Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
PAAD	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.41	-4.7	-0.36	5.77e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13880545	chr9:134755909	MED27	-0.68	-6.74	-0.48	3.15e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs322458	0.550	rs702008	chr3:120636928	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7577696	0.924	rs7605242	chr2:32324135	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-4.67	-0.35	6.63e-6	Inflammatory biomarkers;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15267303	chr11:34127610	NAT10	0.7	6.35	0.46	2.35e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg10356904	chr22:49881777	NA	-0.51	-5.63	-0.42	8.39e-8	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg21589280	chr1:85930151	DDAH1	-0.56	-4.25	-0.33	3.76e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.1	-0.59	4.84e-16	Mean platelet volume;
PAAD	cis	rs66530629	0.874	rs6600274	chr1:25162444	T/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.64	-0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-1.11	-8.26	-0.56	6.79e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9581857	0.547	rs75783371	chr13:28109961	T/C	cg22138327	chr13:27999177	GTF3A	0.8	5.33	0.4	3.46e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.5	0.47	1.11e-9	Multiple sclerosis;
PAAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg26497354	chr6:109612229	NA	-0.46	-4.5	-0.34	1.36e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg21483415	chr3:195448197	MUC20	-0.45	-4.27	-0.33	3.43e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.52	0.41	1.41e-7	Alzheimer's disease;
PAAD	cis	rs2280630	1.000	rs2280630	chr3:39195964	C/T	cg01426195	chr3:39028469	NA	-0.45	-4.69	-0.36	6.1e-6	Verbal declarative memory;
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg04106633	chr4:1044584	NA	0.62	5.3	0.4	3.97e-7	Recombination rate (females);
PAAD	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.61	-5.78	-0.42	4.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.61	0.61	2.18e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.67	-6.29	-0.45	3.24e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.76	-5.76	-0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.47	4.59	0.35	9.25e-6	HDL cholesterol;
PAAD	cis	rs1799810	0.640	rs55998444	chr2:128119846	T/C	cg09760422	chr2:128146352	NA	0.39	6.17	0.45	5.83e-9	Self-rated health;
PAAD	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-0.98	-6.32	-0.46	2.75e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19910323	chr2:47168440	MCFD2;TTC7A	-0.8	-7.16	-0.5	3.16e-11	Neuroticism;
PAAD	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg26935685	chr1:15502881	TMEM51	-0.51	-4.32	-0.33	2.8e-5	Systolic blood pressure;
PAAD	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg22467129	chr15:76604101	ETFA	0.51	4.89	0.37	2.51e-6	Blood metabolite levels;
PAAD	cis	rs7180079	1.000	rs8032196	chr15:64515822	A/C	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.56	-0.35	1.06e-5	Neuroticism;
PAAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg20628663	chr10:43360327	NA	-0.82	-4.6	-0.35	9e-6	Pediatric bone mineral content (radius);
PAAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg05110241	chr16:68378359	PRMT7	-0.97	-5.7	-0.42	6.08e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg14583973	chr4:3374767	RGS12	-0.38	-5.89	-0.43	2.4e-8	Parental longevity (mother's age at death);
PAAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg03983715	chr16:68378420	PRMT7	-0.83	-6.01	-0.44	1.31e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.59	5.15	0.39	8.02e-7	Lung function (FEV1/FVC);
PAAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.75	8.34	0.56	4.05e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.64	6.65	0.47	5.03e-10	Homocysteine levels;
PAAD	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.72	7.91	0.54	5.03e-13	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs939584	0.935	rs12995480	chr2:629881	T/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.62	0.35	7.98e-6	Breast cancer;
PAAD	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.71	5.85	0.43	2.87e-8	Menarche (age at onset);
PAAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-4.61	-0.35	8.58e-6	Huntington's disease progression;
PAAD	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06606381	chr12:133084897	FBRSL1	-0.93	-6.54	-0.47	9.06e-10	Depression;
PAAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg25456477	chr12:86230367	RASSF9	0.48	4.31	0.33	2.96e-5	Major depressive disorder;
PAAD	cis	rs11809207	0.719	rs4659415	chr1:26580790	C/T	cg24519413	chr1:26490540	NA	0.56	5.13	0.38	8.74e-7	Height;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg26338869	chr17:61819248	STRADA	0.51	4.97	0.37	1.82e-6	Height;
PAAD	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	6.55	0.47	8.32e-10	Neuroticism;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.14e-15	Prostate cancer;
PAAD	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	4.88	0.37	2.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08625556	chr2:42068380	NA	0.58	6.39	0.46	1.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3960554	0.696	rs10952869	chr7:75846453	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	8.52	0.57	1.47e-14	Eotaxin levels;
PAAD	cis	rs12136530	0.593	rs34873850	chr1:19723310	T/C	cg25104613	chr1:20649108	VWA5B1	-0.44	-4.79	-0.36	3.98e-6	Lead levels in blood;
PAAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.41	5.0	0.38	1.58e-6	Iron status biomarkers;
PAAD	cis	rs375066	0.868	rs368079	chr19:44393356	C/T	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs288342	0.832	rs288308	chr2:183651818	T/G	cg02625481	chr2:183667124	NA	-0.46	-4.75	-0.36	4.74e-6	Recurrent major depressive disorder;
PAAD	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.53	5.59	0.41	1.04e-7	Height;
PAAD	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.47	0.41	1.78e-7	Mean platelet volume;
PAAD	cis	rs54211	0.731	rs137663	chr22:39734668	G/T	cg24399712	chr22:39784796	NA	-0.77	-4.35	-0.33	2.47e-5	Sudden cardiac arrest;
PAAD	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.1	-8.04	-0.55	2.4e-13	Diabetic kidney disease;
PAAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.86	0.37	2.91e-6	Vitiligo;
PAAD	cis	rs829661	1.000	rs829582	chr2:30678057	C/T	cg12454169	chr2:30669597	LCLAT1	0.66	4.94	0.37	2.02e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg26248373	chr2:1572462	NA	-1.1	-9.42	-0.61	6.95e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.59	6.89	0.49	1.41e-10	Bipolar disorder;
PAAD	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.66	-0.35	6.97e-6	Colorectal cancer;
PAAD	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg21466736	chr12:48725269	NA	-0.47	-4.38	-0.33	2.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.44	-4.29	-0.33	3.13e-5	Schizophrenia;
PAAD	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.36	0.46	2.25e-9	Hip circumference;
PAAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-9.68	-0.62	1.5e-17	Personality dimensions;
PAAD	cis	rs3131513	0.596	rs2206047	chr1:25194700	A/G	cg22509179	chr1:25234806	RUNX3	-0.43	-4.29	-0.33	3.18e-5	Alcohol dependence;
PAAD	cis	rs12913538	0.747	rs7167910	chr15:62888516	C/T	cg09983546	chr15:62884068	NA	-0.63	-6.59	-0.47	6.81e-10	Sleep depth;
PAAD	cis	rs215088	0.843	rs215086	chr16:16067699	C/T	cg08996506	chr16:16070868	ABCC1	0.36	4.27	0.33	3.47e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg15309053	chr8:964076	NA	0.61	7.08	0.5	4.9e-11	Schizophrenia;
PAAD	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs73019876	0.869	rs2158107	chr19:22151345	T/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	2e-5	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-5.72	-0.42	5.54e-8	Mood instability;
PAAD	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.86	0.43	2.71e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs3736485	0.966	rs10467924	chr15:51787579	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg03188948	chr7:1209495	NA	1.06	5.41	0.4	2.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-5.09	-0.38	1.04e-6	Mean platelet volume;
PAAD	cis	rs1499972	0.887	rs62264956	chr3:117530775	C/T	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.49	-5.1	-0.38	9.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg09035930	chr12:129282057	SLC15A4	-0.74	-4.35	-0.33	2.5e-5	Systemic lupus erythematosus;
PAAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.68	7.44	0.52	7.07e-12	Personality dimensions;
PAAD	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg19637330	chr1:19110922	NA	-0.6	-4.93	-0.37	2.17e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.86	-0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.85	-9.22	-0.6	2.28e-16	Corneal astigmatism;
PAAD	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg08888203	chr3:10149979	C3orf24	0.82	6.9	0.49	1.33e-10	Alzheimer's disease;
PAAD	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg00700412	chr12:58011837	NA	0.44	4.62	0.35	8.17e-6	Multiple sclerosis;
PAAD	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.9	0.54	5.25e-13	Eotaxin levels;
PAAD	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg04289385	chr6:36355825	ETV7	-0.45	-4.79	-0.36	3.85e-6	Platelet distribution width;
PAAD	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg21951975	chr1:209979733	IRF6	0.56	5.44	0.4	2.13e-7	Coronary artery disease;
PAAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.71	7.92	0.54	4.68e-13	Melanoma;
PAAD	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21659725	chr3:3221576	CRBN	0.84	9.84	0.62	5.39e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.63	8.22	0.55	8.38e-14	Renal cell carcinoma;
PAAD	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg22467129	chr15:76604101	ETFA	0.53	4.99	0.38	1.64e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10442759	chr12:65673274	MSRB3	0.63	6.39	0.46	1.91e-9	Obesity-related traits;
PAAD	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg21231944	chr12:82153410	PPFIA2	-0.55	-4.58	-0.35	9.5e-6	Resting heart rate;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.71	5.83	0.43	3.22e-8	Alzheimer's disease;
PAAD	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.48	4.88	0.37	2.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.74	-0.42	5.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.7	-0.62	1.31e-17	Tonsillectomy;
PAAD	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.66	6.53	0.47	9.14e-10	Platelet count;
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.74	0.48	3.02e-10	Eosinophil percentage of white cells;
PAAD	trans	rs12406019	0.510	rs12126464	chr1:78608215	T/C	cg20826526	chr3:156266748	SSR3	-0.66	-6.59	-0.47	6.65e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg22947322	chr17:47091978	IGF2BP1	0.43	5.23	0.39	5.65e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.76	-9.26	-0.6	1.87e-16	Height;
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13126279	chr21:47581558	C21orf56	-0.41	-4.59	-0.35	9.09e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-4.86	-0.37	2.96e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs10392	0.850	rs74272986	chr20:37558270	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.64	-4.76	-0.36	4.56e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs35955747	0.778	rs9609263	chr22:31745274	G/T	cg02404636	chr22:31891804	SFI1	-0.49	-5.16	-0.39	7.67e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-4.41	-0.34	1.94e-5	Testicular germ cell tumor;
PAAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.66	7.69	0.53	1.75e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.28	-0.39	4.47e-7	Other erythrocyte phenotypes;
PAAD	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.86	-0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg21589280	chr1:85930151	DDAH1	-0.6	-4.57	-0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg15192750	chr16:69999425	NA	0.75	6.0	0.44	1.39e-8	IgE levels;
PAAD	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.62	-4.79	-0.36	3.95e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.53	5.53	0.41	1.38e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.95	0.43	1.79e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.52	-4.8	-0.36	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg14847009	chr1:175162515	KIAA0040	0.33	5.26	0.39	4.72e-7	Alcohol dependence;
PAAD	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4450131	0.522	rs4962679	chr10:126353865	G/A	cg20435097	chr10:126320824	FAM53B	0.47	4.56	0.35	1.07e-5	White blood cell count (basophil);
PAAD	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.6	-6.92	-0.49	1.17e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.45	4.82	0.36	3.47e-6	Cystic fibrosis severity;
PAAD	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg23860436	chr12:58378763	NA	0.46	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.584	rs1704223	chr10:44677014	C/T	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.8	9.88	0.63	4.37e-18	Height;
PAAD	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.45	-0.34	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg09913449	chr8:42400586	C8orf40	-0.47	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.39	0.4	2.68e-7	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23846145	chr4:103266423	SLC39A8	-0.73	-6.54	-0.47	8.63e-10	Neuroticism;
PAAD	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg01890435	chr5:442385	EXOC3;C5orf55	-0.49	-4.36	-0.33	2.39e-5	Cystic fibrosis severity;
PAAD	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg08390786	chr10:135334061	NA	0.48	4.64	0.35	7.5e-6	Obesity-related traits;
PAAD	cis	rs1692120	0.545	rs962370	chr11:61408401	A/T	cg23038520	chr11:61406508	RPLP0P2	0.51	5.31	0.4	3.78e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.52	-6.93	-0.49	1.12e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.67	6.66	0.48	4.79e-10	Orofacial clefts;
PAAD	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.56	4.95	0.37	1.99e-6	Lung cancer;
PAAD	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Obesity;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.8	8.44	0.56	2.27e-14	Corneal astigmatism;
PAAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg03808351	chr9:123631620	PHF19	0.47	5.03	0.38	1.34e-6	Rheumatoid arthritis;
PAAD	cis	rs3206736	0.548	rs1649224	chr7:34990996	G/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg12072164	chr19:44306565	LYPD5	-0.45	-4.83	-0.36	3.32e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.82	-8.82	-0.58	2.44e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.75	9.23	0.6	2.15e-16	Bone mineral density;
PAAD	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg18898632	chr2:242989856	NA	-0.81	-6.03	-0.44	1.22e-8	Obesity-related traits;
PAAD	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.44	-4.35	-0.33	2.47e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.34	0.33	2.6e-5	Bipolar disorder;
PAAD	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.47	0.61	5.19e-17	Bipolar disorder;
PAAD	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.72	7.67	0.53	1.86e-12	Type 2 diabetes;
PAAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs185694	1.000	rs202083	chr13:30881316	C/T	cg07600127	chr13:30881527	KATNAL1	-0.68	-4.42	-0.34	1.9e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs41311933	1.000	rs41311933	chr9:123739560	C/T	cg13567360	chr9:123745713	C5	-0.71	-4.41	-0.34	1.95e-5	Coronary artery disease;
PAAD	cis	rs7951870	0.673	rs4606447	chr11:46691737	A/G	cg19486271	chr11:47235900	DDB2	-0.55	-4.99	-0.38	1.61e-6	Schizophrenia;
PAAD	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	5.84	0.43	3.01e-8	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.89	10.74	0.66	2.2e-20	Type 2 diabetes;
PAAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.84	0.37	3.22e-6	Breast cancer;
PAAD	cis	rs9322817	0.593	rs9404579	chr6:105229807	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-5.43	-0.4	2.17e-7	Thyroid stimulating hormone;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg22352273	chr2:238969464	SCLY	-0.59	-7.02	-0.49	7.06e-11	Body fat percentage;
PAAD	cis	rs806215	0.951	rs327521	chr7:127249143	G/A	cg25922125	chr7:127225783	GCC1	0.71	5.34	0.4	3.35e-7	Type 2 diabetes;
PAAD	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.33	0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-8.32	-0.56	4.63e-14	Electrocardiographic conduction measures;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25627055	chr5:180650368	TRIM41	-0.64	-6.68	-0.48	4.23e-10	Smoking initiation;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.98	-0.37	1.67e-6	Electroencephalogram traits;
PAAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.84	0.43	3.01e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.47	4.94	0.37	2.03e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.58	5.35	0.4	3.25e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12615435	1.000	rs12615435	chr2:200638509	A/C	cg23649088	chr2:200775458	C2orf69	0.8	4.5	0.34	1.36e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);
PAAD	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.89	-0.37	2.5e-6	Height;
PAAD	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg26585981	chr11:48327164	OR4S1	0.49	4.3	0.33	3.01e-5	Migraine - clinic-based;
PAAD	cis	rs6137287	0.924	rs2093069	chr20:21140342	C/T	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-6.72	-0.48	3.37e-10	Hemoglobin concentration;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.63	0.35	7.74e-6	Obesity-related traits;
PAAD	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	1.06	6.94	0.49	1.04e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg11062466	chr8:58055876	NA	0.72	4.87	0.37	2.78e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.42	-0.74	1.38e-27	Primary sclerosing cholangitis;
PAAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.68	-8.63	-0.57	7.76e-15	Menopause (age at onset);
PAAD	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.43e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs41311933	0.710	rs2300930	chr9:123717389	C/A	cg21241889	chr9:123690658	TRAF1	-0.69	-4.36	-0.33	2.41e-5	Coronary artery disease;
PAAD	cis	rs2964802	0.505	rs11957751	chr5:10819973	A/G	cg14521931	chr5:10832172	NA	0.45	4.67	0.35	6.58e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.69	-7.63	-0.53	2.38e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs10488172	0.857	rs17167135	chr7:133223017	A/G	cg10665199	chr7:133106180	EXOC4	0.6	4.99	0.38	1.61e-6	Tonometry;
PAAD	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-9.72	-0.62	1.13e-17	Chronic sinus infection;
PAAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg09760422	chr2:128146352	NA	0.44	7.18	0.5	2.96e-11	Protein C levels;
PAAD	cis	rs58521262	0.556	rs465723	chr19:23131463	G/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.63	-0.47	5.5e-10	Mood instability;
PAAD	cis	rs881827	0.681	rs2277827	chr21:47986001	T/G	cg00621197	chr21:48018790	S100B	0.4	4.47	0.34	1.53e-5	Lymphocyte counts;
PAAD	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.73	5.68	0.42	6.54e-8	Resting heart rate;
PAAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11141652	chr22:24348549	GSTTP1	0.5	4.71	0.36	5.59e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg18093559	chr17:18951025	GRAP	-0.46	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.77	8.25	0.56	6.96e-14	Menopause (age at onset);
PAAD	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-4.9	-0.37	2.47e-6	Personality dimensions;
PAAD	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.34	4.76	0.36	4.41e-6	Migraine;
PAAD	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.64	6.79	0.48	2.33e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-4.31	-0.33	2.92e-5	Educational attainment;
PAAD	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-5.72	-0.42	5.42e-8	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.49	5.0	0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.6	-6.35	-0.46	2.4e-9	Fibrinogen levels;
PAAD	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.68	7.96	0.54	3.7e-13	Colorectal cancer;
PAAD	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	6.69	0.48	4.12e-10	Mood instability;
PAAD	cis	rs3106136	0.678	rs6532485	chr4:95297120	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	4.9	0.37	2.42e-6	Capecitabine sensitivity;
PAAD	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg20003494	chr4:90757398	SNCA	0.65	6.07	0.44	9.86e-9	Neuroticism;
PAAD	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	15.71	0.79	1.2e-33	Testicular germ cell tumor;
PAAD	cis	rs7627468	0.657	rs937626	chr3:121971802	G/A	cg03198317	chr3:121949109	CASR	0.49	4.44	0.34	1.75e-5	Kidney stones;
PAAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	trans	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg02569823	chr6:5851330	NA	0.63	6.63	0.47	5.51e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.4	-5.14	-0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.55	6.86	0.49	1.66e-10	Atrioventricular conduction;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg08888203	chr3:10149979	C3orf24	0.61	5.36	0.4	3e-7	Alzheimer's disease;
PAAD	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.71	-6.43	-0.46	1.54e-9	Blood pressure (smoking interaction);
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs757081	0.648	rs214923	chr11:17237080	G/C	cg04705435	chr11:17411270	KCNJ11	-0.56	-5.65	-0.42	7.54e-8	Systolic blood pressure;
PAAD	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11995313	chr8:8860691	ERI1	0.52	5.29	0.39	4.17e-7	Joint mobility (Beighton score);
PAAD	cis	rs728616	0.510	rs17617406	chr10:82174556	C/T	cg19423196	chr10:82049429	MAT1A	-0.51	-4.8	-0.36	3.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-4.4	-0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.56	5.95	0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17410650	chr12:54324560	NA	-0.47	-8.0	-0.54	3e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.99	-0.49	8.08e-11	Height;
PAAD	cis	rs3736485	0.934	rs11634999	chr15:51871461	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.28	-0.33	3.35e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.63	7.1	0.5	4.56e-11	Emphysema distribution in smoking;
PAAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs7260598	0.539	rs10424758	chr19:24090500	C/T	cg09235885	chr19:23456588	NA	-0.64	-4.47	-0.34	1.5e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.84	10.05	0.63	1.59e-18	Multiple sclerosis;
PAAD	cis	rs4908768	0.657	rs11121229	chr1:8831283	C/T	cg12700319	chr1:8272199	NA	0.41	4.35	0.33	2.46e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02945294	chr17:2206979	SRR;SMG6	-0.62	-6.39	-0.46	1.97e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.53	5.57	0.41	1.1e-7	Red blood cell count;
PAAD	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg06636001	chr8:8085503	FLJ10661	0.76	7.4	0.51	8.77e-12	Mood instability;
PAAD	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.98	0.63	2.31e-18	Prudent dietary pattern;
PAAD	cis	rs17318866	1.000	rs3734220	chr6:3832574	G/T	cg23955161	chr6:3737956	C6orf145	-0.49	-4.45	-0.34	1.67e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.63	-5.65	-0.42	7.74e-8	Mitral valve prolapse;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.01	0.38	1.47e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19300632	chr2:55746645	CCDC104	0.62	7.04	0.5	6.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.858	rs9931366	chr16:67725347	C/G	cg09835421	chr16:68378352	PRMT7	-0.64	-4.42	-0.34	1.85e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg17326555	chr1:119535693	NA	0.43	5.09	0.38	1.03e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.85	-0.37	3.07e-6	Height;
PAAD	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.91	9.59	0.61	2.59e-17	Inhibitory control;
PAAD	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs988913	0.914	rs9396006	chr6:54787888	G/A	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs12295403	0.691	rs12792736	chr11:18673155	C/A	cg07538406	chr11:18686895	NA	-0.46	-4.27	-0.33	3.37e-5	Ovarian reserve;
PAAD	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.75	5.5	0.41	1.57e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.42	0.52	7.54e-12	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	5.64	0.42	7.99e-8	Schizophrenia;
PAAD	cis	rs727479	0.502	rs8029120	chr15:51504934	A/C	cg21478137	chr15:51532386	CYP19A1	0.46	4.66	0.35	6.89e-6	Estradiol levels;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08677398	chr8:58056175	NA	-0.65	-4.43	-0.34	1.79e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-5.74	-0.42	4.92e-8	Total cholesterol levels;
PAAD	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg08717414	chr16:71523259	ZNF19	-0.91	-5.54	-0.41	1.28e-7	Post bronchodilator FEV1;
PAAD	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.88	8.83	0.58	2.33e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.61	-6.22	-0.45	4.49e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.79	-7.14	-0.5	3.66e-11	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg23024343	chr7:107201750	COG5	0.58	4.75	0.36	4.61e-6	Coronary artery disease;
PAAD	cis	rs9657904	0.774	rs2399056	chr3:105517330	A/G	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.89e-6	Multiple sclerosis;
PAAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg17987982	chr7:158820591	NA	-0.43	-4.74	-0.36	4.81e-6	Facial morphology (factor 20);
PAAD	cis	rs4740619	0.619	rs1410451	chr9:16039579	G/A	cg14451791	chr9:16040625	NA	-0.43	-4.95	-0.37	1.94e-6	Body mass index;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.67	-4.42	-0.34	1.85e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	7.31	0.51	1.43e-11	Eotaxin levels;
PAAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg02555727	chr12:129281546	SLC15A4	0.46	4.86	0.37	2.96e-6	Systemic lupus erythematosus;
PAAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg06521852	chr22:38141419	TRIOBP	0.43	4.52	0.34	1.25e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg22138327	chr13:27999177	GTF3A	0.89	5.5	0.41	1.55e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg08847533	chr14:75593920	NEK9	-1.02	-15.61	-0.78	2.13e-33	Height;
PAAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.5	4.9	0.37	2.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.01	0.54	2.85e-13	Lymphocyte counts;Red cell distribution width;
PAAD	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg03894339	chr8:19674705	INTS10	0.45	4.34	0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9649465	1.000	rs10270877	chr7:123327860	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.33	-0.33	2.7e-5	Aortic root size;
PAAD	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.61	-5.45	-0.4	1.96e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg24044776	chr19:53454761	ZNF816A	-0.51	-5.59	-0.41	1.04e-7	Psoriasis;
PAAD	cis	rs58653258	0.730	rs2673943	chr1:234988968	A/G	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.27	0.45	3.55e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs7922314	0.571	rs16917946	chr10:64717750	G/C	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.72	-7.09	-0.5	4.6e-11	Height;
PAAD	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-10.06	-0.63	1.44e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.57	-5.51	-0.41	1.52e-7	Crohn's disease;
PAAD	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.78	0.36	4.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26795923	chr22:19165960	SLC25A1	0.62	6.34	0.46	2.48e-9	Obesity-related traits;
PAAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg06569542	chr10:98946673	SLIT1	-0.51	-5.76	-0.42	4.61e-8	Monocyte count;
PAAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-5.92	-0.43	2.11e-8	Inflammatory bowel disease;
PAAD	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg02660097	chr11:68866761	NA	0.45	5.02	0.38	1.45e-6	Blond vs. brown hair color;
PAAD	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.42	5.69	0.42	6.35e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9652601	0.959	rs9746695	chr16:11207894	C/T	cg04616529	chr16:11181986	CLEC16A	-0.42	-4.6	-0.35	8.93e-6	Systemic lupus erythematosus;
PAAD	cis	rs950173	0.793	rs1105265	chr2:172715401	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-6.03	-0.44	1.2e-8	Hippocampal volume;
PAAD	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg26174226	chr8:58114915	NA	-0.67	-5.42	-0.4	2.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.09	0.5	4.66e-11	Rheumatoid arthritis;
PAAD	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	0.97	11.36	0.68	5.03e-22	Schizophrenia;
PAAD	cis	rs9659323	0.640	rs11800444	chr1:119639675	T/C	cg26570165	chr1:119541833	NA	-0.47	-5.08	-0.38	1.12e-6	Body mass index;
PAAD	cis	rs9815354	0.762	rs794899	chr3:42028722	T/C	cg03022575	chr3:42003672	ULK4	-0.73	-5.27	-0.39	4.65e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11105468	0.701	rs61926987	chr12:90409494	C/T	cg16962463	chr12:89968675	NA	0.46	4.37	0.33	2.25e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg23281280	chr6:28129359	ZNF389	0.5	4.25	0.33	3.65e-5	Cardiac Troponin-T levels;
PAAD	cis	rs72960926	1.000	rs117827660	chr6:75159847	C/A	cg13997649	chr6:74171430	MTO1	0.88	4.42	0.34	1.87e-5	Metabolite levels (MHPG);
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg15693483	chr7:1102177	C7orf50	0.4	4.56	0.35	1.05e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.72	7.37	0.51	1.04e-11	Lung cancer;
PAAD	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg11395062	chr17:14139857	CDRT15	0.58	5.9	0.43	2.26e-8	Temperament;
PAAD	cis	rs939584	1.000	rs6744646	chr2:628504	A/G	cg03610516	chr2:642275	NA	0.63	5.78	0.42	4.08e-8	Body mass index;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg07154921	chr7:157260426	NA	0.46	4.53	0.34	1.18e-5	Body mass index;
PAAD	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-6.46	-0.46	1.36e-9	Blood protein levels;
PAAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg09873201	chr16:3507582	NAT15	-0.58	-5.45	-0.4	1.96e-7	Tuberculosis;
PAAD	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.09e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	6.81	0.48	2.08e-10	Lung cancer in ever smokers;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.65	0.42	7.77e-8	Eosinophil percentage of white cells;
PAAD	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.39	-0.4	2.61e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.59	5.0	0.38	1.56e-6	Common traits (Other);
PAAD	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	6.87	0.49	1.52e-10	Eye color traits;
PAAD	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	5.51	0.41	1.47e-7	Cognitive test performance;
PAAD	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.34	4.6	0.35	8.66e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	1.08	12.17	0.7	3.27e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-4.51	-0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	1.02	6.6	0.47	6.29e-10	Fat distribution (HIV);
PAAD	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.02	-0.55	2.63e-13	Inflammatory bowel disease;
PAAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.97	0.37	1.76e-6	Parkinson's disease;
PAAD	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.33e-7	Noise-induced hearing loss;
PAAD	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.6	-5.96	-0.43	1.73e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg11619707	chr19:22235551	ZNF257	0.58	5.34	0.4	3.39e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.39	-0.34	2.12e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.75e-6	Mononucleosis;
PAAD	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13911269	chr15:44580143	CASC4	-0.54	-5.51	-0.41	1.49e-7	Lung cancer in ever smokers;
PAAD	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	1.01	14.15	0.75	1.52e-29	Heart rate;
PAAD	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.7	0.36	5.68e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4795519	0.602	rs12451024	chr17:22183514	A/G	cg22648282	chr17:21454238	C17orf51	-0.55	-5.24	-0.39	5.32e-7	Chronic myeloid leukemia;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	0.9	5.36	0.4	3.02e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-1.04	-13.55	-0.74	6.08e-28	Uric acid levels;
PAAD	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.65	5.87	0.43	2.64e-8	Blood metabolite levels;
PAAD	cis	rs6817170	0.577	rs7688335	chr4:154386317	C/T	cg24020152	chr4:154419554	KIAA0922	0.4	4.36	0.33	2.35e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15778346	chr7:75947261	NA	0.73	7.29	0.51	1.6e-11	Obesity-related traits;
PAAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.1	0.38	1e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11771526	0.681	rs11767011	chr7:32420648	G/A	cg13207630	chr7:32358064	NA	0.94	4.59	0.35	9.31e-6	Body mass index;
PAAD	cis	rs2885056	0.599	rs73018654	chr19:10689518	G/A	cg06392426	chr19:10676186	KRI1	0.56	5.38	0.4	2.82e-7	Red cell distribution width;
PAAD	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg00540400	chr15:79124168	NA	-0.69	-9.25	-0.6	2e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs62025270	0.547	rs338540	chr15:86195731	C/T	cg13263323	chr15:86062960	AKAP13	-0.48	-4.72	-0.36	5.27e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs11811982	0.793	rs74840653	chr1:227281814	A/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs8077577	0.708	rs2290503	chr17:18135753	T/C	cg16794390	chr17:18148240	FLII	-0.52	-4.46	-0.34	1.57e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.77	5.15	0.39	8.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.49	4.76	0.36	4.55e-6	Morning vs. evening chronotype;
PAAD	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg06740227	chr12:86229804	RASSF9	-0.53	-4.84	-0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.6	10.2	0.64	6.26e-19	IgG glycosylation;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg25703541	chr22:24373054	LOC391322	-0.67	-5.01	-0.38	1.49e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.5	4.56	0.35	1.06e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg10356904	chr22:49881777	NA	0.49	5.12	0.38	9.28e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-5.25	-0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.73	6.66	0.48	4.62e-10	Breast cancer;
PAAD	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.65	9.13	0.59	4.07e-16	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg17372657	chr7:1216933	NA	-0.39	-4.8	-0.36	3.71e-6	Longevity;Endometriosis;
PAAD	cis	rs4523957	0.890	rs216191	chr17:2188639	C/T	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.91	-15.27	-0.78	1.67e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.638	rs113496706	chr3:42028574	G/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.66	0.57	6.36e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19337854	chr7:99768885	GPC2	-0.45	-4.79	-0.36	3.98e-6	Coronary artery disease;
PAAD	cis	rs9462846	0.919	rs12202901	chr6:42828550	A/T	cg02353165	chr6:42928485	GNMT	0.57	4.91	0.37	2.36e-6	Blood protein levels;
PAAD	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12516959	chr21:47718080	NA	0.44	4.34	0.33	2.58e-5	Testicular germ cell tumor;
PAAD	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.61	6.25	0.45	3.91e-9	Coronary artery disease;
PAAD	cis	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.46	0.34	1.58e-5	Depression;
PAAD	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.52	5.17	0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs7202877	0.611	rs56092808	chr16:75312716	A/T	cg03315344	chr16:75512273	CHST6	0.58	4.62	0.35	8.26e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg03037974	chr15:76606532	NA	0.51	5.9	0.43	2.27e-8	Blood metabolite levels;
PAAD	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.63	-6.66	-0.48	4.72e-10	Blood protein levels;
PAAD	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.49	-5.01	-0.38	1.47e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.73	-5.54	-0.41	1.27e-7	Initial pursuit acceleration;
PAAD	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.9	-5.93	-0.43	1.99e-8	Severe influenza A (H1N1) infection;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.63	-7.02	-0.5	6.75e-11	Schizophrenia;
PAAD	trans	rs901683	1.000	rs12764652	chr10:45991978	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.52	-7.65	-0.53	2.18e-12	Diastolic blood pressure;
PAAD	cis	rs6782228	1.000	rs35871360	chr3:128336129	G/A	cg15607142	chr3:128420513	NA	-0.44	-4.72	-0.36	5.24e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.51	7.9	0.54	5.28e-13	Mean corpuscular volume;
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.74	5.59	0.41	1.04e-7	Initial pursuit acceleration;
PAAD	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg03700679	chr2:178418002	TTC30B	-0.52	-4.26	-0.33	3.51e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.47	5.37	0.4	2.88e-7	Height;
PAAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg23346134	chr3:49453900	TCTA	-0.46	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14557816	chr3:48282905	ZNF589	0.7	6.39	0.46	1.9e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.48	-0.34	1.49e-5	Triglycerides;
PAAD	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg10356904	chr22:49881777	NA	-0.5	-5.37	-0.4	2.94e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.57	7.63	0.53	2.43e-12	Renal cell carcinoma;
PAAD	cis	rs6782025	0.837	rs2331521	chr3:120768859	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9535307	0.584	rs61961506	chr13:50401701	C/A	cg04663916	chr13:50265991	EBPL	-0.72	-5.43	-0.4	2.19e-7	Obesity-related traits;
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg15691649	chr6:25882328	NA	-0.54	-5.09	-0.38	1.05e-6	Blood metabolite levels;
PAAD	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.87	-0.37	2.75e-6	Tuberculosis;
PAAD	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg27094323	chr7:1216898	NA	-0.43	-4.93	-0.37	2.17e-6	Longevity;Endometriosis;
PAAD	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.92e-16	Motion sickness;
PAAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.49	4.65	0.35	7.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs6076960	0.741	rs2021702	chr20:6178954	T/A	cg21095983	chr6:86352623	SYNCRIP	0.63	6.33	0.46	2.64e-9	Smooth-surface caries;
PAAD	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10929159	0.928	rs7557044	chr2:236932554	A/G	cg11007962	chr2:236923454	AGAP1	-0.32	-4.62	-0.35	8.02e-6	Parkinson's disease;
PAAD	cis	rs9581857	0.547	rs9579096	chr13:28084069	T/C	cg22138327	chr13:27999177	GTF3A	0.85	5.42	0.4	2.27e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	5.86	0.43	2.79e-8	Lymphocyte counts;Red cell distribution width;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16084842	chr5:64064841	SDCCAG10;SFRS12IP1	0.58	6.54	0.47	8.81e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7631605	0.875	rs28754348	chr3:37063728	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.23	17.4	0.82	5.47e-38	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01860947	chr19:15442741	NA	0.6	6.72	0.48	3.38e-10	Monocyte percentage of white cells;
PAAD	cis	rs4073221	1.000	rs4074941	chr3:18277909	A/G	cg07694806	chr3:18168406	NA	-0.75	-5.07	-0.38	1.15e-6	Parkinson's disease;
PAAD	cis	rs3764400	0.567	rs2325804	chr17:46218545	G/A	cg24322968	chr17:46507895	SKAP1	-0.85	-5.27	-0.39	4.5e-7	Body mass index;
PAAD	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg11439826	chr17:76250004	NA	0.45	4.48	0.34	1.47e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs881827	0.821	rs1047221	chr21:48003193	A/G	cg11766577	chr21:47581405	C21orf56	-0.43	-4.54	-0.35	1.13e-5	Lymphocyte counts;
PAAD	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg21108841	chr4:24914750	CCDC149	-0.54	-4.46	-0.34	1.55e-5	Heschl's gyrus morphology;
PAAD	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.53	7.12	0.5	3.98e-11	Primary biliary cholangitis;
PAAD	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg18551225	chr6:44695536	NA	-0.63	-5.88	-0.43	2.46e-8	Total body bone mineral density;
PAAD	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.8	-6.18	-0.45	5.64e-9	Psoriasis;
PAAD	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.55	-6.06	-0.44	1.04e-8	Longevity;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.67	8.71	0.58	4.78e-15	Lymphocyte counts;
PAAD	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.52	5.32	0.4	3.59e-7	Colorectal cancer;
PAAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-4.61	-0.35	8.41e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.45	-4.76	-0.36	4.54e-6	Dementia with Lewy bodies;
PAAD	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs6976053	0.868	rs314374	chr7:100456611	G/C	cg22425096	chr7:100417404	EPHB4	0.51	4.44	0.34	1.69e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24607948	chr9:100459097	XPA	0.58	6.36	0.46	2.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58521262	0.556	rs289342	chr19:23150389	T/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg12935359	chr14:103987150	CKB	-0.6	-6.4	-0.46	1.83e-9	Body mass index;
PAAD	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	4.48	0.34	1.44e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.73	-7.75	-0.53	1.23e-12	DNA methylation (variation);
PAAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.17	17.66	0.82	1.14e-38	Cognitive function;
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.03	-0.44	1.21e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg15472797	chr10:135243109	NA	-0.42	-4.53	-0.35	1.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.16	-0.39	7.65e-7	Mean corpuscular volume;
PAAD	cis	rs7785730	1.000	rs17156314	chr7:28100538	C/G	cg15506609	chr7:27206073	HOXA9	-0.22	-4.56	-0.35	1.05e-5	Free thyroxine concentration;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06956232	chr14:78432436	NA	0.68	7.36	0.51	1.06e-11	Pancreatic cancer;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	9.95	0.63	2.91e-18	Prudent dietary pattern;
PAAD	cis	rs950881	0.932	rs13408569	chr2:102955056	G/C	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.59	7.37	0.51	1e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9287719	0.614	rs10929681	chr2:10723283	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.7	0.42	6.13e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs5751901	1.000	rs5751901	chr22:24992266	C/T	cg08808123	chr22:24999002	GGT1	0.44	4.8	0.36	3.68e-6	Protein quantitative trait loci;
PAAD	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.6	5.29	0.39	4.23e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10848704	0.525	rs4073984	chr12:2885780	G/A	cg19945202	chr12:2788847	CACNA1C	-0.46	-4.85	-0.37	3.04e-6	Quantitative traits;
PAAD	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg16501237	chr10:99081016	FRAT1	0.35	4.29	0.33	3.21e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.48	4.93	0.37	2.1e-6	Pulmonary function;
PAAD	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14324370	chr2:177042789	NA	0.32	4.76	0.36	4.38e-6	IgG glycosylation;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.62	-6.69	-0.48	4.08e-10	Vitiligo;
PAAD	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg20406979	chr6:167373233	NA	0.32	4.42	0.34	1.88e-5	Crohn's disease;
PAAD	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg09638344	chr4:6271000	WFS1	-0.53	-4.54	-0.35	1.14e-5	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg21448613	chr3:49828315	CDH29	0.47	4.4	0.34	2.03e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.88	-9.06	-0.59	6.05e-16	Inhibitory control;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21120402	chr2:148893152	NA	-0.54	-6.64	-0.47	5.37e-10	Energy expenditure (24h);
PAAD	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.61	0.47	6.02e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.8	8.94	0.59	1.21e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg24044776	chr19:53454761	ZNF816A	-0.44	-4.81	-0.36	3.55e-6	Psoriasis;
PAAD	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.36	0.4	3.09e-7	Educational attainment;
PAAD	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.25	0.39	4.99e-7	Free thyroxine concentration;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg14926445	chr8:58193284	C8orf71	-0.72	-5.54	-0.41	1.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	5.6	0.41	9.69e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg09242541	chr1:10490025	APITD1	0.37	4.71	0.36	5.6e-6	Breast cancer;
PAAD	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.68	-5.45	-0.4	1.98e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg24296786	chr1:45957014	TESK2	-0.59	-6.25	-0.45	3.96e-9	High light scatter reticulocyte count;
PAAD	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.813	rs1608663	chr7:27623776	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs939584	1.000	rs7560246	chr2:643469	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.76	-8.25	-0.56	6.92e-14	Type 2 diabetes;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10819733	chr22:24237672	NA	-0.63	-7.35	-0.51	1.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg01176363	chr20:62369445	LIME1	-0.58	-5.67	-0.42	6.97e-8	Prostate cancer;
PAAD	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.76	-7.87	-0.54	6.09e-13	Itch intensity from mosquito bite;
PAAD	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.48	5.23	0.39	5.65e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05025164	chr4:1340916	KIAA1530	0.57	5.78	0.42	4.01e-8	Obesity-related traits;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.2	-0.45	5.2e-9	Menopause (age at onset);
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.66	-6.27	-0.45	3.47e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-1.0	-7.93	-0.54	4.42e-13	Initial pursuit acceleration;
PAAD	cis	rs4704187	0.687	rs6864485	chr5:74497984	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg23018236	chr17:30244563	NA	-0.63	-5.07	-0.38	1.14e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.1	-17.39	-0.82	5.7800000000000005e-38	Myeloid white cell count;
PAAD	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg03684893	chr10:554711	DIP2C	-0.44	-4.7	-0.36	5.77e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.21	0.67	1.21e-21	Total body bone mineral density;
PAAD	cis	rs4588572	0.686	rs34262593	chr5:77666427	T/C	cg11547950	chr5:77652471	NA	0.92	8.0	0.54	2.89e-13	Triglycerides;
PAAD	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.69	5.06	0.38	1.17e-6	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07037045	chr6:86324743	SYNCRIP	0.51	7.07	0.5	5.39e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1365505	0.600	rs1648350	chr15:50486400	G/A	cg26188685	chr15:50540269	HDC	-0.44	-4.78	-0.36	4.05e-6	Blood metabolite ratios;
PAAD	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.91	-7.33	-0.51	1.28e-11	Blood protein levels;
PAAD	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg23435118	chr5:141488016	NDFIP1	-0.57	-5.52	-0.41	1.42e-7	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24638722	chr8:105509494	LRP12	-0.67	-7.12	-0.5	4.07e-11	Obesity-related traits;
PAAD	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg26220594	chr1:19110978	NA	-0.49	-4.76	-0.36	4.4e-6	Knee osteoarthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04579211	chr15:41221939	DLL4	0.59	6.83	0.48	1.94e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.9e-5	Total body bone mineral density;
PAAD	cis	rs922692	0.696	rs1809420	chr15:79056769	A/G	cg00540400	chr15:79124168	NA	-0.41	-4.59	-0.35	9.39e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26291195	chr7:98610531	TRRAP	-0.67	-6.6	-0.47	6.62e-10	Obesity-related traits;
PAAD	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.35	-0.4	3.25e-7	Number of children ever born;
PAAD	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	9.73	0.62	1.08e-17	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.13	-0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.38	-5.26	-0.39	4.87e-7	Age at first birth;
PAAD	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg01528321	chr10:82214614	TSPAN14	0.97	10.33	0.64	2.8e-19	Post bronchodilator FEV1;
PAAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.74	8.51	0.57	1.54e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg09695851	chr17:3907499	NA	0.61	5.9	0.43	2.26e-8	Type 2 diabetes;
PAAD	cis	rs4918918	0.628	rs10786198	chr10:97066298	A/T	cg14101359	chr10:97300930	SORBS1	0.39	4.35	0.33	2.44e-5	Suicide risk;
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.78	7.97	0.54	3.43e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.53	4.6	0.35	8.73e-6	Multiple sclerosis;
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	12.31	0.71	1.37e-24	Platelet count;
PAAD	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16576597	chr16:28551801	NUPR1	0.65	7.39	0.51	9.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12612619	0.668	rs2304682	chr2:27307769	G/C	cg00617064	chr2:27272375	NA	-0.51	-5.23	-0.39	5.45e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6995541	0.776	rs4840517	chr8:10668047	C/T	cg14855657	chr8:10587604	SOX7	-0.45	-4.31	-0.33	2.98e-5	Triglyceride levels;
PAAD	cis	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	cis	rs4740619	0.933	rs10810434	chr9:15713775	G/C	cg14451791	chr9:16040625	NA	-0.39	-4.4	-0.34	2.03e-5	Body mass index;
PAAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.47	-5.85	-0.43	2.86e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs12935418	0.616	rs2549863	chr16:81029367	C/G	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg26248373	chr2:1572462	NA	-1.03	-7.94	-0.54	4.17e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.16	-0.55	1.21e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9361491	0.508	rs9352611	chr6:79396968	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.89	-0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg21479132	chr6:26055353	NA	0.94	5.4	0.4	2.47e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.55	5.91	0.43	2.13e-8	Menopause (age at onset);
PAAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.08e-7	Tonsillectomy;
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.81	-6.98	-0.49	8.65e-11	Initial pursuit acceleration;
PAAD	cis	rs498136	0.966	rs1485993	chr11:69362414	A/G	cg24388239	chr11:68438018	NA	-0.43	-4.38	-0.33	2.24e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs11971779	0.715	rs6467856	chr7:139127299	A/C	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.12	0.7	4.45e-24	Prudent dietary pattern;
PAAD	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	1.06	6.65	0.47	5e-10	Alzheimer's disease;
PAAD	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.39	-0.46	1.94e-9	Retinal vascular caliber;
PAAD	cis	rs7551345	0.853	rs12123798	chr1:31780081	C/T	cg17086398	chr1:31896392	SERINC2	-0.49	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.55	-0.57	1.25e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.48	-4.75	-0.36	4.62e-6	Pancreatic cancer;
PAAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.62	6.51	0.47	1.04e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg13859433	chr6:33739653	LEMD2	0.65	4.41	0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	1.07	13.94	0.75	5.66e-29	Menarche (age at onset);
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg02555727	chr12:129281546	SLC15A4	0.5	5.17	0.39	7.41e-7	Systemic lupus erythematosus;
PAAD	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.48	0.34	1.48e-5	Bipolar disorder;
PAAD	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg18721089	chr20:30220636	NA	-0.59	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.73	-7.06	-0.5	5.41e-11	Platelet distribution width;
PAAD	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs595018	1.000	rs556357	chr11:60593329	G/C	cg07588442	chr11:60673866	PRPF19	-0.53	-4.45	-0.34	1.64e-5	Wegener's granulomatosis;
PAAD	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg12386194	chr3:101231763	SENP7	0.6	6.12	0.44	7.64e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.59	-8.72	-0.58	4.42e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8005172	0.750	rs2119702	chr14:88453278	T/G	cg18078958	chr14:88630771	NA	0.48	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs6070	0.933	rs198958	chr19:51388878	T/A	cg11738530	chr19:51047879	LRRC4B	0.41	4.3	0.33	3e-5	Prostate-specific antigen levels;Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs965469	0.779	rs6037543	chr20:3289505	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs28595532	0.925	rs2728305	chr4:119487022	T/G	cg21605333	chr4:119757512	SEC24D	1.64	8.16	0.55	1.18e-13	Cannabis dependence symptom count;
PAAD	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.45	-4.65	-0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg09796270	chr17:17721594	SREBF1	0.48	5.32	0.4	3.65e-7	Total body bone mineral density;
PAAD	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg07168214	chr17:7380112	ZBTB4	-0.64	-5.61	-0.41	9.45e-8	Androgen levels;
PAAD	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.75	6.71	0.48	3.66e-10	Large artery stroke;
PAAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.3e-10	Coronary artery disease;
PAAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.61	6.34	0.46	2.55e-9	Monocyte count;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg15438404	chr12:57916622	MBD6	-0.63	-6.38	-0.46	2.02e-9	Dental caries;
PAAD	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.63	5.81	0.43	3.5e-8	Obesity-related traits;
PAAD	cis	rs12753569	0.748	rs1340689	chr1:76506409	T/A	cg00791851	chr1:76518896	NA	0.42	4.73	0.36	5.05e-6	Personality dimensions;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg07930192	chr7:1003750	NA	0.6	7.85	0.54	6.87e-13	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg24633833	chr3:10029261	TMEM111	0.6	4.34	0.33	2.61e-5	Alzheimer's disease;
PAAD	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	1.0	9.79	0.62	7.44e-18	Red cell distribution width;
PAAD	cis	rs76793172	1.000	rs28433213	chr19:46341168	C/T	cg13320842	chr19:46175254	GIPR	0.63	4.84	0.37	3.21e-6	Eosinophil counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02779429	chr16:88753010	MGC23284;SNAI3	0.64	7.32	0.51	1.36e-11	Myopia (pathological);
PAAD	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg20003494	chr4:90757398	SNCA	-0.4	-4.53	-0.35	1.16e-5	Dementia with Lewy bodies;
PAAD	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.51	4.52	0.34	1.25e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.73	0.42	5.28e-8	Lung cancer in ever smokers;
PAAD	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06998765	chr14:75389618	RPS6KL1	0.28	4.98	0.37	1.72e-6	Caffeine consumption;
PAAD	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.59	0.47	6.76e-10	Lung cancer;
PAAD	cis	rs11264213	0.892	rs16822339	chr1:36220558	A/C	cg27506609	chr1:36549197	TEKT2	-0.59	-4.32	-0.33	2.79e-5	Schizophrenia;
PAAD	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.31	-0.33	2.9e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg13722127	chr7:150037890	RARRES2	0.52	5.2	0.39	6.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7584330	0.666	rs6760963	chr2:238398268	C/T	cg08992911	chr2:238395768	MLPH	-0.69	-5.1	-0.38	9.91e-7	Prostate cancer;
PAAD	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.05	-0.75	2.85e-29	Headache;
PAAD	cis	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg18612461	chr15:75251733	NA	0.57	7.2	0.5	2.6e-11	Breast cancer;
PAAD	cis	rs7714584	1.000	rs11747065	chr5:150295486	C/T	cg22134413	chr5:150180641	NA	0.98	6.63	0.47	5.43e-10	Crohn's disease;
PAAD	cis	rs308971	0.520	rs373827	chr3:12076475	C/T	cg02700894	chr3:12045449	SYN2	0.61	4.43	0.34	1.79e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg22990158	chr14:24802150	ADCY4	-0.43	-4.56	-0.35	1.04e-5	Height;
PAAD	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg23202291	chr11:1979235	NA	-0.51	-4.53	-0.34	1.2e-5	DNA methylation (variation);
PAAD	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-4.74	-0.36	4.82e-6	Mean corpuscular volume;
PAAD	cis	rs1879734	0.775	rs1614395	chr1:54181668	G/A	cg14659662	chr1:54151053	GLIS1	0.38	6.1	0.44	8.25e-9	Mitral valve prolapse;
PAAD	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.79	5.88	0.43	2.47e-8	Vitiligo;
PAAD	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.69	-0.36	6.15e-6	Type 1 diabetes;
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg09179987	chr1:167433047	CD247	0.49	5.72	0.42	5.5e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	4.25	0.33	3.77e-5	Aortic root size;
PAAD	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.65	7.91	0.54	5.02e-13	Schizophrenia;
PAAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg16205897	chr5:131564050	P4HA2	-0.5	-5.41	-0.4	2.42e-7	Blood metabolite levels;
PAAD	cis	rs28830936	0.966	rs28373318	chr15:42126725	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.99e-10	Diastolic blood pressure;
PAAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-5.97	-0.44	1.61e-8	Dental caries;
PAAD	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.99e-10	Schizophrenia;
PAAD	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.43	0.4	2.22e-7	Schizophrenia;
PAAD	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.51	5.4	0.4	2.5e-7	Longevity;Endometriosis;
PAAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.6	0.35	8.83e-6	Breast cancer;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg11802864	chr11:65308245	LTBP3	1.37	7.07	0.5	5.15e-11	Height;
PAAD	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26742440	chr11:73472391	RAB6A	0.58	6.41	0.46	1.75e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.25	0.45	4.04e-9	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6466055	0.661	rs12532188	chr7:104922834	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.0	0.38	1.56e-6	Colorectal cancer;
PAAD	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg04657146	chr19:12876947	HOOK2	0.51	4.42	0.34	1.87e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
PAAD	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.59	5.8	0.43	3.68e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.35e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.28	0.33	3.29e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg14196790	chr5:131705035	SLC22A5	-0.44	-4.8	-0.36	3.75e-6	Blood metabolite levels;
PAAD	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.59	4.65	0.35	7.01e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.98	8.18	0.55	1.07e-13	Neutrophil percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07309102	chr9:110251826	KLF4	-0.79	-6.9	-0.49	1.35e-10	Neuroticism;
PAAD	cis	rs6723162	1.000	rs6723162	chr2:71102286	A/T	cg14911521	chr2:71113568	NA	-0.41	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg10932868	chr11:921992	NA	0.49	5.82	0.43	3.37e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg21226059	chr5:178986404	RUFY1	0.46	4.57	0.35	1.01e-5	Lung cancer;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg17674042	chr6:34482479	PACSIN1	-1.06	-7.09	-0.5	4.76e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.49	-5.25	-0.39	4.96e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06998765	chr14:75389618	RPS6KL1	-0.25	-4.35	-0.33	2.52e-5	Caffeine consumption;
PAAD	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg08807892	chr2:162101083	NA	-0.52	-5.11	-0.38	9.34e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs1497828	0.871	rs2646842	chr1:217555946	G/A	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-6.02	-0.44	1.27e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2885056	0.891	rs73016784	chr19:10688785	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.57	5.5	0.41	1.56e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.71	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.47	5.91	0.43	2.17e-8	Crohn's disease;
PAAD	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.76	7.67	0.53	1.96e-12	Anterior chamber depth;
PAAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.43	5.46	0.41	1.88e-7	Psoriasis;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25257644	chr10:23002598	PIP4K2A	0.45	4.68	0.35	6.43e-6	Monocyte percentage of white cells;
PAAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.58	-7.61	-0.53	2.68e-12	Height;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-4.97	-0.37	1.8e-6	Total body bone mineral density;
PAAD	cis	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg27395922	chr11:50257633	LOC441601	0.41	4.36	0.33	2.43e-5	Coronary artery disease;
PAAD	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg00101154	chr16:420108	MRPL28	-0.45	-4.3	-0.33	3.07e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg17524265	chr8:144659883	NAPRT1	-0.89	-4.66	-0.35	6.84e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9398803	0.687	rs4626447	chr6:126964675	G/A	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.5	-4.87	-0.37	2.75e-6	Longevity;
PAAD	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg18833306	chr6:118973337	C6orf204	-0.55	-4.49	-0.34	1.37e-5	Diastolic blood pressure;
PAAD	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs7588746	0.621	rs1816541	chr2:201151011	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.38	-0.4	2.72e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.86	9.82	0.62	6.23e-18	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.7	7.93	0.54	4.28e-13	Age at first birth;
PAAD	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.4	-5.1	-0.38	9.95e-7	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg18323236	chr1:24743029	NIPAL3	0.43	4.67	0.35	6.49e-6	Response to interferon beta in multiple sclerosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16562913	chr10:92682357	ANKRD1	-0.55	-6.62	-0.47	5.77e-10	Monocyte percentage of white cells;
PAAD	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.37	-7.37	-0.51	1.03e-11	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.81	-0.36	3.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1983170	0.808	rs10874787	chr1:92017749	A/G	cg25838465	chr1:92012736	NA	-0.42	-4.25	-0.33	3.74e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg26014466	chr7:809109	HEATR2	-0.68	-7.63	-0.53	2.44e-12	Subjective well-being;
PAAD	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.53	5.74	0.42	5.07e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg04352962	chr1:209979756	IRF6	0.54	4.72	0.36	5.26e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.63	6.57	0.47	7.72e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg23153227	chr6:27725408	NA	-0.49	-4.49	-0.34	1.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	8.36	0.56	3.79e-14	Alzheimer's disease;
PAAD	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.97	0.44	1.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg02841227	chr6:26021843	HIST1H4A	0.43	4.45	0.34	1.65e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.75	-7.84	-0.54	7.47e-13	Blood metabolite levels;
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.09	-0.38	1.05e-6	Systemic lupus erythematosus;
PAAD	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.69	6.29	0.45	3.28e-9	Breast cancer;
PAAD	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg26929925	chr5:138714136	SLC23A1	-0.53	-4.9	-0.37	2.44e-6	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg14345882	chr6:26364793	BTN3A2	0.73	5.01	0.38	1.52e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg24253500	chr15:84953950	NA	0.53	6.15	0.45	6.53e-9	Schizophrenia;
PAAD	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	4.56	0.35	1.05e-5	Joint mobility (Beighton score);
PAAD	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg27411982	chr8:10470053	RP1L1	0.49	5.24	0.39	5.24e-7	Neuroticism;
PAAD	cis	rs6540	1.000	rs472892	chr11:258188	C/T	cg20282913	chr11:252683	PSMD13	-1.03	-4.38	-0.33	2.18e-5	Endometriosis;
PAAD	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.35	5.01	0.38	1.51e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.13e-10	Testicular germ cell tumor;
PAAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.92	-0.37	2.27e-6	Breast cancer;
PAAD	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.36	0.46	2.2e-9	Cognitive test performance;
PAAD	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-1.31	-12.7	-0.72	1.23e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg10395934	chr14:104002654	TRMT61A	0.48	4.64	0.35	7.48e-6	Body mass index;
PAAD	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg10820045	chr2:198174542	NA	-0.43	-4.32	-0.33	2.85e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.46	4.81	0.36	3.58e-6	Dementia with Lewy bodies;
PAAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg01475735	chr3:40494733	NA	-0.45	-4.36	-0.33	2.37e-5	Renal cell carcinoma;
PAAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-5.27	-0.39	4.61e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg02683114	chr2:24398427	C2orf84	-0.55	-5.2	-0.39	6.23e-7	Asthma;
PAAD	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	1.21	15.77	0.79	8.21e-34	Longevity;
PAAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.17	-0.39	7.31e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg26677194	chr12:130822605	PIWIL1	-0.6	-6.24	-0.45	4.05e-9	Menopause (age at onset);
PAAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg23719950	chr11:63933701	MACROD1	0.49	4.31	0.33	2.86e-5	Platelet count;
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.77	9.4	0.61	7.85e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09695851	chr17:3907499	NA	0.69	6.97	0.49	8.86e-11	Type 2 diabetes;
PAAD	cis	rs5753037	0.838	rs28749829	chr22:30219326	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.49	-0.34	1.41e-5	Type 1 diabetes;
PAAD	cis	rs10090774	0.965	rs12548549	chr8:141967272	A/G	cg02508881	chr8:142216119	NA	0.4	4.25	0.33	3.67e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg17346650	chr17:80929145	B3GNTL1	0.46	5.62	0.41	8.93e-8	Glycated hemoglobin levels;
PAAD	cis	rs7172971	0.688	rs4924620	chr15:42380429	C/T	cg07013680	chr15:42186124	SPTBN5	0.53	4.27	0.33	3.4e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.55	0.41	1.23e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.93	-0.49	1.1e-10	Psoriasis;
PAAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.5	-4.78	-0.36	4.1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs41271473	0.687	rs35637401	chr1:228883578	T/C	cg10167378	chr1:228756711	NA	0.54	4.67	0.35	6.45e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg24112000	chr20:60950667	NA	-0.7	-8.95	-0.59	1.15e-15	Colorectal cancer;
PAAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg23033748	chr14:75592666	NEK9	0.41	5.05	0.38	1.27e-6	Height;
PAAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.59	-5.14	-0.38	8.3e-7	Schizophrenia;
PAAD	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg15571903	chr15:79123663	NA	0.4	4.93	0.37	2.1e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.68	7.73	0.53	1.39e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs732765	0.734	rs888418	chr14:75119296	C/T	cg17347104	chr14:75034677	LTBP2	0.64	5.46	0.4	1.9e-7	Non-small cell lung cancer;
PAAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg21994822	chr11:66741747	C11orf86	0.4	4.43	0.34	1.79e-5	HIV-1 susceptibility;
PAAD	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg07978099	chr16:83986941	OSGIN1	0.62	5.07	0.38	1.12e-6	Pursuit maintenance gain;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.8	8.18	0.55	1.04e-13	Corneal astigmatism;
PAAD	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg26585981	chr11:48327164	OR4S1	0.5	4.39	0.34	2.1e-5	Migraine - clinic-based;
PAAD	cis	rs6076065	0.723	rs1419009	chr20:23365094	G/A	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	8.04e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg04398451	chr17:18023971	MYO15A	0.46	4.58	0.35	9.55e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14119001	chr9:139324193	INPP5E	-0.58	-5.41	-0.4	2.43e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10242455	0.702	rs6976017	chr7:99249999	G/A	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.69	7.52	0.52	4.35e-12	Longevity;
PAAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.56	7.36	0.51	1.1e-11	Renal cell carcinoma;
PAAD	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg07475973	chr22:42306951	NA	0.47	4.4	0.34	2.04e-5	Neuroticism;
PAAD	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.33	-0.4	3.45e-7	Schizophrenia;
PAAD	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.43	5.05	0.38	1.25e-6	Uric acid levels;
PAAD	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.35	-0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.78	-0.42	4.14e-8	Airway imaging phenotypes;
PAAD	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg19442545	chr10:75533431	FUT11	-0.43	-4.37	-0.33	2.33e-5	Inflammatory bowel disease;
PAAD	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.97	-10.67	-0.65	3.44e-20	Multiple myeloma;
PAAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg11663144	chr21:46675770	NA	-0.49	-5.98	-0.44	1.5e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.46	4.91	0.37	2.35e-6	Age at first birth;
PAAD	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.76	-7.22	-0.51	2.31e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg09760422	chr2:128146352	NA	-0.33	-5.48	-0.41	1.74e-7	Protein C levels;
PAAD	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.23	0.39	5.62e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6076065	0.723	rs743023	chr20:23400852	T/C	cg11657817	chr20:23433608	CST11	0.5	4.99	0.38	1.65e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.67	-6.36	-0.46	2.25e-9	Breast cancer;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg10434728	chr15:90938212	IQGAP1	-0.44	-4.73	-0.36	5.12e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.94	-0.49	1.08e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10512697	0.655	rs35249343	chr5:3463116	G/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.49	-5.01	-0.38	1.51e-6	Tonsillectomy;
PAAD	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.6	5.45	0.4	1.99e-7	Retinal vascular caliber;
PAAD	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg02696790	chr15:75250997	RPP25	-0.37	-4.43	-0.34	1.77e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.76	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg03700679	chr2:178418002	TTC30B	-0.51	-4.48	-0.34	1.45e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.75	-4.44	-0.34	1.74e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs77633900	0.772	rs2956873	chr15:76695305	G/A	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs860295	0.580	rs11264358	chr1:155280164	T/C	cg02153340	chr1:155202674	NA	-0.52	-4.68	-0.35	6.3e-6	Body mass index;
PAAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	6.17	0.45	6e-9	Initial pursuit acceleration;
PAAD	cis	rs2036402	0.911	rs7717643	chr5:156360193	A/C	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.19e-5	Hypertriglyceridemia;
PAAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.68	-7.52	-0.52	4.36e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.48	4.5	0.34	1.37e-5	Platelet count;
PAAD	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-4.83	-0.36	3.28e-6	Mean platelet volume;
PAAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg04378127	chr16:30968679	SETD1A	-0.62	-6.33	-0.46	2.58e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.6	-6.34	-0.46	2.53e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.65	-7.45	-0.52	6.39e-12	Huntington's disease progression;
PAAD	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.81	10.03	0.63	1.75e-18	Bladder cancer;
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18301423	chr5:131593218	PDLIM4	0.5	4.44	0.34	1.7e-5	Acylcarnitine levels;
PAAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.27	0.39	4.53e-7	Rheumatoid arthritis;
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	1.01	8.26	0.56	6.69e-14	Initial pursuit acceleration;
PAAD	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Bladder cancer;
PAAD	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7799006	0.723	rs4719469	chr7:2286778	T/C	cg08027265	chr7:2291960	NA	-0.67	-6.84	-0.49	1.78e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg00999904	chr2:3704751	ALLC	-0.4	-4.65	-0.35	7.3e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.79	-8.48	-0.57	1.87e-14	Magnesium levels;
PAAD	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.53	4.64	0.35	7.55e-6	Dialysis-related mortality;
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.2	0.7	2.64e-24	Mean corpuscular volume;
PAAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.14	9.78	0.62	8.14e-18	Vitiligo;
PAAD	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.8	7.97	0.54	3.44e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6494488	0.500	rs72741319	chr15:64716977	C/G	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg20673841	chr7:107026890	COG5	0.47	4.29	0.33	3.16e-5	Coronary artery disease;
PAAD	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.4	0.68	3.77e-22	Chronic sinus infection;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg18279126	chr7:2041391	MAD1L1	0.56	5.57	0.41	1.11e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.81	8.55	0.57	1.25e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs13053817	0.846	rs56305531	chr22:29822763	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.56	-4.9	-0.37	2.45e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.58	5.6	0.41	9.87e-8	Neuroticism;
PAAD	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	12.5	0.71	4.27e-25	Primary sclerosing cholangitis;
PAAD	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.51	-5.32	-0.4	3.67e-7	Type 2 diabetes;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	5.94	0.43	1.86e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-5.9	-0.43	2.24e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg15440763	chr7:158190612	PTPRN2	0.49	5.01	0.38	1.5e-6	Obesity-related traits;
PAAD	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-6.67	-0.48	4.52e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg14061069	chr19:46274453	DMPK	-0.59	-5.52	-0.41	1.43e-7	Eosinophil counts;
PAAD	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.73	-7.9	-0.54	5.3e-13	Prudent dietary pattern;
PAAD	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-4.42	-0.34	1.86e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.75	6.37	0.46	2.14e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1497828	1.000	rs2815225	chr1:217529336	C/T	cg04411442	chr1:217543379	NA	-0.47	-4.52	-0.34	1.24e-5	Dialysis-related mortality;
PAAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	1.07	5.73	0.42	5.26e-8	Body mass index;
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.66	-0.42	7.19e-8	Lung cancer;
PAAD	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg00800038	chr16:89945340	TCF25	-0.72	-4.44	-0.34	1.74e-5	Skin colour saturation;
PAAD	cis	rs17539620	0.702	rs62434165	chr6:154876834	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	7.31	0.51	1.42e-11	Lipoprotein (a) levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25753841	chr19:3500584	DOHH	0.59	7.05	0.5	5.83e-11	Monocyte percentage of white cells;
PAAD	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg20487152	chr13:99095054	FARP1	-0.63	-5.76	-0.42	4.53e-8	Neuroticism;
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.51	-4.49	-0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14159672	chr1:205819179	PM20D1	0.86	9.61	0.61	2.21e-17	Monocyte percentage of white cells;
PAAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.16	0.45	6.21e-9	Major depressive disorder;
PAAD	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.45	4.69	0.36	6.12e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg24479590	chr17:7348322	CHRNB1	0.43	4.76	0.36	4.53e-6	Height;
PAAD	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.72	7.1	0.5	4.49e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.39	-0.46	1.97e-9	Neuroticism;
PAAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg18666930	chr2:3658894	COLEC11	-0.43	-4.35	-0.33	2.44e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1376877	0.519	rs113217304	chr2:204281120	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.6	4.91	0.37	2.37e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.55	-5.14	-0.38	8.24e-7	Retinal vascular caliber;
PAAD	cis	rs6804624	0.676	rs2262623	chr3:99164806	A/G	cg02646433	chr3:99218170	NA	0.43	4.36	0.33	2.35e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.51	-5.09	-0.38	1.06e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.57	-5.71	-0.42	5.76e-8	Ulcerative colitis;
PAAD	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.04	-0.38	1.31e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13939156	chr17:80058883	NA	-0.41	-4.4	-0.34	1.99e-5	Life satisfaction;
PAAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09286183	chr16:2042466	SYNGR3	-0.47	-4.53	-0.35	1.17e-5	Insulin-like growth factors;
PAAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1109501	0.689	rs28847396	chr4:71417525	A/T	cg25553522	chr4:71388589	AMTN	0.54	4.59	0.35	9.35e-6	Alcoholism (heaviness of drinking);
PAAD	cis	rs7259965	0.839	rs3786547	chr19:41506191	T/C	cg20630647	chr19:41531805	NA	0.48	4.41	0.34	1.96e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.77	6.83	0.48	1.94e-10	Mean platelet volume;
PAAD	cis	rs7727544	0.548	rs2069616	chr5:131408077	A/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.75	-0.36	4.76e-6	Blood metabolite levels;
PAAD	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.62	5.62	0.42	8.72e-8	HIV-1 control;
PAAD	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg16898833	chr6:26189333	HIST1H4D	0.99	4.96	0.37	1.86e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07432643	chr22:50247581	ZBED4	0.62	6.42	0.46	1.67e-9	Myopia (pathological);
PAAD	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.84	-6.04	-0.44	1.14e-8	Ulcerative colitis;
PAAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	6.0	0.44	1.37e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.48	5.59	0.41	1.03e-7	Coronary artery disease;
PAAD	cis	rs12282928	0.959	rs1393788	chr11:48279416	A/G	cg22827986	chr11:48284249	OR4X1	0.4	5.02	0.38	1.45e-6	Migraine - clinic-based;
PAAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09835421	chr16:68378352	PRMT7	-1.19	-8.53	-0.57	1.34e-14	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs4900109	0.630	rs57484434	chr14:92784669	A/G	cg14476212	chr3:127535191	MGLL	-0.47	-6.32	-0.46	2.72e-9	Iris characteristics;
PAAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg22875332	chr1:76189707	ACADM	-0.5	-5.02	-0.38	1.44e-6	Daytime sleep phenotypes;
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.43	4.8	0.36	3.82e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6683383	1.000	rs17510253	chr1:203083151	C/T	cg17721249	chr1:203598594	ATP2B4	-0.46	-4.29	-0.33	3.13e-5	Asthma;
PAAD	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg21951975	chr1:209979733	IRF6	0.53	5.16	0.39	7.45e-7	Coronary artery disease;
PAAD	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.55	4.87	0.37	2.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs16958440	1.000	rs62096478	chr18:44662409	A/G	cg17192377	chr18:44677553	HDHD2	0.93	5.73	0.42	5.16e-8	Sitting height ratio;
PAAD	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.66	5.67	0.42	6.87e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg18944383	chr4:111397179	ENPEP	-0.68	-8.1	-0.55	1.66e-13	Coronary artery disease;
PAAD	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.5	4.44	0.34	1.72e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs4919087	0.590	rs1253401	chr10:99050270	G/A	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs1561176	0.830	rs34684769	chr7:154991646	G/A	cg08570118	chr7:155025533	NA	-0.49	-4.57	-0.35	9.88e-6	Personality dimensions;
PAAD	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.54	0.41	1.33e-7	Total body bone mineral density;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6137287	0.889	rs6035800	chr20:21151348	C/T	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26155979	chr10:105110866	PCGF6	0.66	6.95	0.49	9.94e-11	Primary biliary cholangitis;
PAAD	cis	rs9815354	0.953	rs1717010	chr3:41946903	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.79	-0.42	3.97e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.14	-0.45	7e-9	Fibrinogen levels;
PAAD	cis	rs7129556	0.954	rs6592738	chr11:77323126	C/T	cg12586386	chr11:77299805	AQP11	0.45	4.26	0.33	3.57e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs990171	0.511	rs4851013	chr2:103116135	C/T	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.22	-0.39	5.67e-7	Lymphocyte counts;
PAAD	cis	rs7236492	0.872	rs79617804	chr18:77237142	G/A	cg15644404	chr18:77186268	NFATC1	-0.96	-5.97	-0.44	1.61e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	1.01	8.26	0.56	6.69e-14	Initial pursuit acceleration;
PAAD	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	4.37	0.33	2.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.68	-6.83	-0.48	1.91e-10	White matter hyperintensity burden;
PAAD	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.48	4.34	0.33	2.55e-5	HDL cholesterol;
PAAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.51	0.61	4.03e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.58	6.14	0.45	6.77e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19337854	chr7:99768885	GPC2	-0.45	-4.79	-0.36	3.98e-6	Coronary artery disease;
PAAD	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.59	7.04	0.5	6.25e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg13259177	chr13:114761607	RASA3	-0.87	-6.93	-0.49	1.14e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-4.6	-0.35	8.75e-6	Cystic fibrosis severity;
PAAD	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.9	-0.37	2.38e-6	Body mass index;
PAAD	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg11657817	chr20:23433608	CST11	0.41	4.49	0.34	1.38e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.98	-0.37	1.73e-6	Pulmonary function;
PAAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs7264396	0.887	rs10359	chr20:34099789	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.77	-0.42	4.33e-8	Total cholesterol levels;
PAAD	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.82	-7.97	-0.54	3.53e-13	Corneal astigmatism;
PAAD	trans	rs901683	1.000	rs35034867	chr10:46039565	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.58	-0.35	9.7e-6	Inflammatory bowel disease;
PAAD	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs12760731	0.517	rs34437852	chr1:178228721	T/C	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg23719950	chr11:63933701	MACROD1	-0.49	-4.26	-0.33	3.62e-5	Platelet count;
PAAD	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.68	8.99	0.59	9.01e-16	Hemoglobin concentration;
PAAD	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20645941	chr18:71815161	FBXO15;C18orf55	-0.66	-6.32	-0.46	2.73e-9	Neuroticism;
PAAD	cis	rs7998202	0.667	rs282569	chr13:113371507	T/C	cg02820901	chr13:113351484	ATP11A	0.71	4.76	0.36	4.49e-6	Glycated hemoglobin levels;
PAAD	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.36	-4.54	-0.35	1.14e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.65	7.74	0.53	1.31e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7119038	0.865	rs7117261	chr11:118741157	T/C	cg04176122	chr11:118779835	BCL9L	-0.46	-4.59	-0.35	9.25e-6	Sjögren's syndrome;
PAAD	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00142150	chr22:38071001	LGALS1	0.69	7.73	0.53	1.39e-12	Fat distribution (HIV);
PAAD	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.45	5.86	0.43	2.77e-8	Primary biliary cholangitis;
PAAD	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg21466736	chr12:48725269	NA	0.51	4.76	0.36	4.47e-6	Glycated hemoglobin levels;
PAAD	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs950037	0.710	rs12066361	chr1:89303698	A/C	cg13109106	chr1:89333529	GTF2B	0.47	4.57	0.35	1e-5	Coronary artery disease;
PAAD	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg23815491	chr16:72088622	HP	0.41	4.44	0.34	1.71e-5	Fibrinogen levels;
PAAD	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4722166	0.597	rs2002792	chr7:22763845	C/G	cg05472934	chr7:22766657	IL6	0.78	9.64	0.62	1.82e-17	Lung cancer;
PAAD	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.67	7.68	0.53	1.77e-12	High light scatter reticulocyte count;
PAAD	cis	rs400736	0.562	rs7550111	chr1:8181825	C/T	cg25007680	chr1:8021821	PARK7	-0.46	-4.27	-0.33	3.45e-5	Response to antidepressants and depression;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.57	-6.45	-0.46	1.42e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs77880822	0.562	rs6078405	chr20:1247246	T/C	cg23117778	chr20:1206693	RAD21L1	0.75	4.6	0.35	8.72e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg02745156	chr12:32552066	NA	0.44	4.87	0.37	2.77e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07362569	chr17:61921086	SMARCD2	0.66	8.16	0.55	1.16e-13	Prudent dietary pattern;
PAAD	cis	rs9944715	1.000	rs12605945	chr18:43834118	A/G	cg00381974	chr18:44260357	ST8SIA5	-0.47	-4.25	-0.33	3.65e-5	Red cell distribution width;Mean corpuscular volume;
PAAD	cis	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg20893579	chr22:38215064	NA	-0.45	-4.58	-0.35	9.43e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	0.47	4.38	0.33	2.18e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2790216	1.000	rs2590348	chr10:60014595	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.63	6.13	0.45	7.08e-9	Hemoglobin concentration;
PAAD	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.65	6.79	0.48	2.37e-10	Testicular germ cell tumor;
PAAD	cis	rs117623576	0.680	rs740859	chr10:32361839	G/A	cg03047570	chr10:32398778	NA	-0.69	-4.61	-0.35	8.56e-6	Anti-saccade response;
PAAD	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.76	-0.48	2.72e-10	Psoriasis;
PAAD	cis	rs9549328	0.837	rs7988967	chr13:113651160	A/G	cg17524180	chr13:113633600	MCF2L	-0.49	-5.16	-0.39	7.7e-7	Systolic blood pressure;
PAAD	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-4.57	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.68	0.35	6.3e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18364779	chr6:26104403	HIST1H4C	0.51	4.75	0.36	4.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12681963	0.688	rs7004466	chr8:30054294	A/T	cg23406830	chr8:30012838	DCTN6	-0.7	-4.34	-0.33	2.57e-5	Migraine;
PAAD	cis	rs354033	0.837	rs59347948	chr7:149193933	T/A	cg06920324	chr7:149264011	ZNF767	-0.59	-4.95	-0.37	1.96e-6	Multiple sclerosis;
PAAD	cis	rs644799	0.562	rs1616015	chr11:95491685	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	-0.67	-7.58	-0.52	3.16e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.21	-0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.69	5.92	0.43	2.04e-8	Common traits (Other);
PAAD	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg22189786	chr22:42395067	WBP2NL	-0.53	-4.42	-0.34	1.89e-5	Birth weight;
PAAD	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg20893579	chr22:38215064	NA	0.51	4.74	0.36	4.94e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg18892244	chr7:807596	HEATR2	-0.61	-6.43	-0.46	1.6e-9	Subjective well-being;
PAAD	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.81	9.5	0.61	4.22e-17	Morning vs. evening chronotype;
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg10864074	chr7:100318194	EPO	-0.47	-4.49	-0.34	1.43e-5	Other erythrocyte phenotypes;
PAAD	cis	rs2117029	0.555	rs9788139	chr12:49520669	C/T	cg05368762	chr12:50135785	TMBIM6	0.44	4.41	0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg10167378	chr1:228756711	NA	0.52	4.8	0.36	3.81e-6	Diastolic blood pressure;
PAAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.52	-4.73	-0.36	5.12e-6	Red blood cell traits;
PAAD	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.69	6.71	0.48	3.67e-10	Cystic fibrosis severity;
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.66	5.94	0.43	1.85e-8	Blood metabolite levels;
PAAD	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.11	9.6	0.61	2.39e-17	Red blood cell traits;
PAAD	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.49	0.34	1.4e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21868353	chr19:12818102	SNORD41;TNPO2	-0.65	-6.42	-0.46	1.67e-9	Obesity-related traits;
PAAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	5.43	0.4	2.23e-7	Mood instability;
PAAD	cis	rs3206736	0.520	rs328934	chr7:35043726	C/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.98	-0.54	3.31e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.03	-0.44	1.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6915773	0.834	rs9401196	chr6:98274551	G/A	cg00987395	chr6:98934664	NA	0.38	4.47	0.34	1.51e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.92	10.44	0.65	1.42e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg26031613	chr14:104095156	KLC1	-0.44	-4.41	-0.34	1.96e-5	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.52	5.36	0.4	3.02e-7	Menopause (age at onset);
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.45	-5.72	-0.42	5.55e-8	Ulcerative colitis;
PAAD	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg13160058	chr8:26243215	BNIP3L	-0.42	-5.17	-0.39	7.26e-7	Red cell distribution width;
PAAD	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.45	4.52	0.34	1.26e-5	Airway imaging phenotypes;
PAAD	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.8e-10	Response to antipsychotic treatment;
PAAD	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-4.41	-0.34	1.91e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12165864	chr7:66369176	NA	-0.82	-5.06	-0.38	1.17e-6	Diabetic kidney disease;
PAAD	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg13374026	chr7:158955107	NA	0.45	4.25	0.33	3.75e-5	Facial morphology (factor 20);
PAAD	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.85	-0.54	7.03e-13	Mosquito bite size;
PAAD	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.04	-0.38	1.3e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05407778	chr3:127399268	ABTB1	0.53	6.32	0.46	2.73e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.33	0.81	8.1e-38	Height;
PAAD	cis	rs3867498	0.943	rs17178750	chr15:25071289	T/G	cg08194505	chr15:25684383	UBE3A	-0.63	-4.52	-0.34	1.22e-5	Pulmonary function;
PAAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1468333	0.667	rs11567972	chr5:137663093	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.42	0.4	2.26e-7	Resting heart rate;
PAAD	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.38	-0.46	2e-9	Retinal vascular caliber;
PAAD	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.79	-6.99	-0.49	8.19e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.88	-14.11	-0.75	1.95e-29	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20517149	chr3:59960363	FHIT	-0.53	-6.66	-0.48	4.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.38	0.56	3.23e-14	Alzheimer's disease;
PAAD	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.24	7.06	0.5	5.5e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.53	5.48	0.41	1.69e-7	Menopause (age at onset);
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.74	7.56	0.52	3.48e-12	Prostate cancer;
PAAD	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg04165759	chr1:150448943	RPRD2	0.51	5.23	0.39	5.44e-7	Migraine;
PAAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-1.03	-14.33	-0.76	5.33e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs62392365	0.536	rs303020	chr6:25137516	C/G	cg01382804	chr6:25931017	SLC17A2	1.02	4.69	0.36	5.92e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13560548	chr3:10150139	C3orf24	0.6	5.56	0.41	1.18e-7	Alzheimer's disease;
PAAD	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.69	4.84	0.37	3.22e-6	Inflammatory bowel disease;
PAAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg05643964	chr20:62369504	LIME1	-0.51	-4.73	-0.36	5.01e-6	Prostate cancer;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg25087352	chr3:24213704	THRB	0.74	6.34	0.46	2.48e-9	Photic sneeze reflex;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.8	6.75	0.48	2.93e-10	Gut microbiome composition (summer);
PAAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs288326	0.561	rs78745965	chr2:183848475	T/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg18964960	chr10:1102726	WDR37	0.82	4.32	0.33	2.82e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.52	5.44	0.4	2.12e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.96	-0.44	1.67e-8	QT interval;
PAAD	cis	rs9810890	1.000	rs116479497	chr3:128545382	G/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.93	12.45	0.71	5.72e-25	Prudent dietary pattern;
PAAD	cis	rs10214930	0.813	rs6946305	chr7:27681195	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.34	0.4	3.31e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6132905	0.596	rs77117476	chr20:2611493	T/C	cg24848351	chr20:2622020	TMC2	-0.64	-4.46	-0.34	1.61e-5	Mumps;
PAAD	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.69	4.75	0.36	4.66e-6	Hip geometry;
PAAD	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.81	-8.43	-0.56	2.48e-14	Cystic fibrosis severity;
PAAD	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.46	5.09	0.38	1.04e-6	Blood protein levels;
PAAD	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.64	5.03	0.38	1.39e-6	IgE levels;
PAAD	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2133450	0.526	rs62237060	chr3:7346588	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.04	-0.38	1.28e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17376030	chr22:41985996	PMM1	-0.68	-4.69	-0.36	6.04e-6	Vitiligo;
PAAD	cis	rs12613586	1	rs12613586	chr2:112948954	C/T	cg02781088	chr2:113192302	RGPD8;RGPD5	0.61	4.69	0.36	6.05e-6	Neuroticism;
PAAD	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg02820901	chr13:113351484	ATP11A	-0.7	-4.49	-0.34	1.38e-5	Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10367011	chr12:132434599	EP400	0.62	7.37	0.51	1.04e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs496547	0.756	rs562059	chr11:118602058	G/T	cg08498647	chr11:118550644	TREH	-0.39	-4.72	-0.36	5.29e-6	Hip minimal joint space width;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.92	-0.37	2.2e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.86	9.66	0.62	1.68e-17	Multiple system atrophy;
PAAD	cis	rs7873102	0.702	rs7034351	chr9:38019458	A/G	cg03528946	chr9:38069800	SHB	-0.53	-5.31	-0.4	3.81e-7	Brain structure;
PAAD	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.1	-0.44	8.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.48	0.41	1.76e-7	Colorectal cancer;
PAAD	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.71	6.22	0.45	4.55e-9	Pubertal anthropometrics;
PAAD	cis	rs7264396	0.887	rs224351	chr20:34052273	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-6.36	-0.46	2.19e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.63	6.23	0.45	4.4e-9	Monocyte count;
PAAD	cis	rs2279817	0.863	rs13375960	chr1:18016687	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.78	-0.42	4.02e-8	Neuroticism;
PAAD	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg08632701	chr21:37451849	NA	-0.64	-6.55	-0.47	8.38e-10	Mitral valve prolapse;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25100011	chr1:33146725	RBBP4;SYNC	-0.58	-6.76	-0.48	2.83e-10	Monocyte percentage of white cells;
PAAD	cis	rs12529514	1.000	rs6932936	chr6:14115090	A/AT	cg01288598	chr6:14118227	CD83	0.59	4.94	0.37	2.01e-6	Rheumatoid arthritis;
PAAD	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.2	0.39	6.27e-7	Schizophrenia;
PAAD	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.81	6.32	0.46	2.71e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs6132905	0.590	rs7269323	chr20:2627197	A/G	cg24848351	chr20:2622020	TMC2	-0.77	-5.57	-0.41	1.12e-7	Mumps;
PAAD	cis	rs60154123	0.730	rs12030512	chr1:210466886	A/G	cg21951975	chr1:209979733	IRF6	0.49	4.44	0.34	1.75e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-1.17	-11.21	-0.67	1.23e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.66	7.15	0.5	3.42e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.55	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.87	-11.0	-0.67	4.6e-21	Aortic root size;
PAAD	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.94	12.49	0.71	4.31e-25	Menopause (age at onset);
PAAD	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.96e-9	Breast cancer;
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.58	5.22	0.39	5.87e-7	Monocyte count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22661341	chr2:36753857	CRIM1	0.68	6.41	0.46	1.7e-9	Neuroticism;
PAAD	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.77	-0.42	4.34e-8	Schizophrenia;
PAAD	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.75	8.11	0.55	1.53e-13	Corneal astigmatism;
PAAD	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.97	8.93	0.59	1.31e-15	Resting heart rate;
PAAD	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-4.32	-0.33	2.75e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg13565585	chr5:132299512	AFF4	0.61	4.36	0.33	2.4e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12233833	chr10:830825	NA	-0.64	-7.55	-0.52	3.74e-12	Body fat percentage;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11855759	chr17:9548802	USP43	0.55	6.34	0.46	2.45e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06060673	chr22:39268830	CBX6	0.62	6.7	0.48	3.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.56	7.65	0.53	2.09e-12	IgA nephropathy;
PAAD	cis	rs74544699	1.000	rs353028	chr4:74777223	C/T	cg16072462	chr4:74847758	PF4	1.18	4.46	0.34	1.59e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.64	-8.19	-0.55	9.75e-14	Body mass index;
PAAD	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.86	0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.77	9.87	0.63	4.52e-18	Alcohol dependence;
PAAD	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.6	7.08	0.5	4.85e-11	Birth weight;
PAAD	cis	rs7615916	0.542	rs12497191	chr3:12390135	A/G	cg23514324	chr3:12329213	PPARG	0.65	4.44	0.34	1.69e-5	Eosinophil percentage of white cells;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg04522676	chr10:134968826	NA	0.48	4.47	0.34	1.5e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02178630	chr2:218678534	TNS1	-0.72	-6.86	-0.49	1.62e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.61	7.43	0.52	7.49e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.35	0.33	2.5e-5	Renal cell carcinoma;
PAAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.64	-5.99	-0.44	1.46e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	trans	rs2725236	0.520	rs6832511	chr4:88909088	G/A	cg23656380	chr20:60877581	ADRM1	-0.61	-6.3	-0.46	2.98e-9	Caffeine consumption;
PAAD	cis	rs11581903	0.929	rs6679249	chr1:53050461	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	-0.79	-5.49	-0.41	1.62e-7	Joint mobility (Beighton score);
PAAD	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.56	6.12	0.44	7.42e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.69	-6.37	-0.46	2.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg20607287	chr7:12443886	VWDE	-0.59	-4.84	-0.37	3.17e-6	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.8	8.31	0.56	4.96e-14	Selective IgA deficiency;
PAAD	cis	rs9394841	0.692	rs3806113	chr6:41876335	C/T	cg08135965	chr6:41755394	TOMM6	0.42	4.42	0.34	1.87e-5	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.73	-7.44	-0.52	6.74e-12	Retinal vascular caliber;
PAAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26926768	chr12:34528122	NA	0.4	4.84	0.37	3.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.55	7.77	0.53	1.07e-12	Schizophrenia;
PAAD	cis	rs300774	0.925	rs300706	chr2:141540	A/C	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7631605	0.905	rs11707197	chr3:37122329	A/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg23216685	chr1:86174607	ZNHIT6	-0.35	-5.57	-0.41	1.11e-7	Urate levels in overweight individuals;
PAAD	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-9.08	-0.59	5.24e-16	Body mass index;
PAAD	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.36	-0.33	2.43e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg17372223	chr3:52568218	NT5DC2	0.57	5.4	0.4	2.56e-7	Electroencephalogram traits;
PAAD	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-4.57	-0.35	1.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6489785	0.547	rs625228	chr12:121278266	G/A	cg02419362	chr12:121203948	SPPL3	-0.48	-5.29	-0.39	4.15e-7	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.2	0.5	2.63e-11	Corneal astigmatism;
PAAD	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.4	5.0	0.38	1.58e-6	Pulmonary function;
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.94	12.03	0.7	7.69e-24	Menopause (age at onset);
PAAD	cis	rs818427	0.964	rs351769	chr5:112199974	C/T	cg06941702	chr5:112196734	SRP19	-0.45	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.46	-0.52	6.07e-12	Height;
PAAD	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg15145965	chr22:50218605	BRD1	0.71	4.37	0.33	2.25e-5	Schizophrenia;
PAAD	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00791764	chr4:53727839	RASL11B	0.51	4.48	0.34	1.45e-5	Optic nerve measurement (cup area);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21132860	chr20:42219846	IFT52	-0.76	-6.36	-0.46	2.22e-9	Neuroticism;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.65	-7.7	-0.53	1.62e-12	Vitiligo;
PAAD	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	1.11	11.55	0.68	1.54e-22	Platelet distribution width;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.64	4.78	0.36	4.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.48	-4.93	-0.37	2.16e-6	Longevity;Endometriosis;
PAAD	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.05	0.5	6e-11	Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09125723	chr2:122096106	CLASP1	-0.65	-6.39	-0.46	1.92e-9	Obesity-related traits;
PAAD	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.83	-9.98	-0.63	2.38e-18	Hemoglobin concentration;
PAAD	cis	rs4705952	0.832	rs2706391	chr5:131843306	T/C	cg05209330	chr5:131550942	P4HA2	0.51	4.26	0.33	3.57e-5	C-reactive protein levels;
PAAD	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	12.04	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg26516362	chr5:178986906	RUFY1	-0.39	-4.63	-0.35	7.95e-6	Lung cancer;
PAAD	cis	rs2415984	0.622	rs61993301	chr14:46949667	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.37e-7	Number of children ever born;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg15181151	chr6:150070149	PCMT1	0.56	6.0	0.44	1.41e-8	Lung cancer;
PAAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg15017067	chr4:17643749	FAM184B	0.38	4.25	0.33	3.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6782025	0.837	rs661160	chr3:120656945	C/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.29	-12.33	-0.71	1.2e-24	Hip circumference adjusted for BMI;
PAAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-1.36	-10.13	-0.63	9.61e-19	Magnesium levels;
PAAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.09	0.38	1.04e-6	Schizophrenia;
PAAD	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.38	-0.51	9.79e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12304921	1.000	rs59546367	chr12:51345373	T/C	cg18059802	chr12:51347058	HIGD1C	-0.72	-5.94	-0.43	1.88e-8	Type 2 diabetes;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg05342682	chr7:94953680	PON1	-0.55	-4.78	-0.36	4.11e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg15890332	chr12:107067104	RFX4	0.42	4.71	0.36	5.48e-6	Total body bone mineral density;
PAAD	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.51	-5.95	-0.43	1.82e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.53	5.42	0.4	2.25e-7	Major depressive disorder;
PAAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg23957660	chr17:17878224	LRRC48	0.37	4.32	0.33	2.77e-5	Total body bone mineral density;
PAAD	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg00262122	chr8:11665843	FDFT1	-0.48	-4.25	-0.33	3.71e-5	Retinal vascular caliber;
PAAD	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg18833306	chr6:118973337	C6orf204	0.44	4.56	0.35	1.06e-5	Electrocardiographic conduction measures;
PAAD	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.93	-10.71	-0.66	2.65e-20	Colorectal adenoma (advanced);
PAAD	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.68	6.54	0.47	9.02e-10	Obesity-related traits;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg07234876	chr8:600039	NA	-1.09	-7.34	-0.51	1.22e-11	IgG glycosylation;
PAAD	cis	rs6460942	0.597	rs17544637	chr7:12521871	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.07	0.5	5.14e-11	Systemic lupus erythematosus;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	1.03	15.04	0.77	6.98e-32	Menarche (age at onset);
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.46	-0.46	1.35e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.73	-0.42	5.12e-8	Total cholesterol levels;
PAAD	cis	rs1539053	0.934	rs1524708	chr1:58102590	T/A	cg00026909	chr1:58089001	DAB1	-0.66	-7.44	-0.52	6.92e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.52	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs66530629	0.874	rs4648876	chr1:25097392	A/G	cg01905478	chr1:25040257	NA	-0.46	-5.03	-0.38	1.35e-6	Plateletcrit;
PAAD	cis	rs6142102	0.517	rs6142046	chr20:32514061	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.57	0.35	9.84e-6	Skin pigmentation;
PAAD	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.61	-5.89	-0.43	2.38e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-1.2	-9.88	-0.63	4.47e-18	Obesity-related traits;
PAAD	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg11204139	chr17:3907470	NA	-0.68	-6.97	-0.49	8.94e-11	Type 2 diabetes;
PAAD	cis	rs617219	0.710	rs2607141	chr5:78558635	G/T	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg13919466	chr1:32135498	COL16A1	-0.43	-4.73	-0.36	5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.18	8.78	0.58	3.16e-15	Lymphocyte counts;
PAAD	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.31	0.73	2.77e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13090596	chr6:74079540	OOEP	0.58	6.73	0.48	3.2e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg01200585	chr1:228362443	C1orf69	0.64	6.48	0.47	1.21e-9	Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg05697835	chr1:2722811	NA	-0.43	-4.74	-0.36	4.79e-6	Ulcerative colitis;
PAAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.65	5.46	0.4	1.94e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.71	6.61	0.47	6.26e-10	Parkinson's disease;
PAAD	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg24881330	chr22:46731750	TRMU	1.17	5.76	0.42	4.49e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.98	12.47	0.71	4.97e-25	Age-related hearing impairment;
PAAD	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.33	-6.06	-0.44	1.02e-8	Type 2 diabetes;
PAAD	cis	rs853679	0.567	rs16894091	chr6:28390137	A/T	cg14547644	chr6:28411285	ZSCAN23	0.46	4.59	0.35	9.36e-6	Depression;
PAAD	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg22482690	chr17:47019901	SNF8	0.45	4.84	0.37	3.17e-6	Type 2 diabetes;
PAAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg12564285	chr5:131593104	PDLIM4	0.47	4.86	0.37	2.89e-6	Blood metabolite levels;
PAAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.67	5.86	0.43	2.72e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.99	-0.49	8.18e-11	Hip circumference;
PAAD	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08219700	chr8:58056026	NA	0.63	4.93	0.37	2.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs959260	0.765	rs12945469	chr17:73372243	G/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2252790	0.859	rs1204823	chr6:116563767	C/A	cg18764771	chr6:116381957	FRK	-0.27	-4.63	-0.35	7.93e-6	Fast beta electroencephalogram;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05358815	chr2:200324281	SATB2	-0.67	-6.84	-0.49	1.78e-10	Smoking initiation;
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.52	-5.0	-0.38	1.56e-6	Mortality in heart failure;
PAAD	cis	rs72960926	0.744	rs55795936	chr6:75006841	A/G	cg03266952	chr6:74778945	NA	-1.11	-6.35	-0.46	2.32e-9	Metabolite levels (MHPG);
PAAD	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.63	-0.35	7.79e-6	Mean corpuscular volume;
PAAD	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.78e-6	Height;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.71	-5.91	-0.43	2.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg01388757	chr2:102091195	RFX8	-0.64	-8.04	-0.55	2.3e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.13e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12476592	0.571	rs7577952	chr2:63787212	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg21775007	chr8:11205619	TDH	-0.56	-5.16	-0.39	7.67e-7	Morning vs. evening chronotype;
PAAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-6.11	-0.44	8.05e-9	Body mass index;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.47	-0.68	2.53e-22	Longevity;Endometriosis;
PAAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg18867708	chr6:26865862	GUSBL1	0.44	4.47	0.34	1.53e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-5.1	-0.38	9.94e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.72	7.34	0.51	1.23e-11	Response to antidepressants and depression;
PAAD	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.13	14.82	0.77	2.58e-31	Schizophrenia;
PAAD	cis	rs73198271	0.920	rs11783112	chr8:8606193	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	4.61	0.35	8.35e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.64	6.12	0.44	7.68e-9	Breast cancer;
PAAD	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.54	-4.75	-0.36	4.69e-6	Total body bone mineral density;
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.89	-10.52	-0.65	8.55e-20	Iron status biomarkers;
PAAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.49	0.57	1.72e-14	Homoarginine levels;
PAAD	cis	rs10821973	0.527	rs7099161	chr10:63969311	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.44	-0.34	1.75e-5	Hypothyroidism;
PAAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	8.23e-8	Life satisfaction;
PAAD	cis	rs2275565	0.872	rs12136861	chr1:237029590	T/C	cg17297354	chr1:237056641	MTR	-0.53	-4.74	-0.36	4.95e-6	Homocysteine levels;
PAAD	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.86	8.14	0.55	1.32e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs10924309	0.889	rs10924307	chr1:245858125	C/T	cg00036263	chr1:245852353	KIF26B	-0.7	-6.03	-0.44	1.2e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.71	6.53	0.47	9.3e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.64	-0.42	8.11e-8	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-6.94	-0.49	1.07e-10	Breast cancer;
PAAD	cis	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg16898833	chr6:26189333	HIST1H4D	0.99	4.9	0.37	2.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs732505	0.764	rs28528202	chr19:5583129	A/G	cg26242866	chr19:5711310	LONP1	0.98	5.38	0.4	2.7e-7	vWF and FVIII levels;
PAAD	cis	rs77880822	0.562	rs56046688	chr20:1232308	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs71415016	0.685	rs12885123	chr14:96422899	A/G	cg18424965	chr14:96670634	BDKRB2	0.55	4.35	0.33	2.49e-5	Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-4.59	-0.35	9.1e-6	Mean corpuscular volume;
PAAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-1.4	-10.44	-0.65	1.43e-19	Schizophrenia;
PAAD	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg02404636	chr22:31891804	SFI1	0.55	4.9	0.37	2.42e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.58	5.62	0.41	9.07e-8	Multiple sclerosis;
PAAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs7692976	0.503	rs9991904	chr4:110922579	A/G	cg06981781	chr4:110842888	EGF	-0.41	-4.65	-0.35	7.28e-6	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.71	8.77	0.58	3.34e-15	Dupuytren's disease;
PAAD	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.75	-0.66	2.07e-20	Ulcerative colitis;
PAAD	cis	rs10905065	0.931	rs10795510	chr10:5758827	G/A	cg11519256	chr10:5708881	ASB13	0.5	4.27	0.33	3.44e-5	Menopause (age at onset);
PAAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.91	-8.89	-0.58	1.63e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.82	-8.81	-0.58	2.62e-15	Morning vs. evening chronotype;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.96	0.44	1.71e-8	Platelet count;
PAAD	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.2	-0.5	2.55e-11	Hemoglobin concentration;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg18769074	chr3:133464867	TF	0.42	4.87	0.37	2.76e-6	Iron status biomarkers;
PAAD	cis	rs7654585	0.782	rs2309288	chr4:25947097	C/A	cg10409131	chr4:25915609	C4orf52	0.61	5.79	0.43	3.89e-8	Obesity-related traits;
PAAD	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg02770688	chr6:168491649	NA	0.48	4.95	0.37	1.91e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-8.05	-0.55	2.18e-13	Systemic lupus erythematosus;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.61	-5.79	-0.42	3.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17824933	0.848	rs11230564	chr11:60776465	A/G	cg27098804	chr11:60776124	CD6	0.45	4.38	0.33	2.21e-5	Multiple sclerosis;
PAAD	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.57	5.62	0.41	8.88e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.28	12.46	0.71	5.46e-25	Corneal structure;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.43	-4.53	-0.34	1.18e-5	Huntington's disease progression;
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.68	6.53	0.47	9.11e-10	Prostate cancer;
PAAD	cis	rs507080	0.771	rs687664	chr11:118574185	C/A	cg08498647	chr11:118550644	TREH	-0.39	-4.42	-0.34	1.83e-5	Serum metabolite levels;
PAAD	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.75	-8.3	-0.56	5.35e-14	Sudden cardiac arrest;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.41	-0.46	1.71e-9	Hemoglobin concentration;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg18281939	chr5:77783895	LHFPL2	-0.44	-5.04	-0.38	1.29e-6	Triglycerides;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg02877791	chr2:177005403	NA	0.45	4.44	0.34	1.71e-5	IgG glycosylation;
PAAD	cis	rs58653258	0.730	rs962642	chr1:234988537	G/A	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.8	-0.53	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.75	-8.74	-0.58	3.93e-15	Eye color traits;
PAAD	cis	rs950880	0.710	rs1474309	chr2:103091001	C/T	cg23450938	chr2:102972792	NA	0.42	4.4	0.34	2.05e-5	Serum protein levels (sST2);
PAAD	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1997066	0.831	rs73342230	chr10:106822962	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs11892454	0.515	rs13413825	chr2:26024450	T/A	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.09e-6	Heschl's gyrus morphology;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16149437	chr2:39245178	SOS1	0.59	6.69	0.48	3.99e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg10396713	chr8:602097	NA	-0.71	-5.05	-0.38	1.27e-6	IgG glycosylation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17639265	chr6:35887853	SRPK1	-0.7	-6.48	-0.47	1.2e-9	Neuroticism;
PAAD	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.45	-0.34	1.68e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9659323	0.632	rs12045138	chr1:119619448	G/T	cg17326555	chr1:119535693	NA	-0.38	-5.39	-0.4	2.62e-7	Body mass index;
PAAD	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.49	-4.38	-0.34	2.16e-5	Vitiligo;
PAAD	cis	rs1035491	0.715	rs1912006	chr5:63920084	G/A	cg01791865	chr5:63954708	NA	0.51	5.47	0.41	1.79e-7	Body mass index;
PAAD	cis	rs2649	0.518	rs7162745	chr15:63878889	T/A	cg22599514	chr15:63798201	USP3	0.59	4.92	0.37	2.19e-6	Aortic root size;
PAAD	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.76	6.11	0.44	7.96e-9	Weight;
PAAD	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg17524180	chr13:113633600	MCF2L	-0.49	-5.14	-0.38	8.27e-7	Systolic blood pressure;
PAAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	7.65	0.53	2.18e-12	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.55	-5.63	-0.42	8.52e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.78	-0.42	4.19e-8	Colorectal cancer;
PAAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.02	-0.63	1.81e-18	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00567696	chr6:46097521	ENPP4	0.57	6.57	0.47	7.54e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11700980	0.551	rs11701783	chr21:30115629	C/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs72827839	1.000	rs17695373	chr17:46375467	G/A	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.46	4.55	0.35	1.08e-5	Aortic root size;
PAAD	cis	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg08365438	chr10:21683093	NA	-0.68	-5.47	-0.41	1.83e-7	Photic sneeze reflex;
PAAD	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs790110	1.000	rs60226894	chr3:122384152	C/T	cg16054280	chr3:122517974	DIRC2	0.86	4.53	0.34	1.21e-5	Acoustic startle blink response;
PAAD	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.43e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.71	7.39	0.51	8.97e-12	Body mass index;
PAAD	cis	rs11892454	0.604	rs13430199	chr2:25938177	C/G	cg25181710	chr2:26045287	ASXL2	0.38	4.27	0.33	3.37e-5	Heschl's gyrus morphology;
PAAD	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	0.82	6.75	0.48	2.97e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.32	-0.33	2.86e-5	Mood instability;
PAAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.62	-0.35	8.18e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.49	4.98	0.37	1.69e-6	Colorectal cancer;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.99	13.38	0.74	1.82e-27	Menarche (age at onset);
PAAD	cis	rs6466055	0.589	rs2299298	chr7:104745818	G/A	cg04380332	chr7:105027541	SRPK2	-0.48	-4.73	-0.36	4.99e-6	Schizophrenia;
PAAD	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26031613	chr14:104095156	KLC1	1.16	15.15	0.78	3.47e-32	Body mass index;
PAAD	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.53	-5.78	-0.42	4.09e-8	Metabolite levels;
PAAD	cis	rs2882667	0.690	rs13158360	chr5:138258177	G/A	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg12623918	chr2:306882	NA	0.45	4.59	0.35	9.32e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.79	0.42	3.95e-8	Tonsillectomy;
PAAD	cis	rs986417	0.892	rs8017336	chr14:60798682	G/A	cg27398547	chr14:60952738	C14orf39	-0.81	-4.83	-0.36	3.37e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.16	-0.39	7.76e-7	Mortality in heart failure;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.87e-10	Lymphocyte counts;
PAAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.83	8.14	0.55	1.29e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs8032158	0.702	rs1042477	chr15:56121886	C/A	cg02198044	chr15:56286336	NEDD4	-0.42	-4.38	-0.33	2.21e-5	Keloid;
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.41	-0.52	8.04e-12	Total body bone mineral density;
PAAD	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	0.95	6.86	0.49	1.6e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.29	0.64	3.55e-19	Menopause (age at onset);
PAAD	cis	rs2880058	1.000	rs2880058	chr1:162014632	A/G	cg02858267	chr1:162336877	NOS1AP	0.42	4.29	0.33	3.17e-5	QT interval;
PAAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.51	4.88	0.37	2.7e-6	Hip circumference;
PAAD	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.65	6.68	0.48	4.32e-10	Breast cancer;
PAAD	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.84	-9.0	-0.59	8.59e-16	Mortality in heart failure;
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1020064	0.636	rs1529974	chr2:105927996	T/C	cg02543470	chr2:105862877	NA	-0.48	-5.33	-0.4	3.43e-7	AIDS;
PAAD	cis	rs62392365	0.543	rs1665820	chr6:25070838	C/T	cg09546929	chr6:25930894	SLC17A2	0.79	4.4	0.34	2.01e-5	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.76	9.07	0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs11168618	0.740	rs4523733	chr12:48927514	C/T	cg01881778	chr12:48919444	OR8S1	0.52	5.72	0.42	5.52e-8	Adiponectin levels;
PAAD	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.7	6.52	0.47	9.77e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9395066	0.545	rs2396372	chr6:44966867	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.85e-5	Height;
PAAD	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg24330906	chr2:85765176	MAT2A	0.43	4.35	0.33	2.51e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.48	4.29	0.33	3.18e-5	Blood metabolite levels;
PAAD	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg00749118	chr7:1938791	MAD1L1	-0.64	-4.71	-0.36	5.58e-6	Bipolar disorder;
PAAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23598886	chr18:12777645	NA	-0.77	-6.47	-0.46	1.28e-9	Inflammatory skin disease;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246760	1.000	rs1592997	chr19:9900983	G/A	cg16876255	chr19:9731953	ZNF561	0.94	4.54	0.35	1.15e-5	Pursuit maintenance gain;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.89	-0.37	2.55e-6	Longevity;Endometriosis;
PAAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18598877	chr14:102414986	NA	0.61	6.99	0.49	7.97e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1476587	0.527	rs1859127	chr7:86752142	T/A	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Brachial circumference;
PAAD	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.46	4.28	0.33	3.33e-5	High light scatter reticulocyte count;
PAAD	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg26068271	chr17:76253126	NA	0.53	5.07	0.38	1.13e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.53	-0.47	9.37e-10	Breast cancer;
PAAD	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-7.07	-0.5	5.31e-11	Ulcerative colitis;
PAAD	cis	rs12681288	1.000	rs2336696	chr8:1033802	T/C	cg04851639	chr8:1020857	NA	-0.64	-7.75	-0.53	1.24e-12	Schizophrenia;
PAAD	cis	rs1018697	1.000	rs7911528	chr10:104551567	A/G	cg04362960	chr10:104952993	NT5C2	0.6	6.17	0.45	5.83e-9	Colorectal adenoma (advanced);
PAAD	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg01305830	chr4:1604576	NA	-0.46	-4.55	-0.35	1.1e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06850241	chr22:41845214	NA	-0.48	-4.84	-0.37	3.14e-6	Vitiligo;
PAAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.18	0.5	2.85e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.51	-5.97	-0.44	1.59e-8	Dilated cardiomyopathy;
PAAD	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.94	7.59	0.52	2.97e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg16928487	chr17:17741425	SREBF1	0.37	4.83	0.36	3.33e-6	Total body bone mineral density;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg09472211	chr10:89622126	PTEN;KILLIN	-0.68	-6.85	-0.49	1.72e-10	Body mass index;
PAAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg14631576	chr9:95140430	CENPP	0.45	4.45	0.34	1.64e-5	Height;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00166722	chr3:10149974	C3orf24	0.68	6.12	0.44	7.8e-9	Alzheimer's disease;
PAAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.7	8.17	0.55	1.09e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.76	8.41	0.56	2.72e-14	Lung cancer;
PAAD	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.58	5.36	0.4	3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.96	-7.92	-0.54	4.63e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	6.33	0.46	2.56e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg18569988	chr3:195679450	NA	0.49	4.67	0.35	6.69e-6	Pancreatic cancer;
PAAD	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg25364880	chr3:44379878	C3orf23	0.56	5.05	0.38	1.26e-6	Depressive symptoms;
PAAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.86	5.76	0.42	4.61e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08677398	chr8:58056175	NA	0.73	4.89	0.37	2.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.73	-9.25	-0.6	1.94e-16	Educational attainment;
PAAD	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs7594192	0.744	rs35332031	chr2:199364616	C/T	cg03163783	chr2:200326591	SATB2	-0.33	-4.49	-0.34	1.37e-5	Educational attainment;
PAAD	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.13	9.46	0.61	5.66e-17	Red blood cell traits;
PAAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs755249	0.567	rs66727439	chr1:39711930	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs76419734	0.558	rs17260183	chr4:106533196	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	4.61	0.35	8.46e-6	Post bronchodilator FEV1;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06858584	chr2:131904854	PLEKHB2	-0.61	-7.28	-0.51	1.72e-11	Monocyte percentage of white cells;
PAAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg10645314	chr2:3704589	ALLC	-0.46	-4.84	-0.37	3.23e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.1	16.78	0.81	2.07e-36	Myeloid white cell count;
PAAD	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.45	-4.59	-0.35	9.14e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs35084382	0.793	rs34683389	chr5:172198639	C/A	cg09799633	chr5:172199460	DUSP1	-0.95	-4.55	-0.35	1.1e-5	Optic cup area;
PAAD	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg08758996	chr17:66097529	LOC651250	0.55	4.48	0.34	1.48e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7714584	1.000	rs10057988	chr5:150272062	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16296290	chr1:2136845	C1orf86	-0.69	-6.49	-0.47	1.15e-9	Neuroticism;
PAAD	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg10434728	chr15:90938212	IQGAP1	0.43	4.41	0.34	1.91e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg12623918	chr2:306882	NA	-0.45	-4.85	-0.37	2.97e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg07741184	chr6:167504864	NA	-0.35	-4.53	-0.34	1.2e-5	Primary biliary cholangitis;
PAAD	cis	rs5750830	0.594	rs6001566	chr22:39774448	A/G	cg02038168	chr22:39784481	NA	-0.54	-5.15	-0.39	7.86e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.8	-5.68	-0.42	6.65e-8	Coronary artery disease;
PAAD	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.01	0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.72	8.89	0.58	1.64e-15	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs4517514	0.509	rs11018894	chr11:89904238	C/A	cg05041596	chr11:89867385	NAALAD2	0.66	4.83	0.36	3.31e-6	Trans fatty acid levels;
PAAD	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.18	13.07	0.73	1.21e-26	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs6066825	0.606	rs4810830	chr20:47219740	T/C	cg18078177	chr20:47281410	PREX1	0.51	4.74	0.36	4.87e-6	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04226542	chr12:64173449	TMEM5	0.55	6.35	0.46	2.36e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg21427119	chr20:30132790	HM13	0.63	5.03	0.38	1.39e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs735539	0.521	rs2763001	chr13:21378018	A/C	cg27234864	chr13:21295941	IL17D	0.59	4.87	0.37	2.8e-6	Dental caries;
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.43	0.4	2.19e-7	Total body bone mineral density;
PAAD	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.14	0.45	6.82e-9	Hair morphology;
PAAD	cis	rs10789491	1.000	rs4097354	chr1:47187073	T/G	cg15501359	chr1:47185051	KIAA0494	0.86	8.48	0.57	1.81e-14	Response to hepatitis C treatment;
PAAD	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	1.02	16.68	0.8	3.58e-36	Height;
PAAD	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27229823	chr2:105858015	GPR45	-0.53	-6.29	-0.45	3.22e-9	Energy expenditure (24h);
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg18279126	chr7:2041391	MAD1L1	0.63	6.5	0.47	1.07e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg08994789	chr17:28903642	LRRC37B2	0.56	4.49	0.34	1.38e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	0.98	10.81	0.66	1.5e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21775007	chr8:11205619	TDH	0.55	4.93	0.37	2.12e-6	Neuroticism;
PAAD	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs8112211	0.682	rs11671779	chr19:38833350	C/T	cg14299480	chr19:38876666	GGN	-0.66	-6.27	-0.45	3.51e-9	Blood protein levels;
PAAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.7	0.69	6.09e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.85	9.03	0.59	7.26e-16	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20071051	chr14:75593943	NEK9	-0.8	-6.91	-0.49	1.27e-10	Neuroticism;
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.09	8.15	0.55	1.27e-13	Alzheimer's disease;
PAAD	cis	rs3026101	0.624	rs60116755	chr17:5303215	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg02640540	chr1:67518911	SLC35D1	0.56	4.8	0.36	3.69e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2555155	0.806	rs10839574	chr11:6551470	C/T	cg10208301	chr11:6592745	DNHD1	-0.42	-4.34	-0.33	2.6e-5	DNA methylation (variation);
PAAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.98	-0.37	1.68e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg25364880	chr3:44379878	C3orf23	0.62	6.01	0.44	1.33e-8	Depressive symptoms;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11802732	chr17:2206917	SRR;SMG6	0.59	6.42	0.46	1.65e-9	Metabolite levels  (X-11787);
PAAD	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.73	-6.36	-0.46	2.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.49	4.59	0.35	9.12e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg18721089	chr20:30220636	NA	-0.79	-6.02	-0.44	1.23e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.3e-6	Tuberculosis;
PAAD	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-6.87	-0.49	1.55e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04016957	chr4:1044486	NA	-0.52	-5.68	-0.42	6.61e-8	Recombination rate (males);
PAAD	cis	rs11671005	0.779	rs731259	chr19:58989424	C/T	cg25952890	chr19:58913133	NA	0.77	5.95	0.43	1.82e-8	Mean platelet volume;
PAAD	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.57	7.09	0.5	4.83e-11	Crohn's disease;
PAAD	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.8	-9.49	-0.61	4.46e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg07617317	chr6:118971624	C6orf204	0.53	4.47	0.34	1.53e-5	Diastolic blood pressure;
PAAD	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-5.66	-0.42	7.25e-8	Crohn's disease;
PAAD	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.5	-4.56	-0.35	1.07e-5	Cancer;
PAAD	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg14349672	chr11:133703707	NA	-0.58	-6.95	-0.49	1.02e-10	Childhood ear infection;
PAAD	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.49	5.59	0.41	1.02e-7	Platelet count;
PAAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.59	5.74	0.42	5.05e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.92	-0.37	2.23e-6	Breast cancer;
PAAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.2e-14	Bone mineral density;
PAAD	cis	rs939584	1.000	rs7569210	chr2:631462	G/A	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.71	7.02	0.49	7.08e-11	Prostate cancer;
PAAD	cis	rs17095355	1.000	rs72828245	chr10:111746596	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.8	-0.36	3.77e-6	Biliary atresia;
PAAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	1.01	6.51	0.47	1.05e-9	Type 2 diabetes;
PAAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg14847009	chr1:175162515	KIAA0040	0.3	4.63	0.35	7.89e-6	Alcohol dependence;
PAAD	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.56	5.73	0.42	5.11e-8	Dupuytren's disease;
PAAD	cis	rs1075265	0.704	rs13417926	chr2:54052657	T/G	cg04546899	chr2:54196757	PSME4	0.31	4.68	0.35	6.4e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9487051	0.582	rs9386779	chr6:109583656	C/G	cg21918786	chr6:109611834	NA	-0.48	-4.93	-0.37	2.14e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg15478930	chr2:27652102	NRBP1	0.55	4.51	0.34	1.27e-5	Blood metabolite levels;
PAAD	cis	rs2085601	0.519	rs1708680	chr4:89976967	T/G	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12138061	0.954	rs68007327	chr1:50316592	C/T	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.56	-0.35	1.03e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.81	6.96	0.49	9.3e-11	Recombination rate (females);
PAAD	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.53	5.15	0.39	7.82e-7	Fractional excretion of uric acid;
PAAD	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.42	-4.65	-0.35	7.31e-6	HDL cholesterol levels;
PAAD	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.19e-7	Red blood cell count;
PAAD	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.93	-0.43	1.94e-8	Waist circumference adjusted for body mass index;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13012494	chr21:47604986	C21orf56	0.48	5.08	0.38	1.07e-6	Testicular germ cell tumor;
PAAD	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg26031613	chr14:104095156	KLC1	0.79	8.1	0.55	1.62e-13	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23671600	chr1:11724392	FBXO6	0.64	7.2	0.5	2.62e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.68	-0.35	6.36e-6	Coronary artery disease;
PAAD	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-6.19	-0.45	5.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.64	7.05	0.5	5.74e-11	Corneal astigmatism;
PAAD	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg08975724	chr8:8085496	FLJ10661	0.72	7.28	0.51	1.63e-11	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.59	-4.85	-0.37	2.98e-6	Breast cancer;
PAAD	cis	rs12438356	1.000	rs76907455	chr15:69580820	C/T	cg02375503	chr15:69591110	PAQR5	-0.62	-4.3	-0.33	3.06e-5	CTACK levels;
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg16249355	chr17:76310516	NA	-0.78	-5.13	-0.38	8.75e-7	Airflow obstruction;
PAAD	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.83	8.83	0.58	2.36e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.64	7.63	0.53	2.45e-12	Coronary artery disease;
PAAD	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg10820045	chr2:198174542	NA	0.45	4.44	0.34	1.7e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg00206168	chr11:65308501	LTBP3	0.83	5.65	0.42	7.72e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg05250797	chr16:70222502	NA	0.84	6.38	0.46	1.99e-9	IgE levels;
PAAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs2916733	0.530	rs2442523	chr8:6289668	G/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.51	-0.34	1.31e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	7.18	0.5	2.94e-11	Body mass index (adult);
PAAD	cis	rs6499244	0.526	rs7193221	chr16:69848721	C/G	cg05250797	chr16:70222502	NA	0.48	4.4	0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg19904058	chr10:135279010	LOC619207	-0.38	-5.16	-0.39	7.64e-7	Systemic lupus erythematosus;
PAAD	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-5.75	-0.42	4.85e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.68	-0.42	6.68e-8	Longevity;Endometriosis;
PAAD	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Androgen levels;
PAAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-4.6	-0.35	8.83e-6	Bone mineral density;
PAAD	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.2	12.05	0.7	6.99e-24	Corneal structure;
PAAD	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.54	-7.26	-0.51	1.91e-11	Endometriosis;
PAAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.51	-4.86	-0.37	2.95e-6	Vitiligo;
PAAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg10589385	chr1:150898437	SETDB1	0.4	4.88	0.37	2.6e-6	Tonsillectomy;
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.55	-6.71	-0.48	3.63e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7011049	1.000	rs72643577	chr8:53846358	A/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg23465465	chr6:26364728	BTN3A2	0.8	4.72	0.36	5.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs652260	1.000	rs652260	chr19:7900562	C/T	cg26014689	chr19:7917955	EVI5L	-0.5	-5.02	-0.38	1.4e-6	Menarche (age at onset);
PAAD	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.74	8.36	0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.76	7.79	0.53	9.94e-13	Prostate-specific antigen levels;
PAAD	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.54	5.54	0.41	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10263684	chr2:46520913	NA	-0.67	-6.52	-0.47	9.96e-10	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg09835421	chr16:68378352	PRMT7	-1.1	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.53	-4.92	-0.37	2.26e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs7923609	0.875	rs6479877	chr10:64878118	C/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.08	-0.38	1.11e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg23685149	chr10:99205954	ZDHHC16;EXOSC1	0.59	6.31	0.46	2.89e-9	Morning vs. evening chronotype;
PAAD	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg20487152	chr13:99095054	FARP1	-0.5	-4.81	-0.36	3.55e-6	Longevity;
PAAD	cis	rs427941	0.632	rs201470	chr7:101744045	G/A	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.51	4.64	0.35	7.44e-6	IFN-related cytopenia;
PAAD	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs488248	0.574	rs7983057	chr13:106590000	C/T	cg03898952	chr13:107069935	NA	0.7	4.45	0.34	1.66e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.79	-6.89	-0.49	1.36e-10	Coronary artery disease;
PAAD	cis	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg14329783	chr7:75779857	NA	0.8	4.76	0.36	4.51e-6	Mononucleosis;
PAAD	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.6e-12	Obesity-related traits;
PAAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.36	-0.4	2.96e-7	Mood instability;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.59	6.56	0.47	8.17e-10	Iron status biomarkers;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs10663129	1	rs10663129	chr3:141321836	A/ACT	cg25967872	chr3:141205623	RASA2	0.5	4.51	0.34	1.29e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13645001	chr12:22199579	CMAS	-0.69	-7.23	-0.51	2.22e-11	Smoking initiation;
PAAD	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17370364	chr6:572771	EXOC2	-0.65	-7.03	-0.5	6.37e-11	Obesity-related traits;
PAAD	cis	rs9584850	0.794	rs17574433	chr13:99138057	A/G	cg20487152	chr13:99095054	FARP1	-0.56	-4.76	-0.36	4.43e-6	Neuroticism;
PAAD	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs11264213	0.892	rs11264194	chr1:36195372	C/T	cg27506609	chr1:36549197	TEKT2	0.64	4.64	0.35	7.41e-6	Schizophrenia;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg08132940	chr7:1081526	C7orf50	-0.65	-4.62	-0.35	8.17e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-6.53	-0.47	9.12e-10	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.49	5.09	0.38	1.03e-6	Life satisfaction;
PAAD	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	7.36	0.51	1.1e-11	IgG glycosylation;
PAAD	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.65	-9.93	-0.63	3.22e-18	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.76	7.85	0.54	6.77e-13	Breast cancer;
PAAD	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09695851	chr17:3907499	NA	-0.62	-5.85	-0.43	2.94e-8	Type 2 diabetes;
PAAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg10495392	chr1:46806563	NSUN4	0.46	4.32	0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.71	-0.36	5.66e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8033133	0.678	rs7496110	chr15:25347013	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.45	-4.77	-0.36	4.21e-6	Blood osmolality (transformed sodium);
PAAD	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.63	-0.42	8.57e-8	Monocyte percentage of white cells;
PAAD	cis	rs1879734	0.953	rs882879	chr1:54154726	G/T	cg14659662	chr1:54151053	GLIS1	0.41	6.65	0.47	4.91e-10	Mitral valve prolapse;
PAAD	trans	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg26939375	chr7:64535504	NA	0.71	8.53	0.57	1.37e-14	Aortic root size;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21155852	chr7:2048760	MAD1L1	0.45	4.46	0.34	1.6e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.8	0.43	3.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11940219	chr16:30935557	FBXL19;NCRNA00095	-0.59	-6.77	-0.48	2.65e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg21546286	chr11:48923668	NA	-0.44	-4.67	-0.35	6.5e-6	HDL cholesterol;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13767494	chr2:220355154	SPEG	0.6	6.47	0.46	1.28e-9	Smoking initiation;
PAAD	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg14515779	chr1:101123966	NA	-0.53	-6.52	-0.47	9.75e-10	Monocyte count;
PAAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg09222892	chr1:25734099	RHCE	0.48	4.78	0.36	4.09e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1075232	1.000	rs16956838	chr15:31819695	C/G	cg01030201	chr15:31746330	NA	-1.1	-5.15	-0.39	7.91e-7	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg23024343	chr7:107201750	COG5	0.52	4.36	0.33	2.38e-5	Coronary artery disease;
PAAD	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg21523528	chr20:32077966	CBFA2T2	0.51	4.35	0.33	2.48e-5	Height;
PAAD	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg07395648	chr5:131743802	NA	0.52	4.43	0.34	1.78e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.59	-0.35	9.29e-6	Longevity;Endometriosis;
PAAD	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	4.99	0.38	1.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg23283495	chr1:209979779	IRF6	0.78	7.75	0.53	1.25e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg03482866	chr13:111040579	COL4A2	0.46	4.54	0.35	1.14e-5	White matter hyperintensity burden;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs370915	0.549	rs1367933	chr4:187776591	C/T	cg12892747	chr4:187813459	NA	-0.47	-4.85	-0.37	2.97e-6	Gout;
PAAD	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26017679	chr4:148936704	ARHGAP10	-0.66	-6.56	-0.47	8e-10	Obesity-related traits;
PAAD	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg23254163	chr1:152506842	NA	0.6	6.98	0.49	8.54e-11	Hair morphology;
PAAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg09796270	chr17:17721594	SREBF1	-0.44	-4.82	-0.36	3.51e-6	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01311909	chr12:46320890	SFRS2IP	0.57	6.58	0.47	7.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13102973	1.000	rs11722746	chr4:135850567	A/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.21	0.5	2.46e-11	Morning vs. evening chronotype;
PAAD	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.71	7.12	0.5	3.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10178228	chr3:69435618	FRMD4B	-0.68	-6.67	-0.48	4.47e-10	Lung cancer in ever smokers;
PAAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-4.36	-0.33	2.41e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.59e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06938063	chr1:207925405	CD46	0.59	6.63	0.47	5.39e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.53	5.35	0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg27411982	chr8:10470053	RP1L1	-0.49	-5.35	-0.4	3.19e-7	Neuroticism;
PAAD	cis	rs2637266	0.905	rs2130796	chr10:78329712	C/G	cg18941641	chr10:78392320	NA	0.39	4.69	0.36	6.1e-6	Pulmonary function;
PAAD	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14347670	chr6:41908995	CCND3	0.62	7.11	0.5	4.34e-11	Metabolite levels  (X-11787);
PAAD	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.6	5.59	0.41	1.01e-7	Schizophrenia;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg14393609	chr7:65229607	NA	-0.67	-7.43	-0.52	7.49e-12	Corneal structure;
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg02196655	chr2:10830764	NOL10	0.55	5.62	0.41	8.75e-8	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18198301	chr15:36469091	NA	0.55	6.36	0.46	2.21e-9	Smoking initiation;
PAAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg06632027	chr4:90757378	SNCA	-0.53	-4.64	-0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6929137	0.666	rs9784821	chr6:151953309	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-4.28	-0.33	3.34e-5	Bone mineral density (spine);
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg26549601	chr10:134560360	INPP5A	-0.41	-4.63	-0.35	7.92e-6	Gait speed in old age;
PAAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg14008862	chr17:28927542	LRRC37B2	0.79	5.12	0.38	8.95e-7	Body mass index;
PAAD	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg22431228	chr1:16359049	CLCNKA	-0.61	-7.25	-0.51	1.99e-11	Systolic blood pressure;
PAAD	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.73	7.32	0.51	1.35e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs7127900	0.504	rs12420721	chr11:2237667	G/C	cg14271862	chr11:2222076	NA	0.52	4.76	0.36	4.38e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.26	-0.39	4.83e-7	Neuroticism;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.77	-8.25	-0.56	7e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07325092	chr15:34875825	GOLGA8B	0.68	7.22	0.51	2.37e-11	Myopia (pathological);
PAAD	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg09471204	chr22:42347991	LOC339674	-0.4	-5.46	-0.4	1.94e-7	Intelligence;
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg21929781	chr1:2537748	MMEL1	-0.53	-5.6	-0.41	9.73e-8	Ulcerative colitis;
PAAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.8	-5.12	-0.38	9.02e-7	White matter integrity;
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.6	-0.41	9.79e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16718678	chr11:64490633	NRXN2	0.63	6.94	0.49	1.09e-10	Myopia (pathological);
PAAD	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.48	-4.94	-0.37	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs2327429	0.858	rs7769943	chr6:134196327	C/T	cg06643013	chr6:134217242	NA	0.41	4.51	0.34	1.3e-5	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07929700	chr12:52204284	NA	0.56	6.64	0.47	5.16e-10	Smoking initiation;
PAAD	cis	rs7853377	0.771	rs796007	chr9:86577541	G/A	cg03531853	chr9:86535572	KIF27	0.42	4.38	0.33	2.24e-5	Height;
PAAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.18	0.5	2.92e-11	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14077270	chr15:45879818	PLDN	0.56	6.31	0.46	2.85e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs16882447	0.514	rs27677	chr5:53484164	C/G	cg06461071	chr5:53490839	ARL15	-0.41	-4.33	-0.33	2.67e-5	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.49	6.07	0.44	9.63e-9	Crohn's disease;
PAAD	cis	rs3812049	0.611	rs251393	chr5:127533085	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	6.57	0.47	7.56e-10	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04156016	chr5:1868137	NA	0.45	4.6	0.35	8.94e-6	Cardiovascular disease risk factors;
PAAD	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg27455613	chr17:80820699	TBCD	-0.46	-4.59	-0.35	9.38e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs2790216	1.000	rs2790242	chr10:59980652	A/G	cg20442379	chr10:60024634	IPMK	0.58	4.38	0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.52	-0.34	1.24e-5	Triglycerides;
PAAD	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg18833306	chr6:118973337	C6orf204	0.43	4.42	0.34	1.9e-5	Electrocardiographic conduction measures;
PAAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.16	0.39	7.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.64	-7.08	-0.5	5.04e-11	Facial morphology (factor 20);
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16386425	chr10:429943	DIP2C	0.48	4.46	0.34	1.58e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.6	6.46	0.46	1.34e-9	Tonsillectomy;
PAAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.63	-5.21	-0.39	5.99e-7	Diastolic blood pressure;
PAAD	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg03934865	chr2:198174659	NA	-0.47	-4.75	-0.36	4.73e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23544223	chr18:12777786	NA	-0.73	-6.26	-0.45	3.71e-9	Inflammatory skin disease;
PAAD	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.72	-0.36	5.3e-6	Mean platelet volume;
PAAD	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg11395062	chr17:14139857	CDRT15	0.58	6.05	0.44	1.06e-8	Temperament;
PAAD	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.83	9.62	0.62	2.11e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg26318627	chr11:63887540	MACROD1	0.48	5.13	0.38	8.69e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg05250797	chr16:70222502	NA	0.84	6.38	0.46	1.99e-9	IgE levels;
PAAD	cis	rs75920871	0.925	rs56134734	chr11:116833055	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1532557	1.000	rs883116	chr1:224807973	C/T	cg09988837	chr1:224811939	CNIH3	0.6	4.55	0.35	1.11e-5	Cancer;
PAAD	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.46	-0.34	1.57e-5	Renal cell carcinoma;
PAAD	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.65	6.93	0.49	1.11e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	5.29	0.39	4.11e-7	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs1355223	0.573	rs1901830	chr11:34725028	T/G	cg11622362	chr11:34938112	PDHX;APIP	0.44	4.44	0.34	1.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg12227505	chr17:78194145	SLC26A11;SGSH	0.65	6.53	0.47	9.54e-10	Primary biliary cholangitis;
PAAD	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.57e-7	Subjective well-being;
PAAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11615916	0.790	rs7970114	chr12:62709109	C/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	6.52	0.47	9.77e-10	Initial pursuit acceleration;
PAAD	cis	rs1364705	0.955	rs4871600	chr8:120226576	C/G	cg09273054	chr8:120220131	MAL2	-0.46	-5.17	-0.39	7.25e-7	Hippocampal atrophy;
PAAD	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.85	9.47	0.61	5.19e-17	Multiple sclerosis;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg13264159	chr8:625131	ERICH1	0.75	4.7	0.36	5.67e-6	IgG glycosylation;
PAAD	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.81	9.49	0.61	4.48e-17	Blood metabolite ratios;
PAAD	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg17182837	chr8:41585554	ANK1	-0.51	-4.39	-0.34	2.14e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.66	7.35	0.51	1.17e-11	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-4.4	-0.34	2.03e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.87	-9.65	-0.62	1.79e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.76	8.4	0.56	2.98e-14	Longevity;
PAAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg08601574	chr20:25228251	PYGB	0.46	4.4	0.34	2e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs73416724	1.000	rs78567061	chr6:43293446	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2555155	1.000	rs11604149	chr11:6519642	G/A	cg24637308	chr11:6592297	DNHD1	0.49	5.16	0.39	7.5e-7	DNA methylation (variation);
PAAD	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg17595323	chr11:93583763	C11orf90	-0.35	-4.45	-0.34	1.68e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.82	-8.01	-0.54	2.77e-13	Breast cancer;
PAAD	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg26876637	chr1:152193138	HRNR	-0.86	-6.55	-0.47	8.45e-10	Atopic dermatitis;
PAAD	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.64	9.52	0.61	3.76e-17	Huntington's disease progression;
PAAD	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg08079166	chr15:68083412	MAP2K5	-0.61	-4.84	-0.37	3.16e-6	Restless legs syndrome;
PAAD	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-7.34	-0.51	1.18e-11	Coffee consumption (cups per day);
PAAD	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.45	4.7	0.36	5.86e-6	Fibrinogen levels;
PAAD	cis	rs3018712	0.650	rs10791990	chr11:68445573	G/A	cg23009355	chr11:68451396	GAL	-0.54	-5.02	-0.38	1.41e-6	Total body bone mineral density;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg19636519	chr7:99541626	NA	0.4	4.48	0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.67	4.97	0.37	1.78e-6	Mean platelet volume;
PAAD	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg00806126	chr19:22604979	ZNF98	0.41	5.21	0.39	5.93e-7	Pain;
PAAD	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.46	-4.88	-0.37	2.69e-6	Major depressive disorder;
PAAD	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.26	-0.33	3.55e-5	Blood protein levels;
PAAD	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg04877966	chr15:75135169	ULK3	0.54	4.7	0.36	5.74e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.67	7.43	0.52	7.3e-12	Age at first birth;
PAAD	cis	rs9463078	0.546	rs4714836	chr6:45019777	C/T	cg18551225	chr6:44695536	NA	0.43	4.49	0.34	1.39e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	1.08	8.66	0.57	6.29e-15	IgG glycosylation;
PAAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.78	8.05	0.55	2.26e-13	Body mass index;
PAAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.77	-7.99	-0.54	3.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs6500602	1.000	rs4786491	chr16:4493612	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	6.07	0.44	9.81e-9	Schizophrenia;
PAAD	cis	rs7607369	0.748	rs662250	chr2:219374117	T/A	cg02176678	chr2:219576539	TTLL4	0.48	7.68	0.53	1.81e-12	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.67	6.52	0.47	9.86e-10	Prostate cancer;
PAAD	cis	rs11203032	0.831	rs11203017	chr10:90948709	C/T	cg16672925	chr10:90967113	CH25H	0.72	5.59	0.41	1e-7	Heart failure;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.77	-5.92	-0.43	2.06e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs656319	0.702	rs587328	chr8:9809722	C/T	cg03078239	chr8:9040449	NA	0.4	4.28	0.33	3.35e-5	Myopia (pathological);
PAAD	cis	rs13102973	0.965	rs11099302	chr4:135880751	G/T	cg14419869	chr4:135874104	NA	0.56	5.86	0.43	2.77e-8	Subjective well-being;
PAAD	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.44	-0.34	1.75e-5	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.54	6.78	0.48	2.55e-10	Atrioventricular conduction;
PAAD	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg12508331	chr16:3208203	NA	0.49	4.49	0.34	1.42e-5	Body mass index (adult);
PAAD	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg23119463	chr10:134592391	INPP5A	-0.47	-4.42	-0.34	1.89e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs72772090	0.710	rs112178674	chr5:96060355	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.86	-6.52	-0.47	9.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10044254	0.614	rs4146556	chr5:15735956	A/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.2	0.45	5.19e-9	Coffee consumption (cups per day);
PAAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.55	-0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.22	-0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg13266496	chr6:110720918	DDO	0.46	5.03	0.38	1.36e-6	Platelet distribution width;
PAAD	cis	rs2882667	0.654	rs883333	chr5:138155470	C/A	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-4.34	-0.33	2.61e-5	Morning vs. evening chronotype;
PAAD	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.27e-10	Bladder cancer;
PAAD	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg19346786	chr7:2764209	NA	-0.35	-4.78	-0.36	4.1e-6	Height;
PAAD	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.73	-7.29	-0.51	1.62e-11	Retinal vascular caliber;
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.63	6.22	0.45	4.48e-9	Blood metabolite levels;
PAAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs787274	1.000	rs4246892	chr9:115588649	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2051773	0.567	rs7929927	chr11:17044358	T/A	cg15378786	chr11:17036137	PLEKHA7	0.53	4.54	0.35	1.14e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg13722127	chr7:150037890	RARRES2	0.54	5.29	0.39	4.23e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11139399	0.521	rs7864030	chr9:84369450	C/T	cg13475860	chr9:84371897	NA	-0.39	-4.48	-0.34	1.47e-5	Hippocampal atrophy;
PAAD	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	5.41	0.4	2.37e-7	Lung cancer in ever smokers;
PAAD	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.76	7.4	0.51	8.7e-12	Retinal vascular caliber;
PAAD	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg11783602	chr8:55087084	NA	0.58	6.61	0.47	6.09e-10	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01207010	chr5:14664662	FAM105B	0.72	7.81	0.54	8.61e-13	Myopia (pathological);
PAAD	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.54	5.54	0.41	1.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg25952890	chr19:58913133	NA	0.66	5.61	0.41	9.52e-8	Mean platelet volume;
PAAD	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	1.1	15.4	0.78	7.57e-33	Caffeine consumption;
PAAD	cis	rs3925075	0.531	rs4594268	chr16:31343243	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.47	0.41	1.77e-7	IgA nephropathy;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	1.03	7.09	0.5	4.62e-11	IgG glycosylation;
PAAD	cis	rs34043524	1.000	rs6813652	chr4:117996087	T/C	cg14562394	chr4:117851367	NA	0.82	4.35	0.33	2.48e-5	Lateral ventricle volume in trauma-exposed individuals;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11089837	chr14:36295257	BRMS1L	-0.63	-6.57	-0.47	7.75e-10	Lung cancer in ever smokers;
PAAD	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.52	6.89	0.49	1.4e-10	Thyroid hormone levels;
PAAD	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.46	0.4	1.94e-7	Educational attainment (years of education);
PAAD	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.43	-6.83	-0.48	1.94e-10	Cutaneous nevi;
PAAD	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.05e-15	Exhaled nitric oxide output;
PAAD	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.69	0.42	6.19e-8	Tonsillectomy;
PAAD	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.23	-0.64	5.01e-19	Blood trace element (Zn levels);
PAAD	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.64	-5.95	-0.43	1.8e-8	Cognitive test performance;
PAAD	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.49	4.25	0.33	3.7e-5	Atopic dermatitis;
PAAD	cis	rs990171	1.000	rs3755274	chr2:103002395	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.37	0.33	2.31e-5	Lymphocyte counts;
PAAD	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.89	9.78	0.62	8.16e-18	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.09e-6	Life satisfaction;
PAAD	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.63	4.66	0.35	6.85e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.53	-6.59	-0.47	6.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs863345	0.933	rs10908659	chr1:158465858	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.76	-0.36	4.56e-6	Pneumococcal bacteremia;
PAAD	trans	rs61677309	1.000	rs12576941	chr11:118158002	A/G	cg15548380	chr1:19984784	NBL1	-0.64	-6.75	-0.48	2.87e-10	Lung cancer in ever smokers;
PAAD	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.1e-8	Platelet count;
PAAD	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.71	-0.58	4.72e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs501120	1.000	rs554568	chr10:44755446	C/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7173419	0.607	rs11637338	chr15:28217259	C/T	cg20906524	chr15:28200668	OCA2	-0.46	-5.31	-0.4	3.88e-7	Eye color;
PAAD	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18621852	chr3:10150065	C3orf24	0.51	4.83	0.36	3.34e-6	Alzheimer's disease;
PAAD	cis	rs9326726	0.566	rs288237	chr5:107411674	A/T	cg19779370	chr5:108084990	FER	0.58	4.64	0.35	7.38e-6	Resting heart rate;
PAAD	cis	rs12484776	0.729	rs67465697	chr22:40531645	A/G	cg07138101	chr22:40742427	ADSL	0.6	4.47	0.34	1.49e-5	Uterine fibroids;
PAAD	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.72	7.28	0.51	1.65e-11	Morning vs. evening chronotype;
PAAD	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Diabetic kidney disease;
PAAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.64	-7.21	-0.5	2.5e-11	Platelet distribution width;
PAAD	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.99	-9.52	-0.61	3.78e-17	Dilated cardiomyopathy;
PAAD	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.82	-7.49	-0.52	5.18e-12	Exhaled nitric oxide output;
PAAD	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg18551225	chr6:44695536	NA	-0.74	-7.53	-0.52	4.09e-12	Total body bone mineral density;
PAAD	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13556584	chr19:11031456	CARM1	-0.59	-6.32	-0.46	2.8e-9	Obesity-related traits;
PAAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00300879	chr1:26503847	CNKSR1	0.3	4.58	0.35	9.77e-6	Height;
PAAD	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.46	-0.76	2.31e-30	Headache;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.8	0.62	6.9e-18	Prudent dietary pattern;
PAAD	cis	rs9314614	0.789	rs4840643	chr8:6712784	T/A	cg27319216	chr8:6693540	XKR5	-0.4	-5.34	-0.4	3.26e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.8	-7.87	-0.54	6.01e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01283332	chr5:1856932	NA	-0.46	-4.86	-0.37	2.95e-6	Cardiovascular disease risk factors;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14347670	chr6:41908995	CCND3	0.63	7.07	0.5	5.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.45	4.47	0.34	1.51e-5	Chronic sinus infection;
PAAD	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.73	-7.37	-0.51	9.96e-12	Morning vs. evening chronotype;
PAAD	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg03989125	chr22:38214979	NA	0.64	5.84	0.43	3.03e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.93	-10.9	-0.66	8.24e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.91	5.52	0.41	1.46e-7	Gut microbiota (bacterial taxa);
PAAD	trans	rs901683	1.000	rs9422657	chr10:46053061	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs73206853	0.563	rs17682444	chr12:111154626	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	4.28	0.33	3.24e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg15693483	chr7:1102177	C7orf50	0.39	4.7	0.36	5.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg17326555	chr1:119535693	NA	-0.34	-4.27	-0.33	3.41e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.36	0.33	2.42e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6976053	0.846	rs4729615	chr7:100462332	A/G	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg24881330	chr22:46731750	TRMU	1.21	6.3	0.45	3.08e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.9	-7.06	-0.5	5.6e-11	Gut microbiome composition (summer);
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16972079	chr3:183853295	EIF2B5	0.62	6.76	0.48	2.72e-10	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.68	7.44	0.52	6.86e-12	Aortic root size;
PAAD	cis	rs282587	0.569	rs378491	chr13:113398408	C/A	cg04656015	chr13:113407548	ATP11A	0.54	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.94e-6	Triglycerides;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg02683114	chr2:24398427	C2orf84	0.46	4.87	0.37	2.72e-6	Sjögren's syndrome;
PAAD	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-5.2	-0.39	6.46e-7	Coronary artery disease;
PAAD	cis	rs12799264	1.000	rs2625309	chr11:19976923	A/C	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6136489	0.710	rs6136493	chr20:1923973	A/G	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs1198430	0.639	rs685059	chr1:23783185	C/G	cg19827787	chr1:23763612	ASAP3	0.58	4.79	0.36	3.84e-6	Total cholesterol levels;
PAAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.56	5.52	0.41	1.41e-7	Aortic root size;
PAAD	cis	rs6942407	0.546	rs2108272	chr7:86805399	C/T	cg02420886	chr7:86849541	C7orf23	0.67	5.21	0.39	6.07e-7	Food allergy;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg22162314	chr17:61951766	CSH2	0.5	5.07	0.38	1.15e-6	Height;
PAAD	trans	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg19894588	chr14:64061835	NA	-0.76	-6.62	-0.47	5.68e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.53	4.54	0.35	1.15e-5	Height;
PAAD	cis	rs9463078	0.683	rs227841	chr6:44690309	A/T	cg25276700	chr6:44698697	NA	0.53	5.85	0.43	2.86e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1015291	0.680	rs1586837	chr12:19998282	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.26	-0.33	3.52e-5	Renal cell carcinoma;
PAAD	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.86	6.95	0.49	1.01e-10	Type 2 diabetes;
PAAD	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg09226986	chr6:160852328	SLC22A3	-0.48	-4.46	-0.34	1.57e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.53	4.29	0.33	3.2e-5	Lymphocyte counts;
PAAD	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.66	-5.05	-0.38	1.27e-6	Diastolic blood pressure;
PAAD	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.93	-8.09	-0.55	1.77e-13	Other erythrocyte phenotypes;
PAAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.4	4.31	0.33	2.98e-5	Aortic root size;
PAAD	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62435770	1.000	rs73036168	chr6:169522032	T/C	cg07057617	chr6:170405951	NA	0.62	4.25	0.33	3.65e-5	Loneliness;
PAAD	cis	rs7172971	0.688	rs4923925	chr15:42367247	C/G	cg07013680	chr15:42186124	SPTBN5	0.52	4.38	0.33	2.17e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg10820045	chr2:198174542	NA	-0.45	-4.57	-0.35	1.02e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.91	7.19	0.5	2.76e-11	Lymphocyte counts;
PAAD	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.05	6.87	0.49	1.54e-10	Fat distribution (HIV);
PAAD	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.58	-7.93	-0.54	4.34e-13	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21284376	chr1:72748601	NEGR1	-0.62	-6.35	-0.46	2.39e-9	Obesity-related traits;
PAAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.82	9.13	0.6	3.89e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs1372520	0.564	rs356197	chr4:90682750	G/A	cg20003494	chr4:90757398	SNCA	0.58	4.77	0.36	4.36e-6	Neuroticism;
PAAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.16e-5	Breast cancer;
PAAD	cis	rs9715521	0.803	rs62301187	chr4:59840420	T/C	cg11281224	chr4:60001000	NA	-0.61	-5.89	-0.43	2.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.57	5.96	0.44	1.65e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.81	8.58	0.57	1.03e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	4.88	0.37	2.62e-6	Schizophrenia;
PAAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.65	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg08315770	chr6:39281885	KCNK17	-0.61	-6.44	-0.46	1.49e-9	Type 2 diabetes;
PAAD	cis	rs6908034	0.556	rs79028848	chr6:19783153	G/A	cg02682789	chr6:19804855	NA	0.8	4.47	0.34	1.54e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.49	5.49	0.41	1.63e-7	Lung cancer;
PAAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg05333889	chr7:157238977	NA	-0.44	-4.9	-0.37	2.48e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs12545912	0.908	rs7016839	chr8:9587949	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg01851573	chr8:8652454	MFHAS1	-0.5	-4.52	-0.34	1.26e-5	Obesity-related traits;
PAAD	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg19781863	chr12:62918364	MON2	0.71	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg02230254	chr11:65586170	NA	-0.36	-5.45	-0.4	2.02e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg05250797	chr16:70222502	NA	0.78	5.96	0.44	1.66e-8	IgE levels;
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	7.1	0.5	4.54e-11	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	12.17	0.7	3.23e-24	Menopause (age at onset);
PAAD	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.65	7.06	0.5	5.62e-11	Aortic root size;
PAAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg11494091	chr17:61959527	GH2	0.51	4.45	0.34	1.69e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg01270228	chr10:1369114	ADARB2	0.56	5.62	0.41	9e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg15557168	chr22:42548783	NA	-0.52	-5.73	-0.42	5.33e-8	Cognitive function;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.49	-4.97	-0.37	1.76e-6	Height;
PAAD	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg01021169	chr22:30184971	ASCC2	-0.44	-4.38	-0.33	2.18e-5	Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.74	8.7	0.58	5.15e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6489785	0.522	rs1718188	chr12:121343893	T/A	cg02419362	chr12:121203948	SPPL3	-0.49	-5.49	-0.41	1.68e-7	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.88	10.71	0.66	2.65e-20	Methadone dose in opioid dependence;
PAAD	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg02254774	chr11:50257496	LOC441601	0.44	4.52	0.34	1.25e-5	Height;
PAAD	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg17333051	chr19:2783644	SGTA	0.45	4.93	0.37	2.15e-6	Total cholesterol levels;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg07153921	chr17:41440717	NA	0.43	4.55	0.35	1.11e-5	Menopause (age at onset);
PAAD	trans	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2735413	0.514	rs7192129	chr16:78136414	A/G	cg04733911	chr16:78082701	NA	0.47	5.23	0.39	5.61e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg03098721	chr1:84464084	TTLL7	0.5	4.77	0.36	4.26e-6	Obesity-related traits;
PAAD	cis	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg18057887	chr11:133800913	IGSF9B	0.52	5.13	0.38	8.72e-7	Hand grip strength;
PAAD	cis	rs2274459	0.673	rs35328423	chr6:33731592	C/T	cg06253072	chr6:33679850	C6orf125	0.56	4.25	0.33	3.75e-5	Obesity (extreme);
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.63	-6.45	-0.46	1.38e-9	Monocyte count;
PAAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23281280	chr6:28129359	ZNF389	0.7	5.42	0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.8	7.88	0.54	5.82e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.95	0.37	1.94e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg07784872	chr16:85687041	KIAA0182	0.63	5.46	0.4	1.89e-7	Platelet distribution width;
PAAD	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg06606381	chr12:133084897	FBRSL1	0.99	6.4	0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.54	-4.91	-0.37	2.29e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs861020	0.582	rs6675890	chr1:210022893	G/C	cg09163369	chr1:210001066	C1orf107	0.62	6.11	0.44	8.11e-9	Orofacial clefts;
PAAD	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.64	6.93	0.49	1.14e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg21709803	chr11:61594965	FADS2	-0.54	-4.39	-0.34	2.13e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.3	11.38	0.68	4.38e-22	Uric acid levels;
PAAD	cis	rs9896933	0.895	rs6416854	chr17:80899811	T/A	cg20578329	chr17:80767326	TBCD	0.77	4.61	0.35	8.34e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.6	-6.06	-0.44	1.05e-8	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08738443	chr10:8487762	NA	-0.65	-7.14	-0.5	3.69e-11	Obesity-related traits;
PAAD	cis	rs12304921	1.000	rs12304878	chr12:51353851	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg00576331	chr11:65640516	EFEMP2	-0.51	-4.33	-0.33	2.65e-5	Breast cancer;
PAAD	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.51	4.65	0.35	7.09e-6	Schizophrenia;
PAAD	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.52	-6.73	-0.48	3.33e-10	Type 2 diabetes;
PAAD	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.51	-5.59	-0.41	1.03e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.55	5.95	0.43	1.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.39	5.84	0.43	3.02e-8	Educational attainment (years of education);
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.61	5.58	0.41	1.07e-7	Red blood cell count;
PAAD	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs4946900	0.925	rs9372181	chr6:108416483	A/G	cg13435432	chr6:108489292	NR2E1	0.42	4.45	0.34	1.68e-5	Major depressive disorder;
PAAD	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.73e-8	Colorectal cancer;
PAAD	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg16342193	chr10:102329863	NA	-0.78	-8.5	-0.57	1.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs13083990	0.747	rs6438720	chr3:122017232	A/C	cg17133388	chr3:122102727	FAM162A;CCDC58	0.38	4.33	0.33	2.74e-5	Cardiac Troponin-T levels;
PAAD	cis	rs7678296	1.000	rs73126361	chr4:37223383	C/T	cg06805348	chr4:37245195	KIAA1239	0.65	4.83	0.36	3.34e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs733175	0.953	rs4485819	chr4:10037393	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	4.73	0.36	5e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.53	0.52	4.25e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.75	4.44	0.34	1.7e-5	Lung cancer (smoking interaction);
PAAD	cis	rs9810890	1.000	rs73196954	chr3:128429909	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg24733560	chr20:60626293	TAF4	0.45	5.53	0.41	1.39e-7	Body mass index;
PAAD	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.38	-0.46	1.99e-9	HDL cholesterol;
PAAD	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.52	5.0	0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.51e-18	Huntington's disease progression;
PAAD	cis	rs600626	0.947	rs1219549	chr11:75454622	T/C	cg24262691	chr11:75473276	NA	0.53	4.97	0.37	1.8e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.49	0.34	1.4e-5	Homoarginine levels;
PAAD	cis	rs12458462	0.851	rs62097746	chr18:77487508	G/A	cg11879182	chr18:77439856	CTDP1	0.89	9.66	0.62	1.62e-17	Monocyte count;
PAAD	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-5.83	-0.43	3.23e-8	Cognitive function;
PAAD	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg07168214	chr17:7380112	ZBTB4	0.64	6.28	0.45	3.38e-9	Androgen levels;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg02725872	chr8:58115012	NA	0.75	6.0	0.44	1.37e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-8.72	-0.58	4.6e-15	Coronary artery disease;
PAAD	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg12395012	chr8:11607386	GATA4	0.41	4.25	0.33	3.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.46	-4.78	-0.36	4.14e-6	Height;
PAAD	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.01	-0.63	2e-18	Coronary artery disease;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.92	12.21	0.7	2.5e-24	Menarche (age at onset);
PAAD	trans	rs61931739	0.649	rs708136	chr12:33737411	A/G	cg26384229	chr12:38710491	ALG10B	0.69	7.21	0.5	2.4e-11	Morning vs. evening chronotype;
PAAD	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.7	7.48	0.52	5.61e-12	Hemoglobin concentration;
PAAD	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs12220238	0.915	rs11000988	chr10:76073723	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg17201900	chr20:34330562	RBM39	0.61	4.27	0.33	3.48e-5	Total cholesterol levels;
PAAD	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.7	6.52	0.47	9.81e-10	Diabetic retinopathy;
PAAD	cis	rs16975963	0.644	rs11666738	chr19:38130319	C/G	cg14218481	chr19:38281219	NA	0.43	4.72	0.36	5.2e-6	Longevity;
PAAD	cis	rs6681460	0.649	rs1338184	chr1:67005072	C/T	cg02459107	chr1:67143332	SGIP1	-0.56	-5.05	-0.38	1.25e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg01412419	chr16:87856264	NA	0.55	5.22	0.39	5.91e-7	Blood metabolite levels;
PAAD	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.35	-4.6	-0.35	8.99e-6	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26926768	chr12:34528122	NA	0.39	4.63	0.35	7.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg14092571	chr14:90743983	NA	0.46	4.6	0.35	9.01e-6	Mortality in heart failure;
PAAD	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7719624	0.632	rs13189180	chr5:135400035	A/G	cg16684184	chr5:135415129	NA	-0.45	-5.81	-0.43	3.61e-8	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.5	4.86	0.37	2.87e-6	Anxiety disorder;
PAAD	cis	rs4919087	0.532	rs56189004	chr10:99086632	A/G	cg25902810	chr10:99078978	FRAT1	-0.58	-5.41	-0.4	2.36e-7	Monocyte count;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.94	13.39	0.74	1.69e-27	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	9.21	0.6	2.39e-16	Lymphocyte counts;
PAAD	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.38	0.56	3.29e-14	Homoarginine levels;
PAAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs988913	0.813	rs4712082	chr6:54771019	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-5.17	-0.39	7.23e-7	Menarche (age at onset);
PAAD	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.83	-9.26	-0.6	1.8e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg04025307	chr7:1156635	C7orf50	0.7	4.91	0.37	2.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs4462272	0.566	rs7905395	chr10:101996286	C/T	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.25e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.74	5.25	0.39	4.98e-7	Lung cancer;
PAAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-1.04	-14.31	-0.76	5.99e-30	Breast cancer;
PAAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg23463467	chr20:60627584	TAF4	0.43	4.73	0.36	5.17e-6	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16801093	chr18:20513136	RBBP8	-0.76	-6.64	-0.47	5.18e-10	Neuroticism;
PAAD	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.61	5.43	0.4	2.14e-7	Common traits (Other);
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs78411303	0.542	rs58512903	chr3:122378839	C/T	cg17380795	chr3:122379686	NA	0.76	5.7	0.42	6.05e-8	Periodontitis (CDC/AAP);
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03605463	chr16:89740564	NA	-0.51	-4.72	-0.36	5.33e-6	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01753731	chr4:903032	GAK	-0.74	-7.51	-0.52	4.74e-12	Obesity-related traits;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07817810	chr3:47205858	SETD2	-0.66	-7.79	-0.53	9.99e-13	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.56	-0.47	8.02e-10	Lymphocyte counts;
PAAD	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	6.43	0.46	1.57e-9	Schizophrenia;
PAAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.71	-0.82	8.76e-39	Height;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg07362569	chr17:61921086	SMARCD2	0.43	4.87	0.37	2.82e-6	Height;
PAAD	cis	rs11761408	0.585	rs28379233	chr7:5255725	C/T	cg02820836	chr7:4652842	NA	-0.71	-4.38	-0.33	2.19e-5	Mean corpuscular volume;
PAAD	cis	rs16975963	0.644	rs73035164	chr19:38146720	G/C	cg08679971	chr19:38281047	NA	0.46	4.54	0.35	1.15e-5	Longevity;
PAAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.73	-7.56	-0.52	3.5e-12	Urate levels;
PAAD	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg21855830	chr2:127963489	CYP27C1	0.46	4.5	0.34	1.34e-5	Protein C levels;
PAAD	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs27434	0.539	rs40604	chr5:96155900	G/A	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.65	-7.18	-0.5	2.82e-11	Caffeine consumption;
PAAD	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.09	-9.22	-0.6	2.26e-16	Vitiligo;
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.5	5.56	0.41	1.21e-7	Calcium levels;
PAAD	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.61	-6.08	-0.44	9.23e-9	Systolic blood pressure;
PAAD	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.46	4.82	0.36	3.39e-6	HDL cholesterol;
PAAD	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg10253484	chr15:75165896	SCAMP2	0.49	4.72	0.36	5.2e-6	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg16898833	chr6:26189333	HIST1H4D	1.06	5.72	0.42	5.54e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7168353	0.519	rs11074142	chr15:93639102	A/G	cg12595281	chr15:93633172	RGMA	0.38	5.1	0.38	1e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg22325292	chr17:80708367	FN3K	0.7	5.0	0.38	1.56e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10164272	chr16:89456328	ANKRD11	-0.58	-6.46	-0.46	1.32e-9	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Neutrophil percentage of white cells;
PAAD	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.49	4.79	0.36	3.85e-6	Hepatocellular carcinoma;
PAAD	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg27121462	chr16:89883253	FANCA	0.75	4.43	0.34	1.82e-5	Skin colour saturation;
PAAD	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.46	-0.4	1.92e-7	Height;
PAAD	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.53	8.28	0.56	5.83e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.59	-6.14	-0.45	6.83e-9	Blood metabolite levels;
PAAD	trans	rs61931739	0.620	rs1482981	chr12:33691763	C/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.34	-0.51	1.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-7.04	-0.5	6.31e-11	Mitochondrial DNA levels;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-4.89	-0.37	2.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6906287	0.647	rs12665409	chr6:118685043	G/A	cg18833306	chr6:118973337	C6orf204	0.41	4.28	0.33	3.29e-5	Electrocardiographic conduction measures;
PAAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg15847926	chr7:2749597	AMZ1	-0.43	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs367943	0.514	rs2081925	chr5:113004028	A/T	cg12552261	chr5:112820674	MCC	0.52	5.28	0.39	4.39e-7	Type 2 diabetes;
PAAD	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs7259965	0.804	rs8106911	chr19:41486066	A/G	cg20630647	chr19:41531805	NA	0.51	4.59	0.35	9.29e-6	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg03161606	chr19:29218774	NA	0.58	4.38	0.33	2.24e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.6	-6.51	-0.47	1.03e-9	Tonsillectomy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23373153	chr14:65346875	NA	0.57	6.6	0.47	6.53e-10	Monocyte percentage of white cells;
PAAD	cis	rs2880058	0.958	rs6427648	chr1:162029690	C/G	cg23260004	chr1:161736072	ATF6	-0.5	-4.49	-0.34	1.4e-5	QT interval;
PAAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	1.09	12.09	0.7	5.31e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg17347104	chr14:75034677	LTBP2	0.55	4.57	0.35	9.9e-6	Non-small cell lung cancer;
PAAD	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg18195628	chr11:73498948	MRPL48	0.71	4.85	0.37	3.07e-6	Hand grip strength;
PAAD	cis	rs5015933	0.801	rs4837016	chr9:128141809	A/G	cg14078157	chr9:128172775	NA	0.41	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs8070740	0.559	rs58351927	chr17:5297038	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	4.62	0.35	8.21e-6	Menopause (age at onset);
PAAD	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg12395012	chr8:11607386	GATA4	-0.4	-4.49	-0.34	1.42e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Educational attainment (college completion);
PAAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg11247378	chr22:39784982	NA	-0.71	-7.25	-0.51	1.95e-11	IgG glycosylation;
PAAD	cis	rs2834256	0.517	rs9974470	chr21:35012066	A/T	cg14850771	chr21:34775459	IFNGR2	0.43	4.49	0.34	1.39e-5	Red cell distribution width;
PAAD	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	6.86	0.49	1.65e-10	Multiple sclerosis;
PAAD	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg21770322	chr7:97807741	LMTK2	-0.77	-11.68	-0.69	6.57e-23	Breast cancer;
PAAD	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg14346243	chr4:90757452	SNCA	0.51	4.38	0.33	2.21e-5	Neuroticism;
PAAD	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg15017067	chr4:17643749	FAM184B	0.39	4.25	0.33	3.66e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9581857	0.547	rs9579095	chr13:28082555	C/T	cg22138327	chr13:27999177	GTF3A	0.83	5.34	0.4	3.29e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4742903	0.935	rs9942894	chr9:106914905	A/G	cg14250997	chr9:106856677	SMC2	0.49	5.33	0.4	3.48e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg03605226	chr16:87637261	JPH3	0.41	4.59	0.35	9.28e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.48	0.57	1.82e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22789945	chr11:68382427	SAPS3	-0.68	-6.92	-0.49	1.19e-10	Obesity-related traits;
PAAD	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13614946	chr1:100315421	AGL	0.62	6.84	0.49	1.86e-10	Myopia (pathological);
PAAD	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.57	4.86	0.37	2.89e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg04851639	chr8:1020857	NA	-0.51	-5.75	-0.42	4.77e-8	Schizophrenia;
PAAD	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-1.35	-7.14	-0.5	3.51e-11	Prostate cancer;
PAAD	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.29	0.51	1.56e-11	Educational attainment;
PAAD	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.76	8.78	0.58	3.09e-15	Lung cancer in ever smokers;
PAAD	cis	rs7719624	0.811	rs13159365	chr5:135389433	C/T	cg16684184	chr5:135415129	NA	-0.35	-4.37	-0.33	2.28e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.69	-5.81	-0.43	3.48e-8	Type 2 diabetes;
PAAD	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.54	-4.36	-0.33	2.4e-5	Diastolic blood pressure;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.63	-6.34	-0.46	2.55e-9	Iron status biomarkers;
PAAD	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-6.56	-0.47	7.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.67	5.33	0.4	3.49e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.62	5.25	0.39	4.96e-7	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25649261	chr6:138725556	HEBP2	0.62	6.71	0.48	3.54e-10	Myopia (pathological);
PAAD	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	7.98	0.54	3.25e-13	Bipolar disorder;
PAAD	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg08698997	chr16:88989212	CBFA2T3	0.39	4.86	0.37	2.95e-6	Social autistic-like traits;
PAAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.73	-7.39	-0.51	8.87e-12	Colorectal cancer;
PAAD	cis	rs288326	0.561	rs77227040	chr2:183894166	T/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg16579770	chr16:72058938	DHODH	0.38	4.46	0.34	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.57	6.72	0.48	3.42e-10	Aortic root size;
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	6.74	0.48	3.02e-10	Retinal vascular caliber;
PAAD	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.56	-5.6	-0.41	9.96e-8	Caffeine consumption;
PAAD	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.47	4.46	0.34	1.56e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg08501292	chr6:25962987	TRIM38	1.01	6.41	0.46	1.71e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs412050	0.594	rs113463481	chr22:22097230	G/A	cg17089214	chr22:22089827	YPEL1	0.66	4.31	0.33	2.88e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg04374321	chr14:90722782	PSMC1	0.51	4.3	0.33	3.02e-5	Longevity;
PAAD	cis	rs9315204	0.853	rs4943076	chr13:33689996	C/T	cg22534336	chr13:33112922	N4BP2L2	0.5	4.26	0.33	3.59e-5	Intracranial aneurysm;
PAAD	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg01304814	chr3:48885189	PRKAR2A	1.08	5.74	0.42	5.03e-8	Blood protein levels;
PAAD	cis	rs16975963	0.793	rs11666497	chr19:38464262	C/T	cg08679971	chr19:38281047	NA	0.55	5.24	0.39	5.4e-7	Longevity;
PAAD	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg00531865	chr16:30841666	NA	0.57	4.29	0.33	3.14e-5	Dementia with Lewy bodies;
PAAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.73	6.91	0.49	1.23e-10	Methadone dose in opioid dependence;
PAAD	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14169450	chr9:139327907	INPP5E	0.49	4.69	0.36	6.14e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.56	-0.61	3.08e-17	Schizophrenia;
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg10621924	chr7:39171070	POU6F2	0.33	5.01	0.38	1.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.64	6.32	0.46	2.76e-9	Height;
PAAD	cis	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg11802864	chr11:65308245	LTBP3	0.8	5.64	0.42	7.98e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg06074448	chr4:187884817	NA	0.63	7.16	0.5	3.25e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.83	10.05	0.63	1.57e-18	Height;
PAAD	cis	rs9630089	0.513	rs12571098	chr10:99095208	A/G	cg06569542	chr10:98946673	SLIT1	-0.53	-5.93	-0.43	1.94e-8	Neutrophil percentage of white cells;
PAAD	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg22532475	chr10:104410764	TRIM8	-0.43	-4.95	-0.37	1.94e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg02917321	chr22:38215204	NA	-0.45	-4.6	-0.35	8.88e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19917639	chr1:175128381	KIAA0040	-0.67	-6.88	-0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-6.48	-0.47	1.2e-9	Obesity (extreme);
PAAD	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.03	6.79	0.48	2.41e-10	Mitochondrial DNA levels;
PAAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.72	7.11	0.5	4.25e-11	Tonsillectomy;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.73	-4.51	-0.34	1.29e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.35	-4.7	-0.36	5.88e-6	Myeloid white cell count;
PAAD	cis	rs1539053	1.000	rs11207079	chr1:58097977	T/C	cg00026909	chr1:58089001	DAB1	-0.68	-7.82	-0.54	8.27e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.78	7.19	0.5	2.78e-11	Obesity-related traits;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.44	-5.16	-0.39	7.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs490234	0.812	rs2900229	chr9:128466312	A/G	cg14078157	chr9:128172775	NA	-0.41	-4.76	-0.36	4.5e-6	Mean arterial pressure;
PAAD	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-4.68	-0.35	6.37e-6	Coronary artery disease;
PAAD	cis	rs6074578	0.621	rs6086355	chr20:140853	C/G	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg08888203	chr3:10149979	C3orf24	0.77	5.77	0.42	4.32e-8	Alzheimer's disease;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	1.13	17.32	0.81	8.62e-38	Menarche (age at onset);
PAAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.29	0.39	4.16e-7	Ulcerative colitis;
PAAD	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.53	-0.34	1.18e-5	Recombination measurement;
PAAD	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg03948781	chr1:205179583	DSTYK	0.47	4.36	0.33	2.39e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.54	-4.52	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00700412	chr12:58011837	NA	0.43	4.49	0.34	1.38e-5	Multiple sclerosis;
PAAD	cis	rs743757	0.938	rs12492113	chr3:50521402	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.63	-4.26	-0.33	3.52e-5	Diastolic blood pressure;
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.77	9.92	0.63	3.38e-18	Vitiligo;
PAAD	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.71	-7.12	-0.5	4.01e-11	Retinal vascular caliber;
PAAD	cis	rs911119	0.955	rs8121283	chr20:23605002	G/C	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.47	-5.32	-0.4	3.69e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.67	7.13	0.5	3.81e-11	Schizophrenia;
PAAD	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg18281939	chr5:77783895	LHFPL2	0.49	6.3	0.46	3.02e-9	Triglycerides;
PAAD	cis	rs7180079	1.000	rs4777185	chr15:64672593	G/A	cg18210365	chr15:65066710	RBPMS2	0.68	4.92	0.37	2.2e-6	Monocyte count;
PAAD	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	6.1	0.44	8.58e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9287604	1.000	rs4663674	chr2:237785813	G/C	cg15065627	chr2:237796583	NA	-0.53	-4.33	-0.33	2.71e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18842598	chr12:114273539	RBM19	-0.74	-7.76	-0.53	1.17e-12	Obesity-related traits;
PAAD	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.5	-6.15	-0.45	6.59e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.25	0.64	4.68e-19	Bladder cancer;
PAAD	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.38	0.74	1.77e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.96	5.55	0.41	1.24e-7	Schizophrenia;
PAAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-4.82	-0.36	3.41e-6	Blood metabolite levels;
PAAD	cis	rs7236492	0.935	rs7239086	chr18:77217030	A/C	cg15644404	chr18:77186268	NFATC1	-0.88	-6.13	-0.45	7.12e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	5.87	0.43	2.66e-8	Lung function (FEV1/FVC);
PAAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09695851	chr17:3907499	NA	0.66	7.15	0.5	3.34e-11	Type 2 diabetes;
PAAD	cis	rs6700896	1.000	rs6700896	chr1:66089782	C/T	cg04111102	chr1:66153794	NA	0.45	4.97	0.37	1.76e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.43	-6.2	-0.45	5.04e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6499766	0.516	rs2397721	chr16:55555887	G/A	cg00427604	chr16:55542751	LPCAT2	0.37	4.25	0.33	3.77e-5	Thyroid hormone levels;
PAAD	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.6	4.31	0.33	2.93e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59698941	0.882	rs12521723	chr5:132273808	A/T	cg14825688	chr5:132208181	LEAP2	-0.59	-4.29	-0.33	3.22e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.74	8.4	0.56	2.94e-14	Longevity;
PAAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.83	0.66	1.26e-20	Homoarginine levels;
PAAD	cis	rs939584	1.000	rs6746275	chr2:635857	C/A	cg14515364	chr2:636606	NA	0.48	4.31	0.33	2.88e-5	Body mass index;
PAAD	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.75	-0.42	4.83e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg21191810	chr6:118973309	C6orf204	0.46	5.79	0.43	3.81e-8	Electrocardiographic conduction measures;
PAAD	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg19423196	chr10:82049429	MAT1A	0.45	4.25	0.33	3.7e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg13870426	chr17:30244630	NA	0.73	6.4	0.46	1.83e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.9	0.37	2.42e-6	Lung cancer in ever smokers;
PAAD	cis	rs6442925	1.000	rs6442925	chr3:5013876	C/T	cg26395694	chr3:4783306	ITPR1	-0.42	-4.37	-0.33	2.25e-5	Corneal structure;
PAAD	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs9463078	0.774	rs9357480	chr6:45219512	G/A	cg25276700	chr6:44698697	NA	-0.49	-5.75	-0.42	4.71e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.85	-10.16	-0.64	7.65e-19	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.63	7.61	0.53	2.71e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.04	-0.38	1.32e-6	Mood instability;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.63	-6.65	-0.47	5.05e-10	Brugada syndrome;
PAAD	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg12615879	chr12:58013172	SLC26A10	-0.38	-4.25	-0.33	3.7e-5	Multiple sclerosis;
PAAD	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg05805236	chr11:65401703	PCNXL3	0.41	4.38	0.33	2.21e-5	Acne (severe);
PAAD	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-7.54	-0.52	3.95e-12	Brugada syndrome;
PAAD	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg11214348	chr21:47283868	PCBP3	-0.49	-4.42	-0.34	1.85e-5	Schizophrenia;
PAAD	cis	rs10768122	0.738	rs10836356	chr11:35271419	A/G	cg13971030	chr11:35366721	SLC1A2	0.41	4.98	0.37	1.72e-6	Vitiligo;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.93	-0.37	2.16e-6	Platelet count;
PAAD	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.14	-0.38	8.32e-7	Cognitive function;
PAAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.75	8.1	0.55	1.68e-13	Menopause (age at onset);
PAAD	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.46	-0.34	1.6e-5	Plateletcrit;Platelet count;
PAAD	cis	rs3126085	0.515	rs11204995	chr1:152359168	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.77	5.92	0.43	2.01e-8	Diisocyanate-induced asthma;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-4.97	-0.37	1.78e-6	Lung cancer;
PAAD	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.28	-14.14	-0.75	1.61e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.82e-9	Height;
PAAD	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg27411982	chr8:10470053	RP1L1	-0.53	-5.81	-0.43	3.61e-8	Retinal vascular caliber;
PAAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.34	-0.33	2.55e-5	Menarche (age at onset);
PAAD	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg14458575	chr2:238380390	NA	0.66	5.6	0.41	9.81e-8	Prostate cancer;
PAAD	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.39	0.34	2.15e-5	Menarche (age at onset);
PAAD	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg02683114	chr2:24398427	C2orf84	-0.45	-4.72	-0.36	5.41e-6	Sjögren's syndrome;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg18171855	chr10:2543474	NA	0.41	4.29	0.33	3.17e-5	Age-related hearing impairment;
PAAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs288326	0.561	rs17703779	chr2:183895919	C/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs802075	1.000	rs4711935	chr6:49647822	C/T	cg20364632	chr6:49636226	NA	-0.55	-6.37	-0.46	2.12e-9	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg00262122	chr8:11665843	FDFT1	0.5	4.35	0.33	2.44e-5	Retinal vascular caliber;
PAAD	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.49	-0.61	4.64e-17	Type 2 diabetes;
PAAD	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg01305830	chr4:1604576	NA	-0.44	-4.35	-0.33	2.45e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs569214	0.648	rs561690	chr8:27510463	A/G	cg04264299	chr8:27491209	SCARA3	0.51	4.62	0.35	8.01e-6	Alzheimer's disease;
PAAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-8.62	-0.57	8.24e-15	Coronary artery disease;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg01097406	chr16:89675127	NA	0.36	4.41	0.34	1.93e-5	Vitiligo;
PAAD	cis	rs9398803	0.687	rs853986	chr6:127023336	C/G	cg19875578	chr6:126661172	C6orf173	-0.44	-4.59	-0.35	9.14e-6	Male-pattern baldness;
PAAD	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.74	7.66	0.53	2.04e-12	Uric acid levels;
PAAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00982548	chr2:198649783	BOLL	-0.83	-5.81	-0.43	3.55e-8	Ulcerative colitis;
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2061333	0.894	rs2284981	chr19:44633558	G/C	cg23489630	chr19:44645078	ZNF234	-0.58	-4.33	-0.33	2.68e-5	Alzheimer's disease;
PAAD	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.63	6.67	0.48	4.5e-10	Hemoglobin concentration;
PAAD	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.63	5.0	0.38	1.58e-6	Common traits (Other);
PAAD	cis	rs868943	0.582	rs12196141	chr6:116489550	C/T	cg18764771	chr6:116381957	FRK	-0.29	-4.58	-0.35	9.76e-6	Total cholesterol levels;
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg00590817	chr1:8272081	NA	-0.4	-4.91	-0.37	2.31e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg22437258	chr11:111473054	SIK2	0.62	6.03	0.44	1.17e-8	Primary sclerosing cholangitis;
PAAD	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.22	0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.81	0.36	3.63e-6	Schizophrenia;
PAAD	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg04450456	chr4:17643702	FAM184B	-0.48	-4.92	-0.37	2.24e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.43	4.4	0.34	2.03e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	6.68	0.48	4.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg12165864	chr7:66369176	NA	-0.79	-5.28	-0.39	4.43e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.06	-0.5	5.47e-11	Life satisfaction;
PAAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.6	5.11	0.38	9.48e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21545522	chr1:205238299	TMCC2	0.48	4.32	0.33	2.82e-5	Red blood cell count;
PAAD	cis	rs6084875	0.733	rs4143674	chr20:4741304	T/C	cg05143360	chr20:4741328	NA	0.49	4.44	0.34	1.69e-5	Systemic lupus erythematosus;
PAAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.62	5.57	0.41	1.11e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs62264129	0.500	rs62278843	chr3:112041382	T/C	cg01411366	chr3:112012867	SLC9A10	-0.3	-4.89	-0.37	2.57e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	7.29	0.51	1.62e-11	Response to antipsychotic treatment;
PAAD	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg08316009	chr16:89165765	ACSF3	-0.5	-4.37	-0.33	2.26e-5	Tanning;
PAAD	cis	rs3784262	0.565	rs9635350	chr15:58298412	G/A	cg12031962	chr15:58353849	ALDH1A2	0.38	4.55	0.35	1.1e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.09	-0.59	5.15e-16	Blood trace element (Zn levels);
PAAD	cis	rs7627468	1.000	rs61203229	chr3:121943859	A/G	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg10494973	chr17:80897199	TBCD	0.56	4.56	0.35	1.05e-5	Breast cancer;
PAAD	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-8.73	-0.58	4.37e-15	Gut microbiome composition (summer);
PAAD	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.5	-4.32	-0.33	2.77e-5	Obesity-related traits;
PAAD	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.36	5.45e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.46	-0.41	1.87e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.57	-5.02	-0.38	1.43e-6	Mean corpuscular volume;
PAAD	cis	rs2061333	0.947	rs1236715	chr19:44639558	C/G	cg18700516	chr19:44507157	ZNF230	-0.66	-5.0	-0.38	1.56e-6	Alzheimer's disease;
PAAD	cis	rs1190596	1.000	rs1190596	chr14:102595625	A/G	cg23904247	chr14:102554826	HSP90AA1	-0.43	-4.61	-0.35	8.57e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11892454	0.533	rs10193672	chr2:26104264	C/G	cg25181710	chr2:26045287	ASXL2	0.39	4.28	0.33	3.32e-5	Heschl's gyrus morphology;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.74e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11955175	1.000	rs45480797	chr5:40680964	C/G	cg17351974	chr5:40835760	RPL37	0.77	4.52	0.34	1.23e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6499129	0.764	rs16957291	chr16:67326102	T/A	cg09395969	chr16:67918001	EDC4;NRN1L	0.63	4.49	0.34	1.38e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg17674042	chr6:34482479	PACSIN1	-1.26	-7.44	-0.52	6.8e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg01214346	chr17:406501	NA	0.47	4.36	0.33	2.35e-5	Prostate cancer;
PAAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg07559730	chr19:53497048	ZNF702P	-0.5	-5.44	-0.4	2.12e-7	Psoriasis;
PAAD	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs2859741	0.608	rs532719	chr1:37477380	C/T	cg09363841	chr1:37513479	NA	0.54	6.55	0.47	8.39e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	4.5	0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.49	5.07	0.38	1.13e-6	Red blood cell count;
PAAD	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg02415014	chr8:143852576	LYNX1	0.38	4.37	0.33	2.31e-5	Urinary tract infection frequency;
PAAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.13	-7.82	-0.54	8.21e-13	Lung cancer in ever smokers;
PAAD	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.9	9.48	0.61	4.88e-17	Breast cancer;
PAAD	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.67	6.35	0.46	2.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.49	-5.19	-0.39	6.67e-7	Inflammatory bowel disease;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.38	4.59	0.35	9.31e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.97	13.14	0.73	7.96e-27	Menarche (age at onset);
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.66	6.09	0.44	8.66e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.26	7.2	0.5	2.63e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg21546286	chr11:48923668	NA	-0.6	-6.24	-0.45	4.06e-9	HDL cholesterol;
PAAD	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg10327424	chr1:202611933	SYT2	-0.42	-4.39	-0.34	2.07e-5	Mean platelet volume;
PAAD	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	4.43	0.34	1.8e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg17718321	chr1:152188247	HRNR	0.52	5.07	0.38	1.16e-6	Inflammatory skin disease;
PAAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs617219	0.671	rs2220839	chr5:78603510	T/A	cg24856658	chr5:78533917	JMY	0.38	4.28	0.33	3.29e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23762105	chr12:34175262	ALG10	-0.55	-6.58	-0.47	7.09e-10	Body fat percentage;
PAAD	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg07395648	chr5:131743802	NA	-0.62	-6.4	-0.46	1.83e-9	Blood metabolite levels;
PAAD	cis	rs412658	0.504	rs385774	chr19:22096075	G/A	cg07498013	chr19:22123504	NA	-0.42	-4.47	-0.34	1.49e-5	Telomere length;
PAAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg12215294	chr3:40350768	EIF1B	0.49	4.77	0.36	4.29e-6	Renal cell carcinoma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00907843	chr7:73038888	MLXIPL	-0.73	-8.06	-0.55	2.13e-13	Smoking initiation;
PAAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06850241	chr22:41845214	NA	-0.57	-5.07	-0.38	1.14e-6	Vitiligo;
PAAD	cis	rs7264396	0.887	rs224354	chr20:34054609	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.54	0.35	1.16e-5	Renal cell carcinoma;
PAAD	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.83	4.42	0.34	1.88e-5	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22749736	chr11:1306759	TOLLIP	0.59	6.85	0.49	1.72e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.06e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-5.24	-0.39	5.28e-7	Red cell distribution width;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	trans	rs901683	0.850	rs74500471	chr10:46031735	A/T	cg12869334	chr8:37699360	GPR124	0.98	6.78	0.48	2.44e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.12	0.38	9.22e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6466055	0.777	rs3801278	chr7:104907017	C/T	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.35	0.33	2.46e-5	Menopause (age at onset);
PAAD	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.57	-5.46	-0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs11807834	0.522	rs1998068	chr1:230238063	C/G	cg09847368	chr1:230250326	GALNT2	-0.68	-8.21	-0.55	8.65e-14	Schizophrenia;
PAAD	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.71e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7904985	1.000	rs12777097	chr10:88115638	G/A	cg07322936	chr10:88137208	NA	-0.49	-4.44	-0.34	1.7e-5	Barrett's esophagus;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-5.46	-0.41	1.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6929137	0.666	rs56681564	chr6:151938465	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.4	-0.34	2.03e-5	Bone mineral density (spine);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26291519	chr15:76640005	NA	0.58	6.41	0.46	1.69e-9	Myopia (pathological);
PAAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26549601	chr10:134560360	INPP5A	-0.44	-4.41	-0.34	1.95e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08219700	chr8:58056026	NA	0.72	5.65	0.42	7.72e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.58	0.61	2.66e-17	Prudent dietary pattern;
PAAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.84	6.98	0.49	8.66e-11	Recombination rate (females);
PAAD	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.5	-4.85	-0.37	3.08e-6	Platelet count;
PAAD	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.93	-0.37	2.16e-6	Personality dimensions;
PAAD	cis	rs11563648	0.553	rs1419423	chr7:127018215	C/T	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.97	-0.54	3.47e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	6.87	0.49	1.53e-10	Mean platelet volume;
PAAD	cis	rs12612619	0.704	rs2384571	chr2:27324724	G/C	cg00617064	chr2:27272375	NA	-0.48	-4.62	-0.35	8.05e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.75	-7.8	-0.53	9.42e-13	Asperger disorder;
PAAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.17	14.46	0.76	2.28e-30	IgG glycosylation;
PAAD	cis	rs7945718	0.650	rs4316494	chr11:12664541	C/T	cg25843174	chr11:12811716	TEAD1	-0.31	-4.53	-0.35	1.16e-5	Educational attainment (years of education);
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.48	-4.53	-0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11168618	0.715	rs35367885	chr12:48919660	G/A	cg01881778	chr12:48919444	OR8S1	-0.45	-4.47	-0.34	1.5e-5	Adiponectin levels;
PAAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.78	6.92	0.49	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.21	0.51	2.41e-11	Multiple sclerosis;
PAAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs6088813	0.702	rs6060378	chr20:33923001	T/G	cg14752227	chr20:34000481	UQCC	0.5	4.48	0.34	1.46e-5	Height;
PAAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.48	4.9	0.37	2.38e-6	Major depressive disorder;
PAAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.71	-0.62	1.23e-17	Height;
PAAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.62	-7.24	-0.51	2.04e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.76	-8.69	-0.58	5.34e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9677476	0.517	rs62197322	chr2:232061520	A/G	cg07929768	chr2:232055508	NA	0.46	5.31	0.4	3.76e-7	Food antigen IgG levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25397718	chr9:140317786	EXD3;NOXA1	0.58	6.51	0.47	1.06e-9	Metabolite levels  (X-11787);
PAAD	cis	rs80130819	0.688	rs11168455	chr12:48592792	G/A	cg26205652	chr12:48591994	NA	0.68	4.65	0.35	7.23e-6	Prostate cancer;
PAAD	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.33	-0.33	2.66e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.57e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.41	0.4	2.4e-7	Lung cancer in ever smokers;
PAAD	cis	rs74181299	0.684	rs17040050	chr2:65327042	G/A	cg20592124	chr2:65290738	CEP68	-0.46	-4.33	-0.33	2.68e-5	Pulse pressure;
PAAD	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01688590	chr15:32163153	NA	-0.54	-6.5	-0.47	1.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.58	-7.46	-0.52	6.14e-12	Lewy body disease;
PAAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	1.35	10.02	0.63	1.85e-18	Schizophrenia;
PAAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15556689	chr8:8085844	FLJ10661	0.76	7.32	0.51	1.34e-11	Mood instability;
PAAD	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg17330251	chr7:94953956	PON1	-0.54	-4.43	-0.34	1.77e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg11335335	chr11:637885	DRD4	-0.39	-5.39	-0.4	2.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs13065560	0.533	rs4580488	chr3:38882438	G/T	cg01426195	chr3:39028469	NA	-0.44	-4.32	-0.33	2.8e-5	Interleukin-18 levels;
PAAD	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.88	10.69	0.66	3.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.48	4.33	0.33	2.65e-5	Acylcarnitine levels;
PAAD	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.74	-8.32	-0.56	4.59e-14	Colorectal cancer;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg03199926	chr20:60860733	OSBPL2	-0.44	-5.56	-0.41	1.16e-7	Pelvic organ prolapse;
PAAD	cis	rs60154123	0.881	rs1774107	chr1:210453923	C/T	cg22029157	chr1:209979665	IRF6	0.67	6.21	0.45	4.78e-9	Coronary artery disease;
PAAD	cis	rs7705042	0.865	rs12656877	chr5:141490091	T/C	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.25	-0.39	5.02e-7	Asthma;
PAAD	cis	rs9503598	0.502	rs2326231	chr6:3433925	T/G	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg00459043	chr17:30771460	PSMD11	0.55	4.51	0.34	1.26e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	cis	rs787274	1.000	rs1418409	chr9:115573707	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.4	4.41	0.34	1.93e-5	Facial morphology (factor 20);
PAAD	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg09754948	chr16:28834200	ATXN2L	0.45	4.29	0.33	3.13e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg16386425	chr10:429943	DIP2C	0.51	5.12	0.38	9.09e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg05585544	chr11:47624801	NA	-0.48	-5.35	-0.4	3.16e-7	Subjective well-being;
PAAD	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.62	-6.34	-0.46	2.49e-9	Monocyte count;
PAAD	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg22691776	chr3:15032403	NR2C2	0.29	4.36	0.33	2.37e-5	Mean platelet volume;
PAAD	cis	rs2004318	1.000	rs75376732	chr19:55125237	C/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7247513	0.658	rs4804728	chr19:12752928	G/A	cg01871581	chr19:12707946	ZNF490	-0.76	-8.23	-0.56	7.95e-14	Bipolar disorder;
PAAD	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.9	7.44	0.52	6.74e-12	Vitiligo;
PAAD	cis	rs7301016	0.947	rs10877862	chr12:62888647	T/C	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs7646881	0.812	rs73017536	chr3:158460602	C/T	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs8044868	0.530	rs7189115	chr16:72098952	C/T	cg16579770	chr16:72058938	DHODH	0.4	4.49	0.34	1.42e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg18898632	chr2:242989856	NA	-0.66	-5.03	-0.38	1.36e-6	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09360458	chr1:14075560	PRDM2	-0.62	-6.91	-0.49	1.25e-10	Smoking initiation;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.8	-0.36	3.79e-6	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	1.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.67	-4.64	-0.35	7.36e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg11335335	chr11:637885	DRD4	-0.36	-5.05	-0.38	1.26e-6	Systemic lupus erythematosus;
PAAD	cis	rs7922314	0.571	rs7083998	chr10:64750962	G/A	cg08989932	chr10:65390526	NA	-0.95	-4.69	-0.36	5.92e-6	Cutaneous psoriasis;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg01763666	chr17:80159506	CCDC57	0.45	4.6	0.35	8.75e-6	Life satisfaction;
PAAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	8.13	0.55	1.36e-13	Lewy body disease;
PAAD	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs509477	0.811	rs12964519	chr18:32583580	T/G	cg23791764	chr18:32556832	MAPRE2	0.58	4.69	0.36	6.11e-6	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.63	-6.39	-0.46	1.9e-9	Schizophrenia;
PAAD	cis	rs2137920	0.529	rs12774742	chr10:50216323	C/G	cg02657375	chr10:50863136	CHAT	0.6	4.53	0.34	1.19e-5	Migraine with aura;
PAAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg19257562	chr1:2043853	PRKCZ	-0.42	-5.06	-0.38	1.19e-6	Height;
PAAD	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.64	0.57	7.07e-15	Motion sickness;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02556042	chr12:117471086	NA	-0.48	-4.87	-0.37	2.73e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-10.43	-0.65	1.54e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.68	-0.48	4.28e-10	Body mass index;
PAAD	cis	rs7217780	0.527	rs230951	chr17:15199814	T/A	cg20358362	chr17:14248304	HS3ST3B1	0.6	4.84	0.37	3.16e-6	Preterm birth (maternal effect);
PAAD	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	1.16	13.18	0.73	5.98e-27	Hair shape;
PAAD	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-1.05	-18.71	-0.83	2.86e-41	Urate levels in lean individuals;
PAAD	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.93	-5.26	-0.39	4.72e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.73	-8.7	-0.58	5.16e-15	Diastolic blood pressure;
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg05627522	chr15:75251581	NA	-0.46	-5.7	-0.42	6.06e-8	Breast cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12504415	chr17:74722752	JMJD6;C17orf95	0.53	6.37	0.46	2.19e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg20790798	chr5:1857306	NA	-0.53	-6.06	-0.44	1.01e-8	Cardiovascular disease risk factors;
PAAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.16	-8.78	-0.58	3.11e-15	Mitochondrial DNA levels;
PAAD	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.8	8.72	0.58	4.5e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.54	4.35	0.33	2.49e-5	Alzheimer's disease;
PAAD	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.56	5.36	0.4	3.1e-7	Platelet count;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-6.97	-0.49	8.96e-11	Prudent dietary pattern;
PAAD	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg09579323	chr1:150459698	TARS2	0.45	4.27	0.33	3.41e-5	Migraine;
PAAD	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6782025	1.000	rs6793029	chr3:121104262	A/G	cg16417163	chr3:121280760	NA	-0.47	-4.87	-0.37	2.82e-6	Aging (facial);
PAAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25833597	chr17:30823145	MYO1D	0.53	5.38	0.4	2.77e-7	Schizophrenia;
PAAD	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg03999872	chr20:62272968	STMN3	-0.72	-6.34	-0.46	2.45e-9	Atopic dermatitis;
PAAD	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg09017928	chr7:158110068	PTPRN2	-0.55	-4.98	-0.37	1.7e-6	Response to amphetamines;
PAAD	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17741873	0.720	rs2227562	chr10:75672961	G/A	cg01368488	chr10:75493387	NA	-0.57	-4.42	-0.34	1.88e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.54	-4.98	-0.37	1.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg02380750	chr20:61661411	NA	0.36	4.34	0.33	2.56e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2555155	1.000	rs2250886	chr11:6529642	G/A	cg24637308	chr11:6592297	DNHD1	0.48	4.97	0.37	1.79e-6	DNA methylation (variation);
PAAD	cis	rs73198271	0.515	rs78790301	chr8:8625786	G/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07175191	chr17:26988607	SUPT6H;SDF2	-0.64	-6.76	-0.48	2.85e-10	Smoking initiation;
PAAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg19680485	chr15:31195859	MTMR15	-0.45	-4.57	-0.35	1e-5	Huntington's disease progression;
PAAD	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.73	-0.53	1.4e-12	Exhaled nitric oxide output;
PAAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	9.37	0.61	9.23e-17	Parkinson's disease;
PAAD	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.39	-0.46	1.9e-9	Hip circumference;
PAAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.69	-7.85	-0.54	6.91e-13	Height;
PAAD	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.52	-4.4	-0.34	2.05e-5	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs735539	0.517	rs9552241	chr13:21127569	C/G	cg27234864	chr13:21295941	IL17D	-0.64	-5.71	-0.42	5.85e-8	Dental caries;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.92	-9.51	-0.61	4.19e-17	Response to antineoplastic agents;
PAAD	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs501916	0.728	rs1993150	chr15:48067518	A/T	cg16110827	chr15:48056943	SEMA6D	-0.44	-4.88	-0.37	2.71e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs28647808	1.000	rs28729896	chr9:136277796	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.49	5.84	0.43	3.02e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-5.4	-0.4	2.5e-7	Electroencephalogram traits;
PAAD	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg12757816	chr2:10669957	NA	0.53	5.87	0.43	2.66e-8	Prostate cancer;
PAAD	cis	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.54	-0.41	1.31e-7	Obesity-related traits;
PAAD	cis	rs9488822	0.623	rs195516	chr6:116241548	T/A	cg18764771	chr6:116381957	FRK	0.29	4.62	0.35	8.12e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.76	7.92	0.54	4.79e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	1.02	5.0	0.38	1.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12788159	chr2:228632759	NA	0.5	6.52	0.47	1.01e-9	Body fat percentage;
PAAD	cis	rs6466055	0.777	rs3801281	chr7:104889573	T/C	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01774471	chr2:86790641	VPS24	0.61	6.65	0.47	4.84e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg27398547	chr14:60952738	C14orf39	1.03	6.64	0.47	5.34e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs1451375	0.550	rs2242042	chr7:50529852	T/G	cg14593290	chr7:50529359	DDC	-0.66	-6.07	-0.44	9.6e-9	Malaria;
PAAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.59	-0.35	9.21e-6	Triglycerides;
PAAD	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.45	-4.98	-0.37	1.7e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4588572	0.686	rs4470742	chr5:77657957	T/G	cg18281939	chr5:77783895	LHFPL2	-0.51	-5.78	-0.42	4.12e-8	Triglycerides;
PAAD	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	7.88	0.54	5.81e-13	Prudent dietary pattern;
PAAD	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.53	4.98	0.37	1.7e-6	Schizophrenia;
PAAD	cis	rs55951657	1	rs55951657	chr14:74074732	G/A	cg18635207	chr14:74891800	TMEM90A	0.74	4.42	0.34	1.9e-5	Hippocampal volume;
PAAD	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg03264133	chr6:25882463	NA	0.44	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs1468333	0.697	rs35931944	chr5:137629132	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00838150	chr3:69788442	MITF	0.56	6.34	0.46	2.48e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.74	-4.7	-0.36	5.89e-6	Body mass index;
PAAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.63	5.82	0.43	3.32e-8	Prostate cancer;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.26e-6	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.57	6.56	0.47	8e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14677317	chr19:7460061	ARHGEF18	0.67	6.77	0.48	2.69e-10	Obesity-related traits;
PAAD	cis	rs1020064	0.636	rs2679883	chr2:105949668	C/T	cg02543470	chr2:105862877	NA	-0.48	-5.32	-0.4	3.64e-7	AIDS;
PAAD	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.48	5.18	0.39	7.07e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs8099014	1.000	rs7238962	chr18:56130112	A/G	cg12907477	chr18:56117327	MIR122	0.53	4.29	0.33	3.19e-5	Platelet count;
PAAD	cis	rs2281636	0.931	rs2804419	chr10:101509113	A/G	cg05149213	chr10:101381631	SLC25A28	-0.48	-4.58	-0.35	9.64e-6	Obesity-related traits;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10858572	chr8:67976441	CSPP1	0.73	6.43	0.46	1.55e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg05721444	chr7:32995514	FKBP9	-0.55	-5.5	-0.41	1.59e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.55	7.78	0.53	1.04e-12	Diastolic blood pressure;
PAAD	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.71	0.42	5.77e-8	Life satisfaction;
PAAD	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg22027985	chr11:4115532	RRM1	-0.5	-4.55	-0.35	1.07e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.72	-0.48	3.36e-10	Post bronchodilator FEV1;
PAAD	cis	rs11187837	1.000	rs17109875	chr10:96026575	T/C	cg07388132	chr10:96306137	HELLS	-0.67	-4.45	-0.34	1.64e-5	Sudden cardiac arrest;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.47	-5.08	-0.38	1.12e-6	Educational attainment;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25214684	chr1:39457099	AKIRIN1	0.63	6.85	0.49	1.72e-10	Myopia (pathological);
PAAD	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.5	-5.35	-0.4	3.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.41	0.61	7.25e-17	Response to antipsychotic treatment;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg12705353	chr12:122356852	WDR66	-0.42	-4.26	-0.33	3.59e-5	Mean corpuscular volume;
PAAD	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg05110241	chr16:68378359	PRMT7	-0.98	-8.09	-0.55	1.72e-13	Magnesium levels;
PAAD	cis	rs7577696	0.925	rs212718	chr2:32461833	C/A	cg02381751	chr2:32503542	YIPF4	0.44	4.75	0.36	4.61e-6	Inflammatory biomarkers;
PAAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.78	-0.48	2.49e-10	Total body bone mineral density;
PAAD	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg26031613	chr14:104095156	KLC1	-0.56	-5.74	-0.42	5.02e-8	Reticulocyte count;
PAAD	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg10431340	chr1:161279108	MPZ	-0.6	-5.45	-0.4	1.95e-7	Rheumatoid arthritis;
PAAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.86	8.64	0.57	7.18e-15	Cognitive function;
PAAD	cis	rs8113142	0.614	rs59394095	chr19:29192112	C/A	cg04546413	chr19:29218101	NA	0.42	4.25	0.33	3.73e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16582344	chr1:228270207	ARF1	0.59	6.58	0.47	7.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.84	0.43	3.04e-8	Alzheimer's disease;
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.54	-5.15	-0.39	7.89e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.85	9.66	0.62	1.68e-17	Lewy body disease;
PAAD	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs8060686	0.748	rs3785098	chr16:67993643	T/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.96	-0.44	1.7e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg10589385	chr1:150898437	SETDB1	-0.38	-4.65	-0.35	7.16e-6	Tonsillectomy;
PAAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.71	10.4	0.64	1.85e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	6.86e-8	Urinary metabolites;
PAAD	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg03665132	chr1:2137325	C1orf86	-0.44	-4.27	-0.33	3.38e-5	Height;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-5.66	-0.42	7.22e-8	Crohn's disease;
PAAD	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.49	-5.43	-0.4	2.24e-7	Menarche (age at onset);
PAAD	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21619639	chr4:155471134	PLRG1	0.67	7.78	0.53	1.03e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25833597	chr17:30823145	MYO1D	-0.52	-4.97	-0.37	1.81e-6	Schizophrenia;
PAAD	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06634786	chr22:41940651	POLR3H	-0.68	-5.16	-0.39	7.66e-7	Vitiligo;
PAAD	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.58	-6.39	-0.46	1.9e-9	Body mass index;
PAAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.53	-6.6	-0.47	6.61e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.69	7.35	0.51	1.14e-11	Schizophrenia;
PAAD	cis	rs939584	1.000	rs13012571	chr2:632550	A/G	cg14515364	chr2:636606	NA	-0.51	-4.72	-0.36	5.37e-6	Body mass index;
PAAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs939584	1.000	rs11127491	chr2:646145	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg08999081	chr20:33150536	PIGU	0.61	6.74	0.48	3.06e-10	Height;
PAAD	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.51	0.34	1.3e-5	IgG glycosylation;
PAAD	cis	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg22101045	chr11:47927509	NA	0.56	4.37	0.33	2.27e-5	Axial length;
PAAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.88	0.43	2.53e-8	Lung cancer;
PAAD	cis	rs714515	0.586	rs2032530	chr1:172451886	C/T	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.76	6.18	0.45	5.51e-9	Coronary artery disease;
PAAD	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg05457628	chr5:178986728	RUFY1	-0.44	-4.56	-0.35	1.03e-5	Lung cancer;
PAAD	cis	rs112998813	0.571	rs7328349	chr13:114930401	G/A	cg24009030	chr13:114912327	NA	0.57	4.25	0.33	3.77e-5	Nodular sclerosis Hodgkin lymphoma;
PAAD	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg13606994	chr1:44402422	ARTN	-0.49	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.89	11.18	0.67	1.53e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.52	5.19	0.39	6.74e-7	Male sexual orientation;
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.89	12.5	0.71	4.07e-25	Vitiligo;
PAAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs16958440	1.000	rs2289132	chr18:44602292	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.58	-6.37	-0.46	2.17e-9	Body mass index;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.25	-0.39	5.13e-7	Schizophrenia;
PAAD	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg02736288	chr16:86012573	NA	0.6	5.12	0.38	9.3e-7	Multiple sclerosis;
PAAD	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.09	8.53	0.57	1.37e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-9.37	-0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg09127314	chr1:152161683	NA	-0.64	-4.57	-0.35	9.97e-6	Atopic dermatitis;
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.99	11.66	0.69	7.52e-23	Breast cancer;
PAAD	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs4740619	0.709	rs10810461	chr9:15876507	G/T	cg14451791	chr9:16040625	NA	-0.39	-4.42	-0.34	1.83e-5	Body mass index;
PAAD	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.88	0.37	2.67e-6	Motion sickness;
PAAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.62	0.47	5.9e-10	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs533581	0.873	rs529900	chr16:88976968	G/C	cg16701003	chr16:89028210	CBFA2T3	0.55	5.47	0.41	1.81e-7	Social autistic-like traits;
PAAD	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg05721444	chr7:32995514	FKBP9	-0.56	-5.33	-0.4	3.44e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.8e-7	Systemic lupus erythematosus;
PAAD	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	6.91	0.49	1.22e-10	Hip circumference;
PAAD	cis	rs498136	0.764	rs868006	chr11:69354931	G/A	cg24388239	chr11:68438018	NA	-0.43	-4.31	-0.33	2.98e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs8049603	0.812	rs12149898	chr16:23198054	C/T	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.87	5.03	0.38	1.39e-6	Cholesterol, total;
PAAD	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg05805236	chr11:65401703	PCNXL3	0.54	4.61	0.35	8.37e-6	Glomerular filtration rate (creatinine);Chronic kidney disease;
PAAD	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	7.61	0.53	2.62e-12	Schizophrenia;
PAAD	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-7.17	-0.5	3.11e-11	Idiopathic membranous nephropathy;
PAAD	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.48	4.97	0.37	1.81e-6	Breast cancer;
PAAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.45	4.49	0.34	1.41e-5	Aortic root size;
PAAD	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26926768	chr12:34528122	NA	-0.38	-4.68	-0.35	6.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs5751901	0.614	rs5760485	chr22:24986473	A/G	cg15363607	chr22:24998974	GGT1	-0.44	-4.53	-0.34	1.19e-5	Protein quantitative trait loci;
PAAD	cis	rs1864585	0.520	rs17776427	chr8:10672972	G/T	cg21775007	chr8:11205619	TDH	-0.56	-4.47	-0.34	1.52e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs6537837	0.517	rs559479	chr1:110138536	A/T	cg11857025	chr1:109633344	TMEM167B	-0.49	-4.54	-0.35	1.15e-5	Major depressive disorder;
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.86	0.37	2.91e-6	Vitiligo;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-5.13	-0.38	8.63e-7	Bipolar disorder;
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.73	-7.51	-0.52	4.76e-12	Blood metabolite levels;
PAAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.62	6.22	0.45	4.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg11657817	chr20:23433608	CST11	0.52	5.29	0.39	4.2e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.41	1.39e-7	Calcium levels;
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.51	5.36	0.4	3.06e-7	Menopause (age at onset);
PAAD	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-12.8	-0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Bladder cancer;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg08742575	chr21:47604166	C21orf56	0.47	4.67	0.35	6.44e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-1.12	-9.16	-0.6	3.36e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.7	5.54	0.41	1.28e-7	Height;
PAAD	cis	rs72827839	1.000	rs72827899	chr17:46551866	G/A	cg23391107	chr17:45924227	SP6	0.61	5.12	0.38	9.29e-7	Ease of getting up in the morning;
PAAD	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg10935138	chr17:73851978	WBP2	0.48	4.28	0.33	3.26e-5	White matter hyperintensity burden;
PAAD	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg10818794	chr15:86012489	AKAP13	0.49	5.23	0.39	5.53e-7	Bulimia nervosa;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg19895051	chr15:60771505	NARG2	-0.57	-6.4	-0.46	1.87e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg04053776	chr11:6947353	ZNF215	0.49	4.29	0.33	3.15e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg11057378	chr10:81107060	PPIF	0.47	5.51	0.41	1.53e-7	Height;
PAAD	cis	rs11135910	1.000	rs11135910	chr8:25892142	C/T	cg08715231	chr8:25906064	NA	0.39	4.32	0.33	2.86e-5	Prostate cancer;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg19445457	chr11:5799446	OR52N5	-0.51	-4.53	-0.35	1.17e-5	DNA methylation (variation);
PAAD	trans	rs901683	1.000	rs34793991	chr10:46080590	A/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-6.62	-0.47	5.9e-10	Lymphocyte counts;
PAAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.73	-8.65	-0.57	6.81e-15	Height;
PAAD	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg22256960	chr15:77711686	NA	-0.53	-4.3	-0.33	3.06e-5	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.8	0.43	3.65e-8	Alzheimer's disease;
PAAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.45	-5.54	-0.41	1.28e-7	Lewy body disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11656992	chr17:79818741	P4HB	0.59	6.3	0.46	3.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg07362569	chr17:61921086	SMARCD2	0.38	4.29	0.33	3.13e-5	Height;
PAAD	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-5.88	-0.43	2.53e-8	Testicular germ cell tumor;
PAAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.96	12.35	0.71	1.08e-24	Menopause (age at onset);
PAAD	cis	rs28489187	0.617	rs233133	chr1:85796557	G/T	cg16011679	chr1:85725395	C1orf52	0.5	4.64	0.35	7.58e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.7e-6	Personality dimensions;
PAAD	trans	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.74	6.87	0.49	1.51e-10	Vitamin D levels;
PAAD	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.53	5.33	0.4	3.48e-7	Resting heart rate;
PAAD	cis	rs11997175	0.625	rs953617	chr8:33599158	G/C	ch.8.33884649F	chr8:33765107	NA	0.57	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs432925	0.625	rs2858003	chr16:342191	A/G	cg08823186	chr16:347294	AXIN1	0.48	4.57	0.35	9.91e-6	Morning vs. evening chronotype;
PAAD	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg23460851	chr4:1604456	NA	-0.41	-4.3	-0.33	3.07e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	trans	rs901683	0.850	rs117668126	chr10:46062952	G/C	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09386096	chr19:19649054	CILP2	0.6	7.09	0.5	4.75e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.19	17.52	0.82	2.6e-38	IgG glycosylation;
PAAD	cis	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19560979	chr8:11627473	NEIL2	0.45	4.63	0.35	7.71e-6	Triglycerides;
PAAD	cis	rs3112530	1.000	rs160163	chr5:152725255	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.83	-4.37	-0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.75	-0.42	4.7e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg02569823	chr6:5851330	NA	0.61	6.69	0.48	4.1e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg21479132	chr6:26055353	NA	0.97	5.44	0.4	2.12e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs73416724	0.688	rs79761807	chr6:43341088	C/A	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.13	0.38	8.52e-7	HIV-1 control;
PAAD	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.68	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.83	7.66	0.53	1.97e-12	Migraine;Coronary artery disease;
PAAD	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.68	6.29	0.45	3.18e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2657888	0.593	rs2638318	chr12:56857422	C/T	cg23002907	chr12:56915593	RBMS2	0.45	4.38	0.33	2.21e-5	Adiponectin levels;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.54e-6	Lung cancer;
PAAD	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg00614314	chr15:82944287	LOC80154	0.5	5.04	0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.21	-0.39	5.96e-7	Schizophrenia;
PAAD	cis	rs4965869	0.866	rs2412012	chr15:101974653	C/T	cg20720553	chr15:101792477	CHSY1	-0.49	-4.29	-0.33	3.19e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs62392365	0.686	rs10498722	chr6:25186512	C/T	cg26336265	chr6:25042955	NA	0.72	4.97	0.37	1.78e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg02135003	chr7:105160482	PUS7	-0.68	-5.65	-0.42	7.51e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg00206168	chr11:65308501	LTBP3	0.51	5.32	0.4	3.73e-7	Bone mineral density;
PAAD	cis	rs3764400	0.508	rs72823528	chr17:46098944	C/T	cg10706073	chr17:46328419	SKAP1	-1.01	-5.84	-0.43	3.07e-8	Body mass index;
PAAD	cis	rs9397240	0.841	rs9384309	chr6:155620226	G/C	cg06694381	chr6:155569200	TIAM2	-0.47	-4.3	-0.33	2.99e-5	Life satisfaction;
PAAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.83	9.11	0.59	4.47e-16	Tuberculosis;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg21565972	chr17:80109576	CCDC57	0.48	5.2	0.39	6.33e-7	Life satisfaction;
PAAD	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.53	-4.4	-0.34	2.07e-5	Diastolic blood pressure;
PAAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg04450456	chr4:17643702	FAM184B	-0.48	-5.0	-0.38	1.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1419980	0.730	rs7955346	chr12:7739235	T/A	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.82	7.88	0.54	6e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4662592	0.554	rs13026746	chr2:128933224	G/C	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.48	-5.05	-0.38	1.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.8	-8.41	-0.56	2.8e-14	Prostate cancer;
PAAD	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.05	0.38	1.27e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.78	-7.28	-0.51	1.71e-11	Neuroticism;
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.09	-0.38	1.06e-6	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07898084	chr13:53029385	CKAP2	0.57	6.3	0.46	2.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13396519	1.000	rs13384495	chr2:11041283	C/G	cg04169469	chr2:10588434	ODC1;SNORA80B	-0.7	-4.42	-0.34	1.87e-5	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
PAAD	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg26935685	chr1:15502881	TMEM51	-0.49	-4.29	-0.33	3.2e-5	Systolic blood pressure;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	6.86e-11	Life satisfaction;
PAAD	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg25834613	chr7:1915315	MAD1L1	-0.46	-4.39	-0.34	2.14e-5	Bipolar disorder;
PAAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.67	-8.45	-0.57	2.16e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.32	-0.33	2.85e-5	Tonsillectomy;
PAAD	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg09127314	chr1:152161683	NA	-0.73	-4.84	-0.37	3.15e-6	Atopic dermatitis;
PAAD	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg01528321	chr10:82214614	TSPAN14	1.22	12.99	0.73	2.04e-26	Post bronchodilator FEV1;
PAAD	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.34e-9	Lung cancer;
PAAD	cis	rs838147	0.844	rs8108136	chr19:49247693	C/T	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg07883600	chr3:53528162	CACNA1D	0.41	4.42	0.34	1.84e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.58	6.51	0.47	1.02e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19346786	chr7:2764209	NA	-0.38	-5.01	-0.38	1.51e-6	Height;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.89	9.53	0.61	3.62e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs10501293	1.000	rs6485394	chr11:43080041	A/C	cg03447554	chr11:43094025	NA	-0.52	-5.16	-0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs12767760	0.669	rs10882961	chr10:99308703	G/A	cg25247692	chr10:99313390	UBTD1	0.56	5.47	0.41	1.8e-7	Obesity-related traits;
PAAD	cis	rs874426	0.528	rs7110926	chr11:19574469	A/G	cg13922121	chr11:19575262	NAV2	0.39	4.41	0.34	1.98e-5	Attention deficit hyperactivity disorder (time to onset);
PAAD	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg21892295	chr12:121157589	UNC119B	-0.43	-4.3	-0.33	3.02e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs7932354	0.583	rs10769212	chr11:46893498	C/A	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-0.8	-5.81	-0.43	3.5e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.7	8.09	0.55	1.78e-13	Age at first birth;
PAAD	cis	rs939584	1.000	rs6760543	chr2:622388	G/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.55	5.69	0.42	6.3e-8	Alcohol dependence;
PAAD	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg05784532	chr1:230284198	GALNT2	0.64	4.47	0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg24053715	chr22:38214548	NA	0.6	5.98	0.44	1.54e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13198984	chr17:80129470	CCDC57	0.46	5.75	0.42	4.71e-8	Life satisfaction;
PAAD	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2124910	1.000	rs897783	chr19:52031162	A/G	cg12008991	chr19:52034861	SIGLEC6	0.38	5.07	0.38	1.12e-6	Blood protein levels;
PAAD	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.67	8.42	0.56	2.66e-14	Hypertriglyceridemia;
PAAD	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg04520793	chr17:42248056	ASB16	0.41	5.36	0.4	3.06e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21175976	chr8:11421337	BLK	-0.4	-4.32	-0.33	2.85e-5	Triglycerides;
PAAD	cis	rs3736485	0.966	rs8042221	chr15:51774613	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg02527881	chr3:46936655	PTH1R	-0.4	-4.76	-0.36	4.56e-6	Colorectal cancer;
PAAD	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg08992911	chr2:238395768	MLPH	0.7	5.53	0.41	1.39e-7	Prostate cancer;
PAAD	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.8	9.78	0.62	8.15e-18	Breast cancer;
PAAD	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.45	4.28	0.33	3.33e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg02344993	chr17:57696989	CLTC	0.61	5.06	0.38	1.21e-6	Hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.68	5.44	0.4	2.1e-7	Blood protein levels;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.72	7.26	0.51	1.9e-11	Renal function-related traits (BUN);
PAAD	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs12145833	0.538	rs4658547	chr1:243391131	T/G	cg02356786	chr1:243265016	LOC731275	-0.96	-6.23	-0.45	4.33e-9	Obesity (early onset extreme);
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	1.07	9.42	0.61	6.97e-17	Eosinophil percentage of granulocytes;
PAAD	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-5.35	-0.4	3.23e-7	Schizophrenia;
PAAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-1.06	-15.07	-0.77	5.6199999999999995e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg02725872	chr8:58115012	NA	-0.6	-4.93	-0.37	2.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.49	5.03	0.38	1.34e-6	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg08219700	chr8:58056026	NA	0.71	5.33	0.4	3.42e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22508391	chr7:104624890	NA	-0.59	-6.32	-0.46	2.77e-9	Myopia (pathological);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg16272777	chr1:23694780	C1orf213;ZNF436	-0.73	-7.14	-0.5	3.58e-11	Primary biliary cholangitis;
PAAD	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.12	9.25	0.6	1.97e-16	Sexual dysfunction (female);
PAAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.93	-8.3	-0.56	5.25e-14	IgG glycosylation;
PAAD	cis	rs4478858	0.746	rs10798831	chr1:31688385	A/C	cg00250761	chr1:31883323	NA	0.41	4.55	0.35	1.1e-5	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14431789	chr10:97081759	SORBS1	-0.66	-7.07	-0.5	5.14e-11	Obesity-related traits;
PAAD	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.82	-9.22	-0.6	2.32e-16	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.7	-7.27	-0.51	1.76e-11	Morning vs. evening chronotype;
PAAD	cis	rs17095355	0.818	rs11194963	chr10:111806469	C/A	cg00817464	chr10:111662876	XPNPEP1	0.65	4.86	0.37	2.94e-6	Biliary atresia;
PAAD	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.95	7.58	0.52	3.09e-12	Type 2 diabetes;
PAAD	cis	rs9907295	0.591	rs11650668	chr17:34149049	T/A	cg19411729	chr17:34207663	CCL5	-0.53	-4.74	-0.36	4.92e-6	Fibroblast growth factor basic levels;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg20430434	chr16:56642433	MT2A	0.57	6.35	0.46	2.37e-9	Smoking initiation;
PAAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg09945482	chr18:12777974	NA	0.58	5.12	0.38	9.13e-7	Inflammatory skin disease;
PAAD	trans	rs1997066	0.834	rs78304339	chr10:106580735	A/C	cg20244273	chr11:7597349	PPFIBP2	-0.76	-6.33	-0.46	2.6e-9	Diabetic kidney disease;
PAAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs735539	0.556	rs9552277	chr13:21352287	T/A	cg27499820	chr13:21296301	IL17D	0.57	5.45	0.4	1.95e-7	Dental caries;
PAAD	cis	rs7084921	0.839	rs11593916	chr10:101809659	A/G	cg04359915	chr10:101825029	CPN1	0.33	4.65	0.35	7.11e-6	Bone mineral density;
PAAD	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.4	-0.46	1.82e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg04154034	chr17:28927549	LRRC37B2	0.7	4.53	0.34	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.57	6.97	0.49	9.22e-11	Multiple system atrophy;
PAAD	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.42	-4.28	-0.33	3.25e-5	Corneal structure;
PAAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.54	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	6.77	0.48	2.7e-10	Glomerular filtration rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01994328	chr10:30723347	MAP3K8	0.64	6.56	0.47	7.81e-10	Myopia (pathological);
PAAD	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.94e-8	Tonsillectomy;
PAAD	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.25	-0.33	3.72e-5	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03285963	chr2:187350816	ZC3H15	0.72	7.33	0.51	1.26e-11	Obesity-related traits;
PAAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.92	-8.31	-0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg21922841	chr17:72744131	SLC9A3R1	0.42	5.42	0.4	2.32e-7	Monocyte count;
PAAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.46	-5.0	-0.38	1.58e-6	Coronary artery disease;
PAAD	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-7.95	-0.54	3.89e-13	Height;
PAAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.56	5.35	0.4	3.14e-7	Red cell distribution width;
PAAD	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg24565620	chr2:194026	NA	0.55	4.39	0.34	2.08e-5	Blood protein levels;
PAAD	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg10395934	chr14:104002654	TRMT61A	0.55	5.53	0.41	1.39e-7	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21638063	chr5:107717975	FBXL17	0.67	8.3	0.56	5.2e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg06131755	chr6:160182447	ACAT2	0.53	4.41	0.34	1.97e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg00982548	chr2:198649783	BOLL	-0.76	-5.47	-0.41	1.81e-7	Ulcerative colitis;
PAAD	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs10450586	0.863	rs6484284	chr11:27298890	C/T	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg06618935	chr21:46677482	NA	-0.6	-7.84	-0.54	7.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1801251	0.727	rs35853577	chr2:233558879	T/C	cg25237894	chr2:233734115	C2orf82	0.41	4.82	0.36	3.46e-6	Coronary artery disease;
PAAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.75	0.53	1.23e-12	Yeast infection;
PAAD	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg22587600	chr2:46883368	NA	0.34	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs1957429	0.614	rs117722345	chr14:65381464	C/G	cg23373153	chr14:65346875	NA	-1.46	-6.92	-0.49	1.18e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg05062323	chr7:22590069	NA	-0.79	-4.6	-0.35	8.66e-6	Bilirubin levels;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.57	0.41	1.14e-7	Prudent dietary pattern;
PAAD	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.52	4.76	0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg11508081	chr17:41442227	NA	0.41	4.32	0.33	2.78e-5	Menopause (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01879488	chr11:35160498	CD44	0.62	7.14	0.5	3.68e-11	Metabolite levels  (X-11787);
PAAD	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg25364880	chr3:44379878	C3orf23	0.51	5.01	0.38	1.53e-6	Depressive symptoms;
PAAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.71	6.53	0.47	9.1e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21243612	chr9:111700548	C9orf6	0.62	6.46	0.46	1.35e-9	Smoking initiation;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg14926445	chr8:58193284	C8orf71	-0.67	-4.8	-0.36	3.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075265	0.547	rs6741891	chr2:54315666	A/G	cg04546899	chr2:54196757	PSME4	0.31	4.55	0.35	1.09e-5	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24788636	chr1:40562667	PPT1	0.65	7.32	0.51	1.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26549601	chr10:134560360	INPP5A	-0.49	-4.81	-0.36	3.57e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7707921	0.958	rs4703870	chr5:81492643	G/A	cg21483461	chr5:81570383	RPS23	0.51	4.32	0.33	2.83e-5	Breast cancer;
PAAD	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.61	-5.44	-0.4	2.06e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.41	0.34	1.98e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7260598	0.539	rs11670335	chr19:24066910	G/C	cg09235885	chr19:23456588	NA	-0.62	-4.32	-0.33	2.76e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs7188861	0.768	rs243315	chr16:11385011	C/T	cg16532467	chr16:11454386	NA	-0.51	-4.25	-0.33	3.75e-5	HDL cholesterol;
PAAD	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.17	0.5	3.02e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.51	-4.74	-0.36	4.94e-6	Coronary artery disease;
PAAD	cis	rs10504390	0.524	rs78748261	chr8:66625124	G/A	cg21696208	chr8:66556075	MTFR1	0.86	4.75	0.36	4.59e-6	IgG glycosylation;
PAAD	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg02466173	chr16:30829666	NA	-0.52	-4.37	-0.33	2.29e-5	Multiple myeloma;
PAAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg04370829	chr17:406249	NA	0.55	5.45	0.4	1.98e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs258892	0.895	rs34811011	chr5:72030243	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7172971	0.688	rs78042001	chr15:42379431	C/A	cg07013680	chr15:42186124	SPTBN5	0.53	4.29	0.33	3.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs899997	0.906	rs8039600	chr15:78990300	G/A	cg04896959	chr15:78267971	NA	-0.57	-5.08	-0.38	1.09e-6	Coronary artery disease or large artery stroke;
PAAD	cis	rs245880	0.740	rs245886	chr7:29189336	G/T	cg17163760	chr7:29186267	CPVL	-0.49	-5.84	-0.43	3.07e-8	Warfarin maintenance dose;
PAAD	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg26248373	chr2:1572462	NA	-1.08	-9.44	-0.61	6.18e-17	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.8	5.4	0.4	2.53e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.54	-4.72	-0.36	5.22e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.17	6.35	0.46	2.4e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.54	-5.03	-0.38	1.34e-6	Schizophrenia;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11037575	1.000	rs11037571	chr11:43722129	C/G	cg24662154	chr11:44118094	EXT2	0.42	4.29	0.33	3.12e-5	Neuroblastoma;
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.79	6.25	0.45	3.86e-9	Neutrophil percentage of white cells;
PAAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14998713	chr11:128391908	ETS1	0.64	6.45	0.46	1.44e-9	Obesity-related traits;
PAAD	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.82	8.82	0.58	2.49e-15	Height;
PAAD	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg16898833	chr6:26189333	HIST1H4D	1.03	5.18	0.39	6.91e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.44	4.45	0.34	1.68e-5	Longevity;Endometriosis;
PAAD	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs6565180	1.000	rs6565180	chr16:30361341	G/T	cg17640201	chr16:30407289	ZNF48	-0.9	-10.17	-0.64	7.47e-19	Tonsillectomy;
PAAD	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-6.19	-0.45	5.43e-9	Schizophrenia;
PAAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.63	7.03	0.5	6.53e-11	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.24	-9.8	-0.62	7.2e-18	Breast cancer;
PAAD	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg11972305	chr2:233791962	NGEF	-0.42	-4.4	-0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg06057569	chr22:50219754	BRD1	0.7	5.23	0.39	5.61e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg22546130	chr22:19950026	COMT	-0.32	-5.03	-0.38	1.35e-6	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06282829	chr3:140401925	TRIM42	0.48	6.34	0.46	2.53e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.89	0.43	2.43e-8	HIV-1 control;
PAAD	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg10006428	chr1:248814059	OR2T27	0.36	4.5	0.34	1.36e-5	Common traits (Other);
PAAD	cis	rs3018712	0.522	rs4930595	chr11:68435827	A/G	cg23009355	chr11:68451396	GAL	-0.46	-5.47	-0.41	1.8e-7	Total body bone mineral density;
PAAD	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.23	20.64	0.86	6.17e-46	Testicular germ cell tumor;
PAAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.66	7.56	0.52	3.56e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	4.3	0.33	3.06e-5	Schizophrenia;
PAAD	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg07061783	chr6:25882402	NA	-0.5	-4.86	-0.37	2.88e-6	Blood metabolite levels;
PAAD	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.49	-0.41	1.67e-7	Prostate cancer;
PAAD	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.37	-5.29	-0.39	4.12e-7	Cutaneous nevi;
PAAD	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg03989125	chr22:38214979	NA	-0.56	-5.4	-0.4	2.48e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08894960	chr1:237061516	MTR	-0.67	-6.91	-0.49	1.24e-10	Obesity-related traits;
PAAD	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.66	7.13	0.5	3.74e-11	Crohn's disease;
PAAD	cis	rs7631605	0.875	rs56198917	chr3:37017798	C/G	cg17445812	chr3:36986805	TRANK1	0.33	4.35	0.33	2.53e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4800452	0.871	rs9961220	chr18:20733201	G/T	cg26136497	chr18:20735537	CABLES1	-0.47	-4.48	-0.34	1.48e-5	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9876781	1.000	rs13314659	chr3:48449149	A/G	cg24898236	chr3:49228699	LOC646498	-0.39	-4.3	-0.33	3.07e-5	Longevity;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.38	4.42	0.34	1.84e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg03894339	chr8:19674705	INTS10	0.45	4.34	0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.72	8.95	0.59	1.15e-15	Dupuytren's disease;
PAAD	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.6	6.01	0.44	1.3e-8	Alcohol dependence;
PAAD	cis	rs4740619	0.745	rs961117	chr9:15938548	A/C	cg14451791	chr9:16040625	NA	-0.41	-4.7	-0.36	5.73e-6	Body mass index;
PAAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.41	-0.34	1.97e-5	Bipolar disorder;
PAAD	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg19767477	chr5:127420684	SLC12A2	-0.6	-4.88	-0.37	2.68e-6	Ileal carcinoids;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.91	11.52	0.68	1.76e-22	Menarche (age at onset);
PAAD	cis	rs2899832	0.641	rs10047949	chr14:35727366	G/T	cg09327582	chr14:35236912	BAZ1A	0.57	4.62	0.35	8.26e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.88	11.2	0.67	1.32e-21	Prudent dietary pattern;
PAAD	cis	rs58521262	0.585	rs2645877	chr19:23210811	G/A	cg03433597	chr19:22806448	NA	0.24	4.36	0.33	2.39e-5	Testicular germ cell tumor;
PAAD	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg04013166	chr16:89971882	TCF25	0.65	4.41	0.34	1.98e-5	Skin colour saturation;
PAAD	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.55	-0.41	1.22e-7	Adiposity;
PAAD	cis	rs300774	0.925	rs300734	chr2:167167	T/G	cg23649280	chr2:140451	NA	-0.47	-4.35	-0.33	2.5e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.92	-14.86	-0.77	2.08e-31	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs114540395	0.858	rs79010936	chr10:103300909	T/C	cg21381511	chr10:104264849	SUFU	-0.86	-4.32	-0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.47	4.93	0.37	2.14e-6	Testicular germ cell tumor;
PAAD	cis	rs6087771	0.821	rs6058444	chr20:30315137	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.7	0.58	4.97e-15	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2030114	0.555	rs2647984	chr16:51599657	T/C	cg03758633	chr16:51611768	NA	0.51	4.98	0.37	1.68e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.86	9.47	0.61	5.13e-17	Menopause (age at onset);
PAAD	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.0	9.56	0.61	3e-17	Monocyte percentage of white cells;
PAAD	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.52	4.33	0.33	2.64e-5	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24716420	chr4:7802369	AFAP1	0.55	6.59	0.47	6.75e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.6	6.05	0.44	1.09e-8	Iron status biomarkers;
PAAD	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.69	-0.58	5.34e-15	Exhaled nitric oxide output;
PAAD	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg08345082	chr10:99160200	RRP12	-0.31	-4.46	-0.34	1.56e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.8	-0.66	1.51e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.43	0.34	1.82e-5	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.9	6.4	0.46	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg14709524	chr16:89940631	TCF25	1.01	4.73	0.36	5.1e-6	Skin colour saturation;
PAAD	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.59	-4.75	-0.36	4.74e-6	Prostate cancer;
PAAD	cis	rs732765	0.657	rs10134147	chr14:75216814	G/C	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg10591111	chr5:226296	SDHA	-0.69	-5.21	-0.39	5.94e-7	Breast cancer;
PAAD	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.44	4.46	0.34	1.59e-5	Age of smoking initiation;
PAAD	cis	rs669446	0.562	rs3791036	chr1:44155383	A/G	cg12908607	chr1:44402522	ARTN	-0.42	-4.56	-0.35	1.06e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.87	11.29	0.68	7.6e-22	Subjective well-being (multi-trait analysis);
PAAD	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.3	11.28	0.68	8.02e-22	Uric acid levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20046119	chr8:145981207	ZNF251	-0.68	-7.73	-0.53	1.33e-12	Smoking initiation;
PAAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1497406	0.607	rs6688638	chr1:16505304	T/C	cg20167471	chr1:16528984	ARHGEF19	0.45	4.43	0.34	1.78e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.65	-0.53	2.2e-12	Morning vs. evening chronotype;
PAAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg14829360	chr17:73884958	NA	-0.66	-5.86	-0.43	2.83e-8	Psoriasis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01583657	chr4:91760141	TMSL3;FAM190A	0.68	7.59	0.52	2.92e-12	Smoking initiation;
PAAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg12072164	chr19:44306565	LYPD5	0.48	5.02	0.38	1.43e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg24553058	chr2:113831203	IL1F10	0.45	4.98	0.37	1.71e-6	Protein quantitative trait loci;
PAAD	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.69	7.78	0.53	1.04e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg24253500	chr15:84953950	NA	-0.47	-5.14	-0.38	8.38e-7	P wave terminal force;
PAAD	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	4.95	0.37	1.97e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.88	5.8	0.43	3.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg11062466	chr8:58055876	NA	0.72	5.3	0.39	4.05e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg15446613	chr6:107077566	QRSL1;RTN4IP1	0.51	6.48	0.47	1.2e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10090774	0.965	rs57416159	chr8:141746995	T/G	cg02508881	chr8:142216119	NA	0.41	4.42	0.34	1.84e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.45	-0.46	1.4e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9463078	0.528	rs11966936	chr6:45053672	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.88e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7301016	0.520	rs73126004	chr12:63004975	T/C	cg11441379	chr12:63026424	NA	0.63	5.21	0.39	6.09e-7	IgG glycosylation;
PAAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	8.74	0.58	4.05e-15	Parkinson's disease;
PAAD	cis	rs2718812	0.740	rs12637070	chr3:133341508	T/G	cg08048268	chr3:133502702	NA	-0.45	-5.27	-0.39	4.51e-7	Iron status biomarkers;
PAAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg18944383	chr4:111397179	ENPEP	0.63	7.43	0.52	7.36e-12	Coronary artery disease;
PAAD	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.86	11.18	0.67	1.49e-21	Subjective well-being (multi-trait analysis);
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg01097406	chr16:89675127	NA	0.34	4.32	0.33	2.76e-5	Vitiligo;
PAAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg04287289	chr16:89883240	FANCA	-0.43	-4.3	-0.33	3.06e-5	Vitiligo;
PAAD	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.5	-5.25	-0.39	4.96e-7	Morning vs. evening chronotype;
PAAD	cis	rs1075265	0.749	rs805436	chr2:54064980	T/C	cg04546899	chr2:54196757	PSME4	0.32	4.81	0.36	3.58e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10569807	chr12:25404368	KRAS	-0.65	-6.88	-0.49	1.44e-10	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.51	-5.02	-0.38	1.44e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg20487152	chr13:99095054	FARP1	-0.49	-4.73	-0.36	5.17e-6	Neuroticism;
PAAD	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.59	-6.46	-0.46	1.33e-9	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12229505	chr15:80351983	ZFAND6	-0.63	-6.61	-0.47	6.03e-10	Smoking initiation;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03326608	chr5:145316080	SH3RF2	-0.63	-6.31	-0.46	2.89e-9	Lung cancer in ever smokers;
PAAD	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg03030879	chr14:75389066	RPS6KL1	0.41	4.35	0.33	2.44e-5	Height;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26549601	chr10:134560360	INPP5A	-0.47	-4.86	-0.37	2.87e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10851411	0.518	rs17767264	chr15:42886656	C/T	cg21293051	chr15:42870591	STARD9	0.59	4.81	0.36	3.62e-6	Glucose homeostasis traits;
PAAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-5.71	-0.42	5.64e-8	Mood instability;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26841017	chr5:34929960	DNAJC21	-0.75	-8.17	-0.55	1.12e-13	Smoking initiation;
PAAD	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.43	-0.34	1.76e-5	Mood instability;
PAAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-5.82	-0.43	3.4e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09513672	chr1:28908770	SNORA16A;SNHG12	-0.62	-6.41	-0.46	1.76e-9	Smoking initiation;
PAAD	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg06740227	chr12:86229804	RASSF9	0.47	4.54	0.35	1.15e-5	Major depressive disorder;
PAAD	cis	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg00806245	chr18:76673096	NA	-0.82	-5.6	-0.41	9.68e-8	Obesity-related traits;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.47	4.7	0.36	5.85e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.81	-0.54	8.69e-13	Coronary artery disease;
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg24879335	chr3:133465180	TF	0.58	6.38	0.46	1.98e-9	Iron status biomarkers;
PAAD	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs288326	0.561	rs77024950	chr2:183797227	T/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15128208	chr22:42549153	NA	-0.44	-4.39	-0.34	2.09e-5	Cognitive function;
PAAD	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg02353165	chr6:42928485	GNMT	0.57	4.84	0.37	3.15e-6	Blood protein levels;
PAAD	cis	rs73416724	0.688	rs75966707	chr6:43356743	A/C	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg03808351	chr9:123631620	PHF19	0.46	5.01	0.38	1.52e-6	Rheumatoid arthritis;
PAAD	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.61	-5.9	-0.43	2.3e-8	Schizophrenia;
PAAD	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg20813462	chr7:2646259	IQCE	0.65	4.66	0.35	6.92e-6	Urate levels in lean individuals;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.3	-0.39	4.08e-7	Lung cancer;
PAAD	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.38	0.4	2.76e-7	Male-pattern baldness;
PAAD	cis	rs10073892	0.785	rs1823692	chr5:101637590	T/C	cg17280723	chr5:101634495	NA	0.41	4.26	0.33	3.63e-5	Cognitive decline (age-related);
PAAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg01831904	chr17:28903510	LRRC37B2	0.78	6.01	0.44	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2302729	0.515	rs7136840	chr12:2768723	C/T	cg19945202	chr12:2788847	CACNA1C	-0.74	-7.36	-0.51	1.06e-11	Sleep quality;
PAAD	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg04415270	chr2:102091202	RFX8	-0.56	-6.98	-0.49	8.36e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.87e-5	Intracranial aneurysm;
PAAD	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.4	-0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.82	9.63	0.62	2.01e-17	Blood metabolite ratios;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22878469	chr5:235427	SDHA	-0.68	-6.84	-0.49	1.8e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.57	0.35	1.02e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.08	-0.59	5.39e-16	Type 2 diabetes;
PAAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15128208	chr22:42549153	NA	-0.51	-4.85	-0.37	3.08e-6	Cognitive function;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.26e-8	Life satisfaction;
PAAD	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg09168692	chr1:7887560	PER3	0.5	4.74	0.36	4.82e-6	Inflammatory bowel disease;
PAAD	cis	rs200880	0.525	rs6135962	chr20:1759791	C/T	cg11784305	chr20:1757812	NA	-0.55	-4.4	-0.34	2.06e-5	Mean platelet volume;
PAAD	cis	rs9535307	0.651	rs1198327	chr13:50387759	G/A	cg03658251	chr13:50265850	EBPL	-0.78	-4.76	-0.36	4.48e-6	Obesity-related traits;
PAAD	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09695851	chr17:3907499	NA	0.67	6.77	0.48	2.67e-10	Type 2 diabetes;
PAAD	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11584989	chr19:19387371	SF4	-0.77	-6.48	-0.47	1.23e-9	Attention deficit hyperactivity disorder symptom score;
PAAD	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.89	10.52	0.65	8.59e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg22153463	chr1:85462885	MCOLN2	0.72	5.38	0.4	2.81e-7	Serum sulfate level;
PAAD	cis	rs7873102	0.654	rs7862130	chr9:37966970	G/A	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.44	-4.98	-0.37	1.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1678618	0.616	rs1245530	chr10:73792268	C/T	cg20897136	chr10:74034667	DDIT4	0.36	4.28	0.33	3.29e-5	Smoking behavior;
PAAD	cis	rs72960926	0.744	rs72950570	chr6:74913740	T/C	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.71	6.99	0.49	8.22e-11	Total body bone mineral density;
PAAD	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.49	4.51	0.34	1.27e-5	Breast cancer;
PAAD	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.58	5.21	0.39	6.18e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg23920097	chr1:209922102	NA	-0.48	-4.67	-0.35	6.6e-6	Red blood cell count;
PAAD	cis	rs4474465	0.915	rs12277503	chr11:78140373	A/C	cg02023728	chr11:77925099	USP35	0.44	4.54	0.35	1.15e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.87	5.36	0.4	3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg00614314	chr15:82944287	LOC80154	0.45	4.59	0.35	9.37e-6	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21372595	chr12:14136152	NA	0.57	6.41	0.46	1.77e-9	Smoking initiation;
PAAD	cis	rs329674	0.556	rs61910566	chr11:133735545	A/G	cg06766960	chr11:133703094	NA	-0.7	-4.28	-0.33	3.24e-5	Bipolar disorder;
PAAD	cis	rs6028335	0.610	rs67343649	chr20:37557894	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.66	-4.94	-0.37	2.08e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	1.12	8.69	0.58	5.42e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.61	-5.34	-0.4	3.36e-7	Resistin levels;
PAAD	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.49	-4.39	-0.34	2.09e-5	Multiple sclerosis;
PAAD	cis	rs3026101	0.671	rs3026109	chr17:5284480	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.5	-5.54	-0.41	1.32e-7	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04281268	chr14:102606293	WDR20;HSP90AA1	0.57	6.36	0.46	2.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-7.65	-0.53	2.11e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs62025270	0.688	rs12148571	chr15:86267393	G/A	cg13263323	chr15:86062960	AKAP13	0.5	4.47	0.34	1.54e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.24e-6	Tonsillectomy;
PAAD	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.54	5.89	0.43	2.35e-8	Heart rate;
PAAD	cis	rs11696501	0.739	rs6104285	chr20:44295416	A/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg05342682	chr7:94953680	PON1	-0.53	-4.59	-0.35	9.28e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	8.31e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg08200582	chr11:442649	ANO9	0.55	4.46	0.34	1.57e-5	Systemic lupus erythematosus;
PAAD	cis	rs16975963	0.644	rs2290999	chr19:38138887	T/C	cg08679971	chr19:38281047	NA	0.46	4.54	0.35	1.15e-5	Longevity;
PAAD	cis	rs12282928	1.000	rs4980423	chr11:48258607	C/G	cg04721828	chr11:48285200	OR4X1	0.42	4.91	0.37	2.35e-6	Migraine - clinic-based;
PAAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.05	-0.38	1.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1015291	0.966	rs7302479	chr12:19992477	A/G	cg25401612	chr12:20009446	NA	-0.49	-4.69	-0.36	5.98e-6	Diastolic blood pressure;
PAAD	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.88	-5.32	-0.4	3.71e-7	Hypertriglyceridemia;
PAAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	5.08	0.38	1.1e-6	Total body bone mineral density;
PAAD	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.83	-0.36	3.27e-6	Breast cancer;
PAAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-5.25	-0.39	5.13e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.36	4.44	0.34	1.7e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08770580	chr3:183979197	ECE2;CAMK2N2	0.62	6.4	0.46	1.8e-9	Obesity-related traits;
PAAD	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.94	0.37	2.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.72	7.44	0.52	6.77e-12	Menarche (age at onset);
PAAD	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.28e-12	Prostate cancer;
PAAD	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-7.08	-0.5	4.89e-11	Height;
PAAD	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.3	-0.33	3.02e-5	Resting heart rate;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18621852	chr3:10150065	C3orf24	0.64	5.84	0.43	3.03e-8	Alzheimer's disease;
PAAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-1.05	-14.69	-0.77	5.67e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs6089829	0.747	rs57767914	chr20:61659108	C/G	cg08045932	chr20:61659980	NA	-0.58	-6.29	-0.45	3.26e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg17372657	chr7:1216933	NA	-0.37	-4.77	-0.36	4.29e-6	Longevity;Endometriosis;
PAAD	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.05	9.22	0.6	2.28e-16	Vitiligo;
PAAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.63	6.52	0.47	9.99e-10	Multiple sclerosis;
PAAD	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.73	7.11	0.5	4.13e-11	Asthma;
PAAD	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.81	-8.24	-0.56	7.59e-14	Selective IgA deficiency;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11415402	chr1:10509733	APITD1;CORT	0.62	6.73	0.48	3.22e-10	Smoking initiation;
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	11.37	0.68	4.72e-22	Platelet count;
PAAD	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.55	-0.35	1.11e-5	Lung cancer in ever smokers;
PAAD	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.03	0.38	1.37e-6	Systemic lupus erythematosus;
PAAD	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.73	5.1	0.38	9.83e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	4.67	0.35	6.51e-6	Educational attainment;
PAAD	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg14440974	chr22:39074834	NA	-0.55	-6.91	-0.49	1.27e-10	Menopause (age at onset);
PAAD	cis	rs3206736	0.593	rs328923	chr7:35035695	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg02316283	chr14:23313866	MMP14	-0.4	-4.76	-0.36	4.42e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23281280	chr6:28129359	ZNF389	0.7	5.49	0.41	1.67e-7	Depression;
PAAD	cis	rs9815354	1.000	rs1628874	chr3:41955714	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.91e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-4.78	-0.36	4.19e-6	Pulmonary function;
PAAD	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg20356878	chr3:121714668	ILDR1	0.5	4.81	0.36	3.67e-6	Cognitive performance;
PAAD	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg09659197	chr4:152720779	NA	-0.37	-5.43	-0.4	2.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	1.0	8.54	0.57	1.32e-14	Triglycerides;
PAAD	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.49	-0.47	1.15e-9	Morning vs. evening chronotype;
PAAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Diabetic kidney disease;
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.69	7.59	0.52	2.93e-12	Aortic root size;
PAAD	cis	rs10887741	0.646	rs12413510	chr10:89436979	T/C	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg04554929	chr8:105342491	NA	0.43	7.26	0.51	1.83e-11	Paget's disease;
PAAD	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg04374321	chr14:90722782	PSMC1	-0.59	-5.81	-0.43	3.57e-8	Mortality in heart failure;
PAAD	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.42	5.13	0.38	8.85e-7	Colorectal cancer;
PAAD	cis	rs10450586	0.677	rs7110359	chr11:27300429	A/T	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.96	0.49	9.77e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.69	7.13	0.5	3.73e-11	Body mass index;
PAAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	10.16	0.64	8.07e-19	Bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04577214	chr19:36422477	NA	-0.6	-7.16	-0.5	3.14e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819852	1.000	rs2073743	chr22:19989612	C/G	cg07821417	chr22:19972146	ARVCF	0.7	7.02	0.49	6.91e-11	Pulse pressure;
PAAD	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.46	-4.34	-0.33	2.54e-5	Red blood cell count;
PAAD	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15378786	chr11:17036137	PLEKHA7	0.53	4.92	0.37	2.22e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25015735	chr1:92852629	RPAP2	-0.57	-6.97	-0.49	9.18e-11	Monocyte percentage of white cells;
PAAD	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.69	6.63	0.47	5.55e-10	Lymphocyte counts;
PAAD	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.62	5.67	0.42	7.05e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs7799006	0.608	rs12699820	chr7:2332968	G/T	cg00749118	chr7:1938791	MAD1L1	-0.45	-4.41	-0.34	1.98e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg21823605	chr1:152486609	CRCT1	0.52	6.62	0.47	5.72e-10	Hair morphology;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.67	-0.53	1.92e-12	Bipolar disorder and schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06697294	chr19:54385412	PRKCG	-0.65	-6.52	-0.47	9.78e-10	Smoking initiation;
PAAD	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.65	-4.93	-0.37	2.11e-6	Post bronchodilator FEV1;
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg22601191	chr20:60968625	CABLES2	-0.46	-4.37	-0.33	2.32e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs9535307	0.858	rs6561553	chr13:50261089	A/G	cg04663916	chr13:50265991	EBPL	0.57	4.38	0.33	2.2e-5	Obesity-related traits;
PAAD	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-5.64	-0.42	8.06e-8	Renal function-related traits (BUN);
PAAD	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.03	0.44	1.17e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.73	-6.29	-0.45	3.29e-9	Type 2 diabetes;
PAAD	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg05392440	chr1:2478653	NA	0.55	6.2	0.45	5.15e-9	Ulcerative colitis;
PAAD	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg14768367	chr16:72042858	DHODH	-0.64	-4.7	-0.36	5.78e-6	Blood protein levels;
PAAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.51	4.79	0.36	3.99e-6	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10784777	chr12:56552019	MYL6	-0.69	-7.41	-0.52	8.38e-12	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26525486	chr22:32146186	C22orf30	0.62	6.35	0.46	2.4e-9	Obesity-related traits;
PAAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-8.69	-0.58	5.55e-15	Calcium levels;
PAAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.74	8.43	0.56	2.52e-14	Total body bone mineral density;
PAAD	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.79	-8.32	-0.56	4.65e-14	Cystic fibrosis severity;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg01064725	chr1:204461714	NA	-0.51	-4.66	-0.35	6.91e-6	Schizophrenia;
PAAD	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg03101763	chr11:65319844	LTBP3	0.46	5.03	0.38	1.37e-6	Plateletcrit;
PAAD	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.67	-6.91	-0.49	1.27e-10	Magnesium levels;
PAAD	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.76	7.85	0.54	7.03e-13	Mosquito bite size;
PAAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Renal cell carcinoma;
PAAD	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.7	-6.83	-0.48	1.91e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.7	-8.03	-0.55	2.42e-13	Renal function-related traits (BUN);
PAAD	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-4.45	-0.34	1.62e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12523822	0.913	rs9479916	chr6:154960939	G/A	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs3753841	0.752	rs11164637	chr1:103382943	A/G	cg24495344	chr1:103574097	COL11A1	0.39	4.29	0.33	3.21e-5	Glaucoma (primary angle closure);
PAAD	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00864171	chr11:67383662	NA	0.54	5.58	0.41	1.1e-7	Mean corpuscular volume;
PAAD	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.87	6.93	0.49	1.09e-10	Axial length;
PAAD	trans	rs901683	1.000	rs71496612	chr10:46032505	C/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12108527	chr1:43233151	LEPRE1;C1orf50	0.64	6.95	0.49	9.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.38e-8	QT interval;
PAAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg26022315	chr17:47021804	SNF8	-0.47	-4.84	-0.37	3.12e-6	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs863345	0.604	rs7518808	chr1:158491820	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	1.24	11.34	0.68	5.51e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs8060686	0.858	rs12449157	chr16:67708897	A/G	cg09835421	chr16:68378352	PRMT7	-0.66	-4.55	-0.35	1.11e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.37	0.46	2.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs914615	0.507	rs4971085	chr1:155138222	T/C	cg18645493	chr1:154167437	MIR190B	0.45	4.29	0.33	3.13e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.46	-4.5	-0.34	1.36e-5	Body mass index;
PAAD	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg08992911	chr2:238395768	MLPH	0.62	5.19	0.39	6.76e-7	Prostate cancer;
PAAD	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg00179576	chr16:74483694	GLG1	-0.4	-4.36	-0.33	2.43e-5	Testicular germ cell tumor;
PAAD	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg24069376	chr3:38537580	EXOG	0.41	4.94	0.37	2.07e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2688608	0.698	rs2633323	chr10:75694826	G/A	cg19442545	chr10:75533431	FUT11	-0.42	-4.25	-0.33	3.76e-5	Inflammatory bowel disease;
PAAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.62	-7.35	-0.51	1.15e-11	Bipolar disorder;
PAAD	cis	rs7799006	0.600	rs13233723	chr7:2338087	C/A	cg00749118	chr7:1938791	MAD1L1	-0.44	-4.27	-0.33	3.45e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	5.15e-7	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.06	0.5	5.63e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.58	-6.21	-0.45	4.76e-9	Pelvic organ prolapse;
PAAD	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.84	9.95	0.63	2.83e-18	Monocyte count;
PAAD	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.62	4.94	0.37	2.03e-6	Cholesterol, total;
PAAD	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.46	-4.5	-0.34	1.34e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.54	-0.41	1.29e-7	Lung cancer;
PAAD	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.79	7.86	0.54	6.7e-13	Corneal astigmatism;
PAAD	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-5.42	-0.4	2.3e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg05627522	chr15:75251581	NA	-0.41	-4.87	-0.37	2.75e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.64	6.83	0.48	1.94e-10	Crohn's disease;
PAAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-7.52	-0.52	4.44e-12	Blood pressure (smoking interaction);
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg14393609	chr7:65229607	NA	0.68	7.53	0.52	4.09e-12	Aortic root size;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs4711350	0.871	rs1998949	chr6:33721457	T/C	cg13859433	chr6:33739653	LEMD2	-0.57	-4.28	-0.33	3.34e-5	Schizophrenia;
PAAD	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg18984983	chr10:135342936	CYP2E1	0.46	4.3	0.33	3.01e-5	Gout;
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg01324507	chr7:1177794	C7orf50	0.55	4.32	0.33	2.81e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.39	-0.4	2.64e-7	Cognitive function;
PAAD	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.32e-7	Body mass index;
PAAD	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg09835421	chr16:68378352	PRMT7	0.78	6.44	0.46	1.5e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-4.79	-0.36	3.87e-6	Coronary artery disease;
PAAD	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.07	14.43	0.76	2.86e-30	Testicular germ cell tumor;
PAAD	cis	rs7179456	0.610	rs650366	chr15:59061142	A/G	cg05156742	chr15:59063176	FAM63B	0.78	8.35	0.56	3.96e-14	Asperger disorder;
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg13482628	chr17:19912719	NA	0.5	4.95	0.37	1.93e-6	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.54	5.17	0.39	7.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg11764359	chr7:65958608	NA	0.8	5.1	0.38	1.01e-6	Diabetic kidney disease;
PAAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg25783544	chr11:47291846	MADD	0.53	4.27	0.33	3.37e-5	HDL cholesterol;
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs757978	0.810	rs34123564	chr2:242404437	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.75	-4.67	-0.35	6.71e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs308971	0.563	rs453131	chr3:12140953	C/G	cg02700894	chr3:12045449	SYN2	0.62	4.53	0.34	1.19e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.47	-4.25	-0.33	3.69e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1555895	0.576	rs4881537	chr10:848059	A/T	cg20503657	chr10:835505	NA	0.48	4.96	0.37	1.87e-6	Survival in rectal cancer;
PAAD	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.61	0.35	8.48e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.42	-0.34	1.9e-5	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.52	5.83	0.43	3.18e-8	Testicular germ cell tumor;
PAAD	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg04257695	chr17:30186438	C17orf79	-0.63	-5.0	-0.38	1.55e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg16257655	chr7:1659720	NA	0.43	4.44	0.34	1.74e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.55	4.5	0.34	1.34e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18802601	chr5:34698640	RAI14	-0.69	-6.97	-0.49	9.18e-11	Obesity-related traits;
PAAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs136211	1.000	rs5995288	chr22:36762634	T/C	cg11153328	chr22:36877737	TXN2	-0.5	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs7551222	0.752	rs4252725	chr1:204513256	A/G	cg01064725	chr1:204461714	NA	-0.49	-4.54	-0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.57	-6.6	-0.47	6.31e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs7291412	0.601	rs7292407	chr22:46453712	A/C	cg05468064	chr22:46423449	NA	-0.4	-4.82	-0.36	3.49e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg14343924	chr8:8086146	FLJ10661	-0.54	-5.11	-0.38	9.7e-7	Mood instability;
PAAD	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.49	-4.49	-0.34	1.42e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.44	4.54	0.35	1.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg12473912	chr3:136751656	NA	0.39	4.47	0.34	1.53e-5	Gestational age at birth (child effect);
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs72827839	0.802	rs16953925	chr17:46294498	C/T	cg23391107	chr17:45924227	SP6	0.63	5.34	0.4	3.39e-7	Ease of getting up in the morning;
PAAD	cis	rs8112211	0.519	rs117624491	chr19:38808505	A/C	cg14299480	chr19:38876666	GGN	-0.51	-6.49	-0.47	1.17e-9	Blood protein levels;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21016266	chr12:122356598	WDR66	0.67	7.12	0.5	4.02e-11	Mean corpuscular volume;
PAAD	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-6.92	-0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg21351543	chr2:191399470	TMEM194B	0.59	4.6	0.35	8.96e-6	Diastolic blood pressure;
PAAD	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg09695851	chr17:3907499	NA	-0.56	-5.36	-0.4	3.07e-7	Type 2 diabetes;
PAAD	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.68	6.36	0.46	2.3e-9	IgG glycosylation;
PAAD	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs679087	0.900	rs12811019	chr12:29935396	C/A	cg14258853	chr12:29935411	TMTC1	0.67	7.64	0.53	2.24e-12	Schizophrenia;
PAAD	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-1.13	-12.43	-0.71	6.56e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs7219021	0.961	rs9906942	chr17:46864634	G/A	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.43	-0.34	1.77e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg22143856	chr6:28129313	ZNF389	0.49	4.48	0.34	1.47e-5	Parkinson's disease;
PAAD	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3784262	0.565	rs2642632	chr15:58308254	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.65	-0.35	7.12e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg04520793	chr17:42248056	ASB16	0.44	5.17	0.39	7.35e-7	Total body bone mineral density;
PAAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.87	9.32	0.6	1.3e-16	Parkinson's disease;
PAAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg05110241	chr16:68378359	PRMT7	-0.99	-5.88	-0.43	2.54e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.83	-0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17095355	1.000	rs7079713	chr10:111755416	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.81	-0.36	3.64e-6	Biliary atresia;
PAAD	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.64	-5.13	-0.38	8.53e-7	Vitiligo;
PAAD	cis	rs17253792	0.500	rs17745274	chr14:55997881	T/C	cg01858014	chr14:56050164	KTN1	-0.84	-4.98	-0.37	1.68e-6	Putamen volume;
PAAD	cis	rs2579500	0.807	rs6741277	chr2:97294903	C/T	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7714584	1.000	rs4958422	chr5:150186734	T/G	cg22134413	chr5:150180641	NA	0.95	6.41	0.46	1.71e-9	Crohn's disease;
PAAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg12700464	chr11:78128424	GAB2	0.6	4.38	0.33	2.19e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.15	16.1	0.79	1.14e-34	Cognitive function;
PAAD	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.57	5.03	0.38	1.38e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.25	4.27	0.33	3.39e-5	IgG glycosylation;
PAAD	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.06	-0.55	2.04e-13	Exhaled nitric oxide output;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.71e-8	Life satisfaction;
PAAD	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-5.0	-0.38	1.57e-6	Kawasaki disease;
PAAD	cis	rs346785	0.614	rs407281	chr17:74311343	C/T	cg09812376	chr17:74270190	QRICH2	-0.41	-5.28	-0.39	4.41e-7	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-8.34	-0.56	4.17e-14	Prostate cancer;
PAAD	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg00207534	chr16:71929512	KIAA0174	0.76	4.72	0.36	5.27e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg04705435	chr11:17411270	KCNJ11	0.64	6.62	0.47	5.78e-10	Type 2 diabetes;
PAAD	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.21e-5	Educational attainment (years of education);
PAAD	cis	rs7580658	0.711	rs12469035	chr2:127984917	A/G	cg10985347	chr2:127963512	CYP27C1	0.49	4.76	0.36	4.55e-6	Protein C levels;
PAAD	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	8.68	0.58	5.74e-15	Post bronchodilator FEV1;
PAAD	cis	rs215088	0.810	rs215049	chr16:16070768	C/G	cg08996506	chr16:16070868	ABCC1	0.36	4.29	0.33	3.14e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs8077577	0.747	rs11867895	chr17:18146721	A/C	cg16794390	chr17:18148240	FLII	0.53	4.57	0.35	9.87e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg26174226	chr8:58114915	NA	-0.64	-4.49	-0.34	1.39e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6908034	0.607	rs79162793	chr6:19813065	A/G	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg00806126	chr19:22604979	ZNF98	0.36	4.64	0.35	7.43e-6	Pain;
PAAD	cis	rs2213920	0.915	rs980176	chr9:118260408	T/G	cg13918206	chr9:118159781	DEC1	0.81	5.54	0.41	1.32e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-4.64	-0.35	7.46e-6	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.83	-0.54	7.86e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.33	0.33	2.7e-5	Tonsillectomy;
PAAD	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	0.79	5.3	0.39	4.07e-7	Body mass index;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9364554	0.676	rs3088442	chr6:160872652	G/A	cg25313204	chr6:160768801	SLC22A3	0.54	4.87	0.37	2.72e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.84	10.25	0.64	4.65e-19	Menopause (age at onset);
PAAD	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	4.56	0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.53	5.39	0.4	2.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg19337854	chr7:99768885	GPC2	-0.44	-4.7	-0.36	5.67e-6	Coronary artery disease;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg04089426	chr11:65307791	LTBP3	1.1	5.12	0.38	9.26e-7	Height;
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.86	9.97	0.63	2.51e-18	Prostate cancer;
PAAD	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg26935685	chr1:15502881	TMEM51	-0.49	-4.25	-0.33	3.78e-5	Systolic blood pressure;
PAAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.75	-7.71	-0.53	1.52e-12	Cognitive function;
PAAD	cis	rs859767	0.501	rs11898465	chr2:135431449	G/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.66	-0.35	6.75e-6	Neuroticism;
PAAD	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.78	0.48	2.43e-10	Lung cancer in ever smokers;
PAAD	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg25251562	chr2:3704773	ALLC	-0.57	-5.21	-0.39	5.95e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.75	9.32	0.6	1.3e-16	Bone mineral density;
PAAD	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.76	-0.62	8.83e-18	Blood trace element (Zn levels);
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg22764044	chr5:178986830	RUFY1	-0.57	-6.14	-0.45	6.87e-9	Lung cancer;
PAAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6531209	0.888	rs975950	chr2:20331128	T/A	cg18868357	chr2:20425395	SDC1	-0.53	-4.29	-0.33	3.16e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.7	7.06	0.5	5.63e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35424364	1	rs35424364	chr6:109643605	A/AT	cg21918786	chr6:109611834	NA	-0.53	-4.28	-0.33	3.33e-5	Obstructive sleep apnea trait (average respiratory event duration);
PAAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	6.11	0.44	8.07e-9	Personality dimensions;
PAAD	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.83	-9.87	-0.62	4.65e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg05725404	chr16:58534157	NDRG4	-0.79	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg00579200	chr11:133705235	NA	-0.47	-5.24	-0.39	5.28e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg21546286	chr11:48923668	NA	-0.45	-4.69	-0.36	6.16e-6	Height;
PAAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.9	-11.03	-0.67	3.66e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg08601574	chr20:25228251	PYGB	0.64	6.96	0.49	9.66e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg14393609	chr7:65229607	NA	0.48	4.56	0.35	1.03e-5	Aortic root size;
PAAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.52	-0.34	1.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088813	0.702	rs6060370	chr20:33909752	A/G	cg14752227	chr20:34000481	UQCC	0.47	4.31	0.33	2.98e-5	Height;
PAAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.14e-5	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs7210086	0.768	rs4485409	chr17:70640381	C/T	cg04206342	chr17:70636940	NA	-0.45	-5.39	-0.4	2.58e-7	Ulcerative colitis;
PAAD	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.72	7.34	0.51	1.2e-11	Uric acid levels;
PAAD	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg07154921	chr7:157260426	NA	0.44	4.25	0.33	3.71e-5	Body mass index;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg07336987	chr11:625147	MUPCDH	-0.37	-4.64	-0.35	7.33e-6	Systemic lupus erythematosus;
PAAD	cis	rs12136530	0.651	rs4912081	chr1:19710002	G/T	cg25104613	chr1:20649108	VWA5B1	-0.38	-4.53	-0.34	1.21e-5	Lead levels in blood;
PAAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.84	-10.34	-0.64	2.57e-19	Height;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.64	0.42	8.03e-8	Alzheimer's disease;
PAAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.46	-5.28	-0.39	4.38e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs35123781	0.580	rs355163	chr5:138958078	T/C	cg26929925	chr5:138714136	SLC23A1	-0.5	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00543658	chr7:30634387	GARS	-0.56	-6.43	-0.46	1.59e-9	Body fat percentage;
PAAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs10191559	0.590	rs10930953	chr2:181951427	C/G	cg00816152	chr3:120222812	NA	-0.56	-6.35	-0.46	2.38e-9	Red blood cell count;
PAAD	cis	rs2117029	0.586	rs11168904	chr12:49571017	G/A	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.71	-7.31	-0.51	1.46e-11	Triglycerides;
PAAD	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg25233709	chr10:116636983	FAM160B1	0.45	5.74	0.42	4.92e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	1.01	7.11	0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7577696	0.785	rs660393	chr2:32281509	G/T	cg02381751	chr2:32503542	YIPF4	-0.42	-4.51	-0.34	1.27e-5	Inflammatory biomarkers;
PAAD	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.67	6.96	0.49	9.46e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg06917634	chr15:78832804	PSMA4	-0.44	-4.44	-0.34	1.74e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.9	5.69	0.42	6.31e-8	Schizophrenia;
PAAD	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg07148914	chr20:33460835	GGT7	-0.46	-4.47	-0.34	1.54e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.66	7.07	0.5	5.24e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.49	-5.2	-0.39	6.25e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.57	4.45	0.34	1.68e-5	Pancreatic cancer;
PAAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6782025	0.837	rs1795416	chr3:120705873	A/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.89	0.37	2.56e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg12633918	chr20:23549525	CST9L	-0.43	-4.7	-0.36	5.79e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.68	-0.42	6.61e-8	Mean corpuscular volume;
PAAD	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs732505	1.000	rs4807789	chr19:5584448	T/C	cg26242866	chr19:5711310	LONP1	1.05	5.76	0.42	4.49e-8	vWF and FVIII levels;
PAAD	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg02883595	chr6:39281421	KCNK17	-0.45	-4.32	-0.33	2.77e-5	Type 2 diabetes;
PAAD	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.69	7.73	0.53	1.4e-12	Morning vs. evening chronotype;
PAAD	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.51	-5.52	-0.41	1.42e-7	Testicular germ cell tumor;
PAAD	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg17479956	chr11:44115929	EXT2	0.64	4.81	0.36	3.55e-6	IgA nephropathy;
PAAD	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs12044355	0.827	rs11586191	chr1:231831781	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.29	0.39	4.29e-7	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09529537	chr5:78531947	JMY	0.57	6.3	0.46	2.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.99	9.24	0.6	2.03e-16	Psoriasis;
PAAD	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.78	-7.67	-0.53	1.91e-12	Primary sclerosing cholangitis;
PAAD	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.04	0.38	1.32e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.51	-4.27	-0.33	3.38e-5	Glioblastoma;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.56	6.28	0.45	3.43e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9810890	1.000	rs114431655	chr3:128459173	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg15117754	chr3:10150083	C3orf24	0.76	6.57	0.47	7.57e-10	Alzheimer's disease;
PAAD	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg06636001	chr8:8085503	FLJ10661	0.64	6.55	0.47	8.29e-10	Retinal vascular caliber;
PAAD	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.88	6.8	0.48	2.3e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs6908034	0.505	rs76709285	chr6:19804330	C/G	cg02682789	chr6:19804855	NA	0.8	4.43	0.34	1.81e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.92	-0.54	4.76e-13	Bipolar disorder and schizophrenia;
PAAD	trans	rs1948915	0.782	rs16902043	chr8:128231945	C/T	cg08060810	chr11:55587104	OR5D18	-0.61	-6.29	-0.45	3.21e-9	Multiple myeloma;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07701084	chr6:150067640	NUP43	0.62	6.1	0.44	8.24e-9	Testicular germ cell tumor;
PAAD	cis	rs11230563	0.501	rs4939488	chr11:60786474	T/C	cg10158843	chr11:60776172	CD6	0.53	5.36	0.4	2.96e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6142102	0.961	rs1319363	chr20:32541876	T/A	cg08999081	chr20:33150536	PIGU	0.46	4.31	0.33	2.98e-5	Skin pigmentation;
PAAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs258892	0.895	rs3846645	chr5:72023160	T/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	1.27	11.98	0.7	1.04e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7953508	0.741	rs1498706	chr12:93996980	C/T	cg18151635	chr12:93972918	NA	-0.56	-6.07	-0.44	9.87e-9	Pubertal anthropometrics;
PAAD	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs9346353	0.713	rs1457499	chr6:70417997	G/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.93e-5	Sleep duration;
PAAD	cis	rs9467603	1.000	rs6902211	chr6:25767437	G/A	cg01099526	chr6:26124504	HIST1H2AC;HIST1H2BC	0.77	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04362095	chr11:63592001	C11orf84	-0.5	-4.46	-0.34	1.6e-5	Platelet count;
PAAD	cis	rs6964492	0.576	rs12666177	chr7:134417204	G/A	cg22430036	chr7:134592620	CALD1	-0.51	-4.63	-0.35	7.76e-6	Tonsillectomy;
PAAD	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs743757	1.000	rs2282756	chr3:50452237	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.64	0.35	7.31e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg11062466	chr8:58055876	NA	0.69	4.79	0.36	3.92e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4908760	0.827	rs1463053	chr1:8705037	C/T	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.53e-5	Vitiligo;
PAAD	cis	rs1561176	0.830	rs11773201	chr7:154994653	G/A	cg25063631	chr7:155025500	NA	-0.5	-4.36	-0.33	2.36e-5	Personality dimensions;
PAAD	cis	rs4450131	0.522	rs34410705	chr10:126352680	C/T	cg20435097	chr10:126320824	FAM53B	0.46	4.45	0.34	1.62e-5	White blood cell count (basophil);
PAAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.81	-9.11	-0.59	4.59e-16	Total body bone mineral density;
PAAD	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4711350	0.723	rs6915136	chr6:33651322	A/G	cg18005901	chr6:33739558	LEMD2	0.64	4.55	0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs1419980	0.730	rs1558531	chr12:7735753	A/C	cg25828445	chr12:7781288	NA	0.87	4.48	0.34	1.45e-5	HDL cholesterol levels;
PAAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-8.46	-0.57	2.05e-14	Height;
PAAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.35	-0.4	3.19e-7	Retinal vascular caliber;
PAAD	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.9	-10.11	-0.63	1.06e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs72827839	0.846	rs16954204	chr17:46315198	T/C	cg23391107	chr17:45924227	SP6	0.63	5.34	0.4	3.39e-7	Ease of getting up in the morning;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg19413350	chr8:57351067	NA	-0.5	-4.58	-0.35	9.62e-6	Obesity-related traits;
PAAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.75	-4.47	-0.34	1.53e-5	Tuberculosis;
PAAD	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.08	0.5	5e-11	Lung cancer in ever smokers;
PAAD	cis	rs12257961	0.640	rs1955346	chr10:15366362	G/A	cg10616319	chr10:15468812	NA	-0.47	-4.46	-0.34	1.57e-5	Selective IgA deficiency;
PAAD	cis	rs2137920	0.685	rs12765141	chr10:50242320	T/C	cg02657375	chr10:50863136	CHAT	0.56	4.57	0.35	1e-5	Migraine with aura;
PAAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.58	8.38	0.56	3.3e-14	IgG glycosylation;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg10396713	chr8:602097	NA	-0.66	-4.26	-0.33	3.64e-5	IgG glycosylation;
PAAD	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.67	6.49	0.47	1.17e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs58521262	0.519	rs11666618	chr19:22906921	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs12711490	0.581	rs12149636	chr16:85971220	C/G	cg05709598	chr16:85699621	KIAA0182	0.42	4.42	0.34	1.89e-5	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;
PAAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.97	12.81	0.72	6.19e-26	Menopause (age at onset);
PAAD	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.58	5.82	0.43	3.32e-8	Primary sclerosing cholangitis;
PAAD	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.61	-0.41	9.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.92	-0.49	1.19e-10	Longevity;Endometriosis;
PAAD	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	4.57	0.35	9.94e-6	Educational attainment;
PAAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.75	-7.09	-0.5	4.74e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-6.29	-0.45	3.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs28647808	1.000	rs7032021	chr9:136276601	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg22705602	chr4:152727874	NA	0.48	5.18	0.39	7.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs258892	0.947	rs266444	chr5:72181404	C/T	cg21869765	chr5:72125136	TNPO1	0.72	5.16	0.39	7.64e-7	Small cell lung carcinoma;
PAAD	trans	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg25214090	chr10:38739885	LOC399744	0.66	7.47	0.52	5.85e-12	Corneal astigmatism;
PAAD	cis	rs7786877	0.723	rs62482237	chr7:100213476	A/G	cg16850897	chr7:100343110	ZAN	-0.67	-5.36	-0.4	2.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg21855830	chr2:127963489	CYP27C1	0.46	4.53	0.34	1.19e-5	Protein C levels;
PAAD	cis	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.83	-0.36	3.28e-6	HDL cholesterol;
PAAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.69	-0.36	6.11e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24321774	chr2:27193835	MAPRE3	0.58	6.65	0.47	4.88e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs6782025	0.837	rs7615991	chr3:120792926	C/T	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.83	-0.54	7.68e-13	Diastolic blood pressure;
PAAD	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.76	8.29	0.56	5.44e-14	Body mass index;
PAAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.2	-0.39	6.47e-7	Mean platelet volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18856894	chr3:63850083	THOC7;ATXN7	-0.63	-6.34	-0.46	2.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg11764359	chr7:65958608	NA	0.54	5.01	0.38	1.51e-6	Corneal structure;
PAAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Depression;
PAAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.98e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.14	-0.5	3.55e-11	Coronary artery disease;
PAAD	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg24296786	chr1:45957014	TESK2	0.65	7.23	0.51	2.21e-11	High light scatter reticulocyte count;
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.72	9.98	0.63	2.34e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.87	-8.3	-0.56	5.27e-14	Response to diuretic therapy;
PAAD	cis	rs72960926	0.661	rs56374639	chr6:75182535	C/T	cg03266952	chr6:74778945	NA	-1.06	-4.94	-0.37	2.02e-6	Metabolite levels (MHPG);
PAAD	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg10621924	chr7:39171070	POU6F2	0.27	4.51	0.34	1.29e-5	IgG glycosylation;
PAAD	cis	rs8010715	0.816	rs7153156	chr14:24598846	A/G	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs55720021	1	rs55720021	chr19:49144241	G/T	cg06677660	chr19:49140777	SEC1;DBP	0.65	5.46	0.4	1.92e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
PAAD	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.66	-0.53	2.05e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.34	0.4	3.27e-7	Lung cancer in ever smokers;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-7.63	-0.53	2.44e-12	Longevity;Endometriosis;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.56	5.65	0.42	7.73e-8	Parkinson's disease;
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.87	9.33	0.6	1.23e-16	Blood metabolite levels;
PAAD	cis	rs12681963	0.688	rs6997926	chr8:30054900	C/T	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24729792	chr2:113192114	RGPD8;RGPD5	0.6	4.66	0.35	6.93e-6	Yeast infection;
PAAD	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.43	0.34	1.82e-5	Height;
PAAD	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	9.85	0.62	5.09e-18	Smoking behavior;
PAAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg16850897	chr7:100343110	ZAN	-0.6	-4.93	-0.37	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg14343924	chr8:8086146	FLJ10661	0.53	4.55	0.35	1.07e-5	Neuroticism;
PAAD	cis	rs89107	0.576	rs17825393	chr6:118772583	A/G	cg21191810	chr6:118973309	C6orf204	0.38	4.48	0.34	1.45e-5	Cardiac structure and function;
PAAD	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12986453	chr22:49137906	FAM19A5	-0.45	-4.33	-0.33	2.66e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7524258	0.900	rs4908606	chr1:7259321	A/C	cg04342483	chr1:7259290	CAMTA1	-0.41	-4.26	-0.33	3.53e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs8179	0.700	rs42040	chr7:92245927	C/T	cg03496780	chr7:92466842	CDK6	0.48	4.27	0.33	3.4e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.6	-5.67	-0.42	7.12e-8	Coronary artery disease;
PAAD	cis	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg14345882	chr6:26364793	BTN3A2	-0.66	-4.51	-0.34	1.29e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg09127314	chr1:152161683	NA	0.7	5.08	0.38	1.11e-6	Atopic dermatitis;
PAAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.59	-0.82	1.73e-38	Height;
PAAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02543470	chr2:105862877	NA	-0.55	-5.15	-0.39	7.95e-7	Obesity-related traits;
PAAD	cis	rs4720118	0.660	rs1420148	chr7:33217665	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.49	-4.25	-0.33	3.71e-5	Leprosy;
PAAD	cis	rs8032158	0.896	rs8028559	chr15:56130909	A/G	cg02198044	chr15:56286336	NEDD4	-0.51	-5.49	-0.41	1.64e-7	Keloid;
PAAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg20295408	chr7:1910781	MAD1L1	0.46	4.3	0.33	3.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09640425	chr7:158790006	NA	-0.5	-5.62	-0.41	8.81e-8	Facial morphology (factor 20);
PAAD	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.62	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg07423050	chr13:99094983	FARP1	-0.38	-4.3	-0.33	3.07e-5	Longevity;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.62	6.17	0.45	5.91e-9	Monocyte count;
PAAD	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11159840	0.565	rs4899939	chr14:88553352	G/A	cg18078958	chr14:88630771	NA	0.41	4.76	0.36	4.43e-6	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.4	-0.34	2.01e-5	Platelet count;
PAAD	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.98	8.77	0.58	3.34e-15	Bipolar disorder;
PAAD	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	cis	rs3087591	0.659	rs2525570	chr17:29681245	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	4.47	0.34	1.54e-5	Hip circumference;
PAAD	cis	rs4462272	0.566	rs12254005	chr10:102038685	T/A	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18313106	chr1:229694614	ABCB10	0.55	6.33	0.46	2.59e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.6	6.38	0.46	2e-9	Huntington's disease progression;
PAAD	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg08975724	chr8:8085496	FLJ10661	0.67	6.99	0.49	8.01e-11	Neuroticism;
PAAD	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.66	-6.83	-0.48	1.9e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6496667	0.642	rs62019395	chr15:91066309	G/T	cg22089800	chr15:90895588	ZNF774	0.61	4.76	0.36	4.4e-6	Rheumatoid arthritis;
PAAD	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg13397359	chr6:42928475	GNMT	0.61	4.55	0.35	1.07e-5	Blood protein levels;
PAAD	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.17e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09889103	chr19:55770147	SAPS1	0.63	6.87	0.49	1.51e-10	Monocyte percentage of white cells;
PAAD	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.74	7.31	0.51	1.44e-11	Asthma;
PAAD	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg02135003	chr7:105160482	PUS7	0.81	6.6	0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15575017	chr2:237010430	AGAP1	0.58	7.18	0.5	2.84e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg08601574	chr20:25228251	PYGB	0.57	5.71	0.42	5.9e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09597638	chr17:3907349	NA	0.88	9.38	0.61	8.87e-17	Type 2 diabetes;
PAAD	cis	rs12612619	0.658	rs112794902	chr2:27151586	T/C	cg00617064	chr2:27272375	NA	-0.43	-4.62	-0.35	8.19e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18174569	chr15:31775049	NA	0.57	6.45	0.46	1.41e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.54	0.35	1.13e-5	Alzheimer's disease;
PAAD	cis	rs1198430	0.571	rs1001207	chr1:23749148	G/A	cg19827787	chr1:23763612	ASAP3	0.53	5.03	0.38	1.37e-6	Total cholesterol levels;
PAAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.61	5.99	0.44	1.48e-8	Systolic blood pressure;
PAAD	cis	rs9535307	0.929	rs9535310	chr13:50296026	T/C	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.61	6.16	0.45	6.36e-9	Depressive symptoms;
PAAD	cis	rs2072732	0.821	rs12034573	chr1:2948020	C/T	cg15211996	chr1:2936768	ACTRT2	0.46	4.67	0.35	6.54e-6	Plateletcrit;
PAAD	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg14388049	chr10:71211838	TSPAN15	-0.55	-5.61	-0.41	9.28e-8	Venous thromboembolism;
PAAD	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs76917914	0.820	rs7046514	chr9:100815088	C/T	cg21225548	chr9:100864335	TRIM14	-0.51	-5.08	-0.38	1.07e-6	Immature fraction of reticulocytes;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22433775	chr8:67976671	CSPP1	0.59	6.36	0.46	2.24e-9	Morning vs. evening chronotype;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4740619	0.587	rs2382551	chr9:16033443	C/T	cg14451791	chr9:16040625	NA	-0.47	-5.39	-0.4	2.61e-7	Body mass index;
PAAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.84	-0.43	3.04e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20046875	chr15:72766637	ARIH1	0.6	6.62	0.47	5.81e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17023223	0.509	rs10923740	chr1:119600287	C/T	cg17326555	chr1:119535693	NA	-0.46	-5.48	-0.41	1.72e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1499972	0.941	rs56051552	chr3:117613726	C/T	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.96	0.63	2.74e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.58	6.27	0.45	3.58e-9	Testicular germ cell tumor;
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	4.27	0.33	3.48e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.85	-0.43	2.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg07166546	chr14:35805898	NA	-0.31	-4.75	-0.36	4.76e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11811982	0.793	rs75330309	chr1:227509115	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7804356	0.834	rs7457076	chr7:26793215	C/T	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs1884136	1.000	rs67897813	chr20:10840823	C/G	cg12909741	chr20:10199469	SNAP25	-0.64	-4.25	-0.33	3.67e-5	Information processing speed;
PAAD	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.56	-0.41	1.19e-7	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.55	-0.35	1.11e-5	Educational attainment;
PAAD	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg20893579	chr22:38215064	NA	-0.45	-4.7	-0.36	5.72e-6	Glioblastoma;Glioma;
PAAD	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.52e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06799790	chr17:61951754	CSH2	-0.44	-4.51	-0.34	1.27e-5	Height;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg10544611	chr16:67998164	SLC12A4	-0.64	-4.35	-0.33	2.48e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.87	-0.37	2.78e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-11.76	-0.69	4.04e-23	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs74544699	1.000	rs149611	chr4:74780396	C/A	cg02530824	chr4:74847766	PF4	1.17	4.49	0.34	1.4e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg08132940	chr7:1081526	C7orf50	-0.64	-4.84	-0.37	3.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.65	4.62	0.35	8.01e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06956232	chr14:78432436	NA	-0.77	-8.19	-0.55	1e-13	Smoking initiation;
PAAD	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.68	-4.82	-0.36	3.46e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.07	-0.38	1.16e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9534288	0.619	rs1326397	chr13:46682122	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-5.64	-0.42	7.89e-8	Blood protein levels;
PAAD	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.57	-5.02	-0.38	1.42e-6	Mean corpuscular volume;
PAAD	cis	rs17155006	0.655	rs437336	chr7:107728634	G/T	cg05962710	chr7:107745446	LAMB4	-0.45	-5.52	-0.41	1.42e-7	Pneumococcal bacteremia;
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.12	-14.72	-0.77	4.7e-31	Urate levels;
PAAD	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.67	7.0	0.49	7.79e-11	N-glycan levels;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg16606324	chr3:10149918	C3orf24	0.67	5.28	0.39	4.32e-7	Alzheimer's disease;
PAAD	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.73	7.02	0.49	7.06e-11	Schizophrenia;
PAAD	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg15017067	chr4:17643749	FAM184B	0.43	5.12	0.38	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.16	-0.5	3.3e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs4646404	0.509	rs4646396	chr17:17432744	G/A	cg07083043	chr17:17397972	RASD1	-0.4	-4.29	-0.33	3.19e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
PAAD	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg21479132	chr6:26055353	NA	0.92	5.2	0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2252790	0.640	rs10484838	chr6:116597724	C/G	cg18764771	chr6:116381957	FRK	-0.29	-4.79	-0.36	3.91e-6	Fast beta electroencephalogram;
PAAD	cis	rs6991838	0.778	rs11779601	chr8:66462476	T/C	cg15971335	chr8:66515592	ARMC1	0.46	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.54	5.09	0.38	1.05e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs787274	1.000	rs700122	chr9:115551847	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7925523	0.891	rs58217294	chr11:61469503	T/A	cg12472022	chr11:61462803	DAGLA	0.6	4.67	0.35	6.61e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.86	-9.81	-0.62	6.83e-18	Morning vs. evening chronotype;
PAAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19346786	chr7:2764209	NA	-0.4	-4.8	-0.36	3.77e-6	Height;
PAAD	cis	rs4704187	0.687	rs1544756	chr5:74508412	G/T	cg03227963	chr5:74354835	NA	0.53	5.09	0.38	1.04e-6	Response to amphetamines;
PAAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.49	0.57	1.72e-14	Homoarginine levels;
PAAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg14709524	chr16:89940631	TCF25	0.73	4.34	0.33	2.6e-5	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.06	17.62	0.82	1.46e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-5.53	-0.41	1.36e-7	Hypospadias;
PAAD	cis	rs1198430	0.562	rs10917384	chr1:23798312	C/A	cg27447006	chr1:23763279	ASAP3	0.63	5.54	0.41	1.33e-7	Total cholesterol levels;
PAAD	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.61	5.58	0.41	1.1e-7	Platelet count;
PAAD	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg20814179	chr4:940893	TMEM175	0.75	9.1	0.59	4.8e-16	Sjögren's syndrome;
PAAD	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.62	6.86	0.49	1.64e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs73416724	0.544	rs6930150	chr6:43249510	C/A	cg00507679	chr6:43251876	TTBK1	0.58	4.71	0.36	5.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-5.05	-0.38	1.27e-6	Vitiligo;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-5.16	-0.39	7.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg09659197	chr4:152720779	NA	0.41	5.31	0.4	3.78e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.65	6.45	0.46	1.43e-9	Depressive symptoms;
PAAD	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg15117754	chr3:10150083	C3orf24	-0.68	-5.79	-0.43	3.85e-8	Alzheimer's disease;
PAAD	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg17347104	chr14:75034677	LTBP2	-0.45	-4.46	-0.34	1.56e-5	Caffeine consumption;
PAAD	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	12.59	0.71	2.31e-25	Colorectal cancer;
PAAD	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.08	0.38	1.09e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.619	rs10810517	chr9:16026664	C/T	cg14451791	chr9:16040625	NA	-0.46	-5.27	-0.39	4.68e-7	Body mass index;
PAAD	cis	rs1497828	1.000	rs2810769	chr1:217563585	A/T	cg04411442	chr1:217543379	NA	-0.52	-5.12	-0.38	9.28e-7	Dialysis-related mortality;
PAAD	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.29e-7	Obesity-related traits;
PAAD	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22244076	chr20:33872703	EIF6	0.74	8.67	0.58	5.98e-15	Myopia (pathological);
PAAD	cis	rs6074578	0.740	rs1858596	chr20:147497	G/A	cg16931068	chr20:139680	DEFB127	0.41	5.55	0.41	1.22e-7	Hirschsprung disease;
PAAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.58	-0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4343996	0.869	rs4544975	chr7:3385384	G/T	cg21248987	chr7:3385318	SDK1	-0.46	-5.05	-0.38	1.25e-6	Motion sickness;
PAAD	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-4.81	-0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.58	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.53	-6.68	-0.48	4.31e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg05084668	chr3:125655381	ALG1L	-0.5	-5.07	-0.38	1.16e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.78	8.0	0.54	2.95e-13	Vitiligo;
PAAD	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.71	11.11	0.67	2.27e-21	Breast cancer;
PAAD	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	0.87	8.4	0.56	2.99e-14	Blood protein levels;
PAAD	cis	rs7765175	0.775	rs6900728	chr6:113675986	T/G	cg19037598	chr6:113666021	NA	-0.44	-4.86	-0.37	2.95e-6	Coronary artery calcification;
PAAD	cis	rs75920871	0.589	rs2306473	chr11:117097952	C/T	cg20270762	chr11:117014891	PAFAH1B2	-0.77	-4.38	-0.33	2.23e-5	Subjective well-being;
PAAD	cis	rs10899021	1.000	rs7102084	chr11:74358132	T/C	cg25880958	chr11:74394337	NA	-0.82	-5.19	-0.39	6.6e-7	Response to metformin (IC50);
PAAD	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg21017887	chr14:105400489	NA	1.0	13.32	0.73	2.53e-27	Systemic lupus erythematosus;
PAAD	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	8.38	0.56	3.26e-14	Bone mineral density;
PAAD	cis	rs3996993	0.550	rs2474462	chr6:52620740	A/G	cg00536792	chr6:53530503	KLHL31	0.49	4.89	0.37	2.57e-6	Hemoglobin concentration;
PAAD	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.97	0.63	2.54e-18	Response to antipsychotic treatment;
PAAD	cis	rs61863818	0.557	rs7895646	chr10:99167436	A/G	cg12074985	chr10:99080756	FRAT1	0.37	4.28	0.33	3.35e-5	Monocyte percentage of white cells;
PAAD	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg14993813	chr1:46806288	NSUN4	-0.56	-5.05	-0.38	1.25e-6	Menopause (age at onset);
PAAD	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	ch.11.42038R	chr11:967971	AP2A2	0.63	6.15	0.45	6.4e-9	Alzheimer's disease (late onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25978313	chr4:2733839	FAM193A	0.66	6.65	0.47	4.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg22143856	chr6:28129313	ZNF389	0.6	4.33	0.33	2.71e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20957382	chr12:105501358	KIAA1033	0.54	6.44	0.46	1.5e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.78	0.48	2.45e-10	Resting heart rate;
PAAD	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg16579770	chr16:72058938	DHODH	0.39	4.5	0.34	1.33e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs6991838	0.806	rs11777025	chr8:66463673	A/C	cg15971335	chr8:66515592	ARMC1	-0.45	-4.59	-0.35	9.3e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	-0.61	-6.35	-0.46	2.36e-9	Iris heterochromicity;
PAAD	cis	rs12044355	0.892	rs10429979	chr1:231843569	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.2	0.39	6.32e-7	Alzheimer's disease;
PAAD	cis	rs370915	0.578	rs1431929	chr4:187775324	A/G	cg12892747	chr4:187813459	NA	-0.46	-4.65	-0.35	7.1e-6	Gout;
PAAD	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	6.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.14	0.6	3.69e-16	Menopause (age at onset);
PAAD	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-5.81	-0.43	3.55e-8	Resting heart rate;
PAAD	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg18551225	chr6:44695536	NA	-0.7	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-7.08	-0.5	5.12e-11	Colorectal cancer;
PAAD	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.72	-0.53	1.46e-12	Brugada syndrome;
PAAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg23947450	chr7:900037	UNC84A	-0.55	-4.47	-0.34	1.51e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01942863	chr7:99769432	GPC2	0.52	4.34	0.33	2.55e-5	Platelet count;
PAAD	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.48	4.74	0.36	4.79e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	trans	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.55	-0.47	8.35e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2292864	0.764	rs3785872	chr17:45372075	G/A	cg18085866	chr17:45331354	ITGB3	-0.94	-5.35	-0.4	3.23e-7	Left atrial antero-posterior diameter;
PAAD	cis	rs12153243	0.714	rs1946237	chr5:142895450	A/T	cg13907255	chr5:142895549	NA	-0.49	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.75	6.73	0.48	3.27e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg09658497	chr7:2847517	GNA12	-0.4	-4.29	-0.33	3.14e-5	Height;
PAAD	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs62025270	0.688	rs17638180	chr15:86278395	A/C	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.74e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg14583973	chr4:3374767	RGS12	-0.37	-5.51	-0.41	1.52e-7	Parental longevity (mother's age at death);
PAAD	cis	rs2221894	0.881	rs1948132	chr8:28900087	T/C	cg20212339	chr8:28908912	HMBOX1	-0.5	-5.36	-0.4	3.1e-7	Obesity-related traits;
PAAD	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.19	0.45	5.43e-9	Mean platelet volume;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg07559730	chr19:53497048	ZNF702P	-0.49	-5.27	-0.39	4.5e-7	Psoriasis;
PAAD	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.75	-8.5	-0.57	1.63e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.44	-0.34	1.7e-5	Ileal carcinoids;
PAAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs12753920	0.816	rs34090353	chr1:92823698	G/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.47	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.69	-6.13	-0.45	7.3e-9	IgG glycosylation;
PAAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.46	4.79	0.36	4.01e-6	Menopause (age at onset);
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.7e-6	Testicular germ cell tumor;
PAAD	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.81	0.54	8.7e-13	Lung cancer in ever smokers;
PAAD	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg04129946	chr2:201753996	PPIL3;NIF3L1	0.59	6.41	0.46	1.75e-9	Erectile dysfunction in type 1 diabetes;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.52	5.54	0.41	1.3e-7	Life satisfaction;
PAAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg05082376	chr22:42548792	NA	-0.55	-5.59	-0.41	1.02e-7	Cognitive function;
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs13380717	1.000	rs13380717	chr16:86904135	C/T	cg10861807	chr17:40575499	PTRF	-0.75	-6.99	-0.49	8.03e-11	Sepsis in extremely premature infants;
PAAD	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.64	-6.28	-0.45	3.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.71	11.12	0.67	2.14e-21	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs4356203	0.870	rs10832745	chr11:17249675	G/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.62	-6.51	-0.47	1.05e-9	IgG glycosylation;
PAAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.6	-6.92	-0.49	1.2e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.84	-9.12	-0.59	4.29e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	9.85	0.62	5.12e-18	Prudent dietary pattern;
PAAD	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs76419734	0.558	rs73837046	chr4:106523319	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.45	0.34	1.62e-5	Post bronchodilator FEV1;
PAAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg10395934	chr14:104002654	TRMT61A	0.54	5.47	0.41	1.81e-7	Body mass index;
PAAD	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.68	-7.2	-0.5	2.56e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16294425	chr4:1091520	RNF212	-0.63	-6.29	-0.45	3.17e-9	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24979348	chr12:15374303	RERG	0.6	6.7	0.48	3.76e-10	Monocyte percentage of white cells;
PAAD	cis	rs2555155	0.935	rs10769694	chr11:6520503	T/C	cg24637308	chr11:6592297	DNHD1	0.48	4.96	0.37	1.88e-6	DNA methylation (variation);
PAAD	cis	rs9649465	0.967	rs13225110	chr7:123340849	C/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg20243544	chr17:37824526	PNMT	-0.52	-4.57	-0.35	1.02e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.77	10.09	0.63	1.18e-18	Cardiovascular disease risk factors;
PAAD	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg14345882	chr6:26364793	BTN3A2	0.63	4.61	0.35	8.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.49	-6.0	-0.44	1.35e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg18939081	chr1:31884902	SERINC2	-0.47	-5.52	-0.41	1.44e-7	Alcohol dependence;
PAAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21166445	chr2:181843895	UBE2E3	0.6	6.94	0.49	1.04e-10	Smoking initiation;
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.81	-6.73	-0.48	3.27e-10	Initial pursuit acceleration;
PAAD	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg18898632	chr2:242989856	NA	-0.81	-6.03	-0.44	1.22e-8	Obesity-related traits;
PAAD	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.58e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs728616	0.867	rs12411407	chr10:81828231	C/T	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17095355	0.818	rs11195006	chr10:111903306	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.9	-0.37	2.47e-6	Biliary atresia;
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.7	-7.83	-0.54	7.6e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14300559	chr11:133772963	LOC283174	-0.56	-6.63	-0.47	5.51e-10	Monocyte percentage of white cells;
PAAD	cis	rs476633	0.595	rs11857726	chr15:41530359	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-8.11	-0.55	1.53e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.05	12.8	0.72	6.58e-26	Schizophrenia;
PAAD	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg20243544	chr17:37824526	PNMT	0.52	4.51	0.34	1.29e-5	Self-reported allergy;
PAAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg01503450	chr10:980765	NA	-0.53	-4.83	-0.36	3.27e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.84	-8.97	-0.59	1.04e-15	Corneal astigmatism;
PAAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.47	5.85	0.43	2.92e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02689951	chr3:197463378	KIAA0226	-0.66	-6.74	-0.48	3.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7551345	0.853	rs7513215	chr1:31754367	T/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.44	-0.71	6e-25	Ulcerative colitis;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	6.09	0.44	8.67e-9	Renal function-related traits (BUN);
PAAD	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	1.03	9.59	0.61	2.49e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg11271282	chr2:238384023	NA	0.74	4.27	0.33	3.39e-5	Prostate cancer;
PAAD	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22905274	chr4:154170538	TRIM2	0.65	6.61	0.47	6.04e-10	Obesity-related traits;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	1.08	8.85	0.58	2.14e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs8067287	0.749	rs62065427	chr17:16831560	C/T	cg26910001	chr17:16838321	NA	-0.68	-6.09	-0.44	8.7e-9	Diabetic kidney disease;
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.72	-5.89	-0.43	2.44e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg11812906	chr14:75593930	NEK9	-0.45	-4.4	-0.34	2.01e-5	Neuroticism;
PAAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg27490568	chr2:178487706	NA	0.38	4.27	0.33	3.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.39	4.99	0.38	1.62e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.41	4.58	0.35	9.65e-6	Refractive error;
PAAD	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.79	7.62	0.53	2.53e-12	Post bronchodilator FEV1;
PAAD	cis	rs2075671	0.818	rs10953303	chr7:100365613	G/T	cg16850897	chr7:100343110	ZAN	-0.54	-4.25	-0.33	3.67e-5	Other erythrocyte phenotypes;
PAAD	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.79	-6.4	-0.46	1.81e-9	Platelet distribution width;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg05627522	chr15:75251581	NA	0.52	6.23	0.45	4.32e-9	Caffeine consumption;
PAAD	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.69	-7.06	-0.5	5.52e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg22338127	chr1:209979572	IRF6	0.55	4.57	0.35	1e-5	Coronary artery disease;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg21698718	chr17:80085957	CCDC57	0.45	5.13	0.38	8.64e-7	Life satisfaction;
PAAD	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.48	-0.41	1.69e-7	Triglycerides;
PAAD	cis	rs9810890	1.000	rs73196954	chr3:128429909	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.72	6.86	0.49	1.59e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	5.28	0.39	4.45e-7	Height;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.28	0.33	3.28e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.73	6.05	0.44	1.09e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.76e-16	Morning vs. evening chronotype;
PAAD	cis	rs367943	0.665	rs6877548	chr5:112970054	C/T	cg12552261	chr5:112820674	MCC	0.49	4.96	0.37	1.84e-6	Type 2 diabetes;
PAAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs2295359	0.697	rs11209017	chr1:67666235	A/T	cg03340356	chr1:67600835	NA	0.44	5.09	0.38	1.06e-6	Psoriasis;
PAAD	cis	rs6466055	0.612	rs1135958	chr7:104920741	C/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs13006833	0.635	rs2664251	chr2:191147667	C/T	cg27211696	chr2:191398769	TMEM194B	0.46	4.53	0.34	1.2e-5	Urinary metabolites;
PAAD	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.27	-0.39	4.5e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.14	-0.6	3.79e-16	Mean platelet volume;
PAAD	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.56	5.59	0.41	1e-7	Resting heart rate;
PAAD	cis	rs10186876	0.541	rs11124953	chr2:44191555	G/A	cg14673618	chr2:45170322	SIX3	0.29	4.59	0.35	9.31e-6	Hand grip strength;
PAAD	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-4.57	-0.35	9.91e-6	Menopause (age at onset);
PAAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-8.7	-0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs41311933	0.615	rs7045519	chr9:123717840	C/A	cg21241889	chr9:123690658	TRAF1	-0.69	-4.36	-0.33	2.4e-5	Coronary artery disease;
PAAD	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.62	6.95	0.49	1e-10	Melanoma;
PAAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12667521	chr19:29218732	NA	0.61	5.39	0.4	2.61e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.88	9.0	0.59	8.65e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg23024343	chr7:107201750	COG5	0.56	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.52	5.45	0.4	1.98e-7	Body mass index;
PAAD	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.75	-9.47	-0.61	5.17e-17	Survival in pancreatic cancer;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.48	4.81	0.36	3.57e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg14132834	chr19:41945861	ATP5SL	-0.54	-5.21	-0.39	5.92e-7	Height;
PAAD	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg00250761	chr1:31883323	NA	-0.54	-6.32	-0.46	2.81e-9	Alcohol dependence;
PAAD	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg20243544	chr17:37824526	PNMT	0.58	5.2	0.39	6.38e-7	Self-reported allergy;
PAAD	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.65e-5	Neuroticism;
PAAD	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.79	6.28	0.45	3.41e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17789479	chr17:39845073	EIF1	-0.8	-6.89	-0.49	1.38e-10	Neuroticism;
PAAD	cis	rs8060686	0.858	rs7206671	chr16:67807146	A/G	cg05110241	chr16:68378359	PRMT7	-0.7	-5.17	-0.39	7.39e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.21	10.66	0.65	3.73e-20	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg16898833	chr6:26189333	HIST1H4D	0.87	4.71	0.36	5.56e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.689	rs9969791	chr9:15956164	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.02	-0.38	1.45e-6	Body mass index;
PAAD	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.73	6.42	0.46	1.66e-9	Dilated cardiomyopathy;
PAAD	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-6.98	-0.49	8.75e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.43e-9	Skin colour saturation;
PAAD	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg24053715	chr22:38214548	NA	-0.5	-5.15	-0.39	8.07e-7	Glioblastoma;Glioma;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg03983715	chr16:68378420	PRMT7	-0.66	-4.48	-0.34	1.44e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.62	6.23	0.45	4.28e-9	Depressive symptoms;
PAAD	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.34	16.17	0.8	7.48e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg04160749	chr8:58172571	NA	-0.75	-4.44	-0.34	1.74e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.5	-4.64	-0.35	7.51e-6	Sudden cardiac arrest;
PAAD	cis	rs12760731	0.565	rs7550699	chr1:178209584	T/G	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.26	-0.51	1.86e-11	Alcohol dependence;
PAAD	cis	rs1595825	0.732	rs7577835	chr2:198378056	T/C	cg00982548	chr2:198649783	BOLL	-0.66	-4.3	-0.33	3.04e-5	Ulcerative colitis;
PAAD	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg20503657	chr10:835505	NA	0.53	5.64	0.42	8.12e-8	Survival in rectal cancer;
PAAD	cis	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs1376877	0.519	rs4675332	chr2:204190907	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.6	4.91	0.37	2.37e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg14349672	chr11:133703707	NA	-0.6	-6.9	-0.49	1.32e-10	Childhood ear infection;
PAAD	cis	rs2016586	0.965	rs5995162	chr22:36118936	T/C	cg26342177	chr22:36113512	APOL5	-0.47	-4.65	-0.35	7.3e-6	Body mass index;
PAAD	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.8	9.24	0.6	2.01e-16	Breast cancer;
PAAD	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg06096015	chr1:231504339	EGLN1	0.65	8.51	0.57	1.57e-14	Hemoglobin concentration;
PAAD	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.69	10.6	0.65	5.29e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16707128	chr1:38325974	MTF1	-0.63	-6.34	-0.46	2.55e-9	Lung cancer in ever smokers;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08081407	chr3:57583693	ARF4	-0.55	-6.61	-0.47	6.14e-10	Body fat percentage;
PAAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg08888203	chr3:10149979	C3orf24	0.91	7.99	0.54	3.06e-13	Alzheimer's disease;
PAAD	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg09357268	chr20:43379437	KCNK15	-0.45	-4.74	-0.36	4.9100000000000004e-06	Obesity-related traits;
PAAD	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.3	-0.39	4.09e-7	Common traits (Other);
PAAD	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs12153243	0.686	rs6580291	chr5:142942129	A/G	cg13907255	chr5:142895549	NA	-0.57	-4.89	-0.37	2.55e-6	Migraine;
PAAD	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.48	-5.17	-0.39	7.24e-7	Diastolic blood pressure;
PAAD	cis	rs4234798	0.933	rs10020957	chr4:7222436	C/T	cg18431297	chr4:7219810	SORCS2	-0.41	-5.07	-0.38	1.15e-6	Insulin-like growth factors;
PAAD	cis	rs2253017	0.767	rs4770070	chr13:21330776	G/A	cg27499820	chr13:21296301	IL17D	0.57	5.25	0.39	4.99e-7	PR segment;
PAAD	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.54	-0.41	1.33e-7	Mood instability;
PAAD	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg17595323	chr11:93583763	C11orf90	-0.35	-4.46	-0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs8014252	0.614	rs60251828	chr14:71061451	C/G	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Gut microbiome composition (summer);
PAAD	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.87	10.93	0.66	7.11e-21	Body mass index;
PAAD	cis	rs7678296	1.000	rs16993295	chr4:37173081	G/A	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	5.28	0.39	4.33e-7	Mood instability;
PAAD	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg05250797	chr16:70222502	NA	0.87	6.5	0.47	1.09e-9	IgE levels;
PAAD	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2506028	1.000	rs788266	chr10:43435628	C/T	cg20628663	chr10:43360327	NA	-0.37	-4.28	-0.33	3.24e-5	Blood protein levels;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.11	-0.55	1.6e-13	Height;
PAAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.52	5.53	0.41	1.39e-7	Lung cancer;
PAAD	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg04398451	chr17:18023971	MYO15A	-0.72	-7.73	-0.53	1.38e-12	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19003389	chr17:17876154	LRRC48;TOM1L2	-0.59	-6.41	-0.46	1.75e-9	Smoking initiation;
PAAD	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.42	-0.4	2.3e-7	Monocyte count;
PAAD	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.38	-0.4	2.75e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg27478167	chr7:817139	HEATR2	-0.73	-5.68	-0.42	6.55e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.56	-0.41	1.2e-7	Iron status biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01286950	chr2:100618399	AFF3	0.52	6.55	0.47	8.22e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg13870426	chr17:30244630	NA	-0.72	-5.05	-0.38	1.23e-6	Height;
PAAD	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.13	-0.5	3.78e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs75920871	0.925	rs4936359	chr11:116893724	T/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.68	6.48	0.47	1.23e-9	Obesity-related traits;
PAAD	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	5.24	0.39	5.23e-7	Monocyte percentage of white cells;
PAAD	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.35	-0.51	1.16e-11	Body mass index;
PAAD	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.34	4.3	0.33	3.02e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg11335335	chr11:637885	DRD4	-0.38	-4.91	-0.37	2.37e-6	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23281280	chr6:28129359	ZNF389	0.67	5.1	0.38	1.02e-6	Depression;
PAAD	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	7.31	0.51	1.42e-11	Lymphocyte counts;
PAAD	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.64	-8.22	-0.55	8.57e-14	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26145223	chr11:63993388	NUDT22;TRPT1	0.58	6.52	0.47	9.91e-10	Monocyte percentage of white cells;
PAAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.28e-6	Rheumatoid arthritis;
PAAD	cis	rs3790455	0.560	rs1171557	chr1:156451264	C/T	cg14087168	chr1:156450669	MEF2D	-0.4	-4.33	-0.33	2.74e-5	Migraine;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg01028140	chr2:1542097	TPO	-1.05	-9.46	-0.61	5.6e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg14844989	chr11:31128820	NA	-0.42	-4.25	-0.33	3.64e-5	Red blood cell count;
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02071572	chr4:1403502	NA	0.5	6.66	0.48	4.67e-10	Longevity;
PAAD	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg10820045	chr2:198174542	NA	0.56	5.71	0.42	5.65e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.48e-6	Lung cancer;
PAAD	cis	rs346785	0.692	rs2279054	chr17:74287594	G/A	cg09812376	chr17:74270190	QRICH2	-0.45	-5.26	-0.39	4.72e-7	White matter hyperintensities in ischemic stroke;
PAAD	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg05585544	chr11:47624801	NA	0.48	5.27	0.39	4.5e-7	Subjective well-being;
PAAD	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg03417191	chr3:183542750	MAP6D1	0.48	4.26	0.33	3.51e-5	Anterior chamber depth;
PAAD	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.38	-0.34	2.17e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-7.02	-0.49	6.8e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.64	-7.35	-0.51	1.16e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs10073892	0.703	rs62372166	chr5:101629644	C/G	cg17280723	chr5:101634495	NA	0.4	4.27	0.33	3.48e-5	Cognitive decline (age-related);
PAAD	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs7551345	0.853	rs34746219	chr1:31819407	A/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.58	-0.35	9.53e-6	Schizophrenia;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.8	-8.39	-0.56	3.1e-14	Menopause (age at onset);
PAAD	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.72	10.97	0.66	5.52e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg07152487	chr11:14665355	PDE3B;PSMA1	0.59	6.37	0.46	2.17e-9	Positive affect;
PAAD	cis	rs375066	0.762	rs239939	chr19:44387967	A/T	cg21496419	chr19:44306685	LYPD5	0.42	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.55	6.29	0.45	3.25e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs6596140	0.917	rs55742238	chr5:133022616	G/A	cg19585597	chr5:150326193	LOC134466	-0.57	-6.52	-0.47	9.59e-10	Hypertension;
PAAD	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.9	11.42	0.68	3.3e-22	Mean corpuscular volume;
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.71	-0.36	5.55e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2000999	0.514	rs16970719	chr16:72252104	G/C	cg00207534	chr16:71929512	KIAA0174	0.71	4.36	0.33	2.37e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.6	4.27	0.33	3.49e-5	Gut microbiome composition (summer);
PAAD	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.94	0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12949688	0.600	rs10083861	chr17:55838072	C/T	cg12582317	chr17:55822272	NA	0.43	4.94	0.37	2.05e-6	Schizophrenia;
PAAD	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg02683114	chr2:24398427	C2orf84	-0.47	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	6.21	0.45	4.84e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg04844267	chr4:1394941	NA	0.41	4.47	0.34	1.54e-5	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg17325771	chr7:75508891	RHBDD2	0.32	4.6	0.35	8.73e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.8	8.34	0.56	4.2e-14	Body mass index;
PAAD	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg10705379	chr10:99080932	FRAT1	0.44	5.19	0.39	6.56e-7	Monocyte count;
PAAD	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.84	10.71	0.66	2.69e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.58	4.62	0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs60154123	0.730	rs12074229	chr1:210474602	A/G	cg21951975	chr1:209979733	IRF6	0.47	4.34	0.33	2.56e-5	Coronary artery disease;
PAAD	cis	rs1497828	1.000	rs11810416	chr1:217558447	A/G	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.47	0.46	1.28e-9	Bladder cancer;
PAAD	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.68	0.58	5.69e-15	Bipolar disorder;
PAAD	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs6687430	0.512	rs11121587	chr1:10618109	A/G	cg17425144	chr1:10567563	PEX14	-0.42	-4.62	-0.35	8.24e-6	Hand grip strength;
PAAD	cis	rs7688540	0.800	rs12501727	chr4:288074	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.65	0.35	7.1e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs9463078	0.565	rs1284980	chr6:45081428	A/G	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4835937	0.633	rs9327463	chr5:127315137	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	4.6	0.35	8.9e-6	Cancer;
PAAD	cis	rs4918918	0.868	rs7079293	chr10:97119593	T/C	cg03417182	chr10:97121241	SORBS1	-0.46	-4.27	-0.33	3.42e-5	Suicide risk;
PAAD	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.74	7.75	0.53	1.23e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.95	7.61	0.53	2.71e-12	Alzheimer's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15077012	chr10:99400394	PI4K2A	-0.59	-6.89	-0.49	1.4e-10	Energy expenditure (24h);
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.48	0.34	1.48e-5	Asthma;
PAAD	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.65	6.42	0.46	1.64e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.63	0.42	8.46e-8	Electroencephalogram traits;
PAAD	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg08390786	chr10:135334061	NA	0.47	4.62	0.35	8e-6	Obesity-related traits;
PAAD	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.44	4.96	0.37	1.84e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.97	12.12	0.7	4.42e-24	Menopause (age at onset);
PAAD	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.59	5.99	0.44	1.44e-8	Bladder cancer;
PAAD	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	1.29	6.79	0.48	2.37e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.53	5.35	0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.2	-0.39	6.37e-7	Schizophrenia (age at onset);
PAAD	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.67	6.75	0.48	2.94e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.71	0.66	2.76e-20	Cognitive ability;
PAAD	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs11563648	0.553	rs10954148	chr7:127006996	A/G	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.48e-5	Resting heart rate;
PAAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.3	-0.46	3e-9	Obesity-related traits;
PAAD	cis	rs959260	1.000	rs2117563	chr17:73368985	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.65	4.44	0.34	1.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.31	-0.4	3.84e-7	Retinal vascular caliber;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16327227	chr2:25896721	DTNB	-0.69	-7.07	-0.5	5.4e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1419980	0.730	rs7132588	chr12:7754616	T/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs6784615	0.744	rs164637	chr3:52265215	G/A	cg27565382	chr3:53032988	SFMBT1	1.06	4.65	0.35	7.13e-6	Waist-hip ratio;
PAAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.56	6.49	0.47	1.17e-9	Psoriasis;
PAAD	cis	rs17761864	0.718	rs8064885	chr17:2047564	G/A	cg20777128	chr17:1945076	DPH1;OVCA2	-0.42	-4.25	-0.33	3.77e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2077654	0.822	rs7932122	chr11:17431361	A/G	cg25308976	chr11:17434268	ABCC8	-0.86	-5.8	-0.43	3.74e-8	Gout;
PAAD	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.56	0.41	1.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.94	12.57	0.71	2.64e-25	Prudent dietary pattern;
PAAD	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg15691649	chr6:25882328	NA	0.49	4.51	0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-1.12	-10.65	-0.65	3.82e-20	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16781439	chr22:29469035	KREMEN1	0.76	9.07	0.59	5.64e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2010672	0.500	rs11631439	chr15:91143805	C/A	cg15547629	chr15:90437138	AP3S2	-0.51	-4.42	-0.34	1.9e-5	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg11441379	chr12:63026424	NA	0.8	6.3	0.46	3.02e-9	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.53	-0.47	9.4e-10	Aortic root size;
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg03400443	chr2:74347616	NA	-0.51	-4.3	-0.33	3.1e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.39	4.75	0.36	4.76e-6	Coronary artery disease;
PAAD	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg10820045	chr2:198174542	NA	0.43	4.34	0.33	2.56e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg25801113	chr15:45476975	SHF	0.42	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11696501	0.688	rs6094197	chr20:44316492	C/T	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.98	-12.71	-0.72	1.1e-25	Coronary artery disease;
PAAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg18827107	chr12:86230957	RASSF9	0.4	4.26	0.33	3.52e-5	Major depressive disorder;
PAAD	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.77	-0.53	1.07e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg09597638	chr17:3907349	NA	0.86	9.14	0.6	3.76e-16	Type 2 diabetes;
PAAD	cis	rs9810888	0.535	rs3774475	chr3:53650483	T/A	cg21574565	chr3:53855125	CHDH	0.33	4.25	0.33	3.69e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;
PAAD	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.35	4.47	0.34	1.52e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	6.17	0.45	5.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.1	0.81	3.03e-37	Prudent dietary pattern;
PAAD	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19400545	chr4:124319236	SPRY1	0.66	6.65	0.47	4.97e-10	Obesity-related traits;
PAAD	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg09491104	chr22:46646882	C22orf40	-1.01	-6.08	-0.44	9.17e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1371614	0.545	rs1057115	chr2:27172069	T/C	cg00617064	chr2:27272375	NA	0.45	4.6	0.35	8.67e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7577696	0.853	rs212699	chr2:32443519	A/G	cg02381751	chr2:32503542	YIPF4	0.44	4.69	0.36	6.1e-6	Inflammatory biomarkers;
PAAD	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.2	-10.6	-0.65	5.23e-20	Uric acid levels;
PAAD	cis	rs533581	0.816	rs8058234	chr16:88975447	C/G	cg16701003	chr16:89028210	CBFA2T3	0.55	5.49	0.41	1.67e-7	Social autistic-like traits;
PAAD	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.69	7.33	0.51	1.3e-11	Platelet distribution width;
PAAD	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.22	0.51	2.26e-11	Menopause (age at onset);
PAAD	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg12935359	chr14:103987150	CKB	-0.54	-4.69	-0.36	6.04e-6	Monocyte count;
PAAD	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.89	-0.37	2.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg16558253	chr16:72132732	DHX38	-0.61	-5.48	-0.41	1.73e-7	Coronary artery disease;
PAAD	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.99	13.85	0.75	9.72e-29	Heart rate;
PAAD	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg15038512	chr6:170123185	PHF10	0.54	4.37	0.33	2.32e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs795484	0.824	rs428073	chr12:118682751	C/T	cg16572268	chr12:118583242	PEBP1	-0.47	-4.55	-0.35	1.08e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg25364880	chr3:44379878	C3orf23	0.58	5.4	0.4	2.55e-7	Depressive symptoms;
PAAD	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.98	-0.54	3.24e-13	Neuroticism;
PAAD	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.77	-6.93	-0.49	1.09e-10	Blood protein levels;
PAAD	cis	rs2531992	0.800	rs2907272	chr16:4019350	C/T	cg05927578	chr16:4029543	ADCY9	0.67	5.82	0.43	3.32e-8	Waist circumference;
PAAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg27494647	chr7:150038898	RARRES2	0.51	5.04	0.38	1.28e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12940923	0.507	rs16942914	chr17:56373071	T/C	cg26072851	chr17:56296444	MKS1	-0.58	-5.02	-0.38	1.42e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg10011062	chr15:43941034	CATSPER2	-0.81	-4.92	-0.37	2.26e-6	Lung cancer in ever smokers;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg09835421	chr16:68378352	PRMT7	-0.93	-5.18	-0.39	6.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-7.81	-0.53	8.88e-13	Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.59	4.94	0.37	2.02e-6	Menarche (age at onset);
PAAD	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.27	0.45	3.58e-9	Hip circumference;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg00450029	chr8:599525	NA	0.81	5.36	0.4	3.08e-7	IgG glycosylation;
PAAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.81	0.36	3.56e-6	Major depressive disorder;
PAAD	cis	rs80130819	0.688	rs7305418	chr12:48586112	A/G	cg26205652	chr12:48591994	NA	0.7	4.83	0.36	3.34e-6	Prostate cancer;
PAAD	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.94	12.91	0.72	3.3e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs732765	0.734	rs12323899	chr14:75117513	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.53	-0.35	1.17e-5	Non-small cell lung cancer;
PAAD	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.7	-4.41	-0.34	1.94e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.68	5.0	0.38	1.53e-6	Fat distribution (HIV);
PAAD	cis	rs6782228	0.527	rs6767383	chr3:128413587	C/A	cg16766828	chr3:128327626	NA	-0.47	-6.27	-0.45	3.51e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	cis	rs6494488	0.500	rs79652764	chr15:64800532	A/C	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg21775007	chr8:11205619	TDH	-0.51	-4.59	-0.35	9.23e-6	Morning vs. evening chronotype;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00101118	chr1:51701740	RNF11	-0.64	-6.36	-0.46	2.21e-9	Lung cancer in ever smokers;
PAAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg12215294	chr3:40350768	EIF1B	-0.49	-4.83	-0.36	3.34e-6	Renal cell carcinoma;
PAAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg14580859	chr9:123691850	NA	0.4	4.44	0.34	1.69e-5	Rheumatoid arthritis;
PAAD	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-4.54	-0.35	1.13e-5	Self-reported allergy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09484638	chr19:12992426	DNASE2	0.58	6.39	0.46	1.95e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg09127314	chr1:152161683	NA	0.68	5.04	0.38	1.32e-6	Atopic dermatitis;
PAAD	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-6.43	-0.46	1.57e-9	Systolic blood pressure;
PAAD	cis	rs5758659	0.810	rs5758623	chr22:42566314	G/C	cg22189786	chr22:42395067	WBP2NL	-0.47	-4.78	-0.36	4.05e-6	Cognitive function;
PAAD	cis	rs11892454	0.504	rs55737015	chr2:26010303	G/A	cg25181710	chr2:26045287	ASXL2	0.43	5.01	0.38	1.48e-6	Heschl's gyrus morphology;
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg07159951	chr1:45983175	PRDX1	0.4	4.42	0.34	1.89e-5	High light scatter reticulocyte count;
PAAD	trans	rs1442089	1.000	rs79227994	chr18:51102127	C/T	cg24118715	chr10:70232072	DNA2	0.77	6.81	0.48	2.1e-10	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.61	5.53	0.41	1.38e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg00431813	chr7:1051703	C7orf50	-0.36	-4.25	-0.33	3.75e-5	Longevity;Endometriosis;
PAAD	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.02	0.44	1.23e-8	Rheumatoid arthritis;
PAAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg05835009	chr4:710272	PCGF3	0.71	6.31	0.46	2.9e-9	White blood cell count;
PAAD	cis	rs12476592	0.530	rs115404815	chr2:64246885	A/G	cg20249169	chr2:64881356	SERTAD2	-0.5	-4.26	-0.33	3.56e-5	Childhood ear infection;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	5.08e-8	Life satisfaction;
PAAD	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.53	5.24	0.39	5.29e-7	Anterior chamber depth;
PAAD	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.04	-0.38	1.32e-6	Coronary artery disease;
PAAD	cis	rs4443100	0.916	rs2078726	chr22:23382483	T/C	cg14186256	chr22:23484241	RTDR1	0.51	4.49	0.34	1.39e-5	Serum parathyroid hormone levels;
PAAD	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg04520793	chr17:42248056	ASB16	0.43	5.02	0.38	1.45e-6	Total body bone mineral density;
PAAD	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.77	-6.11	-0.44	7.86e-9	Heart failure;
PAAD	cis	rs75920871	1.000	rs59294170	chr11:116841446	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14008631	chr9:125377340	OR1Q1	-0.74	-8.02	-0.55	2.67e-13	Obesity-related traits;
PAAD	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.38	-0.46	1.99e-9	HDL cholesterol;
PAAD	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs10045504	0.502	rs72746043	chr5:38757226	T/C	cg15396434	chr5:38725168	NA	-0.87	-6.17	-0.45	5.9e-9	Night sleep phenotypes;
PAAD	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.59	6.38	0.46	2.05e-9	High light scatter reticulocyte count;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.71	8.34	0.56	4.19e-14	Height;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-1.13	-9.32	-0.6	1.3e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.86	6.61	0.47	6.05e-10	Alzheimer's disease;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.55	-5.59	-0.41	1.04e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.93	0.63	3.26e-18	Total body bone mineral density;
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.9	-7.4	-0.51	8.45e-12	Initial pursuit acceleration;
PAAD	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.55	-5.71	-0.42	5.76e-8	Testicular germ cell tumor;
PAAD	trans	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg15770106	chr1:208133116	NA	-0.66	-6.48	-0.47	1.2e-9	Corneal structure;
PAAD	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg21589280	chr1:85930151	DDAH1	-0.58	-4.32	-0.33	2.77e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.71	5.89	0.43	2.43e-8	Common traits (Other);
PAAD	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.43	4.41	0.34	1.96e-5	Sarcoidosis;
PAAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.67	-7.54	-0.52	3.91e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	1.11	11.58	0.68	1.25e-22	Platelet distribution width;
PAAD	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.82	0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.51	4.74	0.36	4.78e-6	Kawasaki disease;
PAAD	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs4239252	0.725	rs1994182	chr17:34087704	C/G	cg19411729	chr17:34207663	CCL5	0.46	4.25	0.33	3.78e-5	Blood protein levels;
PAAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs354033	0.800	rs1046140	chr7:149170236	C/T	cg06920324	chr7:149264011	ZNF767	-0.52	-4.28	-0.33	3.23e-5	Multiple sclerosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26068169	chr12:123717786	C12orf65	-0.7	-7.22	-0.51	2.27e-11	Smoking initiation;
PAAD	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-5.73	-0.42	5.28e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg13047869	chr3:10149882	C3orf24	0.81	6.15	0.45	6.69e-9	Alzheimer's disease;
PAAD	cis	rs12541635	0.967	rs13256474	chr8:107086419	T/C	cg10147462	chr8:107024639	NA	-0.44	-4.62	-0.35	8.06e-6	Age of smoking initiation;
PAAD	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.07	-0.38	1.15e-6	Interstitial lung disease;
PAAD	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.72	9.34	0.6	1.15e-16	Weight;
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.71	5.31	0.4	3.75e-7	Initial pursuit acceleration;
PAAD	cis	rs6715793	0.869	rs7580348	chr2:33428767	C/T	cg26672287	chr2:33391915	LTBP1	-0.41	-4.75	-0.36	4.66e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9503598	0.502	rs1077845	chr6:3433201	G/T	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs10274279	1.000	rs2021742	chr7:157381671	T/A	cg09270525	chr7:157391030	PTPRN2	0.71	5.32	0.4	3.64e-7	Myopia (pathological);
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-5.01	-0.38	1.51e-6	Total body bone mineral density;
PAAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs728616	0.614	rs12411833	chr10:82103230	T/C	cg19423196	chr10:82049429	MAT1A	0.45	4.44	0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3206736	0.548	rs328901	chr7:35020451	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg23958373	chr8:599963	NA	-1.1	-8.04	-0.55	2.4e-13	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg13447295	chr6:887704	NA	-0.75	-6.88	-0.49	1.45e-10	Aging;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.49	-0.47	1.15e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg26818257	chr2:241905806	NA	0.46	4.86	0.37	2.92e-6	Joint mobility (Beighton score);
PAAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.78	-6.25	-0.45	3.96e-9	Coronary artery disease;
PAAD	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-10.26	-0.64	4.23e-19	Chronic sinus infection;
PAAD	cis	rs6132905	0.590	rs2092656	chr20:2625850	A/T	cg24848351	chr20:2622020	TMC2	-0.76	-5.54	-0.41	1.31e-7	Mumps;
PAAD	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.74	7.86	0.54	6.48e-13	Carotid intima media thickness;
PAAD	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg26248373	chr2:1572462	NA	-1.08	-7.53	-0.52	4.23e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4523957	0.928	rs4790325	chr17:2192085	C/T	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.59	-7.93	-0.54	4.47e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.6	6.25	0.45	3.91e-9	Body mass index;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg26338869	chr17:61819248	STRADA	0.49	4.78	0.36	4.09e-6	Height;
PAAD	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.46	0.34	1.59e-5	Neuroticism;
PAAD	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.79	9.04	0.59	6.74e-16	Breast cancer;
PAAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.7	-0.36	5.75e-6	Body mass index;
PAAD	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg19423196	chr10:82049429	MAT1A	0.61	4.72	0.36	5.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg00207534	chr16:71929512	KIAA0174	0.76	4.72	0.36	5.27e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.78	8.04	0.55	2.35e-13	Body mass index;
PAAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.8	-8.59	-0.57	9.65e-15	Prostate cancer;
PAAD	cis	rs883565	0.682	rs35219579	chr3:39044665	A/T	cg01426195	chr3:39028469	NA	-0.74	-8.04	-0.55	2.36e-13	Handedness;
PAAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs41311933	1.000	rs41259344	chr9:123751648	C/T	cg13567360	chr9:123745713	C5	-0.73	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg15192750	chr16:69999425	NA	0.73	5.57	0.41	1.11e-7	IgE levels;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	6.37	0.46	2.16e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg23346134	chr3:49453900	TCTA	0.42	4.43	0.34	1.79e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.63	-6.53	-0.47	9.44e-10	Childhood ear infection;
PAAD	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.43	-0.4	2.16e-7	Pulmonary function;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-8.96	-0.59	1.06e-15	Systemic lupus erythematosus;
PAAD	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg18721089	chr20:30220636	NA	-0.51	-4.48	-0.34	1.46e-5	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7101378	0.577	rs7930665	chr11:108896862	T/G	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg19257562	chr1:2043853	PRKCZ	0.45	5.32	0.4	3.6e-7	Height;
PAAD	cis	rs89107	0.967	rs6912208	chr6:118566516	A/G	cg18833306	chr6:118973337	C6orf204	-0.49	-5.52	-0.41	1.4e-7	Cardiac structure and function;
PAAD	cis	rs9287719	0.649	rs10208103	chr2:10720867	G/A	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12582317	chr17:55822272	NA	0.71	8.7	0.58	5.07e-15	Schizophrenia;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11199448	chr12:133374911	GOLGA3	0.6	6.43	0.46	1.58e-9	Warfarin maintenance dose;
PAAD	cis	rs564309	0.681	rs4581279	chr1:228622347	A/G	cg13099616	chr1:227751251	ZNF678	0.68	4.56	0.35	1.04e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs2790216	0.901	rs2590310	chr10:59982823	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs3736485	0.966	rs2414114	chr15:51905781	T/G	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.51e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs527409	1.000	rs77222875	chr1:58721909	C/G	cg26513689	chr1:58717632	DAB1	0.71	4.27	0.33	3.42e-5	Kawasaki disease;
PAAD	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg14583973	chr4:3374767	RGS12	0.41	6.19	0.45	5.34e-9	Serum sulfate level;
PAAD	cis	rs17023223	0.537	rs12086	chr1:119573860	T/C	cg17326555	chr1:119535693	NA	-0.45	-5.04	-0.38	1.34e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.46	-4.66	-0.35	6.91e-6	Type 1 diabetes;
PAAD	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.53	-4.52	-0.34	1.22e-5	Large artery stroke;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19729279	chr5:133861951	PHF15	0.61	6.82	0.48	2.02e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg02733842	chr7:1102375	C7orf50	-0.77	-6.12	-0.44	7.77e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg05562828	chr17:3906858	NA	0.53	5.83	0.43	3.2e-8	Type 2 diabetes;
PAAD	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.94	-0.49	1.09e-10	Neuroticism;
PAAD	cis	rs13065560	0.594	rs4234133	chr3:38888021	T/C	cg01426195	chr3:39028469	NA	-0.57	-5.91	-0.43	2.18e-8	Interleukin-18 levels;
PAAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-6.78	-0.48	2.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg12310025	chr6:25882481	NA	0.44	4.3	0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.81	7.9	0.54	5.11e-13	Body mass index;
PAAD	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	1.09	6.16	0.45	6.31e-9	Plasma clusterin levels;
PAAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs6585424	1.000	rs35025775	chr10:81924285	C/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26378065	chr17:18585709	ZNF286B	-0.63	-4.72	-0.36	5.23e-6	Pancreatic cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15226715	chr17:73257618	GGA3;MRPS7	0.57	6.49	0.47	1.12e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	5.12	0.38	9.04e-7	Iron status biomarkers;
PAAD	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.65	6.6	0.47	6.52e-10	Alcohol dependence;
PAAD	cis	rs12989701	0.778	rs7584040	chr2:127863224	C/T	cg08168897	chr2:127865431	BIN1	0.51	5.27	0.39	4.65e-7	Alzheimer's disease (late onset);
PAAD	cis	rs261532	0.861	rs2434576	chr5:138917674	A/G	cg26929925	chr5:138714136	SLC23A1	-0.57	-5.15	-0.39	7.89e-7	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.79	8.22	0.55	8.34e-14	Body mass index;
PAAD	cis	rs80346118	0.673	rs6019421	chr20:47410020	T/C	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.59	-4.27	-0.33	3.39e-5	Diastolic blood pressure;
PAAD	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	9.0	0.59	8.38e-16	Lymphocyte counts;
PAAD	cis	rs950037	0.710	rs786914	chr1:89295765	C/A	cg13109106	chr1:89333529	GTF2B	-0.47	-4.43	-0.34	1.76e-5	Coronary artery disease;
PAAD	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.88	-9.78	-0.62	8.07e-18	Obesity-related traits;
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs2514805	0.803	rs2514803	chr8:95135888	T/C	cg25183890	chr8:94929275	PDP1	0.67	4.38	0.33	2.17e-5	Diisocyanate-induced asthma;
PAAD	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.54	-0.35	1.12e-5	Biliary atresia;
PAAD	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.45	5.53	0.41	1.39e-7	Body mass index in non-asthmatics;
PAAD	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9361491	0.508	rs9343789	chr6:79426581	A/G	cg05283184	chr6:79620031	NA	-0.41	-5.09	-0.38	1.03e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12346351	chr4:152330392	FAM160A1	0.65	7.06	0.5	5.6e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.22	0.55	8.14e-14	Lung cancer;
PAAD	cis	rs59104589	0.583	rs12624195	chr2:242254734	G/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.57	5.83	0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20994703	chr7:149542110	ZNF862	0.73	7.93	0.54	4.49e-13	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04047127	chr2:203500074	FAM117B	-0.64	-6.62	-0.47	5.82e-10	Warfarin maintenance dose;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.95	-8.59	-0.57	9.67e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.45	6.03	0.44	1.22e-8	Childhood ear infection;
PAAD	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg11441379	chr12:63026424	NA	0.88	6.45	0.46	1.38e-9	IgG glycosylation;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	5.98	0.44	1.53e-8	Height;
PAAD	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg25828445	chr12:7781288	NA	0.8	5.74	0.42	4.93e-8	HDL cholesterol levels;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02071572	chr4:1403502	NA	0.41	5.72	0.42	5.5e-8	Obesity-related traits;
PAAD	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg02683114	chr2:24398427	C2orf84	-0.61	-6.55	-0.47	8.4e-10	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2882667	0.690	rs4835705	chr5:138163576	T/C	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.5	4.64	0.35	7.39e-6	Refractive astigmatism;
PAAD	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.49	-5.17	-0.39	7.17e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.55	6.08	0.44	9.51e-9	Type 2 diabetes;
PAAD	trans	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg00717180	chr2:96193071	NA	-0.61	-7.18	-0.5	2.82e-11	Height;
PAAD	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	5.27	0.39	4.64e-7	Homocysteine levels;
PAAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.52	6.96	0.49	9.76e-11	Diastolic blood pressure;
PAAD	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg23752985	chr2:85803571	VAMP8	-0.49	-5.66	-0.42	7.3e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg15226275	chr6:116381976	FRK	0.27	4.41	0.34	1.97e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.93	11.67	0.69	7.23e-23	Prudent dietary pattern;
PAAD	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.14	-0.5	3.52e-11	Triglycerides;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19160799	chr12:56101445	ITGA7	0.56	6.48	0.47	1.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.66	6.27	0.45	3.62e-9	Mood instability;
PAAD	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.67	7.76	0.53	1.16e-12	Testicular germ cell tumor;
PAAD	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	5.59	0.41	1.02e-7	Myopia (pathological);
PAAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-5.2	-0.39	6.45e-7	Blood pressure (smoking interaction);
PAAD	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.72	6.37	0.46	2.18e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.76	7.81	0.54	8.66e-13	Prostate cancer;
PAAD	cis	rs4343996	0.530	rs10262783	chr7:3431165	T/C	cg21248987	chr7:3385318	SDK1	0.41	4.29	0.33	3.2e-5	Motion sickness;
PAAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg14346243	chr4:90757452	SNCA	-0.51	-4.39	-0.34	2.07e-5	Neuroticism;
PAAD	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.82	-0.36	3.38e-6	Body mass index;
PAAD	cis	rs4356203	0.905	rs35933265	chr11:17115254	C/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.44	-0.34	1.72e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg03098721	chr1:84464084	TTLL7	0.48	4.63	0.35	7.76e-6	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg21698718	chr17:80085957	CCDC57	-0.45	-5.09	-0.38	1.06e-6	Life satisfaction;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09667226	chr13:73632762	KLF5	0.56	6.33	0.46	2.63e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg27149285	chr3:50375164	RASSF1	-0.64	-4.34	-0.33	2.56e-5	Schizophrenia;
PAAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs12979813	1.000	rs10418759	chr19:11340242	A/G	cg08405405	chr19:11485325	C19orf39	-0.58	-4.25	-0.33	3.75e-5	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08312600	chr19:14607318	GIPC1	0.73	7.59	0.52	2.95e-12	Obesity-related traits;
PAAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg10729496	chr3:10149963	C3orf24	0.77	6.39	0.46	1.95e-9	Alzheimer's disease;
PAAD	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs72627123	1.000	rs76553384	chr14:74383679	T/C	cg19860245	chr14:74300557	NA	-0.71	-4.8	-0.36	3.74e-6	Morning vs. evening chronotype;
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.47	-4.8	-0.36	3.78e-6	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08838260	chr4:140004785	ELF2	0.65	6.32	0.46	2.72e-9	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.83	-0.48	1.89e-10	Personality dimensions;
PAAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.53	-6.38	-0.46	2e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs78132593	0.917	rs267734	chr1:150951477	C/T	cg15448220	chr1:150897856	SETDB1	0.52	4.31	0.33	2.87e-5	High light scatter reticulocyte count;
PAAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg14079463	chr6:127796989	C6orf174	-0.36	-4.26	-0.33	3.57e-5	Breast cancer;
PAAD	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.62	8.28	0.56	5.73e-14	Crohn's disease;
PAAD	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.62	5.49	0.41	1.61e-7	Mean platelet volume;
PAAD	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26926768	chr12:34528122	NA	0.4	4.84	0.37	3.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg12437481	chr16:420112	MRPL28	-0.63	-5.46	-0.41	1.88e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.67	6.23	0.45	4.47e-9	Platelet count;
PAAD	cis	rs955333	0.571	rs4302678	chr6:154928528	T/C	cg20019720	chr6:154832845	CNKSR3	0.32	4.33	0.33	2.72e-5	Diabetic kidney disease;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.43e-8	Prudent dietary pattern;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15481429	chr15:94945799	MCTP2	0.66	6.9	0.49	1.3e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.49	5.73	0.42	5.23e-8	Electroencephalogram traits;
PAAD	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	1.0	8.14	0.55	1.34e-13	Triglycerides;
PAAD	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg15145965	chr22:50218605	BRD1	0.6	5.2	0.39	6.4e-7	Schizophrenia;
PAAD	cis	rs77633900	0.772	rs77582696	chr15:76669153	A/G	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg08779649	chr13:50194554	NA	0.42	5.76	0.42	4.52e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.47	-5.03	-0.38	1.38e-6	Motion sickness;
PAAD	cis	rs2131877	0.827	rs6784890	chr3:194842145	A/C	cg19760965	chr3:194868843	C3orf21	0.38	4.3	0.33	3.03e-5	Non-small cell lung cancer;
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg27057461	chr7:158136379	PTPRN2	-0.48	-4.36	-0.33	2.35e-5	Response to amphetamines;
PAAD	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.83	8.8	0.58	2.87e-15	Itch intensity from mosquito bite;
PAAD	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg10011062	chr15:43941034	CATSPER2	-0.76	-4.4	-0.34	2.07e-5	Lung cancer in ever smokers;
PAAD	cis	rs7172689	0.908	rs11637363	chr15:81567973	A/C	cg05624577	chr15:81411055	NA	-0.56	-4.3	-0.33	3.01e-5	Inattentive symptoms;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg23920097	chr1:209922102	NA	-0.58	-5.36	-0.4	3.04e-7	Red blood cell count;
PAAD	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.66	-6.58	-0.47	7.07e-10	Coronary artery disease;
PAAD	cis	rs6066835	0.572	rs6125413	chr20:47257145	G/A	cg18078177	chr20:47281410	PREX1	1.03	5.34	0.4	3.37e-7	Multiple myeloma;
PAAD	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.85	6.43	0.46	1.54e-9	Alzheimer's disease;
PAAD	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	6.85	0.49	1.7e-10	Mean platelet volume;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg06815965	chr1:205818668	PM20D1	0.58	6.48	0.47	1.23e-9	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05789608	chr1:205180802	DSTYK	-0.73	-7.76	-0.53	1.14e-12	Smoking initiation;
PAAD	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.67	-0.72	1.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs501120	0.564	rs12415866	chr10:44686664	A/G	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg26876637	chr1:152193138	HRNR	-0.79	-5.41	-0.4	2.4e-7	Atopic dermatitis;
PAAD	cis	rs2017305	0.831	rs3740596	chr10:70674178	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg05717871	chr11:638507	DRD4	-0.57	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg20850873	chr3:10149803	C3orf24	0.53	4.27	0.33	3.38e-5	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.53	-0.35	1.17e-5	Neuroticism;
PAAD	cis	rs1519814	0.956	rs4871036	chr8:121101758	T/C	cg22335954	chr8:121166405	COL14A1	-0.63	-5.38	-0.4	2.8e-7	Breast cancer;
PAAD	cis	rs2030114	1.000	rs11643964	chr16:51612424	G/T	cg03758633	chr16:51611768	NA	-0.58	-4.89	-0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.57	-4.69	-0.36	5.93e-6	Vitiligo;
PAAD	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.78	-0.36	4.18e-6	Lung cancer in ever smokers;
PAAD	cis	rs3126085	0.560	rs1923505	chr1:152359837	T/C	cg26876637	chr1:152193138	HRNR	-0.63	-4.51	-0.34	1.28e-5	Atopic dermatitis;
PAAD	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.73	-0.36	5.16e-6	Myopia (pathological);
PAAD	trans	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs71636778	0.631	rs12735407	chr1:27198937	C/G	cg12203394	chr1:27248618	NUDC	0.64	4.57	0.35	9.9e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-1.06	-7.06	-0.5	5.48e-11	Mitochondrial DNA levels;
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13012494	chr21:47604986	C21orf56	0.43	4.73	0.36	5.07e-6	Testicular germ cell tumor;
PAAD	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-1.25	-9.47	-0.61	5.14e-17	Obesity-related traits;
PAAD	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.8	-8.67	-0.58	5.99e-15	Caffeine consumption;
PAAD	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.84	8.45	0.57	2.17e-14	Response to diuretic therapy;
PAAD	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg07395648	chr5:131743802	NA	-0.58	-5.18	-0.39	7e-7	Blood metabolite levels;
PAAD	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.58	-0.57	1e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg22875332	chr1:76189707	ACADM	0.52	5.21	0.39	6.04e-7	Daytime sleep phenotypes;
PAAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg27182935	chr16:89790473	ZNF276	0.72	4.52	0.34	1.21e-5	Skin colour saturation;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg11601000	chr22:42348013	LOC339674	0.39	4.49	0.34	1.41e-5	Cognitive function;
PAAD	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07741184	chr6:167504864	NA	-0.37	-4.83	-0.36	3.26e-6	Primary biliary cholangitis;
PAAD	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.54	-0.47	8.67e-10	Eye color traits;
PAAD	cis	rs300774	0.844	rs300729	chr2:131788	C/G	cg21211680	chr2:198530	NA	0.65	6.0	0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.2	-0.5	2.52e-11	Alcohol dependence;
PAAD	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.51	5.12	0.38	9.13e-7	Type 2 diabetes;
PAAD	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.48	5.17	0.39	7.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.88	-0.37	2.6e-6	Pulmonary function;
PAAD	cis	rs9322817	0.691	rs6907016	chr6:105211360	G/A	cg02098413	chr6:105308735	HACE1	-0.44	-5.49	-0.41	1.63e-7	Thyroid stimulating hormone;
PAAD	cis	rs375066	0.935	rs423765	chr19:44416199	C/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6800768	0.633	rs60635484	chr3:24101328	G/A	cg10674438	chr3:24145617	LOC152024	-0.47	-4.35	-0.33	2.5e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11995313	chr8:8860691	ERI1	0.52	5.31	0.4	3.91e-7	Joint mobility (Beighton score);
PAAD	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.23	9.85	0.62	5.27e-18	Alzheimer's disease (late onset);
PAAD	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-4.55	-0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.62	6.62	0.47	5.68e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.01	-0.54	2.85e-13	Alcohol dependence;
PAAD	cis	rs7567389	0.719	rs1011019	chr2:128037560	A/G	cg09760422	chr2:128146352	NA	-0.38	-5.93	-0.43	1.97e-8	Self-rated health;
PAAD	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.09	0.38	1.04e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg23127183	chr11:57508653	C11orf31	-0.51	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23158103	chr7:148848205	ZNF398	-0.6	-5.79	-0.42	3.96e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2117029	0.619	rs2241727	chr12:49525008	G/C	cg05368762	chr12:50135785	TMBIM6	0.43	4.31	0.33	2.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg09626299	chr10:82213104	TSPAN14	-0.43	-4.5	-0.34	1.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs899997	1.000	rs11852909	chr15:79030499	C/T	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.51	6.97	0.49	8.89e-11	Dupuytren's disease;
PAAD	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg20805835	chr1:248005719	OR11L1	-0.49	-4.32	-0.33	2.79e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs686320	0.667	rs666834	chr11:65183815	A/G	cg21890820	chr11:65308645	LTBP3	-0.8	-5.25	-0.39	5.03e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11811982	0.793	rs78634790	chr1:227610481	C/G	cg06057666	chr1:227327429	CDC42BPA	0.7	4.26	0.33	3.62e-5	Optic disc area;
PAAD	cis	rs6693295	0.729	rs10802326	chr1:246216665	T/C	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs1723838	0.826	rs9651759	chr11:73602950	G/A	cg26954736	chr11:73693896	UCP2	1.09	4.75	0.36	4.64e-6	Obesity-related traits;
PAAD	cis	rs438465	1.000	rs425239	chr6:169813758	A/C	cg11181693	chr6:169825345	NA	-0.57	-4.38	-0.34	2.16e-5	Corneal astigmatism;
PAAD	cis	rs3026101	0.671	rs929262	chr17:5312271	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	6.38	0.46	2.05e-9	Initial pursuit acceleration;
PAAD	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg15192750	chr16:69999425	NA	0.72	5.47	0.41	1.83e-7	IgE levels;
PAAD	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.4	0.34	2.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg22517653	chr1:2918612	NA	-0.6	-4.94	-0.37	2.05e-6	Plateletcrit;
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg06883089	chr1:45254480	BEST4	0.36	4.67	0.35	6.48e-6	High light scatter reticulocyte count;
PAAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.85	0.62	5.28e-18	Total body bone mineral density;
PAAD	cis	rs11650175	0.740	rs11655011	chr17:63761554	A/G	cg07283582	chr17:63770753	CCDC46	0.41	4.59	0.35	9.12e-6	Chin dimples;
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg13206674	chr6:150067644	NUP43	0.6	6.45	0.46	1.42e-9	Testicular germ cell tumor;
PAAD	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.72	8.11	0.55	1.61e-13	Morning vs. evening chronotype;
PAAD	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.79	-4.73	-0.36	5.04e-6	Cholesterol, total;
PAAD	trans	rs7594645	0.661	rs115839833	chr2:207619434	T/C	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.6	0.47	6.53e-10	Body mass index;
PAAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.64	-0.57	7.33e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg18093559	chr17:18951025	GRAP	-0.46	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.67	-5.88	-0.43	2.47e-8	Prostate cancer;
PAAD	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.59	-7.26	-0.51	1.85e-11	Blood pressure (smoking interaction);
PAAD	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.35e-13	Coronary artery disease;
PAAD	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.55	-5.89	-0.43	2.45e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.71	-7.28	-0.51	1.72e-11	Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11381792	chr21:45432451	TRAPPC10	-0.64	-6.69	-0.48	4.06e-10	Smoking initiation;
PAAD	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs7580658	1.000	rs7580658	chr2:128159261	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.29	-0.51	1.57e-11	Protein C levels;
PAAD	cis	rs35160687	0.712	rs6547668	chr2:86490661	C/G	cg10973622	chr2:86423274	IMMT	-0.43	-4.65	-0.35	7.2e-6	Night sleep phenotypes;
PAAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-1.42	-10.48	-0.65	1.13e-19	Magnesium levels;
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.05	-18.72	-0.84	2.73e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.71	7.58	0.52	3.18e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.69	0.58	5.24e-15	Rheumatoid arthritis;
PAAD	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.06	0.38	1.2e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.68	7.36	0.51	1.08e-11	Vitiligo;
PAAD	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-1.03	-12.9	-0.72	3.4e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-8.3	-0.56	5.1e-14	Monocyte percentage of white cells;
PAAD	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.46	-0.4	1.91e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.7	-5.78	-0.42	4.19e-8	Neuroticism;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg20007245	chr22:24372913	LOC391322	-0.65	-6.06	-0.44	1.04e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.12	-0.59	4.14e-16	Gut microbiome composition (summer);
PAAD	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.71	-5.63	-0.42	8.34e-8	Cancer;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.34e-7	Electroencephalogram traits;
PAAD	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.88	-0.37	2.63e-6	Menarche (age at onset);
PAAD	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg21483461	chr5:81570383	RPS23	0.57	5.1	0.38	1.02e-6	Breast cancer;
PAAD	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.92	-0.77	1.44e-31	Ulcerative colitis;
PAAD	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05346536	chr7:128769728	NA	0.59	6.31	0.46	2.89e-9	Smoking initiation;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.56	4.54	0.35	1.15e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.77	8.23	0.56	8.06e-14	Age at first birth;
PAAD	trans	rs12786942	0.800	rs11224805	chr11:101373514	C/T	cg19874726	chr14:61114476	SIX1	-0.84	-6.29	-0.45	3.22e-9	Facial depth;
PAAD	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.72	7.61	0.53	2.67e-12	Platelet distribution width;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.51	-6.92	-0.49	1.19e-10	Life satisfaction;
PAAD	cis	rs7737355	0.738	rs7734666	chr5:130861456	A/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.52	-0.34	1.26e-5	Height;
PAAD	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.41	0.56	2.8e-14	Menopause (age at onset);
PAAD	trans	rs901683	1.000	rs36052429	chr10:46082345	T/A	cg23720331	chr10:123873670	TACC2	-0.87	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg13263323	chr15:86062960	AKAP13	-0.63	-7.12	-0.5	4.03e-11	Coronary artery disease;
PAAD	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg27449745	chr7:23145252	KLHL7	-0.57	-4.97	-0.37	1.77e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.48	4.56	0.35	1.03e-5	Fear of minor pain;
PAAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg16083429	chr3:49237500	CCDC36	-0.42	-4.43	-0.34	1.82e-5	Parkinson's disease;
PAAD	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.72	-7.26	-0.51	1.89e-11	Morning vs. evening chronotype;
PAAD	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.26	0.33	3.6e-5	Cancer;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.44	7.26	0.51	1.82e-11	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.65	-0.35	7.14e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg06484146	chr7:12443880	VWDE	-0.63	-4.73	-0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.69	-8.43	-0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg24585817	chr7:64895279	NA	0.41	4.62	0.35	8.04e-6	Calcium levels;
PAAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.66	-7.58	-0.52	3.2e-12	Huntington's disease progression;
PAAD	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.44	-4.88	-0.37	2.71e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs17824933	0.848	rs11230564	chr11:60776465	A/G	cg16817237	chr11:60793675	NA	0.53	6.24	0.45	4.2e-9	Multiple sclerosis;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	1.0	7.6	0.52	2.76e-12	IgG glycosylation;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.44	-4.95	-0.37	1.97e-6	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.24e-7	Alzheimer's disease (late onset);
PAAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.5e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg19090574	chr1:205240910	TMCC2	-0.4	-4.29	-0.33	3.13e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	4.55	0.35	1.09e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg05305434	chr11:1874049	LSP1	0.47	5.32	0.4	3.71e-7	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.81	11.19	0.67	1.42e-21	Bone mineral density;
PAAD	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg01176363	chr20:62369445	LIME1	-0.54	-5.34	-0.4	3.37e-7	Prostate cancer;
PAAD	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg09597638	chr17:3907349	NA	0.68	7.04	0.5	6.36e-11	Type 2 diabetes;
PAAD	cis	rs6066835	1.000	rs6066831	chr20:47354131	C/A	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.6	8.25	0.56	6.87e-14	Renal cell carcinoma;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10467557	chr13:21893662	NA	-0.4	-4.46	-0.34	1.6e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.17	-0.39	7.22e-7	Systemic lupus erythematosus;
PAAD	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.82	6.06	0.44	1.05e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.17	12.07	0.7	5.97e-24	Corneal structure;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg22162314	chr17:61951766	CSH2	-0.55	-5.57	-0.41	1.12e-7	Height;
PAAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg00988841	chr10:134556463	INPP5A	-0.46	-4.34	-0.33	2.64e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg16714752	chr4:39368184	RFC1	0.47	4.83	0.37	3.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.62	5.72	0.42	5.37e-8	Coronary artery disease;
PAAD	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-6.82	-0.48	2.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.35	-0.64	2.51e-19	Response to antipsychotic treatment;
PAAD	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg15628303	chr1:26608928	UBXN11	0.65	6.47	0.46	1.26e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11167764	0.945	rs891985	chr5:141466066	C/G	cg08523384	chr5:141488047	NDFIP1	-0.58	-5.2	-0.39	6.3e-7	Crohn's disease;
PAAD	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.15	-0.39	7.83e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.45	6.21	0.45	4.74e-9	Cardiovascular disease risk factors;
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg12143784	chr7:64541923	NA	0.34	4.32	0.33	2.78e-5	Aortic root size;
PAAD	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-8.96	-0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg14440974	chr22:39074834	NA	0.55	6.66	0.48	4.81e-10	Menopause (age at onset);
PAAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg12215294	chr3:40350768	EIF1B	-0.5	-4.98	-0.37	1.68e-6	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23996037	chr6:134142087	MGC34034	-0.55	-6.32	-0.46	2.81e-9	Obesity-related traits;
PAAD	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.83	11.3	0.68	6.95e-22	Menopause (age at onset);
PAAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.54	5.71	0.42	5.67e-8	Menopause (age at onset);
PAAD	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.37	-0.33	2.34e-5	Resting heart rate;
PAAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.53	5.68	0.42	6.51e-8	Major depressive disorder;
PAAD	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.23	9.85	0.62	5.27e-18	Alzheimer's disease (late onset);
PAAD	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	0.8	5.87	0.43	2.62e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9463078	0.617	rs9395063	chr6:45040793	T/G	cg25276700	chr6:44698697	NA	-0.52	-5.72	-0.42	5.39e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg00944433	chr1:107599041	PRMT6	0.39	4.37	0.33	2.29e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-8.38	-0.56	3.31e-14	Hemoglobin concentration;
PAAD	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-7.21	-0.5	2.39e-11	Neuroticism;
PAAD	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.3	-0.39	4.09e-7	Fear of minor pain;
PAAD	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg12183467	chr14:104352244	NA	0.34	4.35	0.33	2.51e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.52	5.58	0.41	1.1e-7	Mitral valve prolapse;
PAAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.75	-8.58	-0.57	1.05e-14	Huntington's disease progression;
PAAD	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.9	11.83	0.69	2.69e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.44	-4.67	-0.35	6.51e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg01942863	chr7:99769432	GPC2	0.47	4.4	0.34	2.02e-5	Coronary artery disease;
PAAD	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.64	4.52	0.34	1.22e-5	Mean platelet volume;
PAAD	cis	rs1359582	0.793	rs10736361	chr10:90403797	C/T	cg15661332	chr10:90342814	RNLS	-0.51	-4.53	-0.35	1.18e-5	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg05338066	chr1:7812865	CAMTA1	-0.52	-4.6	-0.35	9e-6	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.11	-0.38	9.45e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.67	-7.0	-0.49	7.57e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.78	-9.82	-0.62	6.11e-18	Morning vs. evening chronotype;
PAAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg21951975	chr1:209979733	IRF6	0.56	5.44	0.4	2.13e-7	Coronary artery disease;
PAAD	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.05e-8	Blood metabolite levels;
PAAD	trans	rs1442089	0.764	rs74506862	chr18:51140138	C/A	cg24118715	chr10:70232072	DNA2	0.75	6.42	0.46	1.63e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7904368	0.614	rs4747285	chr10:16871936	G/T	cg23933602	chr10:16859644	RSU1	0.72	5.86	0.43	2.8e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.57	6.22	0.45	4.48e-9	Longevity;Endometriosis;
PAAD	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.7	-5.1	-0.38	1.01e-6	Blood trace element (Cu levels);
PAAD	cis	rs2119480	0.927	rs11069863	chr13:111329665	T/C	cg24331049	chr13:111365604	ING1	0.67	5.4	0.4	2.48e-7	Diastolic blood pressure;
PAAD	cis	rs62120679	0.552	rs730417	chr19:2317666	T/C	cg12199618	chr19:2353492	SPPL2B	0.49	4.33	0.33	2.72e-5	Parkinson's disease;
PAAD	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg12568669	chr8:11666485	FDFT1	-0.27	-4.3	-0.33	2.99e-5	Monocyte count;
PAAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.73	10.6	0.65	5.37e-20	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.76	-0.42	4.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.72	-7.72	-0.53	1.46e-12	DNA methylation (variation);
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg08888203	chr3:10149979	C3orf24	0.89	7.41	0.52	8.24e-12	Alzheimer's disease;
PAAD	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	4.58	0.35	9.79e-6	Parkinson's disease;
PAAD	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.62	5.51	0.41	1.53e-7	Coronary heart disease;
PAAD	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.03	0.55	2.44e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.64	5.47	0.41	1.85e-7	QRS duration;
PAAD	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-5.94	-0.43	1.87e-8	Obesity (extreme);
PAAD	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg11874272	chr3:121773564	CD86	-0.42	-4.39	-0.34	2.14e-5	Multiple sclerosis;
PAAD	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.35	15.11	0.77	4.39e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs13144136	0.687	rs4235336	chr4:10663850	C/T	cg10242279	chr4:10666415	CLNK	-0.47	-5.98	-0.44	1.54e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.37	5.05	0.38	1.24e-6	Schizophrenia;
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.48	0.34	1.48e-5	Asthma;
PAAD	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6748734	0.548	rs12618707	chr2:241874559	T/C	cg26818257	chr2:241905806	NA	-0.47	-4.98	-0.37	1.69e-6	Urinary metabolites;
PAAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs4986172	0.881	rs9894577	chr17:43223292	G/A	cg10701640	chr17:43249399	NA	0.45	5.7	0.42	6.01e-8	Height;
PAAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.72	-8.84	-0.58	2.16e-15	Vitiligo;
PAAD	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg06096015	chr1:231504339	EGLN1	0.68	8.84	0.58	2.27e-15	Hemoglobin concentration;
PAAD	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs6466055	0.674	rs6967587	chr7:104744041	C/T	cg04380332	chr7:105027541	SRPK2	-0.6	-6.56	-0.47	8.13e-10	Schizophrenia;
PAAD	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg06558623	chr16:89946397	TCF25	1.36	7.1	0.5	4.51e-11	Skin colour saturation;
PAAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-5.72	-0.42	5.37e-8	Vitiligo;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.91	7.68	0.53	1.81e-12	Alzheimer's disease;
PAAD	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.73	0.36	5.06e-6	Resting heart rate;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.7	-8.13	-0.55	1.39e-13	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23666229	chr11:6633238	TAF10	-0.81	-6.85	-0.49	1.74e-10	Neuroticism;
PAAD	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.22	-9.84	-0.62	5.39e-18	Breast cancer;
PAAD	cis	rs2790216	1.000	rs2590370	chr10:60049020	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg22729335	chr19:2427816	TIMM13	1.11	14.08	0.75	2.37e-29	Cortisol levels (saliva);
PAAD	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.51	-4.85	-0.37	2.97e-6	Cognitive ability;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.69	-8.59	-0.57	9.93e-15	Educational attainment;
PAAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.82	8.0	0.54	2.99e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.37	0.46	2.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.91	7.94	0.54	4.05e-13	Alzheimer's disease;
PAAD	cis	rs6493487	0.600	rs11070841	chr15:51493967	G/A	cg21478137	chr15:51532386	CYP19A1	-0.49	-4.26	-0.33	3.57e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.5	4.99	0.37	1.66e-6	Height;
PAAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06002616	chr8:101225028	SPAG1	0.47	5.58	0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg05090351	chr10:126851162	NA	0.6	6.82	0.48	2.01e-10	Menarche (age at onset);
PAAD	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.18e-17	Resting heart rate;
PAAD	cis	rs13070279	0.655	rs13079978	chr3:71786919	A/C	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs73225842	0.702	rs7829907	chr8:22039299	T/C	cg02938601	chr8:22961088	TNFRSF10C	-0.81	-4.37	-0.33	2.34e-5	Coronary artery disease;
PAAD	cis	rs2637266	0.783	rs846640	chr10:78524293	T/C	cg18941641	chr10:78392320	NA	0.37	4.44	0.34	1.75e-5	Pulmonary function;
PAAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg15061591	chr7:98625706	SMURF1	-0.49	-4.58	-0.35	9.45e-6	Breast cancer;
PAAD	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg09237302	chr4:906077	GAK	-0.43	-4.41	-0.34	1.99e-5	Type 2 diabetes;
PAAD	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg09998033	chr7:158218633	PTPRN2	-0.76	-7.88	-0.54	5.88e-13	Obesity-related traits;
PAAD	cis	rs6594713	0.533	rs67693282	chr5:112980912	C/T	cg12552261	chr5:112820674	MCC	0.71	4.42	0.34	1.84e-5	Brain cytoarchitecture;
PAAD	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.45e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.42	-0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs59888335	0.964	rs61623958	chr3:80664090	A/T	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.2	-0.39	6.21e-7	Schizophrenia;
PAAD	cis	rs7072216	0.687	rs7907555	chr10:100155810	A/G	cg19567339	chr10:100142640	NA	-0.41	-4.3	-0.33	3.06e-5	Metabolite levels;
PAAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg22189786	chr22:42395067	WBP2NL	0.42	4.42	0.34	1.91e-5	Cognitive function;
PAAD	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.54	-5.0	-0.38	1.53e-6	Cancer;
PAAD	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.76	-5.72	-0.42	5.49e-8	Mean platelet volume;
PAAD	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs6754311	0.589	rs2011724	chr2:136818006	A/G	cg07169764	chr2:136633963	MCM6	-0.63	-6.01	-0.44	1.32e-8	Mosquito bite size;
PAAD	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.4	0.46	1.85e-9	Triglyceride levels;
PAAD	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.53	-4.79	-0.36	4e-6	HDL cholesterol;
PAAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg09002919	chr12:50339186	NA	0.59	4.56	0.35	1.05e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg16576597	chr16:28551801	NUPR1	-0.64	-6.31	-0.46	2.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02949469	chr2:219135266	PNKD;AAMP	0.66	6.79	0.48	2.38e-10	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24892241	chr6:28105103	NA	0.67	6.98	0.49	8.55e-11	Obesity-related traits;
PAAD	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	5.87	0.43	2.69e-8	Blood metabolite levels;
PAAD	cis	rs2555155	0.840	rs11040911	chr11:6551889	C/A	cg11185456	chr11:6592066	DNHD1	-0.43	-4.41	-0.34	1.94e-5	DNA methylation (variation);
PAAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg14393609	chr7:65229607	NA	-0.48	-4.9	-0.37	2.44e-6	Aortic root size;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.75	9.61	0.61	2.21e-17	Cardiovascular disease risk factors;
PAAD	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.5	-0.47	1.07e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.57	-5.52	-0.41	1.4e-7	Iron status biomarkers;
PAAD	cis	rs6142102	0.651	rs6059692	chr20:32746203	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.47	-4.64	-0.35	7.47e-6	Skin pigmentation;
PAAD	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	4.49	0.34	1.38e-5	Vitiligo;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg00280220	chr17:61926910	NA	0.42	4.52	0.34	1.25e-5	Prudent dietary pattern;
PAAD	cis	rs72960926	1.000	rs2171709	chr6:75100810	A/T	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg00700412	chr12:58011837	NA	0.44	4.73	0.36	5.17e-6	Multiple sclerosis;
PAAD	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg01362358	chr17:58117360	NA	0.38	4.33	0.33	2.72e-5	Hemoglobin concentration;
PAAD	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg15047889	chr8:124780837	FAM91A1	-0.64	-4.97	-0.37	1.78e-6	Pancreatic cancer;
PAAD	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg02072170	chr3:194406190	FAM43A	0.53	5.39	0.4	2.67e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg26138144	chr22:38071188	LGALS1	0.54	5.84	0.43	2.99e-8	Fat distribution (HIV);
PAAD	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	7.14	0.5	3.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg08029281	chr1:67600428	NA	0.46	5.15	0.39	8.02e-7	Psoriasis;
PAAD	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.99	-0.38	1.65e-6	High light scatter reticulocyte count;
PAAD	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg04315214	chr1:2043799	PRKCZ	0.4	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.57	5.83	0.43	3.26e-8	Multiple sclerosis;
PAAD	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.52	4.5	0.34	1.35e-5	Serum parathyroid hormone levels;
PAAD	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.81	5.68	0.42	6.68e-8	Blood protein levels;
PAAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg04398451	chr17:18023971	MYO15A	-0.78	-9.06	-0.59	6.08e-16	Total body bone mineral density;
PAAD	cis	rs12893597	0.580	rs12586708	chr14:76840497	C/T	cg20290672	chr14:76816747	NA	0.48	4.32	0.33	2.8e-5	Maximal oxygen uptake response;
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg09473613	chr1:24152604	HMGCL	0.54	5.61	0.41	9.36e-8	Immature fraction of reticulocytes;
PAAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.52	4.42	0.34	1.85e-5	Height;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.61	5.27	0.39	4.52e-7	Breast cancer;
PAAD	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7635838	0.819	rs2443709	chr3:11541814	C/T	cg00170343	chr3:11313890	ATG7	0.49	4.54	0.35	1.12e-5	HDL cholesterol;
PAAD	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg16341495	chr8:142228727	SLC45A4	-0.56	-5.51	-0.41	1.49e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2030114	1.000	rs7193868	chr16:51614281	A/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs11700980	0.551	rs2832047	chr21:30117970	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.23e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.68	-6.28	-0.45	3.44e-9	White matter hyperintensity burden;
PAAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.55	-5.98	-0.44	1.54e-8	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-6.45	-0.46	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs9913156	0.841	rs7223840	chr17:4562150	T/C	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14829378	chr9:33167077	B4GALT1	0.69	7.41	0.52	8.06e-12	Myopia (pathological);
PAAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.53	-0.41	1.39e-7	Atrioventricular conduction;
PAAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.3	0.39	4.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2241685	0.621	rs11127305	chr2:1902562	A/G	cg22511877	chr2:1942942	MYT1L	-0.74	-5.08	-0.38	1.11e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg10377582	chr12:51612794	POU6F1	0.45	4.96	0.37	1.83e-6	Cisplatin-induced ototoxicity;
PAAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg01851573	chr8:8652454	MFHAS1	-0.5	-4.52	-0.34	1.26e-5	Obesity-related traits;
PAAD	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg15571903	chr15:79123663	NA	-0.44	-5.74	-0.42	5.07e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17389149	chr7:55227884	EGFR	-0.65	-6.71	-0.48	3.6e-10	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.6	-6.75	-0.48	2.95e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.64	6.62	0.47	5.69e-10	Resting heart rate;
PAAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.46	-0.4	1.9e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg11441379	chr12:63026424	NA	-0.85	-6.7	-0.48	3.84e-10	IgG glycosylation;
PAAD	cis	rs818427	0.795	rs454968	chr5:112188456	T/C	cg06941702	chr5:112196734	SRP19	-0.49	-4.68	-0.35	6.43e-6	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01414886	chr20:62551784	DNAJC5	0.56	6.35	0.46	2.4e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg09640425	chr7:158790006	NA	0.52	5.13	0.38	8.84e-7	Facial morphology (factor 20);
PAAD	cis	rs375066	0.935	rs423752	chr19:44423195	G/A	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-5.53	-0.41	1.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.61	5.9	0.43	2.24e-8	Systolic blood pressure;
PAAD	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg12395012	chr8:11607386	GATA4	-0.39	-4.27	-0.33	3.37e-5	Myopia (pathological);
PAAD	cis	rs2944755	0.723	rs13273553	chr8:141588265	C/G	cg18491938	chr8:141590271	EIF2C2	-0.54	-5.02	-0.38	1.4e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1497828	0.956	rs1497833	chr1:217535580	T/G	cg04411442	chr1:217543379	NA	-0.48	-4.69	-0.36	6.12e-6	Dialysis-related mortality;
PAAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg19413350	chr8:57351067	NA	0.46	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	5.11	0.38	9.68e-7	Personality dimensions;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6496932	0.635	rs11632761	chr15:85930793	T/C	cg19183879	chr15:85880815	NA	-0.61	-5.7	-0.42	6.17e-8	Central corneal thickness;Corneal structure;
PAAD	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.49	-8.34	-0.56	4.21e-14	Mean corpuscular volume;
PAAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.03	-0.38	1.36e-6	Joint mobility (Beighton score);
PAAD	cis	rs3996993	0.597	rs62412891	chr6:52713902	C/T	cg00536792	chr6:53530503	KLHL31	-0.41	-4.5	-0.34	1.36e-5	Hemoglobin concentration;
PAAD	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.46	4.7	0.36	5.71e-6	Menopause (age at onset);
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg01763666	chr17:80159506	CCDC57	0.43	4.37	0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.61	-0.35	8.42e-6	Prevalent atrial fibrillation;
PAAD	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg23605961	chr7:751331	PRKAR1B	0.29	4.57	0.35	1e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs4946900	1.000	rs4946900	chr6:108415392	C/T	cg13435432	chr6:108489292	NR2E1	-0.41	-4.47	-0.34	1.53e-5	Major depressive disorder;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.85	9.02	0.59	7.44e-16	Prudent dietary pattern;
PAAD	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.42	-4.4	-0.34	2e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.62	-0.47	5.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg04063615	chr12:132293388	NA	0.46	4.7	0.36	5.84e-6	Migraine;
PAAD	cis	rs77880822	0.562	rs74988075	chr20:1245189	A/T	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	5.19	0.39	6.68e-7	Schizophrenia;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg06873352	chr17:61820015	STRADA	-0.56	-5.86	-0.43	2.77e-8	Height;
PAAD	cis	rs929596	0.564	rs2741042	chr2:234565917	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.35	-0.33	2.53e-5	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00231006	chr5:130599637	CDC42SE2	0.66	6.51	0.47	1.02e-9	Smoking initiation;
PAAD	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs3764400	0.508	rs2240121	chr17:46152322	T/C	cg24322968	chr17:46507895	SKAP1	0.87	5.24	0.39	5.34e-7	Body mass index;
PAAD	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg25233709	chr10:116636983	FAM160B1	0.44	5.61	0.41	9.5e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-5.23	-0.39	5.46e-7	Morning vs. evening chronotype;
PAAD	cis	rs73198271	0.628	rs11783944	chr8:8597801	A/G	cg01851573	chr8:8652454	MFHAS1	0.6	4.44	0.34	1.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg21929781	chr1:2537748	MMEL1	0.54	5.7	0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.58	-5.96	-0.44	1.68e-8	Body mass index;
PAAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.89	-10.41	-0.65	1.73e-19	IgG glycosylation;
PAAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.46	0.34	1.6e-5	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.23	-0.39	5.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.58	-5.62	-0.42	8.69e-8	Monocyte count;
PAAD	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.79	9.15	0.6	3.49e-16	Heart rate;
PAAD	cis	rs2017305	0.915	rs1058645	chr10:70776587	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.88	9.75	0.62	9.55e-18	Prudent dietary pattern;
PAAD	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.59	-5.66	-0.42	7.27e-8	Common traits (Other);
PAAD	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.7	-0.36	5.66e-6	Height;
PAAD	cis	rs1043763	0.826	rs2017594	chr12:122631208	A/C	cg26218692	chr12:122497826	BCL7A	-0.56	-5.65	-0.42	7.79e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.3	0.6	1.47e-16	Lymphocyte counts;
PAAD	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.58	-5.31	-0.4	3.85e-7	Macular telangiectasia type 2;
PAAD	cis	rs6137287	0.924	rs6047274	chr20:21135126	T/C	cg04219410	chr20:21106687	PLK1S1	0.4	4.61	0.35	8.34e-6	Height;
PAAD	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.94	12.49	0.71	4.54e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.51	0.41	1.47e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.51	-4.49	-0.34	1.4e-5	Depressive symptoms;
PAAD	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.67	-5.75	-0.42	4.63e-8	Total ventricular volume;
PAAD	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg09796270	chr17:17721594	SREBF1	0.45	4.97	0.37	1.81e-6	Total body bone mineral density;
PAAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg12072164	chr19:44306565	LYPD5	0.61	6.56	0.47	8.09e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14759740	chr20:60962311	RPS21	-0.77	-6.57	-0.47	7.66e-10	Neuroticism;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg00450029	chr8:599525	NA	-0.85	-5.6	-0.41	9.6e-8	IgG glycosylation;
PAAD	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg04330084	chr7:123175371	IQUB	0.5	4.66	0.35	6.92e-6	Migraine;
PAAD	cis	rs2190422	0.651	rs6945055	chr7:103086835	T/G	cg04218035	chr7:103086829	SLC26A5	0.35	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs7260329	0.713	rs7254579	chr19:41494891	T/C	cg23925301	chr19:41220945	ADCK4	-0.49	-4.28	-0.33	3.25e-5	Smoking behavior;
PAAD	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.67	0.35	6.51e-6	Tonsillectomy;
PAAD	cis	rs12989701	0.877	rs12994718	chr2:127874226	T/A	cg08168897	chr2:127865431	BIN1	0.68	5.9	0.43	2.26e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.75	-8.27	-0.56	6.23e-14	Inflammatory bowel disease;
PAAD	cis	rs6596100	0.538	rs17166268	chr5:132180990	C/T	cg14825688	chr5:132208181	LEAP2	0.66	4.89	0.37	2.59e-6	Breast cancer;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.57	6.08	0.44	9.08e-9	Cognitive function;
PAAD	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg23860436	chr12:58378763	NA	0.47	4.41	0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62025270	0.576	rs55639123	chr15:86160268	A/G	cg13263323	chr15:86062960	AKAP13	0.5	4.3	0.33	3.07e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.97	14.58	0.76	1.1e-30	Dental caries;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.81	5.65	0.42	7.78e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.69	6.17	0.45	5.9e-9	Response to diuretic therapy;
PAAD	cis	rs1949733	1.000	rs3103099	chr4:8511567	G/A	cg11789530	chr4:8429930	ACOX3	-0.95	-9.59	-0.61	2.54e-17	Response to antineoplastic agents;
PAAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg14180030	chr9:123475675	MEGF9	-0.45	-5.04	-0.38	1.29e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2458413	1.000	rs2458414	chr8:105355840	A/G	cg04554929	chr8:105342491	NA	0.33	5.54	0.41	1.27e-7	Paget's disease;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	6.19	0.45	5.4e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2885056	0.824	rs2360747	chr19:10693753	T/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg09709951	chr12:54017699	ATF7	0.54	4.77	0.36	4.37e-6	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12418985	chr1:145507397	RBM8A	0.61	6.8	0.48	2.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00933542	chr6:150070202	PCMT1	0.54	5.74	0.42	5.05e-8	Lung cancer;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.58	-5.97	-0.44	1.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11750568	0.902	rs12522073	chr5:178487452	T/C	cg10208897	chr5:178548229	ADAMTS2	-0.51	-4.73	-0.36	5.12e-6	Height;
PAAD	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg15914589	chr3:10206523	IRAK2	0.6	6.76	0.48	2.79e-10	Smoking initiation;
PAAD	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	trans	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg26043149	chr18:55253948	FECH	0.88	8.15	0.55	1.23e-13	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg21922841	chr17:72744131	SLC9A3R1	0.39	4.68	0.35	6.39e-6	Monocyte count;
PAAD	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg27449745	chr7:23145252	KLHL7	-0.52	-4.54	-0.35	1.14e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.77	-0.42	4.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2421770	0.731	rs3763889	chr11:35306893	G/T	cg13971030	chr11:35366721	SLC1A2	0.47	4.74	0.36	4.95e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.34	14.98	0.77	9.9e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg16205897	chr5:131564050	P4HA2	0.42	4.51	0.34	1.3e-5	Breast cancer;Mosquito bite size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08569242	chr17:66508525	PRKAR1A	0.7	7.73	0.53	1.36e-12	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18271256	chr14:23528361	ACIN1	0.64	6.66	0.48	4.66e-10	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.96	0.44	1.68e-8	Longevity;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.7	-6.99	-0.49	7.92e-11	Blood metabolite levels;
PAAD	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.82	-4.87	-0.37	2.78e-6	Alzheimer's disease (late onset);
PAAD	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg24565620	chr2:194026	NA	-0.68	-5.78	-0.42	4.02e-8	Blood protein levels;
PAAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs988913	0.706	rs4521592	chr6:54955279	A/T	cg03513858	chr6:54763001	FAM83B	-0.39	-4.32	-0.33	2.83e-5	Menarche (age at onset);
PAAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg20003494	chr4:90757398	SNCA	-0.6	-5.97	-0.44	1.65e-8	Neuroticism;
PAAD	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.42	5.24	0.39	5.39e-7	Colorectal cancer;
PAAD	cis	rs17683430	0.681	rs12159823	chr22:32563229	A/G	cg00543991	chr22:32367038	NA	0.76	5.84	0.43	3.01e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs13401104	0.680	rs72620813	chr2:237146225	C/T	cg02367144	chr2:237146137	ASB18	0.37	4.66	0.35	6.86e-6	Educational attainment;
PAAD	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.68e-7	Type 2 diabetes;
PAAD	cis	rs35000415	0.938	rs12536266	chr7:128611035	G/A	cg19972273	chr7:128594194	NA	0.97	5.64	0.42	7.88e-8	Systemic lupus erythematosus;
PAAD	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg01851573	chr8:8652454	MFHAS1	-0.47	-4.77	-0.36	4.35e-6	Mood instability;
PAAD	cis	rs988913	0.957	rs6908170	chr6:54821152	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.8	-0.36	3.7e-6	Menarche (age at onset);
PAAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06115741	chr20:33292138	TP53INP2	0.64	6.87	0.49	1.51e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs9633835	0.547	rs7949336	chr11:13319894	A/G	cg15603424	chr11:13300592	ARNTL	-0.52	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg01503450	chr10:980765	NA	-0.56	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.73	-7.64	-0.53	2.29e-12	Lewy body disease;
PAAD	cis	rs9467603	0.800	rs28360585	chr6:25790356	A/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	5.41	0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs5417	0.627	rs62059170	chr17:7155056	T/C	cg14660024	chr17:7154518	C17orf81;DULLARD	0.73	7.81	0.54	8.74e-13	Diastolic blood pressure;
PAAD	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-5.98	-0.44	1.56e-8	Bladder cancer;
PAAD	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.67	7.2	0.5	2.6e-11	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg05434287	chr7:2030229	MAD1L1	0.42	4.69	0.36	5.98e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.1	0.63	1.16e-18	Platelet count;
PAAD	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.26e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg20007245	chr22:24372913	LOC391322	-0.71	-7.03	-0.5	6.59e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg20913747	chr6:44695427	NA	-0.66	-6.53	-0.47	9.28e-10	Total body bone mineral density;
PAAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg17372223	chr3:52568218	NT5DC2	0.53	5.29	0.39	4.26e-7	Bipolar disorder;
PAAD	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg01620082	chr3:125678407	NA	-1.15	-7.73	-0.53	1.35e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.08	0.38	1.11e-6	Breast cancer;
PAAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.41	-0.4	2.39e-7	Glaucoma (primary open-angle);
PAAD	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.7	10.0	0.63	2.03e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.28e-7	Diabetic kidney disease;
PAAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.32	0.33	2.83e-5	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13530621	chr13:20735337	GJA3	-0.68	-6.82	-0.48	2.04e-10	Smoking initiation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12159575	chr19:4910274	UHRF1	0.63	6.53	0.47	9.22e-10	Myopia (pathological);
PAAD	cis	rs6442522	0.673	rs7628975	chr3:15502130	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-5.25	-0.39	5.09e-7	Uric acid levels;
PAAD	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.64	6.04	0.44	1.14e-8	Serum parathyroid hormone levels;
PAAD	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.85	10.21	0.64	5.66e-19	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.9	0.37	2.42e-6	Breast cancer;
PAAD	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.36	0.4	3.02e-7	Rheumatoid arthritis;
PAAD	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-6.62	-0.47	5.83e-10	Monocyte percentage of white cells;
PAAD	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.44	4.48	0.34	1.43e-5	Testicular germ cell tumor;
PAAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs9463078	0.528	rs12214778	chr6:44924412	A/G	cg18551225	chr6:44695536	NA	-0.41	-4.32	-0.33	2.83e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.53	5.42	0.4	2.32e-7	Interleukin-18 levels;
PAAD	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.77	6.17	0.45	5.92e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs939584	1.000	rs2867122	chr2:624581	A/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	trans	rs901683	0.702	rs113478021	chr10:46063563	C/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-5.34	-0.4	3.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.51	0.41	1.53e-7	Prudent dietary pattern;
PAAD	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.68	0.35	6.38e-6	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7104764	0.778	rs7930823	chr11:206767	C/T	cg25796445	chr11:207425	RIC8A;BET1L	0.53	4.93	0.37	2.14e-6	Menarche (age at onset);
PAAD	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg06219351	chr7:158114137	PTPRN2	-0.82	-7.51	-0.52	4.66e-12	Response to amphetamines;
PAAD	cis	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg20159608	chr7:32802032	NA	-0.53	-5.23	-0.39	5.55e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg01090926	chr14:75137805	KIAA0317	-0.52	-4.74	-0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14169450	chr9:139327907	INPP5E	0.56	5.92	0.43	2.02e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12989701	1.000	rs12989701	chr2:127887985	C/A	cg08168897	chr2:127865431	BIN1	0.64	5.15	0.39	8.01e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9283706	0.608	rs10065036	chr5:66338084	G/A	cg11590213	chr5:66331682	MAST4	0.62	4.93	0.37	2.15e-6	Coronary artery disease;
PAAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg26138144	chr22:38071188	LGALS1	0.51	5.57	0.41	1.12e-7	Fat distribution (HIV);
PAAD	cis	rs1678542	1.000	rs11172254	chr12:57968738	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.33	-0.4	3.57e-7	Rheumatoid arthritis;
PAAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17554472	chr22:41940697	POLR3H	0.61	4.38	0.33	2.22e-5	Vitiligo;
PAAD	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg07506560	chr2:240697449	NA	0.62	6.28	0.45	3.45e-9	Obesity-related traits;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.62	6.32	0.46	2.72e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.62	-6.94	-0.49	1.07e-10	Platelet distribution width;
PAAD	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.57	4.99	0.38	1.65e-6	Common traits (Other);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14185801	chr12:124915185	NCOR2	-0.58	-6.57	-0.47	7.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.97	0.54	3.6e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14019695	chr9:139328340	INPP5E	0.6	5.17	0.39	7.26e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-0.7	-5.49	-0.41	1.66e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.85e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.96	-7.16	-0.5	3.24e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs597583	0.575	rs35200015	chr11:117383215	G/A	cg27161313	chr11:117392002	DSCAML1	-0.56	-4.53	-0.35	1.16e-5	Putamen volume;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26926768	chr12:34528122	NA	0.36	4.27	0.33	3.5e-5	Morning vs. evening chronotype;
PAAD	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.67	6.94	0.49	1.09e-10	Schizophrenia;
PAAD	cis	rs4938573	0.526	rs11216973	chr11:118587001	T/C	cg08498647	chr11:118550644	TREH	0.41	4.37	0.33	2.33e-5	Follicular lymphoma;
PAAD	cis	rs9652601	0.691	rs12708717	chr16:11192379	G/C	cg04616529	chr16:11181986	CLEC16A	0.38	4.57	0.35	1.01e-5	Systemic lupus erythematosus;
PAAD	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-0.93	-6.19	-0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.61	-5.57	-0.41	1.11e-7	Mean corpuscular volume;
PAAD	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg19781863	chr12:62918364	MON2	-0.73	-4.33	-0.33	2.68e-5	IgG glycosylation;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.68	-0.36	6.24e-6	Breast cancer;
PAAD	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15340874	chr1:174969621	CACYBP	0.66	7.12	0.5	4.04e-11	Myopia (pathological);
PAAD	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.82	5.25	0.39	4.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.5	4.94	0.37	2.01e-6	Type 2 diabetes;
PAAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14342823	chr17:10584091	SCO1	-0.73	-7.77	-0.53	1.06e-12	Obesity-related traits;
PAAD	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg10820045	chr2:198174542	NA	0.55	5.71	0.42	5.64e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-5.5	-0.41	1.58e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg08308459	chr2:38893161	GALM	0.63	4.26	0.33	3.52e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs12136530	0.593	rs2314145	chr1:19736843	C/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.81	-8.69	-0.58	5.54e-15	Body mass index;
PAAD	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs59104589	0.583	rs62186377	chr2:242211450	A/G	cg04488487	chr2:242709673	NA	0.57	4.29	0.33	3.16e-5	Fibrinogen levels;
PAAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.69	-8.16	-0.55	1.2e-13	Huntington's disease progression;
PAAD	cis	rs7873102	0.654	rs4878729	chr9:37998489	A/G	cg03528946	chr9:38069800	SHB	-0.51	-5.14	-0.38	8.49e-7	Brain structure;
PAAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.71	7.67	0.53	1.86e-12	Schizophrenia;
PAAD	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-4.8	-0.36	3.81e-6	Daytime sleep phenotypes;
PAAD	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg09654669	chr8:57350985	NA	-0.52	-4.49	-0.34	1.37e-5	Obesity-related traits;
PAAD	cis	rs757081	0.648	rs11024223	chr11:17277693	A/T	cg15432903	chr11:17409602	KCNJ11	0.57	5.83	0.43	3.17e-8	Systolic blood pressure;
PAAD	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.96	13.89	0.75	7.82e-29	Intelligence (multi-trait analysis);
PAAD	cis	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg21546286	chr11:48923668	NA	-0.47	-4.93	-0.37	2.14e-6	Coronary artery disease;
PAAD	cis	rs427941	0.694	rs2529094	chr7:101739617	C/T	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs727479	0.502	rs4774583	chr15:51505993	A/G	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.55e-5	Estradiol levels;
PAAD	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.34	-0.33	2.55e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2882667	0.690	rs288026	chr5:138222594	A/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.75	5.92	0.43	2.05e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11761408	0.585	rs28479319	chr7:5259199	G/A	cg02820836	chr7:4652842	NA	-0.72	-4.35	-0.33	2.52e-5	Mean corpuscular volume;
PAAD	cis	rs797680	0.856	rs7540025	chr1:93759228	C/T	cg04535902	chr1:92947332	GFI1	-0.45	-4.46	-0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Dermatomyositis;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.49	-5.78	-0.42	4.1e-8	Iron status biomarkers;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.2	0.45	5.21e-9	Lung cancer;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02071572	chr4:1403502	NA	0.41	5.72	0.42	5.5e-8	Obesity-related traits;
PAAD	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.54	5.17	0.39	7.24e-7	Mortality in heart failure;
PAAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-7.22	-0.51	2.33e-11	Vitiligo;
PAAD	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg09127314	chr1:152161683	NA	-0.61	-4.26	-0.33	3.53e-5	Atopic dermatitis;
PAAD	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.47	-4.86	-0.37	2.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg01612440	chr4:3296283	NA	0.43	4.33	0.33	2.69e-5	Serum sulfate level;
PAAD	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.94	0.37	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg14343924	chr8:8086146	FLJ10661	0.55	4.94	0.37	2.01e-6	Mood instability;
PAAD	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	4.31	0.33	2.86e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7264396	0.943	rs11167267	chr20:34109273	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.85	-0.43	2.91e-8	Total cholesterol levels;
PAAD	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.9	5.89	0.43	2.36e-8	Major depressive disorder;
PAAD	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg26174226	chr8:58114915	NA	-0.67	-4.78	-0.36	4.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.71	6.4	0.46	1.79e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg21770322	chr7:97807741	LMTK2	0.51	7.24	0.51	2.11e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.55	6.14	0.45	6.96e-9	Cognitive function;
PAAD	cis	rs7264396	0.887	rs3818441	chr20:34046501	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs4790333	0.571	rs2012068	chr17:2255351	C/T	cg02569219	chr17:2266849	SGSM2	0.51	4.77	0.36	4.2e-6	Proinsulin levels;
PAAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.67	7.55	0.52	3.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.74	-8.46	-0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.6	5.53	0.41	1.34e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.75	8.1	0.55	1.7e-13	Obesity-related traits;
PAAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg10591111	chr5:226296	SDHA	-0.66	-5.22	-0.39	5.78e-7	Breast cancer;
PAAD	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.51	-0.41	1.52e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	4.85	0.37	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg15212455	chr7:39170539	POU6F2	0.41	5.64	0.42	7.91e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8170	0.603	rs4808621	chr19:17414267	C/T	cg04749549	chr19:17459798	NA	-0.45	-4.85	-0.37	3.02e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.52	-5.45	-0.4	1.98e-7	Mitral valve prolapse;
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg00717180	chr2:96193071	NA	-0.62	-7.41	-0.52	8.33e-12	Height;
PAAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg24675658	chr1:53192096	ZYG11B	0.68	6.61	0.47	6.27e-10	Monocyte count;
PAAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg23283495	chr1:209979779	IRF6	-0.62	-5.72	-0.42	5.37e-8	Coronary artery disease;
PAAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00982548	chr2:198649783	BOLL	-0.83	-5.87	-0.43	2.67e-8	Ulcerative colitis;
PAAD	cis	rs259282	0.560	rs4805786	chr19:33120265	T/C	cg02997394	chr19:33096574	ANKRD27	-0.45	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	5.78	0.42	4.05e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg20406979	chr6:167373233	NA	0.37	4.82	0.36	3.51e-6	Crohn's disease;
PAAD	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.74	6.99	0.49	8.14e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg26174226	chr8:58114915	NA	-0.68	-6.08	-0.44	9.38e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.65	0.53	2.11e-12	Systolic blood pressure;
PAAD	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	1.03	9.88	0.63	4.31e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs41308713	0.606	rs77984335	chr20:37073286	G/A	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.16	5.72	0.42	5.44e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg00717180	chr2:96193071	NA	-0.66	-8.15	-0.55	1.25e-13	Height;
PAAD	cis	rs12612619	0.732	rs11897106	chr2:27196299	A/G	cg00617064	chr2:27272375	NA	0.49	5.34	0.4	3.35e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.83	9.54	0.61	3.4e-17	Ulcerative colitis;
PAAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg24110177	chr3:50126178	RBM5	-0.56	-5.49	-0.41	1.65e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.62	-6.26	-0.45	3.77e-9	Iron status biomarkers;
PAAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.95	0.37	1.92e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03676636	chr4:99064102	C4orf37	-0.34	-6.18	-0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.83	0.48	1.89e-10	Coronary artery disease;
PAAD	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.07	-0.38	1.15e-6	Interstitial lung disease;
PAAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06217245	chr20:33103252	DYNLRB1	0.35	4.26	0.33	3.56e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs877426	0.609	rs56287057	chr13:114829267	C/A	cg00571178	chr13:114841904	RASA3	-0.58	-4.96	-0.37	1.84e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg23920097	chr1:209922102	NA	-0.44	-4.27	-0.33	3.38e-5	Red blood cell count;
PAAD	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-6.94	-0.49	1.04e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.74	-8.81	-0.58	2.6e-15	Body mass index;
PAAD	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg21605333	chr4:119757512	SEC24D	1.94	10.25	0.64	4.46e-19	Cannabis dependence symptom count;
PAAD	cis	rs6693295	0.536	rs59080925	chr1:246221360	C/G	cg11798871	chr1:246315928	SMYD3	-0.79	-5.71	-0.42	5.86e-8	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.77	-6.24	-0.45	4.21e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.55	5.95	0.43	1.8e-8	Bladder cancer;
PAAD	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg18404041	chr3:52824283	ITIH1	-0.6	-6.85	-0.49	1.74e-10	Bipolar disorder;
PAAD	cis	rs9659323	0.632	rs10923743	chr1:119612632	C/T	cg17326555	chr1:119535693	NA	-0.38	-5.38	-0.4	2.76e-7	Body mass index;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	1.18	13.24	0.73	4.29e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-5.13	-0.38	8.56e-7	Bladder cancer;
PAAD	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.57	5.42	0.4	2.32e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.7	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	trans	rs9409082	0.798	rs35627296	chr9:108925899	G/A	cg07010948	chr13:79181613	NA	-0.35	-6.47	-0.46	1.29e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.5	-5.22	-0.39	5.71e-7	Verbal declarative memory;
PAAD	cis	rs4834770	0.792	rs6823331	chr4:120180790	T/C	cg09307838	chr4:120376055	NA	0.55	5.13	0.38	8.75e-7	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02796405	chr4:78739402	CNOT6L	0.64	7.3	0.51	1.47e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.33	-0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg02135003	chr7:105160482	PUS7	-0.69	-6.34	-0.46	2.44e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.25	-0.39	5.04e-7	Lung cancer;
PAAD	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-5.72	-0.42	5.55e-8	Educational attainment;
PAAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	cis	rs55728055	0.661	rs16989635	chr22:31847912	A/C	cg01338084	chr22:32026380	PISD	1.4	7.05	0.5	5.87e-11	Age-related hearing impairment;
PAAD	cis	rs1042026	0.848	rs4699738	chr4:100175530	C/T	cg09112717	chr4:100009950	ADH5	-0.52	-4.61	-0.35	8.52e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.54	5.16	0.39	7.45e-7	Platelet count;
PAAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg00459043	chr17:30771460	PSMD11	-0.56	-4.58	-0.35	9.61e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg27494647	chr7:150038898	RARRES2	0.45	4.91	0.37	2.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7260598	0.539	rs57417281	chr19:24060770	G/A	cg09235885	chr19:23456588	NA	-0.64	-4.29	-0.33	3.15e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	1.0	12.47	0.71	4.98e-25	Breast cancer;
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.7	-7.46	-0.52	6.34e-12	Blood metabolite levels;
PAAD	cis	rs59888335	0.858	rs13076655	chr3:80920612	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2016586	0.929	rs5999960	chr22:36105267	T/A	cg26342177	chr22:36113512	APOL5	-0.49	-4.93	-0.37	2.14e-6	Body mass index;
PAAD	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.51e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.86	-9.98	-0.63	2.4e-18	Ulcerative colitis;
PAAD	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.29	0.51	1.56e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg25614726	chr1:10490058	APITD1	0.36	4.27	0.33	3.41e-5	Prostate cancer;
PAAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.6	5.36	0.4	2.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.74	-0.36	4.84e-6	Body mass index;
PAAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	trans	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg26501369	chr6:133561814	EYA4	-0.85	-6.54	-0.47	8.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.51	4.68	0.36	6.17e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.41	-4.75	-0.36	4.67e-6	Metabolic traits;
PAAD	cis	rs9663711	1	rs9663711	chr10:104547628	C/A	cg04362960	chr10:104952993	NT5C2	0.59	6.02	0.44	1.25e-8	Carotid plaque burden;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14096962	chr3:58419817	PDHB	0.66	6.44	0.46	1.45e-9	Obesity-related traits;
PAAD	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.43	4.84	0.37	3.11e-6	Refractive error;
PAAD	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg00540400	chr15:79124168	NA	-0.55	-6.47	-0.46	1.26e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs227833	1.000	rs227833	chr6:44681840	G/C	cg20913747	chr6:44695427	NA	0.57	5.98	0.44	1.57e-8	Monobrow;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-5.83	-0.43	3.2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12773846	0.506	rs2885518	chr10:126275049	C/T	cg04949429	chr10:126290192	LHPP	0.62	5.41	0.4	2.36e-7	Subcutaneous adipose tissue;
PAAD	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg14191688	chr11:70257035	CTTN	0.57	4.3	0.33	3.05e-5	Coronary artery disease;
PAAD	cis	rs7301016	1.000	rs10877855	chr12:62870510	C/G	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24897291	chr6:136910199	MAP3K5	-0.67	-7.17	-0.5	3.06e-11	Obesity-related traits;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.62	-6.01	-0.44	1.32e-8	Resistin levels;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.81	-0.36	3.62e-6	Height;
PAAD	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg00450029	chr8:599525	NA	-0.85	-5.6	-0.41	9.6e-8	IgG glycosylation;
PAAD	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg23112188	chr14:24563095	PCK2	-0.5	-5.54	-0.41	1.31e-7	IgG glycosylation;
PAAD	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg05585544	chr11:47624801	NA	0.47	5.19	0.39	6.76e-7	Subjective well-being;
PAAD	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.47	-5.87	-0.43	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg01329690	chr21:38580129	DSCR9	-0.33	-4.46	-0.34	1.55e-5	Eye color traits;
PAAD	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	6.79	0.48	2.32e-10	Mean platelet volume;
PAAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.73	6.42	0.46	1.66e-9	Dilated cardiomyopathy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10757852	chr3:141319363	RASA2	-0.65	-6.53	-0.47	9.32e-10	Smoking initiation;
PAAD	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg12568669	chr8:11666485	FDFT1	0.29	4.81	0.36	3.53e-6	Retinal vascular caliber;
PAAD	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.14e-15	Prostate cancer;
PAAD	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg23024343	chr7:107201750	COG5	0.56	4.55	0.35	1.11e-5	Osteoarthritis;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.94	-16.21	-0.8	5.95e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.63	6.71	0.48	3.66e-10	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18898632	chr2:242989856	NA	-0.75	-5.46	-0.4	1.91e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.5	-4.94	-0.37	2.02e-6	Menopause (age at onset);
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	1.01	6.9	0.49	1.35e-10	IgG glycosylation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13252710	chr13:20134915	NA	-0.66	-7.22	-0.51	2.27e-11	Myopia (pathological);
PAAD	cis	rs7534824	0.625	rs12569251	chr1:101372040	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21545522	chr1:205238299	TMCC2	0.47	4.33	0.33	2.75e-5	Red blood cell count;
PAAD	cis	rs10799599	0.585	rs12733637	chr1:20288255	A/G	cg14477205	chr1:20817076	NA	-0.4	-4.25	-0.33	3.69e-5	Immunoglobulin light chain (AL) amyloidosis;
PAAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs1043763	0.826	rs73217773	chr12:122513322	T/A	cg26218692	chr12:122497826	BCL7A	-0.58	-5.35	-0.4	3.17e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-6.62	-0.47	5.71e-10	Lymphocyte counts;
PAAD	cis	rs863345	0.604	rs950260	chr1:158491520	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg08999081	chr20:33150536	PIGU	-0.53	-5.86	-0.43	2.81e-8	Height;
PAAD	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.85	9.62	0.62	2.06e-17	Resting heart rate;
PAAD	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg00864860	chr1:7907996	UTS2	-0.57	-4.9	-0.37	2.48e-6	Crohn's disease;
PAAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg09654669	chr8:57350985	NA	-0.53	-5.0	-0.38	1.54e-6	Obesity-related traits;
PAAD	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	8.45	0.57	2.24e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs6500395	0.584	rs1345433	chr16:48738222	A/G	cg04672837	chr16:48644449	N4BP1	0.56	4.5	0.34	1.34e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs72960926	1.000	rs11751231	chr6:75138811	T/C	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	trans	rs9217	1.000	rs9217	chr17:7363088	T/C	cg08566640	chr11:64091735	NA	-0.6	-6.68	-0.48	4.2e-10	Height;
PAAD	cis	rs1371614	0.502	rs4572551	chr2:27194013	T/C	cg00617064	chr2:27272375	NA	-0.48	-5.06	-0.38	1.2e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	1.04	7.16	0.5	3.14e-11	IgG glycosylation;
PAAD	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.42	4.86	0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.24	-0.6	2.03e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1468333	1.000	rs17171767	chr5:137493528	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.59	-6.29	-0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg20893579	chr22:38215064	NA	0.51	4.74	0.36	4.94e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.98	11.53	0.68	1.66e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.93	10.16	0.64	7.67e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08651674	chr6:7108441	RREB1	0.58	6.47	0.46	1.29e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.43	4.39	0.34	2.14e-5	Red cell distribution width;
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg03264133	chr6:25882463	NA	-0.47	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs1109114	0.738	rs2289283	chr5:148621805	C/T	cg06539116	chr5:148597365	ABLIM3	0.35	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg15192750	chr16:69999425	NA	0.62	4.8	0.36	3.83e-6	IgE levels;
PAAD	cis	rs847851	1.000	rs2473615	chr6:34893910	C/G	cg05379947	chr6:35436047	RPL10A	0.52	4.32	0.33	2.76e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.23	-0.7	2.18e-24	Urate levels in overweight individuals;
PAAD	cis	rs72827839	0.740	rs72825548	chr17:46231108	A/G	cg23391107	chr17:45924227	SP6	0.62	5.31	0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg18489755	chr3:183533873	MAP6D1	0.35	4.33	0.33	2.75e-5	Anterior chamber depth;
PAAD	cis	rs4460308	1.000	rs4460308	chr7:104420060	C/T	cg10575219	chr7:105313992	ATXN7L1	0.44	4.45	0.34	1.62e-5	Social communication problems;
PAAD	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.38	-0.33	2.21e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.47	-0.41	1.84e-7	Neuroticism;
PAAD	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg18721089	chr20:30220636	NA	-0.61	-5.04	-0.38	1.3e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.56	5.3	0.39	4.07e-7	Neuroticism;
PAAD	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	1.09	15.49	0.78	4.38e-33	Caffeine consumption;
PAAD	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.65	0.35	7.04e-6	Height;
PAAD	cis	rs11203032	1.000	rs11203033	chr10:90964731	C/G	cg16672925	chr10:90967113	CH25H	-0.78	-5.94	-0.43	1.84e-8	Heart failure;
PAAD	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg01966878	chr4:90757139	SNCA	-0.47	-4.43	-0.34	1.76e-5	Dementia with Lewy bodies;
PAAD	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg01244601	chr4:120671846	NA	-0.5	-4.4	-0.34	2.06e-5	Corneal astigmatism;
PAAD	trans	rs6946969	0.597	rs6460553	chr7:70215224	A/C	cg05384198	chr9:101016191	TBC1D2	-0.68	-6.43	-0.46	1.55e-9	Motion sickness;
PAAD	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg11783602	chr8:55087084	NA	-0.45	-4.62	-0.35	8.21e-6	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg10547527	chr2:198650123	BOLL	-0.72	-5.04	-0.38	1.33e-6	Ulcerative colitis;
PAAD	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.84	-0.43	3.03e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg12037450	chr1:85513124	MCOLN3	-0.48	-4.37	-0.33	2.3e-5	Serum sulfate level;
PAAD	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.68	-7.07	-0.5	5.24e-11	Leprosy;
PAAD	cis	rs12714314	0.914	rs12986730	chr2:1959401	G/A	cg22350835	chr2:1868857	MYT1L	0.46	4.82	0.36	3.48e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.51	4.75	0.36	4.75e-6	Height;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.75	-7.87	-0.54	6.26e-13	Paraoxonase activity;
PAAD	cis	rs2415984	0.600	rs2084823	chr14:46966454	C/G	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs6715793	0.901	rs6543699	chr2:33403002	G/A	cg26672287	chr2:33391915	LTBP1	-0.42	-4.77	-0.36	4.29e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-4.77	-0.36	4.25e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.49	6.85	0.49	1.68e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs9880772	0.711	rs4522733	chr3:27807006	C/T	cg21473142	chr3:27762095	EOMES	0.35	6.43	0.46	1.6e-9	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	6.69	0.48	4.06e-10	Height;
PAAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.14	0.55	1.35e-13	Schizophrenia;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.69	-7.11	-0.5	4.14e-11	Menopause (age at onset);
PAAD	cis	rs12760731	0.668	rs4573483	chr1:178268075	C/A	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	trans	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg01620082	chr3:125678407	NA	1.1	6.38	0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.73	-9.16	-0.6	3.34e-16	Educational attainment;
PAAD	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg21937377	chr3:194868750	C3orf21	0.46	4.85	0.37	2.97e-6	Non-small cell lung cancer;
PAAD	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.76	0.36	4.42e-6	Axial length;
PAAD	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg13397359	chr6:42928475	GNMT	0.59	4.78	0.36	4.03e-6	Blood protein levels;
PAAD	cis	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.75	8.58	0.57	1.01e-14	Age-related hearing impairment;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.33	0.33	2.72e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.59	-6.31	-0.46	2.86e-9	Mitral valve prolapse;
PAAD	cis	rs10792830	0.832	rs583162	chr11:85813817	A/G	cg07180834	chr11:85838833	NA	-0.59	-7.26	-0.51	1.9e-11	Psychosis and Alzheimer's disease;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.92	0.37	2.22e-6	Vitiligo;
PAAD	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-5.76	-0.42	4.48e-8	Neuroticism;
PAAD	cis	rs35084382	1.000	rs17658229	chr5:172191052	T/C	cg19801141	chr5:172198162	DUSP1	1.42	6.58	0.47	7.35e-10	Optic cup area;
PAAD	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.7	7.18	0.5	2.86e-11	Morning vs. evening chronotype;
PAAD	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.72	-8.5	-0.57	1.64e-14	Dental caries;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.5	-4.67	-0.35	6.45e-6	Monocyte count;
PAAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.79	-8.4	-0.56	2.92e-14	Systemic sclerosis;
PAAD	cis	rs1497828	1.000	rs2646810	chr1:217523112	A/G	cg04411442	chr1:217543379	NA	-0.45	-4.46	-0.34	1.56e-5	Dialysis-related mortality;
PAAD	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg20913747	chr6:44695427	NA	-0.67	-6.77	-0.48	2.63e-10	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.73	7.1	0.5	4.56e-11	Asthma;
PAAD	cis	rs2221894	1.000	rs6558084	chr8:28757632	A/G	cg20212339	chr8:28908912	HMBOX1	0.5	5.22	0.39	5.75e-7	Obesity-related traits;
PAAD	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.98	10.36	0.64	2.37e-19	Platelet distribution width;
PAAD	cis	rs501120	0.584	rs7086639	chr10:44698695	C/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg24881330	chr22:46731750	TRMU	1.09	5.75	0.42	4.76e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.27	0.45	3.55e-9	Bladder cancer;
PAAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg23281280	chr6:28129359	ZNF389	0.53	4.72	0.36	5.36e-6	Parkinson's disease;
PAAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.68	5.31	0.4	3.77e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.45	5.1	0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	1.54	9.51	0.61	4.03e-17	Age-related hearing impairment;
PAAD	cis	rs11159840	0.510	rs7161182	chr14:88541964	C/G	cg18078958	chr14:88630771	NA	-0.39	-4.3	-0.33	3.1e-5	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg12661370	chr5:149340060	SLC26A2	-0.69	-5.81	-0.43	3.47e-8	HIV-1 control;
PAAD	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.82	5.38	0.4	2.81e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.68	-9.51	-0.61	4.13e-17	Breast cancer;
PAAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs1075232	1.000	rs9672214	chr15:31677775	A/T	cg06530883	chr15:30699977	NA	1.06	4.61	0.35	8.56e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.7	-5.89	-0.43	2.39e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12476592	0.530	rs79284842	chr2:64240519	C/A	cg10828910	chr2:63850056	LOC388955	-0.51	-4.27	-0.33	3.36e-5	Childhood ear infection;
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.8	6.22	0.45	4.6e-9	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05796909	chr17:7465070	SENP3	0.66	7.38	0.51	9.43e-12	Myopia (pathological);
PAAD	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-1.02	-10.08	-0.63	1.25e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-5.16	-0.39	7.76e-7	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00180909	chr6:166824474	RPS6KA2	0.52	6.49	0.47	1.16e-9	Body fat percentage;
PAAD	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24110177	chr3:50126178	RBM5	-0.61	-6.86	-0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.5	-4.47	-0.34	1.52e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2882667	0.690	rs1627698	chr5:138077466	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.92	-0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs747650	0.504	rs7124648	chr11:47044249	T/C	cg19486271	chr11:47235900	DDB2	-0.67	-6.2	-0.45	5.16e-9	Acne (severe);
PAAD	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs300774	0.748	rs413523	chr2:131203	C/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	trans	rs61677309	1.000	rs7110019	chr11:118168617	A/G	cg15548380	chr1:19984784	NBL1	-0.61	-6.42	-0.46	1.62e-9	Lung cancer in ever smokers;
PAAD	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg15017067	chr4:17643749	FAM184B	0.41	4.82	0.36	3.46e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs807669	0.527	rs11089259	chr22:19190143	C/T	cg02655711	chr22:19163373	SLC25A1	0.86	11.49	0.68	2.12e-22	Metabolite levels;
PAAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.75	0.36	4.68e-6	Breast cancer;
PAAD	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07639963	chr12:77157760	ZDHHC17	0.68	7.33	0.51	1.3e-11	Myopia (pathological);
PAAD	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.05	-0.38	1.26e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20295408	chr7:1910781	MAD1L1	-0.53	-4.98	-0.37	1.68e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs3126085	0.560	rs3120667	chr1:152318161	A/G	cg26876637	chr1:152193138	HRNR	-0.73	-5.56	-0.41	1.19e-7	Atopic dermatitis;
PAAD	cis	rs732765	0.734	rs12323528	chr14:75152068	G/T	cg17347104	chr14:75034677	LTBP2	0.55	4.81	0.36	3.65e-6	Non-small cell lung cancer;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.64	-8.25	-0.56	6.81e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg10494973	chr17:80897199	TBCD	-0.51	-4.62	-0.35	8.2e-6	Breast cancer;
PAAD	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs372883	0.509	rs28462110	chr21:30544318	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-4.7	-0.36	5.89e-6	Pancreatic cancer;
PAAD	cis	rs9287719	0.601	rs62128635	chr2:10725334	G/C	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.51	4.95	0.37	1.92e-6	High light scatter reticulocyte count;
PAAD	cis	rs9914578	1.000	rs9914577	chr17:2005130	C/T	cg16513277	chr17:2031491	SMG6	-0.59	-5.35	-0.4	3.23e-7	Body mass index;
PAAD	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.52	5.02	0.38	1.41e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg15049549	chr3:48732213	IP6K2	0.48	4.26	0.33	3.58e-5	Cognitive function;
PAAD	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.82	7.66	0.53	2.04e-12	Colorectal cancer;
PAAD	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06850241	chr22:41845214	NA	0.53	5.08	0.38	1.11e-6	Vitiligo;
PAAD	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.32	-4.51	-0.34	1.27e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg09168692	chr1:7887560	PER3	0.41	4.25	0.33	3.72e-5	Inflammatory bowel disease;
PAAD	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.37	4.44	0.34	1.72e-5	Pulmonary function;
PAAD	cis	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.31	-0.33	2.97e-5	Neuroticism;
PAAD	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	2.99e-5	Tuberculosis;
PAAD	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.56	-5.3	-0.39	4.09e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.57	0.41	1.15e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs508970	0.556	rs677303	chr11:60924738	T/C	cg03055440	chr11:59950405	MS4A6A	-0.41	-4.34	-0.33	2.64e-5	Rheumatoid arthritis;
PAAD	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.54	5.51	0.41	1.49e-7	Testicular germ cell tumor;
PAAD	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs10901513	0.861	rs10901504	chr10:127685570	A/G	cg22975853	chr10:127789788	ADAM12	0.43	4.58	0.35	9.51e-6	Visceral fat;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.52	4.7	0.36	5.89e-6	Lung cancer;
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26549601	chr10:134560360	INPP5A	-0.49	-4.76	-0.36	4.43e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4750440	0.642	rs7921741	chr10:14030776	G/A	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.26	-0.33	3.53e-5	Adiponectin levels;
PAAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg20913747	chr6:44695427	NA	-0.63	-6.55	-0.47	8.27e-10	Total body bone mineral density;
PAAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.5	0.34	1.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16351318	chr13:113642709	MCF2L	0.54	6.78	0.48	2.44e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.74	0.42	5e-8	Prudent dietary pattern;
PAAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.95	-0.37	1.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.6	-0.47	6.4e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00125455	chr20:44574271	PCIF1	-0.42	-4.43	-0.34	1.82e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs1497828	0.913	rs1032599	chr1:217548568	T/A	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-9.71	-0.62	1.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10849893	0.538	rs4980994	chr12:121919295	G/A	cg01154721	chr12:121881891	KDM2B	0.52	4.86	0.37	2.92e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs3745621	0.925	rs309182	chr19:47662716	C/G	cg24326880	chr19:47634349	SAE1	0.59	4.89	0.37	2.58e-6	Lymphocyte counts;
PAAD	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg04117972	chr1:227635322	NA	0.73	4.86	0.37	2.84e-6	Major depressive disorder;
PAAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	9.97	0.63	2.58e-18	Platelet count;
PAAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.47e-6	White blood cell count;
PAAD	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.59	6.61	0.47	6.08e-10	Carotid intima media thickness;
PAAD	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-1.0	-8.61	-0.57	8.86e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg16602846	chr15:78114278	NA	0.41	4.49	0.34	1.39e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.71	0.36	5.43e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.53	5.46	0.41	1.89e-7	Corneal astigmatism;
PAAD	cis	rs11264213	0.901	rs653417	chr1:36356842	G/T	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.81	-8.68	-0.58	5.56e-15	Mortality in heart failure;
PAAD	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.81	8.18	0.55	1.03e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs669446	0.562	rs304303	chr1:44178070	T/G	cg12908607	chr1:44402522	ARTN	-0.42	-4.32	-0.33	2.78e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-5.35	-0.4	3.23e-7	Monocyte percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16782613	chr7:44058922	POLR2J4	-0.57	-6.5	-0.47	1.09e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs1903068	0.853	rs28411232	chr4:56000009	A/T	cg09978860	chr4:56023921	NA	0.41	4.45	0.34	1.67e-5	Endometriosis;
PAAD	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20087917	chr14:77924039	C14orf133;AHSA1	0.57	6.33	0.46	2.56e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4148087	1.000	rs8126971	chr21:43636412	C/T	cg08841829	chr21:43638893	ABCG1	-0.72	-4.87	-0.37	2.79e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.76	7.2	0.5	2.55e-11	Response to hepatitis C treatment;
PAAD	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-5.66	-0.42	7.27e-8	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14568749	chr10:5499025	NET1	0.61	6.43	0.46	1.53e-9	Smoking initiation;
PAAD	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg13918804	chr1:2043761	PRKCZ	-0.39	-5.23	-0.39	5.56e-7	Height;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.74	-0.48	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.55	4.65	0.35	7.15e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15676125	chr6:33679581	C6orf125	0.65	7.02	0.49	6.84e-11	Myopia (pathological);
PAAD	cis	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.89	0.43	2.41e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.42	-0.34	1.85e-5	Dupuytren's disease;
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.99	13.36	0.73	1.98e-27	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.91	0.54	4.79e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg13388692	chr1:86081680	NA	0.77	6.69	0.48	4.03e-10	Photic sneeze reflex;
PAAD	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07362569	chr17:61921086	SMARCD2	-0.64	-7.96	-0.54	3.68e-13	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08719139	chr16:57223804	RSPRY1	-0.56	-6.41	-0.46	1.69e-9	Monocyte percentage of white cells;
PAAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs12304921	1.000	rs76604840	chr12:51376494	A/G	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.34	-0.33	2.55e-5	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26554170	chr1:227968812	SNAP47	-0.63	-6.66	-0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.61	0.47	6.09e-10	High light scatter reticulocyte count;
PAAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	4.76	0.36	4.39e-6	Coronary artery disease;
PAAD	cis	rs6700896	0.500	rs12130476	chr1:66124850	G/C	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.7e-6	Testicular germ cell tumor;
PAAD	cis	rs818427	0.858	rs698405	chr5:112243527	C/T	cg06941702	chr5:112196734	SRP19	0.5	4.65	0.35	7.16e-6	Total body bone mineral density;
PAAD	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.63	0.42	8.63e-8	Platelet count;
PAAD	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.51	-9.5	-0.61	4.39e-17	Self-rated health;
PAAD	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.7	6.0	0.44	1.39e-8	Weight;
PAAD	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.42	4.33	0.33	2.67e-5	Behcet's disease;
PAAD	cis	rs2190422	0.651	rs6953562	chr7:103102579	A/G	cg04218035	chr7:103086829	SLC26A5	0.33	4.42	0.34	1.83e-5	Morning vs. evening chronotype;
PAAD	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.37e-6	Prudent dietary pattern;
PAAD	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.65	7.22	0.51	2.33e-11	Alcohol dependence;
PAAD	cis	rs939584	1.000	rs7601028	chr2:642499	C/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg00181669	chr3:44000978	NA	-0.45	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg11949866	chr1:10754891	CASZ1	0.54	4.37	0.33	2.29e-5	Ewing sarcoma;
PAAD	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.8	0.53	9.33e-13	Prudent dietary pattern;
PAAD	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.54	0.47	8.74e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs12612619	0.724	rs7355650	chr2:27245475	T/C	cg00617064	chr2:27272375	NA	0.55	5.83	0.43	3.2e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg06784991	chr1:53308768	ZYG11A	0.29	4.42	0.34	1.86e-5	Monocyte count;
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.72	7.91	0.54	4.98e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.8	9.85	0.62	5.3e-18	Bone mineral density;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.99	7.51	0.52	4.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.82	-10.34	-0.64	2.65e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg23860436	chr12:58378763	NA	0.49	4.53	0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6594713	0.732	rs13174206	chr5:112728482	C/T	cg12552261	chr5:112820674	MCC	-0.62	-4.68	-0.35	6.39e-6	Brain cytoarchitecture;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.78e-6	Type 2 diabetes;
PAAD	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.81	8.52	0.57	1.46e-14	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.55	6.2	0.45	5.12e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.25	0.6	1.92e-16	Hemoglobin concentration;
PAAD	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.32	-0.4	3.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7551345	1.000	rs10914347	chr1:31773496	G/T	cg17086398	chr1:31896392	SERINC2	-0.47	-4.43	-0.34	1.79e-5	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6541297	0.757	rs600845	chr1:230322708	C/T	cg22153407	chr1:230290089	GALNT2	0.47	4.26	0.33	3.53e-5	Coronary artery disease;
PAAD	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs939584	1.000	rs2867113	chr2:651365	C/T	cg14515364	chr2:636606	NA	-0.45	-4.25	-0.33	3.76e-5	Body mass index;
PAAD	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg20169779	chr10:135381914	SYCE1	0.46	4.57	0.35	9.94e-6	Obesity-related traits;
PAAD	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg06131755	chr6:160182447	ACAT2	0.55	4.88	0.37	2.68e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.25	12.85	0.72	4.88e-26	Post bronchodilator FEV1;
PAAD	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.46	6.57	0.47	7.41e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.66	6.01	0.44	1.3e-8	Mean platelet volume;
PAAD	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.45	4.33	0.33	2.73e-5	Parkinson's disease;
PAAD	cis	rs6681460	0.966	rs11208932	chr1:67097853	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.81	0.53	8.87e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-8.13	-0.55	1.42e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs950881	0.808	rs11679146	chr2:103009412	A/G	cg20060108	chr2:102954350	IL1RL1	0.61	4.43	0.34	1.79e-5	Allergy;
PAAD	cis	rs12432203	1.000	rs13156	chr14:51722349	T/C	cg23942311	chr14:51606299	NA	-0.73	-4.66	-0.35	6.76e-6	Cancer;
PAAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-8.08	-0.55	1.83e-13	Personality dimensions;
PAAD	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.52	-6.04	-0.44	1.15e-8	Mean arterial pressure;
PAAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.46	0.34	1.6e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.95e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg18225595	chr11:63971243	STIP1	-0.5	-4.98	-0.37	1.74e-6	Platelet count;
PAAD	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.14	17.77	0.82	6.03e-39	Platelet distribution width;
PAAD	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27022615	chr11:70049105	FADD	0.59	6.64	0.47	5.28e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg05562828	chr17:3906858	NA	0.5	5.32	0.4	3.57e-7	Type 2 diabetes;
PAAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.63	6.49	0.47	1.13e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.69	0.48	4.05e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg14092988	chr3:52407081	DNAH1	0.4	5.13	0.38	8.59e-7	Electroencephalogram traits;
PAAD	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg07884673	chr3:53033167	SFMBT1	-0.65	-4.3	-0.33	3.09e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.41	-4.92	-0.37	2.24e-6	Uric acid levels;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.57	5.89	0.43	2.44e-8	Longevity;Endometriosis;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.86	-0.37	2.84e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.41	5.26	0.39	4.91e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.51	0.57	1.54e-14	Lung cancer;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs8102137	1.000	rs7247779	chr19:30297919	G/C	cg27475126	chr19:30303651	CCNE1	-0.46	-5.1	-0.38	1e-6	Bladder cancer;
PAAD	cis	rs3136739	0.614	rs8178769	chr8:42041443	T/C	cg17828057	chr8:42037527	PLAT	0.7	4.76	0.36	4.49e-6	Plasma plasminogen activator levels;
PAAD	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg05250797	chr16:70222502	NA	0.79	5.88	0.43	2.56e-8	IgE levels;
PAAD	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.16	-0.39	7.54e-7	Interstitial lung disease;
PAAD	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24549020	chr5:56110836	MAP3K1	0.49	4.29	0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.95	-12.73	-0.72	1.01e-25	Menopause (age at onset);
PAAD	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	1.09	11.9	0.69	1.67e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs35160687	0.644	rs56394965	chr2:86498349	A/T	cg10973622	chr2:86423274	IMMT	-0.47	-5.14	-0.38	8.5e-7	Night sleep phenotypes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24464805	chr12:133683533	ZNF140	0.58	6.53	0.47	9.5e-10	Smoking initiation;
PAAD	cis	rs7714584	1.000	rs7714584	chr5:150270420	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs12304921	0.639	rs7722	chr12:51455404	C/A	cg18059802	chr12:51347058	HIGD1C	-0.62	-4.89	-0.37	2.6e-6	Type 2 diabetes;
PAAD	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-4.54	-0.35	1.14e-5	Colorectal cancer;
PAAD	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg17796960	chr10:135278976	LOC619207	-0.57	-6.33	-0.46	2.63e-9	Systemic lupus erythematosus;
PAAD	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.63	-7.02	-0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	0.93	6.03	0.44	1.22e-8	Fat distribution (HIV);
PAAD	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.88	6.89	0.49	1.38e-10	Total cholesterol levels;
PAAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg09835421	chr16:68378352	PRMT7	-1.13	-7.87	-0.54	6.1e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22442454	chr1:209979470	IRF6	0.53	4.58	0.35	9.55e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.5	-0.47	1.09e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg23752985	chr2:85803571	VAMP8	0.56	6.26	0.45	3.77e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg00129232	chr17:37814104	STARD3	0.51	4.39	0.34	2.15e-5	Self-reported allergy;
PAAD	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg12310025	chr6:25882481	NA	0.45	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.82	9.22	0.6	2.36e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.45	-6.96	-0.49	9.32e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-4.46	-0.34	1.59e-5	Metabolite levels;
PAAD	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.93	-8.9	-0.59	1.54e-15	Schizophrenia;
PAAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	7.14	0.5	3.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs863345	0.935	rs10797025	chr1:158519525	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg00129232	chr17:37814104	STARD3	0.53	4.73	0.36	5.04e-6	Self-reported allergy;
PAAD	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6700896	0.522	rs4655778	chr1:66142336	G/A	cg04111102	chr1:66153794	NA	0.48	4.5	0.34	1.37e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05739825	chr11:125439882	EI24	0.61	6.89	0.49	1.35e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.62	-6.9	-0.49	1.34e-10	Menopause (age at onset);
PAAD	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.48	4.35	0.33	2.44e-5	Bipolar disorder;
PAAD	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg21775007	chr8:11205619	TDH	-0.47	-4.42	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-4.76	-0.36	4.55e-6	Menarche (age at onset);
PAAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.86	8.85	0.58	2.1e-15	Cognitive function;
PAAD	cis	rs9810890	1.000	rs73196960	chr3:128432222	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2882667	0.728	rs7722413	chr5:138278251	T/C	cg09476006	chr5:138032270	NA	0.46	5.72	0.42	5.61e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg13263323	chr15:86062960	AKAP13	-0.61	-6.87	-0.49	1.51e-10	Coronary artery disease;
PAAD	cis	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg13870426	chr17:30244630	NA	-0.78	-5.16	-0.39	7.51e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.0	-0.44	1.41e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.75	-0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.39	5.06	0.38	1.19e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs757081	0.684	rs214071	chr11:17305294	T/G	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.88	-0.43	2.55e-8	Systolic blood pressure;
PAAD	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.89	7.37	0.51	9.92e-12	Triglycerides;
PAAD	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.6	-6.3	-0.45	3.11e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.42	0.61	6.98e-17	Platelet count;
PAAD	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg26149184	chr10:133730230	NA	0.78	6.86	0.49	1.64e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.43	0.52	7.27e-12	Menarche (age at onset);
PAAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.3	-0.39	4.02e-7	Diastolic blood pressure;
PAAD	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs7264396	0.887	rs3818441	chr20:34046501	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs4148087	1.000	rs4148101	chr21:43640183	G/A	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05287206	chr19:17377977	C19orf62	-0.73	-7.24	-0.51	2.07e-11	Lung cancer in ever smokers;
PAAD	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.52	-6.07	-0.44	9.71e-9	Blood pressure (smoking interaction);
PAAD	cis	rs10274279	0.660	rs2021743	chr7:157381899	T/C	cg26886268	chr7:157387156	PTPRN2	-0.53	-4.89	-0.37	2.51e-6	Myopia (pathological);
PAAD	cis	rs4668356	0.773	rs73017292	chr2:172049344	C/A	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.79	8.4	0.56	2.89e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.5	-4.76	-0.36	4.5e-6	Pancreatic cancer;
PAAD	cis	rs747650	0.504	rs7111270	chr11:47019777	G/C	cg19486271	chr11:47235900	DDB2	-0.68	-6.23	-0.45	4.47e-9	Acne (severe);
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.64	-6.15	-0.45	6.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.07e-5	Type 2 diabetes;
PAAD	cis	rs12550646	0.600	rs10110994	chr8:41671503	A/G	cg12180191	chr8:41686706	ANK1	-0.47	-4.55	-0.35	1.11e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg03030879	chr14:75389066	RPS6KL1	0.43	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	IgG glycosylation;
PAAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01616529	chr11:638424	DRD4	-0.62	-5.82	-0.43	3.39e-8	Systemic lupus erythematosus;
PAAD	cis	rs3763048	0.963	rs9790867	chr5:169455225	A/C	cg01585372	chr5:169931363	KCNIP1	-0.44	-4.48	-0.34	1.46e-5	IgG glycosylation;
PAAD	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg10932868	chr11:921992	NA	0.49	5.89	0.43	2.39e-8	Alzheimer's disease (late onset);
PAAD	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.54	9.13	0.6	4.04e-16	Cutaneous nevi;
PAAD	cis	rs3790455	0.610	rs3790458	chr1:156459699	A/T	cg14087168	chr1:156450669	MEF2D	-0.43	-5.29	-0.39	4.23e-7	Migraine;
PAAD	cis	rs8083432	0.799	rs7230316	chr18:22710340	A/T	cg13981356	chr18:22006370	IMPACT	0.55	4.36	0.33	2.39e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.45	4.47	0.34	1.54e-5	Systemic lupus erythematosus;
PAAD	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.28	-0.33	3.36e-5	Aortic root size;
PAAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-4.67	-0.35	6.68e-6	Blood metabolite levels;
PAAD	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.64	-0.35	7.36e-6	Height;
PAAD	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.58	-5.6	-0.41	9.84e-8	Gut microbiome composition (summer);
PAAD	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.76	8.19	0.55	9.75e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11620996	chr4:39368162	RFC1	0.57	6.44	0.46	1.52e-9	Metabolite levels  (X-11787);
PAAD	trans	rs970548	0.954	rs2291429	chr10:45958881	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg03983715	chr16:68378420	PRMT7	-0.95	-7.14	-0.5	3.61e-11	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg22907277	chr7:1156413	C7orf50	0.66	4.77	0.36	4.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs3736485	0.966	rs4775961	chr15:51892959	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.49e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg15017067	chr4:17643749	FAM184B	0.44	5.15	0.39	8.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.43	0.65	1.47e-19	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21365899	chr1:231558446	EGLN1	0.61	6.61	0.47	6.07e-10	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.64	0.35	7.37e-6	Bipolar disorder;
PAAD	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg02380750	chr20:61661411	NA	0.36	4.31	0.33	2.95e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4144027	0.935	rs881056	chr14:104354225	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.38	-4.52	-0.34	1.26e-5	Blood metabolite levels;
PAAD	cis	rs9535307	0.929	rs942032	chr13:50251145	T/G	cg04663916	chr13:50265991	EBPL	0.59	4.61	0.35	8.42e-6	Obesity-related traits;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	9.45	0.61	5.77e-17	Platelet count;
PAAD	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.71	6.19	0.45	5.48e-9	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12648482	chr13:52768676	THSD1P	-0.75	-6.59	-0.47	6.94e-10	Neuroticism;
PAAD	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.16	-0.55	1.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13365781	chr4:106067872	TET2	0.55	6.31	0.46	2.97e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.83	-0.36	3.27e-6	Mood instability;
PAAD	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs829661	0.947	rs829679	chr2:30709421	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.24	-0.39	5.29e-7	Blood metabolite levels;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg19660806	chr8:588740	NA	-0.64	-4.31	-0.33	2.89e-5	IgG glycosylation;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.8	-0.36	3.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01616529	chr11:638424	DRD4	-0.63	-5.96	-0.44	1.69e-8	Systemic lupus erythematosus;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg24585817	chr7:64895279	NA	0.4	4.54	0.35	1.14e-5	Calcium levels;
PAAD	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.81	8.81	0.58	2.71e-15	Bladder cancer;
PAAD	cis	rs9487051	0.834	rs6919423	chr6:109558471	C/T	cg21918786	chr6:109611834	NA	-0.44	-4.81	-0.36	3.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23476955	chr19:16308634	AP1M1	0.7	8.61	0.57	8.71e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12016809	chr21:47604291	C21orf56	-0.45	-4.61	-0.35	8.43e-6	Testicular germ cell tumor;
PAAD	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.53	5.17	0.39	7.27e-7	Rheumatoid arthritis;
PAAD	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.56	-0.35	1.05e-5	Rheumatoid arthritis;
PAAD	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.56	4.71	0.36	5.56e-6	Plateletcrit;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.64	0.35	7.59e-6	IgG glycosylation;
PAAD	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg01612440	chr4:3296283	NA	0.46	4.58	0.35	9.46e-6	Serum sulfate level;
PAAD	cis	rs56046484	0.956	rs35533990	chr15:85664821	G/C	cg08123816	chr15:85640762	PDE8A	-0.5	-5.15	-0.39	7.93e-7	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.58	6.84	0.49	1.82e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00612714	chr7:6006566	RSPH10B2;RSPH10B	-0.62	-6.43	-0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-0.57	-4.28	-0.33	3.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg10556349	chr10:835070	NA	0.55	4.96	0.37	1.86e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.52	5.07	0.38	1.13e-6	Cognitive function;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg14851468	chr5:179071604	C5orf60	0.48	5.2	0.39	6.35e-7	Lung cancer;
PAAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.33e-7	Ulcerative colitis;
PAAD	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.41	0.65	1.75e-19	Smoking behavior;
PAAD	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.89	0.37	2.57e-6	Longevity;
PAAD	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.2	0.64	6.02e-19	Smoking behavior;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.72	8.54	0.57	1.32e-14	Lung cancer;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.64	4.58	0.35	9.81e-6	Alzheimer's disease;
PAAD	cis	rs1997066	0.831	rs73344306	chr10:106824756	C/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg18551225	chr6:44695536	NA	-0.64	-7.3	-0.51	1.47e-11	Total body bone mineral density;
PAAD	cis	rs1109501	0.689	rs28846795	chr4:71417273	A/C	cg25553522	chr4:71388589	AMTN	0.54	4.51	0.34	1.3e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs4880487	0.888	rs67456501	chr10:1252400	G/A	cg03183215	chr10:1252341	ADARB2	-0.48	-4.75	-0.36	4.77e-6	Migraine;
PAAD	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	1.16	7.25	0.51	1.99e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg01420254	chr6:26195488	NA	0.89	6.65	0.47	4.95e-10	Gout;Renal underexcretion gout;
PAAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs863345	0.604	rs10908670	chr1:158502113	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs16838233	1.000	rs4654311	chr1:29746132	C/T	cg12609322	chr1:29490924	SFRS4	0.53	4.28	0.33	3.3e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs10936602	0.527	rs9878316	chr3:169533717	T/A	cg08193579	chr3:169529701	LRRC34	0.42	4.28	0.33	3.29e-5	Renal cell carcinoma;
PAAD	trans	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg20587970	chr11:113659929	NA	-1.04	-11.21	-0.67	1.24e-21	Hip circumference adjusted for BMI;
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.5	-5.6	-0.41	9.68e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.46	6.36	0.46	2.25e-9	Schizophrenia;
PAAD	cis	rs4819143	0.517	rs1736424	chr21:47373605	T/C	cg13695288	chr21:47294981	PCBP3	0.55	4.81	0.36	3.64e-6	Insulin resistance/response;
PAAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.74	-9.05	-0.59	6.31e-16	Prudent dietary pattern;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.85	10.76	0.66	2e-20	Vitiligo;
PAAD	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.53	4.78	0.36	4.14e-6	Anxiety disorder;
PAAD	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.69	6.91	0.49	1.22e-10	Mosquito bite size;
PAAD	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg07725925	chr16:89976287	TCF25	0.66	4.29	0.33	3.19e-5	Skin colour saturation;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs5009270	0.512	rs6977807	chr7:112249863	C/T	cg25550468	chr7:112262557	NA	0.5	4.52	0.34	1.21e-5	Osteoarthritis (hip);
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.93	10.51	0.65	9.25e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.53	13.24	0.73	4.14e-27	Atopic dermatitis;
PAAD	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.48	-5.3	-0.39	4e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02740969	chr7:139477893	TBXAS1;HIPK2	0.6	6.44	0.46	1.52e-9	Myopia (pathological);
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg04089426	chr11:65307791	LTBP3	0.9	4.33	0.33	2.69e-5	Height;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.7e-6	Cognitive function;
PAAD	cis	rs6689305	0.545	rs11166329	chr1:100237542	G/T	cg22872634	chr1:100462710	SLC35A3	-0.44	-4.25	-0.33	3.71e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs11590090	0.861	rs12739033	chr1:113319536	T/C	cg25707805	chr1:113285387	NA	0.35	4.66	0.35	6.86e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg06815965	chr1:205818668	PM20D1	0.57	6.19	0.45	5.38e-9	Menarche (age at onset);
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.61	-5.72	-0.42	5.58e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06873352	chr17:61820015	STRADA	-0.56	-5.85	-0.43	2.91e-8	Height;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg15117754	chr3:10150083	C3orf24	-0.63	-5.5	-0.41	1.6e-7	Alzheimer's disease;
PAAD	cis	rs1595825	0.786	rs1902246	chr2:198492827	C/T	cg00982548	chr2:198649783	BOLL	-0.72	-5.17	-0.39	7.4e-7	Ulcerative colitis;
PAAD	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg09659197	chr4:152720779	NA	0.37	5.37	0.4	2.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.75	7.79	0.53	9.6e-13	Breast cancer;
PAAD	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.7	5.41	0.4	2.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.56	0.41	1.19e-7	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24343413	chr1:151735844	OAZ3;MRPL9	0.59	6.58	0.47	7.18e-10	Myopia (pathological);
PAAD	cis	rs72960926	1.000	rs16884746	chr6:75066404	A/G	cg03266952	chr6:74778945	NA	-1.02	-5.51	-0.41	1.47e-7	Metabolite levels (MHPG);
PAAD	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.5	0.57	1.68e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10002088	chr19:9271911	ZNF317	-0.67	-6.9	-0.49	1.35e-10	Obesity-related traits;
PAAD	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-6.56	-0.47	8.04e-10	Cognitive test performance;
PAAD	cis	rs476633	0.708	rs13329237	chr15:41450808	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-8.31	-0.56	4.98e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs62025270	0.547	rs386346	chr15:86194559	A/T	cg13263323	chr15:86062960	AKAP13	0.49	4.72	0.36	5.38e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.5	4.53	0.35	1.18e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.51	6.49	0.47	1.14e-9	Huntington's disease progression;
PAAD	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.04	0.5	6.31e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg24060327	chr5:131705240	SLC22A5	0.62	5.08	0.38	1.08e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs11264213	0.901	rs584873	chr1:36431806	C/A	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.4e-9	Schizophrenia;
PAAD	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.96	-7.9	-0.54	5.19e-13	Vitiligo;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	6.22	0.45	4.65e-9	Prudent dietary pattern;
PAAD	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-1.08	-12.99	-0.73	1.97e-26	Breast cancer;
PAAD	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.48	4.58	0.35	9.71e-6	Mean platelet volume;
PAAD	cis	rs17681684	0.565	rs62066044	chr17:9762454	G/A	cg26853458	chr17:9805074	RCVRN	0.77	8.23	0.56	7.89e-14	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs7092929	1.000	rs684240	chr10:3558799	A/G	cg14308648	chr10:3568949	NA	0.71	5.09	0.38	1.04e-6	Coronary artery calcification;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08677398	chr8:58056175	NA	0.68	4.65	0.35	7.16e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.57	0.35	9.97e-6	Electrocardiographic conduction measures;
PAAD	cis	rs17169634	1.000	rs6945116	chr7:34082875	C/G	cg24927974	chr7:35078269	DPY19L1	-0.63	-5.23	-0.39	5.59e-7	Alzheimer's disease;
PAAD	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.57	0.61	2.87e-17	Response to antipsychotic treatment;
PAAD	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.67	4.97	0.37	1.78e-6	Mean platelet volume;
PAAD	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-5.42	-0.4	2.28e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.64	-8.08	-0.55	1.83e-13	Body mass index;
PAAD	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.49	4.89	0.37	2.51e-6	Lewy body disease;
PAAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.87	9.62	0.62	2.08e-17	Systemic sclerosis;
PAAD	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg27211696	chr2:191398769	TMEM194B	0.45	4.57	0.35	1e-5	Urinary metabolites;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11235543	chr10:131557193	MGMT	-0.49	-7.13	-0.5	3.86e-11	Body fat percentage;
PAAD	cis	rs6850606	0.577	rs35985903	chr4:42868557	G/C	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg19784903	chr17:45786737	TBKBP1	-0.68	-7.48	-0.52	5.39e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1419980	0.730	rs1833148	chr12:7774680	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.42e-11	Eye color traits;
PAAD	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.81	-6.77	-0.48	2.67e-10	Cancer;
PAAD	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.41	13.34	0.73	2.31e-27	Corneal structure;
PAAD	cis	rs17032980	0.956	rs3770659	chr2:67307294	T/C	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.6e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg25124228	chr12:125621409	AACS	-0.65	-6.19	-0.45	5.4e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09822136	chr5:14144123	TRIO	0.61	6.83	0.48	1.94e-10	Monocyte percentage of white cells;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg13264159	chr8:625131	ERICH1	0.7	4.64	0.35	7.48e-6	IgG glycosylation;
PAAD	cis	rs282587	0.502	rs382758	chr13:113400169	C/T	cg02820901	chr13:113351484	ATP11A	-0.64	-4.93	-0.37	2.09e-6	Glycated hemoglobin levels;
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg11271282	chr2:238384023	NA	0.71	4.26	0.33	3.54e-5	Prostate cancer;
PAAD	cis	rs16975963	0.644	rs59426132	chr19:38092770	T/G	cg08679971	chr19:38281047	NA	0.46	4.53	0.34	1.19e-5	Longevity;
PAAD	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg18721089	chr20:30220636	NA	-0.79	-6.02	-0.44	1.23e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg02254774	chr11:50257496	LOC441601	-0.47	-4.38	-0.33	2.2e-5	Height;
PAAD	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.87	7.08	0.5	4.88e-11	Chronic kidney disease;
PAAD	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg18551225	chr6:44695536	NA	-0.7	-8.28	-0.56	5.86e-14	Total body bone mineral density;
PAAD	cis	rs6743376	0.556	rs2515391	chr2:113815997	C/T	cg24553058	chr2:113831203	IL1F10	0.38	4.34	0.33	2.63e-5	Inflammatory biomarkers;
PAAD	cis	rs12304921	1.000	rs2269684	chr12:51417758	A/T	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.46	-0.34	1.57e-5	Type 2 diabetes;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12483801	chr4:183727862	NA	0.77	5.74	0.42	4.91e-8	Pediatric autoimmune diseases;
PAAD	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg23127183	chr11:57508653	C11orf31	-0.52	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.85	-9.64	-0.62	1.89e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.48	-4.25	-0.33	3.69e-5	Myopia (pathological);
PAAD	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.39	0.34	2.11e-5	Blood metabolite levels;
PAAD	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg10434728	chr15:90938212	IQGAP1	-0.43	-4.3	-0.33	3e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.84	0.48	1.84e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-1.09	-10.68	-0.65	3.17e-20	Red cell distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20139898	chr1:26437522	PDIK1L	0.57	6.33	0.46	2.63e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg09242541	chr1:10490025	APITD1	0.44	5.54	0.41	1.29e-7	Prostate cancer;
PAAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg02367144	chr2:237146137	ASB18	0.41	5.26	0.39	4.78e-7	Educational attainment;
PAAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg01299579	chr2:10830716	NOL10	-0.57	-5.75	-0.42	4.79e-8	Prostate cancer;
PAAD	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	1.01	13.9	0.75	7.32e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.69	-7.76	-0.53	1.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	4.33	0.33	2.68e-5	Renal cell carcinoma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17347400	chr20:633844	SRXN1	0.65	7.24	0.51	2.06e-11	Myopia (pathological);
PAAD	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg05925327	chr15:68127851	NA	-0.61	-5.41	-0.4	2.42e-7	Restless legs syndrome;
PAAD	cis	rs2915864	0.800	rs78403069	chr5:141514866	T/C	cg24865955	chr5:141576963	NA	0.81	4.27	0.33	3.37e-5	Facial morphology (factor 20);
PAAD	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.68e-11	Total cholesterol levels;
PAAD	cis	rs2952768	0.828	rs2551935	chr2:208497287	A/G	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	5.05	0.38	1.24e-6	Joint mobility (Beighton score);
PAAD	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.51	4.55	0.35	1.1e-5	Anterior chamber depth;
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg08284496	chr17:37894027	GRB7	0.26	4.41	0.34	1.93e-5	Asthma;
PAAD	cis	rs3126085	0.825	rs4298736	chr1:152240269	A/T	cg09127314	chr1:152161683	NA	0.71	5.03	0.38	1.35e-6	Atopic dermatitis;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg06045062	chr4:100009749	ADH5	-0.69	-6.87	-0.49	1.56e-10	Body mass index;
PAAD	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.79e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg13468214	chr4:1046988	NA	-0.51	-5.05	-0.38	1.22e-6	Recombination rate (females);
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs3736485	0.932	rs4775966	chr15:51913788	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.7e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg08975724	chr8:8085496	FLJ10661	-0.67	-6.77	-0.48	2.66e-10	Retinal vascular caliber;
PAAD	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.71	-0.36	5.55e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg13447295	chr6:887704	NA	0.62	6.1	0.44	8.53e-9	Aging;
PAAD	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.57	5.05	0.38	1.25e-6	Height;
PAAD	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.58	-7.51	-0.52	4.75e-12	Lewy body disease;
PAAD	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	5.15	0.39	8.03e-7	Neuroticism;
PAAD	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs42648	0.564	rs10224488	chr7:89810261	A/G	cg27367526	chr7:89841692	STEAP2	-0.31	-4.37	-0.33	2.3e-5	Homocysteine levels;
PAAD	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.75	-4.81	-0.36	3.66e-6	Body mass index;
PAAD	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.9	-10.85	-0.66	1.17e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21241219	chr9:139965163	C9orf140	0.7	7.31	0.51	1.41e-11	Myopia (pathological);
PAAD	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.72	5.46	0.41	1.88e-7	Electroencephalogram traits;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10240744	chr15:101792713	CHSY1	-0.68	-6.44	-0.46	1.45e-9	Lung cancer in ever smokers;
PAAD	cis	rs7582720	0.945	rs72932722	chr2:203647598	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.47	0.52	5.81e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.19e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs28472312	0.894	rs7498491	chr16:28844068	A/T	cg16576597	chr16:28551801	NUPR1	0.52	5.33	0.4	3.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18906043	chr17:18967111	NA	0.56	6.59	0.47	6.75e-10	Monocyte percentage of white cells;
PAAD	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.58	-4.69	-0.36	6.02e-6	QRS complex (12-leadsum);
PAAD	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-4.38	-0.33	2.23e-5	Obesity (extreme);
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-4.7	-0.36	5.75e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.78	-0.42	4.18e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.27	-0.39	4.69e-7	Blood pressure;
PAAD	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.36	-0.56	3.75e-14	Mean corpuscular volume;
PAAD	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.61	-4.25	-0.33	3.67e-5	Vitiligo;
PAAD	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	5.74	0.42	4.95e-8	Total cholesterol levels;
PAAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.75	-7.32	-0.51	1.31e-11	DNA methylation (variation);
PAAD	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	4.75	0.36	4.76e-6	Height;
PAAD	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.54	5.71	0.42	5.79e-8	Male-pattern baldness;
PAAD	cis	rs66530629	0.917	rs12121345	chr1:25130783	T/C	cg22509179	chr1:25234806	RUNX3	0.51	4.73	0.36	5.11e-6	Plateletcrit;
PAAD	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg16342193	chr10:102329863	NA	-0.83	-8.95	-0.59	1.19e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9346353	0.737	rs12665798	chr6:70436084	A/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.4	-0.34	2.03e-5	Sleep duration;
PAAD	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg20814179	chr4:940893	TMEM175	-0.51	-5.69	-0.42	6.21e-8	Parkinson's disease;
PAAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg16083429	chr3:49237500	CCDC36	-0.42	-4.52	-0.34	1.26e-5	Parkinson's disease;
PAAD	trans	rs2441026	0.666	rs702626	chr5:53463748	C/T	cg05651688	chr1:35734284	ZMYM4	-0.65	-6.41	-0.46	1.75e-9	Lung function (FVC);
PAAD	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-4.46	-0.34	1.57e-5	Mean corpuscular volume;
PAAD	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12144049	0.662	rs6691989	chr1:152402383	A/G	cg25605289	chr1:151974222	NA	-0.34	-4.43	-0.34	1.76e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.71	9.92	0.63	3.36e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.7	5.71	0.42	5.77e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	trans	rs1282545	0.540	rs6785450	chr3:107183439	T/A	cg22635088	chr5:2096922	NA	-0.4	-6.35	-0.46	2.41e-9	Neuroticism;
PAAD	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.47	-6.08	-0.44	9.13e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.65	6.77	0.48	2.7e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs793571	0.822	rs10518991	chr15:59190930	C/T	cg05156742	chr15:59063176	FAM63B	0.6	4.75	0.36	4.59e-6	Schizophrenia;
PAAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.55	-5.64	-0.42	8.19e-8	Testicular germ cell tumor;
PAAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.66	5.73	0.42	5.35e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs17123764	0.786	rs7980979	chr12:50122588	G/T	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22442454	chr1:209979470	IRF6	0.52	4.46	0.34	1.59e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.39	0.46	1.97e-9	Body mass index;
PAAD	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg09399716	chr2:46890238	NA	-0.63	-5.11	-0.38	9.59e-7	Height;
PAAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-4.61	-0.35	8.32e-6	Coronary artery disease;
PAAD	cis	rs3996993	0.597	rs62412889	chr6:52703158	G/A	cg00536792	chr6:53530503	KLHL31	-0.42	-4.43	-0.34	1.8e-5	Hemoglobin concentration;
PAAD	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs11159840	0.510	rs8008885	chr14:88543442	A/G	cg18078958	chr14:88630771	NA	-0.39	-4.25	-0.33	3.74e-5	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.76	-0.42	4.48e-8	Coronary artery disease;
PAAD	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01585852	chr22:24235823	MIF	-0.41	-4.27	-0.33	3.38e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-4.48	-0.34	1.46e-5	Lung cancer;
PAAD	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.6	-5.41	-0.4	2.37e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.49	-0.61	4.51e-17	Response to antipsychotic treatment;
PAAD	cis	rs582384	0.630	rs558368	chr2:45869980	T/A	cg13704086	chr2:45177125	NA	-0.47	-4.49	-0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.82	-5.47	-0.41	1.79e-7	Anti-saccade response;
PAAD	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-6.25	-0.45	3.84e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs7534824	0.625	rs61782085	chr1:101518270	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.69	0.36	6.06e-6	Refractive astigmatism;
PAAD	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.55	5.41	0.4	2.44e-7	Educational attainment (years of education);
PAAD	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.54	6.2	0.45	5e-9	Prostate cancer;
PAAD	cis	rs1419980	0.730	rs11054586	chr12:7730981	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.43	-0.52	7.23e-12	Personality dimensions;
PAAD	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.36	-0.6	9.97e-17	Depression;
PAAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.69	-0.36	6.14e-6	Breast cancer;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.51	-6.49	-0.47	1.17e-9	Longevity;Endometriosis;
PAAD	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.6	-5.91	-0.43	2.19e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.42	0.4	2.26e-7	Life satisfaction;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08677398	chr8:58056175	NA	0.6	4.38	0.33	2.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.66	-0.35	6.97e-6	Joint mobility (Beighton score);
PAAD	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg23127183	chr11:57508653	C11orf31	-0.49	-4.25	-0.33	3.72e-5	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02339418	chr12:123717776	C12orf65	0.7	6.58	0.47	7.25e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.48	5.89	0.43	2.38e-8	Sitting height ratio;
PAAD	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg08079166	chr15:68083412	MAP2K5	-0.66	-5.17	-0.39	7.21e-7	Restless legs syndrome;
PAAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg02117656	chr17:79614917	TSPAN10	0.55	5.61	0.41	9.11e-8	Eye color traits;
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24110177	chr3:50126178	RBM5	0.6	6.39	0.46	1.93e-9	Body mass index;
PAAD	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.68	9.05	0.59	6.29e-16	Hemoglobin concentration;
PAAD	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs6460942	0.597	rs7778131	chr7:12543233	T/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs12311304	1.000	rs12307658	chr12:15388131	A/C	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.86e-6	Behavioural disinhibition (generation interaction);
PAAD	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19520219	chr11:810109	RPLP2	0.6	6.74	0.48	3.05e-10	Monocyte percentage of white cells;
PAAD	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg27449745	chr7:23145252	KLHL7	-0.51	-4.35	-0.33	2.44e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.31	-0.4	3.77e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25650185	chr19:21324782	ZNF431	-0.48	-4.34	-0.33	2.58e-5	Pain;
PAAD	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg05372495	chr19:1063624	ABCA7	-0.5	-4.47	-0.34	1.53e-5	Alzheimer's disease (late onset);
PAAD	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.76	-0.42	4.57e-8	Androgen levels;
PAAD	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.39	-0.4	2.61e-7	Response to antipsychotic treatment;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10002088	chr19:9271911	ZNF317	-0.57	-6.51	-0.47	1.05e-9	Immature fraction of reticulocytes;
PAAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.54	4.94	0.37	2.05e-6	Blood metabolite levels;
PAAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.51	-4.86	-0.37	2.95e-6	Vitiligo;
PAAD	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.7	0.48	3.83e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-4.59	-0.35	9.21e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.41	-4.25	-0.33	3.68e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs797680	0.856	rs4240966	chr1:93774812	C/A	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs72960926	1.000	rs72960926	chr6:75158266	C/A	cg03266952	chr6:74778945	NA	-1.35	-6.81	-0.48	2.13e-10	Metabolite levels (MHPG);
PAAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.67	0.42	6.89e-8	Bipolar disorder;
PAAD	cis	rs2242420	0.920	rs16825749	chr1:21958918	A/G	cg26362272	chr1:22108717	USP48	0.55	4.3	0.33	3.01e-5	Hematological and biochemical traits;
PAAD	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg06217245	chr20:33103252	DYNLRB1	0.42	4.82	0.36	3.52e-6	Height;
PAAD	cis	rs427941	0.703	rs201440	chr7:101735599	C/T	cg06246474	chr7:101738831	CUX1	0.45	4.65	0.35	7.09e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg19486271	chr11:47235900	DDB2	-0.59	-6.02	-0.44	1.27e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg13560548	chr3:10150139	C3orf24	0.54	4.35	0.33	2.5e-5	Alzheimer's disease;
PAAD	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.9	-8.06	-0.55	2.08e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2279817	0.731	rs76970608	chr1:18010198	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27503015	chr2:162270453	NA	0.58	6.59	0.47	6.92e-10	Smoking initiation;
PAAD	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.52	5.76	0.42	4.42e-8	Testicular germ cell tumor;
PAAD	cis	rs11696501	0.739	rs6073846	chr20:44296323	G/T	cg11783356	chr20:44313418	WFDC10B	0.59	5.0	0.38	1.56e-6	Brain structure;
PAAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.57	-6.66	-0.48	4.67e-10	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.75	-6.84	-0.49	1.81e-10	Schizophrenia;
PAAD	cis	rs116175783	0.557	rs62197071	chr2:162149214	C/G	cg08807892	chr2:162101083	NA	-0.68	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9910055	0.550	rs850856	chr17:42157739	C/T	cg16434002	chr17:42200994	HDAC5	0.58	4.51	0.34	1.31e-5	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs76917914	0.589	rs10985065	chr9:100866903	C/T	cg21225548	chr9:100864335	TRIM14	-0.52	-5.86	-0.43	2.76e-8	Immature fraction of reticulocytes;
PAAD	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg08079166	chr15:68083412	MAP2K5	0.7	5.41	0.4	2.41e-7	Restless legs syndrome;
PAAD	cis	rs743757	1.000	rs2236962	chr3:50448515	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.64	0.35	7.31e-6	Diastolic blood pressure;
PAAD	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg14343924	chr8:8086146	FLJ10661	-0.6	-5.13	-0.38	8.53e-7	Mood instability;
PAAD	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.63	-4.34	-0.33	2.6e-5	Toenail selenium levels;
PAAD	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.51	4.33	0.33	2.74e-5	Cocaine dependence;
PAAD	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg10356904	chr22:49881777	NA	-0.5	-5.44	-0.4	2.09e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6700896	0.500	rs66470832	chr1:66130631	T/A	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg20850873	chr3:10149803	C3orf24	0.55	4.35	0.33	2.48e-5	Alzheimer's disease;
PAAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg19636519	chr7:99541626	NA	0.39	4.28	0.33	3.32e-5	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2798269	0.646	rs4770182	chr13:22179186	G/T	cg17543804	chr13:22179073	EFHA1	-0.5	-4.66	-0.35	6.99e-6	PR segment;
PAAD	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.45	5.71	0.42	5.8e-8	Panic disorder;
PAAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4919087	0.715	rs793524	chr10:99024572	A/G	cg06569542	chr10:98946673	SLIT1	0.5	4.91	0.37	2.3e-6	Monocyte count;
PAAD	trans	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg08885800	chr1:201084119	NA	0.75	8.46	0.57	2.03e-14	Permanent tooth development;
PAAD	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg00806126	chr19:22604979	ZNF98	0.41	5.16	0.39	7.63e-7	Pain;
PAAD	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.64	-6.92	-0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs8112211	0.689	rs3816044	chr19:38794750	G/A	cg01275006	chr19:38876250	GGN	-0.86	-5.53	-0.41	1.37e-7	Blood protein levels;
PAAD	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg01338084	chr22:32026380	PISD	-0.5	-4.42	-0.34	1.87e-5	Intelligence;
PAAD	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.8	-0.36	3.8e-6	Body mass index;
PAAD	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg15557168	chr22:42548783	NA	0.47	4.98	0.37	1.71e-6	Cognitive function;
PAAD	cis	rs2371030	1.000	rs10211086	chr2:211575748	C/G	cg18417063	chr2:211583084	NA	-0.44	-4.28	-0.33	3.29e-5	Non-small cell lung cancer;
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.52	4.84	0.37	3.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7127900	0.519	rs7112959	chr11:2233609	G/A	cg25635251	chr11:2234043	NA	0.81	7.82	0.54	8.13e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs7567389	0.504	rs2069895	chr2:128174068	A/G	cg09760422	chr2:128146352	NA	0.41	6.08	0.44	9.39e-9	Self-rated health;
PAAD	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg10694442	chr22:20004377	ARVCF	0.6	6.73	0.48	3.26e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg26071806	chr7:100318239	EPO	-0.46	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.72	-0.42	5.52e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.85	6.14	0.45	6.89e-9	Eosinophil percentage of granulocytes;
PAAD	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.86	-10.27	-0.64	3.96e-19	Height;
PAAD	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.5	-5.04	-0.38	1.31e-6	Daytime sleep phenotypes;
PAAD	cis	rs6547631	0.622	rs10203826	chr2:85926190	A/C	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs73416724	0.688	rs10498755	chr6:43330756	C/T	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.53	-4.93	-0.37	2.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9815354	0.904	rs6776724	chr3:41841270	A/G	cg03022575	chr3:42003672	ULK4	0.81	6.13	0.45	7.34e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11200358	chr6:24719988	C6orf62	-0.62	-6.7	-0.48	3.83e-10	Smoking initiation;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg06629702	chr1:2706960	NA	0.36	4.34	0.33	2.6e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.66	6.31	0.46	2.84e-9	Pulse pressure;
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg11859384	chr17:80120422	CCDC57	0.47	4.85	0.37	3.05e-6	Life satisfaction;
PAAD	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.41	-4.83	-0.37	3.24e-6	Coronary artery disease;
PAAD	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.92	-0.37	2.22e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.5	-6.16	-0.45	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.63	0.65	4.54e-20	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23605547	chr14:33408460	NPAS3	-0.64	-6.64	-0.47	5.12e-10	Smoking initiation;
PAAD	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg21300403	chr2:198650112	BOLL	-0.49	-4.32	-0.33	2.85e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00437311	chr19:37178174	NA	0.59	6.53	0.47	9.48e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.02	-0.77	7.71e-32	Height;
PAAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	6.16	0.45	6.12e-9	Personality dimensions;
PAAD	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-6.07	-0.44	9.89e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg20933634	chr6:27740509	NA	0.76	6.96	0.49	9.44e-11	Breast cancer;
PAAD	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg11297586	chr4:3513846	NA	-0.46	-4.38	-0.33	2.24e-5	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.77	4.89	0.37	2.56e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.24	0.39	5.27e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06338299	chr10:98591780	LCOR	-0.74	-6.39	-0.46	1.94e-9	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19183433	chr2:180871780	CWC22	-0.6	-6.76	-0.48	2.78e-10	Smoking initiation;
PAAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.73	7.55	0.52	3.85e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs11694441	0.618	rs58857371	chr2:119575325	G/A	cg14634534	chr2:119616825	NA	-0.41	-4.49	-0.34	1.41e-5	Monobrow;
PAAD	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-4.29	-0.33	3.14e-5	IgG glycosylation;
PAAD	cis	rs16854884	0.770	rs920158	chr3:143799289	A/T	cg06585982	chr3:143692056	C3orf58	0.57	5.61	0.41	9.4e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs3112530	0.901	rs159759	chr5:152724544	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.35	-0.46	2.38e-9	Triglycerides;
PAAD	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.6	-4.68	-0.35	6.3e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	6.53	0.47	9.32e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	6.95	0.49	1.01e-10	Prudent dietary pattern;
PAAD	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.9	-7.74	-0.53	1.26e-12	Diastolic blood pressure;
PAAD	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg26935685	chr1:15502881	TMEM51	-0.53	-4.5	-0.34	1.35e-5	Systolic blood pressure;
PAAD	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.83	-0.36	3.37e-6	Lung cancer;
PAAD	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.09	-0.59	5.15e-16	Blood trace element (Zn levels);
PAAD	cis	rs354033	0.837	rs6949316	chr7:149180625	C/G	cg24335155	chr7:149193227	ZNF746	0.49	4.36	0.33	2.41e-5	Multiple sclerosis;
PAAD	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.77	-7.83	-0.54	7.9e-13	Colorectal adenoma (advanced);
PAAD	cis	rs8077577	0.895	rs13284	chr17:18112130	C/T	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.07	-0.38	1.13e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-5.01	-0.38	1.5e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20597127	chr1:48460182	NA	-0.62	-6.3	-0.46	3.08e-9	Obesity-related traits;
PAAD	cis	rs10267417	0.603	rs28770193	chr7:19860804	A/T	cg05791153	chr7:19748676	TWISTNB	0.84	5.45	0.4	1.97e-7	Night sleep phenotypes;
PAAD	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.77	7.62	0.53	2.47e-12	Coronary artery disease;
PAAD	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.76	7.04	0.5	6.27e-11	Systemic lupus erythematosus;
PAAD	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.71	7.29	0.51	1.62e-11	Coronary artery disease;
PAAD	cis	rs16852403	0.619	rs10798597	chr1:178108248	G/A	cg00404053	chr1:178313656	RASAL2	0.44	4.28	0.33	3.27e-5	Childhood ear infection;
PAAD	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs6499244	0.552	rs7196917	chr16:69896527	A/G	cg00738113	chr16:70207722	CLEC18C	-0.42	-4.45	-0.34	1.67e-5	Menarche (age at onset);
PAAD	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg03161606	chr19:29218774	NA	-0.58	-4.47	-0.34	1.55e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10793968	0.748	rs7041983	chr9:133605045	C/T	cg01474677	chr9:133586259	NA	0.55	4.3	0.33	3.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg14515779	chr1:101123966	NA	-0.52	-6.5	-0.47	1.08e-9	Monocyte count;
PAAD	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-5.62	-0.41	9e-8	Crohn's disease;
PAAD	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-4.3	-0.33	3.1e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.58	-5.79	-0.42	3.98e-8	IgG glycosylation;
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg01064725	chr1:204461714	NA	-0.52	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10037758	0.569	rs1898547	chr5:128290787	G/A	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.79	6.82	0.48	2.01e-10	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.65	-0.42	7.87e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg13798912	chr7:905769	UNC84A	0.58	4.39	0.34	2.13e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4074493	1.000	rs4075892	chr1:231171807	G/A	cg22172038	chr1:231176991	FAM89A	0.51	4.77	0.36	4.24e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.08	0.63	1.26e-18	Smoking behavior;
PAAD	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.88	12.18	0.7	3.02e-24	Height;
PAAD	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.29	5.62	0.41	8.74e-8	Urinary metabolites;
PAAD	cis	rs300774	0.925	rs300726	chr2:132490	C/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-6.8	-0.48	2.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.51	5.23	0.39	5.58e-7	Schizophrenia;
PAAD	cis	rs56309584	0.678	rs8076031	chr17:8150404	G/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.46	-4.66	-0.35	6.75e-6	Initial pursuit acceleration;
PAAD	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg27631724	chr1:11040367	C1orf127	0.52	6.38	0.46	1.99e-9	Ewing sarcoma;
PAAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg14851346	chr12:38532713	NA	0.52	4.77	0.36	4.21e-6	Morning vs. evening chronotype;
PAAD	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg21138405	chr5:131827807	IRF1	-0.48	-6.35	-0.46	2.35e-9	Breast cancer;Mosquito bite size;
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.68	6.19	0.45	5.47e-9	Breast cancer;
PAAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22601191	chr20:60968625	CABLES2	0.59	5.26	0.39	4.91e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17159098	chr11:120196353	TMEM136	-0.69	-6.29	-0.45	3.17e-9	Neuroticism;
PAAD	cis	rs9659323	0.596	rs6656528	chr1:119477594	A/T	cg17326555	chr1:119535693	NA	-0.35	-4.25	-0.33	3.7e-5	Body mass index;
PAAD	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.06	0.38	1.18e-6	Blood protein levels;
PAAD	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg11766577	chr21:47581405	C21orf56	-0.41	-4.66	-0.35	6.75e-6	Testicular germ cell tumor;
PAAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg10494973	chr17:80897199	TBCD	-0.55	-4.57	-0.35	1.02e-5	Breast cancer;
PAAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg19413350	chr8:57351067	NA	-0.47	-4.43	-0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Depression;
PAAD	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-1.11	-7.03	-0.5	6.71e-11	Skin colour saturation;
PAAD	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.07	-11.59	-0.68	1.2e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.47	4.99	0.38	1.61e-6	Longevity;
PAAD	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg27129171	chr3:47204927	SETD2	0.6	6.05	0.44	1.08e-8	Birth weight;
PAAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14180030	chr9:123475675	MEGF9	-0.46	-5.07	-0.38	1.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.95	0.66	6.14e-21	Smoking behavior;
PAAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.48	-4.87	-0.37	2.79e-6	Type 2 diabetes;
PAAD	cis	rs13361707	0.666	rs59585832	chr5:40744038	C/T	cg17351974	chr5:40835760	RPL37	-0.46	-4.35	-0.33	2.44e-5	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.7	7.73	0.53	1.4e-12	Prostate cancer;
PAAD	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	7.89	0.54	5.64e-13	Coronary artery disease;
PAAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg00944433	chr1:107599041	PRMT6	-0.41	-4.63	-0.35	7.93e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg14349672	chr11:133703707	NA	-0.55	-6.02	-0.44	1.28e-8	Childhood ear infection;
PAAD	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-6.06	-0.44	1.04e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9463078	0.565	rs1797145	chr6:45155782	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-6.46	-0.46	1.31e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	1.08	16.71	0.8	3.03e-36	Height;
PAAD	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19671926	chr4:122722719	EXOSC9	-0.72	-6.96	-0.49	9.72e-11	Type 2 diabetes;
PAAD	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.48	-0.71	4.65e-25	Ulcerative colitis;
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.66	6.89	0.49	1.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-6.07	-0.44	9.99e-9	Lung cancer;
PAAD	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg08562672	chr19:21860753	NA	0.45	4.68	0.36	6.24e-6	Pain;
PAAD	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.25	0.33	3.75e-5	Tonsillectomy;
PAAD	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03224364	chr1:235667348	B3GALNT2	-0.64	-6.37	-0.46	2.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	0.65	4.48	0.34	1.45e-5	Blood protein levels;
PAAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg15841412	chr13:111365552	ING1	0.51	4.32	0.33	2.84e-5	Coronary artery disease;
PAAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg10356904	chr22:49881777	NA	-0.49	-4.86	-0.37	2.93e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg00206168	chr11:65308501	LTBP3	-0.54	-5.51	-0.41	1.48e-7	Bone mineral density;
PAAD	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs9652601	0.959	rs9888908	chr16:11181244	C/A	cg04616529	chr16:11181986	CLEC16A	0.47	5.11	0.38	9.37e-7	Systemic lupus erythematosus;
PAAD	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg23018236	chr17:30244563	NA	-0.52	-4.31	-0.33	2.94e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg17507749	chr15:85114479	UBE2QP1	0.74	7.99	0.54	3.05e-13	Schizophrenia;
PAAD	cis	rs6693295	0.729	rs2787995	chr1:246232189	C/G	cg26013412	chr1:247094486	AHCTF1	-0.58	-4.34	-0.33	2.62e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs66530629	0.917	rs4351587	chr1:25155188	G/C	cg22509179	chr1:25234806	RUNX3	0.48	4.45	0.34	1.66e-5	Plateletcrit;
PAAD	cis	rs9928842	0.823	rs6564243	chr16:75296001	A/C	cg09066997	chr16:75300724	BCAR1	0.62	4.62	0.35	8.24e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.66	0.57	6.25e-15	Alzheimer's disease;
PAAD	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.58	-0.47	7.15e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	1.06	8.23	0.56	7.69e-14	Menopause (age at onset);
PAAD	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.53	5.83	0.43	3.18e-8	Schizophrenia;
PAAD	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.7	0.36	5.84e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.78	-0.36	4.18e-6	Tuberculosis;
PAAD	cis	rs939584	1.000	rs6756518	chr2:651483	G/A	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs300774	0.925	rs300721	chr2:134436	A/T	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6991838	0.806	rs17302392	chr8:66463308	C/T	cg15971335	chr8:66515592	ARMC1	0.45	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.42	-0.34	1.89e-5	Morning vs. evening chronotype;
PAAD	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs12470837	1	rs12470837	chr2:132582511	T/C	cg16789863	chr2:132589606	NA	0.61	5.2	0.39	6.34e-7	Cerebrospinal fluid clusterin levels in APOEe4+ carriers;Cerebrospinal fluid clusterin levels;
PAAD	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	trans	rs61677309	1.000	rs56938099	chr11:118156688	A/G	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.47	4.35	0.33	2.45e-5	Red blood cell count;
PAAD	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg00255919	chr5:131827918	IRF1	-0.46	-5.48	-0.41	1.75e-7	Asthma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19337852	chr19:38755293	SPINT2	-0.68	-6.67	-0.48	4.55e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg02476566	chr12:106696527	TCP11L2	-0.45	-4.34	-0.33	2.59e-5	Tourette syndrome;
PAAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg25811867	chr2:3488468	NA	0.46	4.38	0.33	2.17e-5	Neurofibrillary tangles;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18621852	chr3:10150065	C3orf24	0.62	5.37	0.4	2.95e-7	Alzheimer's disease;
PAAD	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.81	9.64	0.62	1.82e-17	Bladder cancer;
PAAD	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg12046867	chr14:103022105	NA	-0.6	-4.71	-0.36	5.61e-6	Platelet count;
PAAD	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg17385448	chr1:15911702	AGMAT	0.35	4.31	0.33	2.88e-5	Systolic blood pressure;
PAAD	cis	rs5417	0.636	rs427784	chr17:7157516	C/T	cg25256661	chr17:7137939	DVL2	-0.95	-10.12	-0.63	1.04e-18	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7627468	0.837	rs9866419	chr3:121940209	G/A	cg03198317	chr3:121949109	CASR	0.51	4.59	0.35	9.19e-6	Kidney stones;
PAAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.61	-6.47	-0.46	1.28e-9	Monocyte count;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs300774	1.000	rs436446	chr2:106409	T/C	cg23649280	chr2:140451	NA	-0.54	-4.89	-0.37	2.5e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.59	-4.39	-0.34	2.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.36	0.33	2.42e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg10547527	chr2:198650123	BOLL	-0.62	-4.33	-0.33	2.68e-5	Ulcerative colitis;
PAAD	cis	rs2252790	1.000	rs12212609	chr6:116614045	A/T	cg26893134	chr6:116381904	FRK	0.27	4.28	0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-7.36	-0.51	1.08e-11	Type 2 diabetes;
PAAD	cis	rs76419734	0.558	rs58412572	chr4:106518970	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	4.39	0.34	2.07e-5	Post bronchodilator FEV1;
PAAD	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg08648136	chr8:956695	NA	-0.45	-4.86	-0.37	2.95e-6	Schizophrenia;
PAAD	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.19	0.64	6.71e-19	Bladder cancer;
PAAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	4.88	0.37	2.68e-6	Breast cancer;
PAAD	cis	rs11681884	0.786	rs34466405	chr2:113808054	A/T	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.39	-4.37	-0.33	2.27e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.51	4.56	0.35	1.06e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.62	6.35	0.46	2.39e-9	Resting heart rate;
PAAD	cis	rs11235843	0.790	rs11235881	chr11:73438237	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.13	-0.44	7.4e-9	Type 2 diabetes;
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.15e-12	Calcium levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16577540	chr5:139682757	PFDN1	0.57	6.41	0.46	1.74e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17095355	1.000	rs7906904	chr10:111708193	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.6	-0.35	8.72e-6	Biliary atresia;
PAAD	cis	rs9390123	0.621	rs3811094	chr6:143927922	T/A	cg25407410	chr6:143891975	LOC285740	-0.49	-4.87	-0.37	2.76e-6	Lung Cancer (DNA repair capacity);
PAAD	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.47	-0.34	1.53e-5	Eosinophil percentage of white cells;
PAAD	cis	rs3126085	0.560	rs11204982	chr1:152322042	A/G	cg26876637	chr1:152193138	HRNR	-0.59	-4.56	-0.35	1.06e-5	Atopic dermatitis;
PAAD	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.47	5.87	0.43	2.62e-8	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg27449745	chr7:23145252	KLHL7	-0.57	-5.09	-0.38	1.04e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.24	0.56	7.33e-14	Lung cancer;
PAAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.87	-9.38	-0.61	8.68e-17	Cognitive function;
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.68	-4.58	-0.35	9.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.78	-0.42	4.16e-8	Type 2 diabetes;
PAAD	cis	rs300774	0.925	rs300735	chr2:167739	C/G	cg21211680	chr2:198530	NA	-0.64	-5.93	-0.43	1.96e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.64	6.97	0.49	8.97e-11	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs2147959	0.883	rs7529055	chr1:228636824	T/G	cg18477163	chr1:228402036	OBSCN	-0.44	-4.63	-0.35	7.91e-6	Adult asthma;
PAAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.86	0.37	2.85e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs74544699	1.000	rs499141	chr4:74768970	A/C	cg16072462	chr4:74847758	PF4	1.12	4.28	0.33	3.28e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.7	5.33	0.4	3.51e-7	Electroencephalogram traits;
PAAD	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.48	6.73	0.48	3.32e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.66	-5.29	-0.39	4.2e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.65	6.6	0.47	6.52e-10	Alcohol dependence;
PAAD	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.06	-0.55	2.05e-13	Coffee consumption (cups per day);
PAAD	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19230459	chr11:63933996	MACROD1	0.58	6.33	0.46	2.6e-9	Monocyte percentage of white cells;
PAAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg07395648	chr5:131743802	NA	-0.48	-4.29	-0.33	3.16e-5	Blood metabolite levels;
PAAD	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.94	-6.48	-0.47	1.18e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.62	6.8	0.48	2.22e-10	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09581848	chr17:37909335	NA	0.56	6.44	0.46	1.5e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg19413350	chr8:57351067	NA	-0.52	-4.92	-0.37	2.2e-6	Obesity-related traits;
PAAD	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.05	17.73	0.82	7.61e-39	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.78	7.38	0.51	9.47e-12	Corneal astigmatism;
PAAD	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg12560992	chr17:57184187	TRIM37	0.68	5.0	0.38	1.59e-6	Vitamin D levels;
PAAD	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.75	-7.51	-0.52	4.71e-12	Sleep quality;
PAAD	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4919087	0.715	rs1253387	chr10:99032968	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-5.58	-0.41	1.09e-7	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12164202	chr8:144403306	TOP1MT	-0.63	-6.38	-0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs6715793	0.901	rs62146677	chr2:33401581	C/T	cg26672287	chr2:33391915	LTBP1	-0.45	-5.26	-0.39	4.83e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.9e-5	Total body bone mineral density;
PAAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.97	11.67	0.69	7.2e-23	Osteoporosis;
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.49	7.53	0.52	4.27e-12	Mean corpuscular volume;
PAAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.53	4.58	0.35	9.67e-6	Corneal astigmatism;
PAAD	cis	rs1570884	0.539	rs7982964	chr13:50111762	G/A	cg08779649	chr13:50194554	NA	0.34	4.25	0.33	3.65e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-7.51	-0.52	4.75e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4305276	0.724	rs7562186	chr2:241477739	G/C	cg07929629	chr2:241523174	NA	-0.47	-4.31	-0.33	2.93e-5	Mean platelet volume;
PAAD	cis	rs1419980	0.730	rs11054916	chr12:7777083	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	cis	rs28408315	0.958	rs34851962	chr15:79203038	A/C	cg15571903	chr15:79123663	NA	0.4	4.26	0.33	3.62e-5	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
PAAD	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.25	4.33	0.33	2.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7246865	0.859	rs12461874	chr19:17180358	C/A	cg19418318	chr19:17219073	MYO9B	0.49	5.73	0.42	5.26e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.85	-0.58	2.16e-15	Exhaled nitric oxide output;
PAAD	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4280164	0.945	rs4374085	chr14:24771080	T/C	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs501120	1.000	rs493874	chr10:44764077	C/T	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs7552393	0.636	rs12406928	chr1:84298457	G/T	cg10977910	chr1:84465055	TTLL7	0.57	5.18	0.39	6.93e-7	Select biomarker traits;
PAAD	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg17644776	chr2:200775616	C2orf69	-0.58	-4.94	-0.37	2.08e-6	Schizophrenia;
PAAD	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs245880	0.740	rs245902	chr7:29194919	T/A	cg17163760	chr7:29186267	CPVL	-0.52	-6.18	-0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs2061333	0.500	rs10408901	chr19:44634552	T/A	cg18700516	chr19:44507157	ZNF230	-0.82	-5.96	-0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg12923728	chr3:195709715	SDHAP1	-0.79	-6.0	-0.44	1.35e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2798269	0.726	rs7339080	chr13:22040100	G/A	cg17543804	chr13:22179073	EFHA1	0.49	4.8	0.36	3.8e-6	PR segment;
PAAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.78	-7.97	-0.54	3.5e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11264799	0.626	rs12726950	chr1:157575676	A/T	cg18268488	chr1:157545234	FCRL4	0.43	4.9	0.37	2.42e-6	IgA nephropathy;
PAAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00498438	chr7:66460676	SBDS;TYW1	0.62	6.45	0.46	1.38e-9	Myopia (pathological);
PAAD	cis	rs7582720	0.731	rs10207567	chr2:203714973	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	5.93	0.43	1.95e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-6.0	-0.44	1.35e-8	IgG glycosylation;
PAAD	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.78	6.64	0.47	5.32e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.88	-0.58	1.78e-15	Morning vs. evening chronotype;
PAAD	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.92	11.22	0.67	1.16e-21	Schizophrenia;
PAAD	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg20333904	chr2:240724165	NA	-0.4	-4.34	-0.33	2.62e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.38	13.01	0.73	1.8e-26	Corneal structure;
PAAD	cis	rs2839627	0.638	rs8134227	chr21:44257902	C/T	cg03543861	chr21:44258195	NA	0.62	4.5	0.34	1.34e-5	Information processing speed;
PAAD	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.79	0.53	9.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2445762	0.518	rs7172765	chr15:51642674	G/A	cg20344442	chr15:51633704	GLDN	0.46	4.66	0.35	6.94e-6	Hormone measurements;
PAAD	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg01489256	chr8:11204017	TDH	-0.45	-4.43	-0.34	1.76e-5	Retinal vascular caliber;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.78	9.45	0.61	5.9e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26561342	chr1:45241260	SNORD55;RPS8;SNORD46	0.62	6.85	0.49	1.74e-10	Myopia (pathological);
PAAD	cis	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.22	0.64	5.41e-19	Response to antipsychotic treatment;
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.41	-5.64	-0.42	8.14e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	0.87	5.43	0.4	2.22e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.35	-0.33	2.52e-5	Neuroticism;
PAAD	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.81	-9.04	-0.59	6.69e-16	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg27413539	chr10:131576096	NA	-0.55	-5.63	-0.42	8.64e-8	Vitamin D levels;
PAAD	cis	rs2029362	0.591	rs10835210	chr11:27695910	G/T	cg10635145	chr11:27742435	BDNF	0.32	4.46	0.34	1.58e-5	Total body bone mineral density;
PAAD	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg22875332	chr1:76189707	ACADM	-0.48	-4.76	-0.36	4.56e-6	Daytime sleep phenotypes;
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.74	-8.45	-0.57	2.22e-14	Body mass index;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.88	-13.72	-0.74	2.21e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg24253500	chr15:84953950	NA	0.42	4.44	0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.64	-6.88	-0.49	1.43e-10	IgG glycosylation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08128889	chr17:80828176	TBCD	0.57	6.46	0.46	1.34e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4908760	0.965	rs12080583	chr1:8524877	G/A	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.51e-5	Vitiligo;
PAAD	cis	rs7551345	0.853	rs7541442	chr1:31778457	T/A	cg17086398	chr1:31896392	SERINC2	-0.49	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
PAAD	cis	rs939584	1.000	rs7559447	chr2:645646	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs6681460	0.625	rs12138066	chr1:67103816	C/T	cg02459107	chr1:67143332	SGIP1	0.54	5.06	0.38	1.22e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.85	-8.33	-0.56	4.45e-14	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10187365	chr21:34860956	DNAJC28	-0.71	-7.36	-0.51	1.09e-11	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs1532331	0.548	rs6894506	chr5:43169096	C/T	cg09164108	chr5:43007320	NA	0.48	5.51	0.41	1.48e-7	Menarche (age at onset);
PAAD	cis	rs58521262	0.585	rs1645767	chr19:23209237	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg04844267	chr4:1394941	NA	0.4	4.41	0.34	1.95e-5	Obesity-related traits;
PAAD	cis	rs12136530	0.593	rs881248	chr1:19733961	C/T	cg25104613	chr1:20649108	VWA5B1	0.42	4.79	0.36	3.99e-6	Lead levels in blood;
PAAD	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg02696790	chr15:75250997	RPP25	-0.45	-5.18	-0.39	7.02e-7	Systemic lupus erythematosus;
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.95	12.28	0.71	1.65e-24	Menopause (age at onset);
PAAD	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.74	7.34	0.51	1.23e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	5.92	0.43	2.1e-8	Neutrophil percentage of white cells;
PAAD	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.6	6.42	0.46	1.62e-9	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-1.15	-11.21	-0.67	1.23e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17167289	chr3:42846087	HIGD1A	-0.63	-6.31	-0.46	2.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg05250797	chr16:70222502	NA	0.81	6.11	0.44	8.08e-9	IgE levels;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg05671241	chr3:126373822	NA	0.93	6.99	0.49	7.93e-11	Lung function (FEV1/FVC);
PAAD	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg23024343	chr7:107201750	COG5	0.51	4.27	0.33	3.47e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.86	6.31	0.46	2.97e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6578985	0.636	rs734351	chr11:2156213	A/G	cg07296665	chr11:2109690	NA	0.39	4.25	0.33	3.74e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs8005172	0.778	rs12050084	chr14:88482577	C/A	cg18078958	chr14:88630771	NA	0.5	5.93	0.43	1.98e-8	Parkinson's disease;
PAAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24549020	chr5:56110836	MAP3K1	-0.68	-4.95	-0.37	1.98e-6	Initial pursuit acceleration;
PAAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.93	-11.21	-0.67	1.22e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs838147	0.844	rs8111399	chr19:49247963	G/T	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16402817	chr2:165698673	COBLL1	-0.71	-6.33	-0.46	2.55e-9	Neuroticism;
PAAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.55	4.45	0.34	1.68e-5	Response to antidepressants in depression;
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg19357499	chr8:144660631	NAPRT1	0.86	5.87	0.43	2.64e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs2882667	0.690	rs288018	chr5:138192416	G/A	cg09476006	chr5:138032270	NA	-0.43	-5.39	-0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9463078	0.774	rs10948222	chr6:45244415	T/C	cg25276700	chr6:44698697	NA	-0.48	-5.45	-0.4	1.95e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.78	-8.35	-0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.64	-5.72	-0.42	5.45e-8	Coronary artery disease;
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg16040993	chr19:53496440	ZNF702P	-0.43	-4.31	-0.33	2.97e-5	Psoriasis;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg00450029	chr8:599525	NA	-0.8	-4.95	-0.37	1.94e-6	IgG glycosylation;
PAAD	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.7	-0.42	6.06e-8	Mood instability;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.48e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.88	10.74	0.66	2.21e-20	Prudent dietary pattern;
PAAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.26	0.45	3.76e-9	Rheumatoid arthritis;
PAAD	cis	rs4523957	0.583	rs2641442	chr17:2035071	C/T	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.55	5.27	0.39	4.5e-7	Testicular germ cell tumor;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26488985	chr16:89584852	SPG7	-0.56	-6.47	-0.46	1.27e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.77e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.39	-0.46	1.88e-9	HDL cholesterol;
PAAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg18005901	chr6:33739558	LEMD2	-0.61	-5.02	-0.38	1.43e-6	Schizophrenia;
PAAD	cis	rs7084921	0.809	rs2902364	chr10:101817542	A/G	cg04359915	chr10:101825029	CPN1	-0.37	-5.33	-0.4	3.56e-7	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.58	7.05	0.5	5.86e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.7	5.35	0.4	3.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.46	-0.34	1.6e-5	Plateletcrit;Platelet count;
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21224049	chr4:668623	ATP5I	0.63	6.97	0.49	9.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.99	12.39	0.71	8.13e-25	Gestational age at birth (maternal effect);
PAAD	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.92	7.48	0.52	5.63e-12	Nonalcoholic fatty liver disease;
PAAD	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg13263323	chr15:86062960	AKAP13	-0.62	-7.17	-0.5	3.02e-11	Interstitial lung disease;
PAAD	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg10664184	chr19:17420304	DDA1	0.47	4.39	0.34	2.15e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.42	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs58799304	0.588	rs11590832	chr1:156079306	C/T	cg15685922	chr1:156045208	MEX3A	-0.68	-7.77	-0.53	1.11e-12	Ischemic stroke;
PAAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.01	-0.38	1.48e-6	Mood instability;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg22903657	chr4:1355424	KIAA1530	-0.46	-4.65	-0.35	7.23e-6	Obesity-related traits;
PAAD	cis	rs11997175	0.546	rs11775414	chr8:33615826	A/G	ch.8.33884649F	chr8:33765107	NA	0.62	6.65	0.47	4.89e-10	Body mass index;
PAAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.3	-0.39	4.08e-7	Height;
PAAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	1.13	11.88	0.69	1.92e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.61	-7.17	-0.5	3.07e-11	Dementia with Lewy bodies;
PAAD	cis	rs5756391	0.782	rs5756389	chr22:37290547	A/T	cg16356956	chr22:37317934	CSF2RB	0.37	4.63	0.35	7.65e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10501293	1.000	rs12222341	chr11:43126722	T/G	cg03447554	chr11:43094025	NA	-0.49	-4.9	-0.37	2.4e-6	Cognitive performance;
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.85	-9.95	-0.63	2.88e-18	Iron status biomarkers;
PAAD	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg02389323	chr16:88786976	FAM38A	0.96	6.31	0.46	2.87e-9	Plateletcrit;
PAAD	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	ch.11.42038R	chr11:967971	AP2A2	0.63	6.15	0.45	6.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg05585544	chr11:47624801	NA	0.46	5.13	0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg18551225	chr6:44695536	NA	-0.7	-6.94	-0.49	1.05e-10	Total body bone mineral density;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.71	-0.53	1.5e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9463078	0.809	rs6933553	chr6:45027770	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.26	-0.39	4.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-7.9	-0.54	5.11e-13	Menarche (age at onset);
PAAD	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.45	4.94	0.37	2.01e-6	Schizophrenia;
PAAD	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.31	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	7.42	0.52	7.57e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.82	-0.36	3.52e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.56	4.49	0.34	1.38e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12246027	0.505	rs10903832	chr10:320954	A/G	cg16386425	chr10:429943	DIP2C	-0.71	-4.71	-0.36	5.57e-6	Blood metabolite levels;
PAAD	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg00531865	chr16:30841666	NA	-0.5	-4.49	-0.34	1.41e-5	Dementia with Lewy bodies;
PAAD	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.74	7.37	0.51	9.91e-12	Corneal astigmatism;
PAAD	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.64	6.21	0.45	4.87e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg27455613	chr17:80820699	TBCD	0.46	4.63	0.35	7.83e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs939584	1.000	rs6734363	chr2:635200	G/A	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg22903657	chr4:1355424	KIAA1530	0.42	4.48	0.34	1.46e-5	Obesity-related traits;
PAAD	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.66	-8.11	-0.55	1.61e-13	Alcohol dependence;
PAAD	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.88	-0.63	4.22e-18	Response to antipsychotic treatment;
PAAD	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.77	-6.92	-0.49	1.17e-10	Body mass index;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg04520793	chr17:42248056	ASB16	0.4	4.54	0.35	1.16e-5	Total body bone mineral density;
PAAD	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-5.86	-0.43	2.84e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg12639453	chr1:2035780	PRKCZ	0.47	4.94	0.37	2e-6	Height;
PAAD	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.35	-0.33	2.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.42	-0.4	2.24e-7	Schizophrenia;
PAAD	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.56	-5.77	-0.42	4.26e-8	Multiple myeloma;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg15117754	chr3:10150083	C3orf24	0.64	5.44	0.4	2.05e-7	Alzheimer's disease;
PAAD	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.63	9.11	0.59	4.42e-16	Breast cancer;
PAAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Parkinson's disease;
PAAD	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.51	-4.85	-0.37	3.03e-6	Psoriasis;
PAAD	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-4.26	-0.33	3.58e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	1.08	6.11	0.44	7.84e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-4.67	-0.35	6.46e-6	Sitting height ratio;
PAAD	cis	rs2790216	1.000	rs2790235	chr10:59985274	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.75	6.72	0.48	3.44e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg18171855	chr10:2543474	NA	0.66	8.09	0.55	1.72e-13	Age-related hearing impairment;
PAAD	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs34112283	0.592	rs34657736	chr2:144234252	A/G	cg10530280	chr1:167759869	MPZL1	-0.65	-6.38	-0.46	2.04e-9	Neuroticism;
PAAD	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.8	-0.43	3.75e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg26876637	chr1:152193138	HRNR	-0.81	-5.43	-0.4	2.2e-7	Atopic dermatitis;
PAAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.54	-5.89	-0.43	2.39e-8	Total body bone mineral density;
PAAD	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.26	0.45	3.72e-9	Coffee consumption (cups per day);
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg16850897	chr7:100343110	ZAN	-0.77	-6.34	-0.46	2.52e-9	Other erythrocyte phenotypes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08779779	chr2:200322566	SATB2	0.59	6.92	0.49	1.2e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg26554054	chr8:600488	NA	0.97	6.96	0.49	9.69e-11	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19475930	chr12:120907604	DYNLL1;SFRS9	0.59	6.47	0.46	1.27e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.92	0.72	3.1e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2944591	0.505	rs747462	chr2:233790171	A/C	cg11972305	chr2:233791962	NGEF	-0.42	-4.41	-0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs730566	0.619	rs3731529	chr3:48213498	A/T	cg07636037	chr3:49044803	WDR6	-0.6	-4.57	-0.35	9.98e-6	Prion diseases;
PAAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs16958440	0.867	rs77348110	chr18:44674167	T/C	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg15117754	chr3:10150083	C3orf24	0.71	6.08	0.44	9.39e-9	Alzheimer's disease;
PAAD	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.81	12.22	0.7	2.32e-24	Lymphocyte counts;
PAAD	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.78	7.69	0.53	1.67e-12	Retinal vascular caliber;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg20848291	chr7:100343083	ZAN	-0.91	-8.43	-0.56	2.52e-14	Other erythrocyte phenotypes;
PAAD	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.41	-0.34	1.93e-5	Dupuytren's disease;
PAAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.94	-11.0	-0.67	4.65e-21	Coronary artery disease;
PAAD	cis	rs10450586	0.932	rs6484289	chr11:27317383	A/C	cg10370305	chr11:27303972	NA	0.41	5.01	0.38	1.52e-6	Total body bone mineral density;
PAAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg18402987	chr7:1209562	NA	1.11	5.6	0.41	9.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.34	-0.33	2.55e-5	Longevity;Endometriosis;
PAAD	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.53	-4.59	-0.35	9.32e-6	IgG glycosylation;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.48	6.45	0.46	1.41e-9	Ulcerative colitis;
PAAD	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	5.46	0.4	1.89e-7	Adiposity;
PAAD	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.91e-6	Neuroticism;
PAAD	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs11168618	0.509	rs2731092	chr12:48880550	T/C	cg01881778	chr12:48919444	OR8S1	0.45	4.54	0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.52	6.31	0.46	2.89e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg21361702	chr7:150065534	REPIN1	0.56	4.71	0.36	5.57e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	9.85e-11	Axial length;
PAAD	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg18232548	chr7:50535776	DDC	-0.49	-4.41	-0.34	1.97e-5	Systemic sclerosis;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg14433983	chr11:636460	DRD4	-0.47	-4.95	-0.37	1.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg05299278	chr17:33885742	SLFN14	-0.44	-5.19	-0.39	6.78e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs6723108	0.651	rs6724774	chr2:135407285	C/T	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg05484376	chr2:27715224	FNDC4	0.46	4.68	0.36	6.23e-6	Total body bone mineral density;
PAAD	cis	rs2916733	0.530	rs2442520	chr8:6290914	A/G	cg01691696	chr8:6734962	DEFB1	-0.55	-4.74	-0.36	4.83e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.46	0.34	1.57e-5	Myopia (pathological);
PAAD	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.63	6.89	0.49	1.37e-10	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.43	-0.52	7.27e-12	Colorectal cancer;
PAAD	cis	rs3857067	1.000	rs1585652	chr4:95014313	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-6.12	-0.44	7.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg05861140	chr6:150128134	PCMT1	-0.45	-4.8	-0.36	3.76e-6	Lung cancer;
PAAD	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.45	4.34	0.33	2.54e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.69	6.8	0.48	2.24e-10	Platelet distribution width;
PAAD	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.38	0.46	1.99e-9	Lung cancer in ever smokers;
PAAD	cis	rs375066	0.935	rs423320	chr19:44422982	G/A	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9646944	0.501	rs10176820	chr2:103054420	T/C	cg20060108	chr2:102954350	IL1RL1	0.58	4.79	0.36	3.95e-6	Blood protein levels;
PAAD	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.5	-0.41	1.54e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3026101	0.671	rs2309372	chr17:5298396	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg04520793	chr17:42248056	ASB16	0.39	4.63	0.35	7.69e-6	Total body bone mineral density;
PAAD	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.46	-0.4	1.93e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08821160	chr11:73309466	FAM168A	-0.73	-6.45	-0.46	1.43e-9	Neuroticism;
PAAD	cis	rs6473252	0.584	rs7825743	chr8:81807098	G/A	cg08595989	chr8:81827712	NA	-0.32	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.71	-6.9	-0.49	1.3e-10	Urate levels in lean individuals;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.8	-7.5	-0.52	4.89e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.52	4.98	0.37	1.7e-6	Mortality in heart failure;
PAAD	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg08886695	chr4:3369023	RGS12	-0.48	-4.59	-0.35	9.42e-6	Parental longevity (mother's age at death);
PAAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12016809	chr21:47604291	C21orf56	0.43	4.25	0.33	3.68e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26097999	chr17:72983826	CDR2L	0.59	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	1.02	10.64	0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.72	10.42	0.65	1.58e-19	Crohn's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05696109	chr1:223316668	TLR5	-0.64	-6.46	-0.46	1.34e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.71	6.81	0.48	2.13e-10	Parkinson's disease;
PAAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg10589385	chr1:150898437	SETDB1	-0.46	-5.56	-0.41	1.17e-7	Tonsillectomy;
PAAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.52	4.7	0.36	5.88e-6	Height;
PAAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.62	-6.32	-0.46	2.71e-9	Menopause (age at onset);
PAAD	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg08992911	chr2:238395768	MLPH	0.55	4.89	0.37	2.52e-6	Prostate cancer;
PAAD	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg27124370	chr19:33622961	WDR88	0.59	5.51	0.41	1.52e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10267417	0.603	rs4275126	chr7:19911030	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-7.6	-0.52	2.81e-12	Pulse pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22157823	chr3:47517263	SCAP	0.59	6.34	0.46	2.45e-9	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05264578	chr1:1886865	KIAA1751	0.61	6.35	0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs13006833	0.703	rs291459	chr2:191181527	T/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg20283391	chr11:68216788	NA	0.55	5.3	0.39	4.05e-7	Total body bone mineral density;
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg04520793	chr17:42248056	ASB16	0.48	6.48	0.47	1.22e-9	Total body bone mineral density;
PAAD	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.57	9.72	0.62	1.15e-17	Age-related hearing impairment;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.65	0.57	6.91e-15	Lung cancer;
PAAD	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.97	10.45	0.65	1.3e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13309018	chr9:130965761	CIZ1;DNM1	0.57	6.31	0.46	2.86e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg21849932	chr20:62369462	LIME1	-0.44	-4.25	-0.33	3.71e-5	Prostate cancer;
PAAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23158103	chr7:148848205	ZNF398	-0.64	-6.41	-0.46	1.69e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.43	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg20003494	chr4:90757398	SNCA	0.42	4.67	0.35	6.67e-6	Dementia with Lewy bodies;
PAAD	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg08390786	chr10:135334061	NA	0.47	4.53	0.34	1.18e-5	Obesity-related traits;
PAAD	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.31	-0.33	2.92e-5	Neuroticism;
PAAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg05725404	chr16:58534157	NDRG4	-0.78	-4.77	-0.36	4.2e-6	Schizophrenia;
PAAD	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.55	5.76	0.42	4.62e-8	Menarche (age at onset);
PAAD	cis	rs4743820	0.651	rs73494917	chr9:93923120	T/G	cg14446406	chr9:93919335	NA	0.45	5.44	0.4	2.1e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg16558253	chr16:72132732	DHX38	-0.55	-5.62	-0.41	9.09e-8	Fibrinogen levels;
PAAD	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.69	8.15	0.55	1.27e-13	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.8	9.09	0.59	5.06e-16	Breast cancer;
PAAD	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.73	0.48	3.2e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-7.95	-0.54	3.95e-13	Coffee consumption (cups per day);
PAAD	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.82	-8.65	-0.57	6.86e-15	Corneal astigmatism;
PAAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.41	4.88	0.37	2.65e-6	Tonsillectomy;
PAAD	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.85	10.15	0.64	8.39e-19	Blood metabolite ratios;
PAAD	cis	rs501120	0.584	rs11595946	chr10:44685695	C/T	cg09554077	chr10:44749378	NA	0.43	5.04	0.38	1.32e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.69	7.01	0.49	7.47e-11	Prostate cancer;
PAAD	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.46	-4.44	-0.34	1.69e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14019695	chr9:139328340	INPP5E	-0.59	-5.29	-0.39	4.11e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.91	12.02	0.7	7.96e-24	Prudent dietary pattern;
PAAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.42	0.34	1.87e-5	Iron status biomarkers;
PAAD	cis	rs10267417	0.603	rs10273885	chr7:19911992	T/C	cg05791153	chr7:19748676	TWISTNB	0.66	4.72	0.36	5.37e-6	Night sleep phenotypes;
PAAD	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg03700679	chr2:178418002	TTC30B	-0.5	-4.33	-0.33	2.74e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg21929781	chr1:2537748	MMEL1	-0.54	-5.61	-0.41	9.34e-8	Ulcerative colitis;
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg02966332	chr20:62369605	LIME1	0.47	4.41	0.34	1.96e-5	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.78	-0.36	4.02e-6	Resting heart rate;
PAAD	cis	rs9876781	0.967	rs34761139	chr3:48427979	C/T	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs28530618	0.500	rs6058770	chr20:31223633	A/C	cg27643859	chr20:30720887	TM9SF4	0.48	4.26	0.33	3.61e-5	Birth weight;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.91	11.87	0.69	2.01e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00837649	chr3:67705228	SUCLG2	0.53	6.37	0.46	2.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21825625	chr3:194393329	LSG1	-0.59	-6.84	-0.49	1.83e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.51	-5.39	-0.4	2.69e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.78	-7.8	-0.53	9.19e-13	Coronary artery disease;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg05627522	chr15:75251581	NA	0.59	7.21	0.5	2.45e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4979906	1.000	rs11002249	chr10:79447228	C/T	cg07817648	chr10:79422355	NA	-0.55	-4.99	-0.38	1.65e-6	Mortality in heart failure;
PAAD	cis	rs2302729	0.858	rs10431348	chr12:2784534	A/G	cg19945202	chr12:2788847	CACNA1C	-0.67	-5.35	-0.4	3.2e-7	Sleep quality;
PAAD	cis	rs7678296	1.000	rs73140729	chr4:37167806	G/T	cg06805348	chr4:37245195	KIAA1239	0.61	4.45	0.34	1.63e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6594713	0.717	rs2972690	chr5:112945945	T/C	cg12552261	chr5:112820674	MCC	-0.77	-5.52	-0.41	1.42e-7	Brain cytoarchitecture;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	15.67	0.79	1.48e-33	Prudent dietary pattern;
PAAD	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.69	7.2	0.5	2.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg16928487	chr17:17741425	SREBF1	0.34	4.56	0.35	1.06e-5	Total body bone mineral density;
PAAD	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.53	0.52	4.25e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3734905	0.708	rs4469299	chr6:169818001	A/G	cg11181693	chr6:169825345	NA	-0.84	-5.23	-0.39	5.57e-7	HIV-1 control;
PAAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.42	5.3	0.39	4.05e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.76	0.42	4.52e-8	Menopause (age at onset);
PAAD	cis	rs2555155	0.935	rs10769693	chr11:6520346	C/G	cg11185456	chr11:6592066	DNHD1	0.43	4.65	0.35	7.14e-6	DNA methylation (variation);
PAAD	cis	rs7260329	0.713	rs55721612	chr19:41486375	T/C	cg23925301	chr19:41220945	ADCK4	-0.49	-4.31	-0.33	2.89e-5	Smoking behavior;
PAAD	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Alcohol dependence;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.89	11.11	0.67	2.35e-21	Prudent dietary pattern;
PAAD	cis	rs12450239	0.514	rs35884841	chr17:77459907	C/T	cg09567646	chr17:76962761	NA	-0.42	-4.57	-0.35	9.87e-6	Body mass index;
PAAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.86e-9	Bladder cancer;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg13047869	chr3:10149882	C3orf24	0.62	5.4	0.4	2.46e-7	Alzheimer's disease;
PAAD	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.82	-10.48	-0.65	1.14e-19	Breast cancer;
PAAD	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg08501292	chr6:25962987	TRIM38	0.84	4.31	0.33	2.88e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg01796438	chr3:11312864	ATG7	-0.58	-4.55	-0.35	1.07e-5	Circulating chemerin levels;
PAAD	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.6	5.01	0.38	1.5e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.4	-0.4	2.52e-7	Subjective well-being;
PAAD	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.69	-7.81	-0.54	8.56e-13	Motion sickness;
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg11941060	chr3:133502564	NA	0.54	5.64	0.42	8.08e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg15208524	chr1:10270712	KIF1B	0.46	4.26	0.33	3.61e-5	Hepatocellular carcinoma;
PAAD	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.64	6.06	0.44	1.04e-8	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg24280607	chr15:41709584	RTF1	-0.61	-6.7	-0.48	3.83e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.84	-7.79	-0.53	9.8e-13	Resting heart rate;
PAAD	cis	rs9810890	1.000	rs73198869	chr3:128530365	G/A	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22117172	chr7:91764530	CYP51A1	0.33	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs2882667	0.690	rs311601	chr5:138053386	G/A	cg09476006	chr5:138032270	NA	0.48	6.02	0.44	1.26e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.73	-8.37	-0.56	3.41e-14	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg07362569	chr17:61921086	SMARCD2	0.43	4.75	0.36	4.74e-6	Height;
PAAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.72	-7.99	-0.54	3.11e-13	Eosinophil percentage of white cells;
PAAD	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.85	0.58	2.07e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.43	4.88	0.37	2.69e-6	Coronary artery disease;
PAAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.8	-5.77	-0.42	4.35e-8	Vitiligo;
PAAD	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg13722127	chr7:150037890	RARRES2	0.51	5.22	0.39	5.82e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.56	-4.89	-0.37	2.58e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs600550	0.588	rs7103808	chr11:60078176	A/G	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg13897122	chr2:103039542	IL18RAP	0.4	4.92	0.37	2.25e-6	Asthma;
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.87	-9.97	-0.63	2.44e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.46	4.31	0.33	2.95e-5	HDL cholesterol;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22035320	chr15:42170125	SPTBN5	-0.67	-6.62	-0.47	5.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9659323	0.931	rs113197996	chr1:119522426	G/A	cg17326555	chr1:119535693	NA	-0.43	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-7.79	-0.53	9.76e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs959260	1.000	rs7226070	chr17:73372811	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-4.32	-0.33	2.86e-5	Tuberculosis;
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	5.65	0.42	7.84e-8	Obesity-related traits;
PAAD	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.6	6.02	0.44	1.26e-8	Educational attainment (years of education);
PAAD	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg10523679	chr1:76189770	ACADM	0.52	4.92	0.37	2.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs10899021	0.920	rs11236174	chr11:74334201	G/A	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.92	9.66	0.62	1.66e-17	Parkinson's disease;
PAAD	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-4.76	-0.36	4.56e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.97	-11.58	-0.68	1.24e-22	Coronary artery disease;
PAAD	cis	rs12145833	1.000	rs10926984	chr1:243462153	T/G	cg02356786	chr1:243265016	LOC731275	0.68	4.66	0.35	6.74e-6	Obesity (early onset extreme);
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.17	0.5	3.09e-11	Renal function-related traits (BUN);
PAAD	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.79	-0.53	9.56e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.78	-8.19	-0.55	9.87e-14	Facial morphology (factor 23);
PAAD	cis	rs1620921	0.505	rs12526591	chr6:161204311	T/A	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg04545296	chr12:48745243	ZNF641	0.36	4.61	0.35	8.42e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.56	-0.41	1.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg23024343	chr7:107201750	COG5	0.58	4.76	0.36	4.42e-6	Coronary artery disease;
PAAD	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.57	0.47	7.75e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.2e-5	Life satisfaction;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.43	4.34	0.33	2.61e-5	Longevity;Endometriosis;
PAAD	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg00531865	chr16:30841666	NA	0.54	5.25	0.39	4.96e-7	Dementia with Lewy bodies;
PAAD	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.53	4.79	0.36	3.88e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	7.96	0.54	3.65e-13	Menarche (age at onset);
PAAD	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.31	-0.33	2.97e-5	Ileal carcinoids;
PAAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg03983715	chr16:68378420	PRMT7	0.69	5.05	0.38	1.27e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6700896	0.522	rs59258332	chr1:66143591	C/G	cg04111102	chr1:66153794	NA	0.48	4.5	0.34	1.37e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg10556349	chr10:835070	NA	0.7	5.25	0.39	5.06e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg18357526	chr6:26021779	HIST1H4A	0.57	5.09	0.38	1.04e-6	Educational attainment;
PAAD	cis	rs8005172	0.750	rs12888666	chr14:88431898	C/T	cg18078958	chr14:88630771	NA	0.47	5.4	0.4	2.51e-7	Parkinson's disease;
PAAD	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg09760422	chr2:128146352	NA	-0.35	-6.25	-0.45	3.95e-9	Protein C levels;
PAAD	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.79	-0.36	3.94e-6	Blood pressure;
PAAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.67	-8.8	-0.58	2.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs113779084	0.728	rs17273094	chr7:11951809	G/A	cg15090509	chr7:11872073	THSD7A	0.39	4.86	0.37	2.87e-6	Educational attainment (years of education);
PAAD	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.93	0.49	1.14e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.76	8.94	0.59	1.22e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.55	-5.03	-0.38	1.37e-6	Mean platelet volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10857489	chr5:1064245	SLC12A7	0.55	6.52	0.47	9.6e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.55	5.65	0.42	7.62e-8	Dupuytren's disease;
PAAD	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.38	4.46	0.34	1.58e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg00944433	chr1:107599041	PRMT6	0.38	4.26	0.33	3.56e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.35	-0.33	2.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs721399	0.539	rs2898476	chr8:18266924	G/A	cg18736775	chr8:18248649	NAT2	-0.6	-4.41	-0.34	1.91e-5	Blood metabolite levels;
PAAD	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.64	-6.11	-0.44	8.2e-9	Schizophrenia;
PAAD	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.13	0.38	8.78e-7	HIV-1 control;
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.34	-0.33	2.6e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.51	-5.44	-0.4	2.04e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg18518183	chr2:172544446	DYNC1I2	0.5	4.41	0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs2688419	0.565	rs2688414	chr3:23078904	T/C	cg00327796	chr3:23032191	NA	-0.51	-4.92	-0.37	2.19e-6	Type 2 diabetes;
PAAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg08132940	chr7:1081526	C7orf50	0.62	4.62	0.35	8.19e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg20003494	chr4:90757398	SNCA	-0.44	-5.04	-0.38	1.31e-6	Dementia with Lewy bodies;
PAAD	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg01620082	chr3:125678407	NA	-1.32	-7.76	-0.53	1.15e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.863	rs8097455	chr18:44593122	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-6.29	-0.45	3.17e-9	Personality dimensions;
PAAD	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.71	7.3	0.51	1.51e-11	Retinal vascular caliber;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.09	8.13	0.55	1.41e-13	Alzheimer's disease;
PAAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.1	0.59	4.77e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.62	-0.35	8.23e-6	Blood protein levels;
PAAD	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg15208524	chr1:10270712	KIF1B	0.51	4.7	0.36	5.69e-6	Hepatocellular carcinoma;
PAAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.85	0.49	1.69e-10	Rheumatoid arthritis;
PAAD	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.39	4.97	0.37	1.79e-6	Educational attainment (years of education);
PAAD	cis	rs416603	0.755	rs2301127	chr16:11367477	G/A	cg00044050	chr16:11439710	C16orf75	-0.62	-5.77	-0.42	4.3e-8	Type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.89	-15.2	-0.78	2.55e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.61	0.82	1.61e-38	Height;
PAAD	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	6.56	0.47	7.91e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6908034	0.769	rs6916589	chr6:19761363	T/G	cg02682789	chr6:19804855	NA	0.81	5.23	0.39	5.45e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9616064	0.849	rs73181057	chr22:46972152	G/A	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.54	-0.35	1.14e-5	Urate levels in obese individuals;
PAAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.16	-0.39	7.56e-7	Body mass index;
PAAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09906224	chr5:141995186	FGF1	-0.64	-6.44	-0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.75	8.27	0.56	6.16e-14	Heart rate;
PAAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg15193198	chr20:60906057	LAMA5	-0.49	-5.29	-0.39	4.21e-7	Colorectal cancer;
PAAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg05110241	chr16:68378359	PRMT7	-1.12	-7.74	-0.53	1.28e-12	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.42	0.46	1.62e-9	Calcium levels;
PAAD	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg25204440	chr1:209979598	IRF6	0.59	5.06	0.38	1.2e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg23995914	chr4:10459228	ZNF518B	-0.38	-4.56	-0.35	1.07e-5	Schizophrenia (age at onset);
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.68	-7.43	-0.52	7.19e-12	Blood metabolite levels;
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.84	-8.97	-0.59	1.01e-15	Prostate cancer;
PAAD	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.7	7.35	0.51	1.12e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg10973622	chr2:86423274	IMMT	0.48	5.62	0.41	8.91e-8	Night sleep phenotypes;
PAAD	cis	rs802075	1.000	rs360565	chr6:49657805	C/T	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg27529037	chr20:44575021	PCIF1	-0.51	-4.33	-0.33	2.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.5	-5.18	-0.39	7.07e-7	Tonsillectomy;
PAAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs287982	0.932	rs11887231	chr2:9967116	C/A	cg01119585	chr2:10571959	NA	0.39	4.43	0.34	1.78e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg04218760	chr10:45406644	TMEM72	-0.28	-4.82	-0.36	3.38e-6	Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73207973	chr3:128568365	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg09915433	chr19:53449742	NA	-0.79	-11.61	-0.69	1.01e-22	Psoriasis;
PAAD	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs863345	0.604	rs12120526	chr1:158498404	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs797680	0.891	rs9432453	chr1:93771629	G/A	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-4.81	-0.36	3.53e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.76	0.42	4.43e-8	Prudent dietary pattern;
PAAD	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg16794390	chr17:18148240	FLII	0.57	4.71	0.36	5.61e-6	Obesity-related traits;
PAAD	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg16329197	chr12:53359506	NA	-0.86	-9.7	-0.62	1.3e-17	Prostate cancer;
PAAD	cis	rs8067287	0.708	rs1004439	chr17:16841924	A/G	cg26910001	chr17:16838321	NA	-0.59	-5.34	-0.4	3.37e-7	Diabetic kidney disease;
PAAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-14.83	-0.77	2.5e-31	Coronary artery disease;
PAAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg25809561	chr17:30822961	MYO1D	0.61	6.29	0.45	3.13e-9	Schizophrenia;
PAAD	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.15	-0.39	7.98e-7	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22054364	chr7:4308739	NA	-0.64	-6.64	-0.47	5.13e-10	Obesity-related traits;
PAAD	cis	rs2236918	0.710	rs3094880	chr1:242020391	T/A	cg17736920	chr1:242011382	EXO1	0.56	5.65	0.42	7.58e-8	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs10159528	0.691	rs7904922	chr10:87472196	C/A	cg03356747	chr10:88126089	GRID1	-0.38	-4.39	-0.34	2.07e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg04287289	chr16:89883240	FANCA	0.93	11.89	0.69	1.84e-23	Schizophrenia;
PAAD	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg07384165	chr1:10488281	NA	-0.48	-5.0	-0.38	1.54e-6	Breast size;
PAAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg21665744	chr7:39171113	POU6F2	0.32	5.49	0.41	1.65e-7	IgG glycosylation;
PAAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg00990874	chr7:1149470	C7orf50	-0.75	-5.87	-0.43	2.62e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.23e-5	Life satisfaction;
PAAD	cis	rs13242816	1.000	rs7796429	chr7:116144369	T/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs10090774	0.930	rs8180948	chr8:141982653	T/C	cg02508881	chr8:142216119	NA	-0.41	-4.38	-0.33	2.21e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.9	-0.49	1.3100000000000001e-10	Triglycerides;
PAAD	cis	rs6558530	0.836	rs11136424	chr8:1717036	C/T	cg19131313	chr8:1704013	NA	-0.4	-4.42	-0.34	1.86e-5	Systolic blood pressure;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg25487775	chr2:162093969	NA	-0.58	-6.53	-0.47	9.42e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs4141404	0.512	rs1018490	chr22:31996625	A/C	cg02404636	chr22:31891804	SFI1	0.52	4.95	0.37	1.93e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.64	-0.42	8.13e-8	Crohn's disease;
PAAD	cis	rs9810890	1.000	rs73198839	chr3:128500442	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.68	0.35	6.31e-6	Breast cancer;
PAAD	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.94	10.21	0.64	5.76e-19	Inhibitory control;
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.6	6.47	0.46	1.28e-9	Lung cancer;
PAAD	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs834603	0.569	rs834602	chr7:47446215	A/C	cg07298482	chr7:48068728	SUNC1	-0.36	-4.4	-0.34	2.06e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg05084668	chr3:125655381	ALG1L	-0.46	-5.09	-0.38	1.07e-6	Blood pressure (smoking interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07428804	chr11:62599512	STX5	-0.58	-6.54	-0.47	8.76e-10	Smoking initiation;
PAAD	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.56e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3857067	1.000	rs7682116	chr4:95002704	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.97	-8.93	-0.59	1.29e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.26	-19.21	-0.84	1.63e-42	Ulcerative colitis;
PAAD	cis	rs1903068	0.886	rs1551644	chr4:55994266	A/T	cg01777861	chr4:56023843	NA	0.36	4.26	0.33	3.54e-5	Endometriosis;
PAAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.59	6.23	0.45	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.38	4.28	0.33	3.3e-5	Carotid intima media thickness;
PAAD	trans	rs100537	0.720	rs61800587	chr1:165392570	G/A	cg09024962	chr5:132707300	FSTL4	-0.35	-6.36	-0.46	2.28e-9	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.88	6.62	0.47	5.77e-10	Alzheimer's disease;
PAAD	cis	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg12395012	chr8:11607386	GATA4	0.44	4.3	0.33	3.04e-5	Neuroticism;
PAAD	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.55	-4.65	-0.35	7.12e-6	Schizophrenia;
PAAD	cis	rs7326068	0.557	rs4331211	chr13:21125299	T/C	cg27234864	chr13:21295941	IL17D	0.61	5.47	0.41	1.85e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	4.93	0.37	2.11e-6	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg00310523	chr12:86230176	RASSF9	0.43	4.54	0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.56	-0.35	1.04e-5	Schizophrenia;
PAAD	cis	rs5746492	0.642	rs72490631	chr22:18357509	T/C	cg06148736	chr22:18985691	NA	-0.4	-4.39	-0.34	2.09e-5	Eotaxin levels;
PAAD	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.59	-0.41	1.05e-7	Urate levels in overweight individuals;
PAAD	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15145965	chr22:50218605	BRD1	-0.57	-4.93	-0.37	2.12e-6	Schizophrenia;
PAAD	cis	rs79481398	0.616	rs79413113	chr15:57788740	G/A	cg14807837	chr15:57668552	CGNL1	0.66	4.35	0.33	2.53e-5	Facial morphology (factor 19);
PAAD	cis	rs4596713	0.538	rs10781440	chr9:71762766	A/G	cg14300048	chr9:72046240	APBA1	-0.43	-4.38	-0.33	2.24e-5	Headache;
PAAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg01262667	chr19:19385393	TM6SF2	0.46	5.23	0.39	5.43e-7	Tonsillectomy;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.49	7.27	0.51	1.72e-11	Mean platelet volume;
PAAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.47	4.43	0.34	1.78e-5	RR interval (heart rate);
PAAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg27539214	chr16:67997921	SLC12A4	-0.69	-5.3	-0.4	3.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.32	-0.46	2.78e-9	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.82	-8.62	-0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.95	-0.54	3.94e-13	Schizophrenia;
PAAD	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg00745463	chr17:30367425	LRRC37B	-0.6	-4.7	-0.36	5.75e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.94	0.37	2.06e-6	Longevity;
PAAD	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.39	-0.76	3.65e-30	Primary sclerosing cholangitis;
PAAD	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.43	4.79	0.36	3.96e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.34	0.51	1.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg11657440	chr19:46296263	DMWD	-0.63	-5.46	-0.4	1.91e-7	Coronary artery disease;
PAAD	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs11669133	1.000	rs74522500	chr19:11100460	C/T	cg25243385	chr19:11167475	SMARCA4	0.93	4.35	0.33	2.44e-5	LDL cholesterol;
PAAD	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg18286501	chr10:63213339	TMEM26	0.38	4.28	0.33	3.33e-5	Night sleep phenotypes;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.88	-10.7	-0.66	2.82e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.48	-4.75	-0.36	4.74e-6	Multiple sclerosis;
PAAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.58	-5.89	-0.43	2.37e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	7.72	0.53	1.45e-12	Cognitive test performance;
PAAD	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	1.92	10.46	0.65	1.24e-19	Cannabis dependence symptom count;
PAAD	cis	rs11159086	0.793	rs10147316	chr14:74942391	A/C	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.7	-7.77	-0.53	1.07e-12	Aortic root size;
PAAD	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg22029157	chr1:209979665	IRF6	0.73	6.25	0.45	3.88e-9	Coronary artery disease;
PAAD	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.67	6.61	0.47	6.16e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.76	7.57	0.52	3.4e-12	Obesity-related traits;
PAAD	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.76	-7.75	-0.53	1.19e-12	Monocyte count;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	0.39	4.37	0.33	2.26e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.49	-6.12	-0.44	7.73e-9	Colorectal cancer;
PAAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg27234864	chr13:21295941	IL17D	-0.54	-4.78	-0.36	4.07e-6	Dental caries;
PAAD	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.47	-5.35	-0.4	3.19e-7	Body mass index;
PAAD	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg16586182	chr3:47516702	SCAP	-0.68	-7.74	-0.53	1.31e-12	Colorectal cancer;
PAAD	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg12639453	chr1:2035780	PRKCZ	0.49	4.64	0.35	7.48e-6	Height;
PAAD	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-1.01	-10.92	-0.66	7.36e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6718203	1.000	rs55994735	chr2:60636157	T/C	cg10480506	chr2:60280451	NA	0.76	4.64	0.35	7.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.61	6.29	0.45	3.27e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg15604389	chr3:122379662	NA	0.58	6.24	0.45	4.11e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.91	-8.79	-0.58	2.95e-15	Tuberculosis;
PAAD	cis	rs6715793	0.901	rs7595240	chr2:33402716	C/T	cg26672287	chr2:33391915	LTBP1	-0.45	-5.16	-0.39	7.71e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7188861	0.813	rs1541701	chr16:11445640	G/A	cg01510278	chr16:11456238	NA	-0.43	-4.28	-0.33	3.3e-5	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19830245	chr17:17141047	FLCN	0.66	7.33	0.51	1.29e-11	Obesity-related traits;
PAAD	cis	rs7945718	0.621	rs11022465	chr11:12686139	C/T	cg25843174	chr11:12811716	TEAD1	-0.3	-4.39	-0.34	2.13e-5	Educational attainment (years of education);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24293976	chr12:111843567	SH2B3	0.65	7.22	0.51	2.29e-11	Myopia (pathological);
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17706896	chr19:46406599	MYPOP	0.55	6.38	0.46	2.06e-9	Response to antipsychotic treatment;
PAAD	cis	rs4948102	0.667	rs7811270	chr7:56139990	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.54	0.41	1.31e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg05418105	chr22:50981406	NA	-0.51	-4.71	-0.36	5.66e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.66	5.75	0.42	4.71e-8	Schizophrenia;
PAAD	cis	rs790123	0.579	rs1512047	chr3:122398524	C/T	cg15604389	chr3:122379662	NA	0.52	4.9	0.37	2.42e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg12923728	chr3:195709715	SDHAP1	-0.6	-5.86	-0.43	2.74e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.81	-8.38	-0.56	3.32e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.61	6.4	0.46	1.84e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs893363	0.621	rs14165	chr3:53847408	A/G	cg15798837	chr3:54122146	NA	0.36	4.35	0.33	2.44e-5	Axial length;
PAAD	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Educational attainment (college completion);
PAAD	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.75	-6.17	-0.45	5.96e-9	Coronary artery disease;
PAAD	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs4919087	0.545	rs793531	chr10:99041167	G/T	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.73	-7.61	-0.53	2.72e-12	Type 2 diabetes;
PAAD	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	-0.62	-5.02	-0.38	1.42e-6	Breast cancer;
PAAD	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-9.87	-0.62	4.74e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.56	6.01	0.44	1.31e-8	Testicular germ cell tumor;
PAAD	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg14393609	chr7:65229607	NA	0.57	5.96	0.43	1.73e-8	Aortic root size;
PAAD	cis	rs1864585	0.520	rs9650659	chr8:10667765	G/T	cg21775007	chr8:11205619	TDH	-0.56	-4.4	-0.34	2.02e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs864745	0.579	rs849336	chr7:28224053	A/G	cg01883759	chr7:28220576	JAZF1	-0.5	-5.13	-0.38	8.56e-7	Crohn's disease;Type 2 diabetes;
PAAD	cis	rs7714584	0.826	rs12655654	chr5:150174295	A/C	cg22134413	chr5:150180641	NA	0.95	6.39	0.46	1.92e-9	Crohn's disease;
PAAD	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg09066997	chr16:75300724	BCAR1	0.63	4.58	0.35	9.76e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs12780845	0.964	rs34539222	chr10:17238890	G/A	cg00857480	chr10:17188594	TRDMT1	0.36	4.51	0.34	1.32e-5	Homocysteine levels;
PAAD	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs6669119	1.000	rs9439747	chr1:19111912	G/C	cg26220594	chr1:19110978	NA	0.74	4.53	0.35	1.18e-5	Percentage gas trapping;
PAAD	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.93	10.75	0.66	2.13e-20	Colorectal adenoma (advanced);
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11563648	0.553	rs6978090	chr7:127029429	C/A	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg06375148	chr1:209958343	C1orf74	0.67	5.71	0.42	5.84e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg26031613	chr14:104095156	KLC1	-0.55	-5.6	-0.41	9.6e-8	Reticulocyte count;
PAAD	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg21130718	chr4:1044621	NA	0.53	4.55	0.35	1.08e-5	Recombination rate (females);
PAAD	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.65	0.35	7.22e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg02795151	chr17:7402630	POLR2A	0.62	5.81	0.43	3.6e-8	Androgen levels;
PAAD	cis	rs6473252	0.584	rs59439286	chr8:81817148	T/C	cg08595989	chr8:81827712	NA	-0.34	-4.73	-0.36	5.04e-6	Breast cancer;
PAAD	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.5	-6.1	-0.44	8.35e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10901513	0.932	rs7085584	chr10:127677570	C/T	cg22975853	chr10:127789788	ADAM12	0.43	4.68	0.36	6.18e-6	Visceral fat;
PAAD	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19175649	chr17:15164120	PMP22	-0.69	-6.43	-0.46	1.59e-9	Neuroticism;
PAAD	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg03367679	chr17:38183553	MED24;SNORD124	-0.38	-5.13	-0.38	8.64e-7	Myeloid white cell count;
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-5.02	-0.38	1.42e-6	Vitiligo;
PAAD	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.46	4.75	0.36	4.57e-6	Breast cancer;
PAAD	cis	rs9815354	1.000	rs1716660	chr3:41929960	G/A	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.99	11.42	0.68	3.31e-22	Parkinson's disease;
PAAD	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.22	0.55	8.23e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs11700980	0.551	rs2832015	chr21:30111192	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.53	8.28	0.56	5.83e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2124969	0.549	rs56296079	chr2:160941461	C/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-5.67	-0.42	7.02e-8	Waist circumference adjusted for body mass index;
PAAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.54	-0.35	1.13e-5	Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01585852	chr22:24235823	MIF	0.47	5.15	0.39	8.1e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.45	6.18	0.45	5.65e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10112672	chr14:59104396	DACT1	-0.76	-6.61	-0.47	6.19e-10	Neuroticism;
PAAD	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.51	5.28	0.39	4.3e-7	Male-pattern baldness;
PAAD	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg21419209	chr3:44054225	NA	-0.74	-7.4	-0.51	8.75e-12	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.79	-5.35	-0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.53	5.31	0.4	3.82e-7	Longevity;Endometriosis;
PAAD	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.27	-0.6	1.77e-16	Pancreatic cancer;
PAAD	cis	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg21546286	chr11:48923668	NA	0.55	5.6	0.41	9.75e-8	HDL cholesterol;
PAAD	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14169450	chr9:139327907	INPP5E	0.5	4.81	0.36	3.6e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.73	-8.23	-0.56	7.74e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.41	0.46	1.78e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.85	10.52	0.65	8.91e-20	Schizophrenia;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg25618597	chr12:133433795	CHFR	-0.64	-6.4	-0.46	1.84e-9	Dental caries;
PAAD	cis	rs2637266	0.846	rs2579773	chr10:78402847	A/C	cg18941641	chr10:78392320	NA	0.37	4.3	0.33	3.04e-5	Pulmonary function;
PAAD	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg01426195	chr3:39028469	NA	-0.77	-8.56	-0.57	1.18e-14	Handedness;
PAAD	cis	rs12889267	0.722	rs2319625	chr14:21565146	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	0.53	4.82	0.36	3.51e-6	Hematocrit;Resting heart rate;
PAAD	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs73019876	0.869	rs4378732	chr19:22153696	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	4.38	0.33	2.2e-5	Skin pigmentation;
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	5.66	0.42	7.22e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg10932868	chr11:921992	NA	0.44	4.81	0.36	3.59e-6	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03383661	chr6:42714115	TBCC	0.62	6.87	0.49	1.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.56	-4.88	-0.37	2.62e-6	P wave terminal force;
PAAD	cis	rs2518049	0.500	rs7088288	chr10:5157139	G/A	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg23298862	chr7:158159286	PTPRN2	-0.45	-4.28	-0.33	3.33e-5	Calcium levels;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.81	-8.65	-0.57	6.98e-15	Menopause (age at onset);
PAAD	cis	rs9657904	0.865	rs3996189	chr3:105576911	G/A	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs6466055	0.589	rs67780803	chr7:104977168	C/T	cg04380332	chr7:105027541	SRPK2	0.5	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.47	-4.27	-0.33	3.49e-5	Arsenic metabolism;
PAAD	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.5	-5.26	-0.39	4.81e-7	Menarche (age at onset);
PAAD	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.11	0.38	9.35e-7	Common traits (Other);
PAAD	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18357526	chr6:26021779	HIST1H4A	0.53	4.68	0.35	6.32e-6	Height;
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.59	4.68	0.36	6.19e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15464645	chr15:28380110	HERC2	-0.61	-6.45	-0.46	1.38e-9	Myopia (pathological);
PAAD	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-6.38	-0.46	2.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.59	6.1	0.44	8.33e-9	Coronary artery disease;
PAAD	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.75	6.98	0.49	8.66e-11	Platelet distribution width;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.75	-8.7	-0.58	5.05e-15	Lung cancer;
PAAD	cis	rs911119	0.908	rs6048950	chr20:23603252	A/G	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg23024343	chr7:107201750	COG5	0.55	4.41	0.34	1.98e-5	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4073221	0.789	rs9824915	chr3:18263272	G/T	cg07694806	chr3:18168406	NA	-0.74	-4.99	-0.38	1.65e-6	Parkinson's disease;
PAAD	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg17868515	chr10:100992068	HPSE2	-0.44	-5.18	-0.39	7.04e-7	Metabolite levels;
PAAD	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg05895507	chr15:77155635	SCAPER	0.41	4.94	0.37	2.03e-6	Blood metabolite levels;
PAAD	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs3758785	0.512	rs7950328	chr11:94099615	C/T	cg04065909	chr11:94964294	SESN3	-0.47	-4.32	-0.33	2.77e-5	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.71	8.35	0.56	3.96e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.84	10.18	0.64	6.87e-19	Ulcerative colitis;
PAAD	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.66	-7.24	-0.51	2.14e-11	Age-related hearing impairment;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	7.44	0.52	6.98e-12	Lymphocyte counts;
PAAD	cis	rs438465	1.000	rs391468	chr6:169809099	C/T	cg11181693	chr6:169825345	NA	-0.57	-4.54	-0.35	1.14e-5	Corneal astigmatism;
PAAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17140797	chr19:15529788	AKAP8L	-0.78	-8.78	-0.58	3.1e-15	Smoking initiation;
PAAD	cis	rs9913156	0.748	rs7219787	chr17:4562257	A/T	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg04865290	chr3:52927548	TMEM110	0.68	4.5	0.34	1.35e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	1.1	8.76	0.58	3.66e-15	Iron status biomarkers;
PAAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.62	5.9	0.43	2.27e-8	Blood metabolite levels;
PAAD	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.56	-0.41	1.18e-7	Mood instability;
PAAD	cis	rs2415984	0.500	rs12323609	chr14:46976023	C/G	cg14871534	chr14:47121158	RPL10L	-0.49	-5.04	-0.38	1.31e-6	Number of children ever born;
PAAD	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.55	-0.35	1.07e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.77	9.01	0.59	8.18e-16	Emphysema distribution in smoking;
PAAD	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-5.94	-0.43	1.84e-8	Inflammatory bowel disease;
PAAD	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg22349387	chr12:9600060	DDX12	-0.42	-4.46	-0.34	1.59e-5	Breast size;
PAAD	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.59	5.5	0.41	1.56e-7	Height;
PAAD	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.92	-0.43	2.1e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.24e-5	Cognitive function;
PAAD	cis	rs1015291	0.670	rs1492114	chr12:19995128	A/G	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg22663859	chr13:21900854	NA	0.57	6.37	0.46	2.17e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.45	-4.43	-0.34	1.79e-5	Schizophrenia;
PAAD	cis	rs7301826	0.610	rs7961690	chr12:131296880	G/T	cg11011512	chr12:131303247	STX2	-0.42	-4.35	-0.33	2.44e-5	Plasma plasminogen activator levels;
PAAD	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.9	-5.94	-0.43	1.87e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-5.6	-0.41	9.82e-8	Subjective well-being;
PAAD	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs499368	0.519	rs216245	chr12:310419	G/T	cg02925805	chr12:298484	NA	0.48	4.81	0.36	3.61e-6	Blood metabolite levels;Metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01544807	chr8:42195539	POLB	0.65	7.35	0.51	1.15e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	6.12	0.44	7.72e-9	Mood instability;
PAAD	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.68	-0.48	4.28e-10	Body mass index;
PAAD	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.94	9.66	0.62	1.66e-17	Response to antineoplastic agents;
PAAD	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.57	5.5	0.41	1.61e-7	Osteoporosis;
PAAD	trans	rs10515808	0.558	rs75856775	chr5:159815980	C/T	cg04842426	chr7:136555777	CHRM2	-0.55	-6.35	-0.46	2.39e-9	Weight loss (gastric bypass surgery);
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg01763666	chr17:80159506	CCDC57	-0.45	-4.51	-0.34	1.27e-5	Life satisfaction;
PAAD	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.71	-9.16	-0.6	3.27e-16	Asthma;
PAAD	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.56	5.89	0.43	2.39e-8	Dupuytren's disease;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.69	-0.53	1.7e-12	Body mass index;
PAAD	trans	rs901683	0.850	rs12774453	chr10:46038921	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-1.05	-7.53	-0.52	4.27e-12	Blood pressure (smoking interaction);
PAAD	cis	rs12586317	0.653	rs4981287	chr14:35828198	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	7.43	0.52	7.43e-12	Psoriasis;
PAAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs412658	0.523	rs440597	chr19:22096519	T/C	cg23859931	chr19:22123797	NA	-0.42	-4.29	-0.33	3.17e-5	Telomere length;
PAAD	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.01	-0.38	1.52e-6	Mean corpuscular volume;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg07068956	chr7:100330872	ZAN	-0.62	-4.78	-0.36	4.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2456568	0.733	rs7946312	chr11:93688541	G/T	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.16	-0.39	7.52e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs863345	0.604	rs2054993	chr1:158505968	T/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg23860436	chr12:58378763	NA	0.46	4.26	0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.55	-0.47	8.4e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22856287	chr6:34204459	HMGA1	0.63	6.37	0.46	2.17e-9	Myopia (pathological);
PAAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.94	12.06	0.7	6.28e-24	Menopause (age at onset);
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.33	5.24	0.39	5.2e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.52	5.08	0.38	1.09e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2415984	0.622	rs17672908	chr14:46934527	T/C	cg14871534	chr14:47121158	RPL10L	-0.53	-5.52	-0.41	1.44e-7	Number of children ever born;
PAAD	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.57	5.16	0.39	7.5e-7	Mean corpuscular volume;
PAAD	cis	rs4903604	0.581	rs4903606	chr14:78036935	A/G	cg18872420	chr14:78023429	SPTLC2	0.42	4.38	0.33	2.18e-5	Gut microbiome composition (winter);
PAAD	cis	rs1109501	0.770	rs28408923	chr4:71407154	T/C	cg25553522	chr4:71388589	AMTN	0.51	4.37	0.33	2.3e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs727479	0.502	rs1065779	chr15:51504811	A/C	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.55e-5	Estradiol levels;
PAAD	cis	rs564309	0.867	rs12093491	chr1:228569498	C/G	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.68	-7.29	-0.51	1.6e-11	Post bronchodilator FEV1;
PAAD	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.43	-0.34	1.76e-5	Mood instability;
PAAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.84	-8.57	-0.57	1.08e-14	Schizophrenia;
PAAD	cis	rs2797160	0.904	rs1739366	chr6:126007409	T/C	cg05901451	chr6:126070800	HEY2	0.5	4.63	0.35	7.82e-6	Endometrial cancer;
PAAD	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23158103	chr7:148848205	ZNF398	-0.56	-5.06	-0.38	1.17e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg20243544	chr17:37824526	PNMT	0.72	6.75	0.48	2.86e-10	Asthma;
PAAD	cis	rs9314614	0.789	rs2951862	chr8:6711304	C/G	cg27319216	chr8:6693540	XKR5	-0.35	-4.56	-0.35	1.05e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs72901758	0.739	rs72901754	chr17:76244398	G/A	cg11439826	chr17:76250004	NA	0.45	4.48	0.34	1.47e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.32	0.4	3.59e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.69	-6.07	-0.44	9.8e-9	Type 2 diabetes;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg22903657	chr4:1355424	KIAA1530	0.44	4.65	0.35	7.18e-6	Obesity-related traits;
PAAD	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg25730555	chr22:47059586	GRAMD4	0.46	4.47	0.34	1.52e-5	Urate levels in obese individuals;
PAAD	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.65	6.66	0.48	4.7e-10	Colorectal cancer;
PAAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.7	7.03	0.5	6.62e-11	Morning vs. evening chronotype;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg23958373	chr8:599963	NA	-1.08	-7.78	-0.53	1.03e-12	IgG glycosylation;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09376583	chr16:88111425	NA	-0.53	-4.58	-0.35	9.66e-6	Menopause (age at onset);
PAAD	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.65	8.08	0.55	1.82e-13	Educational attainment;
PAAD	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg11271282	chr2:238384023	NA	0.65	4.36	0.33	2.38e-5	Prostate cancer;
PAAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	0.69	5.63	0.42	8.58e-8	Blood protein levels;
PAAD	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg20019720	chr6:154832845	CNKSR3	0.64	7.56	0.52	3.53e-12	Lipoprotein (a) levels;
PAAD	cis	rs73019876	0.901	rs1848998	chr19:22135280	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	cis	rs6460942	0.597	rs4721106	chr7:12535053	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7259965	0.834	rs11673270	chr19:41520844	A/C	cg20630647	chr19:41531805	NA	0.48	4.29	0.33	3.22e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs9810890	1.000	rs73198852	chr3:128508858	A/C	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.61	-0.53	2.62e-12	Diastolic blood pressure;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.78	-5.13	-0.38	8.59e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.92e-7	Ulcerative colitis;
PAAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21016266	chr12:122356598	WDR66	0.58	6.97	0.49	9.06e-11	Mean corpuscular volume;
PAAD	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.72	-0.36	5.32e-6	Joint mobility (Beighton score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.66	7.33	0.51	1.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg14349672	chr11:133703707	NA	-0.59	-6.88	-0.49	1.43e-10	Childhood ear infection;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.73	-8.68	-0.58	5.8e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-4.75	-0.36	4.69e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.64	6.89	0.49	1.36e-10	Huntington's disease progression;
PAAD	cis	rs17739167	0.532	rs11638953	chr15:42245652	G/A	cg20935245	chr15:42234343	EHD4	0.57	6.1	0.44	8.21e-9	Monocyte count;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07677032	chr17:61819896	STRADA	0.53	5.16	0.39	7.57e-7	Prudent dietary pattern;
PAAD	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.78	5.94	0.43	1.86e-8	Mean platelet volume;
PAAD	cis	rs6710503	0.547	rs17734407	chr2:24730581	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.69e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs2036402	0.866	rs6555761	chr5:156365472	A/C	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.19e-5	Hypertriglyceridemia;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.47	4.99	0.38	1.6e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs354225	0.539	rs6545440	chr2:54959862	A/T	cg01766943	chr2:54829624	SPTBN1	0.54	4.37	0.33	2.29e-5	Schizophrenia;
PAAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.68	6.23	0.45	4.33e-9	Monocyte count;
PAAD	cis	rs7550636	0.658	rs1775686	chr1:192810167	A/G	cg05576974	chr1:193028138	TROVE2;UCHL5	0.45	4.43	0.34	1.81e-5	Coronary artery calcification;
PAAD	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg14851346	chr12:38532713	NA	-0.47	-4.52	-0.34	1.22e-5	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14107273	chr22:21271661	CRKL	0.62	6.34	0.46	2.49e-9	Obesity-related traits;
PAAD	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg16447950	chr5:562315	NA	-0.67	-5.95	-0.43	1.77e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg08824895	chr13:115047677	UPF3A	0.5	4.68	0.35	6.31e-6	Schizophrenia;
PAAD	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg20487152	chr13:99095054	FARP1	-0.52	-5.04	-0.38	1.31e-6	Longevity;
PAAD	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-5.52	-0.41	1.46e-7	Coronary artery disease;
PAAD	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg17783671	chr19:59070436	UBE2M;LOC100131691	-0.66	-6.64	-0.47	5.29e-10	Body mass index;
PAAD	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	4.46	0.34	1.55e-5	Blood protein levels;
PAAD	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.6	-0.35	8.68e-6	Pulmonary function;
PAAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.54	5.7	0.42	5.96e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2302729	0.929	rs7306298	chr12:2777311	G/A	cg19945202	chr12:2788847	CACNA1C	-0.74	-6.84	-0.48	1.86e-10	Sleep quality;
PAAD	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-1.27	-10.06	-0.63	1.46e-18	Obesity-related traits;
PAAD	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg15571903	chr15:79123663	NA	-0.47	-6.11	-0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs41311933	1.000	rs16910255	chr9:123756983	C/T	cg13567360	chr9:123745713	C5	-0.72	-4.59	-0.35	9.12e-6	Coronary artery disease;
PAAD	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.24	-0.39	5.22e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.95	8.84	0.58	2.18e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg10517517	chr7:158649165	WDR60	-0.46	-4.45	-0.34	1.67e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg26668828	chr6:292823	DUSP22	-0.68	-6.82	-0.48	2.03e-10	Menopause (age at onset);
PAAD	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg09659197	chr4:152720779	NA	0.36	5.29	0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.8	5.61	0.41	9.37e-8	Blood protein levels;
PAAD	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg13263323	chr15:86062960	AKAP13	0.62	7.0	0.49	7.64e-11	Coronary artery disease;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.59	6.57	0.47	7.38e-10	Lymphocyte counts;
PAAD	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs4729127	1.000	rs17166205	chr7:94003841	T/A	cg20814616	chr7:94014465	NA	-0.61	-4.53	-0.35	1.17e-5	Intelligence;
PAAD	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.64	6.44	0.46	1.45e-9	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs35049879	chr10:46081744	C/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg05132306	chr1:1846340	CALML6	-0.44	-5.17	-0.39	7.43e-7	Body mass index;
PAAD	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.9	0.37	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8077577	0.747	rs3829956	chr17:18219835	A/G	cg16794390	chr17:18148240	FLII	0.49	4.31	0.33	2.95e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs78766622	chr10:46087519	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.52	0.34	1.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.74	7.08	0.5	4.94e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.57	-6.24	-0.45	4.25e-9	Electroencephalogram traits;
PAAD	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.42e-5	Calcium levels;
PAAD	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs6988985	0.678	rs7011889	chr8:144005260	A/C	cg10324643	chr8:143916377	GML	0.44	4.92	0.37	2.18e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.97	-0.54	3.41e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg01620082	chr3:125678407	NA	-1.28	-7.6	-0.52	2.79e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg04896959	chr15:78267971	NA	-0.6	-4.61	-0.35	8.51e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7173743	0.525	rs7166723	chr15:79133848	C/T	cg00540400	chr15:79124168	NA	0.45	4.68	0.36	6.24e-6	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23790345	chr11:13689489	FAR1	-0.57	-6.68	-0.48	4.29e-10	Smoking initiation;
PAAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.61	-6.45	-0.46	1.37e-9	Height;
PAAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg03264133	chr6:25882463	NA	-0.5	-4.34	-0.33	2.58e-5	Iron status biomarkers;
PAAD	cis	rs258892	0.895	rs7737643	chr5:72058445	G/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs7769051	0.614	rs62426674	chr6:133227476	G/A	cg07930552	chr6:133119739	C6orf192	0.86	4.41	0.34	1.91e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14827643	chr4:3365442	RGS12	-0.63	-6.4	-0.46	1.83e-9	Obesity-related traits;
PAAD	cis	rs2279817	0.863	rs34430730	chr1:18015100	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	cis	rs2252790	1.000	rs10456907	chr6:116621036	T/C	cg18764771	chr6:116381957	FRK	0.26	4.41	0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg03684893	chr10:554711	DIP2C	0.48	4.61	0.35	8.57e-6	Psychosis in Alzheimer's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg22247194	chr4:6271904	WFS1	-0.54	-6.43	-0.46	1.58e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs55788414	1.000	rs35667589	chr16:81180829	A/T	cg06400318	chr16:81190750	PKD1L2	-1.08	-7.18	-0.5	2.9e-11	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.96	-9.09	-0.59	5.02e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.38	-0.33	2.23e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs9649465	0.967	rs12539091	chr7:123291314	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.76	-0.36	4.38e-6	Migraine;
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.57	-0.47	7.72e-10	Lung cancer;
PAAD	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.99	-10.98	-0.66	5.24e-21	Homoarginine levels;
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.89	-8.93	-0.59	1.29e-15	Asthma;
PAAD	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9425766	1.000	rs9425766	chr1:173853127	A/G	cg14047008	chr1:173887011	SERPINC1	-0.41	-4.26	-0.33	3.51e-5	Life satisfaction;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02071572	chr4:1403502	NA	0.49	6.25	0.45	3.97e-9	Longevity;
PAAD	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	1.57	9.43	0.61	6.71e-17	Age-related hearing impairment;
PAAD	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.76	7.14	0.5	3.6e-11	Asthma;
PAAD	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg09760422	chr2:128146352	NA	0.38	5.66	0.42	7.51e-8	Self-rated health;
PAAD	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06307176	chr5:131281290	NA	-0.61	-5.18	-0.39	7.01e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3736485	0.966	rs8040080	chr15:51904459	C/T	cg08986416	chr15:51914746	DMXL2	-0.47	-4.4	-0.34	2.01e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs1656368	0.726	rs73154326	chr3:158254806	A/G	cg16708174	chr3:158430962	RARRES1	0.56	5.14	0.38	8.52e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	0.521	rs9552281	chr13:21365407	A/G	cg27234864	chr13:21295941	IL17D	0.56	4.6	0.35	8.68e-6	Dental caries;
PAAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.53	-0.34	1.2e-5	Mood instability;
PAAD	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.25	0.39	5.1e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.8	8.51	0.57	1.58e-14	Multiple system atrophy;
PAAD	cis	rs7301016	1.000	rs11613132	chr12:62856444	A/C	cg19781863	chr12:62918364	MON2	0.76	4.5	0.34	1.32e-5	IgG glycosylation;
PAAD	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.39	4.72	0.36	5.27e-6	Mean corpuscular volume;
PAAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg14440974	chr22:39074834	NA	-0.57	-6.58	-0.47	7.02e-10	Menopause (age at onset);
PAAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg09473613	chr1:24152604	HMGCL	0.42	4.28	0.33	3.24e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg00262122	chr8:11665843	FDFT1	-0.48	-4.29	-0.33	3.19e-5	Retinal vascular caliber;
PAAD	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.7e-6	Neuroticism;
PAAD	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	6.24	0.45	4.2e-9	Ileal carcinoids;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21783428	chr6:3118692	BPHL	0.61	6.85	0.49	1.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.56	6.01	0.44	1.32e-8	Menopause (age at onset);
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.64	-6.1	-0.44	8.45e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2936519	0.858	rs2912024	chr8:6638899	C/T	cg22103414	chr8:6638082	NA	-0.4	-4.26	-0.33	3.56e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs1499972	0.941	rs62263082	chr3:117605611	C/T	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs66530629	1.000	rs12043858	chr1:25047459	C/T	cg01905478	chr1:25040257	NA	0.55	6.0	0.44	1.38e-8	Plateletcrit;
PAAD	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs113835537	0.877	rs2229456	chr11:66328741	A/C	cg22134325	chr11:66188745	NPAS4	0.41	5.0	0.38	1.56e-6	Airway imaging phenotypes;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	11.85	0.69	2.35e-23	Menopause (age at onset);
PAAD	cis	rs3018712	0.590	rs7930683	chr11:68495640	A/C	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs10916814	0.632	rs1890003	chr1:20899101	T/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2790216	1.000	rs2790189	chr10:60042576	A/G	cg20442379	chr10:60024634	IPMK	-0.56	-4.29	-0.33	3.22e-5	Inflammatory bowel disease;
PAAD	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg18281939	chr5:77783895	LHFPL2	0.5	5.62	0.41	8.78e-8	Triglycerides;
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg14008862	chr17:28927542	LRRC37B2	0.88	6.35	0.46	2.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs950169	0.920	rs34672825	chr15:84703470	C/T	cg24253500	chr15:84953950	NA	0.57	6.46	0.46	1.33e-9	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.47	-4.43	-0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-6.01	-0.44	1.35e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10872587	0.598	rs10457057	chr6:146542320	G/T	cg05347473	chr6:146136440	FBXO30	0.61	4.92	0.37	2.21e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8077577	0.708	rs3889544	chr17:18133788	C/T	cg03916694	chr17:18150707	FLII	-0.39	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg27394845	chr17:28928406	LRRC37B2	-0.61	-4.28	-0.33	3.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	1.03	13.76	0.74	1.76e-28	Menarche (age at onset);
PAAD	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.57	5.05	0.38	1.24e-6	Common traits (Other);
PAAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11051970	0.513	rs4931013	chr12:32560722	C/A	cg24626660	chr12:32551988	NA	0.43	4.63	0.35	7.74e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.7	0.36	5.84e-6	Educational attainment;
PAAD	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.58	6.3	0.46	3.05e-9	Testicular germ cell tumor;
PAAD	cis	rs16970672	0.920	rs4789523	chr17:76012854	C/T	cg18935231	chr17:76464784	DNAH17	-0.39	-4.26	-0.33	3.62e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.5	7.19	0.5	2.77e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05564831	chr3:52568323	NT5DC2	0.48	4.91	0.37	2.34e-6	Electroencephalogram traits;
PAAD	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg08498647	chr11:118550644	TREH	0.44	4.31	0.33	2.95e-5	Sjögren's syndrome;
PAAD	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg14403583	chr14:105418241	AHNAK2	-0.76	-8.12	-0.55	1.46e-13	Rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.74	8.18	0.55	1.05e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs12447804	0.871	rs12928392	chr16:58070964	T/A	cg04270274	chr16:58662988	CNOT1	0.54	4.32	0.33	2.83e-5	Pulmonary function;Pulmonary function (smoking interaction);
PAAD	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.28	0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-1.08	-7.77	-0.53	1.09e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10870270	0.564	rs45519634	chr10:133782616	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.59	-4.56	-0.35	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs7084921	0.839	rs12772115	chr10:101806523	T/C	cg04359915	chr10:101825029	CPN1	-0.36	-5.1	-0.38	9.92e-7	Bone mineral density;
PAAD	cis	rs818427	1.000	rs514763	chr5:112215156	C/T	cg06941702	chr5:112196734	SRP19	0.46	4.31	0.33	2.91e-5	Total body bone mineral density;
PAAD	cis	rs55665837	0.539	rs12794714	chr11:14913575	G/A	cg19336497	chr11:14380999	RRAS2	-0.42	-4.45	-0.34	1.68e-5	Vitamin D levels;
PAAD	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg24241305	chr13:114826075	RASA3	-0.62	-4.81	-0.36	3.66e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg05110241	chr16:68378359	PRMT7	-1.18	-8.58	-0.57	1e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs743757	1.000	rs762897	chr3:50428766	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.65	4.55	0.35	1.08e-5	Diastolic blood pressure;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.74	0.82	7.26e-39	Height;
PAAD	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.77	-0.36	4.31e-6	Type 2 diabetes;
PAAD	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.51	-6.25	-0.45	3.99e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg01620082	chr3:125678407	NA	-1.46	-8.21	-0.55	8.69e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	0.850	rs76040096	chr10:46094626	C/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	8.09e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2506028	0.930	rs2995411	chr10:43440777	C/T	cg20628663	chr10:43360327	NA	-0.36	-4.29	-0.33	3.14e-5	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg23024343	chr7:107201750	COG5	0.56	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	trans	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg11421182	chr20:36153479	BLCAP	-0.54	-6.55	-0.47	8.45e-10	IgG glycosylation;
PAAD	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-4.28	-0.33	3.29e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.74	-7.9	-0.54	5.2e-13	Blood metabolite levels;
PAAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-4.57	-0.35	1.02e-5	Parkinson's disease;
PAAD	cis	rs8067287	0.597	rs4985724	chr17:16863362	A/G	cg26910001	chr17:16838321	NA	0.46	4.44	0.34	1.72e-5	Diabetic kidney disease;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.7	7.9	0.54	5.09e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.84	-9.89	-0.63	4.04e-18	Iron status biomarkers;
PAAD	cis	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg21546286	chr11:48923668	NA	0.55	5.71	0.42	5.84e-8	HDL cholesterol;
PAAD	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg27490568	chr2:178487706	NA	0.42	4.41	0.34	1.94e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6710503	0.574	rs62142284	chr2:24790666	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.3	-0.33	3.07e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.4	0.4	2.54e-7	Bipolar disorder;
PAAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.32e-8	Alzheimer's disease;
PAAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.51	4.99	0.38	1.64e-6	Mean corpuscular volume;
PAAD	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.62	-4.41	-0.34	1.95e-5	Inhibitory control;
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg19673125	chr6:150240577	RAET1G	-0.42	-5.95	-0.43	1.76e-8	Testicular germ cell tumor;
PAAD	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Iron status biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23395165	chr19:4483111	HDGF2	0.57	6.5	0.47	1.09e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	cis	rs8014252	0.803	rs17108264	chr14:71066484	A/G	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs89107	0.641	rs431115	chr6:118612615	C/T	cg21191810	chr6:118973309	C6orf204	0.46	6.47	0.46	1.26e-9	Cardiac structure and function;
PAAD	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-4.25	-0.33	3.77e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg03188948	chr7:1209495	NA	0.76	6.42	0.46	1.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs494003	0.951	rs11227302	chr11:65554502	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.6	4.27	0.33	3.41e-5	Systemic lupus erythematosus;
PAAD	trans	rs901683	1.000	rs35934513	chr10:46059781	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.54	-5.94	-0.43	1.88e-8	Longevity;
PAAD	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.92	-7.54	-0.52	4.03e-12	Blood protein levels;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.29	-0.39	4.17e-7	Life satisfaction;
PAAD	cis	rs9810890	1.000	rs56003071	chr3:128596048	T/C	cg18531004	chr3:128564980	NA	-0.8	-5.1	-0.38	9.99e-7	Dental caries;
PAAD	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.83	9.72	0.62	1.14e-17	Breast cancer;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	5.24	0.39	5.34e-7	Oropharynx cancer;
PAAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.69	-0.42	6.28e-8	Personality dimensions;
PAAD	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.96	-6.32	-0.46	2.73e-9	Post bronchodilator FEV1;
PAAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.92	-0.43	2.08e-8	IgG glycosylation;
PAAD	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg14515779	chr1:101123966	NA	-0.52	-6.29	-0.45	3.29e-9	Monocyte count;
PAAD	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg03948781	chr1:205179583	DSTYK	0.46	4.38	0.33	2.24e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14019695	chr9:139328340	INPP5E	0.58	4.96	0.37	1.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3857067	1.000	rs1904095	chr4:95012530	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg18569988	chr3:195679450	NA	0.42	4.3	0.33	3e-5	Pancreatic cancer;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg05554000	chr7:158905015	VIPR2	0.57	4.98	0.37	1.71e-6	Facial morphology (factor 20);
PAAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.73	-0.42	5.24e-8	Mood instability;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.87	10.47	0.65	1.17e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	6.86e-8	Urinary metabolites;
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.81	0.72	6.14e-26	Breast cancer;
PAAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.1	0.38	9.86e-7	Parkinson's disease;
PAAD	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.75	-0.48	2.95e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.96	-0.44	1.72e-8	Lymphocyte counts;
PAAD	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.53	5.05	0.38	1.23e-6	Acylcarnitine levels;
PAAD	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg06856378	chr2:160759118	LY75	0.51	4.68	0.35	6.3e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.24	0.56	7.28e-14	Alzheimer's disease;
PAAD	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.91	10.51	0.65	9.34e-20	Height;
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.55	-5.69	-0.42	6.34e-8	Tonsillectomy;
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg11218175	chr11:495084	RNH1	0.77	4.44	0.34	1.69e-5	Body mass index;
PAAD	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.58	5.93	0.43	1.92e-8	Systolic blood pressure;
PAAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.72	7.45	0.52	6.64e-12	Mood instability;
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.73	7.13	0.5	3.76e-11	Asthma;
PAAD	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.52	4.45	0.34	1.68e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.61	-0.41	9.33e-8	Iron status biomarkers;
PAAD	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.5e-5	Life satisfaction;
PAAD	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.7	8.94	0.59	1.22e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.83	-0.58	2.35e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg20003494	chr4:90757398	SNCA	-0.67	-6.25	-0.45	3.86e-9	Neuroticism;
PAAD	cis	rs863345	0.933	rs1418843	chr1:158450382	A/G	cg12129480	chr1:158549410	OR10X1	0.41	4.57	0.35	9.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.47	4.38	0.33	2.2e-5	Height;
PAAD	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.65	-5.57	-0.41	1.14e-7	LDL cholesterol to HDL cholesterol ratio;
PAAD	cis	rs7567389	0.710	rs72848615	chr2:128133598	T/A	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.19	0.64	6.56e-19	Platelet count;
PAAD	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.36	4.45	0.34	1.64e-5	Mean corpuscular volume;
PAAD	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4742903	0.935	rs4743692	chr9:106931890	A/G	cg14250997	chr9:106856677	SMC2	0.46	4.94	0.37	2.06e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.33	-7.78	-0.53	1.05e-12	Psoriasis vulgaris;
PAAD	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	5.35	0.4	3.14e-7	Height;
PAAD	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.77	0.36	4.31e-6	Blood metabolite levels;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.59	6.29	0.45	3.22e-9	Lung cancer;
PAAD	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.82	9.67	0.62	1.56e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs13424612	1.000	rs66534347	chr2:240899346	G/A	cg12807937	chr2:240965920	NDUFA10	-0.45	-4.44	-0.34	1.69e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.03	9.16	0.6	3.32e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.54	5.61	0.41	9.39e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.76e-9	Cognitive function;
PAAD	cis	rs9880772	0.743	rs4680730	chr3:27804731	C/T	cg21473142	chr3:27762095	EOMES	0.35	6.42	0.46	1.64e-9	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.85	-9.6	-0.61	2.34e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg21438018	chr1:76262537	MSH4	0.48	4.46	0.34	1.58e-5	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg24253500	chr15:84953950	NA	0.59	6.66	0.48	4.72e-10	Schizophrenia;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.77e-5	Life satisfaction;
PAAD	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg13611204	chr9:139324423	INPP5E	-0.55	-4.55	-0.35	1.07e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.76	-7.74	-0.53	1.27e-12	Uric acid clearance;
PAAD	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.49e-5	Electrocardiographic conduction measures;
PAAD	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.96	0.37	1.83e-6	Ovarian reserve;
PAAD	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.9	0.43	2.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.41	-4.34	-0.33	2.59e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.17	0.39	7.17e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.64	-6.89	-0.49	1.42e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg11266682	chr4:10021025	SLC2A9	-0.7	-6.08	-0.44	9.26e-9	Schizophrenia (age at onset);
PAAD	cis	rs863345	0.604	rs10908660	chr1:158466189	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6141769	0.542	rs6058840	chr20:31319116	A/T	cg13636640	chr20:31349939	DNMT3B	0.5	4.66	0.35	6.99e-6	Subjective well-being;
PAAD	trans	rs16893526	0.649	rs9344225	chr6:82524543	C/G	cg00035630	chr11:33036664	DEPDC7	-0.6	-6.56	-0.47	8.12e-10	Coronary heart disease;
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.71	-6.55	-0.47	8.34e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.64	-0.53	2.33e-12	Morning vs. evening chronotype;
PAAD	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.46	4.58	0.35	9.68e-6	Schizophrenia;
PAAD	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg17737388	chr1:85724454	C1orf52	0.49	4.25	0.33	3.67e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8062405	0.540	rs480400	chr16:28574615	A/G	cg16576597	chr16:28551801	NUPR1	0.52	5.86	0.43	2.8e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04717802	chr22:42394638	WBP2NL	0.42	4.4	0.34	2.05e-5	Cognitive function;
PAAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.51	-0.34	1.31e-5	Eosinophil percentage of white cells;
PAAD	cis	rs853679	0.567	rs16894106	chr6:28400339	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.31	-0.33	2.9e-5	Depression;
PAAD	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.4	-0.4	2.54e-7	Neuroticism;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	5.99	0.44	1.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26114804	chr3:47616147	CSPG5	-0.58	-7.29	-0.51	1.62e-11	Monocyte percentage of white cells;
PAAD	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs728616	0.614	rs59806247	chr10:82097974	T/C	cg19423196	chr10:82049429	MAT1A	0.45	4.44	0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.54	-5.18	-0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.04	0.59	6.73e-16	Menopause (age at onset);
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg06074448	chr4:187884817	NA	-0.65	-8.36	-0.56	3.76e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1190552	0.639	rs12887671	chr14:102946341	A/G	cg18135206	chr14:102964638	TECPR2	0.66	4.49	0.34	1.43e-5	Blood protein levels;
PAAD	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg01851573	chr8:8652454	MFHAS1	0.58	5.01	0.38	1.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06850241	chr22:41845214	NA	-0.58	-5.14	-0.38	8.27e-7	Vitiligo;
PAAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.12	-0.44	7.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.63	6.5	0.47	1.06e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.65	-7.68	-0.53	1.83e-12	Sense of smell;
PAAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.56	-0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.46	0.61	5.38e-17	Platelet count;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.64	6.58	0.47	7.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg06375148	chr1:209958343	C1orf74	0.65	5.19	0.39	6.77e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.49	-4.94	-0.37	2e-6	Breast cancer;
PAAD	cis	rs1190552	0.894	rs1190546	chr14:102904966	A/G	cg18135206	chr14:102964638	TECPR2	-0.66	-5.26	-0.39	4.86e-7	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs41311933	0.656	rs72758183	chr9:123786336	C/T	cg13567360	chr9:123745713	C5	-0.69	-4.27	-0.33	3.37e-5	Coronary artery disease;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.05	0.55	2.26e-13	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11276506	chr19:14186130	NA	0.71	7.22	0.51	2.29e-11	Obesity-related traits;
PAAD	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	8.04e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg07469887	chr10:131262384	NA	0.39	4.29	0.33	3.12e-5	Response to temozolomide;
PAAD	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.64	-8.13	-0.55	1.4e-13	Schizophrenia;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.58	-7.3	-0.51	1.5e-11	Longevity;Endometriosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08241225	chr19:36041510	ATP4A	0.61	6.98	0.49	8.52e-11	Smoking initiation;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg21698718	chr17:80085957	CCDC57	-0.45	-5.12	-0.38	9.07e-7	Life satisfaction;
PAAD	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-4.3	-0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg27539214	chr16:67997921	SLC12A4	-0.62	-4.7	-0.36	5.87e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	cis	rs7539409	0.584	rs6695415	chr1:84194514	C/T	cg10977910	chr1:84465055	TTLL7	0.89	5.02	0.38	1.44e-6	Alzheimer's disease;
PAAD	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs12304921	1.000	rs12315928	chr12:51355931	T/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.62	6.27	0.45	3.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.0	0.59	8.42e-16	Hemoglobin concentration;
PAAD	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.81	5.39	0.4	2.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08856697	chr17:61627902	DCAF7	-0.63	-7.39	-0.51	8.95e-12	Body fat percentage;
PAAD	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.59	4.31	0.33	2.98e-5	Exhaled nitric oxide output;
PAAD	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.62	-5.99	-0.44	1.44e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.1e-8	Electroencephalogram traits;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01931797	chr11:77899910	KCTD21;USP35	0.68	6.74	0.48	3.02e-10	Myopia (pathological);
PAAD	cis	rs9469890	0.604	rs7754038	chr6:34505194	T/G	cg14254433	chr6:34482411	PACSIN1	-0.9	-5.79	-0.43	3.87e-8	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	1.18	11.74	0.69	4.59e-23	Corneal structure;
PAAD	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg27211696	chr2:191398769	TMEM194B	0.44	4.4	0.34	2.02e-5	Urinary metabolites;
PAAD	trans	rs61931739	0.620	rs61927734	chr12:33691977	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.34	-0.51	1.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs747650	0.504	rs11602250	chr11:46965730	G/A	cg19486271	chr11:47235900	DDB2	0.64	6.11	0.44	7.9e-9	Acne (severe);
PAAD	cis	rs4668356	1.000	rs16859121	chr2:171882754	A/G	cg13882835	chr2:172017928	TLK1	-0.91	-4.83	-0.36	3.3e-6	Cognitive performance;
PAAD	cis	rs1015291	1.000	rs1015293	chr12:19984383	T/C	cg25401612	chr12:20009446	NA	0.47	4.34	0.33	2.61e-5	Diastolic blood pressure;
PAAD	cis	rs732765	0.734	rs6574189	chr14:75166493	C/T	cg17347104	chr14:75034677	LTBP2	-0.52	-4.5	-0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.73	-7.64	-0.53	2.21e-12	Platelet count;
PAAD	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg18551225	chr6:44695536	NA	-0.69	-8.07	-0.55	1.97e-13	Total body bone mineral density;
PAAD	cis	rs12209128	0.929	rs9369755	chr6:47885016	C/A	cg20497205	chr6:47754005	OPN5	-0.36	-4.29	-0.33	3.18e-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs863345	0.967	rs863361	chr1:158549420	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.94	-0.37	2.04e-6	Pneumococcal bacteremia;
PAAD	cis	rs6499244	0.510	rs7206585	chr16:69872404	A/G	cg00738113	chr16:70207722	CLEC18C	0.39	4.32	0.33	2.84e-5	Menarche (age at onset);
PAAD	cis	rs2299587	0.866	rs208765	chr8:17805448	C/T	cg08627089	chr8:17753878	FGL1	0.42	4.25	0.33	3.73e-5	Economic and political preferences;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12315302	chr6:26189340	HIST1H4D	0.57	4.59	0.35	9.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.53	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.35	-0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg06815965	chr1:205818668	PM20D1	0.61	6.88	0.49	1.5e-10	Menarche (age at onset);
PAAD	cis	rs829661	0.793	rs2121600	chr2:30842625	T/C	cg12454169	chr2:30669597	LCLAT1	0.62	4.36	0.33	2.35e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.58	-0.35	9.76e-6	Glomerular filtration rate;
PAAD	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg07159951	chr1:45983175	PRDX1	-0.41	-4.46	-0.34	1.56e-5	High light scatter reticulocyte count;
PAAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg03676636	chr4:99064102	C4orf37	-0.32	-5.38	-0.4	2.75e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg02683114	chr2:24398427	C2orf84	-0.52	-5.09	-0.38	1.07e-6	Asthma;
PAAD	cis	rs9842133	0.587	rs16830924	chr3:179647808	A/G	cg18765712	chr3:179670323	PEX5L	-0.52	-4.58	-0.35	9.55e-6	Blood metabolite levels;
PAAD	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.2	-0.39	6.43e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.12e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Cleft lip with or without cleft palate;
PAAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.81	9.81	0.62	6.62e-18	Blood metabolite ratios;
PAAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.35	4.6	0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.3	15.05	0.77	6.29e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.95	0.37	1.91e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs3106136	0.678	rs3919616	chr4:95281663	A/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg16989719	chr2:238392110	NA	-0.35	-4.34	-0.33	2.54e-5	Prostate cancer;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.61	-5.67	-0.42	7.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.54	-0.35	1.13e-5	Lung cancer;
PAAD	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs2133450	0.780	rs2030154	chr3:7361512	T/A	cg19930620	chr3:7340148	GRM7	-0.43	-4.53	-0.34	1.2e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs346785	0.692	rs9900514	chr17:74285595	T/C	cg09812376	chr17:74270190	QRICH2	-0.53	-6.73	-0.48	3.21e-10	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg14393609	chr7:65229607	NA	0.67	7.42	0.52	7.82e-12	Aortic root size;
PAAD	cis	rs11966931	0.711	rs9320236	chr6:108089688	G/T	cg02790471	chr6:108093511	SCML4	0.5	4.38	0.33	2.19e-5	Neutrophil percentage of white cells;
PAAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-5.62	-0.41	9.03e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7537660	0.636	rs10749635	chr1:248014615	C/T	cg00785941	chr1:248100591	OR2L13	0.44	5.87	0.43	2.69e-8	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27009036	chr2:233722726	GIGYF2	-0.69	-7.16	-0.5	3.26e-11	Obesity-related traits;
PAAD	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg06484146	chr7:12443880	VWDE	-0.79	-5.34	-0.4	3.37e-7	Coronary artery disease;
PAAD	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.82	9.05	0.59	6.52e-16	Mortality in heart failure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15828828	chr19:36980699	ZNF566	0.63	7.05	0.5	5.96e-11	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25104716	chr18:45936047	NA	0.65	6.48	0.47	1.19e-9	Obesity-related traits;
PAAD	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.8	7.96	0.54	3.77e-13	Retinal vascular caliber;
PAAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg09835421	chr16:68378352	PRMT7	-1.09	-7.96	-0.54	3.67e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9876781	1.000	rs7651407	chr3:48443816	C/T	cg24898236	chr3:49228699	LOC646498	0.39	4.28	0.33	3.25e-5	Longevity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08748207	chr12:46777589	NA	0.58	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15746198	chr11:82645442	C11orf82	-0.62	-6.4	-0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.56	5.9	0.43	2.27e-8	Dupuytren's disease;
PAAD	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs9398803	0.584	rs3850234	chr6:127001534	T/G	cg19875578	chr6:126661172	C6orf173	0.42	4.35	0.33	2.53e-5	Male-pattern baldness;
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg12315302	chr6:26189340	HIST1H4D	0.79	4.33	0.33	2.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg18641463	chr7:2144579	MAD1L1	0.48	4.54	0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg15145965	chr22:50218605	BRD1	0.71	4.37	0.33	2.25e-5	Mean platelet volume;
PAAD	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.47	-0.41	1.79e-7	Bladder cancer;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.5	5.17	0.39	7.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-5.45	-0.4	1.99e-7	Lung cancer;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg09163369	chr1:210001066	C1orf107	0.39	4.56	0.35	1.06e-5	Monobrow;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.62	5.65	0.42	7.51e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17376030	chr22:41985996	PMM1	-0.67	-4.57	-0.35	1e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs7922314	0.571	rs57307942	chr10:64722904	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg10438391	chr8:144631915	NA	-0.29	-4.42	-0.34	1.87e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2249694	0.509	rs9419072	chr10:135310445	G/A	cg20169779	chr10:135381914	SYCE1	0.51	4.8	0.36	3.79e-6	Obesity-related traits;
PAAD	cis	rs877529	0.967	rs139410	chr22:39552597	A/G	cg18708252	chr22:39545030	CBX7	-0.45	-4.37	-0.33	2.29e-5	Multiple myeloma;
PAAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.64	-5.62	-0.41	9.07e-8	Psoriasis;
PAAD	cis	rs7631605	0.935	rs4647224	chr3:37043230	G/A	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3812111	0.525	rs6755	chr6:116571255	G/A	cg18828861	chr6:116576566	TSPYL4	0.48	5.05	0.38	1.28e-6	Age-related macular degeneration;
PAAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9535307	0.522	rs9316476	chr13:50409652	G/T	cg04663916	chr13:50265991	EBPL	-0.67	-4.8	-0.36	3.69e-6	Obesity-related traits;
PAAD	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7818345	0.737	rs17407149	chr8:19274848	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.37	0.33	2.34e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.53	4.83	0.37	3.24e-6	Platelet count;
PAAD	cis	rs75757892	0.544	rs75278228	chr6:7316199	C/T	cg02954307	chr6:7269328	NA	0.59	4.98	0.37	1.68e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.98	10.37	0.64	2.2e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-5.31	-0.4	3.82e-7	IgG glycosylation;
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.51	-8.78	-0.58	3.11e-15	IgG glycosylation;
PAAD	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.57	-4.74	-0.36	4.95e-6	Type 2 diabetes;
PAAD	cis	rs75920871	0.513	rs76904522	chr11:117014863	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.84	-4.82	-0.36	3.41e-6	Subjective well-being;
PAAD	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.65	5.77	0.42	4.21e-8	Corneal astigmatism;
PAAD	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.95	0.37	1.96e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.59	-5.57	-0.41	1.15e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6688613	1.000	rs7528849	chr1:166954870	A/G	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.55	-6.79	-0.48	2.34e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.66	-6.58	-0.47	7.3e-10	Glomerular filtration rate;
PAAD	cis	rs2968864	0.956	rs1805123	chr7:150645534	T/G	cg06221570	chr7:150558377	ABP1	0.48	5.53	0.41	1.35e-7	QT interval;
PAAD	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.85	7.05	0.5	5.84e-11	Pulmonary function decline;
PAAD	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.53	-6.38	-0.46	1.97e-9	Mean corpuscular volume;
PAAD	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg20503657	chr10:835505	NA	0.49	5.09	0.38	1.03e-6	Survival in rectal cancer;
PAAD	cis	rs4073221	0.585	rs34078971	chr3:18323115	A/G	cg07694806	chr3:18168406	NA	-0.62	-4.58	-0.35	9.43e-6	Parkinson's disease;
PAAD	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.83	-0.36	3.27e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.88	9.52	0.61	3.79e-17	Cognitive function;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.74	0.36	4.8e-6	Lung function (FEV1/FVC);
PAAD	cis	rs35955747	0.902	rs7288735	chr22:31679546	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.51	4.65	0.35	7.22e-6	Mean corpuscular volume;
PAAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.71	6.87	0.49	1.57e-10	Parkinson's disease;
PAAD	cis	rs67257959	0.708	rs10405158	chr19:17195997	A/G	cg19418318	chr19:17219073	MYO9B	0.31	4.42	0.34	1.9e-5	Selective IgA deficiency;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg10729496	chr3:10149963	C3orf24	0.94	7.97	0.54	3.51e-13	Alzheimer's disease;
PAAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.83	-0.54	7.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.5	5.4	0.4	2.54e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.87	9.36	0.6	1.01e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.57	-7.76	-0.53	1.17e-12	Renal cell carcinoma;
PAAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.77	-7.92	-0.54	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.75	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs900145	0.906	rs1384024	chr11:13296644	C/A	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg02820901	chr13:113351484	ATP11A	0.72	4.65	0.35	7.09e-6	Glycated hemoglobin levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14582845	chr17:9234053	STX8	0.63	6.69	0.48	4.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg00543991	chr22:32367038	NA	1.08	6.77	0.48	2.67e-10	Childhood ear infection;
PAAD	cis	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs11671653	1.000	rs59715646	chr19:10839447	G/A	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11327029	chr10:22826133	PIP4K2A	-0.47	-5.19	-0.39	6.7e-7	Monocyte percentage of white cells;
PAAD	cis	rs59918340	0.738	rs3739240	chr8:142221414	G/A	cg23750338	chr8:142222470	SLC45A4	0.55	6.34	0.46	2.5e-9	Immature fraction of reticulocytes;
PAAD	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg13926569	chr10:89418898	PAPSS2	-0.75	-7.96	-0.54	3.71e-13	Magnesium levels;
PAAD	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.96	0.7	1.2e-23	Menopause (age at onset);
PAAD	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12317783	chr3:178789784	ZMAT3	0.66	6.8	0.48	2.28e-10	Obesity-related traits;
PAAD	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.68	5.65	0.42	7.8e-8	Common traits (Other);
PAAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg01966878	chr4:90757139	SNCA	-0.66	-5.17	-0.39	7.19e-7	Neuroticism;
PAAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.92	-10.64	-0.65	4.16e-20	Total body bone mineral density;
PAAD	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.59	6.55	0.47	8.21e-10	Coronary artery disease;
PAAD	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg05064044	chr6:292385	DUSP22	-0.78	-7.81	-0.54	8.59e-13	Menopause (age at onset);
PAAD	cis	rs12753920	0.712	rs35513239	chr1:92682286	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.3	-0.33	3.08e-5	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg05110241	chr16:68378359	PRMT7	-0.73	-6.22	-0.45	4.59e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg06899799	chr12:56650233	ANKRD52	0.33	4.31	0.33	2.94e-5	Cancer;
PAAD	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg21977766	chr11:1107580	NA	0.43	4.37	0.33	2.28e-5	Alzheimer's disease (late onset);
PAAD	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.47	4.7	0.36	5.85e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.54	-5.13	-0.38	8.86e-7	Schizophrenia;
PAAD	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.68	10.43	0.65	1.48e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22958231	chr4:177116835	SPATA4	-0.68	-7.01	-0.49	7.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35160687	0.712	rs12476826	chr2:86489520	T/C	cg10973622	chr2:86423274	IMMT	-0.43	-4.65	-0.35	7.2e-6	Night sleep phenotypes;
PAAD	cis	rs112591243	0.685	rs80124066	chr21:47912913	A/G	cg26904215	chr21:47823096	PCNT	-0.82	-4.31	-0.33	2.87e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs57920188	0.535	rs4295855	chr1:4094993	C/T	cg20703997	chr1:4087676	NA	0.56	4.78	0.36	4.11e-6	Interleukin-17 levels;
PAAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	1.06	16.93	0.81	8.36e-37	Height;
PAAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.11	15.52	0.78	3.78e-33	Cognitive function;
PAAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg03538708	chr1:25844672	NA	-0.5	-5.17	-0.39	7.39e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2299116	1.000	rs2299116	chr7:28815239	C/A	cg06647007	chr7:28747836	CREB5	-0.46	-4.27	-0.33	3.39e-5	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg07527105	chr16:88053339	BANP	0.46	4.8	0.36	3.8e-6	Menopause (age at onset);
PAAD	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.67	7.55	0.52	3.84e-12	Resting heart rate;
PAAD	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.99e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg03037974	chr15:76606532	NA	0.51	5.68	0.42	6.74e-8	Blood metabolite levels;
PAAD	cis	rs16933812	0.510	rs7868685	chr9:36989837	G/T	cg13738729	chr9:36989127	PAX5	-0.53	-7.57	-0.52	3.4e-12	Obesity-related traits;
PAAD	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.79	-7.8	-0.53	9.09e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.47	-0.34	1.5e-5	Asthma;
PAAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02807482	chr3:125708958	NA	-0.46	-4.28	-0.33	3.3e-5	Blood pressure (smoking interaction);
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg24849736	chr1:201084428	NA	0.48	4.73	0.36	5e-6	Permanent tooth development;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.36	-0.46	2.3e-9	Lung cancer;
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg05717871	chr11:638507	DRD4	-0.57	-5.47	-0.41	1.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.5	-5.45	-0.4	1.95e-7	Prevalent atrial fibrillation;
PAAD	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg17346650	chr17:80929145	B3GNTL1	0.44	5.32	0.4	3.63e-7	Glycated hemoglobin levels;
PAAD	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.55	4.67	0.35	6.51e-6	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12591289	chr3:99833051	C3orf26;FILIP1L	-0.62	-6.48	-0.47	1.22e-9	Obesity-related traits;
PAAD	cis	rs6956675	0.534	rs1806453	chr7:62641533	A/G	cg12712659	chr7:61818348	NA	0.39	4.32	0.33	2.76e-5	Obesity-related traits;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.37	-0.4	2.93e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs941024	0.651	rs17511746	chr12:56038760	T/G	cg20737382	chr12:56040096	NA	-0.73	-4.73	-0.36	5.02e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.89	9.69	0.62	1.36e-17	Corneal astigmatism;
PAAD	trans	rs405795	1.000	rs314412	chr13:89787277	G/T	cg27422345	chr7:1715242	NA	-0.99	-6.36	-0.46	2.22e-9	Yeast infection;
PAAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12476592	0.500	rs78152709	chr2:64235780	A/G	cg20249169	chr2:64881356	SERTAD2	-0.53	-4.38	-0.33	2.2e-5	Childhood ear infection;
PAAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.73	-7.44	-0.52	6.75e-12	Neurofibrillary tangles;
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.7	6.73	0.48	3.33e-10	Cystic fibrosis severity;
PAAD	cis	rs17155006	0.612	rs401145	chr7:107737278	T/C	cg05962710	chr7:107745446	LAMB4	-0.4	-4.7	-0.36	5.71e-6	Pneumococcal bacteremia;
PAAD	cis	rs227833	1.000	rs227830	chr6:44680555	G/C	cg18551225	chr6:44695536	NA	0.49	4.88	0.37	2.63e-6	Monobrow;
PAAD	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.69	0.53	1.75e-12	Motion sickness;
PAAD	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg08439880	chr3:133502540	NA	-0.47	-5.27	-0.39	4.59e-7	Iron status biomarkers;
PAAD	trans	rs8026198	0.929	rs7086	chr15:42451108	G/C	cg08326933	chr19:49967537	ALDH16A1	0.71	6.52	0.47	9.85e-10	Fibrinogen levels;
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.76	-5.95	-0.43	1.81e-8	Platelet count;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	4.94	0.37	2e-6	Prostate cancer;
PAAD	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.68	-0.35	6.37e-6	Body mass index;
PAAD	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.47e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg22349387	chr12:9600060	DDX12	-0.41	-4.3	-0.33	3e-5	Breast size;
PAAD	cis	rs821931	0.744	rs821952	chr10:108471072	T/C	cg16415058	chr10:108923781	SORCS1	0.37	4.34	0.33	2.57e-5	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
PAAD	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	1.14	13.4	0.74	1.61e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.83	0.36	3.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg19680485	chr15:31195859	MTMR15	0.44	4.34	0.33	2.63e-5	Huntington's disease progression;
PAAD	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.44	4.58	0.35	9.52e-6	Resting heart rate;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03098356	chr6:87865314	ZNF292	-0.77	-6.84	-0.49	1.81e-10	Neuroticism;
PAAD	cis	rs7619427	0.507	rs6806526	chr3:44015285	T/C	cg16646616	chr3:44040527	NA	-0.53	-4.35	-0.33	2.44e-5	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.62	6.27	0.45	3.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-7.93	-0.54	4.34e-13	Prudent dietary pattern;
PAAD	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.42	6.38	0.46	2.07e-9	Serum sulfate level;
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1468333	0.824	rs4835673	chr5:137607680	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.57	5.83	0.43	3.22e-8	Resting heart rate;
PAAD	cis	rs7795096	0.743	rs9648730	chr7:151537785	G/A	cg17008978	chr7:151542804	PRKAG2	0.43	5.05	0.38	1.26e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.65	0.47	4.89e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.5	5.93	0.43	1.96e-8	Lung cancer;
PAAD	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.5	5.16	0.39	7.78e-7	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.56	-0.83	6.71e-41	Ulcerative colitis;
PAAD	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.49	-0.41	1.65e-7	Monocyte percentage of white cells;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.65	6.41	0.46	1.7e-9	Height;
PAAD	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	-0.69	-7.23	-0.51	2.23e-11	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg08754654	chr5:154026448	NA	0.57	7.65	0.53	2.08e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10267417	0.603	rs7794070	chr7:19899716	C/T	cg05791153	chr7:19748676	TWISTNB	0.67	4.73	0.36	5.1e-6	Night sleep phenotypes;
PAAD	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.9	-0.49	1.3100000000000001e-10	Triglycerides;
PAAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.34	-0.33	2.55e-5	Menarche (age at onset);
PAAD	cis	rs17209837	1.000	rs4148814	chr7:87091543	T/C	cg00919237	chr7:87102261	ABCB4	-0.83	-5.88	-0.43	2.54e-8	Gallbladder cancer;
PAAD	cis	rs3126085	0.515	rs11204997	chr1:152364653	T/A	cg26876637	chr1:152193138	HRNR	-0.6	-4.48	-0.34	1.43e-5	Atopic dermatitis;
PAAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.78	-8.61	-0.57	8.78e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.46	6.29	0.45	3.21e-9	Cardiovascular disease risk factors;
PAAD	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg02297831	chr4:17616191	MED28	0.61	6.21	0.45	4.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs763512	0.532	rs3094499	chr17:35891336	A/G	cg16670864	chr17:35848621	DUSP14	0.51	4.28	0.33	3.31e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16988970	chr17:42248062	ASB16	-0.36	-5.17	-0.39	7.25e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg08601574	chr20:25228251	PYGB	0.57	5.79	0.42	3.99e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.44	4.76	0.36	4.44e-6	Bipolar disorder;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.58	6.39	0.46	1.94e-9	Lung cancer;
PAAD	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.64	0.42	8.07e-8	Sum eosinophil basophil counts;
PAAD	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg20356878	chr3:121714668	ILDR1	0.53	5.1	0.38	1.01e-6	Cognitive performance;
PAAD	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.55	-5.59	-0.41	1.04e-7	Homocysteine levels;
PAAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.46	4.35	0.33	2.52e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22402555	chr4:68552362	UBA6	-0.59	-6.65	-0.47	4.95e-10	Monocyte percentage of white cells;
PAAD	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	4.58	0.35	9.42e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.92	0.54	4.6e-13	Parkinson's disease;
PAAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.71	9.36	0.6	1.02e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2278796	0.639	rs4950977	chr1:204970777	T/A	cg04862289	chr1:204966208	NFASC	0.5	5.18	0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg15847926	chr7:2749597	AMZ1	-0.39	-4.73	-0.36	5.12e-6	Height;
PAAD	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.35	0.51	1.14e-11	Educational attainment;
PAAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.4	-0.34	2.05e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18202627	chr2:200776533	C2orf69	0.6	6.91	0.49	1.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs17032980	0.956	rs55719437	chr2:67309787	G/A	cg06994420	chr2:66672553	MEIS1	-0.51	-4.51	-0.34	1.3e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9472414	0.510	rs227840	chr6:44686304	C/G	cg18551225	chr6:44695536	NA	-0.55	-5.26	-0.39	4.86e-7	Height;
PAAD	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.35	-0.4	3.25e-7	Number of children ever born;
PAAD	cis	rs3736485	0.934	rs1077361	chr15:51880919	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.51	0.57	1.58e-14	Bipolar disorder;
PAAD	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21141354	chr1:222988439	NA	-0.62	-6.48	-0.47	1.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.72	5.95	0.43	1.81e-8	Cognitive function;
PAAD	cis	rs6142102	0.517	rs6142050	chr20:32527128	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	4.26	0.33	3.6e-5	Skin pigmentation;
PAAD	cis	rs10768122	0.932	rs3847604	chr11:35320561	A/G	cg13971030	chr11:35366721	SLC1A2	-0.37	-4.3	-0.33	3.01e-5	Vitiligo;
PAAD	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg14393609	chr7:65229607	NA	0.63	6.83	0.48	1.93e-10	Aortic root size;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1561288	0.731	rs13003881	chr2:25352091	G/A	cg02492873	chr2:25193821	DNAJC27	0.49	4.28	0.33	3.3e-5	Body mass index;
PAAD	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg11764359	chr7:65958608	NA	0.78	5.11	0.38	9.56e-7	Diabetic kidney disease;
PAAD	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg09010748	chr1:235293032	TOMM20	-0.41	-4.42	-0.34	1.86e-5	Adiposity;
PAAD	cis	rs7119038	0.779	rs73005502	chr11:118697906	A/G	cg19308663	chr11:118741387	NA	0.55	4.25	0.33	3.76e-5	Sjögren's syndrome;
PAAD	cis	rs17095355	0.605	rs3740140	chr10:111632937	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.49	-0.34	1.41e-5	Biliary atresia;
PAAD	cis	rs62025270	0.848	rs62025269	chr15:86300090	C/T	cg13263323	chr15:86062960	AKAP13	0.59	5.5	0.41	1.55e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg15654264	chr1:150340011	RPRD2	0.51	4.93	0.37	2.1e-6	Migraine;
PAAD	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.41	4.25	0.33	3.74e-5	Psoriasis;
PAAD	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.72	-8.75	-0.58	3.75e-15	Body mass index;
PAAD	cis	rs16852403	0.583	rs10798596	chr1:178082642	T/C	cg00404053	chr1:178313656	RASAL2	0.48	4.51	0.34	1.3e-5	Childhood ear infection;
PAAD	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.48	-7.93	-0.54	4.46e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs41005	0.603	rs13016634	chr2:8117195	C/T	cg03155496	chr2:8117019	LOC339788	-0.51	-4.41	-0.34	1.93e-5	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.84	-10.38	-0.64	2.02e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg08992911	chr2:238395768	MLPH	0.65	6.38	0.46	2e-9	Prostate cancer;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg19337854	chr7:99768885	GPC2	0.5	4.72	0.36	5.31e-6	Platelet count;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.89	-9.51	-0.61	4.08e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs116248771	0.739	rs73156455	chr3:158367557	A/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs4979906	1.000	rs1972097	chr10:79464062	G/A	cg07817648	chr10:79422355	NA	-0.65	-5.84	-0.43	3.01e-8	Mortality in heart failure;
PAAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.66	4.98	0.37	1.67e-6	Breast cancer;
PAAD	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg00571178	chr13:114841904	RASA3	-0.56	-4.79	-0.36	3.85e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs11958404	0.517	rs17679725	chr5:157221489	A/G	cg05962755	chr5:157440814	NA	0.66	4.56	0.35	1.05e-5	IgG glycosylation;
PAAD	cis	rs394563	0.775	rs399673	chr6:149783221	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.42	-0.34	1.85e-5	Dupuytren's disease;
PAAD	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.75	-9.33	-0.6	1.22e-16	Body mass index;
PAAD	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.86	11.29	0.68	7.33e-22	Emphysema distribution in smoking;
PAAD	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-6.48	-0.47	1.2e-9	Colorectal cancer;
PAAD	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.74	-0.42	5.04e-8	Response to antipsychotic treatment;
PAAD	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg03999872	chr20:62272968	STMN3	0.64	5.86	0.43	2.73e-8	Atopic dermatitis;
PAAD	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.26	-0.33	3.6e-5	Mood instability;
PAAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16847604	chr10:3500727	NA	0.73	7.84	0.54	7.25e-13	Smoking initiation;
PAAD	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg07617317	chr6:118971624	C6orf204	0.52	4.43	0.34	1.76e-5	Diastolic blood pressure;
PAAD	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.58	-6.2	-0.45	5.11e-9	Post bronchodilator FEV1;
PAAD	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.61	5.61	0.41	9.31e-8	Height;
PAAD	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.45	10.52	0.65	8.45e-20	Opioid sensitivity;
PAAD	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.64	-7.48	-0.52	5.6e-12	Bipolar disorder;
PAAD	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.44	7.26	0.51	1.82e-11	Mean corpuscular volume;
PAAD	cis	rs3760982	0.747	rs62116990	chr19:44301608	G/A	cg21496419	chr19:44306685	LYPD5	-0.39	-4.82	-0.36	3.46e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.71	-8.98	-0.59	9.81e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs1561176	1.000	rs11770633	chr7:155008951	C/T	cg08570118	chr7:155025533	NA	-0.5	-4.45	-0.34	1.64e-5	Personality dimensions;
PAAD	cis	rs17284969	0.579	rs2371671	chr7:83044481	G/C	cg14519356	chr7:83097669	SEMA3E	0.4	4.28	0.33	3.32e-5	Blood protein levels;
PAAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.11	14.48	0.76	2.13e-30	Body mass index;
PAAD	cis	rs4455778	0.538	rs6977073	chr7:49115340	C/T	cg26309511	chr7:48887640	NA	0.4	5.09	0.38	1.03e-6	Lung cancer in never smokers;
PAAD	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg04018474	chr16:31008003	STX1B	-0.29	-4.48	-0.34	1.47e-5	Dementia with Lewy bodies;
PAAD	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg08514558	chr10:81106712	PPIF	0.52	6.34	0.46	2.48e-9	Height;
PAAD	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.43	-4.79	-0.36	4.01e-6	Mean arterial pressure;
PAAD	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg13786083	chr1:19110734	NA	-0.73	-6.5	-0.47	1.07e-9	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.67	6.82	0.48	2.04e-10	Obesity-related traits;
PAAD	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.55	-6.14	-0.45	6.79e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs1867631	0.585	rs11208922	chr1:67080226	T/C	cg02459107	chr1:67143332	SGIP1	0.44	4.33	0.33	2.72e-5	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.51	4.93	0.37	2.16e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7873102	0.617	rs2244731	chr9:37982916	A/G	cg03528946	chr9:38069800	SHB	-0.53	-5.3	-0.39	4.04e-7	Brain structure;
PAAD	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.68e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.87	-0.37	2.75e-6	Mood instability;
PAAD	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.56	-6.33	-0.46	2.58e-9	Educational attainment;
PAAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	8.41	0.56	2.83e-14	Schizophrenia;
PAAD	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.66	-8.58	-0.57	1.05e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.56	0.57	1.13e-14	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08754610	chr22:29949725	THOC5	0.63	7.2	0.5	2.66e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1075232	0.826	rs4779556	chr15:32173245	T/C	cg01030201	chr15:31746330	NA	1.01	4.3	0.33	3.07e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.98	8.77	0.58	3.34e-15	Bipolar disorder;
PAAD	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.66	-6.84	-0.48	1.84e-10	Multiple myeloma (IgH translocation);
PAAD	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.68	4.66	0.35	6.92e-6	Major depressive disorder;
PAAD	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg06014892	chr15:79103753	ADAMTS7	0.54	4.41	0.34	1.93e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg18279126	chr7:2041391	MAD1L1	0.65	6.53	0.47	9.21e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	5.42	0.4	2.31e-7	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24204556	chr22:22222030	MAPK1	0.68	7.21	0.5	2.48e-11	Obesity-related traits;
PAAD	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg19445457	chr11:5799446	OR52N5	-0.51	-4.6	-0.35	8.77e-6	DNA methylation (variation);
PAAD	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-5.58	-0.41	1.07e-7	Pancreatic cancer;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.63	6.79	0.48	2.31e-10	Menarche (age at onset);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23708337	chr7:1209742	NA	0.46	4.91	0.37	2.38e-6	Longevity;Endometriosis;
PAAD	cis	rs9463078	0.764	rs9357464	chr6:44952441	T/C	cg25276700	chr6:44698697	NA	-0.48	-5.5	-0.41	1.57e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg02404636	chr22:31891804	SFI1	0.63	5.85	0.43	2.93e-8	Colorectal cancer;
PAAD	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg21937377	chr3:194868750	C3orf21	0.46	4.85	0.37	2.97e-6	Non-small cell lung cancer;
PAAD	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.11	14.48	0.76	2.13e-30	Body mass index;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23210687	chr2:96874507	STARD7	0.58	6.47	0.46	1.26e-9	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.77	8.69	0.58	5.3e-15	Total body bone mineral density;
PAAD	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.07	0.59	5.6e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.46	4.94	0.37	2.04e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.56	5.34	0.4	3.26e-7	Corneal astigmatism;
PAAD	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.54	-4.49	-0.34	1.39e-5	Heschl's gyrus morphology;
PAAD	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.72	0.48	3.5e-10	IgG glycosylation;
PAAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.34	-0.4	3.37e-7	Plateletcrit;
PAAD	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.59	6.32	0.46	2.8e-9	Testicular germ cell tumor;
PAAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg16147221	chr4:10020634	SLC2A9	0.46	4.26	0.33	3.62e-5	Bone mineral density;
PAAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2e-27	Height;
PAAD	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.42	-4.25	-0.33	3.67e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	8.76	0.58	3.6e-15	Bipolar disorder;
PAAD	cis	rs7873102	0.669	rs10973654	chr9:38055919	T/A	cg03528946	chr9:38069800	SHB	-0.53	-5.4	-0.4	2.48e-7	Brain structure;
PAAD	cis	rs8133932	0.636	rs2014421	chr21:47278308	A/G	cg13695288	chr21:47294981	PCBP3	-0.49	-4.84	-0.37	3.22e-6	Schizophrenia;
PAAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs4731207	0.967	rs3807544	chr7:124400705	G/A	cg14311320	chr7:124405732	GPR37	0.44	4.71	0.36	5.56e-6	Cutaneous malignant melanoma;
PAAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.25	14.87	0.77	1.88e-31	Eosinophil percentage of granulocytes;
PAAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.79	8.3	0.56	5.2e-14	Coronary artery disease;
PAAD	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.49	5.05	0.38	1.28e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs26528	0.584	rs153103	chr16:28528623	A/G	cg09754948	chr16:28834200	ATXN2L	-0.47	-4.47	-0.34	1.52e-5	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.58	-0.35	9.6e-6	IgG glycosylation;
PAAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2446066	0.872	rs3741651	chr12:53777171	A/G	cg14275095	chr12:52828633	KRT75	-0.65	-4.67	-0.35	6.62e-6	Red blood cell count;
PAAD	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10973934	chr10:21787596	C10orf114	-0.47	-5.82	-0.43	3.32e-8	Monocyte percentage of white cells;
PAAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg14686297	chr22:46650375	NA	0.46	4.7	0.36	5.83e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	ch.8.33884649F	chr8:33765107	NA	0.56	5.56	0.41	1.2e-7	Body mass index;
PAAD	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19055217	chr17:12921270	ELAC2	0.64	6.53	0.47	9.39e-10	Obesity-related traits;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.52	-5.0	-0.38	1.55e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.62	-0.35	8.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73019876	0.868	rs2666450	chr19:22131688	G/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07536341	chr12:4758250	NDUFA9	-0.66	-6.58	-0.47	7.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.83	-0.43	3.15e-8	Glomerular filtration rate;
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02071572	chr4:1403502	NA	0.47	5.91	0.43	2.2e-8	Longevity;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg10864074	chr7:100318194	EPO	-0.47	-4.6	-0.35	8.97e-6	Other erythrocyte phenotypes;
PAAD	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.89	9.6	0.61	2.38e-17	Lewy body disease;
PAAD	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.55	5.59	0.41	1.04e-7	Menopause (age at onset);
PAAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.73	-8.98	-0.59	9.79e-16	Emphysema distribution in smoking;
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.98e-10	Lung cancer;
PAAD	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.96e-16	Motion sickness;
PAAD	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg22153407	chr1:230290089	GALNT2	0.5	5.19	0.39	6.61e-7	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.8	5.4	0.4	2.53e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2284367	1.000	rs3758733	chr11:34516856	A/G	cg20406267	chr11:34377921	ABTB2	0.42	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.21e-6	Skin colour saturation;
PAAD	cis	rs6028335	0.877	rs73621992	chr20:37780297	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.37	-0.33	2.29e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.54	-4.38	-0.33	2.18e-5	Blood protein levels;
PAAD	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.28	-0.51	1.7e-11	Neuroticism;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.81	-7.61	-0.53	2.75e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25377178	chr2:232651151	COPS7B	0.61	6.3	0.46	3.01e-9	Myopia (pathological);
PAAD	cis	rs2492906	0.600	rs2637333	chr10:28068615	A/T	cg25523538	chr10:28031957	MKX	-0.46	-4.31	-0.33	2.93e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.59	-8.33	-0.56	4.36e-14	Asthma (sex interaction);
PAAD	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18297960	chr7:1142765	C7orf50	-0.55	-4.33	-0.33	2.7e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03605463	chr16:89740564	NA	-0.52	-4.93	-0.37	2.15e-6	Vitiligo;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.75	-0.36	4.61e-6	Breast cancer;
PAAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg23306229	chr2:178417860	TTC30B	0.65	4.54	0.35	1.16e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.69	7.31	0.51	1.44e-11	Longevity;
PAAD	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg01868782	chr6:126071099	HEY2	0.42	4.71	0.36	5.58e-6	Brugada syndrome;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.01	0.63	1.98e-18	Menopause (age at onset);
PAAD	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.72	-6.94	-0.49	1.04e-10	Anterior chamber depth;
PAAD	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.32	-0.33	2.81e-5	Schizophrenia;
PAAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-4.36	-0.33	2.41e-5	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.45	7.2	0.5	2.57e-11	Mean corpuscular volume;
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.75	0.69	4.47e-23	Platelet count;
PAAD	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.58	0.41	1.09e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg06618935	chr21:46677482	NA	0.56	6.0	0.44	1.4e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg02415014	chr8:143852576	LYNX1	0.39	4.55	0.35	1.07e-5	Urinary tract infection frequency;
PAAD	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg09467607	chr2:36825704	FEZ2	0.65	6.46	0.46	1.37e-9	Height;
PAAD	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg07741184	chr6:167504864	NA	-0.47	-5.78	-0.42	4.16e-8	Crohn's disease;
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg08501292	chr6:25962987	TRIM38	0.98	5.33	0.4	3.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.42	0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.44	0.61	6.1e-17	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07402062	chr16:89894098	SPIRE2	0.38	4.72	0.36	5.24e-6	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08535148	chr4:26321143	RBPJ	-0.67	-6.94	-0.49	1.05e-10	Smoking initiation;
PAAD	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.63	5.54	0.41	1.32e-7	Corneal astigmatism;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.45	5.06	0.38	1.18e-6	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.88	-10.39	-0.64	1.96e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs11807834	0.505	rs7530960	chr1:230234084	C/T	cg00566187	chr1:230250356	GALNT2	-0.61	-6.49	-0.47	1.13e-9	Schizophrenia;
PAAD	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.56	-5.99	-0.44	1.43e-8	Menopause (age at onset);
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.69	7.68	0.53	1.84e-12	Mean corpuscular volume;
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg27436995	chr16:743998	FBXL16	-0.36	-4.32	-0.33	2.77e-5	Height;
PAAD	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.56	-5.46	-0.4	1.93e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-7.15	-0.5	3.45e-11	Colorectal cancer;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	7.7	0.53	1.66e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs375066	1.000	rs375066	chr19:44423570	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.76	7.83	0.54	7.73e-13	Retinal vascular caliber;
PAAD	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg19700328	chr14:106028568	NA	-0.62	-6.09	-0.44	8.65e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg01262667	chr19:19385393	TM6SF2	0.45	5.04	0.38	1.33e-6	Tonsillectomy;
PAAD	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg08648136	chr8:956695	NA	0.41	4.4	0.34	2.05e-5	Schizophrenia;
PAAD	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.45	4.53	0.35	1.17e-5	Airway imaging phenotypes;
PAAD	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05212510	chr18:77623544	KCNG2	-0.45	-4.62	-0.35	8.2e-6	Schizophrenia;
PAAD	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.68	-0.35	6.41e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.55	4.79	0.36	3.99e-6	Total body bone mineral density;
PAAD	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.61	-5.28	-0.39	4.33e-7	Mean corpuscular volume;
PAAD	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10373645	chr2:74007265	DUSP11	-0.56	-6.37	-0.46	2.18e-9	Body fat percentage;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16148416	chr1:33116824	RBBP4;ZBTB8OS	0.61	6.34	0.46	2.5e-9	Myopia (pathological);
PAAD	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.59	6.14	0.45	6.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg20503657	chr10:835505	NA	0.5	5.1	0.38	1.02e-6	Survival in rectal cancer;
PAAD	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs9788721	0.501	rs1021071	chr15:78968179	G/C	cg00540400	chr15:79124168	NA	-0.45	-5.08	-0.38	1.1e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.26e-18	Vitiligo;
PAAD	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.49	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.58	-5.84	-0.43	3.08e-8	Inflammatory bowel disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14456034	chr9:139362909	SEC16A	-0.62	-6.3	-0.46	3.08e-9	Obesity-related traits;
PAAD	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg26097391	chr2:54893211	SPTBN1	0.45	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs2279817	0.780	rs79136279	chr1:18008121	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.65	-0.53	2.12e-12	Migraine;Coronary artery disease;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06873352	chr17:61820015	STRADA	-0.66	-7.09	-0.5	4.65e-11	Height;
PAAD	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.03	0.38	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg10483660	chr13:112241077	NA	0.52	4.84	0.37	3.21e-6	Menarche (age at onset);
PAAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.8	8.06	0.55	2.15e-13	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16137891	chr11:75047111	ARRB1;MIR326	-0.64	-6.76	-0.48	2.8e-10	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs73198823	chr3:128484405	G/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14823967	chr13:107220428	ARGLU1	-0.77	-6.76	-0.48	2.83e-10	Neuroticism;
PAAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.19	-10.79	-0.66	1.62e-20	Breast cancer;
PAAD	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.77	-9.07	-0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs10998941	0.591	rs2616112	chr10:71465646	G/A	cg26770870	chr10:71561502	COL13A1	0.48	4.39	0.34	2.09e-5	CSF tryptophan concentration in tuberculous meningitis;
PAAD	cis	rs10982213	1.000	rs766835	chr9:117166547	A/G	cg00078025	chr9:117159975	NA	0.58	4.32	0.33	2.76e-5	Interleukin-6 levels;
PAAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.92	12.22	0.7	2.33e-24	Menopause (age at onset);
PAAD	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg15309053	chr8:964076	NA	0.62	7.09	0.5	4.62e-11	Schizophrenia;
PAAD	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.53	-5.2	-0.39	6.29e-7	Multiple sclerosis;
PAAD	cis	rs216303	0.642	rs216335	chr12:6148005	T/C	cg12895370	chr12:6755816	ACRBP	-0.59	-4.65	-0.35	7.08e-6	Low vWF levels;
PAAD	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.83	-0.36	3.28e-6	Hirschsprung disease;
PAAD	cis	rs2124910	0.689	rs10420446	chr19:52003058	C/T	cg14953197	chr19:52005651	SIGLEC12	0.47	4.97	0.37	1.82e-6	Blood protein levels;
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg02475695	chr16:616220	NHLRC4	0.47	5.43	0.4	2.2e-7	Height;
PAAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.64	5.17	0.39	7.2e-7	Response to antidepressants in depression;
PAAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.72	0.58	4.57e-15	Personality dimensions;
PAAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.65	0.42	7.86e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	4.97	0.37	1.79e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.64	6.42	0.46	1.65e-9	Gestational age at birth (maternal effect);
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14159672	chr1:205819179	PM20D1	0.52	5.01	0.38	1.52e-6	Parkinson's disease;
PAAD	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.62	5.6	0.41	9.65e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	10.97	0.66	5.3e-21	Menopause (age at onset);
PAAD	cis	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg21546286	chr11:48923668	NA	0.55	5.8	0.43	3.7e-8	HDL cholesterol;
PAAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg10820045	chr2:198174542	NA	0.56	5.71	0.42	5.65e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.73	-7.56	-0.52	3.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.54	6.44	0.46	1.49e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-5.47	-0.41	1.83e-7	Fibrinogen levels;
PAAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	8.76	0.58	3.57e-15	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.71	5.64	0.42	8.23e-8	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.96	0.49	9.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.92	-0.77	1.44e-31	Ulcerative colitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12698834	chr17:18128735	LLGL1	0.62	6.78	0.48	2.43e-10	Myopia (pathological);
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.67	-0.53	1.91e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs901683	1.000	rs12775527	chr10:46024990	G/A	cg14076390	chr17:34947837	DHRS11	0.88	6.62	0.47	5.87e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-5.11	-0.38	9.44e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.85	8.62	0.57	7.97e-15	Cognitive function;
PAAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg17644776	chr2:200775616	C2orf69	-0.7	-5.37	-0.4	2.92e-7	Schizophrenia;
PAAD	cis	rs12760731	0.623	rs10465514	chr1:178334035	G/T	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg05895507	chr15:77155635	SCAPER	-0.35	-4.31	-0.33	2.94e-5	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07820528	chr22:41809549	NA	-0.56	-6.36	-0.46	2.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.47	4.72	0.36	5.29e-6	Interleukin-18 levels;
PAAD	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15149876	chr8:125988915	ZNF572	0.57	6.45	0.46	1.44e-9	Smoking initiation;
PAAD	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.99	11.62	0.69	9.53e-23	Breast cancer;
PAAD	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.62	-0.41	9.01e-8	Alzheimer's disease (late onset);
PAAD	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.65	7.53	0.52	4.14e-12	Sense of smell;
PAAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.53	0.34	1.2e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg21724239	chr8:58056113	NA	0.68	5.34	0.4	3.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.55	-5.13	-0.38	8.9e-7	Obesity-related traits;
PAAD	cis	rs28489187	0.643	rs2011825	chr1:85844671	T/C	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	5.83	0.43	3.18e-8	Obesity-related traits;
PAAD	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg21929781	chr1:2537748	MMEL1	0.5	5.31	0.4	3.86e-7	Ulcerative colitis;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.9	-11.73	-0.69	4.86e-23	Total body bone mineral density;
PAAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.78	-7.91	-0.54	4.87e-13	Cognitive function;
PAAD	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.52	-4.53	-0.34	1.19e-5	Type 1 diabetes;
PAAD	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16576597	chr16:28551801	NUPR1	0.67	7.5	0.52	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.69	-5.96	-0.44	1.68e-8	Diabetic retinopathy;
PAAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg14092988	chr3:52407081	DNAH1	0.44	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.93	0.43	1.93e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.56	-6.09	-0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs3764400	0.567	rs741058	chr17:46205353	T/C	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.48	5.05	0.38	1.24e-6	Testicular germ cell tumor;
PAAD	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg00806126	chr19:22604979	ZNF98	-0.4	-5.07	-0.38	1.12e-6	Pain;
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg01181863	chr3:195395398	SDHAP2	-0.79	-7.6	-0.52	2.77e-12	Pancreatic cancer;
PAAD	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.7	7.39	0.51	9.01e-12	Dental caries;
PAAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg01800442	chr17:74086473	EXOC7	0.52	4.28	0.33	3.33e-5	Psoriasis;
PAAD	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.26e-18	Vitiligo;
PAAD	cis	rs13278732	0.500	rs3088121	chr8:99048049	A/G	cg16297171	chr8:99017690	MATN2	-0.45	-4.29	-0.33	3.17e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.18e-6	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.13	9.04	0.59	6.92e-16	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.47e-6	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11793701	chr2:206547163	NRP2	0.68	7.01	0.49	7.23e-11	Obesity-related traits;
PAAD	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg16680214	chr1:154839983	KCNN3	-0.5	-5.48	-0.41	1.7e-7	Prostate cancer;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.49	4.29	0.33	3.15e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.55	6.56	0.47	7.94e-10	Multiple sclerosis;
PAAD	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.58	-5.84	-0.43	3.09e-8	Reticulocyte count;
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.17	-0.39	7.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg00035636	chr13:21900591	NA	0.6	6.06	0.44	1.01e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2594989	0.943	rs4580536	chr3:11422319	A/G	cg01796438	chr3:11312864	ATG7	-0.6	-4.78	-0.36	4.19e-6	Circulating chemerin levels;
PAAD	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.7	-7.98	-0.54	3.31e-13	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22019806	chr20:1918249	SIRPA	-0.69	-6.62	-0.47	5.71e-10	Obesity-related traits;
PAAD	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg00717180	chr2:96193071	NA	-0.64	-7.85	-0.54	7.08e-13	HDL cholesterol;
PAAD	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.72	6.9	0.49	1.35e-10	Obesity-related traits;
PAAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg21419209	chr3:44054225	NA	-0.72	-7.23	-0.51	2.16e-11	Coronary artery disease;
PAAD	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.72	-8.03	-0.55	2.46e-13	Colorectal cancer;
PAAD	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs73568641	0.583	rs73570617	chr6:154062194	T/C	cg15658985	chr6:154448740	OPRM1	0.5	4.27	0.33	3.39e-5	Methadone dose in opioid dependence;
PAAD	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20307385	chr11:47447363	PSMC3	-0.52	-4.9	-0.37	2.47e-6	Subjective well-being;
PAAD	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg04160749	chr8:58172571	NA	0.67	4.62	0.35	8.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945718	0.621	rs10831890	chr11:12671211	A/G	cg25843174	chr11:12811716	TEAD1	0.32	4.75	0.36	4.7e-6	Educational attainment (years of education);
PAAD	cis	rs3112530	0.901	rs2546328	chr5:152619464	T/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.86	-4.57	-0.35	1.02e-5	Aging (time to event);
PAAD	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg07159951	chr1:45983175	PRDX1	0.42	4.69	0.36	5.93e-6	High light scatter reticulocyte count;
PAAD	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.54	5.05	0.38	1.22e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg20487152	chr13:99095054	FARP1	0.46	4.91	0.37	2.33e-6	Longevity;
PAAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg12639453	chr1:2035780	PRKCZ	0.56	5.98	0.44	1.53e-8	Height;
PAAD	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs9815354	0.857	rs1474219	chr3:42000913	G/A	cg03022575	chr3:42003672	ULK4	-0.75	-5.4	-0.4	2.47e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.81	-0.54	8.51e-13	Prudent dietary pattern;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01593751	chr17:52977904	TOM1L1	0.61	6.8	0.48	2.21e-10	Immature fraction of reticulocytes;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.8	-7.87	-0.54	6.2800000000000005e-13	Menopause (age at onset);
PAAD	cis	rs2300603	0.840	rs34695601	chr14:76014298	T/C	cg01624173	chr14:75981868	NA	0.56	5.37	0.4	2.87e-7	Multiple sclerosis;
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.58	5.91	0.43	2.18e-8	Menarche (age at onset);
PAAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg20243544	chr17:37824526	PNMT	0.53	4.67	0.35	6.71e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-5.52	-0.41	1.41e-7	Prevalent atrial fibrillation;
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02071572	chr4:1403502	NA	-0.48	-6.17	-0.45	5.97e-9	Obesity-related traits;
PAAD	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.95	-11.08	-0.67	2.83e-21	Gut microbiome composition (winter);
PAAD	cis	rs17135859	1.000	rs34751560	chr5:112993920	G/A	cg12552261	chr5:112820674	MCC	0.73	4.64	0.35	7.52e-6	F-cell distribution;
PAAD	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.77	9.44	0.61	6.06e-17	Metabolite levels;
PAAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg20381115	chr15:45671148	LOC145663;GATM	-0.39	-4.32	-0.33	2.85e-5	Glomerular filtration rate;
PAAD	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.52	-4.73	-0.36	5.03e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22122680	chr1:220219742	EPRS	-0.74	-6.31	-0.46	2.87e-9	Neuroticism;
PAAD	cis	rs6076065	0.510	rs6137899	chr20:23320137	C/T	cg11657817	chr20:23433608	CST11	0.51	5.1	0.38	9.81e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.66	6.5	0.47	1.1e-9	Schizophrenia;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.53	5.34	0.4	3.34e-7	Obesity-related traits;
PAAD	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.71e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1532557	1.000	rs12089565	chr1:224775840	C/T	cg09988837	chr1:224811939	CNIH3	0.66	5.01	0.38	1.49e-6	Cancer;
PAAD	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg08992911	chr2:238395768	MLPH	0.59	5.58	0.41	1.08e-7	Prostate cancer;
PAAD	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg14581129	chr12:53358946	NA	-1.2	-7.37	-0.51	1e-11	Prostate cancer;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.86	9.53	0.61	3.71e-17	Prudent dietary pattern;
PAAD	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs7707921	0.881	rs73136777	chr5:81434479	T/A	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09597638	chr17:3907349	NA	0.72	7.54	0.52	4.04e-12	Type 2 diabetes;
PAAD	cis	rs9616064	0.710	rs12053764	chr22:46999703	C/T	cg03318428	chr22:46971703	NA	0.4	4.64	0.35	7.57e-6	Urate levels in obese individuals;
PAAD	cis	rs1997066	0.748	rs73338291	chr10:106796079	G/A	cg17321814	chr10:106440892	SORCS3	0.63	4.26	0.33	3.57e-5	Diabetic kidney disease;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg20521031	chr10:95574575	NA	-0.63	-6.56	-0.47	7.79e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02419362	chr12:121203948	SPPL3	0.53	6.05	0.44	1.09e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-8.46	-0.57	2.05e-14	Height;
PAAD	cis	rs1045714	1.000	rs1045714	chr7:2653582	A/G	cg20813462	chr7:2646259	IQCE	0.62	4.25	0.33	3.71e-5	Urate levels in lean individuals;
PAAD	cis	rs9584850	0.915	rs9517310	chr13:99100474	C/T	cg20487152	chr13:99095054	FARP1	0.58	4.96	0.37	1.87e-6	Neuroticism;
PAAD	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.63	6.75	0.48	2.87e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg17366294	chr4:99064904	C4orf37	0.55	5.81	0.43	3.51e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4792901	0.802	rs9895324	chr17:41594168	G/A	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg00531865	chr16:30841666	NA	-0.64	-4.65	-0.35	7.12e-6	Diastolic blood pressure;
PAAD	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.75	8.19	0.55	1e-13	Migraine;Coronary artery disease;
PAAD	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.54	6.74	0.48	3.05e-10	Crohn's disease;
PAAD	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	6.95	0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs1144333	0.655	rs79376884	chr1:76465401	C/T	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-5.89	-0.43	2.36e-8	Menarche (age at onset);
PAAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.42	5.0	0.38	1.55e-6	Psoriasis;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg02440177	chr19:53496695	ZNF702P	-0.63	-6.63	-0.47	5.64e-10	Psoriasis;
PAAD	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg20283391	chr11:68216788	NA	-0.53	-5.13	-0.38	8.73e-7	Total body bone mineral density;
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.88	-10.84	-0.66	1.22e-20	Body mass index;
PAAD	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.85	-0.49	1.69e-10	Atrioventricular conduction;
PAAD	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.36	-4.37	-0.33	2.31e-5	Electrocardiographic conduction measures;
PAAD	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-9.95	-0.63	2.92e-18	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04904530	chr17:18086472	ALKBH5	0.69	7.17	0.5	3e-11	Obesity-related traits;
PAAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-5.58	-0.41	1.09e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.61	-7.01	-0.49	7.45e-11	Corneal astigmatism;
PAAD	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg12215294	chr3:40350768	EIF1B	0.5	5.06	0.38	1.21e-6	Renal cell carcinoma;
PAAD	cis	rs4074493	1.000	rs4658875	chr1:231168994	C/T	cg22172038	chr1:231176991	FAM89A	-0.48	-4.45	-0.34	1.64e-5	Carotid plaque burden (smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09859794	chr8:144911744	PUF60	0.61	6.43	0.46	1.53e-9	Myopia (pathological);
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	4.27	0.33	3.48e-5	Longevity;
PAAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg01176363	chr20:62369445	LIME1	-0.58	-5.5	-0.41	1.56e-7	Prostate cancer;
PAAD	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg02887458	chr19:19495540	GATAD2A	-0.5	-4.59	-0.35	9.23e-6	Bipolar disorder;
PAAD	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.59	-8.33	-0.56	4.36e-14	Asthma (sex interaction);
PAAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.61	5.85	0.43	2.95e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs11264213	0.901	rs79303353	chr1:36402056	G/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs6142102	0.923	rs4911379	chr20:32535305	A/C	cg08999081	chr20:33150536	PIGU	0.46	4.26	0.33	3.56e-5	Skin pigmentation;
PAAD	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.15	-0.39	8.09e-7	Common traits (Other);
PAAD	cis	rs927821	0.941	rs12776002	chr10:104199624	A/T	cg14737131	chr10:104680354	CNNM2	0.53	4.28	0.33	3.29e-5	Social autistic-like traits;
PAAD	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-8.06	-0.55	2.1e-13	Hemoglobin concentration;
PAAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg06632027	chr4:90757378	SNCA	-0.5	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	1.19	15.91	0.79	3.57e-34	Ewing sarcoma;
PAAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.68	-5.78	-0.42	4.19e-8	Blood protein levels;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11051970	0.918	rs12229856	chr12:32531220	C/T	cg24626660	chr12:32551988	NA	0.4	4.52	0.34	1.23e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.48	-0.34	1.47e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35740288	0.770	rs11630112	chr15:86120246	T/C	cg07943548	chr15:86304357	KLHL25	-0.65	-5.67	-0.42	6.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.43	6.31	0.46	2.88e-9	Information processing speed;
PAAD	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.79	9.66	0.62	1.65e-17	Breast cancer;
PAAD	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg14343924	chr8:8086146	FLJ10661	0.5	4.37	0.33	2.28e-5	Joint mobility (Beighton score);
PAAD	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.58	0.61	2.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.65	6.34	0.46	2.54e-9	Type 2 diabetes;
PAAD	cis	rs17102423	0.896	rs11158577	chr14:65596490	A/G	cg11161011	chr14:65562177	MAX	-0.48	-4.29	-0.33	3.2e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.37e-7	Life satisfaction;
PAAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs7539409	0.667	rs723251	chr1:84214171	A/C	cg10977910	chr1:84465055	TTLL7	0.9	4.99	0.38	1.6e-6	Alzheimer's disease;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg04844267	chr4:1394941	NA	0.42	4.75	0.36	4.74e-6	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.8	-5.19	-0.39	6.6e-7	Diabetic kidney disease;
PAAD	cis	rs7082209	0.877	rs7913265	chr10:44807379	G/A	cg13191911	chr10:44806660	NA	-0.96	-5.07	-0.38	1.14e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs507080	0.845	rs613377	chr11:118556084	C/T	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-4.28	-0.33	3.35e-5	Red blood cell count;
PAAD	cis	rs59888335	0.858	rs13067977	chr3:80928262	T/C	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg09436375	chr6:42928200	GNMT	-0.45	-6.3	-0.46	2.98e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.61	0.35	8.34e-6	Height;
PAAD	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.83	0.43	3.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.73	8.47	0.57	1.97e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs939584	1.000	rs10193244	chr2:647580	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.33	0.33	2.66e-5	Breast cancer;
PAAD	cis	rs72828912	0.831	rs2176933	chr6:24094140	A/G	cg27524988	chr6:24583477	KIAA0319	-0.5	-4.44	-0.34	1.76e-5	Squamous cell lung carcinoma;
PAAD	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.99	0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.99	0.37	1.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg21496419	chr19:44306685	LYPD5	0.44	5.43	0.4	2.15e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01558307	chr20:3827325	MAVS	-0.68	-6.92	-0.49	1.21e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4073221	0.929	rs35274326	chr3:18282459	C/G	cg07694806	chr3:18168406	NA	-0.75	-5.07	-0.38	1.15e-6	Parkinson's disease;
PAAD	cis	rs9942416	0.858	rs2307111	chr5:75003678	T/C	cg07025548	chr5:74632477	HMGCR	-0.46	-4.37	-0.33	2.28e-5	Age-related disease endophenotypes;
PAAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.68	-0.42	6.68e-8	Personality dimensions;
PAAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg10920065	chr6:169824652	NA	-0.47	-4.65	-0.35	7.05e-6	Obesity-related traits;
PAAD	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	5.58	0.41	1.1e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg20360395	chr12:132671235	NA	0.42	4.57	0.35	1.01e-5	Anti-saccade response;
PAAD	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.56	-0.47	8.07e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.56	-5.93	-0.43	1.92e-8	Subjective well-being;
PAAD	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs901683	0.867	rs17157885	chr10:46020094	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-8.44	-0.56	2.32e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.75	-8.38	-0.56	3.22e-14	Colorectal cancer;
PAAD	cis	rs12760731	0.565	rs12732507	chr1:178098296	A/G	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	ch.11.42038R	chr11:967971	AP2A2	0.63	6.15	0.45	6.4e-9	Alzheimer's disease (late onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11157016	chr6:157528657	ARID1B	0.63	6.69	0.48	4.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.86	7.86	0.54	6.44e-13	Response to diuretic therapy;
PAAD	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg02367144	chr2:237146137	ASB18	-0.42	-5.43	-0.4	2.17e-7	Educational attainment;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	6.0	0.44	1.4e-8	Prudent dietary pattern;
PAAD	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.57	5.97	0.44	1.64e-8	Menarche (age at onset);
PAAD	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg11518657	chr1:67396239	MIER1	0.68	5.11	0.38	9.43e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.83	-7.62	-0.53	2.53e-12	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg01299579	chr2:10830716	NOL10	-0.57	-5.69	-0.42	6.32e-8	Prostate cancer;
PAAD	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.54	-5.5	-0.41	1.56e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2031532	0.587	rs721457	chr13:50035151	G/C	cg08779649	chr13:50194554	NA	0.36	4.77	0.36	4.2e-6	Cardiac hypertrophy;
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.59	-4.27	-0.33	3.42e-5	Initial pursuit acceleration;
PAAD	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.91	-10.3	-0.64	3.37e-19	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg01868782	chr6:126071099	HEY2	0.4	4.58	0.35	9.66e-6	High light scatter reticulocyte count;
PAAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs111342015	0.892	rs78652437	chr6:43205361	T/A	cg17076780	chr6:43251928	TTBK1	0.7	4.69	0.36	5.96e-6	Breast cancer;
PAAD	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-7.46	-0.52	6.19e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12432203	1.000	rs72622441	chr14:51742365	G/C	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg12661370	chr5:149340060	SLC26A2	0.64	5.52	0.41	1.4e-7	HIV-1 control;
PAAD	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.64	6.17	0.45	5.85e-9	Cancer;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.95	12.27	0.71	1.74e-24	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.87	-7.17	-0.5	2.98e-11	Initial pursuit acceleration;
PAAD	cis	rs7072216	0.555	rs7921146	chr10:100186601	G/A	cg17552801	chr10:99332121	ANKRD2	-0.44	-4.67	-0.35	6.53e-6	Metabolite levels;
PAAD	cis	rs2000999	0.514	rs35223533	chr16:72252544	A/T	cg16558253	chr16:72132732	DHX38	-0.66	-4.27	-0.33	3.41e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.77	-5.52	-0.41	1.46e-7	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15815730	chr19:52491114	ZNF350	-0.67	-6.74	-0.48	3.05e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-1.13	-8.96	-0.59	1.11e-15	Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.94	-7.56	-0.52	3.46e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs59888335	0.825	rs9858346	chr3:80988363	T/A	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2412208	0.565	rs11120822	chr1:7113112	G/C	cg20434152	chr1:7120926	CAMTA1	-0.5	-5.59	-0.41	1.03e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.59	6.63	0.47	5.54e-10	Coronary artery disease;
PAAD	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.71	-0.48	3.59e-10	Retinal vascular caliber;
PAAD	trans	rs901683	1.000	rs71494792	chr10:45983049	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.57	-6.41	-0.46	1.73e-9	Lymphocyte counts;
PAAD	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.69	6.68	0.48	4.33e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.95	8.73	0.58	4.34e-15	Gut microbiome composition (summer);
PAAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	7.61	0.53	2.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.49e-11	Total cholesterol levels;
PAAD	cis	rs11051970	0.918	rs76930558	chr12:32538839	A/C	cg24626660	chr12:32551988	NA	0.42	4.59	0.35	9.36e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	11.22	0.67	1.14e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.49	4.56	0.35	1.05e-5	Mood instability;
PAAD	cis	rs2137920	0.735	rs12779947	chr10:50224404	G/T	cg02657375	chr10:50863136	CHAT	0.54	4.37	0.33	2.29e-5	Migraine with aura;
PAAD	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-4.88	-0.37	2.7e-6	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg17105886	chr17:28927953	LRRC37B2	0.76	4.88	0.37	2.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.79	0.53	9.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.73	-0.36	5.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08855249	chr1:207975363	MIR29C	-0.58	-6.3	-0.46	3.03e-9	Obesity-related traits;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-7.56	-0.52	3.62e-12	Systemic lupus erythematosus;
PAAD	cis	rs743757	1.000	rs2236988	chr3:50504896	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.73	5.04	0.38	1.29e-6	Diastolic blood pressure;
PAAD	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.53	0.47	9.47e-10	Mood instability;
PAAD	cis	rs7116495	0.609	rs1791456	chr11:71594888	G/C	cg26138937	chr11:71823887	C11orf51	0.95	4.34	0.33	2.56e-5	Severe influenza A (H1N1) infection;
PAAD	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	1.09	7.41	0.52	8.25e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.58	-7.2	-0.5	2.6e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11809230	0.541	rs59103514	chr1:70139971	A/G	cg01791338	chr1:70606906	NA	0.77	4.96	0.37	1.89e-6	Cannabis use (initiation);
PAAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.57	5.34	0.4	3.3e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-1.01	-9.65	-0.62	1.76e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg16898833	chr6:26189333	HIST1H4D	0.86	4.74	0.36	4.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs58653258	0.730	rs2796166	chr1:234984583	C/G	cg03518729	chr1:235147744	NA	-0.46	-4.59	-0.35	9.28e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-4.46	-0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1903068	0.785	rs10020668	chr4:55996903	C/T	cg20092376	chr4:56023423	NA	0.43	4.27	0.33	3.36e-5	Endometriosis;
PAAD	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	5.18	0.39	7.03e-7	Mean platelet volume;
PAAD	cis	rs7180079	1.000	rs7177457	chr15:64530839	C/T	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.99	11.6	0.69	1.08e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs59104589	0.617	rs111937035	chr2:242212177	C/T	cg19488206	chr2:242435732	STK25	0.46	4.32	0.33	2.84e-5	Fibrinogen levels;
PAAD	cis	rs9659323	0.632	rs10802074	chr1:119624996	C/G	cg26570165	chr1:119541833	NA	-0.56	-6.31	-0.46	2.89e-9	Body mass index;
PAAD	cis	rs877529	0.605	rs139380	chr22:39526174	T/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.82	-0.48	2.05e-10	Multiple myeloma;
PAAD	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	7.92e-11	Gout;Renal underexcretion gout;
PAAD	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.9	-10.31	-0.64	3.23e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11168618	0.904	rs7137866	chr12:48922802	T/C	cg01881778	chr12:48919444	OR8S1	-0.45	-4.51	-0.34	1.3e-5	Adiponectin levels;
PAAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.55	-5.65	-0.42	7.79e-8	Testicular germ cell tumor;
PAAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.68	0.65	3.19e-20	Homoarginine levels;
PAAD	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.66e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.7	-0.36	5.88e-6	Lung cancer in ever smokers;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.68	0.35	6.33e-6	Electroencephalogram traits;
PAAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg10591111	chr5:226296	SDHA	-0.64	-4.55	-0.35	1.08e-5	Breast cancer;
PAAD	cis	rs2637266	0.783	rs12268496	chr10:78487192	G/A	cg18941641	chr10:78392320	NA	0.36	4.37	0.33	2.34e-5	Pulmonary function;
PAAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs990171	0.538	rs6543154	chr2:103114334	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.49	-0.34	1.41e-5	Lymphocyte counts;
PAAD	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg22467129	chr15:76604101	ETFA	0.5	4.68	0.36	6.17e-6	Blood metabolite levels;
PAAD	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	5.16	0.39	7.5e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.78	8.14	0.55	1.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.28	-0.39	4.46e-7	Inflammatory bowel disease;
PAAD	cis	rs77633900	0.881	rs80003765	chr15:76657075	T/A	cg21673338	chr15:77095150	SCAPER	-0.89	-4.62	-0.35	8.29e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20887711	chr4:1340912	KIAA1530	-0.46	-4.6	-0.35	8.75e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25937494	chr22:42228971	SREBF2	0.55	6.39	0.46	1.91e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.57	5.93	0.43	1.98e-8	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg18612461	chr15:75251733	NA	0.69	8.91	0.59	1.49e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.57	-0.52	3.31e-12	Blood metabolite levels;
PAAD	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20561984	chr2:196521792	SLC39A10	0.59	6.38	0.46	2.05e-9	Myopia (pathological);
PAAD	cis	rs6929137	0.666	rs11753383	chr6:151954659	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.32	-0.33	2.76e-5	Bone mineral density (spine);
PAAD	cis	rs6813479	0.562	rs2634900	chr4:137733596	C/A	cg16185213	chr4:137733633	NA	0.41	4.46	0.34	1.61e-5	Longevity;
PAAD	cis	rs4356203	0.870	rs12286505	chr11:17163725	G/A	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7636293	1.000	rs7636293	chr3:129045906	A/G	cg04578792	chr3:128152268	NA	-0.4	-4.3	-0.33	3e-5	Height;
PAAD	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs990171	0.538	rs4851606	chr2:103120889	G/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg23973274	chr1:155060172	NA	-0.41	-4.25	-0.33	3.65e-5	Serum magnesium levels;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg05313129	chr8:58192883	C8orf71	-0.73	-6.48	-0.47	1.23e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06998765	chr14:75389618	RPS6KL1	0.29	5.07	0.38	1.14e-6	Caffeine consumption;
PAAD	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-5.95	-0.43	1.75e-8	Hypospadias;
PAAD	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg03999872	chr20:62272968	STMN3	0.64	5.86	0.43	2.73e-8	Atopic dermatitis;
PAAD	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-7.48	-0.52	5.56e-12	Morning vs. evening chronotype;
PAAD	cis	rs62264129	0.500	rs62278843	chr3:112041382	T/C	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.04	-0.38	1.3e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19394731	chr11:57283269	SLC43A1	-0.74	-6.62	-0.47	5.71e-10	Neuroticism;
PAAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.59	-6.1	-0.44	8.62e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.45	-0.4	1.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7577696	0.626	rs3769603	chr2:32360887	G/T	cg02381751	chr2:32503542	YIPF4	-0.48	-4.71	-0.36	5.62e-6	Inflammatory biomarkers;
PAAD	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-5.63	-0.42	8.64e-8	Personality dimensions;
PAAD	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-4.54	-0.35	1.15e-5	Red blood cell count;
PAAD	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs256277	0.657	rs194360	chr5:111374252	C/T	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.57	5.82	0.43	3.37e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.5	4.42	0.34	1.87e-5	Corneal astigmatism;
PAAD	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26913058	chr16:419975	MRPL28	-0.5	-4.81	-0.36	3.58e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.34	-0.33	2.57e-5	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.94	8.05	0.55	2.17e-13	Alzheimer's disease;
PAAD	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.2	0.55	9.41e-14	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03671748	chr4:2965203	GRK4;NOP14	0.65	6.46	0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.87	4.6	0.35	8.97e-6	Childhood ear infection;
PAAD	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg24687543	chr11:63912206	MACROD1	0.61	5.38	0.4	2.7e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.65	0.65	3.91e-20	Prudent dietary pattern;
PAAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.38	-0.46	2.02e-9	IgG glycosylation;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	1.01	6.49	0.47	1.12e-9	IgG glycosylation;
PAAD	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.7	8.32	0.56	4.79e-14	Lung cancer;
PAAD	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.77	0.75	1.62e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.11	-0.5	4.29e-11	Neuroticism;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73198271	0.628	rs75693229	chr8:8590926	G/A	cg01851573	chr8:8652454	MFHAS1	0.6	4.7	0.36	5.89e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.91	-6.61	-0.47	5.97e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg16342193	chr10:102329863	NA	-0.82	-8.99	-0.59	9.15e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.4	-4.41	-0.34	1.92e-5	Monocyte percentage of white cells;
PAAD	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	4.62	0.35	8.26e-6	Monocyte percentage of white cells;
PAAD	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.6	6.18	0.45	5.62e-9	Crohn's disease;
PAAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.22	-0.39	5.73e-7	Height;
PAAD	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.55	-0.57	1.22e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs432925	0.572	rs2685120	chr16:342080	C/G	cg06233593	chr16:337645	AXIN1	0.48	5.33	0.4	3.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs1198430	0.639	rs16860685	chr1:23766644	A/G	cg27447006	chr1:23763279	ASAP3	0.65	5.05	0.38	1.27e-6	Total cholesterol levels;
PAAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.31	-0.33	2.88e-5	Neuroticism;
PAAD	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg01851573	chr8:8652454	MFHAS1	-0.49	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg21300403	chr2:198650112	BOLL	-0.69	-4.5	-0.34	1.35e-5	Ulcerative colitis;
PAAD	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg08992911	chr2:238395768	MLPH	0.9	7.21	0.5	2.45e-11	Prostate cancer;
PAAD	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.03e-5	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg26027780	chr6:27100370	HIST1H2AG;HIST1H2BJ	0.51	4.32	0.33	2.82e-5	Educational attainment;
PAAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.54	6.11	0.44	8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs741013	1.000	rs73128699	chr3:64293384	C/T	cg20180538	chr3:64559102	ADAMTS9	-0.9	-4.34	-0.33	2.64e-5	Coronary artery calcification;
PAAD	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.66	-0.35	6.95e-6	Rheumatoid arthritis;
PAAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.73	-7.75	-0.53	1.24e-12	Blood metabolite levels;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-7.66	-0.53	2.07e-12	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05612640	chr18:77748679	TXNL4A	0.67	6.62	0.47	5.79e-10	Obesity-related traits;
PAAD	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.02	0.38	1.44e-6	Prostate cancer;
PAAD	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3.09e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.16e-8	Vitiligo;
PAAD	cis	rs728616	0.681	rs117420340	chr10:82166495	T/C	cg19423196	chr10:82049429	MAT1A	0.54	4.94	0.37	2.01e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	4.7	0.36	5.72e-6	Homocysteine levels;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.45	-4.7	-0.36	5.69e-6	Dementia with Lewy bodies;
PAAD	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.98	-6.19	-0.45	5.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.51	-4.59	-0.35	9.28e-6	IgG glycosylation;
PAAD	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.87	-0.54	6.3e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	cis	rs818427	0.635	rs2546110	chr5:112162413	A/G	cg07820702	chr5:112228657	REEP5	0.51	4.5	0.34	1.36e-5	Total body bone mineral density;
PAAD	cis	rs427941	0.659	rs2529373	chr7:101739618	A/G	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7692976	0.578	rs12506489	chr4:110843148	T/G	cg06981781	chr4:110842888	EGF	-0.36	-4.3	-0.33	2.99e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg13263323	chr15:86062960	AKAP13	0.61	6.75	0.48	3.01e-10	Interstitial lung disease;
PAAD	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.56	7.34	0.51	1.17e-11	Schizophrenia;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.83	10.84	0.66	1.22e-20	Vitiligo;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.82	6.05	0.44	1.06e-8	Alzheimer's disease;
PAAD	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg13444538	chr7:158905317	VIPR2	-0.7	-5.29	-0.39	4.16e-7	Facial morphology (factor 20);
PAAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.47	5.1	0.38	1e-6	Calcium levels;
PAAD	cis	rs2004318	1.000	rs7246195	chr19:55080842	T/G	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs2302729	1.000	rs7974589	chr12:2785089	G/A	cg19945202	chr12:2788847	CACNA1C	-0.65	-6.26	-0.45	3.65e-9	Sleep quality;
PAAD	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs4427176	0.769	rs35039536	chr8:9578146	T/C	cg03024720	chr8:9765601	NA	-0.48	-4.61	-0.35	8.54e-6	Mosquito bite size;
PAAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.09	-8.35	-0.56	3.88e-14	Diabetic kidney disease;
PAAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.79	-6.24	-0.45	4.22e-9	Schizophrenia;
PAAD	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.66	6.98	0.49	8.64e-11	Longevity;
PAAD	cis	rs9657904	0.687	rs1992522	chr3:105544863	C/T	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs7772697	0.635	rs7773409	chr6:149414376	G/C	cg21368479	chr6:149415018	NA	0.45	4.58	0.35	9.73e-6	Diabetic retinopathy;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	5.08e-8	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg07701084	chr6:150067640	NUP43	0.59	5.0	0.38	1.55e-6	Lung cancer;
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.59	-5.59	-0.41	1.04e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg15192750	chr16:69999425	NA	0.77	6.02	0.44	1.27e-8	IgE levels;
PAAD	cis	rs4481887	0.861	rs6676064	chr1:248443890	G/C	cg00666640	chr1:248458726	OR2T12	0.6	5.08	0.38	1.1e-6	Common traits (Other);
PAAD	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg05038881	chr1:10490043	APITD1	0.4	4.65	0.35	7.1e-6	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs7765004	1.000	rs9372375	chr6:114074915	C/T	cg13100190	chr6:114053961	NA	0.35	4.37	0.33	2.26e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23637004	chr20:10414904	C20orf94;MKKS	-0.58	-6.75	-0.48	2.86e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.96	-10.03	-0.63	1.78e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.74	-0.42	4.98e-8	Obesity-related traits;
PAAD	cis	rs1859596	0.646	rs6964644	chr7:79092822	C/T	cg06809544	chr7:79081666	MAGI2	-0.41	-4.26	-0.33	3.53e-5	Reading or mathematical ability;
PAAD	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	trans	rs11794666	0.929	rs11794737	chr9:31665305	G/A	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	5.34	0.4	3.29e-7	Axial length;
PAAD	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg16451430	chr20:42940032	FITM2	0.45	4.51	0.34	1.3e-5	Positive affect;
PAAD	cis	rs988913	0.874	rs12662124	chr6:54802336	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.5	5.87	0.43	2.61e-8	Height;
PAAD	cis	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg20159608	chr7:32802032	NA	-0.48	-4.96	-0.37	1.84e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs3787159	0.521	rs483569	chr20:56884186	T/G	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.14e-5	Systolic blood pressure;
PAAD	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.56	-5.67	-0.42	7.09e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs732765	0.734	rs17782707	chr14:75179102	T/A	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg21724239	chr8:58056113	NA	0.67	5.09	0.38	1.04e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg03959625	chr15:84868606	LOC388152	0.41	4.32	0.33	2.76e-5	Schizophrenia;
PAAD	cis	rs564309	0.764	rs35553922	chr1:228531093	C/T	cg01328119	chr1:228783545	DUSP5P	0.74	4.25	0.33	3.76e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.55	-6.5	-0.47	1.08e-9	Urate levels in overweight individuals;
PAAD	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs72634258	0.786	rs6577468	chr1:8183921	T/C	cg09168692	chr1:7887560	PER3	0.48	4.63	0.35	7.86e-6	Inflammatory bowel disease;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	7.84	0.54	7.42e-13	Hemoglobin concentration;
PAAD	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg13918804	chr1:2043761	PRKCZ	0.38	5.06	0.38	1.22e-6	Height;
PAAD	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.85	-9.65	-0.62	1.79e-17	Morning vs. evening chronotype;
PAAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.92	11.55	0.68	1.55e-22	Monocyte percentage of white cells;
PAAD	cis	rs2738048	0.545	rs2738046	chr8:6823542	C/A	cg04178011	chr8:6876155	DEFA3;DEFA1B;DEFA1	0.42	4.3	0.33	3.01e-5	IgA nephropathy;
PAAD	cis	rs1816752	0.819	rs4769349	chr13:24982832	A/G	cg02811702	chr13:24901961	NA	-0.51	-5.57	-0.41	1.11e-7	Obesity-related traits;
PAAD	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02556042	chr12:117471086	NA	0.47	4.82	0.36	3.4e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.49	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	8.08	0.55	1.85e-13	Prudent dietary pattern;
PAAD	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.62	-6.32	-0.46	2.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.92e-7	Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.49	-0.34	1.4e-5	Prevalent atrial fibrillation;
PAAD	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg18551225	chr6:44695536	NA	-0.74	-7.42	-0.52	7.85e-12	Total body bone mineral density;
PAAD	cis	rs7188861	0.681	rs55752638	chr16:11409493	T/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.56	-7.58	-0.52	3.2e-12	Renal cell carcinoma;
PAAD	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg21269045	chr12:125625041	AACS	-0.48	-4.61	-0.35	8.42e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.67	6.75	0.48	2.94e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs6604026	0.656	rs9440134	chr1:93370813	C/T	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.97	-0.49	9.24e-11	Hip circumference;
PAAD	cis	rs4140564	0.730	rs8179485	chr1:186701124	C/T	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg03371404	chr2:241525653	CAPN10	-0.55	-4.89	-0.37	2.51e-6	Bipolar disorder;
PAAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	6.68	0.48	4.3e-10	Menarche (age at onset);
PAAD	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.47	5.83	0.43	3.26e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs714515	0.586	rs4916267	chr1:172450888	A/G	cg13446689	chr1:172328377	DNM3	-0.44	-5.36	-0.4	3.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2882667	0.690	rs10068280	chr5:138267083	T/C	cg09476006	chr5:138032270	NA	0.45	5.51	0.41	1.47e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.48	0.52	5.44e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.91	10.6	0.65	5.44e-20	Myeloid white cell count;
PAAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.61	0.47	6.07e-10	Body mass index;
PAAD	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.46	-0.34	1.56e-5	Body mass index;
PAAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.62	8.76	0.58	3.49e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24729792	chr2:113192114	RGPD8;RGPD5	0.6	4.46	0.34	1.59e-5	Yeast infection;
PAAD	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.46	4.42	0.34	1.9e-5	Schizophrenia;
PAAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.47	4.38	0.33	2.19e-5	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs11159086	1.000	rs4903232	chr14:74963288	A/C	cg10195687	chr14:74926396	NA	-0.45	-4.9	-0.37	2.47e-6	Advanced glycation end-product levels;
PAAD	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.12e-9	Type 2 diabetes;
PAAD	cis	rs11615916	0.790	rs79021534	chr12:62658986	T/C	cg11441379	chr12:63026424	NA	0.64	4.41	0.34	1.98e-5	Pulmonary function decline;
PAAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg11764359	chr7:65958608	NA	0.78	5.14	0.38	8.29e-7	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.37	0.4	2.89e-7	Cognitive test performance;
PAAD	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg21351543	chr2:191399470	TMEM194B	-0.69	-5.2	-0.39	6.27e-7	Diastolic blood pressure;
PAAD	trans	rs11794666	0.929	rs72719239	chr9:31804484	G/A	cg05628366	chr6:35744188	C6orf126	1.13	6.98	0.49	8.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-5.6	-0.41	9.98e-8	Electroencephalogram traits;
PAAD	cis	rs4740619	0.592	rs3008744	chr9:15975800	T/C	cg14451791	chr9:16040625	NA	0.37	4.28	0.33	3.24e-5	Body mass index;
PAAD	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26775843	chr4:88343678	NUDT9	-0.72	-6.48	-0.47	1.18e-9	Neuroticism;
PAAD	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg02487422	chr3:49467188	NICN1	0.45	4.56	0.35	1.04e-5	Resting heart rate;
PAAD	cis	rs6142102	0.602	rs1054534	chr20:32605327	G/C	cg06115741	chr20:33292138	TP53INP2	0.57	5.15	0.39	7.96e-7	Skin pigmentation;
PAAD	cis	rs7833787	0.929	rs7844317	chr8:18697046	T/A	cg17701159	chr8:18705777	PSD3	-0.44	-5.21	-0.39	5.93e-7	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.09	0.55	1.77e-13	Height;
PAAD	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.34	4.8	0.36	3.8e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg09324608	chr17:30823087	MYO1D	0.48	4.82	0.36	3.41e-6	Schizophrenia;
PAAD	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.75	-7.69	-0.53	1.69e-12	Blood metabolite levels;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.61	5.48	0.41	1.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg18833306	chr6:118973337	C6orf204	-0.55	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13665852	chr10:13146898	OPTN	-0.65	-6.38	-0.46	1.98e-9	Primary biliary cholangitis;
PAAD	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.72	6.58	0.47	7.04e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg14851346	chr12:38532713	NA	0.47	4.26	0.33	3.5e-5	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21155852	chr7:2048760	MAD1L1	-0.46	-4.73	-0.36	5e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.86	9.66	0.62	1.64e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs66530629	1.000	rs4601530	chr1:25044111	A/G	cg01905478	chr1:25040257	NA	-0.55	-5.92	-0.43	2.01e-8	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16079414	chr2:168244895	NA	-0.56	-6.62	-0.47	5.92e-10	Obesity-related traits;
PAAD	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.75	8.77	0.58	3.31e-15	Prostate cancer;
PAAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg10556349	chr10:835070	NA	0.59	4.95	0.37	1.98e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14019695	chr9:139328340	INPP5E	0.61	6.41	0.46	1.77e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.84	10.09	0.63	1.24e-18	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09225295	chr7:95405749	DYNC1I1	-0.65	-6.92	-0.49	1.15e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.29	-0.33	3.19e-5	Prostate cancer;
PAAD	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg03983476	chr2:10830698	NOL10	-0.62	-6.3	-0.46	3.02e-9	Prostate cancer;
PAAD	cis	rs28595532	0.641	rs116674223	chr4:119371479	G/C	cg21605333	chr4:119757512	SEC24D	1.54	7.94	0.54	4.05e-13	Cannabis dependence symptom count;
PAAD	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	1.0	4.93	0.37	2.13e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.4	0.56	2.86e-14	Prudent dietary pattern;
PAAD	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg21419209	chr3:44054225	NA	-0.73	-7.47	-0.52	5.91e-12	Coronary artery disease;
PAAD	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg14515779	chr1:101123966	NA	-0.54	-6.63	-0.47	5.62e-10	Monocyte count;
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg23018236	chr17:30244563	NA	-0.62	-4.78	-0.36	4.19e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.94	8.19	0.55	9.82e-14	IgG glycosylation;
PAAD	cis	rs2133450	0.526	rs41346444	chr3:7341994	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.26e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.61	-4.42	-0.34	1.85e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10483554	0.554	rs1952855	chr14:49880194	G/T	cg10380165	chr14:50360598	ARF6	0.54	4.86	0.37	2.85e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.85	6.97	0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg19223190	chr17:80058835	NA	-0.54	-5.44	-0.4	2.08e-7	Life satisfaction;
PAAD	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg17691542	chr6:26056736	HIST1H1C	0.52	4.61	0.35	8.42e-6	Height;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.27e-7	Life satisfaction;
PAAD	cis	rs59888335	0.858	rs34669609	chr3:81027242	A/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg21496419	chr19:44306685	LYPD5	-0.39	-4.98	-0.37	1.7e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg26497354	chr6:109612229	NA	-0.43	-4.33	-0.33	2.72e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1190596	0.689	rs2224460	chr14:102563797	A/T	cg23904247	chr14:102554826	HSP90AA1	-0.49	-5.53	-0.41	1.34e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.53	4.37	0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.51	6.87	0.49	1.53e-10	Life satisfaction;
PAAD	cis	rs7260329	0.670	rs8109525	chr19:41491918	A/G	cg23925301	chr19:41220945	ADCK4	-0.51	-4.5	-0.34	1.37e-5	Smoking behavior;
PAAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-6.04	-0.44	1.14e-8	Lymphocyte counts;
PAAD	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.42	-4.6	-0.35	8.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs427941	0.843	rs10255251	chr7:101828876	G/T	cg06721601	chr7:101762633	CUX1	0.45	4.67	0.35	6.71e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg10556349	chr10:835070	NA	0.57	4.85	0.37	3.09e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06850241	chr22:41845214	NA	-0.61	-5.37	-0.4	2.93e-7	Vitiligo;
PAAD	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.63	-6.13	-0.45	7.06e-9	Fibrinogen levels;
PAAD	cis	rs2171564	0.557	rs3846043	chr3:112436847	A/C	cg06685282	chr3:112453648	NA	-0.52	-5.44	-0.4	2.09e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1996152	0.543	rs4789658	chr17:72389526	A/T	cg23221732	chr17:72383708	NA	0.61	5.8	0.43	3.74e-8	Interleukin-12p70 levels;
PAAD	cis	rs1556659	1.000	rs1556659	chr10:130834698	C/T	cg06344553	chr10:131684893	EBF3	0.42	4.25	0.33	3.72e-5	Tonsillectomy;
PAAD	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.46	-4.46	-0.34	1.56e-5	Alzheimer's disease (late onset);
PAAD	cis	rs798766	0.909	rs11724531	chr4:1753424	A/G	cg01305830	chr4:1604576	NA	-0.47	-4.58	-0.35	9.44e-6	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05977230	chr11:68115417	LRP5	0.6	7.0	0.49	7.73e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.5	-6.39	-0.46	1.88e-9	Height;
PAAD	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.77	-7.32	-0.51	1.35e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg00206168	chr11:65308501	LTBP3	0.52	5.4	0.4	2.5e-7	Bone mineral density;
PAAD	cis	rs6585424	1.000	rs11201972	chr10:81932680	C/T	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.31	4.73	0.36	5.12e-6	Red cell distribution width;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg26338869	chr17:61819248	STRADA	0.49	4.66	0.35	6.79e-6	Height;
PAAD	cis	rs72960926	1.000	rs16884746	chr6:75066404	A/G	cg13997649	chr6:74171430	MTO1	0.8	4.47	0.34	1.53e-5	Metabolite levels (MHPG);
PAAD	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.78	-0.36	4.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs59888335	0.964	rs34052939	chr3:80765431	C/T	cg21735741	chr3:80819488	NA	0.55	4.87	0.37	2.79e-6	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.87	-0.37	2.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.67	6.38	0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.56	4.7	0.36	5.76e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19267910	chr2:142948816	NA	-0.49	-6.7	-0.48	3.9e-10	Energy expenditure (24h);
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12516959	chr21:47718080	NA	0.44	4.34	0.33	2.58e-5	Testicular germ cell tumor;
PAAD	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg14582100	chr15:45693742	SPATA5L1	0.56	8.04	0.55	2.36e-13	Homoarginine levels;
PAAD	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.5	4.91	0.37	2.33e-6	HDL cholesterol;
PAAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.56	-0.41	1.17e-7	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14968838	chr1:11724397	FBXO6	0.56	6.39	0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.14	-14.22	-0.76	1.02e-29	Colorectal cancer;
PAAD	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-5.19	-0.39	6.77e-7	Recombination measurement;
PAAD	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.67	6.36	0.46	2.25e-9	Parkinson's disease;
PAAD	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs3736485	0.844	rs79654603	chr15:51884862	G/A	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4499344	0.881	rs6510263	chr19:33067367	A/G	cg22980127	chr19:33182716	NUDT19	0.47	4.32	0.33	2.8e-5	Mean platelet volume;
PAAD	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.62	5.58	0.41	1.09e-7	Response to diuretic therapy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18307767	chr18:43684181	ATP5A1;HAUS1	0.62	6.88	0.49	1.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1514658	0.868	rs13145902	chr4:119282478	C/A	cg23709618	chr4:119273073	PRSS12	0.31	4.38	0.33	2.22e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.67	4.62	0.35	7.99e-6	Mean platelet volume;
PAAD	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07232103	chr12:112566177	TRAFD1	-0.54	-6.47	-0.46	1.3e-9	Monocyte percentage of white cells;
PAAD	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.98	0.37	1.73e-6	Myopia (pathological);
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	trans	rs901683	1.000	rs34309840	chr10:46039361	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs45430	0.665	rs431563	chr21:42740949	C/T	cg22778903	chr21:42741698	MX2	0.57	6.05	0.44	1.06e-8	Melanoma;
PAAD	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.85	5.88	0.43	2.47e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.37	-0.4	2.87e-7	Blood metabolite levels;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg09417038	chr21:47716443	C21orf57	-0.57	-5.97	-0.44	1.59e-8	Testicular germ cell tumor;
PAAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg10589385	chr1:150898437	SETDB1	0.35	4.36	0.33	2.35e-5	Melanoma;
PAAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.49	0.34	1.38e-5	Breast cancer;
PAAD	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.17	-0.6	3.2e-16	Schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19960880	chr10:97050830	PDLIM1	0.54	6.42	0.46	1.68e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.77	-9.01	-0.59	8.21e-16	Total body bone mineral density;
PAAD	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg03651054	chr13:50194643	NA	0.38	5.32	0.4	3.62e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.46	6.6	0.47	6.47e-10	Schizophrenia;
PAAD	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.75	-8.86	-0.58	1.93e-15	Lung function (FVC);
PAAD	cis	rs8077577	0.708	rs28364628	chr17:18163262	C/T	cg16794390	chr17:18148240	FLII	0.58	5.08	0.38	1.12e-6	Obesity-related traits;
PAAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.77	7.84	0.54	7.37e-13	Calcium levels;
PAAD	cis	rs2730260	0.736	rs73169220	chr7:158846197	A/C	cg13444538	chr7:158905317	VIPR2	-0.63	-4.52	-0.34	1.24e-5	Myopia (pathological);
PAAD	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg19760965	chr3:194868843	C3orf21	0.47	4.26	0.33	3.53e-5	Non-small cell lung cancer;
PAAD	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.21	0.39	5.98e-7	Educational attainment;
PAAD	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12432203	1.000	rs72622439	chr14:51736948	C/A	cg23942311	chr14:51606299	NA	-0.7	-4.75	-0.36	4.65e-6	Cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03468023	chr6:42419163	TRERF1	-0.67	-6.53	-0.47	9.54e-10	Lung cancer in ever smokers;
PAAD	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs2061333	0.557	rs10410306	chr19:44601537	T/C	cg18700516	chr19:44507157	ZNF230	-0.77	-5.36	-0.4	2.99e-7	Alzheimer's disease;
PAAD	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07701084	chr6:150067640	NUP43	0.62	6.25	0.45	3.91e-9	Lung cancer;
PAAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7577696	0.597	rs56322034	chr2:32353013	T/C	cg02381751	chr2:32503542	YIPF4	-0.51	-4.9	-0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.59	-0.35	9.25e-6	Total body bone mineral density;
PAAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs9463078	0.764	rs1935551	chr6:44786035	T/G	cg25276700	chr6:44698697	NA	-0.46	-5.05	-0.38	1.26e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12431939	0.598	rs7144511	chr14:51740243	A/G	cg23942311	chr14:51606299	NA	0.55	5.14	0.38	8.49e-7	Cancer;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.8	5.54	0.41	1.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs1555399	1.000	rs1555398	chr14:67984373	C/G	cg25006823	chr14:67982456	TMEM229B	0.37	4.26	0.33	3.53e-5	Parkinson's disease;
PAAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.49	5.38	0.4	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.33	11.25	0.67	9.95e-22	Uric acid levels;
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07751222	chr4:102268245	PPP3CA	0.6	6.76	0.48	2.81e-10	Immature fraction of reticulocytes;
PAAD	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.73	7.07	0.5	5.14e-11	Asthma;
PAAD	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.61	4.84	0.37	3.15e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs1190596	0.558	rs10047840	chr14:102703201	A/G	cg23904247	chr14:102554826	HSP90AA1	0.44	5.08	0.38	1.1e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs16958440	0.867	rs28578518	chr18:44687548	A/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.97	-0.37	1.81e-6	Mean corpuscular volume;
PAAD	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg07395648	chr5:131743802	NA	0.51	4.28	0.33	3.26e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.62	-7.38	-0.51	9.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.42	4.57	0.35	9.9e-6	HDL cholesterol levels;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.901	rs6714362	chr2:86476588	A/G	cg10973622	chr2:86423274	IMMT	-0.42	-4.84	-0.37	3.13e-6	Night sleep phenotypes;
PAAD	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.37	-13.09	-0.73	1.06e-26	Corneal structure;
PAAD	cis	rs17824933	0.836	rs2074233	chr11:60785464	G/A	cg16817237	chr11:60793675	NA	0.54	6.53	0.47	9.33e-10	Multiple sclerosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04981696	chr16:16044519	ABCC1	-0.56	-6.66	-0.48	4.81e-10	Body fat percentage;
PAAD	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.54	-5.22	-0.39	5.68e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs7772697	0.635	rs2185250	chr6:149412228	A/G	cg21368479	chr6:149415018	NA	-0.44	-4.64	-0.35	7.42e-6	Diabetic retinopathy;
PAAD	cis	rs939584	1.000	rs13386627	chr2:650560	G/C	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg06606381	chr12:133084897	FBRSL1	-0.91	-6.53	-0.47	9.1e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.99	7.46	0.52	6.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07362569	chr17:61921086	SMARCD2	-0.63	-8.13	-0.55	1.42e-13	Prudent dietary pattern;
PAAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	5.87	0.43	2.63e-8	Personality dimensions;
PAAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg01075559	chr1:2537774	MMEL1	0.52	5.46	0.4	1.93e-7	Ulcerative colitis;
PAAD	cis	rs1468333	0.507	rs13361619	chr5:137648679	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg23708337	chr7:1209742	NA	0.63	4.55	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05025164	chr4:1340916	KIAA1530	0.56	5.48	0.41	1.71e-7	Obesity-related traits;
PAAD	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.55	4.79	0.36	3.93e-6	RR interval (heart rate);
PAAD	trans	rs901683	1.000	rs34879733	chr10:45997761	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg18357526	chr6:26021779	HIST1H4A	0.55	4.97	0.37	1.77e-6	Educational attainment;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24740632	chr5:134486678	NA	0.67	6.86	0.49	1.59e-10	Smoking initiation;
PAAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.72	7.92	0.54	4.77e-13	Longevity;
PAAD	cis	rs1345301	0.552	rs1558626	chr2:102862070	T/A	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.46	-0.34	1.57e-5	Waist circumference;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg16926213	chr1:1841314	NA	0.37	4.52	0.34	1.25e-5	Body mass index;
PAAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.73	9.06	0.59	6.01e-16	Coronary artery disease;
PAAD	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.72	4.73	0.36	5.18e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.71	0.48	3.56e-10	Height;
PAAD	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.68	-7.83	-0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs747650	0.504	rs4548577	chr11:46998512	C/T	cg19486271	chr11:47235900	DDB2	0.66	6.49	0.47	1.14e-9	Acne (severe);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg10033612	chr16:1664176	CRAMP1L	0.65	6.35	0.46	2.36e-9	Primary biliary cholangitis;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-10.81	-0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs9900972	0.720	rs6501257	chr17:76877655	G/A	cg00961940	chr17:76876995	TIMP2	0.58	5.38	0.4	2.73e-7	Obesity-related traits;
PAAD	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg05110241	chr16:68378359	PRMT7	0.82	6.8	0.48	2.23e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.89	5.85	0.43	2.95e-8	Body mass index;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02697246	chr12:117187890	RNFT2	-0.66	-7.45	-0.52	6.68e-12	Monocyte percentage of white cells;
PAAD	cis	rs6723226	0.732	rs6747560	chr2:32784766	T/G	cg02381751	chr2:32503542	YIPF4	0.84	9.65	0.62	1.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs977987	0.864	rs37594	chr16:75496943	T/C	cg03315344	chr16:75512273	CHST6	-0.66	-8.15	-0.55	1.26e-13	Dupuytren's disease;
PAAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	trans	rs901683	1.000	rs34574958	chr10:46087040	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.28	0.33	3.33e-5	Cognitive function;
PAAD	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.31	-0.33	2.86e-5	Joint mobility (Beighton score);
PAAD	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.59	0.35	9.25e-6	Educational attainment;
PAAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.23	-0.39	5.64e-7	Life satisfaction;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg20578329	chr17:80767326	TBCD	-0.81	-5.19	-0.39	6.5e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-4.28	-0.33	3.24e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.81	6.68	0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	5.5	0.41	1.6e-7	Neuroticism;
PAAD	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg02527881	chr3:46936655	PTH1R	-0.82	-12.49	-0.71	4.54e-25	Birth weight;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg11650704	chr1:154556575	ADAR	0.38	4.46	0.34	1.57e-5	Blood protein levels;
PAAD	cis	rs713477	0.712	rs72717779	chr14:55893440	A/G	cg23573665	chr14:55907122	TBPL2	-0.33	-4.46	-0.34	1.55e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08150755	chr16:624161	PIGQ	-0.61	-6.31	-0.46	2.93e-9	Myopia (pathological);
PAAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.58	5.13	0.38	8.88e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2133450	0.524	rs56209862	chr3:7349037	G/A	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.78	8.33	0.56	4.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs9659323	0.650	rs1155949	chr1:119496579	C/T	cg17326555	chr1:119535693	NA	-0.37	-4.59	-0.35	9.24e-6	Body mass index;
PAAD	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg15208524	chr1:10270712	KIF1B	0.48	4.46	0.34	1.57e-5	Hepatocellular carcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08693705	chr5:179719171	MAPK9	0.68	8.03	0.55	2.51e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.920	rs67114979	chr16:67691645	G/T	cg05110241	chr16:68378359	PRMT7	-0.98	-4.9	-0.37	2.48e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.98	0.44	1.57e-8	Prudent dietary pattern;
PAAD	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.77	4.89	0.37	2.56e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.17	0.5	3e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs6028335	0.674	rs66476511	chr20:37605303	T/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	trans	rs901683	1.000	rs34574958	chr10:46087040	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs12136530	0.625	rs61334679	chr1:19754993	G/A	cg25104613	chr1:20649108	VWA5B1	-0.41	-4.49	-0.34	1.42e-5	Lead levels in blood;
PAAD	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.62	4.94	0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg22753661	chr15:79092743	ADAMTS7	0.51	4.27	0.33	3.36e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs75757892	0.544	rs6934847	chr6:7318928	G/A	cg02954307	chr6:7269328	NA	0.51	4.44	0.34	1.75e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.61	5.69	0.42	6.38e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.52	4.61	0.35	8.46e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs6558530	0.730	rs10100341	chr8:1723749	A/G	cg19131313	chr8:1704013	NA	-0.38	-4.27	-0.33	3.4e-5	Systolic blood pressure;
PAAD	cis	rs17152411	0.625	rs4962713	chr10:126654536	A/T	cg07081759	chr10:126330905	FAM53B	-0.41	-4.41	-0.34	1.96e-5	Height;
PAAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	1.18	7.61	0.53	2.68e-12	Skin colour saturation;
PAAD	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-4.94	-0.37	2.04e-6	Schizophrenia;
PAAD	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-4.25	-0.33	3.72e-5	Waist circumference;Body mass index;
PAAD	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg24634471	chr8:143751801	JRK	-0.51	-4.61	-0.35	8.59e-6	Urinary tract infection frequency;
PAAD	cis	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.12	-0.38	8.97e-7	Neuroticism;
PAAD	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg16898833	chr6:26189333	HIST1H4D	0.82	4.82	0.36	3.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.0	-0.44	1.38e-8	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg24069376	chr3:38537580	EXOG	0.39	4.86	0.37	2.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	7.62	0.53	2.52e-12	Coffee consumption (cups per day);
PAAD	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg02135003	chr7:105160482	PUS7	-0.92	-6.7	-0.48	3.84e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg19539972	chr4:7069911	GRPEL1	0.8	6.46	0.46	1.36e-9	Monocyte percentage of white cells;
PAAD	cis	rs8133932	0.667	rs3788218	chr21:47287332	A/G	cg13695288	chr21:47294981	PCBP3	-0.47	-4.61	-0.35	8.65e-6	Schizophrenia;
PAAD	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.79	8.77	0.58	3.27e-15	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23193116	chr12:96184799	NTN4	0.64	6.86	0.49	1.59e-10	Myopia (pathological);
PAAD	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.64	-0.57	7.28e-15	Electrocardiographic conduction measures;
PAAD	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.6	-0.52	2.89e-12	Body mass index;
PAAD	trans	rs901683	0.850	rs80222863	chr10:46016975	C/T	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs7598759	1.000	rs7598759	chr2:232321956	C/T	cg10034588	chr2:232392055	NMUR1	-0.36	-4.26	-0.33	3.57e-5	Noise-induced hearing loss;
PAAD	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.53	-5.18	-0.39	7.03e-7	Hypospadias;
PAAD	cis	rs16975963	0.843	rs2382624	chr19:38419025	A/G	cg08679971	chr19:38281047	NA	0.56	5.36	0.4	3.07e-7	Longevity;
PAAD	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.5	-0.34	1.35e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11203032	0.831	rs9651495	chr10:90932381	G/A	cg16672925	chr10:90967113	CH25H	0.7	5.34	0.4	3.3e-7	Heart failure;
PAAD	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg27490568	chr2:178487706	NA	0.42	4.61	0.35	8.48e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.75	5.42	0.4	2.28e-7	Major depressive disorder;
PAAD	cis	rs9815354	0.638	rs73073267	chr3:42021163	A/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22947322	chr17:47091978	IGF2BP1	0.38	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs2456568	0.808	rs908749	chr11:93685035	T/A	cg19264203	chr11:92714893	MTNR1B	0.43	4.86	0.37	2.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.87	0.49	1.5e-10	Systemic lupus erythematosus;
PAAD	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	4.99e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.51	5.27	0.39	4.69e-7	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.47	4.49	0.34	1.4e-5	Breast cancer;
PAAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.56	-5.14	-0.38	8.49e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35995292	1.000	rs3779119	chr7:38942248	C/G	cg19327137	chr7:38886074	VPS41	0.42	4.35	0.33	2.53e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg20541187	chr2:68882627	PROKR1	0.5	6.5	0.47	1.11e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg21253087	chr9:139290292	SNAPC4	0.43	4.39	0.34	2.13e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.72	-9.21	-0.6	2.51e-16	Educational attainment;
PAAD	cis	rs10958605	0.796	rs4496955	chr8:40030155	T/A	cg14545590	chr8:40388592	ZMAT4	-0.39	-4.41	-0.34	1.91e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.72e-7	Alzheimer's disease;
PAAD	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.27	0.39	4.56e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.5	5.03	0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs564309	0.681	rs1188487	chr1:228620247	A/G	cg00655913	chr1:228633920	NA	-0.64	-4.74	-0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs6732160	0.593	rs2288630	chr2:73457552	C/T	cg24220031	chr2:73402428	NA	-0.42	-6.39	-0.46	1.95e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.546	rs11968042	chr6:45046735	A/G	cg25276700	chr6:44698697	NA	0.46	5.19	0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.96	12.04	0.7	7.04e-24	Menarche (age at onset);
PAAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg06740227	chr12:86229804	RASSF9	-0.5	-4.55	-0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.81	7.37	0.51	1.01e-11	Psoriasis;
PAAD	cis	rs2275565	0.808	rs12138911	chr1:236977143	T/C	cg17297354	chr1:237056641	MTR	-0.5	-4.42	-0.34	1.84e-5	Homocysteine levels;
PAAD	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.75	7.15	0.5	3.42e-11	Platelet distribution width;
PAAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.58	5.49	0.41	1.63e-7	Blood metabolite levels;
PAAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.49	4.93	0.37	2.13e-6	Menopause (age at onset);
PAAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.7e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00367488	chr2:120020686	STEAP3	0.57	6.89	0.49	1.39e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3106136	0.649	rs4699411	chr4:95299347	T/C	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs16933812	0.510	rs7854114	chr9:36989004	T/C	cg13738729	chr9:36989127	PAX5	0.56	8.02	0.55	2.63e-13	Obesity-related traits;
PAAD	cis	rs1348850	0.526	rs4243391	chr2:178468089	A/T	cg27490568	chr2:178487706	NA	0.96	9.68	0.62	1.49e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs322144	0.967	rs322145	chr19:11423677	G/C	cg22357700	chr19:11805638	NA	0.46	4.4	0.34	2.01e-5	Breast cancer;
PAAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.67	2.39e-21	Tonsillectomy;
PAAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.42	4.57	0.35	9.94e-6	Life satisfaction;
PAAD	cis	rs931127	0.836	rs523029	chr11:65476487	T/G	cg26668713	chr11:65405903	SIPA1	0.4	4.6	0.35	8.8e-6	Systemic lupus erythematosus;
PAAD	cis	rs727479	0.502	rs2289106	chr15:51507782	T/G	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.55e-5	Estradiol levels;
PAAD	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg03037974	chr15:76606532	NA	0.55	6.54	0.47	8.74e-10	Blood metabolite levels;
PAAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.29	-0.51	1.56e-11	Cognitive function;
PAAD	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg14003231	chr6:33640908	ITPR3	0.35	4.45	0.34	1.66e-5	Plateletcrit;
PAAD	cis	rs6494488	0.500	rs67108203	chr15:65005952	C/T	cg16425858	chr15:64791681	ZNF609	0.86	4.86	0.37	2.89e-6	Coronary artery disease;
PAAD	cis	rs7786877	0.679	rs10953301	chr7:100264893	A/G	cg07068956	chr7:100330872	ZAN	-0.6	-4.69	-0.36	5.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.76	-7.86	-0.54	6.7e-13	Mosquito bite size;
PAAD	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.68	6.24	0.45	4.23e-9	Plateletcrit;Platelet count;
PAAD	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.56	5.81	0.43	3.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10750165	0.644	rs10790342	chr11:119630418	A/G	cg24085502	chr11:119066850	CCDC153	-0.34	-4.39	-0.34	2.12e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.53	-5.42	-0.4	2.3e-7	Number of children ever born;
PAAD	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.32	4.39	0.34	2.13e-5	Asthma;
PAAD	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg03264133	chr6:25882463	NA	0.43	4.25	0.33	3.76e-5	Schizophrenia;
PAAD	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	1.05	9.41	0.61	7.65e-17	IgG glycosylation;
PAAD	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.68	-0.35	6.39e-6	Height;
PAAD	cis	rs10905065	0.569	rs4750553	chr10:5728174	C/T	cg24392574	chr10:5541423	CALML5	-0.47	-4.29	-0.33	3.16e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.64e-5	Life satisfaction;
PAAD	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg21269045	chr12:125625041	AACS	-0.45	-4.35	-0.33	2.52e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs17407555	0.632	rs12510727	chr4:10271070	T/G	cg11266682	chr4:10021025	SLC2A9	0.41	4.3	0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg10494973	chr17:80897199	TBCD	0.48	4.68	0.35	6.42e-6	Breast cancer;
PAAD	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.57	-0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9287719	0.614	rs12622053	chr2:10722140	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.4	-0.34	2.07e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	0.695	rs908748	chr11:93690148	G/A	cg19264203	chr11:92714893	MTNR1B	-0.43	-4.88	-0.37	2.63e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.48	-4.6	-0.35	8.9e-6	Coronary artery disease;
PAAD	cis	rs3733606	0.832	rs34411702	chr4:6835635	G/A	cg05012661	chr4:6891264	NA	0.53	4.52	0.34	1.24e-5	Platelet count;
PAAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.44	-5.93	-0.43	1.98e-8	Type 1 diabetes;
PAAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12582317	chr17:55822272	NA	0.71	8.74	0.58	3.97e-15	Schizophrenia;
PAAD	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09597638	chr17:3907349	NA	0.72	7.54	0.52	4.04e-12	Type 2 diabetes;
PAAD	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-5.67	-0.42	6.9e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs12935418	0.583	rs2549848	chr16:81024298	G/C	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg03684893	chr10:554711	DIP2C	-0.5	-5.54	-0.41	1.31e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.65	-9.72	-0.62	1.16e-17	Longevity;Endometriosis;
PAAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.8	8.87	0.58	1.88e-15	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-15.5	-0.78	4.15e-33	Height;
PAAD	cis	rs9581857	0.547	rs75085794	chr13:28095944	A/C	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.9e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	1.06	5.65	0.42	7.52e-8	Body mass index;
PAAD	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22153463	chr1:85462885	MCOLN2	-0.71	-5.36	-0.4	3.08e-7	Serum sulfate level;
PAAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg18833306	chr6:118973337	C6orf204	-0.56	-4.53	-0.35	1.17e-5	Diastolic blood pressure;
PAAD	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.05	-0.5	5.89e-11	Cognitive function;
PAAD	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.23e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	5.87	0.43	2.58e-8	Schizophrenia;
PAAD	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	4.25	0.33	3.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9810890	1.000	rs73198861	chr3:128516182	A/G	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.95	10.18	0.64	7.11e-19	Alcohol dependence;
PAAD	cis	rs4908760	0.965	rs10864356	chr1:8569871	A/T	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Vitiligo;
PAAD	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg02264943	chr11:130785842	SNX19	0.41	4.88	0.37	2.63e-6	Schizophrenia;
PAAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.83	-0.48	1.9e-10	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.28e-29	Rheumatoid arthritis;
PAAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.33	-0.4	3.5e-7	Personality dimensions;
PAAD	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg21890820	chr11:65308645	LTBP3	0.64	7.82	0.54	8.44e-13	Bone mineral density;
PAAD	cis	rs4742903	0.935	rs10119876	chr9:106961080	T/G	cg14250997	chr9:106856677	SMC2	0.44	4.69	0.36	5.96e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg00990874	chr7:1149470	C7orf50	-0.75	-5.87	-0.43	2.62e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.13	18.03	0.83	1.35e-39	Menarche (age at onset);
PAAD	cis	rs2236267	0.726	rs6574994	chr14:88614541	A/G	cg18078958	chr14:88630771	NA	-0.51	-6.61	-0.47	6.15e-10	Food antigen IgG levels;
PAAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.72	7.66	0.53	1.98e-12	Loneliness (linear analysis);
PAAD	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.5	-5.69	-0.42	6.24e-8	Coronary artery disease;
PAAD	cis	rs1006703	0.544	rs8068346	chr17:3838717	T/C	cg06463185	chr17:3833770	ATP2A3	-0.9	-7.44	-0.52	6.91e-12	Glucose homeostasis traits;
PAAD	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.69	-5.43	-0.4	2.16e-7	Vitiligo;
PAAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.75	6.73	0.48	3.33e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg02254261	chr7:158964346	NA	-0.61	-4.67	-0.35	6.65e-6	Myopia (pathological);
PAAD	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.48	-4.7	-0.36	5.69e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg17868515	chr10:100992068	HPSE2	-0.4	-4.74	-0.36	4.83e-6	Metabolite levels;
PAAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.54	-7.88	-0.54	5.94e-13	Diastolic blood pressure;
PAAD	cis	rs9903692	0.505	rs208009	chr17:46229691	C/T	cg24322968	chr17:46507895	SKAP1	-0.85	-5.27	-0.39	4.5e-7	Pulse pressure;
PAAD	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg18833306	chr6:118973337	C6orf204	0.43	4.44	0.34	1.74e-5	Electrocardiographic conduction measures;
PAAD	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.58	-0.47	7.33e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.75	-8.21	-0.55	9.02e-14	Melanoma;
PAAD	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg25070565	chr17:20044324	CYTSB	0.45	4.35	0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs13272623	0.536	rs11985127	chr8:71743943	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	1.01	5.44	0.4	2.06e-7	IgG glycosylation;
PAAD	cis	rs2562456	0.876	rs2650844	chr19:21602090	A/T	cg08562672	chr19:21860753	NA	-0.43	-4.25	-0.33	3.75e-5	Pain;
PAAD	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.89	10.54	0.65	7.6e-20	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.86	-10.07	-0.63	1.34e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21545522	chr1:205238299	TMCC2	0.48	4.32	0.33	2.82e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	5.89	0.43	2.45e-8	Cognitive test performance;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26385494	chr3:123303464	PTPLB	-0.56	-6.68	-0.48	4.29e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13227646	chr10:102045829	BLOC1S2	-0.71	-7.21	-0.5	2.44e-11	Lung cancer in ever smokers;
PAAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.0	-0.49	7.65e-11	Breast cancer;
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8112211	0.554	rs11673203	chr19:38851930	G/C	cg14299480	chr19:38876666	GGN	-0.67	-5.48	-0.41	1.7e-7	Blood protein levels;
PAAD	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.79	6.31	0.46	2.88e-9	Weight;
PAAD	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.42	4.36	0.33	2.36e-5	QRS complex (12-leadsum);
PAAD	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	9.52	0.61	3.89e-17	Platelet count;
PAAD	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg02404636	chr22:31891804	SFI1	-0.55	-4.99	-0.38	1.62e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg16989719	chr2:238392110	NA	-0.39	-4.94	-0.37	2.02e-6	Prostate cancer;
PAAD	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.43	-0.65	1.54e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-5.62	-0.41	8.97e-8	Monocyte count;
PAAD	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs10512697	0.772	rs62336077	chr5:3516458	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.06	-0.38	1.2e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.8	-0.87	1.21e-48	Myeloid white cell count;
PAAD	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg02683114	chr2:24398427	C2orf84	0.65	7.29	0.51	1.58e-11	Asthma;
PAAD	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26820223	chr1:150898727	SETDB1	0.61	6.79	0.48	2.39e-10	Monocyte percentage of white cells;
PAAD	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	5.99	0.44	1.48e-8	Mean platelet volume;
PAAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.77	-0.36	4.27e-6	Personality dimensions;
PAAD	cis	rs4343996	1.000	rs12537549	chr7:3361023	T/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.52	-6.0	-0.44	1.36e-8	Major depressive disorder;
PAAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg10207240	chr12:122356781	WDR66	0.54	5.64	0.42	7.94e-8	Mean corpuscular volume;
PAAD	cis	rs6011674	1.000	rs9808612	chr20:61868348	T/C	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.79	-4.73	-0.36	5.14e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.8	0.43	3.63e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.62	-7.61	-0.53	2.64e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg03871329	chr12:110338662	TCHP	-0.62	-4.76	-0.36	4.52e-6	Neuroticism;
PAAD	cis	rs4455778	0.580	rs4275185	chr7:49114615	C/G	cg26309511	chr7:48887640	NA	0.39	4.96	0.37	1.88e-6	Lung cancer in never smokers;
PAAD	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.36	-0.51	1.05e-11	Colorectal cancer;
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg26071806	chr7:100318239	EPO	-0.47	-4.49	-0.34	1.38e-5	Other erythrocyte phenotypes;
PAAD	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-4.69	-0.36	6.14e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg05627522	chr15:75251581	NA	0.47	5.63	0.42	8.29e-8	Breast cancer;
PAAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.14	0.55	1.34e-13	Menopause (age at onset);
PAAD	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg10434728	chr15:90938212	IQGAP1	-0.49	-4.95	-0.37	1.99e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.71	-7.49	-0.52	5.32e-12	Menarche (age at onset);
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg03188948	chr7:1209495	NA	0.98	5.04	0.38	1.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.7	6.06	0.44	1.03e-8	Diabetic retinopathy;
PAAD	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.83	-7.0	-0.49	7.65e-11	Vitiligo;
PAAD	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.6	0.35	8.89e-6	Serum sulfate level;
PAAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg01320130	chr1:67600311	NA	0.53	5.53	0.41	1.35e-7	Psoriasis;
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06217245	chr20:33103252	DYNLRB1	0.4	4.6	0.35	8.86e-6	Coronary artery disease;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.67	6.44	0.46	1.45e-9	Coronary artery disease;
PAAD	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg05528293	chr18:74961138	GALR1	0.61	4.93	0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	4.32	0.33	2.8e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.15	-0.39	8.04e-7	Systolic blood pressure;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg15117754	chr3:10150083	C3orf24	0.6	5.68	0.42	6.57e-8	Alzheimer's disease;
PAAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.58	5.99	0.44	1.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.58	-6.07	-0.44	9.86e-9	White matter hyperintensity burden;
PAAD	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.64	6.26	0.45	3.71e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg13039199	chr15:92455658	SLCO3A1	1.29	6.46	0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs79911532	0.515	rs17148944	chr7:75601867	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.84	-5.15	-0.39	7.96e-7	Mononucleosis;
PAAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg25124228	chr12:125621409	AACS	-0.61	-5.99	-0.44	1.47e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.46	0.34	1.55e-5	Personality dimensions;
PAAD	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.62	7.07	0.5	5.31e-11	Dupuytren's disease;
PAAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg25809561	chr17:30822961	MYO1D	0.59	6.12	0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg07648498	chr16:89883185	FANCA	0.69	7.12	0.5	4.07e-11	Vitiligo;
PAAD	cis	rs9815354	0.680	rs78402272	chr3:42028425	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.7	7.49	0.52	5.29e-12	Triglyceride levels;
PAAD	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg16230307	chr14:35515116	FAM177A1	0.43	4.47	0.34	1.54e-5	Psoriasis;
PAAD	cis	rs11264799	0.655	rs1806798	chr1:157651017	T/C	cg18268488	chr1:157545234	FCRL4	0.46	4.89	0.37	2.59e-6	IgA nephropathy;
PAAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.63	0.35	7.84e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	5.44	0.4	2.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg26816564	chr1:7831052	VAMP3	0.75	5.77	0.42	4.21e-8	Inflammatory bowel disease;
PAAD	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.57	4.98	0.37	1.73e-6	Neutrophil percentage of white cells;
PAAD	cis	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg20893579	chr22:38215064	NA	0.54	5.13	0.38	8.65e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.67	5.96	0.44	1.68e-8	Response to diuretic therapy;
PAAD	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg03538708	chr1:25844672	NA	0.48	4.88	0.37	2.64e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05025164	chr4:1340916	KIAA1530	0.55	5.18	0.39	6.92e-7	Obesity-related traits;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg10729496	chr3:10149963	C3orf24	0.65	5.72	0.42	5.51e-8	Alzheimer's disease;
PAAD	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.82e-6	Personality dimensions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22541098	chr19:47747364	NA	0.56	6.43	0.46	1.55e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2744375	0.600	rs2744369	chr6:7553470	G/T	cg27023638	chr6:7288726	SSR1	-0.41	-4.28	-0.33	3.34e-5	Resting heart rate;
PAAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs2160050	0.524	rs58781511	chr3:118714922	C/T	cg11869695	chr3:118686312	IGSF11	-0.6	-4.85	-0.37	2.97e-6	Response to amphetamines;
PAAD	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.5	6.03	0.44	1.2e-8	Sitting height ratio;
PAAD	cis	rs654384	0.545	rs4723418	chr7:4174701	C/T	cg27574739	chr7:4176374	SDK1	-0.49	-4.61	-0.35	8.48e-6	Positive affect;
PAAD	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.06	6.95	0.49	1.03e-10	Plateletcrit;
PAAD	trans	rs61677309	1.000	rs59399105	chr11:118168568	C/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14036303	chr3:125876217	ALDH1L1	0.55	6.45	0.46	1.39e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11026330	chr4:18023101	LCORL	0.66	6.34	0.46	2.55e-9	Obesity-related traits;
PAAD	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.48	5.32	0.4	3.59e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11020478	0.585	rs1939581	chr11:93371000	A/T	cg10523193	chr11:93463762	SNORA25	0.46	4.72	0.36	5.33e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7255436	0.898	rs7252574	chr19:8441779	C/T	cg16745616	chr19:8428856	ANGPTL4	-0.54	-4.99	-0.38	1.62e-6	HDL cholesterol;
PAAD	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg12610070	chr10:71211762	TSPAN15	-0.62	-8.75	-0.58	3.68e-15	Thrombosis;
PAAD	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	1.04	7.66	0.53	2.02e-12	Lymphocyte counts;
PAAD	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21196551	chr9:98173099	NA	-0.67	-6.98	-0.49	8.77e-11	Obesity-related traits;
PAAD	cis	rs3779195	0.697	rs1688606	chr7:97974851	G/A	cg24562669	chr7:97807699	LMTK2	0.49	4.68	0.35	6.4e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	4.43	0.34	1.79e-5	Hip circumference;
PAAD	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg14789911	chr21:47582049	C21orf56	-0.51	-5.07	-0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	6.77	0.48	2.57e-10	Resting heart rate;
PAAD	cis	rs375066	0.901	rs376069	chr19:44417295	T/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22509189	chr2:225307070	NA	0.44	4.34	0.33	2.59e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.39	-0.46	1.93e-9	Schizophrenia;
PAAD	cis	rs5769707	0.521	rs74351010	chr22:50036820	G/A	cg20744362	chr22:50050164	C22orf34	-0.57	-5.24	-0.39	5.32e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11159840	0.609	rs6574995	chr14:88618902	T/C	cg18078958	chr14:88630771	NA	-0.42	-5.37	-0.4	2.85e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.62	-7.69	-0.53	1.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs89107	0.688	rs281867	chr6:118575808	C/T	cg21191810	chr6:118973309	C6orf204	0.44	6.24	0.45	4.17e-9	Cardiac structure and function;
PAAD	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg10395934	chr14:104002654	TRMT61A	0.56	5.73	0.42	5.35e-8	Body mass index;
PAAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.44	-4.25	-0.33	3.68e-5	Height;
PAAD	cis	rs73019876	0.869	rs6511303	chr19:22145868	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs1997066	0.831	rs73340293	chr10:106814387	C/T	cg17321814	chr10:106440892	SORCS3	0.64	4.36	0.33	2.38e-5	Diabetic kidney disease;
PAAD	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.67	6.01	0.44	1.31e-8	Common traits (Other);
PAAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg02773041	chr1:40204384	PPIE	0.75	7.47	0.52	5.94e-12	Blood protein levels;
PAAD	cis	rs58521262	0.929	rs2362806	chr19:23233047	G/A	cg22640819	chr19:22990650	NA	0.35	4.28	0.33	3.33e-5	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg21698718	chr17:80085957	CCDC57	0.45	5.08	0.38	1.07e-6	Life satisfaction;
PAAD	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg08676812	chr11:65308423	LTBP3	0.79	5.54	0.41	1.32e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.5e-7	Tonsillectomy;
PAAD	cis	rs9810890	1.000	rs9862461	chr3:128572314	C/G	cg18531004	chr3:128564980	NA	-0.78	-4.94	-0.37	2.03e-6	Dental caries;
PAAD	cis	rs1468333	0.592	rs13185930	chr5:137577513	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	5.16	0.39	7.71e-7	Resting heart rate;
PAAD	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg10591111	chr5:226296	SDHA	-0.71	-5.62	-0.41	9.06e-8	Breast cancer;
PAAD	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.6	0.47	6.6e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.7	-0.48	3.87e-10	Systolic blood pressure;
PAAD	cis	rs4908768	0.579	rs56280806	chr1:8875542	G/A	cg06780032	chr1:8272277	NA	-0.34	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9612	0.718	rs346532	chr19:44248878	A/G	cg08581076	chr19:44259116	C19orf61	0.64	4.79	0.36	3.93e-6	Exhaled nitric oxide output;
PAAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs151997	0.537	rs11746939	chr5:50268856	G/A	cg06027927	chr5:50259733	NA	0.62	5.49	0.41	1.67e-7	Callous-unemotional behaviour;
PAAD	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	5.37	0.4	2.93e-7	Total cholesterol levels;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.5	4.9	0.37	2.42e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.62	-7.67	-0.53	1.94e-12	Prudent dietary pattern;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg08088566	chr11:430123	ANO9	0.87	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg03983715	chr16:68378420	PRMT7	-0.95	-7.14	-0.5	3.61e-11	Schizophrenia;
PAAD	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-1.02	-10.51	-0.65	9.17e-20	Blood pressure (smoking interaction);
PAAD	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14169450	chr9:139327907	INPP5E	-0.54	-5.55	-0.41	1.21e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.68	-7.01	-0.49	7.19e-11	DNA methylation (variation);
PAAD	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.77	-5.03	-0.38	1.37e-6	Platelet distribution width;
PAAD	cis	rs600626	0.947	rs643884	chr11:75452518	T/C	cg24262691	chr11:75473276	NA	0.48	4.62	0.35	8.27e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12611296	chr13:76056336	TBC1D4	0.63	7.09	0.5	4.72e-11	Monocyte percentage of white cells;
PAAD	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg00230899	chr16:89766723	SPATA2L	0.82	4.25	0.33	3.69e-5	Red blood cell count;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.8	-0.36	3.74e-6	Life satisfaction;
PAAD	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.86	10.37	0.64	2.15e-19	Dental caries;
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg20302533	chr7:39170763	POU6F2	0.43	5.83	0.43	3.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.65	4.44	0.34	1.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16988008	chr11:108463728	EXPH5	0.55	6.29	0.45	3.24e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg10920065	chr6:169824652	NA	-0.48	-4.76	-0.36	4.56e-6	Obesity-related traits;
PAAD	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.0	-0.44	1.41e-8	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	5.78	0.42	4.02e-8	Height;
PAAD	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.95	-8.98	-0.59	9.57e-16	Blood protein levels;
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.78	-8.11	-0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.65	7.3	0.51	1.47e-11	Coronary artery disease;
PAAD	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.41	0.34	1.96e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.59	-0.35	9.04e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6604026	0.656	rs9651257	chr1:93385136	A/G	cg13858687	chr1:93297071	RPL5	0.48	4.31	0.33	2.87e-5	Multiple sclerosis;
PAAD	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.75	-0.42	4.7e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.79	8.6	0.57	9.21e-15	Schizophrenia;
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs501120	0.584	rs11238898	chr10:44679016	T/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2479106	0.791	rs2536951	chr9:126646519	A/G	cg16191174	chr9:126692580	DENND1A	0.5	4.29	0.33	3.23e-5	Polycystic ovary syndrome;
PAAD	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg21994712	chr19:21861136	NA	-0.45	-4.43	-0.34	1.78e-5	Pain;
PAAD	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg16230307	chr14:35515116	FAM177A1	0.43	4.52	0.34	1.23e-5	Psoriasis;
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.67	7.47	0.52	5.96e-12	Mean corpuscular volume;
PAAD	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	4.71	0.36	5.56e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs4853525	0.559	rs10167514	chr2:191860529	C/T	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.4	-0.34	2.06e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.07	13.82	0.75	1.18e-28	Primary sclerosing cholangitis;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.25	0.33	3.69e-5	Bipolar disorder;
PAAD	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.8	6.56	0.47	7.99e-10	Pulmonary function decline;
PAAD	cis	rs1846974	1	rs1846974	chr5:87969927	G/A	cg02225085	chr5:87975992	LOC645323	-0.69	-5.15	-0.39	8.03e-7	Body mass index;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg27490568	chr2:178487706	NA	0.44	4.79	0.36	3.92e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.62	-5.07	-0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs6687840	0.544	rs11265205	chr1:159443054	T/C	cg13968061	chr1:159557257	APCS	-0.46	-4.5	-0.34	1.34e-5	Chemerin levels;
PAAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.86	8.12	0.55	1.49e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00815214	chr21:47717953	NA	-0.42	-4.4	-0.34	2.04e-5	Testicular germ cell tumor;
PAAD	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.49	0.34	1.37e-5	Height;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.78	9.86	0.62	4.93e-18	Vitiligo;
PAAD	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg15841412	chr13:111365552	ING1	0.54	4.61	0.35	8.61e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.77	0.48	2.59e-10	Height;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg07677032	chr17:61819896	STRADA	0.53	5.02	0.38	1.41e-6	Prudent dietary pattern;
PAAD	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	1.16	7.25	0.51	1.99e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.9100000000000004e-06	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.64	0.62	1.89e-17	Bladder cancer;
PAAD	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg06569542	chr10:98946673	SLIT1	0.45	4.59	0.35	9.05e-6	Monocyte count;
PAAD	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs564309	0.867	rs12094956	chr1:228570582	A/C	cg01328119	chr1:228783545	DUSP5P	-0.69	-4.31	-0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.39	4.34	0.33	2.54e-5	High light scatter reticulocyte count;
PAAD	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.0	-7.11	-0.5	4.21e-11	Lung cancer in ever smokers;
PAAD	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.58	5.39	0.4	2.61e-7	Malaria;
PAAD	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg23202291	chr11:1979235	NA	-0.5	-4.57	-0.35	9.88e-6	DNA methylation (variation);
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.48	-4.47	-0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.35	-0.33	2.46e-5	Asthma;
PAAD	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.29	-0.45	3.28e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.57	0.35	9.91e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-4.43	-0.34	1.82e-5	Blood metabolite levels;
PAAD	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg10396713	chr8:602097	NA	0.73	5.55	0.41	1.22e-7	IgG glycosylation;
PAAD	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg00614314	chr15:82944287	LOC80154	0.49	4.82	0.36	3.47e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs78761021	0.824	rs17743050	chr17:9772261	A/G	cg26853458	chr17:9805074	RCVRN	0.71	8.33	0.56	4.52e-14	Type 2 diabetes;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.13e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.83	0.43	3.23e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4742903	0.935	rs7875929	chr9:106931408	A/G	cg14250997	chr9:106856677	SMC2	0.46	4.94	0.37	1.99e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6700896	0.931	rs10889569	chr1:66086194	A/T	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.58e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.76	-5.58	-0.41	1.09e-7	Initial pursuit acceleration;
PAAD	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg05212510	chr18:77623544	KCNG2	-0.44	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.57	7.49	0.52	5.17e-12	Primary biliary cholangitis;
PAAD	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.87	-0.37	2.71e-6	Height;
PAAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.94	12.5	0.71	4.13e-25	Menarche (age at onset);
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.62	-6.61	-0.47	6e-10	Lymphocyte counts;
PAAD	cis	rs1318772	1.000	rs66629800	chr5:112712238	G/T	cg12552261	chr5:112820674	MCC	0.58	4.28	0.33	3.28e-5	F-cell distribution;
PAAD	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.52	-4.75	-0.36	4.65e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg16898833	chr6:26189333	HIST1H4D	0.83	4.53	0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.43	4.41	0.34	1.92e-5	Response to statin therapy;
PAAD	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg06217071	chr17:408420	NA	0.79	8.88	0.58	1.8e-15	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23346625	chr5:146619708	STK32A	-0.61	-6.62	-0.47	5.81e-10	Obesity-related traits;
PAAD	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-7.98	-0.54	3.23e-13	Alcohol dependence;
PAAD	cis	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg08224773	chr8:11311868	FAM167A	-0.36	-4.29	-0.33	3.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs6964833	1.000	rs17515241	chr7:74132014	C/T	cg07594833	chr7:73919889	GTF2IRD1	-0.47	-4.32	-0.33	2.75e-5	Menarche (age at onset);
PAAD	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg20893579	chr22:38215064	NA	0.5	4.89	0.37	2.51e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs742132	0.520	rs4712950	chr6:25657590	A/G	cg03264133	chr6:25882463	NA	0.67	4.57	0.35	9.87e-6	Uric acid levels;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg26554054	chr8:600488	NA	0.89	5.94	0.43	1.86e-8	IgG glycosylation;
PAAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-9.52	-0.61	3.92e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10875746	0.903	rs11168370	chr12:48435280	A/C	cg26205652	chr12:48591994	NA	0.88	8.96	0.59	1.07e-15	Longevity (90 years and older);
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.17	0.73	6.43e-27	Platelet count;
PAAD	cis	rs6693295	0.755	rs1933530	chr1:246231677	T/G	cg26013412	chr1:247094486	AHCTF1	-0.66	-4.65	-0.35	7.2e-6	Migraine - clinic-based;Migraine with aura;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05264110	chr4:76912154	SDAD1	0.56	6.33	0.46	2.66e-9	Metabolite levels  (X-11787);
PAAD	cis	rs364477	0.904	rs279898	chr9:965191	C/T	cg13952963	chr9:998547	NA	0.64	4.38	0.33	2.19e-5	Major depressive disorder;
PAAD	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.59	-0.35	9.25e-6	Total body bone mineral density;
PAAD	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.69	-0.36	6.03e-6	Height;
PAAD	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.97	12.53	0.71	3.51e-25	Bone mineral density;
PAAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.71	0.42	5.84e-8	Menarche (age at onset);
PAAD	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-1.01	-6.97	-0.49	8.83e-11	Coronary artery disease;
PAAD	cis	rs2992756	0.663	rs1360919	chr1:18805844	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.75	-0.36	4.61e-6	Breast cancer;
PAAD	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.78	-9.16	-0.6	3.26e-16	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20034215	chr18:77724692	HSBP1L1	0.54	6.38	0.46	2.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs8064454	0.870	rs11263763	chr17:36103565	C/T	cg04198914	chr17:36106025	HNF1B	-0.36	-4.89	-0.37	2.51e-6	Prostate cancer;
PAAD	cis	rs72827839	1.000	rs72827885	chr17:46534423	C/G	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs642743	0.934	rs677904	chr10:105957613	G/A	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.3	0.33	3.07e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.94	-7.27	-0.51	1.73e-11	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.5	4.55	0.35	1.1e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.64	-6.45	-0.46	1.38e-9	Menopause (age at onset);
PAAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.71	6.82	0.48	2.04e-10	Asthma;
PAAD	cis	rs519973	0.545	rs2679506	chr3:187672023	T/C	cg25500028	chr3:187336889	NA	0.36	4.34	0.33	2.59e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg20673841	chr7:107026890	COG5	0.51	4.37	0.33	2.26e-5	Coronary artery disease;
PAAD	cis	rs62400317	0.701	rs12195339	chr6:44796179	T/C	cg19254793	chr6:44695348	NA	-0.46	-4.29	-0.33	3.21e-5	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.61	7.22	0.51	2.29e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs757978	1.000	rs757978	chr2:242371101	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-4.93	-0.37	2.11e-6	Chronic lymphocytic leukemia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16127845	chr7:1126423	GPER;C7orf50	0.7	6.36	0.46	2.22e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs13382275	0.908	rs13429476	chr2:964442	A/G	cg02924234	chr2:420061	NA	0.57	4.71	0.36	5.6e-6	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.55	4.77	0.36	4.23e-6	Mean platelet volume;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	7.33	0.51	1.27e-11	Lymphocyte counts;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.87	6.52	0.47	9.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7255045	0.742	rs4804738	chr19:12953183	T/G	cg09980403	chr19:12975529	MAST1	0.31	4.74	0.36	4.9e-6	Mean corpuscular volume;
PAAD	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg10705379	chr10:99080932	FRAT1	0.39	4.52	0.34	1.26e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9527	0.518	rs12776863	chr10:104641679	T/C	cg14737131	chr10:104680354	CNNM2	0.71	6.06	0.44	1.01e-8	Arsenic metabolism;
PAAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.65	4.61	0.35	8.32e-6	Parkinson's disease;
PAAD	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.63	-0.42	8.28e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09040699	chr11:8009242	EIF3F	0.59	6.43	0.46	1.58e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7246657	0.551	rs62108899	chr19:37595183	C/T	cg23950597	chr19:37808831	NA	-0.73	-4.57	-0.35	1.01e-5	Coronary artery calcification;
PAAD	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg18518183	chr2:172544446	DYNC1I2	-0.5	-4.47	-0.34	1.53e-5	Schizophrenia;
PAAD	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.38e-5	Testicular germ cell tumor;
PAAD	cis	rs7567389	0.719	rs6738690	chr2:127992725	T/C	cg09760422	chr2:128146352	NA	-0.38	-5.94	-0.43	1.84e-8	Self-rated health;
PAAD	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.62	-4.83	-0.36	3.31e-6	Rheumatoid arthritis;
PAAD	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.82	7.42	0.52	7.63e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.6	0.47	6.49e-10	IgG glycosylation;
PAAD	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.81	0.58	2.69e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg20607798	chr8:58055168	NA	-0.64	-4.61	-0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.58	-7.43	-0.52	7.22e-12	Lewy body disease;
PAAD	cis	rs4668356	1.000	rs2723245	chr2:171875997	T/C	cg13882835	chr2:172017928	TLK1	0.88	4.66	0.35	6.86e-6	Cognitive performance;
PAAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.37	0.33	2.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.74	-7.53	-0.52	4.2e-12	Monocyte count;
PAAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.51	-4.56	-0.35	1.03e-5	Smoking behavior;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.46	4.88	0.37	2.69e-6	Lung cancer;
PAAD	cis	rs639012	0.698	rs567075	chr11:85830157	T/C	cg07180834	chr11:85838833	NA	-0.43	-4.59	-0.35	9.07e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs733175	0.830	rs714871	chr4:10059631	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	4.32	0.33	2.83e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12315302	chr6:26189340	HIST1H4D	0.57	4.59	0.35	9.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11853189	0.938	rs78151008	chr15:78592706	T/C	cg22935921	chr15:78556834	DNAJA4	0.77	5.21	0.39	6.04e-7	Red cell distribution width;
PAAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg24920358	chr1:40204285	PPIE	0.62	6.32	0.46	2.73e-9	Blood protein levels;
PAAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg16205897	chr5:131564050	P4HA2	0.45	5.0	0.38	1.55e-6	Breast cancer;
PAAD	cis	rs12760731	0.720	rs7548163	chr1:178306695	G/A	cg00404053	chr1:178313656	RASAL2	0.68	4.86	0.37	2.86e-6	Obesity-related traits;
PAAD	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg16342193	chr10:102329863	NA	-0.75	-8.13	-0.55	1.44e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.78	-10.17	-0.64	7.59e-19	Bone mineral density;
PAAD	cis	rs501120	0.929	rs605425	chr10:44750669	T/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.56	0.35	1.03e-5	Breast cancer;
PAAD	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg09659197	chr4:152720779	NA	0.35	5.13	0.38	8.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg07648498	chr16:89883185	FANCA	0.48	4.57	0.35	1.01e-5	Vitiligo;
PAAD	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.54	-4.84	-0.37	3.21e-6	Mean platelet volume;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.65	5.67	0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07179924	chr11:18655979	SPTY2D1	-0.74	-6.48	-0.47	1.2e-9	Neuroticism;
PAAD	cis	rs11018904	0.817	rs11606060	chr11:89928597	T/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.35	-0.33	2.53e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-1.26	-8.91	-0.59	1.43e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg22189786	chr22:42395067	WBP2NL	-0.46	-5.02	-0.38	1.4e-6	Cognitive function;
PAAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2526932	0.625	rs2803947	chr14:73059305	C/T	cg13588403	chr14:73209128	DPF3	-0.41	-5.5	-0.41	1.56e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11867129	1.000	rs4786271	chr16:2368142	A/T	cg05196366	chr16:3239155	NA	-0.47	-4.51	-0.34	1.29e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
PAAD	cis	rs258892	1.000	rs258892	chr5:72305846	A/C	cg21869765	chr5:72125136	TNPO1	-0.66	-4.82	-0.36	3.45e-6	Small cell lung carcinoma;
PAAD	cis	rs7567389	0.576	rs2069902	chr2:128174863	C/G	cg09760422	chr2:128146352	NA	0.41	6.08	0.44	9.39e-9	Self-rated health;
PAAD	cis	rs116248771	0.739	rs73156437	chr3:158359284	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.67	-5.95	-0.43	1.74e-8	Mean corpuscular volume;
PAAD	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.56	5.37	0.4	2.95e-7	Coronary artery disease;
PAAD	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg13047869	chr3:10149882	C3orf24	0.54	4.75	0.36	4.74e-6	Alzheimer's disease;
PAAD	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg11946769	chr3:48343235	NME6	-0.52	-4.96	-0.37	1.87e-6	Educational attainment (years of education);
PAAD	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.78	8.67	0.58	5.94e-15	Breast cancer;
PAAD	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.65	6.74	0.48	3.13e-10	Resting heart rate;
PAAD	cis	rs112990264	1.000	rs112856622	chr1:213020143	G/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg27449745	chr7:23145252	KLHL7	-0.51	-4.47	-0.34	1.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2421770	0.701	rs7124327	chr11:35258739	A/C	cg13971030	chr11:35366721	SLC1A2	-0.49	-5.01	-0.38	1.51e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs10821973	0.527	rs4246940	chr10:64021586	G/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs988913	0.957	rs2397177	chr6:54834133	A/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.63	-0.35	7.84e-6	Menarche (age at onset);
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.93	11.57	0.68	1.37e-22	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06336613	chr15:77223807	RCN2	0.56	6.3	0.46	3.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.58	7.43	0.52	7.33e-12	Hypertriglyceridemia;
PAAD	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.17	-0.39	7.37e-7	Personality dimensions;
PAAD	cis	rs28595532	0.720	rs72670225	chr4:119302167	C/T	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs6494488	0.500	rs72741357	chr15:64783452	C/G	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	6.49	0.47	1.13e-9	Monocyte count;
PAAD	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.95	9.19	0.6	2.81e-16	Psoriasis;
PAAD	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.05	0.38	1.24e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6594713	0.837	rs13181732	chr5:112724778	C/T	cg12552261	chr5:112820674	MCC	-0.58	-4.31	-0.33	2.94e-5	Brain cytoarchitecture;
PAAD	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg15816464	chr17:2026533	SMG6	0.46	5.08	0.38	1.11e-6	Total body bone mineral density;
PAAD	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	4.36	0.33	2.41e-5	Response to bleomycin (chromatid breaks);
PAAD	trans	rs11794666	0.929	rs114234624	chr9:31663911	T/C	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08754654	chr5:154026448	NA	0.47	6.91	0.49	1.22e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.91	5.45	0.4	2.02e-7	Tuberculosis;
PAAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.3	-0.33	3.07e-5	Height;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.38	0.4	2.7e-7	Obesity-related traits;
PAAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg08029281	chr1:67600428	NA	0.5	6.23	0.45	4.28e-9	Psoriasis;
PAAD	cis	rs2030114	0.768	rs4784368	chr16:51594190	A/G	cg03758633	chr16:51611768	NA	0.5	4.58	0.35	9.67e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs965469	1.000	rs6037533	chr20:3268817	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.67	-8.77	-0.58	3.3e-15	Schizophrenia;
PAAD	cis	rs6540	1.000	rs6540	chr11:252649	C/T	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.51	-4.93	-0.37	2.11e-6	Uric acid clearance;
PAAD	cis	rs639012	0.698	rs474479	chr11:85828551	C/G	cg07180834	chr11:85838833	NA	-0.43	-4.61	-0.35	8.35e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg14515779	chr1:101123966	NA	-0.52	-6.28	-0.45	3.3e-9	Monocyte count;
PAAD	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.56	5.65	0.42	7.81e-8	White matter hyperintensity burden;
PAAD	cis	rs732765	0.580	rs10151838	chr14:75132155	A/G	cg17347104	chr14:75034677	LTBP2	0.63	4.68	0.36	6.18e-6	Non-small cell lung cancer;
PAAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.98	11.5	0.68	2.03e-22	Cognitive function;
PAAD	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.23	-15.81	-0.79	6.49e-34	Type 1 diabetes nephropathy;
PAAD	cis	rs1421334	0.703	rs9694122	chr8:30830808	G/C	cg00964221	chr8:30240029	NA	0.43	4.28	0.33	3.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16472060	chr15:60690385	ANXA2	-0.64	-7.25	-0.51	1.99e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg22349387	chr12:9600060	DDX12	-0.4	-4.28	-0.33	3.36e-5	Breast size;
PAAD	cis	rs11696501	0.688	rs59196188	chr20:44278868	C/T	cg11783356	chr20:44313418	WFDC10B	-0.59	-5.17	-0.39	7.29e-7	Brain structure;
PAAD	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg02734326	chr4:10020555	SLC2A9	-0.5	-4.56	-0.35	1.06e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg19486271	chr11:47235900	DDB2	-0.55	-5.53	-0.41	1.36e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.84	6.86	0.49	1.59e-10	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.96	8.68	0.58	5.58e-15	Alzheimer's disease;
PAAD	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg21366198	chr4:185655624	MLF1IP	0.56	5.22	0.39	5.91e-7	Kawasaki disease;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs4698934	0.545	rs4273475	chr4:106247762	T/C	cg27505036	chr16:1497467	CLCN7	0.83	6.32	0.46	2.82e-9	Melanoma;
PAAD	cis	rs4478147	0.548	rs4693140	chr4:87240799	T/C	cg10685359	chr4:87814065	C4orf36	-0.47	-4.6	-0.35	8.67e-6	Migraine - clinic-based;
PAAD	cis	rs290268	0.874	rs290990	chr9:93561695	A/G	cg02608019	chr9:93564028	SYK	-0.63	-6.41	-0.46	1.74e-9	Platelet count;
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg13047869	chr3:10149882	C3orf24	0.58	5.16	0.39	7.61e-7	Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.82	-9.13	-0.6	3.95e-16	Prostate cancer;
PAAD	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	9.76	0.62	8.86e-18	Smoking behavior;
PAAD	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.5	4.41	0.34	1.93e-5	HDL cholesterol;
PAAD	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.74	7.38	0.51	9.55e-12	Tonsillectomy;
PAAD	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.09	8.6	0.57	8.91e-15	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.48	5.24	0.39	5.17e-7	Electroencephalogram traits;
PAAD	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg18939081	chr1:31884902	SERINC2	0.46	5.32	0.4	3.66e-7	Alcohol dependence;
PAAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.36	6.23e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23544223	chr18:12777786	NA	-0.69	-5.89	-0.43	2.36e-8	Inflammatory skin disease;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.62	5.05	0.38	1.27e-6	Pediatric autoimmune diseases;
PAAD	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	1.06	12.09	0.7	5.4e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg05250797	chr16:70222502	NA	0.87	6.71	0.48	3.7e-10	IgE levels;
PAAD	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg27490568	chr2:178487706	NA	0.38	4.31	0.33	2.93e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg20092376	chr4:56023423	NA	0.49	5.08	0.38	1.07e-6	Endometriosis;
PAAD	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.9	-6.15	-0.45	6.46e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg17366294	chr4:99064904	C4orf37	0.45	4.96	0.37	1.88e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.75	7.5	0.52	4.92e-12	Corneal astigmatism;
PAAD	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12681288	0.782	rs2600497	chr8:1026220	A/G	cg04851639	chr8:1020857	NA	-0.66	-8.11	-0.55	1.61e-13	Schizophrenia;
PAAD	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg03517284	chr6:25882590	NA	-0.53	-4.43	-0.34	1.78e-5	Iron status biomarkers;
PAAD	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.47	0.41	1.8e-7	Ileal carcinoids;
PAAD	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	4.28	0.33	3.36e-5	Mean platelet volume;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16988970	chr17:42248062	ASB16	-0.37	-5.42	-0.4	2.32e-7	Total body bone mineral density;
PAAD	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-5.09	-0.38	1.03e-6	Total body bone mineral density;
PAAD	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg26935685	chr1:15502881	TMEM51	-0.5	-4.26	-0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.8	-0.43	3.74e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.89	0.58	1.67e-15	Menopause (age at onset);
PAAD	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26428731	chr1:35334352	DLGAP3	-0.65	-6.96	-0.49	9.42e-11	Obesity-related traits;
PAAD	cis	rs669446	0.527	rs667676	chr1:44082216	G/A	cg12908607	chr1:44402522	ARTN	-0.41	-4.37	-0.33	2.29e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.73	-9.08	-0.59	5.3e-16	Dental caries;
PAAD	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	9.07e-9	Lung cancer;
PAAD	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.68e-7	Personality dimensions;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22162314	chr17:61951766	CSH2	-0.61	-6.29	-0.45	3.15e-9	Height;
PAAD	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.1	0.44	8.5e-9	Height;
PAAD	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.61	6.14	0.45	6.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.57	-5.48	-0.41	1.72e-7	Paraoxonase activity;
PAAD	cis	rs57786342	0.539	rs4902652	chr14:69280309	A/G	cg03189333	chr14:69283534	NA	0.58	5.0	0.38	1.55e-6	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs9581857	0.615	rs927576	chr13:28097477	C/A	cg22138327	chr13:27999177	GTF3A	-0.77	-5.23	-0.39	5.61e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	10.41	0.65	1.75e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7619427	1.000	rs7635417	chr3:44074449	C/T	cg12796028	chr3:44040206	NA	-0.53	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.73	-7.58	-0.52	3.11e-12	Neurofibrillary tangles;
PAAD	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.78	-8.65	-0.57	6.68e-15	Handedness;
PAAD	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.91	7.71	0.53	1.52e-12	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg02887458	chr19:19495540	GATAD2A	-0.57	-5.51	-0.41	1.51e-7	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs2046867	0.908	rs62251600	chr3:72778545	C/T	cg25664220	chr3:72788482	NA	-0.71	-7.15	-0.5	3.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg02198044	chr15:56286336	NEDD4	-0.52	-5.24	-0.39	5.24e-7	Keloid;
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.58	6.77	0.48	2.7e-10	Aortic root size;
PAAD	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.74	-6.32	-0.46	2.76e-9	Exhaled nitric oxide output;
PAAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	12.18	0.7	3.06e-24	Birth weight;
PAAD	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg05250797	chr16:70222502	NA	0.74	5.76	0.42	4.46e-8	IgE levels;
PAAD	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.65	6.42	0.46	1.67e-9	Coronary artery disease;
PAAD	cis	rs10886094	0.922	rs17096333	chr10:119271219	G/A	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg05283184	chr6:79620031	NA	-0.5	-6.1	-0.44	8.35e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs76849715	chr10:46080433	G/A	cg12869334	chr8:37699360	GPR124	1.07	7.26	0.51	1.91e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs987237	1.000	rs62405422	chr6:50796905	T/C	cg24161652	chr6:50813859	TFAP2B	0.35	4.27	0.33	3.4e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Childhood body mass index;Adiposity;Body mass index in physically active individuals;
PAAD	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	1.11	12.69	0.72	1.25e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg13777783	chr17:79615861	NA	-0.41	-4.31	-0.33	2.93e-5	Eye color traits;
PAAD	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.89	10.11	0.63	1.1e-18	Resting heart rate;
PAAD	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg13207630	chr7:32358064	NA	0.8	4.58	0.35	9.55e-6	Body mass index;
PAAD	cis	rs7246657	0.508	rs1628959	chr19:37490376	G/A	cg23950597	chr19:37808831	NA	-0.77	-5.36	-0.4	3.06e-7	Coronary artery calcification;
PAAD	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.65	-8.27	-0.56	6.32e-14	Inflammatory bowel disease;
PAAD	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs7570971	0.617	rs935613	chr2:136022798	C/T	cg07169764	chr2:136633963	MCM6	0.71	7.01	0.49	7.46e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.15	0.6	3.57e-16	Asthma;
PAAD	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Electroencephalogram traits;
PAAD	cis	rs8070740	0.838	rs3786054	chr17:5339059	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.52	-4.89	-0.37	2.55e-6	Menopause (age at onset);
PAAD	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg27499820	chr13:21296301	IL17D	0.55	5.21	0.39	6.1e-7	Dental caries;
PAAD	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-4.92	-0.37	2.21e-6	Reticulocyte count;
PAAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	9.71	0.62	1.22e-17	Tonsillectomy;
PAAD	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.41	-5.38	-0.4	2.73e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.4	-0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7260329	0.713	rs8100458	chr19:41500213	T/C	cg23925301	chr19:41220945	ADCK4	-0.48	-4.38	-0.33	2.17e-5	Smoking behavior;
PAAD	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.86	6.01	0.44	1.33e-8	Crohn's disease;
PAAD	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00142150	chr22:38071001	LGALS1	0.86	9.65	0.62	1.79e-17	Fat distribution (HIV);
PAAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg03188948	chr7:1209495	NA	1.07	5.56	0.41	1.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.82	-8.61	-0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.89	7.85	0.54	6.88e-13	Recombination rate (females);
PAAD	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.82	-6.25	-0.45	3.85e-9	Coronary artery calcification;
PAAD	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg18135206	chr14:102964638	TECPR2	0.96	12.25	0.7	1.98e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.33	0.46	2.65e-9	Bladder cancer;
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.66	-7.27	-0.51	1.76e-11	Schizophrenia;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.55	6.26	0.45	3.77e-9	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.77	-9.03	-0.59	7.03e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.8	-0.43	3.63e-8	Life satisfaction;
PAAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.53	4.88	0.37	2.7e-6	Schizophrenia;
PAAD	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.89	7.63	0.53	2.43e-12	Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.33	0.33	2.73e-5	Personality dimensions;
PAAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg01475735	chr3:40494733	NA	-0.47	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.23	17.36	0.82	6.78e-38	Triglycerides;
PAAD	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.52	4.89	0.37	2.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg10168330	chr8:27262164	PTK2B	0.37	4.45	0.34	1.69e-5	Neuroticism;
PAAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg20933634	chr6:27740509	NA	0.67	6.47	0.46	1.26e-9	Parkinson's disease;
PAAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.0	-11.75	-0.69	4.38e-23	Obesity-related traits;
PAAD	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.53	5.69	0.42	6.48e-8	Lung cancer;
PAAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg09835421	chr16:68378352	PRMT7	-1.29	-8.99	-0.59	9.26e-16	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02400139	chr5:145890299	TCERG1	-0.64	-6.38	-0.46	2.05e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs12044355	0.827	rs16854779	chr1:231827318	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.78	-0.42	4.2e-8	Alzheimer's disease;
PAAD	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.58	5.89	0.43	2.4e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs11673344	0.562	rs7250507	chr19:37586674	A/T	cg23950597	chr19:37808831	NA	-0.5	-4.27	-0.33	3.48e-5	Obesity-related traits;
PAAD	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.23	0.64	5.09e-19	Bladder cancer;
PAAD	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.98	10.69	0.66	2.98e-20	Systemic lupus erythematosus;
PAAD	cis	rs11168618	0.740	rs12425460	chr12:48919796	C/T	cg01881778	chr12:48919444	OR8S1	-0.52	-5.59	-0.41	1.05e-7	Adiponectin levels;
PAAD	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.64	9.06	0.59	6.15e-16	Airflow obstruction;
PAAD	cis	rs12893597	0.580	rs2360999	chr14:76818989	A/C	cg20290672	chr14:76816747	NA	-0.47	-4.35	-0.33	2.49e-5	Maximal oxygen uptake response;
PAAD	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	0.97	5.96	0.44	1.7e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	1.21	7.6	0.52	2.88e-12	Severe influenza A (H1N1) infection;
PAAD	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.09	-11.79	-0.69	3.45e-23	Blood pressure (smoking interaction);
PAAD	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.58	-5.35	-0.4	3.19e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.72	0.48	3.48e-10	Longevity;Endometriosis;
PAAD	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg05337019	chr1:16062361	SLC25A34	-0.51	-4.26	-0.33	3.5e-5	Systolic blood pressure;
PAAD	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.47	4.38	0.33	2.19e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.34	0.46	2.45e-9	Morning vs. evening chronotype;
PAAD	cis	rs4523957	0.583	rs2760735	chr17:2036835	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.74	8.11	0.55	1.61e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.75	-7.01	-0.49	7.15e-11	Lymphocyte percentage of white cells;
PAAD	cis	rs721399	0.568	rs13254811	chr8:18273018	A/G	cg18736775	chr8:18248649	NAT2	-0.62	-4.7	-0.36	5.7e-6	Blood metabolite levels;
PAAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs116248771	0.739	rs4680454	chr3:158377913	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.94	12.77	0.72	7.72e-26	Prudent dietary pattern;
PAAD	cis	rs12282928	1.000	rs10769339	chr11:48294296	T/A	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.19	0.45	5.39e-9	Schizophrenia;
PAAD	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.45	-0.34	1.68e-5	Obesity (extreme);
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.1e-9	Life satisfaction;
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg13978441	chr8:144649358	C8orf73	0.78	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.72	-7.14	-0.5	3.56e-11	Platelet distribution width;
PAAD	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs818427	0.865	rs1093611	chr5:112218476	A/T	cg07820702	chr5:112228657	REEP5	0.54	4.87	0.37	2.73e-6	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.73	-4.32	-0.33	2.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.18	0.5	2.83e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.7	6.4	0.46	1.83e-9	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg09659197	chr4:152720779	NA	-0.36	-4.41	-0.34	1.92e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02172790	chr2:61404147	AHSA2	0.64	6.55	0.47	8.31e-10	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06885652	chr20:50768702	ZFP64	0.62	6.6	0.47	6.53e-10	Smoking initiation;
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg18402987	chr7:1209562	NA	1.01	5.94	0.43	1.91e-8	Longevity;Endometriosis;
PAAD	cis	rs741013	1.000	rs73128698	chr3:64293383	A/T	cg20180538	chr3:64559102	ADAMTS9	-0.9	-4.34	-0.33	2.64e-5	Coronary artery calcification;
PAAD	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.02e-8	Electrocardiographic conduction measures;
PAAD	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.57	4.98	0.37	1.73e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg14703610	chr5:56206110	C5orf35	-0.63	-5.78	-0.42	4.12e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg12432903	chr7:1882776	MAD1L1	0.55	4.3	0.33	3.07e-5	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13758310	chr4:1834493	LETM1	0.54	6.34	0.46	2.5e-9	Body fat percentage;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg17633681	chr16:88106987	BANP	0.63	8.14	0.55	1.3e-13	Menopause (age at onset);
PAAD	cis	rs12935418	0.583	rs2549843	chr16:81023745	C/T	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs6537837	0.701	rs17595368	chr1:110154390	C/T	cg05049280	chr1:110155535	GNAT2	0.76	7.14	0.5	3.69e-11	Major depressive disorder;
PAAD	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.35	4.32	0.33	2.85e-5	Pulmonary function;
PAAD	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	7.72	0.53	1.41e-12	Monocyte percentage of white cells;
PAAD	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-5.79	-0.42	3.99e-8	Colorectal cancer;
PAAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	trans	rs1027796	0.960	rs2725427	chr11:132751612	C/T	cg07868599	chr16:3079708	CCDC64B	0.5	6.4	0.46	1.8e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03644271	chr11:18415989	LDHA	-0.72	-6.63	-0.47	5.41e-10	Neuroticism;
PAAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg19257562	chr1:2043853	PRKCZ	0.48	5.87	0.43	2.67e-8	Height;
PAAD	cis	rs732765	0.657	rs3764920	chr14:75291431	C/T	cg17347104	chr14:75034677	LTBP2	0.57	4.28	0.33	3.29e-5	Non-small cell lung cancer;
PAAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.89	6.02	0.44	1.28e-8	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs992157	0.764	rs1870124	chr2:219187740	C/T	cg00012203	chr2:219082015	ARPC2	0.59	5.67	0.42	7.08e-8	Colorectal cancer;
PAAD	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	1.04	12.64	0.72	1.71e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.97	-13.79	-0.75	1.44e-28	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13840032	chr18:46385379	KIAA0427	-0.75	-7.51	-0.52	4.79e-12	Obesity-related traits;
PAAD	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26306683	chr17:18585705	ZNF286B	0.57	5.88	0.43	2.51e-8	Educational attainment (years of education);
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.83	9.67	0.62	1.54e-17	Age at first birth;
PAAD	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	4.58	0.35	9.43e-6	Height;
PAAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.53	-4.76	-0.36	4.4e-6	Schizophrenia;
PAAD	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg08999081	chr20:33150536	PIGU	0.5	4.41	0.34	1.95e-5	Protein C levels;
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg04257695	chr17:30186438	C17orf79	-0.54	-4.78	-0.36	4.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	1.25	11.98	0.7	1.05e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg19423196	chr10:82049429	MAT1A	0.61	4.69	0.36	6.03e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.81	-0.43	3.58e-8	Rheumatoid arthritis;
PAAD	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg05925327	chr15:68127851	NA	-0.57	-5.11	-0.38	9.59e-7	Restless legs syndrome;
PAAD	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.46	-4.29	-0.33	3.18e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg17346650	chr17:80929145	B3GNTL1	0.35	4.66	0.35	6.99e-6	Glycated hemoglobin levels;
PAAD	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.51e-6	Vitiligo;
PAAD	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.57	6.52	0.47	9.62e-10	Schizophrenia;
PAAD	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.15	0.39	7.84e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-6.51	-0.47	1.01e-9	Menopause (age at onset);
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg26338869	chr17:61819248	STRADA	0.51	4.88	0.37	2.65e-6	Height;
PAAD	cis	rs8005172	0.808	rs4899932	chr14:88486054	C/T	cg18078958	chr14:88630771	NA	0.5	5.91	0.43	2.14e-8	Parkinson's disease;
PAAD	cis	rs10988449	1.000	rs55700157	chr9:132371965	C/A	cg18327994	chr9:132372705	NA	-0.65	-4.26	-0.33	3.59e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.77	-5.4	-0.4	2.54e-7	Yeast infection;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.75	-11.9	-0.69	1.77e-23	Body mass index;
PAAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.67	0.53	1.89e-12	IgG glycosylation;
PAAD	cis	rs6782228	1.000	rs6775011	chr3:128396483	T/C	cg15607142	chr3:128420513	NA	-0.41	-4.41	-0.34	1.94e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	8.67	0.58	6.16e-15	Personality dimensions;
PAAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg21918786	chr6:109611834	NA	-0.68	-7.57	-0.52	3.43e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.92	10.88	0.66	9.58e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3857067	0.550	rs12646201	chr4:95027846	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.55	-4.78	-0.36	4.1e-6	QT interval;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.49	-4.97	-0.37	1.79e-6	Bipolar disorder;
PAAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.06	8.13	0.55	1.41e-13	Diabetic kidney disease;
PAAD	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.65	6.15	0.45	6.46e-9	Obesity-related traits;
PAAD	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.59	6.07	0.44	9.68e-9	Coronary artery disease;
PAAD	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	1.02	12.45	0.71	5.56e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg09695851	chr17:3907499	NA	-0.68	-7.07	-0.5	5.32e-11	Type 2 diabetes;
PAAD	cis	rs4774830	0.590	rs62045210	chr15:56249542	A/G	cg24530489	chr15:56299380	NA	-1.08	-4.51	-0.34	1.31e-5	Delta-5 desaturase activity;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.62	5.93	0.43	1.94e-8	Lung cancer;
PAAD	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.67	4.67	0.35	6.46e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.8	6.81	0.48	2.15e-10	Morning vs. evening chronotype;
PAAD	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.51	0.47	1.03e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25388168	chr10:43904408	HNRNPF	0.71	7.97	0.54	3.52e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.52	5.14	0.39	8.17e-7	Trans fatty acid levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14584431	chr19:32836476	ZNF507	-0.76	-6.54	-0.47	9.03e-10	Neuroticism;
PAAD	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.0	-0.38	1.56e-6	Hirschsprung disease;
PAAD	cis	rs829661	0.948	rs829619	chr2:30749567	C/T	cg12454169	chr2:30669597	LCLAT1	0.64	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.33	-0.33	2.7e-5	Systolic blood pressure;
PAAD	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.72	0.69	5.26e-23	Smoking behavior;
PAAD	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12292205	chr6:26970375	C6orf41	-0.48	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs72827839	0.779	rs58953228	chr17:46513814	A/G	cg23391107	chr17:45924227	SP6	0.5	4.78	0.36	4.17e-6	Ease of getting up in the morning;
PAAD	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.74	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-6.3	-0.46	3.13e-9	Menarche (age at onset);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17084289	chr5:131992225	NA	-0.55	-6.62	-0.47	5.94e-10	Body fat percentage;
PAAD	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.69	7.78	0.53	1.06e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs3112530	0.818	rs1462114	chr5:152693367	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.46	4.54	0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.56	0.52	3.52e-12	Prudent dietary pattern;
PAAD	cis	rs4705952	0.775	rs72797340	chr5:131867565	G/A	cg05209330	chr5:131550942	P4HA2	0.51	4.25	0.33	3.69e-5	C-reactive protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14779627	chr7:6048715	PMS2;AIMP2	-0.75	-6.41	-0.46	1.77e-9	Neuroticism;
PAAD	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	7.38	0.51	9.6e-12	Verbal declarative memory;
PAAD	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.5	-5.18	-0.39	6.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg05313129	chr8:58192883	C8orf71	-0.65	-5.14	-0.38	8.24e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg27335600	chr3:53528857	CACNA1D	-0.38	-4.25	-0.33	3.65e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	10.8	0.66	1.59e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.54	-0.35	1.15e-5	Colorectal cancer;
PAAD	cis	rs2217332	1.000	rs2518058	chr16:56966554	T/C	cg05953549	chr16:56966104	HERPUD1	0.72	4.25	0.33	3.68e-5	Metabolic syndrome;
PAAD	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-12.3	-0.71	1.39e-24	Primary sclerosing cholangitis;
PAAD	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg00484396	chr16:3507460	NAT15	0.91	7.65	0.53	2.14e-12	Tuberculosis;
PAAD	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.78	-0.42	4.14e-8	Airway imaging phenotypes;
PAAD	cis	rs2019216	0.571	rs7405455	chr17:21977621	C/T	cg05591447	chr17:21909280	FLJ36000	-0.33	-4.38	-0.33	2.21e-5	Pelvic organ prolapse;
PAAD	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.57	-0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg10932868	chr11:921992	NA	-0.45	-5.01	-0.38	1.52e-6	Alzheimer's disease (late onset);
PAAD	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.45	-4.37	-0.33	2.32e-5	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03935448	chr8:54818075	RGS20	0.55	6.33	0.46	2.64e-9	Smoking initiation;
PAAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	1.07	8.44	0.57	2.26e-14	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06434972	chr7:44122219	POLM	0.59	6.62	0.47	5.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.66	-6.32	-0.46	2.81e-9	Parkinson's disease;
PAAD	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.22	0.39	5.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	cis	rs11807834	0.522	rs754665	chr1:230250297	T/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.59e-14	Schizophrenia;
PAAD	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs7551222	0.681	rs4245739	chr1:204518842	G/T	cg01064725	chr1:204461714	NA	-0.57	-5.05	-0.38	1.28e-6	Schizophrenia;
PAAD	trans	rs901683	1.000	rs17157928	chr10:46048229	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg18171855	chr10:2543474	NA	0.64	7.61	0.53	2.61e-12	Age-related hearing impairment;
PAAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg18833306	chr6:118973337	C6orf204	0.43	4.46	0.34	1.58e-5	Electrocardiographic conduction measures;
PAAD	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03681679	chr16:4748915	ANKS3	0.52	6.3	0.46	3.07e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.91	-8.1	-0.55	1.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.76	0.42	4.52e-8	Menopause (age at onset);
PAAD	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.97	12.72	0.72	1.09e-25	Age-related hearing impairment;
PAAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.4	-0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.65	-0.35	7.17e-6	Neuroticism;
PAAD	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.08	0.44	9.19e-9	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10684905	chr12:2999782	TULP3	-0.66	-8.0	-0.54	2.87e-13	Body fat percentage;
PAAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	6.07	0.44	9.86e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs2017305	0.831	rs17555735	chr10:70662860	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.08	-0.38	1.08e-6	Depression (quantitative trait);
PAAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.46	-4.56	-0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.48	-0.34	1.49e-5	Height;
PAAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg06671706	chr8:8559999	CLDN23	0.76	7.27	0.51	1.78e-11	Obesity-related traits;
PAAD	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.36	-0.51	1.05e-11	Neuroticism;
PAAD	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.57	0.52	3.41e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.89e-9	Lung cancer;
PAAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-5.84	-0.43	2.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.44	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.59	-6.06	-0.44	1.05e-8	Tonsillectomy;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.9e-24	Platelet count;
PAAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.3	0.64	3.25e-19	Prudent dietary pattern;
PAAD	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15145965	chr22:50218605	BRD1	-0.53	-4.48	-0.34	1.45e-5	Schizophrenia;
PAAD	cis	rs62264129	0.500	rs9837134	chr3:112047402	C/T	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.95	-0.37	1.91e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.88	-12.37	-0.71	9.39e-25	Height;
PAAD	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg13482628	chr17:19912719	NA	0.71	7.13	0.5	3.76e-11	Schizophrenia;
PAAD	cis	rs4787491	0.729	rs11642399	chr16:30059593	T/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.41	-0.34	1.92e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg05342682	chr7:94953680	PON1	-0.51	-4.48	-0.34	1.47e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs2131877	0.830	rs1874104	chr3:194845226	A/C	cg19760965	chr3:194868843	C3orf21	-0.49	-4.79	-0.36	3.96e-6	Non-small cell lung cancer;
PAAD	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.39	-0.4	2.65e-7	Daytime sleep phenotypes;
PAAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.81	-7.63	-0.53	2.45e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.67	6.99	0.49	7.91e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.21	0.45	4.75e-9	Ileal carcinoids;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02607330	chr4:3510935	NA	0.64	6.35	0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.76	-8.75	-0.58	3.8e-15	Handedness;
PAAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg08029281	chr1:67600428	NA	0.45	5.24	0.39	5.21e-7	Psoriasis;
PAAD	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.94	-0.54	4.07e-13	Coronary artery disease;
PAAD	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.63	4.49	0.34	1.41e-5	Vitiligo;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.46	6.4	0.46	1.83e-9	Vitiligo;
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.53	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	5.91	0.43	2.16e-8	Cognitive test performance;
PAAD	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg12454169	chr2:30669597	LCLAT1	0.69	5.17	0.39	7.12e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg23034840	chr1:205782522	SLC41A1	0.74	5.89	0.43	2.43e-8	Prostate-specific antigen levels;
PAAD	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg06585982	chr3:143692056	C3orf58	0.58	5.66	0.42	7.31e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.52e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12913538	0.547	rs4774440	chr15:62887685	G/T	cg09983546	chr15:62884068	NA	-0.76	-6.93	-0.49	1.13e-10	Sleep depth;
PAAD	cis	rs72634501	0.517	rs6684217	chr1:39587278	C/T	cg11070191	chr1:39582205	MACF1	0.52	4.63	0.35	7.85e-6	HDL cholesterol;
PAAD	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.82	-9.16	-0.6	3.32e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26660305	chr17:73571056	LLGL2	0.63	6.35	0.46	2.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.64	-0.47	5.18e-10	Retinal vascular caliber;
PAAD	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19327137	chr7:38886074	VPS41	0.41	4.25	0.33	3.77e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.55	-5.02	-0.38	1.46e-6	Mean corpuscular volume;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg13206674	chr6:150067644	NUP43	0.62	6.53	0.47	9.27e-10	Testicular germ cell tumor;
PAAD	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg09760422	chr2:128146352	NA	0.4	6.01	0.44	1.33e-8	Self-rated health;
PAAD	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg11262906	chr1:85462892	MCOLN2	0.66	4.94	0.37	2.02e-6	Serum sulfate level;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09221314	chr3:69063234	C3orf64	-0.74	-6.36	-0.46	2.25e-9	Neuroticism;
PAAD	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.75	7.62	0.53	2.58e-12	Obesity-related traits;
PAAD	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg09366796	chr5:75012313	C5orf37	0.5	4.52	0.34	1.23e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg07622451	chr1:3079886	PRDM16	0.39	4.69	0.36	6.04e-6	Migraine;
PAAD	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.83	-10.61	-0.65	4.86e-20	Breast cancer;
PAAD	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.69	8.04	0.55	2.34e-13	Colorectal cancer;
PAAD	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.53	5.15	0.39	7.82e-7	Fractional excretion of uric acid;
PAAD	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.46	-5.09	-0.38	1.02e-6	Pneumonia;
PAAD	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg18721089	chr20:30220636	NA	-0.5	-4.32	-0.33	2.76e-5	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.58	5.45	0.4	1.98e-7	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4908768	0.639	rs4908512	chr1:8830366	A/T	cg00590817	chr1:8272081	NA	-0.36	-4.29	-0.33	3.12e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs8133932	0.654	rs10854474	chr21:47332700	A/G	cg11214348	chr21:47283868	PCBP3	0.48	4.36	0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.42	-4.88	-0.37	2.68e-6	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.59	-4.74	-0.36	4.9100000000000004e-06	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg04775059	chr7:64541387	NA	-0.57	-5.86	-0.43	2.77e-8	Calcium levels;
PAAD	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.79	-8.79	-0.58	2.94e-15	Morning vs. evening chronotype;
PAAD	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg08562672	chr19:21860753	NA	0.45	4.67	0.35	6.44e-6	Pain;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs7101378	0.502	rs11212867	chr11:108910103	A/T	cg10610482	chr11:108093212	ATM;NPAT	-0.49	-4.61	-0.35	8.37e-6	IgG glycosylation;
PAAD	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs9535307	0.929	rs9526593	chr13:50288777	T/C	cg03658251	chr13:50265850	EBPL	0.81	5.61	0.41	9.52e-8	Obesity-related traits;
PAAD	cis	rs13273891	1.000	rs7010934	chr8:58977019	A/G	cg05901852	chr8:59757290	TOX	0.52	4.86	0.37	2.85e-6	Pit-and-Fissure caries;
PAAD	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.56	4.77	0.36	4.36e-6	Tonsillectomy;
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02071572	chr4:1403502	NA	-0.48	-6.1	-0.44	8.51e-9	Obesity-related traits;
PAAD	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg08053846	chr7:100769605	SERPINE1	-0.42	-4.42	-0.34	1.87e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg18316498	chr11:111250196	POU2AF1	0.34	4.44	0.34	1.73e-5	Primary biliary cholangitis;
PAAD	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.75	-6.43	-0.46	1.55e-9	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.98	0.44	1.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.46	-7.02	-0.49	6.98e-11	Cutaneous nevi;
PAAD	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.55	0.35	1.07e-5	Neuroticism;
PAAD	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.63	5.4	0.4	2.5e-7	Neutrophil percentage of white cells;
PAAD	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg00614314	chr15:82944287	LOC80154	0.53	5.43	0.4	2.18e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.58	-5.31	-0.4	3.78e-7	Post bronchodilator FEV1;
PAAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.23e-14	Colorectal cancer;
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-8.81	-0.58	2.73e-15	Prostate cancer;
PAAD	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06307176	chr5:131281290	NA	0.51	4.66	0.35	6.9e-6	Life satisfaction;
PAAD	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg25124228	chr12:125621409	AACS	-0.63	-6.51	-0.47	1.05e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs12772102	chr10:46081101	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.84	-4.87	-0.37	2.72e-6	Lung cancer in ever smokers;
PAAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg22549504	chr19:17448937	GTPBP3	0.61	4.94	0.37	2.08e-6	Systemic lupus erythematosus;
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg21016266	chr12:122356598	WDR66	-0.47	-4.75	-0.36	4.6e-6	Mean corpuscular volume;
PAAD	cis	rs73416724	1.000	rs75320251	chr6:43395101	G/A	cg17076780	chr6:43251928	TTBK1	0.57	4.64	0.35	7.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.75	0.48	2.87e-10	Bladder cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19313034	chr8:103551067	NA	-0.68	-6.46	-0.46	1.36e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg21483461	chr5:81570383	RPS23	0.56	5.0	0.38	1.58e-6	Breast cancer;
PAAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-7.39	-0.51	9.1e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-5.33	-0.4	3.42e-7	Lymphocyte counts;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25749165	chr10:75634242	CAMK2G	0.6	7.08	0.5	5.08e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg08562672	chr19:21860753	NA	0.46	4.77	0.36	4.36e-6	Pain;
PAAD	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01927065	chr2:97001301	NCAPH	-0.63	-6.47	-0.46	1.3e-9	Smoking initiation;
PAAD	cis	rs795484	0.926	rs708865	chr12:118683533	A/C	cg16572268	chr12:118583242	PEBP1	-0.49	-4.81	-0.36	3.55e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.11	0.44	7.94e-9	Lymphocyte counts;
PAAD	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.82	-6.63	-0.47	5.55e-10	Blood protein levels;
PAAD	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.7	-0.36	5.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.18	0.45	5.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.49	5.1	0.38	9.94e-7	Testicular germ cell tumor;
PAAD	cis	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg21546286	chr11:48923668	NA	-0.44	-4.55	-0.35	1.08e-5	HDL cholesterol;
PAAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg18944383	chr4:111397179	ENPEP	-0.68	-8.1	-0.55	1.66e-13	Coronary artery disease;
PAAD	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg08079166	chr15:68083412	MAP2K5	-0.51	-4.73	-0.36	5.02e-6	Restless legs syndrome;
PAAD	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.84	-9.62	-0.62	2.12e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.9	-8.18	-0.55	1.08e-13	Body mass index;
PAAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.57	5.32	0.4	3.72e-7	Type 2 diabetes;
PAAD	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.6	6.39	0.46	1.9e-9	Testicular germ cell tumor;
PAAD	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg17868515	chr10:100992068	HPSE2	-0.38	-4.46	-0.34	1.59e-5	Metabolite levels;
PAAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.81	7.41	0.52	8.06e-12	Psoriasis;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6137287	0.855	rs6137292	chr20:21195803	A/C	cg04219410	chr20:21106687	PLK1S1	0.39	4.41	0.34	1.92e-5	Height;
PAAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.75	8.53	0.57	1.34e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.61	-6.09	-0.44	8.7e-9	Height;
PAAD	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs12136530	0.593	rs881248	chr1:19733961	C/T	cg03321592	chr1:19991676	HTR6	-0.51	-4.6	-0.35	8.77e-6	Lead levels in blood;
PAAD	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg15282417	chr9:129245246	FAM125B	0.41	4.82	0.36	3.5e-6	Intraocular pressure;
PAAD	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.59	-0.35	9.31e-6	Alcohol dependence;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg16362232	chr11:430036	ANO9	0.87	5.36	0.4	2.97e-7	Body mass index;
PAAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	trans	rs10769691	0.850	rs7112142	chr11:6383720	C/G	cg04914894	chr7:155283738	NA	-1.03	-6.65	-0.47	5.05e-10	Diisocyanate-induced asthma;
PAAD	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.93	-10.98	-0.67	5.07e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-9.03	-0.59	7.36e-16	Body mass index;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14892517	chr2:53898063	LOC100302652;ASB3	-0.68	-6.93	-0.49	1.11e-10	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.66	6.11	0.44	8.18e-9	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.45	5.81	0.43	3.56e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.93	-0.54	4.5e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs35955747	0.869	rs131213	chr22:31753849	C/T	cg07969918	chr22:31682909	PIK3IP1	0.37	4.84	0.37	3.21e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16645584	chr1:59247487	JUN	0.57	6.72	0.48	3.42e-10	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.85	-0.37	3.07e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg20169779	chr10:135381914	SYCE1	-0.44	-4.62	-0.35	8.22e-6	Obesity-related traits;
PAAD	cis	rs11024102	1.000	rs4141194	chr11:17011176	A/C	cg15378786	chr11:17036137	PLEKHA7	-0.52	-4.63	-0.35	7.64e-6	Glaucoma (primary angle closure);
PAAD	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	5.1	0.38	1.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.51	-4.87	-0.37	2.79e-6	Hepatocellular carcinoma;
PAAD	cis	rs4664293	0.605	rs890095	chr2:160461219	A/G	cg04215213	chr2:159602169	NA	0.4	4.42	0.34	1.84e-5	Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.93	7.53	0.52	4.22e-12	Iron status biomarkers;
PAAD	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg16584290	chr5:462447	EXOC3	-0.44	-4.83	-0.36	3.35e-6	Cystic fibrosis severity;
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.84	8.9	0.59	1.6e-15	Total body bone mineral density;
PAAD	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.37	4.47	0.34	1.54e-5	Pulmonary function;
PAAD	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.28	-0.33	3.31e-5	Bipolar disorder;
PAAD	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-1.0	-10.51	-0.65	9.31e-20	Platelet distribution width;
PAAD	trans	rs901683	0.572	rs17157859	chr10:45989409	T/C	cg12869334	chr8:37699360	GPR124	0.98	6.53	0.47	9.52e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.56	4.86	0.37	2.87e-6	Mean platelet volume;
PAAD	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.31	-0.51	1.45e-11	Total cholesterol levels;
PAAD	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11578532	chr1:161008127	TSTD1	0.47	5.29	0.39	4.27e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.38	0.33	2.23e-5	Tonsillectomy;
PAAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.25	0.39	5.12e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg02631450	chr22:32366979	NA	1.06	5.73	0.42	5.14e-8	Childhood ear infection;
PAAD	cis	rs12282928	0.700	rs10838817	chr11:48200265	G/A	cg04721828	chr11:48285200	OR4X1	-0.4	-5.19	-0.39	6.68e-7	Migraine - clinic-based;
PAAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.69	6.71	0.48	3.66e-10	Recombination rate (males);
PAAD	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	5.76	0.42	4.51e-8	Lung cancer in ever smokers;
PAAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18867708	chr6:26865862	GUSBL1	-0.44	-4.52	-0.34	1.24e-5	Schizophrenia;
PAAD	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.38	-0.33	2.22e-5	Total body bone mineral density;
PAAD	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.78	0.42	4.04e-8	Prostate cancer;
PAAD	cis	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg25753631	chr6:25732923	NA	-0.47	-5.24	-0.39	5.29e-7	Iron status biomarkers;
PAAD	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.87	-9.45	-0.61	5.95e-17	Urate levels in obese individuals;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13272327	chr3:137906213	ARMC8	0.62	6.83	0.48	1.9e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.34	0.6	1.14e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg00262122	chr8:11665843	FDFT1	0.51	4.52	0.34	1.25e-5	Retinal vascular caliber;
PAAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs17169635	0.819	rs6956447	chr7:134501132	A/C	cg02516134	chr7:134575187	CALD1	-0.45	-4.65	-0.35	7.14e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.53	-4.59	-0.35	9.32e-6	IgG glycosylation;
PAAD	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg04257695	chr17:30186438	C17orf79	0.69	4.73	0.36	5.08e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	4.96	0.37	1.89e-6	Serum sulfate level;
PAAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35955747	0.902	rs131209	chr22:31732461	A/G	cg02404636	chr22:31891804	SFI1	0.5	4.92	0.37	2.26e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.54	-5.48	-0.41	1.72e-7	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.63	-0.35	7.77e-6	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs7772697	0.632	rs9498214	chr6:149418310	C/T	cg21368479	chr6:149415018	NA	0.41	4.3	0.33	3.01e-5	Diabetic retinopathy;
PAAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg24253500	chr15:84953950	NA	0.56	6.54	0.47	9.05e-10	Schizophrenia;
PAAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-6.33	-0.46	2.55e-9	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27299406	chr2:43020013	HAAO	0.57	6.54	0.47	8.79e-10	Monocyte percentage of white cells;
PAAD	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-8.72	-0.58	4.65e-15	Dental caries;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.91	12.34	0.71	1.09e-24	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.21	0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.69	-7.48	-0.52	5.57e-12	Prudent dietary pattern;
PAAD	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.54	5.31	0.4	3.85e-7	Asthma;
PAAD	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg02421172	chr7:1938701	MAD1L1	0.55	4.54	0.35	1.14e-5	Bipolar disorder;
PAAD	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.86	-0.43	2.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg10729496	chr3:10149963	C3orf24	0.83	6.76	0.48	2.84e-10	Alzheimer's disease;
PAAD	cis	rs11853189	0.938	rs75369292	chr15:78555357	T/C	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.54	4.84	0.37	3.17e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.02e-11	Corneal astigmatism;
PAAD	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.47	4.62	0.35	8.29e-6	Menarche (age at onset);
PAAD	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-4.82	-0.36	3.5e-6	Psoriasis;
PAAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.48	-5.4	-0.4	2.48e-7	Platelet distribution width;
PAAD	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.52e-8	Mean corpuscular volume;
PAAD	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.74	6.73	0.48	3.26e-10	Breast cancer;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg01763666	chr17:80159506	CCDC57	0.44	4.51	0.34	1.3e-5	Life satisfaction;
PAAD	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.63	-6.16	-0.45	6.23e-9	Monocyte count;
PAAD	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09597638	chr17:3907349	NA	-0.74	-7.88	-0.54	5.89e-13	Type 2 diabetes;
PAAD	cis	rs1075265	0.783	rs6708095	chr2:53937502	A/T	cg04546899	chr2:54196757	PSME4	0.3	4.42	0.34	1.85e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs943466	0.955	rs1887340	chr6:33730095	C/T	cg04704449	chr6:33738291	NA	-0.48	-4.76	-0.36	4.52e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg08209042	chr3:196295218	WDR53;FBXO45	-0.6	-4.83	-0.36	3.36e-6	Fat distribution (HIV);
PAAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg21918786	chr6:109611834	NA	-0.46	-4.97	-0.37	1.77e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11651753	0.636	rs4793733	chr17:46033982	G/A	cg24458315	chr17:46148407	CBX1	0.42	4.44	0.34	1.75e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg02780029	chr10:43622663	RET	-0.48	-4.75	-0.36	4.73e-6	Hirschsprung disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12090105	chr18:6287052	L3MBTL4	-0.51	-6.5	-0.47	1.12e-9	Energy expenditure (24h);
PAAD	cis	rs3206736	0.556	rs1649235	chr7:35003882	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg10820045	chr2:198174542	NA	0.5	5.15	0.39	7.92e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.65	-4.88	-0.37	2.69e-6	Post bronchodilator FEV1;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05492660	chr2:71205564	ANKRD53	-0.69	-6.35	-0.46	2.31e-9	Neuroticism;
PAAD	cis	rs7619427	1.000	rs7631201	chr3:44069531	A/C	cg12796028	chr3:44040206	NA	-0.53	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	1.09	11.25	0.67	9.8e-22	Platelet distribution width;
PAAD	cis	rs950880	0.710	rs17026974	chr2:102952360	A/G	cg23450938	chr2:102972792	NA	-0.45	-4.91	-0.37	2.36e-6	Serum protein levels (sST2);
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.68	-0.36	6.18e-6	Aortic root size;
PAAD	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg25672287	chr16:452092	DECR2	-0.8	-6.52	-0.47	9.76e-10	Parkinson's disease;
PAAD	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.01	-0.38	1.52e-6	Vitiligo;
PAAD	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.46	-0.34	1.57e-5	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.5	-0.41	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg05627522	chr15:75251581	NA	0.4	4.54	0.35	1.14e-5	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg06145435	chr7:1022769	CYP2W1	0.34	4.47	0.34	1.51e-5	Longevity;Endometriosis;
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07869135	chr8:123794843	ZHX2	0.66	7.7	0.53	1.59e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.47	4.8	0.36	3.8e-6	Cognitive function;
PAAD	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.51	-4.47	-0.34	1.55e-5	Obesity;
PAAD	cis	rs7224685	0.637	rs35618711	chr17:4229258	A/T	cg09597638	chr17:3907349	NA	0.61	4.99	0.38	1.64e-6	Type 2 diabetes;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-4.84	-0.37	3.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22223531	chr1:53163893	C1orf163	0.58	6.69	0.48	3.98e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.53	-5.21	-0.39	6.09e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6995541	0.699	rs7836833	chr8:10667673	T/C	cg14855657	chr8:10587604	SOX7	0.46	4.46	0.34	1.61e-5	Triglyceride levels;
PAAD	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs72772787	1.000	rs72772787	chr1:248016378	C/T	cg08944170	chr1:248100614	OR2L13	0.6	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg02462569	chr6:150064036	NUP43	-0.48	-5.52	-0.41	1.41e-7	Lung cancer;
PAAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.55	5.81	0.43	3.56e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20095674	chr2:210673274	UNC80	0.56	6.57	0.47	7.71e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.91	-6.05	-0.44	1.09e-8	Body mass index;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-8.01	-0.54	2.8e-13	Prudent dietary pattern;
PAAD	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.61	6.46	0.46	1.36e-9	Mean platelet volume;
PAAD	cis	rs11159086	0.793	rs9285594	chr14:74955956	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.14	-0.38	8.25e-7	Advanced glycation end-product levels;
PAAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.61	-5.84	-0.43	3.08e-8	Aortic root size;
PAAD	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.61	6.68	0.48	4.23e-10	Tumor biomarkers;
PAAD	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg16205897	chr5:131564050	P4HA2	-0.46	-4.81	-0.36	3.55e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.36e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs2882667	0.690	rs825746	chr5:138136619	C/T	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs757110	1.000	rs757110	chr11:17418477	C/A	cg15432903	chr11:17409602	KCNJ11	0.8	8.7	0.58	5.08e-15	Type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.54	-4.63	-0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	4.91	0.37	2.31e-6	Educational attainment;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.83	-0.43	3.25e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg23860436	chr12:58378763	NA	0.46	4.41	0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-4.93	-0.37	2.14e-6	Cognitive test performance;
PAAD	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-8.48	-0.57	1.89e-14	Vitiligo;
PAAD	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	8.07e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.97e-16	Cannabis dependence symptom count;
PAAD	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.53	0.34	1.19e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg04154034	chr17:28927549	LRRC37B2	0.7	4.75	0.36	4.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs4294134	0.608	rs13237671	chr7:135244604	T/C	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.56	-4.76	-0.36	4.49e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.78	8.38	0.56	3.24e-14	Body mass index;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg23465465	chr6:26364728	BTN3A2	0.86	4.99	0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24051152	chr8:145133159	EXOSC4	0.56	6.39	0.46	1.88e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.61	5.49	0.41	1.67e-7	Red blood cell count;
PAAD	cis	rs2521634	0.938	rs71537272	chr7:24356899	G/A	cg15037663	chr7:24797835	DFNA5	-0.47	-4.34	-0.33	2.64e-5	Periodontitis;
PAAD	cis	rs4819852	1.000	rs7285377	chr22:19987202	G/T	cg07821417	chr22:19972146	ARVCF	0.68	6.76	0.48	2.73e-10	Pulse pressure;
PAAD	cis	rs58521262	0.585	rs291772	chr19:23207386	A/G	cg03433597	chr19:22806448	NA	0.24	4.36	0.33	2.39e-5	Testicular germ cell tumor;
PAAD	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	1.06	14.17	0.75	1.38e-29	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.95	12.29	0.71	1.51e-24	Menopause (age at onset);
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.75	-8.55	-0.57	1.21e-14	Renal function-related traits (BUN);
PAAD	cis	rs73019876	0.869	rs2214297	chr19:22177099	A/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	8.94	0.59	1.24e-15	Height;
PAAD	cis	rs2147959	0.882	rs6666241	chr1:228629759	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.48	-0.34	1.46e-5	Adult asthma;
PAAD	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg23127183	chr11:57508653	C11orf31	-0.52	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.79	7.72	0.53	1.46e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.73	0.62	1.05e-17	Electrocardiographic conduction measures;
PAAD	cis	rs6882716	1.000	rs6882716	chr5:10797886	G/A	cg14521931	chr5:10832172	NA	-0.82	-4.79	-0.36	3.95e-6	Alcohol consumption (maxi-drinks);
PAAD	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.68	-0.35	6.3e-6	Lung cancer in ever smokers;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	0.36	4.73	0.36	5.1e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg07689907	chr11:61582574	FADS1	0.46	4.58	0.35	9.8e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.79	-7.73	-0.53	1.36e-12	DNA methylation (variation);
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02071572	chr4:1403502	NA	-0.43	-5.57	-0.41	1.11e-7	Obesity-related traits;
PAAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg05479556	chr5:449004	EXOC3	0.44	4.53	0.34	1.19e-5	Fat distribution (HIV);
PAAD	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.81	8.44	0.57	2.28e-14	Breast cancer;
PAAD	cis	rs251130	0.540	rs253976	chr5:110862216	C/G	cg11925263	chr5:110849104	STARD4	0.39	4.35	0.33	2.44e-5	Menarche (age at onset);
PAAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg14092988	chr3:52407081	DNAH1	0.5	6.31	0.46	2.85e-9	Bipolar disorder;
PAAD	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.06	-0.59	6.17e-16	Height;
PAAD	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.66	-5.68	-0.42	6.58e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg08601574	chr20:25228251	PYGB	0.62	6.92	0.49	1.18e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-1.39	-10.25	-0.64	4.59e-19	Magnesium levels;
PAAD	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12220238	0.822	rs73286281	chr10:76083337	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg22875332	chr1:76189707	ACADM	-0.51	-5.08	-0.38	1.1e-6	Daytime sleep phenotypes;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.57	-0.35	9.87e-6	Longevity;Endometriosis;
PAAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6499766	0.518	rs1558665	chr16:55558576	C/T	cg00427604	chr16:55542751	LPCAT2	0.37	4.28	0.33	3.26e-5	Thyroid hormone levels;
PAAD	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.33	-0.51	1.3e-11	Chronic sinus infection;
PAAD	cis	rs9646944	0.501	rs3213733	chr2:102997884	C/A	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg12907477	chr18:56117327	MIR122	0.61	4.77	0.36	4.3e-6	Platelet count;
PAAD	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg23167506	chr7:1303302	NA	0.38	6.42	0.46	1.67e-9	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.76	7.63	0.53	2.33e-12	Breast cancer;
PAAD	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.74	-8.57	-0.57	1.1e-14	Corneal astigmatism;
PAAD	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.65	8.95	0.59	1.19e-15	Breast size;
PAAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.65	6.44	0.46	1.49e-9	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.58	-5.4	-0.4	2.49e-7	White matter hyperintensity burden;
PAAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.63	-6.19	-0.45	5.28e-9	DNA methylation (variation);
PAAD	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.8	8.3	0.56	5.23e-14	Uric acid levels;
PAAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.16	-0.5	3.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.77	-0.48	2.57e-10	Atrioventricular conduction;
PAAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.66	-7.58	-0.52	3.2e-12	Huntington's disease progression;
PAAD	cis	rs8014252	0.803	rs17108246	chr14:71054992	G/A	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg18833306	chr6:118973337	C6orf204	0.47	5.36	0.4	3.03e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.72	7.32	0.51	1.36e-11	Uric acid levels;
PAAD	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.74	4.65	0.35	7.06e-6	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs2272006	chr3:41997059	C/T	cg03022575	chr3:42003672	ULK4	-0.76	-5.57	-0.41	1.12e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.67	-0.42	6.9e-8	Tonsillectomy;
PAAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.33	-0.46	2.65e-9	Hip circumference;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.29	0.45	3.22e-9	Mean platelet volume;
PAAD	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.42e-5	Resting heart rate;
PAAD	cis	rs1642645	0.597	rs4660585	chr1:42393001	G/A	cg01990334	chr1:42801334	FOXJ3	-0.67	-5.63	-0.42	8.29e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.71	5.38	0.4	2.74e-7	Vitiligo;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.65	0.47	4.94e-10	Alzheimer's disease;
PAAD	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.15	0.6	3.57e-16	Asthma;
PAAD	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.55	4.52	0.34	1.22e-5	Dementia with Lewy bodies;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.72	-7.01	-0.49	7.46e-11	Blood metabolite levels;
PAAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.53	-6.1	-0.44	8.25e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.81	-6.18	-0.45	5.68e-9	Coronary artery calcification;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg27113419	chr16:58533979	NDRG4	-0.73	-4.47	-0.34	1.5e-5	Schizophrenia;
PAAD	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg04990556	chr1:26633338	UBXN11	-0.53	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.97	8.71	0.58	4.71e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.77	8.21	0.55	9.01e-14	Uric acid levels;
PAAD	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	4.26	0.33	3.52e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs35955747	0.902	rs11703927	chr22:31644964	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.42	-0.34	1.89e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4343996	0.566	rs55940354	chr7:3431534	C/T	cg21248987	chr7:3385318	SDK1	0.41	4.29	0.33	3.2e-5	Motion sickness;
PAAD	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg14583973	chr4:3374767	RGS12	0.33	4.76	0.36	4.56e-6	Mean platelet volume;
PAAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.69	-6.63	-0.47	5.51e-10	Schizophrenia;
PAAD	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.54	5.15	0.39	7.92e-7	Pancreatic cancer;
PAAD	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg03115019	chr17:80708279	FN3K	0.52	4.73	0.36	5e-6	Glycated hemoglobin levels;
PAAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.95	0.37	1.94e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7577696	0.925	rs408813	chr2:32476390	T/G	cg02381751	chr2:32503542	YIPF4	0.44	4.66	0.35	6.81e-6	Inflammatory biomarkers;
PAAD	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.33	0.51	1.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs3753841	0.832	rs7513722	chr1:103285283	T/C	cg24495344	chr1:103574097	COL11A1	0.4	4.73	0.36	5.16e-6	Glaucoma (primary angle closure);
PAAD	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg17551891	chr7:1960795	MAD1L1	-0.48	-4.28	-0.33	3.34e-5	Bipolar disorder;
PAAD	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.62	6.93	0.49	1.1e-10	Colorectal cancer;
PAAD	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.51	5.05	0.38	1.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14331148	chr19:47551893	TMEM160	-0.59	-6.73	-0.48	3.29e-10	Body fat percentage;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05620814	chr16:74640948	GLG1	-0.67	-6.84	-0.49	1.84e-10	Smoking initiation;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.7	7.99	0.54	3.07e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.14	0.55	1.36e-13	Educational attainment;
PAAD	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.89	7.18	0.5	2.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg00864860	chr1:7907996	UTS2	-0.55	-5.0	-0.38	1.58e-6	Crohn's disease;
PAAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.78	8.3	0.56	5.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.65	-5.94	-0.43	1.9e-8	Psoriasis;
PAAD	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16470957	chr3:50388565	TUSC4;CYB561D2	0.65	6.83	0.48	1.88e-10	Myopia (pathological);
PAAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.77	9.76	0.62	8.99e-18	Iron status biomarkers (transferrin levels);
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02071572	chr4:1403502	NA	0.4	5.42	0.4	2.26e-7	Obesity-related traits;
PAAD	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg00647820	chr17:40259828	DHX58	-0.44	-5.31	-0.4	3.75e-7	Fibrinogen levels;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.63	-5.96	-0.44	1.66e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.72	5.93	0.43	1.99e-8	Alzheimer's disease;
PAAD	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg15604389	chr3:122379662	NA	0.43	4.31	0.33	2.92e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6700559	0.679	rs7520407	chr1:200655728	C/T	cg07804481	chr1:200639085	DDX59	0.44	4.29	0.33	3.12e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.65	-0.42	7.62e-8	Lung cancer;
PAAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23641158	chr19:18043661	CCDC124	-0.63	-6.83	-0.48	1.88e-10	Smoking initiation;
PAAD	cis	rs7688540	0.511	rs4522818	chr4:181762	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg08648136	chr8:956695	NA	0.55	5.9	0.43	2.32e-8	Schizophrenia;
PAAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.95	-13.21	-0.73	5.26e-27	Height;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.76	8.8	0.58	2.88e-15	Lung cancer;
PAAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.25	0.45	3.97e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.73	6.77	0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg09366796	chr5:75012313	C5orf37	-0.49	-4.45	-0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg16898833	chr6:26189333	HIST1H4D	0.92	4.81	0.36	3.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg16584676	chr17:46985605	UBE2Z	0.52	5.2	0.39	6.27e-7	Type 2 diabetes;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.53	-5.65	-0.42	7.8e-8	Obesity-related traits;
PAAD	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	4.94	0.37	2.08e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg26950739	chr16:89183275	ACSF3	0.72	5.21	0.39	6.15e-7	Red blood cell count;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.98	-0.54	3.31e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.57	-6.41	-0.46	1.7e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg07514654	chr7:157258062	NA	-0.4	-4.45	-0.34	1.66e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4343996	0.934	rs10261250	chr7:3340187	C/G	cg21248987	chr7:3385318	SDK1	0.49	5.52	0.41	1.41e-7	Motion sickness;
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.87	-10.8	-0.66	1.54e-20	Body mass index;
PAAD	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs12935418	0.579	rs7197606	chr16:81053519	T/A	cg16651780	chr16:81037892	C16orf61	0.69	6.36	0.46	2.27e-9	Mean corpuscular volume;
PAAD	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06850241	chr22:41845214	NA	-0.52	-4.75	-0.36	4.74e-6	Vitiligo;
PAAD	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.47	5.02	0.38	1.44e-6	Type 1 diabetes;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.78	9.81	0.62	6.63e-18	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02120071	chr2:114737129	NA	0.57	6.71	0.48	3.63e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg03959625	chr15:84868606	LOC388152	0.52	5.73	0.42	5.12e-8	Schizophrenia;
PAAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg03289416	chr15:75166202	SCAMP2	0.59	6.09	0.44	8.64e-9	Breast cancer;
PAAD	cis	rs12936587	0.633	rs11869600	chr17:17504856	G/A	cg03427841	chr17:16610318	CCDC144A	-0.42	-4.33	-0.33	2.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs10916814	0.632	rs6691041	chr1:20898650	A/G	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.61	6.07	0.44	9.84e-9	Blood protein levels;
PAAD	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	5.26	0.39	4.83e-7	Parkinson's disease;
PAAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg03983715	chr16:68378420	PRMT7	-0.8	-5.82	-0.43	3.43e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs853679	0.567	rs7740429	chr6:28399246	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.67	-0.35	6.51e-6	Depression;
PAAD	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.37	0.56	3.42e-14	Corneal astigmatism;
PAAD	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	trans	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	trans	rs11212737	0.694	rs2624134	chr11:108513335	C/T	cg13462821	chr8:86214814	NA	-0.56	-6.39	-0.46	1.94e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg02297831	chr4:17616191	MED28	-0.63	-5.96	-0.44	1.66e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg09796270	chr17:17721594	SREBF1	-0.44	-4.74	-0.36	4.94e-6	Total body bone mineral density;
PAAD	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-5.0	-0.38	1.55e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4704187	0.687	rs6864324	chr5:74497885	C/T	cg03227963	chr5:74354835	NA	-0.49	-4.81	-0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.73	-0.36	5.12e-6	HDL cholesterol;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18845801	chr7:16793338	TSPAN13	-0.84	-7.48	-0.52	5.56e-12	Neuroticism;
PAAD	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.92	10.79	0.66	1.61e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.61	-0.41	9.44e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	5.8	0.43	3.74e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg05064044	chr6:292385	DUSP22	-0.78	-7.81	-0.54	8.86e-13	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7188861	0.813	rs34787601	chr16:11399538	T/A	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg25664220	chr3:72788482	NA	-0.68	-6.91	-0.49	1.26e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1190596	0.525	rs8013308	chr14:102733525	A/C	cg23904247	chr14:102554826	HSP90AA1	0.44	5.03	0.38	1.39e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.14	15.52	0.78	3.76e-33	Schizophrenia;
PAAD	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs967616	0.568	rs35821317	chr4:171964764	T/G	cg03413465	chr4:172734776	GALNTL6	0.36	4.56	0.35	1.04e-5	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.51	-0.34	1.28e-5	Mood instability;
PAAD	cis	rs863345	0.604	rs11265007	chr1:158498522	C/T	cg12129480	chr1:158549410	OR10X1	0.42	4.84	0.37	3.1e-6	Pneumococcal bacteremia;
PAAD	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.64	5.82	0.43	3.32e-8	Obesity-related traits;
PAAD	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.6	6.09	0.44	9.01e-9	Monocyte count;
PAAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.66	4.73	0.36	5.15e-6	Parkinson's disease;
PAAD	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	4.54	0.35	1.15e-5	Menarche (age at onset);
PAAD	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	5.96	0.44	1.69e-8	Mean platelet volume;
PAAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-5.32	-0.4	3.72e-7	IgG glycosylation;
PAAD	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg15253520	chr8:87521369	FAM82B	0.45	4.26	0.33	3.56e-5	Caudate activity during reward;
PAAD	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.91e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-1.12	-6.51	-0.47	1.01e-9	Inflammatory biomarkers;
PAAD	cis	rs863345	0.967	rs10908679	chr1:158506275	T/G	cg12129480	chr1:158549410	OR10X1	-0.47	-5.31	-0.4	3.81e-7	Pneumococcal bacteremia;
PAAD	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma (childhood onset);
PAAD	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg14593290	chr7:50529359	DDC	0.44	4.38	0.33	2.24e-5	Body mass index;
PAAD	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-9.82	-0.62	6.31e-18	Height;
PAAD	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.92	9.87	0.63	4.48e-18	Corneal astigmatism;
PAAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.55	5.67	0.42	7.14e-8	Facial morphology (factor 20);
PAAD	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.77	8.81	0.58	2.7e-15	Blood metabolite ratios;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs728616	0.717	rs12414332	chr10:81840955	C/T	cg05935833	chr10:81318306	SFTPA2	-0.58	-4.55	-0.35	1.09e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2133450	0.526	rs17047063	chr3:7343584	G/A	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg20003494	chr4:90757398	SNCA	-0.43	-4.96	-0.37	1.85e-6	Dementia with Lewy bodies;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23842205	chr11:66394024	RBM14	-0.61	-6.79	-0.48	2.38e-10	Monocyte percentage of white cells;
PAAD	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg00405596	chr8:11794950	NA	0.45	4.73	0.36	5.06e-6	Myopia (pathological);
PAAD	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg24737193	chr18:12778029	NA	0.63	5.32	0.4	3.62e-7	Inflammatory skin disease;
PAAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.56	-6.89	-0.49	1.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg00792783	chr2:198669748	PLCL1	-0.48	-4.42	-0.34	1.9e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.91	-10.37	-0.64	2.22e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.58	5.05	0.38	1.24e-6	Life satisfaction;
PAAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg23281280	chr6:28129359	ZNF389	0.51	4.59	0.35	9.3e-6	Parkinson's disease;
PAAD	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-6.25	-0.45	3.93e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs863345	0.564	rs12145401	chr1:158494693	A/G	cg12129480	chr1:158549410	OR10X1	-0.41	-4.66	-0.35	6.98e-6	Pneumococcal bacteremia;
PAAD	cis	rs12432203	1.000	rs61685874	chr14:51746018	A/G	cg23942311	chr14:51606299	NA	-0.75	-5.02	-0.38	1.45e-6	Cancer;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg01763666	chr17:80159506	CCDC57	0.46	4.55	0.35	1.1e-5	Life satisfaction;
PAAD	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.82	8.95	0.59	1.16e-15	Tuberculosis;
PAAD	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.77	8.81	0.58	2.7e-15	Blood metabolite ratios;
PAAD	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	ch.11.42038R	chr11:967971	AP2A2	0.62	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.48	-5.12	-0.38	9.08e-7	Menarche (age at onset);
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.73	-0.48	3.32e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.85	-9.4	-0.61	8.04e-17	Obesity-related traits;
PAAD	cis	rs2278796	1.000	rs58066240	chr1:204953727	C/T	cg17947172	chr1:204966197	NFASC	0.41	4.59	0.35	9.27e-6	Mean platelet volume;
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21862992	chr11:68658383	NA	0.42	4.6	0.35	8.68e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.41	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	cis	rs2299587	0.841	rs17514812	chr8:17880869	T/A	cg08627089	chr8:17753878	FGL1	-0.44	-4.37	-0.33	2.33e-5	Economic and political preferences;
PAAD	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.56	0.35	1.03e-5	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19587168	chr10:120925186	SFXN4	0.61	7.08	0.5	5.01e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26770187	chr3:14693171	C3orf19	0.62	6.61	0.47	6.04e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.77	7.35	0.51	1.12e-11	White blood cell types;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg23463467	chr20:60627584	TAF4	0.46	5.02	0.38	1.43e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25007939	chr1:6761657	DNAJC11	0.58	6.45	0.46	1.41e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs2479106	0.963	rs7850520	chr9:126509806	C/T	cg16191174	chr9:126692580	DENND1A	-0.48	-4.38	-0.33	2.17e-5	Polycystic ovary syndrome;
PAAD	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.84	10.1	0.63	1.14e-18	Methadone dose in opioid dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19140602	chr10:28233109	ARMC4	-0.62	-6.35	-0.46	2.41e-9	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16583279	chr13:25086642	PARP4	0.58	6.39	0.46	1.91e-9	Myopia (pathological);
PAAD	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.74	0.42	5.1e-8	Lung cancer in ever smokers;
PAAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.54	-7.69	-0.53	1.74e-12	Schizophrenia;
PAAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.92	10.05	0.63	1.57e-18	Parkinson's disease;
PAAD	cis	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-5.5	-0.41	1.59e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg07617317	chr6:118971624	C6orf204	0.56	4.67	0.35	6.44e-6	Diastolic blood pressure;
PAAD	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.51	-5.95	-0.43	1.74e-8	Mean arterial pressure;
PAAD	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg00207534	chr16:71929512	KIAA0174	0.76	4.72	0.36	5.27e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg10223061	chr2:219282414	VIL1	-0.37	-4.47	-0.34	1.52e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.94	-0.37	2e-6	Neuroticism;
PAAD	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs10929159	0.894	rs1349729	chr2:236928217	A/G	cg14226755	chr2:236923322	AGAP1	0.29	4.58	0.35	9.66e-6	Parkinson's disease;
PAAD	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs10242455	0.702	rs6956305	chr7:99241310	A/G	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2051773	0.567	rs11024113	chr11:17042444	G/A	cg15432903	chr11:17409602	KCNJ11	-0.53	-4.77	-0.36	4.34e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg04497992	chr16:616212	NHLRC4	0.37	4.35	0.33	2.53e-5	Height;
PAAD	cis	rs7766436	0.885	rs13209127	chr6:22597625	A/G	cg13666174	chr6:22585274	NA	0.54	5.05	0.38	1.24e-6	Coronary artery disease;
PAAD	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg23283495	chr1:209979779	IRF6	0.64	6.19	0.45	5.46e-9	Coronary artery disease;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.39	-4.28	-0.33	3.34e-5	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs11696501	0.792	rs2235584	chr20:44172436	C/T	cg11783356	chr20:44313418	WFDC10B	-0.54	-5.55	-0.41	1.23e-7	Brain structure;
PAAD	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	6.09	0.44	8.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.51	5.52	0.41	1.42e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.64	-4.48	-0.34	1.49e-5	LDL cholesterol levels;
PAAD	trans	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.33	-0.46	2.61e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.73	-0.58	4.23e-15	Total body bone mineral density;
PAAD	cis	rs7593730	0.636	rs1020731	chr2:161144055	A/G	cg22609984	chr2:161126801	NA	-0.52	-4.32	-0.33	2.86e-5	Type 2 diabetes;
PAAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	6.69	0.48	3.99e-10	Neuroticism;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.67	0.48	4.56e-10	Alzheimer's disease;
PAAD	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg10518543	chr12:38710700	ALG10B	0.51	4.91	0.37	2.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.81	6.88	0.49	1.5e-10	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22269913	chr19:49956353	PIH1D1;ALDH16A1	0.61	6.67	0.48	4.48e-10	Monocyte percentage of white cells;
PAAD	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	7.92	0.54	4.6e-13	Lymphocyte counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09698166	chr20:21106763	PLK1S1	0.61	6.7	0.48	3.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.71	6.49	0.47	1.13e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg10370574	chr19:1840461	REXO1	-0.5	-4.64	-0.35	7.32e-6	Bipolar disorder;
PAAD	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.8	7.65	0.53	2.12e-12	Neuroticism;
PAAD	cis	rs10242455	0.702	rs6977165	chr7:99269397	T/C	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.68	-6.99	-0.49	7.92e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg05250797	chr16:70222502	NA	-0.52	-4.41	-0.34	1.95e-5	Sjögren's syndrome;
PAAD	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.85	-0.62	5.37e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.74	-8.3	-0.56	5.17e-14	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2286379	0.626	rs10848557	chr12:1827810	G/T	cg11558135	chr12:861715	WNK1	-0.45	-4.41	-0.34	1.96e-5	Blood pressure (smoking interaction);
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.56	-7.12	-0.5	4e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.78	-5.52	-0.41	1.4e-7	Coronary artery calcification;
PAAD	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg01631408	chr1:248437212	OR2T33	-0.57	-5.48	-0.41	1.72e-7	Common traits (Other);
PAAD	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.41	-0.34	1.96e-5	Reticulocyte count;
PAAD	cis	rs971768	0.892	rs974396	chr22:17599170	A/G	cg24435209	chr22:17640972	CECR5;CECR4	-0.56	-4.39	-0.34	2.08e-5	Heschl's gyrus morphology;
PAAD	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg08079166	chr15:68083412	MAP2K5	0.53	5.04	0.38	1.31e-6	Restless legs syndrome;
PAAD	cis	rs9900972	0.721	rs11656224	chr17:76867996	A/G	cg20937029	chr17:76870563	TIMP2	0.53	4.75	0.36	4.67e-6	Obesity-related traits;
PAAD	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg21823605	chr1:152486609	CRCT1	0.48	6.05	0.44	1.07e-8	Hair morphology;
PAAD	cis	rs11651753	0.636	rs12602494	chr17:46037607	G/A	cg24458315	chr17:46148407	CBX1	0.42	4.46	0.34	1.6e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg20913747	chr6:44695427	NA	-0.66	-6.71	-0.48	3.69e-10	Total body bone mineral density;
PAAD	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.96e-6	Cognitive ability;
PAAD	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg00647403	chr16:23521932	GGA2	-0.71	-7.37	-0.51	9.95e-12	Dental caries;
PAAD	cis	rs988913	0.723	rs7761568	chr6:55005426	C/A	cg03513858	chr6:54763001	FAM83B	0.4	4.34	0.33	2.61e-5	Menarche (age at onset);
PAAD	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18482256	chr19:38865041	PSMD8	-0.64	-7.79	-0.53	9.93e-13	Body fat percentage;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09584658	chr16:85589984	NA	-0.58	-6.6	-0.47	6.56e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg14393609	chr7:65229607	NA	0.43	4.47	0.34	1.5e-5	Aortic root size;
PAAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg13468214	chr4:1046988	NA	-0.54	-5.15	-0.39	8.06e-7	Recombination rate (females);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14077301	chr14:58766370	ARID4A	-0.61	-7.17	-0.5	3.09e-11	Body fat percentage;
PAAD	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg14191688	chr11:70257035	CTTN	0.57	5.19	0.39	6.63e-7	Coronary artery disease;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg21226059	chr5:178986404	RUFY1	0.51	5.59	0.41	1.01e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.62e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.72	-0.36	5.22e-6	Menarche (age at onset);
PAAD	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.46	-4.43	-0.34	1.76e-5	Type 2 diabetes;
PAAD	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	7.41	0.52	8.15e-12	Monocyte percentage of white cells;
PAAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.72	9.22	0.6	2.3e-16	Coronary artery disease;
PAAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-1.07	-8.94	-0.59	1.24e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.51	-4.49	-0.34	1.42e-5	Parkinson's disease;
PAAD	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.16	16.63	0.8	4.95e-36	Body mass index;
PAAD	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg08732750	chr1:87598351	LOC339524	0.29	4.53	0.35	1.16e-5	Smoking behavior;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.85	6.4	0.46	1.86e-9	Alzheimer's disease;
PAAD	cis	rs9652601	0.691	rs12922303	chr16:11193465	A/T	cg04616529	chr16:11181986	CLEC16A	0.36	4.41	0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.76	-9.07	-0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13319406	0.546	rs16865077	chr3:189830554	C/T	cg03343083	chr3:189718843	LEPREL1	-0.85	-5.29	-0.39	4.2e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4668356	1.000	rs4668356	chr2:171822466	C/T	cg13882835	chr2:172017928	TLK1	-0.9	-4.52	-0.34	1.24e-5	Cognitive performance;
PAAD	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.22	-0.39	5.88e-7	Monocyte count;
PAAD	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs73019876	0.901	rs2097733	chr19:22130311	C/T	cg11619707	chr19:22235551	ZNF257	0.41	4.34	0.33	2.54e-5	Testicular germ cell tumor;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg07982082	chr11:65414261	SIPA1	-0.47	-4.26	-0.33	3.59e-5	Blood pressure (age interaction);
PAAD	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.6	5.98	0.44	1.51e-8	Monocyte count;
PAAD	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.49	5.69	0.42	6.49e-8	Tuberculosis;
PAAD	cis	rs728616	0.681	rs36073865	chr10:81916055	C/T	cg11900509	chr10:81946545	ANXA11	-0.62	-4.31	-0.33	2.9e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.62	5.66	0.42	7.25e-8	Mean corpuscular volume;
PAAD	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.8	5.79	0.43	3.84e-8	Vitiligo;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.56	-0.35	1.03e-5	Lung cancer;
PAAD	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.94	-9.32	-0.6	1.26e-16	Obesity-related traits;
PAAD	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07739727	chr11:85339663	TMEM126B;DLG2	-0.67	-6.36	-0.46	2.19e-9	Neuroticism;
PAAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.87	-0.54	6.01e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg01631408	chr1:248437212	OR2T33	0.58	5.21	0.39	5.97e-7	Common traits (Other);
PAAD	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	10.03	0.63	1.71e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg22467129	chr15:76604101	ETFA	0.54	4.84	0.37	3.17e-6	Blood metabolite levels;
PAAD	cis	rs6674176	0.551	rs72683973	chr1:44453025	C/T	cg12908607	chr1:44402522	ARTN	0.76	4.43	0.34	1.82e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13006259	chr12:56546315	MYL6B	-0.64	-6.5	-0.47	1.06e-9	Smoking initiation;
PAAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg05110241	chr16:68378359	PRMT7	-1.11	-8.12	-0.55	1.47e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.78e-6	Type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10215766	chr19:19612808	GATAD2A	-0.72	-6.39	-0.46	1.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.89	7.0	0.49	7.69e-11	Tuberculosis;
PAAD	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.47	-0.34	1.54e-5	Post bronchodilator FEV1;
PAAD	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.71	7.98	0.54	3.21e-13	Colorectal cancer;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02339418	chr12:123717776	C12orf65	0.7	7.24	0.51	2.11e-11	Obesity-related traits;
PAAD	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.96	-10.13	-0.63	9.44e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.72	-0.42	5.39e-8	Blood metabolite levels;
PAAD	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.88	-8.5	-0.57	1.61e-14	Body mass index;
PAAD	cis	rs12096438	1.000	rs7491	chr1:25895238	C/T	cg06359931	chr1:25893405	LDLRAP1	0.36	4.27	0.33	3.49e-5	Platelet count;Mean platelet volume;
PAAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.84	7.38	0.51	9.83e-12	IgG glycosylation;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.37	-5.41	-0.4	2.35e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.54	-6.42	-0.46	1.67e-9	Body mass index;
PAAD	cis	rs4787491	0.704	rs12445768	chr16:30089911	T/C	cg06015834	chr16:30021696	DOC2A	-0.44	-4.47	-0.34	1.5e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.65	6.9	0.49	1.3100000000000001e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26418147	chr1:205743515	RAB7L1	-0.46	-5.17	-0.39	7.4e-7	Prostate-specific antigen levels;
PAAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-5.11	-0.38	9.6e-7	Mood instability;
PAAD	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg18279126	chr7:2041391	MAD1L1	0.62	6.17	0.45	6.02e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	5.66	0.42	7.34e-8	Schizophrenia;
PAAD	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.97	10.45	0.65	1.3e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.11	0.38	9.52e-7	Lung cancer in ever smokers;
PAAD	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.3e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.41	0.46	1.71e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg14092988	chr3:52407081	DNAH1	0.41	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-7.06	-0.5	5.62e-11	Parkinson's disease;
PAAD	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.25	-0.39	5.08e-7	Schizophrenia;
PAAD	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.56	2.93e-14	Morning vs. evening chronotype;
PAAD	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.81	6.8	0.48	2.3e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-4.3	-0.33	3.04e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg07559730	chr19:53497048	ZNF702P	-0.51	-5.58	-0.41	1.07e-7	Psoriasis;
PAAD	cis	rs7715811	1.000	rs1502041	chr5:13758529	A/G	cg07548982	chr5:13769939	DNAH5	-0.64	-6.22	-0.45	4.51e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.45	-5.69	-0.42	6.39e-8	Lewy body disease;
PAAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg09835421	chr16:68378352	PRMT7	-0.95	-7.55	-0.52	3.79e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-4.8	-0.36	3.84e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.56	-5.41	-0.4	2.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.74	4.7	0.36	5.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.75	-6.61	-0.47	6.07e-10	Body mass index;
PAAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg01489256	chr8:11204017	TDH	-0.45	-4.39	-0.34	2.12e-5	Retinal vascular caliber;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg17633681	chr16:88106987	BANP	0.53	6.64	0.47	5.2e-10	Menopause (age at onset);
PAAD	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.33	0.33	2.74e-5	Iron status biomarkers;
PAAD	cis	rs16958440	0.541	rs11876448	chr18:44644530	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-5.04	-0.38	1.33e-6	Sitting height ratio;
PAAD	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg07154921	chr7:157260426	NA	0.45	4.35	0.33	2.49e-5	Body mass index;
PAAD	cis	rs600626	0.891	rs695110	chr11:75456581	T/C	cg24262691	chr11:75473276	NA	0.51	4.89	0.37	2.57e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg19486271	chr11:47235900	DDB2	0.52	5.34	0.4	3.28e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.62	6.35	0.46	2.33e-9	Testicular germ cell tumor;
PAAD	cis	rs3753841	0.832	rs10874661	chr1:103328929	G/T	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.33e-6	Glaucoma (primary angle closure);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25767859	chr7:47859324	PKD1L1;C7orf69	0.68	7.5	0.52	4.85e-12	Smoking initiation;
PAAD	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.6	-0.41	9.96e-8	Triglycerides;
PAAD	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-5.7	-0.42	5.92e-8	Prostate cancer;
PAAD	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-1.0	-8.61	-0.57	8.86e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7082209	1.000	rs4491167	chr10:44810820	T/A	cg13191911	chr10:44806660	NA	-0.93	-5.39	-0.4	2.7e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs6604026	0.656	rs7417198	chr1:93391445	T/C	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.5	-5.33	-0.4	3.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.72	7.7	0.53	1.58e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs755249	0.567	rs16826069	chr1:39797055	A/G	cg14018543	chr1:39659967	MACF1	-0.53	-4.39	-0.34	2.11e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10849004	1.000	rs11063022	chr12:4296517	T/C	cg03803796	chr12:3575061	NA	0.52	4.35	0.33	2.46e-5	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.78	-0.36	4.09e-6	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19526908	chr3:49058333	NDUFAF3;DALRD3;MIR425;MIR191	0.71	6.93	0.49	1.11e-10	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21739009	chr19:1591627	MBD3	0.64	7.26	0.51	1.84e-11	Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.32	-0.33	2.85e-5	Iron status biomarkers;
PAAD	cis	rs11807834	0.522	rs12083455	chr1:230253034	C/T	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.47	4.25	0.33	3.66e-5	Arsenic metabolism;
PAAD	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.54	5.62	0.41	8.92e-8	Subjective well-being;
PAAD	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg21775007	chr8:11205619	TDH	0.46	4.41	0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs7487075	0.647	rs4077708	chr12:46857373	A/G	cg14671384	chr12:47219920	SLC38A4	0.45	4.47	0.34	1.55e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.29	4.27	0.33	3.4e-5	Alopecia areata;
PAAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg00750074	chr16:89608354	SPG7	-0.59	-5.55	-0.41	1.23e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	4.48	0.34	1.48e-5	Height;
PAAD	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.61	6.99	0.49	8.1e-11	High light scatter reticulocyte count;
PAAD	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.61	5.99	0.44	1.47e-8	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05069728	chr7:116869944	ST7	0.61	6.29	0.45	3.14e-9	Lung cancer in ever smokers;
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.48	-0.61	4.83e-17	Tonsillectomy;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.48	-0.47	1.21e-9	Bipolar disorder;
PAAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg09491104	chr22:46646882	C22orf40	-0.71	-4.27	-0.33	3.47e-5	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11442185	chr12:56693681	CS	-0.64	-7.2	-0.5	2.6e-11	Immature fraction of reticulocytes;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg19930314	chr7:98593876	TRRAP	-0.5	-4.67	-0.35	6.58e-6	Breast cancer;
PAAD	cis	rs13242816	1.000	rs56063232	chr7:116172808	G/T	cg16553024	chr7:116138462	CAV2	-0.61	-4.29	-0.33	3.18e-5	P wave duration;
PAAD	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.81	5.38	0.4	2.7e-7	Diabetic kidney disease;
PAAD	trans	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg20641545	chr12:89984390	ATP2B1	-0.55	-6.71	-0.48	3.55e-10	Cancer;
PAAD	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	trans	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg19862616	chr7:65841803	NCRNA00174	0.91	9.49	0.61	4.6e-17	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs185694	0.947	rs169331	chr13:30878695	G/T	cg07600127	chr13:30881527	KATNAL1	-0.7	-4.48	-0.34	1.43e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs11811982	0.793	rs114536396	chr1:227536087	C/G	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.31	-0.4	3.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg14092988	chr3:52407081	DNAH1	-0.4	-5.02	-0.38	1.44e-6	Electroencephalogram traits;
PAAD	cis	rs2882667	0.690	rs10071381	chr5:138272848	C/T	cg09476006	chr5:138032270	NA	0.46	5.87	0.43	2.63e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-4.81	-0.36	3.61e-6	Menarche (age at onset);
PAAD	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.57	5.8	0.43	3.72e-8	Testicular germ cell tumor;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25872816	chr18:74168914	ZNF516	-0.41	-4.4	-0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26718354	chr11:2907071	CDKN1C	-0.64	-6.58	-0.47	7.13e-10	Smoking initiation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00819114	chr17:74733447	MIR636;SFRS2;MFSD11	-0.66	-6.87	-0.49	1.57e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg23649088	chr2:200775458	C2orf69	-0.71	-5.84	-0.43	3.04e-8	Schizophrenia;
PAAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16262614	chr3:133464971	TF	0.46	5.07	0.38	1.16e-6	Iron status biomarkers;
PAAD	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-4.6	-0.35	8.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4144027	1.000	rs4144027	chr14:104357638	T/C	cg19582115	chr14:103436037	CDC42BPB	-0.47	-4.48	-0.34	1.48e-5	Blood metabolite levels;
PAAD	cis	rs6782228	0.606	rs6787559	chr3:128381086	T/C	cg16766828	chr3:128327626	NA	-0.47	-6.31	-0.46	2.95e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.69	-6.35	-0.46	2.4e-9	Mean platelet volume;
PAAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg10356904	chr22:49881777	NA	-0.46	-4.59	-0.35	9.36e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1018697	1.000	rs7896903	chr10:104566417	A/G	cg04362960	chr10:104952993	NT5C2	0.58	5.99	0.44	1.45e-8	Colorectal adenoma (advanced);
PAAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.49	6.17	0.45	5.85e-9	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg10518543	chr12:38710700	ALG10B	-0.47	-4.31	-0.33	2.97e-5	Morning vs. evening chronotype;
PAAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg05697835	chr1:2722811	NA	-0.42	-4.75	-0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs3779195	0.585	rs73709460	chr7:97895254	C/T	cg24562669	chr7:97807699	LMTK2	-0.54	-4.43	-0.34	1.8e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.48	-0.47	1.22e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04045327	chr4:905805	GAK	0.33	4.33	0.33	2.75e-5	Systemic sclerosis;
PAAD	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.66	7.56	0.52	3.52e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs300774	1.000	rs300692	chr2:181415	C/T	cg21211680	chr2:198530	NA	-0.66	-5.92	-0.43	2.04e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg19052272	chr2:3704530	ALLC	-0.45	-5.36	-0.4	3.01e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.49	-5.27	-0.39	4.67e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg21211680	chr2:198530	NA	0.49	5.41	0.4	2.44e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.75	8.36	0.56	3.75e-14	Type 2 diabetes;
PAAD	cis	rs6988985	0.678	rs28491316	chr8:143992661	C/T	cg10324643	chr8:143916377	GML	0.41	4.7	0.36	5.78e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	trans	rs61931739	0.620	rs708141	chr12:33719664	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg05697835	chr1:2722811	NA	0.42	4.75	0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg05110241	chr16:68378359	PRMT7	-0.73	-5.7	-0.42	5.93e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-5.89	-0.43	2.38e-8	Menopause (age at onset);
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg15212455	chr7:39170539	POU6F2	0.43	6.0	0.44	1.37e-8	IgG glycosylation;
PAAD	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg23093090	chr10:104574429	C10orf26	-0.42	-4.52	-0.34	1.22e-5	Arsenic metabolism;
PAAD	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.96	6.27	0.45	3.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg02344993	chr17:57696989	CLTC	0.6	4.96	0.37	1.9e-6	Hemoglobin concentration;
PAAD	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs354033	1.000	rs354034	chr7:149290497	G/A	cg06920324	chr7:149264011	ZNF767	-0.61	-5.08	-0.38	1.08e-6	Multiple sclerosis;
PAAD	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.93	-7.66	-0.53	2.06e-12	Alopecia areata;
PAAD	cis	rs7009110	0.706	rs6991991	chr8:81271432	T/C	cg21158561	chr8:81178149	NA	0.44	4.78	0.36	4.18e-6	Asthma and hay fever;
PAAD	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.75	-5.16	-0.39	7.78e-7	Vitiligo;
PAAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Aortic root size;
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg14779329	chr11:130786720	SNX19	-0.47	-4.63	-0.35	7.65e-6	Schizophrenia;
PAAD	cis	rs10214930	0.697	rs1524532	chr7:27625686	G/T	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.48	6.05	0.44	1.05e-8	Crohn's disease;
PAAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs12550646	0.625	rs1549064	chr8:41684488	A/C	cg19997384	chr8:41685595	ANK1	-0.32	-4.67	-0.35	6.58e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.84	-0.43	3.11e-8	Retinal vascular caliber;
PAAD	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	1.03	7.46	0.52	6.06e-12	Dental caries;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.92	-10.92	-0.66	7.58e-21	Menarche (age at onset);
PAAD	cis	rs4073221	0.929	rs35846759	chr3:18282821	A/G	cg07694806	chr3:18168406	NA	-0.77	-5.02	-0.38	1.44e-6	Parkinson's disease;
PAAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg10547527	chr2:198650123	BOLL	-0.71	-4.8	-0.36	3.72e-6	Ulcerative colitis;
PAAD	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.65	-0.47	4.95e-10	Total body bone mineral density;
PAAD	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.73	6.53	0.47	9.21e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.57	6.51	0.47	1.05e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs600626	0.529	rs57188913	chr11:75473294	T/C	cg24262691	chr11:75473276	NA	0.75	6.18	0.45	5.65e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.8	0.48	2.25e-10	Coffee consumption (cups per day);
PAAD	cis	rs9810890	1.000	rs73210606	chr3:128617426	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.47	-0.34	1.55e-5	Dental caries;
PAAD	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.54	-4.79	-0.36	3.89e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg07777115	chr5:623756	CEP72	-0.67	-4.28	-0.33	3.27e-5	Obesity-related traits;
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.69	7.61	0.53	2.7e-12	Schizophrenia;
PAAD	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg20933634	chr6:27740509	NA	0.63	4.74	0.36	4.87e-6	Parkinson's disease;
PAAD	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.07	-0.38	1.14e-6	Pulmonary function;
PAAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.63	-6.0	-0.44	1.4e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg27170260	chr1:38156575	C1orf109	-0.45	-4.29	-0.33	3.21e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg14008862	chr17:28927542	LRRC37B2	0.73	5.13	0.38	8.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.83	6.99	0.49	8.18e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs364477	0.547	rs438294	chr9:979611	A/T	cg13952963	chr9:998547	NA	0.57	4.72	0.36	5.33e-6	Major depressive disorder;
PAAD	cis	rs8014252	0.803	rs12586441	chr14:70988062	T/C	cg11204974	chr14:71022665	NA	-0.76	-4.79	-0.36	3.95e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.06	-0.38	1.21e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16417436	chr16:28758564	NA	0.45	4.3	0.33	3.06e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg25686905	chr3:183603175	PARL	-0.32	-4.33	-0.33	2.68e-5	Menopause (age at onset);
PAAD	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04240589	chr12:50017272	PRPF40B	0.61	6.56	0.47	7.93e-10	Myopia (pathological);
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.3	-0.33	3e-5	Lung cancer;
PAAD	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17712928	chr7:2124974	MAD1L1	0.57	6.44	0.46	1.46e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg00999904	chr2:3704751	ALLC	-0.81	-8.13	-0.55	1.39e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12648482	chr13:52768676	THSD1P	0.58	6.39	0.46	1.91e-9	Monocyte percentage of white cells;
PAAD	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg00262122	chr8:11665843	FDFT1	-0.48	-4.42	-0.34	1.88e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs9810890	1.000	rs116142295	chr3:128447372	G/C	cg15676455	chr3:128564943	NA	-0.81	-4.78	-0.36	4.09e-6	Dental caries;
PAAD	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	1e-10	Axial length;
PAAD	cis	rs2404602	0.669	rs12911987	chr15:76953256	C/T	cg05895507	chr15:77155635	SCAPER	0.4	4.62	0.35	8.12e-6	Blood metabolite levels;
PAAD	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.74	7.67	0.53	1.94e-12	Mean corpuscular volume;
PAAD	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs2637266	0.600	rs2395430	chr10:78465471	G/A	cg18941641	chr10:78392320	NA	0.36	4.36	0.33	2.38e-5	Pulmonary function;
PAAD	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-1.21	-6.08	-0.44	9.3e-9	Adiponectin levels;
PAAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.48	5.68	0.42	6.57e-8	Psoriasis;
PAAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9876781	1.000	rs6804774	chr3:48430617	G/C	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.21	-0.39	5.98e-7	Longevity;Endometriosis;
PAAD	cis	rs900145	0.906	rs10832014	chr11:13295415	T/A	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.71	7.95	0.54	3.98e-13	Corneal astigmatism;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg19673125	chr6:150240577	RAET1G	0.43	6.08	0.44	9.23e-9	Testicular germ cell tumor;
PAAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg24562669	chr7:97807699	LMTK2	0.68	10.26	0.64	4.35e-19	Breast cancer;
PAAD	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.43	4.27	0.33	3.41e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg00599163	chr2:162100495	NA	0.36	4.34	0.33	2.63e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25036197	chr15:72876508	ARIH1	0.61	6.35	0.46	2.32e-9	Smoking initiation;
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.7	8.2	0.55	9.2e-14	Height;
PAAD	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg24555670	chr8:18244502	NA	0.58	5.4	0.4	2.53e-7	Total cholesterol levels;
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg10407489	chr4:1043616	NA	0.33	4.77	0.36	4.27e-6	Recombination rate (males);
PAAD	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg03115019	chr17:80708279	FN3K	-0.52	-4.72	-0.36	5.41e-6	Glycated hemoglobin levels;
PAAD	cis	rs7567389	0.710	rs72848618	chr2:128135325	A/C	cg11380483	chr2:127933992	NA	0.45	4.45	0.34	1.63e-5	Self-rated health;
PAAD	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg09659197	chr4:152720779	NA	0.36	5.28	0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg06637938	chr14:75390232	RPS6KL1	0.53	5.35	0.4	3.12e-7	Height;
PAAD	cis	rs6066835	0.764	rs3091617	chr20:47386290	G/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.57	-4.8	-0.36	3.72e-6	Iron status biomarkers;
PAAD	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.51	5.43	0.4	2.21e-7	Male-pattern baldness;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02984193	chr15:91260561	BLM	0.57	6.59	0.47	6.65e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1014246	0.826	rs1900509	chr10:118470942	T/C	cg14471191	chr10:117818509	GFRA1	0.38	4.34	0.33	2.54e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08833546	chr7:66461892	TYW1;SBDS	0.6	6.36	0.46	2.24e-9	Myopia (pathological);
PAAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.63	6.49	0.47	1.14e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9928842	0.722	rs4888362	chr16:75268245	T/C	cg09066997	chr16:75300724	BCAR1	0.59	4.25	0.33	3.64e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg26897989	chr16:1907736	C16orf73	-0.45	-4.63	-0.35	7.95e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08808811	chr3:184079573	CLCN2	0.72	8.06	0.55	2.12e-13	Myopia (pathological);
PAAD	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.81	-9.39	-0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg24253500	chr15:84953950	NA	0.58	6.72	0.48	3.39e-10	Schizophrenia;
PAAD	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-5.54	-0.41	1.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.88	-6.06	-0.44	1.01e-8	Post bronchodilator FEV1;
PAAD	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.52	0.34	1.24e-5	Colorectal cancer;
PAAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.97	10.22	0.64	5.32e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg22437258	chr11:111473054	SIK2	0.61	6.02	0.44	1.28e-8	Primary sclerosing cholangitis;
PAAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09695851	chr17:3907499	NA	-0.66	-6.82	-0.48	1.99e-10	Type 2 diabetes;
PAAD	cis	rs818427	0.593	rs368575	chr5:112204896	G/T	cg06941702	chr5:112196734	SRP19	-0.53	-5.21	-0.39	6.05e-7	Total body bone mineral density;
PAAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg06346307	chr22:19949965	COMT	-0.31	-4.78	-0.36	4.09e-6	Blood metabolite levels;
PAAD	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.92	-12.38	-0.71	8.84e-25	Ulcerative colitis;
PAAD	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.66	-0.77	6.93e-31	Height;
PAAD	cis	rs75920871	1.000	rs11216221	chr11:116868137	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02815900	chr16:30960301	ORAI3	-0.67	-7.23	-0.51	2.19e-11	Smoking initiation;
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.56	-5.12	-0.38	9.22e-7	Total body bone mineral density;
PAAD	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.65	6.94	0.49	1.05e-10	Type 2 diabetes;
PAAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.58	6.13	0.45	7.18e-9	Huntington's disease progression;
PAAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	1.13	11.82	0.69	2.78e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs7607369	0.748	rs662250	chr2:219374117	T/A	cg10223061	chr2:219282414	VIL1	-0.37	-4.39	-0.34	2.11e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.66	5.0	0.38	1.54e-6	Hip geometry;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.0	0.63	2.11e-18	Prudent dietary pattern;
PAAD	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.72	7.62	0.53	2.48e-12	Triglyceride levels;
PAAD	cis	rs12476592	0.530	rs6708611	chr2:64168232	C/T	cg20249169	chr2:64881356	SERTAD2	-0.54	-4.31	-0.33	2.91e-5	Childhood ear infection;
PAAD	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.63	-7.31	-0.51	1.45e-11	Endometriosis;
PAAD	cis	rs2137920	0.685	rs12767010	chr10:50236480	C/A	cg02657375	chr10:50863136	CHAT	0.54	4.39	0.34	2.15e-5	Migraine with aura;
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.9	9.72	0.62	1.13e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg10438391	chr8:144631915	NA	-0.29	-4.43	-0.34	1.82e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.67	-7.92	-0.54	4.67e-13	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs10490913	1.000	rs7916161	chr10:120145648	A/G	cg04126427	chr10:120840676	EIF3A	0.49	5.13	0.38	8.62e-7	Cancer;
PAAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.65	-4.88	-0.37	2.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.55	-0.41	1.27e-7	Coronary artery disease;
PAAD	cis	rs9463078	0.617	rs1359336	chr6:45071874	T/A	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.94	-0.43	1.87e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.73	6.86	0.49	1.66e-10	Total body bone mineral density;
PAAD	cis	rs2885056	0.830	rs10409805	chr19:10691445	A/C	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.58	-8.24	-0.56	7.59e-14	Thyroid hormone levels;
PAAD	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg11232448	chr19:2858854	NA	-0.46	-4.49	-0.34	1.38e-5	Total cholesterol levels;
PAAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg14709524	chr16:89940631	TCF25	0.93	4.89	0.37	2.58e-6	Skin colour saturation;
PAAD	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.37	-4.69	-0.36	5.99e-6	Plateletcrit;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg08994789	chr17:28903642	LRRC37B2	0.65	5.13	0.38	8.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs17123764	0.710	rs7137976	chr12:50099067	A/G	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg03781084	chr7:26191726	NFE2L3	0.49	4.5	0.34	1.32e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg00262122	chr8:11665843	FDFT1	-0.57	-5.16	-0.39	7.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.6	6.44	0.46	1.47e-9	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.54e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.13	-0.45	7.37e-9	Lung cancer;
PAAD	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg12549451	chr6:135224345	NA	0.48	4.92	0.37	2.19e-6	Red blood cell count;
PAAD	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg03658251	chr13:50265850	EBPL	0.76	5.59	0.41	1.05e-7	Obesity-related traits;
PAAD	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.5	-0.34	1.35e-5	Body mass index;
PAAD	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-9.11	-0.59	4.61e-16	Gut microbiome composition (summer);
PAAD	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg14248031	chr19:58907397	NA	0.39	4.37	0.33	2.33e-5	Uric acid clearance;
PAAD	cis	rs2492906	0.600	rs2815488	chr10:28061237	C/G	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27511599	chr7:32358540	NA	-0.78	-4.68	-0.36	6.24e-6	Body mass index;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg27490568	chr2:178487706	NA	0.44	4.91	0.37	2.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19578388	chr18:71815073	FBXO15;C18orf55	0.6	6.42	0.46	1.62e-9	Obesity-related traits;
PAAD	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.93	-9.23	-0.6	2.16e-16	Corneal astigmatism;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.9	-0.49	1.35e-10	Lung cancer;
PAAD	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.65	-6.49	-0.47	1.17e-9	Bipolar disorder;
PAAD	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08219700	chr8:58056026	NA	0.82	5.38	0.4	2.74e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00097177	chr10:99609865	GOLGA7B	0.7	7.6	0.52	2.91e-12	Myopia (pathological);
PAAD	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg04809136	chr2:24300158	SF3B14	-0.4	-4.75	-0.36	4.69e-6	Quantitative traits;
PAAD	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs854572	0.509	rs12534274	chr7:95057510	G/A	cg01874867	chr7:94954059	PON1	-0.51	-4.33	-0.33	2.65e-5	Paraoxonase activity;
PAAD	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.54	0.41	1.27e-7	Myopia (pathological);
PAAD	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg27490568	chr2:178487706	NA	0.43	4.8	0.36	3.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1883415	0.534	rs2817208	chr6:24481373	T/A	cg20631270	chr6:24437470	GPLD1	0.45	4.35	0.33	2.44e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-7.31	-0.51	1.45e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12144094	0.882	rs1853048	chr1:120240114	C/A	cg20995928	chr1:120229863	NA	0.51	4.62	0.35	8.21e-6	Height;
PAAD	cis	rs1359582	0.736	rs1980813	chr10:90354888	A/T	cg15661332	chr10:90342814	RNLS	-0.56	-5.05	-0.38	1.27e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.62	-5.07	-0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs300774	0.858	rs444497	chr2:123332	C/G	cg23649280	chr2:140451	NA	-0.47	-4.33	-0.33	2.74e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.68	-7.37	-0.51	9.99e-12	Mean platelet volume;
PAAD	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.82	-0.43	3.37e-8	Schizophrenia;
PAAD	cis	rs35160687	0.644	rs11127024	chr2:86505453	C/T	cg10973622	chr2:86423274	IMMT	-0.47	-5.33	-0.4	3.5e-7	Night sleep phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19844840	chr11:71497552	FAM86C	-0.75	-7.23	-0.51	2.25e-11	Neuroticism;
PAAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg19680485	chr15:31195859	MTMR15	-0.45	-4.65	-0.35	7.23e-6	Huntington's disease progression;
PAAD	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.51	5.52	0.41	1.45e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	1.07	8.44	0.57	2.26e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg00522288	chr12:125625016	AACS	-0.56	-6.25	-0.45	4.01e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.67	5.37	0.4	2.85e-7	Obesity (extreme);
PAAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.99	7.46	0.52	6.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23897733	chr8:21924153	EPB49	0.64	6.77	0.48	2.65e-10	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26321464	chr19:7968588	MAP2K7	0.66	6.82	0.48	1.98e-10	Obesity-related traits;
PAAD	cis	rs3760982	0.776	rs56103707	chr19:44304188	G/A	cg12072164	chr19:44306565	LYPD5	-0.47	-4.78	-0.36	4.01e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.92	0.59	1.41e-15	Menopause (age at onset);
PAAD	cis	rs2885056	0.891	rs116449616	chr19:10689023	C/T	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.69	7.63	0.53	2.42e-12	Cognitive function;
PAAD	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg01759136	chr6:27242945	NA	0.43	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	5.37	0.4	2.9e-7	Blood protein levels;
PAAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg06792262	chr3:44622596	ZNF167	0.4	4.3	0.33	3.07e-5	Depressive symptoms;
PAAD	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9302065	0.636	rs2389235	chr13:95955623	G/T	cg26751094	chr13:95954534	ABCC4	-0.39	-4.61	-0.35	8.35e-6	Blood metabolite levels;
PAAD	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.66	0.48	4.69e-10	Height;
PAAD	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.91	-8.47	-0.57	1.91e-14	Asthma;
PAAD	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.74	-8.46	-0.57	2.11e-14	Handedness;
PAAD	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg00717180	chr2:96193071	NA	0.6	6.7	0.48	3.76e-10	HDL cholesterol;
PAAD	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg15956490	chr3:53032818	SFMBT1	0.82	4.81	0.36	3.58e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg21191810	chr6:118973309	C6orf204	0.49	6.29	0.45	3.21e-9	Electrocardiographic conduction measures;
PAAD	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg02404636	chr22:31891804	SFI1	0.6	5.44	0.4	2.04e-7	Colorectal cancer;
PAAD	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.9	8.42	0.56	2.66e-14	Cognitive function;
PAAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.55	4.33	0.33	2.74e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg04482110	chr17:41364121	TMEM106A	0.4	4.59	0.35	9.17e-6	Menopause (age at onset);
PAAD	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg05535760	chr7:792225	HEATR2	-0.45	-4.58	-0.35	9.56e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg05082376	chr22:42548792	NA	-0.56	-5.99	-0.44	1.43e-8	Cognitive function;
PAAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg06671706	chr8:8559999	CLDN23	0.76	7.5	0.52	5.08e-12	Obesity-related traits;
PAAD	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.66	-5.23	-0.39	5.44e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs72827839	0.740	rs72823509	chr17:46044589	G/A	cg23391107	chr17:45924227	SP6	0.6	4.98	0.37	1.72e-6	Ease of getting up in the morning;
PAAD	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.61	0.35	8.62e-6	Personality dimensions;
PAAD	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.53	5.25	0.39	5.03e-7	Parkinson's disease;
PAAD	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs1879734	0.953	rs3013767	chr1:54156757	C/T	cg14659662	chr1:54151053	GLIS1	0.42	6.76	0.48	2.72e-10	Mitral valve prolapse;
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg15117754	chr3:10150083	C3orf24	0.74	6.16	0.45	6.2e-9	Alzheimer's disease;
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.35	-4.3	-0.33	3.08e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.35	0.6	1.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg04160749	chr8:58172571	NA	-0.68	-4.83	-0.36	3.36e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.97	10.57	0.65	6.24e-20	Corneal astigmatism;
PAAD	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-1.06	-8.94	-0.59	1.24e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.57	-0.35	1.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13970942	chr9:129673409	NA	0.62	6.66	0.48	4.8e-10	Smoking initiation;
PAAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.65	4.45	0.34	1.66e-5	Blood protein levels;
PAAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.66	-6.95	-0.49	1.01e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.8	7.69	0.53	1.75e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.55	5.14	0.38	8.24e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs3753841	0.832	rs11164616	chr1:103286648	C/T	cg24495344	chr1:103574097	COL11A1	-0.39	-4.7	-0.36	5.84e-6	Glaucoma (primary angle closure);
PAAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.48	-0.47	1.21e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15083158	chr17:2615176	KIAA0664	0.56	6.44	0.46	1.49e-9	Monocyte percentage of white cells;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05983229	chr2:204192854	ABI2	0.65	6.4	0.46	1.83e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg21892295	chr12:121157589	UNC119B	-0.43	-4.26	-0.33	3.55e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04497992	chr16:616212	NHLRC4	0.37	4.26	0.33	3.51e-5	Height;
PAAD	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs338389	0.516	rs4777016	chr15:68314919	C/T	cg09788352	chr15:68522666	CLN6	0.35	4.33	0.33	2.72e-5	Survival in rectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22654626	chr19:18699620	C19orf60	-0.82	-7.58	-0.52	3.08e-12	Neuroticism;
PAAD	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.52	7.32	0.51	1.35e-11	Diastolic blood pressure;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs6494488	0.500	rs72744749	chr15:65062819	G/C	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg12927641	chr6:109611667	NA	-0.4	-4.32	-0.33	2.84e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.94	-0.49	1.04e-10	Glomerular filtration rate (creatinine);
PAAD	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-4.68	-0.35	6.28e-6	Lung cancer;
PAAD	cis	rs7923609	1.000	rs7073746	chr10:64904071	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-4.27	-0.33	3.44e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs490234	0.841	rs626667	chr9:128428404	A/G	cg14078157	chr9:128172775	NA	0.45	5.23	0.39	5.58e-7	Mean arterial pressure;
PAAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg10556349	chr10:835070	NA	0.7	5.25	0.39	5.06e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs9918079	0.542	rs12499412	chr4:15602252	G/C	cg16509355	chr4:15471240	CC2D2A	0.34	4.27	0.33	3.38e-5	Obesity-related traits;
PAAD	cis	rs1075265	0.575	rs2692531	chr2:54003777	A/G	cg04546899	chr2:54196757	PSME4	0.3	4.3	0.33	3.02e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs4743820	0.590	rs73650935	chr9:93917658	T/C	cg14446406	chr9:93919335	NA	0.5	6.03	0.44	1.21e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.96	8.57	0.57	1.11e-14	Psoriasis;
PAAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.49	-4.35	-0.33	2.51e-5	IgG glycosylation;
PAAD	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.36	5.45e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs783540	0.934	rs783532	chr15:83249367	C/T	cg00614314	chr15:82944287	LOC80154	0.44	4.52	0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs41563	0.607	rs6955349	chr7:104601236	G/A	cg04380332	chr7:105027541	SRPK2	-0.63	-6.5	-0.47	1.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg14851346	chr12:38532713	NA	-0.46	-4.36	-0.33	2.43e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-4.36	-0.33	2.34e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35740288	0.822	rs11630549	chr15:86275796	C/T	cg07943548	chr15:86304357	KLHL25	-0.58	-4.88	-0.37	2.69e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg13736514	chr6:26305472	NA	-0.58	-6.13	-0.45	7.24e-9	Educational attainment;
PAAD	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.88	9.16	0.6	3.41e-16	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9659323	1.000	rs6680737	chr1:119521631	G/A	cg17326555	chr1:119535693	NA	-0.44	-5.84	-0.43	3.06e-8	Body mass index;
PAAD	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg27499820	chr13:21296301	IL17D	0.5	4.79	0.36	3.91e-6	Dental caries;
PAAD	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Lymphocyte counts;
PAAD	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs7180079	0.620	rs1008917	chr15:65059651	A/G	cg18210365	chr15:65066710	RBPMS2	0.5	4.3	0.33	2.99e-5	Monocyte count;
PAAD	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.8	8.72	0.58	4.5e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs7246760	1.000	rs58137206	chr19:9856624	G/A	cg16876255	chr19:9731953	ZNF561	0.92	4.52	0.34	1.22e-5	Pursuit maintenance gain;
PAAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.78	-10.18	-0.64	6.77e-19	Bone mineral density;
PAAD	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.92	12.07	0.7	5.93e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg09491104	chr22:46646882	C22orf40	-0.94	-5.98	-0.44	1.52e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	1.01	8.01	0.54	2.86e-13	Post bronchodilator FEV1;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg13444538	chr7:158905317	VIPR2	0.53	4.99	0.38	1.65e-6	Facial morphology (factor 20);
PAAD	cis	rs4740619	0.619	rs10738427	chr9:16041822	C/T	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg01831904	chr17:28903510	LRRC37B2	0.78	5.92	0.43	2.04e-8	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09560953	chr3:23846810	UBE2E1	-0.53	-6.45	-0.46	1.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.8	8.41	0.56	2.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.47	-4.81	-0.36	3.59e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs643506	0.845	rs2850245	chr11:111760738	G/T	cg09085632	chr11:111637200	PPP2R1B	0.53	4.45	0.34	1.66e-5	Breast cancer;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.53	6.73	0.48	3.21e-10	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.65	-7.8	-0.53	9.37e-13	Longevity;Endometriosis;
PAAD	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.4	4.44	0.34	1.7e-5	High light scatter reticulocyte count;
PAAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg05564831	chr3:52568323	NT5DC2	-0.41	-4.28	-0.33	3.28e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg06636001	chr8:8085503	FLJ10661	0.74	7.57	0.52	3.31e-12	Triglycerides;
PAAD	cis	rs78761021	0.867	rs62066059	chr17:9784989	T/G	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.12e-13	Type 2 diabetes;
PAAD	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.08	-0.55	1.89e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.57	-0.35	9.92e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11037575	0.739	rs10838151	chr11:43708409	G/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.13e-6	Cognitive performance;
PAAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.59	6.71	0.48	3.6e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg14092988	chr3:52407081	DNAH1	0.44	5.52	0.41	1.41e-7	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08219700	chr8:58056026	NA	0.71	5.6	0.41	9.57e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.56	-5.57	-0.41	1.14e-7	Capecitabine sensitivity;
PAAD	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.78	6.11	0.44	8.09e-9	IgE levels;
PAAD	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.65	-5.94	-0.43	1.87e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg22467129	chr15:76604101	ETFA	0.52	4.88	0.37	2.6e-6	Blood metabolite levels;
PAAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs10887741	0.646	rs1358863	chr10:89426508	T/G	cg13926569	chr10:89418898	PAPSS2	0.48	4.8	0.36	3.7e-6	Exercise (leisure time);
PAAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.78	6.68	0.48	4.22e-10	Bronchopulmonary dysplasia;
PAAD	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg08885076	chr2:99613938	TSGA10	0.53	5.08	0.38	1.07e-6	Chronic sinus infection;
PAAD	cis	rs6681460	0.576	rs1338194	chr1:66986476	T/A	cg02459107	chr1:67143332	SGIP1	0.52	4.62	0.35	8.26e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.85	5.88	0.43	2.47e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.91	0.49	1.24e-10	Cognitive ability;
PAAD	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg18281939	chr5:77783895	LHFPL2	-0.5	-5.6	-0.41	9.98e-8	Triglycerides;
PAAD	cis	rs11887277	0.708	rs12470698	chr2:27063261	A/G	cg12368169	chr2:27073192	DPYSL5	-0.44	-4.79	-0.36	3.93e-6	Obesity-related traits;
PAAD	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg00277334	chr10:82204260	NA	-0.57	-5.78	-0.42	4.17e-8	Post bronchodilator FEV1;
PAAD	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.83	10.04	0.63	1.64e-18	Menopause (age at onset);
PAAD	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg00579200	chr11:133705235	NA	0.45	5.25	0.39	5.1e-7	Childhood ear infection;
PAAD	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.35	-0.33	2.45e-5	Height;
PAAD	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.05e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg21479132	chr6:26055353	NA	0.9	6.32	0.46	2.69e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10988802	0.673	rs2405069	chr9:98386345	A/G	cg16575184	chr9:99179480	ZNF367	-0.67	-4.82	-0.36	3.5e-6	Chemerin levels;
PAAD	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.13e-6	Motion sickness;
PAAD	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg18621852	chr3:10150065	C3orf24	0.64	5.85	0.43	2.89e-8	Alzheimer's disease;
PAAD	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.47	-6.73	-0.48	3.27e-10	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10012599	chr11:46744754	F2	-0.67	-6.8	-0.48	2.28e-10	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.96	0.7	1.2e-23	Menopause (age at onset);
PAAD	cis	rs11700980	0.551	rs2832042	chr21:30116127	A/C	cg24692254	chr21:30365293	RNF160	-0.69	-5.08	-0.38	1.08e-6	QRS complex (12-leadsum);
PAAD	trans	rs901683	1.000	rs35047800	chr10:46089047	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.51	0.47	1.03e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	Cognitive function;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.6	6.04	0.44	1.15e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.44	4.61	0.35	8.33e-6	Tonsillectomy;
PAAD	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.89	11.59	0.69	1.15e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.97	-11.33	-0.68	5.91e-22	Refractive error;
PAAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.21	-0.55	8.74e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.57	-5.1	-0.38	9.89e-7	Obesity-related traits;
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.74	-11.68	-0.69	6.85e-23	Body mass index;
PAAD	cis	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg21546286	chr11:48923668	NA	-0.56	-5.89	-0.43	2.44e-8	HDL cholesterol;
PAAD	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9657904	0.774	rs6795961	chr3:105524643	A/G	cg16975614	chr3:105601834	NA	0.47	4.61	0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.93	-0.37	2.15e-6	Breast cancer;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg14433983	chr11:636460	DRD4	-0.45	-4.69	-0.36	6.14e-6	Systemic lupus erythematosus;
PAAD	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.57	4.25	0.33	3.75e-5	Exhaled nitric oxide output;
PAAD	cis	rs9535307	0.522	rs3851166	chr13:50409236	G/T	cg03658251	chr13:50265850	EBPL	-0.83	-5.36	-0.4	2.98e-7	Obesity-related traits;
PAAD	cis	rs4604234	0.541	rs11963917	chr6:81004560	T/C	cg23115158	chr6:80341412	SH3BGRL2	-1.08	-4.25	-0.33	3.72e-5	Cancer;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.6	4.47	0.34	1.5e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg22508957	chr16:3507546	NAT15	0.79	6.25	0.45	3.95e-9	Tuberculosis;
PAAD	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.71	5.19	0.39	6.76e-7	Orofacial clefts;
PAAD	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg21452805	chr1:244014465	NA	0.46	4.35	0.33	2.45e-5	RR interval (heart rate);
PAAD	cis	rs8112211	0.689	rs11669230	chr19:38802989	C/G	cg01275006	chr19:38876250	GGN	-0.92	-5.95	-0.43	1.75e-8	Blood protein levels;
PAAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.45	4.48	0.34	1.48e-5	Aortic root size;
PAAD	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs12754538	0.595	rs12025126	chr1:8759554	C/T	cg06159269	chr1:8767347	RERE	-0.4	-4.59	-0.35	9.16e-6	Subjective well-being;
PAAD	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.8	-8.76	-0.58	3.53e-15	Colorectal cancer;
PAAD	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-1.05	-14.77	-0.77	3.53e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg04450456	chr4:17643702	FAM184B	0.48	4.96	0.37	1.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.52	5.25	0.39	4.95e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9409082	0.677	rs9408819	chr9:108914546	C/T	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.41	-4.59	-0.35	9.25e-6	Refractive error;
PAAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg11859384	chr17:80120422	CCDC57	0.5	5.17	0.39	7.32e-7	Life satisfaction;
PAAD	trans	rs7594645	1.000	rs75607323	chr2:207635770	C/T	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.59	-8.44	-0.57	2.28e-14	Huntington's disease progression;
PAAD	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.74	6.35	0.46	2.32e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg02631450	chr22:32366979	NA	0.96	5.55	0.41	1.21e-7	Childhood ear infection;
PAAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.47	5.98	0.44	1.5e-8	Childhood ear infection;
PAAD	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs818427	0.613	rs818797	chr5:112219140	G/A	cg06941702	chr5:112196734	SRP19	0.54	5.31	0.4	3.74e-7	Total body bone mineral density;
PAAD	cis	rs4343996	0.934	rs4320450	chr7:3372308	G/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.13	-0.38	8.67e-7	Motion sickness;
PAAD	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.63	7.21	0.5	2.52e-11	Coronary artery disease;
PAAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03676636	chr4:99064102	C4orf37	0.31	5.23	0.39	5.57e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg18518183	chr2:172544446	DYNC1I2	0.5	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs2718812	1.000	rs2718811	chr3:133399738	T/A	cg11941060	chr3:133502564	NA	0.47	4.86	0.37	2.92e-6	Iron status biomarkers;
PAAD	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.75	7.33	0.51	1.27e-11	Total body bone mineral density;
PAAD	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.47	-4.74	-0.36	4.88e-6	Inflammatory skin disease;
PAAD	cis	rs12931792	0.840	rs8049778	chr16:30163166	C/T	cg17640201	chr16:30407289	ZNF48	0.6	6.36	0.46	2.23e-9	Tonsillectomy;
PAAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19346786	chr7:2764209	NA	-0.38	-5.19	-0.39	6.56e-7	Height;
PAAD	cis	rs6449957	0.832	rs12660017	chr5:67450350	T/C	cg23036683	chr5:67512108	NA	0.49	4.55	0.35	1.1e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13560548	chr3:10150139	C3orf24	0.61	5.56	0.41	1.19e-7	Alzheimer's disease;
PAAD	cis	rs10791323	0.604	rs7928888	chr11:133703696	A/C	cg00579200	chr11:133705235	NA	-0.49	-5.62	-0.41	8.9e-8	Childhood ear infection;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.78	0.42	4.04e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs10838687	0.673	rs17790204	chr11:46969281	C/G	cg19486271	chr11:47235900	DDB2	0.58	4.46	0.34	1.59e-5	Proinsulin levels;
PAAD	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg08079166	chr15:68083412	MAP2K5	0.62	4.92	0.37	2.25e-6	Restless legs syndrome;
PAAD	cis	rs6076065	0.513	rs13037787	chr20:23425811	C/T	cg11657817	chr20:23433608	CST11	0.51	4.83	0.36	3.32e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.67	-5.01	-0.38	1.47e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	1.14	10.31	0.64	3.07e-19	Colorectal cancer;
PAAD	cis	rs2960422	0.546	rs6782178	chr3:12334555	C/T	cg25357825	chr3:11697138	VGLL4	0.36	4.67	0.35	6.58e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.75	8.04	0.55	2.38e-13	Blood protein levels;
PAAD	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg10064339	chr11:73693792	UCP2	1.53	6.68	0.48	4.25e-10	Obesity-related traits;
PAAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg16584676	chr17:46985605	UBE2Z	0.57	5.72	0.42	5.44e-8	Type 2 diabetes;
PAAD	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg20893579	chr22:38215064	NA	-0.45	-4.83	-0.37	3.24e-6	Glioblastoma;Glioma;
PAAD	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.8	8.04	0.55	2.41e-13	Testicular germ cell tumor;
PAAD	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.66	6.31	0.46	2.96e-9	Platelet count;
PAAD	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg16506815	chr2:162101123	NA	0.57	6.04	0.44	1.16e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10104683	chr2:20424989	SDC1	-0.68	-6.59	-0.47	6.73e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.83	-0.58	2.29e-15	Depression;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	cis	rs548987	0.529	rs1165164	chr6:25863481	G/A	cg18357526	chr6:26021779	HIST1H4A	0.57	4.53	0.34	1.2e-5	Homocysteine levels;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.92e-6	Lung cancer;
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.75	-7.57	-0.52	3.35e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg14196790	chr5:131705035	SLC22A5	0.58	6.47	0.46	1.25e-9	Blood metabolite levels;
PAAD	cis	rs2882667	0.690	rs1828188	chr5:138171996	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.31	0.6	1.37e-16	Parkinson's disease;
PAAD	cis	rs2249694	0.503	rs9418982	chr10:135320622	C/T	cg20169779	chr10:135381914	SYCE1	0.51	4.78	0.36	4.1e-6	Obesity-related traits;
PAAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.26	0.39	4.87e-7	Bone mineral density;
PAAD	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	0.99	6.12	0.44	7.66e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11522493	chr1:14149815	PRDM2	0.6	6.98	0.49	8.6e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg02683114	chr2:24398427	C2orf84	0.51	4.88	0.37	2.61e-6	Asthma;
PAAD	cis	rs332507	0.830	rs11718359	chr3:124395987	G/A	cg05980111	chr3:124395277	KALRN	0.42	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.32	-0.33	2.82e-5	Subjective well-being;
PAAD	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.84	0.43	3.05e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.77	-6.73	-0.48	3.21e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	4.28	0.33	3.27e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs2976388	0.647	rs13272904	chr8:143782614	T/C	cg06565975	chr8:143823917	SLURP1	0.21	4.72	0.36	5.23e-6	Urinary tract infection frequency;
PAAD	cis	rs216026	0.689	rs216048	chr12:2766700	A/C	cg19945202	chr12:2788847	CACNA1C	0.6	4.62	0.35	8.07e-6	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.74	-0.36	4.95e-6	Asthma;
PAAD	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.76	7.36	0.51	1.08e-11	Resting heart rate;
PAAD	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.4	-4.38	-0.33	2.2e-5	Fibrinogen levels;
PAAD	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs4462272	0.557	rs17668255	chr10:102000701	C/T	cg11888571	chr10:102027403	CWF19L1	-0.49	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-4.58	-0.35	9.61e-6	Vitiligo;
PAAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.79	10.13	0.63	9.53e-19	Bone mineral density;
PAAD	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.48	1.85e-10	Response to antipsychotic treatment;
PAAD	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.82	8.07	0.55	2.02e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-6.12	-0.44	7.48e-9	Airway imaging phenotypes;
PAAD	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.38	0.4	2.74e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs56133113	0.710	rs79746021	chr11:72781835	C/T	cg25124030	chr11:73498278	MRPL48	0.49	4.46	0.34	1.57e-5	Mean platelet volume;
PAAD	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-4.5	-0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg07166546	chr14:35805898	NA	-0.29	-4.45	-0.34	1.68e-5	Psoriasis;
PAAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg23153227	chr6:27725408	NA	0.43	4.7	0.36	5.9e-6	Pubertal anthropometrics;
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.74	-5.69	-0.42	6.48e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs2662368	0.542	rs171705	chr5:77101549	C/T	cg02570643	chr5:77531473	AP3B1	-0.42	-4.53	-0.34	1.18e-5	Platelet distribution width;
PAAD	cis	rs4538187	1.000	rs6546030	chr2:64071651	G/A	cg08613950	chr2:64719184	NA	-0.65	-4.3	-0.33	3.08e-5	Systolic blood pressure;
PAAD	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.56	4.88	0.37	2.69e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.57	-5.9	-0.43	2.32e-8	Hypospadias;
PAAD	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg24879335	chr3:133465180	TF	0.4	4.39	0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.8	9.66	0.62	1.66e-17	Lung cancer;
PAAD	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.5	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.54	-0.57	1.28e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.44	-0.34	1.69e-5	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg10729496	chr3:10149963	C3orf24	0.88	7.31	0.51	1.42e-11	Alzheimer's disease;
PAAD	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26306683	chr17:18585705	ZNF286B	-0.59	-4.44	-0.34	1.75e-5	Pancreatic cancer;
PAAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.56	-0.41	1.17e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9398803	0.687	rs1262552	chr6:127078752	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.47	-0.34	1.51e-5	Male-pattern baldness;
PAAD	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08886695	chr4:3369023	RGS12	-0.51	-4.83	-0.36	3.31e-6	Mean platelet volume;
PAAD	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg25886479	chr11:50257625	LOC441601	0.4	4.25	0.33	3.74e-5	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs798766	0.903	rs811316	chr4:1689377	T/C	cg23460851	chr4:1604456	NA	-0.43	-4.49	-0.34	1.43e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.79	5.88	0.43	2.47e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg09796270	chr17:17721594	SREBF1	-0.46	-5.14	-0.38	8.28e-7	Total body bone mineral density;
PAAD	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.61	-5.77	-0.42	4.39e-8	Neuroticism;
PAAD	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg25838818	chr2:108905173	SULT1C2	-0.59	-5.71	-0.42	5.68e-8	Lobe size;
PAAD	cis	rs7833787	1.000	rs6993404	chr8:18705723	C/T	cg17701159	chr8:18705777	PSD3	0.45	5.35	0.4	3.18e-7	Obesity-related traits;
PAAD	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg10437265	chr15:77819839	NA	0.41	4.72	0.36	5.21e-6	Type 2 diabetes;
PAAD	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg00071950	chr4:10020882	SLC2A9	0.44	4.36	0.33	2.34e-5	Blood metabolite levels;
PAAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.57	6.18	0.45	5.58e-9	Blood metabolite levels;
PAAD	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.29	0.6	1.54e-16	Post bronchodilator FEV1;
PAAD	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3996993	0.737	rs2608653	chr6:52644356	A/T	cg00536792	chr6:53530503	KLHL31	0.4	4.29	0.33	3.13e-5	Hemoglobin concentration;
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.82	6.03	0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg22800045	chr5:56110881	MAP3K1	-0.93	-7.29	-0.51	1.6e-11	Initial pursuit acceleration;
PAAD	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.66	7.45	0.52	6.7e-12	Heart rate;
PAAD	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg01304814	chr3:48885189	PRKAR2A	0.97	5.2	0.39	6.23e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.64	-0.35	7.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.26	0.51	1.84e-11	Body mass index (adult);
PAAD	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg26528668	chr16:1614120	IFT140	0.46	4.29	0.33	3.16e-5	Coronary artery disease;
PAAD	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg24733560	chr20:60626293	TAF4	0.43	5.03	0.38	1.4e-6	Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02782622	chr2:69534307	NA	-0.57	-6.62	-0.47	5.88e-10	Body fat percentage;
PAAD	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg01868782	chr6:126071099	HEY2	0.47	5.56	0.41	1.18e-7	Brugada syndrome;
PAAD	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	7.69	0.53	1.74e-12	Body mass index (adult);
PAAD	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg19423196	chr10:82049429	MAT1A	0.57	4.39	0.34	2.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs10140922	0.966	rs4982265	chr14:35828393	T/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-4.89	-0.37	2.55e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.3	7.96	0.54	3.67e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg06057569	chr22:50219754	BRD1	0.6	4.63	0.35	7.71e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6011002	0.745	rs1758206	chr20:62336334	T/C	cg01176363	chr20:62369445	LIME1	-0.78	-4.25	-0.33	3.65e-5	Dental caries;
PAAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.11	0.5	4.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.59	-5.45	-0.4	1.97e-7	Obesity-related traits;
PAAD	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.61	7.09	0.5	4.74e-11	Dupuytren's disease;
PAAD	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.5	-4.97	-0.37	1.8e-6	Parkinson's disease;
PAAD	cis	rs35160687	0.688	rs12466728	chr2:86484099	G/A	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.27	0.39	4.7e-7	Body mass index;
PAAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	10.54	0.65	7.6e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2147959	0.882	rs6666241	chr1:228629759	A/G	cg02753203	chr1:228287806	NA	-0.59	-4.78	-0.36	4.15e-6	Adult asthma;
PAAD	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19636519	chr7:99541626	NA	0.41	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.85	10.3	0.64	3.33e-19	Lung cancer;
PAAD	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.17	-0.39	7.16e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg18279126	chr7:2041391	MAD1L1	0.55	5.73	0.42	5.35e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.7	6.61	0.47	6.17e-10	Lymphocyte counts;
PAAD	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg15226751	chr1:10001911	LZIC	0.4	4.52	0.34	1.23e-5	Hepatocellular carcinoma;
PAAD	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg24721873	chr10:135334122	NA	0.57	4.29	0.33	3.19e-5	Gout;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs35150201	0.838	rs6959832	chr7:135289854	G/A	cg23117316	chr7:135346802	PL-5283	-0.4	-6.05	-0.44	1.06e-8	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
PAAD	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.8	9.18	0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2131877	0.913	rs1874099	chr3:194848766	G/T	cg21937377	chr3:194868750	C3orf21	0.46	4.75	0.36	4.58e-6	Non-small cell lung cancer;
PAAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.7	7.34	0.51	1.18e-11	Calcium levels;
PAAD	cis	rs1468734	1.000	rs35555573	chr16:5003581	G/A	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.47	-4.59	-0.35	9.42e-6	Educational attainment (years of education);
PAAD	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14169450	chr9:139327907	INPP5E	0.57	5.84	0.43	3.09e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	4.3	0.33	3.08e-5	Axial length;
PAAD	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.84	-9.34	-0.6	1.16e-16	Mortality in heart failure;
PAAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14180030	chr9:123475675	MEGF9	-0.48	-5.2	-0.39	6.26e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs78472555	1.000	rs11247124	chr15:100265725	C/T	cg18869061	chr15:100272053	LYSMD4	-0.69	-5.6	-0.41	9.88e-8	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.34	0.33	2.64e-5	Self-reported allergy;
PAAD	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.88	-4.25	-0.33	3.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07362569	chr17:61921086	SMARCD2	-0.63	-7.9	-0.54	5.24e-13	Prudent dietary pattern;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.53	5.12	0.38	9.04e-7	Lung cancer;
PAAD	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-5.96	-0.44	1.69e-8	Neuroticism;
PAAD	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg12062639	chr20:23401060	NAPB	0.97	5.22	0.39	5.71e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg10621924	chr7:39171070	POU6F2	-0.33	-5.29	-0.39	4.26e-7	IgG glycosylation;
PAAD	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.72	-0.36	5.21e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6663390	0.510	rs1932818	chr1:208078257	C/T	cg00387621	chr1:208086895	NA	0.75	4.41	0.34	1.94e-5	Facial morphology (factor 18);
PAAD	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-4.9	-0.37	2.48e-6	Neuroticism;
PAAD	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.93	-0.49	1.13e-10	Eye color traits;
PAAD	cis	rs4281086	0.897	rs34037334	chr8:10345133	C/T	cg01072821	chr8:10382165	T-SP1	-0.45	-4.35	-0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.04	-0.44	1.12e-8	Lymphocyte counts;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.54	5.24	0.39	5.2e-7	Lung cancer;
PAAD	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg08501292	chr6:25962987	TRIM38	0.97	5.75	0.42	4.69e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg04160749	chr8:58172571	NA	-0.72	-4.91	-0.37	2.38e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.42	-5.42	-0.4	2.24e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.41	-0.34	1.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.66	-7.08	-0.5	5.11e-11	Iron status biomarkers;
PAAD	cis	rs1801239	1.000	rs78625146	chr10:16933839	T/A	cg00939682	chr10:16933505	CUBN	0.72	5.04	0.38	1.31e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg21601837	chr3:125900065	ALDH1L1	0.47	5.23	0.39	5.62e-7	Metabolite levels;
PAAD	cis	rs6960043	0.584	rs2189725	chr7:15041873	G/A	cg19272540	chr7:15055459	NA	0.32	5.66	0.42	7.48e-8	Type 2 diabetes;
PAAD	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.91	0.49	1.22e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.27	0.33	3.39e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs59698941	0.882	rs12521723	chr5:132273808	A/T	cg13565585	chr5:132299512	AFF4	0.62	4.52	0.34	1.25e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs258892	0.842	rs11952089	chr5:72020508	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg05468064	chr22:46423449	NA	0.38	4.59	0.35	9.37e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs17655565	0.581	rs1622677	chr12:52762444	A/G	cg22980804	chr12:52818037	KRT75	0.49	4.46	0.34	1.56e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.85	0.49	1.69e-10	Renal function-related traits (BUN);
PAAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.96	-13.13	-0.73	8.54e-27	Height;
PAAD	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.58	-5.19	-0.39	6.55e-7	Macular telangiectasia type 2;
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg03289416	chr15:75166202	SCAMP2	-0.52	-5.59	-0.41	1.05e-7	Breast cancer;
PAAD	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg18833306	chr6:118973337	C6orf204	0.42	4.44	0.34	1.75e-5	Electrocardiographic conduction measures;
PAAD	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.55	5.45	0.4	1.98e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg14196790	chr5:131705035	SLC22A5	0.43	4.62	0.35	8.08e-6	Breast cancer;
PAAD	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg01620082	chr3:125678407	NA	-1.01	-6.5	-0.47	1.09e-9	Breast cancer;
PAAD	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg08562672	chr19:21860753	NA	0.41	4.32	0.33	2.77e-5	Pain;
PAAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.56	4.44	0.34	1.69e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.17	-0.5	3.08e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.29	0.51	1.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.36	4.26	0.33	3.62e-5	Schizophrenia;
PAAD	cis	rs2882667	0.690	rs825749	chr5:138135921	C/A	cg09476006	chr5:138032270	NA	-0.49	-6.43	-0.46	1.54e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-13.96	-0.75	5.16e-29	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7786877	0.679	rs10953301	chr7:100264893	A/G	cg26071806	chr7:100318239	EPO	-0.43	-4.32	-0.33	2.82e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6442522	0.644	rs6783160	chr3:15509018	C/T	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg20966754	chr17:47091339	IGF2BP1	-0.43	-5.46	-0.4	1.93e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.77	7.77	0.53	1.08e-12	Methadone dose in opioid dependence;
PAAD	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.53	-6.1	-0.44	8.58e-9	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg19337854	chr7:99768885	GPC2	-0.51	-5.24	-0.39	5.37e-7	Coronary artery disease;
PAAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.69	-6.69	-0.48	3.94e-10	Mood instability;
PAAD	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg07469887	chr10:131262384	NA	-0.43	-5.1	-0.38	9.95e-7	Response to temozolomide;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg15691649	chr6:25882328	NA	-0.54	-4.91	-0.37	2.28e-6	Blood metabolite levels;
PAAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs4969178	0.645	rs4366775	chr17:76382079	C/T	cg05887092	chr17:76393375	PGS1	-0.54	-6.06	-0.44	1e-8	HDL cholesterol levels;
PAAD	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg25008857	chr14:105974488	NA	0.4	4.32	0.33	2.78e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.93	-12.26	-0.71	1.89e-24	Body mass index (adult);
PAAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	1.22	10.42	0.65	1.59e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.5	-4.91	-0.37	2.29e-6	Facial morphology (factor 20);
PAAD	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09267776	chr1:205538427	MFSD4	-0.69	-6.38	-0.46	2.01e-9	Neuroticism;
PAAD	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.54	-5.15	-0.39	8.03e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.69	4.75	0.36	4.73e-6	Vitiligo;
PAAD	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg05250797	chr16:70222502	NA	0.83	6.37	0.46	2.14e-9	IgE levels;
PAAD	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	0.98	7.92	0.54	4.79e-13	Vitiligo;
PAAD	cis	rs9462027	0.628	rs7745097	chr6:34794434	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.27	-0.39	4.5e-7	Systemic lupus erythematosus;
PAAD	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.61	-4.42	-0.34	1.85e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs8179	0.514	rs11773884	chr7:92285123	A/G	cg03496780	chr7:92466842	CDK6	0.47	4.59	0.35	9.35e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.32	-5.95	-0.43	1.8e-8	Type 2 diabetes;
PAAD	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	5.22	0.39	5.71e-7	Blood metabolite levels;
PAAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg16205897	chr5:131564050	P4HA2	-0.46	-4.88	-0.37	2.64e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-1.04	-10.94	-0.66	6.66e-21	Platelet distribution width;
PAAD	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.7	-7.8	-0.53	9.4e-13	Colorectal cancer;
PAAD	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg09754948	chr16:28834200	ATXN2L	-0.48	-4.42	-0.34	1.86e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.3	-0.33	3.02e-5	Schizophrenia;
PAAD	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.65	6.94	0.49	1.04e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.45	0.52	6.52e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg17326555	chr1:119535693	NA	-0.35	-4.39	-0.34	2.1e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7945718	0.621	rs4606460	chr11:12687781	A/G	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.99	-0.38	1.6e-6	Neuroticism;
PAAD	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.5	6.21	0.45	4.81e-9	Sitting height ratio;
PAAD	cis	rs2241685	0.790	rs6722043	chr2:1950521	T/C	cg22511877	chr2:1942942	MYT1L	-0.71	-5.08	-0.38	1.09e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg27395922	chr11:50257633	LOC441601	-0.42	-4.57	-0.35	1e-5	Height;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg02462569	chr6:150064036	NUP43	-0.43	-4.61	-0.35	8.35e-6	Testicular germ cell tumor;
PAAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.74	8.5	0.57	1.65e-14	Methadone dose in opioid dependence;
PAAD	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.86	-8.18	-0.55	1.07e-13	Homoarginine levels;
PAAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.87e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs9549328	0.837	rs7988967	chr13:113651160	A/G	cg08614441	chr13:113633676	MCF2L	-0.43	-4.29	-0.33	3.13e-5	Systolic blood pressure;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.73	-7.52	-0.52	4.53e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2278796	0.639	rs11240330	chr1:204968258	C/A	cg04862289	chr1:204966208	NFASC	0.48	4.93	0.37	2.09e-6	Mean platelet volume;
PAAD	cis	rs4478147	0.506	rs17449582	chr4:87240157	C/T	cg10685359	chr4:87814065	C4orf36	-0.49	-4.85	-0.37	3.08e-6	Migraine - clinic-based;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.58	5.82	0.43	3.44e-8	Resistin levels;
PAAD	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22509189	chr2:225307070	NA	-0.43	-4.26	-0.33	3.53e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.76	9.03	0.59	7.19e-16	Huntington's disease progression;
PAAD	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16447950	chr5:562315	NA	-0.67	-6.02	-0.44	1.26e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.61	4.55	0.35	1.11e-5	Neuroblastoma;
PAAD	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg23465465	chr6:26364728	BTN3A2	0.91	5.23	0.39	5.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	6.4	0.46	1.78e-9	Body mass index;
PAAD	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs4356203	0.905	rs618331	chr11:17247336	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4843185	0.764	rs12149202	chr16:85700360	G/A	cg26571870	chr16:85723150	GINS2	-0.46	-5.21	-0.39	6.06e-7	Platelet distribution width;
PAAD	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg18833306	chr6:118973337	C6orf204	0.47	4.92	0.37	2.26e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.4	-4.27	-0.33	3.45e-5	Platelet distribution width;
PAAD	cis	rs3784262	0.528	rs4238327	chr15:58336218	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.38	-0.33	2.21e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs863345	0.527	rs7514555	chr1:158445138	G/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.27e-6	Pneumococcal bacteremia;
PAAD	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.94	-0.37	2.04e-6	Schizophrenia;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg01097406	chr16:89675127	NA	-0.35	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg02532672	chr7:808649	HEATR2	-0.58	-6.18	-0.45	5.62e-9	Subjective well-being;
PAAD	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	1.04	12.45	0.71	5.63e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg18367735	chr17:79674897	NA	1.01	7.21	0.5	2.46e-11	Dental caries;
PAAD	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	1.12	8.58	0.57	1.04e-14	Inflammatory bowel disease;
PAAD	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.73	-7.43	-0.52	7.12e-12	Retinal vascular caliber;
PAAD	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.58	-0.35	9.58e-6	Bipolar disorder;
PAAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg07703079	chr11:430292	ANO9	0.77	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs72843506	0.656	rs2385960	chr17:19938217	C/A	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.56	5.9	0.43	2.32e-8	Longevity;Endometriosis;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg17372223	chr3:52568218	NT5DC2	0.51	4.86	0.37	2.94e-6	Bipolar disorder;
PAAD	cis	rs58521262	0.556	rs390911	chr19:23124745	A/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg08704250	chr15:31115839	NA	-0.62	-8.39	-0.56	3.15e-14	Huntington's disease progression;
PAAD	cis	rs3736485	0.966	rs7170444	chr15:51890500	G/A	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28655083	0.529	rs682081	chr16:77103050	T/C	cg06128999	chr16:77247126	NA	-0.42	-5.14	-0.38	8.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg08619932	chr19:49200058	FUT2	0.58	6.42	0.46	1.62e-9	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs189798	0.845	rs330904	chr8:8991825	T/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.42	-0.4	2.24e-7	Myopia (pathological);
PAAD	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg00257455	chr1:65530538	NA	0.41	4.54	0.35	1.13e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22162314	chr17:61951766	CSH2	-0.56	-5.76	-0.42	4.49e-8	Height;
PAAD	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-5.48	-0.41	1.76e-7	Intelligence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01294270	chr2:37475524	C2orf56	-0.49	-6.33	-0.46	2.56e-9	Monocyte percentage of white cells;
PAAD	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.64	-5.46	-0.4	1.94e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg09127314	chr1:152161683	NA	-0.72	-5.14	-0.38	8.45e-7	Atopic dermatitis;
PAAD	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs10090774	0.965	rs61661433	chr8:141986395	C/T	cg02508881	chr8:142216119	NA	0.41	4.43	0.34	1.8e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg17330251	chr7:94953956	PON1	-0.55	-4.53	-0.34	1.2e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.6	6.09	0.44	9.01e-9	Monocyte count;
PAAD	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-4.82	-0.36	3.5e-6	Psoriasis;
PAAD	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	10.9	0.66	8.38e-21	Smoking behavior;
PAAD	cis	rs7089973	0.584	rs4752347	chr10:116646860	T/A	cg23260525	chr10:116636907	FAM160B1	0.44	6.58	0.47	7e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs41311933	0.706	rs41308028	chr9:123792469	T/C	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg21709803	chr11:61594965	FADS2	-0.54	-4.4	-0.34	2e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.66	-6.6	-0.47	6.49e-10	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg12143784	chr7:64541923	NA	0.33	4.26	0.33	3.64e-5	Aortic root size;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg13560548	chr3:10150139	C3orf24	0.54	5.02	0.38	1.44e-6	Alzheimer's disease;
PAAD	cis	rs346785	0.965	rs17509527	chr17:74286173	A/G	cg09812376	chr17:74270190	QRICH2	-0.42	-5.76	-0.42	4.48e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.65	0.57	6.71e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg22349387	chr12:9600060	DDX12	-0.41	-4.3	-0.33	3e-5	Breast size;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg19337854	chr7:99768885	GPC2	0.53	4.95	0.37	1.95e-6	Platelet count;
PAAD	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.96	11.47	0.68	2.43e-22	Osteoporosis;
PAAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08418111	chr11:18433745	LDHC	0.6	6.31	0.46	2.86e-9	Calcium levels;
PAAD	cis	rs9324022	0.790	rs56011271	chr14:101167732	C/T	cg18089426	chr14:101175970	NA	0.73	5.34	0.4	3.39e-7	Plateletcrit;
PAAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg27005118	chr17:13972210	COX10	-0.44	-5.96	-0.44	1.69e-8	Temperament;
PAAD	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.82e-6	Personality dimensions;
PAAD	cis	rs12304921	0.683	rs12582592	chr12:51513608	C/T	cg04427360	chr12:51347099	HIGD1C	-0.59	-4.45	-0.34	1.67e-5	Type 2 diabetes;
PAAD	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	6.41	0.46	1.78e-9	Cognitive test performance;
PAAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	5.91	0.43	2.11e-8	Multiple sclerosis;
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg02841227	chr6:26021843	HIST1H4A	0.54	5.27	0.39	4.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4281086	0.861	rs4339601	chr8:10359537	C/T	cg01072821	chr8:10382165	T-SP1	-0.44	-4.26	-0.33	3.51e-5	Obesity-related traits;
PAAD	cis	rs3026101	0.671	rs8077471	chr17:5299356	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.49	-5.58	-0.41	1.09e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.93	-0.37	2.18e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8051149	0.738	rs2287120	chr16:87871582	G/A	cg01412419	chr16:87856264	NA	0.74	6.34	0.46	2.51e-9	Blood metabolite levels;
PAAD	cis	rs17592366	0.540	rs7145614	chr14:35290846	C/T	cg09327582	chr14:35236912	BAZ1A	-0.57	-5.38	-0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs802075	0.905	rs9395522	chr6:49637975	T/A	cg20364632	chr6:49636226	NA	-0.56	-6.7	-0.48	3.81e-10	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.85	11.97	0.7	1.1e-23	Vitiligo;
PAAD	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs12922040	1.000	rs12922040	chr16:15869466	C/T	cg01223135	chr16:15826468	MYH11	-0.44	-4.68	-0.36	6.19e-6	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg01064725	chr1:204461714	NA	-0.5	-4.75	-0.36	4.76e-6	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.65	6.97	0.49	9.28e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs4747197	1.000	rs4747194	chr10:73558886	G/A	cg04506911	chr10:72937119	NA	0.4	4.36	0.33	2.35e-5	Progranulin levels;
PAAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.51	-4.8	-0.36	3.78e-6	Menarche (age at onset);
PAAD	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.6	5.84	0.43	3.06e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-5.35	-0.4	3.14e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg17143192	chr8:8559678	CLDN23	0.7	6.8	0.48	2.29e-10	Obesity-related traits;
PAAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.23	-0.39	5.5e-7	QT interval;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26931308	chr10:22292816	DNAJC1	0.51	5.64	0.42	7.9e-8	Monocyte percentage of white cells;
PAAD	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.35	0.46	2.34e-9	Lung cancer in ever smokers;
PAAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg26528668	chr16:1614120	IFT140	0.56	5.32	0.4	3.63e-7	Coronary artery disease;
PAAD	cis	rs9649465	0.967	rs2286831	chr7:123303477	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.65	-0.35	7.11e-6	Migraine;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Electroencephalogram traits;
PAAD	cis	rs776905	0.598	rs6042	chr13:113770068	C/T	cg09069900	chr13:113776964	F10	-0.58	-4.82	-0.36	3.5e-6	Blood protein levels;
PAAD	cis	rs3733418	0.860	rs12647427	chr4:165929209	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.58	-5.34	-0.4	3.33e-7	Obesity-related traits;
PAAD	cis	rs564309	0.681	rs1150918	chr1:228608689	T/C	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.33	0.33	2.65e-5	Self-reported allergy;
PAAD	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.91	11.1	0.67	2.5e-21	Schizophrenia;
PAAD	cis	rs6466055	0.661	rs7780006	chr7:104936469	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg23649088	chr2:200775458	C2orf69	-0.69	-5.56	-0.41	1.18e-7	Schizophrenia;
PAAD	cis	rs9907295	0.591	rs6505498	chr17:34130051	T/C	cg24325790	chr17:34345392	CCL23	-0.47	-4.34	-0.33	2.64e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg14440974	chr22:39074834	NA	-0.57	-6.75	-0.48	2.9e-10	Menopause (age at onset);
PAAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg03983715	chr16:68378420	PRMT7	-0.83	-6.01	-0.44	1.31e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.62	4.63	0.35	7.81e-6	Thyroid stimulating hormone;
PAAD	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	6.12	0.44	7.71e-9	Blood protein levels;
PAAD	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.71	8.35	0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14339778	chr10:134359611	INPP5A	0.69	6.98	0.49	8.41e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.52	6.52	0.47	1e-9	Crohn's disease;
PAAD	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.4	4.83	0.36	3.33e-6	Intraocular pressure;
PAAD	cis	rs7624766	0.901	rs7633816	chr3:160461351	C/T	cg22637730	chr3:160473554	PPM1L	0.47	4.27	0.33	3.42e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs476633	0.679	rs72737734	chr15:41432899	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-7.89	-0.54	5.64e-13	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02247183	chr16:4664062	FAM100A	-0.72	-7.84	-0.54	7.47e-13	Smoking initiation;
PAAD	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	1.18	6.93	0.49	1.1e-10	Cannabis dependence symptom count;
PAAD	cis	rs732765	0.774	rs67212334	chr14:75317699	A/G	cg01090926	chr14:75137805	KIAA0317	0.49	4.35	0.33	2.46e-5	Non-small cell lung cancer;
PAAD	cis	rs1144333	0.826	rs1146645	chr1:76265056	T/C	cg22875332	chr1:76189707	ACADM	-0.77	-4.73	-0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs1879734	0.636	rs12091931	chr1:54191103	G/A	cg14659662	chr1:54151053	GLIS1	-0.32	-4.55	-0.35	1.08e-5	Mitral valve prolapse;
PAAD	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs73019876	0.502	rs28456336	chr19:22268779	T/G	cg08394602	chr19:22123885	NA	-0.41	-4.27	-0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg23119463	chr10:134592391	INPP5A	-0.44	-4.25	-0.33	3.67e-5	Migraine;
PAAD	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg01388757	chr2:102091195	RFX8	-0.6	-7.73	-0.53	1.34e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg16386425	chr10:429943	DIP2C	0.46	4.25	0.33	3.66e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg19680485	chr15:31195859	MTMR15	0.5	5.12	0.38	9.31e-7	Huntington's disease progression;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	7.78e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg22143635	chr11:980567	AP2A2	-0.53	-5.61	-0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.57	-7.51	-0.52	4.8e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs519973	0.545	rs524873	chr3:187671824	A/G	cg25500028	chr3:187336889	NA	0.36	4.34	0.33	2.59e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	7.04	0.5	6.22e-11	Height;
PAAD	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2249296	0.504	rs1334140	chr1:86801238	A/G	cg17424433	chr1:86913263	CLCA2	0.45	4.33	0.33	2.72e-5	Crohn's disease-related phenotypes;
PAAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.45	-0.34	1.64e-5	Mean platelet volume;
PAAD	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg14500798	chr7:98100126	NA	0.41	4.32	0.33	2.8e-5	Breast cancer;
PAAD	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Reticulocyte count;High light scatter reticulocyte count;
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.66	-0.57	6.34e-15	Gut microbiome composition (summer);
PAAD	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06913508	chr2:207630136	FASTKD2;MDH1B	0.6	6.93	0.49	1.14e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6681460	0.625	rs6696812	chr1:67100309	T/C	cg02459107	chr1:67143332	SGIP1	0.54	5.06	0.38	1.22e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.85	-8.62	-0.57	7.91e-15	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.79	-8.96	-0.59	1.11e-15	Lung cancer;
PAAD	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg20913747	chr6:44695427	NA	0.6	5.92	0.43	2.09e-8	Total body bone mineral density;
PAAD	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.91	11.2	0.67	1.29e-21	Heart rate;
PAAD	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.3	0.45	3.13e-9	Schizophrenia;
PAAD	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.56	5.48	0.41	1.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.57	-6.8	-0.48	2.25e-10	Blood pressure (smoking interaction);
PAAD	trans	rs2880058	0.788	rs10753746	chr1:162037856	A/G	cg22816059	chr5:422114	AHRR	-0.62	-6.51	-0.47	1.02e-9	QT interval;
PAAD	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09597638	chr17:3907349	NA	0.74	7.88	0.54	5.85e-13	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs79146658	0.736	rs4894057	chr2:179735372	A/G	cg17765952	chr2:179737173	CCDC141	0.6	4.5	0.34	1.37e-5	Diastolic blood pressure;
PAAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.41	5.11	0.38	9.47e-7	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg27394845	chr17:28928406	LRRC37B2	0.66	4.73	0.36	5.15e-6	Body mass index;
PAAD	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.5	5.27	0.39	4.67e-7	Breast cancer;
PAAD	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg23033748	chr14:75592666	NEK9	0.43	5.26	0.39	4.84e-7	Height;
PAAD	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg02876276	chr17:77834299	NA	0.63	4.33	0.33	2.71e-5	Electroencephalogram traits;
PAAD	cis	rs4757319	0.515	rs10832403	chr11:15334129	A/G	cg03245590	chr11:15329459	NA	-0.45	-5.38	-0.4	2.79e-7	Breast cancer;
PAAD	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.34e-6	Prudent dietary pattern;
PAAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.87	5.89	0.43	2.39e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9467160	1.000	rs9467160	chr6:24441746	C/T	cg16211469	chr6:24423932	MRS2	0.46	4.67	0.35	6.68e-6	Liver enzyme levels;
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.28	0.33	3.31e-5	Menopause (age at onset);
PAAD	cis	rs16867321	0.950	rs16867322	chr2:181369403	A/G	cg23363182	chr2:181467187	NA	-0.48	-4.33	-0.33	2.64e-5	Obesity;
PAAD	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.37	-5.77	-0.42	4.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	0.5	4.64	0.35	7.52e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08363605	chr15:50474388	SLC27A2	-0.78	-6.59	-0.47	6.88e-10	Neuroticism;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg13244804	chr8:128749511	MYC	-0.63	-6.51	-0.47	1.05e-9	Dental caries;
PAAD	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.45	-0.34	1.63e-5	Breast cancer;
PAAD	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.57	-7.58	-0.52	3.16e-12	Urate levels in overweight individuals;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.48	4.68	0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.76	0.66	1.93e-20	Smoking behavior;
PAAD	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00262122	chr8:11665843	FDFT1	0.47	4.3	0.33	2.99e-5	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg07725925	chr16:89976287	TCF25	0.65	4.37	0.33	2.32e-5	Skin colour saturation;
PAAD	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	4.9	0.37	2.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12667521	chr19:29218732	NA	0.68	6.66	0.48	4.75e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs72960926	0.744	rs114317207	chr6:74955867	C/T	cg03266952	chr6:74778945	NA	-1.12	-6.45	-0.46	1.41e-9	Metabolite levels (MHPG);
PAAD	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.61	5.51	0.41	1.49e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.89	-0.37	2.55e-6	Vitiligo;
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.46	4.91	0.37	2.34e-6	Testicular germ cell tumor;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.01	0.54	2.77e-13	Lymphocyte counts;
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.71	7.58	0.52	3.13e-12	Lung cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26894839	chr5:1511271	LPCAT1	0.67	8.13	0.55	1.42e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.52	-5.31	-0.4	3.76e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg17401720	chr7:158221031	PTPRN2	-0.41	-4.77	-0.36	4.32e-6	Obesity-related traits;
PAAD	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs757081	0.658	rs214069	chr11:17305600	G/A	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.69	-0.36	6.03e-6	Systolic blood pressure;
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg15226275	chr6:116381976	FRK	0.36	6.6	0.47	6.61e-10	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11925488	chr11:45825579	SLC35C1	0.52	6.61	0.47	6.16e-10	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.82	-0.43	3.45e-8	Monocyte count;
PAAD	cis	rs11191205	0.865	rs76134290	chr10:103559245	G/T	cg15320455	chr10:103880129	LDB1	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1032355	0.558	rs1491245	chr4:100534554	T/G	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.96	11.27	0.67	8.67e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.28	0.33	3.24e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg02404636	chr22:31891804	SFI1	-0.6	-5.45	-0.4	1.98e-7	Colorectal cancer;
PAAD	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.61	-5.85	-0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg10729496	chr3:10149963	C3orf24	0.77	6.39	0.46	1.95e-9	Alzheimer's disease;
PAAD	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg03233332	chr7:66118400	NA	-0.47	-4.38	-0.33	2.19e-5	Aortic root size;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg08219700	chr8:58056026	NA	0.69	5.22	0.39	5.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9517302	0.544	rs2281766	chr13:99098882	A/C	cg22223119	chr13:99095684	FARP1	-0.74	-7.57	-0.52	3.39e-12	Obesity-related traits;
PAAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.58	-5.04	-0.38	1.3e-6	Schizophrenia;
PAAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.87e-5	Height;
PAAD	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg21770322	chr7:97807741	LMTK2	0.75	11.39	0.68	4e-22	Breast cancer;
PAAD	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg20813462	chr7:2646259	IQCE	0.65	4.61	0.35	8.38e-6	Urate levels in lean individuals;
PAAD	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.95	-7.82	-0.54	8.37e-13	Bipolar disorder;
PAAD	cis	rs10950821	0.770	rs77926987	chr7:20692384	C/A	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg02297831	chr4:17616191	MED28	0.56	5.14	0.38	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg14171486	chr1:155139557	NA	-0.34	-4.53	-0.34	1.2e-5	Breast cancer;
PAAD	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	10.3	0.64	3.45e-19	Nonalcoholic fatty liver disease;
PAAD	cis	rs9815354	1.000	rs13087719	chr3:41951576	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.91e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.39	-0.34	2.08e-5	Lung cancer in ever smokers;
PAAD	cis	rs77880822	0.562	rs76271720	chr20:1251112	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6142102	0.580	rs9753679	chr20:32540860	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.34	1.49e-5	Skin pigmentation;
PAAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.81	-5.18	-0.39	7e-7	Tuberculosis;
PAAD	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.68	-6.85	-0.49	1.69e-10	Coronary artery disease;
PAAD	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07685180	chr8:600429	NA	0.84	5.35	0.4	3.14e-7	IgG glycosylation;
PAAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg10494973	chr17:80897199	TBCD	0.56	4.55	0.35	1.08e-5	Breast cancer;
PAAD	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13424612	0.930	rs6748327	chr2:240902511	G/A	cg01812947	chr2:240904978	NDUFA10	0.57	5.0	0.38	1.58e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.72	8.32	0.56	4.56e-14	Lung cancer;
PAAD	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg05250797	chr16:70222502	NA	0.7	5.23	0.39	5.52e-7	IgE levels;
PAAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.81	-9.22	-0.6	2.35e-16	Lung cancer;
PAAD	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-6.5	-0.47	1.12e-9	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.59	-0.35	9.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs2072732	0.861	rs10909866	chr1:2960372	C/T	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg14631576	chr9:95140430	CENPP	-0.45	-4.4	-0.34	2.06e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.64	-7.1	-0.5	4.51e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.64	7.63	0.53	2.39e-12	Alcohol dependence;
PAAD	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg03188948	chr7:1209495	NA	1.11	5.54	0.41	1.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg02440177	chr19:53496695	ZNF702P	-0.58	-6.08	-0.44	9.15e-9	Psoriasis;
PAAD	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.64	-5.5	-0.41	1.57e-7	Diastolic blood pressure;
PAAD	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-0.93	-7.64	-0.53	2.26e-12	Dupuytren's disease;
PAAD	cis	rs72960926	1.000	rs11755340	chr6:75164320	G/T	cg03266952	chr6:74778945	NA	-1.27	-6.22	-0.45	4.57e-9	Metabolite levels (MHPG);
PAAD	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25632853	chr15:73088954	NA	0.4	4.55	0.35	1.08e-5	Triglyceride levels;
PAAD	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg13256891	chr4:100009986	ADH5	0.6	5.73	0.42	5.25e-8	Alcohol dependence;
PAAD	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg13446199	chr8:143762866	PSCA	0.38	4.48	0.34	1.44e-5	Urinary tract infection frequency;
PAAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.85	8.46	0.57	2.08e-14	Cognitive function;
PAAD	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.82	-5.02	-0.38	1.43e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.59	-6.3	-0.46	3.01e-9	Schizophrenia;
PAAD	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg16596103	chr2:233749413	NGEF	-0.43	-4.58	-0.35	9.73e-6	Schizophrenia;
PAAD	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.76	-0.48	2.74e-10	Coffee consumption (cups per day);
PAAD	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.8	0.43	3.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.94	9.81	0.62	6.46e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.79	-7.94	-0.54	4.16e-13	Colorectal cancer;
PAAD	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17376030	chr22:41985996	PMM1	-0.61	-4.44	-0.34	1.74e-5	Vitiligo;
PAAD	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.46	5.25	0.39	4.98e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6604026	0.656	rs6604029	chr1:93394125	C/G	cg13858687	chr1:93297071	RPL5	0.47	4.28	0.33	3.24e-5	Multiple sclerosis;
PAAD	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.32	4.31	0.33	2.91e-5	Asthma;
PAAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6142102	0.961	rs2284389	chr20:32656841	C/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.67	0.35	6.63e-6	Skin pigmentation;
PAAD	cis	rs2790216	1.000	rs2590308	chr10:59977569	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.57	5.87	0.43	2.61e-8	Multiple sclerosis;
PAAD	cis	rs787274	0.867	rs1711744	chr9:115453484	A/T	cg13803584	chr9:115635662	SNX30	-0.92	-5.8	-0.43	3.71e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.83	7.11	0.5	4.31e-11	Alzheimer's disease;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.66	-6.4	-0.46	1.81e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15128208	chr22:42549153	NA	-0.43	-4.27	-0.33	3.44e-5	Cognitive function;
PAAD	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg08390786	chr10:135334061	NA	0.47	4.53	0.34	1.18e-5	Obesity-related traits;
PAAD	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.5	4.44	0.34	1.72e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9815354	0.812	rs7652506	chr3:42060235	C/T	cg03022575	chr3:42003672	ULK4	0.77	5.44	0.4	2.12e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.8	-0.48	2.19e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.51	-4.7	-0.36	5.91e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.6	-5.94	-0.43	1.89e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08077726	chr17:74734280	SFRS2;MFSD11	0.6	6.82	0.48	2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.9	-7.29	-0.51	1.63e-11	Orofacial clefts;
PAAD	cis	rs9815354	0.812	rs73069356	chr3:41752845	G/A	cg03022575	chr3:42003672	ULK4	0.88	5.83	0.43	3.28e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.52	-4.59	-0.35	9.31e-6	Menopause (age at onset);
PAAD	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.53	-4.9	-0.37	2.45e-6	Barrett's esophagus;
PAAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg03923535	chr7:1197113	ZFAND2A	0.43	4.28	0.33	3.36e-5	Longevity;Endometriosis;
PAAD	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.53	-5.08	-0.38	1.07e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.61	6.73	0.48	3.22e-10	Obesity-related traits;
PAAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-11.12	-0.67	2.12e-21	Height;
PAAD	cis	rs10450586	0.932	rs9299997	chr11:27336872	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.71	-0.58	4.72e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.57	-5.3	-0.4	3.97e-7	Obesity-related traits;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg12573674	chr2:1569213	NA	-0.69	-5.44	-0.4	2.09e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1436294	0.757	rs474286	chr4:20194553	G/A	cg18206137	chr4:20811042	KCNIP4	-0.45	-4.28	-0.33	3.23e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg10818794	chr15:86012489	AKAP13	-0.44	-4.71	-0.36	5.53e-6	Interstitial lung disease;
PAAD	cis	rs1997066	0.831	rs116835358	chr10:106813379	A/T	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04426326	chr15:59499030	LDHAL6B;MYO1E	0.57	6.33	0.46	2.59e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.49	-5.15	-0.39	7.9e-7	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02951021	chr12:120934296	DYNLL1	0.6	7.0	0.49	7.58e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-1.15	-4.5	-0.34	1.37e-5	Asthma (childhood onset);
PAAD	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs1419980	0.730	rs11054871	chr12:7770878	C/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg12661370	chr5:149340060	SLC26A2	-0.66	-5.63	-0.42	8.31e-8	HIV-1 control;
PAAD	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.17	-0.67	1.63e-21	Rheumatoid arthritis;
PAAD	cis	rs9715521	0.803	rs62301188	chr4:59840423	A/G	cg11281224	chr4:60001000	NA	-0.61	-5.89	-0.43	2.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-1.04	-9.83	-0.62	5.99e-18	IgG glycosylation;
PAAD	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.56	-5.67	-0.42	6.98e-8	Childhood ear infection;
PAAD	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg15208524	chr1:10270712	KIF1B	0.48	4.41	0.34	1.94e-5	Hepatocellular carcinoma;
PAAD	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.3	0.56	5.24e-14	Asthma;
PAAD	trans	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg07817883	chr1:32538562	TMEM39B	1.62	7.71	0.53	1.49e-12	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6681460	0.634	rs12143964	chr1:67010266	T/G	cg02459107	chr1:67143332	SGIP1	0.57	5.03	0.38	1.35e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.59	5.28	0.39	4.48e-7	Coronary heart disease;
PAAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.82	6.99	0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.51	6.04	0.44	1.12e-8	Alcohol dependence;
PAAD	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.45	-4.92	-0.37	2.24e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.79	8.36	0.56	3.61e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg10864074	chr7:100318194	EPO	-0.46	-4.45	-0.34	1.62e-5	Other erythrocyte phenotypes;
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-1.18	-5.58	-0.41	1.05e-7	Breast cancer;
PAAD	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7210086	0.808	rs72849443	chr17:70637437	G/A	cg04206342	chr17:70636940	NA	-0.46	-5.76	-0.42	4.58e-8	Ulcerative colitis;
PAAD	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.44	-4.39	-0.34	2.12e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.61	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12681963	0.614	rs73234779	chr8:30058513	G/A	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.51e-38	Height;
PAAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.65	8.91	0.59	1.51e-15	Breast cancer;
PAAD	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	0.75	5.16	0.39	7.47e-7	Body mass index;
PAAD	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	1.14	12.14	0.7	3.82e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.96	10.26	0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.75	-6.56	-0.47	8.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9398803	0.686	rs3861458	chr6:126912162	G/A	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs7577696	0.853	rs56740303	chr2:32304656	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.83e-6	Inflammatory biomarkers;
PAAD	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg13397359	chr6:42928475	GNMT	0.59	4.78	0.36	4.03e-6	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.59	-4.81	-0.36	3.59e-6	Mammographic density (dense area);
PAAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.79	-9.83	-0.62	5.95e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9810890	1.000	rs114261227	chr3:128469760	A/C	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg16584676	chr17:46985605	UBE2Z	0.6	6.27	0.45	3.61e-9	Type 2 diabetes;
PAAD	cis	rs488248	0.540	rs56065380	chr13:106581548	G/T	cg03898952	chr13:107069935	NA	0.71	4.61	0.35	8.58e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs3106136	0.649	rs4699440	chr4:95306151	T/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.06	0.38	1.19e-6	Capecitabine sensitivity;
PAAD	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-4.67	-0.35	6.51e-6	Menarche (age at onset);
PAAD	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg05038881	chr1:10490043	APITD1	0.36	4.33	0.33	2.69e-5	Breast cancer;
PAAD	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg04749549	chr19:17459798	NA	-0.38	-4.52	-0.34	1.25e-5	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.3e-5	Parkinson's disease;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21016266	chr12:122356598	WDR66	0.58	6.97	0.49	9.06e-11	Mean corpuscular volume;
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.46	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9395066	0.545	rs4711807	chr6:44911652	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg16419906	chr5:132167176	NA	-0.61	-4.87	-0.37	2.8e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.77	-8.55	-0.57	1.25e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.72	-0.36	5.23e-6	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26122012	chr8:144450933	RHPN1;C8orf51	0.63	6.48	0.47	1.19e-9	Myopia (pathological);
PAAD	cis	rs2017305	0.834	rs12253140	chr10:70780708	G/T	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.54	-0.41	1.31e-7	Depression (quantitative trait);
PAAD	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.5	4.49	0.34	1.4e-5	Corneal astigmatism;
PAAD	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.7	6.61	0.47	6.19e-10	Mosquito bite size;
PAAD	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-9.04	-0.59	6.61e-16	Vitiligo;
PAAD	cis	rs9810890	1.000	rs73198847	chr3:128507476	C/G	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs643506	0.790	rs688095	chr11:111678771	T/C	cg09085632	chr11:111637200	PPP2R1B	0.56	4.85	0.37	3.02e-6	Breast cancer;
PAAD	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.41	-0.4	2.41e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-5.7	-0.42	6.05e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg11802864	chr11:65308245	LTBP3	0.44	4.33	0.33	2.65e-5	Bone mineral density;
PAAD	cis	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg25287198	chr4:183728479	NA	0.91	8.04	0.55	2.35e-13	Pediatric autoimmune diseases;
PAAD	cis	rs56011263	0.512	rs12502944	chr4:736054	G/A	cg14024328	chr4:719362	PCGF3	-0.54	-5.24	-0.39	5.3e-7	White blood cell count;
PAAD	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.54	0.47	8.96e-10	Aortic root size;
PAAD	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.57	-7.05	-0.5	5.75e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg27234864	chr13:21295941	IL17D	0.59	4.75	0.36	4.57e-6	Dental caries;
PAAD	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.79	5.31	0.4	3.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.96	10.26	0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.72	9.16	0.6	3.42e-16	Cancer;
PAAD	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-4.87	-0.37	2.75e-6	Facial morphology (factor 19);
PAAD	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg23387401	chr17:4582204	PELP1	-0.46	-4.94	-0.37	2.06e-6	Lymphocyte counts;
PAAD	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.85	-5.32	-0.4	3.67e-7	Response to metformin (IC50);
PAAD	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs2839627	0.564	rs57692532	chr21:44305283	C/T	cg03543861	chr21:44258195	NA	0.6	4.37	0.33	2.31e-5	Information processing speed;
PAAD	cis	rs9785234	0.838	rs714677	chr9:98940012	A/G	cg07115975	chr9:98273907	PTCH1	0.48	4.36	0.33	2.38e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs3800461	0.509	rs73407707	chr6:34476644	T/G	cg17674042	chr6:34482479	PACSIN1	-1.26	-7.44	-0.52	6.8e-12	Chronic lymphocytic leukemia;
PAAD	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.45	4.96	0.37	1.87e-6	Schizophrenia;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg10659216	chr11:65838237	PACS1	0.5	5.16	0.39	7.74e-7	Eosinophil percentage of white cells;
PAAD	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg19486271	chr11:47235900	DDB2	-0.57	-5.8	-0.43	3.7e-8	Acne (severe);
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.91	12.07	0.7	6.12e-24	Body mass index;
PAAD	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.71	9.16	0.6	3.26e-16	Coronary artery disease;
PAAD	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.61	4.89	0.37	2.6e-6	Information processing speed;
PAAD	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.47	4.44	0.34	1.69e-5	HDL cholesterol;
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.69	6.75	0.48	2.96e-10	Blood metabolite levels;
PAAD	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-9.14	-0.6	3.83e-16	Dental caries;
PAAD	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17467752	chr17:38218738	THRA	0.73	6.95	0.49	1e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.95	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.27	10.28	0.64	3.82e-19	Uric acid levels;
PAAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg25204440	chr1:209979598	IRF6	0.59	5.09	0.38	1.03e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs7631605	0.905	rs11711968	chr3:37224967	C/G	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.33e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8018808	1.000	rs35881785	chr14:77873571	C/T	cg20045696	chr14:77926864	AHSA1	0.52	5.04	0.38	1.29e-6	Myeloid white cell count;
PAAD	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.4	-0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg06569542	chr10:98946673	SLIT1	0.5	5.59	0.41	1.05e-7	Monocyte count;
PAAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.64	5.33	0.4	3.5e-7	Schizophrenia;
PAAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	1.08	9.68	0.62	1.49e-17	Monocyte percentage of white cells;
PAAD	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.81	-0.43	3.51e-8	Total cholesterol levels;
PAAD	cis	rs4740619	0.598	rs4741552	chr9:15959700	G/A	cg14451791	chr9:16040625	NA	-0.4	-4.28	-0.33	3.24e-5	Body mass index;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.15.84103R	chr15:25807768	NA	-0.66	-6.91	-0.49	1.22e-10	Lung cancer in ever smokers;
PAAD	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg08992911	chr2:238395768	MLPH	0.74	5.68	0.42	6.62e-8	Prostate cancer;
PAAD	cis	rs10804591	0.832	rs1075469	chr3:129340295	C/T	cg18548199	chr3:129281892	PLXND1	-0.56	-4.31	-0.33	2.93e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1436294	0.757	rs510228	chr4:20199584	T/C	cg18206137	chr4:20811042	KCNIP4	-0.45	-4.28	-0.33	3.23e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.65	7.6	0.52	2.87e-12	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.71	6.79	0.48	2.4e-10	Hip circumference;
PAAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.64	-5.57	-0.41	1.15e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.42	-0.52	7.9e-12	Coronary artery disease;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.53	-5.43	-0.4	2.14e-7	Testicular germ cell tumor;
PAAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.55	6.91	0.49	1.24e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.21	0.39	6.05e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.93e-6	Coronary artery disease;
PAAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg20744362	chr22:50050164	C22orf34	0.68	7.73	0.53	1.36e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.93	-10.23	-0.64	4.99e-19	Parkinson's disease;
PAAD	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16946033	chr10:737336	NA	-0.53	-6.92	-0.49	1.21e-10	Myopia (pathological);
PAAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.66	-0.35	6.93e-6	Personality dimensions;
PAAD	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.89e-8	Ileal carcinoids;
PAAD	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg24375607	chr4:120327624	NA	0.55	5.25	0.39	5.15e-7	Corneal astigmatism;
PAAD	cis	rs61173913	1	rs61173913	chr2:201351874	TA/T	cg17079352	chr2:201936157	NDUFB3;FAM126B	-0.71	-4.28	-0.33	3.33e-5	Pelvic organ prolapse;
PAAD	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.7	-9.96	-0.63	2.63e-18	Breast cancer;
PAAD	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg04165759	chr1:150448943	RPRD2	-0.54	-5.69	-0.42	6.3e-8	Migraine;
PAAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.33	0.33	2.73e-5	Personality dimensions;
PAAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.72	6.39	0.46	1.95e-9	Dilated cardiomyopathy;
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg19337854	chr7:99768885	GPC2	0.54	5.05	0.38	1.22e-6	Platelet count;
PAAD	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.92	-0.37	2.19e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.2	-0.55	9.24e-14	Hemoglobin concentration;
PAAD	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	1.0	10.76	0.66	1.93e-20	Breast cancer;
PAAD	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.58	0.35	9.49e-6	Iron status biomarkers;
PAAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs804292	0.800	rs8191589	chr8:11634194	T/A	cg26752888	chr8:11627280	NEIL2	1.14	10.62	0.65	4.68e-20	Alcohol dependence;Nicotine use;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-1.1	-10.56	-0.65	7e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.63	5.12	0.38	9.09e-7	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22955491	chr19:5661782	SAFB	0.59	6.74	0.48	3.1e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-7.83	-0.54	7.7e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.92	-12.3	-0.71	1.44e-24	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.43	0.34	1.78e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg02404636	chr22:31891804	SFI1	0.62	5.6	0.41	9.55e-8	Colorectal cancer;
PAAD	cis	rs4924935	0.683	rs34413375	chr17:18802028	C/A	cg26306683	chr17:18585705	ZNF286B	-0.63	-4.68	-0.35	6.38e-6	Pancreatic cancer;
PAAD	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.82e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg15838173	chr10:75533400	FUT11	-0.43	-4.29	-0.33	3.22e-5	Inflammatory bowel disease;
PAAD	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg00238848	chr11:72408252	ARAP1	0.43	4.41	0.34	1.95e-5	Body mass index;
PAAD	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.94	-7.83	-0.54	7.82e-13	Dupuytren's disease;
PAAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg06740227	chr12:86229804	RASSF9	0.58	5.36	0.4	3.04e-7	Major depressive disorder;
PAAD	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.76e-6	Anterior chamber depth;
PAAD	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.64	7.33	0.51	1.25e-11	Vitamin D levels;
PAAD	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Dermatomyositis;
PAAD	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg13385521	chr17:29058706	SUZ12P	0.82	4.26	0.33	3.53e-5	Body mass index;
PAAD	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.46	-4.95	-0.37	1.98e-6	Corneal astigmatism;
PAAD	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.62	-0.41	8.99e-8	Vitiligo;
PAAD	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.67	-5.75	-0.42	4.76e-8	Cognitive test performance;
PAAD	cis	rs4759375	0.588	rs28421567	chr12:123853182	C/T	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-5.72	-0.42	5.45e-8	Schizophrenia;
PAAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22524267	chr4:4543474	STX18	0.58	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg23018236	chr17:30244563	NA	-0.65	-5.47	-0.41	1.77e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg10396713	chr8:602097	NA	0.65	4.4	0.34	2.03e-5	IgG glycosylation;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.51	5.27	0.39	4.6e-7	Testicular germ cell tumor;
PAAD	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.56	4.66	0.35	6.89e-6	RR interval (heart rate);
PAAD	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.58	0.47	7.08e-10	Body mass index;
PAAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg06740227	chr12:86229804	RASSF9	0.5	4.95	0.37	1.91e-6	Major depressive disorder;
PAAD	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.35e-17	Resting heart rate;
PAAD	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs800160	0.777	rs962903	chr11:2352341	A/G	cg09785033	chr11:2336066	TSPAN32	-0.56	-4.64	-0.35	7.5e-6	Bacteremia;
PAAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.84	9.27	0.6	1.7e-16	Cognitive function;
PAAD	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.13	0.38	8.69e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.79	-8.22	-0.55	8.38e-14	Menopause (age at onset);
PAAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.59	0.35	9.36e-6	Eosinophil percentage of white cells;
PAAD	cis	rs89107	0.576	rs11967375	chr6:118823975	A/G	cg21191810	chr6:118973309	C6orf204	0.38	4.37	0.33	2.3e-5	Cardiac structure and function;
PAAD	cis	rs597583	0.806	rs1941390	chr11:117396991	G/A	cg27161313	chr11:117392002	DSCAML1	-0.76	-6.36	-0.46	2.19e-9	Putamen volume;
PAAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.26	-0.39	4.74e-7	Mean corpuscular volume;
PAAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg13722127	chr7:150037890	RARRES2	0.66	6.37	0.46	2.11e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2291447	0.934	rs4986169	chr17:43207849	G/A	cg10701640	chr17:43249399	NA	0.36	4.39	0.34	2.12e-5	Economic and political preferences;
PAAD	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.92	-11.53	-0.68	1.7e-22	Pulse pressure;
PAAD	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.44	9.63	0.62	2.03e-17	Atopic dermatitis;
PAAD	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.64	-6.09	-0.44	9.02e-9	Asthma;
PAAD	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.59	0.35	9.22e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg14703610	chr5:56206110	C5orf35	0.56	5.23	0.39	5.44e-7	Initial pursuit acceleration;
PAAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-14.84	-0.77	2.31e-31	Coronary artery disease;
PAAD	cis	rs600626	0.947	rs1219550	chr11:75453877	A/G	cg24262691	chr11:75473276	NA	0.54	5.08	0.38	1.08e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.72	6.95	0.49	1.02e-10	Resting heart rate;
PAAD	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.57	-6.68	-0.48	4.19e-10	Schizophrenia;
PAAD	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00540400	chr15:79124168	NA	0.59	6.7	0.48	3.9e-10	Coronary artery disease;
PAAD	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.67	6.77	0.48	2.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.08	-19.24	-0.84	1.44e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07930192	chr7:1003750	NA	0.41	5.15	0.39	8.1e-7	Longevity;Endometriosis;
PAAD	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.46	-4.33	-0.33	2.69e-5	Tonsillectomy;
PAAD	cis	rs1371614	0.545	rs1057115	chr2:27172069	T/C	cg07507200	chr2:27712693	IFT172	0.48	4.34	0.33	2.55e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12963246	chr6:28129442	ZNF389	0.54	4.27	0.33	3.37e-5	Parkinson's disease;
PAAD	cis	rs1468333	1.000	rs17171772	chr5:137514853	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.29	0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-6.03	-0.44	1.21e-8	Total body bone mineral density;
PAAD	cis	rs3857067	0.967	rs5019896	chr4:95035751	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	4.27	0.33	3.44e-5	QT interval;
PAAD	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.8	-9.09	-0.59	4.95e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.72	-9.02	-0.59	7.87e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.1	-0.44	8.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.62	7.9	0.54	5.21e-13	Renal cell carcinoma;
PAAD	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg01868782	chr6:126071099	HEY2	0.45	5.39	0.4	2.64e-7	Brugada syndrome;
PAAD	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg21300403	chr2:198650112	BOLL	0.48	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.54	-5.28	-0.39	4.49e-7	Prudent dietary pattern;
PAAD	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.97	-14.55	-0.76	1.33e-30	Height;
PAAD	cis	rs3206736	0.548	rs2021177	chr7:35020188	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10943724	0.679	rs2322843	chr6:81267912	A/T	cg19323245	chr6:80716898	TTK	-0.42	-4.45	-0.34	1.68e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg17710535	chr19:10819994	QTRT1	0.48	4.26	0.33	3.54e-5	Inflammatory skin disease;
PAAD	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.45	-0.34	1.65e-5	Tonsillectomy;
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.57	6.04	0.44	1.12e-8	Systemic lupus erythematosus;
PAAD	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.56	-6.5	-0.47	1.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02417684	chr16:31483534	TGFB1I1	-0.56	-6.38	-0.46	2.05e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs375066	0.762	rs2284245	chr19:44422589	A/T	cg08633290	chr19:44405433	NA	0.51	4.82	0.36	3.41e-6	Breast cancer;
PAAD	cis	rs6466055	0.661	rs6954421	chr7:104925970	A/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.49	-0.47	1.14e-9	Neuroticism;
PAAD	cis	rs13092825	0.794	rs34627996	chr3:113276381	G/C	cg08171471	chr3:113771720	KIAA1407	0.55	5.0	0.38	1.57e-6	Dental caries;
PAAD	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.4	-4.96	-0.37	1.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.84	0.37	3.16e-6	Cognitive performance;
PAAD	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg22467129	chr15:76604101	ETFA	0.5	4.77	0.36	4.29e-6	Blood metabolite levels;
PAAD	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.51	-4.64	-0.35	7.46e-6	Retinal vascular caliber;
PAAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	5.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs3996993	0.809	rs4715332	chr6:52669185	C/A	cg20803780	chr6:52668592	GSTA1	-0.35	-4.48	-0.34	1.47e-5	Hemoglobin concentration;
PAAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg04450456	chr4:17643702	FAM184B	0.46	4.89	0.37	2.54e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg11262906	chr1:85462892	MCOLN2	0.59	4.65	0.35	7.3e-6	Serum sulfate level;
PAAD	trans	rs2999052	1.000	rs4555544	chr3:127978795	G/A	cg18206867	chr2:62422351	B3GNT2	-0.46	-6.41	-0.46	1.74e-9	Hypospadias;
PAAD	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.63	7.79	0.53	9.94e-13	Schizophrenia;
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02071572	chr4:1403502	NA	0.49	6.35	0.46	2.41e-9	Longevity;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg07472159	chr6:116447667	COL10A1;NT5DC1	-0.65	-7.15	-0.5	3.36e-11	Alcohol dependence;
PAAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.97	11.12	0.67	2.2e-21	Parkinson's disease;
PAAD	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg14393609	chr7:65229607	NA	0.61	6.46	0.46	1.37e-9	Aortic root size;
PAAD	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7932354	0.583	rs6485692	chr11:46804583	G/C	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.59	6.07	0.44	9.96e-9	Pancreatic cancer;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.57	-6.73	-0.48	3.31e-10	Aortic root size;
PAAD	cis	rs7092929	0.883	rs551307	chr10:3597542	T/C	cg14308648	chr10:3568949	NA	0.69	4.99	0.38	1.62e-6	Coronary artery calcification;
PAAD	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.3	-5.56	-0.41	1.19e-7	Type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg05082376	chr22:42548792	NA	-0.5	-5.43	-0.4	2.21e-7	Cognitive function;
PAAD	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs300774	0.800	rs393008	chr2:125639	A/G	cg21211680	chr2:198530	NA	-0.64	-5.84	-0.43	3e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6585424	1.000	rs2228427	chr10:81926718	A/G	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs72772090	0.710	rs56122780	chr5:96059895	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.86	-6.52	-0.47	9.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.78	-6.66	-0.48	4.79e-10	Other erythrocyte phenotypes;
PAAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.97	11.03	0.67	3.74e-21	Parkinson's disease;
PAAD	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	4.79	0.36	3.99e-6	Breast cancer;
PAAD	cis	rs1358748	0.522	rs1321153	chr1:67584824	T/C	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs10207060	0.500	rs1316923	chr2:240719792	A/G	cg07506560	chr2:240697449	NA	-0.53	-5.55	-0.41	1.24e-7	Obesity-related traits;
PAAD	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.69	-4.84	-0.37	3.1e-6	Type 2 diabetes;
PAAD	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.02	-0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.85	-8.52	-0.57	1.5e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg20356878	chr3:121714668	ILDR1	0.57	5.27	0.39	4.51e-7	Cognitive performance;
PAAD	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.47	-4.27	-0.33	3.43e-5	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17714010	chr17:78968450	CHMP6	0.56	6.43	0.46	1.56e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg22800045	chr5:56110881	MAP3K1	0.59	5.31	0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.22	0.45	4.63e-9	Testicular germ cell tumor;
PAAD	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg01329690	chr21:38580129	DSCR9	-0.33	-4.46	-0.34	1.55e-5	Eye color traits;
PAAD	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg05038881	chr1:10490043	APITD1	0.42	5.02	0.38	1.4e-6	Prostate cancer;
PAAD	cis	rs6076065	0.723	rs2424532	chr20:23373877	G/A	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-6.25	-0.45	3.88e-9	Mitochondrial DNA levels;
PAAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.47	-5.11	-0.38	9.71e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg05418105	chr22:50981406	NA	-0.48	-4.4	-0.34	2.01e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.6	-6.0	-0.44	1.4e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs708547	0.957	rs1718875	chr4:57837438	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	4.69	0.36	6.07e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-4.25	-0.33	3.7e-5	Educational attainment;
PAAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.5	5.09	0.38	1.03e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg05299278	chr17:33885742	SLFN14	-0.44	-5.19	-0.39	6.78e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1930961	1.000	rs997873	chr22:25878282	C/G	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg10631289	chr15:39006617	NA	0.47	4.62	0.35	8.12e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.48	5.29	0.39	4.11e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.83	9.48	0.61	5.02e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.43e-7	Inflammatory bowel disease;
PAAD	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	5.34	0.4	3.33e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.66	-6.58	-0.47	7.3e-10	Glomerular filtration rate;
PAAD	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.15	0.55	1.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-7.49	-0.52	5.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg01097406	chr16:89675127	NA	-0.39	-4.73	-0.36	5.18e-6	Vitiligo;
PAAD	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.13	-0.38	8.86e-7	Bipolar disorder;
PAAD	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.72	0.48	3.38e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.88	-11.06	-0.67	3.13e-21	Prudent dietary pattern;
PAAD	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.98	0.54	3.36e-13	Response to antipsychotic treatment;
PAAD	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg23920097	chr1:209922102	NA	-0.5	-4.64	-0.35	7.46e-6	Red blood cell count;
PAAD	cis	rs11694441	0.618	rs56225271	chr2:119572685	T/C	cg14634534	chr2:119616825	NA	-0.41	-4.49	-0.34	1.41e-5	Monobrow;
PAAD	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17554472	chr22:41940697	POLR3H	0.59	4.27	0.33	3.47e-5	Vitiligo;
PAAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.84	-9.27	-0.6	1.7e-16	Obesity-related traits;
PAAD	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg01097406	chr16:89675127	NA	0.47	5.84	0.43	3.06e-8	Vitiligo;
PAAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	1.04	17.62	0.82	1.49e-38	Height;
PAAD	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.36	-0.33	2.35e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02071572	chr4:1403502	NA	0.49	6.25	0.45	3.97e-9	Longevity;
PAAD	cis	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs11018904	0.906	rs11603498	chr11:89928783	C/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.31	-0.33	2.95e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00742472	chr14:31889912	NA	0.55	6.45	0.46	1.38e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7713065	0.765	rs10076733	chr5:131760731	G/T	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.6	-0.35	8.93e-6	Lung function (FEV1/FVC);
PAAD	cis	rs2271001	0.955	rs7129212	chr11:19147268	C/T	cg00161556	chr11:19138045	ZDHHC13	0.49	5.28	0.39	4.4e-7	Gut microbiome composition (winter);
PAAD	cis	rs17683430	0.558	rs4488763	chr22:32380164	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	4.5	0.34	1.33e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs11024102	0.962	rs12575487	chr11:17019317	C/T	cg15378786	chr11:17036137	PLEKHA7	0.51	4.52	0.34	1.21e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6594713	0.759	rs13181944	chr5:112687535	T/A	cg12552261	chr5:112820674	MCC	0.61	4.27	0.33	3.47e-5	Brain cytoarchitecture;
PAAD	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg21770322	chr7:97807741	LMTK2	0.73	11.07	0.67	3e-21	Breast cancer;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	4.27	0.33	3.47e-5	Resistin levels;
PAAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Subjective well-being;
PAAD	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs5009270	0.553	rs1922901	chr7:112236153	A/G	cg23628563	chr7:112262597	NA	0.65	5.82	0.43	3.42e-8	Osteoarthritis (hip);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03923535	chr7:1197113	ZFAND2A	0.43	4.4	0.34	1.99e-5	Longevity;Endometriosis;
PAAD	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg10494973	chr17:80897199	TBCD	-0.5	-4.97	-0.37	1.8e-6	Breast cancer;
PAAD	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg00334542	chr7:100209784	MOSPD3	-0.63	-4.8	-0.36	3.78e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.64	-7.73	-0.53	1.4e-12	Renal function-related traits (BUN);
PAAD	cis	rs17213078	0.505	rs2167531	chr2:106738625	A/G	cg15412446	chr2:106886593	NA	-0.58	-5.82	-0.43	3.44e-8	Facial morphology (factor 23);
PAAD	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.45	0.52	6.71e-12	Body mass index;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13198984	chr17:80129470	CCDC57	0.42	5.16	0.39	7.66e-7	Life satisfaction;
PAAD	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg12473912	chr3:136751656	NA	0.4	4.46	0.34	1.59e-5	Gestational age at birth (child effect);
PAAD	cis	rs2594989	0.943	rs2595004	chr3:11406721	C/T	cg01796438	chr3:11312864	ATG7	-0.59	-4.42	-0.34	1.84e-5	Circulating chemerin levels;
PAAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg00579200	chr11:133705235	NA	-0.48	-5.54	-0.41	1.27e-7	Childhood ear infection;
PAAD	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg25635251	chr11:2234043	NA	0.79	7.62	0.53	2.51e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg01605746	chr5:669925	TPPP	-0.41	-4.42	-0.34	1.89e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13814496	chr9:129567797	ZBTB43	0.63	7.15	0.5	3.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.67	-5.91	-0.43	2.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.65	-6.84	-0.49	1.82e-10	Corneal astigmatism;
PAAD	cis	rs6743376	0.556	rs1800930	chr2:113820530	A/G	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.71	-6.57	-0.47	7.59e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg14983838	chr19:29218262	NA	0.71	5.88	0.43	2.56e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg10437265	chr15:77819839	NA	0.35	4.26	0.33	3.56e-5	Type 2 diabetes;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.86	0.43	2.83e-8	Platelet count;
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.61	-0.88	1.74e-50	Myeloid white cell count;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.81	-8.76	-0.58	3.65e-15	Prostate cancer;
PAAD	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-4.81	-0.36	3.66e-6	Mean corpuscular volume;
PAAD	cis	rs2286379	0.565	rs7138924	chr12:1790035	C/T	cg05227549	chr12:1770782	NA	-0.39	-4.41	-0.34	1.93e-5	Blood pressure (smoking interaction);
PAAD	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.71	7.21	0.5	2.49e-11	Uric acid levels;
PAAD	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.72	-0.42	5.57e-8	Total cholesterol levels;
PAAD	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg23665729	chr3:49977591	RBM6	0.63	4.41	0.34	1.98e-5	Schizophrenia;
PAAD	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.61	-5.93	-0.43	1.95e-8	Ear protrusion;
PAAD	cis	rs375066	0.935	rs448823	chr19:44406291	T/C	cg08633290	chr19:44405433	NA	-0.56	-5.69	-0.42	6.4e-8	Breast cancer;
PAAD	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.79e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs77106637	0.585	rs12292949	chr11:72457531	C/T	cg04827223	chr11:72435913	ARAP1	-0.52	-5.57	-0.41	1.15e-7	Type 2 diabetes;
PAAD	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg14146966	chr2:61757674	XPO1	0.38	4.63	0.35	7.72e-6	Tuberculosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05913233	chr17:7518500	FXR2;SHBG	-0.69	-6.52	-0.47	1.01e-9	Neuroticism;
PAAD	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.62	6.48	0.47	1.23e-9	Type 2 diabetes;
PAAD	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg03665132	chr1:2137325	C1orf86	-0.44	-4.27	-0.33	3.38e-5	Height;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	1.0	12.43	0.71	6.55e-25	Breast cancer;
PAAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.59	7.17	0.5	2.97e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.95	7.39	0.51	9.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7523050	1.000	rs7523050	chr1:109417679	C/A	cg08274380	chr1:109419600	GPSM2	0.66	4.85	0.37	3.09e-6	Fat distribution (HIV);
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg00024416	chr22:24240387	NA	-0.46	-4.53	-0.34	1.18e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.83	7.85	0.54	6.94e-13	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24260218	chr8:29208126	DUSP4	0.58	6.62	0.47	5.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.793	rs75322809	chr1:227573821	T/C	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.95	-6.15	-0.45	6.43e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg14146966	chr2:61757674	XPO1	0.37	4.65	0.35	7.28e-6	Tuberculosis;
PAAD	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.46	4.81	0.36	3.58e-6	Dementia with Lewy bodies;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24763094	chr2:160569157	MARCH7	-0.61	-6.58	-0.47	7.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg14393609	chr7:65229607	NA	0.64	6.99	0.49	7.95e-11	Calcium levels;
PAAD	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.81	9.64	0.62	1.86e-17	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13229655	chr1:10532570	DFFA	0.73	8.69	0.58	5.42e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02598441	chr17:62777298	LOC146880	-0.63	-4.83	-0.36	3.29e-6	QT interval;
PAAD	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.41	-0.46	1.72e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg01620082	chr3:125678407	NA	-1.25	-7.5	-0.52	5.03e-12	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.6	6.15	0.45	6.62e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.4	4.41	0.34	1.94e-5	Calcium levels;
PAAD	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.62	6.48	0.47	1.18e-9	Resting heart rate;
PAAD	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.35	0.33	2.47e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.66	-0.35	6.85e-6	Schizophrenia;
PAAD	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg11657440	chr19:46296263	DMWD	0.92	11.08	0.67	2.74e-21	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08463543	chr3:69788984	MITF	0.67	6.51	0.47	1.02e-9	Obesity-related traits;
PAAD	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg21253087	chr9:139290292	SNAPC4	0.42	4.29	0.33	3.15e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3206736	0.548	rs328895	chr7:35016387	G/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs77774742	0.887	rs6936928	chr6:145348107	C/T	cg11675148	chr6:146285568	SHPRH	-0.71	-4.47	-0.34	1.51e-5	Loneliness (multivariate analysis);
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg04733302	chr10:75118678	TTC18	-0.71	-4.66	-0.35	6.86e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2302729	0.515	rs7310079	chr12:2775477	T/C	cg19945202	chr12:2788847	CACNA1C	-0.75	-7.67	-0.53	1.88e-12	Sleep quality;
PAAD	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.78	9.07	0.59	5.56e-16	Noise-induced hearing loss;
PAAD	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs2997447	0.637	rs3008413	chr1:26407063	G/A	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg27211696	chr2:191398769	TMEM194B	0.44	4.34	0.33	2.55e-5	Urinary metabolites;
PAAD	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg23281280	chr6:28129359	ZNF389	0.5	4.44	0.34	1.69e-5	Parkinson's disease;
PAAD	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg19700328	chr14:106028568	NA	-0.64	-6.05	-0.44	1.09e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg23346134	chr3:49453900	TCTA	-0.46	-4.96	-0.37	1.9e-6	Menarche (age at onset);
PAAD	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg26597838	chr10:835615	NA	0.61	5.12	0.38	9.14e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.9	9.62	0.62	2.08e-17	Testicular germ cell tumor;
PAAD	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.4e-9	Schizophrenia;
PAAD	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.6	6.75	0.48	2.87e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.84	-0.43	3e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.61	-6.24	-0.45	4.19e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.39	13.4	0.74	1.56e-27	Corneal structure;
PAAD	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.75	-8.06	-0.55	2.14e-13	Asperger disorder;
PAAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-11.03	-0.67	3.8e-21	Coronary artery disease;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg12705353	chr12:122356852	WDR66	0.47	5.42	0.4	2.34e-7	Mean corpuscular volume;
PAAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.52	5.02	0.38	1.46e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg19792802	chr11:65647270	CTSW	-0.37	-4.76	-0.36	4.47e-6	DNA methylation (variation);
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.88	11.21	0.67	1.22e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.48	4.67	0.35	6.7e-6	Cancer;
PAAD	cis	rs7627468	1.000	rs12489943	chr3:121929287	G/A	cg17240004	chr3:121949083	CASR	0.52	4.49	0.34	1.41e-5	Kidney stones;
PAAD	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.79	6.22	0.45	4.5e-9	Schizophrenia;
PAAD	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.4	13.67	0.74	3.06e-28	Corneal structure;
PAAD	cis	rs1419980	0.730	rs11054552	chr12:7727532	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg22143635	chr11:980567	AP2A2	-0.54	-5.59	-0.41	1.03e-7	Alzheimer's disease (late onset);
PAAD	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg10820045	chr2:198174542	NA	-0.43	-4.36	-0.33	2.35e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1577917	0.545	rs9344548	chr6:86487337	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.6	0.41	9.94e-8	Response to antipsychotic treatment;
PAAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.47	4.47	0.34	1.54e-5	Menopause (age at onset);
PAAD	cis	rs7591163	0.959	rs11685995	chr2:228722008	T/C	cg22994281	chr2:228029448	COL4A3;COL4A4	0.48	4.8	0.36	3.72e-6	Blood pressure;
PAAD	cis	rs9918079	0.560	rs4698406	chr4:15640617	A/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.37	-0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.34	-0.46	2.47e-9	Hip circumference;
PAAD	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	6.55	0.47	8.23e-10	Leprosy;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs7651511	0.963	rs13099945	chr3:141232186	T/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg25037394	chr1:24152592	HMGCL	0.41	4.4	0.34	2.06e-5	Immature fraction of reticulocytes;
PAAD	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg16606324	chr3:10149918	C3orf24	0.8	6.26	0.45	3.66e-9	Alzheimer's disease;
PAAD	cis	rs2070677	0.932	rs3020499	chr10:135381215	A/G	cg18984983	chr10:135342936	CYP2E1	-0.49	-4.52	-0.34	1.25e-5	Gout;
PAAD	cis	rs6466055	0.661	rs7808226	chr7:104916166	T/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg25452165	chr22:42524984	CYP2D6	0.61	5.89	0.43	2.42e-8	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.94	8.09	0.55	1.73e-13	Triglycerides;
PAAD	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14319842	chr11:129734478	NFRKB	0.59	6.37	0.46	2.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.01	-0.54	2.75e-13	Brugada syndrome;
PAAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.82	-9.25	-0.6	1.91e-16	Lung cancer;
PAAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.85e-6	Personality dimensions;
PAAD	cis	rs959260	0.800	rs8081778	chr17:73312272	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.27	-0.33	3.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2555155	1.000	rs2250886	chr11:6529642	G/A	cg10208301	chr11:6592745	DNHD1	0.42	4.38	0.33	2.23e-5	DNA methylation (variation);
PAAD	cis	rs7786877	0.587	rs56328569	chr7:100202219	C/G	cg15510373	chr7:100224934	TFR2	-0.57	-4.75	-0.36	4.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg20356878	chr3:121714668	ILDR1	0.53	5.1	0.38	1.01e-6	Cognitive performance;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.92	-0.37	2.22e-6	Obesity-related traits;
PAAD	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.65	-4.82	-0.36	3.48e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.53	5.61	0.41	9.14e-8	Testicular germ cell tumor;
PAAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.4	-0.34	2.07e-5	Coronary artery disease;
PAAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.43	-0.46	1.59e-9	Mood instability;
PAAD	cis	rs12780845	1.000	rs7912093	chr10:17203934	A/T	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs7984522	1.000	rs9514880	chr13:109342767	C/T	cg11693848	chr13:109793698	MYO16	0.44	4.45	0.34	1.66e-5	Blood pressure;
PAAD	cis	rs72827839	0.740	rs72823594	chr17:46124276	C/T	cg23391107	chr17:45924227	SP6	0.77	5.99	0.44	1.49e-8	Ease of getting up in the morning;
PAAD	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg17771515	chr6:154831774	CNKSR3	0.59	4.26	0.33	3.55e-5	Lipoprotein (a) levels;
PAAD	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13964906	chr3:45016900	EXOSC7;ZDHHC3	0.6	6.72	0.48	3.34e-10	Monocyte percentage of white cells;
PAAD	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.46	-4.54	-0.35	1.13e-5	Breast cancer;
PAAD	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg16922058	chr20:1206700	RAD21L1	0.65	6.78	0.48	2.47e-10	Multiple sclerosis;
PAAD	cis	rs7904985	0.813	rs1077092	chr10:88101391	G/A	cg07322936	chr10:88137208	NA	-0.47	-4.34	-0.33	2.59e-5	Barrett's esophagus;
PAAD	cis	rs9486594	0.627	rs2430466	chr6:107636031	A/G	cg23052020	chr6:106960170	AIM1	0.62	4.55	0.35	1.08e-5	Airway responsiveness in chronic obstructive pulmonary disease;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg05627522	chr15:75251581	NA	0.54	6.35	0.46	2.36e-9	Caffeine consumption;
PAAD	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.54	4.67	0.35	6.55e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06481639	chr22:41940642	POLR3H	0.6	4.34	0.33	2.55e-5	Vitiligo;
PAAD	cis	rs802075	0.905	rs1025348	chr6:49652760	T/C	cg20364632	chr6:49636226	NA	-0.5	-5.79	-0.43	3.92e-8	Bone mineral density (hip) and age at menarche;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06879406	chr19:797398	PTBP1	0.67	7.28	0.51	1.64e-11	Myopia (pathological);
PAAD	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.59	-6.15	-0.45	6.51e-9	Hypospadias;
PAAD	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.73	-5.97	-0.44	1.62e-8	Gallbladder cancer;
PAAD	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.75	5.57	0.41	1.14e-7	Initial pursuit acceleration;
PAAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	2.04e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg11380483	chr2:127933992	NA	0.48	4.97	0.37	1.75e-6	Self-rated health;
PAAD	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.66	0.48	4.63e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1656368	0.655	rs10936144	chr3:158189962	C/T	cg16708174	chr3:158430962	RARRES1	0.62	5.52	0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.8	-7.18	-0.5	2.94e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg12395012	chr8:11607386	GATA4	0.39	4.28	0.33	3.27e-5	Monocyte count;
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.85	-0.37	3.01e-6	Eosinophil percentage of white cells;
PAAD	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg25649188	chr17:73499917	CASKIN2	0.62	5.69	0.42	6.33e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.53	-5.48	-0.41	1.73e-7	White blood cell count;
PAAD	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg04087571	chr11:116723030	SIK3	-0.44	-5.08	-0.38	1.07e-6	Subjective well-being;
PAAD	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.29	0.51	1.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.11	0.38	9.36e-7	Educational attainment;
PAAD	cis	rs6074578	0.740	rs1858597	chr20:147685	G/T	cg16931068	chr20:139680	DEFB127	-0.39	-5.21	-0.39	5.97e-7	Hirschsprung disease;
PAAD	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.98	-6.65	-0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.61	-0.35	8.49e-6	Prevalent atrial fibrillation;
PAAD	cis	rs2153535	0.518	rs1998265	chr6:8652162	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	4.34	0.33	2.58e-5	Motion sickness;
PAAD	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.87	0.37	2.79e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.58	-0.47	7.29e-10	Neuroticism;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14574726	chr11:809735	RPLP2	0.6	6.87	0.49	1.54e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg12705353	chr12:122356852	WDR66	0.45	4.72	0.36	5.25e-6	Mean corpuscular volume;
PAAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.61	-6.61	-0.47	5.98e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.75	8.61	0.57	8.42e-15	Colorectal cancer;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.69	-7.83	-0.54	7.91e-13	Iron status biomarkers;
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.76	0.42	4.59e-8	Bipolar disorder;
PAAD	cis	rs4629180	0.917	rs7560926	chr2:102125098	C/A	cg04415270	chr2:102091202	RFX8	0.71	8.66	0.57	6.37e-15	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs732765	0.734	rs17183132	chr14:75153818	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.5	-0.34	1.34e-5	Non-small cell lung cancer;
PAAD	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Depression;
PAAD	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.09	-0.38	1.04e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.87	6.46	0.46	1.33e-9	Axial length;
PAAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg03959625	chr15:84868606	LOC388152	-0.49	-5.37	-0.4	2.88e-7	Schizophrenia;
PAAD	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.46	5.59	0.41	1e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg04545296	chr12:48745243	ZNF641	0.34	4.33	0.33	2.74e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-4.61	-0.35	8.54e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.55	-0.41	1.21e-7	Bipolar disorder;
PAAD	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg08898775	chr15:59042684	ADAM10	0.37	4.75	0.36	4.67e-6	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06382786	chr17:57297815	GDPD1	-0.75	-6.63	-0.47	5.51e-10	Neuroticism;
PAAD	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.81	10.03	0.63	1.75e-18	Bladder cancer;
PAAD	trans	rs9328321	0.505	rs77757738	chr6:5583883	C/T	cg20268689	chr2:20431435	NA	-0.43	-6.6	-0.47	6.59e-10	Obesity (early onset extreme);
PAAD	cis	rs1712517	0.525	rs7911488	chr10:105154089	A/G	cg04362960	chr10:104952993	NT5C2	-0.51	-4.97	-0.37	1.77e-6	Migraine;
PAAD	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.55	5.6	0.41	1e-7	Resting heart rate;
PAAD	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.98	-0.44	1.55e-8	Calcium levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13904842	chr6:28180511	NA	0.68	7.57	0.52	3.37e-12	Myopia (pathological);
PAAD	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg20259534	chr15:40453036	BUB1B	0.74	5.74	0.42	4.87e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26306683	chr17:18585705	ZNF286B	0.58	5.92	0.43	2.04e-8	Educational attainment (years of education);
PAAD	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.71	8.34	0.56	4.27e-14	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.75	6.18	0.45	5.48e-9	Blood protein levels;
PAAD	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.79	-0.36	3.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.31	0.51	1.42e-11	Eosinophil percentage of white cells;
PAAD	cis	rs757081	0.579	rs11024221	chr11:17274550	T/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.49	-0.41	1.63e-7	Systolic blood pressure;
PAAD	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7301016	0.948	rs12370404	chr12:62923340	T/C	cg11441379	chr12:63026424	NA	0.84	6.07	0.44	9.66e-9	IgG glycosylation;
PAAD	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.65	8.93	0.59	1.34e-15	Breast size;
PAAD	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.93	5.52	0.41	1.41e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01765077	chr12:122356316	WDR66	0.58	6.43	0.46	1.53e-9	Mean corpuscular volume;
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Body mass index;
PAAD	cis	rs59698941	0.943	rs72801413	chr5:132314105	G/A	cg16419906	chr5:132167176	NA	-0.62	-4.59	-0.35	9.03e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08677398	chr8:58056175	NA	0.66	4.94	0.37	2.01e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.46	-0.34	1.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.49	-5.49	-0.41	1.66e-7	Migraine;
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.53	0.47	9.22e-10	Cystic fibrosis severity;
PAAD	cis	rs2885056	0.891	rs892082	chr19:10680478	A/G	cg04833646	chr19:10679720	CDKN2D	1.02	10.2	0.64	6.02e-19	Red cell distribution width;
PAAD	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28647808	1.000	rs4962143	chr9:136275137	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs2034650	0.544	rs11070272	chr15:40725263	A/G	cg05276125	chr15:40653601	DISP2	0.51	4.74	0.36	4.89e-6	Interstitial lung disease;
PAAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00142150	chr22:38071001	LGALS1	0.81	9.09	0.59	5.15e-16	Fat distribution (HIV);
PAAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7127900	1.000	rs11043134	chr11:2232682	T/C	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg10856724	chr12:34555212	NA	0.43	4.46	0.34	1.56e-5	Morning vs. evening chronotype;
PAAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-4.34	-0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs4716602	0.828	rs10270046	chr7:156159047	T/C	cg04090468	chr7:156181990	NA	0.5	4.82	0.36	3.42e-6	Anti-saccade response;
PAAD	cis	rs62025270	0.632	rs78572940	chr15:86239770	A/C	cg13263323	chr15:86062960	AKAP13	0.52	4.63	0.35	7.78e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02725872	chr8:58115012	NA	-0.6	-5.14	-0.38	8.32e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2109514	1.000	rs4727833	chr7:116147908	C/G	cg19719915	chr7:115928094	NA	-0.45	-4.3	-0.33	3.06e-5	Prevalent atrial fibrillation;
PAAD	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg21605333	chr4:119757512	SEC24D	0.76	5.95	0.43	1.79e-8	Cannabis dependence symptom count;
PAAD	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.49	4.67	0.35	6.47e-6	Corneal structure;
PAAD	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs9810890	1.000	rs114329538	chr3:128558387	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6137287	0.924	rs6035790	chr20:21135597	G/T	cg04219410	chr20:21106687	PLK1S1	0.4	4.61	0.35	8.34e-6	Height;
PAAD	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.44	6.79	0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.79e-5	Migraine;
PAAD	cis	rs2944755	0.580	rs13251004	chr8:141586126	G/A	cg08632810	chr8:141609470	EIF2C2	-0.37	-4.54	-0.35	1.13e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs8170	0.603	rs3745187	chr19:17414126	C/T	cg10664184	chr19:17420304	DDA1	0.48	4.38	0.33	2.18e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg06815965	chr1:205818668	PM20D1	-0.61	-6.89	-0.49	1.38e-10	Menarche (age at onset);
PAAD	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.79	-5.61	-0.41	9.27e-8	Coronary artery calcification;
PAAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Tonsillectomy;Mean corpuscular volume;
PAAD	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.75	-8.06	-0.55	2.07e-13	Blood metabolite levels;
PAAD	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.9	12.23	0.7	2.19e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2131877	0.830	rs952586	chr3:194842322	G/A	cg21937377	chr3:194868750	C3orf21	0.47	4.68	0.35	6.35e-6	Non-small cell lung cancer;
PAAD	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg21280320	chr1:152162025	NA	-0.53	-4.57	-0.35	9.92e-6	Inflammatory skin disease;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg05457628	chr5:178986728	RUFY1	0.67	6.98	0.49	8.62e-11	Lung cancer;
PAAD	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg10820045	chr2:198174542	NA	0.53	5.24	0.39	5.2e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12541635	1.000	rs11992752	chr8:107083122	G/A	cg10147462	chr8:107024639	NA	-0.44	-4.64	-0.35	7.54e-6	Age of smoking initiation;
PAAD	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg10977910	chr1:84465055	TTLL7	0.49	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs2073300	1.000	rs6048824	chr20:23457645	C/A	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg13798912	chr7:905769	UNC84A	0.56	4.33	0.33	2.64e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19500275	chr17:80737654	TBCD	0.53	4.35	0.33	2.49e-5	Glycated hemoglobin levels;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	4.28	0.33	3.29e-5	Bone mineral density;
PAAD	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.47	-4.83	-0.36	3.28e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	trans	rs4272720	0.855	rs11817325	chr10:50237784	C/T	cg15329866	chr3:171455826	PLD1	0.74	6.57	0.47	7.38e-10	Platelet count;Plateletcrit;
PAAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg18833306	chr6:118973337	C6orf204	-0.53	-4.35	-0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs894157	0.920	rs11073876	chr15:90105083	C/T	cg06792126	chr15:90365488	NA	-0.62	-4.34	-0.33	2.62e-5	Obesity-related traits;
PAAD	cis	rs6445967	1.000	rs2292674	chr3:58302404	A/T	cg23715586	chr3:58305044	RPP14	0.48	4.31	0.33	2.88e-5	Platelet count;
PAAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.94	12.25	0.7	1.93e-24	Menopause (age at onset);
PAAD	trans	rs1442089	0.764	rs56227427	chr18:51104342	G/A	cg24118715	chr10:70232072	DNA2	0.71	6.4	0.46	1.79e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs6604026	0.630	rs11583491	chr1:93463949	C/T	cg13858687	chr1:93297071	RPL5	0.48	4.28	0.33	3.31e-5	Multiple sclerosis;
PAAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.09	0.44	8.72e-9	Menopause (age at onset);
PAAD	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.44	7.06	0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	4.5	0.34	1.34e-5	Height;
PAAD	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.1	10.34	0.64	2.62e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg02841227	chr6:26021843	HIST1H4A	0.47	4.62	0.35	8.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-4.46	-0.34	1.56e-5	Mean corpuscular volume;
PAAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.9	11.04	0.67	3.55e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg23119463	chr10:134592391	INPP5A	-0.51	-4.74	-0.36	4.88e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.36	0.51	1.08e-11	Alzheimer's disease;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg12757816	chr2:10669957	NA	0.54	5.84	0.43	3.05e-8	Prostate cancer;
PAAD	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.63	-5.73	-0.42	5.19e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.89	-7.39	-0.51	9.05e-12	Triglycerides;
PAAD	cis	rs6141769	0.542	rs6087976	chr20:31316287	G/A	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09162158	chr7:150945869	SMARCD3	-0.75	-6.29	-0.45	3.17e-9	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06482044	chr16:31191169	FUS	-0.65	-6.78	-0.48	2.53e-10	Smoking initiation;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.86	10.51	0.65	9.46e-20	Prudent dietary pattern;
PAAD	cis	rs17601876	0.679	rs11636403	chr15:51548744	A/G	cg21478137	chr15:51532386	CYP19A1	-0.46	-4.57	-0.35	1.01e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.27e-17	Schizophrenia;
PAAD	cis	rs300774	0.925	rs408074	chr2:150853	T/C	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.04	0.63	1.63e-18	Prudent dietary pattern;
PAAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.26	-0.45	3.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg20129853	chr10:51489980	NA	0.5	4.75	0.36	4.62e-6	Prostate-specific antigen levels;
PAAD	trans	rs901683	1.000	rs34654893	chr10:45979828	C/T	cg23720331	chr10:123873670	TACC2	-0.9	-6.68	-0.48	4.21e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.5	-4.8	-0.36	3.72e-6	Mean platelet volume;
PAAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.78	8.81	0.58	2.6e-15	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg00684032	chr4:1343700	KIAA1530	0.63	6.56	0.47	7.99e-10	Longevity;
PAAD	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.47	4.83	0.36	3.35e-6	Male-pattern baldness;
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.91	9.75	0.62	9.78e-18	Blood metabolite levels;
PAAD	cis	rs7763441	0.836	rs9503194	chr6:2445280	G/A	cg18740289	chr6:2437142	NA	-0.53	-4.93	-0.37	2.16e-6	Monobrow;
PAAD	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.11	0.38	9.33e-7	Childhood ear infection;
PAAD	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.57	-5.21	-0.39	6.04e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg23446514	chr15:66797150	ZWILCH;SNORD18A;RPL4	0.62	6.92	0.49	1.18e-10	Iris heterochromicity;
PAAD	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs10901513	0.932	rs7078337	chr10:127663957	C/T	cg22975853	chr10:127789788	ADAM12	0.42	4.55	0.35	1.1e-5	Visceral fat;
PAAD	cis	rs2131877	0.871	rs28569214	chr3:194871488	A/G	cg11177333	chr3:195857752	NA	0.44	4.28	0.33	3.3e-5	Non-small cell lung cancer;
PAAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg03808351	chr9:123631620	PHF19	0.46	4.96	0.37	1.87e-6	Rheumatoid arthritis;
PAAD	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.91	-0.66	8.07e-21	Platelet distribution width;
PAAD	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.86	9.81	0.62	6.49e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg10556349	chr10:835070	NA	0.54	4.25	0.33	3.72e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.88	8.09	0.55	1.72e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg22396632	chr1:3079212	PRDM16	-0.44	-4.62	-0.35	8.19e-6	Migraine;
PAAD	cis	rs12681288	0.782	rs2600498	chr8:1026520	A/G	cg04851639	chr8:1020857	NA	-0.65	-8.1	-0.55	1.64e-13	Schizophrenia;
PAAD	cis	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.55	0.35	1.08e-5	Neuroticism;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.71	7.94	0.54	4.22e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg17595323	chr11:93583763	C11orf90	-0.37	-4.61	-0.35	8.41e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg13332499	chr17:408570	NA	0.65	7.12	0.5	4.04e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg01299579	chr2:10830716	NOL10	0.58	5.97	0.44	1.65e-8	Prostate cancer;
PAAD	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.59	-0.35	9.4e-6	Type 2 diabetes;
PAAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.72	6.77	0.48	2.67e-10	Monocyte count;
PAAD	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg04165759	chr1:150448943	RPRD2	0.51	5.18	0.39	6.82e-7	Migraine;
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01616529	chr11:638424	DRD4	-0.62	-5.82	-0.43	3.39e-8	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12520249	chr4:87260624	MAPK10	-0.6	-6.52	-0.47	9.64e-10	Obesity-related traits;
PAAD	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg02631450	chr22:32366979	NA	1.01	5.36	0.4	3.04e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.61	5.0	0.38	1.54e-6	Alzheimer's disease (late onset);
PAAD	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg18944383	chr4:111397179	ENPEP	0.65	7.19	0.5	2.75e-11	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15462247	chr14:74182558	PNMA1;C14orf43	-0.61	-6.68	-0.48	4.24e-10	Obesity-related traits;
PAAD	cis	rs67385638	0.802	rs7119142	chr11:5309078	A/G	cg12559170	chr11:5275217	HBG2	0.44	4.34	0.33	2.57e-5	Hemoglobin levels;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.45	-4.56	-0.35	1.04e-5	Ovarian reserve;
PAAD	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.73	0.36	4.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.67	6.84	0.49	1.8e-10	Menarche (age at onset);
PAAD	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.24	-0.64	4.7e-19	Response to antipsychotic treatment;
PAAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg15674680	chr20:60982522	CABLES2	-0.49	-4.43	-0.34	1.8e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	5.88	0.43	2.48e-8	Total body bone mineral density;
PAAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg12037450	chr1:85513124	MCOLN3	-0.46	-4.49	-0.34	1.43e-5	Serum sulfate level;
PAAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg04450456	chr4:17643702	FAM184B	0.45	4.43	0.34	1.8e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg07943548	chr15:86304357	KLHL25	-0.71	-5.93	-0.43	1.99e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.76	-6.29	-0.45	3.25e-9	Pancreatic cancer;
PAAD	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14061529	chr6:109416235	SESN1;C6orf182	0.69	7.04	0.5	6.1e-11	Obesity-related traits;
PAAD	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.64	6.36	0.46	2.19e-9	Depressive symptoms;
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18800785	chr3:186083922	NA	0.4	4.75	0.36	4.6e-6	Myopia (pathological);
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.63	-5.79	-0.43	3.83e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg11062466	chr8:58055876	NA	0.68	4.79	0.36	3.97e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.52	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.47	4.49	0.34	1.39e-5	Airway imaging phenotypes;
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.66	-0.42	7.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.41	-6.02	-0.44	1.26e-8	Educational attainment (years of education);
PAAD	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.76	-8.82	-0.58	2.46e-15	Pulse pressure;
PAAD	cis	rs3829109	0.564	rs11145793	chr9:139274523	G/A	cg21253087	chr9:139290292	SNAPC4	0.53	4.77	0.36	4.37e-6	Peak insulin response;Acute insulin response;
PAAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05665937	chr4:1216051	CTBP1	0.53	5.82	0.43	3.38e-8	Obesity-related traits;
PAAD	cis	rs3136739	0.614	rs2020923	chr8:42037630	C/T	cg12054981	chr8:42037387	PLAT	0.75	5.47	0.41	1.78e-7	Plasma plasminogen activator levels;
PAAD	cis	rs55637147	0.703	rs3781899	chr11:57126897	G/A	cg25492363	chr11:57319872	UBE2L6	-0.39	-4.31	-0.33	2.93e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.53e-9	Cognitive function;
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.68	-5.76	-0.42	4.57e-8	Bone mineral density;
PAAD	cis	rs11811982	0.793	rs76860817	chr1:227358442	C/T	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.53e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.38e-6	Morning vs. evening chronotype;
PAAD	cis	rs7651511	1.000	rs9836050	chr3:141257285	A/G	cg25967872	chr3:141205623	RASA2	0.51	4.53	0.35	1.16e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.55	-5.51	-0.41	1.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.57	4.62	0.35	8e-6	Mammographic density (dense area);
PAAD	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.86	9.71	0.62	1.25e-17	Mortality in heart failure;
PAAD	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-6.45	-0.46	1.38e-9	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11450715	chr2:171627404	NA	0.57	6.63	0.47	5.6e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg24881330	chr22:46731750	TRMU	1.15	5.48	0.41	1.71e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg04160749	chr8:58172571	NA	-0.63	-4.26	-0.33	3.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs11686241	1.000	rs11886888	chr2:217289413	C/T	cg15830940	chr2:217278069	SMARCAL1	0.43	4.26	0.33	3.57e-5	Cancer;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg13012494	chr21:47604986	C21orf56	0.44	4.83	0.36	3.33e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg05805236	chr11:65401703	PCNXL3	-0.45	-5.19	-0.39	6.74e-7	Systemic lupus erythematosus;
PAAD	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.8	0.43	3.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2632516	1.000	rs2526378	chr17:56404349	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.88	0.37	2.68e-6	Alzheimer's disease;Alzheimer's disease in APOE e4- carriers;Monocyte count;
PAAD	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	1.15	11.49	0.68	2.13e-22	Cisplatin-induced ototoxicity;
PAAD	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.27	-0.33	3.48e-5	Coronary artery disease;
PAAD	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.59	6.23	0.45	4.4e-9	Bladder cancer;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.97	8.17	0.55	1.12e-13	Blood protein levels;
PAAD	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.61	0.35	8.62e-6	Personality dimensions;
PAAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.08	0.59	5.46e-16	Menopause (age at onset);
PAAD	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg14003231	chr6:33640908	ITPR3	0.48	5.65	0.42	7.52e-8	Platelet count;
PAAD	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg17644776	chr2:200775616	C2orf69	-0.45	-4.33	-0.33	2.7e-5	QT interval;
PAAD	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.53	-5.36	-0.4	3e-7	Parkinson's disease;
PAAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.31	0.46	2.96e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.7	6.83	0.48	1.91e-10	Blood metabolite levels;
PAAD	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg08992911	chr2:238395768	MLPH	0.7	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg17759274	chr19:39260954	NA	0.52	6.05	0.44	1.08e-8	Heart rate;
PAAD	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.79	-8.32	-0.56	4.74e-14	Systolic blood pressure;
PAAD	cis	rs4795519	0.808	rs11650291	chr17:22153109	A/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.28	-0.39	4.44e-7	Chronic myeloid leukemia;
PAAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.76	9.35	0.6	1.04e-16	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17417787	chr12:112123558	ACAD10;BRAP	0.66	6.31	0.46	2.84e-9	Obesity-related traits;
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.51	5.57	0.41	1.15e-7	Total body bone mineral density;
PAAD	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg27490568	chr2:178487706	NA	0.63	6.46	0.46	1.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.94	6.62	0.47	5.86e-10	Opioid sensitivity;
PAAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg05110241	chr16:68378359	PRMT7	-0.93	-7.29	-0.51	1.61e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs988913	1.000	rs7765236	chr6:54835567	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs7084921	0.608	rs11596211	chr10:101840119	T/A	cg04359915	chr10:101825029	CPN1	-0.32	-4.63	-0.35	7.7e-6	Bone mineral density;
PAAD	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.55	-0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs138918	0.776	rs138938	chr22:43569608	C/A	cg00343092	chr22:43547974	TSPO	0.42	4.69	0.36	6e-6	Monocyte count;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.73	-8.37	-0.56	3.6e-14	Renal function-related traits (BUN);
PAAD	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7922314	0.571	rs11816955	chr10:64722455	T/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg14515779	chr1:101123966	NA	-0.48	-5.15	-0.39	7.79e-7	Breast cancer;
PAAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.92	-10.71	-0.66	2.78e-20	Total body bone mineral density;
PAAD	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.46	4.38	0.33	2.23e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs6604026	0.656	rs2481713	chr1:93354889	G/T	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.65	-7.08	-0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg19223190	chr17:80058835	NA	0.56	5.76	0.42	4.62e-8	Life satisfaction;
PAAD	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.77	-6.53	-0.47	9.08e-10	Vitiligo;
PAAD	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.66	0.48	4.83e-10	Coronary artery disease;
PAAD	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg07636037	chr3:49044803	WDR6	0.56	4.39	0.34	2.1e-5	Menarche (age at onset);
PAAD	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.13	-0.38	8.62e-7	Neuroticism;
PAAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.76	-8.89	-0.58	1.65e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg23587288	chr2:27483067	SLC30A3	-0.79	-6.6	-0.47	6.54e-10	Blood metabolite levels;
PAAD	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.9	7.44	0.52	6.93e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2004318	0.850	rs116885287	chr19:55077296	C/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-5.7	-0.42	5.92e-8	Prostate cancer;
PAAD	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	1.16	11.78	0.69	3.55e-23	Cisplatin-induced ototoxicity;
PAAD	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg18084798	chr19:33555255	RHPN2	0.48	5.01	0.38	1.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.49	-5.13	-0.38	8.8e-7	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07269724	chr19:12904655	NA	0.59	6.68	0.48	4.31e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg06917634	chr15:78832804	PSMA4	-0.46	-4.51	-0.34	1.28e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.71	-4.25	-0.33	3.68e-5	Tuberculosis;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.42	0.56	2.69e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs6684514	1.000	rs12132919	chr1:156318141	C/A	cg16558208	chr1:156270281	VHLL	0.49	4.64	0.35	7.51e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9810890	1.000	rs73210606	chr3:128617426	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.11	0.5	4.31e-11	Dental caries;
PAAD	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs134594	0.885	rs134660	chr22:29490956	G/C	cg01361351	chr22:29467363	NA	-0.39	-4.35	-0.33	2.51e-5	Birth weight;
PAAD	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23138678	chr14:75894283	JDP2	-0.74	-7.7	-0.53	1.66e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg11196182	chr7:1989412	MAD1L1	0.41	4.33	0.33	2.7e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg15192750	chr16:69999425	NA	0.74	5.74	0.42	4.99e-8	IgE levels;
PAAD	cis	rs501120	0.584	rs11238891	chr10:44670992	A/C	cg09554077	chr10:44749378	NA	-0.43	-4.94	-0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg18551225	chr6:44695536	NA	-0.7	-7.02	-0.5	6.72e-11	Total body bone mineral density;
PAAD	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.65	4.9	0.37	2.39e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg13821571	chr21:34406537	NA	-0.46	-4.46	-0.34	1.57e-5	Gastritis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10230308	chr17:61678218	TACO1	-0.66	-6.64	-0.47	5.1e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.88	-10.24	-0.64	4.94e-19	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.12e-6	Life satisfaction;
PAAD	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.78	-10.64	-0.65	4.11e-20	Iron status biomarkers;
PAAD	cis	rs9503598	0.522	rs6938957	chr6:3430835	G/A	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.32	-0.33	2.77e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg14774817	chr2:182183372	NA	-0.6	-6.31	-0.46	2.93e-9	Alcohol dependence;
PAAD	cis	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.49	4.45	0.34	1.62e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1334894	1.000	rs55922240	chr6:35608096	T/C	cg07213720	chr6:35227408	ZNF76	-0.89	-4.85	-0.37	3.01e-6	Coronary artery disease;
PAAD	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.66	6.59	0.47	6.83e-10	Multiple sclerosis;
PAAD	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7833787	1.000	rs7844375	chr8:18703258	A/G	cg17701159	chr8:18705777	PSD3	-0.46	-5.39	-0.4	2.63e-7	Obesity-related traits;
PAAD	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06998765	chr14:75389618	RPS6KL1	-0.28	-4.95	-0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.43	-5.45	-0.4	1.95e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00002490	chr4:2264510	MXD4	0.45	4.38	0.34	2.16e-5	Obesity-related traits;
PAAD	cis	rs365132	0.934	rs183686	chr5:176494102	A/G	cg25401027	chr5:176370377	UIMC1	0.55	5.3	0.4	3.98e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16308101	chr1:67895914	SERBP1	0.58	6.32	0.46	2.78e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6782228	1.000	rs6782228	chr3:128323424	G/C	cg07730360	chr3:128845626	NA	-0.49	-4.27	-0.33	3.38e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg13736514	chr6:26305472	NA	-0.59	-6.27	-0.45	3.63e-9	Educational attainment;
PAAD	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-8.04	-0.55	2.29e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.63	6.98	0.49	8.6e-11	Coronary artery disease;
PAAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-8.67	-0.58	6.08e-15	Coronary artery disease;
PAAD	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.54	-4.89	-0.37	2.5e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg16539640	chr15:22945028	CYFIP1	0.61	6.5	0.47	1.07e-9	Educational attainment (years of education);
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.95	6.63	0.47	5.63e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.76	7.4	0.51	8.6e-12	Gout;
PAAD	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.5	-0.52	4.83e-12	Blood metabolite levels;
PAAD	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.58	0.47	7.08e-10	Body mass index;
PAAD	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.42	4.62	0.35	8.15e-6	Dietary macronutrient intake;
PAAD	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs1420338	1.000	rs918038	chr7:34153768	A/G	cg01275685	chr7:34179230	BMPER	-0.54	-5.11	-0.38	9.73e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg11859384	chr17:80120422	CCDC57	-0.49	-5.13	-0.38	8.85e-7	Life satisfaction;
PAAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.63	6.52	0.47	9.68e-10	Coronary artery disease;
PAAD	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.62	-0.47	5.68e-10	Lung cancer;
PAAD	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.71	-6.43	-0.46	1.53e-9	Blood pressure (smoking interaction);
PAAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-1.02	-5.43	-0.4	2.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14331002	chr19:11201349	LDLR	-0.71	-6.36	-0.46	2.28e-9	Neuroticism;
PAAD	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg02811702	chr13:24901961	NA	0.54	5.82	0.43	3.38e-8	Obesity-related traits;
PAAD	cis	rs11264799	0.765	rs12136747	chr1:157636930	C/G	cg18268488	chr1:157545234	FCRL4	-0.42	-4.76	-0.36	4.54e-6	IgA nephropathy;
PAAD	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00292662	chr22:38071168	LGALS1	0.68	6.96	0.49	9.64e-11	Fat distribution (HIV);
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-6.78	-0.48	2.44e-10	Lymphocyte counts;
PAAD	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.36	0.46	2.29e-9	Blood protein levels;
PAAD	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.55	4.5	0.34	1.36e-5	Heschl's gyrus morphology;
PAAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	Schizophrenia;
PAAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.87	9.68	0.62	1.43e-17	Cognitive function;
PAAD	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.68	-6.56	-0.47	7.83e-10	Platelet distribution width;
PAAD	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.73e-8	Migraine;
PAAD	cis	rs6908034	0.600	rs79733895	chr6:19799541	A/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15312298	chr8:127570908	FAM84B	0.59	6.45	0.46	1.42e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-5.27	-0.39	4.67e-7	Response to metformin (IC50);
PAAD	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg10705379	chr10:99080932	FRAT1	-0.45	-5.28	-0.39	4.34e-7	Monocyte count;
PAAD	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17376030	chr22:41985996	PMM1	0.67	4.59	0.35	9.34e-6	Vitiligo;
PAAD	cis	rs9322817	0.691	rs7743022	chr6:105170381	G/T	cg02098413	chr6:105308735	HACE1	-0.41	-5.14	-0.38	8.37e-7	Thyroid stimulating hormone;
PAAD	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.94	12.4	0.71	7.56e-25	Menopause (age at onset);
PAAD	cis	rs1903068	0.853	rs9997685	chr4:56022903	A/T	cg01777861	chr4:56023843	NA	0.35	4.52	0.34	1.23e-5	Endometriosis;
PAAD	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.73	0.72	9.85e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3981351	0.797	rs61866461	chr10:115454862	C/A	cg24846397	chr10:115438155	CASP7	-0.56	-5.19	-0.39	6.64e-7	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.52	-4.96	-0.37	1.86e-6	Mortality in heart failure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09278885	chr1:2126389	C1orf86;LOC100128003	0.65	7.05	0.5	5.89e-11	Monocyte percentage of white cells;
PAAD	cis	rs863345	0.604	rs6674656	chr1:158495431	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs35740288	0.706	rs2614664	chr15:86298716	G/A	cg07943548	chr15:86304357	KLHL25	-0.52	-5.02	-0.38	1.41e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.48	-5.22	-0.39	5.87e-7	Ulcerative colitis;
PAAD	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs1997066	0.831	rs73342296	chr10:106823336	C/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg06637938	chr14:75390232	RPS6KL1	0.48	4.66	0.35	6.74e-6	Height;
PAAD	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.23	-0.39	5.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg16434002	chr17:42200994	HDAC5	-0.65	-5.72	-0.42	5.36e-8	Total body bone mineral density;
PAAD	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs1535500	0.967	rs10947804	chr6:39282036	T/C	cg02883595	chr6:39281421	KCNK17	-0.45	-4.32	-0.33	2.77e-5	Type 2 diabetes;
PAAD	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-7.4	-0.51	8.73e-12	Total cholesterol levels;
PAAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.4	-5.14	-0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg17325771	chr7:75508891	RHBDD2	0.31	4.39	0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06723301	chr22:21213449	SNAP29;PI4KA	0.56	6.37	0.46	2.13e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.53	-0.52	4.19e-12	Mosquito bite size;
PAAD	cis	rs10450586	0.899	rs11029916	chr11:27311695	T/C	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg10556349	chr10:835070	NA	0.59	4.89	0.37	2.53e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.97	-9.8	-0.62	6.98e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg07341007	chr3:195489909	MUC4	-0.66	-5.05	-0.38	1.26e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg16898833	chr6:26189333	HIST1H4D	0.78	4.62	0.35	8.29e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9463078	0.546	rs1284972	chr6:45077398	T/C	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.61	-6.37	-0.46	2.14e-9	Height;
PAAD	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.9	0.37	2.42e-6	Lung cancer in ever smokers;
PAAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.47	-5.16	-0.39	7.52e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.76	5.26	0.39	4.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg15181151	chr6:150070149	PCMT1	0.6	6.6	0.47	6.36e-10	Lung cancer;
PAAD	cis	rs16958440	0.867	rs77615793	chr18:44684464	C/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.81	-0.36	3.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1950626	0.743	rs12884454	chr14:101465627	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.99	12.24	0.7	2.13e-24	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs76419734	0.614	rs17036097	chr4:106597295	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	4.71	0.36	5.55e-6	Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11087736	chr15:51200195	AP4E1	0.64	6.9	0.49	1.28e-10	Myopia (pathological);
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs2594989	0.831	rs7620624	chr3:11476270	C/G	cg01796438	chr3:11312864	ATG7	-0.59	-4.57	-0.35	9.85e-6	Circulating chemerin levels;
PAAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg12623918	chr2:306882	NA	0.44	4.47	0.34	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg00601450	chr5:74908170	NA	0.5	4.94	0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18357526	chr6:26021779	HIST1H4A	0.53	4.64	0.35	7.61e-6	Height;
PAAD	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.7	0.58	5.1e-15	Coffee consumption (cups per day);
PAAD	cis	rs7567389	0.677	rs11680949	chr2:128123562	C/G	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.61	-0.35	8.57e-6	Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.86	10.0	0.63	2.07e-18	Prudent dietary pattern;
PAAD	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.84	9.79	0.62	7.37e-18	Ulcerative colitis;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15556090	chr7:149195153	ZNF746	-0.7	-7.21	-0.5	2.41e-11	Primary biliary cholangitis;
PAAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9659323	1.000	rs6700415	chr1:119516174	A/T	cg26570165	chr1:119541833	NA	-0.46	-4.56	-0.35	1.03e-5	Body mass index;
PAAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.65	7.0	0.49	7.84e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg23461800	chr14:103021989	NA	-0.58	-4.4	-0.34	1.99e-5	Platelet count;
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg04398451	chr17:18023971	MYO15A	0.74	7.81	0.54	8.74e-13	Total body bone mineral density;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-5.07	-0.38	1.13e-6	Insulin-like growth factors;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2795502	0.702	rs3123750	chr10:43227824	C/A	cg20628663	chr10:43360327	NA	-0.75	-5.78	-0.42	4.17e-8	Blood protein levels;
PAAD	cis	rs300774	0.748	rs409657	chr2:129009	C/T	cg23649280	chr2:140451	NA	-0.47	-4.53	-0.34	1.18e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.87	0.43	2.66e-8	Personality dimensions;
PAAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg14393609	chr7:65229607	NA	-0.45	-4.48	-0.34	1.47e-5	Aortic root size;
PAAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.83	-0.58	2.31e-15	Type 2 diabetes;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.72	-0.42	5.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg07150166	chr2:30669952	LCLAT1	0.82	5.95	0.43	1.81e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs11264213	0.901	rs716925	chr1:36424517	A/G	cg27506609	chr1:36549197	TEKT2	0.74	5.15	0.39	7.81e-7	Schizophrenia;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg00035074	chr7:2701567	TTYH3	0.63	4.34	0.33	2.63e-5	Bipolar disorder;
PAAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs597480	0.864	rs683105	chr11:85483225	G/A	cg11817631	chr11:85522609	SYTL2	-0.46	-4.5	-0.34	1.34e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg02487422	chr3:49467188	NICN1	0.46	4.72	0.36	5.28e-6	Resting heart rate;
PAAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg26554054	chr8:600488	NA	1.04	7.27	0.51	1.81e-11	IgG glycosylation;
PAAD	cis	rs1032355	0.558	rs2903202	chr4:100517005	A/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27139943	chr2:219502866	ZNF142	-0.56	-6.56	-0.47	8.03e-10	Monocyte percentage of white cells;
PAAD	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg01426195	chr3:39028469	NA	0.63	6.27	0.45	3.52e-9	Handedness;
PAAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.72	-0.36	5.29e-6	Type 2 diabetes;
PAAD	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.57	0.35	9.91e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1198430	0.562	rs504145	chr1:23788310	C/T	cg27447006	chr1:23763279	ASAP3	0.67	5.88	0.43	2.47e-8	Total cholesterol levels;
PAAD	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.61	-6.02	-0.44	1.27e-8	Ear protrusion;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09032840	chr1:179851019	TOR1AIP1	0.57	6.33	0.46	2.58e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4743820	0.503	rs10820833	chr9:93917362	C/G	cg14446406	chr9:93919335	NA	-0.37	-5.05	-0.38	1.23e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-1.25	-11.03	-0.67	3.85e-21	Obesity-related traits;
PAAD	cis	rs2295499	0.515	rs3733222	chr4:2745734	A/G	cg00231918	chr4:2819393	SH3BP2	0.41	4.39	0.34	2.1e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14019695	chr9:139328340	INPP5E	0.58	5.04	0.38	1.32e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg00717180	chr2:96193071	NA	-0.58	-6.41	-0.46	1.7e-9	HDL cholesterol;
PAAD	cis	rs8099014	0.861	rs8097365	chr18:56131080	G/A	cg12907477	chr18:56117327	MIR122	0.61	4.68	0.36	6.25e-6	Platelet count;
PAAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg01585852	chr22:24235823	MIF	-0.43	-4.65	-0.35	7.02e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-7.48	-0.52	5.55e-12	Heart rate;
PAAD	cis	rs2252790	1.000	rs10456907	chr6:116621036	T/C	cg26893134	chr6:116381904	FRK	0.27	4.28	0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15962187	chr10:103052327	NA	0.59	7.08	0.5	4.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-6.95	-0.49	1.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs2235642	0.682	rs4787271	chr16:1572314	T/C	cg06970076	chr16:1560791	IFT140	0.52	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.84	7.26	0.51	1.9e-11	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs73416724	1.000	rs112336903	chr6:43338115	T/C	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.7	-4.89	-0.37	2.52e-6	Coronary artery disease;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.62	6.87	0.49	1.53e-10	Longevity;Endometriosis;
PAAD	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg14703610	chr5:56206110	C5orf35	0.63	5.78	0.42	4.12e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21545522	chr1:205238299	TMCC2	0.57	5.43	0.4	2.15e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9467603	0.925	rs6910549	chr6:25780811	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.75	-4.91	-0.37	2.29e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs72960926	0.744	rs768509	chr6:75005487	G/A	cg03266952	chr6:74778945	NA	-1.13	-6.26	-0.45	3.68e-9	Metabolite levels (MHPG);
PAAD	cis	rs113779084	0.728	rs35847732	chr7:11953581	G/C	cg15090509	chr7:11872073	THSD7A	0.38	4.78	0.36	4.06e-6	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03770147	chr2:208029836	KLF7	0.56	6.37	0.46	2.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73019876	0.869	rs2359815	chr19:22187760	C/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.33	-0.33	2.69e-5	Testicular germ cell tumor;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs89107	0.603	rs399844	chr6:118613435	A/G	cg18833306	chr6:118973337	C6orf204	0.48	5.65	0.42	7.71e-8	Cardiac structure and function;
PAAD	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.66	-6.86	-0.49	1.61e-10	Body mass index;
PAAD	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	5.46	0.4	1.9e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.77	-8.37	-0.56	3.45e-14	Prostate cancer;
PAAD	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	11.6	0.69	1.11e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.85	-9.86	-0.62	4.91e-18	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.71	5.48	0.41	1.7e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.64	8.56	0.57	1.15e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.54	-6.39	-0.46	1.95e-9	Mean arterial pressure;
PAAD	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.72	-0.36	5.33e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg19630374	chr17:18023558	MYO15A	-0.4	-4.3	-0.33	3.07e-5	Total body bone mineral density;
PAAD	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.81	-0.48	2.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	5.29	0.39	4.19e-7	Calcium levels;
PAAD	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg00012203	chr2:219082015	ARPC2	0.6	5.77	0.42	4.39e-8	Colorectal cancer;
PAAD	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-6.46	-0.46	1.32e-9	Body mass index;
PAAD	cis	rs7580658	0.929	rs13029237	chr2:128147854	C/T	cg10985347	chr2:127963512	CYP27C1	0.48	4.39	0.34	2.07e-5	Protein C levels;
PAAD	cis	rs797680	0.821	rs7551485	chr1:93751280	G/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.43	-0.34	1.76e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs863345	0.565	rs12403685	chr1:158452399	C/T	cg12129480	chr1:158549410	OR10X1	0.4	4.63	0.35	7.75e-6	Pneumococcal bacteremia;
PAAD	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-1.35	-9.53	-0.61	3.54e-17	Prostate cancer;
PAAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07395648	chr5:131743802	NA	-0.51	-4.67	-0.35	6.69e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs9345521	0.967	rs6929009	chr6:65495682	T/C	cg26414000	chr1:85721327	C1orf52	0.54	6.6	0.47	6.51e-10	Iris color (a* coordinate);
PAAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg22800045	chr5:56110881	MAP3K1	0.6	4.69	0.36	6.02e-6	Coronary artery disease;
PAAD	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.44	-6.13	-0.45	7.1e-9	Cutaneous nevi;
PAAD	cis	rs8112211	0.554	rs2302183	chr19:38853297	G/A	cg14299480	chr19:38876666	GGN	-0.61	-5.08	-0.38	1.09e-6	Blood protein levels;
PAAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg19337854	chr7:99768885	GPC2	0.57	5.83	0.43	3.16e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-6.0	-0.44	1.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg25319279	chr11:5960081	NA	-0.61	-5.72	-0.42	5.48e-8	DNA methylation (variation);
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg16362232	chr11:430036	ANO9	-0.8	-5.09	-0.38	1.04e-6	Body mass index;
PAAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg26022315	chr17:47021804	SNF8	0.46	4.65	0.35	7.01e-6	Type 2 diabetes;
PAAD	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-5.17	-0.39	7.3e-7	Urinary metabolites;
PAAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg15061591	chr7:98625706	SMURF1	-0.47	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.83	-0.36	3.28e-6	HDL cholesterol;
PAAD	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.64	-0.35	7.39e-6	Resting heart rate;
PAAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.49	5.52	0.41	1.46e-7	Platelet distribution width;
PAAD	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17945195	chr7:99698344	MCM7;AP4M1	0.65	6.9	0.49	1.29e-10	Myopia (pathological);
PAAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs258892	0.895	rs13157632	chr5:72036499	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	6.29	0.45	3.2e-9	Calcium levels;
PAAD	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.76	8.0	0.54	2.97e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs4073221	0.789	rs35709168	chr3:18236105	G/A	cg07694806	chr3:18168406	NA	-0.82	-5.19	-0.39	6.65e-7	Parkinson's disease;
PAAD	cis	rs10849605	1.000	rs10849605	chr12:1064438	C/T	cg22937753	chr12:1022477	RAD52	0.53	5.38	0.4	2.81e-7	Lung cancer;
PAAD	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.57	-5.96	-0.44	1.69e-8	Lung cancer;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.31	-0.51	1.41e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18898632	chr2:242989856	NA	-0.83	-6.69	-0.48	4.09e-10	Obesity-related traits;
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs7236492	0.748	rs11660128	chr18:77227950	G/T	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.94	8.13	0.55	1.44e-13	Inflammatory bowel disease;
PAAD	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-6.32	-0.46	2.79e-9	Colorectal cancer;
PAAD	cis	rs9659323	0.670	rs6701378	chr1:119638553	G/A	cg17326555	chr1:119535693	NA	-0.36	-5.02	-0.38	1.45e-6	Body mass index;
PAAD	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg04192923	chr4:3473232	DOK7	0.44	4.28	0.33	3.27e-5	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.33	-4.84	-0.37	3.21e-6	Alopecia areata;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20898347	chr17:21117939	TMEM11	-0.71	-7.61	-0.53	2.63e-12	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.6	6.07	0.44	9.97e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg14092988	chr3:52407081	DNAH1	0.51	6.3	0.46	3.03e-9	Bipolar disorder;
PAAD	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs58521262	1.000	rs1836017	chr19:23158720	A/T	cg22640819	chr19:22990650	NA	0.36	4.4	0.34	2.06e-5	Testicular germ cell tumor;
PAAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.53	0.34	1.2e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.53	-0.47	9.07e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2790216	0.950	rs2790156	chr10:59974721	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.79	-5.92	-0.43	2.08e-8	Coronary artery calcification;
PAAD	cis	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg22863700	chr5:28928346	NA	0.56	5.45	0.4	1.99e-7	Hip geometry;
PAAD	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg20917491	chr3:195578259	NA	-0.61	-7.16	-0.5	3.18e-11	Pancreatic cancer;
PAAD	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.63	-4.86	-0.37	2.87e-6	Osteoarthritis;
PAAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.71	7.02	0.49	7.09e-11	Schizophrenia;
PAAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-5.12	-0.38	9.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg09667013	chr22:42394590	WBP2NL	0.47	4.45	0.34	1.66e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs3787159	0.523	rs6070417	chr20:56869768	G/C	cg15032960	chr20:56888536	RAB22A	0.41	4.4	0.34	2.02e-5	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07908229	chr1:182353640	GLUL	-0.63	-6.83	-0.48	1.91e-10	Myopia (pathological);
PAAD	cis	rs4253772	0.530	rs7284664	chr22:46807698	A/G	cg24881330	chr22:46731750	TRMU	0.93	5.03	0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.29e-6	Airway imaging phenotypes;
PAAD	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.61	5.85	0.43	2.85e-8	Lymphocyte counts;
PAAD	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	trans	rs901683	0.850	rs12778143	chr10:46063540	T/C	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.72	-7.14	-0.5	3.56e-11	Platelet distribution width;
PAAD	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg04990556	chr1:26633338	UBXN11	0.68	4.87	0.37	2.72e-6	Obesity-related traits;
PAAD	cis	rs929596	0.564	rs2741024	chr2:234517745	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08479976	chr1:90286333	LRRC8D	-0.72	-7.8	-0.53	9.43e-13	Smoking initiation;
PAAD	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.35	9.33	0.6	1.22e-16	Diabetic retinopathy;
PAAD	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.71	7.5	0.52	4.9e-12	Morning vs. evening chronotype;
PAAD	cis	rs9866391	0.670	rs13100711	chr3:141082990	C/T	cg00789793	chr3:141329863	RASA2	0.51	4.32	0.33	2.83e-5	Myopia;
PAAD	cis	rs134594	0.885	rs134653	chr22:29486779	A/T	cg01361351	chr22:29467363	NA	0.38	4.26	0.33	3.58e-5	Birth weight;
PAAD	cis	rs7873102	0.654	rs10733491	chr9:37956724	C/T	cg03528946	chr9:38069800	SHB	0.56	5.62	0.41	8.86e-8	Brain structure;
PAAD	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	1.12	9.77	0.62	8.42e-18	Red blood cell traits;
PAAD	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.81	-6.42	-0.46	1.65e-9	Blood protein levels;
PAAD	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.48	-0.47	1.22e-9	Hip circumference;
PAAD	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.61	5.59	0.41	1.03e-7	Obesity-related traits;
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg25037394	chr1:24152592	HMGCL	0.41	4.48	0.34	1.49e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.56	7.36	0.51	1.08e-11	Ewing sarcoma;
PAAD	cis	rs2662368	0.522	rs2663083	chr5:77101251	G/A	cg02570643	chr5:77531473	AP3B1	-0.42	-4.53	-0.34	1.18e-5	Platelet distribution width;
PAAD	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg03894339	chr8:19674705	INTS10	-0.46	-4.4	-0.34	2.04e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg18764771	chr6:116381957	FRK	0.41	7.01	0.49	7.28e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.8	-0.87	1.21e-48	Myeloid white cell count;
PAAD	cis	rs72960926	1.000	rs72956984	chr6:75109496	G/A	cg13997649	chr6:74171430	MTO1	0.81	4.5	0.34	1.37e-5	Metabolite levels (MHPG);
PAAD	cis	rs35955747	0.533	rs5998004	chr22:31881829	C/T	cg02404636	chr22:31891804	SFI1	-0.56	-5.55	-0.41	1.26e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.17	0.73	6.67e-27	Platelet count;
PAAD	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.04	-0.5	6.15e-11	Parkinson's disease;
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27436995	chr16:743998	FBXL16	-0.37	-4.46	-0.34	1.58e-5	Height;
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg19673125	chr6:150240577	RAET1G	0.41	5.69	0.42	6.32e-8	Lung cancer;
PAAD	cis	rs959260	0.614	rs9914731	chr17:73408824	T/G	cg14668889	chr17:73230827	NUP85	-0.69	-4.32	-0.33	2.83e-5	Systemic lupus erythematosus;
PAAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs863345	0.625	rs11264978	chr1:158447921	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.94	-0.37	2.08e-6	Pneumococcal bacteremia;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02359409	chr6:42947317	PEX6	-0.46	-4.42	-0.34	1.9e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs818427	0.929	rs153550	chr5:112234957	C/T	cg07820702	chr5:112228657	REEP5	-0.55	-4.93	-0.37	2.09e-6	Total body bone mineral density;
PAAD	cis	rs9463078	0.546	rs4412189	chr6:45023226	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg01620082	chr3:125678407	NA	-1.07	-7.25	-0.51	1.95e-11	Depression;
PAAD	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.53	-0.41	1.35e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.69	0.36	6.1e-6	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15476229	chr15:38987310	C15orf53	-0.63	-6.46	-0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg20848291	chr7:100343083	ZAN	0.63	5.94	0.43	1.85e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.88	11.2	0.67	1.32e-21	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg20607287	chr7:12443886	VWDE	-0.68	-5.39	-0.4	2.61e-7	Coronary artery disease;
PAAD	cis	rs9715521	0.645	rs6832242	chr4:59842630	A/T	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3733631	0.948	rs28438896	chr4:104625753	C/T	cg21490444	chr5:171095097	NA	0.79	6.68	0.48	4.25e-10	Menarche (age at onset);
PAAD	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.88	-0.43	2.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.93	12.12	0.7	4.26e-24	Mean corpuscular volume;
PAAD	cis	rs3981351	0.797	rs4353229	chr10:115489589	T/C	cg24846397	chr10:115438155	CASP7	-0.52	-4.76	-0.36	4.57e-6	Obesity-related traits;
PAAD	cis	rs1497828	0.956	rs2815234	chr1:217540734	T/C	cg04411442	chr1:217543379	NA	-0.5	-4.88	-0.37	2.68e-6	Dialysis-related mortality;
PAAD	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.42	5.59	0.41	1e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26301516	chr3:171930178	FNDC3B	-0.62	-6.43	-0.46	1.55e-9	Obesity-related traits;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-7.5	-0.52	4.97e-12	Renal function-related traits (BUN);
PAAD	cis	rs1144333	0.737	rs1144339	chr1:76280543	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-4.93	-0.37	2.13e-6	Lung cancer;
PAAD	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6942407	0.592	rs6959152	chr7:86751607	G/T	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16083429	chr3:49237500	CCDC36	-0.46	-5.07	-0.38	1.14e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	1.06	9.16	0.6	3.28e-16	Red cell distribution width;
PAAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg00431813	chr7:1051703	C7orf50	0.75	4.54	0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01930518	chr15:91414850	FURIN	-0.57	-6.6	-0.47	6.31e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.36	-0.46	2.21e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.15e-8	Colorectal cancer;
PAAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs4450131	0.898	rs10794173	chr10:126330565	C/T	cg20435097	chr10:126320824	FAM53B	-0.48	-5.32	-0.4	3.57e-7	White blood cell count (basophil);
PAAD	cis	rs16975963	0.644	rs73037036	chr19:38161070	A/T	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.33e-5	Longevity;
PAAD	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg07234876	chr8:600039	NA	-1.1	-7.4	-0.51	8.56e-12	IgG glycosylation;
PAAD	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.53e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.01e-18	Prudent dietary pattern;
PAAD	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.52	-5.0	-0.38	1.53e-6	Hepatocellular carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15391425	chr1:3106994	PRDM16	-0.56	-6.42	-0.46	1.67e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.51	-6.67	-0.48	4.52e-10	Life satisfaction;
PAAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg00579200	chr11:133705235	NA	-0.42	-4.7	-0.36	5.68e-6	Childhood ear infection;
PAAD	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.935	rs424729	chr19:44422802	G/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02833597	chr17:8029360	NA	-0.68	-6.9	-0.49	1.34e-10	Neuroticism;
PAAD	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg26027780	chr6:27100370	HIST1H2AG;HIST1H2BJ	0.52	4.36	0.33	2.4e-5	Educational attainment;
PAAD	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.46	-0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg16590910	chr6:42928470	GNMT	0.49	4.86	0.37	2.88e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg13859433	chr6:33739653	LEMD2	-0.61	-4.75	-0.36	4.67e-6	Plateletcrit;
PAAD	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.21	0.39	6.01e-7	Menarche (age at onset);
PAAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	9.11	0.59	4.5e-16	Bone mineral density;
PAAD	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg19767477	chr5:127420684	SLC12A2	-0.59	-4.8	-0.36	3.73e-6	Ileal carcinoids;
PAAD	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.84	9.85	0.62	5.34e-18	Selective IgA deficiency;
PAAD	cis	rs900145	0.773	rs10832017	chr11:13309671	G/A	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.6	-4.88	-0.37	2.63e-6	Gut microbiome composition (summer);
PAAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.57	4.47	0.34	1.5e-5	Gut microbiome composition (summer);
PAAD	cis	rs17227506	0.704	rs13263028	chr8:13453490	C/A	cg02718516	chr8:13424094	C8orf48	-0.31	-4.28	-0.33	3.31e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.64	7.38	0.51	9.56e-12	Dupuytren's disease;
PAAD	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.8	-8.05	-0.55	2.27e-13	Colorectal adenoma (advanced);
PAAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg10556349	chr10:835070	NA	0.67	5.27	0.39	4.69e-7	Eosinophil percentage of granulocytes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17103705	chr17:26972054	KIAA0100	0.59	6.42	0.46	1.63e-9	Myopia (pathological);
PAAD	cis	rs57709857	0.957	rs10095753	chr8:38236890	C/T	cg16625770	chr8:38300134	FGFR1	-0.47	-4.47	-0.34	1.53e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs6782025	0.837	rs1688687	chr3:120675390	G/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-5.66	-0.42	7.25e-8	Daytime sleep phenotypes;
PAAD	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.17	-0.45	5.87e-9	Schizophrenia;
PAAD	cis	rs17123764	0.710	rs12310510	chr12:50066244	T/C	cg14846292	chr12:49726500	C1QL4	-0.69	-4.54	-0.35	1.15e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg00717180	chr2:96193071	NA	-0.59	-6.63	-0.47	5.38e-10	HDL cholesterol;
PAAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	1.12	8.69	0.58	5.42e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.37	0.4	2.84e-7	Bipolar disorder;
PAAD	cis	rs9434723	0.844	rs2268174	chr1:9300668	C/A	cg04199779	chr1:9294473	H6PD	0.57	4.97	0.37	1.75e-6	Height;
PAAD	cis	rs4478858	0.735	rs12404861	chr1:31861271	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.35	0.4	3.24e-7	Alcohol dependence;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs66530629	0.874	rs6604978	chr1:25090446	C/G	cg22509179	chr1:25234806	RUNX3	-0.52	-4.88	-0.37	2.68e-6	Plateletcrit;
PAAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg11663144	chr21:46675770	NA	-0.49	-5.64	-0.42	8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg08029281	chr1:67600428	NA	-0.4	-4.64	-0.35	7.52e-6	Psoriasis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14574905	chr2:122176293	CLASP1	0.57	6.91	0.49	1.22e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Urinary tract infection frequency;
PAAD	cis	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs7729723	0.591	rs4835682	chr5:137784254	C/T	cg26069252	chr5:137800343	EGR1	-0.48	-4.44	-0.34	1.75e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	trans	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16788391	chr20:35201809	TGIF2	0.57	6.32	0.46	2.71e-9	Monocyte percentage of white cells;
PAAD	trans	rs3131856	1	rs3131856	chr6:29607101	T/C	cg01620082	chr3:125678407	NA	-1.6	-9.47	-0.61	5.28e-17	Tuberculosis;
PAAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18867708	chr6:26865862	GUSBL1	0.44	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.69	-0.62	1.38e-17	Height;
PAAD	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.56	4.76	0.36	4.4e-6	Coronary heart disease;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg11157771	chr17:3474873	TRPV1	-0.6	-6.94	-0.49	1.09e-10	Gut microbiota (bacterial taxa);
PAAD	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.46	0.34	1.57e-5	Depression;
PAAD	cis	rs501120	0.584	rs11238911	chr10:44695862	A/G	cg09554077	chr10:44749378	NA	-0.43	-5.07	-0.38	1.15e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-8.14	-0.55	1.34e-13	Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17128823	chr12:89919812	GALNT4;WDR51B	-0.75	-6.35	-0.46	2.35e-9	Neuroticism;
PAAD	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	1.01	8.31	0.56	4.84e-14	Initial pursuit acceleration;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg23018236	chr17:30244563	NA	-0.63	-5.07	-0.38	1.14e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.04e-5	Vitiligo;
PAAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-6.41	-0.46	1.69e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs742132	0.520	rs4140641	chr6:25635400	C/T	cg03264133	chr6:25882463	NA	0.67	4.59	0.35	9.22e-6	Uric acid levels;
PAAD	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg02580895	chr19:2754563	NA	-0.63	-5.51	-0.41	1.49e-7	Total cholesterol levels;
PAAD	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.42	5.13	0.38	8.78e-7	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14881284	chr14:76044828	FLVCR2	-0.81	-7.18	-0.5	2.9100000000000002e-11	Neuroticism;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg20003494	chr4:90757398	SNCA	-0.43	-4.67	-0.35	6.46e-6	Dementia with Lewy bodies;
PAAD	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs6991838	0.806	rs13262793	chr8:66461897	T/C	cg15971335	chr8:66515592	ARMC1	0.45	4.6	0.35	8.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-7.48	-0.52	5.55e-12	Heart rate;
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.52	6.29	0.45	3.13e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21678189	chr6:10838625	NA	0.69	7.55	0.52	3.67e-12	Myopia (pathological);
PAAD	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	1.0	11.72	0.69	5.11e-23	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14576616	chr7:91763911	CYP51A1	-0.85	-7.26	-0.51	1.82e-11	Neuroticism;
PAAD	cis	rs6804624	0.613	rs2700632	chr3:99160577	G/T	cg02646433	chr3:99218170	NA	0.42	4.35	0.33	2.5e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs1797885	0.714	rs299661	chr3:12554069	A/G	cg07775309	chr3:12595852	NA	0.41	4.47	0.34	1.51e-5	Immature fraction of reticulocytes;
PAAD	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg04844267	chr4:1394941	NA	0.47	4.93	0.37	2.09e-6	Obesity-related traits;
PAAD	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs287982	1.000	rs1119633	chr2:9967532	G/A	cg01119585	chr2:10571959	NA	0.38	4.25	0.33	3.65e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	4.27	0.33	3.37e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	trans	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg14171944	chr9:126323477	DENND1A	0.54	6.49	0.47	1.13e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.99	8.78	0.58	3.2e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.78e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg23298862	chr7:158159286	PTPRN2	0.54	4.33	0.33	2.71e-5	Response to amphetamines;
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-11.29	-0.68	7.68e-22	Height;
PAAD	trans	rs61677309	1.000	rs55806415	chr11:118162862	G/A	cg15548380	chr1:19984784	NBL1	-0.64	-6.6	-0.47	6.4e-10	Lung cancer in ever smokers;
PAAD	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.72	0.42	5.6e-8	Adiposity;
PAAD	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg21929781	chr1:2537748	MMEL1	0.49	5.21	0.39	5.93e-7	Ulcerative colitis;
PAAD	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.63	-5.37	-0.4	2.85e-7	Lung cancer;
PAAD	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.49e-11	Total cholesterol levels;
PAAD	trans	rs4705952	0.832	rs2706390	chr5:131842280	C/A	cg22730004	chr1:158656718	SPTA1	-0.73	-6.31	-0.46	2.86e-9	C-reactive protein levels;
PAAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	11.24	0.67	1.02e-21	Platelet count;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	1.0	8.44	0.57	2.29e-14	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.0	-0.49	7.53e-11	Coffee consumption (cups per day);
PAAD	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg20893579	chr22:38215064	NA	0.53	4.91	0.37	2.34e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.82	7.47	0.52	6.01e-12	Psoriasis;
PAAD	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.46	-4.62	-0.35	8.21e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8077577	0.895	rs62072498	chr17:18125951	C/G	cg16794390	chr17:18148240	FLII	0.65	5.07	0.38	1.15e-6	Obesity-related traits;
PAAD	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	6.52	0.47	1e-9	Breast cancer;
PAAD	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.83	-0.37	3.24e-6	Height;
PAAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.71	7.72	0.53	1.47e-12	Lung cancer;
PAAD	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.8	8.97	0.59	1.01e-15	Mean platelet volume;
PAAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.47	6.02	0.44	1.22e-8	Ulcerative colitis;
PAAD	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.0	0.59	8.54e-16	Motion sickness;
PAAD	cis	rs35955747	0.902	rs713947	chr22:31639509	G/T	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.41	-0.34	1.93e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.69	7.21	0.5	2.52e-11	Lung cancer;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06079273	chr8:97247865	UQCRB	0.73	8.07	0.55	2e-13	Myopia (pathological);
PAAD	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	7.97	0.54	3.43e-13	Homoarginine levels;
PAAD	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.56	4.37	0.33	2.34e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.66	-6.35	-0.46	2.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7932354	0.550	rs2035068	chr11:46915993	T/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.95	-0.43	1.79e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.53e-6	Life satisfaction;
PAAD	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.46	5.78	0.42	4.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.51	-6.71	-0.48	3.63e-10	Height;
PAAD	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.4e-6	Depressive symptoms;
PAAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.58	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.42e-6	Aortic root size;
PAAD	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg12508331	chr16:3208203	NA	0.48	4.54	0.35	1.15e-5	Body mass index (adult);
PAAD	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.63	-4.49	-0.34	1.39e-5	Smoking behavior;
PAAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.27	-0.39	4.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3818285	0.885	rs10787217	chr10:111621103	A/T	cg00817464	chr10:111662876	XPNPEP1	0.69	6.81	0.48	2.14e-10	Superior crus of antihelix expression;
PAAD	cis	rs4455778	0.600	rs34886560	chr7:49120470	G/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06116271	chr12:120906938	DYNLL1;SFRS9	-0.77	-8.49	-0.57	1.74e-14	Smoking initiation;
PAAD	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg16434002	chr17:42200994	HDAC5	-0.43	-4.28	-0.33	3.32e-5	Total body bone mineral density;
PAAD	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg00490450	chr3:139108681	COPB2	0.63	5.57	0.41	1.12e-7	Obesity-related traits;
PAAD	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.81	7.33	0.51	1.3e-11	Exhaled nitric oxide levels;
PAAD	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg05484376	chr2:27715224	FNDC4	0.44	4.47	0.34	1.53e-5	Oral cavity cancer;
PAAD	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09220393	chr16:1703475	CRAMP1L	0.62	6.42	0.46	1.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12582317	chr17:55822272	NA	0.71	8.7	0.58	5.07e-15	Schizophrenia;
PAAD	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.77	-0.42	4.36e-8	Testicular germ cell tumor;
PAAD	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.66	6.73	0.48	3.21e-10	Blood protein levels;
PAAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.31	0.33	2.97e-5	Breast cancer;
PAAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.48	-4.58	-0.35	9.67e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg21823605	chr1:152486609	CRCT1	0.49	6.11	0.44	7.95e-9	Hair morphology;
PAAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg08125733	chr17:73851984	WBP2	0.92	8.01	0.54	2.78e-13	Psoriasis;
PAAD	cis	rs9810890	1.000	rs77303548	chr3:128454766	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg15181151	chr6:150070149	PCMT1	0.55	5.5	0.41	1.58e-7	Lung cancer;
PAAD	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg24330906	chr2:85765176	MAT2A	0.57	5.42	0.4	2.24e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.47	-6.46	-0.46	1.36e-9	Height;
PAAD	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg00024416	chr22:24240387	NA	-0.48	-4.86	-0.37	2.89e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg09017928	chr7:158110068	PTPRN2	0.59	5.35	0.4	3.25e-7	Response to amphetamines;
PAAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.37	0.51	1.04e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-11.71	-0.69	5.53e-23	Lymphocyte percentage of white cells;
PAAD	cis	rs16975963	1.000	rs16975963	chr19:38325536	C/G	cg08679971	chr19:38281047	NA	-0.43	-4.67	-0.35	6.51e-6	Longevity;
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.98	14.57	0.76	1.17e-30	Dental caries;
PAAD	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.5	5.5	0.41	1.55e-7	Electroencephalogram traits;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.49	4.96	0.37	1.83e-6	Lymphocyte counts;
PAAD	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.51	-5.04	-0.38	1.3e-6	Testicular germ cell tumor;
PAAD	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-5.09	-0.38	1.04e-6	Axial length;
PAAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.23	0.51	2.22e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.21	0.55	8.74e-14	Hypertriglyceridemia;
PAAD	cis	rs58521262	0.519	rs12609255	chr19:22938305	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.26	-0.33	3.53e-5	Testicular germ cell tumor;
PAAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.51	0.34	1.31e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.34	-0.4	3.32e-7	Chronic sinus infection;
PAAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg08885800	chr1:201084119	NA	0.65	7.25	0.51	1.92e-11	Permanent tooth development;
PAAD	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg22601191	chr20:60968625	CABLES2	-0.6	-5.72	-0.42	5.4e-8	Colorectal cancer;
PAAD	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.77	0.53	1.07e-12	Motion sickness;
PAAD	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.52	-5.41	-0.4	2.42e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.88	11.23	0.67	1.13e-21	Aortic root size;
PAAD	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.18	15.4	0.78	7.5e-33	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg17105886	chr17:28927953	LRRC37B2	0.7	4.75	0.36	4.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.63	-7.16	-0.5	3.21e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs16976116	0.530	rs486913	chr15:55413298	C/T	cg11288833	chr15:55489084	RSL24D1	-0.56	-4.38	-0.33	2.23e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25599619	chr1:1804256	GNB1	0.58	6.34	0.46	2.47e-9	Smoking initiation;
PAAD	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.35	0.51	1.13e-11	HIV-1 control;
PAAD	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.44	4.41	0.34	1.97e-5	Hirschsprung disease;
PAAD	cis	rs12410462	0.688	rs35582095	chr1:227959206	A/G	cg23173402	chr1:227635558	NA	0.67	4.74	0.36	4.96e-6	Major depressive disorder;
PAAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.73	-0.42	5.33e-8	Diabetic kidney disease;
PAAD	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg20673841	chr7:107026890	COG5	0.51	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.65	4.61	0.35	8.32e-6	Parkinson's disease;
PAAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.52	4.87	0.37	2.75e-6	Educational attainment;
PAAD	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg10239410	chr1:235292449	SNORA14B;TOMM20	0.42	4.44	0.34	1.75e-5	Adiposity;
PAAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg11143131	chr5:131608246	PDLIM4	-0.5	-5.03	-0.38	1.36e-6	Blood metabolite levels;
PAAD	cis	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg02835301	chr3:11609216	VGLL4	-0.47	-4.43	-0.34	1.81e-5	Circulating chemerin levels;
PAAD	cis	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg08079166	chr15:68083412	MAP2K5	0.62	4.91	0.37	2.31e-6	Restless legs syndrome;
PAAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.81	-5.18	-0.39	7e-7	Tuberculosis;
PAAD	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg10828910	chr2:63850056	LOC388955	0.51	4.46	0.34	1.57e-5	Childhood ear infection;
PAAD	cis	rs9810890	1.000	rs73210622	chr3:128659748	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.96	9.6	0.61	2.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.8	-5.05	-0.38	1.25e-6	Mononucleosis;
PAAD	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.86	-9.19	-0.6	2.84e-16	Platelet distribution width;
PAAD	cis	rs72827839	0.779	rs72827844	chr17:46434441	A/G	cg23391107	chr17:45924227	SP6	0.53	5.03	0.38	1.35e-6	Ease of getting up in the morning;
PAAD	cis	rs10924309	0.686	rs4658796	chr1:245854680	A/G	cg00036263	chr1:245852353	KIF26B	-0.68	-6.37	-0.46	2.16e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.57	5.4	0.4	2.51e-7	Electroencephalogram traits;
PAAD	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.06	-0.44	1.01e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.74	-9.07	-0.59	5.84e-16	Motion sickness;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.51	5.49	0.41	1.63e-7	Insulin-like growth factors;
PAAD	cis	rs6547631	0.622	rs11127	chr2:85924729	C/T	cg24620635	chr2:85921963	GNLY	0.42	5.54	0.41	1.27e-7	Blood protein levels;
PAAD	cis	rs990171	0.538	rs2075191	chr2:103118299	G/T	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.74	7.57	0.52	3.3e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg18200150	chr17:30822561	MYO1D	0.56	7.2	0.5	2.58e-11	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27155504	chr12:98992140	SLC25A3;SNORA53	0.6	6.57	0.47	7.7e-10	Smoking initiation;
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg18769074	chr3:133464867	TF	-0.46	-5.67	-0.42	6.87e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg09701102	chr11:67373083	NDUFV1	-0.42	-4.29	-0.33	3.13e-5	Mean corpuscular volume;
PAAD	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	6.45	0.46	1.41e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.51	0.34	1.29e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs539096	0.624	rs11210892	chr1:44100084	A/G	cg12908607	chr1:44402522	ARTN	0.45	4.83	0.36	3.31e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.76	8.91	0.59	1.47e-15	Emphysema distribution in smoking;
PAAD	cis	rs1413885	0.516	rs7537733	chr1:65838229	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.71	0.42	5.73e-8	Anticoagulant levels;
PAAD	cis	rs7131987	0.630	rs1006409	chr12:29435675	A/G	cg09582351	chr12:29534625	ERGIC2	-0.3	-4.37	-0.33	2.3e-5	QT interval;
PAAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg08732750	chr1:87598351	LOC339524	-0.27	-4.29	-0.33	3.13e-5	Smoking behavior;
PAAD	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-7.2	-0.5	2.59e-11	Height;
PAAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.34	0.81	7.65e-38	Height;
PAAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11700980	0.551	rs2832011	chr21:30110690	T/C	cg24692254	chr21:30365293	RNF160	-0.71	-5.07	-0.38	1.15e-6	QRS complex (12-leadsum);
PAAD	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg11367502	chr7:22862612	TOMM7	0.52	5.07	0.38	1.14e-6	Fibrinogen;
PAAD	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg02493740	chr2:85810744	VAMP5	-0.45	-5.07	-0.38	1.14e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01825986	chr20:47804552	STAU1	0.58	6.33	0.46	2.63e-9	Myopia (pathological);
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10769945	0.834	rs217207	chr11:1974831	G/A	cg23202291	chr11:1979235	NA	-0.48	-4.55	-0.35	1.08e-5	DNA methylation (variation);
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg17120908	chr11:65337727	SSSCA1	-1.01	-4.7	-0.36	5.66e-6	Height;
PAAD	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg24721873	chr10:135334122	NA	0.58	4.43	0.34	1.77e-5	Gout;
PAAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23161317	chr6:28129485	ZNF389	-0.55	-4.26	-0.33	3.51e-5	Depression;
PAAD	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-9.26	-0.6	1.87e-16	Bladder cancer;
PAAD	cis	rs62408225	0.925	rs6925032	chr6:91008027	C/A	cg03795776	chr6:90687632	BACH2	0.44	4.38	0.33	2.23e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	1.06	6.44	0.46	1.48e-9	Schizophrenia;
PAAD	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.49	0.47	1.17e-9	Lung cancer in ever smokers;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.58	-5.63	-0.42	8.33e-8	Acylcarnitine levels;
PAAD	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.86	9.73	0.62	1.08e-17	Resting heart rate;
PAAD	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.98	12.05	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.51	5.4	0.4	2.49e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7766436	0.767	rs6456498	chr6:22603610	A/G	cg13666174	chr6:22585274	NA	0.51	5.55	0.41	1.22e-7	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22038579	chr12:8849964	RIMKLB	0.56	6.55	0.47	8.4e-10	Monocyte percentage of white cells;
PAAD	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.63	-5.65	-0.42	7.51e-8	Multiple myeloma;
PAAD	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg00179576	chr16:74483694	GLG1	-0.4	-4.47	-0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg09677638	chr11:61582810	MIR1908;FADS1	0.57	4.94	0.37	2.05e-6	Trans fatty acid levels;
PAAD	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	0.8	5.85	0.43	2.93e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg02297831	chr4:17616191	MED28	0.58	5.39	0.4	2.63e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2131877	0.599	rs61218008	chr3:194881130	A/G	cg11177333	chr3:195857752	NA	0.44	4.76	0.36	4.54e-6	Non-small cell lung cancer;
PAAD	cis	rs899997	1.000	rs1383635	chr15:79029511	T/C	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg15181151	chr6:150070149	PCMT1	0.59	6.09	0.44	8.98e-9	Lung cancer;
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.61	-5.8	-0.43	3.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3753841	0.743	rs1932341	chr1:103228021	T/C	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.58	-0.35	9.56e-6	Platelet count;
PAAD	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.33	-0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.81	-7.67	-0.53	1.89e-12	Body mass index;
PAAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg02376097	chr19:46275166	DMPK	-0.6	-6.09	-0.44	9.04e-9	Coronary artery disease;
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.81	10.36	0.64	2.36e-19	Vitiligo;
PAAD	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.91e-5	Total body bone mineral density;
PAAD	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg25809561	chr17:30822961	MYO1D	0.47	4.77	0.36	4.3e-6	Schizophrenia;
PAAD	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg01631408	chr1:248437212	OR2T33	-0.55	-5.2	-0.39	6.4e-7	Common traits (Other);
PAAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg22800045	chr5:56110881	MAP3K1	0.7	5.78	0.42	4e-8	Coronary artery disease;
PAAD	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.57	5.13	0.38	8.73e-7	Common traits (Other);
PAAD	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg21823605	chr1:152486609	CRCT1	0.54	6.17	0.45	5.81e-9	Hair morphology;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs41271473	0.687	rs10916364	chr1:228884405	A/G	cg16512390	chr1:228756714	NA	-0.56	-4.78	-0.36	4.02e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02071572	chr4:1403502	NA	0.51	6.49	0.47	1.15e-9	Longevity;
PAAD	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.82	9.81	0.62	6.73e-18	Blood metabolite ratios;
PAAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.72	7.11	0.5	4.21e-11	Cognitive function;
PAAD	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-4.31	-0.33	2.97e-5	Renal cell carcinoma;
PAAD	cis	rs11669133	1.000	rs115221947	chr19:11107769	C/T	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11379392	chr19:47291807	SLC1A5	0.67	7.57	0.52	3.35e-12	Monocyte percentage of white cells;
PAAD	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.45	4.28	0.33	3.28e-5	Schizophrenia;
PAAD	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9816226	0.591	rs80080062	chr3:185812169	C/G	cg00760338	chr3:185826511	ETV5	-0.72	-5.68	-0.42	6.76e-8	Obesity;Body mass index;
PAAD	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg12517394	chr11:61582795	MIR1908;FADS1	-0.49	-4.9	-0.37	2.43e-6	Trans fatty acid levels;
PAAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.76	0.48	2.76e-10	Schizophrenia;
PAAD	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.57	-4.99	-0.38	1.6e-6	Type 2 diabetes;
PAAD	cis	rs2694528	0.686	rs7729652	chr5:59872414	A/G	cg11474532	chr5:59995715	DEPDC1B	1.0	5.6	0.41	9.87e-8	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08359347	chr11:86667175	FZD4	-0.81	-7.62	-0.53	2.56e-12	Neuroticism;
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg19673125	chr6:150240577	RAET1G	0.45	6.26	0.45	3.72e-9	Testicular germ cell tumor;
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.51	5.8	0.43	3.77e-8	Prostate cancer;
PAAD	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.64	6.79	0.48	2.33e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.26e-9	Personality dimensions;
PAAD	cis	rs7567389	0.504	rs2069895	chr2:128174068	A/G	cg11380483	chr2:127933992	NA	0.52	4.9	0.37	2.45e-6	Self-rated health;
PAAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-1.04	-17.48	-0.82	3.42e-38	Height;
PAAD	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.67	4.8	0.36	3.7e-6	Neuroticism;
PAAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg25204440	chr1:209979598	IRF6	-0.59	-4.58	-0.35	9.57e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7727544	0.625	rs3864277	chr5:131420249	G/A	cg16205897	chr5:131564050	P4HA2	-0.48	-5.11	-0.38	9.49e-7	Blood metabolite levels;
PAAD	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.57	5.59	0.41	1.03e-7	Monocyte count;
PAAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.69	6.98	0.49	8.49e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	5.4	0.4	2.48e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.41	0.34	1.94e-5	IgG glycosylation;
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-4.34	-0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg11859384	chr17:80120422	CCDC57	0.48	4.85	0.37	3.04e-6	Life satisfaction;
PAAD	cis	rs4919087	0.887	rs1890966	chr10:99094436	G/A	cg06569542	chr10:98946673	SLIT1	0.47	4.96	0.37	1.89e-6	Monocyte count;
PAAD	cis	rs9659323	1.000	rs10923714	chr1:119512913	C/T	cg26570165	chr1:119541833	NA	-0.46	-4.63	-0.35	7.9e-6	Body mass index;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.87	0.49	1.55e-10	Renal function-related traits (BUN);
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg21130718	chr4:1044621	NA	0.57	5.01	0.38	1.49e-6	Recombination rate (females);
PAAD	cis	rs7713065	0.765	rs2158101	chr5:131769273	G/A	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.6	-0.35	8.93e-6	Lung function (FEV1/FVC);
PAAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.56	-5.83	-0.43	3.26e-8	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07232103	chr12:112566177	TRAFD1	0.6	6.52	0.47	9.98e-10	Smoking initiation;
PAAD	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.54	-4.52	-0.34	1.24e-5	Heschl's gyrus morphology;
PAAD	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.55	7.91	0.54	5.04e-13	Frontotemporal dementia;
PAAD	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.67	0.58	5.9e-15	Morning vs. evening chronotype;
PAAD	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.83	-8.01	-0.54	2.85e-13	Breast cancer;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.7	-7.23	-0.51	2.15e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.68	6.03	0.44	1.22e-8	Inflammatory skin disease;
PAAD	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.88	9.48	0.61	4.77e-17	Corneal astigmatism;
PAAD	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.44	-5.31	-0.4	3.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg09491104	chr22:46646882	C22orf40	-0.93	-8.67	-0.58	5.95e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs4792901	0.802	rs28581728	chr17:41609336	T/C	cg05614735	chr17:40936078	WNK4	-0.37	-4.34	-0.33	2.6e-5	Dupuytren's disease;
PAAD	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg04106633	chr4:1044584	NA	0.53	4.96	0.37	1.88e-6	Recombination rate (males);
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.54	5.4	0.4	2.52e-7	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs863345	0.967	rs7527623	chr1:158469859	G/A	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs494459	0.838	rs566733	chr11:118608625	C/G	cg08498647	chr11:118550644	TREH	-0.39	-4.92	-0.37	2.27e-6	Height;
PAAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.67e-9	Prostate cancer;
PAAD	cis	rs2555155	0.935	rs2555150	chr11:6532223	T/C	cg24637308	chr11:6592297	DNHD1	0.46	4.65	0.35	7.24e-6	DNA methylation (variation);
PAAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.72	-9.02	-0.59	7.87e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs2744375	0.600	rs2237103	chr6:7552162	A/C	cg27023638	chr6:7288726	SSR1	-0.42	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.66	7.38	0.51	9.44e-12	Menarche (age at onset);
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.37	0.33	2.29e-5	Bipolar disorder;
PAAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	1.06	14.67	0.77	6.67e-31	Breast cancer;
PAAD	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg27395922	chr11:50257633	LOC441601	0.47	4.75	0.36	4.74e-6	Coronary artery disease;
PAAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.73	7.95	0.54	3.93e-13	Longevity;
PAAD	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg03030879	chr14:75389066	RPS6KL1	0.63	6.7	0.48	3.87e-10	Caffeine consumption;
PAAD	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg03254818	chr6:169586852	NA	-0.62	-5.54	-0.41	1.31e-7	Pulse pressure;
PAAD	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs8049634	0.764	rs11864937	chr16:84228199	G/T	cg26466773	chr16:84211947	TAF1C	0.57	5.25	0.39	5.07e-7	Small cell lung carcinoma;
PAAD	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg27478167	chr7:817139	HEATR2	0.69	5.28	0.39	4.34e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs847851	0.834	rs2504164	chr6:34914378	G/A	cg13196216	chr6:34231128	NA	-0.61	-5.0	-0.38	1.59e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1075265	0.620	rs2542584	chr2:54009844	C/T	cg16115072	chr17:25938812	KSR1	0.59	6.31	0.46	2.85e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-10.49	-0.65	1.02e-19	Total body bone mineral density;
PAAD	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.5	4.79	0.36	4e-6	Eotaxin levels;
PAAD	cis	rs357618	0.897	rs357630	chr5:150851258	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.51	-0.34	1.28e-5	Basophil percentage of white cells;
PAAD	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.81	-7.23	-0.51	2.23e-11	Cancer;
PAAD	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.97e-5	Primary biliary cholangitis;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.74	-10.17	-0.64	7.5e-19	Iron status biomarkers;
PAAD	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.73	7.9	0.54	5.22e-13	Mean corpuscular volume;
PAAD	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	1.15	6.16	0.45	6.23e-9	Skin colour saturation;
PAAD	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg08120226	chr3:195531633	MUC4	-0.44	-4.72	-0.36	5.23e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.07	-19.64	-0.85	1.5e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	17.11	0.81	2.95e-37	Height;
PAAD	cis	rs11264799	0.773	rs17727339	chr1:157680114	A/G	cg18268488	chr1:157545234	FCRL4	0.58	5.29	0.39	4.25e-7	IgA nephropathy;
PAAD	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.45	-0.4	1.99e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12233208	chr19:47729796	BBC3	0.62	7.17	0.5	3.05e-11	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg03303774	chr4:1407052	NA	-0.37	-4.94	-0.37	2.04e-6	Obesity-related traits;
PAAD	cis	rs4561483	0.815	rs11646545	chr16:11934594	T/G	cg08843971	chr16:11963173	GSPT1	0.5	5.24	0.39	5.29e-7	Testicular germ cell tumor;
PAAD	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.7	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.5	-0.61	4.27e-17	Response to antipsychotic treatment;
PAAD	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.89	7.6	0.52	2.89e-12	IgG glycosylation;
PAAD	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	5.52	0.41	1.44e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg26935685	chr1:15502881	TMEM51	-0.5	-4.26	-0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.61	-6.01	-0.44	1.31e-8	Height;
PAAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	12.49	0.71	4.51e-25	Bone mineral density;
PAAD	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.65	-0.35	7.04e-6	Refractive error;
PAAD	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-5.41	-0.4	2.44e-7	Longevity;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	6.24	0.45	4.11e-9	Prudent dietary pattern;
PAAD	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.62	5.3	0.39	4.02e-7	Common traits (Other);
PAAD	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg02153855	chr1:11041070	C1orf127	0.34	4.3	0.33	3.05e-5	Hepatocellular carcinoma;
PAAD	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg02683114	chr2:24398427	C2orf84	-0.57	-5.5	-0.41	1.57e-7	Asthma;
PAAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg01851573	chr8:8652454	MFHAS1	0.46	4.52	0.34	1.22e-5	Mood instability;
PAAD	cis	rs4731207	0.596	rs6956910	chr7:124642364	A/C	cg14311320	chr7:124405732	GPR37	-0.44	-4.6	-0.35	8.88e-6	Cutaneous malignant melanoma;
PAAD	trans	rs73635312	0.568	rs290898	chr10:8933437	C/T	cg00598021	chr4:10113794	WDR1	0.89	6.43	0.46	1.59e-9	Basal cell carcinoma;
PAAD	cis	rs9472414	0.510	rs227852	chr6:44699559	A/G	cg20913747	chr6:44695427	NA	-0.58	-6.2	-0.45	5.19e-9	Height;
PAAD	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.78	8.95	0.59	1.15e-15	Heart rate;
PAAD	cis	rs1864585	0.552	rs17776497	chr8:10675162	C/A	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.35	1.1e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.57	5.45	0.4	1.95e-7	Blood metabolite levels;
PAAD	cis	rs1667255	0.830	rs1667254	chr18:29186128	C/T	cg18808318	chr18:29669225	NA	0.51	4.98	0.37	1.69e-6	Retinol levels;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.81	9.01	0.59	8.23e-16	Iron status biomarkers;
PAAD	cis	rs686320	0.748	rs481335	chr11:65207469	T/C	cg16175245	chr11:65246563	NA	0.45	4.4	0.34	2.02e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09654157	chr20:271184	C20orf96	0.54	6.34	0.46	2.44e-9	Energy expenditure (24h);
PAAD	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg01777861	chr4:56023843	NA	0.36	4.57	0.35	1.01e-5	Endometriosis;
PAAD	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.53	5.13	0.38	8.55e-7	Metabolic traits;
PAAD	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9463078	0.683	rs12215252	chr6:44736265	C/T	cg25276700	chr6:44698697	NA	0.53	6.17	0.45	6.06e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.65	-7.75	-0.53	1.23e-12	Sense of smell;
PAAD	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.83	10.02	0.63	1.81e-18	Bladder cancer;
PAAD	cis	rs367943	0.712	rs10053654	chr5:112724314	G/C	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.84	6.92	0.49	1.2e-10	Pulmonary function decline;
PAAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00982548	chr2:198649783	BOLL	-0.8	-5.76	-0.42	4.45e-8	Ulcerative colitis;
PAAD	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	5.34	0.4	3.29e-7	Axial length;
PAAD	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg25114630	chr15:101792522	CHSY1	0.55	4.93	0.37	2.1e-6	Corneal structure;
PAAD	cis	rs11240594	0.512	rs3811426	chr1:205892415	C/T	cg12458003	chr1:204960826	NFASC	0.72	4.31	0.33	2.88e-5	Response to antipsychotic treatment;
PAAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg11802864	chr11:65308245	LTBP3	0.46	4.64	0.35	7.61e-6	Bone mineral density;
PAAD	cis	rs10958605	0.761	rs724322	chr8:40038804	C/T	cg14545590	chr8:40388592	ZMAT4	0.41	4.64	0.35	7.52e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs7127900	1.000	rs4077457	chr11:2230354	T/C	cg25635251	chr11:2234043	NA	0.84	7.53	0.52	4.15e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.56	5.98	0.44	1.54e-8	Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs6011002	0.683	rs6089966	chr20:62361250	A/G	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.66	6.48	0.47	1.22e-9	White matter hyperintensity burden;
PAAD	cis	rs72901758	0.810	rs72901751	chr17:76243732	T/G	cg11439826	chr17:76250004	NA	0.46	4.56	0.35	1.05e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.35	-0.33	2.49e-5	Ovarian reserve;
PAAD	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg05110241	chr16:68378359	PRMT7	-1.17	-8.25	-0.56	6.87e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5753037	0.653	rs131270	chr22:30149896	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.79	-0.36	3.99e-6	Type 1 diabetes;
PAAD	cis	rs41311933	0.561	rs41309866	chr9:123774889	T/C	cg13567360	chr9:123745713	C5	-0.71	-4.44	-0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg01620082	chr3:125678407	NA	0.88	6.65	0.47	4.87e-10	Depression;
PAAD	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs2070677	0.501	rs2274665	chr10:135295630	T/C	cg20169779	chr10:135381914	SYCE1	0.54	5.03	0.38	1.36e-6	Gout;
PAAD	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg14581129	chr12:53358946	NA	-0.96	-10.61	-0.65	4.85e-20	Prostate cancer;
PAAD	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-6.51	-0.47	1.04e-9	Neuroticism;
PAAD	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08704250	chr15:31115839	NA	-0.6	-8.25	-0.56	7.16e-14	Huntington's disease progression;
PAAD	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.36	-0.33	2.34e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9810890	1.000	rs76610941	chr3:128524526	G/A	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs904092	0.720	rs1229970	chr4:100204380	A/C	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.49	4.49	0.34	1.37e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg08898775	chr15:59042684	ADAM10	0.4	5.31	0.4	3.77e-7	Schizophrenia;
PAAD	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg02811702	chr13:24901961	NA	0.54	5.79	0.42	3.98e-8	Obesity-related traits;
PAAD	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg26621607	chr12:133180238	NA	0.62	4.44	0.34	1.7e-5	Urate levels in overweight individuals;
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12893428	chr3:195717962	SDHAP1	0.4	4.31	0.33	2.97e-5	Pancreatic cancer;
PAAD	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.58	5.26	0.39	4.71e-7	Mean platelet volume;
PAAD	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.55	-0.41	1.25e-7	Common traits (Other);
PAAD	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs17209837	0.915	rs12538707	chr7:87124268	T/C	cg00919237	chr7:87102261	ABCB4	-0.76	-5.01	-0.38	1.47e-6	Gallbladder cancer;
PAAD	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.48	4.78	0.36	4.03e-6	Schizophrenia;
PAAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.68	0.35	6.28e-6	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27373627	chr17:4871234	SPAG7	0.58	6.44	0.46	1.46e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11807834	0.522	rs11585739	chr1:230245900	C/T	cg09847368	chr1:230250326	GALNT2	0.75	9.13	0.6	4.04e-16	Schizophrenia;
PAAD	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg16306870	chr3:194868790	C3orf21	0.42	4.34	0.33	2.56e-5	Non-small cell lung cancer;
PAAD	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.83	-9.08	-0.59	5.28e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-4.48	-0.34	1.46e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.54	-6.05	-0.44	1.06e-8	Immature fraction of reticulocytes;
PAAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.8	-8.39	-0.56	3.19e-14	DNA methylation (variation);
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.85	-0.37	3.07e-6	Height;
PAAD	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.66	7.03	0.5	6.5e-11	Aortic root size;
PAAD	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg21466736	chr12:48725269	NA	0.49	4.48	0.34	1.46e-5	Glycated hemoglobin levels;
PAAD	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.8	8.04	0.55	2.41e-13	Testicular germ cell tumor;
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.62	6.86	0.49	1.65e-10	Vitiligo;
PAAD	cis	rs80346118	0.673	rs2145837	chr20:47425799	T/C	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.63	-4.66	-0.35	6.97e-6	Diastolic blood pressure;
PAAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg19592336	chr6:28129416	ZNF389	0.61	4.28	0.33	3.28e-5	Parkinson's disease;
PAAD	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.06	-0.44	1.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg06972019	chr1:8937448	ENO1	-0.44	-4.77	-0.36	4.23e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs6537837	0.793	rs12045311	chr1:110087405	T/C	cg05049280	chr1:110155535	GNAT2	0.44	4.58	0.35	9.68e-6	Major depressive disorder;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg26893134	chr6:116381904	FRK	0.39	6.23	0.45	4.43e-9	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4280164	0.945	rs1131941	chr14:24760808	C/T	cg07162820	chr14:24837146	NFATC4	0.37	4.29	0.33	3.2e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	6.25	0.45	3.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27656074	chr7:157414580	PTPRN2	0.67	6.63	0.47	5.57e-10	Smoking initiation;
PAAD	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.58e-11	Aortic root size;
PAAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-1.03	-8.9	-0.59	1.6e-15	Schizophrenia;
PAAD	cis	rs7873102	0.630	rs10814637	chr9:37994334	A/G	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg03983715	chr16:68378420	PRMT7	-0.79	-5.63	-0.42	8.67e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs6952407	1	rs6952407	chr7:66045512	A/G	cg26939375	chr7:64535504	NA	-0.76	-9.18	-0.6	2.89e-16	Cotinine glucuronidation;
PAAD	cis	rs7594192	0.736	rs17812440	chr2:199437457	C/T	cg03163783	chr2:200326591	SATB2	-0.36	-4.96	-0.37	1.89e-6	Educational attainment;
PAAD	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.59	5.29	0.39	4.26e-7	Coronary heart disease;
PAAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.65	-0.35	7.11e-6	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg10437265	chr15:77819839	NA	-0.43	-4.75	-0.36	4.66e-6	Type 2 diabetes;
PAAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg03128945	chr5:622914	CEP72	-0.5	-4.31	-0.33	2.89e-5	Obesity-related traits;
PAAD	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs1903068	0.853	rs9312656	chr4:56002972	C/G	cg20092376	chr4:56023423	NA	0.41	4.27	0.33	3.48e-5	Endometriosis;
PAAD	cis	rs11807834	0.522	rs2057231	chr1:230231546	T/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.52	-0.57	1.44e-14	Schizophrenia;
PAAD	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.39	-0.34	2.08e-5	Mood instability;
PAAD	cis	rs6774721	1.000	rs6774721	chr3:49381898	G/A	cg19401529	chr3:49056140	DALRD3	0.91	6.19	0.45	5.3e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.66	5.84	0.43	3.04e-8	Coronary artery disease;
PAAD	cis	rs66530629	0.958	rs3131502	chr1:25066448	A/G	cg01905478	chr1:25040257	NA	-0.47	-5.27	-0.39	4.68e-7	Plateletcrit;
PAAD	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg13332499	chr17:408570	NA	0.69	8.19	0.55	1.02e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs654384	0.798	rs13223924	chr7:4177170	C/T	cg00055292	chr7:4846846	RADIL	-0.48	-4.63	-0.35	7.78e-6	Positive affect;
PAAD	cis	rs6604026	0.656	rs2774949	chr1:93352553	T/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.96	-11.5	-0.68	2.08e-22	Height;
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.55	5.17	0.39	7.16e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.8	-10.07	-0.63	1.36e-18	Hemoglobin concentration;
PAAD	cis	rs7809950	0.620	rs2248464	chr7:107303622	A/T	cg23024343	chr7:107201750	COG5	0.91	10.62	0.65	4.81e-20	Coronary artery disease;
PAAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg27113419	chr16:58533979	NDRG4	-0.74	-4.6	-0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.1	-12.68	-0.72	1.32e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.41	-5.98	-0.44	1.55e-8	Oropharynx cancer;
PAAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg15956490	chr3:53032818	SFMBT1	0.78	4.39	0.34	2.16e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.67	7.44	0.52	6.79e-12	Emphysema distribution in smoking;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10131910	chr8:101964575	YWHAZ	0.57	6.61	0.47	6.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4792901	0.729	rs9891052	chr17:41592519	A/G	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg12639453	chr1:2035780	PRKCZ	0.54	5.03	0.38	1.36e-6	Height;
PAAD	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg19767477	chr5:127420684	SLC12A2	0.48	4.42	0.34	1.83e-5	Ileal carcinoids;
PAAD	cis	rs755249	0.567	rs67020650	chr1:39668015	T/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2299587	0.500	rs7815785	chr8:17730338	T/C	cg08627089	chr8:17753878	FGL1	-0.46	-4.32	-0.33	2.8e-5	Economic and political preferences;
PAAD	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.52	5.44	0.4	2.13e-7	Daytime sleep phenotypes;
PAAD	cis	rs9888739	0.800	rs7200615	chr16:31337155	G/A	cg15817542	chr16:31343056	ITGAM	-0.46	-4.53	-0.35	1.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.84	10.72	0.66	2.6e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9463078	0.505	rs2038556	chr6:44740568	A/G	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg11952622	chr19:58962976	ZNF324B	0.45	4.33	0.33	2.68e-5	Uric acid clearance;
PAAD	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs7731390	0.717	rs113742046	chr5:131610995	T/C	cg07395648	chr5:131743802	NA	-0.74	-4.31	-0.33	2.87e-5	IgG glycosylation;
PAAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.48	-5.87	-0.43	2.69e-8	Schizophrenia;
PAAD	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.56	5.89	0.43	2.44e-8	Menarche (age at onset);
PAAD	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-7.97	-0.54	3.42e-13	Brugada syndrome;
PAAD	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.63	6.08	0.44	9.4e-9	Itch intensity from mosquito bite;
PAAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.15	-6.1	-0.44	8.25e-9	Body mass index;
PAAD	cis	rs11159086	0.793	rs1029700	chr14:74941012	C/A	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.95	0.54	3.87e-13	Parkinson's disease;
PAAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg01503450	chr10:980765	NA	-0.54	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.77	8.0	0.54	2.88e-13	Body mass index;
PAAD	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.94	6.8	0.48	2.21e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg13263323	chr15:86062960	AKAP13	-0.59	-6.89	-0.49	1.42e-10	Interstitial lung disease;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.74	-10.29	-0.64	3.61e-19	Iron status biomarkers;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.73	7.29	0.51	1.54e-11	Prostate cancer;
PAAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.72	-8.15	-0.55	1.26e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.19	6.31	0.46	2.93e-9	Skin colour saturation;
PAAD	cis	rs2744375	0.600	rs2237104	chr6:7552172	A/C	cg27023638	chr6:7288726	SSR1	0.41	4.3	0.33	3.01e-5	Resting heart rate;
PAAD	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.4	9.54	0.61	3.37e-17	Diabetic retinopathy;
PAAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg05373962	chr22:49881684	NA	-0.5	-5.57	-0.41	1.12e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3753841	0.832	rs12144719	chr1:103238411	G/A	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs10155981	0.510	rs4719706	chr7:22592796	G/A	cg05062323	chr7:22590069	NA	-0.84	-4.91	-0.37	2.37e-6	Bilirubin levels;
PAAD	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.72	8.03	0.55	2.54e-13	Prostate cancer;
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg16926213	chr1:1841314	NA	0.39	4.64	0.35	7.6e-6	Body mass index;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg04520793	chr17:42248056	ASB16	-0.49	-6.7	-0.48	3.91e-10	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19711075	chr11:33795713	FBXO3	-0.57	-6.33	-0.46	2.67e-9	Body fat percentage;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs1692120	0.897	rs1692122	chr11:61430988	A/C	cg23038520	chr11:61406508	RPLP0P2	0.45	5.45	0.4	2e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.94	-9.81	-0.62	6.57e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.95	7.63	0.53	2.37e-12	Bipolar disorder;
PAAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg02917321	chr22:38215204	NA	0.48	4.96	0.37	1.84e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.57	-6.27	-0.45	3.5e-9	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7631605	0.905	rs4647222	chr3:37042960	A/C	cg17445812	chr3:36986805	TRANK1	0.34	4.59	0.35	9.18e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23544223	chr18:12777786	NA	0.68	5.81	0.43	3.54e-8	Inflammatory skin disease;
PAAD	cis	rs8060686	0.920	rs67114979	chr16:67691645	G/T	cg09835421	chr16:68378352	PRMT7	-0.99	-5.02	-0.38	1.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.25	-0.51	2e-11	Gut microbiome composition (summer);
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.96	8.51	0.57	1.52e-14	Alzheimer's disease;
PAAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.71	-0.36	5.54e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs621942	0.718	rs2509606	chr11:85749858	T/C	cg07180834	chr11:85838833	NA	-0.51	-5.09	-0.38	1.05e-6	Tourette syndrome;
PAAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03605463	chr16:89740564	NA	0.8	8.06	0.55	2.15e-13	Vitiligo;
PAAD	cis	rs11247915	0.583	rs34058882	chr1:26659794	C/T	cg15628303	chr1:26608928	UBXN11	0.66	6.66	0.48	4.66e-10	Obesity-related traits;
PAAD	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.51e-21	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21672889	chr12:109250988	SSH1	-0.66	-6.64	-0.47	5.33e-10	Smoking initiation;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.81	9.46	0.61	5.36e-17	Hemoglobin concentration;
PAAD	cis	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.31	-0.4	3.78e-7	Mononucleosis;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg26939375	chr7:64535504	NA	0.58	6.17	0.45	5.86e-9	Calcium levels;
PAAD	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg27478167	chr7:817139	HEATR2	0.7	5.35	0.4	3.18e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2384207	0.818	rs7962969	chr12:113674461	C/T	cg22376712	chr12:113623594	C12orf52;DDX54	0.6	5.28	0.39	4.47e-7	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15254424	chr3:50388344	TUSC4;CYB561D2	0.66	6.72	0.48	3.43e-10	Smoking initiation;
PAAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg04450456	chr4:17643702	FAM184B	-0.47	-4.85	-0.37	3.08e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg15193198	chr20:60906057	LAMA5	0.59	6.68	0.48	4.25e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.86	0.49	1.63e-10	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17389149	chr7:55227884	EGFR	-0.57	-6.55	-0.47	8.49e-10	Monocyte percentage of white cells;
PAAD	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs11811982	0.793	rs116274842	chr1:227368819	C/T	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.41	4.47	0.34	1.5e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
PAAD	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.81	-8.69	-0.58	5.46e-15	Lung cancer;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.63	6.57	0.47	7.44e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg04683509	chr19:45885800	PPP1R13L	0.4	4.28	0.33	3.35e-5	Coronary artery disease;
PAAD	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.47	-4.57	-0.35	1.02e-5	Mean platelet volume;
PAAD	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.34e-8	Obesity-related traits;
PAAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.53	4.65	0.35	7.06e-6	Facial morphology (factor 20);
PAAD	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-1.35	-10.59	-0.65	5.58e-20	Obesity-related traits;
PAAD	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.79	9.55	0.61	3.11e-17	Height;
PAAD	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg18765565	chr5:669397	TPPP	-0.41	-4.47	-0.34	1.51e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.41	4.75	0.36	4.75e-6	Cystic fibrosis severity;
PAAD	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg10395934	chr14:104002654	TRMT61A	0.54	5.75	0.42	4.75e-8	Body mass index;
PAAD	cis	rs988913	0.957	rs9382396	chr6:54760686	G/T	cg03513858	chr6:54763001	FAM83B	-0.46	-5.16	-0.39	7.57e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.88	7.26	0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs16958440	1.000	rs60854219	chr18:44646664	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs2555155	0.840	rs10839576	chr11:6552107	C/T	cg11185456	chr11:6592066	DNHD1	-0.44	-4.53	-0.35	1.18e-5	DNA methylation (variation);
PAAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg01942863	chr7:99769432	GPC2	0.45	4.35	0.33	2.53e-5	Coronary artery disease;
PAAD	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg24565620	chr2:194026	NA	-0.69	-5.19	-0.39	6.64e-7	Blood protein levels;
PAAD	cis	rs75757892	0.664	rs80334339	chr6:7277801	A/G	cg02954307	chr6:7269328	NA	0.59	4.56	0.35	1.04e-5	Hematocrit;Red blood cell count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10986814	chr5:109025713	MAN2A1	-0.64	-6.47	-0.46	1.29e-9	Smoking initiation;
PAAD	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	4.26	0.33	3.54e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	12.17	0.7	3.18e-24	Post bronchodilator FEV1;
PAAD	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.73	7.22	0.51	2.26e-11	Neuroticism;
PAAD	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg21518248	chr2:162101506	NA	0.51	5.37	0.4	2.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.61	7.34	0.51	1.18e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg10729496	chr3:10149963	C3orf24	0.85	7.21	0.5	2.44e-11	Alzheimer's disease;
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.67	6.83	0.48	1.89e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.76	8.09	0.55	1.78e-13	Prostate cancer;
PAAD	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.7	6.53	0.47	9.24e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.47	6.77	0.48	2.57e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.96	10.0	0.63	2.12e-18	Blood pressure (smoking interaction);
PAAD	cis	rs2562456	0.833	rs1626404	chr19:21483788	C/A	cg21994712	chr19:21861136	NA	-0.44	-4.26	-0.33	3.53e-5	Pain;
PAAD	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg00277334	chr10:82204260	NA	-0.49	-4.78	-0.36	4.11e-6	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09203029	chr20:61431311	C20orf20	-0.66	-6.44	-0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs2671540	0.574	rs4520478	chr10:65652643	C/T	cg19573236	chr10:65733388	NA	0.56	4.48	0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.11e-7	Glomerular filtration rate;
PAAD	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs1656368	0.726	rs17684859	chr3:158213841	T/C	cg16708174	chr3:158430962	RARRES1	0.6	5.44	0.4	2.07e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs457162	0.643	rs283060	chr6:118622306	C/T	cg21191810	chr6:118973309	C6orf204	0.68	4.66	0.35	6.81e-6	QT interval;
PAAD	cis	rs75920871	0.925	rs4936360	chr11:116893769	C/G	cg04087571	chr11:116723030	SIK3	0.41	4.38	0.33	2.23e-5	Subjective well-being;
PAAD	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.3	0.45	3.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs17155006	0.561	rs22783	chr7:107743243	G/T	cg05962710	chr7:107745446	LAMB4	-0.53	-7.09	-0.5	4.68e-11	Pneumococcal bacteremia;
PAAD	cis	rs7640424	0.618	rs35798995	chr3:107914313	G/A	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-5.84	-0.43	3.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22778180	chr12:112280887	C12orf47;MAPKAPK5	-0.66	-6.39	-0.46	1.92e-9	Lung cancer in ever smokers;
PAAD	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.83	-0.36	3.33e-6	Red cell distribution width;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08914378	chr7:98923334	ARPC1A	0.6	6.32	0.46	2.71e-9	Myopia (pathological);
PAAD	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.58	-5.96	-0.44	1.71e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs11807834	0.522	rs56230791	chr1:230245015	T/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.44	-0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs4679121	0.643	rs78727515	chr3:126143054	C/T	cg05485589	chr3:126194908	ZXDC	-0.99	-4.77	-0.36	4.26e-6	Pursuit maintenance gain;
PAAD	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-6.44	-0.46	1.47e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	4.95e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3206736	0.548	rs6963995	chr7:35058349	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.62	-0.35	8.21e-6	Diastolic blood pressure;
PAAD	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2562456	0.833	rs1781867	chr19:21487170	T/C	cg08562672	chr19:21860753	NA	-0.46	-4.8	-0.36	3.69e-6	Pain;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21365914	chr17:77813616	CBX4	0.58	6.58	0.47	7.32e-10	Monocyte percentage of white cells;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04121368	chr10:122316088	PPAPDC1A	-0.5	-6.64	-0.47	5.26e-10	Energy expenditure (24h);
PAAD	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.83	10.8	0.66	1.54e-20	Vitiligo;
PAAD	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg25155006	chr6:37138205	PIM1	-0.51	-4.62	-0.35	8.17e-6	QRS duration;
PAAD	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg19792802	chr11:65647270	CTSW	0.53	6.91	0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26667720	chr2:219773728	NA	-0.7	-6.33	-0.46	2.58e-9	Neuroticism;
PAAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.1	0.38	9.86e-7	Parkinson's disease;
PAAD	cis	rs438034	0.807	rs12121403	chr1:214807473	A/C	cg16144317	chr1:214725524	PTPN14	-0.4	-4.31	-0.33	2.95e-5	Response to antineoplastic agents;
PAAD	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.74	8.0	0.54	2.98e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg22189786	chr22:42395067	WBP2NL	-0.43	-4.5	-0.34	1.34e-5	Cognitive function;
PAAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07685180	chr8:600429	NA	0.81	5.19	0.39	6.53e-7	IgG glycosylation;
PAAD	cis	rs2278796	0.639	rs4950976	chr1:204970243	C/T	cg04862289	chr1:204966208	NFASC	-0.49	-5.09	-0.38	1.05e-6	Mean platelet volume;
PAAD	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.71	7.16	0.5	3.19e-11	Coronary artery disease;
PAAD	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.79	-9.69	-0.62	1.38e-17	Height;
PAAD	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.83	-5.62	-0.42	8.71e-8	Schizophrenia;
PAAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.42	-4.99	-0.38	1.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.56	-5.67	-0.42	7.04e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.34	0.4	3.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	1.000	rs17157839	chr10:45963777	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.47	-6.35	-0.46	2.4e-9	Height;
PAAD	cis	rs4704187	0.687	rs2335134	chr5:74478843	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07266299	chr4:187112145	CYP4V2	0.7	6.57	0.47	7.42e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.49e-11	Retinal vascular caliber;
PAAD	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.12	-0.38	9.31e-7	Mood instability;
PAAD	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.55	-5.23	-0.39	5.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg21565972	chr17:80109576	CCDC57	0.47	5.1	0.38	1.01e-6	Life satisfaction;
PAAD	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.38	0.33	2.24e-5	Diisocyanate-induced asthma;
PAAD	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.54	-0.52	3.86e-12	Retinal vascular caliber;
PAAD	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.43	-4.3	-0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	1.14	17.57	0.82	2.01e-38	Menarche (age at onset);
PAAD	cis	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg07791997	chr11:73882526	PPME1;C2CD3	-0.51	-4.29	-0.33	3.21e-5	Blood protein levels;
PAAD	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.45	4.52	0.34	1.25e-5	Prostate-specific antigen levels;
PAAD	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg23241863	chr10:102295624	HIF1AN	0.49	4.31	0.33	2.95e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg12696750	chr1:38022466	DNALI1	0.47	4.29	0.33	3.14e-5	Axial length;
PAAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg19847866	chr10:1019161	NA	-0.54	-4.42	-0.34	1.86e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg04257695	chr17:30186438	C17orf79	-0.59	-4.69	-0.36	6.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.47	-0.41	1.83e-7	Alcohol dependence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25718732	chr17:42276040	ATXN7L3	0.64	7.56	0.52	3.53e-12	Monocyte percentage of white cells;
PAAD	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.84	-9.45	-0.61	5.81e-17	Caffeine consumption;
PAAD	cis	rs1997066	0.831	rs73342210	chr10:106817326	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-1.1	-9.91	-0.63	3.56e-18	Platelet count;
PAAD	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-7.52	-0.52	4.33e-12	Morning vs. evening chronotype;
PAAD	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg18252515	chr7:66147081	NA	1.03	7.71	0.53	1.53e-12	Diabetic kidney disease;
PAAD	cis	rs6137287	0.813	rs4813418	chr20:21202815	C/T	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16497277	chr3:49208875	KLHDC8B	0.59	5.55	0.41	1.24e-7	Menarche (age at onset);
PAAD	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg14631576	chr9:95140430	CENPP	-0.44	-4.33	-0.33	2.74e-5	Height;
PAAD	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26306683	chr17:18585705	ZNF286B	-0.5	-5.01	-0.38	1.53e-6	Educational attainment (years of education);
PAAD	cis	rs12410462	0.551	rs1923819	chr1:227874314	C/T	cg23173402	chr1:227635558	NA	-0.55	-4.37	-0.33	2.31e-5	Major depressive disorder;
PAAD	cis	rs12304921	1.000	rs61577980	chr12:51345370	G/C	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.42	-0.34	1.85e-5	Type 2 diabetes;
PAAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.51	6.34	0.46	2.49e-9	Vitiligo;
PAAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	5.05	0.38	1.28e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg21890820	chr11:65308645	LTBP3	0.65	7.8	0.53	8.94e-13	Bone mineral density;
PAAD	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.93	11.48	0.68	2.34e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg07527105	chr16:88053339	BANP	-0.46	-4.58	-0.35	9.54e-6	Menopause (age at onset);
PAAD	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg14631576	chr9:95140430	CENPP	-0.53	-5.31	-0.4	3.86e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg23719950	chr11:63933701	MACROD1	-0.49	-4.26	-0.33	3.62e-5	Platelet count;
PAAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.41	6.1	0.44	8.43e-9	Subjective well-being;
PAAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg21929781	chr1:2537748	MMEL1	-0.49	-5.23	-0.39	5.54e-7	Ulcerative colitis;
PAAD	cis	rs422249	0.634	rs174615	chr11:61628964	T/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.51	0.34	1.29e-5	Trans fatty acid levels;
PAAD	cis	rs6782025	0.794	rs7643780	chr3:120895620	A/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.85	8.32	0.56	4.78e-14	Cognitive function;
PAAD	cis	rs10141207	0.531	rs1547213	chr14:32678646	C/A	cg23627301	chr14:32673368	NA	0.43	4.49	0.34	1.42e-5	Asthma;
PAAD	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg12486944	chr17:80159399	CCDC57	-0.51	-4.87	-0.37	2.72e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.46	4.73	0.36	5.17e-6	Longevity;Endometriosis;
PAAD	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21907156	chr5:79703652	ZFYVE16	0.58	6.34	0.46	2.48e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg21665744	chr7:39171113	POU6F2	0.34	5.61	0.41	9.27e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.89	0.49	1.41e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.33	0.4	3.47e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg09854653	chr6:163834903	QKI	-0.69	-4.31	-0.33	2.87e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.34	-0.33	2.59e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.92	-0.49	1.18e-10	Morning vs. evening chronotype;
PAAD	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.73	-7.73	-0.53	1.35e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs818427	0.506	rs153559	chr5:112255219	C/T	cg06941702	chr5:112196734	SRP19	0.5	4.64	0.35	7.51e-6	Total body bone mineral density;
PAAD	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.5	5.44	0.4	2.11e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-1.0	-6.06	-0.44	1.04e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8067287	1.000	rs8067287	chr17:16816656	A/T	cg26910001	chr17:16838321	NA	-0.64	-5.65	-0.42	7.52e-8	Diabetic kidney disease;
PAAD	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs367943	0.698	rs728915	chr5:112995748	C/T	cg12552261	chr5:112820674	MCC	0.68	7.33	0.51	1.3e-11	Type 2 diabetes;
PAAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.8	-8.48	-0.57	1.89e-14	Coronary artery disease;
PAAD	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg11498726	chr8:26250323	BNIP3L	-0.51	-5.02	-0.38	1.46e-6	Red cell distribution width;
PAAD	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg11822372	chr1:151115635	SEMA6C	0.53	5.12	0.38	9.14e-7	Childhood ear infection;
PAAD	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.39	-4.25	-0.33	3.7e-5	Height;
PAAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.76	8.73	0.58	4.25e-15	Type 2 diabetes;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg14092988	chr3:52407081	DNAH1	-0.4	-5.15	-0.39	7.89e-7	Electroencephalogram traits;
PAAD	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg01966878	chr4:90757139	SNCA	-0.46	-4.51	-0.34	1.31e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs12136530	0.593	rs9287046	chr1:19736395	C/G	cg03321592	chr1:19991676	HTR6	0.54	4.88	0.37	2.69e-6	Lead levels in blood;
PAAD	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg10932868	chr11:921992	NA	0.49	5.9	0.43	2.23e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8018808	0.936	rs4903576	chr14:77844869	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg19508488	chr2:152266495	RIF1	-0.51	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.58	6.05	0.44	1.08e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs75920871	0.800	rs1900198	chr11:116784486	G/T	cg04087571	chr11:116723030	SIK3	0.46	5.66	0.42	7.3900000000000007e-08	Subjective well-being;
PAAD	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg16447950	chr5:562315	NA	-0.48	-4.55	-0.35	1.09e-5	Obesity-related traits;
PAAD	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.62	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	6.0	0.44	1.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg02573091	chr5:74908125	NA	0.54	4.41	0.34	1.99e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg07153921	chr17:41440717	NA	-0.42	-4.54	-0.35	1.13e-5	Menopause (age at onset);
PAAD	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.79	6.2	0.45	5.04e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg02415014	chr8:143852576	LYNX1	0.5	6.22	0.45	4.49e-9	Urinary tract infection frequency;
PAAD	cis	rs4237845	0.611	rs4583019	chr12:58316745	T/C	cg23860436	chr12:58378763	NA	0.5	4.96	0.37	1.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.76	-5.71	-0.42	5.89e-8	Coronary artery calcification;
PAAD	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg27511599	chr7:32358540	NA	0.73	4.33	0.33	2.72e-5	Body mass index;
PAAD	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg04877966	chr15:75135169	ULK3	-0.52	-4.57	-0.35	9.84e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs4740619	0.619	rs10810522	chr9:16031644	C/A	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.73	6.24	0.45	4.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg00546117	chr1:8445545	RERE	0.44	4.35	0.33	2.5e-5	Crohn's disease;
PAAD	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.54	-0.35	1.14e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22906224	chr7:99728672	NA	0.62	5.29	0.39	4.29e-7	Coronary artery disease;
PAAD	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.4	-4.63	-0.35	7.63e-6	Intelligence;
PAAD	cis	rs4073221	0.654	rs56267653	chr3:18271910	T/C	cg07694806	chr3:18168406	NA	-0.67	-4.72	-0.36	5.2e-6	Parkinson's disease;
PAAD	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.8e-6	Height;
PAAD	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.58	5.31	0.4	3.83e-7	Blood metabolite levels;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24452069	chr19:4867631	PLIN3	0.55	6.41	0.46	1.71e-9	Immature fraction of reticulocytes;
PAAD	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs4704187	0.687	rs10079346	chr5:74536655	G/A	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09367696	chr2:220420805	OBSL1	0.65	6.82	0.48	2.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.77	-9.3	-0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.56	-0.35	1.05e-5	Atopic dermatitis;
PAAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.72	0.36	5.33e-6	HDL cholesterol;
PAAD	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs11669133	1.000	rs76200030	chr19:11095831	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg22189786	chr22:42395067	WBP2NL	-0.42	-4.51	-0.34	1.31e-5	Cognitive function;
PAAD	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.76	8.64	0.57	7.11e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs883565	0.582	rs7623343	chr3:39146792	A/C	cg01426195	chr3:39028469	NA	-0.67	-7.5	-0.52	4.95e-12	Handedness;
PAAD	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg18898632	chr2:242989856	NA	-0.83	-6.2	-0.45	5.01e-9	Obesity-related traits;
PAAD	cis	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg21546286	chr11:48923668	NA	-0.57	-5.97	-0.44	1.62e-8	HDL cholesterol;
PAAD	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.98	-10.51	-0.65	9.14e-20	Systemic lupus erythematosus;
PAAD	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg09659197	chr4:152720779	NA	0.4	4.93	0.37	2.12e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg26209169	chr5:1316264	NA	0.38	4.3	0.33	2.99e-5	Lung cancer;
PAAD	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.3	4.34	0.33	2.62e-5	Asthma;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.48	4.66	0.35	6.78e-6	Blood pressure;
PAAD	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.68	0.58	5.55e-15	Exhaled nitric oxide output;
PAAD	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.42	-0.34	1.87e-5	Fear of minor pain;
PAAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.51	5.61	0.41	9.3e-8	Height;
PAAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.7	8.27	0.56	6.4e-14	Eye color traits;
PAAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.8	11.72	0.69	5.22e-23	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14403776	chr9:97050131	ZNF169	-0.66	-6.6	-0.47	6.38e-10	Obesity-related traits;
PAAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg19257562	chr1:2043853	PRKCZ	0.49	6.05	0.44	1.08e-8	Height;
PAAD	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg04450456	chr4:17643702	FAM184B	-0.49	-4.92	-0.37	2.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.44	-5.93	-0.43	2e-8	Type 1 diabetes;
PAAD	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-1.49	-9.46	-0.61	5.56e-17	Depression;
PAAD	cis	rs6594713	0.533	rs6889304	chr5:112965020	C/T	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs11078597	0.767	rs874424	chr17:1640034	G/A	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.4e-8	Serum albumin level;
PAAD	cis	rs10274279	1.000	rs73163815	chr7:157388047	A/G	cg09270525	chr7:157391030	PTPRN2	0.72	5.6	0.41	9.65e-8	Myopia (pathological);
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.57	-0.41	1.1e-7	Crohn's disease;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.68	-7.05	-0.5	5.88e-11	Menopause (age at onset);
PAAD	cis	rs904092	0.720	rs1230025	chr4:100186376	A/T	cg12011299	chr4:100065546	ADH4	0.58	5.36	0.4	2.98e-7	Alcohol dependence;
PAAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg26044340	chr1:207277291	C4BPA	-0.68	-4.67	-0.35	6.67e-6	C4b binding protein levels;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.3e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Night sleep phenotypes;
PAAD	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg16211469	chr6:24423932	MRS2	-0.52	-5.34	-0.4	3.4e-7	Liver enzyme levels;
PAAD	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.72	0.62	1.12e-17	Total body bone mineral density;
PAAD	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.57	-5.55	-0.41	1.24e-7	Systemic sclerosis;
PAAD	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg04851639	chr8:1020857	NA	-0.66	-8.22	-0.55	8.42e-14	Schizophrenia;
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg17178900	chr1:205818956	PM20D1	0.52	5.13	0.38	8.62e-7	Prostate-specific antigen levels;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg11995313	chr8:8860691	ERI1	0.49	4.82	0.36	3.39e-6	Joint mobility (Beighton score);
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg08219700	chr8:58056026	NA	0.7	5.58	0.41	1.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.66	0.42	7.45e-8	Colorectal cancer;
PAAD	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06544989	chr22:39130855	UNC84B	0.52	5.22	0.39	5.82e-7	Menopause (age at onset);
PAAD	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg00490450	chr3:139108681	COPB2	-0.63	-5.54	-0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.78	-0.58	3.17e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.7	0.58	4.99e-15	Colorectal cancer;
PAAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-9.54	-0.61	3.36e-17	Total body bone mineral density;
PAAD	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg21565972	chr17:80109576	CCDC57	-0.56	-6.4	-0.46	1.78e-9	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.58	-0.47	7.23e-10	Lung cancer;
PAAD	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg11833968	chr6:79620685	NA	-0.43	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9682041	0.622	rs7640791	chr3:170155726	G/C	cg11886554	chr3:170076028	SKIL	0.83	4.71	0.36	5.56e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.79	0.36	4.01e-6	HDL cholesterol;
PAAD	cis	rs27434	0.583	rs28129	chr5:96155518	G/A	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.8	8.32	0.56	4.78e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg23920097	chr1:209922102	NA	0.5	4.48	0.34	1.43e-5	Red blood cell count;
PAAD	cis	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg00400743	chr4:148603008	PRMT10	-0.7	-4.45	-0.34	1.67e-5	Pulse pressure;
PAAD	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	4.75	0.36	4.76e-6	Height;
PAAD	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg19423196	chr10:82049429	MAT1A	0.48	5.01	0.38	1.47e-6	Borderline personality disorder;
PAAD	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg09796270	chr17:17721594	SREBF1	-0.51	-5.59	-0.41	1.03e-7	Total body bone mineral density;
PAAD	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg10437265	chr15:77819839	NA	0.39	4.4	0.34	2e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.83	0.43	3.23e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2221894	0.853	rs1976610	chr8:28784015	T/C	cg20212339	chr8:28908912	HMBOX1	0.5	5.26	0.39	4.74e-7	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.81	0.43	3.54e-8	Alzheimer's disease;
PAAD	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.68	6.9	0.49	1.3100000000000001e-10	Schizophrenia;
PAAD	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs3747547	1.000	rs3747547	chr9:37916408	T/C	cg13774184	chr9:37916125	SHB	-0.6	-4.46	-0.34	1.57e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.4	-5.73	-0.42	5.23e-8	Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04578193	chr1:150947589	LASS2	-0.77	-6.85	-0.49	1.72e-10	Neuroticism;
PAAD	cis	rs59888335	0.767	rs35464452	chr3:80526069	A/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs9567406	0.702	rs12427551	chr13:44869365	C/T	cg08635097	chr13:44833857	NA	-0.58	-4.59	-0.35	9.28e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	5.07	0.38	1.12e-6	Lung cancer in ever smokers;
PAAD	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	4.89	0.37	2.52e-6	Lung cancer in ever smokers;
PAAD	cis	rs7567389	0.677	rs72845997	chr2:128110082	T/C	cg09760422	chr2:128146352	NA	0.38	6.06	0.44	1.04e-8	Self-rated health;
PAAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg02117656	chr17:79614917	TSPAN10	-0.58	-6.32	-0.46	2.72e-9	Eye color traits;
PAAD	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.81	-9.82	-0.62	6.18e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.64	-7.41	-0.51	8.39e-12	Platelet distribution width;
PAAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg22903657	chr4:1355424	KIAA1530	-0.48	-5.02	-0.38	1.45e-6	Obesity-related traits;
PAAD	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg14393609	chr7:65229607	NA	0.6	6.37	0.46	2.14e-9	Aortic root size;
PAAD	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.35	-4.31	-0.33	2.9e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16793043	chr3:43328001	SNRK	-0.63	-6.62	-0.47	5.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg18084798	chr19:33555255	RHPN2	0.48	5.01	0.38	1.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs12935418	0.504	rs1549288	chr16:81060761	C/T	cg16651780	chr16:81037892	C16orf61	0.52	5.26	0.39	4.86e-7	Mean corpuscular volume;
PAAD	cis	rs883565	0.531	rs813668	chr3:39180867	G/T	cg01426195	chr3:39028469	NA	0.6	5.79	0.42	3.96e-8	Handedness;
PAAD	cis	rs939584	0.877	rs11687052	chr2:623740	A/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	12.46	0.71	5.44e-25	Cognitive ability;
PAAD	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.75	-4.91	-0.37	2.37e-6	Lung cancer;
PAAD	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.93	12.27	0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg22916017	chr11:64110731	CCDC88B	0.4	4.64	0.35	7.5e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.47	4.37	0.33	2.26e-5	Airway imaging phenotypes;
PAAD	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-5.91	-0.43	2.15e-8	Crohn's disease;
PAAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.8	7.14	0.5	3.57e-11	Recombination rate (females);
PAAD	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	4.87	0.37	2.74e-6	Menarche (age at onset);
PAAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.54	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg00800038	chr16:89945340	TCF25	-0.71	-4.41	-0.34	1.96e-5	Skin colour saturation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07305215	chr18:5296031	ZFP161	0.56	6.4	0.46	1.81e-9	Monocyte percentage of white cells;
PAAD	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg07159951	chr1:45983175	PRDX1	-0.41	-4.46	-0.34	1.56e-5	High light scatter reticulocyte count;
PAAD	cis	rs35740288	0.822	rs56322219	chr15:86276340	A/T	cg07943548	chr15:86304357	KLHL25	-0.58	-4.88	-0.37	2.69e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.14	0.38	8.34e-7	Childhood ear infection;
PAAD	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.91	11.13	0.67	2.05e-21	Alcohol dependence;
PAAD	cis	rs35785195	0.633	rs1035775	chr12:114230578	A/G	cg24771877	chr12:114234123	NA	0.61	4.72	0.36	5.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs35785195	0.593	rs12821514	chr12:114233825	G/A	cg08193681	chr12:114234200	NA	0.6	4.62	0.35	8.21e-6	Daytime sleep phenotypes;
PAAD	cis	rs73198271	0.515	rs113524005	chr8:8634672	C/A	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-7.26	-0.51	1.86e-11	Initial pursuit acceleration;
PAAD	cis	rs7009516	0.766	rs13279289	chr8:24232368	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.52	-6.16	-0.45	6.25e-9	Hair greying;
PAAD	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-7.0	-0.49	7.72e-11	Colorectal cancer;
PAAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.64	6.92	0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.7	6.57	0.47	7.42e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.62	-6.96	-0.49	9.62e-11	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11224423	chr12:56136943	GDF11	0.59	6.44	0.46	1.47e-9	Myopia (pathological);
PAAD	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.76	8.74	0.58	4.09e-15	Total body bone mineral density;
PAAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	1.02	7.2	0.5	2.65e-11	Gout;Renal underexcretion gout;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21819024	chr1:52344978	NRD1	0.59	6.54	0.47	9.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs564309	1.000	rs34090141	chr1:228580816	G/T	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg17771515	chr6:154831774	CNKSR3	0.59	4.32	0.33	2.84e-5	Lipoprotein (a) levels;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08204369	chr17:73150733	HN1	0.62	6.7	0.48	3.86e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg13611204	chr9:139324423	INPP5E	-0.52	-4.27	-0.33	3.43e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	6.98	0.49	8.54e-11	Systemic lupus erythematosus;
PAAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4605213	0.510	rs12946936	chr17:49287320	G/A	cg22932220	chr17:49244634	NME2;NME1-NME2	0.44	5.49	0.41	1.62e-7	Height;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs2617583	0.967	rs2937640	chr5:1443604	C/T	cg07151155	chr5:1473589	LPCAT1	-0.49	-4.86	-0.37	2.89e-6	Breast cancer;
PAAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.64	6.6	0.47	6.34e-10	Blood protein levels;
PAAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.94	12.58	0.71	2.46e-25	Menopause (age at onset);
PAAD	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.57	-6.97	-0.49	8.94e-11	Educational attainment;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.43	-0.46	1.57e-9	Lung cancer;
PAAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.43	4.84	0.37	3.1e-6	Refractive error;
PAAD	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2637266	0.905	rs11001834	chr10:78360494	T/C	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.68e-5	Pulmonary function;
PAAD	cis	rs12257961	0.521	rs10796280	chr10:15375511	A/T	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.62	6.75	0.48	2.95e-10	Prostate cancer;
PAAD	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-6.2	-0.45	5.2e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.68e-7	Alcohol dependence;
PAAD	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.61	7.02	0.49	6.91e-11	Cognitive performance;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10482924	chr11:62539163	TAF6L	-0.72	-7.76	-0.53	1.16e-12	Smoking initiation;
PAAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs2730245	0.608	rs2657391	chr7:158741776	T/C	cg24397884	chr7:158709396	WDR60	-1.04	-10.28	-0.64	3.7e-19	Height;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg12820946	chr3:52029954	RPL29	-0.47	-4.39	-0.34	2.13e-5	Height;
PAAD	cis	rs6976053	0.870	rs314372	chr7:100455733	C/T	cg22425096	chr7:100417404	EPHB4	0.51	4.44	0.34	1.69e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27297192	chr10:134578999	INPP5A	0.61	5.42	0.4	2.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23220551	chr2:24232889	MFSD2B	0.63	7.16	0.5	3.15e-11	Monocyte percentage of white cells;
PAAD	cis	rs8077577	0.895	rs62073602	chr17:18057907	A/G	cg16794390	chr17:18148240	FLII	0.66	5.45	0.4	2.02e-7	Obesity-related traits;
PAAD	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-8.38	-0.56	3.24e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	trans	rs901683	1.000	rs35172875	chr10:46004160	T/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg16434002	chr17:42200994	HDAC5	0.63	6.03	0.44	1.2e-8	Total body bone mineral density;
PAAD	cis	rs11563648	0.517	rs2269728	chr7:127032580	A/G	cg13381984	chr7:127881344	LEP	-0.29	-4.38	-0.33	2.23e-5	Resting heart rate;
PAAD	cis	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg27411982	chr8:10470053	RP1L1	-0.49	-5.38	-0.4	2.71e-7	Triglycerides;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18621852	chr3:10150065	C3orf24	-0.52	-4.96	-0.37	1.88e-6	Alzheimer's disease;
PAAD	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.67	0.35	6.7e-6	Height;
PAAD	cis	rs6191	0.904	rs4582314	chr5:142780695	C/A	cg08845721	chr5:142780693	NR3C1	-0.4	-4.47	-0.34	1.55e-5	Night sleep phenotypes;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg20528787	chr7:158032352	PTPRN2	0.4	6.29	0.45	3.24e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	6.13	0.45	7.34e-9	Cognitive test performance;
PAAD	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.62	6.08	0.44	9.13e-9	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs11892454	0.515	rs4063544	chr2:26042515	A/C	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg20003494	chr4:90757398	SNCA	-0.41	-4.53	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs61123157	0.895	rs9398069	chr6:106601165	A/G	cg09187505	chr6:106434429	NA	0.39	4.55	0.35	1.08e-5	Monobrow;Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs16895831	0.519	rs12196290	chr6:42552548	G/A	cg10605015	chr6:42532144	UBR2	-0.74	-5.57	-0.41	1.14e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg04482110	chr17:41364121	TMEM106A	-0.39	-4.51	-0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg21589280	chr1:85930151	DDAH1	-0.53	-4.47	-0.34	1.51e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.84	9.86	0.62	5.02e-18	Lewy body disease;
PAAD	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg24553058	chr2:113831203	IL1F10	0.45	4.98	0.37	1.71e-6	Protein quantitative trait loci;
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.6	-5.59	-0.41	1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11828289	0.660	rs11027043	chr11:23212893	C/T	cg20040320	chr11:23191996	NA	-0.76	-5.59	-0.41	1.01e-7	Cancer;
PAAD	cis	rs904092	0.605	rs2866149	chr4:100190732	C/G	cg12011299	chr4:100065546	ADH4	0.49	4.44	0.34	1.74e-5	Alcohol dependence;
PAAD	cis	rs6499129	0.867	rs11859352	chr16:67390448	A/G	cg09395969	chr16:67918001	EDC4;NRN1L	0.62	4.39	0.34	2.08e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9463078	0.845	rs9369514	chr6:44797271	C/A	cg25276700	chr6:44698697	NA	-0.5	-5.63	-0.42	8.47e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12445022	0.571	rs4843625	chr16:87576996	G/C	cg08031982	chr16:87577539	NA	0.4	4.48	0.34	1.47e-5	Small vessel stroke;Systemic juvenile idiopathic arthritis;
PAAD	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg05484376	chr2:27715224	FNDC4	0.46	4.7	0.36	5.88e-6	Total body bone mineral density;
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.8	7.07	0.5	5.27e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4690686	0.769	rs7660827	chr4:177274542	T/C	cg17059388	chr4:177262070	NA	0.52	5.05	0.38	1.25e-6	Essential tremor;
PAAD	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.73	-7.02	-0.49	7.01e-11	Retinal vascular caliber;
PAAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.71	4.41	0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs427941	0.703	rs201448	chr7:101738860	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4751058	0.578	rs7099230	chr10:130856644	C/T	cg27413539	chr10:131576096	NA	-0.51	-4.4	-0.34	2.05e-5	Vitamin D levels;
PAAD	cis	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.88	-8.44	-0.56	2.31e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg20887711	chr4:1340912	KIAA1530	0.47	4.55	0.35	1.08e-5	Obesity-related traits;
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14520079	chr3:106825871	NA	-0.69	-6.92	-0.49	1.16e-10	Smoking initiation;
PAAD	cis	rs7084921	0.809	rs11599088	chr10:101804114	C/T	cg04359915	chr10:101825029	CPN1	-0.36	-5.14	-0.38	8.51e-7	Bone mineral density;
PAAD	cis	rs67385638	1.000	rs72872548	chr11:5289139	C/A	cg12559170	chr11:5275217	HBG2	0.57	5.84	0.43	3.12e-8	Hemoglobin levels;
PAAD	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.77	8.05	0.55	2.24e-13	Magnesium levels;
PAAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg05342682	chr7:94953680	PON1	0.48	4.26	0.33	3.51e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.53	6.36	0.46	2.24e-9	Systemic lupus erythematosus;
PAAD	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	ch.8.33884649F	chr8:33765107	NA	0.58	5.53	0.41	1.34e-7	Body mass index;
PAAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.64	8.48	0.57	1.82e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.74	-8.93	-0.59	1.33e-15	Body mass index;
PAAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.58	0.61	2.62e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7896729	0.943	rs10904453	chr10:5348036	C/T	cg07902545	chr10:6194255	PFKFB3	-0.44	-4.55	-0.35	1.08e-5	Intelligence;
PAAD	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.925	rs492152	chr10:44757677	C/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg12757816	chr2:10669957	NA	-0.54	-5.79	-0.42	3.97e-8	Prostate cancer;
PAAD	cis	rs728616	0.867	rs57257258	chr10:81844020	T/C	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.49	-0.34	1.38e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4448343	1.000	rs28629854	chr9:98262833	A/G	cg13428213	chr9:98267529	PTCH1	0.45	4.25	0.33	3.78e-5	Height;
PAAD	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg15654264	chr1:150340011	RPRD2	0.51	4.84	0.37	3.18e-6	Migraine;
PAAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.31	0.4	3.87e-7	Eosinophil percentage of white cells;
PAAD	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.49	5.57	0.41	1.11e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.42	-4.83	-0.37	3.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	1.03	7.33	0.51	1.26e-11	Alzheimer's disease;
PAAD	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.82	-0.36	3.43e-6	Depression;
PAAD	cis	rs1529711	0.636	rs11670365	chr19:11004833	A/G	cg18582342	chr19:11591989	ELAVL3	0.6	4.98	0.37	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24629445	chr6:10723409	TMEM14C	0.6	6.41	0.46	1.77e-9	Myopia (pathological);
PAAD	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs9810890	1.000	rs73198889	chr3:128547620	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs7956193	0.511	rs1293756	chr12:113435293	A/C	cg20102336	chr12:113376681	OAS3	0.45	4.44	0.34	1.72e-5	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg00334542	chr7:100209784	MOSPD3	-0.66	-4.74	-0.36	4.98e-6	Other erythrocyte phenotypes;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.86	0.43	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02500152	chr12:48357316	TMEM106C	0.57	6.41	0.46	1.7e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10046574	0.656	rs17403326	chr7:135194440	T/G	cg27474649	chr7:135195673	CNOT4	0.72	5.06	0.38	1.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9361491	0.608	rs1180822	chr6:79431051	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.5	-4.25	-0.33	3.7e-5	Type 2 diabetes;
PAAD	cis	rs28472312	0.832	rs28433345	chr16:28883327	T/C	cg16576597	chr16:28551801	NUPR1	0.49	5.17	0.39	7.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.88	-7.86	-0.54	6.49e-13	Body mass index;
PAAD	cis	rs4704187	0.663	rs17738989	chr5:74533730	C/T	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg00522288	chr12:125625016	AACS	-0.56	-6.02	-0.44	1.26e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg18944383	chr4:111397179	ENPEP	-0.63	-7.38	-0.51	9.81e-12	Coronary artery disease;
PAAD	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.54	6.27	0.45	3.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	4.6	0.35	8.86e-6	Iron status biomarkers;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.91	10.93	0.66	7.08e-21	Menarche (age at onset);
PAAD	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.54	-6.26	-0.45	3.75e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	6.83	0.48	1.96e-10	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.43	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.85	-0.43	2.95e-8	Total body bone mineral density;
PAAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.69	7.33	0.51	1.28e-11	Obesity-related traits;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.62	0.57	8.32e-15	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11971779	0.729	rs10464730	chr7:139002227	A/T	cg07862535	chr7:139043722	LUC7L2	0.66	4.86	0.37	2.93e-6	Diisocyanate-induced asthma;
PAAD	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.56	5.31	0.4	3.91e-7	Schizophrenia;
PAAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.82	-5.2	-0.39	6.45e-7	Tuberculosis;
PAAD	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.62	5.98	0.44	1.53e-8	Monocyte count;
PAAD	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.3	4.26	0.33	3.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg24733560	chr20:60626293	TAF4	0.53	6.7	0.48	3.78e-10	Body mass index;
PAAD	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.38	-4.34	-0.33	2.55e-5	Obesity-related traits;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.56	-6.95	-0.49	9.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs3106136	0.678	rs17021531	chr4:95280514	A/C	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs60617249	0.560	rs9642401	chr7:50928077	C/A	cg15805451	chr7:51135775	COBL	-0.43	-4.59	-0.35	9.24e-6	Major depression and alcohol dependence;
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.94	-16.98	-0.81	6.33e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.39	-0.71	8.24e-25	Urate levels in overweight individuals;
PAAD	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.9	-0.43	2.23e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg26876637	chr1:152193138	HRNR	0.87	6.96	0.49	9.64e-11	Atopic dermatitis;
PAAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.69	-6.37	-0.46	2.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7551345	0.853	rs7555364	chr1:31753884	A/G	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg22244940	chr12:132335942	MMP17	0.48	5.24	0.39	5.33e-7	Migraine;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.12	14.72	0.77	4.68e-31	Subjective well-being;
PAAD	cis	rs564309	0.764	rs3795814	chr1:228543800	C/T	cg01328119	chr1:228783545	DUSP5P	0.68	4.49	0.34	1.4e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.45	-0.34	1.64e-5	Mean platelet volume;
PAAD	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.66	4.95	0.37	1.98e-6	Exhaled nitric oxide output;
PAAD	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg16928487	chr17:17741425	SREBF1	-0.34	-4.4	-0.34	2.04e-5	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.61	-5.42	-0.4	2.3e-7	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs1519814	0.740	rs2326433	chr8:121043723	T/A	cg22335954	chr8:121166405	COL14A1	-0.63	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Gut microbiome composition (summer);
PAAD	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg23387401	chr17:4582204	PELP1	-0.45	-4.52	-0.34	1.24e-5	Lymphocyte counts;
PAAD	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09926380	chr3:10052611	LOC401052	0.53	6.31	0.46	2.97e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.43	-6.65	-0.47	5e-10	Cutaneous nevi;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25595541	chr3:73109909	FLJ10213;PPP4R2	-0.54	-6.29	-0.45	3.2e-9	Energy expenditure (24h);
PAAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	12.68	0.72	1.37e-25	Bone mineral density;
PAAD	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.67	0.42	7.01e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.47	6.14	0.45	6.97e-9	Prostate cancer;
PAAD	cis	rs1227969	1.000	rs1652802	chr10:71267700	G/A	cg12610070	chr10:71211762	TSPAN15	-0.31	-4.64	-0.35	7.37e-6	Response to taxane treatment (placlitaxel);
PAAD	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	1.01	14.15	0.75	1.52e-29	Heart rate;
PAAD	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05585630	chr7:157510462	PTPRN2	-0.78	-9.09	-0.59	5.14e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.49	-4.61	-0.35	8.52e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.55	0.41	1.23e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.66	-6.31	-0.46	2.87e-9	Post bronchodilator FEV1;
PAAD	cis	rs12042052	1.000	rs12042052	chr1:232935719	C/T	cg02903907	chr1:232941055	KIAA1383	-0.84	-4.54	-0.35	1.13e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs28719689	0.504	rs17669535	chr8:1244224	C/G	cg22761795	chr8:1265118	NA	0.8	5.27	0.39	4.52e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.52	0.41	1.45e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg05805236	chr11:65401703	PCNXL3	-0.58	-6.03	-0.44	1.21e-8	Acne (severe);
PAAD	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg21775007	chr8:11205619	TDH	-0.52	-4.97	-0.37	1.77e-6	Systolic blood pressure;
PAAD	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg26205652	chr12:48591994	NA	0.85	7.74	0.53	1.26e-12	Longevity (90 years and older);
PAAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-4.81	-0.36	3.64e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	6.86	0.49	1.61e-10	Blood protein levels;
PAAD	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.27	-0.33	3.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950037	0.710	rs430600	chr1:89225976	A/G	cg13109106	chr1:89333529	GTF2B	-0.46	-4.47	-0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg16535667	chr11:65410126	SIPA1	-0.51	-4.65	-0.35	7.29e-6	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.76	7.53	0.52	4.14e-12	Resting heart rate;
PAAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.77	-8.26	-0.56	6.59e-14	Calcium levels;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.98	11.83	0.69	2.63e-23	Obesity-related traits;
PAAD	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-4.93	-0.37	2.12e-6	Schizophrenia (age at onset);
PAAD	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.6	5.66	0.42	7.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	1.33	6.91	0.49	1.27e-10	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03104808	chr8:652622	ERICH1	-0.61	-6.4	-0.46	1.85e-9	Myopia (pathological);
PAAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.87	9.35	0.6	1.08e-16	Menopause (age at onset);
PAAD	cis	rs7582720	1.000	rs72932737	chr2:203654540	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.53	0.52	4.22e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-7.8	-0.53	9.15e-13	Colorectal cancer;
PAAD	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.39	0.4	2.68e-7	Morning vs. evening chronotype;
PAAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg14507445	chr22:49886340	NA	-0.5	-4.55	-0.35	1.07e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12767760	0.669	rs10882959	chr10:99304801	C/T	cg25247692	chr10:99313390	UBTD1	0.56	5.4	0.4	2.56e-7	Obesity-related traits;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg21548813	chr6:291882	DUSP22	-0.74	-8.04	-0.55	2.31e-13	Menopause (age at onset);
PAAD	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg14703610	chr5:56206110	C5orf35	-0.61	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.45	-4.57	-0.35	1.01e-5	Plateletcrit;
PAAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-6.06	-0.44	1.02e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.08	0.38	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7765004	1.000	rs7765004	chr6:114071720	G/T	cg13100190	chr6:114053961	NA	-0.34	-4.29	-0.33	3.2e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.61	6.56	0.47	8.12e-10	Eye color traits;
PAAD	cis	rs2279817	0.863	rs34679654	chr1:18012034	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-5.83	-0.43	3.19e-8	Neuroticism;
PAAD	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.52	0.71	3.64e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg25753631	chr6:25732923	NA	0.47	5.88	0.43	2.51e-8	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17076539	chr3:57204284	NA	-0.63	-6.29	-0.45	3.21e-9	Smoking initiation;
PAAD	cis	rs60154123	0.730	rs58366398	chr1:210471924	G/A	cg22029157	chr1:209979665	IRF6	0.7	6.06	0.44	1.05e-8	Coronary artery disease;
PAAD	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.5	-4.53	-0.34	1.19e-5	Multiple sclerosis;
PAAD	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	6.28	0.45	3.42e-9	Hip circumference;
PAAD	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.27	-0.33	3.38e-5	Adiponectin levels;
PAAD	cis	rs12986413	0.651	rs2238610	chr19:2146852	T/C	cg09261902	chr19:2140048	AP3D1	0.61	6.06	0.44	1.04e-8	Height;
PAAD	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16417436	chr16:28758564	NA	0.47	4.35	0.33	2.46e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	trans	rs9409082	0.627	rs2138628	chr9:108931732	T/A	cg07010948	chr13:79181613	NA	-0.35	-6.58	-0.47	7.27e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2070677	0.935	rs3020502	chr10:135381623	T/C	cg08390786	chr10:135334061	NA	-0.65	-5.71	-0.42	5.8e-8	Gout;
PAAD	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.3	-0.33	3.02e-5	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.65	7.35	0.51	1.11e-11	Vitiligo;
PAAD	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.5	-5.08	-0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-5.49	-0.41	1.65e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-5.04	-0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.71	8.22	0.55	8.44e-14	Age-related hearing impairment;
PAAD	cis	rs4073221	0.547	rs35087715	chr3:18326931	C/G	cg07694806	chr3:18168406	NA	-0.63	-4.61	-0.35	8.64e-6	Parkinson's disease;
PAAD	cis	rs6466055	0.932	rs2057884	chr7:104930250	T/C	cg04380332	chr7:105027541	SRPK2	0.62	6.75	0.48	2.98e-10	Schizophrenia;
PAAD	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.35	0.56	3.83e-14	Dupuytren's disease;
PAAD	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.74	6.86	0.49	1.59e-10	Obesity-related traits;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg07212818	chr11:638076	DRD4	-0.7	-6.91	-0.49	1.21e-10	Systemic lupus erythematosus;
PAAD	cis	rs10885582	0.839	rs10885581	chr10:116316483	A/T	cg17056676	chr10:116301354	ABLIM1	0.37	5.13	0.38	8.57e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	7.55	0.52	3.72e-12	Menopause (age at onset);
PAAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.46	0.82	3.82e-38	Height;
PAAD	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.48	5.84	0.43	3.11e-8	Sitting height ratio;
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.53	-0.34	1.19e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.57	6.41	0.46	1.71e-9	Quantitative traits;
PAAD	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.69	-0.42	6.35e-8	Systolic blood pressure;
PAAD	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.53	-0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.66	-8.11	-0.55	1.61e-13	Alcohol dependence;
PAAD	cis	rs939584	1.000	rs13397165	chr2:653354	G/A	cg03610516	chr2:642275	NA	-0.64	-5.72	-0.42	5.51e-8	Body mass index;
PAAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.21	0.64	5.89e-19	Menopause (age at onset);
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.42	5.13	0.38	8.82e-7	Pulmonary function;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.34	0.4	3.33e-7	Bipolar disorder;
PAAD	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-5.44	-0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg09839279	chr12:125627357	AACS	-0.47	-4.32	-0.33	2.78e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6604026	0.922	rs11586570	chr1:93305371	A/C	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg08099141	chr12:7053170	C12orf57	0.45	4.54	0.35	1.15e-5	IgG glycosylation;
PAAD	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.67	-7.98	-0.54	3.25e-13	Sense of smell;
PAAD	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-1.05	-14.77	-0.77	3.53e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.83	8.82	0.58	2.48e-15	Anterior chamber depth;
PAAD	cis	rs863345	0.967	rs7526514	chr1:158532405	T/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg15674680	chr20:60982522	CABLES2	0.53	4.65	0.35	7.28e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.71e-8	Life satisfaction;
PAAD	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg21775007	chr8:11205619	TDH	0.8	7.95	0.54	4.01e-13	Retinal vascular caliber;
PAAD	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg14343924	chr8:8086146	FLJ10661	0.53	4.48	0.34	1.47e-5	Mood instability;
PAAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg01075559	chr1:2537774	MMEL1	-0.52	-5.39	-0.4	2.65e-7	Multiple sclerosis;
PAAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg05392440	chr1:2478653	NA	0.56	6.05	0.44	1.09e-8	Ulcerative colitis;
PAAD	cis	rs939584	1.000	rs2867110	chr2:651105	C/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg05110241	chr16:68378359	PRMT7	-0.88	-7.16	-0.5	3.24e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs367615	1.000	rs367615	chr5:108948937	C/T	cg17395555	chr5:108820864	NA	-0.43	-4.62	-0.35	8.04e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02106306	chr15:31620290	KLF13	-0.65	-6.31	-0.46	2.86e-9	Smoking initiation;
PAAD	cis	rs6011674	0.803	rs6011692	chr20:61867828	G/A	cg12002882	chr20:62461365	NA	-0.76	-4.56	-0.35	1.06e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.39	-0.34	2.11e-5	Glomerular filtration rate;
PAAD	cis	rs282587	0.569	rs914012	chr13:113386715	C/T	cg19217778	chr13:113420270	ATP11A	-0.58	-4.62	-0.35	8.12e-6	Glycated hemoglobin levels;
PAAD	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	1.02	6.73	0.48	3.24e-10	Fat distribution (HIV);
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.63	-5.78	-0.42	4.07e-8	Lung cancer;
PAAD	cis	rs7766436	0.583	rs6936809	chr6:22559825	T/G	cg13666174	chr6:22585274	NA	-0.51	-4.28	-0.33	3.33e-5	Coronary artery disease;
PAAD	cis	rs1879734	0.689	rs12040081	chr1:54168609	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.55	4.49	0.34	1.4e-5	Corneal structure;
PAAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs10750165	0.716	rs11217502	chr11:119652763	G/A	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs2790216	0.950	rs2790245	chr10:59978087	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.31e-7	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04604666	chr4:37828046	PGM2	0.59	6.37	0.46	2.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs10768122	1.000	rs10768120	chr11:35270854	G/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.32	-0.33	2.76e-5	Vitiligo;
PAAD	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg03568305	chr17:38183559	MED24;SNORD124	0.36	4.75	0.36	4.66e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.58	-5.23	-0.39	5.64e-7	White blood cell count;
PAAD	cis	rs422249	0.727	rs174606	chr11:61626973	G/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.39	4.43	0.34	1.77e-5	Trans fatty acid levels;
PAAD	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.52	4.99	0.37	1.65e-6	Hip circumference;
PAAD	cis	rs595018	0.505	rs565539	chr11:60602297	G/A	cg07588442	chr11:60673866	PRPF19	-0.65	-4.56	-0.35	1.04e-5	Wegener's granulomatosis;
PAAD	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.85	0.37	3.02e-6	Height;
PAAD	cis	rs7216064	1.000	rs62084210	chr17:65828710	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-5.42	-0.4	2.26e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.63	-5.72	-0.42	5.43e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09578018	chr15:60883649	RORA	0.67	8.06	0.55	2.13e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.19e-10	Lymphocyte counts;
PAAD	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg11494091	chr17:61959527	GH2	0.52	4.4	0.34	1.99e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-17.57	-0.82	1.96e-38	Ulcerative colitis;
PAAD	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00587304	chr3:172468157	NA	0.59	6.73	0.48	3.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg13535736	chr9:111863775	C9orf5	0.34	4.33	0.33	2.69e-5	Menarche (age at onset);
PAAD	cis	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7922314	0.571	rs61282002	chr10:64738038	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.67	-0.42	6.98e-8	Crohn's disease;
PAAD	cis	rs300774	1.000	rs2015419	chr2:118385	A/G	cg21211680	chr2:198530	NA	-0.56	-4.99	-0.38	1.61e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.41	-4.55	-0.35	1.1e-5	Aortic root size;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.72	7.96	0.54	3.69e-13	Systemic lupus erythematosus;
PAAD	cis	rs11669133	1.000	rs17001090	chr19:11118711	C/T	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19932974	chr4:108911074	HADH	0.67	6.5	0.47	1.09e-9	Obesity-related traits;
PAAD	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg01851573	chr8:8652454	MFHAS1	-0.57	-4.91	-0.37	2.33e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.73	0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs8040855	0.627	rs35668291	chr15:85652813	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.65	6.5	0.47	1.07e-9	Coronary artery disease;
PAAD	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.75	-8.34	-0.56	4.22e-14	Coronary artery disease;
PAAD	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	trans	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg15770106	chr1:208133116	NA	-0.64	-6.42	-0.46	1.68e-9	Corneal structure;
PAAD	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg00181669	chr3:44000978	NA	-0.46	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs787274	0.850	rs7047914	chr9:115620773	A/C	cg13803584	chr9:115635662	SNX30	-0.86	-4.73	-0.36	5.1e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg02870584	chr11:65547924	DKFZp761E198	0.45	4.42	0.34	1.86e-5	Urate levels;
PAAD	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.78	8.8	0.58	2.8e-15	Heart rate;
PAAD	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.92	-8.79	-0.58	3.03e-15	Asthma;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.5	0.41	1.56e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7113874	0.802	rs10840102	chr11:8676238	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-4.58	-0.35	9.81e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg19000871	chr14:103996768	TRMT61A	0.49	5.62	0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs7312933	0.509	rs12831750	chr12:42466477	G/A	cg19980929	chr12:42632907	YAF2	0.48	4.25	0.33	3.68e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.57	5.14	0.38	8.24e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	1.17	9.71	0.62	1.25e-17	Initial pursuit acceleration;
PAAD	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg00310523	chr12:86230176	RASSF9	-0.47	-5.19	-0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	6.03	0.44	1.21e-8	Platelet count;
PAAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-4.93	-0.37	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.5	5.03	0.38	1.37e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.55	-6.5	-0.47	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.73	-0.36	5.11e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.33	-0.51	1.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.77	7.67	0.53	1.91e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.5	5.68	0.42	6.59e-8	Coronary artery disease;
PAAD	cis	rs7616330	0.836	rs6780338	chr3:71029408	C/T	cg01511742	chr3:71112437	FOXP1	0.76	5.59	0.41	1.02e-7	QT interval;
PAAD	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.9	10.88	0.66	9.47e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	trans	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg26939375	chr7:64535504	NA	0.63	6.98	0.49	8.76e-11	Aortic root size;
PAAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs17407555	0.954	rs714815	chr4:10181206	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.84	-0.37	3.22e-6	Schizophrenia (age at onset);
PAAD	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-5.83	-0.43	3.17e-8	Menarche (age at onset);
PAAD	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.25	0.33	3.71e-5	Rheumatoid arthritis;
PAAD	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg22815214	chr1:201083145	CACNA1S	0.56	4.81	0.36	3.64e-6	Permanent tooth development;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.13	-0.5	3.74e-11	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05134775	chr10:98273510	TLL2	0.69	7.6	0.52	2.87e-12	Myopia (pathological);
PAAD	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.65	-10.15	-0.64	8.2e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.66	0.48	4.59e-10	Schizophrenia;
PAAD	cis	rs6088813	0.961	rs745931	chr20:33956004	A/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05708079	chr12:90102477	LOC338758	0.69	6.37	0.46	2.14e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23559352	chr18:74203659	NA	0.5	4.87	0.37	2.73e-6	Obesity-related traits;
PAAD	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg00614314	chr15:82944287	LOC80154	-0.5	-5.04	-0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg11941060	chr3:133502564	NA	0.51	5.21	0.39	6.02e-7	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs8084125	0.765	rs62105164	chr18:74944367	C/T	cg15443732	chr18:74961078	GALR1	0.54	4.71	0.36	5.48e-6	Obesity-related traits;
PAAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.86	-0.37	2.86e-6	Menopause (age at onset);
PAAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.76	7.84	0.54	7.46e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.42	-0.4	2.3e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs8081395	0.769	rs12449331	chr17:57883646	T/C	cg02344993	chr17:57696989	CLTC	-0.44	-4.44	-0.34	1.73e-5	White blood cell count;
PAAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01200585	chr1:228362443	C1orf69	-0.52	-5.84	-0.43	3.08e-8	Diastolic blood pressure;
PAAD	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.45	0.46	1.42e-9	Lung cancer;
PAAD	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.36	4.84	0.37	3.12e-6	Abdominal aortic aneurysm;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	6.12	0.44	7.54e-9	Body mass index;
PAAD	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.82	-9.73	-0.62	1.05e-17	Colorectal cancer;
PAAD	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.56	-5.37	-0.4	2.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.42	5.5	0.41	1.58e-7	Diastolic blood pressure;
PAAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-1.05	-13.7	-0.74	2.56e-28	Headache;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg10729496	chr3:10149963	C3orf24	0.84	6.62	0.47	5.76e-10	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04918900	chr1:40204479	PPIE	0.57	6.42	0.46	1.65e-9	Monocyte percentage of white cells;
PAAD	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.56	6.05	0.44	1.08e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	6.57	0.47	7.64e-10	Schizophrenia;
PAAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.33	0.33	2.75e-5	Parkinson's disease;
PAAD	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg08345082	chr10:99160200	RRP12	-0.31	-4.43	-0.34	1.79e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.25	-0.7	1.98e-24	Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23675362	chr1:180601130	XPR1	0.6	7.14	0.5	3.67e-11	Monocyte percentage of white cells;
PAAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.88	9.58	0.61	2.66e-17	Cognitive function;
PAAD	cis	rs2899832	0.714	rs10144857	chr14:35761084	A/G	cg09327582	chr14:35236912	BAZ1A	0.6	4.68	0.35	6.26e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.45	6.25	0.45	3.93e-9	Congenital heart disease (maternal effect);
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.59	-5.42	-0.4	2.28e-7	Obesity-related traits;
PAAD	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.75	-6.88	-0.49	1.43e-10	Coronary artery disease;
PAAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg04267008	chr7:1944627	MAD1L1	0.62	6.0	0.44	1.36e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.58	0.47	7.09e-10	Coffee consumption (cups per day);
PAAD	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.6	6.1	0.44	8.34e-9	Schizophrenia;
PAAD	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg02297831	chr4:17616191	MED28	0.58	5.68	0.42	6.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7090512	0.570	rs4747880	chr10:6152967	A/G	cg17191567	chr10:6178319	NA	0.42	4.33	0.33	2.66e-5	Multiple sclerosis;
PAAD	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg01851573	chr8:8652454	MFHAS1	-0.47	-4.72	-0.36	5.24e-6	Parkinson's disease;
PAAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg01503450	chr10:980765	NA	-0.54	-4.88	-0.37	2.64e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.2	-0.39	6.3e-7	Mood instability;
PAAD	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.83	-6.22	-0.45	4.49e-9	Hair shape;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.91	11.57	0.68	1.31e-22	Menarche (age at onset);
PAAD	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-5.58	-0.41	1.09e-7	Ulcerative colitis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15613982	chr20:18488017	SEC23B	0.56	6.41	0.46	1.78e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.25	-0.51	2.01e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.55	0.57	1.2e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs62238980	0.901	rs62238999	chr22:32584787	C/T	cg02631450	chr22:32366979	NA	1.01	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.71	0.42	5.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16527794	chr11:47600580	NDUFS3;KBTBD4	0.6	6.87	0.49	1.57e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.46	4.93	0.37	2.09e-6	Age of smoking initiation;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.66	-5.97	-0.44	1.64e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.59	5.04	0.38	1.32e-6	Type 2 diabetes;
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.55	-5.23	-0.39	5.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.45e-9	Schizophrenia;
PAAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.69	7.21	0.5	2.42e-11	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	8.43	0.56	2.49e-14	Total body bone mineral density;
PAAD	cis	rs12286929	0.609	rs7479259	chr11:115090715	T/A	cg04055981	chr11:115044050	NA	0.46	4.5	0.34	1.35e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg21395723	chr22:39101663	GTPBP1	-0.48	-4.77	-0.36	4.27e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.29	0.39	4.29e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.91	-0.54	5.04e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.46	-0.41	1.89e-7	Vitiligo;
PAAD	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg08992911	chr2:238395768	MLPH	0.7	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg13565585	chr5:132299512	AFF4	0.51	4.98	0.37	1.71e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.3e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6066825	0.605	rs4325821	chr20:47224787	T/C	cg18078177	chr20:47281410	PREX1	0.5	4.57	0.35	9.99e-6	Colorectal cancer;
PAAD	cis	rs6496044	0.507	rs7175731	chr15:86154346	C/T	cg10818794	chr15:86012489	AKAP13	0.44	4.61	0.35	8.33e-6	Interstitial lung disease;
PAAD	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.94	-9.06	-0.59	6.07e-16	Exhaled nitric oxide output;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.96	-0.37	1.87e-6	Bipolar disorder;
PAAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg13786083	chr1:19110734	NA	-0.61	-5.35	-0.4	3.18e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19455421	chr7:30174596	C7orf41	-0.87	-7.92	-0.54	4.52e-13	Neuroticism;
PAAD	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.29	-0.45	3.2e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg21280320	chr1:152162025	NA	-0.53	-4.6	-0.35	8.8e-6	Inflammatory skin disease;
PAAD	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg00806126	chr19:22604979	ZNF98	-0.4	-5.11	-0.38	9.36e-7	Pain;
PAAD	cis	rs10943724	0.704	rs7763364	chr6:81269431	G/A	cg19323245	chr6:80716898	TTK	-0.42	-4.49	-0.34	1.38e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg13397359	chr6:42928475	GNMT	0.61	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.48	6.06	0.44	1.02e-8	Prostate cancer;
PAAD	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg00262122	chr8:11665843	FDFT1	0.49	4.7	0.36	5.68e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs642743	0.967	rs1147610	chr10:105941167	G/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.55	0.35	1.08e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg05935833	chr10:81318306	SFTPA2	-0.52	-4.27	-0.33	3.48e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.13e-5	Menopause (age at onset);
PAAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.59	-8.44	-0.57	2.28e-14	Huntington's disease progression;
PAAD	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.71	6.96	0.49	9.36e-11	Anterior chamber depth;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14135272	chr6:166799902	NA	-0.67	-6.91	-0.49	1.26e-10	Obesity-related traits;
PAAD	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.26	0.39	4.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2017305	0.915	rs75765214	chr10:70715357	C/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.82	-8.74	-0.58	4.09e-15	Total body bone mineral density;
PAAD	trans	rs1075265	0.587	rs2949811	chr2:54024165	G/A	cg16115072	chr17:25938812	KSR1	0.6	6.31	0.46	2.89e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg23930083	chr7:100816912	C7orf52	-0.51	-4.35	-0.33	2.46e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.14	0.38	8.31e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7326068	0.647	rs2818978	chr13:21319537	C/G	cg27499820	chr13:21296301	IL17D	0.57	5.34	0.4	3.39e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-1.04	-17.03	-0.81	4.78e-37	Height;
PAAD	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg21479132	chr6:26055353	NA	0.84	5.28	0.39	4.35e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.27	0.45	3.54e-9	Height;
PAAD	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	5.89	0.43	2.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs60154123	0.730	rs12074229	chr1:210474602	A/G	cg25204440	chr1:209979598	IRF6	0.54	4.5	0.34	1.36e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg08888203	chr3:10149979	C3orf24	0.66	5.95	0.43	1.77e-8	Alzheimer's disease;
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg19673125	chr6:150240577	RAET1G	0.42	5.87	0.43	2.58e-8	Testicular germ cell tumor;
PAAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.58	6.03	0.44	1.19e-8	Huntington's disease progression;
PAAD	cis	rs7537660	0.562	rs4417105	chr1:248016487	G/T	cg04028570	chr1:248100427	OR2L13	-0.41	-4.41	-0.34	1.91e-5	Platelet distribution width;
PAAD	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg10437265	chr15:77819839	NA	0.4	4.33	0.33	2.74e-5	Type 2 diabetes;
PAAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.61	6.23	0.45	4.37e-9	Multiple sclerosis;
PAAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.5	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg09659197	chr4:152720779	NA	-0.42	-5.6	-0.41	9.79e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg04315214	chr1:2043799	PRKCZ	-0.47	-5.65	-0.42	7.66e-8	Coronary artery disease;
PAAD	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg02415014	chr8:143852576	LYNX1	0.49	6.0	0.44	1.38e-8	Urinary tract infection frequency;
PAAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00933542	chr6:150070202	PCMT1	0.54	5.81	0.43	3.51e-8	Lung cancer;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	1.0	7.13	0.5	3.8e-11	IgG glycosylation;
PAAD	cis	rs911119	0.955	rs8121405	chr20:23605226	G/A	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs6681460	1.000	rs4655636	chr1:67068537	A/G	cg02459107	chr1:67143332	SGIP1	0.77	7.92	0.54	4.59e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2744375	0.600	rs2744371	chr6:7554174	A/C	cg27023638	chr6:7288726	SSR1	-0.42	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.69	5.67	0.42	7.01e-8	Type 2 diabetes;
PAAD	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.97	7.86	0.54	6.7e-13	Vitiligo;
PAAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg04398451	chr17:18023971	MYO15A	0.75	7.96	0.54	3.69e-13	Total body bone mineral density;
PAAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg06740227	chr12:86229804	RASSF9	0.5	4.64	0.35	7.44e-6	Major depressive disorder;
PAAD	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.46	4.33	0.33	2.65e-5	Mean corpuscular volume;
PAAD	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	cis	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs10214930	0.813	rs11764753	chr7:27672959	T/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.66	-0.79	1.63e-33	Height;
PAAD	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.64	-6.5	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg14926445	chr8:58193284	C8orf71	-0.62	-4.76	-0.36	4.46e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg16434002	chr17:42200994	HDAC5	0.61	5.52	0.41	1.45e-7	Total body bone mineral density;
PAAD	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-4.65	-0.35	7.18e-6	Retinal vascular caliber;
PAAD	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.33	0.33	2.65e-5	Immature fraction of reticulocytes;
PAAD	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	7.55	0.52	3.76e-12	Multiple sclerosis;
PAAD	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.53	5.58	0.41	1.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	1.09	15.32	0.78	1.26e-32	Breast cancer;
PAAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg10587741	chr22:38071170	LGALS1	0.61	6.83	0.48	1.92e-10	Fat distribution (HIV);
PAAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.55	7.24	0.51	2.1e-11	Renal cell carcinoma;
PAAD	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg19637330	chr1:19110922	NA	0.6	4.76	0.36	4.53e-6	Percentage gas trapping;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15391271	chr1:249153457	ZNF692	0.72	6.51	0.47	1.03e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2242420	0.920	rs72876070	chr1:21965486	C/T	cg26362272	chr1:22108717	USP48	0.57	4.45	0.34	1.65e-5	Hematological and biochemical traits;
PAAD	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	6.01	0.44	1.29e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.74	8.97	0.59	1.03e-15	Bone mineral density;
PAAD	cis	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.75	-0.36	4.6e-6	Neuroticism;
PAAD	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg20913747	chr6:44695427	NA	-0.69	-6.92	-0.49	1.2e-10	Total body bone mineral density;
PAAD	cis	rs12449964	0.524	rs7224619	chr17:17572384	C/T	cg04398451	chr17:18023971	MYO15A	0.49	4.75	0.36	4.61e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.49	-0.34	1.42e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.71	7.65	0.53	2.14e-12	Triglyceride levels;
PAAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.95	-12.86	-0.72	4.44e-26	Height;
PAAD	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.54	5.18	0.39	6.96e-7	Multiple myeloma;
PAAD	cis	rs10101158	0.737	rs1446939	chr8:142930514	C/T	cg07295586	chr8:142984467	NA	-0.37	-4.27	-0.33	3.49e-5	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.67	-6.64	-0.47	5.13e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.48	0.47	1.22e-9	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.26	-0.33	3.63e-5	Skin colour saturation;
PAAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg06375148	chr1:209958343	C1orf74	0.65	4.85	0.37	3.02e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.7	6.64	0.47	5.23e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg11859384	chr17:80120422	CCDC57	0.49	5.04	0.38	1.28e-6	Life satisfaction;
PAAD	cis	rs2241685	0.573	rs11127302	chr2:1935709	A/G	cg22511877	chr2:1942942	MYT1L	-0.58	-4.58	-0.35	9.75e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.5	-0.34	1.35e-5	Neuroticism;
PAAD	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.59	0.61	2.57e-17	Response to antipsychotic treatment;
PAAD	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.5	-5.34	-0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.98	-12.14	-0.7	3.85e-24	Refractive error;
PAAD	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.66	6.66	0.48	4.75e-10	Renal function-related traits (BUN);
PAAD	cis	rs7635838	0.819	rs2454478	chr3:11541885	A/G	cg00170343	chr3:11313890	ATG7	0.49	4.54	0.35	1.12e-5	HDL cholesterol;
PAAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.85	-8.85	-0.58	2.04e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.85	-9.62	-0.62	2.09e-17	Prostate cancer;
PAAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.74	5.64	0.42	7.9e-8	Fat distribution (HIV);
PAAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.5	-0.34	1.37e-5	Neuroticism;
PAAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.69	-7.61	-0.53	2.73e-12	Melanoma;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10819733	chr22:24237672	NA	-0.58	-6.31	-0.46	2.92e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.23	0.64	5.02e-19	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg01075559	chr1:2537774	MMEL1	-0.5	-5.2	-0.39	6.25e-7	Ulcerative colitis;
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	1.0	7.8	0.53	9.1e-13	Initial pursuit acceleration;
PAAD	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.41	0.34	1.97e-5	Lung cancer;
PAAD	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.53	-4.74	-0.36	4.83e-6	P wave terminal force;
PAAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14180030	chr9:123475675	MEGF9	-0.46	-5.08	-0.38	1.1e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.62	6.29	0.45	3.2e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9503598	0.502	rs4518545	chr6:3433890	T/A	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18368637	chr6:144179905	LTV1	0.56	6.47	0.46	1.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs258892	0.895	rs34656	chr5:72148117	C/T	cg21869765	chr5:72125136	TNPO1	0.77	5.25	0.39	5.03e-7	Small cell lung carcinoma;
PAAD	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.46	-4.56	-0.35	1.06e-5	Birth weight;
PAAD	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	4.99	0.37	1.66e-6	Axial length;
PAAD	cis	rs763512	1.000	rs763512	chr17:35889531	C/T	cg16670864	chr17:35848621	DUSP14	0.43	4.33	0.33	2.68e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.66	8.48	0.57	1.85e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9401295	0.635	rs7759889	chr6:98266586	A/G	cg00987395	chr6:98934664	NA	0.37	4.41	0.34	1.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.83	7.9	0.54	5.26e-13	Response to hepatitis C treatment;
PAAD	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.65	6.06	0.44	1.05e-8	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.72e-7	Life satisfaction;
PAAD	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg02344993	chr17:57696989	CLTC	0.62	5.22	0.39	5.73e-7	Hemoglobin concentration;
PAAD	cis	rs2384207	0.818	rs1458366	chr12:113672577	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.6	5.44	0.4	2.06e-7	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs7915414	0.951	rs68157779	chr10:96432689	A/G	cg00735080	chr21:47285121	PCBP3	0.51	6.41	0.46	1.73e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs9810890	0.850	rs73198858	chr3:128514061	T/G	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.87	-0.43	2.59e-8	Type 2 diabetes;
PAAD	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs4234284	0.900	rs12491804	chr3:126983124	G/T	cg16216305	chr3:127842716	RUVBL1	0.41	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs3733418	0.860	rs13110286	chr4:165956403	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.5	-4.79	-0.36	3.94e-6	Obesity-related traits;
PAAD	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg03252829	chr6:39282164	KCNK17	-0.56	-5.89	-0.43	2.38e-8	Type 2 diabetes;
PAAD	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg16579770	chr16:72058938	DHODH	0.38	4.37	0.33	2.26e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg25364880	chr3:44379878	C3orf23	0.63	5.91	0.43	2.16e-8	Depressive symptoms;
PAAD	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.27	-0.33	3.43e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg00024989	chr19:17902242	NA	0.43	4.68	0.35	6.41e-6	Tumor biomarkers;
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.8	8.68	0.58	5.84e-15	Prostate cancer;
PAAD	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.76	5.64	0.42	8.05e-8	Initial pursuit acceleration;
PAAD	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.51	-0.34	1.29e-5	Morning vs. evening chronotype;
PAAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.23	-0.39	5.5e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg04154034	chr17:28927549	LRRC37B2	0.69	4.34	0.33	2.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs282587	0.569	rs419334	chr13:113415346	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.97	-0.37	1.82e-6	Glycated hemoglobin levels;
PAAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-9.0	-0.59	8.53e-16	Body mass index;
PAAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.76	0.53	1.17e-12	Melanoma;
PAAD	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-7.11	-0.5	4.22e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.69	-7.1	-0.5	4.55e-11	Tourette syndrome;
PAAD	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg02389323	chr16:88786976	FAM38A	1.12	6.73	0.48	3.26e-10	Plateletcrit;
PAAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg13870426	chr17:30244630	NA	-0.74	-6.56	-0.47	7.8e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.57e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	4.87	0.37	2.8e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.68	5.99	0.44	1.43e-8	Lung cancer;
PAAD	cis	rs9810890	1.000	rs78543474	chr3:128561638	T/C	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.64	5.2	0.39	6.33e-7	Serum sulfate level;
PAAD	trans	rs2725236	0.520	rs4128340	chr4:88908136	C/A	cg23656380	chr20:60877581	ADRM1	-0.64	-6.62	-0.47	5.81e-10	Caffeine consumption;
PAAD	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg10208897	chr5:178548229	ADAMTS2	0.54	4.82	0.36	3.46e-6	Pubertal anthropometrics;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.27e-5	Rheumatoid arthritis;
PAAD	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg12458913	chr13:53173898	NA	0.48	4.89	0.37	2.51e-6	Lewy body disease;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.55	4.99	0.38	1.63e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-6.45	-0.46	1.42e-9	Lymphocyte counts;
PAAD	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg08079166	chr15:68083412	MAP2K5	0.64	5.04	0.38	1.31e-6	Restless legs syndrome;
PAAD	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.7	-7.1	-0.5	4.43e-11	Mosquito bite size;
PAAD	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg23688817	chr7:87105293	ABCB4	0.56	4.66	0.35	6.95e-6	Gallbladder cancer;
PAAD	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.52	5.54	0.41	1.28e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.5	6.32	0.46	2.81e-9	Schizophrenia;
PAAD	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.22	-0.45	4.56e-9	Alcohol dependence;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12754538	0.665	rs12037534	chr1:8649924	G/A	cg06159269	chr1:8767347	RERE	0.47	5.5	0.41	1.59e-7	Subjective well-being;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08460226	chr3:186501131	SNORD2;EIF4A2	0.58	6.52	0.47	9.98e-10	Monocyte percentage of white cells;
PAAD	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.52	5.06	0.38	1.18e-6	Type 2 diabetes;
PAAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.71	6.96	0.49	9.77e-11	Hip circumference;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg04160749	chr8:58172571	NA	-0.59	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg10072921	chr12:121022843	NA	-0.36	-4.73	-0.36	5.04e-6	High light scatter reticulocyte count;
PAAD	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.43	-5.43	-0.4	2.18e-7	Lewy body disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18838207	chr2:190649256	PMS1;ORMDL1	0.65	6.38	0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs6460942	0.597	rs17277369	chr7:12536192	A/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs3925075	0.531	rs9673519	chr16:31347557	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.46	0.41	1.86e-7	IgA nephropathy;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg23298862	chr7:158159286	PTPRN2	0.57	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs4764124	0.616	rs2052325	chr12:14948434	C/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.55	6.36	0.46	2.27e-9	Pubertal anthropometrics;
PAAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.57	5.15	0.39	7.82e-7	Corneal astigmatism;
PAAD	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg27455613	chr17:80820699	TBCD	-0.44	-4.35	-0.33	2.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10450586	0.863	rs7481109	chr11:27298062	A/G	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg16898833	chr6:26189333	HIST1H4D	0.97	4.83	0.36	3.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	8.32	0.56	4.6e-14	Coronary artery disease;
PAAD	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.42	5.29	0.39	4.17e-7	Pulmonary function;
PAAD	cis	rs1135314	0.580	rs10870116	chr9:139287674	G/A	cg21253087	chr9:139290292	SNAPC4	0.51	4.47	0.34	1.52e-5	Acute insulin response;
PAAD	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.67	-5.29	-0.39	4.15e-7	Alzheimer's disease;
PAAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg03983476	chr2:10830698	NOL10	-0.62	-6.17	-0.45	5.82e-9	Prostate cancer;
PAAD	cis	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs12780845	1.000	rs12780845	chr10:17223244	A/G	cg00857480	chr10:17188594	TRDMT1	0.35	4.62	0.35	8.16e-6	Homocysteine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01168283	chr16:86542789	FOXF1	0.64	6.62	0.47	5.77e-10	Obesity-related traits;
PAAD	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg08501292	chr6:25962987	TRIM38	0.96	5.41	0.4	2.45e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs7009110	0.706	rs6992476	chr8:81267706	C/T	cg21158561	chr8:81178149	NA	-0.43	-4.63	-0.35	7.67e-6	Asthma and hay fever;
PAAD	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs6700896	0.500	rs6693842	chr1:66078405	T/C	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.64e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg10356904	chr22:49881777	NA	-0.52	-5.51	-0.41	1.52e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7916697	1.000	rs7916697	chr10:69991853	A/G	cg18338521	chr10:69995036	NA	0.36	4.51	0.34	1.27e-5	Optic disc area;
PAAD	cis	rs2109514	1.000	rs7795510	chr7:116156961	T/C	cg19719915	chr7:115928094	NA	-0.45	-4.3	-0.33	3.06e-5	Prevalent atrial fibrillation;
PAAD	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg11232448	chr19:2858854	NA	-0.49	-4.83	-0.36	3.37e-6	Total cholesterol levels;
PAAD	cis	rs7638995	0.878	rs3968927	chr3:69183404	C/T	cg26574240	chr3:69171822	LMOD3	-0.72	-4.99	-0.38	1.6e-6	Alzheimer's disease (late onset);
PAAD	cis	rs988913	0.874	rs9382398	chr6:54783266	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.92e-6	Tonsillectomy;
PAAD	cis	rs12826942	0.605	rs17801484	chr12:42483931	T/C	cg19980929	chr12:42632907	YAF2	0.49	4.37	0.33	2.25e-5	Coronary artery disease;
PAAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.5	0.34	1.33e-5	Tonsillectomy;
PAAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg03538708	chr1:25844672	NA	0.48	4.88	0.37	2.64e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-1.15	-9.49	-0.61	4.49e-17	Obesity-related traits;
PAAD	cis	rs75920871	0.764	rs1473327	chr11:116823996	A/T	cg04087571	chr11:116723030	SIK3	-0.48	-4.8	-0.36	3.7e-6	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14517108	chr17:76921504	TIMP2	0.67	6.71	0.48	3.68e-10	Obesity-related traits;
PAAD	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.53	-5.7	-0.42	6.03e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7264396	0.887	rs224364	chr20:34063865	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.8	-0.43	3.7e-8	Total cholesterol levels;
PAAD	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.91	0.49	1.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.12	14.18	0.75	1.32e-29	Schizophrenia;
PAAD	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg06042504	chr8:55087323	NA	-0.61	-5.89	-0.43	2.42e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.69	-5.68	-0.42	6.57e-8	Neuroticism;
PAAD	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.54	4.33	0.33	2.7e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs757081	0.533	rs7949405	chr11:17085192	A/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.29	0.33	3.21e-5	Systolic blood pressure;
PAAD	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.43	5.06	0.38	1.22e-6	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.65	0.47	5.03e-10	Morning vs. evening chronotype;
PAAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.92	10.41	0.65	1.69e-19	Tonsillectomy;
PAAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.69	6.06	0.44	1.04e-8	Asthma;
PAAD	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs4740619	0.967	rs1553728	chr9:15667702	G/T	cg14451791	chr9:16040625	NA	-0.38	-4.5	-0.34	1.36e-5	Body mass index;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27297192	chr10:134578999	INPP5A	0.59	5.29	0.39	4.26e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg16898833	chr6:26189333	HIST1H4D	1.05	5.36	0.4	3.06e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg25664220	chr3:72788482	NA	-0.71	-7.24	-0.51	2.11e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.55	5.59	0.41	1.01e-7	Testicular germ cell tumor;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg02696790	chr15:75250997	RPP25	0.4	4.73	0.36	5.01e-6	Breast cancer;
PAAD	cis	rs58521262	0.519	rs56104003	chr19:23000432	T/A	cg07749055	chr19:23076870	NA	-0.6	-4.58	-0.35	9.65e-6	Testicular germ cell tumor;
PAAD	cis	rs73416724	0.688	rs113283188	chr6:43355266	A/C	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4742903	0.967	rs4743690	chr9:106909577	T/C	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs6466055	0.649	rs7794285	chr7:104849737	A/G	cg04380332	chr7:105027541	SRPK2	0.46	4.39	0.34	2.09e-5	Schizophrenia;
PAAD	cis	rs34599045	0.708	rs12027303	chr1:152897923	C/T	cg02855850	chr1:152882420	IVL	0.7	4.38	0.33	2.2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs13011075	0.535	rs3732044	chr2:68623915	T/C	cg06275642	chr2:68546038	CNRIP1	0.35	4.66	0.35	6.94e-6	Mean corpuscular volume;
PAAD	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg23465465	chr6:26364728	BTN3A2	0.79	4.4	0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs501120	0.584	rs1704228	chr10:44673050	C/T	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs11563648	0.500	rs4728068	chr7:127021822	C/T	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-1.0	-10.57	-0.65	6.5e-20	Platelet distribution width;
PAAD	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg01631408	chr1:248437212	OR2T33	-0.6	-5.27	-0.39	4.54e-7	Common traits (Other);
PAAD	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.49	4.9	0.37	2.39e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg08048268	chr3:133502702	NA	-0.53	-6.64	-0.47	5.11e-10	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-4.63	-0.35	7.9e-6	Mean platelet volume;
PAAD	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.49	-0.52	5.36e-12	Triglycerides;
PAAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg19630374	chr17:18023558	MYO15A	0.47	4.86	0.37	2.86e-6	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg16083429	chr3:49237500	CCDC36	-0.46	-4.48	-0.34	1.43e-5	Menarche (age at onset);
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08167039	chr1:762232	NCRNA00115;LOC643837	0.65	7.53	0.52	4.16e-12	Metabolite levels  (X-11787);
PAAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.83	9.1	0.59	4.81e-16	Schizophrenia;
PAAD	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15557168	chr22:42548783	NA	-0.54	-5.94	-0.43	1.84e-8	Cognitive function;
PAAD	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.67	-6.52	-0.47	9.76e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg15117754	chr3:10150083	C3orf24	0.58	4.34	0.33	2.57e-5	Alzheimer's disease;
PAAD	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg01064725	chr1:204461714	NA	-0.51	-4.83	-0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg19192590	chr2:178524533	PDE11A	0.4	4.63	0.35	7.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg09873201	chr16:3507582	NAT15	0.57	5.29	0.39	4.12e-7	Tuberculosis;
PAAD	cis	rs2442825	0.526	rs6443237	chr3:9437461	A/G	cg26143413	chr3:9428045	THUMPD3	-0.5	-4.3	-0.33	3.07e-5	Cerebrospinal fluid clusterin levels;
PAAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.74	6.9	0.49	1.3100000000000001e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs10924309	0.737	rs4378245	chr1:245852727	G/A	cg00036263	chr1:245852353	KIF26B	-0.61	-5.94	-0.43	1.83e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.58	6.34	0.46	2.52e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1419980	0.730	rs73260715	chr12:7781252	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01516076	chr20:60581659	TAF4	-0.64	-6.76	-0.48	2.71e-10	Myopia (pathological);
PAAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.81	0.43	3.63e-8	Menopause (age at onset);
PAAD	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	8.13	0.55	1.36e-13	Lewy body disease;
PAAD	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.85	9.63	0.62	2e-17	Lewy body disease;
PAAD	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg08099141	chr12:7053170	C12orf57	0.43	4.39	0.34	2.12e-5	IgG glycosylation;
PAAD	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.1	-0.55	1.69e-13	Response to antipsychotic treatment;
PAAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.96	-12.55	-0.71	3.07e-25	Height;
PAAD	cis	rs17150703	0.722	rs10092705	chr8:9774258	G/T	cg09500200	chr8:9763033	NA	0.36	4.29	0.33	3.11e-5	Obesity (early onset extreme);
PAAD	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs13102973	0.682	rs13107817	chr4:135885535	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg17514665	chr17:1657533	SERPINF2	-0.65	-6.03	-0.44	1.18e-8	Serum albumin level;
PAAD	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.64	-6.08	-0.44	9.1e-9	Mean platelet volume;
PAAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg26513180	chr16:89883248	FANCA	-0.44	-4.41	-0.34	1.98e-5	Vitiligo;
PAAD	cis	rs990171	0.955	rs3755268	chr2:103038527	C/G	cg03938978	chr2:103052716	IL18RAP	0.43	4.29	0.33	3.17e-5	Lymphocyte counts;
PAAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	trans	rs225245	0.817	rs225290	chr17:33927904	C/G	cg19694781	chr19:47549865	TMEM160	-0.56	-6.31	-0.46	2.9e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.82	-7.49	-0.52	5.18e-12	Exhaled nitric oxide output;
PAAD	cis	rs2017305	0.915	rs77723660	chr10:70657028	C/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.08	-0.38	1.08e-6	Depression (quantitative trait);
PAAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.51	-5.15	-0.39	7.93e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg00749118	chr7:1938791	MAD1L1	0.69	5.09	0.38	1.03e-6	Bipolar disorder;
PAAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg18944383	chr4:111397179	ENPEP	-0.76	-9.0	-0.59	8.78e-16	Coronary artery disease;
PAAD	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs12195424	0.558	rs74408362	chr6:56294480	T/G	cg10030658	chr6:56298004	NA	-0.76	-4.38	-0.34	2.16e-5	Cerebrospinal fluid clusterin levels;
PAAD	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.99	-0.38	1.63e-6	Mean corpuscular volume;
PAAD	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.49	0.41	1.61e-7	Schizophrenia;
PAAD	cis	rs3796727	0.739	rs3756162	chr4:8617329	C/T	cg05284713	chr4:8621361	CPZ	-0.43	-4.3	-0.33	3.1e-5	Sporadic neuroblastoma;
PAAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.56	4.74	0.36	4.81e-6	Alcohol dependence (age at onset);
PAAD	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.57	-0.35	1.02e-5	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.48	-4.33	-0.33	2.74e-5	Hypospadias;
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg15660573	chr17:549704	VPS53	-0.74	-7.8	-0.53	9.37e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6840360	1.000	rs6535821	chr4:152678974	T/C	cg22705602	chr4:152727874	NA	-0.5	-5.17	-0.39	7.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg04018474	chr16:31008003	STX1B	0.27	4.26	0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.44	5.71	0.42	5.88e-8	Longevity;
PAAD	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	7.73	0.53	1.37e-12	Personality dimensions;
PAAD	cis	rs4731207	0.570	rs2086505	chr7:124664157	A/T	cg14311320	chr7:124405732	GPR37	-0.41	-4.26	-0.33	3.55e-5	Cutaneous malignant melanoma;
PAAD	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.67	6.57	0.47	7.59e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs4851870	0.542	rs13003975	chr2:106497649	C/A	cg21551182	chr2:106399873	NCK2	0.44	4.53	0.34	1.2e-5	Addiction;
PAAD	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg09760422	chr2:128146352	NA	-0.33	-5.54	-0.41	1.33e-7	Protein C levels;
PAAD	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.72	-7.63	-0.53	2.46e-12	Verbal declarative memory;
PAAD	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg14711859	chr11:8959438	ASCL3	0.35	4.42	0.34	1.87e-5	Hemoglobin concentration;
PAAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.78	0.48	2.56e-10	Coronary artery disease;
PAAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg25837213	chr17:80849375	TBCD	-0.48	-4.4	-0.34	2e-5	Breast cancer;
PAAD	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg02421172	chr7:1938701	MAD1L1	-0.63	-4.39	-0.34	2.15e-5	Bipolar disorder;
PAAD	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-1.01	-12.76	-0.72	8.33e-26	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.9	0.66	8.42e-21	Electrocardiographic conduction measures;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg25439992	chr11:126173954	DCPS	0.61	6.31	0.46	2.93e-9	Iris heterochromicity;
PAAD	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	5.72	0.42	5.44e-8	Mood instability;
PAAD	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	5.26	0.39	4.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.24	0.39	5.38e-7	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg24642844	chr7:1081250	C7orf50	0.56	4.46	0.34	1.57e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg00255919	chr5:131827918	IRF1	0.4	5.24	0.39	5.39e-7	Asthma;
PAAD	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	High light scatter reticulocyte count;
PAAD	cis	rs9463078	0.665	rs9367214	chr6:45025912	G/A	cg25276700	chr6:44698697	NA	-0.51	-5.7	-0.42	6.06e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.49e-8	Menopause (age at onset);
PAAD	cis	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.78	-0.36	4.05e-6	Eotaxin levels;
PAAD	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.47	7.64	0.53	2.23e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs5756391	0.546	rs1807546	chr22:37311425	A/C	cg16356956	chr22:37317934	CSF2RB	0.37	4.52	0.34	1.25e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.2	0.55	9.24e-14	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20830389	chr12:105724410	C12orf75	-0.77	-6.52	-0.47	9.57e-10	Neuroticism;
PAAD	cis	rs910187	0.538	rs2868849	chr20:45802273	G/A	cg27589058	chr20:45804311	EYA2	-0.48	-5.18	-0.39	7.06e-7	Migraine;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09555073	chr3:122747539	SEMA5B	0.56	6.42	0.46	1.64e-9	Monocyte percentage of white cells;
PAAD	cis	rs35955747	0.840	rs9621221	chr22:31616169	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.35	-4.3	-0.33	3.09e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.16	-0.39	7.65e-7	Mean corpuscular volume;
PAAD	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.04	0.44	1.14e-8	Rheumatoid arthritis;
PAAD	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23935120	chr1:25757374	TMEM57	0.62	7.08	0.5	5.09e-11	Monocyte percentage of white cells;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	4.53	0.34	1.2e-5	Urinary tract infection frequency;
PAAD	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg06636001	chr8:8085503	FLJ10661	0.69	6.98	0.49	8.45e-11	Triglycerides;
PAAD	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.92	-8.5	-0.57	1.62e-14	Obesity-related traits;
PAAD	cis	rs6594713	0.533	rs35552641	chr5:112971132	T/G	cg12552261	chr5:112820674	MCC	0.77	4.97	0.37	1.75e-6	Brain cytoarchitecture;
PAAD	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg20406979	chr6:167373233	NA	0.34	4.53	0.34	1.19e-5	Crohn's disease;
PAAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22482690	chr17:47019901	SNF8	0.47	5.11	0.38	9.5e-7	Type 2 diabetes;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.36	-5.03	-0.38	1.38e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-5.64	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs881827	1.000	rs881827	chr21:48019868	C/T	cg08742575	chr21:47604166	C21orf56	0.45	4.27	0.33	3.42e-5	Lymphocyte counts;
PAAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.16	-0.39	7.76e-7	Mortality in heart failure;
PAAD	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.27	-0.6	1.71e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7172677	1.000	rs62027286	chr15:75429720	T/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.72	-0.36	5.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg20356878	chr3:121714668	ILDR1	0.48	4.58	0.35	9.72e-6	Cognitive performance;
PAAD	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.31	0.4	3.89e-7	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.58	4.38	0.33	2.23e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg00781540	chr3:50396681	TMEM115	0.64	4.34	0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.56	5.5	0.41	1.6e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs1413885	0.504	rs7524932	chr1:65865993	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	5.02	0.38	1.46e-6	Anticoagulant levels;
PAAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.47	-5.4	-0.4	2.57e-7	Breast size;
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.41	0.34	1.94e-5	IgG glycosylation;
PAAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	trans	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.78	-9.01	-0.59	8.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6519955	0.755	rs8135712	chr22:46425388	T/C	cg00147172	chr22:46423604	NA	0.41	5.49	0.41	1.66e-7	Dupuytren's disease;
PAAD	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23158103	chr7:148848205	ZNF398	-0.57	-5.71	-0.42	5.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	0.562	rs8025019	chr15:45735865	C/T	cg26924012	chr15:45694286	SPATA5L1	0.77	4.69	0.36	6.08e-6	Homoarginine levels;
PAAD	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-4.73	-0.36	5.11e-6	Pulmonary function;
PAAD	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.92	8.31	0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs10186876	0.541	rs12712902	chr2:44189487	G/A	cg14673618	chr2:45170322	SIX3	0.3	4.74	0.36	4.78e-6	Hand grip strength;
PAAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg23947450	chr7:900037	UNC84A	-0.52	-4.46	-0.34	1.59e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08550205	chr17:45786854	TBKBP1	-0.4	-4.37	-0.33	2.3e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.38	-0.33	2.2e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	Schizophrenia;
PAAD	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.01	-0.38	1.49e-6	Metabolite levels;
PAAD	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg04389838	chr3:44770851	ZNF501	-0.51	-4.39	-0.34	2.09e-5	Depressive symptoms;
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg03909863	chr11:638404	DRD4	-0.67	-5.71	-0.42	5.68e-8	Systemic lupus erythematosus;
PAAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.81	-7.63	-0.53	2.45e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs469568	0.562	rs11746802	chr5:178665185	C/T	cg08999896	chr5:178685787	ADAMTS2	0.53	5.39	0.4	2.62e-7	Stroke (pediatric);
PAAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.45	-4.75	-0.36	4.61e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.91	9.73	0.62	1.09e-17	QRS duration;
PAAD	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.64	6.17	0.45	6.01e-9	Subjective well-being;
PAAD	cis	rs713587	0.571	rs563590	chr2:25331172	A/G	cg01884057	chr2:25150051	NA	-0.37	-4.3	-0.33	3e-5	Body mass index in non-asthmatics;
PAAD	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.87	-10.5	-0.65	9.96e-20	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg19856771	chr13:42780042	DGKH	-0.61	-6.32	-0.46	2.82e-9	Alcohol dependence;
PAAD	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.29	-0.39	4.14e-7	Coronary artery disease;
PAAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.7	7.84	0.54	7.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.59	-5.75	-0.42	4.75e-8	Systolic blood pressure;
PAAD	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	4.51	0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.84	-9.99	-0.63	2.26e-18	Height;
PAAD	cis	rs89107	0.688	rs281861	chr6:118579357	T/G	cg21191810	chr6:118973309	C6orf204	0.45	6.23	0.45	4.32e-9	Cardiac structure and function;
PAAD	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.57	4.74	0.36	4.86e-6	Bitter taste perception;
PAAD	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg27449745	chr7:23145252	KLHL7	0.5	4.42	0.34	1.89e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg06203364	chr1:2137307	C1orf86	-0.47	-4.46	-0.34	1.56e-5	Height;
PAAD	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.94	0.43	1.84e-8	Breast cancer;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg01620082	chr3:125678407	NA	-1.55	-9.14	-0.6	3.86e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62264129	0.500	rs9829698	chr3:112028239	A/G	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.25	-0.33	3.72e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs608114	0.623	rs17776837	chr6:96357413	T/C	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg14146966	chr2:61757674	XPO1	0.38	4.79	0.36	4e-6	Tuberculosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25599950	chr7:51259763	COBL	0.58	6.56	0.47	7.9e-10	Smoking initiation;
PAAD	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.58	-0.41	1.07e-7	Adiposity;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.65	6.99	0.49	8.16e-11	Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs329674	0.556	rs484210	chr11:133762767	G/A	cg06766960	chr11:133703094	NA	-0.71	-4.5	-0.34	1.34e-5	Bipolar disorder;
PAAD	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.55	-4.77	-0.36	4.2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73210606	chr3:128617426	A/G	cg15676455	chr3:128564943	NA	-0.87	-5.1	-0.38	1e-6	Dental caries;
PAAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	8.71	0.58	4.9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.49	7.94	0.54	4.24e-13	Cutaneous nevi;
PAAD	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.51	2.4e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.45	-4.9	-0.37	2.39e-6	Blood metabolite levels;
PAAD	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.59	-5.83	-0.43	3.14e-8	Rheumatoid arthritis;
PAAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg00919237	chr7:87102261	ABCB4	-0.8	-6.46	-0.46	1.32e-9	Gallbladder cancer;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.31	-0.56	4.84e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	4.99	0.38	1.61e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg16342193	chr10:102329863	NA	-0.74	-8.18	-0.55	1.03e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35160687	0.901	rs12472390	chr2:86475083	T/C	cg10973622	chr2:86423274	IMMT	0.45	5.2	0.39	6.34e-7	Night sleep phenotypes;
PAAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.52	-4.28	-0.33	3.34e-5	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-4.96	-0.37	1.83e-6	Height;
PAAD	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.87	-8.02	-0.55	2.57e-13	Breast cancer;
PAAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.37	-4.41	-0.34	1.95e-5	Schizophrenia;
PAAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg15061591	chr7:98625706	SMURF1	-0.49	-4.58	-0.35	9.45e-6	Breast cancer;
PAAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg24733560	chr20:60626293	TAF4	0.45	5.43	0.4	2.15e-7	Body mass index;
PAAD	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.61	-5.27	-0.39	4.56e-7	Mean corpuscular volume;
PAAD	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg09661865	chr17:56042910	NA	-0.5	-4.3	-0.33	3.05e-5	Testicular germ cell tumor;
PAAD	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg27478167	chr7:817139	HEATR2	-0.57	-4.43	-0.34	1.78e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.54	-0.35	1.13e-5	Joint mobility (Beighton score);
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg09197432	chr4:183729176	NA	0.64	5.46	0.41	1.87e-7	Pediatric autoimmune diseases;
PAAD	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.56	-6.14	-0.45	6.71e-9	Post bronchodilator FEV1;
PAAD	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.56	5.68	0.42	6.75e-8	Systolic blood pressure;
PAAD	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.53	-5.01	-0.38	1.51e-6	Educational attainment;
PAAD	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	5.15	0.39	7.88e-7	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs3764618	1.000	rs2303049	chr19:49494812	C/T	cg12515942	chr19:49552529	CGB8	-0.71	-4.31	-0.33	2.97e-5	Follicule stimulating hormone;
PAAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg17031739	chr1:67600172	NA	0.41	4.25	0.33	3.74e-5	Psoriasis;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.52	-5.17	-0.39	7.15e-7	Iron status biomarkers;
PAAD	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.9	8.91	0.59	1.44e-15	Post bronchodilator FEV1;
PAAD	cis	rs727479	0.523	rs7176330	chr15:51530458	A/G	cg21478137	chr15:51532386	CYP19A1	0.53	5.25	0.39	5.01e-7	Estradiol levels;
PAAD	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.67	-6.02	-0.44	1.25e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.62	6.07	0.44	9.99e-9	Schizophrenia;
PAAD	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.7	-7.68	-0.53	1.79e-12	Type 2 diabetes;
PAAD	cis	rs28830936	0.966	rs11635067	chr15:42124673	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.73	-0.48	3.23e-10	Diastolic blood pressure;
PAAD	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.74	-12.57	-0.71	2.72e-25	Urate levels in overweight individuals;
PAAD	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.22	21.24	0.86	2.36e-47	Testicular germ cell tumor;
PAAD	cis	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg20159608	chr7:32802032	NA	-0.53	-5.23	-0.39	5.55e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.95	-0.43	1.81e-8	Schizophrenia;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg02869306	chr7:64672164	INTS4L1	0.45	5.26	0.39	4.75e-7	Calcium levels;
PAAD	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg00179576	chr16:74483694	GLG1	0.44	4.86	0.37	2.9e-6	Testicular germ cell tumor;
PAAD	cis	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.53	5.55	0.41	1.25e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.64	-7.04	-0.5	6.14e-11	Height;
PAAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.41e-10	Coronary artery disease;
PAAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg16928487	chr17:17741425	SREBF1	0.37	5.01	0.38	1.49e-6	Total body bone mineral density;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.82	-0.36	3.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	cis	rs11264213	0.786	rs72659695	chr1:36311143	T/G	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.84	9.57	0.61	2.84e-17	Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.95	-0.37	1.93e-6	Monocyte percentage of white cells;
PAAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg16205897	chr5:131564050	P4HA2	-0.38	-4.32	-0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.56	6.86	0.49	1.63e-10	Monobrow;
PAAD	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg20406979	chr6:167373233	NA	0.38	5.28	0.39	4.35e-7	Crohn's disease;
PAAD	cis	rs758324	0.812	rs11954609	chr5:131165738	A/G	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7219021	0.961	rs67469980	chr17:46878250	C/G	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.42	-0.34	1.85e-5	Schizophrenia or bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14641829	chr9:33270634	SUGT1P1;CHMP5	0.61	6.42	0.46	1.67e-9	Smoking initiation;
PAAD	cis	rs722208	0.565	rs2982705	chr6:152347858	C/G	cg24128593	chr6:151712759	ZBTB2	0.42	4.5	0.34	1.37e-5	Developmental language disorder;
PAAD	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	7.06	0.5	5.63e-11	Response to antipsychotic treatment;
PAAD	cis	rs12484776	0.677	rs8136269	chr22:40532444	G/C	cg07138101	chr22:40742427	ADSL	0.6	4.47	0.34	1.49e-5	Uterine fibroids;
PAAD	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.32	-0.56	4.66e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12743169	chr17:40021713	KLHL11	0.66	6.72	0.48	3.44e-10	Obesity-related traits;
PAAD	cis	rs62025270	0.632	rs7163838	chr15:86207621	T/C	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.7e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01616529	chr11:638424	DRD4	-0.58	-5.68	-0.42	6.8e-8	Systemic lupus erythematosus;
PAAD	cis	rs2115386	0.717	rs2042902	chr19:7204470	G/A	cg09779027	chr19:7224513	INSR	0.47	4.77	0.36	4.32e-6	Diabetic retinopathy;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg25936770	chr7:122321411	CADPS2	-0.6	-6.67	-0.48	4.53e-10	Iris heterochromicity;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3809060	0.920	rs3886325	chr11:32458507	G/A	cg27259320	chr11:32460587	WIT1	0.36	4.58	0.35	9.81e-6	Inguinal hernia;
PAAD	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.75	-9.27	-0.6	1.67e-16	Motion sickness;
PAAD	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.49e-11	Retinal vascular caliber;
PAAD	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16576597	chr16:28551801	NUPR1	0.66	7.4	0.51	8.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg16116066	chr17:79895073	PYCR1	0.5	4.52	0.34	1.26e-5	Breast cancer;
PAAD	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.99	-0.38	1.6e-6	Blood pressure;
PAAD	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.48	-0.34	1.46e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs12450239	0.885	rs12451758	chr17:77446494	A/G	cg09567646	chr17:76962761	NA	-0.45	-4.55	-0.35	1.1e-5	Body mass index;
PAAD	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	7.77	0.53	1.11e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg10705379	chr10:99080932	FRAT1	-0.44	-5.15	-0.39	8e-7	Monocyte count;
PAAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.96	-11.16	-0.67	1.68e-21	Height;
PAAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg23752985	chr2:85803571	VAMP8	0.55	5.94	0.43	1.9e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.7	-6.33	-0.46	2.59e-9	Triglycerides;
PAAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg10591111	chr5:226296	SDHA	-0.68	-4.75	-0.36	4.72e-6	Breast cancer;
PAAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg02951883	chr7:2050386	MAD1L1	0.48	4.48	0.34	1.47e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	4.58	0.35	9.75e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	5.42	0.4	2.33e-7	Total body bone mineral density;
PAAD	cis	rs73719811	1.000	rs17143500	chr7:121210373	T/A	cg22032706	chr7:120498729	TSPAN12	0.64	4.28	0.33	3.28e-5	Total body bone mineral density;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.56	-4.59	-0.35	9.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.51	5.13	0.38	8.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg18370025	chr7:2749541	AMZ1	-0.36	-4.27	-0.33	3.46e-5	Height;
PAAD	cis	rs12714314	0.957	rs6723932	chr2:1954897	T/C	cg22350835	chr2:1868857	MYT1L	0.48	4.76	0.36	4.47e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs16958440	0.867	rs75901436	chr18:44689644	C/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.26	0.56	6.72e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.55	6.3	0.45	3.11e-9	Mean corpuscular volume;
PAAD	cis	rs7264396	0.667	rs224368	chr20:34070380	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-5.38	-0.4	2.83e-7	Total cholesterol levels;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13424612	1.000	rs34849118	chr2:240919912	T/C	cg01812947	chr2:240904978	NDUFA10	0.57	4.94	0.37	2.04e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs516243	0.688	rs11121606	chr1:10742916	G/A	cg02903756	chr1:10750680	CASZ1	-0.45	-4.67	-0.35	6.51e-6	Migraine - clinic-based;
PAAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg00999904	chr2:3704751	ALLC	-0.4	-4.62	-0.35	8.27e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.51	6.39	0.46	1.92e-9	Renal cell carcinoma;
PAAD	cis	rs4660214	0.671	rs72661956	chr1:39784888	G/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.41	-0.34	1.97e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.89	10.65	0.65	3.97e-20	Total body bone mineral density;
PAAD	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.59	5.16	0.39	7.54e-7	Response to diuretic therapy;
PAAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg02696790	chr15:75250997	RPP25	0.44	5.05	0.38	1.25e-6	Breast cancer;
PAAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.03	-0.44	1.2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg12850546	chr22:42539477	CYP2D7P1	-0.51	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg23127183	chr11:57508653	C11orf31	-0.52	-4.41	-0.34	1.98e-5	Schizophrenia;
PAAD	cis	rs3736485	0.932	rs2899477	chr15:51937701	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.25	-0.33	3.74e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs600626	0.578	rs10793126	chr11:75453982	C/T	cg24262691	chr11:75473276	NA	-0.82	-6.33	-0.46	2.66e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.29e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.91	-7.41	-0.52	8.15e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.48	5.02	0.38	1.4e-6	Testicular germ cell tumor;
PAAD	cis	rs863345	0.604	rs10797011	chr1:158465371	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.7	7.13	0.5	3.8e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25005135	chr6:167592854	TCP10L2	0.63	6.68	0.48	4.23e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04693873	chr6:89855887	PM20D2	0.62	6.99	0.49	8.2e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67257959	0.586	rs8105085	chr19:17159962	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.76	0.36	4.56e-6	Selective IgA deficiency;
PAAD	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg08501292	chr6:25962987	TRIM38	-0.98	-5.38	-0.4	2.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg00474734	chr12:53645975	MFSD5	0.65	6.83	0.48	1.96e-10	Primary biliary cholangitis;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg18209359	chr17:80159595	CCDC57	0.49	5.03	0.38	1.39e-6	Life satisfaction;
PAAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs7132746	0.808	rs77393865	chr12:86238478	T/A	cg13084525	chr11:34642463	EHF	0.67	6.32	0.46	2.77e-9	Lewy body disease;
PAAD	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.48	5.59	0.41	1.03e-7	Coronary artery disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg00016718	chr6:49405490	MUT	-0.51	-6.29	-0.45	3.26e-9	Energy expenditure (24h);
PAAD	cis	rs2033529	0.851	rs34765854	chr6:40368860	T/G	cg10553343	chr6:40360437	LRFN2	0.38	4.29	0.33	3.1e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Waist circumference;
PAAD	cis	rs1448094	0.617	rs952851	chr12:86477341	C/T	cg06740227	chr12:86229804	RASSF9	-0.53	-5.05	-0.38	1.27e-6	Major depressive disorder;
PAAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.89	-0.37	2.52e-6	Bone mineral density;
PAAD	cis	rs56309584	0.755	rs59922886	chr17:8139772	A/T	cg25053252	chr17:7589358	TP53;WRAP53	-0.44	-4.43	-0.34	1.76e-5	Initial pursuit acceleration;
PAAD	cis	rs72960926	0.744	rs55784940	chr6:74923315	G/T	cg03266952	chr6:74778945	NA	-1.17	-6.5	-0.47	1.1e-9	Metabolite levels (MHPG);
PAAD	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.31	0.33	2.9e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-4.89	-0.37	2.52e-6	Schizophrenia;
PAAD	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg10434728	chr15:90938212	IQGAP1	0.44	4.55	0.35	1.08e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.52	-7.2	-0.5	2.61e-11	Rheumatoid arthritis;
PAAD	cis	rs73206853	0.841	rs2339511	chr12:110789372	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	4.3	0.33	3e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13920784	chr6:52900225	ICK	0.66	6.6	0.47	6.42e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg10705379	chr10:99080932	FRAT1	-0.45	-5.22	-0.39	5.72e-7	Monocyte count;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07562458	chr1:224622430	WDR26	-0.58	-6.9	-0.49	1.32e-10	Body fat percentage;
PAAD	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.64	6.25	0.45	3.88e-9	Mood instability;
PAAD	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs66530629	0.917	rs58521331	chr1:25163173	A/T	cg01905478	chr1:25040257	NA	0.5	5.6	0.41	9.73e-8	Plateletcrit;
PAAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.43	-6.64	-0.47	5.27e-10	Height;
PAAD	cis	rs7619427	0.544	rs58289556	chr3:44034726	C/T	cg12796028	chr3:44040206	NA	-0.56	-4.77	-0.36	4.22e-6	Schizophrenia;
PAAD	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.34	0.4	3.35e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.58	6.98	0.49	8.56e-11	Lung cancer;
PAAD	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.47	0.46	1.3e-9	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19988671	chr7:155589783	NA	0.51	6.38	0.46	2.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg14169450	chr9:139327907	INPP5E	0.54	5.26	0.39	4.85e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.13	-11.78	-0.69	3.61e-23	Blood pressure (smoking interaction);
PAAD	cis	rs10450586	0.863	rs10437623	chr11:27307247	C/T	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.58	6.1	0.44	8.52e-9	Lung cancer;
PAAD	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.54	-5.91	-0.43	2.17e-8	Testicular germ cell tumor;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13435101	chr6:74171350	MTO1	0.58	6.9	0.49	1.3e-10	Immature fraction of reticulocytes;
PAAD	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg20090143	chr19:45452003	APOC2	-0.44	-5.47	-0.41	1.79e-7	Blood protein levels;
PAAD	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.89	0.49	1.37e-10	Exhaled nitric oxide levels;
PAAD	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.56	4.89	0.37	2.57e-6	Response to diuretic therapy;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.53	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12315590	chr3:128997497	C3orf37	0.62	7.18	0.5	2.86e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.55	5.04	0.38	1.31e-6	Resting heart rate;
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.66	-5.72	-0.42	5.53e-8	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.66	-0.35	7e-6	Lung cancer;
PAAD	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.6	5.42	0.4	2.34e-7	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.86	-9.82	-0.62	6.23e-18	Iron status biomarkers;
PAAD	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.55	6.2	0.45	5.15e-9	Cognitive function;
PAAD	cis	rs1497828	1.000	rs2810767	chr1:217564937	T/C	cg04411442	chr1:217543379	NA	0.52	5.27	0.39	4.6e-7	Dialysis-related mortality;
PAAD	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-4.54	-0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.32	-0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg05585544	chr11:47624801	NA	-0.49	-5.45	-0.4	2.03e-7	Subjective well-being;
PAAD	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.53	0.41	1.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.55e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs863345	0.584	rs6672789	chr1:158497139	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.23e-6	Pneumococcal bacteremia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18154642	chr2:3391955	TTC15	0.62	6.29	0.45	3.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11172134	0.508	rs1800154	chr12:57589659	C/T	cg01515074	chr12:57585135	LRP1	0.5	4.7	0.36	5.77e-6	Urate levels in overweight individuals;
PAAD	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	7.21	0.5	2.51e-11	Breast cancer;
PAAD	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.92	-6.37	-0.46	2.16e-9	D-dimer levels;
PAAD	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.71	9.94	0.63	3e-18	Crohn's disease;
PAAD	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-6.8	-0.48	2.25e-10	Hemoglobin concentration;
PAAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.68	5.94	0.43	1.91e-8	Breast cancer;
PAAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg19257562	chr1:2043853	PRKCZ	0.35	4.26	0.33	3.6e-5	Height;
PAAD	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.56	-5.13	-0.38	8.68e-7	Intelligence (multi-trait analysis);Educational attainment (years of education);
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	5.01e-14	Prudent dietary pattern;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.0	-0.38	1.57e-6	Cystic fibrosis severity;
PAAD	cis	rs9646944	0.501	rs2110736	chr2:103050855	T/C	cg20060108	chr2:102954350	IL1RL1	0.55	4.53	0.34	1.19e-5	Blood protein levels;
PAAD	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg14146966	chr2:61757674	XPO1	0.39	4.97	0.37	1.81e-6	Tuberculosis;
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.57	5.41	0.4	2.39e-7	Electroencephalogram traits;
PAAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg10587741	chr22:38071170	LGALS1	0.61	6.83	0.48	1.92e-10	Fat distribution (HIV);
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03885332	chr11:832357	CD151	-0.46	-5.37	-0.4	2.91e-7	Mean platelet volume;
PAAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.46	-5.21	-0.39	6.03e-7	Breast size;
PAAD	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-6.12	-0.44	7.48e-9	Airway imaging phenotypes;
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg04520793	chr17:42248056	ASB16	-0.43	-5.1	-0.38	9.93e-7	Total body bone mineral density;
PAAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.66	6.59	0.47	6.79e-10	Urate levels in lean individuals;
PAAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03611598	chr17:48586076	MYCBPAP	0.48	4.75	0.36	4.66e-6	Visceral fat;
PAAD	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-5.89	-0.43	2.4e-8	Neuroticism;
PAAD	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.62	-6.07	-0.44	9.63e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.63	0.35	7.86e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1370916	0.669	rs7793574	chr7:47236828	C/G	cg17445213	chr7:47408746	TNS3	-0.35	-4.29	-0.33	3.11e-5	Colorectal cancer (diet interaction);
PAAD	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg23947450	chr7:900037	UNC84A	-0.57	-4.68	-0.36	6.24e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17554472	chr22:41940697	POLR3H	0.59	4.25	0.33	3.65e-5	Vitiligo;
PAAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.56	-6.71	-0.48	3.58e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg00105475	chr2:10696890	NA	0.64	6.93	0.49	1.12e-10	Prostate cancer;
PAAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg00049323	chr5:472564	LOC25845	0.42	4.97	0.37	1.76e-6	Cystic fibrosis severity;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22821026	chr1:155108104	RAG1AP1	-0.7	-6.65	-0.47	4.99e-10	Lung cancer in ever smokers;
PAAD	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.52	-4.88	-0.37	2.68e-6	Daytime sleep phenotypes;
PAAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.11	0.55	1.55e-13	Height;
PAAD	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.41	5.03	0.38	1.36e-6	Joint mobility (Beighton score);
PAAD	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.37	-0.51	1.02e-11	Chronic sinus infection;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	8.83	0.58	2.35e-15	Platelet count;
PAAD	cis	rs300774	0.925	rs424939	chr2:128894	C/T	cg21211680	chr2:198530	NA	-0.61	-5.73	-0.42	5.19e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6844506	1.000	rs35067299	chr4:185218513	T/C	cg12654155	chr4:185238627	NA	-0.54	-5.03	-0.38	1.4e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.74	-0.48	3.01e-10	Aortic root size;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.92	-8.56	-0.57	1.16e-14	Body mass index;
PAAD	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.79e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg10168330	chr8:27262164	PTK2B	0.37	4.4	0.34	2.03e-5	Neuroticism;
PAAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg02841227	chr6:26021843	HIST1H4A	-0.41	-4.25	-0.33	3.78e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.47	4.58	0.35	9.47e-6	Urate levels in obese individuals;
PAAD	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.72	6.9	0.49	1.33e-10	Obesity-related traits;
PAAD	cis	rs8113142	0.614	rs16961775	chr19:29196997	C/A	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.08e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.48	-7.27	-0.51	1.8e-11	Cutaneous nevi;
PAAD	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.32	-0.33	2.77e-5	Obesity (extreme);
PAAD	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg24112000	chr20:60950667	NA	-0.6	-7.34	-0.51	1.24e-11	Colorectal cancer;
PAAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.96	8.57	0.57	1.11e-14	Psoriasis;
PAAD	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.58	-5.18	-0.39	6.9e-7	Platelet count;
PAAD	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23538226	chr2:25016181	CENPO;C2orf79	0.57	6.35	0.46	2.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.84	-7.15	-0.5	3.48e-11	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.88	-10.05	-0.63	1.57e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg23205692	chr1:25664452	TMEM50A	0.51	5.0	0.38	1.55e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.82e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg11251234	chr10:101825055	CPN1	-0.3	-4.31	-0.33	2.92e-5	Bone mineral density;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg20007245	chr22:24372913	LOC391322	-0.63	-4.6	-0.35	8.93e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.16	12.83	0.72	5.5e-26	Post bronchodilator FEV1;
PAAD	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg19438565	chr8:143695827	ARC	-0.58	-5.8	-0.43	3.8e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.81	9.77	0.62	8.62e-18	Colorectal cancer;
PAAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.76	-0.48	2.79e-10	Triglycerides;
PAAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.5	5.63	0.42	8.42e-8	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.05e-5	Skin colour saturation;
PAAD	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	7.87	0.54	6.2e-13	Mean platelet volume;
PAAD	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg18898632	chr2:242989856	NA	-0.83	-6.69	-0.48	4.09e-10	Obesity-related traits;
PAAD	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.72	-7.68	-0.53	1.78e-12	Neuroticism;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs2115536	0.630	rs12102032	chr15:80233399	A/C	cg00225070	chr15:80189496	MTHFS	0.46	4.36	0.33	2.38e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs1075265	0.692	rs805361	chr2:54165846	G/T	cg04546899	chr2:54196757	PSME4	0.33	5.02	0.38	1.4e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2898290	0.601	rs1478892	chr8:11448529	G/T	cg21175976	chr8:11421337	BLK	0.4	4.26	0.33	3.54e-5	Systolic blood pressure;
PAAD	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg12633918	chr20:23549525	CST9L	-0.44	-4.88	-0.37	2.68e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.63e-14	Colorectal cancer;
PAAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17554472	chr22:41940697	POLR3H	0.6	4.36	0.33	2.35e-5	Vitiligo;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.66	6.9	0.49	1.28e-10	Multiple sclerosis;
PAAD	cis	rs8112211	0.773	rs45437199	chr19:38795250	G/A	cg14299480	chr19:38876666	GGN	-0.61	-6.07	-0.44	9.84e-9	Blood protein levels;
PAAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.17	17.66	0.82	1.14e-38	Cognitive function;
PAAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.41	4.54	0.35	1.13e-5	Aortic root size;
PAAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg13010199	chr12:38710504	ALG10B	0.41	4.28	0.33	3.24e-5	Heart rate;
PAAD	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.54	5.6	0.41	9.94e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg23442198	chr4:187126114	CYP4V2	0.7	4.64	0.35	7.47e-6	Blood protein levels;
PAAD	cis	rs7674212	0.507	rs10516495	chr4:103900090	A/T	cg16532752	chr4:104119610	CENPE	-0.52	-4.46	-0.34	1.57e-5	Type 2 diabetes;
PAAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg14393609	chr7:65229607	NA	-0.49	-4.95	-0.37	1.91e-6	Aortic root size;
PAAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg11262906	chr1:85462892	MCOLN2	0.61	4.85	0.37	2.98e-6	Serum sulfate level;
PAAD	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	1.0	13.64	0.74	3.52e-28	Menarche (age at onset);
PAAD	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.74	6.02	0.44	1.23e-8	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg08562672	chr19:21860753	NA	-0.43	-4.31	-0.33	2.86e-5	Pain;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26582706	chr6:170241199	NA	0.64	6.29	0.45	3.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10888329	0.744	rs6587431	chr1:248354978	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Autism spectrum disorder;
PAAD	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg26174226	chr8:58114915	NA	-0.62	-5.14	-0.38	8.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg00590817	chr1:8272081	NA	-0.39	-4.83	-0.36	3.3e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.74	-8.05	-0.55	2.17e-13	Idiopathic membranous nephropathy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21786349	chr20:33460740	GGT7	-0.75	-6.45	-0.46	1.42e-9	Neuroticism;
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.47	5.1	0.38	1.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs35160687	0.901	rs17738096	chr2:86513893	C/G	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17918089	chr1:150899251	SETDB1	0.61	6.8	0.48	2.21e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.72	7.08	0.5	5.12e-11	Blood metabolite levels;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs507080	0.501	rs626645	chr11:118575180	A/G	cg08498647	chr11:118550644	TREH	-0.42	-5.21	-0.39	6.01e-7	Serum metabolite levels;
PAAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg20805835	chr1:248005719	OR11L1	0.44	4.3	0.33	3.04e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.83	0.43	3.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.46	4.58	0.35	9.51e-6	Interstitial lung disease;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg08648136	chr8:956695	NA	0.41	4.3	0.33	3.02e-5	Schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20315445	chr10:55393450	NA	-0.56	-7.27	-0.51	1.76e-11	Energy expenditure (24h);
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.84	0.43	3.03e-8	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg02631450	chr22:32366979	NA	1.02	5.56	0.41	1.19e-7	Childhood ear infection;
PAAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	7.09	0.5	4.79e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.52	4.63	0.35	7.8e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11825064	0.524	rs7949949	chr11:134458102	T/A	cg06603561	chr11:134479413	NA	-1.21	-6.05	-0.44	1.1e-8	Seasonality;
PAAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-4.66	-0.35	6.8e-6	Blood metabolite levels;
PAAD	cis	rs4906172	1.000	rs4906172	chr14:102454933	C/A	cg23289024	chr14:102554846	HSP90AA1	0.4	4.48	0.34	1.47e-5	Menopause (age at onset);
PAAD	cis	rs138918	1.000	rs138918	chr22:43559451	G/A	cg08909806	chr22:43548696	TSPO	0.49	4.8	0.36	3.7e-6	Monocyte count;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.65	7.04	0.5	6.21e-11	Mean corpuscular volume;
PAAD	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06998765	chr14:75389618	RPS6KL1	0.28	4.89	0.37	2.59e-6	Caffeine consumption;
PAAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Height;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12612619	0.732	rs10432697	chr2:27272052	T/C	cg00617064	chr2:27272375	NA	-0.53	-5.63	-0.42	8.63e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.14	11.44	0.68	2.9e-22	Corneal structure;
PAAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.79	-9.67	-0.62	1.53e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.7	-6.68	-0.48	4.17e-10	Schizophrenia;
PAAD	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.82	-0.48	2.07e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6782025	0.837	rs17195196	chr3:120833403	C/T	cg16417163	chr3:121280760	NA	0.44	4.5	0.34	1.33e-5	Aging (facial);
PAAD	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-4.82	-0.36	3.44e-6	Electrocardiographic conduction measures;
PAAD	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08695707	chr1:197871847	C1orf53	0.58	6.33	0.46	2.67e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.49	-0.47	1.12e-9	Neuroticism;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg24879335	chr3:133465180	TF	0.55	5.96	0.44	1.67e-8	Iron status biomarkers;
PAAD	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.07	0.59	5.6e-16	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11031429	chr7:39662998	RALA	-0.72	-6.34	-0.46	2.52e-9	Neuroticism;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs17770015	0.602	rs7923203	chr10:115197414	C/T	cg17116091	chr10:114807157	TCF7L2	0.61	4.76	0.36	4.43e-6	Migraine without aura;
PAAD	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	6.96	0.49	9.3e-11	Lung cancer in ever smokers;
PAAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-8.33	-0.56	4.33e-14	Body mass index;
PAAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg06740227	chr12:86229804	RASSF9	0.59	5.69	0.42	6.43e-8	Major depressive disorder;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.82	-0.54	8.01e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.89	9.5	0.61	4.22e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg18856388	chr5:1875886	NA	0.24	4.25	0.33	3.78e-5	Gut microbiome composition (winter);
PAAD	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs2147959	1.000	rs2147959	chr1:228644232	A/T	cg18477163	chr1:228402036	OBSCN	-0.44	-4.57	-0.35	9.94e-6	Adult asthma;
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg08835956	chr7:39171034	POU6F2	0.32	5.64	0.42	7.9e-8	IgG glycosylation;
PAAD	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.89	7.23	0.51	2.2e-11	Chronic kidney disease;
PAAD	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg01064725	chr1:204461714	NA	-0.52	-4.85	-0.37	2.96e-6	Schizophrenia;
PAAD	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.67	8.09	0.55	1.78e-13	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17146352	chr2:128051828	ERCC3	0.64	6.78	0.48	2.45e-10	Obesity-related traits;
PAAD	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.32	0.46	2.73e-9	Morning vs. evening chronotype;
PAAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.71	8.47	0.57	1.97e-14	Methadone dose in opioid dependence;
PAAD	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg08632701	chr21:37451849	NA	-0.6	-6.44	-0.46	1.45e-9	Mitral valve prolapse;
PAAD	cis	rs1468333	0.567	rs6889491	chr5:137672151	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	4.84	0.37	3.15e-6	Resting heart rate;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.46	-5.6	-0.41	9.79e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.6	5.44	0.4	2.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.45	5.45	0.4	1.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs16975963	0.644	rs73033145	chr19:38097313	T/G	cg14218481	chr19:38281219	NA	0.42	4.45	0.34	1.64e-5	Longevity;
PAAD	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1577917	0.559	rs7763210	chr6:86808618	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.58	-0.41	1.06e-7	Response to antipsychotic treatment;
PAAD	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.3	-0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs17135859	0.715	rs2416329	chr5:113023119	A/C	cg12552261	chr5:112820674	MCC	-0.67	-4.32	-0.33	2.79e-5	F-cell distribution;
PAAD	cis	rs962856	0.575	rs6740919	chr2:67620055	C/G	cg09028215	chr2:67624308	ETAA1	0.47	4.32	0.33	2.85e-5	Pancreatic cancer;
PAAD	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.26	-0.33	3.51e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.66	6.42	0.46	1.67e-9	Gastritis;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-0.93	-11.22	-0.67	1.14e-21	Eosinophil percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26525486	chr22:32146186	C22orf30	0.58	6.74	0.48	3.04e-10	Monocyte percentage of white cells;
PAAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg08934286	chr12:123463762	ARL6IP4;OGFOD2	0.45	4.47	0.34	1.54e-5	Platelet count;
PAAD	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg16589663	chr20:23618590	CST3	0.79	6.85	0.49	1.75e-10	Chronic kidney disease;
PAAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26209169	chr5:1316264	NA	0.36	4.3	0.33	3.05e-5	Lung cancer;
PAAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg15017067	chr4:17643749	FAM184B	0.38	4.29	0.33	3.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg17507749	chr15:85114479	UBE2QP1	0.55	4.77	0.36	4.3e-6	Alzheimer's disease (age of onset);
PAAD	cis	rs9810890	1.000	rs115284166	chr3:128492511	A/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-7.59	-0.52	3.04e-12	Neuroticism;
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.7	5.46	0.4	1.92e-7	Alzheimer's disease;
PAAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs78761021	0.720	rs55872800	chr17:9794823	G/A	cg26853458	chr17:9805074	RCVRN	0.73	8.65	0.57	6.9e-15	Type 2 diabetes;
PAAD	cis	rs11615916	0.790	rs73136834	chr12:62734666	G/A	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	7.93	0.54	4.48e-13	Caffeine consumption;
PAAD	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-5.31	-0.4	3.74e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg00383909	chr3:49044727	WDR6	0.44	4.53	0.34	1.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.21	0.39	6.09e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2421770	0.532	rs3903688	chr11:35350090	A/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.74	0.66	2.29e-20	Prudent dietary pattern;
PAAD	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	5.07	0.38	1.15e-6	Waist circumference;Hip circumference;
PAAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.79	-8.76	-0.58	3.52e-15	Aortic root size;
PAAD	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg24253500	chr15:84953950	NA	0.57	6.48	0.47	1.19e-9	Schizophrenia;
PAAD	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	7.63	0.53	2.33e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg09002919	chr12:50339186	NA	0.58	4.92	0.37	2.21e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg10072921	chr12:121022843	NA	-0.42	-5.1	-0.38	9.92e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg15485101	chr11:133734466	NA	0.46	5.87	0.43	2.64e-8	Childhood ear infection;
PAAD	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.36	6.03e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.72e-5	Life satisfaction;
PAAD	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.98	0.54	3.38e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11172511	chr1:228328483	GUK1	-0.58	-6.6	-0.47	6.58e-10	Body fat percentage;
PAAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg00999904	chr2:3704751	ALLC	-0.55	-6.0	-0.44	1.35e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.64	-5.36	-0.4	3.06e-7	Diastolic blood pressure;
PAAD	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-4.36	-0.33	2.36e-5	Red blood cell count;
PAAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20557534	chr7:105925814	NAMPT	-0.6	-7.01	-0.49	7.47e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.86	10.82	0.66	1.39e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7742824	1.000	rs7752653	chr6:44093808	T/G	cg21657043	chr6:44035552	NA	0.5	5.15	0.39	7.83e-7	Major depressive disorder;
PAAD	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	6.95	0.49	9.99e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs9825119	chr3:128595514	C/G	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg23241863	chr10:102295624	HIF1AN	0.47	4.26	0.33	3.62e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.47	4.75	0.36	4.67e-6	Mean corpuscular volume;
PAAD	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg01097406	chr16:89675127	NA	0.46	5.85	0.43	2.91e-8	Vitiligo;
PAAD	cis	rs12760731	0.623	rs10913549	chr1:178383657	C/G	cg00404053	chr1:178313656	RASAL2	0.65	5.42	0.4	2.24e-7	Obesity-related traits;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.62	4.91	0.37	2.34e-6	Alzheimer's disease;
PAAD	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.81	7.24	0.51	2.04e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-4.55	-0.35	1.09e-5	Bipolar disorder;
PAAD	cis	rs959260	1.000	rs4789184	chr17:73383314	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.67	-7.36	-0.51	1.09e-11	Eosinophil percentage of white cells;
PAAD	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.36	0.56	3.65e-14	Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg25886479	chr11:50257625	LOC441601	-0.39	-4.31	-0.33	2.88e-5	Height;
PAAD	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.43	4.26	0.33	3.62e-5	Red cell distribution width;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24833071	chr7:75115655	POM121C	0.57	6.6	0.47	6.58e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg16147221	chr4:10020634	SLC2A9	-0.48	-4.31	-0.33	2.97e-5	Bone mineral density;
PAAD	cis	rs10214930	0.697	rs2110528	chr7:27643019	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	1.09	11.25	0.67	9.8e-22	Platelet distribution width;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18154642	chr2:3391955	TTC15	-0.75	-7.18	-0.5	2.9100000000000002e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.59	-6.04	-0.44	1.13e-8	Height;
PAAD	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.54	5.44	0.4	2.07e-7	Resting heart rate;
PAAD	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.9	10.52	0.65	8.48e-20	Alcohol dependence;
PAAD	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.18	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg05479556	chr5:449004	EXOC3	0.44	4.41	0.34	1.91e-5	Fat distribution (HIV);
PAAD	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.59	-6.37	-0.46	2.11e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.73	8.23	0.56	7.75e-14	Breast cancer;
PAAD	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.32	0.33	2.82e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.64	8.83	0.58	2.37e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	4.94	0.37	1.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs3857067	1.000	rs1509940	chr4:95018758	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-5.42	-0.4	2.34e-7	QT interval;
PAAD	cis	rs11634944	0.676	rs220028	chr15:25201037	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.44	-4.54	-0.35	1.12e-5	Interleukin-8 levels;
PAAD	cis	rs988712	0.705	rs4074134	chr11:27647285	C/T	cg10635145	chr11:27742435	BDNF	-0.37	-4.49	-0.34	1.4e-5	Obesity;
PAAD	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.33	-0.46	2.68e-9	Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26097210	chr10:70092729	PBLD;HNRNPH3	-0.65	-6.49	-0.47	1.16e-9	Lung cancer in ever smokers;
PAAD	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.8	7.39	0.51	8.98e-12	Colorectal cancer;
PAAD	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs459193	0.917	rs40270	chr5:55804552	A/C	cg18302225	chr5:55776401	NA	0.47	4.55	0.35	1.09e-5	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs61677309	1.000	rs1318166	chr11:118171058	A/G	cg15548380	chr1:19984784	NBL1	-0.62	-6.42	-0.46	1.62e-9	Lung cancer in ever smokers;
PAAD	cis	rs2790216	1.000	rs2790178	chr10:60034083	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9584850	0.708	rs4411372	chr13:99130423	T/C	cg20487152	chr13:99095054	FARP1	0.63	5.53	0.41	1.36e-7	Neuroticism;
PAAD	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg19442545	chr10:75533431	FUT11	-0.52	-5.33	-0.4	3.56e-7	Inflammatory bowel disease;
PAAD	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg06197492	chr11:2016605	H19	-0.41	-4.25	-0.33	3.65e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12476592	0.571	rs185499	chr2:63867523	G/T	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	9.65	0.62	1.72e-17	Cognitive test performance;
PAAD	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25809561	chr17:30822961	MYO1D	-0.57	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs11828289	0.607	rs76811253	chr11:23222885	G/A	cg20040320	chr11:23191996	NA	-0.77	-5.45	-0.4	2e-7	Cancer;
PAAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg19636519	chr7:99541626	NA	0.48	5.28	0.39	4.32e-7	Coronary artery disease;
PAAD	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26378065	chr17:18585709	ZNF286B	0.56	5.55	0.41	1.24e-7	Educational attainment (years of education);
PAAD	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.73	6.88	0.49	1.49e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.51	-5.33	-0.4	3.48e-7	Height;
PAAD	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.52	5.83	0.43	3.26e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.51	-0.34	1.31e-5	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.88e-7	Rheumatoid arthritis;
PAAD	cis	rs12431939	1.000	rs34063246	chr14:51663719	G/C	cg23942311	chr14:51606299	NA	-0.72	-5.79	-0.42	3.94e-8	Cancer;
PAAD	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg00717180	chr2:96193071	NA	-0.59	-6.63	-0.47	5.38e-10	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06958567	chr18:52495541	RAB27B	0.55	6.71	0.48	3.65e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.45	5.76	0.42	4.52e-8	Childhood ear infection;
PAAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.61	-6.87	-0.49	1.53e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs72960926	1.000	rs80317771	chr6:75174070	C/A	cg03266952	chr6:74778945	NA	-1.28	-6.61	-0.47	6.06e-10	Metabolite levels (MHPG);
PAAD	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.25e-20	Heart rate;
PAAD	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg22189786	chr22:42395067	WBP2NL	-0.45	-4.92	-0.37	2.28e-6	Cognitive function;
PAAD	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.41	-0.4	2.37e-7	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.87	-0.37	2.74e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	4.53	0.34	1.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-5.04	-0.38	1.31e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.18	0.39	6.88e-7	Initial pursuit acceleration;
PAAD	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08601984	chr6:112184093	FYN	0.64	6.33	0.46	2.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24636258	chr12:53068882	KRT1	-0.66	-7.09	-0.5	4.8e-11	Obesity-related traits;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg00106254	chr7:1943704	MAD1L1	-0.57	-5.59	-0.41	1.01e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs78707713	0.836	rs112843485	chr10:71211707	T/C	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	trans	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.46	-0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02985541	chr2:219472218	PLCD4	0.28	4.36	0.33	2.36e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg19413350	chr8:57351067	NA	-0.47	-4.44	-0.34	1.69e-5	Obesity-related traits;
PAAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.41	4.46	0.34	1.58e-5	Aortic root size;
PAAD	cis	rs6710503	0.574	rs11125673	chr2:24782836	G/A	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7487075	0.619	rs12824565	chr12:46834693	A/G	cg09447675	chr12:46877466	NA	-0.47	-4.3	-0.33	3.09e-5	Itch intensity from mosquito bite;
PAAD	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.79	5.9	0.43	2.3e-8	White matter hyperintensity burden;
PAAD	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.5	5.26	0.39	4.86e-7	Body mass index;
PAAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6494488	0.500	rs72744764	chr15:65076887	G/A	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs11083840	0.504	rs12974594	chr19:47144650	C/A	cg07844738	chr19:47129343	PTGIR	-0.41	-4.8	-0.36	3.76e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	5.58	0.41	1.05e-7	Body mass index;
PAAD	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-8.18	-0.55	1.05e-13	Vitiligo;
PAAD	cis	rs259282	0.605	rs36107586	chr19:33109674	G/A	cg02997394	chr19:33096574	ANKRD27	-0.41	-4.4	-0.34	2.05e-5	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00634644	chr5:268995	NA	0.61	6.53	0.47	9.53e-10	Smoking initiation;
PAAD	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.45	5.61	0.41	9.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.51	-4.53	-0.34	1.19e-5	Lung cancer;
PAAD	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg24747557	chr10:131355152	MGMT	0.46	4.62	0.35	8.09e-6	Response to temozolomide;
PAAD	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.52	-4.39	-0.34	2.13e-5	Alcohol dependence (age at onset);
PAAD	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg03989125	chr22:38214979	NA	0.63	5.68	0.42	6.6e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.86	-0.37	2.92e-6	Height;
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.67	7.88	0.54	5.98e-13	Vitiligo;
PAAD	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.39	-4.37	-0.33	2.34e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg21665744	chr7:39171113	POU6F2	0.39	5.88	0.43	2.53e-8	IgG glycosylation;
PAAD	cis	rs73198271	0.515	rs75990942	chr8:8639761	C/T	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg21724239	chr8:58056113	NA	0.67	5.31	0.4	3.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs4750440	0.670	rs7917314	chr10:14029682	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.45	-4.54	-0.35	1.14e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.55	-5.2	-0.39	6.42e-7	Malaria;
PAAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg25809561	chr17:30822961	MYO1D	0.58	6.04	0.44	1.12e-8	Schizophrenia;
PAAD	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.66	7.79	0.53	9.66e-13	Weight;
PAAD	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg09399716	chr2:46890238	NA	-0.71	-5.67	-0.42	7.01e-8	Height;
PAAD	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg00262122	chr8:11665843	FDFT1	-0.52	-4.5	-0.34	1.36e-5	Neuroticism;
PAAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.6	5.72	0.42	5.47e-8	Cleft lip with or without cleft palate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07545535	chr7:76256818	POMZP3;LOC100133091	0.63	6.72	0.48	3.45e-10	Myopia (pathological);
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.7	5.35	0.4	3.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7951870	0.645	rs57804402	chr11:46729872	T/C	cg19486271	chr11:47235900	DDB2	0.62	6.31	0.46	2.88e-9	Schizophrenia;
PAAD	cis	rs863345	0.901	rs2213947	chr1:158445699	A/G	cg12129480	chr1:158549410	OR10X1	-0.4	-4.57	-0.35	1.02e-5	Pneumococcal bacteremia;
PAAD	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.55	0.41	1.22e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg15181151	chr6:150070149	PCMT1	0.56	6.17	0.45	5.92e-9	Lung cancer;
PAAD	cis	rs55788414	0.818	rs28712554	chr16:81188748	G/A	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.55	-0.57	1.24e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.7	-0.42	5.9e-8	Total body bone mineral density;
PAAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.81	5.99	0.44	1.42e-8	Vitiligo;
PAAD	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.94	0.37	2.05e-6	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.43	0.4	2.17e-7	Menarche (age at onset);
PAAD	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg16205897	chr5:131564050	P4HA2	-0.4	-4.35	-0.33	2.47e-5	Blood metabolite levels;
PAAD	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg21395723	chr22:39101663	GTPBP1	0.44	4.36	0.33	2.37e-5	Menopause (age at onset);
PAAD	cis	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg02694489	chr17:7348399	CHRNB1	0.37	4.26	0.33	3.6e-5	Height;
PAAD	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg10437265	chr15:77819839	NA	0.43	4.84	0.37	3.17e-6	Type 2 diabetes;
PAAD	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg02811702	chr13:24901961	NA	0.54	5.79	0.42	3.98e-8	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06856563	chr7:75623987	TMEM120A	-0.7	-7.81	-0.54	8.79e-13	Smoking initiation;
PAAD	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.78	-7.67	-0.53	1.91e-12	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15541040	chr2:3486749	NA	-0.76	-7.59	-0.52	2.95e-12	Neurofibrillary tangles;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs58521262	0.556	rs290578	chr19:23221489	T/G	cg02350677	chr19:23254381	NA	0.25	4.56	0.35	1.03e-5	Testicular germ cell tumor;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs3826795	0.569	rs73059725	chr19:46796768	G/A	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs258892	0.841	rs266426	chr5:72131255	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.41	4.54	0.35	1.13e-5	Aortic root size;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.2	-0.45	5.04e-9	Lung cancer;
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg19223190	chr17:80058835	NA	-0.54	-5.44	-0.4	2.1e-7	Life satisfaction;
PAAD	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.73	0.48	3.2e-10	Coffee consumption (cups per day);
PAAD	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	-0.55	-4.67	-0.35	6.65e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11168618	0.509	rs2731100	chr12:48884158	G/C	cg01881778	chr12:48919444	OR8S1	0.45	4.54	0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs3206736	0.548	rs328896	chr7:35017222	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg03315344	chr16:75512273	CHST6	0.63	5.29	0.39	4.17e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg03959625	chr15:84868606	LOC388152	0.41	4.28	0.33	3.23e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.91e-7	Red blood cell count;
PAAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg10556349	chr10:835070	NA	0.58	4.97	0.37	1.8e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-5.95	-0.43	1.77e-8	Crohn's disease;
PAAD	cis	rs6076065	0.723	rs2424530	chr20:23369354	A/G	cg11657817	chr20:23433608	CST11	0.49	5.0	0.38	1.54e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.14	-16.91	-0.81	9.57e-37	Primary sclerosing cholangitis;
PAAD	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.79	7.31	0.51	1.41e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg14926445	chr8:58193284	C8orf71	-0.69	-5.0	-0.38	1.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.46	-4.91	-0.37	2.3e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg24699146	chr1:24152579	HMGCL	0.47	5.17	0.39	7.39e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg00631329	chr6:26305371	NA	-0.49	-5.11	-0.38	9.34e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs72960926	0.744	rs72964214	chr6:74864851	T/C	cg03266952	chr6:74778945	NA	-1.12	-7.04	-0.5	6.22e-11	Metabolite levels (MHPG);
PAAD	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	5.15	0.39	7.92e-7	Response to antipsychotic treatment;
PAAD	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg09659197	chr4:152720779	NA	0.36	5.26	0.39	4.84e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10462751	chr12:107168330	RIC8B	-0.68	-6.67	-0.48	4.37e-10	Smoking initiation;
PAAD	cis	rs75920871	0.589	rs56081989	chr11:117085305	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-5.08	-0.38	1.08e-6	Subjective well-being;
PAAD	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg02016764	chr4:38805732	TLR1	-0.54	-4.26	-0.33	3.64e-5	Breast cancer;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.95	11.93	0.7	1.4e-23	Menarche (age at onset);
PAAD	cis	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.35	-0.4	3.23e-7	Neuroticism;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07234876	chr8:600039	NA	0.89	5.68	0.42	6.69e-8	IgG glycosylation;
PAAD	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-1.17	-7.83	-0.54	7.91e-13	Depression;
PAAD	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.68	6.96	0.49	9.62e-11	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.84	9.93	0.63	3.26e-18	Blood metabolite ratios;
PAAD	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs6688613	1.000	rs12130629	chr1:166953284	C/T	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg21546286	chr11:48923668	NA	-0.59	-6.18	-0.45	5.5e-9	HDL cholesterol;
PAAD	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.77	-8.34	-0.56	4.11e-14	Morning vs. evening chronotype;
PAAD	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg17346650	chr17:80929145	B3GNTL1	0.43	5.14	0.39	8.19e-7	Glycated hemoglobin levels;
PAAD	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg02380750	chr20:61661411	NA	0.37	4.4	0.34	2.01e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19671926	chr4:122722719	EXOSC9	-0.64	-6.18	-0.45	5.48e-9	Type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12667521	chr19:29218732	NA	0.78	7.12	0.5	4.04e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-1.12	-9.05	-0.59	6.55e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg04160749	chr8:58172571	NA	-0.6	-4.38	-0.33	2.22e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.63	6.88	0.49	1.45e-10	Resting heart rate;
PAAD	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg25620797	chr2:55921863	PNPT1	-0.52	-5.09	-0.38	1.03e-6	Metabolic syndrome;
PAAD	cis	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.73	4.92	0.37	2.19e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9522267	1.000	rs9522267	chr13:112196367	C/T	cg10483660	chr13:112241077	NA	-0.48	-5.04	-0.38	1.31e-6	Hepatitis;
PAAD	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.92	12.07	0.7	5.93e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.45	-0.4	1.99e-7	Gut microbiome composition (summer);
PAAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-4.43	-0.34	1.76e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.85	10.93	0.66	6.8e-21	Aortic root size;
PAAD	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.88	7.07	0.5	5.2e-11	Axial length;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg21565972	chr17:80109576	CCDC57	0.55	6.48	0.47	1.21e-9	Life satisfaction;
PAAD	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.52	5.48	0.41	1.76e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.95	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17561243	chr8:179176	RPL23AP53	0.62	6.5	0.47	1.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.5	4.62	0.35	8.07e-6	Hepatocellular carcinoma;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.43	0.4	2.15e-7	Schizophrenia;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.89	10.0	0.63	2.1e-18	Cleft lip with or without cleft palate;
PAAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.95	-6.97	-0.49	8.8e-11	Breast cancer;
PAAD	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs2790216	0.853	rs2590331	chr10:60008361	G/A	cg20442379	chr10:60024634	IPMK	-0.61	-4.64	-0.35	7.33e-6	Inflammatory bowel disease;
PAAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11614333	0.920	rs67615407	chr12:15000160	A/T	cg00431549	chr12:15039025	MGP	-0.36	-4.29	-0.33	3.21e-5	Hand grip strength;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17347593	chr7:155577749	NA	0.63	6.47	0.46	1.29e-9	Smoking initiation;
PAAD	cis	rs72901758	0.768	rs56046325	chr17:76251998	G/T	cg26068271	chr17:76253126	NA	0.52	4.91	0.37	2.29e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	-0.62	-7.57	-0.52	3.41e-12	Body fat percentage;
PAAD	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg23024343	chr7:107201750	COG5	0.57	4.67	0.35	6.67e-6	Coronary artery disease;
PAAD	cis	rs17023223	0.537	rs17023185	chr1:119610787	C/T	cg17326555	chr1:119535693	NA	-0.43	-5.07	-0.38	1.12e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	1.11	7.03	0.5	6.71e-11	Skin colour saturation;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.43	4.26	0.33	3.53e-5	Longevity;Endometriosis;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.71	7.04	0.5	6.33e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.94	-0.37	2.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.88	-0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg09941381	chr10:64027924	RTKN2	-0.38	-4.61	-0.35	8.64e-6	Rheumatoid arthritis;
PAAD	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg14583973	chr4:3374767	RGS12	0.34	4.96	0.37	1.83e-6	Mean platelet volume;
PAAD	cis	rs78761021	0.720	rs7221637	chr17:9797209	C/T	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.87	10.96	0.66	5.65e-21	Prudent dietary pattern;
PAAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg23788917	chr6:8435910	SLC35B3	-0.5	-5.36	-0.4	3.1e-7	Motion sickness;
PAAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.4	-4.43	-0.34	1.76e-5	Schizophrenia;
PAAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.57	-0.41	1.14e-7	P wave terminal force;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.49	-0.41	1.64e-7	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00045532	chr12:38493714	NA	-0.63	-6.42	-0.46	1.61e-9	Smoking initiation;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.6	5.79	0.42	3.95e-8	Prudent dietary pattern;
PAAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg12215294	chr3:40350768	EIF1B	0.44	4.28	0.33	3.27e-5	Renal cell carcinoma;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01616529	chr11:638424	DRD4	-0.59	-5.74	-0.42	4.99e-8	Systemic lupus erythematosus;
PAAD	cis	rs11159086	1.000	rs8006958	chr14:74944851	C/A	cg10195687	chr14:74926396	NA	-0.47	-5.06	-0.38	1.17e-6	Advanced glycation end-product levels;
PAAD	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	6.81	0.48	2.08e-10	Lung cancer in ever smokers;
PAAD	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs2834902	0.633	rs2834892	chr21:36679371	C/T	cg04915566	chr21:36421472	RUNX1	-0.32	-4.32	-0.33	2.79e-5	Corneal curvature;
PAAD	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-11.13	-0.67	2.02e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.29	0.64	3.61e-19	Bladder cancer;
PAAD	cis	rs8112211	0.648	rs77862444	chr19:38820528	C/T	cg01275006	chr19:38876250	GGN	-0.89	-5.63	-0.42	8.45e-8	Blood protein levels;
PAAD	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg05484376	chr2:27715224	FNDC4	-0.46	-4.77	-0.36	4.36e-6	Oral cavity cancer;
PAAD	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.73	-6.97	-0.49	8.86e-11	Platelet distribution width;
PAAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.64	-8.16	-0.55	1.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08260549	chr8:21777063	XPO7	0.61	6.29	0.45	3.16e-9	Myopia (pathological);
PAAD	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.55	4.47	0.34	1.53e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2594989	0.831	rs7642605	chr3:11469503	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.44	-0.34	1.7e-5	Circulating chemerin levels;
PAAD	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.55	-5.57	-0.41	1.1e-7	Iron status biomarkers;
PAAD	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06481639	chr22:41940642	POLR3H	-0.59	-4.39	-0.34	2.07e-5	Vitiligo;
PAAD	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.82	9.44	0.61	6.19e-17	Mean platelet volume;
PAAD	cis	rs375066	0.935	rs388706	chr19:44418693	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg27182935	chr16:89790473	ZNF276	-0.78	-4.5	-0.34	1.35e-5	Skin colour saturation;
PAAD	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.67	7.65	0.53	2.19e-12	Body mass index;
PAAD	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg25432232	chr19:57742423	AURKC	0.41	4.28	0.33	3.36e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg26685658	chr5:74633012	HMGCR	-0.51	-4.25	-0.33	3.66e-5	Age-related disease endophenotypes;
PAAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.92	6.82	0.48	2.05e-10	Breast cancer;
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg25037394	chr1:24152592	HMGCL	0.43	4.72	0.36	5.24e-6	Immature fraction of reticulocytes;
PAAD	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.51	0.47	1.03e-9	Primary sclerosing cholangitis;
PAAD	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg15847926	chr7:2749597	AMZ1	-0.38	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.49	6.03	0.44	1.17e-8	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19979355	chr17:5095218	ZNF594	0.63	6.67	0.48	4.42e-10	Obesity-related traits;
PAAD	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg20243544	chr17:37824526	PNMT	0.56	5.32	0.4	3.63e-7	Self-reported allergy;
PAAD	cis	rs17641971	0.684	rs4873093	chr8:49974740	G/T	cg00325661	chr8:49890786	NA	0.53	5.42	0.4	2.24e-7	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg00450029	chr8:599525	NA	0.92	6.38	0.46	2.04e-9	IgG glycosylation;
PAAD	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg23108931	chr8:105342351	NA	-0.29	-4.39	-0.34	2.08e-5	Paget's disease;
PAAD	cis	rs1468734	0.929	rs11645150	chr16:5005222	C/G	cg06510647	chr16:5006106	NA	0.58	5.42	0.4	2.27e-7	Cancer;
PAAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.9	6.05	0.44	1.07e-8	Diabetic kidney disease;
PAAD	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg10820045	chr2:198174542	NA	0.55	5.5	0.41	1.58e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6604026	0.656	rs4351651	chr1:93414508	A/C	cg13858687	chr1:93297071	RPL5	0.47	4.36	0.33	2.35e-5	Multiple sclerosis;
PAAD	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.26	-0.51	1.86e-11	Coronary artery disease;
PAAD	cis	rs2004318	1.000	rs113727664	chr19:55138759	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs35740288	0.587	rs4843089	chr15:86176136	C/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09876101	chr16:699357	WDR90	-0.75	-6.66	-0.48	4.64e-10	Neuroticism;
PAAD	trans	rs901683	1.000	rs3764990	chr10:45956828	G/A	cg14076390	chr17:34947837	DHRS11	0.93	6.81	0.48	2.08e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.97	10.43	0.65	1.49e-19	Pulmonary function decline;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.23	0.56	7.74e-14	Lung cancer;
PAAD	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg04877966	chr15:75135169	ULK3	0.55	4.65	0.35	7.07e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2404602	0.622	rs2280194	chr15:77239651	C/T	cg22467129	chr15:76604101	ETFA	0.56	5.28	0.39	4.4e-7	Blood metabolite levels;
PAAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.67	6.42	0.46	1.66e-9	Platelet distribution width;
PAAD	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg15145965	chr22:50218605	BRD1	0.61	4.72	0.36	5.41e-6	Schizophrenia;
PAAD	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.78e-5	Cognitive function;
PAAD	cis	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.62	-7.52	-0.52	4.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg06740227	chr12:86229804	RASSF9	0.59	5.19	0.39	6.76e-7	Major depressive disorder;
PAAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg10589385	chr1:150898437	SETDB1	0.39	4.87	0.37	2.79e-6	Melanoma;
PAAD	cis	rs7646881	1.000	rs59918529	chr3:158452705	T/C	cg19483011	chr3:158453295	NA	-0.63	-5.43	-0.4	2.22e-7	Tetralogy of Fallot;
PAAD	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08704250	chr15:31115839	NA	-0.6	-8.2	-0.55	9.46e-14	Huntington's disease progression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16333971	chr13:30424821	UBL3	0.64	6.46	0.46	1.33e-9	Obesity-related traits;
PAAD	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg14515779	chr1:101123966	NA	0.44	4.94	0.37	2.05e-6	Monocyte count;
PAAD	cis	rs10991814	1.000	rs76226649	chr9:93964150	G/A	cg14446406	chr9:93919335	NA	0.57	4.73	0.36	5.01e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg02459107	chr1:67143332	SGIP1	0.75	7.54	0.52	3.86e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.91	8.03	0.55	2.42e-13	Alzheimer's disease;
PAAD	cis	rs7474896	0.806	rs1779150	chr10:38038687	C/G	cg20424709	chr10:37940673	NA	-0.96	-6.0	-0.44	1.38e-8	Obesity (extreme);
PAAD	trans	rs4815879	1.000	rs4815879	chr20:5949534	G/A	cg22510814	chr11:68773285	MRGPRF	-1.08	-6.39	-0.46	1.89e-9	Preeclampsia;
PAAD	cis	rs9395066	0.545	rs10456119	chr6:44889045	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs1497828	0.956	rs2454117	chr1:217552823	T/C	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg13160058	chr8:26243215	BNIP3L	-0.38	-4.66	-0.35	6.86e-6	Red cell distribution width;
PAAD	cis	rs6494488	0.500	rs72741315	chr15:64713525	T/C	cg15337035	chr15:64978493	NA	1.02	4.55	0.35	1.08e-5	Coronary artery disease;
PAAD	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.28	10.93	0.66	7.02e-21	Uric acid levels;
PAAD	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg15181151	chr6:150070149	PCMT1	0.61	6.53	0.47	9.16e-10	Lung cancer;
PAAD	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.31	0.4	3.8e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg25204440	chr1:209979598	IRF6	0.63	4.92	0.37	2.22e-6	Coronary artery disease;
PAAD	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg20636351	chr8:55087400	NA	0.75	7.78	0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7873102	0.654	rs2266013	chr9:37980210	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg16926213	chr1:1841314	NA	0.38	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg10356904	chr22:49881777	NA	-0.54	-5.64	-0.42	8.19e-8	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.33	5.69	0.42	6.35e-8	Type 2 diabetes;
PAAD	cis	rs4454254	1.000	rs4454254	chr8:141060027	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.35	-4.97	-0.37	1.82e-6	Pulse pressure;
PAAD	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	5.04	0.38	1.33e-6	Asthma;
PAAD	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.81	9.39	0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs728616	0.681	rs36073865	chr10:81916055	C/T	cg27417294	chr10:81904244	PLAC9	0.56	4.29	0.33	3.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2031532	0.524	rs1409017	chr13:50059531	T/C	cg08779649	chr13:50194554	NA	0.33	4.43	0.34	1.81e-5	Cardiac hypertrophy;
PAAD	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.62	-6.28	-0.45	3.42e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-4.73	-0.36	5.14e-6	Menarche (age at onset);
PAAD	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.09	-0.5	4.79e-11	Neuroticism;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg07677032	chr17:61819896	STRADA	0.45	4.32	0.33	2.83e-5	Height;
PAAD	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.07	14.03	0.75	3.18e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.05	0.38	1.24e-6	Axial length;
PAAD	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.68	-0.53	1.81e-12	Hemoglobin concentration;
PAAD	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	5.33	0.4	3.51e-7	Mean platelet volume;
PAAD	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs3106136	0.814	rs6532481	chr4:95277311	T/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.03	0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.62	-0.35	8.18e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg19640517	chr22:41707109	ZC3H7B	-0.46	-4.25	-0.33	3.65e-5	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14102272	chr2:201729414	CLK1	0.65	6.45	0.46	1.39e-9	Obesity-related traits;
PAAD	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.58	-6.53	-0.47	9.51e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	7.08	0.5	4.97e-11	Lymphocyte counts;
PAAD	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-8.14	-0.55	1.32e-13	Monocyte percentage of white cells;
PAAD	cis	rs4819143	0.517	rs451920	chr21:47374699	A/C	cg13695288	chr21:47294981	PCBP3	0.51	4.38	0.33	2.19e-5	Insulin resistance/response;
PAAD	cis	rs9567406	0.841	rs12427563	chr13:44869457	C/T	cg08635097	chr13:44833857	NA	-0.65	-4.57	-0.35	9.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg23024343	chr7:107201750	COG5	0.59	4.9	0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.5	-4.8	-0.36	3.68e-6	Inflammatory biomarkers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13760038	chr22:25801048	NA	0.65	6.85	0.49	1.76e-10	Myopia (pathological);
PAAD	cis	rs8005172	0.676	rs2269313	chr14:88410811	A/C	cg18078958	chr14:88630771	NA	0.46	5.53	0.41	1.35e-7	Parkinson's disease;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27297192	chr10:134578999	INPP5A	0.61	5.75	0.42	4.7e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.26	-0.39	4.81e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.88	7.73	0.53	1.4e-12	Recombination rate (females);
PAAD	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.82	-7.1	-0.5	4.46e-11	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.59	6.45	0.46	1.4e-9	Colorectal cancer;
PAAD	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	4.9	0.37	2.47e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.99	8.92	0.59	1.36e-15	Vitiligo;
PAAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.51	5.15	0.39	8.07e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg18357526	chr6:26021779	HIST1H4A	0.7	7.26	0.51	1.89e-11	Height;
PAAD	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.0	-0.49	7.81e-11	Triglycerides;
PAAD	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.5	-4.35	-0.33	2.46e-5	Airflow obstruction;
PAAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.54	-7.03	-0.5	6.53e-11	Height;
PAAD	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.5	-0.76	1.84e-30	Headache;
PAAD	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.54	4.99	0.37	1.66e-6	Facial morphology (factor 20);
PAAD	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.66	6.52	0.47	9.77e-10	Retinal vascular caliber;
PAAD	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	6.19	0.45	5.48e-9	Systolic blood pressure;
PAAD	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	6.98	0.49	8.62e-11	Hip circumference;
PAAD	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg01942863	chr7:99769432	GPC2	0.51	4.67	0.35	6.62e-6	Coronary artery disease;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.54	-4.36	-0.33	2.35e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4908760	0.899	rs6577496	chr1:8581227	C/A	cg20416874	chr1:8611966	RERE	-0.46	-4.34	-0.33	2.61e-5	Vitiligo;
PAAD	cis	rs4740619	0.661	rs10756722	chr9:15932659	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.83	10.11	0.63	1.07e-18	Menopause (age at onset);
PAAD	cis	rs6782025	0.802	rs338994	chr3:121008589	A/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-4.37	-0.33	2.32e-5	Red blood cell count;
PAAD	cis	rs10493340	0.857	rs66949534	chr1:63599712	G/A	cg08634298	chr1:64337861	ROR1	-0.47	-4.56	-0.35	1.05e-5	Blood pressure;
PAAD	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-4.36	-0.33	2.36e-5	Red blood cell count;
PAAD	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.7	-11.76	-0.69	4.22e-23	Urate levels in overweight individuals;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg09339527	chr5:178322752	ZFP2	-0.41	-4.29	-0.33	3.15e-5	Sleep duration;
PAAD	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.57e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.44	-5.27	-0.39	4.69e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.64	-6.26	-0.45	3.83e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8037137	0.915	rs8028409	chr15:91506422	A/T	cg23684204	chr15:91497937	RCCD1	0.73	4.71	0.36	5.46e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs9868809	0.764	rs41290686	chr3:48604059	G/A	cg00383909	chr3:49044727	WDR6	1.15	5.35	0.4	3.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs354033	0.837	rs6949316	chr7:149180625	C/G	cg06920324	chr7:149264011	ZNF767	-0.57	-4.9	-0.37	2.44e-6	Multiple sclerosis;
PAAD	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.7	6.7	0.48	3.79e-10	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.51	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.82	7.13	0.5	3.78e-11	Recombination rate (females);
PAAD	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg10223061	chr2:219282414	VIL1	0.36	4.33	0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg24327109	chr1:151020084	C1orf56	-0.47	-4.26	-0.33	3.61e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs939584	1.000	rs11127485	chr2:632028	C/T	cg03610516	chr2:642275	NA	0.59	5.28	0.39	4.38e-7	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26095694	chr13:26789271	RNF6	0.57	6.86	0.49	1.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7873102	0.630	rs4878731	chr9:37999037	A/G	cg03528946	chr9:38069800	SHB	-0.51	-5.14	-0.38	8.49e-7	Brain structure;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg00431813	chr7:1051703	C7orf50	-0.37	-4.65	-0.35	7.05e-6	Longevity;Endometriosis;
PAAD	cis	rs3771514	0.543	rs4852595	chr2:70679759	C/T	cg18150120	chr2:71134936	VAX2	-0.38	-4.58	-0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2882667	0.690	rs11953339	chr5:138259542	T/A	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.41	-0.34	1.99e-5	Red blood cell count;
PAAD	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.56	12.17	0.7	3.3e-24	Atopic dermatitis;
PAAD	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.98	6.57	0.47	7.53e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.59	7.43	0.52	7.13e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg23506979	chr15:79090958	ADAMTS7	-0.25	-4.29	-0.33	3.2e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs829661	0.793	rs860487	chr2:30703971	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.44	0.34	1.73e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg10820045	chr2:198174542	NA	0.55	5.72	0.42	5.53e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7180079	1.000	rs12148898	chr15:64643691	T/C	cg18210365	chr15:65066710	RBPMS2	0.64	4.92	0.37	2.24e-6	Monocyte count;
PAAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.98e-9	Skin colour saturation;
PAAD	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.5	4.53	0.34	1.18e-5	Red blood cell count;
PAAD	cis	rs3807375	1.000	rs3807375	chr7:150667210	C/T	cg10636020	chr7:150656979	KCNH2	-0.59	-5.7	-0.42	6.02e-8	Electrocardiographic traits;QT interval;
PAAD	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg23093090	chr10:104574429	C10orf26	-0.43	-5.03	-0.38	1.36e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	cis	rs35000415	0.938	rs12535158	chr7:128625019	C/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg14851346	chr12:38532713	NA	0.47	4.77	0.36	4.27e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs58521262	0.556	rs380541	chr19:23118931	C/T	cg02350677	chr19:23254381	NA	-0.27	-4.78	-0.36	4.17e-6	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07915976	chr12:54414427	HOXC4;HOXC5;HOXC6	0.62	7.22	0.51	2.32e-11	Smoking initiation;
PAAD	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg22482690	chr17:47019901	SNF8	0.5	5.42	0.4	2.28e-7	Type 2 diabetes;
PAAD	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg27494647	chr7:150038898	RARRES2	0.53	5.38	0.4	2.77e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.48	-4.3	-0.33	3.06e-5	Testicular germ cell tumor;
PAAD	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg01657329	chr11:68192670	LRP5	0.54	4.71	0.36	5.48e-6	Total body bone mineral density;
PAAD	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.58	-4.9	-0.37	2.42e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.51	4.73	0.36	5.06e-6	Dialysis-related mortality;
PAAD	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.83	9.82	0.62	6.25e-18	Coronary artery disease;
PAAD	cis	rs11638352	0.661	rs2733210	chr15:44457206	G/C	cg10011062	chr15:43941034	CATSPER2	1.17	4.39	0.34	2.15e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.69	-6.83	-0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg18016565	chr1:150552671	MCL1	-0.44	-4.32	-0.33	2.79e-5	Tonsillectomy;
PAAD	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-4.53	-0.35	1.17e-5	Vitiligo;
PAAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.32	-0.4	3.67e-7	Height;
PAAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.56	6.01	0.44	1.31e-8	Menopause (age at onset);
PAAD	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs797680	0.856	rs12124011	chr1:93652544	C/A	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg03538708	chr1:25844672	NA	-0.51	-5.38	-0.4	2.72e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg12908607	chr1:44402522	ARTN	-0.7	-6.42	-0.46	1.68e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs7945718	0.591	rs7937898	chr11:12703561	G/T	cg25843174	chr11:12811716	TEAD1	-0.31	-4.48	-0.34	1.45e-5	Educational attainment (years of education);
PAAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs452036	0.625	rs8019322	chr14:23892581	T/C	cg23613857	chr14:23356614	REM2	0.41	4.56	0.35	1.06e-5	Resting heart rate;P wave duration;
PAAD	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	1.04	13.89	0.75	7.52e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	4.28	0.33	3.34e-5	Tonsillectomy;
PAAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.49	5.38	0.4	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2131877	0.913	rs950256	chr3:194847752	C/T	cg21937377	chr3:194868750	C3orf21	0.46	4.75	0.36	4.58e-6	Non-small cell lung cancer;
PAAD	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg02421172	chr7:1938701	MAD1L1	0.57	4.27	0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.83	6.01	0.44	1.32e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.18	-0.5	2.85e-11	Colorectal cancer;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.36	-0.4	3.08e-7	Testicular germ cell tumor;
PAAD	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs300774	0.925	rs300715	chr2:137962	A/G	cg21211680	chr2:198530	NA	-0.55	-5.08	-0.38	1.08e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs282587	0.569	rs385990	chr13:113396575	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.97	-0.37	1.78e-6	Glycated hemoglobin levels;
PAAD	cis	rs7715811	1.000	rs6554814	chr5:13774231	T/A	cg07548982	chr5:13769939	DNAH5	-0.57	-5.46	-0.4	1.9e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs17125944	0.615	rs6572867	chr14:53319283	C/T	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs864537	1.000	rs840016	chr1:167408670	C/T	cg22356347	chr1:167427500	CD247	-0.44	-4.55	-0.35	1.09e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs5742933	0.857	rs12471217	chr2:190572063	G/A	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg10556349	chr10:835070	NA	0.57	4.96	0.37	1.9e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg15117754	chr3:10150083	C3orf24	0.64	5.44	0.4	2.05e-7	Alzheimer's disease;
PAAD	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.76	-5.24	-0.39	5.32e-7	Coronary artery calcification;
PAAD	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02711726	chr17:80685570	FN3KRP	-0.47	-4.63	-0.35	7.9e-6	Glycated hemoglobin levels;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg17372657	chr7:1216933	NA	-0.35	-4.36	-0.33	2.39e-5	Longevity;Endometriosis;
PAAD	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.06	0.38	1.2e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg00898013	chr13:113819073	PROZ	-0.69	-6.49	-0.47	1.17e-9	Platelet distribution width;
PAAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.81	9.39	0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.54	-0.35	1.13e-5	Neuroticism;
PAAD	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.5	6.55	0.47	8.2e-10	Thyroid hormone levels;
PAAD	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg25233709	chr10:116636983	FAM160B1	0.35	4.32	0.33	2.83e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18357526	chr6:26021779	HIST1H4A	0.67	6.52	0.47	9.74e-10	Blood metabolite levels;
PAAD	cis	rs4787951	0.698	rs4238955	chr16:27316576	G/T	cg08008352	chr16:27322356	NA	0.52	4.47	0.34	1.51e-5	Eosinophil percentage of white cells;
PAAD	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11411904	chr1:153935719	SLC39A1	0.58	6.54	0.47	8.68e-10	Myopia (pathological);
PAAD	cis	rs2271001	0.955	rs1503506	chr11:19145974	G/A	cg00161556	chr11:19138045	ZDHHC13	0.49	5.38	0.4	2.82e-7	Gut microbiome composition (winter);
PAAD	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.44	5.52	0.41	1.43e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs11024102	0.962	rs34927905	chr11:17001427	C/T	cg15084286	chr11:17036142	PLEKHA7	0.51	4.68	0.35	6.27e-6	Glaucoma (primary angle closure);
PAAD	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.67	-7.86	-0.54	6.51e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7487075	0.619	rs11183488	chr12:46841836	A/G	cg14671384	chr12:47219920	SLC38A4	0.44	4.33	0.33	2.66e-5	Itch intensity from mosquito bite;
PAAD	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg18021393	chr1:145516084	GNRHR2;PEX11B	0.59	6.46	0.46	1.36e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.82	5.88	0.43	2.56e-8	Iron status biomarkers;
PAAD	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.51	-0.34	1.29e-5	Blood protein levels;
PAAD	cis	rs9463078	0.845	rs1329713	chr6:45004028	A/C	cg25276700	chr6:44698697	NA	-0.47	-5.3	-0.4	3.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.85	7.28	0.51	1.68e-11	Phospholipid levels (plasma);
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.59	-5.52	-0.41	1.43e-7	Monocyte count;
PAAD	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg08601574	chr20:25228251	PYGB	0.64	7.08	0.5	5.07e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	9.56	0.61	3.1e-17	Prudent dietary pattern;
PAAD	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg12568669	chr8:11666485	FDFT1	0.32	5.4	0.4	2.49e-7	Monocyte count;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.48	6.86	0.49	1.66e-10	Mean corpuscular volume;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.74	-10.09	-0.63	1.2e-18	Iron status biomarkers;
PAAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.39e-7	Monocyte count;
PAAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg09158336	chr17:76338205	NA	-0.73	-4.75	-0.36	4.58e-6	Airflow obstruction;
PAAD	cis	rs72960926	0.744	rs55755114	chr6:74823870	A/G	cg03266952	chr6:74778945	NA	-1.24	-6.95	-0.49	1e-10	Metabolite levels (MHPG);
PAAD	cis	rs7040024	0.754	rs10122680	chr9:852557	A/T	cg14021170	chr9:826657	NA	-0.46	-4.32	-0.33	2.8e-5	Testicular germ cell tumor;Testicular cancer;
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.57	-6.44	-0.46	1.49e-9	Prostate cancer;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg21037935	chr19:58911965	NA	0.52	4.5	0.34	1.33e-5	Mean platelet volume;
PAAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.69	-6.33	-0.46	2.65e-9	Breast cancer;
PAAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.65	-0.57	6.99e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg27086773	chr12:14927345	H2AFJ	0.57	6.89	0.49	1.35e-10	Immature fraction of reticulocytes;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.41	4.82	0.36	3.45e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5756391	0.546	rs4821566	chr22:37314507	C/G	cg21209356	chr22:37319042	CSF2RB	0.35	4.25	0.33	3.78e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	5.2	0.39	6.3e-7	Motion sickness;
PAAD	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.81	9.39	0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-4.92	-0.37	2.23e-6	Height;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg26338869	chr17:61819248	STRADA	0.5	4.76	0.36	4.5e-6	Height;
PAAD	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.52	5.28	0.39	4.47e-7	Corneal astigmatism;
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.91	9.37	0.6	9.65e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.62	-5.84	-0.43	3.03e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9517320	1.000	rs7338549	chr13:99142745	C/T	cg20487152	chr13:99095054	FARP1	0.5	5.14	0.38	8.45e-7	Longevity;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg10818794	chr15:86012489	AKAP13	-0.6	-4.99	-0.38	1.61e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs10887741	0.606	rs3824722	chr10:89435723	C/G	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.51	-5.28	-0.39	4.35e-7	Myocardial infarction;
PAAD	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.84	0.37	3.1e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.69	-5.03	-0.38	1.35e-6	Type 2 diabetes;
PAAD	cis	rs863345	0.584	rs10908677	chr1:158506186	C/T	cg12129480	chr1:158549410	OR10X1	0.47	5.63	0.42	8.65e-8	Pneumococcal bacteremia;
PAAD	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9880772	0.747	rs9817112	chr3:27827733	A/G	cg21473142	chr3:27762095	EOMES	0.33	5.84	0.43	3.04e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.9	-10.49	-0.65	1.06e-19	Refractive error;
PAAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-4.32	-0.33	2.81e-5	Type 2 diabetes;
PAAD	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.59	-5.63	-0.42	8.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg20893579	chr22:38215064	NA	0.52	4.76	0.36	4.54e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20095920	chr10:32217009	ARHGAP12	-0.65	-6.78	-0.48	2.56e-10	Smoking initiation;
PAAD	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg04717802	chr22:42394638	WBP2NL	0.49	4.63	0.35	7.72e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.52	-6.73	-0.48	3.33e-10	Type 2 diabetes;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg22868518	chr11:507468	RNH1	-0.91	-4.78	-0.36	4.17e-6	Body mass index;
PAAD	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs1519814	1.000	rs7826920	chr8:121121010	T/C	cg22335954	chr8:121166405	COL14A1	-0.61	-5.35	-0.4	3.14e-7	Breast cancer;
PAAD	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs6718203	0.730	rs45564436	chr2:60708402	G/A	cg10480506	chr2:60280451	NA	0.67	4.44	0.34	1.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.46	-4.55	-0.35	1.11e-5	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg23024343	chr7:107201750	COG5	0.57	4.62	0.35	8.11e-6	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24689976	chr6:88187068	SLC35A1	0.58	6.45	0.46	1.42e-9	Smoking initiation;
PAAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg03983715	chr16:68378420	PRMT7	-0.72	-5.23	-0.39	5.43e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.05	0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.07	0.55	1.95e-13	Height;
PAAD	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.28	12.46	0.71	5.46e-25	Corneal structure;
PAAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg25246084	chr19:4971487	KDM4B	-0.46	-5.67	-0.42	7.09e-8	Monocyte percentage of white cells;
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-7.49	-0.52	5.29e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.95	-7.96	-0.54	3.61e-13	Bipolar disorder;
PAAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	1.3	12.88	0.72	4.01e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs7771547	0.723	rs7759778	chr6:36552267	C/G	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg24519413	chr1:26490540	NA	0.53	4.93	0.37	2.17e-6	Height;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg10729496	chr3:10149963	C3orf24	0.87	7.28	0.51	1.63e-11	Alzheimer's disease;
PAAD	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg12555334	chr7:56120290	CCT6A;PSPH	0.37	5.19	0.39	6.58e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg10395934	chr14:104002654	TRMT61A	-0.57	-6.16	-0.45	6.26e-9	Body mass index;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs4450131	0.868	rs10794175	chr10:126358073	G/T	cg20435097	chr10:126320824	FAM53B	0.41	4.69	0.36	6.01e-6	White blood cell count (basophil);
PAAD	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.23	20.41	0.86	2.16e-45	Testicular germ cell tumor;
PAAD	cis	rs7804356	0.871	rs2189017	chr7:26795073	A/G	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.68	-7.64	-0.53	2.31e-12	Menopause (age at onset);
PAAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.39	4.05e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.78	8.96	0.59	1.06e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18464790	chr6:90539804	CASP8AP2	0.7	7.66	0.53	2.07e-12	Myopia (pathological);
PAAD	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg02135003	chr7:105160482	PUS7	-0.8	-6.16	-0.45	6.15e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35160687	0.865	rs10189492	chr2:86478902	G/A	cg10973622	chr2:86423274	IMMT	0.42	4.79	0.36	4e-6	Night sleep phenotypes;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.85e-7	Life satisfaction;
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.97e-6	Neuroticism;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg09361488	chr1:12677666	DHRS3	0.58	6.42	0.46	1.66e-9	Morning vs. evening chronotype;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.63	-8.31	-0.56	4.89e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs427941	0.632	rs201527	chr7:101774451	T/C	cg06246474	chr7:101738831	CUX1	0.43	4.28	0.33	3.29e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.62	-8.41	-0.56	2.75e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13882835	chr2:172017928	TLK1	-0.56	-6.36	-0.46	2.24e-9	Body fat percentage;
PAAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.5	0.61	4.34e-17	Cognitive function;
PAAD	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg01305830	chr4:1604576	NA	-0.51	-4.84	-0.37	3.13e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.53	7.31	0.51	1.42e-11	Crohn's disease;
PAAD	cis	rs6132905	0.590	rs79001633	chr20:2626462	T/C	cg24848351	chr20:2622020	TMC2	-0.76	-5.54	-0.41	1.31e-7	Mumps;
PAAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-8.44	-0.56	2.32e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg05392440	chr1:2478653	NA	0.56	6.07	0.44	9.64e-9	Ulcerative colitis;
PAAD	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg20673841	chr7:107026890	COG5	0.47	4.36	0.33	2.41e-5	Coronary artery disease;
PAAD	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.49	-4.78	-0.36	4.09e-6	Obesity-related traits;
PAAD	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.39	-0.34	2.12e-5	Body mass index;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg23442198	chr4:187126114	CYP4V2	0.6	4.32	0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs9815354	0.951	rs1717018	chr3:41913617	G/A	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4908768	0.582	rs11121241	chr1:8895970	C/G	cg00590817	chr1:8272081	NA	-0.35	-4.31	-0.33	2.89e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs75920871	0.688	rs61905679	chr11:116834787	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.39	-0.34	2.11e-5	Subjective well-being;
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-1.3	-11.47	-0.68	2.46e-22	Obesity-related traits;
PAAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.48	0.61	4.76e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.25	-4.29	-0.33	3.2e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.96	-11.08	-0.67	2.75e-21	Height;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03964851	chr5:93905427	MIR1974;C5orf36	0.67	6.99	0.49	7.99e-11	Pancreatic cancer;
PAAD	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg04156016	chr5:1868137	NA	0.44	4.43	0.34	1.8e-5	Cardiovascular disease risk factors;
PAAD	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg10382835	chr6:42185730	MRPS10	0.78	5.63	0.42	8.59e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg05555928	chr11:63887634	MACROD1	-0.72	-5.58	-0.41	1.1e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6496932	1.000	rs35796484	chr15:85825250	C/T	cg19183879	chr15:85880815	NA	0.57	4.74	0.36	4.92e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs7707921	0.881	rs324914	chr5:81389950	C/T	cg21483461	chr5:81570383	RPS23	0.49	4.25	0.33	3.65e-5	Breast cancer;
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg20821713	chr7:1055600	C7orf50	-0.53	-4.51	-0.34	1.29e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.5	-5.59	-0.41	1.02e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.43	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs490234	0.966	rs509753	chr9:128303518	G/A	cg14078157	chr9:128172775	NA	0.39	4.25	0.33	3.65e-5	Mean arterial pressure;
PAAD	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg15117754	chr3:10150083	C3orf24	0.67	5.65	0.42	7.54e-8	Alzheimer's disease;
PAAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.51	5.8	0.43	3.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.23e-5	Testicular germ cell tumor;
PAAD	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer;
PAAD	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.7	0.62	1.29e-17	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg08601574	chr20:25228251	PYGB	0.48	4.81	0.36	3.55e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1355223	0.573	rs1148930	chr11:34732225	C/T	cg11622362	chr11:34938112	PDHX;APIP	-0.43	-4.34	-0.33	2.57e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs732505	1.000	rs4807790	chr19:5584614	A/G	cg26242866	chr19:5711310	LONP1	1.01	5.55	0.41	1.22e-7	vWF and FVIII levels;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg17372223	chr3:52568218	NT5DC2	0.53	5.56	0.41	1.21e-7	Electroencephalogram traits;
PAAD	cis	rs4417704	0.551	rs4077132	chr2:241889937	A/G	cg26818257	chr2:241905806	NA	0.51	5.46	0.41	1.88e-7	Joint mobility (Beighton score);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05794954	chr1:100817839	CDC14A	0.66	6.77	0.48	2.58e-10	Obesity-related traits;
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-7.33	-0.51	1.25e-11	Initial pursuit acceleration;
PAAD	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.83	9.28	0.6	1.58e-16	Total cholesterol levels;
PAAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.63	6.52	0.47	9.68e-10	Coronary artery disease;
PAAD	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.81	9.09	0.59	5.18e-16	Body mass index;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg21724239	chr8:58056113	NA	0.63	4.61	0.35	8.49e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg10290764	chr8:4849399	CSMD1	-0.38	-6.3	-0.46	2.99e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23052039	chr6:647366	EXOC2	-0.6	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.97	-0.44	1.61e-8	Dental caries;
PAAD	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg24053715	chr22:38214548	NA	-0.5	-5.19	-0.39	6.73e-7	Glioblastoma;Glioma;
PAAD	cis	rs1075265	0.933	rs11888384	chr2:54338121	C/T	cg04546899	chr2:54196757	PSME4	0.32	4.46	0.34	1.56e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs3774830	0.714	rs17464616	chr4:5465004	G/A	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.2e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.28	-0.39	4.37e-7	Systolic blood pressure;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22162314	chr17:61951766	CSH2	-0.57	-6.01	-0.44	1.3e-8	Height;
PAAD	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg00806126	chr19:22604979	ZNF98	0.45	5.67	0.42	6.9e-8	Pain;
PAAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	6.06	0.44	1.02e-8	Personality dimensions;
PAAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.29	-0.39	4.11e-7	Bladder cancer;
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg13264159	chr8:625131	ERICH1	-0.64	-4.48	-0.34	1.47e-5	IgG glycosylation;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.5	5.08	0.38	1.08e-6	Height;
PAAD	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.96	-10.6	-0.65	5.3e-20	Multiple sclerosis;
PAAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.77	-7.83	-0.54	7.86e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs72827839	1.000	rs72827832	chr17:46407108	C/A	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs17461620	1.000	rs62573370	chr9:88883182	T/C	cg13456106	chr9:88897068	ISCA1	0.62	4.37	0.33	2.32e-5	Diisocyanate-induced asthma;
PAAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg18279126	chr7:2041391	MAD1L1	0.51	4.96	0.37	1.85e-6	Schizophrenia;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.82	0.36	3.5e-6	Height;
PAAD	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.77	-7.21	-0.5	2.45e-11	Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.65	-0.35	7.03e-6	Breast cancer;
PAAD	cis	rs12304921	1.000	rs73090649	chr12:51349641	C/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.39	-0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.71	0.48	3.52e-10	Schizophrenia;
PAAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Aortic root size;
PAAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg20295408	chr7:1910781	MAD1L1	-0.67	-6.73	-0.48	3.28e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25069772	chr6:12867139	PHACTR1	-0.61	-6.34	-0.46	2.43e-9	Obesity-related traits;
PAAD	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg25319279	chr11:5960081	NA	-0.64	-6.42	-0.46	1.61e-9	DNA methylation (variation);
PAAD	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.57	0.35	9.91e-6	Educational attainment;
PAAD	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg00262122	chr8:11665843	FDFT1	0.62	6.13	0.45	7.29e-9	Neuroticism;
PAAD	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.84	-9.27	-0.6	1.71e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.68	0.53	1.84e-12	IgG glycosylation;
PAAD	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.77e-10	Neurofibrillary tangles;
PAAD	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.57	-4.26	-0.33	3.64e-5	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg11952622	chr19:58962976	ZNF324B	0.46	4.39	0.34	2.08e-5	Uric acid clearance;
PAAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.76	-9.09	-0.59	4.98e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.6	8.19	0.55	9.87e-14	Eye color traits;
PAAD	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.46	-4.51	-0.34	1.27e-5	Platelet count;
PAAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.26	7.48	0.52	5.5e-12	Lung cancer in ever smokers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12812760	chr12:53645951	MFSD5	0.56	6.44	0.46	1.45e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.8	-7.2	-0.5	2.57e-11	Body mass index;
PAAD	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg15841412	chr13:111365552	ING1	-0.57	-4.64	-0.35	7.52e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg18621852	chr3:10150065	C3orf24	0.54	5.06	0.38	1.19e-6	Alzheimer's disease;
PAAD	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-9.98	-0.63	2.36e-18	Response to antipsychotic treatment;
PAAD	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.96	-0.37	1.84e-6	Smoking behavior;
PAAD	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-11.15	-0.67	1.78e-21	Ulcerative colitis;
PAAD	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	cis	rs3736485	0.652	rs2054166	chr15:51974910	A/T	cg19558802	chr15:51695713	GLDN	-0.43	-4.42	-0.34	1.9e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6466055	0.661	rs6966539	chr7:104880551	G/A	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	1.08	6.51	0.47	1.02e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs863345	0.967	rs1117124	chr1:158509851	G/C	cg12129480	chr1:158549410	OR10X1	-0.45	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.19	7.38	0.51	9.57e-12	Lung cancer in ever smokers;
PAAD	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.51	-0.41	1.51e-7	Neuroticism;
PAAD	trans	rs10826182	0.543	rs4390300	chr10:60144207	G/A	cg04777091	chr4:6050440	JAKMIP1	-0.37	-6.3	-0.46	3.01e-9	Midgestational circulating levels of PCBs;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	5.99e-8	Life satisfaction;
PAAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-1.07	-14.66	-0.77	6.72e-31	Breast cancer;
PAAD	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.89	-10.04	-0.63	1.61e-18	Cognitive function;
PAAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-6.5	-0.47	1.11e-9	Initial pursuit acceleration;
PAAD	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.11	13.78	0.75	1.51e-28	Schizophrenia;
PAAD	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg19423196	chr10:82049429	MAT1A	0.53	4.94	0.37	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg16586182	chr3:47516702	SCAP	0.65	7.12	0.5	4.1e-11	Colorectal cancer;
PAAD	cis	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.59	5.8	0.43	3.65e-8	Multiple sclerosis;
PAAD	cis	rs959260	0.588	rs8079197	chr17:73316679	G/C	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.29	-0.39	4.17e-7	Monocyte count;
PAAD	cis	rs367943	0.666	rs7725589	chr5:112693366	G/A	cg12552261	chr5:112820674	MCC	0.64	6.36	0.46	2.23e-9	Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.51	-4.25	-0.33	3.66e-5	Type 2 diabetes;
PAAD	cis	rs740474	0.569	rs4912762	chr5:140881691	A/G	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.5	6.11	0.44	7.92e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.99	10.42	0.65	1.61e-19	Pulmonary function decline;
PAAD	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg17380795	chr3:122379686	NA	0.53	5.71	0.42	5.77e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16262614	chr3:133464971	TF	-0.41	-4.28	-0.33	3.31e-5	Iron status biomarkers;
PAAD	cis	rs11668609	0.515	rs13346480	chr19:24072073	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs12935418	0.552	rs2549842	chr16:81023659	A/G	cg16651780	chr16:81037892	C16orf61	0.63	5.54	0.41	1.31e-7	Mean corpuscular volume;
PAAD	cis	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg21605333	chr4:119757512	SEC24D	0.8	5.98	0.44	1.5e-8	Cannabis dependence symptom count;
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.24	-0.6	2.04e-16	Prostate cancer;
PAAD	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.56e-11	Retinal vascular caliber;
PAAD	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.57	5.04	0.38	1.28e-6	Common traits (Other);
PAAD	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Breast cancer;
PAAD	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs3764400	0.506	rs72827851	chr17:46452495	C/A	cg10706073	chr17:46328419	SKAP1	-1.07	-6.37	-0.46	2.13e-9	Body mass index;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.93	6.93	0.49	1.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg27211696	chr2:191398769	TMEM194B	0.46	4.53	0.34	1.2e-5	Urinary metabolites;
PAAD	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.46	-4.28	-0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2239785	0.920	rs136154	chr22:36656138	A/T	cg15716373	chr22:36655542	APOL1	-0.46	-4.36	-0.33	2.36e-5	Glomerulosclerosis;
PAAD	cis	rs965469	0.779	rs6051740	chr20:3301165	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs897984	0.760	rs11150596	chr16:30850242	C/T	cg02466173	chr16:30829666	NA	-0.6	-6.83	-0.48	1.87e-10	Dementia with Lewy bodies;
PAAD	cis	rs1879734	0.731	rs6588486	chr1:54166777	G/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-10.57	-0.65	6.5e-20	Platelet distribution width;
PAAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg02297831	chr4:17616191	MED28	0.62	6.26	0.45	3.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.587	rs9788082	chr12:48752056	C/A	cg26205652	chr12:48591994	NA	0.77	6.88	0.49	1.45e-10	Longevity (90 years and older);
PAAD	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.43e-11	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09971309	chr7:126884276	GRM8	-0.68	-7.08	-0.5	4.88e-11	Obesity-related traits;
PAAD	cis	rs12550646	0.612	rs13439740	chr8:41686017	C/T	cg19997384	chr8:41685595	ANK1	-0.38	-5.01	-0.38	1.46e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.54	5.92	0.43	2.03e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg00262122	chr8:11665843	FDFT1	-0.46	-4.33	-0.33	2.68e-5	Retinal vascular caliber;
PAAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00540400	chr15:79124168	NA	-0.53	-6.07	-0.44	9.74e-9	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	trans	rs4272720	0.855	rs61850678	chr10:50245557	T/C	cg15329866	chr3:171455826	PLD1	0.78	6.79	0.48	2.37e-10	Platelet count;Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22165071	chr15:35384714	NA	-0.68	-7.02	-0.49	6.86e-11	Obesity-related traits;
PAAD	cis	rs72960926	0.744	rs72954354	chr6:74949552	C/G	cg03266952	chr6:74778945	NA	-1.12	-6.45	-0.46	1.41e-9	Metabolite levels (MHPG);
PAAD	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg26174226	chr8:58114915	NA	-0.44	-4.4	-0.34	2.05e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.55	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.29	0.51	1.59e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.28	0.51	1.67e-11	Educational attainment;
PAAD	cis	rs2992756	0.663	rs1360915	chr1:18801804	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.51	5.0	0.38	1.58e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.39	-0.4	2.67e-7	Pulmonary function;
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg12552261	chr5:112820674	MCC	0.63	6.3	0.46	3.04e-9	Type 2 diabetes;
PAAD	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.54e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg09237302	chr4:906077	GAK	-0.33	-4.41	-0.34	1.93e-5	Systemic sclerosis;
PAAD	cis	rs6066835	1.000	rs56343427	chr20:47355273	C/T	cg18078177	chr20:47281410	PREX1	0.94	4.61	0.35	8.34e-6	Multiple myeloma;
PAAD	cis	rs7165102	0.965	rs7178686	chr15:65911228	G/C	cg22900193	chr15:65823441	PTPLAD1	0.46	4.38	0.33	2.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7713065	0.840	rs10077785	chr5:131801158	A/G	cg14196790	chr5:131705035	SLC22A5	0.54	5.3	0.39	4.1e-7	Lung function (FEV1/FVC);
PAAD	cis	rs10982213	1.000	rs4979379	chr9:117167192	T/C	cg00078025	chr9:117159975	NA	0.58	4.29	0.33	3.2e-5	Interleukin-6 levels;
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.56	5.77	0.42	4.26e-8	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06026331	chr20:60912101	LAMA5	0.57	4.62	0.35	8.13e-6	Colorectal cancer;
PAAD	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg14440974	chr22:39074834	NA	-0.56	-6.48	-0.47	1.21e-9	Menopause (age at onset);
PAAD	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg00631329	chr6:26305371	NA	-0.44	-4.61	-0.35	8.44e-6	Mosquito bite size;
PAAD	cis	rs9502570	0.578	rs7763140	chr6:7269567	C/T	cg02954307	chr6:7269328	NA	0.53	4.25	0.33	3.67e-5	Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs2299587	0.552	rs1978054	chr8:17868521	T/C	cg08627089	chr8:17753878	FGL1	-0.46	-4.29	-0.33	3.14e-5	Economic and political preferences;
PAAD	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg26874164	chr19:58962979	ZNF324B	0.5	4.65	0.35	7.23e-6	Uric acid clearance;
PAAD	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg09127314	chr1:152161683	NA	-0.64	-4.5	-0.34	1.32e-5	Atopic dermatitis;
PAAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	1.02	12.05	0.7	6.87e-24	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg03954927	chr1:10346856	KIF1B	0.38	4.27	0.33	3.47e-5	Hepatocellular carcinoma;
PAAD	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.46	-5.99	-0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg00543991	chr22:32367038	NA	1.2	7.35	0.51	1.12e-11	Childhood ear infection;
PAAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg14196790	chr5:131705035	SLC22A5	0.43	4.73	0.36	5.09e-6	Breast cancer;
PAAD	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg13870426	chr17:30244630	NA	0.75	6.31	0.46	2.86e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.97	-0.54	3.56e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.84e-8	Personality dimensions;
PAAD	cis	rs367943	0.698	rs2115207	chr5:112998285	C/T	cg12552261	chr5:112820674	MCC	0.62	6.67	0.48	4.36e-10	Type 2 diabetes;
PAAD	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg12963246	chr6:28129442	ZNF389	0.57	4.56	0.35	1.06e-5	Parkinson's disease;
PAAD	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg10515125	chr16:89437361	ANKRD11	0.46	4.38	0.34	2.16e-5	Squamous cell carcinoma;
PAAD	cis	rs9992101	0.547	rs11722924	chr4:77396854	G/C	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	4.78	0.36	4.07e-6	Neuroticism;
PAAD	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs7264396	0.887	rs6060435	chr20:34069370	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.54	-4.36	-0.33	2.35e-5	Total cholesterol levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15402992	chr20:44714513	NCOA5	-0.65	-6.4	-0.46	1.81e-9	Obesity-related traits;
PAAD	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg16989719	chr2:238392110	NA	-0.32	-4.44	-0.34	1.7e-5	Prostate cancer;
PAAD	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg08897044	chr19:12950850	MAST1	-0.36	-4.64	-0.35	7.5e-6	Mean corpuscular volume;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.72	5.46	0.41	1.86e-7	Initial pursuit acceleration;
PAAD	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg27170260	chr1:38156575	C1orf109	-0.45	-4.28	-0.33	3.25e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	trans	rs6964492	0.602	rs13232134	chr7:134398435	T/C	cg01839993	chr10:74034644	DDIT4	0.6	6.41	0.46	1.71e-9	Tonsillectomy;
PAAD	cis	rs9677476	0.821	rs6708809	chr2:232112730	A/C	cg07929768	chr2:232055508	NA	0.39	4.41	0.34	1.96e-5	Food antigen IgG levels;
PAAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs490234	0.841	rs829314	chr9:128415506	A/T	cg14078157	chr9:128172775	NA	0.45	5.11	0.38	9.57e-7	Mean arterial pressure;
PAAD	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-6.45	-0.46	1.43e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs4450131	0.522	rs4962680	chr10:126358833	C/T	cg20435097	chr10:126320824	FAM53B	0.53	5.44	0.4	2.08e-7	White blood cell count (basophil);
PAAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg14393609	chr7:65229607	NA	-0.47	-4.77	-0.36	4.22e-6	Aortic root size;
PAAD	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	1.11	9.93	0.63	3.28e-18	Orofacial clefts;
PAAD	cis	rs113779084	0.623	rs4373426	chr7:11989874	T/C	cg15090509	chr7:11872073	THSD7A	0.41	5.03	0.38	1.36e-6	Educational attainment (years of education);
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.52	-0.34	1.25e-5	Biliary atresia;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.38	4.58	0.35	9.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21558508	chr5:133968566	SAR1B	0.67	8.18	0.55	1.07e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.58	-5.78	-0.42	4.05e-8	Tonsillectomy;
PAAD	cis	rs6735179	0.532	rs6756670	chr2:1761496	A/G	cg06599209	chr2:1746509	PXDN	0.26	4.36	0.33	2.4e-5	Response to antipsychotic treatment;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.54	-4.83	-0.36	3.25e-6	Acylcarnitine levels;
PAAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.57	5.44	0.4	2.06e-7	Platelet count;
PAAD	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.75	9.44	0.61	6.05e-17	Cancer;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg19223190	chr17:80058835	NA	0.53	5.5	0.41	1.59e-7	Life satisfaction;
PAAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.49	-4.87	-0.37	2.77e-6	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs6558530	0.730	rs7014327	chr8:1724052	C/T	cg19131313	chr8:1704013	NA	-0.38	-4.27	-0.33	3.44e-5	Systolic blood pressure;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg27394845	chr17:28928406	LRRC37B2	0.65	4.68	0.36	6.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2637266	0.783	rs846634	chr10:78535323	C/A	cg18941641	chr10:78392320	NA	0.39	4.68	0.35	6.34e-6	Pulmonary function;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg07029226	chr1:2104223	PRKCZ	-0.63	-6.31	-0.46	2.97e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-8.16	-0.55	1.2e-13	Colorectal cancer;
PAAD	cis	rs12889267	0.551	rs12432623	chr14:21588779	G/T	cg02988727	chr14:21567520	ZNF219;C14orf176	-0.64	-5.53	-0.41	1.36e-7	Hematocrit;Resting heart rate;
PAAD	cis	rs12620999	0.627	rs12986628	chr2:238103439	C/T	cg23555395	chr2:238036564	NA	-0.48	-5.44	-0.4	2.13e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15189567	chr20:3066643	AVP	-0.61	-6.3	-0.46	2.98e-9	Obesity-related traits;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-6.25	-0.45	3.97e-9	Schizophrenia (age at onset);
PAAD	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs12136530	0.625	rs12726614	chr1:19730957	G/C	cg01468656	chr1:19991678	HTR6	0.49	4.43	0.34	1.77e-5	Lead levels in blood;
PAAD	cis	rs939584	1.000	rs1320338	chr2:649347	T/G	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15064681	chr1:116312839	CASQ2	-0.7	-7.92	-0.54	4.69e-13	Obesity-related traits;
PAAD	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.58	6.04	0.44	1.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	1.04	13.92	0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7651511	1.000	rs12695741	chr3:141285783	G/A	cg25967872	chr3:141205623	RASA2	0.51	4.62	0.35	8.18e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-4.94	-0.37	2.05e-6	Menopause (age at onset);
PAAD	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.61	-5.85	-0.43	2.94e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.67	5.39	0.4	2.66e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs4704187	0.687	rs4447960	chr5:74361857	C/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.76	8.82	0.58	2.47e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.67	0.48	4.57e-10	Lung cancer;
PAAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	4.96	0.37	1.88e-6	Asthma;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg26174226	chr8:58114915	NA	-0.63	-5.07	-0.38	1.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.8	-8.3	-0.56	5.19e-14	Total body bone mineral density;
PAAD	cis	rs4450131	0.522	rs6597851	chr10:126413773	A/C	cg20435097	chr10:126320824	FAM53B	-0.5	-5.0	-0.38	1.56e-6	White blood cell count (basophil);
PAAD	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg05425664	chr17:57184151	TRIM37	0.49	4.72	0.36	5.25e-6	Testicular germ cell tumor;
PAAD	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.4	0.64	1.77e-19	Electrocardiographic conduction measures;
PAAD	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.6	-5.44	-0.4	2.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9810890	1.000	rs73198874	chr3:128538514	A/T	cg15676455	chr3:128564943	NA	-0.86	-5.2	-0.39	6.2e-7	Dental caries;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.61	0.53	2.69e-12	Prudent dietary pattern;
PAAD	cis	rs501120	1.000	rs671765	chr10:44752976	A/G	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-5.56	-0.41	1.18e-7	Bladder cancer;
PAAD	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.75	-9.49	-0.61	4.6e-17	Neuroticism;
PAAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.88	-9.56	-0.61	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg13789015	chr9:136890014	NCRNA00094	0.54	4.37	0.33	2.27e-5	Mosquito bite size;
PAAD	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.86	0.37	2.85e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs9463078	0.605	rs10948188	chr6:44926212	G/A	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.52	-5.03	-0.38	1.39e-6	Menarche (age at onset);
PAAD	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.88	-7.28	-0.51	1.66e-11	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06162264	chr12:49628356	NA	0.62	6.36	0.46	2.24e-9	Myopia (pathological);
PAAD	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg10932868	chr11:921992	NA	0.45	4.78	0.36	4.07e-6	Alzheimer's disease (late onset);
PAAD	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg22143856	chr6:28129313	ZNF389	0.65	5.3	0.4	3.97e-7	Depression;
PAAD	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	5.62	0.41	9.04e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13056815	1	rs13056815	chr22:31668250	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.32	-0.4	3.62e-7	Cognitive function;
PAAD	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.68	6.81	0.48	2.12e-10	Cancer;
PAAD	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.6	4.79	0.36	3.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.55	5.45	0.4	1.99e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.31	-0.33	2.89e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.48	4.34	0.33	2.54e-5	Neuroticism;
PAAD	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs4262150	0.544	rs55802718	chr5:151916541	G/A	cg12297329	chr5:152029980	NA	-0.58	-4.26	-0.33	3.64e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2448490	0.642	rs573589	chr11:65483981	C/T	cg01098237	chr11:65601417	SNX32	-0.39	-4.27	-0.33	3.38e-5	Platelet count;
PAAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.35	0.4	3.19e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.69	6.15	0.45	6.44e-9	Asthma;
PAAD	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.49e-8	Obesity-related traits;
PAAD	cis	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg11530693	chr1:120165357	ZNF697	0.5	4.67	0.35	6.46e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.49	5.15	0.39	7.81e-7	Type 2 diabetes;
PAAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.52	-4.64	-0.35	7.35e-6	IgG glycosylation;
PAAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	1.07	5.73	0.42	5.26e-8	Body mass index;
PAAD	cis	rs539096	0.706	rs618369	chr1:44071796	G/T	cg12908607	chr1:44402522	ARTN	-0.41	-4.28	-0.33	3.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg14343924	chr8:8086146	FLJ10661	0.52	5.04	0.38	1.3e-6	Joint mobility (Beighton score);
PAAD	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.48	-5.15	-0.39	8.01e-7	Lung cancer;
PAAD	cis	rs1101081	0.543	rs2982565	chr6:152051854	A/G	cg10274830	chr6:151774009	C6orf211;RMND1	0.57	4.51	0.34	1.28e-5	Birth weight;
PAAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg08029281	chr1:67600428	NA	0.48	5.49	0.41	1.62e-7	Psoriasis;
PAAD	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.58	-5.24	-0.39	5.4e-7	P wave terminal force;
PAAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.77	8.23	0.56	7.74e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.68	7.47	0.52	5.8e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-5.01	-0.38	1.47e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.68	-4.74	-0.36	4.82e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.59	-6.09	-0.44	8.91e-9	Testicular germ cell tumor;
PAAD	cis	rs12044355	0.896	rs12723735	chr1:231860372	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	4.99	0.38	1.6e-6	Alzheimer's disease;
PAAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-4.84	-0.37	3.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.858	rs7187476	chr16:67699948	T/C	cg09835421	chr16:68378352	PRMT7	-0.65	-4.32	-0.33	2.79e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.54	-5.69	-0.42	6.3e-8	Daytime sleep phenotypes;
PAAD	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg14196790	chr5:131705035	SLC22A5	-0.48	-5.05	-0.38	1.26e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs793571	0.822	rs28709922	chr15:59173481	G/A	cg05156742	chr15:59063176	FAM63B	0.59	4.71	0.36	5.44e-6	Schizophrenia;
PAAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg19784903	chr17:45786737	TBKBP1	0.53	5.66	0.42	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8102137	1.000	rs79576418	chr19:30290890	A/G	cg27475126	chr19:30303651	CCNE1	-0.45	-5.01	-0.38	1.47e-6	Bladder cancer;
PAAD	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg24110177	chr3:50126178	RBM5	-0.56	-4.42	-0.34	1.91e-5	Menarche (age at onset);
PAAD	cis	rs10821973	0.527	rs4979775	chr10:63981847	G/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.65	6.16	0.45	6.19e-9	Corneal astigmatism;
PAAD	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.68	6.3	0.46	3.05e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs950880	0.710	rs55927292	chr2:102964861	C/T	cg23450938	chr2:102972792	NA	0.44	4.68	0.35	6.41e-6	Serum protein levels (sST2);
PAAD	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.72	-0.48	3.48e-10	Retinal vascular caliber;
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg03938978	chr2:103052716	IL18RAP	0.6	5.58	0.41	1.09e-7	Blood protein levels;
PAAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.54	-5.15	-0.39	7.95e-7	Neurofibrillary tangles;
PAAD	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg00982548	chr2:198649783	BOLL	-0.73	-5.21	-0.39	6.09e-7	Ulcerative colitis;
PAAD	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.37	0.46	2.09e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.71	6.81	0.48	2.13e-10	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	4.65	0.35	7.04e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	cg21977766	chr11:1107580	NA	0.44	4.46	0.34	1.57e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.68	6.57	0.47	7.52e-10	Platelet distribution width;
PAAD	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg14393609	chr7:65229607	NA	-0.67	-7.27	-0.51	1.73e-11	Aortic root size;
PAAD	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.52e-8	Coronary artery disease;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.8	-6.85	-0.49	1.75e-10	Other erythrocyte phenotypes;
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.84	-9.12	-0.59	4.29e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-4.33	-0.33	2.72e-5	Testicular germ cell tumor;
PAAD	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg20406979	chr6:167373233	NA	0.34	4.52	0.34	1.25e-5	Crohn's disease;
PAAD	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs13380717	1.000	rs13380717	chr16:86904135	C/T	cg09586080	chr16:86543543	FOXF1	-0.5	-4.28	-0.33	3.29e-5	Sepsis in extremely premature infants;
PAAD	cis	rs16975963	0.644	rs111319455	chr19:38162647	A/C	cg14218481	chr19:38281219	NA	0.43	4.58	0.35	9.45e-6	Longevity;
PAAD	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.47	-4.85	-0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg10820045	chr2:198174542	NA	-0.49	-4.98	-0.37	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.5	-4.45	-0.34	1.66e-5	IgG glycosylation;
PAAD	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg26585981	chr11:48327164	OR4S1	-0.49	-4.3	-0.33	3.01e-5	Migraine - clinic-based;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23934503	chr14:21945053	RAB2B;TOX4	-0.78	-6.72	-0.48	3.47e-10	Neuroticism;
PAAD	cis	rs8081395	0.836	rs1292061	chr17:57911230	A/G	cg02344993	chr17:57696989	CLTC	-0.44	-4.32	-0.33	2.76e-5	White blood cell count;
PAAD	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg04165759	chr1:150448943	RPRD2	-0.53	-5.55	-0.41	1.23e-7	Migraine;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	1.2	12.26	0.71	1.85e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.96	-11.11	-0.67	2.24e-21	Myeloid white cell count;
PAAD	cis	rs6942407	0.744	rs6980450	chr7:86861201	C/G	cg02420886	chr7:86849541	C7orf23	0.55	4.43	0.34	1.79e-5	Food allergy;
PAAD	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.43	4.54	0.35	1.15e-5	Aortic root size;
PAAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs17155006	0.655	rs367538	chr7:107729565	C/T	cg05962710	chr7:107745446	LAMB4	0.47	5.81	0.43	3.54e-8	Pneumococcal bacteremia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02468154	chr11:43755634	HSD17B12	-0.58	-6.46	-0.46	1.36e-9	Myopia (pathological);
PAAD	cis	rs9322817	0.583	rs9391226	chr6:105158405	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-5.54	-0.41	1.33e-7	Thyroid stimulating hormone;
PAAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-5.99	-0.44	1.48e-8	Mood instability;
PAAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg09835421	chr16:68378352	PRMT7	-1.18	-8.79	-0.58	2.95e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.93e-19	Coronary artery disease;
PAAD	cis	rs860295	0.541	rs11264359	chr1:155282829	A/G	cg02153340	chr1:155202674	NA	-0.48	-4.46	-0.34	1.58e-5	Body mass index;
PAAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg12215294	chr3:40350768	EIF1B	0.5	4.69	0.36	6.04e-6	Renal cell carcinoma;
PAAD	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.12	-0.5	4.05e-11	Parkinson's disease;
PAAD	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02743256	chr7:2109353	MAD1L1	-0.68	-5.9	-0.43	2.3e-8	Neuroticism;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7082209	0.591	rs61856385	chr10:44818278	G/T	cg13191911	chr10:44806660	NA	-0.98	-4.42	-0.34	1.89e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs375066	0.901	rs12977303	chr19:44377669	G/A	cg21496419	chr19:44306685	LYPD5	0.44	5.28	0.39	4.45e-7	Breast cancer;
PAAD	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.29	0.39	4.22e-7	Free thyroxine concentration;
PAAD	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.71	-0.36	5.43e-6	Parkinson's disease;
PAAD	cis	rs7714584	1.000	rs11167521	chr5:150271785	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.34e-6	Lung cancer;
PAAD	cis	rs8077577	0.895	rs735960	chr17:18057301	G/A	cg16794390	chr17:18148240	FLII	0.66	5.35	0.4	3.17e-7	Obesity-related traits;
PAAD	cis	rs8077577	0.708	rs2290504	chr17:18136988	T/C	cg16794390	chr17:18148240	FLII	-0.52	-4.46	-0.34	1.57e-5	Obesity-related traits;
PAAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg25452165	chr22:42524984	CYP2D6	0.57	5.48	0.41	1.71e-7	Schizophrenia;
PAAD	cis	rs732765	0.734	rs12323899	chr14:75117513	T/C	cg01090926	chr14:75137805	KIAA0317	0.49	4.29	0.33	3.22e-5	Non-small cell lung cancer;
PAAD	cis	rs332507	0.789	rs13097459	chr3:124398112	C/T	cg05980111	chr3:124395277	KALRN	0.43	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg10072921	chr12:121022843	NA	0.41	4.86	0.37	2.96e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs370915	0.550	rs28504498	chr4:187767430	C/T	cg12892747	chr4:187813459	NA	-0.44	-4.4	-0.34	2.05e-5	Gout;
PAAD	cis	rs3814231	0.531	rs12773054	chr10:115476042	C/T	cg24846397	chr10:115438155	CASP7	-0.52	-5.17	-0.39	7.16e-7	Vitiligo;
PAAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.51	-0.61	3.98e-17	Colorectal cancer;
PAAD	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg24846680	chr1:228362309	C1orf69	0.45	4.31	0.33	2.96e-5	Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.57	-7.63	-0.53	2.45e-12	Eye color traits;
PAAD	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.56	0.57	1.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.34	0.33	2.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg21479132	chr6:26055353	NA	0.79	4.33	0.33	2.65e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.62	6.33	0.46	2.6e-9	Monocyte count;
PAAD	cis	rs7009516	0.792	rs13265142	chr8:24229709	T/A	cg01759110	chr8:24241694	ADAMDEC1	-0.47	-5.54	-0.41	1.29e-7	Hair greying;
PAAD	cis	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg00614314	chr15:82944287	LOC80154	-0.55	-5.75	-0.42	4.73e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9303280	0.818	rs9747973	chr17:37905107	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.51	0.41	1.53e-7	Self-reported allergy;
PAAD	cis	rs16852403	0.583	rs1855174	chr1:178063040	G/A	cg00404053	chr1:178313656	RASAL2	0.5	4.56	0.35	1.03e-5	Childhood ear infection;
PAAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg12215294	chr3:40350768	EIF1B	0.47	4.72	0.36	5.26e-6	Renal cell carcinoma;
PAAD	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.51	0.52	4.65e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs6688613	1.000	rs10918605	chr1:166955638	A/G	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	1.24	12.51	0.71	3.86e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.56	4.28	0.33	3.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.93	-8.82	-0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14166788	chr9:98515469	NA	-0.57	-6.6	-0.47	6.33e-10	Monocyte percentage of white cells;
PAAD	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.34	4.99	0.37	1.65e-6	Alopecia areata;
PAAD	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.5e-12	Resting heart rate;
PAAD	cis	rs2124910	1.000	rs1457098	chr19:52021537	A/G	cg12008991	chr19:52034861	SIGLEC6	0.34	4.47	0.34	1.5e-5	Blood protein levels;
PAAD	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg01631408	chr1:248437212	OR2T33	-0.62	-5.27	-0.39	4.63e-7	Common traits (Other);
PAAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.55	6.57	0.47	7.52e-10	Multiple system atrophy;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg23096020	chr7:158799433	NA	0.46	4.33	0.33	2.71e-5	Facial morphology (factor 20);
PAAD	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.87	-9.98	-0.63	2.42e-18	Type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.61	-5.43	-0.4	2.15e-7	Monocyte count;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg23708337	chr7:1209742	NA	0.63	4.51	0.34	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs950880	0.710	rs17027166	chr2:103055420	C/T	cg23450938	chr2:102972792	NA	0.45	4.48	0.34	1.45e-5	Serum protein levels (sST2);
PAAD	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.64	6.97	0.49	8.97e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2492906	0.531	rs1907397	chr10:28069411	C/T	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs6499244	0.510	rs7206585	chr16:69872404	A/G	cg05250797	chr16:70222502	NA	-0.49	-4.43	-0.34	1.8e-5	Menarche (age at onset);
PAAD	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg09760422	chr2:128146352	NA	-0.26	-4.29	-0.33	3.18e-5	Protein C levels;
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-5.5	-0.41	1.54e-7	Obesity-related traits;
PAAD	trans	rs4272720	0.805	rs61848124	chr10:50210710	T/C	cg15329866	chr3:171455826	PLD1	0.77	6.71	0.48	3.68e-10	Platelet count;Plateletcrit;
PAAD	cis	rs111684993	1	rs111684993	chr15:41436737	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.29	-0.56	5.65e-14	Coronary artery disease;
PAAD	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-4.37	-0.33	2.33e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg19337854	chr7:99768885	GPC2	-0.43	-4.49	-0.34	1.41e-5	Coronary artery disease;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.34	-0.33	2.55e-5	Breast cancer;
PAAD	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs59918340	0.738	rs3739241	chr8:142221361	C/G	cg16494567	chr8:142200140	DENND3	0.44	4.52	0.34	1.23e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.39	5.14	0.38	8.39e-7	Schizophrenia;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.53	-5.87	-0.43	2.61e-8	Migraine;
PAAD	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.73	6.45	0.46	1.44e-9	Type 2 diabetes;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	8.54	0.57	1.33e-14	Lymphocyte counts;
PAAD	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs863345	0.967	rs10797016	chr1:158468413	T/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	4.26	0.33	3.56e-5	Tonsillectomy;
PAAD	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs59104589	0.617	rs59487360	chr2:242270433	A/G	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.5	-4.32	-0.33	2.78e-5	Triglycerides;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg07116851	chr12:58146173	CDK4	0.6	6.52	0.47	9.79e-10	Iris heterochromicity;
PAAD	cis	rs6594713	0.533	rs35128463	chr5:112959758	G/A	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs56046484	0.871	rs12900736	chr15:85558140	C/T	cg08123816	chr15:85640762	PDE8A	-0.43	-4.34	-0.33	2.6e-5	Testicular germ cell tumor;
PAAD	trans	rs11675636	0.571	rs10928560	chr2:136991807	C/T	cg27075654	chr16:1503444	CLCN7	0.73	6.35	0.46	2.31e-9	Alcohol dependence;
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.44	5.46	0.41	1.87e-7	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg03999872	chr20:62272968	STMN3	-0.76	-7.08	-0.5	4.94e-11	Atopic dermatitis;
PAAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg20243544	chr17:37824526	PNMT	0.54	4.76	0.36	4.4e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.27	0.45	3.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg15145965	chr22:50218605	BRD1	-0.62	-5.45	-0.4	1.99e-7	Schizophrenia;
PAAD	cis	rs12431939	1.000	rs7140375	chr14:51637242	T/G	cg23942311	chr14:51606299	NA	-0.72	-5.66	-0.42	7.26e-8	Cancer;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg14789911	chr21:47582049	C21orf56	0.53	5.67	0.42	6.92e-8	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.13	-0.45	7.09e-9	Coronary artery disease;
PAAD	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.79e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg00945038	chr17:61921165	SMARCD2	0.45	5.33	0.4	3.5e-7	Prudent dietary pattern;
PAAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg18370025	chr7:2749541	AMZ1	-0.42	-5.05	-0.38	1.24e-6	Height;
PAAD	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.78	8.06	0.55	2.09e-13	Body mass index;
PAAD	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs7804356	0.871	rs2189019	chr7:26798581	C/T	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.35	-0.51	1.16e-11	Diastolic blood pressure;
PAAD	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs3784262	0.669	rs12909979	chr15:58241022	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.62	-0.42	8.71e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18297960	chr7:1142765	C7orf50	-0.56	-4.42	-0.34	1.89e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73198271	1.000	rs11774744	chr8:8607764	A/G	cg01851573	chr8:8652454	MFHAS1	0.57	4.57	0.35	1e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg01059385	chr22:42394853	WBP2NL	0.56	4.45	0.34	1.65e-5	Birth weight;
PAAD	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg19418458	chr7:158789849	NA	0.54	4.4	0.34	2.03e-5	Facial morphology (factor 20);
PAAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg10518543	chr12:38710700	ALG10B	0.52	4.94	0.37	2.03e-6	Morning vs. evening chronotype;
PAAD	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.35	4.57	0.35	1.01e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-1.06	-15.22	-0.78	2.26e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs901683	1.000	rs12763285	chr10:46082869	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.98	-0.37	1.69e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.49	-0.41	1.66e-7	Prostate cancer;
PAAD	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg06636001	chr8:8085503	FLJ10661	-0.78	-8.33	-0.56	4.31e-14	Neuroticism;
PAAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.93	10.06	0.63	1.49e-18	Cognitive function;
PAAD	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.98	6.65	0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs8027181	0.839	rs7167076	chr15:73028873	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.69	-7.2	-0.5	2.62e-11	Triglyceride levels;
PAAD	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.74	-9.35	-0.6	1.1e-16	Body mass index;
PAAD	cis	rs282587	0.569	rs1756076	chr13:113395819	T/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-6.01	-0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.64	5.78	0.42	4.11e-8	Height;
PAAD	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.55	0.47	8.19e-10	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg09179987	chr1:167433047	CD247	0.37	4.37	0.33	2.31e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.04	0.38	1.32e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs62064224	1.000	rs62064224	chr17:30635115	G/A	cg18200150	chr17:30822561	MYO1D	0.7	10.0	0.63	2.05e-18	Schizophrenia;
PAAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg03959625	chr15:84868606	LOC388152	0.49	5.42	0.4	2.28e-7	Schizophrenia;
PAAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.73	-0.36	5.02e-6	Menarche (age at onset);
PAAD	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.41	5.08	0.38	1.1e-6	Corneal astigmatism;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg21496419	chr19:44306685	LYPD5	0.39	5.0	0.38	1.57e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg13798912	chr7:905769	UNC84A	0.57	4.4	0.34	2.03e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs899997	1.000	rs2017091	chr15:79032744	G/A	cg22753661	chr15:79092743	ADAMTS7	0.54	4.57	0.35	1e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg14851346	chr12:38532713	NA	-0.49	-4.34	-0.33	2.6e-5	Morning vs. evening chronotype;
PAAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.56e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	ch.11.42038R	chr11:967971	AP2A2	-0.6	-6.28	-0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.56	-5.9	-0.43	2.23e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.47	-0.46	1.27e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12541635	0.966	rs16873989	chr8:106966381	C/T	cg10147462	chr8:107024639	NA	0.45	4.6	0.35	8.91e-6	Age of smoking initiation;
PAAD	cis	rs2952768	1.000	rs2709382	chr2:208496715	G/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11752832	chr7:134001865	SLC35B4	0.58	5.17	0.39	7.35e-7	Mean platelet volume;
PAAD	cis	rs55986470	0.630	rs116252536	chr2:239394268	T/C	cg18131467	chr2:239335373	ASB1	-0.76	-5.9	-0.43	2.27e-8	Chronotype;
PAAD	cis	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg25886479	chr11:50257625	LOC441601	-0.4	-4.28	-0.33	3.32e-5	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1625975	0.681	rs1900514	chr10:73408326	A/G	cg26005973	chr10:72643678	PCBD1	0.72	5.05	0.38	1.23e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1190596	0.525	rs72698572	chr14:102756207	T/C	cg23904247	chr14:102554826	HSP90AA1	0.42	4.86	0.37	2.96e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.48	5.69	0.42	6.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.46	-4.51	-0.34	1.28e-5	Uric acid levels;
PAAD	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs2271001	0.910	rs2134622	chr11:19169508	G/C	cg00161556	chr11:19138045	ZDHHC13	0.51	5.51	0.41	1.5e-7	Gut microbiome composition (winter);
PAAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.54	0.61	3.36e-17	Lymphocyte counts;
PAAD	cis	rs89107	0.688	rs283086	chr6:118596941	C/T	cg21191810	chr6:118973309	C6orf204	0.44	6.08	0.44	9.38e-9	Cardiac structure and function;
PAAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg03959625	chr15:84868606	LOC388152	0.5	5.46	0.4	1.91e-7	Schizophrenia;
PAAD	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	7.62	0.53	2.53e-12	Post bronchodilator FEV1;
PAAD	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-1.03	-14.16	-0.75	1.43e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9646944	0.636	rs72998585	chr2:102858490	A/T	cg20060108	chr2:102954350	IL1RL1	0.59	4.42	0.34	1.85e-5	Blood protein levels;
PAAD	cis	rs939584	1.000	rs6548238	chr2:634905	A/G	cg03610516	chr2:642275	NA	0.64	5.94	0.43	1.9e-8	Body mass index;
PAAD	trans	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg26939375	chr7:64535504	NA	0.74	8.68	0.58	5.86e-15	Aortic root size;
PAAD	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.68	-0.53	1.82e-12	Bladder cancer;
PAAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.81	-6.81	-0.48	2.11e-10	Initial pursuit acceleration;
PAAD	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.79	9.18	0.6	3.01e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.42	4.63	0.35	7.93e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	5.43	0.4	2.22e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.5	-4.35	-0.33	2.48e-5	Glycated hemoglobin levels;
PAAD	cis	rs16910800	0.689	rs7101825	chr11:23164951	C/G	cg20040320	chr11:23191996	NA	0.78	6.8	0.48	2.25e-10	Cancer;
PAAD	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.46	4.42	0.34	1.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.79	7.14	0.5	3.58e-11	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02240066	chr2:170220975	NA	-0.58	-6.74	-0.48	3.15e-10	Body fat percentage;
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.6	6.69	0.48	4.04e-10	Vitiligo;
PAAD	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	6.43	0.46	1.53e-9	Initial pursuit acceleration;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.67	7.9	0.54	5.22e-13	Recombination rate (males);
PAAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg10356904	chr22:49881777	NA	-0.47	-4.67	-0.35	6.62e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.55	5.76	0.42	4.62e-8	Menarche (age at onset);
PAAD	cis	rs9942416	0.533	rs4704235	chr5:75024380	A/C	cg07025548	chr5:74632477	HMGCR	-0.56	-4.36	-0.33	2.35e-5	Age-related disease endophenotypes;
PAAD	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.9	-7.34	-0.51	1.22e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.95	-0.37	1.96e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg23250157	chr14:64679961	SYNE2	0.56	5.65	0.42	7.8e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg07061783	chr6:25882402	NA	0.49	4.62	0.35	8.06e-6	Blood metabolite levels;
PAAD	trans	rs9372498	0.908	rs3900941	chr6:118575602	G/A	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.63	-0.42	8.67e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.09	0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	4.85	0.37	3e-6	Breast cancer;
PAAD	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg18093559	chr17:18951025	GRAP	0.45	4.71	0.36	5.59e-6	Schizophrenia;
PAAD	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13432906	chr9:130984483	DNM1	0.58	7.24	0.51	2.08e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	4.98	0.37	1.69e-6	Height;
PAAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.58	0.35	9.68e-6	Melanoma;
PAAD	cis	rs12681963	0.614	rs2341179	chr8:30100766	A/G	cg23406830	chr8:30012838	DCTN6	-0.72	-4.47	-0.34	1.49e-5	Migraine;
PAAD	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg13535736	chr9:111863775	C9orf5	0.36	4.47	0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.39	-5.15	-0.39	7.93e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg00540400	chr15:79124168	NA	0.7	8.87	0.58	1.84e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23482986	chr6:36179489	BRPF3	-0.64	-6.66	-0.48	4.8e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.93e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.41	-0.52	8.12e-12	Neuroticism;
PAAD	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.77	7.6	0.52	2.81e-12	Coronary artery disease;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg02493798	chr17:6899577	ALOX12	0.44	4.39	0.34	2.15e-5	Tonsillectomy;
PAAD	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.39	0.74	1.72e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1620921	0.505	rs2115870	chr6:161207992	A/G	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00864171	chr11:67383662	NA	-0.53	-5.09	-0.38	1.04e-6	Mean corpuscular volume;
PAAD	cis	rs9462027	0.628	rs2814953	chr6:34697767	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	0.81	6.3	0.46	3.1e-9	Obesity-related traits;
PAAD	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.76	9.53	0.61	3.62e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.93	9.08	0.59	5.25e-16	Gestational age at birth (maternal effect);
PAAD	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs75920871	1.000	rs17120233	chr11:116871223	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.29	-0.39	4.25e-7	Neuroticism;
PAAD	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7567389	0.785	rs4150474	chr2:128033327	C/A	cg11380483	chr2:127933992	NA	-0.44	-4.44	-0.34	1.71e-5	Self-rated health;
PAAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.16	-19.73	-0.85	9.27e-44	Myeloid white cell count;
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.7	5.71	0.42	5.67e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-4.52	-0.34	1.23e-5	Parkinson's disease;
PAAD	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.65	-7.5	-0.52	5e-12	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs7092929	0.883	rs705459	chr10:3615477	T/C	cg14308648	chr10:3568949	NA	0.67	4.82	0.36	3.52e-6	Coronary artery calcification;
PAAD	cis	rs10779751	0.762	rs1074078	chr1:11326788	C/T	cg08854313	chr1:11322531	MTOR	-0.75	-9.33	-0.6	1.2e-16	Body mass index;
PAAD	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg08514558	chr10:81106712	PPIF	0.47	5.71	0.42	5.77e-8	Height;
PAAD	cis	rs62025270	0.806	rs7173923	chr15:86292471	A/T	cg13263323	chr15:86062960	AKAP13	0.6	5.64	0.42	8.17e-8	Idiopathic pulmonary fibrosis;
PAAD	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.54	-6.26	-0.45	3.75e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-4.91	-0.37	2.35e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.71	8.24	0.56	7.46e-14	Colorectal cancer;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs3818285	1.000	rs3740138	chr10:111630931	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.75	-7.58	-0.52	3.17e-12	Superior crus of antihelix expression;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26900034	chr2:88355166	KRCC1	-0.64	-6.36	-0.46	2.28e-9	Primary biliary cholangitis;
PAAD	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.42	-0.4	2.26e-7	Schizophrenia;
PAAD	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg23995914	chr4:10459228	ZNF518B	-0.37	-4.49	-0.34	1.38e-5	Schizophrenia (age at onset);
PAAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08284150	chr5:111094830	C5orf13	-0.6	-6.44	-0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9549260	0.753	rs61963264	chr13:41154792	G/A	cg21288729	chr13:41239152	FOXO1	0.59	4.83	0.36	3.34e-6	Red blood cell count;
PAAD	cis	rs9568281	0.786	rs61961440	chr13:50163822	C/T	cg17099306	chr13:50123645	RCBTB1	0.92	4.59	0.35	9.19e-6	Multiple sclerosis;
PAAD	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg01798341	chr17:80842262	TBCD	0.41	4.57	0.35	9.89e-6	Breast cancer;
PAAD	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg14631576	chr9:95140430	CENPP	-0.47	-4.56	-0.35	1.05e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs988913	0.957	rs2064432	chr6:54782652	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25833597	chr17:30823145	MYO1D	0.55	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs17407555	0.710	rs7696388	chr4:10272933	T/A	cg00071950	chr4:10020882	SLC2A9	0.44	4.58	0.35	9.43e-6	Schizophrenia (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27405321	chr20:34359917	PHF20	-0.63	-6.55	-0.47	8.51e-10	Smoking initiation;
PAAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.43	-5.69	-0.42	6.47e-8	Alcohol dependence;
PAAD	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	5.25	0.39	4.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	5.97	0.44	1.62e-8	Body mass index;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	5.98	0.44	1.5e-8	Platelet count;
PAAD	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.15	-0.45	6.43e-9	Lung cancer;
PAAD	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg25418670	chr11:30344373	C11orf46	0.59	5.74	0.42	4.9e-8	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg24829409	chr8:58192753	C8orf71	-0.91	-8.1	-0.55	1.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.62	-5.84	-0.43	3.03e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs375066	0.935	rs417699	chr19:44417575	A/G	cg08633290	chr19:44405433	NA	-0.59	-5.93	-0.43	1.99e-8	Breast cancer;
PAAD	cis	rs3731896	0.615	rs80322301	chr2:220173501	C/A	cg04062965	chr2:219188029	PNKD	0.72	4.46	0.34	1.57e-5	Educational attainment;
PAAD	cis	rs12304921	0.810	rs73090660	chr12:51355161	A/G	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.31	-0.33	2.91e-5	Type 2 diabetes;
PAAD	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.78	-8.72	-0.58	4.49e-15	Multiple sclerosis;
PAAD	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.85	8.35	0.56	4e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg17960426	chr8:142067321	NA	-0.62	-5.27	-0.39	4.58e-7	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.38	-5.49	-0.41	1.62e-7	Breast cancer;
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01765077	chr12:122356316	WDR66	0.61	6.29	0.45	3.27e-9	Mean corpuscular volume;
PAAD	cis	rs2286492	0.655	rs117841439	chr7:22910541	C/T	cg04907244	chr7:22894795	SNORD93	0.61	4.44	0.34	1.73e-5	Bipolar disorder;
PAAD	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.45	-0.46	1.43e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs9409082	0.699	rs10118978	chr9:108979480	G/A	cg07010948	chr13:79181613	NA	-0.35	-6.65	-0.47	5.02e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22241593	chr17:42083989	NAGS	-0.69	-6.37	-0.46	2.11e-9	Neuroticism;
PAAD	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.53	5.48	0.41	1.7e-7	Male-pattern baldness;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg19337854	chr7:99768885	GPC2	0.52	4.91	0.37	2.36e-6	Platelet count;
PAAD	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg26528668	chr16:1614120	IFT140	0.54	5.2	0.39	6.29e-7	Coronary artery disease;
PAAD	cis	rs6066835	1.000	rs6066833	chr20:47354494	G/C	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg07117364	chr1:16154769	NA	-0.44	-4.33	-0.33	2.73e-5	Dilated cardiomyopathy;
PAAD	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.37	4.55	0.35	1.11e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.97	-13.78	-0.75	1.53e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.88	-0.49	1.48e-10	Response to antipsychotic treatment;
PAAD	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-1.14	-9.67	-0.62	1.6e-17	Blood trace element (Zn levels);
PAAD	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg21226059	chr5:178986404	RUFY1	0.44	4.35	0.33	2.44e-5	Lung cancer;
PAAD	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.8	-0.36	3.71e-6	Joint mobility (Beighton score);
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.26e-6	Prostate cancer;
PAAD	cis	rs300774	0.925	rs300721	chr2:134436	A/T	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.81	-9.04	-0.59	6.8e-16	Idiopathic membranous nephropathy;
PAAD	cis	rs11702148	0.552	rs3787708	chr21:34906039	C/T	cg14850771	chr21:34775459	IFNGR2	0.44	4.56	0.35	1.03e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.26	-0.33	3.55e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22509189	chr2:225307070	NA	-0.48	-4.49	-0.34	1.39e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73416724	1.000	rs112472472	chr6:43279276	G/A	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.05	6.99	0.49	8.16e-11	Body mass index;
PAAD	cis	rs1519814	0.654	rs6469882	chr8:121010471	A/G	cg22335954	chr8:121166405	COL14A1	-0.64	-4.9	-0.37	2.39e-6	Breast cancer;
PAAD	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.74e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.36	-4.6	-0.35	8.83e-6	Menarche (age at onset);
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.51	4.97	0.37	1.79e-6	Pancreatic cancer;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.75	-8.4	-0.56	2.96e-14	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13518366	chr19:55417390	NCR1	-0.56	-6.6	-0.47	6.43e-10	Obesity-related traits;
PAAD	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.6	-6.11	-0.44	7.95e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-5.04	-0.38	1.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs59191668	0.834	rs2053154	chr15:62820239	A/T	cg12918536	chr15:62891943	NA	0.35	4.64	0.35	7.45e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg23587288	chr2:27483067	SLC30A3	-0.84	-7.32	-0.51	1.31e-11	Blood metabolite levels;
PAAD	cis	rs2000999	0.514	rs35223533	chr16:72252544	A/T	cg00207534	chr16:71929512	KIAA0174	0.71	4.36	0.33	2.37e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg11250194	chr11:61601937	FADS2	-0.52	-4.71	-0.36	5.47e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs6834538	0.577	rs13106473	chr4:113542066	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.13	0.38	8.57e-7	Free thyroxine concentration;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05434287	chr7:2030229	MAD1L1	0.41	4.58	0.35	9.8200000000000008e-06	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1113500	0.580	rs1781058	chr1:108564059	C/G	cg06207961	chr1:108661230	NA	0.49	5.43	0.4	2.21e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.6	5.72	0.42	5.37e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs62283056	1.000	rs62283056	chr4:6276630	G/C	cg00701064	chr4:6280414	WFS1	-0.57	-4.36	-0.33	2.37e-5	Cisplatin-induced ototoxicity;
PAAD	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs1816752	0.669	rs7984513	chr13:25019255	A/G	cg02811702	chr13:24901961	NA	-0.46	-4.56	-0.35	1.04e-5	Obesity-related traits;
PAAD	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg00531865	chr16:30841666	NA	0.5	4.82	0.36	3.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.66	-0.35	6.84e-6	Mean corpuscular volume;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14095283	chr1:230513277	PGBD5	-0.64	-6.38	-0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs797680	0.856	rs6703310	chr1:93788740	A/C	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs17641971	0.862	rs341817	chr8:50023600	A/C	cg00325661	chr8:49890786	NA	-0.54	-5.17	-0.39	7.43e-7	Blood metabolite levels;
PAAD	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.4	-4.96	-0.37	1.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg16576597	chr16:28551801	NUPR1	0.63	6.8	0.48	2.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.53	-5.52	-0.41	1.42e-7	Post bronchodilator FEV1;
PAAD	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg10820045	chr2:198174542	NA	-0.46	-4.64	-0.35	7.62e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.75	7.08	0.5	5.01e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.58	4.88	0.37	2.6e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg25833597	chr17:30823145	MYO1D	0.52	5.04	0.38	1.3e-6	Schizophrenia;
PAAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg14829360	chr17:73884958	NA	-0.68	-5.95	-0.43	1.82e-8	Psoriasis;
PAAD	cis	rs987724	0.738	rs2321297	chr3:156680113	G/A	cg03445587	chr3:156544078	LEKR1	-0.47	-4.29	-0.33	3.19e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7550636	1.000	rs7534380	chr1:192805990	C/T	cg05576974	chr1:193028138	TROVE2;UCHL5	0.46	4.27	0.33	3.49e-5	Coronary artery calcification;
PAAD	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.45	-4.6	-0.35	8.75e-6	Personality dimensions;
PAAD	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.78	-7.59	-0.52	3.01e-12	Vitamin D levels;
PAAD	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.77	9.0	0.59	8.7e-16	Blood metabolite ratios;
PAAD	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg11204139	chr17:3907470	NA	0.66	6.83	0.48	1.95e-10	Type 2 diabetes;
PAAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12311346	chr5:56204834	C5orf35	-0.54	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.9	-0.37	2.39e-6	Mean corpuscular volume;
PAAD	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.72	-6.71	-0.48	3.69e-10	Platelet distribution width;
PAAD	cis	rs12949688	0.967	rs2332966	chr17:55819335	T/C	cg12582317	chr17:55822272	NA	0.7	8.59	0.57	9.62e-15	Schizophrenia;
PAAD	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-5.11	-0.38	9.56e-7	Eosinophil percentage of white cells;
PAAD	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Bladder cancer;
PAAD	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.77	-0.36	4.2e-6	Colorectal cancer;
PAAD	cis	rs10090774	0.965	rs7815898	chr8:141876541	C/G	cg02508881	chr8:142216119	NA	0.41	4.33	0.33	2.73e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.6	5.83	0.43	3.24e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26115470	chr1:32757834	HDAC1	0.7	8.0	0.54	2.91e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.62	6.58	0.47	7.16e-10	Morning vs. evening chronotype;
PAAD	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.0	-0.38	1.57e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs7260329	0.713	rs4803414	chr19:41486082	T/C	cg04530860	chr19:41870213	B9D2;TMEM91	-0.51	-4.37	-0.33	2.25e-5	Smoking behavior;
PAAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg05110241	chr16:68378359	PRMT7	-1.11	-7.76	-0.53	1.15e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.25e-9	Lymphocyte counts;
PAAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg00922110	chr4:57842668	C4orf14	-0.45	-4.56	-0.35	1.06e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs16975963	0.644	rs12462505	chr19:38138125	C/G	cg14218481	chr19:38281219	NA	0.43	4.58	0.35	9.45e-6	Longevity;
PAAD	cis	rs6066835	1.000	rs3817991	chr20:47296365	G/C	cg18078177	chr20:47281410	PREX1	0.99	4.7	0.36	5.72e-6	Multiple myeloma;
PAAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs4743820	0.651	rs4744036	chr9:93932466	G/A	cg14446406	chr9:93919335	NA	-0.52	-6.4	-0.46	1.79e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs367943	0.608	rs4705563	chr5:112979539	T/C	cg12552261	chr5:112820674	MCC	0.55	5.85	0.43	2.85e-8	Type 2 diabetes;
PAAD	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.71	7.62	0.53	2.6e-12	Response to antipsychotic treatment;
PAAD	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-11.06	-0.67	3.07e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.36	-4.37	-0.33	2.31e-5	Electrocardiographic conduction measures;
PAAD	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.57	5.06	0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg14191688	chr11:70257035	CTTN	0.68	5.49	0.41	1.64e-7	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg09579323	chr1:150459698	TARS2	0.45	4.28	0.33	3.25e-5	Migraine;
PAAD	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.72	0.36	5.37e-6	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg04160749	chr8:58172571	NA	-0.65	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3204270	0.759	rs77740144	chr17:79608968	G/A	cg18367735	chr17:79674897	NA	0.9	6.31	0.46	2.86e-9	Dental caries;
PAAD	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg19792802	chr11:65647270	CTSW	0.36	4.62	0.35	8.13e-6	DNA methylation (variation);
PAAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.61	4.89	0.37	2.57e-6	Vitiligo;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17357984	chr19:532039	CDC34	0.6	6.85	0.49	1.74e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.69	4.94	0.37	2.01e-6	Tuberculosis;
PAAD	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.18	19.19	0.84	1.9e-42	Platelet distribution width;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.77	7.06	0.5	5.54e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18337363	chr3:52569053	NT5DC2	-0.42	-4.62	-0.35	8.09e-6	Electroencephalogram traits;
PAAD	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	0.92	6.21	0.45	4.88e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs13242816	1.000	rs62471198	chr7:116107963	T/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07504288	chr2:175870204	CHN1	0.62	6.8	0.48	2.24e-10	Myopia (pathological);
PAAD	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg07283582	chr17:63770753	CCDC46	-0.57	-6.67	-0.48	4.36e-10	Total body bone mineral density;
PAAD	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	19.14	0.84	2.42e-42	IgG glycosylation;
PAAD	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.69	-6.81	-0.48	2.17e-10	Blood metabolite levels;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.61	0.35	8.63e-6	Electroencephalogram traits;
PAAD	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg26031613	chr14:104095156	KLC1	-0.44	-4.41	-0.34	1.96e-5	Coronary artery disease;
PAAD	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.74	-5.04	-0.38	1.33e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9463078	0.605	rs3799981	chr6:44882380	T/A	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs308971	0.803	rs310760	chr3:12220535	C/T	cg03310376	chr3:12229001	SYN2	-0.5	-4.33	-0.33	2.66e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg26205652	chr12:48591994	NA	0.96	10.21	0.64	5.86e-19	Longevity (90 years and older);
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08048268	chr3:133502702	NA	-0.53	-6.23	-0.45	4.28e-9	Iron status biomarkers;
PAAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.64	-8.38	-0.56	3.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.83	7.87	0.54	6.17e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg12092346	chr18:77659572	KCNG2	-0.66	-4.71	-0.36	5.52e-6	Opioid sensitivity;
PAAD	cis	rs2952768	1.000	rs2709386	chr2:208497034	G/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.41	0.34	1.96e-5	Opioid sensitivity;
PAAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg03714773	chr7:91764589	CYP51A1	0.34	4.74	0.36	4.79e-6	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25726414	chr10:21785708	C10orf114;MIR1915	-0.72	-6.36	-0.46	2.2e-9	Neuroticism;
PAAD	cis	rs73394838	0.590	rs8138165	chr22:30167343	C/A	cg14926439	chr22:29999402	NF2	-0.88	-4.37	-0.33	2.25e-5	Telomere length;
PAAD	cis	rs8005172	0.750	rs8009445	chr14:88455786	C/G	cg18078958	chr14:88630771	NA	0.46	5.45	0.4	1.94e-7	Parkinson's disease;
PAAD	cis	rs1692580	0.807	rs12040414	chr1:2192948	T/C	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.86	-0.37	2.92e-6	Coronary artery disease;
PAAD	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	4.96	0.37	1.9e-6	Systolic blood pressure;
PAAD	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.45	-0.34	1.66e-5	Educational attainment;
PAAD	cis	rs2885056	0.891	rs73018644	chr19:10689015	A/C	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg27029450	chr22:50098074	NA	0.68	4.82	0.36	3.52e-6	Natriuretic peptide levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17108838	chr11:10327138	ADM	0.61	7.13	0.5	3.87e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.91	6.97	0.49	9.21e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.52	4.3	0.33	3.08e-5	Red blood cell count;
PAAD	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	1.02	10.77	0.66	1.84e-20	Menarche (age at onset);
PAAD	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.84	-8.8	-0.58	2.83e-15	Obesity-related traits;
PAAD	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.05	-0.38	1.24e-6	Systolic blood pressure;
PAAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.07	0.38	1.15e-6	Schizophrenia;
PAAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs11700980	0.551	rs2832013	chr21:30110940	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.51	-4.36	-0.33	2.43e-5	Cocaine dependence;
PAAD	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg10072921	chr12:121022843	NA	0.44	5.34	0.4	3.33e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg14709524	chr16:89940631	TCF25	0.95	4.37	0.33	2.27e-5	Skin colour saturation;
PAAD	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.83	9.65	0.62	1.74e-17	Blood metabolite ratios;
PAAD	cis	rs412658	0.504	rs369128	chr19:22107866	A/T	cg07498013	chr19:22123504	NA	-0.42	-4.52	-0.34	1.23e-5	Telomere length;
PAAD	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.62	-5.17	-0.39	7.17e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg18721089	chr20:30220636	NA	-0.79	-5.94	-0.43	1.85e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.6	6.45	0.46	1.38e-9	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg00431813	chr7:1051703	C7orf50	0.55	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-5.72	-0.42	5.45e-8	Vitiligo;
PAAD	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.55	5.16	0.39	7.67e-7	Resting heart rate;
PAAD	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg15145965	chr22:50218605	BRD1	0.62	5.38	0.4	2.75e-7	Schizophrenia;
PAAD	cis	rs7326068	0.558	rs4770071	chr13:21330883	C/G	cg27234864	chr13:21295941	IL17D	0.58	4.79	0.36	3.85e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.88	11.21	0.67	1.22e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg27499820	chr13:21296301	IL17D	0.58	5.51	0.41	1.53e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-8.04	-0.55	2.4e-13	Lung cancer in ever smokers;
PAAD	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.49	-0.34	1.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.55	8.18	0.55	1.03e-13	Temperament;
PAAD	cis	rs6466055	0.636	rs12155184	chr7:104941798	G/A	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.64	5.6	0.41	9.81e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.49	4.94	0.37	2.05e-6	Height;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.65	4.34	0.33	2.54e-5	Systolic blood pressure;
PAAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg07622451	chr1:3079886	PRDM16	-0.38	-4.65	-0.35	7.14e-6	Migraine;
PAAD	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.5	4.81	0.36	3.54e-6	Longevity;Endometriosis;
PAAD	cis	rs7627468	1.000	rs1354159	chr3:121941456	C/T	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	7.98e-6	Kidney stones;
PAAD	cis	rs9535307	0.929	rs9535316	chr13:50312397	G/A	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	5.35	0.4	3.12e-7	Educational attainment (years of education);
PAAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg24253500	chr15:84953950	NA	0.54	6.22	0.45	4.67e-9	Schizophrenia;
PAAD	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs8032158	1.000	rs8029247	chr15:56273446	C/T	cg02198044	chr15:56286336	NEDD4	0.54	5.53	0.41	1.39e-7	Keloid;
PAAD	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.51	5.11	0.38	9.43e-7	Longevity;Endometriosis;
PAAD	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg20607287	chr7:12443886	VWDE	-0.58	-4.71	-0.36	5.63e-6	Coronary artery disease;
PAAD	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg06728252	chr6:26598149	ABT1	0.36	4.28	0.33	3.27e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	cis	rs11807834	0.522	rs910500	chr1:230244458	A/G	cg09847368	chr1:230250326	GALNT2	-0.69	-8.44	-0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg09168692	chr1:7887560	PER3	0.42	4.4	0.34	2e-5	Inflammatory bowel disease;
PAAD	cis	rs10140922	1.000	rs4982267	chr14:35828489	T/C	cg03549618	chr14:35838977	NA	-0.41	-4.29	-0.33	3.14e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01066212	chr17:40729653	PSMC3IP	0.63	6.88	0.49	1.47e-10	Myopia (pathological);
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.82	5.91	0.43	2.16e-8	Diisocyanate-induced asthma;
PAAD	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.52	-5.15	-0.39	8.02e-7	Motion sickness;
PAAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.3	0.68	7.09e-22	Menopause (age at onset);
PAAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.7	7.93	0.54	4.48e-13	Melanoma;
PAAD	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-5.93	-0.43	1.96e-8	Coronary artery disease;
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.58	-6.82	-0.48	2.04e-10	Aortic root size;
PAAD	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.63	6.6	0.47	6.46e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.49	-4.25	-0.33	3.66e-5	Asthma;
PAAD	cis	rs9463078	0.528	rs12208023	chr6:45024687	T/C	cg25276700	chr6:44698697	NA	0.45	5.04	0.38	1.31e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.62	5.65	0.42	7.55e-8	Schizophrenia;
PAAD	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-1.01	-9.15	-0.6	3.55e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg04106633	chr4:1044584	NA	0.68	5.81	0.43	3.52e-8	Recombination rate (females);
PAAD	cis	rs501120	0.584	rs674746	chr10:44733522	A/T	cg09554077	chr10:44749378	NA	0.45	5.26	0.39	4.92e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-1.09	-11.65	-0.69	8.08e-23	Longevity;
PAAD	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg12310025	chr6:25882481	NA	0.44	4.32	0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg14851346	chr12:38532713	NA	-0.45	-4.27	-0.33	3.37e-5	Bladder cancer;
PAAD	cis	rs8016947	0.583	rs7140505	chr14:35830213	C/G	cg03549618	chr14:35838977	NA	0.45	4.79	0.36	3.95e-6	Psoriasis;
PAAD	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.54e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.6	7.17	0.5	3.12e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.93	0.49	1.14e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg21493583	chr2:46842958	PIGF;CRIPT	0.32	4.31	0.33	2.88e-5	Height;
PAAD	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.74e-7	Body mass index;
PAAD	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.48	5.16	0.39	7.7e-7	Parental longevity (combined parental age at death);
PAAD	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-5.49	-0.41	1.66e-7	Schizophrenia;
PAAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.61	-6.87	-0.49	1.52e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg24330906	chr2:85765176	MAT2A	0.58	5.75	0.42	4.67e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.54	-4.98	-0.37	1.67e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.59	4.47	0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	1.0	10.27	0.64	3.98e-19	Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg02743256	chr7:2109353	MAD1L1	-0.59	-4.45	-0.34	1.68e-5	Bipolar disorder;
PAAD	cis	rs3748682	0.861	rs28420383	chr1:38346405	T/C	cg12658694	chr1:38397304	INPP5B	0.48	4.48	0.34	1.46e-5	Hypothyroidism;
PAAD	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.97e-6	Neuroticism;
PAAD	cis	rs2249296	0.504	rs6692784	chr1:86794839	C/T	cg17424433	chr1:86913263	CLCA2	0.45	4.26	0.33	3.61e-5	Crohn's disease-related phenotypes;
PAAD	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg00531865	chr16:30841666	NA	-0.64	-5.91	-0.43	2.18e-8	Multiple myeloma;
PAAD	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.68	-0.35	6.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs6681460	0.966	rs7524851	chr1:67093018	T/C	cg02459107	chr1:67143332	SGIP1	0.79	7.81	0.54	8.48e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs10450586	0.932	rs10742172	chr11:27314297	C/T	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs7260329	0.670	rs1872122	chr19:41497997	C/T	cg06653635	chr19:40910092	PRX	-0.49	-4.6	-0.35	8.67e-6	Smoking behavior;
PAAD	cis	rs6942407	0.512	rs1859124	chr7:86747876	C/T	cg02420886	chr7:86849541	C7orf23	-0.66	-4.88	-0.37	2.69e-6	Food allergy;
PAAD	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.64	-6.57	-0.47	7.71e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.55e-6	Skin colour saturation;
PAAD	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.64	0.35	7.48e-6	Body mass index;
PAAD	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.63	0.35	7.86e-6	Iron status biomarkers;
PAAD	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7550636	0.836	rs4140450	chr1:192845807	C/T	cg05576974	chr1:193028138	TROVE2;UCHL5	-0.46	-4.55	-0.35	1.08e-5	Coronary artery calcification;
PAAD	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs593531	0.571	rs10898983	chr11:74093992	C/T	cg15670924	chr11:73669256	DNAJB13	-0.43	-4.46	-0.34	1.55e-5	Neuroticism;
PAAD	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.94	-10.92	-0.66	7.6e-21	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.38	4.91	0.37	2.32e-6	Calcium levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02522952	chr6:119671260	MAN1A1	0.53	6.34	0.46	2.5e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7081476	0.737	rs74544016	chr10:27482395	T/C	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg15693483	chr7:1102177	C7orf50	0.38	4.58	0.35	9.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg02569219	chr17:2266849	SGSM2	0.46	4.64	0.35	7.39e-6	Autism spectrum disorder;
PAAD	cis	rs10878977	0.542	rs9645827	chr12:69814495	G/A	cg13322954	chr12:69198953	NA	0.68	4.32	0.33	2.79e-5	Colorectal cancer;
PAAD	cis	rs9398803	0.687	rs1826189	chr6:126922214	C/T	cg19875578	chr6:126661172	C6orf173	0.45	4.62	0.35	7.98e-6	Male-pattern baldness;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.51e-9	Bipolar disorder;
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.49e-12	Aortic root size;
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24432295	chr17:70101836	NA	0.54	5.33	0.4	3.54e-7	Smoking initiation;
PAAD	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg08917208	chr2:24149416	ATAD2B	0.5	4.5	0.34	1.32e-5	Asthma;
PAAD	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-4.36	-0.33	2.39e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg03315344	chr16:75512273	CHST6	0.57	4.82	0.36	3.39e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2271001	0.759	rs12801321	chr11:19181590	A/G	cg00161556	chr11:19138045	ZDHHC13	0.54	5.95	0.43	1.8e-8	Gut microbiome composition (winter);
PAAD	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs11828289	0.660	rs17306433	chr11:23223034	C/G	cg20040320	chr11:23191996	NA	-0.77	-5.45	-0.4	2e-7	Cancer;
PAAD	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg19000871	chr14:103996768	TRMT61A	-0.56	-6.0	-0.44	1.36e-8	Coronary artery disease;
PAAD	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.53	0.41	1.39e-7	Cognitive test performance;
PAAD	cis	rs881827	0.888	rs3804040	chr21:48015322	C/G	cg11766577	chr21:47581405	C21orf56	-0.41	-4.33	-0.33	2.74e-5	Lymphocyte counts;
PAAD	cis	rs338389	0.516	rs7359201	chr15:68313749	T/C	cg09788352	chr15:68522666	CLN6	0.35	4.37	0.33	2.28e-5	Survival in rectal cancer;
PAAD	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg26138144	chr22:38071188	LGALS1	0.41	4.61	0.35	8.54e-6	Fat distribution (HIV);
PAAD	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.68	0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.22	0.6	2.27e-16	Menopause (age at onset);
PAAD	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg08079166	chr15:68083412	MAP2K5	0.68	5.33	0.4	3.53e-7	Restless legs syndrome;
PAAD	cis	rs3812111	0.525	rs2232472	chr6:116574455	G/A	cg18764771	chr6:116381957	FRK	-0.27	-4.28	-0.33	3.3e-5	Age-related macular degeneration;
PAAD	cis	rs2882667	0.690	rs11954103	chr5:138269148	G/A	cg09476006	chr5:138032270	NA	0.44	5.45	0.4	1.96e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg08992911	chr2:238395768	MLPH	0.73	5.42	0.4	2.3e-7	Prostate cancer;
PAAD	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg13002189	chr3:66846049	NA	0.57	5.53	0.41	1.35e-7	Type 2 diabetes;
PAAD	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg07636037	chr3:49044803	WDR6	-0.56	-4.33	-0.33	2.64e-5	Menarche (age at onset);
PAAD	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.28	-0.56	5.78e-14	Hemoglobin concentration;
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg04257695	chr17:30186438	C17orf79	-0.63	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.15	17.63	0.82	1.39e-38	Multiple myeloma;
PAAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg05134918	chr12:132603531	EP400NL	-0.61	-5.08	-0.38	1.09e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.54	5.08	0.38	1.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.55	6.04	0.44	1.16e-8	Major depressive disorder;
PAAD	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.14	-0.55	1.3e-13	Brugada syndrome;
PAAD	cis	rs7561149	0.527	rs2366912	chr2:179693712	A/C	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.52	-4.47	-0.34	1.54e-5	QT interval;
PAAD	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-1.25	-13.87	-0.75	8.91e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs4938096	0.661	rs57482688	chr11:114211014	A/C	cg00557402	chr11:114466517	FAM55D	0.71	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.44	-5.87	-0.43	2.69e-8	White blood cell count;
PAAD	cis	rs17021463	0.673	rs57939388	chr4:95282365	A/G	cg11021082	chr4:95130006	SMARCAD1	0.57	5.82	0.43	3.3e-8	Testicular germ cell tumor;
PAAD	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg24585817	chr7:64895279	NA	-0.44	-4.45	-0.34	1.68e-5	Aortic root size;
PAAD	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.02	0.38	1.46e-6	Educational attainment;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg03651054	chr13:50194643	NA	0.39	5.44	0.4	2.07e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg27094323	chr7:1216898	NA	-0.4	-4.5	-0.34	1.35e-5	Longevity;Endometriosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25110239	chr10:75538458	NA	-0.54	-6.43	-0.46	1.55e-9	Monocyte percentage of white cells;
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg03094675	chr11:5960213	NA	-0.48	-4.47	-0.34	1.52e-5	DNA methylation (variation);
PAAD	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.9	7.16	0.5	3.16e-11	Blood protein levels;
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.41	-0.4	2.38e-7	Initial pursuit acceleration;
PAAD	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs13065560	0.594	rs7620018	chr3:38886649	C/T	cg01426195	chr3:39028469	NA	-0.57	-5.91	-0.43	2.18e-8	Interleukin-18 levels;
PAAD	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.35	12.77	0.72	7.83e-26	Corneal structure;
PAAD	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.83	9.35	0.6	1.08e-16	Ulcerative colitis;
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.96	-7.65	-0.53	2.08e-12	Initial pursuit acceleration;
PAAD	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg21918786	chr6:109611834	NA	-0.42	-4.56	-0.35	1.03e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9398803	0.678	rs9375448	chr6:126896782	A/T	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	1.03	4.76	0.36	4.48e-6	Blood metabolite levels;
PAAD	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs2492906	0.515	rs2815565	chr10:27982296	G/A	cg25523538	chr10:28031957	MKX	0.51	4.35	0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8112211	0.731	rs118185142	chr19:38821709	G/A	cg14299480	chr19:38876666	GGN	-0.62	-6.07	-0.44	9.63e-9	Blood protein levels;
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.66	-7.4	-0.51	8.76e-12	Body mass index;
PAAD	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.96	6.16	0.45	6.24e-9	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg12757816	chr2:10669957	NA	0.55	5.97	0.44	1.59e-8	Prostate cancer;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg16850897	chr7:100343110	ZAN	-0.7	-5.85	-0.43	2.95e-8	Other erythrocyte phenotypes;
PAAD	cis	rs758324	0.773	rs804058	chr5:131266362	T/C	cg06307176	chr5:131281290	NA	-0.55	-4.7	-0.36	5.89e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-1.04	-12.46	-0.71	5.27e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62264129	0.500	rs62278765	chr3:112024739	A/G	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.9	-0.37	2.4e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	trans	rs11794666	0.872	rs288903	chr9:31713315	C/T	cg05628366	chr6:35744188	C6orf126	-0.96	-6.46	-0.46	1.37e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4742903	0.935	rs1507515	chr9:106989653	A/G	cg14250997	chr9:106856677	SMC2	-0.43	-4.65	-0.35	7.26e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg04810063	chr16:88703634	IL17C	-0.54	-4.99	-0.38	1.63e-6	Menopause (age at onset);
PAAD	cis	rs569214	0.648	rs552536	chr8:27513396	A/G	cg04264299	chr8:27491209	SCARA3	-0.52	-4.74	-0.36	4.89e-6	Alzheimer's disease;
PAAD	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg12310025	chr6:25882481	NA	0.45	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs892512	chr2:198905910	C/A	cg00982548	chr2:198649783	BOLL	-0.64	-4.36	-0.33	2.36e-5	Ulcerative colitis;
PAAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.57	4.76	0.36	4.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.7	0.42	6.02e-8	Prudent dietary pattern;
PAAD	cis	rs1499972	0.887	rs62266061	chr3:117536409	C/T	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	10.15	0.64	8.23e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8112211	0.682	rs11672793	chr19:38827357	T/A	cg14299480	chr19:38876666	GGN	-0.59	-5.85	-0.43	2.89e-8	Blood protein levels;
PAAD	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.6	-5.79	-0.43	3.85e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg21790657	chr18:77675478	PQLC1	0.59	6.48	0.47	1.21e-9	Educational attainment (years of education);
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.76	-8.31	-0.56	5.06e-14	Menopause (age at onset);
PAAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.63	6.34	0.46	2.46e-9	Multiple sclerosis;
PAAD	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.07	-0.77	5.6199999999999995e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg22189786	chr22:42395067	WBP2NL	-0.4	-4.32	-0.33	2.8e-5	Cognitive function;
PAAD	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.59	6.11	0.44	7.87e-9	Lung cancer;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs73419609	1.000	rs8029654	chr15:54736484	T/C	cg11288833	chr15:55489084	RSL24D1	-0.98	-4.29	-0.33	3.22e-5	Post-traumatic stress disorder;
PAAD	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.57	-0.35	9.83e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg16576597	chr16:28551801	NUPR1	0.52	5.76	0.42	4.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4462272	0.605	rs12242503	chr10:102028467	T/C	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.91	10.42	0.65	1.62e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.61	-4.62	-0.35	7.97e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs258892	0.895	rs10072874	chr5:72044283	G/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.44	-0.4	2.08e-7	Small cell lung carcinoma;
PAAD	cis	rs11203032	0.634	rs3802657	chr10:90965708	G/T	cg16672925	chr10:90967113	CH25H	0.79	6.24	0.45	4.15e-9	Heart failure;
PAAD	cis	rs71560490	0.730	rs13244483	chr7:75445848	C/G	cg15798862	chr7:76129360	DTX2	0.62	4.25	0.33	3.71e-5	White blood cell count (basophil);
PAAD	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06307176	chr5:131281290	NA	-0.51	-4.66	-0.35	6.9e-6	Life satisfaction;
PAAD	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2017305	0.915	rs76725293	chr10:70722122	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.73	-9.16	-0.6	3.3e-16	Dental caries;
PAAD	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg01176363	chr20:62369445	LIME1	-0.58	-5.67	-0.42	6.97e-8	Prostate cancer;
PAAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.48	10.32	0.64	3.02e-19	Opioid sensitivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18762736	chr1:145549283	ANKRD35	0.59	6.36	0.46	2.3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7804356	0.651	rs763616	chr7:26784600	T/A	cg03456212	chr7:26904342	SKAP2	0.58	5.02	0.38	1.42e-6	Type 1 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10654496	chr10:118609261	NA	0.58	7.16	0.5	3.16e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2718812	1.000	rs2718812	chr3:133399702	C/T	cg12372414	chr3:134319805	KY	-0.41	-4.48	-0.34	1.44e-5	Iron status biomarkers;
PAAD	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.61	-0.41	9.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16298238	chr2:179343258	FKBP7;MIR548N	0.64	6.66	0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.66e-5	Life satisfaction;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23797200	chr17:40174494	NKIRAS2	0.53	6.32	0.46	2.72e-9	Body fat percentage;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02423659	chr4:871439	GAK	0.63	6.32	0.46	2.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.77	7.62	0.53	2.49e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	4.91	0.37	2.34e-6	Neuroticism;
PAAD	cis	rs28493229	0.708	rs10425069	chr19:41152847	C/T	cg21869046	chr19:41225005	ITPKC	0.51	5.33	0.4	3.46e-7	Kawasaki disease;
PAAD	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6882716	0.534	rs7719906	chr5:10809586	G/A	cg14521931	chr5:10832172	NA	-0.87	-6.06	-0.44	1.01e-8	Alcohol consumption (maxi-drinks);
PAAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.93	-7.96	-0.54	3.61e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg06437144	chr17:45973627	SP2	-0.76	-7.25	-0.51	2e-11	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.56	-0.57	1.17e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4965359	0.665	rs11853661	chr15:101598314	C/T	cg02262866	chr15:101593693	LRRK1	0.47	4.43	0.34	1.83e-5	Central corneal thickness;
PAAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg05341575	chr12:125625032	AACS	-0.47	-4.49	-0.34	1.41e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-6.48	-0.47	1.23e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.85	10.3	0.64	3.33e-19	Lung cancer;
PAAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg02389323	chr16:88786976	FAM38A	0.9	4.78	0.36	4.02e-6	Plateletcrit;
PAAD	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.22	5.89	0.43	2.4e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg06637938	chr14:75390232	RPS6KL1	0.45	4.37	0.33	2.31e-5	Height;
PAAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg15908580	chr10:134496731	INPP5A	-0.53	-4.5	-0.34	1.35e-5	Primary sclerosing cholangitis;
PAAD	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	1.08	8.77	0.58	3.43e-15	Post bronchodilator FEV1;
PAAD	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs4704187	0.663	rs4404659	chr5:74422119	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	5.98	0.44	1.5e-8	Platelet count;
PAAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.24e-6	Tonsillectomy;
PAAD	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg21724239	chr8:58056113	NA	0.67	5.16	0.39	7.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs569214	0.620	rs576029	chr8:27513480	G/A	cg04264299	chr8:27491209	SCARA3	0.52	4.75	0.36	4.64e-6	Alzheimer's disease;
PAAD	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.63	0.35	7.73e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21793857	chr7:43966216	URGCP;UBE2D4	0.61	7.11	0.5	4.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10512697	0.772	rs62336081	chr5:3528961	G/A	cg19473799	chr5:3511975	NA	-1.02	-4.55	-0.35	1.09e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs300774	0.925	rs384286	chr2:128345	C/T	cg23649280	chr2:140451	NA	-0.44	-4.32	-0.33	2.84e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-1.25	-6.12	-0.44	7.67e-9	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73019876	0.869	rs6511305	chr19:22162924	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9810890	1.000	rs73198886	chr3:128546420	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	14.27	0.76	7.63e-30	Schizophrenia;
PAAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg03538708	chr1:25844672	NA	-0.53	-5.4	-0.4	2.52e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg13446199	chr8:143762866	PSCA	0.37	4.36	0.33	2.34e-5	Urinary tract infection frequency;
PAAD	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.19	-0.39	6.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg12046867	chr14:103022105	NA	-0.66	-5.39	-0.4	2.69e-7	Platelet count;
PAAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg25837213	chr17:80849375	TBCD	-0.52	-4.79	-0.36	3.96e-6	Breast cancer;
PAAD	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.38	-0.33	2.22e-5	Tuberculosis;
PAAD	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg17270257	chr6:166074870	PDE10A	0.34	4.26	0.33	3.56e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9463078	0.528	rs1284992	chr6:45071144	C/A	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg12310025	chr6:25882481	NA	0.46	4.56	0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs35000415	0.938	rs17424602	chr7:128687940	A/G	cg19972273	chr7:128594194	NA	0.9	5.45	0.4	1.99e-7	Systemic lupus erythematosus;
PAAD	cis	rs375066	0.762	rs17656688	chr19:44425077	T/C	cg08633290	chr19:44405433	NA	0.5	4.71	0.36	5.65e-6	Breast cancer;
PAAD	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg04415270	chr2:102091202	RFX8	-0.52	-6.47	-0.46	1.24e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg05110241	chr16:68378359	PRMT7	-0.78	-6.34	-0.46	2.55e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.03	-16.67	-0.8	3.81e-36	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.72	-0.53	1.45e-12	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.8	0.66	1.52e-20	Platelet count;
PAAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.46	-4.91	-0.37	2.3e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18007899	chr9:100396413	TSTD2;NCBP1	0.58	6.44	0.46	1.48e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1894633	0.555	rs5029891	chr1:172451759	T/G	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.85	9.41	0.61	7.34e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.43	0.34	1.8e-5	Axial length;
PAAD	cis	rs10214930	0.697	rs1404278	chr7:27634726	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.98	-14.32	-0.76	5.46e-30	Dental caries;
PAAD	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-4.64	-0.35	7.52e-6	Common traits (Other);
PAAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg09526685	chr4:187126073	CYP4V2	0.74	5.93	0.43	1.93e-8	Blood protein levels;
PAAD	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.66	-7.0	-0.49	7.7e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.93e-6	Coronary artery disease;
PAAD	cis	rs10044254	0.563	rs6892021	chr5:15689838	G/T	cg07238450	chr5:15720153	FBXL7	-0.56	-5.22	-0.39	5.76e-7	Asthma (corticosteroid response);
PAAD	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.41	1.1e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs904092	0.592	rs1229969	chr4:100206718	C/T	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24226138	chr2:19562810	NA	0.68	6.64	0.47	5.36e-10	Obesity-related traits;
PAAD	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-5.84	-0.43	2.99e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	6.67	0.48	4.41e-10	Gastritis;
PAAD	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.67	7.66	0.53	2.05e-12	Body mass index;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.89e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-5.01	-0.38	1.48e-6	Axial length;
PAAD	cis	rs11638815	0.626	rs4779041	chr15:83337059	G/A	cg00614314	chr15:82944287	LOC80154	-0.48	-4.77	-0.36	4.28e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.58	7.78	0.53	1.05e-12	IgA nephropathy;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.9	-0.43	2.23e-8	Schizophrenia;
PAAD	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs2327429	0.858	rs12524865	chr6:134196674	C/A	cg06643013	chr6:134217242	NA	0.41	4.51	0.34	1.3e-5	Coronary artery disease;
PAAD	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	4.71	0.36	5.43e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.56	-5.79	-0.43	3.92e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg09796270	chr17:17721594	SREBF1	-0.49	-5.39	-0.4	2.66e-7	Total body bone mineral density;
PAAD	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	8.32	0.56	4.68e-14	Prostate-specific antigen levels;
PAAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs12098973	0.591	rs78493164	chr11:131804530	C/T	cg13055484	chr11:132662455	OPCML	0.51	4.39	0.34	2.08e-5	Cardiac Troponin-T levels;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	1.0	6.53	0.47	9.44e-10	IgG glycosylation;
PAAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.81	7.41	0.52	8.06e-12	Psoriasis;
PAAD	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.65	7.16	0.5	3.2e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.57	-0.35	9.98e-6	Lung cancer in ever smokers;
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.54	-6.51	-0.47	1.04e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg10985347	chr2:127963512	CYP27C1	0.46	4.27	0.33	3.44e-5	Protein C levels;
PAAD	cis	rs28602288	1	rs28602288	chr19:41388740	C/T	cg09508736	chr19:41385865	CYP2A7	-0.46	-4.27	-0.33	3.42e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
PAAD	cis	rs2882667	0.690	rs288042	chr5:138203034	T/G	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.65	-6.09	-0.44	9.01e-9	Corneal astigmatism;
PAAD	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.4	-4.56	-0.35	1.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.56	7.56	0.52	3.64e-12	Renal cell carcinoma;
PAAD	trans	rs61931739	0.574	rs12578378	chr12:33669639	C/G	cg26384229	chr12:38710491	ALG10B	-0.63	-6.35	-0.46	2.31e-9	Morning vs. evening chronotype;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22015966	chr11:47198573	ARFGAP2	0.58	6.68	0.48	4.28e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00166722	chr3:10149974	C3orf24	0.84	7.22	0.51	2.35e-11	Alzheimer's disease;
PAAD	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg08648136	chr8:956695	NA	0.5	5.38	0.4	2.82e-7	Schizophrenia;
PAAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.29	-0.45	3.16e-9	Type 2 diabetes;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg26939375	chr7:64535504	NA	0.72	8.33	0.56	4.35e-14	Calcium levels;
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	5.26	0.39	4.8e-7	Menarche (age at onset);
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.56	5.82	0.43	3.38e-8	Longevity;Endometriosis;
PAAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg21890820	chr11:65308645	LTBP3	0.65	7.8	0.53	8.94e-13	Bone mineral density;
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg26695010	chr11:65641043	EFEMP2	-0.54	-5.17	-0.39	7.21e-7	Eosinophil percentage of white cells;
PAAD	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.73	8.43	0.56	2.44e-14	Metabolic syndrome;
PAAD	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.85	-9.98	-0.63	2.32e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14169450	chr9:139327907	INPP5E	0.58	6.02	0.44	1.28e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg12457986	chr21:27107982	ATP5J;GABPA	0.62	6.78	0.48	2.46e-10	Iris heterochromicity;
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27436995	chr16:743998	FBXL16	-0.37	-4.48	-0.34	1.47e-5	Height;
PAAD	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.12	0.7	4.26e-24	Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10125865	chr2:170683981	UBR3	-0.83	-7.72	-0.53	1.41e-12	Neuroticism;
PAAD	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.45	7.32	0.51	1.33e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-7.43	-0.52	7.35e-12	Renal function-related traits (BUN);
PAAD	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg15017067	chr4:17643749	FAM184B	0.41	4.87	0.37	2.73e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.79	-8.94	-0.59	1.24e-15	DNA methylation (variation);
PAAD	cis	rs6991838	0.725	rs6995134	chr8:66467707	T/C	cg15971335	chr8:66515592	ARMC1	0.44	4.41	0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7727544	0.564	rs3852206	chr5:131415436	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	4.62	0.35	7.98e-6	Blood metabolite levels;
PAAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.69	-0.36	6.11e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.75	-6.3	-0.46	3.06e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.84	-0.66	1.2e-20	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.65	7.13	0.5	3.77e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg03959625	chr15:84868606	LOC388152	-0.42	-4.26	-0.33	3.61e-5	P wave terminal force;
PAAD	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.64	-7.65	-0.53	2.08e-12	Mean arterial pressure;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.91	7.97	0.54	3.57e-13	Alzheimer's disease;
PAAD	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	1.1	12.98	0.72	2.16e-26	Longevity;
PAAD	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs11807834	0.522	rs10489614	chr1:230247369	G/A	cg00566187	chr1:230250356	GALNT2	-0.66	-7.05	-0.5	5.72e-11	Schizophrenia;
PAAD	cis	rs7301016	0.707	rs7302602	chr12:63052199	C/T	cg11441379	chr12:63026424	NA	-0.86	-6.46	-0.46	1.36e-9	IgG glycosylation;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.07	-0.38	1.14e-6	Menarche (age at onset);
PAAD	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.78	-8.86	-0.58	1.94e-15	DNA methylation (variation);
PAAD	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg23024343	chr7:107201750	COG5	0.58	4.72	0.36	5.36e-6	Coronary artery disease;
PAAD	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg23587717	chr6:166797178	BRP44L	-0.62	-6.58	-0.47	7.03e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg06636372	chr16:89349979	ANKRD11	-0.82	-4.84	-0.37	3.19e-6	Red blood cell count;
PAAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.76	7.21	0.5	2.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.585	rs10807319	chr6:45229123	C/G	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.25e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.87	-11.47	-0.68	2.51e-22	Height;
PAAD	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.8	10.41	0.65	1.72e-19	Colorectal cancer;
PAAD	cis	rs1497406	0.772	rs1497407	chr1:16499605	T/C	cg20167471	chr1:16528984	ARHGEF19	0.48	4.72	0.36	5.27e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.6	5.83	0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.65	-0.35	7.3e-6	Ulcerative colitis;
PAAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg14092988	chr3:52407081	DNAH1	0.41	5.29	0.39	4.19e-7	Electroencephalogram traits;
PAAD	cis	rs490234	0.902	rs7853181	chr9:128223024	C/T	cg14078157	chr9:128172775	NA	0.43	4.72	0.36	5.39e-6	Mean arterial pressure;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg09835421	chr16:68378352	PRMT7	-1.1	-8.22	-0.55	8.24e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2286503	0.839	rs2240728	chr7:22852499	C/T	cg04907244	chr7:22894795	SNORD93	-0.39	-4.7	-0.36	5.73e-6	Fibrinogen;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19506755	chr20:54967495	AURKA;CSTF1	-0.72	-6.3	-0.46	3.02e-9	Neuroticism;
PAAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg18302933	chr2:88491318	NA	-0.41	-4.89	-0.37	2.5e-6	Response to metformin (IC50);
PAAD	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg00455402	chr19:21769736	NA	-0.49	-4.36	-0.33	2.37e-5	Pain;
PAAD	cis	rs8099014	0.814	rs9966765	chr18:56116790	C/G	cg12907477	chr18:56117327	MIR122	0.64	4.97	0.37	1.82e-6	Platelet count;
PAAD	cis	rs10267417	0.603	rs4721829	chr7:19873199	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	4.5	0.34	1.32e-5	Night sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14887955	chr3:46651373	NA	-0.66	-6.7	-0.48	3.84e-10	Obesity-related traits;
PAAD	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-4.68	-0.35	6.3e-6	Sitting height ratio;
PAAD	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.74	0.66	2.24e-20	Electrocardiographic conduction measures;
PAAD	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.91	-0.37	2.29e-6	Pulmonary function;
PAAD	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.98	-10.45	-0.65	1.32e-19	Systemic lupus erythematosus;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.77	-7.68	-0.53	1.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	1.08	13.98	0.75	4.55e-29	Breast cancer;
PAAD	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg23860436	chr12:58378763	NA	0.48	4.65	0.35	7.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.85	-9.85	-0.62	5.07e-18	Monocyte count;
PAAD	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.92	0.49	1.15e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.85	0.43	2.9e-8	Breast cancer;
PAAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4629180	0.538	rs6746761	chr2:102122390	G/T	cg01388757	chr2:102091195	RFX8	-0.59	-7.49	-0.52	5.31e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2790216	0.627	rs1769039	chr10:59953829	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.82	-8.83	-0.58	2.41e-15	Mortality in heart failure;
PAAD	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2882667	0.690	rs288029	chr5:138217305	A/G	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.56e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg18105134	chr13:113819100	PROZ	-0.97	-8.12	-0.55	1.49e-13	Platelet distribution width;
PAAD	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.72	6.55	0.47	8.31e-10	Morning vs. evening chronotype;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.89	-13.75	-0.74	1.84e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.47	4.29	0.33	3.16e-5	Arsenic metabolism;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.57	6.67	0.48	4.38e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.57	5.22	0.39	5.75e-7	Common traits (Other);
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.73	-0.48	3.24e-10	Life satisfaction;
PAAD	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.53	-5.5	-0.41	1.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs2006771	0.618	rs470072	chr22:32263131	A/G	cg01338084	chr22:32026380	PISD	0.51	4.78	0.36	4.11e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-4.33	-0.33	2.7e-5	Renal cell carcinoma;
PAAD	cis	rs258892	0.895	rs34252662	chr5:72054308	G/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	trans	rs901683	1.000	rs74411575	chr10:46071967	A/T	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.61	-0.35	8.51e-6	Height;
PAAD	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg24213567	chr19:53496664	ZNF702P	-0.44	-4.56	-0.35	1.05e-5	Psoriasis;
PAAD	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.81	10.1	0.63	1.13e-18	Morning vs. evening chronotype;
PAAD	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg18898632	chr2:242989856	NA	-0.81	-6.03	-0.44	1.22e-8	Obesity-related traits;
PAAD	cis	rs12949688	0.570	rs12600654	chr17:55834916	G/A	cg12582317	chr17:55822272	NA	0.47	5.49	0.41	1.65e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08808811	chr3:184079573	CLCN2	0.58	6.59	0.47	6.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.96	-6.42	-0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	-0.51	-4.93	-0.37	2.17e-6	Trans fatty acid levels;
PAAD	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs10214930	0.781	rs961723	chr7:27657973	G/A	cg22168087	chr7:27702803	HIBADH	0.48	4.3	0.33	3.08e-5	Hypospadias;
PAAD	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13047869	chr3:10149882	C3orf24	0.86	7.13	0.5	3.71e-11	Alzheimer's disease;
PAAD	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.06	-0.55	2.07e-13	Mean corpuscular volume;
PAAD	cis	rs10073892	0.830	rs72777945	chr5:101600283	A/C	cg17280723	chr5:101634495	NA	0.44	4.55	0.35	1.1e-5	Cognitive decline (age-related);
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27395288	chr20:31407532	MAPRE1	0.71	6.86	0.49	1.67e-10	Obesity-related traits;
PAAD	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.65	-6.43	-0.46	1.54e-9	Coronary artery disease or large artery stroke;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18056097	chr20:32441571	CHMP4B	0.59	6.34	0.46	2.53e-9	Smoking initiation;
PAAD	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.22	0.39	5.73e-7	Monocyte percentage of white cells;
PAAD	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.57	4.59	0.35	9.14e-6	Bone mineral density (spine);
PAAD	cis	rs6942407	0.640	rs17698411	chr7:86749197	C/T	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	7.71	0.53	1.51e-12	Alzheimer's disease;
PAAD	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.58	-0.35	9.71e-6	Lung cancer in ever smokers;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.79	-0.36	3.94e-6	Lymphocyte counts;
PAAD	cis	rs2279817	0.820	rs76593741	chr1:18010067	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	cis	rs7487075	0.619	rs10880968	chr12:46822960	C/T	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg04851639	chr8:1020857	NA	-0.65	-8.24	-0.56	7.42e-14	Schizophrenia;
PAAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.86	9.14	0.6	3.81e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.7	-7.32	-0.51	1.32e-11	Body mass index;
PAAD	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.93	-7.78	-0.53	1.05e-12	Dupuytren's disease;
PAAD	cis	rs13418717	1.000	rs7572403	chr2:127662420	G/A	cg16909742	chr2:127635678	NA	0.86	4.29	0.33	3.15e-5	Heart failure;
PAAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.67e-19	Tonsillectomy;
PAAD	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.53	-0.41	1.35e-7	Atrioventricular conduction;
PAAD	cis	rs2252790	1.000	rs12212556	chr6:116613907	A/G	cg26893134	chr6:116381904	FRK	0.27	4.28	0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.09	14.01	0.75	3.69e-29	Schizophrenia;
PAAD	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06307176	chr5:131281290	NA	-0.61	-5.17	-0.39	7.13e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.38	-0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg10207240	chr12:122356781	WDR66	0.53	5.56	0.41	1.17e-7	Mean corpuscular volume;
PAAD	cis	rs863345	0.935	rs10908678	chr1:158506223	A/T	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	1.02e-6	Pneumococcal bacteremia;
PAAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs375066	0.762	rs239938	chr19:44390305	T/C	cg11993925	chr19:44307056	LYPD5	0.51	6.28	0.45	3.33e-9	Breast cancer;
PAAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg14517863	chr17:44321492	NA	-0.41	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7072216	0.687	rs11189586	chr10:100154096	A/G	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08473456	chr1:151032324	MLLT11;CDC42SE1	-0.77	-6.72	-0.48	3.41e-10	Neuroticism;
PAAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14180030	chr9:123475675	MEGF9	-0.43	-4.57	-0.35	1.02e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.81	8.13	0.55	1.43e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg26818257	chr2:241905806	NA	0.45	4.68	0.35	6.43e-6	Joint mobility (Beighton score);
PAAD	trans	rs16966918	0.649	rs1362885	chr13:106259884	C/T	cg11316503	chr17:40949085	NA	1.08	6.64	0.47	5.36e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs11892454	0.515	rs2176180	chr2:26030368	C/T	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13090220	chr12:130338646	TMEM132D	-0.57	-6.41	-0.46	1.69e-9	Obesity-related traits;
PAAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15369054	chr17:80825471	TBCD	-0.65	-5.78	-0.42	4.09e-8	Breast cancer;
PAAD	cis	rs4795519	0.634	rs12453003	chr17:22180392	G/A	cg22648282	chr17:21454238	C17orf51	-0.53	-4.71	-0.36	5.43e-6	Chronic myeloid leukemia;
PAAD	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.68e-8	Schizophrenia;
PAAD	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-5.68	-0.42	6.57e-8	Cognitive test performance;
PAAD	cis	rs2302729	0.578	rs11062299	chr12:2771738	T/C	cg19945202	chr12:2788847	CACNA1C	-0.78	-8.05	-0.55	2.18e-13	Sleep quality;
PAAD	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.55	5.59	0.41	1.01e-7	Testicular germ cell tumor;
PAAD	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.58	-0.35	9.8e-6	Rheumatoid arthritis;
PAAD	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg22467129	chr15:76604101	ETFA	0.51	4.76	0.36	4.39e-6	Blood metabolite levels;
PAAD	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.69	6.84	0.49	1.8e-10	Smoking initiation;
PAAD	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs7577696	0.671	rs13427170	chr2:32398110	C/T	cg02381751	chr2:32503542	YIPF4	-0.42	-4.28	-0.33	3.36e-5	Inflammatory biomarkers;
PAAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1561176	0.540	rs3111876	chr7:154975758	A/G	cg23863891	chr7:155363328	NA	-0.48	-4.56	-0.35	1.06e-5	Personality dimensions;
PAAD	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg04520793	chr17:42248056	ASB16	0.43	4.9	0.37	2.4e-6	Total body bone mineral density;
PAAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg10932868	chr11:921992	NA	0.52	6.26	0.45	3.76e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg12826209	chr6:26865740	GUSBL1	0.82	4.35	0.33	2.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4144027	0.967	rs4900601	chr14:104358076	C/T	cg19582115	chr14:103436037	CDC42BPB	-0.47	-4.48	-0.34	1.47e-5	Blood metabolite levels;
PAAD	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.98	11.64	0.69	8.64e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10046574	0.731	rs17481669	chr7:135193029	G/T	cg27474649	chr7:135195673	CNOT4	0.84	4.39	0.34	2.14e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.84	8.35	0.56	4.02e-14	Cognitive function;
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg01840333	chr6:26225767	HIST1H3E	0.41	4.28	0.33	3.32e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-15.77	-0.79	8.48e-34	Prudent dietary pattern;
PAAD	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.54	5.1	0.38	9.97e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3736485	0.932	rs8037167	chr15:51918126	G/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.34	-0.33	2.55e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg03605463	chr16:89740564	NA	-0.55	-5.32	-0.4	3.67e-7	Vitiligo;
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.71	7.18	0.5	2.86e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.43	4.62	0.35	8.17e-6	Aortic root size;
PAAD	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg21905437	chr5:178450457	ZNF879	0.62	5.2	0.39	6.24e-7	Pubertal anthropometrics;
PAAD	cis	rs2916733	0.530	rs2440423	chr8:6290206	T/C	cg01691696	chr8:6734962	DEFB1	-0.55	-4.74	-0.36	4.83e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs8077059	0.851	rs9905773	chr17:55808064	T/A	cg12582317	chr17:55822272	NA	0.48	4.54	0.35	1.12e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.74	-7.87	-0.54	6.04e-13	Blood metabolite levels;
PAAD	cis	rs89107	0.688	rs372237	chr6:118608979	G/T	cg18833306	chr6:118973337	C6orf204	0.5	5.71	0.42	5.77e-8	Cardiac structure and function;
PAAD	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs7766436	0.922	rs13217043	chr6:22612831	T/A	cg13666174	chr6:22585274	NA	-0.5	-4.56	-0.35	1.03e-5	Coronary artery disease;
PAAD	cis	rs61884328	0.657	rs12578030	chr11:47234601	A/G	cg23433285	chr11:47201945	PACSIN3	0.85	4.48	0.34	1.46e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.83	-6.81	-0.48	2.13e-10	Lung function (FEV1/FVC);
PAAD	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	10.72	0.66	2.48e-20	Chronic sinus infection;
PAAD	cis	rs6041	0.822	rs493833	chr13:113769639	T/G	cg09069900	chr13:113776964	F10	-0.57	-4.83	-0.36	3.27e-6	End-stage coagulation;
PAAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-4.47	-0.34	1.5e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11697226	chr18:59992385	TNFRSF11A	0.66	6.63	0.47	5.66e-10	Obesity-related traits;
PAAD	cis	rs6445525	0.935	rs4688632	chr3:66000290	A/G	cg06109867	chr3:66002991	MAGI1	-0.47	-4.74	-0.36	4.8e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.76	-0.36	4.54e-6	Joint mobility (Beighton score);
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.57	-0.35	9.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs56104184	0.779	rs17206693	chr19:49360252	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.2	-8.74	-0.58	4.12e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	0.82	5.79	0.42	3.96e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03508643	chr3:100428398	TFG	0.6	6.92	0.49	1.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.64	7.05	0.5	6.01e-11	Smoking initiation;
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	5.94	0.43	1.84e-8	Total body bone mineral density;
PAAD	cis	rs11650494	0.710	rs2165701	chr17:47475822	A/G	cg08112188	chr17:47440006	ZNF652	1.48	7.28	0.51	1.68e-11	Prostate cancer;
PAAD	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.6	-0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg21546286	chr11:48923668	NA	0.58	6.09	0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	trans	rs901683	1.000	rs9422652	chr10:46047934	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.1	0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15063753	chr1:145139679	NA	0.64	6.4	0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs72827839	0.779	rs72827808	chr17:46352080	C/A	cg23391107	chr17:45924227	SP6	0.55	5.19	0.39	6.52e-7	Ease of getting up in the morning;
PAAD	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg21479132	chr6:26055353	NA	0.89	4.71	0.36	5.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6563943	0.892	rs8059833	chr16:83639311	C/T	cg01935413	chr16:83636749	CDH13	0.54	4.97	0.37	1.8e-6	Height;
PAAD	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.45	-0.46	1.42e-9	Neuroticism;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.01	0.55	2.71e-13	Alzheimer's disease;
PAAD	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg16586182	chr3:47516702	SCAP	0.65	7.17	0.5	3.1e-11	Colorectal cancer;
PAAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg02887458	chr19:19495540	GATAD2A	-0.5	-4.59	-0.35	9.23e-6	Bipolar disorder;
PAAD	cis	rs1519814	0.696	rs7822000	chr8:121034112	C/G	cg22335954	chr8:121166405	COL14A1	-0.67	-5.12	-0.38	9.04e-7	Breast cancer;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.66	-5.41	-0.4	2.39e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.08	0.59	5.29e-16	Cognitive test performance;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10078703	chr11:35963440	NA	-0.57	-6.54	-0.47	8.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.46	4.76	0.36	4.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2280630	0.529	rs784495	chr3:39178899	C/T	cg01426195	chr3:39028469	NA	0.67	7.08	0.5	4.95e-11	Verbal declarative memory;
PAAD	cis	rs6460942	0.908	rs78780802	chr7:12233216	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24158452	chr17:40428550	STAT5B	0.56	6.31	0.46	2.89e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.7	8.04	0.55	2.3e-13	Bladder cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11836369	chr1:160254759	PEX19	-0.6	-6.43	-0.46	1.53e-9	Smoking initiation;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.82	6.1	0.44	8.29e-9	Alzheimer's disease;
PAAD	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.31	0.46	2.84e-9	Breast cancer;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg26174226	chr8:58114915	NA	-0.57	-4.31	-0.33	2.87e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.86	11.18	0.67	1.49e-21	Subjective well-being (multi-trait analysis);
PAAD	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	1.04	13.25	0.73	4.05e-27	Breast cancer;
PAAD	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	cis	rs2384207	0.789	rs7137793	chr12:113658124	T/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.6	5.47	0.41	1.82e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17655565	0.581	rs74672767	chr12:52764049	C/A	cg22980804	chr12:52818037	KRT75	-0.49	-4.35	-0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.58	5.66	0.42	7.42e-8	Caffeine consumption;
PAAD	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.61	6.77	0.48	2.66e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.31	-0.33	2.92e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.57e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12292205	chr6:26970375	C6orf41	-0.57	-5.05	-0.38	1.24e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg02440177	chr19:53496695	ZNF702P	-0.64	-6.69	-0.48	3.93e-10	Psoriasis;
PAAD	cis	rs2594989	0.943	rs6442251	chr3:11417477	A/G	cg01796438	chr3:11312864	ATG7	-0.62	-4.86	-0.37	2.84e-6	Circulating chemerin levels;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg10467557	chr13:21893662	NA	-0.43	-4.8	-0.36	3.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs375066	0.901	rs372491	chr19:44401793	G/A	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.46	4.88	0.37	2.71e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.24	-0.67	1.01e-21	Chronic sinus infection;
PAAD	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs17601876	0.807	rs4545755	chr15:51549044	G/A	cg21478137	chr15:51532386	CYP19A1	0.43	4.25	0.33	3.77e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.51	5.54	0.41	1.32e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4843747	0.749	rs8053309	chr16:88044980	G/A	cg17633681	chr16:88106987	BANP	0.5	5.73	0.42	5.29e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.83	0.62	5.85e-18	Prudent dietary pattern;
PAAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.06	0.38	1.2e-6	Rheumatoid arthritis;
PAAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.98	-7.36	-0.51	1.09e-11	Multiple sclerosis;
PAAD	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.76	8.7	0.58	5.09e-15	Heart rate;
PAAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.52	5.06	0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11056409	chr2:9143142	MBOAT2	-0.65	-6.56	-0.47	7.96e-10	Smoking initiation;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.7	8.1	0.55	1.68e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg13452994	chr2:3699195	NA	-0.46	-4.64	-0.35	7.46e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14180030	chr9:123475675	MEGF9	-0.44	-4.84	-0.37	3.19e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.92	7.7	0.53	1.62e-12	Triglycerides;
PAAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.27	-0.33	3.38e-5	Blood metabolite levels;
PAAD	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.88	8.59	0.57	9.43e-15	Eosinophil percentage of granulocytes;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26418147	chr1:205743515	RAB7L1	-0.5	-5.98	-0.44	1.53e-8	Menarche (age at onset);
PAAD	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.37e-6	Type 2 diabetes;
PAAD	cis	rs12041331	1.000	rs12041331	chr1:156869714	C/T	cg00353407	chr1:156974025	ARHGEF11	0.6	4.53	0.35	1.18e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs2637266	0.599	rs2395425	chr10:78461920	C/T	cg18941641	chr10:78392320	NA	0.36	4.38	0.33	2.19e-5	Pulmonary function;
PAAD	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-4.41	-0.34	1.91e-5	Height;
PAAD	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-5.4	-0.4	2.48e-7	Total body bone mineral density;
PAAD	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.94	9.83	0.62	5.95e-18	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15094104	chr5:133406808	NA	0.59	6.65	0.47	5.04e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8105895	0.935	rs10406119	chr19:22245009	C/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	7.88	0.54	5.82e-13	Menopause (age at onset);
PAAD	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.9	-0.54	5.35e-13	Neuroticism;
PAAD	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg26924012	chr15:45694286	SPATA5L1	0.47	4.32	0.33	2.85e-5	Uric acid levels;
PAAD	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg14952266	chr13:112191215	NA	0.43	4.88	0.37	2.63e-6	Hepatitis;
PAAD	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs55793580	1	rs55793580	chr9:127009395	C/T	cg14385362	chr9:127054095	NEK6	0.52	4.89	0.37	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;Monocyte count;
PAAD	cis	rs9913156	0.748	rs55869432	chr17:4562901	A/G	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs8018808	0.967	rs10133896	chr14:77853806	C/T	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.55	5.64	0.42	8.04e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg03983476	chr2:10830698	NOL10	-0.45	-4.38	-0.34	2.16e-5	Prostate cancer;
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.57	0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.88	10.8	0.66	1.52e-20	Ulcerative colitis;
PAAD	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.52	5.05	0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.82	9.81	0.62	6.73e-18	Blood metabolite ratios;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03857632	chr5:75013392	C5orf37	0.53	6.36	0.46	2.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs597583	0.755	rs685440	chr11:117429718	G/T	cg27161313	chr11:117392002	DSCAML1	-0.73	-6.18	-0.45	5.76e-9	Putamen volume;
PAAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.96	-9.77	-0.62	8.63e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.45	4.33	0.33	2.72e-5	Malaria;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.64	-8.19	-0.55	9.72e-14	Body mass index;
PAAD	cis	rs1420338	1.000	rs4723351	chr7:34155813	T/G	cg01275685	chr7:34179230	BMPER	-0.54	-5.11	-0.38	9.73e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.78	8.72	0.58	4.44e-15	Type 2 diabetes;
PAAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg06740227	chr12:86229804	RASSF9	0.57	5.21	0.39	6.16e-7	Major depressive disorder;
PAAD	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.48	4.75	0.36	4.67e-6	Hepatocellular carcinoma;
PAAD	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.86	-10.1	-0.63	1.11e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.52	5.22	0.39	5.87e-7	Schizophrenia;
PAAD	cis	rs111342015	1.000	rs111822813	chr6:43219468	C/T	cg18683047	chr6:43424751	DLK2	0.78	4.3	0.33	3.01e-5	Breast cancer;
PAAD	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.55	-5.41	-0.4	2.45e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.7	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-6.45	-0.46	1.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.62	5.68	0.42	6.68e-8	Late-onset Alzheimer's disease;
PAAD	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.28	7.35	0.51	1.15e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs1982963	0.627	rs8013745	chr14:52496745	G/T	cg20550154	chr14:52487779	NID2	0.59	4.84	0.37	3.1e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs2061333	0.557	rs8104573	chr19:44603385	A/G	cg20607764	chr19:44506953	ZNF230	-0.7	-4.61	-0.35	8.57e-6	Alzheimer's disease;
PAAD	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs863345	0.967	rs7550787	chr1:158469908	C/T	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	4.6	0.35	8.75e-6	Height;
PAAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7011192	0.793	rs11774104	chr8:10526434	C/G	cg04501334	chr8:10513686	RP1L1	-0.77	-5.76	-0.42	4.54e-8	Suicide;
PAAD	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg09835421	chr16:68378352	PRMT7	-0.88	-7.03	-0.5	6.61e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.6	-5.34	-0.4	3.35e-7	Mean corpuscular volume;
PAAD	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg10920065	chr6:169824652	NA	-0.47	-4.65	-0.35	7.02e-6	Obesity-related traits;
PAAD	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.4	4.63	0.35	7.74e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg06565975	chr8:143823917	SLURP1	-0.22	-4.9	-0.37	2.42e-6	Urinary tract infection frequency;
PAAD	cis	rs12711490	0.559	rs8059144	chr16:85970476	T/C	cg05709598	chr16:85699621	KIAA0182	0.42	4.44	0.34	1.76e-5	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;
PAAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12463550	chr7:65579703	CRCP	-0.84	-5.24	-0.39	5.19e-7	Diabetic kidney disease;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg19598514	chr11:442149	ANO9	-0.52	-4.25	-0.33	3.7e-5	Systemic lupus erythematosus;
PAAD	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg00262263	chr6:170184901	NA	0.58	4.25	0.33	3.72e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18621852	chr3:10150065	C3orf24	0.66	5.82	0.43	3.32e-8	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25015735	chr1:92852629	RPAP2	0.68	6.46	0.46	1.32e-9	Neuroticism;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-8.31	-0.56	5e-14	Prudent dietary pattern;
PAAD	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.14e-7	Lung cancer;
PAAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg18612461	chr15:75251733	NA	0.65	7.96	0.54	3.67e-13	Breast cancer;
PAAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.72	-8.13	-0.55	1.44e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs6887276	0.504	rs1003136	chr5:127347815	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	4.67	0.35	6.44e-6	Height;
PAAD	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17757281	chr20:44604666	NA	-0.64	-6.59	-0.47	6.98e-10	Smoking initiation;
PAAD	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.9	-11.02	-0.67	3.96e-21	Coronary artery disease;
PAAD	cis	rs6508941	1.000	rs77315262	chr19:41017484	A/T	cg25811527	chr19:40791102	AKT2	0.53	4.37	0.33	2.3e-5	Antibody level in response to infection;
PAAD	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.7	-0.36	5.81e-6	Refractive error;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09106303	chr6:41036672	C6orf130	-0.63	-6.44	-0.46	1.45e-9	Obesity-related traits;
PAAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg01059385	chr22:42394853	WBP2NL	-0.45	-4.68	-0.35	6.34e-6	Cognitive function;
PAAD	cis	rs3761847	0.508	rs4837813	chr9:123934463	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	6.38	0.46	2.07e-9	Rheumatoid arthritis;
PAAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6693295	0.605	rs6692457	chr1:246216326	A/C	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg15956490	chr3:53032818	SFMBT1	0.75	4.34	0.33	2.58e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.58	-5.95	-0.43	1.79e-8	Hypospadias;
PAAD	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg20283391	chr11:68216788	NA	0.55	5.29	0.39	4.16e-7	Total body bone mineral density;
PAAD	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg14703610	chr5:56206110	C5orf35	0.59	5.71	0.42	5.86e-8	Coronary artery disease;
PAAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.86	-11.38	-0.68	4.39e-22	Menopause (age at onset);
PAAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.55	0.47	8.33e-10	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg25173405	chr17:45401733	C17orf57	-0.66	-5.99	-0.44	1.47e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09336228	chr16:70380615	DDX19A	-0.6	-6.39	-0.46	1.95e-9	Lung cancer in ever smokers;
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.79	-10.1	-0.63	1.11e-18	Vitiligo;
PAAD	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs4704187	0.574	rs4704184	chr5:74471677	A/G	cg03227963	chr5:74354835	NA	0.5	4.88	0.37	2.64e-6	Response to amphetamines;
PAAD	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.69	-10.2	-0.64	6.21e-19	Breast cancer;
PAAD	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.77	-5.88	-0.43	2.5e-8	Mean platelet volume;
PAAD	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.81	9.88	0.63	4.42e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.52	5.1	0.38	9.89e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7577696	0.962	rs6738349	chr2:32314131	G/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg21194808	chr1:2205498	SKI	0.49	5.34	0.4	3.3e-7	Coronary artery disease;
PAAD	cis	rs7671266	0.532	rs733175	chr4:10050141	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.52	0.34	1.22e-5	Cardiovascular disease risk factors;
PAAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-1.01	-15.34	-0.78	1.08e-32	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00945038	chr17:61921165	SMARCD2	-0.47	-5.59	-0.41	1.04e-7	Prudent dietary pattern;
PAAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7873102	0.654	rs10973633	chr9:37992119	C/T	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg15017067	chr4:17643749	FAM184B	0.4	4.44	0.34	1.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13047869	chr3:10149882	C3orf24	0.84	7.0	0.49	7.6e-11	Alzheimer's disease;
PAAD	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.96	0.49	9.79e-11	Rheumatoid arthritis;
PAAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07536341	chr12:4758250	NDUFA9	0.69	6.48	0.47	1.2e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	ch.16.271253R	chr16:5918149	NA	-0.57	-6.48	-0.47	1.22e-9	Body fat percentage;
PAAD	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.69	6.83	0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.43e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05731713	chr7:157510257	PTPRN2	0.52	4.93	0.37	2.16e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg08562672	chr19:21860753	NA	0.44	4.51	0.34	1.31e-5	Pain;
PAAD	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg13565585	chr5:132299512	AFF4	0.62	4.51	0.34	1.31e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg18093559	chr17:18951025	GRAP	0.47	4.58	0.35	9.45e-6	Schizophrenia;
PAAD	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.63	-0.35	7.64e-6	Schizophrenia (age at onset);
PAAD	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.68	-6.74	-0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	cis	rs2004318	1.000	rs10409765	chr19:55120906	G/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs59888335	0.743	rs6548734	chr3:81010147	G/A	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.49	5.25	0.39	5.1e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.56	0.35	1.04e-5	Asthma;
PAAD	cis	rs11037575	0.739	rs10838149	chr11:43705623	C/G	cg24662154	chr11:44118094	EXT2	-0.44	-4.5	-0.34	1.34e-5	Neuroblastoma;
PAAD	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg04254540	chr16:71951199	KIAA0174	-0.52	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs2460882	1	rs2460882	chr12:53787953	T/C	cg20591337	chr12:53693442	C12orf10	-0.63	-4.4	-0.34	2.05e-5	Percentage gas trapping;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18504358	chr14:23340787	LRP10	0.71	8.38	0.56	3.22e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg00684032	chr4:1343700	KIAA1530	-0.55	-4.71	-0.36	5.5e-6	Systolic blood pressure;
PAAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.09	0.59	5.15e-16	Parkinson's disease;
PAAD	cis	rs30380	1.000	rs30379	chr5:96122260	T/G	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.32	-0.33	2.85e-5	Tonsillectomy;
PAAD	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg21479132	chr6:26055353	NA	0.93	6.06	0.44	1.02e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.62	7.1	0.5	4.48e-11	Mean corpuscular volume;
PAAD	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.55	6.31	0.46	2.87e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs682748	0.846	rs12657901	chr5:17162704	A/G	cg23987134	chr5:17158319	LOC285696	-0.36	-4.41	-0.34	1.91e-5	Hippocampal atrophy;
PAAD	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.95	0.37	1.98e-6	Colorectal cancer;
PAAD	cis	rs7719624	0.846	rs2237066	chr5:135367603	C/T	cg16684184	chr5:135415129	NA	-0.35	-4.29	-0.33	3.21e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.68	-0.42	6.51e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.51	-0.34	1.29e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg02683114	chr2:24398427	C2orf84	-0.51	-4.88	-0.37	2.61e-6	Asthma;
PAAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.8	-0.43	3.75e-8	Mood instability;
PAAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.63	5.78	0.42	4.14e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.7	-8.13	-0.55	1.39e-13	Schizophrenia;
PAAD	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00262122	chr8:11665843	FDFT1	0.48	4.57	0.35	9.86e-6	Myopia (pathological);
PAAD	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.04	13.71	0.74	2.27e-28	Body mass index;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.92	7.9	0.54	5.16e-13	Alzheimer's disease;
PAAD	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.48	-6.06	-0.44	1.03e-8	Crohn's disease;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.29	0.33	3.15e-5	Bipolar disorder;
PAAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.08	0.44	9.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.76	0.53	1.12e-12	Prudent dietary pattern;
PAAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.53	0.61	3.7e-17	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-4.3	-0.33	3.04e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-5.06	-0.38	1.19e-6	Electroencephalogram traits;
PAAD	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.48e-6	Daytime sleep phenotypes;
PAAD	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.55	0.47	8.19e-10	Schizophrenia;
PAAD	cis	rs59888335	0.929	rs66902125	chr3:80816920	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.59	-0.52	3.03e-12	Protein C levels;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.48	4.33	0.33	2.65e-5	Acylcarnitine levels;
PAAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.95	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.32	-0.33	2.77e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.78	6.76	0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs4668356	0.881	rs58028937	chr2:171996629	A/T	cg13882835	chr2:172017928	TLK1	0.93	4.35	0.33	2.49e-5	Cognitive performance;
PAAD	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.58	5.76	0.42	4.41e-8	Inflammatory bowel disease;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00864171	chr11:67383662	NA	0.6	6.31	0.46	2.93e-9	Mean corpuscular volume;
PAAD	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg05347473	chr6:146136440	FBXO30	-0.7	-6.23	-0.45	4.42e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	trans	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg10920065	chr6:169824652	NA	-0.45	-4.52	-0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg09491104	chr22:46646882	C22orf40	-0.93	-8.66	-0.57	6.58e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs13242816	1.000	rs34082946	chr7:116154313	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.5	-0.34	1.37e-5	Recombination measurement;
PAAD	cis	rs4443100	0.958	rs13057385	chr22:23380955	G/A	cg14186256	chr22:23484241	RTDR1	0.53	4.62	0.35	8.08e-6	Serum parathyroid hormone levels;
PAAD	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg10871876	chr19:53194124	ZNF83	0.62	5.47	0.41	1.81e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.5	-0.34	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	0.81	5.46	0.4	1.93e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.5	4.42	0.34	1.89e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.61	5.24	0.39	5.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.8	4.77	0.36	4.21e-6	Obesity-related traits;
PAAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg24053715	chr22:38214548	NA	0.63	6.03	0.44	1.21e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg09659197	chr4:152720779	NA	0.36	5.24	0.39	5.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6466055	0.661	rs2299309	chr7:104838876	T/C	cg04380332	chr7:105027541	SRPK2	0.52	5.17	0.39	7.43e-7	Schizophrenia;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.7	7.82	0.54	8.01e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg12463550	chr7:65579703	CRCP	-0.8	-5.12	-0.38	8.94e-7	Diabetic kidney disease;
PAAD	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.61	-5.68	-0.42	6.64e-8	Blood protein levels;
PAAD	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg27490568	chr2:178487706	NA	0.83	7.21	0.5	2.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23708337	chr7:1209742	NA	0.45	4.67	0.35	6.48e-6	Longevity;Endometriosis;
PAAD	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg13535736	chr9:111863775	C9orf5	-0.36	-4.62	-0.35	8.12e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg02725872	chr8:58115012	NA	-0.6	-5.2	-0.39	6.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs11696501	0.688	rs6104295	chr20:44326917	C/T	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg16766828	chr3:128327626	NA	-0.46	-6.14	-0.45	7e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.58	-4.35	-0.33	2.5e-5	Vitiligo;
PAAD	cis	rs740474	0.569	rs4912761	chr5:140881474	G/T	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.51	6.26	0.45	3.67e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6578985	0.894	rs78299129	chr11:2144411	T/C	cg12383159	chr11:1262597	MUC5B	0.46	4.52	0.34	1.24e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.74	-12.57	-0.71	2.72e-25	Urate levels in overweight individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22614631	chr3:196733464	MFI2	-0.69	-7.12	-0.5	4.11e-11	Obesity-related traits;
PAAD	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.87	10.93	0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	4.52	0.34	1.22e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.48	-4.42	-0.34	1.86e-5	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs9487051	0.621	rs429534	chr6:109523256	A/G	cg21918786	chr6:109611834	NA	-0.42	-4.34	-0.33	2.57e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg08493051	chr2:3487164	NA	-0.72	-6.96	-0.49	9.61e-11	Neurofibrillary tangles;
PAAD	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs4073221	0.858	rs73034316	chr3:18268543	G/A	cg07694806	chr3:18168406	NA	-0.76	-5.04	-0.38	1.28e-6	Parkinson's disease;
PAAD	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.1e-8	Platelet count;
PAAD	cis	rs6782025	1.000	rs587553	chr3:121265913	T/C	cg16417163	chr3:121280760	NA	-0.45	-4.56	-0.35	1.03e-5	Aging (facial);
PAAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	11.2	0.67	1.35e-21	Menopause (age at onset);
PAAD	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.25	-0.39	5.15e-7	Fibrinogen levels;
PAAD	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.61	7.55	0.52	3.7e-12	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4294134	0.608	rs11535258	chr7:135247547	A/G	cg04619859	chr7:134855396	C7orf49	0.56	4.37	0.33	2.33e-5	Paget's disease;
PAAD	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg22800045	chr5:56110881	MAP3K1	-0.57	-5.01	-0.38	1.5e-6	Initial pursuit acceleration;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg06613012	chr11:126225376	ST3GAL4	0.62	6.43	0.46	1.58e-9	Iris heterochromicity;
PAAD	cis	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg05927578	chr16:4029543	ADCY9	0.71	5.92	0.43	2.04e-8	Waist circumference;
PAAD	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.75	-7.5	-0.52	4.85e-12	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg00228799	chr9:131580591	ENDOG	0.64	6.37	0.46	2.11e-9	Blood metabolite levels;
PAAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.51	6.56	0.47	8.11e-10	Huntington's disease progression;
PAAD	cis	rs9287719	0.649	rs10929684	chr2:10732224	C/T	cg00105475	chr2:10696890	NA	-0.62	-6.55	-0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg02734326	chr4:10020555	SLC2A9	0.51	5.02	0.38	1.43e-6	Bone mineral density;
PAAD	cis	rs6942407	0.649	rs4727146	chr7:86856555	A/G	cg02420886	chr7:86849541	C7orf23	0.61	4.74	0.36	4.87e-6	Food allergy;
PAAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.21	0.5	2.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg18198730	chr1:247681584	NA	-0.52	-4.73	-0.36	5e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7631605	0.935	rs4234259	chr3:37048633	A/G	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.73	-0.53	1.36e-12	Morning vs. evening chronotype;
PAAD	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg15208524	chr1:10270712	KIF1B	-0.5	-4.68	-0.35	6.38e-6	Hepatocellular carcinoma;
PAAD	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg20933634	chr6:27740509	NA	0.7	4.42	0.34	1.85e-5	Breast cancer;
PAAD	cis	rs10078	0.660	rs11746538	chr5:427466	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.69	5.1	0.38	1.02e-6	Fat distribution (HIV);
PAAD	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg00129232	chr17:37814104	STARD3	-0.51	-4.3	-0.33	3.04e-5	Self-reported allergy;
PAAD	cis	rs10512697	0.655	rs13166953	chr5:3472213	A/G	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.69	-6.69	-0.48	3.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg23127183	chr11:57508653	C11orf31	-0.49	-4.25	-0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.6	-0.57	8.92e-15	Longevity;Endometriosis;
PAAD	cis	rs17095355	0.818	rs7071509	chr10:111775849	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	cis	rs116175783	0.557	rs1733180	chr2:162133630	C/T	cg08807892	chr2:162101083	NA	0.7	5.01	0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.713	rs352171	chr3:52234203	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-5.2	-0.39	6.42e-7	Electroencephalogram traits;
PAAD	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.77	7.06	0.5	5.5e-11	Acylcarnitine levels;
PAAD	cis	rs66731853	0.845	rs602950	chr1:20915531	A/G	cg04087271	chr1:20915334	CDA	-0.59	-6.61	-0.47	6.27e-10	Mean corpuscular volume;
PAAD	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs9535307	0.719	rs10492591	chr13:50385256	C/T	cg04663916	chr13:50265991	EBPL	-0.57	-4.31	-0.33	2.94e-5	Obesity-related traits;
PAAD	cis	rs17021463	0.643	rs17311521	chr4:95298060	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.16	-0.39	7.46e-7	Testicular germ cell tumor;
PAAD	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.59	0.47	6.84e-10	Schizophrenia;
PAAD	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg19744528	chr7:157553346	PTPRN2	0.39	4.26	0.33	3.63e-5	Body mass index;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.69	5.87	0.43	2.69e-8	Common traits (Other);
PAAD	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-1.12	-11.8	-0.69	3.27e-23	Platelet distribution width;
PAAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.82	9.55	0.61	3.25e-17	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.55	-5.38	-0.4	2.82e-7	Multiple sclerosis;
PAAD	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.15	-0.55	1.26e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg26501369	chr6:133561814	EYA4	-0.89	-6.59	-0.47	6.69e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.54	-5.22	-0.39	5.91e-7	Monocyte count;
PAAD	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg02887458	chr19:19495540	GATAD2A	-0.57	-5.51	-0.41	1.51e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg06095790	chr10:131460030	MGMT	-0.4	-4.33	-0.33	2.67e-5	Vitamin D levels;
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.49	5.77	0.42	4.38e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs427941	0.632	rs201497	chr7:101755928	A/C	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs6142102	0.923	rs6059635	chr20:32613493	A/T	cg06115741	chr20:33292138	TP53INP2	0.53	4.45	0.34	1.63e-5	Skin pigmentation;
PAAD	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.74	-8.59	-0.57	9.83e-15	Height;
PAAD	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.88	10.96	0.66	5.85e-21	Mean corpuscular volume;
PAAD	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.31	-0.33	2.93e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.48	0.34	1.46e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8077577	0.708	rs3829589	chr17:18134266	T/C	cg16794390	chr17:18148240	FLII	-0.52	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg10587741	chr22:38071170	LGALS1	0.45	5.03	0.38	1.37e-6	Fat distribution (HIV);
PAAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.5	-0.34	1.34e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	1.13	11.82	0.69	2.78e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.74	-5.69	-0.42	6.23e-8	Height;
PAAD	cis	rs2790216	0.901	rs4405261	chr10:59965514	G/A	cg20442379	chr10:60024634	IPMK	-0.6	-4.6	-0.35	8.86e-6	Inflammatory bowel disease;
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.88	15.27	0.78	1.7e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg19407955	chr1:165599744	MGST3	-0.49	-4.64	-0.35	7.48e-6	Total ventricular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27105478	chr5:60628018	ZSWIM6	-0.75	-6.41	-0.46	1.76e-9	Neuroticism;
PAAD	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.46	4.54	0.35	1.13e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	9.54	0.61	3.33e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg26060667	chr1:247681242	NA	0.45	5.35	0.4	3.23e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg06492744	chr11:65406254	SIPA1	0.52	4.76	0.36	4.4e-6	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg21994712	chr19:21861136	NA	0.45	4.27	0.33	3.47e-5	Pain;
PAAD	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.75	-0.42	4.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs795484	0.926	rs708867	chr12:118629699	T/C	cg16572268	chr12:118583242	PEBP1	-0.45	-4.41	-0.34	1.95e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.6	4.97	0.37	1.8e-6	Lymphocyte counts;
PAAD	cis	rs57244997	0.652	rs73030422	chr6:162432688	T/A	cg17173639	chr6:162384350	PARK2	-0.63	-4.73	-0.36	5.19e-6	Mosquito bite size;
PAAD	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-4.26	-0.33	3.62e-5	Osteoarthritis;
PAAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.44	5.52	0.41	1.46e-7	Psoriasis;
PAAD	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg26149184	chr10:133730230	NA	-0.66	-5.76	-0.42	4.42e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs10178094	0.528	rs62175963	chr2:161339964	T/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-4.37	-0.33	2.3e-5	White blood cell count;
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.45	4.29	0.33	3.13e-5	Renal cell carcinoma;
PAAD	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.81	-6.4	-0.46	1.84e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg03404566	chr17:6899310	ALOX12	0.47	5.06	0.38	1.18e-6	Blood metabolite levels;
PAAD	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.5	-5.42	-0.4	2.26e-7	Testicular germ cell tumor;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.66	-7.26	-0.51	1.87e-11	Lung cancer;
PAAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	1.07	13.84	0.75	1.07e-28	Breast cancer;
PAAD	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.85	9.71	0.62	1.19e-17	Metabolic syndrome;
PAAD	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.76	7.96	0.54	3.73e-13	Blood protein levels;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg06740227	chr12:86229804	RASSF9	0.61	5.51	0.41	1.5e-7	Major depressive disorder;
PAAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.58	6.39	0.46	1.92e-9	Mean corpuscular volume;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.76	-7.92	-0.54	4.78e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg23708337	chr7:1209742	NA	0.69	5.23	0.39	5.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg15145965	chr22:50218605	BRD1	0.76	4.67	0.35	6.46e-6	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs17683430	0.614	rs2006233	chr22:32530848	A/G	cg02631450	chr22:32366979	NA	0.76	5.23	0.39	5.62e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8112211	0.648	rs79590641	chr19:38807541	T/C	cg01275006	chr19:38876250	GGN	-0.89	-5.73	-0.42	5.26e-8	Blood protein levels;
PAAD	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.72	7.1	0.5	4.48e-11	Coronary artery disease;
PAAD	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs30380	1.000	rs27710	chr5:96126197	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.4	-4.29	-0.33	3.18e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg11204139	chr17:3907470	NA	0.64	6.46	0.46	1.35e-9	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14796370	chr20:61273660	SLCO4A1	0.59	7.05	0.5	5.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	5.19	0.39	6.7e-7	Menarche (age at onset);
PAAD	cis	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6782025	0.837	rs619802	chr3:120727553	T/C	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10819733	chr22:24237672	NA	0.61	6.68	0.48	4.32e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.5	5.1	0.38	1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg10820045	chr2:198174542	NA	0.56	5.71	0.42	5.65e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.95	10.18	0.64	7.11e-19	Alcohol dependence;
PAAD	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg01489032	chr8:143877656	NA	0.44	4.63	0.35	7.91e-6	Urinary tract infection frequency;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2271400	0.529	rs7009837	chr8:56736654	G/A	cg08894788	chr8:56792171	LYN	-0.54	-4.97	-0.37	1.77e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg03983715	chr16:68378420	PRMT7	-1.05	-7.01	-0.49	7.29e-11	Magnesium levels;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.0	11.78	0.69	3.69e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.71	9.1	0.59	4.76e-16	Weight;
PAAD	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.72	5.23	0.39	5.54e-7	Major depressive disorder;
PAAD	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10490913	0.583	rs853926	chr10:120155733	C/T	cg04126427	chr10:120840676	EIF3A	0.44	4.42	0.34	1.88e-5	Cancer;
PAAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.65	0.42	7.85e-8	Major depressive disorder;
PAAD	cis	rs9462846	1.000	rs1150797	chr6:42841231	G/A	cg02353165	chr6:42928485	GNMT	0.61	4.72	0.36	5.38e-6	Blood protein levels;
PAAD	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg17470449	chr10:769945	NA	-0.46	-4.71	-0.36	5.61e-6	Uric acid levels;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8e-6	Life satisfaction;
PAAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.46	4.38	0.33	2.23e-5	Dupuytren's disease;Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13324568	chr11:61197484	CPSF7;SDHAF2	-0.74	-6.51	-0.47	1.05e-9	Neuroticism;
PAAD	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg02404636	chr22:31891804	SFI1	-0.58	-5.22	-0.39	5.85e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs818427	0.896	rs430665	chr5:112228667	G/A	cg06941702	chr5:112196734	SRP19	0.51	4.75	0.36	4.67e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.06	-0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs3136739	0.614	rs2070711	chr8:42045933	G/A	cg12054981	chr8:42037387	PLAT	0.74	5.4	0.4	2.48e-7	Plasma plasminogen activator levels;
PAAD	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.77	8.04	0.55	2.36e-13	Corneal astigmatism;
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg06637938	chr14:75390232	RPS6KL1	0.49	4.96	0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.64	7.64	0.53	2.2e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13319406	0.508	rs6788208	chr3:189832890	A/G	cg03343083	chr3:189718843	LEPREL1	0.82	5.42	0.4	2.3e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.58	6.31	0.46	2.85e-9	Lung cancer;
PAAD	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.75	-0.42	4.65e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12936587	0.720	rs113347218	chr17:17548845	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-4.63	-0.35	7.86e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.6	-6.97	-0.49	8.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02419362	chr12:121203948	SPPL3	-0.49	-5.4	-0.4	2.51e-7	Systemic lupus erythematosus;
PAAD	cis	rs13144136	0.664	rs12501252	chr4:10661563	A/G	cg10242279	chr4:10666415	CLNK	-0.47	-5.84	-0.43	3.08e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg21211680	chr2:198530	NA	0.67	5.47	0.41	1.81e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.48	0.47	1.19e-9	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg17551891	chr7:1960795	MAD1L1	-0.41	-4.46	-0.34	1.56e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.51	-0.34	1.28e-5	Rheumatoid arthritis;
PAAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.53	-0.34	1.2e-5	Breast cancer;
PAAD	cis	rs55823223	0.680	rs3744020	chr17:73871773	G/A	cg01800442	chr17:74086473	EXOC7	0.54	4.31	0.33	2.89e-5	Psoriasis;
PAAD	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.43	-0.34	1.77e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.79	0.42	3.95e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1018697	1.000	rs4919677	chr10:104554304	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	trans	rs901683	1.000	rs17157825	chr10:45958676	G/A	cg13065504	chr15:42448234	PLA2G4F	0.82	6.41	0.46	1.72e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg11995313	chr8:8860691	ERI1	0.49	4.62	0.35	8.09e-6	Joint mobility (Beighton score);
PAAD	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg08992911	chr2:238395768	MLPH	0.7	5.57	0.41	1.15e-7	Prostate cancer;
PAAD	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs1912528	0.814	rs769672	chr4:140883254	G/C	cg11128457	chr4:140864437	MAML3	-0.33	-4.43	-0.34	1.83e-5	Educational attainment (years of education);
PAAD	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.5	5.2	0.39	6.34e-7	Type 2 diabetes;
PAAD	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs8126001	0.573	rs6090043	chr20:62717930	C/T	cg07246713	chr20:62722933	OPRL1	0.54	6.21	0.45	4.85e-9	Pulse pressure;Mean corpuscular volume;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg10191248	chr10:134441085	INPP5A	-0.45	-4.25	-0.33	3.67e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg09626299	chr10:82213104	TSPAN14	-0.44	-4.75	-0.36	4.69e-6	Post bronchodilator FEV1;
PAAD	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg27449745	chr7:23145252	KLHL7	-0.52	-4.67	-0.35	6.59e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.29	-0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.83	8.61	0.57	8.61e-15	Cardiac hypertrophy;
PAAD	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.73	7.34	0.51	1.18e-11	Tonsillectomy;
PAAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.4	-0.4	2.48e-7	Personality dimensions;
PAAD	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.7	9.32	0.6	1.28e-16	Hemoglobin concentration;
PAAD	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.36	-4.67	-0.35	6.57e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.55	-4.49	-0.34	1.4e-5	Corneal structure;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07701084	chr6:150067640	NUP43	0.62	6.15	0.45	6.42e-9	Testicular germ cell tumor;
PAAD	cis	rs72827839	0.744	rs16956892	chr17:46523919	C/G	cg23391107	chr17:45924227	SP6	0.5	4.78	0.36	4.17e-6	Ease of getting up in the morning;
PAAD	cis	rs57244997	0.725	rs73785320	chr6:162439590	A/C	cg17173639	chr6:162384350	PARK2	-0.66	-5.1	-0.38	9.81e-7	Mosquito bite size;
PAAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg14851346	chr12:38532713	NA	0.46	4.25	0.33	3.67e-5	Morning vs. evening chronotype;
PAAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg09654669	chr8:57350985	NA	-0.53	-5.0	-0.38	1.54e-6	Obesity-related traits;
PAAD	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.75	8.27	0.56	6.16e-14	Heart rate;
PAAD	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.68	6.39	0.46	1.9e-9	Lymphocyte counts;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-7.06	-0.5	5.51e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.49	5.96	0.44	1.68e-8	Vitiligo;
PAAD	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.56	-5.19	-0.39	6.52e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13932035	chr19:11266624	SPC24	0.68	6.52	0.47	9.86e-10	Obesity-related traits;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs7714584	0.793	rs12653039	chr5:150252631	G/A	cg22134413	chr5:150180641	NA	0.92	6.2	0.45	5.14e-9	Crohn's disease;
PAAD	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	9.98	0.63	2.41e-18	Cognitive test performance;
PAAD	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs829661	0.947	rs829578	chr2:30680232	G/T	cg12454169	chr2:30669597	LCLAT1	0.67	5.09	0.38	1.04e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2295359	0.697	rs11209017	chr1:67666235	A/T	cg01320130	chr1:67600311	NA	0.45	4.77	0.36	4.27e-6	Psoriasis;
PAAD	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.66	-4.78	-0.36	4.1e-6	Neuroticism;
PAAD	cis	rs4690686	0.500	rs72623908	chr4:177261971	A/G	cg17059388	chr4:177262070	NA	0.61	6.01	0.44	1.31e-8	Essential tremor;
PAAD	cis	rs10885582	0.677	rs4751583	chr10:116295510	A/T	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.27	-0.39	4.57e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg21890820	chr11:65308645	LTBP3	1.51	9.51	0.61	3.97e-17	Height;
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs116248771	0.739	rs16829122	chr3:158312667	T/C	cg16708174	chr3:158430962	RARRES1	0.68	5.15	0.39	7.88e-7	diarrhoeal disease at age 2;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12229505	chr15:80351983	ZFAND6	0.57	6.73	0.48	3.3e-10	Immature fraction of reticulocytes;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.67	-6.73	-0.48	3.24e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg10645314	chr2:3704589	ALLC	-0.42	-4.53	-0.34	1.19e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.56	-5.69	-0.42	6.27e-8	Iron status biomarkers;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.9	-7.87	-0.54	6.31e-13	Alzheimer's disease;
PAAD	cis	rs7191439	0.589	rs12709104	chr16:88757940	G/A	cg27087555	chr16:88793112	FAM38A	-0.94	-5.47	-0.41	1.8e-7	Plateletcrit;
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.48	-4.87	-0.37	2.76e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.73	-8.49	-0.57	1.76e-14	Lung function (FVC);
PAAD	cis	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg11619707	chr19:22235551	ZNF257	0.58	5.77	0.42	4.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-6.07	-0.44	9.58e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03627880	chr6:151815985	C6orf97	-0.52	-4.68	-0.36	6.19e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.74	8.27	0.56	6.13e-14	Schizophrenia;
PAAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg25204440	chr1:209979598	IRF6	0.61	4.91	0.37	2.35e-6	Coronary artery disease;
PAAD	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.51	-0.34	1.31e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.67	-6.73	-0.48	3.31e-10	Blood metabolite levels;
PAAD	cis	rs8044995	0.563	rs79543001	chr16:68387341	C/T	cg09835421	chr16:68378352	PRMT7	-1.34	-8.95	-0.59	1.14e-15	Schizophrenia;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07167872	chr1:205819463	PM20D1	0.57	5.77	0.42	4.28e-8	Prostate cancer;
PAAD	cis	rs2282300	0.956	rs1222212	chr11:30374643	C/T	cg25418670	chr11:30344373	C11orf46	-0.6	-5.63	-0.42	8.38e-8	Morning vs. evening chronotype;
PAAD	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs72741340	chr15:64763135	T/A	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg23750338	chr8:142222470	SLC45A4	0.41	4.54	0.35	1.12e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs300774	0.925	rs300737	chr2:170576	A/G	cg23649280	chr2:140451	NA	-0.5	-4.52	-0.34	1.26e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg02397686	chr17:73851076	WBP2	0.62	4.47	0.34	1.55e-5	Psoriasis;
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.62	7.53	0.52	4.29e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.54	4.69	0.36	6.02e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg09127314	chr1:152161683	NA	-0.67	-4.64	-0.35	7.58e-6	Atopic dermatitis;
PAAD	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg02196655	chr2:10830764	NOL10	-0.55	-5.68	-0.42	6.73e-8	Prostate cancer;
PAAD	cis	rs138918	0.967	rs105585	chr22:43557492	G/A	cg00343092	chr22:43547974	TSPO	0.52	6.07	0.44	9.88e-9	Monocyte count;
PAAD	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-6.86	-0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08393828	chr14:102228221	PPP2R5C	0.63	7.4	0.51	8.46e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.46	-5.31	-0.4	3.81e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg06883089	chr1:45254480	BEST4	-0.35	-4.45	-0.34	1.62e-5	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.42	4.6	0.35	9.01e-6	Dietary macronutrient intake;
PAAD	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg11766577	chr21:47581405	C21orf56	-0.41	-4.67	-0.35	6.54e-6	Testicular germ cell tumor;
PAAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg23188684	chr11:67383651	NA	-0.49	-4.93	-0.37	2.12e-6	Mean corpuscular volume;
PAAD	cis	rs1692580	0.807	rs60635488	chr1:2202572	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.84	-0.37	3.16e-6	Coronary artery disease;
PAAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg01689657	chr7:91764605	CYP51A1	0.36	4.79	0.36	3.85e-6	Breast cancer;
PAAD	cis	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.83	-0.36	3.33e-6	Red cell distribution width;
PAAD	cis	rs2221894	1.000	rs4732896	chr8:28825474	A/T	cg20212339	chr8:28908912	HMBOX1	0.55	5.92	0.43	2.03e-8	Obesity-related traits;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07677032	chr17:61819896	STRADA	-0.52	-5.06	-0.38	1.19e-6	Prudent dietary pattern;
PAAD	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.15	-12.66	-0.72	1.54e-25	Hip circumference adjusted for BMI;
PAAD	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg05805236	chr11:65401703	PCNXL3	-0.43	-4.41	-0.34	1.93e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg18721089	chr20:30220636	NA	-0.82	-6.17	-0.45	5.79e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg02153855	chr1:11041070	C1orf127	-0.34	-4.26	-0.33	3.53e-5	Hepatocellular carcinoma;
PAAD	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-5.81	-0.43	3.55e-8	Inflammatory bowel disease;
PAAD	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.57	0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.68	6.03	0.44	1.22e-8	Inflammatory skin disease;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.3	-4.36	-0.33	2.37e-5	Mean corpuscular volume;
PAAD	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg00147160	chr1:26503991	CNKSR1	0.41	4.43	0.34	1.76e-5	Height;
PAAD	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.93	8.43	0.56	2.47e-14	Gut microbiome composition (summer);
PAAD	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-5.35	-0.4	3.23e-7	Mean platelet volume;
PAAD	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg16341495	chr8:142228727	SLC45A4	0.5	4.81	0.36	3.66e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.57	5.81	0.43	3.57e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs654384	0.798	rs13223924	chr7:4177170	C/T	cg27574739	chr7:4176374	SDK1	-0.48	-4.71	-0.36	5.55e-6	Positive affect;
PAAD	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.51	5.18	0.39	7.04e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.74	6.35	0.46	2.35e-9	Glioblastoma;
PAAD	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg12362517	chr11:133800685	IGSF9B	0.54	5.45	0.4	2e-7	Parkinson's disease;
PAAD	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.77	7.45	0.52	6.72e-12	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs16975963	0.843	rs77895245	chr19:38419780	G/C	cg08679971	chr19:38281047	NA	0.56	5.36	0.4	3.07e-7	Longevity;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.83	-7.14	-0.5	3.64e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1519814	0.659	rs7387672	chr8:121024511	A/G	cg22335954	chr8:121166405	COL14A1	-0.64	-4.97	-0.37	1.82e-6	Breast cancer;
PAAD	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.57	-5.1	-0.38	1.02e-6	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg00280220	chr17:61926910	NA	0.46	4.76	0.36	4.5e-6	Prudent dietary pattern;
PAAD	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg12639453	chr1:2035780	PRKCZ	0.54	5.79	0.43	3.93e-8	Height;
PAAD	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6442522	0.673	rs1869855	chr3:15501142	G/T	cg16303742	chr3:15540471	COLQ	0.48	5.19	0.39	6.75e-7	Uric acid levels;
PAAD	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.96	10.35	0.64	2.45e-19	Corneal astigmatism;
PAAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.09	0.38	1.03e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07701084	chr6:150067640	NUP43	0.59	5.77	0.42	4.29e-8	Testicular germ cell tumor;
PAAD	cis	rs1015291	0.635	rs2694978	chr12:20009962	A/G	cg25401612	chr12:20009446	NA	-0.55	-5.41	-0.4	2.41e-7	Diastolic blood pressure;
PAAD	cis	rs797680	0.786	rs9432465	chr1:93780591	G/A	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs5743890	1.000	rs5743890	chr11:1325829	A/G	cg15607277	chr11:1312923	TOLLIP	-0.68	-4.28	-0.33	3.29e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg23346134	chr3:49453900	TCTA	-0.46	-4.93	-0.37	2.17e-6	Menarche (age at onset);
PAAD	cis	rs7714584	1.000	rs7736873	chr5:150258482	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs66530629	1.000	rs66530629	chr1:25032168	G/A	cg01905478	chr1:25040257	NA	0.54	5.84	0.43	3.05e-8	Plateletcrit;
PAAD	cis	rs7998202	0.667	rs7989810	chr13:113370627	C/T	cg02820901	chr13:113351484	ATP11A	0.7	4.64	0.35	7.44e-6	Glycated hemoglobin levels;
PAAD	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.6	5.71	0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.4e-10	Lung cancer;
PAAD	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.8	-9.72	-0.62	1.15e-17	Height;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs89107	0.575	rs72958930	chr6:118983681	G/C	cg21191810	chr6:118973309	C6orf204	0.37	4.44	0.34	1.71e-5	Cardiac structure and function;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs258892	0.895	rs13158966	chr5:72059510	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.71	7.1	0.5	4.56e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2000999	0.573	rs34682685	chr16:72096227	G/A	cg04254540	chr16:71951199	KIAA0174	-0.71	-4.26	-0.33	3.63e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.81	-5.89	-0.43	2.36e-8	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22510582	chr2:72376066	CYP26B1	0.64	6.68	0.48	4.31e-10	Obesity-related traits;
PAAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.27	0.33	3.36e-5	Asthma;
PAAD	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4417704	0.551	rs10169006	chr2:241898824	A/G	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.91e-7	Joint mobility (Beighton score);
PAAD	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg12184421	chr1:167409136	CD247	-0.38	-4.35	-0.33	2.45e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27417922	chr7:75988359	YWHAG	-0.78	-7.02	-0.49	6.93e-11	Neuroticism;
PAAD	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg06241208	chr11:30344200	C11orf46	0.51	4.57	0.35	9.98e-6	Morning vs. evening chronotype;
PAAD	cis	rs7534824	0.625	rs3087816	chr1:101441775	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs868943	0.582	rs9488861	chr6:116502405	A/G	cg05304507	chr6:116381966	FRK	0.26	4.63	0.35	7.72e-6	Total cholesterol levels;
PAAD	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg05341575	chr12:125625032	AACS	-0.47	-4.29	-0.33	3.17e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.57	6.14	0.45	6.81e-9	Lung cancer;
PAAD	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.44	0.57	2.29e-14	Dupuytren's disease;
PAAD	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg02487422	chr3:49467188	NICN1	0.45	4.5	0.34	1.32e-5	Resting heart rate;
PAAD	cis	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.51e-5	Dental caries;
PAAD	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.62	7.32	0.51	1.31e-11	Height;
PAAD	trans	rs9345521	0.967	rs4434453	chr6:65517441	A/G	cg26414000	chr1:85721327	C1orf52	0.52	6.42	0.46	1.64e-9	Iris color (a* coordinate);
PAAD	cis	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-10.17	-0.64	7.45e-19	Vitiligo;
PAAD	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.67	6.77	0.48	2.63e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-1.09	-7.91	-0.54	4.88e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24311947	chr1:28286409	XKR8	0.66	7.4	0.51	8.57e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06648483	chr3:125802615	SLC41A3	-0.65	-7.72	-0.53	1.42e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs58521262	0.560	rs11085545	chr19:22975346	T/C	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.33e-5	Testicular germ cell tumor;
PAAD	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13559217	chr19:5119331	KDM4B	0.64	7.62	0.53	2.59e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12220238	0.915	rs2894235	chr10:76082945	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg10006428	chr1:248814059	OR2T27	0.39	4.78	0.36	4.07e-6	Common traits (Other);
PAAD	cis	rs7247513	0.892	rs1864081	chr19:12707978	G/A	cg01871581	chr19:12707946	ZNF490	-0.9	-11.1	-0.67	2.4e-21	Bipolar disorder;
PAAD	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.86	-6.17	-0.45	5.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11168618	0.626	rs2731107	chr12:48887159	G/C	cg05152354	chr12:48152931	RAPGEF3	0.54	4.79	0.36	3.86e-6	Adiponectin levels;
PAAD	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.95e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg20312557	chr2:97357134	FER1L5	-0.82	-4.37	-0.33	2.34e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-10.81	-0.66	1.48e-20	Ulcerative colitis;
PAAD	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.67	6.92	0.49	1.21e-10	Multiple sclerosis;
PAAD	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.66	-0.35	6.95e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg12432903	chr7:1882776	MAD1L1	0.54	4.26	0.33	3.5e-5	Neuroticism;
PAAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.67	4.79	0.36	3.94e-6	Parkinson's disease;
PAAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.57	4.5	0.34	1.37e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.49	5.53	0.41	1.39e-7	Prevalent atrial fibrillation;
PAAD	trans	rs901683	0.850	rs117668126	chr10:46062952	G/C	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.9	-5.94	-0.43	1.83e-8	Body mass index;
PAAD	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg24565620	chr2:194026	NA	0.64	5.53	0.41	1.37e-7	Blood protein levels;
PAAD	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10601939	chr10:18948058	ARL5B	0.6	6.57	0.47	7.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.75	-4.44	-0.34	1.69e-5	Toenail selenium levels;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.41e-7	Cognitive function;
PAAD	cis	rs7577696	0.597	rs13006495	chr2:32355490	C/T	cg02381751	chr2:32503542	YIPF4	-0.5	-4.87	-0.37	2.82e-6	Inflammatory biomarkers;
PAAD	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.54	-0.35	1.15e-5	Pulmonary function;
PAAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg03037974	chr15:76606532	NA	0.51	5.7	0.42	5.9e-8	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22747643	chr7:1499391	MICALL2	-0.65	-7.66	-0.53	2.06e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.85	-11.97	-0.7	1.1e-23	Vitiligo;
PAAD	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg07517944	chr15:51633816	GLDN	0.44	4.44	0.34	1.7e-5	Hormone measurements;
PAAD	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.84	7.1	0.5	4.4e-11	Neutrophil percentage of white cells;
PAAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.83	-0.48	1.92e-10	Mood instability;
PAAD	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg07395648	chr5:131743802	NA	0.59	5.42	0.4	2.26e-7	Breast cancer;
PAAD	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12986453	chr22:49137906	FAM19A5	0.45	4.33	0.33	2.72e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.6	6.36	0.46	2.27e-9	Body mass index;
PAAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.92	8.33	0.56	4.51e-14	Gut microbiome composition (summer);
PAAD	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09065629	chr16:1709722	CRAMP1L	0.46	4.77	0.36	4.34e-6	Coronary artery disease;
PAAD	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	10.62	0.65	4.78e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	5.58	0.41	1.08e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.52	4.99	0.38	1.65e-6	Mortality in heart failure;
PAAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.56	-4.27	-0.33	3.5e-5	Gut microbiome composition (summer);
PAAD	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg21890820	chr11:65308645	LTBP3	0.65	7.8	0.53	8.94e-13	Bone mineral density;
PAAD	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	4.77	0.36	4.34e-6	Colorectal cancer;
PAAD	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.57	5.03	0.38	1.35e-6	Monocyte count;
PAAD	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg27335600	chr3:53528857	CACNA1D	-0.39	-4.29	-0.33	3.22e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.55	0.57	1.24e-14	Vitiligo;
PAAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg25547332	chr5:131281432	NA	0.54	4.33	0.33	2.72e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.81	8.79	0.58	2.92e-15	Height;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg06375148	chr1:209958343	C1orf74	0.63	5.42	0.4	2.25e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg10518543	chr12:38710700	ALG10B	0.52	4.94	0.37	2.03e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.55	0.35	1.11e-5	Melanoma;
PAAD	cis	rs11771526	0.551	rs2392053	chr7:32259056	C/T	cg27511599	chr7:32358540	NA	-0.65	-4.34	-0.33	2.54e-5	Body mass index;
PAAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14580859	chr9:123691850	NA	0.39	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.14	-0.55	1.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22025132	chr6:143771787	ADAT2;PEX3	0.69	6.45	0.46	1.41e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg02038168	chr22:39784481	NA	-0.51	-4.95	-0.37	1.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.43	0.61	6.55e-17	Cognitive test performance;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg14008862	chr17:28927542	LRRC37B2	0.84	6.02	0.44	1.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg22338127	chr1:209979572	IRF6	0.53	4.28	0.33	3.36e-5	Coronary artery disease;
PAAD	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.18	-0.39	6.83e-7	Tonsillectomy;
PAAD	cis	rs66530629	0.874	rs7528154	chr1:25130083	T/C	cg01905478	chr1:25040257	NA	-0.48	-5.31	-0.4	3.81e-7	Plateletcrit;
PAAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.38	0.33	2.18e-5	Asthma;
PAAD	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg14851346	chr12:38532713	NA	-0.46	-4.36	-0.33	2.43e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17155006	0.746	rs435125	chr7:107748934	A/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg26354017	chr1:205819088	PM20D1	0.47	4.33	0.33	2.64e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26714650	chr12:56694279	CS	-1.29	-6.05	-0.44	1.08e-8	Psoriasis vulgaris;
PAAD	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.55	-6.5	-0.47	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs901683	1.000	rs36052429	chr10:46082345	T/A	cg14076390	chr17:34947837	DHRS11	0.92	6.67	0.48	4.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.76	-8.33	-0.56	4.49e-14	Mean platelet volume;
PAAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg09324608	chr17:30823087	MYO1D	0.47	4.97	0.37	1.82e-6	Schizophrenia;
PAAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	10.81	0.66	1.5e-20	Menopause (age at onset);
PAAD	cis	rs797680	0.856	rs12030549	chr1:93669218	T/C	cg04535902	chr1:92947332	GFI1	0.46	4.42	0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-6.23	-0.45	4.34e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088813	0.961	rs981819	chr20:33924112	C/T	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-6.07	-0.44	1e-8	Dental caries;
PAAD	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.88	-0.37	2.67e-6	Menopause (age at onset);
PAAD	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg04450456	chr4:17643702	FAM184B	0.47	4.64	0.35	7.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.49	5.39	0.4	2.61e-7	Electroencephalogram traits;
PAAD	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.84	6.99	0.49	8.2e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.72	-8.74	-0.58	4.04e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	5.13	0.38	8.66e-7	Height;
PAAD	cis	rs501120	0.584	rs1704221	chr10:44710930	G/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.46	4.25	0.33	3.64e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7260598	0.539	rs61693040	chr19:24066172	A/G	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.6	0.47	6.59e-10	Bladder cancer;
PAAD	cis	rs8063761	0.568	rs4350572	chr16:90043840	A/G	cg05185784	chr16:90016020	DEF8	0.49	4.84	0.37	3.18e-6	Squamous cell carcinoma;
PAAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.85	-10.05	-0.63	1.53e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs10768122	0.966	rs6484778	chr11:35317415	A/G	cg13971030	chr11:35366721	SLC1A2	-0.37	-4.44	-0.34	1.75e-5	Vitiligo;
PAAD	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.64	-6.63	-0.47	5.38e-10	Leprosy;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21963583	chr11:68658836	MRPL21	0.54	5.89	0.43	2.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg27411982	chr8:10470053	RP1L1	-0.52	-5.37	-0.4	2.94e-7	Neuroticism;
PAAD	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg00700412	chr12:58011837	NA	0.41	4.42	0.34	1.89e-5	Multiple sclerosis;
PAAD	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.81	7.13	0.5	3.84e-11	Exhaled nitric oxide levels;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01765077	chr12:122356316	WDR66	0.66	6.79	0.48	2.35e-10	Mean corpuscular volume;
PAAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.91	-7.16	-0.5	3.21e-11	Gut microbiome composition (summer);
PAAD	cis	rs2555155	1.000	rs2256920	chr11:6508124	G/C	cg24637308	chr11:6592297	DNHD1	0.47	4.93	0.37	2.1e-6	DNA methylation (variation);
PAAD	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-8.19	-0.55	9.76e-14	Brugada syndrome;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.86	9.37	0.61	9.37e-17	Prudent dietary pattern;
PAAD	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg25811867	chr2:3488468	NA	0.47	4.41	0.34	1.95e-5	Neurofibrillary tangles;
PAAD	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.66	-4.76	-0.36	4.44e-6	Schizophrenia;
PAAD	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.93	0.66	7.06e-21	Chronic sinus infection;
PAAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg14092988	chr3:52407081	DNAH1	0.38	4.59	0.35	9.26e-6	Bipolar disorder;
PAAD	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.61	6.07	0.44	9.64e-9	Hemoglobin concentration;
PAAD	cis	rs7565124	0.818	rs13415152	chr2:20233345	G/A	cg23821541	chr2:20251993	LAPTM4A	0.62	5.09	0.38	1.02e-6	Major depressive disorder;
PAAD	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.3	-0.46	3.09e-9	Triglycerides;
PAAD	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg08501292	chr6:25962987	TRIM38	0.83	4.97	0.37	1.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg05717871	chr11:638507	DRD4	-0.58	-5.44	-0.4	2.09e-7	Systemic lupus erythematosus;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25755500	chr12:72148739	RAB21	-0.75	-6.32	-0.46	2.71e-9	Neuroticism;
PAAD	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	1.02	11.01	0.67	4.34e-21	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg19723775	chr5:179050963	HNRNPH1	0.56	4.57	0.35	9.9e-6	Lung cancer;
PAAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.76	5.64	0.42	8.05e-8	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg00262122	chr8:11665843	FDFT1	-0.52	-4.56	-0.35	1.03e-5	Morning vs. evening chronotype;
PAAD	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.6	5.55	0.41	1.25e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs4908768	0.501	rs11121194	chr1:8569906	C/T	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.82e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg21300403	chr2:198650112	BOLL	-0.64	-4.25	-0.33	3.71e-5	Ulcerative colitis;
PAAD	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.6e-12	Obesity-related traits;
PAAD	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg05585544	chr11:47624801	NA	-0.48	-5.33	-0.4	3.43e-7	Subjective well-being;
PAAD	cis	rs2131877	0.868	rs12633566	chr3:194880989	A/G	cg11177333	chr3:195857752	NA	0.44	4.25	0.33	3.65e-5	Non-small cell lung cancer;
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.07	15.18	0.78	2.92e-32	Multiple system atrophy;
PAAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.56	-5.97	-0.44	1.59e-8	Lung cancer;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.65	8.42	0.56	2.57e-14	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02768352	chr17:18023695	MYO15A	0.54	6.32	0.46	2.74e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg03233332	chr7:66118400	NA	0.4	4.25	0.33	3.65e-5	Aortic root size;
PAAD	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg02683114	chr2:24398427	C2orf84	-0.46	-4.85	-0.37	3.03e-6	Sjögren's syndrome;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-4.33	-0.33	2.64e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7623687	0.786	rs73077157	chr3:49749705	A/C	cg19401529	chr3:49056140	DALRD3	0.84	5.2	0.39	6.37e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg07362569	chr17:61921086	SMARCD2	0.44	5.01	0.38	1.48e-6	Height;
PAAD	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.44	-4.32	-0.33	2.78e-5	Mean platelet volume;
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.8	-0.43	3.81e-8	Lung cancer;
PAAD	trans	rs6433921	1.000	rs2368212	chr2:182397401	A/G	cg25572309	chr10:134145729	LRRC27	-0.64	-6.29	-0.45	3.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.35	-0.33	2.48e-5	Height;
PAAD	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.03	0.38	1.38e-6	Breast cancer;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg16850897	chr7:100343110	ZAN	-0.76	-6.75	-0.48	2.9e-10	Other erythrocyte phenotypes;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.47e-10	Morning vs. evening chronotype;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13685139	chr3:69812820	MITF	-0.72	-6.72	-0.48	3.42e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10101158	0.737	rs12678389	chr8:142915360	A/T	cg07295586	chr8:142984467	NA	-0.37	-4.25	-0.33	3.78e-5	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
PAAD	cis	rs12620999	0.941	rs62183342	chr2:237979140	C/A	cg23555395	chr2:238036564	NA	0.49	5.83	0.43	3.27e-8	Systemic lupus erythematosus;
PAAD	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.97	-0.44	1.6e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.43	4.48	0.34	1.47e-5	Lung cancer;
PAAD	cis	rs73069940	1.000	rs3755934	chr4:1236083	C/T	cg26210267	chr4:668877	ATP5I	0.75	4.29	0.33	3.22e-5	Type 2 diabetes;
PAAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.24	-6.68	-0.48	4.22e-10	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07920434	chr1:224518279	NVL	0.6	6.8	0.48	2.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg07725925	chr16:89976287	TCF25	0.69	4.56	0.35	1.03e-5	Skin colour saturation;
PAAD	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.64	-6.36	-0.46	2.2e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg08601574	chr20:25228251	PYGB	0.54	5.51	0.41	1.47e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18760729	chr1:93646329	CCDC18;TMED5	-0.56	-6.41	-0.46	1.69e-9	Body fat percentage;
PAAD	cis	rs1035491	0.753	rs6886740	chr5:63928254	T/C	cg01791865	chr5:63954708	NA	0.43	4.46	0.34	1.57e-5	Body mass index;
PAAD	cis	rs72634501	0.568	rs6679564	chr1:39617080	A/G	cg11070191	chr1:39582205	MACF1	0.48	4.43	0.34	1.8e-5	HDL cholesterol;
PAAD	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg15693483	chr7:1102177	C7orf50	0.38	4.61	0.35	8.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg23719950	chr11:63933701	MACROD1	-0.73	-5.37	-0.4	2.91e-7	Mean platelet volume;
PAAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21036936	chr15:74317780	PML	-0.6	-6.36	-0.46	2.28e-9	Obesity-related traits;
PAAD	cis	rs12523822	0.956	rs12662219	chr6:154958120	A/G	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs2455826	0.521	rs2345734	chr3:15808890	A/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.49	-0.34	1.42e-5	Inflammatory skin disease;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.65	5.07	0.38	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4843185	0.646	rs35953313	chr16:85710476	T/A	cg26571870	chr16:85723150	GINS2	-0.47	-5.25	-0.39	4.96e-7	Platelet distribution width;
PAAD	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.48	0.41	1.77e-7	Resting heart rate;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13047869	chr3:10149882	C3orf24	0.77	6.51	0.47	1.05e-9	Alzheimer's disease;
PAAD	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.54	0.61	3.39e-17	Electrocardiographic conduction measures;
PAAD	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.68	7.32	0.51	1.38e-11	Triglyceride levels;
PAAD	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	trans	rs11794666	1.000	rs79485103	chr9:31667065	A/T	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.77	8.27	0.56	6.09e-14	Mean corpuscular volume;
PAAD	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg18833306	chr6:118973337	C6orf204	0.41	4.28	0.33	3.28e-5	Electrocardiographic conduction measures;
PAAD	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.75	6.38	0.46	2e-9	Pediatric autoimmune diseases;
PAAD	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.54	-4.9	-0.37	2.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.49	-0.52	5.31e-12	Aortic root size;
PAAD	cis	rs11051970	0.879	rs2728682	chr12:32580193	G/A	cg24626660	chr12:32551988	NA	0.39	4.33	0.33	2.7e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg14906510	chr12:7781169	NA	0.64	4.67	0.35	6.63e-6	HDL cholesterol levels;
PAAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.7	7.77	0.53	1.12e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.74	7.8	0.53	8.95e-13	Body mass index;
PAAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.7	6.45	0.46	1.42e-9	Cleft lip with or without cleft palate;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-6.63	-0.47	5.57e-10	Lymphocyte counts;
PAAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg16205897	chr5:131564050	P4HA2	-0.38	-4.32	-0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs988913	0.957	rs4141552	chr6:54759929	A/G	cg03513858	chr6:54763001	FAM83B	-0.47	-5.22	-0.39	5.83e-7	Menarche (age at onset);
PAAD	cis	rs17095355	0.748	rs6584972	chr10:111901567	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.96	-0.37	1.91e-6	Biliary atresia;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.55	-6.87	-0.49	1.52e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12773846	0.600	rs12768700	chr10:126275899	C/T	cg04949429	chr10:126290192	LHPP	0.52	4.81	0.36	3.62e-6	Subcutaneous adipose tissue;
PAAD	cis	rs17407555	0.586	rs16895836	chr4:10278349	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	4.96	0.37	1.86e-6	Schizophrenia (age at onset);
PAAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.6	-5.93	-0.43	1.99e-8	Blood metabolite levels;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.66	6.67	0.48	4.39e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.59	-6.88	-0.49	1.47e-10	Lung cancer;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00280220	chr17:61926910	NA	0.43	4.53	0.35	1.17e-5	Prudent dietary pattern;
PAAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg04106633	chr4:1044584	NA	0.71	5.8	0.43	3.66e-8	Recombination rate (females);
PAAD	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg23743573	chr11:89867420	NAALAD2	0.56	4.56	0.35	1.06e-5	White blood cell types;
PAAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg10556349	chr10:835070	NA	0.67	5.16	0.39	7.55e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg02359409	chr6:42947317	PEX6	-0.49	-4.83	-0.36	3.28e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs6712232	0.681	rs6742118	chr2:72152148	C/T	cg11309785	chr2:72922245	EXOC6B	0.57	4.42	0.34	1.87e-5	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks);
PAAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.8	8.26	0.56	6.67e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1358748	0.522	rs11209001	chr1:67587723	C/T	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs71403859	0.541	rs73588051	chr16:71388627	A/G	cg08717414	chr16:71523259	ZNF19	-0.92	-4.98	-0.37	1.7e-6	Post bronchodilator FEV1;
PAAD	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.58	-5.63	-0.42	8.52e-8	Itch intensity from mosquito bite;
PAAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg27426351	chr10:43362370	NA	0.7	4.71	0.36	5.64e-6	Blood protein levels;
PAAD	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.32e-5	Skin colour saturation;
PAAD	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.88	-9.81	-0.62	6.68e-18	Tonsillectomy;
PAAD	cis	rs76878669	0.917	rs10896110	chr11:66101978	G/A	cg10685839	chr11:66611485	RCE1	0.45	4.27	0.33	3.42e-5	Educational attainment (years of education);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.34	-0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-5.35	-0.4	3.11e-7	Reticulocyte count;
PAAD	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg08992911	chr2:238395768	MLPH	0.59	5.63	0.42	8.63e-8	Prostate cancer;
PAAD	cis	rs6519955	0.722	rs7511186	chr22:46436973	T/A	cg00147172	chr22:46423604	NA	0.39	5.75	0.42	4.77e-8	Dupuytren's disease;
PAAD	cis	rs1144333	0.655	rs114457542	chr1:76449314	A/C	cg22875332	chr1:76189707	ACADM	0.76	4.46	0.34	1.59e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22151941	chr17:1957066	HIC1	0.61	6.48	0.47	1.24e-9	Myopia (pathological);
PAAD	cis	rs4455778	0.580	rs7808082	chr7:49124973	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.47	-5.26	-0.39	4.83e-7	Age at first birth;
PAAD	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.13	-0.38	8.83e-7	Glomerular filtration rate;
PAAD	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg23024343	chr7:107201750	COG5	0.52	4.42	0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.55	-6.06	-0.44	1.04e-8	Body mass index;
PAAD	cis	rs2242420	0.920	rs72876053	chr1:21949724	A/G	cg26362272	chr1:22108717	USP48	0.56	4.29	0.33	3.13e-5	Hematological and biochemical traits;
PAAD	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.53	-5.06	-0.38	1.21e-6	Mortality in heart failure;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.52	-5.54	-0.41	1.27e-7	Life satisfaction;
PAAD	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg14092571	chr14:90743983	NA	0.53	5.05	0.38	1.23e-6	Mortality in heart failure;
PAAD	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.55	-5.7	-0.42	5.9e-8	Menarche (age at onset);
PAAD	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg02683114	chr2:24398427	C2orf84	0.59	6.8	0.48	2.29e-10	Asthma;
PAAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.67	0.53	1.88e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6141769	0.569	rs6058807	chr20:31264608	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.77	-0.36	4.33e-6	Subjective well-being;
PAAD	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.58	5.27	0.39	4.65e-7	Schizophrenia;
PAAD	cis	rs6669119	0.818	rs74814455	chr1:19077963	T/A	cg19637330	chr1:19110922	NA	0.73	4.57	0.35	9.95e-6	Percentage gas trapping;
PAAD	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg23254163	chr1:152506842	NA	0.6	7.05	0.5	5.94e-11	Hair morphology;
PAAD	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.68	6.88	0.49	1.44e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.26e-11	Lung cancer in ever smokers;
PAAD	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg10518543	chr12:38710700	ALG10B	0.5	4.78	0.36	4.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg21565972	chr17:80109576	CCDC57	-0.47	-5.11	-0.38	9.36e-7	Life satisfaction;
PAAD	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg27396498	chr16:55794478	CES4	-0.69	-5.53	-0.41	1.34e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs4588572	0.686	rs34262593	chr5:77666427	T/C	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.65	-0.42	7.61e-8	Triglycerides;
PAAD	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg06569542	chr10:98946673	SLIT1	-0.51	-5.77	-0.42	4.31e-8	Monocyte count;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg06375148	chr1:209958343	C1orf74	0.63	5.42	0.4	2.25e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-1.02	-7.4	-0.51	8.59e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.84	0.62	5.68e-18	Prudent dietary pattern;
PAAD	cis	rs2019216	0.500	rs908696	chr17:21940987	T/G	cg22648282	chr17:21454238	C17orf51	-0.52	-4.85	-0.37	3e-6	Pelvic organ prolapse;
PAAD	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg11251234	chr10:101825055	CPN1	-0.32	-4.79	-0.36	3.95e-6	Bone mineral density;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg00035636	chr13:21900591	NA	0.58	5.74	0.42	4.98e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19754187	chr17:5186141	RABEP1	0.61	6.47	0.46	1.26e-9	Obesity-related traits;
PAAD	cis	rs7071247	0.915	rs3014204	chr10:105260229	G/T	cg06423925	chr10:105883847	C10orf78	0.56	4.39	0.34	2.08e-5	Platelet aggregation;
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.58	7.91	0.54	5.02e-13	Renal cell carcinoma;
PAAD	cis	rs3087591	0.639	rs2854333	chr17:29713300	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	4.35	0.33	2.52e-5	Hip circumference;
PAAD	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.67	0.42	7.08e-8	Colorectal cancer;
PAAD	cis	rs59888335	0.858	rs13088181	chr3:80922357	C/T	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.39	0.4	2.69e-7	Bipolar disorder;
PAAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.93	9.51	0.61	3.97e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg00576331	chr11:65640516	EFEMP2	-0.45	-4.3	-0.33	3e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg04160749	chr8:58172571	NA	-0.68	-4.63	-0.35	7.73e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733418	0.860	rs2056252	chr4:165947490	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	0.56	5.22	0.39	5.76e-7	Obesity-related traits;
PAAD	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.84	6.92	0.49	1.2e-10	Pulmonary function decline;
PAAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15197218	chr19:49197853	FUT2	-0.49	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs4740619	0.592	rs2987039	chr9:16002064	A/T	cg14451791	chr9:16040625	NA	0.38	4.63	0.35	7.72e-6	Body mass index;
PAAD	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.8	-0.48	2.2e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2036402	0.866	rs6555762	chr5:156365576	G/A	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.19e-5	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs2992756	0.617	rs3007719	chr1:18811668	C/T	cg14356550	chr1:18808102	KLHDC7A	0.55	5.68	0.42	6.6e-8	Breast cancer;
PAAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg12623918	chr2:306882	NA	0.46	4.78	0.36	4.03e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs12144094	0.882	rs10218713	chr1:120247899	A/G	cg20995928	chr1:120229863	NA	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.53	-0.34	1.21e-5	Educational attainment;
PAAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.45	-4.78	-0.36	4.04e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.9	6.65	0.47	4.94e-10	Iron status biomarkers;
PAAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.28	-0.33	3.24e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs72627123	1.000	rs7148538	chr14:74392342	G/C	cg19860245	chr14:74300557	NA	-0.74	-5.4	-0.4	2.55e-7	Morning vs. evening chronotype;
PAAD	cis	rs4234284	1.000	rs2358766	chr3:126966294	A/G	cg27326032	chr3:127006922	NA	-0.51	-5.15	-0.39	8.03e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-4.6	-0.35	8.75e-6	Body mass index;
PAAD	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.96	0.37	1.91e-6	Lung cancer in ever smokers;
PAAD	cis	rs9283706	0.595	rs6866433	chr5:66324152	A/G	cg11590213	chr5:66331682	MAST4	0.61	5.09	0.38	1.06e-6	Coronary artery disease;
PAAD	cis	rs11563648	0.553	rs2402859	chr7:127046472	T/G	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg11441379	chr12:63026424	NA	0.85	6.3	0.45	3.13e-9	IgG glycosylation;
PAAD	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.69	5.26	0.39	4.71e-7	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.9e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.0	-0.38	1.54e-6	Platelet count;
PAAD	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.99	-0.49	8.28e-11	Neuroticism;
PAAD	cis	rs72960926	0.744	rs7774793	chr6:75125541	T/G	cg03266952	chr6:74778945	NA	0.65	4.48	0.34	1.46e-5	Metabolite levels (MHPG);
PAAD	cis	rs77880822	0.562	rs77145042	chr20:1242634	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.82	-8.62	-0.57	7.95e-15	Coronary artery disease;
PAAD	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.57	5.42	0.4	2.3e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg21665744	chr7:39171113	POU6F2	0.39	5.84	0.43	3.03e-8	IgG glycosylation;
PAAD	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg12907477	chr18:56117327	MIR122	0.61	4.77	0.36	4.3e-6	Platelet count;
PAAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.47	4.47	0.34	1.49e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.53	-4.49	-0.34	1.41e-5	Morning vs. evening chronotype;
PAAD	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg13446199	chr8:143762866	PSCA	0.37	4.4	0.34	1.99e-5	Urinary tract infection frequency;
PAAD	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg05250797	chr16:70222502	NA	0.81	6.17	0.45	5.92e-9	IgE levels;
PAAD	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.91	-8.45	-0.57	2.17e-14	Body mass index;
PAAD	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg09127314	chr1:152161683	NA	-0.73	-4.74	-0.36	4.79e-6	Atopic dermatitis;
PAAD	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.95	-10.88	-0.66	9.55e-21	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs5417	0.627	rs62059170	chr17:7155056	T/C	cg13768953	chr17:7114967	DLG4	0.41	4.84	0.37	3.23e-6	Diastolic blood pressure;
PAAD	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg10556349	chr10:835070	NA	0.6	4.97	0.37	1.77e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg20913747	chr6:44695427	NA	-0.57	-5.27	-0.39	4.55e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.8	0.58	2.8e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2885056	0.891	rs1045361	chr19:10692000	T/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs12612619	0.732	rs722911	chr2:27211212	A/G	cg00617064	chr2:27272375	NA	-0.47	-5.06	-0.38	1.2e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.86	-9.2	-0.6	2.62e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg08619932	chr19:49200058	FUT2	0.57	6.19	0.45	5.4e-9	Dietary macronutrient intake;
PAAD	cis	rs3814231	0.589	rs12357967	chr10:115469710	G/A	cg24846397	chr10:115438155	CASP7	-0.53	-5.21	-0.39	6.05e-7	Vitiligo;
PAAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.66e-7	Blood metabolite levels;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs9534288	0.789	rs4942470	chr13:46636652	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-6.94	-0.49	1.04e-10	Blood protein levels;
PAAD	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.67	-0.53	1.96e-12	Total cholesterol levels;
PAAD	cis	rs9472414	0.622	rs7381290	chr6:44733725	T/G	cg20913747	chr6:44695427	NA	0.48	4.53	0.34	1.19e-5	Height;
PAAD	trans	rs3935740	0.649	rs4077174	chr15:81632077	A/C	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg12573674	chr2:1569213	NA	-0.61	-4.95	-0.37	1.96e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg01953289	chr20:60874239	NA	0.7	5.36	0.4	3.09e-7	Obesity-related traits;
PAAD	cis	rs6681460	0.834	rs1280310	chr1:67216823	T/A	cg02459107	chr1:67143332	SGIP1	-0.72	-6.75	-0.48	2.91e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.07	0.59	5.76e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.52	4.78	0.36	4.19e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	1.0	8.76	0.58	3.64e-15	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02972334	chr7:91764095	CYP51A1	-0.79	-6.75	-0.48	2.87e-10	Neuroticism;
PAAD	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.59	4.66	0.35	6.98e-6	Schizophrenia;
PAAD	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.5	0.41	1.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg05697835	chr1:2722811	NA	-0.43	-4.79	-0.36	3.88e-6	Ulcerative colitis;
PAAD	cis	rs478665	0.661	rs576563	chr1:65522102	C/T	cg24306340	chr1:64937451	CACHD1	-0.97	-4.89	-0.37	2.51e-6	Estradiol plasma levels (breast cancer);
PAAD	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.83	-9.08	-0.59	5.21e-16	Total body bone mineral density;
PAAD	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.84	-0.62	5.7e-18	Response to antipsychotic treatment;
PAAD	cis	rs6681460	0.625	rs4488004	chr1:67073314	T/C	cg02459107	chr1:67143332	SGIP1	0.55	5.15	0.39	7.96e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06307176	chr5:131281290	NA	0.49	4.49	0.34	1.41e-5	Life satisfaction;
PAAD	cis	rs9816226	0.591	rs6809651	chr3:185814642	G/A	cg00760338	chr3:185826511	ETV5	-0.71	-5.59	-0.41	1.02e-7	Obesity;Body mass index;
PAAD	cis	rs4450131	0.522	rs11245323	chr10:126344624	C/T	cg20435097	chr10:126320824	FAM53B	0.5	4.98	0.37	1.69e-6	White blood cell count (basophil);
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.76	-7.48	-0.52	5.48e-12	Urate levels in lean individuals;
PAAD	cis	rs422249	0.615	rs174612	chr11:61628266	C/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.51	0.34	1.29e-5	Trans fatty acid levels;
PAAD	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg26138144	chr22:38071188	LGALS1	0.41	4.61	0.35	8.54e-6	Fat distribution (HIV);
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg11335335	chr11:637885	DRD4	-0.36	-4.59	-0.35	9.07e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.53	5.54	0.41	1.29e-7	Diastolic blood pressure;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs10924309	0.855	rs7413150	chr1:245858729	G/A	cg00036263	chr1:245852353	KIF26B	-0.68	-6.08	-0.44	9.23e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs35955747	0.869	rs8142988	chr22:31587158	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-4.87	-0.37	2.81e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.62	6.61	0.47	6e-10	Lymphocyte counts;
PAAD	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9910055	0.520	rs479044	chr17:42158613	A/G	cg16434002	chr17:42200994	HDAC5	0.62	4.99	0.37	1.66e-6	Total body bone mineral density;
PAAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.69	-7.22	-0.51	2.3e-11	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-4.32	-0.33	2.8e-5	Aortic root size;
PAAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.66	-7.57	-0.52	3.34e-12	Huntington's disease progression;
PAAD	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.42	4.45	0.34	1.64e-5	Ulcerative colitis;
PAAD	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.64	6.5	0.47	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.6	7.4	0.51	8.81e-12	Multiple system atrophy;
PAAD	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg23093090	chr10:104574429	C10orf26	-0.41	-4.36	-0.33	2.42e-5	Colorectal cancer;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.48	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.58	-5.57	-0.41	1.13e-7	Blood metabolite levels;
PAAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg14196790	chr5:131705035	SLC22A5	0.49	5.16	0.39	7.78e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.8e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.89	0.43	2.45e-8	Tonsillectomy;
PAAD	cis	rs6442522	0.678	rs2345106	chr3:15509028	A/G	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.66	7.22	0.51	2.35e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg19630374	chr17:18023558	MYO15A	0.47	4.86	0.37	2.86e-6	Schizophrenia;
PAAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg09491104	chr22:46646882	C22orf40	-0.93	-8.95	-0.59	1.16e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.54	6.25	0.45	3.85e-9	Alzheimer's disease (late onset);
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05665937	chr4:1216051	CTBP1	-0.42	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs7537660	1.000	rs72761014	chr1:248006564	G/T	cg00785941	chr1:248100591	OR2L13	0.38	4.46	0.34	1.61e-5	Platelet distribution width;
PAAD	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg03871329	chr12:110338662	TCHP	0.67	4.99	0.38	1.63e-6	Neuroticism;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.38	-4.59	-0.35	9.22e-6	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.9	10.71	0.66	2.64e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg14820908	chr5:178986412	RUFY1	0.55	5.44	0.4	2.07e-7	Lung cancer;
PAAD	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.46	4.8	0.36	3.69e-6	Age of smoking initiation;
PAAD	trans	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg14703610	chr5:56206110	C5orf35	0.55	5.16	0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.4	-0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.48	0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7577696	0.554	rs35978916	chr2:32400635	T/C	cg02381751	chr2:32503542	YIPF4	-0.51	-4.79	-0.36	3.92e-6	Inflammatory biomarkers;
PAAD	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.62	6.73	0.48	3.2e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.31	-0.33	2.91e-5	Neuroticism;
PAAD	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.99	12.56	0.71	2.78e-25	Breast cancer;
PAAD	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.75	7.37	0.51	1.04e-11	Corneal astigmatism;
PAAD	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.35	0.33	2.51e-5	Plateletcrit;
PAAD	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.52	-4.56	-0.35	1.07e-5	Orofacial clefts;
PAAD	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg14393609	chr7:65229607	NA	-0.52	-4.48	-0.34	1.45e-5	Aortic root size;
PAAD	cis	rs2235573	0.657	rs760973	chr22:38447266	C/A	cg20893579	chr22:38215064	NA	-0.49	-5.28	-0.39	4.45e-7	Glioblastoma;Glioma;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.12	-0.5	4.1e-11	Coffee consumption (cups per day);
PAAD	cis	rs17125944	0.686	rs11157933	chr14:53349798	G/A	cg13660082	chr14:53194042	PSMC6	0.73	4.54	0.35	1.16e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	5.05	0.38	1.22e-6	Systolic blood pressure;
PAAD	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05585630	chr7:157510462	PTPRN2	-0.79	-9.37	-0.61	9.31e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16656979	chr15:37403242	NA	0.66	7.45	0.52	6.56e-12	Myopia (pathological);
PAAD	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.65	-0.57	6.73e-15	Morning vs. evening chronotype;
PAAD	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg00262122	chr8:11665843	FDFT1	-0.57	-5.45	-0.4	1.96e-7	Neuroticism;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-5.98	-0.44	1.56e-8	Lung cancer;
PAAD	cis	rs75757892	0.542	rs9505162	chr6:7326681	A/T	cg02954307	chr6:7269328	NA	0.5	4.27	0.33	3.44e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg23112188	chr14:24563095	PCK2	-0.58	-6.05	-0.44	1.09e-8	IgG glycosylation;
PAAD	cis	rs1519814	1.000	rs12678023	chr8:121123494	G/A	cg22335954	chr8:121166405	COL14A1	-0.61	-5.35	-0.4	3.14e-7	Breast cancer;
PAAD	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02419362	chr12:121203948	SPPL3	0.53	5.79	0.43	3.84e-8	Systemic lupus erythematosus;
PAAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-1.04	-14.62	-0.76	8.81e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.67	-6.7	-0.48	3.79e-10	Blood metabolite levels;
PAAD	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2229238	0.915	rs7514452	chr1:154438084	C/T	cg21262032	chr1:154437693	IL6R	0.45	4.7	0.36	5.88e-6	Coronary heart disease;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01516881	chr6:292596	DUSP22	-0.71	-6.96	-0.49	9.63e-11	Menopause (age at onset);
PAAD	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.65	-9.96	-0.63	2.65e-18	Asthma (sex interaction);
PAAD	cis	rs59191668	0.868	rs11071673	chr15:62819584	C/T	cg12918536	chr15:62891943	NA	0.35	4.64	0.35	7.42e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg02780029	chr10:43622663	RET	-0.45	-4.56	-0.35	1.05e-5	Hirschsprung disease;
PAAD	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	8.13	0.55	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs35504302	chr10:46010505	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.62	-0.47	5.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.55	4.6	0.35	9e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24543097	chr20:388556	RBCK1	0.71	8.1	0.55	1.63e-13	Myopia (pathological);
PAAD	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.91	5.88	0.43	2.45e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg21823605	chr1:152486609	CRCT1	0.49	6.15	0.45	6.54e-9	Hair morphology;
PAAD	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.53	5.31	0.4	3.87e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.78	8.63	0.57	7.78e-15	Longevity;
PAAD	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs13418717	1.000	rs951817	chr2:127664894	G/T	cg16909742	chr2:127635678	NA	0.86	4.29	0.33	3.15e-5	Heart failure;
PAAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.88	9.25	0.6	1.9e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.85	-6.13	-0.45	7.23e-9	Ulcerative colitis;
PAAD	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.83e-7	Total body bone mineral density;
PAAD	cis	rs2278796	0.608	rs6700069	chr1:204968945	A/G	cg17947172	chr1:204966197	NFASC	0.43	4.68	0.35	6.44e-6	Mean platelet volume;
PAAD	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	4.42	0.34	1.84e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.46	4.6	0.35	8.95e-6	Mean corpuscular volume;
PAAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs72960926	0.744	rs77045321	chr6:74915572	T/C	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.64	-5.88	-0.43	2.46e-8	Breast size;
PAAD	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.71	0.62	1.24e-17	Chronic sinus infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25642126	chr3:36898405	TRANK1	-0.64	-6.74	-0.48	3.03e-10	Obesity-related traits;
PAAD	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.73	-5.43	-0.4	2.21e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.5	-5.37	-0.4	2.87e-7	Calcium levels;
PAAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.62	-0.35	8.23e-6	Glomerular filtration rate;
PAAD	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg24881330	chr22:46731750	TRMU	1.22	6.61	0.47	6.1e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs17407555	0.837	rs10939710	chr4:10116801	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-6.15	-0.45	6.44e-9	Schizophrenia (age at onset);
PAAD	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg14146966	chr2:61757674	XPO1	0.4	4.95	0.37	1.97e-6	Tuberculosis;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.59	-5.67	-0.42	7.01e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11892454	0.565	rs10190878	chr2:25943374	A/G	cg25181710	chr2:26045287	ASXL2	0.41	4.7	0.36	5.72e-6	Heschl's gyrus morphology;
PAAD	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg27411982	chr8:10470053	RP1L1	-0.4	-4.26	-0.33	3.62e-5	Triglycerides;
PAAD	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg16578609	chr1:2399051	NA	-0.42	-4.37	-0.33	2.25e-5	Non-obstructive azoospermia;
PAAD	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	1.24	10.45	0.65	1.34e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.57	-6.24	-0.45	4.06e-9	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.63	-6.36	-0.46	2.22e-9	Iron status biomarkers;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.5	7.19	0.5	2.74e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg23153227	chr6:27725408	NA	0.43	4.64	0.35	7.49e-6	Parkinson's disease;
PAAD	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.35	-0.33	2.52e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.74	7.19	0.5	2.72e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.57	-7.3	-0.51	1.49e-11	Lewy body disease;
PAAD	cis	rs1359582	0.813	rs1555840	chr10:90382790	G/T	cg15661332	chr10:90342814	RNLS	0.54	4.69	0.36	6.08e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs2882667	0.690	rs825747	chr5:138136585	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.94	-0.43	1.87e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg14078157	chr9:128172775	NA	-0.53	-6.35	-0.46	2.33e-9	Mean arterial pressure;
PAAD	cis	rs8044995	0.636	rs77517043	chr16:68301410	G/A	cg05110241	chr16:68378359	PRMT7	-1.28	-7.55	-0.52	3.74e-12	Schizophrenia;
PAAD	cis	rs732765	0.689	rs10139925	chr14:75123076	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.44	-0.34	1.74e-5	Non-small cell lung cancer;
PAAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.96	-11.04	-0.67	3.61e-21	Prostate cancer;
PAAD	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.47	-0.41	1.84e-7	Schizophrenia;
PAAD	cis	rs9467603	0.566	rs10214468	chr6:25789390	T/A	cg08501292	chr6:25962987	TRIM38	0.79	5.05	0.38	1.24e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs225245	0.755	rs226441	chr17:34033072	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.56	-0.47	7.89e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.84	7.26	0.51	1.88e-11	Alzheimer's disease;
PAAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.97	8.45	0.57	2.14e-14	Alzheimer's disease;
PAAD	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.48	-4.88	-0.37	2.71e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.54	-5.21	-0.39	6.08e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.62	-4.85	-0.37	2.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	cis	rs977987	0.864	rs37593	chr16:75496907	T/C	cg03315344	chr16:75512273	CHST6	-0.66	-8.12	-0.55	1.51e-13	Dupuytren's disease;
PAAD	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg15226751	chr1:10001911	LZIC	0.38	4.25	0.33	3.72e-5	Hepatocellular carcinoma;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.38	0.4	2.72e-7	Prudent dietary pattern;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.76	9.41	0.61	7.33e-17	Lymphocyte counts;
PAAD	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg08390786	chr10:135334061	NA	0.47	4.53	0.34	1.18e-5	Obesity-related traits;
PAAD	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.75	8.64	0.57	7.03e-15	Methadone dose in opioid dependence;
PAAD	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.92	-7.36	-0.51	1.09e-11	Blood protein levels;
PAAD	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.64	5.76	0.42	4.5e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.11	-0.38	9.6e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.51	4.56	0.35	1.06e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.67	7.57	0.52	3.38e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.7	8.11	0.55	1.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.64	-6.67	-0.48	4.4e-10	Multiple sclerosis;
PAAD	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.8	-9.24	-0.6	2.1e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs10865550	chr2:641718	T/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg14703610	chr5:56206110	C5orf35	0.57	5.32	0.4	3.66e-7	Coronary artery disease;
PAAD	cis	rs501120	0.584	rs61855739	chr10:44679603	G/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg21905437	chr5:178450457	ZNF879	0.69	5.97	0.44	1.62e-8	Pubertal anthropometrics;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14853946	chr4:6883863	KIAA0232	-0.67	-6.35	-0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.9e-6	Coronary artery disease;
PAAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.35	4.83	0.36	3.3e-6	Height;
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.25	0.33	3.69e-5	Bipolar disorder;
PAAD	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg02135003	chr7:105160482	PUS7	-0.84	-6.75	-0.48	2.97e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-6.84	-0.49	1.83e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.91	-9.78	-0.62	8.02e-18	Breast cancer;
PAAD	cis	rs7567389	0.504	rs2069898	chr2:128174227	T/C	cg09760422	chr2:128146352	NA	0.41	6.08	0.44	9.39e-9	Self-rated health;
PAAD	cis	rs6191	0.838	rs852983	chr5:142712064	G/A	cg08845721	chr5:142780693	NR3C1	-0.4	-4.41	-0.34	1.93e-5	Night sleep phenotypes;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.51	5.24	0.39	5.16e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs818427	0.548	rs149193	chr5:112250361	A/C	cg06941702	chr5:112196734	SRP19	0.56	5.19	0.39	6.7e-7	Total body bone mineral density;
PAAD	cis	rs7210086	0.808	rs3935122	chr17:70641315	C/T	cg04206342	chr17:70636940	NA	-0.44	-5.57	-0.41	1.11e-7	Ulcerative colitis;
PAAD	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.62	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.61	5.45	0.4	1.97e-7	Alzheimer's disease (late onset);
PAAD	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg06007645	chr1:55107421	C1orf175	0.45	5.48	0.41	1.72e-7	Survival in pancreatic cancer;
PAAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.97	-9.13	-0.6	3.99e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.01	0.49	7.42e-11	Life satisfaction;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.4	-0.56	2.89e-14	Longevity;Endometriosis;
PAAD	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.75	7.47	0.52	5.87e-12	Corneal astigmatism;
PAAD	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg19760965	chr3:194868843	C3orf21	0.47	4.26	0.33	3.53e-5	Non-small cell lung cancer;
PAAD	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-5.2	-0.39	6.33e-7	Aortic root size;
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs838147	0.537	rs602662	chr19:49206985	G/A	cg08619932	chr19:49200058	FUT2	0.57	6.05	0.44	1.06e-8	Dietary macronutrient intake;
PAAD	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.8	9.37	0.61	9.46e-17	Colorectal cancer;
PAAD	cis	rs9976767	0.792	rs883868	chr21:43845092	C/T	cg23042151	chr21:43824109	UBASH3A	0.38	4.8	0.36	3.77e-6	Type 1 diabetes;
PAAD	trans	rs901683	1.000	rs34415465	chr10:45985580	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg15557168	chr22:42548783	NA	-0.55	-6.06	-0.44	1.05e-8	Cognitive function;
PAAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg12639453	chr1:2035780	PRKCZ	0.55	5.3	0.4	3.94e-7	Height;
PAAD	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg12037450	chr1:85513124	MCOLN3	-0.46	-4.31	-0.33	2.97e-5	Serum sulfate level;
PAAD	cis	rs2117029	0.553	rs11168903	chr12:49568666	C/G	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.81	7.89	0.54	5.65e-13	Corneal astigmatism;
PAAD	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs74961584	chr3:128567032	T/C	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.46	-4.79	-0.36	3.89e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9850225	0.887	rs62259209	chr3:80879357	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Erectile dysfunction in type 1 diabetes;
PAAD	cis	rs72780191	0.574	rs55836224	chr2:23895597	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	6.47	0.46	1.27e-9	White blood cell count;
PAAD	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.9	-10.07	-0.63	1.38e-18	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg22143856	chr6:28129313	ZNF389	0.52	4.81	0.36	3.55e-6	Parkinson's disease;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs5009270	0.524	rs11770706	chr7:112211275	G/T	cg23628563	chr7:112262597	NA	0.57	4.84	0.37	3.21e-6	Osteoarthritis (hip);
PAAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.46	3.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.47	-5.16	-0.39	7.52e-7	Coronary artery disease;
PAAD	cis	rs11037575	0.647	rs7948942	chr11:43724466	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2e-5	Neuroblastoma;
PAAD	cis	rs4919087	0.561	rs10082521	chr10:99070526	A/T	cg25902810	chr10:99078978	FRAT1	-0.57	-5.35	-0.4	3.16e-7	Monocyte count;
PAAD	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs10929159	0.928	rs2317305	chr2:236922151	G/A	cg14226755	chr2:236923322	AGAP1	0.29	4.55	0.35	1.08e-5	Parkinson's disease;
PAAD	cis	rs9346353	0.737	rs1563606	chr6:70497503	C/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.64	-5.87	-0.43	2.68e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.46	-4.91	-0.37	2.31e-6	Breast cancer;
PAAD	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.71	6.0	0.44	1.38e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.7	-0.36	5.79e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.08	0.44	9.51e-9	Colorectal cancer;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.5	5.07	0.38	1.15e-6	Obesity-related traits;
PAAD	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.68	-0.35	6.4e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11087736	chr15:51200195	AP4E1	0.59	6.72	0.48	3.49e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg19254793	chr6:44695348	NA	-0.47	-4.45	-0.34	1.65e-5	Total body bone mineral density;
PAAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg09835421	chr16:68378352	PRMT7	-0.92	-7.24	-0.51	2.14e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.52	4.7	0.36	5.67e-6	Optic cup area;
PAAD	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02419362	chr12:121203948	SPPL3	-0.5	-5.58	-0.41	1.06e-7	Systemic lupus erythematosus;
PAAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.83	0.48	1.89e-10	Yeast infection;
PAAD	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg01796438	chr3:11312864	ATG7	-0.72	-5.37	-0.4	2.84e-7	Circulating chemerin levels;
PAAD	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.55	-5.47	-0.41	1.85e-7	Motion sickness;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg24553058	chr2:113831203	IL1F10	0.46	5.16	0.39	7.47e-7	Protein quantitative trait loci;
PAAD	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.98	6.97	0.49	9.28e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs11628318	0.853	rs4906224	chr14:103025040	C/T	cg12046867	chr14:103022105	NA	-0.65	-5.19	-0.39	6.57e-7	Platelet count;
PAAD	cis	rs6256	1.000	rs75576868	chr11:13570708	G/A	cg11976911	chr11:13509032	NA	-0.66	-5.11	-0.38	9.6e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs16975963	0.843	rs17249047	chr19:38336563	A/G	cg14218481	chr19:38281219	NA	0.43	4.49	0.34	1.42e-5	Longevity;
PAAD	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.71	-6.14	-0.45	6.9e-9	Schizophrenia;
PAAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.96	7.95	0.54	4e-13	Gut microbiome composition (summer);
PAAD	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg00101154	chr16:420108	MRPL28	-0.65	-6.29	-0.45	3.13e-9	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12428298	chr2:71206811	ANKRD53	-0.71	-7.54	-0.52	4.03e-12	Obesity-related traits;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs6142102	0.580	rs6142101	chr20:32697845	G/A	cg06115741	chr20:33292138	TP53INP2	0.58	5.22	0.39	5.69e-7	Skin pigmentation;
PAAD	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.24	-0.39	5.25e-7	Systolic blood pressure;
PAAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.84	-0.58	2.17e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.9	-4.6	-0.35	8.94e-6	Toenail selenium levels;
PAAD	cis	rs2030114	1.000	rs7184672	chr16:51614153	C/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.3	-0.76	6.24e-30	Primary sclerosing cholangitis;
PAAD	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.03	-0.59	7.24e-16	Exhaled nitric oxide output;
PAAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9810890	1.000	rs73196956	chr3:128430834	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg21918786	chr6:109611834	NA	-0.6	-6.49	-0.47	1.16e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.77	6.15	0.45	6.57e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.81	10.1	0.63	1.15e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.99	10.88	0.66	9.38e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs73072330	1.000	rs73072330	chr3:48165089	G/A	cg09665691	chr3:47563885	NA	1.22	5.55	0.41	1.25e-7	Stem cell growth factor beta levels;
PAAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-6.69	-0.48	4.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs2404602	0.622	rs2280194	chr15:77239651	C/T	cg26408565	chr15:76604113	ETFA	0.47	4.25	0.33	3.73e-5	Blood metabolite levels;
PAAD	cis	rs340029	0.798	rs339989	chr15:60914821	G/T	cg00200653	chr15:60883225	RORA	0.52	4.5	0.34	1.34e-5	C-reactive protein levels;
PAAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg21361702	chr7:150065534	REPIN1	0.57	4.58	0.35	9.8200000000000008e-06	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg07548257	chr22:31686466	PIK3IP1	-0.35	-4.28	-0.33	3.28e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6460942	0.597	rs35589221	chr7:12535841	T/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg16928487	chr17:17741425	SREBF1	0.33	4.48	0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs9907295	0.818	rs4795093	chr17:34180141	T/C	cg16983627	chr17:34238386	NA	-0.56	-4.37	-0.33	2.33e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.39	-0.34	2.09e-5	Ileal carcinoids;
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	8.01	0.54	2.74e-13	Schizophrenia;
PAAD	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.84	6.5	0.47	1.07e-9	Axial length;
PAAD	cis	rs501120	0.925	rs1746049	chr10:44776310	C/T	cg09554077	chr10:44749378	NA	0.48	5.84	0.43	3.12e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.97	0.44	1.58e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7210086	0.808	rs4331375	chr17:70640082	A/G	cg04206342	chr17:70636940	NA	-0.47	-6.15	-0.45	6.52e-9	Ulcerative colitis;
PAAD	cis	rs17407555	0.657	rs4698001	chr4:10279413	A/T	cg11266682	chr4:10021025	SLC2A9	0.42	4.34	0.33	2.63e-5	Schizophrenia (age at onset);
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06112835	chr11:68658793	MRPL21	0.61	6.02	0.44	1.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg03999872	chr20:62272968	STMN3	0.72	6.36	0.46	2.29e-9	Atopic dermatitis;
PAAD	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs13160562	0.666	rs26481	chr5:96103352	C/T	cg21635917	chr5:96038401	CAST	0.46	4.34	0.33	2.63e-5	Alcohol dependence;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.79	6.63	0.47	5.61e-10	Alzheimer's disease;
PAAD	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	1.0	11.64	0.69	8.88e-23	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs80262450	1	rs80262450	chr18:12818922	G/A	cg23544223	chr18:12777786	NA	-0.67	-4.27	-0.33	3.45e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7715811	1.000	rs2896103	chr5:13764419	G/A	cg07548982	chr5:13769939	DNAH5	-0.64	-6.23	-0.45	4.43e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.39	5.63	0.42	8.48e-8	Educational attainment (years of education);
PAAD	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.51	6.11	0.44	8.19e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.41	4.55	0.35	1.11e-5	Dietary macronutrient intake;
PAAD	cis	rs10887741	0.624	rs7088341	chr10:89427820	C/T	cg13926569	chr10:89418898	PAPSS2	0.5	5.05	0.38	1.26e-6	Exercise (leisure time);
PAAD	cis	rs7534824	0.625	rs61780321	chr1:101428304	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg13498757	chr1:152161927	NA	0.52	5.16	0.39	7.65e-7	Inflammatory skin disease;
PAAD	trans	rs901683	1.000	rs35349326	chr10:45973624	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.86	-10.2	-0.64	6.22e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.58	6.39	0.46	1.89e-9	Cardiovascular disease risk factors;
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.25	-0.51	1.99e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg01388757	chr2:102091195	RFX8	-0.53	-6.68	-0.48	4.15e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-6.4	-0.46	1.87e-9	Bipolar disorder;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg23281280	chr6:28129359	ZNF389	0.52	4.73	0.36	5.06e-6	Parkinson's disease;
PAAD	trans	rs11794666	0.799	rs11787576	chr9:31742190	C/A	cg05628366	chr6:35744188	C6orf126	0.95	6.7	0.48	3.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.99	10.54	0.65	7.53e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.54	5.06	0.38	1.17e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs151997	0.720	rs152096	chr5:50213850	A/G	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs714515	0.586	rs10911792	chr1:172451378	G/C	cg13446689	chr1:172328377	DNM3	-0.44	-5.36	-0.4	3.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs7933455	0.502	rs1385850	chr11:12234595	C/T	cg10383724	chr11:12228521	MICAL2	0.59	4.25	0.33	3.69e-5	Cold sores;
PAAD	cis	rs11992162	0.506	rs55948474	chr8:11809662	A/G	cg00262122	chr8:11665843	FDFT1	-0.5	-4.53	-0.34	1.18e-5	Monocyte count;
PAAD	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.89	-0.37	2.5e-6	Thrombosis;
PAAD	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21963583	chr11:68658836	MRPL21	-0.39	-4.46	-0.34	1.57e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.72	8.98	0.59	9.93e-16	Dupuytren's disease;
PAAD	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-8.67	-0.58	6.08e-15	Coronary artery disease;
PAAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-0.93	-9.23	-0.6	2.13e-16	Exhaled nitric oxide output;
PAAD	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	6.65	0.47	5.03e-10	Lung cancer in ever smokers;
PAAD	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg22467129	chr15:76604101	ETFA	0.53	4.99	0.38	1.64e-6	Blood metabolite levels;
PAAD	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.49	-5.11	-0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg13264159	chr8:625131	ERICH1	-0.78	-5.25	-0.39	5.06e-7	IgG glycosylation;
PAAD	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg18209359	chr17:80159595	CCDC57	-0.45	-4.39	-0.34	2.12e-5	Life satisfaction;
PAAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.71	-6.41	-0.46	1.71e-9	Urate levels in obese individuals;
PAAD	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.53	5.48	0.41	1.69e-7	Red blood cell count;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-6.25	-0.45	4e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs66530629	1.000	rs72654647	chr1:25022314	G/A	cg22509179	chr1:25234806	RUNX3	0.55	4.92	0.37	2.26e-6	Plateletcrit;
PAAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-5.66	-0.42	7.47e-8	Renal function-related traits (BUN);
PAAD	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.74	-7.2	-0.5	2.54e-11	DNA methylation (variation);
PAAD	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg02527881	chr3:46936655	PTH1R	0.38	4.64	0.35	7.59e-6	Colorectal cancer;
PAAD	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg25364880	chr3:44379878	C3orf23	0.56	5.48	0.41	1.7e-7	Depressive symptoms;
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23863100	chr12:108912661	FICD	-0.68	-7.04	-0.5	6.21e-11	Obesity-related traits;
PAAD	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-4.76	-0.36	4.39e-6	Aortic root size;
PAAD	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.37	0.51	9.94e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2929278	0.617	rs694461	chr15:44096063	C/T	cg26247942	chr15:43984922	CKMT1A	0.36	4.65	0.35	7.29e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02242080	chr9:128469270	MAPKAP1	0.57	6.35	0.46	2.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12681288	0.578	rs73176535	chr8:971916	C/T	cg08648136	chr8:956695	NA	0.52	5.53	0.41	1.38e-7	Schizophrenia;
PAAD	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.69	6.75	0.48	2.97e-10	Coronary artery disease;
PAAD	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg22800045	chr5:56110881	MAP3K1	0.7	5.78	0.42	4e-8	Coronary artery disease;
PAAD	cis	rs730532	0.556	rs1497086	chr14:52517190	C/G	cg10149976	chr14:52535953	NID2	-0.64	-4.98	-0.37	1.71e-6	Pulmonary function;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.51	-0.41	1.53e-7	Electroencephalogram traits;
PAAD	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.95	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.73	8.56	0.57	1.18e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1015291	0.708	rs1586839	chr12:19998176	C/A	cg25401612	chr12:20009446	NA	-0.54	-5.27	-0.39	4.52e-7	Diastolic blood pressure;
PAAD	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.79	-8.26	-0.56	6.67e-14	Corneal astigmatism;
PAAD	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22509189	chr2:225307070	NA	-0.49	-4.74	-0.36	4.84e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	4.38	0.33	2.24e-5	Crohn's disease;
PAAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg23463467	chr20:60627584	TAF4	0.47	4.96	0.37	1.84e-6	Body mass index;
PAAD	cis	rs2124910	1.000	rs1551559	chr19:52034940	C/T	cg12008991	chr19:52034861	SIGLEC6	0.38	4.92	0.37	2.23e-6	Blood protein levels;
PAAD	cis	rs2004318	1.000	rs80310208	chr19:55132238	T/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.68	7.74	0.53	1.32e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7532866	1.000	rs17163904	chr1:26741106	C/T	cg17456097	chr1:26900765	RPS6KA1	0.52	4.43	0.34	1.78e-5	Height;
PAAD	cis	rs11235843	0.853	rs17132369	chr11:73519075	T/G	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.18e-5	Hand grip strength;
PAAD	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.62	5.83	0.43	3.23e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.23e-27	Height;
PAAD	cis	rs2085601	0.542	rs6532094	chr4:89946734	G/A	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04063615	chr12:132293388	NA	-0.45	-4.52	-0.34	1.23e-5	Migraine;
PAAD	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg08079166	chr15:68083412	MAP2K5	0.65	5.14	0.39	8.16e-7	Restless legs syndrome;
PAAD	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.67	7.68	0.53	1.82e-12	Verbal declarative memory;
PAAD	trans	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg00717180	chr2:96193071	NA	0.62	6.92	0.49	1.18e-10	HDL cholesterol;
PAAD	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6496932	0.802	rs8038403	chr15:85856595	G/T	cg19183879	chr15:85880815	NA	0.52	4.78	0.36	4.07e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.45	-5.19	-0.39	6.75e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.79	-0.48	2.42e-10	Mitochondrial DNA levels;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg05313129	chr8:58192883	C8orf71	-0.65	-5.17	-0.39	7.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10450586	0.932	rs61890486	chr11:27321035	G/A	cg10370305	chr11:27303972	NA	0.38	4.56	0.35	1.05e-5	Total body bone mineral density;
PAAD	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.37e-11	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.6	-0.35	8.67e-6	Lung cancer;
PAAD	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg19630374	chr17:18023558	MYO15A	-0.56	-5.93	-0.43	1.99e-8	Total body bone mineral density;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01017895	chr20:388559	RBCK1	0.6	6.52	0.47	9.81e-10	Iris heterochromicity;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21155852	chr7:2048760	MAD1L1	-0.44	-4.46	-0.34	1.62e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.23	-0.6	2.22e-16	Colorectal cancer;
PAAD	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg19980929	chr12:42632907	YAF2	0.54	6.3	0.46	3.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06634786	chr22:41940651	POLR3H	-0.55	-4.4	-0.34	2.03e-5	Vitiligo;
PAAD	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg03315344	chr16:75512273	CHST6	0.63	5.29	0.39	4.17e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg06784991	chr1:53308768	ZYG11A	0.29	4.42	0.34	1.86e-5	Monocyte count;
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.63	8.11	0.55	1.5700000000000001e-13	Hypertriglyceridemia;
PAAD	cis	rs12438356	1.000	rs74860015	chr15:69587410	A/G	cg02375503	chr15:69591110	PAQR5	-0.62	-4.3	-0.33	3.06e-5	CTACK levels;
PAAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg12215294	chr3:40350768	EIF1B	0.5	5.04	0.38	1.31e-6	Renal cell carcinoma;
PAAD	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.67	5.75	0.42	4.79e-8	Obesity-related traits;
PAAD	cis	rs10958605	0.761	rs2980818	chr8:40030736	T/A	cg14545590	chr8:40388592	ZMAT4	0.43	4.73	0.36	4.99e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.71	6.77	0.48	2.67e-10	Obesity-related traits;
PAAD	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.44	4.34	0.33	2.62e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg18265118	chr7:2139243	MAD1L1	0.54	4.5	0.34	1.34e-5	Neuroticism;
PAAD	cis	rs12431939	0.947	rs59298295	chr14:51659047	T/G	cg23942311	chr14:51606299	NA	-0.71	-5.64	-0.42	8.01e-8	Cancer;
PAAD	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg05925327	chr15:68127851	NA	-0.5	-4.43	-0.34	1.76e-5	Obesity;
PAAD	cis	rs4668356	1.000	rs73029214	chr2:171947672	A/G	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg08558340	chr7:100472263	SRRT	0.51	4.51	0.34	1.27e-5	Resting heart rate;
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.7	8.94	0.59	1.22e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.92	-0.37	2.24e-6	Platelet count;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.57e-6	Bipolar disorder;
PAAD	cis	rs89107	0.576	rs17227124	chr6:118741382	T/C	cg21191810	chr6:118973309	C6orf204	0.37	4.28	0.33	3.35e-5	Cardiac structure and function;
PAAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.49	4.52	0.34	1.22e-5	Monocyte count;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg26554054	chr8:600488	NA	0.97	6.96	0.49	9.69e-11	IgG glycosylation;
PAAD	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg01815783	chr4:1047043	NA	0.45	5.84	0.43	3.13e-8	Recombination rate (males);
PAAD	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.82	0.36	3.4e-6	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14136781	chr9:124087974	GSN	-0.59	-6.41	-0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.43	4.87	0.37	2.81e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.47	0.57	1.97e-14	Dupuytren's disease;
PAAD	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.66	-5.98	-0.44	1.56e-8	Response to antineoplastic agents;
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.61	5.77	0.42	4.32e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10905065	0.895	rs1858447	chr10:5852230	A/G	cg11519256	chr10:5708881	ASB13	-0.52	-4.48	-0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg13606994	chr1:44402422	ARTN	-0.42	-4.62	-0.35	8.27e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9517320	0.935	rs56294784	chr13:99123198	C/T	cg20487152	chr13:99095054	FARP1	0.47	4.77	0.36	4.31e-6	Longevity;
PAAD	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.04	-7.78	-0.53	1.02e-12	Diabetic kidney disease;
PAAD	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg12639453	chr1:2035780	PRKCZ	-0.53	-5.51	-0.41	1.52e-7	Height;
PAAD	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.69	0.58	5.24e-15	Bipolar disorder;
PAAD	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.59	-5.33	-0.4	3.42e-7	Systemic lupus erythematosus;
PAAD	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.41	-0.71	7.1e-25	Primary sclerosing cholangitis;
PAAD	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-4.42	-0.34	1.88e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-5.76	-0.42	4.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8077577	0.747	rs16961153	chr17:18227101	A/G	cg03916694	chr17:18150707	FLII	-0.4	-4.44	-0.34	1.69e-5	Obesity-related traits;
PAAD	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs2555155	1.000	rs2723620	chr11:6523657	A/G	cg11185456	chr11:6592066	DNHD1	0.41	4.3	0.33	3.04e-5	DNA methylation (variation);
PAAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.49	5.47	0.41	1.82e-7	Height;
PAAD	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11954230	chr10:105677556	OBFC1	-0.6	-6.3	-0.46	3.05e-9	Height;
PAAD	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs686320	0.748	rs550894	chr11:65211940	C/A	cg16175245	chr11:65246563	NA	0.49	4.69	0.36	5.97e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs3857067	0.550	rs6840757	chr4:95003200	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03312703	chr1:205548992	MFSD4	-0.62	-6.56	-0.47	7.99e-10	Smoking initiation;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg16434002	chr17:42200994	HDAC5	0.65	6.94	0.49	1.05e-10	Total body bone mineral density;
PAAD	cis	rs2718812	1.000	rs2718813	chr3:133399212	A/G	cg08048268	chr3:133502702	NA	0.43	5.24	0.39	5.18e-7	Iron status biomarkers;
PAAD	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.95	-8.93	-0.59	1.29e-15	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14280576	chr9:133580010	EXOSC2	-0.69	-7.01	-0.49	7.35e-11	Obesity-related traits;
PAAD	cis	rs8113142	0.614	rs4804848	chr19:29139728	A/T	cg04546413	chr19:29218101	NA	0.42	4.25	0.33	3.77e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg08222618	chr4:941054	TMEM175	0.79	10.56	0.65	6.86e-20	Sjögren's syndrome;
PAAD	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg00359181	chr2:38893519	GALM	-0.6	-4.48	-0.34	1.44e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs259282	0.628	rs2287669	chr19:33110204	T/C	cg02997394	chr19:33096574	ANKRD27	-0.43	-4.55	-0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.61	7.49	0.52	5.22e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3764400	0.567	rs9890691	chr17:46192936	G/T	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg09127314	chr1:152161683	NA	0.68	4.91	0.37	2.28e-6	Atopic dermatitis;
PAAD	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.86	-0.43	2.8e-8	Mean corpuscular volume;
PAAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.5	2.45e-11	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.65	-6.97	-0.49	9.13e-11	Brugada syndrome;
PAAD	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7577696	0.693	rs466126	chr2:32462094	G/A	cg02381751	chr2:32503542	YIPF4	0.41	4.37	0.33	2.3e-5	Inflammatory biomarkers;
PAAD	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.09	-0.38	1.07e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs6662572	0.950	rs11579176	chr1:46050561	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	4.37	0.33	2.26e-5	Blood protein levels;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.72	-0.62	1.16e-17	Response to antipsychotic treatment;
PAAD	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.69	6.51	0.47	1.05e-9	Endometrial cancer;
PAAD	cis	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs4679121	0.730	rs62264698	chr3:126159711	T/G	cg05485589	chr3:126194908	ZXDC	-0.94	-4.89	-0.37	2.53e-6	Pursuit maintenance gain;
PAAD	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.77	0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11966931	0.948	rs17528484	chr6:108095573	A/G	cg13784235	chr6:108495865	NR2E1	-0.32	-4.31	-0.33	2.96e-5	Neutrophil percentage of white cells;
PAAD	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03176143	chr19:4066940	ZBTB7A	0.58	6.31	0.46	2.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4605213	0.510	rs12946936	chr17:49287320	G/A	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.63	-0.35	7.77e-6	Height;
PAAD	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-5.51	-0.41	1.53e-7	Personality dimensions;
PAAD	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.49	-5.69	-0.42	6.32e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	4.47	0.34	1.53e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg22467129	chr15:76604101	ETFA	0.53	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-13.06	-0.73	1.3e-26	Longevity;Endometriosis;
PAAD	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.29e-8	Colorectal cancer;
PAAD	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	1.17	17.01	0.81	5.24e-37	Gut microbiome composition (winter);
PAAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.49	4.53	0.34	1.18e-5	Renal cell carcinoma;
PAAD	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg16926213	chr1:1841314	NA	0.38	4.54	0.35	1.15e-5	Body mass index;
PAAD	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg14393609	chr7:65229607	NA	-0.54	-4.52	-0.34	1.25e-5	Aortic root size;
PAAD	cis	rs15676	0.947	rs7854319	chr9:131567995	G/A	cg00228799	chr9:131580591	ENDOG	-0.6	-5.95	-0.43	1.81e-8	Blood metabolite levels;
PAAD	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.41	0.34	1.98e-5	Tonsillectomy;
PAAD	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.56	-4.85	-0.37	3.09e-6	Total body bone mineral density;
PAAD	cis	rs55665837	0.539	rs12794714	chr11:14913575	G/A	cg16394018	chr11:14927549	NA	0.45	4.97	0.37	1.79e-6	Vitamin D levels;
PAAD	cis	rs2880058	1.000	rs2880058	chr1:162014632	A/G	cg00101227	chr1:161280266	MPZ	0.43	4.4	0.34	1.99e-5	QT interval;
PAAD	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg14926445	chr8:58193284	C8orf71	-0.66	-5.38	-0.4	2.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.62	5.41	0.4	2.35e-7	Red blood cell count;
PAAD	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.76	-0.62	9.06e-18	Response to antipsychotic treatment;
PAAD	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.7	-4.33	-0.33	2.65e-5	White matter integrity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20243816	chr12:113573611	RASAL1	-0.73	-6.51	-0.47	1.04e-9	Neuroticism;
PAAD	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27333274	chr16:57279026	ARL2BP	0.63	7.0	0.49	7.63e-11	Myopia (pathological);
PAAD	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-4.48	-0.34	1.46e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg16306870	chr3:194868790	C3orf21	0.42	4.46	0.34	1.56e-5	Non-small cell lung cancer;
PAAD	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg06637938	chr14:75390232	RPS6KL1	0.46	4.5	0.34	1.36e-5	Height;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.95	-12.53	-0.71	3.5e-25	Menarche (age at onset);
PAAD	cis	rs6137287	0.813	rs6035787	chr20:21117840	T/C	cg04219410	chr20:21106687	PLK1S1	0.38	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg19949948	chr17:19361230	NA	0.42	4.45	0.34	1.66e-5	Schizophrenia;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-1.01	-8.75	-0.58	3.72e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.61	6.4	0.46	1.84e-9	Lung cancer;
PAAD	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg26876637	chr1:152193138	HRNR	-0.88	-6.85	-0.49	1.68e-10	Atopic dermatitis;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07685180	chr8:600429	NA	0.83	5.32	0.4	3.71e-7	IgG glycosylation;
PAAD	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.68	7.99	0.54	3.2e-13	Alcohol dependence;
PAAD	cis	rs1879734	0.689	rs12097598	chr1:54170801	C/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.38	-0.46	2.02e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg14926445	chr8:58193284	C8orf71	-0.76	-6.04	-0.44	1.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.95	-5.7	-0.42	6.11e-8	Body mass index;
PAAD	cis	rs1448094	0.565	rs10863107	chr12:86319548	C/T	cg06740227	chr12:86229804	RASSF9	0.47	4.27	0.33	3.4e-5	Major depressive disorder;
PAAD	cis	rs950880	0.710	rs3771177	chr2:102955860	G/T	cg23450938	chr2:102972792	NA	0.45	4.8	0.36	3.78e-6	Serum protein levels (sST2);
PAAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg03676636	chr4:99064102	C4orf37	0.25	4.43	0.34	1.78e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3206736	0.548	rs1186716	chr7:34970685	C/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.76	-0.36	4.56e-6	Diastolic blood pressure;
PAAD	cis	rs7853377	0.723	rs6559751	chr9:86551269	A/G	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs3112530	1.000	rs3111205	chr5:152641607	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.48	-5.84	-0.43	3.03e-8	Sitting height ratio;
PAAD	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-6.4	-0.46	1.83e-9	Morning vs. evening chronotype;
PAAD	cis	rs2242420	0.920	rs12567723	chr1:21954666	G/A	cg26362272	chr1:22108717	USP48	0.59	4.49	0.34	1.38e-5	Hematological and biochemical traits;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13560548	chr3:10150139	C3orf24	0.61	5.45	0.4	2.01e-7	Alzheimer's disease;
PAAD	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg21095983	chr6:86352623	SYNCRIP	0.63	6.43	0.46	1.56e-9	Smooth-surface caries;
PAAD	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.4	5.3	0.4	3.97e-7	Obesity-related traits;
PAAD	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg11822372	chr1:151115635	SEMA6C	0.53	4.91	0.37	2.3e-6	Childhood ear infection;
PAAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg10935138	chr17:73851978	WBP2	0.89	7.35	0.51	1.11e-11	Psoriasis;
PAAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.64	7.11	0.5	4.24e-11	Emphysema distribution in smoking;
PAAD	cis	rs4739066	0.579	rs77643961	chr8:63879716	A/G	cg20602954	chr8:63776762	NKAIN3	0.8	5.16	0.39	7.64e-7	Myocardial infarction;
PAAD	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21066735	chr11:15671806	NA	-0.81	-7.33	-0.51	1.26e-11	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27018240	chr12:68647387	IL22	-0.57	-6.31	-0.46	2.85e-9	Obesity-related traits;
PAAD	cis	rs3743102	0.591	rs10520565	chr15:83255074	C/T	cg00614314	chr15:82944287	LOC80154	-0.76	-5.35	-0.4	3.18e-7	Colorectal adenoma (advanced);
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg19761014	chr17:28927070	LRRC37B2	0.73	5.25	0.39	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	4.28	0.33	3.24e-5	Systolic blood pressure;
PAAD	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg24110177	chr3:50126178	RBM5	-0.82	-9.14	-0.6	3.72e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.81	7.92	0.54	4.69e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.65	0.35	7.25e-6	Breast cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg00586537	chr16:67571354	FAM65A	0.62	6.39	0.46	1.95e-9	Primary biliary cholangitis;
PAAD	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg01329690	chr21:38580129	DSCR9	0.31	4.27	0.33	3.42e-5	Eye color traits;
PAAD	cis	rs7209700	0.692	rs11652097	chr17:45316717	C/T	cg08085267	chr17:45401833	C17orf57	0.49	4.47	0.34	1.49e-5	IgG glycosylation;
PAAD	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.37	-4.61	-0.35	8.45e-6	Menarche (age at onset);
PAAD	cis	rs4740619	0.630	rs2987025	chr9:15987122	C/A	cg14451791	chr9:16040625	NA	0.37	4.39	0.34	2.07e-5	Body mass index;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.64	-7.08	-0.5	5.04e-11	Facial morphology (factor 20);
PAAD	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-6.3	-0.45	3.1e-9	Vitamin D levels;
PAAD	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.13	-0.5	3.79e-11	Neuroticism;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.57	0.65	6.39e-20	Platelet count;
PAAD	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	5.43	0.4	2.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.49	-4.4	-0.34	1.99e-5	Asthma;
PAAD	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.57	6.3	0.46	2.98e-9	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg00262122	chr8:11665843	FDFT1	-0.57	-5.45	-0.4	1.96e-7	Neuroticism;
PAAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg15691649	chr6:25882328	NA	0.66	6.17	0.45	6.03e-9	Blood metabolite levels;
PAAD	cis	rs7129556	0.906	rs72945508	chr11:77267537	G/C	cg24456632	chr11:77314957	AQP11	-0.5	-4.36	-0.33	2.4e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs7624766	0.778	rs7634342	chr3:160485789	G/A	cg22637730	chr3:160473554	PPM1L	0.55	4.99	0.38	1.65e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg15412446	chr2:106886593	NA	0.59	5.83	0.43	3.15e-8	Facial morphology (factor 23);
PAAD	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	5.69	0.42	6.3e-8	Body mass index;
PAAD	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs4740619	0.711	rs10756730	chr9:15975069	T/C	cg14451791	chr9:16040625	NA	-0.38	-4.37	-0.33	2.32e-5	Body mass index;
PAAD	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	4.4	0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs10821973	0.527	rs4586044	chr10:63979074	A/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.32	-0.33	2.75e-5	Hypothyroidism;
PAAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg26174226	chr8:58114915	NA	-0.62	-5.14	-0.38	8.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.48	4.75	0.36	4.76e-6	Mean corpuscular volume;
PAAD	cis	rs621942	0.718	rs622110	chr11:85668163	G/A	cg07180834	chr11:85838833	NA	-0.49	-4.87	-0.37	2.75e-6	Tourette syndrome;
PAAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.77	-6.93	-0.49	1.09e-10	Blood protein levels;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.58	-6.48	-0.47	1.2e-9	Cognitive function;
PAAD	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg03989125	chr22:38214979	NA	0.6	5.48	0.41	1.76e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg20805835	chr1:248005719	OR11L1	0.51	4.57	0.35	1.02e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg14500267	chr11:67383377	NA	0.47	4.67	0.35	6.71e-6	Mean corpuscular volume;
PAAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.34	16.32	0.8	3.13e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs28830936	0.966	rs2303516	chr15:42128568	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.86e-10	Diastolic blood pressure;
PAAD	cis	rs56046484	0.871	rs34978449	chr15:85580148	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	cis	rs4691139	0.658	rs4691142	chr4:165926786	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.4	-4.37	-0.33	2.25e-5	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg13722127	chr7:150037890	RARRES2	0.57	5.89	0.43	2.37e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01585852	chr22:24235823	MIF	-0.46	-4.93	-0.37	2.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg02696790	chr15:75250997	RPP25	0.4	4.58	0.35	9.45e-6	Breast cancer;
PAAD	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg11812906	chr14:75593930	NEK9	-0.45	-4.44	-0.34	1.75e-5	Neuroticism;
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.62	-5.82	-0.43	3.41e-8	Blood metabolite levels;
PAAD	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg11143131	chr5:131608246	PDLIM4	0.48	4.78	0.36	4.11e-6	Blood metabolite levels;
PAAD	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.9	-10.38	-0.64	2e-19	Total body bone mineral density;
PAAD	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs300774	0.748	rs413523	chr2:131203	C/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs302972	0.826	rs79738691	chr6:25148560	A/G	cg19882886	chr6:25043046	NA	1.0	4.41	0.34	1.95e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.84	-10.11	-0.63	1.07e-18	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27373134	chr22:31090740	OSBP2	-0.67	-7.02	-0.49	6.8e-11	Smoking initiation;
PAAD	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	6.65	0.47	4.89e-10	Retinal vascular caliber;
PAAD	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg09168692	chr1:7887560	PER3	0.45	4.26	0.33	3.58e-5	Inflammatory bowel disease;
PAAD	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg21479132	chr6:26055353	NA	0.97	5.83	0.43	3.16e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg04851639	chr8:1020857	NA	-0.65	-7.97	-0.54	3.46e-13	Schizophrenia;
PAAD	cis	rs2019872	0.810	rs9892559	chr17:2067737	C/A	cg02569219	chr17:2266849	SGSM2	-0.65	-4.62	-0.35	8.11e-6	Schizophrenia;
PAAD	cis	rs4691139	0.658	rs6839773	chr4:165925846	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.4	-4.25	-0.33	3.7e-5	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.59	-4.88	-0.37	2.71e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12292205	chr6:26970375	C6orf41	-0.5	-4.88	-0.37	2.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs76533333	0.646	rs12861423	chr13:113387084	C/A	cg02820901	chr13:113351484	ATP11A	-0.79	-4.69	-0.36	5.98e-6	Red cell distribution width;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24454698	chr1:24126991	GALE	0.6	6.76	0.48	2.77e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.41	5.07	0.38	1.12e-6	Lung cancer;
PAAD	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg10168330	chr8:27262164	PTK2B	0.36	4.28	0.33	3.24e-5	Neuroticism;
PAAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.55	-4.68	-0.36	6.2e-6	Schizophrenia;
PAAD	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10044254	0.763	rs7732283	chr5:15698391	T/C	cg07238450	chr5:15720153	FBXL7	-0.51	-4.34	-0.33	2.54e-5	Asthma (corticosteroid response);
PAAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg00750074	chr16:89608354	SPG7	0.57	5.39	0.4	2.58e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs7570971	0.761	rs3940549	chr2:136138627	A/G	cg07169764	chr2:136633963	MCM6	0.61	5.48	0.41	1.73e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.24	-0.39	5.38e-7	Pulmonary function;
PAAD	cis	rs10804591	1.000	rs11718169	chr3:129342459	T/C	cg18548199	chr3:129281892	PLXND1	0.56	4.56	0.35	1.03e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01032946	chr16:30991033	SETD1A	0.58	6.55	0.47	8.5e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.63	-6.76	-0.48	2.84e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2798269	0.604	rs2185883	chr13:22157265	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.51	-4.72	-0.36	5.31e-6	PR segment;
PAAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg08975724	chr8:8085496	FLJ10661	0.45	4.55	0.35	1.11e-5	Mean corpuscular volume;
PAAD	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg20283391	chr11:68216788	NA	-0.53	-5.08	-0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs71520386	0.632	rs35353454	chr7:22861739	T/C	cg04907244	chr7:22894795	SNORD93	0.5	5.44	0.4	2.1e-7	Fibrinogen levels;
PAAD	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg16898833	chr6:26189333	HIST1H4D	0.86	5.73	0.42	5.25e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	5.77	0.42	4.36e-8	Height;
PAAD	cis	rs89107	0.603	rs414091	chr6:118613398	T/C	cg18833306	chr6:118973337	C6orf204	0.49	5.78	0.42	4.02e-8	Cardiac structure and function;
PAAD	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.76	9.07	0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1075265	0.870	rs6749817	chr2:54259533	G/T	cg04546899	chr2:54196757	PSME4	0.38	5.63	0.42	8.26e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	4.67	0.35	6.59e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg02367144	chr2:237146137	ASB18	0.42	5.42	0.4	2.24e-7	Educational attainment;
PAAD	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg09914555	chr8:142094789	NA	-0.55	-4.7	-0.36	5.79e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-1.49	-9.02	-0.59	7.87e-16	Depression;
PAAD	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg07943548	chr15:86304357	KLHL25	0.63	5.57	0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.55	4.72	0.36	5.21e-6	Myeloid white cell count;
PAAD	cis	rs13223928	0.541	rs17132968	chr7:3136074	T/G	cg19214707	chr7:3157722	NA	-0.62	-5.79	-0.43	3.93e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs2997447	0.846	rs3008419	chr1:26402820	A/C	cg24519413	chr1:26490540	NA	0.47	4.38	0.33	2.21e-5	QRS complex (12-leadsum);
PAAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg13639937	chr1:92012655	NA	-0.41	-4.4	-0.34	2.04e-5	Breast cancer;
PAAD	cis	rs7677751	1.000	rs7677751	chr4:55124460	C/T	cg17187183	chr4:55093834	PDGFRA	0.66	4.26	0.33	3.54e-5	Corneal astigmatism;
PAAD	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.62	6.79	0.48	2.35e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.2	0.39	6.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg21856205	chr7:94953877	PON1	-0.53	-4.46	-0.34	1.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13115444	chr11:66339199	NA	-0.52	-6.56	-0.47	7.91e-10	Monocyte percentage of white cells;
PAAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.8	8.06	0.55	2.07e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg25558440	chr8:11882962	NA	-0.45	-4.3	-0.33	3.08e-5	Neuroticism;
PAAD	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.7	-0.36	5.71e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677032	chr17:61819896	STRADA	-0.54	-5.25	-0.39	5.05e-7	Prudent dietary pattern;
PAAD	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.94	-9.76	-0.62	9e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.51e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs73058052	0.597	rs2288921	chr19:50092002	G/T	cg14048834	chr19:49990801	RPL13AP5;RPL13A	0.53	4.64	0.35	7.51e-6	Fibrinogen levels;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.98	-10.09	-0.63	1.2e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg07469887	chr10:131262384	NA	-0.44	-5.17	-0.39	7.18e-7	Response to temozolomide;
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.63	6.6	0.47	6.61e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4908768	0.501	rs6668508	chr1:8574118	C/T	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	1.0	15.75	0.79	9.29e-34	Height;
PAAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.81	10.29	0.64	3.5e-19	Bone mineral density;
PAAD	trans	rs9929218	0.530	rs1111720	chr16:68698886	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-7.54	-0.52	4.03e-12	Colorectal cancer;
PAAD	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.55	4.79	0.36	3.87e-6	Dialysis-related mortality;
PAAD	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.57	4.57	0.35	9.88e-6	Mean platelet volume;
PAAD	cis	rs988913	0.837	rs9475109	chr6:54861913	T/C	cg03513858	chr6:54763001	FAM83B	-0.43	-4.64	-0.35	7.49e-6	Menarche (age at onset);
PAAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg26513180	chr16:89883248	FANCA	-0.44	-4.43	-0.34	1.82e-5	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20613337	chr1:21113199	HP1BP3	-0.62	-6.34	-0.46	2.48e-9	Smoking initiation;
PAAD	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg11657440	chr19:46296263	DMWD	0.95	11.4	0.68	3.88e-22	Coronary artery disease;
PAAD	cis	rs11807834	0.505	rs1967707	chr1:230241456	A/G	cg00566187	chr1:230250356	GALNT2	0.67	6.93	0.49	1.15e-10	Schizophrenia;
PAAD	cis	rs258892	0.895	rs67011705	chr5:72076538	T/G	cg21869765	chr5:72125136	TNPO1	-0.79	-5.3	-0.39	4.01e-7	Small cell lung carcinoma;
PAAD	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	1.11	14.49	0.76	1.93e-30	Migraine;
PAAD	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.3	-0.39	4.01e-7	Glomerular filtration rate;
PAAD	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg02997394	chr19:33096574	ANKRD27	-0.41	-4.4	-0.34	2.05e-5	Schizophrenia;
PAAD	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg15676125	chr6:33679581	C6orf125	0.48	4.79	0.36	3.93e-6	Plateletcrit;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.93	12.45	0.71	5.72e-25	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20500836	chr17:78818645	RPTOR	0.53	6.29	0.45	3.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg02841227	chr6:26021843	HIST1H4A	0.51	5.29	0.39	4.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.45	0.34	1.67e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4668356	0.687	rs7563109	chr2:172047280	A/C	cg13882835	chr2:172017928	TLK1	0.72	4.26	0.33	3.61e-5	Cognitive performance;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18621852	chr3:10150065	C3orf24	0.52	4.99	0.38	1.63e-6	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24805396	chr5:137043431	KLHL3	-0.62	-6.42	-0.46	1.66e-9	Obesity-related traits;
PAAD	cis	rs2051773	0.567	rs7934608	chr11:17038917	A/C	cg15432903	chr11:17409602	KCNJ11	-0.52	-4.71	-0.36	5.43e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19825600	chr2:3704501	ALLC	-0.58	-4.79	-0.36	3.89e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01114163	chr5:1856713	NA	-0.42	-4.41	-0.34	1.92e-5	Cardiovascular disease risk factors;
PAAD	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.5	6.48	0.47	1.19e-9	Schizophrenia;
PAAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg05392440	chr1:2478653	NA	0.56	6.05	0.44	1.1e-8	Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.23	0.45	4.46e-9	Lung cancer;
PAAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg04520793	chr17:42248056	ASB16	-0.4	-5.33	-0.4	3.45e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs72960926	1.000	rs16879383	chr6:75097185	A/G	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Body mass index;
PAAD	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.5	-4.75	-0.36	4.71e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.82	7.4	0.51	8.6e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg18595228	chr15:67193261	NA	0.89	5.11	0.38	9.7e-7	Lung cancer (smoking interaction);
PAAD	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.43	-0.46	1.6e-9	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg27121462	chr16:89883253	FANCA	0.85	5.04	0.38	1.3e-6	Skin colour saturation;
PAAD	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05585630	chr7:157510462	PTPRN2	-0.79	-9.24	-0.6	2.09e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg04034577	chr2:241836375	C2orf54	0.35	5.33	0.4	3.44e-7	Urinary metabolites;
PAAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.2	0.45	4.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs10426930	0.816	rs858414	chr19:5055196	T/C	cg08036796	chr19:5034282	KDM4B	-0.47	-4.73	-0.36	5.19e-6	Monocyte percentage of white cells;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg01053087	chr8:637909	ERICH1	0.64	4.53	0.34	1.19e-5	IgG glycosylation;
PAAD	cis	rs1144	0.537	rs2470950	chr7:104592077	C/T	cg04380332	chr7:105027541	SRPK2	-0.65	-6.91	-0.49	1.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.93e-9	Lung cancer;
PAAD	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.54	4.77	0.36	4.2e-6	Lung cancer;
PAAD	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.53	-5.58	-0.41	1.08e-7	Pancreatic cancer;
PAAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.96	-12.24	-0.7	2.09e-24	Height;
PAAD	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.53	6.39	0.46	1.97e-9	Alcohol dependence;
PAAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.1	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs901683	1.000	rs35639934	chr10:46070627	T/A	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.69	-6.22	-0.45	4.53e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg21546286	chr11:48923668	NA	-0.52	-5.2	-0.39	6.42e-7	HDL cholesterol;
PAAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.99	0.49	7.93e-11	Mood instability;
PAAD	cis	rs34779708	0.801	rs12242110	chr10:35535695	A/G	cg03585969	chr10:35415529	CREM	0.54	4.78	0.36	4.02e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg03999872	chr20:62272968	STMN3	-0.62	-5.43	-0.4	2.19e-7	Glioblastoma;
PAAD	cis	rs1800469	0.928	rs12462166	chr19:41857404	T/C	cg09537434	chr19:41945824	ATP5SL	-0.64	-6.14	-0.45	6.94e-9	Colorectal cancer;
PAAD	cis	rs1371614	0.550	rs2384508	chr2:27143056	T/A	cg00617064	chr2:27272375	NA	-0.45	-4.71	-0.36	5.48e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-7.99	-0.54	3.21e-13	Hemoglobin concentration;
PAAD	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.5	5.18	0.39	6.96e-7	Interleukin-18 levels;
PAAD	cis	rs62400317	0.821	rs72857080	chr6:45198373	G/A	cg20913747	chr6:44695427	NA	-0.69	-6.79	-0.48	2.41e-10	Total body bone mineral density;
PAAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.92	-0.77	1.44e-31	Ulcerative colitis;
PAAD	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.57	0.35	9.87e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.14	-0.5	3.58e-11	Personality dimensions;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	8.85	0.58	2.14e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2085601	0.542	rs1795728	chr4:89962341	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.5	-0.41	1.6e-7	Hair greying;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01733459	chr4:1388830	CRIPAK	-0.67	-6.36	-0.46	2.28e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs10863681	0.764	rs10495184	chr1:222259677	C/A	cg08695703	chr17:73762337	GALK1	-0.59	-6.54	-0.47	8.72e-10	Metabolite levels (HVA-5-HIAA Factor score);
PAAD	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.35	-0.4	3.19e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs939584	0.932	rs2903490	chr2:651290	A/G	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.84	-0.43	3.04e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.61	5.18	0.39	7.01e-7	Initial pursuit acceleration;
PAAD	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-4.85	-0.37	3.01e-6	Schizophrenia;
PAAD	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.92	7.0	0.49	7.54e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg15117754	chr3:10150083	C3orf24	0.58	5.46	0.4	1.93e-7	Alzheimer's disease;
PAAD	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.74	7.53	0.52	4.2e-12	Type 2 diabetes;
PAAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Diastolic blood pressure;
PAAD	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs894157	0.668	rs8179067	chr15:90211686	T/C	cg05600044	chr1:222721340	HHIPL2	1.04	6.35	0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs7711186	0.708	rs1967419	chr5:178017695	T/C	cg17371294	chr5:178012716	COL23A1	-0.85	-4.47	-0.34	1.55e-5	Urate levels in obese individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08413565	chr3:129035733	H1FX;C3orf47	0.65	7.69	0.53	1.74e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05258489	chr8:61593179	CHD7	-0.56	-6.7	-0.48	3.82e-10	Body fat percentage;
PAAD	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg06728252	chr6:26598149	ABT1	0.37	4.36	0.33	2.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3018712	0.590	rs10750834	chr11:68505375	C/T	cg23009355	chr11:68451396	GAL	-0.44	-4.25	-0.33	3.75e-5	Total body bone mineral density;
PAAD	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.81	-0.36	3.63e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13329981	chr12:57119060	NACA	0.62	7.11	0.5	4.23e-11	Monocyte percentage of white cells;
PAAD	cis	rs5417	0.610	rs222843	chr17:7145981	T/C	cg25256661	chr17:7137939	DVL2	1.01	11.45	0.68	2.73e-22	Diastolic blood pressure;
PAAD	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.63	-6.01	-0.44	1.3e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.59	0.57	9.59e-15	Alzheimer's disease;
PAAD	cis	rs4605213	1.000	rs4605213	chr17:49244747	C/G	cg25022915	chr17:49243257	NME2;NME1-NME2	0.34	4.7	0.36	5.78e-6	Height;
PAAD	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.55	6.3	0.45	3.11e-9	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs829880	0.558	rs249817	chr12:98896910	T/A	cg25150519	chr12:98850993	NA	0.7	6.53	0.47	9.5e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.54	0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs7873102	0.654	rs4878735	chr9:38012492	G/A	cg03528946	chr9:38069800	SHB	-0.49	-4.88	-0.37	2.7e-6	Brain structure;
PAAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg06740227	chr12:86229804	RASSF9	0.6	5.41	0.4	2.38e-7	Major depressive disorder;
PAAD	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	0.77	5.08	0.38	1.07e-6	Body mass index;
PAAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs501120	1.000	rs522293	chr10:44756703	G/A	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7092929	0.843	rs591531	chr10:3557731	G/C	cg14308648	chr10:3568949	NA	0.69	4.97	0.37	1.75e-6	Coronary artery calcification;
PAAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.57	5.94	0.43	1.89e-8	Huntington's disease progression;
PAAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg05457628	chr5:178986728	RUFY1	0.62	6.3	0.45	3.1e-9	Lung cancer;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.77	6.01	0.44	1.3e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.97	8.24	0.56	7.23e-14	IgG glycosylation;
PAAD	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg10705379	chr10:99080932	FRAT1	0.37	4.28	0.33	3.28e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg16584676	chr17:46985605	UBE2Z	0.57	5.72	0.42	5.44e-8	Type 2 diabetes;
PAAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg26528668	chr16:1614120	IFT140	0.52	4.29	0.33	3.17e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10679147	chr20:60877989	ADRM1	-0.75	-6.33	-0.46	2.63e-9	Neuroticism;
PAAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.52	5.25	0.39	5.04e-7	Prostate cancer;
PAAD	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	4.93e-16	Motion sickness;
PAAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.89	0.43	2.35e-8	Eosinophil percentage of white cells;
PAAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg03517284	chr6:25882590	NA	-0.58	-4.73	-0.36	5.03e-6	Iron status biomarkers;
PAAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.03	-16.67	-0.8	3.81e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7727544	0.548	rs2069614	chr5:131407601	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	4.76	0.36	4.46e-6	Blood metabolite levels;
PAAD	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg16306870	chr3:194868790	C3orf21	0.42	4.39	0.34	2.14e-5	Non-small cell lung cancer;
PAAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs965469	0.779	rs6037544	chr20:3290570	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.41	-0.34	1.98e-5	IFN-related cytopenia;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.51	-0.47	1.04e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23708337	chr7:1209742	NA	0.46	4.67	0.35	6.57e-6	Longevity;Endometriosis;
PAAD	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.73	7.74	0.53	1.26e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg06057569	chr22:50219754	BRD1	0.68	5.05	0.38	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs11723261	0.621	rs61794960	chr4:150459	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.53	4.45	0.34	1.68e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.97	11.48	0.68	2.26e-22	Breast cancer;
PAAD	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.24	-0.56	7.52e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.41	5.11	0.38	9.65e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.85	8.49	0.57	1.73e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.79	9.46	0.61	5.66e-17	Brugada syndrome;
PAAD	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs111342015	0.803	rs2233823	chr6:43193947	G/A	cg17076780	chr6:43251928	TTBK1	0.59	4.32	0.33	2.85e-5	Breast cancer;
PAAD	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.66	6.48	0.47	1.22e-9	White matter hyperintensity burden;
PAAD	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06850241	chr22:41845214	NA	-0.61	-5.27	-0.39	4.62e-7	Vitiligo;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-1.02	-14.36	-0.76	4.2000000000000004e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10210959	chr5:112257975	REEP5	0.56	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.58	5.59	0.41	1.02e-7	Asthma;
PAAD	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-10.34	-0.64	2.61e-19	Height;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.37	0.6	9.71e-17	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.78	-9.18	-0.6	3.01e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs89107	0.967	rs6912208	chr6:118566516	A/G	cg21191810	chr6:118973309	C6orf204	-0.41	-5.33	-0.4	3.49e-7	Cardiac structure and function;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00149659	chr3:10157352	C3orf10	0.57	4.56	0.35	1.04e-5	Alzheimer's disease;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg00280220	chr17:61926910	NA	0.42	4.32	0.33	2.84e-5	Prudent dietary pattern;
PAAD	cis	rs13144136	0.748	rs4697773	chr4:10668379	C/T	cg10242279	chr4:10666415	CLNK	-0.37	-4.58	-0.35	9.68e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg22029157	chr1:209979665	IRF6	0.68	6.26	0.45	3.77e-9	Coronary artery disease;
PAAD	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-4.69	-0.36	6.04e-6	Height;
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15054260	chr8:90769710	RIPK2	0.66	7.88	0.54	5.79e-13	Metabolite levels  (X-11787);
PAAD	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.03	0.55	2.45e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22301154	chr7:1008311	COX19	-0.62	-6.39	-0.46	1.91e-9	Obesity-related traits;
PAAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7260598	0.539	rs11672509	chr19:24068769	A/G	cg09235885	chr19:23456588	NA	-0.62	-4.32	-0.33	2.76e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.82e-7	Aortic root size;
PAAD	cis	rs1020064	0.636	rs2679876	chr2:105938107	T/C	cg02543470	chr2:105862877	NA	-0.48	-5.33	-0.4	3.43e-7	AIDS;
PAAD	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.82	-6.63	-0.47	5.55e-10	Blood protein levels;
PAAD	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.54	4.58	0.35	9.53e-6	Sudden cardiac arrest;
PAAD	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg14458575	chr2:238380390	NA	0.64	6.79	0.48	2.32e-10	Prostate cancer;
PAAD	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10421328	0.950	rs55831814	chr19:19777644	C/T	cg11584989	chr19:19387371	SF4	0.76	6.23	0.45	4.34e-9	Parental longevity (combined parental age at death);
PAAD	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.57	4.3	0.33	3.04e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08110718	chr16:2827420	TCEB2	-0.63	-6.34	-0.46	2.48e-9	Smoking initiation;
PAAD	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.71	-6.03	-0.44	1.19e-8	Diabetic retinopathy;
PAAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	10.6	0.65	5.31e-20	Tonsillectomy;
PAAD	cis	rs6499244	0.510	rs2173714	chr16:69878534	C/G	cg05250797	chr16:70222502	NA	0.47	4.29	0.33	3.19e-5	Menarche (age at onset);
PAAD	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg07701084	chr6:150067640	NUP43	0.62	5.23	0.39	5.57e-7	Lung cancer;
PAAD	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs1997066	0.831	rs79760260	chr10:106828106	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg13777783	chr17:79615861	NA	0.41	4.3	0.33	3.04e-5	Eye color traits;
PAAD	cis	rs2814982	0.605	rs114672114	chr6:34480065	A/G	cg17674042	chr6:34482479	PACSIN1	-1.27	-7.48	-0.52	5.43e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg09211372	chr6:168490623	NA	-0.46	-4.86	-0.37	2.94e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12286929	0.679	rs11606814	chr11:115042513	G/T	cg04055981	chr11:115044050	NA	0.47	4.98	0.37	1.73e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.19	0.55	9.64e-14	Rheumatoid arthritis;
PAAD	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	4.61	0.35	8.46e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12550646	0.612	rs13439740	chr8:41686017	C/T	cg12180191	chr8:41686706	ANK1	-0.53	-5.01	-0.38	1.5e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.84	0.37	3.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.62	5.67	0.42	7.05e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg24562669	chr7:97807699	LMTK2	0.49	6.98	0.49	8.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.68	7.56	0.52	3.63e-12	Morning vs. evening chronotype;
PAAD	cis	rs288342	0.832	rs288296	chr2:183658360	A/G	cg02625481	chr2:183667124	NA	-0.46	-4.67	-0.35	6.5e-6	Recurrent major depressive disorder;
PAAD	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.58	-7.3	-0.51	1.5e-11	Longevity;Endometriosis;
PAAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.81	5.9	0.43	2.32e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.77	8.51	0.57	1.54e-14	Lung cancer;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	5.51	0.41	1.52e-7	Monocyte percentage of white cells;
PAAD	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg21775007	chr8:11205619	TDH	-0.47	-4.27	-0.33	3.36e-5	Triglycerides;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06186877	chr10:88198874	WAPAL	0.64	6.94	0.49	1.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.46	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs3812111	0.641	rs1547030	chr6:116418158	G/A	cg15226275	chr6:116381976	FRK	-0.25	-4.4	-0.34	2e-5	Age-related macular degeneration;
PAAD	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.59	5.56	0.41	1.18e-7	Height;
PAAD	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	1.05	12.62	0.72	1.96e-25	Breast cancer;
PAAD	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.88	5.59	0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.96	-10.07	-0.63	1.35e-18	Monocyte percentage of white cells;
PAAD	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.7	-7.42	-0.52	7.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg07469887	chr10:131262384	NA	-0.46	-5.66	-0.42	7.33e-8	Response to temozolomide;
PAAD	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg10544611	chr16:67998164	SLC12A4	-0.75	-4.4	-0.34	2.07e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.61	-0.35	8.49e-6	Menarche (age at onset);
PAAD	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-4.7	-0.36	5.85e-6	Selective IgA deficiency;
PAAD	cis	rs7129556	0.859	rs11237215	chr11:77247515	G/A	cg24456632	chr11:77314957	AQP11	-0.5	-4.36	-0.33	2.41e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.47	4.47	0.34	1.5e-5	Stearic acid (18:0) levels;
PAAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	5.01	0.38	1.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20978766	chr1:197704881	DENND1B	-0.67	-6.93	-0.49	1.09e-10	Obesity-related traits;
PAAD	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.64	6.94	0.49	1.05e-10	Coronary artery disease;
PAAD	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.03e-11	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24802244	chr17:17207017	NT5M	0.67	6.63	0.47	5.43e-10	Obesity-related traits;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.66	5.89	0.43	2.4e-8	Response to diuretic therapy;
PAAD	cis	rs7656342	0.535	rs4575993	chr4:9858744	A/G	cg16147221	chr4:10020634	SLC2A9	0.45	4.33	0.33	2.69e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2229238	0.911	rs6674171	chr1:154491683	A/G	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.91e-6	Coronary heart disease;
PAAD	cis	rs728616	0.867	rs61859008	chr10:81831711	C/G	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-6.12	-0.44	7.65e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs2916733	0.607	rs2922823	chr8:6313611	T/G	cg02465761	chr8:6735510	DEFB1	0.47	4.53	0.35	1.18e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.62	5.93	0.43	1.94e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.71e-10	Life satisfaction;
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7129556	0.954	rs4509797	chr11:77263203	C/T	cg24456632	chr11:77314957	AQP11	0.5	4.41	0.34	1.94e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs55728055	0.661	rs8142821	chr22:31941240	A/C	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg11965913	chr1:205819406	PM20D1	0.63	6.72	0.48	3.45e-10	Prostate cancer;
PAAD	cis	rs13070279	0.655	rs11927001	chr3:71795224	A/G	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs11264799	0.681	rs10908589	chr1:157699867	A/T	cg18268488	chr1:157545234	FCRL4	0.51	4.86	0.37	2.84e-6	IgA nephropathy;
PAAD	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg11802864	chr11:65308245	LTBP3	0.82	5.59	0.41	1.04e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	0.837	rs10742851	chr11:48534771	A/G	cg04721828	chr11:48285200	OR4X1	-0.44	-5.58	-0.41	1.1e-7	Migraine - clinic-based;
PAAD	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9649465	0.807	rs11770249	chr7:123286412	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.62	-0.35	8.25e-6	Migraine;
PAAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.67	4.36	0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg26898376	chr11:64110657	CCDC88B	0.56	5.89	0.43	2.42e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg06057569	chr22:50219754	BRD1	0.67	5.06	0.38	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg12639453	chr1:2035780	PRKCZ	-0.59	-6.5	-0.47	1.07e-9	Height;
PAAD	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.53	-0.35	1.16e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg10729496	chr3:10149963	C3orf24	0.7	6.29	0.45	3.23e-9	Alzheimer's disease;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg00990874	chr7:1149470	C7orf50	-0.52	-4.71	-0.36	5.47e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14019695	chr9:139328340	INPP5E	0.58	4.89	0.37	2.58e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.25	0.33	3.7e-5	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.16	9.54	0.61	3.42e-17	Breast cancer;
PAAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.55	5.91	0.43	2.13e-8	Menopause (age at onset);
PAAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.57	-0.41	1.12e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg22587600	chr2:46883368	NA	0.34	4.58	0.35	9.73e-6	Height;
PAAD	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg21929781	chr1:2537748	MMEL1	0.51	5.37	0.4	2.93e-7	Multiple sclerosis;
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.79	-5.94	-0.43	1.9e-8	Initial pursuit acceleration;
PAAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.44	-0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-1.04	-11.21	-0.67	1.24e-21	Longevity;
PAAD	cis	rs72960926	0.744	rs72964259	chr6:74882885	A/T	cg03266952	chr6:74778945	NA	-1.11	-5.96	-0.44	1.7e-8	Metabolite levels (MHPG);
PAAD	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.87	-0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22633769	chr20:60982531	CABLES2	-0.47	-4.63	-0.35	7.69e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.62	-6.77	-0.48	2.66e-10	Colorectal cancer;
PAAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg20243544	chr17:37824526	PNMT	-0.55	-4.71	-0.36	5.64e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.52	4.8	0.36	3.76e-6	Uric acid clearance;
PAAD	cis	rs2571445	0.760	rs2161969	chr2:218680570	A/G	cg18102446	chr2:218934044	RUFY4	-0.38	-4.69	-0.36	6.07e-6	Pulmonary function;Coronary artery disease;Lung function (FEV1);High light scatter reticulocyte count;Pulmonary function (smoking interaction);High light scatter reticulocyte percentage of red cells;Lung function (FEV1/FVC);Lung function (FVC);Immature fraction of reticulocytes;
PAAD	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.5	4.57	0.35	1.01e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg00522288	chr12:125625016	AACS	-0.44	-4.66	-0.35	6.92e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.6	-5.07	-0.38	1.13e-6	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.32e-8	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2835872	0.737	rs1787404	chr21:39049362	C/T	cg06728970	chr21:39037746	KCNJ6	-0.53	-6.36	-0.46	2.27e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.5	5.53	0.41	1.37e-7	Prostate cancer;
PAAD	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.74	-8.46	-0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg17346650	chr17:80929145	B3GNTL1	-0.44	-5.46	-0.41	1.88e-7	Glycated hemoglobin levels;
PAAD	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21175976	chr8:11421337	BLK	0.4	4.33	0.33	2.65e-5	Triglycerides;
PAAD	cis	rs4740619	0.661	rs10810483	chr9:15932052	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.46	4.42	0.34	1.9e-5	Renal cell carcinoma;
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg21937377	chr3:194868750	C3orf21	0.46	4.9	0.37	2.42e-6	Non-small cell lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09584691	chr10:44285881	HNRNPA3P1	-0.63	-6.99	-0.49	8.03e-11	Smoking initiation;
PAAD	cis	rs62025270	0.688	rs7164373	chr15:86265663	T/A	cg13263323	chr15:86062960	AKAP13	0.47	4.25	0.33	3.76e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg01657329	chr11:68192670	LRP5	0.67	4.74	0.36	4.85e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg05110241	chr16:68378359	PRMT7	-0.9	-7.29	-0.51	1.59e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.95	12.28	0.71	1.65e-24	Menopause (age at onset);
PAAD	cis	rs10044254	0.587	rs11748790	chr5:15723633	A/G	cg07238450	chr5:15720153	FBXL7	-0.51	-4.82	-0.36	3.52e-6	Asthma (corticosteroid response);
PAAD	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-4.92	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.84	0.43	3.11e-8	Platelet count;
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg26071806	chr7:100318239	EPO	-0.51	-4.94	-0.37	1.99e-6	Other erythrocyte phenotypes;
PAAD	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.07	0.38	1.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg09491104	chr22:46646882	C22orf40	-1.0	-5.82	-0.43	3.37e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.41	-0.4	2.39e-7	Longevity;Endometriosis;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg13498757	chr1:152161927	NA	0.58	5.69	0.42	6.31e-8	Inflammatory skin disease;
PAAD	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.33	0.4	3.46e-7	Body mass index;
PAAD	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.65	-7.36	-0.51	1.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09027436	chr1:230829276	COG2	-0.68	-6.99	-0.49	8.02e-11	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13560548	chr3:10150139	C3orf24	0.59	5.18	0.39	6.82e-7	Alzheimer's disease;
PAAD	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.78	7.91	0.54	4.9e-13	Menopause (age at onset);
PAAD	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg14515779	chr1:101123966	NA	0.49	6.36	0.46	2.27e-9	Monocyte count;
PAAD	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.5	-0.52	4.91e-12	Eosinophil percentage of white cells;
PAAD	cis	rs2594989	0.806	rs2606746	chr3:11375120	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-4.57	-0.35	9.92e-6	Circulating chemerin levels;
PAAD	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.55e-6	Migraine;
PAAD	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02419362	chr12:121203948	SPPL3	0.53	6.05	0.44	1.09e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.17	-0.39	7.23e-7	Mortality in heart failure;
PAAD	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.47	0.41	1.78e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.57	5.47	0.41	1.8e-7	Itch intensity from mosquito bite;
PAAD	cis	rs7582720	0.945	rs72932759	chr2:203674288	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs9398803	0.723	rs853981	chr6:127045460	C/T	cg19875578	chr6:126661172	C6orf173	-0.46	-4.88	-0.37	2.67e-6	Male-pattern baldness;
PAAD	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg25200586	chr1:148000763	NA	-0.61	-6.37	-0.46	2.1e-9	Hip geometry;
PAAD	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.56	-4.92	-0.37	2.21e-6	Myeloid white cell count;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg00362322	chr16:88704230	IL17C	-0.43	-4.53	-0.34	1.18e-5	Menopause (age at onset);
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.82	9.13	0.6	4.04e-16	Iron status biomarkers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14753293	chr10:34399844	NA	0.7	7.22	0.51	2.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2286503	0.839	rs10276099	chr7:22862950	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12102702	chr10:120817577	EIF3A	-0.69	-6.75	-0.48	2.91e-10	Obesity-related traits;
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg17724175	chr1:150552817	MCL1	0.41	4.55	0.35	1.07e-5	Melanoma;
PAAD	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.93	-8.86	-0.58	1.96e-15	Asthma;
PAAD	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.68e-8	Retinal vascular caliber;
PAAD	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg26904215	chr21:47823096	PCNT	-0.82	-4.34	-0.33	2.63e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.41	-4.27	-0.33	3.4e-5	Sarcoidosis;
PAAD	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.72	-8.22	-0.55	8.36e-14	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19825600	chr2:3704501	ALLC	-0.51	-4.4	-0.34	2.03e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg12035532	chr1:1886765	KIAA1751	0.4	4.26	0.33	3.51e-5	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22179015	chr5:148960866	FLJ41603	0.63	6.81	0.48	2.1e-10	Myopia (pathological);
PAAD	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.85	7.18	0.5	2.89e-11	Bipolar disorder;
PAAD	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg04370829	chr17:406249	NA	-0.5	-4.6	-0.35	8.66e-6	Prostate cancer;
PAAD	cis	rs1190596	0.581	rs1190571	chr14:102634901	C/A	cg23904247	chr14:102554826	HSP90AA1	-0.41	-5.07	-0.38	1.14e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg23153227	chr6:27725408	NA	0.43	4.7	0.36	5.9e-6	Pubertal anthropometrics;
PAAD	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.68	-7.38	-0.51	9.45e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg19336497	chr11:14380999	RRAS2	0.46	4.81	0.36	3.64e-6	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.56	5.68	0.42	6.75e-8	Systolic blood pressure;
PAAD	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.55	-7.04	-0.5	6.05e-11	Lewy body disease;
PAAD	cis	rs10463316	0.817	rs7713109	chr5:150789284	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.96	-0.44	1.69e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5756391	0.568	rs10222238	chr22:37318014	G/T	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg05082376	chr22:42548792	NA	0.52	5.56	0.41	1.2e-7	Cognitive function;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.62	-0.41	8.86e-8	Life satisfaction;
PAAD	cis	rs1419980	0.556	rs11054598	chr12:7732403	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.33e-6	Tuberculosis;
PAAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.86	10.4	0.64	1.81e-19	Aortic root size;
PAAD	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.79	0.48	2.4e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2790216	1.000	rs2590358	chr10:60020982	G/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs16975963	0.644	rs73035158	chr19:38141880	C/A	cg14218481	chr19:38281219	NA	0.43	4.58	0.35	9.45e-6	Longevity;
PAAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.57	7.64	0.53	2.23e-12	Renal cell carcinoma;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg14349672	chr11:133703707	NA	-0.47	-5.07	-0.38	1.16e-6	Childhood ear infection;
PAAD	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26850624	chr5:429559	AHRR	-0.79	-8.32	-0.56	4.54e-14	Cystic fibrosis severity;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg08975724	chr8:8085496	FLJ10661	0.45	4.53	0.34	1.18e-5	Joint mobility (Beighton score);
PAAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.54	7.39	0.51	8.88e-12	Huntington's disease progression;
PAAD	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.75	6.57	0.47	7.69e-10	Coronary artery disease;
PAAD	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.61	5.78	0.42	4.03e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.45	6.08	0.44	9.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.51	5.07	0.38	1.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04362095	chr11:63592001	C11orf84	-0.5	-4.47	-0.34	1.51e-5	Platelet count;
PAAD	cis	rs9549328	0.796	rs7993665	chr13:113651132	T/C	cg17524180	chr13:113633600	MCF2L	-0.48	-5.07	-0.38	1.13e-6	Systolic blood pressure;
PAAD	cis	rs10740039	0.729	rs6479728	chr10:62490801	A/G	cg02922035	chr10:62493342	NA	-0.48	-4.53	-0.34	1.21e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-4.54	-0.35	1.14e-5	Self-reported allergy;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.35e-7	Ulcerative colitis;
PAAD	cis	rs12304921	0.935	rs79534240	chr12:51354696	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.44	-0.46	1.47e-9	Monocyte percentage of white cells;
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg23605961	chr7:751331	PRKAR1B	0.28	4.4	0.34	2.03e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-5.62	-0.42	8.72e-8	Platelet count;
PAAD	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg10705379	chr10:99080932	FRAT1	0.39	4.33	0.33	2.7e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs96067	0.607	rs274761	chr1:36574023	C/T	cg27506609	chr1:36549197	TEKT2	-0.83	-5.0	-0.38	1.55e-6	Corneal structure;
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.77	8.32	0.56	4.58e-14	Selective IgA deficiency;
PAAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.5	4.9	0.37	2.45e-6	Testicular germ cell tumor;
PAAD	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg01868782	chr6:126071099	HEY2	-0.46	-5.34	-0.4	3.36e-7	Brugada syndrome;
PAAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.68	0.53	1.76e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	1.12	16.71	0.8	3e-36	Breast cancer;
PAAD	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.15e-12	Aortic root size;
PAAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg20913747	chr6:44695427	NA	-0.51	-5.33	-0.4	3.51e-7	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.53	0.41	1.35e-7	Alzheimer's disease;
PAAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	6.34	0.46	2.43e-9	Mood instability;
PAAD	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.81e-7	White blood cell count (neutrophil);
PAAD	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs818427	0.593	rs67293732	chr5:112217964	G/C	cg05511853	chr5:112182657	NA	-0.47	-4.42	-0.34	1.89e-5	Total body bone mineral density;
PAAD	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.6	7.03	0.5	6.41e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.73	7.29	0.51	1.56e-11	HIV-1 control;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.72	5.03	0.38	1.35e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10901513	0.932	rs11814311	chr10:127669555	T/C	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.27	0.33	3.45e-5	Bipolar disorder;
PAAD	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.87	-0.37	2.79e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.53	4.33	0.33	2.65e-5	Asthma (childhood onset);
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg08501292	chr6:25962987	TRIM38	0.8	4.34	0.33	2.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-4.27	-0.33	3.42e-5	Red blood cell count;
PAAD	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-5.45	-0.4	2e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2834188	0.889	rs2040108	chr21:34676158	T/C	cg04842828	chr21:34696676	IFNAR1	0.47	4.58	0.35	9.49e-6	Narcolepsy;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg08436684	chr16:88034427	BANP	-0.53	-4.46	-0.34	1.57e-5	Menopause (age at onset);
PAAD	cis	rs3812111	0.545	rs9387389	chr6:116573667	G/A	cg18828861	chr6:116576566	TSPYL4	0.47	4.81	0.36	3.61e-6	Age-related macular degeneration;
PAAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.61	5.61	0.41	9.33e-8	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.16e-6	Lung cancer;
PAAD	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.62	-6.2	-0.45	4.99e-9	Lymphocyte counts;
PAAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs10901513	0.932	rs1913740	chr10:127670780	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs282587	0.569	rs7982564	chr13:113398930	G/A	cg04656015	chr13:113407548	ATP11A	0.54	4.34	0.33	2.54e-5	Glycated hemoglobin levels;
PAAD	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-4.27	-0.33	3.44e-5	Bipolar disorder;
PAAD	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.86	-6.9	-0.49	1.34e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.71e-10	Life satisfaction;
PAAD	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.86	-0.37	2.87e-6	Blood pressure;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.55e-5	Life satisfaction;
PAAD	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.61	5.39	0.4	2.63e-7	Height;
PAAD	cis	rs6066835	1.000	rs742645	chr20:47323655	G/A	cg18078177	chr20:47281410	PREX1	0.97	4.69	0.36	6.14e-6	Multiple myeloma;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.68	7.4	0.51	8.84e-12	Iron status biomarkers;
PAAD	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.44	4.68	0.35	6.38e-6	Plateletcrit;
PAAD	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.44	4.59	0.35	9.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.52	-5.64	-0.42	8.16e-8	Vitamin D levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15332441	chr14:81902154	NA	0.56	6.3	0.46	3.03e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	4.3	0.33	3.01e-5	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-0.87	-5.59	-0.41	1.02e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs2279817	0.863	rs871087	chr1:18017522	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.66	5.78	0.42	4.02e-8	Neuroticism;
PAAD	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.77	-0.42	4.4e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.68	-0.35	6.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.6	5.43	0.4	2.15e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.61e-8	Height;
PAAD	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg25124228	chr12:125621409	AACS	-0.65	-6.19	-0.45	5.4e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.7	-0.48	3.8e-10	Body mass index;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg15117754	chr3:10150083	C3orf24	0.58	4.3	0.33	3.06e-5	Alzheimer's disease;
PAAD	cis	rs6689305	0.674	rs11166324	chr1:100214777	C/G	cg22872634	chr1:100462710	SLC35A3	0.51	4.49	0.34	1.41e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs9649465	1.000	rs55633050	chr7:123388474	A/G	cg04330084	chr7:123175371	IQUB	-0.49	-4.53	-0.35	1.17e-5	Migraine;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3747547	0.892	rs1976936	chr9:37955433	G/A	cg13774184	chr9:37916125	SHB	-0.6	-4.25	-0.33	3.71e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.73	6.84	0.48	1.85e-10	Diabetic kidney disease;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.06	0.55	2.1e-13	Alzheimer's disease;
PAAD	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.81	9.18	0.6	2.99e-16	Menarche (age at onset);
PAAD	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs11761441	1.000	rs12718067	chr7:82873	T/C	cg22368281	chr7:82270	NA	-0.33	-4.44	-0.34	1.69e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-6.2	-0.45	5.15e-9	Hippocampal volume;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16010809	chr1:198828243	MIR181B1;MIR181A1	-0.7	-6.64	-0.47	5.1e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs72843506	0.656	rs74648067	chr17:19926251	C/T	cg05625806	chr17:19284432	MAPK7	0.66	4.3	0.33	3.1e-5	Schizophrenia;
PAAD	cis	rs4908768	0.582	rs12410893	chr1:8878885	A/G	cg00590817	chr1:8272081	NA	-0.36	-4.32	-0.33	2.8e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg24747557	chr10:131355152	MGMT	-0.45	-4.93	-0.37	2.15e-6	Response to temozolomide;
PAAD	cis	rs2574704	0.532	rs2616551	chr3:11667123	A/G	cg07643000	chr3:11666825	VGLL4	-0.56	-4.47	-0.34	1.51e-5	Body mass index;
PAAD	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.52	4.85	0.37	3.03e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.38	0.56	3.3e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg05791153	chr7:19748676	TWISTNB	-0.64	-4.59	-0.35	9.25e-6	Night sleep phenotypes;
PAAD	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.53	5.75	0.42	4.85e-8	Bladder cancer;
PAAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09188300	chr8:37887903	EIF4EBP1	-0.75	-6.64	-0.47	5.13e-10	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01952144	chr5:96143244	ERAP1	0.59	6.56	0.47	8.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg23167506	chr7:1303302	NA	0.38	6.44	0.46	1.52e-9	Menopause (age at onset);
PAAD	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.62	5.57	0.41	1.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg05579598	chr16:88989069	CBFA2T3	0.53	8.01	0.54	2.83e-13	Social autistic-like traits;
PAAD	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg19192590	chr2:178524533	PDE11A	0.42	4.28	0.33	3.24e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg00976097	chr5:421733	AHRR	-0.49	-4.71	-0.36	5.47e-6	Cystic fibrosis severity;
PAAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.89	-13.79	-0.75	1.44e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.58	0.61	2.69e-17	Cognitive function;
PAAD	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg20913747	chr6:44695427	NA	-0.66	-6.62	-0.47	5.71e-10	Total body bone mineral density;
PAAD	cis	rs847851	1.000	rs847859	chr6:34937472	G/C	cg13196216	chr6:34231128	NA	-0.61	-5.02	-0.38	1.44e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.48	-4.53	-0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.66	0.35	7e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.59	4.94	0.37	2.05e-6	Schizophrenia;
PAAD	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-5.71	-0.42	5.66e-8	Common traits (Other);
PAAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6558530	0.863	rs4595147	chr8:1703569	G/T	cg19131313	chr8:1704013	NA	-0.4	-4.44	-0.34	1.7e-5	Systolic blood pressure;
PAAD	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg09179987	chr1:167433047	CD247	0.51	5.89	0.43	2.38e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-5.49	-0.41	1.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg24503407	chr1:205819492	PM20D1	0.61	6.04	0.44	1.13e-8	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-1.09	-11.89	-0.69	1.78e-23	Longevity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21501195	chr7:46464272	NA	0.64	7.37	0.51	1.01e-11	Smoking initiation;
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.56	6.05	0.44	1.07e-8	Obesity-related traits;
PAAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg21395723	chr22:39101663	GTPBP1	0.45	4.55	0.35	1.07e-5	Menopause (age at onset);
PAAD	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.26e-9	Personality dimensions;
PAAD	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg08219700	chr8:58056026	NA	0.71	5.33	0.4	3.42e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.45	-0.34	1.68e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-5.08	-0.38	1.08e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg15145965	chr22:50218605	BRD1	0.61	5.29	0.39	4.28e-7	Schizophrenia;
PAAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.39	-0.34	2.08e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.85	-7.2	-0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2936519	0.872	rs2912022	chr8:6641529	C/G	cg22103414	chr8:6638082	NA	-0.41	-4.34	-0.33	2.56e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs3736485	0.966	rs4774595	chr15:51893161	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.43e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7009516	0.625	rs1056222	chr8:24263345	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.48	5.61	0.41	9.18e-8	Hair greying;
PAAD	cis	rs911555	0.603	rs8020912	chr14:103847274	C/T	cg12935359	chr14:103987150	CKB	-0.62	-5.81	-0.43	3.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.49	4.5	0.34	1.37e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg01267373	chr18:77410094	NA	0.42	4.4	0.34	2.06e-5	Monocyte count;
PAAD	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg23895963	chr12:117471115	NA	0.48	4.27	0.33	3.41e-5	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg00800038	chr16:89945340	TCF25	-0.71	-4.41	-0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.57	-5.24	-0.39	5.27e-7	Multiple myeloma;
PAAD	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.0	-0.44	1.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.0	5.07	0.38	1.13e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs2734839	0.964	rs4587762	chr11:113306893	G/A	cg14159747	chr11:113255604	NA	0.44	6.51	0.47	1.01e-9	Information processing speed;
PAAD	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.83	10.21	0.64	5.76e-19	Bladder cancer;
PAAD	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.7	9.17	0.6	3.07e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.65	-0.35	7.3e-6	Obesity-related traits;
PAAD	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.95	9.44	0.61	6.23e-17	Post bronchodilator FEV1;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25355226	chr3:150320980	SELT	0.63	7.46	0.52	6.03e-12	Metabolite levels  (X-11787);
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.29	-0.39	4.17e-7	Monocyte count;
PAAD	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.68	6.39	0.46	1.9e-9	Lymphocyte counts;
PAAD	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.57	-5.43	-0.4	2.2e-7	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.8	0.48	2.26e-10	Total body bone mineral density;
PAAD	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg05925327	chr15:68127851	NA	-0.59	-5.2	-0.39	6.36e-7	Restless legs syndrome;
PAAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.66	7.54	0.52	4.06e-12	Bone mineral density;
PAAD	cis	rs12767760	0.681	rs10882967	chr10:99333808	C/T	cg25247692	chr10:99313390	UBTD1	-0.49	-4.84	-0.37	3.11e-6	Obesity-related traits;
PAAD	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.74	0.53	1.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2133450	0.526	rs62234954	chr3:7342912	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.06	-0.38	1.19e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg04520793	chr17:42248056	ASB16	-0.49	-6.72	-0.48	3.48e-10	Total body bone mineral density;
PAAD	cis	rs2286379	0.596	rs7955261	chr12:1789371	C/T	cg11558135	chr12:861715	WNK1	-0.49	-4.73	-0.36	5e-6	Blood pressure (smoking interaction);
PAAD	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs16958440	1.000	rs61316646	chr18:44610670	G/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs3026101	0.578	rs1806237	chr17:5295399	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9463078	0.546	rs12190261	chr6:45029019	T/A	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg10437265	chr15:77819839	NA	0.43	4.79	0.36	3.92e-6	Type 2 diabetes;
PAAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.14	-0.6	3.78e-16	Type 2 diabetes;
PAAD	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.47	-5.3	-0.4	3.93e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.99	-0.38	1.64e-6	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.6	-0.35	8.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.66	-6.68	-0.48	4.15e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9395066	0.545	rs3799976	chr6:44835622	T/G	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	4.36	0.33	2.41e-5	Bipolar disorder;
PAAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg00179576	chr16:74483694	GLG1	-0.39	-4.36	-0.33	2.36e-5	Testicular germ cell tumor;
PAAD	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.84	11.02	0.67	4.09e-21	Menopause (age at onset);
PAAD	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs15676	0.783	rs10988134	chr9:131595407	C/T	cg00228799	chr9:131580591	ENDOG	-0.65	-5.91	-0.43	2.16e-8	Blood metabolite levels;
PAAD	cis	rs508970	0.578	rs948731	chr11:60918344	T/C	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.76	9.63	0.62	1.94e-17	Cancer;
PAAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg11896795	chr7:5465465	NA	0.57	6.32	0.46	2.71e-9	Iris heterochromicity;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.48	5.2	0.39	6.22e-7	Hemoglobin concentration;
PAAD	cis	rs9649465	1.000	rs2109723	chr7:123325339	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.39e-9	Lung cancer;
PAAD	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.05	-0.38	1.26e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg09127314	chr1:152161683	NA	0.75	5.44	0.4	2.09e-7	Atopic dermatitis;
PAAD	cis	rs10793968	0.688	rs11244120	chr9:133627495	C/A	cg01474677	chr9:133586259	NA	-0.62	-4.72	-0.36	5.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.53	0.61	3.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02228675	chr17:40259724	DHX58	-0.47	-5.65	-0.42	7.6e-8	Fibrinogen levels;
PAAD	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg19337854	chr7:99768885	GPC2	-0.41	-4.4	-0.34	2e-5	Coronary artery disease;
PAAD	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg07469887	chr10:131262384	NA	-0.44	-5.17	-0.39	7.18e-7	Response to temozolomide;
PAAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22633769	chr20:60982531	CABLES2	0.5	4.64	0.35	7.57e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9462027	0.628	rs2744944	chr6:34658080	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.38	4.47	0.34	1.53e-5	Systemic lupus erythematosus;
PAAD	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.52	-5.41	-0.4	2.44e-7	Height;
PAAD	cis	rs3206736	0.514	rs1637679	chr7:35001022	C/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs7156960	1.000	rs7156960	chr14:76703351	C/G	cg13981132	chr14:76734493	NA	0.51	5.05	0.38	1.28e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.49	4.81	0.36	3.64e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs74181299	0.717	rs11893423	chr2:65350949	G/A	cg20592124	chr2:65290738	CEP68	-0.47	-4.41	-0.34	1.91e-5	Pulse pressure;
PAAD	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.57	-0.52	3.3e-12	Protein C levels;
PAAD	cis	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.04	-0.38	1.31e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.83	-9.32	-0.6	1.27e-16	Age at first birth;
PAAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.52	0.34	1.26e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.78	5.62	0.41	8.87e-8	Coronary artery disease;
PAAD	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs282587	0.502	rs391107	chr13:113416198	T/C	cg02820901	chr13:113351484	ATP11A	-0.68	-5.17	-0.39	7.27e-7	Glycated hemoglobin levels;
PAAD	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.42	-0.52	7.8e-12	Eosinophil percentage of white cells;
PAAD	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.48	-5.11	-0.38	9.49e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg27478167	chr7:817139	HEATR2	-0.64	-4.99	-0.38	1.63e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.65	-0.53	2.2e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs642743	0.901	rs674850	chr10:105961427	A/C	cg03775802	chr10:105978702	MIR609;C10orf79	0.32	4.41	0.34	1.98e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2117029	0.554	rs12306494	chr12:49530781	A/G	cg05368762	chr12:50135785	TMBIM6	0.45	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.65	-4.61	-0.35	8.53e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.71	-0.42	5.65e-8	Mood instability;
PAAD	cis	rs9287719	0.649	rs12104950	chr2:10732105	G/A	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.95	-10.13	-0.63	9.59e-19	Asthma;
PAAD	cis	rs1642645	0.872	rs7550500	chr1:42505522	T/C	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.62	-0.41	8.96e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4704187	0.687	rs6862754	chr5:74427193	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-5.48	-0.41	1.69e-7	Mean corpuscular volume;
PAAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.45	5.45	0.4	1.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.15	0.55	1.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08348831	chr16:58767863	GOT2	-0.73	-7.75	-0.53	1.21e-12	Smoking initiation;
PAAD	cis	rs9463078	0.585	rs4072928	chr6:45291229	A/G	cg25276700	chr6:44698697	NA	-0.47	-5.5	-0.41	1.6e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.7	5.77	0.42	4.41e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg08992911	chr2:238395768	MLPH	0.66	5.27	0.39	4.61e-7	Prostate cancer;
PAAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg02683114	chr2:24398427	C2orf84	-0.47	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.56	5.82	0.43	3.41e-8	Asthma (bronchodilator response);
PAAD	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	0.98	7.66	0.53	1.98e-12	Breast cancer;
PAAD	cis	rs4765663	0.932	rs2283274	chr12:2184466	G/C	cg24952640	chr12:3108225	TEAD4	-0.57	-4.67	-0.35	6.45e-6	Aortic root size;
PAAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.85	7.85	0.54	6.79e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.84	9.85	0.62	5.34e-18	Selective IgA deficiency;
PAAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg17724175	chr1:150552817	MCL1	-0.5	-5.59	-0.41	1.04e-7	Tonsillectomy;
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.53	-0.57	1.41e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4668356	0.773	rs73017282	chr2:172047986	G/T	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.7	6.51	0.47	1.04e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1075265	0.584	rs7590846	chr2:54278667	T/C	cg04546899	chr2:54196757	PSME4	0.37	5.45	0.4	2.04e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.5	-4.43	-0.34	1.83e-5	Menarche (age at onset);
PAAD	cis	rs11172134	0.508	rs11837145	chr12:57570014	C/A	cg01515074	chr12:57585135	LRP1	0.49	4.59	0.35	9.13e-6	Urate levels in overweight individuals;
PAAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.88	9.58	0.61	2.69e-17	Cognitive function;
PAAD	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg18279126	chr7:2041391	MAD1L1	0.58	5.78	0.42	4.15e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.47	-4.41	-0.34	1.97e-5	Schizophrenia;
PAAD	cis	rs8005677	0.828	rs3794452	chr14:23386682	T/G	cg01529538	chr14:23388837	RBM23	0.48	4.8	0.36	3.8e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.42	0.34	1.9e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10958605	0.761	rs2980817	chr8:40036626	A/G	cg14545590	chr8:40388592	ZMAT4	0.42	4.75	0.36	4.73e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.37	-0.46	2.11e-9	Capecitabine sensitivity;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26549601	chr10:134560360	INPP5A	-0.48	-4.6	-0.35	8.79e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6596100	0.500	rs35534543	chr5:132160057	C/T	cg14825688	chr5:132208181	LEAP2	-0.65	-4.51	-0.34	1.27e-5	Breast cancer;
PAAD	cis	rs2882667	0.690	rs1567313	chr5:138110702	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.52	-4.46	-0.34	1.59e-5	Schizophrenia;
PAAD	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-4.74	-0.36	4.95e-6	Self-reported allergy;
PAAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.13	0.38	8.88e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.73	-5.81	-0.43	3.47e-8	Birth weight;
PAAD	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg12395012	chr8:11607386	GATA4	0.51	4.26	0.33	3.56e-5	Myopia (pathological);
PAAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg23283495	chr1:209979779	IRF6	-0.51	-6.4	-0.46	1.79e-9	Monobrow;
PAAD	trans	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg26501369	chr6:133561814	EYA4	-0.89	-6.59	-0.47	6.69e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02606505	chr3:42689703	NKTR	0.59	6.32	0.46	2.78e-9	Smoking initiation;
PAAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg13722127	chr7:150037890	RARRES2	0.59	6.01	0.44	1.3e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg24154853	chr7:158122151	PTPRN2	0.8	7.42	0.52	7.71e-12	Response to amphetamines;
PAAD	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg05562828	chr17:3906858	NA	-0.53	-5.97	-0.44	1.59e-8	Type 2 diabetes;
PAAD	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12304921	0.549	rs11169692	chr12:51458565	G/A	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.49	-0.34	1.41e-5	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs7250872	0.540	rs12460791	chr19:1842919	A/G	cg10370574	chr19:1840461	REXO1	-0.49	-4.58	-0.35	9.6e-6	Bipolar disorder;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg11961642	chr12:124272362	DNAH10	-0.64	-6.97	-0.49	9.11e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.55	-5.96	-0.43	1.73e-8	Pancreatic cancer;
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.46	-4.88	-0.37	2.61e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.42e-5	Bipolar disorder;
PAAD	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.06	0.38	1.19e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.68	5.17	0.39	7.36e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	0.78	5.43	0.4	2.16e-7	Body mass index;
PAAD	cis	rs375066	0.868	rs378112	chr19:44421929	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.05	-0.55	2.25e-13	Brugada syndrome;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.75	8.71	0.58	4.69e-15	Huntington's disease progression;
PAAD	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	12.67	0.72	1.45e-25	Platelet count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26922706	chr5:133513036	SKP1	-0.64	-6.58	-0.47	7.11e-10	Smoking initiation;
PAAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16083429	chr3:49237500	CCDC36	-0.46	-5.12	-0.38	9.28e-7	Menarche (age at onset);
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.66	0.35	6.96e-6	Height;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.26	0.39	4.72e-7	Prudent dietary pattern;
PAAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.26	0.39	4.86e-7	Tonsillectomy;
PAAD	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.45	-4.48	-0.34	1.49e-5	Type 2 diabetes;
PAAD	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.63	-7.47	-0.52	5.99e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs2882667	0.690	rs311597	chr5:138055901	A/G	cg09476006	chr5:138032270	NA	0.48	6.16	0.45	6.14e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.54	-6.32	-0.46	2.76e-9	Facial morphology (factor 20);
PAAD	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg01851573	chr8:8652454	MFHAS1	0.57	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.79	-5.06	-0.38	1.17e-6	White matter integrity;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.19	0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01219382	chr4:184328462	NA	0.66	6.41	0.46	1.76e-9	Obesity-related traits;
PAAD	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.42	0.56	2.63e-14	Alzheimer's disease;
PAAD	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.48	-4.39	-0.34	2.11e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15506890	chr2:3487001	NA	-0.75	-7.72	-0.53	1.41e-12	Neurofibrillary tangles;
PAAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg05484376	chr2:27715224	FNDC4	0.49	5.07	0.38	1.17e-6	Total body bone mineral density;
PAAD	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.97	8.02	0.55	2.64e-13	Blood trace element (Cu levels);
PAAD	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.82	-9.63	-0.62	1.96e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs597583	0.806	rs11605509	chr11:117396433	T/C	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.25	-0.45	4e-9	Putamen volume;
PAAD	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.6	5.68	0.42	6.6e-8	Morning vs. evening chronotype;
PAAD	cis	rs793571	0.915	rs11071400	chr15:59183646	T/C	cg05156742	chr15:59063176	FAM63B	-0.59	-4.95	-0.37	1.94e-6	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.66	-5.25	-0.39	5.03e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg20283391	chr11:68216788	NA	-0.53	-5.08	-0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.93	-6.73	-0.48	3.21e-10	Initial pursuit acceleration;
PAAD	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.49	5.07	0.38	1.13e-6	Red blood cell count;
PAAD	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs911119	0.818	rs12625182	chr20:23604023	G/T	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.63	-6.94	-0.49	1.05e-10	Diastolic blood pressure;
PAAD	cis	rs11955175	1.000	rs11951044	chr5:40671189	G/A	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs62179067	1.000	rs74552817	chr2:179990932	T/A	cg23458843	chr12:58136445	AGAP2	0.96	6.36	0.46	2.21e-9	Late-onset Alzheimer's disease;
PAAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs3734905	1.000	rs80297937	chr6:170015384	G/A	cg11181693	chr6:169825345	NA	-0.85	-5.16	-0.39	7.45e-7	HIV-1 control;
PAAD	cis	rs755249	0.567	rs41270803	chr1:39766041	A/G	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg01798341	chr17:80842262	TBCD	0.41	4.57	0.35	9.89e-6	Breast cancer;
PAAD	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs9857275	0.594	rs13059128	chr3:141171190	G/A	cg25967872	chr3:141205623	RASA2	0.53	4.42	0.34	1.86e-5	Prion diseases;
PAAD	cis	rs16889362	0.929	rs16889370	chr6:36968063	A/T	cg18891604	chr6:36319055	NA	-0.5	-5.44	-0.4	2.08e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.64	-5.74	-0.42	5.04e-8	Total body bone mineral density;
PAAD	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.79	-5.94	-0.43	1.87e-8	Diisocyanate-induced asthma;
PAAD	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.94	-10.49	-0.65	1.01e-19	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2252790	1.000	rs10456906	chr6:116621035	C/A	cg26893134	chr6:116381904	FRK	0.27	4.28	0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.89	11.08	0.67	2.74e-21	Coronary artery disease;
PAAD	cis	rs11168618	0.740	rs4760723	chr12:48925862	A/T	cg01881778	chr12:48919444	OR8S1	-0.51	-5.56	-0.41	1.2e-7	Adiponectin levels;
PAAD	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.83e-7	Total body bone mineral density;
PAAD	cis	rs754423	0.600	rs754424	chr14:52527188	T/G	cg10149976	chr14:52535953	NID2	-0.59	-5.01	-0.38	1.52e-6	Craniofacial microsomia;
PAAD	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.59	0.47	6.98e-10	Body mass index;
PAAD	cis	rs6718203	1.000	rs17330904	chr2:60639733	T/C	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8105895	0.935	rs62111038	chr19:22286614	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.75	10.17	0.64	7.43e-19	Coronary artery disease;
PAAD	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg21479132	chr6:26055353	NA	0.99	5.56	0.41	1.16e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg17775713	chr3:133465469	TF	0.49	5.54	0.41	1.31e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.94	10.78	0.66	1.8e-20	Tonsillectomy;
PAAD	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.73	6.44	0.46	1.51e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.75	-6.73	-0.48	3.25e-10	Blood protein levels;
PAAD	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg16964102	chr10:135390573	NA	0.41	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.56	5.96	0.44	1.67e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs988913	0.957	rs4437472	chr6:54838438	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.9	-0.37	2.43e-6	Menarche (age at onset);
PAAD	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg00455402	chr19:21769736	NA	-0.48	-4.3	-0.33	3.06e-5	Pain;
PAAD	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.7	-5.09	-0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs884843	0.839	rs2239691	chr7:73469169	A/G	cg23513211	chr7:72726717	TRIM50	0.39	5.03	0.38	1.37e-6	Pulse pressure;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23500774	chr7:65540903	ASL	0.55	6.42	0.46	1.64e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	1.0	10.16	0.64	8.04e-19	Blood pressure (smoking interaction);
PAAD	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.92e-6	Oral cavity cancer;
PAAD	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg06636001	chr8:8085503	FLJ10661	0.76	7.84	0.54	7.36e-13	Neuroticism;
PAAD	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	0.96	7.02	0.49	6.88e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg12454169	chr2:30669597	LCLAT1	-0.75	-6.2	-0.45	5.19e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.54	-5.38	-0.4	2.81e-7	Gut microbiome composition (summer);
PAAD	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg15117754	chr3:10150083	C3orf24	0.69	6.07	0.44	9.87e-9	Alzheimer's disease;
PAAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.07	0.5	5.27e-11	Rheumatoid arthritis;
PAAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg15017067	chr4:17643749	FAM184B	-0.39	-4.29	-0.33	3.2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg09179987	chr1:167433047	CD247	0.42	4.85	0.37	2.99e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.43	0.4	2.18e-7	Mammographic density (dense area);
PAAD	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26897989	chr16:1907736	C16orf73	-0.56	-4.95	-0.37	1.95e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9815354	1.000	rs1716657	chr3:41918456	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05321808	chr4:187647457	NA	0.55	6.33	0.46	2.59e-9	Immature fraction of reticulocytes;
PAAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg10556349	chr10:835070	NA	0.63	4.33	0.33	2.66e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.41	0.51	8.35e-12	Melanoma;
PAAD	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.45	0.68	2.87e-22	Menopause (age at onset);
PAAD	cis	rs3814231	0.531	rs12771689	chr10:115467068	A/G	cg24846397	chr10:115438155	CASP7	-0.56	-5.69	-0.42	6.38e-8	Vitiligo;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg00576331	chr11:65640516	EFEMP2	0.46	4.42	0.34	1.89e-5	Eosinophil percentage of white cells;
PAAD	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.76	-7.46	-0.52	6.32e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	4.26	0.33	3.53e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.51	4.7	0.36	5.85e-6	Dental caries;
PAAD	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.42	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs10821973	0.527	rs6479796	chr10:64016250	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.88	10.66	0.65	3.58e-20	Aortic root size;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.88	-8.8	-0.58	2.88e-15	Strep throat;
PAAD	cis	rs5742933	0.857	rs11685425	chr2:190612703	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.49	4.58	0.35	9.55e-6	Uric acid clearance;
PAAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.52	6.67	0.48	4.48e-10	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg22663859	chr13:21900854	NA	0.59	6.41	0.46	1.72e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg03983715	chr16:68378420	PRMT7	-0.8	-5.88	-0.43	2.55e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.43	4.51	0.34	1.3e-5	Fear of minor pain;
PAAD	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg09242541	chr1:10490025	APITD1	0.36	4.54	0.35	1.15e-5	Breast cancer;
PAAD	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.7	6.78	0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.56	-5.65	-0.42	7.7e-8	Multiple myeloma;
PAAD	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.81	-10.29	-0.64	3.58e-19	Height;
PAAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.94	11.91	0.69	1.59e-23	Menopause (age at onset);
PAAD	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.48	4.69	0.36	6.15e-6	Longevity;Endometriosis;
PAAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	8.06	0.55	2.14e-13	Menarche (age at onset);
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs308971	0.711	rs310764	chr3:12232074	A/G	cg03310376	chr3:12229001	SYN2	-0.5	-4.33	-0.33	2.66e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.89	10.33	0.64	2.84e-19	Resting heart rate;
PAAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg06375148	chr1:209958343	C1orf74	0.51	5.11	0.38	9.68e-7	Monobrow;
PAAD	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.84	-0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.75	-0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg00750074	chr16:89608354	SPG7	-0.58	-5.42	-0.4	2.27e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg05373962	chr22:49881684	NA	-0.57	-5.28	-0.39	4.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs3812111	0.774	rs509859	chr6:116423244	A/C	cg18764771	chr6:116381957	FRK	-0.26	-4.54	-0.35	1.13e-5	Age-related macular degeneration;
PAAD	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06850241	chr22:41845214	NA	-0.56	-4.85	-0.37	2.97e-6	Vitiligo;
PAAD	cis	rs1075265	0.783	rs805453	chr2:54182898	G/C	cg04546899	chr2:54196757	PSME4	0.33	5.03	0.38	1.34e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.67	-8.56	-0.57	1.16e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11618113	0.634	rs75470101	chr13:111181943	G/T	cg11688093	chr13:111178359	RAB20	-0.78	-4.9	-0.37	2.48e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.8	9.46	0.61	5.51e-17	Metabolic syndrome;
PAAD	cis	rs853679	1.000	rs735765	chr6:28170297	G/A	cg20933634	chr6:27740509	NA	0.68	4.42	0.34	1.89e-5	Depression;
PAAD	cis	rs12986413	0.967	rs1074047	chr19:2158748	A/G	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.15e-6	Height;
PAAD	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.63	6.02	0.44	1.27e-8	Height;
PAAD	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg14343924	chr8:8086146	FLJ10661	0.53	4.55	0.35	1.07e-5	Neuroticism;
PAAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs30380	0.506	rs469735	chr5:96130014	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.13	-0.38	8.71e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg24699146	chr1:24152579	HMGCL	0.54	5.7	0.42	6.02e-8	Immature fraction of reticulocytes;
PAAD	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg00750074	chr16:89608354	SPG7	-0.6	-5.7	-0.42	6.11e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-4.83	-0.36	3.28e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.72	7.98	0.54	3.39e-13	Prostate cancer;
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-4.56	-0.35	1.05e-5	Eosinophil percentage of white cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19983627	chr4:108852959	CYP2U1	-0.59	-6.97	-0.49	8.95e-11	Body fat percentage;
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.95	10.75	0.66	2.12e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg16590910	chr6:42928470	GNMT	0.56	5.65	0.42	7.75e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-1.08	-7.3	-0.51	1.48e-11	Post bronchodilator FEV1;
PAAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.41	5.0	0.38	1.57e-6	Iron status biomarkers;
PAAD	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs17266958	0.792	rs62572809	chr9:83187240	G/A	cg13911576	chr9:84174038	NA	0.84	4.33	0.33	2.67e-5	Preschool internalizing problems;
PAAD	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-6.53	-0.47	9.36e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.7	8.27	0.56	6.16e-14	Age at first birth;
PAAD	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	0.81	5.88	0.43	2.57e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg17633681	chr16:88106987	BANP	0.61	7.36	0.51	1.07e-11	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6141769	0.542	rs28548540	chr20:31294655	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.69	-0.36	5.94e-6	Subjective well-being;
PAAD	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg06484146	chr7:12443880	VWDE	-0.64	-4.77	-0.36	4.3e-6	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.9e-10	Bladder cancer;
PAAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.83	8.75	0.58	3.81e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.15	-0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.62	5.96	0.44	1.67e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs61677309	0.929	rs12576119	chr11:118158441	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.55	5.29	0.39	4.13e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs9888739	0.800	rs1143678	chr16:31343005	C/T	cg15817542	chr16:31343056	ITGAM	-0.44	-4.3	-0.33	3.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.12	-0.55	1.52e-13	Prostate cancer;
PAAD	cis	rs2594989	0.895	rs2594980	chr3:11381387	C/T	cg01796438	chr3:11312864	ATG7	-0.51	-4.45	-0.34	1.68e-5	Circulating chemerin levels;
PAAD	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs12257961	0.640	rs3891994	chr10:15388903	A/G	cg10616319	chr10:15468812	NA	0.46	4.35	0.33	2.49e-5	Selective IgA deficiency;
PAAD	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.64	-5.07	-0.38	1.16e-6	Osteoarthritis;
PAAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg19423196	chr10:82049429	MAT1A	0.48	4.68	0.36	6.18e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.71	11.28	0.67	8.06e-22	Breast cancer;
PAAD	cis	rs12760731	0.565	rs12027396	chr1:178149200	T/C	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs59888335	0.825	rs7428659	chr3:80990525	A/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs78761021	0.720	rs7220089	chr17:9796985	G/A	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.0	-12.02	-0.7	7.95e-24	Dilated cardiomyopathy;
PAAD	cis	rs7598759	0.617	rs6437017	chr2:232327584	C/A	cg19187155	chr2:232395269	NMUR1	0.53	5.81	0.43	3.59e-8	Noise-induced hearing loss;
PAAD	cis	rs990171	0.955	rs6734736	chr2:103062880	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs75920871	0.841	rs61903430	chr11:116987342	G/C	cg04087571	chr11:116723030	SIK3	-0.45	-4.68	-0.35	6.38e-6	Subjective well-being;
PAAD	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.05	6.92	0.49	1.18e-10	Body mass index;
PAAD	cis	rs10849605	0.867	rs10849602	chr12:1062479	A/G	cg09629631	chr12:1974724	CACNA2D4	0.46	4.67	0.35	6.44e-6	Lung cancer;
PAAD	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	9.77	0.62	8.42e-18	Smoking behavior;
PAAD	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.48	-4.37	-0.33	2.32e-5	Systemic sclerosis;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.9	-0.43	2.24e-8	Cystic fibrosis severity;
PAAD	trans	rs2999052	1.000	rs9843281	chr3:127961396	A/T	cg18206867	chr2:62422351	B3GNT2	-0.46	-6.41	-0.46	1.74e-9	Hypospadias;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.9	12.21	0.7	2.54e-24	Vitiligo;
PAAD	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.7	-6.52	-0.47	9.73e-10	Serum sulfate level;
PAAD	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg14345882	chr6:26364793	BTN3A2	0.63	4.51	0.34	1.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs11195062	0.693	rs7912643	chr10:112027936	A/G	cg19214408	chr10:111981687	MXI1	-0.43	-4.36	-0.33	2.4e-5	Multiple myeloma;
PAAD	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.36	4.34	0.33	2.61e-5	Pulmonary function;
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.64	-8.2	-0.55	9.49e-14	Body mass index;
PAAD	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg17351974	chr5:40835760	RPL37	0.83	4.83	0.36	3.28e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.25	-0.51	1.99e-11	Response to antipsychotic treatment;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.49	-5.34	-0.4	3.29e-7	Testicular germ cell tumor;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.56	5.46	0.41	1.86e-7	Menarche (age at onset);
PAAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg15782153	chr7:917662	C7orf20	0.49	4.79	0.36	3.92e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs72960926	1.000	rs72956984	chr6:75109496	G/A	cg03266952	chr6:74778945	NA	-1.04	-5.63	-0.42	8.51e-8	Metabolite levels (MHPG);
PAAD	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg15192750	chr16:69999425	NA	0.74	5.74	0.42	4.99e-8	IgE levels;
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.71	-7.93	-0.54	4.49e-13	Mean corpuscular volume;
PAAD	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	7.18	0.5	2.9e-11	IgG glycosylation;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.82	-0.36	3.44e-6	Lymphocyte counts;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.89	0.63	3.97e-18	Platelet count;
PAAD	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.87	-5.57	-0.41	1.12e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.59	5.44	0.4	2.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.44	-5.57	-0.41	1.15e-7	Lewy body disease;
PAAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.5	-5.09	-0.38	1.05e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.53	6.23	0.45	4.38e-9	Mean corpuscular volume;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7129556	0.954	rs10899386	chr11:77246426	T/C	cg24456632	chr11:77314957	AQP11	-0.49	-4.31	-0.33	2.9e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.62	-6.05	-0.44	1.06e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7572733	1.000	rs7587251	chr2:198930197	A/C	cg10820045	chr2:198174542	NA	0.42	4.27	0.33	3.37e-5	Dermatomyositis;
PAAD	cis	rs10078545	0.787	rs67210481	chr5:82145021	G/A	cg20697188	chr5:82360356	TMEM167A;SCARNA18	-0.44	-4.58	-0.35	9.65e-6	Chin dimples;
PAAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.37	4.85	0.37	3.03e-6	Schizophrenia;
PAAD	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18898632	chr2:242989856	NA	-0.84	-6.75	-0.48	2.9e-10	Obesity-related traits;
PAAD	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.55	5.6	0.41	9.93e-8	Interleukin-18 levels;
PAAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13739025	chr9:125572818	NA	-0.67	-6.46	-0.46	1.34e-9	Lung cancer in ever smokers;
PAAD	cis	rs7165102	1.000	rs8031179	chr15:65952034	T/C	cg22900193	chr15:65823441	PTPLAD1	0.46	4.28	0.33	3.35e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09597638	chr17:3907349	NA	0.68	7.22	0.51	2.36e-11	Type 2 diabetes;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.53	5.19	0.39	6.57e-7	Parkinson's disease;
PAAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg23649088	chr2:200775458	C2orf69	-0.71	-5.84	-0.43	3.04e-8	Schizophrenia;
PAAD	cis	rs6066835	0.867	rs11698171	chr20:47359645	A/G	cg18078177	chr20:47281410	PREX1	0.86	4.59	0.35	9.29e-6	Multiple myeloma;
PAAD	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg13870426	chr17:30244630	NA	-0.67	-6.48	-0.47	1.21e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.92	0.59	1.41e-15	Menopause (age at onset);
PAAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs2229238	0.824	rs6669229	chr1:154444591	A/G	cg21262032	chr1:154437693	IL6R	0.46	4.77	0.36	4.37e-6	Coronary heart disease;
PAAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.29e-5	Renal cell carcinoma;
PAAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.63	6.6	0.47	6.38e-10	Mood instability;
PAAD	cis	rs11671653	0.688	rs11669339	chr19:10836601	A/C	cg16667279	chr19:11591998	ELAVL3	-0.73	-4.7	-0.36	5.8e-6	LDL cholesterol;
PAAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.68	8.04	0.55	2.36e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs28655083	0.529	rs285026	chr16:77100089	G/T	cg06128999	chr16:77247126	NA	-0.42	-5.0	-0.38	1.54e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.56	-0.57	1.17e-14	Thrombosis;
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg25037394	chr1:24152592	HMGCL	0.43	4.72	0.36	5.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.57	5.2	0.39	6.34e-7	AIDS;
PAAD	cis	rs793571	0.736	rs34629633	chr15:59269263	C/T	cg05156742	chr15:59063176	FAM63B	0.56	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.8	6.79	0.48	2.4e-10	Morning vs. evening chronotype;
PAAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg13777783	chr17:79615861	NA	-0.42	-4.33	-0.33	2.66e-5	Eye color traits;
PAAD	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs1198430	0.602	rs12401753	chr1:23762679	A/G	cg27447006	chr1:23763279	ASAP3	0.7	6.31	0.46	2.83e-9	Total cholesterol levels;
PAAD	cis	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.87	-9.89	-0.63	4.11e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4352251	0.543	rs17025378	chr2:101919539	C/G	cg01660407	chr2:101008576	CHST10	-0.53	-4.27	-0.33	3.43e-5	Adiponectin levels (BMI-adjusted);Adiponectin levels;
PAAD	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg03543861	chr21:44258195	NA	0.58	4.53	0.34	1.19e-5	Information processing speed;
PAAD	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.0	-12.7	-0.72	1.18e-25	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg00492521	chr16:88997837	CBFA2T3	-0.46	-4.4	-0.34	2.01e-5	Social autistic-like traits;
PAAD	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.5	-5.1	-0.38	1.02e-6	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04525773	chr7:87506040	DBF4;SLC25A40	0.58	6.44	0.46	1.48e-9	Myopia (pathological);
PAAD	cis	rs7714584	1.000	rs10061105	chr5:150255185	C/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7082209	0.702	rs61856384	chr10:44813027	C/T	cg13191911	chr10:44806660	NA	-0.94	-4.53	-0.34	1.21e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs7707921	0.671	rs2406911	chr5:81312256	A/G	cg15871215	chr5:81402204	ATG10	0.42	4.3	0.33	3.06e-5	Breast cancer;
PAAD	cis	rs9287719	0.649	rs10198971	chr2:10718699	G/C	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg24154853	chr7:158122151	PTPRN2	0.72	7.5	0.52	5.01e-12	Calcium levels;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.64	7.03	0.5	6.41e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg15145965	chr22:50218605	BRD1	0.71	4.37	0.33	2.25e-5	Schizophrenia;
PAAD	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23350087	chr19:7587498	MCOLN1	-0.8	-7.38	-0.51	9.39e-12	Neuroticism;
PAAD	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.71	6.27	0.45	3.62e-9	Schizophrenia;
PAAD	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg00405596	chr8:11794950	NA	0.45	4.83	0.36	3.27e-6	Myopia (pathological);
PAAD	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.76	-6.98	-0.49	8.63e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.58	-5.35	-0.4	3.24e-7	Total body bone mineral density;
PAAD	cis	rs7213347	0.579	rs8072532	chr17:2045273	G/A	cg15816464	chr17:2026533	SMG6	0.52	5.72	0.42	5.47e-8	Total body bone mineral density;
PAAD	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg01631408	chr1:248437212	OR2T33	0.57	5.27	0.39	4.59e-7	Common traits (Other);
PAAD	cis	rs7714584	1.000	rs75774363	chr5:150223722	C/T	cg22134413	chr5:150180641	NA	0.8	5.73	0.42	5.33e-8	Crohn's disease;
PAAD	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.45	-5.11	-0.38	9.74e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.45	0.34	1.68e-5	Axial length;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.75e-5	Calcium levels;
PAAD	cis	rs2456568	0.722	rs2399748	chr11:93687675	C/A	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.16	-0.39	7.52e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs72960926	1.000	rs72958996	chr6:75131378	A/G	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-6.39	-0.46	1.93e-9	Total cholesterol levels;
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.62	5.92	0.43	2.05e-8	Lung cancer;
PAAD	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.49	-5.63	-0.42	8.49e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs75757892	0.583	rs10080449	chr6:7315232	A/C	cg02954307	chr6:7269328	NA	0.53	4.5	0.34	1.36e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg10431340	chr1:161279108	MPZ	-0.62	-5.7	-0.42	6.01e-8	Rheumatoid arthritis;
PAAD	trans	rs901683	1.000	rs34731408	chr10:45961020	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg12666980	chr3:126703080	NA	-0.64	-6.35	-0.46	2.35e-9	Primary biliary cholangitis;
PAAD	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-5.5	-0.41	1.58e-7	Total cholesterol levels;
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.71	-6.92	-0.49	1.19e-10	Blood metabolite levels;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.63	7.03	0.5	6.66e-11	Longevity;Endometriosis;
PAAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-7.03	-0.5	6.58e-11	Gut microbiome composition (summer);
PAAD	cis	rs904092	0.605	rs7673231	chr4:100173272	C/T	cg12011299	chr4:100065546	ADH4	-0.47	-4.39	-0.34	2.15e-5	Alcohol dependence;
PAAD	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.71	7.95	0.54	3.93e-13	Motion sickness;
PAAD	cis	rs9918079	0.524	rs4235379	chr4:15659278	T/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.32	-0.33	2.85e-5	Obesity-related traits;
PAAD	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.9	6.46	0.46	1.35e-9	Height;
PAAD	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg03910582	chr17:19030146	GRAPL	-0.5	-4.94	-0.37	2.01e-6	Schizophrenia;
PAAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11811982	0.793	rs116805426	chr1:227394024	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.55	5.34	0.4	3.32e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs282587	0.569	rs415552	chr13:113407564	A/C	cg02820901	chr13:113351484	ATP11A	-0.67	-5.14	-0.38	8.31e-7	Glycated hemoglobin levels;
PAAD	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	4.88	0.37	2.67e-6	Joint mobility (Beighton score);
PAAD	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg21037935	chr19:58911965	NA	0.52	4.5	0.34	1.33e-5	Mean platelet volume;
PAAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg11833968	chr6:79620685	NA	-0.41	-4.25	-0.33	3.7e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg08999081	chr20:33150536	PIGU	0.54	5.85	0.43	2.9e-8	Height;
PAAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	5.67	0.42	6.91e-8	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05943476	chr2:70780904	TGFA	-0.82	-7.05	-0.5	5.9e-11	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00066508	chr12:110355602	TCHP	-0.66	-6.68	-0.48	4.16e-10	Obesity-related traits;
PAAD	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg27478167	chr7:817139	HEATR2	-0.6	-4.68	-0.36	6.24e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-4.74	-0.36	4.85e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09270044	chr1:186344798	TPR;C1orf27;MIR548F1	0.61	6.86	0.49	1.66e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.08	0.38	1.11e-6	Childhood ear infection;
PAAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.51	0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.21	0.51	2.41e-11	Multiple sclerosis;
PAAD	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.39	-4.65	-0.35	7.28e-6	Mean corpuscular volume;
PAAD	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.59	6.48	0.47	1.19e-9	Testicular germ cell tumor;
PAAD	cis	rs10768122	0.966	rs4755395	chr11:35317860	C/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.29	-0.33	3.17e-5	Vitiligo;
PAAD	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.7	6.86	0.49	1.64e-10	Cancer;
PAAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs12304921	0.625	rs17125369	chr12:51496659	T/C	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.45	-0.4	2e-7	Type 2 diabetes;
PAAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23347835	chr12:46599935	SLC38A1	-0.55	-6.71	-0.48	3.62e-10	Monocyte percentage of white cells;
PAAD	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.84	8.26	0.56	6.76e-14	Response to antineoplastic agents;
PAAD	cis	rs4356203	0.905	rs9919600	chr11:17079745	A/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-7.83	-0.54	7.54e-13	Morning vs. evening chronotype;
PAAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.84	7.02	0.49	6.98e-11	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg05341575	chr12:125625032	AACS	-0.48	-4.38	-0.34	2.16e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.89	-0.54	5.4e-13	Hemoglobin concentration;
PAAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg19630374	chr17:18023558	MYO15A	-0.56	-5.91	-0.43	2.16e-8	Total body bone mineral density;
PAAD	cis	rs12422267	1.000	rs12422267	chr12:132601596	A/G	cg05134918	chr12:132603531	EP400NL	-0.82	-5.02	-0.38	1.44e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.2	0.39	6.35e-7	Myeloid white cell count;
PAAD	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg25070565	chr17:20044324	CYTSB	0.44	4.67	0.35	6.69e-6	Obesity-related traits;
PAAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	1.01	11.8	0.69	3.16e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs17155006	0.655	rs389486	chr7:107727804	C/G	cg05962710	chr7:107745446	LAMB4	-0.45	-5.54	-0.41	1.29e-7	Pneumococcal bacteremia;
PAAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.68	-7.36	-0.51	1.05e-11	Brugada syndrome;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26119740	chr11:73881915	C2CD3;PPME1	0.64	6.3	0.46	3.04e-9	Primary biliary cholangitis;
PAAD	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg10072921	chr12:121022843	NA	-0.43	-5.32	-0.4	3.6e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs10886094	1.000	rs7068819	chr10:119270469	T/A	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.07	-0.38	1.16e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg12963866	chr19:57752005	ZNF805	-0.49	-4.75	-0.36	4.61e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs2790216	1.000	rs2254775	chr10:60036815	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7707921	1.000	rs6884232	chr5:81550043	G/A	cg21483461	chr5:81570383	RPS23	0.54	4.55	0.35	1.11e-5	Breast cancer;
PAAD	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.94	-11.21	-0.67	1.25e-21	Bone mineral density;
PAAD	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.34	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs798766	0.909	rs11724531	chr4:1753424	A/G	cg05874882	chr4:1763078	NA	-0.37	-5.07	-0.38	1.13e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2506028	1.000	rs2488278	chr10:43446335	T/C	cg20628663	chr10:43360327	NA	-0.36	-4.29	-0.33	3.14e-5	Blood protein levels;
PAAD	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.45	0.4	1.95e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.66	7.84	0.54	7.49e-13	Weight;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg16606324	chr3:10149918	C3orf24	0.53	4.51	0.34	1.3e-5	Alzheimer's disease;
PAAD	cis	rs6076065	0.755	rs6076071	chr20:23406380	A/C	cg11657817	chr20:23433608	CST11	0.48	4.94	0.37	2.08e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs1018697	1.000	rs1018696	chr10:104549066	A/G	cg04362960	chr10:104952993	NT5C2	0.6	6.17	0.45	5.83e-9	Colorectal adenoma (advanced);
PAAD	cis	rs11696501	0.792	rs2227290	chr20:44176142	G/T	cg11783356	chr20:44313418	WFDC10B	-0.54	-5.55	-0.41	1.23e-7	Brain structure;
PAAD	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.58	0.41	1.09e-7	Mean platelet volume;
PAAD	cis	rs7162310	1.000	rs7163368	chr15:63571121	T/C	cg05375668	chr15:63796746	USP3	0.57	4.29	0.33	3.19e-5	Myopia;
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.59	6.93	0.49	1.09e-10	Mean corpuscular volume;
PAAD	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg13880726	chr7:1868755	MAD1L1	0.45	4.41	0.34	1.97e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg10729496	chr3:10149963	C3orf24	0.84	6.8	0.48	2.28e-10	Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg13877915	chr19:58951672	ZNF132	0.54	5.08	0.38	1.11e-6	Uric acid clearance;
PAAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.65	-0.42	7.6e-8	Schizophrenia;
PAAD	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.5	0.41	1.59e-7	HDL cholesterol;
PAAD	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.92	5.84	0.43	3e-8	Eosinophilic esophagitis;
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.83	-5.07	-0.38	1.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg27121462	chr16:89883253	FANCA	-0.47	-5.06	-0.38	1.19e-6	Vitiligo;
PAAD	cis	rs2017305	0.834	rs12242235	chr10:70782556	A/T	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.54	-0.41	1.31e-7	Depression (quantitative trait);
PAAD	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.89	6.2	0.45	5.14e-9	Fat distribution (HIV);
PAAD	cis	rs2085601	0.503	rs2670630	chr4:89971342	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.5	-0.41	1.6e-7	Hair greying;
PAAD	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.21e-17	Electrocardiographic conduction measures;
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg04154034	chr17:28927549	LRRC37B2	0.68	4.33	0.33	2.68e-5	Body mass index;
PAAD	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.54	6.27	0.45	3.5e-9	Total body bone mineral density;
PAAD	cis	rs360071	0.528	rs360100	chr1:226067382	G/A	cg05376267	chr1:226075388	LEFTY1	0.4	4.34	0.33	2.55e-5	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs8121916	1.000	rs961900	chr20:12412558	G/A	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	1.01	5.87	0.43	2.66e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.74	0.42	5.08e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg15192750	chr16:69999425	NA	0.73	5.57	0.41	1.12e-7	IgE levels;
PAAD	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg24053715	chr22:38214548	NA	0.57	5.25	0.39	4.95e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.51	0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs6785206	0.554	rs9853945	chr3:128528630	A/G	cg19205850	chr3:128446370	RAB7A	0.74	5.6	0.41	9.61e-8	Lymphocyte percentage of white cells;
PAAD	cis	rs89107	0.549	rs4945623	chr6:118980556	G/C	cg21191810	chr6:118973309	C6orf204	0.37	4.44	0.34	1.71e-5	Cardiac structure and function;
PAAD	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14705919	chr3:47205664	SETD2	-0.66	-6.6	-0.47	6.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6604026	0.656	rs12060952	chr1:93381273	T/C	cg13858687	chr1:93297071	RPL5	0.48	4.36	0.33	2.34e-5	Multiple sclerosis;
PAAD	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.72	-0.48	3.4e-10	Morning vs. evening chronotype;
PAAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg04111992	chr7:158790115	NA	-0.59	-5.34	-0.4	3.28e-7	Facial morphology (factor 20);
PAAD	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg01305830	chr4:1604576	NA	-0.48	-4.59	-0.35	9.08e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg21724239	chr8:58056113	NA	0.64	4.95	0.37	1.93e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg24053715	chr22:38214548	NA	0.58	5.64	0.42	8.16e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.52	4.99	0.38	1.65e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35096708	0.525	rs34177108	chr16:89893375	C/A	cg27130406	chr16:89901659	SPIRE2	-0.64	-5.33	-0.4	3.5e-7	Skin aging (microtopography measurement);
PAAD	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg02631450	chr22:32366979	NA	-1.07	-5.77	-0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs3764400	0.506	rs56103412	chr17:46542302	T/A	cg10706073	chr17:46328419	SKAP1	-0.89	-5.11	-0.38	9.36e-7	Body mass index;
PAAD	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg13736514	chr6:26305472	NA	-0.59	-6.27	-0.45	3.63e-9	Educational attainment;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-1.28	-12.37	-0.71	9.31e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg23254163	chr1:152506842	NA	0.57	6.61	0.47	6.05e-10	Hair morphology;
PAAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.53	4.85	0.37	3.09e-6	Monocyte count;
PAAD	cis	rs9810890	1.000	rs13325671	chr3:128461047	C/T	cg19129842	chr3:128565090	NA	-0.87	-5.48	-0.41	1.72e-7	Dental caries;
PAAD	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6681460	0.800	rs485543	chr1:67194372	C/T	cg02459107	chr1:67143332	SGIP1	-0.69	-6.37	-0.46	2.17e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.98e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.51	6.2	0.45	5.07e-9	Monobrow;
PAAD	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs9659323	0.730	rs7512189	chr1:119542532	A/T	cg17326555	chr1:119535693	NA	-0.44	-6.16	-0.45	6.21e-9	Body mass index;
PAAD	cis	rs7487075	0.619	rs7485580	chr12:46830374	A/C	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-7.59	-0.52	3.03e-12	Prudent dietary pattern;
PAAD	cis	rs2679053	0.556	rs11037564	chr11:43708725	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.25	-0.33	3.7e-5	Coronary artery disease;
PAAD	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg10434728	chr15:90938212	IQGAP1	-0.49	-4.92	-0.37	2.21e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	9.12	0.59	4.19e-16	Cognitive test performance;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg07362569	chr17:61921086	SMARCD2	0.59	7.0	0.49	7.85e-11	Prudent dietary pattern;
PAAD	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.25	0.33	3.69e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg22875332	chr1:76189707	ACADM	-0.51	-5.12	-0.38	9.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs89107	0.640	rs281864	chr6:118576233	A/C	cg18833306	chr6:118973337	C6orf204	0.48	5.61	0.41	9.41e-8	Cardiac structure and function;
PAAD	cis	rs6804624	0.654	rs2670323	chr3:99168893	T/A	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg12395012	chr8:11607386	GATA4	0.42	4.27	0.33	3.42e-5	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20725670	chr17:38444322	CDC6	-0.63	-6.49	-0.47	1.13e-9	Lung cancer in ever smokers;
PAAD	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.58	-4.79	-0.36	3.9e-6	Diabetic retinopathy;
PAAD	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.93	-9.31	-0.6	1.34e-16	Obesity-related traits;
PAAD	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.44	0.34	1.75e-5	Myopia (pathological);
PAAD	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg23033748	chr14:75592666	NEK9	0.42	5.09	0.38	1.05e-6	Height;
PAAD	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg16606324	chr3:10149918	C3orf24	0.64	5.12	0.38	8.94e-7	Alzheimer's disease;
PAAD	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg09760422	chr2:128146352	NA	-0.34	-6.09	-0.44	8.75e-9	Protein C levels;
PAAD	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg17351974	chr5:40835760	RPL37	0.83	4.83	0.36	3.28e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7631605	0.905	rs1468713	chr3:37106115	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.38	-0.4	2.74e-7	Prevalent atrial fibrillation;
PAAD	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.79e-5	Migraine;
PAAD	cis	rs67257959	0.708	rs11671858	chr19:17201520	T/G	cg19418318	chr19:17219073	MYO9B	0.31	4.32	0.33	2.78e-5	Selective IgA deficiency;
PAAD	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.78e-5	Neuroticism;
PAAD	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg06057569	chr22:50219754	BRD1	0.67	5.06	0.38	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.98	-10.68	-0.65	3.33e-20	Refractive error;
PAAD	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg23752985	chr2:85803571	VAMP8	0.55	6.19	0.45	5.45e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-5.97	-0.44	1.59e-8	Response to antipsychotic treatment;
PAAD	cis	rs8077059	1.000	rs9944404	chr17:55809972	T/A	cg12582317	chr17:55822272	NA	0.51	4.76	0.36	4.47e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.66	6.58	0.47	7.14e-10	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.4	4.36	0.33	2.36e-5	Triglycerides;
PAAD	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.64	5.34	0.4	3.37e-7	Mammographic density (dense area);
PAAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.51	-6.34	-0.46	2.49e-9	Vitiligo;
PAAD	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs12776158	0.901	rs12413873	chr10:71212091	C/G	cg12610070	chr10:71211762	TSPAN15	-0.43	-4.58	-0.35	9.7e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.49	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-5.34	-0.4	3.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.07	0.5	5.27e-11	Rheumatoid arthritis;
PAAD	cis	rs332507	0.830	rs333355	chr3:124393595	A/G	cg05980111	chr3:124395277	KALRN	0.46	4.6	0.35	8.92e-6	Plateletcrit;
PAAD	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6.02e-9	Subjective well-being;
PAAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg12757816	chr2:10669957	NA	-0.56	-5.94	-0.43	1.86e-8	Prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19927780	chr1:90286561	LRRC8D	-0.79	-6.73	-0.48	3.19e-10	Neuroticism;
PAAD	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	5.04e-11	Total body bone mineral density;
PAAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.51	-4.72	-0.36	5.32e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2526932	0.625	rs2526899	chr14:73053290	C/T	cg13588403	chr14:73209128	DPF3	0.4	5.42	0.4	2.3e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06850241	chr22:41845214	NA	0.49	4.41	0.34	1.96e-5	Vitiligo;
PAAD	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.34	0.4	3.28e-7	Bipolar disorder;
PAAD	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg15956490	chr3:53032818	SFMBT1	0.78	4.45	0.34	1.65e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-5.55	-0.41	1.22e-7	Schizophrenia;
PAAD	cis	rs12826942	0.765	rs17592014	chr12:42550147	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	4.29	0.33	3.1e-5	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.59	0.35	9.19e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9039	1.000	rs67302637	chr16:9221100	C/T	cg08831531	chr16:9218945	NA	-0.62	-6.21	-0.45	4.9e-9	Menopause (age at onset);
PAAD	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.51	5.29	0.39	4.16e-7	Menopause (age at onset);
PAAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg06375148	chr1:209958343	C1orf74	0.67	5.21	0.39	6.09e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg15117754	chr3:10150083	C3orf24	0.65	6.21	0.45	4.82e-9	Alzheimer's disease;
PAAD	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.54	-4.66	-0.35	6.85e-6	Mean corpuscular volume;
PAAD	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.74	-6.9	-0.49	1.3100000000000001e-10	Cognitive ability;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22633769	chr20:60982531	CABLES2	-0.45	-4.51	-0.34	1.31e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.97	-9.62	-0.62	2.05e-17	Prostate cancer;
PAAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.9	0.66	8.63e-21	Homoarginine levels;
PAAD	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg07697006	chr5:132202367	UQCRQ	0.55	4.78	0.36	4.12e-6	Breast cancer;
PAAD	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs6142102	0.625	rs4911137	chr20:32535463	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.55	0.35	1.1e-5	Skin pigmentation;
PAAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg05754148	chr16:3507555	NAT15	0.72	5.16	0.39	7.44e-7	Tuberculosis;
PAAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg09873201	chr16:3507582	NAT15	-0.57	-4.63	-0.35	7.77e-6	Tuberculosis;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs7224685	0.689	rs4508454	chr17:4198650	C/T	cg09597638	chr17:3907349	NA	-0.62	-5.26	-0.39	4.86e-7	Type 2 diabetes;
PAAD	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg10631289	chr15:39006617	NA	0.46	4.66	0.35	6.84e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs7554547	0.756	rs11121840	chr1:11968356	G/A	cg07603449	chr1:11986842	KIAA2013	-0.38	-6.06	-0.44	1.03e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.58	6.11	0.44	7.82e-9	Obesity-related traits;
PAAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs375066	0.901	rs376069	chr19:44417295	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg07873178	chr11:65307616	LTBP3	0.97	4.6	0.35	8.7e-6	Height;
PAAD	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.81	8.51	0.57	1.57e-14	Uric acid levels;
PAAD	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg04877966	chr15:75135169	ULK3	-0.51	-4.44	-0.34	1.71e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.69	6.01	0.44	1.35e-8	Menarche (age at onset);
PAAD	cis	rs6804624	0.700	rs2670338	chr3:99162536	A/G	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.72e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.63	-6.33	-0.46	2.62e-9	Ear protrusion;
PAAD	cis	rs4800452	0.956	rs4369779	chr18:20735408	T/C	cg26136497	chr18:20735537	CABLES1	-0.5	-4.65	-0.35	7.06e-6	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9815354	1.000	rs11928580	chr3:41885722	C/T	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-5.33	-0.4	3.43e-7	Ileal carcinoids;
PAAD	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg00369613	chr2:3483100	TTC15	-0.59	-4.43	-0.34	1.8e-5	Type 2 diabetes;
PAAD	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.68	6.88	0.49	1.43e-10	Schizophrenia;
PAAD	cis	rs2147959	0.714	rs6659690	chr1:228628170	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.43	-0.34	1.83e-5	Adult asthma;
PAAD	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-1.01	-7.75	-0.53	1.2e-12	Blood protein levels;
PAAD	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg18302933	chr2:88491318	NA	-0.42	-5.05	-0.38	1.22e-6	Response to metformin (IC50);
PAAD	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Lymphocyte counts;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.67	7.18	0.5	2.89e-11	Iron status biomarkers;
PAAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg05110241	chr16:68378359	PRMT7	-1.14	-8.55	-0.57	1.26e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs490234	0.576	rs3104554	chr9:128152615	C/T	cg14078157	chr9:128172775	NA	-0.59	-6.68	-0.48	4.18e-10	Mean arterial pressure;
PAAD	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.83	9.92	0.63	3.34e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	0.87	5.43	0.4	2.22e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs7619427	0.507	rs7616472	chr3:44016039	G/A	cg12796028	chr3:44040206	NA	-0.58	-5.07	-0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs17032980	0.910	rs7603586	chr2:67327915	C/T	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.03e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1419980	0.730	rs7314851	chr12:7740776	C/G	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.4	-4.91	-0.37	2.33e-6	Prostate cancer;
PAAD	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.54	5.48	0.41	1.75e-7	Lewy body disease;
PAAD	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg09980403	chr19:12975529	MAST1	0.31	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.8	9.76	0.62	8.88e-18	Breast cancer;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.68	-6.28	-0.45	3.41e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.82	8.99	0.59	9.35e-16	Schizophrenia;
PAAD	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg04704449	chr6:33738291	NA	-0.46	-4.75	-0.36	4.72e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg17737388	chr1:85724454	C1orf52	0.5	4.34	0.33	2.63e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg15798862	chr7:76129360	DTX2	-0.42	-5.41	-0.4	2.37e-7	Multiple sclerosis;
PAAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.82	-0.48	2.02e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg03959625	chr15:84868606	LOC388152	0.43	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg26597838	chr10:835615	NA	0.86	6.78	0.48	2.55e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.52	-0.41	1.41e-7	Alcohol dependence;
PAAD	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg09659197	chr4:152720779	NA	-0.41	-5.28	-0.39	4.45e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.31e-26	Breast cancer;
PAAD	cis	rs12051548	1	rs12051548	chr17:4683035	C/G	cg19442264	chr17:4168034	ANKFY1	-0.94	-5.29	-0.39	4.25e-7	Metabolite levels;Sphingolipid levels;
PAAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.49	-4.65	-0.35	7.31e-6	Body mass index;
PAAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-1.02	-5.38	-0.4	2.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13560548	chr3:10150139	C3orf24	-0.54	-4.96	-0.37	1.88e-6	Alzheimer's disease;
PAAD	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.37	-0.46	2.15e-9	Breast cancer;
PAAD	cis	rs939584	0.825	rs7579971	chr2:631603	C/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.26	-0.33	3.51e-5	Systemic lupus erythematosus;
PAAD	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.42	5.03	0.38	1.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.48	0.41	1.73e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs877529	1.000	rs139402	chr22:39546145	T/C	cg18708252	chr22:39545030	CBX7	-0.44	-4.27	-0.33	3.36e-5	Multiple myeloma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13988995	chr13:111340350	CARS2	-0.59	-6.8	-0.48	2.19e-10	Monocyte percentage of white cells;
PAAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg05785598	chr3:49045655	WDR6	0.41	4.85	0.37	3.04e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs3847687	1.000	rs11061292	chr12:131518981	T/A	cg13406893	chr12:131568647	GPR133	-0.47	-4.66	-0.35	6.97e-6	Longevity;
PAAD	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.09	8.53	0.57	1.38e-14	Vitiligo;
PAAD	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs2031532	0.587	rs2077848	chr13:50035208	G/A	cg03651054	chr13:50194643	NA	0.33	4.41	0.34	1.98e-5	Cardiac hypertrophy;
PAAD	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg10589385	chr1:150898437	SETDB1	-0.44	-5.26	-0.39	4.84e-7	Tonsillectomy;
PAAD	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg00898013	chr13:113819073	PROZ	0.73	7.06	0.5	5.47e-11	Platelet distribution width;
PAAD	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg02640540	chr1:67518911	SLC35D1	0.56	4.8	0.36	3.69e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.6	6.75	0.48	2.98e-10	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg27478167	chr7:817139	HEATR2	-0.66	-5.08	-0.38	1.09e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs564148	0.515	rs617364	chr1:34154015	G/A	cg08884588	chr1:34096783	CSMD2	-0.73	-4.58	-0.35	9.79e-6	Response to amphetamines;
PAAD	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.63	-6.13	-0.44	7.4e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.37	-0.46	2.12e-9	Neuroticism;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.25	-0.51	1.99e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.96	0.49	9.41e-11	Menarche (age at onset);
PAAD	cis	rs56046484	0.711	rs71397835	chr15:85530771	C/T	cg08123816	chr15:85640762	PDE8A	-0.47	-4.42	-0.34	1.89e-5	Testicular germ cell tumor;
PAAD	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.58	-0.41	1.06e-7	Fear of minor pain;
PAAD	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.35	0.4	3.16e-7	Morning vs. evening chronotype;
PAAD	cis	rs17162190	0.590	rs7524421	chr1:26810612	C/G	cg17456097	chr1:26900765	RPS6KA1	0.6	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.74	-5.36	-0.4	2.99e-7	Blood protein levels;
PAAD	cis	rs3867498	1.000	rs3867498	chr15:25078787	A/G	cg08194505	chr15:25684383	UBE3A	0.64	4.44	0.34	1.72e-5	Pulmonary function;
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-0.9	-15.01	-0.77	8.38e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.49	5.5	0.41	1.59e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.86	8.08	0.55	1.92e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09314301	chr1:2329589	RER1	-0.67	-6.36	-0.46	2.3e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.77	-8.42	-0.56	2.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.67	-7.38	-0.51	9.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.15	-16.03	-0.79	1.72e-34	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg19223190	chr17:80058835	NA	-0.54	-5.7	-0.42	6.17e-8	Life satisfaction;
PAAD	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	1.17	8.67	0.58	5.96e-15	Lymphocyte counts;
PAAD	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.48	-0.34	1.48e-5	Triglycerides;
PAAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-5.35	-0.4	3.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11051970	0.592	rs11051987	chr12:32555406	C/T	cg24626660	chr12:32551988	NA	0.43	4.56	0.35	1.03e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.52	-5.98	-0.44	1.55e-8	Tonsillectomy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08450256	chr7:100487572	UFSP1	0.76	8.92	0.59	1.37e-15	Myopia (pathological);
PAAD	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-9.99	-0.63	2.24e-18	Response to antipsychotic treatment;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.61	-7.21	-0.51	2.4e-11	Systolic blood pressure;
PAAD	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg03342759	chr3:160939853	NMD3	-0.7	-7.23	-0.51	2.15e-11	Morning vs. evening chronotype;
PAAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg12215294	chr3:40350768	EIF1B	-0.47	-4.72	-0.36	5.42e-6	Renal cell carcinoma;
PAAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.88	9.73	0.62	1.09e-17	Cognitive function;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	trans	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.78	-0.48	2.5e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26752888	chr8:11627280	NEIL2	-0.67	-7.1	-0.5	4.45e-11	Smoking initiation;
PAAD	cis	rs7678555	0.520	rs13146693	chr4:120863250	G/A	cg09307838	chr4:120376055	NA	0.46	4.28	0.33	3.29e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	5.81	0.43	3.48e-8	Lung cancer in ever smokers;
PAAD	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.71	6.68	0.48	4.16e-10	Schizophrenia;
PAAD	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.34	-0.6	1.11e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.54	5.96	0.44	1.7e-8	Heart rate;
PAAD	cis	rs11051970	0.918	rs1055876	chr12:32536200	C/T	cg24626660	chr12:32551988	NA	0.42	4.66	0.35	6.93e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg01868782	chr6:126071099	HEY2	0.44	5.12	0.38	8.95e-7	Brugada syndrome;
PAAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	9.56	0.61	3.04e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.7	8.01	0.54	2.81e-13	N-glycan levels;
PAAD	cis	rs2882667	0.690	rs311599	chr5:138054683	G/A	cg09476006	chr5:138032270	NA	0.48	6.16	0.45	6.14e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.52	4.94	0.37	2.02e-6	Metabolic traits;
PAAD	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.59	5.09	0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs4148087	1.000	rs1117640	chr21:43625274	T/G	cg08841829	chr21:43638893	ABCG1	-0.68	-4.59	-0.35	9.26e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs16975963	0.843	rs11672257	chr19:38439362	A/G	cg08679971	chr19:38281047	NA	0.56	5.35	0.4	3.12e-7	Longevity;
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.73	-7.44	-0.52	6.99e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03347828	chr17:7739579	NA	0.65	7.19	0.5	2.71e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg03371404	chr2:241525653	CAPN10	-0.56	-4.96	-0.37	1.84e-6	Bipolar disorder;
PAAD	cis	rs1879734	1.000	rs55888542	chr1:54144297	T/C	cg14659662	chr1:54151053	GLIS1	-0.39	-6.12	-0.44	7.75e-9	Mitral valve prolapse;
PAAD	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.65	4.47	0.34	1.49e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.74	6.83	0.48	1.95e-10	Obesity-related traits;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.26	-0.39	4.9e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.87	-7.37	-0.51	1.01e-11	Gastritis;
PAAD	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg26695010	chr11:65641043	EFEMP2	0.57	5.04	0.38	1.3e-6	DNA methylation (variation);
PAAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg26022315	chr17:47021804	SNF8	0.46	4.64	0.35	7.57e-6	Type 2 diabetes;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	9.73	0.62	1.07e-17	Platelet count;
PAAD	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.98	10.96	0.66	5.82e-21	Gestational age at birth (maternal effect);
PAAD	trans	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.58	-5.78	-0.42	4.04e-8	Lymphocyte counts;
PAAD	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg19486271	chr11:47235900	DDB2	-0.52	-5.05	-0.38	1.28e-6	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg02524346	chr8:600233	NA	-0.98	-6.77	-0.48	2.6e-10	IgG glycosylation;
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21016266	chr12:122356598	WDR66	0.62	6.82	0.48	1.99e-10	Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.4	-0.46	1.79e-9	Menarche (age at onset);
PAAD	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	6.66	0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.48	4.7	0.36	5.91e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg20003494	chr4:90757398	SNCA	-0.6	-5.97	-0.44	1.65e-8	Neuroticism;
PAAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.62	0.41	8.91e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs7816613	0.850	rs4734564	chr8:102664103	A/G	cg20585841	chr8:102729926	NCALD	-0.65	-5.49	-0.41	1.61e-7	Age-related hearing impairment;
PAAD	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.48	6.13	0.45	7.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg22349387	chr12:9600060	DDX12	-0.41	-4.51	-0.34	1.31e-5	Breast size;
PAAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.84	10.37	0.64	2.14e-19	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.87	10.81	0.66	1.43e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg14196790	chr5:131705035	SLC22A5	0.57	6.54	0.47	9e-10	Blood metabolite levels;
PAAD	cis	rs5751901	0.614	rs4820599	chr22:24990213	A/G	cg15363607	chr22:24998974	GGT1	-0.47	-4.77	-0.36	4.32e-6	Protein quantitative trait loci;
PAAD	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg11232448	chr19:2858854	NA	-0.49	-4.8	-0.36	3.84e-6	Total cholesterol levels;
PAAD	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.85	7.2	0.5	2.54e-11	Neutrophil percentage of white cells;
PAAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.74	-7.66	-0.53	2.03e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg08888203	chr3:10149979	C3orf24	0.86	6.55	0.47	8.61e-10	Alzheimer's disease;
PAAD	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.35	0.33	2.53e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.45	5.33	0.4	3.43e-7	Psoriasis;
PAAD	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg13171406	chr11:92712998	MTNR1B	-0.49	-4.34	-0.33	2.6e-5	Pulmonary function decline;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13080195	chr4:83719908	SCD5	0.59	6.68	0.48	4.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.86	-7.47	-0.52	5.88e-12	Lymphocyte counts;
PAAD	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.66	7.49	0.52	5.2e-12	Dupuytren's disease;
PAAD	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.21	0.5	2.43e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7301826	0.651	rs7968675	chr12:131303377	C/T	cg11011512	chr12:131303247	STX2	0.5	5.16	0.39	7.56e-7	Plasma plasminogen activator levels;
PAAD	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.63	8.21	0.55	8.59e-14	Renal cell carcinoma;
PAAD	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.75	-12.73	-0.72	1.02e-25	Urate levels in overweight individuals;
PAAD	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.73	-7.28	-0.51	1.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-1.34	-10.8	-0.66	1.52e-20	Schizophrenia;
PAAD	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.72	7.61	0.53	2.63e-12	Alcohol dependence;
PAAD	cis	rs11945232	0.624	rs10035024	chr4:88367469	C/T	cg23841344	chr4:88312519	HSD17B11	-0.59	-4.74	-0.36	4.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.22	-0.39	5.72e-7	Neuroticism;
PAAD	cis	rs4654438	1.000	rs10753381	chr1:4565906	C/T	cg15088574	chr1:4848991	NA	-0.3	-4.41	-0.34	1.96e-5	Smooth-surface caries;
PAAD	cis	rs863345	0.604	rs1157524	chr1:158457298	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg24703168	chr6:28411309	ZSCAN23	-0.33	-4.25	-0.33	3.78e-5	Pubertal anthropometrics;
PAAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.58	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.65	-0.35	7.3e-6	Ulcerative colitis;
PAAD	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.33	6.84	0.49	1.78e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.47	-4.73	-0.36	5.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs7873102	0.654	rs4878733	chr9:38010025	A/G	cg03528946	chr9:38069800	SHB	0.48	4.8	0.36	3.72e-6	Brain structure;
PAAD	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg10818794	chr15:86012489	AKAP13	0.51	5.6	0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	trans	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg07211511	chr3:129823064	LOC729375	-1.28	-7.44	-0.52	6.94e-12	Blood pressure (smoking interaction);
PAAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.51	4.56	0.35	1.05e-5	Mean corpuscular volume;
PAAD	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.65	-6.5	-0.47	1.09e-9	Cognitive test performance;
PAAD	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg06067394	chr11:133789110	IGSF9B	-0.44	-4.79	-0.36	3.94e-6	Parkinson's disease;
PAAD	cis	rs761746	0.577	rs2012150	chr22:32216139	G/C	cg01338084	chr22:32026380	PISD	0.52	4.52	0.34	1.21e-5	Intelligence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17182048	chr12:66348387	HMGA2	-0.59	-6.46	-0.46	1.35e-9	Obesity-related traits;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg27094323	chr7:1216898	NA	-0.43	-5.0	-0.38	1.58e-6	Longevity;Endometriosis;
PAAD	cis	rs9900972	0.842	rs2009196	chr17:76870581	C/G	cg20937029	chr17:76870563	TIMP2	-0.58	-5.88	-0.43	2.45e-8	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg02135003	chr7:105160482	PUS7	-0.84	-6.75	-0.48	2.97e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg00071950	chr4:10020882	SLC2A9	0.63	5.59	0.41	1e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg18551225	chr6:44695536	NA	-0.58	-5.18	-0.39	6.86e-7	Total body bone mineral density;
PAAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.33	0.33	2.73e-5	Personality dimensions;
PAAD	cis	rs507080	0.733	rs570949	chr11:118571911	G/T	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.67	4.96	0.37	1.85e-6	Obesity-related traits;
PAAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg16205897	chr5:131564050	P4HA2	-0.55	-6.04	-0.44	1.14e-8	Blood metabolite levels;
PAAD	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00166722	chr3:10149974	C3orf24	0.9	7.73	0.53	1.37e-12	Alzheimer's disease;
PAAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14580859	chr9:123691850	NA	-0.38	-4.33	-0.33	2.67e-5	Rheumatoid arthritis;
PAAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.42	6.16	0.45	6.26e-9	Subjective well-being;
PAAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.75	6.2	0.45	5e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs900145	0.817	rs10766064	chr11:13277932	C/T	cg15603424	chr11:13300592	ARNTL	0.53	4.52	0.34	1.25e-5	Menarche (age at onset);
PAAD	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.45	4.41	0.34	1.91e-5	Malaria;
PAAD	cis	rs422249	0.634	rs174614	chr11:61628915	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.51	0.34	1.29e-5	Trans fatty acid levels;
PAAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12871990	chr3:88199156	C3orf38	0.65	6.64	0.47	5.21e-10	Obesity-related traits;
PAAD	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg21419209	chr3:44054225	NA	-0.75	-7.66	-0.53	2e-12	Coronary artery disease;
PAAD	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	0.66	4.62	0.35	8.19e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg19223190	chr17:80058835	NA	0.51	5.23	0.39	5.61e-7	Life satisfaction;
PAAD	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24002010	chr19:55741862	TMEM86B;SAPS1	0.54	6.32	0.46	2.69e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8044995	0.636	rs77517043	chr16:68301410	G/A	cg09835421	chr16:68378352	PRMT7	-1.3	-7.77	-0.53	1.11e-12	Schizophrenia;
PAAD	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg03522150	chr11:46969673	C11orf49	0.43	5.19	0.39	6.72e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg11271282	chr2:238384023	NA	0.53	4.87	0.37	2.8e-6	Prostate cancer;
PAAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.61	6.56	0.47	8.12e-10	Eye color traits;
PAAD	cis	rs12949688	1.000	rs12949688	chr17:55825701	C/T	cg12582317	chr17:55822272	NA	-0.68	-8.66	-0.57	6.48e-15	Schizophrenia;
PAAD	cis	rs7584330	0.504	rs6742601	chr2:238427940	C/G	cg08992911	chr2:238395768	MLPH	0.61	5.32	0.4	3.58e-7	Prostate cancer;
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.36	0.33	2.39e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg17541715	chr7:1216824	NA	-0.51	-5.78	-0.42	4.14e-8	Longevity;Endometriosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14592024	chr15:48624386	DUT	-0.6	-7.01	-0.49	7.29e-11	Body fat percentage;
PAAD	cis	rs9810890	1.000	rs73198811	chr3:128470749	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.66	7.01	0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs10500715	0.638	rs11042575	chr11:9995399	T/C	cg06875754	chr11:10328428	ADM	-0.32	-4.4	-0.34	2.06e-5	Pancreatic cancer;
PAAD	cis	rs955333	0.685	rs6924083	chr6:154899155	G/A	cg20019720	chr6:154832845	CNKSR3	0.35	4.47	0.34	1.54e-5	Diabetic kidney disease;
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-5.12	-0.38	9.13e-7	Body mass index;
PAAD	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.52	4.55	0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.6	-7.7	-0.53	1.63e-12	Longevity;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs10044254	0.563	rs4702102	chr5:15698919	A/T	cg07238450	chr5:15720153	FBXL7	-0.52	-4.79	-0.36	3.9e-6	Asthma (corticosteroid response);
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg07061783	chr6:25882402	NA	0.49	4.68	0.35	6.37e-6	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.75	7.3	0.51	1.47e-11	Corneal astigmatism;
PAAD	cis	rs7922314	0.571	rs61865687	chr10:64726329	C/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg12081754	chr8:22256438	SLC39A14	-0.54	-5.5	-0.41	1.59e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.08	-0.44	9.13e-9	Menarche (age at onset);
PAAD	cis	rs6594535	1.000	rs6594535	chr5:111094074	T/C	cg06838283	chr5:111090142	C5orf13	0.5	4.47	0.34	1.55e-5	Chickenpox;
PAAD	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.87	-8.22	-0.55	8.13e-14	Dilated cardiomyopathy;
PAAD	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.65	6.86	0.49	1.67e-10	Platelet distribution width;
PAAD	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg16342193	chr10:102329863	NA	-0.76	-8.17	-0.55	1.1e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg16300553	chr8:8131077	NA	0.36	4.26	0.33	3.63e-5	Mood instability;
PAAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg14440974	chr22:39074834	NA	-0.59	-7.27	-0.51	1.8e-11	Menopause (age at onset);
PAAD	cis	rs4401971	0.518	rs4740508	chr9:11932268	G/A	cg14390656	chr9:11618691	NA	0.46	4.49	0.34	1.41e-5	Obsessive-compulsive disorder;
PAAD	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06850241	chr22:41845214	NA	-0.56	-5.34	-0.4	3.28e-7	Vitiligo;
PAAD	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-6.97	-0.49	9.08e-11	Total cholesterol levels;
PAAD	cis	rs5752326	0.558	rs1023496	chr22:26865238	T/C	cg21431832	chr22:26875652	HPS4	-0.64	-4.35	-0.33	2.46e-5	Ischemic stroke;
PAAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2882667	0.690	rs906695	chr5:138139277	A/G	cg09476006	chr5:138032270	NA	0.44	5.43	0.4	2.21e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06307176	chr5:131281290	NA	0.51	4.63	0.35	7.71e-6	Life satisfaction;
PAAD	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg25364880	chr3:44379878	C3orf23	0.6	5.49	0.41	1.68e-7	Depressive symptoms;
PAAD	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-4.29	-0.33	3.17e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.79	0.48	2.32e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg10495392	chr1:46806563	NSUN4	0.56	5.48	0.41	1.71e-7	Menopause (age at onset);
PAAD	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.91	12.07	0.7	6.12e-24	Body mass index;
PAAD	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.57	5.59	0.41	1.02e-7	Blood protein levels;
PAAD	cis	rs12580194	0.593	rs61071395	chr12:55721228	G/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.33	0.33	2.74e-5	Cancer;
PAAD	cis	rs4774830	1.000	rs12439559	chr15:56118175	G/T	cg24530489	chr15:56299380	NA	1.03	4.45	0.34	1.66e-5	Delta-5 desaturase activity;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.18	-0.5	2.83e-11	Life satisfaction;
PAAD	cis	rs11864146	0.764	rs75397367	chr16:84041217	T/C	cg02489493	chr16:83842257	HSBP1	0.88	4.29	0.33	3.13e-5	Non-alcoholic fatty liver disease histology (other);
PAAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg21929781	chr1:2537748	MMEL1	-0.53	-5.62	-0.41	9.06e-8	Ulcerative colitis;
PAAD	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18682921	chr6:8432072	SLC35B3	-0.49	-6.33	-0.46	2.67e-9	Energy expenditure (24h);
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg05643964	chr20:62369504	LIME1	-0.51	-4.73	-0.36	5.01e-6	Prostate cancer;
PAAD	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg18551225	chr6:44695536	NA	-0.68	-6.76	-0.48	2.79e-10	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	5.02	0.38	1.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	4.88	0.37	2.64e-6	Personality dimensions;
PAAD	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.53	5.12	0.38	9.03e-7	Mortality in heart failure;
PAAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.16	-0.39	7.72e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6715793	0.665	rs6543691	chr2:33393902	C/G	cg26672287	chr2:33391915	LTBP1	-0.4	-4.66	-0.35	6.98e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.65	-5.99	-0.44	1.42e-8	Blood metabolite levels;
PAAD	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.35	-0.33	2.45e-5	Fibrinogen levels;
PAAD	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.35e-6	Tuberculosis;
PAAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.91e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg15211996	chr1:2936768	ACTRT2	0.46	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs6011674	1.000	rs45469101	chr20:61875007	C/T	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.72	-4.35	-0.33	2.5e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg23119463	chr10:134592391	INPP5A	-0.5	-4.7	-0.36	5.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.59	-5.64	-0.42	8.13e-8	Smoking behavior;
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs17428704	0.522	rs10056415	chr5:14421026	T/C	cg12964346	chr5:14507533	TRIO	-0.86	-4.26	-0.33	3.53e-5	Electroencephalogram traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07066918	chr10:129910468	MKI67	-0.61	-6.31	-0.46	2.85e-9	Obesity-related traits;
PAAD	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.53	5.58	0.41	1.06e-7	Diastolic blood pressure;
PAAD	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.51	-0.34	1.31e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1015291	1.000	rs1015291	chr12:19984779	A/G	cg25401612	chr12:20009446	NA	-0.48	-4.63	-0.35	7.9e-6	Diastolic blood pressure;
PAAD	cis	rs2327429	0.858	rs34523729	chr6:134184826	C/A	cg06296503	chr6:134217401	NA	0.48	4.95	0.37	1.96e-6	Coronary artery disease;
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-6.0	-0.44	1.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.34	-4.51	-0.34	1.29e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.52	6.62	0.47	5.67e-10	Body mass index;
PAAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.66	0.57	6.59e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs7623687	0.892	rs73077107	chr3:49671037	G/A	cg19401529	chr3:49056140	DALRD3	0.78	4.47	0.34	1.54e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.78	-9.23	-0.6	2.15e-16	Height;
PAAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08428512	chr8:128748147	MYC	0.58	6.45	0.46	1.4e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2302045	1.000	rs740393	chr2:242065498	A/G	cg01305291	chr2:242003078	SNED1	0.64	4.34	0.33	2.62e-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03647317	chr4:187891568	NA	-0.51	-6.23	-0.45	4.47e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.49	4.89	0.37	2.49e-6	Trans fatty acid levels;
PAAD	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg02918577	chr15:93633145	RGMA	0.42	5.33	0.4	3.51e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs1519814	0.654	rs1401810	chr8:121015820	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-4.92	-0.37	2.28e-6	Breast cancer;
PAAD	cis	rs9397240	1.000	rs9371884	chr6:155645607	G/A	cg06694381	chr6:155569200	TIAM2	-0.5	-4.46	-0.34	1.57e-5	Life satisfaction;
PAAD	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.28	-0.71	1.66e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg04362095	chr11:63592001	C11orf84	-0.54	-4.73	-0.36	4.98e-6	Platelet count;
PAAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg20893579	chr22:38215064	NA	0.52	4.91	0.37	2.29e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.96	-11.52	-0.68	1.85e-22	Height;
PAAD	cis	rs469568	0.523	rs11738217	chr5:178669893	C/T	cg08999896	chr5:178685787	ADAMTS2	0.55	5.75	0.42	4.85e-8	Stroke (pediatric);
PAAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.94	-0.49	1.04e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.63	4.92	0.37	2.24e-6	Serum sulfate level;
PAAD	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg15145965	chr22:50218605	BRD1	-0.55	-4.59	-0.35	9.29e-6	Schizophrenia;
PAAD	cis	rs6494488	0.500	rs72742907	chr15:64837935	A/G	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-8.29	-0.56	5.55e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.8	-0.43	3.79e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs41311933	0.710	rs12004487	chr9:123716681	T/C	cg21241889	chr9:123690658	TRAF1	-0.68	-4.32	-0.33	2.75e-5	Coronary artery disease;
PAAD	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.61	-0.41	9.17e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.51	4.85	0.37	3.03e-6	Psoriasis;
PAAD	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	2.02e-11	Dupuytren's disease;
PAAD	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23221052	chr5:179740743	GFPT2	-0.72	-7.13	-0.5	3.85e-11	Height;
PAAD	cis	rs16858210	0.520	rs12636861	chr3:183549788	T/C	cg03417191	chr3:183542750	MAP6D1	-0.79	-6.01	-0.44	1.33e-8	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.62	8.15	0.55	1.25e-13	Renal cell carcinoma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03086376	chr16:1876114	HAGH;FAHD1	0.65	6.86	0.49	1.6e-10	Myopia (pathological);
PAAD	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.14	8.39	0.56	3.09e-14	Type 2 diabetes;
PAAD	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.56	0.35	1.03e-5	Blood protein levels;
PAAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.56	0.47	7.83e-10	Body mass index;
PAAD	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg21937377	chr3:194868750	C3orf21	0.52	4.85	0.37	3.06e-6	Non-small cell lung cancer;
PAAD	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.43	-4.27	-0.33	3.37e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	8.77	0.58	3.41e-15	Platelet count;
PAAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg03037974	chr15:76606532	NA	-0.61	-6.95	-0.49	9.99e-11	Blood metabolite levels;
PAAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.53	-0.41	1.37e-7	Monocyte count;
PAAD	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02244288	chr16:89573955	SPG7	-0.33	-4.3	-0.33	3.06e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6876032	0.520	rs3888550	chr5:136369218	A/C	cg19853413	chr5:135468610	SMAD5;SMAD5OS	-0.8	-4.54	-0.35	1.14e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.63	-7.43	-0.52	7.47e-12	Schizophrenia;
PAAD	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	10.23	0.64	5.05e-19	Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10943724	0.679	rs953498	chr6:81266538	C/G	cg19323245	chr6:80716898	TTK	-0.43	-4.54	-0.35	1.14e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg07527105	chr16:88053339	BANP	-0.47	-4.68	-0.36	6.24e-6	Menopause (age at onset);
PAAD	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.47	-4.88	-0.37	2.64e-6	Neuroticism;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.61	6.41	0.46	1.72e-9	Testicular germ cell tumor;
PAAD	cis	rs7224737	1.000	rs8072215	chr17:40271970	A/G	cg02450064	chr17:40260053	DHX58	-0.38	-4.4	-0.34	2.02e-5	Fibrinogen levels;
PAAD	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.33	-0.33	2.68e-5	Educational attainment;
PAAD	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.7	9.41	0.61	7.6e-17	Hemoglobin concentration;
PAAD	cis	rs4889855	0.556	rs3923514	chr17:78515210	A/G	cg16591659	chr17:78472290	NA	0.52	5.03	0.38	1.38e-6	Fractional excretion of uric acid;
PAAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg25204440	chr1:209979598	IRF6	0.61	4.91	0.37	2.35e-6	Coronary artery disease;
PAAD	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.5	5.59	0.41	1.04e-7	Total cholesterol levels;
PAAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.63	-0.42	8.32e-8	Iron status biomarkers;
PAAD	cis	rs10737909	0.728	rs1780588	chr1:15554229	T/G	cg21012057	chr1:15538911	TMEM51	-0.48	-4.82	-0.36	3.5e-6	Migraine;
PAAD	cis	rs1209950	0.866	rs1734588	chr21:40180889	A/G	cg01359822	chr21:40176597	ETS2	0.31	5.02	0.38	1.44e-6	Non-small cell lung cancer (survival);
PAAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.77	8.62	0.57	7.92e-15	Total body bone mineral density;
PAAD	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.42e-5	Calcium levels;
PAAD	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg24253500	chr15:84953950	NA	0.41	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-5.88	-0.43	2.55e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.61	6.22	0.45	4.62e-9	Schizophrenia;
PAAD	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.56	4.6	0.35	8.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04592976	chr16:89984572	MC1R	0.65	7.4	0.51	8.45e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05567409	chr5:68485104	CENPH	0.53	6.43	0.46	1.54e-9	Myopia (pathological);
PAAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg24209194	chr3:40518798	ZNF619	0.48	4.41	0.34	1.92e-5	Renal cell carcinoma;
PAAD	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-5.05	-0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27099511	chr16:88729703	MGC23284;MVD	-0.82	-4.37	-0.33	2.3e-5	Plateletcrit;
PAAD	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg21479132	chr6:26055353	NA	0.96	5.35	0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.63	3.21e-18	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2092319	0.649	rs2786871	chr1:26028775	C/T	cg02327719	chr1:26185386	C1orf135	-0.88	-4.94	-0.37	2.06e-6	Nose morphology;
PAAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.44	-5.37	-0.4	2.93e-7	Schizophrenia;
PAAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.55	4.89	0.37	2.52e-6	Type 2 diabetes;
PAAD	cis	rs17169634	0.557	rs17169632	chr7:34089098	C/A	cg24927974	chr7:35078269	DPY19L1	-0.64	-4.81	-0.36	3.62e-6	Alzheimer's disease;
PAAD	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg13263323	chr15:86062960	AKAP13	-0.48	-4.89	-0.37	2.51e-6	Coronary artery disease;
PAAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.22e-5	HDL cholesterol;
PAAD	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9992101	0.838	rs1398016	chr4:77367688	C/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.25	-0.33	3.73e-5	Creatinine levels;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	4.76	0.36	4.47e-6	Vitiligo;
PAAD	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg00806126	chr19:22604979	ZNF98	0.4	5.15	0.39	8.07e-7	Pain;
PAAD	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs17095355	0.792	rs3780953	chr10:111650634	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.29	-0.33	3.12e-5	Biliary atresia;
PAAD	cis	rs11037575	0.900	rs10838157	chr11:43745564	A/G	cg24662154	chr11:44118094	EXT2	0.43	4.37	0.33	2.29e-5	Neuroblastoma;
PAAD	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg02640540	chr1:67518911	SLC35D1	0.52	4.66	0.35	6.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg11057378	chr10:81107060	PPIF	0.45	5.31	0.4	3.8e-7	Height;
PAAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.52	-4.39	-0.34	2.09e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg08513622	chr7:1889785	MAD1L1	-0.52	-4.72	-0.36	5.37e-6	Schizophrenia;
PAAD	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.56	-5.66	-0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs78472555	0.739	rs11634364	chr15:100261042	G/A	cg23669855	chr15:100272142	LYSMD4	-0.7	-5.91	-0.43	2.21e-8	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.73	8.24	0.56	7.42e-14	Lung cancer;
PAAD	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.66	-4.64	-0.35	7.52e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg26571870	chr16:85723150	GINS2	0.38	4.42	0.34	1.88e-5	Platelet distribution width;
PAAD	trans	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.57	-5.17	-0.39	7.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs59888335	0.964	rs2372502	chr3:80655763	A/G	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs6011002	0.636	rs7267230	chr20:62354572	G/A	cg01176363	chr20:62369445	LIME1	-0.92	-4.29	-0.33	3.21e-5	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24483552	chr8:67687060	SGK3	0.65	7.58	0.52	3.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.76	-8.64	-0.57	7.11e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.08	-0.38	1.11e-6	Electroencephalogram traits;
PAAD	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg26816564	chr1:7831052	VAMP3	0.6	5.02	0.38	1.4e-6	Inflammatory bowel disease;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.49	-4.51	-0.34	1.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.75	-8.08	-0.55	1.85e-13	Aortic root size;
PAAD	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg21995147	chr19:1064017	ABCA7	-0.6	-5.36	-0.4	3.01e-7	Alzheimer's disease (late onset);
PAAD	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.01	-0.38	1.49e-6	Mean corpuscular volume;
PAAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24763094	chr2:160569157	MARCH7	0.66	7.17	0.5	3.04e-11	Obesity-related traits;
PAAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.32	-0.4	3.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg05315796	chr3:52349193	DNAH1	0.41	4.54	0.35	1.16e-5	Bipolar disorder;
PAAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.4	4.71	0.36	5.59e-6	Tonsillectomy;
PAAD	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs8053891	0.756	rs9928413	chr16:72001110	C/T	cg04254540	chr16:71951199	KIAA0174	-0.54	-4.61	-0.35	8.59e-6	Coronary artery disease;
PAAD	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.38e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.76	6.68	0.48	4.21e-10	Morning vs. evening chronotype;
PAAD	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.95	-16.1	-0.79	1.17e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17641971	0.684	rs1511367	chr8:49949412	T/C	cg00325661	chr8:49890786	NA	0.53	5.34	0.4	3.27e-7	Blood metabolite levels;
PAAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.6	7.1	0.5	4.54e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.96	-8.87	-0.58	1.86e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.24	-0.39	5.29e-7	Blood metabolite levels;
PAAD	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.73	5.2	0.39	6.46e-7	Neuroticism;
PAAD	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08738430	chr2:43452561	ZFP36L2	-0.64	-8.11	-0.55	1.59e-13	Smoking initiation;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.67	6.06	0.44	1e-8	Schizophrenia;
PAAD	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg11502198	chr6:26597334	ABT1	0.43	4.38	0.33	2.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06307176	chr5:131281290	NA	0.51	4.7	0.36	5.85e-6	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13983578	chr8:29208153	DUSP4	0.63	6.64	0.47	5.13e-10	Myopia (pathological);
PAAD	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg16558253	chr16:72132732	DHX38	-0.63	-5.28	-0.39	4.42e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.8	-8.45	-0.57	2.14e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.81	7.91	0.54	4.97e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.68	7.65	0.53	2.16e-12	Corneal astigmatism;
PAAD	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg08601574	chr20:25228251	PYGB	0.57	5.79	0.42	3.99e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-8.76	-0.58	3.58e-15	Vitiligo;
PAAD	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.46	-4.75	-0.36	4.71e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg18357526	chr6:26021779	HIST1H4A	0.5	4.45	0.34	1.63e-5	Height;
PAAD	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.53	-4.97	-0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs7246760	1.000	rs10412903	chr19:9880927	C/A	cg16876255	chr19:9731953	ZNF561	0.93	4.59	0.35	9.12e-6	Pursuit maintenance gain;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10505813	chr15:50647051	GABPB1;FLJ10038;LOC100129387	-0.64	-6.41	-0.46	1.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.69e-8	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26659410	chr1:212004468	LPGAT1	0.57	7.12	0.5	4.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	1.0	7.64	0.53	2.3e-12	Gut microbiome composition (summer);
PAAD	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.66	0.53	2.05e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.39	-5.51	-0.41	1.51e-7	Cutaneous nevi;
PAAD	cis	rs6442522	0.867	rs12637268	chr3:15500248	T/C	cg16303742	chr3:15540471	COLQ	0.44	4.72	0.36	5.23e-6	Uric acid levels;
PAAD	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.12	0.44	7.61e-9	Rheumatoid arthritis;
PAAD	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg12623918	chr2:306882	NA	0.47	4.8	0.36	3.75e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.83	5.15	0.39	8.04e-7	Yeast infection;
PAAD	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg10596483	chr8:143751796	JRK	-0.49	-4.57	-0.35	9.95e-6	Urinary tract infection frequency;
PAAD	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg06217071	chr17:408420	NA	0.8	10.61	0.65	5.14e-20	Hip circumference adjusted for BMI;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	6.83	0.48	1.93e-10	Platelet count;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.61	-5.99	-0.44	1.46e-8	Prudent dietary pattern;
PAAD	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.52	-4.77	-0.36	4.36e-6	Height;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01381679	chr16:70834771	VAC14	-0.8	-7.12	-0.5	4.08e-11	Neuroticism;
PAAD	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	5.43	0.4	2.18e-7	IgG glycosylation;
PAAD	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	trans	rs7594645	1.000	rs74957607	chr2:207583731	A/T	cg25244921	chr15:65342634	OSTBETA	-1.17	-6.4	-0.46	1.81e-9	Episodic memory;
PAAD	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.61	-0.35	8.48e-6	Total body bone mineral density;
PAAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.98	-8.42	-0.56	2.57e-14	Gut microbiome composition (summer);
PAAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.28	-0.33	3.31e-5	Ileal carcinoids;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg04287289	chr16:89883240	FANCA	-0.61	-6.88	-0.49	1.43e-10	Vitiligo;
PAAD	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg24687543	chr11:63912206	MACROD1	0.63	5.45	0.4	2e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg13047869	chr3:10149882	C3orf24	0.57	4.82	0.36	3.39e-6	Alzheimer's disease;
PAAD	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg20003494	chr4:90757398	SNCA	-0.43	-4.87	-0.37	2.81e-6	Dementia with Lewy bodies;
PAAD	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg15443732	chr18:74961078	GALR1	0.72	5.91	0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.44	9.74	0.62	1.04e-17	Prostate cancer;
PAAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.93	-0.37	2.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg20913747	chr6:44695427	NA	-0.65	-6.43	-0.46	1.55e-9	Total body bone mineral density;
PAAD	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.56	4.78	0.36	4.02e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9287719	0.649	rs10202370	chr2:10727043	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs1497828	0.912	rs1497832	chr1:217527626	A/G	cg04411442	chr1:217543379	NA	-0.46	-4.39	-0.34	2.09e-5	Dialysis-related mortality;
PAAD	cis	rs6735179	0.603	rs736868	chr2:1748429	T/C	cg08534653	chr2:1747700	PXDN	0.24	4.28	0.33	3.24e-5	Response to antipsychotic treatment;
PAAD	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg09168692	chr1:7887560	PER3	0.52	4.97	0.37	1.75e-6	Inflammatory bowel disease;
PAAD	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.46	-0.34	1.56e-5	Body mass index;
PAAD	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.74e-7	Motion sickness;
PAAD	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.6	-5.61	-0.41	9.34e-8	Mean corpuscular volume;
PAAD	cis	rs1879734	1.000	rs3013771	chr1:54155902	C/T	cg14659662	chr1:54151053	GLIS1	0.4	6.37	0.46	2.15e-9	Mitral valve prolapse;
PAAD	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg13590414	chr9:128173245	NA	-0.46	-4.68	-0.35	6.43e-6	Mean arterial pressure;
PAAD	cis	rs2882667	0.690	rs288002	chr5:138232087	T/C	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.16	0.39	7.74e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs7243821	0.921	rs8098996	chr18:52634275	G/A	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs4795519	0.743	rs71371102	chr17:22166358	A/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.44	-4.36	-0.33	2.43e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.41	-4.34	-0.33	2.59e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs7132746	0.808	rs61930136	chr12:86242156	A/G	cg13084525	chr11:34642463	EHF	0.67	6.32	0.46	2.77e-9	Lewy body disease;
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg11204139	chr17:3907470	NA	0.64	6.29	0.45	3.22e-9	Type 2 diabetes;
PAAD	cis	rs11955175	1.000	rs11954632	chr5:40674929	C/G	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.67	6.49	0.47	1.16e-9	IgG glycosylation;
PAAD	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23281280	chr6:28129359	ZNF389	0.7	5.35	0.4	3.21e-7	Depression;
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg15571903	chr15:79123663	NA	-0.49	-6.28	-0.45	3.38e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg04087571	chr11:116723030	SIK3	-0.35	-4.51	-0.34	1.3e-5	Subjective well-being;
PAAD	cis	rs6971211	0.679	rs12113206	chr7:155670894	C/G	cg14601210	chr7:155671264	NA	0.44	4.95	0.37	1.98e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg13468214	chr4:1046988	NA	-0.53	-5.7	-0.42	5.94e-8	Recombination rate (males);
PAAD	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.91e-16	Cannabis dependence symptom count;
PAAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.44	-0.34	1.72e-5	Initial pursuit acceleration;
PAAD	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.11e-13	Corneal astigmatism;
PAAD	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.74	8.41	0.56	2.78e-14	Sjögren's syndrome;
PAAD	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.79	6.5	0.47	1.07e-9	Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2031532	0.587	rs9535247	chr13:50030265	C/G	cg08779649	chr13:50194554	NA	0.37	4.87	0.37	2.79e-6	Cardiac hypertrophy;
PAAD	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg02811702	chr13:24901961	NA	0.54	5.82	0.43	3.38e-8	Obesity-related traits;
PAAD	cis	rs78707713	0.786	rs12258136	chr10:71213995	C/T	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.29	-0.39	4.27e-7	Venous thromboembolism;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.65	4.75	0.36	4.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg01631408	chr1:248437212	OR2T33	-0.62	-5.27	-0.39	4.63e-7	Common traits (Other);
PAAD	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.4	-0.34	2.03e-5	Height;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.48	-4.99	-0.37	1.67e-6	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07372840	chr5:180296196	NA	0.58	6.47	0.46	1.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.31	6.67	0.48	4.4e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2004318	1.000	rs78747672	chr19:55077875	A/G	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.39	-0.34	2.08e-5	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.9	8.85	0.58	2.1e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg08439880	chr3:133502540	NA	-0.44	-4.74	-0.36	4.9100000000000004e-06	Iron status biomarkers;
PAAD	cis	rs8049603	0.615	rs7404408	chr16:23196738	C/T	cg16484020	chr16:23217411	SCNN1G	-0.48	-4.26	-0.33	3.52e-5	Multiple sclerosis;
PAAD	cis	rs6499755	0.897	rs8046197	chr16:55346012	A/C	cg02859129	chr16:55357253	IRX6	0.33	4.4	0.34	2.01e-5	Hypospadias;
PAAD	cis	rs8014252	0.803	rs73282153	chr14:71002310	C/T	cg11204974	chr14:71022665	NA	-0.7	-4.57	-0.35	1e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.09	-0.38	1.02e-6	Reticulocyte count;High light scatter reticulocyte count;
PAAD	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs72627123	1.000	rs72627119	chr14:74356274	C/G	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg04359828	chr10:32216031	ARHGAP12	0.26	4.31	0.33	2.92e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs988913	1.000	rs9396007	chr6:54807622	T/A	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg14154082	chr13:112174009	NA	0.37	4.31	0.33	2.93e-5	Menarche (age at onset);
PAAD	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.72	-0.36	5.35e-6	Type 2 diabetes;
PAAD	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.63	-7.09	-0.5	4.62e-11	Aortic root size;
PAAD	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18252515	chr7:66147081	NA	-0.49	-4.72	-0.36	5.4e-6	Corneal structure;
PAAD	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.9	10.11	0.63	1.08e-18	Total cholesterol levels;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.7	-0.36	5.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1519814	0.696	rs2326434	chr8:121047798	A/C	cg22335954	chr8:121166405	COL14A1	-0.64	-5.31	-0.4	3.91e-7	Breast cancer;
PAAD	cis	rs3857067	1.000	rs2865332	chr4:95013858	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.76	-8.79	-0.58	2.92e-15	Childhood ear infection;
PAAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.25	0.45	3.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg21724239	chr8:58056113	NA	0.67	5.09	0.38	1.04e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg27478167	chr7:817139	HEATR2	-0.59	-4.65	-0.35	7.1e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25556614	chr13:49797957	NA	0.64	6.78	0.48	2.46e-10	Smoking initiation;
PAAD	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg15676125	chr6:33679581	C6orf125	-0.44	-4.25	-0.33	3.68e-5	Plateletcrit;
PAAD	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-9.42	-0.61	6.95e-17	Height;
PAAD	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.48	-4.53	-0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2252790	0.899	rs1204854	chr6:116580896	T/A	cg26893134	chr6:116381904	FRK	-0.27	-4.28	-0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs9535307	0.929	rs942032	chr13:50251145	T/G	cg03658251	chr13:50265850	EBPL	0.78	5.5	0.41	1.59e-7	Obesity-related traits;
PAAD	cis	rs4750440	0.702	rs7918501	chr10:14029895	C/T	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.27	-0.33	3.42e-5	Adiponectin levels;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.74	-8.79	-0.58	2.99e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg13002189	chr3:66846049	NA	0.53	5.16	0.39	7.69e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.06	-0.5	5.51e-11	Neuroticism;
PAAD	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.84	8.22	0.55	8.17e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.8	7.53	0.52	4.17e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.57	-6.76	-0.48	2.74e-10	Aortic root size;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.67	5.25	0.39	4.93e-7	Alzheimer's disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15816511	chr8:95731770	DPY19L4	0.72	6.63	0.47	5.47e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs10214930	0.813	rs2391446	chr7:27648920	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs59888335	0.929	rs34924262	chr3:80887839	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.54	-5.22	-0.39	5.81e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg12705353	chr12:122356852	WDR66	0.47	5.42	0.4	2.34e-7	Mean corpuscular volume;
PAAD	cis	rs8084125	1.000	rs62105167	chr18:74944594	G/A	cg15443732	chr18:74961078	GALR1	0.72	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg06740227	chr12:86229804	RASSF9	0.5	4.95	0.37	1.91e-6	Major depressive disorder;
PAAD	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.83	9.45	0.61	5.99e-17	Total body bone mineral density;
PAAD	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.75	4.75	0.36	4.69e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg16211469	chr6:24423932	MRS2	0.46	4.55	0.35	1.1e-5	Liver enzyme levels;
PAAD	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-4.9	-0.37	2.41e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.71	-9.08	-0.59	5.46e-16	Educational attainment;
PAAD	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs4148087	1.000	rs4148087	chr21:43622267	C/T	cg08841829	chr21:43638893	ABCG1	-0.65	-4.28	-0.33	3.27e-5	Eating disorder in bipolar disorder;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-7.55	-0.52	3.67e-12	Heart rate;
PAAD	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg17105886	chr17:28927953	LRRC37B2	0.7	4.75	0.36	4.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1144333	0.655	rs968018	chr1:76395662	G/A	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	9.9e-6	Renal cell carcinoma;
PAAD	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg05895507	chr15:77155635	SCAPER	0.41	4.56	0.35	1.06e-5	Blood metabolite levels;
PAAD	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.1	-0.55	1.7e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	1.14	7.63	0.53	2.44e-12	IgG glycosylation;
PAAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.22	0.6	2.29e-16	Parkinson's disease;
PAAD	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.6	6.09	0.44	9.01e-9	Monocyte count;
PAAD	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.71	-0.36	5.44e-6	Mood instability;
PAAD	cis	rs11051970	0.879	rs73081911	chr12:32539124	C/G	cg24626660	chr12:32551988	NA	0.41	4.52	0.34	1.26e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.75	-7.66	-0.53	2.03e-12	Monocyte count;
PAAD	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg05627522	chr15:75251581	NA	-0.4	-4.64	-0.35	7.58e-6	Systemic lupus erythematosus;
PAAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg04575393	chr19:53496094	ZNF702P	-0.41	-4.44	-0.34	1.7e-5	Psoriasis;
PAAD	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.75	-5.03	-0.38	1.35e-6	Coronary artery calcification;
PAAD	cis	rs2342371	0.756	rs12637868	chr3:196106754	G/A	cg08209042	chr3:196295218	WDR53;FBXO45	-0.58	-4.64	-0.35	7.38e-6	Fat distribution (HIV);
PAAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg01075559	chr1:2537774	MMEL1	0.46	4.97	0.37	1.75e-6	Ulcerative colitis;
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg23461800	chr14:103021989	NA	-0.65	-5.19	-0.39	6.73e-7	Platelet count;
PAAD	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.49	6.12	0.44	7.51e-9	Crohn's disease;
PAAD	cis	rs6088813	1.000	rs2425065	chr20:33926268	A/T	cg14752227	chr20:34000481	UQCC	0.53	5.35	0.4	3.14e-7	Height;
PAAD	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.78	8.03	0.55	2.49e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg17366294	chr4:99064904	C4orf37	-0.47	-5.16	-0.39	7.53e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-8.11	-0.55	1.58e-13	Parkinson's disease;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7646881	0.812	rs61387735	chr3:158456161	G/A	cg19483011	chr3:158453295	NA	-0.72	-5.87	-0.43	2.63e-8	Tetralogy of Fallot;
PAAD	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.01	14.04	0.75	2.99e-29	Heart rate;
PAAD	cis	rs364477	0.859	rs279884	chr9:984220	C/G	cg13952963	chr9:998547	NA	0.58	4.81	0.36	3.68e-6	Major depressive disorder;
PAAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg13379983	chr2:198649727	BOLL	-0.56	-4.29	-0.33	3.12e-5	Ulcerative colitis;
PAAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg21890820	chr11:65308645	LTBP3	-0.64	-7.79	-0.53	9.96e-13	Bone mineral density;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.5	5.02	0.38	1.44e-6	Height;
PAAD	cis	rs9888739	1.000	rs11865746	chr16:31326587	T/G	cg02256631	chr16:31342952	ITGAM	-0.53	-4.32	-0.33	2.78e-5	Systemic lupus erythematosus;
PAAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15145965	chr22:50218605	BRD1	0.62	5.22	0.39	5.85e-7	Schizophrenia;
PAAD	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.74	-6.87	-0.49	1.57e-10	Asthma;
PAAD	cis	rs4662592	0.554	rs35895113	chr2:128903979	A/G	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs11051970	0.918	rs6488050	chr12:32532499	A/T	cg02745156	chr12:32552066	NA	0.45	4.56	0.35	1.06e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg20085588	chr10:81316188	SFTPA2	0.39	4.26	0.33	3.55e-5	Post bronchodilator FEV1;
PAAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs11811982	0.744	rs116035891	chr1:227618836	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	4.98	0.37	1.74e-6	Optic disc area;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.37	-0.33	2.29e-5	Breast cancer;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg05717871	chr11:638507	DRD4	-0.58	-5.53	-0.41	1.37e-7	Systemic lupus erythematosus;
PAAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg00540400	chr15:79124168	NA	-0.57	-6.7	-0.48	3.75e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.42	-4.35	-0.33	2.53e-5	Plateletcrit;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22444102	chr18:74175208	ZNF516	-0.41	-4.49	-0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.55	-6.2	-0.45	5e-9	Schizophrenia;
PAAD	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg13476313	chr9:127244764	NR5A1	0.32	5.18	0.39	6.96e-7	Menarche (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11910118	chr12:54718916	COPZ1	0.55	6.32	0.46	2.71e-9	Monocyte percentage of white cells;
PAAD	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg13010199	chr12:38710504	ALG10B	0.52	4.45	0.34	1.65e-5	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.83	6.08	0.44	9.08e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.904	rs2981857	chr1:2971521	T/C	cg22517653	chr1:2918612	NA	-0.61	-4.77	-0.36	4.35e-6	Plateletcrit;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.62	6.87	0.49	1.53e-10	Longevity;Endometriosis;
PAAD	cis	rs569214	0.515	rs577803	chr8:27513683	T/G	cg04264299	chr8:27491209	SCARA3	0.58	5.57	0.41	1.12e-7	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15688767	chr3:125093330	ZNF148	0.7	8.26	0.56	6.6e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.42	4.37	0.33	2.29e-5	Bulimia nervosa;
PAAD	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.82	-8.78	-0.58	3.21e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg13514324	chr8:145755804	MGC70857;KIAA1688	-0.3	-4.69	-0.36	6.08e-6	Age at first birth;
PAAD	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.94	-0.49	1.07e-10	Platelet distribution width;
PAAD	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.78	5.94	0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.83	-0.54	7.6e-13	Height;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06877860	chr20:55043471	C20orf43	0.68	6.6	0.47	6.4e-10	Primary biliary cholangitis;
PAAD	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.7	-7.68	-0.53	1.81e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-4.67	-0.35	6.45e-6	Neuroticism;
PAAD	cis	rs901683	0.850	rs76879426	chr10:46044857	G/A	cg16908948	chr10:45500256	ZNF22	0.79	4.26	0.33	3.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg10253484	chr15:75165896	SCAMP2	-0.66	-5.87	-0.43	2.61e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.8	-10.07	-0.63	1.34e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs6594713	0.533	rs17333665	chr5:112970602	C/T	cg12552261	chr5:112820674	MCC	0.75	4.92	0.37	2.2e-6	Brain cytoarchitecture;
PAAD	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.68	-6.74	-0.48	3.05e-10	Obesity-related traits;
PAAD	cis	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg00262122	chr8:11665843	FDFT1	-0.53	-4.8	-0.36	3.8e-6	Neuroticism;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08169830	chr7:97822374	LMTK2	0.54	6.31	0.46	2.89e-9	Body fat percentage;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11406300	chr15:69687028	PAQR5	0.67	8.27	0.56	6.11e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.55	-5.48	-0.41	1.7e-7	Coronary artery disease;
PAAD	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs6466055	0.720	rs12334245	chr7:104995627	T/C	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-6.84	-0.49	1.8e-10	Triglycerides;
PAAD	cis	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg11592613	chr18:23806284	TAF4B	-0.49	-4.49	-0.34	1.37e-5	Dental caries;
PAAD	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.7	6.68	0.48	4.26e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Tonsillectomy;
PAAD	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg01616529	chr11:638424	DRD4	-0.61	-6.22	-0.45	4.52e-9	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.49	-0.52	5.36e-12	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01704862	chr7:150780657	TMUB1	0.6	6.88	0.49	1.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6141769	0.518	rs28565102	chr20:31285458	T/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.62	-0.35	8.13e-6	Subjective well-being;
PAAD	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.48	-0.52	5.5e-12	Neuroticism;
PAAD	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.78	-0.66	1.78e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg07959070	chr22:50026188	C22orf34	-0.38	-4.46	-0.34	1.58e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.5	-5.76	-0.42	4.57e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg07617317	chr6:118971624	C6orf204	0.56	4.67	0.35	6.65e-6	Diastolic blood pressure;
PAAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.68e-7	Diabetic kidney disease;
PAAD	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	1.04	11.87	0.69	2.06e-23	Breast cancer;
PAAD	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.22	10.76	0.66	2.03e-20	Vitiligo;
PAAD	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.69	6.38	0.46	1.99e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.28	-14.14	-0.75	1.61e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.34	-10.49	-0.65	1.04e-19	Breast cancer;
PAAD	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7101378	0.577	rs1396910	chr11:108897500	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.74	5.72	0.42	5.39e-8	Atopic dermatitis;
PAAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs10501293	1.000	rs4495880	chr11:43133626	A/C	cg03447554	chr11:43094025	NA	-0.5	-4.92	-0.37	2.18e-6	Cognitive performance;
PAAD	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.51	-5.14	-0.38	8.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04875987	chr17:79981264	STRA13;LRRC45	0.66	6.37	0.46	2.1e-9	Myopia (pathological);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25014224	chr1:29474864	SFRS4	0.64	6.4	0.46	1.8e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.67	7.3	0.51	1.49e-11	Morning vs. evening chronotype;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.94	9.81	0.62	6.46e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-6.58	-0.47	7.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25105919	chr18:21083459	C18orf8	0.74	7.5	0.52	5.04e-12	Obesity-related traits;
PAAD	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.86	-9.77	-0.62	8.68e-18	Morning vs. evening chronotype;
PAAD	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg05344495	chr19:3478662	C19orf77	0.32	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs4343996	0.967	rs4588749	chr7:3363992	A/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.14	-0.38	8.48e-7	Motion sickness;
PAAD	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.14	7.8	0.53	9.39e-13	Alzheimer's disease (late onset);
PAAD	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg08704217	chr1:110036942	CYB561D1	0.48	4.39	0.34	2.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg00280220	chr17:61926910	NA	0.42	4.3	0.33	3.01e-5	Prudent dietary pattern;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-11.39	-0.68	3.99e-22	Longevity;Endometriosis;
PAAD	cis	rs8113142	0.550	rs66459748	chr19:29131294	T/G	cg04546413	chr19:29218101	NA	0.4	4.28	0.33	3.32e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg21892295	chr12:121157589	UNC119B	-0.44	-4.32	-0.33	2.86e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9527	0.518	rs12771834	chr10:104655419	G/A	cg14737131	chr10:104680354	CNNM2	0.75	6.33	0.46	2.58e-9	Arsenic metabolism;
PAAD	cis	rs1413885	1.000	rs10789182	chr1:65816780	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.99	0.38	1.63e-6	Anticoagulant levels;
PAAD	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7011049	1.000	rs72643580	chr8:53846710	T/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	5.71	0.42	5.89e-8	Lung cancer in ever smokers;
PAAD	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg23254163	chr1:152506842	NA	0.57	6.59	0.47	6.92e-10	Hair morphology;
PAAD	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg15193198	chr20:60906057	LAMA5	0.6	6.76	0.48	2.84e-10	Colorectal cancer;
PAAD	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.61	5.25	0.39	5.07e-7	Height;
PAAD	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.54	-0.47	8.98e-10	HDL cholesterol;
PAAD	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.56	4.8	0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs990171	0.874	rs6419573	chr2:103027103	T/C	cg03938978	chr2:103052716	IL18RAP	0.47	4.61	0.35	8.36e-6	Lymphocyte counts;
PAAD	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.52	6.17	0.45	6.02e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.98	-0.49	8.7e-11	Capecitabine sensitivity;
PAAD	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.05	-0.38	1.23e-6	Interstitial lung disease;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg08501292	chr6:25962987	TRIM38	0.74	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.63	-7.62	-0.53	2.57e-12	Lung cancer;
PAAD	cis	rs1577917	0.687	rs13197828	chr6:86805630	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.72	-7.41	-0.52	7.95e-12	Response to antipsychotic treatment;
PAAD	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-7.37	-0.51	1.02e-11	Coronary artery disease;
PAAD	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.46	-5.02	-0.38	1.46e-6	Electroencephalogram traits;
PAAD	cis	rs10918270	0.710	rs2340723	chr1:161940254	A/G	cg11744295	chr1:161283833	SDHC;LOC642502	0.43	4.35	0.33	2.48e-5	Parkinson's disease (age of onset);
PAAD	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg23024343	chr7:107201750	COG5	0.6	4.88	0.37	2.63e-6	Coronary artery disease;
PAAD	cis	rs1912528	0.814	rs813979	chr4:140880322	A/G	cg11128457	chr4:140864437	MAML3	-0.33	-4.42	-0.34	1.86e-5	Educational attainment (years of education);
PAAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg08125733	chr17:73851984	WBP2	0.82	7.5	0.52	5.05e-12	Psoriasis;
PAAD	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.96	8.15	0.55	1.22e-13	Dupuytren's disease;
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-4.48	-0.34	1.47e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg12756303	chr2:74692479	MOGS	-0.5	-4.41	-0.34	1.94e-5	Metabolite levels;
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.77	-0.42	4.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.68	-7.41	-0.52	8.25e-12	DNA methylation (variation);
PAAD	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.55	-0.47	8.18e-10	HDL cholesterol;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg25204440	chr1:209979598	IRF6	-0.63	-4.94	-0.37	2.01e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg14403583	chr14:105418241	AHNAK2	-0.72	-7.49	-0.52	5.21e-12	Rheumatoid arthritis;
PAAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs2004318	1.000	rs113092603	chr19:55078755	G/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.96	0.44	1.71e-8	Platelet count;
PAAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg26528668	chr16:1614120	IFT140	0.53	4.97	0.37	1.76e-6	Coronary artery disease;
PAAD	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.41	5.03	0.38	1.36e-6	Sitting height ratio;
PAAD	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.37	-0.4	2.92e-7	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs62264129	0.500	rs9829698	chr3:112028239	A/G	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.92	-0.37	2.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.68e-6	Oral cavity cancer;
PAAD	cis	rs728616	0.764	rs12413678	chr10:81687099	G/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.46	-0.34	1.58e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8018808	0.967	rs12889722	chr14:77850267	T/C	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs6028335	0.935	rs67138525	chr20:37756342	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.36	-0.33	2.43e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.48	7.09	0.5	4.81e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.38	0.46	2.07e-9	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26415393	chr7:155574244	NA	-0.65	-6.47	-0.46	1.27e-9	Obesity-related traits;
PAAD	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg25566285	chr7:158114605	PTPRN2	0.83	8.51	0.57	1.55e-14	Calcium levels;
PAAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.85	4.29	0.33	3.12e-5	Plasma clusterin levels;
PAAD	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.79	7.61	0.53	2.61e-12	Response to diuretic therapy;
PAAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.75	-0.53	1.21e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13390484	chr9:80765924	NA	-0.69	-6.65	-0.47	5.08e-10	Obesity-related traits;
PAAD	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.02	0.49	6.78e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg09839279	chr12:125627357	AACS	-0.48	-4.61	-0.35	8.47e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg21226059	chr5:178986404	RUFY1	-0.6	-7.04	-0.5	6.11e-11	Lung cancer;
PAAD	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg23435118	chr5:141488016	NDFIP1	-0.55	-5.3	-0.4	3.99e-7	Crohn's disease;
PAAD	cis	rs62408225	1.000	rs1604831	chr6:90967197	G/A	cg03795776	chr6:90687632	BACH2	0.43	4.29	0.33	3.23e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.23	-0.39	5.48e-7	Alcohol dependence;
PAAD	cis	rs57994353	0.600	rs11145974	chr9:139316744	A/G	cg14169450	chr9:139327907	INPP5E	-0.52	-4.52	-0.34	1.23e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.48	-4.71	-0.36	5.47e-6	Type 1 diabetes;
PAAD	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.43	-6.56	-0.47	7.79e-10	Subjective well-being;
PAAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg19592336	chr6:28129416	ZNF389	0.68	4.87	0.37	2.81e-6	Parkinson's disease;
PAAD	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.32	0.46	2.79e-9	Coronary artery disease;
PAAD	cis	rs6074578	0.679	rs6039035	chr20:140280	C/T	cg16931068	chr20:139680	DEFB127	-0.38	-5.22	-0.39	5.84e-7	Hirschsprung disease;
PAAD	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.73	7.34	0.51	1.17e-11	Methadone dose in opioid dependence;
PAAD	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg05805236	chr11:65401703	PCNXL3	-0.58	-5.99	-0.44	1.49e-8	Acne (severe);
PAAD	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.56	-0.47	8.05e-10	Colorectal cancer;
PAAD	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	6.46	0.46	1.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.02	7.54	0.52	4.07e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2302729	0.578	rs10848682	chr12:2771756	C/G	cg19945202	chr12:2788847	CACNA1C	-0.78	-8.05	-0.55	2.18e-13	Sleep quality;
PAAD	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.1	-0.38	9.98e-7	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12112058	chr1:224622605	WDR26	0.62	7.02	0.49	6.84e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.47	0.41	1.82e-7	Prudent dietary pattern;
PAAD	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg10818794	chr15:86012489	AKAP13	-0.46	-5.05	-0.38	1.25e-6	Interstitial lung disease;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.39	-0.68	3.99e-22	Total body bone mineral density;
PAAD	cis	rs57709857	0.915	rs3824289	chr8:38130433	C/A	cg16625770	chr8:38300134	FGFR1	-0.5	-4.61	-0.35	8.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.02	-0.44	1.25e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg03676636	chr4:99064102	C4orf37	0.26	4.4	0.34	2.01e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg06714761	chr1:201096289	NA	0.31	4.76	0.36	4.56e-6	Permanent tooth development;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg00166722	chr3:10149974	C3orf24	0.86	7.05	0.5	5.8200000000000003e-11	Alzheimer's disease;
PAAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.97	8.75	0.58	3.72e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.83	-6.58	-0.47	7.23e-10	Diastolic blood pressure;
PAAD	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.46	5.41	0.4	2.46e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg00717180	chr2:96193071	NA	-0.63	-7.74	-0.53	1.28e-12	HDL cholesterol;
PAAD	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.58	-5.13	-0.38	8.87e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.77	8.39	0.56	3.17e-14	Schizophrenia;
PAAD	trans	rs901683	0.702	rs78757497	chr10:46161918	T/C	cg07935355	chr19:50391064	TBC1D17	1.34	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg27511599	chr7:32358540	NA	0.75	4.53	0.34	1.21e-5	Body mass index;
PAAD	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-8.45	-0.57	2.23e-14	Exhaled nitric oxide output;
PAAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg20344442	chr15:51633704	GLDN	0.51	4.82	0.36	3.42e-6	Hormone measurements;
PAAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.45	-4.69	-0.36	6.02e-6	Blood protein levels;
PAAD	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.79	5.8	0.43	3.74e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10547527	chr2:198650123	BOLL	0.48	4.27	0.33	3.4e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.54	-5.38	-0.4	2.8e-7	Platelet count;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.54	-4.26	-0.33	3.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg04156016	chr5:1868137	NA	0.49	4.93	0.37	2.16e-6	Cardiovascular disease risk factors;
PAAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.44	4.52	0.34	1.24e-5	Plateletcrit;
PAAD	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.5	-4.65	-0.35	7.24e-6	Cancer;
PAAD	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.61	5.41	0.4	2.41e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	4.38	0.33	2.19e-5	Free thyroxine concentration;
PAAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.86	0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg20891283	chr12:69753455	YEATS4	0.79	8.52	0.57	1.45e-14	Blood protein levels;
PAAD	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg04415270	chr2:102091202	RFX8	-0.52	-6.38	-0.46	2.02e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.51	5.42	0.4	2.27e-7	Dementia with Lewy bodies;
PAAD	cis	rs59888335	0.895	rs58145326	chr3:80601983	T/C	cg21735741	chr3:80819488	NA	0.59	5.15	0.39	7.95e-7	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17562763	chr11:67398026	NUDT8	-0.55	-6.55	-0.47	8.51e-10	Body fat percentage;
PAAD	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg16964102	chr10:135390573	NA	0.43	4.66	0.35	6.93e-6	Obesity-related traits;
PAAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.44	-4.79	-0.36	3.86e-6	Birth weight;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.95	12.19	0.7	2.77e-24	Menarche (age at onset);
PAAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.99e-9	Schizophrenia;
PAAD	cis	rs12801636	0.557	rs3741378	chr11:65408937	C/T	cg06492744	chr11:65406254	SIPA1	0.48	4.33	0.33	2.67e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs950037	0.816	rs10801689	chr1:89356844	A/G	cg13109106	chr1:89333529	GTF2B	0.47	4.34	0.33	2.62e-5	Coronary artery disease;
PAAD	cis	rs11696501	0.688	rs1013562	chr20:44310744	A/G	cg11783356	chr20:44313418	WFDC10B	-0.63	-5.18	-0.39	6.79e-7	Brain structure;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.42	0.4	2.26e-7	Life satisfaction;
PAAD	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11343870	chr11:67888858	CHKA	0.6	6.9	0.49	1.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23281280	chr6:28129359	ZNF389	0.8	6.3	0.45	3.07e-9	Parkinson's disease;
PAAD	cis	rs75920871	0.541	rs76690043	chr11:116801529	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-4.55	-0.35	1.09e-5	Subjective well-being;
PAAD	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17372223	chr3:52568218	NT5DC2	-0.48	-4.82	-0.36	3.51e-6	Bipolar disorder;
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg20302533	chr7:39170763	POU6F2	0.45	6.18	0.45	5.62e-9	IgG glycosylation;
PAAD	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.99	-10.33	-0.64	2.87e-19	Platelet distribution width;
PAAD	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.99	8.26	0.56	6.64e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7173419	0.716	rs7162812	chr15:28233734	G/A	cg20906524	chr15:28200668	OCA2	-0.53	-5.77	-0.42	4.21e-8	Eye color;
PAAD	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-1.02	-9.31	-0.6	1.33e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.4	-0.34	2.04e-5	Retinal vascular caliber;
PAAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg14686297	chr22:46650375	NA	-0.47	-4.25	-0.33	3.76e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4343996	0.967	rs10260145	chr7:3345308	C/T	cg21248987	chr7:3385318	SDK1	0.47	5.17	0.39	7.36e-7	Motion sickness;
PAAD	cis	rs7737355	0.773	rs4705895	chr5:131102194	T/C	cg06307176	chr5:131281290	NA	0.49	4.31	0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.94	12.47	0.71	5.12e-25	Menopause (age at onset);
PAAD	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.39	-0.4	2.66e-7	Joint mobility (Beighton score);
PAAD	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg08732750	chr1:87598351	LOC339524	-0.33	-4.64	-0.35	7.52e-6	Smoking behavior;
PAAD	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.5	-4.34	-0.33	2.59e-5	Extraversion;
PAAD	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.76	-0.53	1.16e-12	Triglycerides;
PAAD	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg20813462	chr7:2646259	IQCE	0.65	4.61	0.35	8.38e-6	Urate levels in lean individuals;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.53	-0.47	9.44e-10	Lung cancer;
PAAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	7.07	0.5	5.38e-11	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg20893579	chr22:38215064	NA	0.43	4.48	0.34	1.47e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.68	0.35	6.35e-6	Breast cancer;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.47	5.61	0.41	9.21e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6089829	0.723	rs747128	chr20:61656398	G/A	cg03213289	chr20:61660250	NA	-0.48	-6.27	-0.45	3.59e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	1.08	9.7	0.62	1.32e-17	Initial pursuit acceleration;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.92	13.25	0.73	3.92e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-4.33	-0.33	2.73e-5	Neuroticism;
PAAD	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-5.39	-0.4	2.58e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.47	-4.66	-0.35	6.86e-6	Total body bone mineral density;
PAAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg18230493	chr5:56204884	C5orf35	-0.57	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.75	10.78	0.66	1.72e-20	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7989332	1.000	rs7989332	chr13:21050575	A/C	cg06710890	chr13:21477865	XPO4	0.51	4.28	0.33	3.26e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.73e-6	Coronary artery disease;
PAAD	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg10072921	chr12:121022843	NA	-0.34	-4.53	-0.34	1.2e-5	High light scatter reticulocyte count;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg21280719	chr6:42927975	GNMT	-0.46	-7.06	-0.5	5.48e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg03303774	chr4:1407052	NA	0.47	5.97	0.44	1.59e-8	Obesity-related traits;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.82	-7.11	-0.5	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.75	6.53	0.47	9.12e-10	Coronary artery disease;
PAAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.25	-0.39	4.97e-7	Multiple sclerosis;
PAAD	cis	rs7187994	0.848	rs35210690	chr16:84782857	C/G	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	trans	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.43	-0.56	2.44e-14	Aortic root size;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.72	-5.36	-0.4	3.08e-7	Psoriasis vulgaris;
PAAD	cis	rs1018697	1.000	rs7092051	chr10:104559477	C/T	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg10820045	chr2:198174542	NA	0.51	5.11	0.38	9.36e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.87	-10.63	-0.65	4.32e-20	Dental caries;
PAAD	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	7.04	0.5	6.08e-11	Educational attainment;
PAAD	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.67	-4.84	-0.37	3.15e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.73	-0.42	5.34e-8	Resting heart rate;
PAAD	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.79	6.96	0.49	9.69e-11	Schizophrenia;
PAAD	cis	rs12681963	0.688	rs7817838	chr8:30062814	T/C	cg23406830	chr8:30012838	DCTN6	-0.7	-4.34	-0.33	2.57e-5	Migraine;
PAAD	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.07	-0.38	1.13e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.64	6.51	0.47	1.05e-9	Testicular germ cell tumor;
PAAD	cis	rs4751058	0.526	rs10764841	chr10:130856829	A/C	cg04854917	chr10:131378330	MGMT	-0.43	-4.32	-0.33	2.76e-5	Vitamin D levels;
PAAD	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg06569542	chr10:98946673	SLIT1	-0.51	-5.75	-0.42	4.71e-8	Monocyte count;
PAAD	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg08601574	chr20:25228251	PYGB	0.66	7.32	0.51	1.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14216142	chr3:138313050	CEP70	0.61	6.94	0.49	1.08e-10	Monocyte percentage of white cells;
PAAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.78	9.25	0.6	1.99e-16	Emphysema distribution in smoking;
PAAD	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.53	5.52	0.41	1.46e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs654384	0.798	rs12701426	chr7:4176315	A/G	cg00055292	chr7:4846846	RADIL	0.49	4.65	0.35	7.03e-6	Positive affect;
PAAD	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg10556349	chr10:835070	NA	0.61	4.38	0.33	2.24e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg08390786	chr10:135334061	NA	-0.62	-4.96	-0.37	1.86e-6	Gout;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.58	-5.4	-0.4	2.56e-7	Acylcarnitine levels;
PAAD	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg04990556	chr1:26633338	UBXN11	0.64	4.69	0.36	5.95e-6	Obesity-related traits;
PAAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.39	-0.51	8.87e-12	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22466716	chr5:13735996	DNAH5	-0.69	-7.52	-0.52	4.55e-12	Obesity-related traits;
PAAD	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	6.67	0.48	4.41e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg07701084	chr6:150067640	NUP43	0.59	4.98	0.37	1.68e-6	Lung cancer;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.32	-0.33	2.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.87	-0.37	2.82e-6	Blood pressure;
PAAD	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg16589663	chr20:23618590	CST3	0.85	7.26	0.51	1.85e-11	Chronic kidney disease;
PAAD	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs7922314	0.571	rs59286975	chr10:64736664	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs7173419	0.655	rs12903382	chr15:28226949	A/G	cg20906524	chr15:28200668	OCA2	-0.46	-5.29	-0.39	4.1e-7	Eye color;
PAAD	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04013166	chr16:89971882	TCF25	0.64	4.26	0.33	3.62e-5	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.97	15.43	0.78	6.49e-33	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14588686	chr15:102261251	TARSL2	0.58	6.33	0.46	2.68e-9	Smoking initiation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22535163	chr4:81075674	NA	0.58	6.3	0.46	3.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-5.51	-0.41	1.53e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg13160058	chr8:26243215	BNIP3L	-0.38	-4.69	-0.36	6.16e-6	Red cell distribution width;
PAAD	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23281280	chr6:28129359	ZNF389	0.64	4.95	0.37	1.94e-6	Parkinson's disease;
PAAD	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.69	8.49	0.57	1.78e-14	Dupuytren's disease;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs564309	0.764	rs12065815	chr1:228555794	A/G	cg01328119	chr1:228783545	DUSP5P	0.66	4.3	0.33	3.01e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs10950821	0.770	rs73688305	chr7:20682189	A/G	cg21202529	chr7:20656503	ABCB5	-0.49	-4.76	-0.36	4.38e-6	Response to statin therapy;
PAAD	cis	rs11807834	0.522	rs2078219	chr1:230242962	A/G	cg09847368	chr1:230250326	GALNT2	0.69	8.44	0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.97	10.75	0.66	2.05e-20	Primary sclerosing cholangitis;
PAAD	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg22431228	chr1:16359049	CLCNKA	0.42	5.12	0.38	9.31e-7	Systolic blood pressure;
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.53	-5.26	-0.39	4.71e-7	Menarche (age at onset);
PAAD	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-13.65	-0.74	3.46e-28	Height;
PAAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.31	0.64	3.1400000000000002e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3745672	0.590	rs10401283	chr19:12167353	C/T	cg11321965	chr19:12780562	MORG1;C19orf56	-0.98	-4.33	-0.33	2.66e-5	Multiple sclerosis;
PAAD	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.01	0.44	1.29e-8	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.29	-0.39	4.15e-7	IgG glycosylation;
PAAD	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.18	17.67	0.82	1.12e-38	Exhaled nitric oxide output;
PAAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25522232	chr5:195132	LRRC14B	0.6	7.24	0.51	2.08e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg26513180	chr16:89883248	FANCA	0.7	8.23	0.56	7.97e-14	Vitiligo;
PAAD	cis	rs939584	1.000	rs2867125	chr2:622827	T/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-1.42	-10.38	-0.64	1.99e-19	Magnesium levels;
PAAD	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.89	9.66	0.62	1.62e-17	Monocyte count;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.65	7.02	0.49	6.89e-11	Lung cancer;
PAAD	cis	rs2964802	0.505	rs6876703	chr5:10831629	G/A	cg14521931	chr5:10832172	NA	-0.47	-4.91	-0.37	2.28e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs12760731	0.668	rs10913532	chr1:178278692	A/G	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs2790216	1.000	rs1199100	chr10:59948044	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg19257562	chr1:2043853	PRKCZ	0.48	5.87	0.43	2.67e-8	Height;
PAAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.71	7.92	0.54	4.68e-13	Melanoma;
PAAD	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg19792802	chr11:65647270	CTSW	0.42	4.79	0.36	3.88e-6	Crohn's disease;
PAAD	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg17326555	chr1:119535693	NA	-0.36	-4.66	-0.35	6.76e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11723261	0.582	rs11248005	chr4:166615	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.27	0.39	4.65e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg13263323	chr15:86062960	AKAP13	-0.6	-7.0	-0.49	7.66e-11	Interstitial lung disease;
PAAD	cis	rs17407555	0.683	rs4697999	chr4:10274934	C/G	cg00071950	chr4:10020882	SLC2A9	0.5	5.42	0.4	2.34e-7	Schizophrenia (age at onset);
PAAD	cis	rs1075265	0.716	rs7573991	chr2:53953967	C/G	cg04546899	chr2:54196757	PSME4	0.3	4.56	0.35	1.05e-5	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs901683	1.000	rs34163035	chr10:46080719	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1519814	1.000	rs7000103	chr8:121166200	A/C	cg22335954	chr8:121166405	COL14A1	-0.61	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-17.39	-0.82	5.8e-38	Exhaled nitric oxide output;
PAAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg08975724	chr8:8085496	FLJ10661	0.74	7.26	0.51	1.91e-11	Mood instability;
PAAD	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.49	-5.19	-0.39	6.76e-7	Ulcerative colitis;
PAAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-6.13	-0.45	7.3e-9	Schizophrenia;
PAAD	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.29	-0.56	5.43e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13877106	chr11:126173568	DCPS	0.48	6.55	0.47	8.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg03367679	chr17:38183553	MED24;SNORD124	-0.35	-4.59	-0.35	9.12e-6	Myeloid white cell count;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.52	5.49	0.41	1.62e-7	Tonsillectomy;
PAAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	1.06	11.17	0.67	1.56e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.72	9.63	0.62	2.01e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg24879335	chr3:133465180	TF	0.59	6.74	0.48	3.16e-10	Iron status biomarkers (transferrin levels);
PAAD	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg15660573	chr17:549704	VPS53	0.54	5.99	0.44	1.44e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg05805236	chr11:65401703	PCNXL3	0.42	4.42	0.34	1.83e-5	Acne (severe);
PAAD	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg23254163	chr1:152506842	NA	0.51	5.51	0.41	1.49e-7	Hair morphology;
PAAD	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.3	-0.33	3.02e-5	Schizophrenia;
PAAD	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.84	-0.54	7.22e-13	Migraine;Coronary artery disease;
PAAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg19337854	chr7:99768885	GPC2	0.42	4.35	0.33	2.5e-5	Coronary artery disease;
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg10253484	chr15:75165896	SCAMP2	0.51	4.68	0.36	6.22e-6	Breast cancer;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.45	5.86	0.43	2.81e-8	Cystic fibrosis severity;
PAAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07472159	chr6:116447667	COL10A1;NT5DC1	-0.51	-6.49	-0.47	1.16e-9	Energy expenditure (24h);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19377384	chr3:140951430	ACPL2	0.65	7.75	0.53	1.21e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.8	7.24	0.51	2.09e-11	Breast cancer;
PAAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.96	11.15	0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	5.43	0.4	2.2e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.66e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.63	4.56	0.35	1.06e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg24879335	chr3:133465180	TF	-0.54	-5.73	-0.42	5.15e-8	Iron status biomarkers;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.58	-6.87	-0.49	1.51e-10	Menopause (age at onset);
PAAD	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg08992911	chr2:238395768	MLPH	0.63	5.33	0.4	3.47e-7	Prostate cancer;
PAAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg06740227	chr12:86229804	RASSF9	0.58	5.31	0.4	3.74e-7	Major depressive disorder;
PAAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.73	6.24	0.45	4.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs9826463	0.757	rs66597875	chr3:142264782	T/C	cg20824294	chr3:142316082	PLS1	0.42	4.72	0.36	5.38e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs34845616	0.520	rs1793680	chr11:133798762	C/T	cg12362517	chr11:133800685	IGSF9B	0.53	5.42	0.4	2.28e-7	Hand grip strength;
PAAD	cis	rs2031532	0.587	rs7991226	chr13:50032293	C/T	cg08779649	chr13:50194554	NA	0.36	4.78	0.36	4.1e-6	Cardiac hypertrophy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22542663	chr21:34915757	GART;SON	-0.64	-6.58	-0.47	7.21e-10	Smoking initiation;
PAAD	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.41	-0.4	2.45e-7	Response to antipsychotic treatment;
PAAD	cis	rs75920871	0.764	rs76136280	chr11:116788491	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.87	-4.69	-0.36	6.02e-6	Subjective well-being;
PAAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.77	-8.72	-0.58	4.49e-15	Mean platelet volume;
PAAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.57	0.57	1.1e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs7714584	1.000	rs7734778	chr5:150256556	G/A	cg22134413	chr5:150180641	NA	0.72	5.03	0.38	1.34e-6	Crohn's disease;
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg24112000	chr20:60950667	NA	-0.69	-6.76	-0.48	2.74e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg26205652	chr12:48591994	NA	0.96	10.21	0.64	5.86e-19	Longevity (90 years and older);
PAAD	cis	rs2834188	0.557	rs3171425	chr21:34668747	A/G	cg04842828	chr21:34696676	IFNAR1	0.49	5.14	0.38	8.29e-7	Narcolepsy;
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg09517075	chr8:22133004	PIWIL2	0.57	7.25	0.51	1.95e-11	Hypertriglyceridemia;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.95	7.81	0.54	8.53e-13	Eotaxin levels;
PAAD	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-6.84	-0.49	1.78e-10	Height;
PAAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06307176	chr5:131281290	NA	-0.52	-4.74	-0.36	4.96e-6	Life satisfaction;
PAAD	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.28	-0.45	3.39e-9	Hip circumference;
PAAD	trans	rs62179067	0.708	rs1875782	chr2:179896526	A/G	cg13380624	chr19:7735426	NA	-0.73	-6.96	-0.49	9.73e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs8112211	0.689	rs3816044	chr19:38794750	G/A	cg14299480	chr19:38876666	GGN	-0.52	-4.46	-0.34	1.57e-5	Blood protein levels;
PAAD	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg10973622	chr2:86423274	IMMT	0.4	4.6	0.35	8.94e-6	Night sleep phenotypes;
PAAD	cis	rs732765	0.734	rs10142036	chr14:75126992	T/A	cg17347104	chr14:75034677	LTBP2	0.58	5.12	0.38	9.05e-7	Non-small cell lung cancer;
PAAD	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.96	-10.78	-0.66	1.75e-20	Coronary artery disease;
PAAD	cis	rs652260	0.967	rs520802	chr19:7915451	A/C	cg26014689	chr19:7917955	EVI5L	-0.53	-5.19	-0.39	6.57e-7	Menarche (age at onset);
PAAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs35955747	0.870	rs5997986	chr22:31834939	C/T	cg07969918	chr22:31682909	PIK3IP1	-0.34	-4.33	-0.33	2.69e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.81	-0.48	2.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs78049276	0.688	rs80157433	chr4:148370548	A/G	cg00400743	chr4:148603008	PRMT10	-0.71	-4.48	-0.34	1.48e-5	Pulse pressure;
PAAD	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg10935138	chr17:73851978	WBP2	0.5	4.36	0.33	2.38e-5	White matter hyperintensity burden;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg06026331	chr20:60912101	LAMA5	0.58	5.46	0.41	1.86e-7	Pelvic organ prolapse;
PAAD	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.71	7.03	0.5	6.49e-11	Coronary artery disease;
PAAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg04087571	chr11:116723030	SIK3	0.37	5.49	0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg20582800	chr6:43612764	RSPH9	-0.56	-4.44	-0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12476592	0.530	rs77804166	chr2:64160237	G/A	cg20249169	chr2:64881356	SERTAD2	-0.54	-4.31	-0.33	2.91e-5	Childhood ear infection;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg00166722	chr3:10149974	C3orf24	0.69	6.22	0.45	4.62e-9	Alzheimer's disease;
PAAD	cis	rs1539053	1.000	rs11207079	chr1:58097977	T/C	cg20292791	chr1:58089357	DAB1	-0.54	-5.32	-0.4	3.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs80282103	0.618	rs11250249	chr10:1116999	T/C	cg05228244	chr10:1102351	WDR37	1.03	4.53	0.34	1.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	4.35	0.33	2.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72960926	1.000	rs72960926	chr6:75158266	C/A	cg13435101	chr6:74171350	MTO1	1.01	4.91	0.37	2.35e-6	Metabolite levels (MHPG);
PAAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg17366294	chr4:99064904	C4orf37	-0.56	-6.62	-0.47	5.93e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.26	0.39	4.75e-7	Life satisfaction;
PAAD	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.56	-5.81	-0.43	3.52e-8	Hepatitis;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.41	-0.34	1.92e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.72	6.67	0.48	4.5e-10	Obesity-related traits;
PAAD	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.67	-5.95	-0.43	1.79e-8	Mean platelet volume;
PAAD	cis	rs6496932	0.755	rs6497021	chr15:85896267	G/A	cg19183879	chr15:85880815	NA	-0.54	-4.83	-0.36	3.33e-6	Central corneal thickness;Corneal structure;
PAAD	trans	rs4815879	0.925	rs8124775	chr20:5960092	C/T	cg22510814	chr11:68773285	MRGPRF	1.07	6.77	0.48	2.64e-10	Preeclampsia;
PAAD	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	5.12	0.38	9.04e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.94	12.37	0.71	9.43e-25	Menopause (age at onset);
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg20848291	chr7:100343083	ZAN	-0.93	-7.85	-0.54	6.88e-13	Other erythrocyte phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12025027	chr17:1531232	SLC43A2	0.57	6.41	0.46	1.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg14515779	chr1:101123966	NA	-0.52	-6.28	-0.45	3.3e-9	Monocyte count;
PAAD	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs6466055	0.625	rs2074753	chr7:104786593	T/C	cg04380332	chr7:105027541	SRPK2	0.49	4.76	0.36	4.47e-6	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-8.65	-0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.43	-4.5	-0.34	1.32e-5	Aortic root size;
PAAD	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg20291162	chr17:40259547	DHX58	-0.6	-6.44	-0.46	1.52e-9	Fibrinogen levels;
PAAD	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.15	0.39	7.97e-7	Lung cancer;
PAAD	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.89	11.4	0.68	3.7e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg26939375	chr7:64535504	NA	-0.77	-8.9	-0.59	1.52e-15	Aortic root size;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.49	-4.74	-0.36	4.83e-6	Lung cancer;
PAAD	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.7	-4.78	-0.36	4.09e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs800160	0.777	rs11022289	chr11:2345417	T/G	cg09785033	chr11:2336066	TSPAN32	-0.5	-4.32	-0.33	2.83e-5	Bacteremia;
PAAD	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs17152411	0.652	rs4246208	chr10:126654898	C/T	cg04726013	chr10:126223236	LHPP	-0.31	-4.52	-0.34	1.23e-5	Height;
PAAD	cis	rs349045	0.560	rs10416177	chr19:44301543	G/T	cg11993925	chr19:44307056	LYPD5	-0.46	-5.92	-0.43	2.1e-8	Reading or mathematical ability;
PAAD	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg19980929	chr12:42632907	YAF2	0.63	7.54	0.52	4.01e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.82	-8.71	-0.58	4.65e-15	Prostate cancer;
PAAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.48	4.67	0.35	6.59e-6	Resistin levels;
PAAD	cis	rs7896471	0.655	rs7080344	chr10:101790076	C/G	cg09956859	chr10:101293089	NKX2-3	-0.8	-4.5	-0.34	1.34e-5	Blood protein levels;
PAAD	cis	rs727479	0.502	rs2289105	chr15:51507508	C/T	cg21478137	chr15:51532386	CYP19A1	-0.46	-4.47	-0.34	1.52e-5	Estradiol levels;
PAAD	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg14393609	chr7:65229607	NA	0.6	6.45	0.46	1.42e-9	Aortic root size;
PAAD	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.68	0.65	3.19e-20	Homoarginine levels;
PAAD	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg04374321	chr14:90722782	PSMC1	0.51	4.3	0.33	3.02e-5	Longevity;
PAAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Diastolic blood pressure;
PAAD	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.58	-6.07	-0.44	9.94e-9	Total body bone mineral density;
PAAD	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-7.57	-0.52	3.44e-12	Gout;
PAAD	cis	rs600626	0.947	rs531117	chr11:75456134	C/T	cg24262691	chr11:75473276	NA	0.49	4.69	0.36	6.13e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.62	5.65	0.42	7.51e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.69	-6.57	-0.47	7.48e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg03268063	chr7:1337281	NA	-0.5	-4.41	-0.34	1.99e-5	Neuroticism;
PAAD	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.49	-4.61	-0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.3	0.6	1.48e-16	Rheumatoid arthritis;
PAAD	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.61	-5.34	-0.4	3.28e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg00262122	chr8:11665843	FDFT1	-0.64	-5.46	-0.4	1.9e-7	Neuroticism;
PAAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.83e-10	Glomerular filtration rate;
PAAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg21929781	chr1:2537748	MMEL1	0.54	5.7	0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.57	5.96	0.44	1.72e-8	Bladder cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24539459	chr1:146658275	FMO5	0.61	6.51	0.47	1.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.81	0.48	2.09e-10	IgG glycosylation;
PAAD	cis	rs7763441	0.836	rs9378332	chr6:2446420	A/T	cg18740289	chr6:2437142	NA	-0.53	-4.93	-0.37	2.16e-6	Monobrow;
PAAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg15956490	chr3:53032818	SFMBT1	0.81	4.81	0.36	3.63e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11807834	0.522	rs7529009	chr1:230232080	C/T	cg00566187	chr1:230250356	GALNT2	0.61	6.44	0.46	1.51e-9	Schizophrenia;
PAAD	cis	rs6987853	0.583	rs2974311	chr8:42455166	G/A	cg09913449	chr8:42400586	C8orf40	0.52	5.81	0.43	3.48e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12667521	chr19:29218732	NA	0.74	7.17	0.5	3.06e-11	Methadone dose in opioid dependence;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.44	5.64	0.42	8.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62264129	0.500	rs62278843	chr3:112041382	T/C	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.3	-0.33	3.04e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs8053891	0.756	rs9925462	chr16:72000195	C/G	cg16558253	chr16:72132732	DHX38	-0.56	-5.1	-0.38	1e-6	Coronary artery disease;
PAAD	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg00629941	chr15:75287862	SCAMP5	-0.56	-4.29	-0.33	3.22e-5	Blood trace element (Zn levels);
PAAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.84e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg27494647	chr7:150038898	RARRES2	0.45	4.91	0.37	2.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg02841227	chr6:26021843	HIST1H4A	0.45	4.26	0.33	3.6e-5	Urate levels;
PAAD	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.52	7.32	0.51	1.35e-11	Diastolic blood pressure;
PAAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	11.08	0.67	2.81e-21	Menopause (age at onset);
PAAD	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.62	-6.87	-0.49	1.55e-10	Vitamin D levels;
PAAD	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	12.2	0.7	2.63e-24	Primary sclerosing cholangitis;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg00106254	chr7:1943704	MAD1L1	0.56	5.14	0.39	8.17e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.29	-4.26	-0.33	3.62e-5	Urate levels in overweight individuals;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg17178900	chr1:205818956	PM20D1	0.45	4.37	0.33	2.3e-5	Parkinson's disease;
PAAD	cis	rs4740619	0.836	rs13292699	chr9:15910044	A/C	cg14451791	chr9:16040625	NA	-0.39	-4.41	-0.34	1.94e-5	Body mass index;
PAAD	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg04520793	chr17:42248056	ASB16	0.44	5.07	0.38	1.16e-6	Bone mineral density (hip);Bone mineral density (spine);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15687622	chr5:180229164	MGAT1	-0.65	-7.72	-0.53	1.44e-12	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05378295	chr18:19284987	ABHD3	0.66	6.41	0.46	1.74e-9	Obesity-related traits;
PAAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.44	-4.47	-0.34	1.49e-5	Height;
PAAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02743256	chr7:2109353	MAD1L1	-0.71	-6.57	-0.47	7.56e-10	Neuroticism;
PAAD	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.77	-5.46	-0.4	1.89e-7	Plateletcrit;
PAAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg22338127	chr1:209979572	IRF6	0.54	4.36	0.33	2.35e-5	Coronary artery disease;
PAAD	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.6	6.08	0.44	9.11e-9	Monocyte count;
PAAD	cis	rs12098973	0.528	rs920139	chr11:131793993	C/T	cg13055484	chr11:132662455	OPCML	0.5	4.34	0.33	2.57e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2275565	0.872	rs7527957	chr1:237022870	T/C	cg17297354	chr1:237056641	MTR	-0.52	-4.57	-0.35	1.01e-5	Homocysteine levels;
PAAD	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.49	-4.5	-0.34	1.34e-5	Tuberculosis;
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg14851468	chr5:179071604	C5orf60	0.48	5.07	0.38	1.15e-6	Lung cancer;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14893161	chr1:205819251	PM20D1	0.87	9.85	0.62	5.36e-18	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25215049	chr4:721972	PCGF3	-0.64	-6.76	-0.48	2.79e-10	Obesity-related traits;
PAAD	cis	rs9595066	0.627	rs4394973	chr13:44753309	G/A	cg04068111	chr13:44716778	NA	0.4	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs722599	0.501	rs2286914	chr14:75387012	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.63	-6.1	-0.44	8.24e-9	IgG glycosylation;
PAAD	cis	rs11235843	0.790	rs11235898	chr11:73488027	A/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07362569	chr17:61921086	SMARCD2	0.63	8.0	0.54	2.88e-13	Prudent dietary pattern;
PAAD	cis	rs9487051	0.646	rs11153166	chr6:109622494	C/T	cg21918786	chr6:109611834	NA	0.5	5.53	0.41	1.36e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg15660573	chr17:549704	VPS53	-0.77	-7.57	-0.52	3.32e-12	Prostate cancer;
PAAD	cis	rs939317	0.678	rs843372	chr3:183996213	C/T	cg09405238	chr3:183994500	ECE2	0.52	4.8	0.36	3.76e-6	Menarche (age at onset);
PAAD	cis	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg03022575	chr3:42003672	ULK4	0.78	5.47	0.41	1.81e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6597981	0.592	rs28625355	chr11:736334	G/T	cg17739936	chr11:789930	CEND1	-0.53	-5.13	-0.38	8.87e-7	Breast cancer;
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg05554000	chr7:158905015	VIPR2	0.5	4.28	0.33	3.27e-5	Facial morphology (factor 20);
PAAD	cis	rs7081476	0.737	rs7918793	chr10:27497191	C/T	cg20349793	chr10:26911186	NA	0.84	4.65	0.35	7.24e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05379784	chr14:74111382	DNAL1	0.64	6.98	0.49	8.47e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.64	7.36	0.51	1.09e-11	Carotid intima media thickness;
PAAD	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg14146966	chr2:61757674	XPO1	-0.38	-4.71	-0.36	5.43e-6	Tuberculosis;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2882667	0.690	rs167009	chr5:138200457	G/C	cg09476006	chr5:138032270	NA	-0.43	-5.39	-0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.86	9.24	0.6	2.06e-16	Cognitive function;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.88	-13.13	-0.73	8.33e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10450586	0.863	rs7123838	chr11:27303826	C/T	cg10370305	chr11:27303972	NA	0.38	4.51	0.34	1.31e-5	Total body bone mineral density;
PAAD	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.47	0.41	1.79e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00616525	chr17:26646045	TMEM97	-0.79	-7.13	-0.5	3.7e-11	Neuroticism;
PAAD	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg12437481	chr16:420112	MRPL28	-0.75	-6.95	-0.49	9.83e-11	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg27411982	chr8:10470053	RP1L1	0.42	4.55	0.35	1.08e-5	Neuroticism;
PAAD	cis	rs1113500	0.541	rs11185240	chr1:108582810	A/G	cg06207961	chr1:108661230	NA	0.48	5.09	0.38	1.07e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.71	7.62	0.53	2.47e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.56	5.08	0.38	1.11e-6	Corneal astigmatism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11912272	chr2:201204807	SPATS2L	-0.55	-6.29	-0.45	3.2e-9	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22910715	chr19:1491229	REEP6;PCSK4	0.64	6.31	0.46	2.9e-9	Obesity-related traits;
PAAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs3206736	0.548	rs73110557	chr7:35068057	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.49	-4.63	-0.35	7.71e-6	Diastolic blood pressure;
PAAD	cis	rs80346118	0.673	rs2869675	chr20:47420680	C/T	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.6	-4.42	-0.34	1.91e-5	Diastolic blood pressure;
PAAD	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-4.71	-0.36	5.54e-6	Menarche (age at onset);
PAAD	cis	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs1075265	0.783	rs805439	chr2:54056574	C/T	cg04546899	chr2:54196757	PSME4	0.31	4.55	0.35	1.11e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg14926445	chr8:58193284	C8orf71	-0.67	-4.82	-0.36	3.52e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4605213	1.000	rs4605213	chr17:49244747	C/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.5	5.15	0.39	7.91e-7	Height;
PAAD	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.78	-7.41	-0.52	8.24e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7582720	1.000	rs72932725	chr2:203649341	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.47	0.52	5.81e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.87	5.19	0.39	6.59e-7	Lifespan;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg00280220	chr17:61926910	NA	0.45	4.68	0.35	6.38e-6	Prudent dietary pattern;
PAAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg01075559	chr1:2537774	MMEL1	-0.49	-5.2	-0.39	6.37e-7	Ulcerative colitis;
PAAD	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg08514558	chr10:81106712	PPIF	0.48	5.9	0.43	2.32e-8	Height;
PAAD	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.58	-5.65	-0.42	7.86e-8	Systolic blood pressure;
PAAD	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.71	7.29	0.51	1.55e-11	Schizophrenia;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.76	-0.42	4.54e-8	Psoriasis;
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.29	0.64	3.56e-19	Platelet count;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.82e-9	Height;
PAAD	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg10935138	chr17:73851978	WBP2	0.81	7.13	0.5	3.8e-11	Psoriasis;
PAAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.66	0.35	6.97e-6	Bone mineral density;
PAAD	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21028142	chr17:79581711	NPLOC4	0.49	5.85	0.43	2.93e-8	Eye color traits;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.57e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg07810366	chr2:100720526	AFF3	-0.37	-4.57	-0.35	9.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.62	8.06	0.55	2.14e-13	Multiple sclerosis;
PAAD	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.57	5.0	0.38	1.54e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.56	-7.1	-0.5	4.43e-11	Educational attainment;
PAAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.55	-6.17	-0.45	5.9e-9	Type 2 diabetes;
PAAD	cis	rs59104589	0.583	rs73018185	chr2:242241706	C/T	cg04488487	chr2:242709673	NA	0.57	4.31	0.33	2.9e-5	Fibrinogen levels;
PAAD	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.78	9.38	0.61	8.79e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4417704	0.551	rs6735127	chr2:241885932	G/T	cg26818257	chr2:241905806	NA	0.51	5.42	0.4	2.27e-7	Joint mobility (Beighton score);
PAAD	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.56	5.3	0.4	3.98e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg15691649	chr6:25882328	NA	-0.49	-4.5	-0.34	1.36e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13784866	chr9:139269562	CARD9	-0.57	-6.3	-0.46	3.12e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.65	-0.47	4.95e-10	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10706266	chr8:66546233	ARMC1	0.6	6.42	0.46	1.63e-9	Monocyte percentage of white cells;
PAAD	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-4.54	-0.35	1.14e-5	Neuroticism;
PAAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.8	8.54	0.57	1.32e-14	Calcium levels;
PAAD	cis	rs66530629	0.917	rs9259	chr1:25168124	C/G	cg22509179	chr1:25234806	RUNX3	-0.51	-4.82	-0.36	3.4e-6	Plateletcrit;
PAAD	cis	rs7567389	0.600	rs11691088	chr2:128131853	A/G	cg09760422	chr2:128146352	NA	0.4	6.04	0.44	1.15e-8	Self-rated health;
PAAD	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.67	0.69	7.12e-23	Platelet count;
PAAD	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg08975724	chr8:8085496	FLJ10661	0.46	4.7	0.36	5.87e-6	Joint mobility (Beighton score);
PAAD	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg12615879	chr12:58013172	SLC26A10	0.42	4.87	0.37	2.77e-6	Multiple sclerosis;
PAAD	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs6137287	0.855	rs6137285	chr20:21179248	T/A	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.42	0.34	1.84e-5	Platelet count;
PAAD	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-6.17	-0.45	5.85e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1372356	0.780	rs11159838	chr14:88545833	G/T	cg18078958	chr14:88630771	NA	0.49	6.19	0.45	5.23e-9	Food antigen IgG levels;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg15181151	chr6:150070149	PCMT1	0.6	6.53	0.47	9.18e-10	Lung cancer;
PAAD	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg27417294	chr10:81904244	PLAC9	0.56	4.28	0.33	3.31e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.59	6.03	0.44	1.2e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg01426195	chr3:39028469	NA	-0.68	-6.92	-0.49	1.16e-10	Handedness;
PAAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.08	-0.44	9.46e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg09998033	chr7:158218633	PTPRN2	-0.74	-7.88	-0.54	5.9e-13	Obesity-related traits;
PAAD	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.56	-0.35	1.05e-5	Mood instability;
PAAD	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg04717802	chr22:42394638	WBP2NL	0.48	4.6	0.35	8.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs151997	1.000	rs42736	chr5:50244838	G/C	cg06027927	chr5:50259733	NA	0.7	7.0	0.49	7.81e-11	Callous-unemotional behaviour;
PAAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.12	0.38	9.02e-7	Multiple sclerosis;
PAAD	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-7.47	-0.52	5.78e-12	Coronary artery disease;
PAAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg10356904	chr22:49881777	NA	-0.5	-5.46	-0.4	1.91e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.66	0.42	7.16e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs758324	0.626	rs676944	chr5:131288468	A/G	cg06307176	chr5:131281290	NA	0.52	4.36	0.33	2.39e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.18	-0.45	5.5e-9	Adiposity;
PAAD	cis	rs11811982	0.793	rs116588679	chr1:227535745	C/T	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14169450	chr9:139327907	INPP5E	0.56	5.8	0.43	3.81e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	7.29	0.51	1.54e-11	Renal function-related traits (BUN);
PAAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.56	-6.19	-0.45	5.25e-9	Cognitive function;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.82	-0.36	3.49e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg03714773	chr7:91764589	CYP51A1	0.33	4.54	0.35	1.16e-5	Breast cancer;
PAAD	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg01426195	chr3:39028469	NA	-0.62	-6.15	-0.45	6.56e-9	Handedness;
PAAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg17739936	chr11:789930	CEND1	0.56	5.51	0.41	1.49e-7	Breast cancer;
PAAD	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.49	-6.04	-0.44	1.16e-8	Pelvic organ prolapse;
PAAD	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg04896959	chr15:78267971	NA	0.63	6.21	0.45	4.89e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg00179576	chr16:74483694	GLG1	-0.42	-4.6	-0.35	8.76e-6	Testicular germ cell tumor;
PAAD	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg21823605	chr1:152486609	CRCT1	0.49	6.11	0.44	7.91e-9	Hair morphology;
PAAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg12215294	chr3:40350768	EIF1B	-0.49	-4.88	-0.37	2.66e-6	Renal cell carcinoma;
PAAD	cis	rs7714584	1.000	rs7714415	chr5:150270292	A/G	cg22134413	chr5:150180641	NA	0.69	5.02	0.38	1.42e-6	Crohn's disease;
PAAD	cis	rs939584	1.000	rs7567368	chr2:645082	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg20742385	chr13:113633654	MCF2L	-0.46	-4.66	-0.35	6.74e-6	Systolic blood pressure;
PAAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg25452165	chr22:42524984	CYP2D6	0.6	5.85	0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.34e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7577696	0.853	rs212701	chr2:32444054	T/C	cg02381751	chr2:32503542	YIPF4	0.44	4.69	0.36	6.1e-6	Inflammatory biomarkers;
PAAD	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.62	-6.13	-0.45	7.24e-9	Systemic sclerosis;
PAAD	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.72	-4.66	-0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9816226	0.591	rs77805826	chr3:185798025	C/T	cg00760338	chr3:185826511	ETV5	-0.73	-5.64	-0.42	8.16e-8	Obesity;Body mass index;
PAAD	cis	rs1035491	0.715	rs876355	chr5:63919625	G/T	cg01791865	chr5:63954708	NA	-0.51	-5.43	-0.4	2.15e-7	Body mass index;
PAAD	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.57	5.49	0.41	1.62e-7	Hemoglobin concentration;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-1.16	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.36	-0.33	2.43e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.69	-0.42	6.2e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg07148914	chr20:33460835	GGT7	0.51	4.85	0.37	3.01e-6	Coronary artery disease;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.49	4.64	0.35	7.41e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.61	-8.78	-0.58	3.23e-15	Huntington's disease progression;
PAAD	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.85	-9.98	-0.63	2.32e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.44	-4.41	-0.34	1.91e-5	Menarche (age at onset);
PAAD	cis	rs5751901	0.614	rs6519520	chr22:24991895	A/G	cg08808123	chr22:24999002	GGT1	-0.47	-4.86	-0.37	2.86e-6	Protein quantitative trait loci;
PAAD	cis	rs11696501	0.688	rs6104293	chr20:44326298	T/C	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.68	-6.93	-0.49	1.14e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4757319	0.515	rs12809040	chr11:15431903	G/A	cg03245590	chr11:15329459	NA	0.43	5.19	0.39	6.66e-7	Breast cancer;
PAAD	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.69	-4.79	-0.36	4.01e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs329674	0.597	rs329665	chr11:133757175	C/T	cg06766960	chr11:133703094	NA	-0.71	-4.5	-0.34	1.34e-5	Bipolar disorder;
PAAD	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg05717871	chr11:638507	DRD4	-0.6	-5.4	-0.4	2.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs2211560	0.789	rs1877734	chr1:61282089	C/T	cg00575674	chr1:61314297	NA	-0.48	-4.25	-0.33	3.71e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg17541715	chr7:1216824	NA	-0.46	-5.14	-0.38	8.5e-7	Longevity;Endometriosis;
PAAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg12927641	chr6:109611667	NA	-0.43	-4.59	-0.35	9.08e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4750440	0.702	rs33945078	chr10:14022425	G/A	cg27542038	chr10:14027202	FRMD4A	-0.44	-4.51	-0.34	1.29e-5	Adiponectin levels;
PAAD	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.08	0.44	9.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.57	-6.71	-0.48	3.53e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.42	-0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs9283706	0.655	rs4016246	chr5:66310192	A/G	cg11590213	chr5:66331682	MAST4	0.51	4.31	0.33	2.96e-5	Coronary artery disease;
PAAD	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.78	-0.36	4.11e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.56	5.14	0.39	8.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.48	4.48	0.34	1.43e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg20731937	chr12:48336164	NA	0.52	4.41	0.34	1.98e-5	Longevity (90 years and older);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07920855	chr1:185286635	IVNS1ABP	-0.61	-7.56	-0.52	3.6e-12	Body fat percentage;
PAAD	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.72	8.95	0.59	1.15e-15	Dupuytren's disease;
PAAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs7765175	0.698	rs2029555	chr6:113671846	C/T	cg19037598	chr6:113666021	NA	-0.42	-4.58	-0.35	9.62e-6	Coronary artery calcification;
PAAD	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg12573674	chr2:1569213	NA	-0.66	-5.26	-0.39	4.84e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3126085	0.935	rs12407156	chr1:152295942	A/G	cg26876637	chr1:152193138	HRNR	-0.8	-5.43	-0.4	2.19e-7	Atopic dermatitis;
PAAD	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg01370759	chr7:2701419	TTYH3	0.64	4.42	0.34	1.85e-5	Neuroticism;
PAAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg10547527	chr2:198650123	BOLL	0.76	5.45	0.4	1.98e-7	Ulcerative colitis;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.44	0.46	1.49e-9	Vitiligo;
PAAD	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.68	-7.21	-0.5	2.5e-11	Height;
PAAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-5.06	-0.38	1.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.64	6.07	0.44	9.72e-9	Hip circumference;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03896792	chr12:96794507	CDK17	-0.7	-7.48	-0.52	5.59e-12	Smoking initiation;
PAAD	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg00383909	chr3:49044727	WDR6	0.82	5.4	0.4	2.53e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-5.0	-0.38	1.58e-6	Mean platelet volume;
PAAD	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.29	4.27	0.33	3.4e-5	Alopecia areata;
PAAD	cis	rs12136530	0.651	rs12140654	chr1:19716801	C/T	cg25104613	chr1:20649108	VWA5B1	-0.37	-4.28	-0.33	3.33e-5	Lead levels in blood;
PAAD	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg10828910	chr2:63850056	LOC388955	0.49	4.31	0.33	2.95e-5	Childhood ear infection;
PAAD	cis	rs904092	0.720	rs1230028	chr4:100182886	C/G	cg12011299	chr4:100065546	ADH4	0.58	5.43	0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs375066	0.935	rs421512	chr19:44415580	A/T	cg11993925	chr19:44307056	LYPD5	0.54	6.86	0.49	1.59e-10	Breast cancer;
PAAD	cis	rs2072732	0.706	rs12564456	chr1:2936386	C/G	cg15211996	chr1:2936768	ACTRT2	0.48	4.83	0.36	3.32e-6	Plateletcrit;
PAAD	cis	rs9472414	0.680	rs34577161	chr6:44696401	A/G	cg20913747	chr6:44695427	NA	0.54	5.01	0.38	1.5e-6	Height;
PAAD	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.37	-0.56	3.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs593531	0.614	rs623065	chr11:74071210	A/G	cg15670924	chr11:73669256	DNAJB13	-0.43	-4.46	-0.34	1.56e-5	Neuroticism;
PAAD	cis	rs4356203	0.905	rs545773	chr11:17213636	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12612619	0.732	rs7560144	chr2:27280460	A/G	cg00617064	chr2:27272375	NA	-0.56	-5.99	-0.44	1.48e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.58	5.5	0.41	1.56e-7	HDL cholesterol;
PAAD	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-5.27	-0.39	4.59e-7	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.84	10.38	0.64	2.04e-19	Menopause (age at onset);
PAAD	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.66	-0.53	2.05e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2279817	0.820	rs12754031	chr1:18006619	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.6	-5.15	-0.39	8.11e-7	Neuroticism;
PAAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2651899	0.966	rs2742663	chr1:3084905	T/C	cg22396632	chr1:3079212	PRDM16	-0.58	-6.38	-0.46	2.04e-9	Migraine;
PAAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg05313129	chr8:58192883	C8orf71	-0.65	-5.17	-0.39	7.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08115069	chr19:55866329	COX6B2;FAM71E2	0.61	6.77	0.48	2.69e-10	Myopia (pathological);
PAAD	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg15549821	chr19:49342101	PLEKHA4	-1.25	-9.84	-0.62	5.6e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.59	0.47	6.83e-10	Coffee consumption (cups per day);
PAAD	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg01236616	chr12:121019343	POP5	0.46	4.28	0.33	3.27e-5	High light scatter reticulocyte count;
PAAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg15847926	chr7:2749597	AMZ1	-0.42	-5.01	-0.38	1.48e-6	Height;
PAAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.46e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17209837	1.000	rs4148807	chr7:87105812	G/A	cg00919237	chr7:87102261	ABCB4	-0.78	-5.23	-0.39	5.52e-7	Gallbladder cancer;
PAAD	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.47	0.57	1.91e-14	Coffee consumption (cups per day);
PAAD	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg23032965	chr3:12705835	RAF1	0.62	4.53	0.35	1.17e-5	Cholesterol, total;
PAAD	cis	rs245880	0.666	rs245894	chr7:29192686	G/C	cg17163760	chr7:29186267	CPVL	-0.52	-6.18	-0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.26	7.91	0.54	4.87e-13	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12955076	chr3:186389477	HRG	-0.65	-6.62	-0.47	5.83e-10	Obesity-related traits;
PAAD	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.9	-9.78	-0.62	7.98e-18	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg19090574	chr1:205240910	TMCC2	-0.41	-4.28	-0.33	3.3e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.43	4.26	0.33	3.53e-5	Longevity;Endometriosis;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4443100	0.916	rs875602	chr22:23395684	C/T	cg14186256	chr22:23484241	RTDR1	0.51	4.5	0.34	1.32e-5	Serum parathyroid hormone levels;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg23119463	chr10:134592391	INPP5A	-0.51	-4.69	-0.36	6.07e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg12559170	chr11:5275217	HBG2	0.46	4.52	0.34	1.23e-5	Hemoglobin levels;
PAAD	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg04315214	chr1:2043799	PRKCZ	0.6	7.81	0.54	8.67e-13	Height;
PAAD	cis	rs4819852	1.000	rs4819852	chr22:19988167	G/A	cg07821417	chr22:19972146	ARVCF	0.68	6.76	0.48	2.73e-10	Pulse pressure;
PAAD	cis	rs6132905	0.590	rs79409802	chr20:2606485	C/T	cg24848351	chr20:2622020	TMC2	-0.7	-4.98	-0.37	1.72e-6	Mumps;
PAAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.59	0.35	9.18e-6	Melanoma;
PAAD	cis	rs12304921	1.000	rs12304921	chr12:51357542	C/T	cg04427360	chr12:51347099	HIGD1C	0.63	4.89	0.37	2.56e-6	Type 2 diabetes;
PAAD	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.64	-5.92	-0.43	2.1e-8	Diisocyanate-induced asthma;
PAAD	cis	rs3106136	0.678	rs1529339	chr4:95297283	T/A	cg11021082	chr4:95130006	SMARCAD1	0.52	4.9	0.37	2.42e-6	Capecitabine sensitivity;
PAAD	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15707544	chr1:10093239	UBE4B	-0.61	-6.33	-0.46	2.58e-9	Smoking initiation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02326328	chr3:183967536	ALG3;ECE2	-0.76	-6.69	-0.48	4.02e-10	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12484590	chr1:156475177	NA	0.75	9.19	0.6	2.75e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg23442198	chr4:187126114	CYP4V2	0.63	4.48	0.34	1.43e-5	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03697316	chr22:21336741	LZTR1	0.63	6.66	0.48	4.66e-10	Myopia (pathological);
PAAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs13144136	0.687	rs11734917	chr4:10660359	C/T	cg10242279	chr4:10666415	CLNK	-0.49	-6.25	-0.45	3.88e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg08601574	chr20:25228251	PYGB	0.54	5.51	0.41	1.47e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg10253484	chr15:75165896	SCAMP2	0.5	4.66	0.35	6.73e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14286274	chr1:211555998	C1orf97	0.57	6.67	0.48	4.39e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.62	-5.0	-0.38	1.54e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9463078	0.546	rs6458418	chr6:45014997	G/A	cg25276700	chr6:44698697	NA	0.46	5.32	0.4	3.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs10261878	0.826	rs57665417	chr7:26009645	G/C	cg01322214	chr7:25219198	C7orf31	1.03	4.29	0.33	3.2e-5	Body mass index;
PAAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs943466	0.911	rs73746509	chr6:33729825	C/T	cg04704449	chr6:33738291	NA	-0.47	-4.67	-0.35	6.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.96	-12.4	-0.71	7.95e-25	Refractive error;
PAAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.27e-7	Electroencephalogram traits;
PAAD	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.75	8.94	0.59	1.22e-15	Bladder cancer;
PAAD	cis	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg18809830	chr7:99032528	PTCD1	-1.22	-5.29	-0.39	4.25e-7	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg07153921	chr17:41440717	NA	-0.43	-4.55	-0.35	1.09e-5	Menopause (age at onset);
PAAD	cis	rs28655083	0.636	rs61117898	chr16:77050736	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-4.59	-0.35	9.11e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.03e-5	Systolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14764050	chr21:46221651	UBE2G2	0.6	6.59	0.47	6.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2555155	0.806	rs10839574	chr11:6551470	C/T	cg11185456	chr11:6592066	DNHD1	-0.44	-4.63	-0.35	7.7e-6	DNA methylation (variation);
PAAD	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg08853572	chr16:1843915	IGFALS	-0.26	-4.28	-0.33	3.32e-5	Blood metabolite levels;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg11416102	chr8:651193	ERICH1	-0.72	-4.46	-0.34	1.56e-5	IgG glycosylation;
PAAD	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.76	-6.69	-0.48	4.05e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs496547	0.719	rs598373	chr11:118664377	T/C	cg19308663	chr11:118741387	NA	-0.46	-4.3	-0.33	3.08e-5	Hip minimal joint space width;
PAAD	cis	rs9473924	0.913	rs2744475	chr6:50784880	C/G	cg24161652	chr6:50813859	TFAP2B	0.3	4.36	0.33	2.34e-5	Body mass index;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19732469	chr14:96968481	PAPOLA	0.69	7.83	0.54	7.81e-13	Myopia (pathological);
PAAD	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.65	-0.35	7.23e-6	Testicular germ cell tumor;
PAAD	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg23004174	chr6:74404879	CD109	0.51	5.31	0.4	3.89e-7	Blood protein levels;Calcium levels;
PAAD	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg17470449	chr10:769945	NA	0.49	4.91	0.37	2.3e-6	Uric acid levels;
PAAD	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	10.55	0.65	7.3e-20	Lymphocyte percentage of white cells;
PAAD	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.49e-10	Blood pressure (smoking interaction);
PAAD	cis	rs13024765	0.573	rs34870637	chr2:225172260	T/C	cg22455342	chr2:225449267	CUL3	0.47	4.36	0.33	2.39e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg21823605	chr1:152486609	CRCT1	0.5	6.41	0.46	1.74e-9	Hair morphology;
PAAD	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12432903	chr7:1882776	MAD1L1	0.63	4.32	0.33	2.82e-5	Bipolar disorder;
PAAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05410609	chr14:100070556	CCDC85C	-0.64	-7.5	-0.52	4.92e-12	Body fat percentage;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg11416102	chr8:651193	ERICH1	0.94	5.9	0.43	2.27e-8	IgG glycosylation;
PAAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.62	-5.9	-0.43	2.3e-8	Monocyte count;
PAAD	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg20356878	chr3:121714668	ILDR1	0.49	4.68	0.35	6.29e-6	Cognitive performance;
PAAD	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-5.12	-0.38	9.31e-7	Schizophrenia;
PAAD	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15128208	chr22:42549153	NA	-0.47	-4.62	-0.35	8.13e-6	Cognitive function;
PAAD	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg00601450	chr5:74908170	NA	0.49	5.07	0.38	1.15e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs9463078	0.507	rs1023089	chr6:45012346	G/A	cg25276700	chr6:44698697	NA	0.46	5.32	0.4	3.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg03098721	chr1:84464084	TTLL7	0.48	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.85	-9.86	-0.62	4.91e-18	Iron status biomarkers;
PAAD	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg06217245	chr20:33103252	DYNLRB1	0.39	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.47	4.54	0.35	1.13e-5	Electroencephalogram traits;
PAAD	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.66	-6.97	-0.49	9.17e-11	Schizophrenia;
PAAD	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.45	4.58	0.35	9.43e-6	Menopause (age at onset);
PAAD	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg08885800	chr1:201084119	NA	0.56	4.83	0.37	3.24e-6	Permanent tooth development;
PAAD	cis	rs1879734	1.000	rs2141082	chr1:54138698	C/T	cg14659662	chr1:54151053	GLIS1	-0.37	-5.51	-0.41	1.49e-7	Mitral valve prolapse;
PAAD	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.56e-10	Obesity-related traits;
PAAD	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-4.25	-0.33	3.73e-5	Educational attainment;
PAAD	cis	rs9463078	0.565	rs6922660	chr6:45059674	C/A	cg25276700	chr6:44698697	NA	0.46	5.3	0.39	4.04e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	trans	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg03021296	chr7:158060614	PTPRN2	-0.58	-6.31	-0.46	2.96e-9	Breast cancer;
PAAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.65	-7.13	-0.5	3.87e-11	Childhood ear infection;
PAAD	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg20003494	chr4:90757398	SNCA	-0.4	-4.46	-0.34	1.57e-5	Dementia with Lewy bodies;
PAAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.63	-6.76	-0.48	2.77e-10	Facial morphology (factor 20);
PAAD	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg09659197	chr4:152720779	NA	-0.37	-5.21	-0.39	6.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg21859623	chr20:33103246	DYNLRB1	0.44	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs300774	1.000	rs300793	chr2:108411	A/T	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-6.82	-0.48	2.01e-10	Body mass index;
PAAD	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg03098721	chr1:84464084	TTLL7	0.46	4.4	0.34	2.04e-5	Obesity-related traits;
PAAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg10137597	chr8:22132714	PIWIL2	0.5	5.92	0.43	2.06e-8	Hypertriglyceridemia;
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.6	-0.47	6.54e-10	Lung cancer;
PAAD	cis	rs72843506	0.586	rs74811834	chr17:19885584	A/G	cg05625806	chr17:19284432	MAPK7	0.67	4.36	0.33	2.39e-5	Schizophrenia;
PAAD	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.68	0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.42	4.3	0.33	3.07e-5	Coronary artery disease;
PAAD	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	4.32	0.33	2.85e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-4.92	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.63	-0.35	7.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs909341	0.909	rs2253823	chr20:62372956	C/T	cg03999872	chr20:62272968	STMN3	-0.68	-5.97	-0.44	1.62e-8	Atopic dermatitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06528214	chr1:178995107	FAM20B	-0.74	-6.34	-0.46	2.52e-9	Neuroticism;
PAAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg18357526	chr6:26021779	HIST1H4A	0.64	6.1	0.44	8.46e-9	Blood metabolite levels;
PAAD	cis	rs507080	0.922	rs642662	chr11:118567020	A/G	cg08498647	chr11:118550644	TREH	-0.38	-4.31	-0.33	2.96e-5	Serum metabolite levels;
PAAD	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.58	7.03	0.5	6.56e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs16975963	0.843	rs11672163	chr19:38373856	G/A	cg14218481	chr19:38281219	NA	0.43	4.45	0.34	1.63e-5	Longevity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24716125	chr3:46933808	PTH1R	-0.71	-7.83	-0.54	7.62e-13	Smoking initiation;
PAAD	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.24	-0.39	5.29e-7	Blood metabolite levels;
PAAD	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg03367679	chr17:38183553	MED24;SNORD124	-0.33	-4.33	-0.33	2.69e-5	White blood cell count;
PAAD	cis	rs12776158	0.901	rs59262400	chr10:71216310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.51	-5.0	-0.38	1.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21229044	chr9:71669714	FXN	-0.64	-6.7	-0.48	3.89e-10	Obesity-related traits;
PAAD	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.28	0.6	1.65e-16	Schizophrenia;
PAAD	cis	rs11009175	0.556	rs7923985	chr10:33304618	G/T	cg00146027	chr10:33299147	NA	-0.38	-4.47	-0.34	1.53e-5	Depression (quantitative trait);
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.66	-6.62	-0.47	5.82e-10	Tuberculosis;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3737883	1.000	rs7538696	chr1:203034309	G/A	cg03900565	chr1:203031815	PPFIA4	0.34	5.59	0.41	1.04e-7	Early onset atrial fibrillation;
PAAD	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg21775007	chr8:11205619	TDH	-0.46	-4.32	-0.33	2.81e-5	Neuroticism;
PAAD	cis	rs4740619	0.661	rs10756721	chr9:15932465	C/A	cg14451791	chr9:16040625	NA	-0.4	-4.66	-0.35	6.75e-6	Body mass index;
PAAD	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg27094323	chr7:1216898	NA	-0.56	-6.96	-0.49	9.39e-11	Longevity;Endometriosis;
PAAD	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg24220031	chr2:73402428	NA	-0.42	-6.28	-0.45	3.32e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.63	-4.51	-0.34	1.28e-5	Depression;
PAAD	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.99	8.31	0.56	5.02e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.92	7.06	0.5	5.59e-11	Alzheimer's disease;
PAAD	cis	rs13034020	0.522	rs4564760	chr2:61248575	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.6	4.52	0.34	1.23e-5	Hodgkin's lymphoma;
PAAD	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg18655438	chr5:1077845	SLC12A7	0.57	5.5	0.41	1.59e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs59104589	0.521	rs34506685	chr2:242439988	A/G	cg19488206	chr2:242435732	STK25	0.47	4.64	0.35	7.61e-6	Fibrinogen levels;
PAAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.85e-6	Personality dimensions;
PAAD	cis	rs829661	0.739	rs829563	chr2:30695497	T/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.6	0.35	8.76e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.52	-4.75	-0.36	4.73e-6	Asthma;
PAAD	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg08632701	chr21:37451849	NA	-0.62	-6.79	-0.48	2.43e-10	Mitral valve prolapse;
PAAD	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg18281939	chr5:77783895	LHFPL2	-0.52	-6.74	-0.48	3.08e-10	Triglycerides;
PAAD	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.52e-8	Mean corpuscular volume;
PAAD	cis	rs3779195	0.520	rs17169479	chr7:97868033	A/G	cg24562669	chr7:97807699	LMTK2	0.55	4.75	0.36	4.6e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg01503450	chr10:980765	NA	-0.57	-4.93	-0.37	2.11e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs72901758	0.810	rs72901751	chr17:76243732	T/G	cg26068271	chr17:76253126	NA	0.57	5.65	0.42	7.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.54	-4.52	-0.34	1.23e-5	Atopic dermatitis;
PAAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.74	-6.63	-0.47	5.5e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24997677	chr4:187524686	FAT1	-0.67	-6.76	-0.48	2.81e-10	Obesity-related traits;
PAAD	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs881827	1.000	rs2839337	chr21:47987167	C/T	cg11766577	chr21:47581405	C21orf56	0.4	4.43	0.34	1.81e-5	Lymphocyte counts;
PAAD	cis	rs4356203	0.905	rs635802	chr11:17204793	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg03732007	chr1:2071316	PRKCZ	-0.5	-5.24	-0.39	5.24e-7	Height;
PAAD	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.68	-7.59	-0.52	3.02e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9913156	0.517	rs11868227	chr17:4614539	G/A	cg00122941	chr17:4613640	ARRB2	0.66	7.03	0.5	6.45e-11	Lymphocyte counts;
PAAD	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg04920474	chr2:44395004	PPM1B	0.45	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-1.04	-7.13	-0.5	3.8e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.85	10.15	0.64	8.59e-19	Selective IgA deficiency;
PAAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs288342	0.902	rs1584733	chr2:183661578	T/A	cg02625481	chr2:183667124	NA	-0.43	-4.44	-0.34	1.71e-5	Recurrent major depressive disorder;
PAAD	trans	rs9982086	0.557	rs396969	chr21:27281177	A/G	cg04970570	chr5:87990145	NA	0.66	6.88	0.49	1.44e-10	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg05562828	chr17:3906858	NA	-0.56	-6.36	-0.46	2.2e-9	Type 2 diabetes;
PAAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.61	-8.78	-0.58	3.23e-15	Huntington's disease progression;
PAAD	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.76	8.68	0.58	5.57e-15	Eosinophil percentage of white cells;
PAAD	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs59888335	0.858	rs9842552	chr3:81029370	G/A	cg21735741	chr3:80819488	NA	0.52	4.55	0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.04	-16.86	-0.81	1.28e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.97	13.1	0.73	1e-26	Rheumatoid arthritis;
PAAD	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02228675	chr17:40259724	DHX58	-0.47	-5.77	-0.42	4.27e-8	Fibrinogen levels;
PAAD	cis	rs6132905	0.520	rs2422824	chr20:2647370	C/T	cg11105029	chr20:2362041	TGM6	0.35	4.32	0.33	2.82e-5	Mumps;
PAAD	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.69	6.84	0.48	1.85e-10	Uric acid levels;
PAAD	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.42	-4.67	-0.35	6.71e-6	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12751404	chr1:11866034	MTHFR;CLCN6	0.62	6.79	0.48	2.37e-10	Myopia (pathological);
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.67	0.62	1.58e-17	Platelet count;
PAAD	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.92	7.21	0.5	2.5e-11	Iron status biomarkers;
PAAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.71	-6.6	-0.47	6.4e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.86	-7.61	-0.53	2.72e-12	HIV-1 control;
PAAD	cis	rs58521262	0.556	rs390911	chr19:23124745	A/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-4.64	-0.35	7.59e-6	Parkinson's disease;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg03983715	chr16:68378420	PRMT7	-0.73	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg13271783	chr10:134563150	INPP5A	-0.51	-5.48	-0.41	1.73e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.15e-8	Colorectal cancer;
PAAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-5.51	-0.41	1.47e-7	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg02462569	chr6:150064036	NUP43	-0.48	-5.33	-0.4	3.44e-7	Lung cancer;
PAAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.86	7.65	0.53	2.08e-12	Recombination rate (females);
PAAD	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg09659197	chr4:152720779	NA	0.32	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg23346134	chr3:49453900	TCTA	0.4	4.27	0.33	3.4e-5	Menarche (age at onset);
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.67	0.48	4.41e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.72	6.88	0.49	1.49e-10	Schizophrenia;
PAAD	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.27	-0.33	3.47e-5	Tuberculosis;
PAAD	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg08999081	chr20:33150536	PIGU	0.51	5.6	0.41	9.67e-8	Height;
PAAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.65	8.29	0.56	5.59e-14	Multiple sclerosis;
PAAD	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.65	5.98	0.44	1.54e-8	Corneal astigmatism;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.51	7.94	0.54	4.06e-13	Mean corpuscular volume;
PAAD	cis	rs72827839	0.696	rs117974417	chr17:46156510	C/G	cg03474202	chr17:45855739	NA	0.48	4.39	0.34	2.07e-5	Ease of getting up in the morning;
PAAD	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.8	-6.33	-0.46	2.66e-9	Mean platelet volume;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.95	-9.09	-0.59	4.91e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.25	-0.39	5.06e-7	Reticulocyte count;
PAAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.29	-0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.48	4.94	0.37	2.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.53	0.41	1.35e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs251130	0.540	rs251128	chr5:110861199	G/A	cg11925263	chr5:110849104	STARD4	0.39	4.37	0.33	2.25e-5	Menarche (age at onset);
PAAD	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg10072921	chr12:121022843	NA	-0.42	-5.21	-0.39	6.17e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.4	-0.4	2.52e-7	Subjective well-being;
PAAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.32	4.35	0.33	2.48e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.56	5.29	0.39	4.23e-7	Type 2 diabetes;
PAAD	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs11668609	0.505	rs115627793	chr19:24062265	C/A	cg09235885	chr19:23456588	NA	0.63	4.35	0.33	2.45e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs2299587	0.932	rs1121879	chr8:17850265	G/A	cg08627089	chr8:17753878	FGL1	-0.45	-4.28	-0.33	3.27e-5	Economic and political preferences;
PAAD	cis	rs743757	1.000	rs2236975	chr3:50483437	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.65	4.37	0.33	2.25e-5	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09511724	chr1:10804939	CASZ1	0.55	6.5	0.47	1.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg12864912	chr4:6988209	TBC1D14	-0.4	-4.4	-0.34	2.07e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.89	10.22	0.64	5.5e-19	Sudden cardiac arrest;
PAAD	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.8	8.12	0.55	1.46e-13	Response to diuretic therapy;
PAAD	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg16417436	chr16:28758564	NA	-0.49	-4.86	-0.37	2.87e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-5.49	-0.41	1.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7792596	0.964	rs2374717	chr7:93992345	C/T	cg20814616	chr7:94014465	NA	-0.43	-4.45	-0.34	1.64e-5	Intelligence;
PAAD	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	5.28	0.39	4.36e-7	Axial length;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.03e-11	Lung cancer in ever smokers;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.08	0.55	1.82e-13	Lymphocyte counts;
PAAD	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg16898833	chr6:26189333	HIST1H4D	0.92	5.04	0.38	1.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.6	-6.82	-0.48	2.01e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.7	-8.28	-0.56	5.76e-14	Educational attainment;
PAAD	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.41e-10	Coronary artery disease;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg18279126	chr7:2041391	MAD1L1	0.6	5.78	0.42	4.07e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1891275	0.551	rs2000177	chr10:93412994	T/G	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs8081395	0.801	rs2645479	chr17:57920532	A/G	cg02344993	chr17:57696989	CLTC	0.44	4.29	0.33	3.21e-5	White blood cell count;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15998962	chr2:25565459	DNMT3A	-0.58	-6.77	-0.48	2.65e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7577696	0.925	rs212715	chr2:32460886	C/G	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.78e-6	Inflammatory biomarkers;
PAAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.89	0.43	2.38e-8	Prudent dietary pattern;
PAAD	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg01528321	chr10:82214614	TSPAN14	0.75	6.86	0.49	1.64e-10	Post bronchodilator FEV1;
PAAD	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.6	5.33	0.4	3.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04718055	chr1:78149336	ZZZ3	0.57	6.36	0.46	2.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7577696	0.962	rs4952248	chr2:32343669	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-4.72	-0.36	5.2e-6	Inflammatory biomarkers;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.78	-9.56	-0.61	2.99e-17	Vitiligo;
PAAD	cis	rs72827839	0.802	rs72825584	chr17:46293089	G/A	cg23391107	chr17:45924227	SP6	0.62	5.31	0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg23587288	chr2:27483067	SLC30A3	0.69	6.47	0.46	1.27e-9	Blood metabolite levels;
PAAD	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.9	7.19	0.5	2.75e-11	Chronic kidney disease;
PAAD	cis	rs7180079	1.000	rs7165405	chr15:64662900	C/T	cg18210365	chr15:65066710	RBPMS2	-0.64	-4.89	-0.37	2.54e-6	Monocyte count;
PAAD	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.8	6.62	0.47	5.95e-10	Pulmonary function decline;
PAAD	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.64	-5.44	-0.4	2.06e-7	Corneal structure;
PAAD	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg20607287	chr7:12443886	VWDE	-0.69	-5.46	-0.41	1.86e-7	Coronary artery disease;
PAAD	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg06728252	chr6:26598149	ABT1	-0.38	-4.5	-0.34	1.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg09327582	chr14:35236912	BAZ1A	0.49	4.34	0.33	2.54e-5	Psoriasis;
PAAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.54	-5.07	-0.38	1.14e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24107979	chr18:35147246	BRUNOL4	-0.55	-6.66	-0.48	4.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	1.09	13.98	0.75	4.55e-29	Breast cancer;
PAAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1419980	0.730	rs11054899	chr12:7774445	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.41	0.34	1.91e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg12143784	chr7:64541923	NA	0.37	4.69	0.36	5.97e-6	Aortic root size;
PAAD	cis	rs1865721	0.761	rs11660256	chr18:73219532	C/T	cg26385618	chr18:73139727	C18orf62	-0.45	-5.25	-0.39	4.98e-7	Intelligence;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.92	6.72	0.48	3.5e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939584	1.000	rs13393304	chr2:637830	A/G	cg03610516	chr2:642275	NA	0.6	5.41	0.4	2.44e-7	Body mass index;
PAAD	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-1.19	-6.68	-0.48	4.24e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.73	0.48	3.19e-10	Lung cancer in ever smokers;
PAAD	trans	rs12137025	1.000	rs1419310	chr1:223859188	A/G	cg18879828	chr11:46942432	NA	0.74	6.44	0.46	1.52e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.12e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.45	4.59	0.35	9.35e-6	Longevity;Endometriosis;
PAAD	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg16221875	chr6:21588597	NA	0.56	6.37	0.46	2.09e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg27094323	chr7:1216898	NA	-0.43	-5.04	-0.38	1.3e-6	Longevity;Endometriosis;
PAAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.68	0.35	6.31e-6	Breast cancer;
PAAD	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.47	4.42	0.34	1.84e-5	Optic cup area;
PAAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.87	10.56	0.65	7.01e-20	Monocyte percentage of white cells;
PAAD	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-4.58	-0.35	9.65e-6	Mean corpuscular volume;
PAAD	cis	rs16975963	0.644	rs73031322	chr19:38040879	C/A	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.8	-0.36	3.84e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg06375148	chr1:209958343	C1orf74	0.69	4.95	0.37	1.97e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg05650719	chr12:132293520	NA	0.48	5.13	0.38	8.7e-7	Migraine;
PAAD	cis	rs6700896	0.931	rs1938492	chr1:66117829	A/C	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.43	-0.34	1.76e-5	Height;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.83	8.98	0.59	9.94e-16	Total body bone mineral density;
PAAD	cis	rs1413885	0.538	rs1570869	chr1:65830905	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.42	4.42	0.34	1.84e-5	Anticoagulant levels;
PAAD	cis	rs6700896	0.500	rs7518632	chr1:66103350	C/A	cg04111102	chr1:66153794	NA	0.48	4.55	0.35	1.09e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.76	5.9	0.43	2.28e-8	Pulmonary function decline;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg05313129	chr8:58192883	C8orf71	-0.63	-5.6	-0.41	1e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg20007245	chr22:24372913	LOC391322	-0.7	-6.79	-0.48	2.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg21546286	chr11:48923668	NA	-0.59	-6.23	-0.45	4.39e-9	HDL cholesterol;
PAAD	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg11939631	chr5:178977406	RUFY1	0.58	4.51	0.34	1.27e-5	Lung cancer;
PAAD	cis	rs374532236	1	rs374532236	chr10:130837274	C/T	cg06344553	chr10:131684893	EBF3	0.45	4.4	0.34	2.06e-5	Hand grip strength;
PAAD	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-4.53	-0.34	1.21e-5	Primary biliary cholangitis;
PAAD	cis	rs11997175	0.713	rs4733454	chr8:33651253	C/A	ch.8.33884649F	chr8:33765107	NA	0.56	6.35	0.46	2.37e-9	Body mass index;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07930192	chr7:1003750	NA	-0.4	-5.05	-0.38	1.24e-6	Longevity;Endometriosis;
PAAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg10370574	chr19:1840461	REXO1	-0.5	-4.64	-0.35	7.32e-6	Bipolar disorder;
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.06	-0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs7122257	0.507	rs7103691	chr11:11150830	A/C	cg16931664	chr11:11169707	NA	-0.29	-4.27	-0.33	3.46e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs4750440	0.676	rs12779988	chr10:14020404	T/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.71	6.81	0.48	2.13e-10	Parkinson's disease;
PAAD	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg14146966	chr2:61757674	XPO1	0.41	5.06	0.38	1.21e-6	Tuberculosis;
PAAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.95	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.81	9.39	0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.23	-0.39	5.61e-7	Monocyte percentage of white cells;
PAAD	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs300774	0.925	rs300710	chr2:139574	C/T	cg21211680	chr2:198530	NA	0.65	6.0	0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg08975724	chr8:8085496	FLJ10661	0.48	4.57	0.35	1.01e-5	Mood instability;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg21565972	chr17:80109576	CCDC57	0.59	6.93	0.49	1.15e-10	Life satisfaction;
PAAD	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.94	11.06	0.67	3.19e-21	IgG glycosylation;
PAAD	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.56	-0.35	1.06e-5	IFN-related cytopenia;
PAAD	cis	rs9323205	0.798	rs4465517	chr14:51673715	C/A	cg23942311	chr14:51606299	NA	0.51	4.9	0.37	2.39e-6	Cancer;
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.73	6.96	0.49	9.57e-11	Asthma;
PAAD	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-6.14	-0.45	7e-9	Fibrinogen levels;
PAAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.52	-5.0	-0.38	1.58e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.49	-0.34	1.4e-5	Coronary artery disease;
PAAD	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.58	-5.36	-0.4	2.99e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs2415984	0.579	rs12147928	chr14:46972569	C/T	cg14871534	chr14:47121158	RPL10L	0.48	5.01	0.38	1.5e-6	Number of children ever born;
PAAD	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.02	0.63	1.88e-18	Cognitive test performance;
PAAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg21951975	chr1:209979733	IRF6	0.41	5.21	0.39	6e-7	Monobrow;
PAAD	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.59	5.76	0.42	4.43e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1198430	0.673	rs7511979	chr1:23747425	G/T	cg27447006	chr1:23763279	ASAP3	0.58	4.6	0.35	8.72e-6	Total cholesterol levels;
PAAD	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.53	-5.15	-0.39	8.02e-7	Body mass index;
PAAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.48	-4.82	-0.36	3.44e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg20197358	chr14:69619916	DCAF5	-0.97	-6.45	-0.46	1.42e-9	Psoriasis;
PAAD	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.54	5.1	0.38	1.02e-6	Educational attainment;
PAAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-1.57	-9.93	-0.63	3.26e-18	Depression;
PAAD	cis	rs9463078	0.817	rs3799978	chr6:44837532	A/G	cg25276700	chr6:44698697	NA	-0.48	-5.56	-0.41	1.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.65	-6.81	-0.48	2.12e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.68	6.13	0.45	7.23e-9	Platelet count;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7598759	0.679	rs6437019	chr2:232327707	T/C	cg19187155	chr2:232395269	NMUR1	0.53	5.81	0.43	3.59e-8	Noise-induced hearing loss;
PAAD	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg15654264	chr1:150340011	RPRD2	0.52	4.94	0.37	2e-6	Migraine;
PAAD	cis	rs10899021	0.790	rs12288525	chr11:74332589	T/A	cg25880958	chr11:74394337	NA	-0.71	-4.46	-0.34	1.58e-5	Response to metformin (IC50);
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg25037394	chr1:24152592	HMGCL	0.42	4.6	0.35	8.77e-6	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22246918	chr13:51094655	NA	-0.7	-7.13	-0.5	3.8e-11	Obesity-related traits;
PAAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg18833306	chr6:118973337	C6orf204	0.56	4.55	0.35	1.09e-5	Diastolic blood pressure;
PAAD	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg24296786	chr1:45957014	TESK2	-0.48	-4.35	-0.33	2.53e-5	Homocysteine levels;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg18402987	chr7:1209562	NA	0.99	5.26	0.39	4.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09590228	chr22:31608055	LIMK2	0.62	6.82	0.48	2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.62	4.83	0.36	3.35e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.63	6.38	0.46	2.03e-9	Testicular germ cell tumor;
PAAD	cis	rs73195822	0.667	rs55799214	chr12:111229700	G/T	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.3	-0.33	3e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	1.07	5.73	0.42	5.26e-8	Body mass index;
PAAD	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.17	-0.39	7.18e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.66	5.94	0.43	1.85e-8	Blood metabolite levels;
PAAD	cis	rs12257961	0.521	rs7899540	chr10:15382782	G/A	cg10616319	chr10:15468812	NA	0.46	4.43	0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.53	-0.41	1.38e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.33	-0.46	2.68e-9	Longevity;
PAAD	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00166722	chr3:10149974	C3orf24	0.79	5.88	0.43	2.48e-8	Alzheimer's disease;
PAAD	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.84	-9.61	-0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg00750074	chr16:89608354	SPG7	-0.5	-4.87	-0.37	2.81e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.16e-8	Total body bone mineral density;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg02071572	chr4:1403502	NA	0.44	5.33	0.4	3.51e-7	Obesity-related traits;
PAAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg03128945	chr5:622914	CEP72	-0.5	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg25233709	chr10:116636983	FAM160B1	0.42	5.34	0.4	3.34e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.62	5.54	0.41	1.31e-7	Coronary heart disease;
PAAD	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.84	9.73	0.62	1.05e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.55	-0.35	1.07e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.13	-0.45	7.35e-9	Lung cancer;
PAAD	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.5	-5.22	-0.39	5.68e-7	Testicular germ cell tumor;
PAAD	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19671926	chr4:122722719	EXOSC9	-0.53	-4.73	-0.36	5.08e-6	Type 2 diabetes;
PAAD	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg19567339	chr10:100142640	NA	0.42	4.6	0.35	9.01e-6	Metabolite levels;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg04775059	chr7:64541387	NA	0.57	5.91	0.43	2.16e-8	Calcium levels;
PAAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg20243544	chr17:37824526	PNMT	-0.49	-4.27	-0.33	3.43e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.46	-4.93	-0.37	2.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.51	-6.78	-0.48	2.5e-10	Longevity;
PAAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4343996	0.935	rs4722673	chr7:3357183	C/G	cg21248987	chr7:3385318	SDK1	-0.48	-5.27	-0.39	4.62e-7	Motion sickness;
PAAD	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.46e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg07395648	chr5:131743802	NA	-0.62	-6.4	-0.46	1.82e-9	Blood metabolite levels;
PAAD	cis	rs73019876	0.869	rs10410985	chr19:22147337	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	10.58	0.65	6.14e-20	Colorectal cancer;
PAAD	cis	rs17155006	0.783	rs410286	chr7:107749257	A/T	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg03289416	chr15:75166202	SCAMP2	0.52	5.32	0.4	3.57e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.72	-7.22	-0.51	2.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03605463	chr16:89740564	NA	-0.56	-5.41	-0.4	2.44e-7	Vitiligo;
PAAD	cis	rs7631605	0.905	rs6786584	chr3:37225728	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.33e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.41	5.07	0.38	1.16e-6	Pulmonary function;
PAAD	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg05528293	chr18:74961138	GALR1	0.61	5.02	0.38	1.4e-6	Obesity-related traits;
PAAD	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21659725	chr3:3221576	CRBN	0.96	13.21	0.73	5.06e-27	Intelligence (multi-trait analysis);
PAAD	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.45	0.34	1.67e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs818427	0.927	rs153546	chr5:112238039	A/C	cg07820702	chr5:112228657	REEP5	-0.51	-4.59	-0.35	9.4e-6	Total body bone mineral density;
PAAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg08835956	chr7:39171034	POU6F2	0.32	5.69	0.42	6.27e-8	IgG glycosylation;
PAAD	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.56	-5.26	-0.39	4.73e-7	Neuroticism;
PAAD	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.12	9.29	0.6	1.57e-16	Sexual dysfunction (female);
PAAD	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-5.82	-0.43	3.44e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02035330	chr19:36036387	TMEM147	0.61	6.88	0.49	1.43e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.09	-0.38	1.07e-6	Platelet count;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.4	-7.52	-0.52	4.35e-12	Psoriasis vulgaris;
PAAD	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg06697600	chr4:7070879	GRPEL1	0.99	6.2	0.45	4.97e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg08514558	chr10:81106712	PPIF	0.5	6.04	0.44	1.16e-8	Height;
PAAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.25	-0.51	1.98e-11	Personality dimensions;
PAAD	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.66	7.06	0.5	5.6e-11	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs35740288	0.752	rs11636138	chr15:86287547	T/A	cg07943548	chr15:86304357	KLHL25	-0.52	-4.44	-0.34	1.75e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.48	-5.31	-0.4	3.84e-7	Major depressive disorder;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.99	-0.49	8.15e-11	Life satisfaction;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg20302533	chr7:39170763	POU6F2	0.38	5.34	0.4	3.28e-7	IgG glycosylation;
PAAD	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.37	-4.66	-0.35	6.72e-6	Menarche (age at onset);
PAAD	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.57	-5.1	-0.38	1.02e-6	Life satisfaction;
PAAD	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.14	15.88	0.79	4.24e-34	Exhaled nitric oxide output;
PAAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.53	5.27	0.39	4.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.68	-6.56	-0.47	7.87e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.55	5.39	0.4	2.67e-7	Mortality in heart failure;
PAAD	cis	rs10821973	0.527	rs4636536	chr10:63979147	C/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.47	-0.34	1.52e-5	Hypothyroidism;
PAAD	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.49	-0.34	1.39e-5	Triglycerides;
PAAD	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs2296225	0.722	rs12022873	chr1:21046569	G/A	cg24673385	chr1:21051448	SH2D5	0.49	4.29	0.33	3.12e-5	Eosinophilic esophagitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01398299	chr7:2761640	NA	0.59	6.9	0.49	1.33e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.23	-9.43	-0.61	6.66e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07701084	chr6:150067640	NUP43	0.64	6.29	0.45	3.26e-9	Testicular germ cell tumor;
PAAD	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.36	11.44	0.68	2.99e-22	Uric acid levels;
PAAD	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg08109568	chr15:31115862	NA	-0.7	-7.7	-0.53	1.61e-12	Huntington's disease progression;
PAAD	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.54	-6.99	-0.49	8.26e-11	Menopause (age at onset);
PAAD	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg05712524	chr7:100608590	NA	-0.4	-4.37	-0.33	2.31e-5	Resting heart rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10805667	chr11:71814220	LRTOMT;C11orf59	0.62	6.48	0.47	1.21e-9	Myopia (pathological);
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Renal cell carcinoma;
PAAD	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg24330906	chr2:85765176	MAT2A	-0.58	-5.7	-0.42	6.09e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg00717180	chr2:96193071	NA	0.65	6.91	0.49	1.26e-10	Migraine - clinic-based;
PAAD	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.88	7.24	0.51	2.04e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-5.88	-0.43	2.46e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.27	-0.39	4.54e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.56	-5.85	-0.43	2.91e-8	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2249694	1.000	rs8192781	chr10:135354251	T/G	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.43	5.5	0.41	1.54e-7	Ulcerative colitis;
PAAD	cis	rs3136739	0.614	rs2070711	chr8:42045933	G/A	cg17828057	chr8:42037527	PLAT	0.7	4.76	0.36	4.49e-6	Plasma plasminogen activator levels;
PAAD	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.68e-5	Skin colour saturation;
PAAD	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.55e-5	Life satisfaction;
PAAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.59	7.21	0.5	2.52e-11	Monobrow;
PAAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg16147221	chr4:10020634	SLC2A9	0.47	4.37	0.33	2.33e-5	Bone mineral density;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.85	5.35	0.4	3.24e-7	Body mass index;
PAAD	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg02683114	chr2:24398427	C2orf84	-0.59	-6.28	-0.45	3.43e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.52	-5.99	-0.44	1.47e-8	Alcohol dependence;
PAAD	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.77	8.1	0.55	1.65e-13	Uric acid levels;
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.64	8.16	0.55	1.19e-13	Hypertriglyceridemia;
PAAD	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.44	-5.05	-0.38	1.28e-6	Blood pressure (smoking interaction);
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg14926445	chr8:58193284	C8orf71	-0.65	-5.3	-0.39	4.01e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg12641515	chr19:46296257	DMWD	0.45	4.42	0.34	1.89e-5	Coronary artery disease;
PAAD	cis	rs1144333	0.737	rs1144331	chr1:76272357	G/A	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.68	-6.9	-0.49	1.33e-10	Body mass index;
PAAD	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg07930552	chr6:133119739	C6orf192	0.96	4.5	0.34	1.34e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs7189233	1.000	rs7194519	chr16:53535276	C/G	cg00221382	chr16:54322308	NA	-0.28	-4.29	-0.33	3.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.39	-5.15	-0.39	7.95e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.74	0.62	1.03e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg09760422	chr2:128146352	NA	-0.39	-6.64	-0.47	5.29e-10	Protein C levels;
PAAD	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.29	0.39	4.22e-7	Free thyroxine concentration;
PAAD	cis	rs3136739	0.614	rs12543326	chr8:42003663	G/A	cg12054981	chr8:42037387	PLAT	0.66	4.78	0.36	4.08e-6	Plasma plasminogen activator levels;
PAAD	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-0.93	-5.61	-0.41	9.39e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs4740619	0.661	rs10810486	chr9:15943599	C/T	cg14451791	chr9:16040625	NA	-0.44	-5.05	-0.38	1.23e-6	Body mass index;
PAAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.71	-8.26	-0.56	6.45e-14	Huntington's disease progression;
PAAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg08514558	chr10:81106712	PPIF	0.5	6.04	0.44	1.16e-8	Height;
PAAD	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.74	6.77	0.48	2.63e-10	Mean platelet volume;
PAAD	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.85e-5	Pubertal anthropometrics;
PAAD	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.59	-0.35	9.35e-6	Height;
PAAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs4450131	0.900	rs11245333	chr10:126383088	C/A	cg20435097	chr10:126320824	FAM53B	0.38	4.25	0.33	3.71e-5	White blood cell count (basophil);
PAAD	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.5	-0.52	4.86e-12	Neuroticism;
PAAD	cis	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg26528668	chr16:1614120	IFT140	0.53	4.96	0.37	1.89e-6	Coronary artery disease;
PAAD	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.44	-5.17	-0.39	7.29e-7	Mean arterial pressure;
PAAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.75	8.8	0.58	2.89e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs4605213	0.528	rs12602155	chr17:49313772	A/C	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg23465465	chr6:26364728	BTN3A2	0.85	5.12	0.38	9.01e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs755249	0.532	rs61779277	chr1:39833535	G/A	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs13177180	0.705	rs256965	chr5:114937967	G/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.44	-4.67	-0.35	6.69e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg10820045	chr2:198174542	NA	0.54	5.6	0.41	9.6e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6988985	0.618	rs62525983	chr8:143988986	C/G	cg10324643	chr8:143916377	GML	0.41	4.72	0.36	5.35e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.77e-6	Recombination rate (females);
PAAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg16205897	chr5:131564050	P4HA2	-0.48	-5.11	-0.38	9.49e-7	Blood metabolite levels;
PAAD	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.75	-6.89	-0.49	1.37e-10	Total body bone mineral density;
PAAD	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg02917321	chr22:38215204	NA	-0.46	-4.97	-0.37	1.81e-6	Glioblastoma;Glioma;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg08677398	chr8:58056175	NA	0.6	4.56	0.35	1.05e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.84	9.22	0.6	2.26e-16	Anterior chamber depth;
PAAD	cis	rs16867321	0.853	rs58388320	chr2:181340490	C/T	cg23363182	chr2:181467187	NA	-0.52	-4.39	-0.34	2.13e-5	Obesity;
PAAD	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06850241	chr22:41845214	NA	-0.5	-4.48	-0.34	1.45e-5	Vitiligo;
PAAD	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	7.23	0.51	2.25e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.43	5.44	0.4	2.13e-7	Psoriasis;
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.52	0.34	1.21e-5	Retinal vascular caliber;
PAAD	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.21	-0.5	2.49e-11	Morning vs. evening chronotype;
PAAD	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.39e-9	Lung cancer;
PAAD	cis	rs3812762	0.912	rs11042058	chr11:8763815	A/T	cg11156914	chr11:8892616	ST5	0.57	4.72	0.36	5.36e-6	Hypospadias;
PAAD	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.58	4.87	0.37	2.74e-6	Neutrophil percentage of white cells;
PAAD	cis	rs62025270	0.522	rs16943120	chr15:86226297	A/G	cg13263323	chr15:86062960	AKAP13	0.5	4.46	0.34	1.6e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.69	6.84	0.49	1.79e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.97	-0.37	1.77e-6	Menopause (age at onset);
PAAD	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.58	-5.63	-0.42	8.55e-8	Gut microbiome composition (summer);
PAAD	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg19847866	chr10:1019161	NA	-0.57	-4.61	-0.35	8.39e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg17845761	chr1:175162550	KIAA0040	0.32	5.19	0.39	6.6e-7	Alcohol dependence;
PAAD	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.1	-9.8	-0.62	7.07e-18	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg05110241	chr16:68378359	PRMT7	-1.07	-7.98	-0.54	3.22e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg25922239	chr6:33757077	LEMD2	0.47	4.33	0.33	2.72e-5	Crohn's disease;
PAAD	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.55	5.06	0.38	1.2e-6	Life satisfaction;
PAAD	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11160944	chr17:45570048	NA	0.56	6.69	0.48	4.07e-10	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06591892	chr19:47353883	AP2S1	0.64	7.23	0.51	2.17e-11	Monocyte percentage of white cells;
PAAD	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg22857025	chr5:266934	NA	-1.17	-5.54	-0.41	1.32e-7	Breast cancer;
PAAD	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.51	-0.34	1.27e-5	Diastolic blood pressure;
PAAD	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.23	18.92	0.84	8.64e-42	IgG glycosylation;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.88	6.74	0.48	3.04e-10	Schizophrenia;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.27	-0.45	3.58e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12465520	chr5:14733886	ANKH	0.57	7.0	0.49	7.76e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg01866162	chr16:67596514	CTCF	0.57	4.32	0.33	2.77e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.56	-6.08	-0.44	9.4e-9	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs6921542	0.861	rs2151068	chr6:131343696	A/G	cg17329834	chr6:131380543	EPB41L2	-0.48	-4.34	-0.33	2.61e-5	Mean corpuscular volume;
PAAD	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-0.72	-7.49	-0.52	5.33e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20797740	chr17:45727226	KPNB1	-0.81	-7.02	-0.49	6.81e-11	Neuroticism;
PAAD	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00152838	chr16:24741724	TNRC6A	-0.52	-4.41	-0.34	1.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg14583973	chr4:3374767	RGS12	-0.37	-5.61	-0.41	9.13e-8	Parental longevity (mother's age at death);
PAAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-6.0	-0.44	1.39e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	6.16	0.45	6.36e-9	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg15192750	chr16:69999425	NA	0.72	5.54	0.41	1.33e-7	IgE levels;
PAAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg00012203	chr2:219082015	ARPC2	-0.78	-7.78	-0.53	1.01e-12	Colorectal cancer;
PAAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.78	7.56	0.52	3.64e-12	Corneal astigmatism;
PAAD	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.16	-0.45	6.28e-9	Schizophrenia;
PAAD	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg03605463	chr16:89740564	NA	-0.53	-4.94	-0.37	2.01e-6	Vitiligo;
PAAD	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-4.67	-0.35	6.61e-6	Joint mobility (Beighton score);
PAAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-5.07	-0.38	1.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.67	-7.75	-0.53	1.23e-12	Lung cancer;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs9398803	0.650	rs1101559	chr6:127047683	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.44	-0.34	1.7e-5	Male-pattern baldness;
PAAD	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.13	-0.38	8.81e-7	Personality dimensions;
PAAD	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg17674042	chr6:34482479	PACSIN1	-1.0	-6.81	-0.48	2.1e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg06740227	chr12:86229804	RASSF9	0.5	4.95	0.37	1.91e-6	Major depressive disorder;
PAAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg15017067	chr4:17643749	FAM184B	-0.4	-4.46	-0.34	1.61e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg16362232	chr11:430036	ANO9	0.86	5.31	0.4	3.79e-7	Body mass index;
PAAD	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.69	7.96	0.54	3.62e-13	Height;
PAAD	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs7936247	1.000	rs10741452	chr11:92689350	A/G	cg26929280	chr11:92402250	FAT3	-0.42	-4.25	-0.33	3.78e-5	Glycemic traits (pregnancy);
PAAD	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.77	-7.48	-0.52	5.45e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs12979813	1.000	rs10406522	chr19:11341635	T/C	cg03333546	chr19:13263065	IER2	-0.87	-6.3	-0.46	3.12e-9	HDL cholesterol;
PAAD	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg11667643	chr8:748456	NA	-0.47	-4.62	-0.35	8.06e-6	Clozapine-induced cytotoxicity;
PAAD	cis	rs385076	0.503	rs212702	chr2:32444250	A/G	cg02381751	chr2:32503542	YIPF4	0.52	4.97	0.37	1.75e-6	Interleukin-18 levels;
PAAD	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg11494091	chr17:61959527	GH2	0.52	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.67	-0.35	6.65e-6	Neuroticism;
PAAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Electroencephalogram traits;
PAAD	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg06917634	chr15:78832804	PSMA4	-0.46	-4.48	-0.34	1.45e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4280164	0.945	rs4981503	chr14:24786293	T/G	cg07162820	chr14:24837146	NFATC4	-0.38	-4.38	-0.33	2.24e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.9	-8.61	-0.57	8.72e-15	Blood protein levels;
PAAD	cis	rs988913	0.723	rs4715515	chr6:54968444	C/G	cg03513858	chr6:54763001	FAM83B	-0.4	-4.35	-0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs4273100	0.790	rs60606605	chr17:19277144	G/A	cg18093559	chr17:18951025	GRAP	-0.52	-4.38	-0.33	2.17e-5	Schizophrenia;
PAAD	cis	rs11023332	0.641	rs4281505	chr11:14800660	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-4.3	-0.33	3.09e-5	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs9283706	0.641	rs6414805	chr5:66322600	T/C	cg11590213	chr5:66331682	MAST4	0.59	4.82	0.36	3.49e-6	Coronary artery disease;
PAAD	cis	rs3126085	0.560	rs6587668	chr1:152333958	A/G	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	4.53	0.34	1.2e-5	Hip circumference;
PAAD	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.31	7.92	0.54	4.69e-13	Psoriasis vulgaris;
PAAD	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg20639618	chr4:183729073	NA	0.67	5.31	0.4	3.9e-7	Pediatric autoimmune diseases;
PAAD	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.43	4.37	0.33	2.26e-5	Height;
PAAD	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	6.49	0.47	1.12e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.52	-4.46	-0.34	1.61e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.37	-0.33	2.29e-5	Breast cancer;
PAAD	cis	rs13424612	0.764	rs66958587	chr2:240889538	C/T	cg01812947	chr2:240904978	NDUFA10	0.59	5.61	0.41	9.52e-8	Odorant perception (isobutyraldehyde);
PAAD	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.72	-8.66	-0.57	6.52e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.12	0.55	1.51e-13	Lung cancer in ever smokers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00668442	chr16:2318234	RNPS1	0.77	8.59	0.57	9.81e-15	Myopia (pathological);
PAAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.71	-5.19	-0.39	6.64e-7	Hand grip strength;
PAAD	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg13160058	chr8:26243215	BNIP3L	-0.4	-4.92	-0.37	2.27e-6	Red cell distribution width;
PAAD	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.64	0.47	5.34e-10	IgG glycosylation;
PAAD	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg25886479	chr11:50257625	LOC441601	0.43	5.16	0.39	7.52e-7	Height;
PAAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.99	-12.45	-0.71	5.61e-25	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20168823	chr18:34916738	BRUNOL4	0.65	6.44	0.46	1.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg14343924	chr8:8086146	FLJ10661	0.52	4.37	0.33	2.32e-5	Systolic blood pressure;
PAAD	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.99	-8.04	-0.55	2.3e-13	Blood protein levels;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.55	-0.41	1.21e-7	Lung cancer;
PAAD	cis	rs9393777	0.668	rs72839449	chr6:27261661	A/C	cg22548220	chr6:27277996	POM121L2	0.57	4.4	0.34	2.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1497828	0.956	rs2815230	chr1:217536114	T/C	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs8040855	0.894	rs6496770	chr15:85705121	T/A	cg08123816	chr15:85640762	PDE8A	0.39	4.72	0.36	5.38e-6	Bulimia nervosa;
PAAD	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.74e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21626886	chr20:30193307	ID1	-0.66	-6.47	-0.46	1.26e-9	Smoking initiation;
PAAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.55	-4.96	-0.37	1.84e-6	Glycated hemoglobin levels;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg26338869	chr17:61819248	STRADA	0.5	4.7	0.36	5.71e-6	Height;
PAAD	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.93	12.59	0.71	2.41e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.42	-0.34	1.84e-5	Tuberculosis;
PAAD	cis	rs6011674	1.000	rs9808612	chr20:61868348	T/C	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.75	-4.61	-0.35	8.32e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg08648136	chr8:956695	NA	0.43	4.59	0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.65	7.47	0.52	5.92e-12	Mosquito bite size;
PAAD	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.71	-7.62	-0.53	2.51e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.57	5.7	0.42	5.99e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-4.92	-0.37	2.26e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs375066	0.901	rs12977303	chr19:44377669	G/A	cg11993925	chr19:44307056	LYPD5	0.55	6.97	0.49	9.23e-11	Breast cancer;
PAAD	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.46	6.35	0.46	2.41e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg22442454	chr1:209979470	IRF6	0.51	4.46	0.34	1.6e-5	Coronary artery disease;
PAAD	cis	rs6597981	0.675	rs1138714	chr11:825110	A/G	cg01741372	chr11:783889	NA	0.61	7.68	0.53	1.82e-12	Breast cancer;
PAAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg16928487	chr17:17741425	SREBF1	0.34	4.6	0.35	8.98e-6	Total body bone mineral density;
PAAD	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.48	5.63	0.42	8.35e-8	Immature fraction of reticulocytes;
PAAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.92	4.97	0.37	1.78e-6	Childhood ear infection;
PAAD	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg00982548	chr2:198649783	BOLL	-0.75	-5.25	-0.39	5.02e-7	Ulcerative colitis;
PAAD	cis	rs194045	0.609	rs252344	chr16:29184882	G/A	cg06048556	chr16:29151034	NA	-0.58	-4.35	-0.33	2.46e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.66	-7.93	-0.54	4.32e-13	Breast cancer;
PAAD	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.7	-0.36	5.74e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg13444538	chr7:158905317	VIPR2	-0.58	-4.76	-0.36	4.54e-6	Facial morphology (factor 20);
PAAD	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00152838	chr16:24741724	TNRC6A	0.52	4.38	0.33	2.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg11783602	chr8:55087084	NA	-0.63	-7.43	-0.52	7.34e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.61	7.74	0.53	1.28e-12	Hypertriglyceridemia;
PAAD	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg26205652	chr12:48591994	NA	0.84	7.47	0.52	5.84e-12	Longevity (90 years and older);
PAAD	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.89	6.4	0.46	1.78e-9	Pulse pressure;
PAAD	trans	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg26501369	chr6:133561814	EYA4	-0.9	-6.63	-0.47	5.62e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.67	-8.74	-0.58	4e-15	Schizophrenia;
PAAD	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg04176122	chr11:118779835	BCL9L	-0.43	-4.46	-0.34	1.57e-5	Rheumatoid arthritis;
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.39e-9	Lung cancer;
PAAD	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg16342193	chr10:102329863	NA	0.78	8.66	0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4455778	0.580	rs7780178	chr7:49085140	A/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.56	4.92	0.37	2.22e-6	Life satisfaction;
PAAD	cis	rs71520386	0.632	rs1474349	chr7:22853765	G/A	cg04907244	chr7:22894795	SNORD93	0.51	5.52	0.41	1.42e-7	Fibrinogen levels;
PAAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.45	0.34	1.68e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.44	5.16	0.39	7.62e-7	Melanoma;
PAAD	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-23.05	-0.88	1.76e-51	Myeloid white cell count;
PAAD	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.87	-0.37	2.83e-6	Triglycerides;
PAAD	cis	rs1499972	0.887	rs73168397	chr3:117657197	C/T	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22664307	chr6:144471564	STX11	0.67	7.35	0.51	1.12e-11	Myopia (pathological);
PAAD	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.58	-0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg21724239	chr8:58056113	NA	0.67	5.17	0.39	7.28e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.83	8.26	0.56	6.55e-14	Coronary artery disease;
PAAD	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	6.5	0.47	1.07e-9	Bipolar disorder;
PAAD	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	cis	rs11618113	0.634	rs9588186	chr13:111183205	T/A	cg11688093	chr13:111178359	RAB20	-0.72	-4.51	-0.34	1.28e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.68	-7.29	-0.51	1.6e-11	Post bronchodilator FEV1;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs78761021	0.898	rs73257187	chr17:9776719	T/C	cg26853458	chr17:9805074	RCVRN	0.7	8.26	0.56	6.64e-14	Type 2 diabetes;
PAAD	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.96	8.3	0.56	5.24e-14	Blood protein levels;
PAAD	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.87	-9.51	-0.61	4.02e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.93	-10.1	-0.63	1.16e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.51	-0.34	1.27e-5	Aortic root size;
PAAD	cis	rs6076065	0.723	rs2424544	chr20:23390314	C/T	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs1880828	0.500	rs697938	chr3:55165175	C/G	cg01972071	chr7:136849018	NA	-0.89	-6.47	-0.46	1.28e-9	Lung cancer in ever smokers;
PAAD	cis	rs300774	1.000	rs300777	chr2:112026	T/C	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-5.29	-0.39	4.18e-7	Coronary artery disease;
PAAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.48	8.46	0.57	2.11e-14	Multiple system atrophy;
PAAD	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.19	0.64	6.57e-19	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.9	-10.79	-0.66	1.68e-20	Sudden cardiac arrest;
PAAD	cis	rs1419980	0.730	rs73260714	chr12:7781057	C/G	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.43	-0.34	1.81e-5	Renal cell carcinoma;
PAAD	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.72	7.85	0.54	6.98e-13	Morning vs. evening chronotype;
PAAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg03808351	chr9:123631620	PHF19	0.44	4.86	0.37	2.93e-6	Rheumatoid arthritis;
PAAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.57	6.59	0.47	6.88e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.52	4.92	0.37	2.19e-6	Red cell distribution width;
PAAD	cis	rs6669119	0.591	rs9439748	chr1:19112836	A/G	cg26220594	chr1:19110978	NA	0.72	4.32	0.33	2.78e-5	Percentage gas trapping;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.9	12.11	0.7	4.81e-24	Superior crus of antihelix expression;
PAAD	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.7	-0.36	5.84e-6	Primary sclerosing cholangitis;
PAAD	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg08514558	chr10:81106712	PPIF	0.51	6.18	0.45	5.52e-9	Height;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.49	-4.94	-0.37	2.01e-6	Testicular germ cell tumor;
PAAD	cis	rs288326	0.561	rs41270217	chr2:183850877	C/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.34	0.46	2.47e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11853189	0.938	rs16969707	chr15:78594105	A/T	cg22935921	chr15:78556834	DNAJA4	0.73	5.11	0.38	9.62e-7	Red cell distribution width;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.63	-0.47	5.47e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.63	6.1	0.44	8.44e-9	Mosquito bite size;
PAAD	cis	rs16910800	0.953	rs7110229	chr11:23200546	C/T	cg20040320	chr11:23191996	NA	-0.61	-5.26	-0.39	4.81e-7	Cancer;
PAAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.91	12.31	0.71	1.39e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.68	5.85	0.43	2.84e-8	Platelet count;
PAAD	trans	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.67	-0.48	4.39e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6137287	0.924	rs910975	chr20:21156169	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22135468	chr22:20104774	TRMT2A;RANBP1	-0.67	-7.08	-0.5	4.99e-11	Smoking initiation;
PAAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.63	7.07	0.5	5.15e-11	Body mass index;
PAAD	cis	rs282587	0.597	rs438116	chr13:113392149	G/C	cg19217778	chr13:113420270	ATP11A	-0.55	-4.34	-0.33	2.6e-5	Glycated hemoglobin levels;
PAAD	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.64e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg21724239	chr8:58056113	NA	0.67	5.31	0.4	3.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.97	-12.62	-0.72	2.02e-25	Heart rate;
PAAD	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	1.95	10.88	0.66	9.67e-21	Cannabis dependence symptom count;
PAAD	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.56	5.16	0.39	7.77e-7	HDL cholesterol;
PAAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21643547	chr1:205240462	TMCC2	-0.41	-4.67	-0.35	6.51e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2744375	0.600	rs2237102	chr6:7552145	A/G	cg27023638	chr6:7288726	SSR1	-0.41	-4.26	-0.33	3.56e-5	Resting heart rate;
PAAD	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg16419906	chr5:132167176	NA	-0.66	-5.28	-0.39	4.38e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs137887	0.935	rs137885	chr22:50463231	T/C	cg23116504	chr22:50470537	TTLL8	-0.51	-5.23	-0.39	5.6e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.89	-10.31	-0.64	3.1400000000000002e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	1.92	10.46	0.65	1.24e-19	Cannabis dependence symptom count;
PAAD	cis	rs7598759	0.527	rs4973417	chr2:232349636	G/T	cg19187155	chr2:232395269	NMUR1	0.78	9.07	0.59	5.68e-16	Noise-induced hearing loss;
PAAD	cis	rs8105895	0.935	rs62110989	chr19:22260299	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs2073300	1.000	rs6048834	chr20:23462213	C/T	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17272331	chr6:101328506	ASCC3	0.69	7.87	0.54	6.2e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.55	0.35	1.09e-5	Testicular germ cell tumor;
PAAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.58	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg16898833	chr6:26189333	HIST1H4D	0.81	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.61	-7.05	-0.5	6.02e-11	Blood protein levels;
PAAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg10547527	chr2:198650123	BOLL	-0.82	-5.56	-0.41	1.2e-7	Ulcerative colitis;
PAAD	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.95	5.28	0.39	4.31e-7	Plateletcrit;
PAAD	cis	rs4454254	0.589	rs9987138	chr8:141076623	C/G	cg06693505	chr8:141057453	TRAPPC9	-0.35	-4.75	-0.36	4.74e-6	Pulse pressure;
PAAD	cis	rs67072384	0.584	rs12275279	chr11:72437296	C/A	cg04827223	chr11:72435913	ARAP1	-0.55	-4.31	-0.33	2.98e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
PAAD	cis	rs959260	0.528	rs4559942	chr17:73309269	G/A	cg23244877	chr17:73518230	TSEN54	0.5	4.36	0.33	2.39e-5	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.52	-4.98	-0.37	1.72e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.88	-7.3	-0.51	1.48e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg13057898	chr1:3703894	LRRC47	0.44	4.71	0.36	5.43e-6	Red cell distribution width;
PAAD	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.6	5.97	0.44	1.58e-8	Monocyte count;
PAAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14180030	chr9:123475675	MEGF9	-0.46	-5.12	-0.38	9.14e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg02555727	chr12:129281546	SLC15A4	0.46	4.86	0.37	2.96e-6	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.0	-8.58	-0.57	1.03e-14	Vitiligo;
PAAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.77	8.93	0.59	1.27e-15	DNA methylation (variation);
PAAD	cis	rs8099014	0.861	rs6566974	chr18:56131156	A/G	cg12907477	chr18:56117327	MIR122	0.61	4.68	0.36	6.25e-6	Platelet count;
PAAD	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg01329690	chr21:38580129	DSCR9	-0.34	-4.5	-0.34	1.37e-5	Eye color traits;
PAAD	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.76	7.82	0.54	8.05e-13	Breast cancer;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.07	-18.86	-0.84	1.22e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg25809561	chr17:30822961	MYO1D	0.56	5.97	0.44	1.63e-8	Schizophrenia;
PAAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.66	-7.23	-0.51	2.24e-11	Adiponectin levels;
PAAD	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg19875578	chr6:126661172	C6orf173	0.48	4.8	0.36	3.68e-6	Male-pattern baldness;
PAAD	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.53	-5.21	-0.39	6.1e-7	Testicular germ cell tumor;
PAAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg07469887	chr10:131262384	NA	-0.43	-5.11	-0.38	9.74e-7	Response to temozolomide;
PAAD	cis	rs2271001	0.911	rs3802796	chr11:19171021	C/T	cg00161556	chr11:19138045	ZDHHC13	0.52	5.55	0.41	1.24e-7	Gut microbiome composition (winter);
PAAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg07371521	chr5:154026371	NA	-0.51	-6.43	-0.46	1.57e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	4.28	0.33	3.32e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg10547527	chr2:198650123	BOLL	-0.64	-4.3	-0.33	3.02e-5	Ulcerative colitis;
PAAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg06375148	chr1:209958343	C1orf74	0.45	4.57	0.35	1.01e-5	Monobrow;
PAAD	cis	rs9942416	0.586	rs111745049	chr5:75037761	T/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.54	4.35	0.33	2.46e-5	Age-related disease endophenotypes;
PAAD	cis	rs350729	0.568	rs7595603	chr2:53179680	C/A	cg07782112	chr2:53107842	NA	-0.36	-4.28	-0.33	3.36e-5	Bronchodilator response in asthma;
PAAD	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.62	4.88	0.37	2.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2777491	0.522	rs7169278	chr15:41696932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-7.97	-0.54	3.55e-13	Ulcerative colitis;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.71	-6.49	-0.47	1.12e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg07883600	chr3:53528162	CACNA1D	0.41	4.45	0.34	1.64e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.78	-9.16	-0.6	3.26e-16	Colorectal cancer;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg15117754	chr3:10150083	C3orf24	0.58	5.4	0.4	2.48e-7	Alzheimer's disease;
PAAD	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg14181355	chr19:12984996	MAST1	-0.45	-4.45	-0.34	1.66e-5	Mean corpuscular volume;
PAAD	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.45	-4.29	-0.33	3.16e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg16356956	chr22:37317934	CSF2RB	-0.37	-4.53	-0.34	1.19e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	6.92	0.49	1.16e-10	Systemic lupus erythematosus;
PAAD	trans	rs901683	1.000	rs36070535	chr10:46022238	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs77106637	0.530	rs1785212	chr11:72462375	T/C	cg04827223	chr11:72435913	ARAP1	-0.53	-5.71	-0.42	5.84e-8	Type 2 diabetes;
PAAD	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.87	-11.15	-0.67	1.8e-21	Dental caries;
PAAD	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6942407	0.546	rs10952896	chr7:86765763	G/A	cg02420886	chr7:86849541	C7orf23	0.59	4.61	0.35	8.46e-6	Food allergy;
PAAD	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg11601000	chr22:42348013	LOC339674	-0.4	-4.5	-0.34	1.32e-5	Cognitive function;
PAAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.71	7.88	0.54	5.79e-13	Corneal astigmatism;
PAAD	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-5.83	-0.43	3.24e-8	Cognitive test performance;
PAAD	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	4.48	0.34	1.43e-5	Breast cancer;
PAAD	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg02733842	chr7:1102375	C7orf50	-0.77	-6.12	-0.44	7.77e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.57	-0.35	1e-5	Skin colour saturation;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.81	-0.43	3.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg16306870	chr3:194868790	C3orf21	0.55	5.31	0.4	3.83e-7	Non-small cell lung cancer;
PAAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.53	5.59	0.41	1.01e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10419226	0.625	rs12974777	chr19:18765663	C/T	cg14292368	chr19:18793705	CRTC1	-0.47	-4.94	-0.37	2.07e-6	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.96	6.96	0.49	9.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.28	-0.39	4.41e-7	Common traits (Other);
PAAD	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.57	5.43	0.4	2.22e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg01422370	chr2:73384389	NA	0.39	5.12	0.38	9.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.44	4.54	0.35	1.15e-5	Response to statin therapy;
PAAD	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.75	4.79	0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs10736390	0.813	rs6687894	chr1:55105038	A/C	cg06007645	chr1:55107421	C1orf175	0.44	5.0	0.38	1.58e-6	Survival in pancreatic cancer;
PAAD	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	6.96	0.49	9.51e-11	Lung function (FEV1/FVC);
PAAD	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.49	-0.41	1.68e-7	Bladder cancer;
PAAD	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg08619932	chr19:49200058	FUT2	0.6	6.59	0.47	6.64e-10	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
PAAD	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.51	-6.25	-0.45	3.99e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.72	11.26	0.67	9.09e-22	Breast cancer;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg15251779	chr7:150929295	CHPF2	-0.55	-6.68	-0.48	4.29e-10	Alzheimer's disease (survival time);
PAAD	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.75	5.53	0.41	1.33e-7	Coronary artery calcification;
PAAD	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.43	-5.33	-0.4	3.57e-7	Endometriosis;
PAAD	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg24112000	chr20:60950667	NA	0.8	10.37	0.64	2.21e-19	Colorectal cancer;
PAAD	cis	rs6496932	0.802	rs4843047	chr15:85859776	G/A	cg19183879	chr15:85880815	NA	0.51	4.73	0.36	4.99e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs4713118	1.000	rs9468195	chr6:27676309	A/G	cg22143856	chr6:28129313	ZNF389	0.48	4.36	0.33	2.38e-5	Parkinson's disease;
PAAD	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg20893579	chr22:38215064	NA	0.49	4.61	0.35	8.39e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.68	6.75	0.48	2.91e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg19413350	chr8:57351067	NA	0.46	4.35	0.33	2.44e-5	Obesity-related traits;
PAAD	cis	rs7567389	0.719	rs4662713	chr2:127994103	C/T	cg11380483	chr2:127933992	NA	-0.45	-4.43	-0.34	1.82e-5	Self-rated health;
PAAD	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.57	5.42	0.4	2.32e-7	Corneal astigmatism;
PAAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg27494647	chr7:150038898	RARRES2	0.45	4.87	0.37	2.78e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.72	-5.36	-0.4	3.09e-7	Mean platelet volume;
PAAD	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.57	-5.83	-0.43	3.14e-8	Systemic sclerosis;
PAAD	cis	rs10189230	0.935	rs3770145	chr2:222345147	T/C	cg14652038	chr2:222343519	EPHA4	0.54	5.94	0.43	1.9e-8	Urate levels in lean individuals;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	10.05	0.63	1.51e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.43	-5.37	-0.4	2.91e-7	Lewy body disease;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13939156	chr17:80058883	NA	0.45	4.83	0.36	3.35e-6	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg12046867	chr14:103022105	NA	-0.57	-4.77	-0.36	4.19e-6	Platelet count;
PAAD	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg04450456	chr4:17643702	FAM184B	0.51	5.22	0.39	5.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg20312557	chr2:97357134	FER1L5	-0.83	-4.43	-0.34	1.79e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg19847866	chr10:1019161	NA	-0.58	-4.51	-0.34	1.3e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg14393609	chr7:65229607	NA	-0.5	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.02	-0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs2834188	0.961	rs8130807	chr21:34690013	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	4.47	0.34	1.5e-5	Narcolepsy;
PAAD	cis	rs8070740	0.559	rs1806263	chr17:5317492	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	-0.47	-4.9	-0.37	2.4e-6	Menopause (age at onset);
PAAD	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.63	-5.47	-0.41	1.78e-7	Coronary artery disease;
PAAD	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg01304814	chr3:48885189	PRKAR2A	0.92	5.3	0.4	3.92e-7	Blood protein levels;
PAAD	cis	rs988913	0.624	rs3125260	chr6:54846044	G/A	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.37	-0.33	2.26e-5	Body mass index;
PAAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.4	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.39e-7	Monocyte count;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs12304921	1.000	rs76604840	chr12:51376494	A/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.46	-0.4	1.92e-7	Type 2 diabetes;
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.67	-6.73	-0.48	3.31e-10	Blood metabolite levels;
PAAD	cis	rs682748	0.846	rs6893755	chr5:17140421	A/T	cg23987134	chr5:17158319	LOC285696	-0.35	-4.33	-0.33	2.7e-5	Hippocampal atrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24663090	chr5:53182145	ARL15	-0.62	-6.59	-0.47	6.66e-10	Obesity-related traits;
PAAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.78	-6.12	-0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.49	5.17	0.39	7.32e-7	Personality dimensions;
PAAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-5.99	-0.44	1.45e-8	Longevity;Endometriosis;
PAAD	cis	rs3812111	0.525	rs1052443	chr6:116568773	A/C	cg05304507	chr6:116381966	FRK	-0.25	-4.26	-0.33	3.54e-5	Age-related macular degeneration;
PAAD	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.46	-4.27	-0.33	3.5e-5	Triglycerides;
PAAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	1.08	8.25	0.56	7.16e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-5.84	-0.43	3.11e-8	Prudent dietary pattern;
PAAD	cis	rs9463078	0.625	rs679713	chr6:44899632	T/C	cg25276700	chr6:44698697	NA	-0.54	-6.1	-0.44	8.24e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08478250	chr15:93957936	NA	0.54	6.47	0.46	1.26e-9	Smoking initiation;
PAAD	cis	rs7072216	0.587	rs2296435	chr10:100182285	C/T	cg26618903	chr10:100175079	PYROXD2	0.52	5.28	0.39	4.49e-7	Metabolite levels;
PAAD	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.69	7.11	0.5	4.18e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg24503407	chr1:205819492	PM20D1	0.59	4.99	0.38	1.64e-6	Prostate-specific antigen levels;
PAAD	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg09455208	chr3:40491958	NA	-0.43	-5.7	-0.42	5.97e-8	Renal cell carcinoma;
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.58	6.81	0.48	2.16e-10	Aortic root size;
PAAD	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.45	-0.34	1.64e-5	Response to amphetamines;
PAAD	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.54	5.44	0.4	2.07e-7	Resting heart rate;
PAAD	cis	rs7957197	0.873	rs7965349	chr12:121471931	C/T	cg17118599	chr12:121079482	CABP1	0.48	4.36	0.33	2.39e-5	Type 2 diabetes;
PAAD	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	High light scatter reticulocyte count;
PAAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.62	6.59	0.47	6.89e-10	Iron status biomarkers;
PAAD	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.7	9.58	0.61	2.6e-17	Hemoglobin concentration;
PAAD	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.72	0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs7714584	1.000	rs11746560	chr5:150185925	T/G	cg22134413	chr5:150180641	NA	0.95	6.41	0.46	1.71e-9	Crohn's disease;
PAAD	trans	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs35160687	0.901	rs12714180	chr2:86525323	G/T	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00982548	chr2:198649783	BOLL	-0.82	-5.92	-0.43	2.07e-8	Ulcerative colitis;
PAAD	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.81	-7.19	-0.5	2.78e-11	Homoarginine levels;
PAAD	cis	rs3931020	0.616	rs277381	chr1:75266815	T/A	cg26752657	chr1:75199075	CRYZ;TYW3	-0.55	-4.73	-0.36	5.03e-6	Resistin levels;
PAAD	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6976664	1.000	rs61739531	chr7:45016621	C/T	cg13400493	chr7:44826786	NA	0.46	4.3	0.33	3.03e-5	Pursuit maintenance gain;
PAAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.51	6.56	0.47	8.1e-10	Schizophrenia;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01238044	chr22:24384105	GSTT1	-0.49	-4.61	-0.35	8.44e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12949688	0.682	rs11657181	chr17:55838543	C/T	cg12582317	chr17:55822272	NA	0.42	4.85	0.37	3.07e-6	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	5.99e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg03676636	chr4:99064102	C4orf37	0.26	4.5	0.34	1.37e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-8.42	-0.56	2.6e-14	Colorectal cancer;
PAAD	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.75	-7.76	-0.53	1.17e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19933833	chr11:66247701	DPP3	0.64	7.35	0.51	1.16e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14128708	chr11:2176433	INS-IGF2	-0.73	-7.82	-0.54	8.24e-13	Obesity-related traits;
PAAD	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg14664628	chr15:75095509	CSK	0.49	4.75	0.36	4.69e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.72	0.36	5.28e-6	Resting heart rate;
PAAD	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.71	7.8	0.53	9.27e-13	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.48	5.4	0.4	2.57e-7	Major depressive disorder;
PAAD	trans	rs785830	0.538	rs573071	chr9:256994	A/G	cg17093826	chr7:138458720	ATP6V0A4	0.52	6.8	0.48	2.2e-10	Platelet distribution width;
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.55	8.65	0.57	6.95e-15	IgG glycosylation;
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16988970	chr17:42248062	ASB16	-0.37	-5.33	-0.4	3.55e-7	Total body bone mineral density;
PAAD	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs1620921	0.505	rs4708892	chr6:161209101	T/C	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.84	-9.61	-0.61	2.22e-17	Monocyte percentage of white cells;
PAAD	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.53	5.6	0.41	9.83e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs7127900	1.000	rs6579000	chr11:2232042	C/T	cg25635251	chr11:2234043	NA	0.85	7.58	0.52	3.18e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg23957660	chr17:17878224	LRRC48	0.37	4.32	0.33	2.77e-5	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg10973622	chr2:86423274	IMMT	0.46	5.36	0.4	3e-7	Night sleep phenotypes;
PAAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg18761221	chr20:60518478	NA	0.75	8.07	0.55	1.93e-13	Obesity-related traits;
PAAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.18	-0.39	7.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11614333	0.920	rs1800801	chr12:15038788	C/T	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24483552	chr8:67687060	SGK3	0.61	6.47	0.46	1.28e-9	Myopia (pathological);
PAAD	cis	rs9810890	0.850	rs13322981	chr3:128571735	G/A	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg14393609	chr7:65229607	NA	-0.48	-4.63	-0.35	7.79e-6	Aortic root size;
PAAD	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs793571	0.779	rs28611776	chr15:59258334	G/A	cg05156742	chr15:59063176	FAM63B	0.59	4.34	0.33	2.58e-5	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17074213	chr1:92351695	TGFBR3	-0.62	-6.63	-0.47	5.44e-10	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00431236	chr2:264988	ACP1;SH3YL1	0.58	6.46	0.46	1.34e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-5.2	-0.39	6.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg05697835	chr1:2722811	NA	-0.44	-4.93	-0.37	2.16e-6	Ulcerative colitis;
PAAD	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg23684204	chr15:91497937	RCCD1	0.7	5.77	0.42	4.34e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.42	4.72	0.36	5.38e-6	Schizophrenia;
PAAD	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg12395012	chr8:11607386	GATA4	0.43	4.38	0.34	2.16e-5	Morning vs. evening chronotype;
PAAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.89	0.54	5.4e-13	Menarche (age at onset);
PAAD	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-6.58	-0.47	7.32e-10	Morning vs. evening chronotype;
PAAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg24253500	chr15:84953950	NA	-0.55	-6.42	-0.46	1.61e-9	Schizophrenia;
PAAD	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	8.8	0.58	2.85e-15	Alzheimer's disease;
PAAD	cis	rs10861342	1.000	rs11112373	chr12:105503708	G/A	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg05585630	chr7:157510462	PTPRN2	-0.66	-6.26	-0.45	3.67e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.76	-8.57	-0.57	1.06e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg02230254	chr11:65586170	NA	-0.32	-4.63	-0.35	7.86e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11618113	0.634	rs11617401	chr13:111198459	C/T	cg11688093	chr13:111178359	RAB20	-0.77	-4.73	-0.36	5.03e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg18357526	chr6:26021779	HIST1H4A	0.53	4.58	0.35	9.54e-6	Height;
PAAD	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.02	0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.92	-6.36	-0.46	2.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.72	6.91	0.49	1.27e-10	Mood instability;
PAAD	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.57	5.92	0.43	2.02e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg05342945	chr12:48394962	COL2A1	-0.72	-4.67	-0.35	6.58e-6	Lung cancer;
PAAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg03037974	chr15:76606532	NA	0.53	6.05	0.44	1.07e-8	Blood metabolite levels;
PAAD	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.28	-14.14	-0.75	1.61e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg02780029	chr10:43622663	RET	-0.48	-4.9	-0.37	2.46e-6	Hirschsprung disease;
PAAD	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg06792262	chr3:44622596	ZNF167	0.4	4.31	0.33	2.87e-5	Depressive symptoms;
PAAD	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72772787	1.000	rs72772787	chr1:248016378	C/T	cg00785941	chr1:248100591	OR2L13	0.51	4.97	0.37	1.75e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg00543991	chr22:32367038	NA	1.08	6.43	0.46	1.56e-9	Childhood ear infection;
PAAD	cis	rs13011075	0.535	rs6546401	chr2:68630873	A/T	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg03959625	chr15:84868606	LOC388152	0.48	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs35740288	0.857	rs3803506	chr15:86290940	A/C	cg07943548	chr15:86304357	KLHL25	-0.52	-4.44	-0.34	1.7e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg06060754	chr5:176797920	RGS14	0.72	8.43	0.56	2.43e-14	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.37	0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg24747557	chr10:131355152	MGMT	0.48	4.91	0.37	2.34e-6	Response to temozolomide;
PAAD	cis	rs5742933	0.744	rs13002216	chr2:190611084	T/C	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs72960926	1.000	rs72958996	chr6:75131378	A/G	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg18551225	chr6:44695536	NA	0.65	6.42	0.46	1.69e-9	Total body bone mineral density;
PAAD	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.78	7.38	0.51	9.47e-12	Corneal astigmatism;
PAAD	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.23	0.51	2.24e-11	Educational attainment;
PAAD	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.53	5.2	0.39	6.39e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.85	-0.37	3.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8067354	0.872	rs2645483	chr17:57848184	T/G	cg02344993	chr17:57696989	CLTC	0.54	4.96	0.37	1.86e-6	Hemoglobin concentration;
PAAD	cis	rs6694270	0.529	rs12041777	chr1:19109193	T/C	cg26220594	chr1:19110978	NA	-0.69	-5.64	-0.42	7.97e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs2421770	1.000	rs4756208	chr11:35320084	A/T	cg13971030	chr11:35366721	SLC1A2	0.54	6.56	0.47	7.94e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.18e-10	Initial pursuit acceleration;
PAAD	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.3	-0.33	3.05e-5	Educational attainment;
PAAD	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs490234	0.691	rs3104551	chr9:128164279	G/A	cg14078157	chr9:128172775	NA	-0.52	-6.03	-0.44	1.19e-8	Mean arterial pressure;
PAAD	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3764618	1.000	rs76771366	chr19:49507119	C/T	cg12515942	chr19:49552529	CGB8	-0.72	-4.3	-0.33	3.06e-5	Follicule stimulating hormone;
PAAD	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.86	9.52	0.61	3.74e-17	Mortality in heart failure;
PAAD	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg27436995	chr16:743998	FBXL16	-0.37	-4.55	-0.35	1.09e-5	Height;
PAAD	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg00262122	chr8:11665843	FDFT1	-0.64	-5.58	-0.41	1.06e-7	Triglycerides;
PAAD	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.81	8.87	0.58	1.83e-15	Mortality in heart failure;
PAAD	cis	rs5753037	0.653	rs131277	chr22:30154101	C/A	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.62	6.93	0.49	1.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg20893579	chr22:38215064	NA	-0.45	-4.83	-0.37	3.24e-6	Glioblastoma;Glioma;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.86	9.94	0.63	3.01e-18	Tuberculosis;
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.52	4.73	0.36	5.03e-6	Total body bone mineral density;
PAAD	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg07220939	chr11:64358617	SLC22A12	-0.42	-4.26	-0.33	3.61e-5	Urate levels;
PAAD	cis	rs3018712	0.590	rs10791992	chr11:68489173	C/T	cg23009355	chr11:68451396	GAL	-0.44	-4.25	-0.33	3.75e-5	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.58	6.24	0.45	4.1e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg24699146	chr1:24152579	HMGCL	0.49	5.13	0.38	8.91e-7	Immature fraction of reticulocytes;
PAAD	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06850241	chr22:41845214	NA	0.56	4.9	0.37	2.41e-6	Vitiligo;
PAAD	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.84	8.58	0.57	1.03e-14	Hair shape;
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.55	-5.31	-0.4	3.88e-7	Tonsillectomy;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.39	-4.9	-0.37	2.42e-6	Longevity;Endometriosis;
PAAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg04738700	chr2:239367308	NA	0.47	5.14	0.39	8.15e-7	Multiple system atrophy;
PAAD	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.76	-7.72	-0.53	1.45e-12	Resting heart rate;
PAAD	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.45	-0.52	6.43e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.51	6.52	0.47	9.77e-10	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg24641125	chr21:40721130	HMGN1	0.62	6.46	0.46	1.33e-9	Body mass index;
PAAD	cis	rs17407555	0.955	rs56332418	chr4:10249535	C/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.78	-0.36	4.05e-6	Schizophrenia (age at onset);
PAAD	cis	rs3772130	0.649	rs57636696	chr3:121619464	A/T	cg20356878	chr3:121714668	ILDR1	0.59	5.66	0.42	7.28e-8	Cognitive performance;
PAAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.65	-6.32	-0.46	2.82e-9	Body mass index;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.49	-0.41	1.68e-7	Psoriasis;
PAAD	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.61	-5.79	-0.42	3.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.71	5.34	0.4	3.29e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-0.93	-6.28	-0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.63	-5.73	-0.42	5.19e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11141652	chr22:24348549	GSTTP1	0.53	4.97	0.37	1.78e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs490592	0.568	rs693603	chr11:116296243	A/G	cg13436940	chr11:116064295	NA	-0.74	-4.5	-0.34	1.33e-5	Brain structure;
PAAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg04844267	chr4:1394941	NA	0.53	5.85	0.43	2.91e-8	Obesity-related traits;
PAAD	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.45	4.39	0.34	2.1e-5	Type 2 diabetes;
PAAD	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.69	-0.36	5.97e-6	Total cholesterol levels;
PAAD	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	7.89	0.54	5.48e-13	Hemoglobin concentration;
PAAD	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.17	-0.6	3.08e-16	Exhaled nitric oxide output;
PAAD	cis	rs12989701	0.877	rs7557280	chr2:127873161	T/A	cg00091827	chr2:127863656	BIN1	0.59	4.32	0.33	2.78e-5	Alzheimer's disease (late onset);
PAAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.86	-7.42	-0.52	7.91e-12	Recombination rate (females);
PAAD	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-10.11	-0.63	1.04e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.59	5.75	0.42	4.7e-8	Prudent dietary pattern;
PAAD	cis	rs7567389	0.719	rs1011019	chr2:128037560	A/G	cg11380483	chr2:127933992	NA	-0.47	-4.67	-0.35	6.58e-6	Self-rated health;
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg18612461	chr15:75251733	NA	-0.58	-7.5	-0.52	4.93e-12	Breast cancer;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.83	-9.94	-0.63	3.07e-18	Coronary artery disease;
PAAD	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg19090574	chr1:205240910	TMCC2	-0.43	-4.66	-0.35	6.8e-6	Red blood cell count;
PAAD	cis	rs2242420	0.704	rs10917026	chr1:21961995	A/G	cg26362272	chr1:22108717	USP48	0.54	4.56	0.35	1.07e-5	Hematological and biochemical traits;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05025164	chr4:1340916	KIAA1530	-0.56	-5.48	-0.41	1.74e-7	Obesity-related traits;
PAAD	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.85	0.58	2.07e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Body mass index;
PAAD	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01446612	chr12:125510168	BRI3BP	-0.68	-6.72	-0.48	3.4e-10	Obesity-related traits;
PAAD	cis	rs1448094	0.558	rs7485285	chr12:86483641	G/A	cg06740227	chr12:86229804	RASSF9	-0.53	-4.79	-0.36	3.91e-6	Major depressive disorder;
PAAD	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.76	-0.48	2.71e-10	Coronary artery disease;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.61	7.34	0.51	1.19e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs747650	0.504	rs4752816	chr11:46979023	A/G	cg19486271	chr11:47235900	DDB2	-0.64	-6.11	-0.44	7.9e-9	Acne (severe);
PAAD	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.19	0.6	2.86e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg20913747	chr6:44695427	NA	-0.59	-6.59	-0.47	6.98e-10	Total body bone mineral density;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	8.73	0.58	4.21e-15	Lymphocyte counts;
PAAD	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.4	0.46	1.85e-9	Triglyceride levels;
PAAD	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18089569	chr11:14996490	NA	-0.61	-7.65	-0.53	2.1e-12	Body fat percentage;
PAAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.27e-7	Electroencephalogram traits;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg21929781	chr1:2537748	MMEL1	0.48	5.14	0.38	8.49e-7	Ulcerative colitis;
PAAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.83	9.61	0.61	2.18e-17	Tuberculosis;
PAAD	cis	rs7116495	0.867	rs510925	chr11:71809500	C/T	cg10381502	chr11:71823885	C11orf51	1.07	4.98	0.37	1.72e-6	Severe influenza A (H1N1) infection;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-6.18	-0.45	5.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.75	-6.73	-0.48	3.25e-10	Blood protein levels;
PAAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.42	0.46	1.66e-9	Personality dimensions;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04534503	chr16:1432422	NA	0.57	6.67	0.48	4.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg26876637	chr1:152193138	HRNR	-0.87	-6.5	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.47	0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17949255	chr17:48942907	TOB1	-0.75	-6.58	-0.47	7.13e-10	Neuroticism;
PAAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg03303774	chr4:1407052	NA	0.48	6.02	0.44	1.27e-8	Obesity-related traits;
PAAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.62	6.09	0.44	9.06e-9	Multiple sclerosis;
PAAD	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.62	-5.0	-0.38	1.54e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.89	-0.43	2.44e-8	Tonsillectomy;
PAAD	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.96	11.26	0.67	8.93e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1144	0.537	rs2470940	chr7:104581974	A/C	cg04380332	chr7:105027541	SRPK2	-0.65	-6.92	-0.49	1.17e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.95	-10.16	-0.64	8.01e-19	Cancer (pleiotropy);
PAAD	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.06	0.5	5.47e-11	Eosinophil percentage of white cells;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00350885	chr7:50860872	GRB10	-0.63	-6.28	-0.45	3.3e-9	Smoking initiation;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.49	4.92	0.37	2.26e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg18367735	chr17:79674897	NA	0.95	7.44	0.52	6.98e-12	Dental caries;
PAAD	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs12144094	0.882	rs11577560	chr1:120229865	A/G	cg20995928	chr1:120229863	NA	0.49	4.55	0.35	1.11e-5	Height;
PAAD	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs72827839	0.681	rs76811231	chr17:46476403	C/A	cg23391107	chr17:45924227	SP6	0.56	5.37	0.4	2.88e-7	Ease of getting up in the morning;
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg12193833	chr17:30244370	NA	-0.66	-5.29	-0.39	4.18e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.67	0.35	6.66e-6	Menopause (age at onset);
PAAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.49	-5.01	-0.38	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.51	-5.52	-0.41	1.42e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.78	-6.46	-0.46	1.36e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02158565	chr7:150788256	AGAP3	-0.56	-6.51	-0.47	1.02e-9	Immature fraction of reticulocytes;
PAAD	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.56	-5.6	-0.41	9.67e-8	Coronary artery disease;
PAAD	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg07777115	chr5:623756	CEP72	-0.47	-4.28	-0.33	3.23e-5	Cystic fibrosis severity;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01246421	chr22:18632905	USP18	-0.56	-6.32	-0.46	2.73e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.51	-6.04	-0.44	1.12e-8	Mean arterial pressure;
PAAD	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	0.68	4.8	0.36	3.77e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs7945718	0.591	rs7102432	chr11:12700132	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.57	0.35	1.02e-5	Educational attainment (years of education);
PAAD	cis	rs2271001	0.869	rs4757759	chr11:19155219	A/G	cg00161556	chr11:19138045	ZDHHC13	0.51	5.41	0.4	2.38e-7	Gut microbiome composition (winter);
PAAD	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg17947172	chr1:204966197	NFASC	0.41	4.35	0.33	2.51e-5	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.76	-6.31	-0.46	2.88e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.73	7.36	0.51	1.1e-11	Colorectal cancer;
PAAD	cis	rs4455778	0.580	rs4273799	chr7:49079809	T/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.43	4.91	0.37	2.28e-6	Psoriasis;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.86	10.7	0.66	2.9e-20	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7707921	0.881	rs60733727	chr5:81448283	G/A	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.43	0.34	1.82e-5	Mean corpuscular volume;
PAAD	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs73086581	0.947	rs56123574	chr20:3878081	C/G	cg02187196	chr20:3869020	PANK2	0.62	5.07	0.38	1.14e-6	Response to antidepressants in depression;
PAAD	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.68	9.03	0.59	7.03e-16	Hemoglobin concentration;
PAAD	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.7	-8.0	-0.54	2.97e-13	Bladder cancer;
PAAD	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.48	-0.34	1.46e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.6	6.29	0.45	3.24e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.81	-9.36	-0.6	1.02e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9810890	1.000	rs73198849	chr3:128507879	G/C	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.98	9.9	0.63	3.8e-18	Corneal astigmatism;
PAAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.64	6.6	0.47	6.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg07068956	chr7:100330872	ZAN	0.54	4.94	0.37	2.06e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.69	7.91	0.54	4.95e-13	Parkinson's disease;
PAAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.35	0.4	3.19e-7	Personality dimensions;
PAAD	cis	rs9900972	0.918	rs2889530	chr17:76878706	C/T	cg20937029	chr17:76870563	TIMP2	0.58	5.17	0.39	7.15e-7	Obesity-related traits;
PAAD	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.37	9.39	0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs508970	0.556	rs1783873	chr11:60922835	G/A	cg24692310	chr11:60915630	VPS37C	0.33	4.63	0.35	7.69e-6	Rheumatoid arthritis;
PAAD	cis	rs11811982	0.793	rs116838175	chr1:227442373	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs75920871	0.800	rs11826742	chr11:116924366	C/G	cg04087571	chr11:116723030	SIK3	-0.46	-5.81	-0.43	3.58e-8	Subjective well-being;
PAAD	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	5.55	0.41	1.26e-7	Mood instability;
PAAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.8	-0.53	8.95e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	6.18	0.45	5.72e-9	Lung cancer in ever smokers;
PAAD	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-8.04	-0.55	2.37e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.85	8.89	0.58	1.67e-15	Corneal astigmatism;
PAAD	cis	rs883565	0.696	rs7620304	chr3:39079623	T/A	cg01426195	chr3:39028469	NA	-0.7	-7.43	-0.52	7.5e-12	Handedness;
PAAD	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.65	6.74	0.48	3.13e-10	Hemoglobin concentration;
PAAD	cis	rs72960926	0.744	rs72959653	chr6:75012112	C/T	cg03266952	chr6:74778945	NA	-1.13	-6.26	-0.45	3.68e-9	Metabolite levels (MHPG);
PAAD	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs7527798	1.000	rs12744104	chr1:207819000	G/A	cg05831823	chr1:207627978	CR2	-0.53	-4.33	-0.33	2.7e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs2882667	0.690	rs6890932	chr5:138246328	G/A	cg09476006	chr5:138032270	NA	0.47	5.93	0.43	1.97e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg08648136	chr8:956695	NA	0.5	5.37	0.4	2.91e-7	Schizophrenia;
PAAD	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.46	4.68	0.35	6.37e-6	Breast cancer;
PAAD	cis	rs795484	0.926	rs383371	chr12:118625251	C/G	cg16572268	chr12:118583242	PEBP1	0.43	4.36	0.33	2.41e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.83	-9.93	-0.63	3.16e-18	Coronary artery disease;
PAAD	cis	rs72627123	1.000	rs72627122	chr14:74368236	A/G	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	cis	rs908922	0.962	rs4240882	chr1:152456358	G/C	cg21823605	chr1:152486609	CRCT1	0.5	5.78	0.42	4.05e-8	Hair morphology;
PAAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.69	7.44	0.52	6.79e-12	Melanoma;
PAAD	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7172689	0.908	rs11637313	chr15:81567752	C/A	cg05624577	chr15:81411055	NA	-0.57	-4.32	-0.33	2.77e-5	Inattentive symptoms;
PAAD	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.67	-0.77	6.55e-31	Height;
PAAD	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9815354	1.000	rs1716668	chr3:41907850	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-4.76	-0.36	4.45e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.22	21.24	0.86	2.36e-47	Testicular germ cell tumor;
PAAD	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg01047959	chr19:17666446	GLT25D1	0.49	4.37	0.33	2.32e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg02683114	chr2:24398427	C2orf84	-0.52	-5.09	-0.38	1.07e-6	Asthma;
PAAD	cis	rs790123	0.842	rs2650958	chr3:122396187	A/T	cg17380795	chr3:122379686	NA	0.52	5.39	0.4	2.68e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs2241685	0.646	rs7588882	chr2:1931058	A/G	cg22511877	chr2:1942942	MYT1L	-0.58	-4.58	-0.35	9.75e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs3764400	0.567	rs4995899	chr17:46150730	G/A	cg24322968	chr17:46507895	SKAP1	0.87	5.3	0.39	4.06e-7	Body mass index;
PAAD	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.25	-0.33	3.66e-5	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07893149	chr3:186285238	TBCCD1	0.46	4.71	0.36	5.46e-6	Myopia (pathological);
PAAD	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	1.16	6.12	0.44	7.71e-9	Skin colour saturation;
PAAD	cis	rs66530629	0.874	rs6600274	chr1:25162444	T/G	cg01905478	chr1:25040257	NA	-0.55	-6.1	-0.44	8.26e-9	Plateletcrit;
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg16040993	chr19:53496440	ZNF702P	-0.47	-4.66	-0.35	6.78e-6	Psoriasis;
PAAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg04106633	chr4:1044584	NA	0.66	5.46	0.4	1.9e-7	Recombination rate (females);
PAAD	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg24375607	chr4:120327624	NA	0.42	4.28	0.33	3.26e-5	Diastolic blood pressure;
PAAD	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	1.16	7.25	0.51	1.99e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6137287	0.813	rs6075780	chr20:21217621	G/A	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.46	0.4	1.91e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.57	6.49	0.47	1.17e-9	Major depressive disorder;
PAAD	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.22	-13.5	-0.74	8.48e-28	Hip circumference adjusted for BMI;
PAAD	cis	rs75920871	1.000	rs7130531	chr11:116863833	C/T	cg04087571	chr11:116723030	SIK3	-0.43	-4.54	-0.35	1.13e-5	Subjective well-being;
PAAD	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.58	-6.39	-0.46	1.96e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.59	-0.41	1.02e-7	Common traits (Other);
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg20639618	chr4:183729073	NA	0.66	5.48	0.41	1.74e-7	Pediatric autoimmune diseases;
PAAD	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	4.9	0.37	2.48e-6	Bone mineral density;
PAAD	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.41	-0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg25200586	chr1:148000763	NA	-0.62	-6.48	-0.47	1.23e-9	Hip geometry;
PAAD	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11124272	0.951	rs6748639	chr2:31922672	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-4.71	-0.36	5.45e-6	Interleukin-18 levels;
PAAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg05373962	chr22:49881684	NA	-0.44	-4.62	-0.35	8.07e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09820084	chr6:18387507	RNF144B	0.67	7.83	0.54	7.94e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07157834	chr1:205819609	PM20D1	0.53	5.09	0.38	1.05e-6	Parkinson's disease;
PAAD	cis	rs11235843	0.778	rs72976852	chr11:73442650	T/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.65	-4.46	-0.34	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24295551	chr3:51422506	MANF	0.6	6.59	0.47	6.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.58	6.18	0.45	5.73e-9	Lung cancer;
PAAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs1847202	1.000	rs7610496	chr3:72926390	A/G	cg25664220	chr3:72788482	NA	-0.46	-4.9	-0.37	2.46e-6	Motion sickness;
PAAD	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1359582	0.801	rs1555839	chr10:90382820	C/T	cg15661332	chr10:90342814	RNLS	0.54	4.69	0.36	6.08e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.81	9.98	0.63	2.32e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg25558440	chr8:11882962	NA	0.44	4.36	0.33	2.42e-5	Retinal vascular caliber;
PAAD	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26926768	chr12:34528122	NA	0.4	4.96	0.37	1.85e-6	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.5	0.41	1.55e-7	Orofacial clefts;
PAAD	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.73	7.12	0.5	3.98e-11	Asthma;
PAAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-9.98	-0.63	2.43e-18	Cognitive function;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.97e-10	Platelet distribution width;
PAAD	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.52	-4.58	-0.35	9.61e-6	Schizophrenia;
PAAD	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg12310025	chr6:25882481	NA	-0.47	-4.43	-0.34	1.76e-5	Blood metabolite levels;
PAAD	cis	rs9815354	0.951	rs4616614	chr3:41753648	T/G	cg03022575	chr3:42003672	ULK4	0.84	6.09	0.44	8.73e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3996993	0.809	rs6917325	chr6:52666273	A/G	cg20803780	chr6:52668592	GSTA1	-0.35	-4.48	-0.34	1.47e-5	Hemoglobin concentration;
PAAD	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg08975724	chr8:8085496	FLJ10661	0.51	4.97	0.37	1.76e-6	Neuroticism;
PAAD	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg16736954	chr20:23401023	NAPB	-0.74	-4.27	-0.33	3.47e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22971415	chr2:88355312	KRCC1	-0.82	-7.25	-0.51	2.01e-11	Neuroticism;
PAAD	cis	rs2599510	0.811	rs2243844	chr2:32775984	G/T	cg02381751	chr2:32503542	YIPF4	0.53	5.48	0.41	1.77e-7	Interleukin-18 levels;
PAAD	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	10.53	0.65	8.25e-20	Homoarginine levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00450571	chr11:10716455	MRVI1	0.65	6.66	0.48	4.81e-10	Smoking initiation;
PAAD	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.73	0.36	5.03e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs77633900	0.881	rs1875883	chr15:76638231	C/T	cg21673338	chr15:77095150	SCAPER	-0.87	-4.42	-0.34	1.91e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg25834613	chr7:1915315	MAD1L1	-0.47	-4.27	-0.33	3.42e-5	Bipolar disorder;
PAAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.94	6.43	0.46	1.54e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.25	-0.39	5.03e-7	Height;
PAAD	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.85	0.37	3.05e-6	Schizophrenia;
PAAD	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.72	7.88	0.54	5.69e-13	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	6.02	0.44	1.25e-8	Platelet count;
PAAD	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg15590007	chr10:45870220	ALOX5	-0.57	-5.85	-0.43	2.94e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs2139634	1.000	rs10514713	chr3:46543617	G/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.3	4.4	0.34	2e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.56	-0.47	7.93e-10	Chronic sinus infection;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	6.85	0.49	1.71e-10	Lymphocyte counts;
PAAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg21130718	chr4:1044621	NA	-0.54	-4.66	-0.35	6.93e-6	Recombination rate (females);
PAAD	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	trans	rs3131085	1	rs3131085	chr6:29044701	G/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.83	-9.51	-0.61	4.18e-17	Prudent dietary pattern;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03771739	chr10:22826164	PIP4K2A	-0.41	-4.51	-0.34	1.28e-5	Monocyte percentage of white cells;
PAAD	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.41	5.07	0.38	1.14e-6	Pulmonary function;
PAAD	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg06217245	chr20:33103252	DYNLRB1	0.45	5.23	0.39	5.53e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15212821	chr22:44395017	PARVB	-0.65	-6.61	-0.47	6.06e-10	Obesity-related traits;
PAAD	cis	rs11997175	0.656	rs2350007	chr8:33585353	C/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.57	0.47	7.51e-10	Body mass index;
PAAD	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg18110333	chr6:292329	DUSP22	0.63	6.5	0.47	1.11e-9	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg11143131	chr5:131608246	PDLIM4	-0.46	-4.69	-0.36	5.98e-6	Blood metabolite levels;
PAAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.41	4.88	0.37	2.65e-6	Tonsillectomy;
PAAD	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg10395934	chr14:104002654	TRMT61A	0.53	5.03	0.38	1.39e-6	Body mass index;
PAAD	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-5.31	-0.4	3.89e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.45e-9	Schizophrenia;
PAAD	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg19486271	chr11:47235900	DDB2	0.6	5.95	0.43	1.79e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1198430	0.500	rs968280	chr1:23801965	A/T	cg27447006	chr1:23763279	ASAP3	0.63	5.46	0.4	1.93e-7	Total cholesterol levels;
PAAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.62	-7.48	-0.52	5.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.87	7.39	0.51	9.2e-12	Alzheimer's disease;
PAAD	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg04990556	chr1:26633338	UBXN11	0.67	4.96	0.37	1.85e-6	Obesity-related traits;
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	trans	rs11794666	0.799	rs11788394	chr9:31738785	G/A	cg05628366	chr6:35744188	C6orf126	0.95	6.7	0.48	3.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.5	0.41	1.55e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg19337854	chr7:99768885	GPC2	0.5	4.72	0.36	5.31e-6	Platelet count;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.29	0.64	3.48e-19	Menopause (age at onset);
PAAD	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg20169779	chr10:135381914	SYCE1	-0.45	-4.66	-0.35	7e-6	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg00531865	chr16:30841666	NA	-0.52	-5.08	-0.38	1.09e-6	Dementia with Lewy bodies;
PAAD	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.69	6.66	0.48	4.74e-10	Type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.03e-9	Monobrow;
PAAD	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.47	4.62	0.35	8.18e-6	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.56	-0.41	1.2e-7	Lung cancer;
PAAD	cis	rs66530629	0.874	rs10903106	chr1:25148686	G/A	cg01905478	chr1:25040257	NA	-0.48	-5.24	-0.39	5.38e-7	Plateletcrit;
PAAD	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.0	-0.38	1.59e-6	Mean corpuscular volume;
PAAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.64	-8.38	-0.56	3.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10626959	chr7:4800797	FOXK1	0.66	6.4	0.46	1.87e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1572438	1.000	rs1572438	chr6:858970	A/G	cg13447295	chr6:887704	NA	0.5	4.61	0.35	8.43e-6	Aging;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.74	9.05	0.59	6.42e-16	Lung cancer;
PAAD	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg23995914	chr4:10459228	ZNF518B	-0.4	-4.79	-0.36	3.9e-6	Schizophrenia (age at onset);
PAAD	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg05250797	chr16:70222502	NA	-0.83	-6.36	-0.46	2.29e-9	IgE levels;
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg00106254	chr7:1943704	MAD1L1	-0.59	-5.79	-0.43	3.87e-8	Testicular germ cell tumor;
PAAD	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.28	0.51	1.69e-11	Eye color traits;
PAAD	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	1.16	9.89	0.63	4.04e-18	Height;
PAAD	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg03999872	chr20:62272968	STMN3	-0.61	-5.43	-0.4	2.18e-7	Atopic dermatitis;
PAAD	cis	rs17534004	1.000	rs71436418	chr13:31455888	G/A	cg00570269	chr13:31480942	C13orf33	0.58	4.4	0.34	1.99e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg05313129	chr8:58192883	C8orf71	-0.44	-4.25	-0.33	3.65e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs7804356	0.651	rs1023712	chr7:26803163	A/C	cg03456212	chr7:26904342	SKAP2	-0.57	-4.86	-0.37	2.95e-6	Type 1 diabetes;
PAAD	cis	rs761746	0.543	rs5998122	chr22:32173053	G/A	cg01338084	chr22:32026380	PISD	0.58	5.01	0.38	1.5e-6	Intelligence;
PAAD	cis	rs61759167	1.000	rs2376495	chr1:3095126	C/G	cg22396632	chr1:3079212	PRDM16	0.54	5.13	0.38	8.79e-7	Motion sickness;
PAAD	cis	rs2153535	0.518	rs9406187	chr6:8654609	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	4.34	0.33	2.58e-5	Motion sickness;
PAAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.5	0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2882667	0.690	rs6880786	chr5:138181563	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12284171	chr11:129814770	PRDM10	-0.56	-6.49	-0.47	1.14e-9	Monocyte percentage of white cells;
PAAD	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.82	7.34	0.51	1.21e-11	Waist circumference;
PAAD	cis	rs13273891	1.000	rs13268233	chr8:58986367	G/T	cg05901852	chr8:59757290	TOX	0.48	4.47	0.34	1.49e-5	Pit-and-Fissure caries;
PAAD	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.77	6.42	0.46	1.62e-9	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09719331	chr20:44486197	ZSWIM3;ACOT8	-0.62	-6.45	-0.46	1.43e-9	Smoking initiation;
PAAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.38e-12	Height;
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.67	0.62	1.52e-17	Platelet count;
PAAD	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.71	7.32	0.51	1.32e-11	Anterior chamber depth;
PAAD	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs300774	0.925	rs300727	chr2:132469	C/A	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.55	5.17	0.39	7.14e-7	White matter hyperintensity burden;
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg02071572	chr4:1403502	NA	0.41	5.17	0.39	7.2e-7	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.66	-0.53	2.05e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs282587	0.597	rs390177	chr13:113413033	A/G	cg02820901	chr13:113351484	ATP11A	-0.65	-5.17	-0.39	7.26e-7	Glycated hemoglobin levels;
PAAD	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12394067	chr5:90679220	LOC100129716;ARRDC3	-0.56	-6.45	-0.46	1.41e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.81	9.35	0.6	1.06e-16	Metabolic syndrome;
PAAD	cis	rs6782228	0.883	rs6439142	chr3:128420557	G/A	cg15607142	chr3:128420513	NA	-0.43	-4.79	-0.36	3.85e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg05457628	chr5:178986728	RUFY1	0.49	4.69	0.36	6.05e-6	Lung cancer;
PAAD	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg25620797	chr2:55921863	PNPT1	-0.52	-5.09	-0.38	1.03e-6	Metabolic syndrome;
PAAD	cis	rs3812111	0.545	rs2235980	chr6:116565504	G/A	cg05304507	chr6:116381966	FRK	-0.26	-4.32	-0.33	2.8e-5	Age-related macular degeneration;
PAAD	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg20019720	chr6:154832845	CNKSR3	0.68	8.71	0.58	4.75e-15	Lipoprotein (a) levels;
PAAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.48	-0.34	1.44e-5	Aortic root size;
PAAD	trans	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg00717180	chr2:96193071	NA	-0.62	-6.61	-0.47	6.2e-10	Migraine - clinic-based;
PAAD	cis	rs8005677	0.828	rs12437151	chr14:23372913	G/A	cg01529538	chr14:23388837	RBM23	0.46	4.5	0.34	1.33e-5	Cognitive ability (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg23024343	chr7:107201750	COG5	0.57	4.69	0.36	6.08e-6	Coronary artery disease;
PAAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg05110241	chr16:68378359	PRMT7	-0.83	-6.84	-0.49	1.8e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.36	-0.33	2.39e-5	Fear of minor pain;
PAAD	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.62	6.02	0.44	1.24e-8	Alcohol dependence;
PAAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.58	5.75	0.42	4.84e-8	Longevity;
PAAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.21	-0.55	8.67e-14	Height;
PAAD	cis	rs7631605	0.905	rs11916897	chr3:37211128	C/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.56	0.61	2.93e-17	Diabetic retinopathy;
PAAD	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg20936604	chr3:58311152	NA	-0.79	-4.83	-0.36	3.37e-6	Cholesterol, total;
PAAD	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.0	0.38	1.53e-6	Educational attainment;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg08088566	chr11:430123	ANO9	0.86	5.45	0.4	2.02e-7	Body mass index;
PAAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	8.48	0.57	1.85e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.51	-5.62	-0.42	8.71e-8	Testicular germ cell tumor;
PAAD	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.56	-6.14	-0.45	6.94e-9	Testicular germ cell tumor;
PAAD	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.42	0.46	1.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.67	-9.28	-0.6	1.64e-16	Birth weight;
PAAD	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs755249	0.567	rs61779308	chr1:39938257	C/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.74	-0.36	4.78e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.38	-0.33	2.23e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.81	-6.04	-0.44	1.15e-8	Coronary artery calcification;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03629926	chr19:8438839	ANGPTL4	0.55	6.34	0.46	2.45e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs76866386	1.000	rs4953023	chr2:44074000	C/T	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.95	-5.72	-0.42	5.55e-8	Cholesterol, total;
PAAD	cis	rs6494488	0.500	rs7165925	chr15:64985604	A/G	cg16425858	chr15:64791681	ZNF609	-0.89	-5.06	-0.38	1.2e-6	Coronary artery disease;
PAAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg09796270	chr17:17721594	SREBF1	-0.48	-5.33	-0.4	3.51e-7	Total body bone mineral density;
PAAD	trans	rs901683	0.867	rs71496625	chr10:46086649	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.63	-5.64	-0.42	8.08e-8	Response to antineoplastic agents;
PAAD	cis	rs427941	0.667	rs201436	chr7:101733576	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.65	0.35	7.09e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg18551225	chr6:44695536	NA	-0.7	-6.96	-0.49	9.42e-11	Total body bone mineral density;
PAAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.38e-12	Height;
PAAD	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.03	-0.5	6.65e-11	Alcohol dependence;
PAAD	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	4.58	0.35	9.52e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8077577	0.836	rs58441148	chr17:18106498	T/A	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.65	-8.27	-0.56	6.32e-14	Inflammatory bowel disease;
PAAD	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.66	4.41	0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.64	-0.35	7.62e-6	Total body bone mineral density;
PAAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg14349672	chr11:133703707	NA	-0.55	-6.37	-0.46	2.18e-9	Childhood ear infection;
PAAD	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14216029	chr19:42901307	NA	-0.76	-6.54	-0.47	8.73e-10	Neuroticism;
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	4.89	0.37	2.57e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	5.37	0.4	2.88e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.62	-6.04	-0.44	1.15e-8	Systolic blood pressure;
PAAD	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17599958	chr11:993718	AP2A2	0.63	7.72	0.53	1.45e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2415984	0.509	rs4506807	chr14:46794059	G/A	cg14871534	chr14:47121158	RPL10L	-0.48	-5.29	-0.39	4.19e-7	Number of children ever born;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.87	0.72	4.07e-26	Platelet count;
PAAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.57	5.48	0.41	1.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.8	-0.36	3.8e-6	Schizophrenia;
PAAD	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg19980929	chr12:42632907	YAF2	0.57	6.77	0.48	2.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.58	6.52	0.47	9.81e-10	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg01299579	chr2:10830716	NOL10	0.57	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.65	6.74	0.48	3.16e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg25251562	chr2:3704773	ALLC	-0.56	-6.49	-0.47	1.12e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.72	8.49	0.57	1.76e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.47	4.46	0.34	1.6e-5	Mean platelet volume;
PAAD	cis	rs7567389	0.671	rs72845993	chr2:128108601	T/C	cg09760422	chr2:128146352	NA	0.38	6.06	0.44	1.04e-8	Self-rated health;
PAAD	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg12568669	chr8:11666485	FDFT1	-0.29	-4.56	-0.35	1.03e-5	Retinal vascular caliber;
PAAD	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.35	0.33	2.49e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.75	8.68	0.58	5.7e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-5.61	-0.41	9.23e-8	Total body bone mineral density;
PAAD	cis	rs7631605	0.905	rs9852386	chr3:37222329	G/A	cg17445812	chr3:36986805	TRANK1	0.33	4.47	0.34	1.54e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg14092988	chr3:52407081	DNAH1	0.41	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.75	8.59	0.57	9.63e-15	Morning vs. evening chronotype;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10766172	chr7:27498479	NA	0.58	6.49	0.47	1.17e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.71	-0.36	5.6e-6	Blood pressure;
PAAD	cis	rs72960926	1.000	rs16884858	chr6:75107741	C/A	cg03266952	chr6:74778945	NA	-1.04	-5.63	-0.42	8.51e-8	Metabolite levels (MHPG);
PAAD	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.79	0.58	3.06e-15	Colorectal cancer;
PAAD	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg02404636	chr22:31891804	SFI1	0.64	6.19	0.45	5.36e-9	Colorectal cancer;
PAAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs35740288	0.640	rs11632164	chr15:86109539	A/G	cg07943548	chr15:86304357	KLHL25	-0.58	-5.97	-0.44	1.6e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.52	0.34	1.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs11992162	0.636	rs113416335	chr8:11809421	C/T	cg00262122	chr8:11665843	FDFT1	-0.49	-4.39	-0.34	2.1e-5	Monocyte count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09597616	chr11:107729479	SLC35F2	0.66	7.17	0.5	3.04e-11	Myopia (pathological);
PAAD	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.27	-0.33	3.36e-5	Systemic lupus erythematosus;
PAAD	cis	rs1642645	0.793	rs642579	chr1:42431397	C/T	cg01990334	chr1:42801334	FOXJ3	-0.65	-5.78	-0.42	4.1e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6137287	0.889	rs4813414	chr20:21133212	A/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.43	0.34	1.78e-5	Height;
PAAD	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.62	-4.57	-0.35	9.96e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg07671805	chr5:74907694	NA	0.57	4.44	0.34	1.75e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	0.850	rs73196955	chr3:128430599	C/A	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-1.05	-13.0	-0.73	1.84e-26	Breast cancer;
PAAD	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.67	6.31	0.46	2.94e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.7	6.82	0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.5	0.41	1.56e-7	Alzheimer's disease (late onset);
PAAD	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.62	-5.64	-0.42	7.91e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.29	-0.45	3.13e-9	Hip circumference;
PAAD	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.56	6.05	0.44	1.06e-8	Major depressive disorder;
PAAD	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.38	-0.4	2.74e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg10137597	chr8:22132714	PIWIL2	0.48	5.76	0.42	4.43e-8	Hypertriglyceridemia;
PAAD	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg20607287	chr7:12443886	VWDE	-0.73	-5.61	-0.41	9.38e-8	Coronary artery disease;
PAAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.46	4.82	0.36	3.4e-6	Menopause (age at onset);
PAAD	cis	rs4704187	0.687	rs4404660	chr5:74422210	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg04374321	chr14:90722782	PSMC1	0.53	4.3	0.33	3e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.8	9.18	0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	8.45	0.57	2.16e-14	Bone mineral density;
PAAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.9	-8.45	-0.57	2.24e-14	Asthma;
PAAD	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.55	0.35	1.1e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13560548	chr3:10150139	C3orf24	-0.6	-5.34	-0.4	3.29e-7	Alzheimer's disease;
PAAD	cis	rs6718203	1.000	rs1011406	chr2:60666075	C/G	cg10480506	chr2:60280451	NA	0.75	4.6	0.35	8.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10988802	0.673	rs2405068	chr9:98386311	G/A	cg16575184	chr9:99179480	ZNF367	-0.67	-4.82	-0.36	3.5e-6	Chemerin levels;
PAAD	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg24879335	chr3:133465180	TF	0.56	6.01	0.44	1.33e-8	Iron status biomarkers;
PAAD	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg21132104	chr15:45694354	SPATA5L1	0.54	4.83	0.37	3.24e-6	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.62	0.41	8.84e-8	Tonsillectomy;
PAAD	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.49	-0.47	1.16e-9	Alcohol dependence;
PAAD	cis	rs758324	0.773	rs630044	chr5:131258378	G/T	cg06307176	chr5:131281290	NA	0.52	4.48	0.34	1.46e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs16958440	0.867	rs12386076	chr18:44673340	T/C	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.38	-5.07	-0.38	1.14e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg05554000	chr7:158905015	VIPR2	0.49	4.26	0.33	3.62e-5	Facial morphology (factor 20);
PAAD	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-5.3	-0.39	4.01e-7	Bipolar disorder;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg20075270	chr10:46168220	ANUBL1	0.62	6.64	0.47	5.37e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4417704	0.551	rs56237031	chr2:241875360	C/A	cg26818257	chr2:241905806	NA	-0.52	-5.53	-0.41	1.39e-7	Joint mobility (Beighton score);
PAAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.49	-4.72	-0.36	5.37e-6	Multiple sclerosis;
PAAD	cis	rs72960926	1.000	rs16884731	chr6:75064418	A/G	cg13997649	chr6:74171430	MTO1	0.83	4.63	0.35	7.84e-6	Metabolite levels (MHPG);
PAAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.63	0.62	1.96e-17	Rheumatoid arthritis;
PAAD	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.64	0.62	1.9e-17	Bladder cancer;
PAAD	cis	rs12612619	0.732	rs893790	chr2:27201857	T/C	cg00617064	chr2:27272375	NA	0.52	5.51	0.41	1.47e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1497828	0.956	rs2646818	chr1:217525655	A/T	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-4.59	-0.35	9.28e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26850624	chr5:429559	AHRR	-0.79	-9.43	-0.61	6.75e-17	Cystic fibrosis severity;
PAAD	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.04	18.74	0.84	2.35e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg08992911	chr2:238395768	MLPH	0.91	6.48	0.47	1.18e-9	Prostate cancer;
PAAD	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05049329	chr1:226924846	ITPKB	0.51	6.62	0.47	5.71e-10	Parkinson's disease;
PAAD	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.54	5.36	0.4	3.06e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg03989125	chr22:38214979	NA	-0.62	-6.41	-0.46	1.74e-9	Glioblastoma;Glioma;
PAAD	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg01631408	chr1:248437212	OR2T33	-0.55	-4.64	-0.35	7.52e-6	Common traits (Other);
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.65	6.17	0.45	5.82e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2555155	0.935	rs10839567	chr11:6520664	G/A	cg24637308	chr11:6592297	DNHD1	0.48	4.94	0.37	2e-6	DNA methylation (variation);
PAAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.06	-0.44	1.02e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs13256369	0.671	rs57506062	chr8:8554535	G/A	cg17143192	chr8:8559678	CLDN23	0.68	6.47	0.46	1.25e-9	Obesity-related traits;
PAAD	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-5.15	-0.39	7.94e-7	Chronic sinus infection;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.4	4.31	0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.58	4.3	0.33	3.04e-5	Alzheimer's disease (survival time);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04575087	chr11:46867195	CKAP5	-0.6	-7.05	-0.5	5.83e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2562456	0.520	rs250001	chr19:21408189	A/G	cg08562672	chr19:21860753	NA	-0.47	-4.62	-0.35	8.01e-6	Pain;
PAAD	cis	rs78472555	0.739	rs11634364	chr15:100261042	G/A	cg18869061	chr15:100272053	LYSMD4	-0.62	-4.99	-0.38	1.61e-6	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.74	8.05	0.55	2.26e-13	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.7	7.51	0.52	4.74e-12	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.8	8.98	0.59	9.59e-16	Prudent dietary pattern;
PAAD	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.7	9.24	0.6	2.05e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27297192	chr10:134578999	INPP5A	0.53	5.11	0.38	9.75e-7	Migraine;
PAAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.55	-4.59	-0.35	9.16e-6	Coronary artery disease;
PAAD	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg07810366	chr2:100720526	AFF3	-0.37	-4.54	-0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13148126	chr17:8924759	NTN1	0.69	6.97	0.49	9.15e-11	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg26876637	chr1:152193138	HRNR	0.85	6.86	0.49	1.66e-10	Atopic dermatitis;
PAAD	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.69	-0.36	6.01e-6	Colorectal cancer;
PAAD	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg10596483	chr8:143751796	JRK	-0.49	-4.6	-0.35	8.88e-6	Urinary tract infection frequency;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26847109	chr2:141821182	LRP1B	-0.6	-6.44	-0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-4.84	-0.37	3.16e-6	Blood metabolite levels;
PAAD	cis	rs6136489	0.710	rs6132105	chr20:1923674	G/A	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg23465465	chr6:26364728	BTN3A2	0.55	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.65	7.59	0.52	2.96e-12	Vitiligo;
PAAD	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.71	6.11	0.44	8e-9	Interstitial lung disease;
PAAD	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg04450456	chr4:17643702	FAM184B	-0.44	-4.31	-0.33	2.92e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.55	6.36	0.46	2.25e-9	Total body bone mineral density;
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.82e-6	Lymphocyte counts;
PAAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.61	6.79	0.48	2.42e-10	Huntington's disease progression;
PAAD	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.87e-5	Total body bone mineral density;
PAAD	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg12560992	chr17:57184187	TRIM37	0.65	4.98	0.37	1.67e-6	Vitamin D levels;
PAAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.44	-4.34	-0.33	2.64e-5	Menarche (age at onset);
PAAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.82	-8.8	-0.58	2.88e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg10518543	chr12:38710700	ALG10B	0.52	4.92	0.37	2.26e-6	Heart rate;
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.79	-9.06	-0.59	6.16e-16	Body mass index;
PAAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2659067	1.000	rs2659067	chr19:51485622	A/G	cg26241993	chr19:51487245	KLK7	-0.75	-4.77	-0.36	4.3e-6	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.56	-4.88	-0.37	2.64e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg18721089	chr20:30220636	NA	-0.8	-6.51	-0.47	1.04e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg08975724	chr8:8085496	FLJ10661	0.64	6.24	0.45	4.15e-9	Mood instability;
PAAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.25	-0.81	1.27e-37	Height;
PAAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.51	-5.38	-0.4	2.82e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs6909834	0.636	rs1412740	chr6:12817590	A/G	cg17869960	chr6:12718530	PHACTR1	0.35	4.25	0.33	3.66e-5	Gait speed in old age;
PAAD	cis	rs9810890	1.000	rs114441742	chr3:128547271	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.45	-0.4	1.98e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10154626	chr10:121410473	BAG3	0.58	6.42	0.46	1.62e-9	Monocyte percentage of white cells;
PAAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.94	-0.49	1.04e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg14092988	chr3:52407081	DNAH1	0.4	4.75	0.36	4.75e-6	Bipolar disorder;
PAAD	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs3857067	0.550	rs113785667	chr4:94999566	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.5	-0.41	1.58e-7	QT interval;
PAAD	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.83	-9.44	-0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg12935359	chr14:103987150	CKB	-0.55	-5.72	-0.42	5.53e-8	Body mass index;
PAAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg03586839	chr1:150601711	ENSA	0.45	4.32	0.33	2.81e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2677744	0.719	rs12902422	chr15:91469846	T/C	cg23684204	chr15:91497937	RCCD1	0.58	4.68	0.36	6.25e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09065629	chr16:1709722	CRAMP1L	0.47	5.1	0.38	9.81e-7	Coronary artery disease;
PAAD	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg15128208	chr22:42549153	NA	0.52	4.34	0.33	2.55e-5	Birth weight;
PAAD	cis	rs4780401	0.728	rs7198518	chr16:11771094	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.9	-0.43	2.29e-8	Rheumatoid arthritis;
PAAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.65	7.37	0.51	1.01e-11	Height;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.77	-4.79	-0.36	3.93e-6	Body mass index;
PAAD	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26926768	chr12:34528122	NA	0.4	4.96	0.37	1.85e-6	Morning vs. evening chronotype;
PAAD	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	8.63	0.57	7.55e-15	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.6	0.57	8.96e-15	Coffee consumption (cups per day);
PAAD	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.0	14.06	0.75	2.69e-29	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08188400	chr19:7969347	MAP2K7	0.64	7.21	0.5	2.44e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6882716	0.636	rs10043680	chr5:10804522	A/G	cg14521931	chr5:10832172	NA	0.86	6.11	0.44	7.89e-9	Alcohol consumption (maxi-drinks);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00162541	chr19:16607016	C19orf44;CALR3	0.72	6.52	0.47	9.68e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs8067354	0.540	rs12600680	chr17:58037374	T/C	cg02344993	chr17:57696989	CLTC	0.55	4.46	0.34	1.57e-5	Hemoglobin concentration;
PAAD	cis	rs7542091	0.518	rs6675416	chr1:210061006	A/G	cg06375148	chr1:209958343	C1orf74	-0.45	-4.56	-0.35	1.06e-5	Monobrow;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.13	14.65	0.77	7.27e-31	Subjective well-being;
PAAD	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.82	-9.15	-0.6	3.46e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.87	-0.43	2.6e-8	Type 2 diabetes;
PAAD	cis	rs35160687	0.644	rs4832271	chr2:86505327	T/C	cg10973622	chr2:86423274	IMMT	-0.46	-5.12	-0.38	9.04e-7	Night sleep phenotypes;
PAAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	1.09	6.01	0.44	1.3e-8	Body mass index;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	1.71	9.48	0.61	4.78e-17	Height;
PAAD	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg12573791	chr2:3828286	NA	0.45	4.29	0.33	3.17e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg15770106	chr1:208133116	NA	-0.65	-6.52	-0.47	9.79e-10	Corneal structure;
PAAD	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs7932354	0.583	rs10769210	chr11:46872227	G/A	cg19486271	chr11:47235900	DDB2	-0.6	-5.72	-0.42	5.53e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs778371	0.722	rs778348	chr2:233802635	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.87	-0.43	2.59e-8	Schizophrenia;
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-4.55	-0.35	1.1e-5	Tonsillectomy;
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.64	-7.57	-0.52	3.34e-12	Mean corpuscular volume;
PAAD	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.47	-4.8	-0.36	3.82e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.36	4.4	0.34	2.07e-5	Calcium levels;
PAAD	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.49	-6.96	-0.49	9.72e-11	Homoarginine levels;
PAAD	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.66	-8.46	-0.57	2.12e-14	Birth weight;
PAAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg09695851	chr17:3907499	NA	0.81	8.2	0.55	9.61e-14	Type 2 diabetes;
PAAD	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg05562828	chr17:3906858	NA	0.61	6.88	0.49	1.46e-10	Type 2 diabetes;
PAAD	cis	rs2278796	0.608	rs6700069	chr1:204968945	A/G	cg04862289	chr1:204966208	NFASC	0.49	5.12	0.38	9.07e-7	Mean platelet volume;
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.24e-5	Skin colour saturation;
PAAD	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg10223061	chr2:219282414	VIL1	0.38	4.51	0.34	1.28e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.68	0.58	5.82e-15	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.49	4.94	0.37	2e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3136441	1.000	rs3136457	chr11:46746258	G/C	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg23461800	chr14:103021989	NA	0.6	4.71	0.36	5.66e-6	Platelet count;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg04106633	chr4:1044584	NA	0.62	5.18	0.39	7.1e-7	Recombination rate (females);
PAAD	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4834770	1.000	rs878374	chr4:120237564	A/G	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs1514658	0.903	rs7674055	chr4:119272958	T/C	cg23709618	chr4:119273073	PRSS12	0.31	4.37	0.33	2.31e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg08501292	chr6:25962987	TRIM38	0.98	5.33	0.4	3.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.76	-7.12	-0.5	3.94e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg08200582	chr11:442649	ANO9	0.56	4.68	0.36	6.17e-6	Systemic lupus erythematosus;
PAAD	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-5.86	-0.43	2.77e-8	Menopause (age at onset);
PAAD	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	trans	rs1406084	0.541	rs1372384	chr2:154630881	G/A	cg01088528	chr2:201753695	PPIL3;NIF3L1	0.98	6.42	0.46	1.68e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	5.54	0.41	1.29e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01997696	chr20:43374401	KCNK15	0.66	6.54	0.47	8.95e-10	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2393895	0.688	rs7073406	chr10:64335377	T/C	cg22582187	chr10:63394414	NA	-0.81	-4.28	-0.33	3.31e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19327137	chr7:38886074	VPS41	0.43	4.38	0.33	2.19e-5	Subjective well-being (multi-trait analysis);
PAAD	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.96	-0.37	1.9e-6	Personality dimensions;
PAAD	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.87	10.64	0.65	4.11e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.91	-9.85	-0.62	5.3e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.46	5.31	0.4	3.75e-7	Migraine;
PAAD	cis	rs2694528	0.609	rs1379112	chr5:59995742	C/A	cg11474532	chr5:59995715	DEPDC1B	1.0	5.6	0.41	9.87e-8	Parkinson's disease;
PAAD	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.62	6.3	0.46	3.01e-9	Migraine;
PAAD	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg03315344	chr16:75512273	CHST6	0.64	5.35	0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg19423196	chr10:82049429	MAT1A	0.59	4.36	0.33	2.41e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs72960926	0.744	rs72953763	chr6:74983753	G/C	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.72e-10	Metabolite levels (MHPG);
PAAD	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg27205649	chr11:78285834	NARS2	0.63	4.75	0.36	4.69e-6	Alzheimer's disease (survival time);
PAAD	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg21351543	chr2:191399470	TMEM194B	-0.7	-5.33	-0.4	3.47e-7	Diastolic blood pressure;
PAAD	cis	rs2790216	1.000	rs2590336	chr10:60010497	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg12658694	chr1:38397304	INPP5B	0.63	6.9	0.49	1.3e-10	Coronary artery disease;
PAAD	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg24565620	chr2:194026	NA	0.55	4.52	0.34	1.22e-5	Blood protein levels;
PAAD	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg22753661	chr15:79092743	ADAMTS7	0.51	4.34	0.33	2.62e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.61	0.35	8.49e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs838147	0.844	rs11672046	chr19:49247601	C/T	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.74	-6.53	-0.47	9.36e-10	Blood pressure (smoking interaction);
PAAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.76	7.29	0.51	1.6e-11	Corneal astigmatism;
PAAD	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.55	5.77	0.42	4.3e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg02683114	chr2:24398427	C2orf84	-0.61	-6.45	-0.46	1.43e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg05925327	chr15:68127851	NA	-0.62	-5.5	-0.41	1.59e-7	Obesity;
PAAD	cis	rs7853377	0.800	rs296888	chr9:86595498	G/A	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.07	-0.5	5.16e-11	Schizophrenia;
PAAD	cis	rs4662592	0.590	rs11892307	chr2:128863512	T/C	cg17144508	chr2:128283727	IWS1	-0.54	-4.25	-0.33	3.67e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.5	0.57	1.6e-14	Bipolar disorder;
PAAD	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg08992911	chr2:238395768	MLPH	-0.61	-5.2	-0.39	6.48e-7	Prostate cancer;
PAAD	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	1.01	12.63	0.72	1.89e-25	Testicular germ cell tumor;
PAAD	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg10560079	chr2:191398806	TMEM194B	-0.84	-6.78	-0.48	2.47e-10	Diastolic blood pressure;
PAAD	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg25902810	chr10:99078978	FRAT1	-0.64	-5.96	-0.44	1.68e-8	Monocyte count;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02396143	chr1:29063512	YTHDF2	0.58	6.82	0.48	2.02e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.9	5.54	0.41	1.32e-7	Alzheimer's disease;
PAAD	cis	rs621942	0.718	rs61907308	chr11:85736436	G/T	cg07180834	chr11:85838833	NA	-0.52	-5.16	-0.39	7.58e-7	Tourette syndrome;
PAAD	cis	rs9815354	1.000	rs9847006	chr3:41755359	T/C	cg03022575	chr3:42003672	ULK4	0.77	5.55	0.41	1.25e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.64	5.6	0.41	9.81e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.49	-0.41	1.64e-7	Blood metabolite levels;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-6.44	-0.46	1.52e-9	Lymphocyte counts;
PAAD	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.13	-0.67	2.08e-21	Ulcerative colitis;
PAAD	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.83	9.62	0.62	2.06e-17	Body mass index;
PAAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.47	4.87	0.37	2.81e-6	Major depressive disorder;
PAAD	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.4	-9.95	-0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.74	0.42	4.9e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg24618514	chr3:194868507	C3orf21	0.48	4.33	0.33	2.69e-5	Non-small cell lung cancer;
PAAD	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs6733011	0.628	rs6726156	chr2:99458607	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.65	-0.35	7.05e-6	Bipolar disorder;
PAAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.55	-7.55	-0.52	3.66e-12	Renal cell carcinoma;
PAAD	cis	rs12136530	0.593	rs4911989	chr1:19727743	C/G	cg03321592	chr1:19991676	HTR6	-0.51	-4.45	-0.34	1.66e-5	Lead levels in blood;
PAAD	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg12046867	chr14:103022105	NA	-0.65	-5.14	-0.38	8.28e-7	Platelet count;
PAAD	cis	rs4676482	0.578	rs784504	chr3:39195260	G/C	cg02254461	chr3:39195904	CSRNP1	-0.76	-6.72	-0.48	3.38e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2147959	0.714	rs6659690	chr1:228628170	A/G	cg00655913	chr1:228633920	NA	0.51	4.67	0.35	6.51e-6	Adult asthma;
PAAD	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.96	-0.44	1.72e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.88	13.1	0.73	1.04e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg17366294	chr4:99064904	C4orf37	0.46	5.03	0.38	1.35e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg19337854	chr7:99768885	GPC2	0.42	4.35	0.33	2.5e-5	Coronary artery disease;
PAAD	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.5	-0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-5.4	-0.4	2.51e-7	Obesity (extreme);
PAAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg18370025	chr7:2749541	AMZ1	-0.43	-5.28	-0.39	4.34e-7	Height;
PAAD	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	1.0	7.26	0.51	1.86e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs501916	0.575	rs56345741	chr15:48065010	A/C	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.59	5.73	0.42	5.12e-8	Orofacial clefts;
PAAD	cis	rs8070740	0.898	rs4605225	chr17:5324136	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.81	0.36	3.65e-6	Menopause (age at onset);
PAAD	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.35	4.74	0.36	4.82e-6	Schizophrenia;
PAAD	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg19567339	chr10:100142640	NA	-0.42	-4.59	-0.35	9.41e-6	Metabolite levels;
PAAD	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg04165759	chr1:150448943	RPRD2	0.5	5.17	0.39	7.4e-7	Migraine;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg09888468	chr15:81410853	NA	-0.53	-4.67	-0.35	6.64e-6	QT interval (drug interaction);
PAAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.63e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.27	-0.33	3.48e-5	Dupuytren's disease;
PAAD	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg08079166	chr15:68083412	MAP2K5	0.69	5.44	0.4	2.11e-7	Restless legs syndrome;
PAAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.92	-8.0	-0.54	2.87e-13	Gut microbiome composition (summer);
PAAD	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg19510604	chr15:74901076	CLK3	0.52	4.29	0.33	3.22e-5	Blood trace element (Zn levels);
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.09	0.44	8.86e-9	Schizophrenia;
PAAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.84	6.26	0.45	3.79e-9	Tuberculosis;
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg24044776	chr19:53454761	ZNF816A	0.52	5.76	0.42	4.5e-8	Psoriasis;
PAAD	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.76	-5.82	-0.43	3.38e-8	Coronary artery calcification;
PAAD	cis	rs17154702	0.506	rs28583936	chr8:8647160	C/T	cg01851573	chr8:8652454	MFHAS1	0.91	6.37	0.46	2.1e-9	Neurocognitive impairment in HIV-1 infection (continuous);
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.6	8.17	0.55	1.13e-13	Primary biliary cholangitis;
PAAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.23	-0.51	2.22e-11	Breast cancer;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg11062466	chr8:58055876	NA	0.69	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21554501	chr17:38474539	RARA	0.57	6.38	0.46	2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg16444942	chr12:129309117	SLC15A4	-0.7	-4.26	-0.33	3.53e-5	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17093401	chr10:44070178	ZNF239	0.69	6.97	0.49	9.09e-11	Obesity-related traits;
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.56	7.17	0.5	3.09e-11	Body mass index;
PAAD	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.79	6.69	0.48	4.09e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.75	-0.42	4.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7618915	0.962	rs2272088	chr3:52456973	A/G	cg14092988	chr3:52407081	DNAH1	0.61	7.63	0.53	2.39e-12	Bipolar disorder;
PAAD	cis	rs5756391	0.568	rs4821570	chr22:37317177	C/G	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.73	8.38	0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.39	-8.02	-0.55	2.69e-13	Mean corpuscular volume;
PAAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02244288	chr16:89573955	SPG7	-0.3	-4.25	-0.33	3.72e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.57	-0.41	1.12e-7	Monocyte percentage of white cells;
PAAD	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.85	10.97	0.66	5.41e-21	Aortic root size;
PAAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg05697835	chr1:2722811	NA	0.39	4.28	0.33	3.29e-5	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs2492906	0.600	rs2815493	chr10:28077000	C/T	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.54	4.92	0.37	2.22e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs3747547	0.710	rs2091415	chr9:37951176	T/C	cg13774184	chr9:37916125	SHB	-0.6	-4.44	-0.34	1.75e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg17201900	chr20:34330562	RBM39	0.62	4.32	0.33	2.85e-5	Total cholesterol levels;
PAAD	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	-0.44	-4.3	-0.33	3e-5	Lung cancer;
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.72	-8.33	-0.56	4.53e-14	Iron status biomarkers;
PAAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14180030	chr9:123475675	MEGF9	-0.43	-5.07	-0.38	1.13e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11871801	0.881	rs2071046	chr17:40689613	G/C	cg21692620	chr17:40835849	CNTNAP1	0.49	5.01	0.38	1.5e-6	Crohn's disease;
PAAD	cis	rs9467603	0.858	rs1937126	chr6:25769608	G/C	cg23465465	chr6:26364728	BTN3A2	-0.69	-4.47	-0.34	1.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2688419	0.527	rs1355740	chr3:23070957	C/T	cg00327796	chr3:23032191	NA	0.47	4.66	0.35	6.94e-6	Type 2 diabetes;
PAAD	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs2279817	0.735	rs11580813	chr1:17981913	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.6	5.73	0.42	5.16e-8	Neuroticism;
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.92	12.24	0.7	2.06e-24	Heart rate;
PAAD	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.71	6.86	0.49	1.67e-10	Platelet count;
PAAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	cis	rs10501293	0.746	rs1544871	chr11:43054122	T/C	cg03447554	chr11:43094025	NA	0.46	4.28	0.33	3.24e-5	Cognitive performance;
PAAD	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg08835956	chr7:39171034	POU6F2	0.28	5.07	0.38	1.17e-6	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg06236206	chr7:66120395	NA	-0.51	-4.25	-0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.41	-0.4	2.39e-7	Intelligence;
PAAD	cis	rs13144136	0.687	rs13143538	chr4:10656897	T/C	cg10242279	chr4:10666415	CLNK	-0.46	-5.77	-0.42	4.26e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.55	4.63	0.35	7.83e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15128208	chr22:42549153	NA	0.43	4.41	0.34	1.94e-5	Cognitive function;
PAAD	cis	rs282587	0.569	rs9604422	chr13:113410586	C/T	cg04656015	chr13:113407548	ATP11A	0.54	4.29	0.33	3.1e-5	Glycated hemoglobin levels;
PAAD	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg14709524	chr16:89940631	TCF25	1.01	4.73	0.36	5.1e-6	Skin colour saturation;
PAAD	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.84	-9.46	-0.61	5.66e-17	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05017253	chr19:52490211	ZNF350	0.58	6.44	0.46	1.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.97	-0.44	1.61e-8	Blood metabolite levels;
PAAD	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.59	5.26	0.39	4.75e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7873102	0.630	rs4637938	chr9:37966131	T/C	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.38	0.33	2.24e-5	Iron status biomarkers;
PAAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.5	2.45e-11	Schizophrenia;
PAAD	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.46	0.4	1.94e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26320410	chr3:9851826	TTLL3	-0.84	-7.58	-0.52	3.13e-12	Neuroticism;
PAAD	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg02734326	chr4:10020555	SLC2A9	-0.51	-4.3	-0.33	3.06e-5	Schizophrenia (age at onset);
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg00738919	chr7:1100172	C7orf50	0.69	4.93	0.37	2.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9815354	1.000	rs73077367	chr3:41851959	G/A	cg03022575	chr3:42003672	ULK4	0.81	6.04	0.44	1.13e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs66530629	0.958	rs1002707	chr1:25051102	C/T	cg01905478	chr1:25040257	NA	0.49	5.15	0.39	8.01e-7	Plateletcrit;
PAAD	cis	rs4356203	0.875	rs214935	chr11:17193122	T/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.72	5.0	0.38	1.55e-6	HDL cholesterol levels;
PAAD	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg24747557	chr10:131355152	MGMT	-0.49	-5.31	-0.4	3.84e-7	Response to temozolomide;
PAAD	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg26935685	chr1:15502881	TMEM51	-0.55	-4.46	-0.34	1.57e-5	Systolic blood pressure;
PAAD	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg21419209	chr3:44054225	NA	-0.74	-7.62	-0.53	2.55e-12	Coronary artery disease;
PAAD	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg03538708	chr1:25844672	NA	-0.52	-5.41	-0.4	2.41e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs12282928	0.700	rs10838817	chr11:48200265	G/A	cg04607699	chr11:48328132	OR4S1	-0.52	-4.99	-0.38	1.63e-6	Migraine - clinic-based;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg02286717	chr10:75415704	SYNPO2L	-0.44	-4.26	-0.33	3.54e-5	Incident atrial fibrillation;
PAAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.58	-5.13	-0.38	8.88e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.66	-6.96	-0.49	9.67e-11	Type 2 diabetes;
PAAD	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.57	-5.96	-0.44	1.69e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.36	-0.33	2.39e-5	Asthma;
PAAD	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg23435118	chr5:141488016	NDFIP1	0.56	6.01	0.44	1.29e-8	Asthma;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-1.2	-9.93	-0.63	3.18e-18	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.03	-0.59	7.26e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.88	9.67	0.62	1.52e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.12	7.34	0.51	1.18e-11	Plateletcrit;
PAAD	cis	rs1539053	0.932	rs12038397	chr1:58108237	C/G	cg20292791	chr1:58089357	DAB1	-0.53	-5.13	-0.38	8.57e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	9.85	0.62	5.12e-18	Platelet count;
PAAD	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg02883595	chr6:39281421	KCNK17	-0.44	-4.26	-0.33	3.57e-5	Type 2 diabetes;
PAAD	cis	rs939584	0.935	rs13396119	chr2:637508	T/C	cg14515364	chr2:636606	NA	0.47	4.38	0.33	2.24e-5	Body mass index;
PAAD	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	5.81	0.43	3.48e-8	Blood protein levels;
PAAD	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg00277334	chr10:82204260	NA	-0.63	-6.7	-0.48	3.77e-10	Post bronchodilator FEV1;
PAAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24798414	chr8:73848252	KCNB2	-0.65	-6.65	-0.47	4.93e-10	Obesity-related traits;
PAAD	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg19949948	chr17:19361230	NA	0.45	4.66	0.35	7e-6	Schizophrenia;
PAAD	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.35	0.6	1.05e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.93e-11	Mosquito bite size;
PAAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg12215294	chr3:40350768	EIF1B	0.47	4.73	0.36	4.98e-6	Renal cell carcinoma;
PAAD	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg04415270	chr2:102091202	RFX8	-0.59	-7.57	-0.52	3.44e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg25251562	chr2:3704773	ALLC	-0.48	-5.56	-0.41	1.2e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg01815783	chr4:1047043	NA	-0.44	-4.27	-0.33	3.4e-5	Recombination rate (females);
PAAD	cis	rs7873102	0.654	rs6476666	chr9:37963047	C/T	cg03528946	chr9:38069800	SHB	0.55	5.48	0.41	1.7e-7	Brain structure;
PAAD	cis	rs1499972	0.529	rs1499982	chr3:117820386	C/T	cg07612923	chr3:117604196	NA	-0.68	-4.91	-0.37	2.35e-6	Schizophrenia;
PAAD	cis	rs7714584	1.000	rs7709464	chr5:150269441	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs795484	0.890	rs61945179	chr12:118652976	A/G	cg16572268	chr12:118583242	PEBP1	-0.44	-4.37	-0.33	2.31e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	10.11	0.63	1.07e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg23463467	chr20:60627584	TAF4	0.43	4.55	0.35	1.11e-5	Body mass index;
PAAD	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08045932	chr20:61659980	NA	-0.58	-6.29	-0.45	3.26e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.04	0.5	6.19e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs7084921	0.520	rs2902377	chr10:101876770	G/A	cg04359915	chr10:101825029	CPN1	-0.28	-4.31	-0.33	2.88e-5	Bone mineral density;
PAAD	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.31	-0.33	2.87e-5	Blood metabolite levels;
PAAD	cis	rs12906542	0.516	rs56357772	chr15:78313041	C/G	cg23683012	chr15:78369302	TBC1D2B	0.69	5.15	0.39	8.04e-7	Breast cancer;
PAAD	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.98	-9.92	-0.63	3.46e-18	Blood trace element (Zn levels);
PAAD	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.58	6.89	0.49	1.35e-10	Multiple sclerosis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24591318	chr4:40632020	RBM47	-0.69	-6.61	-0.47	6.09e-10	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.92	9.15	0.6	3.46e-16	Orofacial clefts;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs28647808	1.000	rs2285481	chr9:136271744	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs12136530	0.625	rs4912086	chr1:19730181	A/G	cg03321592	chr1:19991676	HTR6	0.53	4.72	0.36	5.3e-6	Lead levels in blood;
PAAD	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.5e-7	Reticulocyte count;High light scatter reticulocyte count;
PAAD	cis	rs11681884	0.786	rs11897709	chr2:113809290	G/A	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg21724239	chr8:58056113	NA	0.72	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.71	9.09	0.59	5.16e-16	Educational attainment;
PAAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3e-7	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.58	4.6	0.35	8.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4751058	0.526	rs10764842	chr10:130861658	A/C	cg00118712	chr10:131686819	EBF3	0.52	4.94	0.37	2.04e-6	Vitamin D levels;
PAAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg03983715	chr16:68378420	PRMT7	-0.82	-5.89	-0.43	2.37e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.37	4.27	0.33	3.49e-5	Blood protein levels;
PAAD	trans	rs901683	1.000	rs71494785	chr10:45964553	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8040855	0.627	rs12913859	chr15:85638418	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.88	-0.49	1.48e-10	Atrioventricular conduction;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg14500267	chr11:67383377	NA	0.47	4.72	0.36	5.31e-6	Mean corpuscular volume;
PAAD	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.59	5.33	0.4	3.54e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs501120	1.000	rs622956	chr10:44755183	A/G	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg05585544	chr11:47624801	NA	0.48	5.35	0.4	3.16e-7	Subjective well-being;
PAAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.8	-7.81	-0.54	8.56e-13	Schizophrenia;
PAAD	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg22138327	chr13:27999177	GTF3A	0.85	5.56	0.41	1.18e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs438034	0.807	rs35993967	chr1:214806476	T/C	cg16144317	chr1:214725524	PTPN14	0.4	4.3	0.33	3e-5	Response to antineoplastic agents;
PAAD	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg17796960	chr10:135278976	LOC619207	-0.57	-6.36	-0.46	2.24e-9	Systemic lupus erythematosus;
PAAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg16205897	chr5:131564050	P4HA2	-0.55	-6.06	-0.44	1.04e-8	Blood metabolite levels;
PAAD	cis	rs4908768	0.582	rs11121241	chr1:8895970	C/G	cg01329153	chr1:8417399	RERE	0.47	4.31	0.33	2.95e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.59	5.63	0.42	8.66e-8	Mortality in heart failure;
PAAD	cis	rs9810890	1.000	rs73198889	chr3:128547620	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg10437265	chr15:77819839	NA	0.43	4.79	0.36	3.92e-6	Type 2 diabetes;
PAAD	cis	rs10794720	0.529	rs11250278	chr10:1173765	G/A	cg05228244	chr10:1102351	WDR37	1.05	4.6	0.35	8.68e-6	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
PAAD	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg11441379	chr12:63026424	NA	-0.88	-6.48	-0.47	1.21e-9	IgG glycosylation;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01809819	chr1:31192165	MATN1	0.71	8.53	0.57	1.39e-14	Metabolite levels  (X-11787);
PAAD	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-7.08	-0.5	5.06e-11	Hip circumference;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg16926213	chr1:1841314	NA	0.38	4.62	0.35	8.23e-6	Body mass index;
PAAD	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg03989125	chr22:38214979	NA	0.6	5.48	0.41	1.76e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg16898833	chr6:26189333	HIST1H4D	0.62	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.52	-4.81	-0.36	3.57e-6	Strep throat;
PAAD	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg15193198	chr20:60906057	LAMA5	0.54	6.09	0.44	8.98e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.46	-0.34	1.58e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs17533156	0.612	rs12603478	chr17:75128651	A/G	cg11416367	chr17:75137675	SEC14L1	0.51	4.29	0.33	3.17e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	4.67	0.35	6.58e-6	Mean corpuscular volume;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.75	9.61	0.61	2.21e-17	Cardiovascular disease risk factors;
PAAD	cis	rs4523957	0.928	rs452363	chr17:2194028	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg06057569	chr22:50219754	BRD1	0.59	4.3	0.33	3.1e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.37	0.4	2.84e-7	Bipolar disorder;
PAAD	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.91	9.55	0.61	3.21e-17	Testicular germ cell tumor;
PAAD	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg20406979	chr6:167373233	NA	0.33	4.43	0.34	1.76e-5	Crohn's disease;
PAAD	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.68	5.68	0.42	6.73e-8	Response to antidepressants in depression;
PAAD	cis	rs41563	0.593	rs6466034	chr7:104598750	T/C	cg04380332	chr7:105027541	SRPK2	-0.51	-5.03	-0.38	1.37e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg22189786	chr22:42395067	WBP2NL	0.4	4.29	0.33	3.2e-5	Cognitive function;
PAAD	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg05555928	chr11:63887634	MACROD1	-0.72	-5.65	-0.42	7.66e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.69	7.28	0.51	1.64e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg16667279	chr19:11591998	ELAVL3	-0.64	-4.7	-0.36	5.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs17407555	0.909	rs58440238	chr4:10245311	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.61	-0.35	8.6e-6	Schizophrenia (age at onset);
PAAD	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg00181669	chr3:44000978	NA	-0.44	-4.33	-0.33	2.75e-5	Coronary artery disease;
PAAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.98	8.76	0.58	3.61e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17135859	0.669	rs13178544	chr5:113021965	A/G	cg12552261	chr5:112820674	MCC	0.74	4.47	0.34	1.51e-5	F-cell distribution;
PAAD	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.01	-0.67	4.22e-21	Ulcerative colitis;
PAAD	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.65	7.14	0.5	3.54e-11	Blood protein levels;
PAAD	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.93e-5	Pain;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.86	7.12	0.5	3.92e-11	Alzheimer's disease;
PAAD	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.54	5.8	0.43	3.67e-8	Obesity-related traits;
PAAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.6	8.28	0.56	5.88e-14	Eye color traits;
PAAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.76	-7.4	-0.51	8.67e-12	Breast cancer;
PAAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.9100000000000004e-06	Developmental language disorder (linguistic errors);
PAAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.86	10.16	0.64	7.88e-19	Blood protein levels;
PAAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg25452165	chr22:42524984	CYP2D6	0.61	5.84	0.43	3.12e-8	Schizophrenia;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.95	11.87	0.69	2.01e-23	Menarche (age at onset);
PAAD	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg02421172	chr7:1938701	MAD1L1	0.58	4.48	0.34	1.46e-5	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.66	6.83	0.48	1.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6906287	0.647	rs6569014	chr6:118681539	T/G	cg21191810	chr6:118973309	C6orf204	-0.43	-5.4	-0.4	2.54e-7	Electrocardiographic conduction measures;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg10729496	chr3:10149963	C3orf24	0.67	5.95	0.43	1.76e-8	Alzheimer's disease;
PAAD	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg05895507	chr15:77155635	SCAPER	0.36	4.38	0.33	2.19e-5	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.47	4.45	0.34	1.67e-5	Total body bone mineral density;
PAAD	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs3736757	1.000	rs9661314	chr1:184667608	A/G	cg05045817	chr1:184633523	NA	0.4	4.3	0.33	3.02e-5	Obesity-related traits;
PAAD	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-5.17	-0.39	7.43e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01850934	chr14:68141664	VTI1B	-0.64	-6.44	-0.46	1.52e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg03277515	chr1:153321198	PGLYRP4	0.39	4.56	0.35	1.06e-5	Psoriasis;
PAAD	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.64	-6.91	-0.49	1.24e-10	Longevity;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.71	8.09	0.55	1.79e-13	Lung cancer;
PAAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.78	7.51	0.52	4.67e-12	Cognitive function;
PAAD	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg21918786	chr6:109611834	NA	-0.46	-4.94	-0.37	2e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10885582	0.781	rs10159807	chr10:116293790	C/G	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.27	-0.39	4.62e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg11779900	chr17:80519722	FOXK2	0.49	5.15	0.39	7.9e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs17087282	0.574	rs4870439	chr6:156577593	C/T	cg14533737	chr6:157455836	ARID1B	-0.64	-4.28	-0.33	3.3e-5	Survival in microsatellite instability low/stable colorectal cancer;
PAAD	cis	rs9905704	0.633	rs2680697	chr17:56478711	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.29	-0.45	3.14e-9	Longevity;Endometriosis;
PAAD	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg13798780	chr7:105162888	PUS7	0.61	4.34	0.33	2.61e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-6.12	-0.44	7.46e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs9535307	0.727	rs7983303	chr13:50358053	T/A	cg03658251	chr13:50265850	EBPL	0.83	5.68	0.42	6.7e-8	Obesity-related traits;
PAAD	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.52	-5.03	-0.38	1.35e-6	Motion sickness;
PAAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.46	5.87	0.43	2.63e-8	Cystic fibrosis severity;
PAAD	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg22535103	chr8:58192502	C8orf71	-1.14	-10.38	-0.64	2.06e-19	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.36	0.33	2.42e-5	Iron status biomarkers;
PAAD	cis	rs76533333	0.646	rs71446627	chr13:113392773	G/A	cg02820901	chr13:113351484	ATP11A	-0.76	-4.57	-0.35	1.01e-5	Red cell distribution width;
PAAD	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.34	-0.6	1.16e-16	Mortality in heart failure;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1499972	0.590	rs62264770	chr3:117645883	C/T	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.51	5.19	0.39	6.73e-7	Schizophrenia;
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.04	0.38	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	5.87	0.43	2.66e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg00792783	chr2:198669748	PLCL1	-0.46	-4.27	-0.33	3.45e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4740619	0.905	rs10756677	chr9:15615321	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.38	-0.33	2.21e-5	Body mass index;
PAAD	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg20283391	chr11:68216788	NA	-0.52	-4.87	-0.37	2.79e-6	Total body bone mineral density;
PAAD	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-5.02	-0.38	1.46e-6	Body mass index;
PAAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.57	7.49	0.52	5.28e-12	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
PAAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.67	0.42	7.01e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	1.11	8.38	0.56	3.21e-14	Left atrial antero-posterior diameter;
PAAD	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.63	7.06	0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg14515779	chr1:101123966	NA	0.41	4.39	0.34	2.13e-5	Breast cancer;
PAAD	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.47	0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35740288	0.787	rs2008916	chr15:86221190	C/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.61	-0.35	8.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.52	-0.47	9.87e-10	Response to antipsychotic treatment;
PAAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg08316699	chr6:150357289	NA	0.39	4.34	0.33	2.62e-5	Alopecia areata;
PAAD	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs17407555	0.865	rs78272916	chr4:10286838	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.63	-0.35	7.76e-6	Schizophrenia (age at onset);
PAAD	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	6.2	0.45	5e-9	Response to bleomycin (chromatid breaks);
PAAD	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-4.25	-0.33	3.77e-5	Height;
PAAD	cis	rs61542988	0.570	rs7781074	chr7:22826360	A/G	cg11367502	chr7:22862612	TOMM7	-0.61	-5.62	-0.41	9.07e-8	Fibrinogen levels;
PAAD	cis	rs4356203	0.905	rs7930058	chr11:17066618	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2421770	0.532	rs2281633	chr11:35343767	G/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.76	-0.42	4.44e-8	HDL cholesterol;
PAAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.69	6.6	0.47	6.32e-10	Neurofibrillary tangles;
PAAD	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg00666640	chr1:248458726	OR2T12	0.47	4.81	0.36	3.63e-6	Common traits (Other);
PAAD	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.5	5.19	0.39	6.62e-7	Colorectal cancer;
PAAD	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.89	-10.55	-0.65	7.03e-20	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7823896	0.858	rs73303256	chr8:110252470	C/T	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg08390786	chr10:135334061	NA	-0.46	-4.3	-0.33	3.09e-5	Obesity-related traits;
PAAD	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg01612440	chr4:3296283	NA	0.45	4.44	0.34	1.69e-5	Serum sulfate level;
PAAD	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	6.32	0.46	2.78e-9	Lymphocyte counts;
PAAD	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg13263323	chr15:86062960	AKAP13	-0.54	-5.82	-0.43	3.34e-8	Interstitial lung disease;
PAAD	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg08999081	chr20:33150536	PIGU	0.6	6.68	0.48	4.13e-10	Height;
PAAD	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg22134325	chr11:66188745	NPAS4	0.27	4.26	0.33	3.54e-5	Airway imaging phenotypes;
PAAD	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.41	-5.07	-0.38	1.15e-6	Menopause (age at onset);
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg15212455	chr7:39170539	POU6F2	0.39	5.55	0.41	1.22e-7	IgG glycosylation;
PAAD	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg12437481	chr16:420112	MRPL28	-0.54	-5.42	-0.4	2.26e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7631605	0.743	rs9839933	chr3:37195162	G/T	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.22e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7624766	0.743	rs13073659	chr3:160542087	A/T	cg22637730	chr3:160473554	PPM1L	0.51	4.59	0.35	9.16e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.57	5.28	0.39	4.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-6.2	-0.45	5.04e-9	Lung cancer;
PAAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4780401	0.703	rs8191295	chr16:11766905	A/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.87	-0.43	2.61e-8	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13127159	chr13:114206805	NA	-0.58	-6.8	-0.48	2.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.6	0.35	8.74e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.7	7.11	0.5	4.19e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg01422370	chr2:73384389	NA	0.35	4.7	0.36	5.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.45	-0.34	1.65e-5	Tonsillectomy;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.28	-0.39	4.49e-7	Number of children ever born;
PAAD	cis	rs7165102	1.000	rs429657	chr15:65813764	G/A	cg22900193	chr15:65823441	PTPLAD1	-0.49	-4.63	-0.35	7.84e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs721399	0.568	rs34987019	chr8:18274443	T/C	cg18736775	chr8:18248649	NAT2	-0.66	-4.94	-0.37	2e-6	Blood metabolite levels;
PAAD	cis	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg21546286	chr11:48923668	NA	-0.58	-6.08	-0.44	9.44e-9	HDL cholesterol;
PAAD	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg12700464	chr11:78128424	GAB2	-0.58	-4.25	-0.33	3.67e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg06784218	chr1:46089804	CCDC17	-0.34	-4.68	-0.35	6.39e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.45	5.26	0.39	4.92e-7	QRS complex (12-leadsum);
PAAD	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.44	-5.38	-0.4	2.71e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.75	5.05	0.38	1.23e-6	Platelet distribution width;
PAAD	cis	rs28830936	0.966	rs4924576	chr15:42119593	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.71	-0.48	3.62e-10	Diastolic blood pressure;
PAAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg05643964	chr20:62369504	LIME1	-0.5	-4.61	-0.35	8.44e-6	Prostate cancer;
PAAD	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.61	5.49	0.41	1.67e-7	Red blood cell count;
PAAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.66	7.4	0.51	8.7e-12	Melanoma;
PAAD	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.32	-0.33	2.77e-5	Aortic root size;
PAAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg19847866	chr10:1019161	NA	0.74	7.43	0.52	7.44e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13102973	0.899	rs13104539	chr4:135904385	G/A	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg04165759	chr1:150448943	RPRD2	-0.53	-5.47	-0.41	1.79e-7	Migraine;
PAAD	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.69e-10	Exhaled nitric oxide output;
PAAD	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.79	-5.23	-0.39	5.5e-7	Platelet distribution width;
PAAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs863345	0.967	rs12753013	chr1:158505221	T/A	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	1.02e-6	Pneumococcal bacteremia;
PAAD	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.74	-6.52	-0.47	9.72e-10	Obesity-related traits;
PAAD	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg24879335	chr3:133465180	TF	0.64	8.01	0.54	2.84e-13	Iron status biomarkers (transferrin levels);
PAAD	cis	rs12304921	0.639	rs2018022	chr12:51475353	C/T	cg18059802	chr12:51347058	HIGD1C	-0.59	-4.74	-0.36	4.93e-6	Type 2 diabetes;
PAAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.82	8.58	0.57	1.04e-14	Calcium levels;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.44	-0.34	1.7e-5	Ileal carcinoids;
PAAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.45	-4.41	-0.34	1.93e-5	Height;
PAAD	cis	rs790110	1.000	rs790130	chr3:122384661	C/G	cg22468055	chr3:122334227	PARP15	0.84	4.67	0.35	6.47e-6	Acoustic startle blink response;
PAAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.84	7.4	0.51	8.43e-12	Schizophrenia;
PAAD	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.55	-5.31	-0.4	3.9e-7	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.25e-6	Type 2 diabetes;
PAAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg13611204	chr9:139324423	INPP5E	-0.56	-4.7	-0.36	5.77e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.86	-9.78	-0.62	8.05e-18	Tonsillectomy;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	5.4	0.4	2.47e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.77	0.66	1.9e-20	Smoking behavior;
PAAD	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.63	-5.68	-0.42	6.81e-8	Type 2 diabetes;
PAAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.4	-5.43	-0.4	2.15e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg18964960	chr10:1102726	WDR37	-0.59	-5.29	-0.39	4.25e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.68	-7.72	-0.53	1.41e-12	Airway imaging phenotypes;
PAAD	cis	rs12799264	0.915	rs4757869	chr11:19980809	A/G	cg17303119	chr11:19974895	NAV2	0.69	4.64	0.35	7.45e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.7	-7.32	-0.51	1.32e-11	Body mass index;
PAAD	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg20406979	chr6:167373233	NA	0.35	4.67	0.35	6.57e-6	Crohn's disease;
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg03999872	chr20:62272968	STMN3	-0.76	-7.06	-0.5	5.47e-11	Atopic dermatitis;
PAAD	trans	rs901683	0.850	rs113588255	chr10:46067333	C/G	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.49	-4.37	-0.33	2.32e-5	Testicular germ cell tumor;
PAAD	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg17385448	chr1:15911702	AGMAT	0.38	4.65	0.35	7.13e-6	Systolic blood pressure;
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg20295408	chr7:1910781	MAD1L1	-0.56	-5.23	-0.39	5.51e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.45	-4.31	-0.33	2.89e-5	Response to metformin (IC50);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20257171	chr11:18548408	TSG101	0.68	6.41	0.46	1.76e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.67	7.19	0.5	2.71e-11	Body mass index;
PAAD	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03398303	chr18:12702742	PSMG2;CEP76	0.57	6.58	0.47	7.27e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-5.86	-0.43	2.77e-8	Menopause (age at onset);
PAAD	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-20.13	-0.85	1e-44	Myeloid white cell count;
PAAD	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.6	5.34	0.4	3.3e-7	Retinal vascular caliber;
PAAD	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.68	6.76	0.48	2.79e-10	Economic and political preferences (feminism/equality);
PAAD	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs16852403	0.658	rs10157702	chr1:178109045	G/A	cg00404053	chr1:178313656	RASAL2	0.44	4.28	0.33	3.27e-5	Childhood ear infection;
PAAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.82	10.25	0.64	4.55e-19	Bone mineral density;
PAAD	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs818427	0.964	rs818425	chr5:112226655	C/T	cg07820702	chr5:112228657	REEP5	-0.5	-4.56	-0.35	1.05e-5	Total body bone mineral density;
PAAD	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.7	6.21	0.45	4.94e-9	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.26	-0.64	4.17e-19	Response to antipsychotic treatment;
PAAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	1.04	17.47	0.82	3.47e-38	Height;
PAAD	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs6084875	0.733	rs6037959	chr20:4741723	A/G	cg05143360	chr20:4741328	NA	0.48	4.32	0.33	2.8e-5	Systemic lupus erythematosus;
PAAD	cis	rs58521262	0.556	rs289322	chr19:23157270	G/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.72	6.63	0.47	5.51e-10	Obesity-related traits;
PAAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.4	-0.46	1.78e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2997447	0.748	rs112813126	chr1:26432239	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.09	10.55	0.65	7.19e-20	Orofacial clefts;
PAAD	cis	rs11628318	0.951	rs10134794	chr14:103034195	C/A	cg12046867	chr14:103022105	NA	-0.57	-4.77	-0.36	4.19e-6	Platelet count;
PAAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Aortic root size;
PAAD	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08045932	chr20:61659980	NA	-0.71	-8.71	-0.58	4.8e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs71520386	0.632	rs71520387	chr7:22869676	C/A	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs9928842	0.882	rs11641896	chr16:75300179	T/C	cg09066997	chr16:75300724	BCAR1	0.64	4.69	0.36	5.98e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg11062466	chr8:58055876	NA	0.66	4.73	0.36	5.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9463078	0.547	rs34907292	chr6:44729708	A/G	cg25276700	chr6:44698697	NA	0.45	5.38	0.4	2.76e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg26061582	chr7:22766209	IL6	0.51	4.68	0.35	6.28e-6	Lung cancer;
PAAD	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs58521262	0.556	rs289318	chr19:23159486	T/C	cg03433597	chr19:22806448	NA	0.24	4.26	0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg15847926	chr7:2749597	AMZ1	-0.4	-4.81	-0.36	3.63e-6	Height;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18337363	chr3:52569053	NT5DC2	0.42	4.4	0.34	2e-5	Bipolar disorder;
PAAD	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.56	-4.58	-0.35	9.43e-6	Facial morphology (factor 19);
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg07777115	chr5:623756	CEP72	-0.47	-4.34	-0.33	2.64e-5	Cystic fibrosis severity;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.57	6.35	0.46	2.33e-9	Lung cancer;
PAAD	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.44	-4.85	-0.37	3.05e-6	Mean arterial pressure;
PAAD	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg14851346	chr12:38532713	NA	-0.49	-4.52	-0.34	1.25e-5	Morning vs. evening chronotype;
PAAD	cis	rs10750165	0.669	rs4331115	chr11:119650848	C/T	cg24085502	chr11:119066850	CCDC153	-0.35	-4.45	-0.34	1.66e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.05	-0.38	1.23e-6	Blood metabolite levels;
PAAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-4.29	-0.33	3.12e-5	Total body bone mineral density;
PAAD	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg00806126	chr19:22604979	ZNF98	0.4	5.03	0.38	1.36e-6	Pain;
PAAD	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.92	-10.21	-0.64	5.83e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg20487152	chr13:99095054	FARP1	-0.47	-4.61	-0.35	8.4e-6	Neuroticism;
PAAD	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.25	0.39	5.06e-7	Ovarian reserve;
PAAD	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg21698718	chr17:80085957	CCDC57	-0.44	-5.02	-0.38	1.42e-6	Life satisfaction;
PAAD	cis	rs9826463	0.757	rs73240305	chr3:142222770	A/G	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg13870426	chr17:30244630	NA	-0.73	-6.65	-0.47	4.94e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.51	4.25	0.33	3.68e-5	Lymphocyte counts;
PAAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs9322817	0.583	rs7746856	chr6:105146360	A/C	cg02098413	chr6:105308735	HACE1	0.43	5.45	0.4	2e-7	Thyroid stimulating hormone;
PAAD	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	1.01	10.92	0.66	7.47e-21	Homoarginine levels;
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10064575	chr17:40610771	ATP6V0A1	0.61	6.51	0.47	1.01e-9	Myopia (pathological);
PAAD	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.43	-4.3	-0.33	2.98e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg09699651	chr6:150184138	LRP11	0.48	5.12	0.38	9.07e-7	Lung cancer;
PAAD	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	10.79	0.66	1.67e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg21573476	chr21:45109991	RRP1B	-0.48	-4.3	-0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg21565972	chr17:80109576	CCDC57	-0.58	-6.78	-0.48	2.44e-10	Life satisfaction;
PAAD	cis	rs2944755	0.723	rs34051681	chr8:141587701	G/A	cg18491938	chr8:141590271	EIF2C2	-0.54	-4.75	-0.36	4.66e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.71	7.15	0.5	3.43e-11	Anterior chamber depth;
PAAD	cis	rs6708331	0.517	rs7599072	chr2:70360006	C/T	cg01613454	chr2:70366299	NA	0.44	4.63	0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	6.16	0.45	6.28e-9	Mean platelet volume;
PAAD	cis	rs7173419	0.655	rs12899295	chr15:28226597	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.3	-0.4	3.93e-7	Eye color;
PAAD	cis	rs4742903	0.935	rs10991168	chr9:106974902	C/T	cg14250997	chr9:106856677	SMC2	0.41	4.31	0.33	2.89e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.97	4.77	0.36	4.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.73	8.64	0.57	7.32e-15	Vitiligo;Type 1 diabetes;
PAAD	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.78	-0.48	2.55e-10	Atrioventricular conduction;
PAAD	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg01620082	chr3:125678407	NA	-1.5	-8.89	-0.58	1.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.64	-7.08	-0.5	4.89e-11	N-glycan levels;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15617292	chr20:33460744	GGT7	-0.82	-7.53	-0.52	4.23e-12	Neuroticism;
PAAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.45	-4.6	-0.35	8.8e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.96	-0.54	3.7e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg05725404	chr16:58534157	NDRG4	-0.82	-5.1	-0.38	9.92e-7	Schizophrenia;
PAAD	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.43e-5	Resting heart rate;
PAAD	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23098811	chr1:215450695	NA	-0.61	-6.33	-0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs1371614	0.610	rs3820822	chr2:27155862	G/A	cg00617064	chr2:27272375	NA	0.43	4.59	0.35	9.29e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.59	6.31	0.46	2.97e-9	Lung cancer;
PAAD	cis	rs17123764	0.539	rs7979262	chr12:50065146	T/C	cg14846292	chr12:49726500	C1QL4	-0.69	-4.54	-0.35	1.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	4.53	0.34	1.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16975963	0.790	rs11083434	chr19:38283953	A/G	cg25793785	chr19:38281423	NA	0.57	4.75	0.36	4.69e-6	Longevity;
PAAD	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.1	0.67	2.4e-21	Breast cancer;
PAAD	cis	rs6893807	1.000	rs1422192	chr5:87959023	G/A	cg02225085	chr5:87975992	LOC645323	-0.63	-4.64	-0.35	7.38e-6	Body mass index;
PAAD	cis	rs13380717	0.628	rs4581707	chr16:86913229	G/T	cg07769121	chr16:86543519	FOXF1	0.56	4.39	0.34	2.09e-5	Sepsis in extremely premature infants;
PAAD	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.56	5.67	0.42	6.98e-8	Parkinson's disease;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.49	5.42	0.4	2.34e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4740619	0.607	rs2382547	chr9:15988870	G/T	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.17e-5	Body mass index;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.56	-5.54	-0.41	1.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg19264203	chr11:92714893	MTNR1B	-0.38	-4.51	-0.34	1.27e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg09242541	chr1:10490025	APITD1	0.47	5.73	0.42	5.27e-8	Prostate cancer;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.4e-5	Iron status biomarkers;
PAAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg24519413	chr1:26490540	NA	0.48	6.22	0.45	4.71e-9	Height;
PAAD	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.65	-7.75	-0.53	1.23e-12	Sense of smell;
PAAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.75	-7.26	-0.51	1.85e-11	Neurofibrillary tangles;
PAAD	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.61	7.97	0.54	3.58e-13	Breast cancer;
PAAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg11062466	chr8:58055876	NA	0.7	5.11	0.38	9.39e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs6011002	1.000	rs56010802	chr20:62304114	G/C	cg05643964	chr20:62369504	LIME1	0.91	4.32	0.33	2.84e-5	Dental caries;
PAAD	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-5.78	-0.42	4.11e-8	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs34566829	chr10:45973598	G/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg25204440	chr1:209979598	IRF6	0.66	5.63	0.42	8.64e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs6494488	0.500	rs72742934	chr15:64875723	T/C	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg11779900	chr17:80519722	FOXK2	-0.48	-4.96	-0.37	1.85e-6	Reticulocyte count;
PAAD	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.69	4.74	0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg24053715	chr22:38214548	NA	-0.62	-6.53	-0.47	9.28e-10	Glioblastoma;Glioma;
PAAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.51	5.28	0.39	4.49e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.35	0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg09021430	chr5:549028	NA	-0.84	-7.08	-0.5	5.11e-11	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24906519	chr6:53409386	GCLC	0.66	7.56	0.52	3.47e-12	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.88	10.79	0.66	1.69e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.85	-7.95	-0.54	4.03e-13	Exhaled nitric oxide output;
PAAD	trans	rs6506900	0.840	rs12606446	chr18:28813937	C/A	cg21548032	chr12:104850767	CHST11	1.35	6.5	0.47	1.08e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg10223061	chr2:219282414	VIL1	0.37	4.26	0.33	3.62e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.84e-9	Blood metabolite levels;
PAAD	cis	rs375066	0.935	rs430667	chr19:44413253	T/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23158103	chr7:148848205	ZNF398	-0.6	-5.56	-0.41	1.17e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.36	0.4	2.97e-7	Type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16118529	chr1:166136507	FAM78B	0.57	6.44	0.46	1.52e-9	Metabolite levels  (X-11787);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00810836	chr12:32832043	DNM1L	0.7	8.44	0.56	2.27e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg01262667	chr19:19385393	TM6SF2	-0.43	-4.66	-0.35	6.92e-6	Tonsillectomy;
PAAD	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg26597838	chr10:835615	NA	0.47	5.15	0.39	7.99e-7	Survival in rectal cancer;
PAAD	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.81	-0.36	3.59e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12257961	0.549	rs7900826	chr10:15382981	C/A	cg10616319	chr10:15468812	NA	0.46	4.43	0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg14146966	chr2:61757674	XPO1	0.41	5.07	0.38	1.12e-6	Tuberculosis;
PAAD	cis	rs595018	0.505	rs56131811	chr11:60595943	G/A	cg07588442	chr11:60673866	PRPF19	0.65	4.47	0.34	1.55e-5	Wegener's granulomatosis;
PAAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg10589385	chr1:150898437	SETDB1	0.36	4.44	0.34	1.71e-5	Melanoma;
PAAD	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg26097391	chr2:54893211	SPTBN1	0.45	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.57	6.2	0.45	5.14e-9	Testicular germ cell tumor;
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.56	6.1	0.44	8.31e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	11.2	0.67	1.34e-21	Smoking behavior;
PAAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.77	-0.62	8.69e-18	Total body bone mineral density;
PAAD	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	4.31	0.33	2.96e-5	Red cell distribution width;
PAAD	cis	rs35160687	0.712	rs4832261	chr2:86484498	A/G	cg10973622	chr2:86423274	IMMT	0.44	4.98	0.37	1.71e-6	Night sleep phenotypes;
PAAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.61	-5.94	-0.43	1.91e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7588746	0.621	rs11691757	chr2:201148951	C/T	cg23649088	chr2:200775458	C2orf69	-0.51	-4.8	-0.36	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.61	-6.53	-0.47	9.35e-10	Bladder cancer;
PAAD	cis	rs9463078	0.546	rs7758031	chr6:45025836	T/C	cg25276700	chr6:44698697	NA	0.45	5.04	0.38	1.31e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20584918	chr3:196295759	WDR53;FBXO45	0.64	6.38	0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1572438	0.760	rs7766714	chr6:869519	C/T	cg13447295	chr6:887704	NA	-0.54	-5.3	-0.39	4e-7	Aging;
PAAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.69	0.62	1.37e-17	Smoking behavior;
PAAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.66	7.15	0.5	3.41e-11	Corneal astigmatism;
PAAD	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.72	7.66	0.53	2.01e-12	Post bronchodilator FEV1;
PAAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.59	5.97	0.44	1.6e-8	Multiple sclerosis;
PAAD	cis	rs1144333	0.655	rs12401729	chr1:76336586	T/G	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.68	6.3	0.46	3.04e-9	Blood metabolite levels;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.57	-4.53	-0.35	1.17e-5	Type 2 diabetes;
PAAD	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.62	5.95	0.43	1.74e-8	Uric acid clearance;
PAAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.68	7.13	0.5	3.78e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.78	-7.4	-0.51	8.55e-12	Retinal vascular caliber;
PAAD	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.94	13.48	0.74	9.91e-28	Alcohol dependence;
PAAD	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.53	-0.35	1.17e-5	Blood protein levels;
PAAD	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.68	6.37	0.46	2.14e-9	Lymphocyte counts;
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9287719	0.566	rs34595606	chr2:10722518	G/A	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.7	8.98	0.59	9.8e-16	Asthma;
PAAD	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg04398451	chr17:18023971	MYO15A	0.75	8.35	0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.8	6.96	0.49	9.32e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg16589663	chr20:23618590	CST3	0.79	6.88	0.49	1.5e-10	Chronic kidney disease;
PAAD	cis	rs10784762	1.000	rs10784762	chr12:69523923	C/T	cg25697314	chr12:68619556	IL26	-0.41	-4.73	-0.36	5.16e-6	QRS duration;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg06483076	chr3:194406458	FAM43A	0.54	5.28	0.39	4.31e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs1801239	1.000	rs17343073	chr10:16932196	A/T	cg00939682	chr10:16933505	CUBN	0.71	5.0	0.38	1.53e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.8	-0.53	9.16e-13	Total cholesterol levels;
PAAD	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs73019876	0.522	rs2043318	chr19:22241615	G/C	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.39	-0.61	8.35e-17	Blood trace element (Zn levels);
PAAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	5.59	0.41	1.02e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg03894339	chr8:19674705	INTS10	-0.45	-4.34	-0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12906542	0.516	rs10444863	chr15:78358837	T/C	cg23683012	chr15:78369302	TBC1D2B	0.68	4.96	0.37	1.88e-6	Breast cancer;
PAAD	cis	rs427941	0.632	rs201492	chr7:101754138	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4751058	0.578	rs7099230	chr10:130856644	C/T	cg00118712	chr10:131686819	EBF3	-0.52	-4.26	-0.33	3.6e-5	Vitamin D levels;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.37	4.54	0.35	1.12e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg00792783	chr2:198669748	PLCL1	0.48	4.33	0.33	2.75e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.9	6.6	0.47	6.49e-10	Opioid sensitivity;
PAAD	cis	rs1190552	0.637	rs7150548	chr14:102959962	T/C	cg18135206	chr14:102964638	TECPR2	0.59	4.27	0.33	3.39e-5	Blood protein levels;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02071572	chr4:1403502	NA	0.46	5.77	0.42	4.25e-8	Obesity-related traits;
PAAD	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.48	-5.06	-0.38	1.21e-6	Male-pattern baldness;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg10962407	chr2:203736738	ICA1L	0.57	6.34	0.46	2.5e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs492146	0.935	rs375887	chr6:52843477	A/G	cg24393602	chr6:52860404	GSTA4	-0.44	-4.29	-0.33	3.18e-5	Epilepsy (remission after treatment);
PAAD	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-4.64	-0.35	7.31e-6	Fat distribution (HIV);
PAAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg12639453	chr1:2035780	PRKCZ	-0.55	-5.99	-0.44	1.49e-8	Height;
PAAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.9	11.17	0.67	1.61e-21	Blood protein levels;
PAAD	cis	rs34734847	0.750	rs708783	chr12:121173932	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-4.73	-0.36	5.01e-6	Mean corpuscular volume;
PAAD	cis	rs11563648	0.535	rs1419416	chr7:127041014	A/G	cg21885361	chr7:127911034	NA	-0.4	-4.36	-0.33	2.35e-5	Resting heart rate;
PAAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.95	9.94	0.63	2.94e-18	Blood metabolite levels;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18758796	chr5:131593413	PDLIM4	0.51	4.6	0.35	8.97e-6	Acylcarnitine levels;
PAAD	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	8.96	0.59	1.08e-15	Cognitive test performance;
PAAD	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.22	0.45	4.5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.8	8.12	0.55	1.52e-13	Blood protein levels;
PAAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.93	-8.9	-0.59	1.53e-15	Asthma;
PAAD	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	6.0	0.44	1.41e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11638352	0.661	rs2463448	chr15:44480315	G/C	cg10011062	chr15:43941034	CATSPER2	-1.21	-4.31	-0.33	2.93e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.5	4.54	0.35	1.14e-5	Height;
PAAD	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02637241	chr17:78965697	CHMP6	-0.67	-6.87	-0.49	1.51e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11260013	0.904	rs12973524	chr19:7758263	G/A	cg04764898	chr19:7562249	C19orf45	0.42	4.36	0.33	2.42e-5	Blood protein levels;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.58	0.8	6.69e-36	Prudent dietary pattern;
PAAD	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.11e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.01e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23425280	chr12:56401806	NA	-0.57	-6.46	-0.46	1.31e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs78761021	0.573	rs7207205	chr17:9767275	T/C	cg26853458	chr17:9805074	RCVRN	0.45	5.29	0.39	4.25e-7	Type 2 diabetes;
PAAD	cis	rs10916814	1.000	rs7365904	chr1:20904528	G/A	cg04087271	chr1:20915334	CDA	0.37	4.32	0.33	2.81e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6449957	0.832	rs7715780	chr5:67453288	A/G	cg23036683	chr5:67512108	NA	0.5	4.6	0.35	8.71e-6	Cleft lip with or without cleft palate;
PAAD	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-7.82	-0.54	8.31e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.7e-6	Cognitive function;
PAAD	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.38	-0.56	3.23e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg10761708	chr20:43804764	PI3	0.5	4.26	0.33	3.63e-5	Blood protein levels;
PAAD	cis	rs7508	0.512	rs2283114	chr8:17880260	C/G	cg08627089	chr8:17753878	FGL1	-0.44	-4.37	-0.33	2.33e-5	Atrial fibrillation;
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.53	-4.7	-0.36	5.79e-6	Lung cancer;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21155852	chr7:2048760	MAD1L1	-0.45	-4.56	-0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.49	4.54	0.35	1.12e-5	Renal cell carcinoma;
PAAD	cis	rs8112211	0.731	rs931750	chr19:38818751	T/C	cg14299480	chr19:38876666	GGN	-0.62	-6.01	-0.44	1.3e-8	Blood protein levels;
PAAD	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.56	-0.52	3.52e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg03894339	chr8:19674705	INTS10	1.12	8.09	0.55	1.8e-13	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg19413350	chr8:57351067	NA	-0.44	-4.32	-0.33	2.84e-5	Obesity-related traits;
PAAD	cis	rs943466	1.000	rs943466	chr6:33731787	A/G	cg04704449	chr6:33738291	NA	0.47	4.59	0.35	9.38e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg23254163	chr1:152506842	NA	0.49	4.74	0.36	4.95e-6	Hair morphology;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.68	5.89	0.43	2.39e-8	Common traits (Other);
PAAD	cis	rs829661	0.947	rs829682	chr2:30708430	G/T	cg12454169	chr2:30669597	LCLAT1	0.64	4.89	0.37	2.51e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg16417436	chr16:28758564	NA	0.47	4.53	0.34	1.21e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.63	6.96	0.49	9.46e-11	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05727691	chr6:34855839	TAF11;ANKS1A	0.61	7.04	0.5	6.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-4.43	-0.34	1.77e-5	Aortic root size;
PAAD	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.8	-9.01	-0.59	8.11e-16	Colorectal cancer;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg23281280	chr6:28129359	ZNF389	0.69	5.23	0.39	5.52e-7	Depression;
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg21269045	chr12:125625041	AACS	-0.48	-4.65	-0.35	7.06e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	1.01	7.81	0.53	8.94e-13	Initial pursuit acceleration;
PAAD	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.53	-5.26	-0.39	4.92e-7	Coronary artery disease;
PAAD	trans	rs17073641	0.500	rs28576551	chr18:62478507	A/T	cg08832414	chr3:183993571	ECE2	-0.65	-6.43	-0.46	1.53e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs2019960	0.759	rs2608025	chr8:129173122	A/G	cg15331705	chr8:129180010	NA	-0.44	-5.77	-0.42	4.37e-8	Hodgkin's lymphoma;Multiple sclerosis;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg02683114	chr2:24398427	C2orf84	0.6	6.83	0.48	1.9e-10	Asthma;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.58	-5.8	-0.43	3.77e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-4.77	-0.36	4.25e-6	Longevity;
PAAD	cis	rs9395066	0.545	rs12525009	chr6:44875843	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg09324608	chr17:30823087	MYO1D	0.44	4.3	0.33	3.02e-5	Schizophrenia;
PAAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.55	-5.87	-0.43	2.61e-8	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9361491	0.508	rs9343787	chr6:79415606	A/C	cg05283184	chr6:79620031	NA	-0.4	-5.03	-0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.67	0.35	6.65e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12044355	0.927	rs16854809	chr1:231839247	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.92	0.37	2.22e-6	Alzheimer's disease;
PAAD	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg21300403	chr2:198650112	BOLL	0.47	4.32	0.33	2.84e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00142150	chr22:38071001	LGALS1	0.81	9.09	0.59	5.15e-16	Fat distribution (HIV);
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg11416102	chr8:651193	ERICH1	-1.0	-6.05	-0.44	1.1e-8	IgG glycosylation;
PAAD	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.83	9.66	0.62	1.6e-17	Blood metabolite ratios;
PAAD	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs2229238	0.911	rs73023346	chr1:154512077	C/T	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.89	-0.43	2.44e-8	Tonsillectomy;
PAAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14008862	chr17:28927542	LRRC37B2	0.8	6.0	0.44	1.38e-8	Body mass index;
PAAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-1.35	-10.53	-0.65	8.15e-20	Schizophrenia;
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg16331281	chr10:4445958	NA	0.68	4.3	0.33	3.02e-5	Major depressive disorder;
PAAD	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.69	7.45	0.52	6.55e-12	Schizophrenia;
PAAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.61	-8.49	-0.57	1.72e-14	Height;
PAAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.94	10.65	0.65	3.92e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg21448613	chr3:49828315	CDH29	0.46	4.36	0.33	2.43e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg20713898	chr8:124780851	FAM91A1	-0.82	-6.44	-0.46	1.46e-9	Pancreatic cancer;
PAAD	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.67	-0.42	7.12e-8	Crohn's disease;
PAAD	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.88	0.54	5.88e-13	Monocyte percentage of white cells;
PAAD	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.67	7.2	0.5	2.6e-11	Testicular germ cell tumor;
PAAD	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.76	-6.62	-0.47	5.68e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg11494091	chr17:61959527	GH2	-0.97	-14.4	-0.76	3.46e-30	Prudent dietary pattern;
PAAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs73416724	0.688	rs75966707	chr6:43356743	A/C	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	0.66	5.93	0.43	2e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.48	0.57	1.79e-14	Menarche (age at onset);
PAAD	cis	rs3762637	0.941	rs9863712	chr3:122099906	C/T	cg24169773	chr3:122142474	KPNA1	-0.65	-4.45	-0.34	1.69e-5	LDL cholesterol levels;
PAAD	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.76	8.11	0.55	1.56e-13	Hemoglobin concentration;
PAAD	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.57	-0.41	1.14e-7	Tonsillectomy;
PAAD	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg24687543	chr11:63912206	MACROD1	-0.54	-4.85	-0.37	3.03e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg21130718	chr4:1044621	NA	0.54	4.58	0.35	9.43e-6	Recombination rate (females);
PAAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg07959070	chr22:50026188	C22orf34	-0.36	-4.36	-0.33	2.39e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.74	8.54	0.57	1.33e-14	Height;
PAAD	cis	rs7264396	0.887	rs58458373	chr20:34045611	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.7	-7.16	-0.5	3.28e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.08	-0.44	9.22e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9595066	0.712	rs4391951	chr13:44755071	C/T	cg04068111	chr13:44716778	NA	0.47	5.09	0.38	1.04e-6	Schizophrenia;
PAAD	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.52	0.65	8.52e-20	Bladder cancer;
PAAD	cis	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs965469	1.000	rs2236117	chr20:3302021	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg16583315	chr14:65563665	MAX	-0.41	-4.36	-0.33	2.42e-5	Obesity-related traits;
PAAD	cis	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.75	8.0	0.54	2.91e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.72	10.96	0.66	5.66e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.63	5.82	0.43	3.4e-8	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07066860	chr12:11932089	ETV6	0.6	6.4	0.46	1.79e-9	Smoking initiation;
PAAD	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09826364	chr7:158789723	NA	-0.4	-5.12	-0.38	9.15e-7	Facial morphology (factor 20);
PAAD	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg12193833	chr17:30244370	NA	0.59	4.41	0.34	1.92e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs329648	0.571	rs510306	chr11:133774863	G/T	cg18057887	chr11:133800913	IGSF9B	-0.63	-7.27	-0.51	1.79e-11	Parkinson's disease;
PAAD	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.84	10.03	0.63	1.78e-18	Blood metabolite ratios;
PAAD	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg18939081	chr1:31884902	SERINC2	0.47	5.33	0.4	3.44e-7	Alcohol dependence;
PAAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg08698997	chr16:88989212	CBFA2T3	0.4	4.73	0.36	5.1e-6	Social autistic-like traits;
PAAD	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg00531865	chr16:30841666	NA	-0.56	-4.33	-0.33	2.64e-5	Dementia with Lewy bodies;
PAAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.6	5.58	0.41	1.08e-7	Mean corpuscular volume;
PAAD	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg15764593	chr10:829463	NA	-0.76	-6.0	-0.44	1.39e-8	Uric acid levels;
PAAD	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.58	-6.3	-0.46	2.98e-9	Calcium levels;
PAAD	cis	rs2494979	0.958	rs1608696	chr6:71329265	C/T	cg15045441	chr6:72130432	C6orf155	-0.44	-4.35	-0.33	2.46e-5	Platelet distribution width;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.71	5.5	0.41	1.6e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg03676636	chr4:99064102	C4orf37	0.32	4.89	0.37	2.54e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.54	-4.91	-0.37	2.32e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs863345	0.504	rs2482966	chr1:158563321	T/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.62	4.81	0.36	3.61e-6	Exhaled nitric oxide output;
PAAD	cis	rs4737010	0.644	rs506763	chr8:41612487	C/T	cg17182837	chr8:41585554	ANK1	0.47	4.57	0.35	1e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.84	7.64	0.53	2.24e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs12304921	0.549	rs11169692	chr12:51458565	G/A	cg18059802	chr12:51347058	HIGD1C	-0.61	-4.63	-0.35	7.84e-6	Type 2 diabetes;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg14789911	chr21:47582049	C21orf56	0.54	5.84	0.43	3.13e-8	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.54	-5.49	-0.41	1.66e-7	Iron status biomarkers;
PAAD	cis	rs7772697	0.632	rs1316536	chr6:149417910	A/C	cg21368479	chr6:149415018	NA	0.41	4.32	0.33	2.77e-5	Diabetic retinopathy;
PAAD	cis	rs12935418	0.616	rs718954	chr16:80987116	C/G	cg16651780	chr16:81037892	C16orf61	0.58	4.76	0.36	4.51e-6	Mean corpuscular volume;
PAAD	cis	rs73621547	0.558	rs17460566	chr9:132103842	T/C	cg18217252	chr9:133027791	NA	-0.8	-4.26	-0.33	3.53e-5	Caudate activity during reward;
PAAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24549020	chr5:56110836	MAP3K1	-0.6	-4.31	-0.33	2.92e-5	Initial pursuit acceleration;
PAAD	cis	rs8170	0.603	rs3745187	chr19:17414126	C/T	cg01047959	chr19:17666446	GLT25D1	0.51	4.68	0.36	6.21e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg14703610	chr5:56206110	C5orf35	0.61	5.92	0.43	2.07e-8	Coronary artery disease;
PAAD	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.27	-0.39	4.56e-7	High light scatter reticulocyte count;
PAAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.92	-8.31	-0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.66	-0.35	6.83e-6	Diastolic blood pressure;
PAAD	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-5.46	-0.4	1.89e-7	Prudent dietary pattern;
PAAD	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19404896	chr1:109969078	PSMA5	0.61	6.34	0.46	2.49e-9	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11599694	chr6:134374934	SLC2A12	-0.58	-6.6	-0.47	6.45e-10	Obesity-related traits;
PAAD	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-1.05	-13.7	-0.74	2.56e-28	Headache;
PAAD	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg07469887	chr10:131262384	NA	0.43	5.03	0.38	1.34e-6	Response to temozolomide;
PAAD	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.55	-0.35	1.1e-5	Resting heart rate;
PAAD	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.78	-4.98	-0.37	1.71e-6	Toenail selenium levels;
PAAD	cis	rs11023332	0.706	rs10766197	chr11:14921880	G/A	cg16394018	chr11:14927549	NA	0.42	4.77	0.36	4.31e-6	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg16362232	chr11:430036	ANO9	0.86	5.31	0.4	3.79e-7	Body mass index;
PAAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.76	0.48	2.76e-10	Schizophrenia;
PAAD	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-1.0	-6.86	-0.49	1.59e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24349573	chr21:43430466	ZNF295	0.64	6.41	0.46	1.76e-9	Obesity-related traits;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.68	-7.56	-0.52	3.45e-12	Facial morphology (factor 20);
PAAD	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02742186	chr13:21100191	CRYL1	-0.8	-7.34	-0.51	1.22e-11	Neuroticism;
PAAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg26751094	chr13:95954534	ABCC4	-0.36	-4.28	-0.33	3.35e-5	Blood metabolite levels;
PAAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.76	-8.54	-0.57	1.3e-14	Childhood ear infection;
PAAD	cis	rs1499972	0.517	rs13080344	chr3:117634193	G/A	cg07612923	chr3:117604196	NA	-0.64	-5.02	-0.38	1.45e-6	Schizophrenia;
PAAD	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg24881330	chr22:46731750	TRMU	1.06	4.88	0.37	2.71e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.69	5.33	0.4	3.46e-7	Alzheimer's disease (survival time);
PAAD	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.34	0.68	5.65e-22	Primary sclerosing cholangitis;
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.47	-4.55	-0.35	1.07e-5	Longevity;
PAAD	cis	rs477895	0.639	rs2289573	chr11:64127902	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	5.16	0.39	7.44e-7	Mean platelet volume;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs6066835	0.764	rs28741053	chr20:47378114	T/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs6991838	0.806	rs35284121	chr8:66463465	A/G	cg15971335	chr8:66515592	ARMC1	0.45	4.54	0.35	1.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1008126	0.600	rs2965098	chr7:103124785	T/C	cg04218035	chr7:103086829	SLC26A5	0.33	4.51	0.34	1.29e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.58e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.55	4.78	0.36	4.04e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14180030	chr9:123475675	MEGF9	-0.46	-5.12	-0.38	9.14e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7084783	0.538	rs7067892	chr10:105339698	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.45	4.48	0.34	1.44e-5	Fear of pain;
PAAD	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.26	-0.45	3.66e-9	Alcohol dependence;
PAAD	cis	rs2072883	0.669	rs2038063	chr22:43449508	T/C	cg16973406	chr22:43265991	NA	0.37	4.41	0.34	1.93e-5	Schizophrenia;
PAAD	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.42	0.56	2.6e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9549328	0.837	rs9549330	chr13:113648404	G/T	cg25790453	chr13:113633590	MCF2L	-0.39	-4.52	-0.34	1.26e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.77	-0.36	4.31e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs593531	0.513	rs4944887	chr11:74029883	G/A	cg15670924	chr11:73669256	DNAJB13	0.45	4.92	0.37	2.27e-6	Neuroticism;
PAAD	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.8	9.51	0.61	4.09e-17	Crohn's disease;
PAAD	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-8.88	-0.58	1.76e-15	Colorectal cancer;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.57	-6.24	-0.45	4.14e-9	Electroencephalogram traits;
PAAD	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs3125734	0.719	rs1835861	chr10:64056141	T/A	cg19640130	chr10:64028056	RTKN2	-0.37	-4.28	-0.33	3.31e-5	Rheumatoid arthritis;
PAAD	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg22431228	chr1:16359049	CLCNKA	0.43	5.17	0.39	7.36e-7	Systolic blood pressure;
PAAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.54	-0.47	8.74e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg22399232	chr2:33824342	FAM98A	0.58	6.57	0.47	7.59e-10	Immature fraction of reticulocytes;
PAAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.55	5.13	0.38	8.57e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg23283495	chr1:209979779	IRF6	-0.79	-7.1	-0.5	4.37e-11	Coronary artery disease;
PAAD	cis	rs4668356	0.730	rs16823191	chr2:171930818	A/G	cg13882835	chr2:172017928	TLK1	0.89	5.04	0.38	1.32e-6	Cognitive performance;
PAAD	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg02876276	chr17:77834299	NA	0.62	4.41	0.34	1.91e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs1519814	0.696	rs2875927	chr8:121036841	G/A	cg22335954	chr8:121166405	COL14A1	-0.64	-4.96	-0.37	1.88e-6	Breast cancer;
PAAD	cis	rs66530629	0.874	rs10903106	chr1:25148686	G/A	cg22509179	chr1:25234806	RUNX3	-0.5	-4.59	-0.35	9.16e-6	Plateletcrit;
PAAD	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.82	-6.83	-0.48	1.9e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-6.0	-0.44	1.39e-8	Homocysteine levels;
PAAD	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.51	4.68	0.35	6.37e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.9	-7.35	-0.51	1.13e-11	Initial pursuit acceleration;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.59	0.41	1.03e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.59	-4.93	-0.37	2.14e-6	Schizophrenia;
PAAD	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.08e-7	Atrioventricular conduction;
PAAD	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Vitiligo;
PAAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs17095355	0.901	rs12572168	chr10:111764786	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.31	-0.33	2.97e-5	Biliary atresia;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.87	0.49	1.55e-10	Renal function-related traits (BUN);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02949469	chr2:219135266	PNKD;AAMP	-0.66	-6.44	-0.46	1.45e-9	Lung cancer in ever smokers;
PAAD	cis	rs9942416	0.524	rs34350	chr5:74945108	G/C	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.46	-4.33	-0.33	2.65e-5	Age-related disease endophenotypes;
PAAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.3	-13.12	-0.73	9.03e-27	Hip circumference adjusted for BMI;
PAAD	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg10818794	chr15:86012489	AKAP13	-0.52	-5.81	-0.43	3.49e-8	Coronary artery disease;
PAAD	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.65	-6.37	-0.46	2.18e-9	White matter hyperintensity burden;
PAAD	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-4.84	-0.37	3.13e-6	Schizophrenia;
PAAD	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.44	-0.34	1.75e-5	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.45	0.4	1.97e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.59	-6.06	-0.44	1.01e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs35084382	1.000	rs114015958	chr5:172194282	G/C	cg09799633	chr5:172199460	DUSP1	-0.96	-4.36	-0.33	2.42e-5	Optic cup area;
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16083429	chr3:49237500	CCDC36	-0.43	-4.64	-0.35	7.63e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.82	0.58	2.46e-15	Menopause (age at onset);
PAAD	cis	rs6577655	0.517	rs9693237	chr8:135578218	G/A	cg17885191	chr8:135476712	NA	0.54	4.47	0.34	1.54e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.96	-8.43	-0.56	2.52e-14	Other erythrocyte phenotypes;
PAAD	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.61	7.02	0.49	6.91e-11	Cognitive performance;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.3e-7	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14209793	chr10:105614994	SH3PXD2A	0.64	7.18	0.5	2.84e-11	Monocyte percentage of white cells;
PAAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.83	-5.62	-0.41	8.76e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs4388249	0.687	rs11745926	chr5:109145190	T/C	cg17395555	chr5:108820864	NA	0.33	4.61	0.35	8.44e-6	Schizophrenia;
PAAD	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg01620082	chr3:125678407	NA	-1.1	-7.35	-0.51	1.16e-11	Depression;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.44	5.61	0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.79	-8.49	-0.57	1.76e-14	Obesity-related traits;
PAAD	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26926768	chr12:34528122	NA	0.4	4.95	0.37	1.95e-6	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg09835421	chr16:68378352	PRMT7	-1.15	-8.68	-0.58	5.56e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg27478167	chr7:817139	HEATR2	-0.65	-5.02	-0.38	1.4e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.42	-0.34	1.9e-5	Fear of minor pain;
PAAD	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg12193833	chr17:30244370	NA	-0.63	-5.36	-0.4	3.08e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.58	5.22	0.39	5.83e-7	Retinal vascular caliber;
PAAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg19847866	chr10:1019161	NA	-0.57	-4.61	-0.35	8.39e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg23465465	chr6:26364728	BTN3A2	-0.83	-4.88	-0.37	2.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.87	-8.01	-0.55	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs939584	1.000	rs6749375	chr2:636017	C/T	cg03610516	chr2:642275	NA	0.59	5.36	0.4	3.03e-7	Body mass index;
PAAD	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg20406979	chr6:167373233	NA	0.33	4.54	0.35	1.15e-5	Crohn's disease;
PAAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6906287	0.647	rs12665409	chr6:118685043	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.49	0.41	1.63e-7	Electrocardiographic conduction measures;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19623624	chr10:135278901	LOC619207	-0.54	-5.48	-0.41	1.75e-7	Systemic lupus erythematosus;
PAAD	cis	rs7833787	0.832	rs7827258	chr8:18698295	G/C	cg17701159	chr8:18705777	PSD3	-0.43	-4.96	-0.37	1.83e-6	Obesity-related traits;
PAAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18364779	chr6:26104403	HIST1H4C	0.52	5.25	0.39	4.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs112556034	chr16:68045724	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-6.19	-0.45	5.3e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.64	5.71	0.42	5.84e-8	Menarche (age at onset);
PAAD	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	17.56	0.82	2.15e-38	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs5756391	0.568	rs4821567	chr22:37316388	T/G	cg16356956	chr22:37317934	CSF2RB	0.39	4.77	0.36	4.28e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.53	-4.97	-0.37	1.79e-6	Kawasaki disease;
PAAD	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.74	-7.69	-0.53	1.75e-12	Obesity-related traits;
PAAD	cis	rs10821973	0.527	rs7092746	chr10:63971245	T/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.43	-0.34	1.79e-5	Hypothyroidism;
PAAD	cis	rs2790216	1.000	rs1698402	chr10:59936444	C/T	cg20442379	chr10:60024634	IPMK	-0.56	-4.28	-0.33	3.32e-5	Inflammatory bowel disease;
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01616529	chr11:638424	DRD4	-0.6	-5.55	-0.41	1.24e-7	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23708337	chr7:1209742	NA	0.47	4.73	0.36	5.07e-6	Longevity;Endometriosis;
PAAD	cis	rs76866386	0.786	rs4076834	chr2:44081627	T/G	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.83	-0.43	3.26e-8	Cholesterol, total;
PAAD	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg18105134	chr13:113819100	PROZ	-0.97	-7.66	-0.53	2.01e-12	Platelet distribution width;
PAAD	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.72	-8.52	-0.57	1.45e-14	Colorectal cancer;
PAAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.82	-6.22	-0.45	4.69e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.35	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg00717180	chr2:96193071	NA	-0.61	-7.18	-0.5	2.82e-11	Height;
PAAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.75	-7.82	-0.54	8.22e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	6.86	0.49	1.65e-10	Schizophrenia;
PAAD	cis	rs3771514	1.000	rs3771514	chr2:70697667	G/A	cg12850242	chr2:70484614	PCYOX1	-0.49	-4.31	-0.33	2.89e-5	Obesity-related traits;
PAAD	cis	rs2279817	0.735	rs34571066	chr1:18002777	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-5.68	-0.42	6.54e-8	Neuroticism;
PAAD	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg19510604	chr15:74901076	CLK3	0.56	4.47	0.34	1.54e-5	Blood trace element (Zn levels);
PAAD	cis	rs4804368	0.714	rs4804372	chr19:7191712	A/G	cg08379738	chr19:6477033	DENND1C	0.4	4.28	0.33	3.3e-5	Renal cell carcinoma;
PAAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg02734326	chr4:10020555	SLC2A9	0.49	4.84	0.37	3.14e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.95	0.43	1.8e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.75	-7.6	-0.52	2.87e-12	Prostate cancer;
PAAD	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.63	6.6	0.47	6.49e-10	Resting heart rate;
PAAD	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09256448	chr16:638327	NA	0.41	4.28	0.33	3.31e-5	Height;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs8014252	0.803	rs74062769	chr14:71070576	A/C	cg11204974	chr14:71022665	NA	-0.73	-4.85	-0.37	3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.99	7.53	0.52	4.3e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs743757	1.000	rs916217	chr3:50457227	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.68	-4.64	-0.35	7.31e-6	Diastolic blood pressure;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.99	13.61	0.74	4.26e-28	Menarche (age at onset);
PAAD	cis	rs7260329	0.670	rs6508963	chr19:41498733	A/G	cg23925301	chr19:41220945	ADCK4	-0.49	-4.4	-0.34	2.02e-5	Smoking behavior;
PAAD	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15664640	chr17:80829946	TBCD	-0.68	-4.73	-0.36	5.11e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.84	0.54	7.21e-13	Mean platelet volume;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07157834	chr1:205819609	PM20D1	0.57	5.56	0.41	1.18e-7	Parkinson's disease;
PAAD	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.64	-5.35	-0.4	3.11e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1035491	0.715	rs6878515	chr5:63925029	G/C	cg01791865	chr5:63954708	NA	0.52	5.56	0.41	1.2e-7	Body mass index;
PAAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	6.41	0.46	1.71e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg18357526	chr6:26021779	HIST1H4A	0.64	5.16	0.39	7.65e-7	Homocysteine levels;
PAAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-7.92	-0.54	4.63e-13	Body mass index;
PAAD	cis	rs3206736	0.548	rs73110554	chr7:35066531	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.54	-0.35	1.12e-5	Diastolic blood pressure;
PAAD	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg03037974	chr15:76606532	NA	0.53	6.27	0.45	3.54e-9	Blood metabolite levels;
PAAD	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.52	5.55	0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs9463078	0.774	rs4510673	chr6:45350107	A/G	cg25276700	chr6:44698697	NA	0.47	5.47	0.41	1.84e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.93	-0.37	2.09e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19248958	chr10:130828579	NA	-0.59	-6.71	-0.48	3.69e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg14329783	chr7:75779857	NA	0.8	4.76	0.36	4.51e-6	Mononucleosis;
PAAD	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.74	-0.36	4.95e-6	Resting heart rate;
PAAD	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg09659197	chr4:152720779	NA	0.4	4.98	0.37	1.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11264799	0.639	rs2210909	chr1:157744848	C/T	cg18268488	chr1:157545234	FCRL4	0.57	4.85	0.37	3.09e-6	IgA nephropathy;
PAAD	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.29	-0.51	1.56e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-1.04	-14.15	-0.75	1.53e-29	Breast cancer;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.72	-7.8	-0.53	9.2e-13	Caffeine consumption;
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	5.04	0.38	1.33e-6	Thyroid stimulating hormone;
PAAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.63	8.22	0.55	8.11e-14	Renal cell carcinoma;
PAAD	cis	rs17407555	0.657	rs12508233	chr4:10271037	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	4.3	0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.69	7.1	0.5	4.55e-11	Tourette syndrome;
PAAD	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3745621	1.000	rs3745621	chr19:47689921	C/G	cg24326880	chr19:47634349	SAE1	0.55	4.62	0.35	8.26e-6	Lymphocyte counts;
PAAD	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.82	-6.63	-0.47	5.55e-10	Blood protein levels;
PAAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs30380	0.632	rs26495	chr5:96137840	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.22	-0.39	5.87e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9463078	0.774	rs6935398	chr6:45262427	G/A	cg25276700	chr6:44698697	NA	-0.47	-5.44	-0.4	2.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.8	-9.24	-0.6	2e-16	Sudden cardiac arrest;
PAAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.68	-9.08	-0.59	5.48e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.89	9.27	0.6	1.69e-16	Cognitive function;
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.58	0.47	7.27e-10	Lung cancer;
PAAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.46	4.59	0.35	9.38e-6	Schizophrenia;
PAAD	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg15956490	chr3:53032818	SFMBT1	0.71	4.48	0.34	1.45e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg00806126	chr19:22604979	ZNF98	-0.4	-4.9	-0.37	2.39e-6	Pain;
PAAD	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	1.09	9.62	0.62	2.11e-17	Orofacial clefts;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg01144275	chr17:79478508	ACTG1	-0.65	-6.6	-0.47	6.54e-10	Body mass index;
PAAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6132905	0.590	rs76972451	chr20:2599723	C/A	cg24848351	chr20:2622020	TMC2	-0.67	-4.75	-0.36	4.63e-6	Mumps;
PAAD	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.69	0.36	5.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.74	7.53	0.52	4.12e-12	Tonsillectomy;
PAAD	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg00806126	chr19:22604979	ZNF98	-0.39	-4.97	-0.37	1.8e-6	Pain;
PAAD	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	6.44	0.46	1.5e-9	Resting heart rate;
PAAD	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg10820045	chr2:198174542	NA	0.48	4.95	0.37	1.91e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	1.12	8.87	0.58	1.82e-15	Iron status biomarkers;
PAAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.26	-0.39	4.9e-7	Recombination rate (females);
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	6.67	0.48	4.43e-10	Height;
PAAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.72	-8.23	-0.56	7.93e-14	Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg04287289	chr16:89883240	FANCA	0.87	4.31	0.33	2.97e-5	Skin colour saturation;
PAAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.5	5.11	0.38	9.6e-7	Colorectal cancer;
PAAD	cis	rs425535	0.757	rs2117721	chr4:74786885	T/C	cg01447579	chr4:74847100	PF4	0.62	4.26	0.33	3.63e-5	Blood protein levels;
PAAD	cis	rs12153243	0.686	rs4392659	chr5:142938964	A/G	cg13907255	chr5:142895549	NA	-0.57	-4.89	-0.37	2.55e-6	Migraine;
PAAD	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg23283495	chr1:209979779	IRF6	0.77	7.05	0.5	5.97e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.43	-4.87	-0.37	2.73e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10892866	chr1:154934115	PYGO2	0.58	6.63	0.47	5.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg21798802	chr22:38057573	PDXP	0.49	5.2	0.39	6.31e-7	Fat distribution (HIV);
PAAD	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.36	0.4	3.04e-7	Body mass index;
PAAD	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	1.07	6.42	0.46	1.64e-9	Plateletcrit;
PAAD	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs728616	0.510	rs17679603	chr10:82181434	C/T	cg19423196	chr10:82049429	MAT1A	0.49	4.38	0.33	2.18e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17095355	0.818	rs57239324	chr10:111770871	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.41	-0.34	1.92e-5	Biliary atresia;
PAAD	cis	rs9398803	0.713	rs3861455	chr6:126897969	A/C	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs61861422	0.516	rs11814062	chr10:134439823	C/T	cg15908580	chr10:134496731	INPP5A	-0.57	-4.95	-0.37	1.96e-6	Primary sclerosing cholangitis;
PAAD	cis	rs11159086	1.000	rs11159086	chr14:74962275	A/G	cg10195687	chr14:74926396	NA	-0.46	-5.0	-0.38	1.55e-6	Advanced glycation end-product levels;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-7.06	-0.5	5.51e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs732765	0.734	rs10136897	chr14:75173392	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.63	-6.33	-0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.74	5.18	0.39	7.1e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs2479106	0.727	rs10986139	chr9:126689150	C/G	cg16191174	chr9:126692580	DENND1A	0.55	4.67	0.35	6.65e-6	Polycystic ovary syndrome;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.45	0.34	1.68e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs790110	1.000	rs2668336	chr3:122384469	T/A	cg16054280	chr3:122517974	DIRC2	0.86	4.53	0.34	1.21e-5	Acoustic startle blink response;
PAAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.8	0.48	2.21e-10	Exhaled nitric oxide levels;
PAAD	cis	rs288326	0.561	rs80252162	chr2:183717105	G/A	cg09997497	chr2:183902928	NCKAP1	0.86	4.84	0.37	3.13e-6	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg04545296	chr12:48745243	ZNF641	0.36	4.51	0.34	1.26e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	6.14	0.45	7.04e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8037137	0.915	rs79548680	chr15:91505779	G/C	cg23684204	chr15:91497937	RCCD1	0.69	4.57	0.35	9.91e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.58	-8.38	-0.56	3.34e-14	Huntington's disease progression;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg18769074	chr3:133464867	TF	0.41	4.67	0.35	6.54e-6	Iron status biomarkers;
PAAD	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	5.89	0.43	2.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.37	5.54	0.41	1.33e-7	Educational attainment (years of education);
PAAD	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.48	-6.36	-0.46	2.29e-9	Ulcerative colitis;
PAAD	cis	rs8063160	0.740	rs35850949	chr16:89720724	C/A	cg07984980	chr16:89898383	SPIRE2	0.89	4.99	0.38	1.63e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs4742903	0.818	rs1857981	chr9:106992584	T/G	cg14250997	chr9:106856677	SMC2	0.44	4.68	0.35	6.31e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.99	10.4	0.64	1.79e-19	Primary sclerosing cholangitis;
PAAD	cis	rs17428041	0.625	rs17428027	chr8:21709512	A/G	cg17168535	chr8:21777572	XPO7	0.48	4.35	0.33	2.46e-5	Neuropathic pain in type 2 diabetes;
PAAD	cis	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg04374321	chr14:90722782	PSMC1	0.51	4.3	0.33	3.02e-5	Longevity;
PAAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.56	4.58	0.35	9.61e-6	Schizophrenia;
PAAD	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.52	0.34	1.24e-5	Educational attainment;
PAAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs7172971	0.688	rs75621794	chr15:42377366	C/T	cg07013680	chr15:42186124	SPTBN5	0.57	4.68	0.35	6.26e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.45	-5.82	-0.43	3.35e-8	Ulcerative colitis;
PAAD	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.73	-0.36	5.15e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.77	7.16	0.5	3.21e-11	Obesity-related traits;
PAAD	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-4.62	-0.35	8.15e-6	Monocyte percentage of white cells;
PAAD	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.78	7.83	0.54	7.64e-13	Uric acid levels;
PAAD	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg24220031	chr2:73402428	NA	-0.3	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.35	0.56	4.02e-14	Hypertriglyceridemia;
PAAD	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.61	6.46	0.46	1.32e-9	Crohn's disease;
PAAD	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.64	-7.65	-0.53	2.12e-12	Mean arterial pressure;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg18736775	chr8:18248649	NAT2	-0.57	-5.17	-0.39	7.12e-7	Blood metabolite levels;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-10.81	-0.66	1.49e-20	Total body bone mineral density;
PAAD	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.53	4.25	0.33	3.69e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.62	5.47	0.41	1.83e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7243821	0.921	rs12327372	chr18:52636783	A/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.71	-9.47	-0.61	5.17e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs901683	0.850	rs79529960	chr10:46045315	C/T	cg12869334	chr8:37699360	GPR124	0.98	6.79	0.48	2.32e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs9463078	0.683	rs227848	chr6:44698499	G/A	cg25276700	chr6:44698697	NA	0.51	5.97	0.44	1.62e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.89	11.13	0.67	1.98e-21	Coronary artery disease;
PAAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg09667013	chr22:42394590	WBP2NL	0.58	4.95	0.37	1.92e-6	Birth weight;
PAAD	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9311474	0.713	rs104903	chr3:52230475	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.2	-0.39	6.22e-7	Electroencephalogram traits;
PAAD	cis	rs1722141	0.633	rs903889	chr7:45964995	A/C	cg13814990	chr7:46016683	NA	-0.53	-4.26	-0.33	3.57e-5	Sitting height ratio;
PAAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	1.03	16.55	0.8	7.74e-36	Height;
PAAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14180030	chr9:123475675	MEGF9	0.45	5.12	0.38	9.17e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2980439	0.517	rs712253	chr8:8103782	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.57	-0.41	1.1e-7	Neuroticism;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.57	-6.57	-0.47	7.72e-10	Lung cancer;
PAAD	cis	rs2730260	0.537	rs55683317	chr7:158878599	C/T	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.73	7.5	0.52	4.89e-12	Lung cancer;
PAAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg26751094	chr13:95954534	ABCC4	-0.45	-4.73	-0.36	4.99e-6	Blood metabolite levels;
PAAD	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg25547332	chr5:131281432	NA	-0.56	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	6.99	0.49	8.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.85	0.37	3.05e-6	Vitiligo;
PAAD	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg01942863	chr7:99769432	GPC2	0.5	4.67	0.35	6.61e-6	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs2279433	chr10:45954807	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12541635	1.000	rs2881037	chr8:107090901	C/T	cg10147462	chr8:107024639	NA	-0.46	-4.8	-0.36	3.83e-6	Age of smoking initiation;
PAAD	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.45	-4.59	-0.35	9.09e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04995860	chr1:53192072	ZYG11B	0.64	6.68	0.48	4.2e-10	Obesity-related traits;
PAAD	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg11157765	chr11:69982996	ANO1	0.62	5.27	0.39	4.64e-7	Survival in rectal cancer;
PAAD	cis	rs3996993	0.573	rs10948726	chr6:52695461	G/T	cg00536792	chr6:53530503	KLHL31	-0.42	-4.45	-0.34	1.68e-5	Hemoglobin concentration;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs7534824	0.625	rs6699653	chr1:101499162	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.71	0.36	5.52e-6	Refractive astigmatism;
PAAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg17401720	chr7:158221031	PTPRN2	0.46	4.81	0.36	3.53e-6	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.55	-7.11	-0.5	4.21e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25732426	chr21:46294058	PTTG1IP	-0.55	-6.82	-0.48	2.04e-10	Body fat percentage;
PAAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg19784903	chr17:45786737	TBKBP1	0.49	5.2	0.39	6.35e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.38	0.56	3.21e-14	Homoarginine levels;
PAAD	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.97	7.99	0.54	3.13e-13	Eosinophilic esophagitis;
PAAD	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg18764771	chr6:116381957	FRK	0.33	5.81	0.43	3.56e-8	Total cholesterol levels;
PAAD	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg04520793	chr17:42248056	ASB16	0.37	4.29	0.33	3.11e-5	Total body bone mineral density;
PAAD	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg24565620	chr2:194026	NA	0.62	5.11	0.38	9.72e-7	Blood protein levels;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg04352962	chr1:209979756	IRF6	0.53	4.73	0.36	5.03e-6	Cleft lip with or without cleft palate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14626490	chr9:131710514	NUP188;DOLK	0.73	7.51	0.52	4.62e-12	Obesity-related traits;
PAAD	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.96	6.39	0.46	1.95e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs78761021	0.617	rs4791898	chr17:9769635	G/A	cg26853458	chr17:9805074	RCVRN	0.47	5.55	0.41	1.21e-7	Type 2 diabetes;
PAAD	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.75	-7.85	-0.54	7.06e-13	Gut microbiome composition (winter);
PAAD	cis	rs12989701	0.825	rs4663097	chr2:127861906	C/G	cg08168897	chr2:127865431	BIN1	-0.59	-5.68	-0.42	6.6e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3796727	0.690	rs4696864	chr4:8614792	C/T	cg05284713	chr4:8621361	CPZ	-0.44	-4.36	-0.33	2.42e-5	Sporadic neuroblastoma;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg21421171	chr8:145755615	MGC70857;KIAA1688	-0.26	-4.25	-0.33	3.72e-5	Age at first birth;
PAAD	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.46	-4.31	-0.33	2.93e-5	Endometrial cancer;
PAAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	Trans fatty acid levels;
PAAD	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.32e-7	Protein quantitative trait loci;
PAAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-1.02	-14.17	-0.75	1.36e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg11235426	chr6:292522	DUSP22	-0.74	-7.62	-0.53	2.46e-12	Menopause (age at onset);
PAAD	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.58	5.35	0.4	3.25e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.5	-5.02	-0.38	1.46e-6	Mortality in heart failure;
PAAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.03e-6	Skin colour saturation;
PAAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.48	4.36	0.33	2.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg18551225	chr6:44695536	NA	0.7	7.0	0.49	7.87e-11	Total body bone mineral density;
PAAD	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg11601000	chr22:42348013	LOC339674	-0.5	-5.91	-0.43	2.15e-8	Intelligence;
PAAD	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.91	7.12	0.5	3.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg05392440	chr1:2478653	NA	0.54	5.82	0.43	3.34e-8	Ulcerative colitis;
PAAD	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.58	5.16	0.39	7.47e-7	Common traits (Other);
PAAD	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7932354	0.528	rs11039112	chr11:47174296	C/T	cg19486271	chr11:47235900	DDB2	0.52	5.34	0.4	3.28e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.7	0.42	5.93e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.66	7.37	0.51	1e-11	Atrial fibrillation;
PAAD	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs4742903	0.904	rs971969	chr9:106929798	A/C	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.95e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.29e-5	Rheumatoid arthritis;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.48	5.91	0.43	2.13e-8	Iron status biomarkers;
PAAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.72	-8.91	-0.59	1.48e-15	Dupuytren's disease;
PAAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.51	4.62	0.35	7.97e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.85	5.88	0.43	2.47e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.98	11.81	0.69	3.08e-23	Breast cancer;
PAAD	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg11416102	chr8:651193	ERICH1	0.75	4.83	0.36	3.31e-6	IgG glycosylation;
PAAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.2e-14	Eye color traits;
PAAD	cis	rs13424612	0.896	rs878925	chr2:240918502	A/G	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.63	-0.35	7.8e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.49	-5.99	-0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.51e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg21784768	chr11:537496	LRRC56	-0.86	-4.46	-0.34	1.6e-5	Body mass index;
PAAD	cis	rs9547692	0.938	rs4520715	chr13:37459113	C/T	cg01493522	chr13:37497338	NA	-0.65	-6.26	-0.45	3.77e-9	Coronary artery disease;
PAAD	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-13.31	-0.73	2.84e-27	Headache;
PAAD	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg04330084	chr7:123175371	IQUB	0.52	4.47	0.34	1.5e-5	Plateletcrit;Platelet count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27317218	chr14:75894692	JDP2	-0.66	-6.63	-0.47	5.54e-10	Smoking initiation;
PAAD	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.8	-5.99	-0.44	1.49e-8	Hair shape;
PAAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.2	-0.39	6.29e-7	Electroencephalogram traits;
PAAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.96	-7.51	-0.52	4.75e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg03808351	chr9:123631620	PHF19	0.45	4.85	0.37	3.02e-6	Rheumatoid arthritis;
PAAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs11690462	0.500	rs34952935	chr2:26627940	C/T	cg13255216	chr2:26625047	C2orf39	-0.44	-4.68	-0.35	6.27e-6	Coronary artery disease;
PAAD	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.55	-4.53	-0.35	1.17e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.86	-5.28	-0.39	4.3e-7	Cholesterol, total;
PAAD	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.84	6.57	0.47	7.65e-10	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg02900253	chr1:6673709	PHF13	-0.69	-6.94	-0.49	1.06e-10	Blood protein levels;
PAAD	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg16989719	chr2:238392110	NA	-0.35	-4.41	-0.34	1.93e-5	Prostate cancer;
PAAD	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12936587	0.777	rs12951347	chr17:17534513	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-4.52	-0.34	1.22e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.86e-5	Dermatomyositis;
PAAD	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs1499972	0.941	rs62264779	chr3:117654731	G/T	cg07612923	chr3:117604196	NA	1.01	6.97	0.49	9.27e-11	Schizophrenia;
PAAD	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg17640201	chr16:30407289	ZNF48	-0.89	-10.16	-0.64	7.94e-19	Tonsillectomy;
PAAD	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.47	-4.54	-0.35	1.14e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg21395723	chr22:39101663	GTPBP1	0.45	4.55	0.35	1.07e-5	Menopause (age at onset);
PAAD	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.73	0.36	5.16e-6	Axial length;
PAAD	cis	rs7136716	0.541	rs115700308	chr12:7783726	C/T	cg25757697	chr12:8220002	C3AR1	-0.87	-4.38	-0.33	2.19e-5	Hematological and biochemical traits;
PAAD	cis	rs863345	0.604	rs59427353	chr1:158500621	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14180030	chr9:123475675	MEGF9	-0.39	-4.38	-0.33	2.21e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.74	-8.27	-0.56	6.33e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.38	0.33	2.23e-5	Electroencephalogram traits;
PAAD	cis	rs13382275	0.632	rs13384065	chr2:940126	T/G	cg02924234	chr2:420061	NA	0.52	4.47	0.34	1.53e-5	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	4.82	0.36	3.44e-6	Lung function (FEV1/FVC);
PAAD	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-8.02	-0.55	2.63e-13	Vitiligo;
PAAD	cis	rs9876781	1.000	rs6770470	chr3:48435123	G/C	cg24898236	chr3:49228699	LOC646498	0.39	4.37	0.33	2.34e-5	Longevity;
PAAD	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg10547527	chr2:198650123	BOLL	-0.63	-4.33	-0.33	2.65e-5	Ulcerative colitis;
PAAD	cis	rs2882667	0.658	rs288003	chr5:138231955	T/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs863345	0.967	rs863359	chr1:158544733	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg24250549	chr1:154909240	PMVK	0.47	4.67	0.35	6.53e-6	Schizophrenia;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.98	-11.11	-0.67	2.32e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.69	7.07	0.5	5.33e-11	Menarche (age at onset);
PAAD	cis	rs939584	0.866	rs5017304	chr2:630903	A/G	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs10768122	0.966	rs35629461	chr11:35267044	C/A	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.34	-0.33	2.59e-5	Vitiligo;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24227390	chr20:34207470	SPAG4	-0.71	-6.3	-0.46	3.05e-9	Neuroticism;
PAAD	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.89	-10.44	-0.65	1.46e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg14345882	chr6:26364793	BTN3A2	-0.68	-4.62	-0.35	8.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3812111	0.774	rs509859	chr6:116423244	A/C	cg05304507	chr6:116381966	FRK	-0.27	-5.09	-0.38	1.04e-6	Age-related macular degeneration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01272081	chr9:32551527	TOPORS	0.64	7.18	0.5	2.96e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg09658497	chr7:2847517	GNA12	-0.41	-4.44	-0.34	1.72e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22050555	chr5:171615449	STK10	0.6	6.59	0.47	6.94e-10	Myopia (pathological);
PAAD	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg21775007	chr8:11205619	TDH	-0.46	-4.32	-0.33	2.81e-5	Neuroticism;
PAAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.52	4.5	0.34	1.35e-5	Serum parathyroid hormone levels;
PAAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg24253500	chr15:84953950	NA	0.43	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7580658	0.895	rs4662580	chr2:128102806	C/A	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg00864171	chr11:67383662	NA	-0.47	-4.87	-0.37	2.76e-6	Mean corpuscular volume;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs6473252	0.584	rs6989517	chr8:81806206	A/G	cg08595989	chr8:81827712	NA	-0.32	-4.34	-0.33	2.55e-5	Breast cancer;
PAAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.84	-7.36	-0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.91	10.67	0.65	3.43e-20	Total body bone mineral density;
PAAD	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.9	-10.27	-0.64	4.11e-19	Refractive error;
PAAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg16928487	chr17:17741425	SREBF1	0.34	4.56	0.35	1.06e-5	Strep throat;
PAAD	cis	rs1045714	1.000	rs1045713	chr7:2653579	G/A	cg20813462	chr7:2646259	IQCE	0.62	4.25	0.33	3.71e-5	Urate levels in lean individuals;
PAAD	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.85	-8.52	-0.57	1.5e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg21589280	chr1:85930151	DDAH1	-0.56	-4.25	-0.33	3.76e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25908613	chr15:25436246	SNORD115-9;SNORD115-10;SNORD115-12;SNORD115-5	0.71	7.91	0.54	4.86e-13	Smoking initiation;
PAAD	cis	rs3018712	0.700	rs2510387	chr11:68445902	A/G	cg02340541	chr11:68451699	GAL	0.62	5.22	0.39	5.69e-7	Total body bone mineral density;
PAAD	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.19	17.46	0.82	3.71e-38	Triglycerides;
PAAD	cis	rs2133450	0.526	rs17047058	chr3:7343176	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.62	-5.84	-0.43	3.06e-8	Vitamin D levels;
PAAD	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg24296786	chr1:45957014	TESK2	0.49	4.53	0.34	1.19e-5	Homocysteine levels;
PAAD	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs959260	0.541	rs58935635	chr17:73357744	C/T	cg14668889	chr17:73230827	NUP85	0.65	4.42	0.34	1.85e-5	Systemic lupus erythematosus;
PAAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.3e-19	Bone mineral density;
PAAD	cis	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs28489187	0.597	rs233053	chr1:85839507	G/A	cg16011679	chr1:85725395	C1orf52	0.51	4.85	0.37	3.04e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg04025307	chr7:1156635	C7orf50	0.61	4.57	0.35	9.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02034447	chr16:89574710	SPG7	0.47	4.33	0.33	2.68e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs56046484	0.778	rs1606119	chr15:85671379	G/T	cg08123816	chr15:85640762	PDE8A	-0.4	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.81	5.42	0.4	2.3e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg15621731	chr19:5074616	KDM4B	0.33	4.78	0.36	4.14e-6	Monocyte percentage of white cells;
PAAD	cis	rs12526480	0.521	rs60626645	chr6:25674896	C/T	cg03264133	chr6:25882463	NA	0.57	4.26	0.33	3.52e-5	Mean platelet volume;Plateletcrit;
PAAD	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.6	0.61	2.37e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.55	0.35	1.09e-5	Trans fatty acid levels;
PAAD	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.64	0.47	5.34e-10	IgG glycosylation;
PAAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.67	-0.48	4.4e-10	Personality dimensions;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.42	5.33	0.4	3.47e-7	Ulcerative colitis;
PAAD	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg00277334	chr10:82204260	NA	-0.58	-5.29	-0.39	4.16e-7	Post bronchodilator FEV1;
PAAD	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.64	4.29	0.33	3.11e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg05341575	chr12:125625032	AACS	-0.55	-4.94	-0.37	2.01e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg05503412	chr4:57843540	C4orf14	0.61	6.55	0.47	8.29e-10	Iris heterochromicity;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs3136441	1.000	rs12575609	chr11:46807378	C/T	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.34	-0.33	2.61e-5	Height;
PAAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-5.28	-0.39	4.36e-7	Type 2 diabetes;
PAAD	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.51	5.34	0.4	3.38e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1144333	0.850	rs1144341	chr1:76282659	T/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.5	-0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg04450456	chr4:17643702	FAM184B	0.51	5.5	0.41	1.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg09417038	chr21:47716443	C21orf57	0.59	6.41	0.46	1.76e-9	Testicular germ cell tumor;
PAAD	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.85	-0.58	2.07e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7301016	0.901	rs7975109	chr12:62941643	C/T	cg11441379	chr12:63026424	NA	0.86	6.39	0.46	1.93e-9	IgG glycosylation;
PAAD	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg18612461	chr15:75251733	NA	-0.51	-6.19	-0.45	5.3e-9	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.91	-11.18	-0.67	1.44e-21	Dental caries;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.9	6.56	0.47	8.16e-10	Alzheimer's disease;
PAAD	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.72	8.98	0.59	9.93e-16	Dupuytren's disease;
PAAD	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.76e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg27205649	chr11:78285834	NARS2	-0.58	-4.27	-0.33	3.47e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.81	7.39	0.51	9.25e-12	Neurofibrillary tangles;
PAAD	cis	rs346785	0.692	rs6501881	chr17:74289839	G/A	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.76	7.34	0.51	1.19e-11	Corneal astigmatism;
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.78e-5	Cognitive function;
PAAD	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.63	-6.39	-0.46	1.91e-9	Age at first birth;
PAAD	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg00898013	chr13:113819073	PROZ	-0.66	-6.11	-0.44	8.2e-9	Platelet distribution width;
PAAD	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg10705379	chr10:99080932	FRAT1	0.4	4.67	0.35	6.63e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	4.82	0.36	3.41e-6	Type 2 diabetes;
PAAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg08085267	chr17:45401833	C17orf57	-0.75	-8.0	-0.54	2.96e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.44	0.34	1.69e-5	Menarche (age at onset);
PAAD	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs35955747	0.869	rs5997909	chr22:31591228	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-4.78	-0.36	4.09e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg17771515	chr6:154831774	CNKSR3	0.66	4.78	0.36	4.08e-6	Lipoprotein (a) levels;
PAAD	cis	rs7567389	0.505	rs56273408	chr2:128095588	T/C	cg09760422	chr2:128146352	NA	0.39	6.17	0.45	5.83e-9	Self-rated health;
PAAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00849435	chr19:14607052	GIPC1	0.68	6.79	0.48	2.32e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11028950	chr20:50808697	ZFP64	0.68	6.87	0.49	1.55e-10	Obesity-related traits;
PAAD	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	6.25	0.45	3.96e-9	Monocyte count;
PAAD	cis	rs2278796	0.608	rs6700188	chr1:204969066	A/G	cg04862289	chr1:204966208	NFASC	0.49	5.12	0.38	9.07e-7	Mean platelet volume;
PAAD	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.61	-5.91	-0.43	2.12e-8	Fibrinogen levels;
PAAD	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.99	14.76	0.77	3.71e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-10.28	-0.64	3.89e-19	Height;
PAAD	cis	rs75920871	0.858	rs17120280	chr11:116942132	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.28	-0.33	3.33e-5	Subjective well-being;
PAAD	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-6.3	-0.46	2.98e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4555772	1.000	rs4555772	chr5:74302658	A/G	cg03227963	chr5:74354835	NA	0.43	4.32	0.33	2.84e-5	Stearic acid (18:0) levels;
PAAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.07e-20	Total body bone mineral density;
PAAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.88	-8.41	-0.56	2.73e-14	Gestational age at birth (maternal effect);
PAAD	cis	rs9815354	0.812	rs704964	chr3:42053899	G/A	cg03022575	chr3:42003672	ULK4	-0.73	-5.29	-0.39	4.21e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs75920871	0.800	rs723953	chr11:116924978	A/C	cg04087571	chr11:116723030	SIK3	-0.44	-5.56	-0.41	1.17e-7	Subjective well-being;
PAAD	cis	rs10943724	0.679	rs6918721	chr6:81272896	G/A	cg19323245	chr6:80716898	TTK	-0.42	-4.45	-0.34	1.68e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg16342193	chr10:102329863	NA	-0.79	-8.86	-0.58	1.95e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9472414	0.510	rs227840	chr6:44686304	C/G	cg20913747	chr6:44695427	NA	-0.61	-6.01	-0.44	1.29e-8	Height;
PAAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.27	-0.45	3.63e-9	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.5	0.68	2.06e-22	Menopause (age at onset);
PAAD	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.97	9.51	0.61	4.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.69	-7.81	-0.53	8.83e-13	Colorectal cancer;
PAAD	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.64	-6.88	-0.49	1.44e-10	Height;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg01762785	chr22:42226837	NA	-0.43	-4.79	-0.36	3.94e-6	Intelligence;
PAAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.49	-5.07	-0.38	1.13e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg08779649	chr13:50194554	NA	0.41	5.54	0.41	1.29e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-5.24	-0.39	5.28e-7	Red cell distribution width;
PAAD	cis	rs76917914	0.561	rs2224773	chr9:100824223	C/A	cg03040243	chr9:100819229	NANS	0.51	4.34	0.33	2.63e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.67e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.4	0.64	1.83e-19	Menopause (age at onset);
PAAD	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.48	4.69	0.36	6.15e-6	Longevity;Endometriosis;
PAAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg13918804	chr1:2043761	PRKCZ	0.42	5.55	0.41	1.26e-7	Height;
PAAD	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg14926445	chr8:58193284	C8orf71	-0.65	-4.79	-0.36	3.87e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.74e-6	Pain;
PAAD	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.52	-5.03	-0.38	1.37e-6	White matter hyperintensity burden;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.5	4.89	0.37	2.53e-6	Testicular germ cell tumor;
PAAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-6.72	-0.48	3.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.7	7.82	0.54	8.01e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.15	0.55	1.24e-13	Coffee consumption (cups per day);
PAAD	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	trans	rs1015213	0.609	rs115542794	chr8:52868111	A/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02071572	chr4:1403502	NA	0.48	6.29	0.45	3.28e-9	Longevity;
PAAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg11707556	chr5:10655725	ANKRD33B	0.66	7.22	0.51	2.31e-11	Coronary artery disease;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg00450029	chr8:599525	NA	0.91	6.03	0.44	1.22e-8	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.47	-0.52	5.77e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg17470449	chr10:769945	NA	0.43	4.82	0.36	3.43e-6	Uric acid levels;
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg18279126	chr7:2041391	MAD1L1	0.57	5.69	0.42	6.42e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9659323	0.632	rs10802074	chr1:119624996	C/G	cg17326555	chr1:119535693	NA	-0.36	-5.02	-0.38	1.45e-6	Body mass index;
PAAD	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.67	-9.87	-0.62	4.66e-18	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.47	-0.34	1.51e-5	Mood instability;
PAAD	cis	rs7246760	0.867	rs10410379	chr19:9902197	G/A	cg16876255	chr19:9731953	ZNF561	0.94	4.46	0.34	1.6e-5	Pursuit maintenance gain;
PAAD	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg16898833	chr6:26189333	HIST1H4D	0.48	4.33	0.33	2.75e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs875971	0.660	rs801211	chr7:66015689	T/G	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs7542091	0.518	rs6675416	chr1:210061006	A/G	cg22029157	chr1:209979665	IRF6	-0.59	-7.15	-0.5	3.48e-11	Monobrow;
PAAD	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg18595228	chr15:67193261	NA	0.61	4.32	0.33	2.84e-5	Lung cancer (smoking interaction);
PAAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg00750074	chr16:89608354	SPG7	-0.58	-5.46	-0.41	1.87e-7	Multiple myeloma (IgH translocation);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13173722	chr20:60553138	TAF4	-0.71	-7.08	-0.5	5.1e-11	Primary biliary cholangitis;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs758324	0.773	rs11951407	chr5:131142661	T/C	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11958404	0.615	rs7703242	chr5:157447920	T/C	cg05962755	chr5:157440814	NA	0.57	5.42	0.4	2.34e-7	IgG glycosylation;
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	6.25	0.45	4.02e-9	Obesity-related traits;
PAAD	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.74	5.12	0.38	9.04e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg01786075	chr1:165738056	TMCO1	0.82	6.49	0.47	1.16e-9	Atopic dermatitis;
PAAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.7	6.06	0.44	1.03e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.81	-7.22	-0.51	2.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.75	-7.32	-0.51	1.32e-11	Menopause (age at onset);
PAAD	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.25	-0.39	5.14e-7	Mean corpuscular volume;
PAAD	cis	rs116248771	0.739	rs7648050	chr3:158377470	G/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.56	-0.35	1.04e-5	Resting heart rate;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25820033	chr12:42681744	NA	-0.79	-7.42	-0.52	7.63e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg26816564	chr1:7831052	VAMP3	-0.61	-5.21	-0.39	6.09e-7	Inflammatory bowel disease;
PAAD	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.69	-6.97	-0.49	8.91e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.31	0.46	2.88e-9	Breast cancer;
PAAD	cis	rs642743	0.967	rs686441	chr10:105950233	C/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.57	0.35	9.97e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05746407	chr16:85646856	KIAA0182	0.68	6.96	0.49	9.75e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.9	7.85	0.54	6.93e-13	Alzheimer's disease;
PAAD	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg08632701	chr21:37451849	NA	-0.59	-6.17	-0.45	6.02e-9	Mitral valve prolapse;
PAAD	cis	rs13256369	0.737	rs34194904	chr8:8554553	C/T	cg17143192	chr8:8559678	CLDN23	0.68	6.48	0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg20406979	chr6:167373233	NA	-0.37	-5.01	-0.38	1.46e-6	Crohn's disease;
PAAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.46	-5.75	-0.42	4.68e-8	Childhood ear infection;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.94	-12.53	-0.71	3.41e-25	Prudent dietary pattern;
PAAD	cis	rs61861422	0.516	rs11814062	chr10:134439823	C/T	cg20090690	chr10:134436459	INPP5A	0.6	5.18	0.39	6.88e-7	Primary sclerosing cholangitis;
PAAD	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.65	-4.58	-0.35	9.66e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg03037974	chr15:76606532	NA	0.51	5.7	0.42	5.9e-8	Blood metabolite levels;
PAAD	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00149659	chr3:10157352	C3orf10	0.56	4.42	0.34	1.85e-5	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.79e-5	Migraine;
PAAD	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.51	4.81	0.36	3.64e-6	Uric acid clearance;
PAAD	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-5.58	-0.41	1.09e-7	Schizophrenia;
PAAD	cis	rs1799810	0.523	rs11683986	chr2:128196398	A/G	cg09760422	chr2:128146352	NA	-0.38	-5.71	-0.42	5.7e-8	Self-rated health;
PAAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.4	-5.14	-0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs7804356	0.871	rs6964817	chr7:26756424	G/C	cg03456212	chr7:26904342	SKAP2	0.54	4.36	0.33	2.36e-5	Type 1 diabetes;
PAAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg14349672	chr11:133703707	NA	-0.47	-5.02	-0.38	1.45e-6	Childhood ear infection;
PAAD	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.66	5.69	0.42	6.21e-8	Hemoglobin concentration;
PAAD	cis	rs7833787	0.832	rs12546229	chr8:18701879	C/T	cg17701159	chr8:18705777	PSD3	-0.43	-4.98	-0.37	1.69e-6	Obesity-related traits;
PAAD	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	1.05	6.9	0.49	1.35e-10	Plateletcrit;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.03	0.5	6.5e-11	Eosinophil percentage of white cells;
PAAD	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs9612	0.848	rs7181	chr19:44270925	G/A	cg08581076	chr19:44259116	C19orf61	0.63	4.49	0.34	1.39e-5	Exhaled nitric oxide output;
PAAD	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.52	-0.57	1.45e-14	Vitiligo;
PAAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.58	5.17	0.39	7.13e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg21496419	chr19:44306685	LYPD5	-0.38	-4.64	-0.35	7.57e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00280220	chr17:61926910	NA	-0.42	-4.46	-0.34	1.58e-5	Prudent dietary pattern;
PAAD	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.49	-0.34	1.42e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.71	-7.23	-0.51	2.21e-11	Type 2 diabetes;
PAAD	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.56	-5.48	-0.41	1.73e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.42	5.0	0.38	1.55e-6	Psoriasis;
PAAD	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-4.47	-0.34	1.51e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs62270313	1.000	rs62270313	chr3:134649766	T/C	cg02732671	chr3:134204521	CEP63;ANAPC13	-0.76	-4.35	-0.33	2.49e-5	Epilepsy and lamotrigine-induced maculopapular eruptions;
PAAD	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg10790723	chr22:36903033	FOXRED2	0.43	4.32	0.33	2.85e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9595066	0.938	rs9567377	chr13:44720217	G/T	cg04068111	chr13:44716778	NA	-0.63	-6.5	-0.47	1.09e-9	Schizophrenia;
PAAD	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.8	-0.43	3.78e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.7	7.39	0.51	9.01e-12	Dental caries;
PAAD	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	6.46	0.46	1.33e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.94	12.51	0.71	3.95e-25	Menopause (age at onset);
PAAD	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.63	-7.58	-0.52	3.12e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.14	0.38	8.3e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg00543991	chr22:32367038	NA	1.13	7.12	0.5	3.95e-11	Childhood ear infection;
PAAD	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.88	-0.37	2.66e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00645897	chr1:46713442	RAD54L	0.58	6.55	0.47	8.53e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09598590	chr13:46563704	ZC3H13	0.71	6.43	0.46	1.55e-9	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27664844	chr2:119532486	NA	0.55	6.3	0.46	3e-9	Monocyte percentage of white cells;
PAAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.8	-0.62	6.86e-18	Type 2 diabetes;
PAAD	cis	rs72960926	1.000	rs72958951	chr6:75118214	G/A	cg13997649	chr6:74171430	MTO1	0.82	4.49	0.34	1.38e-5	Metabolite levels (MHPG);
PAAD	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.83	-0.43	3.18e-8	QT interval;
PAAD	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg27411982	chr8:10470053	RP1L1	-0.43	-4.63	-0.35	7.88e-6	Triglycerides;
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.26	-0.39	4.92e-7	Systemic lupus erythematosus;
PAAD	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.41	-4.89	-0.37	2.54e-6	Lewy body disease;
PAAD	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.53	-0.34	1.2e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.48	5.25	0.39	5.13e-7	Schizophrenia;
PAAD	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg26446133	chr18:72167187	CNDP2	-0.86	-7.98	-0.54	3.32e-13	Refractive error;
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Body mass index;
PAAD	cis	rs300774	0.925	rs375613	chr2:130618	C/G	cg21211680	chr2:198530	NA	0.65	6.0	0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1667255	0.830	rs3794884	chr18:29176971	A/C	cg18808318	chr18:29669225	NA	0.55	5.19	0.39	6.54e-7	Retinol levels;
PAAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	5.29	0.39	4.13e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg14847009	chr1:175162515	KIAA0040	0.33	5.27	0.39	4.66e-7	Alcohol dependence;
PAAD	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.99	-0.38	1.61e-6	Pulmonary function;
PAAD	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg04656015	chr13:113407548	ATP11A	0.55	4.51	0.34	1.27e-5	Glycated hemoglobin levels;
PAAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.62	5.71	0.42	5.68e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.45	7.13	0.5	3.86e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07975834	chr1:112282151	C1orf183	0.64	6.71	0.48	3.54e-10	Myopia (pathological);
PAAD	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.75	-6.7	-0.48	3.87e-10	Triglycerides;
PAAD	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9616064	0.678	rs9616052	chr22:46967634	A/G	cg03318428	chr22:46971703	NA	0.4	4.6	0.35	8.7e-6	Urate levels in obese individuals;
PAAD	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4450131	0.522	rs11245325	chr10:126348061	C/T	cg20435097	chr10:126320824	FAM53B	0.5	4.98	0.37	1.69e-6	White blood cell count (basophil);
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	4.48	0.34	1.44e-5	Eosinophil percentage of white cells;
PAAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg25342568	chr4:1768564	NA	0.34	4.54	0.35	1.13e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.64	-8.29	-0.56	5.7e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13034020	0.522	rs12998880	chr2:61240882	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs9859260	0.616	rs9867473	chr3:195831098	A/C	cg12923728	chr3:195709715	SDHAP1	-0.58	-5.51	-0.41	1.51e-7	Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	1.0	13.17	0.73	6.6e-27	Eosinophil percentage of white cells;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.86	11.13	0.67	2e-21	Vitiligo;
PAAD	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.58	-0.41	1.09e-7	Reticulocyte count;
PAAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.18	-0.78	2.89e-32	Height;
PAAD	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.59	5.72	0.42	5.6e-8	Adiposity;
PAAD	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.59	5.38	0.4	2.71e-7	Common traits (Other);
PAAD	cis	rs7619427	0.507	rs7616472	chr3:44016039	G/A	cg02774523	chr3:44039657	NA	-0.48	-4.38	-0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg26929247	chr19:58907184	NA	-0.39	-4.39	-0.34	2.11e-5	Uric acid clearance;
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg02841227	chr6:26021843	HIST1H4A	0.52	4.89	0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16442450	chr15:69111511	ANP32A	0.64	6.42	0.46	1.68e-9	Smoking initiation;
PAAD	cis	rs4750440	0.706	rs11258770	chr10:14018910	G/T	cg27542038	chr10:14027202	FRMD4A	-0.44	-4.51	-0.34	1.29e-5	Adiponectin levels;
PAAD	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.49	-4.41	-0.34	1.92e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg26554054	chr8:600488	NA	0.92	5.85	0.43	2.93e-8	IgG glycosylation;
PAAD	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg07469887	chr10:131262384	NA	-0.39	-4.56	-0.35	1.06e-5	Response to temozolomide;
PAAD	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.86	7.79	0.53	9.77e-13	Coronary artery disease;
PAAD	cis	rs28719689	0.892	rs28658015	chr8:1273053	G/A	cg22761795	chr8:1265118	NA	0.82	6.02	0.44	1.25e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2885056	0.891	rs28367549	chr19:10689184	A/C	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08484665	chr2:70314817	PCBP1	0.62	6.32	0.46	2.76e-9	Obesity-related traits;
PAAD	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.81	-6.04	-0.44	1.15e-8	Coronary artery calcification;
PAAD	cis	rs2999052	0.502	rs9855015	chr3:127808815	A/G	cg07478098	chr3:127799975	RUVBL1	0.71	4.59	0.35	9.31e-6	Hypospadias;
PAAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.76	8.18	0.55	1.08e-13	Neuroticism;
PAAD	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.01	-0.38	1.52e-6	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00997172	chr20:32399000	CHMP4B	0.58	6.61	0.47	6.07e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.82	-9.13	-0.6	3.98e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg21937377	chr3:194868750	C3orf21	0.45	4.82	0.36	3.51e-6	Non-small cell lung cancer;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg17326555	chr1:119535693	NA	-0.43	-5.12	-0.38	9.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11825064	0.673	rs80332462	chr11:134496895	C/T	cg02089395	chr11:134479357	NA	-0.93	-5.53	-0.41	1.34e-7	Seasonality;
PAAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.84	-0.43	2.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg13560548	chr3:10150139	C3orf24	0.58	5.28	0.39	4.43e-7	Alzheimer's disease;
PAAD	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.62	5.31	0.4	3.79e-7	QRS duration;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg27121462	chr16:89883253	FANCA	-0.47	-5.1	-0.38	1.02e-6	Vitiligo;
PAAD	cis	rs216303	1.000	rs216301	chr12:6157988	A/G	cg12895370	chr12:6755816	ACRBP	-0.49	-4.26	-0.33	3.52e-5	Low vWF levels;
PAAD	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.84	-0.37	3.15e-6	Blood pressure;
PAAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.56	5.18	0.39	6.82e-7	Mood instability;
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg11766577	chr21:47581405	C21orf56	-0.41	-4.61	-0.35	8.37e-6	Testicular germ cell tumor;
PAAD	cis	rs2281636	1.000	rs2231675	chr10:101492241	G/A	cg05149213	chr10:101381631	SLC25A28	-0.48	-4.58	-0.35	9.47e-6	Obesity-related traits;
PAAD	cis	rs2882667	0.690	rs10463975	chr5:138263249	G/A	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.21e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.95	7.84	0.54	7.44e-13	Triglycerides;
PAAD	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.85	0.37	3.07e-6	Longevity;
PAAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.64	6.58	0.47	7.14e-10	Blood protein levels;
PAAD	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs56046484	0.871	rs62021230	chr15:85583952	C/T	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07005078	chr4:17578674	LAP3	0.62	6.37	0.46	2.15e-9	Obesity-related traits;
PAAD	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.43	-5.22	-0.39	5.83e-7	Coronary artery disease;
PAAD	cis	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.17e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.75	6.75	0.48	2.97e-10	Coronary artery disease;
PAAD	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.34	4.85	0.37	3e-6	Migraine;
PAAD	cis	rs8077577	0.747	rs7215678	chr17:18139793	A/C	cg16794390	chr17:18148240	FLII	-0.53	-4.6	-0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs553086	0.818	rs11228858	chr11:56722835	G/A	cg12795368	chr11:57103544	SSRP1	0.51	4.32	0.33	2.85e-5	Fear of severe pain;
PAAD	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg01047959	chr19:17666446	GLT25D1	0.48	4.48	0.34	1.46e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg15478930	chr2:27652102	NRBP1	0.47	4.4	0.34	2.04e-5	Total body bone mineral density;
PAAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.73	8.11	0.55	1.59e-13	Colorectal or endometrial cancer;
PAAD	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.36	-0.33	2.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Osteoarthritis;
PAAD	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs1941184	0.526	rs10084010	chr18:29027745	C/T	cg03238162	chr18:29027701	DSG3	0.42	4.33	0.33	2.7e-5	Parkinson's disease (age of onset);
PAAD	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17714025	chr11:30038619	KCNA4	-0.39	-7.04	-0.5	6.06e-11	Obesity-related traits;
PAAD	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.71	-5.95	-0.43	1.74e-8	Menarche (age at onset);
PAAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg19052272	chr2:3704530	ALLC	-0.53	-6.28	-0.45	3.31e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.67	-6.68	-0.48	4.25e-10	Schizophrenia;
PAAD	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11235843	0.706	rs10898949	chr11:73581672	C/T	cg15670924	chr11:73669256	DNAJB13	-0.76	-4.69	-0.36	5.95e-6	Hand grip strength;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24044288	chr5:180632321	TRIM7	0.61	7.22	0.51	2.3e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg08999081	chr20:33150536	PIGU	-0.51	-5.59	-0.41	1.04e-7	Height;
PAAD	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.82	0.66	1.34e-20	Menopause (age at onset);
PAAD	cis	rs1075265	0.587	rs2949811	chr2:54024165	G/A	cg04546899	chr2:54196757	PSME4	0.3	4.26	0.33	3.54e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.44	6.21	0.45	4.71e-9	Vitiligo;
PAAD	trans	rs901683	1.000	rs35349326	chr10:45973624	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25750018	chr22:21141659	PI4KA;SERPIND1	0.6	6.6	0.47	6.34e-10	Lung cancer in ever smokers;
PAAD	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7554547	0.526	rs4846078	chr1:11967356	C/T	cg07603449	chr1:11986842	KIAA2013	-0.33	-5.2	-0.39	6.3e-7	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-6.98	-0.49	8.69e-11	Gut microbiome composition (summer);
PAAD	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.52	4.5	0.34	1.36e-5	Height;
PAAD	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12304921	0.935	rs4768941	chr12:51355601	A/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07677032	chr17:61819896	STRADA	0.52	5.16	0.39	7.7300000000000005e-07	Prudent dietary pattern;
PAAD	cis	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg27411982	chr8:10470053	RP1L1	0.42	4.57	0.35	1.02e-5	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.5	-5.14	-0.38	8.41e-7	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16612471	chr10:27793255	RAB18	0.6	6.49	0.47	1.12e-9	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21740204	chr9:72873544	SMC5	0.64	6.32	0.46	2.69e-9	Obesity-related traits;
PAAD	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.88	11.21	0.67	1.21e-21	Body mass index;
PAAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.32e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs2790216	1.000	rs1618814	chr10:59963477	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-7.45	-0.52	6.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.69	7.09	0.5	4.77e-11	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.51	-5.92	-0.43	2.04e-8	Breast cancer;
PAAD	cis	rs6256	1.000	rs10832063	chr11:13574634	T/C	cg11976911	chr11:13509032	NA	-0.65	-5.01	-0.38	1.51e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	trans	rs61677309	1.000	rs59450866	chr11:118167707	C/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.04e-5	Migraine;
PAAD	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg16576597	chr16:28551801	NUPR1	-0.55	-5.23	-0.39	5.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs867529	0.695	rs62157805	chr2:89014728	T/C	cg26627705	chr2:89060884	NA	-0.48	-4.68	-0.35	6.35e-6	Height;
PAAD	cis	rs2463822	0.583	rs11600383	chr11:62060451	A/G	cg06239285	chr11:62104954	ASRGL1	0.81	5.06	0.38	1.22e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4740619	0.619	rs10810520	chr9:16029467	G/T	cg14451791	chr9:16040625	NA	-0.46	-5.28	-0.39	4.32e-7	Body mass index;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.27	-0.33	3.36e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.8	8.29	0.56	5.67e-14	Schizophrenia;
PAAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.72	6.61	0.47	6.16e-10	Menarche (age at onset);
PAAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg09835421	chr16:68378352	PRMT7	-0.91	-7.08	-0.5	4.91e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs728616	0.510	rs12411989	chr10:81937850	G/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.77	9.23	0.6	2.21e-16	Lung cancer;
PAAD	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9913156	0.748	rs56124631	chr17:4561378	A/G	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	7.63	0.53	2.44e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg00262122	chr8:11665843	FDFT1	0.5	4.64	0.35	7.48e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2834188	0.924	rs6517159	chr21:34673400	C/G	cg04842828	chr21:34696676	IFNAR1	0.49	4.81	0.36	3.55e-6	Narcolepsy;
PAAD	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.62	-5.63	-0.42	8.61e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.46	4.26	0.33	3.61e-5	Red cell distribution width;
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10886678	chr20:30946050	ASXL1	0.59	6.46	0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.73	7.4	0.51	8.48e-12	Prostate cancer;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg20302533	chr7:39170763	POU6F2	0.5	7.0	0.49	7.65e-11	IgG glycosylation;
PAAD	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.04	-0.38	1.32e-6	Mood instability;
PAAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00292662	chr22:38071168	LGALS1	0.65	6.81	0.48	2.14e-10	Fat distribution (HIV);
PAAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg19636519	chr7:99541626	NA	0.48	5.17	0.39	7.34e-7	Coronary artery disease;
PAAD	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.87	0.54	6.17e-13	Motion sickness;
PAAD	trans	rs2257129	1.000	rs56351107	chr10:122915497	C/G	cg03717442	chr2:45172201	SIX3	-1.33	-6.47	-0.46	1.25e-9	Coronary artery disease;Body mass index;
PAAD	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.01	-0.38	1.5e-6	Joint mobility (Beighton score);
PAAD	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs9462027	0.606	rs4513788	chr6:34694779	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.37	-0.4	2.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-4.25	-0.33	3.66e-5	Coronary artery disease;
PAAD	cis	rs12533831	0.627	rs2435610	chr7:150890034	C/A	cg09611742	chr7:150745473	ACCN3	0.42	4.41	0.34	1.96e-5	Childhood ear infection;
PAAD	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.49	0.41	1.63e-7	Electrocardiographic conduction measures;
PAAD	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg04520793	chr17:42248056	ASB16	0.39	5.07	0.38	1.16e-6	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.49	-0.34	1.43e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.45	-4.51	-0.34	1.3e-5	Vitiligo;
PAAD	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg16586182	chr3:47516702	SCAP	0.65	7.22	0.51	2.34e-11	Colorectal cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06748231	chr5:1112251	SLC12A7	0.66	7.16	0.5	3.18e-11	Myopia (pathological);
PAAD	cis	rs7873102	0.654	rs10283803	chr9:38019145	T/C	cg03528946	chr9:38069800	SHB	-0.52	-5.17	-0.39	7.16e-7	Brain structure;
PAAD	cis	rs7896729	0.943	rs7901719	chr10:5355420	C/A	cg07902545	chr10:6194255	PFKFB3	-0.41	-4.39	-0.34	2.11e-5	Intelligence;
PAAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg11204139	chr17:3907470	NA	0.85	8.7	0.58	5.01e-15	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02396009	chr11:126081672	RPUSD4;FAM118B	-0.7	-6.3	-0.46	3.04e-9	Neuroticism;
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs929596	0.564	rs2741028	chr2:234518914	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.83	-9.56	-0.61	2.97e-17	Menarche (age at onset);
PAAD	cis	rs12681963	0.688	rs73242331	chr8:30055844	G/A	cg23406830	chr8:30012838	DCTN6	-0.7	-4.34	-0.33	2.57e-5	Migraine;
PAAD	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.52	5.53	0.41	1.35e-7	Obesity-related traits;
PAAD	cis	rs1468333	1.000	rs6867242	chr5:137561186	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.34	0.46	2.42e-9	Resting heart rate;
PAAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-1.22	-12.07	-0.7	5.9e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06714021	chr16:19179512	SYT17	-0.67	-6.43	-0.46	1.55e-9	Primary biliary cholangitis;
PAAD	cis	rs4936891	0.577	rs4565912	chr11:123904395	A/G	cg22125253	chr11:123886957	OR10G4	-0.43	-4.27	-0.33	3.38e-5	Male fertility;
PAAD	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2562456	0.833	rs56179986	chr19:21520684	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs6604026	0.656	rs2255723	chr1:93368309	A/C	cg17283838	chr1:93427260	FAM69A	0.62	5.66	0.42	7.4e-8	Multiple sclerosis;
PAAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.84	10.01	0.63	1.91e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.61	-4.95	-0.37	1.97e-6	Neuroblastoma;
PAAD	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.62	5.35	0.4	3.15e-7	Resistin levels;
PAAD	cis	rs35000415	0.938	rs34381587	chr7:128666825	A/G	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg22161983	chr8:103818636	NA	0.61	7.09	0.5	4.62e-11	Metabolite levels  (X-11787);
PAAD	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.79	8.44	0.56	2.39e-14	Multiple sclerosis;
PAAD	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg14515779	chr1:101123966	NA	0.47	6.06	0.44	1.04e-8	Monocyte count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17753496	chr6:108881018	FOXO3	-0.62	-6.58	-0.47	7.11e-10	Smoking initiation;
PAAD	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs58653258	0.730	rs2802976	chr1:234989174	A/G	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.04e-6	Life satisfaction;
PAAD	cis	rs2908197	0.737	rs2109857	chr7:75963169	T/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg05484376	chr2:27715224	FNDC4	-0.51	-5.17	-0.39	7.42e-7	Oral cavity cancer;
PAAD	cis	rs3774830	0.743	rs6810392	chr4:5459932	C/T	cg26943120	chr4:5472116	STK32B	0.34	4.26	0.33	3.55e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.46	4.55	0.35	1.09e-5	Visceral fat;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00166722	chr3:10149974	C3orf24	0.92	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs12541635	0.966	rs11782609	chr8:106967919	G/A	cg10147462	chr8:107024639	NA	0.45	4.6	0.35	8.91e-6	Age of smoking initiation;
PAAD	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-5.74	-0.42	5.05e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg20821713	chr7:1055600	C7orf50	-0.54	-4.41	-0.34	1.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.46	1.47e-9	Intraocular pressure;
PAAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	9.87e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.81	-6.94	-0.49	1.09e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg05643964	chr20:62369504	LIME1	-0.5	-4.61	-0.35	8.44e-6	Prostate cancer;
PAAD	cis	rs2153535	0.518	rs9505503	chr6:8638805	G/A	cg07606381	chr6:8435919	SLC35B3	0.44	4.38	0.33	2.21e-5	Motion sickness;
PAAD	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.5	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs113588255	chr10:46067333	C/G	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg09127314	chr1:152161683	NA	-0.64	-4.57	-0.35	9.97e-6	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17162190	0.698	rs6690458	chr1:26789787	T/C	cg17456097	chr1:26900765	RPS6KA1	0.57	4.53	0.35	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg22134325	chr11:66188745	NPAS4	0.29	4.3	0.33	2.99e-5	Airway imaging phenotypes;
PAAD	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.45	-0.34	1.68e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg00666640	chr1:248458726	OR2T12	0.59	4.86	0.37	2.94e-6	Autism spectrum disorder;
PAAD	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15422644	chr12:52116112	SCN8A	-0.7	-7.25	-0.51	1.97e-11	Obesity-related traits;
PAAD	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07374403	chr1:47134188	ATPAF1	0.66	7.54	0.52	4.05e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.77	8.29	0.56	5.58e-14	Mean corpuscular volume;
PAAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg17541715	chr7:1216824	NA	-0.55	-6.35	-0.46	2.39e-9	Longevity;Endometriosis;
PAAD	cis	rs9467160	0.644	rs62400468	chr6:24457358	C/T	cg16211469	chr6:24423932	MRS2	0.48	4.45	0.34	1.64e-5	Liver enzyme levels;
PAAD	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.84	0.37	3.1e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.5	-4.88	-0.37	2.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-9.43	-0.61	6.49e-17	Vitiligo;
PAAD	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.64	-0.53	2.24e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs2786865	0.708	rs2744761	chr1:26040514	T/G	cg12074707	chr1:27019787	NA	0.7	4.63	0.35	7.78e-6	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.54	5.25	0.39	5.14e-7	Motion sickness;
PAAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.39	-0.34	2.08e-5	Obesity-related traits;
PAAD	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.61	-5.94	-0.43	1.85e-8	Systolic blood pressure;
PAAD	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg02297831	chr4:17616191	MED28	-0.6	-5.56	-0.41	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.97	9.91	0.63	3.58e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.53	6.17	0.45	5.84e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.71	-4.87	-0.37	2.83e-6	Smoking behavior;
PAAD	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg22437258	chr11:111473054	SIK2	0.63	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.75e-9	Cognitive function;
PAAD	cis	rs7487075	0.550	rs1472179	chr12:46810514	T/C	cg14671384	chr12:47219920	SLC38A4	0.45	4.46	0.34	1.57e-5	Itch intensity from mosquito bite;
PAAD	cis	rs501916	0.727	rs12439630	chr15:48035191	C/T	cg16110827	chr15:48056943	SEMA6D	-0.54	-5.25	-0.39	5.03e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg05038881	chr1:10490043	APITD1	-0.39	-4.57	-0.35	1e-5	Prostate cancer;
PAAD	cis	rs8025118	0.583	rs7163859	chr15:79552585	A/G	cg11862246	chr15:78730200	IREB2	-0.56	-4.7	-0.36	5.73e-6	Cognitive function;
PAAD	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.62	0.57	8.17e-15	Morning vs. evening chronotype;
PAAD	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg20636351	chr8:55087400	NA	-0.67	-6.53	-0.47	9.22e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	4.31	0.33	2.98e-5	Vitiligo;
PAAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs939584	1.000	rs11127491	chr2:646145	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.59	-5.45	-0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.62	-0.35	8.29e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9287719	0.624	rs10211190	chr2:10725428	A/G	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.6e-6	Childhood ear infection;
PAAD	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-5.35	-0.4	3.23e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.61	-0.53	2.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg03938978	chr2:103052716	IL18RAP	0.51	5.18	0.39	6.86e-7	Blood protein levels;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	1.14	17.77	0.82	6.14e-39	Menarche (age at onset);
PAAD	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.74	0.42	5.08e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg07220939	chr11:64358617	SLC22A12	-0.41	-4.45	-0.34	1.65e-5	Urate levels in obese individuals;
PAAD	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.55	4.43	0.34	1.78e-5	Bone mineral density (spine);
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg20578329	chr17:80767326	TBCD	0.64	4.7	0.36	5.84e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg21191810	chr6:118973309	C6orf204	-0.52	-5.11	-0.38	9.75e-7	Renal cell carcinoma;
PAAD	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.11	0.5	4.23e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg18833306	chr6:118973337	C6orf204	0.47	5.36	0.4	3.03e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.8	4.35	0.33	2.45e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	1.04	12.67	0.72	1.45e-25	Breast cancer;
PAAD	cis	rs939584	0.935	rs12995480	chr2:629881	T/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg03885332	chr11:832357	CD151	-0.45	-5.34	-0.4	3.33e-7	Mean platelet volume;
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg26441486	chr22:50317300	CRELD2	0.45	5.03	0.38	1.36e-6	Schizophrenia;
PAAD	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg27449745	chr7:23145252	KLHL7	-0.59	-5.4	-0.4	2.52e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.45	5.52	0.41	1.42e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.47	5.64	0.42	8.09e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6256	0.932	rs76107484	chr11:13511832	C/T	cg11976911	chr11:13509032	NA	-0.63	-4.73	-0.36	5.14e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.87	5.54	0.41	1.29e-7	Diabetic kidney disease;
PAAD	cis	rs1018697	1.000	rs7896903	chr10:104566417	A/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.28	-0.33	3.24e-5	Colorectal adenoma (advanced);
PAAD	cis	rs655641	0.539	rs694011	chr11:85760028	T/C	cg07180834	chr11:85838833	NA	-0.47	-5.2	-0.39	6.39e-7	Platelet count;
PAAD	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg12700464	chr11:78128424	GAB2	-0.6	-4.49	-0.34	1.41e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs2790216	1.000	rs2590323	chr10:60000781	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.58	-4.78	-0.36	4.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17227506	0.704	rs34621320	chr8:13434824	A/C	cg02718516	chr8:13424094	C8orf48	-0.31	-4.26	-0.33	3.53e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.8	4.3	0.33	3.06e-5	Coronary artery disease;
PAAD	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.33	0.4	3.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.35	-0.46	2.36e-9	Blood trace element (Zn levels);
PAAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs112427907	1	rs112427907	chr3:47995270	G/A	cg04507495	chr3:47563649	NA	1.12	5.49	0.41	1.67e-7	Stem cell growth factor beta levels;
PAAD	trans	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg26939375	chr7:64535504	NA	-0.73	-8.53	-0.57	1.4e-14	Aortic root size;
PAAD	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg15571903	chr15:79123663	NA	-0.5	-6.38	-0.46	2.03e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	trans	rs901683	1.000	rs35187216	chr10:45986620	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.6	-0.47	6.47e-10	HDL cholesterol;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.49	-4.83	-0.36	3.35e-6	Vitiligo;
PAAD	cis	rs4141404	0.740	rs4820946	chr22:31551160	A/G	cg02404636	chr22:31891804	SFI1	0.53	4.48	0.34	1.46e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs10887741	0.507	rs791874	chr10:89406070	T/G	cg13926569	chr10:89418898	PAPSS2	-0.52	-5.28	-0.39	4.36e-7	Exercise (leisure time);
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.64e-7	Lung cancer;
PAAD	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.77	6.35	0.46	2.35e-9	Glioblastoma;
PAAD	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.5	0.85	3.21e-43	IgG glycosylation;
PAAD	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg10523679	chr1:76189770	ACADM	0.52	4.83	0.36	3.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg00253185	chr1:247542119	NA	0.54	4.39	0.34	2.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.82	-0.43	3.45e-8	Mood instability;
PAAD	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg26318627	chr11:63887540	MACROD1	-0.44	-4.34	-0.33	2.62e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6501435	0.810	rs9915679	chr17:69083685	T/G	cg00193521	chr17:68133597	NA	0.46	4.57	0.35	1.01e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.45	-4.32	-0.33	2.77e-5	Motion sickness;
PAAD	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.58	5.8	0.43	3.71e-8	Inflammatory bowel disease;
PAAD	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg06627628	chr2:24431161	ITSN2	-0.57	-5.5	-0.41	1.6e-7	Sjögren's syndrome;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs8005172	0.750	rs17203398	chr14:88449847	G/C	cg18078958	chr14:88630771	NA	0.44	5.21	0.39	6.02e-7	Parkinson's disease;
PAAD	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	7.2	0.5	2.65e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.5	-0.34	1.35e-5	Body mass index;
PAAD	trans	rs9409082	0.798	rs35367349	chr9:108922078	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.34	-0.46	2.42e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg25364880	chr3:44379878	C3orf23	0.57	5.14	0.38	8.48e-7	Depressive symptoms;
PAAD	cis	rs9401295	0.635	rs7763892	chr6:98266607	T/C	cg00987395	chr6:98934664	NA	0.37	4.41	0.34	1.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg23112188	chr14:24563095	PCK2	-0.52	-5.6	-0.41	9.99e-8	IgG glycosylation;
PAAD	cis	rs7577696	0.719	rs3752916	chr2:32354558	C/T	cg02381751	chr2:32503542	YIPF4	-0.49	-4.83	-0.36	3.28e-6	Inflammatory biomarkers;
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Body mass index;
PAAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg14388049	chr10:71211838	TSPAN15	-0.47	-4.95	-0.37	1.95e-6	Venous thromboembolism;
PAAD	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.3	-0.56	5.32e-14	Morning vs. evening chronotype;
PAAD	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.39	-4.71	-0.36	5.6e-6	Coronary artery disease;
PAAD	cis	rs7998202	0.667	rs282575	chr13:113359524	G/C	cg02820901	chr13:113351484	ATP11A	0.66	4.51	0.34	1.3e-5	Glycated hemoglobin levels;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.4	-0.34	2e-5	Platelet count;
PAAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.74	0.36	4.81e-6	Melanoma;
PAAD	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-5.85	-0.43	2.95e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg27490568	chr2:178487706	NA	0.43	4.56	0.35	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2133450	0.526	rs73020271	chr3:7346412	C/T	cg19930620	chr3:7340148	GRM7	-0.46	-4.91	-0.37	2.31e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg20159608	chr7:32802032	NA	-0.54	-5.27	-0.39	4.51e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-17.71	-0.82	8.76e-39	Height;
PAAD	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-5.56	-0.41	1.21e-7	Plateletcrit;Platelet count;
PAAD	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg23283495	chr1:209979779	IRF6	-0.76	-7.01	-0.49	7.42e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.94	8.91	0.59	1.43e-15	Gut microbiome composition (summer);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23958684	chr5:112631526	MCC	0.62	7.37	0.51	1.01e-11	Smoking initiation;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.25	0.39	5.01e-7	Renal function-related traits (BUN);
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg19761014	chr17:28927070	LRRC37B2	0.95	6.45	0.46	1.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg24330906	chr2:85765176	MAT2A	0.55	5.32	0.4	3.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.71	6.98	0.49	8.6e-11	Uric acid levels;
PAAD	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.75	-6.73	-0.48	3.25e-10	Blood protein levels;
PAAD	cis	rs11668609	0.515	rs2195971	chr19:24079993	T/C	cg09235885	chr19:23456588	NA	-0.64	-4.47	-0.34	1.5e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg02475695	chr16:616220	NHLRC4	0.47	5.37	0.4	2.93e-7	Height;
PAAD	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.93	9.0	0.59	8.87e-16	Psoriasis;
PAAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg14440974	chr22:39074834	NA	-0.55	-6.76	-0.48	2.75e-10	Menopause (age at onset);
PAAD	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.56	0.61	3e-17	Bladder cancer;
PAAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.92	0.59	1.41e-15	Menopause (age at onset);
PAAD	cis	rs1879734	0.636	rs12080993	chr1:54178501	A/C	cg14659662	chr1:54151053	GLIS1	0.37	5.29	0.39	4.13e-7	Mitral valve prolapse;
PAAD	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.59	7.95	0.54	3.98e-13	Primary biliary cholangitis;
PAAD	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg27326032	chr3:127006922	NA	-0.67	-6.08	-0.44	9.17e-9	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs7567389	0.573	rs11541137	chr2:128145771	C/T	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs10789285	0.681	rs2248775	chr1:69697308	G/T	cg04447890	chr1:68697988	GPR177	-0.55	-4.48	-0.34	1.44e-5	Psoriasis;
PAAD	cis	rs6141769	0.542	rs6057625	chr20:31304994	G/A	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.29	-4.98	-0.37	1.74e-6	Caffeine consumption;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.66	-0.35	6.9e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.94	-0.49	1.08e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs901683	0.850	rs17157890	chr10:46020652	T/C	cg12869334	chr8:37699360	GPR124	0.98	6.78	0.48	2.44e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.45	-0.34	1.63e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg18769074	chr3:133464867	TF	0.48	5.84	0.43	3.09e-8	Iron status biomarkers (transferrin levels);
PAAD	trans	rs61677309	1.000	rs3782040	chr11:118176097	A/G	cg15548380	chr1:19984784	NBL1	-0.62	-6.42	-0.46	1.62e-9	Lung cancer in ever smokers;
PAAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18404041	chr3:52824283	ITIH1	0.42	4.49	0.34	1.39e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg02569219	chr17:2266849	SGSM2	0.47	4.53	0.34	1.21e-5	Proinsulin levels;
PAAD	cis	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg20159608	chr7:32802032	NA	0.49	5.13	0.38	8.64e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg07617317	chr6:118971624	C6orf204	0.56	4.72	0.36	5.38e-6	Diastolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02867162	chr16:1020843	LMF1	-0.75	-6.3	-0.46	2.99e-9	Neuroticism;
PAAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	1.05	9.19	0.6	2.81e-16	Initial pursuit acceleration;
PAAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg25809561	chr17:30822961	MYO1D	0.55	5.48	0.41	1.75e-7	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg14851346	chr12:38532713	NA	0.44	4.31	0.33	2.95e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs868036	0.561	rs28376697	chr15:68140315	A/G	cg05925327	chr15:68127851	NA	-0.59	-5.32	-0.4	3.63e-7	Restless legs syndrome;
PAAD	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg04990556	chr1:26633338	UBXN11	0.65	4.82	0.36	3.4e-6	Obesity-related traits;
PAAD	cis	rs6466055	0.661	rs12538590	chr7:104896470	C/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg10871876	chr19:53194124	ZNF83	0.58	5.23	0.39	5.52e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.09	8.45	0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.58	6.01	0.44	1.35e-8	Huntington's disease progression;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04798676	chr3:196230670	RNF168	-0.63	-6.51	-0.47	1.04e-9	Smoking initiation;
PAAD	trans	rs785830	0.538	rs581500	chr9:259331	C/T	cg17093826	chr7:138458720	ATP6V0A4	0.53	6.85	0.49	1.76e-10	Platelet distribution width;
PAAD	cis	rs4588572	0.779	rs3088102	chr5:77654679	G/A	cg18281939	chr5:77783895	LHFPL2	-0.43	-4.95	-0.37	1.98e-6	Triglycerides;
PAAD	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.94	-0.37	2.08e-6	Toenail selenium levels;
PAAD	cis	rs4605213	0.528	rs1860574	chr17:49299294	T/C	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.6	5.84	0.43	3.08e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs761746	0.739	rs5998086	chr22:32080244	C/T	cg01338084	chr22:32026380	PISD	0.66	5.58	0.41	1.08e-7	Intelligence;
PAAD	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.67	7.46	0.52	6.19e-12	Prostate cancer;
PAAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-1.11	-7.58	-0.52	3.18e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.83	-0.37	3.23e-6	Recombination measurement;
PAAD	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.64	6.24	0.45	4.05e-9	IgG glycosylation;
PAAD	cis	rs11024102	1.000	rs11024102	chr11:17008605	T/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.46	0.34	1.59e-5	Glaucoma (primary angle closure);
PAAD	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg00431813	chr7:1051703	C7orf50	0.74	4.8	0.36	3.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg20558230	chr5:484149	SLC9A3	0.4	5.36	0.4	3.08e-7	Cystic fibrosis severity;
PAAD	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.12	9.76	0.62	8.87e-18	Red blood cell traits;
PAAD	cis	rs57994353	0.566	rs10870160	chr9:139312996	C/T	cg21253087	chr9:139290292	SNAPC4	0.54	4.79	0.36	3.88e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.5	7.06	0.5	5.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8063160	0.756	rs35749174	chr16:89716493	G/A	cg07984980	chr16:89898383	SPIRE2	0.89	5.01	0.38	1.49e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs375066	0.710	rs11881193	chr19:44421516	G/T	cg21496419	chr19:44306685	LYPD5	-0.4	-4.63	-0.35	7.65e-6	Breast cancer;
PAAD	cis	rs12230513	0.732	rs67290413	chr12:55869876	T/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.25	0.33	3.76e-5	Contrast sensitivity;
PAAD	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg13263323	chr15:86062960	AKAP13	0.64	7.35	0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg07648498	chr16:89883185	FANCA	0.47	4.54	0.35	1.14e-5	Vitiligo;
PAAD	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.41	-0.4	2.45e-7	Bladder cancer;
PAAD	cis	rs4668356	1.000	rs73013465	chr2:172010801	T/C	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.26	-0.45	3.68e-9	Coffee consumption (cups per day);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25698777	chr8:124780690	FAM91A1	-0.77	-7.0	-0.49	7.6e-11	Neuroticism;
PAAD	cis	rs564309	1.000	rs13373984	chr1:228580454	C/A	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg04809136	chr2:24300158	SF3B14	-0.41	-4.77	-0.36	4.22e-6	Quantitative traits;
PAAD	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.63e-9	Alcohol dependence;
PAAD	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.66	7.24	0.51	2.03e-11	Blood protein levels;
PAAD	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.64	5.98	0.44	1.56e-8	Obesity-related traits;
PAAD	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs959260	1.000	rs959260	chr17:73369422	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.79	-0.48	2.41e-10	Glomerular filtration rate;
PAAD	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.73	9.37	0.6	9.64e-17	Cancer;
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.85	-9.72	-0.62	1.16e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.87	0.37	2.73e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.65e-8	Coronary artery disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01249735	chr7:156742241	NOM1	-0.61	-6.31	-0.46	2.93e-9	Pancreatic cancer;
PAAD	cis	rs747650	0.504	rs4581406	chr11:46962451	T/C	cg19486271	chr11:47235900	DDB2	0.62	5.92	0.43	2.06e-8	Acne (severe);
PAAD	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg08886695	chr4:3369023	RGS12	0.45	4.43	0.34	1.78e-5	Parental longevity (mother's age at death);
PAAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.7	-0.36	5.79e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9815354	1.000	rs6599170	chr3:41772718	C/G	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg21724239	chr8:58056113	NA	0.7	5.37	0.4	2.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2744375	0.600	rs2008748	chr6:7551678	T/G	cg27023638	chr6:7288726	SSR1	-0.41	-4.26	-0.33	3.56e-5	Resting heart rate;
PAAD	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg24881330	chr22:46731750	TRMU	1.22	6.61	0.47	6.1e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7534824	0.625	rs7521668	chr1:101491108	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.69	-4.7	-0.36	5.79e-6	Refractive astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15569224	chr13:52733656	NEK3	0.64	6.29	0.45	3.26e-9	Obesity-related traits;
PAAD	cis	rs2555155	0.840	rs10839576	chr11:6552107	C/T	cg24637308	chr11:6592297	DNHD1	-0.51	-5.23	-0.39	5.47e-7	DNA methylation (variation);
PAAD	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg02344993	chr17:57696989	CLTC	0.62	5.2	0.39	6.47e-7	Hemoglobin concentration;
PAAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2790457	0.792	rs1265830	chr10:28912223	A/G	cg05705492	chr10:28955341	NA	0.43	4.31	0.33	2.97e-5	Multiple myeloma;
PAAD	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.78	9.51	0.61	4.03e-17	Bladder cancer;
PAAD	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.21	-0.39	6.02e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.23	0.39	5.53e-7	Lung cancer;
PAAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.92	10.89	0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-4.56	-0.35	1.06e-5	Vitiligo;
PAAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg10018233	chr7:150070692	REPIN1	0.61	6.41	0.46	1.73e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Red blood cell count;
PAAD	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	1.96	11.2	0.67	1.34e-21	Cannabis dependence symptom count;
PAAD	cis	rs6499755	0.896	rs8058278	chr16:55344508	G/A	cg02859129	chr16:55357253	IRX6	0.34	4.55	0.35	1.07e-5	Hypospadias;
PAAD	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.48	0.61	4.89e-17	Fuchs's corneal dystrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11213987	chr17:4607616	PELP1	0.58	6.34	0.46	2.47e-9	Obesity-related traits;
PAAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23281280	chr6:28129359	ZNF389	-0.61	-4.71	-0.36	5.51e-6	Parkinson's disease;
PAAD	cis	rs2249694	0.920	rs1536826	chr10:135357239	A/C	cg16964102	chr10:135390573	NA	-0.43	-4.37	-0.33	2.25e-5	Obesity-related traits;
PAAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.93	-9.86	-0.62	4.92e-18	Testicular germ cell tumor;
PAAD	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.38	-0.33	2.18e-5	Educational attainment;
PAAD	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg05082376	chr22:42548792	NA	-0.43	-4.27	-0.33	3.37e-5	Cognitive function;
PAAD	cis	rs2229238	0.826	rs111742980	chr1:154508764	T/A	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg12395012	chr8:11607386	GATA4	-0.39	-4.42	-0.34	1.87e-5	Neuroticism;
PAAD	cis	rs6088813	0.883	rs1406949	chr20:33905904	C/A	cg14752227	chr20:34000481	UQCC	0.51	5.03	0.38	1.38e-6	Height;
PAAD	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	cis	rs11811982	0.793	rs74433506	chr1:227426502	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1879734	1.000	rs7543166	chr1:54143423	T/C	cg14659662	chr1:54151053	GLIS1	-0.39	-6.12	-0.44	7.75e-9	Mitral valve prolapse;
PAAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.15	0.39	8.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg22256960	chr15:77711686	NA	-0.51	-4.77	-0.36	4.26e-6	Type 2 diabetes;
PAAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.69	7.23	0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.53	-0.34	1.2e-5	Tonsillectomy;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg16898833	chr6:26189333	HIST1H4D	0.62	4.92	0.37	2.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg20487152	chr13:99095054	FARP1	-0.52	-5.03	-0.38	1.37e-6	Neuroticism;
PAAD	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	12.09	0.7	5.21e-24	Body mass index (adult);
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs11811982	0.793	rs11808670	chr1:227516011	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-1.12	-15.43	-0.78	6.58e-33	Total body bone mineral density;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg20295408	chr7:1910781	MAD1L1	0.5	4.5	0.34	1.32e-5	Schizophrenia;
PAAD	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg02135003	chr7:105160482	PUS7	-0.68	-5.65	-0.42	7.51e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9657904	0.805	rs1867195	chr3:105548176	G/A	cg16975614	chr3:105601834	NA	-0.47	-4.51	-0.34	1.27e-5	Multiple sclerosis;
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.42	4.6	0.35	8.91e-6	Cystic fibrosis severity;
PAAD	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg08992911	chr2:238395768	MLPH	0.59	5.63	0.42	8.63e-8	Prostate cancer;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg19500098	chr13:21900506	NA	0.59	6.34	0.46	2.51e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11239930	1.000	rs11239930	chr1:146560564	C/T	cg17856063	chr1:146543992	NA	0.42	4.44	0.34	1.69e-5	AIDS progression;
PAAD	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.54	5.09	0.38	1.05e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.5	4.31	0.33	2.86e-5	Corneal astigmatism;
PAAD	cis	rs2562456	0.520	rs582992	chr19:21449546	G/T	cg08562672	chr19:21860753	NA	0.46	4.52	0.34	1.25e-5	Pain;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.09	0.67	2.59e-21	Platelet count;
PAAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg13859433	chr6:33739653	LEMD2	-0.65	-5.09	-0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07395648	chr5:131743802	NA	0.48	4.5	0.34	1.35e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.93	8.82	0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.51	-4.84	-0.37	3.22e-6	Neutrophil percentage of white cells;
PAAD	cis	rs116248771	0.793	rs6765967	chr3:158347310	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07725036	chr17:7531119	SHBG;SAT2	0.63	6.35	0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8040855	0.576	rs62022528	chr15:85535261	C/T	cg08123816	chr15:85640762	PDE8A	-0.41	-4.54	-0.35	1.13e-5	Bulimia nervosa;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01756327	chr17:74350268	PRPSAP1	0.68	7.32	0.51	1.36e-11	Obesity-related traits;
PAAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg07648498	chr16:89883185	FANCA	0.5	4.79	0.36	3.85e-6	Vitiligo;
PAAD	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.46	4.31	0.33	2.92e-5	Endometrial cancer;
PAAD	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06392426	chr19:10676186	KRI1	0.66	6.41	0.46	1.74e-9	Red cell distribution width;
PAAD	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.55	5.62	0.41	8.85e-8	Coronary artery disease;
PAAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg03340356	chr1:67600835	NA	0.52	6.26	0.45	3.67e-9	Psoriasis;
PAAD	trans	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg11421182	chr20:36153479	BLCAP	-0.54	-6.45	-0.46	1.4e-9	IgG glycosylation;
PAAD	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg09667013	chr22:42394590	WBP2NL	0.51	5.02	0.38	1.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.76	-8.66	-0.57	6.44e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.43	0.52	7.21e-12	Body mass index;
PAAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.36	-0.33	2.42e-5	Retinal vascular caliber;
PAAD	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg26618903	chr10:100175079	PYROXD2	-0.44	-4.9	-0.37	2.46e-6	Metabolite levels;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	6.96e-8	Obesity-related traits;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.7	5.61	0.41	9.41e-8	Alzheimer's disease;
PAAD	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05267876	chr1:229644265	NUP133	0.64	6.42	0.46	1.69e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.73	-0.48	3.24e-10	Life satisfaction;
PAAD	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.49	-0.34	1.4e-5	IgG glycosylation;
PAAD	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.96	-10.13	-0.63	9.44e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.38	-4.62	-0.35	8.26e-6	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs28647808	1.000	rs2285483	chr9:136271838	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs1545257	0.537	rs11125582	chr2:24646213	C/T	cg02683114	chr2:24398427	C2orf84	-0.48	-4.98	-0.37	1.69e-6	Sjögren's syndrome;
PAAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg27490568	chr2:178487706	NA	0.42	4.44	0.34	1.7e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.57	-5.44	-0.4	2.06e-7	Obesity-related traits;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg00166722	chr3:10149974	C3orf24	0.77	6.72	0.48	3.42e-10	Alzheimer's disease;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.45	-6.86	-0.49	1.62e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.54	6.72	0.48	3.5e-10	Psoriasis;
PAAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.96	-0.59	1.12e-15	Bone mineral density;
PAAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.3	0.45	3.1e-9	Initial pursuit acceleration;
PAAD	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.43	-5.65	-0.42	7.81e-8	Prostate cancer;
PAAD	cis	rs16975963	0.843	rs73041045	chr19:38296026	C/T	cg08679971	chr19:38281047	NA	0.55	5.18	0.39	6.92e-7	Longevity;
PAAD	cis	rs17021463	0.617	rs34872198	chr4:95326957	T/C	cg11021082	chr4:95130006	SMARCAD1	0.48	4.58	0.35	9.64e-6	Testicular germ cell tumor;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02263426	chr18:14378524	NA	0.63	6.91	0.49	1.22e-10	Pancreatic cancer;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs939584	1.000	rs11127486	chr2:632101	C/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg09835421	chr16:68378352	PRMT7	-0.86	-6.92	-0.49	1.19e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.16	-0.39	7.74e-7	Body mass index;
PAAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg01176363	chr20:62369445	LIME1	-0.58	-5.5	-0.41	1.56e-7	Prostate cancer;
PAAD	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.16	0.55	1.2e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15369054	chr17:80825471	TBCD	0.44	4.32	0.33	2.84e-5	Breast cancer;
PAAD	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg08999081	chr20:33150536	PIGU	0.51	5.5	0.41	1.6e-7	Height;
PAAD	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.28	-0.39	4.46e-7	Inflammatory bowel disease;
PAAD	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.78	-9.98	-0.63	2.42e-18	Coronary artery disease;
PAAD	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.23	0.45	4.43e-9	Coffee consumption (cups per day);
PAAD	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs755249	0.567	rs41270807	chr1:39801815	A/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Bladder cancer;
PAAD	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.52	-0.41	1.43e-7	Chronic sinus infection;
PAAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.71	-7.36	-0.51	1.06e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.42	-4.61	-0.35	8.34e-6	Refractive error;
PAAD	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg22875332	chr1:76189707	ACADM	-0.5	-5.02	-0.38	1.41e-6	Daytime sleep phenotypes;
PAAD	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.45	-4.77	-0.36	4.31e-6	Systolic blood pressure;
PAAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.66	-7.05	-0.5	6.02e-11	Age at first birth;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs943466	1.000	rs73412140	chr6:33757014	G/T	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.83	-6.41	-0.46	1.77e-9	Psoriasis;
PAAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg18370025	chr7:2749541	AMZ1	-0.36	-4.42	-0.34	1.83e-5	Height;
PAAD	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg20607287	chr7:12443886	VWDE	-0.69	-5.32	-0.4	3.59e-7	Coronary artery disease;
PAAD	trans	rs901683	0.850	rs117582049	chr10:46050228	C/A	cg11747279	chr17:21096632	NA	0.88	6.71	0.48	3.53e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16401214	chr16:15982478	C16orf63	0.61	6.32	0.46	2.81e-9	Myopia (pathological);
PAAD	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.51	4.81	0.36	3.64e-6	Uric acid clearance;
PAAD	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.78	-0.36	4.16e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-5.11	-0.38	9.36e-7	Lung cancer;
PAAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.46	-4.32	-0.33	2.86e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg23119463	chr10:134592391	INPP5A	-0.5	-4.64	-0.35	7.53e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.24e-6	Lung cancer;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2019960	0.679	rs7007953	chr8:129206486	A/C	cg15331705	chr8:129180010	NA	0.43	5.76	0.42	4.57e-8	Hodgkin's lymphoma;Multiple sclerosis;
PAAD	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg20761395	chr17:511517	VPS53	0.7	7.86	0.54	6.53e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.77	7.63	0.53	2.42e-12	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs501120	0.584	rs906944	chr10:44705439	G/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.93	-0.54	4.5e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg00431813	chr7:1051703	C7orf50	0.56	4.64	0.35	7.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg05338066	chr1:7812865	CAMTA1	-0.47	-4.26	-0.33	3.5e-5	Inflammatory bowel disease;
PAAD	cis	rs2236267	0.726	rs4341685	chr14:88575161	G/A	cg18078958	chr14:88630771	NA	0.5	6.25	0.45	3.85e-9	Food antigen IgG levels;
PAAD	cis	rs1198430	0.571	rs1001207	chr1:23749148	G/A	cg24580199	chr1:23763081	ASAP3	0.53	4.73	0.36	4.98e-6	Total cholesterol levels;
PAAD	cis	rs4074493	0.963	rs6541251	chr1:231173596	T/C	cg22172038	chr1:231176991	FAM89A	0.53	4.86	0.37	2.94e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.98	13.98	0.75	4.41e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg02297831	chr4:17616191	MED28	0.57	5.5	0.41	1.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.1	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-5.88	-0.43	2.5e-8	Mood instability;
PAAD	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2659703	0.653	rs6439128	chr3:128172356	A/T	cg03902093	chr3:128444369	RAB7A	0.41	4.36	0.33	2.42e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-5.79	-0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg07202610	chr7:1142643	C7orf50	-0.71	-4.82	-0.36	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.42	-4.89	-0.37	2.52e-6	Testicular germ cell tumor;
PAAD	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg10818794	chr15:86012489	AKAP13	0.46	5.09	0.38	1.06e-6	Interstitial lung disease;
PAAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg11663144	chr21:46675770	NA	-0.49	-6.02	-0.44	1.29e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.64	-0.47	5.14e-10	Schizophrenia (age at onset);
PAAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg12757816	chr2:10669957	NA	-0.56	-5.94	-0.43	1.86e-8	Prostate cancer;
PAAD	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.29	-0.33	3.17e-5	Morning vs. evening chronotype;
PAAD	cis	rs7260538	0.773	rs1552223	chr19:41525952	A/G	cg13322449	chr19:42300200	CEACAM3	-0.39	-4.52	-0.34	1.21e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs6940638	0.637	rs13217239	chr6:27254967	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.27	-0.33	3.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9649465	1.000	rs10228367	chr7:123370903	C/T	cg04330084	chr7:123175371	IQUB	-0.49	-4.52	-0.34	1.26e-5	Migraine;
PAAD	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-4.71	-0.36	5.48e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg14440974	chr22:39074834	NA	0.58	6.81	0.48	2.17e-10	Menopause (age at onset);
PAAD	cis	rs9506514	0.760	rs9506518	chr13:21134982	T/A	cg27234864	chr13:21295941	IL17D	-0.44	-4.29	-0.33	3.15e-5	Coronary artery calcification;
PAAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.58	4.83	0.36	3.26e-6	Obesity-related traits;
PAAD	cis	rs5751901	0.929	rs2330805	chr22:24998619	A/G	cg08808123	chr22:24999002	GGT1	-0.47	-4.85	-0.37	3.04e-6	Protein quantitative trait loci;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21032728	chr14:65007066	HSPA2	0.62	6.5	0.47	1.09e-9	Obesity-related traits;
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg00522288	chr12:125625016	AACS	-0.56	-6.02	-0.44	1.26e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.19	-10.03	-0.63	1.8e-18	Vitiligo;
PAAD	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.89	-4.56	-0.35	1.03e-5	Toenail selenium levels;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-1.06	-12.95	-0.72	2.57e-26	Urate levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21248028	chr9:90999353	NA	-0.56	-6.79	-0.48	2.38e-10	Monocyte percentage of white cells;
PAAD	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg19257562	chr1:2043853	PRKCZ	0.47	5.78	0.42	4.06e-8	Height;
PAAD	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00152838	chr16:24741724	TNRC6A	-0.51	-4.36	-0.33	2.4e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21246243	chr17:3777064	CAMKK1	-0.63	-7.14	-0.5	3.65e-11	Obesity-related traits;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg03101763	chr11:65319844	LTBP3	-0.88	-4.45	-0.34	1.66e-5	Height;
PAAD	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.65	6.9	0.49	1.29e-10	Aortic root size;
PAAD	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.43	4.83	0.36	3.37e-6	Retinal vascular caliber;
PAAD	cis	rs3136441	0.892	rs2306036	chr11:46911704	C/T	cg19486271	chr11:47235900	DDB2	-0.52	-4.27	-0.33	3.42e-5	HDL cholesterol;
PAAD	cis	rs6796502	0.500	rs7636089	chr3:46873957	A/G	cg22309949	chr3:46792192	NA	-0.58	-4.36	-0.33	2.35e-5	Breast cancer;
PAAD	cis	rs9663711	1	rs9663711	chr10:104547628	C/A	cg14489801	chr10:103603810	KCNIP2	-0.3	-4.35	-0.33	2.44e-5	Carotid plaque burden;
PAAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.6	-6.74	-0.48	3.03e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16405210	chr4:1374714	KIAA1530	-0.57	-5.57	-0.41	1.1e-7	Longevity;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-5.4	-0.4	2.5e-7	Daytime sleep phenotypes;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg16040993	chr19:53496440	ZNF702P	-0.43	-4.28	-0.33	3.27e-5	Psoriasis;
PAAD	cis	rs7873102	0.647	rs56225059	chr9:38058578	G/A	cg03528946	chr9:38069800	SHB	-0.55	-5.68	-0.42	6.59e-8	Brain structure;
PAAD	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.48	-5.16	-0.39	7.75e-7	Body mass index;
PAAD	cis	rs9522267	1.000	rs9522266	chr13:112195456	C/T	cg10483660	chr13:112241077	NA	-0.5	-5.24	-0.39	5.39e-7	Hepatitis;
PAAD	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg01320130	chr1:67600311	NA	-0.43	-4.5	-0.34	1.34e-5	Psoriasis;
PAAD	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.42	4.28	0.33	3.31e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2131877	0.701	rs61231387	chr3:194832120	G/T	cg16306870	chr3:194868790	C3orf21	0.5	4.83	0.37	3.24e-6	Non-small cell lung cancer;
PAAD	cis	rs75920871	0.841	rs112151056	chr11:116919368	G/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg10356904	chr22:49881777	NA	-0.48	-4.73	-0.36	5.16e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6449957	0.832	rs11742365	chr5:67470244	C/G	cg23036683	chr5:67512108	NA	0.5	4.59	0.35	9.14e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.93	6.9	0.49	1.35e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg06815965	chr1:205818668	PM20D1	0.64	7.2	0.5	2.59e-11	Menarche (age at onset);
PAAD	cis	rs9314614	0.789	rs4840641	chr8:6712743	T/C	cg27319216	chr8:6693540	XKR5	-0.41	-5.36	-0.4	2.97e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs863345	0.967	rs9804005	chr1:158520414	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.59	4.75	0.36	4.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-8.48	-0.57	1.81e-14	Alzheimer's disease;
PAAD	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.69	-0.36	6.15e-6	Joint mobility (Beighton score);
PAAD	cis	rs27434	0.583	rs151909	chr5:96156888	T/C	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.73	4.61	0.35	8.49e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg05373962	chr22:49881684	NA	-0.46	-4.45	-0.34	1.64e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg12568669	chr8:11666485	FDFT1	0.3	5.09	0.38	1.06e-6	Monocyte count;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.27e-9	Lymphocyte counts;
PAAD	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.49	-7.83	-0.54	7.85e-13	Cutaneous nevi;
PAAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg05697835	chr1:2722811	NA	0.37	4.32	0.33	2.82e-5	Ulcerative colitis;
PAAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.42e-10	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs11638352	0.661	rs2696074	chr15:44479709	A/C	cg10011062	chr15:43941034	CATSPER2	1.21	4.31	0.33	2.93e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.75	0.42	4.75e-8	Schizophrenia;
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.72	5.96	0.44	1.72e-8	Gallbladder cancer;
PAAD	cis	rs7168353	0.500	rs4778100	chr15:93639244	G/T	cg02918577	chr15:93633145	RGMA	-0.38	-5.07	-0.38	1.12e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg12082025	chr19:1064218	ABCA7	-0.74	-7.21	-0.5	2.52e-11	Alzheimer's disease (late onset);
PAAD	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.49	-5.19	-0.39	6.54e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13939156	chr17:80058883	NA	0.4	4.31	0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.94	8.1	0.55	1.69e-13	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.55	4.46	0.34	1.6e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7583236	0.500	rs6728352	chr2:70343432	G/A	cg19638749	chr2:70312615	NA	1.04	6.74	0.48	3.13e-10	Obesity-related traits;
PAAD	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.46	5.86	0.43	2.8e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs78761021	0.720	rs56086072	chr17:9798412	C/T	cg26853458	chr17:9805074	RCVRN	0.75	8.51	0.57	1.53e-14	Type 2 diabetes;
PAAD	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg10820045	chr2:198174542	NA	-0.44	-4.35	-0.33	2.49e-5	Dermatomyositis;
PAAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.77	8.35	0.56	4e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.92	-0.37	2.18e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13144136	0.664	rs6448177	chr4:10666272	C/T	cg10242279	chr4:10666415	CLNK	-0.46	-5.76	-0.42	4.5e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs317865	0.529	rs57811439	chr4:16194667	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.82	6.11	0.44	8.14e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs256277	0.554	rs173899	chr5:111394892	T/C	cg17919331	chr5:112312406	DCP2	-0.57	-4.35	-0.33	2.51e-5	Coronary artery disease;
PAAD	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg20673091	chr1:2541236	MMEL1	0.73	7.75	0.53	1.24e-12	Ulcerative colitis;
PAAD	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg00919237	chr7:87102261	ABCB4	-0.78	-6.35	-0.46	2.38e-9	Gallbladder cancer;
PAAD	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg16049864	chr8:95962084	TP53INP1	-0.71	-7.35	-0.51	1.12e-11	Type 2 diabetes;
PAAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.97	-0.37	1.82e-6	Neuroticism;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.86	-0.58	1.96e-15	Calcium levels;
PAAD	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.67	-6.95	-0.49	1.02e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7619427	1.000	rs7619427	chr3:44077041	G/A	cg12796028	chr3:44040206	NA	-0.53	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs9985399	1.000	rs17067132	chr3:40002028	A/G	cg00372169	chr3:40547346	ZNF620	0.56	4.25	0.33	3.74e-5	Information processing speed;
PAAD	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg23093090	chr10:104574429	C10orf26	-0.43	-4.64	-0.35	7.53e-6	Colorectal cancer;
PAAD	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg17143192	chr8:8559678	CLDN23	0.66	5.98	0.44	1.57e-8	Obesity-related traits;
PAAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.66	7.42	0.52	7.52e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.34	0.68	5.7e-22	Menopause (age at onset);
PAAD	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.78	8.2	0.55	9.09e-14	Sudden cardiac arrest;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19932343	chr11:66610763	RCE1;C11orf80	-0.63	-6.62	-0.47	5.88e-10	Smoking initiation;
PAAD	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg21823605	chr1:152486609	CRCT1	0.48	6.05	0.44	1.07e-8	Hair morphology;
PAAD	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06771106	chr2:113671356	IL1F7	0.62	6.47	0.46	1.28e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.52	4.43	0.34	1.79e-5	Fat distribution (HIV);
PAAD	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	7.14	0.5	3.5e-11	Triglycerides;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg07685180	chr8:600429	NA	-1.01	-6.39	-0.46	1.92e-9	IgG glycosylation;
PAAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.81	-8.13	-0.55	1.43e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg15443732	chr18:74961078	GALR1	0.74	6.02	0.44	1.27e-8	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.82	-8.9	-0.59	1.59e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.77	-7.92	-0.54	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.92	7.85	0.54	7.05e-13	Eotaxin levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18795127	chr10:135212911	MTG1	0.57	6.94	0.49	1.08e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg12218747	chr21:37451666	NA	-0.57	-6.47	-0.46	1.24e-9	Mitral valve prolapse;
PAAD	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	trans	rs61677309	1.000	rs7480736	chr11:118172364	A/G	cg15548380	chr1:19984784	NBL1	-0.61	-6.4	-0.46	1.82e-9	Lung cancer in ever smokers;
PAAD	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs508970	0.556	rs10792306	chr11:60910740	T/A	cg03055440	chr11:59950405	MS4A6A	-0.42	-4.38	-0.34	2.16e-5	Rheumatoid arthritis;
PAAD	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10547527	chr2:198650123	BOLL	0.48	4.27	0.33	3.4e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.85	-8.75	-0.58	3.84e-15	Type 2 diabetes;
PAAD	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg02887458	chr19:19495540	GATAD2A	0.55	5.13	0.38	8.54e-7	Bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22808750	chr8:9123484	NA	0.56	6.48	0.47	1.19e-9	Smoking initiation;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs36715	0.953	rs36706	chr5:127556698	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.15	0.45	6.6e-9	Breast cancer;
PAAD	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg18898632	chr2:242989856	NA	-0.63	-4.82	-0.36	3.48e-6	Obesity-related traits;
PAAD	cis	rs78472555	0.954	rs2123926	chr15:100264518	T/C	cg18869061	chr15:100272053	LYSMD4	-0.78	-6.41	-0.46	1.73e-9	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg19901468	chr14:105411992	AHNAK2	-0.91	-10.75	-0.66	2.06e-20	Systemic lupus erythematosus;
PAAD	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.69	6.66	0.48	4.74e-10	Subjective well-being;
PAAD	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.69	5.76	0.42	4.43e-8	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.3	-0.33	3.05e-5	Body mass index;
PAAD	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.42	0.61	7.14e-17	Post bronchodilator FEV1;
PAAD	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg21918786	chr6:109611834	NA	-0.44	-4.78	-0.36	4.17e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.63	6.55	0.47	8.23e-10	Leprosy;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.29	-0.33	3.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs965469	1.000	rs6051809	chr20:3352551	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs4668356	0.773	rs75974549	chr2:172047919	T/C	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs2786865	0.708	rs2786873	chr1:26040962	T/G	cg12074707	chr1:27019787	NA	0.7	4.63	0.35	7.78e-6	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg07168214	chr17:7380112	ZBTB4	0.62	5.74	0.42	4.88e-8	Androgen levels;
PAAD	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg14061069	chr19:46274453	DMPK	0.6	5.51	0.41	1.51e-7	Eosinophil counts;
PAAD	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg24585817	chr7:64895279	NA	0.44	4.4	0.34	2.04e-5	Aortic root size;
PAAD	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.68	-7.11	-0.5	4.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs6908034	0.607	rs113894708	chr6:19806066	G/T	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.4	7.48	0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg18210365	chr15:65066710	RBPMS2	-0.45	-4.51	-0.34	1.29e-5	Monocyte count;
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.57	6.1	0.44	8.62e-9	Menopause (age at onset);
PAAD	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.76	-0.42	4.57e-8	Androgen levels;
PAAD	cis	rs9687846	0.808	rs9686661	chr5:55861786	C/T	cg15001016	chr5:55860904	NA	-0.51	-4.93	-0.37	2.15e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg14926445	chr8:58193284	C8orf71	-0.65	-4.79	-0.36	3.87e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19671926	chr4:122722719	EXOSC9	-0.67	-6.15	-0.45	6.57e-9	Type 2 diabetes;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg11416102	chr8:651193	ERICH1	0.89	5.62	0.41	8.94e-8	IgG glycosylation;
PAAD	trans	rs901683	0.850	rs34081552	chr10:45971156	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.62	6.07	0.44	9.88e-9	Multiple sclerosis;
PAAD	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.87	-0.37	2.81e-6	Bipolar disorder;
PAAD	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.46	4.81	0.36	3.58e-6	Dementia with Lewy bodies;
PAAD	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	8.01	0.54	2.84e-13	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg01631408	chr1:248437212	OR2T33	0.59	5.16	0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg09163369	chr1:210001066	C1orf107	0.69	6.62	0.47	5.69e-10	Orofacial clefts;
PAAD	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.49	-5.04	-0.38	1.29e-6	Immature fraction of reticulocytes;
PAAD	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-1.17	-9.62	-0.62	2.05e-17	Obesity-related traits;
PAAD	cis	rs842828	0.710	rs295145	chr2:201222159	C/T	cg26842802	chr2:202125212	CASP8	-0.59	-4.42	-0.34	1.86e-5	Urate levels in lean individuals;
PAAD	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.4	-0.46	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9430161	0.611	rs72644044	chr1:11034347	C/G	cg27631724	chr1:11040367	C1orf127	0.5	6.23	0.45	4.4e-9	Ewing sarcoma;
PAAD	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs7158300	0.515	rs3783937	chr14:92407693	C/T	cg15480367	chr14:93389485	CHGA	0.27	4.39	0.34	2.08e-5	Height;
PAAD	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs77880822	0.562	rs78448673	chr20:1230074	C/T	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.53	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	1.12	6.87	0.49	1.55e-10	Gut microbiota (bacterial taxa);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11910829	chr17:79670396	MRPL12	0.6	6.84	0.49	1.77e-10	Monocyte percentage of white cells;
PAAD	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	1.16	9.19	0.6	2.79e-16	Inflammatory bowel disease;
PAAD	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.53	-5.02	-0.38	1.42e-6	Itch intensity from mosquito bite;
PAAD	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	7.57	0.52	3.31e-12	Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11991866	chr15:44092800	SERINC4;C15orf63	-0.59	-5.82	-0.43	3.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs72827839	0.761	rs79541578	chr17:46102728	G/A	cg23391107	chr17:45924227	SP6	0.55	4.69	0.36	6.11e-6	Ease of getting up in the morning;
PAAD	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg19264203	chr11:92714893	MTNR1B	0.43	4.98	0.37	1.73e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7714584	1.000	rs4958843	chr5:150224924	T/C	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.47	5.82	0.43	3.42e-8	Crohn's disease;
PAAD	cis	rs1008126	0.600	rs7783672	chr7:103145336	T/G	cg04218035	chr7:103086829	SLC26A5	0.35	4.84	0.37	3.22e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg02781088	chr2:113192302	RGPD8;RGPD5	0.94	6.79	0.48	2.39e-10	Yeast infection;
PAAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-1.09	-15.62	-0.79	1.99e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs73416724	1.000	rs112870457	chr6:43280714	T/G	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17361889	0.517	rs62441879	chr7:16329820	G/A	cg08893298	chr7:16437376	ISPD	0.47	4.25	0.33	3.76e-5	Pediatric bone mineral content (hip);
PAAD	cis	rs11966931	0.948	rs72933160	chr6:108088865	G/T	cg10566610	chr6:108093680	SCML4	0.48	4.52	0.34	1.24e-5	Neutrophil percentage of white cells;
PAAD	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.11	14.52	0.76	1.61e-30	Body mass index;
PAAD	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg09127314	chr1:152161683	NA	-0.72	-5.04	-0.38	1.29e-6	Atopic dermatitis;
PAAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.66	5.64	0.42	8.14e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg21300403	chr2:198650112	BOLL	-0.49	-4.36	-0.33	2.37e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.66	0.57	6.46e-15	Bladder cancer;
PAAD	cis	rs7165102	1.000	rs11632310	chr15:65882326	G/C	cg22900193	chr15:65823441	PTPLAD1	0.46	4.41	0.34	1.96e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9913156	0.894	rs28365158	chr17:4620928	T/C	cg23387401	chr17:4582204	PELP1	0.48	4.63	0.35	7.69e-6	Lymphocyte counts;
PAAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.78	6.92	0.49	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07685180	chr8:600429	NA	0.81	5.16	0.39	7.57e-7	IgG glycosylation;
PAAD	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg15764593	chr10:829463	NA	-0.88	-4.35	-0.33	2.49e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-1.0	-10.76	-0.66	2.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.64	-0.35	7.62e-6	Total body bone mineral density;
PAAD	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs16933812	0.500	rs883967	chr9:36993788	T/C	cg13738729	chr9:36989127	PAX5	0.52	7.1	0.5	4.48e-11	Obesity-related traits;
PAAD	cis	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.29	-0.33	3.11e-5	Eotaxin levels;
PAAD	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg22771759	chr13:24902376	NA	0.45	4.44	0.34	1.75e-5	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00462311	chr14:24837184	NFATC4	0.58	6.64	0.47	5.35e-10	Monocyte percentage of white cells;
PAAD	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.44	0.52	6.95e-12	HIV-1 control;
PAAD	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.48	-4.33	-0.33	2.65e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08893839	chr5:154027129	NA	0.76	5.78	0.42	4.01e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.42	0.4	2.29e-7	Lung cancer in ever smokers;
PAAD	cis	rs3736485	0.932	rs2278989	chr15:51914716	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.4	-0.34	2.01e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	6.38	0.46	2e-9	Lung cancer in ever smokers;
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.98	13.02	0.73	1.65e-26	Menopause (age at onset);
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12599982	chr1:44399894	ARTN	0.46	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs797680	0.897	rs2295424	chr1:93580879	T/C	cg04535902	chr1:92947332	GFI1	0.45	4.35	0.33	2.48e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.66	-7.0	-0.49	7.53e-11	Brugada syndrome;
PAAD	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg22482690	chr17:47019901	SNF8	0.5	5.42	0.4	2.28e-7	Type 2 diabetes;
PAAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05330668	chr14:24836090	NFATC4	-0.63	-6.57	-0.47	7.69e-10	Smoking initiation;
PAAD	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg02733842	chr7:1102375	C7orf50	-0.56	-4.57	-0.35	9.94e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.23	-0.39	5.6e-7	QT interval;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27367512	chr5:126405711	FLJ44606	0.57	6.67	0.48	4.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg05333889	chr7:157238977	NA	-0.45	-4.78	-0.36	4.12e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg04342483	chr1:7259290	CAMTA1	-0.41	-4.42	-0.34	1.85e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg21466736	chr12:48725269	NA	0.48	4.37	0.33	2.3e-5	Glycated hemoglobin levels;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07362569	chr17:61921086	SMARCD2	0.63	8.0	0.54	3.01e-13	Prudent dietary pattern;
PAAD	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg15733309	chr7:157513707	PTPRN2	0.63	7.89	0.54	5.61e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs13424612	1.000	rs7590071	chr2:240900947	G/C	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.76	-0.36	4.52e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.43	0.46	1.57e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.98	9.9	0.63	3.8e-18	Corneal astigmatism;
PAAD	cis	rs375066	0.935	rs385321	chr19:44405287	C/T	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs2279817	0.863	rs6689540	chr1:18013820	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-6.04	-0.44	1.13e-8	Neuroticism;
PAAD	cis	rs501120	0.584	rs7902040	chr10:44695308	A/G	cg09554077	chr10:44749378	NA	0.46	5.48	0.41	1.74e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10943724	0.679	rs667882	chr6:81244041	G/T	cg19323245	chr6:80716898	TTK	-0.45	-4.78	-0.36	4.17e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg00655913	chr1:228633920	NA	0.51	4.59	0.35	9.17e-6	Adult asthma;
PAAD	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.67	-5.95	-0.43	1.81e-8	Coronary artery disease;
PAAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.9	10.82	0.66	1.37e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.86	10.11	0.63	1.09e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.41	-0.34	1.94e-5	Resting heart rate;
PAAD	cis	rs939584	1.000	rs13021737	chr2:632348	A/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.39	6.01	0.44	1.34e-8	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.75	-7.41	-0.52	8.08e-12	Breast cancer;
PAAD	cis	rs62229266	0.659	rs2835258	chr21:37424365	G/A	cg12218747	chr21:37451666	NA	-0.47	-5.11	-0.38	9.75e-7	Mitral valve prolapse;
PAAD	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14019695	chr9:139328340	INPP5E	0.6	5.05	0.38	1.23e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg08079166	chr15:68083412	MAP2K5	0.52	4.95	0.37	1.96e-6	Restless legs syndrome;
PAAD	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.48	-4.35	-0.33	2.48e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.59	-6.19	-0.45	5.41e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.33	0.6	1.19e-16	Response to antipsychotic treatment;
PAAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.24	0.64	4.76e-19	Menopause (age at onset);
PAAD	cis	rs9652601	0.748	rs12924112	chr16:11219720	T/G	cg04616529	chr16:11181986	CLEC16A	0.4	4.48	0.34	1.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs7953508	0.711	rs11107120	chr12:93985482	T/C	cg18151635	chr12:93972918	NA	-0.72	-7.14	-0.5	3.65e-11	Pubertal anthropometrics;
PAAD	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.59	-6.11	-0.44	7.98e-9	Response to antidepressants and depression;
PAAD	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg11498726	chr8:26250323	BNIP3L	-0.46	-4.9	-0.37	2.39e-6	Height;
PAAD	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.71	7.79	0.53	9.57e-13	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.67	0.58	5.99e-15	Lung cancer;
PAAD	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.69	-6.97	-0.49	8.91e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11168618	0.567	rs12372687	chr12:48811799	G/T	cg01881778	chr12:48919444	OR8S1	-0.45	-4.58	-0.35	9.73e-6	Adiponectin levels;
PAAD	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.51	5.9	0.43	2.31e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-7.41	-0.52	8.03e-12	Colorectal cancer;
PAAD	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg01304814	chr3:48885189	PRKAR2A	0.97	5.59	0.41	1e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs738321	0.756	rs11089863	chr22:38512402	G/A	cg25457927	chr22:38595422	NA	-0.39	-5.6	-0.41	9.86e-8	Breast cancer;
PAAD	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.47	4.58	0.35	9.71e-6	Fear of minor pain;
PAAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.86	7.64	0.53	2.29e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	7.83	0.54	7.57e-13	LDL cholesterol;
PAAD	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg08390786	chr10:135334061	NA	0.48	4.68	0.36	6.22e-6	Obesity-related traits;
PAAD	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg12508331	chr16:3208203	NA	0.48	4.54	0.35	1.12e-5	Body mass index (adult);
PAAD	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.27e-20	Electrocardiographic conduction measures;
PAAD	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg01489256	chr8:11204017	TDH	-0.42	-4.3	-0.33	3.04e-5	Retinal vascular caliber;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg10729496	chr3:10149963	C3orf24	0.95	8.06	0.55	2.12e-13	Alzheimer's disease;
PAAD	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.14	-17.01	-0.81	5.18e-37	Multiple myeloma;
PAAD	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.72	-5.24	-0.39	5.18e-7	Mosquito bite size;
PAAD	cis	rs114540395	0.858	rs75919232	chr10:103289312	A/G	cg21381511	chr10:104264849	SUFU	-0.86	-4.32	-0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs2637030	0.559	rs7728496	chr5:52867330	G/T	cg17674090	chr5:52083609	ITGA1;PELO	-0.57	-4.31	-0.33	2.89e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.16	0.39	7.67e-7	Tonsillectomy;
PAAD	cis	rs1519814	0.659	rs7817075	chr8:121032846	G/C	cg22335954	chr8:121166405	COL14A1	-0.64	-4.96	-0.37	1.88e-6	Breast cancer;
PAAD	cis	rs2200578	0.626	rs72959128	chr2:99769602	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	4.4	0.34	2.04e-5	IgG glycosylation;
PAAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg15061591	chr7:98625706	SMURF1	-0.5	-4.69	-0.36	6.05e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.49	-4.86	-0.37	2.95e-6	Birth weight;
PAAD	cis	rs900145	0.817	rs998089	chr11:13284111	C/T	cg15603424	chr11:13300592	ARNTL	-0.52	-4.29	-0.33	3.16e-5	Menarche (age at onset);
PAAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg08200582	chr11:442649	ANO9	0.54	4.34	0.33	2.64e-5	Systemic lupus erythematosus;
PAAD	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.51	6.12	0.44	7.77e-9	Sitting height ratio;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg06375148	chr1:209958343	C1orf74	0.45	4.57	0.35	1.01e-5	Monobrow;
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	9.9e-7	Lung cancer;
PAAD	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg05392440	chr1:2478653	NA	0.56	6.05	0.44	1.09e-8	Ulcerative colitis;
PAAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.52	-4.52	-0.34	1.24e-5	White blood cell count;
PAAD	cis	rs8081395	0.801	rs2777895	chr17:57879610	A/G	cg02344993	chr17:57696989	CLTC	-0.44	-4.44	-0.34	1.73e-5	White blood cell count;
PAAD	cis	rs4908768	0.555	rs11582339	chr1:8898807	A/C	cg00590817	chr1:8272081	NA	0.33	4.37	0.33	2.32e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.54	-0.35	1.12e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17095355	0.818	rs4275548	chr10:111910971	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.91	-0.37	2.37e-6	Biliary atresia;
PAAD	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.66e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
PAAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.82	7.65	0.53	2.08e-12	Cleft lip with or without cleft palate;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01997696	chr20:43374401	KCNK15	-0.68	-6.94	-0.49	1.07e-10	Smoking initiation;
PAAD	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.13	7.13	0.5	3.78e-11	Lung cancer in ever smokers;
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.68	-0.35	6.4e-6	Lung cancer;
PAAD	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06850241	chr22:41845214	NA	0.48	4.71	0.36	5.58e-6	Vitiligo;
PAAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.21e-5	Skin colour saturation;
PAAD	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg07166546	chr14:35805898	NA	-0.3	-4.6	-0.35	8.9e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.51	-0.57	1.55e-14	Obesity-related traits;
PAAD	cis	rs6754311	0.589	rs11681659	chr2:136820960	C/T	cg07169764	chr2:136633963	MCM6	-0.63	-6.07	-0.44	9.71e-9	Mosquito bite size;
PAAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.79	6.25	0.45	3.86e-9	Neutrophil percentage of white cells;
PAAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.51e-8	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-4.28	-0.33	3.35e-5	Menarche (age at onset);
PAAD	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.41	6.16	0.45	6.35e-9	Subjective well-being;
PAAD	cis	rs17152411	0.652	rs4962412	chr10:126654643	C/G	cg07081759	chr10:126330905	FAM53B	-0.41	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.86	8.56	0.57	1.18e-14	Response to hepatitis C treatment;
PAAD	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.19	0.64	6.76e-19	Menopause (age at onset);
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg16083429	chr3:49237500	CCDC36	-0.43	-4.36	-0.33	2.36e-5	Menarche (age at onset);
PAAD	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.42	-6.56	-0.47	8.17e-10	Mean corpuscular volume;
PAAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.41	0.46	1.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.75	8.1	0.55	1.64e-13	Eye color traits;
PAAD	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg08992911	chr2:238395768	MLPH	0.81	6.94	0.49	1.08e-10	Prostate cancer;
PAAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg23463467	chr20:60627584	TAF4	0.46	4.92	0.37	2.18e-6	Body mass index;
PAAD	cis	rs4655582	0.527	rs4655794	chr1:66159301	T/C	cg04111102	chr1:66153794	NA	0.44	4.58	0.35	9.53e-6	Fibrinogen levels;
PAAD	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg16342193	chr10:102329863	NA	-0.75	-8.1	-0.55	1.7e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg20243544	chr17:37824526	PNMT	0.5	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3736485	0.934	rs4143724	chr15:51870413	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-1.39	-10.41	-0.65	1.75e-19	Magnesium levels;
PAAD	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.61	0.53	2.72e-12	Motion sickness;
PAAD	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg20487152	chr13:99095054	FARP1	-0.5	-4.89	-0.37	2.54e-6	Longevity;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.03	-0.38	1.39e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.61	-5.98	-0.44	1.54e-8	Calcium levels;
PAAD	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.73	8.23	0.56	7.75e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-6.14	-0.45	6.92e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg23387401	chr17:4582204	PELP1	-0.48	-4.81	-0.36	3.66e-6	Lymphocyte counts;
PAAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg11833968	chr6:79620685	NA	-0.42	-4.29	-0.33	3.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.64	6.97	0.49	8.97e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1144	0.537	rs2470948	chr7:104588533	A/G	cg04380332	chr7:105027541	SRPK2	-0.65	-6.89	-0.49	1.35e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs72960926	1.000	rs11751066	chr6:75177049	G/A	cg03266952	chr6:74778945	NA	-1.24	-6.13	-0.45	7.3e-9	Metabolite levels (MHPG);
PAAD	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	10.01	0.63	2e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg22338127	chr1:209979572	IRF6	0.53	4.3	0.33	3.02e-5	Coronary artery disease;
PAAD	cis	rs6688613	1.000	rs7550698	chr1:166951081	A/G	cg07049167	chr1:166818506	POGK	0.48	4.79	0.36	3.92e-6	Refractive astigmatism;
PAAD	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.47	5.0	0.38	1.53e-6	Coronary heart disease;
PAAD	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg14515779	chr1:101123966	NA	0.39	4.31	0.33	2.88e-5	Monocyte count;
PAAD	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.53	4.61	0.35	8.34e-6	Lymphocyte counts;
PAAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.12	0.67	2.12e-21	Parkinson's disease;
PAAD	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.61	-5.98	-0.44	1.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.59	-6.55	-0.47	8.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg25155006	chr6:37138205	PIM1	-0.52	-4.58	-0.35	9.44e-6	QRS duration;
PAAD	cis	rs7487075	0.619	rs7968897	chr12:46813824	T/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.41	0.34	1.92e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.84	7.24	0.51	2.13e-11	Schizophrenia;
PAAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13606994	chr1:44402422	ARTN	-0.49	-5.25	-0.39	5.03e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1386478	0.585	rs6809347	chr3:113682744	C/T	cg24004780	chr3:113683598	KIAA1407	-0.5	-4.92	-0.37	2.2e-6	Crohn's disease and psoriasis;
PAAD	cis	rs1925576	0.935	rs7094030	chr10:68677554	A/C	cg04444303	chr10:69634106	NA	-0.45	-4.43	-0.34	1.81e-5	Educational attainment (years of education);
PAAD	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg05805236	chr11:65401703	PCNXL3	0.41	4.38	0.33	2.21e-5	Acne (severe);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07311968	chr7:100027471	MEPCE;ZCWPW1	-0.79	-6.73	-0.48	3.3e-10	Neuroticism;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg27507254	chr1:43206037	CLDN19	0.26	4.73	0.36	5.01e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.45	-4.4	-0.34	2e-5	Breast cancer;
PAAD	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.94	-0.37	2.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-1.06	-12.95	-0.72	2.57e-26	Urate levels;
PAAD	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.79	0.36	3.98e-6	Height;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.39	0.4	2.64e-7	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23581698	chr14:81686396	GTF2A1	0.6	6.61	0.47	6.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.72	7.26	0.51	1.9e-11	Renal function-related traits (BUN);
PAAD	cis	rs925642	0.639	rs7677267	chr4:187671393	C/A	cg20274950	chr4:187647402	NA	-0.38	-4.5	-0.34	1.37e-5	Obesity;
PAAD	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.61	5.97	0.44	1.64e-8	Testicular germ cell tumor;
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-1.08	-15.21	-0.78	2.47e-32	Total body bone mineral density;
PAAD	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.66	4.87	0.37	2.72e-6	Optic nerve measurement (cup area);
PAAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.65	8.34	0.56	4.25e-14	Skin aging (microtopography measurement);
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg05338066	chr1:7812865	CAMTA1	0.68	4.96	0.37	1.89e-6	Inflammatory bowel disease;
PAAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04362095	chr11:63592001	C11orf84	-0.52	-4.75	-0.36	4.74e-6	Platelet count;
PAAD	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg15556689	chr8:8085844	FLJ10661	0.8	8.0	0.54	2.91e-13	Schizophrenia;
PAAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.67	7.02	0.5	6.74e-11	Schizophrenia;
PAAD	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg00250761	chr1:31883323	NA	-0.52	-5.82	-0.43	3.3e-8	Alcohol dependence;
PAAD	trans	rs901683	1.000	rs71494791	chr10:45978331	C/T	cg11747279	chr17:21096632	NA	0.81	6.4	0.46	1.81e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg24881330	chr22:46731750	TRMU	1.16	5.73	0.42	5.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7688540	0.760	rs7687833	chr4:237320	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.4	0.34	2e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.91	5.83	0.43	3.27e-8	Prostate cancer;
PAAD	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.81	6.07	0.44	9.87e-9	Height;
PAAD	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.45	5.79	0.43	3.86e-8	Ulcerative colitis;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.88	12.19	0.7	2.76e-24	Vitiligo;
PAAD	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.67	-8.99	-0.59	8.98e-16	Eye color traits;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.51	6.72	0.48	3.48e-10	Thyroid hormone levels;
PAAD	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs2286503	0.839	rs4722189	chr7:22860474	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.82	9.19	0.6	2.71e-16	Tuberculosis;
PAAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.37	0.33	2.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	1.06	13.46	0.74	1.09e-27	Breast cancer;
PAAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.62	-5.37	-0.4	2.94e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.7	0.36	5.66e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9287719	0.578	rs10175555	chr2:10703233	T/C	cg00105475	chr2:10696890	NA	0.67	7.01	0.49	7.1e-11	Prostate cancer;
PAAD	trans	rs1015213	0.609	rs75774497	chr8:52877428	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs3787159	0.523	rs529525	chr20:56879349	T/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-4.26	-0.33	3.62e-5	Osteoarthritis;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-1.2	-9.84	-0.62	5.59e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.46	-0.34	1.61e-5	Ileal carcinoids;
PAAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23281280	chr6:28129359	ZNF389	-0.69	-5.4	-0.4	2.56e-7	Depression;
PAAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg09796270	chr17:17721594	SREBF1	0.42	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.02	0.59	7.68e-16	Rheumatoid arthritis;
PAAD	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs2036402	0.704	rs56812478	chr5:156345403	A/G	cg21915449	chr5:156456672	HAVCR1	-0.45	-4.81	-0.36	3.68e-6	Hypertriglyceridemia;
PAAD	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg01612440	chr4:3296283	NA	0.45	4.46	0.34	1.59e-5	Serum sulfate level;
PAAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.65e-6	Cognitive function;
PAAD	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.42	4.56	0.35	1.04e-5	Pulse pressure;
PAAD	cis	rs1075265	0.836	rs1363063	chr2:54274570	C/G	cg04546899	chr2:54196757	PSME4	0.34	4.86	0.37	2.86e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-15.15	-0.78	3.42e-32	Height;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	1.01	12.45	0.71	5.63e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.73	9.21	0.6	2.4e-16	Menopause (age at onset);
PAAD	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.43	-5.77	-0.42	4.26e-8	Platelet count;
PAAD	cis	rs6066835	0.702	rs2073073	chr20:47269537	A/G	cg18078177	chr20:47281410	PREX1	1.1	5.07	0.38	1.13e-6	Multiple myeloma;
PAAD	cis	rs9356171	0.572	rs2281406	chr6:164325848	C/T	cg25752492	chr6:164341247	NA	-0.47	-5.18	-0.39	7.01e-7	Diisocyanate-induced asthma;
PAAD	cis	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg08224773	chr8:11311868	FAM167A	0.4	4.79	0.36	3.87e-6	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg21890820	chr11:65308645	LTBP3	0.98	7.86	0.54	6.37e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs6844506	0.624	rs2665738	chr4:185214172	G/A	cg12654155	chr4:185238627	NA	0.58	5.5	0.41	1.61e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.64	-0.42	7.88e-8	Personality dimensions;
PAAD	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.48	-0.47	1.21e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg15117754	chr3:10150083	C3orf24	0.61	5.78	0.42	4.14e-8	Alzheimer's disease;
PAAD	cis	rs2455826	0.521	rs7626198	chr3:15826432	A/G	cg13420985	chr3:16524424	RFTN1	-0.47	-4.49	-0.34	1.42e-5	Inflammatory skin disease;
PAAD	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10068491	chr16:3183125	NA	-0.49	-6.35	-0.46	2.32e-9	Monocyte percentage of white cells;
PAAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	0.96	8.9	0.59	1.57e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2555155	0.806	rs10839573	chr11:6551339	C/T	cg10208301	chr11:6592745	DNHD1	0.42	4.33	0.33	2.73e-5	DNA methylation (variation);
PAAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.62	5.28	0.39	4.41e-7	Initial pursuit acceleration;
PAAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.67	-8.45	-0.57	2.16e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.97	-8.28	-0.56	5.99e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.66	-0.35	6.9e-6	Neuroticism;
PAAD	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg25452165	chr22:42524984	CYP2D6	0.52	4.96	0.37	1.88e-6	Schizophrenia;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.57	6.73	0.48	3.17e-10	Atrioventricular conduction;
PAAD	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg06484146	chr7:12443880	VWDE	-0.61	-4.39	-0.34	2.08e-5	Coronary artery disease;
PAAD	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	10.8	0.66	1.6e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.89	9.87	0.62	4.7e-18	Cognitive function;
PAAD	cis	rs9652601	0.959	rs741172	chr16:11200798	C/T	cg04616529	chr16:11181986	CLEC16A	0.45	4.8	0.36	3.78e-6	Systemic lupus erythematosus;
PAAD	cis	rs11828289	0.660	rs74388652	chr11:23188048	A/G	cg20040320	chr11:23191996	NA	-0.78	-5.55	-0.41	1.27e-7	Cancer;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.6	-6.03	-0.44	1.21e-8	Post bronchodilator FEV1;
PAAD	cis	rs9581857	0.547	rs9581872	chr13:28086058	C/T	cg22138327	chr13:27999177	GTF3A	0.81	5.26	0.39	4.71e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.57	4.86	0.37	2.86e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg25319279	chr11:5960081	NA	-0.6	-6.07	-0.44	9.89e-9	DNA methylation (variation);
PAAD	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg09640425	chr7:158790006	NA	-0.44	-4.72	-0.36	5.25e-6	Facial morphology (factor 20);
PAAD	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-10.92	-0.66	7.43e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.72	6.39	0.46	1.94e-9	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs6137287	0.883	rs6132406	chr20:21173708	G/C	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.59	-0.35	9.31e-6	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23561859	chr2:96931676	CIAO1;TMEM127	-0.73	-6.48	-0.47	1.24e-9	Neuroticism;
PAAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg03959625	chr15:84868606	LOC388152	0.43	4.47	0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.52	-4.41	-0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-4.59	-0.35	9.09e-6	Total body bone mineral density (age 45-60);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16836583	chr3:57583277	ARF4	-0.64	-6.49	-0.47	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.68	-7.29	-0.51	1.61e-11	Mean platelet volume;
PAAD	cis	rs3931020	0.745	rs1980851	chr1:75268971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	4.47	0.34	1.5e-5	Resistin levels;
PAAD	cis	rs863345	0.604	rs6664542	chr1:158462431	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-7.12	-0.5	4.08e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.83	9.75	0.62	9.34e-18	Breast cancer;
PAAD	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.77	-0.53	1.07e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.41	-4.38	-0.33	2.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs36715	0.953	rs2617613	chr5:127552589	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.22	0.45	4.59e-9	Breast cancer;
PAAD	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg00677455	chr12:58241039	CTDSP2	0.55	5.71	0.42	5.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg27455613	chr17:80820699	TBCD	-0.44	-4.35	-0.33	2.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.18	0.45	5.54e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26897989	chr16:1907736	C16orf73	-0.56	-4.95	-0.37	1.95e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg00277334	chr10:82204260	NA	0.58	5.76	0.42	4.6e-8	Post bronchodilator FEV1;
PAAD	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	1.0	8.8	0.58	2.79e-15	Bipolar disorder;
PAAD	cis	rs743757	0.877	rs11130250	chr3:50508326	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.73	5.04	0.38	1.29e-6	Diastolic blood pressure;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-6.45	-0.46	1.42e-9	Lymphocyte counts;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.88	0.37	2.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs838721	0.740	rs838718	chr2:234296650	G/A	cg17212304	chr2:234394541	USP40	0.47	4.97	0.37	1.78e-6	Total body bone mineral density;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.23	-0.39	5.46e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.68	-7.61	-0.53	2.74e-12	Corneal astigmatism;
PAAD	trans	rs901683	0.867	rs35003524	chr10:46086781	C/T	cg06308084	chr22:50493570	TTLL8	0.88	6.47	0.46	1.28e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	1.01	8.33	0.56	4.51e-14	IgG glycosylation;
PAAD	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-4.91	-0.37	2.28e-6	Common traits (Other);
PAAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.6	-0.35	8.79e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.93	10.27	0.64	4.09e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg19413350	chr8:57351067	NA	-0.45	-4.27	-0.33	3.44e-5	Obesity-related traits;
PAAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.83	11.13	0.67	2.04e-21	Emphysema distribution in smoking;
PAAD	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg00206168	chr11:65308501	LTBP3	0.81	5.7	0.42	5.96e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.41	4.46	0.34	1.6e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg06464468	chr11:65414413	SIPA1	-0.52	-4.27	-0.33	3.43e-5	Blood pressure (age interaction);
PAAD	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.88	0.37	2.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-6.17	-0.45	5.83e-9	Urate levels in overweight individuals;
PAAD	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.87	-11.0	-0.67	4.6e-21	Aortic root size;
PAAD	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg14784868	chr12:69753453	YEATS4	0.52	4.33	0.33	2.69e-5	Response to diuretic therapy;
PAAD	cis	rs225245	0.610	rs321608	chr17:33880636	A/G	cg05299278	chr17:33885742	SLFN14	0.35	4.26	0.33	3.6e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.58	7.17	0.5	2.99e-11	Lung cancer;
PAAD	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.51	-6.0	-0.44	1.38e-8	Mean arterial pressure;
PAAD	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.84	7.52	0.52	4.37e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.9e-7	Blood metabolite levels;
PAAD	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.59	-0.52	2.96e-12	Protein C levels;
PAAD	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs4774830	0.744	rs62046379	chr15:56299233	G/A	cg24530489	chr15:56299380	NA	-0.99	-4.62	-0.35	8.22e-6	Delta-5 desaturase activity;
PAAD	cis	rs2494979	0.830	rs2691478	chr6:71327874	A/C	cg15045441	chr6:72130432	C6orf155	0.47	4.3	0.33	3.03e-5	Platelet distribution width;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.04	0.79	1.69e-34	Prudent dietary pattern;
PAAD	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.7	5.23	0.39	5.5e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.5	4.79	0.36	3.98e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9463078	0.585	rs12529946	chr6:45255294	G/A	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.03e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	cis	rs12753920	0.775	rs12759512	chr1:92680246	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.48	-0.34	1.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs17023223	0.509	rs6668960	chr1:119600812	C/T	cg26570165	chr1:119541833	NA	-0.45	-4.26	-0.33	3.63e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.71	-9.08	-0.59	5.44e-16	Educational attainment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17731079	chr2:37899023	CDC42EP3	0.6	6.55	0.47	8.18e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs939584	0.668	rs13008590	chr2:630788	A/G	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-5.05	-0.38	1.27e-6	Blood protein levels;
PAAD	cis	rs7627468	0.955	rs6788304	chr3:121930840	C/A	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg14515779	chr1:101123966	NA	-0.54	-6.36	-0.46	2.29e-9	Monocyte count;
PAAD	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.47	5.04	0.38	1.3e-6	Vitiligo;
PAAD	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.61	-4.26	-0.33	3.56e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.81	-8.86	-0.58	1.97e-15	DNA methylation (variation);
PAAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.5	5.02	0.38	1.41e-6	Menopause (age at onset);
PAAD	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg25382128	chr12:54346509	NA	-0.45	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.41	-5.52	-0.41	1.42e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.77	0.62	8.41e-18	Menopause (age at onset);
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03605463	chr16:89740564	NA	-0.56	-5.4	-0.4	2.47e-7	Vitiligo;
PAAD	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg03948781	chr1:205179583	DSTYK	0.48	4.4	0.34	1.99e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05357209	chr7:872208	UNC84A	-0.37	-4.35	-0.33	2.47e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg01075559	chr1:2537774	MMEL1	0.52	5.34	0.4	3.38e-7	Ulcerative colitis;
PAAD	cis	rs10905065	0.827	rs7089100	chr10:5849877	C/G	cg11519256	chr10:5708881	ASB13	0.5	4.3	0.33	3.01e-5	Menopause (age at onset);
PAAD	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Night sleep phenotypes;
PAAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.61	-4.83	-0.37	3.24e-6	Vitiligo;
PAAD	cis	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs2555155	0.806	rs10839574	chr11:6551470	C/T	cg24637308	chr11:6592297	DNHD1	-0.48	-4.92	-0.37	2.25e-6	DNA methylation (variation);
PAAD	cis	rs6940638	0.637	rs13217239	chr6:27254967	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.39	-4.58	-0.35	9.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4073221	0.584	rs56058600	chr3:18295064	T/C	cg07694806	chr3:18168406	NA	-0.64	-4.57	-0.35	1e-5	Parkinson's disease;
PAAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.85	7.22	0.51	2.39e-11	Alzheimer's disease;
PAAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.84	8.51	0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.74	-6.41	-0.46	1.75e-9	Exhaled nitric oxide output;
PAAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-8.42	-0.56	2.64e-14	Homoarginine levels;
PAAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.85	7.48	0.52	5.67e-12	Schizophrenia;
PAAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg23205692	chr1:25664452	TMEM50A	0.5	4.79	0.36	3.9e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.74	0.36	4.9100000000000004e-06	Height;
PAAD	cis	rs2420316	1	rs2420316	chr10:118399377	C/T	cg10511988	chr10:118891706	VAX1	0.38	4.45	0.34	1.67e-5	Loneliness (linear analysis);
PAAD	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.48	5.65	0.42	7.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09894072	chr16:68279486	PLA2G15	0.58	6.6	0.47	6.33e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.62	-6.07	-0.44	9.89e-9	Height;
PAAD	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	8.31e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs17095355	0.818	rs35096721	chr10:111775907	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	cis	rs12612619	0.579	rs41448746	chr2:27080706	A/G	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.47	-0.34	1.51e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.49	5.2	0.39	6.45e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.33	4.79	0.36	3.85e-6	Platelet count;
PAAD	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.5	-4.87	-0.37	2.83e-6	Corneal structure;
PAAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00142150	chr22:38071001	LGALS1	0.69	7.74	0.53	1.31e-12	Fat distribution (HIV);
PAAD	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.65	9.13	0.59	4.07e-16	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.57	0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	4.92	0.37	2.25e-6	Educational attainment;
PAAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.35e-14	Renal cell carcinoma;
PAAD	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.59	5.59	0.41	1e-7	Schizophrenia;
PAAD	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg20607287	chr7:12443886	VWDE	-0.58	-4.71	-0.36	5.63e-6	Coronary artery disease;
PAAD	cis	rs12304921	0.748	rs73090619	chr12:51333033	C/A	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.13	-0.38	8.65e-7	Type 2 diabetes;
PAAD	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-5.74	-0.42	4.96e-8	Colorectal cancer;
PAAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.92	-0.43	2.11e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg24253500	chr15:84953950	NA	0.56	6.45	0.46	1.43e-9	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08635118	chr7:6144369	USP42	0.64	7.28	0.51	1.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg01489032	chr8:143877656	NA	-0.38	-4.38	-0.33	2.23e-5	Urinary tract infection frequency;
PAAD	cis	rs6074578	0.650	rs6077288	chr20:138460	A/G	cg16931068	chr20:139680	DEFB127	0.36	4.82	0.36	3.51e-6	Hirschsprung disease;
PAAD	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg08619932	chr19:49200058	FUT2	0.61	6.72	0.48	3.47e-10	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18099408	chr3:52552593	STAB1	-0.52	-5.9	-0.43	2.23e-8	Electroencephalogram traits;
PAAD	cis	rs9646944	0.501	rs7586983	chr2:103028066	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg01075559	chr1:2537774	MMEL1	0.52	5.43	0.4	2.14e-7	Ulcerative colitis;
PAAD	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.31	-4.61	-0.35	8.45e-6	Urate levels in overweight individuals;
PAAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.84	-6.85	-0.49	1.73e-10	Coronary artery disease;
PAAD	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg00750074	chr16:89608354	SPG7	-0.54	-5.12	-0.38	9.18e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.5	4.25	0.33	3.7e-5	Lymphocyte counts;
PAAD	cis	rs595018	0.505	rs56130163	chr11:60605547	C/T	cg23904249	chr11:60608951	CCDC86	0.69	4.95	0.37	1.95e-6	Wegener's granulomatosis;
PAAD	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.52	-4.82	-0.36	3.39e-6	Putamen volume;
PAAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.75	-8.01	-0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.05	-5.61	-0.41	9.22e-8	Plateletcrit;
PAAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.97	0.49	8.91e-11	Yeast infection;
PAAD	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.35	-0.33	2.44e-5	IgG glycosylation;
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg00484396	chr16:3507460	NAT15	0.88	6.78	0.48	2.52e-10	Tuberculosis;
PAAD	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg01812947	chr2:240904978	NDUFA10	0.54	4.58	0.35	9.49e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs877426	0.681	rs877425	chr13:114833726	G/C	cg00571178	chr13:114841904	RASA3	-0.56	-4.63	-0.35	7.91e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.59	6.45	0.46	1.41e-9	Lung cancer;
PAAD	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.54	5.46	0.41	1.86e-7	Ulcerative colitis;
PAAD	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-1.09	-7.66	-0.53	1.98e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs10450586	0.863	rs7126943	chr11:27303937	A/G	cg10370305	chr11:27303972	NA	-0.38	-4.58	-0.35	9.77e-6	Total body bone mineral density;
PAAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.43	4.39	0.34	2.14e-5	Red cell distribution width;
PAAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg11812906	chr14:75593930	NEK9	0.52	5.08	0.38	1.08e-6	Caffeine consumption;
PAAD	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs8105895	0.935	rs7252380	chr19:22245715	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	1.07	7.35	0.51	1.15e-11	IgG glycosylation;
PAAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.89	-0.37	2.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	4.92	0.37	2.24e-6	Prostate cancer;
PAAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.59	-6.12	-0.44	7.71e-9	Monocyte count;
PAAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.62	-6.1	-0.44	8.6e-9	Itch intensity from mosquito bite;
PAAD	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg21483461	chr5:81570383	RPS23	0.59	5.26	0.39	4.91e-7	Breast cancer;
PAAD	cis	rs72781680	1.000	rs7355559	chr2:24256946	G/T	cg08917208	chr2:24149416	ATAD2B	-0.95	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.85	0.37	3.08e-6	Breast cancer;
PAAD	cis	rs3736485	0.966	rs2305708	chr15:51909960	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02071572	chr4:1403502	NA	0.35	4.34	0.33	2.56e-5	Longevity;
PAAD	cis	rs8077577	0.708	rs7498	chr17:18148485	G/A	cg16794390	chr17:18148240	FLII	0.52	4.46	0.34	1.56e-5	Obesity-related traits;
PAAD	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.79	5.94	0.43	1.91e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05031240	chr7:6676784	NA	-0.77	-6.99	-0.49	7.99e-11	Neuroticism;
PAAD	cis	rs282587	0.569	rs282600	chr13:113391602	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.59	5.39	0.4	2.68e-7	Obesity-related traits;
PAAD	cis	rs802075	0.967	rs360563	chr6:49658270	C/T	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.81	8.46	0.57	2.05e-14	Cognitive function;
PAAD	cis	rs5756391	0.546	rs9610607	chr22:37315759	T/C	cg16356956	chr22:37317934	CSF2RB	0.38	4.71	0.36	5.64e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07677032	chr17:61819896	STRADA	-0.53	-5.19	-0.39	6.57e-7	Prudent dietary pattern;
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg03115019	chr17:80708279	FN3K	0.66	7.16	0.5	3.17e-11	Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19743433	chr2:240965015	NDUFA10	0.67	7.15	0.5	3.46e-11	Obesity-related traits;
PAAD	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg18016565	chr1:150552671	MCL1	-0.45	-4.48	-0.34	1.44e-5	Tonsillectomy;
PAAD	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.85	-8.56	-0.57	1.14e-14	Multiple sclerosis;
PAAD	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.53	4.7	0.36	5.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.6	4.45	0.34	1.65e-5	Exhaled nitric oxide output;
PAAD	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg14092571	chr14:90743983	NA	0.46	4.51	0.34	1.27e-5	Mortality in heart failure;
PAAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs7246865	0.510	rs3816550	chr19:17173487	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.72	0.42	5.37e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.29	-0.39	4.17e-7	Longevity;Endometriosis;
PAAD	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.55	5.39	0.4	2.67e-7	Mortality in heart failure;
PAAD	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg15145965	chr22:50218605	BRD1	0.6	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg25566285	chr7:158114605	PTPRN2	0.85	8.9	0.59	1.56e-15	Calcium levels;
PAAD	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.98	10.91	0.66	7.97e-21	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg15654264	chr1:150340011	RPRD2	0.51	4.92	0.37	2.26e-6	Migraine;
PAAD	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.79	-9.15	-0.6	3.57e-16	Heart rate;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.34	-0.4	3.3e-7	Joint mobility (Beighton score);
PAAD	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.9	5.92	0.43	2.11e-8	Major depressive disorder;
PAAD	cis	rs2051773	0.567	rs6486346	chr11:17049890	A/G	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg18279126	chr7:2041391	MAD1L1	-0.55	-5.11	-0.38	9.48e-7	Schizophrenia;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-1.13	-6.6	-0.47	6.4e-10	Body mass index;
PAAD	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.87	10.47	0.65	1.16e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-7.52	-0.52	4.48e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg04025307	chr7:1156635	C7orf50	0.7	4.95	0.37	1.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-0.96	-10.72	-0.66	2.53e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.5	5.1	0.38	1.01e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-4.87	-0.37	2.81e-6	Common traits (Other);
PAAD	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.66	-5.92	-0.43	2.07e-8	Mortality in heart failure;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07362569	chr17:61921086	SMARCD2	0.64	7.96	0.54	3.68e-13	Prudent dietary pattern;
PAAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.42	-0.4	2.3e-7	Monocyte count;
PAAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg10494973	chr17:80897199	TBCD	0.55	4.49	0.34	1.37e-5	Breast cancer;
PAAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs6585424	1.000	rs10466228	chr10:81924373	A/G	cg19423196	chr10:82049429	MAT1A	0.43	4.43	0.34	1.83e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.59	5.34	0.4	3.26e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.63	6.56	0.47	7.88e-10	Obesity-related traits;
PAAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.44	5.28	0.39	4.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20167471	chr1:16528984	ARHGEF19	0.46	4.66	0.35	6.96e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.73	7.52	0.52	4.39e-12	Colorectal cancer;
PAAD	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg18939081	chr1:31884902	SERINC2	0.47	5.24	0.39	5.36e-7	Alcohol dependence;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	11.94	0.7	1.3e-23	Platelet count;
PAAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12379764	chr21:47803548	PCNT	-0.49	-4.74	-0.36	4.83e-6	Testicular germ cell tumor;
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.32	-0.33	2.83e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.45	4.33	0.33	2.66e-5	Mood instability;
PAAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg12486944	chr17:80159399	CCDC57	0.56	4.96	0.37	1.9e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.15	0.5	3.39e-11	Eye color traits;
PAAD	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.59	5.34	0.4	3.27e-7	Interleukin-17 levels;
PAAD	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.27	0.39	4.53e-7	Body mass index;
PAAD	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20167471	chr1:16528984	ARHGEF19	0.48	4.9	0.37	2.39e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14097499	chr9:138441348	OBP2A	0.52	5.25	0.39	5.05e-7	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
PAAD	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.45	4.49	0.34	1.38e-5	Type 2 diabetes;
PAAD	cis	rs9616064	0.744	rs9616058	chr22:46974203	G/A	cg05621596	chr22:47072043	GRAMD4	-0.55	-4.5	-0.34	1.32e-5	Urate levels in obese individuals;
PAAD	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.63	0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.64	-6.79	-0.48	2.42e-10	Menarche (age at onset);
PAAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.49	-0.47	1.17e-9	Life satisfaction;
PAAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg00922110	chr4:57842668	C4orf14	-0.43	-4.68	-0.35	6.4e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg00590817	chr1:8272081	NA	-0.36	-4.29	-0.33	3.12e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11876979	chr3:14988829	NR2C2	-0.68	-6.72	-0.48	3.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.65	-6.5	-0.47	1.06e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg21269045	chr12:125625041	AACS	-0.46	-4.53	-0.34	1.21e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.59	5.72	0.42	5.51e-8	Schizophrenia;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg24879335	chr3:133465180	TF	-0.5	-5.37	-0.4	2.9e-7	Iron status biomarkers;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08575399	chr20:60719638	PSMA7;SS18L1	0.67	7.76	0.53	1.14e-12	Metabolite levels  (X-11787);
PAAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs8060686	0.858	rs28563117	chr16:67782130	C/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.81	-0.36	3.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07537819	chr6:156886127	NA	0.64	7.85	0.54	6.83e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.41	4.39	0.34	2.09e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.63	7.2	0.5	2.57e-11	Emphysema distribution in smoking;
PAAD	cis	rs7829975	0.627	rs2979172	chr8:8310508	G/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.89	0.49	1.38e-10	Mood instability;
PAAD	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.59	-6.78	-0.48	2.48e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg15123519	chr2:136567270	LCT	-0.39	-4.66	-0.35	6.73e-6	Mosquito bite size;
PAAD	cis	rs838147	0.733	rs8106205	chr19:49250197	T/C	cg13540341	chr19:49222985	MAMSTR	0.38	4.45	0.34	1.65e-5	Dietary macronutrient intake;
PAAD	cis	rs17592366	0.540	rs3818801	chr14:35242700	C/T	cg09327582	chr14:35236912	BAZ1A	0.53	4.72	0.36	5.41e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.72	-7.22	-0.51	2.38e-11	Lung cancer;
PAAD	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Lymphocyte counts;
PAAD	cis	rs7561149	1.000	rs7561149	chr2:179689856	T/C	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.48	4.65	0.35	7.1e-6	QT interval;
PAAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-7.54	-0.52	3.9e-12	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.62e-7	Life satisfaction;
PAAD	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.51	5.02	0.38	1.43e-6	Malaria;
PAAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.55	-6.13	-0.45	7.07e-9	Total body bone mineral density;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg24503407	chr1:205819492	PM20D1	0.52	5.2	0.39	6.38e-7	Parkinson's disease;
PAAD	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.5	-4.84	-0.37	3.17e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14693961	chr19:42388097	ARHGEF1	0.68	6.59	0.47	6.91e-10	Obesity-related traits;
PAAD	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	0.94	10.45	0.65	1.32e-19	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.49	-0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs12422267	1.000	rs12422267	chr12:132601596	A/G	cg26561844	chr12:132562101	EP400	-0.81	-4.52	-0.34	1.26e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg14061069	chr19:46274453	DMPK	-0.61	-6.53	-0.47	9.31e-10	Coronary artery disease;
PAAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg14146966	chr2:61757674	XPO1	-0.35	-4.44	-0.34	1.75e-5	Tuberculosis;
PAAD	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg16810054	chr20:33298113	TP53INP2	0.59	4.62	0.35	8.17e-6	Neuroticism;
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.51	5.45	0.4	1.98e-7	Obesity-related traits;
PAAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg03137908	chr10:81447366	LOC650623	-0.38	-4.27	-0.33	3.43e-5	Height;
PAAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.48	-4.28	-0.33	3.26e-5	Platelet count;
PAAD	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.39	-4.78	-0.36	4.12e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.5e-5	Testicular germ cell tumor;
PAAD	cis	rs116248771	0.690	rs116470672	chr3:158337762	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs8016982	0.531	rs2241622	chr14:81737290	A/G	cg01989461	chr14:81687754	GTF2A1	0.58	4.54	0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.22e-17	Electrocardiographic conduction measures;
PAAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-6.32	-0.46	2.7e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-4.55	-0.35	1.11e-5	Alzheimer's disease (survival time);
PAAD	cis	rs78761021	0.867	rs8077037	chr17:9788746	G/A	cg26853458	chr17:9805074	RCVRN	0.71	8.24	0.56	7.24e-14	Type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18176105	chr2:18744324	NT5C1B	0.54	6.41	0.46	1.73e-9	Smoking initiation;
PAAD	cis	rs10207060	0.500	rs56346503	chr2:240719409	T/C	cg07506560	chr2:240697449	NA	0.55	5.68	0.42	6.79e-8	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.8	-0.87	1.21e-48	Myeloid white cell count;
PAAD	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	1.03	5.36	0.4	3.08e-7	Body mass index;
PAAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg23463467	chr20:60627584	TAF4	0.47	4.96	0.37	1.84e-6	Body mass index;
PAAD	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.36	-4.96	-0.37	1.87e-6	Pulse pressure;
PAAD	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.5	4.84	0.37	3.13e-6	Parkinson's disease;
PAAD	cis	rs258892	0.895	rs6452657	chr5:72022918	G/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.81	10.82	0.66	1.34e-20	Metabolite levels;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs89107	0.531	rs1690662	chr6:118612354	A/G	cg18833306	chr6:118973337	C6orf204	0.48	5.65	0.42	7.71e-8	Cardiac structure and function;
PAAD	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.53	-4.94	-0.37	2.01e-6	Endometrial cancer;
PAAD	cis	rs2790216	0.950	rs2590375	chr10:59967478	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06184056	chr8:124545375	FBXO32	-0.54	-6.52	-0.47	9.69e-10	Monocyte percentage of white cells;
PAAD	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.96	6.22	0.45	4.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	5.15	0.39	8.1e-7	Mood instability;
PAAD	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs12935418	0.583	rs2549852	chr16:81026015	G/A	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.57	4.85	0.37	2.99e-6	Menopause (age at onset);
PAAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg05627522	chr15:75251581	NA	0.49	5.84	0.43	3.06e-8	Breast cancer;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.59	6.48	0.47	1.22e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.55	-4.36	-0.33	2.37e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.1	-0.38	9.93e-7	Systemic lupus erythematosus;
PAAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.68	9.91	0.63	3.71e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs116248771	0.739	rs4680456	chr3:158397842	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.65	-6.81	-0.48	2.12e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.87	-10.74	-0.66	2.25e-20	Aortic root size;
PAAD	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.21	0.55	8.74e-14	Hypertriglyceridemia;
PAAD	cis	rs13424612	1.000	rs4149551	chr2:240921463	C/T	cg12807937	chr2:240965920	NDUFA10	-0.5	-5.0	-0.38	1.58e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs1018697	1.000	rs7073114	chr10:104555651	C/T	cg04362960	chr10:104952993	NT5C2	0.59	6.02	0.44	1.28e-8	Colorectal adenoma (advanced);
PAAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs302972	0.826	rs9461103	chr6:25099116	C/T	cg09546929	chr6:25930894	SLC17A2	0.73	4.33	0.33	2.66e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg25025879	chr12:53359317	NA	-0.89	-5.57	-0.41	1.11e-7	Prostate cancer;
PAAD	cis	rs9815354	1.000	rs6599176	chr3:41788492	G/T	cg03022575	chr3:42003672	ULK4	-0.7	-5.11	-0.38	9.46e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.81	6.69	0.48	4.1e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.6	-0.35	8.93e-6	Testicular germ cell tumor;
PAAD	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.76	-8.01	-0.54	2.85e-13	Magnesium levels;
PAAD	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.56	-0.41	1.18e-7	Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs375066	0.935	rs398388	chr19:44425682	C/T	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.49	5.42	0.4	2.32e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs300774	0.800	rs300732	chr2:166725	A/G	cg21211680	chr2:198530	NA	-0.65	-5.98	-0.44	1.51e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg10556349	chr10:835070	NA	0.59	4.95	0.37	1.96e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-6.38	-0.46	2.03e-9	Lung cancer;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	4.37	0.33	2.29e-5	Tonsillectomy;
PAAD	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.7	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.93	7.83	0.54	7.61e-13	Alzheimer's disease;
PAAD	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg26203845	chr14:105293866	NA	0.38	4.51	0.34	1.28e-5	IgG glycosylation;
PAAD	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.36	-0.4	3.01e-7	Number of children ever born;
PAAD	cis	rs12431939	0.626	rs3924306	chr14:51715566	C/A	cg23942311	chr14:51606299	NA	0.53	4.78	0.36	4.02e-6	Cancer;
PAAD	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg21994712	chr19:21861136	NA	-0.47	-4.61	-0.35	8.36e-6	Pain;
PAAD	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.62	-4.54	-0.35	1.14e-5	Refractive astigmatism;
PAAD	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-7.23	-0.51	2.19e-11	Initial pursuit acceleration;
PAAD	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg01942863	chr7:99769432	GPC2	0.51	4.76	0.36	4.42e-6	Coronary artery disease;
PAAD	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg13859433	chr6:33739653	LEMD2	-0.66	-4.57	-0.35	1.02e-5	Schizophrenia;
PAAD	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.56	5.93	0.43	1.95e-8	Lung cancer;
PAAD	cis	rs863345	0.625	rs10908663	chr1:158492121	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs9463078	0.790	rs1324531	chr6:45136224	T/C	cg25276700	chr6:44698697	NA	-0.48	-5.51	-0.41	1.5e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.68	5.52	0.41	1.43e-7	Brain cytoarchitecture;
PAAD	cis	rs1864585	0.520	rs10503409	chr8:10669654	C/G	cg21775007	chr8:11205619	TDH	0.55	4.62	0.35	8.27e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs2412208	0.796	rs11588097	chr1:7071415	A/G	cg26570804	chr1:6352357	ACOT7	0.56	5.31	0.4	3.74e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.52	-5.09	-0.38	1.02e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.12	0.55	1.48e-13	Asthma;
PAAD	cis	rs7638995	0.652	rs77902570	chr3:69194090	A/T	cg26574240	chr3:69171822	LMOD3	-0.71	-4.97	-0.37	1.81e-6	Alzheimer's disease (late onset);
PAAD	cis	rs17155006	0.664	rs405869	chr7:107742609	T/C	cg05962710	chr7:107745446	LAMB4	-0.53	-7.09	-0.5	4.68e-11	Pneumococcal bacteremia;
PAAD	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg27205649	chr11:78285834	NARS2	0.57	4.31	0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs818427	0.548	rs374613	chr5:112192072	A/G	cg06941702	chr5:112196734	SRP19	-0.52	-5.18	-0.39	7.05e-7	Total body bone mineral density;
PAAD	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg09065629	chr16:1709722	CRAMP1L	0.46	4.82	0.36	3.42e-6	Coronary artery disease;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	5.05	0.38	1.25e-6	Menarche (age at onset);
PAAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.47	-0.34	1.5e-5	Post bronchodilator FEV1;
PAAD	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.11	0.44	7.87e-9	Body mass index;
PAAD	cis	rs62264129	0.500	rs9816969	chr3:112037942	G/A	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.91	-11.39	-0.68	4.18e-22	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.56	0.52	3.53e-12	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.73	0.58	4.16e-15	Lung cancer;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	1.12	7.98	0.54	3.37e-13	IgG glycosylation;
PAAD	cis	rs2213920	0.920	rs9408871	chr9:118263618	C/T	cg13918206	chr9:118159781	DEC1	0.77	5.29	0.39	4.16e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs3126085	0.515	rs11204998	chr1:152365655	A/C	cg26876637	chr1:152193138	HRNR	-0.66	-4.93	-0.37	2.17e-6	Atopic dermatitis;
PAAD	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg15841412	chr13:111365552	ING1	-0.55	-4.56	-0.35	1.04e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10203711	0.553	rs4663937	chr2:239546209	G/A	cg26118367	chr2:240010016	HDAC4	0.46	4.25	0.33	3.65e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.59	-6.72	-0.48	3.46e-10	Prostate cancer;
PAAD	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg13256891	chr4:100009986	ADH5	0.58	5.65	0.42	7.61e-8	Alcohol dependence;
PAAD	cis	rs300774	0.925	rs12233125	chr2:118611	A/T	cg23649280	chr2:140451	NA	-0.52	-4.65	-0.35	7.1e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs590121	0.876	rs604021	chr11:75276769	G/C	cg26104986	chr11:75275303	SERPINH1	-0.46	-4.53	-0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.75	-6.91	-0.49	1.25e-10	Acylcarnitine levels;
PAAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.53	-5.75	-0.42	4.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.663	rs7735057	chr5:74403857	T/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg01244601	chr4:120671846	NA	-0.5	-4.28	-0.33	3.23e-5	Corneal astigmatism;
PAAD	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.59	-0.8	6.23e-36	Height;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg20064231	chr18:74608296	ZNF236	0.65	6.33	0.46	2.59e-9	Body mass index;
PAAD	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-4.58	-0.35	9.43e-6	Menopause (age at onset);
PAAD	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg09324608	chr17:30823087	MYO1D	0.48	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21243150	chr15:40751171	BAHD1	0.56	6.29	0.45	3.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-7.55	-0.52	3.68e-12	Hemoglobin concentration;
PAAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs4908768	0.501	rs1922983	chr1:8531326	A/G	cg20416874	chr1:8611966	RERE	-0.47	-4.58	-0.35	9.71e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.8	9.18	0.6	2.97e-16	Lung cancer;
PAAD	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.79	10.08	0.63	1.3e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.77	7.2	0.5	2.53e-11	Cognitive function;
PAAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	9.4	0.61	8.09e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	5.94	0.43	1.87e-8	Platelet count;
PAAD	cis	rs7925908	0.659	rs1894218	chr11:131158533	G/T	cg13391028	chr11:130657123	NA	0.36	4.28	0.33	3.29e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);Glucocorticoid-induced osteonecrosis (time dependent analysis);
PAAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.48	-0.34	1.43e-5	Mean corpuscular volume;
PAAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.51	-5.64	-0.42	7.99e-8	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14032218	chr1:171755066	METTL13	-0.68	-6.56	-0.47	7.78e-10	Obesity-related traits;
PAAD	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.73	8.53	0.57	1.35e-14	Lung cancer;
PAAD	cis	rs2282978	0.557	rs191777	chr7:92250374	T/A	cg06556290	chr7:92222188	NA	-0.44	-4.43	-0.34	1.79e-5	Height;
PAAD	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.39	9.48	0.61	4.92e-17	Diabetic retinopathy;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.03e-23	Platelet count;
PAAD	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.28e-8	Triglycerides;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.44	6.29	0.45	3.16e-9	Information processing speed;
PAAD	cis	rs112990264	1.000	rs56300028	chr1:212943796	C/T	cg01785514	chr1:212988523	TATDN3	1.27	7.82	0.54	8.27e-13	Itch intensity from mosquito bite;
PAAD	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.1	7.72	0.53	1.42e-12	Type 2 diabetes;
PAAD	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.44	0.46	1.5e-9	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg11764359	chr7:65958608	NA	0.78	5.17	0.39	7.13e-7	Diabetic kidney disease;
PAAD	cis	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg18809830	chr7:99032528	PTCD1	1.0	5.18	0.39	6.98e-7	Blood metabolite levels;
PAAD	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.29	0.33	3.11e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11048434	0.535	rs2377680	chr12:9191405	A/G	cg04548204	chr12:9162872	KLRG1	0.43	4.72	0.36	5.37e-6	Sjögren's syndrome;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg26516362	chr5:178986906	RUFY1	0.42	4.62	0.35	8.19e-6	Lung cancer;
PAAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs4547160	0.821	rs951359	chr12:63482309	G/A	cg26727693	chr12:63544175	AVPR1A	-0.37	-4.43	-0.34	1.81e-5	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs337161	0.719	rs10779415	chr1:220935808	C/T	cg09023136	chr1:220959637	MOSC1	-0.6	-4.49	-0.34	1.42e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.98	-13.07	-0.73	1.24e-26	QRS duration;
PAAD	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.64	-6.57	-0.47	7.71e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.71	7.58	0.52	3.24e-12	Blood protein levels;
PAAD	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs2555155	1.000	rs11040899	chr11:6520015	A/C	cg10208301	chr11:6592745	DNHD1	-0.44	-4.54	-0.35	1.12e-5	DNA methylation (variation);
PAAD	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-6.66	-0.48	4.73e-10	Menarche (age at onset);
PAAD	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.99	6.54	0.47	8.72e-10	Parkinson's disease;
PAAD	cis	rs6076065	0.683	rs1419010	chr20:23365254	G/C	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	8.04e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-8.95	-0.59	1.17e-15	Vitiligo;
PAAD	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.75	0.42	4.65e-8	Coffee consumption (cups per day);
PAAD	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	4.28	0.33	3.27e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs5009270	0.524	rs11770458	chr7:112210496	C/T	cg23628563	chr7:112262597	NA	0.57	4.84	0.37	3.21e-6	Osteoarthritis (hip);
PAAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg07371521	chr5:154026371	NA	0.54	6.74	0.48	3.15e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg03948781	chr1:205179583	DSTYK	0.47	4.32	0.33	2.86e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.74	-9.57	-0.61	2.81e-17	Bone mineral density;
PAAD	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg13263323	chr15:86062960	AKAP13	-0.61	-6.87	-0.49	1.51e-10	Coronary artery disease;
PAAD	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	5.26	0.39	4.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.3	-0.51	1.5e-11	Migraine;Coronary artery disease;
PAAD	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg23649088	chr2:200775458	C2orf69	-0.67	-4.39	-0.34	2.11e-5	Schizophrenia;
PAAD	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.64	-7.04	-0.5	6.14e-11	Height;
PAAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.46	0.34	1.56e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.85	10.05	0.63	1.5e-18	Blood protein levels;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01283332	chr5:1856932	NA	-0.47	-4.92	-0.37	2.19e-6	Cardiovascular disease risk factors;
PAAD	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg25457927	chr22:38595422	NA	-0.4	-5.96	-0.44	1.71e-8	Cutaneous nevi;
PAAD	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg08992911	chr2:238395768	MLPH	0.59	5.67	0.42	6.87e-8	Prostate cancer;
PAAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg18769074	chr3:133464867	TF	0.48	5.81	0.43	3.59e-8	Iron status biomarkers (transferrin levels);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20937886	chr14:25351079	STXBP6	-0.63	-6.36	-0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17284481	chr2:30670304	LCLAT1	0.66	6.64	0.47	5.3e-10	Obesity-related traits;
PAAD	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.26	16.04	0.79	1.69e-34	Schizophrenia;
PAAD	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg07701084	chr6:150067640	NUP43	0.56	4.86	0.37	2.94e-6	Lung cancer;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-6.76	-0.48	2.85e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg18833306	chr6:118973337	C6orf204	0.45	4.68	0.35	6.28e-6	Electrocardiographic conduction measures;
PAAD	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.73	7.7	0.53	1.59e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg04775059	chr7:64541387	NA	-0.56	-5.87	-0.43	2.67e-8	Calcium levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12664207	chr15:76196150	FBXO22	-0.6	-6.41	-0.46	1.71e-9	Smoking initiation;
PAAD	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.87	-0.37	2.71e-6	Height;
PAAD	cis	rs136211	0.599	rs9610497	chr22:36767359	C/T	cg10790723	chr22:36903033	FOXRED2	0.44	4.35	0.33	2.51e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.55e-7	Prudent dietary pattern;
PAAD	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs3106136	0.843	rs11097414	chr4:95260301	A/T	cg11021082	chr4:95130006	SMARCAD1	0.63	6.1	0.44	8.23e-9	Capecitabine sensitivity;
PAAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-7.19	-0.5	2.67e-11	Bipolar disorder;
PAAD	cis	rs881375	0.501	rs10739591	chr9:123885728	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	5.3	0.39	4.08e-7	Rheumatoid arthritis;
PAAD	cis	rs11614333	0.959	rs11056230	chr12:15043884	C/A	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17021725	chr1:178694150	RALGPS2	0.62	6.52	0.47	9.75e-10	Myopia (pathological);
PAAD	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03372659	chr22:49698771	NA	-0.56	-6.4	-0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg13397359	chr6:42928475	GNMT	0.61	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs4792901	0.802	rs72833136	chr17:41599690	G/A	cg05614735	chr17:40936078	WNK4	-0.36	-4.28	-0.33	3.28e-5	Dupuytren's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14145653	chr9:5184772	INSL6	0.69	6.94	0.49	1.08e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12483801	chr4:183727862	NA	0.77	5.78	0.42	4.14e-8	Pediatric autoimmune diseases;
PAAD	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.54	-5.91	-0.43	2.17e-8	Neuroticism;
PAAD	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.98	-10.38	-0.64	2.11e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07097265	chr17:17727093	SREBF1	0.54	6.3	0.46	3.06e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg18370025	chr7:2749541	AMZ1	-0.38	-4.4	-0.34	2.02e-5	Height;
PAAD	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.94	0.59	1.25e-15	Fuchs's corneal dystrophy;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	5.83	0.43	3.24e-8	Renal function-related traits (BUN);
PAAD	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.7	-5.14	-0.38	8.32e-7	Neuroticism;
PAAD	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg20243544	chr17:37824526	PNMT	0.57	5.3	0.39	4e-7	Self-reported allergy;
PAAD	cis	rs72717751	0.504	rs78360804	chr14:55957886	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-4.26	-0.33	3.57e-5	Platelet distribution width;
PAAD	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg21859623	chr20:33103246	DYNLRB1	0.48	4.62	0.35	8.21e-6	Height;
PAAD	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg09980403	chr19:12975529	MAST1	0.29	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22162314	chr17:61951766	CSH2	-0.61	-6.26	-0.45	3.79e-9	Height;
PAAD	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.23	-0.64	5.01e-19	Blood trace element (Zn levels);
PAAD	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.42	-6.93	-0.49	1.14e-10	Paget's disease;
PAAD	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.75	6.86	0.49	1.64e-10	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06296021	chr5:133702588	CDKL3	0.59	6.37	0.46	2.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.73	-6.95	-0.49	1.02e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.34	-0.56	4.05e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.49	5.41	0.4	2.38e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10791097	0.519	rs74866549	chr11:130730380	A/G	cg12179176	chr11:130786555	SNX19	0.7	7.4	0.51	8.52e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.68	-6.18	-0.45	5.74e-9	Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.85	4.64	0.35	7.35e-6	Childhood ear infection;
PAAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs9314998	0.700	rs9508666	chr13:30747725	C/T	cg12316290	chr13:30425969	UBL3	-0.48	-4.52	-0.34	1.22e-5	Male-pattern baldness;
PAAD	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg21565972	chr17:80109576	CCDC57	0.58	6.72	0.48	3.39e-10	Life satisfaction;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg04539111	chr16:67997858	SLC12A4	-0.58	-4.26	-0.33	3.63e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg08027265	chr7:2291960	NA	-0.52	-5.25	-0.39	5.01e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs72960926	0.744	rs72954341	chr6:74947167	A/G	cg03266952	chr6:74778945	NA	-1.12	-6.45	-0.46	1.41e-9	Metabolite levels (MHPG);
PAAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg13770153	chr20:60521292	NA	-0.58	-5.83	-0.43	3.23e-8	Body mass index;
PAAD	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.16	10.02	0.63	1.84e-18	Vitiligo;
PAAD	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.99	-0.38	1.61e-6	Height;
PAAD	cis	rs34375054	0.687	rs12303572	chr12:125611271	G/T	cg09839279	chr12:125627357	AACS	-0.48	-4.86	-0.37	2.85e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.69	7.58	0.52	3.09e-12	Calcium levels;
PAAD	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.55	0.41	1.22e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.43	4.43	0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-1.03	-6.99	-0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	4.83	0.36	3.36e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.6	6.6	0.47	6.48e-10	Facial morphology (factor 20);
PAAD	cis	rs490234	0.841	rs1250736	chr9:128438005	A/G	cg14078157	chr9:128172775	NA	0.44	4.96	0.37	1.84e-6	Mean arterial pressure;
PAAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25550546	chr5:139682720	PFDN1	0.68	7.83	0.54	7.58e-13	Myopia (pathological);
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.63	-7.84	-0.54	7.49e-13	Inflammatory skin disease;
PAAD	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg16447950	chr5:562315	NA	-0.48	-4.55	-0.35	1.09e-5	Ulcerative colitis;
PAAD	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	8.07e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs727479	0.962	rs2414097	chr15:51529835	G/A	cg21478137	chr15:51532386	CYP19A1	0.62	6.95	0.49	1.03e-10	Estradiol levels;
PAAD	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.56	4.66	0.35	6.84e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.687	rs1600074	chr5:74436574	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.6	-7.05	-0.5	5.83e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20681931	chr6:10723052	TMEM14C	0.59	6.56	0.47	8.12e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2712184	0.756	rs2712163	chr2:217660346	G/A	cg05032264	chr2:217675019	NA	-0.59	-6.72	-0.48	3.52e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs1113500	0.565	rs11185226	chr1:108548051	G/A	cg06207961	chr1:108661230	NA	0.53	5.35	0.4	3.24e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg05304507	chr6:116381966	FRK	0.39	7.3	0.51	1.49e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7567389	0.677	rs7556675	chr2:128053747	C/T	cg11380483	chr2:127933992	NA	-0.48	-4.71	-0.36	5.48e-6	Self-rated health;
PAAD	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg17325771	chr7:75508891	RHBDD2	0.3	4.26	0.33	3.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.53	4.41	0.34	1.96e-5	Type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.36	-0.33	2.35e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4454254	0.871	rs4374967	chr8:141061798	A/G	cg06693505	chr8:141057453	TRAPPC9	-0.32	-4.49	-0.34	1.39e-5	Pulse pressure;
PAAD	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.73	-0.58	4.31e-15	Exhaled nitric oxide output;
PAAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.78	-0.36	4.18e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs71494797	chr10:45997458	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg27411982	chr8:10470053	RP1L1	0.48	5.06	0.38	1.21e-6	Retinal vascular caliber;
PAAD	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.6	-6.37	-0.46	2.11e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs13070279	0.655	rs35281203	chr3:71801535	G/A	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg06375148	chr1:209958343	C1orf74	-0.55	-5.58	-0.41	1.06e-7	Orofacial clefts;
PAAD	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.68	-7.49	-0.52	5.18e-12	Alcohol dependence;
PAAD	cis	rs10901513	1.000	rs3781001	chr10:127706028	C/T	cg22975853	chr10:127789788	ADAM12	0.41	4.28	0.33	3.32e-5	Visceral fat;
PAAD	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs2446066	1.000	rs2446066	chr12:53778650	G/T	cg20591337	chr12:53693442	C12orf10	-0.63	-4.4	-0.34	2.05e-5	Red blood cell count;
PAAD	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.8	9.43	0.61	6.74e-17	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.24	0.39	5.36e-7	Lung cancer in ever smokers;
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-4.68	-0.35	6.35e-6	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg09945482	chr18:12777974	NA	0.58	5.12	0.38	9.13e-7	Inflammatory skin disease;
PAAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	1.12	14.9	0.77	1.63e-31	Breast cancer;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg05313129	chr8:58192883	C8orf71	-0.67	-5.68	-0.42	6.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.78	10.77	0.66	1.91e-20	Cannabis dependence symptom count;
PAAD	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg06917450	chr1:38156652	C1orf109	-0.51	-4.48	-0.34	1.49e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.58	5.34	0.4	3.27e-7	Urate levels;
PAAD	cis	rs9324022	0.722	rs17099613	chr14:101164715	T/A	cg18089426	chr14:101175970	NA	0.66	4.3	0.33	3.05e-5	Plateletcrit;
PAAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.57	-0.35	1.02e-5	Systemic lupus erythematosus;
PAAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.75	-7.83	-0.54	7.67e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25561939	chr20:34359976	PHF20	0.59	6.37	0.46	2.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	1.01	10.46	0.65	1.25e-19	Post bronchodilator FEV1;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-6.6	-0.47	6.31e-10	Calcium levels;
PAAD	cis	rs6076065	0.723	rs6083119	chr20:23390923	T/G	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.93	-0.37	2.1e-6	High light scatter reticulocyte count;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg00450029	chr8:599525	NA	0.78	5.16	0.39	7.56e-7	IgG glycosylation;
PAAD	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.37	11.97	0.7	1.12e-23	Uric acid levels;
PAAD	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.98	-8.45	-0.57	2.26e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2440012	0.586	rs17272235	chr13:19422894	T/G	cg08120511	chr13:19412184	LOC284232	-0.66	-4.37	-0.33	2.27e-5	Longevity;
PAAD	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.49	5.2	0.39	6.45e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg13859433	chr6:33739653	LEMD2	-0.66	-4.57	-0.35	1.02e-5	Schizophrenia;
PAAD	cis	rs10943724	0.679	rs4394171	chr6:81265100	C/T	cg19323245	chr6:80716898	TTK	0.42	4.39	0.34	2.15e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.06	-0.44	1.01e-8	Monocyte count;
PAAD	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.46	4.75	0.36	4.57e-6	Breast cancer;
PAAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg01411142	chr8:19674711	INTS10	0.83	5.21	0.39	5.93e-7	Lipid metabolism phenotypes;
PAAD	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.76	-0.48	2.8e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-4.99	-0.38	1.65e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16414030	chr3:133502952	NA	-0.47	-4.98	-0.37	1.72e-6	Iron status biomarkers;
PAAD	trans	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg11421182	chr20:36153479	BLCAP	-0.54	-6.55	-0.47	8.2e-10	IgG glycosylation;
PAAD	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg15352829	chr14:105391018	PLD4	-0.57	-7.66	-0.53	2.02e-12	Systemic lupus erythematosus;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg00450029	chr8:599525	NA	0.9	5.86	0.43	2.73e-8	IgG glycosylation;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg27394845	chr17:28928406	LRRC37B2	0.6	4.28	0.33	3.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs62179067	0.708	rs62175994	chr2:179906277	T/A	cg13380624	chr19:7735426	NA	-0.74	-7.09	-0.5	4.64e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs6604026	0.643	rs1360366	chr1:93330987	A/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs1879734	0.953	rs3013769	chr1:54156323	G/A	cg14659662	chr1:54151053	GLIS1	0.4	6.53	0.47	9.52e-10	Mitral valve prolapse;
PAAD	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.43	-0.4	2.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.57	5.42	0.4	2.32e-7	Corneal astigmatism;
PAAD	cis	rs9322817	0.691	rs2290515	chr6:105232204	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-5.48	-0.41	1.7e-7	Thyroid stimulating hormone;
PAAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-4.7	-0.36	5.73e-6	Glomerular filtration rate;
PAAD	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg10729496	chr3:10149963	C3orf24	0.98	6.75	0.48	3e-10	Alzheimer's disease;
PAAD	cis	rs863345	0.933	rs2051068	chr1:158507184	A/G	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	1.02e-6	Pneumococcal bacteremia;
PAAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.28	-0.39	4.49e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23708337	chr7:1209742	NA	0.46	4.84	0.37	3.12e-6	Longevity;Endometriosis;
PAAD	cis	rs6066835	1.000	rs4568007	chr20:47316575	C/G	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs569214	0.515	rs516125	chr8:27520266	A/G	cg04264299	chr8:27491209	SCARA3	0.53	5.17	0.39	7.41e-7	Alzheimer's disease;
PAAD	cis	rs2526932	0.625	rs2158540	chr14:73052433	A/G	cg13588403	chr14:73209128	DPF3	-0.41	-5.49	-0.41	1.66e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2296225	0.722	rs12403580	chr1:21049518	C/T	cg24673385	chr1:21051448	SH2D5	0.5	4.68	0.36	6.22e-6	Eosinophilic esophagitis;
PAAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4072705	0.585	rs7852843	chr9:127233823	C/T	cg13476313	chr9:127244764	NR5A1	-0.32	-4.83	-0.36	3.29e-6	Menarche (age at onset);
PAAD	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.09	6.36	0.46	2.29e-9	Body mass index;
PAAD	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg23127183	chr11:57508653	C11orf31	-0.53	-4.5	-0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.51	6.17	0.45	5.86e-9	Sitting height ratio;
PAAD	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.48	5.16	0.39	7.75e-7	Body mass index;
PAAD	cis	rs9907295	0.591	rs6505496	chr17:34129067	A/G	cg19411729	chr17:34207663	CCL5	-0.5	-4.45	-0.34	1.68e-5	Fibroblast growth factor basic levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00226754	chr12:124068984	TMED2	0.65	6.93	0.49	1.11e-10	Myopia (pathological);
PAAD	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs62179067	0.708	rs62175987	chr2:179876514	A/G	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.85e-6	Type 2 diabetes;
PAAD	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg08992911	chr2:238395768	MLPH	0.61	5.14	0.39	8.15e-7	Prostate cancer;
PAAD	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs67133203	0.851	rs4768967	chr12:51506328	C/T	cg02675652	chr12:51477739	CSRNP2	0.49	4.4	0.34	2.04e-5	Urinary tract infection frequency;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7624766	0.555	rs9814394	chr3:160490977	T/C	cg22637730	chr3:160473554	PPM1L	0.56	4.86	0.37	2.85e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.68	5.68	0.42	6.73e-8	Response to antidepressants in depression;
PAAD	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.63	6.93	0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13146426	chr11:122932858	HSPA8	0.65	6.98	0.49	8.79e-11	Myopia (pathological);
PAAD	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg26205652	chr12:48591994	NA	0.76	7.03	0.5	6.6e-11	Longevity (90 years and older);
PAAD	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01942863	chr7:99769432	GPC2	0.52	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg20487152	chr13:99095054	FARP1	0.6	5.26	0.39	4.78e-7	Neuroticism;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26996874	chr6:158677312	NA	-0.65	-6.5	-0.47	1.07e-9	Primary biliary cholangitis;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg23465465	chr6:26364728	BTN3A2	0.78	4.81	0.36	3.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	6.77	0.48	2.64e-10	Hip circumference;
PAAD	cis	rs9810890	1.000	rs73198889	chr3:128547620	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs1797885	0.689	rs796169	chr3:12565796	T/C	cg07775309	chr3:12595852	NA	0.41	4.42	0.34	1.84e-5	Immature fraction of reticulocytes;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.0	-0.38	1.57e-6	Cystic fibrosis severity;
PAAD	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	1.06	6.54	0.47	8.73e-10	Fat distribution (HIV);
PAAD	cis	rs58521262	0.530	rs289356	chr19:23144334	G/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08953461	chr5:157158882	THG1L	0.57	6.4	0.46	1.81e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	6.38	0.46	2.07e-9	Schizophrenia;
PAAD	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.6	-6.61	-0.47	6.04e-10	Melanoma;
PAAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.65	6.55	0.47	8.42e-10	Diastolic blood pressure;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.85	9.79	0.62	7.4e-18	Iron status biomarkers;
PAAD	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.07	-0.38	1.14e-6	Fear of minor pain;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-5.94	-0.43	1.86e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10214930	0.813	rs2160125	chr7:27688286	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.49	-4.26	-0.33	3.63e-5	Aortic root size;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.72	7.66	0.53	1.99e-12	Longevity;
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	1.23	11.9	0.69	1.76e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2004318	0.850	rs61739244	chr19:55144684	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.68	6.03	0.44	1.22e-8	Inflammatory skin disease;
PAAD	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	7.62	0.53	2.59e-12	Eotaxin levels;
PAAD	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7615952	0.605	rs34865555	chr3:125304134	C/T	cg05084668	chr3:125655381	ALG1L	-0.56	-5.33	-0.4	3.56e-7	Blood pressure (smoking interaction);
PAAD	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.63	-6.01	-0.44	1.29e-8	Cognitive function;
PAAD	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg15838173	chr10:75533400	FUT11	-0.43	-4.3	-0.33	3.04e-5	Inflammatory bowel disease;
PAAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.47	-4.66	-0.35	6.86e-6	Total body bone mineral density;
PAAD	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.98	-0.44	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2393895	0.688	rs10995218	chr10:64334119	G/A	cg22582187	chr10:63394414	NA	-0.81	-4.28	-0.33	3.31e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg05082376	chr22:42548792	NA	-0.55	-5.66	-0.42	7.19e-8	Cognitive function;
PAAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg04106633	chr4:1044584	NA	0.53	4.96	0.37	1.85e-6	Recombination rate (males);
PAAD	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.77	6.17	0.45	5.92e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs11159086	0.793	rs28612392	chr14:74934597	C/G	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.54	-5.93	-0.43	1.99e-8	Post bronchodilator FEV1;
PAAD	cis	rs899997	1.000	rs755998	chr15:79032469	C/T	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.63	-6.93	-0.49	1.12e-10	Colorectal cancer;
PAAD	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.47	4.28	0.33	3.32e-5	White matter hyperintensity burden;
PAAD	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-5.44	-0.4	2.06e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.7	8.17	0.55	1.13e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.85	-9.62	-0.62	2.09e-17	Prostate cancer;
PAAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.18	-0.39	6.88e-7	Aortic root size;
PAAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg15598662	chr11:61582890	MIR1908;FADS1	0.53	4.74	0.36	4.8e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.92	-8.52	-0.57	1.44e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg03037974	chr15:76606532	NA	0.52	6.03	0.44	1.2e-8	Blood metabolite levels;
PAAD	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg17812751	chr4:3478348	DOK7	0.43	4.76	0.36	4.46e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.45	-0.57	2.26e-14	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02463494	chr2:160568812	MARCH7	0.71	7.21	0.5	2.43e-11	Obesity-related traits;
PAAD	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.72	-0.42	5.41e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.42	-0.46	1.67e-9	Life satisfaction;
PAAD	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg26248373	chr2:1572462	NA	-1.09	-7.55	-0.52	3.72e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.39	-0.34	2.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	4.47	0.34	1.53e-5	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	4.48	0.34	1.45e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.99	-9.77	-0.62	8.25e-18	Cognitive ability;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg00262122	chr8:11665843	FDFT1	0.58	5.25	0.39	5.1e-7	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg08992911	chr2:238395768	MLPH	0.83	6.09	0.44	8.89e-9	Prostate cancer;
PAAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs35955747	0.902	rs713947	chr22:31639509	G/T	cg02404636	chr22:31891804	SFI1	-0.49	-4.89	-0.37	2.54e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1008126	0.800	rs2528862	chr7:103155944	C/G	cg04218035	chr7:103086829	SLC26A5	0.32	4.35	0.33	2.44e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs874628	0.686	rs885683	chr19:18244690	A/G	cg02814054	chr19:18234911	MAST3	-0.44	-4.36	-0.33	2.4e-5	Multiple sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06327849	chr3:129035119	H1FX;C3orf47	0.57	6.53	0.47	9.13e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.66	-6.33	-0.46	2.58e-9	Total body bone mineral density;
PAAD	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.79	7.77	0.53	1.09e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	10.22	0.64	5.44e-19	Cognitive test performance;
PAAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.6	5.61	0.41	9.31e-8	Prostate cancer;
PAAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.86	-7.61	-0.53	2.64e-12	Recombination rate (females);
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.6	-0.35	8.93e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19117517	chr17:685695	GLOD4;RNMTL1	0.7	6.89	0.49	1.36e-10	Obesity-related traits;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg10351095	chr21:47802916	PCNT	0.5	4.88	0.37	2.65e-6	Testicular germ cell tumor;
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.51	-7.17	-0.5	3.1e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	4.56	0.35	1.05e-5	Menarche (age at onset);
PAAD	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.56	-5.29	-0.39	4.19e-7	Neuroticism;
PAAD	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-5.31	-0.4	3.91e-7	Mood instability;
PAAD	cis	rs3106136	0.649	rs11097419	chr4:95298601	A/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.9	11.32	0.68	6.25e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg07856975	chr6:36356162	ETV7	0.46	5.24	0.39	5.38e-7	Platelet distribution width;
PAAD	cis	rs56046484	0.750	rs12900078	chr15:85523969	G/A	cg08123816	chr15:85640762	PDE8A	-0.47	-4.33	-0.33	2.64e-5	Testicular germ cell tumor;
PAAD	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.82	-9.93	-0.63	3.21e-18	Monocyte percentage of white cells;
PAAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg00999904	chr2:3704751	ALLC	-0.39	-4.49	-0.34	1.39e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs10261878	0.826	rs2067617	chr7:26013959	G/A	cg01322214	chr7:25219198	C7orf31	1.03	4.29	0.33	3.2e-5	Body mass index;
PAAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg20900008	chr2:392811	NA	-0.51	-4.46	-0.34	1.58e-5	Blood protein levels;
PAAD	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg09760422	chr2:128146352	NA	0.26	4.5	0.34	1.36e-5	Protein C levels;
PAAD	cis	rs28829049	0.861	rs67113006	chr1:19376566	A/G	cg17445618	chr1:19577962	KIAA0090;MRTO4	-0.5	-4.47	-0.34	1.5e-5	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg04850017	chr11:63683019	RCOR2	0.38	4.29	0.33	3.16e-5	Pulse pressure;
PAAD	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-4.4	-0.34	2.06e-5	Cystic fibrosis severity;
PAAD	cis	rs1564892	0.615	rs66613683	chr12:104409025	T/C	cg08101375	chr12:104443925	GLT8D2	0.57	4.54	0.35	1.14e-5	Corneal structure;
PAAD	cis	rs6494488	0.500	rs56105035	chr15:64752131	T/C	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.44	4.85	0.37	3.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg18721089	chr20:30220636	NA	-0.78	-6.25	-0.45	3.93e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs863345	0.604	rs12034004	chr1:158463885	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.92e-6	Pneumococcal bacteremia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17165303	chr1:982308	AGRN	-0.63	-6.99	-0.49	7.94e-11	Myopia (pathological);
PAAD	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	4.27	0.33	3.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.6	-7.98	-0.54	3.33e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.96	0.49	9.32e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6604026	0.656	rs6698179	chr1:93390714	G/C	cg13858687	chr1:93297071	RPL5	0.49	4.5	0.34	1.33e-5	Multiple sclerosis;
PAAD	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.73e-7	Daytime sleep phenotypes;
PAAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg23346134	chr3:49453900	TCTA	-0.45	-4.9	-0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.75	-7.94	-0.54	4.08e-13	Type 2 diabetes;
PAAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.72	5.62	0.42	8.68e-8	Initial pursuit acceleration;
PAAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg11995313	chr8:8860691	ERI1	0.49	4.71	0.36	5.66e-6	Joint mobility (Beighton score);
PAAD	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg09876464	chr15:85330779	ZNF592	0.45	4.49	0.34	1.39e-5	P wave terminal force;
PAAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.41	4.8	0.36	3.77e-6	Schizophrenia;
PAAD	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.55	6.25	0.45	3.85e-9	Mean corpuscular volume;
PAAD	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	0.89	8.8	0.58	2.77e-15	Exhaled nitric oxide output;
PAAD	cis	rs2694528	0.844	rs7701624	chr5:60027752	C/T	cg11474532	chr5:59995715	DEPDC1B	0.73	4.43	0.34	1.76e-5	Parkinson's disease;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.4	-0.4	2.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6032067	0.683	rs16989769	chr20:43780475	A/G	cg10761708	chr20:43804764	PI3	-0.47	-4.25	-0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.5e-6	Cognitive function;
PAAD	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg02403541	chr12:121454288	C12orf43	0.63	6.83	0.48	1.92e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg24733560	chr20:60626293	TAF4	0.52	6.48	0.47	1.21e-9	Body mass index;
PAAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg05110241	chr16:68378359	PRMT7	-1.17	-8.25	-0.56	6.87e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-5.25	-0.39	5.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg26138144	chr22:38071188	LGALS1	0.51	5.62	0.41	8.98e-8	Fat distribution (HIV);
PAAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs939584	1.000	rs13007080	chr2:630024	A/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.22e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05030574	chr11:65189075	NEAT1	0.6	6.98	0.49	8.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg14393609	chr7:65229607	NA	-0.63	-6.7	-0.48	3.76e-10	Aortic root size;
PAAD	cis	rs6466055	0.589	rs12536794	chr7:104990954	T/C	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	6.39	0.46	1.9e-9	Mood instability;
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg26939375	chr7:64535504	NA	-0.75	-9.06	-0.59	6.19e-16	Aortic root size;
PAAD	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.54	5.35	0.4	3.24e-7	Asthma (bronchodilator response);
PAAD	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg19744528	chr7:157553346	PTPRN2	0.4	4.29	0.33	3.19e-5	Body mass index;
PAAD	cis	rs9834373	0.614	rs4560262	chr3:78502283	A/G	cg06138941	chr3:78371609	NA	-0.39	-4.41	-0.34	1.97e-5	Protein quantitative trait loci;
PAAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg24253500	chr15:84953950	NA	-0.45	-4.97	-0.37	1.75e-6	P wave terminal force;
PAAD	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-5.12	-0.38	8.95e-7	Bipolar disorder;
PAAD	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg21361702	chr7:150065534	REPIN1	0.59	4.76	0.36	4.41e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	0.95	6.7	0.48	3.8e-10	Pulse pressure;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.661	rs6955133	chr7:104915625	A/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.8	9.15	0.6	3.52e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.37	0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg10253484	chr15:75165896	SCAMP2	0.6	5.56	0.41	1.2e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg02640540	chr1:67518911	SLC35D1	-0.61	-4.83	-0.37	3.24e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.67	-7.29	-0.51	1.57e-11	Menarche (age at onset);
PAAD	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.79	-6.9	-0.49	1.28e-10	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs13011075	0.535	rs6419643	chr2:68631260	A/C	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg24739098	chr15:79297159	RASGRF1	0.32	4.34	0.33	2.59e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.59	-5.39	-0.4	2.7e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.73	-7.59	-0.52	3.06e-12	Magnesium levels;
PAAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.8	-0.36	3.69e-6	Breast cancer;
PAAD	cis	rs755249	0.567	rs16825939	chr1:39662508	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs6558530	0.836	rs7461600	chr8:1714642	G/T	cg02000426	chr8:1759815	NA	-0.41	-4.28	-0.33	3.26e-5	Systolic blood pressure;
PAAD	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.96	-9.96	-0.63	2.69e-18	Homoarginine levels;
PAAD	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02598441	chr17:62777298	LOC146880	-0.54	-4.42	-0.34	1.87e-5	QT interval;
PAAD	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.03	-0.38	1.38e-6	Mean corpuscular volume;
PAAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.6e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1499972	0.938	rs861673	chr3:117733019	A/G	cg07612923	chr3:117604196	NA	-0.93	-6.28	-0.45	3.45e-9	Schizophrenia;
PAAD	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg14583973	chr4:3374767	RGS12	0.39	5.94	0.43	1.89e-8	Serum sulfate level;
PAAD	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg01657329	chr11:68192670	LRP5	-0.59	-4.26	-0.33	3.62e-5	Total body bone mineral density (age 45-60);
PAAD	cis	rs4948496	0.600	rs3740355	chr10:63810458	C/A	cg09941381	chr10:64027924	RTKN2	-0.39	-4.29	-0.33	3.14e-5	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs742132	0.545	rs11969981	chr6:25650817	T/A	cg12310025	chr6:25882481	NA	0.65	4.35	0.33	2.47e-5	Uric acid levels;
PAAD	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.47	-0.34	1.51e-5	Neuroticism;
PAAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg02580895	chr19:2754563	NA	-0.51	-4.47	-0.34	1.51e-5	Total cholesterol levels;
PAAD	cis	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg08274380	chr1:109419600	GPSM2	0.8	5.46	0.41	1.88e-7	Fat distribution (HIV);
PAAD	cis	rs7071247	0.915	rs3014204	chr10:105260229	G/T	cg20028483	chr10:104949090	NT5C2	0.6	4.4	0.34	2.02e-5	Platelet aggregation;
PAAD	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.67	6.71	0.48	3.62e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs939584	0.778	rs12992154	chr2:632300	G/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg22153407	chr1:230290089	GALNT2	-0.49	-4.76	-0.36	4.38e-6	Coronary artery disease;
PAAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.84	-6.23	-0.45	4.4e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
PAAD	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.28	-14.14	-0.75	1.61e-29	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01159004	chr20:48330681	B4GALT5	0.73	7.31	0.51	1.45e-11	Obesity-related traits;
PAAD	cis	rs9815354	1.000	rs1717017	chr3:41915616	A/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.8	8.06	0.55	2.14e-13	Vitiligo;
PAAD	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3761218	0.668	rs6052079	chr20:3774209	G/T	cg02737268	chr20:3780182	CDC25B	0.49	5.11	0.38	9.48e-7	Bipolar disorder;
PAAD	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-5.2	-0.39	6.25e-7	Magnesium levels;
PAAD	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg22029157	chr1:209979665	IRF6	0.7	6.16	0.45	6.17e-9	Coronary artery disease;
PAAD	cis	rs4704187	0.687	rs11950665	chr5:74423339	A/G	cg03227963	chr5:74354835	NA	0.5	4.86	0.37	2.94e-6	Response to amphetamines;
PAAD	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg16898833	chr6:26189333	HIST1H4D	0.86	4.74	0.36	4.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs7688540	0.760	rs12506250	chr4:227382	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.48	0.34	1.44e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs12753569	0.934	rs6676370	chr1:76490185	G/T	cg00791851	chr1:76518896	NA	-0.43	-4.54	-0.35	1.13e-5	Personality dimensions;
PAAD	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.67	6.48	0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.24	0.6	2.04e-16	Mortality in heart failure;
PAAD	cis	rs757081	0.648	rs10832750	chr11:17260918	A/T	cg04705435	chr11:17411270	KCNJ11	0.55	5.58	0.41	1.05e-7	Systolic blood pressure;
PAAD	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg04450456	chr4:17643702	FAM184B	0.46	4.7	0.36	5.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg12549451	chr6:135224345	NA	-0.5	-5.38	-0.4	2.82e-7	Red blood cell count;
PAAD	cis	rs11700980	0.551	rs2832012	chr21:30110932	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7922314	0.571	rs16918003	chr10:64751852	T/C	cg08989932	chr10:65390526	NA	-0.95	-4.69	-0.36	5.92e-6	Cutaneous psoriasis;
PAAD	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.74e-27	Height;
PAAD	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.52	4.47	0.34	1.55e-5	Cocaine dependence;
PAAD	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.21	16.56	0.8	7.58e-36	Schizophrenia;
PAAD	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.82	-9.52	-0.61	3.81e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg11993925	chr19:44307056	LYPD5	0.52	7.11	0.5	4.33e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.91	-0.37	2.33e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1160297	0.552	rs6545316	chr2:53223038	A/G	cg07782112	chr2:53107842	NA	-0.36	-4.28	-0.33	3.32e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2562456	0.752	rs7258562	chr19:21514564	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.26	-0.33	3.59e-5	Pain;
PAAD	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.8	5.73	0.42	5.25e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.06	-13.7	-0.74	2.41e-28	Prudent dietary pattern;
PAAD	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.64	6.93	0.49	1.12e-10	Aortic root size;
PAAD	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-5.15	-0.39	8.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.72	7.83	0.54	7.92e-13	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02858843	chr1:26324688	PAFAH2	0.59	6.73	0.48	3.2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg04482110	chr17:41364121	TMEM106A	0.41	4.64	0.35	7.44e-6	Menopause (age at onset);
PAAD	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	7.73	0.53	1.33e-12	HIV-1 control;
PAAD	cis	rs10214930	0.752	rs12531518	chr7:27661139	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.76	8.69	0.58	5.48e-15	Prostate cancer;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11100077	chr12:56546410	MYL6B	-0.56	-6.35	-0.46	2.31e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7873102	0.654	rs1928232	chr9:37989697	G/A	cg03528946	chr9:38069800	SHB	0.5	5.07	0.38	1.12e-6	Brain structure;
PAAD	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.05	0.5	5.79e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.49	4.36	0.33	2.4e-5	Acne (severe);
PAAD	cis	rs16975963	0.644	rs78644049	chr19:38113042	T/A	cg14218481	chr19:38281219	NA	0.41	4.4	0.34	2.03e-5	Longevity;
PAAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg12639453	chr1:2035780	PRKCZ	-0.55	-5.93	-0.43	1.97e-8	Height;
PAAD	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs5417	0.636	rs2074217	chr17:7150552	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.64	-6.36	-0.46	2.23e-9	Diastolic blood pressure;
PAAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg06375148	chr1:209958343	C1orf74	0.68	5.27	0.39	4.57e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs16958440	0.541	rs62095459	chr18:44621382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-5.04	-0.38	1.33e-6	Sitting height ratio;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.45	-0.34	1.68e-5	Obesity (extreme);
PAAD	cis	rs1497828	0.956	rs2646802	chr1:217522359	G/A	cg04411442	chr1:217543379	NA	-0.48	-4.76	-0.36	4.46e-6	Dialysis-related mortality;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.72	-7.79	-0.53	9.88e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.16	17.66	0.82	1.18e-38	Cognitive function;
PAAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg21951975	chr1:209979733	IRF6	0.59	5.44	0.4	2.09e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg25801113	chr15:45476975	SHF	0.42	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg21565972	chr17:80109576	CCDC57	0.62	7.19	0.5	2.81e-11	Life satisfaction;
PAAD	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs6784615	0.744	rs13071708	chr3:52322680	G/A	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.64	-7.57	-0.52	3.32e-12	Schizophrenia;
PAAD	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	5.58	0.41	1.08e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9581857	0.547	rs9581870	chr13:28083957	T/G	cg22138327	chr13:27999177	GTF3A	0.8	5.19	0.39	6.79e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs11123610	0.698	rs72769388	chr2:3725964	C/T	cg10645314	chr2:3704589	ALLC	-0.47	-4.57	-0.35	9.93e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.78	-0.42	4.05e-8	Airway imaging phenotypes;
PAAD	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.95	-7.82	-0.54	8.37e-13	Bipolar disorder;
PAAD	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-4.76	-0.36	4.46e-6	Mean platelet volume;
PAAD	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg23684204	chr15:91497937	RCCD1	0.71	5.69	0.42	6.3e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs4662750	0.859	rs2245297	chr2:128382859	C/T	cg09760422	chr2:128146352	NA	0.33	4.8	0.36	3.71e-6	Renal cell carcinoma;
PAAD	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.81	-8.43	-0.56	2.48e-14	Cystic fibrosis severity;
PAAD	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg12633918	chr20:23549525	CST9L	-0.44	-4.84	-0.37	3.19e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.13	14.93	0.77	1.31e-31	Schizophrenia;
PAAD	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.73	-7.28	-0.51	1.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg10356904	chr22:49881777	NA	-0.48	-4.7	-0.36	5.76e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.63	-0.62	1.93e-17	Lung cancer;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7896691	0.925	rs6602023	chr10:3155217	A/G	cg15228268	chr10:3146741	PFKP	-0.8	-5.0	-0.38	1.53e-6	Disc degeneration (lumbar);
PAAD	cis	rs7651511	0.926	rs7629035	chr3:141231920	A/C	cg25967872	chr3:141205623	RASA2	0.51	4.53	0.35	1.16e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg10544611	chr16:67998164	SLC12A4	-0.79	-4.34	-0.33	2.6e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg14254433	chr6:34482411	PACSIN1	-0.96	-6.13	-0.44	7.37e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg01796438	chr3:11312864	ATG7	-0.64	-4.88	-0.37	2.6e-6	Circulating chemerin levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25526717	chr21:45719687	PFKL	0.7	6.39	0.46	1.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs287982	0.932	rs9973577	chr2:9960703	C/G	cg01119585	chr2:10571959	NA	0.4	4.36	0.33	2.39e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs11892454	0.565	rs6748220	chr2:26101403	A/C	cg25181710	chr2:26045287	ASXL2	0.39	4.32	0.33	2.78e-5	Heschl's gyrus morphology;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs797680	0.856	rs627779	chr1:93684089	T/C	cg04535902	chr1:92947332	GFI1	-0.46	-4.42	-0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg08698997	chr16:88989212	CBFA2T3	0.4	5.03	0.38	1.39e-6	Social autistic-like traits;
PAAD	cis	rs7165102	1.000	rs6494528	chr15:65865632	T/G	cg22900193	chr15:65823441	PTPLAD1	0.49	4.63	0.35	7.89e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs427941	1.000	rs407943	chr7:101859050	G/A	cg06721601	chr7:101762633	CUX1	-0.42	-4.34	-0.33	2.55e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	cis	rs3106136	0.678	rs12646487	chr4:95279907	T/A	cg11021082	chr4:95130006	SMARCAD1	0.58	5.64	0.42	8.17e-8	Capecitabine sensitivity;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg22029157	chr1:209979665	IRF6	0.68	6.43	0.46	1.59e-9	Coronary artery disease;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg04575393	chr19:53496094	ZNF702P	-0.41	-4.41	-0.34	1.95e-5	Psoriasis;
PAAD	cis	rs10901513	0.932	rs11244741	chr10:127662975	A/G	cg22975853	chr10:127789788	ADAM12	0.42	4.61	0.35	8.56e-6	Visceral fat;
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg04482110	chr17:41364121	TMEM106A	0.41	4.62	0.35	8.02e-6	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.38	-4.27	-0.33	3.47e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.59	0.61	2.44e-17	Rheumatoid arthritis;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06799790	chr17:61951754	CSH2	-0.47	-4.81	-0.36	3.62e-6	Height;
PAAD	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg03989125	chr22:38214979	NA	0.54	4.69	0.36	6e-6	Fat distribution (HIV);
PAAD	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	IgG glycosylation;
PAAD	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02359409	chr6:42947317	PEX6	-0.49	-4.97	-0.37	1.77e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-6.11	-0.44	8.2e-9	Schizophrenia;
PAAD	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.7	8.54	0.57	1.3e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg20283391	chr11:68216788	NA	-0.52	-4.96	-0.37	1.84e-6	Total body bone mineral density;
PAAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.76	6.82	0.48	1.97e-10	White blood cell count;
PAAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-6.03	-0.44	1.19e-8	Bipolar disorder;
PAAD	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg06740227	chr12:86229804	RASSF9	-0.55	-5.3	-0.39	4.09e-7	Major depressive disorder;
PAAD	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.68	8.38	0.56	3.29e-14	Educational attainment;
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.92	0.37	2.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.88	-0.37	2.62e-6	Blood metabolite levels;
PAAD	cis	rs17023223	0.537	rs12081585	chr1:119615956	A/C	cg17326555	chr1:119535693	NA	-0.41	-4.72	-0.36	5.38e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-1.06	-18.77	-0.84	2.02e-41	Urate levels in lean individuals;
PAAD	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.45e-7	Crohn's disease;
PAAD	cis	rs12476592	0.602	rs262485	chr2:63878413	T/G	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs12760731	0.720	rs10913540	chr1:178340060	T/C	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23158103	chr7:148848205	ZNF398	-0.64	-6.37	-0.46	2.16e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9944715	0.954	rs12607898	chr18:43802778	A/G	cg00381974	chr18:44260357	ST8SIA5	-0.48	-4.4	-0.34	2e-5	Red cell distribution width;Mean corpuscular volume;
PAAD	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.43	5.99	0.44	1.49e-8	Vitiligo;
PAAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.75e-9	Cognitive function;
PAAD	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.47	4.34	0.33	2.6e-5	Lung cancer;
PAAD	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-4.37	-0.33	2.33e-5	Inflammatory bowel disease;
PAAD	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.73	7.3	0.51	1.51e-11	Obesity-related traits;
PAAD	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	4.33	0.33	2.74e-5	Hip circumference;
PAAD	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.55	-5.68	-0.42	6.73e-8	Total body bone mineral density;
PAAD	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.31	-0.33	2.97e-5	Resting heart rate;
PAAD	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg12615879	chr12:58013172	SLC26A10	-0.47	-5.24	-0.39	5.32e-7	Multiple sclerosis;
PAAD	cis	rs7833787	1.000	rs7833787	chr8:18707871	A/G	cg17701159	chr8:18705777	PSD3	-0.45	-5.25	-0.39	4.98e-7	Obesity-related traits;
PAAD	cis	rs2882667	0.690	rs6872423	chr5:138246778	T/C	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.36	0.56	3.61e-14	Prudent dietary pattern;
PAAD	cis	rs13065560	0.534	rs4637231	chr3:38909115	T/C	cg01426195	chr3:39028469	NA	-0.46	-4.41	-0.34	1.99e-5	Interleukin-18 levels;
PAAD	cis	rs11264213	1.000	rs12083902	chr1:36275112	G/A	cg27506609	chr1:36549197	TEKT2	0.7	4.78	0.36	4.1e-6	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.33	-0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16867321	0.951	rs13413574	chr2:181364491	A/G	cg23363182	chr2:181467187	NA	-0.48	-4.33	-0.33	2.64e-5	Obesity;
PAAD	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.97	7.01	0.49	7.1e-11	Dental caries;
PAAD	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10915437	1.000	rs6675734	chr1:4185002	C/T	cg27165836	chr1:4193882	NA	0.47	4.54	0.35	1.14e-5	Migraine - clinic-based;
PAAD	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg05925327	chr15:68127851	NA	-0.61	-5.5	-0.41	1.56e-7	Obesity;
PAAD	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.12	0.55	1.51e-13	Lung cancer in ever smokers;
PAAD	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.62	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs7714584	1.000	rs7736554	chr5:150258308	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.91	-0.43	2.2e-8	Total body bone mineral density;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.49	4.42	0.34	1.87e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24614420	chr3:188675062	NA	-0.65	-6.35	-0.46	2.33e-9	Obesity-related traits;
PAAD	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg13540341	chr19:49222985	MAMSTR	0.41	4.51	0.34	1.3e-5	Dietary macronutrient intake;
PAAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.69	-8.47	-0.57	1.96e-14	Lymphocyte counts;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg19429281	chr19:53496738	ZNF702P	-0.6	-6.36	-0.46	2.27e-9	Psoriasis;
PAAD	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.56	-7.24	-0.51	2.11e-11	Longevity;
PAAD	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.28	0.51	1.71e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs1975974	0.511	rs66461325	chr17:21755430	A/G	cg18423549	chr17:21743878	NA	-0.59	-5.35	-0.4	3.21e-7	Psoriasis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg22577136	chr1:206644165	IKBKE	0.6	6.79	0.48	2.41e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.67	6.65	0.47	4.87e-10	Schizophrenia;
PAAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg17366294	chr4:99064904	C4orf37	0.61	6.51	0.47	1.03e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs12752838	0.777	rs11590606	chr1:8917669	C/T	cg24027679	chr1:9086621	SLC2A7	0.38	4.61	0.35	8.38e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16989797	chr9:139378060	C9orf163;SEC16A	0.59	6.45	0.46	1.41e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg11062466	chr8:58055876	NA	0.8	5.2	0.39	6.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg23352942	chr3:46931381	PTH1R	-0.46	-4.87	-0.37	2.76e-6	Birth weight;
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.42e-19	Menopause (age at onset);
PAAD	trans	rs2018683	0.711	rs1874977	chr7:28968083	A/G	cg19402173	chr7:128379420	CALU	-0.64	-7.54	-0.52	3.96e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	0.87	5.43	0.4	2.22e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.55	-5.0	-0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.76	8.82	0.58	2.44e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg05134918	chr12:132603531	EP400NL	-0.61	-4.87	-0.37	2.78e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg10223061	chr2:219282414	VIL1	0.37	4.39	0.34	2.1e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-5.44	-0.4	2.13e-7	Tonsillectomy;
PAAD	cis	rs9314614	0.899	rs2977802	chr8:6694845	C/G	cg27319216	chr8:6693540	XKR5	0.32	4.34	0.33	2.55e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs10885997	0.626	rs4751995	chr10:118397884	A/G	cg09194742	chr10:118576158	NA	0.44	4.34	0.33	2.61e-5	Phospholipid levels (plasma);
PAAD	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.91	0.37	2.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.94	-8.36	-0.56	3.71e-14	Bipolar disorder;
PAAD	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg19337854	chr7:99768885	GPC2	0.54	4.77	0.36	4.31e-6	Platelet count;
PAAD	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.75	7.4	0.51	8.84e-12	Resting heart rate;
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	8.16e-9	Lung cancer;
PAAD	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.3	0.45	3.12e-9	IgG glycosylation;
PAAD	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg25456477	chr12:86230367	RASSF9	0.49	4.33	0.33	2.65e-5	Major depressive disorder;
PAAD	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg02820901	chr13:113351484	ATP11A	0.73	4.83	0.36	3.34e-6	Glycated hemoglobin levels;
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.59	6.1	0.44	8.56e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.86	-7.3	-0.51	1.49e-11	Blood protein levels;
PAAD	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.63	7.22	0.51	2.39e-11	Carotid intima media thickness;
PAAD	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg18833306	chr6:118973337	C6orf204	0.51	5.91	0.43	2.13e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.65	5.51	0.41	1.47e-7	Morning vs. evening chronotype;
PAAD	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-8.9	-0.59	1.52e-15	Type 2 diabetes;
PAAD	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg14515779	chr1:101123966	NA	-0.54	-6.63	-0.47	5.62e-10	Monocyte count;
PAAD	cis	rs7582720	1.000	rs80087860	chr2:203673072	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs901683	1.000	rs12779005	chr10:46087374	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs838147	0.537	rs602662	chr19:49206985	G/A	cg21064579	chr19:49206444	FUT2	0.4	4.28	0.33	3.32e-5	Dietary macronutrient intake;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.49	-6.01	-0.44	1.35e-8	Lymphocyte counts;
PAAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg10547527	chr2:198650123	BOLL	-0.67	-4.3	-0.33	3.07e-5	Ulcerative colitis;
PAAD	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.43	4.51	0.34	1.28e-5	Brain structure;
PAAD	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-6.94	-0.49	1.03e-10	Personality dimensions;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.72	7.77	0.53	1.07e-12	Cystic fibrosis severity;
PAAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25833597	chr17:30823145	MYO1D	0.52	5.04	0.38	1.29e-6	Schizophrenia;
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-5.27	-0.39	4.6e-7	Colorectal cancer;
PAAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.48	-5.72	-0.42	5.42e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9926296	0.632	rs8048331	chr16:89793042	G/T	cg26513180	chr16:89883248	FANCA	-0.61	-6.74	-0.48	3.1e-10	Vitiligo;
PAAD	cis	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg21546286	chr11:48923668	NA	-0.47	-4.99	-0.38	1.62e-6	HDL cholesterol;
PAAD	cis	rs9908102	0.638	rs2072261	chr17:12893089	G/A	cg26162695	chr17:12921313	ELAC2	0.51	4.32	0.33	2.83e-5	Schizophrenia;
PAAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-4.71	-0.36	5.48e-6	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18245365	chr6:170615736	FAM120B	-0.76	-6.77	-0.48	2.67e-10	Neuroticism;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.44	5.26	0.39	4.8e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg20302533	chr7:39170763	POU6F2	0.41	6.57	0.47	7.69e-10	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg13918804	chr1:2043761	PRKCZ	-0.39	-5.23	-0.39	5.56e-7	Height;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.58	-5.36	-0.4	2.99e-7	Lung cancer;
PAAD	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	4.27	0.33	3.37e-5	Thyroid stimulating hormone;
PAAD	cis	rs6715793	0.665	rs10495783	chr2:33401632	C/T	cg26672287	chr2:33391915	LTBP1	-0.39	-4.66	-0.35	6.91e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11168351	0.889	rs12817104	chr12:48382573	G/C	cg21466736	chr12:48725269	NA	-0.55	-4.98	-0.37	1.7e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1035491	0.896	rs1459194	chr5:63966889	A/G	cg01791865	chr5:63954708	NA	-0.49	-5.3	-0.39	4e-7	Body mass index;
PAAD	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.7	-7.94	-0.54	4.22e-13	Alcohol dependence;
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.7	-6.17	-0.45	5.8e-9	Systemic lupus erythematosus;
PAAD	cis	rs6700896	0.500	rs112247468	chr1:66115008	T/C	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.07e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.4	0.51	8.5e-12	Alzheimer's disease;
PAAD	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.61	-5.23	-0.39	5.51e-7	Corneal structure;
PAAD	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg21209356	chr22:37319042	CSF2RB	-0.35	-4.39	-0.34	2.12e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.89	5.42	0.4	2.25e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1499972	0.938	rs843852	chr3:117721428	A/G	cg07612923	chr3:117604196	NA	-0.96	-6.48	-0.47	1.19e-9	Schizophrenia;
PAAD	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.39	-5.8	-0.43	3.78e-8	Educational attainment (years of education);
PAAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.75	-4.47	-0.34	1.53e-5	Tuberculosis;
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.7	0.36	5.87e-6	Iron status biomarkers;
PAAD	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.43	-0.4	2.19e-7	Heart rate;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg15691649	chr6:25882328	NA	-0.58	-5.65	-0.42	7.64e-8	Blood metabolite levels;
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.72	-7.9	-0.54	5.2e-13	Prudent dietary pattern;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg08886695	chr4:3369023	RGS12	-0.51	-4.82	-0.36	3.39e-6	Mean platelet volume;
PAAD	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg20356878	chr3:121714668	ILDR1	0.54	5.11	0.38	9.39e-7	Cognitive performance;
PAAD	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.71	7.06	0.5	5.61e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg21855830	chr2:127963489	CYP27C1	0.45	4.36	0.33	2.42e-5	Protein C levels;
PAAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.24	0.64	4.85e-19	Menopause (age at onset);
PAAD	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.51	-0.41	1.47e-7	Mood instability;
PAAD	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.77e-8	Migraine;
PAAD	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.59	6.05	0.44	1.1e-8	QT interval;
PAAD	cis	rs7951870	0.617	rs12361673	chr11:46723937	G/A	cg19486271	chr11:47235900	DDB2	-0.58	-5.83	-0.43	3.15e-8	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.49	-0.34	1.4e-5	Alzheimer's disease (survival time);
PAAD	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg26031613	chr14:104095156	KLC1	-0.47	-5.2	-0.39	6.24e-7	Schizophrenia;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-6.77	-0.48	2.6e-10	Longevity;Endometriosis;
PAAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.39	4.14e-7	Breast cancer;
PAAD	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.35	4.47	0.34	1.52e-5	Educational attainment (years of education);
PAAD	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23209459	chr19:56652545	ZNF444	-0.77	-6.53	-0.47	9.4e-10	Neuroticism;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.71	5.66	0.42	7.31e-8	Height;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.66	-7.25	-0.51	1.93e-11	Total body bone mineral density;
PAAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24549020	chr5:56110836	MAP3K1	-0.7	-5.12	-0.38	9.16e-7	Initial pursuit acceleration;
PAAD	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.75	-0.36	4.68e-6	Body mass index;
PAAD	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.85	0.54	6.89e-13	Menarche (age at onset);
PAAD	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg16736954	chr20:23401023	NAPB	-0.76	-4.33	-0.33	2.72e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.63	6.25	0.45	3.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-8.8	-0.58	2.86e-15	Height;
PAAD	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.56	-4.46	-0.34	1.55e-5	IFN-related cytopenia;
PAAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.04	0.59	6.73e-16	Menopause (age at onset);
PAAD	cis	rs9652601	0.691	rs9926078	chr16:11203565	G/C	cg04616529	chr16:11181986	CLEC16A	0.38	4.56	0.35	1.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.31	0.4	3.89e-7	Colorectal cancer;
PAAD	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.68	-0.42	6.59e-8	Coronary artery disease;
PAAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-6.9	-0.49	1.29e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.81	9.81	0.62	6.62e-18	Blood metabolite ratios;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18954051	chr12:66554863	TMBIM4	0.55	6.82	0.48	2.01e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.68	-6.07	-0.44	9.63e-9	Breast cancer;
PAAD	cis	rs3136739	0.614	rs2020923	chr8:42037630	C/T	cg17828057	chr8:42037527	PLAT	0.71	4.82	0.36	3.46e-6	Plasma plasminogen activator levels;
PAAD	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.84	-10.37	-0.64	2.2e-19	Dental caries;
PAAD	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg12756303	chr2:74692479	MOGS	-0.5	-4.49	-0.34	1.39e-5	Metabolite levels;
PAAD	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.75	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg05434287	chr7:2030229	MAD1L1	0.43	4.59	0.35	9.28e-6	Bipolar disorder and schizophrenia;
PAAD	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.51	-5.07	-0.38	1.16e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.61	-6.04	-0.44	1.13e-8	Prudent dietary pattern;
PAAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs941024	0.651	rs73117220	chr12:56038283	C/T	cg20737382	chr12:56040096	NA	-0.73	-4.76	-0.36	4.56e-6	Conotruncal heart defects (inherited effects);
PAAD	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.83	-0.54	7.6e-13	Height;
PAAD	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg08495239	chr10:135273341	LOC619207	-0.42	-4.36	-0.33	2.38e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.67	-5.72	-0.42	5.53e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	5.78	0.42	4.18e-8	Joint mobility (Beighton score);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01485165	chr20:49411421	BCAS4	0.61	6.6	0.47	6.38e-10	Myopia (pathological);
PAAD	cis	rs10804591	0.666	rs13079843	chr3:129308096	G/A	cg18548199	chr3:129281892	PLXND1	0.5	4.31	0.33	2.88e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6893807	0.620	rs34483452	chr5:87986314	C/A	cg02225085	chr5:87975992	LOC645323	-0.71	-5.04	-0.38	1.3e-6	Body mass index;
PAAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.74	8.52	0.57	1.43e-14	Sjögren's syndrome;
PAAD	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg25364880	chr3:44379878	C3orf23	0.59	5.43	0.4	2.17e-7	Depressive symptoms;
PAAD	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg14851346	chr12:38532713	NA	-0.47	-4.53	-0.35	1.17e-5	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.85	6.74	0.48	3.07e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg04291430	chr17:48206283	SAMD14	-0.34	-4.58	-0.35	9.63e-6	Temporomandibular joint disorder;
PAAD	cis	rs8060686	0.920	rs56845922	chr16:67770828	T/C	cg27539214	chr16:67997921	SLC12A4	-0.67	-4.5	-0.34	1.34e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1879734	0.636	rs2186041	chr1:54180287	G/A	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg01759136	chr6:27242945	NA	0.4	4.35	0.33	2.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.1	-0.38	9.81e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01360067	chr10:75256027	PPP3CB	0.56	6.7	0.48	3.87e-10	Metabolite levels  (X-11787);
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg27057461	chr7:158136379	PTPRN2	-0.48	-4.36	-0.33	2.35e-5	Response to amphetamines;
PAAD	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.38	-0.56	3.38e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs8060686	0.858	rs7206671	chr16:67807146	A/G	cg09835421	chr16:68378352	PRMT7	-0.63	-4.66	-0.35	7.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg14393609	chr7:65229607	NA	-0.66	-7.19	-0.5	2.67e-11	Aortic root size;
PAAD	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.93	-0.66	7.01e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.81	5.61	0.41	9.4e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.66	0.35	6.98e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4662592	0.554	rs17793615	chr2:128939695	A/G	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.46	-0.82	3.84e-38	Height;
PAAD	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg12924262	chr12:102091054	CHPT1	0.67	7.13	0.5	3.79e-11	Blood protein levels;
PAAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-7.72	-0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.33	-0.4	3.55e-7	Educational attainment (years of education);
PAAD	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg03989125	chr22:38214979	NA	-0.64	-6.61	-0.47	6.08e-10	Glioblastoma;Glioma;
PAAD	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg11271282	chr2:238384023	NA	0.65	4.38	0.33	2.17e-5	Prostate cancer;
PAAD	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.63	-5.78	-0.42	4.09e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.44	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs757978	0.500	rs79443259	chr2:242297624	A/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.98	-4.64	-0.35	7.48e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08439880	chr3:133502540	NA	-0.52	-5.7	-0.42	6.1e-8	Iron status biomarkers;
PAAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.48	-4.97	-0.37	1.82e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg25952890	chr19:58913133	NA	0.65	5.42	0.4	2.32e-7	Mean platelet volume;
PAAD	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.63	6.3	0.46	3.05e-9	Type 2 diabetes;
PAAD	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.05	0.38	1.24e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs567508	0.539	rs483611	chr11:126013781	A/G	cg08415973	chr6:40346114	TDRG1	-0.72	-6.51	-0.47	1.03e-9	Lung function (FEV1);
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.99	-0.38	1.63e-6	Type 2 diabetes;
PAAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	trans	rs12786942	1.000	rs12793746	chr11:101367985	G/A	cg19874726	chr14:61114476	SIX1	-0.84	-6.29	-0.45	3.22e-9	Facial depth;
PAAD	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.84	-6.0	-0.44	1.37e-8	Atopic dermatitis;
PAAD	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.72	-8.23	-0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg08885076	chr2:99613938	TSGA10	-0.53	-4.28	-0.33	3.32e-5	Bipolar disorder;
PAAD	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.93	9.71	0.62	1.21e-17	Post bronchodilator FEV1;
PAAD	cis	rs322458	0.573	rs628600	chr3:120621043	C/T	cg16417163	chr3:121280760	NA	0.46	4.7	0.36	5.87e-6	Aging (facial);
PAAD	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg23387468	chr7:139079360	LUC7L2	0.38	4.29	0.33	3.17e-5	Diisocyanate-induced asthma;
PAAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.57	5.45	0.4	2.02e-7	Blood metabolite levels;
PAAD	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9395066	0.545	rs12526711	chr6:44883873	C/T	cg25276700	chr6:44698697	NA	0.48	5.48	0.41	1.76e-7	Height;
PAAD	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.36	-4.79	-0.36	3.91e-6	Dupuytren's disease;
PAAD	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs2594989	0.887	rs6442253	chr3:11474238	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-4.27	-0.33	3.45e-5	Circulating chemerin levels;
PAAD	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.74	-8.35	-0.56	3.83e-14	Huntington's disease progression;
PAAD	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.45	-4.31	-0.33	2.89e-5	Response to metformin (IC50);
PAAD	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg22815214	chr1:201083145	CACNA1S	0.56	4.78	0.36	4.04e-6	Permanent tooth development;
PAAD	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4704187	0.687	rs10462512	chr5:74387317	C/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.51	-0.41	1.5e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.57	0.47	7.44e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-9.96	-0.63	2.73e-18	Headache;
PAAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg18551225	chr6:44695536	NA	0.72	6.95	0.49	1.03e-10	Total body bone mineral density;
PAAD	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.78	-7.82	-0.54	8.13e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.96e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.93	12.73	0.72	9.85e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs6499255	0.953	rs3811349	chr16:69791266	T/G	cg15192750	chr16:69999425	NA	0.66	5.07	0.38	1.15e-6	IgE levels;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.58	5.55	0.41	1.26e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.53	0.68	1.73e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.5	-0.34	1.37e-5	Tonsillectomy;
PAAD	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.61	4.45	0.34	1.67e-5	Neuroblastoma;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs4908768	0.501	rs35865480	chr1:8603777	C/T	cg20416874	chr1:8611966	RERE	-0.46	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg14196790	chr5:131705035	SLC22A5	-0.45	-4.85	-0.37	3.02e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.05	-6.2	-0.45	5.2e-9	Fat distribution (HIV);
PAAD	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.35	0.4	3.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9463078	0.585	rs9463075	chr6:45149650	C/T	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10943724	0.704	rs62406533	chr6:81259463	A/G	cg19323245	chr6:80716898	TTK	-0.46	-4.86	-0.37	2.9e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs28830936	0.934	rs4923915	chr15:42119606	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.71	-0.48	3.62e-10	Diastolic blood pressure;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg21665744	chr7:39171113	POU6F2	0.35	5.36	0.4	3.04e-7	IgG glycosylation;
PAAD	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg23973274	chr1:155060172	NA	-0.44	-4.62	-0.35	8.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.69	4.82	0.36	3.43e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.94	6.41	0.46	1.73e-9	Prostate cancer;
PAAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.57	8.02	0.55	2.6e-13	Rheumatoid arthritis;
PAAD	cis	rs7009516	0.783	rs4872228	chr8:24219671	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.52	-6.45	-0.46	1.38e-9	Hair greying;
PAAD	cis	rs282587	0.569	rs282562	chr13:113375249	T/G	cg19217778	chr13:113420270	ATP11A	0.57	4.38	0.33	2.17e-5	Glycated hemoglobin levels;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg24101359	chr6:42928495	GNMT	0.64	6.74	0.48	3.06e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.63	6.27	0.45	3.59e-9	Height;
PAAD	cis	rs2117029	0.521	rs1039225	chr12:49582692	A/C	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18404041	chr3:52824283	ITIH1	0.41	4.41	0.34	1.95e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.85	-9.0	-0.59	8.52e-16	Menopause (age at onset);
PAAD	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.68	-6.05	-0.44	1.08e-8	Mortality in heart failure;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.59	0.35	9.36e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.74	-6.18	-0.45	5.52e-9	Schizophrenia;
PAAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs3087591	0.639	rs734403	chr17:29723346	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	4.46	0.34	1.56e-5	Hip circumference;
PAAD	cis	rs7577696	0.962	rs2280967	chr2:32289746	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.38	5.43	0.4	2.16e-7	Educational attainment (years of education);
PAAD	cis	rs1879734	0.731	rs7555908	chr1:54158462	A/G	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg02527881	chr3:46936655	PTH1R	-0.8	-12.21	-0.7	2.45e-24	Birth weight;
PAAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.47	-4.37	-0.33	2.26e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs8133932	0.654	rs7280405	chr21:47275611	C/T	cg13695288	chr21:47294981	PCBP3	-0.46	-4.41	-0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg05627522	chr15:75251581	NA	0.49	5.84	0.43	3.06e-8	Breast cancer;
PAAD	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg07395648	chr5:131743802	NA	-0.57	-5.02	-0.38	1.41e-6	Acylcarnitine levels;
PAAD	cis	rs9815354	1.000	rs7616844	chr3:41874343	A/G	cg03022575	chr3:42003672	ULK4	0.77	5.7	0.42	6.11e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs9467603	0.925	rs1892253	chr6:25782314	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.83	0.36	3.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6700896	0.966	rs12067936	chr1:66088701	C/A	cg04111102	chr1:66153794	NA	0.43	4.65	0.35	7.2e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg27565382	chr3:53032988	SFMBT1	-0.76	-4.35	-0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg16342193	chr10:102329863	NA	-0.82	-9.11	-0.59	4.42e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.75	-8.52	-0.57	1.44e-14	Height;
PAAD	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.29	-0.33	3.16e-5	Height;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg04882365	chr1:3234186	PRDM16	-0.62	-6.34	-0.46	2.43e-9	Primary biliary cholangitis;
PAAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.74	-6.84	-0.49	1.79e-10	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04169263	chr16:1756061	MAPK8IP3	0.6	6.3	0.46	3.12e-9	Myopia (pathological);
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.56	6.04	0.44	1.11e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	ch.11.42038R	chr11:967971	AP2A2	0.64	6.12	0.44	7.61e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7577696	0.924	rs3769604	chr2:32322495	C/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.62	-0.35	8.17e-6	Inflammatory biomarkers;
PAAD	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.2	0.55	9.29e-14	Asthma;
PAAD	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs282587	0.569	rs9604415	chr13:113393615	G/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.96	-0.37	1.87e-6	Glycated hemoglobin levels;
PAAD	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg05528293	chr18:74961138	GALR1	0.61	4.92	0.37	2.24e-6	Obesity-related traits;
PAAD	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.58	-0.47	7.28e-10	Mood instability;
PAAD	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.64	-0.53	2.22e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.54	5.12	0.38	9.25e-7	Lung cancer;
PAAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg26138144	chr22:38071188	LGALS1	0.51	5.59	0.41	1.01e-7	Fat distribution (HIV);
PAAD	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg22601191	chr20:60968625	CABLES2	-0.59	-5.71	-0.42	5.76e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg03605463	chr16:89740564	NA	-0.55	-5.34	-0.4	3.28e-7	Vitiligo;
PAAD	cis	rs818427	0.508	rs12656359	chr5:112151551	G/T	cg06941702	chr5:112196734	SRP19	-0.52	-4.74	-0.36	4.98e-6	Total body bone mineral density;
PAAD	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg13957827	chr4:164415471	C4orf43	-0.53	-6.48	-0.47	1.18e-9	Serum protein levels (sST2);
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.45	0.71	5.72e-25	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24141078	chr1:32671127	IQCC	0.63	6.47	0.46	1.28e-9	Myopia (pathological);
PAAD	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.91	-10.56	-0.65	6.83e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.74e-7	Tonsillectomy;
PAAD	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.59	-4.54	-0.35	1.11e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg14926445	chr8:58193284	C8orf71	-0.66	-5.48	-0.41	1.72e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.67	-0.35	6.51e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.71	-9.09	-0.59	5.02e-16	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg22467129	chr15:76604101	ETFA	0.53	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.67	5.33	0.4	3.5e-7	Pediatric autoimmune diseases;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.48	5.01	0.38	1.48e-6	Lymphocyte counts;
PAAD	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.61	6.89	0.49	1.41e-10	Corneal astigmatism;
PAAD	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.75	0.42	4.75e-8	Schizophrenia;
PAAD	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-16.13	-0.79	9.58e-35	Schizophrenia;
PAAD	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.53	4.83	0.37	3.24e-6	Platelet count;
PAAD	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.59	-5.05	-0.38	1.23e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg25649188	chr17:73499917	CASKIN2	0.51	4.76	0.36	4.46e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.33	-0.4	3.45e-7	Aortic root size;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15179595	chr13:92003418	MIR92A1;MIR17HG;MIR19B1	-0.65	-6.35	-0.46	2.38e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1941184	0.759	rs2035043	chr18:29023275	G/A	cg03238162	chr18:29027701	DSG3	0.4	4.56	0.35	1.05e-5	Parkinson's disease (age of onset);
PAAD	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs642743	0.934	rs677904	chr10:105957613	G/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.72	0.36	5.41e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs6679454	1.000	rs11207128	chr1:58361567	A/G	cg17491850	chr1:57888480	DAB1	0.43	4.93	0.37	2.11e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-23.73	-0.89	5.71e-53	Myeloid white cell count;
PAAD	trans	rs41264869	0.891	rs2305278	chr1:205028581	C/G	cg08840230	chr19:15622718	CYP4F22	0.49	6.43	0.46	1.54e-9	Blood protein levels;
PAAD	cis	rs732765	0.734	rs12323361	chr14:75171706	T/C	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.5	-4.57	-0.35	1e-5	Anterior chamber depth;
PAAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.46	-8.4	-0.56	2.86e-14	Multiple system atrophy;
PAAD	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg10495392	chr1:46806563	NSUN4	-0.59	-5.78	-0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg26528668	chr16:1614120	IFT140	0.56	5.19	0.39	6.53e-7	Coronary artery disease;
PAAD	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg00277334	chr10:82204260	NA	-0.5	-5.07	-0.38	1.13e-6	Post bronchodilator FEV1;
PAAD	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-4.82	-0.36	3.46e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	4.87	0.37	2.71e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-11.27	-0.67	8.4e-22	Coronary artery disease;
PAAD	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.64	-7.68	-0.53	1.82e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.1	0.38	9.88e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.51	-0.47	1.05e-9	Body mass index;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg20406979	chr6:167373233	NA	0.35	4.87	0.37	2.73e-6	Crohn's disease;
PAAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg18196295	chr10:418757	DIP2C	-0.44	-4.35	-0.33	2.47e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg09955084	chr16:413813	NA	0.28	4.39	0.34	2.11e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4280164	0.562	rs78807053	chr14:24740272	G/A	cg07162820	chr14:24837146	NFATC4	0.43	4.82	0.36	3.4e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg23995914	chr4:10459228	ZNF518B	-0.36	-4.43	-0.34	1.77e-5	Schizophrenia (age at onset);
PAAD	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.37	4.47	0.34	1.51e-5	Pulmonary function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14614693	chr5:114961897	TMED7-TICAM2;TMED7	-0.56	-6.78	-0.48	2.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg27411982	chr8:10470053	RP1L1	0.44	4.65	0.35	7.27e-6	Triglycerides;
PAAD	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.64	-6.97	-0.49	8.96e-11	Blood protein levels;
PAAD	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg20761395	chr17:511517	VPS53	-0.51	-4.73	-0.36	5.09e-6	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg15117754	chr3:10150083	C3orf24	0.69	5.92	0.43	2.07e-8	Alzheimer's disease;
PAAD	trans	rs3020418	0.963	rs3020429	chr6:152356649	C/T	cg09520904	chr11:69462943	CCND1	-0.54	-6.62	-0.47	5.7e-10	Height;
PAAD	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-6.23	-0.45	4.32e-9	Diabetic retinopathy;
PAAD	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.78	9.8	0.62	7.19e-18	Bone mineral density;
PAAD	cis	rs7224685	0.815	rs8070159	chr17:4073447	A/G	cg09695851	chr17:3907499	NA	0.5	4.59	0.35	9.41e-6	Type 2 diabetes;
PAAD	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.07	15.28	0.78	1.58e-32	Body mass index (adult);
PAAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.74	-6.27	-0.45	3.53e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.35e-7	Prostate cancer;
PAAD	trans	rs12738007	0.967	rs12032470	chr1:29464954	C/A	cg14140554	chr6:157804039	ZDHHC14	0.64	6.47	0.46	1.27e-9	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.94	11.39	0.68	4.13e-22	Lewy body disease;
PAAD	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs7188861	0.638	rs35342456	chr16:11401503	A/C	cg16532467	chr16:11454386	NA	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;
PAAD	cis	rs3136441	0.892	rs2306037	chr11:46911781	G/C	cg19486271	chr11:47235900	DDB2	0.62	4.9	0.37	2.46e-6	HDL cholesterol;
PAAD	cis	rs6466055	0.720	rs1204066	chr7:104971987	G/T	cg04380332	chr7:105027541	SRPK2	0.58	6.63	0.47	5.45e-10	Schizophrenia;
PAAD	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.28	-0.39	4.42e-7	Height;
PAAD	cis	rs3026101	0.671	rs1806240	chr17:5298320	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-8.85	-0.58	2.13e-15	Total body bone mineral density;
PAAD	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg04824913	chr4:887549	GAK	0.62	4.79	0.36	3.98e-6	Parkinson's disease;
PAAD	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg08601574	chr20:25228251	PYGB	0.48	4.81	0.36	3.55e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs732765	0.819	rs714788	chr14:75320043	G/A	cg01515732	chr14:76012927	BATF	0.55	4.31	0.33	2.94e-5	Non-small cell lung cancer;
PAAD	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg26384229	chr12:38710491	ALG10B	0.7	7.29	0.51	1.59e-11	Morning vs. evening chronotype;
PAAD	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.97	-13.25	-0.73	4.01e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg07595035	chr13:111291582	CARKD	0.8	4.97	0.37	1.76e-6	Coronary artery disease;
PAAD	cis	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27572510	chr17:35474613	ACACA	0.59	6.75	0.48	2.87e-10	Smoking initiation;
PAAD	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs755249	0.567	rs61779309	chr1:39940499	T/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.74	-0.36	4.78e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.54	0.47	9.04e-10	Coronary artery disease;
PAAD	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03388025	chr16:89894329	SPIRE2	0.32	4.3	0.33	3.05e-5	Vitiligo;
PAAD	cis	rs2492906	0.515	rs2815561	chr10:27978360	C/G	cg25523538	chr10:28031957	MKX	0.49	4.3	0.33	3.08e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	6.16	0.45	6.11e-9	Schizophrenia;
PAAD	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg21300403	chr2:198650112	BOLL	0.5	4.43	0.34	1.79e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.2	9.47	0.61	5.31e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg14036092	chr11:66035641	RAB1B	0.62	5.13	0.38	8.76e-7	Gout;
PAAD	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.64	6.7	0.48	3.91e-10	Platelet distribution width;
PAAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-5.38	-0.4	2.73e-7	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs2446066	0.872	rs12368491	chr12:53782959	G/A	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg17372223	chr3:52568218	NT5DC2	-0.55	-5.51	-0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs13242816	1.000	rs6968230	chr7:116137049	G/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs3763048	0.963	rs4582295	chr5:169458002	C/T	cg01585372	chr5:169931363	KCNIP1	-0.43	-4.29	-0.33	3.22e-5	IgG glycosylation;
PAAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg00579200	chr11:133705235	NA	-0.44	-4.78	-0.36	4.11e-6	Childhood ear infection;
PAAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs288342	0.832	rs288253	chr2:183609373	A/T	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg03338584	chr11:507455	RNH1	0.56	4.41	0.34	1.95e-5	Systemic lupus erythematosus;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg26338869	chr17:61819248	STRADA	0.49	4.66	0.35	6.79e-6	Height;
PAAD	cis	rs2211560	0.789	rs12759959	chr1:61280352	G/A	cg00575674	chr1:61314297	NA	-0.51	-4.61	-0.35	8.49e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.77	5.57	0.41	1.13e-7	White matter hyperintensity burden;
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.44	0.46	1.47e-9	Intraocular pressure;
PAAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.84	0.66	1.24e-20	Homoarginine levels;
PAAD	cis	rs12681963	0.702	rs11777119	chr8:29932284	C/T	cg18070061	chr8:29207457	DUSP4	0.51	4.79	0.36	3.98e-6	Migraine;
PAAD	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.65	-7.04	-0.5	6.09e-11	Leprosy;
PAAD	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.19	-10.14	-0.64	8.82e-19	Vitiligo;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.45	0.46	1.42e-9	Lung cancer;
PAAD	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.56	-0.35	1.05e-5	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3736485	0.934	rs2414105	chr15:51868373	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.34	-0.33	2.57e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs4455778	0.600	rs4461853	chr7:49090901	T/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg23033748	chr14:75592666	NEK9	0.43	5.21	0.39	6.09e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10684627	chr10:73288563	CDH23	-0.63	-6.61	-0.47	6.13e-10	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs12995666	chr2:629959	T/C	cg03610516	chr2:642275	NA	0.65	5.76	0.42	4.44e-8	Body mass index;
PAAD	cis	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg18551225	chr6:44695536	NA	0.62	5.27	0.39	4.53e-7	Total body bone mineral density;
PAAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg23298862	chr7:158159286	PTPRN2	-0.45	-4.28	-0.33	3.33e-5	Calcium levels;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg21698718	chr17:80085957	CCDC57	-0.44	-5.0	-0.38	1.59e-6	Life satisfaction;
PAAD	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg27542038	chr10:14027202	FRMD4A	-0.44	-4.3	-0.33	3.05e-5	Adiponectin levels;
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26549601	chr10:134560360	INPP5A	-0.44	-4.47	-0.34	1.51e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1497828	1.000	rs2815246	chr1:217560463	T/C	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.5	0.41	1.56e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg02696790	chr15:75250997	RPP25	0.39	4.83	0.37	3.24e-6	Systemic lupus erythematosus;
PAAD	trans	rs901683	1.000	rs35916836	chr10:46082516	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11245990	chr11:68621969	NA	0.37	4.83	0.36	3.34e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4453791	0.725	rs1877564	chr3:39160399	A/G	cg02254461	chr3:39195904	CSRNP1	0.56	4.9	0.37	2.45e-6	Social communication problems;
PAAD	cis	rs806321	0.538	rs2066690	chr13:50881018	G/A	cg03369344	chr13:50705024	NA	0.43	4.34	0.33	2.59e-5	Multiple sclerosis;
PAAD	cis	rs655641	0.539	rs682928	chr11:85741130	C/T	cg07180834	chr11:85838833	NA	-0.46	-4.91	-0.37	2.34e-6	Platelet count;
PAAD	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.82	-9.66	-0.62	1.64e-17	Brugada syndrome;
PAAD	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg01868782	chr6:126071099	HEY2	0.43	4.7	0.36	5.87e-6	Brugada syndrome;
PAAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg26513180	chr16:89883248	FANCA	0.65	7.43	0.52	7.38e-12	Vitiligo;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.88	-7.3	-0.51	1.51e-11	Gestational age at birth (maternal effect);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25087958	chr5:34915621	RAD1;BRIX1	-0.71	-7.26	-0.51	1.85e-11	Smoking initiation;
PAAD	cis	rs258892	0.947	rs266446	chr5:72182030	T/G	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg05338066	chr1:7812865	CAMTA1	0.52	4.41	0.34	1.94e-5	Inflammatory bowel disease;
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs367943	0.667	rs13173069	chr5:113011778	T/G	cg12552261	chr5:112820674	MCC	0.58	5.69	0.42	6.32e-8	Type 2 diabetes;
PAAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.85	9.77	0.62	8.28e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs66530629	0.761	rs7519508	chr1:25147750	G/A	cg22509179	chr1:25234806	RUNX3	-0.5	-4.59	-0.35	9.16e-6	Plateletcrit;
PAAD	cis	rs6593803	0.547	rs7528262	chr1:147248817	C/T	cg27546670	chr1:147246839	GJA5	-0.56	-4.5	-0.34	1.36e-5	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
PAAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg06521852	chr22:38141419	TRIOBP	0.44	4.56	0.35	1.04e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg26516362	chr5:178986906	RUFY1	0.55	6.64	0.47	5.12e-10	Lung cancer;
PAAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.89	-0.43	2.34e-8	IgG glycosylation;
PAAD	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.67	7.07	0.5	5.39e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.47	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.47	-0.34	1.5e-5	Metabolite levels;
PAAD	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg27411982	chr8:10470053	RP1L1	0.43	4.39	0.34	2.14e-5	Retinal vascular caliber;
PAAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg27119904	chr13:114814333	RASA3	0.42	4.42	0.34	1.89e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	6.13	0.45	7.34e-9	Cognitive test performance;
PAAD	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-7.2	-0.5	2.55e-11	Neuroticism;
PAAD	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	1.04	19.22	0.84	1.58e-42	Birth weight;
PAAD	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-9.98	-0.63	2.4e-18	Height;
PAAD	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.78	8.33	0.56	4.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg18904891	chr8:8559673	CLDN23	0.7	6.09	0.44	8.81e-9	Obesity-related traits;
PAAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.09	0.5	4.64e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.03	0.44	1.2e-8	Platelet count;
PAAD	cis	rs6715793	0.702	rs6708836	chr2:33413030	G/A	cg26672287	chr2:33391915	LTBP1	-0.37	-4.41	-0.34	1.97e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.68	-0.65	3.24e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg26174226	chr8:58114915	NA	-0.59	-4.4	-0.34	2.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg27411982	chr8:10470053	RP1L1	0.41	4.43	0.34	1.79e-5	Neuroticism;
PAAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.15	0.55	1.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14169450	chr9:139327907	INPP5E	0.6	5.59	0.41	1.03e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10901513	0.861	rs34203433	chr10:127667543	G/A	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22117172	chr7:91764530	CYP51A1	0.33	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.63	-6.29	-0.45	3.28e-9	Aortic root size;
PAAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.88	0.37	2.7e-6	Personality dimensions;
PAAD	cis	rs2415984	0.579	rs12147933	chr14:46972443	G/A	cg14871534	chr14:47121158	RPL10L	-0.48	-5.01	-0.38	1.51e-6	Number of children ever born;
PAAD	cis	rs7989332	1.000	rs7320606	chr13:21052521	T/C	cg06710890	chr13:21477865	XPO4	0.51	4.28	0.33	3.26e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg21665744	chr7:39171113	POU6F2	0.35	5.73	0.42	5.18e-8	IgG glycosylation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09629053	chr12:31812505	C12orf72	0.58	6.52	0.47	9.81e-10	Monocyte percentage of white cells;
PAAD	cis	rs6586111	0.967	rs6586106	chr10:82372300	A/C	cg18643199	chr10:82363313	SH2D4B	0.4	4.27	0.33	3.4e-5	Capecitabine sensitivity;
PAAD	cis	rs7098414	0.530	rs12220655	chr10:82219066	T/C	cg00277334	chr10:82204260	NA	-0.76	-9.11	-0.59	4.49e-16	Post bronchodilator FEV1;
PAAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.73	8.41	0.56	2.84e-14	Cognitive function;
PAAD	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.64	-5.11	-0.38	9.34e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.83	-9.68	-0.62	1.47e-17	Body mass index;
PAAD	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.85	-9.56	-0.61	3.05e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.58	-6.11	-0.44	7.86e-9	Crohn's disease;
PAAD	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.41	5.05	0.38	1.25e-6	Body mass index in non-asthmatics;
PAAD	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.31	0.73	2.74e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.19	0.39	6.64e-7	Bone mineral density;
PAAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-4.65	-0.35	7.2e-6	Height;
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Body mass index;
PAAD	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.56	-4.51	-0.34	1.29e-5	Corneal structure;
PAAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.13	-0.55	1.44e-13	Hemoglobin concentration;
PAAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs2882667	0.690	rs9942422	chr5:138272536	A/G	cg09476006	chr5:138032270	NA	0.46	5.82	0.43	3.33e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.84	9.85	0.62	5.34e-18	Selective IgA deficiency;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg10729496	chr3:10149963	C3orf24	0.82	6.75	0.48	2.9e-10	Alzheimer's disease;
PAAD	cis	rs704	0.726	rs11080055	chr17:26649724	A/C	cg10342447	chr17:26645325	TMEM97	-0.39	-4.89	-0.37	2.55e-6	Osteoprotegerin levels;
PAAD	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.89	11.58	0.68	1.21e-22	Body mass index;
PAAD	cis	rs6466055	0.777	rs6466053	chr7:104923929	C/T	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.79	9.48	0.61	4.75e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.55	-5.57	-0.41	1.1e-7	Iron status biomarkers;
PAAD	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.62	5.86	0.43	2.73e-8	Vitamin D levels;
PAAD	cis	rs4780401	0.728	rs8191290	chr16:11765954	C/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.89	-0.43	2.4e-8	Rheumatoid arthritis;
PAAD	cis	rs965513	1.000	rs10983701	chr9:100537577	G/A	cg13688889	chr9:100608707	NA	-0.52	-4.27	-0.33	3.43e-5	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
PAAD	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.87	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.5e-8	Lung cancer;
PAAD	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08550205	chr17:45786854	TBKBP1	-0.41	-4.4	-0.34	2.01e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg03990033	chr1:208084030	CD34	0.47	4.38	0.33	2.22e-5	Facial morphology (factor 18);
PAAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg02297831	chr4:17616191	MED28	0.55	5.48	0.41	1.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.52	8.19	0.55	1.02e-13	Neuroticism;
PAAD	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.49	0.41	1.65e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.09	0.67	2.59e-21	Platelet count;
PAAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.62	-5.32	-0.4	3.65e-7	Common traits (Other);
PAAD	cis	rs4740619	0.766	rs36013000	chr9:15751913	T/C	cg14451791	chr9:16040625	NA	0.37	4.26	0.33	3.61e-5	Body mass index;
PAAD	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg18093559	chr17:18951025	GRAP	0.46	4.56	0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg09017928	chr7:158110068	PTPRN2	0.59	5.3	0.4	3.98e-7	Response to amphetamines;
PAAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.67	0.48	4.43e-10	Rheumatoid arthritis;
PAAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.72	5.19	0.39	6.76e-7	Tuberculosis;
PAAD	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.86	-0.43	2.79e-8	Blood protein levels;
PAAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	5.03	0.38	1.38e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.83	9.77	0.62	8.57e-18	Methadone dose in opioid dependence;
PAAD	cis	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg18809830	chr7:99032528	PTCD1	-1.22	-5.29	-0.39	4.25e-7	Blood metabolite levels;
PAAD	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.73	6.98	0.49	8.55e-11	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs939584	0.935	rs6751994	chr2:635866	A/G	cg14515364	chr2:636606	NA	0.48	4.31	0.33	2.88e-5	Body mass index;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.53	-6.31	-0.46	2.96e-9	Monobrow;
PAAD	cis	rs863345	0.526	rs857724	chr1:158607372	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.71	-0.36	5.61e-6	Pneumococcal bacteremia;
PAAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06753367	chr22:24256600	NA	-0.4	-4.3	-0.33	3.03e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7771547	0.692	rs9380580	chr6:36551396	T/C	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.69	-0.36	6.11e-6	Renal cell carcinoma;
PAAD	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-4.53	-0.35	1.17e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9815354	0.812	rs73069357	chr3:41753319	T/G	cg03022575	chr3:42003672	ULK4	0.88	5.83	0.43	3.28e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8067287	0.749	rs62065421	chr17:16827887	T/C	cg26910001	chr17:16838321	NA	-0.68	-6.1	-0.44	8.35e-9	Diabetic kidney disease;
PAAD	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg06212747	chr3:49208901	KLHDC8B	0.55	4.43	0.34	1.76e-5	Menarche (age at onset);
PAAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.57	-6.21	-0.45	4.8e-9	Birth weight;
PAAD	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.58	4.3	0.33	2.99e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.94	-0.37	2.01e-6	Neuroticism;
PAAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg19053889	chr7:1098703	C7orf50;GPR146	-0.5	-4.57	-0.35	1.01e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg14349672	chr11:133703707	NA	-0.47	-5.01	-0.38	1.48e-6	Childhood ear infection;
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.54	5.8	0.43	3.69e-8	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg22835712	chr2:102737379	NA	0.45	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs282587	0.530	rs282602	chr13:113392644	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg18984983	chr10:135342936	CYP2E1	0.47	4.32	0.33	2.81e-5	Gout;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.65	-0.35	7.21e-6	Blood metabolite levels;
PAAD	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.62e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg26536354	chr8:144654954	C8orf73	0.77	4.83	0.36	3.32e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg03180429	chr4:186128663	NA	0.58	4.29	0.33	3.19e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg20673841	chr7:107026890	COG5	0.48	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-4.32	-0.33	2.84e-5	Renal cell carcinoma;
PAAD	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg05768032	chr16:30646687	NA	0.55	5.0	0.38	1.55e-6	Multiple myeloma;
PAAD	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs761746	0.960	rs4820980	chr22:31917415	A/G	cg01338084	chr22:32026380	PISD	-0.49	-4.56	-0.35	1.06e-5	Intelligence;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.51	5.45	0.4	1.98e-7	Testicular germ cell tumor;
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.73	0.36	5.01e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg16928487	chr17:17741425	SREBF1	0.38	5.11	0.38	9.74e-7	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01524091	chr6:44281032	AARS2	0.55	6.33	0.46	2.68e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.4	-4.88	-0.37	2.69e-6	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.4	-0.51	8.73e-12	Response to antipsychotic treatment;
PAAD	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.83	-0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg24098013	chr12:12878779	APOLD1	0.44	4.41	0.34	1.97e-5	Pulse pressure;
PAAD	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.62	9.68	0.62	1.48e-17	Migraine;
PAAD	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.42	-6.24	-0.45	4.23e-9	Subjective well-being;
PAAD	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-9.19	-0.6	2.77e-16	Total body bone mineral density;
PAAD	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	7.75e-7	Aortic root size;
PAAD	cis	rs2834188	1.000	rs2026254	chr21:34688032	C/T	cg04842828	chr21:34696676	IFNAR1	0.46	4.41	0.34	1.92e-5	Narcolepsy;
PAAD	cis	rs9361491	0.608	rs7766517	chr6:79458748	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-6.47	-0.46	1.29e-9	Body mass index;
PAAD	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg14343924	chr8:8086146	FLJ10661	0.52	4.37	0.33	2.32e-5	Mood instability;
PAAD	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.61	-6.0	-0.44	1.37e-8	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10663220	chr12:13249129	GSG1	-0.63	-6.38	-0.46	2.03e-9	Obesity-related traits;
PAAD	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.58	-0.35	9.46e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.42	0.34	1.89e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg27539214	chr16:67997921	SLC12A4	-0.62	-4.7	-0.36	5.87e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.36e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.54	-5.02	-0.38	1.46e-6	Endometrial cancer;
PAAD	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.46	-4.47	-0.34	1.54e-5	Retinal vascular caliber;
PAAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.37	5.03	0.38	1.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs367943	0.634	rs2195377	chr5:112973620	G/A	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6494488	0.500	rs16948182	chr15:64979382	T/G	cg16425858	chr15:64791681	ZNF609	0.92	4.69	0.36	5.99e-6	Coronary artery disease;
PAAD	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.84	-0.49	1.78e-10	Eye color traits;
PAAD	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.89	0.37	2.5e-6	Lung cancer in ever smokers;
PAAD	cis	rs4363385	1.000	rs310124	chr1:153020275	C/T	cg22204954	chr1:153085998	SPRR2F	0.44	4.36	0.33	2.4e-5	Inflammatory skin disease;
PAAD	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-6.56	-0.47	7.95e-10	Coronary artery disease;
PAAD	cis	rs138918	0.772	rs138935	chr22:43567459	C/T	cg00343092	chr22:43547974	TSPO	0.42	4.66	0.35	6.84e-6	Monocyte count;
PAAD	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.42	-4.74	-0.36	4.9e-6	Refractive error;
PAAD	cis	rs899997	1.000	rs1814880	chr15:79021140	T/C	cg22753661	chr15:79092743	ADAMTS7	0.51	4.5	0.34	1.35e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.48	4.73	0.36	4.99e-6	Lewy body disease;
PAAD	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	1.12	10.02	0.63	1.88e-18	IgG glycosylation;
PAAD	cis	rs7236492	0.935	rs60115988	chr18:77226571	G/A	cg15644404	chr18:77186268	NFATC1	-0.88	-6.32	-0.46	2.81e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs300774	1.000	rs300799	chr2:105514	G/A	cg23649280	chr2:140451	NA	-0.52	-5.0	-0.38	1.57e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.46	4.26	0.33	3.56e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.51	-5.86	-0.43	2.74e-8	Breast cancer;
PAAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.84	-9.21	-0.6	2.5e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.49	4.43	0.34	1.77e-5	Height;
PAAD	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg21419209	chr3:44054225	NA	0.72	7.4	0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs258892	0.947	rs62360681	chr5:72187013	T/G	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	trans	rs11794666	1.000	rs17180162	chr9:31635015	C/T	cg05628366	chr6:35744188	C6orf126	-0.88	-6.31	-0.46	2.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	10.51	0.65	9.34e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.71	5.26	0.39	4.85e-7	Gut microbiome composition (summer);
PAAD	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg26116260	chr4:7069785	GRPEL1	0.5	5.13	0.38	8.7e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg19784903	chr17:45786737	TBKBP1	0.56	6.29	0.45	3.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.32	-0.33	2.81e-5	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01493318	chr18:8705700	NA	-0.67	-6.79	-0.48	2.4e-10	Smoking initiation;
PAAD	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg13002189	chr3:66846049	NA	0.58	5.61	0.41	9.38e-8	Type 2 diabetes;
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4792901	0.802	rs56357945	chr17:41613691	G/T	cg05614735	chr17:40936078	WNK4	-0.36	-4.29	-0.33	3.18e-5	Dupuytren's disease;
PAAD	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.51	4.87	0.37	2.82e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12935418	0.616	rs13336629	chr16:81005806	C/T	cg16651780	chr16:81037892	C16orf61	0.65	6.23	0.45	4.37e-9	Mean corpuscular volume;
PAAD	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.8	7.14	0.5	3.59e-11	Exhaled nitric oxide levels;
PAAD	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.89e-9	Bladder cancer;
PAAD	cis	rs654384	0.507	rs1077473	chr7:4175508	C/T	cg27574739	chr7:4176374	SDK1	-0.47	-4.51	-0.34	1.31e-5	Positive affect;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.64	0.35	7.5e-6	IgG glycosylation;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg11218175	chr11:495084	RNH1	0.76	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg27121462	chr16:89883253	FANCA	-0.47	-5.1	-0.38	1.02e-6	Vitiligo;
PAAD	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.51	4.33	0.33	2.64e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg16850897	chr7:100343110	ZAN	-0.57	-4.81	-0.36	3.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12044355	0.827	rs7552630	chr1:231824286	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.87	0.43	2.59e-8	Alzheimer's disease;
PAAD	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg23093090	chr10:104574429	C10orf26	-0.5	-5.91	-0.43	2.2e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg25487775	chr2:162093969	NA	0.56	5.49	0.41	1.61e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-6.07	-0.44	9.99e-9	Lung cancer;
PAAD	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.64	5.85	0.43	2.96e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs6041	0.822	rs1755685	chr13:113757192	A/C	cg09069900	chr13:113776964	F10	0.58	4.76	0.36	4.41e-6	End-stage coagulation;
PAAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.56	4.76	0.36	4.57e-6	Cystic fibrosis severity;
PAAD	cis	rs4664308	0.740	rs877635	chr2:160902847	A/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-7.53	-0.52	4.22e-12	Idiopathic membranous nephropathy;
PAAD	trans	rs13160562	0.623	rs26509	chr5:96082680	A/C	cg19854470	chr1:109419421	GPSM2	-0.64	-6.37	-0.46	2.15e-9	Alcohol dependence;
PAAD	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.38	-4.44	-0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	trans	rs12545912	0.866	rs4626603	chr8:9588107	C/G	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.81	-8.93	-0.59	1.31e-15	Height;
PAAD	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.59	5.96	0.44	1.65e-8	Kawasaki disease;
PAAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.39	-4.89	-0.37	2.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2262909	1.000	rs2262909	chr19:22135270	A/C	cg02912127	chr19:22235281	ZNF257	-0.42	-4.29	-0.33	3.12e-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.08	0.59	5.29e-16	Cognitive test performance;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12599982	chr1:44399894	ARTN	-0.43	-4.63	-0.35	7.91e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.69e-6	Oral cavity cancer;
PAAD	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.49	6.22	0.45	4.62e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg08886695	chr4:3369023	RGS12	0.53	5.08	0.38	1.07e-6	Serum sulfate level;
PAAD	cis	rs4629180	0.917	rs1110947	chr2:102118712	T/C	cg04415270	chr2:102091202	RFX8	-0.67	-8.43	-0.56	2.41e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06738889	chr1:150208936	ANP32E	0.59	6.66	0.48	4.77e-10	Metabolite levels  (X-11787);
PAAD	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg10432947	chr4:2062441	NAT8L	0.52	4.5	0.34	1.35e-5	Systolic blood pressure;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs10789285	0.650	rs2248437	chr1:69694912	A/G	cg04447890	chr1:68697988	GPR177	-0.52	-4.27	-0.33	3.39e-5	Psoriasis;
PAAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg01223673	chr11:15133828	INSC	-0.34	-4.43	-0.34	1.77e-5	Mitochondrial DNA levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24779751	chr19:36545850	WDR62;THAP8	-0.65	-6.82	-0.48	1.98e-10	Smoking initiation;
PAAD	cis	rs10448080	0.959	rs4732873	chr8:28601554	A/C	cg07962641	chr8:28805897	HMBOX1	0.41	4.35	0.33	2.45e-5	Height;
PAAD	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg22587600	chr2:46883368	NA	0.34	4.59	0.35	9.34e-6	Height;
PAAD	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg12395012	chr8:11607386	GATA4	-0.42	-4.72	-0.36	5.3e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.84	0.37	3.09e-6	Blood metabolite levels;
PAAD	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.71	-0.42	5.65e-8	Lung cancer;
PAAD	cis	rs6537837	1.000	rs6537837	chr1:110119732	C/T	cg05049280	chr1:110155535	GNAT2	0.46	4.6	0.35	8.87e-6	Major depressive disorder;
PAAD	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.91	-6.77	-0.48	2.57e-10	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.35	-0.56	4.04e-14	Urate levels in overweight individuals;
PAAD	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.55	-5.14	-0.38	8.37e-7	Total body bone mineral density;
PAAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.31	13.64	0.74	3.56e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs1941184	0.759	rs10048282	chr18:29025644	G/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs9443189	0.762	rs2748955	chr6:76464302	C/G	cg01950844	chr6:76311363	SENP6	-0.67	-4.54	-0.35	1.12e-5	Prostate cancer;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02071572	chr4:1403502	NA	0.43	5.86	0.43	2.8e-8	Obesity-related traits;
PAAD	cis	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg11619707	chr19:22235551	ZNF257	0.57	5.7	0.42	6.08e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.53	-4.43	-0.34	1.82e-5	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.96	-6.41	-0.46	1.76e-9	Coronary artery disease;
PAAD	cis	rs7923609	0.846	rs10761731	chr10:65027610	A/T	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.53	-5.55	-0.41	1.24e-7	Bladder cancer;
PAAD	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.65	5.7	0.42	6e-8	Response to diuretic therapy;
PAAD	cis	rs7144011	0.654	rs4899740	chr14:79848261	G/A	cg18311665	chr14:79483171	NRXN3	0.36	4.58	0.35	9.47e-6	Waist circumference;Hip circumference;
PAAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.61	-7.05	-0.5	6.02e-11	Blood protein levels;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg00976097	chr5:421733	AHRR	-0.44	-4.39	-0.34	2.09e-5	Cystic fibrosis severity;
PAAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.54	4.94	0.37	2.05e-6	Blood metabolite levels;
PAAD	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.77	-8.34	-0.56	4.05e-14	Idiopathic membranous nephropathy;
PAAD	cis	rs17023223	0.537	rs10802073	chr1:119604655	T/C	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.62	-0.35	8.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.82	0.36	3.5e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg17052926	chr7:915758	C7orf20	-0.48	-4.87	-0.37	2.78e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	6.84	0.49	1.81e-10	Body mass index (adult);
PAAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.4	0.46	1.85e-9	Personality dimensions;
PAAD	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.65	-6.31	-0.46	2.92e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.61	-4.42	-0.34	1.85e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg17052926	chr7:915758	C7orf20	-0.48	-4.82	-0.36	3.38e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	1.01	14.15	0.75	1.52e-29	Heart rate;
PAAD	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.54	-5.69	-0.42	6.3e-8	Daytime sleep phenotypes;
PAAD	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg03989125	chr22:38214979	NA	0.54	4.69	0.36	6e-6	Fat distribution (HIV);
PAAD	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.88	-0.37	2.7e-6	Height;
PAAD	trans	rs943072	0.765	rs12660375	chr6:43801582	C/T	cg08992360	chr8:1440917	NA	0.8	6.39	0.46	1.91e-9	Ulcerative colitis;
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg08029281	chr1:67600428	NA	0.49	6.08	0.44	9.18e-9	Psoriasis;
PAAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs939584	1.000	rs4613321	chr2:650647	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.46	-7.44	-0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.94	0.54	4.2e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26926768	chr12:34528122	NA	0.4	4.87	0.37	2.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs2147959	0.941	rs6426503	chr1:228651011	A/G	cg02753203	chr1:228287806	NA	-0.59	-4.76	-0.36	4.39e-6	Adult asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02278228	chr7:43313745	HECW1	-0.61	-6.47	-0.46	1.26e-9	Obesity-related traits;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.75	-7.34	-0.51	1.18e-11	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12858300	chr1:209957965	C1orf74	0.62	6.89	0.49	1.41e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9535307	1.000	rs2897770	chr13:50325070	A/G	cg03658251	chr13:50265850	EBPL	0.83	5.64	0.42	8.09e-8	Obesity-related traits;
PAAD	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.64	-6.77	-0.48	2.57e-10	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	1.1	15.83	0.79	5.88e-34	Systemic lupus erythematosus;
PAAD	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.46	-0.34	1.61e-5	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3734905	1.000	rs3734905	chr6:169958982	G/A	cg11181693	chr6:169825345	NA	-0.84	-5.16	-0.39	7.7300000000000005e-07	HIV-1 control;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.82	0.54	8.19e-13	Prudent dietary pattern;
PAAD	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.81	-0.36	3.57e-6	Venous thromboembolism;
PAAD	cis	rs3996993	0.724	rs2749008	chr6:52626120	C/T	cg00536792	chr6:53530503	KLHL31	0.47	4.95	0.37	1.94e-6	Hemoglobin concentration;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg14092988	chr3:52407081	DNAH1	0.38	4.59	0.35	9.24e-6	Electroencephalogram traits;
PAAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.04	0.38	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11614333	1.000	rs67436073	chr12:15050409	A/G	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs3026101	0.671	rs3944127	chr17:5297766	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.98	0.44	1.51e-8	Body mass index;
PAAD	cis	rs8044995	0.929	rs3743739	chr16:68293320	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.89	-0.43	2.38e-8	Schizophrenia;
PAAD	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg26248373	chr2:1572462	NA	-1.05	-9.35	-0.6	1.04e-16	IgG glycosylation;
PAAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.43	-5.04	-0.38	1.3e-6	Body mass index;
PAAD	cis	rs939584	1.000	rs6751993	chr2:635864	A/G	cg03610516	chr2:642275	NA	0.56	4.92	0.37	2.25e-6	Body mass index;
PAAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.47	4.85	0.37	3.08e-6	Longevity;Endometriosis;
PAAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.82	-0.82	4.74e-39	Height;
PAAD	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	6.17	0.45	5.86e-9	Homoarginine levels;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg17650747	chr5:1873721	NA	0.45	4.65	0.35	7.17e-6	Cardiovascular disease risk factors;
PAAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg04705435	chr11:17411270	KCNJ11	0.61	6.34	0.46	2.43e-9	Type 2 diabetes;
PAAD	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg24555670	chr8:18244502	NA	0.58	5.48	0.41	1.73e-7	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21157357	chr5:140851830	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	0.64	6.85	0.49	1.7e-10	Smoking initiation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07810072	chr11:66610236	RCE1;C11orf80	-0.61	-6.42	-0.46	1.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-5.92	-0.43	2.03e-8	Menarche (age at onset);
PAAD	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.56	6.01	0.44	1.35e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.46	-5.72	-0.42	5.44e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.7	6.91	0.49	1.24e-10	Lymphocyte counts;
PAAD	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.76	-0.48	2.74e-10	Coffee consumption (cups per day);
PAAD	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg04398451	chr17:18023971	MYO15A	-0.89	-8.68	-0.58	5.86e-15	Total body bone mineral density;
PAAD	cis	rs2092319	0.649	rs2786864	chr1:26014024	A/G	cg02327719	chr1:26185386	C1orf135	-0.79	-4.71	-0.36	5.62e-6	Nose morphology;
PAAD	cis	rs931127	0.836	rs523029	chr11:65476487	T/G	cg06492744	chr11:65406254	SIPA1	0.33	4.95	0.37	1.98e-6	Systemic lupus erythematosus;
PAAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.81	-9.1	-0.59	4.89e-16	Total body bone mineral density;
PAAD	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24637319	chr11:88071195	CTSC	-0.74	-6.42	-0.46	1.62e-9	Neuroticism;
PAAD	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.81	7.44	0.52	6.75e-12	Breast cancer;
PAAD	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.64	-4.82	-0.36	3.51e-6	Tonsillectomy;
PAAD	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.62	5.8	0.43	3.69e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg04257695	chr17:30186438	C17orf79	-0.6	-4.73	-0.36	5.04e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs595018	0.505	rs56131811	chr11:60595943	G/A	cg23904249	chr11:60608951	CCDC86	0.67	4.89	0.37	2.49e-6	Wegener's granulomatosis;
PAAD	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.84	-9.92	-0.63	3.36e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11191270	0.554	rs3781293	chr10:104166257	T/C	cg15320455	chr10:103880129	LDB1	0.6	4.77	0.36	4.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.663	rs56012051	chr5:74551828	A/G	cg03227963	chr5:74354835	NA	0.48	4.69	0.36	5.92e-6	Response to amphetamines;
PAAD	cis	rs8070740	0.617	rs1058115	chr17:5323269	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.5	-5.38	-0.4	2.7e-7	Menopause (age at onset);
PAAD	cis	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg25886479	chr11:50257625	LOC441601	0.42	4.53	0.35	1.16e-5	Coronary artery disease;
PAAD	cis	rs593531	0.571	rs3862799	chr11:74050262	C/A	cg23327896	chr11:73669290	DNAJB13	-0.36	-4.57	-0.35	9.94e-6	Neuroticism;
PAAD	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg21178979	chr7:1889533	MAD1L1	0.4	4.37	0.33	2.26e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.71	6.92	0.49	1.2e-10	Lymphocyte percentage of white cells;
PAAD	cis	rs61759167	1.000	rs61759167	chr1:3091587	C/T	cg22396632	chr1:3079212	PRDM16	-0.56	-5.27	-0.39	4.59e-7	Motion sickness;
PAAD	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs12432203	0.831	rs72622424	chr14:51730989	T/A	cg23942311	chr14:51606299	NA	-0.7	-4.82	-0.36	3.52e-6	Cancer;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.65	-6.41	-0.46	1.69e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26383870	chr18:43754049	C18orf25	0.62	7.32	0.51	1.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg05082376	chr22:42548792	NA	0.52	5.6	0.41	9.67e-8	Cognitive function;
PAAD	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	18.49	0.83	9.87e-41	IgG glycosylation;
PAAD	cis	rs4450131	0.902	rs10794174	chr10:126357981	T/C	cg20435097	chr10:126320824	FAM53B	-0.49	-5.53	-0.41	1.33e-7	White blood cell count (basophil);
PAAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.62	-7.33	-0.51	1.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.52	-5.11	-0.38	9.71e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs728616	0.867	rs12781912	chr10:81918128	G/T	cg11900509	chr10:81946545	ANXA11	-0.63	-4.4	-0.34	2.07e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg13012494	chr21:47604986	C21orf56	0.43	4.44	0.34	1.73e-5	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15836374	chr12:132938027	NA	-0.61	-6.54	-0.47	8.62e-10	Obesity-related traits;
PAAD	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00529946	chr2:26568848	SELI;GPR113	0.56	6.41	0.46	1.75e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20848291	chr7:100343083	ZAN	-0.99	-8.96	-0.59	1.1e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg14348967	chr4:10160060	NA	-0.36	-4.27	-0.33	3.49e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24686825	chr1:36642396	MAP7D1	0.58	6.32	0.46	2.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14159747	chr11:113255604	NA	0.4	5.63	0.42	8.64e-8	Neuroticism;
PAAD	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.72	8.12	0.55	1.48e-13	Prostate cancer;
PAAD	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg02072170	chr3:194406190	FAM43A	-0.48	-4.85	-0.37	2.97e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs6137287	0.924	rs6035795	chr20:21145885	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.34	0.33	2.6e-5	Platelet count;
PAAD	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-7.22	-0.51	2.32e-11	Mosquito bite size;
PAAD	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg16576597	chr16:28551801	NUPR1	-0.64	-6.35	-0.46	2.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.73	8.25	0.56	7.21e-14	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.69	9.89	0.63	4.1e-18	Schizophrenia;
PAAD	cis	rs4668356	1.000	rs55997598	chr2:171959140	G/A	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs7765175	0.521	rs2842843	chr6:113634650	A/C	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.89	9.69	0.62	1.34e-17	Testicular germ cell tumor;
PAAD	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg17372657	chr7:1216933	NA	-0.39	-5.11	-0.38	9.56e-7	Longevity;Endometriosis;
PAAD	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg20302342	chr1:156215951	PAQR6	0.61	6.72	0.48	3.52e-10	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg03098644	chr7:100410630	EPHB4	0.6	4.39	0.34	2.08e-5	Other erythrocyte phenotypes;
PAAD	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.56	4.66	0.35	6.89e-6	RR interval (heart rate);
PAAD	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.5	-4.93	-0.37	2.11e-6	Fibrinogen levels;
PAAD	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg08099141	chr12:7053170	C12orf57	-0.47	-4.84	-0.37	3.19e-6	IgG glycosylation;
PAAD	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.62	0.41	8.97e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg08886695	chr4:3369023	RGS12	0.5	4.96	0.37	1.91e-6	Parental longevity (mother's age at death);
PAAD	cis	rs6879260	0.682	rs12173080	chr5:179741411	A/C	cg23221052	chr5:179740743	GFPT2	-0.73	-7.18	-0.5	2.93e-11	Height;
PAAD	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25632853	chr15:73088954	NA	0.4	4.55	0.35	1.08e-5	Triglyceride levels;
PAAD	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg27449745	chr7:23145252	KLHL7	-0.54	-4.9	-0.37	2.44e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg05805236	chr11:65401703	PCNXL3	-0.47	-5.03	-0.38	1.35e-6	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.56	5.22	0.39	5.84e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.55	-0.52	3.77e-12	Response to antipsychotic treatment;
PAAD	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.11	9.42	0.61	6.97e-17	Red blood cell traits;
PAAD	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg23188684	chr11:67383651	NA	0.43	4.46	0.34	1.55e-5	Mean corpuscular volume;
PAAD	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg10705379	chr10:99080932	FRAT1	0.37	4.34	0.33	2.62e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.68	-7.79	-0.53	9.78e-13	Alcohol dependence;
PAAD	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.52	5.15	0.39	7.88e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.92	11.57	0.68	1.35e-22	Menarche (age at onset);
PAAD	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.43	0.65	1.49e-19	Smoking behavior;
PAAD	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg04545296	chr12:48745243	ZNF641	0.36	4.52	0.34	1.24e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg16558208	chr1:156270281	VHLL	0.49	4.61	0.35	8.5e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg14345882	chr6:26364793	BTN3A2	-0.44	-4.31	-0.33	2.86e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.79	-0.36	4e-6	Educational attainment;
PAAD	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.06e-7	Testicular germ cell tumor;
PAAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-4.57	-0.35	1e-5	Menarche (age at onset);
PAAD	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg00149659	chr3:10157352	C3orf10	0.85	6.46	0.46	1.32e-9	Alzheimer's disease;
PAAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16008631	chr17:132067	RPH3AL	-0.64	-6.3	-0.46	3.06e-9	Obesity-related traits;
PAAD	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg13660082	chr14:53194042	PSMC6	0.73	4.54	0.35	1.16e-5	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.8	-0.48	2.26e-10	Aortic root size;
PAAD	cis	rs13175840	0.645	rs6877237	chr5:133211782	C/G	cg18514949	chr5:133563216	PPP2CA	-0.32	-4.44	-0.34	1.7e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.18	-0.39	7.04e-7	Mortality in heart failure;
PAAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11245990	chr11:68621969	NA	0.38	4.81	0.36	3.61e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg10547527	chr2:198650123	BOLL	-0.64	-4.31	-0.33	2.95e-5	Ulcerative colitis;
PAAD	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.92	0.37	2.23e-6	Breast cancer;
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.79	-11.18	-0.67	1.5e-21	Psoriasis;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.66	-0.42	7.5e-8	Response to antipsychotic treatment;
PAAD	cis	rs1075265	0.584	rs1862121	chr2:54285239	G/A	cg04546899	chr2:54196757	PSME4	0.36	5.13	0.38	8.59e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.25	0.33	3.69e-5	Bipolar disorder;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg17105886	chr17:28927953	LRRC37B2	0.69	4.43	0.34	1.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.53	4.97	0.37	1.81e-6	Coronary artery disease;
PAAD	cis	rs89107	0.688	rs283091	chr6:118588684	A/G	cg21191810	chr6:118973309	C6orf204	-0.45	-6.22	-0.45	4.5e-9	Cardiac structure and function;
PAAD	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	7.95	0.54	3.85e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.68	5.65	0.42	7.8e-8	Common traits (Other);
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.62	-5.74	-0.42	4.94e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	9.93	0.63	3.21e-18	Smoking behavior;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06019718	chr3:186288436	TBCCD1;DNAJB11	0.5	5.05	0.38	1.23e-6	Myopia (pathological);
PAAD	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg13160058	chr8:26243215	BNIP3L	-0.4	-4.9	-0.37	2.47e-6	Red cell distribution width;
PAAD	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg18939081	chr1:31884902	SERINC2	0.47	5.41	0.4	2.35e-7	Alcohol dependence;
PAAD	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg23719950	chr11:63933701	MACROD1	-0.71	-4.99	-0.37	1.67e-6	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	5.48	0.41	1.73e-7	Blood protein levels;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs300774	1.000	rs400978	chr2:119437	A/G	cg21211680	chr2:198530	NA	-0.62	-5.48	-0.41	1.74e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg06569542	chr10:98946673	SLIT1	-0.51	-5.77	-0.42	4.31e-8	Monocyte count;
PAAD	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.34	-0.4	3.34e-7	Daytime sleep phenotypes;
PAAD	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.6	5.45	0.4	1.99e-7	Retinal vascular caliber;
PAAD	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Lymphocyte counts;
PAAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.5	4.74	0.36	4.9100000000000004e-06	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11961683	chr8:121824433	SNTB1	0.7	7.6	0.52	2.8e-12	Myopia (pathological);
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg11416102	chr8:651193	ERICH1	-0.88	-5.4	-0.4	2.5e-7	IgG glycosylation;
PAAD	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-4.6	-0.35	8.67e-6	Coronary artery disease;
PAAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.81	-10.42	-0.65	1.56e-19	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.65	7.02	0.49	7.02e-11	Morning vs. evening chronotype;
PAAD	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.76	-8.29	-0.56	5.71e-14	Colorectal cancer;
PAAD	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.42	0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.95	0.49	9.89e-11	Morning vs. evening chronotype;
PAAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs732765	0.734	rs35461658	chr14:75207264	T/C	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.79	8.5	0.57	1.66e-14	Prostate cancer;
PAAD	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.82	-0.62	6.17e-18	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.88e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.71	-4.25	-0.33	3.68e-5	Tuberculosis;
PAAD	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	1.02	8.7	0.58	5.02e-15	Triglycerides;
PAAD	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs722864	0.742	rs4972529	chr2:173952115	T/C	cg09210666	chr2:173941575	ZAK	0.49	4.62	0.35	8.17e-6	Lung cancer;
PAAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.69	6.66	0.48	4.61e-10	Methadone dose in opioid dependence;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07001909	chr14:80328262	NRXN3	-0.65	-6.51	-0.47	1.04e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.7	8.2	0.55	9.26e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11018904	0.636	rs61903695	chr11:89922417	A/G	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.75	-0.36	4.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.7	0.36	5.84e-6	Educational attainment;
PAAD	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.67	7.61	0.53	2.72e-12	Heart rate;
PAAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg27417659	chr7:98567827	TRRAP	0.46	4.4	0.34	2.05e-5	Breast cancer;
PAAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	4.52	0.34	1.24e-5	Body mass index;
PAAD	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	5.54	0.41	1.28e-7	Neuroticism;
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.61	4.91	0.37	2.29e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1512829	0.578	rs3907923	chr11:9907037	G/A	cg06876053	chr11:9810051	SBF2	-0.4	-4.62	-0.35	8.09e-6	Lung adenocarcinoma;
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01765077	chr12:122356316	WDR66	0.64	6.58	0.47	7.2e-10	Mean corpuscular volume;
PAAD	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.99	8.76	0.58	3.6e-15	Bipolar disorder;
PAAD	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.68	6.4	0.46	1.87e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg13677279	chr10:103911811	NOLC1	0.48	4.26	0.33	3.59e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.46	4.31	0.33	2.88e-5	Height;
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.58	4.89	0.37	2.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg10183150	chr4:120222239	C4orf3	-0.37	-5.2	-0.39	6.47e-7	Corneal astigmatism;
PAAD	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.49	5.47	0.41	1.83e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.7e-5	Bone mineral density;
PAAD	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg12517394	chr11:61582795	MIR1908;FADS1	-0.51	-5.1	-0.38	1.02e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg19500098	chr13:21900506	NA	0.57	5.81	0.43	3.54e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6460942	0.597	rs6968664	chr7:12515493	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-4.87	-0.37	2.75e-6	Coronary artery disease;
PAAD	cis	rs6715793	0.653	rs55957962	chr2:33419770	A/G	cg26672287	chr2:33391915	LTBP1	-0.38	-4.38	-0.33	2.21e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.54	4.65	0.35	7.22e-6	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13920784	chr6:52900225	ICK	-0.7	-7.08	-0.5	5.1e-11	Obesity-related traits;
PAAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.71	-7.67	-0.53	1.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.66	6.4	0.46	1.83e-9	Mosquito bite size;
PAAD	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.72	7.21	0.51	2.39e-11	Obesity-related traits;
PAAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	1.39	10.37	0.64	2.17e-19	Schizophrenia;
PAAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.51	5.67	0.42	6.82e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1018697	0.966	rs6584526	chr10:104566241	G/C	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	trans	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.67	-0.48	4.39e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg00179576	chr16:74483694	GLG1	-0.4	-4.36	-0.33	2.43e-5	Testicular germ cell tumor;
PAAD	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg16964102	chr10:135390573	NA	0.48	4.4	0.34	2.05e-5	Gout;
PAAD	cis	rs77633900	0.772	rs2957560	chr15:76700310	A/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs785830	0.558	rs549624	chr9:259554	G/A	cg17093826	chr7:138458720	ATP6V0A4	0.5	6.45	0.46	1.39e-9	Platelet distribution width;
PAAD	cis	rs6604026	0.656	rs6694051	chr1:93392760	A/G	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg20805835	chr1:248005719	OR11L1	0.51	4.51	0.34	1.31e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10821973	0.527	rs10733770	chr10:63982386	C/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg01631684	chr10:65280961	REEP3	-0.46	-4.66	-0.35	6.86e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.3	-0.39	4.01e-7	Glomerular filtration rate;
PAAD	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.87	-0.43	2.67e-8	Lung cancer;
PAAD	cis	rs10768122	0.642	rs11033087	chr11:35374044	G/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-5.33	-0.4	3.51e-7	Vitiligo;
PAAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg02428538	chr16:24856791	SLC5A11	0.62	4.6	0.35	8.77e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.67	-6.58	-0.47	7.29e-10	Total body bone mineral density;
PAAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.94	-9.98	-0.63	2.37e-18	Birth weight;
PAAD	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.58	5.99	0.44	1.42e-8	White matter hyperintensity burden;
PAAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.1e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg13606994	chr1:44402422	ARTN	-0.4	-4.37	-0.33	2.27e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg18446336	chr7:2847575	GNA12	0.51	5.48	0.41	1.72e-7	Height;
PAAD	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.69	-7.06	-0.5	5.63e-11	Brugada syndrome;
PAAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-4.5	-0.34	1.32e-5	Menarche (age at onset);
PAAD	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.08	-0.38	1.09e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-4.98	-0.37	1.68e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs3736485	0.903	rs9944241	chr15:51898058	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.3	-0.33	3.07e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.81	7.85	0.54	7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg09839279	chr12:125627357	AACS	-0.45	-4.52	-0.34	1.25e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08418111	chr11:18433745	LDHC	0.62	6.53	0.47	9.3e-10	Calcium levels;
PAAD	cis	rs2241685	0.850	rs7582679	chr2:1942742	A/G	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.91	-6.12	-0.44	7.73e-9	Systolic blood pressure;
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg17595323	chr11:93583763	C11orf90	0.35	4.31	0.33	2.91e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs965469	0.779	rs2236112	chr20:3294983	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.72	7.98	0.54	3.22e-13	Melanoma;
PAAD	cis	rs7627468	1.000	rs6776280	chr3:121932092	G/A	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.74	-0.36	4.92e-6	Lymphocyte counts;
PAAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-1.06	-15.07	-0.77	5.6199999999999995e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.54	5.83	0.43	3.18e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9815354	0.904	rs73079327	chr3:41864697	A/T	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.82	-8.92	-0.59	1.41e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg09509183	chr1:209979624	IRF6	0.54	5.28	0.39	4.39e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.4	4.9	0.37	2.41e-6	Pulmonary function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18192808	chr1:15853278	DNAJC16	0.66	6.52	0.47	9.65e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	5.12	0.38	9.04e-7	Prudent dietary pattern;
PAAD	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.71	-5.78	-0.42	4.03e-8	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07796735	chr12:49932860	KCNH3	0.61	7.26	0.51	1.86e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.47	5.38	0.4	2.77e-7	Testicular germ cell tumor;
PAAD	cis	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.39	-0.4	2.66e-7	Mononucleosis;
PAAD	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14019695	chr9:139328340	INPP5E	0.5	4.64	0.35	7.56e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.34	-0.46	2.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg26248373	chr2:1572462	NA	-1.09	-7.65	-0.53	2.13e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05277466	chr16:88082055	BANP	-0.56	-6.65	-0.47	4.93e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.79	-0.36	3.94e-6	Personality dimensions;
PAAD	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg20270762	chr11:117014891	PAFAH1B2	0.5	4.53	0.35	1.17e-5	Blood protein levels;
PAAD	cis	rs16910800	1.000	rs2449439	chr11:23200798	C/T	cg20040320	chr11:23191996	NA	0.58	4.88	0.37	2.65e-6	Cancer;
PAAD	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.46	5.38	0.4	2.81e-7	Atrioventricular conduction;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-8.13	-0.55	1.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg20295408	chr7:1910781	MAD1L1	0.56	5.72	0.42	5.41e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.33e-6	Diastolic blood pressure;
PAAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.79	7.0	0.49	7.8e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs4325129	1.000	rs67371748	chr1:159489964	T/C	cg08665772	chr1:160051377	KCNJ9	0.44	4.26	0.33	3.57e-5	Obesity-related traits;
PAAD	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.66	-5.73	-0.42	5.33e-8	Schizophrenia;
PAAD	cis	rs72960926	1.000	rs72958951	chr6:75118214	G/A	cg03266952	chr6:74778945	NA	-1.08	-5.73	-0.42	5.28e-8	Metabolite levels (MHPG);
PAAD	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg24747557	chr10:131355152	MGMT	-0.45	-4.95	-0.37	1.98e-6	Response to temozolomide;
PAAD	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg01868782	chr6:126071099	HEY2	0.44	5.07	0.38	1.13e-6	High light scatter reticulocyte count;
PAAD	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg26876637	chr1:152193138	HRNR	-0.83	-6.05	-0.44	1.09e-8	Atopic dermatitis;
PAAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.47	6.02	0.44	1.22e-8	Ulcerative colitis;
PAAD	cis	rs8133932	0.701	rs6518258	chr21:47281829	C/T	cg13695288	chr21:47294981	PCBP3	-0.48	-4.76	-0.36	4.57e-6	Schizophrenia;
PAAD	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.71	-7.68	-0.53	1.8e-12	Neuroticism;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.57	-0.41	1.14e-7	Prudent dietary pattern;
PAAD	cis	rs12681963	0.614	rs16876663	chr8:30059698	G/T	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg17551891	chr7:1960795	MAD1L1	-0.46	-4.25	-0.33	3.72e-5	Neuroticism;
PAAD	cis	rs75920871	0.920	rs7924318	chr11:116816630	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg15604389	chr3:122379662	NA	0.57	6.14	0.45	6.73e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs8105895	0.935	rs8104630	chr19:22247277	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg15383120	chr6:291909	DUSP22	-0.66	-7.12	-0.5	4.01e-11	Menopause (age at onset);
PAAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.75	7.32	0.51	1.33e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-5.88	-0.43	2.5e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.46	-0.34	1.55e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.54	5.1	0.38	9.88e-7	Multiple sclerosis;
PAAD	cis	rs4478858	0.735	rs12408524	chr1:31835853	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.3	-0.46	3.05e-9	Alcohol dependence;
PAAD	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.62	-0.35	8.26e-6	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01697732	chr17:66597500	FAM20A	0.58	6.66	0.48	4.68e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg06606381	chr12:133084897	FBRSL1	-1.17	-7.59	-0.52	2.94e-12	Urinary tract infection frequency;
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.49	4.6	0.35	8.88e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-6.66	-0.48	4.83e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg20060109	chr17:81052770	NA	0.44	4.36	0.33	2.35e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs17407555	0.779	rs17250843	chr4:10127978	C/G	cg11266682	chr4:10021025	SLC2A9	-0.64	-5.53	-0.41	1.34e-7	Schizophrenia (age at onset);
PAAD	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.66	7.57	0.52	3.34e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg11235426	chr6:292522	DUSP22	-0.76	-7.88	-0.54	5.88e-13	Menopause (age at onset);
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.48	-7.91	-0.54	4.87e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg10756475	chr4:1757242	NA	0.46	4.44	0.34	1.74e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4663866	1.000	rs4663866	chr2:239150815	A/C	cg16914508	chr2:239161102	PER2	0.79	4.39	0.34	2.1e-5	Irritable bowel syndrome;
PAAD	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.44	-0.34	1.73e-5	Height;
PAAD	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.75	4.75	0.36	4.73e-6	Yeast infection;
PAAD	cis	rs6908034	0.607	rs111533721	chr6:19803745	C/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg26506288	chr17:46804123	HOXB13	0.34	4.3	0.33	3.09e-5	Type 2 diabetes;
PAAD	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.39	-0.56	3.08e-14	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	14.16	0.75	1.42e-29	Chronic sinus infection;
PAAD	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.41e-6	Blood metabolite levels;
PAAD	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg05627522	chr15:75251581	NA	-0.39	-4.38	-0.33	2.18e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg27005118	chr17:13972210	COX10	-0.41	-5.42	-0.4	2.32e-7	Temperament;
PAAD	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	5.14	0.38	8.35e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs57709857	0.957	rs7841617	chr8:38167649	C/T	cg16625770	chr8:38300134	FGFR1	-0.46	-4.3	-0.33	2.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.47	-4.44	-0.34	1.7e-5	Pulse pressure;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.05e-15	Exhaled nitric oxide output;
PAAD	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.85	9.71	0.62	1.23e-17	Resting heart rate;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg01244601	chr4:120671846	NA	-0.52	-4.47	-0.34	1.54e-5	Corneal astigmatism;
PAAD	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg07469887	chr10:131262384	NA	-0.44	-5.06	-0.38	1.2e-6	Response to temozolomide;
PAAD	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg06484146	chr7:12443880	VWDE	-0.85	-5.63	-0.42	8.58e-8	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.54	5.49	0.41	1.67e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg27411982	chr8:10470053	RP1L1	-0.49	-4.88	-0.37	2.7e-6	Neuroticism;
PAAD	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.66	-7.3	-0.51	1.46e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.64	6.93	0.49	1.1e-10	Mean corpuscular volume;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.91	12.34	0.71	1.09e-24	Prudent dietary pattern;
PAAD	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	12.52	0.71	3.78e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs16975963	0.843	rs112628349	chr19:38268238	G/C	cg25793785	chr19:38281423	NA	0.55	4.54	0.35	1.14e-5	Longevity;
PAAD	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs6784615	0.744	rs10865972	chr3:52491447	G/T	cg15956490	chr3:53032818	SFMBT1	-1.04	-4.58	-0.35	9.62e-6	Waist-hip ratio;
PAAD	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg01631408	chr1:248437212	OR2T33	-0.51	-4.43	-0.34	1.77e-5	Autism spectrum disorder;
PAAD	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs3781458	0.842	rs897300	chr10:126320902	A/G	cg20435097	chr10:126320824	FAM53B	0.55	6.11	0.44	7.87e-9	Male-pattern baldness;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-5.45	-0.4	1.97e-7	Lymphocyte counts;
PAAD	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg21253282	chr4:146019006	ABCE1;ANAPC10	-0.67	-7.18	-0.5	2.9100000000000002e-11	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs6466055	0.661	rs66912872	chr7:104937147	A/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg24053715	chr22:38214548	NA	-0.61	-6.53	-0.47	9.29e-10	Glioblastoma;Glioma;
PAAD	cis	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg17325771	chr7:75508891	RHBDD2	-0.43	-5.19	-0.39	6.77e-7	Eotaxin levels;
PAAD	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.17	-0.6	3.08e-16	Exhaled nitric oxide output;
PAAD	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24110177	chr3:50126178	RBM5	-0.69	-6.42	-0.46	1.67e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.01	0.67	4.16e-21	Parkinson's disease;
PAAD	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.47	0.65	1.21e-19	Bladder cancer;
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.15	0.39	7.96e-7	Prostate cancer;
PAAD	cis	rs42648	0.596	rs194507	chr7:89843560	A/C	cg27367526	chr7:89841692	STEAP2	0.3	4.25	0.33	3.67e-5	Homocysteine levels;
PAAD	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-7.62	-0.53	2.53e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs1018697	0.966	rs6584526	chr10:104566241	G/C	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	0.88	4.47	0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-7.29	-0.51	1.57e-11	Vitiligo;
PAAD	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.64	-0.53	2.24e-12	Neuroticism;
PAAD	cis	rs8112211	0.648	rs4804016	chr19:38815665	C/A	cg14299480	chr19:38876666	GGN	-0.54	-4.66	-0.35	6.96e-6	Blood protein levels;
PAAD	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg08120226	chr3:195531633	MUC4	-0.42	-4.73	-0.36	5.11e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg24253500	chr15:84953950	NA	0.42	4.35	0.33	2.48e-5	Schizophrenia;
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg24879335	chr3:133465180	TF	0.57	6.51	0.47	1.03e-9	Iron status biomarkers;
PAAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg27094323	chr7:1216898	NA	-0.45	-5.38	-0.4	2.8e-7	Longevity;Endometriosis;
PAAD	cis	rs3736485	0.966	rs7177720	chr15:51890282	T/C	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20703375	chr7:98957328	ARPC1A	0.62	7.27	0.51	1.77e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs16975963	0.843	rs73029180	chr19:38420406	C/T	cg14218481	chr19:38281219	NA	0.48	5.01	0.38	1.49e-6	Longevity;
PAAD	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.82	8.85	0.58	2.12e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs288326	0.561	rs77184695	chr2:183802573	G/A	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.61	6.02	0.44	1.23e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg13114125	chr14:105738426	BRF1	-0.62	-5.55	-0.41	1.25e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.44	0.46	1.47e-9	Lung cancer in ever smokers;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-7.96	-0.54	3.66e-13	Prostate cancer;
PAAD	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.23	-0.7	2.18e-24	Urate levels in overweight individuals;
PAAD	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.75	6.17	0.45	5.96e-9	Prostate cancer;
PAAD	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg08888203	chr3:10149979	C3orf24	0.69	6.27	0.45	3.58e-9	Alzheimer's disease;
PAAD	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.97	-10.15	-0.64	8.33e-19	Post bronchodilator FEV1;
PAAD	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.58e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg20744362	chr22:50050164	C22orf34	0.66	7.75	0.53	1.23e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg08601574	chr20:25228251	PYGB	-0.6	-6.56	-0.47	7.81e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg20761395	chr17:511517	VPS53	0.47	4.85	0.37	3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg14926445	chr8:58193284	C8orf71	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs1015291	0.708	rs1352900	chr12:20005490	C/T	cg25401612	chr12:20009446	NA	-0.54	-5.29	-0.39	4.29e-7	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg22875332	chr1:76189707	ACADM	0.52	5.21	0.39	6.04e-7	Daytime sleep phenotypes;
PAAD	cis	rs6496044	0.507	rs410522	chr15:86207044	G/T	cg10818794	chr15:86012489	AKAP13	0.42	4.42	0.34	1.85e-5	Interstitial lung disease;
PAAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.9	9.32	0.6	1.31e-16	Height;
PAAD	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.46	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs72827839	0.793	rs72825512	chr17:46155069	C/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.51	4.82	0.36	3.43e-6	Aortic root size;
PAAD	cis	rs6942407	0.542	rs6958797	chr7:86751668	A/C	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.07	-0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.66	-6.25	-0.45	3.84e-9	Neuroticism;
PAAD	cis	rs2030114	1.000	rs59786459	chr16:51613534	T/C	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg18370025	chr7:2749541	AMZ1	-0.39	-4.73	-0.36	5e-6	Height;
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg26876637	chr1:152193138	HRNR	-0.79	-5.29	-0.39	4.21e-7	Atopic dermatitis;
PAAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-6.79	-0.48	2.4e-10	Schizophrenia;
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg11335335	chr11:637885	DRD4	-0.37	-4.82	-0.36	3.44e-6	Systemic lupus erythematosus;
PAAD	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.52	5.71	0.42	5.74e-8	Major depressive disorder;
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12525822	chr1:91487036	ZNF644	0.66	6.91	0.49	1.27e-10	Obesity-related traits;
PAAD	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg20761395	chr17:511517	VPS53	-0.47	-4.43	-0.34	1.81e-5	Prostate cancer;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	1.13	17.86	0.82	3.65e-39	Menarche (age at onset);
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00507354	chr4:76598817	G3BP2	0.65	7.25	0.51	2.01e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15541040	chr2:3486749	NA	-0.74	-7.76	-0.53	1.18e-12	Neurofibrillary tangles;
PAAD	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.87	8.44	0.57	2.26e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.72	0.53	1.43e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04047483	chr16:2732327	KCTD5	-0.64	-6.54	-0.47	8.81e-10	Smoking initiation;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.36	-0.4	3e-7	Personality dimensions;
PAAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.43	-4.41	-0.34	1.96e-5	Sarcoidosis;
PAAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.43	-4.93	-0.37	2.09e-6	Abdominal aortic aneurysm;
PAAD	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg22143856	chr6:28129313	ZNF389	0.54	5.03	0.38	1.39e-6	Parkinson's disease;
PAAD	cis	rs12620999	0.941	rs62183343	chr2:237979163	T/C	cg23555395	chr2:238036564	NA	0.49	5.83	0.43	3.27e-8	Systemic lupus erythematosus;
PAAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.81	6.96	0.49	9.3e-11	Recombination rate (females);
PAAD	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.23	-0.39	5.43e-7	Mood instability;
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Electroencephalogram traits;
PAAD	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.96	9.72	0.62	1.12e-17	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.38	0.51	9.59e-12	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-4.94	-0.37	2.07e-6	Menarche (age at onset);
PAAD	cis	rs6028335	0.877	rs66855787	chr20:37761558	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.33	-0.33	2.69e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.65	-0.35	7.1e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.83	-9.13	-0.6	3.91e-16	Body mass index;
PAAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.41	-4.53	-0.34	1.21e-5	Lung cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15076659	chr1:27481857	SLC9A1	-0.64	-6.52	-0.47	9.96e-10	Lung cancer in ever smokers;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01765077	chr12:122356316	WDR66	0.63	6.55	0.47	8.51e-10	Mean corpuscular volume;
PAAD	cis	rs10155981	0.510	rs28673155	chr7:22593935	C/T	cg05062323	chr7:22590069	NA	-0.91	-5.43	-0.4	2.15e-7	Bilirubin levels;
PAAD	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14795281	chr19:13953361	NA	0.67	6.76	0.48	2.75e-10	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08546335	chr16:1877338	HAGH;FAHD1	0.54	6.3	0.46	3.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7577696	0.889	rs212737	chr2:32474291	T/C	cg02381751	chr2:32503542	YIPF4	0.43	4.79	0.36	3.95e-6	Inflammatory biomarkers;
PAAD	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.57	-5.15	-0.39	8.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.28	-0.33	3.26e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.67	6.58	0.47	6.99e-10	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.47	-4.79	-0.36	3.92e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg20003494	chr4:90757398	SNCA	-0.73	-6.99	-0.49	7.97e-11	Neuroticism;
PAAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.44	-4.27	-0.33	3.36e-5	Renal cell carcinoma;
PAAD	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.85	8.69	0.58	5.42e-15	Schizophrenia;
PAAD	cis	rs1075265	0.749	rs805375	chr2:54090405	C/T	cg04546899	chr2:54196757	PSME4	0.3	4.49	0.34	1.38e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06026331	chr20:60912101	LAMA5	0.5	4.65	0.35	7.08e-6	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07156959	chr12:121975669	KDM2B	0.61	6.91	0.49	1.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772697	0.632	rs1316534	chr6:149417543	T/C	cg21368479	chr6:149415018	NA	0.42	4.46	0.34	1.57e-5	Diabetic retinopathy;
PAAD	cis	rs939584	1.000	rs12463617	chr2:629244	A/C	cg14515364	chr2:636606	NA	0.53	4.8	0.36	3.7e-6	Body mass index;
PAAD	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg14926445	chr8:58193284	C8orf71	-0.55	-4.41	-0.34	1.94e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg20607287	chr7:12443886	VWDE	-0.58	-4.71	-0.36	5.63e-6	Coronary artery disease;
PAAD	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg01444801	chr10:135216882	MTG1	-0.67	-5.73	-0.42	5.31e-8	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06869415	chr14:35183946	CFL2	0.61	6.91	0.49	1.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg11143131	chr5:131608246	PDLIM4	-0.51	-5.14	-0.38	8.4e-7	Blood metabolite levels;
PAAD	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs12431939	0.626	rs7161242	chr14:51716188	A/C	cg23942311	chr14:51606299	NA	0.53	4.86	0.37	2.84e-6	Cancer;
PAAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg00431813	chr7:1051703	C7orf50	0.76	4.6	0.35	8.88e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7922314	0.571	rs10509179	chr10:64725740	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9395066	0.525	rs1971482	chr6:44991113	C/T	cg18551225	chr6:44695536	NA	-0.42	-4.33	-0.33	2.66e-5	Height;
PAAD	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.34	-0.76	4.73e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg12623918	chr2:306882	NA	0.46	4.74	0.36	4.79e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.61	0.35	8.52e-6	Free thyroxine concentration;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg22143856	chr6:28129313	ZNF389	0.51	4.72	0.36	5.42e-6	Parkinson's disease;
PAAD	cis	rs4740619	0.935	rs10810436	chr9:15723547	T/C	cg14451791	chr9:16040625	NA	-0.4	-4.73	-0.36	5.13e-6	Body mass index;
PAAD	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.94	0.37	2.04e-6	Post bronchodilator FEV1;
PAAD	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg08999081	chr20:33150536	PIGU	0.54	5.88	0.43	2.48e-8	Height;
PAAD	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.65	-6.22	-0.45	4.57e-9	Corneal astigmatism;
PAAD	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.91	-11.01	-0.67	4.26e-21	Eosinophil percentage of white cells;
PAAD	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg23024343	chr7:107201750	COG5	0.61	4.66	0.35	6.84e-6	Coronary artery disease;
PAAD	cis	rs59888335	0.894	rs7642458	chr3:80859757	C/A	cg21735741	chr3:80819488	NA	-0.5	-4.33	-0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.48	8.57	0.57	1.11e-14	Multiple system atrophy;
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.39	0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs75757892	0.536	rs12192672	chr6:7229619	G/A	cg15365232	chr6:7261319	NA	0.41	4.27	0.33	3.49e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7707921	0.881	rs111907176	chr5:81312399	A/G	cg21483461	chr5:81570383	RPS23	-0.51	-4.27	-0.33	3.38e-5	Breast cancer;
PAAD	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg25558440	chr8:11882962	NA	-0.46	-4.38	-0.33	2.21e-5	Triglycerides;
PAAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.42	4.72	0.36	5.27e-6	Height;
PAAD	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg25620797	chr2:55921863	PNPT1	-0.5	-4.92	-0.37	2.2e-6	Metabolic syndrome;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg13852536	chr9:32567045	NDUFB6	0.63	6.4	0.46	1.82e-9	Body mass index;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.56e-8	Life satisfaction;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs787274	1.000	rs4979165	chr9:115609539	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-4.54	-0.35	1.14e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.13e-6	Lung cancer;
PAAD	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-5.88	-0.43	2.52e-8	Homocysteine levels;
PAAD	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.19	0.39	6.6e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1075265	0.568	rs7604357	chr2:54301163	G/C	cg04546899	chr2:54196757	PSME4	0.34	5.04	0.38	1.33e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2221894	1.000	rs2292478	chr8:28807356	T/G	cg20212339	chr8:28908912	HMBOX1	0.53	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.71	-0.36	5.6e-6	Type 2 diabetes;
PAAD	cis	rs11871801	0.541	rs4793090	chr17:40686342	G/A	cg21692620	chr17:40835849	CNTNAP1	0.5	5.13	0.38	8.58e-7	Crohn's disease;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03591917	chr3:197476477	FYTTD1;KIAA0226	0.69	8.21	0.55	8.9e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73019876	0.869	rs10402796	chr19:22174236	T/C	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.62	-6.32	-0.46	2.8e-9	Waist-hip ratio;
PAAD	trans	rs62209635	0.500	rs6088295	chr20:32344656	G/A	cg25517427	chr17:12921477	ELAC2	-1.13	-6.65	-0.47	4.94e-10	Loneliness;
PAAD	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.14e-10	Cutaneous nevi;
PAAD	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.85	5.73	0.42	5.1e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.58	-0.41	1.09e-7	Bladder cancer;
PAAD	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg14146966	chr2:61757674	XPO1	0.38	4.78	0.36	4.11e-6	Tuberculosis;
PAAD	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.52	4.87	0.37	2.8e-6	Night sleep phenotypes;
PAAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg03040243	chr9:100819229	NANS	0.58	4.69	0.36	5.91e-6	Immature fraction of reticulocytes;
PAAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.52	-4.83	-0.36	3.26e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6784615	0.744	rs35130772	chr3:52325106	C/G	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.68	6.45	0.46	1.4e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg14440974	chr22:39074834	NA	0.58	6.87	0.49	1.51e-10	Menopause (age at onset);
PAAD	cis	rs58521262	0.556	rs380541	chr19:23118931	C/T	cg22640819	chr19:22990650	NA	-0.28	-4.32	-0.33	2.79e-5	Testicular germ cell tumor;
PAAD	cis	rs6681460	0.649	rs4655494	chr1:67002876	G/A	cg02459107	chr1:67143332	SGIP1	0.56	5.0	0.38	1.53e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.48	-4.88	-0.37	2.6e-6	Hirschsprung disease;
PAAD	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.47	-4.42	-0.34	1.89e-5	Breast cancer;
PAAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.42	4.29	0.33	3.21e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg21191810	chr6:118973309	C6orf204	-0.51	-4.95	-0.37	1.94e-6	Renal cell carcinoma;
PAAD	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.81	9.09	0.59	4.95e-16	Metabolic syndrome;
PAAD	cis	rs7633770	0.735	rs12491294	chr3:46688498	G/T	cg11219411	chr3:46661640	NA	-0.59	-6.92	-0.49	1.18e-10	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09364328	chr19:59010904	SLC27A5	0.58	6.6	0.47	6.32e-10	Myopia (pathological);
PAAD	trans	rs4915077	0.649	rs4073682	chr1:108372838	T/A	cg18565342	chr10:124714098	C10orf88	-1.19	-6.35	-0.46	2.34e-9	Hypothyroidism;
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.52	-0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07608671	chr7:75115567	POM121C	-0.65	-6.6	-0.47	6.34e-10	Smoking initiation;
PAAD	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.14	-0.5	3.53e-11	Triglycerides;
PAAD	cis	rs787274	0.850	rs2645985	chr9:115510812	A/G	cg13803584	chr9:115635662	SNX30	0.81	4.44	0.34	1.72e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs2320952	0.903	rs11078852	chr17:10487306	A/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	6.03	0.44	1.2e-8	Body mass index;
PAAD	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.64	7.48	0.52	5.58e-12	Dupuytren's disease;
PAAD	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.78	-7.65	-0.53	2.13e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.37	-0.4	2.95e-7	Monocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.77	-8.18	-0.55	1.06e-13	Cognitive function;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg02569219	chr17:2266849	SGSM2	-0.52	-4.4	-0.34	2.05e-5	Total body bone mineral density;
PAAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.82	-9.12	-0.59	4.1e-16	Prostate cancer;
PAAD	cis	rs6743376	0.532	rs2515403	chr2:113820732	T/C	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs2085601	0.542	rs2670626	chr4:89967292	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg14686297	chr22:46650375	NA	-0.43	-4.37	-0.33	2.26e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.3	-0.4	3.93e-7	Total body bone mineral density;
PAAD	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs2249694	0.620	rs9418990	chr10:135337966	C/T	cg16964102	chr10:135390573	NA	-0.47	-4.71	-0.36	5.47e-6	Obesity-related traits;
PAAD	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	6.17	0.45	5.8e-9	Post bronchodilator FEV1;
PAAD	cis	rs7274811	0.846	rs57668191	chr20:32289763	A/G	cg21523528	chr20:32077966	CBFA2T2	0.58	4.31	0.33	2.98e-5	Height;
PAAD	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.88	10.22	0.64	5.53e-19	Adiposity;
PAAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2268667	0.597	rs1403955	chr1:85940105	G/T	cg16011679	chr1:85725395	C1orf52	-0.49	-4.75	-0.36	4.58e-6	Asymmetrical dimethylarginine levels;
PAAD	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.68	0.36	6.23e-6	Neuroticism;
PAAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.17	16.91	0.81	9.48e-37	Cognitive function;
PAAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg19592336	chr6:28129416	ZNF389	0.61	4.3	0.33	3.02e-5	Parkinson's disease;
PAAD	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	3e-7	Migraine;
PAAD	cis	rs4919087	0.590	rs701821	chr10:99038562	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs863345	0.604	rs10908658	chr1:158465256	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.54	-5.03	-0.38	1.37e-6	Multiple myeloma;
PAAD	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26031613	chr14:104095156	KLC1	1.15	16.12	0.79	1e-34	Body mass index;
PAAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg20913747	chr6:44695427	NA	-0.69	-6.9	-0.49	1.29e-10	Total body bone mineral density;
PAAD	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg16576597	chr16:28551801	NUPR1	0.62	6.63	0.47	5.62e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.98	-0.44	1.52e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17906523	chr1:94883536	ABCD3	0.62	6.96	0.49	9.41e-11	Metabolite levels  (X-11787);
PAAD	cis	rs9535307	0.929	rs9535310	chr13:50296026	T/C	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01507833	chr14:74771154	ABCD4	0.57	6.41	0.46	1.7e-9	Smoking initiation;
PAAD	cis	rs4148087	1.000	rs4148094	chr21:43635381	C/T	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg24642844	chr7:1081250	C7orf50	-0.54	-4.92	-0.37	2.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg25319279	chr11:5960081	NA	-0.65	-6.2	-0.45	5.1e-9	DNA methylation (variation);
PAAD	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.52	-5.06	-0.38	1.19e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.82	-0.43	3.34e-8	Lung cancer;
PAAD	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.68	5.59	0.41	1.04e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs2373794	0.583	rs7570522	chr2:40386331	A/G	cg12449404	chr2:40437698	SLC8A1	0.56	4.61	0.35	8.41e-6	Asthma;
PAAD	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg20356878	chr3:121714668	ILDR1	0.49	4.68	0.36	6.18e-6	Cognitive performance;
PAAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.59	0.57	9.51e-15	Menarche (age at onset);
PAAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.71	-7.59	-0.52	3.05e-12	Colorectal cancer;
PAAD	cis	rs2178146	0.512	rs12446923	chr16:86447328	A/G	cg06405820	chr16:86951397	NA	-0.38	-4.44	-0.34	1.74e-5	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
PAAD	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg16322792	chr1:120165303	ZNF697	0.54	7.33	0.51	1.3e-11	Systemic lupus erythematosus;
PAAD	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg00383909	chr3:49044727	WDR6	-0.43	-4.42	-0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.8	-8.48	-0.57	1.89e-14	Coronary artery disease;
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg12705353	chr12:122356852	WDR66	0.48	5.05	0.38	1.25e-6	Mean corpuscular volume;
PAAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg18892244	chr7:807596	HEATR2	-0.69	-5.25	-0.39	4.95e-7	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs73019876	0.901	rs2522089	chr19:22132687	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25147866	chr1:180992098	STX6	0.56	6.29	0.45	3.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.03	-0.44	1.19e-8	Menarche (age at onset);
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg00700412	chr12:58011837	NA	0.42	4.34	0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs3763048	0.889	rs12653623	chr5:169454134	A/G	cg01585372	chr5:169931363	KCNIP1	-0.43	-4.28	-0.33	3.34e-5	IgG glycosylation;
PAAD	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	12.7	0.72	1.23e-25	Colorectal cancer;
PAAD	cis	rs116095464	1.000	rs116095464	chr5:345109	T/C	cg22857025	chr5:266934	NA	-1.1	-5.41	-0.4	2.39e-7	Breast cancer;
PAAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg19680485	chr15:31195859	MTMR15	-0.43	-4.35	-0.33	2.49e-5	Huntington's disease progression;
PAAD	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.72	6.97	0.49	9.19e-11	Hip circumference;
PAAD	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs9359856	0.550	rs1179905	chr6:90322922	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.38	-0.4	2.82e-7	Bipolar disorder;
PAAD	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.5	-5.22	-0.39	5.87e-7	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09516362	chr16:69760459	NQO1	-0.74	-6.71	-0.48	3.63e-10	Neuroticism;
PAAD	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.72	8.72	0.58	4.54e-15	Monocyte percentage of white cells;
PAAD	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.63	6.54	0.47	8.94e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.71	-0.36	5.55e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg25037394	chr1:24152592	HMGCL	-0.4	-4.27	-0.33	3.45e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg25649188	chr17:73499917	CASKIN2	-0.63	-5.89	-0.43	2.42e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs151997	0.649	rs152688	chr5:50211776	C/T	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	5.49	0.41	1.62e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg21905437	chr5:178450457	ZNF879	0.64	5.36	0.4	3.08e-7	Pubertal anthropometrics;
PAAD	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19671926	chr4:122722719	EXOSC9	-0.61	-5.81	-0.43	3.49e-8	Type 2 diabetes;
PAAD	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	6.99	0.49	8.05e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	1.07	14.96	0.77	1.09e-31	Breast cancer;
PAAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs8040855	0.627	rs11630697	chr15:85606445	C/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.52	-5.06	-0.38	1.21e-6	Metabolic traits;
PAAD	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-8.65	-0.57	6.9e-15	Vitiligo;
PAAD	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.42	4.57	0.35	9.9e-6	HDL cholesterol levels;
PAAD	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.34	1.36e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.93	8.82	0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.23	17.36	0.82	6.78e-38	Triglycerides;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.7	-7.26	-0.51	1.84e-11	Metabolic syndrome;
PAAD	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.56	-5.6	-0.41	9.61e-8	Coronary artery disease;
PAAD	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19671926	chr4:122722719	EXOSC9	-0.57	-5.06	-0.38	1.18e-6	Type 2 diabetes;
PAAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	1.27	12.48	0.71	4.69e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.31	-0.76	5.97e-30	Ulcerative colitis;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg13560548	chr3:10150139	C3orf24	0.56	5.0	0.38	1.53e-6	Alzheimer's disease;
PAAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-0.88	-9.59	-0.61	2.52e-17	Body mass index;
PAAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.94	11.16	0.67	1.72e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.94	7.71	0.53	1.52e-12	Tuberculosis;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg22307297	chr20:60903441	LAMA5	-0.42	-4.4	-0.34	2.06e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg20913747	chr6:44695427	NA	-0.62	-7.06	-0.5	5.63e-11	Total body bone mineral density;
PAAD	cis	rs9535307	0.858	rs2025263	chr13:50308847	C/T	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.57	5.38	0.4	2.81e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-4.76	-0.36	4.46e-6	Coronary artery disease;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg02524346	chr8:600233	NA	-1.04	-6.05	-0.44	1.06e-8	IgG glycosylation;
PAAD	cis	rs1723838	0.510	rs2471904	chr11:73690599	G/A	cg10064339	chr11:73693792	UCP2	1.31	5.98	0.44	1.52e-8	Obesity-related traits;
PAAD	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg10223061	chr2:219282414	VIL1	0.4	4.76	0.36	4.48e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs829661	0.790	rs1252651	chr2:30703758	C/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.44	0.34	1.73e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg14092571	chr14:90743983	NA	0.46	4.44	0.34	1.73e-5	Mortality in heart failure;
PAAD	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg01942863	chr7:99769432	GPC2	-0.49	-4.49	-0.34	1.4e-5	Coronary artery disease;
PAAD	cis	rs13424612	1.000	rs66534347	chr2:240899346	G/A	cg01812947	chr2:240904978	NDUFA10	0.58	5.05	0.38	1.22e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs5417	0.636	rs2074217	chr17:7150552	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.71	7.65	0.53	2.12e-12	Diastolic blood pressure;
PAAD	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14180030	chr9:123475675	MEGF9	0.45	5.11	0.38	9.54e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg27411982	chr8:10470053	RP1L1	-0.47	-5.24	-0.39	5.25e-7	Systolic blood pressure;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.92	7.66	0.53	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg09065629	chr16:1709722	CRAMP1L	0.44	4.57	0.35	9.89e-6	Coronary artery disease;
PAAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg25251562	chr2:3704773	ALLC	0.67	7.11	0.5	4.25e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.18	-0.39	6.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg21130718	chr4:1044621	NA	0.53	4.57	0.35	1.02e-5	Recombination rate (females);
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.59	-5.84	-0.43	3.07e-8	Paraoxonase activity;
PAAD	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg12193833	chr17:30244370	NA	-0.5	-4.61	-0.35	8.36e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg12935359	chr14:103987150	CKB	-0.55	-5.72	-0.42	5.53e-8	Body mass index;
PAAD	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg13535736	chr9:111863775	C9orf5	-0.37	-4.47	-0.34	1.51e-5	Menarche (age at onset);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09903262	chr2:106809735	UXS1	-0.66	-6.37	-0.46	2.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs10501293	0.956	rs10837999	chr11:43068860	T/G	cg03447554	chr11:43094025	NA	0.52	5.16	0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.55	-4.95	-0.37	1.93e-6	P wave terminal force;
PAAD	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs11105468	0.659	rs10858966	chr12:90567026	G/C	cg16962463	chr12:89968675	NA	0.42	4.36	0.33	2.37e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07362569	chr17:61921086	SMARCD2	-0.56	-6.73	-0.48	3.18e-10	Prudent dietary pattern;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.58	6.18	0.45	5.66e-9	Lung cancer;
PAAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.82	-6.87	-0.49	1.57e-10	Gut microbiome composition (summer);
PAAD	cis	rs17227506	0.543	rs6981209	chr8:13416666	A/G	cg02718516	chr8:13424094	C8orf48	0.36	4.74	0.36	4.85e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg19052272	chr2:3704530	ALLC	0.57	6.6	0.47	6.44e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs868943	0.582	rs12214665	chr6:116466990	G/A	cg18764771	chr6:116381957	FRK	0.27	4.42	0.34	1.89e-5	Total cholesterol levels;
PAAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg03037974	chr15:76606532	NA	0.52	5.99	0.44	1.46e-8	Blood metabolite levels;
PAAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.36	0.64	2.36e-19	Smoking behavior;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.93	0.37	2.09e-6	Breast cancer;
PAAD	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg04877966	chr15:75135169	ULK3	0.55	4.65	0.35	7.07e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08105174	chr11:100502854	NA	0.55	6.29	0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg03983715	chr16:68378420	PRMT7	-0.7	-5.29	-0.39	4.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.43	-0.4	2.17e-7	Blood metabolite levels;
PAAD	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.92	-0.37	2.19e-6	Thrombosis;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.32	0.46	2.72e-9	Lung cancer;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.69	-7.18	-0.5	2.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg04906043	chr13:21280425	IL17D	-0.5	-4.6	-0.35	9.01e-6	Dental caries;
PAAD	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg19752551	chr11:57585705	CTNND1	-0.54	-4.7	-0.36	5.69e-6	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07704144	chr20:1247415	SNPH	0.62	6.43	0.46	1.59e-9	Myopia (pathological);
PAAD	cis	rs138918	1.000	rs47341	chr22:43560763	C/T	cg00343092	chr22:43547974	TSPO	0.55	6.3	0.46	3.03e-9	Monocyte count;
PAAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14180030	chr9:123475675	MEGF9	-0.45	-5.01	-0.38	1.49e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.47	4.44	0.34	1.73e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4668356	1.000	rs56934523	chr2:171972766	C/T	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs12913538	0.755	rs12915312	chr15:62895475	G/C	cg09983546	chr15:62884068	NA	0.65	6.8	0.48	2.26e-10	Sleep depth;
PAAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.7	-4.98	-0.37	1.72e-6	Monocyte count;
PAAD	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.45	0.46	1.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.13	-0.5	3.79e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	5.86	0.43	2.84e-8	Height;
PAAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.64	6.44	0.46	1.52e-9	Monocyte count;
PAAD	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg23711669	chr6:146136114	FBXO30	-0.88	-9.19	-0.6	2.83e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg07061783	chr6:25882402	NA	-0.53	-5.23	-0.39	5.51e-7	Blood metabolite levels;
PAAD	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-5.34	-0.4	3.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.66	6.55	0.47	8.19e-10	Schizophrenia;
PAAD	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.56	6.1	0.44	8.62e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs17123764	0.710	rs7688	chr12:50157071	T/C	cg14846292	chr12:49726500	C1QL4	-0.66	-4.25	-0.33	3.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg15181151	chr6:150070149	PCMT1	-0.56	-6.07	-0.44	9.75e-9	Lung cancer;
PAAD	cis	rs7922314	0.571	rs77174926	chr10:64720555	G/T	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13582818	chr12:45609227	ANO6;PLEKHA9	0.64	6.38	0.46	2.04e-9	Obesity-related traits;
PAAD	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.77	7.59	0.52	3.01e-12	Corneal astigmatism;
PAAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.76e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.75	-10.12	-0.63	1.04e-18	Iron status biomarkers;
PAAD	cis	rs7246865	0.510	rs11086051	chr19:17168590	A/G	cg19418318	chr19:17219073	MYO9B	0.36	5.23	0.39	5.59e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.55	5.68	0.42	6.51e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg26071806	chr7:100318239	EPO	-0.46	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg18850127	chr7:39170497	POU6F2	0.54	7.85	0.54	6.93e-13	IgG glycosylation;
PAAD	cis	rs950880	0.710	rs11693204	chr2:102935974	G/A	cg23450938	chr2:102972792	NA	0.41	4.55	0.35	1.08e-5	Serum protein levels (sST2);
PAAD	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg00750074	chr16:89608354	SPG7	-0.55	-5.35	-0.4	3.13e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg01966878	chr4:90757139	SNCA	0.45	4.25	0.33	3.73e-5	Dementia with Lewy bodies;
PAAD	cis	rs57244997	0.725	rs67597312	chr6:162411023	A/G	cg17173639	chr6:162384350	PARK2	-0.59	-4.43	-0.34	1.78e-5	Mosquito bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15828558	chr21:34864352	DNAJC28	0.56	6.34	0.46	2.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.46	-4.41	-0.34	1.92e-5	Red blood cell count;
PAAD	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.35e-6	Parkinson's disease;
PAAD	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.55	-0.35	1.11e-5	Lung cancer in ever smokers;
PAAD	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.62	6.73	0.48	3.22e-10	Leprosy;
PAAD	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.61	-5.46	-0.41	1.86e-7	Coronary heart disease;
PAAD	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	trans	rs12714314	0.957	rs11678039	chr2:1951389	G/A	cg17170872	chr1:91487911	ZNF644	-0.75	-6.34	-0.46	2.5e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	5.63	0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.51	-4.67	-0.35	6.61e-6	Response to temozolomide;
PAAD	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17809895	chr20:51589197	TSHZ2	-0.68	-6.78	-0.48	2.56e-10	Lung cancer in ever smokers;
PAAD	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.48	-4.6	-0.35	8.85e-6	Urinary tract infection frequency;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-4.37	-0.33	2.26e-5	Testicular germ cell tumor;
PAAD	cis	rs9652601	0.691	rs6498160	chr16:11199447	T/C	cg04616529	chr16:11181986	CLEC16A	0.38	4.6	0.35	8.82e-6	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.89	9.96	0.63	2.65e-18	Total cholesterol levels;
PAAD	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.93	0.54	4.46e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1007738	0.542	rs10838664	chr11:47203904	G/A	cg19486271	chr11:47235900	DDB2	0.63	5.87	0.43	2.64e-8	Bone mineral density (hip);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21173623	chr9:139685156	TMEM141	0.57	6.36	0.46	2.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.5	-5.35	-0.4	3.11e-7	Alzheimer's disease;
PAAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg18765565	chr5:669397	TPPP	-0.45	-4.84	-0.37	3.16e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg16909742	chr2:127635678	NA	0.82	4.6	0.35	8.77e-6	Heart failure;
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.7	-6.63	-0.47	5.43e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg15192750	chr16:69999425	NA	0.74	5.65	0.42	7.71e-8	IgE levels;
PAAD	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg02876276	chr17:77834299	NA	0.62	4.41	0.34	1.91e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs9810890	1.000	rs74961584	chr3:128567032	T/C	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.91e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.49	4.8	0.36	3.68e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg27398640	chr15:77910606	LINGO1	0.48	4.7	0.36	5.88e-6	Type 2 diabetes;
PAAD	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.89	0.37	2.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg01422370	chr2:73384389	NA	0.35	4.7	0.36	5.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.09e-13	Diastolic blood pressure;
PAAD	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.55	-0.41	1.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.8	-9.95	-0.63	2.77e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs10916814	0.546	rs10799643	chr1:20903181	G/C	cg04087271	chr1:20915334	CDA	0.38	4.66	0.35	6.8e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.62	6.52	0.47	9.64e-10	Multiple sclerosis;
PAAD	cis	rs12476592	0.516	rs1922421	chr2:63592792	G/A	cg10828910	chr2:63850056	LOC388955	0.5	4.33	0.33	2.65e-5	Childhood ear infection;
PAAD	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg12893428	chr3:195717962	SDHAP1	0.45	4.45	0.34	1.65e-5	Pancreatic cancer;
PAAD	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-1.06	-15.43	-0.78	6.27e-33	Total body bone mineral density;
PAAD	cis	rs11955175	1.000	rs78855960	chr5:40657221	C/G	cg17351974	chr5:40835760	RPL37	0.81	4.66	0.35	6.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.64	-9.18	-0.6	2.88e-16	Schizophrenia;
PAAD	cis	rs301801	0.513	rs2708629	chr1:8454792	T/C	cg23262827	chr1:8395557	SLC45A1	-0.46	-4.29	-0.33	3.13e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg18551225	chr6:44695536	NA	-0.64	-7.29	-0.51	1.56e-11	Total body bone mineral density;
PAAD	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	trans	rs901683	1.000	rs35183751	chr10:46081358	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.95	-0.49	1.01e-10	Life satisfaction;
PAAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22601191	chr20:60968625	CABLES2	-0.51	-4.67	-0.35	6.71e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.77	-9.57	-0.61	2.92e-17	Height;
PAAD	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs6700896	0.500	rs67051863	chr1:66114975	G/A	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.07e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.79	-0.53	9.89e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs12738007	0.901	rs755294	chr1:29460759	C/T	cg03512248	chr1:28517610	PTAFR	0.43	4.37	0.33	2.27e-5	Schizophrenia;
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Body mass index;
PAAD	cis	rs7219021	1.000	rs4553671	chr17:46848272	T/C	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.31e-6	Diastolic blood pressure;
PAAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.57	-7.6	-0.52	2.91e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg25233709	chr10:116636983	FAM160B1	0.41	5.05	0.38	1.24e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs7651039	0.641	rs2455810	chr3:15657082	A/T	cg16303742	chr3:15540471	COLQ	0.52	5.41	0.4	2.46e-7	Coronary heart disease;
PAAD	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.53	5.21	0.39	6.17e-7	Parkinson's disease;
PAAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg04106633	chr4:1044584	NA	0.71	5.8	0.43	3.66e-8	Recombination rate (females);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02664162	chr19:49469375	FTL	0.56	6.46	0.46	1.32e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11383747	chr17:260000	C17orf97	0.55	6.4	0.46	1.83e-9	Metabolite levels  (X-11787);
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.74	6.63	0.47	5.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2147959	1.000	rs2147959	chr1:228644232	A/T	cg00655913	chr1:228633920	NA	0.51	4.59	0.35	9.17e-6	Adult asthma;
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg06115741	chr20:33292138	TP53INP2	-0.44	-4.26	-0.33	3.55e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.33	4.71	0.36	5.45e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs4704187	0.640	rs7721018	chr5:74492978	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg15117754	chr3:10150083	C3orf24	0.8	6.09	0.44	9.01e-9	Alzheimer's disease;
PAAD	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg11057378	chr10:81107060	PPIF	0.5	5.87	0.43	2.61e-8	Height;
PAAD	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg08917208	chr2:24149416	ATAD2B	-0.95	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.28	0.39	4.46e-7	Gut microbiome composition (summer);
PAAD	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-4.63	-0.35	7.73e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg04398451	chr17:18023971	MYO15A	0.78	8.56	0.57	1.19e-14	Total body bone mineral density;
PAAD	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg15192750	chr16:69999425	NA	0.71	5.76	0.42	4.52e-8	IgE levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18152809	chr8:42249056	VDAC3	0.65	6.49	0.47	1.17e-9	Primary biliary cholangitis;
PAAD	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.49	4.39	0.34	2.13e-5	Anterior chamber depth;
PAAD	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.56	-6.31	-0.46	2.9e-9	Educational attainment;
PAAD	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08978859	chr3:49066699	IMPDH2	-0.72	-7.68	-0.53	1.76e-12	Smoking initiation;
PAAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18099408	chr3:52552593	STAB1	0.45	4.96	0.37	1.86e-6	Bipolar disorder;
PAAD	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.68	-7.29	-0.51	1.61e-11	Post bronchodilator FEV1;
PAAD	cis	rs79481398	0.616	rs11857296	chr15:57789897	G/A	cg14807837	chr15:57668552	CGNL1	0.72	4.37	0.33	2.32e-5	Facial morphology (factor 19);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14672293	chr2:48542674	FOXN2	-0.62	-6.36	-0.46	2.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17169635	0.579	rs1563047	chr7:134573443	C/G	cg02516134	chr7:134575187	CALD1	0.47	4.6	0.35	9.02e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.61	4.9	0.37	2.48e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg23759393	chr7:158110405	PTPRN2	0.32	4.36	0.33	2.34e-5	Calcium levels;
PAAD	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg04106633	chr4:1044584	NA	0.66	5.57	0.41	1.11e-7	Recombination rate (females);
PAAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.59	-0.41	1.04e-7	Common traits (Other);
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.38	-5.52	-0.41	1.45e-7	Cutaneous nevi;
PAAD	cis	rs2716882	1.000	rs2716882	chr17:5582334	A/G	cg15754901	chr17:5402972	LOC728392	-0.6	-4.53	-0.35	1.17e-5	Gut microbiome composition (summer);
PAAD	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-1.13	-14.27	-0.76	7.42e-30	Height;
PAAD	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1e-7	Life satisfaction;
PAAD	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.43	5.4	0.4	2.49e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-6.13	-0.45	7.07e-9	Pancreatic cancer;
PAAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.67	-4.97	-0.37	1.76e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.39	4.4	0.34	2.06e-5	High light scatter reticulocyte count;
PAAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13770153	chr20:60521292	NA	-0.46	-4.5	-0.34	1.36e-5	Body mass index;
PAAD	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	8.57	0.57	1.1e-14	Homoarginine levels;
PAAD	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-7.84	-0.54	7.36e-13	Prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13971260	chr10:71993216	PPA1	-0.75	-6.82	-0.48	1.96e-10	Neuroticism;
PAAD	cis	rs9810890	1.000	rs115221473	chr3:128547136	T/G	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.67	-5.73	-0.42	5.16e-8	Menarche (age at onset);
PAAD	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.52	4.31	0.33	2.92e-5	Cocaine dependence;
PAAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg25839482	chr15:75931953	IMP3	0.44	4.27	0.33	3.46e-5	Breast cancer;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.52	5.05	0.38	1.24e-6	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18434673	chr17:40333360	KCNH4	0.62	6.81	0.48	2.13e-10	Myopia (pathological);
PAAD	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.77	-8.14	-0.55	1.34e-13	Uric acid clearance;
PAAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.87	8.58	0.57	1.04e-14	Methadone dose in opioid dependence;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06753367	chr22:24256600	NA	-0.45	-4.88	-0.37	2.67e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.95	-9.62	-0.62	2.06e-17	Obesity-related traits;
PAAD	cis	rs1355223	0.902	rs61881050	chr11:34719749	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-4.28	-0.33	3.24e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.77	0.58	3.36e-15	Corneal astigmatism;
PAAD	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.41	-0.52	8.32e-12	Neuroticism;
PAAD	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	4.75	0.36	4.58e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg00262122	chr8:11665843	FDFT1	-0.64	-5.64	-0.42	7.89e-8	Neuroticism;
PAAD	cis	rs758324	0.812	rs601441	chr5:131284433	C/T	cg06307176	chr5:131281290	NA	-0.54	-4.7	-0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg23119463	chr10:134592391	INPP5A	0.53	5.12	0.38	8.98e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg26031613	chr14:104095156	KLC1	0.52	5.52	0.41	1.46e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03043709	chr7:2046920	MAD1L1	0.58	7.03	0.5	6.57e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25971741	chr6:15343116	JARID2	-0.57	-6.46	-0.46	1.31e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.52	0.61	3.74e-17	Bladder cancer;
PAAD	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs909002	0.849	rs7546297	chr1:32106494	A/G	cg13919466	chr1:32135498	COL16A1	-0.4	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.32	-0.56	4.66e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9913156	0.841	rs34230287	chr17:4613630	C/T	cg19197139	chr17:4613644	ARRB2	0.84	8.48	0.57	1.84e-14	Lymphocyte counts;
PAAD	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.62	0.57	8.17e-15	Morning vs. evening chronotype;
PAAD	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.48	-5.11	-0.38	9.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2421770	0.532	rs4756215	chr11:35365963	A/G	cg13971030	chr11:35366721	SLC1A2	-0.56	-5.37	-0.4	2.83e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-4.63	-0.35	7.73e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12379764	chr21:47803548	PCNT	-0.47	-4.44	-0.34	1.7e-5	Testicular germ cell tumor;
PAAD	cis	rs2133450	0.712	rs28571091	chr3:7367231	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs7729447	0.566	rs3792765	chr5:32713836	A/G	cg16267343	chr5:32710456	NPR3	0.49	4.91	0.37	2.32e-6	Blood pressure;
PAAD	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	1.95	10.97	0.66	5.61e-21	Cannabis dependence symptom count;
PAAD	cis	rs7236492	0.572	rs7242868	chr18:77179564	G/A	cg15644404	chr18:77186268	NFATC1	-0.88	-5.17	-0.39	7.25e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg19774624	chr17:42201019	HDAC5	0.71	7.96	0.54	3.75e-13	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.57	7.0	0.49	7.51e-11	Schizophrenia;
PAAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.62	5.08	0.38	1.08e-6	Schizophrenia;
PAAD	cis	rs1468734	0.929	rs3890988	chr16:5006210	G/A	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.53	-4.39	-0.34	2.12e-5	Cancer;
PAAD	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.65	-0.65	3.95e-20	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.65e-6	Alzheimer's disease;
PAAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26994253	chr10:126370282	FAM53B	0.57	6.72	0.48	3.46e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.02	-0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.3	0.33	3.06e-5	Bipolar disorder;
PAAD	cis	rs9463078	0.546	rs1937047	chr6:45048254	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-5.69	-0.42	6.22e-8	Response to antipsychotic treatment;
PAAD	cis	rs7326068	0.610	rs2314719	chr13:21313282	G/A	cg27499820	chr13:21296301	IL17D	0.57	5.34	0.4	3.39e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.79	8.56	0.57	1.19e-14	Neuroticism;
PAAD	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg08345082	chr10:99160200	RRP12	-0.29	-4.25	-0.33	3.67e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.63	0.47	5.6e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.89e-10	Glomerular filtration rate;
PAAD	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg03517284	chr6:25882590	NA	-0.57	-4.69	-0.36	5.96e-6	Iron status biomarkers;
PAAD	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.45	0.4	1.95e-7	Body mass index;
PAAD	cis	rs1532557	1.000	rs73115958	chr1:224774618	A/G	cg09988837	chr1:224811939	CNIH3	0.57	4.47	0.34	1.49e-5	Cancer;
PAAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.98	9.57	0.61	2.84e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.88	0.66	9.62e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs2885056	0.891	rs1821282	chr19:10692714	G/T	cg04833646	chr19:10679720	CDKN2D	0.94	9.15	0.6	3.53e-16	Red cell distribution width;
PAAD	cis	rs11221332	0.938	rs61907765	chr11:128391937	C/T	cg04367216	chr11:128737201	KCNJ1	0.4	4.26	0.33	3.56e-5	Celiac disease;Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.39	-4.34	-0.33	2.57e-5	Prostate cancer;
PAAD	cis	rs6141769	0.542	rs4425162	chr20:31312916	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-7.65	-0.53	2.1e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.39	0.46	1.95e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.574	rs1366067	chr3:134168830	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.63	-0.42	8.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs901683	1.000	rs9422650	chr10:46045761	G/T	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.35	-6.3	-0.46	3e-9	Type 2 diabetes;
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.84	-9.21	-0.6	2.54e-16	Prostate cancer;
PAAD	cis	rs11638352	0.661	rs2696072	chr15:44477381	G/A	cg10011062	chr15:43941034	CATSPER2	-1.21	-4.31	-0.33	2.93e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22338127	chr1:209979572	IRF6	0.54	4.74	0.36	4.9e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10267417	0.603	rs4721835	chr7:19910273	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	4.92	0.37	2.2e-6	Night sleep phenotypes;
PAAD	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg02734326	chr4:10020555	SLC2A9	-0.51	-5.01	-0.38	1.5e-6	Bone mineral density;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg20913747	chr6:44695427	NA	-0.66	-6.53	-0.47	9.28e-10	Total body bone mineral density;
PAAD	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	1.03	9.43	0.61	6.57e-17	Triglycerides;
PAAD	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.13	0.5	3.83e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.88	10.89	0.66	8.96e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.8	0.36	3.83e-6	Breast cancer;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.53	0.34	1.21e-5	Menopause (age at onset);
PAAD	cis	rs12257961	0.521	rs10796281	chr10:15375605	T/G	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs4740619	0.592	rs2987032	chr9:15995559	G/C	cg14451791	chr9:16040625	NA	0.37	4.36	0.33	2.41e-5	Body mass index;
PAAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.83	-9.64	-0.62	1.88e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.8	8.72	0.58	4.5e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.05	-0.67	3.37e-21	Chronic sinus infection;
PAAD	cis	rs59888335	0.858	rs7431697	chr3:80953422	G/A	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.12	-7.95	-0.54	4.01e-13	Mitochondrial DNA levels;
PAAD	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.57	4.96	0.37	1.86e-6	Parkinson's disease;
PAAD	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.81	-0.36	3.65e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs300774	0.925	rs365967	chr2:123233	G/A	cg23649280	chr2:140451	NA	-0.47	-4.33	-0.33	2.74e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs8062405	0.558	rs231976	chr16:28545587	C/G	cg16576597	chr16:28551801	NUPR1	0.51	5.76	0.42	4.51e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07402062	chr16:89894098	SPIRE2	0.37	4.59	0.35	9.1e-6	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05602212	chr5:79703393	ZFYVE16	0.66	7.54	0.52	3.93e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg01028140	chr2:1542097	TPO	-1.02	-9.37	-0.61	9.54e-17	IgG glycosylation;
PAAD	cis	rs41271473	0.687	rs12078883	chr1:228875567	C/T	cg16512390	chr1:228756714	NA	0.56	4.8	0.36	3.76e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	4.73	0.36	5.09e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs883565	0.740	rs11925218	chr3:39081171	C/A	cg01426195	chr3:39028469	NA	-0.7	-7.43	-0.52	7.5e-12	Handedness;
PAAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg17775713	chr3:133465469	TF	-0.47	-5.44	-0.4	2.11e-7	Iron status biomarkers (transferrin levels);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18939117	chr10:103587925	KCNIP2	-0.65	-6.85	-0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.48	-5.04	-0.38	1.33e-6	Calcium levels;
PAAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg21929781	chr1:2537748	MMEL1	-0.49	-5.21	-0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg25204440	chr1:209979598	IRF6	0.58	4.64	0.35	7.34e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-5.8	-0.43	3.72e-8	Cognitive function;
PAAD	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.66	5.0	0.38	1.55e-6	Dialysis-related mortality;
PAAD	cis	rs2249694	0.922	rs8192780	chr10:135354125	T/G	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg11232448	chr19:2858854	NA	-0.5	-4.9	-0.37	2.38e-6	Total cholesterol levels;
PAAD	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.32	6.19	0.45	5.23e-9	Skin colour saturation;
PAAD	cis	rs116248771	0.739	rs6801874	chr3:158347396	C/G	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.79	-0.75	1.47e-28	Primary sclerosing cholangitis;
PAAD	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg08316699	chr6:150357289	NA	0.39	4.38	0.33	2.2e-5	Alopecia areata;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22382663	chr15:68346430	PIAS1	0.73	7.06	0.5	5.71e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4356203	0.792	rs677540	chr11:17213759	A/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg24503407	chr1:205819492	PM20D1	0.53	5.24	0.39	5.26e-7	Parkinson's disease;
PAAD	cis	rs9361491	0.608	rs9352626	chr6:79455091	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01942863	chr7:99769432	GPC2	0.52	4.25	0.33	3.67e-5	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05721253	chr8:37553136	ZNF703	0.64	6.63	0.47	5.44e-10	Myopia (pathological);
PAAD	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs12044355	0.789	rs11589082	chr1:231824656	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	6.09	0.44	8.95e-9	Alzheimer's disease;
PAAD	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.62	-0.35	7.97e-6	Myopia (pathological);
PAAD	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs34734847	0.777	rs555404	chr12:121175984	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-4.67	-0.35	6.56e-6	Mean corpuscular volume;
PAAD	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.59	-5.18	-0.39	6.86e-7	Type 1 diabetes nephropathy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09344943	chr11:65082364	CDC42EP2	-0.73	-6.68	-0.48	4.3e-10	Neuroticism;
PAAD	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.71	5.49	0.41	1.66e-7	Thyroid stimulating hormone;
PAAD	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg12454169	chr2:30669597	LCLAT1	0.68	5.46	0.4	1.91e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg01982873	chr5:490308	SLC9A3	0.43	4.94	0.37	2.04e-6	Cystic fibrosis severity;
PAAD	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.57	-5.55	-0.41	1.22e-7	Chronic sinus infection;
PAAD	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs17152411	1.000	rs41303609	chr10:126670613	G/T	cg07906193	chr10:126599966	NA	0.71	5.66	0.42	7.33e-8	Height;
PAAD	cis	rs4481887	0.538	rs6697831	chr1:248392205	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-4.64	-0.35	7.52e-6	Common traits (Other);
PAAD	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg14440974	chr22:39074834	NA	-0.6	-7.33	-0.51	1.27e-11	Menopause (age at onset);
PAAD	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.64	-8.18	-0.55	1.04e-13	Schizophrenia;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11992162	0.591	rs56001613	chr8:11809480	G/C	cg12395012	chr8:11607386	GATA4	0.43	4.53	0.34	1.21e-5	Monocyte count;
PAAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.98	-8.39	-0.56	3.12e-14	Schizophrenia;
PAAD	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.44	0.68	3.03e-22	Smoking behavior;
PAAD	cis	rs1414896	1.000	rs4146667	chr1:95703597	C/G	cg20701556	chr1:95698924	RWDD3	-0.29	-4.52	-0.34	1.24e-5	Non-alcoholic fatty liver disease histology (AST);
PAAD	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.47	4.73	0.36	5.12e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg17366294	chr4:99064904	C4orf37	0.59	6.3	0.46	3.02e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.94	-0.49	1.08e-10	Coronary artery disease;
PAAD	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.95e-8	HIV-1 control;
PAAD	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg00806126	chr19:22604979	ZNF98	-0.36	-4.57	-0.35	9.87e-6	Pain;
PAAD	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.75	-8.34	-0.56	4.22e-14	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.81	5.26	0.39	4.76e-7	Systolic blood pressure;
PAAD	cis	rs4619890	0.518	rs7689238	chr4:7936605	C/T	cg18538662	chr4:7941764	AFAP1	-0.53	-5.45	-0.4	2.03e-7	Glaucoma (primary open-angle);
PAAD	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.32	0.33	2.85e-5	Total cholesterol levels;
PAAD	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg08514558	chr10:81106712	PPIF	0.46	5.53	0.41	1.36e-7	Height;
PAAD	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-4.98	-0.37	1.74e-6	Pulmonary function;
PAAD	cis	rs11811982	0.793	rs75213165	chr1:227280520	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.48	-5.23	-0.39	5.45e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs705471	0.651	rs705464	chr10:3643035	G/A	cg16819272	chr10:3212304	PITRM1	-0.43	-4.3	-0.33	3.02e-5	Capecitabine sensitivity;
PAAD	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.69	5.66	0.42	7.45e-8	Height;
PAAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.51	-5.07	-0.38	1.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.49	-0.41	1.67e-7	Prostate cancer;
PAAD	cis	rs9815354	1.000	rs9875107	chr3:41822313	A/T	cg03022575	chr3:42003672	ULK4	0.81	6.09	0.44	8.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.0	-12.02	-0.7	7.95e-24	Dilated cardiomyopathy;
PAAD	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg14851346	chr12:38532713	NA	-0.47	-4.49	-0.34	1.4e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg26516362	chr5:178986906	RUFY1	0.5	5.52	0.41	1.46e-7	Lung cancer;
PAAD	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg14361252	chr13:111465457	NA	0.41	4.51	0.34	1.31e-5	White matter hyperintensity burden;
PAAD	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.72	-7.09	-0.5	4.6e-11	Plateletcrit;Platelet count;
PAAD	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg19486271	chr11:47235900	DDB2	-0.53	-5.37	-0.4	2.91e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg16938614	chr7:106685021	PRKAR2B	-0.54	-4.38	-0.33	2.2e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs787274	1.000	rs787294	chr9:115540424	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.45	-0.34	1.68e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.63	-5.9	-0.43	2.24e-8	Breast size;
PAAD	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.65	9.97	0.63	2.47e-18	Asthma (sex interaction);
PAAD	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-4.35	-0.33	2.47e-5	Interleukin-17 levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15249411	chr12:54673020	HNRNPA1;CBX5	0.6	7.25	0.51	1.92e-11	Monocyte percentage of white cells;
PAAD	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.86	-0.43	2.76e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-4.36	-0.33	2.34e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	1.11	9.16	0.6	3.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-1.19	-13.25	-0.73	3.91e-27	Hair shape;
PAAD	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs6710503	0.574	rs62142282	chr2:24780953	C/T	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	7.51	0.52	4.63e-12	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.68	7.02	0.49	7.04e-11	Heart rate;
PAAD	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.58	-4.87	-0.37	2.77e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21016266	chr12:122356598	WDR66	0.6	7.16	0.5	3.24e-11	Mean corpuscular volume;
PAAD	cis	rs375066	0.935	rs406968	chr19:44418343	C/T	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs7264396	0.887	rs6060442	chr20:34093757	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.82	-7.47	-0.52	6.01e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00611818	chr4:78074683	NA	0.61	6.86	0.49	1.59e-10	Smoking initiation;
PAAD	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.6	-0.35	8.93e-6	Bipolar disorder;
PAAD	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.82	-7.95	-0.54	3.89e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg21858823	chr1:15850916	CASP9	0.43	4.51	0.34	1.29e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.34	-5.31	-0.4	3.8e-7	Alcohol dependence;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19483126	chr3:55504238	WNT5A	0.64	6.75	0.48	2.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs939584	0.735	rs62105303	chr2:632922	G/A	cg03610516	chr2:642275	NA	0.59	5.24	0.39	5.32e-7	Body mass index;
PAAD	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg19192590	chr2:178524533	PDE11A	0.43	5.14	0.38	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.33	-4.45	-0.34	1.62e-5	Cutaneous nevi;
PAAD	cis	rs9287719	0.649	rs10184776	chr2:10726446	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg06484146	chr7:12443880	VWDE	-0.63	-4.51	-0.34	1.26e-5	Coronary artery disease;
PAAD	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.94	-0.37	2.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg10932868	chr11:921992	NA	0.45	4.83	0.36	3.34e-6	Alzheimer's disease (late onset);
PAAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg05110241	chr16:68378359	PRMT7	-1.21	-8.53	-0.57	1.37e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.44	-5.57	-0.41	1.15e-7	Lewy body disease;
PAAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg10494973	chr17:80897199	TBCD	0.56	4.53	0.34	1.2e-5	Breast cancer;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.78	-7.82	-0.54	8.29e-13	Menopause (age at onset);
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.6	-6.07	-0.44	9.67e-9	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.82	7.1	0.5	4.46e-11	Alzheimer's disease;
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.61	-6.37	-0.46	2.13e-9	Lung cancer;
PAAD	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.15	0.45	6.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.78	-0.36	4.15e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.84	9.23	0.6	2.21e-16	Schizophrenia;
PAAD	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.51	4.92	0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs939584	1.000	rs12995666	chr2:629959	T/C	cg14515364	chr2:636606	NA	0.52	4.64	0.35	7.49e-6	Body mass index;
PAAD	cis	rs553086	0.592	rs648409	chr11:56910484	A/C	cg01427848	chr11:56972618	NA	0.42	4.28	0.33	3.31e-5	Fear of severe pain;
PAAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.17	13.57	0.74	5.41e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg27455613	chr17:80820699	TBCD	-0.44	-4.35	-0.33	2.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs5753037	0.653	rs140131	chr22:30151716	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg01176363	chr20:62369445	LIME1	-0.58	-5.5	-0.41	1.56e-7	Prostate cancer;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.26	0.33	3.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.23	0.56	7.98e-14	Prudent dietary pattern;
PAAD	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.64	6.95	0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14440974	chr22:39074834	NA	-0.58	-5.33	-0.4	3.41e-7	Menopause (age at onset);
PAAD	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg00922110	chr4:57842668	C4orf14	0.37	4.31	0.33	2.89e-5	Breast cancer;
PAAD	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18024684	chr1:147379964	GJA8	-0.61	-6.62	-0.47	5.78e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22994582	chr6:1774548	GMDS	-0.6	-6.33	-0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs17381785	0.531	rs34479500	chr4:14939389	G/A	cg12377275	chr4:15005593	CPEB2	0.51	4.25	0.33	3.76e-5	Urate levels in overweight individuals;
PAAD	cis	rs508970	0.556	rs507009	chr11:60911922	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.59	0.35	9.05e-6	Rheumatoid arthritis;
PAAD	cis	rs7101378	0.599	rs7927284	chr11:108899563	C/G	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.63	-5.25	-0.39	5.09e-7	Fibrinogen levels;
PAAD	cis	rs1561288	0.639	rs2099598	chr2:25347046	T/C	cg02492873	chr2:25193821	DNAJC27	0.48	4.3	0.33	3.02e-5	Body mass index;
PAAD	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.42	-4.33	-0.33	2.72e-5	Resting heart rate;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.51	-5.15	-0.39	7.9e-7	Subjective well-being;
PAAD	cis	rs901683	0.850	rs76294334	chr10:45964279	T/C	cg16908948	chr10:45500256	ZNF22	0.82	4.35	0.33	2.49e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs4427176	0.598	rs12542420	chr8:9451815	A/G	cg03024720	chr8:9765601	NA	-0.43	-4.47	-0.34	1.5e-5	Mosquito bite size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11271505	chr10:75545666	KIAA0913	-0.72	-7.38	-0.51	9.67e-12	Smoking initiation;
PAAD	cis	rs3734905	1.000	rs73790069	chr6:170026273	G/A	cg11181693	chr6:169825345	NA	-0.85	-5.16	-0.39	7.45e-7	HIV-1 control;
PAAD	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.73	5.14	0.38	8.39e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg17052926	chr7:915758	C7orf20	-0.48	-4.67	-0.35	6.46e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.62	5.08	0.38	1.11e-6	Red blood cell count;
PAAD	cis	rs9810890	1.000	rs73196987	chr3:128453382	A/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.66	-6.5	-0.47	1.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03480067	chr7:148286320	C7orf33	0.71	7.0	0.49	7.76e-11	Lung cancer in ever smokers;
PAAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg25319279	chr11:5960081	NA	0.61	6.1	0.44	8.44e-9	DNA methylation (variation);
PAAD	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs317865	0.737	rs16893153	chr4:16181798	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.88	6.32	0.46	2.71e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg08886695	chr4:3369023	RGS12	-0.48	-4.58	-0.35	9.78e-6	Mean platelet volume;
PAAD	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.94	0.49	1.04e-10	Cognitive ability;
PAAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg01075559	chr1:2537774	MMEL1	-0.5	-5.2	-0.39	6.2e-7	Ulcerative colitis;
PAAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-5.13	-0.38	8.66e-7	Height;
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg05554000	chr7:158905015	VIPR2	0.57	4.99	0.38	1.64e-6	Facial morphology (factor 20);
PAAD	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.28	0.45	3.41e-9	Rheumatoid arthritis;
PAAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.71	6.28	0.45	3.47e-9	Menarche (age at onset);
PAAD	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-4.67	-0.35	6.57e-6	Blood protein levels;
PAAD	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg19402173	chr7:128379420	CALU	-0.64	-7.54	-0.52	3.95e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.7	-0.36	5.73e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg10547527	chr2:198650123	BOLL	-0.72	-4.83	-0.37	3.24e-6	Ulcerative colitis;
PAAD	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.49	4.48	0.34	1.43e-5	Total body bone mineral density;
PAAD	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs1499972	0.941	rs73168388	chr3:117645824	C/T	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.57e-8	Menopause (age at onset);
PAAD	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.76	6.54	0.47	8.75e-10	Pulmonary function decline;
PAAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg03808351	chr9:123631620	PHF19	0.45	4.89	0.37	2.51e-6	Rheumatoid arthritis;
PAAD	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.56	6.75	0.48	2.96e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	1.13	11.88	0.69	1.92e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg14851346	chr12:38532713	NA	-0.46	-4.44	-0.34	1.7e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg24739098	chr15:79297159	RASGRF1	0.34	4.35	0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.73	-9.79	-0.62	7.37e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10023613	chr17:42248099	ASB16	-0.3	-4.28	-0.33	3.35e-5	Total body bone mineral density;
PAAD	cis	rs7896729	1.000	rs7921213	chr10:5355475	T/C	cg07902545	chr10:6194255	PFKFB3	-0.41	-4.37	-0.33	2.32e-5	Intelligence;
PAAD	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.56	-5.43	-0.4	2.2e-7	Cancer;
PAAD	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.19	-0.45	5.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2133450	0.724	rs1858061	chr3:7361210	C/A	cg19930620	chr3:7340148	GRM7	-0.43	-4.53	-0.34	1.2e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg10820045	chr2:198174542	NA	-0.44	-4.4	-0.34	2.03e-5	Dermatomyositis;
PAAD	trans	rs225245	0.782	rs225272	chr17:33969911	T/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs728616	0.558	rs35698456	chr10:82141562	C/G	cg19423196	chr10:82049429	MAT1A	0.47	4.67	0.35	6.59e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	1.04	7.21	0.5	2.51e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg13918804	chr1:2043761	PRKCZ	-0.39	-5.23	-0.39	5.56e-7	Height;
PAAD	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg12696750	chr1:38022466	DNALI1	0.47	4.34	0.33	2.54e-5	Axial length;
PAAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs9467160	0.765	rs793712	chr6:24446882	T/C	cg16211469	chr6:24423932	MRS2	-0.5	-4.85	-0.37	3.02e-6	Liver enzyme levels;
PAAD	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg09659197	chr4:152720779	NA	0.37	5.26	0.39	4.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg11757124	chr7:157526947	PTPRN2	-0.58	-5.53	-0.41	1.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg19847866	chr10:1019161	NA	-0.6	-4.67	-0.35	6.54e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.62	6.69	0.48	3.97e-10	High light scatter reticulocyte count;
PAAD	cis	rs6496044	0.507	rs410522	chr15:86207044	G/T	cg13263323	chr15:86062960	AKAP13	0.5	5.33	0.4	3.45e-7	Interstitial lung disease;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg00280220	chr17:61926910	NA	0.42	4.5	0.34	1.33e-5	Prudent dietary pattern;
PAAD	cis	rs7011192	0.793	rs11774104	chr8:10526434	C/G	cg25377605	chr8:10513717	RP1L1	-0.7	-5.11	-0.38	9.37e-7	Suicide;
PAAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs12458462	0.851	rs62097746	chr18:77487508	G/A	cg01267373	chr18:77410094	NA	0.42	4.34	0.33	2.54e-5	Monocyte count;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.69	-7.17	-0.5	3.11e-11	Menopause (age at onset);
PAAD	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.51	4.63	0.35	7.95e-6	Height;
PAAD	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.34	-0.33	2.62e-5	Height;
PAAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.55	-5.28	-0.39	4.47e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg12927641	chr6:109611667	NA	-0.41	-4.37	-0.33	2.32e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg05110241	chr16:68378359	PRMT7	-0.72	-4.88	-0.37	2.64e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	4.26	0.33	3.56e-5	Acylcarnitine levels;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs1355223	0.573	rs7125773	chr11:34723573	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.43	4.3	0.33	3.1e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.67	5.76	0.42	4.54e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.64	6.84	0.49	1.77e-10	Mean corpuscular volume;
PAAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.58	6.07	0.44	1e-8	Longevity;
PAAD	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.29	-5.2	-0.39	6.37e-7	Type 2 diabetes;
PAAD	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.68	4.68	0.35	6.36e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4979906	1.000	rs1609790	chr10:79464078	C/T	cg07817648	chr10:79422355	NA	-0.6	-5.49	-0.41	1.69e-7	Mortality in heart failure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25623174	chr19:1487019	PCSK4	0.63	6.43	0.46	1.58e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-6.33	-0.46	2.65e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	trans	rs901683	0.850	rs79529960	chr10:46045315	C/T	cg13065504	chr15:42448234	PLA2G4F	0.81	6.49	0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2637266	0.783	rs7914756	chr10:78476406	A/T	cg18941641	chr10:78392320	NA	-0.36	-4.33	-0.33	2.66e-5	Pulmonary function;
PAAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.45	-4.76	-0.36	4.54e-6	Dementia with Lewy bodies;
PAAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.46	-4.76	-0.36	4.56e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11264799	0.681	rs72708390	chr1:157688796	A/G	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg18815343	chr6:28367644	ZSCAN12	0.58	5.27	0.39	4.66e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.83	9.73	0.62	1.1e-17	Breast cancer;
PAAD	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg27449745	chr7:23145252	KLHL7	-0.53	-4.71	-0.36	5.65e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg14092988	chr3:52407081	DNAH1	0.45	5.44	0.4	2.12e-7	Bipolar disorder;
PAAD	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg03115019	chr17:80708279	FN3K	0.49	4.44	0.34	1.75e-5	Glycated hemoglobin levels;
PAAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg00969815	chr22:42536375	CYP2D7P1	0.5	4.29	0.33	3.2e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.54	-5.39	-0.4	2.68e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.82	0.36	3.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg02841227	chr6:26021843	HIST1H4A	0.5	4.91	0.37	2.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6714788	0.565	rs9308833	chr2:100662618	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-4.49	-0.34	1.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.63	7.18	0.5	2.84e-11	High light scatter reticulocyte count;
PAAD	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg08992911	chr2:238395768	MLPH	0.57	5.07	0.38	1.14e-6	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25024515	chr12:124763658	NA	0.64	6.75	0.48	3e-10	Smoking initiation;
PAAD	cis	rs8112211	0.691	rs77912794	chr19:38808512	A/G	cg14299480	chr19:38876666	GGN	-0.51	-6.49	-0.47	1.17e-9	Blood protein levels;
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-7.32	-0.51	1.33e-11	Menarche (age at onset);
PAAD	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs427943	0.864	rs2838815	chr21:46629590	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	4.4	0.34	2.06e-5	Body mass index;
PAAD	cis	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg04359915	chr10:101825029	CPN1	-0.36	-5.62	-0.42	8.71e-8	Bone mineral density;
PAAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.42	4.28	0.33	3.23e-5	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs7072216	0.687	rs7924303	chr10:100155963	C/T	cg19567339	chr10:100142640	NA	-0.41	-4.34	-0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6782025	0.837	rs1191310	chr3:120897521	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.52	-0.41	1.42e-7	Personality dimensions;
PAAD	cis	rs6594713	0.717	rs2914198	chr5:112950253	C/G	cg12552261	chr5:112820674	MCC	-0.77	-5.52	-0.41	1.42e-7	Brain cytoarchitecture;
PAAD	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg09491104	chr22:46646882	C22orf40	-0.98	-8.69	-0.58	5.27e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg00129232	chr17:37814104	STARD3	-0.53	-4.46	-0.34	1.56e-5	Self-reported allergy;
PAAD	cis	rs3106136	0.609	rs11097407	chr4:95146135	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.15	-0.45	6.55e-9	Capecitabine sensitivity;
PAAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-8.64	-0.57	7.33e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg16316162	chr8:144660157	NAPRT1	0.86	4.54	0.35	1.15e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs59888335	0.929	rs17391539	chr3:80827422	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.55	5.11	0.38	9.57e-7	Resting heart rate;
PAAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs75920871	1.000	rs7125788	chr11:116883396	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs939584	1.000	rs7567368	chr2:645082	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.35	-0.56	3.87e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2457480	0.602	rs17155641	chr10:44708346	A/G	cg09554077	chr10:44749378	NA	0.34	4.87	0.37	2.81e-6	Coronary artery disease;
PAAD	cis	rs1542829	0.540	rs12485492	chr3:130179966	C/G	cg03541853	chr3:129408948	TMCC1	0.68	4.56	0.35	1.03e-5	Body mass index;
PAAD	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.66	7.69	0.53	1.75e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	4.81	0.36	3.63e-6	Hirschsprung disease;
PAAD	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg22517653	chr1:2918612	NA	-0.59	-5.32	-0.4	3.57e-7	Plateletcrit;
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	6.17	0.45	5.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg08088566	chr11:430123	ANO9	0.92	5.53	0.41	1.36e-7	Body mass index;
PAAD	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg13540341	chr19:49222985	MAMSTR	0.44	5.13	0.38	8.68e-7	Dietary macronutrient intake;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.97	0.44	1.58e-8	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.06e-8	Life satisfaction;
PAAD	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.67	6.98	0.49	8.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.44	0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8077577	0.895	rs16960980	chr17:18100858	C/T	cg16794390	chr17:18148240	FLII	0.59	4.81	0.36	3.56e-6	Obesity-related traits;
PAAD	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs137887	1.000	rs137887	chr22:50464439	C/G	cg23116504	chr22:50470537	TTLL8	-0.49	-5.0	-0.38	1.56e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg02440177	chr19:53496695	ZNF702P	-0.63	-6.63	-0.47	5.64e-10	Psoriasis;
PAAD	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.59e-7	Lung cancer;
PAAD	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.45	-0.34	1.64e-5	Morning vs. evening chronotype;
PAAD	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19700328	chr14:106028568	NA	-0.63	-6.08	-0.44	9.29e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	trans	rs5417	0.627	rs62059170	chr17:7155056	T/C	cg15655154	chr3:113604241	GRAMD1C	-0.66	-6.6	-0.47	6.48e-10	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4729127	1.000	rs4729127	chr7:94008535	A/G	cg20814616	chr7:94014465	NA	-0.6	-4.41	-0.34	1.96e-5	Intelligence;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.61	4.51	0.34	1.27e-5	Fat distribution (HIV);
PAAD	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.56	5.12	0.38	9.26e-7	Type 2 diabetes;
PAAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-4.38	-0.33	2.22e-5	Monocyte count;
PAAD	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.35	-0.46	2.39e-9	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg11262906	chr1:85462892	MCOLN2	0.61	5.04	0.38	1.32e-6	Serum sulfate level;
PAAD	cis	rs7094131	0.523	rs10828322	chr10:22876002	G/A	cg19500236	chr10:22911537	PIP4K2A	0.44	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg14003231	chr6:33640908	ITPR3	0.37	4.75	0.36	4.59e-6	Plateletcrit;
PAAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.74	0.62	1.01e-17	Total body bone mineral density;
PAAD	cis	rs904092	0.554	rs4699733	chr4:100137534	G/C	cg12011299	chr4:100065546	ADH4	-0.53	-5.19	-0.39	6.54e-7	Alcohol dependence;
PAAD	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-7.34	-0.51	1.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-8.37	-0.56	3.59e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.77	-5.48	-0.41	1.74e-7	Yeast infection;
PAAD	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg14343924	chr8:8086146	FLJ10661	-0.63	-5.49	-0.41	1.68e-7	Mood instability;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs9900972	0.918	rs6501258	chr17:76877824	T/A	cg20937029	chr17:76870563	TIMP2	0.59	5.35	0.4	3.2e-7	Obesity-related traits;
PAAD	cis	rs2456568	0.695	rs877341	chr11:93689293	C/T	cg19264203	chr11:92714893	MTNR1B	-0.43	-4.88	-0.37	2.63e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.13	-0.67	2.08e-21	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.62	5.8	0.43	3.72e-8	Coronary artery disease;
PAAD	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.67	5.17	0.39	7.41e-7	Menarche (age at onset);
PAAD	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg15193198	chr20:60906057	LAMA5	0.59	6.6	0.47	6.57e-10	Colorectal cancer;
PAAD	cis	rs7301016	0.707	rs11174588	chr12:63052601	G/T	cg11441379	chr12:63026424	NA	0.83	5.95	0.43	1.8e-8	IgG glycosylation;
PAAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14895029	chr7:2775587	GNA12	-0.45	-4.33	-0.33	2.73e-5	Height;
PAAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19784903	chr17:45786737	TBKBP1	-0.5	-5.27	-0.39	4.58e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05329982	chr11:62359210	TUT1	0.58	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.64	6.16	0.45	6.21e-9	Uric acid clearance;
PAAD	cis	rs16966142	0.786	rs2238533	chr16:89871344	T/C	cg26513180	chr16:89883248	FANCA	0.76	5.41	0.4	2.45e-7	Caffeine consumption;
PAAD	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-4.55	-0.35	1.08e-5	Chronic sinus infection;
PAAD	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04731861	chr2:219085781	ARPC2	0.36	4.33	0.33	2.74e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs910187	1.000	rs910187	chr20:45841052	A/G	cg27589058	chr20:45804311	EYA2	0.47	4.79	0.36	3.9e-6	Migraine;
PAAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.69	7.22	0.51	2.3e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs72829446	0.530	rs7215056	chr17:7350050	C/A	cg07168214	chr17:7380112	ZBTB4	-0.65	-5.81	-0.43	3.58e-8	Androgen levels;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-1.1	-11.65	-0.69	7.97e-23	Longevity;
PAAD	cis	rs7809615	0.748	rs34257469	chr7:99150185	T/C	cg12290671	chr7:99195819	NA	-0.91	-5.21	-0.39	6.19e-7	Blood metabolite ratios;
PAAD	cis	rs7662987	0.938	rs28730592	chr4:100003743	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-4.25	-0.33	3.73e-5	Smoking initiation;
PAAD	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.46	-4.55	-0.35	1.1e-5	Asthma (bronchodilator response);
PAAD	cis	rs72634258	0.519	rs35197830	chr1:7930983	A/G	cg26816564	chr1:7831052	VAMP3	0.86	7.05	0.5	5.76e-11	Inflammatory bowel disease;
PAAD	cis	rs7631605	0.819	rs1392748	chr3:37265313	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.28	0.33	3.33e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.48	4.5	0.34	1.36e-5	Breast cancer;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg21565972	chr17:80109576	CCDC57	-0.6	-6.97	-0.49	8.88e-11	Life satisfaction;
PAAD	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.54	-0.35	1.16e-5	Pulmonary function;
PAAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.73	-6.1	-0.44	8.39e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg23131131	chr22:24373011	LOC391322	-0.49	-4.61	-0.35	8.59e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.75	7.41	0.52	8e-12	Response to diuretic therapy;
PAAD	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	4.47	0.34	1.51e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg08992911	chr2:238395768	MLPH	0.59	5.64	0.42	8.14e-8	Prostate cancer;
PAAD	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-4.62	-0.35	8.08e-6	Joint mobility (Beighton score);
PAAD	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-5.2	-0.39	6.22e-7	Chronic sinus infection;
PAAD	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.71	8.93	0.59	1.32e-15	Dupuytren's disease;
PAAD	cis	rs6466055	0.661	rs1468359	chr7:104922022	C/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs12935418	0.616	rs2549854	chr16:81026639	C/T	cg16651780	chr16:81037892	C16orf61	0.63	5.74	0.42	4.94e-8	Mean corpuscular volume;
PAAD	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06771106	chr2:113671356	IL1F7	0.61	6.61	0.47	6.25e-10	Pulmonary function;
PAAD	cis	rs375066	0.901	rs451945	chr19:44408753	T/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.77	0.48	2.59e-10	Height;
PAAD	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.48	6.82	0.48	1.97e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.75	-0.36	4.6e-6	Bipolar disorder;
PAAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.68	5.06	0.38	1.22e-6	Yeast infection;
PAAD	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs4759375	0.667	rs28655516	chr12:123879975	T/C	cg05908960	chr12:123472150	PITPNM2	0.69	4.41	0.34	1.95e-5	HDL cholesterol;
PAAD	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.42	0.4	2.32e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.66	6.27	0.45	3.54e-9	Corneal astigmatism;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	4.84	0.37	3.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20167471	chr1:16528984	ARHGEF19	-0.46	-4.49	-0.34	1.4e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	5.45	0.4	2.02e-7	Joint mobility (Beighton score);
PAAD	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg10437265	chr15:77819839	NA	0.41	4.32	0.33	2.76e-5	Type 2 diabetes;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18654873	chr6:91296666	MAP3K7	0.5	5.63	0.42	8.3e-8	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20005934	chr14:100706390	YY1	0.59	6.55	0.47	8.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.52	-4.61	-0.35	8.58e-6	Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15861578	chr12:56511939	ZC3H10	0.58	6.68	0.48	4.33e-10	Metabolite levels  (X-11787);
PAAD	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg01953289	chr20:60874239	NA	0.69	5.12	0.38	9.17e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.58	6.25	0.45	3.85e-9	Lung cancer;
PAAD	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.62	-5.95	-0.43	1.79e-8	Mean corpuscular volume;
PAAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.67	5.24	0.39	5.29e-7	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.43	-5.65	-0.42	7.52e-8	Alcohol dependence;
PAAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg23281280	chr6:28129359	ZNF389	0.51	4.33	0.33	2.75e-5	Parkinson's disease;
PAAD	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg03482866	chr13:111040579	COL4A2	0.44	4.27	0.33	3.46e-5	White matter hyperintensity burden;
PAAD	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-4.54	-0.35	1.12e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.74e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg10494973	chr17:80897199	TBCD	-0.54	-5.04	-0.38	1.34e-6	Breast cancer;
PAAD	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg21518248	chr2:162101506	NA	-0.51	-5.47	-0.41	1.78e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.11	0.38	9.63e-7	Birth weight;
PAAD	cis	rs7084921	0.552	rs11598495	chr10:101889417	T/C	cg04359915	chr10:101825029	CPN1	-0.3	-4.39	-0.34	2.11e-5	Bone mineral density;
PAAD	cis	rs73416724	0.920	rs76088627	chr6:43311851	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs28489187	0.666	rs233132	chr1:85796545	A/G	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.3e-6	Calcium levels;
PAAD	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.51	4.64	0.35	7.5e-6	Life satisfaction;
PAAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19346786	chr7:2764209	NA	-0.39	-5.35	-0.4	3.25e-7	Height;
PAAD	trans	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg01957732	chr6:133561716	EYA4	-0.96	-7.02	-0.49	7.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.74	8.46	0.57	2.05e-14	Age-related hearing impairment;
PAAD	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg20761395	chr17:511517	VPS53	0.59	6.26	0.45	3.71e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.16	-0.45	6.13e-9	Height;
PAAD	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg15660573	chr17:549704	VPS53	-0.77	-7.54	-0.52	3.88e-12	Prostate cancer;
PAAD	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.03	-0.55	2.53e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11264799	0.603	rs7520627	chr1:157568371	A/T	cg18268488	chr1:157545234	FCRL4	0.45	5.15	0.39	7.88e-7	IgA nephropathy;
PAAD	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.68	-4.57	-0.35	9.92e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg09659197	chr4:152720779	NA	0.36	5.3	0.39	3.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs6715793	0.901	rs5006126	chr2:33405465	A/T	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.42	-4.3	-0.33	3.1e-5	Response to statin therapy;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs9422658	chr10:46059667	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Body mass index;
PAAD	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg20243544	chr17:37824526	PNMT	0.52	4.52	0.34	1.25e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.65	-0.47	4.95e-10	Total body bone mineral density;
PAAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.33	0.33	2.73e-5	Personality dimensions;
PAAD	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs12780845	0.931	rs3758418	chr10:17245638	G/C	cg00857480	chr10:17188594	TRDMT1	0.34	4.28	0.33	3.32e-5	Homocysteine levels;
PAAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg26205652	chr12:48591994	NA	0.91	9.04	0.59	6.64e-16	Longevity (90 years and older);
PAAD	cis	rs593531	0.571	rs11236088	chr11:74094343	A/G	cg15851278	chr11:73669449	DNAJB13	-0.36	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.57	-5.69	-0.42	6.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18621852	chr3:10150065	C3orf24	-0.59	-5.23	-0.39	5.5e-7	Alzheimer's disease;
PAAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.87	-9.62	-0.62	2.08e-17	Body mass index;
PAAD	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg16596103	chr2:233749413	NGEF	0.4	4.25	0.33	3.67e-5	Schizophrenia;
PAAD	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.75	-8.55	-0.57	1.23e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7627468	0.909	rs9821555	chr3:121942302	T/G	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs1012068	1.000	rs1012068	chr22:32265903	A/C	cg01338084	chr22:32026380	PISD	0.62	5.86	0.43	2.83e-8	Chronic hepatitis C infection;
PAAD	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg00717180	chr2:96193071	NA	0.59	6.46	0.46	1.32e-9	HDL cholesterol;
PAAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.9	0.49	1.32e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7953508	0.741	rs12312736	chr12:93997264	C/G	cg18151635	chr12:93972918	NA	-0.56	-5.71	-0.42	5.65e-8	Pubertal anthropometrics;
PAAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	1.25	10.17	0.64	7.4e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-5.38	-0.4	2.73e-7	Reticulocyte count;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15287987	chr7:118004330	NA	-0.57	-6.9	-0.49	1.29e-10	Energy expenditure (24h);
PAAD	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	11.31	0.68	6.64e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg23112188	chr14:24563095	PCK2	-0.5	-5.54	-0.41	1.31e-7	IgG glycosylation;
PAAD	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg23254163	chr1:152506842	NA	0.56	6.01	0.44	1.3e-8	Hair morphology;
PAAD	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	6.39	0.46	1.94e-9	Body mass index;
PAAD	cis	rs8017423	0.605	rs2149652	chr14:90813429	T/C	cg14092571	chr14:90743983	NA	0.46	4.36	0.33	2.36e-5	Mortality in heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20865048	chr2:196570925	SLC39A10	0.53	6.32	0.46	2.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6604026	0.740	rs6604031	chr1:93400766	T/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.25	-0.33	3.74e-5	Multiple sclerosis;
PAAD	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	4.7	0.36	5.72e-6	IgG glycosylation;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs829661	0.793	rs2602767	chr2:30853300	A/G	cg12454169	chr2:30669597	LCLAT1	-0.63	-4.39	-0.34	2.15e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg09659197	chr4:152720779	NA	0.42	5.09	0.38	1.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg25364880	chr3:44379878	C3orf23	0.63	5.79	0.42	4e-8	Depressive symptoms;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07722505	chr6:26458093	BTN2A1	0.65	7.54	0.52	3.9e-12	Metabolite levels  (X-11787);
PAAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.74	-7.24	-0.51	2.09e-11	Urate levels in lean individuals;
PAAD	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg18721089	chr20:30220636	NA	-0.6	-5.01	-0.38	1.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	cis	rs11997175	0.935	rs3903385	chr8:33687399	T/G	ch.8.33884649F	chr8:33765107	NA	0.68	7.9	0.54	5.34e-13	Body mass index;
PAAD	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg06057569	chr22:50219754	BRD1	0.57	4.43	0.34	1.8e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6508941	0.550	rs10413521	chr19:41023511	C/T	cg26971411	chr19:41016501	SPTBN4	-0.45	-4.56	-0.35	1.06e-5	Antibody level in response to infection;
PAAD	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.58	5.57	0.41	1.14e-7	Platelet count;
PAAD	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.42	6.19	0.45	5.32e-9	Migraine;
PAAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.54	4.62	0.35	8.03e-6	Height;
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg24879335	chr3:133465180	TF	0.58	6.58	0.47	7.25e-10	Iron status biomarkers;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs901683	0.850	rs112997714	chr10:46097216	A/G	cg07935355	chr19:50391064	TBC1D17	1.11	6.3	0.46	2.98e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7901135	0.962	rs4344442	chr10:60577393	A/G	cg22639768	chr10:61122535	FAM13C	-0.58	-4.4	-0.34	2.01e-5	Morning vs. evening chronotype;
PAAD	cis	rs1329189	1.000	rs6482666	chr10:129994790	G/T	cg17972361	chr10:130010134	NA	-0.46	-4.79	-0.36	3.99e-6	Orofacial clefts;
PAAD	cis	rs12946454	0.521	rs4559944	chr17:43260880	A/G	cg10701640	chr17:43249399	NA	-0.65	-8.77	-0.58	3.4e-15	Systolic blood pressure;
PAAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg12046867	chr14:103022105	NA	-0.62	-4.84	-0.37	3.14e-6	Platelet count;
PAAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-6.27	-0.45	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs73019876	0.836	rs8108535	chr19:22160304	T/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.56	-5.21	-0.39	5.95e-7	Obesity-related traits;
PAAD	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.32	0.33	2.76e-5	Educational attainment;
PAAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg19337854	chr7:99768885	GPC2	-0.41	-4.44	-0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.43	-5.32	-0.4	3.73e-7	Rheumatoid arthritis;
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2236267	0.726	rs1940551	chr14:88603859	T/C	cg18078958	chr14:88630771	NA	-0.51	-6.44	-0.46	1.51e-9	Food antigen IgG levels;
PAAD	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg10208897	chr5:178548229	ADAMTS2	0.55	4.99	0.38	1.6e-6	Pubertal anthropometrics;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-4.97	-0.37	1.79e-6	Longevity;Endometriosis;
PAAD	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg04176122	chr11:118779835	BCL9L	0.43	4.46	0.34	1.57e-5	Sjögren's syndrome;
PAAD	cis	rs11825685	0.945	rs77292504	chr11:134572985	G/A	cg06603561	chr11:134479413	NA	-0.74	-4.77	-0.36	4.2e-6	IgG glycosylation;
PAAD	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg00677455	chr12:58241039	CTDSP2	0.47	4.79	0.36	3.9e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.06	0.38	1.2e-6	Personality dimensions;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14639822	chr9:136131484	ABO	0.54	6.3	0.46	3.02e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.27	-0.33	3.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.75	7.31	0.51	1.44e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.95	-8.33	-0.56	4.42e-14	Bipolar disorder;
PAAD	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs1144333	0.655	rs1361487	chr1:76430471	A/C	cg22875332	chr1:76189707	ACADM	0.76	4.49	0.34	1.38e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.53	5.0	0.38	1.56e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg10645314	chr2:3704589	ALLC	-0.53	-5.61	-0.41	9.31e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.45e-7	Pulmonary function;
PAAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.72	7.64	0.53	2.26e-12	Obesity-related traits;
PAAD	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg00614314	chr15:82944287	LOC80154	-0.54	-5.47	-0.41	1.79e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-1.06	-10.04	-0.63	1.65e-18	IgG glycosylation;
PAAD	cis	rs7551345	0.853	rs12135033	chr1:31772492	T/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg07166546	chr14:35805898	NA	-0.31	-4.75	-0.36	4.6e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	1.14	13.17	0.73	6.45e-27	Eosinophil percentage of granulocytes;
PAAD	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21016266	chr12:122356598	WDR66	0.64	6.97	0.49	9.08e-11	Mean corpuscular volume;
PAAD	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.49	-4.61	-0.35	8.6e-6	Hepatocellular carcinoma;
PAAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.54	5.25	0.39	4.98e-7	Aortic root size;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13560548	chr3:10150139	C3orf24	0.58	5.12	0.38	9.02e-7	Alzheimer's disease;
PAAD	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	4.65	0.35	7.02e-6	Thyroid stimulating hormone;
PAAD	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg10578991	chr7:12443926	VWDE	-0.66	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03466779	chr4:7666141	SORCS2	-0.51	-6.46	-0.46	1.32e-9	Monocyte percentage of white cells;
PAAD	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-5.71	-0.42	5.73e-8	Schizophrenia;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.72	-5.45	-0.4	1.97e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg07061783	chr6:25882402	NA	-0.48	-4.35	-0.33	2.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.54	4.88	0.37	2.61e-6	Anterior chamber depth;
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg01206211	chr2:36825736	FEZ2	0.65	6.76	0.48	2.71e-10	Height;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg25204440	chr1:209979598	IRF6	-0.45	-4.8	-0.36	3.82e-6	Monobrow;
PAAD	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.85	-0.37	3.08e-6	Parkinson's disease;
PAAD	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg00543991	chr22:32367038	NA	1.08	6.43	0.46	1.56e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7771547	0.723	rs7760766	chr6:36552685	G/T	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27436995	chr16:743998	FBXL16	-0.36	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg13870426	chr17:30244630	NA	-0.76	-5.7	-0.42	5.96e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7202877	0.706	rs11149812	chr16:75323645	T/C	cg03315344	chr16:75512273	CHST6	0.56	4.75	0.36	4.65e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.22	-0.51	2.37e-11	Cognitive function;
PAAD	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg21905437	chr5:178450457	ZNF879	-0.6	-5.0	-0.38	1.55e-6	Pubertal anthropometrics;
PAAD	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.6	-0.35	8.85e-6	Type 2 diabetes;
PAAD	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.57	-4.94	-0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.53	6.1	0.44	8.31e-9	Prostate cancer;
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.78	-8.72	-0.58	4.43e-15	Height;
PAAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.93	8.11	0.55	1.53e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg10977910	chr1:84465055	TTLL7	0.51	4.6	0.35	8.87e-6	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg05785598	chr3:49045655	WDR6	0.44	5.26	0.39	4.73e-7	Parkinson's disease;
PAAD	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg03989125	chr22:38214979	NA	-0.65	-6.83	-0.48	1.89e-10	Glioblastoma;Glioma;
PAAD	cis	rs7631605	0.875	rs55898028	chr3:37248337	A/G	cg17445812	chr3:36986805	TRANK1	0.36	4.71	0.36	5.58e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7551345	0.851	rs10914330	chr1:31691577	A/C	cg17086398	chr1:31896392	SERINC2	0.47	4.27	0.33	3.47e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-7.06	-0.5	5.51e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg20243544	chr17:37824526	PNMT	0.53	4.57	0.35	9.86e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg23153227	chr6:27725408	NA	0.49	4.67	0.35	6.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg06138931	chr13:21896616	NA	0.75	5.58	0.41	1.05e-7	White matter hyperintensity burden;
PAAD	cis	rs2072732	0.656	rs113272167	chr1:2954051	C/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.4	0.34	2.01e-5	Plateletcrit;
PAAD	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.05	0.38	1.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6782025	0.837	rs339000	chr3:120969322	T/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7809615	0.901	rs10215765	chr7:99101280	G/C	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-5.76	-0.42	4.58e-8	Body mass index (adult);
PAAD	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.8	-9.9	-0.63	3.89e-18	Hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20729316	chr21:33104864	SFRS15	0.58	6.31	0.46	2.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.8	8.58	0.57	1.05e-14	Caffeine consumption;
PAAD	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg27005118	chr17:13972210	COX10	-0.41	-5.62	-0.41	8.84e-8	Temperament;
PAAD	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.64	6.17	0.45	6.05e-9	Corneal astigmatism;
PAAD	cis	rs743757	1.000	rs2236983	chr3:50490244	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.69	4.62	0.35	8.18e-6	Diastolic blood pressure;
PAAD	cis	rs1035491	0.753	rs10059137	chr5:63931133	C/T	cg01791865	chr5:63954708	NA	0.44	4.55	0.35	1.08e-5	Body mass index;
PAAD	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg21466736	chr12:48725269	NA	-0.5	-4.65	-0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs6137287	0.924	rs2328609	chr20:21156578	T/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.97	8.11	0.55	1.6e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.88	-6.83	-0.48	1.89e-10	Psoriasis;
PAAD	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg13468214	chr4:1046988	NA	-0.56	-6.07	-0.44	9.73e-9	Recombination rate (males);
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.67	-7.16	-0.5	3.29e-11	Dupuytren's disease;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.38	-9.61	-0.61	2.2e-17	Diabetic retinopathy;
PAAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg23033748	chr14:75592666	NEK9	0.43	5.26	0.39	4.83e-7	Height;
PAAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.38	0.4	2.71e-7	Schizophrenia;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg08513622	chr7:1889785	MAD1L1	-0.47	-4.31	-0.33	2.96e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.47	-4.66	-0.35	6.87e-6	Type 2 diabetes;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs859767	0.679	rs1104801	chr2:135436601	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.39	-0.34	2.11e-5	Neuroticism;
PAAD	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.78	7.13	0.5	3.8e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
PAAD	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	5.62	0.42	8.68e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg14146966	chr2:61757674	XPO1	0.39	4.81	0.36	3.55e-6	Tuberculosis;
PAAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.48	-5.24	-0.39	5.23e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.57	-0.41	1.1e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	5.55	0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.47	4.85	0.37	3.02e-6	Blood metabolite levels;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg02875869	chr16:89901417	SPIRE2	-0.71	-5.83	-0.43	3.22e-8	Vitiligo;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-6.27	-0.45	3.55e-9	Lymphocyte counts;
PAAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.49e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg15117754	chr3:10150083	C3orf24	0.76	6.57	0.47	7.57e-10	Alzheimer's disease;
PAAD	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-6.64	-0.47	5.32e-10	Blood pressure (smoking interaction);
PAAD	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg01426195	chr3:39028469	NA	0.65	6.5	0.47	1.1e-9	Handedness;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05522885	chr19:4471596	HDGF2	0.62	6.52	0.47	1e-9	Pancreatic cancer;
PAAD	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	6.91	0.49	1.22e-10	Migraine;Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.57	-5.91	-0.43	2.18e-8	Systemic sclerosis;
PAAD	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.4	0.56	2.87e-14	Corneal astigmatism;
PAAD	cis	rs3106136	0.649	rs7672613	chr4:95299150	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.02	-0.38	1.45e-6	Lung cancer in ever smokers;
PAAD	cis	rs7101378	0.577	rs2136534	chr11:108900066	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs7101378	0.577	rs1912235	chr11:108898072	T/G	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg00999904	chr2:3704751	ALLC	-0.81	-8.13	-0.55	1.39e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.81	9.31	0.6	1.36e-16	Lung cancer;
PAAD	trans	rs10500871	1.000	rs12361708	chr11:20215688	G/C	cg02956962	chr6:161097311	NA	0.6	6.31	0.46	2.89e-9	Educational attainment;
PAAD	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.47	-4.45	-0.34	1.66e-5	Endometrial cancer;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07157834	chr1:205819609	PM20D1	0.53	5.09	0.38	1.05e-6	Parkinson's disease;
PAAD	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg20283391	chr11:68216788	NA	-0.55	-4.89	-0.37	2.51e-6	Total body bone mineral density;
PAAD	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.69	6.6	0.47	6.54e-10	Corneal astigmatism;
PAAD	cis	rs2562456	0.752	rs279809	chr19:21467531	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.38	-0.33	2.19e-5	Pain;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09256448	chr16:638327	NA	0.42	4.38	0.33	2.23e-5	Height;
PAAD	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.88	7.1	0.5	4.47e-11	Axial length;
PAAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.77	0.62	8.5e-18	Cognitive function;
PAAD	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg09654669	chr8:57350985	NA	-0.54	-5.04	-0.38	1.3e-6	Obesity-related traits;
PAAD	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03115019	chr17:80708279	FN3K	0.51	4.61	0.35	8.6e-6	Glycated hemoglobin levels;
PAAD	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.93	-8.04	-0.55	2.32e-13	Alzheimer's disease;
PAAD	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.85	8.84	0.58	2.24e-15	Lymphocyte counts;
PAAD	cis	rs730532	0.597	rs57847444	chr14:52504950	T/C	cg16066272	chr14:52535949	NID2	-0.57	-4.36	-0.33	2.38e-5	Pulmonary function;
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.45	0.46	1.38e-9	Lung cancer;
PAAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg24053715	chr22:38214548	NA	0.64	6.34	0.46	2.45e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.82	-10.08	-0.63	1.26e-18	Height;
PAAD	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.72	-6.65	-0.47	4.94e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg05596517	chr10:131320214	MGMT	-0.47	-4.54	-0.35	1.14e-5	Vitamin D levels;
PAAD	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.57	5.56	0.41	1.18e-7	Resting heart rate;
PAAD	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	0.92	5.96	0.44	1.68e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.47	4.52	0.34	1.24e-5	Morning vs. evening chronotype;
PAAD	cis	rs12286929	0.609	rs11601751	chr11:115094117	C/T	cg04055981	chr11:115044050	NA	0.45	4.47	0.34	1.52e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6604026	0.630	rs35807969	chr1:93459069	T/A	cg17283838	chr1:93427260	FAM69A	0.62	5.73	0.42	5.2e-8	Multiple sclerosis;
PAAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.71	6.32	0.46	2.69e-9	White blood cell count;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg05527609	chr1:210001259	C1orf107	0.59	5.98	0.44	1.54e-8	Monobrow;
PAAD	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17376030	chr22:41985996	PMM1	0.68	4.57	0.35	1.01e-5	Vitiligo;
PAAD	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg18518183	chr2:172544446	DYNC1I2	0.5	4.47	0.34	1.53e-5	Schizophrenia;
PAAD	cis	rs8049040	0.521	rs12935725	chr16:71569388	T/C	cg08717414	chr16:71523259	ZNF19	-0.5	-4.59	-0.35	9.11e-6	Blood protein levels;
PAAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.38	0.4	2.81e-7	Bipolar disorder;
PAAD	cis	rs7816613	0.920	rs10093301	chr8:102665893	A/C	cg20585841	chr8:102729926	NCALD	-0.66	-5.41	-0.4	2.45e-7	Age-related hearing impairment;
PAAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12599982	chr1:44399894	ARTN	0.44	4.34	0.33	2.61e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs501120	0.657	rs11238909	chr10:44688088	C/T	cg09554077	chr10:44749378	NA	0.47	5.78	0.42	4.05e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg13263323	chr15:86062960	AKAP13	0.48	4.87	0.37	2.78e-6	Coronary artery disease;
PAAD	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg04362960	chr10:104952993	NT5C2	-0.5	-4.58	-0.35	9.59e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9463078	0.565	rs1284980	chr6:45081428	A/G	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.88	8.29	0.56	5.59e-14	Colorectal adenoma (advanced);
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs4417704	0.525	rs7585348	chr2:241893716	T/C	cg26818257	chr2:241905806	NA	0.51	5.25	0.39	4.97e-7	Joint mobility (Beighton score);
PAAD	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.41	-4.78	-0.36	4.04e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.65	-4.63	-0.35	7.87e-6	Prostate cancer;
PAAD	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs2594989	0.616	rs6442254	chr3:11474491	T/C	cg01796438	chr3:11312864	ATG7	-0.58	-4.54	-0.35	1.13e-5	Circulating chemerin levels;
PAAD	cis	rs12136530	0.593	rs12125806	chr1:19734781	A/G	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	cis	rs950037	0.710	rs786908	chr1:89253357	A/G	cg13109106	chr1:89333529	GTF2B	-0.47	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs17601876	0.651	rs12908960	chr15:51545860	G/A	cg21478137	chr15:51532386	CYP19A1	0.48	4.77	0.36	4.3e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg15693483	chr7:1102177	C7orf50	0.38	4.3	0.33	3.03e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg04289385	chr6:36355825	ETV7	-0.44	-4.65	-0.35	7.1e-6	Platelet distribution width;
PAAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	7.77	0.53	1.08e-12	Coronary artery disease;
PAAD	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-9.74	-0.62	1.01e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs258892	0.895	rs34646	chr5:72113061	C/T	cg21869765	chr5:72125136	TNPO1	-0.79	-5.25	-0.39	5.02e-7	Small cell lung carcinoma;
PAAD	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.61	4.64	0.35	7.52e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs6466055	0.661	rs12155351	chr7:104943302	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs8014252	0.803	rs60860517	chr14:71029919	A/C	cg11204974	chr14:71022665	NA	-0.69	-4.58	-0.35	9.5e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs6594713	0.837	rs6594715	chr5:112741593	T/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	trans	rs41341749	0.831	rs10491118	chr17:34314886	A/C	cg02458039	chr1:226111372	PYCR2	0.92	6.52	0.47	1e-9	Blood protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15700180	chr18:56435859	NA	-0.78	-6.94	-0.49	1.07e-10	Neuroticism;
PAAD	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.6	-0.41	9.92e-8	Triglycerides;
PAAD	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.75	-5.45	-0.4	2e-7	Mosquito bite size;
PAAD	cis	rs2737618	0.574	rs2252801	chr1:200076652	C/T	cg21825944	chr1:200113062	NR5A2	-0.47	-4.31	-0.33	2.94e-5	Uric acid levels;
PAAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2139634	0.965	rs12489007	chr3:46545408	C/A	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.48	0.34	1.44e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.58	-6.86	-0.49	1.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs823920	1.000	rs823920	chr9:104662585	A/G	cg14235800	chr9:104238593	C9orf125	0.61	4.3	0.33	3.03e-5	Survival in pancreatic cancer;
PAAD	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.57	5.87	0.43	2.66e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.45	-4.81	-0.36	3.53e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Breast cancer;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07362569	chr17:61921086	SMARCD2	0.64	8.24	0.56	7.5e-14	Prudent dietary pattern;
PAAD	trans	rs9478638	0.592	rs162982	chr6:155634614	A/G	cg10853566	chr14:23288993	SLC7A7	-0.62	-6.49	-0.47	1.16e-9	Electroencephalogram traits;
PAAD	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	8.07	0.55	2.02e-13	Response to antipsychotic treatment;
PAAD	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.47	0.52	5.86e-12	Multiple sclerosis;
PAAD	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.96	0.37	1.84e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	10.01	0.63	1.98e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.72	7.26	0.51	1.91e-11	Mean platelet volume;
PAAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg14440974	chr22:39074834	NA	0.52	6.21	0.45	4.76e-9	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.55	-5.02	-0.38	1.46e-6	Myeloid white cell count;
PAAD	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.63	-5.7	-0.42	6.05e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs288342	0.866	rs3738945	chr2:183643889	T/C	cg02625481	chr2:183667124	NA	-0.43	-4.46	-0.34	1.6e-5	Recurrent major depressive disorder;
PAAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.68	-6.24	-0.45	4.11e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Birth weight;
PAAD	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	1.12	9.34	0.6	1.14e-16	Height;
PAAD	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg10183150	chr4:120222239	C4orf3	-0.42	-5.71	-0.42	5.71e-8	Corneal astigmatism;
PAAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.41	4.4	0.34	2.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.57	0.47	7.6e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.66	-6.0	-0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.97	-7.33	-0.51	1.26e-11	Multiple sclerosis;
PAAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	1.13	11.88	0.69	1.92e-23	Eosinophil percentage of granulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21735344	chr14:102553260	HSP90AA1	0.56	6.3	0.46	3.13e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs300774	0.925	rs6732024	chr2:148410	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg18423549	chr17:21743878	NA	-0.51	-4.93	-0.37	2.13e-6	Psoriasis;
PAAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg05717871	chr11:638507	DRD4	-0.55	-4.43	-0.34	1.77e-5	Systemic lupus erythematosus;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.9e-7	Rheumatoid arthritis;
PAAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg11779900	chr17:80519722	FOXK2	-0.47	-4.64	-0.35	7.39e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18621852	chr3:10150065	C3orf24	0.64	5.46	0.41	1.88e-7	Alzheimer's disease;
PAAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.4	-0.4	2.53e-7	Blood metabolite levels;
PAAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.35	4.27	0.33	3.39e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27605414	chr16:87730147	JPH3	-0.57	-6.54	-0.47	8.78e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg23416307	chr4:858299	GAK	0.6	6.29	0.45	3.15e-9	Educational attainment (years of education);
PAAD	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-12.84	-0.72	4.96e-26	Primary sclerosing cholangitis;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.59	6.29	0.45	3.27e-9	Lung cancer;
PAAD	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.68	7.55	0.52	3.82e-12	Schizophrenia;
PAAD	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-6.34	-0.46	2.55e-9	Neuroticism;
PAAD	cis	rs55823223	0.680	rs3744020	chr17:73871773	G/A	cg10935138	chr17:73851978	WBP2	0.93	7.71	0.53	1.55e-12	Psoriasis;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.24	0.56	7.3e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg08648136	chr8:956695	NA	0.49	5.18	0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg02555727	chr12:129281546	SLC15A4	-0.44	-4.65	-0.35	7.01e-6	Systemic lupus erythematosus;
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.8	-8.5	-0.57	1.66e-14	Prostate cancer;
PAAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg14196790	chr5:131705035	SLC22A5	-0.37	-4.34	-0.33	2.61e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs2131877	0.956	rs6775431	chr3:194859194	G/T	cg19760965	chr3:194868843	C3orf21	0.41	4.46	0.34	1.57e-5	Non-small cell lung cancer;
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.13	-0.38	8.69e-7	Lung cancer;
PAAD	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg00206168	chr11:65308501	LTBP3	-0.78	-5.58	-0.41	1.06e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.48	5.33	0.4	3.44e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs501120	0.925	rs1632484	chr10:44773984	C/T	cg09554077	chr10:44749378	NA	0.43	5.3	0.39	4.03e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg13540341	chr19:49222985	MAMSTR	0.41	4.79	0.36	3.91e-6	Dietary macronutrient intake;
PAAD	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg06740227	chr12:86229804	RASSF9	0.47	4.54	0.35	1.15e-5	Major depressive disorder;
PAAD	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg13540341	chr19:49222985	MAMSTR	-0.44	-5.2	-0.39	6.38e-7	Dietary macronutrient intake;
PAAD	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.73	6.35	0.46	2.38e-9	Blood protein levels;
PAAD	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg03948781	chr1:205179583	DSTYK	-0.46	-4.58	-0.35	9.63e-6	Reticulocyte count;
PAAD	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	cg07049167	chr1:166818506	POGK	-0.67	-6.45	-0.46	1.39e-9	Refractive astigmatism;
PAAD	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.7	5.78	0.42	4.13e-8	Exhaled nitric oxide output;
PAAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.62	-5.87	-0.43	2.62e-8	Aortic root size;
PAAD	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.18	13.29	0.73	3.14e-27	Post bronchodilator FEV1;
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg26850624	chr5:429559	AHRR	-0.84	-10.52	-0.65	8.77e-20	Cystic fibrosis severity;
PAAD	cis	rs818427	0.927	rs7213	chr5:112203564	T/A	cg06941702	chr5:112196734	SRP19	-0.46	-4.37	-0.33	2.25e-5	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.91	0.49	1.26e-10	Smoking initiation;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	8.75	0.58	3.82e-15	Alzheimer's disease;
PAAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg01362358	chr17:58117360	NA	0.38	4.33	0.33	2.72e-5	Hemoglobin concentration;
PAAD	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs7084783	0.519	rs10883885	chr10:105333852	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.48	4.73	0.36	5.06e-6	Fear of pain;
PAAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg22815214	chr1:201083145	CACNA1S	0.67	6.98	0.49	8.38e-11	Permanent tooth development;
PAAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg10210715	chr6:160221411	PNLDC1	-0.45	-4.25	-0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs597539	0.597	rs35956171	chr11:68602735	G/C	cg06028808	chr11:68637592	NA	-0.38	-4.44	-0.34	1.74e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.61	-6.08	-0.44	9.31e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7729723	0.653	rs7725416	chr5:137754180	T/A	cg26069252	chr5:137800343	EGR1	-0.46	-4.29	-0.33	3.18e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.21	-18.92	-0.84	8.69e-42	Exhaled nitric oxide output;
PAAD	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.26	-0.39	4.73e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.96	14.29	0.76	6.47e-30	Dental caries;
PAAD	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.8	6.26	0.45	3.73e-9	Platelet count;
PAAD	cis	rs9463078	0.817	rs9369523	chr6:44908728	T/C	cg25276700	chr6:44698697	NA	-0.49	-5.7	-0.42	6.13e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg05925327	chr15:68127851	NA	0.59	5.23	0.39	5.48e-7	Obesity;
PAAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg03983715	chr16:68378420	PRMT7	-0.8	-5.66	-0.42	7.3e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3852527	0.932	rs11601574	chr11:2828799	C/T	cg03571121	chr11:2832861	KCNQ1	-0.6	-4.55	-0.35	1.1e-5	Bacterial meningitis;
PAAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06217245	chr20:33103252	DYNLRB1	0.41	4.92	0.37	2.23e-6	Coronary artery disease;
PAAD	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.83	-0.36	3.36e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.48	4.71	0.36	5.49e-6	Height;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.83	-6.98	-0.49	8.38e-11	Alzheimer's disease;
PAAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.53	-5.18	-0.39	7.08e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-6.11	-0.44	8.17e-9	Electroencephalogram traits;
PAAD	cis	rs12753920	0.775	rs2069051	chr1:92676573	G/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.48	-4.44	-0.34	1.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16417436	chr16:28758564	NA	0.43	4.41	0.34	1.92e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12311346	chr5:56204834	C5orf35	0.54	4.53	0.34	1.21e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg02440177	chr19:53496695	ZNF702P	-0.63	-6.63	-0.47	5.64e-10	Psoriasis;
PAAD	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-10.16	-0.64	7.7e-19	Height;
PAAD	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.48	4.94	0.37	2.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs2061333	0.500	rs8113750	chr19:44608789	C/T	cg18700516	chr19:44507157	ZNF230	-0.81	-5.67	-0.42	6.95e-8	Alzheimer's disease;
PAAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.81	-8.87	-0.58	1.86e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs216303	0.554	rs216320	chr12:6143356	T/C	cg12895370	chr12:6755816	ACRBP	-0.59	-4.66	-0.35	6.8e-6	Low vWF levels;
PAAD	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg27499820	chr13:21296301	IL17D	0.52	4.97	0.37	1.81e-6	Dental caries;
PAAD	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25398598	chr6:42952024	PPP2R5D	0.65	6.32	0.46	2.81e-9	Obesity-related traits;
PAAD	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.71	-7.3	-0.51	1.5e-11	Cognitive function;
PAAD	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.39	0.74	1.72e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14210321	chr2:106509881	NCK2	0.67	6.68	0.48	4.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4919087	0.590	rs78376466	chr10:99034835	G/A	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.49	5.52	0.41	1.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	1.09	14.43	0.76	2.79e-30	Menarche (age at onset);
PAAD	cis	rs4474633	1	rs4474633	chr15:49260601	A/G	cg13780614	chr15:49607868	GALK2	0.49	4.87	0.37	2.72e-6	Major depressive disorder;
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21518248	chr2:162101506	NA	0.68	7.6	0.52	2.81e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.57	0.47	7.49e-10	Body mass index;
PAAD	cis	rs375066	0.901	rs374307	chr19:44404398	G/T	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-4.39	-0.34	2.09e-5	Fear of minor pain;
PAAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	4.8	0.36	3.73e-6	Coronary artery disease;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-7.47	-0.52	5.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12165864	chr7:66369176	NA	-0.79	-5.29	-0.39	4.19e-7	Diabetic kidney disease;
PAAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg16083429	chr3:49237500	CCDC36	-0.44	-4.61	-0.35	8.47e-6	Parkinson's disease;
PAAD	cis	rs8063761	0.568	rs4350572	chr16:90043840	A/G	cg12064134	chr16:90016061	DEF8	0.48	4.47	0.34	1.52e-5	Squamous cell carcinoma;
PAAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.64	-6.68	-0.48	4.23e-10	Body mass index;
PAAD	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg15145965	chr22:50218605	BRD1	0.57	4.82	0.36	3.52e-6	Schizophrenia;
PAAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.58	6.58	0.47	7.28e-10	Blood metabolite levels;
PAAD	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg09839279	chr12:125627357	AACS	-0.47	-4.73	-0.36	5.19e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	8.46	0.57	2.03e-14	Cognitive test performance;
PAAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.37e-5	Parkinson's disease;
PAAD	cis	rs6688613	1.000	rs7545911	chr1:166947681	C/T	cg07049167	chr1:166818506	POGK	0.46	4.51	0.34	1.28e-5	Refractive astigmatism;
PAAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.64	6.31	0.46	2.87e-9	Blood protein levels;
PAAD	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.54	4.89	0.37	2.5e-6	RR interval (heart rate);
PAAD	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.15	-0.5	3.45e-11	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.95	-8.4	-0.56	2.99e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.72	8.27	0.56	6.13e-14	Colorectal cancer;
PAAD	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.47	4.5	0.34	1.35e-5	Breast cancer;
PAAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.67	7.09	0.5	4.61e-11	Renal function-related traits (BUN);
PAAD	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.94	9.32	0.6	1.28e-16	Blood protein levels;
PAAD	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg04034577	chr2:241836375	C2orf54	-0.33	-4.95	-0.37	1.94e-6	Urinary metabolites;
PAAD	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.46	4.51	0.34	1.29e-5	Airway imaging phenotypes;
PAAD	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.19	-8.47	-0.57	2.01e-14	Schizophrenia;
PAAD	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs559928	0.692	rs12146487	chr11:64026639	G/A	cg05555928	chr11:63887634	MACROD1	-0.62	-4.57	-0.35	1.02e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	1.14	13.4	0.74	1.61e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg20636351	chr8:55087400	NA	-0.81	-9.11	-0.59	4.55e-16	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2290419	0.614	rs61167756	chr11:68950835	C/T	cg17042914	chr11:68898666	NA	-0.84	-4.85	-0.37	3.03e-6	Cutaneous malignant melanoma;
PAAD	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.31e-8	Electroencephalogram traits;
PAAD	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.42	-0.34	1.85e-5	Testicular germ cell tumor;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg23982607	chr1:1823379	GNB1	-0.85	-10.43	-0.65	1.52e-19	Body mass index;
PAAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	1.0	12.69	0.72	1.28e-25	Gestational age at birth (maternal effect);
PAAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.77	-0.36	4.31e-6	Height;
PAAD	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.75	-5.95	-0.43	1.78e-8	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs4845552	1.000	rs9436095	chr1:153479777	T/C	cg15998505	chr1:153479701	NA	-0.49	-4.41	-0.34	1.92e-5	Hippocampal atrophy;
PAAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.69	4.91	0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7301016	0.707	rs11174583	chr12:63051064	T/C	cg11441379	chr12:63026424	NA	0.83	5.96	0.43	1.73e-8	IgG glycosylation;
PAAD	cis	rs17095355	0.818	rs12572438	chr10:111769236	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.41	-0.34	1.92e-5	Biliary atresia;
PAAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs7191439	0.790	rs8060966	chr16:88777329	A/G	cg02389323	chr16:88786976	FAM38A	0.95	5.99	0.44	1.43e-8	Plateletcrit;
PAAD	cis	rs9443189	0.526	rs9359124	chr6:76200514	G/A	cg01950844	chr6:76311363	SENP6	0.92	5.85	0.43	2.97e-8	Prostate cancer;
PAAD	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.86	7.75	0.53	1.2e-12	Coronary artery disease;
PAAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.75	-0.53	1.21e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.38	-4.49	-0.34	1.41e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.89	-9.95	-0.63	2.82e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.87	6.46	0.46	1.33e-9	Axial length;
PAAD	cis	rs818427	0.737	rs448162	chr5:112182691	A/G	cg07820702	chr5:112228657	REEP5	0.53	4.73	0.36	5.02e-6	Total body bone mineral density;
PAAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg05110241	chr16:68378359	PRMT7	-1.11	-8.12	-0.55	1.47e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.64	5.14	0.39	8.19e-7	Alzheimer's disease (survival time);
PAAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg02376097	chr19:46275166	DMPK	-0.6	-6.07	-0.44	9.84e-9	Coronary artery disease;
PAAD	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg25401027	chr5:176370377	UIMC1	0.53	5.22	0.39	5.89e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.5	-5.48	-0.41	1.76e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs965469	0.843	rs6051698	chr20:3248983	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-4.33	-0.33	2.71e-5	IFN-related cytopenia;
PAAD	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.6	-4.41	-0.34	1.94e-5	Plateletcrit;Platelet count;
PAAD	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.19	0.5	2.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg03684893	chr10:554711	DIP2C	-0.49	-4.95	-0.37	1.93e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs258892	0.793	rs56762233	chr5:72056882	A/G	cg21869765	chr5:72125136	TNPO1	-0.9	-6.11	-0.44	8.08e-9	Small cell lung carcinoma;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.92	-0.37	2.19e-6	Platelet count;
PAAD	cis	rs7219021	0.743	rs575556	chr17:46857487	A/C	cg12314713	chr17:47074576	IGF2BP1	0.32	4.47	0.34	1.52e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs7081476	0.737	rs7918793	chr10:27497191	C/T	cg25705717	chr10:27608719	NA	0.85	4.47	0.34	1.52e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg13057898	chr1:3703894	LRRC47	0.43	4.61	0.35	8.31e-6	Red cell distribution width;
PAAD	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.7	-0.42	5.93e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-1.08	-9.67	-0.62	1.54e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.97e-7	Monocyte percentage of white cells;
PAAD	cis	rs831571	0.774	rs254858	chr3:64056255	G/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.52	4.44	0.34	1.74e-5	Type 2 diabetes;
PAAD	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg21191810	chr6:118973309	C6orf204	0.48	6.16	0.45	6.1e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1620921	0.505	rs4708886	chr6:161206350	G/T	cg01280913	chr6:161186852	NA	-0.48	-5.33	-0.4	3.48e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg20003494	chr4:90757398	SNCA	0.42	4.6	0.35	9.02e-6	Dementia with Lewy bodies;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04796973	chr4:25314218	ZCCHC4	0.73	7.26	0.51	1.83e-11	Obesity-related traits;
PAAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-5.9	-0.43	2.31e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.5	-6.67	-0.48	4.5e-10	Height;
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.25	9.03	0.59	7.22e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	6.0	0.44	1.38e-8	Schizophrenia;
PAAD	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.66	6.7	0.48	3.73e-10	Crohn's disease;
PAAD	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg08589418	chr20:61993913	CHRNA4	-0.5	-4.32	-0.33	2.86e-5	Atopic dermatitis;
PAAD	cis	rs12304921	0.748	rs17125258	chr12:51445679	G/A	cg18059802	chr12:51347058	HIGD1C	-0.65	-5.14	-0.38	8.39e-7	Type 2 diabetes;
PAAD	cis	rs2120243	0.533	rs34263112	chr3:157056048	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	4.44	0.34	1.69e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg10864074	chr7:100318194	EPO	0.44	5.16	0.39	7.72e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.66	-6.8	-0.48	2.22e-10	Menopause (age at onset);
PAAD	cis	rs7246865	0.510	rs2305757	chr19:17169758	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.56	0.41	1.18e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	4.26	0.33	3.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-4.75	-0.36	4.58e-6	Blood metabolite levels;
PAAD	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.5	4.8	0.36	3.77e-6	Prostate-specific antigen levels;
PAAD	cis	rs4621152	0.775	rs7562029	chr2:217924261	C/T	cg21875423	chr2:217559867	IGFBP5	0.46	4.59	0.35	9.14e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs72681920	0.881	rs4148884	chr4:100066287	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-4.44	-0.34	1.72e-5	Alcohol dependence;
PAAD	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.76	5.53	0.41	1.39e-7	White matter hyperintensity burden;
PAAD	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.82	-4.91	-0.37	2.28e-6	Hippocampal volume;
PAAD	cis	rs11960470	1.000	rs11960470	chr5:50328257	A/C	cg06027927	chr5:50259733	NA	0.68	6.94	0.49	1.08e-10	Breast cancer;
PAAD	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.43	4.79	0.36	3.96e-6	Testicular germ cell tumor;
PAAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg05425664	chr17:57184151	TRIM37	0.5	4.76	0.36	4.48e-6	Testicular germ cell tumor;
PAAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.6200000000000003e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg11416102	chr8:651193	ERICH1	-0.87	-4.96	-0.37	1.84e-6	IgG glycosylation;
PAAD	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs55788414	0.725	rs34929001	chr16:81188792	C/A	cg06400318	chr16:81190750	PKD1L2	-1.13	-8.27	-0.56	6.22e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.49e-5	Electrocardiographic conduction measures;
PAAD	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg01953289	chr20:60874239	NA	0.69	5.17	0.39	7.28e-7	Obesity-related traits;
PAAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.45	-5.82	-0.43	3.41e-8	Cystic fibrosis severity;
PAAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7873102	0.654	rs3861003	chr9:37952631	A/G	cg03528946	chr9:38069800	SHB	0.59	6.02	0.44	1.23e-8	Brain structure;
PAAD	cis	rs9304742	0.573	rs10415950	chr19:53465100	C/T	cg09915433	chr19:53449742	NA	-0.67	-7.86	-0.54	6.56e-13	Psoriasis;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	trans	rs10861342	1.000	rs73395802	chr12:105588718	T/C	cg11421182	chr20:36153479	BLCAP	-0.56	-6.76	-0.48	2.75e-10	IgG glycosylation;
PAAD	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.42	-0.61	6.83e-17	Schizophrenia;
PAAD	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.8	7.07	0.5	5.26e-11	Coronary artery disease;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.51	5.68	0.42	6.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7173419	0.607	rs12914687	chr15:28226541	C/T	cg20906524	chr15:28200668	OCA2	-0.46	-5.29	-0.39	4.1e-7	Eye color;
PAAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.37	0.33	2.29e-5	Melanoma;
PAAD	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg04515608	chr11:48129067	PTPRJ	-0.34	-4.38	-0.33	2.2e-5	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.92	11.18	0.67	1.44e-21	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	6.21	0.45	4.76e-9	Schizophrenia;
PAAD	cis	rs9487051	0.582	rs351723	chr6:109545547	G/A	cg21918786	chr6:109611834	NA	-0.42	-4.37	-0.33	2.34e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	0.92	6.22	0.45	4.67e-9	IgG glycosylation;
PAAD	cis	rs9815354	0.680	rs73073288	chr3:42027637	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.33	-0.33	2.68e-5	Educational attainment;
PAAD	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.46	5.51	0.41	1.5e-7	Body mass index;
PAAD	cis	rs9463078	0.874	rs7743116	chr6:45142858	T/C	cg25276700	chr6:44698697	NA	-0.48	-5.51	-0.41	1.5e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.98	0.54	3.3e-13	Lung cancer in ever smokers;
PAAD	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.61	0.41	9.12e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.55	4.6	0.35	8.93e-6	Red blood cell count;
PAAD	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.07	0.5	5.24e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11245990	chr11:68621969	NA	-0.41	-5.47	-0.41	1.83e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.89	0.37	2.52e-6	Vitiligo;
PAAD	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.78	6.25	0.45	3.87e-9	Neutrophil percentage of white cells;
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg12143784	chr7:64541923	NA	-0.34	-4.42	-0.34	1.84e-5	Aortic root size;
PAAD	cis	rs9646944	0.501	rs2075186	chr2:103057251	G/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.53	0.34	1.19e-5	Blood protein levels;
PAAD	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg02376097	chr19:46275166	DMPK	-0.58	-5.8	-0.43	3.77e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.7	6.66	0.48	4.76e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.59	6.32	0.46	2.8e-9	Testicular germ cell tumor;
PAAD	cis	rs116248771	0.739	rs12629635	chr3:158322069	C/T	cg16708174	chr3:158430962	RARRES1	0.75	5.52	0.41	1.44e-7	diarrhoeal disease at age 2;
PAAD	cis	rs1144333	0.655	rs1146613	chr1:76241846	A/G	cg22875332	chr1:76189707	ACADM	-0.72	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.28	-0.39	4.31e-7	Mononucleosis;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6e-8	Life satisfaction;
PAAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.77	-0.53	1.07e-12	Height;
PAAD	cis	rs12586317	0.642	rs7156944	chr14:35790467	T/G	cg09327582	chr14:35236912	BAZ1A	0.53	5.2	0.39	6.22e-7	Psoriasis;
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg08641963	chr20:44451973	TNNC2	0.3	4.32	0.33	2.83e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg01102307	chr1:9340416	NA	0.43	4.61	0.35	8.62e-6	Eosinophil percentage of white cells;
PAAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.72	0.36	5.29e-6	Menopause (age at onset);
PAAD	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg19875578	chr6:126661172	C6orf173	0.51	5.31	0.4	3.82e-7	Male-pattern baldness;
PAAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg27182935	chr16:89790473	ZNF276	-0.74	-4.54	-0.35	1.15e-5	Skin colour saturation;
PAAD	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	1.12	16.49	0.8	1.15e-35	Breast cancer;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.99	-0.49	8.12e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26388565	chr5:1247091	NA	0.75	7.52	0.52	4.32e-12	Obesity-related traits;
PAAD	cis	rs10875746	0.855	rs2269936	chr12:48425235	G/A	cg26205652	chr12:48591994	NA	0.95	9.51	0.61	4.15e-17	Longevity (90 years and older);
PAAD	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg27284194	chr4:1044797	NA	0.52	5.43	0.4	2.14e-7	Obesity-related traits;
PAAD	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.54	5.36	0.4	3.05e-7	Platelet count;
PAAD	cis	rs12949688	1.000	rs4793566	chr17:55815469	T/C	cg12582317	chr17:55822272	NA	0.69	8.71	0.58	4.7e-15	Schizophrenia;
PAAD	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-7.67	-0.53	1.93e-12	Colorectal cancer;
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.56	5.51	0.41	1.48e-7	Parkinson's disease;
PAAD	cis	rs498136	0.831	rs12793223	chr11:69353963	T/C	cg24388239	chr11:68438018	NA	-0.42	-4.28	-0.33	3.33e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.6e-6	Childhood ear infection;
PAAD	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg22089800	chr15:90895588	ZNF774	0.55	5.28	0.39	4.37e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.57	-0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07804111	chr1:151735543	OAZ3;MRPL9	-0.75	-6.76	-0.48	2.72e-10	Neuroticism;
PAAD	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg02415014	chr8:143852576	LYNX1	-0.4	-5.06	-0.38	1.17e-6	Urinary tract infection frequency;
PAAD	cis	rs7260598	0.539	rs57061964	chr19:24066278	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.55	-5.17	-0.39	7.2e-7	Retinal vascular caliber;
PAAD	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.48	4.34	0.33	2.55e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.61	6.87	0.49	1.56e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs225245	0.765	rs226428	chr17:34049950	C/T	cg19694781	chr19:47549865	TMEM160	0.57	6.61	0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00097177	chr10:99609865	GOLGA7B	0.61	6.9	0.49	1.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg27565382	chr3:53032988	SFMBT1	0.73	4.29	0.33	3.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.94	8.69	0.58	5.46e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg19257562	chr1:2043853	PRKCZ	-0.41	-4.97	-0.37	1.8e-6	Height;
PAAD	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.7	4.67	0.35	6.61e-6	Inflammatory bowel disease;
PAAD	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.66	4.75	0.36	4.58e-6	Carotid intima media thickness;
PAAD	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.0	-0.49	7.84e-11	Triglycerides;
PAAD	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	0.94	11.19	0.67	1.37e-21	Ulcerative colitis;
PAAD	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.14	-7.17	-0.5	3.1e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	6.14	0.45	6.79e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.61	-0.53	2.71e-12	Triglycerides;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-6.24	-0.45	4.08e-9	Type 2 diabetes;
PAAD	cis	rs2284378	0.506	rs6142059	chr20:32544327	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	4.46	0.34	1.59e-5	Breast cancer;
PAAD	trans	rs901683	1.000	rs71496610	chr10:46021646	C/G	cg06308084	chr22:50493570	TTLL8	0.81	6.33	0.46	2.59e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1797885	0.604	rs299628	chr3:12577395	G/C	cg07775309	chr3:12595852	NA	0.43	4.69	0.36	6.1e-6	Immature fraction of reticulocytes;
PAAD	cis	rs6604026	0.740	rs2893225	chr1:93368496	G/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	1.11	9.17	0.6	3.08e-16	Initial pursuit acceleration;
PAAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.76	-9.52	-0.61	3.95e-17	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6991838	0.725	rs6995134	chr8:66467707	T/C	cg19366217	chr8:67351311	ADHFE1	-0.44	-4.33	-0.33	2.65e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2070677	0.866	rs2987796	chr10:135379688	C/T	cg08390786	chr10:135334061	NA	-0.66	-5.53	-0.41	1.37e-7	Gout;
PAAD	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	4.64	0.35	7.5e-6	Hip circumference;
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.8	-0.36	3.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg15017067	chr4:17643749	FAM184B	0.44	5.16	0.39	7.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	5.99	0.44	1.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11260013	0.935	rs12982518	chr19:7758316	C/G	cg04764898	chr19:7562249	C19orf45	0.41	4.33	0.33	2.66e-5	Blood protein levels;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.87	0.37	2.73e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.66	-8.44	-0.56	2.37e-14	Body mass index;
PAAD	cis	rs755249	0.567	rs16825942	chr1:39662618	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg12143784	chr7:64541923	NA	-0.37	-4.68	-0.36	6.18e-6	Calcium levels;
PAAD	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12432903	chr7:1882776	MAD1L1	0.61	4.42	0.34	1.88e-5	Bipolar disorder;
PAAD	cis	rs7168592	1.000	rs59465739	chr15:101732717	A/T	cg24254196	chr15:101719523	CHSY1	-0.66	-4.69	-0.36	6.02e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg25790453	chr13:113633590	MCF2L	-0.39	-4.61	-0.35	8.38e-6	Systolic blood pressure;
PAAD	cis	rs2885056	0.830	rs2360748	chr19:10693624	T/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg21951975	chr1:209979733	IRF6	0.41	5.24	0.39	5.33e-7	Monobrow;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.91	10.95	0.66	6.22e-21	Menarche (age at onset);
PAAD	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg01388757	chr2:102091195	RFX8	-0.59	-7.62	-0.53	2.47e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs4851254	0.626	rs115581542	chr2:100717725	T/A	cg07810366	chr2:100720526	AFF3	-0.44	-4.38	-0.33	2.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-1.08	-9.51	-0.61	3.98e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.89	-8.36	-0.56	3.75e-14	Colorectal adenoma (advanced);
PAAD	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.9	9.48	0.61	4.89e-17	Breast cancer;
PAAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.7	6.52	0.47	9.77e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs2004318	1.000	rs77902349	chr19:55120053	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03965827	chr15:50979356	TRPM7	0.59	6.57	0.47	7.67e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26334299	chr5:139571801	C5orf32	-0.68	-6.93	-0.49	1.12e-10	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg10210715	chr6:160221411	PNLDC1	-0.47	-4.41	-0.34	1.97e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg15181151	chr6:150070149	PCMT1	0.61	6.58	0.47	7.05e-10	Lung cancer;
PAAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg14580859	chr9:123691850	NA	-0.38	-4.28	-0.33	3.24e-5	Rheumatoid arthritis;
PAAD	cis	rs2649	0.518	rs28531781	chr15:63879235	T/C	cg22599514	chr15:63798201	USP3	0.59	4.92	0.37	2.19e-6	Aortic root size;
PAAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg23346134	chr3:49453900	TCTA	-0.46	-4.98	-0.37	1.7e-6	Menarche (age at onset);
PAAD	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg03367679	chr17:38183553	MED24;SNORD124	0.35	4.71	0.36	5.65e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs17155006	0.664	rs448559	chr7:107739485	A/G	cg05962710	chr7:107745446	LAMB4	-0.46	-5.98	-0.44	1.51e-8	Pneumococcal bacteremia;
PAAD	cis	rs2278796	0.639	rs4951153	chr1:204970844	C/A	cg04862289	chr1:204966208	NFASC	0.5	5.18	0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-5.69	-0.42	6.24e-8	Blood protein levels;
PAAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.65	5.4	0.4	2.57e-7	Gut microbiome composition (summer);
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.8	-8.83	-0.58	2.3e-15	Iron status biomarkers;
PAAD	cis	rs2252790	0.859	rs1204825	chr6:116563925	G/C	cg18764771	chr6:116381957	FRK	-0.27	-4.63	-0.35	7.93e-6	Fast beta electroencephalogram;
PAAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.55	-5.51	-0.41	1.53e-7	Platelet count;
PAAD	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.43	0.4	2.19e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	1.32	8.14	0.55	1.32e-13	Skin colour saturation;
PAAD	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg08508325	chr11:3079039	CARS	-0.54	-6.91	-0.49	1.22e-10	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19747744	chr17:4074126	ANKFY1	-0.65	-6.59	-0.47	6.96e-10	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.1	-0.44	8.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.99	8.84	0.58	2.22e-15	Triglycerides;
PAAD	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.77	7.45	0.52	6.58e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg12215294	chr3:40350768	EIF1B	0.47	4.58	0.35	9.52e-6	Renal cell carcinoma;
PAAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.78	-8.38	-0.56	3.28e-14	Schizophrenia;
PAAD	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.88	-10.62	-0.65	4.78e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg16898833	chr6:26189333	HIST1H4D	0.93	4.29	0.33	3.12e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg17294928	chr15:75287854	SCAMP5	0.99	10.22	0.64	5.49e-19	Blood trace element (Zn levels);
PAAD	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs630539	0.655	rs6503710	chr17:40744438	T/A	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.94	-10.4	-0.64	1.78e-19	Calcium levels;
PAAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg14784868	chr12:69753453	YEATS4	0.56	4.89	0.37	2.57e-6	Response to diuretic therapy;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	5.85	0.43	2.96e-8	Eye color traits;
PAAD	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg00262122	chr8:11665843	FDFT1	-0.69	-6.12	-0.44	7.47e-9	Neuroticism;
PAAD	cis	rs12760731	0.668	rs72482621	chr1:178410442	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.96	0.49	9.38e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg26516362	chr5:178986906	RUFY1	0.5	5.88	0.43	2.52e-8	Lung cancer;
PAAD	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.78	8.63	0.57	7.78e-15	Longevity;
PAAD	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.54	-6.76	-0.48	2.75e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.85	-0.43	2.88e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.64	7.16	0.5	3.25e-11	Multiple sclerosis;
PAAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.35e-7	Ulcerative colitis;
PAAD	cis	rs7945718	0.621	rs11022464	chr11:12685477	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.54	0.35	1.15e-5	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04856096	chr8:68255097	ARFGEF1	0.69	8.22	0.55	8.41e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.51	-5.78	-0.42	4.01e-8	Obesity-related traits;
PAAD	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg22587600	chr2:46883368	NA	-0.33	-4.45	-0.34	1.65e-5	Height;
PAAD	cis	rs10073892	0.703	rs10045752	chr5:101638440	C/A	cg17280723	chr5:101634495	NA	0.41	4.38	0.34	2.16e-5	Cognitive decline (age-related);
PAAD	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.4	-0.46	1.8e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.45	-0.34	1.62e-5	Morning vs. evening chronotype;
PAAD	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10988802	0.571	rs10819952	chr9:98398910	G/C	cg14323293	chr9:98280076	PTCH1	-0.52	-4.27	-0.33	3.48e-5	Chemerin levels;
PAAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg11802864	chr11:65308245	LTBP3	0.46	4.75	0.36	4.73e-6	Bone mineral density;
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg14146966	chr2:61757674	XPO1	0.41	4.87	0.37	2.77e-6	Tuberculosis;
PAAD	cis	rs1697139	0.967	rs1705396	chr5:66510876	T/C	cg16691251	chr5:66510806	NA	0.82	9.61	0.61	2.25e-17	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22290704	chr6:144167951	LTV1	-0.63	-6.65	-0.47	4.92e-10	Obesity-related traits;
PAAD	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.69	-4.89	-0.37	2.49e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs58521262	0.556	rs459820	chr19:23131783	C/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.69	-6.73	-0.48	3.18e-10	Initial pursuit acceleration;
PAAD	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20982606	chr12:109535391	UNG	-0.63	-7.29	-0.51	1.56e-11	Body fat percentage;
PAAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.43	6.66	0.48	4.72e-10	Height;
PAAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs8177179	0.503	rs13061966	chr3:133412277	C/A	cg24879335	chr3:133465180	TF	0.44	4.91	0.37	2.28e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg21724239	chr8:58056113	NA	0.7	5.37	0.4	2.92e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13479780	chr6:41909532	CCND3	0.67	7.21	0.5	2.5e-11	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08690812	chr11:18343758	GTF2H1;HPS5	0.68	6.85	0.49	1.76e-10	Obesity-related traits;
PAAD	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg10512202	chr3:45649293	LIMD1	0.44	4.28	0.33	3.35e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.62	5.17	0.39	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.908	rs117753937	chr22:32595919	C/T	cg00543991	chr22:32367038	NA	1.18	6.25	0.45	4.03e-9	Childhood ear infection;
PAAD	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.59	4.76	0.36	4.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	1.11	9.4	0.61	7.77e-17	Vitiligo;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07976390	chr1:154600456	ADAR	0.61	6.63	0.47	5.4e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.73	7.59	0.52	3e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg07068956	chr7:100330872	ZAN	-0.75	-5.75	-0.42	4.79e-8	Other erythrocyte phenotypes;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.55	-0.52	3.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.45	5.66	0.42	7.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03575387	chr20:7999698	TMX4	0.62	6.9	0.49	1.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg26935685	chr1:15502881	TMEM51	-0.52	-4.57	-0.35	9.89e-6	Systolic blood pressure;
PAAD	cis	rs908922	0.923	rs11205010	chr1:152457964	C/T	cg21823605	chr1:152486609	CRCT1	0.53	6.11	0.44	8.04e-9	Hair morphology;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23087020	chr1:167190262	POU2F1	0.62	6.32	0.46	2.71e-9	Pancreatic cancer;
PAAD	trans	rs9257809	1	rs9257809	chr6:29356331	A/G	cg06606381	chr12:133084897	FBRSL1	-1.48	-9.77	-0.62	8.69e-18	Breast cancer;Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27402805	chr16:30681996	FBRS	0.63	6.63	0.47	5.54e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.81	6.05	0.44	1.07e-8	Vitiligo;
PAAD	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.44	4.3	0.33	3.09e-5	Mean corpuscular volume;
PAAD	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.78	-7.89	-0.54	5.37e-13	Itch intensity from mosquito bite;
PAAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.9	-11.25	-0.67	9.93e-22	Menopause (age at onset);
PAAD	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs13253111	0.603	rs17058753	chr8:28090914	T/C	cg26534493	chr8:28060551	NA	0.4	4.38	0.33	2.24e-5	Childhood body mass index;
PAAD	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.56	6.35	0.46	2.37e-9	Mean corpuscular volume;
PAAD	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.77	-9.36	-0.6	1.02e-16	White blood cell count (basophil);
PAAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg01223673	chr11:15133828	INSC	0.34	4.44	0.34	1.74e-5	Mitochondrial DNA levels;
PAAD	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg16745616	chr19:8428856	ANGPTL4	-0.54	-4.86	-0.37	2.94e-6	HDL cholesterol;
PAAD	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.47	-5.58	-0.41	1.06e-7	Eosinophil percentage of white cells;
PAAD	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.97	-6.48	-0.46	1.24e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7714584	1.000	rs17800987	chr5:150323428	A/G	cg22134413	chr5:150180641	NA	0.84	5.93	0.43	1.99e-8	Crohn's disease;
PAAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	1.2	13.25	0.73	4.05e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs4325129	0.871	rs4656827	chr1:159460032	A/G	cg24301350	chr2:200776224	C2orf69	-0.65	-6.68	-0.48	4.27e-10	Obesity-related traits;
PAAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg19847866	chr10:1019161	NA	-0.52	-4.27	-0.33	3.4e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs8060686	0.777	rs73597580	chr16:67679879	G/A	cg27539214	chr16:67997921	SLC12A4	-0.74	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.62	-5.64	-0.42	8.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2019216	0.500	rs2169916	chr17:21884670	G/C	cg22648282	chr17:21454238	C17orf51	-0.58	-5.94	-0.43	1.82e-8	Pelvic organ prolapse;
PAAD	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.88	7.09	0.5	4.74e-11	Axial length;
PAAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.78	7.06	0.5	5.68e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg02811702	chr13:24901961	NA	0.51	5.42	0.4	2.31e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3812111	0.605	rs1204845	chr6:116521190	G/A	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.31	-0.33	2.9e-5	Age-related macular degeneration;
PAAD	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.8	-6.83	-0.48	1.96e-10	Blood protein levels;
PAAD	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg27490568	chr2:178487706	NA	0.45	5.02	0.38	1.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Colorectal cancer;
PAAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs6987853	0.527	rs3935698	chr8:42363694	G/A	cg09913449	chr8:42400586	C8orf40	-0.5	-5.43	-0.4	2.23e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.44	-4.65	-0.35	7.29e-6	HDL cholesterol;
PAAD	cis	rs4704187	0.687	rs1582504	chr5:74479545	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-8.63	-0.57	7.82e-15	Exhaled nitric oxide output;
PAAD	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.23	0.39	5.53e-7	Lung cancer;
PAAD	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2133450	0.508	rs6443100	chr3:7333382	G/T	cg19930620	chr3:7340148	GRM7	0.54	6.23	0.45	4.44e-9	Early response to risperidone in schizophrenia;
PAAD	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg12288994	chr5:1860383	NA	0.6	7.14	0.5	3.61e-11	Cardiovascular disease risk factors;
PAAD	cis	rs35797862	1	rs35797862	chr1:93738515	A/AAG	cg04535902	chr1:92947332	GFI1	-0.46	-4.48	-0.34	1.48e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs501120	0.657	rs115299170	chr10:44742925	T/C	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21862992	chr11:68658383	NA	0.41	4.48	0.34	1.48e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg25558440	chr8:11882962	NA	-0.44	-4.33	-0.33	2.69e-5	Neuroticism;
PAAD	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs9463078	0.546	rs7763450	chr6:45029896	G/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08109568	chr15:31115862	NA	-0.7	-7.87	-0.54	6.06e-13	Huntington's disease progression;
PAAD	cis	rs732765	0.734	rs11844127	chr14:75139936	C/G	cg17347104	chr14:75034677	LTBP2	0.53	4.6	0.35	8.77e-6	Non-small cell lung cancer;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs3116813	1	rs3116813	chr6:29660816	C/A	cg06606381	chr12:133084897	FBRSL1	-1.47	-9.17	-0.6	3.13e-16	Breast cancer;
PAAD	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12710552	chr11:18270955	SAA2	0.62	6.33	0.46	2.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.93	-0.37	2.17e-6	QT interval;
PAAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.52	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg26205652	chr12:48591994	NA	0.95	9.59	0.61	2.56e-17	Longevity (90 years and older);
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.87	11.23	0.67	1.06e-21	Vitiligo;
PAAD	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.45	4.33	0.33	2.72e-5	Malaria;
PAAD	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22162314	chr17:61951766	CSH2	-0.54	-5.53	-0.41	1.35e-7	Height;
PAAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.62	-6.85	-0.49	1.71e-10	Monocyte count;
PAAD	cis	rs6785206	0.614	rs57392614	chr3:128471146	T/C	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.37e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-4.82	-0.36	3.39e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	cis	rs10885582	0.809	rs10885579	chr10:116304958	C/T	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.12	-0.38	9.21e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11634851	0.844	rs12917526	chr15:81025457	G/C	cg03950166	chr15:80988613	FAM108C1	-0.45	-4.72	-0.36	5.23e-6	Systolic blood pressure;
PAAD	cis	rs6782228	0.606	rs4857919	chr3:128407495	C/T	cg16766828	chr3:128327626	NA	-0.47	-6.38	-0.46	2e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.86	7.95	0.54	3.92e-13	Response to diuretic therapy;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.57	5.83	0.43	3.17e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs12764693	chr10:46023327	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.8	-6.63	-0.47	5.38e-10	Chronic kidney disease;
PAAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs10950821	0.770	rs2285555	chr7:20692000	C/G	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.06	0.38	1.19e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.62	4.57	0.35	1.01e-5	Vitiligo;
PAAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg16494567	chr8:142200140	DENND3	-0.42	-4.35	-0.33	2.47e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	6.08	0.44	9.16e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.97	-11.57	-0.68	1.32e-22	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00857660	chr1:173838081	SNORD74;ZBTB37;GAS5	0.55	6.77	0.48	2.69e-10	Monocyte percentage of white cells;
PAAD	cis	rs8062405	0.789	rs28480369	chr16:28627004	T/C	cg16576597	chr16:28551801	NUPR1	-0.71	-7.33	-0.51	1.28e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.81	-8.68	-0.58	5.85e-15	Prostate cancer;
PAAD	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg25233709	chr10:116636983	FAM160B1	-0.38	-4.63	-0.35	7.89e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.98	-5.82	-0.43	3.35e-8	Inflammatory biomarkers;
PAAD	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg11713064	chr6:33730089	NA	0.35	4.26	0.33	3.5e-5	Platelet count;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.78	-7.94	-0.54	4.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.74	8.48	0.57	1.84e-14	Lewy body disease;
PAAD	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02419362	chr12:121203948	SPPL3	0.53	5.9	0.43	2.22e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.8	-7.67	-0.53	1.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2117029	0.553	rs1991427	chr12:49557958	C/T	cg05368762	chr12:50135785	TMBIM6	0.42	4.3	0.33	3.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg00206168	chr11:65308501	LTBP3	-0.54	-5.51	-0.41	1.48e-7	Bone mineral density;
PAAD	cis	rs9938149	0.834	rs9922572	chr16:88334112	G/T	cg01412419	chr16:87856264	NA	0.51	4.32	0.33	2.81e-5	Corneal structure;Central corneal thickness;
PAAD	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.64	-0.42	8.11e-8	Bladder cancer;
PAAD	cis	rs7577696	0.525	rs1580329	chr2:32016677	A/G	cg02381751	chr2:32503542	YIPF4	-0.45	-4.37	-0.33	2.3e-5	Inflammatory biomarkers;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-11.5	-0.68	2.06e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.21	0.73	5.09e-27	Platelet count;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.85	-6.37	-0.46	2.12e-9	Alzheimer's disease;
PAAD	cis	rs9463078	0.546	rs13207575	chr6:45020840	T/C	cg25276700	chr6:44698697	NA	0.44	5.0	0.38	1.59e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.51	-5.95	-0.43	1.76e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21347644	chr2:149401942	EPC2	-0.62	-7.31	-0.51	1.46e-11	Body fat percentage;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20330630	chr15:74660375	CYP11A1	0.56	6.55	0.47	8.23e-10	Smoking initiation;
PAAD	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.92	10.91	0.66	7.74e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	5.32	0.4	3.72e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.27	0.39	4.52e-7	Major depressive disorder;
PAAD	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg00319359	chr11:70116639	PPFIA1	0.71	4.39	0.34	2.08e-5	Coronary artery disease;
PAAD	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg00431813	chr7:1051703	C7orf50	0.49	4.33	0.33	2.68e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.77	0.48	2.61e-10	Total body bone mineral density;
PAAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.95	11.5	0.68	2.05e-22	Breast cancer;
PAAD	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg03989125	chr22:38214979	NA	-0.55	-5.34	-0.4	3.3e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.14	-0.6	3.86e-16	Schizophrenia;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg07777115	chr5:623756	CEP72	-0.47	-4.34	-0.33	2.64e-5	Cystic fibrosis severity;
PAAD	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-6.0	-0.44	1.4e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.88	5.56	0.41	1.17e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.59	8.07	0.55	2e-13	Renal cell carcinoma;
PAAD	cis	rs669446	0.558	rs609171	chr1:44110216	A/C	cg12908607	chr1:44402522	ARTN	-0.41	-4.31	-0.33	2.9e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7707921	0.881	rs112413913	chr5:81359709	A/G	cg21483461	chr5:81570383	RPS23	-0.51	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg01388757	chr2:102091195	RFX8	0.59	7.3	0.51	1.5e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.39	0.46	1.92e-9	Alzheimer's disease;
PAAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.63	-0.53	2.39e-12	Height;
PAAD	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.27	-0.45	3.64e-9	Bipolar disorder;
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.65	6.44	0.46	1.45e-9	Height;
PAAD	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg04330084	chr7:123175371	IQUB	-0.53	-4.99	-0.38	1.62e-6	Migraine;
PAAD	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.62	-6.62	-0.47	5.82e-10	Schizophrenia;
PAAD	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg09760422	chr2:128146352	NA	-0.34	-5.94	-0.43	1.91e-8	Protein C levels;
PAAD	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.76	-0.53	1.15e-12	Hemoglobin concentration;
PAAD	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.61	7.02	0.49	6.91e-11	Cognitive performance;
PAAD	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.54	-7.14	-0.5	3.55e-11	Life satisfaction;
PAAD	cis	rs6010044	0.817	rs12484068	chr22:51099862	C/T	cg07576525	chr22:51146088	SHANK3	0.5	4.32	0.33	2.85e-5	Fibrinogen levels;Fibrinogen;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.72	-7.99	-0.54	3.16e-13	Mean corpuscular volume;
PAAD	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.69	-0.36	6.01e-6	Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25846339	chr11:85359022	TMEM126A	0.57	6.37	0.46	2.12e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.42	5.22	0.39	5.79e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.69	-0.42	6.45e-8	Personality dimensions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02047359	chr10:75174015	ANXA7	0.61	6.57	0.47	7.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg02475695	chr16:616220	NHLRC4	0.45	5.22	0.39	5.85e-7	Height;
PAAD	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.55e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2882667	0.690	rs3763016	chr5:138270732	C/G	cg09476006	chr5:138032270	NA	0.46	5.75	0.42	4.68e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.42	-4.89	-0.37	2.51e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	5.17	0.39	7.32e-7	Blood metabolite levels;
PAAD	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg00646381	chr17:77835854	NA	0.64	4.9	0.37	2.45e-6	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg04455712	chr21:45112962	RRP1B	0.4	4.25	0.33	3.74e-5	Mean corpuscular volume;
PAAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg05725404	chr16:58534157	NDRG4	-0.79	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs7631605	0.875	rs2302506	chr3:37133124	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg09796270	chr17:17721594	SREBF1	0.43	4.85	0.37	2.97e-6	Total body bone mineral density;
PAAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs10155981	0.510	rs4722159	chr7:22584279	C/G	cg05062323	chr7:22590069	NA	-0.86	-5.21	-0.39	6.12e-7	Bilirubin levels;
PAAD	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.51	-5.37	-0.4	2.93e-7	Interleukin-18 levels;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.59	-4.25	-0.33	3.77e-5	Hypertriglyceridemia;
PAAD	cis	rs12780845	1.000	rs45472399	chr10:17209967	G/A	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg19825600	chr2:3704501	ALLC	-0.54	-4.63	-0.35	7.69e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4780401	0.967	rs11075012	chr16:11831030	T/C	cg01061890	chr16:11836724	TXNDC11	-0.47	-4.4	-0.34	2.04e-5	Rheumatoid arthritis;
PAAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.35	4.79	0.36	3.9e-6	Height;
PAAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.45	-5.11	-0.38	9.74e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs4740619	0.630	rs1328271	chr9:15998645	G/A	cg14451791	chr9:16040625	NA	0.38	4.49	0.34	1.41e-5	Body mass index;
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg07061783	chr6:25882402	NA	-0.49	-5.06	-0.38	1.18e-6	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs9815354	1.000	rs6599179	chr3:41855284	C/T	cg03022575	chr3:42003672	ULK4	0.75	5.59	0.41	1.02e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.51	1.64e-11	Response to antipsychotic treatment;
PAAD	cis	rs1256061	0.603	rs3020445	chr14:64788644	A/G	cg23250157	chr14:64679961	SYNE2	0.47	4.65	0.35	7.19e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs16975963	0.843	rs73041047	chr19:38299289	T/C	cg08679971	chr19:38281047	NA	0.55	5.18	0.39	6.92e-7	Longevity;
PAAD	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.68e-6	Pain;
PAAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.6	6.3	0.46	2.98e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.85	10.13	0.63	9.73e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11056748	chr11:66036038	RAB1B	-0.59	-7.0	-0.49	7.76e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg16579770	chr16:72058938	DHODH	0.39	4.5	0.34	1.33e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.7	-9.67	-0.62	1.53e-17	Birth weight;
PAAD	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.98	13.04	0.73	1.42e-26	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18579327	chr2:208395557	CREB1	0.58	6.4	0.46	1.8e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.68	6.4	0.46	1.81e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.51	5.18	0.39	7.08e-7	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg21724239	chr8:58056113	NA	0.67	5.17	0.39	7.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg26850624	chr5:429559	AHRR	0.48	4.69	0.36	6.13e-6	Fat distribution (HIV);
PAAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.73	-0.36	5.13e-6	Parkinson's disease;
PAAD	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.34e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg12463550	chr7:65579703	CRCP	0.91	5.91	0.43	2.22e-8	Diabetic kidney disease;
PAAD	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg27373749	chr11:63775612	MACROD1	0.45	5.25	0.39	5.13e-7	Pulse pressure;
PAAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.62	6.68	0.48	4.34e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3136441	1.000	rs11039017	chr11:46905838	A/G	cg19486271	chr11:47235900	DDB2	0.63	4.89	0.37	2.59e-6	HDL cholesterol;
PAAD	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.73	8.12	0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg14393609	chr7:65229607	NA	-0.61	-6.43	-0.46	1.57e-9	Aortic root size;
PAAD	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg27113419	chr16:58533979	NDRG4	-0.74	-4.6	-0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg20007245	chr22:24372913	LOC391322	-0.66	-6.38	-0.46	2.04e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg26939375	chr7:64535504	NA	-0.74	-8.85	-0.58	2.14e-15	Aortic root size;
PAAD	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.49	-0.34	1.41e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.54	-4.82	-0.36	3.51e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.59	-0.35	9.41e-6	Eosinophil percentage of white cells;
PAAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2668423	0.960	rs2247675	chr19:1361793	T/C	cg02639931	chr19:1387894	NDUFS7	-0.55	-5.63	-0.42	8.48e-8	Nonalcoholic fatty liver disease;
PAAD	cis	rs2952768	1.000	rs2709384	chr2:208496943	G/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.39	0.34	2.14e-5	Opioid sensitivity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25187802	chr10:125600185	CPXM2	-0.53	-6.32	-0.46	2.71e-9	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24627793	chr17:79479216	ACTG1	0.65	6.74	0.48	3.07e-10	Obesity-related traits;
PAAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.7	7.31	0.51	1.45e-11	Colorectal cancer;
PAAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.0	-0.44	1.39e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.41e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.67	7.18	0.5	2.94e-11	Age at first birth;
PAAD	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.54	-0.78	3.23e-33	Height;
PAAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.92	8.95	0.59	1.13e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.53	-6.1	-0.44	8.58e-9	Systemic lupus erythematosus;
PAAD	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.93	0.59	1.28e-15	Fuchs's corneal dystrophy;
PAAD	cis	rs6076065	0.676	rs6076057	chr20:23335982	G/T	cg11657817	chr20:23433608	CST11	-0.5	-5.13	-0.38	8.77e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg16262614	chr3:133464971	TF	0.58	7.18	0.5	2.87e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-4.91	-0.37	2.34e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg03959625	chr15:84868606	LOC388152	-0.44	-4.56	-0.35	1.03e-5	P wave terminal force;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg24503407	chr1:205819492	PM20D1	0.53	4.89	0.37	2.5e-6	White blood cell types;
PAAD	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg16606324	chr3:10149918	C3orf24	0.61	4.75	0.36	4.69e-6	Alzheimer's disease;
PAAD	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.73e-14	Triglycerides;
PAAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.47	4.32	0.33	2.81e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9398803	0.661	rs1101557	chr6:127067996	T/C	cg19875578	chr6:126661172	C6orf173	-0.45	-4.76	-0.36	4.49e-6	Male-pattern baldness;
PAAD	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.72	6.88	0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.02	-12.3	-0.71	1.4e-24	Cognitive ability;
PAAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.22	0.45	4.7e-9	Ileal carcinoids;
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.74	-0.36	4.79e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.91	-0.37	2.34e-6	Body mass index;
PAAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.38	-0.33	2.21e-5	Post bronchodilator FEV1;
PAAD	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-5.83	-0.43	3.29e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.61	7.39	0.51	9.35e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6466055	0.661	rs7805928	chr7:104934662	A/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg00277334	chr10:82204260	NA	-0.61	-6.01	-0.44	1.35e-8	Post bronchodilator FEV1;
PAAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	1.27	11.98	0.7	1.04e-23	Eosinophil percentage of granulocytes;
PAAD	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-5.63	-0.42	8.53e-8	Obesity (extreme);
PAAD	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.92	-5.72	-0.42	5.44e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.75	4.66	0.35	6.97e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-5.2	-0.39	6.34e-7	Subjective well-being;
PAAD	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.5	4.95	0.37	1.95e-6	Height;
PAAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.58	0.41	1.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.21	-0.39	6.15e-7	Longevity;
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-8.28	-0.56	6e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.26	-0.33	3.54e-5	Cognitive function;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12913538	0.550	rs4775518	chr15:62901152	A/G	cg09983546	chr15:62884068	NA	0.79	7.94	0.54	4.09e-13	Sleep depth;
PAAD	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1372520	0.564	rs356196	chr4:90682803	A/T	cg20003494	chr4:90757398	SNCA	0.58	4.77	0.36	4.36e-6	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11210092	chr1:85666159	SYDE2	-0.65	-6.65	-0.47	5e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.81	8.75	0.58	3.72e-15	Height;
PAAD	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.91	-0.37	2.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg08999081	chr20:33150536	PIGU	0.53	5.82	0.43	3.33e-8	Height;
PAAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.87	10.74	0.66	2.25e-20	Aortic root size;
PAAD	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg01426195	chr3:39028469	NA	0.63	6.31	0.46	2.83e-9	Handedness;
PAAD	cis	rs10821973	0.527	rs7895575	chr10:63977537	G/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.3	-0.33	3.06e-5	Hypothyroidism;
PAAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg04482110	chr17:41364121	TMEM106A	0.4	4.59	0.35	9.33e-6	Menopause (age at onset);
PAAD	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg19423196	chr10:82049429	MAT1A	0.61	4.69	0.36	6.03e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3106136	0.586	rs72663787	chr4:95070166	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.94	-0.37	2.01e-6	Capecitabine sensitivity;
PAAD	cis	rs4750440	0.706	rs4503425	chr10:14019034	C/G	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9715521	0.500	rs6551769	chr4:59841570	A/G	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.53	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	cis	rs9361491	0.608	rs9352629	chr6:79461880	T/A	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs595018	0.505	rs1122409	chr11:60605794	C/T	cg23904249	chr11:60608951	CCDC86	0.7	5.17	0.39	7.17e-7	Wegener's granulomatosis;
PAAD	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.23	-0.7	2.18e-24	Urate levels in overweight individuals;
PAAD	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.65	7.75	0.53	1.2e-12	Alcohol dependence;
PAAD	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	4.41	0.34	1.94e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.1e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.76	-0.53	1.14e-12	Hemoglobin concentration;
PAAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.07	-0.44	9.6e-9	Menarche (age at onset);
PAAD	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.85	7.68	0.53	1.85e-12	Coronary artery disease;
PAAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.44	-4.99	-0.38	1.63e-6	Height;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.55	-6.14	-0.45	6.93e-9	Prostate cancer;
PAAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg14703610	chr5:56206110	C5orf35	0.62	5.8	0.43	3.72e-8	Coronary artery disease;
PAAD	cis	rs11761408	0.585	rs77010558	chr7:5259179	C/T	cg02820836	chr7:4652842	NA	-0.72	-4.35	-0.33	2.52e-5	Mean corpuscular volume;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.51	4.98	0.37	1.72e-6	Parkinson's disease;
PAAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.19	-0.39	6.75e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.35	0.71	1.06e-24	Chronic sinus infection;
PAAD	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg07371521	chr5:154026371	NA	-0.49	-6.41	-0.46	1.75e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	4.28	0.33	3.28e-5	Personality dimensions;
PAAD	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg12395012	chr8:11607386	GATA4	0.43	4.38	0.33	2.21e-5	Neuroticism;
PAAD	cis	rs1468333	1.000	rs2967781	chr5:137557609	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	cis	rs10073892	0.667	rs62372160	chr5:101612357	G/A	cg17280723	chr5:101634495	NA	0.42	4.43	0.34	1.81e-5	Cognitive decline (age-related);
PAAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.66	7.91	0.54	5.04e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12986413	0.967	rs1015670	chr19:2171490	G/A	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.13e-6	Height;
PAAD	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg07541023	chr7:19748670	TWISTNB	0.54	4.36	0.33	2.38e-5	Thyroid stimulating hormone;
PAAD	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.94	-0.37	1.99e-6	Personality dimensions;
PAAD	cis	rs3996993	0.737	rs1072340	chr6:52648728	C/T	cg20803780	chr6:52668592	GSTA1	-0.36	-4.45	-0.34	1.62e-5	Hemoglobin concentration;
PAAD	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg06138931	chr13:21896616	NA	0.75	5.58	0.41	1.05e-7	White matter hyperintensity burden;
PAAD	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg08648136	chr8:956695	NA	0.43	4.64	0.35	7.46e-6	Schizophrenia;
PAAD	cis	rs4588572	0.688	rs4590164	chr5:77671870	A/G	cg11547950	chr5:77652471	NA	-0.73	-6.31	-0.46	2.91e-9	Triglycerides;
PAAD	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg06138931	chr13:21896616	NA	-0.67	-4.55	-0.35	1.08e-5	White matter hyperintensity burden;
PAAD	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.56	5.17	0.39	7.36e-7	Testicular germ cell tumor;
PAAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg09654669	chr8:57350985	NA	-0.54	-4.98	-0.37	1.73e-6	Obesity-related traits;
PAAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.76e-7	Alcohol dependence;
PAAD	cis	rs988913	0.541	rs7766546	chr6:55006253	A/G	cg03513858	chr6:54763001	FAM83B	0.4	4.5	0.34	1.34e-5	Menarche (age at onset);
PAAD	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.75	-5.29	-0.39	4.24e-7	Carotid intima media thickness;
PAAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs72960926	1.000	rs55775775	chr6:75133634	A/G	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.66	-7.23	-0.51	2.14e-11	Eosinophil percentage of white cells;
PAAD	cis	rs375066	0.935	rs425221	chr19:44418544	C/T	cg21496419	chr19:44306685	LYPD5	-0.4	-4.89	-0.37	2.51e-6	Breast cancer;
PAAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.73	-7.42	-0.52	7.64e-12	Schizophrenia;
PAAD	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.62	-6.64	-0.47	5.17e-10	Neuroticism;
PAAD	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.64	0.35	7.37e-6	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.74	-0.36	4.97e-6	Height;
PAAD	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg18806716	chr10:30721971	MAP3K8	0.52	4.97	0.37	1.8e-6	Itch intensity from mosquito bite;
PAAD	cis	rs12989701	0.877	rs34745987	chr2:127875384	C/T	cg00091827	chr2:127863656	BIN1	0.59	4.32	0.33	2.78e-5	Alzheimer's disease (late onset);
PAAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.39	-0.56	3.16e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg12215294	chr3:40350768	EIF1B	0.5	5.19	0.39	6.72e-7	Renal cell carcinoma;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs16975963	0.793	rs73041034	chr19:38286272	G/A	cg14218481	chr19:38281219	NA	0.44	4.6	0.35	8.92e-6	Longevity;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.59	-8.08	-0.55	1.84e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6597981	0.592	rs28625355	chr11:736334	G/T	cg08747591	chr11:789928	CEND1	-0.55	-5.39	-0.4	2.69e-7	Breast cancer;
PAAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.57	0.65	6.21e-20	Smoking behavior;
PAAD	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg21775007	chr8:11205619	TDH	-0.49	-4.27	-0.33	3.45e-5	Triglycerides;
PAAD	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg20003494	chr4:90757398	SNCA	0.65	5.87	0.43	2.62e-8	Neuroticism;
PAAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04045327	chr4:905805	GAK	0.4	5.19	0.39	6.53e-7	Systemic sclerosis;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.61	7.43	0.52	7.49e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6782228	0.606	rs2811500	chr3:128366256	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.6	-0.47	6.54e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.94	0.54	4.14e-13	Prudent dietary pattern;
PAAD	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg08898775	chr15:59042684	ADAM10	0.37	4.67	0.35	6.56e-6	Asperger disorder;
PAAD	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	6.68	0.48	4.29e-10	Gastritis;
PAAD	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg03999872	chr20:62272968	STMN3	-0.73	-6.51	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs2446066	0.872	rs57676448	chr12:53794787	C/T	cg20591337	chr12:53693442	C12orf10	-0.62	-4.27	-0.33	3.44e-5	Red blood cell count;
PAAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.87	10.77	0.66	1.87e-20	Menopause (age at onset);
PAAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.57	-6.93	-0.49	1.13e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.78	-5.79	-0.43	3.87e-8	Coronary artery calcification;
PAAD	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Breast cancer;
PAAD	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.7	-5.91	-0.43	2.13e-8	Coronary artery disease;
PAAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs288342	0.832	rs288256	chr2:183604800	A/G	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	1.02	5.51	0.41	1.51e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg19680485	chr15:31195859	MTMR15	-0.45	-4.65	-0.35	7.23e-6	Huntington's disease progression;
PAAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg05895507	chr15:77155635	SCAPER	-0.38	-4.82	-0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.66	0.48	4.6e-10	Lung cancer;
PAAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18777431	chr3:138056475	NA	-0.64	-6.83	-0.48	1.95e-10	Obesity-related traits;
PAAD	cis	rs11892454	0.533	rs13392329	chr2:26065592	G/T	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.2	0.39	6.47e-7	Monocyte percentage of white cells;
PAAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.52	-5.78	-0.42	4.01e-8	Testicular germ cell tumor;
PAAD	cis	rs9467603	0.800	rs1892252	chr6:25772639	C/G	cg21479132	chr6:26055353	NA	-0.81	-5.78	-0.42	4.17e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs959260	0.541	rs61417295	chr17:73356848	T/C	cg14668889	chr17:73230827	NUP85	0.65	4.42	0.34	1.85e-5	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.74	0.42	4.89e-8	Prudent dietary pattern;
PAAD	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.64	-6.2	-0.45	4.99e-9	Breast size;
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.95	10.64	0.65	4.17e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg14851468	chr5:179071604	C5orf60	0.47	5.01	0.38	1.51e-6	Lung cancer;
PAAD	cis	rs13242816	1.000	rs1018859	chr7:116067347	C/T	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs17021463	0.617	rs12499187	chr4:95323917	A/G	cg11021082	chr4:95130006	SMARCAD1	0.5	4.82	0.36	3.51e-6	Testicular germ cell tumor;
PAAD	cis	rs2004318	1.000	rs78456857	chr19:55080487	C/T	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13664146	chr17:71228606	C17orf80;FAM104A	-0.62	-6.69	-0.48	3.92e-10	Lung cancer in ever smokers;
PAAD	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.45	0.4	2.03e-7	Type 2 diabetes;
PAAD	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08219700	chr8:58056026	NA	0.66	5.15	0.39	7.89e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg27130406	chr16:89901659	SPIRE2	-0.81	-5.72	-0.42	5.48e-8	Vitiligo;
PAAD	cis	rs17162190	0.740	rs12046497	chr1:26847640	C/T	cg17456097	chr1:26900765	RPS6KA1	0.6	5.02	0.38	1.41e-6	Mean corpuscular volume;
PAAD	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.14	6.31	0.46	2.97e-9	Body mass index;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21016266	chr12:122356598	WDR66	0.54	5.77	0.42	4.31e-8	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs4268898	0.828	rs2702121	chr2:24610392	C/A	cg06627628	chr2:24431161	ITSN2	0.64	6.02	0.44	1.26e-8	Asthma;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.5	5.05	0.38	1.24e-6	Longevity;Endometriosis;
PAAD	cis	rs755249	0.567	rs61779306	chr1:39922426	G/A	cg14018543	chr1:39659967	MACF1	-0.54	-4.54	-0.35	1.15e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2133450	0.712	rs9990013	chr3:7366352	A/C	cg19930620	chr3:7340148	GRM7	0.46	5.08	0.38	1.1e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg01815783	chr4:1047043	NA	-0.48	-4.6	-0.35	8.77e-6	Recombination rate (females);
PAAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.14	7.71	0.53	1.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.61	-6.84	-0.49	1.82e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg27449745	chr7:23145252	KLHL7	-0.6	-5.49	-0.41	1.63e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.61	7.1	0.5	4.36e-11	Iron status biomarkers (transferrin levels);
PAAD	trans	rs901683	0.702	rs34176769	chr10:46071027	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.29	-8.8	-0.58	2.75e-15	Atopic dermatitis;
PAAD	cis	rs9815354	1.000	rs73069396	chr3:41787236	A/T	cg03022575	chr3:42003672	ULK4	0.71	5.2	0.39	6.36e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.54	-0.35	1.15e-5	Colorectal cancer;
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.47	4.98	0.37	1.68e-6	Age at first birth;
PAAD	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-7.99	-0.54	3.21e-13	Hemoglobin concentration;
PAAD	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.77	0.36	4.31e-6	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11593111	chr5:139493674	PURA	0.66	6.37	0.46	2.09e-9	Obesity-related traits;
PAAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.97	0.49	9.21e-11	Rheumatoid arthritis;
PAAD	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs939584	0.935	rs6732471	chr2:629914	G/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.72	6.65	0.47	4.93e-10	Mean platelet volume;
PAAD	trans	rs1282545	0.560	rs1850344	chr3:107185073	C/T	cg22635088	chr5:2096922	NA	0.4	6.33	0.46	2.61e-9	Neuroticism;
PAAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.51	-5.17	-0.39	7.3e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.64	-9.96	-0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg27455613	chr17:80820699	TBCD	0.45	4.48	0.34	1.46e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-4.77	-0.36	4.2e-6	Colorectal cancer;
PAAD	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-13.65	-0.74	3.46e-28	Height;
PAAD	cis	rs6960043	0.560	rs7811965	chr7:15041076	A/T	cg19272540	chr7:15055459	NA	0.32	5.52	0.41	1.41e-7	Type 2 diabetes;
PAAD	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg21479132	chr6:26055353	NA	0.99	6.41	0.46	1.72e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs9398803	0.589	rs853965	chr6:127036174	C/T	cg19875578	chr6:126661172	C6orf173	-0.44	-4.58	-0.35	9.65e-6	Male-pattern baldness;
PAAD	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.95	-7.83	-0.54	7.83e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.5	4.26	0.33	3.53e-5	Aortic root size;
PAAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-5.62	-0.41	8.97e-8	Monocyte count;
PAAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg00999904	chr2:3704751	ALLC	-0.39	-4.49	-0.34	1.39e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2749097	0.808	rs855355	chr1:64121877	A/G	cg11244180	chr1:64669412	UBE2U	0.57	4.28	0.33	3.29e-5	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19346786	chr7:2764209	NA	-0.33	-4.55	-0.35	1.1e-5	Height;
PAAD	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.37	5.01	0.38	1.52e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg02476566	chr12:106696527	TCP11L2	0.45	4.37	0.33	2.33e-5	Tourette syndrome;
PAAD	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.54	5.33	0.4	3.47e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg09659197	chr4:152720779	NA	-0.36	-5.29	-0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg10932868	chr11:921992	NA	0.45	4.84	0.37	3.21e-6	Alzheimer's disease (late onset);
PAAD	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg15017067	chr4:17643749	FAM184B	-0.4	-4.5	-0.34	1.36e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.67	-6.6	-0.47	6.58e-10	Paraoxonase activity;
PAAD	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.5	-5.42	-0.4	2.26e-7	Testicular germ cell tumor;
PAAD	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-5.69	-0.42	6.23e-8	Longevity;Endometriosis;
PAAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg19680485	chr15:31195859	MTMR15	-0.43	-4.43	-0.34	1.78e-5	Huntington's disease progression;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.76	0.36	4.46e-6	Electroencephalogram traits;
PAAD	cis	rs79839061	0.764	rs12646225	chr4:696848	C/T	cg07828340	chr4:882639	GAK	0.8	5.41	0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs35740288	0.521	rs11073502	chr15:86251534	C/T	cg11345955	chr15:86086674	AKAP13	-0.32	-4.26	-0.33	3.51e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-7.05	-0.5	5.91e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs7583236	0.929	rs3821276	chr2:70187173	A/G	cg19638749	chr2:70312615	NA	-0.71	-4.62	-0.35	8.12e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.73	7.98	0.54	3.33e-13	Lung cancer;
PAAD	cis	rs10450586	0.932	rs10767635	chr11:27333438	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg08601574	chr20:25228251	PYGB	0.63	6.93	0.49	1.12e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.45	-5.16	-0.39	7.51e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.16	-0.39	7.56e-7	Body mass index;
PAAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg17052926	chr7:915758	C7orf20	-0.44	-4.35	-0.33	2.48e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.79	5.65	0.42	7.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.87	7.9	0.54	5.18e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35160687	0.623	rs1863060	chr2:86511456	G/A	cg10973622	chr2:86423274	IMMT	-0.45	-4.98	-0.37	1.7e-6	Night sleep phenotypes;
PAAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.7	8.3	0.56	5.23e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.71	8.68	0.58	5.86e-15	Obesity (extreme);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25903588	chr7:150763533	SLC4A2	-0.71	-7.02	-0.49	6.84e-11	Obesity-related traits;
PAAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.57	6.88	0.49	1.43e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.34	4.39	0.34	2.12e-5	Schizophrenia;
PAAD	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.6	0.47	6.31e-10	Coffee consumption (cups per day);
PAAD	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg22691776	chr3:15032403	NR2C2	0.29	4.33	0.33	2.73e-5	Mean platelet volume;
PAAD	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.5	4.42	0.34	1.89e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.57	0.35	1.02e-5	Electrocardiographic conduction measures;
PAAD	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg12046867	chr14:103022105	NA	-0.62	-4.84	-0.37	3.14e-6	Platelet count;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.34	-0.33	2.54e-5	Platelet count;
PAAD	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.75	8.81	0.58	2.6e-15	Noise-induced hearing loss;
PAAD	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.89	10.74	0.66	2.31e-20	Prudent dietary pattern;
PAAD	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg15208524	chr1:10270712	KIF1B	0.46	4.38	0.33	2.22e-5	Hepatocellular carcinoma;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg12373951	chr3:133503437	NA	-0.37	-4.81	-0.36	3.67e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.94	-0.43	1.87e-8	Schizophrenia;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-4.99	-0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	1.0	9.03	0.59	7.27e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1075265	0.722	rs805374	chr2:54089857	A/G	cg04546899	chr2:54196757	PSME4	0.3	4.53	0.34	1.19e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs67257959	0.708	rs13343952	chr19:17197064	G/C	cg19418318	chr19:17219073	MYO9B	0.31	4.42	0.34	1.9e-5	Selective IgA deficiency;
PAAD	cis	rs795484	0.856	rs1151900	chr12:118686282	A/G	cg16572268	chr12:118583242	PEBP1	-0.46	-4.49	-0.34	1.39e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.72	4.27	0.33	3.45e-5	Type 2 diabetes nephropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18728109	chr3:183639017	ABCC5	-0.68	-6.67	-0.48	4.42e-10	Obesity-related traits;
PAAD	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25632853	chr15:73088954	NA	-0.42	-4.79	-0.36	3.9e-6	Triglyceride levels;
PAAD	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-7.0	-0.49	7.79e-11	Body mass index;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18287962	chr20:25176437	ENTPD6	0.57	6.58	0.47	7.2e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg04398451	chr17:18023971	MYO15A	0.76	8.03	0.55	2.47e-13	Total body bone mineral density;
PAAD	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.22	-0.39	5.9e-7	Height;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg14092988	chr3:52407081	DNAH1	0.41	5.11	0.38	9.63e-7	Bipolar disorder;
PAAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.36	15.59	0.78	2.44e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.99	8.95	0.59	1.17e-15	Vitiligo;
PAAD	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg23950597	chr19:37808831	NA	-0.76	-5.46	-0.4	1.9e-7	Coronary artery calcification;
PAAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.48	0.65	1.14e-19	Homoarginine levels;
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs9462846	0.853	rs7747505	chr6:42839062	A/G	cg02353165	chr6:42928485	GNMT	0.52	4.47	0.34	1.54e-5	Blood protein levels;
PAAD	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.67	-0.35	6.51e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6076065	0.723	rs6083100	chr20:23358651	G/A	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-7.2	-0.5	2.55e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	11.99	0.7	1e-23	Menarche (age at onset);
PAAD	cis	rs4462272	0.557	rs17668357	chr10:102003906	G/C	cg11888571	chr10:102027403	CWF19L1	-0.49	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg07099767	chr17:78039528	CCDC40	-0.5	-4.57	-0.35	1.01e-5	Yeast infection;
PAAD	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg13293535	chr8:11597251	GATA4	0.32	4.29	0.33	3.15e-5	Neuroticism;
PAAD	cis	rs9815354	0.951	rs9864331	chr3:41762217	G/A	cg03022575	chr3:42003672	ULK4	0.83	5.81	0.43	3.55e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.6	4.36	0.33	2.42e-5	Exhaled nitric oxide output;
PAAD	trans	rs901683	0.702	rs75758972	chr10:46081598	C/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	8.09e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.44	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.699	rs4496901	chr7:104898337	G/T	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.41	-0.4	2.39e-7	Glaucoma (primary open-angle);
PAAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.81	7.84	0.54	7.32e-13	Coronary artery disease;
PAAD	cis	rs747650	0.504	rs10838644	chr11:47035761	G/A	cg19486271	chr11:47235900	DDB2	-0.68	-6.26	-0.45	3.73e-9	Acne (severe);
PAAD	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg24565620	chr2:194026	NA	0.66	5.53	0.41	1.37e-7	Blood protein levels;
PAAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.09	-0.38	1.06e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg04165759	chr1:150448943	RPRD2	-0.52	-5.38	-0.4	2.82e-7	Migraine;
PAAD	cis	rs6066825	0.590	rs6063307	chr20:47304045	A/G	cg18078177	chr20:47281410	PREX1	0.46	4.51	0.34	1.3e-5	Colorectal cancer;
PAAD	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.65	-5.14	-0.39	8.17e-7	Breast cancer;
PAAD	cis	rs12282928	0.700	rs2047815	chr11:48199897	C/T	cg04721828	chr11:48285200	OR4X1	0.4	5.19	0.39	6.57e-7	Migraine - clinic-based;
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.72e-9	Prostate cancer;
PAAD	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.12	9.1	0.59	4.89e-16	Corneal structure;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.51	-4.7	-0.36	5.85e-6	Urate levels;
PAAD	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg10820045	chr2:198174542	NA	0.51	5.19	0.39	6.67e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.92	7.5	0.52	4.9e-12	Iron status biomarkers;
PAAD	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.81	-6.81	-0.48	2.17e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.88	10.28	0.64	3.9e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg16926213	chr1:1841314	NA	0.37	4.49	0.34	1.38e-5	Body mass index;
PAAD	cis	rs2518049	0.539	rs4636560	chr10:5157733	T/C	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.71	-5.47	-0.41	1.85e-7	Initial pursuit acceleration;
PAAD	cis	rs6580110	0.837	rs749777	chr5:154074270	T/C	cg05212464	chr5:154071076	NA	0.48	5.05	0.38	1.26e-6	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg03948781	chr1:205179583	DSTYK	0.47	4.32	0.33	2.86e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.51	-5.18	-0.39	7.08e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg11949866	chr1:10754891	CASZ1	0.51	4.42	0.34	1.89e-5	Ewing sarcoma;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg17294928	chr15:75287854	SCAMP5	0.44	4.45	0.34	1.63e-5	Caffeine consumption;
PAAD	cis	rs7623687	1.000	rs73073007	chr3:49496059	G/A	cg19401529	chr3:49056140	DALRD3	0.85	5.13	0.38	8.6e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs35160687	0.644	rs11680025	chr2:86545338	C/T	cg10973622	chr2:86423274	IMMT	-0.47	-5.21	-0.39	6.07e-7	Night sleep phenotypes;
PAAD	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg05085585	chr16:30420623	ZNF771	0.47	4.55	0.35	1.07e-5	Tonsillectomy;
PAAD	cis	rs2446066	1.000	rs2446066	chr12:53778650	G/T	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs11700980	0.591	rs2832025	chr21:30114322	C/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg02986806	chr22:18893533	DGCR6	0.59	6.54	0.47	8.79e-10	Height;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.48	-4.6	-0.35	8.9e-6	Coronary artery disease;
PAAD	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg09127314	chr1:152161683	NA	-0.64	-4.57	-0.35	9.97e-6	Atopic dermatitis;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.53	5.33	0.4	3.46e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.76	6.56	0.47	8.14e-10	Coronary artery disease;
PAAD	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.89	9.72	0.62	1.13e-17	Anterior chamber depth;
PAAD	cis	rs13102973	0.899	rs13126625	chr4:135900322	C/T	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg19673125	chr6:150240577	RAET1G	0.41	5.9	0.43	2.29e-8	Lung cancer;
PAAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.24	-0.45	4.14e-9	Gut microbiome composition (summer);
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg21951975	chr1:209979733	IRF6	0.57	5.88	0.43	2.55e-8	Coronary artery disease;
PAAD	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.74	7.13	0.5	3.71e-11	Coronary artery disease;
PAAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-7.45	-0.52	6.62e-12	Cognitive function;
PAAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.81	-6.55	-0.47	8.24e-10	Gut microbiome composition (summer);
PAAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9322817	0.583	rs6941988	chr6:105146656	C/T	cg02098413	chr6:105308735	HACE1	0.47	6.22	0.45	4.59e-9	Thyroid stimulating hormone;
PAAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.57	5.5	0.41	1.55e-7	Migraine;
PAAD	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.75	4.34	0.33	2.55e-5	Coronary artery disease;
PAAD	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06156847	chr2:113672199	IL1F7	0.59	6.29	0.45	3.16e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18502306	chr4:8376764	ACOX3	0.58	6.83	0.48	1.9e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.24	0.64	4.76e-19	Menopause (age at onset);
PAAD	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-8.06	-0.55	2.08e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg22467129	chr15:76604101	ETFA	0.47	4.42	0.34	1.9e-5	Blood metabolite levels;
PAAD	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.5	4.54	0.35	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	1.01	7.09	0.5	4.68e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg12458913	chr13:53173898	NA	0.48	4.89	0.37	2.51e-6	Lewy body disease;
PAAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs9880772	0.747	rs9838021	chr3:27820995	T/C	cg21473142	chr3:27762095	EOMES	0.33	5.81	0.43	3.61e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.33	-0.4	3.42e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs4455778	0.519	rs34062689	chr7:49035022	G/T	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-6.07	-0.44	9.6e-9	Menopause (age at onset);
PAAD	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs300774	0.800	rs406427	chr2:146263	C/A	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.65	7.02	0.49	7.02e-11	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	5.57	0.41	1.13e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.98	-0.37	1.73e-6	Monocyte percentage of white cells;
PAAD	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.57	7.17	0.5	3.1e-11	Schizophrenia;
PAAD	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg06096015	chr1:231504339	EGLN1	-0.59	-6.51	-0.47	1.03e-9	Red blood cell count;
PAAD	trans	rs901683	1.000	rs78220003	chr10:45988348	A/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.4	0.4	2.48e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09924173	chr13:32526671	EEF1DP3	-0.62	-6.44	-0.46	1.49e-9	Smoking initiation;
PAAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg09654669	chr8:57350985	NA	-0.53	-5.03	-0.38	1.36e-6	Obesity-related traits;
PAAD	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs11997175	0.624	rs7388511	chr8:33735582	C/G	ch.8.33884649F	chr8:33765107	NA	0.58	5.62	0.42	8.68e-8	Body mass index;
PAAD	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.2	0.45	5.18e-9	Electrocardiographic conduction measures;
PAAD	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs4538187	0.906	rs17619753	chr2:63943616	G/A	cg08613950	chr2:64719184	NA	0.65	4.33	0.33	2.74e-5	Systolic blood pressure;
PAAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.7	7.33	0.51	1.24e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg03700679	chr2:178418002	TTC30B	0.57	4.48	0.34	1.44e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.63	5.85	0.43	2.92e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.66	5.84	0.43	3.13e-8	Facial morphology (factor 23);
PAAD	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	4.92	0.37	2.2e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg08676812	chr11:65308423	LTBP3	0.79	5.47	0.41	1.78e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6988985	0.560	rs5301	chr8:143955273	T/C	cg10324643	chr8:143916377	GML	0.42	4.61	0.35	8.37e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs16958440	0.867	rs3809966	chr18:44677627	C/T	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.9e-13	Response to antipsychotic treatment;
PAAD	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.52	-6.36	-0.46	2.24e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg23682824	chr7:23144976	KLHL7	0.48	4.32	0.33	2.82e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06028605	chr16:24865363	SLC5A11	-0.52	-6.25	-0.45	3.99e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.62	-6.34	-0.46	2.49e-9	Monocyte count;
PAAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.25	-0.45	3.98e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-1.25	-9.28	-0.6	1.63e-16	Blood pressure (smoking interaction);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00704012	chr12:49463725	RHEBL1	0.72	6.53	0.47	9.18e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.46	4.71	0.36	5.47e-6	Systemic lupus erythematosus;
PAAD	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	4.29	0.33	3.13e-5	Blood protein levels;
PAAD	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.78	-5.67	-0.42	7.13e-8	Vitiligo;
PAAD	cis	rs874628	0.686	rs11666906	chr19:18241898	A/G	cg02814054	chr19:18234911	MAST3	0.44	4.36	0.33	2.4e-5	Multiple sclerosis;
PAAD	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg00459043	chr17:30771460	PSMD11	-0.55	-4.57	-0.35	9.92e-6	Height;
PAAD	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.78	9.08	0.59	5.49e-16	Heart rate;
PAAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.34	-0.33	2.56e-5	Cystic fibrosis severity;
PAAD	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.8	10.41	0.65	1.72e-19	Colorectal cancer;
PAAD	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-0.73	-8.12	-0.55	1.48e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs8077577	0.945	rs62072496	chr17:18124743	G/A	cg16794390	chr17:18148240	FLII	0.61	4.91	0.37	2.3e-6	Obesity-related traits;
PAAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.51	-0.41	1.51e-7	Alcohol dependence;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg09915433	chr19:53449742	NA	-0.78	-11.37	-0.68	4.52e-22	Psoriasis;
PAAD	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.86	10.88	0.66	9.28e-21	Body mass index;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08395365	chr3:182817479	MCCC1	0.72	6.54	0.47	8.89e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs8053891	0.708	rs8055242	chr16:72006882	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-4.71	-0.36	5.47e-6	Coronary artery disease;
PAAD	cis	rs1144333	0.655	rs7521538	chr1:76420440	A/G	cg22875332	chr1:76189707	ACADM	0.76	4.53	0.35	1.18e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs12311304	0.965	rs12320285	chr12:15372062	G/T	cg08258403	chr12:15378311	NA	0.37	4.67	0.35	6.44e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09424554	chr8:22445599	PDLIM2	-0.68	-6.7	-0.48	3.74e-10	Obesity-related traits;
PAAD	cis	rs10510102	0.608	rs4752607	chr10:123594941	A/G	cg09536375	chr10:123735128	NSMCE4A	0.36	4.54	0.35	1.14e-5	Breast cancer;
PAAD	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.56	6.05	0.44	1.06e-8	Mean corpuscular volume;
PAAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09695851	chr17:3907499	NA	0.84	8.59	0.57	9.75e-15	Type 2 diabetes;
PAAD	cis	rs12612619	0.732	rs1053609	chr2:27293150	G/T	cg00617064	chr2:27272375	NA	-0.56	-6.05	-0.44	1.1e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.88	10.79	0.66	1.61e-20	Prudent dietary pattern;
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Body mass index;
PAAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.93	0.37	2.16e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg07202610	chr7:1142643	C7orf50	-0.77	-5.42	-0.4	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.99	8.43	0.56	2.46e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg01244601	chr4:120671846	NA	-0.5	-4.28	-0.33	3.23e-5	Corneal astigmatism;
PAAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23983436	chr11:842963	TSPAN4;POLR2L	-0.65	-6.51	-0.47	1.01e-9	Smoking initiation;
PAAD	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.12	-0.44	7.79e-9	Type 2 diabetes;
PAAD	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg16583315	chr14:65563665	MAX	-0.41	-4.36	-0.33	2.42e-5	Obesity-related traits;
PAAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	6.55	0.47	8.43e-10	Initial pursuit acceleration;
PAAD	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg01953289	chr20:60874239	NA	0.72	5.49	0.41	1.65e-7	Obesity-related traits;
PAAD	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg11088901	chr6:166572345	T	-0.5	-4.61	-0.35	8.48e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.62	-6.35	-0.46	2.4e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.62	6.67	0.48	4.37e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg14440974	chr22:39074834	NA	-0.55	-6.91	-0.49	1.27e-10	Menopause (age at onset);
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01283332	chr5:1856932	NA	-0.47	-4.86	-0.37	2.94e-6	Cardiovascular disease risk factors;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.54	-0.35	1.13e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4795519	0.922	rs1913800	chr17:22181268	C/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.52	-4.93	-0.37	2.11e-6	Neurofibrillary tangles;
PAAD	cis	rs2109514	1.000	rs3919515	chr7:116151784	C/G	cg19719915	chr7:115928094	NA	0.49	4.67	0.35	6.5e-6	Prevalent atrial fibrillation;
PAAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.79e-9	Menarche (age at onset);
PAAD	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.07	8.64	0.57	7.05e-15	Corneal structure;
PAAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.61	4.95	0.37	1.97e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.94	-10.94	-0.66	6.73e-21	Total body bone mineral density;
PAAD	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.84	10.0	0.63	2.1e-18	Blood metabolite ratios;
PAAD	cis	rs7943953	0.580	rs2198451	chr11:59187545	T/C	cg06466547	chr11:59191289	OR5A2	-0.46	-4.34	-0.33	2.62e-5	Odorant perception (&beta-ionone);
PAAD	cis	rs59888335	0.928	rs966617	chr3:80737264	T/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.53	4.4	0.34	2.05e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10426930	1.000	rs10426930	chr19:5038917	G/A	cg08036796	chr19:5034282	KDM4B	0.55	5.41	0.4	2.42e-7	Monocyte percentage of white cells;
PAAD	cis	rs11677203	1.000	rs12990104	chr2:12564429	G/A	cg01085830	chr2:11774354	GREB1	0.48	4.73	0.36	5.11e-6	Electroencephalogram traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14350088	chr2:234160149	ATG16L1	0.63	6.69	0.48	3.99e-10	Myopia (pathological);
PAAD	cis	rs10274279	1.000	rs73163814	chr7:157388012	A/G	cg09270525	chr7:157391030	PTPRN2	0.72	5.6	0.41	9.65e-8	Myopia (pathological);
PAAD	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.58	6.1	0.44	8.36e-9	Menarche (age at onset);
PAAD	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11209002	0.738	rs10789222	chr1:67566651	C/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Crohn's disease;
PAAD	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.66	0.35	6.88e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9810890	1.000	rs56000731	chr3:128647141	T/C	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.88	7.1	0.5	4.47e-11	Axial length;
PAAD	cis	rs7577696	0.962	rs12989936	chr2:32268586	A/G	cg02381751	chr2:32503542	YIPF4	-0.42	-4.46	-0.34	1.58e-5	Inflammatory biomarkers;
PAAD	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg10589385	chr1:150898437	SETDB1	0.39	4.87	0.37	2.79e-6	Melanoma;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07234876	chr8:600039	NA	1.12	8.39	0.56	3.12e-14	IgG glycosylation;
PAAD	cis	rs3857067	1.000	rs1397025	chr4:95018987	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg22916017	chr11:64110731	CCDC88B	0.38	4.49	0.34	1.38e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.64	-6.97	-0.49	9.03e-11	Diastolic blood pressure;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.49	4.97	0.37	1.77e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	7.33	0.51	1.27e-11	Lymphocyte counts;
PAAD	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg02683114	chr2:24398427	C2orf84	0.65	7.28	0.51	1.72e-11	Asthma;
PAAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg24739098	chr15:79297159	RASGRF1	0.36	4.58	0.35	9.58e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.51	-7.1	-0.5	4.42e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.99	14.06	0.75	2.68e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg14393609	chr7:65229607	NA	-0.48	-4.86	-0.37	2.93e-6	Aortic root size;
PAAD	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.4	0.4	2.57e-7	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.53	5.67	0.42	7.1e-8	Life satisfaction;
PAAD	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.63	0.35	7.66e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.73	-8.94	-0.59	1.24e-15	Breast cancer;
PAAD	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.62	1.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.12	-0.5	4.04e-11	Morning vs. evening chronotype;
PAAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg13468214	chr4:1046988	NA	-0.5	-4.85	-0.37	3e-6	Recombination rate (females);
PAAD	cis	rs1499972	0.878	rs56174517	chr3:117616218	G/T	cg07612923	chr3:117604196	NA	1.05	7.22	0.51	2.36e-11	Schizophrenia;
PAAD	cis	rs3131337	1	rs3131337	chr6:28796071	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.52	4.32	0.33	2.77e-5	Cold sores;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg10407489	chr4:1043616	NA	-0.33	-4.81	-0.36	3.59e-6	Recombination rate (males);
PAAD	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg18655438	chr5:1077845	SLC12A7	0.61	5.87	0.43	2.7e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg17719053	chr1:75198211	TYW3;CRYZ	0.49	4.68	0.35	6.41e-6	Resistin levels;
PAAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06217245	chr20:33103252	DYNLRB1	0.4	4.82	0.36	3.39e-6	Coronary artery disease;
PAAD	cis	rs11168618	0.904	rs4359253	chr12:48927708	G/A	cg01881778	chr12:48919444	OR8S1	-0.44	-4.41	-0.34	1.94e-5	Adiponectin levels;
PAAD	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.87	-10.77	-0.66	1.91e-20	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.59	6.12	0.44	7.76e-9	Response to antidepressants and depression;
PAAD	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg23024343	chr7:107201750	COG5	0.57	4.57	0.35	9.87e-6	Coronary artery disease;
PAAD	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11991859	chr14:33408527	NPAS3	0.56	6.43	0.46	1.59e-9	Metabolite levels  (X-11787);
PAAD	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.53	-5.45	-0.4	1.95e-7	Daytime sleep phenotypes;
PAAD	cis	rs2017305	0.834	rs2246952	chr10:70782592	A/G	cg25290552	chr10:70751067	KIAA1279	-0.85	-5.47	-0.41	1.79e-7	Depression (quantitative trait);
PAAD	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.36	0.6	1e-16	Parkinson's disease;
PAAD	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.51	5.39	0.4	2.67e-7	Red blood cell count;
PAAD	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.7	8.33	0.56	4.49e-14	Lung cancer;
PAAD	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17793497	chr15:89284664	NA	-0.58	-6.58	-0.47	7.31e-10	Obesity-related traits;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg19853413	chr5:135468610	SMAD5;SMAD5OS	0.89	6.41	0.46	1.77e-9	Lung function (FEV1/FVC);
PAAD	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg22916017	chr11:64110731	CCDC88B	0.39	4.67	0.35	6.7e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.45	-5.53	-0.41	1.34e-7	Coronary artery disease;
PAAD	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1.01e-6	Atopic dermatitis;
PAAD	trans	rs12738007	0.870	rs1908088	chr1:29572966	G/C	cg05667379	chr2:115920764	DPP10	0.38	6.41	0.46	1.75e-9	Schizophrenia;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.52	0.41	1.41e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.65	7.07	0.5	5.36e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	7.69	0.53	1.67e-12	Lymphocyte counts;
PAAD	trans	rs7756089	0.677	rs9393994	chr6:11243685	G/T	cg27135788	chr10:104402556	NA	1.0	6.4	0.46	1.84e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.38	-0.46	1.98e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.55	-5.84	-0.43	3.13e-8	White matter hyperintensity burden;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02126098	chr17:61699788	MAP3K3	0.7	7.17	0.5	3.01e-11	Obesity-related traits;
PAAD	cis	rs12620999	0.941	rs4663701	chr2:238036884	C/T	cg23555395	chr2:238036564	NA	-0.54	-6.19	-0.45	5.28e-9	Systemic lupus erythematosus;
PAAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg08134877	chr2:44394819	PPM1B	0.45	4.42	0.34	1.84e-5	Height;
PAAD	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.52	4.91	0.37	2.3e-6	Hirschsprung disease;
PAAD	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-4.79	-0.36	3.9e-6	Educational attainment;
PAAD	cis	rs16975963	0.793	rs73034929	chr19:38456697	T/C	cg08679971	chr19:38281047	NA	0.56	5.35	0.4	3.22e-7	Longevity;
PAAD	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.75	-6.11	-0.44	7.92e-9	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs3743832	1.000	rs3743832	chr16:9213880	A/C	cg08831531	chr16:9218945	NA	-0.4	-4.36	-0.33	2.38e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.51	-4.49	-0.34	1.4e-5	Mean corpuscular volume;
PAAD	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.73	-6.32	-0.46	2.69e-9	Morning vs. evening chronotype;
PAAD	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9876781	1.000	rs11130170	chr3:48449897	C/T	cg24898236	chr3:49228699	LOC646498	0.39	4.31	0.33	2.9e-5	Longevity;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg07061783	chr6:25882402	NA	-0.53	-5.11	-0.38	9.37e-7	Blood metabolite levels;
PAAD	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1198430	0.562	rs10917388	chr1:23803138	A/G	cg24580199	chr1:23763081	ASAP3	0.49	4.28	0.33	3.31e-5	Total cholesterol levels;
PAAD	cis	rs4739066	0.579	rs12541047	chr8:63879476	T/G	cg20602954	chr8:63776762	NKAIN3	0.8	5.16	0.39	7.64e-7	Myocardial infarction;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.6	-6.35	-0.46	2.33e-9	Lung cancer;
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.67	-5.49	-0.41	1.69e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6256	0.929	rs11605533	chr11:13547021	C/T	cg11976911	chr11:13509032	NA	0.66	5.2	0.39	6.22e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.6	6.8	0.48	2.24e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.4	0.46	1.8e-9	Rheumatoid arthritis;
PAAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.2	-0.5	2.55e-11	Coronary artery disease;
PAAD	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg11204139	chr17:3907470	NA	-0.53	-4.94	-0.37	2e-6	Type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.86	-9.21	-0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs12304921	0.683	rs17125286	chr12:51454210	T/C	cg18059802	chr12:51347058	HIGD1C	-0.63	-4.96	-0.37	1.87e-6	Type 2 diabetes;
PAAD	cis	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg24053715	chr22:38214548	NA	0.62	5.8	0.43	3.76e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.28	-0.64	3.71e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg03030879	chr14:75389066	RPS6KL1	0.41	4.35	0.33	2.44e-5	Height;
PAAD	trans	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-6.1	-0.44	8.44e-9	Monocyte count;
PAAD	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	13.78	0.75	1.53e-28	Testicular germ cell tumor;
PAAD	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs11671005	0.656	rs55652736	chr19:59007566	G/T	cg25952890	chr19:58913133	NA	0.65	4.71	0.36	5.43e-6	Mean platelet volume;
PAAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Aortic root size;
PAAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg00701064	chr4:6280414	WFS1	0.85	9.33	0.6	1.23e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	1.0	12.18	0.7	2.97e-24	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15924577	chr11:120039917	NA	0.58	6.59	0.47	6.7e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.6	5.37	0.4	2.93e-7	Obesity-related traits;
PAAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.75	10.17	0.64	7.43e-19	Coronary artery disease;
PAAD	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	6.13	0.45	7.17e-9	Post bronchodilator FEV1;
PAAD	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.13	-0.67	2.08e-21	Ulcerative colitis;
PAAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	6.39	0.46	1.9e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2882667	0.690	rs1976562	chr5:138110594	G/A	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10346535	chr4:106629853	INTS12;GSTCD	0.6	6.77	0.48	2.6e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3812111	0.525	rs3749893	chr6:116571695	A/G	cg18828861	chr6:116576566	TSPYL4	-0.47	-4.96	-0.37	1.87e-6	Age-related macular degeneration;
PAAD	cis	rs2882667	0.722	rs2011462	chr5:138162772	G/A	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs761746	0.960	rs1543416	chr22:31925073	A/G	cg01338084	chr22:32026380	PISD	0.48	4.4	0.34	2.03e-5	Intelligence;
PAAD	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.28	0.33	3.27e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg10729496	chr3:10149963	C3orf24	0.78	5.91	0.43	2.17e-8	Alzheimer's disease;
PAAD	cis	rs3818285	0.610	rs550697	chr10:111637286	A/G	cg00817464	chr10:111662876	XPNPEP1	0.88	11.46	0.68	2.58e-22	Superior crus of antihelix expression;
PAAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.29	0.56	5.61e-14	Menopause (age at onset);
PAAD	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	13.21	0.73	5.25e-27	Primary sclerosing cholangitis;
PAAD	cis	rs4747197	1.000	rs11000003	chr10:73557674	T/A	cg04506911	chr10:72937119	NA	0.4	4.39	0.34	2.15e-5	Progranulin levels;
PAAD	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg20060109	chr17:81052770	NA	-0.45	-4.39	-0.34	2.13e-5	Reticulocyte count;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Personality dimensions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15863254	chr1:226374036	ACBD3	0.57	6.38	0.46	2.07e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.84	9.07	0.59	5.76e-16	Corneal astigmatism;
PAAD	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs1957429	0.614	rs75819890	chr14:65370321	T/G	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.02	-0.44	1.23e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs34638657	0.518	rs7196560	chr16:82168162	A/T	cg09439754	chr16:82129088	HSD17B2	-0.35	-4.28	-0.33	3.29e-5	Lung adenocarcinoma;
PAAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg14345882	chr6:26364793	BTN3A2	0.68	4.91	0.37	2.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.45	-4.28	-0.33	3.33e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1018697	1.000	rs4919677	chr10:104554304	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs9462027	0.628	rs9380455	chr6:34690778	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.47	5.64	0.42	8.09e-8	Systemic lupus erythematosus;
PAAD	cis	rs13177180	0.671	rs10069695	chr5:114960963	G/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-4.84	-0.37	3.15e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.71	-0.36	5.45e-6	Subjective well-being;
PAAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1656368	0.726	rs73154329	chr3:158257762	G/A	cg16708174	chr3:158430962	RARRES1	0.52	4.72	0.36	5.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12620999	0.878	rs59725626	chr2:237970010	G/A	cg23555395	chr2:238036564	NA	0.46	5.23	0.39	5.5e-7	Systemic lupus erythematosus;
PAAD	cis	rs12989701	1.000	rs6710467	chr2:127889932	C/T	cg08168897	chr2:127865431	BIN1	0.52	4.68	0.35	6.34e-6	Alzheimer's disease (late onset);
PAAD	cis	rs10501293	0.917	rs9645617	chr11:43105620	G/A	cg03447554	chr11:43094025	NA	-0.48	-4.86	-0.37	2.94e-6	Cognitive performance;
PAAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg18370025	chr7:2749541	AMZ1	-0.39	-4.73	-0.36	5e-6	Height;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg18110333	chr6:292329	DUSP22	-0.77	-7.82	-0.54	8.44e-13	Menopause (age at onset);
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6681460	0.966	rs1325261	chr1:67110516	G/A	cg02459107	chr1:67143332	SGIP1	0.78	7.81	0.53	8.87e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.91	-0.59	1.45e-15	Calcium levels;
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.05	-0.38	1.23e-6	Life satisfaction;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.58	-5.89	-0.43	2.39e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs488248	0.574	rs17447929	chr13:106584955	A/C	cg03898952	chr13:107069935	NA	0.7	4.54	0.35	1.11e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs7301826	0.651	rs34749116	chr12:131280752	G/A	cg11011512	chr12:131303247	STX2	-0.45	-4.64	-0.35	7.37e-6	Plasma plasminogen activator levels;
PAAD	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.44	7.02	0.49	7.01e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.77e-5	Prostate cancer;
PAAD	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.11	10.91	0.66	8.01e-21	Corneal structure;
PAAD	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	6.72	0.48	3.44e-10	Triglycerides;
PAAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17539620	0.624	rs56791414	chr6:154849605	A/G	cg20019720	chr6:154832845	CNKSR3	0.64	7.33	0.51	1.26e-11	Lipoprotein (a) levels;
PAAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs3764400	0.567	rs8079616	chr17:46213488	C/T	cg24322968	chr17:46507895	SKAP1	-0.85	-5.27	-0.39	4.5e-7	Body mass index;
PAAD	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg09168692	chr1:7887560	PER3	0.43	4.39	0.34	2.09e-5	Inflammatory bowel disease;
PAAD	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.68	6.9	0.49	1.3100000000000001e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.56	5.93	0.43	1.96e-8	Pancreatic cancer;
PAAD	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.25	-0.33	3.67e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2562456	0.876	rs10424079	chr19:21589179	G/A	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	4.28	0.33	3.31e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs9834373	0.553	rs12491264	chr3:78497118	T/C	cg06138941	chr3:78371609	NA	-0.39	-4.42	-0.34	1.89e-5	Protein quantitative trait loci;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.89	7.52	0.52	4.46e-12	Alzheimer's disease;
PAAD	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.46	4.33	0.33	2.72e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.31	0.56	4.85e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-6.3	-0.46	3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs72827839	0.894	rs41336845	chr17:46215110	A/G	cg23391107	chr17:45924227	SP6	-0.62	-5.31	-0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	6.21	0.45	4.84e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.52	-0.34	1.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.65e-7	Alzheimer's disease;
PAAD	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.25	-0.39	4.95e-7	Glomerular filtration rate;
PAAD	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.56	6.46	0.46	1.33e-9	Coronary artery disease;
PAAD	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg25547332	chr5:131281432	NA	-0.57	-4.31	-0.33	2.95e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.49	0.65	1.04e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.72	0.66	2.5e-20	Prudent dietary pattern;
PAAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24729792	chr2:113192114	RGPD8;RGPD5	0.58	4.84	0.37	3.12e-6	Yeast infection;
PAAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	7.65	0.53	2.14e-12	Homoarginine levels;
PAAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.89	8.86	0.58	2.01e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg25828445	chr12:7781288	NA	0.77	5.48	0.41	1.7e-7	HDL cholesterol levels;
PAAD	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg20246863	chr2:73402720	NA	-0.4	-4.27	-0.33	3.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.2	11.48	0.68	2.28e-22	Platelet count;
PAAD	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.42	-4.71	-0.36	5.54e-6	Height;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg11218175	chr11:495084	RNH1	0.86	4.75	0.36	4.58e-6	Body mass index;
PAAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-4.91	-0.37	2.34e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg04944784	chr2:26401820	FAM59B	-0.91	-7.7	-0.53	1.58e-12	Gut microbiome composition (summer);
PAAD	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs11955175	1.000	rs11953942	chr5:40674713	C/A	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.01	0.49	7.24e-11	Blood protein levels;
PAAD	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg01338084	chr22:32026380	PISD	0.49	4.42	0.34	1.85e-5	Intelligence;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg11335335	chr11:637885	DRD4	-0.35	-4.41	-0.34	1.92e-5	Systemic lupus erythematosus;
PAAD	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.63	5.1	0.38	1.01e-6	Bipolar disorder;
PAAD	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.71	0.58	4.91e-15	Homoarginine levels;
PAAD	cis	rs7577696	0.924	rs6748621	chr2:32262201	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.46	-0.34	1.56e-5	Inflammatory biomarkers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08641879	chr20:61436024	OGFR	-0.87	-7.8	-0.53	9.17e-13	Neuroticism;
PAAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg19257562	chr1:2043853	PRKCZ	0.5	6.19	0.45	5.45e-9	Height;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs6743376	0.642	rs4145014	chr2:113831185	A/G	cg24553058	chr2:113831203	IL1F10	0.61	5.84	0.43	2.99e-8	Inflammatory biomarkers;
PAAD	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.06e-6	Lung cancer;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg06740227	chr12:86229804	RASSF9	0.59	5.21	0.39	6.05e-7	Major depressive disorder;
PAAD	cis	rs80346118	0.673	rs6012535	chr20:47423191	G/A	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.63	-4.66	-0.35	6.97e-6	Diastolic blood pressure;
PAAD	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-11.26	-0.67	9.07e-22	Height;
PAAD	cis	rs12767760	0.669	rs1572860	chr10:99310982	T/C	cg25247692	chr10:99313390	UBTD1	0.56	5.46	0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs78761021	0.867	rs62066058	chr17:9784528	A/G	cg26853458	chr17:9805074	RCVRN	0.68	7.75	0.53	1.22e-12	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.65	7.28	0.51	1.67e-11	Coronary artery disease;
PAAD	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.47	5.82	0.43	3.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.54	5.37	0.4	2.86e-7	Hemoglobin levels;
PAAD	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg21823605	chr1:152486609	CRCT1	0.5	6.36	0.46	2.28e-9	Hair morphology;
PAAD	cis	rs11129295	0.584	rs1000361	chr3:27810319	A/G	cg21473142	chr3:27762095	EOMES	0.27	4.55	0.35	1.1e-5	Multiple sclerosis;
PAAD	cis	rs3812111	0.774	rs509002	chr6:116423299	T/C	cg15226275	chr6:116381976	FRK	-0.25	-4.49	-0.34	1.41e-5	Age-related macular degeneration;
PAAD	cis	rs740474	0.768	rs6880745	chr5:140981247	C/A	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.29	4.28	0.33	3.31e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10214930	0.697	rs7811436	chr7:27641286	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.65	-0.35	7.13e-6	Lung cancer;
PAAD	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-6.6	-0.47	6.55e-10	Schizophrenia;
PAAD	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.72	6.34	0.46	2.46e-9	Platelet count;
PAAD	cis	rs863345	0.604	rs975118	chr1:158511445	G/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.88	-0.37	2.65e-6	Pneumococcal bacteremia;
PAAD	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg06618935	chr21:46677482	NA	-0.56	-6.45	-0.46	1.42e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9346455	0.764	rs9354996	chr6:72035192	C/T	cg27238071	chr6:71998145	OGFRL1	-0.83	-4.26	-0.33	3.58e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.6	5.85	0.43	2.97e-8	Type 2 diabetes;
PAAD	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.58	6.81	0.48	2.15e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21944972	chr8:2020566	MYOM2	0.52	6.55	0.47	8.41e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg23920097	chr1:209922102	NA	-0.51	-4.64	-0.35	7.56e-6	Red blood cell count;
PAAD	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.45	-5.16	-0.39	7.5e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	0.89	6.1	0.44	8.44e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-8.41	-0.56	2.84e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg25753631	chr6:25732923	NA	-0.42	-4.55	-0.35	1.11e-5	Height;
PAAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.66	7.06	0.5	5.46e-11	Testicular germ cell tumor;
PAAD	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	1.03	7.01	0.49	7.11e-11	Mitochondrial DNA levels;
PAAD	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.93	-10.1	-0.63	1.16e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg25452165	chr22:42524984	CYP2D6	0.61	5.89	0.43	2.4e-8	Schizophrenia;
PAAD	cis	rs2992756	0.663	rs12750779	chr1:18805048	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.74	-0.36	4.95e-6	Breast cancer;
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.94	8.02	0.55	2.56e-13	Blood protein levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07482826	chr16:1502837	CLCN7	0.57	7.16	0.5	3.2e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs11679640	0.550	rs11124900	chr2:43132284	A/T	cg04767697	chr2:43016446	HAAO	0.46	4.4	0.34	2.02e-5	White matter hyperintensity burden;
PAAD	cis	rs655641	0.539	rs493254	chr11:85765298	G/A	cg07180834	chr11:85838833	NA	-0.44	-4.76	-0.36	4.47e-6	Platelet count;
PAAD	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg12193833	chr17:30244370	NA	-0.62	-4.92	-0.37	2.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13198984	chr17:80129470	CCDC57	0.42	5.2	0.39	6.23e-7	Life satisfaction;
PAAD	cis	rs7671266	0.532	rs733175	chr4:10050141	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	4.88	0.37	2.68e-6	Cardiovascular disease risk factors;
PAAD	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg09491104	chr22:46646882	C22orf40	-0.96	-9.08	-0.59	5.51e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-4.77	-0.36	4.2e-6	Colorectal cancer;
PAAD	cis	rs6439924	0.527	rs6791077	chr3:140176199	A/G	cg22717015	chr3:140951447	ACPL2	-0.52	-4.36	-0.33	2.4e-5	Hodgkin's lymphoma;
PAAD	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg22532475	chr10:104410764	TRIM8	-0.39	-4.52	-0.34	1.21e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs757081	0.648	rs7108315	chr11:17267164	C/T	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.49	-0.41	1.69e-7	Systolic blood pressure;
PAAD	cis	rs1413885	0.505	rs4512686	chr1:65857483	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.41	4.25	0.33	3.67e-5	Anticoagulant levels;
PAAD	cis	rs3764400	0.567	rs8071879	chr17:46217457	G/A	cg10706073	chr17:46328419	SKAP1	1.05	6.3	0.46	3e-9	Body mass index;
PAAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.89	8.71	0.58	4.7e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.01	-0.49	7.3e-11	Morning vs. evening chronotype;
PAAD	cis	rs7165102	1.000	rs17809330	chr15:65889250	C/T	cg22900193	chr15:65823441	PTPLAD1	-0.46	-4.36	-0.33	2.41e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21862992	chr11:68658383	NA	0.41	4.53	0.35	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg16602846	chr15:78114278	NA	0.42	4.59	0.35	9.33e-6	Coronary artery disease or large artery stroke;
PAAD	cis	rs758324	0.812	rs10045303	chr5:131202801	C/T	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.26	-0.33	3.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg01689657	chr7:91764605	CYP51A1	0.36	4.86	0.37	2.84e-6	Breast cancer;
PAAD	cis	rs11208691	0.513	rs10443260	chr1:66128866	A/G	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg04450456	chr4:17643702	FAM184B	0.54	5.93	0.43	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg25588787	chr5:154027256	NA	-0.5	-4.32	-0.33	2.81e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg04450456	chr4:17643702	FAM184B	0.46	4.89	0.37	2.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.6	5.99	0.44	1.43e-8	Body mass index;
PAAD	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.61	5.49	0.41	1.63e-7	Retinal vascular caliber;
PAAD	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-7.32	-0.51	1.33e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12257961	0.578	rs10796284	chr10:15392276	G/T	cg10616319	chr10:15468812	NA	-0.47	-4.46	-0.34	1.56e-5	Selective IgA deficiency;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.43	-4.64	-0.35	7.6e-6	Birth weight;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.6	7.25	0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg21951975	chr1:209979733	IRF6	0.43	5.37	0.4	2.87e-7	Monobrow;
PAAD	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.49	5.08	0.38	1.1e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg24881330	chr22:46731750	TRMU	1.0	4.39	0.34	2.08e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.74	-5.07	-0.38	1.16e-6	Vitiligo;
PAAD	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	4.3	0.33	3.08e-5	Self-reported allergy;
PAAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	8.21	0.55	8.78e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs317865	0.737	rs28516589	chr4:16234111	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.98	6.21	0.45	4.76e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Calcium levels;
PAAD	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.4	4.96	0.37	1.86e-6	Electrocardiographic conduction measures;
PAAD	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg06042504	chr8:55087323	NA	-0.81	-8.8	-0.58	2.79e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00292662	chr22:38071168	LGALS1	0.5	4.45	0.34	1.66e-5	Fat distribution (HIV);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01204305	chr3:49756497	AMIGO3;RNF123	-0.5	-6.61	-0.47	6.17e-10	Body fat percentage;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24796306	chr19:5720138	TMEM146;LONP1	-0.75	-6.7	-0.48	3.84e-10	Neuroticism;
PAAD	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs7894051	0.764	rs12242667	chr10:135192346	G/C	cg24905316	chr10:135186343	ECHS1	-0.73	-4.45	-0.34	1.65e-5	Lifespan;
PAAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg14345882	chr6:26364793	BTN3A2	-0.66	-4.45	-0.34	1.63e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10865541	0.571	rs4854186	chr2:3383957	C/T	cg12447832	chr2:3383257	TTC15	0.38	4.68	0.35	6.34e-6	Obesity-related traits;
PAAD	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs12984174	0.667	rs374614	chr19:18142682	T/C	cg21649277	chr19:18117794	ARRDC2	0.73	5.35	0.4	3.15e-7	Pulmonary function in asthmatics;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg23708337	chr7:1209742	NA	0.63	4.53	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs78761021	0.867	rs62067561	chr17:9785912	C/T	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.04e-13	Type 2 diabetes;
PAAD	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg00629941	chr15:75287862	SCAMP5	0.56	4.31	0.33	2.87e-5	Blood trace element (Zn levels);
PAAD	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.89	-8.85	-0.58	2.12e-15	Obesity-related traits;
PAAD	cis	rs13248545	0.564	rs11786236	chr8:17615649	C/T	cg13252206	chr8:16970768	EFHA2	-0.57	-4.33	-0.33	2.72e-5	Yeast infection;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.83	9.48	0.61	5.02e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-5.24	-0.39	5.18e-7	Daytime sleep phenotypes;
PAAD	cis	rs13168506	0.538	rs12521857	chr5:135440364	G/A	cg16684184	chr5:135415129	NA	-0.36	-4.67	-0.35	6.52e-6	Stroke;
PAAD	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg02027945	chr11:20618230	NA	0.32	4.59	0.35	9.04e-6	Pursuit maintenance gain;
PAAD	cis	rs802075	0.561	rs13198157	chr6:49602760	A/G	cg20364632	chr6:49636226	NA	0.46	5.45	0.4	2.02e-7	Bone mineral density (hip) and age at menarche;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16266536	chr12:56660626	COQ10A	0.65	6.36	0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs6466479	1.000	rs9640751	chr7:113741759	G/A	cg03012726	chr7:113722758	NA	-0.44	-4.3	-0.33	3.07e-5	IgG glycosylation;
PAAD	cis	rs4743820	0.620	rs10991786	chr9:93917158	T/C	cg14446406	chr9:93919335	NA	0.51	6.04	0.44	1.11e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01316535	chr19:9695235	ZNF121	0.62	6.51	0.47	1.03e-9	Myopia (pathological);
PAAD	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg07159951	chr1:45983175	PRDX1	0.45	5.1	0.38	9.94e-7	High light scatter reticulocyte count;
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.76	7.71	0.53	1.49e-12	Menarche (age at onset);
PAAD	cis	rs73019876	0.502	rs4932953	chr19:22249045	G/C	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07650554	chr16:30457408	SEPHS2	0.62	6.87	0.49	1.56e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.95	-8.14	-0.55	1.31e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs58521262	0.556	rs424913	chr19:23122426	G/A	cg22640819	chr19:22990650	NA	-0.29	-4.39	-0.34	2.15e-5	Testicular germ cell tumor;
PAAD	cis	rs9395066	0.560	rs9395065	chr6:45074392	A/G	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Height;
PAAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.47	4.43	0.34	1.76e-5	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg16447950	chr5:562315	NA	-0.47	-4.46	-0.34	1.58e-5	Obesity-related traits;
PAAD	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg05272587	chr13:111038400	COL4A2	-0.54	-4.77	-0.36	4.32e-6	White matter hyperintensity burden;
PAAD	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.22	-0.39	5.78e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.12e-8	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.55	5.06	0.38	1.22e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00145757	chr11:118478637	PHLDB1	0.56	6.6	0.47	6.56e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs13011075	0.535	rs6546404	chr2:68632635	G/T	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs988913	0.957	rs6459035	chr6:54757520	A/G	cg03513858	chr6:54763001	FAM83B	-0.43	-4.85	-0.37	3.03e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.63	0.35	7.66e-6	Iron status biomarkers;
PAAD	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg08562672	chr19:21860753	NA	0.41	4.28	0.33	3.31e-5	Pain;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22466171	chr4:99850251	EIF4E	0.58	6.52	0.47	9.91e-10	Pancreatic cancer;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.5	5.09	0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg18892244	chr7:807596	HEATR2	-0.67	-5.01	-0.38	1.52e-6	Initial pursuit acceleration;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.76	-7.27	-0.51	1.73e-11	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.13	-0.45	7.29e-9	Bone mineral density;
PAAD	cis	rs282587	0.502	rs371150	chr13:113397815	C/T	cg04656015	chr13:113407548	ATP11A	0.54	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg09839279	chr12:125627357	AACS	-0.51	-5.07	-0.38	1.14e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg06145435	chr7:1022769	CYP2W1	-0.34	-4.43	-0.34	1.82e-5	Longevity;Endometriosis;
PAAD	cis	rs7765175	0.549	rs3963345	chr6:113655376	G/C	cg19037598	chr6:113666021	NA	-0.42	-4.53	-0.34	1.18e-5	Coronary artery calcification;
PAAD	cis	rs4668356	1.000	rs2723248	chr2:171873251	C/T	cg13882835	chr2:172017928	TLK1	-0.83	-4.43	-0.34	1.77e-5	Cognitive performance;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs7627468	0.770	rs9875101	chr3:121968090	A/G	cg17240004	chr3:121949083	CASR	0.5	4.78	0.36	4.13e-6	Kidney stones;
PAAD	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	4.93e-11	Total body bone mineral density;
PAAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg05484376	chr2:27715224	FNDC4	0.5	5.25	0.39	5.1e-7	Total body bone mineral density;
PAAD	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.55	5.3	0.39	4.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.63	-4.94	-0.37	2.02e-6	Height;
PAAD	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.76	-8.49	-0.57	1.72e-14	N-glycan levels;
PAAD	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.09	0.59	5.16e-16	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.49	0.34	1.38e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.63	-6.9	-0.49	1.3100000000000001e-10	Neuroticism;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg18279126	chr7:2041391	MAD1L1	-0.61	-6.27	-0.45	3.49e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12893428	chr3:195717962	SDHAP1	-0.43	-4.6	-0.35	8.82e-6	Pancreatic cancer;
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.73	7.54	0.52	3.91e-12	Menarche (age at onset);
PAAD	cis	rs62025270	0.632	rs3169119	chr15:86291269	C/T	cg13263323	chr15:86062960	AKAP13	0.53	4.72	0.36	5.41e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.46	0.4	1.89e-7	Obesity-related traits;
PAAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.78e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8054556	0.935	rs4788203	chr16:29978827	G/A	cg06015834	chr16:30021696	DOC2A	-0.44	-4.34	-0.33	2.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.39	4.8	0.36	3.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg25753631	chr6:25732923	NA	-0.4	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.49	5.01	0.38	1.5e-6	Height;
PAAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg05272587	chr13:111038400	COL4A2	-0.52	-4.81	-0.36	3.68e-6	White matter hyperintensity burden;
PAAD	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-4.73	-0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs28489187	0.683	rs12047422	chr1:85848830	T/G	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.93	-7.93	-0.54	4.42e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs901683	1.000	rs34731408	chr10:45961020	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-5.68	-0.42	6.72e-8	Platelet count;
PAAD	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.55	5.34	0.4	3.35e-7	Alcohol dependence;
PAAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-1.17	-10.97	-0.66	5.35e-21	Colorectal cancer;
PAAD	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.6	-5.46	-0.4	1.94e-7	Obesity-related traits;
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.97	-0.54	3.59e-13	Blood metabolite levels;
PAAD	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs1678542	0.651	rs2888334	chr12:57976647	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.33	-0.4	3.51e-7	Rheumatoid arthritis;
PAAD	cis	rs1142	0.507	rs2470937	chr7:104579775	T/A	cg04380332	chr7:105027541	SRPK2	-0.52	-5.18	-0.39	7.06e-7	Advanced age-related macular degeneration;
PAAD	trans	rs901683	1.000	rs35968565	chr10:46076196	G/T	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs73198271	0.628	rs11783707	chr8:8589609	C/T	cg01851573	chr8:8652454	MFHAS1	0.66	5.14	0.38	8.4e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs7551222	0.752	rs35270244	chr1:204548416	A/C	cg01064725	chr1:204461714	NA	-0.51	-4.89	-0.37	2.57e-6	Schizophrenia;
PAAD	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-4.34	-0.33	2.64e-5	Smoking behavior;
PAAD	cis	rs2274459	1.000	rs35721478	chr6:33725129	T/C	cg06253072	chr6:33679850	C6orf125	0.7	4.96	0.37	1.84e-6	Obesity (extreme);
PAAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00007898	chr1:205180627	DSTYK	0.57	6.69	0.48	4.09e-10	Monocyte percentage of white cells;
PAAD	cis	rs2968864	0.957	rs2968863	chr7:150623137	C/T	cg06221570	chr7:150558377	ABP1	0.49	5.64	0.42	8.02e-8	QT interval;
PAAD	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06392426	chr19:10676186	KRI1	-0.68	-6.58	-0.47	7.1e-10	Red cell distribution width;
PAAD	trans	rs901683	1.000	rs34661476	chr10:45971413	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Night sleep phenotypes;
PAAD	cis	rs4938330	0.600	rs2239010	chr11:117089006	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs56046484	0.750	rs62022525	chr15:85523678	G/T	cg08123816	chr15:85640762	PDE8A	-0.47	-4.33	-0.33	2.64e-5	Testicular germ cell tumor;
PAAD	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg18898632	chr2:242989856	NA	-0.8	-5.69	-0.42	6.32e-8	Obesity-related traits;
PAAD	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.4	7.36	0.51	1.09e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3112530	0.818	rs2609661	chr5:152712555	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.64	6.2	0.45	5.01e-9	Breast cancer;
PAAD	cis	rs300774	0.925	rs432750	chr2:147456	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs12136530	0.593	rs4911988	chr1:19724480	C/T	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.6	-4.86	-0.37	2.84e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg17674042	chr6:34482479	PACSIN1	-1.06	-7.09	-0.5	4.76e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.51	-5.77	-0.42	4.38e-8	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg11196182	chr7:1989412	MAD1L1	0.4	4.26	0.33	3.62e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs9534288	0.659	rs2146883	chr13:46660576	C/A	cg15192986	chr13:46630673	CPB2	-0.7	-5.86	-0.43	2.79e-8	Blood protein levels;
PAAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg03605463	chr16:89740564	NA	-0.52	-4.89	-0.37	2.58e-6	Vitiligo;
PAAD	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg00686598	chr14:53173677	PSMC6	-0.83	-4.89	-0.37	2.51e-6	Alzheimer's disease (late onset);
PAAD	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg12046867	chr14:103022105	NA	-0.66	-5.17	-0.39	7.25e-7	Platelet count;
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-7.75	-0.53	1.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4740619	0.619	rs1887667	chr9:16033109	T/G	cg14451791	chr9:16040625	NA	-0.46	-5.19	-0.39	6.72e-7	Body mass index;
PAAD	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg24097872	chr10:5724021	NA	0.48	4.33	0.33	2.7e-5	Childhood ear infection;
PAAD	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg24220031	chr2:73402428	NA	-0.42	-6.4	-0.46	1.79e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.583	rs9303251	chr17:2047214	C/T	cg16513277	chr17:2031491	SMG6	-0.63	-6.65	-0.47	5.04e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07362569	chr17:61921086	SMARCD2	-0.59	-7.05	-0.5	5.96e-11	Prudent dietary pattern;
PAAD	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg06606381	chr12:133084897	FBRSL1	-1.33	-8.42	-0.56	2.66e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg00982548	chr2:198649783	BOLL	-0.78	-5.51	-0.41	1.49e-7	Ulcerative colitis;
PAAD	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.62	-5.37	-0.4	2.94e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg11993925	chr19:44307056	LYPD5	-0.46	-5.92	-0.43	2.1e-8	Reading or mathematical ability;
PAAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.79	5.74	0.42	5.05e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.57	-5.0	-0.38	1.58e-6	Life satisfaction;
PAAD	cis	rs7172677	1.000	rs8032208	chr15:75431245	A/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.72	-0.36	5.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg09835421	chr16:68378352	PRMT7	-1.0	-6.46	-0.46	1.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.94	-10.38	-0.64	2.03e-19	Breast cancer;
PAAD	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.63	-7.2	-0.5	2.64e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs12138061	0.954	rs55830141	chr1:50377775	G/A	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.6	7.25	0.51	1.95e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9652601	0.959	rs12925642	chr16:11171602	A/G	cg04616529	chr16:11181986	CLEC16A	0.46	5.06	0.38	1.21e-6	Systemic lupus erythematosus;
PAAD	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.51	5.24	0.39	5.24e-7	Height;
PAAD	cis	rs12799264	0.722	rs60990357	chr11:19976433	A/C	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg03303774	chr4:1407052	NA	0.43	5.19	0.39	6.63e-7	Obesity-related traits;
PAAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.86	-9.64	-0.62	1.88e-17	Migraine;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.72	5.25	0.39	5.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.51	-5.31	-0.4	3.81e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02291472	chr10:22292676	DNAJC1	0.43	4.85	0.37	2.97e-6	Monocyte percentage of white cells;
PAAD	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg04515608	chr11:48129067	PTPRJ	-0.36	-4.64	-0.35	7.6e-6	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg19980929	chr12:42632907	YAF2	-0.53	-6.27	-0.45	3.51e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.96	11.15	0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg09184832	chr6:79620586	NA	-0.42	-4.26	-0.33	3.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.65	-7.08	-0.5	5.11e-11	IgG glycosylation;
PAAD	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.8	8.49	0.57	1.69e-14	Prostate cancer;
PAAD	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg07725925	chr16:89976287	TCF25	0.68	4.46	0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg05627522	chr15:75251581	NA	0.47	5.8	0.43	3.71e-8	Breast cancer;
PAAD	cis	rs9913156	0.748	rs55986729	chr17:4560499	G/T	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.56	-4.79	-0.36	3.88e-6	Pursuit maintenance gain;
PAAD	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.51	5.24	0.39	5.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.8	8.07	0.55	1.96e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	0.9	6.22	0.45	4.68e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10339200	chr11:74660161	XRRA1;SPCS2	-0.63	-6.39	-0.46	1.89e-9	Smoking initiation;
PAAD	cis	rs2077212	0.932	rs10088851	chr8:5984917	C/T	cg17754742	chr8:6400956	ANGPT2;MCPH1	-0.35	-4.29	-0.33	3.11e-5	Diabetic kidney disease;
PAAD	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.24	-0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.53e-6	Common traits (Other);
PAAD	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg24268161	chr22:39747459	SYNGR1	-0.37	-4.44	-0.34	1.75e-5	Rheumatoid arthritis;
PAAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.5	4.77	0.36	4.19e-6	Mood instability;
PAAD	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-0.93	-9.16	-0.6	3.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs755249	0.567	rs1537817	chr1:39639653	A/G	cg14018543	chr1:39659967	MACF1	0.56	4.77	0.36	4.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.53	5.23	0.39	5.51e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1015291	0.748	rs941233	chr12:19993676	C/T	cg25401612	chr12:20009446	NA	0.56	5.4	0.4	2.52e-7	Diastolic blood pressure;
PAAD	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg16339924	chr4:17578868	LAP3	0.47	4.39	0.34	2.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2271001	0.876	rs4757757	chr11:19144144	A/G	cg00161556	chr11:19138045	ZDHHC13	0.49	5.28	0.39	4.4e-7	Gut microbiome composition (winter);
PAAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.69	5.88	0.43	2.5e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs300774	0.687	rs79975915	chr2:262119	T/C	cg21211680	chr2:198530	NA	0.72	4.84	0.37	3.12e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.57	-8.44	-0.56	2.37e-14	Homoarginine levels;
PAAD	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.4	13.67	0.74	3.06e-28	Corneal structure;
PAAD	cis	rs6756513	0.520	rs6546560	chr2:70173690	A/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-4.9	-0.37	2.46e-6	Breast cancer;Platelet count;
PAAD	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.55	-0.52	3.83e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.26	10.59	0.65	5.6e-20	Corneal structure;
PAAD	cis	rs375066	0.935	rs376032	chr19:44407564	A/G	cg11993925	chr19:44307056	LYPD5	0.55	6.95	0.49	9.87e-11	Breast cancer;
PAAD	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.86	-10.27	-0.64	3.96e-19	Height;
PAAD	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.51	6.17	0.45	5.86e-9	Sitting height ratio;
PAAD	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg24553058	chr2:113831203	IL1F10	0.51	5.72	0.42	5.58e-8	Protein quantitative trait loci;
PAAD	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.95	10.02	0.63	1.83e-18	Multiple sclerosis;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	4.97	0.37	1.82e-6	Total cholesterol levels;
PAAD	cis	rs72960926	0.744	rs72950524	chr6:74900108	G/A	cg03266952	chr6:74778945	NA	-1.18	-6.6	-0.47	6.43e-10	Metabolite levels (MHPG);
PAAD	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.53	-0.41	1.38e-7	Sjögren's syndrome;
PAAD	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg26597838	chr10:835615	NA	0.49	5.3	0.39	4e-7	Survival in rectal cancer;
PAAD	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.14e-5	Noise-induced hearing loss;
PAAD	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.7	7.26	0.51	1.9e-11	Schizophrenia;
PAAD	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	7.82e-9	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03676636	chr4:99064102	C4orf37	-0.31	-5.58	-0.41	1.08e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.59	5.53	0.41	1.39e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3136441	0.901	rs3136460	chr11:46747065	C/G	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	7.05	0.5	5.99e-11	Menarche (age at onset);
PAAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.8	-8.29	-0.56	5.41e-14	DNA methylation (variation);
PAAD	cis	rs11113894	0.901	rs12422463	chr12:108862961	G/A	cg06834313	chr12:108851556	NA	-0.77	-4.67	-0.35	6.63e-6	Obesity-related traits;
PAAD	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.44	-4.64	-0.35	7.43e-6	Calcium levels;
PAAD	cis	rs10465746	0.573	rs12121175	chr1:84468961	T/G	cg10977910	chr1:84465055	TTLL7	0.49	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg15211996	chr1:2936768	ACTRT2	-0.47	-4.68	-0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs9487051	0.698	rs59502176	chr6:109644719	T/C	cg01475377	chr6:109611718	NA	-0.42	-4.64	-0.35	7.52e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.6	-6.36	-0.46	2.27e-9	Cognitive function;
PAAD	cis	rs7577696	0.889	rs212726	chr2:32469385	T/C	cg02381751	chr2:32503542	YIPF4	0.43	4.76	0.36	4.53e-6	Inflammatory biomarkers;
PAAD	trans	rs901683	1.000	rs12762495	chr10:46013615	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3112530	0.901	rs304864	chr5:152720862	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs6782025	0.837	rs1683979	chr3:120672208	T/C	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.66	-4.6	-0.35	8.91e-6	Hypertriglyceridemia;
PAAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg22325292	chr17:80708367	FN3K	0.6	4.29	0.33	3.2e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3096644	0.893	rs3110609	chr17:46753543	A/G	cg10864433	chr17:46724237	NA	-0.46	-4.51	-0.34	1.26e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.62	5.96	0.44	1.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg15181151	chr6:150070149	PCMT1	0.56	6.15	0.45	6.39e-9	Lung cancer;
PAAD	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg27455613	chr17:80820699	TBCD	-0.46	-4.63	-0.35	7.83e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6723226	0.806	rs2710606	chr2:32811909	A/G	cg02381751	chr2:32503542	YIPF4	0.77	8.14	0.55	1.31e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	7.91	0.54	4.95e-13	Parkinson's disease;
PAAD	cis	rs10501293	0.956	rs10768918	chr11:43134481	C/T	cg03447554	chr11:43094025	NA	-0.5	-5.03	-0.38	1.36e-6	Cognitive performance;
PAAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.77	6.13	0.45	7.31e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19947233	chr4:90032727	TIGD2	0.65	6.64	0.47	5.32e-10	Primary biliary cholangitis;
PAAD	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg02071572	chr4:1403502	NA	-0.45	-6.07	-0.44	9.95e-9	Obesity-related traits;
PAAD	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.61	6.44	0.46	1.5e-9	Body mass index;
PAAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.29	-0.33	3.12e-5	Joint mobility (Beighton score);
PAAD	cis	rs4702	0.611	rs11539637	chr15:91428290	C/T	cg00630237	chr15:91433507	FES	0.5	4.81	0.36	3.57e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs900145	0.859	rs2403662	chr11:13302822	A/G	cg15603424	chr11:13300592	ARNTL	0.51	4.51	0.34	1.3e-5	Menarche (age at onset);
PAAD	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.88	-7.2	-0.5	2.65e-11	Triglycerides;
PAAD	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs10274279	0.660	rs4716760	chr7:157376644	A/G	cg09270525	chr7:157391030	PTPRN2	-0.56	-4.96	-0.37	1.9e-6	Myopia (pathological);
PAAD	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.85	0.49	1.76e-10	Lung cancer in ever smokers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06067932	chr15:74988555	EDC3	0.59	6.4	0.46	1.86e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.76	6.37	0.46	2.09e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.77	4.31	0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	9.12	0.59	4.19e-16	Cognitive test performance;
PAAD	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.37	0.4	2.85e-7	Body mass index;
PAAD	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.93	-0.37	2.12e-6	Pubertal anthropometrics;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.55	5.26	0.39	4.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg21395723	chr22:39101663	GTPBP1	-0.47	-4.86	-0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs12773846	0.522	rs55890241	chr10:126238492	C/T	cg04949429	chr10:126290192	LHPP	0.65	5.43	0.4	2.23e-7	Subcutaneous adipose tissue;
PAAD	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.35e-6	Parkinson's disease;
PAAD	cis	rs1891275	0.551	rs4933687	chr10:93410399	C/T	cg07889827	chr10:93443413	NA	-0.4	-4.31	-0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg09888920	chr5:474111	LOC25845;SLC9A3	0.47	4.27	0.33	3.42e-5	Cystic fibrosis severity;
PAAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.55	6.32	0.46	2.79e-9	Tumor biomarkers;
PAAD	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg10395934	chr14:104002654	TRMT61A	0.54	5.48	0.41	1.77e-7	Body mass index;
PAAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.64	-4.87	-0.37	2.75e-6	Menarche (age at onset);
PAAD	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg21300403	chr2:198650112	BOLL	0.5	4.43	0.34	1.79e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.67	6.59	0.47	6.63e-10	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs11159086	0.793	rs1029701	chr14:74940815	C/G	cg10195687	chr14:74926396	NA	-0.48	-5.45	-0.4	2.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg04374321	chr14:90722782	PSMC1	0.53	4.43	0.34	1.76e-5	Longevity;
PAAD	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	5.77	0.42	4.36e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4742903	0.904	rs10991187	chr9:106996271	C/T	cg14250997	chr9:106856677	SMC2	0.47	5.1	0.38	1.01e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.29	0.39	4.12e-7	Neuroticism;
PAAD	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.66	-4.43	-0.34	1.77e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-4.43	-0.34	1.76e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.43	4.51	0.34	1.31e-5	Bulimia nervosa;
PAAD	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.82	6.15	0.45	6.38e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.45	-4.76	-0.36	4.54e-6	Dementia with Lewy bodies;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg11766577	chr21:47581405	C21orf56	-0.37	-4.29	-0.33	3.18e-5	Testicular germ cell tumor;
PAAD	cis	rs988913	0.957	rs1503146	chr6:54759495	G/T	cg03513858	chr6:54763001	FAM83B	-0.47	-5.22	-0.39	5.83e-7	Menarche (age at onset);
PAAD	cis	rs329648	0.571	rs10894761	chr11:133772854	G/A	cg18057887	chr11:133800913	IGSF9B	0.6	6.67	0.48	4.4e-10	Parkinson's disease;
PAAD	cis	rs12286929	0.609	rs45614535	chr11:115090866	G/A	cg04055981	chr11:115044050	NA	0.46	4.5	0.34	1.35e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.61	-0.47	6.2e-10	Mood instability;
PAAD	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg07167872	chr1:205819463	PM20D1	0.63	5.03	0.38	1.37e-6	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15556553	chr1:17765043	RCC2	0.65	6.7	0.48	3.76e-10	Myopia (pathological);
PAAD	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg03098721	chr1:84464084	TTLL7	0.48	4.64	0.35	7.57e-6	Obesity-related traits;
PAAD	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-9.16	-0.6	3.28e-16	Blood trace element (Zn levels);
PAAD	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.48	5.36	0.4	3.03e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg07979401	chr6:33739406	LEMD2	-0.57	-4.91	-0.37	2.36e-6	Schizophrenia;
PAAD	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.54	4.52	0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs9463078	0.546	rs1937046	chr6:45048243	A/G	cg25276700	chr6:44698697	NA	0.46	5.19	0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.84e-6	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg17380795	chr3:122379686	NA	0.48	4.84	0.37	3.1e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg05925327	chr15:68127851	NA	-0.54	-4.71	-0.36	5.45e-6	Obesity;
PAAD	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.77	9.05	0.59	6.3e-16	Blood metabolite ratios;
PAAD	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg12486944	chr17:80159399	CCDC57	0.53	4.69	0.36	6.05e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg05805236	chr11:65401703	PCNXL3	0.46	5.24	0.39	5.26e-7	Systemic lupus erythematosus;
PAAD	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6496932	0.865	rs10520600	chr15:85908402	A/G	cg19183879	chr15:85880815	NA	0.55	4.58	0.35	9.77e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.63	9.86	0.62	4.89e-18	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21761045	chr8:87354805	WWP1	0.57	6.3	0.46	2.98e-9	Monocyte percentage of white cells;
PAAD	cis	rs17162190	0.685	rs7530096	chr1:26820218	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.73	0.36	5.19e-6	Mean corpuscular volume;
PAAD	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7715811	1.000	rs7446025	chr5:13773800	T/A	cg09526469	chr5:14277668	TRIO	-0.39	-4.26	-0.33	3.61e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.65	7.83	0.54	7.7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.73	7.34	0.51	1.17e-11	Methadone dose in opioid dependence;
PAAD	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.78	-9.53	-0.61	3.57e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.1e-6	Parkinson's disease;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	0.91	6.46	0.46	1.32e-9	Crohn's disease;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.44e-9	Lung cancer;
PAAD	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg26571870	chr16:85723150	GINS2	0.41	4.36	0.33	2.43e-5	Platelet distribution width;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.9e-7	Blood metabolite levels;
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.04	0.38	1.31e-6	Body mass index;
PAAD	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.58	4.61	0.35	8.36e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.33	0.33	2.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-5.17	-0.39	7.23e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.08	0.38	1.09e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05665937	chr4:1216051	CTBP1	0.42	4.55	0.35	1.08e-5	Obesity-related traits;
PAAD	cis	rs13006863	0.541	rs10186159	chr2:74472186	C/T	cg03173679	chr2:74710205	TTC31;CCDC142	-0.48	-4.43	-0.34	1.79e-5	Post-traumatic stress disorder (asjusted for relatedness);Immune reponse to smallpox (secreted TNF-alpha);
PAAD	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.62	6.04	0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.4	-0.34	2.01e-5	IgG glycosylation;
PAAD	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.65	-7.36	-0.51	1.09e-11	White blood cell count (basophil);
PAAD	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg05785598	chr3:49045655	WDR6	0.43	5.03	0.38	1.35e-6	Parkinson's disease;
PAAD	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.73	6.31	0.46	2.83e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1570155	1.000	rs1004255	chr6:20382747	A/G	cg03881924	chr6:20404342	E2F3	0.44	4.41	0.34	1.93e-5	Obesity-related traits;
PAAD	cis	rs116248771	0.739	rs10276	chr3:158415166	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.32	0.4	3.73e-7	diarrhoeal disease at age 2;
PAAD	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg00758881	chr16:58534681	NDRG4	-0.91	-4.9	-0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.87	-9.99	-0.63	2.19e-18	Rheumatoid arthritis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23896253	chr10:14920463	SUV39H2	-0.63	-6.36	-0.46	2.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16083429	chr3:49237500	CCDC36	-0.47	-5.15	-0.39	7.93e-7	Menarche (age at onset);
PAAD	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg15585409	chr19:12750806	NA	-0.48	-4.32	-0.33	2.76e-5	Red blood cell traits;
PAAD	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.87	0.43	2.67e-8	Response to antipsychotic treatment;
PAAD	cis	rs72960926	1.000	rs55775775	chr6:75133634	A/G	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08568561	chr7:42834498	NA	0.58	6.73	0.48	3.21e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13182402	0.901	rs17165056	chr5:125927917	C/T	cg07897069	chr5:126564606	NA	0.65	4.33	0.33	2.66e-5	Osteoporosis;
PAAD	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.44	-4.56	-0.35	1.03e-5	Calcium levels;
PAAD	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.3	0.33	3.08e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10943724	0.704	rs4706850	chr6:81270692	A/G	cg19323245	chr6:80716898	TTK	-0.43	-4.54	-0.35	1.15e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs35160687	0.644	rs2367232	chr2:86541491	A/G	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg08428512	chr8:128748147	MYC	0.58	6.54	0.47	9.06e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.37e-7	Life satisfaction;
PAAD	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg26318627	chr11:63887540	MACROD1	-0.48	-4.95	-0.37	1.99e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg15764593	chr10:829463	NA	-0.74	-4.47	-0.34	1.53e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.12	0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	trans	rs228916	1.000	rs228929	chr22:37509965	A/C	cg14326991	chr6:46889760	GPR116	-0.64	-6.39	-0.46	1.96e-9	Iron status biomarkers (iron levels);
PAAD	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg14146966	chr2:61757674	XPO1	0.38	4.56	0.35	1.03e-5	Tuberculosis;
PAAD	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07362569	chr17:61921086	SMARCD2	-0.5	-6.1	-0.44	8.33e-9	Prudent dietary pattern;
PAAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	1.1	8.2	0.55	9.25e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.8	-9.15	-0.6	3.5e-16	Height;
PAAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.72	6.62	0.47	5.89e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs12612619	0.732	rs1440044	chr2:27226954	A/G	cg00617064	chr2:27272375	NA	-0.45	-4.8	-0.36	3.78e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.64	6.35	0.46	2.32e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-4.75	-0.36	4.59e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.61	-6.16	-0.45	6.18e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.17	0.39	7.17e-7	Childhood ear infection;
PAAD	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg05585544	chr11:47624801	NA	-0.49	-5.4	-0.4	2.52e-7	Subjective well-being;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.63	0.82	1.36e-38	Height;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.83	-0.58	2.36e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.07	-0.38	1.14e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg05868516	chr6:26286170	HIST1H4H	0.51	4.7	0.36	5.85e-6	Educational attainment;
PAAD	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.7	-7.94	-0.54	4.07e-13	Huntington's disease progression;
PAAD	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	7.54	0.52	4e-12	HIV-1 control;
PAAD	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs6494488	0.500	rs72741336	chr15:64757917	T/C	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.81	6.88	0.49	1.5e-10	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg15693483	chr7:1102177	C7orf50	0.47	5.15	0.39	7.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.73	7.39	0.51	8.98e-12	Colorectal cancer;
PAAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15128208	chr22:42549153	NA	0.42	4.35	0.33	2.53e-5	Cognitive function;
PAAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.99	-11.73	-0.69	5.06e-23	Cognitive function;
PAAD	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.91	11.1	0.67	2.5e-21	Schizophrenia;
PAAD	cis	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg00614314	chr15:82944287	LOC80154	0.51	5.14	0.38	8.25e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.73	-6.29	-0.45	3.29e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.67	0.53	1.94e-12	HIV-1 control;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.55	6.26	0.45	3.65e-9	Schizophrenia;
PAAD	cis	rs3981351	0.797	rs28411397	chr10:115439530	G/C	cg24846397	chr10:115438155	CASP7	-0.56	-5.22	-0.39	5.67e-7	Obesity-related traits;
PAAD	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg03037974	chr15:76606532	NA	0.44	4.75	0.36	4.59e-6	Blood metabolite levels;
PAAD	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06850241	chr22:41845214	NA	0.47	4.56	0.35	1.03e-5	Vitiligo;
PAAD	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.41	-0.34	1.91e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.53	-5.58	-0.41	1.09e-7	Subjective well-being;
PAAD	cis	rs8112211	0.911	rs8106895	chr19:38848861	C/G	cg14299480	chr19:38876666	GGN	-0.54	-5.7	-0.42	6.14e-8	Blood protein levels;
PAAD	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.85	8.83	0.58	2.33e-15	Uric acid levels;
PAAD	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.23	-0.39	5.63e-7	P wave terminal force;
PAAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.52	-5.16	-0.39	7.59e-7	Mortality in heart failure;
PAAD	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.48	6.7	0.48	3.77e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.45	-4.79	-0.36	4.01e-6	HDL cholesterol;
PAAD	cis	rs1419980	0.730	rs2004838	chr12:7780920	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-4.74	-0.36	4.88e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.67	-0.77	6.55e-31	Height;
PAAD	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg24690094	chr11:67383802	NA	-0.49	-4.5	-0.34	1.32e-5	Mean corpuscular volume;
PAAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.29	-0.33	3.19e-5	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.1	-0.5	4.55e-11	Gut microbiome composition (summer);
PAAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg03233332	chr7:66118400	NA	-0.41	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg01851573	chr8:8652454	MFHAS1	0.44	4.65	0.35	7.21e-6	Mood instability;
PAAD	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.86	10.38	0.64	2.06e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-8.9	-0.59	1.53e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.79	8.37	0.56	3.41e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	5.08	0.38	1.09e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs3206736	0.548	rs329235	chr7:35056166	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	0.48	4.65	0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg08807101	chr21:30365312	RNF160	-0.63	-4.93	-0.37	2.09e-6	Cognitive test performance;
PAAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.29	-0.33	3.22e-5	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10948783	chr4:113067365	C4orf32	0.67	6.98	0.49	8.5e-11	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs13007086	chr2:630034	A/T	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.22e-6	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02406285	chr3:67048577	KBTBD8	-0.62	-6.29	-0.45	3.13e-9	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg08436684	chr16:88034427	BANP	-0.49	-4.25	-0.33	3.73e-5	Menopause (age at onset);
PAAD	cis	rs8105895	0.935	rs2163835	chr19:22242679	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.33	-0.46	2.68e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg17470449	chr10:769945	NA	0.66	6.42	0.46	1.66e-9	Uric acid levels;
PAAD	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.59	-0.35	9.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.73	-0.36	5.12e-6	HDL cholesterol;
PAAD	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg04154034	chr17:28927549	LRRC37B2	0.68	4.33	0.33	2.68e-5	Body mass index;
PAAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-4.56	-0.35	1.04e-5	Obesity-related traits;
PAAD	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.53	-5.04	-0.38	1.29e-6	Dental caries;
PAAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs54211	0.572	rs79290	chr22:39685832	G/A	cg05872129	chr22:39784769	NA	-0.77	-5.15	-0.39	8.1e-7	Sudden cardiac arrest;
PAAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-4.66	-0.35	6.82e-6	Monobrow;
PAAD	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.64	-7.05	-0.5	5.88e-11	Menarche (age at onset);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg07911682	chr1:51425659	FAF1	-0.6	-6.54	-0.47	8.74e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.53	0.34	1.2e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.61	-6.98	-0.49	8.55e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg07527105	chr16:88053339	BANP	-0.42	-4.35	-0.33	2.53e-5	Menopause (age at onset);
PAAD	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.56	-5.39	-0.4	2.63e-7	QT interval;
PAAD	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.58	5.35	0.4	3.11e-7	Total body bone mineral density;
PAAD	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2242420	0.920	rs853480	chr1:21949537	A/G	cg26362272	chr1:22108717	USP48	0.55	4.27	0.33	3.49e-5	Hematological and biochemical traits;
PAAD	cis	rs7727544	0.545	rs743564	chr5:131410879	T/C	cg14196790	chr5:131705035	SLC22A5	0.46	4.78	0.36	4.06e-6	Blood metabolite levels;
PAAD	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.56	-0.52	3.53e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs600626	0.636	rs11236518	chr11:75453066	C/T	cg24262691	chr11:75473276	NA	0.76	6.17	0.45	5.78e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.72	8.07	0.55	1.99e-13	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.87	10.74	0.66	2.25e-20	Aortic root size;
PAAD	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.37	-0.4	2.87e-7	Blood metabolite levels;
PAAD	cis	rs6546886	0.711	rs6712566	chr2:74245321	C/T	cg20260610	chr2:74347274	NA	0.51	4.39	0.34	2.07e-5	Dialysis-related mortality;
PAAD	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg14583973	chr4:3374767	RGS12	-0.33	-4.93	-0.37	2.11e-6	Parental longevity (mother's age at death);
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg13919466	chr1:32135498	COL16A1	-0.4	-4.47	-0.34	1.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg00945038	chr17:61921165	SMARCD2	0.51	6.03	0.44	1.19e-8	Prudent dietary pattern;
PAAD	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg17724175	chr1:150552817	MCL1	0.37	4.42	0.34	1.84e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.66	0.57	6.59e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6496932	0.913	rs4843037	chr15:85817905	C/T	cg19183879	chr15:85880815	NA	0.51	4.45	0.34	1.63e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2279817	0.863	rs13375581	chr1:18016491	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.78	-0.42	4.02e-8	Neuroticism;
PAAD	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs2445762	0.548	rs56346545	chr15:51666157	C/T	cg25905881	chr15:51634250	GLDN	0.47	4.39	0.34	2.09e-5	Hormone measurements;
PAAD	cis	rs4409675	0.957	rs6656506	chr1:28255000	C/T	cg23691781	chr1:28212827	C1orf38	-0.41	-4.94	-0.37	2.08e-6	Corneal astigmatism;
PAAD	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06360820	chr2:242988706	NA	-1.18	-9.84	-0.62	5.4e-18	Obesity-related traits;
PAAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.73	8.6	0.57	9e-15	Methadone dose in opioid dependence;
PAAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.9	-10.06	-0.63	1.49e-18	Obesity-related traits;
PAAD	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.74	-8.22	-0.55	8.14e-14	Morning vs. evening chronotype;
PAAD	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.63	5.43	0.4	2.23e-7	Pulmonary function decline;
PAAD	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg08698997	chr16:88989212	CBFA2T3	0.4	4.74	0.36	4.86e-6	Social autistic-like traits;
PAAD	cis	rs2030114	0.561	rs1498780	chr16:51611098	C/G	cg03758633	chr16:51611768	NA	0.5	4.96	0.37	1.85e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.76	-8.54	-0.57	1.3e-14	Childhood ear infection;
PAAD	cis	rs6921919	0.848	rs56131013	chr6:28320677	G/A	cg23153227	chr6:27725408	NA	0.54	4.6	0.35	8.98e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs7873102	0.580	rs2244196	chr9:37987524	G/A	cg03528946	chr9:38069800	SHB	0.5	5.15	0.39	7.94e-7	Brain structure;
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg20917491	chr3:195578259	NA	0.49	4.9	0.37	2.38e-6	Pancreatic cancer;
PAAD	cis	rs10435719	0.517	rs2686211	chr8:11628375	T/A	cg00262122	chr8:11665843	FDFT1	0.61	5.76	0.42	4.63e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.52	-4.57	-0.35	9.94e-6	Total body bone mineral density;
PAAD	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.27	-0.33	3.42e-5	IgG glycosylation;
PAAD	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.6	5.46	0.4	1.94e-7	Blood protein levels;
PAAD	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg01304814	chr3:48885189	PRKAR2A	0.67	4.55	0.35	1.09e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	1.16	15.15	0.78	3.6e-32	Longevity;
PAAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14119001	chr9:139324193	INPP5E	-0.56	-5.09	-0.38	1.05e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	1.0	11.04	0.67	3.44e-21	Homoarginine levels;
PAAD	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.3e-7	Monocyte percentage of white cells;
PAAD	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg24503407	chr1:205819492	PM20D1	0.62	5.1	0.38	9.86e-7	Parkinson's disease;
PAAD	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg18898632	chr2:242989856	NA	-0.76	-5.17	-0.39	7.15e-7	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.84	10.38	0.64	2.04e-19	Menopause (age at onset);
PAAD	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg16898833	chr6:26189333	HIST1H4D	0.44	4.34	0.33	2.6e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.66	-0.35	6.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs527409	1.000	rs545696	chr1:58745403	A/C	cg26345888	chr1:58716257	DAB1	-0.69	-4.77	-0.36	4.23e-6	Kawasaki disease;
PAAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg10935138	chr17:73851978	WBP2	0.81	7.14	0.5	3.62e-11	Psoriasis;
PAAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.59	5.49	0.41	1.62e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4660214	0.627	rs16837533	chr1:39703847	G/A	cg14018543	chr1:39659967	MACF1	-0.56	-4.46	-0.34	1.61e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg12639453	chr1:2035780	PRKCZ	-0.56	-6.05	-0.44	1.07e-8	Height;
PAAD	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg06998765	chr14:75389618	RPS6KL1	-0.29	-4.94	-0.37	2.08e-6	Caffeine consumption;
PAAD	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg02023728	chr11:77925099	USP35	-0.44	-4.47	-0.34	1.51e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg14146966	chr2:61757674	XPO1	0.37	4.56	0.35	1.05e-5	Tuberculosis;
PAAD	cis	rs926392	0.965	rs6124106	chr20:37693042	G/A	cg16355469	chr20:37678765	NA	0.48	4.57	0.35	1.01e-5	Dialysis-related mortality;
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.52	-5.92	-0.43	2.04e-8	Prostate cancer;
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg07061783	chr6:25882402	NA	-0.53	-5.02	-0.38	1.45e-6	Blood metabolite levels;
PAAD	trans	rs901683	0.850	rs71515355	chr10:45985356	C/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs282587	0.597	rs1278659	chr13:113386497	G/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.59	6.93	0.49	1.09e-10	Mean corpuscular volume;
PAAD	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	6.05	0.44	1.1e-8	Ileal carcinoids;
PAAD	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.87	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.7	6.93	0.49	1.15e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1032355	0.558	rs17533489	chr4:100518283	T/C	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12826209	chr6:26865740	GUSBL1	0.57	4.78	0.36	4.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	1.08	7.15	0.5	3.38e-11	IgG glycosylation;
PAAD	cis	rs7172971	0.565	rs17748132	chr15:42386002	C/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.58	-6.22	-0.45	4.65e-9	Tonsillectomy;
PAAD	cis	rs1539053	0.966	rs11207077	chr1:58097154	T/C	cg20292791	chr1:58089357	DAB1	-0.55	-5.45	-0.4	2e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.67	-8.37	-0.56	3.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.76	0.36	4.49e-6	Birth weight;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-1.28	-12.37	-0.71	9.31e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.88	10.21	0.64	5.67e-19	Menarche (age at onset);
PAAD	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.66	-0.35	6.81e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg07362569	chr17:61921086	SMARCD2	0.44	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg16205897	chr5:131564050	P4HA2	-0.49	-5.5	-0.41	1.56e-7	Blood metabolite levels;
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.75	-7.71	-0.53	1.5e-12	Prostate cancer;
PAAD	trans	rs901683	0.867	rs35003524	chr10:46086781	C/T	cg23720331	chr10:123873670	TACC2	-0.87	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg03353863	chr19:52618714	ZNF616	-0.68	-6.56	-0.47	7.91e-10	Primary biliary cholangitis;
PAAD	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.11	-0.5	4.24e-11	Protein C levels;
PAAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg01320130	chr1:67600311	NA	-0.54	-5.69	-0.42	6.44e-8	Psoriasis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25150929	chr10:118425627	C10orf82	0.63	7.1	0.5	4.52e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg06728252	chr6:26598149	ABT1	-0.38	-4.5	-0.34	1.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg25204440	chr1:209979598	IRF6	-0.61	-5.39	-0.4	2.61e-7	Coronary artery disease;
PAAD	trans	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg22875332	chr1:76189707	ACADM	-0.49	-4.84	-0.37	3.13e-6	Daytime sleep phenotypes;
PAAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12184541	chr11:3012310	NAP1L4	0.61	7.25	0.51	1.99e-11	Metabolite levels  (X-11787);
PAAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.91	-9.55	-0.61	3.12e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-6.59	-0.47	6.84e-10	Total body bone mineral density;
PAAD	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.67	7.22	0.51	2.29e-11	Resting heart rate;
PAAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg15017067	chr4:17643749	FAM184B	0.39	4.43	0.34	1.81e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	5.44	0.4	2.08e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.48	4.68	0.35	6.3e-6	Coronary artery disease;
PAAD	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.89e-5	Total body bone mineral density;
PAAD	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.71	0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10861342	0.892	rs11112366	chr12:105486108	G/A	cg23923672	chr12:105501055	KIAA1033	0.78	4.62	0.35	8.11e-6	IgG glycosylation;
PAAD	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg12486944	chr17:80159399	CCDC57	-0.5	-4.33	-0.33	2.66e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9907295	0.551	rs4795090	chr17:34123597	A/G	cg24325790	chr17:34345392	CCL23	-0.47	-4.34	-0.33	2.64e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs863345	0.604	rs6666609	chr1:158498124	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	5.94	0.43	1.87e-8	Mean platelet volume;
PAAD	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs11971779	0.680	rs6947215	chr7:139026638	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	4.95	0.37	1.93e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.69	5.2	0.39	6.42e-7	Vitiligo;
PAAD	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg03676636	chr4:99064102	C4orf37	0.32	5.43	0.4	2.21e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.97	-0.59	1.03e-15	Calcium levels;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs72627123	1.000	rs72627120	chr14:74363480	G/A	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.54	-5.03	-0.38	1.37e-6	Multiple myeloma;
PAAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.48	-5.54	-0.41	1.33e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.9	-10.62	-0.65	4.62e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.63	-5.76	-0.42	4.42e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.77	-7.62	-0.53	2.5e-12	Response to antineoplastic agents;
PAAD	cis	rs10044254	0.763	rs11950539	chr5:15708199	T/C	cg07238450	chr5:15720153	FBXL7	-0.54	-4.56	-0.35	1.05e-5	Asthma (corticosteroid response);
PAAD	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.54	-5.03	-0.38	1.34e-6	Strep throat;
PAAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg09659197	chr4:152720779	NA	0.33	4.77	0.36	4.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg02631450	chr22:32366979	NA	0.94	5.5	0.41	1.58e-7	Childhood ear infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23955494	chr6:42713957	TBCC	-0.76	-6.42	-0.46	1.64e-9	Neuroticism;
PAAD	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.81	9.0	0.59	8.48e-16	Myeloid white cell count;
PAAD	trans	rs9810890	1.000	rs73207973	chr3:128568365	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs6466055	0.748	rs41563	chr7:104852654	G/A	cg04380332	chr7:105027541	SRPK2	-0.65	-7.27	-0.51	1.78e-11	Schizophrenia;
PAAD	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.55	-4.8	-0.36	3.69e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2092319	0.649	rs2744774	chr1:26063056	C/T	cg02327719	chr1:26185386	C1orf135	-0.89	-4.99	-0.38	1.61e-6	Nose morphology;
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	6.74	0.48	3.09e-10	Menarche (age at onset);
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.39	-0.34	2.09e-5	Life satisfaction;
PAAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs67257959	0.708	rs10412843	chr19:17198287	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.9	0.37	2.4e-6	Selective IgA deficiency;
PAAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg14349672	chr11:133703707	NA	-0.55	-6.39	-0.46	1.91e-9	Childhood ear infection;
PAAD	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.64	5.07	0.38	1.15e-6	Osteoarthritis;
PAAD	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg16898833	chr6:26189333	HIST1H4D	0.76	4.28	0.33	3.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg22153463	chr1:85462885	MCOLN2	0.68	5.42	0.4	2.32e-7	Serum sulfate level;
PAAD	cis	rs7828089	0.504	rs4872505	chr8:22337996	A/T	cg12081754	chr8:22256438	SLC39A14	0.5	5.44	0.4	2.06e-7	Verbal declarative memory;
PAAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.61	-6.82	-0.48	2.01e-10	Monocyte count;
PAAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	trans	rs17181550	0.500	rs55636927	chr17:70267528	G/A	cg03164275	chr2:219826805	CDK5R2	0.39	6.32	0.46	2.74e-9	Lung adenocarcinoma;Lung cancer;
PAAD	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.58	6.37	0.46	2.15e-9	Fibrinogen levels;
PAAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.85	-6.97	-0.49	9.01e-11	Lung function (FEV1/FVC);
PAAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.38	9.7	0.62	1.28e-17	Atopic dermatitis;
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg10396713	chr8:602097	NA	0.68	4.88	0.37	2.66e-6	IgG glycosylation;
PAAD	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.84	-7.71	-0.53	1.53e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13279858	chr6:4135753	PECI	-0.7	-7.72	-0.53	1.41e-12	Smoking initiation;
PAAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.39	-5.08	-0.38	1.09e-6	Colorectal cancer;
PAAD	cis	rs1561176	0.943	rs12667735	chr7:155003753	G/C	cg23863891	chr7:155363328	NA	-0.56	-4.42	-0.34	1.86e-5	Personality dimensions;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.8e-13	Height;
PAAD	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.67	6.6	0.47	6.5e-10	Tuberculosis;
PAAD	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg22705602	chr4:152727874	NA	0.53	5.46	0.4	1.89e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.77	0.42	4.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs58521262	0.585	rs289368	chr19:23114428	C/A	cg02350677	chr19:23254381	NA	-0.26	-4.62	-0.35	8.2e-6	Testicular germ cell tumor;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03762994	chr17:6899332	ALOX12	0.48	4.93	0.37	2.12e-6	Tonsillectomy;
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Bipolar disorder;
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.76	8.48	0.57	1.83e-14	Longevity;
PAAD	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.8	10.2	0.64	6.2800000000000005e-19	Morning vs. evening chronotype;
PAAD	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg03959625	chr15:84868606	LOC388152	0.43	4.47	0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.51	6.38	0.46	2.04e-9	Monobrow;
PAAD	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.63	6.3	0.46	2.98e-9	Testicular germ cell tumor;
PAAD	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-1.1	-11.48	-0.68	2.28e-22	Longevity;
PAAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.17	-0.39	7.36e-7	Alcohol dependence;
PAAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.89	0.54	5.49e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2190422	0.651	rs1004245	chr7:103088409	A/C	cg04218035	chr7:103086829	SLC26A5	0.35	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.57	-7.19	-0.5	2.67e-11	Body mass index;
PAAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.79	0.48	2.34e-10	Body mass index;
PAAD	cis	rs7766436	0.648	rs3734214	chr6:22571414	C/G	cg13666174	chr6:22585274	NA	-0.47	-4.88	-0.37	2.65e-6	Coronary artery disease;
PAAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.71	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs2342371	0.805	rs55997345	chr3:196218353	T/C	cg05659262	chr3:195539315	MUC4	0.49	4.31	0.33	2.93e-5	Fat distribution (HIV);
PAAD	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg18612461	chr15:75251733	NA	-0.54	-5.09	-0.38	1.03e-6	Blood trace element (Zn levels);
PAAD	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.44	-4.64	-0.35	7.45e-6	Pneumonia;
PAAD	cis	rs17681684	0.565	rs12150476	chr17:9763876	A/C	cg26853458	chr17:9805074	RCVRN	0.77	8.17	0.55	1.13e-13	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs959260	1.000	rs2891713	chr17:73386622	G/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	4.9	0.37	2.48e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.08	0.38	1.09e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.82	5.7	0.42	6.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs73416724	0.688	rs113247464	chr6:43261781	T/A	cg26312998	chr6:43337775	ZNF318	0.63	4.34	0.33	2.61e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg27494647	chr7:150038898	RARRES2	0.44	4.71	0.36	5.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10450586	0.769	rs7483297	chr11:27272733	T/A	cg10370305	chr11:27303972	NA	0.39	4.61	0.35	8.56e-6	Total body bone mineral density;
PAAD	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16645584	chr1:59247487	JUN	-0.64	-6.88	-0.49	1.5e-10	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16548265	chr16:30435302	DCTPP1	-0.65	-6.49	-0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.58	7.89	0.54	5.63e-13	Renal cell carcinoma;
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.78	-8.09	-0.55	1.81e-13	Prostate cancer;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg18279126	chr7:2041391	MAD1L1	0.54	5.39	0.4	2.66e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13112903	chr1:153508542	S100A6	-0.73	-7.12	-0.5	4.09e-11	Neuroticism;
PAAD	cis	rs1642645	0.872	rs1408948	chr1:42417706	C/T	cg01990334	chr1:42801334	FOXJ3	0.6	5.36	0.4	3.01e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7591163	1.000	rs7591163	chr2:228715375	C/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs11686241	1.000	rs2271334	chr2:217297350	G/A	cg15830940	chr2:217278069	SMARCAL1	0.44	4.34	0.33	2.56e-5	Cancer;
PAAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9395066	0.527	rs55893720	chr6:44955716	G/T	cg25276700	chr6:44698697	NA	0.49	5.67	0.42	6.94e-8	Height;
PAAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.61	0.57	8.85e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11615916	0.790	rs73135271	chr12:62681642	G/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.91	-0.63	3.52e-18	Tonsillectomy;
PAAD	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.03	-0.38	1.36e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.59	6.36	0.46	2.23e-9	Lung cancer;
PAAD	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg24585817	chr7:64895279	NA	-0.45	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg04844267	chr4:1394941	NA	0.44	4.53	0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg10589385	chr1:150898437	SETDB1	0.39	4.89	0.37	2.51e-6	Melanoma;
PAAD	cis	rs593531	0.513	rs7930193	chr11:74031557	G/T	cg15851278	chr11:73669449	DNAJB13	0.42	5.4	0.4	2.5e-7	Neuroticism;
PAAD	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.53	-0.52	4.14e-12	Eosinophil percentage of white cells;
PAAD	cis	rs12410462	0.591	rs67676707	chr1:227767165	A/C	cg23173402	chr1:227635558	NA	0.58	4.48	0.34	1.48e-5	Major depressive disorder;
PAAD	cis	rs6782025	0.837	rs2141658	chr3:120994428	C/T	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs9816784	0.696	rs6778081	chr3:195819205	C/T	cg01947751	chr3:196728969	NA	0.44	4.25	0.33	3.67e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1062746	0.520	rs17770965	chr16:87328597	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-6.25	-0.45	3.85e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs10186876	0.542	rs11898901	chr2:44179736	C/T	cg09541576	chr2:44873248	C2orf34	-0.47	-4.77	-0.36	4.32e-6	Hand grip strength;
PAAD	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg27494647	chr7:150038898	RARRES2	0.41	4.25	0.33	3.65e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.17	-0.39	7.36e-7	Alcohol dependence;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg22134325	chr11:66188745	NPAS4	0.43	5.09	0.38	1.05e-6	Airway imaging phenotypes;
PAAD	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.75	0.36	4.65e-6	Obesity-related traits;
PAAD	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-1.08	-15.21	-0.78	2.47e-32	Total body bone mineral density;
PAAD	cis	rs10274279	0.614	rs12669148	chr7:157404930	T/C	cg09270525	chr7:157391030	PTPRN2	0.69	5.08	0.38	1.07e-6	Myopia (pathological);
PAAD	cis	rs763512	0.532	rs1416	chr17:35894811	T/C	cg16670864	chr17:35848621	DUSP14	0.51	4.28	0.33	3.31e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg17366294	chr4:99064904	C4orf37	-0.46	-5.14	-0.38	8.34e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7752195	0.643	rs115578938	chr6:25183640	T/C	cg26336265	chr6:25042955	NA	0.87	4.94	0.37	2.01e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg23461800	chr14:103021989	NA	-0.62	-4.91	-0.37	2.3e-6	Platelet count;
PAAD	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg12560992	chr17:57184187	TRIM37	0.69	5.08	0.38	1.07e-6	Vitamin D levels;
PAAD	cis	rs7957197	0.574	rs7305618	chr12:121402932	A/G	cg02419362	chr12:121203948	SPPL3	0.45	4.49	0.34	1.38e-5	Type 2 diabetes;
PAAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg03037974	chr15:76606532	NA	0.48	5.56	0.41	1.19e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	7.77	0.53	1.07e-12	Electrocardiographic conduction measures;
PAAD	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.91	4.48	0.34	1.44e-5	Delta-5 desaturase activity;
PAAD	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	1.0	13.96	0.75	5.12e-29	Menarche (age at onset);
PAAD	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.79	-8.48	-0.57	1.88e-14	Corneal astigmatism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09761478	chr1:198918461	NA	-0.55	-6.37	-0.46	2.17e-9	Myopia (pathological);
PAAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.72	7.0	0.49	7.87e-11	Recombination rate (males);
PAAD	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.71	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.23	5.52	0.41	1.43e-7	Urinary tract infection frequency;
PAAD	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.37	12.75	0.72	8.67e-26	Corneal structure;
PAAD	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg02700894	chr3:12045449	SYN2	0.44	4.71	0.36	5.48e-6	Plateletcrit;Lymphocyte counts;White blood cell count;
PAAD	cis	rs9810890	1.000	rs73198840	chr3:128502194	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs28647808	1.000	rs6597630	chr9:136279935	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.47	4.91	0.37	2.38e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03195230	chr11:64073135	ESRRA	0.66	7.46	0.52	6.14e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.57	5.6	0.41	9.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	5.6	0.41	9.55e-8	Eye color traits;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg20848291	chr7:100343083	ZAN	-0.93	-7.93	-0.54	4.32e-13	Other erythrocyte phenotypes;
PAAD	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg13722127	chr7:150037890	RARRES2	0.55	5.35	0.4	3.13e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.73	4.65	0.35	7.26e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14272706	chr2:202216039	ALS2CR12	-0.58	-6.41	-0.46	1.78e-9	Obesity-related traits;
PAAD	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.75	-0.48	3.01e-10	Systolic blood pressure;
PAAD	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-8.57	-0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg26248373	chr2:1572462	NA	-1.08	-9.44	-0.61	6.18e-17	IgG glycosylation;
PAAD	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.75	-7.11	-0.5	4.17e-11	Asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22273355	chr13:113439949	ATP11A	-0.55	-6.38	-0.46	2.07e-9	Monocyte percentage of white cells;
PAAD	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-4.41	-0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.05e-7	Life satisfaction;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.43	0.4	2.18e-7	Life satisfaction;
PAAD	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	4.83	0.36	3.36e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.62	6.2	0.45	5.15e-9	Monocyte count;
PAAD	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.43	-5.02	-0.38	1.44e-6	Mean arterial pressure;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.59e-8	Height;
PAAD	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg03538708	chr1:25844672	NA	-0.49	-5.03	-0.38	1.39e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg23643435	chr2:38893251	GALM	-0.62	-4.41	-0.34	1.97e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs35740288	0.770	rs17570529	chr15:86125607	A/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.81	-0.43	3.47e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4740619	0.688	rs4741549	chr9:15937846	T/C	cg14451791	chr9:16040625	NA	-0.42	-4.84	-0.37	3.18e-6	Body mass index;
PAAD	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.2	-0.39	6.27e-7	Pulmonary function;
PAAD	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.82	9.44	0.61	6.19e-17	Mean platelet volume;
PAAD	cis	rs1419980	0.730	rs7132326	chr12:7752391	G/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg07969918	chr22:31682909	PIK3IP1	0.33	4.35	0.33	2.47e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4662592	0.628	rs71420828	chr2:128906797	G/A	cg17144508	chr2:128283727	IWS1	-0.54	-4.25	-0.33	3.67e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.68	-5.69	-0.42	6.31e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg26703956	chr19:39260304	NA	-0.44	-5.61	-0.41	9.1e-8	Heart rate;
PAAD	cis	rs4372836	0.518	rs12472549	chr2:28992004	T/C	cg09009506	chr2:28216851	BRE	0.41	4.37	0.33	2.28e-5	Body mass index;
PAAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg13722127	chr7:150037890	RARRES2	0.68	6.83	0.48	1.87e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg14515779	chr1:101123966	NA	0.4	4.45	0.34	1.65e-5	Monocyte count;
PAAD	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.18e-14	Colorectal cancer;
PAAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg01378222	chr16:28622494	SULT1A1	-0.62	-5.16	-0.39	7.72e-7	Platelet distribution width;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.72	7.18	0.5	2.87e-11	Renal function-related traits (BUN);
PAAD	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.46	4.91	0.37	2.37e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.22	-0.45	4.64e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7301826	0.585	rs6486600	chr12:131292977	C/T	cg11011512	chr12:131303247	STX2	0.46	4.76	0.36	4.4e-6	Plasma plasminogen activator levels;
PAAD	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.6	-5.32	-0.4	3.66e-7	Blood trace element (Cu levels);
PAAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.52	-0.34	1.24e-5	Gut microbiome composition (summer);
PAAD	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.1e-9	Morning vs. evening chronotype;
PAAD	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.4	4.78	0.36	4.13e-6	Tonsillectomy;
PAAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg05338066	chr1:7812865	CAMTA1	0.71	5.2	0.39	6.32e-7	Inflammatory bowel disease;
PAAD	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.73	-0.36	5.04e-6	Height;
PAAD	cis	rs79565040	1	rs79565040	chr1:8917398	T/TTA	cg24027679	chr1:9086621	SLC2A7	0.38	4.61	0.35	8.38e-6	White blood cell count (basophil);
PAAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.95	-8.34	-0.56	4.17e-14	Gut microbiome composition (summer);
PAAD	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg13565585	chr5:132299512	AFF4	0.51	4.9	0.37	2.38e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.21	-0.39	6.06e-7	Lung cancer;
PAAD	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.5	-4.95	-0.37	1.93e-6	Mean platelet volume;
PAAD	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.585	rs12978716	chr19:23216456	C/T	cg02350677	chr19:23254381	NA	0.27	4.65	0.35	7.09e-6	Testicular germ cell tumor;
PAAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.6	7.47	0.52	5.72e-12	Multiple system atrophy;
PAAD	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08452062	chr19:40854347	C19orf47;PLD3	-0.78	-6.61	-0.47	6.15e-10	Neuroticism;
PAAD	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.65	0.35	7.29e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.54	-0.47	8.67e-10	Eye color traits;
PAAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.84	8.36	0.56	3.61e-14	Vitamin D levels;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.74	5.41	0.4	2.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.6	5.29	0.39	4.23e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg27411982	chr8:10470053	RP1L1	-0.47	-5.15	-0.39	8.08e-7	Retinal vascular caliber;
PAAD	cis	rs1504749	0.689	rs17306015	chr8:55288149	C/T	cg10239077	chr8:55294882	NA	-0.47	-4.25	-0.33	3.66e-5	Intracranial aneurysm;
PAAD	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.92e-17	Electrocardiographic conduction measures;
PAAD	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.69	0.48	3.93e-10	Bladder cancer;
PAAD	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg10437265	chr15:77819839	NA	0.39	4.44	0.34	1.7e-5	Type 2 diabetes;
PAAD	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.51	0.34	1.3e-5	Testicular germ cell tumor;
PAAD	cis	rs743757	0.938	rs2236958	chr3:50441613	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	4.58	0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.54	-0.41	1.29e-7	Schizophrenia;
PAAD	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.45	-4.55	-0.35	1.08e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-1.05	-8.16	-0.55	1.2e-13	Post bronchodilator FEV1;
PAAD	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.75	4.64	0.35	7.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18019004	chr20:3209307	SLC4A11	0.57	6.58	0.47	7.08e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3131856	1	rs3131856	chr6:29607101	T/C	cg06606381	chr12:133084897	FBRSL1	-1.47	-9.17	-0.6	3.13e-16	Tuberculosis;
PAAD	cis	rs10821973	0.550	rs1432416	chr10:63975309	A/T	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs6466055	0.636	rs73186054	chr7:104930898	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.27	-0.39	4.51e-7	Height;
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg05082376	chr22:42548792	NA	0.48	5.4	0.4	2.54e-7	Cognitive function;
PAAD	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-4.79	-0.36	3.89e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.83	-0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.38	5.18	0.39	6.98e-7	Coronary artery disease;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg23119463	chr10:134592391	INPP5A	-0.45	-4.33	-0.33	2.71e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg19486271	chr11:47235900	DDB2	0.59	6.07	0.44	9.67e-9	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs11958404	0.615	rs7737601	chr5:157448269	C/T	cg05962755	chr5:157440814	NA	-0.57	-5.49	-0.41	1.63e-7	IgG glycosylation;
PAAD	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	1.13	8.15	0.55	1.27e-13	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.44	-4.98	-0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.25	-0.39	4.97e-7	Reticulocyte count;
PAAD	cis	rs73019876	0.869	rs8101183	chr19:22170551	C/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs11025559	0.617	rs11025592	chr11:20534286	T/C	cg19653624	chr11:20408972	PRMT3	-0.6	-5.32	-0.4	3.68e-7	Pursuit maintenance gain;
PAAD	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.64	-6.68	-0.48	4.23e-10	Body mass index;
PAAD	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	1.07	6.79	0.48	2.42e-10	Skin colour saturation;
PAAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg19847866	chr10:1019161	NA	0.73	7.31	0.51	1.38e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.46	-4.94	-0.37	2.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg11156230	chr4:83351251	HNRPDL;ENOPH1	0.96	6.93	0.49	1.14e-10	Lung function (FEV1/FVC);
PAAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.58	-8.07	-0.55	2.01e-13	Rheumatoid arthritis;
PAAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs9398803	0.616	rs6909149	chr6:126631091	A/T	cg19875578	chr6:126661172	C6orf173	0.53	5.04	0.38	1.31e-6	Male-pattern baldness;
PAAD	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.49	4.99	0.38	1.64e-6	Colorectal cancer;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.88	7.53	0.52	4.26e-12	Alzheimer's disease;
PAAD	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.52	-0.61	3.95e-17	Response to antipsychotic treatment;
PAAD	cis	rs4865169	0.595	rs4865165	chr4:57765546	A/G	cg24291500	chr4:57773398	REST	-0.42	-4.68	-0.35	6.4e-6	Breast cancer;
PAAD	cis	rs6987853	0.563	rs2974301	chr8:42442238	A/G	cg09913449	chr8:42400586	C8orf40	0.52	5.79	0.43	3.82e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.47e-11	Rheumatoid arthritis;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-6.08	-0.44	9.13e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.59	0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.53	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.9	10.79	0.66	1.68e-20	Sudden cardiac arrest;
PAAD	cis	rs4281086	0.931	rs7846328	chr8:10378485	C/T	cg01072821	chr8:10382165	T-SP1	0.45	4.29	0.33	3.21e-5	Obesity-related traits;
PAAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.61	5.76	0.42	4.56e-8	Urate levels;
PAAD	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.92	-7.26	-0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-4.36	-0.33	2.36e-5	Red blood cell count;
PAAD	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.62	6.75	0.48	2.98e-10	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17376030	chr22:41985996	PMM1	-0.64	-4.38	-0.33	2.24e-5	Vitiligo;
PAAD	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg16342193	chr10:102329863	NA	-0.73	-7.61	-0.53	2.63e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.9	11.14	0.67	1.87e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg16262614	chr3:133464971	TF	0.48	5.08	0.38	1.07e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs72960926	0.744	rs6926606	chr6:75034904	T/C	cg03266952	chr6:74778945	NA	-0.86	-5.16	-0.39	7.53e-7	Metabolite levels (MHPG);
PAAD	cis	rs1419980	0.730	rs11559767	chr12:7748555	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs911119	0.866	rs4346460	chr20:23569400	C/T	cg16589663	chr20:23618590	CST3	0.79	6.77	0.48	2.7e-10	Chronic kidney disease;
PAAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7508	0.512	rs2237851	chr8:17877749	C/G	cg08627089	chr8:17753878	FGL1	-0.44	-4.36	-0.33	2.4e-5	Atrial fibrillation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27558594	chr6:91006613	BACH2	-0.62	-6.53	-0.47	9.43e-10	Smoking initiation;
PAAD	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.93	-6.94	-0.49	1.09e-10	Migraine;Coronary artery disease;
PAAD	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg03264133	chr6:25882463	NA	0.44	4.37	0.33	2.31e-5	Schizophrenia;
PAAD	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.8	-0.53	9.16e-13	Total cholesterol levels;
PAAD	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg18769074	chr3:133464867	TF	0.44	5.37	0.4	2.93e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.69	7.24	0.51	2.08e-11	Aortic root size;
PAAD	cis	rs258892	0.895	rs9293450	chr5:72068476	G/A	cg21869765	chr5:72125136	TNPO1	-0.81	-5.44	-0.4	2.07e-7	Small cell lung carcinoma;
PAAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg22143856	chr6:28129313	ZNF389	-0.67	-5.34	-0.4	3.25e-7	Depression;
PAAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.92	7.39	0.51	9.02e-12	Lymphocyte counts;
PAAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg10587741	chr22:38071170	LGALS1	0.66	7.3	0.51	1.52e-11	Fat distribution (HIV);
PAAD	cis	rs6547631	0.622	rs1437742	chr2:85924899	T/A	cg24620635	chr2:85921963	GNLY	0.42	5.53	0.41	1.36e-7	Blood protein levels;
PAAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7786896	0.875	rs6462890	chr7:39093791	A/G	cg13319711	chr7:39015544	NA	0.19	4.29	0.33	3.15e-5	Schizophrenia;
PAAD	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.54	0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs818427	0.896	rs712662	chr5:112222694	C/G	cg06941702	chr5:112196734	SRP19	-0.5	-4.71	-0.36	5.58e-6	Total body bone mineral density;
PAAD	cis	rs1075265	0.791	rs1833498	chr2:54307938	T/C	cg04546899	chr2:54196757	PSME4	0.31	4.37	0.33	2.29e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.84	-9.84	-0.62	5.43e-18	Iron status biomarkers;
PAAD	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21231944	chr12:82153410	PPFIA2	0.54	4.44	0.34	1.72e-5	Resting heart rate;
PAAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.83	-9.1	-0.59	4.78e-16	Tuberculosis;
PAAD	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg19761014	chr17:28927070	LRRC37B2	0.88	6.23	0.45	4.34e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6580649	0.883	rs1793955	chr12:48393106	G/T	cg05342945	chr12:48394962	COL2A1	-0.71	-4.62	-0.35	8.15e-6	Lung cancer;
PAAD	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg07636037	chr3:49044803	WDR6	0.6	5.6	0.41	9.75e-8	Resting heart rate;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg00024416	chr22:24240387	NA	-0.46	-4.53	-0.34	1.18e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg22105103	chr4:187893119	NA	0.62	7.72	0.53	1.48e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4273100	1.000	rs4924986	chr17:19242467	C/T	cg19949948	chr17:19361230	NA	0.53	4.51	0.34	1.29e-5	Schizophrenia;
PAAD	trans	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg26727032	chr16:67993705	SLC12A4	0.64	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.6	0.47	6.31e-10	Coffee consumption (cups per day);
PAAD	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg03252829	chr6:39282164	KCNK17	-0.55	-5.82	-0.43	3.41e-8	Type 2 diabetes;
PAAD	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.78	10.77	0.66	1.91e-20	Cannabis dependence symptom count;
PAAD	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.61	6.94	0.49	1.06e-10	Non-substance related behavioral disinhibition;
PAAD	cis	rs9463078	0.764	rs7754698	chr6:44782717	A/G	cg25276700	chr6:44698697	NA	-0.44	-4.85	-0.37	3e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.54	5.77	0.42	4.38e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.29	-0.45	3.13e-9	Alcohol dependence;
PAAD	trans	rs9810890	0.717	rs73210625	chr3:128668246	G/A	cg05163071	chr3:108476540	RETNLB	1.03	7.45	0.52	6.67e-12	Dental caries;
PAAD	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.49	6.16	0.45	6.1e-9	Crohn's disease;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.45	-4.51	-0.34	1.3e-5	Iron status biomarkers;
PAAD	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	High light scatter reticulocyte count;
PAAD	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.38	-0.4	2.77e-7	Neuroticism;
PAAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.82	-0.48	2.02e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg12311346	chr5:56204834	C5orf35	-0.6	-5.27	-0.39	4.5e-7	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg21951975	chr1:209979733	IRF6	0.58	5.47	0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs7191439	0.584	rs11076698	chr16:88752693	T/G	cg27087555	chr16:88793112	FAM38A	-1.04	-5.75	-0.42	4.79e-8	Plateletcrit;
PAAD	cis	rs62408225	1.000	rs62408227	chr6:90965171	A/G	cg03795776	chr6:90687632	BACH2	0.43	4.29	0.33	3.23e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.14e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3026101	0.587	rs8066000	chr17:5310033	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14580859	chr9:123691850	NA	0.39	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22626574	chr17:69339999	NA	-0.61	-6.48	-0.47	1.23e-9	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12267933	chr2:228176991	COL4A3	-0.63	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.1	-0.77	4.66e-32	Height;
PAAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg14191688	chr11:70257035	CTTN	0.57	5.3	0.4	3.97e-7	Coronary artery disease;
PAAD	cis	rs939584	1.000	rs11127489	chr2:646081	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.83	10.52	0.65	8.63e-20	Aortic root size;
PAAD	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg04160749	chr8:58172571	NA	-0.75	-4.87	-0.37	2.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.65	4.89	0.37	2.52e-6	Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.86	-0.66	1.09e-20	Platelet distribution width;
PAAD	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	1.02	12.35	0.71	1.03e-24	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-4.87	-0.37	2.75e-6	Facial morphology (factor 19);
PAAD	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.73	-0.36	5.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.91	0.59	1.45e-15	Lung cancer;
PAAD	cis	rs6141769	0.542	rs6057630	chr20:31318737	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs8067287	0.688	rs8081126	chr17:16845362	T/C	cg26910001	chr17:16838321	NA	-0.52	-4.86	-0.37	2.92e-6	Diabetic kidney disease;
PAAD	cis	rs457162	0.643	rs283090	chr6:118589682	A/C	cg21191810	chr6:118973309	C6orf204	0.67	4.67	0.35	6.6e-6	QT interval;
PAAD	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.45	-4.34	-0.33	2.64e-5	Schizophrenia;
PAAD	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	4.42	0.34	1.86e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.34	0.51	1.18e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.46	4.71	0.36	5.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939584	1.000	rs4854340	chr2:623216	G/A	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.4e-14	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs6694672	0.681	rs476390	chr1:197253267	T/C	cg26994526	chr18:47719735	MYO5B	-0.84	-6.49	-0.47	1.17e-9	Asthma;
PAAD	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.12	-0.38	9.25e-7	Pulmonary function;
PAAD	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.45	-4.3	-0.33	3.09e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg19223190	chr17:80058835	NA	0.52	5.45	0.4	1.96e-7	Life satisfaction;
PAAD	cis	rs6604026	0.740	rs10782945	chr1:93304272	C/T	cg17283838	chr1:93427260	FAM69A	-0.63	-5.9	-0.43	2.32e-8	Multiple sclerosis;
PAAD	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg12923728	chr3:195709715	SDHAP1	-0.86	-8.26	-0.56	6.47e-14	Pancreatic cancer;
PAAD	cis	rs7729723	0.591	rs4835681	chr5:137783690	C/G	cg26069252	chr5:137800343	EGR1	-0.46	-4.29	-0.33	3.22e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs4356203	0.905	rs1989405	chr11:17184819	C/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs12044355	0.827	rs7552519	chr1:231824147	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.87	0.43	2.59e-8	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09274402	chr7:77166647	PTPN12	-0.6	-6.38	-0.46	2.07e-9	Smoking initiation;
PAAD	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.61	4.31	0.33	2.88e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9815354	0.767	rs75651509	chr3:41953564	A/G	cg03022575	chr3:42003672	ULK4	0.97	6.73	0.48	3.24e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07169764	chr2:136633963	MCM6	-0.75	-7.51	-0.52	4.76e-12	Mosquito bite size;
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08704250	chr15:31115839	NA	-0.58	-7.87	-0.54	6.35e-13	Huntington's disease progression;
PAAD	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.44	0.56	2.36e-14	Dupuytren's disease;
PAAD	cis	rs863345	0.584	rs10797023	chr1:158497079	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.73	5.32	0.4	3.62e-7	Plateletcrit;
PAAD	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.67	-0.42	6.94e-8	Mean corpuscular volume;
PAAD	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.27	0.33	3.46e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.69	8.09	0.55	1.75e-13	Colorectal cancer;
PAAD	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	6.21	0.45	4.75e-9	Migraine;Coronary artery disease;
PAAD	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs7172689	0.908	rs67476632	chr15:81566969	T/C	cg05624577	chr15:81411055	NA	-0.56	-4.3	-0.33	3.01e-5	Inattentive symptoms;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg04352962	chr1:209979756	IRF6	0.54	4.69	0.36	6.17e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.08	0.38	1.11e-6	Vitamin D levels;
PAAD	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg03989125	chr22:38214979	NA	-0.64	-6.83	-0.48	1.87e-10	Glioblastoma;Glioma;
PAAD	trans	rs3742264	0.816	rs9534319	chr13:46664444	C/T	cg13594151	chr19:12405719	ZNF44	0.64	6.32	0.46	2.71e-9	Blood protein levels;
PAAD	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.61	6.64	0.47	5.11e-10	Tumor biomarkers;
PAAD	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.95	0.37	1.93e-6	Colorectal cancer;
PAAD	cis	rs9907295	0.591	rs4251749	chr17:34150425	C/T	cg19411729	chr17:34207663	CCL5	-0.53	-4.74	-0.36	4.92e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.62	4.47	0.34	1.55e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.31	-0.4	3.74e-7	Mean corpuscular volume;
PAAD	cis	rs11159086	0.793	rs1029703	chr14:74940602	T/G	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.74	-7.9	-0.54	5.2e-13	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg11764359	chr7:65958608	NA	0.79	5.22	0.39	5.91e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg08029281	chr1:67600428	NA	0.48	5.51	0.41	1.47e-7	Psoriasis;
PAAD	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg09579323	chr1:150459698	TARS2	0.45	4.37	0.33	2.27e-5	Migraine;
PAAD	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.48	4.92	0.37	2.18e-6	Red blood cell count;
PAAD	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.38	0.46	1.99e-9	Lung cancer in ever smokers;
PAAD	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.96	7.57	0.52	3.26e-12	Migraine;Coronary artery disease;
PAAD	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg17105886	chr17:28927953	LRRC37B2	0.77	5.02	0.38	1.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	1.07	6.66	0.48	4.64e-10	Skin colour saturation;
PAAD	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-4.28	-0.33	3.32e-5	Hemoglobin concentration;
PAAD	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.62	-6.74	-0.48	3.15e-10	High light scatter reticulocyte count;
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	11.7	0.69	5.85e-23	Platelet count;
PAAD	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg09626299	chr10:82213104	TSPAN14	-0.44	-4.88	-0.37	2.64e-6	Post bronchodilator FEV1;
PAAD	cis	rs9463078	0.528	rs13211229	chr6:44912462	G/A	cg25276700	chr6:44698697	NA	0.48	5.48	0.41	1.76e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.47	0.57	1.94e-14	Menarche (age at onset);
PAAD	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-1.01	-10.58	-0.65	5.91e-20	Platelet distribution width;
PAAD	cis	rs4388249	0.687	rs2301002	chr5:109101831	C/T	cg17395555	chr5:108820864	NA	0.34	4.57	0.35	9.95e-6	Schizophrenia;
PAAD	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs4853525	0.923	rs4853523	chr2:191732779	A/G	cg11065262	chr2:191878861	STAT1	-0.5	-4.25	-0.33	3.68e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01492710	chr6:79788336	PHIP	0.59	7.07	0.5	5.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.7	-0.36	5.84e-6	Type 1 diabetes;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg10395934	chr14:104002654	TRMT61A	-0.53	-5.67	-0.42	6.96e-8	Bone mineral density;
PAAD	cis	rs12529514	1.000	rs6932936	chr6:14115090	A/AT	cg11874760	chr6:14118415	CD83	0.74	7.32	0.51	1.38e-11	Rheumatoid arthritis;
PAAD	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.81	-7.22	-0.51	2.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17507749	chr15:85114479	UBE2QP1	0.64	6.38	0.46	2.07e-9	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.63	0.82	1.42e-38	Height;
PAAD	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg14515779	chr1:101123966	NA	0.4	4.45	0.34	1.65e-5	Monocyte count;
PAAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.85	8.0	0.54	2.89e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.54	5.36	0.4	2.99e-7	Mean corpuscular volume;
PAAD	cis	rs7765175	0.698	rs3851198	chr6:113666648	G/A	cg19037598	chr6:113666021	NA	-0.41	-4.39	-0.34	2.1e-5	Coronary artery calcification;
PAAD	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg14343924	chr8:8086146	FLJ10661	-0.65	-5.82	-0.43	3.42e-8	Mood instability;
PAAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg27539214	chr16:67997921	SLC12A4	-0.63	-5.01	-0.38	1.49e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.42	0.4	2.27e-7	Neuroticism;
PAAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.13	-0.38	8.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08276889	chr2:70351524	LOC100133985	0.58	6.39	0.46	1.9e-9	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23401436	chr7:26230758	HNRNPA2B1	0.63	6.66	0.48	4.83e-10	Smoking initiation;
PAAD	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg17644776	chr2:200775616	C2orf69	-0.65	-5.08	-0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.82e-6	Total body bone mineral density;
PAAD	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg00531865	chr16:30841666	NA	-0.64	-5.91	-0.43	2.18e-8	Multiple myeloma;
PAAD	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.27e-20	Electrocardiographic conduction measures;
PAAD	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg24848339	chr3:12840334	CAND2	0.53	6.07	0.44	1e-8	QRS complex (12-leadsum);
PAAD	cis	rs876084	0.505	rs7827219	chr8:121130164	G/A	cg06265175	chr8:121136014	COL14A1	0.49	4.77	0.36	4.3e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.59	-6.59	-0.47	6.67e-10	Testicular germ cell tumor;
PAAD	cis	rs1400816	0.718	rs10930501	chr2:172836677	G/C	cg23624723	chr2:173292262	ITGA6	-0.76	-4.38	-0.33	2.2e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7011049	1.000	rs72643579	chr8:53846705	C/A	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg13263323	chr15:86062960	AKAP13	-0.62	-7.16	-0.5	3.21e-11	Interstitial lung disease;
PAAD	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg08898775	chr15:59042684	ADAM10	0.45	5.88	0.43	2.57e-8	Asperger disorder;
PAAD	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.41	0.34	1.98e-5	Tonsillectomy;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs747650	0.504	rs7950753	chr11:47071897	C/T	cg19486271	chr11:47235900	DDB2	-0.66	-6.07	-0.44	9.71e-9	Acne (severe);
PAAD	cis	rs251130	0.540	rs251129	chr5:110860120	C/T	cg11925263	chr5:110849104	STARD4	-0.38	-4.29	-0.33	3.17e-5	Menarche (age at onset);
PAAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.5	-0.41	1.57e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17169635	0.819	rs1452914	chr7:134497200	G/C	cg02516134	chr7:134575187	CALD1	-0.44	-4.49	-0.34	1.43e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.38	-0.51	9.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.89	-10.49	-0.65	1.07e-19	Iron status biomarkers;
PAAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.53	5.19	0.39	6.59e-7	Blood metabolite levels;
PAAD	cis	rs9659323	0.650	rs12093893	chr1:119490819	G/A	cg17326555	chr1:119535693	NA	-0.36	-4.37	-0.33	2.32e-5	Body mass index;
PAAD	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.6	5.83	0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.3	0.4	3.97e-7	Ovarian reserve;
PAAD	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.64e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.71	-8.13	-0.55	1.4e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.05	8.06	0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.39e-10	Life satisfaction;
PAAD	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.98	10.43	0.65	1.55e-19	Breast cancer;
PAAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg20607287	chr7:12443886	VWDE	-0.74	-5.73	-0.42	5.2e-8	Coronary artery disease;
PAAD	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.69	0.36	5.97e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7941600	0.708	rs10840202	chr11:9320346	G/T	cg19415743	chr11:9336845	TMEM41B	0.96	5.86	0.43	2.73e-8	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4742903	0.904	rs7038714	chr9:106992930	T/G	cg14250997	chr9:106856677	SMC2	0.44	4.68	0.35	6.31e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.91	-9.33	-0.6	1.21e-16	Asthma;
PAAD	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg04165759	chr1:150448943	RPRD2	0.49	5.01	0.38	1.5e-6	Migraine;
PAAD	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21028142	chr17:79581711	NPLOC4	-0.58	-7.85	-0.54	6.96e-13	Eye color traits;
PAAD	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-7.93	-0.54	4.28e-13	Colorectal cancer;
PAAD	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg10072921	chr12:121022843	NA	-0.37	-4.93	-0.37	2.18e-6	High light scatter reticulocyte count;
PAAD	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg10290764	chr8:4849399	CSMD1	-0.39	-6.58	-0.47	7.26e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3736485	0.934	rs8036821	chr15:51861646	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs9549328	0.837	rs9549330	chr13:113648404	G/T	cg20742385	chr13:113633654	MCF2L	-0.44	-4.46	-0.34	1.58e-5	Systolic blood pressure;
PAAD	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-4.65	-0.35	7.18e-6	Retinal vascular caliber;
PAAD	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg14132834	chr19:41945861	ATP5SL	-0.53	-5.07	-0.38	1.16e-6	Height;
PAAD	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg01388757	chr2:102091195	RFX8	-0.6	-7.75	-0.53	1.23e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.68	-8.07	-0.55	1.96e-13	Metabolite levels;
PAAD	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg00806126	chr19:22604979	ZNF98	-0.37	-4.72	-0.36	5.4e-6	Pain;
PAAD	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-4.76	-0.36	4.53e-6	Height;
PAAD	cis	rs1499972	0.715	rs1463403	chr3:117623116	C/T	cg07612923	chr3:117604196	NA	-0.74	-5.66	-0.42	7.5e-8	Schizophrenia;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-4.27	-0.33	3.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs11588062	0.745	rs5019033	chr1:46735072	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.48	4.91	0.37	2.35e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs516243	0.688	rs474404	chr1:10741426	T/C	cg02903756	chr1:10750680	CASZ1	-0.44	-4.84	-0.37	3.13e-6	Migraine - clinic-based;
PAAD	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg11214348	chr21:47283868	PCBP3	-0.49	-4.38	-0.33	2.22e-5	Schizophrenia;
PAAD	cis	rs11603691	0.901	rs61888888	chr11:57103684	A/G	cg17237962	chr11:57479805	MED19;TMX2	0.89	4.37	0.33	2.26e-5	Low high density lipoprotein cholesterol levels;
PAAD	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg10547527	chr2:198650123	BOLL	-0.74	-5.0	-0.38	1.57e-6	Ulcerative colitis;
PAAD	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.69	6.8	0.48	2.26e-10	Depressive symptoms;
PAAD	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs955333	0.565	rs57776280	chr6:154896788	G/T	cg20019720	chr6:154832845	CNKSR3	0.37	5.21	0.39	6.06e-7	Diabetic kidney disease;
PAAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.6	-6.7	-0.48	3.76e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.25	18.29	0.83	3.17e-40	IgG glycosylation;
PAAD	cis	rs9395066	0.545	rs17424547	chr6:44988970	A/G	cg25276700	chr6:44698697	NA	0.49	5.67	0.42	6.99e-8	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25557260	chr7:34977822	DPY19L1	-0.59	-6.41	-0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00968241	chr3:156543833	LEKR1	0.57	6.72	0.48	3.39e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.83	0.54	7.97e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10703506	chr12:109576250	ACACB	0.65	6.75	0.48	2.97e-10	Smoking initiation;
PAAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.63	6.92	0.49	1.21e-10	Multiple sclerosis;
PAAD	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-6.5	-0.47	1.09e-9	Cognitive test performance;
PAAD	cis	rs2882667	0.690	rs825762	chr5:138137670	T/C	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.77	9.56	0.61	2.96e-17	Bladder cancer;
PAAD	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg21194808	chr1:2205498	SKI	0.43	4.29	0.33	3.2e-5	Coronary artery disease;
PAAD	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg03233332	chr7:66118400	NA	-0.41	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg14146966	chr2:61757674	XPO1	-0.4	-5.08	-0.38	1.1e-6	Tuberculosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22544720	chr18:61089873	VPS4B	0.63	6.67	0.48	4.45e-10	Myopia (pathological);
PAAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg09796270	chr17:17721594	SREBF1	0.45	4.71	0.36	5.65e-6	Total body bone mineral density;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.64	-7.17	-0.5	3.12e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg02598441	chr17:62777298	LOC146880	-0.69	-5.3	-0.39	4.01e-7	QT interval;
PAAD	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.61	-5.87	-0.43	2.68e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8121916	1.000	rs8121916	chr20:12401325	A/C	cg16404259	chr20:12988931	SPTLC3	0.42	4.28	0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.81	0.58	2.65e-15	Lung cancer;
PAAD	cis	rs7176527	1.000	rs7176527	chr15:85140794	C/T	cg24253500	chr15:84953950	NA	-0.64	-5.24	-0.39	5.25e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs8005677	0.828	rs35085068	chr14:23409909	C/A	cg01529538	chr14:23388837	RBM23	0.48	4.78	0.36	4.17e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs1620921	0.505	rs1344731	chr6:161205037	G/A	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12003952	chr19:21687300	ZNF429	-0.71	-6.69	-0.48	4.02e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs757081	0.578	rs7109536	chr11:17255512	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-6.06	-0.44	1.01e-8	Systolic blood pressure;
PAAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.74	7.11	0.5	4.24e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2882667	0.628	rs311605	chr5:138045839	T/C	cg09476006	chr5:138032270	NA	0.49	6.29	0.45	3.27e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.74	-7.32	-0.51	1.36e-11	White matter hyperintensity burden;
PAAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.4	-4.4	-0.34	2.06e-5	Bipolar disorder;
PAAD	cis	rs2004318	1.000	rs75022743	chr19:55126228	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs11871801	0.750	rs7216927	chr17:40651497	T/A	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.93	-0.37	2.15e-6	Crohn's disease;
PAAD	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.59	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-7.48	-0.52	5.56e-12	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.42	0.34	1.86e-5	Personality dimensions;
PAAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.64	0.35	7.61e-6	Bone mineral density;
PAAD	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Lung cancer in ever smokers;
PAAD	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg20744362	chr22:50050164	C22orf34	0.66	8.08	0.55	1.91e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2668423	0.959	rs2526134	chr19:1365620	A/T	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.74	-0.48	3.16e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.22	10.42	0.65	1.63e-19	Breast cancer;
PAAD	cis	rs1879734	0.731	rs11206200	chr1:54168545	T/C	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg16591659	chr17:78472290	NA	-0.48	-4.57	-0.35	9.86e-6	Fractional excretion of uric acid;
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.46	4.89	0.37	2.57e-6	QRS complex (12-leadsum);
PAAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.75	-5.75	-0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs13102973	0.931	rs116199858	chr4:135847256	G/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg22710661	chr11:17411071	KCNJ11	0.45	4.42	0.34	1.88e-5	Type 2 diabetes;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.45	-4.97	-0.37	1.8e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg07689907	chr11:61582574	FADS1	0.47	4.49	0.34	1.39e-5	Trans fatty acid levels;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg20850873	chr3:10149803	C3orf24	0.53	4.26	0.33	3.59e-5	Alzheimer's disease;
PAAD	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.85	-0.54	7.03e-13	Mosquito bite size;
PAAD	cis	rs12311304	0.965	rs7969197	chr12:15362066	G/C	cg08258403	chr12:15378311	NA	0.37	4.72	0.36	5.32e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg07166546	chr14:35805898	NA	-0.31	-4.75	-0.36	4.6e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2421770	0.927	rs3818275	chr11:35308783	C/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-6.63	-0.47	5.41e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.55	-5.12	-0.38	9.27e-7	Brugada syndrome;
PAAD	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.79	9.45	0.61	5.9e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg21951975	chr1:209979733	IRF6	0.51	4.91	0.37	2.35e-6	Coronary artery disease;
PAAD	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	6.39	0.46	1.91e-9	Type 2 diabetes;
PAAD	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.79	9.98	0.63	2.3e-18	Alcohol dependence;
PAAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg20821713	chr7:1055600	C7orf50	-0.54	-4.41	-0.34	1.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs13177180	0.671	rs10079000	chr5:114940200	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.46	4.85	0.37	2.99e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.01	5.12	0.38	9.03e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.27	-7.76	-0.53	1.17e-12	Body mass index;
PAAD	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg23250494	chr15:78913474	CHRNA3	-0.44	-4.43	-0.34	1.82e-5	Sudden cardiac arrest;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.98	0.37	1.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.81	-6.77	-0.48	2.66e-10	Other erythrocyte phenotypes;
PAAD	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.65	-8.81	-0.58	2.73e-15	Hemoglobin concentration;
PAAD	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.46	-5.57	-0.41	1.14e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs56046484	0.620	rs34585903	chr15:85528124	G/T	cg08123816	chr15:85640762	PDE8A	-0.47	-4.34	-0.33	2.64e-5	Testicular germ cell tumor;
PAAD	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg11232448	chr19:2858854	NA	-0.48	-4.71	-0.36	5.46e-6	Total cholesterol levels;
PAAD	cis	rs864537	1.000	rs864537	chr1:167411384	A/G	cg09179987	chr1:167433047	CD247	0.41	4.62	0.35	8.03e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.61	0.61	2.2e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.26	-0.33	3.53e-5	Obesity-related traits;
PAAD	cis	rs642743	0.967	rs581686	chr10:105983356	C/T	cg03775802	chr10:105978702	MIR609;C10orf79	0.33	4.53	0.34	1.19e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs714031	1.000	rs714031	chr22:40070234	C/T	cg21377881	chr22:40064566	CACNA1I	0.43	4.28	0.33	3.28e-5	Schizophrenia;
PAAD	cis	rs73198271	0.545	rs78352360	chr8:8627831	G/A	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs76917914	0.820	rs7869762	chr9:100814573	G/T	cg21225548	chr9:100864335	TRIM14	-0.52	-5.33	-0.4	3.44e-7	Immature fraction of reticulocytes;
PAAD	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.18	-0.39	6.88e-7	Schizophrenia;
PAAD	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-4.63	-0.35	7.9e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.56	6.19	0.45	5.25e-9	Cognitive function;
PAAD	cis	rs9810890	1.000	rs73198828	chr3:128489894	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.41	-4.28	-0.33	3.36e-5	Aortic root size;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2455826	0.521	rs9823153	chr3:15821698	C/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg08992911	chr2:238395768	MLPH	0.74	5.61	0.41	9.46e-8	Prostate cancer;
PAAD	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs863345	0.604	rs7548349	chr1:158493726	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.93	8.13	0.55	1.4e-13	Alzheimer's disease;
PAAD	cis	rs3126085	0.515	rs10888484	chr1:152352514	C/T	cg26876637	chr1:152193138	HRNR	-0.6	-4.57	-0.35	1.01e-5	Atopic dermatitis;
PAAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs1497828	0.956	rs2646824	chr1:217537766	C/G	cg04411442	chr1:217543379	NA	-0.47	-4.56	-0.35	1.03e-5	Dialysis-related mortality;
PAAD	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.38	-0.33	2.2e-5	Plateletcrit;
PAAD	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10490913	0.965	rs7083887	chr10:120144338	C/T	cg04126427	chr10:120840676	EIF3A	-0.47	-4.86	-0.37	2.85e-6	Cancer;
PAAD	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.6	6.01	0.44	1.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs876084	0.505	rs7815878	chr8:121103137	C/T	cg06265175	chr8:121136014	COL14A1	0.48	4.75	0.36	4.69e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1443512	0.541	rs1443510	chr12:54340841	C/T	cg17410650	chr12:54324560	NA	-0.42	-5.13	-0.38	8.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.72	7.08	0.5	5e-11	HIV-1 control;
PAAD	cis	rs740474	0.831	rs10477148	chr5:140989242	C/T	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.29	4.34	0.33	2.62e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5752326	0.558	rs6005059	chr22:26879297	C/G	cg21431832	chr22:26875652	HPS4	0.66	4.33	0.33	2.66e-5	Ischemic stroke;
PAAD	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg25364880	chr3:44379878	C3orf23	0.58	5.38	0.4	2.81e-7	Depressive symptoms;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg13198984	chr17:80129470	CCDC57	-0.39	-4.63	-0.35	7.7e-6	Life satisfaction;
PAAD	trans	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg16011800	chr17:1958478	HIC1	-0.68	-6.32	-0.46	2.8e-9	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.51	5.62	0.41	8.9e-8	Longevity;Endometriosis;
PAAD	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.54	5.08	0.38	1.11e-6	Sudden cardiac arrest;
PAAD	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.82	6.52	0.47	9.67e-10	Obesity-related traits;
PAAD	cis	rs1419980	0.730	rs73256883	chr12:7740211	A/C	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg15841412	chr13:111365552	ING1	-0.55	-4.56	-0.35	1.04e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.76	-0.36	4.52e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.97	-7.33	-0.51	1.26e-11	Multiple sclerosis;
PAAD	cis	rs9462027	0.628	rs9469857	chr6:34719793	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.85e-7	Systemic lupus erythematosus;
PAAD	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg11949866	chr1:10754891	CASZ1	0.54	4.6	0.35	8.89e-6	Ewing sarcoma;
PAAD	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-4.33	-0.33	2.72e-5	Testicular germ cell tumor;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01765077	chr12:122356316	WDR66	0.67	7.03	0.5	6.68e-11	Mean corpuscular volume;
PAAD	cis	rs4450131	1.000	rs10901802	chr10:126354554	C/G	cg20435097	chr10:126320824	FAM53B	-0.49	-5.53	-0.41	1.33e-7	White blood cell count (basophil);
PAAD	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.84	-0.49	1.8e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7562790	0.624	rs68111949	chr2:36655465	A/G	cg01206211	chr2:36825736	FEZ2	0.46	4.69	0.36	6.1e-6	QRS duration;QRS complex (Cornell);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07544189	chr16:68348695	PRMT7	-0.57	-7.36	-0.51	1.1e-11	Monocyte percentage of white cells;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-7.1	-0.5	4.39e-11	Vitiligo;
PAAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.16e-32	Height;
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs4751058	0.607	rs4750732	chr10:130864640	C/T	cg07287682	chr7:2281772	NUDT1;FTSJ2	0.68	6.35	0.46	2.36e-9	Vitamin D levels;
PAAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.93	0.37	2.18e-6	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg14440974	chr22:39074834	NA	-0.59	-7.27	-0.51	1.8e-11	Menopause (age at onset);
PAAD	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.6	-5.36	-0.4	3.08e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.96	8.41	0.56	2.82e-14	Bipolar disorder;
PAAD	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg21918786	chr6:109611834	NA	-0.55	-5.91	-0.43	2.12e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.78	12.52	0.71	3.6e-25	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.64	5.97	0.44	1.6e-8	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22550330	chr3:50336343	HYAL3;NAT6	-0.68	-7.29	-0.51	1.6e-11	Smoking initiation;
PAAD	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-7.79	-0.53	9.98e-13	Gut microbiome composition (summer);
PAAD	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg02910952	chr12:132569714	EP400NL	0.62	4.7	0.36	5.68e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg06637938	chr14:75390232	RPS6KL1	0.51	5.03	0.38	1.36e-6	Height;
PAAD	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg23024343	chr7:107201750	COG5	0.57	4.82	0.36	3.45e-6	Coronary artery disease;
PAAD	cis	rs17824933	1.000	rs12791045	chr11:60767964	C/T	cg16817237	chr11:60793675	NA	0.49	5.75	0.42	4.85e-8	Multiple sclerosis;
PAAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg16988970	chr17:42248062	ASB16	0.36	5.19	0.39	6.6e-7	Total body bone mineral density;
PAAD	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.67	6.4	0.46	1.83e-9	Subjective well-being;
PAAD	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs757081	0.676	rs567033	chr11:17207010	C/T	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.73	-0.42	5.15e-8	Systolic blood pressure;
PAAD	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.89	-10.99	-0.67	4.87e-21	Ulcerative colitis;
PAAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg14847009	chr1:175162515	KIAA0040	-0.31	-4.69	-0.36	6.14e-6	Alcohol dependence;
PAAD	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.65	6.66	0.48	4.74e-10	Blood protein levels;
PAAD	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg14393609	chr7:65229607	NA	0.5	4.32	0.33	2.79e-5	Aortic root size;
PAAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.03	-0.44	1.19e-8	Bipolar disorder;
PAAD	cis	rs73206853	0.841	rs56306150	chr12:110716775	A/T	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.35e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06210576	chr12:69892192	FRS2	-0.6	-6.75	-0.48	2.89e-10	Monocyte percentage of white cells;
PAAD	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg25649188	chr17:73499917	CASKIN2	0.63	5.64	0.42	8.07e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg15192750	chr16:69999425	NA	-0.63	-4.9	-0.37	2.46e-6	IgE levels;
PAAD	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.41	5.05	0.38	1.24e-6	Corneal astigmatism;
PAAD	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg10370574	chr19:1840461	REXO1	-0.51	-4.73	-0.36	4.98e-6	Bipolar disorder;
PAAD	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.65	5.22	0.39	5.86e-7	Obesity (extreme);
PAAD	cis	rs564309	0.764	rs12085738	chr1:228553513	C/T	cg01328119	chr1:228783545	DUSP5P	0.71	4.43	0.34	1.81e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs3960554	0.600	rs2302429	chr7:75614777	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	7.97	0.54	3.57e-13	Eotaxin levels;
PAAD	cis	rs684232	0.800	rs2002015	chr17:534525	G/T	cg12384639	chr17:618140	VPS53	-0.45	-4.33	-0.33	2.66e-5	Prostate cancer;
PAAD	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg03983715	chr16:68378420	PRMT7	-0.95	-6.73	-0.48	3.23e-10	Magnesium levels;
PAAD	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.65	-5.71	-0.42	5.87e-8	Mean corpuscular volume;
PAAD	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.93e-6	Total body bone mineral density;
PAAD	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs76866386	1.000	rs75331444	chr2:44069772	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.93	-5.55	-0.41	1.22e-7	Cholesterol, total;
PAAD	cis	rs7301826	0.651	rs2277336	chr12:131286119	A/G	cg11011512	chr12:131303247	STX2	-0.47	-4.85	-0.37	2.98e-6	Plasma plasminogen activator levels;
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	6.27	0.45	3.59e-9	Personality dimensions;
PAAD	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.43	-4.26	-0.33	3.63e-5	Breast cancer;
PAAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-8.41	-0.56	2.84e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.82	9.0	0.59	8.43e-16	Ulcerative colitis;
PAAD	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg27246729	chr12:121163418	ACADS	0.43	4.4	0.34	2e-5	Mean corpuscular volume;
PAAD	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.17	-0.39	7.22e-7	Reticulocyte count;
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.65	-7.24	-0.51	2.12e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.69	6.01	0.44	1.35e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.97	7.86	0.54	6.48e-13	Triglycerides;
PAAD	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg09980403	chr19:12975529	MAST1	0.31	4.71	0.36	5.63e-6	Mean corpuscular volume;
PAAD	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs7650267	0.572	rs1842805	chr3:43591405	T/C	cg07997066	chr3:44154910	MIR138-1	0.55	4.32	0.33	2.83e-5	Obesity-related traits;
PAAD	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.74e-11	Response to antipsychotic treatment;
PAAD	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg13230186	chr13:114743606	NA	0.47	4.48	0.34	1.45e-5	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.43	4.41	0.34	1.96e-5	Sarcoidosis;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg18279126	chr7:2041391	MAD1L1	0.59	5.98	0.44	1.53e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg21300403	chr2:198650112	BOLL	-0.67	-4.48	-0.34	1.48e-5	Ulcerative colitis;
PAAD	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.57	-5.47	-0.41	1.78e-7	Neuroticism;
PAAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg24733560	chr20:60626293	TAF4	0.59	7.87	0.54	6.31e-13	Body mass index;
PAAD	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg00071950	chr4:10020882	SLC2A9	0.62	5.22	0.39	5.71e-7	Blood metabolite levels;
PAAD	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.89	7.17	0.5	3.07e-11	Chronic kidney disease;
PAAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.48e-14	Renal cell carcinoma;
PAAD	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.7	-7.28	-0.51	1.66e-11	Type 2 diabetes;
PAAD	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs4538187	0.502	rs11683408	chr2:64193684	C/T	cg08613950	chr2:64719184	NA	0.85	4.58	0.35	9.44e-6	Systolic blood pressure;
PAAD	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.51	-6.31	-0.46	2.89e-9	Lewy body disease;
PAAD	cis	rs4795519	0.592	rs1813981	chr17:22170994	A/G	cg22648282	chr17:21454238	C17orf51	-0.49	-4.96	-0.37	1.86e-6	Chronic myeloid leukemia;
PAAD	cis	rs9815354	0.761	rs12635286	chr3:42051836	T/C	cg03022575	chr3:42003672	ULK4	0.79	5.65	0.42	7.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs66530629	1.000	rs7520844	chr1:25054223	C/G	cg22509179	chr1:25234806	RUNX3	-0.48	-4.3	-0.33	3.06e-5	Plateletcrit;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.56	0.41	1.18e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg18508148	chr11:34937573	PDHX;APIP	0.51	4.98	0.37	1.71e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	5.62	0.41	9.07e-8	Systolic blood pressure;
PAAD	cis	rs7688540	0.800	rs61794998	chr4:226937	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.47	0.34	1.54e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs12127944	1.000	rs2867890	chr1:205469756	A/G	cg08473693	chr1:205342340	NA	-0.77	-4.66	-0.35	7e-6	IgG glycosylation;
PAAD	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs881827	0.962	rs12483634	chr21:47992401	G/A	cg12016809	chr21:47604291	C21orf56	0.47	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.69	-0.36	6.03e-6	Height;
PAAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.37e-18	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23709855	chr14:21927732	RAB2B	-0.52	-6.97	-0.49	9.26e-11	Monocyte percentage of white cells;
PAAD	cis	rs7173419	0.655	rs12910433	chr15:28228644	A/G	cg20906524	chr15:28200668	OCA2	0.46	5.25	0.39	5.1e-7	Eye color;
PAAD	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.47	4.59	0.35	9.12e-6	Birth weight;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.28	7.35	0.51	1.15e-11	Type 2 diabetes nephropathy;
PAAD	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.96	13.99	0.75	4.14e-29	Intelligence (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27431859	chr19:531042	CDC34	0.59	6.68	0.48	4.34e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg00277334	chr10:82204260	NA	0.54	4.33	0.33	2.7e-5	Post bronchodilator FEV1;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.11e-7	Glomerular filtration rate;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.66e-5	Life satisfaction;
PAAD	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.85	6.45	0.46	1.43e-9	Diisocyanate-induced asthma;
PAAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	1.07	12.86	0.72	4.58e-26	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01757534	chr6:91006597	BACH2	0.73	7.47	0.52	5.85e-12	Obesity-related traits;
PAAD	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg04557057	chr7:12151638	NA	-0.7	-4.57	-0.35	9.9e-6	Coronary artery disease;
PAAD	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-8.63	-0.57	7.55e-15	Total body bone mineral density;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13115616	chr1:17338059	ATP13A2	0.62	6.7	0.48	3.79e-10	Pancreatic cancer;
PAAD	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-5.14	-0.38	8.35e-7	Menopause (age at onset);
PAAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.6	0.52	2.82e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	4.86	0.37	2.85e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg00325661	chr8:49890786	NA	-0.55	-5.25	-0.39	4.93e-7	Blood metabolite levels;
PAAD	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.54	5.25	0.39	5.14e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.63	-0.35	7.83e-6	Resting heart rate;
PAAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.85	-10.15	-0.64	8.45e-19	Rheumatoid arthritis;
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01299854	chr22:21867049	PI4KAP2	-0.57	-6.7	-0.48	3.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	8.12	0.55	1.45e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.53	-5.48	-0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.81	9.84	0.62	5.69e-18	Blood metabolite ratios;
PAAD	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.49	-5.1	-0.38	9.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809615	0.901	rs28862110	chr7:99183531	T/C	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg11494091	chr17:61959527	GH2	0.51	4.28	0.33	3.25e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.59	-5.44	-0.4	2.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg18898632	chr2:242989856	NA	-0.81	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs10121009	0.635	rs494831	chr9:35299165	A/G	cg11846315	chr9:35647073	NA	-0.49	-4.37	-0.33	2.33e-5	Parkinson's disease;
PAAD	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.89	-5.71	-0.42	5.82e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	11.93	0.7	1.44e-23	Cognitive ability;
PAAD	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg02569219	chr17:2266849	SGSM2	0.47	4.53	0.34	1.21e-5	Proinsulin levels;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.7	5.61	0.41	9.41e-8	Alzheimer's disease;
PAAD	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.69	6.01	0.44	1.35e-8	Menarche (age at onset);
PAAD	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.11	0.44	8.07e-9	Lung cancer in ever smokers;
PAAD	cis	rs5009270	0.512	rs1024410	chr7:112247542	A/T	cg23628563	chr7:112262597	NA	0.64	5.62	0.41	9.09e-8	Osteoarthritis (hip);
PAAD	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21385522	chr1:16154831	NA	0.55	4.83	0.36	3.32e-6	Dilated cardiomyopathy;
PAAD	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.4	0.34	2.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.62	-6.07	-0.44	9.74e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.23e-6	Hepatitis;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.64	6.64	0.47	5.23e-10	Mean corpuscular volume;
PAAD	cis	rs13424612	1.000	rs7590071	chr2:240900947	G/C	cg01812947	chr2:240904978	NDUFA10	0.58	5.09	0.38	1.03e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg21890820	chr11:65308645	LTBP3	-0.71	-8.72	-0.58	4.58e-15	Bone mineral density;
PAAD	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg23018236	chr17:30244563	NA	-0.66	-5.05	-0.38	1.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6466055	0.720	rs4730080	chr7:105001133	T/C	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg00334542	chr7:100209784	MOSPD3	-0.75	-5.5	-0.41	1.58e-7	Other erythrocyte phenotypes;
PAAD	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.93	-0.37	2.16e-6	Height;
PAAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.48	-5.31	-0.4	3.88e-7	Major depressive disorder;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03209809	chr3:126422892	CHCHD6	0.65	7.56	0.52	3.62e-12	Metabolite levels  (X-11787);
PAAD	cis	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg25952890	chr19:58913133	NA	0.63	4.55	0.35	1.11e-5	Mean platelet volume;
PAAD	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.56	-6.2	-0.45	5.07e-9	Post bronchodilator FEV1;
PAAD	cis	rs258892	0.895	rs11953055	chr5:72051503	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.47	5.94	0.43	1.86e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.77	9.25	0.6	1.9e-16	Lung cancer;
PAAD	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.46	4.68	0.36	6.19e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.38	-0.51	9.41e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.84	-8.8	-0.58	2.77e-15	Obesity-related traits;
PAAD	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.11	0.5	4.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs1043763	0.784	rs11057403	chr12:122608064	C/T	cg26218692	chr12:122497826	BCL7A	-0.59	-5.62	-0.41	9.06e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.93	7.11	0.5	4.2e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	4.4	0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg24375607	chr4:120327624	NA	0.44	4.51	0.34	1.3e-5	Diastolic blood pressure;
PAAD	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg21269045	chr12:125625041	AACS	-0.45	-4.5	-0.34	1.37e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.7	-7.86	-0.54	6.62e-13	Blood metabolite levels;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	6.54	0.47	8.87e-10	Height;
PAAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	4.98	0.37	1.69e-6	Schizophrenia;
PAAD	cis	rs7243821	0.921	rs61159866	chr18:52628908	C/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.39	0.64	1.99e-19	Electrocardiographic conduction measures;
PAAD	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg03522150	chr11:46969673	C11orf49	0.43	5.19	0.39	6.72e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6681460	1.000	rs9662962	chr1:67121364	C/T	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.58	6.49	0.47	1.15e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg11416102	chr8:651193	ERICH1	0.92	5.61	0.41	9.46e-8	IgG glycosylation;
PAAD	cis	rs11264213	0.892	rs12034163	chr1:36191030	C/G	cg27506609	chr1:36549197	TEKT2	0.63	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.54	4.44	0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs2764208	0.770	rs112283401	chr6:34797756	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-4.77	-0.36	4.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.85	-10.21	-0.64	5.69e-19	Diastolic blood pressure;
PAAD	cis	rs6493487	0.586	rs7166073	chr15:51268452	G/A	cg02888867	chr15:50978624	TRPM7	-0.7	-4.4	-0.34	2e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg00579200	chr11:133705235	NA	-0.51	-5.89	-0.43	2.44e-8	Childhood ear infection;
PAAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs469568	0.543	rs12153128	chr5:178668714	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.52	-5.49	-0.41	1.68e-7	Stroke (pediatric);
PAAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg17351974	chr5:40835760	RPL37	0.77	4.51	0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg24053715	chr22:38214548	NA	0.55	5.67	0.42	7.15e-8	Glioblastoma;Glioma;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.61	-0.41	9.2e-8	Personality dimensions;
PAAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	1.02	7.27	0.51	1.81e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.54	0.41	1.3e-7	Total body bone mineral density;
PAAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg17911788	chr17:44343683	NA	0.51	4.73	0.36	5.12e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs112990264	1.000	rs112247193	chr1:213022615	G/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.55	0.57	1.2e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs4481887	0.597	rs4504921	chr1:248582011	T/C	cg00666640	chr1:248458726	OR2T12	0.6	5.06	0.38	1.18e-6	Common traits (Other);
PAAD	cis	rs78761021	0.867	rs17681684	chr17:9792768	A/G	cg26853458	chr17:9805074	RCVRN	-0.69	-8.04	-0.55	2.37e-13	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs12779198	chr10:46013547	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15024566	chr2:55496144	MTIF2	0.73	7.39	0.51	8.98e-12	Obesity-related traits;
PAAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.72	-6.23	-0.45	4.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.05	-0.44	1.11e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg21855830	chr2:127963489	CYP27C1	0.47	4.35	0.33	2.48e-5	Protein C levels;
PAAD	cis	rs6076065	0.723	rs2424534	chr20:23378866	A/G	cg11657817	chr20:23433608	CST11	-0.5	-5.14	-0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg04154034	chr17:28927549	LRRC37B2	0.61	4.34	0.33	2.62e-5	Body mass index;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg26338869	chr17:61819248	STRADA	0.5	4.74	0.36	4.9100000000000004e-06	Height;
PAAD	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg19482086	chr6:160211437	TCP1;MRPL18	0.54	4.34	0.33	2.62e-5	Iron status biomarkers;
PAAD	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg22467129	chr15:76604101	ETFA	0.53	4.96	0.37	1.86e-6	Blood metabolite levels;
PAAD	cis	rs59918340	0.738	rs3739240	chr8:142221414	G/A	cg16494567	chr8:142200140	DENND3	0.43	4.42	0.34	1.87e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6594713	0.603	rs6879257	chr5:112845803	C/T	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.6	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.9	6.79	0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.99e-6	Body mass index;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.72	0.66	2.5e-20	Prudent dietary pattern;
PAAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs914615	0.552	rs4971089	chr1:155142927	A/G	cg20311333	chr1:155197753	GBAP1	0.43	4.26	0.33	3.56e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs60154123	0.881	rs1774107	chr1:210453923	C/T	cg21951975	chr1:209979733	IRF6	0.53	5.11	0.38	9.4e-7	Coronary artery disease;
PAAD	cis	rs950881	0.601	rs3771164	chr2:102991786	A/T	cg20060108	chr2:102954350	IL1RL1	0.54	4.4	0.34	2.02e-5	Allergy;
PAAD	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.59	6.77	0.48	2.58e-10	Psoriasis;
PAAD	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.85	11.03	0.67	3.8e-21	Height;
PAAD	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.45	0.71	5.72e-25	Prudent dietary pattern;
PAAD	cis	rs4704187	0.553	rs116188801	chr5:74398141	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.53	-0.41	1.39e-7	Atrioventricular conduction;
PAAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12165864	chr7:66369176	NA	-0.79	-5.29	-0.39	4.19e-7	Diabetic kidney disease;
PAAD	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.49	5.02	0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs10885582	0.869	rs7923449	chr10:116323720	A/G	cg17056676	chr10:116301354	ABLIM1	-0.37	-5.07	-0.38	1.14e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg02683114	chr2:24398427	C2orf84	-0.54	-5.23	-0.39	5.45e-7	Asthma;
PAAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-4.66	-0.35	6.78e-6	Monocyte count;
PAAD	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg08917208	chr2:24149416	ATAD2B	0.5	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-5.03	-0.38	1.35e-6	Glycated hemoglobin levels;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg14703610	chr5:56206110	C5orf35	0.63	5.9	0.43	2.23e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg09998033	chr7:158218633	PTPRN2	-0.63	-6.23	-0.45	4.41e-9	Obesity-related traits;
PAAD	cis	rs778371	0.722	rs1996342	chr2:233805499	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	5.89	0.43	2.43e-8	Schizophrenia;
PAAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.63	-6.18	-0.45	5.55e-9	Obesity-related traits;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	1.12	7.9	0.54	5.29e-13	IgG glycosylation;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg08917208	chr2:24149416	ATAD2B	0.49	4.33	0.33	2.74e-5	Asthma;
PAAD	cis	rs16958440	0.867	rs79275306	chr18:44711620	G/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs11825064	0.562	rs7119913	chr11:134502223	A/C	cg02089395	chr11:134479357	NA	0.86	5.56	0.41	1.21e-7	Seasonality;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg07212818	chr11:638076	DRD4	-0.69	-6.8	-0.48	2.3e-10	Systemic lupus erythematosus;
PAAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.46	0.34	1.55e-5	Personality dimensions;
PAAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg18357526	chr6:26021779	HIST1H4A	0.73	7.6	0.52	2.84e-12	Height;
PAAD	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.45	0.4	1.97e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg19223190	chr17:80058835	NA	0.55	5.63	0.42	8.51e-8	Life satisfaction;
PAAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.47	-4.59	-0.35	9.19e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg20503657	chr10:835505	NA	0.83	6.28	0.45	3.39e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.77	-10.56	-0.65	6.68e-20	Iron status biomarkers;
PAAD	cis	rs11650494	0.710	rs57030023	chr17:47468546	T/A	cg08112188	chr17:47440006	ZNF652	1.3	6.56	0.47	7.84e-10	Prostate cancer;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00864171	chr11:67383662	NA	0.6	6.34	0.46	2.47e-9	Mean corpuscular volume;
PAAD	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.62	5.75	0.42	4.66e-8	Coronary artery disease;
PAAD	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.73	0.72	1e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs10861342	0.892	rs7488014	chr12:105657527	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.39	0.34	2.08e-5	IgG glycosylation;
PAAD	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.82	9.85	0.62	5.19e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.6	6.29	0.45	3.29e-9	Sjögren's syndrome;
PAAD	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg25364880	chr3:44379878	C3orf23	0.59	5.44	0.4	2.13e-7	Depressive symptoms;
PAAD	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg16306870	chr3:194868790	C3orf21	0.47	4.29	0.33	3.21e-5	Non-small cell lung cancer;
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg18337363	chr3:52569053	NT5DC2	0.46	5.1	0.38	9.99e-7	Electroencephalogram traits;
PAAD	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9652601	0.959	rs7200940	chr16:11164567	G/C	cg04616529	chr16:11181986	CLEC16A	-0.45	-4.78	-0.36	4.05e-6	Systemic lupus erythematosus;
PAAD	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.32	0.4	3.61e-7	IgG glycosylation;
PAAD	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg00262122	chr8:11665843	FDFT1	-0.62	-5.3	-0.39	4.02e-7	Neuroticism;
PAAD	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.51	5.84	0.43	3.07e-8	Airway imaging phenotypes;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.6	-0.35	8.99e-6	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.72	-8.86	-0.58	1.94e-15	Endometriosis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00329748	chr1:7765245	CAMTA1	-0.71	-7.1	-0.5	4.36e-11	Lung cancer in ever smokers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07050602	chr15:85291082	ZNF592	0.6	6.41	0.46	1.74e-9	Myopia (pathological);
PAAD	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg00666640	chr1:248458726	OR2T12	0.64	5.55	0.41	1.21e-7	Common traits (Other);
PAAD	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.41	5.17	0.39	7.28e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg01868782	chr6:126071099	HEY2	0.47	5.56	0.41	1.18e-7	Brugada syndrome;
PAAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.55	0.61	3.26e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs6445525	0.967	rs2060022	chr3:65999755	A/G	cg06109867	chr3:66002991	MAGI1	-0.46	-4.62	-0.35	8.19e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg15792487	chr17:7348316	CHRNB1	0.49	5.51	0.41	1.48e-7	Height;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg10729496	chr3:10149963	C3orf24	0.88	7.33	0.51	1.27e-11	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20099018	chr17:40169396	DNAJC7;NKIRAS2	0.68	6.68	0.48	4.15e-10	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26876637	chr1:152193138	HRNR	0.86	6.79	0.48	2.4e-10	Atopic dermatitis;
PAAD	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.44	-0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.88	-0.49	1.5e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs564309	0.541	rs1188474	chr1:228613052	T/C	cg13099616	chr1:227751251	ZNF678	0.71	4.46	0.34	1.62e-5	Hip circumference (psychosocial stress interaction);
PAAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2e-27	Height;
PAAD	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.82	-10.03	-0.63	1.74e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.57	-6.93	-0.49	1.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.6	-5.5	-0.41	1.6e-7	Maximal oxygen uptake response;
PAAD	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.55	5.04	0.38	1.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02543470	chr2:105862877	NA	-0.51	-4.92	-0.37	2.18e-6	Obesity-related traits;
PAAD	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.91	12.14	0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.73	-0.42	5.35e-8	Total cholesterol levels;
PAAD	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg05805236	chr11:65401703	PCNXL3	-0.45	-5.18	-0.39	7.07e-7	Systemic lupus erythematosus;
PAAD	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.77	7.72	0.53	1.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1570155	0.967	rs9465729	chr6:20400538	C/T	cg03881924	chr6:20404342	E2F3	0.45	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs9398803	0.723	rs853975	chr6:127070234	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-4.44	-0.34	1.7e-5	Male-pattern baldness;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.64	6.15	0.45	6.65e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.58	5.13	0.38	8.59e-7	Dialysis-related mortality;
PAAD	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.52	-4.7	-0.36	5.7e-6	Lymphocyte counts;
PAAD	cis	rs6782228	0.585	rs3122175	chr3:128361276	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.63	-0.47	5.37e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg12549451	chr6:135224345	NA	0.42	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.16	-0.45	6.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.57	-5.43	-0.4	2.2e-7	Diastolic blood pressure;
PAAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs11997175	0.625	rs4733172	chr8:33618049	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	6.24	0.45	4.13e-9	Body mass index;
PAAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg05110241	chr16:68378359	PRMT7	-1.01	-6.53	-0.47	9.33e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.68	-0.35	6.37e-6	Height;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs9657904	0.906	rs4894960	chr3:105594320	G/A	cg16975614	chr3:105601834	NA	-0.46	-4.62	-0.35	7.98e-6	Multiple sclerosis;
PAAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-7.45	-0.52	6.6e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06264183	chr20:35202306	TGIF2	-0.63	-6.34	-0.46	2.46e-9	Smoking initiation;
PAAD	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.02	0.49	6.83e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9322817	0.583	rs10782363	chr6:105149713	C/G	cg02098413	chr6:105308735	HACE1	0.46	6.03	0.44	1.19e-8	Thyroid stimulating hormone;
PAAD	cis	rs507080	0.961	rs642530	chr11:118550756	A/G	cg08498647	chr11:118550644	TREH	-0.37	-4.33	-0.33	2.73e-5	Serum metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24663984	chr11:118230199	UBE4A	0.67	7.79	0.53	9.97e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.6	5.95	0.43	1.79e-8	Longevity;
PAAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.67	-6.88	-0.49	1.47e-10	Urate levels in lean individuals;
PAAD	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.93	10.87	0.66	1.03e-20	IgG glycosylation;
PAAD	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg20636351	chr8:55087400	NA	-0.79	-8.85	-0.58	2.09e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.55	5.12	0.38	9.13e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9913156	0.517	rs2326118	chr17:4611851	C/T	cg19197139	chr17:4613644	ARRB2	0.61	6.48	0.47	1.23e-9	Lymphocyte counts;
PAAD	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	6.62	0.47	5.7e-10	Mood instability;
PAAD	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-1.22	-12.65	-0.72	1.65e-25	Hair shape;
PAAD	cis	rs12799264	0.915	rs894553	chr11:19977729	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.68	5.71	0.42	5.77e-8	Educational attainment;
PAAD	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.27	-0.33	3.47e-5	Educational attainment (years of education);
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.67	0.58	6.06e-15	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.93	-9.22	-0.6	2.27e-16	Obesity-related traits;
PAAD	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg24881330	chr22:46731750	TRMU	1.09	7.57	0.52	3.27e-12	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	9.79	0.62	7.63e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	cis	rs28489187	0.706	rs233069	chr1:85805466	C/T	cg16011679	chr1:85725395	C1orf52	0.53	4.97	0.37	1.75e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg11271282	chr2:238384023	NA	0.65	4.36	0.33	2.38e-5	Prostate cancer;
PAAD	cis	rs7481584	0.962	rs12805915	chr11:2969771	G/A	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.42	4.6	0.35	8.8e-6	Calcium levels;
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs2902440	0.502	rs58621044	chr1:67664840	G/C	cg08029281	chr1:67600428	NA	0.42	4.76	0.36	4.56e-6	Crohn's disease;
PAAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.6	-6.11	-0.44	7.87e-9	Height;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.64	7.23	0.51	2.18e-11	Iron status biomarkers;
PAAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.38	0.33	2.22e-5	Electroencephalogram traits;
PAAD	cis	rs282587	0.569	rs426765	chr13:113414798	A/T	cg19217778	chr13:113420270	ATP11A	-0.56	-4.49	-0.34	1.42e-5	Glycated hemoglobin levels;
PAAD	cis	rs2445762	0.659	rs55810637	chr15:51664903	G/A	cg25905881	chr15:51634250	GLDN	0.49	4.25	0.33	3.66e-5	Hormone measurements;
PAAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg25319279	chr11:5960081	NA	-0.6	-5.76	-0.42	4.51e-8	DNA methylation (variation);
PAAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg19680485	chr15:31195859	MTMR15	-0.45	-4.34	-0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg00071950	chr4:10020882	SLC2A9	0.51	4.27	0.33	3.39e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-4.71	-0.36	5.49e-6	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25967505	chr3:50606708	HEMK1	0.59	6.63	0.47	5.56e-10	Monocyte percentage of white cells;
PAAD	cis	rs6142102	0.625	rs6142067	chr20:32556572	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.79	0.36	3.99e-6	Skin pigmentation;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg20638045	chr15:100107064	MEF2A	-0.69	-6.96	-0.49	9.38e-11	Dental caries;
PAAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.44	4.76	0.36	4.43e-6	Aortic root size;
PAAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg14703610	chr5:56206110	C5orf35	-0.61	-5.76	-0.42	4.62e-8	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.99	8.76	0.58	3.6e-15	Bipolar disorder;
PAAD	cis	rs7173419	0.685	rs11638265	chr15:28202573	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.29	-0.39	4.13e-7	Eye color;
PAAD	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-6.55	-0.47	8.24e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	6.98	0.49	8.58e-11	Mood instability;
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.32	-4.31	-0.33	2.94e-5	Atrial fibrillation;
PAAD	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg14393609	chr7:65229607	NA	0.58	6.05	0.44	1.1e-8	Calcium levels;
PAAD	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg05250797	chr16:70222502	NA	0.79	6.14	0.45	6.72e-9	IgE levels;
PAAD	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.62	-4.68	-0.35	6.29e-6	Exhaled nitric oxide output;
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg05507819	chr15:63340323	TPM1	0.77	4.95	0.37	1.95e-6	HDL cholesterol;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09177277	chr15:64338794	DAPK2	-0.58	-6.52	-0.47	9.83e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.73	-5.51	-0.41	1.49e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-5.15	-0.39	8.1e-7	Coronary artery disease;
PAAD	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.51	-5.71	-0.42	5.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.01	-0.49	7.19e-11	Gut microbiome composition (summer);
PAAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.68	5.95	0.43	1.76e-8	Asthma;
PAAD	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.59	5.65	0.42	7.76e-8	Uric acid clearance;
PAAD	cis	rs375066	0.762	rs12610287	chr19:44400663	T/C	cg08633290	chr19:44405433	NA	0.54	5.16	0.39	7.61e-7	Breast cancer;
PAAD	cis	rs10924309	0.882	rs10924305	chr1:245856763	A/G	cg00036263	chr1:245852353	KIF26B	0.62	5.47	0.41	1.78e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	6.6	0.47	6.41e-10	Multiple sclerosis;
PAAD	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg04705435	chr11:17411270	KCNJ11	0.49	4.58	0.35	9.78e-6	Body mass index;Social communication problems;
PAAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.87	-10.15	-0.64	8.36e-19	Migraine;
PAAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.4	-4.92	-0.37	2.27e-6	Red cell distribution width;
PAAD	cis	rs11825685	0.639	rs1944875	chr11:134538795	T/A	cg06603561	chr11:134479413	NA	-0.68	-5.78	-0.42	4.07e-8	IgG glycosylation;
PAAD	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.77	7.56	0.52	3.58e-12	Primary sclerosing cholangitis;
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.61	-0.35	8.49e-6	Lung cancer;
PAAD	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.46	4.94	0.37	2.01e-6	Testicular germ cell tumor;
PAAD	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.55	-6.14	-0.45	6.75e-9	Post bronchodilator FEV1;
PAAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg16083429	chr3:49237500	CCDC36	-0.42	-4.45	-0.34	1.64e-5	Parkinson's disease;
PAAD	cis	rs6547631	0.622	rs10180391	chr2:85926345	C/T	cg24620635	chr2:85921963	GNLY	0.43	5.61	0.41	9.15e-8	Blood protein levels;
PAAD	cis	rs72827839	0.793	rs112296021	chr17:46101460	G/A	cg23391107	chr17:45924227	SP6	0.62	5.38	0.4	2.77e-7	Ease of getting up in the morning;
PAAD	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.45	-0.4	2.03e-7	Body mass index;
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.7	7.33	0.51	1.24e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11051970	1.000	rs1872829	chr12:32535100	C/T	cg02745156	chr12:32552066	NA	0.45	4.77	0.36	4.23e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg27319216	chr8:6693540	XKR5	0.32	4.29	0.33	3.22e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-1.0	-7.8	-0.53	9.1e-13	Initial pursuit acceleration;
PAAD	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-8.06	-0.55	2.1e-13	Sudden cardiac arrest;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg04810063	chr16:88703634	IL17C	-0.5	-4.42	-0.34	1.83e-5	Menopause (age at onset);
PAAD	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg01777861	chr4:56023843	NA	-0.4	-5.18	-0.39	6.93e-7	Endometriosis;
PAAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg12215294	chr3:40350768	EIF1B	0.45	4.42	0.34	1.84e-5	Renal cell carcinoma;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg05484376	chr2:27715224	FNDC4	0.49	5.01	0.38	1.5e-6	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.78	5.74	0.42	4.92e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01149896	chr4:37828114	PGM2	0.59	6.43	0.46	1.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg25204440	chr1:209979598	IRF6	0.67	5.73	0.42	5.33e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.56	-5.03	-0.38	1.39e-6	IgG glycosylation;
PAAD	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg23752985	chr2:85803571	VAMP8	0.54	5.84	0.43	3.03e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20893717	chr7:100318190	EPO	0.41	4.48	0.34	1.47e-5	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg22963979	chr7:1858916	MAD1L1	0.77	9.06	0.59	5.87e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.68	-0.35	6.3e-6	Dupuytren's disease;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg07703079	chr11:430292	ANO9	0.9	5.74	0.42	5.06e-8	Body mass index;
PAAD	trans	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.53	5.4	0.4	2.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6011002	0.564	rs2260045	chr20:62343013	T/C	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg02841227	chr6:26021843	HIST1H4A	-0.41	-4.25	-0.33	3.78e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.94	0.49	1.08e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs75757892	0.621	rs1050681	chr6:7289782	A/T	cg02954307	chr6:7269328	NA	0.6	4.65	0.35	7.11e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.27	0.45	3.55e-9	Bladder cancer;
PAAD	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg08632701	chr21:37451849	NA	-0.51	-4.73	-0.36	5.06e-6	Mitral valve prolapse;
PAAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg15510373	chr7:100224934	TFR2	-0.52	-4.25	-0.33	3.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3106136	0.743	rs6847767	chr4:95276951	C/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.03	0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26926768	chr12:34528122	NA	0.38	4.67	0.35	6.67e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs1879734	0.953	rs2950241	chr1:54129591	A/G	cg14659662	chr1:54151053	GLIS1	-0.36	-5.78	-0.42	4.07e-8	Mitral valve prolapse;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs258892	0.793	rs34655	chr5:72147269	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.58	-5.91	-0.43	2.15e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-1.06	-9.12	-0.59	4.32e-16	Post bronchodilator FEV1;
PAAD	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	0.69	5.63	0.42	8.58e-8	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07476653	chr7:5570327	ACTB	-0.61	-6.35	-0.46	2.3e-9	Smoking initiation;
PAAD	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg05697835	chr1:2722811	NA	0.39	4.28	0.33	3.27e-5	Ulcerative colitis;
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg27644672	chr7:1858694	MAD1L1	-0.43	-4.68	-0.35	6.38e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg24881330	chr22:46731750	TRMU	0.96	4.68	0.35	6.37e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg10494973	chr17:80897199	TBCD	-0.5	-4.97	-0.37	1.8e-6	Breast cancer;
PAAD	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg00325661	chr8:49890786	NA	-0.47	-4.52	-0.34	1.23e-5	Sudden cardiac arrest;
PAAD	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.72	-0.48	3.48e-10	Platelet distribution width;
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.75	8.35	0.56	3.82e-14	Longevity;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.87	-0.49	1.52e-10	Life satisfaction;
PAAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.87	-8.47	-0.57	2.01e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs34599045	0.614	rs36033488	chr1:152860594	T/C	cg07796016	chr1:152779584	LCE1C	-0.93	-4.55	-0.35	1.07e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs528301	0.737	rs83995	chr2:45167570	G/T	cg15393275	chr2:45165193	NA	-0.44	-4.9	-0.37	2.39e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.75	-5.49	-0.41	1.62e-7	Coronary artery calcification;
PAAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.76	0.53	1.17e-12	Melanoma;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs4722404	0.592	rs7791687	chr7:3119643	G/A	cg19214707	chr7:3157722	NA	-0.5	-4.79	-0.36	3.9e-6	Atopic dermatitis;
PAAD	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.45	5.05	0.38	1.23e-6	Menarche (age at onset);
PAAD	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg13565585	chr5:132299512	AFF4	0.51	4.94	0.37	2.05e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1468333	0.592	rs4074484	chr5:137576017	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	5.16	0.39	7.71e-7	Resting heart rate;
PAAD	cis	rs67385638	0.792	rs16912979	chr11:5309695	T/C	cg12559170	chr11:5275217	HBG2	0.44	4.34	0.33	2.57e-5	Hemoglobin levels;
PAAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	1.1	15.13	0.78	4e-32	Breast cancer;
PAAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12165864	chr7:66369176	NA	-0.81	-5.17	-0.39	7.29e-7	Diabetic kidney disease;
PAAD	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.73	-6.96	-0.49	9.49e-11	Neuroblastoma (high-risk);
PAAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3018712	0.700	rs2187331	chr11:68446424	C/T	cg23009355	chr11:68451396	GAL	-0.55	-4.96	-0.37	1.9e-6	Total body bone mineral density;
PAAD	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.91	0.37	2.29e-6	Birth weight;
PAAD	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-7.42	-0.52	7.91e-12	Heart rate;
PAAD	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.53	4.51	0.34	1.28e-5	Dementia with Lewy bodies;
PAAD	cis	rs1075232	1.000	rs12439239	chr15:31651718	G/A	cg01030201	chr15:31746330	NA	-1.08	-4.41	-0.34	1.91e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.83	0.54	7.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12714314	0.914	rs1991773	chr2:1957476	A/G	cg22350835	chr2:1868857	MYT1L	-0.43	-4.51	-0.34	1.29e-5	Type 2 diabetes (age of onset);
PAAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12489322	chr5:60628376	ZSWIM6	0.58	6.29	0.45	3.17e-9	Myopia (pathological);
PAAD	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14021714	chr12:3757418	EFCAB4B	0.6	6.38	0.46	2.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg00579200	chr11:133705235	NA	-0.5	-5.75	-0.42	4.7e-8	Childhood ear infection;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03188948	chr7:1209495	NA	0.47	4.76	0.36	4.5e-6	Longevity;Endometriosis;
PAAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg11204139	chr17:3907470	NA	0.86	8.74	0.58	3.99e-15	Type 2 diabetes;
PAAD	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	5.8	0.43	3.79e-8	Rheumatoid arthritis;
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.61	-5.8	-0.43	3.63e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs533581	0.816	rs8058234	chr16:88975447	C/G	cg05579598	chr16:88989069	CBFA2T3	0.65	10.13	0.63	9.7e-19	Social autistic-like traits;
PAAD	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.72	-0.36	5.28e-6	Dupuytren's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16139199	chr18:19180362	ESCO1	0.64	7.16	0.5	3.26e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6142102	0.961	rs2284388	chr20:32655741	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.58	5.1	0.38	1.01e-6	Interleukin-17 levels;
PAAD	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.13	-0.38	8.63e-7	Neuroticism;
PAAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.61	-6.66	-0.48	4.66e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.58	-5.96	-0.44	1.68e-8	Body mass index;
PAAD	cis	rs17123764	0.818	rs11169092	chr12:50008602	C/G	cg14846292	chr12:49726500	C1QL4	-0.67	-4.29	-0.33	3.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.49	-5.18	-0.39	6.99e-7	Vitamin D levels;
PAAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.49e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10819733	chr22:24237672	NA	0.56	6.01	0.44	1.35e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7009516	0.544	rs2291574	chr8:24249668	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.46	-4.94	-0.37	2.07e-6	Hair greying;
PAAD	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg00579200	chr11:133705235	NA	-0.51	-5.69	-0.42	6.33e-8	Childhood ear infection;
PAAD	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg08926642	chr1:7887455	PER3	-0.48	-4.27	-0.33	3.43e-5	Inflammatory bowel disease;
PAAD	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	4.43	0.34	1.77e-5	Thyroid stimulating hormone;
PAAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg19413350	chr8:57351067	NA	-0.55	-5.55	-0.41	1.26e-7	Obesity-related traits;
PAAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.35	0.4	3.15e-7	Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg00280220	chr17:61926910	NA	-0.43	-4.52	-0.34	1.24e-5	Prudent dietary pattern;
PAAD	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.66	6.38	0.46	2e-9	Cystic fibrosis severity;
PAAD	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.58	5.95	0.43	1.77e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg11441379	chr12:63026424	NA	0.81	6.23	0.45	4.33e-9	IgG glycosylation;
PAAD	cis	rs6076065	0.723	rs4815203	chr20:23395633	C/G	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.47	-4.68	-0.35	6.29e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs863345	0.604	rs11265008	chr1:158498671	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.54	-5.2	-0.39	6.26e-7	P wave terminal force;
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.34	5.31	0.4	3.74e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.58	5.61	0.41	9.25e-8	Resistin levels;
PAAD	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg27478167	chr7:817139	HEATR2	-0.58	-4.58	-0.35	9.67e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.1	-0.38	9.79e-7	Fear of minor pain;
PAAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.88e-9	Tonsillectomy;
PAAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7121446	0.512	rs11218516	chr11:121934177	T/C	cg05229759	chr11:122562201	UBASH3B	-0.49	-4.74	-0.36	4.96e-6	Cardiovascular risk factors (age interaction);
PAAD	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg23752985	chr2:85803571	VAMP8	0.55	6.19	0.45	5.45e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.62	0.57	8.14e-15	Bipolar disorder;
PAAD	cis	rs9467603	0.858	rs4712972	chr6:25772047	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.66	-4.6	-0.35	8.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19174634	chr17:71198000	COG1	0.45	4.61	0.35	8.63e-6	Smoking initiation;
PAAD	cis	rs705471	0.725	rs705465	chr10:3645633	G/A	cg14308648	chr10:3568949	NA	0.59	6.09	0.44	8.78e-9	Capecitabine sensitivity;
PAAD	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.28	-0.33	3.32e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-5.19	-0.39	6.65e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg06740227	chr12:86229804	RASSF9	0.6	5.86	0.43	2.72e-8	Major depressive disorder;
PAAD	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	6.08	0.44	9.1e-9	Mean platelet volume;
PAAD	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.44	-4.98	-0.37	1.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.6	6.44	0.46	1.46e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.38	5.2	0.39	6.32e-7	Blood protein levels;
PAAD	cis	rs72627123	1.000	rs17094021	chr14:74394295	C/T	cg19860245	chr14:74300557	NA	-0.74	-5.34	-0.4	3.28e-7	Morning vs. evening chronotype;
PAAD	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02071572	chr4:1403502	NA	0.38	4.82	0.36	3.46e-6	Longevity;
PAAD	cis	rs939584	0.935	rs7569102	chr2:631335	G/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	6.21	0.45	4.84e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.9	-0.37	2.38e-6	Hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-6.32	-0.46	2.77e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.79	8.85	0.58	2.1e-15	Lung cancer;
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg15598662	chr11:61582890	MIR1908;FADS1	0.5	4.52	0.34	1.23e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.85	-0.54	6.88e-13	Height;
PAAD	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.77	-8.04	-0.55	2.31e-13	Cognitive test performance;
PAAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.67	-0.42	7.03e-8	Tonsillectomy;
PAAD	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg04721828	chr11:48285200	OR4X1	0.42	5.51	0.41	1.51e-7	Migraine - clinic-based;
PAAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg02135003	chr7:105160482	PUS7	-0.68	-5.94	-0.43	1.91e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg24253500	chr15:84953950	NA	0.44	4.64	0.35	7.54e-6	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18489440	chr4:25863689	SEL1L3	-0.66	-6.5	-0.47	1.1e-9	Lung cancer in ever smokers;
PAAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.53	5.03	0.38	1.39e-6	Height;
PAAD	cis	rs4343996	0.719	rs7803004	chr7:3474084	A/G	cg21248987	chr7:3385318	SDK1	0.49	5.29	0.39	4.18e-7	Motion sickness;
PAAD	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.4	-0.34	2.01e-5	Life satisfaction;
PAAD	cis	rs7904519	0.935	rs6585200	chr10:114768609	A/G	cg17116091	chr10:114807157	TCF7L2	0.43	4.56	0.35	1.03e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs7731390	0.614	rs75539158	chr5:131648592	C/T	cg07395648	chr5:131743802	NA	-0.7	-4.47	-0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs910873	0.505	rs6059961	chr20:33231490	T/C	cg16810054	chr20:33298113	TP53INP2	-0.56	-4.29	-0.33	3.1e-5	Melanoma;
PAAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-1.06	-9.61	-0.61	2.23e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg04482110	chr17:41364121	TMEM106A	0.39	4.39	0.34	2.09e-5	Menopause (age at onset);
PAAD	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg10356904	chr22:49881777	NA	-0.55	-5.12	-0.38	9.03e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.86	10.16	0.64	7.88e-19	Blood protein levels;
PAAD	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs375066	0.901	rs438517	chr19:44419658	G/A	cg08633290	chr19:44405433	NA	-0.55	-5.42	-0.4	2.31e-7	Breast cancer;
PAAD	cis	rs7765175	0.598	rs6905873	chr6:113655606	A/T	cg19037598	chr6:113666021	NA	-0.43	-4.7	-0.36	5.72e-6	Coronary artery calcification;
PAAD	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.48	-4.64	-0.35	7.37e-6	Menarche (age at onset);
PAAD	cis	rs12615435	1.000	rs35149856	chr2:200639855	A/G	cg23649088	chr2:200775458	C2orf69	0.79	4.3	0.33	3.02e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);
PAAD	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg10290764	chr8:4849399	CSMD1	0.41	6.9	0.49	1.3e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.37	5.19	0.39	6.53e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.47	5.43	0.4	2.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1878047	0.702	rs12972903	chr19:51775738	C/T	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs12476592	0.563	rs78030021	chr2:64201422	C/A	cg10828910	chr2:63850056	LOC388955	-0.55	-4.58	-0.35	9.76e-6	Childhood ear infection;
PAAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15656113	chr5:172482832	C5orf41	-0.67	-6.4	-0.46	1.8e-9	Lung cancer in ever smokers;
PAAD	cis	rs9395066	0.545	rs35813980	chr6:44956008	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.41	-0.34	1.91e-5	Height;
PAAD	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.68	-7.79	-0.53	9.78e-13	Alcohol dependence;
PAAD	cis	rs727479	0.543	rs1143704	chr15:51510702	T/A	cg21478137	chr15:51532386	CYP19A1	0.44	4.45	0.34	1.63e-5	Estradiol levels;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.86	-7.46	-0.52	6.18e-12	Alzheimer's disease;
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.38	0.4	2.74e-7	Total body bone mineral density;
PAAD	cis	rs9398803	0.723	rs853969	chr6:127061318	C/T	cg19875578	chr6:126661172	C6orf173	0.41	4.34	0.33	2.61e-5	Male-pattern baldness;
PAAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.4	4.33	0.33	2.69e-5	Cystic fibrosis severity;
PAAD	cis	rs7523050	0.908	rs17621536	chr1:109396908	A/G	cg08274380	chr1:109419600	GPSM2	0.72	5.12	0.38	8.98e-7	Fat distribution (HIV);
PAAD	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.83	-8.97	-0.59	1.05e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.76	5.54	0.41	1.31e-7	Major depressive disorder;
PAAD	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.59	5.39	0.4	2.68e-7	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs10169736	chr2:641082	A/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs16958440	1.000	rs16958701	chr18:44655241	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs10792830	0.815	rs683494	chr11:85761474	A/T	cg07180834	chr11:85838833	NA	-0.52	-6.13	-0.45	7.19e-9	Psychosis and Alzheimer's disease;
PAAD	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-4.81	-0.36	3.65e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.67	5.09	0.38	1.06e-6	Biliary atresia;
PAAD	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.76	-8.16	-0.55	1.18e-13	Cognitive function;
PAAD	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.47	-0.41	1.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg10494973	chr17:80897199	TBCD	-0.53	-4.98	-0.37	1.7e-6	Breast cancer;
PAAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.77	-7.53	-0.52	4.3e-12	Breast cancer;
PAAD	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01942863	chr7:99769432	GPC2	0.51	4.28	0.33	3.29e-5	Platelet count;
PAAD	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg02683114	chr2:24398427	C2orf84	0.59	6.27	0.45	3.62e-9	Asthma;
PAAD	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.44	7.09	0.5	4.67e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.96	10.26	0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs6466055	0.748	rs6962856	chr7:104953466	A/T	cg04380332	chr7:105027541	SRPK2	-0.56	-6.09	-0.44	9.03e-9	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6880778	0.505	rs7445978	chr5:40381056	A/T	cg05240017	chr5:40756081	TTC33	0.5	4.3	0.33	2.98e-5	Inflammatory bowel disease;
PAAD	cis	rs7932354	0.536	rs10838620	chr11:46818098	G/A	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg00750074	chr16:89608354	SPG7	-0.54	-5.24	-0.39	5.25e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.84	-0.43	3.06e-8	Tonsillectomy;
PAAD	cis	rs9463078	0.625	rs1360197	chr6:44949630	T/C	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10768122	1.000	rs3794100	chr11:35295274	A/T	cg13971030	chr11:35366721	SLC1A2	0.36	4.29	0.33	3.18e-5	Vitiligo;
PAAD	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.45	-4.38	-0.33	2.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.54	5.4	0.4	2.54e-7	Mean corpuscular volume;
PAAD	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.53	5.07	0.38	1.13e-6	Mood instability;
PAAD	cis	rs732765	0.734	rs10136897	chr14:75173392	T/G	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg03700679	chr2:178418002	TTC30B	-0.59	-4.53	-0.35	1.16e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.61	4.5	0.34	1.32e-5	Exhaled nitric oxide output;
PAAD	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.46	0.41	1.87e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6496667	0.558	rs61653706	chr15:91076654	G/A	cg22089800	chr15:90895588	ZNF774	0.65	5.13	0.38	8.74e-7	Rheumatoid arthritis;
PAAD	cis	rs58521262	0.585	rs2935440	chr19:23211171	G/A	cg03433597	chr19:22806448	NA	0.24	4.26	0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg09127314	chr1:152161683	NA	-0.64	-4.57	-0.35	9.97e-6	Atopic dermatitis;
PAAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg08885800	chr1:201084119	NA	0.67	7.4	0.51	8.68e-12	Permanent tooth development;
PAAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg03983715	chr16:68378420	PRMT7	-0.58	-4.68	-0.36	6.22e-6	Schizophrenia;
PAAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.95	11.17	0.67	1.55e-21	Height;
PAAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg26318627	chr11:63887540	MACROD1	-0.44	-4.34	-0.33	2.57e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.09	0.5	4.64e-11	Coffee consumption (cups per day);
PAAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.72	-8.44	-0.56	2.33e-14	Diastolic blood pressure;
PAAD	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg19223190	chr17:80058835	NA	-0.54	-5.71	-0.42	5.89e-8	Life satisfaction;
PAAD	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg13736514	chr6:26305472	NA	-0.48	-5.01	-0.38	1.47e-6	Height;
PAAD	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1478898	0.569	rs2264866	chr8:11388653	C/T	cg00262122	chr8:11665843	FDFT1	-0.55	-4.67	-0.35	6.52e-6	Morning vs. evening chronotype;
PAAD	cis	rs372883	0.600	rs2832291	chr21:30734388	C/T	cg24692254	chr21:30365293	RNF160	0.51	5.03	0.38	1.39e-6	Pancreatic cancer;
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg13206674	chr6:150067644	NUP43	-0.6	-6.28	-0.45	3.34e-9	Testicular germ cell tumor;
PAAD	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.51	-5.31	-0.4	3.78e-7	Height;
PAAD	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.58	0.35	9.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4950322	0.512	rs2883318	chr1:146849143	A/C	cg22381352	chr1:146742008	CHD1L	-0.4	-4.26	-0.33	3.54e-5	Protein quantitative trait loci;
PAAD	cis	rs4919087	0.748	rs793517	chr10:98987522	A/G	cg25902810	chr10:99078978	FRAT1	-0.6	-5.38	-0.4	2.78e-7	Monocyte count;
PAAD	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06217245	chr20:33103252	DYNLRB1	0.4	4.72	0.36	5.27e-6	Coronary artery disease;
PAAD	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.59	5.57	0.41	1.12e-7	Alcohol dependence;
PAAD	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.5	4.46	0.34	1.58e-5	Corneal astigmatism;
PAAD	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg08898775	chr15:59042684	ADAM10	0.4	5.43	0.4	2.19e-7	Asperger disorder;
PAAD	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.94	9.56	0.61	3.04e-17	Response to antineoplastic agents;
PAAD	cis	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg09264619	chr17:80180166	NA	-0.52	-4.42	-0.34	1.9e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs75229567	0.618	rs10219700	chr12:70201730	A/G	cg10114359	chr12:70132523	RAB3IP	-0.89	-5.19	-0.39	6.56e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-4.76	-0.36	4.46e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg24519413	chr1:26490540	NA	0.52	4.81	0.36	3.57e-6	Height;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg15117754	chr3:10150083	C3orf24	0.8	7.0	0.49	7.76e-11	Alzheimer's disease;
PAAD	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-7.81	-0.54	8.76e-13	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.67	-5.23	-0.39	5.44e-7	Vitiligo;
PAAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg00539368	chr18:74514137	NA	0.59	4.69	0.36	6.11e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
PAAD	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg04809136	chr2:24300158	SF3B14	-0.4	-4.75	-0.36	4.69e-6	Quantitative traits;
PAAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg02734326	chr4:10020555	SLC2A9	0.49	4.97	0.37	1.77e-6	Bone mineral density;
PAAD	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	4.69	0.36	6.08e-6	Cognitive ability;
PAAD	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.73	-6.97	-0.49	9e-11	Corneal astigmatism;
PAAD	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg25753631	chr6:25732923	NA	0.44	4.92	0.37	2.27e-6	Iron status biomarkers;
PAAD	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.81	-10.39	-0.64	1.94e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.6	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg05805236	chr11:65401703	PCNXL3	-0.47	-5.39	-0.4	2.67e-7	Systemic lupus erythematosus;
PAAD	cis	rs4787491	0.729	rs4788213	chr16:30034524	T/C	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.51	-5.14	-0.38	8.45e-7	Schizophrenia;
PAAD	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11811982	0.793	rs75053784	chr1:227443324	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4388249	0.687	rs6877418	chr5:109074109	T/C	cg17395555	chr5:108820864	NA	0.31	4.36	0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.7	6.93	0.49	1.15e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.51	4.77	0.36	4.22e-6	Self-reported allergy;
PAAD	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.27	0.33	3.43e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6991838	0.806	rs11781358	chr8:66469926	A/G	cg15971335	chr8:66515592	ARMC1	0.46	4.55	0.35	1.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1519814	0.659	rs6469891	chr8:121037417	A/C	cg22335954	chr8:121166405	COL14A1	-0.66	-5.16	-0.39	7.5e-7	Breast cancer;
PAAD	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.12	-0.59	4.3e-16	Mean platelet volume;
PAAD	cis	rs9463078	0.585	rs988147	chr6:45174380	C/T	cg25276700	chr6:44698697	NA	0.46	5.2	0.39	6.3e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs17169635	0.879	rs7801596	chr7:134544054	T/A	cg02516134	chr7:134575187	CALD1	-0.48	-4.6	-0.35	8.84e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.42	5.31	0.4	3.82e-7	Colorectal cancer;
PAAD	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg04160749	chr8:58172571	NA	-0.72	-5.14	-0.38	8.51e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	6.39	0.46	1.9e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.77	-8.54	-0.57	1.27e-14	Lung cancer;
PAAD	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.66	5.81	0.43	3.55e-8	Response to diuretic therapy;
PAAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg24747557	chr10:131355152	MGMT	0.4	4.37	0.33	2.27e-5	Response to temozolomide;
PAAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.25	0.45	3.86e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2445762	0.518	rs7172765	chr15:51642674	G/A	cg25905881	chr15:51634250	GLDN	0.44	4.27	0.33	3.45e-5	Hormone measurements;
PAAD	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21643547	chr1:205240462	TMCC2	-0.46	-5.13	-0.38	8.63e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs800160	0.777	rs10765944	chr11:2348194	A/G	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.52	-0.34	1.24e-5	Bacteremia;
PAAD	cis	rs78761021	0.553	rs1525058	chr17:9766633	G/A	cg26853458	chr17:9805074	RCVRN	0.45	5.26	0.39	4.86e-7	Type 2 diabetes;
PAAD	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.72	-0.53	1.46e-12	Brugada syndrome;
PAAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.77	5.5	0.41	1.59e-7	Gut microbiome composition (summer);
PAAD	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14495033	chr9:140707378	EHMT1	-0.57	-7.28	-0.51	1.65e-11	Immature fraction of reticulocytes;
PAAD	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.72	-0.42	5.55e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.52	-4.59	-0.35	9.42e-6	Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04212729	chr14:65171037	PLEKHG3	0.6	7.14	0.5	3.57e-11	Metabolite levels  (X-11787);
PAAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.16	17.83	0.82	4.27e-39	Cognitive function;
PAAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg05697835	chr1:2722811	NA	-0.37	-4.28	-0.33	3.33e-5	Ulcerative colitis;
PAAD	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg23024343	chr7:107201750	COG5	0.58	4.79	0.36	3.9e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg09998033	chr7:158218633	PTPRN2	0.75	7.93	0.54	4.37e-13	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs2562456	0.833	rs1932087	chr19:21521427	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.5	-0.34	1.36e-5	Testicular germ cell tumor;
PAAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg06074448	chr4:187884817	NA	-0.72	-9.35	-0.6	1.05e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.5	5.07	0.38	1.16e-6	Longevity;Endometriosis;
PAAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.56	6.19	0.45	5.25e-9	Cognitive function;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12379764	chr21:47803548	PCNT	-0.5	-4.95	-0.37	1.96e-6	Testicular germ cell tumor;
PAAD	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.72	5.84	0.43	3.04e-8	Common traits (Other);
PAAD	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg14547644	chr6:28411285	ZSCAN23	0.39	4.52	0.34	1.23e-5	Pubertal anthropometrics;
PAAD	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg06492744	chr11:65406254	SIPA1	-0.33	-4.8	-0.36	3.78e-6	Systemic lupus erythematosus;
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.49	5.36	0.4	3.09e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24729792	chr2:113192114	RGPD8;RGPD5	0.61	4.85	0.37	3e-6	Yeast infection;
PAAD	cis	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.37	0.33	2.29e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.18e-6	Body mass index;
PAAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-4.98	-0.37	1.72e-6	Gut microbiome composition (summer);
PAAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.6e-6	Childhood ear infection;
PAAD	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.61	7.43	0.52	7.49e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.65	-0.42	7.58e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg26338869	chr17:61819248	STRADA	0.51	4.97	0.37	1.82e-6	Height;
PAAD	cis	rs12098973	0.591	rs75115265	chr11:131799227	C/G	cg13055484	chr11:132662455	OPCML	0.49	4.32	0.33	2.84e-5	Cardiac Troponin-T levels;
PAAD	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg01761236	chr14:102990251	NA	0.39	4.57	0.35	9.96e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.31	-0.33	2.94e-5	Renal cell carcinoma;
PAAD	cis	rs6782025	0.837	rs623175	chr3:120704611	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.76	-7.37	-0.51	1.04e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.54	4.33	0.33	2.68e-5	Coronary artery disease;
PAAD	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.6	-5.4	-0.4	2.48e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7213347	0.799	rs216195	chr17:2203167	T/G	cg15816464	chr17:2026533	SMG6	-0.47	-5.16	-0.39	7.71e-7	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.17	-0.39	7.16e-7	Breast cancer;
PAAD	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.43	-5.4	-0.4	2.56e-7	Thyroid stimulating hormone;
PAAD	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.7	8.07	0.55	1.92e-13	Morning vs. evening chronotype;
PAAD	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05025164	chr4:1340916	KIAA1530	0.59	5.97	0.44	1.58e-8	Obesity-related traits;
PAAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.94	8.08	0.55	1.82e-13	Gut microbiome composition (summer);
PAAD	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.36	0.51	1.1e-11	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.08e-5	Vitiligo;
PAAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.52	-4.68	-0.36	6.22e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg05562828	chr17:3906858	NA	0.5	5.06	0.38	1.2e-6	Type 2 diabetes;
PAAD	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6142102	0.538	rs6142058	chr20:32542801	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.36	3.54e-6	Skin pigmentation;
PAAD	cis	rs7572733	0.719	rs4417706	chr2:198944655	A/T	cg10820045	chr2:198174542	NA	0.44	4.4	0.34	2.06e-5	Dermatomyositis;
PAAD	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.84	-0.37	3.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-1.03	-13.44	-0.74	1.27e-27	Refractive error;
PAAD	cis	rs1678618	0.526	rs4148940	chr10:73765995	A/G	cg20897136	chr10:74034667	DDIT4	0.36	4.28	0.33	3.35e-5	Smoking behavior;
PAAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.62	5.67	0.42	7.08e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg23387401	chr17:4582204	PELP1	0.5	4.9	0.37	2.43e-6	Lymphocyte counts;
PAAD	cis	rs9398803	0.723	rs2793052	chr6:127064917	T/A	cg19875578	chr6:126661172	C6orf173	-0.43	-4.41	-0.34	1.95e-5	Male-pattern baldness;
PAAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs11264799	0.731	rs2317233	chr1:157692264	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.3	-0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.29e-16	Asthma;
PAAD	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.55	7.45	0.52	6.44e-12	IgA nephropathy;
PAAD	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.71	6.98	0.49	8.6e-11	Uric acid levels;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.52	4.98	0.37	1.72e-6	Lung cancer;
PAAD	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.67	7.26	0.51	1.85e-11	Resting heart rate;
PAAD	cis	rs59698941	0.882	rs72801412	chr5:132314039	T/C	cg16419906	chr5:132167176	NA	-0.62	-4.59	-0.35	9.03e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.51	0.47	1.04e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.32	-8.84	-0.58	2.23e-15	Blood pressure (smoking interaction);
PAAD	cis	rs7873102	0.654	rs12338509	chr9:37992582	C/T	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23422583	chr7:6388872	C7orf70	0.65	6.48	0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03583571	chr13:61990741	PCDH20	-0.69	-7.33	-0.51	1.27e-11	Obesity-related traits;
PAAD	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg15571903	chr15:79123663	NA	-0.49	-6.3	-0.45	3.07e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.62	6.2	0.45	5.13e-9	Primary sclerosing cholangitis;
PAAD	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg02462569	chr6:150064036	NUP43	-0.51	-5.93	-0.43	2.01e-8	Lung cancer;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.54	-5.7	-0.42	6.1e-8	Metabolite levels;
PAAD	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.59	-5.01	-0.38	1.49e-6	Metabolite levels;
PAAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.53	0.34	1.19e-5	Personality dimensions;
PAAD	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg05250797	chr16:70222502	NA	0.81	6.1	0.44	8.4e-9	IgE levels;
PAAD	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.5	6.19	0.45	5.27e-9	Sitting height ratio;
PAAD	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs9815354	1.000	rs1607908	chr3:41905196	T/G	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7503168	1.000	rs10512472	chr17:33884804	A/G	cg05299278	chr17:33885742	SLFN14	-0.52	-4.66	-0.35	7e-6	Plateletcrit;
PAAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg02734326	chr4:10020555	SLC2A9	0.5	5.03	0.38	1.39e-6	Bone mineral density;
PAAD	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.52	5.12	0.38	8.97e-7	Parkinson's disease;
PAAD	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02598441	chr17:62777298	LOC146880	-0.62	-4.8	-0.36	3.83e-6	QT interval;
PAAD	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg05791153	chr7:19748676	TWISTNB	0.68	5.14	0.38	8.31e-7	Thyroid stimulating hormone;
PAAD	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.98	13.58	0.74	5.3e-28	Heart rate;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02123667	chr8:127570702	FAM84B	0.62	7.02	0.49	7.04e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg19847866	chr10:1019161	NA	-0.54	-4.36	-0.33	2.38e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.55	-0.41	1.22e-7	Adiposity;
PAAD	cis	rs939584	1.000	rs6743060	chr2:629510	C/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg24642844	chr7:1081250	C7orf50	-0.57	-4.65	-0.35	7.24e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7168592	1.000	rs3784526	chr15:101716797	G/A	cg24254196	chr15:101719523	CHSY1	-0.62	-4.37	-0.33	2.27e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.68	7.55	0.52	3.78e-12	Multiple sclerosis;
PAAD	cis	rs6908034	0.607	rs76245225	chr6:19813188	T/G	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.75	-4.91	-0.37	2.37e-6	Lung cancer;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.51	4.44	0.34	1.75e-5	Height;
PAAD	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.45	-5.59	-0.41	1.04e-7	Pulmonary function;
PAAD	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.77	-8.62	-0.57	8.01e-15	Systemic lupus erythematosus;
PAAD	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg05627522	chr15:75251581	NA	-0.41	-4.97	-0.37	1.8e-6	Systemic lupus erythematosus;
PAAD	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.57	-5.16	-0.39	7.61e-7	Restless legs syndrome;
PAAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17099683	chr14:96969243	PAPOLA	0.69	6.38	0.46	2.01e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1113500	0.548	rs17020971	chr1:108655288	C/A	cg06207961	chr1:108661230	NA	0.45	4.68	0.35	6.26e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	1.04	12.92	0.72	3.02e-26	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.74	7.92	0.54	4.76e-13	Menopause (age at onset);
PAAD	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.84	8.82	0.58	2.57e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1443512	0.947	rs9804784	chr12:54343472	A/C	cg17410650	chr12:54324560	NA	-0.39	-5.7	-0.42	6.13e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg04851639	chr8:1020857	NA	-0.65	-8.09	-0.55	1.79e-13	Schizophrenia;
PAAD	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.5	4.32	0.33	2.85e-5	Atopic dermatitis;
PAAD	cis	rs4917300	0.606	rs4917225	chr8:143116169	T/C	cg26003909	chr8:143102224	NA	-0.3	-4.25	-0.33	3.65e-5	Amyotrophic lateral sclerosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25894985	chr4:83294101	HNRNPD	-0.73	-7.63	-0.53	2.41e-12	Smoking initiation;
PAAD	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2061333	0.557	rs28539456	chr19:44607547	G/T	cg20607764	chr19:44506953	ZNF230	-0.69	-4.91	-0.37	2.37e-6	Alzheimer's disease;
PAAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.52	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.69	6.66	0.48	4.74e-10	Subjective well-being;
PAAD	cis	rs818427	0.555	rs410701	chr5:112206416	G/A	cg06941702	chr5:112196734	SRP19	-0.53	-5.05	-0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.62	5.44	0.4	2.04e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg20197358	chr14:69619916	DCAF5	-1.06	-6.49	-0.47	1.16e-9	Psoriasis;
PAAD	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.74e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg19847866	chr10:1019161	NA	-0.61	-4.92	-0.37	2.19e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg04844267	chr4:1394941	NA	0.46	5.18	0.39	6.95e-7	Longevity;
PAAD	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg21132104	chr15:45694354	SPATA5L1	0.54	4.94	0.37	2.04e-6	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg18093559	chr17:18951025	GRAP	0.45	4.72	0.36	5.26e-6	Schizophrenia;
PAAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.8	8.08	0.55	1.92e-13	Cognitive function;
PAAD	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.77	8.37	0.56	3.55e-14	Body mass index;
PAAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.78	-8.26	-0.56	6.46e-14	Menarche (age at onset);
PAAD	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.54	5.25	0.39	4.94e-7	Multiple myeloma;
PAAD	cis	rs13177180	0.600	rs256995	chr5:114913364	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-4.63	-0.35	7.72e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.33	-0.4	3.44e-7	Mean platelet volume;
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.8	0.36	3.78e-6	Pancreatic cancer;
PAAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.43	-4.76	-0.36	4.54e-6	Platelet distribution width;
PAAD	cis	rs8032158	0.963	rs1912398	chr15:56159103	T/G	cg02198044	chr15:56286336	NEDD4	-0.48	-5.09	-0.38	1.02e-6	Keloid;
PAAD	cis	rs28830936	0.509	rs6493005	chr15:41859152	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.39	-4.33	-0.33	2.75e-5	Diastolic blood pressure;
PAAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg14820908	chr5:178986412	RUFY1	0.43	4.28	0.33	3.31e-5	Lung cancer;
PAAD	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.48	-5.09	-0.38	1.05e-6	Motion sickness;
PAAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23281280	chr6:28129359	ZNF389	0.65	4.77	0.36	4.25e-6	Depression;
PAAD	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs2017305	0.834	rs118076009	chr10:70785933	C/T	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.37	-0.4	2.9e-7	Depression (quantitative trait);
PAAD	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18357526	chr6:26021779	HIST1H4A	0.61	5.47	0.41	1.79e-7	Height;
PAAD	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.97	10.39	0.64	1.9e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.64	6.52	0.47	9.96e-10	Testicular germ cell tumor;
PAAD	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.59	5.24	0.39	5.17e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24706213	chr1:109633347	TMEM167B	0.63	7.02	0.49	7.01e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg08468991	chr1:109506060	CLCC1	0.6	6.44	0.46	1.47e-9	Iris heterochromicity;
PAAD	cis	rs17592366	0.517	rs10145350	chr14:35279109	A/C	cg09327582	chr14:35236912	BAZ1A	0.56	5.14	0.38	8.32e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.52	4.64	0.35	7.36e-6	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24420395	chr8:29206910	DUSP4	0.62	6.99	0.49	8.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg15017067	chr4:17643749	FAM184B	0.41	4.59	0.35	9.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs8077577	0.895	rs11655797	chr17:18107850	C/T	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.24	0.39	5.16e-7	Rheumatoid arthritis;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg14820908	chr5:178986412	RUFY1	0.58	5.94	0.43	1.87e-8	Lung cancer;
PAAD	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.74	5.64	0.42	8e-8	Vitiligo;
PAAD	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg20893579	chr22:38215064	NA	-0.45	-4.83	-0.37	3.24e-6	Glioblastoma;Glioma;
PAAD	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg00369613	chr2:3483100	TTC15	0.58	4.35	0.33	2.52e-5	Type 2 diabetes;
PAAD	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	1.05	6.9	0.49	1.35e-10	Plateletcrit;
PAAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.6	-0.35	8.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg10820045	chr2:198174542	NA	0.53	5.5	0.41	1.55e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.71	6.96	0.49	9.67e-11	Lymphocyte counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21587861	chr12:32260103	BICD1	0.6	6.54	0.47	8.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg21565972	chr17:80109576	CCDC57	0.59	6.89	0.49	1.42e-10	Life satisfaction;
PAAD	cis	rs4740619	0.774	rs2182936	chr9:15918922	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.43	-0.34	1.81e-5	Body mass index;
PAAD	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.81	9.6	0.61	2.4e-17	Colorectal cancer;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg01816997	chr6:44355194	CDC5L	0.54	6.44	0.46	1.51e-9	Energy expenditure (24h);
PAAD	cis	rs1468333	0.930	rs2269954	chr5:137501003	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.35	0.46	2.31e-9	Resting heart rate;
PAAD	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg08926642	chr1:7887455	PER3	0.5	4.33	0.33	2.71e-5	Inflammatory bowel disease;
PAAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg23464041	chr6:33663938	ITPR3	0.47	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs6543140	0.693	rs7579737	chr2:102987361	A/G	cg03938978	chr2:103052716	IL18RAP	0.43	4.55	0.35	1.11e-5	Blood protein levels;
PAAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.93	8.29	0.56	5.6e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11892454	0.504	rs55737015	chr2:26010303	G/A	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.8e-5	Heschl's gyrus morphology;
PAAD	cis	rs61173913	1	rs61173913	chr2:201351874	TA/T	cg14211387	chr2:201677426	BZW1	-0.74	-4.4	-0.34	2.04e-5	Pelvic organ prolapse;
PAAD	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.61	-6.5	-0.47	1.1e-9	HDL cholesterol;
PAAD	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.63	6.22	0.45	4.52e-9	Coronary artery disease;
PAAD	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg10395934	chr14:104002654	TRMT61A	-0.54	-5.69	-0.42	6.25e-8	Body mass index;
PAAD	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.89	9.78	0.62	8.16e-18	Blood protein levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg03508346	chr11:89059855	NOX4	-0.57	-6.93	-0.49	1.09e-10	Energy expenditure (24h);
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg14393609	chr7:65229607	NA	0.67	7.35	0.51	1.11e-11	Aortic root size;
PAAD	cis	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.07	-0.38	1.16e-6	Blood pressure (smoking interaction);
PAAD	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg27398640	chr15:77910606	LINGO1	0.48	4.7	0.36	5.88e-6	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23305502	chr11:71164098	NADSYN1	-0.58	-6.53	-0.47	9.47e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00292662	chr22:38071168	LGALS1	0.64	6.77	0.48	2.66e-10	Fat distribution (HIV);
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Obesity-related traits;
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.58	-6.61	-0.47	6.24e-10	Prostate cancer;
PAAD	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.87	9.43	0.61	6.76e-17	Cognitive function;
PAAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg02917321	chr22:38215204	NA	0.45	4.6	0.35	8.73e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10929159	0.928	rs2123512	chr2:236920731	C/T	cg14226755	chr2:236923322	AGAP1	0.28	4.41	0.34	1.91e-5	Parkinson's disease;
PAAD	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.44	-6.73	-0.48	3.25e-10	Subjective well-being;
PAAD	cis	rs11264799	0.731	rs10489679	chr1:157694755	C/T	cg18268488	chr1:157545234	FCRL4	0.65	5.78	0.42	4.03e-8	IgA nephropathy;
PAAD	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.04	0.38	1.3e-6	Prostate cancer;
PAAD	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.89e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.75	-6.54	-0.47	8.67e-10	Response to amphetamines;
PAAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg08501292	chr6:25962987	TRIM38	0.96	5.23	0.39	5.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg05025164	chr4:1340916	KIAA1530	0.57	5.64	0.42	8.16e-8	Longevity;
PAAD	trans	rs61931739	0.620	rs815052	chr12:33727270	C/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.54	-5.14	-0.38	8.52e-7	Mortality in heart failure;
PAAD	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.73	0.36	5.07e-6	Hepatocellular carcinoma;
PAAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg05110241	chr16:68378359	PRMT7	-1.01	-6.53	-0.47	9.32e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10490913	1.000	rs10787819	chr10:120146612	G/A	cg04126427	chr10:120840676	EIF3A	-0.47	-4.98	-0.37	1.71e-6	Cancer;
PAAD	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.53	4.87	0.37	2.72e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	5.11	0.38	9.53e-7	Menarche (age at onset);
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg17105886	chr17:28927953	LRRC37B2	0.67	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.72	6.91	0.49	1.27e-10	Parkinson's disease;
PAAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.63	-6.39	-0.46	1.89e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.67	7.55	0.52	3.84e-12	Resting heart rate;
PAAD	cis	rs965469	0.724	rs6037527	chr20:3254412	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs8101881	0.757	rs10418164	chr19:33411139	T/G	cg16524284	chr19:33353338	SLC7A9	-0.44	-4.28	-0.33	3.33e-5	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
PAAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-4.52	-0.34	1.22e-5	Mean corpuscular volume;
PAAD	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.79	6.07	0.44	9.95e-9	Mean platelet volume;
PAAD	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.82	-7.18	-0.5	2.86e-11	Pancreatic cancer;
PAAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg17848003	chr1:3704513	LRRC47	0.4	4.4	0.34	2.05e-5	Red cell distribution width;
PAAD	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.51	-4.7	-0.36	5.9e-6	Urate levels;
PAAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg13606994	chr1:44402422	ARTN	-0.41	-4.44	-0.34	1.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs7601028	chr2:642499	C/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg08514558	chr10:81106712	PPIF	0.51	6.18	0.45	5.52e-9	Height;
PAAD	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.36	0.33	2.37e-5	Lung cancer;
PAAD	cis	rs2252790	1.000	rs2498703	chr6:116660670	A/T	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg14343924	chr8:8086146	FLJ10661	0.56	5.13	0.38	8.8e-7	Joint mobility (Beighton score);
PAAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs73206853	0.764	rs7300001	chr12:110581731	A/G	cg12870014	chr12:110450643	ANKRD13A	0.82	4.57	0.35	9.98e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03874728	chr12:96336486	CCDC38;AMDHD1	-0.62	-6.37	-0.46	2.11e-9	Warfarin maintenance dose;
PAAD	cis	rs75920871	0.925	rs61905716	chr11:116919067	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	7.07	0.5	5.15e-11	Body mass index;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2004318	1.000	rs1591294	chr19:55132829	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7188861	0.681	rs12162021	chr16:11403013	G/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.51	-4.81	-0.36	3.64e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2790216	1.000	rs2653505	chr10:59964142	C/T	cg20442379	chr10:60024634	IPMK	-0.57	-4.38	-0.33	2.22e-5	Inflammatory bowel disease;
PAAD	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg22875332	chr1:76189707	ACADM	-0.5	-4.97	-0.37	1.79e-6	Daytime sleep phenotypes;
PAAD	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	4.93	0.37	2.1e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.13	0.45	7.18e-9	Breast cancer;
PAAD	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg12064134	chr16:90016061	DEF8	0.47	4.36	0.33	2.39e-5	Squamous cell carcinoma;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg02917321	chr22:38215204	NA	0.45	4.6	0.35	8.73e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.48	-5.23	-0.39	5.45e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg08885800	chr1:201084119	NA	0.68	7.29	0.51	1.55e-11	Permanent tooth development;
PAAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.3	-0.39	4.02e-7	Diastolic blood pressure;
PAAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.36	0.6	1e-16	Parkinson's disease;
PAAD	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg08619932	chr19:49200058	FUT2	0.56	6.23	0.45	4.43e-9	Dietary macronutrient intake;
PAAD	cis	rs35955747	0.633	rs5998021	chr22:31907427	C/G	cg02404636	chr22:31891804	SFI1	-0.54	-5.42	-0.4	2.33e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.27	-0.33	3.47e-5	Educational attainment (years of education);
PAAD	cis	rs2456568	0.695	rs7129280	chr11:93687158	T/C	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.15	-0.39	8.01e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.67	8.61	0.57	8.77e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4462272	0.605	rs7898075	chr10:101973097	T/C	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.26e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23708337	chr7:1209742	NA	0.45	4.91	0.37	2.28e-6	Longevity;Endometriosis;
PAAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.52	-4.61	-0.35	8.52e-6	IgG glycosylation;
PAAD	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.63	6.81	0.48	2.08e-10	Colorectal cancer;
PAAD	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.34	-0.33	2.6e-5	Aortic root size;
PAAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg01200585	chr1:228362443	C1orf69	0.64	6.53	0.47	9.53e-10	Diastolic blood pressure;
PAAD	cis	rs42648	0.507	rs4397318	chr7:89728269	G/A	cg27367526	chr7:89841692	STEAP2	0.31	4.29	0.33	3.14e-5	Homocysteine levels;
PAAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.36e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13424612	0.839	rs4854063	chr2:240914090	T/C	cg01812947	chr2:240904978	NDUFA10	0.53	4.9	0.37	2.38e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.12	-0.55	1.52e-13	Prostate cancer;
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.77	8.99	0.59	9.37e-16	Noise-induced hearing loss;
PAAD	trans	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.48	-0.34	1.44e-5	Eotaxin levels;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.5	-5.05	-0.38	1.24e-6	Testicular germ cell tumor;
PAAD	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg06812019	chr5:1143331	NA	0.45	4.28	0.33	3.33e-5	Gut microbiome composition (winter);
PAAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg19847866	chr10:1019161	NA	-0.59	-4.68	-0.35	6.34e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7260329	0.670	rs7251950	chr19:41482742	A/G	cg23925301	chr19:41220945	ADCK4	0.56	4.82	0.36	3.51e-6	Smoking behavior;
PAAD	cis	rs7577696	0.962	rs36014814	chr2:32304959	A/G	cg02381751	chr2:32503542	YIPF4	-0.44	-4.73	-0.36	5.14e-6	Inflammatory biomarkers;
PAAD	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.34	0.56	4.11e-14	Mean corpuscular volume;
PAAD	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg08619932	chr19:49200058	FUT2	0.57	6.34	0.46	2.54e-9	Dietary macronutrient intake;
PAAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-4.79	-0.36	3.95e-6	Gut microbiome composition (summer);
PAAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19933343	chr17:71241372	C17orf80	-0.58	-6.37	-0.46	2.12e-9	Obesity-related traits;
PAAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg25452165	chr22:42524984	CYP2D6	0.6	5.54	0.41	1.33e-7	Schizophrenia;
PAAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.71	8.12	0.55	1.46e-13	Multiple sclerosis;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	5.12	0.38	9.23e-7	Lung cancer in ever smokers;
PAAD	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.86	10.37	0.64	2.21e-19	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.56	5.43	0.4	2.19e-7	Resistin levels;
PAAD	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.56	-4.58	-0.35	9.6e-6	Facial morphology (factor 19);
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg18888403	chr1:24152774	HMGCL	0.41	4.65	0.35	7.27e-6	Immature fraction of reticulocytes;
PAAD	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.95	9.21	0.6	2.48e-16	Psoriasis;
PAAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	10.14	0.64	8.87e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2016266	0.806	rs11170494	chr12:53665164	C/A	cg26875137	chr12:53738046	NA	0.38	4.31	0.33	2.94e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6723108	0.651	rs6724866	chr2:135407310	C/A	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Type 2 diabetes;
PAAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg14847009	chr1:175162515	KIAA0040	0.33	5.23	0.39	5.42e-7	Alcohol dependence;
PAAD	cis	rs1334894	1.000	rs2294807	chr6:35555110	C/T	cg07213720	chr6:35227408	ZNF76	-0.84	-4.61	-0.35	8.52e-6	Coronary artery disease;
PAAD	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.62	-5.47	-0.41	1.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.98	13.8	0.75	1.37e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.97	11.01	0.67	4.16e-21	Parkinson's disease;
PAAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.13	0.55	1.43e-13	Schizophrenia;
PAAD	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.48	-0.34	1.49e-5	Inflammatory bowel disease;
PAAD	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg11779900	chr17:80519722	FOXK2	0.47	4.9	0.37	2.39e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.6	0.35	8.79e-6	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09419486	chr15:60690242	ANXA2	-0.65	-6.68	-0.48	4.25e-10	Smoking initiation;
PAAD	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.07e-5	Triglycerides;
PAAD	cis	rs1018836	0.700	rs12678527	chr8:91527411	T/C	cg16814680	chr8:91681699	NA	-0.87	-10.79	-0.66	1.62e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.84	0.37	3.22e-6	Breast cancer;
PAAD	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg23684787	chr19:1848742	REXO1	-0.51	-4.29	-0.33	3.16e-5	Bipolar disorder;
PAAD	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.55	-5.36	-0.4	3.01e-7	Metabolic traits;
PAAD	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg09760422	chr2:128146352	NA	0.34	6.03	0.44	1.22e-8	Protein C levels;
PAAD	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.52	-5.45	-0.4	1.98e-7	Height;
PAAD	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.84e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.95	7.21	0.5	2.51e-11	Axial length;
PAAD	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-5.88	-0.43	2.51e-8	Asthma;
PAAD	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-6.6	-0.47	6.44e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15544637	chr10:89513069	ATAD1	0.53	6.37	0.46	2.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	4.78	0.36	4.17e-6	Obesity-related traits;
PAAD	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg21995147	chr19:1064017	ABCA7	-0.6	-5.38	-0.4	2.7e-7	Alzheimer's disease (late onset);
PAAD	cis	rs11264799	0.520	rs849819	chr1:157541674	A/C	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg13560548	chr3:10150139	C3orf24	0.56	5.13	0.38	8.56e-7	Alzheimer's disease;
PAAD	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.91	-12.06	-0.7	6.2e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.41e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	1.000	rs71499565	chr10:45977715	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23281280	chr6:28129359	ZNF389	-0.7	-5.42	-0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2030114	1.000	rs74369792	chr16:51609871	C/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg18612461	chr15:75251733	NA	-0.4	-4.63	-0.35	7.82e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.77	9.53	0.61	3.67e-17	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg11232448	chr19:2858854	NA	-0.48	-4.77	-0.36	4.34e-6	Total cholesterol levels;
PAAD	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs2835872	0.758	rs1709820	chr21:39035971	A/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.03	0.44	1.21e-8	Electroencephalographic traits in alcoholism;
PAAD	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.05	0.55	2.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.66	-7.84	-0.54	7.13e-13	Longevity;Endometriosis;
PAAD	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.75	7.13	0.5	3.81e-11	Retinal vascular caliber;
PAAD	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.45	0.4	2.03e-7	Type 2 diabetes;
PAAD	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.69	6.87	0.49	1.57e-10	Lymphocyte counts;
PAAD	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg15571903	chr15:79123663	NA	0.39	4.69	0.36	6.13e-6	Coronary artery disease;
PAAD	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.35	4.49	0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.82	7.78	0.53	1.01e-12	Response to hepatitis C treatment;
PAAD	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.82	9.58	0.61	2.71e-17	Breast cancer;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg21280320	chr1:152162025	NA	0.59	6.04	0.44	1.11e-8	Inflammatory skin disease;
PAAD	cis	rs7945718	0.621	rs7931351	chr11:12692162	A/T	cg25843174	chr11:12811716	TEAD1	0.3	4.42	0.34	1.88e-5	Educational attainment (years of education);
PAAD	cis	rs6782025	0.837	rs1191288	chr3:120920493	T/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs821931	1.000	rs911580	chr10:108466775	C/T	cg16415058	chr10:108923781	SORCS1	0.37	4.34	0.33	2.57e-5	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
PAAD	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.41	-0.4	2.4e-7	Reticulocyte count;
PAAD	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.04	0.5	6.07e-11	Coffee consumption (cups per day);
PAAD	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.8	-12.26	-0.71	1.8e-24	Birth weight;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03846689	chr6:111135840	CDK19	-0.59	-6.86	-0.49	1.66e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-5.73	-0.42	5.23e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg17346650	chr17:80929145	B3GNTL1	0.46	5.61	0.41	9.32e-8	Glycated hemoglobin levels;
PAAD	cis	rs2777491	0.874	rs11633799	chr15:41576538	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.84	-0.62	5.58e-18	Ulcerative colitis;
PAAD	cis	rs66478310	0.793	rs73201516	chr12:108716207	C/G	cg04872675	chr12:108983234	NA	0.83	5.0	0.38	1.59e-6	Plasma clusterin levels;
PAAD	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.63	5.29	0.39	4.21e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6594713	0.684	rs1816062	chr5:112856023	A/C	cg12552261	chr5:112820674	MCC	0.76	5.28	0.39	4.48e-7	Brain cytoarchitecture;
PAAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.93	-0.37	2.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg14250997	chr9:106856677	SMC2	0.54	5.78	0.42	4.08e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.63	6.13	0.45	7.07e-9	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.61	-8.19	-0.55	1.01e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.35	-0.33	2.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.83	9.62	0.62	2.11e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-1.2	-9.88	-0.63	4.21e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg25272121	chr1:152190972	HRNR	0.49	4.47	0.34	1.51e-5	Inflammatory skin disease;
PAAD	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.98	11.7	0.69	6.02e-23	Breast cancer;
PAAD	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.77	4.31	0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs55728055	0.661	rs62237796	chr22:31976578	T/G	cg01338084	chr22:32026380	PISD	1.6	8.24	0.56	7.56e-14	Age-related hearing impairment;
PAAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.78	5.62	0.41	8.85e-8	Carotid intima media thickness;
PAAD	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.75	7.27	0.51	1.75e-11	Corneal astigmatism;
PAAD	cis	rs10992471	0.580	rs4743875	chr9:95423674	T/C	cg14631576	chr9:95140430	CENPP	-0.48	-4.62	-0.35	8.19e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg18612461	chr15:75251733	NA	-0.58	-7.27	-0.51	1.74e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg06915872	chr16:87998081	BANP	0.56	5.08	0.38	1.08e-6	Menopause (age at onset);
PAAD	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg23649088	chr2:200775458	C2orf69	0.66	5.6	0.41	9.81e-8	Schizophrenia;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.46	6.37	0.46	2.13e-9	Cardiovascular disease risk factors;
PAAD	cis	rs501120	0.925	rs1657344	chr10:44781234	C/T	cg09554077	chr10:44749378	NA	0.42	4.79	0.36	3.88e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01114163	chr5:1856713	NA	-0.4	-4.25	-0.33	3.71e-5	Cardiovascular disease risk factors;
PAAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.83	0.36	3.36e-6	Diastolic blood pressure;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00612595	chr21:47717864	NA	0.43	4.53	0.34	1.21e-5	Testicular germ cell tumor;
PAAD	cis	rs829661	0.948	rs829675	chr2:30710447	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26926768	chr12:34528122	NA	0.37	4.32	0.33	2.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg19223190	chr17:80058835	NA	0.53	5.48	0.41	1.71e-7	Life satisfaction;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.77	8.2	0.55	9.3e-14	Longevity;
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.53e-9	Cognitive function;
PAAD	cis	rs10450586	0.932	rs10767633	chr11:27329725	T/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.46	-4.79	-0.36	3.98e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.09	0.44	8.96e-9	Subjective well-being;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-4.35	-0.33	2.5e-5	Metabolite levels;
PAAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.76	-8.15	-0.55	1.24e-13	Blood metabolite levels;
PAAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg02869306	chr7:64672164	INTS4L1	0.4	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.99	7.83	0.54	7.57e-13	LDL cholesterol;
PAAD	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.52	4.8	0.36	3.69e-6	Schizophrenia;
PAAD	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.47	4.56	0.35	1.03e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23868848	chr8:128806661	PVT1	0.57	6.3	0.46	3.11e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg09035930	chr12:129282057	SLC15A4	1.11	15.16	0.78	3.38e-32	Systemic lupus erythematosus;
PAAD	cis	rs1419980	0.730	rs7137180	chr12:7745614	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs9905704	0.596	rs2526367	chr17:56470750	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.76	-6.64	-0.47	5.32e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs7092929	0.689	rs964162	chr10:3535233	C/T	cg14308648	chr10:3568949	NA	0.55	5.43	0.4	2.19e-7	Coronary artery calcification;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.57	6.19	0.45	5.36e-9	Longevity;Endometriosis;
PAAD	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs322144	1.000	rs322144	chr19:11423703	C/G	cg22357700	chr19:11805638	NA	0.46	4.4	0.34	2.01e-5	Breast cancer;
PAAD	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-4.48	-0.34	1.49e-5	Personality dimensions;
PAAD	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.54	4.92	0.37	2.27e-6	Airway imaging phenotypes;
PAAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg23985595	chr17:80112537	CCDC57	-0.45	-5.84	-0.43	3.07e-8	Life satisfaction;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg12759597	chr1:155181615	MTX1	0.65	6.74	0.48	3.08e-10	Body mass index;
PAAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Aortic root size;
PAAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg03989125	chr22:38214979	NA	0.55	5.56	0.41	1.17e-7	Glioblastoma;Glioma;
PAAD	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.59	5.82	0.43	3.45e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18621852	chr3:10150065	C3orf24	0.71	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-1.5	-8.89	-0.58	1.66e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg08523384	chr5:141488047	NDFIP1	-0.63	-5.74	-0.42	4.9e-8	Crohn's disease;
PAAD	cis	rs2916733	0.530	rs2440423	chr8:6290206	T/C	cg02465761	chr8:6735510	DEFB1	-0.42	-4.33	-0.33	2.64e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg20913747	chr6:44695427	NA	-0.66	-6.71	-0.48	3.69e-10	Total body bone mineral density;
PAAD	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.88	7.1	0.5	4.47e-11	Axial length;
PAAD	cis	rs11811982	0.793	rs11807375	chr1:227511411	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-8.44	-0.56	2.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg02743256	chr7:2109353	MAD1L1	0.57	4.59	0.35	9.03e-6	Bipolar disorder;
PAAD	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg27411982	chr8:10470053	RP1L1	0.49	5.34	0.4	3.31e-7	Neuroticism;
PAAD	cis	rs10450586	0.863	rs10767631	chr11:27315853	C/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs4509693	0.722	rs10883536	chr10:102489331	A/C	cg24179445	chr10:102496915	NA	0.52	5.52	0.41	1.42e-7	Alzheimer's disease;
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-8.97	-0.59	1e-15	Age at first birth;
PAAD	cis	rs116248771	0.690	rs10936149	chr3:158293893	T/G	cg16708174	chr3:158430962	RARRES1	0.66	5.04	0.38	1.28e-6	diarrhoeal disease at age 2;
PAAD	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-6.4	-0.46	1.84e-9	Parkinson's disease;
PAAD	cis	rs34156428	0.673	rs7128484	chr11:16692990	G/A	cg15111638	chr11:16631993	NA	-0.43	-4.37	-0.33	2.29e-5	Coronary artery disease;
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg27588902	chr6:42928151	GNMT	0.4	4.27	0.33	3.44e-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.3	-0.46	3.07e-9	Triglycerides;
PAAD	cis	rs11264799	0.639	rs12568320	chr1:157744004	A/G	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg04106633	chr4:1044584	NA	0.66	5.57	0.41	1.11e-7	Recombination rate (females);
PAAD	cis	rs11264213	0.901	rs67641270	chr1:36413329	T/C	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	12.12	0.7	4.26e-24	Bone mineral density;
PAAD	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.25	0.33	3.71e-5	Rheumatoid arthritis;
PAAD	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg21191810	chr6:118973309	C6orf204	0.46	5.79	0.43	3.85e-8	Electrocardiographic conduction measures;
PAAD	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs4144027	0.716	rs911338	chr14:104352928	G/A	cg26031613	chr14:104095156	KLC1	0.44	4.32	0.33	2.82e-5	Blood metabolite levels;
PAAD	cis	rs7264396	0.887	rs4911502	chr20:34063034	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.31	-0.4	3.78e-7	Mononucleosis;
PAAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg00540400	chr15:79124168	NA	-0.69	-8.78	-0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9535307	0.719	rs9535341	chr13:50363304	C/T	cg03658251	chr13:50265850	EBPL	-0.79	-5.27	-0.39	4.5e-7	Obesity-related traits;
PAAD	cis	rs71520386	0.607	rs4308627	chr7:22879904	C/T	cg04907244	chr7:22894795	SNORD93	0.51	5.44	0.4	2.12e-7	Fibrinogen levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15150274	chr8:33330294	FUT10	0.6	6.76	0.48	2.81e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg09219196	chr12:53901441	NPFF	-0.63	-4.35	-0.33	2.5e-5	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.59	-6.27	-0.45	3.53e-9	Height;
PAAD	cis	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg11364645	chr3:101405397	RPL24	0.5	5.13	0.38	8.71e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg00666640	chr1:248458726	OR2T12	0.47	4.81	0.36	3.63e-6	Common traits (Other);
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg17524265	chr8:144659883	NAPRT1	0.88	4.44	0.34	1.74e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-6.48	-0.47	1.23e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg05082376	chr22:42548792	NA	-0.44	-4.51	-0.34	1.28e-5	Cognitive function;
PAAD	cis	rs593531	0.524	rs634608	chr11:74084729	G/A	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.52	-0.34	1.24e-5	Neuroticism;
PAAD	cis	rs7818688	0.697	rs17665737	chr8:95986306	A/G	cg16049864	chr8:95962084	TP53INP1	0.57	4.53	0.34	1.2e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg02376097	chr19:46275166	DMPK	-0.6	-6.07	-0.44	9.84e-9	Coronary artery disease;
PAAD	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.17	12.07	0.7	5.97e-24	Corneal structure;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	8.67	0.58	6.18e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg04160749	chr8:58172571	NA	-0.71	-4.89	-0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014252	0.803	rs10483830	chr14:71054478	T/C	cg11204974	chr14:71022665	NA	-0.76	-4.85	-0.37	3.04e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	4.9	0.37	2.42e-6	Height;
PAAD	cis	rs9815354	0.812	rs809930	chr3:42065005	A/G	cg03022575	chr3:42003672	ULK4	0.67	4.85	0.37	3.08e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7487075	0.619	rs4077707	chr12:46858498	T/C	cg14671384	chr12:47219920	SLC38A4	0.44	4.39	0.34	2.07e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1371614	0.632	rs6708148	chr2:27167320	A/G	cg00617064	chr2:27272375	NA	-0.44	-4.47	-0.34	1.51e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.08	0.59	5.29e-16	Cognitive test performance;
PAAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg18888403	chr1:24152774	HMGCL	0.39	4.5	0.34	1.36e-5	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma (childhood onset);
PAAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.43	-0.34	1.81e-5	Colorectal cancer;
PAAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-1.06	-7.27	-0.51	1.77e-11	IgG glycosylation;
PAAD	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs7631605	0.518	rs56231935	chr3:36979260	T/C	cg17445812	chr3:36986805	TRANK1	0.36	5.11	0.38	9.47e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.59	5.77	0.42	4.33e-8	Platelet count;
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.96	12.28	0.71	1.59e-24	Menopause (age at onset);
PAAD	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.51	-4.48	-0.34	1.44e-5	Mean corpuscular volume;
PAAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.52	-4.93	-0.37	2.11e-6	Neurofibrillary tangles;
PAAD	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.23	0.6	2.24e-16	Hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.81	-0.43	3.46e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-5.69	-0.42	6.22e-8	Response to antipsychotic treatment;
PAAD	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.94	-10.22	-0.64	5.53e-19	Parkinson's disease;
PAAD	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.44	-0.34	1.73e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12015310	chr15:37392667	MEIS2	-0.65	-6.34	-0.46	2.44e-9	Neuroticism;
PAAD	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.59	5.28	0.39	4.4e-7	Retinal vascular caliber;
PAAD	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs1941184	0.526	rs8085532	chr18:29027771	C/T	cg03238162	chr18:29027701	DSG3	0.42	4.68	0.35	6.32e-6	Parkinson's disease (age of onset);
PAAD	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.86	10.01	0.63	1.98e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg13057898	chr1:3703894	LRRC47	0.44	4.71	0.36	5.43e-6	Red cell distribution width;
PAAD	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-1.06	-8.69	-0.58	5.48e-15	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.98	0.54	3.32e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.43	-0.46	1.6e-9	Fibrinogen levels;
PAAD	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.36	-4.74	-0.36	4.85e-6	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg19337854	chr7:99768885	GPC2	0.52	4.93	0.37	2.12e-6	Platelet count;
PAAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	5.01	0.38	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.5	0.41	1.58e-7	Body mass index;
PAAD	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg24687543	chr11:63912206	MACROD1	0.57	4.55	0.35	1.08e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14343924	chr8:8086146	FLJ10661	0.5	4.64	0.35	7.53e-6	Mood instability;
PAAD	cis	rs9810890	1.000	rs73198862	chr3:128524945	C/T	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg21775007	chr8:11205619	TDH	-0.58	-4.93	-0.37	2.16e-6	Neuroticism;
PAAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.65	4.61	0.35	8.32e-6	Parkinson's disease;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.7	-7.62	-0.53	2.53e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18380123	chr7:4276204	SDK1	-0.56	-6.56	-0.47	8.13e-10	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-0.97	-14.48	-0.76	2.09e-30	Prudent dietary pattern;
PAAD	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg00383909	chr3:49044727	WDR6	-0.56	-4.37	-0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.78	12.5	0.71	4.04e-25	Breast cancer;
PAAD	cis	rs1982963	0.585	rs61971558	chr14:52496024	G/A	cg20550154	chr14:52487779	NID2	0.59	4.81	0.36	3.57e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.49	-4.8	-0.36	3.68e-6	Multiple sclerosis;
PAAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs829661	0.901	rs829620	chr2:30750660	C/A	cg12454169	chr2:30669597	LCLAT1	0.67	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.45	0.34	1.67e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.71	-0.36	5.48e-6	Neuroticism;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg05082376	chr22:42548792	NA	-0.48	-5.2	-0.39	6.46e-7	Cognitive function;
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-5.39	-0.4	2.58e-7	Prostate cancer;
PAAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.6	6.38	0.46	2.08e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.87	9.54	0.61	3.43e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.52	-4.98	-0.37	1.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	5.32	0.4	3.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-4.43	-0.34	1.76e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-1.34	-11.38	-0.68	4.21e-22	Obesity-related traits;
PAAD	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	7.91	0.54	5.01e-13	Post bronchodilator FEV1;
PAAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	8.8	0.58	2.86e-15	Homoarginine levels;
PAAD	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.45	4.46	0.34	1.62e-5	Blood metabolite levels;
PAAD	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.7	-0.36	5.7e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	8.34	0.56	4.17e-14	Alzheimer's disease;
PAAD	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-5.09	-0.38	1.07e-6	Asthma;
PAAD	cis	rs1436904	0.903	rs335923	chr18:24530559	A/G	cg26527435	chr18:23807285	TAF4B	-0.45	-4.26	-0.33	3.63e-5	Breast cancer;
PAAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.76	7.58	0.52	3.1e-12	Methadone dose in opioid dependence;
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg08835956	chr7:39171034	POU6F2	0.32	5.58	0.41	1.07e-7	IgG glycosylation;
PAAD	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg01631408	chr1:248437212	OR2T33	-0.6	-5.64	-0.42	7.88e-8	Common traits (Other);
PAAD	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg06484146	chr7:12443880	VWDE	-0.63	-4.73	-0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.85	-5.89	-0.43	2.35e-8	Facial morphology (factor 23);
PAAD	cis	rs9398803	0.723	rs853972	chr6:127068293	C/G	cg19875578	chr6:126661172	C6orf173	-0.42	-4.35	-0.33	2.51e-5	Male-pattern baldness;
PAAD	cis	rs2529218	0.551	rs940480	chr7:101422701	C/T	cg09205156	chr7:101991189	SPDYE6	0.55	4.7	0.36	5.79e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg15226751	chr1:10001911	LZIC	0.38	4.29	0.33	3.19e-5	Hepatocellular carcinoma;
PAAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.5	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.65	7.15	0.5	3.47e-11	Blood protein levels;
PAAD	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.6	-7.16	-0.5	3.2e-11	Cotinine glucuronidation;
PAAD	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.76	8.66	0.57	6.49e-15	Age-related hearing impairment;
PAAD	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.42	-0.56	2.56e-14	Urate levels in overweight individuals;
PAAD	cis	rs7684253	0.548	rs13106200	chr4:57718195	C/T	cg24291500	chr4:57773398	REST	-0.46	-4.82	-0.36	3.41e-6	Migraine;
PAAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.62	-5.98	-0.44	1.52e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-1.09	-9.63	-0.62	1.98e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs10407640	1.000	rs62122212	chr19:34771465	T/G	cg02704949	chr19:35607180	FXYD3	0.3	4.34	0.33	2.55e-5	Functional MRI;
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	1.08	5.84	0.43	3.12e-8	Body mass index;
PAAD	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.59	6.02	0.44	1.27e-8	Menopause (age at onset);
PAAD	cis	rs1075265	0.730	rs4413193	chr2:53938038	G/C	cg04546899	chr2:54196757	PSME4	0.31	4.49	0.34	1.39e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs593531	0.592	rs598869	chr11:74046975	C/T	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.65	-0.35	7.16e-6	Neuroticism;
PAAD	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs12799264	0.915	rs6483624	chr11:19973254	T/C	cg17303119	chr11:19974895	NAV2	0.72	4.42	0.34	1.85e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.19	-0.45	5.3300000000000004e-09	Monocyte count;
PAAD	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg17524180	chr13:113633600	MCF2L	-0.52	-5.68	-0.42	6.79e-8	Systolic blood pressure;
PAAD	cis	rs476633	0.708	rs11857484	chr15:41441734	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.29	-0.56	5.65e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.71	-7.05	-0.5	5.94e-11	Parkinson's disease;
PAAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.55	6.99	0.49	8.05e-11	Schizophrenia;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	cis	rs7084783	0.967	rs1994837	chr10:105332302	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.43	4.39	0.34	2.13e-5	Fear of pain;
PAAD	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg12923728	chr3:195709715	SDHAP1	-0.88	-8.53	-0.57	1.38e-14	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg00933542	chr6:150070202	PCMT1	0.54	5.4	0.4	2.54e-7	Lung cancer;
PAAD	cis	rs2131877	0.645	rs75738250	chr3:194880839	T/A	cg11177333	chr3:195857752	NA	0.44	4.76	0.36	4.54e-6	Non-small cell lung cancer;
PAAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.08	0.38	1.1e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12935418	0.579	rs1477381	chr16:81014700	T/C	cg16651780	chr16:81037892	C16orf61	-0.67	-6.19	-0.45	5.31e-9	Mean corpuscular volume;
PAAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.72	8.04	0.55	2.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.5	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.66	0.77	6.92e-31	Chronic sinus infection;
PAAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.55	5.62	0.41	8.96e-8	Bipolar disorder;
PAAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.77	6.64	0.47	5.21e-10	Cognitive function;
PAAD	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.78	0.48	2.45e-10	Resting heart rate;
PAAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg06217071	chr17:408420	NA	0.64	7.18	0.5	2.9e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs7707921	1.000	rs749402	chr5:81561325	C/T	cg21483461	chr5:81570383	RPS23	-0.55	-4.63	-0.35	7.74e-6	Breast cancer;
PAAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.44	-4.76	-0.36	4.49e-6	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16857335	chr19:47633940	SAE1	0.59	6.58	0.47	6.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg27234864	chr13:21295941	IL17D	0.59	5.21	0.39	6.19e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.46	-4.61	-0.35	8.3e-6	Schizophrenia;
PAAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	1.01	11.76	0.69	4.13e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.69	8.3	0.56	5.28e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg24848339	chr3:12840334	CAND2	0.48	5.0	0.38	1.55e-6	QRS complex (12-leadsum);
PAAD	cis	rs727479	0.962	rs12592697	chr15:51525173	T/C	cg21478137	chr15:51532386	CYP19A1	0.61	6.87	0.49	1.51e-10	Estradiol levels;
PAAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.66	-0.42	7.28e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.46	-4.67	-0.35	6.64e-6	Type 2 diabetes;
PAAD	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03264133	chr6:25882463	NA	0.51	5.05	0.38	1.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs79220007	0.557	rs7765813	chr6:25624395	G/T	cg27081928	chr6:25024340	NA	0.78	4.51	0.34	1.31e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.52	4.3	0.33	3.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.22	-0.39	5.66e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg15192750	chr16:69999425	NA	0.89	6.63	0.47	5.46e-10	IgE levels;
PAAD	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.2	-10.34	-0.64	2.57e-19	Vitiligo;
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-1.0	-6.89	-0.49	1.37e-10	IgG glycosylation;
PAAD	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg12623918	chr2:306882	NA	0.67	5.07	0.38	1.14e-6	Blood protein levels;
PAAD	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.45	-0.34	1.67e-5	Type 2 diabetes;
PAAD	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.55	-0.41	1.22e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.3	-5.23	-0.39	5.44e-7	Type 2 diabetes;
PAAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.72	7.98	0.54	3.22e-13	Melanoma;
PAAD	cis	rs35000415	0.938	rs12539476	chr7:128657483	T/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.69	7.58	0.52	3.08e-12	Melanoma;
PAAD	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.53	-4.93	-0.37	2.12e-6	Schizophrenia;
PAAD	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.88	-0.49	1.49e-10	Morning vs. evening chronotype;
PAAD	cis	rs11264213	0.591	rs558120	chr1:36537640	T/C	cg27506609	chr1:36549197	TEKT2	-0.83	-6.12	-0.44	7.56e-9	Schizophrenia;
PAAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.01	0.67	4.24e-21	Menopause (age at onset);
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg13047869	chr3:10149882	C3orf24	0.71	5.25	0.39	5.07e-7	Alzheimer's disease;
PAAD	cis	rs2882877	0.610	rs13008848	chr2:190445284	C/G	cg10752008	chr2:190445175	SLC40A1	0.54	4.46	0.34	1.57e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs17286411	0.814	rs12708919	chr16:71986995	A/G	cg16558253	chr16:72132732	DHX38	0.42	4.6	0.35	8.69e-6	Blood protein levels;
PAAD	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.49	-5.63	-0.42	8.51e-8	Coronary artery disease;
PAAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25833597	chr17:30823145	MYO1D	-0.52	-5.08	-0.38	1.09e-6	Schizophrenia;
PAAD	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-5.62	-0.41	9.08e-8	Sjögren's syndrome;
PAAD	trans	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs6009527	0.762	rs2873856	chr22:49574543	G/A	cg12746016	chr22:49560550	NA	0.52	5.03	0.38	1.38e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-5.74	-0.42	4.99e-8	Schizophrenia;
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.58	-0.52	3.23e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg26695010	chr11:65641043	EFEMP2	0.55	5.16	0.39	7.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-4.56	-0.35	1.03e-5	Diastolic blood pressure;
PAAD	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.69	7.06	0.5	5.5e-11	Platelet count;
PAAD	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	6.3	0.46	2.98e-9	Mean platelet volume;
PAAD	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg25566285	chr7:158114605	PTPRN2	0.8	6.99	0.49	8.1e-11	Response to amphetamines;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8112211	0.598	rs4802351	chr19:38848796	A/G	cg14299480	chr19:38876666	GGN	-0.55	-5.33	-0.4	3.51e-7	Blood protein levels;
PAAD	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.8	8.25	0.56	7.15e-14	Alzheimer's disease (late onset);
PAAD	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.66	7.13	0.5	3.74e-11	Crohn's disease;
PAAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.73	6.93	0.49	1.14e-10	Methadone dose in opioid dependence;
PAAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.76	6.77	0.48	2.64e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	ch.8.33884649F	chr8:33765107	NA	0.53	5.34	0.4	3.39e-7	Body mass index;
PAAD	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.76	5.47	0.41	1.82e-7	Major depressive disorder;
PAAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg05697835	chr1:2722811	NA	0.43	4.85	0.37	2.99e-6	Ulcerative colitis;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.93	6.93	0.49	1.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg12215294	chr3:40350768	EIF1B	-0.45	-4.33	-0.33	2.72e-5	Renal cell carcinoma;
PAAD	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.89	-8.59	-0.57	9.73e-15	DNA methylation (variation);
PAAD	cis	rs75757892	0.564	rs116129080	chr6:7315480	T/C	cg02954307	chr6:7269328	NA	0.54	4.52	0.34	1.23e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.68	-5.03	-0.38	1.35e-6	Vitiligo;
PAAD	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg25952890	chr19:58913133	NA	0.65	5.42	0.4	2.32e-7	Mean platelet volume;
PAAD	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.28	13.24	0.73	4.18e-27	Corneal structure;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.74	-10.09	-0.63	1.2e-18	Iron status biomarkers;
PAAD	cis	rs6723108	0.603	rs1947112	chr2:135715957	A/G	cg26890182	chr2:135621176	ACMSD	0.3	4.27	0.33	3.41e-5	Type 2 diabetes;
PAAD	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.41	-4.43	-0.34	1.82e-5	Calcium levels;
PAAD	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.15	-0.45	6.59e-9	Menopause (age at onset);
PAAD	cis	rs2282978	0.557	rs2040494	chr7:92256905	C/T	cg06556290	chr7:92222188	NA	-0.45	-4.52	-0.34	1.26e-5	Height;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.54	-0.47	8.73e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05716316	chr15:78799689	AGPHD1	0.59	6.59	0.47	6.96e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.48	-0.34	1.44e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg00024416	chr22:24240387	NA	0.61	6.84	0.49	1.82e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.13	0.6	3.94e-16	Morning vs. evening chronotype;
PAAD	cis	rs6715793	0.702	rs4670225	chr2:33402392	C/T	cg26672287	chr2:33391915	LTBP1	0.39	4.68	0.35	6.35e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs600550	0.588	rs11230251	chr11:60088755	G/A	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs8523	0.564	rs2876213	chr6:10951712	G/A	cg03009363	chr6:10419400	TFAP2A	-0.37	-4.26	-0.33	3.59e-5	Red blood cell fatty acid levels;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.77	-6.79	-0.48	2.42e-10	Vitiligo;
PAAD	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-4.32	-0.33	2.86e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4731207	0.596	rs10264766	chr7:124572916	T/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.52	-0.34	1.22e-5	Cutaneous malignant melanoma;
PAAD	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	7.92e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.95	10.41	0.65	1.73e-19	Blood metabolite levels;
PAAD	cis	rs28493229	0.786	rs3745213	chr19:41248009	C/T	cg21869046	chr19:41225005	ITPKC	0.61	6.47	0.46	1.3e-9	Kawasaki disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19701416	chr10:28592092	NA	0.63	7.2	0.5	2.58e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10090774	0.965	rs12677559	chr8:141956904	T/C	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26926768	chr12:34528122	NA	0.39	4.81	0.36	3.58e-6	Morning vs. evening chronotype;
PAAD	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.78	-0.42	4.02e-8	Eye color traits;
PAAD	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.56	-7.4	-0.51	8.64e-12	Urate levels in overweight individuals;
PAAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg21875980	chr1:231553510	EGLN1	-0.46	-4.37	-0.33	2.31e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg26695010	chr11:65641043	EFEMP2	0.55	5.16	0.39	7.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.23	-0.45	4.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	5.21	0.39	5.98e-7	Diastolic blood pressure;
PAAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.73	7.83	0.54	7.87e-13	Schizophrenia;
PAAD	cis	rs11997175	0.653	rs4268089	chr8:33626532	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	6.25	0.45	3.94e-9	Body mass index;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.63	0.53	2.45e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg27542038	chr10:14027202	FRMD4A	-0.46	-4.75	-0.36	4.61e-6	Adiponectin levels;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-6.8	-0.48	2.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.88	-10.16	-0.64	7.76e-19	Caffeine consumption;
PAAD	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08538581	chr1:162500634	NA	0.61	6.6	0.47	6.47e-10	Smoking initiation;
PAAD	cis	rs820218	0.728	rs820149	chr17:73615933	T/C	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.28	-0.33	3.24e-5	Rotator cuff tears;
PAAD	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg16584290	chr5:462447	EXOC3	-0.43	-4.64	-0.35	7.44e-6	Cystic fibrosis severity;
PAAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.55	5.25	0.39	5.05e-7	Tonsillectomy;
PAAD	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs7255045	0.582	rs4804209	chr19:12985955	G/C	cg09980403	chr19:12975529	MAST1	0.33	4.99	0.38	1.62e-6	Mean corpuscular volume;
PAAD	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.57	6.52	0.47	9.62e-10	Schizophrenia;
PAAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg19052272	chr2:3704530	ALLC	-0.58	-6.58	-0.47	7.32e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9907295	0.636	rs4251703	chr17:34134958	T/C	cg19411729	chr17:34207663	CCL5	-0.49	-4.37	-0.33	2.33e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-4.41	-0.34	1.94e-5	Metabolite levels;
PAAD	cis	rs6844506	0.607	rs2136758	chr4:185226060	T/A	cg12654155	chr4:185238627	NA	-0.45	-4.35	-0.33	2.48e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs78472555	0.633	rs8034889	chr15:100239546	T/C	cg18869061	chr15:100272053	LYSMD4	0.49	4.33	0.33	2.65e-5	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.53	4.78	0.36	4.14e-6	Anxiety disorder;
PAAD	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.45	-0.34	1.68e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs910187	0.591	rs13041142	chr20:45788979	C/T	cg27589058	chr20:45804311	EYA2	-0.43	-4.47	-0.34	1.52e-5	Migraine;
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg17105886	chr17:28927953	LRRC37B2	0.67	4.47	0.34	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs829661	0.843	rs829616	chr2:30747996	T/A	cg12454169	chr2:30669597	LCLAT1	0.59	4.25	0.33	3.72e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs3026101	0.624	rs1058400	chr17:5288794	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.45	0.4	1.98e-7	Body mass index;
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-9.48	-0.61	5.02e-17	Colorectal cancer;
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.63	7.01	0.49	7.31e-11	Body mass index;
PAAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.58e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.61	6.39	0.46	1.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.6	4.83	0.36	3.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs73019876	0.869	rs1849006	chr19:22142764	A/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs9283706	0.595	rs1115252	chr5:66322741	A/G	cg11590213	chr5:66331682	MAST4	0.6	5.0	0.38	1.59e-6	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15906515	chr17:65740062	NOL11	-0.67	-6.96	-0.49	9.46e-11	Obesity-related traits;
PAAD	cis	rs6908034	0.660	rs76322282	chr6:19801660	G/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.42	0.34	1.9e-5	Plateletcrit;
PAAD	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.43	5.68	0.42	6.71e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.83	-5.37	-0.4	2.92e-7	Diabetic kidney disease;
PAAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs11825685	0.607	rs61327677	chr11:134552340	C/A	cg02089395	chr11:134479357	NA	-0.64	-4.88	-0.37	2.62e-6	IgG glycosylation;
PAAD	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg19630374	chr17:18023558	MYO15A	-0.55	-5.97	-0.44	1.65e-8	Total body bone mineral density;
PAAD	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.81	9.61	0.61	2.19e-17	Morning vs. evening chronotype;
PAAD	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-4.34	-0.33	2.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.584	rs556434	chr10:44732519	T/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18404041	chr3:52824283	ITIH1	0.41	4.42	0.34	1.89e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs300774	0.925	rs300734	chr2:167167	T/G	cg21211680	chr2:198530	NA	-0.65	-5.98	-0.44	1.51e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.8	-7.89	-0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.77	0.48	2.59e-10	Height;
PAAD	cis	rs2610025	0.694	rs17768737	chr8:57443453	C/T	cg25937216	chr8:58172855	NA	0.45	4.29	0.33	3.19e-5	Suicide in bipolar disorder;
PAAD	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-10.33	-0.64	2.86e-19	Height;
PAAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.33	0.33	2.74e-5	IgG glycosylation;
PAAD	cis	rs593531	0.614	rs10736795	chr11:74039546	A/G	cg23327896	chr11:73669290	DNAJB13	-0.37	-4.62	-0.35	8.27e-6	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03694875	chr16:435915	LOC100134368	-0.55	-6.55	-0.47	8.38e-10	Monocyte percentage of white cells;
PAAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.32	0.33	2.8e-5	Menopause (age at onset);
PAAD	cis	rs7765175	0.598	rs2801437	chr6:113653579	G/A	cg19037598	chr6:113666021	NA	-0.42	-4.62	-0.35	7.96e-6	Coronary artery calcification;
PAAD	cis	rs3736485	0.966	rs11634039	chr15:51895575	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.86e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-5.99	-0.44	1.44e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.75	0.53	1.24e-12	Motion sickness;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg02524346	chr8:600233	NA	-1.17	-7.72	-0.53	1.47e-12	IgG glycosylation;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-0.75	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.55	-4.92	-0.37	2.21e-6	Monocyte count;
PAAD	cis	rs17655565	0.505	rs2658654	chr12:52759239	G/A	cg15701111	chr12:52685334	KRT81	0.48	4.25	0.33	3.66e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.7	7.56	0.52	3.47e-12	Blood protein levels;
PAAD	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.5	5.05	0.38	1.26e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.56	-5.41	-0.4	2.4e-7	P wave terminal force;
PAAD	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg19423196	chr10:82049429	MAT1A	0.53	4.94	0.37	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01280202	chr4:75719350	BTC	0.75	7.72	0.53	1.47e-12	Obesity-related traits;
PAAD	cis	rs5771225	0.505	rs5771111	chr22:50695946	C/G	cg16473166	chr22:50639996	SELO	0.6	5.1	0.38	1e-6	Late-onset Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs757081	0.671	rs214072	chr11:17305270	C/T	cg15432903	chr11:17409602	KCNJ11	-0.65	-6.23	-0.45	4.31e-9	Systolic blood pressure;
PAAD	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	5.29	0.39	4.11e-7	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.71	7.8	0.53	9.13e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs1035491	0.715	rs3846478	chr5:63922006	G/A	cg01791865	chr5:63954708	NA	0.52	5.59	0.41	1.04e-7	Body mass index;
PAAD	cis	rs6449957	0.932	rs7734515	chr5:67483955	C/T	cg23036683	chr5:67512108	NA	0.53	5.21	0.39	5.99e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg14349672	chr11:133703707	NA	-0.49	-5.39	-0.4	2.69e-7	Childhood ear infection;
PAAD	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.62	6.4	0.46	1.84e-9	Height;
PAAD	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21643547	chr1:205240462	TMCC2	-0.4	-4.46	-0.34	1.57e-5	Red blood cell count;
PAAD	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg22517653	chr1:2918612	NA	-0.63	-5.02	-0.38	1.42e-6	Plateletcrit;
PAAD	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs10750165	0.716	rs35662046	chr11:119654326	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21885897	chr19:44008145	PHLDB3	-0.73	-6.47	-0.46	1.28e-9	Neuroticism;
PAAD	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.77	6.86	0.49	1.6e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.51	4.86	0.37	2.93e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	5.88	0.43	2.48e-8	Personality dimensions;
PAAD	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	8.24	0.56	7.31e-14	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	4.51	0.34	1.31e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	4.81	0.36	3.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11245990	chr11:68621969	NA	0.39	5.12	0.38	9.06e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.51	-5.28	-0.39	4.46e-7	Schizophrenia;
PAAD	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.11	0.5	4.22e-11	IgG glycosylation;
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.64	6.72	0.48	3.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.67	-6.97	-0.49	8.92e-11	Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-5.82	-0.43	3.44e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-1.0	-10.8	-0.66	1.52e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	4.97	0.37	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg27449745	chr7:23145252	KLHL7	0.53	4.75	0.36	4.58e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7301016	1.000	rs7962519	chr12:62868885	T/G	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs863345	0.604	rs11264983	chr1:158462218	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9810890	1.000	rs114352136	chr3:128440226	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.14e-6	Testicular germ cell tumor;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00251705	chr11:57434686	ZDHHC5	0.6	6.74	0.48	3.06e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.73	7.23	0.51	2.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9488822	0.651	rs521985	chr6:116264940	G/A	cg18764771	chr6:116381957	FRK	-0.26	-4.25	-0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1879734	0.636	rs11206202	chr1:54174607	A/G	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-4.85	-0.37	3.09e-6	Resting heart rate;
PAAD	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.67	5.78	0.42	4.06e-8	Common traits (Other);
PAAD	cis	rs4731207	0.596	rs10244797	chr7:124571684	C/T	cg14311320	chr7:124405732	GPR37	-0.45	-4.7	-0.36	5.73e-6	Cutaneous malignant melanoma;
PAAD	cis	rs7260598	0.539	rs73525890	chr19:24069911	G/T	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10819733	chr22:24237672	NA	-0.48	-5.11	-0.38	9.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7627468	0.770	rs1965358	chr3:121970301	G/A	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.8e-5	Kidney stones;
PAAD	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.89	0.43	2.45e-8	Tonsillectomy;
PAAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.48	-5.65	-0.42	7.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1656368	0.649	rs73154306	chr3:158211922	T/C	cg16708174	chr3:158430962	RARRES1	0.64	5.82	0.43	3.33e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.75	8.6	0.57	9.19e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18364779	chr6:26104403	HIST1H4C	0.46	4.62	0.35	8.08e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	8.75	0.58	3.82e-15	Alzheimer's disease;
PAAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg26695010	chr11:65641043	EFEMP2	-0.44	-4.27	-0.33	3.45e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21234914	chr17:63204728	RGS9	-0.64	-6.37	-0.46	2.1e-9	Obesity-related traits;
PAAD	cis	rs79911532	0.551	rs41301427	chr7:75614557	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.84	-5.19	-0.39	6.52e-7	Mononucleosis;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg16590910	chr6:42928470	GNMT	0.48	4.67	0.35	6.56e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.59	-0.41	1e-7	Corneal astigmatism;
PAAD	cis	rs7932354	0.583	rs1007738	chr11:46849360	A/G	cg19486271	chr11:47235900	DDB2	0.57	5.75	0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6850606	0.577	rs12503289	chr4:42868690	C/A	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.62	6.77	0.48	2.64e-10	Vitiligo;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-7.32	-0.51	1.33e-11	Menarche (age at onset);
PAAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	cis	rs8049603	0.812	rs4073930	chr16:23195646	C/T	cg16484020	chr16:23217411	SCNN1G	0.49	4.35	0.33	2.51e-5	Multiple sclerosis;
PAAD	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.78	-0.53	1.06e-12	Neuroticism;
PAAD	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.43	4.66	0.35	6.99e-6	Depression;
PAAD	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.78	-0.36	4.05e-6	Biliary atresia;
PAAD	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	14.43	0.76	2.86e-30	Testicular germ cell tumor;
PAAD	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg01970496	chr2:177005398	NA	-0.51	-4.26	-0.33	3.53e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22162314	chr17:61951766	CSH2	-0.57	-5.8	-0.43	3.67e-8	Height;
PAAD	cis	rs8008758	1.000	rs8008758	chr14:101690045	A/C	cg26224664	chr14:101693935	NA	0.43	4.31	0.33	2.9e-5	Body mass index (alcohol intake interaction);
PAAD	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.49	-0.47	1.16e-9	Bipolar disorder;
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg24112000	chr20:60950667	NA	0.69	8.65	0.57	6.71e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.54e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.54	-6.23	-0.45	4.37e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs8040855	0.576	rs62022527	chr15:85531253	A/G	cg08123816	chr15:85640762	PDE8A	-0.41	-4.55	-0.35	1.08e-5	Bulimia nervosa;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.69	7.07	0.5	5.33e-11	Menarche (age at onset);
PAAD	cis	rs2790216	1.000	rs1199103	chr10:59947231	C/T	cg20442379	chr10:60024634	IPMK	0.6	4.6	0.35	8.68e-6	Inflammatory bowel disease;
PAAD	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	11.93	0.7	1.44e-23	Cognitive ability;
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.62	-5.76	-0.42	4.46e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs990171	1.000	rs2110734	chr2:103052206	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.54	4.73	0.36	4.98e-6	Coronary artery disease;
PAAD	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg26209169	chr5:1316264	NA	0.37	4.39	0.34	2.13e-5	Lung cancer;
PAAD	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.66	-7.17	-0.5	3.07e-11	Colorectal cancer;
PAAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.75e-17	Rheumatoid arthritis;
PAAD	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg21535247	chr6:8435926	SLC35B3	-0.47	-4.53	-0.34	1.19e-5	Motion sickness;
PAAD	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.55	6.17	0.45	5.86e-9	Mean corpuscular volume;
PAAD	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.44	-5.34	-0.4	3.26e-7	Colorectal cancer;
PAAD	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg15443732	chr18:74961078	GALR1	0.6	5.44	0.4	2.05e-7	Obesity-related traits;
PAAD	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.65	-6.54	-0.47	8.65e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10342447	chr17:26645325	TMEM97	-0.5	-6.49	-0.47	1.12e-9	Osteoprotegerin levels;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.52	-0.34	1.24e-5	Biliary atresia;
PAAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.41	-0.34	1.97e-5	Schizophrenia;
PAAD	cis	rs593531	0.614	rs623065	chr11:74071210	A/G	cg23327896	chr11:73669290	DNAJB13	-0.36	-4.64	-0.35	7.57e-6	Neuroticism;
PAAD	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.74e-11	Response to antipsychotic treatment;
PAAD	cis	rs17032980	0.910	rs1921278	chr2:67329806	A/T	cg02551743	chr2:66673428	MEIS1	-0.49	-4.34	-0.33	2.55e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20890180	chr2:106560771	NA	0.65	6.9	0.49	1.3e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.63	-5.93	-0.43	1.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg02734326	chr4:10020555	SLC2A9	-0.52	-5.04	-0.38	1.29e-6	Bone mineral density;
PAAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.69	7.23	0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs4287000	0.802	rs10761245	chr9:96387675	A/G	cg13787134	chr9:96362102	PHF2	-0.38	-4.48	-0.34	1.47e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs689449	0.549	rs16835902	chr3:124445764	C/G	cg05638699	chr3:124449152	UMPS	-0.44	-4.42	-0.34	1.88e-5	Mean platelet volume;
PAAD	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.67	-6.77	-0.48	2.58e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg22029157	chr1:209979665	IRF6	0.68	6.26	0.45	3.77e-9	Coronary artery disease;
PAAD	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Diabetic kidney disease;
PAAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.79	-9.83	-0.62	5.95e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg06112835	chr11:68658793	MRPL21	0.45	4.88	0.37	2.71e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.71	8.69	0.58	5.25e-15	Obesity (extreme);
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.88	-14.58	-0.76	1.15e-30	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg10495392	chr1:46806563	NSUN4	0.59	5.82	0.43	3.4e-8	Menopause (age at onset);
PAAD	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.83	-6.84	-0.49	1.79e-10	Diastolic blood pressure;
PAAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg00999904	chr2:3704751	ALLC	-0.44	-5.06	-0.38	1.18e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.49	-0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.59	5.38	0.4	2.73e-7	Mean platelet volume;
PAAD	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20540806	chr5:140019523	TMCO6	-0.64	-6.71	-0.48	3.62e-10	Smoking initiation;
PAAD	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.73	0.36	5.16e-6	Serum sulfate level;
PAAD	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg19192590	chr2:178524533	PDE11A	0.4	4.7	0.36	5.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs116175783	0.793	rs1267044	chr2:162127611	C/T	cg08807892	chr2:162101083	NA	-0.7	-5.11	-0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.65	6.18	0.45	5.7e-9	Corneal astigmatism;
PAAD	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs757081	0.648	rs214102	chr11:17288298	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-5.98	-0.44	1.5e-8	Systolic blood pressure;
PAAD	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg01489256	chr8:11204017	TDH	0.43	4.32	0.33	2.78e-5	Retinal vascular caliber;
PAAD	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.14	10.89	0.66	8.79e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.5	0.47	1.07e-9	Height;
PAAD	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	9.92	0.63	3.43e-18	Platelet count;
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.72	7.34	0.51	1.23e-11	Height;
PAAD	cis	rs490234	0.966	rs534214	chr9:128369224	A/G	cg14078157	chr9:128172775	NA	-0.4	-4.37	-0.33	2.33e-5	Mean arterial pressure;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.76	6.7	0.48	3.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-4.94	-0.37	2.07e-6	Menarche (age at onset);
PAAD	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Subjective well-being;
PAAD	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.61	-0.41	9.1e-8	Schizophrenia (age at onset);
PAAD	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.88	7.29	0.51	1.62e-11	Neutrophil percentage of white cells;
PAAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg00750074	chr16:89608354	SPG7	-0.6	-5.81	-0.43	3.54e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg22800045	chr5:56110881	MAP3K1	0.7	5.78	0.42	4e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs13034020	0.522	rs13017457	chr2:61248645	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20032179	chr7:43946391	URGCP	-0.82	-7.03	-0.5	6.41e-11	Neuroticism;
PAAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg02734326	chr4:10020555	SLC2A9	-0.52	-5.01	-0.38	1.48e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs714031	0.867	rs5750868	chr22:40063012	G/A	cg21377881	chr22:40064566	CACNA1I	-0.45	-4.34	-0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg01338255	chr20:30176054	NA	0.44	4.26	0.33	3.63e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.69	-6.92	-0.49	1.17e-10	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.09e-6	Life satisfaction;
PAAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1413885	0.966	rs12092795	chr1:65815154	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.06	0.38	1.19e-6	Anticoagulant levels;
PAAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.65	9.02	0.59	7.7e-16	Height;
PAAD	cis	rs965469	0.779	rs2236115	chr20:3296279	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.55	5.56	0.41	1.15e-7	Menopause (age at onset);
PAAD	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.91	7.07	0.5	5.33e-11	Axial length;
PAAD	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.81	9.49	0.61	4.48e-17	Blood metabolite ratios;
PAAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	-0.32	-4.69	-0.36	6.13e-6	Asthma;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.49	-0.41	1.64e-7	Blood metabolite levels;
PAAD	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.14	-0.38	8.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg06287003	chr12:125626642	AACS	-0.46	-4.26	-0.33	3.56e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25750404	chr12:6579648	VAMP1	0.66	7.32	0.51	1.31e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.19	0.5	2.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7129556	0.954	rs2032395	chr11:77314503	A/G	cg24456632	chr11:77314957	AQP11	-0.52	-4.54	-0.35	1.13e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg19630374	chr17:18023558	MYO15A	-0.56	-6.02	-0.44	1.26e-8	Total body bone mineral density;
PAAD	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.6	0.52	2.89e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.31e-6	Type 2 diabetes;
PAAD	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg26898376	chr11:64110657	CCDC88B	0.44	4.7	0.36	5.68e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.6	5.74	0.42	4.89e-8	Cancer;
PAAD	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg01942863	chr7:99769432	GPC2	0.53	4.95	0.37	1.94e-6	Coronary artery disease;
PAAD	cis	rs1468333	1.000	rs217274	chr5:137490974	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.95e-9	Resting heart rate;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.2	-0.45	5.04e-9	Lung cancer;
PAAD	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg01503450	chr10:980765	NA	-0.53	-4.4	-0.34	2.03e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7084783	0.519	rs1047425	chr10:105345201	C/A	cg09754828	chr10:105363329	SH3PXD2A	0.44	4.29	0.33	3.11e-5	Fear of pain;
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.67	7.08	0.5	4.91e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.98	-0.44	1.57e-8	Menarche (age at onset);
PAAD	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg25256661	chr17:7137939	DVL2	0.91	9.73	0.62	1.09e-17	Diastolic blood pressure;
PAAD	cis	rs116248771	0.690	rs16847125	chr3:158417699	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.71	5.76	0.42	4.49e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg10090792	chr1:38198142	EPHA10	-0.41	-4.43	-0.34	1.81e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	1.04	7.11	0.5	4.15e-11	Mitochondrial DNA levels;
PAAD	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.32	4.31	0.33	2.93e-5	Dupuytren's disease;
PAAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.61	-4.53	-0.34	1.21e-5	Multiple sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13232119	chr14:69283484	NA	0.69	7.71	0.53	1.52e-12	Myopia (pathological);
PAAD	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	8.87	0.58	1.9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg00031303	chr3:195681400	NA	0.67	6.65	0.47	4.88e-10	Pancreatic cancer;
PAAD	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.68	-5.65	-0.42	7.63e-8	Fibrinogen levels;
PAAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.34	16.32	0.8	3.13e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg15685922	chr1:156045208	MEX3A	-0.69	-8.24	-0.56	7.32e-14	Ischemic stroke;
PAAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg16928487	chr17:17741425	SREBF1	-0.34	-4.77	-0.36	4.26e-6	Total body bone mineral density;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-6.61	-0.47	6.2e-10	Lymphocyte counts;
PAAD	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg16691251	chr5:66510806	NA	0.73	7.84	0.54	7.47e-13	Breast cancer;
PAAD	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.09	9.26	0.6	1.86e-16	Alzheimer's disease;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.28	0.39	4.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.9	7.34	0.51	1.2e-11	Obesity-related traits;
PAAD	cis	rs7572263	0.959	rs6725512	chr2:209050418	A/G	cg23998903	chr2:209048830	C2orf80	-0.49	-4.68	-0.36	6.25e-6	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg26958924	chr4:6296934	WFS1	0.45	4.39	0.34	2.13e-5	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs9303029	1.000	rs72859125	chr17:80427975	G/A	cg19292749	chr17:79650816	ARL16;HGS	-0.59	-4.5	-0.34	1.32e-5	Protein quantitative trait loci;
PAAD	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.23	12.69	0.72	1.3e-25	Platelet count;
PAAD	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.55	-0.52	3.69e-12	Total body bone mineral density;
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07648498	chr16:89883185	FANCA	0.69	7.27	0.51	1.79e-11	Vitiligo;
PAAD	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.58	5.64	0.42	7.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg26816564	chr1:7831052	VAMP3	-0.61	-5.21	-0.39	6.09e-7	Inflammatory bowel disease;
PAAD	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.53	4.9	0.37	2.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1519814	0.696	rs4871031	chr8:121031777	T/C	cg22335954	chr8:121166405	COL14A1	-0.64	-4.97	-0.37	1.75e-6	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.49	4.96	0.37	1.85e-6	Height;
PAAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg03161606	chr19:29218774	NA	0.59	4.36	0.33	2.36e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg20129853	chr10:51489980	NA	-0.48	-4.61	-0.35	8.42e-6	Prostate-specific antigen levels;
PAAD	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.13	0.38	8.57e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs790110	1.000	rs2668336	chr3:122384469	T/A	cg22468055	chr3:122334227	PARP15	0.84	4.67	0.35	6.47e-6	Acoustic startle blink response;
PAAD	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg03805757	chr16:71968109	PKD1L3	-0.64	-5.72	-0.42	5.46e-8	Post bronchodilator FEV1;
PAAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.4	0.34	2.04e-5	Asthma;
PAAD	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg02683114	chr2:24398427	C2orf84	-0.6	-6.39	-0.46	1.96e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.51	-5.28	-0.39	4.3e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06696917	chr16:58718412	SLC38A7	0.56	6.53	0.47	9.22e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.4	-0.4	2.53e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.78	-0.42	4.16e-8	Type 2 diabetes;
PAAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.84	0.48	1.85e-10	Body mass index;
PAAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	5.43	0.4	2.2e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.62	0.65	4.73e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.8	9.29	0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs728616	0.681	rs117420340	chr10:82166495	T/C	cg05935833	chr10:81318306	SFTPA2	-0.56	-4.52	-0.34	1.26e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.63	7.04	0.5	6.16e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.94	11.39	0.68	4.13e-22	Lewy body disease;
PAAD	cis	rs3771514	0.666	rs535331	chr2:70671426	T/C	cg21989299	chr2:70484546	PCYOX1	0.46	4.31	0.33	2.87e-5	Obesity-related traits;
PAAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	7.75e-7	Aortic root size;
PAAD	cis	rs35791980	0.534	rs35429354	chr7:76950928	T/A	cg02756451	chr7:76178720	LOC100133091	0.52	4.46	0.34	1.62e-5	Pursuit maintenance gain;
PAAD	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.21	-0.39	5.96e-7	Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.24	0.39	5.27e-7	Personality dimensions;
PAAD	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.43	-4.45	-0.34	1.63e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs9810890	1.000	rs6778057	chr3:128647823	A/G	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	trans	rs901683	0.850	rs79319916	chr10:46073980	C/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.29	-0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg16606324	chr3:10149918	C3orf24	0.55	4.73	0.36	4.99e-6	Alzheimer's disease;
PAAD	cis	rs3106136	0.649	rs6532487	chr4:95300493	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.06	0.38	1.19e-6	Capecitabine sensitivity;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.51	4.93	0.37	2.14e-6	Lung cancer;
PAAD	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.49	4.49	0.34	1.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24902987	chr3:138170766	ESYT3	-0.65	-6.31	-0.46	2.86e-9	Obesity-related traits;
PAAD	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg16928487	chr17:17741425	SREBF1	-0.34	-4.66	-0.35	6.86e-6	Total body bone mineral density;
PAAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg10547527	chr2:198650123	BOLL	-0.71	-4.89	-0.37	2.51e-6	Ulcerative colitis;
PAAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-7.39	-0.51	9.1e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg21565972	chr17:80109576	CCDC57	0.5	5.52	0.41	1.45e-7	Life satisfaction;
PAAD	cis	rs7552393	0.636	rs6576950	chr1:84273342	T/A	cg10977910	chr1:84465055	TTLL7	0.59	5.52	0.41	1.41e-7	Select biomarker traits;
PAAD	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg01236616	chr12:121019343	POP5	0.46	4.31	0.33	2.97e-5	High light scatter reticulocyte count;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06420324	chr11:73309256	FAM168A	-0.63	-7.42	-0.52	7.53e-12	Body fat percentage;
PAAD	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.71	9.58	0.61	2.64e-17	Hemoglobin concentration;
PAAD	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.94	12.58	0.71	2.51e-25	Menarche (age at onset);
PAAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg01075559	chr1:2537774	MMEL1	0.53	5.52	0.41	1.43e-7	Ulcerative colitis;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03404566	chr17:6899310	ALOX12	-0.43	-4.45	-0.34	1.63e-5	Tonsillectomy;
PAAD	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg03116837	chr8:216703	NA	0.55	5.0	0.38	1.59e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.45	-0.4	1.97e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.09	0.44	9.02e-9	Schizophrenia;
PAAD	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs4654748	0.741	rs1106357	chr1:21817085	C/T	cg02390115	chr1:21767211	NBPF3	0.61	6.35	0.46	2.4e-9	Folate pathway vitamin levels;
PAAD	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.84	9.51	0.61	4.19e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6024905	1.000	rs4592915	chr20:36957921	G/T	cg07053727	chr20:36965646	BPI	0.46	4.87	0.37	2.77e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg05304507	chr6:116381966	FRK	-0.41	-7.87	-0.54	6.25e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05596267	chr15:34331198	CHRM5;AVEN	0.66	7.56	0.52	3.51e-12	Myopia (pathological);
PAAD	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.4	-4.64	-0.35	7.57e-6	Inflammatory bowel disease;
PAAD	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-5.38	-0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.56	-6.15	-0.45	6.55e-9	Psychosis in Alzheimer's disease;
PAAD	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg01612440	chr4:3296283	NA	0.47	4.58	0.35	9.55e-6	Serum sulfate level;
PAAD	cis	rs3206736	0.548	rs329233	chr7:35055831	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.95	-8.3	-0.56	5.21e-14	Body mass index;
PAAD	cis	rs617219	0.737	rs12659709	chr5:78458257	C/G	cg24856658	chr5:78533917	JMY	-0.39	-4.44	-0.34	1.73e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-0.93	-6.15	-0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.88	0.43	2.49e-8	Lung cancer;
PAAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.53	5.17	0.39	7.18e-7	Migraine;
PAAD	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg17325771	chr7:75508891	RHBDD2	-0.32	-4.63	-0.35	7.67e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05212510	chr18:77623544	KCNG2	-0.45	-4.63	-0.35	7.93e-6	Schizophrenia;
PAAD	cis	rs6594713	0.851	rs7717630	chr5:112704266	A/G	cg12552261	chr5:112820674	MCC	0.65	5.22	0.39	5.9e-7	Brain cytoarchitecture;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.7	-0.36	5.72e-6	Breast cancer;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs9652601	0.779	rs725613	chr16:11169683	T/G	cg04616529	chr16:11181986	CLEC16A	0.46	5.25	0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.98	8.18	0.55	1.07e-13	Neutrophil percentage of white cells;
PAAD	cis	rs11951515	0.508	rs67261887	chr5:43612441	T/A	cg01983248	chr5:43482804	C5orf28	-0.3	-4.34	-0.33	2.63e-5	Metabolite levels  (X-11787);
PAAD	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-1.09	-4.95	-0.37	1.95e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24110177	chr3:50126178	RBM5	0.62	6.53	0.47	9.11e-10	Body mass index;
PAAD	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs11264213	0.591	rs603945	chr1:36490186	C/T	cg27506609	chr1:36549197	TEKT2	-0.81	-5.96	-0.44	1.71e-8	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs2415984	0.583	rs2642090	chr14:46968788	C/T	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.52e-5	Electrocardiographic conduction measures;
PAAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg06521852	chr22:38141419	TRIOBP	-0.43	-4.45	-0.34	1.62e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2555155	0.808	rs11604960	chr11:6528619	T/G	cg24637308	chr11:6592297	DNHD1	0.49	5.11	0.38	9.46e-7	DNA methylation (variation);
PAAD	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.78	-5.14	-0.38	8.36e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	1.0	13.27	0.73	3.62e-27	Menopause (age at onset);
PAAD	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.42	-0.56	2.67e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2637266	0.714	rs7082421	chr10:78446313	G/A	cg18941641	chr10:78392320	NA	0.36	4.35	0.33	2.51e-5	Pulmonary function;
PAAD	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs3026101	0.578	rs1806238	chr17:5295502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg11062466	chr8:58055876	NA	0.68	4.98	0.37	1.7e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.62	1.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.79	6.68	0.48	4.21e-10	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.66	-7.36	-0.51	1.08e-11	Total body bone mineral density;
PAAD	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.53	-5.11	-0.38	9.67e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	5.08	0.38	1.1e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.62	5.79	0.43	3.85e-8	Blood protein levels;
PAAD	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	4.98e-7	Coronary artery disease;
PAAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg07371521	chr5:154026371	NA	0.54	6.84	0.49	1.82e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13047869	chr3:10149882	C3orf24	0.67	5.59	0.41	1.04e-7	Alzheimer's disease;
PAAD	cis	rs617219	0.737	rs1915706	chr5:78436211	C/T	cg24856658	chr5:78533917	JMY	-0.41	-4.51	-0.34	1.28e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs6466055	0.661	rs2299327	chr7:104905252	C/T	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.89	0.37	2.59e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.89	11.01	0.67	4.24e-21	Prudent dietary pattern;
PAAD	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg23153227	chr6:27725408	NA	0.43	4.41	0.34	1.94e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.8	-0.43	3.64e-8	Blood pressure (smoking interaction);
PAAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.68	4.84	0.37	3.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg01616529	chr11:638424	DRD4	-0.61	-6.22	-0.45	4.52e-9	Systemic lupus erythematosus;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	0.97	5.94	0.43	1.86e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	cis	rs10512697	0.655	rs62337684	chr5:3491889	G/C	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg10729496	chr3:10149963	C3orf24	-0.87	-7.25	-0.51	1.97e-11	Alzheimer's disease;
PAAD	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.6	-5.4	-0.4	2.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg08917208	chr2:24149416	ATAD2B	-0.55	-4.92	-0.37	2.24e-6	Asthma;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.51	-5.62	-0.41	8.97e-8	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg23283495	chr1:209979779	IRF6	-0.75	-6.6	-0.47	6.38e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.65	0.42	7.51e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.85	10.75	0.66	2.06e-20	Height;
PAAD	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.85	9.28	0.6	1.63e-16	Mortality in heart failure;
PAAD	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.78	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	5.66	0.42	7.16e-8	Calcium levels;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01114163	chr5:1856713	NA	-0.42	-4.43	-0.34	1.78e-5	Cardiovascular disease risk factors;
PAAD	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs72960926	1.000	rs16884733	chr6:75064563	A/G	cg03266952	chr6:74778945	NA	-1.07	-5.76	-0.42	4.45e-8	Metabolite levels (MHPG);
PAAD	cis	rs6596100	0.538	rs4705972	chr5:132179237	T/A	cg14825688	chr5:132208181	LEAP2	-0.68	-4.84	-0.37	3.15e-6	Breast cancer;
PAAD	cis	rs282587	0.569	rs9604422	chr13:113410586	C/T	cg19217778	chr13:113420270	ATP11A	-0.54	-4.3	-0.33	3.03e-5	Glycated hemoglobin levels;
PAAD	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.64	4.99	0.38	1.6e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.5	-4.79	-0.36	4e-6	Mean platelet volume;
PAAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg20517616	chr2:26468218	HADHA;HADHB	0.59	4.39	0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.85	0.43	2.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7577696	0.850	rs2566483	chr2:32484467	G/A	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.78e-6	Inflammatory biomarkers;
PAAD	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.82e-6	Iron status biomarkers;
PAAD	cis	rs375066	0.901	rs376457	chr19:44412757	C/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06497621	chr16:9185470	C16orf72	-0.6	-7.16	-0.5	3.3e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7624766	0.555	rs1851378	chr3:160513520	G/T	cg22637730	chr3:160473554	PPM1L	-0.53	-4.62	-0.35	8.29e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.92	0.37	2.19e-6	Ovarian reserve;
PAAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg19847866	chr10:1019161	NA	-0.58	-4.51	-0.34	1.3e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.94	0.37	2.06e-6	Ovarian reserve;
PAAD	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.4	0.34	2.01e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2997447	0.761	rs17257127	chr1:26452386	C/T	cg24519413	chr1:26490540	NA	0.48	4.3	0.33	3.02e-5	QRS complex (12-leadsum);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14822696	chr17:79935258	ASPSCR1	0.63	6.97	0.49	8.87e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg10437265	chr15:77819839	NA	0.4	4.38	0.34	2.16e-5	Type 2 diabetes;
PAAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg06740227	chr12:86229804	RASSF9	0.59	5.2	0.39	6.35e-7	Major depressive disorder;
PAAD	cis	rs986417	1.000	rs1956555	chr14:60968804	A/G	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-4.58	-0.35	9.55e-6	Menarche (age at onset);
PAAD	cis	rs71520386	0.632	rs10253651	chr7:22870183	A/G	cg04907244	chr7:22894795	SNORD93	0.47	5.21	0.39	6.1e-7	Fibrinogen levels;
PAAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg08886695	chr4:3369023	RGS12	0.53	5.26	0.39	4.77e-7	Mean platelet volume;
PAAD	cis	rs9287719	0.649	rs10175884	chr2:10718534	C/T	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs904092	0.573	rs7684914	chr4:100174544	C/A	cg12011299	chr4:100065546	ADH4	-0.5	-4.6	-0.35	8.82e-6	Alcohol dependence;
PAAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-5.81	-0.43	3.58e-8	Yeast infection;
PAAD	cis	rs9633835	0.504	rs10766075	chr11:13318587	C/T	cg15603424	chr11:13300592	ARNTL	-0.51	-4.33	-0.33	2.72e-5	Body mass index;
PAAD	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.95	-10.22	-0.64	5.48e-19	Monocyte count;
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg27532560	chr4:187881888	NA	-0.54	-6.78	-0.48	2.47e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	0.85	7.83	0.54	7.75e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs4450131	0.618	rs10736889	chr10:126338657	C/T	cg20435097	chr10:126320824	FAM53B	0.55	5.93	0.43	1.96e-8	White blood cell count (basophil);
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00066817	chr18:72777307	ZNF407	-0.51	-5.41	-0.4	2.37e-7	Obesity-related traits;
PAAD	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	4.35	0.33	2.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.92	-9.56	-0.61	2.96e-17	Urate levels in obese individuals;
PAAD	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.33	-0.33	2.65e-5	Menarche (age at onset);
PAAD	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.22	0.39	5.68e-7	Multiple sclerosis;
PAAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18363267	chr10:121652380	SEC23IP	-0.82	-7.47	-0.52	5.99e-12	Neuroticism;
PAAD	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.56	-7.07	-0.5	5.31e-11	Lewy body disease;
PAAD	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs654384	0.830	rs12701405	chr7:4161714	G/C	cg27574739	chr7:4176374	SDK1	0.45	4.45	0.34	1.64e-5	Positive affect;
PAAD	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs4740619	0.933	rs10810433	chr9:15707406	A/T	cg14451791	chr9:16040625	NA	-0.4	-4.62	-0.35	8.29e-6	Body mass index;
PAAD	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.62	-5.32	-0.4	3.64e-7	Corneal structure;
PAAD	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.75	8.2	0.55	9.35e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.98	-9.61	-0.61	2.22e-17	Blood protein levels;
PAAD	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg06618935	chr21:46677482	NA	-0.54	-6.24	-0.45	4.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs959260	0.925	rs1108355	chr17:73383913	A/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs17155006	0.746	rs401066	chr7:107747937	G/A	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10819733	chr22:24237672	NA	-0.62	-6.74	-0.48	3.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs375066	0.935	rs385321	chr19:44405287	C/T	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs1075232	1.000	rs12438318	chr15:31680445	G/A	cg01030201	chr15:31746330	NA	-1.09	-4.45	-0.34	1.67e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.88	8.07	0.55	2.01e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.52	-4.95	-0.37	1.91e-6	HDL cholesterol;
PAAD	cis	rs2274459	0.591	rs16868575	chr6:33629046	A/G	cg06253072	chr6:33679850	C6orf125	0.64	4.9	0.37	2.44e-6	Obesity (extreme);
PAAD	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg14830002	chr1:247616686	OR2B11	0.6	4.94	0.37	2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs735539	0.556	rs9552277	chr13:21352287	T/A	cg27234864	chr13:21295941	IL17D	0.61	5.27	0.39	4.62e-7	Dental caries;
PAAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.69	6.71	0.48	3.53e-10	Prostate cancer;
PAAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.67	-0.42	6.98e-8	Gut microbiome composition (summer);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03527159	chr11:62622985	SNORD27;SLC3A2;SNORD26;SNORD28;SNHG1	0.59	6.39	0.46	1.91e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.27	-0.39	4.62e-7	Glomerular filtration rate;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.47	4.56	0.35	1.03e-5	Height;
PAAD	cis	rs2016586	0.802	rs5999975	chr22:36115911	G/A	cg26342177	chr22:36113512	APOL5	-0.47	-4.68	-0.35	6.41e-6	Body mass index;
PAAD	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.82	-8.35	-0.56	3.97e-14	Response to antineoplastic agents;
PAAD	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.75	8.85	0.58	2.06e-15	Morning vs. evening chronotype;
PAAD	cis	rs12438356	0.773	rs34175310	chr15:69622241	G/A	cg02395280	chr15:69606596	PAQR5	-0.35	-4.37	-0.33	2.33e-5	CTACK levels;
PAAD	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	4.83	0.36	3.32e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02406285	chr3:67048577	KBTBD8	0.73	7.56	0.52	3.56e-12	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04569364	chr19:57922590	ZNF17	0.57	6.45	0.46	1.43e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg19217778	chr13:113420270	ATP11A	0.6	4.28	0.33	3.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg10761708	chr20:43804764	PI3	0.54	4.6	0.35	8.81e-6	Blood protein levels;
PAAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg05082376	chr22:42548792	NA	0.52	5.6	0.41	9.67e-8	Cognitive function;
PAAD	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.75	-8.33	-0.56	4.32e-14	Breast cancer;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg26898376	chr11:64110657	CCDC88B	0.55	5.9	0.43	2.33e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1190596	0.525	rs8010950	chr14:102757857	T/C	cg23904247	chr14:102554826	HSP90AA1	0.42	4.86	0.37	2.96e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.38	4.26	0.33	3.6e-5	Blood protein levels;
PAAD	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg20558230	chr5:484149	SLC9A3	-0.4	-5.31	-0.4	3.82e-7	Cystic fibrosis severity;
PAAD	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.63	-5.58	-0.41	1.06e-7	Coronary artery disease;
PAAD	cis	rs17601876	0.651	rs12050772	chr15:51544871	T/G	cg21478137	chr15:51532386	CYP19A1	0.49	4.9	0.37	2.39e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	4.57	0.35	1.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.69	5.14	0.38	8.28e-7	Bipolar disorder;
PAAD	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg11232448	chr19:2858854	NA	-0.49	-4.83	-0.36	3.37e-6	Total cholesterol levels;
PAAD	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.51	4.69	0.36	6.02e-6	Schizophrenia;
PAAD	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06630098	chr19:16683316	SLC35E1	-0.63	-6.63	-0.47	5.38e-10	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21179912	chr9:2024387	SMARCA2	-0.62	-6.31	-0.46	2.97e-9	Obesity-related traits;
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.53	5.19	0.39	6.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.38	0.4	2.71e-7	Lung cancer in ever smokers;
PAAD	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.85	-0.43	2.93e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4150161	0.656	rs1056612	chr16:84211788	G/C	cg10106505	chr16:84220380	TAF1C	-0.98	-5.65	-0.42	7.75e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.75e-5	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02318866	chr17:74723064	C17orf95;JMJD6	0.66	6.44	0.46	1.46e-9	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs17157931	chr10:46054359	T/C	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg13565585	chr5:132299512	AFF4	0.68	4.97	0.37	1.78e-6	Apolipoprotein A-IV levels;
PAAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs4704187	0.687	rs4621540	chr5:74371203	T/G	cg03227963	chr5:74354835	NA	0.49	4.83	0.36	3.34e-6	Response to amphetamines;
PAAD	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.36	0.33	2.35e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7897654	0.571	rs12771681	chr10:104635620	T/C	cg14737131	chr10:104680354	CNNM2	0.45	4.3	0.33	3.1e-5	Schizophrenia;
PAAD	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.46	-0.76	2.31e-30	Headache;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-1.25	-12.36	-0.71	9.64e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.6	-5.41	-0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg24634471	chr8:143751801	JRK	-0.51	-4.6	-0.35	8.94e-6	Urinary tract infection frequency;
PAAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-6.49	-0.47	1.12e-9	Psoriasis;
PAAD	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.6	4.25	0.33	3.64e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.5	-5.5	-0.41	1.57e-7	Total body bone mineral density;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4e-15	Total body bone mineral density;
PAAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.45	-0.34	1.66e-5	Triglycerides;
PAAD	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.52	0.61	3.88e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4979906	1.000	rs2048788	chr10:79462447	G/T	cg07817648	chr10:79422355	NA	-0.51	-4.7	-0.36	5.7e-6	Mortality in heart failure;
PAAD	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.91	-7.18	-0.5	2.96e-11	Multiple sclerosis;
PAAD	cis	rs1413885	0.549	rs1334877	chr1:65846406	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.71	0.36	5.56e-6	Anticoagulant levels;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.8	-0.48	2.28e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg21937377	chr3:194868750	C3orf21	0.48	4.42	0.34	1.84e-5	Non-small cell lung cancer;
PAAD	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.48	5.07	0.38	1.16e-6	Longevity;Endometriosis;
PAAD	cis	rs375066	0.868	rs378109	chr19:44421937	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	1.01	7.34	0.51	1.17e-11	Dental caries;
PAAD	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.92	12.19	0.7	2.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2790216	1.000	rs9416684	chr10:59994722	A/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.7	-6.1	-0.44	8.29e-9	Schizophrenia;
PAAD	cis	rs2033529	0.885	rs36084479	chr6:40366670	C/T	cg10553343	chr6:40360437	LRFN2	0.38	4.26	0.33	3.6e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Waist circumference;
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg22985122	chr17:73566478	LLGL2	0.71	4.81	0.36	3.59e-6	Psoriasis;
PAAD	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.62	-6.29	-0.45	3.23e-9	Pubertal anthropometrics;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12016809	chr21:47604291	C21orf56	0.42	4.25	0.33	3.71e-5	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.02	-0.38	1.45e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.6	-4.38	-0.33	2.22e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs75920871	0.858	rs78857232	chr11:116727465	C/T	cg04087571	chr11:116723030	SIK3	-0.47	-4.73	-0.36	5.19e-6	Subjective well-being;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.1.4424447F	chr1:226549560	PARP1	-0.66	-6.35	-0.46	2.39e-9	Lung cancer in ever smokers;
PAAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	6.14e-7	Ulcerative colitis;
PAAD	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.97	-8.67	-0.58	6.22e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg10239410	chr1:235292449	SNORA14B;TOMM20	0.42	4.44	0.34	1.75e-5	Adiposity;
PAAD	cis	rs735539	0.521	rs2147347	chr13:21410468	C/T	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	trans	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08418111	chr11:18433745	LDHC	0.6	6.29	0.45	3.17e-9	Calcium levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26253868	chr2:19072283	NA	-0.57	-6.82	-0.48	2e-10	Monocyte percentage of white cells;
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.28	0.39	4.35e-7	Trans fatty acid levels;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.59	5.71	0.42	5.84e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg06569542	chr10:98946673	SLIT1	-0.52	-5.84	-0.43	3.01e-8	Monocyte count;
PAAD	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-5.07	-0.38	1.16e-6	Osteoarthritis;
PAAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-5.88	-0.43	2.56e-8	Personality dimensions;
PAAD	cis	rs7804356	0.834	rs2106905	chr7:26766851	T/C	cg03456212	chr7:26904342	SKAP2	0.53	4.37	0.33	2.25e-5	Type 1 diabetes;
PAAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-4.62	-0.35	8.09e-6	Total body bone mineral density;
PAAD	cis	rs990171	1.000	rs6716784	chr2:103048467	T/G	cg03938978	chr2:103052716	IL18RAP	0.45	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.49	-4.39	-0.34	2.09e-5	Asthma;
PAAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg23887609	chr12:130822674	PIWIL1	0.61	6.02	0.44	1.28e-8	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11665564	chr2:20850802	HS1BP3	0.6	6.83	0.48	1.9e-10	Monocyte percentage of white cells;
PAAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.77	0.36	4.34e-6	Menopause (age at onset);
PAAD	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.61	-6.67	-0.48	4.36e-10	Colorectal cancer;
PAAD	trans	rs901683	0.850	rs112184470	chr10:46093302	G/A	cg07567308	chr20:3149320	ProSAPiP1	0.74	6.52	0.47	9.82e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4455778	0.561	rs6952745	chr7:49122762	C/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.84	6.71	0.48	3.67e-10	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23009452	chr2:25264872	EFR3B	0.61	6.58	0.47	7.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg20848291	chr7:100343083	ZAN	-0.76	-6.55	-0.47	8.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.07	-0.55	1.99e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25995955	chr4:151500631	LRBA	0.55	6.29	0.45	3.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.53	5.38	0.4	2.71e-7	Schizophrenia;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg06815965	chr1:205818668	PM20D1	0.59	6.54	0.47	9.04e-10	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.53	5.68	0.42	6.5e-8	Menopause (age at onset);
PAAD	cis	rs7623687	0.786	rs73088161	chr3:49465162	C/T	cg19401529	chr3:49056140	DALRD3	0.9	6.08	0.44	9.2e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg19264203	chr11:92714893	MTNR1B	0.39	4.44	0.34	1.75e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs2652834	0.950	rs2729801	chr15:63381095	A/G	cg05507819	chr15:63340323	TPM1	0.7	4.61	0.35	8.41e-6	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg09626299	chr10:82213104	TSPAN14	-0.44	-4.82	-0.36	3.45e-6	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00149659	chr3:10157352	C3orf10	0.55	4.35	0.33	2.53e-5	Alzheimer's disease;
PAAD	trans	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21702128	chr5:142784721	NR3C1	0.62	6.81	0.48	2.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6723162	0.757	rs4852724	chr2:71117097	T/A	cg14911521	chr2:71113568	NA	-0.4	-4.27	-0.33	3.4e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.03e-9	Bladder cancer;
PAAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09835421	chr16:68378352	PRMT7	-1.18	-8.67	-0.58	6.19e-15	HDL cholesterol;
PAAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.59	5.87	0.43	2.62e-8	Tonsillectomy;
PAAD	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs8133932	0.654	rs7410101	chr21:47328383	G/A	cg11214348	chr21:47283868	PCBP3	0.48	4.36	0.33	2.43e-5	Schizophrenia;
PAAD	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg04450456	chr4:17643702	FAM184B	-0.47	-4.64	-0.35	7.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.66	7.83	0.54	7.81e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg15145965	chr22:50218605	BRD1	0.71	4.37	0.33	2.25e-5	Mean platelet volume;
PAAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg13468214	chr4:1046988	NA	-0.53	-5.73	-0.42	5.34e-8	Recombination rate (males);
PAAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.41	4.67	0.35	6.71e-6	Fat distribution (HIV);
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.43	0.4	2.21e-7	Platelet count;
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg03586839	chr1:150601711	ENSA	-0.46	-4.31	-0.33	2.9e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.3	0.6	1.41e-16	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.82	-7.95	-0.54	3.88e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.42	5.68	0.42	6.63e-8	Primary biliary cholangitis;
PAAD	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.44	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg09473613	chr1:24152604	HMGCL	-0.53	-5.54	-0.41	1.33e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.68	-7.87	-0.54	6.06e-13	Bone mineral density;
PAAD	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12760731	0.623	rs12691480	chr1:178328790	T/A	cg00404053	chr1:178313656	RASAL2	0.67	5.58	0.41	1.08e-7	Obesity-related traits;
PAAD	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.81	-7.29	-0.51	1.54e-11	Pancreatic cancer;
PAAD	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.54	-6.52	-0.47	9.79e-10	Systemic lupus erythematosus;
PAAD	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg14851346	chr12:38532713	NA	-0.46	-4.36	-0.33	2.43e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg12927641	chr6:109611667	NA	-0.43	-4.51	-0.34	1.28e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.53	-6.88	-0.49	1.47e-10	Height;
PAAD	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9810890	1.000	rs73198872	chr3:128537683	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.2	-0.39	6.2e-7	Dental caries;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.56	-0.35	1.06e-5	Cognitive function;
PAAD	cis	rs12760731	0.720	rs12022646	chr1:178355821	A/G	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg05784532	chr1:230284198	GALNT2	0.71	6.16	0.45	6.13e-9	Coronary artery disease;
PAAD	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.65	-5.74	-0.42	4.89e-8	Coronary artery disease;
PAAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.43	4.41	0.34	1.91e-5	Red cell distribution width;
PAAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs3736485	0.966	rs2124877	chr15:51906275	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.72	7.72	0.53	1.41e-12	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg08069370	chr15:64387884	SNX1	0.5	4.85	0.37	3.08e-6	Monocyte count;
PAAD	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.0	-0.67	4.65e-21	Coronary artery disease;
PAAD	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.44	-0.4	2.09e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11846333	chr4:119757529	SEC24D	0.73	7.73	0.53	1.39e-12	Obesity-related traits;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/A	cg15744005	chr10:104629667	AS3MT	-0.48	-4.69	-0.36	5.92e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs11811982	0.793	rs11800364	chr1:227353932	T/C	cg24860534	chr1:227506868	CDC42BPA	0.53	5.06	0.38	1.2e-6	Optic disc area;
PAAD	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg12661370	chr5:149340060	SLC26A2	0.54	4.6	0.35	8.99e-6	HIV-1 control;
PAAD	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg20673841	chr7:107026890	COG5	0.51	4.27	0.33	3.42e-5	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg02487422	chr3:49467188	NICN1	0.44	4.43	0.34	1.76e-5	Resting heart rate;
PAAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-4.83	-0.36	3.27e-6	Blood metabolite levels;
PAAD	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.8	-5.68	-0.42	6.65e-8	Coronary artery disease;
PAAD	cis	rs17824933	1.000	rs929230	chr11:60760971	C/T	cg16817237	chr11:60793675	NA	0.48	5.71	0.42	5.87e-8	Multiple sclerosis;
PAAD	cis	rs2108225	0.714	rs929394	chr7:107437252	C/T	cg18181496	chr7:107642539	LAMB1	0.49	4.5	0.34	1.33e-5	Ulcerative colitis;
PAAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.16	16.65	0.8	4.46e-36	Exhaled nitric oxide output;
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.83	-8.91	-0.59	1.49e-15	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.49	-5.57	-0.41	1.14e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23236404	chr1:26232706	STMN1	-0.63	-6.59	-0.47	6.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.64	9.12	0.59	4.19e-16	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.9.1539394R	chr9:104170844	ZNF189	-0.81	-8.65	-0.57	6.75e-15	Lung cancer in ever smokers;
PAAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg13918804	chr1:2043761	PRKCZ	-0.37	-4.88	-0.37	2.63e-6	Height;
PAAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.98	8.3	0.56	5.39e-14	Initial pursuit acceleration;
PAAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.56	5.82	0.43	3.45e-8	Cognitive function;
PAAD	trans	rs2982694	0.764	rs2982690	chr6:152285491	G/A	cg08544209	chr10:10837368	SFTA1P	-0.71	-6.43	-0.46	1.56e-9	Sudden cardiac arrest;
PAAD	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg08992911	chr2:238395768	MLPH	-0.66	-5.27	-0.39	4.61e-7	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg14092571	chr14:90743983	NA	0.46	4.43	0.34	1.76e-5	Mortality in heart failure;
PAAD	cis	rs16975963	1.000	rs16975963	chr19:38325536	C/G	cg25793785	chr19:38281423	NA	-0.46	-4.31	-0.33	2.97e-5	Longevity;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07668623	chr13:60971344	TDRD3	-0.59	-7.02	-0.49	6.8e-11	Body fat percentage;
PAAD	trans	rs1490265	0.868	rs9637499	chr3:67443409	A/G	cg11709544	chr1:26233404	STMN1	0.51	6.29	0.45	3.16e-9	Lung function (FVC);
PAAD	cis	rs58521262	0.556	rs55793718	chr19:23143098	A/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15145965	chr22:50218605	BRD1	0.63	5.46	0.41	1.87e-7	Schizophrenia;
PAAD	cis	rs630539	1.000	rs2854977	chr17:40710892	T/C	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.32	-0.33	2.8e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14895029	chr7:2775587	GNA12	-0.48	-4.62	-0.35	8.28e-6	Height;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.36	-0.33	2.41e-5	Life satisfaction;
PAAD	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.36e-7	Number of children ever born;
PAAD	cis	rs877529	1.000	rs139388	chr22:39531732	C/G	cg18708252	chr22:39545030	CBX7	-0.44	-4.25	-0.33	3.73e-5	Multiple myeloma;
PAAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.82	0.58	2.46e-15	Menopause (age at onset);
PAAD	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	11.63	0.69	8.94e-23	Menopause (age at onset);
PAAD	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg13897122	chr2:103039542	IL18RAP	0.37	4.59	0.35	9.09e-6	Asthma;
PAAD	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.64	-6.32	-0.46	2.82e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs9506514	0.509	rs9509294	chr13:21174645	T/A	cg27234864	chr13:21295941	IL17D	-0.47	-4.49	-0.34	1.4e-5	Coronary artery calcification;
PAAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.81	0.36	3.67e-6	Breast cancer;
PAAD	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.92	7.0	0.49	7.54e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.67	5.56	0.41	1.19e-7	Schizophrenia;
PAAD	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg09366796	chr5:75012313	C5orf37	0.49	4.45	0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	4.78	0.36	4.18e-6	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08633923	chr1:236959181	MTR	0.57	6.47	0.46	1.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11168618	0.904	rs7978948	chr12:48930023	A/G	cg01881778	chr12:48919444	OR8S1	-0.45	-4.46	-0.34	1.61e-5	Adiponectin levels;
PAAD	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	4.63	0.35	7.92e-6	Systolic blood pressure;
PAAD	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg15956490	chr3:53032818	SFMBT1	0.73	4.46	0.34	1.6e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.68	5.8	0.43	3.8e-8	Schizophrenia;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg21724239	chr8:58056113	NA	0.67	5.41	0.4	2.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-4.71	-0.36	5.62e-6	Colorectal cancer;
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.53	-4.68	-0.35	6.26e-6	Total body bone mineral density;
PAAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg13374026	chr7:158955107	NA	0.48	4.76	0.36	4.51e-6	Facial morphology (factor 20);
PAAD	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg14825688	chr5:132208181	LEAP2	-0.59	-4.37	-0.33	2.26e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.98	0.49	8.73e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.65	5.82	0.43	3.33e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg25071794	chr5:57791484	GAPT	0.61	6.52	0.47	9.83e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-8.01	-0.54	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg17644776	chr2:200775616	C2orf69	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.84	-0.49	1.85e-10	Neuroticism;
PAAD	cis	rs10540	0.915	rs35333170	chr11:526478	A/G	cg03934478	chr11:495069	RNH1	1.04	5.41	0.4	2.41e-7	Body mass index;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-4.98	-0.37	1.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs300774	0.925	rs300717	chr2:136638	G/A	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.57	5.56	0.41	1.19e-7	Systemic lupus erythematosus;
PAAD	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.0	-12.06	-0.7	6.44e-24	Dilated cardiomyopathy;
PAAD	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.63	6.49	0.47	1.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs375066	0.935	rs450308	chr19:44422358	C/A	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16642003	chr16:30456845	SEPHS2	0.6	6.32	0.46	2.74e-9	Myopia (pathological);
PAAD	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.5	4.99	0.38	1.6e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.1e-7	Schizophrenia;
PAAD	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.29	-0.56	5.71e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.39	-4.48	-0.34	1.48e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.59	-5.72	-0.42	5.46e-8	YKL-40 levels;
PAAD	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.77	4.82	0.36	3.51e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1385374	0.920	rs61946174	chr12:129272971	T/C	cg09035930	chr12:129282057	SLC15A4	-0.77	-4.48	-0.34	1.47e-5	Systemic lupus erythematosus;
PAAD	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.52	-4.25	-0.33	3.68e-5	Body mass index;
PAAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.39	-4.57	-0.35	1.02e-5	Breast cancer;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.17	0.81	2.01e-37	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.86	-9.68	-0.62	1.46e-17	Migraine;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg18764771	chr6:116381957	FRK	-0.44	-7.79	-0.53	9.99e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs2061333	0.947	rs1236715	chr19:44639558	C/G	cg23489630	chr19:44645078	ZNF234	-0.58	-4.32	-0.33	2.82e-5	Alzheimer's disease;
PAAD	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.57	5.56	0.41	1.18e-7	Mortality in heart failure;
PAAD	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.49	0.65	1.06e-19	Cognitive test performance;
PAAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.59	0.35	9.38e-6	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22747994	chr11:64063455	KCNK4	0.54	6.41	0.46	1.76e-9	Smoking initiation;
PAAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21643547	chr1:205240462	TMCC2	-0.39	-4.44	-0.34	1.7e-5	Red blood cell count;
PAAD	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	7.94	0.54	4.18e-13	Homoarginine levels;
PAAD	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.63	6.81	0.48	2.18e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11245990	chr11:68621969	NA	0.34	4.31	0.33	2.92e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9463078	0.585	rs1290386	chr6:45168753	G/A	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.57	-6.14	-0.45	7e-9	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05955802	chr6:118972745	C6orf204	-0.8	-7.17	-0.5	3.13e-11	Neuroticism;
PAAD	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.68	6.78	0.48	2.56e-10	Obesity-related traits;
PAAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.19	0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg23995914	chr4:10459228	ZNF518B	-0.39	-4.27	-0.33	3.45e-5	Schizophrenia (age at onset);
PAAD	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg12568669	chr8:11666485	FDFT1	0.28	4.57	0.35	9.94e-6	Systolic blood pressure;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.44	4.89	0.37	2.54e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4605213	0.528	rs11079949	chr17:49320404	T/C	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.55	0.41	1.24e-7	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.59	0.61	2.44e-17	Rheumatoid arthritis;
PAAD	cis	rs7896729	0.882	rs10904452	chr10:5347916	A/G	cg07902545	chr10:6194255	PFKFB3	-0.44	-4.55	-0.35	1.08e-5	Intelligence;
PAAD	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg06346307	chr22:19949965	COMT	-0.31	-4.8	-0.36	3.82e-6	Blood metabolite levels;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.58e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.73	-5.87	-0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg06740227	chr12:86229804	RASSF9	0.49	4.84	0.37	3.11e-6	Major depressive disorder;
PAAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.77	7.98	0.54	3.33e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.81e-6	Lymphocyte counts;
PAAD	trans	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg20641545	chr12:89984390	ATP2B1	-0.51	-6.31	-0.46	2.95e-9	Cancer;
PAAD	cis	rs72829446	0.530	rs7215056	chr17:7350050	C/A	cg02795151	chr17:7402630	POLR2A	0.59	5.23	0.39	5.53e-7	Androgen levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11949654	chr2:230787847	TRIP12;FBXO36	0.75	7.91	0.54	5.01e-13	Obesity-related traits;
PAAD	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.82	-8.84	-0.58	2.2e-15	Morning vs. evening chronotype;
PAAD	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg17644776	chr2:200775616	C2orf69	-0.45	-4.35	-0.33	2.47e-5	QT interval;
PAAD	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg06740227	chr12:86229804	RASSF9	-0.52	-5.1	-0.38	9.93e-7	Major depressive disorder;
PAAD	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg18357526	chr6:26021779	HIST1H4A	0.72	7.65	0.53	2.14e-12	Height;
PAAD	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg23093090	chr10:104574429	C10orf26	-0.46	-4.95	-0.37	1.99e-6	Waist circumference;Hip circumference;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs62025270	0.688	rs11073516	chr15:86285227	G/C	cg13263323	chr15:86062960	AKAP13	0.48	4.25	0.33	3.66e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7567389	0.677	rs7607907	chr2:128144286	C/T	cg11380483	chr2:127933992	NA	-0.45	-4.45	-0.34	1.63e-5	Self-rated health;
PAAD	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.82	6.07	0.44	9.77e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-5.4	-0.4	2.54e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs35791980	1.000	rs35791980	chr7:76941547	C/A	cg02756451	chr7:76178720	LOC100133091	0.51	4.55	0.35	1.07e-5	Pursuit maintenance gain;
PAAD	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.62	4.57	0.35	9.8200000000000008e-06	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22162314	chr17:61951766	CSH2	-0.57	-5.8	-0.43	3.67e-8	Height;
PAAD	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg00262122	chr8:11665843	FDFT1	-0.51	-4.5	-0.34	1.36e-5	Neuroticism;
PAAD	cis	rs12714314	0.672	rs10181068	chr2:1961211	C/T	cg22350835	chr2:1868857	MYT1L	0.49	4.95	0.37	1.98e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.7	7.93	0.54	4.34e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4795519	0.696	rs7210704	chr17:22168864	A/C	cg22648282	chr17:21454238	C17orf51	-0.54	-5.49	-0.41	1.68e-7	Chronic myeloid leukemia;
PAAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.77	8.99	0.59	9.11e-16	Huntington's disease progression;
PAAD	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.81	-0.48	2.17e-10	Neuroticism;
PAAD	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs9902453	0.654	rs3794809	chr17:28531258	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.17	0.45	5.8e-9	Coffee consumption (cups per day);
PAAD	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.84	10.43	0.65	1.55e-19	Bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27130769	chr7:5417105	TNRC18	0.61	7.17	0.5	2.97e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.47	5.33	0.4	3.57e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.8e-5	Body mass index;
PAAD	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.49	4.25	0.33	3.65e-5	Vitamin D levels;
PAAD	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg08875078	chr22:50639485	SELO	0.47	4.31	0.33	2.86e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.58	8.88	0.58	1.75e-15	Hypertriglyceridemia;
PAAD	cis	rs10916814	0.632	rs12089623	chr1:20903643	G/A	cg04087271	chr1:20915334	CDA	0.38	4.67	0.35	6.62e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs300774	0.925	rs1531374	chr2:127773	A/C	cg21211680	chr2:198530	NA	-0.6	-5.69	-0.42	6.45e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.75	4.77	0.36	4.28e-6	Optic nerve measurement (cup area);
PAAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.71	4.76	0.36	4.39e-6	Yeast infection;
PAAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg05896902	chr15:45671018	LOC145663;GATM	0.51	4.27	0.33	3.44e-5	Homoarginine levels;
PAAD	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.58	-6.14	-0.45	6.81e-9	Menarche (age at onset);
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6782025	0.837	rs338981	chr3:120997953	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.38	4.72	0.36	5.3e-6	Intraocular pressure;
PAAD	cis	rs2635047	0.604	rs1434527	chr18:44742868	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-4.33	-0.33	2.67e-5	Educational attainment;
PAAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.39	-4.85	-0.37	3.05e-6	Personality dimensions;
PAAD	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg17326555	chr1:119535693	NA	-0.41	-5.03	-0.38	1.37e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2016586	0.832	rs5999963	chr22:36105832	T/A	cg26342177	chr22:36113512	APOL5	-0.46	-4.61	-0.35	8.56e-6	Body mass index;
PAAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.88	-0.43	2.53e-8	Prostate cancer;
PAAD	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7011192	0.793	rs7013904	chr8:10523848	G/C	cg25377605	chr8:10513717	RP1L1	-0.73	-4.93	-0.37	2.1e-6	Suicide;
PAAD	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.91	-9.07	-0.59	5.77e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs11066679	1.000	rs11066679	chr12:114123402	G/C	cg18842598	chr12:114273539	RBM19	0.55	4.32	0.33	2.86e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.54	4.73	0.36	5.19e-6	Corneal astigmatism;
PAAD	cis	rs6691722	0.583	rs35671964	chr1:24695749	C/G	cg18323236	chr1:24743029	NIPAL3	0.45	4.67	0.35	6.56e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs253959	0.739	rs712573	chr5:115637818	G/C	cg05931423	chr5:115697214	NA	-0.46	-4.27	-0.33	3.46e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs7957197	0.744	rs11065394	chr12:121446922	A/G	cg02419362	chr12:121203948	SPPL3	-0.46	-4.41	-0.34	1.92e-5	Type 2 diabetes;
PAAD	cis	rs17641971	0.708	rs2137013	chr8:49981091	C/T	cg00325661	chr8:49890786	NA	0.53	5.4	0.4	2.51e-7	Blood metabolite levels;
PAAD	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg15571903	chr15:79123663	NA	0.39	4.69	0.36	6.13e-6	Coronary artery disease;
PAAD	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.5	-4.95	-0.37	1.91e-6	Multiple myeloma;
PAAD	cis	rs8113142	0.614	rs73023299	chr19:29207298	T/G	cg04546413	chr19:29218101	NA	0.42	4.35	0.33	2.47e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs6893807	0.778	rs10514301	chr5:87939654	C/T	cg02225085	chr5:87975992	LOC645323	-0.66	-4.51	-0.34	1.3e-5	Body mass index;
PAAD	cis	rs1371614	0.655	rs7579579	chr2:27151842	C/T	cg00617064	chr2:27272375	NA	0.43	4.51	0.34	1.27e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.39	0.4	2.67e-7	Mean platelet volume;
PAAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-4.38	-0.33	2.24e-5	Schizophrenia;
PAAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.65	7.37	0.51	1.01e-11	Height;
PAAD	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg15192750	chr16:69999425	NA	0.78	6.06	0.44	1.04e-8	IgE levels;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.74	-7.2	-0.5	2.55e-11	Cognitive function;
PAAD	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.74	-8.56	-0.57	1.13e-14	Pulse pressure;
PAAD	cis	rs7577696	0.962	rs10490360	chr2:32296268	A/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.83e-6	Inflammatory biomarkers;
PAAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	1.16	7.25	0.51	1.99e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg13870426	chr17:30244630	NA	-0.76	-6.7	-0.48	3.72e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs3136441	0.892	rs898604	chr11:46917983	A/G	cg19486271	chr11:47235900	DDB2	0.53	4.49	0.34	1.38e-5	HDL cholesterol;
PAAD	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27055846	chr1:228741287	NA	-0.64	-6.42	-0.46	1.69e-9	Obesity-related traits;
PAAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg04106633	chr4:1044584	NA	0.51	4.77	0.36	4.19e-6	Recombination rate (males);
PAAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.73	-9.38	-0.61	8.65e-17	Rheumatoid arthritis;
PAAD	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.42	-0.34	1.87e-5	Ulcerative colitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13682598	chr10:135195405	PAOX	0.57	6.49	0.47	1.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.5	-7.21	-0.5	2.49e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg23506979	chr15:79090958	ADAMTS7	0.27	4.52	0.34	1.23e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg16558253	chr16:72132732	DHX38	-0.63	-5.28	-0.39	4.42e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg09826364	chr7:158789723	NA	0.38	4.34	0.33	2.62e-5	Facial morphology (factor 20);
PAAD	cis	rs12476592	0.599	rs75558118	chr2:63922526	A/G	cg10828910	chr2:63850056	LOC388955	-0.56	-4.44	-0.34	1.74e-5	Childhood ear infection;
PAAD	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg09876464	chr15:85330779	ZNF592	0.45	4.5	0.34	1.36e-5	P wave terminal force;
PAAD	cis	rs7173419	0.607	rs7182323	chr15:28221329	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.43	-0.4	2.16e-7	Eye color;
PAAD	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.77	-8.56	-0.57	1.16e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.51	-0.41	1.51e-7	Alcohol dependence;
PAAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03923535	chr7:1197113	ZFAND2A	0.41	4.28	0.33	3.34e-5	Longevity;Endometriosis;
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03676636	chr4:99064102	C4orf37	0.31	5.8	0.43	3.65e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs80346118	0.673	rs16994152	chr20:47426126	T/G	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.63	-4.58	-0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	4.88	0.37	2.61e-6	Breast cancer;
PAAD	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg17328665	chr1:7887199	PER3	-0.44	-4.31	-0.33	2.97e-5	Crohn's disease;
PAAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.78	8.46	0.57	2.07e-14	Neuroticism;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.5	4.99	0.37	1.66e-6	Height;
PAAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.95	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.42	-0.56	2.67e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.03	13.22	0.73	4.92e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg05250797	chr16:70222502	NA	0.88	6.81	0.48	2.16e-10	IgE levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26703674	chr2:173292216	ITGA6	0.62	7.07	0.5	5.2e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.07	0.44	9.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.69	7.92	0.54	4.64e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.33	-0.33	2.66e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-4.87	-0.37	2.79e-6	Initial pursuit acceleration;
PAAD	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.87	10.71	0.66	2.67e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.32e-7	Body mass index;
PAAD	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.7	-7.47	-0.52	5.96e-12	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.58	-0.35	9.59e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg13535736	chr9:111863775	C9orf5	-0.37	-4.6	-0.35	8.67e-6	Menarche (age at onset);
PAAD	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.73	6.98	0.49	8.38e-11	Coronary artery disease;
PAAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg17120908	chr11:65337727	SSSCA1	-1.01	-4.68	-0.36	6.17e-6	Height;
PAAD	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg21479132	chr6:26055353	NA	0.7	4.49	0.34	1.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7714584	1.000	rs11739619	chr5:150264662	A/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg13903179	chr13:21900392	NA	0.59	6.19	0.45	5.38e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.34	6.3	0.46	3e-9	Type 2 diabetes;
PAAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.57	6.07	0.44	9.78e-9	Huntington's disease progression;
PAAD	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-8.94	-0.59	1.22e-15	Electrocardiographic conduction measures;
PAAD	cis	rs755249	0.567	rs41270799	chr1:39748662	G/A	cg14018543	chr1:39659967	MACF1	-0.53	-4.49	-0.34	1.4e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.92	0.37	2.22e-6	Vitiligo;
PAAD	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.68	0.35	6.38e-6	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6687430	0.532	rs12028449	chr1:10617034	A/G	cg17425144	chr1:10567563	PEX14	0.43	4.75	0.36	4.73e-6	Hand grip strength;
PAAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.75	-8.6	-0.57	9.25e-15	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03628274	chr19:18420511	LSM4	-0.63	-6.29	-0.45	3.29e-9	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07774478	chr2:127865245	BIN1	0.61	6.57	0.47	7.73e-10	Obesity-related traits;
PAAD	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg14003231	chr6:33640908	ITPR3	0.39	5.12	0.38	8.98e-7	Plateletcrit;
PAAD	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg00042356	chr1:8021962	PARK7	0.78	5.38	0.4	2.77e-7	Inflammatory bowel disease;
PAAD	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg08994789	chr17:28903642	LRRC37B2	0.55	4.46	0.34	1.58e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.64	-6.69	-0.48	3.98e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11668609	0.505	rs114333596	chr19:24062569	T/G	cg09235885	chr19:23456588	NA	0.63	4.35	0.33	2.45e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03804148	chr17:1465813	PITPNA	0.65	7.2	0.5	2.55e-11	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg08053846	chr7:100769605	SERPINE1	0.45	4.87	0.37	2.78e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	4.95e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg14458575	chr2:238380390	NA	0.51	5.79	0.43	3.91e-8	Prostate cancer;
PAAD	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.3	-0.4	3.95e-7	Height;
PAAD	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9472414	0.510	rs7746032	chr6:44708613	A/T	cg18551225	chr6:44695536	NA	0.48	4.88	0.37	2.61e-6	Height;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs9976767	0.932	rs28371062	chr21:43828267	C/T	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.59	-0.35	9.04e-6	Type 1 diabetes;
PAAD	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.72	5.31	0.4	3.84e-7	Psoriasis vulgaris;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15176678	chr19:10230499	EIF3G	0.64	6.29	0.45	3.14e-9	Obesity-related traits;
PAAD	cis	rs939584	0.877	rs11127484	chr2:623798	T/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9649465	1.000	rs2299983	chr7:123356642	C/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs6784615	0.744	rs352141	chr3:52267118	G/C	cg27565382	chr3:53032988	SFMBT1	1.03	4.58	0.35	9.68e-6	Waist-hip ratio;
PAAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs34599045	1.000	rs34593101	chr1:152881350	C/T	cg07796016	chr1:152779584	LCE1C	-0.9	-4.58	-0.35	9.69e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4834770	0.792	rs7676969	chr4:120173724	C/T	cg09307838	chr4:120376055	NA	0.55	5.13	0.38	8.75e-7	Blood protein levels;
PAAD	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.99	-10.92	-0.66	7.47e-21	Headache;
PAAD	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.48	-4.93	-0.37	2.14e-6	Type 2 diabetes;
PAAD	cis	rs4454254	0.589	rs9987138	chr8:141076623	C/G	cg05910124	chr8:141057427	TRAPPC9	-0.31	-4.45	-0.34	1.62e-5	Pulse pressure;
PAAD	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.68	0.35	6.42e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.3	-9.36	-0.6	1.01e-16	Blood pressure (smoking interaction);
PAAD	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.84	8.61	0.57	8.73e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs12422267	1.000	rs12422267	chr12:132601596	A/G	cg09764611	chr12:132620959	NA	-0.72	-4.26	-0.33	3.58e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg20503657	chr10:835505	NA	-0.77	-6.61	-0.47	6.05e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs910187	0.596	rs6066222	chr20:45801917	G/A	cg27589058	chr20:45804311	EYA2	-0.49	-5.37	-0.4	2.83e-7	Migraine;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17668562	chr5:68466250	CCNB1	-0.68	-7.04	-0.5	6.33e-11	Obesity-related traits;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg08601574	chr20:25228251	PYGB	0.65	7.23	0.51	2.17e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	5.44	0.4	2.06e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg15181151	chr6:150070149	PCMT1	0.6	6.48	0.47	1.2e-9	Lung cancer;
PAAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.6	-0.35	8.79e-6	Breast cancer;
PAAD	cis	rs7570971	1.000	rs7570971	chr2:135837906	C/A	cg07169764	chr2:136633963	MCM6	0.6	5.42	0.4	2.29e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	trans	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg06606381	chr12:133084897	FBRSL1	-1.21	-7.14	-0.5	3.58e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.67	-0.42	6.94e-8	Schizophrenia;
PAAD	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg23649088	chr2:200775458	C2orf69	-0.65	-4.99	-0.38	1.63e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.49	-4.48	-0.34	1.43e-5	Total body bone mineral density;
PAAD	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.63	5.02	0.38	1.45e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg22800045	chr5:56110881	MAP3K1	0.59	5.31	0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg07362569	chr17:61921086	SMARCD2	0.43	4.92	0.37	2.27e-6	Height;
PAAD	cis	rs112990264	1.000	rs112967044	chr1:213022594	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs2493298	1.000	rs6670123	chr1:3326796	C/G	cg25052274	chr1:3321139	PRDM16	0.52	4.46	0.34	1.61e-5	Coronary artery disease;
PAAD	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg09796270	chr17:17721594	SREBF1	-0.51	-5.53	-0.41	1.38e-7	Lymphocyte counts;
PAAD	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg08601574	chr20:25228251	PYGB	0.64	6.96	0.49	9.66e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.46	4.88	0.37	2.71e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.78	-9.09	-0.59	5.05e-16	Bladder cancer;
PAAD	cis	rs72827839	0.779	rs57583172	chr17:46481963	G/A	cg23391107	chr17:45924227	SP6	0.53	5.09	0.38	1.04e-6	Ease of getting up in the morning;
PAAD	cis	rs3806308	0.966	rs12128452	chr1:20143706	T/G	cg13843611	chr1:20143089	RNF186	0.52	5.31	0.4	3.82e-7	Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.49	0.57	1.71e-14	Alzheimer's disease;
PAAD	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23708337	chr7:1209742	NA	0.45	4.61	0.35	8.6e-6	Longevity;Endometriosis;
PAAD	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.72	5.58	0.41	1.06e-7	Heart failure;
PAAD	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs16975963	0.843	rs241935	chr19:38293963	A/C	cg25793785	chr19:38281423	NA	-0.57	-4.89	-0.37	2.57e-6	Longevity;
PAAD	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.7	-8.07	-0.55	1.99e-13	Diastolic blood pressure;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4455778	0.580	rs3924857	chr7:49121682	C/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.84	0.69	2.55e-23	Menopause (age at onset);
PAAD	cis	rs11641365	0.651	rs2879902	chr16:88778133	C/A	cg26786172	chr16:88781646	CTU2	-0.55	-5.5	-0.41	1.56e-7	Autism spectrum disorder-related traits;
PAAD	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.83	-7.44	-0.52	6.89e-12	Pancreatic cancer;
PAAD	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg01966878	chr4:90757139	SNCA	-0.46	-4.46	-0.34	1.59e-5	Dementia with Lewy bodies;
PAAD	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg00543991	chr22:32367038	NA	1.18	7.23	0.51	2.23e-11	Childhood ear infection;
PAAD	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.67	-6.82	-0.48	2.01e-10	White matter hyperintensity burden;
PAAD	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.43	4.41	0.34	1.91e-5	Sarcoidosis;
PAAD	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-4.9	-0.37	2.46e-6	Reticulocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18357668	chr19:48794673	NA	-0.55	-6.31	-0.46	2.95e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.61	-0.41	9.16e-8	Corneal astigmatism;
PAAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg17366294	chr4:99064904	C4orf37	0.45	5.01	0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.01e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.28	-0.51	1.71e-11	Longevity;
PAAD	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.57	5.2	0.39	6.38e-7	Blood metabolite levels;
PAAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00982548	chr2:198649783	BOLL	-0.77	-5.52	-0.41	1.41e-7	Ulcerative colitis;
PAAD	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.51	0.57	1.51e-14	Dupuytren's disease;
PAAD	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg12184421	chr1:167409136	CD247	0.38	4.44	0.34	1.7e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13795838	chr10:134539818	INPP5A	0.65	7.72	0.53	1.48e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg21211367	chr2:162094118	NA	0.45	4.49	0.34	1.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.98	9.91	0.63	3.69e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1371614	0.632	rs3769135	chr2:27168411	G/A	cg07507200	chr2:27712693	IFT172	0.49	4.32	0.33	2.86e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.68	4.94	0.37	2.05e-6	Hip geometry;
PAAD	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.71	6.99	0.49	8.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.79	9.14	0.6	3.83e-16	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24419099	chr11:47270565	NR1H3;ACP2	0.71	8.4	0.56	3.02e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.71	-7.14	-0.5	3.69e-11	Coronary artery disease;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.95	12.44	0.71	6.02e-25	Menarche (age at onset);
PAAD	cis	rs6681460	0.649	rs6691033	chr1:67007429	C/T	cg02459107	chr1:67143332	SGIP1	0.57	5.08	0.38	1.1e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg25204440	chr1:209979598	IRF6	0.63	5.62	0.41	8.78e-8	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.38	-0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.35	0.33	2.48e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6005807	0.543	rs6005868	chr22:29165766	T/C	cg15103426	chr22:29168792	CCDC117	0.65	4.75	0.36	4.77e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg03676636	chr4:99064102	C4orf37	0.33	4.68	0.36	6.21e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg15997130	chr1:24165203	NA	-0.47	-4.6	-0.35	8.82e-6	Immature fraction of reticulocytes;
PAAD	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg15790184	chr11:494944	RNH1	0.81	4.46	0.34	1.57e-5	Body mass index;
PAAD	trans	rs9863706	0.556	rs7628338	chr3:72432888	C/T	cg17510997	chr11:4116437	RRM1	-0.7	-6.31	-0.46	2.97e-9	Height;
PAAD	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg01851573	chr8:8652454	MFHAS1	-0.67	-5.9	-0.43	2.27e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10512697	0.772	rs13154653	chr5:3518916	C/A	cg19473799	chr5:3511975	NA	-1.03	-4.6	-0.35	8.95e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.28	-5.21	-0.39	5.92e-7	Type 2 diabetes;
PAAD	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.62	-4.83	-0.36	3.31e-6	Rheumatoid arthritis;
PAAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.32	6.04	0.44	1.13e-8	Skin colour saturation;
PAAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs300774	0.925	rs1531374	chr2:127773	A/C	cg23649280	chr2:140451	NA	-0.47	-4.53	-0.34	1.18e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.65	-0.42	7.84e-8	QT interval;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.12	17.44	0.82	4.12e-38	Menarche (age at onset);
PAAD	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.58	-0.35	9.43e-6	Alcohol dependence;
PAAD	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.81	10.14	0.64	8.77e-19	Morning vs. evening chronotype;
PAAD	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg20893579	chr22:38215064	NA	-0.51	-5.36	-0.4	3.1e-7	Glioblastoma;Glioma;
PAAD	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.48	4.78	0.36	4.09e-6	Red cell distribution width;
PAAD	cis	rs741677	0.963	rs9907102	chr17:464832	C/T	cg06217071	chr17:408420	NA	0.59	6.45	0.46	1.39e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg24881330	chr22:46731750	TRMU	1.17	6.43	0.46	1.54e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs939584	0.935	rs7571957	chr2:646803	T/C	cg03610516	chr2:642275	NA	0.61	5.53	0.41	1.37e-7	Body mass index;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.42	0.34	1.91e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg18612461	chr15:75251733	NA	0.69	8.91	0.59	1.49e-15	Breast cancer;
PAAD	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.76	0.36	4.48e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	2.01e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.87e-7	Schizophrenia;
PAAD	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.05	0.63	1.57e-18	Myeloid white cell count;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.3e-6	Height;
PAAD	cis	rs6674176	0.551	rs2242637	chr1:44401384	A/G	cg12908607	chr1:44402522	ARTN	-0.62	-4.26	-0.33	3.55e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.72	-0.42	5.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	7.6	0.52	2.86e-12	Body mass index;
PAAD	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg03959625	chr15:84868606	LOC388152	-0.43	-4.48	-0.34	1.47e-5	Schizophrenia;
PAAD	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	1.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg09381666	chr16:88757816	NA	-0.59	-5.52	-0.41	1.43e-7	Autism spectrum disorder-related traits;
PAAD	cis	rs988913	0.723	rs1393775	chr6:54851958	G/T	cg03513858	chr6:54763001	FAM83B	-0.43	-4.8	-0.36	3.84e-6	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg06360820	chr2:242988706	NA	-1.07	-8.53	-0.57	1.4e-14	Obesity-related traits;
PAAD	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15121860	chr11:56952128	LRRC55	-0.69	-7.47	-0.52	6e-12	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg02696790	chr15:75250997	RPP25	-0.43	-5.24	-0.39	5.39e-7	Caffeine consumption;
PAAD	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	5.69	0.42	6.31e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2069837	0.515	rs12535219	chr7:22806159	C/G	cg05472934	chr7:22766657	IL6	0.64	4.61	0.35	8.62e-6	Longevity;
PAAD	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	1.05	9.07	0.59	5.54e-16	Neutrophil percentage of white cells;
PAAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.65e-10	Hair morphology;
PAAD	cis	rs8060686	0.920	rs73597582	chr16:67683626	G/A	cg27539214	chr16:67997921	SLC12A4	-0.74	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.3	0.51	1.47e-11	Colorectal cancer;
PAAD	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg00806126	chr19:22604979	ZNF98	0.4	5.15	0.39	8.07e-7	Pain;
PAAD	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.3	-0.33	3e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg09473613	chr1:24152604	HMGCL	0.47	4.8	0.36	3.81e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6963495	0.615	rs7384092	chr7:105203084	G/A	cg19920283	chr7:105172520	RINT1	-0.7	-5.64	-0.42	8.26e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.52	5.71	0.42	5.74e-8	Major depressive disorder;
PAAD	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg08999081	chr20:33150536	PIGU	-0.49	-5.34	-0.4	3.27e-7	Height;
PAAD	cis	rs7714584	1.000	rs10463307	chr5:150254620	C/T	cg22134413	chr5:150180641	NA	0.78	5.48	0.41	1.7e-7	Crohn's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06669598	chr6:127622363	ECHDC1	0.6	6.46	0.46	1.35e-9	Smoking initiation;
PAAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.42	0.34	1.86e-5	Personality dimensions;
PAAD	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.92	11.1	0.67	2.38e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.58	-0.35	9.6e-6	Total body bone mineral density;
PAAD	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg18964960	chr10:1102726	WDR37	0.9	4.53	0.34	1.19e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.78	7.58	0.52	3.18e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-7.44	-0.52	6.95e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg23024343	chr7:107201750	COG5	0.56	4.59	0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg14582100	chr15:45693742	SPATA5L1	0.35	5.28	0.39	4.33e-7	Glomerular filtration rate;
PAAD	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.2	0.5	2.58e-11	Eosinophil percentage of white cells;
PAAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.75	-5.29	-0.39	4.24e-7	Carotid intima media thickness;
PAAD	cis	rs2016266	0.502	rs7398676	chr12:53630558	A/C	cg25029197	chr12:52639196	KRT7	0.45	4.51	0.34	1.27e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg18451016	chr1:38461880	NA	0.56	6.2	0.45	4.97e-9	Coronary artery disease;
PAAD	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.78	-8.86	-0.58	2.03e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73206853	0.698	rs73194015	chr12:111116651	C/T	cg12870014	chr12:110450643	ANKRD13A	0.71	4.44	0.34	1.74e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.9	-9.94	-0.63	3.03e-18	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.95	-11.65	-0.69	8.14e-23	Chronic sinus infection;
PAAD	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg24618514	chr3:194868507	C3orf21	0.48	4.33	0.33	2.69e-5	Non-small cell lung cancer;
PAAD	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.61	-5.64	-0.42	8.17e-8	Corneal astigmatism;
PAAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.5	4.51	0.34	1.27e-5	Platelet count;
PAAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg15117754	chr3:10150083	C3orf24	0.68	5.84	0.43	3.04e-8	Alzheimer's disease;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	ch.22.16454022F	chr22:18074022	NA	-0.64	-6.88	-0.49	1.5e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.94	0.43	1.83e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4450131	0.522	rs3781453	chr10:126348761	T/C	cg20435097	chr10:126320824	FAM53B	0.53	5.36	0.4	3e-7	White blood cell count (basophil);
PAAD	cis	rs4759375	0.510	rs28454135	chr12:123857686	C/T	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs10044254	0.763	rs4601044	chr5:15691057	T/G	cg07238450	chr5:15720153	FBXL7	-0.51	-4.33	-0.33	2.65e-5	Asthma (corticosteroid response);
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07685180	chr8:600429	NA	0.87	5.97	0.44	1.6e-8	IgG glycosylation;
PAAD	cis	rs4654748	0.741	rs1106357	chr1:21817085	C/T	cg00786952	chr1:21763130	NA	0.61	6.12	0.44	7.43e-9	Folate pathway vitamin levels;
PAAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg11601000	chr22:42348013	LOC339674	0.4	4.63	0.35	7.72e-6	Cognitive function;
PAAD	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	9.14	0.6	3.76e-16	Post bronchodilator FEV1;
PAAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg15017067	chr4:17643749	FAM184B	0.47	5.48	0.41	1.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs9534288	0.659	rs2031634	chr13:46661129	G/C	cg15192986	chr13:46630673	CPB2	-0.7	-5.95	-0.43	1.77e-8	Blood protein levels;
PAAD	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg08079166	chr15:68083412	MAP2K5	0.65	4.99	0.38	1.61e-6	Restless legs syndrome;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09172770	chr16:1442942	NA	0.55	6.56	0.47	8e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs643506	0.817	rs658373	chr11:111682991	T/C	cg09085632	chr11:111637200	PPP2R1B	0.58	5.03	0.38	1.39e-6	Breast cancer;
PAAD	cis	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg08112188	chr17:47440006	ZNF652	1.29	6.48	0.47	1.2e-9	Prostate cancer;
PAAD	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg13206674	chr6:150067644	NUP43	0.62	5.6	0.41	9.62e-8	Lung cancer;
PAAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.83	-7.23	-0.51	2.19e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg21535942	chr1:75199100	CRYZ;TYW3	0.51	4.95	0.37	1.94e-6	Resistin levels;
PAAD	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg08917208	chr2:24149416	ATAD2B	0.49	4.3	0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.69	-7.47	-0.52	5.71e-12	DNA methylation (variation);
PAAD	cis	rs6604026	0.883	rs7514280	chr1:93320869	C/T	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg00758881	chr16:58534681	NDRG4	-0.88	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg10705379	chr10:99080932	FRAT1	0.43	5.06	0.38	1.17e-6	Monocyte count;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.96	8.02	0.55	2.71e-13	Alzheimer's disease;
PAAD	cis	rs116175783	0.557	rs16845770	chr2:162181787	T/C	cg08807892	chr2:162101083	NA	-0.68	-4.83	-0.37	3.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg23306229	chr2:178417860	TTC30B	0.64	4.7	0.36	5.82e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg01966878	chr4:90757139	SNCA	-0.69	-5.48	-0.41	1.75e-7	Neuroticism;
PAAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg03983715	chr16:68378420	PRMT7	-0.7	-5.15	-0.39	7.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.52	-5.06	-0.38	1.19e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.53	5.41	0.4	2.44e-7	Major depressive disorder;
PAAD	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	14.47	0.76	2.2e-30	Testicular germ cell tumor;
PAAD	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg13282195	chr8:144660772	NAPRT1	-0.78	-6.34	-0.46	2.5e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00791764	chr4:53727839	RASL11B	0.54	4.63	0.35	7.83e-6	Optic nerve measurement (cup area);
PAAD	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11716640	chr1:113933411	MAGI3	0.57	6.54	0.47	8.63e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12315302	chr6:26189340	HIST1H4D	0.56	4.27	0.33	3.44e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12799264	1.000	rs11025342	chr11:19979669	C/T	cg17303119	chr11:19974895	NAV2	-0.71	-4.76	-0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7627468	1.000	rs6783556	chr3:121934360	A/G	cg17240004	chr3:121949083	CASR	-0.51	-4.43	-0.34	1.83e-5	Kidney stones;
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	9.37	0.61	9.24e-17	Platelet count;
PAAD	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg15309053	chr8:964076	NA	0.5	5.62	0.41	8.88e-8	Schizophrenia;
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg15691649	chr6:25882328	NA	-0.49	-4.5	-0.34	1.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-4.68	-0.35	6.43e-6	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.55	-0.41	1.25e-7	Life satisfaction;
PAAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg19847866	chr10:1019161	NA	-0.59	-4.64	-0.35	7.58e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.45	0.34	1.63e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs590121	0.876	rs649257	chr11:75279846	C/T	cg26104986	chr11:75275303	SERPINH1	-0.45	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.64	-5.42	-0.4	2.24e-7	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg17541715	chr7:1216824	NA	-0.41	-4.6	-0.35	8.91e-6	Longevity;Endometriosis;
PAAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12432203	1.000	rs3935982	chr14:51730252	T/A	cg23942311	chr14:51606299	NA	-0.7	-4.82	-0.36	3.52e-6	Cancer;
PAAD	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00724035	chr2:74375213	BOLA3	0.6	6.32	0.46	2.78e-9	Myopia (pathological);
PAAD	cis	rs3809912	0.509	rs4499304	chr18:13001512	G/C	cg12848697	chr18:13133368	NA	0.48	4.46	0.34	1.61e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.71	-5.91	-0.43	2.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.88	4.63	0.35	7.77e-6	Childhood ear infection;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14893161	chr1:205819251	PM20D1	0.63	6.65	0.47	4.84e-10	Prostate cancer;
PAAD	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.85	9.85	0.62	5.14e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	7.08	0.5	4.94e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg20503657	chr10:835505	NA	0.48	5.06	0.38	1.18e-6	Survival in rectal cancer;
PAAD	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.94	-9.99	-0.63	2.26e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg08677398	chr8:58056175	NA	0.61	4.34	0.33	2.57e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg02631450	chr22:32366979	NA	0.99	5.45	0.4	1.95e-7	Childhood ear infection;
PAAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.61	7.07	0.5	5.37e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.35	0.33	2.46e-5	Menopause (age at onset);
PAAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.28	0.39	4.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.82	-0.36	3.38e-6	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14645264	chr3:116134983	LSAMP	0.61	6.66	0.48	4.6e-10	Smoking initiation;
PAAD	cis	rs2688419	0.537	rs711725	chr3:23053020	A/T	cg00327796	chr3:23032191	NA	0.45	4.42	0.34	1.85e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.48	-4.61	-0.35	8.44e-6	Urinary tract infection frequency;
PAAD	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.71	6.68	0.48	4.16e-10	Corneal astigmatism;
PAAD	cis	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-9.03	-0.59	7.09e-16	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18755698	chr11:134046415	NCAPD3	-0.72	-7.63	-0.53	2.4e-12	Obesity-related traits;
PAAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs818427	1.000	rs382260	chr5:112210344	A/G	cg06941702	chr5:112196734	SRP19	0.45	4.28	0.33	3.28e-5	Total body bone mineral density;
PAAD	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.49	4.45	0.34	1.66e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs7873102	0.616	rs10738990	chr9:37975921	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.28	16.8	0.81	1.84e-36	Post bronchodilator FEV1;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03407747	chr17:6899364	ALOX12	-0.5	-5.14	-0.38	8.41e-7	Tonsillectomy;
PAAD	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg07636037	chr3:49044803	WDR6	-0.56	-4.43	-0.34	1.82e-5	Menarche (age at onset);
PAAD	cis	rs2559856	1.000	rs2559854	chr12:102090246	C/T	cg12924262	chr12:102091054	CHPT1	0.68	7.24	0.51	2.1e-11	Blood protein levels;
PAAD	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-7.66	-0.53	2.07e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.73	6.88	0.49	1.49e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.82	8.91	0.59	1.45e-15	Aortic root size;
PAAD	cis	rs4691139	0.658	rs4691141	chr4:165926222	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.4	-4.25	-0.33	3.7e-5	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs73416724	0.841	rs78415183	chr6:43394041	T/G	cg26312998	chr6:43337775	ZNF318	0.69	5.76	0.42	4.59e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.52	-5.69	-0.42	6.19e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs59888335	0.830	rs67828297	chr3:80524260	G/A	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.46	-5.38	-0.4	2.73e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2574704	0.561	rs2574712	chr3:11667602	G/A	cg07643000	chr3:11666825	VGLL4	-0.56	-4.47	-0.34	1.54e-5	Body mass index;
PAAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.51	5.4	0.4	2.48e-7	Asthma or chronic obstructive pulmonary disease;
PAAD	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.63	-5.56	-0.41	1.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.62	-5.37	-0.4	2.9e-7	QRS duration;
PAAD	cis	rs9549328	0.917	rs4907573	chr13:113648742	C/G	cg25790453	chr13:113633590	MCF2L	-0.39	-4.52	-0.34	1.26e-5	Systolic blood pressure;
PAAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.48	4.66	0.35	6.73e-6	Pulse pressure;
PAAD	cis	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.51	4.35	0.33	2.51e-5	Depression;
PAAD	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg08345082	chr10:99160200	RRP12	0.3	4.4	0.34	2.02e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	4.47	0.34	1.52e-5	Tonsillectomy;
PAAD	cis	rs7619833	0.512	rs7634574	chr3:27223319	C/A	cg02860705	chr3:27208620	NA	0.41	4.38	0.33	2.2e-5	Breast cancer;
PAAD	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg12673499	chr10:104412063	TRIM8	-0.36	-4.26	-0.33	3.62e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	4.32	0.33	2.85e-5	Aortic root size;
PAAD	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg23465465	chr6:26364728	BTN3A2	0.72	4.48	0.34	1.47e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg19254793	chr6:44695348	NA	0.52	4.98	0.37	1.74e-6	Total body bone mineral density;
PAAD	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.87	0.37	2.76e-6	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.76	5.91	0.43	2.16e-8	Initial pursuit acceleration;
PAAD	cis	rs7084783	0.519	rs2281584	chr10:105358980	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.47	4.74	0.36	4.87e-6	Fear of pain;
PAAD	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.55	5.25	0.39	4.98e-7	Diastolic blood pressure;
PAAD	trans	rs1075265	0.587	rs2542585	chr2:54013544	T/C	cg16115072	chr17:25938812	KSR1	0.59	6.31	0.46	2.97e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.72	-7.77	-0.53	1.08e-12	Neuroticism;
PAAD	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.84	9.94	0.63	3.06e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.75	-6.8	-0.48	2.25e-10	Blood protein levels;
PAAD	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.59	6.28	0.45	3.45e-9	Bladder cancer;
PAAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg08975724	chr8:8085496	FLJ10661	0.45	4.74	0.36	4.85e-6	Joint mobility (Beighton score);
PAAD	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.73	-0.53	1.34e-12	Hemoglobin concentration;
PAAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg23912435	chr1:150601613	ENSA	-0.49	-4.51	-0.34	1.32e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.47	4.69	0.36	5.95e-6	Pulmonary function;
PAAD	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg13870426	chr17:30244630	NA	-0.73	-6.07	-0.44	9.9e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11748319	chr10:5708674	ASB13	0.6	6.71	0.48	3.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.66	-6.6	-0.47	6.62e-10	Pubertal anthropometrics;
PAAD	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.4	4.33	0.33	2.67e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	6.39	0.46	1.96e-9	Systolic blood pressure;
PAAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-5.97	-0.44	1.59e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs950169	0.690	rs12901166	chr15:84699113	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.69	0.48	4.07e-10	Schizophrenia;
PAAD	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg18281939	chr5:77783895	LHFPL2	0.49	5.59	0.41	1e-7	Triglycerides;
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg25452165	chr22:42524984	CYP2D6	0.6	5.58	0.41	1.07e-7	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs4979764	chr10:64012925	G/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg07873178	chr11:65307616	LTBP3	0.97	4.52	0.34	1.24e-5	Height;
PAAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	7.0	0.49	7.67e-11	Cognitive ability;
PAAD	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-6.5	-0.47	1.08e-9	Urate levels in overweight individuals;
PAAD	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.07	-0.63	1.4e-18	Response to antipsychotic treatment;
PAAD	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.52	-4.47	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.78	-7.46	-0.52	6.21e-12	DNA methylation (variation);
PAAD	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg17076780	chr6:43251928	TTBK1	0.55	4.25	0.33	3.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6596100	0.538	rs34626261	chr5:132174880	A/C	cg14825688	chr5:132208181	LEAP2	-0.68	-4.84	-0.37	3.15e-6	Breast cancer;
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.89	10.77	0.66	1.88e-20	Ulcerative colitis;
PAAD	cis	rs2479106	0.824	rs1752169	chr9:126586563	C/A	cg16191174	chr9:126692580	DENND1A	0.57	5.25	0.39	5.04e-7	Polycystic ovary syndrome;
PAAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs2278796	0.697	rs2278795	chr1:204954993	A/G	cg09852221	chr1:205912646	SLC26A9	-0.39	-4.34	-0.33	2.55e-5	Mean platelet volume;
PAAD	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.82	-8.99	-0.59	9.07e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg02696790	chr15:75250997	RPP25	0.49	5.85	0.43	2.84e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2997447	0.723	rs2802337	chr1:26474398	G/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.87e-6	QRS complex (12-leadsum);
PAAD	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg10820045	chr2:198174542	NA	0.51	5.16	0.39	7.46e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.59	0.52	2.96e-12	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.03	-0.55	2.42e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.56e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.73	-0.36	4.98e-6	Renal cell carcinoma;
PAAD	cis	rs7523050	1.000	rs1690722	chr1:109455379	G/A	cg08274380	chr1:109419600	GPSM2	0.68	5.44	0.4	2.1e-7	Fat distribution (HIV);
PAAD	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.64	6.28	0.45	3.42e-9	Hip circumference;
PAAD	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.31	0.51	1.42e-11	Motion sickness;
PAAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.81	-8.47	-0.57	1.97e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.11	-0.55	1.5700000000000001e-13	Longevity;Endometriosis;
PAAD	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg18904891	chr8:8559673	CLDN23	0.7	6.35	0.46	2.37e-9	Obesity-related traits;
PAAD	cis	rs76793172	1.000	rs8112594	chr19:46365672	T/C	cg13320842	chr19:46175254	GIPR	0.62	4.74	0.36	4.8e-6	Eosinophil counts;
PAAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Height;
PAAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.79	7.96	0.54	3.77e-13	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08573270	chr6:170041713	WDR27	-0.63	-6.62	-0.47	5.96e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs929596	0.531	rs2741019	chr2:234510688	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.41	-0.34	1.91e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.43	5.25	0.39	5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg16083429	chr3:49237500	CCDC36	0.46	4.55	0.35	1.11e-5	Menarche (age at onset);
PAAD	cis	rs7580658	0.521	rs2404535	chr2:127947709	A/G	cg09760422	chr2:128146352	NA	0.26	4.35	0.33	2.48e-5	Protein C levels;
PAAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.6	6.63	0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg05585544	chr11:47624801	NA	-0.54	-5.95	-0.43	1.81e-8	Subjective well-being;
PAAD	cis	rs6504950	0.679	rs9897646	chr17:52985351	G/C	cg18040354	chr17:53800484	TMEM100	0.51	4.43	0.34	1.81e-5	Breast cancer;
PAAD	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg15556689	chr8:8085844	FLJ10661	0.5	5.01	0.38	1.47e-6	Joint mobility (Beighton score);
PAAD	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.33	-4.56	-0.35	1.03e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.59	0.68	1.17e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-5.12	-0.38	9.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.18	16.6	0.8	5.76e-36	Total cholesterol levels;
PAAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.9	10.57	0.65	6.37e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs901683	1.000	rs36102549	chr10:46082043	T/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.75e-5	Systolic blood pressure;
PAAD	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.51	-4.9	-0.37	2.39e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.6	6.65	0.47	4.84e-10	Mean corpuscular volume;
PAAD	cis	rs4795519	0.922	rs8074936	chr17:22179322	G/A	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg19980929	chr12:42632907	YAF2	-0.55	-6.4	-0.46	1.87e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.75	6.7	0.48	3.72e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.68	6.55	0.47	8.52e-10	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.44	7.09	0.5	4.75e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs72960926	1.000	rs72958991	chr6:75130440	T/C	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.75	-5.47	-0.41	1.85e-7	Ulcerative colitis;
PAAD	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.07	-0.55	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.52	-4.47	-0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.72	-6.95	-0.49	9.98e-11	Alcohol dependence;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.85	8.84	0.58	2.18e-15	Corneal astigmatism;
PAAD	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.36	4.72	0.36	5.42e-6	Permanent tooth development;
PAAD	trans	rs901683	1.000	rs74411575	chr10:46071967	A/T	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.37	9.34	0.6	1.1e-16	Diabetic retinopathy;
PAAD	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.31	0.4	3.84e-7	Monocyte percentage of white cells;
PAAD	trans	rs3742264	0.816	rs1952187	chr13:46674909	G/A	cg13594151	chr19:12405719	ZNF44	-0.64	-6.29	-0.45	3.16e-9	Blood protein levels;
PAAD	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg11630242	chr17:19881632	AKAP10	-0.49	-4.71	-0.36	5.61e-6	Schizophrenia;
PAAD	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.45	4.66	0.35	6.86e-6	Gut microbiome composition (winter);
PAAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.36	-4.73	-0.36	5.18e-6	Dupuytren's disease;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-7.22	-0.51	2.32e-11	Renal function-related traits (BUN);
PAAD	cis	rs8040855	0.965	rs6496766	chr15:85702375	C/A	cg08123816	chr15:85640762	PDE8A	0.4	4.93	0.37	2.1e-6	Bulimia nervosa;
PAAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg09835421	chr16:68378352	PRMT7	-0.91	-7.24	-0.51	2.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4454254	0.796	rs35758124	chr8:141048964	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.32	-4.33	-0.33	2.66e-5	Pulse pressure;
PAAD	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.57	5.44	0.4	2.11e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1468734	0.927	rs4786565	chr16:5000945	C/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.57	-4.58	-0.35	9.59e-6	Cancer;
PAAD	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.64e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.56	-4.94	-0.37	2.03e-6	P wave terminal force;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21236462	chr12:57145659	PRIM1	0.59	6.58	0.47	7.21e-10	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs17601876	0.545	rs4775936	chr15:51536022	A/G	cg21478137	chr15:51532386	CYP19A1	-0.5	-4.94	-0.37	2.05e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.51	5.45	0.4	1.99e-7	Non-response to antidepressants and depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07094993	chr16:72659952	NA	0.67	7.58	0.52	3.09e-12	Smoking initiation;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg18621852	chr3:10150065	C3orf24	0.5	4.68	0.36	6.2e-6	Alzheimer's disease;
PAAD	cis	rs7707921	0.881	rs73134739	chr5:81370760	T/C	cg21483461	chr5:81570383	RPS23	-0.51	-4.32	-0.33	2.83e-5	Breast cancer;
PAAD	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.11	-0.63	1.1e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11083840	0.535	rs931647	chr19:47143368	G/A	cg07844738	chr19:47129343	PTGIR	-0.41	-4.82	-0.36	3.49e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.69	-0.42	6.47e-8	Crohn's disease;
PAAD	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	2.97e-7	Migraine;
PAAD	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg09659197	chr4:152720779	NA	-0.36	-5.3	-0.39	4.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4378999	0.660	rs4572801	chr3:51103133	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.55	-4.31	-0.33	2.9e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg02475695	chr16:616220	NHLRC4	0.45	5.22	0.39	5.85e-7	Height;
PAAD	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19671926	chr4:122722719	EXOSC9	-0.61	-5.9	-0.43	2.23e-8	Type 2 diabetes;
PAAD	cis	rs375066	0.901	rs1050054	chr19:44376681	G/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.49e-6	Breast cancer;
PAAD	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.81	7.88	0.54	5.88e-13	Post bronchodilator FEV1;
PAAD	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.51	-0.65	9.26e-20	Cognitive function;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-6.16	-0.45	6.3e-9	Prudent dietary pattern;
PAAD	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.72	6.38	0.46	2.02e-9	Platelet count;
PAAD	trans	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg00626422	chr7:22894849	SNORD93	-0.54	-6.35	-0.46	2.41e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.61	0.82	1.61e-38	Height;
PAAD	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-4.88	-0.37	2.64e-6	Vitiligo;
PAAD	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.57	6.49	0.47	1.16e-9	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6445967	1.000	rs9846885	chr3:58285789	C/T	cg23715586	chr3:58305044	RPP14	0.5	4.45	0.34	1.65e-5	Platelet count;
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.75	8.36	0.56	3.71e-14	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.73	7.26	0.51	1.87e-11	Corneal astigmatism;
PAAD	cis	rs6782025	0.837	rs6438607	chr3:120800796	A/G	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg21823605	chr1:152486609	CRCT1	0.49	6.35	0.46	2.34e-9	Hair morphology;
PAAD	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.6	5.34	0.4	3.39e-7	Coronary heart disease;
PAAD	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.27	-0.39	4.64e-7	Schizophrenia;
PAAD	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-0.84	-5.47	-0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg07475973	chr22:42306951	NA	0.49	4.47	0.34	1.52e-5	Neuroticism;
PAAD	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.24	22.07	0.87	2.9e-49	Testicular germ cell tumor;
PAAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.89	10.96	0.66	5.73e-21	Blood protein levels;
PAAD	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg17644776	chr2:200775616	C2orf69	-0.68	-6.25	-0.45	3.91e-9	Schizophrenia;
PAAD	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs12808519	0.646	rs12361755	chr11:69602646	C/T	cg26765567	chr11:69587473	NA	-0.46	-4.29	-0.33	3.14e-5	Urate levels in overweight individuals;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.38	-0.33	2.21e-5	Depression;
PAAD	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.67	6.81	0.48	2.08e-10	Neuroticism;
PAAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg18279126	chr7:2041391	MAD1L1	0.58	5.75	0.42	4.67e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.87	-0.37	2.75e-6	Menopause (age at onset);
PAAD	cis	rs253959	0.883	rs6594967	chr5:115710803	T/C	cg05931423	chr5:115697214	NA	-0.47	-4.46	-0.34	1.6e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.47	-0.41	1.81e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.71	-0.36	5.46e-6	Breast cancer;
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg26516362	chr5:178986906	RUFY1	-0.56	-6.79	-0.48	2.37e-10	Lung cancer;
PAAD	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.84	9.8	0.62	7.21e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.58	6.62	0.47	5.68e-10	Calcium levels;
PAAD	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.79	-8.86	-0.58	1.97e-15	Colorectal cancer;
PAAD	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg12486944	chr17:80159399	CCDC57	0.55	4.9	0.37	2.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.69	7.44	0.52	6.79e-12	Melanoma;
PAAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.53	-4.64	-0.35	7.44e-6	Glycated hemoglobin levels;
PAAD	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-1.11	-12.19	-0.7	2.83e-24	Hair shape;
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.74	-7.61	-0.53	2.74e-12	DNA methylation (variation);
PAAD	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.4	0.61	7.84e-17	Response to antipsychotic treatment;
PAAD	cis	rs76793172	0.557	rs6509234	chr19:46229711	T/G	cg14061069	chr19:46274453	DMPK	0.58	5.16	0.39	7.6e-7	Eosinophil counts;
PAAD	cis	rs1468333	0.897	rs6888877	chr5:137510357	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	-0.59	-6.25	-0.45	3.95e-9	Resting heart rate;
PAAD	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg17366294	chr4:99064904	C4orf37	0.44	4.85	0.37	2.99e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.71	-7.99	-0.54	3.1400000000000003e-13	Extrinsic epigenetic age acceleration;
PAAD	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.76	-8.09	-0.55	1.78e-13	Prostate cancer;
PAAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.6	6.95	0.49	1.01e-10	Dupuytren's disease;
PAAD	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg23250157	chr14:64679961	SYNE2	0.55	5.79	0.42	3.95e-8	Atrial fibrillation;
PAAD	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg04013166	chr16:89971882	TCF25	0.65	4.41	0.34	1.98e-5	Skin colour saturation;
PAAD	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.39	13.52	0.74	7.43e-28	Corneal structure;
PAAD	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	1.04	7.94	0.54	4.13e-13	Inflammatory bowel disease;
PAAD	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22483191	chr7:20370941	ITGB8	-0.6	-6.34	-0.46	2.48e-9	Smoking initiation;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.61	4.67	0.35	6.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.85	-9.83	-0.62	5.86e-18	Iron status biomarkers;
PAAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	4.61	0.35	8.42e-6	Iron status biomarkers;
PAAD	cis	rs6804624	0.613	rs2700653	chr3:99169966	G/C	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12698343	chr2:158485436	ACVR1C	0.67	7.2	0.5	2.65e-11	Myopia (pathological);
PAAD	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.54	5.22	0.39	5.89e-7	Rheumatoid arthritis;
PAAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.62	-7.1	-0.5	4.47e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.7	7.05	0.5	5.89e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.48	-6.09	-0.44	8.68e-9	Crohn's disease;
PAAD	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.25e-31	Chronic sinus infection;
PAAD	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.51	-4.82	-0.36	3.51e-6	Multiple sclerosis;
PAAD	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg09659197	chr4:152720779	NA	0.42	5.51	0.41	1.52e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26137971	chr22:50920013	ADM2	0.57	6.34	0.46	2.43e-9	Monocyte percentage of white cells;
PAAD	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.72	7.21	0.5	2.41e-11	Colorectal cancer;
PAAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.91	10.75	0.66	2.09e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.62	6.32	0.46	2.76e-9	Motion sickness;
PAAD	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	6.4	0.46	1.79e-9	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00166722	chr3:10149974	C3orf24	0.97	8.23	0.56	7.82e-14	Alzheimer's disease;
PAAD	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.67	5.14	0.38	8.5e-7	Bipolar disorder;
PAAD	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs75757892	0.542	rs9505150	chr6:7323740	A/G	cg02954307	chr6:7269328	NA	0.5	4.28	0.33	3.32e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg17344516	chr5:154026930	NA	0.77	4.45	0.34	1.66e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-1.02	-13.99	-0.75	4.1e-29	Breast cancer;
PAAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg04450456	chr4:17643702	FAM184B	-0.49	-4.92	-0.37	2.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs11563648	0.553	rs1946107	chr7:127050750	A/G	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs77106637	0.585	rs12292949	chr11:72457531	C/T	cg03713592	chr11:72463424	ARAP1	0.75	6.72	0.48	3.35e-10	Type 2 diabetes;
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.54	5.38	0.4	2.73e-7	Menarche (age at onset);
PAAD	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.82	7.92	0.54	4.61e-13	Corneal astigmatism;
PAAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23088430	chr8:144679052	EEF1D;TIGD5	0.65	7.4	0.51	8.79e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.52	-5.29	-0.39	4.29e-7	Testicular germ cell tumor;
PAAD	cis	rs1075265	0.749	rs805380	chr2:54094421	G/C	cg04546899	chr2:54196757	PSME4	0.3	4.49	0.34	1.38e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg16964102	chr10:135390573	NA	-0.43	-4.59	-0.35	9.13e-6	Obesity-related traits;
PAAD	cis	rs1345301	0.518	rs2110661	chr2:102863221	C/T	cg03938978	chr2:103052716	IL18RAP	-0.42	-4.5	-0.34	1.34e-5	Waist circumference;
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	1.02	8.58	0.57	1.01e-14	Initial pursuit acceleration;
PAAD	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg15145965	chr22:50218605	BRD1	-0.6	-5.28	-0.39	4.42e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs12311304	1.000	rs12309210	chr12:15388361	T/C	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.86e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg19445457	chr11:5799446	OR52N5	-0.5	-4.6	-0.35	8.89e-6	DNA methylation (variation);
PAAD	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.6	-5.88	-0.43	2.46e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.51	1.64e-11	Response to antipsychotic treatment;
PAAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg06740227	chr12:86229804	RASSF9	0.54	4.92	0.37	2.2e-6	Major depressive disorder;
PAAD	cis	rs2320952	0.874	rs11653277	chr17:10488791	A/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs1476587	0.527	rs1859126	chr7:86752134	C/A	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Brachial circumference;
PAAD	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg02683114	chr2:24398427	C2orf84	0.59	6.34	0.46	2.5e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg10437265	chr15:77819839	NA	-0.37	-4.29	-0.33	3.1e-5	Type 2 diabetes;
PAAD	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.61	6.63	0.47	5.59e-10	Testicular germ cell tumor;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07866207	chr5:56208137	C5orf35	-0.54	-6.68	-0.48	4.15e-10	Energy expenditure (24h);
PAAD	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg00717180	chr2:96193071	NA	-0.63	-7.63	-0.53	2.44e-12	HDL cholesterol;
PAAD	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.25	18.24	0.83	4.23e-40	Schizophrenia;
PAAD	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.6	6.66	0.48	4.79e-10	Colorectal cancer;
PAAD	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.17	0.6	3.14e-16	Asthma (childhood onset);
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.7e-6	Personality dimensions;
PAAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.58	5.59	0.41	1.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg20913747	chr6:44695427	NA	-0.66	-6.62	-0.47	5.8e-10	Total body bone mineral density;
PAAD	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg10437265	chr15:77819839	NA	0.38	4.34	0.33	2.6e-5	Type 2 diabetes;
PAAD	cis	rs11020478	0.586	rs10765619	chr11:93382017	A/G	cg10523193	chr11:93463762	SNORA25	0.43	4.41	0.34	1.92e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.64	7.47	0.52	5.77e-12	Weight;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01476242	chr17:78774030	RPTOR	-0.66	-6.91	-0.49	1.28e-10	Obesity-related traits;
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.57	-6.77	-0.48	2.7e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6679454	0.726	rs1936407	chr1:58331776	T/C	cg17491850	chr1:57888480	DAB1	-0.37	-4.25	-0.33	3.77e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg24580199	chr1:23763081	ASAP3	0.48	4.27	0.33	3.49e-5	Total cholesterol levels;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24156658	chr11:65122092	TIGD3	0.62	6.74	0.48	3.03e-10	Pancreatic cancer;
PAAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.6	-7.98	-0.54	3.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.89	7.35	0.51	1.11e-11	Vitiligo;
PAAD	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg04450456	chr4:17643702	FAM184B	-0.43	-4.45	-0.34	1.63e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.31	0.71	1.35e-24	Bone mineral density;
PAAD	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.46	0.46	1.34e-9	Tonsillectomy;
PAAD	cis	rs2904967	0.636	rs239253	chr11:64984743	C/T	cg21890820	chr11:65308645	LTBP3	-0.54	-5.35	-0.4	3.2e-7	Mean corpuscular volume;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.5	-4.93	-0.37	2.12e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.71	-0.48	3.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs751728	0.597	rs767895	chr6:33791463	C/G	cg25922239	chr6:33757077	LEMD2	0.56	4.78	0.36	4.1e-6	Crohn's disease;
PAAD	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.97	7.42	0.52	7.72e-12	Eosinophilic esophagitis;
PAAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00300879	chr1:26503847	CNKSR1	0.3	4.58	0.35	9.77e-6	Height;
PAAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg08917208	chr2:24149416	ATAD2B	-0.5	-4.47	-0.34	1.5e-5	Asthma;
PAAD	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.6	-5.49	-0.41	1.62e-7	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs12681963	0.688	rs2938229	chr8:30094947	A/G	cg23406830	chr8:30012838	DCTN6	-0.72	-4.47	-0.34	1.49e-5	Migraine;
PAAD	trans	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg01620082	chr3:125678407	NA	-1.38	-8.02	-0.55	2.61e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.63	8.29	0.56	5.69e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg02683114	chr2:24398427	C2orf84	-0.61	-6.55	-0.47	8.4e-10	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.75	-7.33	-0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.6	-5.09	-0.38	1.06e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	cis	rs4843185	0.646	rs35953313	chr16:85710476	T/A	cg03748158	chr16:85670174	KIAA0182	-0.43	-4.57	-0.35	9.98e-6	Platelet distribution width;
PAAD	cis	rs4478858	0.684	rs12725881	chr1:31736123	C/T	cg18939081	chr1:31884902	SERINC2	-0.51	-5.78	-0.42	4e-8	Alcohol dependence;
PAAD	cis	rs7561149	1.000	rs7561149	chr2:179689856	T/C	cg03283842	chr2:179343803	FKBP7;PLEKHA3;MIR548N	0.43	4.29	0.33	3.21e-5	QT interval;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.83	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.67	5.13	0.38	8.73e-7	Mammographic density (dense area);
PAAD	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg20607287	chr7:12443886	VWDE	-0.63	-5.01	-0.38	1.47e-6	Coronary artery disease;
PAAD	cis	rs2562456	0.833	rs4359573	chr19:21542296	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs9649465	1.000	rs6466881	chr7:123337734	G/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.97	7.42	0.52	7.72e-12	Eosinophilic esophagitis;
PAAD	cis	rs910187	0.901	rs6124969	chr20:45816277	C/T	cg27589058	chr20:45804311	EYA2	-0.44	-4.28	-0.33	3.35e-5	Migraine;
PAAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.71	7.18	0.5	2.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2625529	0.617	rs13858	chr15:72433144	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-4.73	-0.36	5.15e-6	Red blood cell count;
PAAD	cis	rs4427176	1.000	rs4427176	chr8:9533399	T/G	cg03024720	chr8:9765601	NA	0.46	4.36	0.33	2.36e-5	Mosquito bite size;
PAAD	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg10856724	chr12:34555212	NA	-0.47	-4.79	-0.36	3.94e-6	Morning vs. evening chronotype;
PAAD	cis	rs4742903	0.846	rs7022158	chr9:106924872	A/G	cg14250997	chr9:106856677	SMC2	0.47	5.11	0.38	9.56e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.45	-0.46	1.41e-9	Triglycerides;
PAAD	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg14343924	chr8:8086146	FLJ10661	-0.61	-5.13	-0.38	8.68e-7	Mood instability;
PAAD	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.57	6.43	0.46	1.52e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg00571178	chr13:114841904	RASA3	-0.54	-4.6	-0.35	8.73e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs797680	0.856	rs682514	chr1:93719430	A/C	cg04535902	chr1:92947332	GFI1	-0.45	-4.32	-0.33	2.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4605213	0.528	rs9912882	chr17:49271342	C/T	cg22932220	chr17:49244634	NME2;NME1-NME2	-0.44	-5.49	-0.41	1.63e-7	Height;
PAAD	cis	rs1468734	0.929	rs12928442	chr16:5006781	G/C	cg06510647	chr16:5006106	NA	0.61	5.69	0.42	6.3e-8	Cancer;
PAAD	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs713477	0.505	rs9635232	chr14:55887880	T/C	cg13175173	chr14:55914753	NA	-0.36	-4.77	-0.36	4.21e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs757081	0.648	rs10766382	chr11:17274441	A/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.76	-0.42	4.59e-8	Systolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17497419	chr2:24346215	PFN4;LOC375190	0.74	7.79	0.53	9.93e-13	Obesity-related traits;
PAAD	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.48	6.05	0.44	1.08e-8	Crohn's disease;
PAAD	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg10591111	chr5:226296	SDHA	-0.72	-5.4	-0.4	2.52e-7	Breast cancer;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.74	8.5	0.57	1.61e-14	Height;
PAAD	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.62	0.47	5.68e-10	Systemic lupus erythematosus;
PAAD	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-8.67	-0.58	6.19e-15	Coronary artery disease;
PAAD	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.33	-0.33	2.74e-5	Resting heart rate;
PAAD	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.33	-0.33	2.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.77	4.31	0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg24519413	chr1:26490540	NA	0.52	4.89	0.37	2.51e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12715266	chr12:60812459	NA	0.5	6.35	0.46	2.37e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17777628	chr2:232655051	COPS7B	-0.69	-6.76	-0.48	2.83e-10	Obesity-related traits;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.35	6.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg11952622	chr19:58962976	ZNF324B	0.46	4.39	0.34	2.08e-5	Uric acid clearance;
PAAD	cis	rs11051970	0.559	rs11051986	chr12:32555273	A/G	cg24626660	chr12:32551988	NA	0.43	4.56	0.35	1.03e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs427941	0.703	rs201449	chr7:101739054	A/G	cg06246474	chr7:101738831	CUX1	0.45	4.64	0.35	7.57e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.47e-6	Lung cancer;
PAAD	cis	rs8070740	0.617	rs1058119	chr17:5323125	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.69	0.42	6.23e-8	Menopause (age at onset);
PAAD	cis	rs1113500	0.548	rs11185271	chr1:108659933	A/G	cg06207961	chr1:108661230	NA	0.45	4.51	0.34	1.3e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	5.02	0.38	1.43e-6	Systolic blood pressure;
PAAD	cis	rs7904985	1.000	rs7084928	chr10:88122516	C/T	cg07322936	chr10:88137208	NA	-0.48	-4.31	-0.33	2.91e-5	Barrett's esophagus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03822259	chr16:3150413	NA	-0.63	-6.33	-0.46	2.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.92	-8.31	-0.56	4.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-7.99	-0.54	3.21e-13	Hemoglobin concentration;
PAAD	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.56	-4.85	-0.37	3.06e-6	Total body bone mineral density;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.99	0.38	1.65e-6	Obesity-related traits;
PAAD	cis	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg00262122	chr8:11665843	FDFT1	-0.51	-4.66	-0.35	6.95e-6	Neuroticism;
PAAD	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.8	9.93	0.63	3.18e-18	Alcohol dependence;
PAAD	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.59	0.47	6.89e-10	Mood instability;
PAAD	cis	rs73058052	0.597	rs11083979	chr19:50096144	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.59	-5.09	-0.38	1.04e-6	Fibrinogen levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18290026	chr14:104385850	C14orf2	-0.59	-6.44	-0.46	1.49e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg21433313	chr16:3507492	NAT15	0.88	7.76	0.53	1.14e-12	Tuberculosis;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg18621852	chr3:10150065	C3orf24	0.53	5.05	0.38	1.27e-6	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg00750074	chr16:89608354	SPG7	-0.48	-4.57	-0.35	1.01e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.6	-0.35	8.77e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.67	0.53	1.92e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-4.69	-0.36	6.04e-6	Vitiligo;
PAAD	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.74	6.91	0.49	1.28e-10	Cognitive ability;
PAAD	trans	rs901683	1.000	rs35626777	chr10:46088167	G/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.48	4.67	0.35	6.65e-6	Cancer;
PAAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg25809561	chr17:30822961	MYO1D	0.58	6.17	0.45	6.05e-9	Schizophrenia;
PAAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs75920871	1.000	rs61905677	chr11:116833655	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18404041	chr3:52824283	ITIH1	0.42	4.5	0.34	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs6558530	0.836	rs11136424	chr8:1717036	C/T	cg02000426	chr8:1759815	NA	-0.4	-4.27	-0.33	3.41e-5	Systolic blood pressure;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.59	-5.56	-0.41	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.78	7.23	0.51	2.22e-11	Blood metabolite levels;
PAAD	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	9.96	0.63	2.69e-18	Colorectal cancer;
PAAD	cis	rs740474	0.569	rs4912762	chr5:140881691	A/G	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.31	4.61	0.35	8.33e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.31	0.64	3.1400000000000002e-19	Cognitive test performance;
PAAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg10167378	chr1:228756711	NA	0.43	4.26	0.33	3.57e-5	Diastolic blood pressure;
PAAD	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.86	6.94	0.49	1.04e-10	Axial length;
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.72	-0.42	5.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.28	-0.33	3.27e-5	Systemic lupus erythematosus;
PAAD	cis	rs1879734	0.954	rs2950244	chr1:54143759	C/T	cg14659662	chr1:54151053	GLIS1	0.39	6.03	0.44	1.18e-8	Mitral valve prolapse;
PAAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg10935138	chr17:73851978	WBP2	0.48	4.25	0.33	3.69e-5	White matter hyperintensity burden;
PAAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.84	-0.62	5.69e-18	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05189008	chr12:49582177	TUBA1A	0.7	6.95	0.49	1e-10	Obesity-related traits;
PAAD	cis	rs11024102	0.925	rs7127818	chr11:17004090	G/C	cg15084286	chr11:17036142	PLEKHA7	0.51	4.69	0.36	6.01e-6	Glaucoma (primary angle closure);
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.69	0.36	6.16e-6	Height;
PAAD	cis	rs860295	0.580	rs12032720	chr1:155274960	G/C	cg02153340	chr1:155202674	NA	-0.51	-4.58	-0.35	9.45e-6	Body mass index;
PAAD	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg16898833	chr6:26189333	HIST1H4D	0.87	4.7	0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.72	-6.46	-0.46	1.33e-9	Platelet distribution width;
PAAD	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg05283184	chr6:79620031	NA	0.45	4.39	0.34	2.11e-5	Left atrial antero-posterior diameter;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14826516	chr22:50639351	SELO	0.75	9.14	0.6	3.65e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.71e-15	Dupuytren's disease;
PAAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.56	6.03	0.44	1.19e-8	IgG glycosylation;
PAAD	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.36	0.33	2.36e-5	Lung cancer;
PAAD	cis	rs7561149	1.000	rs7600330	chr2:179689985	C/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.55	5.62	0.41	9.01e-8	QT interval;
PAAD	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg00428638	chr19:7224713	INSR	0.53	5.87	0.43	2.58e-8	Hypothyroidism;
PAAD	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg00024416	chr22:24240387	NA	-0.45	-4.35	-0.33	2.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs617219	0.737	rs2166343	chr5:78484060	A/G	cg24856658	chr5:78533917	JMY	-0.38	-4.32	-0.33	2.84e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg27572855	chr1:25598939	RHD	-0.46	-4.61	-0.35	8.41e-6	Erythrocyte sedimentation rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03841784	chr12:1890922	ADIPOR2	-0.49	-6.36	-0.46	2.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs11828289	0.660	rs76458473	chr11:23237355	T/G	cg20040320	chr11:23191996	NA	-0.72	-5.0	-0.38	1.58e-6	Cancer;
PAAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-4.93	-0.37	2.09e-6	Cognitive test performance;
PAAD	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.71	8.1	0.55	1.68e-13	Alcohol dependence;
PAAD	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	0.96	8.07	0.55	1.92e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg16584676	chr17:46985605	UBE2Z	0.57	5.72	0.42	5.44e-8	Type 2 diabetes;
PAAD	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg10729496	chr3:10149963	C3orf24	0.9	6.62	0.47	5.69e-10	Alzheimer's disease;
PAAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg21130718	chr4:1044621	NA	0.57	4.75	0.36	4.71e-6	Recombination rate (females);
PAAD	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.54	-4.92	-0.37	2.18e-6	Menopause (age at onset);
PAAD	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg15816464	chr17:2026533	SMG6	-0.51	-5.45	-0.4	2.03e-7	Total body bone mineral density;
PAAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.47	-4.72	-0.36	5.37e-6	Body mass index;
PAAD	cis	rs829661	0.847	rs829622	chr2:30753445	T/C	cg12454169	chr2:30669597	LCLAT1	0.67	5.04	0.38	1.3e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6466055	0.720	rs2030776	chr7:105008458	C/G	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	6.79e-12	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	5.69	0.42	6.47e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3106136	0.507	rs13134502	chr4:95304507	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.06	0.38	1.19e-6	Capecitabine sensitivity;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg21951975	chr1:209979733	IRF6	-0.41	-5.3	-0.4	3.92e-7	Monobrow;
PAAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg20933634	chr6:27740509	NA	0.8	7.31	0.51	1.4e-11	Depression;
PAAD	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg20003494	chr4:90757398	SNCA	-0.6	-5.97	-0.44	1.65e-8	Neuroticism;
PAAD	trans	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.4	-0.46	1.84e-9	Triglycerides;
PAAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.6	-6.89	-0.49	1.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg21231944	chr12:82153410	PPFIA2	-0.55	-4.58	-0.35	9.5e-6	Resting heart rate;
PAAD	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.02	-0.59	7.59e-16	Response to antipsychotic treatment;
PAAD	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg00919237	chr7:87102261	ABCB4	-0.73	-5.99	-0.44	1.46e-8	Gallbladder cancer;
PAAD	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg21483461	chr5:81570383	RPS23	0.52	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg18833306	chr6:118973337	C6orf204	0.42	4.35	0.33	2.52e-5	Electrocardiographic conduction measures;
PAAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.09	0.44	8.85e-9	Rheumatoid arthritis;
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.66	7.75	0.53	1.22e-12	Age at first birth;
PAAD	cis	rs1075265	0.933	rs929734	chr2:54338295	C/G	cg04546899	chr2:54196757	PSME4	0.33	4.57	0.35	1.01e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg01299579	chr2:10830716	NOL10	0.59	6.13	0.45	7.13e-9	Prostate cancer;
PAAD	cis	rs7562790	0.535	rs28705335	chr2:36655721	T/C	cg01206211	chr2:36825736	FEZ2	0.49	4.89	0.37	2.52e-6	QRS duration;QRS complex (Cornell);
PAAD	cis	rs12808519	0.688	rs3168175	chr11:69586070	A/C	cg26765567	chr11:69587473	NA	-0.48	-4.3	-0.33	3e-5	Urate levels in overweight individuals;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg18279126	chr7:2041391	MAD1L1	0.62	6.08	0.44	9.23e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.52	0.57	1.43e-14	Bipolar disorder;
PAAD	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg27490568	chr2:178487706	NA	0.42	4.47	0.34	1.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21028142	chr17:79581711	NPLOC4	0.57	7.74	0.53	1.31e-12	Eye color traits;
PAAD	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.37	0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16988970	chr17:42248062	ASB16	0.36	5.08	0.38	1.07e-6	Total body bone mineral density;
PAAD	cis	rs6782025	0.837	rs6805670	chr3:120784668	G/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	LDL cholesterol;
PAAD	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs9815354	1.000	rs1717014	chr3:41917395	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.94	0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.43	0.52	7.21e-12	Body mass index;
PAAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg08992911	chr2:238395768	MLPH	0.91	6.58	0.47	7.34e-10	Prostate cancer;
PAAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.62	8.18	0.55	1.07e-13	Renal cell carcinoma;
PAAD	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg27490568	chr2:178487706	NA	-0.39	-4.34	-0.33	2.64e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.21	-0.39	6.16e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg13798912	chr7:905769	UNC84A	0.64	4.5	0.34	1.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-5.98	-0.44	1.55e-8	Monocyte count;
PAAD	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg21452805	chr1:244014465	NA	0.45	4.28	0.33	3.32e-5	RR interval (heart rate);
PAAD	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.45	5.16	0.39	7.76e-7	Testicular germ cell tumor;
PAAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.7	-8.31	-0.56	5.07e-14	Huntington's disease progression;
PAAD	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs2718812	0.935	rs1867502	chr3:133410625	C/A	cg11941060	chr3:133502564	NA	0.46	4.9	0.37	2.47e-6	Iron status biomarkers;
PAAD	cis	rs9469913	0.733	rs11759235	chr6:34795102	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.49	-4.28	-0.33	3.26e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-8.63	-0.57	7.54e-15	Exhaled nitric oxide output;
PAAD	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.53	7.12	0.5	3.98e-11	Primary biliary cholangitis;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.76	0.36	4.5e-6	Height;
PAAD	cis	rs73206853	0.841	rs73206845	chr12:110660556	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.34e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6687430	0.532	rs4846235	chr1:10632235	C/T	cg17425144	chr1:10567563	PEX14	-0.43	-4.67	-0.35	6.65e-6	Hand grip strength;
PAAD	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.7	6.93	0.49	1.11e-10	Coronary artery disease;
PAAD	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-6.79	-0.48	2.42e-10	Educational attainment;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg10156544	chr12:104324016	LOC253724;HSP90B1	0.69	6.38	0.46	2.03e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.43	-5.73	-0.42	5.33e-8	Ulcerative colitis;
PAAD	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.54	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.8	7.15	0.5	3.34e-11	Blood protein levels;
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	1.01	8.26	0.56	6.69e-14	Initial pursuit acceleration;
PAAD	cis	rs17162190	0.698	rs56241541	chr1:26840904	C/T	cg17456097	chr1:26900765	RPS6KA1	0.59	4.79	0.36	3.88e-6	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03676636	chr4:99064102	C4orf37	0.32	5.89	0.43	2.39e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.68	5.83	0.43	3.24e-8	Height;
PAAD	cis	rs8018808	0.967	rs176766	chr14:77865367	G/A	cg20045696	chr14:77926864	AHSA1	0.51	4.98	0.37	1.69e-6	Myeloid white cell count;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.88	10.17	0.64	7.56e-19	Iron status biomarkers;
PAAD	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg21361702	chr7:150065534	REPIN1	0.61	5.05	0.38	1.24e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.18	10.18	0.64	6.86e-19	Vitiligo;
PAAD	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.72	11.27	0.67	8.6e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	5.01	0.38	1.5e-6	Neuroticism;
PAAD	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-6.11	-0.44	7.9e-9	Cognitive function;
PAAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.8	-8.39	-0.56	3.19e-14	DNA methylation (variation);
PAAD	cis	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg21546286	chr11:48923668	NA	0.53	5.37	0.4	2.84e-7	HDL cholesterol;
PAAD	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	7.08	0.5	4.92e-11	Body mass index (adult);
PAAD	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.75	7.87	0.54	6.19e-13	Blood metabolite levels;
PAAD	trans	rs9467603	0.547	rs4712936	chr6:25417423	G/T	cg01620082	chr3:125678407	NA	1.3	6.57	0.47	7.49e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.67	4.56	0.35	1.03e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.920	rs56047901	chr16:67742326	G/A	cg27539214	chr16:67997921	SLC12A4	-0.67	-4.5	-0.34	1.34e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs778371	0.755	rs778352	chr2:233804330	A/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-5.81	-0.43	3.53e-8	Schizophrenia;
PAAD	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.57	5.89	0.43	2.34e-8	Anxiety disorder;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg25319279	chr11:5960081	NA	-0.6	-6.07	-0.44	9.89e-9	DNA methylation (variation);
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg08835956	chr7:39171034	POU6F2	-0.33	-5.31	-0.4	3.76e-7	IgG glycosylation;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg25703541	chr22:24373054	LOC391322	-0.88	-9.97	-0.63	2.56e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.83	-9.24	-0.6	2e-16	Aortic root size;
PAAD	cis	rs1035491	0.715	rs10080155	chr5:63926534	G/T	cg01791865	chr5:63954708	NA	0.51	5.35	0.4	3.13e-7	Body mass index;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27312872	chr1:35321550	C1orf212	-0.67	-6.52	-0.47	9.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.59	-0.35	9.12e-6	Recombination measurement;
PAAD	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.38	4.8	0.36	3.8e-6	Menarche (age at onset);
PAAD	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.58	-5.53	-0.41	1.33e-7	Neuroticism;
PAAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.32	0.33	2.82e-5	Major depressive disorder;
PAAD	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg26935685	chr1:15502881	TMEM51	-0.51	-4.31	-0.33	2.87e-5	Systolic blood pressure;
PAAD	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.48	4.52	0.34	1.26e-5	Neuroticism;
PAAD	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.59	-6.0	-0.44	1.36e-8	Testicular germ cell tumor;
PAAD	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.56	-5.03	-0.38	1.34e-6	White blood cell count;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.9	0.37	2.44e-6	Vitiligo;
PAAD	cis	rs2445762	0.548	rs2445781	chr15:51653260	A/C	cg25905881	chr15:51634250	GLDN	0.52	5.14	0.38	8.32e-7	Hormone measurements;
PAAD	cis	rs4708832	0.508	rs4709324	chr6:159863163	T/C	cg04088182	chr6:159188303	EZR	0.55	5.11	0.38	9.51e-7	QRS duration;
PAAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.85	-0.49	1.71e-10	IgG glycosylation;
PAAD	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06850241	chr22:41845214	NA	0.51	4.9	0.37	2.44e-6	Vitiligo;
PAAD	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.63	4.66	0.35	6.99e-6	Vitiligo;
PAAD	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	4.76	0.36	4.43e-6	Iron status biomarkers;
PAAD	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg07068956	chr7:100330872	ZAN	-0.7	-5.45	-0.4	2.02e-7	Other erythrocyte phenotypes;
PAAD	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.55	5.44	0.4	2.1e-7	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03578886	chr8:94928855	PDP1	0.69	6.81	0.48	2.13e-10	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.44	5.01	0.38	1.47e-6	Colorectal cancer;
PAAD	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs79911532	0.515	rs10235228	chr7:75833282	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.73	-4.83	-0.36	3.36e-6	Mononucleosis;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.84	11.08	0.67	2.69e-21	Vitiligo;
PAAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-4.38	-0.33	2.21e-5	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs452036	0.625	rs2754163	chr14:23897507	A/G	cg23613857	chr14:23356614	REM2	0.4	4.46	0.34	1.58e-5	Resting heart rate;P wave duration;
PAAD	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg04454285	chr16:86016317	NA	-0.51	-4.46	-0.34	1.56e-5	Multiple sclerosis;
PAAD	cis	rs427941	0.703	rs201450	chr7:101739441	A/T	cg06246474	chr7:101738831	CUX1	-0.44	-4.57	-0.35	1.02e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg03808351	chr9:123631620	PHF19	0.45	4.85	0.37	3.02e-6	Rheumatoid arthritis;
PAAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg01489256	chr8:11204017	TDH	0.43	4.45	0.34	1.67e-5	Retinal vascular caliber;
PAAD	cis	rs2882667	0.728	rs13181830	chr5:138280416	A/G	cg09476006	chr5:138032270	NA	-0.44	-5.51	-0.41	1.52e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg18888403	chr1:24152774	HMGCL	0.4	4.56	0.35	1.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg25576086	chr14:70833871	SYNJ2BP	-0.47	-6.09	-0.44	8.87e-9	Prostate cancer;
PAAD	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7929679	0.521	rs10836304	chr11:34794024	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.39	-0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.42	0.4	2.3e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.68	-7.3	-0.51	1.46e-11	Blood metabolite levels;
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16405210	chr4:1374714	KIAA1530	0.49	4.86	0.37	2.96e-6	Obesity-related traits;
PAAD	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg01181863	chr3:195395398	SDHAP2	-0.94	-9.02	-0.59	7.8e-16	Pancreatic cancer;
PAAD	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.98	9.15	0.6	3.55e-16	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.51	-5.24	-0.39	5.39e-7	Inflammatory bowel disease;
PAAD	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12165864	chr7:66369176	NA	-0.73	-4.71	-0.36	5.47e-6	Diabetic kidney disease;
PAAD	cis	rs17135859	0.669	rs4705571	chr5:113046552	A/G	cg12552261	chr5:112820674	MCC	0.63	4.41	0.34	1.97e-5	F-cell distribution;
PAAD	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	1.14	7.52	0.52	4.5e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.57	6.0	0.44	1.4e-8	Immature fraction of reticulocytes;
PAAD	cis	rs13242816	1.000	rs62468976	chr7:116126891	C/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.01	-0.38	1.48e-6	P wave duration;
PAAD	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00977110	chr5:151150581	G3BP1	0.58	6.7	0.48	3.72e-10	Monocyte percentage of white cells;
PAAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19346786	chr7:2764209	NA	-0.41	-5.5	-0.41	1.6e-7	Height;
PAAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.83	8.52	0.57	1.45e-14	Corneal astigmatism;
PAAD	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	0.95	11.04	0.67	3.53e-21	Testicular germ cell tumor;
PAAD	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.41	-4.69	-0.36	6.05e-6	Blood pressure (smoking interaction);
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.37	4.54	0.35	1.12e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.03	-0.5	6.43e-11	Breast cancer;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.76	5.6	0.41	9.95e-8	Initial pursuit acceleration;
PAAD	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.1	-0.38	9.97e-7	Systemic lupus erythematosus;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.66	-6.35	-0.46	2.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11811982	0.793	rs80311310	chr1:227415803	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7833787	1.000	rs17383616	chr8:18704800	A/C	cg17701159	chr8:18705777	PSD3	-0.44	-5.19	-0.39	6.77e-7	Obesity-related traits;
PAAD	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs6466055	0.777	rs2299308	chr7:104825819	A/C	cg04380332	chr7:105027541	SRPK2	-0.66	-7.38	-0.51	9.41e-12	Schizophrenia;
PAAD	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg08992911	chr2:238395768	MLPH	0.6	5.03	0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.55	-0.41	1.24e-7	Lung cancer;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.75	5.32	0.4	3.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.74	10.06	0.63	1.49e-18	Iron status biomarkers;
PAAD	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.84	6.44	0.46	1.5e-9	Axial length;
PAAD	cis	rs7084921	0.579	rs2862947	chr10:101863817	C/G	cg04359915	chr10:101825029	CPN1	-0.35	-5.22	-0.39	5.66e-7	Bone mineral density;
PAAD	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg17524180	chr13:113633600	MCF2L	-0.51	-5.33	-0.4	3.55e-7	Systolic blood pressure;
PAAD	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.51	-5.3	-0.39	4.03e-7	Menarche (age at onset);
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg04482110	chr17:41364121	TMEM106A	0.39	4.47	0.34	1.54e-5	Menopause (age at onset);
PAAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	6.34	0.46	2.43e-9	Mood instability;
PAAD	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg25883020	chr8:41504993	NKX6-3	0.37	4.31	0.33	2.93e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.64	6.93	0.49	1.11e-10	Mean platelet volume;
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.38	-0.64	2.09e-19	Longevity;
PAAD	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg10183150	chr4:120222239	C4orf3	0.33	4.4	0.34	2e-5	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.64	7.79	0.53	9.68e-13	Prudent dietary pattern;
PAAD	cis	rs364477	0.904	rs279897	chr9:966257	T/G	cg13952963	chr9:998547	NA	0.65	4.54	0.35	1.13e-5	Major depressive disorder;
PAAD	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.78	4.71	0.36	5.49e-6	Obesity-related traits;
PAAD	cis	rs716804	0.515	rs2403268	chr11:10037003	G/A	cg06875754	chr11:10328428	ADM	-0.34	-4.44	-0.34	1.72e-5	Neuroticism;
PAAD	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs11892454	0.515	rs10185886	chr2:26077947	G/T	cg25181710	chr2:26045287	ASXL2	-0.44	-5.05	-0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs16854884	1.000	rs16854884	chr3:143778708	A/C	cg06585982	chr3:143692056	C3orf58	0.61	5.89	0.43	2.42e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06341202	chr17:78010343	CCDC40;TBC1D16	0.56	6.37	0.46	2.13e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7246865	0.510	rs7253742	chr19:17171689	C/T	cg19418318	chr19:17219073	MYO9B	-0.36	-5.2	-0.39	6.45e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.51	0.41	1.51e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.68	0.53	1.82e-12	Prudent dietary pattern;
PAAD	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.53	-5.04	-0.38	1.33e-6	Mean platelet volume;
PAAD	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg23417306	chr2:180868811	CWC22	-0.49	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02122052	chr13:46550203	ZC3H13	0.56	6.3	0.46	3.01e-9	Myopia (pathological);
PAAD	cis	rs11264799	0.765	rs67805319	chr1:157622853	G/A	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06915872	chr16:87998081	BANP	0.59	5.4	0.4	2.52e-7	Menopause (age at onset);
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11245990	chr11:68621969	NA	0.38	5.14	0.38	8.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7873102	0.630	rs17438977	chr9:38001834	G/C	cg03528946	chr9:38069800	SHB	-0.5	-5.04	-0.38	1.28e-6	Brain structure;
PAAD	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg03808351	chr9:123631620	PHF19	0.45	4.77	0.36	4.37e-6	Rheumatoid arthritis;
PAAD	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.16	17.57	0.82	1.93e-38	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17429075	chr10:130492994	NA	0.53	6.58	0.47	7.06e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.56	-5.92	-0.43	2.05e-8	Blood metabolite levels;
PAAD	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg01098237	chr11:65601417	SNX32	0.39	4.3	0.33	3.02e-5	Schizophrenia;
PAAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.64	-7.99	-0.54	3.16e-13	Menopause (age at onset);
PAAD	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg06307176	chr5:131281290	NA	0.49	4.34	0.33	2.58e-5	Life satisfaction;
PAAD	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.53	4.9	0.37	2.43e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg24553058	chr2:113831203	IL1F10	0.46	5.19	0.39	6.54e-7	Protein quantitative trait loci;
PAAD	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-6.04	-0.44	1.15e-8	Pancreatic cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13080904	chr7:143534545	LOC154761	0.72	8.66	0.57	6.28e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-4.75	-0.36	4.69e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.62	-5.69	-0.42	6.35e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.9	11.86	0.69	2.22e-23	Total body bone mineral density;
PAAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg09659197	chr4:152720779	NA	0.39	5.08	0.38	1.09e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.86	-6.98	-0.49	8.55e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.5	-5.24	-0.39	5.33e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	4.44	0.34	1.72e-5	Mean corpuscular volume;
PAAD	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg01075559	chr1:2537774	MMEL1	0.47	5.04	0.38	1.32e-6	Ulcerative colitis;
PAAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg20893579	chr22:38215064	NA	0.52	5.0	0.38	1.56e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs59888335	0.858	rs9857591	chr3:81004408	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg17724175	chr1:150552817	MCL1	-0.51	-5.63	-0.42	8.44e-8	Tonsillectomy;
PAAD	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.79	-0.36	3.98e-6	Hirschsprung disease;
PAAD	cis	rs9888739	0.920	rs12920597	chr16:31304382	C/T	cg15817542	chr16:31343056	ITGAM	-0.59	-4.62	-0.35	8.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg19875578	chr6:126661172	C6orf173	0.52	5.39	0.4	2.62e-7	Male-pattern baldness;
PAAD	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4740619	0.630	rs3008739	chr9:15981754	C/T	cg14451791	chr9:16040625	NA	0.39	4.73	0.36	4.99e-6	Body mass index;
PAAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.42	4.38	0.33	2.23e-5	Type 2 diabetes;
PAAD	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg27411982	chr8:10470053	RP1L1	-0.53	-5.86	-0.43	2.78e-8	Retinal vascular caliber;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.68	-4.38	-0.33	2.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.48	-0.34	1.46e-5	Alzheimer's disease (survival time);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15001633	chr8:103265981	UBR5	-0.69	-6.54	-0.47	8.84e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg23682824	chr7:23144976	KLHL7	-0.5	-4.49	-0.34	1.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-1.01	-8.59	-0.57	9.88e-15	Blood trace element (Zn levels);
PAAD	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02172891	chr10:134593761	INPP5A	0.63	6.53	0.47	9.54e-10	Warfarin maintenance dose;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs12042052	1.000	rs10910623	chr1:232938699	G/A	cg02903907	chr1:232941055	KIAA1383	0.79	4.36	0.33	2.37e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg19254793	chr6:44695348	NA	-0.45	-4.4	-0.34	2.05e-5	Total body bone mineral density;
PAAD	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.81	8.14	0.55	1.29e-13	Testicular germ cell tumor;
PAAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg14926445	chr8:58193284	C8orf71	-0.72	-5.54	-0.41	1.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	4.25	0.33	3.74e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.17	19.42	0.84	5.12e-43	Multiple myeloma;
PAAD	cis	rs1499972	0.887	rs7630428	chr3:117528682	A/G	cg07612923	chr3:117604196	NA	1.08	7.07	0.5	5.2e-11	Schizophrenia;
PAAD	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.81	-8.41	-0.56	2.74e-14	Corneal astigmatism;
PAAD	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg19682013	chr15:45996608	NA	0.32	4.27	0.33	3.39e-5	Waist circumference;Weight;
PAAD	cis	rs1035491	0.715	rs876353	chr5:63919557	C/T	cg01791865	chr5:63954708	NA	0.51	5.44	0.4	2.08e-7	Body mass index;
PAAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.52	5.36	0.4	3.02e-7	Menopause (age at onset);
PAAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg19423196	chr10:82049429	MAT1A	0.45	4.25	0.33	3.7e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.72	-0.42	5.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg26954736	chr11:73693896	UCP2	0.97	4.58	0.35	9.8200000000000008e-06	Obesity-related traits;
PAAD	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	19.88	0.85	4.06e-44	IgG glycosylation;
PAAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.54	5.19	0.39	6.57e-7	Cancer;
PAAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg04257695	chr17:30186438	C17orf79	0.73	5.37	0.4	2.92e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg24053715	chr22:38214548	NA	0.57	5.25	0.39	4.95e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.75	-5.4	-0.4	2.47e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6893807	0.667	rs1477290	chr5:87988934	T/C	cg02225085	chr5:87975992	LOC645323	-0.68	-5.09	-0.38	1.05e-6	Body mass index;
PAAD	cis	rs2278796	0.639	rs4950976	chr1:204970243	C/T	cg17947172	chr1:204966197	NFASC	-0.42	-4.62	-0.35	7.97e-6	Mean platelet volume;
PAAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg11833968	chr6:79620685	NA	-0.42	-4.38	-0.33	2.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.8	7.3	0.51	1.51e-11	Blood protein levels;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg17541715	chr7:1216824	NA	-0.55	-6.2	-0.45	5.1e-9	Longevity;Endometriosis;
PAAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg16083429	chr3:49237500	CCDC36	0.46	4.54	0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg16341495	chr8:142228727	SLC45A4	-0.56	-5.28	-0.39	4.49e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.63	-4.89	-0.37	2.51e-6	Osteoarthritis;
PAAD	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.48	-8.06	-0.55	2.07e-13	Mean corpuscular volume;
PAAD	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.96	-7.08	-0.5	5.12e-11	Breast cancer;
PAAD	cis	rs427943	0.639	rs2838820	chr21:46646005	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.46	4.32	0.33	2.78e-5	Body mass index;
PAAD	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.67	4.52	0.34	1.22e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.61	6.24	0.45	4.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.62	5.95	0.43	1.77e-8	Refractive astigmatism;
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg15181151	chr6:150070149	PCMT1	0.56	6.01	0.44	1.34e-8	Lung cancer;
PAAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg20283391	chr11:68216788	NA	-0.53	-5.08	-0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs6804624	0.676	rs2458516	chr3:99161582	C/T	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.72e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-6.43	-0.46	1.53e-9	Mitochondrial DNA levels;
PAAD	cis	rs2051773	0.567	rs58047221	chr11:17056634	G/T	cg15432903	chr11:17409602	KCNJ11	-0.5	-4.28	-0.33	3.36e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs2415984	0.579	rs28636061	chr14:46959848	T/C	cg14871534	chr14:47121158	RPL10L	-0.49	-5.01	-0.38	1.49e-6	Number of children ever born;
PAAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.54e-6	Bipolar disorder;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.45	-0.34	1.68e-5	Longevity;Endometriosis;
PAAD	cis	rs28489187	0.706	rs761601	chr1:85797298	A/G	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3e-7	Heart rate;
PAAD	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.77	0.36	4.27e-6	Lung cancer in ever smokers;
PAAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23463467	chr20:60627584	TAF4	0.4	4.33	0.33	2.73e-5	Body mass index;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.66	0.48	4.83e-10	Platelet count;
PAAD	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.85	0.58	2.13e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.65	-7.46	-0.52	6.14e-12	Refractive error;
PAAD	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.59	-0.35	9.4e-6	Type 2 diabetes;
PAAD	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.44	10.07	0.63	1.37e-18	Opioid sensitivity;
PAAD	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.24	0.39	5.23e-7	Schizophrenia;
PAAD	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	10.49	0.65	1.03e-19	Cognitive test performance;
PAAD	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.99	-0.87	4.48e-49	Myeloid white cell count;
PAAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg23838943	chr19:5049135	KDM4B	-0.44	-4.29	-0.33	3.19e-5	Monocyte percentage of white cells;
PAAD	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg15654264	chr1:150340011	RPRD2	-0.52	-5.0	-0.38	1.54e-6	Migraine;
PAAD	trans	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08418111	chr11:18433745	LDHC	0.6	6.33	0.46	2.64e-9	Calcium levels;
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.67	0.62	1.52e-17	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03062665	chr14:90863127	CALM1	0.63	6.71	0.48	3.55e-10	Myopia (pathological);
PAAD	cis	rs2133450	0.967	rs62234950	chr3:7335338	T/G	cg19930620	chr3:7340148	GRM7	-0.48	-4.88	-0.37	2.63e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-5.23	-0.39	5.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg06565975	chr8:143823917	SLURP1	-0.23	-5.01	-0.38	1.53e-6	Urinary tract infection frequency;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09138267	chr7:150102791	LOC728743	-0.65	-6.44	-0.46	1.48e-9	Lung cancer in ever smokers;
PAAD	cis	rs62025270	0.593	rs62022926	chr15:86239492	C/T	cg13263323	chr15:86062960	AKAP13	0.52	4.7	0.36	5.74e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.8	-0.53	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.6	-4.47	-0.34	1.55e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.57	-0.35	1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.56	-5.16	-0.39	7.51e-7	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs3809060	0.959	rs3858446	chr11:32450890	A/G	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	0.99	13.39	0.74	1.71e-27	Menopause (age at onset);
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.16	0.55	1.17e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg01475377	chr6:109611718	NA	-0.51	-5.98	-0.44	1.54e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10267417	0.603	rs10258214	chr7:19911906	G/A	cg05791153	chr7:19748676	TWISTNB	0.68	4.85	0.37	3.08e-6	Night sleep phenotypes;
PAAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-1.02	-11.14	-0.67	1.88e-21	IgG glycosylation;
PAAD	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg22437258	chr11:111473054	SIK2	0.62	6.03	0.44	1.17e-8	Primary sclerosing cholangitis;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg14829155	chr15:31115871	NA	-0.66	-7.25	-0.51	1.92e-11	Huntington's disease progression;
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.76	7.76	0.53	1.14e-12	Prostate cancer;
PAAD	cis	rs4751058	0.607	rs4750732	chr10:130864640	C/T	cg00118712	chr10:131686819	EBF3	-0.56	-5.1	-0.38	1.02e-6	Vitamin D levels;
PAAD	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.82	9.48	0.61	4.87e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg02869306	chr7:64672164	INTS4L1	-0.42	-4.84	-0.37	3.13e-6	Calcium levels;
PAAD	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	11.27	0.67	8.33e-22	Colorectal cancer;
PAAD	cis	rs12776158	1.000	rs34618077	chr10:71216134	T/C	cg12610070	chr10:71211762	TSPAN15	-0.5	-4.98	-0.37	1.67e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10795130	0.568	rs10904181	chr10:4138459	A/T	cg20016767	chr10:3248143	NA	-0.72	-4.26	-0.33	3.5e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.89	-0.37	2.55e-6	Diabetic retinopathy;
PAAD	cis	rs8077577	0.943	rs62072467	chr17:18116455	C/T	cg16794390	chr17:18148240	FLII	0.59	4.7	0.36	5.8e-6	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.78	-0.36	4.18e-6	Lung cancer in ever smokers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23130686	chr12:53689494	PFDN5	-0.74	-6.86	-0.49	1.59e-10	Neuroticism;
PAAD	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.67	-0.35	6.64e-6	Triglycerides;
PAAD	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.99	-7.46	-0.52	6.03e-12	Blood protein levels;
PAAD	cis	rs508970	0.556	rs7106643	chr11:60891310	T/C	cg24692310	chr11:60915630	VPS37C	0.31	4.31	0.33	2.89e-5	Rheumatoid arthritis;
PAAD	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.53	4.62	0.35	8.07e-6	Serum parathyroid hormone levels;
PAAD	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg06484146	chr7:12443880	VWDE	-0.49	-4.98	-0.37	1.74e-6	Coronary artery disease;
PAAD	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.8	0.48	2.28e-10	Morning vs. evening chronotype;
PAAD	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.75	-0.36	4.59e-6	Life satisfaction;
PAAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.8	8.05	0.55	2.28e-13	Blood protein levels;
PAAD	cis	rs2659067	1.000	rs1654523	chr19:51485194	C/T	cg19471655	chr19:51487109	KLK7	-0.97	-5.77	-0.42	4.32e-8	Blood protein levels;
PAAD	cis	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27595580	chr7:117828179	NAA38	-0.45	-4.56	-0.35	1.06e-5	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.79	-7.38	-0.51	9.81e-12	Asthma;
PAAD	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg27411982	chr8:10470053	RP1L1	0.42	4.52	0.34	1.23e-5	Neuroticism;
PAAD	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs13111989	1.000	rs4690456	chr4:177541567	C/G	cg11287292	chr4:178277261	NEIL3	-0.54	-4.39	-0.34	2.13e-5	HIV-1 viral setpoint;
PAAD	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs516243	0.688	rs7545227	chr1:10740300	G/C	cg02903756	chr1:10750680	CASZ1	-0.44	-4.62	-0.35	8.3e-6	Migraine - clinic-based;
PAAD	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	cis	rs7255045	0.788	rs10424001	chr19:12948462	A/G	cg08897044	chr19:12950850	MAST1	-0.35	-4.45	-0.34	1.62e-5	Mean corpuscular volume;
PAAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg26174226	chr8:58114915	NA	-0.63	-5.09	-0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.93e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18937225	chr1:51793660	TTC39A	-0.65	-6.7	-0.48	3.86e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg04370829	chr17:406249	NA	-0.66	-6.14	-0.45	6.83e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg17325771	chr7:75508891	RHBDD2	0.35	4.91	0.37	2.32e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.96	-0.37	1.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.6	6.94	0.49	1.06e-10	HDL cholesterol levels;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11245990	chr11:68621969	NA	0.4	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.49	5.12	0.38	9.07e-7	Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs13325671	chr3:128461047	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.89	-0.37	2.59e-6	Dental caries;
PAAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg26174226	chr8:58114915	NA	-0.61	-5.01	-0.38	1.53e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg06569542	chr10:98946673	SLIT1	0.51	5.68	0.42	6.62e-8	Monocyte count;
PAAD	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.91	10.18	0.64	7.08e-19	Colorectal adenoma (advanced);
PAAD	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg23860436	chr12:58378763	NA	0.46	4.26	0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.7	-0.42	6.02e-8	Schizophrenia;
PAAD	cis	rs400736	0.526	rs10864329	chr1:8164460	G/A	cg25007680	chr1:8021821	PARK7	-0.48	-4.5	-0.34	1.32e-5	Response to antidepressants and depression;
PAAD	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg27605358	chr2:226265475	KIAA1486	-0.39	-4.25	-0.33	3.78e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.53	-4.68	-0.35	6.4e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs89107	0.576	rs4307206	chr6:118813320	A/C	cg21191810	chr6:118973309	C6orf204	-0.37	-4.38	-0.33	2.18e-5	Cardiac structure and function;
PAAD	cis	rs16858210	0.607	rs35205152	chr3:183563329	C/A	cg25686905	chr3:183603175	PARL	-0.41	-4.77	-0.36	4.33e-6	Menopause (age at onset);
PAAD	cis	rs80064395	0.571	rs4916535	chr3:196373652	T/C	cg20534585	chr3:196373598	LRRC33	0.96	5.31	0.4	3.75e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.86	9.14	0.6	3.81e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.57	6.41	0.46	1.7e-9	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg05925327	chr15:68127851	NA	-0.66	-6.04	-0.44	1.14e-8	Restless legs syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07409897	chr20:13619336	TASP1	0.65	6.7	0.48	3.85e-10	Obesity-related traits;
PAAD	cis	rs8077059	0.959	rs12941732	chr17:55826346	G/C	cg12582317	chr17:55822272	NA	0.46	4.3	0.33	3.09e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.93e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg02733842	chr7:1102375	C7orf50	-0.77	-6.12	-0.44	7.77e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	6.39	0.46	1.91e-9	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.69	7.59	0.52	2.98e-12	Aortic root size;
PAAD	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.83	8.66	0.57	6.53e-15	Calcium levels;
PAAD	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg20913747	chr6:44695427	NA	-0.55	-5.84	-0.43	3.06e-8	Total body bone mineral density;
PAAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26350283	chr19:11546233	PRKCSH;CCDC151	0.69	6.95	0.49	1e-10	Obesity-related traits;
PAAD	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.29	-0.51	1.55e-11	Migraine;Coronary artery disease;
PAAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.69	6.57	0.47	7.49e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.61	5.56	0.41	1.19e-7	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17761864	0.634	rs72815348	chr17:2050835	C/T	cg16513277	chr17:2031491	SMG6	0.45	4.45	0.34	1.64e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg00976097	chr5:421733	AHRR	-0.53	-5.08	-0.38	1.11e-6	Cystic fibrosis severity;
PAAD	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-6.09	-0.44	8.75e-9	Pancreatic cancer;
PAAD	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg21095983	chr6:86352623	SYNCRIP	0.65	6.58	0.47	7.02e-10	Smooth-surface caries;
PAAD	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.72	-0.36	5.33e-6	Mood instability;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.84	6.86	0.49	1.59e-10	Alzheimer's disease;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg11062466	chr8:58055876	NA	0.65	4.72	0.36	5.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11871801	1.000	rs12943498	chr17:40593901	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.62	-0.35	8.12e-6	Crohn's disease;
PAAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.49	-0.57	1.78e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg13271783	chr10:134563150	INPP5A	0.41	4.38	0.33	2.18e-5	Migraine;
PAAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.06	-8.09	-0.55	1.79e-13	Diabetic kidney disease;
PAAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs11997175	0.625	rs7825931	chr8:33583627	A/C	ch.8.33884649F	chr8:33765107	NA	-0.56	-6.23	-0.45	4.28e-9	Body mass index;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.51e-9	Lung cancer;
PAAD	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg18809830	chr7:99032528	PTCD1	-1.04	-4.56	-0.35	1.06e-5	Blood metabolite levels;
PAAD	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-4.72	-0.36	5.42e-6	Height;
PAAD	cis	rs78472555	0.954	rs2123926	chr15:100264518	T/C	cg23669855	chr15:100272142	LYSMD4	-0.68	-5.54	-0.41	1.29e-7	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10513943	chr5:83042603	NA	0.65	7.97	0.54	3.59e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	8.8	0.58	2.85e-15	Alzheimer's disease;
PAAD	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.67	-6.34	-0.46	2.52e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4919087	0.590	rs1253401	chr10:99050270	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg20406979	chr6:167373233	NA	0.35	4.87	0.37	2.73e-6	Crohn's disease;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04156016	chr5:1868137	NA	0.45	4.58	0.35	9.6e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg07617317	chr6:118971624	C6orf204	0.56	4.72	0.36	5.38e-6	Diastolic blood pressure;
PAAD	cis	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg11494091	chr17:61959527	GH2	0.52	4.4	0.34	1.99e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3812111	0.545	rs9387389	chr6:116573667	G/A	cg26893134	chr6:116381904	FRK	-0.29	-4.31	-0.33	2.89e-5	Age-related macular degeneration;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg09509183	chr1:209979624	IRF6	0.55	5.34	0.4	3.34e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-5.88	-0.43	2.53e-8	Crohn's disease;
PAAD	cis	rs11807834	0.505	rs7512794	chr1:230253247	C/T	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg00334542	chr7:100209784	MOSPD3	-0.55	-4.3	-0.33	3e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.76	7.14	0.5	3.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.34	-0.33	2.6e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg10556349	chr10:835070	NA	0.59	4.97	0.37	1.79e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.92	11.51	0.68	1.91e-22	Menarche (age at onset);
PAAD	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs11239930	0.934	rs10900313	chr1:146560747	T/A	cg17856063	chr1:146543992	NA	0.4	4.36	0.33	2.4e-5	AIDS progression;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10119679	chr11:71935353	INPPL1	-0.67	-6.43	-0.46	1.53e-9	Lung cancer in ever smokers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24940248	chr11:118796872	NA	0.57	6.39	0.46	1.93e-9	Monocyte percentage of white cells;
PAAD	cis	rs10214930	0.697	rs10447552	chr7:27683298	A/G	cg22168087	chr7:27702803	HIBADH	-0.48	-4.48	-0.34	1.45e-5	Hypospadias;
PAAD	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.18	8.84	0.58	2.2e-15	Lymphocyte counts;
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg02555727	chr12:129281546	SLC15A4	0.5	5.34	0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs12753569	0.748	rs6668566	chr1:76507675	C/G	cg00791851	chr1:76518896	NA	0.43	4.5	0.34	1.36e-5	Personality dimensions;
PAAD	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01114163	chr5:1856713	NA	-0.41	-4.38	-0.33	2.23e-5	Cardiovascular disease risk factors;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.5	4.91	0.37	2.34e-6	Prostate cancer;
PAAD	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.71	7.01	0.49	7.38e-11	Coronary artery disease;
PAAD	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.6	6.07	0.44	9.81e-9	Essential tremor;
PAAD	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.98	-8.79	-0.58	2.95e-15	Dilated cardiomyopathy;
PAAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19671926	chr4:122722719	EXOSC9	-0.72	-6.45	-0.46	1.44e-9	Type 2 diabetes;
PAAD	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg23327896	chr11:73669290	DNAJB13	0.49	4.31	0.33	2.94e-5	Hand grip strength;
PAAD	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.56	-0.41	1.21e-7	Mood instability;
PAAD	cis	rs4740619	0.647	rs2891007	chr9:15826335	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.43	-0.34	1.76e-5	Body mass index;
PAAD	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg19904058	chr10:135279010	LOC619207	-0.45	-6.3	-0.46	2.99e-9	Systemic lupus erythematosus;
PAAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg05697835	chr1:2722811	NA	-0.41	-4.62	-0.35	8.22e-6	Ulcerative colitis;
PAAD	cis	rs9635231	1	rs9635231	chr14:55887703	C/T	cg23573665	chr14:55907122	TBPL2	-0.33	-4.44	-0.34	1.71e-5	Pediatric bone mineral density (femoral neck);
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.35	0.56	3.85e-14	Lung cancer;
PAAD	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg05484376	chr2:27715224	FNDC4	-0.47	-4.81	-0.36	3.67e-6	Oral cavity cancer;
PAAD	cis	rs6137287	0.889	rs2103976	chr20:21156960	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09597638	chr17:3907349	NA	0.88	9.38	0.61	8.87e-17	Type 2 diabetes;
PAAD	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.86	-10.25	-0.64	4.46e-19	Body mass index;
PAAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg14343924	chr8:8086146	FLJ10661	0.54	4.86	0.37	2.94e-6	Mood instability;
PAAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	9.43	0.61	6.58e-17	Menarche (age at onset);
PAAD	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-4.74	-0.36	4.95e-6	Self-reported allergy;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	trans	rs901683	1.000	rs34661476	chr10:45971413	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-6.12	-0.44	7.66e-9	Inflammatory bowel disease;
PAAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.53	5.55	0.41	1.25e-7	Mean corpuscular volume;
PAAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.81	-8.73	-0.58	4.31e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7714584	1.000	rs34156253	chr5:150226230	A/G	cg22134413	chr5:150180641	NA	0.7	4.86	0.37	2.85e-6	Crohn's disease;
PAAD	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.18	0.55	1.03e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg13476313	chr9:127244764	NR5A1	-0.32	-5.18	-0.39	6.97e-7	Menarche (age at onset);
PAAD	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.36	-0.33	2.39e-5	Asthma;
PAAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.79	8.73	0.58	4.2e-15	Lung cancer;
PAAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.66	-4.89	-0.37	2.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.56	-0.35	1.04e-5	Colorectal cancer;
PAAD	cis	rs4073221	0.615	rs13068830	chr3:18207731	A/C	cg07694806	chr3:18168406	NA	-0.59	-4.28	-0.33	3.24e-5	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs925228	0.504	rs6729231	chr2:24292597	A/T	cg01493198	chr2:24299560	SF3B14	0.81	5.27	0.39	4.69e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg05528293	chr18:74961138	GALR1	0.56	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.61	0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.81	-8.32	-0.56	4.65e-14	Paraoxonase activity;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg27094323	chr7:1216898	NA	-0.54	-6.3	-0.45	3.11e-9	Longevity;Endometriosis;
PAAD	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-1.02	-12.0	-0.7	9.19e-24	Multiple myeloma;
PAAD	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg00717180	chr2:96193071	NA	0.6	6.68	0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Parkinson's disease;
PAAD	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg27411982	chr8:10470053	RP1L1	-0.5	-5.35	-0.4	3.2e-7	Neuroticism;
PAAD	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.74	8.77	0.58	3.28e-15	Emphysema distribution in smoking;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.98	11.43	0.68	3.23e-22	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.53e-6	Vitiligo;
PAAD	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.51	5.85	0.43	2.95e-8	Coronary artery disease;
PAAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg10864074	chr7:100318194	EPO	0.44	5.24	0.39	5.37e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg06671706	chr8:8559999	CLDN23	0.7	6.81	0.48	2.16e-10	Obesity-related traits;
PAAD	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg20487152	chr13:99095054	FARP1	0.47	4.99	0.38	1.65e-6	Longevity;
PAAD	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg00287477	chr4:185721584	ACSL1;SLED1	-0.5	-4.25	-0.33	3.69e-5	Type 2 diabetes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10538494	chr14:97263716	VRK1	0.56	6.94	0.49	1.08e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21428348	chr20:47253976	PREX1	-0.61	-6.34	-0.46	2.51e-9	Obesity-related traits;
PAAD	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.72	4.8	0.36	3.75e-6	Major depressive disorder;
PAAD	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.66	-8.34	-0.56	4.07e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.57	-5.81	-0.43	3.63e-8	Body mass index;
PAAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.75	8.85	0.58	2.14e-15	Blood metabolite ratios;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01814731	chr19:45567904	SFRS16	-0.59	-6.61	-0.47	6.06e-10	Monocyte percentage of white cells;
PAAD	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19671926	chr4:122722719	EXOSC9	-0.57	-5.44	-0.4	2.09e-7	Type 2 diabetes;
PAAD	cis	rs1075232	1.000	rs4450360	chr15:31682030	G/A	cg06530883	chr15:30699977	NA	1.04	4.63	0.35	7.74e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg13606994	chr1:44402422	ARTN	-0.39	-4.36	-0.33	2.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.11	0.44	7.97e-9	Platelet count;
PAAD	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg22029157	chr1:209979665	IRF6	0.71	6.85	0.49	1.73e-10	Coronary artery disease;
PAAD	cis	rs9649465	0.967	rs9641717	chr7:123350060	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs36093844	1.000	rs36093844	chr11:85576127	A/G	cg25872744	chr11:85566296	CCDC83	0.53	4.33	0.33	2.67e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	cis	rs564309	0.681	rs1188482	chr1:228617493	T/G	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13950250	chr8:104430401	DCAF13	-0.68	-7.16	-0.5	3.22e-11	Obesity-related traits;
PAAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg21130718	chr4:1044621	NA	0.56	4.75	0.36	4.7e-6	Recombination rate (females);
PAAD	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.97	6.18	0.45	5.49e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg16083429	chr3:49237500	CCDC36	-0.46	-4.48	-0.34	1.43e-5	Menarche (age at onset);
PAAD	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.4	-0.4	2.57e-7	Mean corpuscular volume;
PAAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.53	7.28	0.51	1.7e-11	Crohn's disease;
PAAD	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-6.96	-0.49	9.3e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.62	-0.41	9e-8	Bladder cancer;
PAAD	cis	rs8067287	0.762	rs11651352	chr17:16824909	A/G	cg26910001	chr17:16838321	NA	0.66	6.03	0.44	1.19e-8	Diabetic kidney disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11249189	chr17:42148592	G6PC3	0.59	6.58	0.47	7.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg16964102	chr10:135390573	NA	0.41	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg16341495	chr8:142228727	SLC45A4	-0.56	-5.53	-0.41	1.35e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.78	-5.79	-0.43	3.87e-8	Coronary artery calcification;
PAAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.53	-0.34	1.2e-5	Breast cancer;
PAAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.37	0.46	2.11e-9	IgG glycosylation;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3007168	1.000	rs3007169	chr14:51607897	A/G	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.91	-0.49	1.26e-10	Atrioventricular conduction;
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03605463	chr16:89740564	NA	-0.5	-4.75	-0.36	4.69e-6	Vitiligo;
PAAD	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.46	4.58	0.35	9.72e-6	Aortic root size;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.28	0.67	8.06e-22	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15571277	chr20:61885249	FLJ16779;NKAIN4	-0.55	-6.31	-0.46	2.86e-9	Smoking initiation;
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg14830002	chr1:247616686	OR2B11	0.59	4.77	0.36	4.27e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.59	6.75	0.48	2.93e-10	Psoriasis;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07362569	chr17:61921086	SMARCD2	0.6	7.05	0.5	5.86e-11	Prudent dietary pattern;
PAAD	cis	rs6908034	0.546	rs73376662	chr6:19806340	G/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.75	8.33	0.56	4.43e-14	Prostate cancer;
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.27	-7.78	-0.53	1.03e-12	Body mass index;
PAAD	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg07622451	chr1:3079886	PRDM16	0.41	4.81	0.36	3.63e-6	Migraine;
PAAD	cis	rs992157	0.932	rs1870125	chr2:219187901	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.45	0.52	6.42e-12	Colorectal cancer;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	9.51	0.61	4.01e-17	Alzheimer's disease;
PAAD	cis	rs12304921	0.639	rs7722	chr12:51455404	C/A	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.58	-0.35	9.51e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25545336	chr2:223520958	FARSB	0.64	7.25	0.51	1.94e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg05082376	chr22:42548792	NA	-0.44	-4.42	-0.34	1.88e-5	Cognitive function;
PAAD	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg17541715	chr7:1216824	NA	-0.44	-4.89	-0.37	2.58e-6	Longevity;Endometriosis;
PAAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.78	12.81	0.72	6.14e-26	Breast cancer;
PAAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.91	-0.59	1.45e-15	Calcium levels;
PAAD	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.1	0.5	4.36e-11	Heart rate;
PAAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	4.36	0.33	2.41e-5	Tonsillectomy;
PAAD	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.54	-0.47	8.85e-10	Neuroticism;
PAAD	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.14	-0.38	8.26e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.98	6.47	0.46	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7187994	0.672	rs7185686	chr16:84799013	C/T	cg07647771	chr16:84786436	USP10	-0.39	-4.64	-0.35	7.61e-6	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15241779	chr12:10459912	KLRD1	-0.6	-6.61	-0.47	6.26e-10	Obesity-related traits;
PAAD	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.6	4.25	0.33	3.7e-5	Resting heart rate;
PAAD	cis	rs9810890	1.000	rs73198822	chr3:128480061	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.42	-0.4	2.3e-7	Dental caries;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.58	6.33	0.46	2.57e-9	Cardiovascular disease risk factors;
PAAD	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.14	15.58	0.78	2.64e-33	Exhaled nitric oxide output;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg19343871	chr19:48103651	NA	0.57	6.39	0.46	1.91e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2952768	1.000	rs2952770	chr2:208496923	G/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.16	-0.5	3.25e-11	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-1.2	-10.02	-0.63	1.86e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg06740227	chr12:86229804	RASSF9	0.55	4.97	0.37	1.75e-6	Major depressive disorder;
PAAD	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg04370829	chr17:406249	NA	-0.44	-4.42	-0.34	1.87e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.54	4.88	0.37	2.62e-6	Type 2 diabetes;
PAAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.76	9.75	0.62	9.3e-18	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.83	8.36	0.56	3.66e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg17640201	chr16:30407289	ZNF48	0.64	6.86	0.49	1.66e-10	Tonsillectomy;
PAAD	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.43	-5.06	-0.38	1.18e-6	Coronary artery disease;
PAAD	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs61542988	0.532	rs12673996	chr7:22833400	C/T	cg11367502	chr7:22862612	TOMM7	0.61	5.94	0.43	1.86e-8	Fibrinogen levels;
PAAD	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.36	-0.33	2.42e-5	Schizophrenia;
PAAD	cis	rs1678618	0.587	rs1245529	chr10:73792436	T/C	cg20897136	chr10:74034667	DDIT4	0.37	4.44	0.34	1.69e-5	Smoking behavior;
PAAD	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-5.15	-0.39	7.95e-7	Brugada syndrome;
PAAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg09017928	chr7:158110068	PTPRN2	0.44	4.45	0.34	1.62e-5	Calcium levels;
PAAD	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.2	9.42	0.61	7.13e-17	Alzheimer's disease (late onset);
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg09755784	chr4:1047097	NA	-0.36	-4.35	-0.33	2.45e-5	Recombination rate (males);
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.07	-9.28	-0.6	1.58e-16	Alzheimer's disease;
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.67	0.35	6.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs4678145	1.000	rs17282057	chr3:124446077	T/C	cg03983498	chr1:55107291	C1orf175	1.06	6.63	0.47	5.58e-10	Coronary artery disease;
PAAD	cis	rs12475964	0.666	rs7580127	chr2:37382754	C/A	cg22370082	chr2:37384244	EIF2AK2	0.44	4.34	0.33	2.54e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.11	-8.4	-0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs7577696	0.785	rs11683110	chr2:32349813	T/C	cg02381751	chr2:32503542	YIPF4	-0.49	-4.83	-0.36	3.28e-6	Inflammatory biomarkers;
PAAD	cis	rs2562456	0.833	rs62110426	chr19:21602926	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.5	5.3	0.4	3.97e-7	Menopause (age at onset);
PAAD	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.48	5.63	0.42	8.62e-8	QRS complex (12-leadsum);
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.18	-0.39	6.83e-7	Tonsillectomy;
PAAD	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg25558440	chr8:11882962	NA	-0.45	-4.28	-0.33	3.27e-5	Retinal vascular caliber;
PAAD	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-6.25	-0.45	3.88e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs73086581	0.898	rs11906452	chr20:3981559	A/G	cg02187196	chr20:3869020	PANK2	0.54	4.49	0.34	1.4e-5	Response to antidepressants in depression;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.61	5.93	0.43	1.96e-8	Diastolic blood pressure;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.75	-0.36	4.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.92e-17	Electrocardiographic conduction measures;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg15117754	chr3:10150083	C3orf24	0.58	5.46	0.4	1.93e-7	Alzheimer's disease;
PAAD	cis	rs10769945	0.592	rs1635155	chr11:1972919	G/T	cg23202291	chr11:1979235	NA	-0.47	-4.34	-0.33	2.62e-5	DNA methylation (variation);
PAAD	cis	rs17824933	0.778	rs17752099	chr11:60760794	G/C	cg16817237	chr11:60793675	NA	0.47	5.55	0.41	1.27e-7	Multiple sclerosis;
PAAD	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	1.03	12.66	0.72	1.54e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.06	0.38	1.19e-6	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.62	0.41	8.78e-8	Prudent dietary pattern;
PAAD	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	9.0	0.59	8.38e-16	Lymphocyte counts;
PAAD	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg02367709	chr17:66097352	LOC651250	0.43	4.39	0.34	2.14e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.63	6.05	0.44	1.1e-8	Corneal astigmatism;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-6.08	-0.44	9.34e-9	Schizophrenia;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.94	-0.37	2e-6	Pulmonary function;
PAAD	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg16434002	chr17:42200994	HDAC5	0.61	5.77	0.42	4.39e-8	Total body bone mineral density;
PAAD	cis	rs17032980	0.910	rs13399908	chr2:67306158	G/A	cg06994420	chr2:66672553	MEIS1	-0.5	-4.45	-0.34	1.66e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs3736485	0.934	rs4143723	chr15:51867172	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11208446	0.769	rs12407601	chr1:64870457	A/G	cg25192081	chr1:65308244	JAK1	-0.64	-4.27	-0.33	3.38e-5	Bilirubin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19355685	chr2:220071637	ZFAND2B	0.57	6.36	0.46	2.3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.65	5.45	0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19346786	chr7:2764209	NA	-0.35	-5.0	-0.38	1.53e-6	Height;
PAAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.76	-0.36	4.48e-6	Blood metabolite levels;
PAAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.39	-0.34	2.15e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg08134877	chr2:44394819	PPM1B	0.44	4.35	0.33	2.49e-5	Height;
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg16898833	chr6:26189333	HIST1H4D	0.97	4.83	0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg14343924	chr8:8086146	FLJ10661	-0.54	-4.87	-0.37	2.83e-6	Neuroticism;
PAAD	cis	rs10029851	0.738	rs1436507	chr4:109630997	T/C	cg16525761	chr4:109541525	LOC285456;RPL34	-0.47	-4.39	-0.34	2.07e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.87	11.05	0.67	3.31e-21	Prudent dietary pattern;
PAAD	cis	rs17125944	0.686	rs1952090	chr14:53342992	A/G	cg13660082	chr14:53194042	PSMC6	0.73	4.62	0.35	8.12e-6	Alzheimer's disease (late onset);
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg15193198	chr20:60906057	LAMA5	-0.51	-5.8	-0.43	3.69e-8	Colorectal cancer;
PAAD	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.56	6.35	0.46	2.32e-9	Mean corpuscular volume;
PAAD	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.77	8.04	0.55	2.36e-13	Corneal astigmatism;
PAAD	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.95	13.93	0.75	6.13e-29	Dental caries;
PAAD	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.8	-7.05	-0.5	5.91e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg25025879	chr12:53359317	NA	-0.87	-10.02	-0.63	1.9e-18	Cancer (pleiotropy);
PAAD	cis	rs735539	0.645	rs9552248	chr13:21159200	G/A	cg27234864	chr13:21295941	IL17D	0.61	5.28	0.39	4.49e-7	Dental caries;
PAAD	cis	rs2736345	0.890	rs4840565	chr8:11345545	G/C	cg08224773	chr8:11311868	FAM167A	0.38	4.26	0.33	3.63e-5	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg15211996	chr1:2936768	ACTRT2	-0.47	-4.57	-0.35	1.01e-5	Plateletcrit;
PAAD	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.65	6.44	0.46	1.45e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.64	-5.87	-0.43	2.58e-8	Exhaled nitric oxide output;
PAAD	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.58	5.34	0.4	3.39e-7	Resting heart rate;
PAAD	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg22800045	chr5:56110881	MAP3K1	0.83	5.36	0.4	2.96e-7	Type 2 diabetes;
PAAD	cis	rs72960926	0.744	rs72969227	chr6:75055450	C/T	cg03266952	chr6:74778945	NA	-1.18	-6.55	-0.47	8.25e-10	Metabolite levels (MHPG);
PAAD	cis	rs7714584	1.000	rs73282255	chr5:150223647	A/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs9868809	0.649	rs17256786	chr3:48604016	C/G	cg00383909	chr3:49044727	WDR6	1.15	5.35	0.4	3.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg10729496	chr3:10149963	C3orf24	-0.7	-6.08	-0.44	9.49e-9	Alzheimer's disease;
PAAD	cis	rs8040855	0.575	rs12912860	chr15:85573498	T/C	cg08123816	chr15:85640762	PDE8A	-0.45	-5.38	-0.4	2.82e-7	Bulimia nervosa;
PAAD	cis	rs9810890	1.000	rs79217699	chr3:128445585	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.78	-0.36	4.09e-6	Dental caries;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.73	6.48	0.47	1.18e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	5.84	0.43	3.01e-8	Body mass index;
PAAD	cis	rs4479964	0.817	rs9398913	chr6:129970962	A/G	cg12774946	chr6:129966801	ARHGAP18	-0.31	-4.49	-0.34	1.42e-5	Gut microbiome composition (summer);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20910303	chr4:147443095	SLC10A7	-0.59	-6.51	-0.47	1.03e-9	Myopia (pathological);
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg09344028	chr17:70110421	NA	0.48	6.38	0.46	2.05e-9	Thyroid hormone levels;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg24879335	chr3:133465180	TF	0.59	6.6	0.47	6.62e-10	Iron status biomarkers;
PAAD	cis	rs757081	0.648	rs10832752	chr11:17285487	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-5.95	-0.43	1.75e-8	Systolic blood pressure;
PAAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.76	-7.9	-0.54	5.21e-13	Brugada syndrome;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03388025	chr16:89894329	SPIRE2	0.34	4.41	0.34	1.92e-5	Vitiligo;
PAAD	cis	rs2051773	0.510	rs11024130	chr11:17056425	G/A	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.36	0.33	2.34e-5	Childhood ear infection;
PAAD	cis	rs6604026	0.656	rs2481712	chr1:93351477	G/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg11416102	chr8:651193	ERICH1	1.03	6.6	0.47	6.3e-10	IgG glycosylation;
PAAD	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.69	-0.42	6.48e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg11949866	chr1:10754891	CASZ1	0.52	4.51	0.34	1.29e-5	Ewing sarcoma;
PAAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg21361702	chr7:150065534	REPIN1	0.57	4.58	0.35	9.8200000000000008e-06	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg20821713	chr7:1055600	C7orf50	-0.57	-5.61	-0.41	9.29e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg09399716	chr2:46890238	NA	-0.72	-5.72	-0.42	5.42e-8	Height;
PAAD	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg17644776	chr2:200775616	C2orf69	-0.58	-4.3	-0.33	3.06e-5	Schizophrenia;
PAAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.59	-0.41	1.01e-7	Ulcerative colitis;
PAAD	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.57	5.27	0.39	4.67e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg24330906	chr2:85765176	MAT2A	0.58	5.69	0.42	6.46e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.56	0.41	1.18e-7	Total body bone mineral density;
PAAD	cis	rs10411262	0.935	rs2312289	chr19:47175615	G/C	cg13467550	chr19:47212573	PRKD2	0.52	5.29	0.39	4.27e-7	Tonsillectomy;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14837980	chr22:50493129	TTLL8	-0.62	-6.38	-0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.98	-14.84	-0.77	2.32e-31	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02257048	chr17:78880031	RPTOR	0.53	6.51	0.47	1.03e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.8	-0.36	3.79e-6	Body mass index;
PAAD	cis	rs6987853	0.527	rs2923412	chr8:42455281	G/A	cg09913449	chr8:42400586	C8orf40	0.48	5.36	0.4	3.09e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.05	-0.38	1.27e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10490913	0.965	rs7901974	chr10:120146097	T/A	cg04126427	chr10:120840676	EIF3A	-0.47	-4.98	-0.37	1.68e-6	Cancer;
PAAD	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.61	5.85	0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs11260013	0.839	rs12971319	chr19:7758154	T/A	cg04764898	chr19:7562249	C19orf45	0.42	4.34	0.33	2.54e-5	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02525785	chr17:7117684	DLG4	0.58	7.04	0.5	6.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs3736485	0.966	rs6493498	chr15:51754451	T/C	cg19558802	chr15:51695713	GLDN	-0.45	-4.67	-0.35	6.67e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27297192	chr10:134578999	INPP5A	0.61	5.48	0.41	1.69e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.27	-0.51	1.8e-11	Total body bone mineral density;
PAAD	cis	rs13053817	1.000	rs13055259	chr22:29856892	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.93	-0.37	2.09e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.52	4.37	0.33	2.27e-5	Lymphocyte counts;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01616529	chr11:638424	DRD4	-0.59	-5.84	-0.43	3.06e-8	Systemic lupus erythematosus;
PAAD	cis	rs8105895	0.866	rs62112908	chr19:22213956	A/G	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-4.26	-0.33	3.57e-5	Longevity;Endometriosis;
PAAD	cis	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg16898833	chr6:26189333	HIST1H4D	1.05	5.33	0.4	3.51e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-5.11	-0.38	9.37e-7	Type 2 diabetes;
PAAD	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	0.65	4.54	0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	4.7	0.36	5.84e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.39	-9.7	-0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg14433983	chr11:636460	DRD4	-0.47	-4.95	-0.37	1.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.59	-5.07	-0.38	1.13e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg22143856	chr6:28129313	ZNF389	0.5	4.46	0.34	1.56e-5	Parkinson's disease;
PAAD	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.42	-0.87	9.32e-48	Myeloid white cell count;
PAAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14008834	chr4:24472254	NA	-0.58	-6.76	-0.48	2.72e-10	Body fat percentage;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.88	7.75	0.53	1.25e-12	Menarche (age at onset);
PAAD	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.51	-4.55	-0.35	1.08e-5	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.74	7.51	0.52	4.56e-12	Lung cancer;
PAAD	cis	rs375066	0.935	rs439665	chr19:44414467	G/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg22143856	chr6:28129313	ZNF389	0.53	4.98	0.37	1.74e-6	Parkinson's disease;
PAAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg05082376	chr22:42548792	NA	-0.44	-4.38	-0.33	2.22e-5	Schizophrenia;
PAAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg21951975	chr1:209979733	IRF6	0.43	5.37	0.4	2.87e-7	Monobrow;
PAAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	4.41	0.34	1.98e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11113894	0.901	rs35173621	chr12:108859470	A/G	cg06834313	chr12:108851556	NA	-0.76	-4.6	-0.35	8.71e-6	Obesity-related traits;
PAAD	cis	rs7326068	0.504	rs7983020	chr13:21239941	C/T	cg27234864	chr13:21295941	IL17D	-0.5	-4.51	-0.34	1.3e-5	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg17594860	chr1:19615358	AKR7A3	0.47	4.42	0.34	1.9e-5	Brain structure;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg06009330	chr2:70485380	PCYOX1	0.56	6.67	0.48	4.57e-10	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.45	-0.46	1.43e-9	Prudent dietary pattern;
PAAD	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.61	-7.04	-0.5	6.23e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-4.72	-0.36	5.29e-6	Menarche (age at onset);
PAAD	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2404602	0.669	rs12911987	chr15:76953256	C/T	cg03037974	chr15:76606532	NA	0.48	5.12	0.38	9.09e-7	Blood metabolite levels;
PAAD	cis	rs10783615	0.719	rs1975471	chr12:54336981	A/G	cg17410650	chr12:54324560	NA	-0.4	-5.08	-0.38	1.07e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.76	8.47	0.57	1.92e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs41271473	0.718	rs4500282	chr1:228878375	T/A	cg16512390	chr1:228756714	NA	0.57	4.82	0.36	3.52e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	6.9	0.49	1.34e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs16958440	0.708	rs62096477	chr18:44662310	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-5.13	-0.38	8.54e-7	Sitting height ratio;
PAAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.78	0.36	4.14e-6	Myopia (pathological);
PAAD	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg01866162	chr16:67596514	CTCF	0.57	4.35	0.33	2.46e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg06287003	chr12:125626642	AACS	-0.44	-4.28	-0.33	3.34e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs340029	0.798	rs235512	chr15:60915470	G/A	cg00200653	chr15:60883225	RORA	0.52	4.5	0.34	1.34e-5	C-reactive protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08002795	chr4:83351453	HNRPDL;ENOPH1	0.67	6.57	0.47	7.37e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	8.9	0.59	1.54e-15	Lymphocyte counts;
PAAD	cis	rs2278796	0.789	rs1078719	chr1:204962405	A/G	cg17947172	chr1:204966197	NFASC	0.43	4.71	0.36	5.46e-6	Mean platelet volume;
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.85	10.17	0.64	7.45e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11141652	chr22:24348549	GSTTP1	0.48	4.61	0.35	8.44e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.55	5.0	0.38	1.58e-6	Neuroticism;
PAAD	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.76	6.53	0.47	9.16e-10	Chronic kidney disease;
PAAD	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.69	7.63	0.53	2.39e-12	Prostate cancer;
PAAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs501120	0.584	rs1615053	chr10:44677935	T/C	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	7.62	0.53	2.58e-12	Coffee consumption (cups per day);
PAAD	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.65	7.5	0.52	4.9e-12	Weight;
PAAD	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs787274	1.000	rs10124260	chr9:115559341	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.48	-0.34	1.48e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.9	11.62	0.69	9.56e-23	Methadone dose in opioid dependence;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs6604026	0.656	rs11164844	chr1:93416650	C/A	cg17283838	chr1:93427260	FAM69A	0.58	5.32	0.4	3.65e-7	Multiple sclerosis;
PAAD	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08568163	chr16:85689819	KIAA0182	0.61	6.37	0.46	2.13e-9	Smoking initiation;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg08601574	chr20:25228251	PYGB	0.46	4.4	0.34	2e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-10.16	-0.64	7.7e-19	Height;
PAAD	cis	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20596348	chr1:20960202	PINK1	0.59	6.35	0.46	2.34e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs797680	0.856	rs7537403	chr1:93777724	T/C	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs476633	0.624	rs28615543	chr15:41556015	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-6.34	-0.46	2.54e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg20007465	chr7:1068125	C7orf50	-0.6	-6.98	-0.49	8.62e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.67	8.03	0.55	2.49e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.65	-0.35	7.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.65	5.38	0.4	2.79e-7	Prostate cancer;
PAAD	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg01267373	chr18:77410094	NA	0.43	4.67	0.35	6.6e-6	Monocyte count;
PAAD	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.91	-0.37	2.3e-6	Diabetic retinopathy;
PAAD	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg16928487	chr17:17741425	SREBF1	0.37	5.08	0.38	1.09e-6	Total body bone mineral density;
PAAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.91	10.01	0.63	1.95e-18	Cognitive function;
PAAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.54	0.47	8.77e-10	Personality dimensions;
PAAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg23346134	chr3:49453900	TCTA	0.4	4.27	0.33	3.4e-5	Menarche (age at onset);
PAAD	cis	rs6864727	1.000	rs2097865	chr5:137245067	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	4.99	0.38	1.61e-6	Atrial fibrillation;
PAAD	cis	rs7326068	0.610	rs2762999	chr13:21445243	G/A	cg27234864	chr13:21295941	IL17D	0.58	4.78	0.36	4.13e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-5.28	-0.39	4.33e-7	Lymphocyte counts;
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs1879734	0.773	rs1465037	chr1:54135078	C/A	cg14659662	chr1:54151053	GLIS1	-0.4	-5.35	-0.4	3.12e-7	Mitral valve prolapse;
PAAD	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.74	7.47	0.52	5.93e-12	Corneal astigmatism;
PAAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.77	9.73	0.62	1.08e-17	Bone mineral density;
PAAD	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg05341575	chr12:125625032	AACS	-0.48	-4.54	-0.35	1.15e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25781202	chr8:33424350	RNF122	0.58	7.23	0.51	2.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.74	5.92	0.43	2.1e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.17	11.0	0.67	4.46e-21	Platelet count;
PAAD	cis	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.75e-6	Mononucleosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26459499	chr12:11005841	PRR4	0.59	6.32	0.46	2.72e-9	Smoking initiation;
PAAD	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg06627628	chr2:24431161	ITSN2	-0.58	-5.62	-0.41	9.08e-8	Sjögren's syndrome;
PAAD	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-6.32	-0.46	2.69e-9	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg05313129	chr8:58192883	C8orf71	-0.68	-6.15	-0.45	6.65e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-4.62	-0.35	8.18e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg03983715	chr16:68378420	PRMT7	-0.89	-6.32	-0.46	2.76e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.72	-8.89	-0.58	1.68e-15	Gut microbiome composition (winter);
PAAD	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.79	0.43	3.93e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.8	8.06	0.55	2.06e-13	Testicular germ cell tumor;
PAAD	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.56	5.58	0.41	1.05e-7	Body mass index;
PAAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.83	8.11	0.55	1.59e-13	Post bronchodilator FEV1;
PAAD	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.96e-6	Vitiligo;
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg25037394	chr1:24152592	HMGCL	-0.4	-4.26	-0.33	3.5e-5	Immature fraction of reticulocytes;
PAAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg09835421	chr16:68378352	PRMT7	-1.09	-7.96	-0.54	3.67e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg01304814	chr3:48885189	PRKAR2A	-0.88	-5.16	-0.39	7.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	5.53	0.41	1.38e-7	Height;
PAAD	cis	rs7534824	0.625	rs10493939	chr1:101378026	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.52	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.96	-0.44	1.67e-8	QT interval;
PAAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg17366294	chr4:99064904	C4orf37	0.59	6.3	0.46	3.02e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg15211996	chr1:2936768	ACTRT2	0.44	4.28	0.33	3.26e-5	Plateletcrit;
PAAD	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg02737268	chr20:3780182	CDC25B	0.5	4.93	0.37	2.17e-6	Bipolar disorder;
PAAD	cis	rs621942	0.718	rs495942	chr11:85812408	G/A	cg07180834	chr11:85838833	NA	-0.48	-4.96	-0.37	1.89e-6	Tourette syndrome;
PAAD	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.92	0.37	2.19e-6	Ovarian reserve;
PAAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.48	-4.62	-0.35	8.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.77	9.02	0.59	7.44e-16	Huntington's disease progression;
PAAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.56	6.11	0.44	8.14e-9	Major depressive disorder;
PAAD	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg02631450	chr22:32366979	NA	1.0	5.45	0.4	1.98e-7	Childhood ear infection;
PAAD	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.9	0.63	3.82e-18	Platelet count;
PAAD	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.58	5.39	0.4	2.61e-7	Malaria;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg14591243	chr3:136471577	STAG1	0.59	6.58	0.47	7.05e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg27094323	chr7:1216898	NA	-0.54	-6.3	-0.45	3.11e-9	Longevity;Endometriosis;
PAAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.52	-0.34	1.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25198584	chr1:4775233	AJAP1	-0.64	-6.85	-0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg12143784	chr7:64541923	NA	0.36	4.6	0.35	8.83e-6	Calcium levels;
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.98	-7.67	-0.53	1.88e-12	Initial pursuit acceleration;
PAAD	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.38	13.29	0.73	3.17e-27	Corneal structure;
PAAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.84	-13.04	-0.73	1.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs859767	0.887	rs859766	chr2:135342254	C/T	cg12500956	chr2:135428796	TMEM163	0.33	4.84	0.37	3.2e-6	Neuroticism;
PAAD	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	4.55	0.35	1.08e-5	Verbal declarative memory;
PAAD	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.67	7.68	0.53	1.76e-12	Bladder cancer;
PAAD	cis	rs2031532	0.587	rs2038638	chr13:50048975	A/G	cg03651054	chr13:50194643	NA	0.32	4.29	0.33	3.11e-5	Cardiac hypertrophy;
PAAD	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.86	0.49	1.66e-10	Educational attainment;
PAAD	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.53	5.8	0.43	3.77e-8	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.53	7.95	0.54	3.88e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.47	7.05	0.5	5.79e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4141404	0.748	rs2232176	chr22:31536133	A/C	cg02404636	chr22:31891804	SFI1	-0.59	-4.81	-0.36	3.55e-6	Paclitaxel-induced neuropathy;
PAAD	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg26816564	chr1:7831052	VAMP3	0.67	5.34	0.4	3.4e-7	Inflammatory bowel disease;
PAAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.71	5.38	0.4	2.76e-7	Obesity;Body mass index;
PAAD	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.81	-11.47	-0.68	2.48e-22	Psoriasis;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg13010199	chr12:38710504	ALG10B	0.52	5.03	0.38	1.36e-6	Morning vs. evening chronotype;
PAAD	cis	rs6686423	0.511	rs72704575	chr1:157387086	G/A	cg24251193	chr1:156676542	CRABP2	-0.44	-4.31	-0.33	2.96e-5	Renal sinus fat;
PAAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.55	5.32	0.4	3.57e-7	Mood instability;
PAAD	cis	rs10044254	0.763	rs7704590	chr5:15709298	A/G	cg07238450	chr5:15720153	FBXL7	-0.51	-4.32	-0.33	2.8e-5	Asthma (corticosteroid response);
PAAD	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21480605	chr15:44092671	SERINC4;C15orf63	-0.48	-4.27	-0.33	3.47e-5	Lung cancer in ever smokers;
PAAD	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.67	7.23	0.51	2.18e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.68	9.14	0.6	3.75e-16	Hemoglobin concentration;
PAAD	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-4.27	-0.33	3.48e-5	Bipolar disorder;
PAAD	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.8	7.37	0.51	1.04e-11	Neurofibrillary tangles;
PAAD	cis	rs4338575	1.000	rs1955357	chr12:77674110	A/G	cg08610361	chr12:77459885	E2F7	0.49	4.34	0.33	2.55e-5	Methadone dose in opioid dependence;
PAAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.73	6.92	0.49	1.21e-10	Methadone dose in opioid dependence;
PAAD	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.49e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.61	6.25	0.45	3.99e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.78	8.11	0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.76	0.48	2.73e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg10483660	chr13:112241077	NA	-0.53	-4.94	-0.37	2.06e-6	Menarche (age at onset);
PAAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.92	0.49	1.16e-10	Menarche (age at onset);
PAAD	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.51	-4.9	-0.37	2.41e-6	Metabolic traits;
PAAD	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs7190551	0.951	rs1657086	chr16:9030916	C/G	cg03441945	chr16:8862653	ABAT	-0.56	-4.4	-0.34	2.07e-5	Platelet distribution width;
PAAD	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg21040360	chr2:3383326	TTC15	0.44	4.57	0.35	1.01e-5	Obesity-related traits;
PAAD	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.84	-9.38	-0.61	8.81e-17	Superior crus of antihelix expression;
PAAD	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg00717180	chr2:96193071	NA	0.57	6.37	0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg20673841	chr7:107026890	COG5	0.48	4.31	0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs6684428	0.656	rs12062107	chr1:56362364	C/T	cg11651538	chr1:56320950	NA	-0.45	-4.36	-0.33	2.41e-5	Airflow obstruction;
PAAD	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.79	-0.75	1.47e-28	Primary sclerosing cholangitis;
PAAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg03037974	chr15:76606532	NA	0.55	6.54	0.47	8.74e-10	Blood metabolite levels;
PAAD	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.94	8.03	0.55	2.47e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.74	6.74	0.48	3.08e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.14	-0.38	8.24e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.78	8.83	0.58	2.38e-15	Iron status biomarkers;
PAAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.23	0.51	2.25e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	5.33	0.4	3.54e-7	Lung cancer in ever smokers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18553762	chr2:234763269	HJURP	-0.81	-7.2	-0.5	2.52e-11	Neuroticism;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.81	7.05	0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs332507	0.830	rs12639478	chr3:124404958	T/A	cg05980111	chr3:124395277	KALRN	0.46	4.59	0.35	9.04e-6	Plateletcrit;
PAAD	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.57e-7	Subjective well-being;
PAAD	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.95	11.54	0.68	1.62e-22	Bone mineral density;
PAAD	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg18105134	chr13:113819100	PROZ	1.01	10.49	0.65	1.06e-19	Platelet distribution width;
PAAD	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg04557057	chr7:12151638	NA	-0.65	-4.28	-0.33	3.26e-5	Coronary artery disease;
PAAD	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.67	-8.31	-0.56	4.85e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.28	-0.56	6.06e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg08514558	chr10:81106712	PPIF	0.49	5.88	0.43	2.56e-8	Height;
PAAD	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-1.07	-9.28	-0.6	1.67e-16	Blood trace element (Zn levels);
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.6	0.47	6.54e-10	Lung cancer;
PAAD	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.62	4.33	0.33	2.67e-5	IgG glycosylation;
PAAD	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg00647317	chr7:50633725	DDC	0.42	4.35	0.33	2.48e-5	Systemic sclerosis;
PAAD	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.65	5.29	0.39	4.12e-7	Morning vs. evening chronotype;
PAAD	cis	rs66530629	0.917	rs7555134	chr1:25161662	C/T	cg22509179	chr1:25234806	RUNX3	0.5	4.66	0.35	6.92e-6	Plateletcrit;
PAAD	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	16.2	0.8	6.34e-35	Exhaled nitric oxide output;
PAAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg19257562	chr1:2043853	PRKCZ	0.45	5.48	0.41	1.77e-7	Height;
PAAD	cis	rs9583531	0.891	rs9521911	chr13:111370615	A/G	cg24331049	chr13:111365604	ING1	-0.81	-5.42	-0.4	2.27e-7	Coronary artery disease;
PAAD	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.59	6.11	0.44	7.99e-9	Testicular germ cell tumor;
PAAD	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.4	4.39	0.34	2.09e-5	Mean arterial pressure;
PAAD	cis	rs9361491	0.608	rs1998252	chr6:79458001	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.81	5.65	0.42	7.84e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.74	-0.48	3.15e-10	Obesity-related traits;
PAAD	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.57	5.48	0.41	1.76e-7	Uric acid clearance;
PAAD	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	9.04e-7	Childhood ear infection;
PAAD	cis	rs2279817	0.863	rs871088	chr1:18017558	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.66	5.78	0.42	4.02e-8	Neuroticism;
PAAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-5.9	-0.43	2.25e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.35	-4.36	-0.33	2.42e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.78	7.89	0.54	5.68e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg03289416	chr15:75166202	SCAMP2	0.52	5.32	0.4	3.57e-7	Breast cancer;
PAAD	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg02264943	chr11:130785842	SNX19	0.37	4.4	0.34	2e-5	Schizophrenia;
PAAD	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14019695	chr9:139328340	INPP5E	0.49	4.59	0.35	9.38e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.14	-0.5	3.55e-11	Coronary artery disease;
PAAD	cis	rs863345	0.526	rs10908669	chr1:158501938	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.6	6.64	0.47	5.22e-10	Coronary artery disease;
PAAD	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg15443732	chr18:74961078	GALR1	0.59	5.58	0.41	1.06e-7	Obesity-related traits;
PAAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	1.08	15.19	0.78	2.83e-32	Caffeine consumption;
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.96	-0.37	1.85e-6	Lung cancer;
PAAD	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg12184421	chr1:167409136	CD247	0.38	4.35	0.33	2.45e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.91	-0.59	1.45e-15	Calcium levels;
PAAD	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.54	5.9	0.43	2.25e-8	Bladder cancer;
PAAD	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.96	-10.72	-0.66	2.53e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.97	-7.99	-0.54	3.13e-13	Alzheimer's disease;
PAAD	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.71	-0.36	5.53e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.27	-0.33	3.37e-5	Total body bone mineral density;
PAAD	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	5.05	0.38	1.26e-6	Night sleep phenotypes;
PAAD	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg19949948	chr17:19361230	NA	0.45	4.43	0.34	1.77e-5	Schizophrenia;
PAAD	cis	rs787274	0.850	rs1324931	chr9:115634282	A/G	cg13803584	chr9:115635662	SNX30	0.78	4.66	0.35	6.91e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13560548	chr3:10150139	C3orf24	0.56	5.03	0.38	1.34e-6	Alzheimer's disease;
PAAD	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.71	7.8	0.53	9.23e-13	Menopause (age at onset);
PAAD	cis	rs2587695	0.901	rs2587683	chr2:120292249	C/T	cg05839767	chr2:119914248	C1QL2	0.42	4.49	0.34	1.41e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.86e-17	Platelet count;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs901683	0.850	rs79022473	chr10:46101768	C/T	cg13065504	chr15:42448234	PLA2G4F	0.82	6.57	0.47	7.37e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.6	-7.95	-0.54	3.81e-13	Height;
PAAD	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.53	4.78	0.36	4.14e-6	Anxiety disorder;
PAAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.52	4.78	0.36	4.19e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg19052272	chr2:3704530	ALLC	-0.54	-6.3	-0.46	2.99e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20700762	chr2:192108893	MYO1B	0.6	6.73	0.48	3.28e-10	Smoking initiation;
PAAD	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.57	-0.35	1.02e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.64	-0.47	5.2e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.15	0.55	1.24e-13	Coffee consumption (cups per day);
PAAD	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.7	8.69	0.58	5.52e-15	Dupuytren's disease;
PAAD	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg00262122	chr8:11665843	FDFT1	-0.46	-4.35	-0.33	2.47e-5	Neuroticism;
PAAD	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.86	-10.34	-0.64	2.67e-19	Schizophrenia;
PAAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2072732	0.716	rs72856433	chr1:2954061	G/A	cg22517653	chr1:2918612	NA	-0.6	-4.72	-0.36	5.38e-6	Plateletcrit;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs10958605	0.731	rs13270220	chr8:40032181	A/T	cg14545590	chr8:40388592	ZMAT4	-0.41	-4.5	-0.34	1.33e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs12936587	0.633	rs12949336	chr17:17509063	T/A	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.45	-0.34	1.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg13397359	chr6:42928475	GNMT	0.58	4.77	0.36	4.31e-6	Blood protein levels;
PAAD	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2061333	0.948	rs62115526	chr19:44604914	T/C	cg18700516	chr19:44507157	ZNF230	-0.65	-5.11	-0.38	9.4e-7	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg00531865	chr16:30841666	NA	-0.52	-5.08	-0.38	1.09e-6	Dementia with Lewy bodies;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.52	5.54	0.41	1.31e-7	Longevity;Endometriosis;
PAAD	cis	rs4343996	0.506	rs7790430	chr7:3432943	G/C	cg21248987	chr7:3385318	SDK1	0.41	4.29	0.33	3.2e-5	Motion sickness;
PAAD	cis	rs1903068	0.925	rs1551643	chr4:55994226	T/A	cg01777861	chr4:56023843	NA	0.36	4.26	0.33	3.54e-5	Endometriosis;
PAAD	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.52	-5.1	-0.38	1e-6	Neuroticism;
PAAD	cis	rs11563648	0.553	rs1057454	chr7:127032599	A/C	cg13381984	chr7:127881344	LEP	-0.29	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.62	4.81	0.36	3.66e-6	Coronary artery disease;
PAAD	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.81	-9.15	-0.6	3.44e-16	Birth weight;
PAAD	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg21775007	chr8:11205619	TDH	-0.46	-4.35	-0.33	2.46e-5	Neuroticism;
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg13647721	chr17:30228624	UTP6	0.57	4.57	0.35	1e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7577696	0.962	rs7575139	chr2:32291334	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.83e-6	Inflammatory biomarkers;
PAAD	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.02	0.38	1.42e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9652601	0.879	rs9926367	chr16:11093179	T/C	cg04616529	chr16:11181986	CLEC16A	0.46	4.83	0.36	3.35e-6	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.49	5.23	0.39	5.6e-7	Longevity;Endometriosis;
PAAD	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg27449745	chr7:23145252	KLHL7	-0.58	-5.31	-0.4	3.8e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg06970076	chr16:1560791	IFT140	0.51	4.56	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.63	5.69	0.42	6.29e-8	Phospholipid levels (plasma);
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg15331088	chr8:600555	NA	0.72	4.48	0.34	1.47e-5	IgG glycosylation;
PAAD	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.61	-4.55	-0.35	1.07e-5	Cholesterol, total;
PAAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.51	0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg18357526	chr6:26021779	HIST1H4A	0.66	6.63	0.47	5.43e-10	Height;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.84	-8.85	-0.58	2.1e-15	Facial morphology (factor 23);
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.46	4.36	0.33	2.42e-5	HDL cholesterol;
PAAD	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg04907244	chr7:22894795	SNORD93	-0.37	-4.32	-0.33	2.86e-5	Fibrinogen;
PAAD	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg05313129	chr8:58192883	C8orf71	-0.67	-6.08	-0.44	9.49e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.57	-0.35	1.02e-5	Type 1 diabetes;
PAAD	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.84	-7.79	-0.53	9.97e-13	Tuberculosis;
PAAD	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg25364880	chr3:44379878	C3orf23	0.49	4.35	0.33	2.49e-5	Depressive symptoms;
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.06	-0.44	1.01e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg00383909	chr3:49044727	WDR6	0.54	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg24879335	chr3:133465180	TF	-0.55	-5.9	-0.43	2.26e-8	Iron status biomarkers;
PAAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.5	-4.98	-0.37	1.71e-6	Ankle injury;
PAAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.7	8.11	0.55	1.6e-13	Type 2 diabetes;
PAAD	cis	rs9473924	1.000	rs9473924	chr6:50834157	A/C	cg24161652	chr6:50813859	TFAP2B	-0.3	-4.27	-0.33	3.5e-5	Body mass index;
PAAD	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.49	5.53	0.41	1.37e-7	Height;
PAAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7552393	0.595	rs4140462	chr1:84269299	A/G	cg10977910	chr1:84465055	TTLL7	-0.56	-5.34	-0.4	3.37e-7	Select biomarker traits;
PAAD	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg22654517	chr2:96458247	NA	0.36	4.27	0.33	3.49e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.72	-6.45	-0.46	1.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg09796270	chr17:17721594	SREBF1	0.48	5.23	0.39	5.59e-7	Total body bone mineral density;
PAAD	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-5.66	-0.42	7.36e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs457162	0.643	rs281862	chr6:118579131	T/C	cg21191810	chr6:118973309	C6orf204	0.7	4.46	0.34	1.56e-5	QT interval;
PAAD	cis	rs838147	0.844	rs8108468	chr19:49247786	G/A	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.62	5.61	0.41	9.25e-8	Platelet count;
PAAD	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg01851573	chr8:8652454	MFHAS1	0.94	7.24	0.51	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-8.15	-0.55	1.28e-13	Hemoglobin concentration;
PAAD	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.56	0.35	1.04e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.71	-6.92	-0.49	1.15e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.4	0.51	8.8e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.34e-9	Lung cancer;
PAAD	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg07784872	chr16:85687041	KIAA0182	-0.57	-4.61	-0.35	8.45e-6	Platelet distribution width;
PAAD	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg15956490	chr3:53032818	SFMBT1	0.81	4.81	0.36	3.63e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.47	-0.41	1.81e-7	Obesity-related traits;
PAAD	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs375066	0.935	rs384522	chr19:44405044	A/T	cg08633290	chr19:44405433	NA	-0.58	-5.74	-0.42	5.01e-8	Breast cancer;
PAAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg10356904	chr22:49881777	NA	-0.51	-4.74	-0.36	4.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs174479	0.677	rs174463	chr11:61657838	G/A	cg06781209	chr11:61594997	FADS2	0.37	4.29	0.33	3.22e-5	Sphingolipid levels;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15491120	chr18:74156897	ZNF516	-0.65	-6.6	-0.47	6.31e-10	Obesity-related traits;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00758701	chr13:49879718	NA	0.57	6.31	0.46	2.89e-9	Warfarin maintenance dose;
PAAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.31e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	5.48	0.41	1.72e-7	Multiple sclerosis;
PAAD	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	5.13	0.38	8.7e-7	Uric acid clearance;
PAAD	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.71	0.42	5.68e-8	Prostate cancer;
PAAD	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.67	-0.35	6.49e-6	Systemic lupus erythematosus;
PAAD	cis	rs4594175	0.847	rs17252303	chr14:51632246	C/T	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.83	6.76	0.48	2.83e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.64	6.76	0.48	2.78e-10	Aortic root size;
PAAD	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	1.21	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg00540400	chr15:79124168	NA	0.68	8.51	0.57	1.58e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs16867321	0.950	rs1919155	chr2:181457053	T/C	cg23363182	chr2:181467187	NA	-0.57	-5.13	-0.38	8.87e-7	Obesity;
PAAD	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.29	0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg04450456	chr4:17643702	FAM184B	0.52	5.77	0.42	4.21e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg27326032	chr3:127006922	NA	-0.69	-6.49	-0.47	1.17e-9	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs600626	0.891	rs695112	chr11:75456580	A/T	cg24262691	chr11:75473276	NA	0.51	4.89	0.37	2.57e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7264396	0.887	rs224344	chr20:34036865	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg22437258	chr11:111473054	SIK2	0.52	4.93	0.37	2.13e-6	Primary sclerosing cholangitis;
PAAD	cis	rs288342	0.797	rs288310	chr2:183650229	G/A	cg02625481	chr2:183667124	NA	-0.46	-4.75	-0.36	4.74e-6	Recurrent major depressive disorder;
PAAD	trans	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.72	-8.17	-0.55	1.12e-13	Childhood ear infection;
PAAD	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.55	-5.34	-0.4	3.3e-7	Gut microbiome composition (summer);
PAAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.38	0.33	2.22e-5	Electroencephalogram traits;
PAAD	cis	rs655641	0.539	rs645299	chr11:85691810	C/A	cg07180834	chr11:85838833	NA	-0.43	-4.69	-0.36	6.03e-6	Platelet count;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-6.42	-0.46	1.69e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	2.02e-13	Melanoma;
PAAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05676635	chr4:142142438	ZNF330	0.64	6.49	0.47	1.13e-9	Obesity-related traits;
PAAD	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.68	-7.45	-0.52	6.67e-12	Platelet distribution width;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.5	8.29	0.56	5.44e-14	IgG glycosylation;
PAAD	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11645453	chr3:52864694	ITIH4	0.3	4.28	0.33	3.34e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02446627	chr2:127865197	BIN1	0.56	6.66	0.48	4.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs12599426	1.000	rs12929970	chr16:34803389	C/T	cg08331635	chr16:34430078	NA	-0.6	-4.67	-0.35	6.62e-6	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.91	0.59	1.45e-15	Lung cancer;
PAAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.93	-10.1	-0.63	1.16e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.7	6.1	0.44	8.51e-9	Pubertal anthropometrics;
PAAD	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.42	-6.34	-0.46	2.45e-9	Breast cancer;
PAAD	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg03538708	chr1:25844672	NA	0.52	5.39	0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg04034577	chr2:241836375	C2orf54	-0.34	-5.15	-0.39	7.79e-7	Urinary metabolites;
PAAD	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg10053473	chr17:62856997	LRRC37A3	0.81	8.2	0.55	9.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg08371190	chr1:87598514	LOC339524	-0.45	-6.01	-0.44	1.32e-8	Smoking behavior;
PAAD	cis	rs7246865	0.859	rs12461874	chr19:17180358	C/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.65	5.19	0.39	6.53e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs73198271	0.515	rs75660006	chr8:8619594	C/T	cg01851573	chr8:8652454	MFHAS1	0.9	6.15	0.45	6.58e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2798269	0.544	rs1200030	chr13:22160604	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.51	-4.72	-0.36	5.31e-6	PR segment;
PAAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00125455	chr20:44574271	PCIF1	0.41	4.25	0.33	3.68e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	7.44	0.52	6.95e-12	Body mass index;
PAAD	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.09	-8.67	-0.58	6.02e-15	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg09667013	chr22:42394590	WBP2NL	0.56	4.63	0.35	7.68e-6	Birth weight;
PAAD	trans	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	4.92	0.37	2.24e-6	Schizophrenia;
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg23018236	chr17:30244563	NA	0.69	5.32	0.4	3.62e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs60154123	0.504	rs11119458	chr1:210491097	T/A	cg25204440	chr1:209979598	IRF6	0.64	4.86	0.37	2.9e-6	Coronary artery disease;
PAAD	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.25	-0.39	4.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.82	-7.95	-0.54	3.89e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg23283495	chr1:209979779	IRF6	0.64	5.71	0.42	5.74e-8	Coronary artery disease;
PAAD	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.59	5.8	0.43	3.79e-8	Blood protein levels;
PAAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-6.45	-0.46	1.39e-9	Bipolar disorder;
PAAD	cis	rs56046484	0.871	rs62021203	chr15:85564077	C/T	cg08123816	chr15:85640762	PDE8A	-0.43	-4.34	-0.33	2.6e-5	Testicular germ cell tumor;
PAAD	cis	rs2120243	0.501	rs1456107	chr3:157119520	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.38	0.33	2.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.75	-5.98	-0.44	1.51e-8	Cancer;
PAAD	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.66	6.81	0.48	2.13e-10	Capecitabine sensitivity;
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg22868518	chr11:507468	RNH1	0.88	4.8	0.36	3.76e-6	Body mass index;
PAAD	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.63	-6.0	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg26248373	chr2:1572462	NA	-1.04	-8.91	-0.59	1.49e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4427176	0.825	rs7464528	chr8:9574277	G/C	cg03024720	chr8:9765601	NA	0.47	4.49	0.34	1.41e-5	Mosquito bite size;
PAAD	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.75	8.77	0.58	3.39e-15	Blood metabolite ratios;
PAAD	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.91	-9.34	-0.6	1.12e-16	Response to antineoplastic agents;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	1.23	8.91	0.59	1.45e-15	IgG glycosylation;
PAAD	cis	rs5751901	0.688	rs2017869	chr22:24997309	C/G	cg15363607	chr22:24998974	GGT1	-0.53	-5.72	-0.42	5.5e-8	Protein quantitative trait loci;
PAAD	cis	rs77880822	0.562	rs78650050	chr20:1255278	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs59698941	0.882	rs12521723	chr5:132273808	A/T	cg16419906	chr5:132167176	NA	-0.68	-5.53	-0.41	1.33e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs1345301	1.000	rs1345302	chr2:102873369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.33	-0.33	2.72e-5	Waist circumference;
PAAD	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.3	-0.39	4.05e-7	Pulmonary function;
PAAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-1.37	-11.09	-0.67	2.66e-21	Schizophrenia;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08677398	chr8:58056175	NA	0.59	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11563648	0.535	rs28729203	chr7:127031917	G/T	cg21885361	chr7:127911034	NA	-0.41	-4.35	-0.33	2.45e-5	Resting heart rate;
PAAD	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg06096015	chr1:231504339	EGLN1	0.68	8.82	0.58	2.53e-15	Hemoglobin concentration;
PAAD	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs9659323	0.804	rs10923722	chr1:119543486	C/T	cg26570165	chr1:119541833	NA	-0.54	-5.68	-0.42	6.73e-8	Body mass index;
PAAD	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.5	6.16e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.25	0.56	7.1e-14	Schizophrenia;
PAAD	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-7.63	-0.53	2.38e-12	Colorectal cancer;
PAAD	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg27411982	chr8:10470053	RP1L1	0.48	5.02	0.38	1.42e-6	Retinal vascular caliber;
PAAD	trans	rs1442089	1.000	rs9948280	chr18:51093474	T/C	cg24118715	chr10:70232072	DNA2	0.68	6.29	0.45	3.25e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs4731207	0.967	rs2299902	chr7:124397814	G/T	cg14311320	chr7:124405732	GPR37	0.43	4.66	0.35	6.87e-6	Cutaneous malignant melanoma;
PAAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.64	5.53	0.41	1.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-9.0	-0.59	8.78e-16	Height;
PAAD	cis	rs1692580	0.807	rs60635488	chr1:2202572	C/T	cg21194808	chr1:2205498	SKI	0.45	4.41	0.34	1.97e-5	Coronary artery disease;
PAAD	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.62	5.82	0.43	3.3e-8	Lymphocyte counts;
PAAD	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.5	-4.66	-0.35	6.89e-6	Cognitive ability;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg00933542	chr6:150070202	PCMT1	0.52	5.2	0.39	6.37e-7	Lung cancer;
PAAD	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg19904058	chr10:135279010	LOC619207	0.47	5.65	0.42	7.57e-8	Systemic lupus erythematosus;
PAAD	cis	rs3925075	0.531	rs4608351	chr16:31348848	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.4	0.4	2.54e-7	IgA nephropathy;
PAAD	cis	rs6466055	0.669	rs6950620	chr7:104770386	A/G	cg04380332	chr7:105027541	SRPK2	0.62	6.94	0.49	1.04e-10	Schizophrenia;
PAAD	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg04717802	chr22:42394638	WBP2NL	0.54	4.77	0.36	4.27e-6	Birth weight;
PAAD	cis	rs9913156	0.841	rs7223840	chr17:4562150	T/C	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs1879734	0.731	rs11206196	chr1:54165624	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.95	-0.43	1.75e-8	Mitral valve prolapse;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13412003	chr19:35455007	ZNF792	0.72	7.41	0.52	8.17e-12	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-9.09	-0.59	5.03e-16	Body mass index;
PAAD	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.74	-5.27	-0.39	4.64e-7	Blood protein levels;
PAAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg04705435	chr11:17411270	KCNJ11	0.61	6.34	0.46	2.43e-9	Type 2 diabetes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00814883	chr7:100076585	TSC22D4	0.57	6.85	0.49	1.71e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg04352962	chr1:209979756	IRF6	0.54	4.72	0.36	5.26e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg07810366	chr2:100720526	AFF3	-0.4	-5.0	-0.38	1.55e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03315687	chr19:40932206	SERTAD1	0.56	6.45	0.46	1.43e-9	Metabolite levels  (X-11787);
PAAD	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg22338127	chr1:209979572	IRF6	0.53	4.31	0.33	2.94e-5	Coronary artery disease;
PAAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.91	-6.93	-0.49	1.12e-10	Initial pursuit acceleration;
PAAD	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.88	8.17	0.55	1.13e-13	Obesity-related traits;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg00181669	chr3:44000978	NA	-0.47	-4.7	-0.36	5.78e-6	Coronary artery disease;
PAAD	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.43	4.39	0.34	2.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg03959625	chr15:84868606	LOC388152	0.49	5.43	0.4	2.22e-7	Schizophrenia;
PAAD	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.83	-5.98	-0.44	1.55e-8	Coronary artery calcification;
PAAD	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.41	13.79	0.75	1.47e-28	Corneal structure;
PAAD	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg10011062	chr15:43941034	CATSPER2	-0.9	-5.56	-0.41	1.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg20283391	chr11:68216788	NA	0.53	5.08	0.38	1.09e-6	Total body bone mineral density;
PAAD	cis	rs7925908	0.659	rs1110301	chr11:131158830	T/C	cg13391028	chr11:130657123	NA	0.36	4.29	0.33	3.12e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);Glucocorticoid-induced osteonecrosis (time dependent analysis);
PAAD	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.58e-5	Schizophrenia;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.77	-0.42	4.27e-8	Life satisfaction;
PAAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg24004478	chr7:855632	UNC84A	0.42	4.29	0.33	3.14e-5	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.64	-0.53	2.28e-12	Height;
PAAD	cis	rs59888335	0.858	rs13061302	chr3:80905940	A/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2982694	1.000	rs2347872	chr6:152292672	T/C	cg26219152	chr6:152443475	SYNE1	-0.65	-4.34	-0.33	2.6e-5	Sudden cardiac arrest;
PAAD	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.45	4.33	0.33	2.67e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
PAAD	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg10820045	chr2:198174542	NA	-0.44	-4.35	-0.33	2.49e-5	Dermatomyositis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21265917	chr7:144100802	NOBOX	-0.55	-6.39	-0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.08	0.73	1.17e-26	Platelet count;
PAAD	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.25	-0.39	5.11e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-5.5	-0.41	1.55e-7	Mood instability;
PAAD	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.54	5.39	0.4	2.66e-7	Height;
PAAD	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg27565382	chr3:53032988	SFMBT1	-0.75	-4.38	-0.33	2.24e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs1318772	1.000	rs68189049	chr5:112690255	C/T	cg12552261	chr5:112820674	MCC	0.59	4.34	0.33	2.61e-5	F-cell distribution;
PAAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09065629	chr16:1709722	CRAMP1L	0.43	4.48	0.34	1.44e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg11062466	chr8:58055876	NA	0.72	5.28	0.39	4.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg06042504	chr8:55087323	NA	-0.77	-8.67	-0.58	6.01e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs375066	0.868	rs370190	chr19:44424254	A/T	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.64	6.93	0.49	1.12e-10	Longevity;
PAAD	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs2143950	0.512	rs62625038	chr14:35517017	A/G	cg14523979	chr14:35838413	NA	-0.49	-4.29	-0.33	3.15e-5	Atopic dermatitis;
PAAD	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	6.61	0.47	6.12e-10	Educational attainment;
PAAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.62	0.41	8.93e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg24879335	chr3:133465180	TF	0.61	6.68	0.48	4.25e-10	Iron status biomarkers;
PAAD	cis	rs12311304	0.932	rs961176	chr12:15375619	A/C	cg08258403	chr12:15378311	NA	0.37	4.63	0.35	7.96e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4750440	0.706	rs4750443	chr10:14019865	A/T	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs508970	0.556	rs562522	chr11:60923787	A/G	cg24692310	chr11:60915630	VPS37C	0.34	4.7	0.36	5.9e-6	Rheumatoid arthritis;
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg23018236	chr17:30244563	NA	-0.55	-4.27	-0.33	3.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.8e-7	Interstitial lung disease;
PAAD	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.81	-6.62	-0.47	5.74e-10	Pulmonary function decline;
PAAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.82	-6.25	-0.45	3.85e-9	Coronary artery calcification;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg11601000	chr22:42348013	LOC339674	-0.4	-4.6	-0.35	8.9e-6	Cognitive function;
PAAD	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg24375607	chr4:120327624	NA	0.58	5.36	0.4	3.06e-7	Educational attainment;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.89e-6	Electroencephalogram traits;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	4.92	0.37	2.25e-6	Renal function-related traits (BUN);
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.69	6.85	0.49	1.69e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10724490	chr7:6523886	KDELR2	0.6	7.05	0.5	5.73e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.64	5.5	0.41	1.55e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg24375607	chr4:120327624	NA	0.53	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg05425664	chr17:57184151	TRIM37	-0.51	-4.94	-0.37	2e-6	Testicular germ cell tumor;
PAAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.86	-7.43	-0.52	7.49e-12	Tuberculosis;
PAAD	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs17162190	0.698	rs55840663	chr1:26840826	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.79	0.36	3.88e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-1.14	-11.03	-0.67	3.66e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.9	10.8	0.66	1.55e-20	Monocyte count;
PAAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg26071806	chr7:100318239	EPO	-0.41	-4.26	-0.33	3.6e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.59	-0.8	6.23e-36	Height;
PAAD	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg04132472	chr17:19861366	AKAP10	0.47	5.29	0.39	4.21e-7	Schizophrenia;
PAAD	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs9810890	1.000	rs115639732	chr3:128555607	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.57	5.02	0.38	1.43e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-4.81	-0.36	3.54e-6	Recombination measurement;
PAAD	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	6.52	0.47	9.78e-10	Menarche (age at onset);
PAAD	cis	rs2526932	0.621	rs11625926	chr14:73071853	G/T	cg13588403	chr14:73209128	DPF3	-0.39	-5.13	-0.38	8.76e-7	C-reactive protein and white blood cell count;
PAAD	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs12760731	0.720	rs3791023	chr1:178398092	A/C	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs35955747	0.902	rs5997932	chr22:31668154	C/G	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.52	-0.47	9.94e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2479106	0.791	rs2670139	chr9:126634255	T/C	cg16191174	chr9:126692580	DENND1A	0.51	4.35	0.33	2.52e-5	Polycystic ovary syndrome;
PAAD	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.58	5.06	0.38	1.2e-6	Lymphocyte counts;
PAAD	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs2282930	0.836	rs2072235	chr7:50737384	C/T	cg07379434	chr7:49814597	VWC2	0.26	4.54	0.35	1.14e-5	Bone mineral density;
PAAD	cis	rs2882667	0.537	rs13181793	chr5:138408956	G/A	cg22797968	chr5:138629998	MATR3	0.46	4.57	0.35	1.01e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.16	16.63	0.8	4.95e-36	Body mass index;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05778415	chr2:75185968	POLE4	0.59	6.83	0.48	1.89e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.86	10.66	0.65	3.7e-20	Bladder cancer;
PAAD	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg03714773	chr7:91764589	CYP51A1	-0.32	-4.48	-0.34	1.44e-5	Breast cancer;
PAAD	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	9.01	0.59	8.12e-16	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg27124370	chr19:33622961	WDR88	0.61	5.88	0.43	2.54e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg21994712	chr19:21861136	NA	0.46	4.5	0.34	1.32e-5	Pain;
PAAD	cis	rs9649465	1.000	rs6951138	chr7:123362070	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg08824895	chr13:115047677	UPF3A	0.47	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.78	-0.36	4.11e-6	Parkinson's disease;
PAAD	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	4.5	0.34	1.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs2885056	0.891	rs73018656	chr19:10689797	C/T	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	1.0	6.36	0.46	2.2e-9	LDL cholesterol;
PAAD	cis	rs16975963	0.639	rs112997435	chr19:38204631	C/T	cg08679971	chr19:38281047	NA	0.47	4.63	0.35	7.72e-6	Longevity;
PAAD	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07372659	chr6:20866952	CDKAL1	0.54	6.76	0.48	2.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	6.04	0.44	1.14e-8	Lung cancer;
PAAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.75	7.12	0.5	4.09e-11	Schizophrenia;
PAAD	cis	rs8113142	0.614	rs4805259	chr19:29171420	C/T	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.08e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.04	-14.68	-0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs9815354	0.597	rs79626430	chr3:42023786	A/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg02573091	chr5:74908125	NA	-0.56	-4.88	-0.37	2.6e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
PAAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg00579200	chr11:133705235	NA	-0.48	-5.33	-0.4	3.5e-7	Childhood ear infection;
PAAD	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.94	-7.25	-0.51	1.98e-11	Multiple sclerosis;
PAAD	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.48	4.88	0.37	2.65e-6	Mean platelet volume;
PAAD	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16603964	chr6:111803680	REV3L	0.65	6.42	0.46	1.61e-9	Obesity-related traits;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.51	5.14	0.38	8.36e-7	Parkinson's disease;
PAAD	cis	rs2885056	0.843	rs11085740	chr19:10694244	C/T	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs10501293	1.000	rs10838010	chr11:43122962	T/C	cg03447554	chr11:43094025	NA	-0.5	-4.96	-0.37	1.86e-6	Cognitive performance;
PAAD	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.51	4.27	0.33	3.41e-5	Height;
PAAD	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.6	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.85	10.95	0.66	6.05e-21	Methadone dose in opioid dependence;
PAAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.26	0.39	4.84e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19674350	chr21:43229429	PRDM15	0.53	6.73	0.48	3.26e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.42	-5.12	-0.38	9.01e-7	Body mass index in non-asthmatics;
PAAD	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg03959625	chr15:84868606	LOC388152	0.5	5.36	0.4	3.09e-7	Schizophrenia;
PAAD	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.75	-4.79	-0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.91	-0.54	4.8e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.73	10.66	0.65	3.65e-20	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.7	-5.99	-0.44	1.45e-8	Quantitative traits;
PAAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.88	10.82	0.66	1.36e-20	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02659055	chr5:180670537	GNB2L1;SNORD95	0.61	7.07	0.5	5.12e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12636108	chr5:176036956	GPRIN1	0.61	6.45	0.46	1.43e-9	Myopia (pathological);
PAAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.49	4.79	0.36	3.97e-6	Pulse pressure;
PAAD	cis	rs508970	0.534	rs537009	chr11:60923319	C/A	cg24692310	chr11:60915630	VPS37C	0.34	4.7	0.36	5.9e-6	Rheumatoid arthritis;
PAAD	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg04359915	chr10:101825029	CPN1	-0.36	-5.59	-0.41	1.05e-7	Bone mineral density;
PAAD	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.11	-0.67	2.35e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7101378	0.599	rs7927428	chr11:108899634	C/A	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.9	9.31	0.6	1.35e-16	Educational attainment;
PAAD	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	6.05	0.44	1.1e-8	Ileal carcinoids;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2279817	0.780	rs3766312	chr1:17978644	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.7	-6.05	-0.44	1.08e-8	Neuroticism;
PAAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.48	-4.71	-0.36	5.46e-6	Body mass index;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24798493	chr7:5463336	TNRC18	-0.66	-6.29	-0.45	3.28e-9	Lung cancer in ever smokers;
PAAD	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.8	-5.76	-0.42	4.48e-8	Vitiligo;
PAAD	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	9.42	0.61	7.08e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.43	4.4	0.34	2.03e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-4.36	-0.33	2.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-4.59	-0.35	9.12e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg18551225	chr6:44695536	NA	-0.71	-7.11	-0.5	4.31e-11	Total body bone mineral density;
PAAD	cis	rs10121009	0.635	rs630255	chr9:35312885	C/A	cg11846315	chr9:35647073	NA	-0.5	-4.52	-0.34	1.25e-5	Parkinson's disease;
PAAD	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg10556349	chr10:835070	NA	-0.59	-4.98	-0.37	1.74e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg27411982	chr8:10470053	RP1L1	0.45	4.75	0.36	4.72e-6	Retinal vascular caliber;
PAAD	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg21523564	chr15:75251491	NA	0.47	4.9	0.37	2.42e-6	Breast cancer;
PAAD	cis	rs2133450	0.935	rs12637466	chr3:7321909	C/T	cg19930620	chr3:7340148	GRM7	-0.42	-4.41	-0.34	1.91e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12893428	chr3:195717962	SDHAP1	0.46	4.5	0.34	1.32e-5	Pancreatic cancer;
PAAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.94	-0.49	1.04e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.18	17.56	0.82	2.04e-38	Cognitive function;
PAAD	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.97	0.54	3.57e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.55	5.46	0.41	1.86e-7	Platelet count;
PAAD	cis	rs16895831	0.519	rs16895856	chr6:42564921	A/C	cg10605015	chr6:42532144	UBR2	-0.71	-5.21	-0.39	5.99e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.49	-0.41	1.65e-7	Schizophrenia;
PAAD	cis	rs10864907	0.680	rs10206205	chr2:113717837	G/A	cg17804723	chr2:114300030	NA	-0.39	-4.49	-0.34	1.39e-5	Pulmonary function;
PAAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.61	-0.35	8.33e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.76	5.26	0.39	4.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.71	7.93	0.54	4.5e-13	Longevity;
PAAD	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67478160	0.584	rs2295151	chr14:104193099	C/G	cg26031613	chr14:104095156	KLC1	-0.54	-5.62	-0.41	8.79e-8	Schizophrenia;
PAAD	cis	rs9488822	0.585	rs195522	chr6:116245016	G/A	cg18764771	chr6:116381957	FRK	0.26	4.25	0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.64	7.01	0.49	7.2e-11	Menarche (age at onset);
PAAD	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg02683114	chr2:24398427	C2orf84	0.56	5.84	0.43	3.06e-8	Asthma;
PAAD	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.76	-0.53	1.18e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18848301	chr6:44590128	NA	-0.67	-7.04	-0.5	6.31e-11	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg24747557	chr10:131355152	MGMT	-0.44	-4.75	-0.36	4.7e-6	Response to temozolomide;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.84	0.62	5.68e-18	Prudent dietary pattern;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg16205897	chr5:131564050	P4HA2	-0.49	-5.49	-0.41	1.64e-7	Blood metabolite levels;
PAAD	cis	rs7849585	0.928	rs7038554	chr9:139134981	A/G	cg14147151	chr9:138948000	NACC2	0.38	4.27	0.33	3.38e-5	Height;
PAAD	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.81	0.36	3.53e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.64	5.88e-19	Morning vs. evening chronotype;
PAAD	cis	rs412658	0.504	rs369128	chr19:22107866	A/T	cg23859931	chr19:22123797	NA	-0.45	-4.64	-0.35	7.36e-6	Telomere length;
PAAD	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.57	-7.1	-0.5	4.55e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.48	-4.69	-0.36	6.15e-6	Systemic lupus erythematosus;
PAAD	cis	rs11811982	0.793	rs79146151	chr1:227539055	G/A	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.98	13.04	0.73	1.42e-26	Menopause (age at onset);
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.61	5.44	0.4	2.13e-7	Blood pressure;
PAAD	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.46	-5.09	-0.38	1.02e-6	Pneumonia;
PAAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg00255919	chr5:131827918	IRF1	0.63	7.45	0.52	6.42e-12	Asthma (sex interaction);
PAAD	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-4.4	-0.34	2.02e-5	Reticulocyte count;
PAAD	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26378065	chr17:18585709	ZNF286B	0.55	5.4	0.4	2.5e-7	Educational attainment (years of education);
PAAD	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.46	-0.57	2.04e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg09659197	chr4:152720779	NA	0.36	5.3	0.4	3.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.55	0.35	1.11e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg02795151	chr17:7402630	POLR2A	0.62	5.71	0.42	5.62e-8	IgM levels;
PAAD	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.7	-0.36	5.71e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.56	-0.35	1.04e-5	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.7	6.79	0.48	2.41e-10	Lymphocyte counts;
PAAD	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.22	7.15	0.5	3.42e-11	Lung cancer in ever smokers;
PAAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15145965	chr22:50218605	BRD1	0.62	5.09	0.38	1.05e-6	Schizophrenia;
PAAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs75920871	0.748	rs7946219	chr11:116962759	C/T	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg02580895	chr19:2754563	NA	-0.54	-4.56	-0.35	1.03e-5	Total cholesterol levels;
PAAD	cis	rs655641	0.539	rs673751	chr11:85670945	A/C	cg07180834	chr11:85838833	NA	-0.46	-5.17	-0.39	7.38e-7	Platelet count;
PAAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg23352942	chr3:46931381	PTH1R	-0.59	-6.52	-0.47	9.72e-10	Birth weight;
PAAD	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.7	0.42	5.96e-8	Restless legs syndrome;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg02462569	chr6:150064036	NUP43	-0.48	-5.33	-0.4	3.52e-7	Lung cancer;
PAAD	cis	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15906409	chr17:17685582	RAI1	0.56	6.36	0.46	2.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg15117754	chr3:10150083	C3orf24	-0.61	-5.8	-0.43	3.8e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.33	-0.33	2.68e-5	Alcohol dependence;
PAAD	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	Cognitive function;
PAAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg23719950	chr11:63933701	MACROD1	-0.5	-4.38	-0.33	2.19e-5	Platelet count;
PAAD	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09065629	chr16:1709722	CRAMP1L	0.44	4.57	0.35	1.01e-5	Coronary artery disease;
PAAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg21033440	chr11:65409861	SIPA1	0.46	5.2	0.39	6.21e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs3782123	0.514	rs11246007	chr11:221584	C/T	cg25796445	chr11:207425	RIC8A;BET1L	-0.81	-5.18	-0.39	7.05e-7	Glycated hemoglobin levels;Red cell distribution width;
PAAD	cis	rs10950821	0.806	rs28645540	chr7:20647637	T/A	cg21202529	chr7:20656503	ABCB5	-0.46	-4.36	-0.33	2.36e-5	Response to statin therapy;
PAAD	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg23346134	chr3:49453900	TCTA	0.5	4.83	0.36	3.27e-6	Menarche (age at onset);
PAAD	cis	rs7580658	0.895	rs4662722	chr2:128102569	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24638667	chr7:128116644	METTL2B	-0.69	-6.4	-0.46	1.85e-9	Neuroticism;
PAAD	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg01305830	chr4:1604576	NA	-0.48	-4.59	-0.35	9.08e-6	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00007324	chr19:4047803	ZBTB7A	-0.66	-7.65	-0.53	2.12e-12	Monocyte percentage of white cells;
PAAD	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.58	-5.03	-0.38	1.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.59	-4.67	-0.35	6.7e-6	Cholesterol, total;
PAAD	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg24253500	chr15:84953950	NA	0.43	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9895232	1.000	rs9895232	chr17:4519139	A/G	cg21809093	chr17:3854700	ATP2A3	-0.41	-4.42	-0.34	1.88e-5	Proteinuria and chronic kidney disease;
PAAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.65	-6.91	-0.49	1.23e-10	Mean platelet volume;
PAAD	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg09066997	chr16:75300724	BCAR1	0.6	4.6	0.35	9.03e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs9535307	0.719	rs1009333	chr13:50383341	T/C	cg03658251	chr13:50265850	EBPL	-0.82	-5.61	-0.41	9.14e-8	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs564309	1.000	rs61825338	chr1:228580165	C/T	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.91	6.05	0.44	1.08e-8	Chronic kidney disease;
PAAD	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.51	-7.1	-0.5	4.51e-11	Dupuytren's disease;
PAAD	cis	rs6460942	0.597	rs12699388	chr7:12536336	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-4.51	-0.34	1.26e-5	Height;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg02743256	chr7:2109353	MAD1L1	-0.55	-4.36	-0.33	2.42e-5	Bipolar disorder;
PAAD	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.64	6.75	0.48	2.94e-10	Systemic lupus erythematosus;
PAAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg17633681	chr16:88106987	BANP	0.65	8.25	0.56	6.96e-14	Menopause (age at onset);
PAAD	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.24	-0.39	5.2e-7	Alcohol dependence;
PAAD	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.71	6.16	0.45	6.07e-9	Pubertal anthropometrics;
PAAD	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.49	4.56	0.35	1.04e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg14146966	chr2:61757674	XPO1	0.43	5.35	0.4	3.14e-7	Tuberculosis;
PAAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg13859433	chr6:33739653	LEMD2	-0.61	-4.82	-0.36	3.52e-6	Schizophrenia;
PAAD	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg01763666	chr17:80159506	CCDC57	0.41	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.74	-6.15	-0.45	6.52e-9	Pancreatic cancer;
PAAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.41	-0.46	1.78e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	9.11	0.59	4.55e-16	Chronic sinus infection;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs7714584	0.793	rs35707106	chr5:150225377	G/A	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg16590910	chr6:42928470	GNMT	0.51	5.28	0.39	4.42e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00068305	chr5:122847680	CSNK1G3	0.67	6.6	0.47	6.44e-10	Obesity-related traits;
PAAD	cis	rs971074	0.764	rs116239629	chr4:100342619	G/A	cg10031042	chr4:101090547	NA	0.61	4.3	0.33	3.05e-5	Oral cavity and pharyngeal cancer;
PAAD	cis	rs2114646	1.000	rs2114646	chr2:170624221	C/T	cg01268571	chr2:170624998	NA	0.56	5.12	0.38	9.09e-7	Obesity-related traits;
PAAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg06393558	chr11:69982916	ANO1	-0.58	-6.29	-0.45	3.14e-9	Survival in rectal cancer;
PAAD	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03543533	chr1:148903479	NA	-0.5	-6.74	-0.48	3.16e-10	Obesity-related traits;
PAAD	cis	rs11264213	0.786	rs72659701	chr1:36317380	C/T	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg05925327	chr15:68127851	NA	-0.6	-5.42	-0.4	2.34e-7	Restless legs syndrome;
PAAD	cis	rs559555	0.523	rs11124270	chr2:32003345	G/A	cg02381751	chr2:32503542	YIPF4	-0.46	-4.3	-0.33	3.01e-5	Blood metabolite ratios;Blood metabolite levels;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	5.48	0.41	1.71e-7	Obesity-related traits;
PAAD	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	High light scatter reticulocyte count;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.02	-0.38	1.43e-6	Longevity;Endometriosis;
PAAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg03517284	chr6:25882590	NA	-0.58	-4.87	-0.37	2.77e-6	Iron status biomarkers;
PAAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg03037974	chr15:76606532	NA	0.55	6.52	0.47	1e-9	Blood metabolite levels;
PAAD	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.88	-0.49	1.46e-10	Response to antipsychotic treatment;
PAAD	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg07154921	chr7:157260426	NA	-0.44	-4.3	-0.33	3.01e-5	Body mass index;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.44	-0.46	1.48e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg12639453	chr1:2035780	PRKCZ	-0.6	-6.59	-0.47	6.73e-10	Height;
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.63	6.22	0.45	4.48e-9	Blood metabolite levels;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.75	7.55	0.52	3.8e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg10437265	chr15:77819839	NA	0.39	4.27	0.33	3.45e-5	Type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23788167	chr9:74979561	ZFAND5	-0.74	-7.95	-0.54	3.98e-13	Smoking initiation;
PAAD	cis	rs7829975	0.539	rs35571782	chr8:8141823	A/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.39	-0.34	2.07e-5	Mood instability;
PAAD	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.93	0.37	2.16e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.87e-7	Bladder cancer;
PAAD	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.12	0.38	9.25e-7	Mood instability;
PAAD	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.07	-0.38	1.14e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.58	6.26	0.45	3.71e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg16342193	chr10:102329863	NA	-0.8	-8.74	-0.58	4.01e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.79	-6.38	-0.46	2.04e-9	Pulmonary function decline;
PAAD	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.7	6.86	0.49	1.64e-10	Cancer;
PAAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg24733560	chr20:60626293	TAF4	0.6	7.97	0.54	3.48e-13	Body mass index;
PAAD	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.32	4.32	0.33	2.83e-5	IgG glycosylation;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.91	-6.58	-0.47	7.04e-10	Body mass index;
PAAD	cis	rs1371614	0.588	rs13017554	chr2:27170982	C/T	cg00617064	chr2:27272375	NA	-0.48	-5.07	-0.38	1.16e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg22863700	chr5:28928346	NA	0.53	4.99	0.38	1.65e-6	Hip geometry;
PAAD	cis	rs507080	0.883	rs693306	chr11:118558333	A/G	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg19131313	chr8:1704013	NA	-0.38	-4.27	-0.33	3.48e-5	Systolic blood pressure;
PAAD	cis	rs7173419	0.607	rs11634923	chr15:28221036	A/C	cg20906524	chr15:28200668	OCA2	-0.47	-5.57	-0.41	1.11e-7	Eye color;
PAAD	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	7.91	0.54	4.99e-13	Coffee consumption (cups per day);
PAAD	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs12754538	0.961	rs11121181	chr1:8477006	G/A	cg06159269	chr1:8767347	RERE	0.37	4.4	0.34	2e-5	Subjective well-being;
PAAD	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.48	7.88	0.54	5.86e-13	Cutaneous nevi;
PAAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.59	5.35	0.4	3.19e-7	Monocyte count;
PAAD	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.17	0.39	7.24e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.01e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg16606324	chr3:10149918	C3orf24	0.79	6.43	0.46	1.58e-9	Alzheimer's disease;
PAAD	cis	rs713477	0.524	rs4901560	chr14:55888533	C/T	cg13175173	chr14:55914753	NA	0.35	4.64	0.35	7.48e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.51	-0.34	1.28e-5	Mean corpuscular volume;
PAAD	cis	rs72960926	0.590	rs11754945	chr6:74732673	A/C	cg03266952	chr6:74778945	NA	1.06	7.19	0.5	2.74e-11	Metabolite levels (MHPG);
PAAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.84	-6.68	-0.48	4.28e-10	Initial pursuit acceleration;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.66	0.42	7.27e-8	Alzheimer's disease;
PAAD	cis	rs282587	0.569	rs7987238	chr13:113409944	G/A	cg04656015	chr13:113407548	ATP11A	0.56	4.51	0.34	1.31e-5	Glycated hemoglobin levels;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg03959625	chr15:84868606	LOC388152	0.52	5.77	0.42	4.33e-8	Schizophrenia;
PAAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg00579200	chr11:133705235	NA	-0.42	-4.77	-0.36	4.27e-6	Childhood ear infection;
PAAD	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg11204139	chr17:3907470	NA	0.85	9.14	0.6	3.64e-16	Type 2 diabetes;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	4.75	0.36	4.59e-6	Renal function-related traits (BUN);
PAAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg05082376	chr22:42548792	NA	0.49	5.18	0.39	6.89e-7	Cognitive function;
PAAD	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.64e-5	Coronary artery disease;
PAAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.72	-0.36	5.41e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg05110241	chr16:68378359	PRMT7	-1.14	-8.31	-0.56	5e-14	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11597332	chr3:49395923	GPX1	0.72	7.06	0.5	5.44e-11	Obesity-related traits;
PAAD	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg12072164	chr19:44306565	LYPD5	0.41	4.42	0.34	1.86e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs818427	0.574	rs460137	chr5:112196949	A/C	cg06941702	chr5:112196734	SRP19	-0.54	-5.25	-0.39	5e-7	Total body bone mineral density;
PAAD	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg01064725	chr1:204461714	NA	-0.51	-4.76	-0.36	4.45e-6	Schizophrenia;
PAAD	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.52	6.38	0.46	2.01e-9	Sitting height ratio;
PAAD	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.9	11.77	0.69	3.96e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg08514558	chr10:81106712	PPIF	0.51	6.14	0.45	6.94e-9	Height;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.45	6.21	0.45	4.74e-9	Cardiovascular disease risk factors;
PAAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.97	-8.13	-0.55	1.37e-13	Dupuytren's disease;
PAAD	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.62	-6.35	-0.46	2.38e-9	Motion sickness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16872693	chr3:42003170	ULK4	-0.78	-6.69	-0.48	4e-10	Neuroticism;
PAAD	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.55	-4.52	-0.34	1.26e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.46	4.75	0.36	4.57e-6	Breast cancer;
PAAD	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.75	6.96	0.49	9.5e-11	Obesity-related traits;
PAAD	cis	rs11647936	0.528	rs11149673	chr16:84702097	C/G	cg02504136	chr16:84698702	NA	-0.44	-4.31	-0.33	2.92e-5	Waist circumference;
PAAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.3e-5	Menopause (age at onset);
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Body mass index;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.92	-0.49	1.19e-10	Life satisfaction;
PAAD	cis	rs7082209	0.587	rs2505738	chr10:44817210	A/C	cg08683644	chr10:44853092	NA	0.54	4.5	0.34	1.34e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.43	4.61	0.35	8.42e-6	Facial morphology (factor 20);
PAAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.53	0.61	3.7e-17	Rheumatoid arthritis;
PAAD	cis	rs6137287	0.924	rs6047281	chr20:21146287	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs1468734	1.000	rs34630219	chr16:5003436	C/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	1.03	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg25122841	chr14:24911839	SDR39U1	0.47	4.26	0.33	3.57e-5	IgG glycosylation;
PAAD	cis	rs4959799	1.000	rs72839341	chr6:3293287	C/T	cg04716048	chr6:3732797	C6orf145	0.81	4.48	0.34	1.47e-5	Survival in rectal cancer;
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg21546286	chr11:48923668	NA	0.55	5.72	0.42	5.41e-8	HDL cholesterol;
PAAD	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.68	-5.81	-0.43	3.47e-8	Systemic lupus erythematosus;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-6.54	-0.47	8.67e-10	Lymphocyte counts;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.63	5.54	0.41	1.31e-7	Pediatric autoimmune diseases;
PAAD	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.36	-0.33	2.37e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.33	6.11	0.44	7.97e-9	Type 2 diabetes;
PAAD	cis	rs4478858	0.746	rs7520468	chr1:31688812	G/A	cg00250761	chr1:31883323	NA	0.4	4.46	0.34	1.61e-5	Alcohol dependence;
PAAD	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg26174226	chr8:58114915	NA	-0.6	-4.45	-0.34	1.66e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13560548	chr3:10150139	C3orf24	0.56	5.04	0.38	1.3e-6	Alzheimer's disease;
PAAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg03351412	chr1:154909251	PMVK	-0.46	-4.46	-0.34	1.56e-5	Prostate cancer;
PAAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.59	-7.93	-0.54	4.32e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.62	6.16	0.45	6.14e-9	Schizophrenia;
PAAD	cis	rs1144713	0.600	rs2683489	chr12:32251181	A/G	cg01321189	chr12:32259338	BICD1	0.4	4.81	0.36	3.63e-6	Obesity-related traits;
PAAD	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.84	8.19	0.55	9.97e-14	Corneal astigmatism;
PAAD	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg02631450	chr22:32366979	NA	1.08	5.76	0.42	4.42e-8	Childhood ear infection;
PAAD	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.69	4.91	0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10820045	chr2:198174542	NA	-0.48	-4.89	-0.37	2.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4845459	0.967	rs1581803	chr1:152592281	A/C	cg03277515	chr1:153321198	PGLYRP4	-0.4	-4.89	-0.37	2.59e-6	Psoriasis;
PAAD	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg09127314	chr1:152161683	NA	-0.72	-5.11	-0.38	9.52e-7	Atopic dermatitis;
PAAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg14926445	chr8:58193284	C8orf71	-0.65	-5.3	-0.39	4.01e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.24	-6.68	-0.48	4.22e-10	Body mass index;
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-4.38	-0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	5.13	0.38	8.81e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.7	7.01	0.49	7.18e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg25287198	chr4:183728479	NA	0.85	7.48	0.52	5.5e-12	Pediatric autoimmune diseases;
PAAD	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.51	6.21	0.45	4.85e-9	Sitting height ratio;
PAAD	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.42	5.36	0.4	3.1e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.54	-5.41	-0.4	2.43e-7	White blood cell count;
PAAD	cis	rs12304921	0.683	rs55864652	chr12:51490334	C/T	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.65	-0.35	7.01e-6	Type 2 diabetes;
PAAD	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.38e-8	QT interval;
PAAD	cis	rs939584	0.935	rs12623218	chr2:632146	A/T	cg14515364	chr2:636606	NA	0.51	4.66	0.35	7e-6	Body mass index;
PAAD	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.39	-0.34	2.07e-5	Mood instability;
PAAD	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg14311320	chr7:124405732	GPR37	-0.45	-4.48	-0.34	1.48e-5	Lewy body disease;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.54	-5.67	-0.42	7.07e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.71	-6.92	-0.49	1.16e-10	Lymphocyte percentage of white cells;
PAAD	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.49	6.06	0.44	1.04e-8	Sitting height ratio;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg07234876	chr8:600039	NA	-1.09	-7.37	-0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs2992756	0.663	rs3007733	chr1:18800911	C/T	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.85	13.48	0.74	9.79e-28	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg15181151	chr6:150070149	PCMT1	0.55	5.93	0.43	1.97e-8	Lung cancer;
PAAD	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg08886695	chr4:3369023	RGS12	0.53	5.26	0.39	4.89e-7	Mean platelet volume;
PAAD	cis	rs113835537	1.000	rs113835537	chr11:66339639	A/G	cg22134325	chr11:66188745	NPAS4	0.37	4.32	0.33	2.83e-5	Airway imaging phenotypes;
PAAD	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg03131358	chr22:42195972	CCDC134	-0.49	-5.07	-0.38	1.17e-6	Birth weight;
PAAD	cis	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg21546286	chr11:48923668	NA	-0.44	-4.72	-0.36	5.42e-6	Height;
PAAD	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg26818257	chr2:241905806	NA	0.43	4.49	0.34	1.41e-5	Urinary metabolites;
PAAD	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.49	5.05	0.38	1.24e-6	Schizophrenia;
PAAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.94	-12.28	-0.71	1.65e-24	Height;
PAAD	cis	rs16944613	0.510	rs8026218	chr15:91145265	C/T	cg15547629	chr15:90437138	AP3S2	-0.5	-4.41	-0.34	1.91e-5	Colorectal cancer;
PAAD	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs1864585	0.520	rs17720365	chr8:10679499	C/G	cg21775007	chr8:11205619	TDH	0.54	4.34	0.33	2.57e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg16928487	chr17:17741425	SREBF1	0.35	4.65	0.35	7.14e-6	Total body bone mineral density;
PAAD	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	1.02	7.7	0.53	1.58e-12	Dental caries;
PAAD	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-4.5	-0.34	1.35e-5	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg17201900	chr20:34330562	RBM39	-0.62	-4.28	-0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.85	9.87	0.62	4.62e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs10861342	0.892	rs9634185	chr12:105624825	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.41	0.34	1.96e-5	IgG glycosylation;
PAAD	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-4.91	-0.37	2.31e-6	Common traits (Other);
PAAD	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.42	7.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg09127314	chr1:152161683	NA	0.74	5.45	0.4	1.95e-7	Atopic dermatitis;
PAAD	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.62	-6.05	-0.44	1.07e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg02869306	chr7:64672164	INTS4L1	-0.42	-4.84	-0.37	3.13e-6	Calcium levels;
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.57	6.56	0.47	8.1e-10	Mean corpuscular volume;
PAAD	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.67	-6.35	-0.46	2.38e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.04e-15	Personality dimensions;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg18551225	chr6:44695536	NA	-0.68	-6.68	-0.48	4.27e-10	Total body bone mineral density;
PAAD	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg07469887	chr10:131262384	NA	-0.42	-4.78	-0.36	4.09e-6	Response to temozolomide;
PAAD	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.47	5.58	0.41	1.06e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg12935359	chr14:103987150	CKB	-0.55	-5.7	-0.42	5.9e-8	Body mass index;
PAAD	cis	rs6604026	0.656	rs2811589	chr1:93367643	C/T	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.05	-0.44	1.11e-8	Lymphocyte counts;
PAAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg13722127	chr7:150037890	RARRES2	0.67	6.6	0.47	6.48e-10	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23042612	chr1:8613264	RERE	0.65	7.13	0.5	3.75e-11	Smoking initiation;
PAAD	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg15654264	chr1:150340011	RPRD2	-0.49	-4.78	-0.36	4.05e-6	Migraine;
PAAD	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.95	-7.39	-0.51	9.33e-12	Monocyte percentage of white cells;
PAAD	cis	rs12282928	0.670	rs12576395	chr11:48355132	A/G	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.61	0.57	8.74e-15	Bipolar disorder;
PAAD	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05640558	chr7:73498304	LIMK1	0.61	6.45	0.46	1.4e-9	Triglycerides;
PAAD	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.92	12.13	0.7	4.07e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.27	-0.33	3.36e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.81	-0.48	2.11e-10	Morning vs. evening chronotype;
PAAD	cis	rs89107	0.576	rs35029749	chr6:118892120	A/C	cg21191810	chr6:118973309	C6orf204	0.39	4.53	0.34	1.18e-5	Cardiac structure and function;
PAAD	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.43e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.16	-0.45	6.2e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	6.6	0.47	6.34e-10	Response to antipsychotic treatment;
PAAD	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-4.94	-0.37	2.06e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.47	8.37	0.56	3.45e-14	Multiple system atrophy;
PAAD	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.7	7.2	0.5	2.64e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	9.77	0.62	8.47e-18	Tonsillectomy;
PAAD	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	9.22	0.6	2.3e-16	Ulcerative colitis;
PAAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg21890820	chr11:65308645	LTBP3	0.64	7.82	0.54	8.44e-13	Bone mineral density;
PAAD	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg18833306	chr6:118973337	C6orf204	0.47	5.36	0.4	3.03e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21020089	chr6:41863578	USP49	-0.64	-6.79	-0.48	2.34e-10	Lung cancer in ever smokers;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.76	5.19	0.39	6.57e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.45	0.34	1.68e-5	Axial length;
PAAD	cis	rs17227506	0.704	rs66965169	chr8:13454056	C/T	cg02718516	chr8:13424094	C8orf48	-0.31	-4.28	-0.33	3.31e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23015897	chr19:48103819	NA	-0.65	-6.48	-0.47	1.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-1.33	-10.66	-0.65	3.72e-20	Schizophrenia;
PAAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.63	7.55	0.52	3.79e-12	Vitiligo;
PAAD	cis	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg16898833	chr6:26189333	HIST1H4D	0.87	5.7	0.42	6.09e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg19847866	chr10:1019161	NA	-0.61	-4.92	-0.37	2.19e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2131877	0.830	rs60922537	chr3:194842785	C/G	cg21937377	chr3:194868750	C3orf21	0.49	4.76	0.36	4.56e-6	Non-small cell lung cancer;
PAAD	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.72	-5.77	-0.42	4.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg24375607	chr4:120327624	NA	0.54	5.04	0.38	1.3e-6	Corneal astigmatism;
PAAD	trans	rs901683	1.000	rs115391636	chr10:46012045	C/T	cg14076390	chr17:34947837	DHRS11	0.86	6.6	0.47	6.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.61	6.37	0.46	2.13e-9	Lung cancer;
PAAD	trans	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	1.02	8.65	0.57	6.67e-15	Triglycerides;
PAAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-8.38	-0.56	3.24e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-6.08	-0.44	9.21e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs73206853	0.686	rs73194018	chr12:111127697	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.4	0.34	1.99e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.7	-0.36	5.78e-6	Personality dimensions;
PAAD	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg27234864	chr13:21295941	IL17D	-0.65	-5.47	-0.41	1.78e-7	Dental caries;
PAAD	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg27121462	chr16:89883253	FANCA	0.75	4.43	0.34	1.82e-5	Skin colour saturation;
PAAD	cis	rs1329189	0.798	rs7101336	chr10:130007209	A/G	cg17972361	chr10:130010134	NA	0.48	4.97	0.37	1.77e-6	Orofacial clefts;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.81	6.84	0.49	1.78e-10	Alzheimer's disease;
PAAD	cis	rs1642645	0.793	rs7546128	chr1:42473659	C/A	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-5.79	-0.43	3.91e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.67	-0.42	6.83e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.69	-6.81	-0.48	2.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.71	-10.25	-0.64	4.63e-19	Breast cancer;
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg02696790	chr15:75250997	RPP25	-0.38	-4.47	-0.34	1.55e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg14458575	chr2:238380390	NA	0.55	6.18	0.45	5.51e-9	Prostate cancer;
PAAD	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg06241208	chr11:30344200	C11orf46	-0.49	-4.48	-0.34	1.48e-5	Morning vs. evening chronotype;
PAAD	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.25	-0.51	1.98e-11	Diastolic blood pressure;
PAAD	cis	rs5753037	0.653	rs140102	chr22:30128443	T/C	cg01021169	chr22:30184971	ASCC2	-0.46	-4.7	-0.36	5.82e-6	Type 1 diabetes;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.75	6.58	0.47	7.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.42e-6	Bipolar disorder;
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.77	8.51	0.57	1.53e-14	Longevity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20244235	chr1:8877763	RERE	-0.73	-6.38	-0.46	2.08e-9	Neuroticism;
PAAD	cis	rs10501293	0.956	rs12361827	chr11:43137261	T/C	cg03447554	chr11:43094025	NA	-0.46	-4.51	-0.34	1.28e-5	Cognitive performance;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21847751	chr2:232379328	C2orf52	0.74	7.49	0.52	5.31e-12	Obesity-related traits;
PAAD	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1619661	0.505	rs10899997	chr10:44683841	T/G	cg09554077	chr10:44749378	NA	0.32	4.76	0.36	4.39e-6	QT interval (ambient particulate matter interaction);
PAAD	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	1.21	7.6	0.52	2.88e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs7614311	0.636	rs57112859	chr3:63842221	A/T	cg22134162	chr3:63841271	THOC7	-0.55	-4.41	-0.34	1.91e-5	Lung function (FVC);Lung function (FEV1);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13265437	chr11:32851260	PRRG4	0.6	6.75	0.48	2.88e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.69	-5.84	-0.43	3.07e-8	Blood protein levels;
PAAD	cis	rs860295	0.812	rs11264363	chr1:155318308	C/G	cg22941637	chr1:155248588	HCN3	-0.42	-4.4	-0.34	2e-5	Body mass index;
PAAD	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18427987	chr14:74551089	LIN52;ALDH6A1	0.58	6.47	0.46	1.29e-9	Myopia (pathological);
PAAD	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg19637330	chr1:19110922	NA	0.61	4.9	0.37	2.45e-6	Percentage gas trapping;
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.46	4.28	0.33	3.32e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62264129	0.500	rs4507229	chr3:112023442	C/G	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.9	-0.37	2.4e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg09835421	chr16:68378352	PRMT7	-0.91	-7.24	-0.51	2.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg10483660	chr13:112241077	NA	0.55	5.04	0.38	1.28e-6	Menarche (age at onset);
PAAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-5.46	-0.4	1.93e-7	Personality dimensions;
PAAD	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.68	-6.17	-0.45	5.8e-9	Response to antineoplastic agents;
PAAD	cis	rs34599045	1.000	rs12240158	chr1:152879103	C/T	cg07796016	chr1:152779584	LCE1C	-0.88	-4.51	-0.34	1.28e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.93e-7	Motion sickness;
PAAD	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.08	0.44	9.51e-9	Colorectal cancer;
PAAD	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg09237302	chr4:906077	GAK	-0.45	-4.65	-0.35	7.06e-6	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs71494792	chr10:45983049	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.94	-12.18	-0.7	3.1e-24	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.19	-0.45	5.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.51	-4.55	-0.35	1.08e-5	Total body bone mineral density;
PAAD	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-1.09	-7.19	-0.5	2.71e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07395648	chr5:131743802	NA	0.5	4.53	0.34	1.18e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.03	-0.38	1.34e-6	Daytime sleep phenotypes;
PAAD	trans	rs901683	0.850	rs76491632	chr10:45966598	T/C	cg13065504	chr15:42448234	PLA2G4F	0.82	6.41	0.46	1.72e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg13119035	chr7:42951436	C7orf25	0.63	6.63	0.47	5.51e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.59	4.54	0.35	1.16e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg12215294	chr3:40350768	EIF1B	-0.47	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	cis	rs9828933	0.701	rs7621544	chr3:63928681	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-5.97	-0.44	1.58e-8	Type 2 diabetes;
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.57	-4.58	-0.35	9.55e-6	Blood protein levels;
PAAD	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs10207060	0.500	rs7566489	chr2:240703985	C/T	cg07506560	chr2:240697449	NA	0.55	5.76	0.42	4.62e-8	Obesity-related traits;
PAAD	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.59	-0.35	9.29e-6	Triglycerides;
PAAD	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.06	0.38	1.21e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.68	-9.11	-0.59	4.48e-16	Hemoglobin concentration;
PAAD	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09090048	chr11:134093731	VPS26B;NCAPD3	0.58	6.99	0.49	8.33e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.62	0.41	8.88e-8	Eosinophil percentage of white cells;
PAAD	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.71	8.5	0.57	1.66e-14	Colorectal cancer;
PAAD	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	6.76	0.48	2.75e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	0.98	6.9	0.49	1.29e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg14343924	chr8:8086146	FLJ10661	-0.68	-6.01	-0.44	1.32e-8	Mood instability;
PAAD	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.65	6.97	0.49	9.08e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs3781871	0.891	rs76585958	chr11:107861049	G/T	cg27262398	chr11:107578793	SLN	0.55	4.3	0.33	3.06e-5	Scarlet fever;
PAAD	cis	rs35740288	0.822	rs11630179	chr15:86282934	G/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.76	-0.36	4.55e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs12136530	0.625	rs10917447	chr1:19749743	T/C	cg25104613	chr1:20649108	VWA5B1	-0.4	-4.49	-0.34	1.42e-5	Lead levels in blood;
PAAD	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg04990556	chr1:26633338	UBXN11	0.66	4.89	0.37	2.54e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg01299579	chr2:10830716	NOL10	0.45	4.31	0.33	2.86e-5	Prostate cancer;
PAAD	cis	rs2143950	0.512	rs77772792	chr14:35520127	C/G	cg14523979	chr14:35838413	NA	-0.51	-4.44	-0.34	1.69e-5	Atopic dermatitis;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.85	9.33	0.6	1.23e-16	Prostate cancer;
PAAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.89	0.66	8.87e-21	Menopause (age at onset);
PAAD	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.53	0.34	1.19e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.46	0.34	1.55e-5	Personality dimensions;
PAAD	cis	rs714031	0.967	rs4821910	chr22:40067470	T/C	cg21377881	chr22:40064566	CACNA1I	-0.47	-4.61	-0.35	8.61e-6	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23625931	chr3:49977418	RBM6	-0.77	-8.44	-0.56	2.39e-14	Smoking initiation;
PAAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.86	-10.76	-0.66	2.01e-20	Height;
PAAD	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.73	6.53	0.47	9.15e-10	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06630098	chr19:16683316	SLC35E1	0.63	6.49	0.47	1.13e-9	Obesity-related traits;
PAAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.45	5.02	0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg17372657	chr7:1216933	NA	-0.38	-5.07	-0.38	1.13e-6	Longevity;Endometriosis;
PAAD	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.41	-0.4	2.41e-7	Schizophrenia;
PAAD	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-5.2	-0.39	6.32e-7	Common traits (Other);
PAAD	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-7.9	-0.54	5.21e-13	Response to antipsychotic treatment;
PAAD	cis	rs11811982	0.793	rs114537871	chr1:227560794	G/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-6.97	-0.49	9.27e-11	Breast cancer;
PAAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21844316	chr22:36851007	NA	0.61	6.5	0.47	1.09e-9	Iris heterochromicity;
PAAD	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg03934865	chr2:198174659	NA	-0.45	-4.68	-0.35	6.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	4.53	0.35	1.17e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg10820045	chr2:198174542	NA	0.44	4.37	0.33	2.31e-5	Dermatomyositis;
PAAD	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs7326068	0.610	rs4769134	chr13:21438871	G/A	cg27499820	chr13:21296301	IL17D	0.53	5.04	0.38	1.32e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs3777722	0.688	rs2757048	chr6:167351120	A/G	cg01837879	chr6:166900442	RPS6KA2	0.62	4.38	0.33	2.23e-5	Spontaneous preterm birth (preterm birth);
PAAD	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg14709524	chr16:89940631	TCF25	0.83	4.38	0.33	2.23e-5	Skin colour saturation;
PAAD	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.53	-4.91	-0.37	2.35e-6	Red blood cell count;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-6.99	-0.49	7.97e-11	Life satisfaction;
PAAD	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.97	8.42	0.56	2.65e-14	Blood protein levels;
PAAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.63	6.76	0.48	2.77e-10	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.85	6.42	0.46	1.69e-9	Axial length;
PAAD	cis	rs860295	0.580	rs11264361	chr1:155289545	T/G	cg02153340	chr1:155202674	NA	-0.51	-4.5	-0.34	1.33e-5	Body mass index;
PAAD	cis	rs3743832	0.966	rs4566166	chr16:9183435	A/G	cg08831531	chr16:9218945	NA	-0.44	-4.61	-0.35	8.48e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.25	0.33	3.76e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2236267	0.601	rs2767532	chr14:88580709	A/G	cg18078958	chr14:88630771	NA	-0.5	-6.41	-0.46	1.75e-9	Food antigen IgG levels;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs7577696	0.924	rs72862234	chr2:32270146	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-4.7	-0.36	5.73e-6	Inflammatory biomarkers;
PAAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.33	-0.4	3.45e-7	Schizophrenia;
PAAD	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.36	0.6	9.97e-17	Colorectal cancer;
PAAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg06375148	chr1:209958343	C1orf74	0.67	5.25	0.39	5.14e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg27426351	chr10:43362370	NA	0.54	4.44	0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg02869306	chr7:64672164	INTS4L1	-0.42	-4.84	-0.37	3.13e-6	Calcium levels;
PAAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg21419209	chr3:44054225	NA	-0.59	-5.89	-0.43	2.42e-8	Coronary artery disease;
PAAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02071572	chr4:1403502	NA	0.38	4.9	0.37	2.45e-6	Longevity;
PAAD	cis	rs6136489	0.710	rs11906768	chr20:1924066	T/C	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg14433983	chr11:636460	DRD4	-0.45	-4.6	-0.35	8.9e-6	Systemic lupus erythematosus;
PAAD	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg25902810	chr10:99078978	FRAT1	-0.53	-4.77	-0.36	4.24e-6	Monocyte count;
PAAD	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.52	7.02	0.5	6.75e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27259323	chr19:14600134	LOC100130932;GIPC1	-0.66	-6.84	-0.49	1.84e-10	Obesity-related traits;
PAAD	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.76	7.53	0.52	4.12e-12	Mood instability;
PAAD	cis	rs80346118	0.673	rs6019421	chr20:47410020	T/C	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.59	-4.39	-0.34	2.12e-5	Diastolic blood pressure;
PAAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg12072164	chr19:44306565	LYPD5	0.48	5.02	0.38	1.43e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.5	0.47	1.07e-9	Height;
PAAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs62045844	0.536	rs9940965	chr16:89180664	C/G	cg26950739	chr16:89183275	ACSF3	0.65	4.38	0.33	2.21e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12148477	0.712	rs56335081	chr15:51655156	G/A	cg25905881	chr15:51634250	GLDN	0.41	4.29	0.33	3.19e-5	Follicule stimulating hormone;
PAAD	cis	rs11247915	0.644	rs11588739	chr1:26653319	G/A	cg15628303	chr1:26608928	UBXN11	0.68	6.79	0.48	2.36e-10	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.71	8.24	0.56	7.46e-14	Colorectal cancer;
PAAD	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg23167506	chr7:1303302	NA	0.38	6.42	0.46	1.64e-9	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.39	-0.34	2.12e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00931619	chr1:6052495	NPHP4	-0.64	-6.52	-0.47	9.61e-10	Smoking initiation;
PAAD	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18905962	chr17:4456069	MYBBP1A	-0.63	-6.33	-0.46	2.66e-9	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg02117656	chr17:79614917	TSPAN10	-0.55	-5.52	-0.41	1.41e-7	Eye color traits;
PAAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.6	7.35	0.51	1.16e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4740619	0.967	rs6474944	chr9:15670445	C/T	cg14451791	chr9:16040625	NA	0.38	4.6	0.35	8.78e-6	Body mass index;
PAAD	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.88	10.65	0.65	4.03e-20	Schizophrenia;
PAAD	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.59	4.52	0.34	1.24e-5	Schizophrenia;
PAAD	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13773148	chr9:136923109	BRD3	0.42	4.29	0.33	3.12e-5	Platelet distribution width;
PAAD	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	cis	rs2371030	1.000	rs2111713	chr2:211576458	G/A	cg18417063	chr2:211583084	NA	-0.44	-4.35	-0.33	2.47e-5	Non-small cell lung cancer;
PAAD	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.78	-0.36	4.04e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg01381637	chr19:50902842	POLD1	0.77	6.31	0.46	2.86e-9	Atopic dermatitis;
PAAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs10768122	0.613	rs7939421	chr11:35362837	C/G	cg13971030	chr11:35366721	SLC1A2	-0.46	-5.49	-0.41	1.68e-7	Vitiligo;
PAAD	cis	rs1941184	0.759	rs10048348	chr18:29023943	T/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11245990	chr11:68621969	NA	0.38	5.05	0.38	1.28e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	cis	rs4523957	0.583	rs2760738	chr17:2024600	A/G	cg16513277	chr17:2031491	SMG6	-0.65	-6.79	-0.48	2.31e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-8.3	-0.56	5.22e-14	Diastolic blood pressure;
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.59	-7.55	-0.52	3.81e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg12395012	chr8:11607386	GATA4	-0.42	-4.64	-0.35	7.47e-6	Myopia (pathological);
PAAD	cis	rs7816613	1.000	rs28564461	chr8:102744721	G/A	cg20585841	chr8:102729926	NCALD	-0.57	-4.89	-0.37	2.52e-6	Age-related hearing impairment;
PAAD	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg12935359	chr14:103987150	CKB	-0.62	-6.74	-0.48	3.06e-10	Body mass index;
PAAD	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.81	7.03	0.5	6.69e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Lymphocyte counts;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09190325	chr6:26539014	HMGN4	0.56	6.36	0.46	2.3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8014252	0.708	rs74062730	chr14:70991650	A/C	cg11204974	chr14:71022665	NA	-0.77	-5.04	-0.38	1.3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.92	0.37	2.18e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg06636001	chr8:8085503	FLJ10661	0.72	7.05	0.5	6e-11	Retinal vascular caliber;
PAAD	cis	rs7219021	0.926	rs56144347	chr17:46856640	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-4.5	-0.34	1.34e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg02869306	chr7:64672164	INTS4L1	-0.5	-6.05	-0.44	1.08e-8	Calcium levels;
PAAD	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.53	-4.85	-0.37	2.98e-6	Primary biliary cholangitis;
PAAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.88	9.43	0.61	6.71e-17	Systemic lupus erythematosus;
PAAD	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.59	-5.14	-0.39	8.19e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02071572	chr4:1403502	NA	0.5	6.66	0.48	4.67e-10	Longevity;
PAAD	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.91	10.72	0.66	2.54e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs78472555	0.661	rs325398	chr15:100226246	G/A	cg18869061	chr15:100272053	LYSMD4	-0.52	-4.48	-0.34	1.48e-5	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.31	0.46	2.89e-9	Lung cancer in ever smokers;
PAAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg16147221	chr4:10020634	SLC2A9	0.48	4.31	0.33	2.98e-5	Bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17271960	chr1:1550779	MIB2	-0.67	-6.73	-0.48	3.26e-10	Smoking initiation;
PAAD	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-1.34	-9.89	-0.63	4.11e-18	Schizophrenia;
PAAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.84	11.44	0.68	3.06e-22	Emphysema distribution in smoking;
PAAD	cis	rs9913156	0.841	rs34230287	chr17:4613630	C/T	cg00122941	chr17:4613640	ARRB2	0.86	8.54	0.57	1.32e-14	Lymphocyte counts;
PAAD	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg01657329	chr11:68192670	LRP5	-0.75	-6.85	-0.49	1.7e-10	Lean body mass;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs59888335	0.964	rs12630377	chr3:80734369	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.75	-5.65	-0.42	7.71e-8	Mean platelet volume;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.76	5.81	0.43	3.51e-8	Lung function (FEV1/FVC);
PAAD	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-10.39	-0.64	1.98e-19	Electrocardiographic conduction measures;
PAAD	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.75	-5.31	-0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg04398451	chr17:18023971	MYO15A	-0.83	-9.55	-0.61	3.19e-17	Total body bone mineral density;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg08439880	chr3:133502540	NA	-0.58	-6.48	-0.47	1.21e-9	Iron status biomarkers;
PAAD	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg25783544	chr11:47291846	MADD	-0.53	-4.34	-0.33	2.58e-5	HDL cholesterol;
PAAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg00944433	chr1:107599041	PRMT6	0.4	4.57	0.35	1.02e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.76	7.15	0.5	3.34e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg03289416	chr15:75166202	SCAMP2	0.54	5.64	0.42	8.18e-8	Breast cancer;
PAAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.65	-5.23	-0.39	5.57e-7	Coronary artery disease;
PAAD	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg19182279	chr4:892011	GAK	0.43	4.34	0.33	2.64e-5	Systemic sclerosis;
PAAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.52	5.39	0.4	2.69e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.67	8.43	0.56	2.42e-14	Alcohol dependence;
PAAD	cis	rs288326	0.561	rs77541378	chr2:183886271	C/A	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.42	-4.38	-0.33	2.22e-5	Breast cancer;
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg26071806	chr7:100318239	EPO	0.49	4.86	0.37	2.89e-6	Other erythrocyte phenotypes;
PAAD	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13822231	chr9:133588088	ABL1	-0.79	-6.95	-0.49	1.02e-10	Neuroticism;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.52	-6.26	-0.45	3.75e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.77	-5.9	-0.43	2.29e-8	Pulmonary function decline;
PAAD	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.71	-0.48	3.54e-10	Morning vs. evening chronotype;
PAAD	cis	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.77	-0.36	4.32e-6	Neuroticism;
PAAD	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	1.05	12.33	0.71	1.17e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.63	-6.19	-0.45	5.45e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7771547	0.692	rs9296192	chr6:36601203	A/G	cg07856975	chr6:36356162	ETV7	0.48	5.41	0.4	2.44e-7	Platelet distribution width;
PAAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.58	6.07	0.44	1e-8	Longevity;
PAAD	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg25418670	chr11:30344373	C11orf46	-0.66	-6.4	-0.46	1.86e-9	Morning vs. evening chronotype;
PAAD	cis	rs185694	1.000	rs653251	chr13:30894542	C/T	cg07600127	chr13:30881527	KATNAL1	-0.67	-4.54	-0.35	1.12e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg16384552	chr7:74938386	SPDYE8P	-0.53	-5.31	-0.4	3.79e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.34	0.33	2.54e-5	IgG glycosylation;
PAAD	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-5.15	-0.39	7.78e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.73	-7.57	-0.52	3.38e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17774797	chr6:83902953	RWDD2A;PGM3	0.68	6.41	0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs2131877	0.701	rs57357728	chr3:194832106	G/A	cg19760965	chr3:194868843	C3orf21	0.5	4.84	0.37	3.1e-6	Non-small cell lung cancer;
PAAD	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	1.01	11.0	0.67	4.4e-21	Bone mineral density;
PAAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	8.05	0.55	2.25e-13	Eotaxin levels;
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg21665744	chr7:39171113	POU6F2	0.33	4.97	0.37	1.8e-6	IgG glycosylation;
PAAD	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg12395012	chr8:11607386	GATA4	-0.69	-8.6	-0.57	8.94e-15	Myopia (pathological);
PAAD	cis	rs7264396	0.887	rs2281849	chr20:34060286	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	1.0	10.69	0.66	3.01e-20	Longevity;
PAAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.57	4.83	0.36	3.33e-6	Response to diuretic therapy;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg12683085	chr13:112690689	NA	0.54	6.81	0.48	2.12e-10	Educational attainment (years of education);
PAAD	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg08835956	chr7:39171034	POU6F2	0.27	4.52	0.34	1.23e-5	IgG glycosylation;
PAAD	cis	rs6066835	0.867	rs16994110	chr20:47360830	T/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	7.59	0.52	3.01e-12	Fuchs's corneal dystrophy;
PAAD	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	Cognitive function;
PAAD	trans	rs901683	1.000	rs71494802	chr10:46005624	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-6.16	-0.45	6.21e-9	Blood protein levels;
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.87	12.35	0.71	1.03e-24	Vitiligo;
PAAD	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.32	0.6	1.25e-16	Prudent dietary pattern;
PAAD	cis	rs9463078	0.546	rs1937047	chr6:45048254	T/C	cg25276700	chr6:44698697	NA	0.46	5.19	0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.71	-7.22	-0.51	2.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.44	-6.57	-0.47	7.44e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.69	-4.32	-0.33	2.81e-5	Body mass index;
PAAD	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg00738919	chr7:1100172	C7orf50	0.53	4.26	0.33	3.55e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.23	-0.39	5.49e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.65	-0.53	2.12e-12	Migraine;Coronary artery disease;
PAAD	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg07541023	chr7:19748670	TWISTNB	0.53	4.33	0.33	2.7e-5	Thyroid stimulating hormone;
PAAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg15017067	chr4:17643749	FAM184B	0.38	4.29	0.33	3.2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07078622	chr17:26645920	TMEM97	0.56	6.41	0.46	1.72e-9	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13647721	chr17:30228624	UTP6	0.58	4.46	0.34	1.56e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2814982	0.605	rs79379247	chr6:34489516	G/A	cg14254433	chr6:34482411	PACSIN1	-1.12	-6.51	-0.47	1.06e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.45	-5.83	-0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05025164	chr4:1340916	KIAA1530	0.52	5.11	0.38	9.49e-7	Obesity-related traits;
PAAD	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.49	-4.36	-0.33	2.39e-5	Plateletcrit;
PAAD	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.59	6.07	0.44	9.96e-9	Coronary artery disease;
PAAD	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.64	0.53	2.32e-12	HIV-1 control;
PAAD	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg19630374	chr17:18023558	MYO15A	-0.57	-6.04	-0.44	1.12e-8	Total body bone mineral density;
PAAD	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs8060686	0.920	rs73597582	chr16:67683626	G/A	cg05110241	chr16:68378359	PRMT7	-0.98	-5.02	-0.38	1.46e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg01851573	chr8:8652454	MFHAS1	0.56	4.94	0.37	2.04e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg00179576	chr16:74483694	GLG1	0.39	4.36	0.33	2.36e-5	Testicular germ cell tumor;
PAAD	cis	rs251130	0.709	rs114667405	chr5:110849504	T/C	cg11925263	chr5:110849104	STARD4	0.37	4.68	0.35	6.26e-6	Menarche (age at onset);
PAAD	cis	rs2229238	0.868	rs72999415	chr1:154513712	C/T	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg14580859	chr9:123691850	NA	0.39	4.34	0.33	2.58e-5	Rheumatoid arthritis;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg26071806	chr7:100318239	EPO	-0.43	-4.4	-0.34	2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.63	-6.9	-0.49	1.35e-10	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg19223190	chr17:80058835	NA	0.53	5.4	0.4	2.49e-7	Life satisfaction;
PAAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg02683114	chr2:24398427	C2orf84	0.56	5.84	0.43	3.06e-8	Asthma;
PAAD	cis	rs16975963	0.644	rs11666662	chr19:38154702	A/T	cg08679971	chr19:38281047	NA	-0.46	-4.41	-0.34	1.92e-5	Longevity;
PAAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg15017067	chr4:17643749	FAM184B	0.43	5.12	0.38	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg09339527	chr5:178322752	ZFP2	-0.42	-4.39	-0.34	2.15e-5	Sleep duration;
PAAD	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.53	5.72	0.42	5.42e-8	Mean corpuscular volume;
PAAD	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.78	-5.25	-0.39	5.03e-7	Coronary artery calcification;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	6.08	0.44	9.36e-9	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19484299	chr2:234775274	MSL3L2	-0.63	-6.66	-0.48	4.78e-10	Myopia (pathological);
PAAD	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.82	8.65	0.57	6.67e-15	Corneal astigmatism;
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.13	-0.5	3.9e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs11191270	0.868	rs77389536	chr10:104168125	T/C	cg15320455	chr10:103880129	LDB1	0.54	4.57	0.35	9.84e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg08975724	chr8:8085496	FLJ10661	0.65	6.89	0.49	1.39e-10	Neuroticism;
PAAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.65	4.92	0.37	2.25e-6	Fat distribution (HIV);
PAAD	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.66	7.79	0.53	9.7e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	5.24	0.39	5.31e-7	Chronic sinus infection;
PAAD	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2421770	0.532	rs7106813	chr11:35372432	C/T	cg13971030	chr11:35366721	SLC1A2	-0.56	-5.37	-0.4	2.83e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.56	4.95	0.37	1.93e-6	Height;
PAAD	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.82	-8.05	-0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	7.63	0.53	2.37e-12	Height;
PAAD	cis	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg08394602	chr19:22123885	NA	0.42	4.32	0.33	2.86e-5	Telomere length;
PAAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg22633769	chr20:60982531	CABLES2	0.6	5.15	0.39	8.13e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4908768	0.501	rs7551849	chr1:8539463	A/G	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg17264618	chr3:40429014	ENTPD3	0.35	4.33	0.33	2.65e-5	Renal cell carcinoma;
PAAD	cis	rs2271001	1.000	rs1503507	chr11:19145847	G/A	cg00161556	chr11:19138045	ZDHHC13	0.49	5.38	0.4	2.82e-7	Gut microbiome composition (winter);
PAAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02072376	chr1:153606637	C1orf77;S100A13	0.59	6.6	0.47	6.47e-10	Pancreatic cancer;
PAAD	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg03277515	chr1:153321198	PGLYRP4	0.42	5.01	0.38	1.52e-6	Psoriasis;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.5	0.57	1.64e-14	Corneal astigmatism;
PAAD	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-7.85	-0.54	7.06e-13	Educational attainment;
PAAD	trans	rs901683	1.000	rs76469200	chr10:46080033	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs35160687	0.666	rs7583074	chr2:86484192	A/G	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	trans	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.74	-8.77	-0.58	3.34e-15	Body mass index;
PAAD	cis	rs11264799	0.603	rs2224607	chr1:157571721	C/T	cg18268488	chr1:157545234	FCRL4	0.43	5.01	0.38	1.46e-6	IgA nephropathy;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.87e-10	Lymphocyte counts;
PAAD	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg21546286	chr11:48923668	NA	-0.56	-5.8	-0.43	3.76e-8	HDL cholesterol;
PAAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg19767477	chr5:127420684	SLC12A2	0.52	4.27	0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.03	-0.55	2.47e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.7	9.25	0.6	1.97e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg23033748	chr14:75592666	NEK9	0.36	4.32	0.33	2.76e-5	Height;
PAAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.82	-5.37	-0.4	2.87e-7	Breast cancer;
PAAD	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg12092346	chr18:77659572	KCNG2	0.64	4.67	0.35	6.49e-6	Opioid sensitivity;
PAAD	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs2051773	0.567	rs6486348	chr11:17057774	T/C	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs11756438	0.572	rs1844963	chr6:119002679	C/G	cg21191810	chr6:118973309	C6orf204	0.4	4.72	0.36	5.38e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.72	9.3	0.6	1.42e-16	Weight;
PAAD	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.48	0.41	1.69e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg08048268	chr3:133502702	NA	0.47	5.91	0.43	2.12e-8	Iron status biomarkers;
PAAD	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.76	8.92	0.59	1.38e-15	Blood metabolite ratios;
PAAD	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Subjective well-being;
PAAD	cis	rs375066	0.762	rs239943	chr19:44374716	A/T	cg08633290	chr19:44405433	NA	-0.54	-5.16	-0.39	7.61e-7	Breast cancer;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs11129295	0.618	rs4279053	chr3:27813319	A/C	cg21473142	chr3:27762095	EOMES	0.27	4.49	0.34	1.4e-5	Multiple sclerosis;
PAAD	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-4.77	-0.36	4.21e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7627468	0.837	rs9866419	chr3:121940209	G/A	cg17240004	chr3:121949083	CASR	0.52	4.83	0.36	3.33e-6	Kidney stones;
PAAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg20673091	chr1:2541236	MMEL1	0.89	10.68	0.65	3.24e-20	Ulcerative colitis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04720665	chr1:245028075	HNRNPU	0.57	6.4	0.46	1.83e-9	Metabolite levels  (X-11787);
PAAD	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg24253500	chr15:84953950	NA	0.41	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs76569448	chr1:227406767	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.91	8.5	0.57	1.61e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.92	11.72	0.69	5.35e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg05484376	chr2:27715224	FNDC4	0.5	5.07	0.38	1.17e-6	Total body bone mineral density;
PAAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.64	6.44	0.46	1.52e-9	Monocyte count;
PAAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs939584	1.000	rs13388043	chr2:637597	A/G	cg14515364	chr2:636606	NA	-0.47	-4.41	-0.34	1.93e-5	Body mass index;
PAAD	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg26220594	chr1:19110978	NA	0.59	4.67	0.35	6.61e-6	Percentage gas trapping;
PAAD	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.01e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6466055	0.508	rs6966728	chr7:104618318	C/T	cg04380332	chr7:105027541	SRPK2	-0.48	-4.62	-0.35	8.12e-6	Schizophrenia;
PAAD	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.62	-5.57	-0.41	1.15e-7	Tonsillectomy;
PAAD	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg24220031	chr2:73402428	NA	-0.33	-4.95	-0.37	1.98e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2131877	0.830	rs62290347	chr3:194852620	A/G	cg24618514	chr3:194868507	C3orf21	0.48	4.27	0.33	3.45e-5	Non-small cell lung cancer;
PAAD	cis	rs17641971	0.700	rs74303757	chr8:50051665	A/G	cg00325661	chr8:49890786	NA	-0.47	-4.4	-0.34	2e-5	Blood metabolite levels;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg02696790	chr15:75250997	RPP25	0.35	4.26	0.33	3.6e-5	Breast cancer;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg04844267	chr4:1394941	NA	0.45	4.75	0.36	4.68e-6	Obesity-related traits;
PAAD	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.84	-6.71	-0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg21859623	chr20:33103246	DYNLRB1	0.46	4.47	0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.62	6.55	0.47	8.49e-10	Bladder cancer;
PAAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	6.82e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg05555928	chr11:63887634	MACROD1	0.6	4.7	0.36	5.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.4	-0.34	2.04e-5	Alcohol dependence;
PAAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs41271473	0.687	rs13349	chr1:228881129	A/G	cg16512390	chr1:228756714	NA	0.56	4.82	0.36	3.47e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg06618935	chr21:46677482	NA	-0.59	-7.3	-0.51	1.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.86	-10.5	-0.65	9.63e-20	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27471156	chr2:102428010	MAP4K4	0.66	6.98	0.49	8.49e-11	Smoking initiation;
PAAD	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg14196790	chr5:131705035	SLC22A5	-0.45	-4.87	-0.37	2.81e-6	Blood metabolite levels;
PAAD	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.83	-6.07	-0.44	9.79e-9	Atopic dermatitis;
PAAD	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg14703610	chr5:56206110	C5orf35	0.61	5.71	0.42	5.68e-8	Coronary artery disease;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.48	4.61	0.35	8.34e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1190596	0.525	rs35350456	chr14:102704751	A/G	cg23904247	chr14:102554826	HSP90AA1	0.42	4.93	0.37	2.11e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg01362358	chr17:58117360	NA	0.38	4.33	0.33	2.72e-5	Hemoglobin concentration;
PAAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.63	5.48	0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-6.53	-0.47	9.38e-10	Longevity;Endometriosis;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.49e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.67	7.26	0.51	1.85e-11	Resting heart rate;
PAAD	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.33	5.69	0.42	6.45e-8	Type 2 diabetes;
PAAD	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.78	-5.91	-0.43	2.14e-8	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs16910800	1.000	rs1531809	chr11:23194373	A/T	cg20040320	chr11:23191996	NA	-0.6	-5.12	-0.38	9.22e-7	Cancer;
PAAD	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.91	8.09	0.55	1.72e-13	IgG glycosylation;
PAAD	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.64	7.67	0.53	1.9e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00292662	chr22:38071168	LGALS1	0.65	6.81	0.48	2.14e-10	Fat distribution (HIV);
PAAD	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg04315214	chr1:2043799	PRKCZ	-0.47	-5.67	-0.42	6.86e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.55	-6.88	-0.49	1.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.92e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg22916017	chr11:64110731	CCDC88B	0.37	4.4	0.34	2.03e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.96	12.42	0.71	6.88e-25	Menopause (age at onset);
PAAD	cis	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg08132940	chr7:1081526	C7orf50	-0.63	-4.52	-0.34	1.25e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.83	-9.31	-0.6	1.39e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.99	-0.87	4.48e-49	Myeloid white cell count;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.65	-8.2	-0.55	9.15e-14	Prudent dietary pattern;
PAAD	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg13590414	chr9:128173245	NA	0.44	4.31	0.33	2.88e-5	Resting heart rate;
PAAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7623687	0.579	rs73082331	chr3:48994943	G/A	cg19401529	chr3:49056140	DALRD3	1.01	6.89	0.49	1.35e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs8102137	1.000	rs8102137	chr19:30296853	T/C	cg27475126	chr19:30303651	CCNE1	-0.46	-5.13	-0.38	8.6e-7	Bladder cancer;
PAAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.77	-8.58	-0.57	1.03e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.86	0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs380904	0.519	rs1377663	chr8:144644787	T/A	cg13399544	chr8:144649678	C8orf73	-0.61	-6.27	-0.45	3.51e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg22764044	chr5:178986830	RUFY1	0.53	5.53	0.41	1.33e-7	Lung cancer;
PAAD	cis	rs2286503	0.780	rs981792	chr7:22861639	C/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	6.6	0.47	6.34e-10	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg17326555	chr1:119535693	NA	-0.41	-4.78	-0.36	4.05e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.91	10.56	0.65	7e-20	Total body bone mineral density;
PAAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06217245	chr20:33103252	DYNLRB1	0.36	4.38	0.33	2.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.79	6.29	0.45	3.19e-9	Alzheimer's disease;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg08219700	chr8:58056026	NA	0.68	5.49	0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6580110	0.714	rs9324791	chr5:154078556	T/C	cg05212464	chr5:154071076	NA	0.48	5.03	0.38	1.35e-6	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.91	11.62	0.69	9.53e-23	Pulse pressure;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.6	5.95	0.43	1.82e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg10494973	chr17:80897199	TBCD	0.5	4.93	0.37	2.14e-6	Breast cancer;
PAAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.85	7.31	0.51	1.4e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.67	4.47	0.34	1.55e-5	Lung cancer in ever smokers;
PAAD	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.5	-5.02	-0.38	1.4e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg09509183	chr1:209979624	IRF6	0.52	4.85	0.37	2.99e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.64	0.47	5.34e-10	IgG glycosylation;
PAAD	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-5.97	-0.44	1.61e-8	Height;
PAAD	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg19025524	chr12:109796872	NA	-0.51	-4.88	-0.37	2.68e-6	Neuroticism;
PAAD	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.87e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.62	0.35	8.05e-6	Homocysteine levels;
PAAD	cis	rs9936833	1.000	rs9933998	chr16:86402140	G/T	cg03554962	chr16:86404423	NA	0.37	4.33	0.33	2.65e-5	Barrett's esophagus;
PAAD	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg10587741	chr22:38071170	LGALS1	0.43	4.76	0.36	4.5e-6	Fat distribution (HIV);
PAAD	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg06812019	chr5:1143331	NA	-0.46	-4.38	-0.34	2.16e-5	Gut microbiome composition (winter);
PAAD	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.42	-4.71	-0.36	5.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.06	-0.44	1.01e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg00334542	chr7:100209784	MOSPD3	-0.72	-5.29	-0.39	4.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.72	-7.51	-0.52	4.62e-12	Monocyte percentage of white cells;
PAAD	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.96	5.32	0.4	3.57e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs1499972	0.941	rs62266064	chr3:117546871	T/C	cg07612923	chr3:117604196	NA	1.02	6.78	0.48	2.55e-10	Schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11032070	chr20:31172387	NA	0.6	6.93	0.49	1.14e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg00806245	chr18:76673096	NA	0.86	6.98	0.49	8.55e-11	Obesity-related traits;
PAAD	cis	rs4907240	0.961	rs66727130	chr2:97324991	G/C	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.61	-0.35	8.39e-6	Event-related brain oscillations;
PAAD	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg26751094	chr13:95954534	ABCC4	-0.45	-4.73	-0.36	4.99e-6	Blood metabolite levels;
PAAD	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg05082376	chr22:42548792	NA	-0.43	-4.28	-0.33	3.36e-5	Cognitive function;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23434461	chr8:119803683	NA	-0.5	-6.3	-0.46	3.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	10.46	0.65	1.28e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg17366294	chr4:99064904	C4orf37	-0.46	-5.14	-0.38	8.47e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs773506	0.966	rs773515	chr9:93982932	C/T	cg14446406	chr9:93919335	NA	-0.32	-4.4	-0.34	2.05e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	9.39	0.61	8.61e-17	Nonalcoholic fatty liver disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15044146	chr17:35501295	ACACA	-0.72	-6.74	-0.48	3.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg04520793	chr17:42248056	ASB16	-0.45	-5.92	-0.43	2.1e-8	Total body bone mineral density;
PAAD	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg26174226	chr8:58114915	NA	-0.58	-4.36	-0.33	2.41e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.86	9.79	0.62	7.72e-18	Body mass index;
PAAD	cis	rs939584	1.000	rs12476198	chr2:625347	T/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg09222892	chr1:25734099	RHCE	-0.46	-4.53	-0.34	1.21e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg00806126	chr19:22604979	ZNF98	0.41	5.22	0.39	5.7e-7	Pain;
PAAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14180030	chr9:123475675	MEGF9	-0.46	-5.08	-0.38	1.1e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.98	13.71	0.74	2.27e-28	Heart rate;
PAAD	cis	rs2229238	0.911	rs3811448	chr1:154516578	G/A	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.62e-6	Coronary heart disease;
PAAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.76	-7.04	-0.5	6.24e-11	Breast cancer;
PAAD	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27467552	chr22:50353597	PIM3	-0.5	-5.01	-0.38	1.5e-6	Ulcerative colitis;
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg04117972	chr1:227635322	NA	0.59	4.26	0.33	3.57e-5	Major depressive disorder;
PAAD	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg25547332	chr5:131281432	NA	-0.59	-4.72	-0.36	5.36e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.23	0.84	1.52e-42	IgG glycosylation;
PAAD	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.47	4.58	0.35	9.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.53	5.7	0.42	5.97e-8	Menopause (age at onset);
PAAD	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.32e-6	Diastolic blood pressure;
PAAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.52	-4.63	-0.35	7.93e-6	Parkinson's disease;
PAAD	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.61	-5.93	-0.43	1.96e-8	Coronary artery disease;
PAAD	cis	rs12893597	0.541	rs12589755	chr14:76841939	A/C	cg20290672	chr14:76816747	NA	-0.53	-4.63	-0.35	7.83e-6	Maximal oxygen uptake response;
PAAD	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg02135003	chr7:105160482	PUS7	-0.67	-6.04	-0.44	1.13e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9463078	0.547	rs1342370	chr6:44747732	A/G	cg25276700	chr6:44698697	NA	-0.38	-4.39	-0.34	2.13e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg05585544	chr11:47624801	NA	-0.48	-5.29	-0.39	4.24e-7	Subjective well-being;
PAAD	cis	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs8181588	1.000	rs11602964	chr11:2825871	C/T	cg10890346	chr11:2207660	NA	0.72	4.9	0.37	2.4e-6	Type 2 diabetes;
PAAD	cis	rs35123781	0.533	rs7728485	chr5:139077144	A/G	cg10513866	chr5:139070639	NA	0.69	5.73	0.42	5.12e-8	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg26876637	chr1:152193138	HRNR	-0.85	-6.21	-0.45	4.86e-9	Atopic dermatitis;
PAAD	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg02016764	chr4:38805732	TLR1	-0.54	-4.26	-0.33	3.64e-5	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05745464	chr10:120514788	C10orf46	0.68	7.06	0.5	5.5e-11	Myopia (pathological);
PAAD	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.28	0.39	4.34e-7	Mean platelet volume;
PAAD	cis	rs910187	1.000	rs6063085	chr20:45840459	A/C	cg27589058	chr20:45804311	EYA2	-0.48	-4.84	-0.37	3.17e-6	Migraine;
PAAD	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.55	5.24	0.39	5.22e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg26695010	chr11:65641043	EFEMP2	-0.55	-5.32	-0.4	3.64e-7	Eosinophil percentage of white cells;
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	1.0	6.67	0.48	4.57e-10	IgG glycosylation;
PAAD	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg25649188	chr17:73499917	CASKIN2	0.63	5.83	0.43	3.22e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.55	5.81	0.43	3.55e-8	Dupuytren's disease;
PAAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg02376097	chr19:46275166	DMPK	-0.59	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.06	-0.38	1.21e-6	Daytime sleep phenotypes;
PAAD	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.74e-6	Pain;
PAAD	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.77	8.01	0.55	2.72e-13	Alzheimer's disease (late onset);
PAAD	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.67	7.08	0.5	4.88e-11	Platelet distribution width;
PAAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs367615	0.842	rs2578484	chr5:108950808	G/A	cg17395555	chr5:108820864	NA	-0.43	-4.67	-0.35	6.65e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.28	-0.51	1.67e-11	Total body bone mineral density;
PAAD	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.67	5.76	0.42	4.6e-8	Schizophrenia;
PAAD	cis	rs2790457	0.958	rs2772433	chr10:28895946	A/G	cg05705492	chr10:28955341	NA	0.43	4.28	0.33	3.26e-5	Multiple myeloma;
PAAD	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg06131755	chr6:160182447	ACAT2	0.53	4.61	0.35	8.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.49	-0.34	1.38e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02244288	chr16:89573955	SPG7	-0.3	-4.25	-0.33	3.72e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg10072921	chr12:121022843	NA	-0.37	-4.94	-0.37	2e-6	High light scatter reticulocyte count;
PAAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg04018474	chr16:31008003	STX1B	0.27	4.26	0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	7.3	0.51	1.53e-11	Renal function-related traits (BUN);
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.71	0.36	5.46e-6	Bipolar disorder;
PAAD	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.57	-0.41	1.14e-7	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09031958	chr5:179203369	MAML1	0.61	6.3	0.46	3.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.27	0.39	4.5e-7	Resting heart rate;
PAAD	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg09184832	chr6:79620586	NA	-0.42	-4.29	-0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-1.02	-10.08	-0.63	1.25e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs9815354	0.680	rs114714860	chr3:41882905	G/C	cg03022575	chr3:42003672	ULK4	0.77	5.7	0.42	6.11e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4455778	0.580	rs6974104	chr7:49126777	C/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs290268	0.803	rs2774260	chr9:93567472	A/G	cg02608019	chr9:93564028	SYK	0.61	5.79	0.43	3.87e-8	Platelet count;
PAAD	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.75	-0.36	4.57e-6	Triglycerides;
PAAD	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg00898013	chr13:113819073	PROZ	0.72	6.31	0.46	2.96e-9	Blood protein levels;
PAAD	cis	rs11264799	0.731	rs2210916	chr1:157687549	C/T	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs9628987	1.000	rs11584485	chr1:8387962	G/A	cg14413262	chr1:8384046	SLC45A1	-0.61	-4.51	-0.34	1.27e-5	Breast cancer;
PAAD	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.77	0.36	4.27e-6	Alzheimer's disease (survival time);
PAAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg21951975	chr1:209979733	IRF6	0.56	5.44	0.4	2.13e-7	Coronary artery disease;
PAAD	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.61	-6.67	-0.48	4.59e-10	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.64e-5	Dental caries;
PAAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.43	-0.46	1.53e-9	IgG glycosylation;
PAAD	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.33	0.46	2.58e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.56	5.34	0.4	3.4e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.79	9.15	0.6	3.48e-16	Breast cancer;
PAAD	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.46	10.03	0.63	1.7e-18	Opioid sensitivity;
PAAD	cis	rs3764400	0.567	rs12946143	chr17:46154943	C/T	cg24322968	chr17:46507895	SKAP1	0.87	5.3	0.39	4.06e-7	Body mass index;
PAAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs3026101	0.647	rs12603729	chr17:5320685	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	6.29	0.45	3.14e-9	Body mass index;
PAAD	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.69	-6.72	-0.48	3.46e-10	Neuroticism;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13560548	chr3:10150139	C3orf24	-0.55	-4.88	-0.37	2.71e-6	Alzheimer's disease;
PAAD	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.54	6.78	0.48	2.55e-10	Atrioventricular conduction;
PAAD	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg21775007	chr8:11205619	TDH	0.77	7.54	0.52	3.98e-12	Retinal vascular caliber;
PAAD	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg00677455	chr12:58241039	CTDSP2	0.54	5.45	0.4	1.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.69	4.83	0.36	3.29e-6	Vitiligo;
PAAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.36	-4.34	-0.33	2.58e-5	Schizophrenia;
PAAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.44	-4.43	-0.34	1.77e-5	Body mass index;
PAAD	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.56	4.99	0.38	1.61e-6	Systemic lupus erythematosus;
PAAD	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-4.9	-0.37	2.45e-6	Self-reported allergy;
PAAD	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.46	-0.34	1.56e-5	Neuroticism;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.53	0.41	1.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg24829409	chr8:58192753	C8orf71	0.61	5.77	0.42	4.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03664217	chr19:44095354	IRGQ	-0.59	-6.74	-0.48	3.06e-10	Monocyte percentage of white cells;
PAAD	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.69e-6	Pain;
PAAD	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg10018233	chr7:150070692	REPIN1	0.58	6.17	0.45	5.97e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg14132834	chr19:41945861	ATP5SL	0.52	4.99	0.38	1.62e-6	Height;
PAAD	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.25	-0.39	4.96e-7	Bipolar disorder;
PAAD	cis	rs8105895	0.935	rs7250905	chr19:22250743	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs12615435	1.000	rs36031708	chr2:200648765	C/A	cg23649088	chr2:200775458	C2orf69	0.82	4.34	0.33	2.63e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);
PAAD	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.63	6.54	0.47	8.94e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg19192590	chr2:178524533	PDE11A	0.43	5.14	0.38	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2786865	0.708	rs2982291	chr1:26040029	A/T	cg12074707	chr1:27019787	NA	0.7	4.63	0.35	7.78e-6	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.47	4.36	0.33	2.37e-5	Tuberculosis;
PAAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.99	11.36	0.68	4.92e-22	Parkinson's disease;
PAAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.77	-0.36	4.23e-6	Renal cell carcinoma;
PAAD	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.37	-0.78	9.44e-33	Height;
PAAD	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	0.96	6.95	0.49	1.01e-10	Glioblastoma;
PAAD	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.48	-0.34	1.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2885056	0.843	rs1821280	chr19:10693007	G/A	cg04833646	chr19:10679720	CDKN2D	0.95	9.06	0.59	5.87e-16	Red cell distribution width;
PAAD	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.94	-7.96	-0.54	3.73e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.85	10.19	0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00540400	chr15:79124168	NA	0.58	6.72	0.48	3.43e-10	Coronary artery disease;
PAAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.86	8.43	0.56	2.5e-14	Cognitive function;
PAAD	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.51	5.49	0.41	1.62e-7	Obesity-related traits;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg26338869	chr17:61819248	STRADA	0.49	4.7	0.36	5.68e-6	Height;
PAAD	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg19423196	chr10:82049429	MAT1A	0.61	4.65	0.35	7.02e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg14926445	chr8:58193284	C8orf71	-0.71	-5.12	-0.38	9.33e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.45	4.42	0.34	1.85e-5	Platelet count;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.79	8.34	0.56	4.16e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs501120	1.000	rs579058	chr10:44755104	A/G	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg08992911	chr2:238395768	MLPH	0.63	5.52	0.41	1.45e-7	Prostate cancer;
PAAD	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg21496419	chr19:44306685	LYPD5	-0.36	-4.35	-0.33	2.46e-5	Reading or mathematical ability;
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg14393609	chr7:65229607	NA	-0.66	-7.32	-0.51	1.33e-11	Aortic root size;
PAAD	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.88	-0.37	2.66e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7624766	0.709	rs1378656	chr3:160526864	A/T	cg22637730	chr3:160473554	PPM1L	0.52	4.66	0.35	6.77e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs2968864	1.000	rs2968856	chr7:150614934	T/C	cg06221570	chr7:150558377	ABP1	0.49	5.67	0.42	7.03e-8	QT interval;
PAAD	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg14703610	chr5:56206110	C5orf35	-0.61	-5.51	-0.41	1.47e-7	Coronary artery disease;
PAAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.83	9.15	0.6	3.48e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.74	-0.36	4.97e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg08390786	chr10:135334061	NA	0.61	5.34	0.4	3.36e-7	Gout;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.86	-13.24	-0.73	4.13e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.39	-0.34	2.08e-5	Neuroticism;
PAAD	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg26750617	chr12:132293702	NA	0.48	5.04	0.38	1.29e-6	Migraine;
PAAD	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.71	-5.26	-0.39	4.91e-7	Hand grip strength;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00492957	chr16:980633	LMF1	0.58	6.87	0.49	1.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg14146966	chr2:61757674	XPO1	0.39	4.91	0.37	2.37e-6	Tuberculosis;
PAAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg03188948	chr7:1209495	NA	1.11	5.54	0.41	1.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7243821	0.921	rs61711309	chr18:52630275	C/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg11288833	chr15:55489084	RSL24D1	0.58	4.69	0.36	6.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.59	-5.95	-0.43	1.79e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs375066	0.935	rs388685	chr19:44418680	C/G	cg11993925	chr19:44307056	LYPD5	0.5	6.36	0.46	2.2e-9	Breast cancer;
PAAD	cis	rs5417	0.636	rs2074217	chr17:7150552	A/G	cg13768953	chr17:7114967	DLG4	0.4	4.83	0.36	3.26e-6	Diastolic blood pressure;
PAAD	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.43	-5.85	-0.43	2.98e-8	White blood cell count;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.55	5.25	0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg06609049	chr19:2785107	THOP1	1.21	17.07	0.81	3.7e-37	Total cholesterol levels;
PAAD	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-4.26	-0.33	3.61e-5	Obesity (extreme);
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.75	-10.27	-0.64	4.12e-19	Iron status biomarkers;
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg15654264	chr1:150340011	RPRD2	0.52	5.09	0.38	1.06e-6	Migraine;
PAAD	cis	rs7945071	0.507	rs2853001	chr11:110286562	C/A	cg04157658	chr11:110243994	NA	0.45	4.41	0.34	1.94e-5	Cognitive function;
PAAD	cis	rs12681288	0.755	rs2123056	chr8:1033366	G/C	cg08648136	chr8:956695	NA	0.42	4.35	0.33	2.45e-5	Schizophrenia;
PAAD	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.63e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06287708	chr2:179345168	MIR548N;PLEKHA3	-0.67	-7.13	-0.5	3.81e-11	Smoking initiation;
PAAD	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12760731	0.565	rs12049568	chr1:178154345	A/G	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.92	-10.89	-0.66	9.14e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11728578	chr19:12476542	ZNF442	0.57	6.38	0.46	2.03e-9	Monocyte percentage of white cells;
PAAD	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.83	-0.36	3.34e-6	Large artery stroke;
PAAD	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.86	6.16	0.45	6.27e-9	Iron status biomarkers;
PAAD	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.42	-0.34	1.89e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.5	4.94	0.37	2.08e-6	Parkinson's disease;
PAAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	7.0	0.49	7.85e-11	Schizophrenia;
PAAD	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.64	6.97	0.49	9.14e-11	Blood protein levels;
PAAD	cis	rs12986413	0.624	rs12979965	chr19:2131148	A/G	cg09261902	chr19:2140048	AP3D1	0.57	5.56	0.41	1.21e-7	Height;
PAAD	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg03286735	chr4:906491	GAK	-0.32	-4.26	-0.33	3.62e-5	Systemic sclerosis;
PAAD	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.58	6.8	0.48	2.3e-10	Monocyte count;
PAAD	cis	rs9880406	1.000	rs9880406	chr3:126049305	C/T	cg13708016	chr3:126007563	NA	-0.43	-4.4	-0.34	2.02e-5	Macular telangiectasia type 2;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14008862	chr17:28927542	LRRC37B2	0.73	4.88	0.37	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs74181299	0.684	rs1420183	chr2:65309988	A/G	cg20592124	chr2:65290738	CEP68	-0.46	-4.39	-0.34	2.11e-5	Pulse pressure;
PAAD	cis	rs74181299	0.712	rs2241161	chr2:65290842	A/C	cg20592124	chr2:65290738	CEP68	-0.57	-5.62	-0.41	9.06e-8	Pulse pressure;
PAAD	cis	rs11615916	0.656	rs73139022	chr12:62818841	T/C	cg11441379	chr12:63026424	NA	0.74	4.69	0.36	6.13e-6	Pulmonary function decline;
PAAD	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg18721089	chr20:30220636	NA	-0.82	-6.65	-0.47	4.93e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.39	10.61	0.65	5.12e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs9463078	0.605	rs1578676	chr6:44906861	G/A	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.74	-8.81	-0.58	2.6e-15	Body mass index;
PAAD	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.6	4.96	0.37	1.85e-6	Response to antidepressants in depression;
PAAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg04876069	chr12:132293656	NA	0.52	5.64	0.42	8.2e-8	Migraine;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg10434728	chr15:90938212	IQGAP1	-0.45	-4.52	-0.34	1.22e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.89	11.35	0.68	5.27e-22	Methadone dose in opioid dependence;
PAAD	cis	rs9918079	0.560	rs6449153	chr4:15631216	C/T	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.37	-0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.95	-9.91	-0.63	3.62e-18	Homoarginine levels;
PAAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.41	-0.52	8.21e-12	Personality dimensions;
PAAD	cis	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.61	-5.84	-0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.76	-9.03	-0.59	7.12e-16	White blood cell count (basophil);
PAAD	cis	rs9399135	0.773	rs949895	chr6:135405359	C/T	cg24558204	chr6:135376177	HBS1L	0.44	4.33	0.33	2.67e-5	Red blood cell count;
PAAD	cis	rs4356203	0.870	rs2171615	chr11:17252641	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.54	-0.35	1.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.1	-8.78	-0.58	3.25e-15	Diabetic kidney disease;
PAAD	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg21191810	chr6:118973309	C6orf204	0.48	6.1	0.44	8.31e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7021589	0.943	rs72758634	chr9:117793413	G/T	cg16682686	chr9:117903983	DEC1	-0.71	-4.66	-0.35	6.89e-6	Blood protein levels;
PAAD	cis	rs1075265	0.605	rs805418	chr2:54125771	C/T	cg04546899	chr2:54196757	PSME4	0.33	5.03	0.38	1.37e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18110553	chr14:55169922	SAMD4A	0.62	6.58	0.47	7.33e-10	Smoking initiation;
PAAD	cis	rs2229238	0.911	rs41269915	chr1:154521584	T/A	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.62e-6	Coronary heart disease;
PAAD	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg21191810	chr6:118973309	C6orf204	0.48	6.05	0.44	1.06e-8	Electrocardiographic conduction measures;
PAAD	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg16606324	chr3:10149918	C3orf24	0.65	5.24	0.39	5.26e-7	Alzheimer's disease;
PAAD	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg22153407	chr1:230290089	GALNT2	0.5	5.07	0.38	1.12e-6	Coronary artery disease;
PAAD	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	4.78	0.36	4.15e-6	HIV-1 control;
PAAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.76	0.36	4.48e-6	Blood metabolite levels;
PAAD	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.46	4.78	0.36	4.12e-6	Menopause (age at onset);
PAAD	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg10856724	chr12:34555212	NA	0.49	4.99	0.38	1.61e-6	Morning vs. evening chronotype;
PAAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg14343924	chr8:8086146	FLJ10661	0.66	5.81	0.43	3.59e-8	Mood instability;
PAAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg25649188	chr17:73499917	CASKIN2	0.64	5.73	0.42	5.16e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg08926642	chr1:7887455	PER3	0.5	4.5	0.34	1.36e-5	Inflammatory bowel disease;
PAAD	cis	rs258892	0.895	rs115204336	chr5:72024800	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs17601876	0.843	rs6493494	chr15:51549835	G/A	cg21478137	chr15:51532386	CYP19A1	0.46	4.48	0.34	1.45e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.25	0.33	3.71e-5	Obesity-related traits;
PAAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg03959625	chr15:84868606	LOC388152	0.48	5.17	0.39	7.11e-7	Schizophrenia;
PAAD	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.07	-0.38	1.13e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3764563	0.825	rs682745	chr19:15701102	A/G	cg20725493	chr19:15740067	CYP4F8	0.75	5.07	0.38	1.16e-6	Inflammatory biomarkers;
PAAD	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.6	-6.03	-0.44	1.21e-8	Post bronchodilator FEV1;
PAAD	cis	rs6908034	0.607	rs73376655	chr6:19805664	C/T	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.13	-0.38	8.81e-7	Subjective well-being;
PAAD	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg07202610	chr7:1142643	C7orf50	-0.72	-5.28	-0.39	4.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.59	-5.12	-0.38	9.28e-7	Total body bone mineral density;
PAAD	cis	rs3733418	0.929	rs1401400	chr4:165927911	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.61	-5.42	-0.4	2.28e-7	Obesity-related traits;
PAAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.61	0.35	8.6e-6	Personality dimensions;
PAAD	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.65	-6.05	-0.44	1.08e-8	Diisocyanate-induced asthma;
PAAD	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.59	8.38	0.56	3.22e-14	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg13870426	chr17:30244630	NA	-0.74	-6.55	-0.47	8.33e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.68	4.94	0.37	2.05e-6	Hip geometry;
PAAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.55	-7.08	-0.5	4.94e-11	Height;
PAAD	cis	rs11807834	0.505	rs880328	chr1:230246806	T/C	cg00566187	chr1:230250356	GALNT2	-0.66	-7.05	-0.5	5.72e-11	Schizophrenia;
PAAD	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.81	-0.43	3.46e-8	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25173574	chr4:154112549	TRIM2	-0.65	-6.59	-0.47	6.8e-10	Obesity-related traits;
PAAD	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.52	-4.28	-0.33	3.33e-5	Systolic blood pressure;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.5	-4.79	-0.36	3.86e-6	Metabolic traits;
PAAD	cis	rs375066	0.935	rs10421518	chr19:44381286	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.67	0.48	4.36e-10	Breast cancer;
PAAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.72	-8.44	-0.56	2.33e-14	Diastolic blood pressure;
PAAD	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs17032980	0.956	rs7600954	chr2:67321682	G/A	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.61e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.65	6.19	0.45	5.41e-9	IgG glycosylation;
PAAD	cis	rs308971	0.572	rs307559	chr3:12094965	G/T	cg15873301	chr3:12045459	SYN2	0.64	5.34	0.4	3.3e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg19000871	chr14:103996768	TRMT61A	-0.46	-4.92	-0.37	2.22e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17822314	chr2:54198336	PSME4	-0.67	-6.56	-0.47	7.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.58	5.87	0.43	2.7e-8	Platelet count;
PAAD	cis	rs4523957	0.614	rs2760736	chr17:2036653	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6493487	0.512	rs35416047	chr15:51188545	T/C	cg02888867	chr15:50978624	TRPM7	-0.64	-4.38	-0.33	2.19e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14019695	chr9:139328340	INPP5E	-0.5	-4.77	-0.36	4.32e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.45	0.34	1.66e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.99	-8.38	-0.56	3.37e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.14	9.91	0.63	3.67e-18	Vitiligo;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg20167471	chr1:16528984	ARHGEF19	0.47	4.62	0.35	8.08e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.05	0.59	6.48e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg13206674	chr6:150067644	NUP43	0.59	5.4	0.4	2.5e-7	Lung cancer;
PAAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2834188	1.000	rs2834188	chr21:34689253	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	4.47	0.34	1.5e-5	Narcolepsy;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.46	-4.44	-0.34	1.69e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg25173405	chr17:45401733	C17orf57	0.49	5.07	0.38	1.13e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg15331088	chr8:600555	NA	0.77	5.07	0.38	1.13e-6	IgG glycosylation;
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07648498	chr16:89883185	FANCA	0.69	7.12	0.5	4.01e-11	Vitiligo;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg02118564	chr11:1241341	NA	-0.29	-4.32	-0.33	2.83e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6850606	0.537	rs62297760	chr4:42890676	T/C	cg24533989	chr4:42659536	ATP8A1	0.5	4.36	0.33	2.34e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Depression;
PAAD	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.62	-0.53	2.51e-12	Parkinson's disease;
PAAD	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.88	-11.08	-0.67	2.77e-21	Heart rate;
PAAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.92	8.31	0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg16818395	chr3:128274084	NA	0.54	4.8	0.36	3.72e-6	Dental caries;
PAAD	cis	rs6743376	0.556	rs768627	chr2:113821653	C/T	cg12858261	chr2:113808755	IL1F8	-0.43	-4.29	-0.33	3.17e-5	Inflammatory biomarkers;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs288342	0.797	rs73975514	chr2:183632968	G/C	cg02625481	chr2:183667124	NA	0.44	4.42	0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg18451016	chr1:38461880	NA	-0.56	-6.51	-0.47	1.03e-9	Coronary artery disease;
PAAD	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.53	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.48	0.57	1.8e-14	Homoarginine levels;
PAAD	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09826364	chr7:158789723	NA	-0.4	-5.18	-0.39	7.02e-7	Facial morphology (factor 20);
PAAD	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.72	9.0	0.59	8.66e-16	Dupuytren's disease;
PAAD	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg11897209	chr6:86302888	SNX14	0.45	4.26	0.33	3.6e-5	Response to antipsychotic treatment;
PAAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.77e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg01796438	chr3:11312864	ATG7	-0.67	-5.1	-0.38	1.02e-6	Circulating chemerin levels;
PAAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.73	-5.99	-0.44	1.49e-8	Neuroticism;
PAAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-4.51	-0.34	1.31e-5	Blood protein levels;
PAAD	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg15117754	chr3:10150083	C3orf24	0.72	5.87	0.43	2.67e-8	Alzheimer's disease;
PAAD	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-11.95	-0.7	1.29e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.79	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.84	7.1	0.5	4.39e-11	Neutrophil percentage of white cells;
PAAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs1012068	0.924	rs5998173	chr22:32305971	T/C	cg01338084	chr22:32026380	PISD	0.58	5.15	0.39	8.06e-7	Chronic hepatitis C infection;
PAAD	cis	rs778371	0.788	rs2675959	chr2:233791988	T/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.64	-0.47	5.36e-10	Schizophrenia;
PAAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg18569988	chr3:195679450	NA	0.45	4.39	0.34	2.13e-5	Pancreatic cancer;
PAAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14159672	chr1:205819179	PM20D1	0.47	4.31	0.33	2.86e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg15047889	chr8:124780837	FAM91A1	-0.69	-5.39	-0.4	2.63e-7	Pancreatic cancer;
PAAD	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	5.24	0.39	5.4e-7	Mean platelet volume;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs8044868	0.893	rs12929749	chr16:72168241	T/G	cg16579770	chr16:72058938	DHODH	0.41	4.27	0.33	3.42e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.79	8.9	0.59	1.54e-15	Schizophrenia;
PAAD	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.45	-5.11	-0.38	9.74e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg12929805	chr1:2399054	NA	-0.47	-5.9	-0.43	2.33e-8	Schizophrenia;
PAAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.52	-5.29	-0.39	4.12e-7	IgG glycosylation;
PAAD	cis	rs2637266	0.703	rs846637	chr10:78534627	G/A	cg18941641	chr10:78392320	NA	0.36	4.4	0.34	2.04e-5	Pulmonary function;
PAAD	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.65	5.83	0.43	3.16e-8	Mean corpuscular volume;
PAAD	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06850241	chr22:41845214	NA	0.57	5.06	0.38	1.2e-6	Vitiligo;
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg04154034	chr17:28927549	LRRC37B2	0.79	4.67	0.35	6.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg21300403	chr2:198650112	BOLL	-0.66	-4.52	-0.34	1.24e-5	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-6.52	-0.47	9.81e-10	Body mass index;
PAAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg11766577	chr21:47581405	C21orf56	-0.43	-4.86	-0.37	2.96e-6	Testicular germ cell tumor;
PAAD	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-4.53	-0.35	1.16e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.8	-0.87	1.21e-48	Myeloid white cell count;
PAAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg23188684	chr11:67383651	NA	-0.49	-4.8	-0.36	3.83e-6	Mean corpuscular volume;
PAAD	cis	rs9394841	0.810	rs1410492	chr6:41907855	G/C	cg08135965	chr6:41755394	TOMM6	0.45	4.5	0.34	1.34e-5	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.89	-7.83	-0.54	7.67e-13	Body mass index;
PAAD	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.82e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.62	-6.12	-0.44	7.77e-9	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.49	-0.47	1.12e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-6.18	-0.45	5.76e-9	Morning vs. evening chronotype;
PAAD	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26926768	chr12:34528122	NA	0.38	4.83	0.36	3.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-4.34	-0.33	2.61e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.7	6.71	0.48	3.54e-10	Blood metabolite levels;
PAAD	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs9652601	0.959	rs9934969	chr16:11166002	G/A	cg04616529	chr16:11181986	CLEC16A	0.47	5.03	0.38	1.39e-6	Systemic lupus erythematosus;
PAAD	cis	rs876084	0.505	rs4409431	chr8:121104019	C/G	cg06265175	chr8:121136014	COL14A1	0.48	4.75	0.36	4.69e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10958605	0.761	rs1481054	chr8:40028062	C/T	cg14545590	chr8:40388592	ZMAT4	-0.39	-4.33	-0.33	2.65e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.5	5.41	0.4	2.4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02543470	chr2:105862877	NA	-0.51	-4.86	-0.37	2.94e-6	Obesity-related traits;
PAAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.8	-9.11	-0.59	4.54e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4150161	0.656	rs2288025	chr16:84211735	A/C	cg10106505	chr16:84220380	TAF1C	-0.97	-5.5	-0.41	1.59e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs7132746	0.570	rs61930067	chr12:86210441	A/G	cg18827107	chr12:86230957	RASSF9	-0.6	-4.97	-0.37	1.77e-6	Lewy body disease;
PAAD	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-5.52	-0.41	1.46e-7	QRS duration;
PAAD	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	0.91	9.65	0.62	1.75e-17	Testicular germ cell tumor;
PAAD	cis	rs9913156	0.748	rs55981776	chr17:4561401	T/C	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg03188948	chr7:1209495	NA	0.7	5.42	0.4	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.43	-4.98	-0.37	1.74e-6	Blood pressure (smoking interaction);
PAAD	cis	rs58521262	0.505	rs457599	chr19:23132717	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs28595532	0.516	rs17594740	chr4:119246754	C/T	cg21605333	chr4:119757512	SEC24D	1.32	7.12	0.5	3.96e-11	Cannabis dependence symptom count;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.61	5.87	0.43	2.59e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs35464392	chr10:45972880	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.59	-5.67	-0.42	7.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg24879335	chr3:133465180	TF	-0.41	-4.36	-0.33	2.34e-5	Iron status biomarkers;
PAAD	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20503657	chr10:835505	NA	-0.79	-8.24	-0.56	7.46e-14	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.61	-7.04	-0.5	6.18e-11	Immature fraction of reticulocytes;
PAAD	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs4953404	0.613	rs6734725	chr2:46897570	G/A	cg12784625	chr2:46524557	EPAS1	-0.49	-4.31	-0.33	2.86e-5	Pulse pressure (alcohol consumption interaction);
PAAD	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg09659197	chr4:152720779	NA	0.46	6.11	0.44	8.11e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs73198271	0.515	rs75155748	chr8:8628957	G/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.36	-0.46	2.29e-9	Triglycerides;
PAAD	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.49	4.26	0.33	3.6e-5	Height;
PAAD	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.5e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs8077577	0.895	rs3088233	chr17:18112675	C/T	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.82	9.41	0.61	7.23e-17	Methadone dose in opioid dependence;
PAAD	cis	rs4938096	1.000	rs7937929	chr11:114241371	G/A	cg00557402	chr11:114466517	FAM55D	0.7	4.26	0.33	3.51e-5	Asthma;
PAAD	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.87	0.37	2.77e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.64	6.21	0.45	4.85e-9	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs2445762	0.659	rs17524318	chr15:51663386	G/A	cg25905881	chr15:51634250	GLDN	0.49	4.32	0.33	2.85e-5	Hormone measurements;
PAAD	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg05935833	chr10:81318306	SFTPA2	-0.53	-4.48	-0.34	1.45e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg22868518	chr11:507468	RNH1	-0.92	-4.95	-0.37	1.93e-6	Body mass index;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.68	-0.36	6.22e-6	Longevity;Endometriosis;
PAAD	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.61	-0.47	6.24e-10	Morning vs. evening chronotype;
PAAD	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg21823605	chr1:152486609	CRCT1	-0.51	-6.63	-0.47	5.51e-10	Hair morphology;
PAAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.57	-7.76	-0.53	1.17e-12	Renal cell carcinoma;
PAAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.66	8.66	0.57	6.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg27121462	chr16:89883253	FANCA	0.8	4.67	0.35	6.54e-6	Interleukin-17 levels;
PAAD	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg12046867	chr14:103022105	NA	-0.65	-5.14	-0.38	8.28e-7	Platelet count;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	4.62	0.35	7.96e-6	Urinary tract infection frequency;
PAAD	cis	rs1879734	0.731	rs72660683	chr1:54191811	T/C	cg14659662	chr1:54151053	GLIS1	-0.34	-4.52	-0.34	1.22e-5	Mitral valve prolapse;
PAAD	cis	rs1443512	0.541	rs1443509	chr12:54340622	T/C	cg17410650	chr12:54324560	NA	-0.41	-4.98	-0.37	1.71e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2131877	1.000	rs2131877	chr3:194858374	C/T	cg21937377	chr3:194868750	C3orf21	0.45	4.75	0.36	4.71e-6	Non-small cell lung cancer;
PAAD	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.68	8.19	0.55	1.02e-13	Coronary artery disease;
PAAD	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs7243821	0.672	rs11661650	chr18:52587751	A/G	cg16669619	chr18:52630472	NA	-0.55	-4.48	-0.34	1.45e-5	Chin dimples;
PAAD	cis	rs6718203	1.000	rs78519266	chr2:60639636	A/C	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07172597	chr19:42817659	TMEM145	0.6	6.56	0.47	7.96e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.66	7.01	0.49	7.42e-11	Multiple sclerosis;
PAAD	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg12310025	chr6:25882481	NA	0.44	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs593531	0.614	rs10793080	chr11:74088743	C/T	cg15851278	chr11:73669449	DNAJB13	-0.38	-4.46	-0.34	1.58e-5	Neuroticism;
PAAD	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.41	-0.61	7.61e-17	Venous thromboembolism;
PAAD	trans	rs901683	1.000	rs17157880	chr10:46014488	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.53	-5.97	-0.44	1.6e-8	Lung cancer;
PAAD	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-5.68	-0.42	6.69e-8	Subjective well-being;
PAAD	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.04	0.38	1.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.49	0.61	4.64e-17	Bladder cancer;
PAAD	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs8077577	0.895	rs16960983	chr17:18104568	A/T	cg16794390	chr17:18148240	FLII	0.52	4.49	0.34	1.41e-5	Obesity-related traits;
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.3	0.45	3.06e-9	Platelet count;
PAAD	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-1.04	-7.43	-0.52	7.37e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.86	9.14	0.6	3.81e-16	Body mass index;
PAAD	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.53	0.57	1.37e-14	Rheumatoid arthritis;
PAAD	cis	rs8063160	0.610	rs12931267	chr16:89818732	C/G	cg07984980	chr16:89898383	SPIRE2	0.84	4.42	0.34	1.86e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg18084798	chr19:33555255	RHPN2	0.41	4.33	0.33	2.65e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs300774	0.925	rs441469	chr2:129028	C/T	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16745091	chr2:122176233	CLASP1	0.55	6.89	0.49	1.42e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.86	7.77	0.53	1.08e-12	Recombination rate (females);
PAAD	cis	rs1879734	0.773	rs6658469	chr1:54133345	C/A	cg14659662	chr1:54151053	GLIS1	-0.4	-5.46	-0.41	1.87e-7	Mitral valve prolapse;
PAAD	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg11962587	chr1:145515913	GNRHR2;PEX11B	-0.52	-4.95	-0.37	1.98e-6	HIV-1 control;
PAAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.9	10.76	0.66	1.98e-20	Sudden cardiac arrest;
PAAD	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.3	-0.33	3.01e-5	Mean corpuscular volume;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg13271783	chr10:134563150	INPP5A	-0.49	-5.22	-0.39	5.79e-7	Migraine;
PAAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.02e-6	Diastolic blood pressure;
PAAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.71	8.13	0.55	1.4e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1903068	0.853	rs28411232	chr4:56000009	A/T	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.69e-5	Endometriosis;
PAAD	cis	rs11588062	0.687	rs3991796	chr1:46802608	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.45	4.29	0.33	3.22e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2790216	1.000	rs2653503	chr10:59964034	C/T	cg20442379	chr10:60024634	IPMK	-0.57	-4.32	-0.33	2.77e-5	Inflammatory bowel disease;
PAAD	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg26898376	chr11:64110657	CCDC88B	0.43	4.49	0.34	1.41e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs12476592	0.530	rs115404815	chr2:64246885	A/G	cg10828910	chr2:63850056	LOC388955	-0.52	-4.45	-0.34	1.64e-5	Childhood ear infection;
PAAD	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	11.44	0.68	2.92e-22	Chronic sinus infection;
PAAD	cis	rs258892	0.895	rs6452660	chr5:72023989	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.57	5.62	0.41	8.85e-8	Narcolepsy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16381596	chr10:99474151	MARVELD1	-0.78	-6.94	-0.49	1.08e-10	Neuroticism;
PAAD	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.16	0.5	3.21e-11	Obesity-related traits;
PAAD	cis	rs16975963	0.793	rs56672492	chr19:38448231	T/C	cg08679971	chr19:38281047	NA	0.53	5.14	0.38	8.37e-7	Longevity;
PAAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.59	7.21	0.5	2.52e-11	Monobrow;
PAAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.68	7.42	0.52	7.79e-12	Melanoma;
PAAD	cis	rs2882667	0.654	rs12517514	chr5:138150119	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs73019876	0.502	rs4244913	chr19:22239919	A/T	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	4.3	0.33	3e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.88	-11.17	-0.67	1.6e-21	Heart rate;
PAAD	cis	rs11208446	0.709	rs78845254	chr1:64878744	A/G	cg25192081	chr1:65308244	JAK1	-0.64	-4.27	-0.33	3.38e-5	Bilirubin levels;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.6	-5.94	-0.43	1.84e-8	Triglyceride levels;
PAAD	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.27	-0.51	1.73e-11	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26124717	chr5:90675823	LOC100129716;ARRDC3	0.69	6.48	0.47	1.23e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg08498647	chr11:118550644	TREH	0.4	4.28	0.33	3.24e-5	Sjögren's syndrome;
PAAD	cis	rs2712184	0.756	rs2712164	chr2:217659916	G/A	cg05032264	chr2:217675019	NA	-0.59	-6.72	-0.48	3.52e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg18209359	chr17:80159595	CCDC57	-0.46	-4.59	-0.35	9.06e-6	Life satisfaction;
PAAD	cis	rs4764124	0.556	rs11614746	chr12:14918756	C/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.47	5.3	0.39	4.04e-7	Pubertal anthropometrics;
PAAD	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg11993925	chr19:44307056	LYPD5	-0.44	-5.96	-0.44	1.72e-8	Breast cancer;
PAAD	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.43	4.25	0.33	3.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.75	-4.28	-0.33	3.23e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.71	6.85	0.49	1.69e-10	Cognitive function;
PAAD	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.68	7.12	0.5	3.93e-11	Beta-trace protein levels;
PAAD	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.49	7.82	0.54	8.27e-13	Neuroticism;
PAAD	cis	rs694739	0.861	rs479552	chr11:64110683	G/C	cg26898376	chr11:64110657	CCDC88B	0.57	6.08	0.44	9.12e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-1.12	-8.97	-0.59	1e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73198822	chr3:128480061	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.82	-0.36	3.41e-6	Dental caries;
PAAD	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-4.44	-0.34	1.72e-5	QT interval;
PAAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg21211367	chr2:162094118	NA	-0.47	-4.36	-0.33	2.4e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs6864727	1.000	rs2349556	chr5:137248721	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	5.12	0.38	9.08e-7	Atrial fibrillation;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.35	4.36	0.33	2.4e-5	Schizophrenia;
PAAD	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.7	0.36	5.76e-6	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg09796270	chr17:17721594	SREBF1	-0.44	-4.98	-0.37	1.68e-6	Total body bone mineral density;
PAAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg15847926	chr7:2749597	AMZ1	-0.43	-4.98	-0.37	1.68e-6	Height;
PAAD	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs3779195	0.929	rs4268041	chr7:98005538	C/T	cg24562669	chr7:97807699	LMTK2	-0.52	-5.13	-0.38	8.82e-7	Sex hormone-binding globulin levels;
PAAD	cis	rs60154123	0.730	rs12074229	chr1:210474602	A/G	cg23283495	chr1:209979779	IRF6	0.59	5.28	0.39	4.31e-7	Coronary artery disease;
PAAD	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.59	-0.35	9.15e-6	Blood protein levels;
PAAD	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.63	-6.44	-0.46	1.51e-9	Monocyte count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27297221	chr19:663093	RNF126	-0.8	-7.29	-0.51	1.57e-11	Neuroticism;
PAAD	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21445541	chr1:167424621	CD247	-0.62	-6.51	-0.47	1.03e-9	Smoking initiation;
PAAD	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.63	-6.49	-0.47	1.13e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2124910	0.967	rs4802801	chr19:52021250	G/C	cg14953197	chr19:52005651	SIGLEC12	0.37	4.3	0.33	3.08e-5	Blood protein levels;
PAAD	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.72	9.3	0.6	1.42e-16	Weight;
PAAD	cis	rs11614333	1.000	rs9668569	chr12:15046950	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg16898833	chr6:26189333	HIST1H4D	0.73	4.35	0.33	2.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.55	6.57	0.47	7.52e-10	Multiple system atrophy;
PAAD	cis	rs2290419	0.730	rs79334774	chr11:68942867	C/T	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4668356	1.000	rs56308745	chr2:171954930	A/T	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.93	7.53	0.52	4.22e-12	Iron status biomarkers;
PAAD	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.99	-15.48	-0.78	4.61e-33	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25573812	chr6:164531921	NA	-0.59	-6.42	-0.46	1.67e-9	Obesity-related traits;
PAAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.93	8.72	0.58	4.61e-15	Gut microbiome composition (summer);
PAAD	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg27499820	chr13:21296301	IL17D	-0.56	-5.43	-0.4	2.2e-7	Dental caries;
PAAD	cis	rs11997175	0.679	rs10954935	chr8:33670379	C/G	ch.8.33884649F	chr8:33765107	NA	0.48	5.08	0.38	1.1e-6	Body mass index;
PAAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.56	7.34	0.51	1.23e-11	Multiple system atrophy;
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-5.01	-0.38	1.5e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.2e-18	Electrocardiographic conduction measures;
PAAD	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.69	-0.48	4.01e-10	Chronic sinus infection;
PAAD	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg02524346	chr8:600233	NA	-0.95	-6.47	-0.46	1.29e-9	IgG glycosylation;
PAAD	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs12893597	0.715	rs12892786	chr14:76833888	C/T	cg20290672	chr14:76816747	NA	-0.55	-4.74	-0.36	4.87e-6	Maximal oxygen uptake response;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg15383120	chr6:291909	DUSP22	-0.64	-6.85	-0.49	1.71e-10	Menopause (age at onset);
PAAD	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-6.31	-0.46	2.91e-9	Hypospadias;
PAAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg05562828	chr17:3906858	NA	-0.55	-6.22	-0.45	4.68e-9	Type 2 diabetes;
PAAD	cis	rs2555155	0.870	rs10839575	chr11:6551635	G/C	cg24637308	chr11:6592297	DNHD1	-0.51	-5.24	-0.39	5.22e-7	DNA methylation (variation);
PAAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.8	-8.87	-0.58	1.84e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs62025270	0.580	rs62022938	chr15:86247995	G/T	cg13263323	chr15:86062960	AKAP13	0.48	4.33	0.33	2.66e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.93e-7	Motion sickness;
PAAD	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg08345082	chr10:99160200	RRP12	-0.31	-4.45	-0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg00080972	chr5:178986291	RUFY1	-0.48	-4.68	-0.36	6.21e-6	Lung cancer;
PAAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.54	-4.99	-0.38	1.6e-6	Retinal vascular caliber;
PAAD	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.6	6.54	0.47	8.72e-10	Morning vs. evening chronotype;
PAAD	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.82e-16	Parkinson's disease;
PAAD	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs743757	1.000	rs71326932	chr3:50485005	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.67	4.53	0.34	1.18e-5	Diastolic blood pressure;
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.54	0.35	1.14e-5	Calcium levels;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.1e-9	Life satisfaction;
PAAD	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.67	6.34	0.46	2.47e-9	Hip circumference;
PAAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.69	7.33	0.51	1.28e-11	Obesity-related traits;
PAAD	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.86	-0.77	2.04e-31	Ulcerative colitis;
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.72	7.48	0.52	5.39e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.37	-0.4	2.88e-7	Aortic root size;
PAAD	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.73	9.43	0.61	6.74e-17	Asthma;
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3733631	1.000	rs28650409	chr4:104628577	C/T	cg21490444	chr5:171095097	NA	0.79	6.68	0.48	4.25e-10	Menarche (age at onset);
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg10518543	chr12:38710700	ALG10B	0.5	4.65	0.35	7.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg01064725	chr1:204461714	NA	-0.5	-4.75	-0.36	4.76e-6	Schizophrenia;
PAAD	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg02389323	chr16:88786976	FAM38A	0.93	5.27	0.39	4.59e-7	Plateletcrit;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.7	-8.49	-0.57	1.72e-14	Type 2 diabetes;
PAAD	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg00024416	chr22:24240387	NA	-0.58	-5.94	-0.43	1.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.54	4.44	0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	5.63	0.42	8.28e-8	Educational attainment;
PAAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg15017067	chr4:17643749	FAM184B	0.43	5.11	0.38	9.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.49	-5.0	-0.38	1.55e-6	Iron status biomarkers;
PAAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00339695	chr16:24857497	SLC5A11	0.46	4.34	0.33	2.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2327429	0.821	rs1967917	chr6:134198175	C/T	cg06296503	chr6:134217401	NA	0.46	4.77	0.36	4.23e-6	Coronary artery disease;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg10396713	chr8:602097	NA	0.75	5.55	0.41	1.27e-7	IgG glycosylation;
PAAD	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9287719	0.614	rs10929680	chr2:10723126	C/T	cg00105475	chr2:10696890	NA	0.62	6.52	0.47	9.94e-10	Prostate cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26336594	chr4:152330339	FAM160A1	-0.64	-7.59	-0.52	2.95e-12	Body fat percentage;
PAAD	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg06816558	chr2:113912567	NA	0.43	4.68	0.35	6.39e-6	Protein quantitative trait loci;
PAAD	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs58365266	0.727	rs4504190	chr3:195839847	G/A	cg12923728	chr3:195709715	SDHAP1	-0.57	-4.58	-0.35	9.51e-6	Red cell distribution width;
PAAD	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg08619932	chr19:49200058	FUT2	0.61	6.73	0.48	3.26e-10	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.55	0.41	1.26e-7	Bipolar disorder;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.96	0.44	1.71e-8	Platelet count;
PAAD	cis	rs2117029	0.521	rs11168910	chr12:49586490	C/T	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg03277515	chr1:153321198	PGLYRP4	0.42	4.99	0.38	1.65e-6	Psoriasis;
PAAD	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.93	10.39	0.64	1.9e-19	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.84	-10.18	-0.64	6.9e-19	Prudent dietary pattern;
PAAD	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs757081	0.658	rs214075	chr11:17300417	G/T	cg22710661	chr11:17411071	KCNJ11	-0.44	-4.6	-0.35	8.66e-6	Systolic blood pressure;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg20850873	chr3:10149803	C3orf24	0.57	4.43	0.34	1.76e-5	Alzheimer's disease;
PAAD	cis	rs6028335	0.877	rs68108082	chr20:37774911	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.54	-4.39	-0.34	2.11e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs12999373	0.501	rs2867134	chr2:697499	C/T	cg05676510	chr2:1311570	SNTG2	-0.38	-4.3	-0.33	3.02e-5	Uric acid levels;Response to fenofibrate (adiponectin levels);
PAAD	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.87	-6.73	-0.48	3.24e-10	Axial length;
PAAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	11.42	0.68	3.36e-22	Bone mineral density;
PAAD	cis	rs6066835	0.614	rs1998287	chr20:47401338	A/G	cg18078177	chr20:47281410	PREX1	-0.86	-4.44	-0.34	1.72e-5	Multiple myeloma;
PAAD	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.69	-6.09	-0.44	8.91e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.23e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg10596483	chr8:143751796	JRK	-0.48	-4.25	-0.33	3.75e-5	Urinary tract infection frequency;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg25581932	chr17:7892150	NA	0.59	6.62	0.47	5.89e-10	Iris heterochromicity;
PAAD	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg25200586	chr1:148000763	NA	-0.61	-6.37	-0.46	2.1e-9	Hip geometry;
PAAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg27113419	chr16:58533979	NDRG4	-0.71	-4.47	-0.34	1.54e-5	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg20607287	chr7:12443886	VWDE	-0.7	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.54	5.1	0.38	9.97e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg14440974	chr22:39074834	NA	-0.57	-6.49	-0.47	1.16e-9	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09047553	chr11:19138639	ZDHHC13	0.65	7.63	0.53	2.37e-12	Monocyte percentage of white cells;
PAAD	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.16	0.39	7.67e-7	Tonsillectomy;
PAAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg05627522	chr15:75251581	NA	0.39	4.26	0.33	3.61e-5	Breast cancer;
PAAD	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-6.42	-0.46	1.62e-9	Urate levels in overweight individuals;
PAAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.88	-9.48	-0.61	4.87e-17	Calcium levels;
PAAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.54	4.29	0.33	3.17e-5	Depression;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.44	-0.4	2.05e-7	Migraine;
PAAD	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.4	5.49	0.41	1.66e-7	Primary biliary cholangitis;
PAAD	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg03989125	chr22:38214979	NA	-0.52	-5.19	-0.39	6.52e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg01262667	chr19:19385393	TM6SF2	0.47	5.35	0.4	3.14e-7	Tonsillectomy;
PAAD	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.62	-6.67	-0.48	4.47e-10	Type 2 diabetes;
PAAD	cis	rs939584	1.000	rs2903489	chr2:649638	C/T	cg14515364	chr2:636606	NA	-0.48	-4.36	-0.33	2.36e-5	Body mass index;
PAAD	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-7.55	-0.52	3.71e-12	Chronic sinus infection;
PAAD	cis	rs11009175	0.556	rs1418540	chr10:33297667	C/T	cg00146027	chr10:33299147	NA	-0.4	-4.84	-0.37	3.17e-6	Depression (quantitative trait);
PAAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.27e-15	Emphysema distribution in smoking;
PAAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.87	8.76	0.58	3.61e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7523050	0.908	rs12404382	chr1:109397129	G/A	cg08274380	chr1:109419600	GPSM2	0.74	5.24	0.39	5.22e-7	Fat distribution (HIV);
PAAD	cis	rs13401620	0.555	rs1437421	chr2:120975831	A/C	cg15425061	chr2:121036351	RALB	-0.49	-4.39	-0.34	2.14e-5	Breast size;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.55	-5.48	-0.41	1.74e-7	Longevity;Endometriosis;
PAAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.87	9.26	0.6	1.84e-16	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17651973	chr2:162095248	NA	0.74	8.03	0.55	2.54e-13	Obesity-related traits;
PAAD	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.91	-7.29	-0.51	1.59e-11	Dupuytren's disease;
PAAD	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.61	-4.66	-0.35	6.73e-6	Smoking behavior;
PAAD	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.57	5.93	0.43	2.01e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.67e-7	Personality dimensions;
PAAD	cis	rs28595532	0.541	rs56055826	chr4:119789424	T/A	cg21605333	chr4:119757512	SEC24D	2.04	10.87	0.66	1.01e-20	Cannabis dependence symptom count;
PAAD	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.61	4.6	0.35	8.87e-6	Thyroid stimulating hormone;
PAAD	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.89	-10.06	-0.63	1.47e-18	Cognitive function;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-5.0	-0.38	1.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg13611204	chr9:139324423	INPP5E	-0.57	-4.87	-0.37	2.82e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12144049	0.662	rs561260	chr1:152410643	T/C	cg25605289	chr1:151974222	NA	-0.35	-4.36	-0.33	2.42e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs863345	0.604	rs11264976	chr1:158446927	G/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.27e-6	Pneumococcal bacteremia;
PAAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg10356904	chr22:49881777	NA	-0.53	-5.55	-0.41	1.27e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.88	-8.64	-0.57	7.19e-15	Asthma;
PAAD	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.31	-4.88	-0.37	2.63e-6	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg24829409	chr8:58192753	C8orf71	-0.92	-7.98	-0.54	3.27e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-5.59	-0.41	1.02e-7	Height;
PAAD	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.2	-0.39	6.21e-7	Schizophrenia;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs11264799	0.581	rs2779158	chr1:157549170	A/T	cg18268488	chr1:157545234	FCRL4	-0.52	-5.84	-0.43	3.11e-8	IgA nephropathy;
PAAD	cis	rs735539	0.593	rs2818997	chr13:21369315	C/T	cg27499820	chr13:21296301	IL17D	0.54	5.14	0.39	8.17e-7	Dental caries;
PAAD	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	11.0	0.67	4.59e-21	Primary sclerosing cholangitis;
PAAD	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.2e-11	Alcohol dependence;
PAAD	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs1903068	0.853	rs28680424	chr4:56009245	T/C	cg01777861	chr4:56023843	NA	0.35	4.42	0.34	1.89e-5	Endometriosis;
PAAD	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs6540556	0.654	rs6540549	chr1:209922668	G/T	cg23920097	chr1:209922102	NA	0.46	4.57	0.35	9.93e-6	Red blood cell count;
PAAD	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.38	5.21	0.39	6.1e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.5	-4.98	-0.37	1.72e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.28	10.39	0.64	1.9e-19	Uric acid levels;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs939584	1.000	rs939582	chr2:622723	A/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg11247378	chr22:39784982	NA	0.66	6.97	0.49	8.84e-11	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.79	-8.76	-0.58	3.52e-15	Aortic root size;
PAAD	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg11288833	chr15:55489084	RSL24D1	0.58	4.69	0.36	6.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.77	9.05	0.59	6.3e-16	Blood metabolite ratios;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.39	-0.34	2.15e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg18093559	chr17:18951025	GRAP	-0.46	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.02	-0.55	2.66e-13	Colorectal cancer;
PAAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-9.71	-0.62	1.23e-17	Electrocardiographic conduction measures;
PAAD	cis	rs3749237	1.000	rs13316065	chr3:49884913	C/T	cg03060546	chr3:49711283	APEH	0.63	6.18	0.45	5.69e-9	Resting heart rate;
PAAD	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg09839279	chr12:125627357	AACS	-0.48	-4.83	-0.36	3.28e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.74e-5	Skin colour saturation;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.6	6.99	0.49	8.31e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.9	-0.37	2.44e-6	Testicular germ cell tumor;
PAAD	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.02	0.38	1.44e-6	Neuroticism;
PAAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.54	-5.49	-0.41	1.67e-7	White blood cell count;
PAAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.72	7.75	0.53	1.23e-12	Schizophrenia;
PAAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-1.09	-11.19	-0.67	1.43e-21	Longevity;
PAAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.59	-7.93	-0.54	4.32e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg07061783	chr6:25882402	NA	0.46	4.38	0.33	2.2e-5	Blood metabolite levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21908638	chr3:101497982	FAM55C	0.67	7.03	0.5	6.64e-11	Myopia (pathological);
PAAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.59	4.88	0.37	2.6e-6	Schizophrenia;
PAAD	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.59	-5.78	-0.42	4.18e-8	Systolic blood pressure;
PAAD	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.43	-6.87	-0.49	1.54e-10	Neuroticism;
PAAD	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.77	0.62	8.47e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg01800442	chr17:74086473	EXOC7	0.64	4.33	0.33	2.72e-5	Psoriasis;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9820070	1.000	rs12696580	chr3:187689345	C/T	cg18245890	chr3:187457316	BCL6	0.47	4.28	0.33	3.26e-5	Hematological and biochemical traits;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25577598	chr11:46722234	ZNF408;ARHGAP1	-0.69	-7.0	-0.49	7.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.58	5.37	0.4	2.93e-7	Malaria;
PAAD	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.47	5.27	0.39	4.53e-7	Body mass index;
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.82	6.03	0.44	1.19e-8	Body mass index;
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Body mass index;
PAAD	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg06883089	chr1:45254480	BEST4	-0.34	-4.26	-0.33	3.61e-5	High light scatter reticulocyte count;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg14008862	chr17:28927542	LRRC37B2	-0.67	-4.91	-0.37	2.33e-6	Body mass index;
PAAD	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.77	-0.36	4.31e-6	Lung cancer;
PAAD	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg01796438	chr3:11312864	ATG7	-0.68	-5.0	-0.38	1.58e-6	Circulating chemerin levels;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg15693483	chr7:1102177	C7orf50	0.49	5.39	0.4	2.64e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs77880822	0.562	rs77953441	chr20:1254284	C/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs11650494	0.710	rs74619404	chr17:47484445	C/T	cg08112188	chr17:47440006	ZNF652	1.71	7.81	0.53	8.87e-13	Prostate cancer;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg15192750	chr16:69999425	NA	-0.67	-5.4	-0.4	2.57e-7	IgE levels;
PAAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Melanoma;
PAAD	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.89	-9.48	-0.61	4.92e-17	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.27	-0.33	3.43e-5	Daytime sleep phenotypes;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.96	8.17	0.55	1.12e-13	Alzheimer's disease;
PAAD	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.87	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-8.65	-0.57	6.83e-15	Prudent dietary pattern;
PAAD	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.81	-11.55	-0.68	1.51e-22	Colorectal cancer;
PAAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.89	6.97	0.49	8.91e-11	Breast cancer;
PAAD	cis	rs5009270	0.513	rs728461	chr7:112217909	A/G	cg23628563	chr7:112262597	NA	0.64	5.45	0.4	2.03e-7	Osteoarthritis (hip);
PAAD	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg00277334	chr10:82204260	NA	-0.76	-8.9	-0.59	1.55e-15	Post bronchodilator FEV1;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg05913198	chr10:21822977	MLLT10	0.58	6.7	0.48	3.91e-10	Primary biliary cholangitis;
PAAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.29e-6	Rheumatoid arthritis;
PAAD	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg19442545	chr10:75533431	FUT11	0.53	5.5	0.41	1.59e-7	Inflammatory bowel disease;
PAAD	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.92	0.37	2.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.7	0.42	5.93e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18950002	chr17:79673969	MRPL12	0.59	6.91	0.49	1.25e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7714584	1.000	rs12659118	chr5:150324622	T/C	cg22134413	chr5:150180641	NA	1.01	6.63	0.47	5.6e-10	Crohn's disease;
PAAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.61	-6.87	-0.49	1.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-1.09	-7.69	-0.53	1.72e-12	Obesity (early onset extreme);
PAAD	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.49	4.65	0.35	7.09e-6	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.55	6.09	0.44	8.88e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	4.27	0.33	3.4e-5	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.44	-0.34	1.7e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.57	-0.52	3.28e-12	Diastolic blood pressure;
PAAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.99	-13.39	-0.74	1.72e-27	Height;
PAAD	cis	rs9659323	0.632	rs6658479	chr1:119627856	C/T	cg17326555	chr1:119535693	NA	-0.37	-5.31	-0.4	3.79e-7	Body mass index;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.99	12.49	0.71	4.35e-25	Systemic lupus erythematosus;
PAAD	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg14515779	chr1:101123966	NA	0.43	4.65	0.35	7.05e-6	Monocyte count;
PAAD	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.74	-8.76	-0.58	3.61e-15	Height;
PAAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.59	5.35	0.4	3.25e-7	Monocyte count;
PAAD	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.74e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6585424	1.000	rs34162901	chr10:81946856	A/C	cg19423196	chr10:82049429	MAT1A	0.46	4.76	0.36	4.56e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.89	11.43	0.68	3.2e-22	Age at first birth;
PAAD	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.5	5.18	0.39	6.9e-7	Red blood cell count;
PAAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.93	0.43	1.94e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14853265	chr12:133460336	CHFR	-0.73	-7.65	-0.53	2.2e-12	Obesity-related traits;
PAAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.44	0.57	2.29e-14	Schizophrenia;
PAAD	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.91	11.99	0.7	9.65e-24	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg06917450	chr1:38156652	C1orf109	0.48	4.67	0.35	6.67e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg00147160	chr1:26503991	CNKSR1	0.39	4.37	0.33	2.26e-5	QRS complex (12-leadsum);
PAAD	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.8	8.72	0.58	4.56e-15	Mortality in heart failure;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.75	0.58	3.79e-15	Bipolar disorder;
PAAD	cis	rs728616	0.681	rs55899456	chr10:82050646	G/A	cg19423196	chr10:82049429	MAT1A	0.5	4.92	0.37	2.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.68	-0.53	1.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	0.94	4.51	0.34	1.28e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11259833	chr6:28249221	PGBD1	-0.63	-6.31	-0.46	2.95e-9	Lung cancer in ever smokers;
PAAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs115201118	chr3:128552140	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.63	5.69	0.42	6.45e-8	Late-onset Alzheimer's disease;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg27094323	chr7:1216898	NA	-0.37	-4.39	-0.34	2.13e-5	Longevity;Endometriosis;
PAAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.81	0.36	3.66e-6	Menopause (age at onset);
PAAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.89	-8.67	-0.58	5.95e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.5	5.09	0.38	1.05e-6	Monocyte count;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.74e-5	Bipolar disorder;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs17683430	0.558	rs4488763	chr22:32380164	C/G	cg02631450	chr22:32366979	NA	0.71	4.39	0.34	2.13e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.52	5.05	0.38	1.23e-6	Parkinson's disease;
PAAD	cis	rs302972	0.826	rs303001	chr6:25056769	A/G	cg01382804	chr6:25931017	SLC17A2	-0.86	-4.69	-0.36	6.15e-6	Creatinine levels in ischemic stroke;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22831607	chr10:99531797	SFRP5	0.63	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.6	-5.26	-0.39	4.82e-7	Retinal vascular caliber;
PAAD	cis	rs10887741	0.646	rs7097212	chr10:89430067	G/A	cg13926569	chr10:89418898	PAPSS2	0.48	4.82	0.36	3.46e-6	Exercise (leisure time);
PAAD	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg17737388	chr1:85724454	C1orf52	0.49	4.28	0.33	3.36e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-5.22	-0.39	5.91e-7	Reticulocyte count;
PAAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	4.64	0.35	7.56e-6	Asthma;
PAAD	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05901462	chr7:158075388	PTPRN2	0.46	4.95	0.37	1.94e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs74544699	1.000	rs585778	chr4:74779005	G/T	cg16072462	chr4:74847758	PF4	1.12	4.28	0.33	3.28e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15733534	chr19:48972397	CYTH2	-0.56	-6.39	-0.46	1.88e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.54	0.35	1.14e-5	Breast cancer;
PAAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.54	5.7	0.42	5.96e-8	Menopause (age at onset);
PAAD	trans	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg10589385	chr1:150898437	SETDB1	0.4	4.85	0.37	3.01e-6	Melanoma;
PAAD	cis	rs595018	0.913	rs529354	chr11:60587182	A/G	cg07588442	chr11:60673866	PRPF19	-0.52	-4.27	-0.33	3.44e-5	Wegener's granulomatosis;
PAAD	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg02795151	chr17:7402630	POLR2A	-0.62	-6.04	-0.44	1.12e-8	Androgen levels;
PAAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.07	-0.38	1.13e-6	Diastolic blood pressure;
PAAD	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.78	8.81	0.58	2.67e-15	Heart rate;
PAAD	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg22868518	chr11:507468	RNH1	0.93	4.83	0.36	3.3e-6	Body mass index;
PAAD	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg13332499	chr17:408570	NA	-0.54	-5.92	-0.43	2.11e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.73	0.53	1.33e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg12935359	chr14:103987150	CKB	-0.58	-6.09	-0.44	8.8e-9	Body mass index;
PAAD	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.65	-6.84	-0.49	1.82e-10	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.54	5.71	0.42	5.67e-8	Menopause (age at onset);
PAAD	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs258892	0.895	rs266424	chr5:72122660	G/A	cg21869765	chr5:72125136	TNPO1	-0.79	-5.25	-0.39	5.02e-7	Small cell lung carcinoma;
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg13263323	chr15:86062960	AKAP13	0.64	7.35	0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26418147	chr1:205743515	RAB7L1	-0.47	-5.52	-0.41	1.43e-7	Menarche (age at onset);
PAAD	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.02	9.2	0.6	2.67e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.54	5.78	0.42	4.08e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.66	7.14	0.5	3.57e-11	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg25431220	chr17:52978035	TOM1L1	0.61	6.69	0.48	4.11e-10	Primary biliary cholangitis;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.68	7.26	0.51	1.86e-11	Mean corpuscular volume;
PAAD	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.45	7.2	0.5	2.54e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg08917208	chr2:24149416	ATAD2B	0.49	4.3	0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg07959070	chr22:50026188	C22orf34	-0.38	-4.51	-0.34	1.29e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03218198	chr16:588562	SOLH	0.58	6.82	0.48	1.98e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.42	4.72	0.36	5.36e-6	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.25	0.33	3.72e-5	Resting heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19168507	chr11:107436485	ALKBH8	0.58	6.38	0.46	2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs617219	0.698	rs13177470	chr5:78495899	T/C	cg24856658	chr5:78533917	JMY	-0.4	-4.51	-0.34	1.31e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.26	0.51	1.87e-11	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.8	8.96	0.59	1.1e-15	Lung cancer;
PAAD	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs9469913	0.799	rs9462016	chr6:34739790	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg11657440	chr19:46296263	DMWD	-0.69	-6.0	-0.44	1.4e-8	Coronary artery disease;
PAAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.77	6.69	0.48	4.04e-10	Obesity-related traits;
PAAD	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg05341575	chr12:125625032	AACS	-0.47	-4.48	-0.34	1.46e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.71	-5.14	-0.38	8.48e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs3026101	0.671	rs2301740	chr17:5319620	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.64	7.21	0.5	2.44e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs17157839	chr10:45963777	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.24	-0.39	5.2e-7	Longevity;Endometriosis;
PAAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg09835421	chr16:68378352	PRMT7	-0.79	-6.49	-0.47	1.12e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08439880	chr3:133502540	NA	-0.58	-6.17	-0.45	5.95e-9	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.42	-0.4	2.27e-7	HDL cholesterol;
PAAD	cis	rs71403859	0.568	rs12149489	chr16:71813780	G/T	cg08717414	chr16:71523259	ZNF19	-0.91	-6.07	-0.44	9.69e-9	Post bronchodilator FEV1;
PAAD	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg24330906	chr2:85765176	MAT2A	0.47	4.53	0.34	1.18e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg14393609	chr7:65229607	NA	0.61	6.32	0.46	2.81e-9	Calcium levels;
PAAD	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg17366294	chr4:99064904	C4orf37	0.61	6.51	0.47	1.03e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.47	-4.94	-0.37	2.07e-6	Obesity-related traits;
PAAD	cis	rs16975963	0.604	rs17305326	chr19:38119547	T/C	cg08679971	chr19:38281047	NA	0.47	4.59	0.35	9.24e-6	Longevity;
PAAD	cis	rs300774	0.925	rs300801	chr2:105259	C/T	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.59	-4.87	-0.37	2.77e-6	Metabolite levels;
PAAD	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg07622451	chr1:3079886	PRDM16	-0.38	-4.39	-0.34	2.08e-5	Migraine;
PAAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg06096015	chr1:231504339	EGLN1	0.69	9.05	0.59	6.51e-16	Hemoglobin concentration;
PAAD	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.68	-4.74	-0.36	4.89e-6	Coronary artery disease;
PAAD	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg06096015	chr1:231504339	EGLN1	0.54	5.45	0.4	1.98e-7	Red blood cell count;
PAAD	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	0.82	6.37	0.46	2.09e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02071572	chr4:1403502	NA	0.43	5.86	0.43	2.75e-8	Obesity-related traits;
PAAD	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg03999872	chr20:62272968	STMN3	-0.76	-7.07	-0.5	5.35e-11	Atopic dermatitis;
PAAD	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.57	0.47	7.69e-10	Retinal vascular caliber;
PAAD	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-1.2	-15.42	-0.78	6.67e-33	Longevity;
PAAD	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.81	8.32	0.56	4.68e-14	Alzheimer's disease (late onset);
PAAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.56	-4.96	-0.37	1.9e-6	Myeloid white cell count;
PAAD	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.33	-0.33	2.73e-5	Triglycerides;
PAAD	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.03	-0.38	1.39e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.68	5.95	0.43	1.79e-8	Breast cancer;
PAAD	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.41	-4.53	-0.34	1.19e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.49	4.45	0.34	1.68e-5	Height;
PAAD	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00079375	chr15:79125835	NA	0.43	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs1878047	0.665	rs1399838	chr19:51779592	T/C	cg14884932	chr19:51774451	NA	-0.4	-4.34	-0.33	2.55e-5	Body mass index;
PAAD	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.52	4.89	0.37	2.53e-6	Educational attainment;
PAAD	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg20936604	chr3:58311152	NA	-0.77	-4.38	-0.34	2.17e-5	Cholesterol, total;
PAAD	cis	rs7627468	0.955	rs2202126	chr3:121942812	A/G	cg17240004	chr3:121949083	CASR	0.55	4.72	0.36	5.37e-6	Kidney stones;
PAAD	cis	rs728616	0.614	rs17678338	chr10:82098146	C/T	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.83	0.54	7.72e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.33	0.33	2.64e-5	Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18621852	chr3:10150065	C3orf24	0.67	6.08	0.44	9.09e-9	Alzheimer's disease;
PAAD	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.88	11.21	0.67	1.22e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14239635	chr6:116892067	RWDD1	0.59	6.78	0.48	2.49e-10	Monocyte percentage of white cells;
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.54	-5.41	-0.4	2.35e-7	Iron status biomarkers;
PAAD	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.25	0.33	3.73e-5	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	10.8	0.66	1.51e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.94	-0.43	1.9e-8	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12354594	chr17:61850856	DDX42;CCDC47	0.58	6.42	0.46	1.68e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg21775007	chr8:11205619	TDH	-0.57	-4.96	-0.37	1.86e-6	Neuroticism;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.84	-12.55	-0.71	2.98e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.71	6.04	0.44	1.13e-8	Inflammatory skin disease;
PAAD	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg02811702	chr13:24901961	NA	0.52	5.7	0.42	5.94e-8	Obesity-related traits;
PAAD	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.55	5.27	0.39	4.53e-7	Type 2 diabetes;
PAAD	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.84	-7.87	-0.54	6.12e-13	IgG glycosylation;
PAAD	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23544223	chr18:12777786	NA	0.68	5.95	0.43	1.77e-8	Inflammatory skin disease;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02433498	chr17:36904779	PCGF2	-0.61	-6.3	-0.46	3.02e-9	Warfarin maintenance dose;
PAAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.65e-6	Cognitive function;
PAAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg23957660	chr17:17878224	LRRC48	0.37	4.31	0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.39	0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.77	-8.72	-0.58	4.49e-15	Mean platelet volume;
PAAD	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg12826209	chr6:26865740	GUSBL1	0.8	4.36	0.33	2.42e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72827839	0.846	rs113187178	chr17:46117471	G/A	cg23391107	chr17:45924227	SP6	0.6	5.24	0.39	5.33e-7	Ease of getting up in the morning;
PAAD	cis	rs1864585	0.520	rs73208773	chr8:10666791	T/A	cg21775007	chr8:11205619	TDH	-0.55	-4.28	-0.33	3.28e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs7131987	0.644	rs6487817	chr12:29548210	G/A	cg09582351	chr12:29534625	ERGIC2	0.34	4.76	0.36	4.48e-6	QT interval;
PAAD	cis	rs1903068	0.925	rs1551641	chr4:55993915	C/T	cg20092376	chr4:56023423	NA	0.49	4.9	0.37	2.42e-6	Endometriosis;
PAAD	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg10820045	chr2:198174542	NA	-0.45	-4.57	-0.35	1.02e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg13229655	chr1:10532570	DFFA	0.91	6.38	0.46	2.06e-9	Lung function (FEV1/FVC);
PAAD	cis	rs2735413	0.914	rs2262658	chr16:78060267	A/G	cg04733911	chr16:78082701	NA	-0.52	-5.07	-0.38	1.16e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs4589502	0.614	rs17273637	chr15:67193084	C/T	cg18595228	chr15:67193261	NA	0.75	4.51	0.34	1.31e-5	Lung cancer (smoking interaction);
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg12310025	chr6:25882481	NA	0.44	4.38	0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.62	5.67	0.42	7.05e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg27494647	chr7:150038898	RARRES2	0.41	4.47	0.34	1.51e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs6694672	1.000	rs1571964	chr1:197113073	G/A	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.77	9.02	0.59	7.53e-16	Colorectal cancer;
PAAD	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09264906	chr11:57424981	CLP1	0.54	6.66	0.48	4.7e-10	Monocyte percentage of white cells;
PAAD	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.86	7.1	0.5	4.47e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg15654264	chr1:150340011	RPRD2	0.49	4.77	0.36	4.31e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.72	0.62	1.15e-17	Chronic sinus infection;
PAAD	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.58	5.71	0.42	5.86e-8	Eye color traits;
PAAD	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg08677398	chr8:58056175	NA	0.6	4.54	0.35	1.16e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01370181	chr15:96874052	NR2F2	0.71	6.89	0.49	1.36e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg16766828	chr3:128327626	NA	-0.46	-6.17	-0.45	5.78e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6445967	1.000	rs11712758	chr3:58306579	T/C	cg23715586	chr3:58305044	RPP14	0.49	4.34	0.33	2.59e-5	Platelet count;
PAAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.17	-0.39	7.14e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19691267	chr14:75530649	ACYP1	0.68	8.14	0.55	1.29e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.66	-7.01	-0.49	7.43e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6784615	0.744	rs3796342	chr3:52324165	C/T	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.63	0.42	8.58e-8	Alcohol dependence;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.66	6.34	0.46	2.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg05562828	chr17:3906858	NA	0.61	6.76	0.48	2.73e-10	Type 2 diabetes;
PAAD	cis	rs9913156	0.708	rs9915105	chr17:4568742	G/C	cg19197139	chr17:4613644	ARRB2	-0.84	-8.81	-0.58	2.61e-15	Lymphocyte counts;
PAAD	cis	rs16857609	0.564	rs12232972	chr2:218257272	C/T	cg15335768	chr2:218268053	DIRC3	-0.49	-5.0	-0.38	1.54e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs2117029	0.554	rs2334931	chr12:49567913	G/T	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18877578	chr6:16870123	NA	-0.64	-6.7	-0.48	3.89e-10	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02733266	chr10:106014410	GSTO1	0.6	7.46	0.52	6.2e-12	Monocyte percentage of white cells;
PAAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.44	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.64	-0.42	8.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg10729496	chr3:10149963	C3orf24	0.66	5.75	0.42	4.82e-8	Alzheimer's disease;
PAAD	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg13047869	chr3:10149882	C3orf24	0.77	5.52	0.41	1.41e-7	Alzheimer's disease;
PAAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.0	-0.44	1.39e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs11614333	1.000	rs7965448	chr12:15049216	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08864318	chr1:11996427	PLOD1	-0.62	-6.3	-0.46	3.09e-9	Obesity-related traits;
PAAD	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.89	10.82	0.66	1.34e-20	Dental caries;
PAAD	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.29e-7	Obesity (extreme);
PAAD	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.89	8.39	0.56	3.08e-14	Response to diuretic therapy;
PAAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	10.51	0.65	9.37e-20	Smoking behavior;
PAAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.51	-0.61	3.98e-17	Colorectal cancer;
PAAD	cis	rs111342015	1.000	rs111822813	chr6:43219468	C/T	cg17076780	chr6:43251928	TTBK1	0.71	4.32	0.33	2.77e-5	Breast cancer;
PAAD	cis	rs2790216	0.901	rs2590343	chr10:60012674	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1355223	0.867	rs7943363	chr11:34691134	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.44	-4.5	-0.34	1.35e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-1.2	-9.93	-0.63	3.18e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.887	rs2236160	chr20:34101821	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16851699	chr7:5938193	C7orf28A	0.57	6.49	0.47	1.12e-9	Monocyte percentage of white cells;
PAAD	cis	rs1359582	0.836	rs10736360	chr10:90366262	C/G	cg15661332	chr10:90342814	RNLS	0.56	5.02	0.38	1.45e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg16205897	chr5:131564050	P4HA2	0.41	4.29	0.33	3.2e-5	Acylcarnitine levels;
PAAD	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.56e-9	Childhood ear infection;
PAAD	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.61	6.5	0.47	1.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	1.17	12.0	0.7	9.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs12826942	0.959	rs12820881	chr12:42726978	G/A	cg19980929	chr12:42632907	YAF2	0.55	5.01	0.38	1.5e-6	Coronary artery disease;
PAAD	cis	rs4417704	0.551	rs13009903	chr2:241900756	A/G	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.69e-7	Joint mobility (Beighton score);
PAAD	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg17366294	chr4:99064904	C4orf37	-0.45	-4.93	-0.37	2.1e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.61	-5.96	-0.44	1.69e-8	Subjective well-being;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg24879335	chr3:133465180	TF	0.55	5.9	0.43	2.26e-8	Iron status biomarkers;
PAAD	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	1.24	10.54	0.65	7.47e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.45	6.05	0.44	1.1e-8	Ulcerative colitis;
PAAD	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg04836472	chr21:34405997	NA	0.35	4.49	0.34	1.41e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.49	5.11	0.38	9.73e-7	Height;
PAAD	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.5	-5.2	-0.39	6.41e-7	Schizophrenia;
PAAD	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	8.27	0.56	6.41e-14	LDL cholesterol;
PAAD	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.47	-5.07	-0.38	1.15e-6	Educational attainment;
PAAD	cis	rs73086581	1.000	rs6107393	chr20:3987738	C/T	cg02187196	chr20:3869020	PANK2	0.6	5.05	0.38	1.26e-6	Response to antidepressants in depression;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.92	0.37	2.26e-6	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13256369	0.671	rs59003218	chr8:8554921	G/A	cg18904891	chr8:8559673	CLDN23	0.67	5.92	0.43	2.09e-8	Obesity-related traits;
PAAD	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.73	-7.92	-0.54	4.64e-13	Sudden cardiac arrest;
PAAD	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.51	-4.29	-0.33	3.21e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs28675843	chr3:128575353	T/C	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-4.83	-0.36	3.3e-6	Breast cancer;
PAAD	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.81	-10.17	-0.64	7.36e-19	Hemoglobin concentration;
PAAD	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.4	-0.46	1.81e-9	Schizophrenia;
PAAD	cis	rs354225	0.584	rs7591231	chr2:54829596	C/G	cg01766943	chr2:54829624	SPTBN1	0.54	4.78	0.36	4.15e-6	Schizophrenia;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.5	5.28	0.39	4.44e-7	Lung cancer;
PAAD	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.59	5.99	0.44	1.48e-8	Obesity;
PAAD	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg20363699	chr7:23626180	CLK2P	0.36	4.36	0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.72	-6.67	-0.48	4.54e-10	Body mass index (adult);
PAAD	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg02344993	chr17:57696989	CLTC	0.61	5.06	0.38	1.21e-6	Hemoglobin concentration;
PAAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg09835421	chr16:68378352	PRMT7	-1.0	-6.46	-0.46	1.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg08316699	chr6:150357289	NA	0.41	4.75	0.36	4.73e-6	Alopecia areata;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.39	4.67	0.35	6.52e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.76	8.67	0.58	6.23e-15	Lung cancer;
PAAD	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg04389838	chr3:44770851	ZNF501	-0.51	-4.32	-0.33	2.82e-5	Depressive symptoms;
PAAD	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg19760965	chr3:194868843	C3orf21	0.47	4.36	0.33	2.41e-5	Non-small cell lung cancer;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg01181863	chr3:195395398	SDHAP2	-0.64	-4.64	-0.35	7.53e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg14440974	chr22:39074834	NA	0.52	6.36	0.46	2.29e-9	Menopause (age at onset);
PAAD	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	7.03	0.5	6.58e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.47	4.39	0.34	2.15e-5	Breast cancer;
PAAD	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.11	-0.38	9.5e-7	Menopause (age at onset);
PAAD	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg14515779	chr1:101123966	NA	-0.39	-4.33	-0.33	2.73e-5	Monocyte count;
PAAD	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.64	4.63	0.35	7.91e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-8.75	-0.58	3.81e-15	Height;
PAAD	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg22134325	chr11:66188745	NPAS4	-0.37	-4.42	-0.34	1.89e-5	Airway imaging phenotypes;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13870426	chr17:30244630	NA	0.59	5.65	0.42	7.62e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-0.91	-8.58	-0.57	1.01e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.55	6.36	0.46	2.25e-9	Total body bone mineral density;
PAAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg19630374	chr17:18023558	MYO15A	-0.45	-4.7	-0.36	5.68e-6	Total body bone mineral density;
PAAD	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg24253500	chr15:84953950	NA	0.41	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg13047869	chr3:10149882	C3orf24	0.8	5.97	0.44	1.64e-8	Alzheimer's disease;
PAAD	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg16898833	chr6:26189333	HIST1H4D	0.81	4.58	0.35	9.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.85e-10	Neurofibrillary tangles;
PAAD	trans	rs62179067	0.708	rs62176021	chr2:179909130	C/G	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg08601574	chr20:25228251	PYGB	0.66	7.23	0.51	2.15e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.9	-7.35	-0.51	1.13e-11	Initial pursuit acceleration;
PAAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg13870426	chr17:30244630	NA	-0.73	-6.84	-0.48	1.84e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3136441	1.000	rs4453193	chr11:46787406	C/G	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg19217778	chr13:113420270	ATP11A	-0.62	-4.41	-0.34	1.95e-5	Glycated hemoglobin levels;
PAAD	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-4.61	-0.35	8.41e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.44	-6.53	-0.47	9.45e-10	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19611786	chr2:61698739	USP34	0.67	6.7	0.48	3.78e-10	Obesity-related traits;
PAAD	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-7.31	-0.51	1.39e-11	Vitiligo;
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.54	5.64	0.42	7.93e-8	Obesity-related traits;
PAAD	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg09659197	chr4:152720779	NA	0.34	5.02	0.38	1.42e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7945718	0.591	rs4489724	chr11:12684166	G/T	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.91	10.01	0.63	1.95e-18	Cognitive function;
PAAD	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-10.04	-0.63	1.6e-18	Height;
PAAD	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.44	4.51	0.34	1.26e-5	Longevity;Endometriosis;
PAAD	cis	rs3799977	0.504	rs227813	chr6:44671471	G/A	cg18551225	chr6:44695536	NA	0.39	4.29	0.33	3.12e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.25	-0.39	4.98e-7	Aortic root size;
PAAD	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg27005118	chr17:13972210	COX10	-0.53	-7.6	-0.52	2.85e-12	Temperament;
PAAD	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.68	7.7	0.53	1.61e-12	Iron status biomarkers;
PAAD	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.4	-4.4	-0.34	2.05e-5	Mean arterial pressure;
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg09021430	chr5:549028	NA	-0.42	-4.4	-0.34	2.01e-5	Cystic fibrosis severity;
PAAD	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.63	6.32	0.46	2.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.83	7.92	0.54	4.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg27449745	chr7:23145252	KLHL7	-0.51	-4.61	-0.35	8.38e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-4.33	-0.33	2.69e-5	Aortic root size;
PAAD	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.49e-5	Electrocardiographic conduction measures;
PAAD	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs755249	0.567	rs16826038	chr1:39758634	G/A	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2790216	0.951	rs1199098	chr10:59949736	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.46	-0.4	1.92e-7	Height;
PAAD	cis	rs2415984	0.622	rs73245837	chr14:46947914	A/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.31	-0.4	3.84e-7	Number of children ever born;
PAAD	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.43	-4.45	-0.34	1.68e-5	Response to antidepressants in depression;
PAAD	cis	rs4704187	0.687	rs4703657	chr5:74461850	T/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.02	0.49	7.05e-11	Life satisfaction;
PAAD	cis	rs2637030	0.559	rs2607501	chr5:52989545	A/T	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.3	0.33	3.05e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.96	-0.37	1.83e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg23283495	chr1:209979779	IRF6	0.78	7.71	0.53	1.52e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg01631408	chr1:248437212	OR2T33	-0.63	-5.39	-0.4	2.69e-7	Common traits (Other);
PAAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg06740227	chr12:86229804	RASSF9	0.6	5.33	0.4	3.46e-7	Major depressive disorder;
PAAD	cis	rs9463078	0.546	rs9369529	chr6:45004533	T/C	cg18551225	chr6:44695536	NA	-0.43	-4.5	-0.34	1.33e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-4.92	-0.37	2.22e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.75	-0.48	2.85e-10	Glomerular filtration rate;
PAAD	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.66	6.75	0.48	2.91e-10	Testicular germ cell tumor;
PAAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.67	6.83	0.48	1.89e-10	Body mass index;
PAAD	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs2221894	1.000	rs2137471	chr8:28805649	G/A	cg20212339	chr8:28908912	HMBOX1	0.53	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs9907295	0.591	rs8069014	chr17:34199998	G/A	cg19411729	chr17:34207663	CCL5	-0.55	-4.81	-0.36	3.58e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs735539	0.521	rs8001074	chr13:21448053	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.51	0.34	1.27e-5	Dental caries;
PAAD	cis	rs4824093	0.544	rs7410765	chr22:50315924	G/T	cg06057569	chr22:50219754	BRD1	0.58	4.25	0.33	3.69e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg02404636	chr22:31891804	SFI1	-0.54	-5.0	-0.38	1.57e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg23018236	chr17:30244563	NA	-0.6	-4.5	-0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg19041857	chr6:27730383	NA	-0.43	-4.35	-0.33	2.49e-5	Parkinson's disease;
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-5.98	-0.44	1.56e-8	Lung cancer;
PAAD	cis	rs72681920	0.881	rs12499210	chr4:100088567	T/C	cg12011299	chr4:100065546	ADH4	-0.8	-4.58	-0.35	9.67e-6	Alcohol dependence;
PAAD	cis	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg25886479	chr11:50257625	LOC441601	0.4	4.25	0.33	3.74e-5	Coronary artery disease;
PAAD	cis	rs1371614	0.632	rs12615423	chr2:27158623	G/T	cg00617064	chr2:27272375	NA	0.42	4.47	0.34	1.5e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.6	-5.36	-0.4	3.08e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.52	-5.29	-0.39	4.11e-7	Gout;
PAAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	7.12	0.5	3.95e-11	Type 2 diabetes;
PAAD	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg04160749	chr8:58172571	NA	-0.65	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs9815354	1.000	rs1716669	chr3:41908681	A/G	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg16606324	chr3:10149918	C3orf24	0.77	6.14	0.45	6.8e-9	Alzheimer's disease;
PAAD	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.03	-0.5	6.69e-11	Chronic sinus infection;
PAAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.55	6.04	0.44	1.14e-8	Eye color traits;
PAAD	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.76	-8.65	-0.57	6.7e-15	Breast cancer;
PAAD	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs73198271	0.515	rs74841285	chr8:8635450	C/T	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs2252790	0.859	rs1204810	chr6:116551638	C/A	cg18764771	chr6:116381957	FRK	-0.27	-4.61	-0.35	8.59e-6	Fast beta electroencephalogram;
PAAD	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.58	-4.96	-0.37	1.84e-6	Mean platelet volume;
PAAD	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.49	4.73	0.36	4.99e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9463078	0.678	rs9395088	chr6:45240267	G/A	cg25276700	chr6:44698697	NA	-0.49	-5.42	-0.4	2.32e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.63	-6.2	-0.45	5.15e-9	Ear protrusion;
PAAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.7	0.58	5.05e-15	Parkinson's disease;
PAAD	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-5.58	-0.41	1.1e-7	Vitiligo;
PAAD	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.59	-5.19	-0.39	6.57e-7	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg24879335	chr3:133465180	TF	0.57	6.51	0.47	1.03e-9	Iron status biomarkers;
PAAD	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.93	-0.43	2.01e-8	Coronary artery disease;
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.51	8.31	0.56	4.91e-14	IgG glycosylation;
PAAD	cis	rs6710503	0.547	rs62142311	chr2:24864686	G/A	cg21151432	chr2:25142229	ADCY3	-0.36	-4.28	-0.33	3.28e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs2668423	0.922	rs2668417	chr19:1365827	C/G	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.74	-0.48	3.16e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-6.89	-0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6504950	0.679	rs9908752	chr17:52983216	C/T	cg18040354	chr17:53800484	TMEM100	0.49	4.43	0.34	1.82e-5	Breast cancer;
PAAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.34	5.09	0.38	1.02e-6	Schizophrenia;
PAAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.94	0.37	2.01e-6	Ovarian reserve;
PAAD	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg22437258	chr11:111473054	SIK2	-0.61	-5.56	-0.41	1.2e-7	Primary sclerosing cholangitis;
PAAD	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.82	5.19	0.39	6.57e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.35	0.56	3.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.1	0.63	1.17e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.74	-0.48	3.16e-10	Aortic root size;
PAAD	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-9.58	-0.61	2.67e-17	Body mass index;
PAAD	cis	rs8025118	0.583	rs1434467	chr15:79543970	C/T	cg24739098	chr15:79297159	RASGRF1	-0.41	-4.56	-0.35	1.05e-5	Cognitive function;
PAAD	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.59	-8.43	-0.56	2.41e-14	Urate levels in overweight individuals;
PAAD	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.28	-9.16	-0.6	3.26e-16	Blood pressure (smoking interaction);
PAAD	cis	rs9815354	1.000	rs7372217	chr3:41990122	G/A	cg03022575	chr3:42003672	ULK4	-0.76	-5.57	-0.41	1.12e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.49	5.21	0.39	5.92e-7	Fibrinogen levels;
PAAD	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.48	-4.65	-0.35	7.03e-6	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg12927641	chr6:109611667	NA	-0.41	-4.37	-0.33	2.32e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs35160687	0.644	rs10165626	chr2:86536707	C/T	cg10973622	chr2:86423274	IMMT	-0.46	-5.12	-0.38	9.23e-7	Night sleep phenotypes;
PAAD	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.8	0.58	2.77e-15	Colorectal cancer;
PAAD	cis	rs4678145	1.000	rs62265615	chr3:124447572	A/T	cg07063911	chr3:125197837	SNX4	0.7	4.26	0.33	3.52e-5	Coronary artery disease;
PAAD	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2030114	0.948	rs2030116	chr16:51606368	T/C	cg03758633	chr16:51611768	NA	0.61	4.93	0.37	2.16e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.08	-15.91	-0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.3	0.46	3.02e-9	Schizophrenia;
PAAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.9	-9.57	-0.61	2.87e-17	DNA methylation (variation);
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7714584	1.000	rs1428552	chr5:150259831	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.9	6.56	0.47	8.16e-10	Alzheimer's disease;
PAAD	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16958440	0.867	rs74411203	chr18:44677466	G/A	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01882471	chr2:99389829	NA	0.6	6.42	0.46	1.68e-9	Smoking initiation;
PAAD	cis	rs704	0.790	rs4795433	chr17:26716821	C/T	cg10342447	chr17:26645325	TMEM97	-0.35	-4.31	-0.33	2.97e-5	Osteoprotegerin levels;
PAAD	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.12	-0.38	8.95e-7	Daytime sleep phenotypes;
PAAD	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs9810890	1.000	rs73196959	chr3:128431919	A/G	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14497545	chr4:140754475	MAML3	0.57	6.67	0.48	4.46e-10	Smoking initiation;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.63	-5.51	-0.41	1.52e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg14436426	chr20:62712394	OPRL1;RGS19	-0.4	-4.29	-0.33	3.23e-5	Pulse pressure;Mean corpuscular volume;
PAAD	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.19	-0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-6.47	-0.46	1.29e-9	Body mass index;
PAAD	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-4.98	-0.37	1.74e-6	Bladder cancer;
PAAD	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.62	-0.35	8.25e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.3	0.51	1.49e-11	Coronary artery disease;
PAAD	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg04450456	chr4:17643702	FAM184B	0.44	4.47	0.34	1.5e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7551345	0.853	rs61779439	chr1:31761056	A/G	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg21448613	chr3:49828315	CDH29	0.44	4.29	0.33	3.16e-5	Menarche (age at onset);
PAAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg19630374	chr17:18023558	MYO15A	-0.44	-4.77	-0.36	4.36e-6	Total body bone mineral density;
PAAD	cis	rs294958	0.585	rs297449	chr5:151483769	G/T	cg04453665	chr5:151504455	NA	-0.45	-4.95	-0.37	1.92e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-7.02	-0.49	6.78e-11	Menarche (age at onset);
PAAD	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg08758996	chr17:66097529	LOC651250	0.52	4.34	0.33	2.6e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.73	-7.73	-0.53	1.36e-12	Aortic root size;
PAAD	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.77	-7.02	-0.49	6.79e-11	Vitamin D levels;
PAAD	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.94	10.71	0.66	2.65e-20	Cognitive ability;
PAAD	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.75	8.15	0.55	1.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.63	-5.41	-0.4	2.4e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.84	8.3	0.56	5.2e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Vascular endothelial growth factor levels;
PAAD	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.95	-6.68	-0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.91	11.1	0.67	2.5e-21	Schizophrenia;
PAAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.69	7.31	0.51	1.39e-11	Colorectal cancer;
PAAD	cis	rs2235573	0.662	rs6000991	chr22:38460484	T/C	cg03989125	chr22:38214979	NA	-0.52	-4.9	-0.37	2.42e-6	Glioblastoma;Glioma;
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.69	7.58	0.52	3.09e-12	Calcium levels;
PAAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17691542	chr6:26056736	HIST1H1C	1.12	8.98	0.59	9.44e-16	Iron status biomarkers;
PAAD	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.49	-5.73	-0.42	5.14e-8	Mean corpuscular volume;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg22535103	chr8:58192502	C8orf71	-0.51	-4.65	-0.35	7.01e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.97	10.74	0.66	2.21e-20	Corneal astigmatism;
PAAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.63	6.16	0.45	6.09e-9	Menopause (age at onset);
PAAD	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg21300403	chr2:198650112	BOLL	0.5	4.43	0.34	1.79e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26574621	chr1:3555038	WDR8	-0.58	-7.11	-0.5	4.19e-11	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15506972	chr13:111367570	ING1	0.57	6.41	0.46	1.72e-9	Monocyte percentage of white cells;
PAAD	cis	rs6893807	0.623	rs112862634	chr5:87970352	G/C	cg02225085	chr5:87975992	LOC645323	-0.69	-5.15	-0.39	8.03e-7	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03500585	chr3:125634452	LOC100125556	-0.73	-6.28	-0.45	3.3e-9	Neuroticism;
PAAD	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.35	5.29	0.39	4.2e-7	Alopecia areata;
PAAD	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg09491104	chr22:46646882	C22orf40	-0.92	-5.99	-0.44	1.45e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg20821713	chr7:1055600	C7orf50	-0.4	-4.48	-0.34	1.46e-5	Longevity;Endometriosis;
PAAD	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg04106633	chr4:1044584	NA	0.53	4.96	0.37	1.88e-6	Recombination rate (males);
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg18281939	chr5:77783895	LHFPL2	0.46	5.08	0.38	1.08e-6	Triglycerides;
PAAD	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.63	6.25	0.45	3.95e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg17372657	chr7:1216933	NA	-0.38	-5.07	-0.38	1.13e-6	Longevity;Endometriosis;
PAAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	5.74	0.42	5.05e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-5.33	-0.4	3.48e-7	Schizophrenia;
PAAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12165864	chr7:66369176	NA	-0.81	-5.34	-0.4	3.29e-7	Gout;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg23083516	chr15:85180758	SCAND2	0.4	4.47	0.34	1.54e-5	P wave terminal force;
PAAD	cis	rs595018	0.505	rs1122409	chr11:60605794	C/T	cg07588442	chr11:60673866	PRPF19	0.66	4.61	0.35	8.62e-6	Wegener's granulomatosis;
PAAD	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs8083432	0.799	rs45590241	chr18:22695677	A/G	cg13981356	chr18:22006370	IMPACT	0.58	4.55	0.35	1.08e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs3996993	0.809	rs3957357	chr6:52668687	A/G	cg20803780	chr6:52668592	GSTA1	-0.34	-4.31	-0.33	2.94e-5	Hemoglobin concentration;
PAAD	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.7	7.1	0.5	4.4e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.83	-9.24	-0.6	2e-16	Aortic root size;
PAAD	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	0.74	5.96	0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.7	6.6	0.47	6.51e-10	Obesity-related traits;
PAAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg12072164	chr19:44306565	LYPD5	0.4	4.34	0.33	2.59e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg25233709	chr10:116636983	FAM160B1	0.41	5.19	0.39	6.57e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs743757	1.000	rs13099869	chr3:50515600	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	5.06	0.38	1.2e-6	Diastolic blood pressure;
PAAD	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.73	7.43	0.52	7.31e-12	Alcohol dependence;
PAAD	trans	rs901683	1.000	rs35918870	chr10:45998278	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg26031613	chr14:104095156	KLC1	0.51	5.58	0.41	1.07e-7	Schizophrenia;
PAAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.51	6.41	0.46	1.72e-9	Monobrow;
PAAD	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.04	-0.38	1.28e-6	Electroencephalogram traits;
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg09127314	chr1:152161683	NA	0.69	5.0	0.38	1.58e-6	Atopic dermatitis;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.46	-0.82	3.85e-38	Height;
PAAD	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg11204139	chr17:3907470	NA	0.69	6.94	0.49	1.08e-10	Type 2 diabetes;
PAAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.42	4.72	0.36	5.29e-6	Type 2 diabetes;
PAAD	cis	rs4679121	0.642	rs16837490	chr3:126167775	C/T	cg05485589	chr3:126194908	ZXDC	-0.92	-4.56	-0.35	1.03e-5	Pursuit maintenance gain;
PAAD	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	1.1	6.47	0.46	1.25e-9	Skin colour saturation;
PAAD	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.4	-0.34	2.03e-5	Height;
PAAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-0.66	-4.59	-0.35	9.2e-6	Blood protein levels;
PAAD	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.64	4.69	0.36	6.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg19847866	chr10:1019161	NA	-0.78	-8.18	-0.55	1.05e-13	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.09	-0.38	1.07e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg02887458	chr19:19495540	GATAD2A	-0.63	-5.66	-0.42	7.26e-8	Bipolar disorder;
PAAD	cis	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.12	-0.5	4.05e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.7	7.1	0.5	4.58e-11	Coronary artery disease;
PAAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg17366294	chr4:99064904	C4orf37	-0.49	-5.3	-0.4	3.94e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs7171171	0.706	rs7164418	chr15:38912822	G/A	cg18894552	chr14:53478112	NA	0.53	6.43	0.46	1.56e-9	Type 1 diabetes;
PAAD	cis	rs1468333	1.000	rs2967782	chr5:137529682	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.37	0.46	2.11e-9	Resting heart rate;
PAAD	cis	rs2000999	0.573	rs34682685	chr16:72096227	G/A	cg00207534	chr16:71929512	KIAA0174	0.76	4.51	0.34	1.29e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.71	4.71	0.36	5.54e-6	Lung cancer in ever smokers;
PAAD	cis	rs28489187	0.660	rs2207368	chr1:85847683	A/G	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-5.62	-0.41	8.86e-8	Ulcerative colitis;
PAAD	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.57	-0.35	1.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg09659197	chr4:152720779	NA	0.36	5.3	0.39	3.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	4.48	0.34	1.47e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.8	7.1	0.5	4.5e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs17095355	0.818	rs12268462	chr10:111775047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.72	8.11	0.55	1.61e-13	Morning vs. evening chronotype;
PAAD	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.53	-5.13	-0.38	8.87e-7	Endometrial cancer;
PAAD	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.77	-6.79	-0.48	2.42e-10	Vitiligo;
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg08057985	chr22:42470123	FAM109B	-0.36	-4.26	-0.33	3.57e-5	Schizophrenia;
PAAD	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16414030	chr3:133502952	NA	-0.45	-4.82	-0.36	3.43e-6	Iron status biomarkers;
PAAD	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.62	-5.37	-0.4	2.94e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.53	-5.5	-0.41	1.57e-7	Daytime sleep phenotypes;
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.01	-0.38	1.52e-6	Mean corpuscular volume;
PAAD	trans	rs4427176	0.507	rs4841202	chr8:9582703	T/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs507080	0.845	rs510408	chr11:118558901	G/C	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.75	-0.36	4.61e-6	Breast cancer;
PAAD	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	1.0	9.13	0.6	3.97e-16	Triglycerides;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18337363	chr3:52569053	NT5DC2	0.49	5.31	0.4	3.86e-7	Electroencephalogram traits;
PAAD	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.8	10.21	0.64	5.98e-19	Alcohol dependence;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs7517847	0.567	rs10489629	chr1:67688349	C/T	cg22500004	chr1:68516272	DIRAS3	0.46	4.51	0.34	1.26e-5	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.68	-0.35	6.43e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.86	-9.43	-0.61	6.45e-17	Urate levels in obese individuals;
PAAD	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-5.85	-0.43	2.91e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.42	-5.41	-0.4	2.44e-7	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg00147160	chr1:26503991	CNKSR1	0.42	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-5.55	-0.41	1.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.57	-7.3	-0.51	1.49e-11	Lewy body disease;
PAAD	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.23	-18.11	-0.83	8.67e-40	Triglycerides;
PAAD	cis	rs28489187	0.706	rs233067	chr1:85804978	C/G	cg16011679	chr1:85725395	C1orf52	0.52	4.89	0.37	2.54e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.49	-5.74	-0.42	4.94e-8	Mean arterial pressure;
PAAD	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.66	7.16	0.5	3.14e-11	Dementia with Lewy bodies;
PAAD	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs11853189	0.671	rs11853191	chr15:78565841	C/T	cg22935921	chr15:78556834	DNAJA4	0.6	4.27	0.33	3.44e-5	Red cell distribution width;
PAAD	cis	rs959260	0.588	rs9894003	chr17:73405860	T/G	cg14668889	chr17:73230827	NUP85	-0.75	-4.84	-0.37	3.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs2445762	0.584	rs17602588	chr15:51655475	A/T	cg25905881	chr15:51634250	GLDN	0.5	4.4	0.34	2.03e-5	Hormone measurements;
PAAD	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.7	7.29	0.51	1.57e-11	Osteoporosis;
PAAD	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg21994712	chr19:21861136	NA	0.46	4.5	0.34	1.32e-5	Pain;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg22199628	chr12:80327755	PPP1R12A	0.53	6.35	0.46	2.34e-9	Metabolite levels  (X-11787);
PAAD	cis	rs762407	0.560	rs11089096	chr21:45188955	C/G	cg09613494	chr21:44846625	SIK1	0.48	4.55	0.35	1.08e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.89	-0.37	2.55e-6	Menarche (age at onset);
PAAD	cis	rs952623	0.717	rs12669446	chr7:39046908	A/G	cg18850127	chr7:39170497	POU6F2	-0.44	-6.07	-0.44	9.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg09659197	chr4:152720779	NA	0.48	6.78	0.48	2.48e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.61	-6.18	-0.45	5.63e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.58	-7.8	-0.53	8.95e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	5.15	0.39	8.04e-7	Thyroid stimulating hormone;
PAAD	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.56	-5.44	-0.4	2.08e-7	Blood protein levels;
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.64	-0.35	7.43e-6	Aortic root size;
PAAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.52	-4.25	-0.33	3.77e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.45	4.52	0.34	1.22e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.61	6.66	0.48	4.76e-10	Testicular germ cell tumor;
PAAD	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.52	-5.93	-0.43	1.94e-8	Total body bone mineral density;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg09915433	chr19:53449742	NA	-0.79	-11.47	-0.68	2.53e-22	Psoriasis;
PAAD	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.55	-4.47	-0.34	1.49e-5	QRS complex (12-leadsum);
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Electroencephalogram traits;
PAAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	5.43	0.4	2.2e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg12288994	chr5:1860383	NA	0.61	7.05	0.5	5.8200000000000003e-11	Cardiovascular disease risk factors;
PAAD	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-0.93	-9.46	-0.61	5.66e-17	Breast cancer;
PAAD	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.73	-7.01	-0.49	7.25e-11	QRS duration;
PAAD	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg20628663	chr10:43360327	NA	0.76	4.73	0.36	5.06e-6	Pediatric bone mineral content (radius);
PAAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.71	-8.83	-0.58	2.31e-15	Coronary artery disease;
PAAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.6	-7.22	-0.51	2.36e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15128208	chr22:42549153	NA	0.42	4.35	0.33	2.53e-5	Cognitive function;
PAAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.46	0.65	1.26e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg16211469	chr6:24423932	MRS2	-0.56	-5.26	-0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16417436	chr16:28758564	NA	0.47	4.41	0.34	1.96e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.8	-9.51	-0.61	3.98e-17	DNA methylation (variation);
PAAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-4.37	-0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.53	7.05	0.5	5.87e-11	Primary biliary cholangitis;
PAAD	cis	rs9815354	0.638	rs73073302	chr3:42029879	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4356203	0.870	rs1979603	chr11:17283386	A/G	cg15432903	chr11:17409602	KCNJ11	-0.47	-4.8	-0.36	3.7e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.19	0.39	6.72e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.67	-8.07	-0.55	1.97e-13	Eye color traits;
PAAD	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.54	5.3	0.39	4.05e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg21951975	chr1:209979733	IRF6	-0.59	-5.26	-0.39	4.75e-7	Coronary artery disease;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	4.97	0.37	1.81e-6	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.85	-9.65	-0.62	1.75e-17	Prudent dietary pattern;
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.75	-5.71	-0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.82	-0.36	3.47e-6	Height;
PAAD	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.48	6.36	0.46	2.28e-9	Height;
PAAD	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.87	9.93	0.63	3.18e-18	Obesity-related traits;
PAAD	cis	rs16852403	0.619	rs6685876	chr1:178135119	G/A	cg00404053	chr1:178313656	RASAL2	0.45	4.49	0.34	1.37e-5	Childhood ear infection;
PAAD	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.66	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs829661	0.793	rs829681	chr2:30708932	A/C	cg12454169	chr2:30669597	LCLAT1	0.64	4.51	0.34	1.28e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.46	-4.74	-0.36	4.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.73	-0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg00922110	chr4:57842668	C4orf14	0.43	4.39	0.34	2.09e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	5.52	0.41	1.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.06	-0.5	5.66e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.64	-6.93	-0.49	1.14e-10	Caffeine consumption;
PAAD	cis	rs2834256	0.552	rs7276923	chr21:34868761	A/G	cg14850771	chr21:34775459	IFNGR2	0.43	4.53	0.35	1.18e-5	Red cell distribution width;
PAAD	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	High light scatter reticulocyte count;
PAAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.62	6.03	0.44	1.21e-8	White matter hyperintensity burden;
PAAD	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.68	5.34	0.4	3.27e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17727725	chr2:131485262	GPR148	0.6	6.59	0.47	6.97e-10	Obesity-related traits;
PAAD	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg15017067	chr4:17643749	FAM184B	0.44	4.84	0.37	3.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs639012	0.660	rs659023	chr11:85824859	C/T	cg07180834	chr11:85838833	NA	0.46	5.38	0.4	2.79e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg06057569	chr22:50219754	BRD1	0.68	5.05	0.38	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.37	-0.4	2.83e-7	Cognitive function;
PAAD	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.52	-4.71	-0.36	5.6e-6	Alzheimer's disease biomarkers;
PAAD	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.98	9.1	0.59	4.82e-16	Migraine;
PAAD	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.87	-0.43	2.64e-8	Mood instability;
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg08501292	chr6:25962987	TRIM38	0.74	4.28	0.33	3.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs5417	0.636	rs427784	chr17:7157516	C/T	cg13768953	chr17:7114967	DLG4	0.41	4.84	0.37	3.23e-6	Diastolic blood pressure;
PAAD	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.55	-6.08	-0.44	9.25e-9	Colorectal cancer;
PAAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg09455208	chr3:40491958	NA	0.45	5.8	0.43	3.7e-8	Renal cell carcinoma;
PAAD	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.78	-5.24	-0.39	5.24e-7	HDL cholesterol;
PAAD	cis	rs608114	0.623	rs75651193	chr6:96340394	A/T	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg23920097	chr1:209922102	NA	-0.46	-4.48	-0.34	1.44e-5	Red blood cell count;
PAAD	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.841	rs73206883	chr12:110849549	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	4.86	0.37	2.88e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-7.97	-0.54	3.42e-13	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.29	-0.39	4.28e-7	Lung cancer;
PAAD	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg27519958	chr1:161735129	ATF6	-0.65	-6.84	-0.49	1.79e-10	IgG glycosylation;
PAAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.29	14.27	0.76	7.5e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Acylcarnitine levels;
PAAD	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs12438356	0.881	rs12437632	chr15:69575082	A/T	cg02375503	chr15:69591110	PAQR5	-0.52	-4.26	-0.33	3.53e-5	CTACK levels;
PAAD	cis	rs62238980	0.808	rs78293816	chr22:32598529	C/T	cg00543991	chr22:32367038	NA	1.18	6.25	0.45	4.03e-9	Childhood ear infection;
PAAD	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-0.87	-8.92	-0.59	1.37e-15	Lymphocyte counts;
PAAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg05785598	chr3:49045655	WDR6	0.41	4.86	0.37	2.87e-6	Parkinson's disease;
PAAD	cis	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg21546286	chr11:48923668	NA	0.57	5.96	0.44	1.68e-8	HDL cholesterol;
PAAD	cis	rs4343996	0.869	rs4719944	chr7:3496032	A/G	cg21248987	chr7:3385318	SDK1	0.52	5.82	0.43	3.31e-8	Motion sickness;
PAAD	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.94	9.04	0.59	6.97e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	5.52	0.41	1.44e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg17372657	chr7:1216933	NA	-0.37	-4.6	-0.35	8.77e-6	Longevity;Endometriosis;
PAAD	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.67	6.36	0.46	2.22e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.79	8.1	0.55	1.62e-13	Vitiligo;
PAAD	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.57	-4.99	-0.38	1.61e-6	Life satisfaction;
PAAD	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg03894339	chr8:19674705	INTS10	0.45	4.34	0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg05585544	chr11:47624801	NA	-0.49	-5.53	-0.41	1.37e-7	Subjective well-being;
PAAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7561149	0.966	rs12471428	chr2:179687519	A/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	-0.49	-4.63	-0.35	7.9e-6	QT interval;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.84	6.71	0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.22	0.55	8.33e-14	Schizophrenia;
PAAD	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg18612461	chr15:75251733	NA	0.53	4.92	0.37	2.21e-6	Blood trace element (Zn levels);
PAAD	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs1519814	1.000	rs7000609	chr8:121106264	C/T	cg22335954	chr8:121166405	COL14A1	0.63	5.54	0.41	1.28e-7	Breast cancer;
PAAD	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.64	6.32	0.46	2.76e-9	Height;
PAAD	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg01851573	chr8:8652454	MFHAS1	0.58	5.06	0.38	1.19e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	4.83	0.36	3.28e-6	Verbal declarative memory;
PAAD	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.5	0.71	4.04e-25	Breast cancer;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.6	-5.47	-0.41	1.79e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs150268548	1	rs150268548	chr19:19494483	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	4.39	0.34	2.14e-5	LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;Response to fenofibrate (LDL cholesterol levels);
PAAD	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg08888203	chr3:10149979	C3orf24	-0.66	-6.04	-0.44	1.14e-8	Alzheimer's disease;
PAAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.82	10.25	0.64	4.56e-19	Methadone dose in opioid dependence;
PAAD	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.59e-21	Ulcerative colitis;
PAAD	cis	rs62264129	0.500	rs9816969	chr3:112037942	G/A	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.92	-0.37	2.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.62	5.81	0.43	3.57e-8	Menopause (age at onset);
PAAD	cis	rs6137287	0.668	rs6047257	chr20:21095977	C/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.76	0.36	4.54e-6	Height;
PAAD	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-6.39	-0.46	1.88e-9	Mean platelet volume;
PAAD	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.5	4.97	0.37	1.78e-6	Mean corpuscular volume;
PAAD	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.7	6.72	0.48	3.47e-10	Obesity-related traits;
PAAD	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.92	10.79	0.66	1.61e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs6711012	chr2:624034	C/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg13175981	chr1:150552382	MCL1	0.64	5.81	0.43	3.5e-8	Urate levels;
PAAD	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg18700516	chr19:44507157	ZNF230	0.7	5.42	0.4	2.3e-7	Alzheimer's disease;
PAAD	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg08079166	chr15:68083412	MAP2K5	0.68	5.33	0.4	3.53e-7	Restless legs syndrome;
PAAD	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.53	-5.44	-0.4	2.05e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg10356904	chr22:49881777	NA	-0.48	-5.21	-0.39	6.16e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.63	4.46	0.34	1.58e-5	Post bronchodilator FEV1;
PAAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg05725404	chr16:58534157	NDRG4	-0.79	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16316695	chr8:29120748	KIF13B	0.62	7.29	0.51	1.55e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.2	0.39	6.46e-7	Lung cancer;
PAAD	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	5.24	0.39	5.31e-7	Motion sickness;
PAAD	cis	rs10214930	0.767	rs42087	chr7:27700482	C/T	cg22168087	chr7:27702803	HIBADH	-0.53	-4.77	-0.36	4.3e-6	Hypospadias;
PAAD	cis	rs2004318	1.000	rs75132967	chr19:55077987	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg02376097	chr19:46275166	DMPK	-0.52	-5.11	-0.38	9.67e-7	Coronary artery disease;
PAAD	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg23032965	chr3:12705835	RAF1	0.62	4.53	0.35	1.17e-5	Cholesterol, total;
PAAD	cis	rs7071247	0.915	rs3740474	chr10:105274941	C/T	cg20028483	chr10:104949090	NT5C2	0.58	4.3	0.33	3.01e-5	Platelet aggregation;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg07167872	chr1:205819463	PM20D1	0.54	5.08	0.38	1.11e-6	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs669446	0.558	rs594293	chr1:44109199	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-4.38	-0.33	2.22e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs2615061	0.580	rs943759	chr1:225886318	C/T	cg24405179	chr1:226411259	MIXL1	0.52	4.46	0.34	1.58e-5	Monocyte count;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.56	-5.39	-0.4	2.7e-7	Multiple sclerosis;
PAAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	1.17	11.88	0.69	1.91e-23	Eosinophil percentage of granulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09984469	chr2:72372162	CYP26B1	-0.55	-6.39	-0.46	1.95e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.74	6.95	0.49	1.03e-10	Obesity-related traits;
PAAD	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-10.62	-0.65	4.72e-20	Ulcerative colitis;
PAAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.68	-0.35	6.28e-6	Breast cancer;
PAAD	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg18612461	chr15:75251733	NA	0.69	8.91	0.59	1.49e-15	Breast cancer;
PAAD	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg08562672	chr19:21860753	NA	0.42	4.42	0.34	1.91e-5	Pain;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.49	4.73	0.36	5.03e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09754948	chr16:28834200	ATXN2L	-0.46	-4.7	-0.36	5.75e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.47	4.54	0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg20487152	chr13:99095054	FARP1	-0.49	-4.77	-0.36	4.25e-6	Neuroticism;
PAAD	trans	rs901683	0.850	rs76879426	chr10:46044857	G/A	cg12869334	chr8:37699360	GPR124	0.98	6.79	0.48	2.32e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg18135206	chr14:102964638	TECPR2	0.65	5.26	0.39	4.9e-7	Blood protein levels;
PAAD	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.86	6.64	0.47	5.22e-10	Axial length;
PAAD	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.73	7.01	0.49	7.45e-11	Coronary artery disease;
PAAD	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg09659197	chr4:152720779	NA	0.36	5.29	0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.5	0.47	1.11e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg02696790	chr15:75250997	RPP25	-0.41	-4.93	-0.37	2.14e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14939300	chr17:8199012	SLC25A35	0.63	6.4	0.46	1.78e-9	Obesity-related traits;
PAAD	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.59	0.35	9.14e-6	HDL cholesterol;
PAAD	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	4.94	0.37	2.02e-6	Educational attainment;
PAAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.72	7.95	0.54	3.99e-13	Mood instability;
PAAD	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.81	6.33	0.46	2.58e-9	Weight;
PAAD	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg10820045	chr2:198174542	NA	0.53	5.34	0.4	3.31e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.6	-0.35	9.02e-6	Personality dimensions;
PAAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg20003494	chr4:90757398	SNCA	-0.66	-6.19	-0.45	5.22e-9	Neuroticism;
PAAD	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.55	6.03	0.44	1.2e-8	Heart rate;
PAAD	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.68	-0.53	1.77e-12	Hemoglobin concentration;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.78	7.71	0.53	1.56e-12	Total body bone mineral density;
PAAD	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg11441379	chr12:63026424	NA	0.85	6.3	0.45	3.13e-9	IgG glycosylation;
PAAD	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg00531865	chr16:30841666	NA	0.52	5.02	0.38	1.4e-6	Dementia with Lewy bodies;
PAAD	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg23461800	chr14:103021989	NA	-0.56	-4.58	-0.35	9.69e-6	Platelet count;
PAAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg18769074	chr3:133464867	TF	0.45	5.55	0.41	1.27e-7	Iron status biomarkers;
PAAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.64	4.98	0.37	1.72e-6	Gut microbiome composition (summer);
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.28	-0.39	4.35e-7	Mean platelet volume;
PAAD	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.34	-0.51	1.18e-11	Mood instability;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	2e-13	Alzheimer's disease;
PAAD	cis	rs12304921	0.872	rs4768869	chr12:51347029	G/A	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.31	-0.33	2.91e-5	Type 2 diabetes;
PAAD	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.91	-8.72	-0.58	4.55e-15	Asthma;
PAAD	trans	rs7172971	0.688	rs76996351	chr15:42382689	T/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.09	-0.38	1.04e-6	Body mass index;
PAAD	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs7202877	0.610	rs247442	chr16:75464621	C/T	cg03315344	chr16:75512273	CHST6	-0.62	-4.35	-0.33	2.45e-5	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00540400	chr15:79124168	NA	0.57	6.5	0.47	1.07e-9	Coronary artery disease;
PAAD	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.45	4.35	0.33	2.53e-5	Prostate-specific antigen levels;
PAAD	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg11204139	chr17:3907470	NA	0.68	6.84	0.49	1.78e-10	Type 2 diabetes;
PAAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.67	0.35	6.65e-6	Renal cell carcinoma;
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.58	7.48	0.52	5.58e-12	Hypertriglyceridemia;
PAAD	cis	rs8067287	0.634	rs17793572	chr17:16843992	A/G	cg26910001	chr17:16838321	NA	0.48	4.65	0.35	7.21e-6	Diabetic kidney disease;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg20558230	chr5:484149	SLC9A3	-0.32	-4.39	-0.34	2.14e-5	Cystic fibrosis severity;
PAAD	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.61	0.47	6.19e-10	Schizophrenia;
PAAD	cis	rs757978	0.929	rs115271170	chr2:242347614	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.83	-4.95	-0.37	1.96e-6	Chronic lymphocytic leukemia;
PAAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.14	-0.5	3.55e-11	Coronary artery disease;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.65	-0.53	2.11e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.94	13.7	0.74	2.43e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg06815965	chr1:205818668	PM20D1	0.6	6.59	0.47	6.63e-10	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.66	7.11	0.5	4.27e-11	Multiple sclerosis;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.75	8.83	0.58	2.38e-15	Morning vs. evening chronotype;
PAAD	cis	rs728616	0.558	rs17616958	chr10:82137461	A/G	cg19423196	chr10:82049429	MAT1A	0.48	4.62	0.35	8.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.67	-6.72	-0.48	3.48e-10	Body mass index;
PAAD	cis	rs929596	0.531	rs2741013	chr2:234509911	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.69	-0.36	6.1e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs9395066	0.527	rs12524069	chr6:44897973	C/A	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs12936587	0.633	rs12946845	chr17:17509010	A/C	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.45	-0.34	1.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs12476592	0.516	rs196124	chr2:63854138	A/G	cg10828910	chr2:63850056	LOC388955	0.5	4.27	0.33	3.36e-5	Childhood ear infection;
PAAD	cis	rs28655083	0.529	rs645878	chr16:77099974	G/A	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07499643	chr1:43424067	SLC2A1	0.66	7.48	0.52	5.6e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9810890	1.000	rs116142295	chr3:128447372	G/C	cg19129842	chr3:128565090	NA	-0.86	-5.4	-0.4	2.48e-7	Dental caries;
PAAD	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs4443100	0.958	rs9620213	chr22:23395411	A/C	cg14186256	chr22:23484241	RTDR1	0.55	4.85	0.37	3e-6	Serum parathyroid hormone levels;
PAAD	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg05299278	chr17:33885742	SLFN14	-0.45	-5.28	-0.39	4.37e-7	Platelet count;Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.7e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.03	6.77	0.48	2.6200000000000003e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.21	-0.39	6.12e-7	Monocyte count;
PAAD	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.82	10.3	0.64	3.3e-19	Alcohol dependence;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs546131	0.642	rs566798	chr11:34852277	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-4.77	-0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.93	4.76	0.36	4.45e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg08200582	chr11:442649	ANO9	0.51	4.37	0.33	2.31e-5	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.13e-6	Life satisfaction;
PAAD	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg14055004	chr2:241860995	NA	0.29	4.58	0.35	9.45e-6	Joint mobility (Beighton score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12583908	chr3:186524777	RFC4	0.62	7.35	0.51	1.13e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.79	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg07416916	chr2:36825888	FEZ2	0.47	4.6	0.35	8.75e-6	Height;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Mosquito bite size;
PAAD	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	12.46	0.71	5.28e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs901683	1.000	rs35183191	chr10:46080617	C/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.6	7.05	0.5	5.98e-11	Dementia with Lewy bodies;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.85	-9.63	-0.62	1.97e-17	Prudent dietary pattern;
PAAD	cis	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.34	-0.4	3.31e-7	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20074042	chr10:33625992	NA	0.55	6.37	0.46	2.13e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.36	-0.4	3e-7	Retinal vascular caliber;
PAAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.98	9.57	0.61	2.84e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7818688	0.697	rs76631135	chr8:95980988	G/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs332507	0.830	rs879535	chr3:124400107	A/G	cg05980111	chr3:124395277	KALRN	0.42	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs17520351	0.609	rs75254222	chr1:95371277	G/C	cg01812146	chr1:94704178	ARHGAP29	0.85	4.46	0.34	1.61e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg03732007	chr1:2071316	PRKCZ	-0.47	-4.95	-0.37	1.95e-6	Height;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg21226059	chr5:178986404	RUFY1	0.52	5.71	0.42	5.63e-8	Lung cancer;
PAAD	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg17105886	chr17:28927953	LRRC37B2	0.77	5.01	0.38	1.49e-6	Body mass index;
PAAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg00990874	chr7:1149470	C7orf50	-0.73	-5.69	-0.42	6.22e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15930798	chr12:93836055	UBE2N	-0.73	-6.52	-0.47	9.8e-10	Neuroticism;
PAAD	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-4.41	-0.34	1.98e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18800827	chr17:42633783	FZD2	-0.63	-8.05	-0.55	2.27e-13	Body fat percentage;
PAAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg10589385	chr1:150898437	SETDB1	0.39	4.8	0.36	3.8e-6	Melanoma;
PAAD	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.5	4.71	0.36	5.62e-6	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08330117	chr8:90770456	RIPK2	0.59	6.36	0.46	2.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12311304	0.932	rs12301533	chr12:15384217	T/C	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.47	5.13	0.38	8.87e-7	Migraine;
PAAD	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.62	-5.64	-0.42	7.91e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs863345	0.564	rs10908662	chr1:158489200	C/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.84	0.37	3.18e-6	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04108811	chr1:246670728	SMYD3	-0.64	-6.59	-0.47	6.82e-10	Smoking initiation;
PAAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs58521262	0.585	rs2548898	chr19:23212933	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19346786	chr7:2764209	NA	0.36	4.99	0.38	1.62e-6	Height;
PAAD	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.56	6.14	0.45	6.86e-9	Menopause (age at onset);
PAAD	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg02404636	chr22:31891804	SFI1	-0.57	-5.19	-0.39	6.76e-7	Colorectal cancer;
PAAD	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg19978312	chr5:179634688	RASGEF1C	0.45	4.55	0.35	1.11e-5	LDL cholesterol;
PAAD	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg10006428	chr1:248814059	OR2T27	0.37	4.45	0.34	1.66e-5	Common traits (Other);
PAAD	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	0.98	6.11	0.44	7.97e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg18209359	chr17:80159595	CCDC57	0.47	4.73	0.36	5.09e-6	Life satisfaction;
PAAD	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.79	9.95	0.63	2.8e-18	Cancer;
PAAD	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.24	0.67	1.05e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.67	6.99	0.49	8.11e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs62025270	0.806	rs62025262	chr15:86293233	G/A	cg13263323	chr15:86062960	AKAP13	0.6	5.58	0.41	1.1e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.74	-7.33	-0.51	1.25e-11	Neuroticism;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.45	-6.96	-0.49	9.32e-11	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6723108	0.603	rs62168897	chr2:135717997	C/T	cg26890182	chr2:135621176	ACMSD	0.32	4.51	0.34	1.29e-5	Type 2 diabetes;
PAAD	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.7	6.79	0.48	2.4e-10	Total body bone mineral density;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21016266	chr12:122356598	WDR66	-0.46	-4.63	-0.35	7.7e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg05313129	chr8:58192883	C8orf71	-0.65	-6.05	-0.44	1.06e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs349045	0.560	rs10416177	chr19:44301543	G/T	cg21496419	chr19:44306685	LYPD5	-0.36	-4.38	-0.33	2.2e-5	Reading or mathematical ability;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03257107	chr10:97514275	ENTPD1	-0.59	-6.91	-0.49	1.24e-10	Obesity-related traits;
PAAD	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13198984	chr17:80129470	CCDC57	-0.36	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs11264799	1.000	rs11264799	chr1:157670757	A/G	cg18268488	chr1:157545234	FCRL4	-0.5	-4.78	-0.36	4.17e-6	IgA nephropathy;
PAAD	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.66	6.39	0.46	1.97e-9	Asthma;
PAAD	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	9.43	0.61	6.58e-17	Ulcerative colitis;
PAAD	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg27449745	chr7:23145252	KLHL7	-0.52	-4.41	-0.34	1.97e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg08698997	chr16:88989212	CBFA2T3	0.46	5.95	0.43	1.79e-8	Social autistic-like traits;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.78	-8.83	-0.58	2.38e-15	Height;
PAAD	cis	rs4919087	0.715	rs1253387	chr10:99032968	G/A	cg06569542	chr10:98946673	SLIT1	0.5	4.91	0.37	2.3e-6	Monocyte count;
PAAD	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	1.02	5.71	0.42	5.7e-8	Breast cancer;
PAAD	cis	rs11168618	0.810	rs11168595	chr12:48868211	C/T	cg01881778	chr12:48919444	OR8S1	-0.49	-4.92	-0.37	2.19e-6	Adiponectin levels;
PAAD	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.56	-4.5	-0.34	1.33e-5	Blood protein levels;
PAAD	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-5.51	-0.41	1.47e-7	Ulcerative colitis;
PAAD	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg18357645	chr12:58087776	OS9	0.46	4.63	0.35	7.93e-6	Multiple sclerosis;
PAAD	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.79	7.4	0.51	8.67e-12	Mean platelet volume;
PAAD	cis	rs6456156	0.904	rs2023305	chr6:167524898	A/G	cg07741184	chr6:167504864	NA	0.35	4.56	0.35	1.06e-5	Primary biliary cholangitis;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07565710	chr19:44805345	ZNF235	-0.56	-6.58	-0.47	7.23e-10	Energy expenditure (24h);
PAAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.71	8.17	0.55	1.14e-13	Morning vs. evening chronotype;
PAAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg12193833	chr17:30244370	NA	-0.61	-4.7	-0.36	5.68e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.53	-0.41	1.38e-7	Personality dimensions;
PAAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg05484376	chr2:27715224	FNDC4	0.49	5.01	0.38	1.5e-6	Total body bone mineral density;
PAAD	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-4.55	-0.35	1.11e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.73	7.49	0.52	5.36e-12	Schizophrenia;
PAAD	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.78	0.42	4.15e-8	Colorectal cancer;
PAAD	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg21823605	chr1:152486609	CRCT1	0.52	5.71	0.42	5.85e-8	Hair morphology;
PAAD	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg04317338	chr11:64019027	PLCB3	0.64	4.49	0.34	1.41e-5	Mean platelet volume;
PAAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs6460942	0.908	rs6979046	chr7:12232744	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.53	5.46	0.4	1.89e-7	Personality dimensions;
PAAD	cis	rs13242816	1.000	rs2191498	chr7:116138569	C/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg12395012	chr8:11607386	GATA4	-0.44	-4.45	-0.34	1.63e-5	Neuroticism;
PAAD	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-6.95	-0.49	1e-10	Schizophrenia (age at onset);
PAAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.79e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.75	7.76	0.53	1.15e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg05341575	chr12:125625032	AACS	-0.54	-5.1	-0.38	1.01e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.48	-4.95	-0.37	1.94e-6	Menarche (age at onset);
PAAD	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg02696790	chr15:75250997	RPP25	0.41	4.47	0.34	1.54e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.63	7.11	0.5	4.33e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1797885	0.714	rs299639	chr3:12533335	A/C	cg07775309	chr3:12595852	NA	0.4	4.39	0.34	2.1e-5	Immature fraction of reticulocytes;
PAAD	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg00614314	chr15:82944287	LOC80154	0.6	6.18	0.45	5.62e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg23024343	chr7:107201750	COG5	0.55	4.64	0.35	7.5e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11422695	chr6:41994020	CCND3	-0.71	-7.68	-0.53	1.79e-12	Obesity-related traits;
PAAD	cis	rs7168353	0.519	rs8028642	chr15:93638128	G/A	cg02918577	chr15:93633145	RGMA	0.38	5.09	0.38	1.02e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs3106136	0.617	rs6839950	chr4:95282772	C/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.55	7.35	0.51	1.17e-11	Renal cell carcinoma;
PAAD	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg15208524	chr1:10270712	KIF1B	0.48	4.36	0.33	2.35e-5	Hepatocellular carcinoma;
PAAD	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg18898632	chr2:242989856	NA	-0.8	-5.69	-0.42	6.32e-8	Obesity-related traits;
PAAD	cis	rs10261878	0.826	rs59344953	chr7:26009668	G/T	cg01322214	chr7:25219198	C7orf31	1.03	4.29	0.33	3.2e-5	Body mass index;
PAAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs7873102	0.702	rs10758467	chr9:37970485	G/A	cg03528946	chr9:38069800	SHB	0.59	6.09	0.44	9.05e-9	Brain structure;
PAAD	cis	rs9810890	1.000	rs114441742	chr3:128547271	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs6762477	0.748	rs11714799	chr3:50217899	T/G	cg24110177	chr3:50126178	RBM5	0.67	6.92	0.49	1.19e-10	Menarche (age at onset);
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg13207630	chr7:32358064	NA	-0.8	-4.47	-0.34	1.53e-5	Body mass index;
PAAD	cis	rs2320952	0.874	rs2063272	chr17:10489808	C/T	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.62	5.95	0.43	1.74e-8	Uric acid clearance;
PAAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	4.6	0.35	9.02e-6	Menarche (age at onset);
PAAD	cis	rs160189	0.834	rs9989553	chr18:77230355	G/C	cg15644404	chr18:77186268	NFATC1	-0.54	-4.43	-0.34	1.82e-5	Mean platelet volume;
PAAD	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.15	-9.44	-0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-5.25	-0.39	5.05e-7	Educational attainment;
PAAD	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs2240255	0.657	rs2240253	chr16:74771844	G/T	cg01733217	chr16:74700730	RFWD3	-0.49	-4.6	-0.35	8.73e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg26939375	chr7:64535504	NA	-0.75	-8.92	-0.59	1.36e-15	Aortic root size;
PAAD	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.56	-5.33	-0.4	3.46e-7	Obesity-related traits;
PAAD	cis	rs733175	0.830	rs6813650	chr4:10061060	T/G	cg00071950	chr4:10020882	SLC2A9	0.49	4.32	0.33	2.83e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg02696790	chr15:75250997	RPP25	0.49	5.85	0.43	2.84e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.81	-0.43	3.46e-8	Lung cancer;
PAAD	cis	rs258892	0.895	rs155429	chr5:72108080	G/A	cg21869765	chr5:72125136	TNPO1	-0.8	-5.32	-0.4	3.63e-7	Small cell lung carcinoma;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7853377	0.760	rs7033292	chr9:86525580	G/A	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg23920097	chr1:209922102	NA	-0.51	-4.59	-0.35	9.35e-6	Red blood cell count;
PAAD	cis	rs6074578	0.679	rs12480529	chr20:137454	T/G	cg16931068	chr20:139680	DEFB127	0.38	5.11	0.38	9.41e-7	Hirschsprung disease;
PAAD	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg26570165	chr1:119541833	NA	-0.47	-4.32	-0.33	2.8e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11203032	0.831	rs11203011	chr10:90931178	A/C	cg16672925	chr10:90967113	CH25H	0.61	4.84	0.37	3.16e-6	Heart failure;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.86	10.11	0.63	1.09e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.88	10.81	0.66	1.46e-20	Menopause (age at onset);
PAAD	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.5	0.34	1.36e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.25	-0.51	2.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.43	-0.34	1.76e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.64	-6.07	-0.44	9.63e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.62	5.9	0.43	2.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.71	4.94	0.37	2.02e-6	Cannabis dependence symptom count;
PAAD	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.95	-8.08	-0.55	1.91e-13	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00724774	chr19:1812282	ATP8B3	0.69	6.6	0.47	6.45e-10	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.83	8.18	0.55	1.04e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-4.37	-0.33	2.3e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs4792901	0.802	rs55956367	chr17:41582284	A/G	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.74	8.65	0.57	6.91e-15	Lung cancer;
PAAD	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.73	0.36	5e-6	Schizophrenia;
PAAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.66	7.54	0.52	3.97e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.63	-7.61	-0.53	2.71e-12	Longevity;Endometriosis;
PAAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.88e-9	Blood metabolite levels;
PAAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	cis	rs7572733	0.792	rs1064213	chr2:198950240	G/A	cg10820045	chr2:198174542	NA	0.46	4.51	0.34	1.3e-5	Dermatomyositis;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs11078597	0.731	rs2287322	chr17:1641035	A/G	cg18436246	chr17:1640651	WDR81	0.85	7.74	0.53	1.27e-12	Serum albumin level;
PAAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.08	-0.38	1.1e-6	Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	cis	rs1823874	0.581	rs12910401	chr15:100339897	T/C	cg16400843	chr15:100339927	C15orf51	0.52	6.28	0.45	3.33e-9	IgG glycosylation;
PAAD	cis	rs818427	1.000	rs712664	chr5:112223601	A/C	cg06941702	chr5:112196734	SRP19	0.48	4.49	0.34	1.4e-5	Total body bone mineral density;
PAAD	cis	rs2271001	0.910	rs11604483	chr11:19144579	C/T	cg00161556	chr11:19138045	ZDHHC13	0.52	5.71	0.42	5.65e-8	Gut microbiome composition (winter);
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.71	-4.64	-0.35	7.47e-6	Body mass index;
PAAD	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg21994712	chr19:21861136	NA	0.45	4.27	0.33	3.47e-5	Pain;
PAAD	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-4.46	-0.34	1.57e-5	Resting heart rate;
PAAD	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.44	-5.94	-0.43	1.87e-8	Type 1 diabetes;
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09826364	chr7:158789723	NA	-0.4	-5.12	-0.38	9.15e-7	Facial morphology (factor 20);
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg00701064	chr4:6280414	WFS1	0.87	10.16	0.64	7.76e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg17644776	chr2:200775616	C2orf69	0.57	4.91	0.37	2.32e-6	Schizophrenia;
PAAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.59	5.82	0.43	3.44e-8	Blood metabolite levels;
PAAD	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.55	-5.11	-0.38	9.58e-7	Subjective well-being;
PAAD	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.56	5.27	0.39	4.65e-7	Schizophrenia;
PAAD	cis	rs2555155	0.935	rs2555157	chr11:6521354	T/C	cg24637308	chr11:6592297	DNHD1	0.47	4.79	0.36	3.99e-6	DNA methylation (variation);
PAAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.45	-0.34	1.65e-5	Menarche (age at onset);
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-6.43	-0.46	1.57e-9	Electroencephalogram traits;
PAAD	cis	rs877529	0.967	rs139410	chr22:39552597	A/G	cg13455509	chr22:39551605	NA	-0.45	-4.46	-0.34	1.59e-5	Multiple myeloma;
PAAD	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.77	-8.2	-0.55	9.51e-14	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13683516	chr12:56618066	OBFC2B	0.55	6.31	0.46	2.84e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21012866	chr6:10747898	TMEM14B	0.62	6.51	0.47	1.01e-9	Myopia (pathological);
PAAD	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs7742824	0.843	rs55772024	chr6:44078830	G/A	cg21657043	chr6:44035552	NA	0.44	4.83	0.36	3.27e-6	Major depressive disorder;
PAAD	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.93	10.41	0.64	1.75e-19	Testicular germ cell tumor;
PAAD	cis	rs8105895	0.935	rs62110986	chr19:22256771	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.87	10.09	0.63	1.18e-18	Ulcerative colitis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03519263	chr14:21152327	RNASE4;ANG	-0.54	-6.47	-0.46	1.25e-9	Body fat percentage;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17030841	chr2:240323363	HDAC4	-0.63	-6.51	-0.47	1.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.813	rs12700825	chr7:27672571	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.16	10.02	0.63	1.84e-18	Vitiligo;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18297960	chr7:1142765	C7orf50	-0.55	-4.33	-0.33	2.7e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg07148914	chr20:33460835	GGT7	0.49	4.85	0.37	3.08e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs13273891	1.000	rs7823853	chr8:58986160	C/G	cg05901852	chr8:59757290	TOX	0.5	4.83	0.37	3.23e-6	Pit-and-Fissure caries;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs9913156	0.517	rs11868227	chr17:4614539	G/A	cg19197139	chr17:4613644	ARRB2	0.6	6.38	0.46	2.01e-9	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.45	5.55	0.41	1.25e-7	Iron status biomarkers;
PAAD	trans	rs12127679	0.688	rs12117180	chr1:244163538	A/G	cg03519879	chr14:74227499	C14orf43	0.9	6.93	0.49	1.11e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.69	5.1	0.38	9.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs2000999	0.524	rs12933482	chr16:72189604	A/G	cg00207534	chr16:71929512	KIAA0174	0.73	4.5	0.34	1.32e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg15674680	chr20:60982522	CABLES2	0.57	4.89	0.37	2.56e-6	Colorectal cancer;
PAAD	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.46	-0.46	1.35e-9	Triglycerides;
PAAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg16083429	chr3:49237500	CCDC36	0.45	4.41	0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26816564	chr1:7831052	VAMP3	0.95	7.83	0.54	7.54e-13	Inflammatory bowel disease;
PAAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-4.32	-0.33	2.83e-5	IFN-related cytopenia;
PAAD	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.53	-0.41	1.38e-7	Mood instability;
PAAD	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg06096015	chr1:231504339	EGLN1	-0.59	-6.46	-0.46	1.34e-9	Red blood cell count;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11974710	chr17:55334278	MSI2	-0.57	-6.53	-0.47	9.24e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15456646	chr14:60716665	PPM1A	-0.75	-8.15	-0.55	1.26e-13	Smoking initiation;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.21	0.39	5.94e-7	Life satisfaction;
PAAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-5.9	-0.43	2.31e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02635644	chr1:981164	AGRN	-0.61	-7.11	-0.5	4.25e-11	Monocyte percentage of white cells;
PAAD	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.53	6.31	0.46	2.97e-9	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.7	-9.34	-0.6	1.14e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.99	8.98	0.59	9.62e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg23950597	chr19:37808831	NA	-0.8	-5.6	-0.41	9.74e-8	Coronary artery calcification;
PAAD	cis	rs1891275	0.551	rs2421626	chr10:93420934	G/C	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.61	4.56	0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	trans	rs12714314	0.830	rs10207910	chr2:1963781	T/C	cg17170872	chr1:91487911	ZNF644	-0.74	-6.41	-0.46	1.77e-9	Type 2 diabetes (age of onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07243141	chr7:73408060	NA	-0.57	-6.61	-0.47	6.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.97e-6	Neuroticism;
PAAD	cis	rs9364554	0.718	rs2048327	chr6:160863532	C/T	cg25313204	chr6:160768801	SLC22A3	-0.48	-4.38	-0.33	2.18e-5	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.69	5.74	0.42	4.93e-8	Common traits (Other);
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.89	-0.49	1.39e-10	Life satisfaction;
PAAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.44e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.04	-0.38	1.31e-6	Obesity-related traits;
PAAD	cis	rs2790457	0.874	rs2790446	chr10:28801030	A/G	cg05705492	chr10:28955341	NA	-0.44	-4.25	-0.33	3.7e-5	Multiple myeloma;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.71	-5.91	-0.43	2.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg02683114	chr2:24398427	C2orf84	-0.58	-6.21	-0.45	4.78e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg02250501	chr15:90694978	NA	-0.47	-4.44	-0.34	1.71e-5	Rheumatoid arthritis;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg00280220	chr17:61926910	NA	0.42	4.52	0.34	1.25e-5	Prudent dietary pattern;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.47	4.73	0.36	5.14e-6	Lymphocyte counts;
PAAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg14440974	chr22:39074834	NA	-0.58	-6.89	-0.49	1.37e-10	Menopause (age at onset);
PAAD	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-6.02	-0.44	1.25e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs7395662	1.000	rs8189391	chr11:48859789	A/G	cg00717180	chr2:96193071	NA	0.6	6.75	0.48	2.89e-10	HDL cholesterol;
PAAD	cis	rs7650267	0.572	rs17075754	chr3:43564734	T/C	cg07997066	chr3:44154910	MIR138-1	0.55	4.32	0.33	2.83e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.52	0.34	1.21e-5	Iron status biomarkers;
PAAD	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	1.05	10.19	0.64	6.49e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.71	7.48	0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.13	7.48	0.52	5.41e-12	Lung cancer in ever smokers;
PAAD	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2790457	0.874	rs1265840	chr10:28919641	C/T	cg05705492	chr10:28955341	NA	-0.43	-4.36	-0.33	2.41e-5	Multiple myeloma;
PAAD	cis	rs7688540	0.515	rs28415975	chr4:260166	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	4.56	0.35	1.06e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs3136739	0.614	rs8178895	chr8:42032379	A/G	cg12054981	chr8:42037387	PLAT	0.65	4.67	0.35	6.49e-6	Plasma plasminogen activator levels;
PAAD	cis	rs17227506	0.504	rs13282162	chr8:13416411	A/G	cg02718516	chr8:13424094	C8orf48	-0.36	-4.78	-0.36	4.16e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs728616	0.614	rs61859196	chr10:82109048	A/G	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg04851639	chr8:1020857	NA	-0.64	-7.92	-0.54	4.61e-13	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26865002	chr1:1913246	KIAA1751	0.59	6.32	0.46	2.73e-9	Smoking initiation;
PAAD	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.94	-0.43	1.9e-8	Schizophrenia;
PAAD	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.51	5.17	0.39	7.23e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.58	-5.96	-0.44	1.72e-8	Cognitive function;
PAAD	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.67	5.89	0.43	2.4e-8	Coronary heart disease;
PAAD	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.85	9.53	0.61	3.52e-17	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg09873201	chr16:3507582	NAT15	0.53	5.04	0.38	1.3e-6	Tuberculosis;
PAAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.69e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.72	7.74	0.53	1.28e-12	Colorectal cancer;
PAAD	cis	rs3136441	0.892	rs11039024	chr11:46923168	C/T	cg19486271	chr11:47235900	DDB2	0.65	5.08	0.38	1.08e-6	HDL cholesterol;
PAAD	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.6	-5.82	-0.43	3.31e-8	Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs4742903	0.904	rs10124553	chr9:106993898	G/A	cg14250997	chr9:106856677	SMC2	0.46	5.0	0.38	1.59e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg00049323	chr5:472564	LOC25845	-0.46	-4.74	-0.36	4.93e-6	Cystic fibrosis severity;
PAAD	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg00031303	chr3:195681400	NA	0.81	7.95	0.54	3.86e-13	Pancreatic cancer;
PAAD	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Red blood cell count;
PAAD	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs112990264	1.000	rs112990264	chr1:213014537	G/C	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.5	-7.22	-0.51	2.31e-11	Diastolic blood pressure;
PAAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.57	-6.35	-0.46	2.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.59	-6.92	-0.49	1.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.55	5.79	0.42	3.96e-8	Lung cancer;
PAAD	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.35	-4.76	-0.36	4.42e-6	Oropharynx cancer;
PAAD	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.98	-13.76	-0.74	1.69e-28	Post bronchodilator FEV1;
PAAD	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.62	-6.64	-0.47	5.2400000000000005e-10	Longevity;
PAAD	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-5.88	-0.43	2.54e-8	Menarche (age at onset);
PAAD	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.7	-0.48	3.75e-10	Total body bone mineral density;
PAAD	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02244288	chr16:89573955	SPG7	-0.33	-4.29	-0.33	3.19e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.68	8.95	0.59	1.19e-15	Hemoglobin concentration;
PAAD	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.55	6.08	0.44	9.35e-9	Bladder cancer;
PAAD	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.73	6.84	0.49	1.78e-10	Diabetic kidney disease;
PAAD	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-4.66	-0.35	7.01e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.71	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.56	6.11	0.44	7.84e-9	Menopause (age at onset);
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.46	-4.5	-0.34	1.36e-5	Paraoxonase activity;
PAAD	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.89	10.39	0.64	1.93e-19	Obesity-related traits;
PAAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.82	-6.09	-0.44	8.74e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.51	-0.61	3.99e-17	Strep throat;
PAAD	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg10224037	chr5:178157518	ZNF354A	0.63	5.08	0.38	1.11e-6	Neutrophil percentage of white cells;
PAAD	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.86	-9.14	-0.6	3.81e-16	Body mass index;
PAAD	cis	rs4356203	0.905	rs536628	chr11:17208092	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.39	-0.34	2.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs72960926	0.744	rs3846756	chr6:75061918	A/T	cg09351254	chr2:242088885	PASK;PPP1R7	1.11	6.29	0.45	3.27e-9	Metabolite levels (MHPG);
PAAD	cis	rs6669119	0.877	rs76369903	chr1:19112568	A/T	cg26220594	chr1:19110978	NA	0.72	4.32	0.33	2.78e-5	Percentage gas trapping;
PAAD	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg23461800	chr14:103021989	NA	-0.58	-4.39	-0.34	2.14e-5	Platelet count;
PAAD	cis	rs4740619	0.967	rs7032755	chr9:15640025	G/T	cg14451791	chr9:16040625	NA	0.48	5.75	0.42	4.65e-8	Body mass index;
PAAD	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	7.08	0.5	4.92e-11	Mean platelet volume;
PAAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.3	-0.46	2.99e-9	Menarche (age at onset);
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02071572	chr4:1403502	NA	0.43	5.86	0.43	2.8e-8	Obesity-related traits;
PAAD	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.56	4.96	0.37	1.84e-6	Testicular germ cell tumor;
PAAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg09796270	chr17:17721594	SREBF1	-0.47	-5.27	-0.39	4.6e-7	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21437722	chr17:27083271	C17orf63	0.6	6.55	0.47	8.36e-10	Myopia (pathological);
PAAD	cis	rs11615916	0.720	rs73135275	chr12:62683167	T/C	cg11441379	chr12:63026424	NA	0.65	4.4	0.34	2.06e-5	Pulmonary function decline;
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg27394845	chr17:28928406	LRRC37B2	0.63	4.46	0.34	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.61	5.21	0.39	5.95e-7	Mean corpuscular volume;
PAAD	cis	rs829661	0.793	rs829664	chr2:30725733	A/G	cg12454169	chr2:30669597	LCLAT1	0.63	4.47	0.34	1.55e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10819733	chr22:24237672	NA	-0.57	-6.58	-0.47	7.2e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16262614	chr3:133464971	TF	0.51	5.49	0.41	1.68e-7	Iron status biomarkers;
PAAD	cis	rs13065560	0.594	rs4575820	chr3:38886179	A/G	cg01426195	chr3:39028469	NA	0.57	5.67	0.42	6.92e-8	Interleukin-18 levels;
PAAD	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg19254793	chr6:44695348	NA	-0.41	-4.42	-0.34	1.88e-5	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.21	0.39	6.01e-7	Childhood ear infection;
PAAD	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.39	0.51	9.29e-12	IgG glycosylation;
PAAD	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.43	0.34	1.81e-5	Plateletcrit;
PAAD	cis	rs7729447	0.813	rs7715571	chr5:32690010	A/C	cg16267343	chr5:32710456	NPR3	0.45	4.42	0.34	1.83e-5	Blood pressure;
PAAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg05627522	chr15:75251581	NA	-0.52	-6.39	-0.46	1.94e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	4.3	0.33	3e-5	Systolic blood pressure;
PAAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg05874882	chr4:1763078	NA	-0.39	-5.5	-0.41	1.6e-7	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg06633402	chr17:20798895	CCDC144NL	0.71	6.47	0.46	1.28e-9	Photic sneeze reflex;
PAAD	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.6	-5.36	-0.4	3.08e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg13798912	chr7:905769	UNC84A	-0.61	-4.47	-0.34	1.51e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.55	-0.52	3.73e-12	Total body bone mineral density;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.67	6.47	0.46	1.28e-9	Type 2 diabetes;
PAAD	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	0.9	6.22	0.45	4.68e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.55	-5.68	-0.42	6.76e-8	Testicular germ cell tumor;
PAAD	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.5	4.95	0.37	1.92e-6	Mean corpuscular volume;
PAAD	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.74	-8.66	-0.57	6.6e-15	Body mass index;
PAAD	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs11563648	0.553	rs10249162	chr7:127016146	G/T	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.64	6.78	0.48	2.48e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20167471	chr1:16528984	ARHGEF19	0.46	4.49	0.34	1.4e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs939584	1.000	rs13012571	chr2:632550	A/G	cg03610516	chr2:642275	NA	-0.59	-5.32	-0.4	3.7e-7	Body mass index;
PAAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.45	5.76	0.42	4.48e-8	Height;
PAAD	cis	rs4243830	1.000	rs4243832	chr1:6577962	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-6.29	-0.45	3.16e-9	Body mass index;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.94	0.37	2.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26913058	chr16:419975	MRPL28	-0.59	-5.22	-0.39	5.87e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	15.29	0.78	1.52e-32	Testicular germ cell tumor;
PAAD	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.47	-0.57	1.91e-14	Coffee consumption (cups per day);
PAAD	cis	rs7818688	0.697	rs76815619	chr8:95981330	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.53	-0.35	1.17e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg02660097	chr11:68866761	NA	0.43	4.78	0.36	4.17e-6	Blond vs. brown hair color;
PAAD	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg14003231	chr6:33640908	ITPR3	-0.35	-4.41	-0.34	1.94e-5	Plateletcrit;
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.7	6.94	0.49	1.04e-10	Prostate cancer;
PAAD	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.9	0.49	1.3100000000000001e-10	Blood protein levels;
PAAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.87	-10.69	-0.66	3.1e-20	Aortic root size;
PAAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg04398451	chr17:18023971	MYO15A	-1.08	-15.65	-0.79	1.66e-33	Total body bone mineral density;
PAAD	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.5	-4.78	-0.36	4.17e-6	Neutrophil percentage of white cells;
PAAD	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg27511599	chr7:32358540	NA	0.9	4.73	0.36	5.09e-6	Body mass index;
PAAD	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.09	0.38	1.07e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.32	-0.33	2.79e-5	Menarche (age at onset);
PAAD	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7243821	0.921	rs62094068	chr18:52630388	C/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.49	4.43	0.34	1.77e-5	Corneal astigmatism;
PAAD	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.6	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs7188861	0.681	rs9932855	chr16:11406544	G/C	cg16532467	chr16:11454386	NA	-0.57	-4.49	-0.34	1.42e-5	HDL cholesterol;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	4.36	0.33	2.35e-5	Thyroid stimulating hormone;
PAAD	cis	rs6700896	0.966	rs10889570	chr1:66088084	C/G	cg04111102	chr1:66153794	NA	0.43	4.65	0.35	7.2e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg23298862	chr7:158159286	PTPRN2	0.56	4.72	0.36	5.41e-6	Response to amphetamines;
PAAD	cis	rs7631605	0.935	rs6780799	chr3:37162758	G/A	cg17445812	chr3:36986805	TRANK1	0.32	4.26	0.33	3.54e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg09659197	chr4:152720779	NA	0.45	6.15	0.45	6.53e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4588572	0.643	rs9293752	chr5:77798432	A/G	cg18281939	chr5:77783895	LHFPL2	-0.5	-6.1	-0.44	8.23e-9	Triglycerides;
PAAD	cis	rs7382539	1.000	rs7451470	chr6:169667234	C/T	cg16479247	chr6:168716332	DACT2	0.58	5.45	0.4	2.03e-7	Liver disease severity in Alagille syndrome;
PAAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg15510373	chr7:100224934	TFR2	-0.52	-4.25	-0.33	3.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs11051970	0.659	rs73088096	chr12:32584403	G/T	cg24626660	chr12:32551988	NA	0.4	4.27	0.33	3.5e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17331151	0.505	rs34182518	chr3:52743854	G/A	cg27565382	chr3:53032988	SFMBT1	0.95	4.55	0.35	1.08e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	1.0	8.3	0.56	5.37e-14	Vitiligo;
PAAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg10589385	chr1:150898437	SETDB1	0.39	4.74	0.36	4.88e-6	Melanoma;
PAAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs2031532	0.587	rs4942830	chr13:50019376	A/T	cg03651054	chr13:50194643	NA	0.34	4.56	0.35	1.05e-5	Cardiac hypertrophy;
PAAD	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	4.56	0.35	1.04e-5	Refractive astigmatism;
PAAD	cis	rs2458413	1.000	rs2458413	chr8:105359432	C/T	cg04554929	chr8:105342491	NA	0.34	5.57	0.41	1.11e-7	Paget's disease;
PAAD	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.74	-8.82	-0.58	2.44e-15	Blood metabolite ratios;
PAAD	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg18551225	chr6:44695536	NA	0.77	7.61	0.53	2.62e-12	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02737068	chr2:73340007	RAB11FIP5	0.6	6.39	0.46	1.95e-9	Myopia (pathological);
PAAD	cis	rs9944715	0.906	rs4453596	chr18:43749826	T/C	cg00381974	chr18:44260357	ST8SIA5	0.48	4.33	0.33	2.71e-5	Red cell distribution width;Mean corpuscular volume;
PAAD	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.67	8.76	0.58	3.49e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.92	9.78	0.62	8.19e-18	Testicular germ cell tumor;
PAAD	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	1.01	5.89	0.43	2.35e-8	Body mass index;
PAAD	cis	rs755249	0.567	rs61779279	chr1:39837102	C/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs59104589	0.617	rs12233133	chr2:242256812	G/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.69	7.02	0.49	6.9e-11	Schizophrenia;
PAAD	cis	rs4690686	0.538	rs13120287	chr4:177260184	T/C	cg17059388	chr4:177262070	NA	0.54	5.23	0.39	5.57e-7	Essential tremor;
PAAD	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.39	0.4	2.64e-7	Monocyte percentage of white cells;
PAAD	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.63	-6.24	-0.45	4.09e-9	Height;
PAAD	cis	rs12681288	0.821	rs2701944	chr8:1034525	T/A	cg08648136	chr8:956695	NA	0.42	4.36	0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs9942416	0.585	rs253409	chr5:74928069	C/G	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.45	-4.43	-0.34	1.79e-5	Age-related disease endophenotypes;
PAAD	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	5.04	0.38	1.29e-6	Colorectal cancer;
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.9	9.8	0.62	7.07e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-5.98	-0.44	1.5e-8	Longevity;Endometriosis;
PAAD	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7131987	0.641	rs2015599	chr12:29435480	G/A	cg09582351	chr12:29534625	ERGIC2	-0.3	-4.37	-0.33	2.3e-5	QT interval;
PAAD	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg14061069	chr19:46274453	DMPK	0.87	14.3	0.76	6.4e-30	Coronary artery disease;
PAAD	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.81	4.91	0.37	2.28e-6	Obesity-related traits;
PAAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.56	5.18	0.39	7.05e-7	Mood instability;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg13374026	chr7:158955107	NA	-0.5	-4.85	-0.37	3.05e-6	Facial morphology (factor 20);
PAAD	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	cis	rs7765175	0.698	rs3851197	chr6:113666000	C/T	cg19037598	chr6:113666021	NA	-0.42	-4.48	-0.34	1.49e-5	Coronary artery calcification;
PAAD	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.44	5.55	0.41	1.26e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg07469887	chr10:131262384	NA	-0.46	-5.66	-0.42	7.33e-8	Response to temozolomide;
PAAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg02297831	chr4:17616191	MED28	-0.6	-5.86	-0.43	2.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg23241863	chr10:102295624	HIF1AN	0.46	4.27	0.33	3.38e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg12661370	chr5:149340060	SLC26A2	0.56	4.46	0.34	1.62e-5	HIV-1 control;
PAAD	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg13590414	chr9:128173245	NA	-0.47	-4.8	-0.36	3.72e-6	Resting heart rate;
PAAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg20003494	chr4:90757398	SNCA	-0.64	-5.92	-0.43	2.08e-8	Neuroticism;
PAAD	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg02820901	chr13:113351484	ATP11A	-0.73	-4.84	-0.37	3.21e-6	Glycated hemoglobin levels;
PAAD	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.82	-8.9	-0.59	1.59e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg09876464	chr15:85330779	ZNF592	0.44	4.4	0.34	2e-5	P wave terminal force;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs829661	0.894	rs1252625	chr2:30747398	C/A	cg12454169	chr2:30669597	LCLAT1	0.64	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7616330	0.673	rs76188283	chr3:71024696	C/T	cg01511742	chr3:71112437	FOXP1	-0.71	-4.31	-0.33	2.89e-5	QT interval;
PAAD	cis	rs1144333	0.850	rs1144342	chr1:76284364	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.64	-5.95	-0.43	1.76e-8	DNA methylation (variation);
PAAD	cis	rs2730260	0.800	rs73169218	chr7:158836906	T/A	cg02254261	chr7:158964346	NA	-0.6	-4.58	-0.35	9.72e-6	Myopia (pathological);
PAAD	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.59	6.89	0.49	1.39e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg10547527	chr2:198650123	BOLL	-0.73	-4.95	-0.37	1.92e-6	Ulcerative colitis;
PAAD	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.87	-9.56	-0.61	3.03e-17	Chronic sinus infection;
PAAD	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.5	0.61	4.39e-17	Psoriasis;
PAAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.59	5.3	0.4	3.93e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs8025118	0.583	rs16970772	chr15:79546155	C/T	cg24739098	chr15:79297159	RASGRF1	-0.39	-4.38	-0.33	2.2e-5	Cognitive function;
PAAD	cis	rs4759375	0.667	rs28397122	chr12:123848896	G/A	cg05908960	chr12:123472150	PITPNM2	0.65	4.61	0.35	8.57e-6	HDL cholesterol;
PAAD	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg10208897	chr5:178548229	ADAMTS2	-0.54	-4.81	-0.36	3.58e-6	Pubertal anthropometrics;
PAAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg21625146	chr5:486483	SLC9A3	0.36	5.31	0.4	3.75e-7	Cystic fibrosis severity;
PAAD	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.64	0.62	1.91e-17	Diabetic retinopathy;
PAAD	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.72	11.0	0.67	4.63e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs6066835	0.764	rs3091540	chr20:47391481	A/G	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs11614333	1.000	rs7306888	chr12:15052835	A/T	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg18402987	chr7:1209562	NA	1.05	5.35	0.4	3.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.42	0.61	7.14e-17	Post bronchodilator FEV1;
PAAD	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg00700412	chr12:58011837	NA	0.42	4.4	0.34	2.06e-5	Multiple sclerosis;
PAAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.89	11.35	0.68	5.15e-22	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs11264213	0.892	rs12037102	chr1:36261733	T/G	cg27506609	chr1:36549197	TEKT2	0.69	4.73	0.36	5.01e-6	Schizophrenia;
PAAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg19784903	chr17:45786737	TBKBP1	-0.6	-6.55	-0.47	8.24e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.82	8.99	0.59	9.35e-16	Schizophrenia;
PAAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.83	9.54	0.61	3.4e-17	Ulcerative colitis;
PAAD	trans	rs3905000	0.920	rs34171271	chr9:107650317	T/C	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-9.56	-0.61	2.96e-17	Total body bone mineral density;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.92	0.54	4.6e-13	Parkinson's disease;
PAAD	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg04287289	chr16:89883240	FANCA	0.87	4.31	0.33	2.97e-5	Skin colour saturation;
PAAD	cis	rs8013055	1.000	rs8013055	chr14:105990620	T/A	cg19700328	chr14:106028568	NA	-0.61	-5.38	-0.4	2.75e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26351406	chr6:106534117	PRDM1	-0.74	-6.78	-0.48	2.45e-10	Neuroticism;
PAAD	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.47	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg15192750	chr16:69999425	NA	0.72	5.47	0.41	1.83e-7	IgE levels;
PAAD	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10950821	0.770	rs17816709	chr7:20691860	C/A	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	trans	rs10863681	0.738	rs12561821	chr1:222261229	T/C	cg08695703	chr17:73762337	GALK1	-0.6	-6.59	-0.47	6.86e-10	Metabolite levels (HVA-5-HIAA Factor score);
PAAD	cis	rs55728055	0.661	rs62237764	chr22:31947393	T/G	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	Cognitive function;
PAAD	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.44	4.28	0.33	3.27e-5	Mortality in heart failure;
PAAD	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg10064339	chr11:73693792	UCP2	1.19	5.68	0.42	6.8e-8	Obesity-related traits;
PAAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg01223673	chr11:15133828	INSC	0.35	4.58	0.35	9.81e-6	Mitochondrial DNA levels;
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg04287289	chr16:89883240	FANCA	0.58	6.51	0.47	1.03e-9	Vitiligo;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg15247247	chr7:4802535	FOXK1	0.85	4.36	0.33	2.34e-5	Borderline personality disorder;
PAAD	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	cis	rs2051773	0.510	rs11024129	chr11:17056417	C/A	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs66530629	0.917	rs3122053	chr1:25094233	G/T	cg01905478	chr1:25040257	NA	-0.47	-5.14	-0.38	8.44e-7	Plateletcrit;
PAAD	cis	rs2229238	0.868	rs12408461	chr1:154512710	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.94	-0.37	2.06e-6	Coronary heart disease;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.71	-5.0	-0.38	1.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg01426195	chr3:39028469	NA	-0.63	-6.31	-0.46	2.84e-9	Handedness;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg19337854	chr7:99768885	GPC2	0.46	4.25	0.33	3.72e-5	Platelet count;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs1545257	0.505	rs894466	chr2:24633771	T/C	cg02683114	chr2:24398427	C2orf84	-0.48	-5.0	-0.38	1.58e-6	Sjögren's syndrome;
PAAD	cis	rs8181588	1.000	rs2074197	chr11:2825279	C/T	cg26401390	chr11:2154638	INS-IGF2;IGF2	0.9	4.49	0.34	1.41e-5	Type 2 diabetes;
PAAD	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg04877966	chr15:75135169	ULK3	-0.43	-4.28	-0.33	3.3e-5	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20094282	chr17:79369258	NA	0.59	6.65	0.47	4.86e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.93	0.54	4.28e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg11062466	chr8:58055876	NA	0.68	5.11	0.38	9.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.7	6.72	0.48	3.42e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9810890	0.850	rs73196977	chr3:128450224	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.57	6.16	0.45	6.09e-9	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg02459107	chr1:67143332	SGIP1	-0.78	-7.48	-0.52	5.57e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.41	0.65	1.75e-19	Smoking behavior;
PAAD	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.32	4.27	0.33	3.38e-5	Asthma;
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.61	-5.98	-0.44	1.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-4.28	-0.33	3.29e-5	Electroencephalogram traits;
PAAD	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.02	0.63	1.81e-18	Bladder cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00914777	chr14:93651123	MOAP1;C14orf109	0.58	6.49	0.47	1.13e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.42	-4.77	-0.36	4.29e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.84	8.35	0.56	4.01e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg25124228	chr12:125621409	AACS	-0.65	-6.76	-0.48	2.72e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.75	10.17	0.64	7.43e-19	Coronary artery disease;
PAAD	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg14851346	chr12:38532713	NA	-0.45	-4.32	-0.33	2.78e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.65	-0.53	2.18e-12	Neuroticism;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.77e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.75e-5	Blood protein levels;
PAAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.66	6.56	0.47	8.16e-10	Coronary artery disease or large artery stroke;
PAAD	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.86	0.37	2.95e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg17351974	chr5:40835760	RPL37	0.81	4.66	0.35	6.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.5	-5.14	-0.39	8.17e-7	Testicular germ cell tumor;
PAAD	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.6	-5.21	-0.39	6.17e-7	Type 2 diabetes;
PAAD	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg14345882	chr6:26364793	BTN3A2	0.73	4.83	0.36	3.27e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-5.84	-0.43	3.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.45	5.28	0.39	4.32e-7	Immature fraction of reticulocytes;
PAAD	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs56046484	0.871	rs12904958	chr15:85558187	G/C	cg08123816	chr15:85640762	PDE8A	-0.43	-4.34	-0.33	2.6e-5	Testicular germ cell tumor;
PAAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.53	5.62	0.41	8.96e-8	Bladder cancer;
PAAD	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26306683	chr17:18585705	ZNF286B	0.56	5.54	0.41	1.32e-7	Educational attainment (years of education);
PAAD	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.94	-13.72	-0.74	2.13e-28	Height;
PAAD	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17467752	chr17:38218738	THRA	0.49	4.44	0.34	1.74e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs5756391	0.546	rs4821561	chr22:37311877	A/G	cg21209356	chr22:37319042	CSF2RB	-0.36	-4.36	-0.33	2.43e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg02135003	chr7:105160482	PUS7	-0.7	-6.15	-0.45	6.59e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.82	-8.2	-0.55	9.35e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21160610	chr15:43662639	TUBGCP4;ZSCAN29	-0.5	-4.55	-0.35	1.09e-5	Lung cancer in ever smokers;
PAAD	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.78	-8.23	-0.56	7.7e-14	Superior crus of antihelix expression;
PAAD	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.37	-0.46	2.14e-9	Hip circumference;
PAAD	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	0.69	4.27	0.33	3.47e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs16910800	0.953	rs73481419	chr11:23204953	A/G	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs7631605	0.576	rs6806158	chr3:36966067	A/G	cg10333520	chr3:36987040	TRANK1	0.35	4.69	0.36	6.05e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.66	-6.22	-0.45	4.68e-9	Urate levels;
PAAD	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.53	4.83	0.37	3.24e-6	Platelet count;
PAAD	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06850241	chr22:41845214	NA	0.57	5.06	0.38	1.21e-6	Vitiligo;
PAAD	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.64	-0.62	1.86e-17	Alzheimer's disease (late onset);
PAAD	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg13535736	chr9:111863775	C9orf5	-0.36	-4.45	-0.34	1.66e-5	Menarche (age at onset);
PAAD	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.86	10.77	0.66	1.9e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg09835421	chr16:68378352	PRMT7	-0.7	-5.39	-0.4	2.64e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg25382128	chr12:54346509	NA	0.47	4.78	0.36	4.18e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg18084798	chr19:33555255	RHPN2	0.47	5.01	0.38	1.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs258892	0.895	rs9654412	chr5:72040659	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg11335335	chr11:637885	DRD4	-0.38	-5.51	-0.41	1.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg03999872	chr20:62272968	STMN3	-0.75	-6.9	-0.49	1.28e-10	Atopic dermatitis;
PAAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.8	9.32	0.6	1.29e-16	Schizophrenia;
PAAD	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-7.39	-0.51	9.37e-12	Blood pressure (smoking interaction);
PAAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.85e-10	Neurofibrillary tangles;
PAAD	cis	rs9913156	0.696	rs9905711	chr17:4558662	G/A	cg00122941	chr17:4613640	ARRB2	-0.83	-8.41	-0.56	2.83e-14	Lymphocyte counts;
PAAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg00806245	chr18:76673096	NA	-0.8	-5.63	-0.42	8.48e-8	Obesity-related traits;
PAAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.26	-0.45	3.74e-9	Neuroticism;
PAAD	cis	rs11807834	0.522	rs12078342	chr1:230252950	G/A	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18364779	chr6:26104403	HIST1H4C	0.45	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs3812762	0.833	rs10500705	chr11:8805261	A/G	cg11156914	chr11:8892616	ST5	0.51	4.43	0.34	1.79e-5	Hypospadias;
PAAD	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg23517279	chr6:96025343	MANEA	-0.6	-4.48	-0.34	1.44e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.34	-0.33	2.59e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg16341495	chr8:142228727	SLC45A4	-0.5	-4.87	-0.37	2.77e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.75	9.23	0.6	2.14e-16	Alcohol dependence;
PAAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.67	7.01	0.49	7.47e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg02835301	chr3:11609216	VGLL4	0.51	4.37	0.33	2.29e-5	Circulating chemerin levels;
PAAD	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11668638	chr6:42952412	PPP2R5D	0.6	6.6	0.47	6.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11252688	1.000	rs11252682	chr10:4769161	T/C	cg04204118	chr10:4194429	NA	0.81	4.61	0.35	8.43e-6	Major depressive disorder;
PAAD	cis	rs12760731	0.565	rs10913519	chr1:178196094	A/T	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27030081	chr8:103573117	ODF1	-0.61	-6.38	-0.46	2.05e-9	Obesity-related traits;
PAAD	cis	rs427943	1.000	rs427943	chr21:46570896	A/C	cg06618935	chr21:46677482	NA	-0.36	-4.39	-0.34	2.11e-5	Body mass index;
PAAD	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.56	6.36	0.46	2.3e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.63	6.66	0.48	4.64e-10	Multiple sclerosis;
PAAD	cis	rs2133450	0.679	rs7615261	chr3:7367637	G/A	cg19930620	chr3:7340148	GRM7	-0.43	-4.75	-0.36	4.61e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.73	0.42	5.35e-8	Immature fraction of reticulocytes;
PAAD	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.73	6.31	0.46	2.91e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.53	-4.67	-0.35	6.55e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03951180	chr7:72742151	TRIM50;FKBP6	-0.55	-6.76	-0.48	2.74e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg08677398	chr8:58056175	NA	0.6	4.32	0.33	2.83e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.7	4.76	0.36	4.4e-6	Major depressive disorder;
PAAD	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.54	-5.17	-0.39	7.25e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7631605	0.905	rs11710860	chr3:37143017	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.68	0.35	6.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.1e-8	Platelet count;
PAAD	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.06	-0.38	1.18e-6	Total body bone mineral density;
PAAD	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.62	-6.38	-0.46	2.03e-9	Body mass index;
PAAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	4.95	0.37	1.97e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Body mass index;
PAAD	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.43	0.71	6.49e-25	Chronic sinus infection;
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.66	-0.48	4.71e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg02683114	chr2:24398427	C2orf84	0.59	6.8	0.48	2.29e-10	Asthma;
PAAD	cis	rs11203032	0.831	rs4417181	chr10:90967093	T/C	cg16672925	chr10:90967113	CH25H	0.79	6.26	0.45	3.73e-9	Heart failure;
PAAD	cis	rs3764563	1.000	rs602300	chr19:15693041	G/A	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs11009175	0.615	rs10763904	chr10:33305090	T/C	cg00146027	chr10:33299147	NA	-0.38	-4.47	-0.34	1.53e-5	Depression (quantitative trait);
PAAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.17	0.39	7.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs300774	0.925	rs300709	chr2:139743	C/T	cg23649280	chr2:140451	NA	0.5	4.8	0.36	3.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.29	0.45	3.21e-9	Bladder cancer;
PAAD	cis	rs802075	0.658	rs11757820	chr6:49636941	A/C	cg20364632	chr6:49636226	NA	0.55	6.82	0.48	1.97e-10	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7786877	0.953	rs7457024	chr7:100215220	A/G	cg16850897	chr7:100343110	ZAN	-0.56	-4.9	-0.37	2.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14580859	chr9:123691850	NA	0.38	4.37	0.33	2.3e-5	Rheumatoid arthritis;
PAAD	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-4.35	-0.33	2.49e-5	Morning vs. evening chronotype;
PAAD	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg09913449	chr8:42400586	C8orf40	-0.43	-4.55	-0.35	1.07e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.39e-7	Life satisfaction;
PAAD	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.9	-7.42	-0.52	7.86e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.65	6.24	0.45	4.11e-9	Uric acid clearance;
PAAD	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.58	6.42	0.46	1.64e-9	Heart rate;
PAAD	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.83	-0.37	3.24e-6	Height;
PAAD	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27612650	chr18:48352559	MRO	-0.6	-6.5	-0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs6580110	0.793	rs10073561	chr5:154095776	C/T	cg17263206	chr5:154071247	NA	0.48	4.81	0.36	3.53e-6	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27511599	chr7:32358540	NA	0.94	5.19	0.39	6.58e-7	Body mass index;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21016266	chr12:122356598	WDR66	0.64	6.96	0.49	9.28e-11	Mean corpuscular volume;
PAAD	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg01851573	chr8:8652454	MFHAS1	-0.5	-4.49	-0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-1.11	-13.45	-0.74	1.16e-27	Longevity;
PAAD	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.35	9.33	0.6	1.22e-16	Diabetic retinopathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22624212	chr21:44298959	WDR4	0.58	6.3	0.46	3.12e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.55	-6.33	-0.46	2.59e-9	Lung cancer;
PAAD	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.91	-11.97	-0.7	1.09e-23	Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09373875	chr4:159182779	NA	0.55	6.69	0.48	4.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-4.48	-0.34	1.46e-5	Type 1 diabetes;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg07362569	chr17:61921086	SMARCD2	0.44	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.65	-0.35	7.1e-6	Mean corpuscular volume;
PAAD	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg10223061	chr2:219282414	VIL1	0.38	4.59	0.35	9.04e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs727479	0.626	rs17703883	chr15:51530097	A/G	cg21478137	chr15:51532386	CYP19A1	-0.57	-5.83	-0.43	3.25e-8	Estradiol levels;
PAAD	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.92	10.67	0.65	3.53e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.48	-5.27	-0.39	4.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs901683	1.000	rs71494799	chr10:46002856	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.49	-0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg02631450	chr22:32366979	NA	1.01	5.36	0.4	3.04e-7	Childhood ear infection;
PAAD	cis	rs2421770	0.586	rs7936950	chr11:35278959	C/T	cg13971030	chr11:35366721	SLC1A2	-0.5	-4.87	-0.37	2.76e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.5	-5.47	-0.41	1.82e-7	Prevalent atrial fibrillation;
PAAD	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	6.13	0.45	7.29e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg19254793	chr6:44695348	NA	-0.41	-4.5	-0.34	1.36e-5	Total body bone mineral density;
PAAD	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg18370025	chr7:2749541	AMZ1	-0.35	-4.26	-0.33	3.56e-5	Height;
PAAD	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.45	-0.34	1.64e-5	Mosquito bite size;
PAAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg11177333	chr3:195857752	NA	0.45	4.31	0.33	2.92e-5	Non-small cell lung cancer;
PAAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	trans	rs3935740	0.649	rs28630072	chr15:81619774	A/C	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.31	0.46	2.94e-9	Lung cancer;
PAAD	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.52	4.69	0.36	6.06e-6	Depressive symptoms;
PAAD	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg01529538	chr14:23388837	RBM23	0.57	5.76	0.42	4.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs8040855	0.965	rs4843027	chr15:85715123	G/A	cg08123816	chr15:85640762	PDE8A	0.36	4.44	0.34	1.74e-5	Bulimia nervosa;
PAAD	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.62	6.23	0.45	4.31e-9	Myopia (pathological);
PAAD	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.8	0.48	2.26e-10	Total body bone mineral density;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18343290	chr7:140218068	NA	-0.58	-6.5	-0.47	1.07e-9	Lung cancer in ever smokers;
PAAD	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.56	5.98	0.44	1.5e-8	Eye color traits;
PAAD	cis	rs7009516	0.587	rs2291577	chr8:24256470	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.8	-0.43	3.76e-8	Hair greying;
PAAD	cis	rs8112211	1.000	rs8112211	chr19:38824581	C/T	cg14299480	chr19:38876666	GGN	-0.57	-7.14	-0.5	3.56e-11	Blood protein levels;
PAAD	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	1.19	14.43	0.76	2.73e-30	Longevity;
PAAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-4.92	-0.37	2.23e-6	Blood metabolite levels;
PAAD	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	8.05	0.55	2.25e-13	Eotaxin levels;
PAAD	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16975963	0.644	rs111319455	chr19:38162647	A/C	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.33e-5	Longevity;
PAAD	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.82	-0.54	8.44e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.34	-0.4	3.28e-7	Life satisfaction;
PAAD	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.45	4.68	0.35	6.32e-6	Corneal astigmatism;
PAAD	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.55	6.62	0.47	5.88e-10	Sitting height ratio;
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg10137597	chr8:22132714	PIWIL2	0.46	5.52	0.41	1.46e-7	Hypertriglyceridemia;
PAAD	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.5	-0.34	1.34e-5	Triglycerides;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.89	-0.37	2.52e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26926768	chr12:34528122	NA	0.4	4.92	0.37	2.27e-6	Morning vs. evening chronotype;
PAAD	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg18612461	chr15:75251733	NA	-0.41	-4.81	-0.36	3.62e-6	Systemic lupus erythematosus;
PAAD	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg23033748	chr14:75592666	NEK9	-0.41	-5.09	-0.38	1.06e-6	Height;
PAAD	cis	rs10901513	0.896	rs2366347	chr10:127674508	G/A	cg22975853	chr10:127789788	ADAM12	0.45	4.8	0.36	3.71e-6	Visceral fat;
PAAD	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.46	4.56	0.35	1.03e-5	Monocyte count;
PAAD	cis	rs952623	0.717	rs12669446	chr7:39046908	A/G	cg20302533	chr7:39170763	POU6F2	-0.37	-5.27	-0.39	4.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg27449745	chr7:23145252	KLHL7	0.57	5.06	0.38	1.17e-6	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.78	-7.56	-0.52	3.64e-12	Corneal astigmatism;
PAAD	cis	rs6496932	0.503	rs4842882	chr15:85984183	G/A	cg19183879	chr15:85880815	NA	-0.5	-4.37	-0.33	2.29e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs12220238	0.915	rs11001003	chr10:76099944	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07814359	chr20:42839582	C20orf111	0.74	7.31	0.51	1.4e-11	Obesity-related traits;
PAAD	cis	rs457162	0.643	rs281865	chr6:118576194	C/G	cg21191810	chr6:118973309	C6orf204	0.7	4.46	0.34	1.56e-5	QT interval;
PAAD	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.52	0.47	9.74e-10	Bladder cancer;
PAAD	cis	rs12148477	0.523	rs1808141	chr15:51657431	G/A	cg25905881	chr15:51634250	GLDN	0.41	4.42	0.34	1.83e-5	Follicule stimulating hormone;
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg21565972	chr17:80109576	CCDC57	-0.49	-5.25	-0.39	5.02e-7	Life satisfaction;
PAAD	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg15440763	chr7:158190612	PTPRN2	0.44	4.45	0.34	1.63e-5	Obesity-related traits;
PAAD	cis	rs6681460	1.000	rs6588207	chr1:67066555	A/G	cg02459107	chr1:67143332	SGIP1	0.77	7.9	0.54	5.22e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-1.1	-10.56	-0.65	7e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.51	4.46	0.34	1.6e-5	Aortic root size;
PAAD	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.22	-0.39	5.72e-7	Neuroticism;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs2244613	0.706	rs7200011	chr16:55794768	C/A	cg27396498	chr16:55794478	CES4	0.67	5.28	0.39	4.39e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs1364705	1.000	rs12677951	chr8:120226900	C/G	cg09273054	chr8:120220131	MAL2	0.46	5.02	0.38	1.4e-6	Hippocampal atrophy;
PAAD	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.4	3.92e-7	Male-pattern baldness;
PAAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	2.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.2	-0.45	5.04e-9	Lung cancer;
PAAD	cis	rs11958404	0.517	rs13154764	chr5:157305206	T/C	cg05962755	chr5:157440814	NA	0.78	5.08	0.38	1.09e-6	IgG glycosylation;
PAAD	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.82	-9.85	-0.62	5.33e-18	Coronary artery disease;
PAAD	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg03700679	chr2:178418002	TTC30B	-0.56	-4.44	-0.34	1.74e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg21523564	chr15:75251491	NA	0.47	4.93	0.37	2.11e-6	Breast cancer;
PAAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.2	10.17	0.64	7.48e-19	Uric acid levels;
PAAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06850241	chr22:41845214	NA	-0.46	-4.32	-0.33	2.86e-5	Vitiligo;
PAAD	cis	rs258892	0.895	rs463250	chr5:72144463	G/C	cg21869765	chr5:72125136	TNPO1	0.77	5.25	0.39	5.03e-7	Small cell lung carcinoma;
PAAD	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg01170276	chr11:64614859	NA	0.64	6.87	0.49	1.52e-10	Triglycerides;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00297737	chr8:97273749	MTERFD1;PTDSS1	0.63	7.26	0.51	1.82e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3857067	1.000	rs28876091	chr4:95000394	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.65	0.35	7.22e-6	Red cell distribution width;
PAAD	cis	rs73206853	0.620	rs73194038	chr12:111172339	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.4	0.34	2.03e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2275731	0.723	rs34184723	chr10:16539378	C/A	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.99	0.38	1.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.31	8.63	0.57	7.55e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.657	rs583489	chr10:44738688	C/G	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.62	0.53	2.58e-12	Hemoglobin concentration;
PAAD	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg05552183	chr6:42928497	GNMT	0.64	5.22	0.39	5.87e-7	Blood protein levels;
PAAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg14393609	chr7:65229607	NA	0.48	4.83	0.36	3.34e-6	Aortic root size;
PAAD	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-7.2	-0.5	2.61e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs6679454	0.801	rs852790	chr1:58308042	A/C	cg17491850	chr1:57888480	DAB1	-0.41	-4.38	-0.33	2.21e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg03605463	chr16:89740564	NA	-0.92	-4.81	-0.36	3.64e-6	Red blood cell count;
PAAD	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg10208897	chr5:178548229	ADAMTS2	0.5	4.43	0.34	1.79e-5	Pubertal anthropometrics;
PAAD	cis	rs990171	0.538	rs7591878	chr2:103112658	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.3	0.39	4.04e-7	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-5.59	-0.41	1.01e-7	Vitiligo;
PAAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.54	-5.88	-0.43	2.52e-8	Total body bone mineral density;
PAAD	cis	rs12949688	0.601	rs11079326	chr17:55837207	G/A	cg12582317	chr17:55822272	NA	0.45	5.27	0.39	4.7e-7	Schizophrenia;
PAAD	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-4.28	-0.33	3.24e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7823896	0.722	rs111732799	chr8:110322319	T/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-4.39	-0.34	2.14e-5	Lung cancer;
PAAD	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg19223190	chr17:80058835	NA	0.53	5.57	0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.49	-5.36	-0.4	3e-7	Huntington's disease progression;
PAAD	cis	rs11997175	0.653	rs7817167	chr8:33633088	A/C	ch.8.33884649F	chr8:33765107	NA	0.56	6.35	0.46	2.37e-9	Body mass index;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg21523564	chr15:75251491	NA	0.47	4.93	0.37	2.11e-6	Breast cancer;
PAAD	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg11498726	chr8:26250323	BNIP3L	-0.5	-4.8	-0.36	3.69e-6	Red cell distribution width;
PAAD	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg24747557	chr10:131355152	MGMT	-0.53	-5.87	-0.43	2.65e-8	Response to temozolomide;
PAAD	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg21427119	chr20:30132790	HM13	-0.66	-5.34	-0.4	3.38e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2637266	0.791	rs2395392	chr10:78359933	C/A	cg18941641	chr10:78392320	NA	0.39	4.63	0.35	7.72e-6	Pulmonary function;
PAAD	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.49	4.75	0.36	4.76e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.47	5.91	0.43	2.17e-8	Crohn's disease;
PAAD	cis	rs10214930	0.671	rs6959495	chr7:27692292	T/C	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs6074578	0.541	rs6077481	chr20:149975	C/T	cg16931068	chr20:139680	DEFB127	0.41	5.36	0.4	3.07e-7	Hirschsprung disease;
PAAD	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-4.68	-0.35	6.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg05717871	chr11:638507	DRD4	-0.6	-5.4	-0.4	2.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21016266	chr12:122356598	WDR66	0.65	7.09	0.5	4.68e-11	Mean corpuscular volume;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-1.1	-8.27	-0.56	6.41e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.66	-7.93	-0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg09659197	chr4:152720779	NA	-0.41	-6.09	-0.44	8.86e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.65	-4.86	-0.37	2.92e-6	Pancreatic cancer;
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.59	6.47	0.46	1.29e-9	Lung cancer;
PAAD	cis	rs7301826	0.651	rs10773824	chr12:131298851	G/A	cg11011512	chr12:131303247	STX2	0.49	5.09	0.38	1.04e-6	Plasma plasminogen activator levels;
PAAD	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-7.85	-0.54	6.76e-13	Colorectal cancer;
PAAD	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-8.78	-0.58	3.11e-15	Depression;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-5.05	-0.38	1.28e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg07617317	chr6:118971624	C6orf204	0.52	4.41	0.34	1.95e-5	Diastolic blood pressure;
PAAD	cis	rs3771180	0.505	rs2160203	chr2:102960824	A/G	cg03938978	chr2:103052716	IL18RAP	0.6	5.84	0.43	3.04e-8	Asthma;
PAAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.0	-11.69	-0.69	6.47e-23	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15790255	chr17:976142	ABR	-0.64	-6.29	-0.45	3.24e-9	Obesity-related traits;
PAAD	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.29	-0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.65	-5.73	-0.42	5.19e-8	Resistin levels;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	1.11	8.12	0.55	1.5e-13	IgG glycosylation;
PAAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.37	-0.4	2.9e-7	Blood metabolite levels;
PAAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.96	10.53	0.65	7.96e-20	Multiple sclerosis;
PAAD	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.27	0.39	4.57e-7	Educational attainment;
PAAD	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg07395648	chr5:131743802	NA	-0.52	-4.3	-0.33	3.03e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.71	5.89	0.43	2.4e-8	Exhaled nitric oxide output;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-1.12	-9.16	-0.6	3.36e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs2862774	0.507	rs62157694	chr2:113807883	T/C	cg06156847	chr2:113672199	IL1F7	-0.46	-4.48	-0.34	1.45e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1977876	0.777	rs11119769	chr1:211713769	C/G	cg01575408	chr1:211752895	SLC30A1	-0.55	-4.56	-0.35	1.04e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs80346118	0.673	rs2869675	chr20:47420680	C/T	cg20907517	chr20:47894756	C20orf199;ZNFX1;SNORD12C	-0.6	-4.5	-0.34	1.36e-5	Diastolic blood pressure;
PAAD	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21646471	chr2:242523971	THAP4	0.65	5.08	0.38	1.07e-6	Prostate cancer;
PAAD	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg05341575	chr12:125625032	AACS	-0.5	-4.46	-0.34	1.6e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.62	7.65	0.53	2.12e-12	Prudent dietary pattern;
PAAD	cis	rs282708	0.743	rs57232417	chr4:59635433	T/C	cg11281224	chr4:60001000	NA	-0.44	-4.36	-0.33	2.37e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-4.55	-0.35	1.09e-5	Rheumatoid arthritis;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.52	0.47	9.93e-10	Lung cancer;
PAAD	cis	rs375066	0.869	rs379785	chr19:44428101	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs1144333	0.510	rs1146652	chr1:76273708	A/G	cg22875332	chr1:76189707	ACADM	-0.77	-4.73	-0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs1903068	0.853	rs12331597	chr4:55997914	T/C	cg20092376	chr4:56023423	NA	0.49	4.88	0.37	2.69e-6	Endometriosis;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.61	5.62	0.41	8.9e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg02153855	chr1:11041070	C1orf127	-0.34	-4.3	-0.33	3.05e-5	Hepatocellular carcinoma;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.88	-10.02	-0.63	1.83e-18	Obesity-related traits;
PAAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg25833597	chr17:30823145	MYO1D	0.48	4.63	0.35	7.93e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07876271	chr5:5422799	KIAA0947	0.65	7.67	0.53	1.88e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67257959	0.739	rs10416982	chr19:17202933	C/A	cg19418318	chr19:17219073	MYO9B	0.31	4.32	0.33	2.78e-5	Selective IgA deficiency;
PAAD	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.5	5.83	0.43	3.24e-8	Platelet count;
PAAD	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.1	-17.28	-0.81	1.06e-37	Myeloid white cell count;
PAAD	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.63	-7.16	-0.5	3.25e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	5.34	0.4	3.33e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.31e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs743757	1.000	rs2236967	chr3:50461240	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.66	-4.58	-0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg10113582	chr4:905918	GAK	-0.41	-4.73	-0.36	5.03e-6	Systemic sclerosis;
PAAD	cis	rs9810890	1.000	rs73196960	chr3:128432222	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.62	7.09	0.5	4.78e-11	Testicular germ cell tumor;
PAAD	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs7300001	0.667	rs7302441	chr12:110506468	T/C	cg12870014	chr12:110450643	ANKRD13A	0.95	5.84	0.43	3.04e-8	Headache;
PAAD	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg22134325	chr11:66188745	NPAS4	0.32	4.4	0.34	2.02e-5	Airway imaging phenotypes;
PAAD	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.6	-5.96	-0.44	1.66e-8	Coronary artery disease;
PAAD	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16857181	chr7:32931955	KBTBD2	0.63	7.12	0.5	3.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs778371	0.755	rs778350	chr2:233803208	T/C	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.84	-0.43	3.04e-8	Schizophrenia;
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs16858210	0.647	rs17683012	chr3:183621991	C/T	cg03417191	chr3:183542750	MAP6D1	-0.6	-4.26	-0.33	3.59e-5	Menopause (age at onset);
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.63	5.29	0.39	4.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	8.85	0.58	2.13e-15	Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.74	8.23	0.56	8.08e-14	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg23281280	chr6:28129359	ZNF389	0.55	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg19337854	chr7:99768885	GPC2	0.51	4.44	0.34	1.74e-5	Lung function (FEV1/FVC);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01528063	chr19:1249902	MIDN	0.68	6.82	0.48	2.01e-10	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.53	-5.32	-0.4	3.72e-7	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23158103	chr7:148848205	ZNF398	0.57	5.52	0.41	1.43e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.46	4.31	0.33	2.92e-5	Endometrial cancer;
PAAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.56	-6.48	-0.47	1.22e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg09491104	chr22:46646882	C22orf40	-0.91	-5.77	-0.42	4.26e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2249694	0.538	rs2026047	chr10:135329616	C/T	cg20169779	chr10:135381914	SYCE1	0.62	5.4	0.4	2.54e-7	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.57	5.61	0.41	9.33e-8	Systolic blood pressure;
PAAD	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.95	-11.56	-0.68	1.38e-22	Osteoporosis;
PAAD	cis	rs7136716	0.541	rs115219271	chr12:7732941	T/C	cg25757697	chr12:8220002	C3AR1	-0.86	-4.37	-0.33	2.32e-5	Hematological and biochemical traits;
PAAD	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg14019146	chr3:50243930	SLC38A3	0.51	5.37	0.4	2.92e-7	Menarche (age at onset);
PAAD	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23158103	chr7:148848205	ZNF398	-0.64	-6.39	-0.46	1.94e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.83	-6.43	-0.46	1.58e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.21	-0.55	8.6e-14	Schizophrenia;
PAAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg23743573	chr11:89867420	NAALAD2	0.57	4.6	0.35	8.9e-6	White blood cell types;
PAAD	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07087018	chr16:56763997	NUP93	-0.56	-6.43	-0.46	1.57e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.32	0.4	3.68e-7	HIV-1 control;
PAAD	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	5.58	0.41	1.05e-7	LDL cholesterol;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.56	0.52	3.53e-12	Alzheimer's disease;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.27	0.45	3.54e-9	Height;
PAAD	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.15	0.5	3.34e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs959260	0.858	rs4788886	chr17:73313326	G/A	cg20590849	chr17:73267439	MIF4GD	-0.53	-4.28	-0.33	3.31e-5	Systemic lupus erythematosus;
PAAD	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg09399716	chr2:46890238	NA	-0.56	-4.94	-0.37	2.08e-6	Height;
PAAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.87	7.45	0.52	6.38e-12	IgG glycosylation;
PAAD	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-1.05	-8.96	-0.59	1.11e-15	Blood trace element (Zn levels);
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.65	-0.47	5.04e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01809675	chr5:170884278	NA	0.65	6.77	0.48	2.69e-10	Lung cancer in ever smokers;
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.61	-0.41	9.14e-8	Lung cancer;
PAAD	cis	rs61861422	0.516	rs11814062	chr10:134439823	C/T	cg24416232	chr10:134405482	INPP5A	-0.45	-4.78	-0.36	4.06e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13560548	chr3:10150139	C3orf24	0.52	4.73	0.36	5e-6	Alzheimer's disease;
PAAD	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg21934504	chr19:4445085	UBXN6	0.6	5.84	0.43	3.12e-8	Mean corpuscular volume;
PAAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.48	-6.22	-0.45	4.56e-9	Huntington's disease progression;
PAAD	cis	rs11615916	0.790	rs78676801	chr12:62654503	C/T	cg11441379	chr12:63026424	NA	0.64	4.41	0.34	1.98e-5	Pulmonary function decline;
PAAD	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12239750	chr10:97416566	ALDH18A1	-0.75	-6.63	-0.47	5.55e-10	Neuroticism;
PAAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg14393609	chr7:65229607	NA	-0.47	-4.82	-0.36	3.48e-6	Aortic root size;
PAAD	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.32	0.33	2.76e-5	Height;
PAAD	cis	rs732765	0.734	rs12323528	chr14:75152068	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.37	-0.33	2.33e-5	Non-small cell lung cancer;
PAAD	cis	rs7937682	0.593	rs1944111	chr11:111364432	G/C	cg09085632	chr11:111637200	PPP2R1B	0.53	4.51	0.34	1.27e-5	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.1e-9	Life satisfaction;
PAAD	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg12661370	chr5:149340060	SLC26A2	0.65	5.53	0.41	1.36e-7	HIV-1 control;
PAAD	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00982548	chr2:198649783	BOLL	-0.64	-4.28	-0.33	3.32e-5	Ulcerative colitis;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.71	-0.42	5.85e-8	Longevity;Endometriosis;
PAAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.1	14.51	0.76	1.76e-30	Cognitive function;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.41	-4.92	-0.37	2.2e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.91	0.37	2.32e-6	Menopause (age at onset);
PAAD	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg02415014	chr8:143852576	LYNX1	0.39	4.55	0.35	1.07e-5	Urinary tract infection frequency;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs2286503	1.000	rs2286501	chr7:22856785	G/C	cg04907244	chr7:22894795	SNORD93	-0.43	-5.33	-0.4	3.51e-7	Fibrinogen;
PAAD	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg07166546	chr14:35805898	NA	-0.3	-4.6	-0.35	8.9e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.51	4.8	0.36	3.82e-6	Educational attainment;
PAAD	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	IgM levels;
PAAD	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.07	-0.55	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.47	6.12	0.44	7.78e-9	Childhood ear infection;
PAAD	cis	rs4740619	0.689	rs1410445	chr9:15927816	G/A	cg14451791	chr9:16040625	NA	-0.4	-4.44	-0.34	1.72e-5	Body mass index;
PAAD	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg18939081	chr1:31884902	SERINC2	0.47	5.23	0.39	5.46e-7	Alcohol dependence;
PAAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg26174226	chr8:58114915	NA	-0.71	-6.35	-0.46	2.36e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Magnesium levels;
PAAD	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.34	-4.97	-0.37	1.82e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg05554000	chr7:158905015	VIPR2	-0.7	-5.09	-0.38	1.04e-6	Facial morphology (factor 20);
PAAD	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg16928487	chr17:17741425	SREBF1	0.35	4.81	0.36	3.64e-6	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.76	6.21	0.45	4.94e-9	Alzheimer's disease;
PAAD	cis	rs7752195	0.643	rs76798435	chr6:25231495	A/C	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs742132	0.520	rs2294344	chr6:25652225	C/A	cg03264133	chr6:25882463	NA	0.67	4.57	0.35	9.87e-6	Uric acid levels;
PAAD	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.33	-0.4	3.52e-7	Monocyte percentage of white cells;
PAAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg05627522	chr15:75251581	NA	0.53	6.23	0.45	4.38e-9	Breast cancer;
PAAD	cis	rs6669119	0.651	rs79435445	chr1:19105023	C/T	cg19637330	chr1:19110922	NA	0.92	5.62	0.41	8.88e-8	Percentage gas trapping;
PAAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	Schizophrenia;
PAAD	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg02353165	chr6:42928485	GNMT	0.6	4.81	0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.55	5.56	0.41	1.16e-7	Parkinson's disease;
PAAD	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs11102986	0.607	rs10776909	chr9:137288746	T/C	cg00753924	chr9:137298813	RXRA	-0.78	-7.91	-0.54	5.01e-13	Intelligence;
PAAD	cis	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg21775007	chr8:11205619	TDH	-0.48	-4.29	-0.33	3.12e-5	Neuroticism;
PAAD	cis	rs7957197	0.628	rs692902	chr12:121197124	A/G	cg21423404	chr12:121976833	KDM2B	-0.44	-4.42	-0.34	1.84e-5	Type 2 diabetes;
PAAD	cis	rs13076750	0.639	rs12629468	chr3:188069360	C/T	cg07599972	chr3:187607070	NA	0.58	4.26	0.33	3.54e-5	Intraocular pressure;
PAAD	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	7.87	0.54	6.34e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs57244997	0.685	rs2226770	chr6:162447251	C/T	cg17173639	chr6:162384350	PARK2	0.69	5.25	0.39	5.16e-7	Mosquito bite size;
PAAD	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs2020921	0.510	rs11774517	chr8:41979110	A/G	cg17828057	chr8:42037527	PLAT	0.81	5.17	0.39	7.29e-7	Plasma plasminogen activator levels;
PAAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-1.12	-8.97	-0.59	1e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg23387401	chr17:4582204	PELP1	0.5	4.91	0.37	2.28e-6	Lymphocyte counts;
PAAD	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs9287604	1.000	rs6712794	chr2:237778159	G/T	cg15065627	chr2:237796583	NA	-0.53	-4.38	-0.33	2.17e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs3857067	0.839	rs12505694	chr4:95042940	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-4.47	-0.34	1.5e-5	QT interval;
PAAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.51	0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.48	4.99	0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs75920871	1.000	rs7950213	chr11:116868654	C/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.51	-5.17	-0.39	7.27e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9810890	1.000	rs73196974	chr3:128449006	A/C	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.8	-9.36	-0.6	1.03e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs2211560	0.789	rs1355912	chr1:61283414	T/C	cg00575674	chr1:61314297	NA	-0.51	-4.61	-0.35	8.49e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.68	7.21	0.5	2.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg04106633	chr4:1044584	NA	0.51	4.77	0.36	4.19e-6	Recombination rate (males);
PAAD	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.68	0.58	5.77e-15	Parkinson's disease;
PAAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs2131877	0.830	rs77855194	chr3:194879589	T/C	cg11177333	chr3:195857752	NA	0.53	4.26	0.33	3.53e-5	Non-small cell lung cancer;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs7129556	0.954	rs11512896	chr11:77275718	A/G	cg24456632	chr11:77314957	AQP11	-0.5	-4.36	-0.33	2.43e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg13535736	chr9:111863775	C9orf5	-0.36	-4.53	-0.35	1.17e-5	Menarche (age at onset);
PAAD	cis	rs5753037	0.809	rs2079338	chr22:30203842	G/A	cg01021169	chr22:30184971	ASCC2	-0.44	-4.48	-0.34	1.47e-5	Type 1 diabetes;
PAAD	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.96	0.44	1.71e-8	Lung cancer;
PAAD	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg23995914	chr4:10459228	ZNF518B	-0.39	-4.9	-0.37	2.42e-6	Schizophrenia (age at onset);
PAAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs10510102	0.608	rs4077606	chr10:123609422	T/G	cg09536375	chr10:123735128	NSMCE4A	0.36	4.54	0.35	1.13e-5	Breast cancer;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs755249	0.529	rs4660732	chr1:39863215	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6733011	0.538	rs7565614	chr2:99464834	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.36	-0.33	2.36e-5	Bipolar disorder;
PAAD	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.59	6.15	0.45	6.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12936587	0.601	rs7222423	chr17:17556707	A/G	cg04398451	chr17:18023971	MYO15A	0.46	4.29	0.33	3.13e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg27411982	chr8:10470053	RP1L1	0.47	5.45	0.4	1.96e-7	Neuroticism;
PAAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg14686297	chr22:46650375	NA	-0.47	-4.62	-0.35	8.22e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.17	-0.39	7.25e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.93	10.53	0.65	7.96e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	4.57	0.35	9.97e-6	Red cell distribution width;Platelet distribution width;
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg00022866	chr11:64108440	CCDC88B	-0.31	-4.32	-0.33	2.82e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-7.08	-0.5	5.01e-11	Mosquito bite size;
PAAD	cis	rs6785206	0.554	rs35653243	chr3:128496410	G/A	cg19205850	chr3:128446370	RAB7A	0.67	5.15	0.39	7.95e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Vitiligo;
PAAD	cis	rs900145	0.773	rs7107287	chr11:13312969	G/T	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs160189	0.834	rs3786201	chr18:77232204	A/G	cg15644404	chr18:77186268	NFATC1	-0.59	-4.95	-0.37	1.93e-6	Mean platelet volume;
PAAD	cis	rs2274459	0.500	rs10947426	chr6:33637897	A/C	cg06253072	chr6:33679850	C6orf125	0.67	4.74	0.36	4.8e-6	Obesity (extreme);
PAAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.84	-8.09	-0.55	1.73e-13	Homoarginine levels;
PAAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.78	0.36	4.06e-6	Breast cancer;
PAAD	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.53	-5.15	-0.39	7.96e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg01416317	chr19:45737208	EXOC3L2	0.5	5.26	0.39	4.85e-7	Monocyte percentage of white cells;
PAAD	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.15	0.45	6.58e-9	Rheumatoid arthritis;
PAAD	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.51	-0.34	1.31e-5	Coronary artery disease;
PAAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg03676636	chr4:99064102	C4orf37	-0.26	-4.5	-0.34	1.37e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs11024102	0.925	rs7127818	chr11:17004090	G/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.45	0.34	1.65e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.38	4.49	0.34	1.42e-5	Tonsillectomy;
PAAD	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.59	4.29	0.33	3.17e-5	Thyroid stimulating hormone;
PAAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.82	-0.43	3.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1075232	1.000	rs72722829	chr15:31639114	G/A	cg15751117	chr15:30700112	NA	0.87	4.62	0.35	8.05e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.49	0.34	1.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-6.86	-0.49	1.65e-10	Total cholesterol levels;
PAAD	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.51	5.15	0.39	8.02e-7	Type 2 diabetes;
PAAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs2817937	0.786	rs78136554	chr6:121097951	G/A	cg22125214	chr7:135612081	LUZP6;MTPN	1.11	6.54	0.47	9.01e-10	Primary tooth development (number of teeth);
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg15510373	chr7:100224934	TFR2	-0.59	-4.79	-0.36	3.95e-6	Other erythrocyte phenotypes;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg26685658	chr5:74633012	HMGCR	0.51	4.41	0.34	1.95e-5	Age-related disease endophenotypes;
PAAD	cis	rs258892	0.895	rs13171293	chr5:72034307	T/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.1	0.59	4.65e-16	Post bronchodilator FEV1;
PAAD	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.46	-4.3	-0.33	3e-5	Type 2 diabetes;
PAAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg21155852	chr7:2048760	MAD1L1	0.45	4.36	0.33	2.42e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg21546286	chr11:48923668	NA	-0.54	-5.54	-0.41	1.31e-7	HDL cholesterol;
PAAD	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.67	7.42	0.52	7.52e-12	Testicular germ cell tumor;
PAAD	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs911119	0.954	rs2254635	chr20:23622758	G/T	cg16589663	chr20:23618590	CST3	0.83	6.77	0.48	2.6200000000000003e-10	Chronic kidney disease;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.41	-5.9	-0.43	2.25e-8	QT interval;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.56	5.86	0.43	2.78e-8	Lung cancer;
PAAD	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.73	6.16	0.45	6.36e-9	Lymphocyte counts;Fibrinogen;
PAAD	trans	rs901683	1.000	rs17157825	chr10:45958676	G/A	cg11747279	chr17:21096632	NA	0.92	6.79	0.48	2.37e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg14440974	chr22:39074834	NA	-0.58	-7.08	-0.5	4.85e-11	Menopause (age at onset);
PAAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.84	-8.5	-0.57	1.66e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg21483461	chr5:81570383	RPS23	-0.52	-4.9	-0.37	2.45e-6	Breast cancer;
PAAD	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.64	7.19	0.5	2.74e-11	Menopause (age at onset);
PAAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-6.88	-0.49	1.48e-10	Psoriasis;
PAAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg15510373	chr7:100224934	TFR2	-0.53	-4.3	-0.33	3.02e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3761847	0.508	rs4837813	chr9:123934463	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	4.76	0.36	4.49e-6	Rheumatoid arthritis;
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg26893134	chr6:116381904	FRK	0.4	6.23	0.45	4.26e-9	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11634851	0.565	rs972481	chr15:81026925	A/G	cg03950166	chr15:80988613	FAM108C1	0.48	4.87	0.37	2.79e-6	Systolic blood pressure;
PAAD	cis	rs6785206	0.614	rs13065032	chr3:128510594	A/G	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs375066	0.934	rs440784	chr19:44404342	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.48	-0.41	1.75e-7	Schizophrenia;
PAAD	cis	rs4142041	0.660	rs6480238	chr10:68658131	A/C	cg04444303	chr10:69634106	NA	-0.45	-4.44	-0.34	1.7e-5	Nicotine dependence;
PAAD	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg13119035	chr7:42951436	C7orf25	0.59	6.85	0.49	1.72e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.89	7.67	0.53	1.88e-12	Psoriasis;
PAAD	cis	rs9463078	0.669	rs7750380	chr6:45070034	A/G	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.88	0.43	2.49e-8	Lung cancer;
PAAD	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg06096015	chr1:231504339	EGLN1	-0.7	-9.5	-0.61	4.34e-17	Hemoglobin concentration;
PAAD	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg25401027	chr5:176370377	UIMC1	0.56	5.55	0.41	1.24e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-4.41	-0.34	1.95e-5	Red blood cell count;
PAAD	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	1.01	8.49	0.57	1.73e-14	Neutrophil percentage of white cells;
PAAD	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs1015291	0.670	rs10841386	chr12:20010785	A/C	cg25401612	chr12:20009446	NA	0.52	5.16	0.39	7.77e-7	Diastolic blood pressure;
PAAD	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-5.79	-0.42	3.96e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.76	-0.36	4.43e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.85	-9.79	-0.62	7.37e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.64	6.54	0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.58	0.57	1e-14	Lung cancer;
PAAD	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg01426195	chr3:39028469	NA	0.65	6.5	0.47	1.1e-9	Handedness;
PAAD	trans	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg07211511	chr3:129823064	LOC729375	-1.28	-7.44	-0.52	6.94e-12	Blood pressure (smoking interaction);
PAAD	cis	rs655641	0.539	rs602222	chr11:85718231	G/T	cg07180834	chr11:85838833	NA	-0.44	-4.89	-0.37	2.56e-6	Platelet count;
PAAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs9463078	0.553	rs227837	chr6:44683123	A/G	cg25276700	chr6:44698697	NA	-0.47	-5.31	-0.4	3.82e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2073300	1.000	rs6114139	chr20:23458390	T/G	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.48	-5.59	-0.41	1.01e-7	Mean arterial pressure;
PAAD	cis	rs4740619	0.689	rs10810506	chr9:15955190	C/A	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.67	-0.48	4.36e-10	Extrinsic epigenetic age acceleration;
PAAD	trans	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs34375054	0.687	rs12303572	chr12:125611271	G/T	cg00522288	chr12:125625016	AACS	-0.46	-4.88	-0.37	2.65e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-8.8	-0.58	2.76e-15	Total body bone mineral density;
PAAD	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg19418458	chr7:158789849	NA	0.54	4.4	0.34	2.03e-5	Facial morphology (factor 20);
PAAD	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	5.34	0.4	3.28e-7	Colorectal cancer;
PAAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00982548	chr2:198649783	BOLL	-0.85	-5.88	-0.43	2.48e-8	Ulcerative colitis;
PAAD	cis	rs2120243	0.533	rs1500921	chr3:157055427	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.3	0.33	3.03e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15593809	chr11:77348873	CLNS1A	-0.73	-6.4	-0.46	1.82e-9	Neuroticism;
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg16300553	chr8:8131077	NA	-0.37	-4.45	-0.34	1.65e-5	Joint mobility (Beighton score);
PAAD	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.45	-5.12	-0.38	9.15e-7	Cognitive function;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-4.4	-0.34	2e-5	Mean corpuscular volume;
PAAD	cis	rs11807834	0.505	rs11806744	chr1:230246454	C/T	cg09847368	chr1:230250326	GALNT2	-0.69	-8.47	-0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs787274	0.867	rs786977	chr9:115459708	A/G	cg13803584	chr9:115635662	SNX30	0.84	5.02	0.38	1.43e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.83	-0.48	1.89e-10	Systolic blood pressure;
PAAD	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.82	-0.43	3.37e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg20673841	chr7:107026890	COG5	-0.51	-4.32	-0.33	2.76e-5	Coronary artery disease;
PAAD	cis	rs3736485	0.934	rs4775952	chr15:51869056	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.34	-0.33	2.57e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13675469	chr1:174992539	MRPS14	0.64	6.56	0.47	7.8e-10	Myopia (pathological);
PAAD	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg19882132	chr14:106167949	NA	-0.58	-5.13	-0.38	8.79e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs10512697	0.772	rs35145280	chr5:3528022	C/G	cg19473799	chr5:3511975	NA	-0.93	-4.29	-0.33	3.18e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.69	4.25	0.33	3.7e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg02356786	chr1:243265016	LOC731275	1.06	6.67	0.48	4.56e-10	Obesity (early onset extreme);
PAAD	cis	rs11700980	0.551	rs2832027	chr21:30114365	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.55	0.57	1.25e-14	Prudent dietary pattern;
PAAD	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.6	-5.88	-0.43	2.53e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17162190	0.590	rs10902748	chr1:26817825	G/A	cg17456097	chr1:26900765	RPS6KA1	0.6	4.85	0.37	3.06e-6	Mean corpuscular volume;
PAAD	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg09242541	chr1:10490025	APITD1	0.44	5.54	0.41	1.29e-7	Prostate cancer;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.54	5.8	0.43	3.69e-8	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.23e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73195822	0.667	rs57302533	chr12:111245613	A/C	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.27	-0.33	3.4e-5	Itch intensity from mosquito bite;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00326559	chr7:4822006	KIAA0415	0.6	6.3	0.46	3.07e-9	Obesity-related traits;
PAAD	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10820045	chr2:198174542	NA	-0.49	-4.9	-0.37	2.39e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	5.28	0.39	4.47e-7	Neuroticism;
PAAD	cis	rs955333	0.571	rs7769675	chr6:154931499	T/C	cg20019720	chr6:154832845	CNKSR3	0.33	4.33	0.33	2.71e-5	Diabetic kidney disease;
PAAD	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.49	5.08	0.38	1.08e-6	Lung cancer;
PAAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs7092929	0.883	rs835960	chr10:3586532	G/C	cg14308648	chr10:3568949	NA	0.65	4.76	0.36	4.44e-6	Coronary artery calcification;
PAAD	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.58	5.58	0.41	1.06e-7	Endometrial cancer;
PAAD	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.33	0.4	3.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7766436	0.922	rs2066338	chr6:22611393	C/T	cg13666174	chr6:22585274	NA	-0.49	-4.49	-0.34	1.38e-5	Coronary artery disease;
PAAD	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-5.4	-0.4	2.48e-7	Schizophrenia;
PAAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.61	7.32	0.51	1.36e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg05925327	chr15:68127851	NA	-0.56	-5.05	-0.38	1.26e-6	Restless legs syndrome;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07167872	chr1:205819463	PM20D1	0.45	4.26	0.33	3.62e-5	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26252220	chr12:72057668	THAP2;ZFC3H1	-0.73	-6.47	-0.46	1.24e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26131879	chr4:714341	PCGF3	-0.64	-6.6	-0.47	6.4e-10	Obesity-related traits;
PAAD	cis	rs2271001	0.876	rs11606057	chr11:19143110	T/G	cg00161556	chr11:19138045	ZDHHC13	0.52	5.71	0.42	5.65e-8	Gut microbiome composition (winter);
PAAD	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.62	5.85	0.43	2.84e-8	Blood protein levels;
PAAD	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.72	0.36	5.29e-6	Electroencephalogram traits;
PAAD	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.72	-0.36	5.37e-6	Resting heart rate;
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg01616529	chr11:638424	DRD4	-0.61	-6.22	-0.45	4.52e-9	Systemic lupus erythematosus;
PAAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.69	7.17	0.5	3.14e-11	Type 2 diabetes;
PAAD	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg20849893	chr7:64541193	NA	0.48	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.75	8.26	0.56	6.66e-14	Colorectal cancer;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.45	-0.4	1.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.31	-0.33	2.97e-5	Lung cancer;
PAAD	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs743757	1.000	rs8180034	chr3:50518935	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	5.06	0.38	1.2e-6	Diastolic blood pressure;
PAAD	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.68	-7.01	-0.49	7.35e-11	Glycated hemoglobin levels;
PAAD	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.68	-7.22	-0.51	2.3e-11	Obesity-related traits;
PAAD	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.5	5.21	0.39	6.05e-7	QT interval;
PAAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg01306824	chr17:77834118	NA	0.58	4.43	0.34	1.77e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-7.65	-0.53	2.09e-12	Morning vs. evening chronotype;
PAAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg23463467	chr20:60627584	TAF4	0.48	5.16	0.39	7.57e-7	Body mass index;
PAAD	cis	rs4739066	0.579	rs78867188	chr8:63870128	A/G	cg12194929	chr8:63776755	NKAIN3	0.73	4.54	0.35	1.13e-5	Myocardial infarction;
PAAD	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.37	-0.51	1.02e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23576258	chr2:39999331	THUMPD2	-0.6	-6.55	-0.47	8.38e-10	Obesity-related traits;
PAAD	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	10.8	0.66	1.59e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.66	7.0	0.49	7.73e-11	Morning vs. evening chronotype;
PAAD	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg00579200	chr11:133705235	NA	-0.51	-5.89	-0.43	2.44e-8	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22846949	chr16:14723829	PARN	0.56	6.3	0.46	3.12e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-18.17	-0.83	6.2e-40	Exhaled nitric oxide output;
PAAD	cis	rs2147959	0.825	rs12746910	chr1:228658133	G/A	cg18477163	chr1:228402036	OBSCN	0.44	4.64	0.35	7.53e-6	Adult asthma;
PAAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg16147221	chr4:10020634	SLC2A9	0.48	4.41	0.34	1.91e-5	Bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16590546	chr2:47169188	MCFD2;TTC7A	-0.62	-6.55	-0.47	8.44e-10	Smoking initiation;
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13870426	chr17:30244630	NA	-0.78	-7.63	-0.53	2.46e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg16898833	chr6:26189333	HIST1H4D	0.48	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs10192350	chr2:652607	T/C	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg16306870	chr3:194868790	C3orf21	0.43	4.42	0.34	1.84e-5	Non-small cell lung cancer;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.76	7.71	0.53	1.49e-12	Menarche (age at onset);
PAAD	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg11157765	chr11:69982996	ANO1	0.62	4.86	0.37	2.86e-6	Survival in rectal cancer;
PAAD	cis	rs12738007	0.967	rs10915233	chr1:29475975	G/A	cg03512248	chr1:28517610	PTAFR	0.43	4.28	0.33	3.33e-5	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.43	-5.43	-0.4	2.18e-7	Lewy body disease;
PAAD	cis	rs17761864	0.555	rs72815304	chr17:2007004	C/T	cg16513277	chr17:2031491	SMG6	0.43	4.25	0.33	3.73e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	6.89	0.49	1.4e-10	Schizophrenia;
PAAD	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.52	-5.03	-0.38	1.35e-6	P wave terminal force;
PAAD	cis	rs3812049	0.532	rs251390	chr5:127538346	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.73	0.42	5.17e-8	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24110177	chr3:50126178	RBM5	-0.72	-6.5	-0.47	1.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs959260	0.925	rs4788890	chr17:73389446	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.05	-0.38	1.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.64e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg26247942	chr15:43984922	CKMT1A	0.35	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs1847202	1.000	rs1847202	chr3:72934371	T/C	cg25664220	chr3:72788482	NA	-0.45	-4.81	-0.36	3.63e-6	Motion sickness;
PAAD	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.31	0.6	1.32e-16	Bipolar disorder;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.69	-6.83	-0.48	1.94e-10	Uric acid levels;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.8	-0.36	3.76e-6	Obesity-related traits;
PAAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25833597	chr17:30823145	MYO1D	0.52	5.02	0.38	1.45e-6	Schizophrenia;
PAAD	cis	rs1334894	0.892	rs12527303	chr6:35487734	C/T	cg07213720	chr6:35227408	ZNF76	-0.83	-4.39	-0.34	2.1e-5	Coronary artery disease;
PAAD	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14644898	chr2:9615234	IAH1	0.58	6.31	0.46	2.96e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.1	14.52	0.76	1.64e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.03	0.44	1.22e-8	Lung cancer in ever smokers;
PAAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27308218	chr2:173893111	RAPGEF4	0.57	7.03	0.5	6.43e-11	Smoking initiation;
PAAD	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg24631222	chr15:78858424	CHRNA5	0.75	5.71	0.42	5.69e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg05110241	chr16:68378359	PRMT7	-1.12	-8.19	-0.55	1.01e-13	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs9581857	0.547	rs9581878	chr13:28104552	T/A	cg22138327	chr13:27999177	GTF3A	0.79	5.31	0.4	3.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08350814	chr2:191045309	C2orf88	-0.75	-6.55	-0.47	8.19e-10	Neuroticism;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08120226	chr3:195531633	MUC4	0.45	4.77	0.36	4.32e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg09941381	chr10:64027924	RTKN2	-0.38	-4.61	-0.35	8.39e-6	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12474201	0.851	rs56288593	chr2:47018772	G/A	cg06386533	chr2:46925753	SOCS5	0.72	7.84	0.54	7.21e-13	Height;
PAAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg14703610	chr5:56206110	C5orf35	-0.55	-5.11	-0.38	9.42e-7	Initial pursuit acceleration;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.51	4.56	0.35	1.07e-5	Testicular germ cell tumor;
PAAD	cis	rs59888335	0.929	rs12631950	chr3:80864190	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg02258303	chr16:87377426	FBXO31	-0.63	-6.25	-0.45	3.85e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs77774742	0.887	rs6911701	chr6:145350949	C/T	cg11675148	chr6:146285568	SHPRH	-0.74	-4.66	-0.35	6.93e-6	Loneliness (multivariate analysis);
PAAD	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg19090574	chr1:205240910	TMCC2	-0.4	-4.36	-0.33	2.36e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs863345	0.604	rs1342948	chr1:158463294	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.94	-0.37	2.08e-6	Pneumococcal bacteremia;
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.83	9.06	0.59	6.2e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg18279126	chr7:2041391	MAD1L1	0.62	6.08	0.44	9.23e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11105468	0.961	rs11105452	chr12:90279165	A/C	cg16962463	chr12:89968675	NA	0.44	4.31	0.33	2.94e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	9.56	0.61	2.99e-17	Ulcerative colitis;
PAAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.64	-6.23	-0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.54	4.58	0.35	9.53e-6	Sudden cardiac arrest;
PAAD	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.49	-4.68	-0.35	6.41e-6	Mean platelet volume;
PAAD	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.86	9.08	0.59	5.26e-16	Corneal astigmatism;
PAAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.66	-8.65	-0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs717267	0.552	rs10511619	chr9:16424985	T/C	cg12478165	chr22:39785435	NA	-0.64	-6.47	-0.46	1.29e-9	Gestational age at birth (maternal effect);
PAAD	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11671653	1.000	rs111957218	chr19:10839089	T/C	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.77	9.23	0.6	2.21e-16	Lung cancer;
PAAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.82e-16	Parkinson's disease;
PAAD	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.47	4.56	0.35	1.07e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1015291	0.671	rs1352904	chr12:19995014	C/T	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg25952890	chr19:58913133	NA	0.64	5.42	0.4	2.29e-7	Mean platelet volume;
PAAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs10929159	0.928	rs34769167	chr2:236920442	A/G	cg14226755	chr2:236923322	AGAP1	0.29	4.61	0.35	8.62e-6	Parkinson's disease;
PAAD	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17376030	chr22:41985996	PMM1	-0.64	-4.4	-0.34	1.99e-5	Vitiligo;
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19926630	chr4:1401854	NA	0.34	4.29	0.33	3.11e-5	Longevity;
PAAD	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg19264203	chr11:92714893	MTNR1B	0.42	4.78	0.36	4.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.56	-0.41	1.15e-7	Mean platelet volume;
PAAD	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.94	8.02	0.55	2.56e-13	Blood protein levels;
PAAD	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.26	0.6	1.87e-16	Post bronchodilator FEV1;
PAAD	cis	rs1443512	0.588	rs10747688	chr12:54346495	C/G	cg17410650	chr12:54324560	NA	-0.38	-4.73	-0.36	5.2e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs901683	1.000	rs36102549	chr10:46082043	T/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2562456	0.754	rs62107469	chr19:21495501	T/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg12454169	chr2:30669597	LCLAT1	0.76	6.22	0.45	4.65e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs17162190	0.698	rs12046614	chr1:26851729	A/C	cg17456097	chr1:26900765	RPS6KA1	0.58	4.64	0.35	7.55e-6	Mean corpuscular volume;
PAAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17848003	chr1:3704513	LRRC47	0.44	4.69	0.36	5.95e-6	Red cell distribution width;
PAAD	cis	rs375066	0.901	rs374307	chr19:44404398	G/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.18	9.82	0.62	6.31e-18	Iron status biomarkers;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.59	5.79	0.43	3.88e-8	Acylcarnitine levels;
PAAD	cis	rs10450586	0.863	rs7102043	chr11:27305839	C/T	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg03517284	chr6:25882590	NA	-0.49	-4.55	-0.35	1.09e-5	Blood metabolite levels;
PAAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg24253500	chr15:84953950	NA	0.56	6.57	0.47	7.64e-10	Schizophrenia;
PAAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.01	-0.38	1.52e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg10396713	chr8:602097	NA	0.7	4.76	0.36	4.51e-6	IgG glycosylation;
PAAD	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-4.37	-0.33	2.33e-5	Height;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13518211	chr9:115142604	HSDL2	-0.58	-6.69	-0.48	4.07e-10	Body fat percentage;
PAAD	cis	rs3125734	0.633	rs1835862	chr10:64056068	G/A	cg19640130	chr10:64028056	RTKN2	-0.36	-4.25	-0.33	3.66e-5	Rheumatoid arthritis;
PAAD	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	4.52	0.34	1.23e-5	Glomerular filtration rate (creatinine);Chronic kidney disease;
PAAD	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg13045555	chr8:105342365	NA	0.24	4.28	0.33	3.26e-5	Paget's disease;
PAAD	cis	rs2371030	0.965	rs4673548	chr2:211571627	T/C	cg18417063	chr2:211583084	NA	-0.43	-4.26	-0.33	3.61e-5	Non-small cell lung cancer;
PAAD	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg22852734	chr6:133119734	C6orf192	0.99	4.41	0.34	1.96e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.78	10.25	0.64	4.5e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg06883089	chr1:45254480	BEST4	-0.36	-4.44	-0.34	1.7e-5	High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.38	0.4	2.73e-7	Prudent dietary pattern;
PAAD	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.46	-0.8	1.35e-35	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04173182	chr4:54446035	LNX1	-0.59	-6.39	-0.46	1.92e-9	Obesity-related traits;
PAAD	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.45	0.34	1.67e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.37	-4.97	-0.37	1.78e-6	Schizophrenia;
PAAD	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.76	-0.36	4.42e-6	Neuroticism;
PAAD	cis	rs12438356	0.881	rs7171293	chr15:69580421	C/T	cg02375503	chr15:69591110	PAQR5	-0.58	-4.29	-0.33	3.11e-5	CTACK levels;
PAAD	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.31	-0.4	3.75e-7	Schizophrenia;
PAAD	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-1.07	-8.77	-0.58	3.39e-15	Blood trace element (Zn levels);
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg26174226	chr8:58114915	NA	-0.56	-4.32	-0.33	2.76e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs901683	0.850	rs77364880	chr10:45996100	G/A	cg11747279	chr17:21096632	NA	0.91	6.76	0.48	2.77e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg26205652	chr12:48591994	NA	0.96	10.34	0.64	2.65e-19	Longevity (90 years and older);
PAAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.76	-8.58	-0.57	1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg12935359	chr14:103987150	CKB	-0.64	-7.23	-0.51	2.22e-11	Body mass index;
PAAD	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	4.34	0.33	2.54e-5	Verbal declarative memory;
PAAD	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.78	9.03	0.59	7.32e-16	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.97	8.36	0.56	3.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.6	6.06	0.44	1.02e-8	Blood metabolite ratios;
PAAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.62	-0.65	4.69e-20	Systemic lupus erythematosus;
PAAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg03732007	chr1:2071316	PRKCZ	-0.48	-5.09	-0.38	1.05e-6	Height;
PAAD	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.67	5.34	0.4	3.34e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg10587741	chr22:38071170	LGALS1	0.66	7.3	0.51	1.52e-11	Fat distribution (HIV);
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.85	-0.62	5.37e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs11638815	0.581	rs28808991	chr15:83260979	G/C	cg00614314	chr15:82944287	LOC80154	0.44	4.42	0.34	1.86e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25744214	chr10:72164137	EIF4EBP2	-0.72	-6.45	-0.46	1.39e-9	Neuroticism;
PAAD	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.57	4.53	0.35	1.18e-5	Obesity-related traits;
PAAD	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.6	8.83	0.58	2.3e-15	Homoarginine levels;
PAAD	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg10433327	chr15:56209506	NEDD4	-0.31	-4.26	-0.33	3.54e-5	Keloid;
PAAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.97	8.93	0.59	1.29e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg00590817	chr1:8272081	NA	-0.35	-4.34	-0.33	2.54e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.61	6.42	0.46	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.61	-5.87	-0.43	2.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg10729496	chr3:10149963	C3orf24	0.85	7.05	0.5	5.8e-11	Alzheimer's disease;
PAAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.49	-0.34	1.38e-5	Schizophrenia;
PAAD	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.73	0.36	4.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.51	4.96	0.37	1.86e-6	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17389218	chr12:52345187	ACVR1B	0.59	6.39	0.46	1.97e-9	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21087902	chr17:79234955	SLC38A10	0.62	6.5	0.47	1.1e-9	Smoking initiation;
PAAD	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.55	5.05	0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	4.47	0.34	1.54e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2812378	1.000	rs2812378	chr9:34710260	A/G	cg18540325	chr9:33795118	PRSS3	-0.44	-4.28	-0.33	3.3e-5	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg15117754	chr3:10150083	C3orf24	0.76	6.57	0.47	7.57e-10	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.79	9.07	0.59	5.72e-16	Lung cancer;
PAAD	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.5	-4.7	-0.36	5.71e-6	Hypospadias;
PAAD	cis	rs2455799	0.964	rs2121731	chr3:15864047	C/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Mean platelet volume;
PAAD	cis	rs6460942	0.597	rs7778131	chr7:12543233	T/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2637266	0.685	rs2395427	chr10:78462535	G/A	cg18941641	chr10:78392320	NA	0.36	4.42	0.34	1.84e-5	Pulmonary function;
PAAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	trans	rs9428104	0.920	rs12734916	chr1:118917162	G/A	cg18701660	chr19:34012935	PEPD	0.67	6.29	0.45	3.17e-9	Height;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs8105895	1.000	rs2359820	chr19:22208114	G/T	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.45	5.63	0.42	8.57e-8	Renal cell carcinoma;
PAAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.56	7.21	0.5	2.44e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.69	7.1	0.5	4.59e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6494488	0.500	rs58590788	chr15:64959617	A/G	cg16425858	chr15:64791681	ZNF609	0.93	4.93	0.37	2.11e-6	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.57	0.35	1.02e-5	Renal cell carcinoma;
PAAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.46	-4.33	-0.33	2.67e-5	Renal cell carcinoma;
PAAD	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Mean platelet volume;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.53e-6	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.79	0.62	7.68e-18	Platelet count;
PAAD	cis	rs35160687	0.712	rs11681689	chr2:86483162	A/G	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	cis	rs10901513	0.932	rs35958975	chr10:127667708	T/G	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs3753841	0.801	rs10782904	chr1:103251006	A/G	cg24495344	chr1:103574097	COL11A1	-0.39	-4.47	-0.34	1.5e-5	Glaucoma (primary angle closure);
PAAD	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.54	-0.47	8.81e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg12362517	chr11:133800685	IGSF9B	0.57	5.63	0.42	8.43e-8	Parkinson's disease;
PAAD	cis	rs3812111	0.641	rs9387383	chr6:116422847	A/G	cg05304507	chr6:116381966	FRK	0.24	4.4	0.34	2.03e-5	Age-related macular degeneration;
PAAD	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg16766828	chr3:128327626	NA	-0.45	-6.01	-0.44	1.31e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg05895507	chr15:77155635	SCAPER	-0.38	-4.29	-0.33	3.2e-5	Blood metabolite levels;
PAAD	cis	rs10821973	0.527	rs4559572	chr10:63974950	C/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.43	-0.34	1.78e-5	IgG glycosylation;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-6.72	-0.48	3.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01765077	chr12:122356316	WDR66	0.68	6.84	0.49	1.78e-10	Mean corpuscular volume;
PAAD	cis	rs10512697	0.655	rs13169644	chr5:3501506	A/T	cg19473799	chr5:3511975	NA	1.03	4.74	0.36	4.97e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.51	0.47	1.04e-9	Aortic root size;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg23985595	chr17:80112537	CCDC57	0.44	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.98e-6	Cognitive ability;
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg10207240	chr12:122356781	WDR66	0.53	5.63	0.42	8.42e-8	Mean corpuscular volume;
PAAD	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	6.69	0.48	3.99e-10	Breast cancer;
PAAD	cis	rs258892	0.947	rs9885319	chr5:72179404	T/G	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.61	6.28	0.45	3.35e-9	Resting heart rate;
PAAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.69	6.77	0.48	2.66e-10	Initial pursuit acceleration;
PAAD	cis	rs1879734	0.636	rs11206211	chr1:54188096	C/T	cg14659662	chr1:54151053	GLIS1	0.32	4.66	0.35	6.84e-6	Mitral valve prolapse;
PAAD	cis	rs12967884	0.892	rs6506863	chr18:76594211	C/A	cg16859165	chr18:76601647	NA	-0.54	-4.37	-0.33	2.26e-5	Subcutaneous adipose tissue;
PAAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg15404791	chr6:16147669	MYLIP	0.72	6.36	0.46	2.23e-9	Photic sneeze reflex;
PAAD	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.75	0.36	4.6e-6	Menopause (age at onset);
PAAD	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.78	9.42	0.61	6.82e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg15556689	chr8:8085844	FLJ10661	-0.72	-7.01	-0.49	7.27e-11	Morning vs. evening chronotype;
PAAD	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-7.55	-0.52	3.67e-12	Heart rate;
PAAD	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.47	7.02	0.49	6.84e-11	Information processing speed;
PAAD	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.64	6.2	0.45	5.19e-9	Corneal astigmatism;
PAAD	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-8.05	-0.55	2.17e-13	Neuroticism;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.73	7.45	0.52	6.5e-12	Lung cancer;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.83	-7.95	-0.54	3.87e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.57	-4.82	-0.36	3.48e-6	Coronary artery disease;
PAAD	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg13207630	chr7:32358064	NA	0.97	4.98	0.37	1.68e-6	Body mass index;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-0.86	-6.87	-0.49	1.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11700980	0.551	rs56165045	chr21:30114027	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs332507	0.830	rs35816663	chr3:124405513	G/T	cg05980111	chr3:124395277	KALRN	0.46	4.59	0.35	9.04e-6	Plateletcrit;
PAAD	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.88	10.51	0.65	8.99e-20	Metabolic syndrome;
PAAD	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg15117754	chr3:10150083	C3orf24	0.8	7.03	0.5	6.39e-11	Alzheimer's disease;
PAAD	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.84	-9.85	-0.62	5.13e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2671540	0.547	rs10822240	chr10:65646831	C/T	cg19573236	chr10:65733388	NA	-0.56	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.17	-0.5	3.1e-11	Morning vs. evening chronotype;
PAAD	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg09597638	chr17:3907349	NA	-0.73	-7.92	-0.54	4.55e-13	Type 2 diabetes;
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg20917491	chr3:195578259	NA	0.5	4.96	0.37	1.89e-6	Pancreatic cancer;
PAAD	cis	rs11897432	0.532	rs72790949	chr2:43858032	T/C	cg08726338	chr2:43904011	PLEKHH2;LOC728819	-0.4	-4.42	-0.34	1.9e-5	DNA methylation (variation);
PAAD	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.52	-4.41	-0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs71636778	0.631	rs74465889	chr1:27209439	A/G	cg12203394	chr1:27248618	NUDC	0.64	4.57	0.35	9.9e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg04809136	chr2:24300158	SF3B14	-0.4	-4.75	-0.36	4.69e-6	Quantitative traits;
PAAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg16964102	chr10:135390573	NA	-0.44	-4.54	-0.35	1.14e-5	Obesity-related traits;
PAAD	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.66	6.33	0.46	2.64e-9	Refractive astigmatism;
PAAD	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg24553058	chr2:113831203	IL1F10	0.46	5.19	0.39	6.54e-7	Protein quantitative trait loci;
PAAD	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.44	0.56	2.37e-14	Vitamin D levels;
PAAD	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01000515	chr17:19265555	B9D1	0.56	6.42	0.46	1.67e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs757110	0.524	rs214095	chr11:17293462	T/A	cg15432903	chr11:17409602	KCNJ11	-0.53	-5.67	-0.42	7.14e-8	Type 2 diabetes;
PAAD	cis	rs66530629	0.917	rs12121345	chr1:25130783	T/C	cg01905478	chr1:25040257	NA	0.49	5.42	0.4	2.27e-7	Plateletcrit;
PAAD	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs7640424	0.649	rs1369555	chr3:107901184	A/G	cg09227934	chr3:107805635	CD47	0.41	4.79	0.36	3.97e-6	Body mass index;
PAAD	cis	rs300774	0.925	rs300707	chr2:141324	G/T	cg21211680	chr2:198530	NA	-0.6	-5.72	-0.42	5.44e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg14403583	chr14:105418241	AHNAK2	-0.76	-8.12	-0.55	1.46e-13	Rheumatoid arthritis;
PAAD	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.23	-0.6	2.16e-16	Schizophrenia;
PAAD	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.79	-7.18	-0.5	2.88e-11	Pancreatic cancer;
PAAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.86	0.37	2.95e-6	Breast cancer;
PAAD	cis	rs34734847	0.933	rs11065202	chr12:121112429	T/C	cg21892295	chr12:121157589	UNC119B	-0.46	-5.87	-0.43	2.68e-8	Mean corpuscular volume;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg07068956	chr7:100330872	ZAN	-0.69	-5.39	-0.4	2.66e-7	Other erythrocyte phenotypes;
PAAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.64	-0.35	7.54e-6	Renal cell carcinoma;
PAAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.86	7.42	0.52	7.91e-12	Recombination rate (females);
PAAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg24253500	chr15:84953950	NA	0.41	4.32	0.33	2.8e-5	Schizophrenia;
PAAD	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.39	-0.4	2.65e-7	Common traits (Other);
PAAD	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-7.09	-0.5	4.66e-11	Parkinson's disease;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.74e-5	Bipolar disorder;
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg04154034	chr17:28927549	LRRC37B2	0.72	4.27	0.33	3.4e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg15192750	chr16:69999425	NA	0.74	5.97	0.44	1.57e-8	IgE levels;
PAAD	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg11802864	chr11:65308245	LTBP3	0.82	5.66	0.42	7.28e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1355223	0.837	rs11600402	chr11:34691751	C/G	cg18508148	chr11:34937573	PDHX;APIP	-0.44	-4.5	-0.34	1.35e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27403822	chr1:179050983	TOR3A	0.65	7.25	0.51	1.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs965604	1.000	rs12903295	chr15:78778972	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-4.55	-0.35	1.1e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	0.99	7.97	0.54	3.46e-13	Neutrophil percentage of white cells;
PAAD	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.76	4.66	0.35	6.72e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.49	5.44	0.4	2.12e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg11383961	chr2:242626575	DTYMK	0.6	6.46	0.46	1.37e-9	Smoking initiation;
PAAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg21395723	chr22:39101663	GTPBP1	0.45	4.53	0.34	1.19e-5	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs375066	0.935	rs397346	chr19:44399115	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.68	0.48	4.19e-10	Breast cancer;
PAAD	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.87	10.09	0.63	1.18e-18	Ulcerative colitis;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	0.681	rs71494795	chr10:45987745	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg21605333	chr4:119757512	SEC24D	0.8	5.98	0.44	1.5e-8	Cannabis dependence symptom count;
PAAD	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.69	-0.36	6.03e-6	Mood instability;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg03538708	chr1:25844672	NA	-0.5	-5.14	-0.38	8.51e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.99	5.27	0.39	4.6e-7	Childhood ear infection;
PAAD	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg24565620	chr2:194026	NA	-0.63	-5.41	-0.4	2.43e-7	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08265889	chr5:63990800	FAM159B	0.63	7.18	0.5	2.83e-11	Smoking initiation;
PAAD	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg16083429	chr3:49237500	CCDC36	-0.43	-4.25	-0.33	3.75e-5	Menarche (age at onset);
PAAD	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs300774	1.000	rs300802	chr2:104762	G/A	cg21211680	chr2:198530	NA	-0.58	-5.39	-0.4	2.61e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.56	0.57	1.18e-14	Morning vs. evening chronotype;
PAAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.71	-4.25	-0.33	3.68e-5	Tuberculosis;
PAAD	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs12936587	0.601	rs11655881	chr17:17553133	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-5.33	-0.4	3.46e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg22565399	chr5:176890677	DBN1	-0.88	-6.43	-0.46	1.53e-9	Red blood cell count;
PAAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg15105011	chr4:940614	TMEM175	0.66	7.65	0.53	2.17e-12	Sjögren's syndrome;
PAAD	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.99	0.49	7.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.55	0.41	1.25e-7	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg03264133	chr6:25882463	NA	0.43	4.25	0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg13722127	chr7:150037890	RARRES2	0.65	6.42	0.46	1.65e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.1	8.34	0.56	4.2e-14	Diabetic kidney disease;
PAAD	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.62	5.27	0.39	4.51e-7	Post bronchodilator FEV1;
PAAD	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	6.71	0.48	3.62e-10	Educational attainment;
PAAD	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.5	6.16	0.45	6.37e-9	Sitting height ratio;
PAAD	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs12475964	0.574	rs13020602	chr2:37381621	T/C	cg22370082	chr2:37384244	EIF2AK2	0.45	4.49	0.34	1.4e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.92	5.68	0.42	6.65e-8	Alzheimer's disease (late onset);
PAAD	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-5.84	-0.43	3.03e-8	Pancreatic cancer;
PAAD	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.49	-5.25	-0.39	5.12e-7	Vitamin D levels;
PAAD	cis	rs4523957	0.928	rs394752	chr17:2199749	C/A	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.93e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg02737268	chr20:3780182	CDC25B	-0.45	-4.48	-0.34	1.45e-5	Bipolar disorder;
PAAD	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.95	13.4	0.74	1.55e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.86	10.24	0.64	4.94e-19	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27279652	chr12:26986506	ITPR2	0.61	7.06	0.5	5.69e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg17425144	chr1:10567563	PEX14	0.62	7.35	0.51	1.12e-11	Prostate cancer;
PAAD	cis	rs7236492	1.000	rs7236492	chr18:77220616	C/T	cg15644404	chr18:77186268	NFATC1	-0.84	-5.83	-0.43	3.15e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg04374321	chr14:90722782	PSMC1	0.54	4.36	0.33	2.35e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs742132	0.520	rs2294344	chr6:25652225	C/A	cg03517284	chr6:25882590	NA	0.65	4.3	0.33	2.99e-5	Uric acid levels;
PAAD	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.28	-0.39	4.41e-7	Common traits (Other);
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.67	-0.35	6.61e-6	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.79	5.55	0.41	1.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg17294928	chr15:75287854	SCAMP5	-0.68	-4.29	-0.33	3.11e-5	Lung cancer;
PAAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12165864	chr7:66369176	NA	-0.81	-5.34	-0.4	3.29e-7	Gout;
PAAD	cis	rs3106136	0.649	rs7672156	chr4:95289935	T/C	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs2735413	0.875	rs8053987	chr16:78084834	G/A	cg04733911	chr16:78082701	NA	0.56	5.93	0.43	1.98e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.56	-0.35	1.06e-5	Longevity;Endometriosis;
PAAD	cis	rs9585327	1.000	rs9585318	chr13:100678751	T/C	cg11288260	chr13:100117058	NA	0.22	4.4	0.34	2e-5	Myopia;
PAAD	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.09	-0.55	1.79e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	6.19	0.45	5.25e-9	Schizophrenia;
PAAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.1	-0.44	8.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg05134918	chr12:132603531	EP400NL	-0.67	-5.51	-0.41	1.53e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg16147221	chr4:10020634	SLC2A9	0.46	4.27	0.33	3.44e-5	Bone mineral density;
PAAD	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg25319279	chr11:5960081	NA	-0.56	-6.0	-0.44	1.37e-8	DNA methylation (variation);
PAAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg05754148	chr16:3507555	NAT15	0.72	5.16	0.39	7.44e-7	Tuberculosis;
PAAD	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg19637330	chr1:19110922	NA	-0.6	-4.94	-0.37	2.07e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11890956	chr21:40555474	PSMG1	1.09	12.0	0.7	9.37e-24	Cognitive function;
PAAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.89	-7.71	-0.53	1.49e-12	IgG glycosylation;
PAAD	cis	rs75920871	0.841	rs78442878	chr11:116922854	A/G	cg04087571	chr11:116723030	SIK3	-0.39	-4.29	-0.33	3.23e-5	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.75	0.62	9.55e-18	Prudent dietary pattern;
PAAD	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3981351	0.797	rs34394259	chr10:115441082	A/G	cg24846397	chr10:115438155	CASP7	-0.54	-5.05	-0.38	1.23e-6	Obesity-related traits;
PAAD	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.55	-0.41	1.23e-7	Bipolar disorder;
PAAD	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.74	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.41	-4.52	-0.34	1.24e-5	Mean platelet volume;
PAAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07395648	chr5:131743802	NA	0.5	4.54	0.35	1.14e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs1864585	0.520	rs17774331	chr8:10631226	C/T	cg21775007	chr8:11205619	TDH	-0.55	-4.28	-0.33	3.29e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.03	-0.5	6.57e-11	Morning vs. evening chronotype;
PAAD	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg07099767	chr17:78039528	CCDC40	-0.43	-4.26	-0.33	3.6e-5	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10821973	0.527	rs6479790	chr10:63980298	A/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07234876	chr8:600039	NA	-1.03	-7.52	-0.52	4.54e-12	IgG glycosylation;
PAAD	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg04106633	chr4:1044584	NA	0.62	5.23	0.39	5.65e-7	Recombination rate (females);
PAAD	cis	rs2637030	0.515	rs449160	chr5:53005969	A/G	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.3	0.33	3.05e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs1569175	0.522	rs2347286	chr2:200946393	T/C	cg23649088	chr2:200775458	C2orf69	-0.74	-5.09	-0.38	1.05e-6	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg01942863	chr7:99769432	GPC2	0.5	4.67	0.35	6.54e-6	Coronary artery disease;
PAAD	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-8.24	-0.56	7.53e-14	Electrocardiographic conduction measures;
PAAD	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.57	5.42	0.4	2.32e-7	Corneal astigmatism;
PAAD	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-5.22	-0.39	5.78e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs595018	0.505	rs56130163	chr11:60605547	C/T	cg07588442	chr11:60673866	PRPF19	0.68	4.57	0.35	9.84e-6	Wegener's granulomatosis;
PAAD	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg21994712	chr19:21861136	NA	-0.53	-5.19	-0.39	6.57e-7	Pain;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg18721089	chr20:30220636	NA	-0.81	-6.64	-0.47	5.17e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.03	11.73	0.69	5.07e-23	Breast cancer;
PAAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.73	-0.36	5.11e-6	Testicular germ cell tumor;
PAAD	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.09	14.88	0.77	1.79e-31	Testicular germ cell tumor;
PAAD	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	1.02	6.73	0.48	3.24e-10	Fat distribution (HIV);
PAAD	cis	rs6604026	0.656	rs2774953	chr1:93355254	G/A	cg13858687	chr1:93297071	RPL5	-0.48	-4.34	-0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.62	6.17	0.45	6.04e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	1.15	9.76	0.62	8.8e-18	Height;
PAAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg18944383	chr4:111397179	ENPEP	0.64	7.75	0.53	1.19e-12	Coronary artery disease;
PAAD	cis	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg14329783	chr7:75779857	NA	0.79	4.71	0.36	5.46e-6	Mononucleosis;
PAAD	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg19980929	chr12:42632907	YAF2	0.53	6.03	0.44	1.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg05294307	chr14:35346193	BAZ1A	-0.52	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-5.73	-0.42	5.18e-8	Major depressive disorder;
PAAD	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.05	0.38	1.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.53	5.12	0.38	9.03e-7	Mortality in heart failure;
PAAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg13263323	chr15:86062960	AKAP13	-0.62	-7.27	-0.51	1.76e-11	Interstitial lung disease;
PAAD	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-5.44	-0.4	2.13e-7	Resting heart rate;
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.47	-5.37	-0.4	2.86e-7	Breast size;
PAAD	cis	rs2271001	0.869	rs11025028	chr11:19145288	A/G	cg00161556	chr11:19138045	ZDHHC13	0.52	5.71	0.42	5.65e-8	Gut microbiome composition (winter);
PAAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.53	-0.34	1.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg08835956	chr7:39171034	POU6F2	0.32	5.58	0.41	1.07e-7	IgG glycosylation;
PAAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14580859	chr9:123691850	NA	0.38	4.28	0.33	3.3e-5	Rheumatoid arthritis;
PAAD	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.89	-0.43	2.45e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.44	4.49	0.34	1.39e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg08886695	chr4:3369023	RGS12	-0.51	-4.96	-0.37	1.89e-6	Serum sulfate level;
PAAD	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg16576597	chr16:28551801	NUPR1	0.68	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.08e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg10705379	chr10:99080932	FRAT1	0.45	5.3	0.4	3.92e-7	Monocyte count;
PAAD	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.24	0.67	1.05e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.86	10.1	0.63	1.13e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.53	-5.44	-0.4	2.07e-7	Body mass index;
PAAD	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.91	5.15	0.39	7.89e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg12046867	chr14:103022105	NA	0.6	4.8	0.36	3.79e-6	Platelet count;
PAAD	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12220238	0.915	rs11000987	chr10:76073265	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.6	5.05	0.38	1.26e-6	Diastolic blood pressure;
PAAD	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.89	11.33	0.68	5.91e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg00346145	chr4:109541559	RPL34;LOC285456	-0.64	-6.53	-0.47	9.2e-10	Dental caries;
PAAD	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.63	5.16	0.39	7.54e-7	Response to antidepressants in depression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25468681	chr1:9428106	SPSB1	-0.61	-6.49	-0.47	1.15e-9	Obesity-related traits;
PAAD	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.44	-4.59	-0.35	9.27e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs360071	0.528	rs360094	chr1:226064846	C/T	cg01472176	chr1:226074946	LEFTY1	-0.61	-5.88	-0.43	2.52e-8	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.97	10.54	0.65	7.88e-20	Platelet distribution width;
PAAD	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg00012203	chr2:219082015	ARPC2	0.59	6.1	0.44	8.43e-9	Colorectal cancer;
PAAD	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg05250797	chr16:70222502	NA	0.88	6.75	0.48	2.89e-10	IgE levels;
PAAD	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.75	7.16	0.5	3.15e-11	Total body bone mineral density;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.83	9.47	0.61	5.17e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg21419209	chr3:44054225	NA	-0.73	-7.49	-0.52	5.2e-12	Coronary artery disease;
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.01	-0.38	1.52e-6	Longevity;
PAAD	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.75	7.27	0.51	1.8e-11	Breast cancer;
PAAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-5.22	-0.39	5.91e-7	Monocyte count;
PAAD	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	1.07	8.34	0.56	4.22e-14	Inflammatory bowel disease;
PAAD	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg19337854	chr7:99768885	GPC2	0.45	4.33	0.33	2.75e-5	Lung function (FEV1/FVC);
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.6	7.62	0.53	2.55e-12	Hypertriglyceridemia;
PAAD	cis	rs2518049	0.539	rs4880709	chr10:5151355	G/A	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.77	-6.31	-0.46	2.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.57	5.77	0.42	4.37e-8	Urate levels;
PAAD	cis	rs6019826	0.524	rs6019838	chr20:48056147	T/C	cg20488617	chr20:48599436	SNAI1	-0.78	-4.5	-0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10819733	chr22:24237672	NA	0.45	4.54	0.35	1.16e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.51	-6.68	-0.48	4.13e-10	Height;
PAAD	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.07e-5	Type 2 diabetes;
PAAD	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	6.51	0.47	1.03e-9	Breast cancer;
PAAD	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg01338084	chr22:32026380	PISD	1.44	8.32	0.56	4.78e-14	Age-related hearing impairment;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02617837	chr12:107349530	C12orf23	-0.67	-6.64	-0.47	5.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg16926213	chr1:1841314	NA	0.38	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.79	0.58	3.03e-15	Parkinson's disease;
PAAD	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg01761236	chr14:102990251	NA	0.41	4.77	0.36	4.25e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg01064725	chr1:204461714	NA	-0.47	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.85	10.05	0.63	1.5e-18	Blood protein levels;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.68	7.31	0.51	1.42e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.24	-0.39	5.32e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1468734	1.000	rs36106459	chr16:5003509	C/T	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.72	-8.23	-0.56	7.71e-14	Handedness;
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00699235	chr12:49962218	MCRS1	0.62	6.79	0.48	2.31e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.13e-10	Testicular germ cell tumor;
PAAD	cis	rs900145	0.906	rs1384028	chr11:13295767	C/T	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.89	-0.69	1.86e-23	Longevity;Endometriosis;
PAAD	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg24375607	chr4:120327624	NA	0.44	4.36	0.33	2.35e-5	Diastolic blood pressure;
PAAD	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.53	5.37	0.4	2.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-7.23	-0.51	2.17e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.77	-8.48	-0.57	1.86e-14	Menopause (age at onset);
PAAD	cis	rs6782025	0.958	rs7645849	chr3:121112036	A/G	cg16417163	chr3:121280760	NA	-0.49	-4.96	-0.37	1.89e-6	Aging (facial);
PAAD	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.57	5.49	0.41	1.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg26570165	chr1:119541833	NA	-0.47	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg23153227	chr6:27725408	NA	0.5	4.76	0.36	4.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11006280	0.708	rs6481441	chr10:60606327	C/G	cg07625992	chr10:61007196	PHYHIPL;FAM13C	-0.46	-5.12	-0.38	9.2e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2115386	0.648	rs1896639	chr19:7203846	C/T	cg00428638	chr19:7224713	INSR	0.48	5.04	0.38	1.31e-6	Diabetic retinopathy;
PAAD	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.54	5.5	0.41	1.58e-7	Multiple sclerosis;
PAAD	cis	rs59888335	0.895	rs6769649	chr3:80862035	T/G	cg21735741	chr3:80819488	NA	0.57	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg20169779	chr10:135381914	SYCE1	-0.45	-4.66	-0.35	7e-6	Obesity-related traits;
PAAD	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.51	-5.28	-0.39	4.4e-7	Height;
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.28	0.56	5.91e-14	Lung cancer;
PAAD	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.66	6.98	0.49	8.38e-11	Testicular germ cell tumor;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05357674	chr10:88963437	NA	-0.63	-6.34	-0.46	2.51e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.62	7.13	0.5	3.7e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7631605	0.623	rs7619689	chr3:36981363	A/C	cg17445812	chr3:36986805	TRANK1	0.32	4.34	0.33	2.54e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.47	-0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs10951983	0.861	rs9374	chr7:6442371	G/A	cg20492034	chr7:6313058	CYTH3	-0.49	-4.3	-0.33	3.07e-5	Coronary artery disease;
PAAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg06375148	chr1:209958343	C1orf74	0.68	5.01	0.38	1.51e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-5.03	-0.38	1.39e-6	Triglycerides;
PAAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.72e-7	Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg06740227	chr12:86229804	RASSF9	0.61	5.18	0.39	6.99e-7	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26429905	chr20:35917924	MANBAL	0.59	6.44	0.46	1.47e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.74	6.45	0.46	1.41e-9	Dilated cardiomyopathy;
PAAD	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.34	-0.33	2.59e-5	Tuberculosis;
PAAD	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.76	-0.42	4.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.82	8.35	0.56	3.97e-14	Retinal vascular caliber;
PAAD	cis	rs12967884	1.000	rs12954385	chr18:76589654	G/A	cg16859165	chr18:76601647	NA	-0.54	-4.37	-0.33	2.26e-5	Subcutaneous adipose tissue;
PAAD	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.87	-0.43	2.68e-8	Total body bone mineral density;
PAAD	cis	rs11811982	0.793	rs75714930	chr1:227318676	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.88	-11.06	-0.67	3.17e-21	Bipolar disorder;
PAAD	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-6.42	-0.46	1.68e-9	Chronic sinus infection;
PAAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.27	-0.39	4.51e-7	Height;
PAAD	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.35	-0.33	2.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg11547950	chr5:77652471	NA	0.91	7.75	0.53	1.24e-12	Triglycerides;
PAAD	cis	rs377457	0.623	rs1053328	chr16:85711860	A/G	cg07784872	chr16:85687041	KIAA0182	0.8	8.75	0.58	3.88e-15	Type 2 diabetes;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-12.72	-0.72	1.08e-25	Longevity;Endometriosis;
PAAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg22442454	chr1:209979470	IRF6	0.51	4.34	0.33	2.61e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.66	-7.53	-0.52	4.26e-12	Vitiligo;
PAAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg14349672	chr11:133703707	NA	-0.48	-5.16	-0.39	7.68e-7	Childhood ear infection;
PAAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.96	10.43	0.65	1.48e-19	Diastolic blood pressure;
PAAD	cis	rs501120	0.929	rs2576355	chr10:44750362	A/G	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg26060667	chr1:247681242	NA	-0.45	-5.32	-0.4	3.71e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs35740288	0.721	rs17637276	chr15:86243520	T/C	cg07943548	chr15:86304357	KLHL25	-0.6	-5.12	-0.38	9.07e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-1.49	-9.02	-0.59	7.87e-16	Depression;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.5	4.5	0.34	1.35e-5	Lung cancer;
PAAD	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.6	7.03	0.5	6.51e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.46	0.34	1.59e-5	Lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04324126	chr2:55277572	RTN4	-0.71	-6.39	-0.46	1.88e-9	Neuroticism;
PAAD	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-4.53	-0.34	1.19e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.62	5.96	0.44	1.67e-8	Blood protein levels;
PAAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg19980929	chr12:42632907	YAF2	-0.5	-5.85	-0.43	2.95e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.68	7.83	0.54	7.9e-13	Systemic lupus erythematosus;
PAAD	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg11271282	chr2:238384023	NA	0.51	4.63	0.35	7.69e-6	Prostate cancer;
PAAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.54	-4.88	-0.37	2.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-1.05	-14.69	-0.77	5.67e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg03989125	chr22:38214979	NA	0.63	6.07	0.44	9.64e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg10495392	chr1:46806563	NSUN4	0.46	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.52	5.28	0.39	4.47e-7	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.71	5.15	0.39	7.89e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.71e-10	Migraine;Coronary artery disease;
PAAD	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.78	9.0	0.59	8.55e-16	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg14393609	chr7:65229607	NA	0.68	7.53	0.52	4.17e-12	Aortic root size;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg27615366	chr5:131592974	PDLIM4	0.41	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.6	7.16	0.5	3.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg21130718	chr4:1044621	NA	0.53	4.5	0.34	1.37e-5	Recombination rate (females);
PAAD	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7616330	0.895	rs7615404	chr3:71045288	T/C	cg01511742	chr3:71112437	FOXP1	-0.75	-6.0	-0.44	1.4e-8	QT interval;
PAAD	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	4.42	0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.5	5.43	0.4	2.17e-7	Longevity;Endometriosis;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10821973	0.527	rs7076775	chr10:64019606	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.7	7.03	0.5	6.48e-11	Lymphocyte counts;
PAAD	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg21479132	chr6:26055353	NA	0.67	4.64	0.35	7.61e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4751006	0.543	rs880761	chr10:128783906	C/T	cg05702161	chr10:128779687	DOCK1	-1.23	-6.98	-0.49	8.36e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.56	-0.35	1.05e-5	Rheumatoid arthritis;
PAAD	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.23	0.45	4.35e-9	Hip circumference;
PAAD	cis	rs2268241	1.000	rs2268241	chr21:34781050	G/A	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg20487152	chr13:99095054	FARP1	0.47	4.99	0.38	1.65e-6	Longevity;
PAAD	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.34	-0.33	2.58e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg14926445	chr8:58193284	C8orf71	0.68	4.94	0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11688874	chr10:28822482	WAC	0.59	6.4	0.46	1.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1903068	0.853	rs9312657	chr4:56003502	G/A	cg20092376	chr4:56023423	NA	0.41	4.27	0.33	3.48e-5	Endometriosis;
PAAD	cis	rs2964802	0.505	rs7715280	chr5:10809219	C/T	cg14521931	chr5:10832172	NA	-0.46	-4.69	-0.36	5.97e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-5.62	-0.41	9.08e-8	Sjögren's syndrome;
PAAD	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.08	-0.63	1.31e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs9788721	0.806	rs72738704	chr15:78719832	G/C	cg18825076	chr15:78729989	IREB2	-0.69	-7.17	-0.5	3.1e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg03605463	chr16:89740564	NA	0.52	4.81	0.36	3.58e-6	Vitiligo;
PAAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.51	-0.47	1.02e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Height;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg22442454	chr1:209979470	IRF6	0.51	4.5	0.34	1.37e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17191518	chr15:52468850	GNB5	-0.65	-6.37	-0.46	2.13e-9	Obesity-related traits;
PAAD	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.54	4.54	0.35	1.13e-5	Sudden cardiac arrest;
PAAD	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.64	7.54	0.52	3.98e-12	Aortic root size;
PAAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.56	0.35	1.05e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs11871801	0.560	rs1905339	chr17:40582296	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.55	-5.65	-0.42	7.73e-8	Crohn's disease;
PAAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.58	5.46	0.41	1.87e-7	Schizophrenia;
PAAD	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg20813462	chr7:2646259	IQCE	0.65	4.61	0.35	8.38e-6	Urate levels in lean individuals;
PAAD	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.8	-8.65	-0.57	6.95e-15	Mortality in heart failure;
PAAD	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.77	0.36	4.28e-6	Menarche (age at onset);
PAAD	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.4	5.48	0.41	1.7e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.06e-8	Life satisfaction;
PAAD	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs2133450	0.526	rs10510356	chr3:7350877	C/G	cg19930620	chr3:7340148	GRM7	-0.49	-5.45	-0.4	2.03e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.61	-6.11	-0.44	7.98e-9	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.88	-9.84	-0.62	5.69e-18	Prudent dietary pattern;
PAAD	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs9581857	0.547	rs74518675	chr13:27972180	A/G	cg22138327	chr13:27999177	GTF3A	0.88	5.57	0.41	1.13e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.44	4.36	0.33	2.34e-5	Dupuytren's disease;
PAAD	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.53	5.49	0.41	1.67e-7	Male-pattern baldness;
PAAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.61	8.14	0.55	1.33e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	12.85	0.72	4.84e-26	Platelet count;
PAAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs507080	0.922	rs644498	chr11:118567486	T/C	cg08498647	chr11:118550644	TREH	-0.38	-4.4	-0.34	2.06e-5	Serum metabolite levels;
PAAD	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.68	4.4	0.34	2.06e-5	Lung cancer in ever smokers;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.68	-8.62	-0.57	8.34e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4740619	0.592	rs2987096	chr9:16009457	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.51	-0.34	1.27e-5	Body mass index;
PAAD	cis	rs1879734	0.731	rs7519965	chr1:54163251	G/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.83	-0.43	3.15e-8	Mitral valve prolapse;
PAAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg06671706	chr8:8559999	CLDN23	0.75	7.36	0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg15181151	chr6:150070149	PCMT1	0.61	6.62	0.47	5.82e-10	Lung cancer;
PAAD	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg18068537	chr15:74660088	CYP11A1	-0.48	-4.32	-0.33	2.81e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs3812111	0.545	rs9387389	chr6:116573667	G/A	cg18764771	chr6:116381957	FRK	-0.27	-4.28	-0.33	3.3e-5	Age-related macular degeneration;
PAAD	cis	rs740474	0.831	rs3828677	chr5:140993623	C/T	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	-0.43	-5.23	-0.39	5.62e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3106136	0.678	rs7666873	chr4:95285342	G/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg26554054	chr8:600488	NA	-0.92	-5.77	-0.42	4.37e-8	IgG glycosylation;
PAAD	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.95	8.38	0.56	3.3e-14	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-5.72	-0.42	5.39e-8	Mean corpuscular volume;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.17e-10	Lymphocyte counts;
PAAD	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.82	8.91	0.59	1.45e-15	Aortic root size;
PAAD	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.76	7.9	0.54	5.17e-13	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg20913747	chr6:44695427	NA	-0.7	-6.86	-0.49	1.62e-10	Total body bone mineral density;
PAAD	cis	rs1443512	0.947	rs4759309	chr12:54342786	G/A	cg17410650	chr12:54324560	NA	-0.4	-5.91	-0.43	2.19e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg16434002	chr17:42200994	HDAC5	0.61	5.64	0.42	8.26e-8	Total body bone mineral density;
PAAD	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18364779	chr6:26104403	HIST1H4C	0.46	4.52	0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.84	-9.45	-0.61	5.81e-17	Caffeine consumption;
PAAD	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs35160687	0.644	rs4832036	chr2:86551302	T/C	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.94	13.06	0.73	1.28e-26	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.77	-7.58	-0.52	3.18e-12	Mosquito bite size;
PAAD	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg12935359	chr14:103987150	CKB	-0.55	-5.94	-0.43	1.9e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05025164	chr4:1340916	KIAA1530	-0.61	-6.44	-0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs7922314	0.571	rs10509180	chr10:64725970	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.8	-5.03	-0.38	1.39e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07638871	chr5:56247860	MIER3	0.67	6.54	0.47	8.93e-10	Obesity-related traits;
PAAD	cis	rs12431939	0.857	rs4547259	chr14:51669224	T/G	cg23942311	chr14:51606299	NA	0.51	4.41	0.34	1.94e-5	Cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25762744	chr1:155278691	FDPS	-0.62	-7.21	-0.5	2.41e-11	Body fat percentage;
PAAD	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.67	6.44	0.46	1.5e-9	Corneal astigmatism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22090150	chr17:4098227	ANKFY1	0.6	7.23	0.51	2.16e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs10792830	0.706	rs2508692	chr11:85756884	T/A	cg07180834	chr11:85838833	NA	-0.47	-5.2	-0.39	6.34e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.58	5.2	0.39	6.25e-7	Retinal vascular caliber;
PAAD	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg18721089	chr20:30220636	NA	-0.79	-6.02	-0.44	1.23e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-4.76	-0.36	4.52e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-1.08	-10.04	-0.63	1.64e-18	IgG glycosylation;
PAAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg20578329	chr17:80767326	TBCD	-0.54	-4.29	-0.33	3.22e-5	Breast cancer;
PAAD	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg09168692	chr1:7887560	PER3	-0.43	-4.4	-0.34	2.04e-5	Inflammatory bowel disease;
PAAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	-0.45	-4.42	-0.34	1.89e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg08886695	chr4:3369023	RGS12	-0.5	-4.83	-0.36	3.33e-6	Mean platelet volume;
PAAD	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg11204139	chr17:3907470	NA	0.75	7.89	0.54	5.47e-13	Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23808301	chr17:4710015	PLD2	-0.67	-6.37	-0.46	2.12e-9	Lung cancer in ever smokers;
PAAD	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.1	0.5	4.42e-11	Morning vs. evening chronotype;
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-6.93	-0.49	1.12e-10	Gut microbiome composition (summer);
PAAD	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.01	0.59	8.07e-16	Hemoglobin concentration;
PAAD	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg26913058	chr16:419975	MRPL28	-0.59	-5.22	-0.39	5.87e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.81	0.66	1.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs6700896	0.966	rs11208689	chr1:66083197	G/A	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.66e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs73019876	0.836	rs58974981	chr19:22151576	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.34	-0.33	2.55e-5	Testicular germ cell tumor;
PAAD	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.64	6.88	0.49	1.48e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	7.09	0.5	4.75e-11	Birth weight;
PAAD	cis	rs667920	0.512	rs13071085	chr3:136014923	G/A	cg15507776	chr3:136538369	TMEM22	-0.68	-4.36	-0.33	2.4e-5	Coronary artery disease;
PAAD	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.66	0.35	6.78e-6	Menopause (age at onset);
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.6	-6.84	-0.49	1.77e-10	Lung cancer;
PAAD	cis	rs58653258	0.554	rs2796159	chr1:234966107	A/C	cg03518729	chr1:235147744	NA	0.47	4.58	0.35	9.61e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.25	-18.58	-0.83	5.89e-41	Ulcerative colitis;
PAAD	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.6	-5.59	-0.41	1.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.59	4.96	0.37	1.88e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg17524180	chr13:113633600	MCF2L	-0.5	-5.47	-0.41	1.77e-7	Systolic blood pressure;
PAAD	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.87	5.36	0.4	3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg13256891	chr4:100009986	ADH5	-0.51	-4.96	-0.37	1.85e-6	Alcohol dependence;
PAAD	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.08	14.43	0.76	2.73e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg25547332	chr5:131281432	NA	-0.56	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs375066	0.935	rs373168	chr19:44430869	C/T	cg08633290	chr19:44405433	NA	-0.57	-5.66	-0.42	7.18e-8	Breast cancer;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10267417	0.603	rs10224406	chr7:19904088	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg18888403	chr1:24152774	HMGCL	0.39	4.42	0.34	1.84e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg11166453	chr1:247681781	NA	-0.56	-6.52	-0.47	9.89e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs9346353	0.713	rs960144	chr6:70413328	T/C	cg03001484	chr6:70507230	LMBRD1	-0.32	-4.45	-0.34	1.64e-5	Sleep duration;
PAAD	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.41	4.43	0.34	1.78e-5	Fibrinogen levels;
PAAD	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11624221	0.896	rs7143439	chr14:21136991	A/G	cg00657582	chr14:21904906	CHD8	0.42	4.34	0.33	2.58e-5	Blood protein levels;
PAAD	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.62	0.35	8.2e-6	Height;
PAAD	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-4.64	-0.35	7.51e-6	Menarche (age at onset);
PAAD	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.27	0.39	4.56e-7	Alcohol dependence;
PAAD	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-5.78	-0.42	4.08e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14893161	chr1:205819251	PM20D1	0.92	11.69	0.69	6.43e-23	Menarche (age at onset);
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.86	11.13	0.67	2e-21	Vitiligo;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg24846680	chr1:228362309	C1orf69	0.45	4.34	0.33	2.58e-5	Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	1.09	15.17	0.78	3.11e-32	Breast cancer;
PAAD	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.74	7.25	0.51	1.92e-11	Retinal vascular caliber;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-4.89	-0.37	2.58e-6	Longevity;Endometriosis;
PAAD	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg08992911	chr2:238395768	MLPH	-0.58	-5.04	-0.38	1.3e-6	Prostate cancer;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13939156	chr17:80058883	NA	-0.41	-4.38	-0.33	2.22e-5	Life satisfaction;
PAAD	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.9	0.37	2.41e-6	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.85	10.15	0.64	8.45e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.71	-6.76	-0.48	2.8e-10	Urate levels;
PAAD	cis	rs71520386	0.632	rs10269414	chr7:22856293	G/A	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.74e-7	Fibrinogen levels;
PAAD	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-9.5	-0.61	4.36e-17	Blood trace element (Zn levels);
PAAD	cis	rs2898290	0.601	rs1478891	chr8:11448328	G/C	cg21775007	chr8:11205619	TDH	0.5	4.48	0.34	1.48e-5	Systolic blood pressure;
PAAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.75	-6.88	-0.49	1.43e-10	Coronary artery disease;
PAAD	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.62	8.77	0.58	3.32e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.71	7.06	0.5	5.51e-11	Lymphocyte counts;
PAAD	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	6.03	0.44	1.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9463078	0.585	rs1748235	chr6:45141361	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg00945666	chr1:160990265	F11R	-0.42	-4.84	-0.37	3.2e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg06483076	chr3:194406458	FAM43A	0.57	5.41	0.4	2.41e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs6782025	1.000	rs7632907	chr3:121141718	C/T	cg16417163	chr3:121280760	NA	0.47	4.92	0.37	2.19e-6	Aging (facial);
PAAD	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.61	5.24	0.39	5.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs89107	0.575	rs11752928	chr6:118977768	C/G	cg21191810	chr6:118973309	C6orf204	0.37	4.44	0.34	1.71e-5	Cardiac structure and function;
PAAD	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.47e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.45	5.62	0.41	8.87e-8	Renal cell carcinoma;
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg01616529	chr11:638424	DRD4	-0.63	-5.68	-0.42	6.62e-8	Systemic lupus erythematosus;
PAAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.72	-4.86	-0.37	2.94e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2658782	0.901	rs2605611	chr11:93229319	T/G	cg15737290	chr11:93063684	CCDC67	0.76	5.66	0.42	7.2e-8	Pulmonary function decline;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.46	-4.58	-0.35	9.48e-6	Prudent dietary pattern;
PAAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06544989	chr22:39130855	UNC84B	0.48	4.92	0.37	2.25e-6	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs7577696	0.785	rs3769602	chr2:32381829	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-4.72	-0.36	5.21e-6	Inflammatory biomarkers;
PAAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.55	5.12	0.38	9.25e-7	Monocyte count;
PAAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg26695010	chr11:65641043	EFEMP2	0.57	5.38	0.4	2.76e-7	Eosinophil percentage of white cells;
PAAD	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.56	5.83	0.43	3.16e-8	Dupuytren's disease;
PAAD	cis	rs7631605	0.905	rs11714716	chr3:37269678	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.44	0.34	1.74e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	7.14	0.5	3.67e-11	Menarche (age at onset);
PAAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg25837213	chr17:80849375	TBCD	0.54	4.3	0.33	2.98e-5	Breast cancer;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.94	-0.66	6.54e-21	Platelet distribution width;
PAAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.58	-7.83	-0.54	7.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6942407	0.543	rs739712	chr7:86746798	G/A	cg14887563	chr7:86849180	C7orf23	0.49	4.27	0.33	3.45e-5	Food allergy;
PAAD	cis	rs30380	0.587	rs151940	chr5:96147777	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.03	-0.38	1.38e-6	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.47	-4.33	-0.33	2.72e-5	Menopause (age at onset);
PAAD	cis	rs4356203	0.870	rs214918	chr11:17239849	A/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs914615	0.529	rs11264338	chr1:155138557	A/G	cg18645493	chr1:154167437	MIR190B	0.45	4.29	0.33	3.13e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7089973	0.584	rs4752347	chr10:116646860	T/A	cg25233709	chr10:116636983	FAM160B1	0.46	5.71	0.42	5.88e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg00944433	chr1:107599041	PRMT6	0.41	4.63	0.35	7.93e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs2790457	0.518	rs2993984	chr10:28798656	A/T	cg05705492	chr10:28955341	NA	-0.44	-4.31	-0.33	2.9e-5	Multiple myeloma;
PAAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.42	-5.42	-0.4	2.31e-7	Ulcerative colitis;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.62	6.78	0.48	2.51e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs8105895	0.935	rs62110993	chr19:22268260	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.55	6.41	0.46	1.76e-9	Total body bone mineral density;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.76	5.94	0.43	1.89e-8	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27498675	chr19:41945691	ATP5SL	0.58	6.63	0.47	5.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg15131784	chr3:139108705	COPB2	-0.51	-4.35	-0.33	2.52e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.75	11.04	0.67	3.55e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6864727	0.855	rs529526	chr5:137443486	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	4.67	0.35	6.64e-6	Atrial fibrillation;
PAAD	cis	rs62025270	0.688	rs62025297	chr15:86316939	G/C	cg13263323	chr15:86062960	AKAP13	0.56	5.02	0.38	1.46e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.84	9.39	0.61	8.26e-17	Schizophrenia;
PAAD	cis	rs73198271	0.595	rs11780672	chr8:8584153	A/C	cg01851573	chr8:8652454	MFHAS1	0.62	4.61	0.35	8.65e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.6	0.41	1e-7	Coronary artery disease;
PAAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg22482690	chr17:47019901	SNF8	0.47	4.99	0.38	1.61e-6	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.68	0.53	1.82e-12	Prudent dietary pattern;
PAAD	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.86	-0.43	2.79e-8	Blood protein levels;
PAAD	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.6	-5.1	-0.38	1e-6	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06850241	chr22:41845214	NA	-0.52	-4.73	-0.36	5.06e-6	Vitiligo;
PAAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-8.33	-0.56	4.47e-14	Coronary artery disease;
PAAD	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg20933634	chr6:27740509	NA	0.78	7.21	0.5	2.43e-11	Breast cancer;
PAAD	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg25936770	chr7:122321411	CADPS2	0.62	6.31	0.46	2.96e-9	Body mass index;
PAAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.75	-6.96	-0.49	9.36e-11	Coronary artery disease;
PAAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.47	-8.44	-0.57	2.27e-14	Multiple system atrophy;
PAAD	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.64	6.97	0.49	9.14e-11	Blood protein levels;
PAAD	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	7.88	0.54	5.79e-13	Schizophrenia;
PAAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	1.04	11.5	0.68	2.05e-22	Gestational age at birth (maternal effect);
PAAD	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.78	-6.68	-0.48	4.15e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg07747251	chr5:1868357	NA	0.58	6.57	0.47	7.38e-10	Cardiovascular disease risk factors;
PAAD	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg05627522	chr15:75251581	NA	-0.52	-6.31	-0.46	2.95e-9	Caffeine consumption;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.54	-4.25	-0.33	3.69e-5	Carotid intima media thickness;
PAAD	cis	rs13065560	0.534	rs4481097	chr3:38909570	C/T	cg01426195	chr3:39028469	NA	0.47	4.48	0.34	1.46e-5	Interleukin-18 levels;
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.59	0.35	9.13e-6	Body mass index;
PAAD	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg24634471	chr8:143751801	JRK	-0.51	-4.6	-0.35	8.94e-6	Urinary tract infection frequency;
PAAD	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.76	8.11	0.55	1.56e-13	Blood metabolite levels;
PAAD	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.81	8.61	0.57	8.43e-15	Osteoporosis;
PAAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.32	0.33	2.77e-5	Blood protein levels;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg03665832	chr7:98923565	ARPC1A	-0.63	-6.35	-0.46	2.42e-9	Body mass index;
PAAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.91	0.37	2.32e-6	Menopause (age at onset);
PAAD	cis	rs370915	0.542	rs28440880	chr4:187793213	T/G	cg12892747	chr4:187813459	NA	-0.43	-4.26	-0.33	3.6e-5	Gout;
PAAD	cis	rs11811982	0.793	rs75679901	chr1:227512080	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.68	5.95	0.43	1.79e-8	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20185145	chr6:7230113	RREB1	0.53	6.34	0.46	2.43e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.38	4.76	0.36	4.38e-6	Red cell distribution width;
PAAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.17	-0.39	7.18e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08392591	chr16:89556376	ANKRD11	0.47	4.69	0.36	6.01e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.44	-6.78	-0.48	2.52e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	7.87	0.54	6.33e-13	Lung function (FEV1/FVC);
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg18279126	chr7:2041391	MAD1L1	-0.52	-5.11	-0.38	9.69e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.96	-7.72	-0.53	1.42e-12	Blood protein levels;
PAAD	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.65	6.08	0.44	9.31e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.75	0.36	4.66e-6	Depressive symptoms;
PAAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.47	-8.36	-0.56	3.68e-14	Multiple system atrophy;
PAAD	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.53	-6.51	-0.47	1.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.18	-11.7	-0.69	6.05e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	4.78	0.36	4.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.73	5.62	0.41	9.01e-8	Crohn's disease;
PAAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.65	6.45	0.46	1.38e-9	Blood metabolite levels;
PAAD	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.66	6.8	0.48	2.24e-10	Dupuytren's disease;
PAAD	cis	rs11971779	0.680	rs4732379	chr7:139122814	T/C	cg07862535	chr7:139043722	LUC7L2	0.62	4.81	0.36	3.68e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg16506815	chr2:162101123	NA	-0.57	-5.2	-0.39	6.42e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.84	9.18	0.6	2.91e-16	Platelet distribution width;
PAAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.69	5.75	0.42	4.67e-8	Gut microbiome composition (summer);
PAAD	cis	rs35164067	1.000	rs35164067	chr19:10525181	G/A	cg07306197	chr19:9546377	ZNF266	0.59	4.48	0.34	1.46e-5	Inflammatory bowel disease;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg16761131	chr22:38142377	TRIOBP	0.88	6.35	0.46	2.34e-9	Lung function (FEV1/FVC);
PAAD	cis	rs74544699	1.000	rs149611	chr4:74780396	C/A	cg05509609	chr4:74847829	PF4	1.13	4.5	0.34	1.34e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.53	0.47	9.4e-10	Coffee consumption (cups per day);
PAAD	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.56	-5.11	-0.38	9.66e-7	Serum sulfate level;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05676593	chr11:67276127	CDK2AP2	-0.73	-6.45	-0.46	1.41e-9	Neuroticism;
PAAD	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	7.42	0.52	7.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11094161	chr14:57736037	MUDENG;EXOC5	0.67	6.42	0.46	1.68e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg25753631	chr6:25732923	NA	0.46	5.75	0.42	4.83e-8	Iron status biomarkers;
PAAD	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg02683114	chr2:24398427	C2orf84	-0.61	-6.42	-0.46	1.65e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.65	6.85	0.49	1.74e-10	Mean corpuscular volume;
PAAD	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg03371404	chr2:241525653	CAPN10	-0.55	-4.84	-0.37	3.12e-6	Bipolar disorder;
PAAD	cis	rs7631605	0.819	rs4678922	chr3:37022864	A/T	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.59e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	4.41	0.34	1.95e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg26497354	chr6:109612229	NA	0.44	4.76	0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.53	-5.02	-0.38	1.46e-6	Menarche (age at onset);
PAAD	cis	rs2229238	0.911	rs7556449	chr1:154505886	C/T	cg21262032	chr1:154437693	IL6R	0.46	4.86	0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs346785	1.000	rs346785	chr17:74283769	C/T	cg09812376	chr17:74270190	QRICH2	0.43	5.96	0.44	1.66e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg19784903	chr17:45786737	TBKBP1	0.49	5.28	0.39	4.49e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.87	10.96	0.66	5.65e-21	Prudent dietary pattern;
PAAD	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.7	-0.42	6.12e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.36	3.64e-6	Coronary artery disease;
PAAD	cis	rs189798	0.738	rs330911	chr8:8996273	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	5.86	0.43	2.72e-8	Myopia (pathological);
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.84	-6.9	-0.49	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12165864	chr7:66369176	NA	0.74	4.71	0.36	5.6e-6	Diabetic kidney disease;
PAAD	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg24881330	chr22:46731750	TRMU	1.16	5.78	0.42	4.11e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.83	-8.3	-0.56	5.23e-14	Body mass index;
PAAD	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.17	-8.4	-0.56	2.89e-14	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11924518	chr12:48213110	HDAC7	0.66	6.64	0.47	5.1e-10	Obesity-related traits;
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.51	4.79	0.36	3.95e-6	Prostate-specific antigen levels;
PAAD	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.96	-0.72	2.42e-26	Primary sclerosing cholangitis;
PAAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-1.03	-14.09	-0.75	2.24e-29	Breast cancer;
PAAD	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.34	4.39	0.34	2.12e-5	Schizophrenia;
PAAD	cis	rs12482904	0.895	rs2839509	chr21:43846729	C/T	cg23042151	chr21:43824109	UBASH3A	0.53	6.35	0.46	2.38e-9	Vitiligo;
PAAD	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg12432903	chr7:1882776	MAD1L1	0.62	4.28	0.33	3.28e-5	Bipolar disorder;
PAAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg26876637	chr1:152193138	HRNR	-0.84	-6.23	-0.45	4.43e-9	Atopic dermatitis;
PAAD	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.21	0.55	8.74e-14	Colorectal cancer;
PAAD	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.76	7.14	0.5	3.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9944275	0.860	rs71396872	chr15:97196158	C/A	cg23969200	chr15:97326567	SPATA8	0.66	4.35	0.33	2.49e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs654384	0.966	rs612476	chr7:4165790	G/A	cg27574739	chr7:4176374	SDK1	0.46	4.59	0.35	9.05e-6	Positive affect;
PAAD	cis	rs13144136	0.664	rs4296670	chr4:10651160	C/T	cg10242279	chr4:10666415	CLNK	-0.49	-6.28	-0.45	3.35e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-5.95	-0.43	1.81e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.06	-0.38	1.18e-6	Body mass index;
PAAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.41	4.49	0.34	1.42e-5	Aortic root size;
PAAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22633769	chr20:60982531	CABLES2	-0.49	-4.84	-0.37	3.17e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs12532960	0.731	rs12532955	chr7:42376839	C/T	cg27332053	chr7:42446175	NA	-0.68	-4.43	-0.34	1.81e-5	Inflammatory biomarkers;
PAAD	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg04717802	chr22:42394638	WBP2NL	0.55	4.72	0.36	5.25e-6	Birth weight;
PAAD	trans	rs7172971	0.506	rs116953180	chr15:42384290	T/C	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.2	0.6	2.63e-16	Gut microbiome composition (summer);
PAAD	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.46	4.74	0.36	4.88e-6	Brain structure;
PAAD	cis	rs939584	1.000	rs10865550	chr2:641718	T/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27297192	chr10:134578999	INPP5A	0.58	5.6	0.41	9.59e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg01851573	chr8:8652454	MFHAS1	0.68	5.49	0.41	1.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.5	5.03	0.38	1.36e-6	Menopause (age at onset);
PAAD	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg06569542	chr10:98946673	SLIT1	0.5	5.62	0.41	8.79e-8	Monocyte count;
PAAD	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06026331	chr20:60912101	LAMA5	0.57	4.62	0.35	8.09e-6	Colorectal cancer;
PAAD	cis	rs1144333	0.655	rs75146987	chr1:76467878	T/G	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.36e-8	Eosinophil percentage of granulocytes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04035353	chr16:89335133	ANKRD11	-0.59	-6.49	-0.47	1.15e-9	Myopia (pathological);
PAAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07395648	chr5:131743802	NA	-0.52	-4.68	-0.36	6.25e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs17032980	0.910	rs6748553	chr2:67320714	G/A	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.01e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.45	4.73	0.36	5.09e-6	Type 1 diabetes;
PAAD	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17274072	chr15:90904227	ZNF774	0.61	7.16	0.5	3.28e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.65	-7.15	-0.5	3.42e-11	Menopause (age at onset);
PAAD	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg22517653	chr1:2918612	NA	-0.65	-5.18	-0.39	6.79e-7	Plateletcrit;
PAAD	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg14146966	chr2:61757674	XPO1	-0.38	-4.8	-0.36	3.84e-6	Tuberculosis;
PAAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg03983715	chr16:68378420	PRMT7	-0.55	-4.25	-0.33	3.78e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs258892	0.895	rs10077575	chr5:72084557	A/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.47	4.87	0.37	2.76e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	Schizophrenia;
PAAD	cis	rs1800469	1.000	rs2241715	chr19:41856886	A/C	cg09537434	chr19:41945824	ATP5SL	-0.57	-5.37	-0.4	2.9e-7	Colorectal cancer;
PAAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg07959070	chr22:50026188	C22orf34	-0.37	-4.28	-0.33	3.26e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.54	5.22	0.39	5.66e-7	Essential tremor;
PAAD	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.55	-7.41	-0.52	8.28e-12	Rheumatoid arthritis;
PAAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.73	-4.41	-0.34	1.93e-5	Tuberculosis;
PAAD	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.6	4.69	0.36	6.01e-6	Neutrophil percentage of white cells;
PAAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.75	8.6	0.57	9.19e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6921919	0.848	rs9468350	chr6:28319107	A/G	cg23153227	chr6:27725408	NA	0.49	4.26	0.33	3.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg05895507	chr15:77155635	SCAPER	-0.38	-4.28	-0.33	3.31e-5	Blood metabolite levels;
PAAD	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-1.1	-5.55	-0.41	1.25e-7	Inflammatory biomarkers;
PAAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.27	-0.6	1.71e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-4.56	-0.35	1.03e-5	Tonsillectomy;
PAAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.45	4.48	0.34	1.48e-5	Aortic root size;
PAAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs11825064	0.666	rs61393915	chr11:134496330	C/T	cg02089395	chr11:134479357	NA	-0.84	-5.53	-0.41	1.34e-7	Seasonality;
PAAD	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	6.8	0.48	2.21e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.57	-5.73	-0.42	5.13e-8	Coronary artery disease;
PAAD	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg02683114	chr2:24398427	C2orf84	-0.54	-5.11	-0.38	9.33e-7	Asthma;
PAAD	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs4948102	0.686	rs11771788	chr7:56158040	T/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.32	0.4	3.68e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg14515779	chr1:101123966	NA	0.39	4.31	0.33	2.88e-5	Monocyte count;
PAAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.28	0.33	3.23e-5	Renal cell carcinoma;
PAAD	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg22356347	chr1:167427500	CD247	-0.55	-6.07	-0.44	9.65e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	1.0	8.67	0.58	6.18e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.77	4.3	0.33	3.09e-5	Childhood ear infection;
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg16031515	chr1:205743344	RAB7L1	-0.45	-5.14	-0.38	8.22e-7	Prostate-specific antigen levels;
PAAD	cis	rs8077059	0.513	rs9892194	chr17:55825825	C/T	cg12582317	chr17:55822272	NA	-0.55	-6.2	-0.45	5.06e-9	Sex hormone-binding globulin levels;
PAAD	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.71	7.18	0.5	2.89e-11	Anterior chamber depth;
PAAD	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.88	7.06	0.5	5.52e-11	Type 2 diabetes;
PAAD	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2017305	0.834	rs2246974	chr10:70783324	T/C	cg25290552	chr10:70751067	KIAA1279	-0.85	-5.47	-0.41	1.79e-7	Depression (quantitative trait);
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.45	-4.48	-0.34	1.46e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.4	-5.06	-0.38	1.2e-6	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg23283495	chr1:209979779	IRF6	0.63	5.86	0.43	2.79e-8	Coronary artery disease;
PAAD	cis	rs58521262	0.530	rs381403	chr19:23126236	C/T	cg02350677	chr19:23254381	NA	-0.26	-4.59	-0.35	9.1e-6	Testicular germ cell tumor;
PAAD	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03351580	chr6:166666210	NA	-0.66	-7.08	-0.5	4.96e-11	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.58	0.35	9.46e-6	Homoarginine levels;
PAAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-10.97	-0.66	5.31e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.9100000000000004e-06	Daytime sleep phenotypes;
PAAD	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.88	-13.18	-0.73	5.99e-27	Alcohol dependence;
PAAD	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg07617317	chr6:118971624	C6orf204	0.56	4.46	0.34	1.6e-5	Diastolic blood pressure;
PAAD	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs7301016	0.846	rs7297093	chr12:63033387	C/T	cg11441379	chr12:63026424	NA	0.89	6.47	0.46	1.26e-9	IgG glycosylation;
PAAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.42	-0.52	7.8e-12	Eosinophil percentage of white cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07546684	chr6:149867573	PPIL4	-0.58	-7.0	-0.49	7.83e-11	Body fat percentage;
PAAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg20913747	chr6:44695427	NA	-0.71	-7.04	-0.5	6.12e-11	Total body bone mineral density;
PAAD	cis	rs77880822	0.562	rs74783122	chr20:1237879	G/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg26497354	chr6:109612229	NA	-0.45	-4.49	-0.34	1.4e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.46	-4.94	-0.37	2.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	0.88	5.85	0.43	2.97e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.82	-7.34	-0.51	1.2e-11	Obesity-related traits;
PAAD	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	High light scatter reticulocyte count;
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12483801	chr4:183727862	NA	0.73	5.63	0.42	8.56e-8	Pediatric autoimmune diseases;
PAAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg13903179	chr13:21900392	NA	0.59	6.35	0.46	2.33e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.78	8.95	0.59	1.14e-15	Breast cancer;
PAAD	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12893428	chr3:195717962	SDHAP1	0.47	4.96	0.37	1.88e-6	Pancreatic cancer;
PAAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs58521262	0.858	rs60907808	chr19:23104068	A/G	cg22640819	chr19:22990650	NA	0.36	4.3	0.33	2.99e-5	Testicular germ cell tumor;
PAAD	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg25558440	chr8:11882962	NA	-0.47	-4.33	-0.33	2.65e-5	Neuroticism;
PAAD	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg14343924	chr8:8086146	FLJ10661	0.47	4.25	0.33	3.72e-5	Mood instability;
PAAD	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg25753631	chr6:25732923	NA	-0.46	-5.2	-0.39	6.25e-7	Iron status biomarkers;
PAAD	cis	rs3136739	0.614	rs35076851	chr8:42017991	C/T	cg12054981	chr8:42037387	PLAT	0.71	5.21	0.39	6.15e-7	Plasma plasminogen activator levels;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.59	-6.77	-0.48	2.63e-10	Lung cancer;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.46	-0.34	1.61e-5	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.31	0.4	3.88e-7	Lung cancer;
PAAD	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.81	0.69	3.05e-23	Platelet count;
PAAD	cis	rs12044355	0.858	rs12040259	chr1:231826253	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	5.7	0.42	6.08e-8	Alzheimer's disease;
PAAD	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.51	-0.34	1.28e-5	Inflammatory bowel disease;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00982548	chr2:198649783	BOLL	0.65	4.42	0.34	1.87e-5	Ulcerative colitis;
PAAD	cis	rs72827839	0.779	rs72823592	chr17:46123004	G/A	cg23391107	chr17:45924227	SP6	0.49	4.36	0.33	2.43e-5	Ease of getting up in the morning;
PAAD	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12511469	0.505	rs1873369	chr4:155408478	C/A	cg04517429	chr4:155413618	DCHS2	0.44	4.41	0.34	1.92e-5	Fibrinogen;
PAAD	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.68	0.35	6.27e-6	HDL cholesterol;
PAAD	cis	rs1075232	1.000	rs12437749	chr15:31649888	C/T	cg06530883	chr15:30699977	NA	0.99	4.6	0.35	8.75e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg22800045	chr5:56110881	MAP3K1	0.62	5.09	0.38	1.03e-6	Coronary artery disease;
PAAD	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg04106633	chr4:1044584	NA	0.7	5.92	0.43	2.01e-8	Recombination rate (females);
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg26060667	chr1:247681242	NA	-0.44	-5.22	-0.39	5.71e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg25922239	chr6:33757077	LEMD2	-0.5	-4.48	-0.34	1.48e-5	Crohn's disease;
PAAD	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.28	-0.39	4.49e-7	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-1.11	-9.57	-0.61	2.92e-17	Blood trace element (Zn levels);
PAAD	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.06	8.39	0.56	3.06e-14	Vitiligo;
PAAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.92	12.34	0.71	1.13e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Pubertal anthropometrics;
PAAD	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07648498	chr16:89883185	FANCA	-0.64	-6.38	-0.46	2.01e-9	Vitiligo;
PAAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.74	7.98	0.54	3.24e-13	Schizophrenia;
PAAD	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg18939081	chr1:31884902	SERINC2	0.47	5.32	0.4	3.57e-7	Alcohol dependence;
PAAD	cis	rs1656368	0.726	rs17628988	chr3:158257394	A/G	cg16708174	chr3:158430962	RARRES1	0.52	4.72	0.36	5.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.65	4.94	0.37	2.04e-6	Breast cancer;
PAAD	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg16329197	chr12:53359506	NA	-0.99	-6.23	-0.45	4.35e-9	Prostate cancer;
PAAD	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg18612461	chr15:75251733	NA	-0.39	-4.46	-0.34	1.62e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.12	0.44	7.44e-9	Birth weight;
PAAD	cis	rs35160687	0.842	rs11685863	chr2:86554484	G/C	cg10973622	chr2:86423274	IMMT	-0.4	-4.52	-0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.55	4.88	0.37	2.71e-6	Common traits (Other);
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.77	8.51	0.57	1.56e-14	Lung cancer;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09736950	chr15:62938334	MGC15885;TLN2	-0.45	-4.92	-0.37	2.23e-6	Immature fraction of reticulocytes;
PAAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg07371521	chr5:154026371	NA	0.53	6.83	0.48	1.92e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6074578	0.541	rs6056336	chr20:149407	C/G	cg16931068	chr20:139680	DEFB127	-0.41	-5.51	-0.41	1.52e-7	Hirschsprung disease;
PAAD	cis	rs73198271	0.515	rs11774722	chr8:8642448	T/C	cg01851573	chr8:8652454	MFHAS1	0.93	6.41	0.46	1.7e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.74	-6.41	-0.46	1.76e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg23387468	chr7:139079360	LUC7L2	0.38	4.48	0.34	1.47e-5	Diisocyanate-induced asthma;
PAAD	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.49e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.58	4.6	0.35	8.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-1.02	-10.55	-0.65	7.15e-20	Blood pressure (smoking interaction);
PAAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.43	0.4	2.21e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.6	-5.76	-0.42	4.43e-8	Eye color traits;
PAAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19825600	chr2:3704501	ALLC	-0.58	-4.79	-0.36	3.89e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.49	-0.41	1.68e-7	Total body bone mineral density;
PAAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg10871876	chr19:53194124	ZNF83	0.59	5.11	0.38	9.36e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.86	-10.5	-0.65	1.01e-19	Body mass index;
PAAD	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg20406979	chr6:167373233	NA	0.37	5.06	0.38	1.17e-6	Crohn's disease;
PAAD	cis	rs6782025	0.802	rs1191297	chr3:120923244	T/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.59	-4.74	-0.36	4.86e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.67	0.48	4.52e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg19894588	chr14:64061835	NA	-0.76	-6.35	-0.46	2.34e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.1	-8.52	-0.57	1.5e-14	Diabetic kidney disease;
PAAD	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.51	4.91	0.37	2.36e-6	Mortality in heart failure;
PAAD	cis	rs11871801	1.000	rs57307201	chr17:40572793	G/A	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.71	-0.36	5.57e-6	Crohn's disease;
PAAD	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg02016764	chr4:38805732	TLR1	-0.6	-4.58	-0.35	9.55e-6	Breast cancer;
PAAD	cis	rs7326068	0.610	rs2477165	chr13:21445435	A/G	cg27234864	chr13:21295941	IL17D	0.63	5.4	0.4	2.55e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs317865	0.609	rs28619251	chr4:16172024	A/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.84	6.11	0.44	7.92e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg24699146	chr1:24152579	HMGCL	-0.48	-5.06	-0.38	1.19e-6	Immature fraction of reticulocytes;
PAAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.87	10.45	0.65	1.34e-19	Ulcerative colitis;
PAAD	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.58	5.55	0.41	1.24e-7	Obesity-related traits;
PAAD	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.51	4.96	0.37	1.85e-6	HDL cholesterol;
PAAD	cis	rs10037758	0.500	rs72663366	chr5:128280291	A/G	cg25555059	chr5:128301488	SLC27A6	0.3	5.0	0.38	1.57e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.47	-4.84	-0.37	3.11e-6	Eosinophil percentage of white cells;
PAAD	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-4.88	-0.37	2.63e-6	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16020556	chr5:96126443	ERAP1	-0.61	-6.3	-0.46	3.05e-9	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16228688	chr11:66247121	DPP3	-0.79	-7.02	-0.49	7.03e-11	Neuroticism;
PAAD	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs4356203	0.905	rs512852	chr11:17214929	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.94	-0.37	2e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.81	-7.75	-0.53	1.2e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.47	5.1	0.38	9.86e-7	Urate levels in lean individuals;
PAAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10924309	0.889	rs1316344	chr1:245859822	C/T	cg00036263	chr1:245852353	KIF26B	-0.68	-5.9	-0.43	2.24e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg02230254	chr11:65586170	NA	-0.32	-4.51	-0.34	1.28e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg24733560	chr20:60626293	TAF4	0.53	6.61	0.47	6.07e-10	Body mass index;
PAAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.6	5.18	0.39	6.97e-7	Mean corpuscular volume;
PAAD	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg27478167	chr7:817139	HEATR2	0.67	4.88	0.37	2.66e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.15	0.39	7.8e-7	Axial length;
PAAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg14393609	chr7:65229607	NA	0.49	4.9	0.37	2.39e-6	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00767560	chr19:19887256	LOC284440	0.64	7.38	0.51	9.85e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.74	6.95	0.49	1.03e-10	Obesity-related traits;
PAAD	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg08992911	chr2:238395768	MLPH	0.6	5.03	0.38	1.36e-6	Prostate cancer;
PAAD	trans	rs3094146	1	rs3094146	chr6:29970960	G/C	cg01620082	chr3:125678407	NA	-1.6	-9.47	-0.61	5.28e-17	Breast cancer;
PAAD	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg12935359	chr14:103987150	CKB	-0.6	-6.4	-0.46	1.83e-9	Body mass index;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13047869	chr3:10149882	C3orf24	0.89	7.32	0.51	1.34e-11	Alzheimer's disease;
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.63	-6.39	-0.46	1.94e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.74e-7	Body mass index;
PAAD	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.79	-8.46	-0.57	2.05e-14	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	6.6	0.47	6.61e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.59	6.08	0.44	9.36e-9	Coronary artery disease;
PAAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg20933634	chr6:27740509	NA	0.8	7.31	0.51	1.4e-11	Depression;
PAAD	cis	rs7260329	0.629	rs2873265	chr19:41505653	G/A	cg23925301	chr19:41220945	ADCK4	-0.5	-4.36	-0.33	2.36e-5	Smoking behavior;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13297007	chr20:42219703	IFT52	0.61	6.71	0.48	3.59e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg13206674	chr6:150067644	NUP43	0.68	7.1	0.5	4.49e-11	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06850241	chr22:41845214	NA	0.55	4.69	0.36	6.13e-6	Vitiligo;
PAAD	cis	rs9463078	0.874	rs2093903	chr6:45177482	A/C	cg25276700	chr6:44698697	NA	-0.49	-5.63	-0.42	8.57e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.68	-6.39	-0.46	1.88e-9	Platelet count;
PAAD	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.56	5.42	0.4	2.3e-7	Bone properties (heel);
PAAD	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.68	6.83	0.48	1.86e-10	Body mass index;
PAAD	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg19744528	chr7:157553346	PTPRN2	0.4	4.29	0.33	3.19e-5	Body mass index;
PAAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs1566080	0.869	rs11777833	chr8:142567377	G/A	cg11798891	chr8:143485435	TSNARE1	-0.31	-4.39	-0.34	2.11e-5	Obesity-related traits;
PAAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg13271783	chr10:134563150	INPP5A	0.42	4.58	0.35	9.78e-6	Migraine;
PAAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.79	-9.26	-0.6	1.85e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.58	5.02	0.38	1.45e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg22875332	chr1:76189707	ACADM	-0.47	-4.7	-0.36	5.79e-6	Daytime sleep phenotypes;
PAAD	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.79	9.06	0.59	5.91e-16	Morning vs. evening chronotype;
PAAD	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg01796438	chr3:11312864	ATG7	0.64	4.95	0.37	1.96e-6	Circulating chemerin levels;
PAAD	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.53	-5.79	-0.43	3.92e-8	Vitamin D levels;
PAAD	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs12786942	0.932	rs12801419	chr11:101356129	T/A	cg19874726	chr14:61114476	SIX1	-0.84	-6.29	-0.45	3.22e-9	Facial depth;
PAAD	cis	rs9287719	0.649	rs10182589	chr2:10720664	C/T	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg00543991	chr22:32367038	NA	0.87	5.66	0.42	7.33e-8	Childhood ear infection;
PAAD	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg04415270	chr2:102091202	RFX8	-0.65	-8.27	-0.56	6.09e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs4704187	0.663	rs9654428	chr5:74466884	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.12	-0.38	9.17e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-4.31	-0.33	2.86e-5	Personality dimensions;
PAAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.91	0.37	2.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg12483801	chr4:183727862	NA	0.56	4.58	0.35	9.48e-6	Pediatric autoimmune diseases;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.61	6.4	0.46	1.84e-9	Lung cancer;
PAAD	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.49	-4.76	-0.36	4.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg18888403	chr1:24152774	HMGCL	0.4	4.53	0.35	1.17e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg02725872	chr8:58115012	NA	-0.61	-4.91	-0.37	2.32e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.56	5.52	0.41	1.41e-7	Aortic root size;
PAAD	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	cis	rs6681460	0.932	rs4655640	chr1:67089220	T/C	cg02459107	chr1:67143332	SGIP1	0.79	7.81	0.54	8.48e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	1.000	rs12764485	chr10:46002587	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.83	6.98	0.49	8.38e-11	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07101654	chr1:12566565	SNORA59A;VPS13D;SNORA59B	-0.56	-7.05	-0.5	6.02e-11	Monocyte percentage of white cells;
PAAD	cis	rs12760731	0.546	rs6699087	chr1:178433200	G/T	cg00404053	chr1:178313656	RASAL2	0.64	5.33	0.4	3.52e-7	Obesity-related traits;
PAAD	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.72	-0.42	5.58e-8	Tonsillectomy;
PAAD	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	6.43	0.46	1.59e-9	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01691987	chr17:7789028	CHD3	0.69	6.92	0.49	1.19e-10	Obesity-related traits;
PAAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.03	-0.59	7.31e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.73	-6.66	-0.48	4.62e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.54	4.73	0.36	4.98e-6	Coronary artery disease;
PAAD	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.41	0.71	7.11e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.61	5.55	0.41	1.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.55	-5.19	-0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.74	6.23	0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.72	7.9	0.54	5.33e-13	Schizophrenia;
PAAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.52	5.34	0.4	3.33e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7326068	0.543	rs2785740	chr13:21423525	C/G	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.39	-4.97	-0.37	1.79e-6	Educational attainment (years of education);
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg26939375	chr7:64535504	NA	0.71	8.15	0.55	1.27e-13	Calcium levels;
PAAD	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.65	6.03	0.44	1.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9361491	0.608	rs4706722	chr6:79462697	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.84	11.61	0.69	1.03e-22	Emphysema distribution in smoking;
PAAD	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg01766943	chr2:54829624	SPTBN1	0.5	4.35	0.33	2.46e-5	Schizophrenia;
PAAD	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg09659197	chr4:152720779	NA	0.4	5.09	0.38	1.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg14349672	chr11:133703707	NA	-0.56	-6.26	-0.45	3.83e-9	Childhood ear infection;
PAAD	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg06643849	chr19:57742421	AURKC	-0.43	-4.32	-0.33	2.82e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00166722	chr3:10149974	C3orf24	0.89	6.34	0.46	2.5e-9	Alzheimer's disease;
PAAD	cis	rs10821973	0.527	rs1432415	chr10:63975339	T/C	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs75920871	1.000	rs75858236	chr11:116872263	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg04877966	chr15:75135169	ULK3	-0.43	-4.29	-0.33	3.16e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.87	9.85	0.62	5.23e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.36	-4.58	-0.35	9.57e-6	Colorectal cancer;
PAAD	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.72	-7.81	-0.54	8.7e-13	Diastolic blood pressure;
PAAD	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.98	10.49	0.65	1.03e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs3026101	0.578	rs3026142	chr17:5315089	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.88	0.43	2.54e-8	Body mass index;
PAAD	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg24585817	chr7:64895279	NA	-0.41	-4.26	-0.33	3.54e-5	Aortic root size;
PAAD	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.08	8.55	0.57	1.24e-14	Cannabis dependence symptom count;
PAAD	cis	rs2262909	0.962	rs7255049	chr19:22213111	A/G	cg11619707	chr19:22235551	ZNF257	-0.54	-5.43	-0.4	2.14e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.55	-5.36	-0.4	2.97e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	4.62	0.35	8.08e-6	Lymphocyte counts;
PAAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.81	9.69	0.62	1.39e-17	Methadone dose in opioid dependence;
PAAD	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.09	8.82	0.58	2.46e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	4.39	0.34	2.08e-5	Uric acid clearance;
PAAD	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.57	-5.94	-0.43	1.91e-8	Bladder cancer;
PAAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9535307	0.584	rs73194445	chr13:50406547	T/C	cg04663916	chr13:50265991	EBPL	-0.66	-4.65	-0.35	7.13e-6	Obesity-related traits;
PAAD	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.6	5.73	0.42	5.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.91	12.89	0.72	3.71e-26	Prostate-specific antigen levels;
PAAD	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.54	-4.41	-0.34	1.95e-5	Dialysis-related mortality;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg16606324	chr3:10149918	C3orf24	0.92	6.21	0.45	4.72e-9	Alzheimer's disease;
PAAD	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.76	-5.17	-0.39	7.37e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs1075232	1.000	rs4450360	chr15:31682030	G/A	cg01030201	chr15:31746330	NA	-1.09	-4.45	-0.34	1.67e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-4.65	-0.35	7.17e-6	Total body bone mineral density;
PAAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.16	-0.81	2.17e-37	Height;
PAAD	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.79	-8.85	-0.58	2.1e-15	Heart rate;
PAAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg10547527	chr2:198650123	BOLL	-0.73	-5.16	-0.39	7.65e-7	Ulcerative colitis;
PAAD	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg20607287	chr7:12443886	VWDE	-0.71	-5.49	-0.41	1.62e-7	Coronary artery disease;
PAAD	cis	rs67072384	0.892	rs72964172	chr11:72436436	G/A	cg04827223	chr11:72435913	ARAP1	-0.6	-4.3	-0.33	3.08e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
PAAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.93	-10.61	-0.65	5.12e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg14664628	chr15:75095509	CSK	-0.49	-4.68	-0.36	6.24e-6	Caffeine consumption;
PAAD	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg02877791	chr2:177005403	NA	0.44	4.34	0.33	2.57e-5	IgG glycosylation;
PAAD	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg07395648	chr5:131743802	NA	-0.62	-6.4	-0.46	1.82e-9	Blood metabolite levels;
PAAD	cis	rs7119038	0.629	rs73001429	chr11:118603165	T/G	cg19308663	chr11:118741387	NA	0.51	4.4	0.34	2.05e-5	Sjögren's syndrome;
PAAD	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.76	7.44	0.52	6.75e-12	Corneal astigmatism;
PAAD	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.51	4.87	0.37	2.76e-6	Endometrial cancer;
PAAD	cis	rs8027181	0.606	rs12911743	chr15:73104935	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.61	6.16	0.45	6.3e-9	Triglyceride levels;
PAAD	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg02421172	chr7:1938701	MAD1L1	-0.62	-5.06	-0.38	1.19e-6	Bipolar disorder;
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.88	11.57	0.68	1.3e-22	Total body bone mineral density;
PAAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.33e-6	Coronary artery disease;
PAAD	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg01028140	chr2:1542097	TPO	-0.95	-8.65	-0.57	6.86e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg07336987	chr11:625147	MUPCDH	-0.37	-4.64	-0.35	7.49e-6	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.86	8.62	0.57	8.13e-15	Blood protein levels;
PAAD	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	8.63	0.57	7.84e-15	LDL cholesterol;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.91	-9.88	-0.63	4.26e-18	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	1.09	15.25	0.78	1.86e-32	Breast cancer;
PAAD	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg00334542	chr7:100209784	MOSPD3	-0.7	-5.3	-0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9815354	1.000	rs1717024	chr3:41984888	G/T	cg03022575	chr3:42003672	ULK4	-0.72	-5.22	-0.39	5.84e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg01585852	chr22:24235823	MIF	-0.47	-4.97	-0.37	1.79e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs4740619	0.661	rs10810481	chr9:15930623	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.51	-0.34	1.28e-5	Body mass index;
PAAD	cis	rs1468734	1.000	rs35486581	chr16:5003586	A/G	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg01489256	chr8:11204017	TDH	0.45	4.67	0.35	6.53e-6	Triglycerides;
PAAD	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-9.5	-0.61	4.26e-17	Diabetic retinopathy;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs877529	0.934	rs139418	chr22:39557162	A/C	cg18708252	chr22:39545030	CBX7	-0.48	-4.59	-0.35	9.28e-6	Multiple myeloma;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs67257959	0.586	rs8105085	chr19:17159962	G/A	cg19418318	chr19:17219073	MYO9B	0.35	4.92	0.37	2.25e-6	Selective IgA deficiency;
PAAD	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	1.04	18.51	0.83	8.71e-41	Birth weight;
PAAD	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.63	6.3	0.46	3.05e-9	Type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs12476592	0.602	rs4671516	chr2:63790555	G/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg21890820	chr11:65308645	LTBP3	0.99	7.46	0.52	6.27e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-6.82	-0.48	2.02e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01591973	chr19:37583283	ZNF420	-0.68	-6.39	-0.46	1.92e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg15181151	chr6:150070149	PCMT1	0.56	6.11	0.44	7.86e-9	Lung cancer;
PAAD	cis	rs6537837	0.838	rs12046010	chr1:110104189	A/C	cg05049280	chr1:110155535	GNAT2	0.47	4.85	0.37	2.98e-6	Major depressive disorder;
PAAD	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-5.05	-0.38	1.27e-6	Vitiligo;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20769059	chr3:46687388	NA	-0.54	-6.35	-0.46	2.32e-9	Monocyte percentage of white cells;
PAAD	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs4273100	0.646	rs4924990	chr17:19294824	G/T	cg18093559	chr17:18951025	GRAP	0.53	4.89	0.37	2.51e-6	Schizophrenia;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.41	0.46	1.74e-9	Lung cancer;
PAAD	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.51	-5.52	-0.41	1.42e-7	Testicular germ cell tumor;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg13706611	chr11:55861503	OR8I2	0.65	6.4	0.46	1.79e-9	Blood protein levels;
PAAD	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.43	-4.29	-0.33	3.18e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9659323	0.601	rs12033970	chr1:119640401	C/G	cg17326555	chr1:119535693	NA	-0.38	-5.25	-0.39	5.12e-7	Body mass index;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.46	6.63	0.47	5.54e-10	Mean corpuscular volume;
PAAD	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.17	-0.39	7.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28647808	1.000	rs28460103	chr9:136278763	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs818427	0.508	rs2909786	chr5:112168065	A/G	cg06941702	chr5:112196734	SRP19	-0.52	-4.89	-0.37	2.52e-6	Total body bone mineral density;
PAAD	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.98	8.22	0.55	8.53e-14	Neutrophil percentage of white cells;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17175984	chr15:90292730	NA	-0.57	-6.45	-0.46	1.41e-9	Energy expenditure (24h);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20844692	chr3:196230657	RNF168	0.68	6.51	0.47	1.03e-9	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10134651	chr19:15539926	WIZ	-0.66	-6.72	-0.48	3.42e-10	Obesity-related traits;
PAAD	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg27205649	chr11:78285834	NARS2	-0.62	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	0.6	5.44	0.4	2.08e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23158103	chr7:148848205	ZNF398	-0.64	-6.47	-0.46	1.3e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.47	-0.46	1.27e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.57	-6.58	-0.47	7.13e-10	Lung cancer;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs427941	0.632	rs201490	chr7:101751910	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18402987	chr7:1209562	NA	0.48	5.09	0.38	1.06e-6	Longevity;Endometriosis;
PAAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.66	-6.19	-0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2070677	0.808	rs3020500	chr10:135381276	T/C	cg20169779	chr10:135381914	SYCE1	0.75	7.36	0.51	1.07e-11	Gout;
PAAD	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.61	-6.73	-0.48	3.23e-10	Coronary artery disease;
PAAD	cis	rs7829975	0.627	rs876954	chr8:8310923	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	6.0	0.44	1.4e-8	Mood instability;
PAAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.52	-4.77	-0.36	4.35e-6	Multiple sclerosis;
PAAD	cis	rs7188861	0.689	rs12600282	chr16:11401866	G/T	cg16532467	chr16:11454386	NA	-0.55	-4.3	-0.33	3.08e-5	HDL cholesterol;
PAAD	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg23346134	chr3:49453900	TCTA	0.41	4.26	0.33	3.57e-5	Menarche (age at onset);
PAAD	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.45	0.34	1.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17123764	0.605	rs4133070	chr12:50078124	A/G	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.91	-0.59	1.44e-15	Total body bone mineral density;
PAAD	cis	rs1797885	0.763	rs299630	chr3:12568425	A/C	cg07775309	chr3:12595852	NA	0.41	4.45	0.34	1.63e-5	Immature fraction of reticulocytes;
PAAD	cis	rs988913	0.957	rs9382397	chr6:54782893	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs375066	0.934	rs2191564	chr19:44367611	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.67	0.48	4.36e-10	Breast cancer;
PAAD	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.53	4.74	0.36	4.8e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.51	-4.71	-0.36	5.45e-6	Red blood cell count;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.92	-15.19	-0.78	2.71e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.71	8.5	0.57	1.61e-14	Bladder cancer;
PAAD	cis	rs2200578	0.786	rs57656020	chr2:99799378	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	4.4	0.34	2e-5	IgG glycosylation;
PAAD	cis	rs9506514	0.617	rs9509352	chr13:21295149	A/G	cg27234864	chr13:21295941	IL17D	-0.57	-5.54	-0.41	1.32e-7	Coronary artery calcification;
PAAD	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.58	5.49	0.41	1.68e-7	Corneal astigmatism;
PAAD	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg27246729	chr12:121163418	ACADS	0.4	4.25	0.33	3.72e-5	Mean corpuscular volume;
PAAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg22143856	chr6:28129313	ZNF389	0.68	5.47	0.41	1.81e-7	Parkinson's disease;
PAAD	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	1.03	13.83	0.75	1.11e-28	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg26695010	chr11:65641043	EFEMP2	0.52	5.09	0.38	1.05e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.75	8.01	0.54	2.81e-13	Renal function-related traits (BUN);
PAAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.87e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.62	-6.74	-0.48	3.13e-10	Neuroticism;
PAAD	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-4.48	-0.34	1.46e-5	Bipolar disorder;
PAAD	cis	rs9810890	0.850	rs115970727	chr3:128559179	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs11992162	0.636	rs35995176	chr8:11809647	G/C	cg00262122	chr8:11665843	FDFT1	-0.5	-4.52	-0.34	1.24e-5	Monocyte count;
PAAD	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg11518657	chr1:67396239	MIER1	-0.68	-5.11	-0.38	9.43e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs11696501	0.739	rs4812938	chr20:44249919	T/A	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23204518	chr14:24563190	PCK2	0.62	6.56	0.47	8.02e-10	Monocyte percentage of white cells;
PAAD	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg05295671	chr13:79234353	RNF219	-0.73	-6.73	-0.48	3.18e-10	Large artery stroke;
PAAD	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.48	0.34	1.49e-5	Height;
PAAD	cis	rs12257961	0.521	rs10796279	chr10:15375400	A/T	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg00277334	chr10:82204260	NA	-0.58	-5.89	-0.43	2.36e-8	Post bronchodilator FEV1;
PAAD	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg08200582	chr11:442649	ANO9	0.51	4.46	0.34	1.59e-5	Systemic lupus erythematosus;
PAAD	cis	rs56046484	0.703	rs116893322	chr15:85524628	G/A	cg08123816	chr15:85640762	PDE8A	-0.47	-4.31	-0.33	2.9e-5	Testicular germ cell tumor;
PAAD	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	8.33	0.56	4.3e-14	Coronary artery disease;
PAAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.84	8.37	0.56	3.51e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4908768	0.639	rs4908512	chr1:8830366	A/T	cg13225830	chr1:9527173	NA	0.37	4.3	0.33	3.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.5	-0.34	1.36e-5	Obesity-related traits;
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06850241	chr22:41845214	NA	0.52	4.9	0.37	2.42e-6	Vitiligo;
PAAD	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.49	5.25	0.39	5.1e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg05805236	chr11:65401703	PCNXL3	-0.62	-6.39	-0.46	1.94e-9	Acne (severe);
PAAD	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.33	-0.46	2.65e-9	Hip circumference;
PAAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.57	-0.41	1.13e-7	Monocyte percentage of white cells;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg24101359	chr6:42928495	GNMT	0.5	5.09	0.38	1.04e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg06569542	chr10:98946673	SLIT1	0.49	4.87	0.37	2.78e-6	Monocyte count;
PAAD	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg09659197	chr4:152720779	NA	0.4	5.45	0.4	2.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.63	5.69	0.42	6.39e-8	Corneal astigmatism;
PAAD	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg00262122	chr8:11665843	FDFT1	-0.52	-4.67	-0.35	6.71e-6	Triglycerides;
PAAD	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg02415014	chr8:143852576	LYNX1	-0.45	-5.77	-0.42	4.28e-8	Urinary tract infection frequency;
PAAD	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.48	-0.47	1.2e-9	Body mass index;
PAAD	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.79e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs2717559	0.541	rs12549240	chr8:143881380	C/T	cg02415014	chr8:143852576	LYNX1	0.42	5.55	0.41	1.23e-7	Urinary tract infection frequency;
PAAD	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.81	4.35	0.33	2.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg10589385	chr1:150898437	SETDB1	0.4	4.92	0.37	2.2e-6	Melanoma;
PAAD	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.9	-10.27	-0.64	4.11e-19	Refractive error;
PAAD	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.56	-0.47	7.85e-10	Retinal vascular caliber;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7737355	0.812	rs6896132	chr5:130773561	C/G	cg06307176	chr5:131281290	NA	0.48	4.37	0.33	2.3e-5	Life satisfaction;
PAAD	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs17052344	0.582	rs111876736	chr17:21747067	A/G	cg18423549	chr17:21743878	NA	-0.64	-5.75	-0.42	4.8e-8	Cutaneous psoriasis;
PAAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg21191810	chr6:118973309	C6orf204	-0.52	-5.16	-0.39	7.47e-7	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.42	-0.4	2.3e-7	Schizophrenia;
PAAD	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.91	-10.8	-0.66	1.58e-20	IgG glycosylation;
PAAD	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.71	-0.58	4.72e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg03700679	chr2:178418002	TTC30B	-0.61	-4.71	-0.36	5.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg11494091	chr17:61959527	GH2	0.55	4.49	0.34	1.43e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.84	6.5	0.47	1.09e-9	Axial length;
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.48	-4.63	-0.35	7.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3736485	0.873	rs12441759	chr15:51755033	C/A	cg19558802	chr15:51695713	GLDN	-0.43	-4.37	-0.33	2.29e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	1.09	13.88	0.75	8.1e-29	Breast cancer;
PAAD	cis	rs2229238	0.911	rs73020234	chr1:154482767	C/A	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.91e-6	Coronary heart disease;
PAAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.85	8.5	0.57	1.62e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.48	4.36	0.33	2.37e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9341808	0.528	rs2322753	chr6:81042865	C/G	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg09659197	chr4:152720779	NA	-0.41	-5.39	-0.4	2.61e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg18518183	chr2:172544446	DYNC1I2	0.49	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.73	-0.36	5.15e-6	Total body bone mineral density;
PAAD	cis	rs4443100	0.916	rs8139695	chr22:23373902	A/T	cg14186256	chr22:23484241	RTDR1	-0.49	-4.27	-0.33	3.47e-5	Serum parathyroid hormone levels;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.47	-0.46	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.07	-0.38	1.15e-6	Initial pursuit acceleration;
PAAD	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.22	0.67	1.19e-21	Cognitive test performance;
PAAD	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg00122941	chr17:4613640	ARRB2	0.83	7.87	0.54	6.08e-13	Lymphocyte counts;
PAAD	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.54	6.72	0.48	3.5e-10	Psoriasis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03431137	chr16:50059103	TMEM188	-0.71	-7.02	-0.49	7.02e-11	Lung cancer in ever smokers;
PAAD	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-6.75	-0.48	2.87e-10	Plateletcrit;Platelet count;
PAAD	cis	rs1043763	0.826	rs28643366	chr12:122499101	C/T	cg26218692	chr12:122497826	BCL7A	-0.58	-5.3	-0.4	3.92e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg21859623	chr20:33103246	DYNLRB1	0.46	4.62	0.35	8.1e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.93e-5	Pain;
PAAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	6.59	0.47	6.7e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.46	-4.99	-0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.64	6.5	0.47	1.1e-9	Diastolic blood pressure;
PAAD	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg10174797	chr19:8464628	RAB11B	0.59	5.48	0.41	1.73e-7	HDL cholesterol;
PAAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg23939001	chr4:940644	TMEM175	-0.44	-4.67	-0.35	6.61e-6	Systemic sclerosis;
PAAD	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg06565975	chr8:143823917	SLURP1	-0.26	-5.44	-0.4	2.13e-7	Urinary tract infection frequency;
PAAD	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62025270	0.547	rs416916	chr15:86192416	G/A	cg13263323	chr15:86062960	AKAP13	0.49	4.74	0.36	4.86e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	5.59	0.41	1.02e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg15017067	chr4:17643749	FAM184B	0.46	5.25	0.39	5.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg13798912	chr7:905769	UNC84A	0.59	4.44	0.34	1.69e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9621305	0.800	rs4989480	chr22:32025318	A/G	cg01338084	chr22:32026380	PISD	0.67	4.86	0.37	2.87e-6	Intelligence;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg02462569	chr6:150064036	NUP43	-0.44	-4.68	-0.35	6.4e-6	Testicular germ cell tumor;
PAAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg03983715	chr16:68378420	PRMT7	-0.89	-6.37	-0.46	2.18e-9	Schizophrenia;
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.68	-7.44	-0.52	6.84e-12	Longevity;
PAAD	cis	rs4343996	0.934	rs6959232	chr7:3376530	A/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.13	-0.38	8.67e-7	Motion sickness;
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg13647721	chr17:30228624	UTP6	0.68	4.63	0.35	7.79e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.99	-0.38	1.62e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.37	4.35	0.33	2.52e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.6	0.47	6.56e-10	IgG glycosylation;
PAAD	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg22089800	chr15:90895588	ZNF774	0.58	5.58	0.41	1.09e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21055978	chr7:38948895	VPS41	-0.8	-7.79	-0.53	9.53e-13	Lung cancer in ever smokers;
PAAD	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.01	-0.38	1.49e-6	Height;
PAAD	cis	rs9487051	0.597	rs412754	chr6:109522057	G/C	cg21918786	chr6:109611834	NA	-0.41	-4.31	-0.33	2.9e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.92	5.12	0.38	9.27e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg23465465	chr6:26364728	BTN3A2	0.77	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.95	-8.08	-0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18621852	chr3:10150065	C3orf24	0.52	4.94	0.37	2.02e-6	Alzheimer's disease;
PAAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-5.97	-0.44	1.63e-8	Bipolar disorder;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg22189786	chr22:42395067	WBP2NL	0.5	5.56	0.41	1.18e-7	Intelligence;
PAAD	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg03805757	chr16:71968109	PKD1L3	-0.58	-5.32	-0.4	3.63e-7	Post bronchodilator FEV1;
PAAD	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	1.08	12.78	0.72	7.1e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10450586	0.932	rs7480168	chr11:27330045	A/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26149738	chr19:34287125	KCTD15	-0.62	-6.34	-0.46	2.45e-9	Smoking initiation;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.58	5.95	0.43	1.77e-8	Testicular germ cell tumor;
PAAD	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.31	-0.33	2.93e-5	Educational attainment (years of education);
PAAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.45	-4.32	-0.33	2.78e-5	Height;
PAAD	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg10523679	chr1:76189770	ACADM	0.52	4.92	0.37	2.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.44	4.5	0.34	1.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.51	-4.91	-0.37	2.28e-6	Corneal structure;
PAAD	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg11204139	chr17:3907470	NA	0.85	9.03	0.59	7.19e-16	Type 2 diabetes;
PAAD	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.48	-4.82	-0.36	3.42e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs72960926	0.744	rs72952275	chr6:74926492	A/G	cg03266952	chr6:74778945	NA	-1.17	-6.5	-0.47	1.07e-9	Metabolite levels (MHPG);
PAAD	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	6.62	0.47	5.83e-10	Lung cancer in ever smokers;
PAAD	cis	rs6921919	0.848	rs6903652	chr6:28322120	C/G	cg23153227	chr6:27725408	NA	0.54	4.6	0.35	8.98e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.27e-9	Lymphocyte counts;
PAAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg23283495	chr1:209979779	IRF6	0.71	6.31	0.46	2.95e-9	Cleft lip with or without cleft palate;
PAAD	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg09582351	chr12:29534625	ERGIC2	-0.32	-4.43	-0.34	1.79e-5	QT interval;
PAAD	cis	rs863345	0.565	rs7551497	chr1:158444925	T/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.72	-0.36	5.28e-6	Pneumococcal bacteremia;
PAAD	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.54	-6.25	-0.45	3.95e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.75	-8.87	-0.58	1.88e-15	Body mass index;
PAAD	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg00310523	chr12:86230176	RASSF9	0.43	4.54	0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg00579200	chr11:133705235	NA	-0.42	-4.65	-0.35	7.26e-6	Childhood ear infection;
PAAD	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.62	0.35	8.05e-6	Homocysteine levels;
PAAD	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.75	5.69	0.42	6.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.27	0.39	4.53e-7	Rheumatoid arthritis;
PAAD	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.7	-6.86	-0.49	1.63e-10	Platelet distribution width;
PAAD	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.86	10.05	0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg08807101	chr21:30365312	RNF160	0.64	5.2	0.39	6.21e-7	Cognitive test performance;
PAAD	cis	rs7189233	0.956	rs62048486	chr16:53448339	G/T	cg00221382	chr16:54322308	NA	-0.29	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg01959980	chr2:73616832	ALMS1	-0.52	-6.4	-0.46	1.86e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.88	-11.0	-0.67	4.65e-21	Heart rate;
PAAD	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.71	7.02	0.49	6.85e-11	Renal function-related traits (BUN);
PAAD	cis	rs621559	0.636	rs611261	chr1:43681872	T/C	cg14851383	chr1:43888477	KIAA0467	0.55	4.33	0.33	2.66e-5	Telomere length;
PAAD	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12136530	0.593	rs881246	chr1:19733255	C/A	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.75	-0.36	4.68e-6	Lead levels in blood;
PAAD	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.37	4.8	0.36	3.82e-6	Schizophrenia;
PAAD	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.36	-0.33	2.36e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs17123764	0.605	rs11169104	chr12:50076287	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.47	-4.66	-0.35	6.96e-6	Multiple sclerosis;
PAAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.98	-0.37	1.73e-6	Neuroticism;
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-4.92	-0.37	2.24e-6	Longevity;
PAAD	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.89	-13.79	-0.75	1.44e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7172971	0.688	rs4923927	chr15:42379002	T/G	cg07013680	chr15:42186124	SPTBN5	0.53	4.29	0.33	3.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.26	0.64	4.21e-19	Menopause (age at onset);
PAAD	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-5.2	-0.39	6.32e-7	Common traits (Other);
PAAD	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.51	-0.41	1.49e-7	Vitamin D levels;
PAAD	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg21518248	chr2:162101506	NA	-0.54	-5.4	-0.4	2.5e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs965469	0.779	rs2236114	chr20:3296040	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-4.41	-0.34	1.96e-5	IFN-related cytopenia;
PAAD	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg11764359	chr7:65958608	NA	-0.72	-4.84	-0.37	3.22e-6	Diabetic kidney disease;
PAAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.66e-6	Aortic root size;
PAAD	cis	rs13242816	1.000	rs13247015	chr7:116095623	A/C	cg16553024	chr7:116138462	CAV2	-0.71	-4.88	-0.37	2.7e-6	P wave duration;
PAAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-4.9	-0.37	2.47e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.82	6.15	0.45	6.38e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg04851639	chr8:1020857	NA	-0.64	-8.11	-0.55	1.5700000000000001e-13	Schizophrenia;
PAAD	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.5	-4.72	-0.36	5.4e-6	Hypospadias;
PAAD	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-4.92	-0.37	2.26e-6	Schizophrenia;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.17	-0.39	7.18e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	6.75	0.48	2.92e-10	Obesity-related traits;
PAAD	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.54	4.91	0.37	2.34e-6	Self-reported allergy;
PAAD	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg21252483	chr19:49399788	TULP2	-0.3	-4.6	-0.35	9.02e-6	Red cell distribution width;
PAAD	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	1.01	9.37	0.61	9.37e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Dermatomyositis;
PAAD	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg03098721	chr1:84464084	TTLL7	0.5	4.77	0.36	4.26e-6	Obesity-related traits;
PAAD	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.66e-5	Life satisfaction;
PAAD	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.72	-7.21	-0.5	2.43e-11	DNA methylation (variation);
PAAD	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.83	-9.89	-0.63	4.09e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs11264799	0.765	rs12128597	chr1:157623603	C/T	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg15193198	chr20:60906057	LAMA5	0.6	6.82	0.48	2.04e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16311803	chr12:88178298	NA	-0.64	-6.45	-0.46	1.44e-9	Smoking initiation;
PAAD	cis	rs7765175	0.698	rs9400613	chr6:113675822	C/T	cg19037598	chr6:113666021	NA	-0.44	-4.77	-0.36	4.29e-6	Coronary artery calcification;
PAAD	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	High light scatter reticulocyte count;
PAAD	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.81	7.25	0.51	1.96e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.58	-5.16	-0.39	7.58e-7	Lung cancer;
PAAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.85	0.37	3.08e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.77e-10	Life satisfaction;
PAAD	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.79	0.36	3.91e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10202638	chr2:173754319	RAPGEF4	0.52	6.32	0.46	2.69e-9	Smoking initiation;
PAAD	cis	rs10916814	1.000	rs72649163	chr1:20900592	G/C	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11252926	0.732	rs10904541	chr10:744008	A/G	cg03684893	chr10:554711	DIP2C	0.48	4.64	0.35	7.36e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1957429	0.614	rs117316280	chr14:65388641	T/C	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg06484146	chr7:12443880	VWDE	-0.87	-5.28	-0.39	4.43e-7	Coronary artery disease;
PAAD	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-6.05	-0.44	1.1e-8	Diabetic retinopathy;
PAAD	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg20130138	chr11:64956067	CAPN1	-0.47	-4.27	-0.33	3.4e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10044254	0.763	rs7725413	chr5:15695987	C/T	cg07238450	chr5:15720153	FBXL7	-0.51	-4.34	-0.33	2.54e-5	Asthma (corticosteroid response);
PAAD	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.64	-5.63	-0.42	8.33e-8	HIV-1 control;
PAAD	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg14413466	chr17:79170920	AZI1	-0.35	-4.38	-0.33	2.2e-5	Frontotemporal dementia;
PAAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg02734326	chr4:10020555	SLC2A9	0.43	4.41	0.34	1.97e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.6	7.43	0.52	7.18e-12	Multiple system atrophy;
PAAD	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs12753569	0.748	rs1013629	chr1:76513759	A/G	cg00791851	chr1:76518896	NA	0.42	4.61	0.35	8.41e-6	Personality dimensions;
PAAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.61	-5.93	-0.43	1.93e-8	Subjective well-being;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.37	4.35	0.33	2.52e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.3	-0.39	4.01e-7	Glomerular filtration rate;
PAAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.94	11.23	0.67	1.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.51	0.52	4.73e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg02743256	chr7:2109353	MAD1L1	-0.63	-5.08	-0.38	1.1e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-6.11	-0.44	7.92e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg16447950	chr5:562315	NA	-0.52	-4.93	-0.37	2.14e-6	Obesity-related traits;
PAAD	trans	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs9815354	0.680	rs73073274	chr3:42022810	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	0.67	4.74	0.36	4.78e-6	Obesity-related traits;
PAAD	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-4.74	-0.36	4.85e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10433812	chr11:10952532	NA	0.66	6.87	0.49	1.57e-10	Obesity-related traits;
PAAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.65	-6.38	-0.46	2.04e-9	White matter hyperintensity burden;
PAAD	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-5.01	-0.38	1.49e-6	Mean platelet volume;
PAAD	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.21	-0.39	6.16e-7	Monocyte percentage of white cells;
PAAD	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.46	-4.6	-0.35	8.97e-6	Urinary metabolites (H-NMR features);
PAAD	cis	rs12753920	0.775	rs1384612	chr1:92675563	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.6	6.3	0.46	3.02e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.63	6.8	0.48	2.23e-10	Heart rate;
PAAD	cis	rs12523822	0.957	rs55703059	chr6:154957754	G/A	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs1329189	1.000	rs10437440	chr10:129995293	T/G	cg17972361	chr10:130010134	NA	-0.45	-4.59	-0.35	9.16e-6	Orofacial clefts;
PAAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-8.51	-0.57	1.59e-14	Coronary artery disease;
PAAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.88	7.28	0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.56	-4.86	-0.37	2.94e-6	Parkinson's disease;
PAAD	cis	rs2997447	0.846	rs76713804	chr1:26392437	G/A	cg24519413	chr1:26490540	NA	0.53	4.99	0.38	1.6e-6	QRS complex (12-leadsum);
PAAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.79	-0.36	3.9e-6	Personality dimensions;
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.72	7.23	0.51	2.18e-11	Prostate cancer;
PAAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg03037974	chr15:76606532	NA	0.5	5.73	0.42	5.14e-8	Blood metabolite levels;
PAAD	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.87	-7.24	-0.51	2.12e-11	Triglycerides;
PAAD	cis	rs8112211	0.731	rs931749	chr19:38818925	C/T	cg14299480	chr19:38876666	GGN	-0.62	-6.01	-0.44	1.3e-8	Blood protein levels;
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.74	8.71	0.58	4.86e-15	Lung cancer;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.94	7.97	0.54	3.51e-13	Alzheimer's disease;
PAAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.62	5.66	0.42	7.23e-8	Insulin-like growth factors;
PAAD	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs507080	0.922	rs561845	chr11:118558827	A/G	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.43	0.56	2.49e-14	Menopause (age at onset);
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.61	10.23	0.64	4.98e-19	IgG glycosylation;
PAAD	cis	rs859767	0.741	rs1104802	chr2:135436366	A/C	cg12500956	chr2:135428796	TMEM163	-0.31	-4.32	-0.33	2.83e-5	Neuroticism;
PAAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	1.09	15.18	0.78	2.89e-32	Breast cancer;
PAAD	cis	rs593531	0.513	rs3867268	chr11:74033377	A/C	cg15851278	chr11:73669449	DNAJB13	0.4	5.01	0.38	1.51e-6	Neuroticism;
PAAD	cis	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg18023558	chr4:10118459	WDR1	-0.46	-4.34	-0.33	2.62e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26031613	chr14:104095156	KLC1	-0.68	-6.86	-0.49	1.61e-10	Body mass index;
PAAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.34	4.63	0.35	7.84e-6	Height;
PAAD	trans	rs992005	0.862	rs7562655	chr2:199520404	T/C	cg12456799	chr10:106441036	SORCS3	-0.37	-6.32	-0.46	2.77e-9	Cognitive ability (multi-trait analysis);
PAAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.38e-22	Rheumatoid arthritis;
PAAD	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.62	0.41	8.91e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.83	7.19	0.5	2.69e-11	Recombination rate (females);
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg10518543	chr12:38710700	ALG10B	0.5	4.84	0.37	3.15e-6	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.72	-5.54	-0.41	1.29e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.8	-7.79	-0.53	9.58e-13	Breast cancer;
PAAD	cis	rs5756391	0.748	rs2413429	chr22:37289869	A/G	cg16356956	chr22:37317934	CSF2RB	0.39	4.88	0.37	2.7e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg21775007	chr8:11205619	TDH	-0.58	-4.93	-0.37	2.16e-6	Neuroticism;
PAAD	cis	rs12042052	1.000	rs6696779	chr1:232920825	G/A	cg02903907	chr1:232941055	KIAA1383	0.85	4.6	0.35	8.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7487075	0.619	rs10880970	chr12:46830420	A/G	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs2120243	0.539	rs722484	chr3:157100627	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	4.65	0.35	7.11e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.57	-5.26	-0.39	4.85e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17842157	chr17:42200988	HDAC5	0.72	7.38	0.51	9.51e-12	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.43	0.46	1.57e-9	Mood instability;
PAAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	4.81	0.36	3.64e-6	Platelet count;
PAAD	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs10214930	0.697	rs6980382	chr7:27637662	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07167872	chr1:205819463	PM20D1	0.75	7.77	0.53	1.07e-12	Monocyte percentage of white cells;
PAAD	trans	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg26939375	chr7:64535504	NA	0.75	9.02	0.59	7.72e-16	Aortic root size;
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.77e-14	Menopause (age at onset);
PAAD	cis	rs6466055	0.661	rs67529088	chr7:104907066	G/C	cg04380332	chr7:105027541	SRPK2	0.52	5.15	0.39	8.14e-7	Schizophrenia;
PAAD	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.59	5.94	0.43	1.84e-8	Menopause (age at onset);
PAAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02556042	chr12:117471086	NA	0.47	4.83	0.36	3.3e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs2077654	0.908	rs7926934	chr11:17433088	A/C	cg25308976	chr11:17434268	ABCC8	0.92	6.22	0.45	4.51e-9	Gout;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	1.11	15.82	0.79	6.29e-34	Systemic lupus erythematosus;
PAAD	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.83	0.48	1.91e-10	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs1018697	1.000	rs2150928	chr10:104550985	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.17	0.45	5.83e-9	Colorectal adenoma (advanced);
PAAD	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg01206211	chr2:36825736	FEZ2	0.53	5.14	0.38	8.37e-7	Height;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs35123781	0.502	rs195674	chr5:138927219	G/A	cg11459648	chr5:138714337	SLC23A1	-0.64	-5.63	-0.42	8.44e-8	Schizophrenia;
PAAD	cis	rs8044868	0.812	rs12935232	chr16:72219984	T/C	cg14768367	chr16:72042858	DHODH	-0.46	-4.31	-0.33	2.87e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.71	0.62	1.19e-17	Total body bone mineral density;
PAAD	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg22153407	chr1:230290089	GALNT2	0.5	5.19	0.39	6.61e-7	Coronary artery disease;
PAAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg09796270	chr17:17721594	SREBF1	0.44	4.92	0.37	2.26e-6	Total body bone mineral density;
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.51	5.36	0.4	3.06e-7	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7688540	0.547	rs11728864	chr4:191307	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs2278796	0.789	rs1078719	chr1:204962405	A/G	cg04862289	chr1:204966208	NFASC	0.45	4.61	0.35	8.36e-6	Mean platelet volume;
PAAD	cis	rs900145	0.817	rs11022738	chr11:13293182	A/G	cg15603424	chr11:13300592	ARNTL	-0.51	-4.46	-0.34	1.58e-5	Menarche (age at onset);
PAAD	cis	rs7009516	0.625	rs6997507	chr8:24254123	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.77	-0.42	4.3e-8	Hair greying;
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.88	-9.62	-0.62	2.05e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.64	5.68	0.42	6.73e-8	Red blood cell count;
PAAD	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg02367709	chr17:66097352	LOC651250	0.44	4.42	0.34	1.9e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02598441	chr17:62777298	LOC146880	-0.54	-4.4	-0.34	1.99e-5	QT interval;
PAAD	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.49	-5.11	-0.38	9.41e-7	Urinary metabolites (H-NMR features);
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-6.97	-0.49	8.96e-11	Prudent dietary pattern;
PAAD	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs9522267	1.000	rs1411628	chr13:112199321	G/A	cg10483660	chr13:112241077	NA	-0.48	-5.03	-0.38	1.36e-6	Hepatitis;
PAAD	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.46	6.79	0.48	2.38e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.63	5.87	0.43	2.61e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.42	4.61	0.35	8.58e-6	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.57	-6.35	-0.46	2.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg15798862	chr7:76129360	DTX2	-0.5	-6.62	-0.47	5.67e-10	Multiple sclerosis;
PAAD	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.3	0.6	1.42e-16	Bipolar disorder;
PAAD	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg03983476	chr2:10830698	NOL10	0.52	5.2	0.39	6.36e-7	Prostate cancer;
PAAD	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.84e-19	Tonsillectomy;
PAAD	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.21	0.67	1.21e-21	Total body bone mineral density;
PAAD	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.85e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg14993813	chr1:46806288	NSUN4	-0.53	-4.86	-0.37	2.87e-6	Menopause (age at onset);
PAAD	cis	rs1930961	1.000	rs6004669	chr22:25875803	T/C	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg05785598	chr3:49045655	WDR6	0.43	5.2	0.39	6.24e-7	Parkinson's disease;
PAAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg24253500	chr15:84953950	NA	0.58	6.54	0.47	9.06e-10	Schizophrenia;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.93	-8.02	-0.55	2.67e-13	Attention deficit hyperactivity disorder;
PAAD	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.68	6.67	0.48	4.55e-10	Cardiac Troponin-T levels;
PAAD	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg14580859	chr9:123691850	NA	0.38	4.28	0.33	3.36e-5	Rheumatoid arthritis;
PAAD	cis	rs6782025	0.716	rs1688685	chr3:120666647	T/C	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs642743	0.967	rs515910	chr10:105966404	A/G	cg03775802	chr10:105978702	MIR609;C10orf79	0.32	4.44	0.34	1.74e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Lung cancer in ever smokers;
PAAD	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-1.1	-8.16	-0.55	1.18e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.93	9.22	0.6	2.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg04717802	chr22:42394638	WBP2NL	0.48	4.6	0.35	8.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2327429	0.858	rs7769943	chr6:134196327	C/T	cg06296503	chr6:134217401	NA	0.47	4.83	0.36	3.31e-6	Coronary artery disease;
PAAD	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.41e-6	Pulmonary function;
PAAD	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.41	-6.04	-0.44	1.13e-8	Subjective well-being;
PAAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg20893579	chr22:38215064	NA	0.54	5.4	0.4	2.56e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-4.52	-0.34	1.22e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13343549	chr17:80983747	B3GNTL1	0.62	6.54	0.47	8.73e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.68	5.29	0.39	4.19e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.55	5.0	0.38	1.59e-6	Bipolar disorder;
PAAD	cis	rs375066	0.935	rs398964	chr19:44413884	G/A	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.66	7.23	0.51	2.21e-11	Lung cancer;
PAAD	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.91	-10.45	-0.65	1.35e-19	Cognitive function;
PAAD	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.74	7.31	0.51	1.44e-11	Asthma;
PAAD	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.45	-5.2	-0.39	6.37e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-0.65	-6.23	-0.45	4.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.89	10.84	0.66	1.22e-20	Menopause (age at onset);
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7567389	0.719	rs4150402	chr2:128050134	C/T	cg11380483	chr2:127933992	NA	0.46	4.63	0.35	7.73e-6	Self-rated health;
PAAD	cis	rs2637266	0.626	rs846617	chr10:78546881	A/G	cg18941641	chr10:78392320	NA	0.36	4.35	0.33	2.53e-5	Pulmonary function;
PAAD	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.82	-7.15	-0.5	3.43e-11	Gut microbiome composition (summer);
PAAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.88	9.97	0.63	2.49e-18	Parkinson's disease;
PAAD	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.6	5.39	0.4	2.65e-7	Crohn's disease;
PAAD	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.48	-5.38	-0.4	2.71e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.62	0.57	8.31e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.47	-0.57	1.91e-14	Coffee consumption (cups per day);
PAAD	cis	rs7772697	0.632	rs7741346	chr6:149425806	A/C	cg21368479	chr6:149415018	NA	0.41	4.32	0.33	2.77e-5	Diabetic retinopathy;
PAAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	1.24	12.51	0.71	3.86e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg04738700	chr2:239367308	NA	0.44	4.73	0.36	5.18e-6	Multiple system atrophy;
PAAD	cis	rs54211	0.908	rs137666	chr22:39735378	C/T	cg24399712	chr22:39784796	NA	-0.77	-4.35	-0.33	2.47e-5	Sudden cardiac arrest;
PAAD	cis	rs859767	0.501	rs10210052	chr2:135417350	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.57	-0.35	1e-5	Neuroticism;
PAAD	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10819733	chr22:24237672	NA	-0.6	-6.44	-0.46	1.45e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg06131755	chr6:160182447	ACAT2	0.56	4.95	0.37	1.97e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-4.77	-0.36	4.26e-6	Kawasaki disease;
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.5	-5.11	-0.38	9.66e-7	Breast cancer;
PAAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg10006428	chr1:248814059	OR2T27	-0.38	-4.46	-0.34	1.58e-5	Common traits (Other);
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	1.12	8.43	0.56	2.53e-14	IgG glycosylation;
PAAD	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.77	7.44	0.52	6.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg16205897	chr5:131564050	P4HA2	-0.42	-4.36	-0.33	2.39e-5	Acylcarnitine levels;
PAAD	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.84	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.57	5.46	0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.53	-5.49	-0.41	1.64e-7	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.75	-0.48	2.87e-10	Lung cancer;
PAAD	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1042026	0.813	rs2051428	chr4:100123186	C/T	cg09112717	chr4:100009950	ADH5	0.5	4.47	0.34	1.53e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Gout;
PAAD	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.04	0.5	6.07e-11	Coffee consumption (cups per day);
PAAD	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg03309721	chr19:2236316	PLEKHJ1;SF3A2	-0.57	-4.46	-0.34	1.58e-5	Bipolar disorder;
PAAD	cis	rs1699337	1.000	rs2938397	chr3:12408278	C/T	cg00923996	chr3:13322657	NA	-0.42	-4.38	-0.33	2.17e-5	Cholesterol, total;
PAAD	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg08676812	chr11:65308423	LTBP3	0.8	5.56	0.41	1.17e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.82e-8	Alzheimer's disease (late onset);
PAAD	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs716316	0.590	rs6135309	chr20:14902522	C/T	cg04470754	chr20:14904432	MACROD2	-0.57	-5.67	-0.42	7.05e-8	Advanced glycation end-product levels;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35785195	0.633	rs1035774	chr12:114230856	G/C	cg11070030	chr12:114232702	NA	0.62	4.77	0.36	4.33e-6	Daytime sleep phenotypes;
PAAD	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.62	6.57	0.47	7.44e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.71	-0.36	5.58e-6	Breast cancer;
PAAD	cis	rs6893807	0.778	rs16903285	chr5:87978252	T/C	cg02225085	chr5:87975992	LOC645323	-0.72	-5.2	-0.39	6.36e-7	Body mass index;
PAAD	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.64	7.14	0.5	3.65e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.38	4.4	0.34	2.02e-5	Fat distribution (HIV);
PAAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg27490568	chr2:178487706	NA	0.42	4.41	0.34	1.92e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.68	-8.07	-0.55	2.03e-13	Lung cancer;
PAAD	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2117029	0.521	rs12227610	chr12:49539936	G/A	cg05368762	chr12:50135785	TMBIM6	0.46	4.63	0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-4.99	-0.38	1.6e-6	P wave terminal force;
PAAD	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.79	-0.42	3.96e-8	Androgen levels;
PAAD	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg18281939	chr5:77783895	LHFPL2	-0.47	-5.51	-0.41	1.51e-7	Triglycerides;
PAAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.39	-0.51	8.9e-12	Total cholesterol levels;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.08	-15.95	-0.79	2.9e-34	Prudent dietary pattern;
PAAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.66	-0.35	7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg26570165	chr1:119541833	NA	-0.47	-4.35	-0.33	2.51e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.82	9.18	0.6	3e-16	Prostate cancer;
PAAD	cis	rs12304921	0.810	rs56087503	chr12:51354506	A/C	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-5.9	-0.43	2.25e-8	Gut microbiome composition (summer);
PAAD	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.52	-0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6445967	1.000	rs12633655	chr3:58306321	T/C	cg23715586	chr3:58305044	RPP14	0.49	4.34	0.33	2.59e-5	Platelet count;
PAAD	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.58	-7.18	-0.5	2.92e-11	Blood pressure (smoking interaction);
PAAD	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-4.77	-0.36	4.26e-6	Mean corpuscular volume;
PAAD	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.63	-0.42	8.42e-8	Monocyte percentage of white cells;
PAAD	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.43	4.77	0.36	4.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2278796	0.528	rs4951151	chr1:204970302	T/C	cg17947172	chr1:204966197	NFASC	0.44	4.51	0.34	1.27e-5	Mean platelet volume;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg11764359	chr7:65958608	NA	-0.75	-4.96	-0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7627468	0.770	rs12493480	chr3:121962963	G/A	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.75	-8.1	-0.55	1.62e-13	Eye color traits;
PAAD	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.6	-5.94	-0.43	1.86e-8	Coronary artery disease;
PAAD	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12165864	chr7:66369176	NA	-0.81	-5.34	-0.4	3.29e-7	Diabetic kidney disease;
PAAD	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg24747557	chr10:131355152	MGMT	0.56	6.21	0.45	4.82e-9	Response to temozolomide;
PAAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg01320130	chr1:67600311	NA	0.53	5.53	0.41	1.35e-7	Psoriasis;
PAAD	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg06569542	chr10:98946673	SLIT1	-0.52	-5.84	-0.43	3.01e-8	Monocyte count;
PAAD	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.58	5.66	0.42	7.18e-8	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.72	-4.89	-0.37	2.51e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.79	-0.81	1.95e-36	Myeloid white cell count;
PAAD	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11700980	0.551	rs56000932	chr21:30116268	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.42	4.39	0.34	2.12e-5	Red cell distribution width;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15597140	chr6:133136317	RPS12;SNORD101	0.72	6.35	0.46	2.35e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.73	-7.98	-0.54	3.39e-13	Dental caries;
PAAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.63	7.49	0.52	5.32e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg05805236	chr11:65401703	PCNXL3	0.43	4.65	0.35	7.07e-6	Acne (severe);
PAAD	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	4.27	0.33	3.37e-5	Recombination measurement;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.79	-8.4	-0.56	2.96e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg07212818	chr11:638076	DRD4	-0.7	-6.66	-0.48	4.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.52	-0.47	9.87e-10	Response to antipsychotic treatment;
PAAD	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs747650	0.504	rs11600292	chr11:46958698	A/G	cg19486271	chr11:47235900	DDB2	0.65	6.13	0.45	7.34e-9	Acne (severe);
PAAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs6074578	0.679	rs6086162	chr20:136025	C/T	cg16931068	chr20:139680	DEFB127	0.37	4.98	0.37	1.67e-6	Hirschsprung disease;
PAAD	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.56	4.55	0.35	1.11e-5	Platelet count;
PAAD	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg10290764	chr8:4849399	CSMD1	0.41	6.9	0.49	1.3e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.8	-0.48	2.3e-10	Retinal vascular caliber;
PAAD	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.6	-5.62	-0.41	8.93e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg05425664	chr17:57184151	TRIM37	0.5	4.76	0.36	4.48e-6	Testicular germ cell tumor;
PAAD	cis	rs8170	0.603	rs4808621	chr19:17414267	C/T	cg10664184	chr19:17420304	DDA1	0.48	4.38	0.33	2.18e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.67	-6.68	-0.48	4.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.61	4.99	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg13870426	chr17:30244630	NA	-0.76	-5.84	-0.43	3.07e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.9	0.43	2.26e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9395066	0.545	rs3799979	chr6:44845514	A/G	cg18551225	chr6:44695536	NA	-0.42	-4.36	-0.33	2.35e-5	Height;
PAAD	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.47	5.54	0.41	1.29e-7	Inattentive symptoms;
PAAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.59	-4.59	-0.35	9.08e-6	Schizophrenia;
PAAD	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.41	5.0	0.38	1.54e-6	Coronary artery disease;
PAAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09597638	chr17:3907349	NA	0.71	7.8	0.53	9e-13	Type 2 diabetes;
PAAD	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg02415014	chr8:143852576	LYNX1	0.51	6.26	0.45	3.8e-9	Urinary tract infection frequency;
PAAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26926768	chr12:34528122	NA	0.39	4.82	0.36	3.46e-6	Morning vs. evening chronotype;
PAAD	cis	rs7168592	1.000	rs34969439	chr15:101743688	A/G	cg24254196	chr15:101719523	CHSY1	-0.68	-4.83	-0.37	3.24e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs10943724	0.704	rs6936716	chr6:81258828	G/C	cg19323245	chr6:80716898	TTK	-0.46	-4.86	-0.37	2.9e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs990171	0.687	rs6761871	chr2:103176797	A/C	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.48	-0.34	1.44e-5	Lymphocyte counts;
PAAD	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.8	-5.61	-0.41	9.37e-8	Blood protein levels;
PAAD	cis	rs7772697	0.635	rs1890610	chr6:149413979	A/G	cg21368479	chr6:149415018	NA	0.43	4.46	0.34	1.59e-5	Diabetic retinopathy;
PAAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg14440974	chr22:39074834	NA	-0.54	-6.11	-0.44	8.08e-9	Menopause (age at onset);
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13198984	chr17:80129470	CCDC57	-0.39	-4.92	-0.37	2.27e-6	Life satisfaction;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.75	-0.42	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.61	7.81	0.54	8.81e-13	Crohn's disease;
PAAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg05373962	chr22:49881684	NA	-0.55	-5.19	-0.39	6.78e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.87	-0.43	2.7e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg01299579	chr2:10830716	NOL10	-0.6	-6.18	-0.45	5.63e-9	Prostate cancer;
PAAD	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg05835009	chr4:710272	PCGF3	0.71	6.32	0.46	2.69e-9	White blood cell count;
PAAD	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.51	-0.34	1.31e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg18764771	chr6:116381957	FRK	-0.44	-7.92	-0.54	4.71e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.64	7.19	0.5	2.74e-11	Menopause (age at onset);
PAAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg08893839	chr5:154027129	NA	-0.7	-5.24	-0.39	5.29e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.49	4.9	0.37	2.4e-6	Testicular germ cell tumor;
PAAD	cis	rs4073221	0.789	rs35171423	chr3:18217771	T/C	cg07694806	chr3:18168406	NA	-0.83	-4.96	-0.37	1.86e-6	Parkinson's disease;
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.98	8.07	0.55	2e-13	Initial pursuit acceleration;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.52	-5.02	-0.38	1.42e-6	Parkinson's disease;
PAAD	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.76	-7.35	-0.51	1.15e-11	Coronary artery disease;
PAAD	cis	rs12311304	0.965	rs12322836	chr12:15368093	G/C	cg08258403	chr12:15378311	NA	0.35	4.41	0.34	1.94e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10459387	chr3:180319718	TTC14	0.66	6.81	0.48	2.14e-10	Obesity-related traits;
PAAD	cis	rs4704187	0.687	rs6894048	chr5:74456838	A/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.5	-7.21	-0.51	2.4e-11	Diastolic blood pressure;
PAAD	cis	rs11264213	0.515	rs9660657	chr1:36548941	C/T	cg27506609	chr1:36549197	TEKT2	-0.83	-6.02	-0.44	1.23e-8	Schizophrenia;
PAAD	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.37	0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs1468333	0.598	rs4639219	chr5:137699620	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs300774	0.925	rs300713	chr2:138363	A/G	cg23649280	chr2:140451	NA	-0.5	-4.86	-0.37	2.88e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg16590910	chr6:42928470	GNMT	0.51	5.28	0.39	4.47e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg03482866	chr13:111040579	COL4A2	0.52	4.87	0.37	2.74e-6	White matter hyperintensity burden;
PAAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg23018236	chr17:30244563	NA	-0.58	-4.48	-0.34	1.47e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg05627522	chr15:75251581	NA	0.52	6.18	0.45	5.57e-9	Caffeine consumption;
PAAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg03732007	chr1:2071316	PRKCZ	-0.43	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg26385993	chr17:80788710	TBCD;ZNF750	0.42	4.32	0.33	2.79e-5	Glycated hemoglobin levels;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg21665744	chr7:39171113	POU6F2	0.39	5.84	0.43	3.03e-8	IgG glycosylation;
PAAD	cis	rs2301573	0.568	rs9990031	chr3:129437836	A/G	cg18548199	chr3:129281892	PLXND1	-0.57	-4.74	-0.36	4.96e-6	Hip circumference;
PAAD	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.44	-4.59	-0.35	9.2e-6	Response to antidepressants in depression;
PAAD	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.49	-4.5	-0.34	1.32e-5	Diastolic blood pressure;
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.57	0.65	6.39e-20	Platelet count;
PAAD	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg09826364	chr7:158789723	NA	0.35	4.56	0.35	1.05e-5	Facial morphology (factor 20);
PAAD	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.08	0.5	5e-11	Lung cancer in ever smokers;
PAAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg27246729	chr12:121163418	ACADS	0.44	4.58	0.35	9.8e-6	Mean corpuscular volume;
PAAD	cis	rs11668609	0.505	rs114822678	chr19:24061884	A/G	cg09235885	chr19:23456588	NA	0.63	4.35	0.33	2.45e-5	Response to taxane treatment (docetaxel);
PAAD	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-6.28	-0.45	3.34e-9	Crohn's disease;
PAAD	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.64	7.54	0.52	3.97e-12	Height;
PAAD	cis	rs2085601	0.542	rs1795733	chr4:89976832	G/A	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg14711859	chr11:8959438	ASCL3	-0.46	-5.07	-0.38	1.15e-6	Hematocrit;
PAAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.69e-5	Coronary artery disease;
PAAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.64	6.52	0.47	9.8e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07362569	chr17:61921086	SMARCD2	0.62	7.6	0.52	2.88e-12	Prudent dietary pattern;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.27	-0.33	3.43e-5	Breast cancer;
PAAD	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00166722	chr3:10149974	C3orf24	0.95	8.3	0.56	5.14e-14	Alzheimer's disease;
PAAD	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.83	-0.36	3.34e-6	Large artery stroke;
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg14393609	chr7:65229607	NA	-0.63	-6.76	-0.48	2.74e-10	Calcium levels;
PAAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.72	-0.36	5.22e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27103680	chr2:86423081	IMMT	0.57	6.31	0.46	2.9e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9326726	0.566	rs288139	chr5:107400505	A/G	cg19779370	chr5:108084990	FER	-0.61	-4.93	-0.37	2.08e-6	Resting heart rate;
PAAD	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	6.69	0.48	3.99e-10	Response to antipsychotic treatment;
PAAD	cis	rs6594713	0.679	rs66572866	chr5:112761470	G/A	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-6.97	-0.49	9.12e-11	Morning vs. evening chronotype;
PAAD	cis	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.74	-0.36	4.9100000000000004e-06	Neuroticism;
PAAD	cis	rs7260598	0.539	rs11672512	chr19:24068750	C/T	cg09235885	chr19:23456588	NA	-0.64	-4.43	-0.34	1.78e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs9487051	0.621	rs396635	chr6:109523508	A/G	cg21918786	chr6:109611834	NA	-0.42	-4.34	-0.33	2.57e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	trans	rs901683	0.850	rs117582049	chr10:46050228	C/A	cg12869334	chr8:37699360	GPR124	0.98	6.79	0.48	2.32e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11718455	0.503	rs4017425	chr3:44028764	C/T	cg21419209	chr3:44054225	NA	-0.61	-6.93	-0.49	1.11e-10	Coronary artery disease;
PAAD	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.9	9.36	0.6	9.94e-17	Height;
PAAD	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	1.12	9.76	0.62	8.87e-18	Red blood cell traits;
PAAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.57	-5.72	-0.42	5.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.95	-8.14	-0.55	1.31e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.66	-7.03	-0.5	6.71e-11	Post bronchodilator FEV1;
PAAD	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs7818688	0.697	rs10504939	chr8:95983354	C/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4478858	0.684	rs12403136	chr1:31728920	A/G	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg26248373	chr2:1572462	NA	-1.08	-7.69	-0.53	1.7e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.79	9.89	0.63	4.06e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs3026101	0.671	rs2407	chr17:5289028	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.49	0.41	1.63e-7	Body mass index;
PAAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.93	10.78	0.66	1.74e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg15510373	chr7:100224934	TFR2	-0.52	-4.25	-0.33	3.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg22617819	chr1:44378782	ST3GAL3	-0.46	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.64	0.42	8.13e-8	Educational attainment;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.61	-5.66	-0.42	7.19e-8	Renal function-related traits (BUN);
PAAD	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg03676636	chr4:99064102	C4orf37	0.25	4.38	0.34	2.16e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.74	0.48	3.02e-10	Blood metabolite levels;
PAAD	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.89	7.03	0.5	6.57e-11	Triglycerides;
PAAD	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg01320130	chr1:67600311	NA	0.44	4.69	0.36	6.08e-6	Psoriasis;
PAAD	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg19875578	chr6:126661172	C6orf173	0.43	4.51	0.34	1.3e-5	Male-pattern baldness;
PAAD	cis	rs6547631	0.622	rs4240200	chr2:85925529	A/G	cg24620635	chr2:85921963	GNLY	0.43	5.63	0.42	8.66e-8	Blood protein levels;
PAAD	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.64	4.33	0.33	2.73e-5	Vitiligo;
PAAD	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.41	-0.4	2.44e-7	Obesity-related traits;
PAAD	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg04289385	chr6:36355825	ETV7	0.44	4.38	0.33	2.18e-5	Platelet distribution width;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg09017928	chr7:158110068	PTPRN2	0.58	5.28	0.39	4.46e-7	Response to amphetamines;
PAAD	cis	rs17169634	1.000	rs80145992	chr7:34088007	A/C	cg24927974	chr7:35078269	DPY19L1	-0.63	-5.23	-0.39	5.59e-7	Alzheimer's disease;
PAAD	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.89	-8.67	-0.58	6.01e-15	Bone mineral density;
PAAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs8121916	1.000	rs6041325	chr20:12401841	A/C	cg16404259	chr20:12988931	SPTLC3	0.42	4.28	0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg11764359	chr7:65958608	NA	0.75	5.1	0.38	1.01e-6	Diabetic kidney disease;
PAAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.39	5.25	0.39	4.98e-7	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs9422441	chr10:46048053	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4740619	0.933	rs10962124	chr9:15716039	T/C	cg14451791	chr9:16040625	NA	-0.41	-4.8	-0.36	3.81e-6	Body mass index;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11614389	chr5:81047184	SSBP2	0.69	6.37	0.46	2.14e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs16867321	0.951	rs61289394	chr2:181354915	T/G	cg23363182	chr2:181467187	NA	-0.48	-4.33	-0.33	2.64e-5	Obesity;
PAAD	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.05e-5	Life satisfaction;
PAAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg02544571	chr7:139187165	NA	-0.62	-6.55	-0.47	8.54e-10	Iris heterochromicity;
PAAD	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.61	-6.78	-0.48	2.48e-10	Type 2 diabetes;
PAAD	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs943072	0.920	rs6940798	chr6:43793391	A/G	cg06892548	chr6:43243945	TTBK1	-0.59	-4.8	-0.36	3.72e-6	Ulcerative colitis;
PAAD	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.98e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs901683	0.850	rs73291122	chr10:46099403	G/C	cg13065504	chr15:42448234	PLA2G4F	0.77	6.42	0.46	1.67e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Educational attainment;
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.55	-5.35	-0.4	3.14e-7	Tonsillectomy;
PAAD	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.55	5.41	0.4	2.4e-7	Blood pressure;
PAAD	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.53	4.7	0.36	5.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.53	0.47	9.23e-10	Lung cancer;
PAAD	cis	rs797680	0.586	rs2281525	chr1:93595306	G/C	cg04535902	chr1:92947332	GFI1	0.45	4.56	0.35	1.06e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs4751058	0.526	rs10764841	chr10:130856829	A/C	cg05596517	chr10:131320214	MGMT	-0.5	-4.67	-0.35	6.67e-6	Vitamin D levels;
PAAD	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.58	-8.65	-0.57	6.9e-15	Homoarginine levels;
PAAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg24253500	chr15:84953950	NA	-0.54	-6.37	-0.46	2.13e-9	Schizophrenia;
PAAD	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.65	5.82	0.43	3.43e-8	Mean platelet volume;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs60624478	0.671	rs10465564	chr1:165101357	A/G	cg25031777	chr1:164528501	PBX1	-0.58	-4.81	-0.36	3.59e-6	Response to methotrexate in juvenile idiopathic arthritis;
PAAD	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.61	4.9	0.37	2.41e-6	Height;
PAAD	cis	rs6669119	1.000	rs6669544	chr1:19109036	C/G	cg19637330	chr1:19110922	NA	-0.81	-5.32	-0.4	3.61e-7	Percentage gas trapping;
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg15181151	chr6:150070149	PCMT1	0.55	5.93	0.43	1.97e-8	Lung cancer;
PAAD	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.73	-0.53	1.33e-12	Coronary artery disease;
PAAD	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.56	5.6	0.41	9.61e-8	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.53	6.22	0.45	4.56e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.12e-5	Major depressive disorder;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.73	5.63	0.42	8.32e-8	Morning vs. evening chronotype;
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg02841227	chr6:26021843	HIST1H4A	0.52	5.1	0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.07	9.63	0.62	2.01e-17	Red blood cell traits;
PAAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Lymphocyte counts;
PAAD	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg07167872	chr1:205819463	PM20D1	0.6	4.6	0.35	8.74e-6	Parkinson's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04741861	chr19:3531604	FZR1	0.56	6.56	0.47	7.83e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7246865	0.510	rs2305757	chr19:17169758	G/C	cg19418318	chr19:17219073	MYO9B	0.36	5.24	0.39	5.25e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.84	-9.4	-0.61	7.93e-17	Prudent dietary pattern;
PAAD	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26378065	chr17:18585709	ZNF286B	0.5	4.88	0.37	2.69e-6	Educational attainment (years of education);
PAAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg26384229	chr12:38710491	ALG10B	0.7	7.11	0.5	4.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18621852	chr3:10150065	C3orf24	0.64	5.66	0.42	7.34e-8	Alzheimer's disease;
PAAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-4.45	-0.34	1.62e-5	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11496792	chr9:123477254	MEGF9	0.6	6.61	0.47	6.06e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.27	-13.29	-0.73	3.18e-27	Corneal structure;
PAAD	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09366988	chr2:204399782	RAPH1	0.68	7.68	0.53	1.79e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.45	4.98	0.37	1.7e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.59	-7.86	-0.54	6.53e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.82	-9.1	-0.59	4.87e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.97	0.44	1.65e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07685180	chr8:600429	NA	0.88	5.42	0.4	2.33e-7	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18621852	chr3:10150065	C3orf24	0.68	5.94	0.43	1.89e-8	Alzheimer's disease;
PAAD	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg21427119	chr20:30132790	HM13	-0.64	-5.14	-0.38	8.37e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9659323	1.000	rs12073056	chr1:119508400	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.5	-0.41	1.55e-7	Body mass index;
PAAD	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs1075265	0.783	rs805438	chr2:54056188	A/T	cg04546899	chr2:54196757	PSME4	0.31	4.66	0.35	6.84e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg10729496	chr3:10149963	C3orf24	0.79	5.83	0.43	3.28e-8	Alzheimer's disease;
PAAD	cis	rs12453935	0.708	rs7223607	chr17:59911477	T/C	cg01765249	chr17:59476334	TBX2	-0.52	-4.59	-0.35	9.2e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.65	-5.33	-0.4	3.47e-7	Fibrinogen levels;
PAAD	cis	rs6604026	0.656	rs9439948	chr1:93370800	A/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg11843238	chr5:131593191	PDLIM4	-0.48	-4.5	-0.34	1.37e-5	Acylcarnitine levels;
PAAD	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.41	-4.64	-0.35	7.6e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.51	-4.99	-0.38	1.63e-6	Pancreatic cancer;
PAAD	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.52	0.34	1.24e-5	Refractive astigmatism;
PAAD	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.47	4.83	0.36	3.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.57	-0.47	7.49e-10	Total body bone mineral density;
PAAD	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.33	0.56	4.29e-14	Monocyte percentage of white cells;
PAAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-1.39	-10.93	-0.66	6.83e-21	Schizophrenia;
PAAD	cis	rs2275731	0.723	rs12572242	chr10:16547995	T/G	cg04254609	chr10:16479192	PTER	-0.42	-4.37	-0.33	2.25e-5	Bone fracture in osteoporosis;
PAAD	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.78	8.97	0.59	1.04e-15	Heart rate;
PAAD	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.4	-4.94	-0.37	2.02e-6	Systolic blood pressure;
PAAD	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.44	-4.95	-0.37	1.99e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs735539	0.555	rs3000678	chr13:21302058	G/A	cg27499820	chr13:21296301	IL17D	0.56	5.16	0.39	7.59e-7	Dental caries;
PAAD	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.95	0.37	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.55	5.3	0.39	4e-7	Multiple myeloma;
PAAD	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg04717802	chr22:42394638	WBP2NL	0.55	4.59	0.35	9.22e-6	Birth weight;
PAAD	cis	rs113779084	0.660	rs4143575	chr7:11968270	G/C	cg15090509	chr7:11872073	THSD7A	0.38	4.6	0.35	8.75e-6	Educational attainment (years of education);
PAAD	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg16417436	chr16:28758564	NA	0.43	4.44	0.34	1.72e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg19438565	chr8:143695827	ARC	-0.56	-5.52	-0.41	1.43e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.68	7.11	0.5	4.35e-11	DNA methylation (variation);
PAAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.05	7.72	0.53	1.48e-12	Alzheimer's disease;
PAAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12599982	chr1:44399894	ARTN	0.47	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg15729578	chr3:195576390	NA	-0.42	-4.27	-0.33	3.45e-5	Pancreatic cancer;
PAAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01451205	chr11:119252210	USP2	-0.65	-6.58	-0.47	7e-10	Smoking initiation;
PAAD	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11958404	0.615	rs10044900	chr5:157451580	C/T	cg05962755	chr5:157440814	NA	-0.57	-5.49	-0.41	1.63e-7	IgG glycosylation;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.74	8.69	0.58	5.29e-15	Height;
PAAD	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.46e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.7	-5.83	-0.43	3.2e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg16810054	chr20:33298113	TP53INP2	-0.62	-4.98	-0.37	1.71e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07945002	chr1:155165037	MIR92B	0.62	6.39	0.46	1.95e-9	Obesity-related traits;
PAAD	cis	rs2252790	0.899	rs1204854	chr6:116580896	T/A	cg18764771	chr6:116381957	FRK	-0.26	-4.41	-0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.81	-0.36	3.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg22601191	chr20:60968625	CABLES2	0.48	4.65	0.35	7.21e-6	Colorectal cancer;
PAAD	cis	rs9318086	0.533	rs7325450	chr13:24467004	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.54	4.68	0.36	6.17e-6	Myopia (pathological);
PAAD	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-4.75	-0.36	4.74e-6	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.39	4.74	0.36	4.77e-6	Pulmonary function;
PAAD	cis	rs9472414	0.689	rs524492	chr6:44796596	C/T	cg20913747	chr6:44695427	NA	0.46	4.52	0.34	1.21e-5	Height;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16209045	chr19:2328691	SPPL2B;LSM7	-0.68	-7.03	-0.5	6.7e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4588572	0.644	rs9293751	chr5:77778296	A/G	cg18281939	chr5:77783895	LHFPL2	0.51	6.73	0.48	3.19e-10	Triglycerides;
PAAD	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.57	6.17	0.45	5.8e-9	Mean corpuscular volume;
PAAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-1.11	-8.26	-0.56	6.79e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.44	-5.13	-0.38	8.67e-7	Rheumatoid arthritis;
PAAD	cis	rs8181166	0.540	rs1360502	chr9:89086290	C/T	cg14198768	chr9:89109504	NA	-0.29	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg06643849	chr19:57742421	AURKC	0.41	4.25	0.33	3.77e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs10957961	0.630	rs4237108	chr8:81061042	G/C	cg10609868	chr8:81963379	PAG1	-0.35	-4.29	-0.33	3.19e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs1018697	1.000	rs7092346	chr10:104559764	A/G	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.47	5.72	0.42	5.37e-8	Vitiligo;
PAAD	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.63	-0.62	2.03e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg18721089	chr20:30220636	NA	-0.51	-4.48	-0.34	1.46e-5	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.63	-7.6	-0.52	2.91e-12	Aortic root size;
PAAD	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.74	7.45	0.52	6.66e-12	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6558530	0.579	rs6558528	chr8:1703063	C/T	cg19131313	chr8:1704013	NA	-0.42	-4.59	-0.35	9.12e-6	Systolic blood pressure;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.66	-7.06	-0.5	5.68e-11	Lung function (FVC);
PAAD	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2885056	0.891	rs12978228	chr19:10691323	G/T	cg04833646	chr19:10679720	CDKN2D	0.96	9.27	0.6	1.77e-16	Red cell distribution width;
PAAD	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg13926569	chr10:89418898	PAPSS2	-0.68	-7.01	-0.49	7.32e-11	Magnesium levels;
PAAD	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg07159951	chr1:45983175	PRDX1	0.42	4.59	0.35	9.37e-6	High light scatter reticulocyte count;
PAAD	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg01489032	chr8:143877656	NA	0.47	4.98	0.37	1.74e-6	Urinary tract infection frequency;
PAAD	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg11518657	chr1:67396239	MIER1	0.7	5.15	0.39	8.01e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10218531	chr3:166528650	NA	-0.65	-6.34	-0.46	2.47e-9	Obesity-related traits;
PAAD	cis	rs7829975	0.627	rs876954	chr8:8310923	G/A	cg14343924	chr8:8086146	FLJ10661	0.5	4.38	0.33	2.17e-5	Mood instability;
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg23018236	chr17:30244563	NA	-0.65	-5.52	-0.41	1.43e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.46e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.6	5.95	0.43	1.79e-8	Blood metabolite levels;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.77	5.67	0.42	7.07e-8	Vitiligo;
PAAD	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.69	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-5.48	-0.41	1.73e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg05528293	chr18:74961138	GALR1	0.56	5.18	0.39	6.97e-7	Obesity-related traits;
PAAD	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.63	6.6	0.47	6.46e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.63	6.93	0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-5.07	-0.38	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.62	-4.29	-0.33	3.2e-5	Urinary tract infection frequency;
PAAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.61	-6.38	-0.46	2.02e-9	Schizophrenia;
PAAD	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg21823605	chr1:152486609	CRCT1	-0.49	-6.29	-0.45	3.14e-9	Hair morphology;
PAAD	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg02887458	chr19:19495540	GATAD2A	0.55	5.13	0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.6	-6.91	-0.49	1.24e-10	Blood metabolite levels;
PAAD	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg01305830	chr4:1604576	NA	0.46	4.57	0.35	9.91e-6	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12057946	chr11:120195905	TMEM136	-0.6	-7.25	-0.51	2.02e-11	Body fat percentage;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13937449	chr12:56320970	WIBG	0.58	6.75	0.48	2.86e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg20893579	chr22:38215064	NA	0.56	5.85	0.43	2.86e-8	Glioblastoma;Glioma;
PAAD	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15369054	chr17:80825471	TBCD	-0.57	-4.62	-0.35	8.28e-6	Breast cancer;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.39	0.34	2.08e-5	Bipolar disorder;
PAAD	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15644404	chr18:77186268	NFATC1	-0.89	-5.18	-0.39	6.83e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.98	6.47	0.46	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-0.91	-14.46	-0.76	2.33e-30	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	cis	rs7588746	0.621	rs2060122	chr2:201153177	A/G	cg23649088	chr2:200775458	C2orf69	-0.51	-4.8	-0.36	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.66	-0.48	4.74e-10	Total body bone mineral density;
PAAD	cis	rs2637030	0.559	rs6881928	chr5:52988609	C/A	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.3	0.33	3.06e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.87	9.53	0.61	3.52e-17	Cognitive function;
PAAD	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.7	-6.81	-0.48	2.07e-10	Breast cancer;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.26e-18	Vitiligo;
PAAD	cis	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.36	-4.39	-0.34	2.09e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.5	-4.6	-0.35	8.75e-6	Neuroticism;
PAAD	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.68	-7.79	-0.53	9.78e-13	Alcohol dependence;
PAAD	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.04	-0.55	2.31e-13	Brugada syndrome;
PAAD	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00292662	chr22:38071168	LGALS1	0.5	4.44	0.34	1.73e-5	Fat distribution (HIV);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23348161	chr2:240964931	NDUFA10	0.65	6.38	0.46	1.99e-9	Obesity-related traits;
PAAD	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg01329690	chr21:38580129	DSCR9	-0.33	-4.54	-0.35	1.15e-5	Eye color traits;
PAAD	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-4.67	-0.35	6.62e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.63	-5.51	-0.41	1.47e-7	Mean corpuscular volume;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg13903179	chr13:21900392	NA	0.59	6.16	0.45	6.18e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg11062466	chr8:58055876	NA	0.68	4.79	0.36	3.97e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg27511599	chr7:32358540	NA	-0.75	-4.39	-0.34	2.12e-5	Body mass index;
PAAD	cis	rs59191668	0.868	rs8030359	chr15:62819996	G/T	cg12918536	chr15:62891943	NA	-0.35	-4.64	-0.35	7.42e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.98	10.81	0.66	1.46e-20	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg26668828	chr6:292823	DUSP22	-0.68	-7.01	-0.49	7.3e-11	Menopause (age at onset);
PAAD	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg02117656	chr17:79614917	TSPAN10	0.8	8.84	0.58	2.26e-15	Myopia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02067580	chr1:153606662	C1orf77;S100A13	-0.65	-6.9	-0.49	1.34e-10	Smoking initiation;
PAAD	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.02	-0.38	1.46e-6	Diastolic blood pressure;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.61	0.41	9.34e-8	Prudent dietary pattern;
PAAD	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.82	-0.48	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2286379	0.544	rs10773980	chr12:1798718	C/T	cg05227549	chr12:1770782	NA	-0.44	-5.03	-0.38	1.36e-6	Blood pressure (smoking interaction);
PAAD	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	10.55	0.65	7.3e-20	Lymphocyte percentage of white cells;
PAAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg16362232	chr11:430036	ANO9	0.84	4.46	0.34	1.56e-5	Body mass index;
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.84	0.58	2.21e-15	Lung cancer;
PAAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-5.11	-0.38	9.56e-7	Longevity;Endometriosis;
PAAD	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-7.64	-0.53	2.24e-12	Colorectal cancer;
PAAD	cis	rs3007168	1.000	rs2999363	chr14:51605141	A/G	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs990171	0.538	rs2075188	chr2:103120232	G/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.73	8.97	0.59	1.04e-15	Bone mineral density;
PAAD	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.66	-6.19	-0.45	5.39e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	8.14	0.55	1.33e-13	Cognitive test performance;
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg07336987	chr11:625147	MUPCDH	-0.38	-4.73	-0.36	5.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.65	6.24	0.45	4.2e-9	Obesity-related traits;
PAAD	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.58	-0.47	7.21e-10	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.46	0.57	2.09e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.52	4.87	0.37	2.83e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.63	6.44	0.46	1.48e-9	Colorectal cancer;
PAAD	cis	rs527409	0.850	rs912502	chr1:58731279	C/A	cg26345888	chr1:58716257	DAB1	-0.69	-4.73	-0.36	4.98e-6	Kawasaki disease;
PAAD	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg16586182	chr3:47516702	SCAP	0.68	7.44	0.52	7.06e-12	Colorectal cancer;
PAAD	cis	rs3736485	0.966	rs11070862	chr15:51902227	G/A	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.51e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg14768367	chr16:72042858	DHODH	-0.76	-5.1	-0.38	9.96e-7	Blood protein levels;
PAAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.28	-0.45	3.31e-9	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.56	0.65	6.76e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.13e-5	Noise-induced hearing loss;
PAAD	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg01426195	chr3:39028469	NA	-0.74	-8.5	-0.57	1.68e-14	Handedness;
PAAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.37	0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.46	4.66	0.35	6.89e-6	Personality dimensions;
PAAD	cis	rs12989701	0.935	rs12994284	chr2:127874020	T/C	cg00091827	chr2:127863656	BIN1	0.6	4.54	0.35	1.14e-5	Alzheimer's disease (late onset);
PAAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.48e-6	Lung cancer;
PAAD	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.61	-5.69	-0.42	6.45e-8	Monocyte count;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25624328	chr15:63334706	TPM1	0.4	4.46	0.34	1.6e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09695851	chr17:3907499	NA	0.66	6.95	0.49	1.01e-10	Type 2 diabetes;
PAAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.84	7.26	0.51	1.88e-11	Alzheimer's disease;
PAAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.55	-7.04	-0.5	6.29e-11	Lewy body disease;
PAAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.15	-0.45	6.48e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.95	-10.18	-0.64	7.11e-19	Alcohol dependence;
PAAD	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.57	5.05	0.38	1.27e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs151997	1.000	rs62367382	chr5:50246715	T/C	cg06027927	chr5:50259733	NA	0.77	7.54	0.52	3.9e-12	Callous-unemotional behaviour;
PAAD	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.69	7.88	0.54	5.9e-13	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.67	0.42	6.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11696845	0.787	rs13043441	chr20:43364308	A/G	cg25301532	chr20:43378953	KCNK15	0.5	5.57	0.41	1.11e-7	Obesity-related traits;
PAAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.23	0.45	4.42e-9	Lung cancer in ever smokers;
PAAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	5.82	0.43	3.39e-8	Mood instability;
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg03538708	chr1:25844672	NA	-0.53	-5.44	-0.4	2.12e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.75	4.64	0.35	7.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs4705952	0.832	rs2548989	chr5:131859705	T/C	cg05209330	chr5:131550942	P4HA2	0.52	4.3	0.33	3.03e-5	C-reactive protein levels;
PAAD	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg23950597	chr19:37808831	NA	-0.77	-5.21	-0.39	6.09e-7	Coronary artery calcification;
PAAD	cis	rs2908197	0.765	rs2098205	chr7:75938888	A/G	cg22830091	chr7:75961684	YWHAG	-0.6	-6.71	-0.48	3.63e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.98	13.45	0.74	1.17e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9287604	1.000	rs30103	chr2:237793336	C/T	cg15065627	chr2:237796583	NA	-0.52	-4.38	-0.33	2.24e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs73416724	0.544	rs111739263	chr6:43243151	G/T	cg17502394	chr6:43251710	TTBK1	0.6	4.33	0.33	2.74e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg17385448	chr1:15911702	AGMAT	0.39	4.72	0.36	5.41e-6	Systolic blood pressure;
PAAD	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg18551225	chr6:44695536	NA	-0.71	-7.3	-0.51	1.46e-11	Total body bone mineral density;
PAAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg07959070	chr22:50026188	C22orf34	-0.36	-4.36	-0.33	2.39e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.4	-8.36	-0.56	3.75e-14	Mean corpuscular volume;
PAAD	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16088307	chr3:185216883	TMEM41A	-0.77	-7.01	-0.49	7.45e-11	Neuroticism;
PAAD	cis	rs9876781	1.000	rs9809843	chr3:48434398	T/C	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.29e-5	Rheumatoid arthritis;
PAAD	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg09626299	chr10:82213104	TSPAN14	0.47	5.06	0.38	1.17e-6	Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg23708337	chr7:1209742	NA	0.65	4.87	0.37	2.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.8	5.06	0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.59	6.55	0.47	8.18e-10	Mean corpuscular volume;
PAAD	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.42	5.25	0.39	5.04e-7	Colorectal cancer;
PAAD	cis	rs755249	0.567	rs72661961	chr1:39831768	A/G	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg10820045	chr2:198174542	NA	0.48	4.88	0.37	2.66e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.38	5.21	0.39	6.1e-7	Blood protein levels;
PAAD	cis	rs12476592	0.530	rs77804166	chr2:64160237	G/A	cg10828910	chr2:63850056	LOC388955	-0.57	-4.65	-0.35	7.11e-6	Childhood ear infection;
PAAD	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.66	-4.32	-0.33	2.82e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs75920871	0.688	rs61905678	chr11:116834785	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs2398893	1.000	rs12004383	chr9:96826239	G/T	cg14459158	chr9:96720562	NA	0.34	4.34	0.33	2.6e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.56	-0.52	3.56e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs35740288	0.822	rs2241268	chr15:86278309	G/A	cg07943548	chr15:86304357	KLHL25	-0.58	-4.88	-0.37	2.69e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.34	0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg10223061	chr2:219282414	VIL1	0.39	4.64	0.35	7.49e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-6.09	-0.44	9e-9	Schizophrenia;
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.62	-6.41	-0.46	1.76e-9	Systemic lupus erythematosus;
PAAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs137603	0.966	rs137616	chr22:39703883	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.55	-4.51	-0.34	1.3e-5	Primary biliary cholangitis;
PAAD	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.53	5.35	0.4	3.15e-7	Social autistic-like traits;
PAAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg21929781	chr1:2537748	MMEL1	-0.54	-5.61	-0.41	9.34e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.55	5.77	0.42	4.31e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.74	6.58	0.47	7.3e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg02493740	chr2:85810744	VAMP5	0.4	4.45	0.34	1.67e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg08992911	chr2:238395768	MLPH	0.91	6.58	0.47	7.34e-10	Prostate cancer;
PAAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.64	0.57	7.26e-15	Homoarginine levels;
PAAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1620921	0.505	rs11756055	chr6:161210622	C/T	cg01280913	chr6:161186852	NA	-0.46	-5.03	-0.38	1.39e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.11e-5	Renal cell carcinoma;
PAAD	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11475922	chr19:12251131	ZNF20	0.59	6.43	0.46	1.6e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.58	5.5	0.41	1.56e-7	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19238422	chr1:228353246	C1orf69	0.65	6.6	0.47	6.42e-10	Obesity-related traits;
PAAD	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg23331303	chr5:5135948	NA	-0.47	-6.6	-0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.69	-6.76	-0.48	2.8e-10	Retinal vascular caliber;
PAAD	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.61	-6.51	-0.47	1.01e-9	High light scatter reticulocyte count;
PAAD	cis	rs910187	0.641	rs6066232	chr20:45818905	C/T	cg27589058	chr20:45804311	EYA2	-0.49	-5.39	-0.4	2.61e-7	Migraine;
PAAD	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	7.76	0.53	1.17e-12	Electrocardiographic conduction measures;
PAAD	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.72	-7.35	-0.51	1.14e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.63	-6.11	-0.44	8e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs12144049	0.705	rs4240879	chr1:152414864	G/T	cg25605289	chr1:151974222	NA	-0.32	-4.36	-0.33	2.43e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg12666980	chr3:126703080	NA	-0.6	-6.94	-0.49	1.08e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg09659197	chr4:152720779	NA	0.47	6.32	0.46	2.76e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.77	-0.42	4.24e-8	Lung cancer;
PAAD	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.72	8.31	0.56	5.02e-14	Height;
PAAD	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.9	6.45	0.46	1.41e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-7.13	-0.5	3.78e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs75757892	0.505	rs112241640	chr6:7316111	A/T	cg02954307	chr6:7269328	NA	0.53	4.47	0.34	1.51e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg01422370	chr2:73384389	NA	0.44	5.63	0.42	8.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs60154123	1.000	rs4844996	chr1:210476423	C/T	cg22029157	chr1:209979665	IRF6	0.69	5.88	0.43	2.52e-8	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs62209635	0.568	rs6088323	chr20:32455866	A/T	cg00699721	chr20:32950990	ITCH	0.74	4.57	0.35	1e-5	Loneliness;
PAAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg05110241	chr16:68378359	PRMT7	-1.01	-6.15	-0.45	6.53e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9535307	0.584	rs7996307	chr13:50408023	C/T	cg03658251	chr13:50265850	EBPL	-0.83	-5.35	-0.4	3.21e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg11547950	chr5:77652471	NA	-0.69	-6.0	-0.44	1.4e-8	Triglycerides;
PAAD	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.52	-5.29	-0.39	4.27e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.32	-0.46	2.7e-9	Lung cancer;
PAAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg14440974	chr22:39074834	NA	-0.59	-7.15	-0.5	3.46e-11	Menopause (age at onset);
PAAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.68	7.19	0.5	2.76e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2637266	0.745	rs2579733	chr10:78441896	C/T	cg18941641	chr10:78392320	NA	-0.36	-4.27	-0.33	3.43e-5	Pulmonary function;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-5.23	-0.39	5.45e-7	Diastolic blood pressure;
PAAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.46	-4.95	-0.37	1.94e-6	Height;
PAAD	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.62	6.81	0.48	2.07e-10	Testicular germ cell tumor;
PAAD	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24179445	chr10:102496915	NA	0.56	6.08	0.44	9.29e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4740619	0.619	rs10810526	chr9:16041399	C/T	cg14451791	chr9:16040625	NA	-0.42	-4.69	-0.36	6.01e-6	Body mass index;
PAAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.78	8.31	0.56	4.86e-14	Coronary artery disease;
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.53	-0.57	1.38e-14	Body mass index;
PAAD	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.96	6.21	0.45	4.89e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.68	4.54	0.35	1.12e-5	Systemic lupus erythematosus;
PAAD	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.39e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg13047869	chr3:10149882	C3orf24	0.56	4.99	0.38	1.61e-6	Alzheimer's disease;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.25e-9	Lymphocyte counts;
PAAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	5.05	0.38	1.27e-6	Schizophrenia;
PAAD	cis	rs8005677	0.828	rs34584578	chr14:23411690	C/T	cg01529538	chr14:23388837	RBM23	0.48	4.78	0.36	4.17e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.98	-15.31	-0.78	1.3e-32	Height;
PAAD	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.93	-9.66	-0.62	1.63e-17	Corneal astigmatism;
PAAD	cis	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg24053715	chr22:38214548	NA	0.63	5.73	0.42	5.3e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.01	-0.59	8.17e-16	Calcium levels;
PAAD	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.55	-4.96	-0.37	1.88e-6	P wave terminal force;
PAAD	cis	rs2300603	0.881	rs72723635	chr14:76018672	C/T	cg01624173	chr14:75981868	NA	0.57	5.78	0.42	4.09e-8	Multiple sclerosis;
PAAD	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.89	-0.58	1.65e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.96	-13.92	-0.75	6.34e-29	Prudent dietary pattern;
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10894147	1.000	rs10750422	chr11:129692580	A/G	cg23827338	chr11:130419778	NA	0.62	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.49	-4.45	-0.34	1.63e-5	Monocyte count;
PAAD	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs863345	0.647	rs923663	chr1:158507732	A/T	cg12129480	chr1:158549410	OR10X1	0.44	5.05	0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs375066	0.935	rs398388	chr19:44425682	C/T	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs2421770	0.827	rs2236273	chr11:35302668	A/G	cg13971030	chr11:35366721	SLC1A2	-0.47	-5.59	-0.41	1.01e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.83	0.48	1.9e-10	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-5.71	-0.42	5.85e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9810890	0.850	rs73198871	chr3:128537238	C/T	cg15676455	chr3:128564943	NA	-0.86	-5.2	-0.39	6.2e-7	Dental caries;
PAAD	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg16386425	chr10:429943	DIP2C	0.49	4.57	0.35	9.9e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.7e-8	Daytime sleep phenotypes;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.16	-0.39	7.45e-7	Mood instability;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg17330251	chr7:94953956	PON1	-0.55	-4.41	-0.34	1.95e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	8.21	0.55	8.73e-14	Rheumatoid arthritis;
PAAD	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.85	9.88	0.63	4.23e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.3	-0.33	3.03e-5	Crohn's disease;
PAAD	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.96	-0.54	3.67e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg20381115	chr15:45671148	LOC145663;GATM	0.4	4.42	0.34	1.84e-5	Glomerular filtration rate;
PAAD	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.51	4.96	0.37	1.89e-6	High light scatter reticulocyte count;
PAAD	cis	rs7929679	0.551	rs11032840	chr11:34779464	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.2	-0.39	6.21e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.69	7.94	0.54	4.19e-13	Colorectal cancer;
PAAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.83	-7.23	-0.51	2.21e-11	Recombination rate (females);
PAAD	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.15e-8	Vitiligo;
PAAD	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.7	7.5	0.52	4.93e-12	Type 2 diabetes;
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg03605226	chr16:87637261	JPH3	0.42	4.81	0.36	3.62e-6	Menopause (age at onset);
PAAD	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.6	5.99	0.44	1.48e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg09366796	chr5:75012313	C5orf37	0.5	4.52	0.34	1.23e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg22338127	chr1:209979572	IRF6	0.53	4.34	0.33	2.55e-5	Coronary artery disease;
PAAD	cis	rs7119038	0.865	rs7951740	chr11:118740418	G/C	cg04176122	chr11:118779835	BCL9L	-0.46	-4.59	-0.35	9.25e-6	Sjögren's syndrome;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.86	6.59	0.47	6.77e-10	Initial pursuit acceleration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03388569	chr15:40426063	NA	-0.52	-6.57	-0.47	7.55e-10	Myopia (pathological);
PAAD	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.49	4.78	0.36	4.03e-6	Red cell distribution width;
PAAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.85e-10	Glomerular filtration rate;
PAAD	cis	rs11120822	0.814	rs6656691	chr1:7122453	C/G	cg20434152	chr1:7120926	CAMTA1	-0.53	-6.01	-0.44	1.33e-8	Stearic acid (18:0) levels;
PAAD	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.66	-5.86	-0.43	2.8e-8	Obesity-related traits;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg08888203	chr3:10149979	C3orf24	0.83	6.08	0.44	9.11e-9	Alzheimer's disease;
PAAD	cis	rs1788820	0.871	rs1623003	chr18:21165163	C/T	cg14672496	chr18:21087552	C18orf8	0.49	4.99	0.37	1.67e-6	Body mass index;
PAAD	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.54	5.02	0.38	1.4e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.35	-0.33	2.46e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.59	-4.32	-0.33	2.84e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg26554054	chr8:600488	NA	1.06	7.65	0.53	2.14e-12	IgG glycosylation;
PAAD	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.94	10.14	0.64	8.77e-19	Breast cancer;
PAAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.47	5.02	0.38	1.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11756438	0.505	rs9481850	chr6:119022953	C/A	cg26247263	chr6:118972830	C6orf204	0.43	4.26	0.33	3.64e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs13418717	0.793	rs4663054	chr2:127639995	C/T	cg25501666	chr2:127640322	NA	-0.92	-4.95	-0.37	1.97e-6	Heart failure;
PAAD	cis	rs2882667	0.628	rs13171173	chr5:138042464	A/C	cg09476006	chr5:138032270	NA	-0.49	-6.22	-0.45	4.49e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	4.3	0.33	3.07e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.71	-9.48	-0.61	4.93e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg21361702	chr7:150065534	REPIN1	0.59	4.76	0.36	4.41e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08130813	chr19:46195655	QPCTL;SNRPD2	0.53	6.29	0.45	3.27e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.42	-0.34	1.88e-5	Mean corpuscular volume;
PAAD	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg17470449	chr10:769945	NA	0.48	4.8	0.36	3.79e-6	Uric acid levels;
PAAD	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.52	-0.34	1.23e-5	Rheumatoid arthritis;
PAAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.17	-0.39	7.36e-7	Alcohol dependence;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg17366294	chr4:99064904	C4orf37	0.42	4.61	0.35	8.49e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg06780032	chr1:8272277	NA	-0.34	-4.37	-0.33	2.31e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-6.23	-0.45	4.37e-9	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg19930314	chr7:98593876	TRRAP	-0.49	-4.75	-0.36	4.62e-6	Breast cancer;
PAAD	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	9.76	0.62	8.83e-18	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10498747	chr16:4817265	ZNF500	0.57	6.59	0.47	6.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.35	-0.4	3.15e-7	Schizophrenia (age at onset);
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09221015	chr4:84256398	HPSE	-0.69	-6.39	-0.46	1.96e-9	Neuroticism;
PAAD	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.62	6.01	0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.44	-0.34	1.7e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10492336	0.636	rs1882110	chr12:114616205	G/T	cg05755906	chr12:113623461	C12orf52;DDX54	0.49	4.38	0.33	2.2e-5	Laryngeal squamous cell carcinoma;
PAAD	cis	rs1532557	1.000	rs1499293	chr1:224763475	G/A	cg09988837	chr1:224811939	CNIH3	0.62	4.54	0.35	1.15e-5	Cancer;
PAAD	cis	rs13102973	0.899	rs13127569	chr4:135900762	C/A	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs501120	0.584	rs58540467	chr10:44705170	T/C	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs35740288	0.721	rs11636347	chr15:86241233	A/G	cg07943548	chr15:86304357	KLHL25	-0.61	-5.19	-0.39	6.77e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.84	-8.92	-0.59	1.38e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg04398451	chr17:18023971	MYO15A	-0.75	-8.28	-0.56	5.81e-14	Total body bone mineral density;
PAAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.61	5.81	0.43	3.54e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.94e-11	Eye color traits;
PAAD	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.7	-5.63	-0.42	8.62e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs990171	0.913	rs2272128	chr2:103039929	G/A	cg03938978	chr2:103052716	IL18RAP	0.43	4.29	0.33	3.17e-5	Lymphocyte counts;
PAAD	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.43	-0.34	1.79e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.48	4.65	0.35	7.18e-6	Trans fatty acid levels;
PAAD	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg14926445	chr8:58193284	C8orf71	-0.65	-4.79	-0.36	3.87e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.04e-6	Life satisfaction;
PAAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.75	-6.23	-0.45	4.32e-9	Neuroticism;
PAAD	cis	rs939584	0.932	rs13022337	chr2:632609	A/G	cg14515364	chr2:636606	NA	0.53	4.82	0.36	3.46e-6	Body mass index;
PAAD	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg10011062	chr15:43941034	CATSPER2	-0.86	-4.94	-0.37	2.02e-6	Lung cancer in ever smokers;
PAAD	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs6715793	0.702	rs961239	chr2:33391003	C/G	cg26672287	chr2:33391915	LTBP1	-0.39	-4.44	-0.34	1.71e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13560548	chr3:10150139	C3orf24	0.59	5.26	0.39	4.83e-7	Alzheimer's disease;
PAAD	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.59	0.35	9.24e-6	Breast cancer;
PAAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.72	6.77	0.48	2.67e-10	Monocyte count;
PAAD	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.94	-0.43	1.82e-8	Schizophrenia;
PAAD	trans	rs2562456	0.526	rs950504	chr19:21783995	A/C	cg21232831	chr20:2489407	ZNF343	0.72	6.96	0.49	9.48e-11	Pain;
PAAD	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.48	4.65	0.35	7.04e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.69	-7.71	-0.53	1.56e-12	Melanoma;
PAAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12523822	0.789	rs12525495	chr6:154959399	T/G	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.64	6.11	0.44	7.84e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1420338	0.967	rs4720151	chr7:34160523	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-4.82	-0.36	3.41e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg02459107	chr1:67143332	SGIP1	0.78	7.63	0.53	2.36e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs2249694	0.810	rs2987785	chr10:135365003	C/T	cg20169779	chr10:135381914	SYCE1	0.44	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.42	-0.4	2.26e-7	Schizophrenia;
PAAD	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.25	-0.39	5.06e-7	Systemic lupus erythematosus;
PAAD	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	4.45	0.34	1.65e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7588746	0.621	rs4672726	chr2:201149413	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-4.77	-0.36	4.27e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg08859447	chr1:110197289	GSTM4	-0.62	-6.39	-0.46	1.91e-9	Iris heterochromicity;
PAAD	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.52	4.75	0.36	4.77e-6	Schizophrenia;
PAAD	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25110106	chr1:110167983	AMPD2	-0.63	-7.15	-0.5	3.42e-11	Monocyte percentage of white cells;
PAAD	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	7.08	0.5	4.98e-11	Chronic sinus infection;
PAAD	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.58	4.65	0.35	7.14e-6	Schizophrenia;
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.82	-5.51	-0.41	1.5e-7	Body mass index;
PAAD	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09377149	chr3:69101222	TMF1	0.7	6.51	0.47	1.06e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs6991838	0.778	rs11782837	chr8:66462563	A/G	cg15971335	chr8:66515592	ARMC1	0.46	4.5	0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10143349	chr1:169337190	BLZF1;NME7	0.61	6.63	0.47	5.63e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg04352962	chr1:209979756	IRF6	0.53	4.73	0.36	5.03e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.57	-7.05	-0.5	5.75e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.39	0.4	2.69e-7	Obesity-related traits;
PAAD	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.81	-5.06	-0.38	1.17e-6	Systolic blood pressure;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.64	-6.1	-0.44	8.46e-9	Blood metabolite levels;
PAAD	cis	rs2139634	0.930	rs12637386	chr3:46528199	G/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.33	4.77	0.36	4.27e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg03037974	chr15:76606532	NA	0.52	6.09	0.44	8.76e-9	Blood metabolite levels;
PAAD	cis	rs2882667	0.659	rs700621	chr5:138098430	C/T	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg23346134	chr3:49453900	TCTA	0.43	4.31	0.33	2.97e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.85	-9.27	-0.6	1.73e-16	Menarche (age at onset);
PAAD	cis	rs10028187	0.515	rs7692557	chr4:154416481	A/C	cg24020152	chr4:154419554	KIAA0922	0.4	4.64	0.35	7.4e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.59	-5.83	-0.43	3.14e-8	Rheumatoid arthritis;
PAAD	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	6.57	0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs1545257	0.550	rs66943245	chr2:24631075	G/A	cg02683114	chr2:24398427	C2orf84	-0.45	-4.67	-0.35	6.62e-6	Sjögren's syndrome;
PAAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.89	0.69	1.79e-23	Menopause (age at onset);
PAAD	cis	rs288326	0.561	rs77460513	chr2:183819625	C/T	cg09997497	chr2:183902928	NCKAP1	0.96	5.73	0.42	5.28e-8	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg11764359	chr7:65958608	NA	-0.81	-5.36	-0.4	3.08e-7	Diabetic kidney disease;
PAAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.35	-4.25	-0.33	3.75e-5	HIV-1 control;
PAAD	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.61	-5.53	-0.41	1.39e-7	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg07701084	chr6:150067640	NUP43	0.59	5.07	0.38	1.17e-6	Lung cancer;
PAAD	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.71	6.59	0.47	6.63e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs12753920	0.775	rs35924548	chr1:92680455	G/A	cg00856177	chr1:93645673	TMED5;CCDC18	-0.45	-4.25	-0.33	3.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.02	-0.44	1.24e-8	Joint mobility (Beighton score);
PAAD	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22509189	chr2:225307070	NA	-0.48	-4.49	-0.34	1.39e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg25547332	chr5:131281432	NA	0.49	4.32	0.33	2.78e-5	Blood metabolite levels;
PAAD	cis	rs12418451	1	rs12418451	chr11:68935419	G/A	cg18141744	chr11:69924156	ANO1	-0.48	-4.47	-0.34	1.51e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.57	-0.35	9.98e-6	Morning vs. evening chronotype;
PAAD	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.3	0.46	3.04e-9	Schizophrenia;
PAAD	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.19e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.46e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.57	-0.41	1.14e-7	Vitiligo;
PAAD	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.93	11.22	0.67	1.15e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.63	6.54	0.47	8.75e-10	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.88	0.66	9.41e-21	Homoarginine levels;
PAAD	cis	rs4936891	0.577	rs12224791	chr11:123919128	A/G	cg22125253	chr11:123886957	OR10G4	-0.45	-4.48	-0.34	1.47e-5	Male fertility;
PAAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg19413350	chr8:57351067	NA	-0.45	-4.27	-0.33	3.44e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.43e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16216305	chr3:127842716	RUVBL1	0.59	6.7	0.48	3.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.67	-7.96	-0.54	3.72e-13	Dupuytren's disease;
PAAD	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.76	4.98	0.37	1.67e-6	Lung cancer in ever smokers;
PAAD	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg19682013	chr15:45996608	NA	0.33	4.38	0.34	2.16e-5	Waist circumference;Weight;
PAAD	cis	rs75920871	0.702	rs11216162	chr11:116728277	A/G	cg04087571	chr11:116723030	SIK3	0.42	5.03	0.38	1.39e-6	Subjective well-being;
PAAD	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.53	-4.69	-0.36	5.96e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.71	8.9	0.59	1.59e-15	Cancer;
PAAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Gut microbiome composition (summer);
PAAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.56	0.35	1.04e-5	Colorectal cancer;
PAAD	cis	rs4740619	0.630	rs6474989	chr9:15987388	A/G	cg14451791	chr9:16040625	NA	0.37	4.4	0.34	1.99e-5	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04348816	chr7:5461417	TNRC18	0.75	7.86	0.54	6.45e-13	Obesity-related traits;
PAAD	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs506597	0.833	rs221793	chr7:100280896	A/C	cg22923895	chr7:101180719	EMID2	0.38	4.25	0.33	3.68e-5	Pursuit maintenance gain in psychotic disorders;
PAAD	cis	rs71560490	0.730	rs13230103	chr7:75447009	T/C	cg15798862	chr7:76129360	DTX2	0.66	4.38	0.33	2.23e-5	White blood cell count (basophil);
PAAD	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.47	-0.46	1.27e-9	Blood metabolite levels;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg12193833	chr17:30244370	NA	-0.62	-5.29	-0.39	4.24e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.39	5.24	0.39	5.2e-7	Coronary artery disease;
PAAD	cis	rs7127900	1.000	rs7127900	chr11:2233574	A/G	cg25635251	chr11:2234043	NA	0.84	7.57	0.52	3.38e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg21395723	chr22:39101663	GTPBP1	-0.49	-5.11	-0.38	9.55e-7	Menopause (age at onset);
PAAD	cis	rs16882447	0.607	rs28701873	chr5:53489782	G/A	cg06461071	chr5:53490839	ARL15	0.46	4.94	0.37	2.03e-6	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.47	-7.71	-0.53	1.57e-12	Neuroticism;
PAAD	cis	rs9810890	1.000	rs6795293	chr3:128592669	C/T	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.11e-7	Glomerular filtration rate;
PAAD	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.68	7.2	0.5	2.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg08390786	chr10:135334061	NA	0.47	4.53	0.34	1.18e-5	Obesity-related traits;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.67	6.91	0.49	1.23e-10	Resistin levels;
PAAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.54	-0.41	1.28e-7	Schizophrenia;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg17650747	chr5:1873721	NA	0.45	4.59	0.35	9.2e-6	Cardiovascular disease risk factors;
PAAD	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg25972092	chr12:117363249	FBXW8	0.81	6.2	0.45	5.06e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.45	5.52	0.41	1.42e-7	Urinary metabolites;
PAAD	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.77	9.21	0.6	2.41e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	1.05	8.43	0.56	2.5e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06544989	chr22:39130855	UNC84B	-0.46	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs5758511	0.573	rs2267439	chr22:42237769	C/T	cg03131358	chr22:42195972	CCDC134	-0.48	-4.99	-0.37	1.65e-6	Birth weight;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	1.72	9.54	0.61	3.41e-17	Height;
PAAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-1.08	-14.51	-0.76	1.76e-30	Total body bone mineral density;
PAAD	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.58	6.35	0.46	2.33e-9	Menopause (age at onset);
PAAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.77	-7.92	-0.54	4.71e-13	Body mass index;
PAAD	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.62e-6	Breast cancer;
PAAD	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.74	7.71	0.53	1.56e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.78	0.42	4.03e-8	IgG glycosylation;
PAAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.57	-6.87	-0.49	1.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.95	-0.37	1.95e-6	Type 2 diabetes;
PAAD	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.87	-10.72	-0.66	2.51e-20	Bipolar disorder;
PAAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.52	5.02	0.38	1.44e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.91	8.5	0.57	1.61e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.58	7.05	0.5	5.99e-11	Monobrow;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg13047869	chr3:10149882	C3orf24	0.58	5.17	0.39	7.23e-7	Alzheimer's disease;
PAAD	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg06609049	chr19:2785107	THOP1	0.89	10.08	0.63	1.32e-18	Total cholesterol levels;
PAAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs11250714	0.845	rs11250703	chr10:1692038	C/A	cg10435618	chr10:838112	NA	-0.49	-4.63	-0.35	7.88e-6	Gut microbiome composition (summer);
PAAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.49	4.86	0.37	2.86e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs941024	0.722	rs55819151	chr12:56047776	C/A	cg20737382	chr12:56040096	NA	-0.73	-4.68	-0.35	6.3e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.65	-8.48	-0.57	1.84e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.59	-0.35	9.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35000415	0.938	rs17338998	chr7:128618559	C/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg12193833	chr17:30244370	NA	-0.63	-4.76	-0.36	4.57e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.35	-0.4	3.19e-7	Retinal vascular caliber;
PAAD	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg03538708	chr1:25844672	NA	-0.53	-5.36	-0.4	3.07e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg15212455	chr7:39170539	POU6F2	0.49	6.91	0.49	1.22e-10	IgG glycosylation;
PAAD	cis	rs251130	0.540	rs251133	chr5:110859246	A/G	cg06321376	chr5:110847639	STARD4	0.49	4.41	0.34	1.92e-5	Menarche (age at onset);
PAAD	cis	rs8067287	0.554	rs56035746	chr17:16841433	C/T	cg26910001	chr17:16838321	NA	-0.58	-5.19	-0.39	6.79e-7	Diabetic kidney disease;
PAAD	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-4.64	-0.35	7.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24054508	chr1:38273761	C1orf122;YRDC	0.63	6.68	0.48	4.18e-10	Myopia (pathological);
PAAD	cis	rs3812111	0.510	rs4946151	chr6:116595289	G/C	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.54	-7.1	-0.5	4.45e-11	Primary biliary cholangitis;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.37	-4.54	-0.35	1.12e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11264799	0.598	rs12567349	chr1:157731186	G/A	cg18268488	chr1:157545234	FCRL4	0.63	5.56	0.41	1.2e-7	IgA nephropathy;
PAAD	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.56	5.89	0.43	2.39e-8	Dupuytren's disease;
PAAD	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-7.82	-0.54	8e-13	Morning vs. evening chronotype;
PAAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.84	7.52	0.52	4.37e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.6	5.36	0.4	2.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3736485	0.932	rs2278988	chr15:51915234	A/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.35	-0.33	2.52e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg09491104	chr22:46646882	C22orf40	-0.8	-4.72	-0.36	5.4e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03987639	chr3:127174481	NA	0.56	6.31	0.46	2.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6499755	0.712	rs31104	chr16:55374309	A/G	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs7584330	0.666	rs6760963	chr2:238398268	C/T	cg14458575	chr2:238380390	NA	-0.6	-4.73	-0.36	5.07e-6	Prostate cancer;
PAAD	cis	rs7188861	0.592	rs1794022	chr16:11376446	A/G	cg01510278	chr16:11456238	NA	0.45	4.44	0.34	1.69e-5	HDL cholesterol;
PAAD	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.48	4.7	0.36	5.66e-6	HDL cholesterol;
PAAD	cis	rs7247513	0.930	rs28368916	chr19:12701577	T/G	cg01871581	chr19:12707946	ZNF490	-0.86	-10.76	-0.66	2.02e-20	Bipolar disorder;
PAAD	cis	rs2997447	0.739	rs3008223	chr1:26389633	T/C	cg24519413	chr1:26490540	NA	0.5	4.8	0.36	3.83e-6	QRS complex (12-leadsum);
PAAD	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg17401720	chr7:158221031	PTPRN2	0.46	4.8	0.36	3.69e-6	Obesity-related traits;
PAAD	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.53	-4.78	-0.36	4.19e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.29e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg17470449	chr10:769945	NA	0.51	4.79	0.36	3.85e-6	Uric acid levels;
PAAD	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg07600127	chr13:30881527	KATNAL1	-0.63	-4.27	-0.33	3.4e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.66	4.41	0.34	1.96e-5	Systolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10679147	chr20:60877989	ADRM1	0.61	6.72	0.48	3.45e-10	Monocyte percentage of white cells;
PAAD	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg04165759	chr1:150448943	RPRD2	0.52	5.38	0.4	2.82e-7	Migraine;
PAAD	cis	rs925946	0.666	rs11030102	chr11:27681596	C/G	cg01418645	chr11:27679469	BDNF;BDNFOS	0.52	4.56	0.35	1.03e-5	Body mass index;Weight;
PAAD	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.67	0.35	6.64e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-4.63	-0.35	7.95e-6	Bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26808417	chr1:202114072	ARL8A	-0.74	-6.56	-0.47	8.15e-10	Neuroticism;
PAAD	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.61	5.41	0.4	2.38e-7	Blood metabolite levels;
PAAD	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg20673841	chr7:107026890	COG5	0.48	4.31	0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs9395066	0.545	rs3799976	chr6:44835622	T/G	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs12935418	0.672	rs2602424	chr16:81043205	A/G	cg16651780	chr16:81037892	C16orf61	-0.68	-6.5	-0.47	1.07e-9	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg10729496	chr3:10149963	C3orf24	0.76	6.23	0.45	4.33e-9	Alzheimer's disease;
PAAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg14709524	chr16:89940631	TCF25	-0.75	-4.36	-0.33	2.42e-5	Skin colour saturation;
PAAD	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.15	0.45	6.38e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs7831492	0.517	rs11995974	chr8:41646683	A/C	cg12180191	chr8:41686706	ANK1	-0.44	-4.34	-0.33	2.63e-5	Colorectal cancer;
PAAD	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.51	5.42	0.4	2.27e-7	Life satisfaction;
PAAD	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.77	-6.7	-0.48	3.83e-10	Exhaled nitric oxide output;
PAAD	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg18451016	chr1:38461880	NA	0.53	6.36	0.46	2.2e-9	Coronary artery disease;
PAAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.53	-0.57	1.39e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg04450456	chr4:17643702	FAM184B	-0.47	-4.84	-0.37	3.18e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10861661	1.000	rs4964491	chr12:107222515	G/A	cg15890332	chr12:107067104	RFX4	0.51	5.18	0.39	7.09e-7	Triglyceride levels;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg05313129	chr8:58192883	C8orf71	0.66	5.74	0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.65	-7.74	-0.53	1.33e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg13397359	chr6:42928475	GNMT	-0.48	-4.64	-0.35	7.37e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.61	-6.91	-0.49	1.23e-10	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.82	-9.13	-0.6	3.98e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9287604	1.000	rs10164769	chr2:237779229	C/T	cg15065627	chr2:237796583	NA	-0.53	-4.37	-0.33	2.3e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs16933812	0.510	rs7026469	chr9:36991227	A/G	cg13738729	chr9:36989127	PAX5	0.54	7.71	0.53	1.56e-12	Obesity-related traits;
PAAD	cis	rs4711350	0.862	rs688209	chr6:33700376	G/T	cg13859433	chr6:33739653	LEMD2	-0.77	-5.34	-0.4	3.28e-7	Schizophrenia;
PAAD	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.85	10.98	0.67	5.09e-21	Aortic root size;
PAAD	cis	rs501120	0.584	rs7100370	chr10:44698508	A/C	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.89	11.96	0.7	1.2e-23	Body mass index;
PAAD	cis	rs1018697	1.000	rs7073114	chr10:104555651	C/T	cg14489801	chr10:103603810	KCNIP2	-0.3	-4.35	-0.33	2.51e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.65e-7	Inflammatory bowel disease;
PAAD	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.44	4.52	0.34	1.25e-5	Age of smoking initiation;
PAAD	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-4.26	-0.33	3.62e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs58521262	0.585	rs2927367	chr19:23230119	A/G	cg22640819	chr19:22990650	NA	0.29	4.43	0.34	1.78e-5	Testicular germ cell tumor;
PAAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9907295	0.901	rs9909416	chr17:34197983	C/T	cg16983627	chr17:34238386	NA	-0.55	-4.33	-0.33	2.69e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.4	-0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg11619707	chr19:22235551	ZNF257	0.56	5.59	0.41	1.01e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.47	-4.96	-0.37	1.9e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.62	-6.98	-0.49	8.54e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg27205649	chr11:78285834	NARS2	-0.62	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg06740227	chr12:86229804	RASSF9	0.58	5.07	0.38	1.14e-6	Major depressive disorder;
PAAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg13722127	chr7:150037890	RARRES2	0.51	5.25	0.39	5.09e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.44	-0.4	2.08e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4343996	1.000	rs7794279	chr7:3341806	A/G	cg21248987	chr7:3385318	SDK1	0.47	5.18	0.39	7e-7	Motion sickness;
PAAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.66	-7.01	-0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg04877966	chr15:75135169	ULK3	-0.5	-4.29	-0.33	3.18e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02085815	chr4:128802010	PLK4	0.69	6.5	0.47	1.09e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.45	0.4	1.95e-7	Body mass index;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.69	-7.7	-0.53	1.66e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7177699	0.534	rs56683682	chr15:79112524	G/T	cg15571903	chr15:79123663	NA	-0.49	-6.35	-0.46	2.32e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.19	18.28	0.83	3.26e-40	Exhaled nitric oxide output;
PAAD	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.63	0.35	7.79e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg08847533	chr14:75593920	NEK9	0.5	4.98	0.37	1.74e-6	Caffeine consumption;
PAAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs12304921	0.748	rs77433345	chr12:51335582	C/T	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.11	-0.38	9.62e-7	Type 2 diabetes;
PAAD	cis	rs1007738	0.542	rs10838662	chr11:47184117	T/G	cg19486271	chr11:47235900	DDB2	0.62	5.79	0.43	3.92e-8	Bone mineral density (hip);
PAAD	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-4.47	-0.34	1.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg14416269	chr4:6271139	WFS1	0.7	7.62	0.53	2.48e-12	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-5.51	-0.41	1.49e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.67	-0.53	1.97e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs909002	0.772	rs6681414	chr1:32070234	G/A	cg13919466	chr1:32135498	COL16A1	-0.42	-4.83	-0.36	3.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.8	9.22	0.6	2.35e-16	Schizophrenia;
PAAD	cis	rs1419980	0.730	rs74058422	chr12:7728395	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.55	-4.94	-0.37	2.06e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg10395934	chr14:104002654	TRMT61A	0.48	4.68	0.35	6.37e-6	Body mass index;
PAAD	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg18589874	chr11:47608310	FAM180B	-0.44	-4.38	-0.33	2.21e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.17	-16.91	-0.81	9.54e-37	Cognitive function;
PAAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs55728055	0.661	rs62237798	chr22:31976839	G/T	cg01338084	chr22:32026380	PISD	1.6	8.24	0.56	7.56e-14	Age-related hearing impairment;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg20821713	chr7:1055600	C7orf50	-0.43	-4.75	-0.36	4.74e-6	Longevity;Endometriosis;
PAAD	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg17385448	chr1:15911702	AGMAT	0.34	4.28	0.33	3.34e-5	Systolic blood pressure;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15620385	chr12:26986279	ITPR2	0.65	6.58	0.47	7.31e-10	Primary biliary cholangitis;
PAAD	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.68	-7.11	-0.5	4.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	1.17	11.76	0.69	4.11e-23	Post bronchodilator FEV1;
PAAD	cis	rs6495122	0.662	rs11072508	chr15:75062397	C/T	cg14664628	chr15:75095509	CSK	-0.72	-6.55	-0.47	8.5e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg18351406	chr4:77819688	ANKRD56	0.76	8.88	0.58	1.8e-15	Emphysema distribution in smoking;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03332314	chr8:146278003	C8orf33	0.6	6.66	0.48	4.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.61	0.47	6.09e-10	High light scatter reticulocyte count;
PAAD	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.72	9.24	0.6	2.02e-16	Eye color traits;
PAAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg08885076	chr2:99613938	TSGA10	0.56	5.46	0.4	1.93e-7	Chronic sinus infection;
PAAD	cis	rs728616	0.867	rs55690691	chr10:81658942	G/T	cg19423196	chr10:82049429	MAT1A	0.59	4.32	0.33	2.76e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg04025307	chr7:1156635	C7orf50	0.7	6.4	0.46	1.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.35	0.33	2.5e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2651899	0.966	rs2742663	chr1:3084905	T/C	cg22674798	chr1:3096360	PRDM16	0.51	6.99	0.49	8.14e-11	Migraine;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg05110241	chr16:68378359	PRMT7	-1.07	-8.21	-0.55	9e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg14580859	chr9:123691850	NA	0.41	4.59	0.35	9.41e-6	Rheumatoid arthritis;
PAAD	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.51	4.51	0.34	1.31e-5	Atopic dermatitis;
PAAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg03714773	chr7:91764589	CYP51A1	0.34	4.76	0.36	4.56e-6	Breast cancer;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.81e-15	Lung cancer;
PAAD	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.48	11.12	0.67	2.1e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg04851639	chr8:1020857	NA	-0.57	-6.73	-0.48	3.21e-10	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.75	4.64	0.35	7.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1279750	0.651	rs2770969	chr5:180586883	C/T	cg06965003	chr5:180616570	NA	-0.64	-4.31	-0.33	2.89e-5	Platelet count;
PAAD	cis	rs3112530	0.636	rs2913310	chr5:152715390	T/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06815965	chr1:205818668	PM20D1	0.71	8.14	0.55	1.3e-13	Menarche (age at onset);
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.8	8.54	0.57	1.33e-14	Renal function-related traits (BUN);
PAAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg05562828	chr17:3906858	NA	0.47	5.29	0.39	4.18e-7	Type 2 diabetes;
PAAD	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.66	-6.26	-0.45	3.76e-9	Subjective well-being;
PAAD	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg15660573	chr17:549704	VPS53	-0.8	-8.3	-0.56	5.38e-14	Prostate cancer;
PAAD	cis	rs11690462	0.500	rs62128677	chr2:26631168	C/T	cg13255216	chr2:26625047	C2orf39	-0.45	-4.4	-0.34	2.05e-5	Coronary artery disease;
PAAD	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg04352962	chr1:209979756	IRF6	0.48	4.28	0.33	3.27e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs728616	0.510	rs34782759	chr10:82195219	T/C	cg19423196	chr10:82049429	MAT1A	0.5	4.42	0.34	1.88e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg13768953	chr17:7114967	DLG4	-0.41	-5.27	-0.39	4.69e-7	Diastolic blood pressure;
PAAD	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.77	-5.24	-0.39	5.28e-7	Red cell distribution width;
PAAD	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.65	5.89	0.43	2.44e-8	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.61	6.77	0.48	2.68e-10	Coronary artery disease;
PAAD	cis	rs3125734	0.719	rs1835861	chr10:64056141	T/A	cg09941381	chr10:64027924	RTKN2	-0.38	-4.4	-0.34	1.99e-5	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	5.17	0.39	7.39e-7	Menarche (age at onset);
PAAD	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.45	4.33	0.33	2.71e-5	Hip circumference;
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.52	-4.84	-0.37	3.13e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.2e-11	Life satisfaction;
PAAD	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.7	-6.03	-0.44	1.22e-8	Diabetic retinopathy;
PAAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.79	8.56	0.57	1.17e-14	Cognitive function;
PAAD	cis	rs12753920	0.696	rs12403353	chr1:92730892	A/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.28	-0.33	3.28e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs597480	0.718	rs11606656	chr11:85524102	C/G	cg11817631	chr11:85522609	SYTL2	0.51	4.49	0.34	1.43e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs4662592	0.511	rs10496666	chr2:128913552	A/G	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs6504950	0.705	rs9899602	chr17:52986908	C/T	cg18040354	chr17:53800484	TMEM100	-0.5	-4.44	-0.34	1.73e-5	Breast cancer;
PAAD	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-4.8	-0.36	3.72e-6	Mean platelet volume;
PAAD	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.74	-6.88	-0.49	1.48e-10	Cognitive test performance;
PAAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.49	-5.16	-0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.52	-0.34	1.23e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg12292205	chr6:26970375	C6orf41	0.59	6.84	0.48	1.84e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs62408225	0.894	rs17585295	chr6:90944831	C/T	cg03795776	chr6:90687632	BACH2	0.44	4.49	0.34	1.38e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.53	7.12	0.5	3.98e-11	Primary biliary cholangitis;
PAAD	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.44	-0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.86	5.54	0.41	1.31e-7	Systolic blood pressure;
PAAD	cis	rs3779195	0.789	rs6965424	chr7:97991125	A/G	cg24562669	chr7:97807699	LMTK2	0.51	4.86	0.37	2.91e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-6.65	-0.47	4.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs58365266	1.000	rs58365266	chr3:195813757	C/T	cg01181863	chr3:195395398	SDHAP2	-0.72	-5.83	-0.43	3.23e-8	Red cell distribution width;
PAAD	cis	rs76917914	0.820	rs55978131	chr9:100813404	G/A	cg03040243	chr9:100819229	NANS	0.59	4.91	0.37	2.34e-6	Immature fraction of reticulocytes;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-12.69	-0.72	1.26e-25	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.68	0.48	4.17e-10	Life satisfaction;
PAAD	cis	rs11668609	0.506	rs8113480	chr19:24061019	G/T	cg09235885	chr19:23456588	NA	0.64	4.42	0.34	1.86e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.54	-0.35	1.15e-5	Bipolar disorder;
PAAD	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.81	-7.75	-0.53	1.21e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12908607	chr1:44402522	ARTN	-0.44	-4.78	-0.36	4.16e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg05993574	chr11:61129284	CYBASC3;TMEM138	0.62	6.33	0.46	2.58e-9	IgG glycosylation;
PAAD	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg24330906	chr2:85765176	MAT2A	0.55	5.32	0.4	3.58e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.04	0.5	6.28e-11	Coffee consumption (cups per day);
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.36	-0.46	2.24e-9	Lymphocyte counts;
PAAD	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs6604026	0.656	rs6604030	chr1:93398336	A/G	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	trans	rs17073641	0.500	rs6566141	chr18:62463372	C/A	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.42	-4.78	-0.36	4.11e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2997447	0.748	rs2783640	chr1:26430447	T/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.71	7.11	0.5	4.31e-11	Platelet count;
PAAD	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.73	-8.02	-0.55	2.6e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs1227969	0.964	rs1236904	chr10:71267849	A/C	cg12610070	chr10:71211762	TSPAN15	-0.29	-4.26	-0.33	3.6e-5	Response to taxane treatment (placlitaxel);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25041148	chr19:58838420	ZSCAN22	0.6	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg00262122	chr8:11665843	FDFT1	-0.57	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.9	11.17	0.67	1.61e-21	Blood protein levels;
PAAD	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.72	-8.23	-0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.61	5.59	0.41	1.04e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs13100165	1.000	rs4608630	chr3:73272236	C/G	cg07385778	chr3:72320634	NA	-0.29	-4.5	-0.34	1.37e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.49	5.33	0.4	3.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.5	-0.41	1.55e-7	Reticulocyte count;
PAAD	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	9.73	0.62	1.11e-17	Monocyte percentage of white cells;
PAAD	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.46	6.63	0.47	5.41e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs35955747	0.722	rs5997898	chr22:31572963	A/C	cg02404636	chr22:31891804	SFI1	-0.49	-4.99	-0.38	1.63e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density (age over 60);Total body bone mineral density;
PAAD	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg09941381	chr10:64027924	RTKN2	-0.37	-4.35	-0.33	2.49e-5	Rheumatoid arthritis;
PAAD	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.34	0.4	3.26e-7	Total body bone mineral density;
PAAD	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-8.84	-0.58	2.29e-15	Body mass index;
PAAD	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg25952890	chr19:58913133	NA	0.73	5.84	0.43	3.05e-8	Mean platelet volume;
PAAD	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.74e-11	Response to antipsychotic treatment;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.59	6.7	0.48	3.83e-10	Mean corpuscular volume;
PAAD	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg04218760	chr10:45406644	TMEM72	-0.27	-4.61	-0.35	8.34e-6	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.61	-0.35	8.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs111547017	1	rs111547017	chr6:43341689	A/G	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Schizophrenia;
PAAD	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.49	4.44	0.34	1.73e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1198430	0.500	rs968280	chr1:23801965	A/T	cg24580199	chr1:23763081	ASAP3	0.5	4.3	0.33	3e-5	Total cholesterol levels;
PAAD	cis	rs5751901	0.614	rs6519519	chr22:24991863	C/T	cg15363607	chr22:24998974	GGT1	-0.44	-4.4	-0.34	2.05e-5	Protein quantitative trait loci;
PAAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg19630374	chr17:18023558	MYO15A	-0.45	-4.87	-0.37	2.78e-6	Total body bone mineral density;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.92	12.12	0.7	4.27e-24	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24543097	chr20:388556	RBCK1	0.58	6.68	0.48	4.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg01329690	chr21:38580129	DSCR9	-0.33	-4.54	-0.35	1.15e-5	Eye color traits;
PAAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-1.08	-15.07	-0.77	5.83e-32	Breast cancer;
PAAD	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.53	0.34	1.19e-5	Total body bone mineral density;
PAAD	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.53	-5.56	-0.41	1.17e-7	Migraine;Coronary artery disease;
PAAD	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs939584	0.877	rs7594220	chr2:643320	G/A	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs73416724	0.535	rs61729324	chr6:43258994	G/A	cg17076780	chr6:43251928	TTBK1	0.88	5.37	0.4	2.89e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg02230254	chr11:65586170	NA	-0.36	-5.08	-0.38	1.1e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.97e-8	Lymphocyte counts;
PAAD	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.79	5.88	0.43	2.47e-8	Vitiligo;
PAAD	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.63	7.11	0.5	4.34e-11	High light scatter reticulocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23944232	chr2:86948118	RMND5A	0.61	6.7	0.48	3.84e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.77	-0.48	2.69e-10	Leprosy;
PAAD	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg08345082	chr10:99160200	RRP12	-0.31	-4.43	-0.34	1.82e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.62	-6.38	-0.46	2.03e-9	Body mass index;
PAAD	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.36	4.67	0.35	6.57e-6	Calcium levels;
PAAD	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.55	-5.01	-0.38	1.52e-6	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.77	-0.36	4.23e-6	Renal cell carcinoma;
PAAD	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.91	-7.29	-0.51	1.54e-11	Psoriasis;
PAAD	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.59	-8.15	-0.55	1.25e-13	Asthma (sex interaction);
PAAD	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.59	0.41	1.04e-7	Height;
PAAD	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg10518543	chr12:38710700	ALG10B	0.51	4.9	0.37	2.44e-6	Morning vs. evening chronotype;
PAAD	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg06484146	chr7:12443880	VWDE	-0.66	-4.85	-0.37	3e-6	Coronary artery disease;
PAAD	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.38	-4.45	-0.34	1.65e-5	Pubertal anthropometrics;
PAAD	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03425219	chr11:18548609	TSG101	0.67	6.69	0.48	4.04e-10	Obesity-related traits;
PAAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.71	0.36	5.65e-6	Breast cancer;
PAAD	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.69	-6.59	-0.47	6.79e-10	Prudent dietary pattern;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06307176	chr5:131281290	NA	-0.56	-4.93	-0.37	2.12e-6	Life satisfaction;
PAAD	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.42	9.9	0.63	3.83e-18	Opioid sensitivity;
PAAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.76e-6	Menarche (age at onset);
PAAD	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.32e-12	Height;
PAAD	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg26205652	chr12:48591994	NA	0.95	9.52	0.61	3.87e-17	Longevity (90 years and older);
PAAD	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	0.9	10.03	0.63	1.7e-18	Schizophrenia;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg09945482	chr18:12777974	NA	0.61	5.36	0.4	3e-7	Inflammatory skin disease;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03605463	chr16:89740564	NA	0.51	4.87	0.37	2.76e-6	Vitiligo;
PAAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.48	5.85	0.43	2.98e-8	Vitiligo;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.56	6.25	0.45	3.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-5.37	-0.4	2.89e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.59	-5.89	-0.43	2.41e-8	Dialysis-related mortality;
PAAD	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg10183150	chr4:120222239	C4orf3	-0.42	-5.71	-0.42	5.71e-8	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg09654669	chr8:57350985	NA	-0.54	-4.98	-0.37	1.73e-6	Obesity-related traits;
PAAD	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.58	4.47	0.34	1.54e-5	Diastolic blood pressure;
PAAD	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.68	-6.62	-0.47	5.9e-10	Lymphocyte counts;
PAAD	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg18093559	chr17:18951025	GRAP	-0.46	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.3	0.46	3e-9	Alzheimer's disease;
PAAD	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.64	-6.79	-0.48	2.43e-10	Ankylosing spondylitis;
PAAD	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.46	4.66	0.35	6.93e-6	Pulmonary function;
PAAD	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg24565620	chr2:194026	NA	-0.59	-4.98	-0.37	1.71e-6	Blood protein levels;
PAAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg21698718	chr17:80085957	CCDC57	0.49	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Gout;
PAAD	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.79	-0.36	3.92e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.63	-4.47	-0.34	1.51e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	9.77	0.62	8.55e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24549020	chr5:56110836	MAP3K1	-0.49	-4.25	-0.33	3.72e-5	Initial pursuit acceleration;
PAAD	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.94	-7.7	-0.53	1.64e-12	Blood protein levels;
PAAD	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.58	4.87	0.37	2.8e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.19	-0.39	6.51e-7	IgG glycosylation;
PAAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.99e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1912528	0.783	rs797090	chr4:140867514	A/G	cg11128457	chr4:140864437	MAML3	-0.32	-4.31	-0.33	2.91e-5	Educational attainment (years of education);
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg13271783	chr10:134563150	INPP5A	-0.58	-5.84	-0.43	3.13e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-6.57	-0.47	7.63e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.94	-0.37	2.04e-6	Mean corpuscular volume;
PAAD	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg07395648	chr5:131743802	NA	-0.5	-4.42	-0.34	1.91e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs2077654	0.822	rs7944045	chr11:17439590	C/T	cg25308976	chr11:17434268	ABCC8	0.92	6.18	0.45	5.49e-9	Gout;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16262614	chr3:133464971	TF	0.41	4.31	0.33	2.87e-5	Iron status biomarkers;
PAAD	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.63	6.1	0.44	8.59e-9	Neuroticism;
PAAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.71	-7.95	-0.54	3.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-7.19	-0.5	2.69e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4321325	0.733	rs4510165	chr2:127936284	C/T	cg11380483	chr2:127933992	NA	0.75	5.59	0.41	1.02e-7	Protein C levels;
PAAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg09242541	chr1:10490025	APITD1	0.47	5.73	0.42	5.27e-8	Prostate cancer;
PAAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	5.0	0.38	1.55e-6	Mean platelet volume;
PAAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.53	5.46	0.4	1.89e-7	Personality dimensions;
PAAD	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.04	-0.38	1.32e-6	Bipolar disorder;
PAAD	cis	rs9815354	1.000	rs1016669	chr3:41894440	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	5.05	0.38	1.24e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7771547	0.723	rs56144242	chr6:36553209	G/T	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs58521262	0.556	rs449210	chr19:23122647	C/A	cg03433597	chr19:22806448	NA	-0.24	-4.4	-0.34	2.07e-5	Testicular germ cell tumor;
PAAD	cis	rs59104589	0.521	rs3771584	chr2:242399493	C/G	cg19488206	chr2:242435732	STK25	0.48	4.7	0.36	5.91e-6	Fibrinogen levels;
PAAD	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.43	-4.28	-0.33	3.33e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.31	-0.4	3.78e-7	P wave terminal force;
PAAD	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.65	6.91	0.49	1.25e-10	Schizophrenia;
PAAD	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg04398451	chr17:18023971	MYO15A	0.75	7.94	0.54	4.11e-13	Total body bone mineral density;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.49	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.71	6.96	0.49	9.67e-11	Lymphocyte counts;
PAAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg02770688	chr6:168491649	NA	0.48	5.09	0.38	1.05e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.64	6.9	0.49	1.3100000000000001e-10	Crohn's disease;
PAAD	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.31	0.56	4.97e-14	Lung cancer;
PAAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.54	4.92	0.37	2.22e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg25828445	chr12:7781288	NA	0.76	5.48	0.41	1.69e-7	HDL cholesterol levels;
PAAD	cis	rs8067287	0.708	rs56408153	chr17:16841034	G/C	cg26910001	chr17:16838321	NA	-0.58	-5.29	-0.39	4.23e-7	Diabetic kidney disease;
PAAD	cis	rs9815354	1.000	rs73069394	chr3:41787233	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.2	0.39	6.36e-7	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.59	6.15	0.45	6.54e-9	Mean corpuscular volume;
PAAD	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg22134325	chr11:66188745	NPAS4	0.29	4.45	0.34	1.68e-5	Airway imaging phenotypes;
PAAD	cis	rs73206853	0.841	rs7971568	chr12:110780612	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.65	6.66	0.48	4.7e-10	Colorectal cancer;
PAAD	cis	rs4523957	0.522	rs8081921	chr17:2021490	C/A	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.52	5.09	0.38	1.02e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.62	-5.69	-0.42	6.21e-8	Adiposity;
PAAD	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.69	-0.42	6.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.57	-5.55	-0.41	1.22e-7	Chronic sinus infection;
PAAD	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.13	-0.63	9.53e-19	Response to antipsychotic treatment;
PAAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.63	-5.88	-0.43	2.53e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg05554000	chr7:158905015	VIPR2	-0.6	-4.51	-0.34	1.29e-5	Facial morphology (factor 20);
PAAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg09376583	chr16:88111425	NA	-0.48	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.95	7.92	0.54	4.7e-13	Triglycerides;
PAAD	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.69	6.08	0.44	9.47e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg19630374	chr17:18023558	MYO15A	-0.55	-6.03	-0.44	1.22e-8	Total body bone mineral density;
PAAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.15	0.45	6.6e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.49	-5.43	-0.4	2.24e-7	Menarche (age at onset);
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.71	0.36	5.46e-6	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.08	0.44	9.41e-9	Lung cancer;
PAAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg14343924	chr8:8086146	FLJ10661	0.54	4.75	0.36	4.75e-6	Mood instability;
PAAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12908607	chr1:44402522	ARTN	-0.43	-4.76	-0.36	4.44e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12146766	chr12:26347100	SSPN	-0.74	-7.49	-0.52	5.19e-12	Obesity-related traits;
PAAD	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg24053715	chr22:38214548	NA	0.64	5.98	0.44	1.55e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.15	0.5	3.34e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.84	0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs59888335	0.825	rs11127720	chr3:81010695	T/A	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	8.15	0.55	1.28e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg04717802	chr22:42394638	WBP2NL	-0.48	-4.67	-0.35	6.55e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.35	-0.33	2.44e-5	Tuberculosis;
PAAD	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg01796438	chr3:11312864	ATG7	0.55	4.42	0.34	1.84e-5	Circulating chemerin levels;
PAAD	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	0.98	9.44	0.61	6.3e-17	Monocyte percentage of white cells;
PAAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs507080	0.922	rs558907	chr11:118558455	A/G	cg08498647	chr11:118550644	TREH	-0.37	-4.27	-0.33	3.49e-5	Serum metabolite levels;
PAAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg23346134	chr3:49453900	TCTA	0.4	4.27	0.33	3.4e-5	Menarche (age at onset);
PAAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg13814708	chr10:81144099	ZCCHC24	-0.4	-4.43	-0.34	1.79e-5	Height;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.75	-7.7	-0.53	1.66e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.24	-0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs35740288	0.770	rs11638379	chr15:86111290	G/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.58	-0.41	1.07e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg00255919	chr5:131827918	IRF1	0.51	6.13	0.45	7.29e-9	Asthma (sex interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08918224	chr11:910348	CHID1	-0.62	-6.89	-0.49	1.37e-10	Smoking initiation;
PAAD	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg00792783	chr2:198669748	PLCL1	-0.48	-4.42	-0.34	1.86e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs5756391	0.568	rs7410682	chr22:37317258	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg18721089	chr20:30220636	NA	0.63	5.08	0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg04520793	chr17:42248056	ASB16	-0.47	-6.32	-0.46	2.8e-9	Total body bone mineral density;
PAAD	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9487051	0.698	rs59502176	chr6:109644719	T/C	cg21918786	chr6:109611834	NA	-0.52	-5.58	-0.41	1.1e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs3733418	0.697	rs13111010	chr4:165956741	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.45	-4.26	-0.33	3.52e-5	Obesity-related traits;
PAAD	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Inflammatory skin disease;
PAAD	cis	rs13102973	0.640	rs34037497	chr4:135833698	C/G	cg14419869	chr4:135874104	NA	0.45	4.59	0.35	9.21e-6	Subjective well-being;
PAAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.63	6.52	0.47	9.68e-10	Coronary artery disease;
PAAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.29e-6	Rheumatoid arthritis;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.82	9.43	0.61	6.42e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2190422	0.577	rs6465922	chr7:103094968	A/G	cg04218035	chr7:103086829	SLC26A5	0.35	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs1555399	1.000	rs1555399	chr14:67984370	T/A	cg25006823	chr14:67982456	TMEM229B	0.38	4.4	0.34	2.06e-5	Parkinson's disease;
PAAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg01075559	chr1:2537774	MMEL1	-0.53	-5.58	-0.41	1.06e-7	Multiple sclerosis;
PAAD	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.93	0.63	3.22e-18	Chronic sinus infection;
PAAD	cis	rs747650	0.504	rs12417519	chr11:47129397	C/T	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.46	2.98e-9	Acne (severe);
PAAD	cis	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg11619707	chr19:22235551	ZNF257	0.58	5.8	0.43	3.65e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.53	8.27	0.56	6.23e-14	Urinary metabolites;
PAAD	cis	rs6681460	0.549	rs963140	chr1:67037576	T/G	cg02459107	chr1:67143332	SGIP1	0.66	7.11	0.5	4.24e-11	Presence of antiphospholipid antibodies;
PAAD	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.89	-8.0	-0.54	2.98e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-4.26	-0.33	3.62e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25036132	chr2:3482002	TTC15	-0.64	-6.46	-0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs11650494	0.516	rs4640235	chr17:47502352	T/C	cg08112188	chr17:47440006	ZNF652	1.2	6.01	0.44	1.3e-8	Prostate cancer;
PAAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.93	-8.57	-0.57	1.09e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg11271282	chr2:238384023	NA	0.7	4.33	0.33	2.66e-5	Prostate cancer;
PAAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.64	-7.51	-0.52	4.68e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.93	10.7	0.66	2.94e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg24881330	chr22:46731750	TRMU	1.08	5.71	0.42	5.82e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs13242816	1.000	rs17138767	chr7:116137677	A/G	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.1	-16.76	-0.81	2.23e-36	Myeloid white cell count;
PAAD	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2031532	0.569	rs6561526	chr13:50066524	G/A	cg03651054	chr13:50194643	NA	0.32	4.36	0.33	2.36e-5	Cardiac hypertrophy;
PAAD	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg15942720	chr14:51706980	TMX1	0.53	4.55	0.35	1.09e-5	Cancer;
PAAD	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-1.01	-15.59	-0.78	2.4e-33	Height;
PAAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg14393609	chr7:65229607	NA	0.68	7.37	0.51	1.02e-11	Aortic root size;
PAAD	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg14906510	chr12:7781169	NA	0.62	4.5	0.34	1.34e-5	HDL cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13341720	chr19:6740888	TRIP10	0.6	6.58	0.47	7.15e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.92	-0.49	1.2e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs8105895	0.935	rs62110985	chr19:22256077	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.9	9.5	0.61	4.31e-17	Corneal astigmatism;
PAAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg04827223	chr11:72435913	ARAP1	-0.51	-5.43	-0.4	2.21e-7	Type 2 diabetes;
PAAD	cis	rs58653258	0.730	rs10495354	chr1:234990732	G/T	cg03518729	chr1:235147744	NA	-0.47	-4.49	-0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.67	4.86	0.37	2.94e-6	Systolic blood pressure;
PAAD	cis	rs30380	0.666	rs26512	chr5:96128400	G/T	cg16492584	chr5:96139282	ERAP1	-0.56	-5.24	-0.39	5.17e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.61	-6.48	-0.47	1.22e-9	Brugada syndrome;
PAAD	cis	rs11051970	0.879	rs73081911	chr12:32539124	C/G	cg02745156	chr12:32552066	NA	0.48	4.84	0.37	3.15e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7924176	0.601	rs2131957	chr10:75866929	C/A	cg01089095	chr10:75541668	CHCHD1	-0.46	-4.27	-0.33	3.48e-5	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
PAAD	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.93	-8.21	-0.55	8.83e-14	Alopecia areata;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg26174226	chr8:58114915	NA	-0.61	-4.57	-0.35	1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg23188684	chr11:67383651	NA	0.44	4.64	0.35	7.6e-6	Mean corpuscular volume;
PAAD	cis	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12379764	chr21:47803548	PCNT	-0.47	-4.44	-0.34	1.71e-5	Testicular germ cell tumor;
PAAD	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16975963	0.644	rs73031321	chr19:38040858	C/T	cg14218481	chr19:38281219	NA	0.42	4.51	0.34	1.28e-5	Longevity;
PAAD	cis	rs757081	0.648	rs7108316	chr11:17275035	T/C	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.65	-0.42	7.7e-8	Systolic blood pressure;
PAAD	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.95	11.33	0.68	5.94e-22	Bone mineral density;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.86e-6	Monocyte percentage of white cells;
PAAD	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg09665691	chr3:47563885	NA	-1.03	-5.02	-0.38	1.44e-6	Stem cell growth factor beta levels;
PAAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.67	-6.93	-0.49	1.09e-10	Menopause (age at onset);
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.78	-10.69	-0.66	3.05e-20	Iron status biomarkers;
PAAD	cis	rs9361491	0.657	rs9361426	chr6:79457550	G/T	cg05283184	chr6:79620031	NA	-0.35	-4.25	-0.33	3.72e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.14	0.38	8.38e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg01851573	chr8:8652454	MFHAS1	0.57	4.91	0.37	2.33e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13932364	chr1:59762531	FGGY	-0.64	-6.42	-0.46	1.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.8	-0.36	3.78e-6	Life satisfaction;
PAAD	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.93	7.16	0.5	3.17e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.5	-4.58	-0.35	9.58e-6	Lymphocyte counts;
PAAD	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26876637	chr1:152193138	HRNR	0.84	6.24	0.45	4.18e-9	Atopic dermatitis;
PAAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.3	-0.51	1.47e-11	Blood metabolite levels;
PAAD	cis	rs1790761	0.505	rs7938563	chr11:67304131	A/G	cg00864171	chr11:67383662	NA	-0.46	-4.68	-0.35	6.38e-6	Mean corpuscular volume;
PAAD	trans	rs9328321	0.505	rs77757738	chr6:5583883	C/T	cg25203007	chr1:24126017	GALE	-0.5	-6.4	-0.46	1.8e-9	Obesity (early onset extreme);
PAAD	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.41	-0.34	1.94e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg14349672	chr11:133703707	NA	0.52	5.71	0.42	5.87e-8	Childhood ear infection;
PAAD	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	5.2	0.39	6.38e-7	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13823205	chr2:153032683	STAM2	-0.69	-6.81	-0.48	2.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs863345	0.604	rs6689657	chr1:158462509	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	5.01	0.38	1.52e-6	Mood instability;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.49	5.85	0.43	2.86e-8	Longevity;Endometriosis;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg11416102	chr8:651193	ERICH1	0.9	5.69	0.42	6.2e-8	IgG glycosylation;
PAAD	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg12756303	chr2:74692479	MOGS	-0.48	-4.26	-0.33	3.59e-5	Metabolite levels;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264213	0.551	rs11263852	chr1:36554442	G/C	cg27506609	chr1:36549197	TEKT2	-0.74	-5.27	-0.39	4.68e-7	Schizophrenia;
PAAD	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg04087571	chr11:116723030	SIK3	0.35	5.25	0.39	5.13e-7	Subjective well-being;
PAAD	cis	rs17095355	0.748	rs2501577	chr10:111846687	C/T	cg00817464	chr10:111662876	XPNPEP1	0.66	5.23	0.39	5.47e-7	Biliary atresia;
PAAD	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.66	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.66	-4.97	-0.37	1.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35084382	0.793	rs34683389	chr5:172198639	C/A	cg19801141	chr5:172198162	DUSP1	1.25	5.95	0.43	1.74e-8	Optic cup area;
PAAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17848003	chr1:3704513	LRRC47	0.45	4.77	0.36	4.21e-6	Red cell distribution width;
PAAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs4750440	0.706	rs11258767	chr10:14016565	C/T	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.32	-0.33	2.79e-5	Adiponectin levels;
PAAD	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.62	7.09	0.5	4.78e-11	Testicular germ cell tumor;
PAAD	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.77	4.34	0.33	2.61e-5	Coronary artery disease;
PAAD	trans	rs61931739	0.620	rs1905241	chr12:33709729	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.7	0.58	5.18e-15	Chronic sinus infection;
PAAD	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg25364880	chr3:44379878	C3orf23	0.57	5.09	0.38	1.04e-6	Depressive symptoms;
PAAD	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg19192590	chr2:178524533	PDE11A	0.4	4.57	0.35	1e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4604732	0.754	rs12080212	chr1:247631606	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	4.65	0.35	7.18e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.68	-0.36	6.21e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7614311	1.000	rs2087704	chr3:63820493	A/C	cg22134162	chr3:63841271	THOC7	0.5	4.34	0.33	2.55e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.86	6.41	0.46	1.74e-9	Bipolar disorder;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg08501292	chr6:25962987	TRIM38	0.97	5.27	0.39	4.66e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.7	4.54	0.35	1.13e-5	Glycated hemoglobin levels;
PAAD	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg01942863	chr7:99769432	GPC2	0.49	4.61	0.35	8.48e-6	Coronary artery disease;
PAAD	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.55	-4.94	-0.37	2.02e-6	P wave terminal force;
PAAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg21395723	chr22:39101663	GTPBP1	0.46	4.86	0.37	2.89e-6	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs1371614	0.545	rs3769138	chr2:27169540	G/T	cg00617064	chr2:27272375	NA	-0.45	-4.62	-0.35	8.08e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.39	-4.34	-0.33	2.57e-5	Prostate cancer;
PAAD	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.73	6.66	0.48	4.79e-10	Schizophrenia;
PAAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg24687543	chr11:63912206	MACROD1	0.51	4.33	0.33	2.69e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.83	-0.48	1.96e-10	Psoriasis;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.47	-4.75	-0.36	4.59e-6	Blood osmolality (transformed sodium);
PAAD	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.84	8.55	0.57	1.2e-14	Height;
PAAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1801239	1.000	rs77744173	chr10:16938271	T/G	cg00939682	chr10:16933505	CUBN	0.72	5.04	0.38	1.31e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg01191920	chr7:158217561	PTPRN2	-0.77	-7.7	-0.53	1.66e-12	Obesity-related traits;
PAAD	cis	rs1519814	1.000	rs4504680	chr8:121132175	T/C	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs58521262	0.652	rs4024169	chr19:22901663	A/G	cg07749055	chr19:23076870	NA	-0.53	-5.21	-0.39	5.99e-7	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.77	-9.24	-0.6	2.12e-16	Lung cancer;
PAAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.16	-0.6	3.33e-16	Mean platelet volume;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.64e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.81	-0.36	3.63e-6	Eotaxin levels;
PAAD	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg20607287	chr7:12443886	VWDE	-0.77	-5.93	-0.43	1.96e-8	Coronary artery disease;
PAAD	cis	rs375066	0.934	rs2191564	chr19:44367611	T/C	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.33e-7	Breast cancer;
PAAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg05342682	chr7:94953680	PON1	-0.56	-4.72	-0.36	5.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6594713	0.566	rs35093510	chr5:112925555	A/G	cg12552261	chr5:112820674	MCC	0.77	5.33	0.4	3.53e-7	Brain cytoarchitecture;
PAAD	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.45e-7	Monocyte percentage of white cells;
PAAD	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.43	-5.66	-0.42	7.36e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg20003494	chr4:90757398	SNCA	-0.44	-5.04	-0.38	1.31e-6	Dementia with Lewy bodies;
PAAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.66	8.1	0.55	1.69e-13	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.5	-0.34	1.34e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-7.38	-0.51	9.76e-12	Prostate cancer;
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.59	5.77	0.42	4.35e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06028605	chr16:24865363	SLC5A11	-0.52	-6.29	-0.45	3.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15128208	chr22:42549153	NA	0.43	4.41	0.34	1.94e-5	Cognitive function;
PAAD	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.6	5.23	0.39	5.63e-7	Platelet count;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.89	0.58	1.67e-15	Menopause (age at onset);
PAAD	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.73	0.36	5.17e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.11	-0.5	4.26e-11	Vitiligo;
PAAD	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg24692254	chr21:30365293	RNF160	0.58	6.39	0.46	1.93e-9	Dental caries;
PAAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	5.44	0.4	2.06e-7	Monocyte count;
PAAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.85	10.97	0.66	5.31e-21	Aortic root size;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	8.13	0.55	1.41e-13	Height;
PAAD	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.61	6.5	0.47	1.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	11.81	0.69	3.03e-23	Menarche (age at onset);
PAAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.67	-0.42	7.03e-8	Tonsillectomy;
PAAD	cis	rs7727544	0.604	rs2069803	chr5:131400433	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	4.8	0.36	3.73e-6	Blood metabolite levels;
PAAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.89	-0.37	2.56e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs55692468	0.606	rs1878632	chr2:153323158	A/C	cg24749089	chr2:153322823	FMNL2	0.27	4.57	0.35	1.02e-5	Intraocular pressure;
PAAD	cis	rs73206853	0.841	rs57726856	chr12:110961123	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.69	0.36	5.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.55	7.78	0.53	1.04e-12	Diastolic blood pressure;
PAAD	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.91	-0.37	2.36e-6	Neuroticism;
PAAD	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.92	-0.54	4.6e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg02250501	chr15:90694978	NA	0.5	4.32	0.33	2.85e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.68	0.35	6.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.63	-6.62	-0.47	5.86e-10	Body mass index;
PAAD	cis	rs10419226	0.515	rs10423102	chr19:18757308	G/C	cg14292368	chr19:18793705	CRTC1	-0.45	-4.77	-0.36	4.32e-6	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg23024343	chr7:107201750	COG5	0.59	4.9	0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs8014252	0.803	rs73283917	chr14:71033156	G/A	cg11204974	chr14:71022665	NA	-0.71	-4.54	-0.35	1.12e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-5.61	-0.41	9.23e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs755249	0.567	rs2036463	chr1:39688075	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.53	5.17	0.39	7.41e-7	Cognitive function;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg05457628	chr5:178986728	RUFY1	0.49	4.69	0.36	6.02e-6	Lung cancer;
PAAD	cis	rs735539	0.593	rs2818997	chr13:21369315	C/T	cg27234864	chr13:21295941	IL17D	0.61	5.31	0.4	3.88e-7	Dental caries;
PAAD	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.62	6.5	0.47	1.12e-9	Morning vs. evening chronotype;
PAAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05640992	chr16:87970367	CA5A	0.62	7.56	0.52	3.49e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.65	0.35	7.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs757081	0.648	rs7940253	chr11:17280596	G/A	cg15432903	chr11:17409602	KCNJ11	-0.58	-5.79	-0.43	3.92e-8	Systolic blood pressure;
PAAD	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.7	5.84	0.43	3.02e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	12.58	0.71	2.49e-25	Colorectal cancer;
PAAD	cis	rs4824093	0.541	rs8142132	chr22:50211294	C/T	cg06057569	chr22:50219754	BRD1	0.74	4.77	0.36	4.29e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg18833306	chr6:118973337	C6orf204	0.43	4.42	0.34	1.9e-5	Electrocardiographic conduction measures;
PAAD	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg10818794	chr15:86012489	AKAP13	-0.45	-4.96	-0.37	1.87e-6	Interstitial lung disease;
PAAD	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg17346650	chr17:80929145	B3GNTL1	0.54	7.11	0.5	4.24e-11	Glycated hemoglobin levels;
PAAD	cis	rs4417704	0.551	rs55978049	chr2:241890228	A/C	cg26818257	chr2:241905806	NA	0.51	5.46	0.41	1.88e-7	Joint mobility (Beighton score);
PAAD	cis	rs9810890	1.000	rs78543474	chr3:128561638	T/C	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg15181151	chr6:150070149	PCMT1	0.51	5.24	0.39	5.2e-7	Lung cancer;
PAAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.81	8.42	0.56	2.69e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.39	-9.59	-0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.63	5.21	0.39	5.96e-7	Diastolic blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14853265	chr12:133460336	CHFR	0.67	6.84	0.49	1.78e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.58	-5.43	-0.4	2.15e-7	White matter hyperintensity burden;
PAAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.76	-8.61	-0.57	8.49e-15	Childhood ear infection;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.61	-6.19	-0.45	5.3300000000000004e-09	Paraoxonase activity;
PAAD	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg14851346	chr12:38532713	NA	0.43	4.29	0.33	3.18e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.8	-7.61	-0.53	2.66e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.8	-8.64	-0.57	7.23e-15	Type 2 diabetes;
PAAD	trans	rs4471226	1.000	rs9425449	chr1:176426953	C/T	cg01325552	chr4:187025420	NA	0.75	6.37	0.46	2.14e-9	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg00262122	chr8:11665843	FDFT1	-0.51	-4.7	-0.36	5.9e-6	Neuroticism;
PAAD	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.88e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.57	4.89	0.37	2.54e-6	Mean platelet volume;
PAAD	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg15654264	chr1:150340011	RPRD2	0.48	4.62	0.35	8.01e-6	Migraine;
PAAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6582630	0.555	rs7956782	chr12:38603641	C/G	cg13010199	chr12:38710504	ALG10B	0.67	6.76	0.48	2.71e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.48	5.14	0.38	8.28e-7	Type 2 diabetes;
PAAD	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs4921915	0.598	rs55686478	chr8:18250375	G/A	cg18736775	chr8:18248649	NAT2	-0.66	-4.65	-0.35	7.3e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00714464	chr2:113670427	IL1F7	0.61	6.52	0.47	9.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs17155006	0.655	rs430995	chr7:107727501	G/T	cg05962710	chr7:107745446	LAMB4	-0.44	-5.48	-0.41	1.76e-7	Pneumococcal bacteremia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23089227	chr13:76112973	COMMD6	0.61	6.41	0.46	1.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12989701	0.877	rs34854727	chr2:127855392	C/T	cg00091827	chr2:127863656	BIN1	0.58	4.26	0.33	3.62e-5	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21790971	chr4:54244117	FIP1L1	0.64	7.02	0.49	7.01e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg17366294	chr4:99064904	C4orf37	0.45	4.92	0.37	2.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.7	6.11	0.44	8.03e-9	Diabetic retinopathy;
PAAD	cis	rs4478147	0.506	rs17409637	chr4:87247384	G/A	cg10685359	chr4:87814065	C4orf36	-0.52	-5.35	-0.4	3.17e-7	Migraine - clinic-based;
PAAD	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.85	-5.74	-0.42	5.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs735539	0.521	rs2031353	chr13:21380474	C/A	cg27234864	chr13:21295941	IL17D	0.58	4.8	0.36	3.81e-6	Dental caries;
PAAD	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.63	6.52	0.47	1.01e-9	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.71	0.48	3.67e-10	Lung cancer;
PAAD	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	1.17	13.57	0.74	5.41e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg14820908	chr5:178986412	RUFY1	0.49	4.82	0.36	3.47e-6	Lung cancer;
PAAD	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.5	-0.34	1.34e-5	Glomerular filtration rate;
PAAD	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-5.88	-0.43	2.56e-8	Schizophrenia;
PAAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.8	5.97	0.44	1.64e-8	Gut microbiome composition (summer);
PAAD	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.06e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg03983715	chr16:68378420	PRMT7	-0.97	-6.86	-0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.52	4.74	0.36	4.94e-6	Total body bone mineral density;
PAAD	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.63	6.93	0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.1	-8.78	-0.58	3.25e-15	Gout;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.52	8.79	0.58	2.91e-15	IgG glycosylation;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.64	-5.78	-0.42	4.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg24110177	chr3:50126178	RBM5	-0.67	-6.83	-0.48	1.91e-10	Menarche (age at onset);
PAAD	cis	rs2764208	0.576	rs2814954	chr6:34698146	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.34	-0.33	2.6e-5	Systemic lupus erythematosus;
PAAD	cis	rs16852403	0.583	rs10494510	chr1:178074581	A/G	cg00404053	chr1:178313656	RASAL2	0.44	4.28	0.33	3.27e-5	Childhood ear infection;
PAAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg05313129	chr8:58192883	C8orf71	-0.44	-4.31	-0.33	2.95e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg17541715	chr7:1216824	NA	-0.43	-4.81	-0.36	3.56e-6	Longevity;Endometriosis;
PAAD	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.85	8.82	0.58	2.54e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg27494647	chr7:150038898	RARRES2	0.44	4.71	0.36	5.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.49	4.29	0.33	3.13e-5	Platelet count;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg10596483	chr8:143751796	JRK	-0.5	-4.4	-0.34	1.99e-5	Urinary tract infection frequency;
PAAD	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.62	-0.53	2.51e-12	Hemoglobin concentration;
PAAD	cis	rs6132905	0.590	rs112911492	chr20:2627936	T/C	cg24848351	chr20:2622020	TMC2	-0.76	-5.82	-0.43	3.44e-8	Mumps;
PAAD	trans	rs61677309	1.000	rs55940627	chr11:118163920	G/A	cg15548380	chr1:19984784	NBL1	-0.64	-6.6	-0.47	6.4e-10	Lung cancer in ever smokers;
PAAD	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.96	11.94	0.7	1.34e-23	Osteoporosis;
PAAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17264618	chr3:40429014	ENTPD3	0.35	4.33	0.33	2.65e-5	Renal cell carcinoma;
PAAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.61	5.43	0.4	2.21e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.46	4.45	0.34	1.68e-5	Depression;
PAAD	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg00999904	chr2:3704751	ALLC	-0.69	-7.12	-0.5	3.92e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg04176122	chr11:118779835	BCL9L	0.42	4.74	0.36	4.89e-6	Sjögren's syndrome;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg12757816	chr2:10669957	NA	-0.54	-5.79	-0.42	3.97e-8	Prostate cancer;
PAAD	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2117029	0.553	rs2162644	chr12:49548190	G/A	cg05368762	chr12:50135785	TMBIM6	0.45	4.49	0.34	1.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs793571	0.505	rs2305421	chr15:58903083	A/G	cg05156742	chr15:59063176	FAM63B	0.64	4.63	0.35	7.72e-6	Schizophrenia;
PAAD	cis	rs6446731	0.568	rs4488885	chr4:3285953	C/T	cg00060484	chr4:3287598	NA	0.56	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.71	0.36	5.59e-6	Schizophrenia;
PAAD	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.67	-7.47	-0.52	6.02e-12	Schizophrenia;
PAAD	cis	rs899997	0.906	rs8039600	chr15:78990300	G/A	cg16602846	chr15:78114278	NA	-0.43	-4.43	-0.34	1.8e-5	Coronary artery disease or large artery stroke;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22565399	chr5:176890677	DBN1	-0.64	-6.52	-0.47	1e-9	Obesity-related traits;
PAAD	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.19	-0.55	1.02e-13	Brugada syndrome;
PAAD	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.0	-0.63	2.08e-18	Blood trace element (Zn levels);
PAAD	cis	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg16898833	chr6:26189333	HIST1H4D	0.97	4.78	0.36	4.02e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.63	-7.27	-0.51	1.74e-11	Vitiligo;
PAAD	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.04	-0.59	6.74e-16	Calcium levels;
PAAD	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.66	-6.29	-0.45	3.14e-9	Platelet distribution width;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg11218175	chr11:495084	RNH1	0.83	4.61	0.35	8.36e-6	Body mass index;
PAAD	cis	rs11892454	0.533	rs10469884	chr2:26101632	G/T	cg03373490	chr2:26702396	OTOF	0.51	4.31	0.33	2.95e-5	Heschl's gyrus morphology;
PAAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg03340356	chr1:67600835	NA	-0.51	-5.91	-0.43	2.19e-8	Psoriasis;
PAAD	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.47	4.83	0.36	3.36e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1075232	0.655	rs28451043	chr15:31587562	A/T	cg06530883	chr15:30699977	NA	0.99	4.26	0.33	3.56e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg20129853	chr10:51489980	NA	0.42	4.29	0.33	3.17e-5	Prostate-specific antigen levels;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs6446731	0.593	rs2858084	chr4:3272118	A/C	cg14583973	chr4:3374767	RGS12	0.32	4.48	0.34	1.48e-5	Mean platelet volume;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.77	0.48	2.68e-10	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg02734326	chr4:10020555	SLC2A9	-0.5	-4.84	-0.37	3.21e-6	Bone mineral density;
PAAD	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg12092346	chr18:77659572	KCNG2	-0.66	-4.71	-0.36	5.52e-6	Opioid sensitivity;
PAAD	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs10768122	1.000	rs7121587	chr11:35296708	T/A	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2.01e-5	Vitiligo;
PAAD	cis	rs2882667	0.587	rs2174972	chr5:138101918	C/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.5	-0.57	1.65e-14	Diabetic kidney disease;
PAAD	cis	rs3106136	0.681	rs11721714	chr4:95310717	C/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.01	0.38	1.53e-6	Capecitabine sensitivity;
PAAD	trans	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg17453767	chr4:144277796	GAB1	0.65	6.36	0.46	2.21e-9	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs62025270	0.632	rs17637411	chr15:86246447	C/G	cg13263323	chr15:86062960	AKAP13	0.48	4.33	0.33	2.66e-5	Idiopathic pulmonary fibrosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14640736	chr13:39612797	NHLRC3;C13orf23	0.64	6.32	0.46	2.69e-9	Obesity-related traits;
PAAD	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg26816564	chr1:7831052	VAMP3	0.78	5.66	0.42	7.4e-8	Inflammatory bowel disease;
PAAD	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-5.34	-0.4	3.33e-7	Educational attainment (years of education);
PAAD	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.41	-0.34	1.92e-5	Educational attainment;
PAAD	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.7	7.5	0.52	4.87e-12	Response to antipsychotic treatment;
PAAD	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg10395934	chr14:104002654	TRMT61A	0.56	5.73	0.42	5.35e-8	Body mass index;
PAAD	cis	rs6995541	0.810	rs11250080	chr8:10674467	C/T	cg14855657	chr8:10587604	SOX7	-0.47	-4.43	-0.34	1.77e-5	Triglyceride levels;
PAAD	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	2.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs58521262	0.556	rs449210	chr19:23122647	C/A	cg02350677	chr19:23254381	NA	-0.27	-4.71	-0.36	5.63e-6	Testicular germ cell tumor;
PAAD	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.42	-4.93	-0.37	2.11e-6	Coronary artery disease;
PAAD	cis	rs747650	0.504	rs6485715	chr11:46975125	C/T	cg19486271	chr11:47235900	DDB2	0.59	5.73	0.42	5.18e-8	Acne (severe);
PAAD	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.68	-7.67	-0.53	1.9e-12	Schizophrenia;
PAAD	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.41	-4.25	-0.33	3.76e-5	Interstitial lung disease;
PAAD	cis	rs2236267	0.726	rs2295740	chr14:88602804	G/C	cg18078958	chr14:88630771	NA	0.51	6.37	0.46	2.08e-9	Food antigen IgG levels;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs4481887	0.573	rs6689894	chr1:248409579	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-4.35	-0.33	2.52e-5	Common traits (Other);
PAAD	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.92	-0.72	3.09e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7624766	0.714	rs1378660	chr3:160535871	T/C	cg22637730	chr3:160473554	PPM1L	0.51	4.59	0.35	9.16e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.5	5.1	0.38	9.78e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10950821	0.770	rs916737	chr7:20689420	G/T	cg21202529	chr7:20656503	ABCB5	0.52	4.69	0.36	6.11e-6	Response to statin therapy;
PAAD	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.76	-7.91	-0.54	4.88e-13	Neuroticism;
PAAD	cis	rs9657904	0.826	rs10933833	chr3:105598185	A/T	cg16975614	chr3:105601834	NA	-0.46	-4.62	-0.35	7.98e-6	Multiple sclerosis;
PAAD	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-7.45	-0.52	6.62e-12	Dental caries;
PAAD	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.28	-0.51	1.64e-11	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.74	0.36	4.93e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.3e-5	Schizophrenia;
PAAD	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.73	0.48	3.19e-10	Lung cancer in ever smokers;
PAAD	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg18769074	chr3:133464867	TF	0.42	4.89	0.37	2.55e-6	Iron status biomarkers;
PAAD	cis	rs3812111	0.525	rs6755	chr6:116571255	G/A	cg05304507	chr6:116381966	FRK	-0.26	-4.54	-0.35	1.13e-5	Age-related macular degeneration;
PAAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	11.64	0.69	8.77e-23	Menopause (age at onset);
PAAD	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg11766577	chr21:47581405	C21orf56	-0.41	-4.45	-0.34	1.67e-5	Testicular germ cell tumor;
PAAD	cis	rs3753841	0.832	rs10874654	chr1:103249183	C/T	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14842520	chr2:118841845	NA	-0.61	-6.41	-0.46	1.76e-9	Obesity-related traits;
PAAD	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	5.25	0.39	5.02e-7	Multiple sclerosis;
PAAD	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.74	-0.36	4.79e-6	Body mass index;
PAAD	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.53	-0.34	1.19e-5	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg05925327	chr15:68127851	NA	-0.5	-4.43	-0.34	1.76e-5	Obesity;
PAAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg15847926	chr7:2749597	AMZ1	-0.4	-4.81	-0.36	3.64e-6	Height;
PAAD	cis	rs7251275	0.744	rs2270075	chr19:44132306	G/A	cg17121205	chr19:44009353	PHLDB3	0.37	4.48	0.34	1.44e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.96	-6.39	-0.46	1.92e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4690686	0.538	rs6855882	chr4:177261061	T/G	cg17059388	chr4:177262070	NA	0.54	5.24	0.39	5.21e-7	Essential tremor;
PAAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.6	-6.2	-0.45	5.18e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs9810890	1.000	rs73207973	chr3:128568365	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.72	-0.36	5.37e-6	Resting heart rate;
PAAD	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.66	-6.25	-0.45	3.94e-9	Corneal astigmatism;
PAAD	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.6	5.82	0.43	3.37e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs8105895	0.935	rs10404669	chr19:22241218	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.58	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06799790	chr17:61951754	CSH2	-0.47	-4.79	-0.36	4e-6	Height;
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg17747265	chr1:1875780	NA	-0.73	-11.0	-0.67	4.66e-21	Body mass index;
PAAD	cis	rs58521262	0.615	rs289364	chr19:23117036	G/T	cg02350677	chr19:23254381	NA	-0.26	-4.47	-0.34	1.53e-5	Testicular germ cell tumor;
PAAD	cis	rs1419980	0.643	rs12228661	chr12:7745882	C/G	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs939584	1.000	rs2867115	chr2:651382	T/C	cg14515364	chr2:636606	NA	-0.47	-4.38	-0.33	2.2e-5	Body mass index;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	1.32	8.27	0.56	6.23e-14	Diabetic retinopathy;
PAAD	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.41	5.03	0.38	1.35e-6	Pulmonary function;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg25487775	chr2:162093969	NA	0.76	8.71	0.58	4.67e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg13259177	chr13:114761607	RASA3	-0.87	-7.21	-0.5	2.5e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg02527881	chr3:46936655	PTH1R	0.37	4.26	0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg05110241	chr16:68378359	PRMT7	-1.01	-6.53	-0.47	9.3e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg12419862	chr22:24373484	LOC391322	-0.81	-6.41	-0.46	1.71e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs11955175	1.000	rs112239156	chr5:40649478	A/C	cg17351974	chr5:40835760	RPL37	0.81	4.66	0.35	6.91e-6	Bipolar disorder and schizophrenia;
PAAD	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	6.3	0.46	2.99e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg05554000	chr7:158905015	VIPR2	-0.6	-4.51	-0.34	1.29e-5	Facial morphology (factor 20);
PAAD	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg13206674	chr6:150067644	NUP43	-0.58	-5.48	-0.41	1.69e-7	Lung cancer;
PAAD	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg14631576	chr9:95140430	CENPP	-0.56	-5.6	-0.41	9.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6679454	0.801	rs17579100	chr1:58332957	T/C	cg17491850	chr1:57888480	DAB1	-0.39	-4.35	-0.33	2.5e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.81	10.14	0.64	8.77e-19	Morning vs. evening chronotype;
PAAD	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	7.52	0.52	4.32e-12	Neuroticism;
PAAD	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.15e-11	Educational attainment;
PAAD	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg20573242	chr4:122745356	CCNA2	0.5	4.31	0.33	2.95e-5	Type 2 diabetes;
PAAD	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26897989	chr16:1907736	C16orf73	-0.56	-4.99	-0.38	1.63e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg05228244	chr10:1102351	WDR37	0.93	4.52	0.34	1.25e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.7	-6.77	-0.48	2.57e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs438465	1.000	rs407690	chr6:169826531	A/C	cg11181693	chr6:169825345	NA	-0.58	-4.6	-0.35	8.83e-6	Corneal astigmatism;
PAAD	cis	rs778371	0.755	rs709936	chr2:233802603	G/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.87	-0.43	2.59e-8	Schizophrenia;
PAAD	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.71	7.7	0.53	1.59e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg25566285	chr7:158114605	PTPRN2	0.79	6.53	0.47	9.55e-10	Response to amphetamines;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.79	8.3	0.56	5.12e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.45	-5.34	-0.4	3.28e-7	Coronary artery disease;
PAAD	trans	rs2880058	0.670	rs12044487	chr1:162039394	G/T	cg22816059	chr5:422114	AHRR	-0.62	-6.48	-0.47	1.23e-9	QT interval;
PAAD	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg01851573	chr8:8652454	MFHAS1	0.97	7.4	0.51	8.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.65	4.54	0.35	1.14e-5	Lung cancer;
PAAD	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.58	6.49	0.47	1.15e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.52	0.47	9.93e-10	Lung cancer;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.5	5.69	0.42	6.43e-8	Tuberculosis;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6088813	0.961	rs6060371	chr20:33913322	G/T	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.89	0.37	2.52e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.6	0.41	9.66e-8	Life satisfaction;
PAAD	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg25753631	chr6:25732923	NA	0.36	4.48	0.34	1.48e-5	Blood metabolite levels;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.87	-9.87	-0.62	4.73e-18	Iron status biomarkers;
PAAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	5.04	0.38	1.29e-6	Tonsillectomy;
PAAD	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.47	0.41	1.84e-7	Prudent dietary pattern;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.6	-6.44	-0.46	1.47e-9	Lymphocyte counts;
PAAD	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.97	10.39	0.64	1.9e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	10.5	0.65	1.01e-19	Platelet count;
PAAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.79	-7.69	-0.53	1.69e-12	DNA methylation (variation);
PAAD	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09597638	chr17:3907349	NA	0.72	7.54	0.52	4.04e-12	Type 2 diabetes;
PAAD	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.51	5.99	0.44	1.45e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg16083429	chr3:49237500	CCDC36	0.47	4.63	0.35	7.71e-6	Menarche (age at onset);
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.42	-0.34	1.88e-5	Vitiligo;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.98	0.44	1.51e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12599982	chr1:44399894	ARTN	0.44	4.82	0.36	3.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.45	5.02	0.38	1.42e-6	Schizophrenia;
PAAD	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-1.0	-12.74	-0.72	9.21e-26	Refractive error;
PAAD	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg21194808	chr1:2205498	SKI	0.43	4.29	0.33	3.23e-5	Coronary artery disease;
PAAD	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.53	-4.38	-0.33	2.24e-5	Pursuit maintenance gain;
PAAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.87	-11.0	-0.67	4.6e-21	Aortic root size;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs501120	0.778	rs523297	chr10:44756557	C/T	cg09554077	chr10:44749378	NA	0.42	4.49	0.34	1.4e-5	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs642743	0.595	rs703343	chr10:105989664	G/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.26	4.32	0.33	2.84e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07227926	chr12:104609526	TXNRD1	0.77	8.61	0.57	8.83e-15	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.73	4.94	0.37	2.08e-6	HDL cholesterol;
PAAD	cis	rs877426	0.667	rs9525231	chr13:114829711	G/A	cg00571178	chr13:114841904	RASA3	-0.58	-4.96	-0.37	1.84e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg01612440	chr4:3296283	NA	0.48	4.6	0.35	8.75e-6	Serum sulfate level;
PAAD	cis	rs55637147	0.671	rs2276042	chr11:57117385	C/T	cg25492363	chr11:57319872	UBE2L6	-0.41	-4.68	-0.36	6.22e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.64	0.35	7.37e-6	Bipolar disorder;
PAAD	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg15282417	chr9:129245246	FAM125B	0.42	5.12	0.38	9.28e-7	Intraocular pressure;
PAAD	cis	rs41311933	1.000	rs41311871	chr9:123753253	T/C	cg13567360	chr9:123745713	C5	-0.73	-4.64	-0.35	7.35e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.77	9.0	0.59	8.55e-16	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07176514	chr1:185126191	C1orf25;C1orf26	-0.64	-6.69	-0.48	4.11e-10	Smoking initiation;
PAAD	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg15309053	chr8:964076	NA	0.58	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs11809443	1.000	rs11809443	chr1:228326492	T/C	cg01200585	chr1:228362443	C1orf69	0.55	4.68	0.36	6.2e-6	Coronary artery disease;
PAAD	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg03392386	chr11:133800800	IGSF9B	-0.59	-5.69	-0.42	6.22e-8	Parkinson's disease;
PAAD	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg09835421	chr16:68378352	PRMT7	-0.69	-5.4	-0.4	2.47e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg24253500	chr15:84953950	NA	0.54	6.27	0.45	3.52e-9	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-5.95	-0.43	1.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.03	-0.38	1.35e-6	Neuroticism;
PAAD	trans	rs11794666	1.000	rs111658236	chr9:31658008	T/C	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.58	-5.03	-0.38	1.37e-6	Obesity-related traits;
PAAD	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.76	9.57	0.61	2.82e-17	Iron status biomarkers (transferrin levels);
PAAD	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.53	-6.31	-0.46	2.83e-9	Alcohol dependence;
PAAD	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.69	-0.53	1.74e-12	Coronary artery disease;
PAAD	trans	rs7615952	0.551	rs58274173	chr3:125800700	G/A	cg07211511	chr3:129823064	LOC729375	-1.24	-7.39	-0.51	9.33e-12	Blood pressure (smoking interaction);
PAAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg07527105	chr16:88053339	BANP	0.49	5.18	0.39	6.94e-7	Menopause (age at onset);
PAAD	cis	rs10450586	0.863	rs10501084	chr11:27323139	T/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-10.93	-0.66	6.97e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.5	-4.99	-0.38	1.61e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.6	-6.58	-0.47	6.98e-10	Testicular germ cell tumor;
PAAD	cis	rs11871801	0.918	rs1032070	chr17:40618251	C/T	cg21692620	chr17:40835849	CNTNAP1	-0.46	-4.62	-0.35	8.02e-6	Crohn's disease;
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg21665744	chr7:39171113	POU6F2	0.39	5.88	0.43	2.53e-8	IgG glycosylation;
PAAD	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.73	0.36	4.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.41e-8	Lewy body disease;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg02743256	chr7:2109353	MAD1L1	-0.5	-4.27	-0.33	3.46e-5	Bipolar disorder;
PAAD	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.7	8.96	0.59	1.12e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg23587288	chr2:27483067	SLC30A3	-0.7	-6.65	-0.47	4.98e-10	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.66	0.57	6.25e-15	Alzheimer's disease;
PAAD	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	1.39	7.45	0.52	6.38e-12	Skin colour saturation;
PAAD	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	4.47	0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.94	10.19	0.64	6.77e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.35	-0.33	2.44e-5	Arsenic metabolism;
PAAD	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.14	-14.61	-0.76	9.3e-31	Schizophrenia;
PAAD	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.64	-6.96	-0.49	9.78e-11	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.8	10.13	0.63	9.34e-19	Morning vs. evening chronotype;
PAAD	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.95	-8.67	-0.58	6e-15	Body mass index;
PAAD	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.37	0.4	2.85e-7	Body mass index;
PAAD	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg09307838	chr4:120376055	NA	0.8	7.49	0.52	5.29e-12	Corneal astigmatism;
PAAD	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.57	4.98	0.37	1.69e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.46	0.57	2.05e-14	Dupuytren's disease;
PAAD	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.93	12.05	0.7	6.67e-24	Menarche (age at onset);
PAAD	cis	rs9815354	1.000	rs1615543	chr3:41906404	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg09222892	chr1:25734099	RHCE	-0.44	-4.34	-0.33	2.61e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs2421770	0.731	rs932634	chr11:35263996	G/A	cg13971030	chr11:35366721	SLC1A2	-0.49	-4.93	-0.37	2.12e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.86	10.88	0.66	9.28e-21	Body mass index;
PAAD	cis	rs730566	0.619	rs3731529	chr3:48213498	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.69	-6.21	-0.45	4.9e-9	Prion diseases;
PAAD	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.63	5.49	0.41	1.68e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5167	0.539	rs4803783	chr19:45470458	G/C	cg03270332	chr19:45594670	GEMIN7	0.26	4.28	0.33	3.3e-5	Blood protein levels;
PAAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg08125733	chr17:73851984	WBP2	0.96	8.4	0.56	2.98e-14	Psoriasis;
PAAD	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.53	-6.34	-0.46	2.54e-9	Alcohol dependence;
PAAD	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg00717180	chr2:96193071	NA	-0.62	-6.89	-0.49	1.38e-10	HDL cholesterol;
PAAD	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.83	-8.82	-0.58	2.5e-15	Urate levels in obese individuals;
PAAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-10.18	-0.64	6.77e-19	Bone mineral density;
PAAD	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2286503	0.809	rs4719716	chr7:22861369	G/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	5.23	0.39	5.59e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7172971	0.808	rs4924609	chr15:42333025	A/G	cg07013680	chr15:42186124	SPTBN5	0.56	4.44	0.34	1.71e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-7.14	-0.5	3.62e-11	Coronary artery disease;
PAAD	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.47	0.46	1.3e-9	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00049323	chr5:472564	LOC25845	0.42	4.93	0.37	2.14e-6	Cystic fibrosis severity;
PAAD	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.63	-7.85	-0.54	7e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.64	5.54	0.41	1.31e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.72	0.48	3.47e-10	Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.17	0.39	7.42e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg11062466	chr8:58055876	NA	0.66	4.73	0.36	5.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6681460	0.649	rs10889625	chr1:67007235	T/C	cg02459107	chr1:67143332	SGIP1	0.55	4.95	0.37	1.94e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	8.07	0.55	2.02e-13	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23539715	chr3:61656598	PTPRG	-0.68	-7.94	-0.54	4.12e-13	Monocyte percentage of white cells;
PAAD	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.67	0.35	6.66e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.13	-0.38	8.73e-7	Initial pursuit acceleration;
PAAD	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.28	11.59	0.69	1.15e-22	Night sleep phenotypes;
PAAD	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.3	-0.33	3.08e-5	Schizophrenia;
PAAD	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.62	6.24	0.45	4.11e-9	Testicular germ cell tumor;
PAAD	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.91	-6.44	-0.46	1.47e-9	Alzheimer's disease (late onset);
PAAD	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg03538708	chr1:25844672	NA	-0.52	-5.35	-0.4	3.24e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.38	5.2	0.39	6.32e-7	Blood protein levels;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14159672	chr1:205819179	PM20D1	0.52	5.03	0.38	1.37e-6	Parkinson's disease;
PAAD	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.32	0.33	2.79e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.56	5.88	0.43	2.48e-8	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.57	-6.18	-0.45	5.59e-9	Motion sickness;
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.73	7.59	0.52	3.03e-12	Height;
PAAD	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg23465465	chr6:26364728	BTN3A2	0.82	4.42	0.34	1.9e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg21269045	chr12:125625041	AACS	-0.5	-4.81	-0.36	3.54e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.72	-8.14	-0.55	1.33e-13	Height;
PAAD	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.64	-0.47	5.36e-10	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs496300	0.668	rs666699	chr21:44786863	A/G	cg18342814	chr21:45755740	C21orf2	-0.45	-4.3	-0.33	3.04e-5	Metabolic syndrome;
PAAD	cis	rs6024905	0.904	rs6014744	chr20:36957584	A/C	cg07053727	chr20:36965646	BPI	0.46	4.87	0.37	2.77e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg09835421	chr16:68378352	PRMT7	-0.91	-7.24	-0.51	2.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs9652601	0.608	rs8061826	chr16:11192787	A/G	cg04616529	chr16:11181986	CLEC16A	0.38	4.57	0.35	1.01e-5	Systemic lupus erythematosus;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.76	-6.93	-0.49	1.14e-10	Coronary artery disease;
PAAD	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.26	0.56	6.79e-14	Exhaled nitric oxide output;
PAAD	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.61	6.36	0.46	2.28e-9	Morning vs. evening chronotype;
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg14092988	chr3:52407081	DNAH1	-0.37	-4.44	-0.34	1.73e-5	Electroencephalogram traits;
PAAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.5	-4.92	-0.37	2.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs7873102	0.654	rs1138374	chr9:37974743	A/G	cg03528946	chr9:38069800	SHB	0.53	5.31	0.4	3.84e-7	Brain structure;
PAAD	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.18e-22	Parkinson's disease;
PAAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.74	7.27	0.51	1.75e-11	Neuroticism;
PAAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.3	-0.39	4.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg00750074	chr16:89608354	SPG7	-0.59	-6.17	-0.45	6e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs360071	0.528	rs360097	chr1:226065755	C/A	cg01472176	chr1:226074946	LEFTY1	0.6	5.82	0.43	3.44e-8	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg25566285	chr7:158114605	PTPRN2	0.8	6.99	0.49	8.1e-11	Response to amphetamines;
PAAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg23860436	chr12:58378763	NA	0.48	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11165354	0.687	rs4370805	chr1:92171866	G/A	cg00730172	chr1:91176405	NA	0.36	4.63	0.35	7.95e-6	Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.14e-7	Prostate cancer;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg15212455	chr7:39170539	POU6F2	0.39	5.55	0.41	1.22e-7	IgG glycosylation;
PAAD	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-6.12	-0.44	7.73e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.49	4.26	0.33	3.51e-5	Homoarginine levels;
PAAD	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.61	-0.35	8.45e-6	Menarche (age at onset);
PAAD	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11264213	0.681	rs116324086	chr1:36287771	A/G	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs1075265	0.704	rs10084374	chr2:54249312	C/T	cg04546899	chr2:54196757	PSME4	0.3	4.33	0.33	2.65e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09695851	chr17:3907499	NA	0.84	8.53	0.57	1.41e-14	Type 2 diabetes;
PAAD	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.51	-4.37	-0.33	2.3e-5	Neuroticism;
PAAD	cis	rs939584	0.935	rs12993295	chr2:632808	G/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.61	-0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.82	9.29	0.6	1.53e-16	Metabolic syndrome;
PAAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-4.28	-0.33	3.24e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.51	-5.44	-0.4	2.11e-7	Testicular germ cell tumor;
PAAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg19592336	chr6:28129416	ZNF389	-0.6	-4.31	-0.33	2.96e-5	Depression;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.13	15.56	0.78	2.9e-33	Subjective well-being;
PAAD	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.94	11.59	0.68	1.2e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs73195822	0.667	rs60579973	chr12:111245629	C/T	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.27	-0.33	3.4e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.88	-0.37	2.61e-6	Menopause (age at onset);
PAAD	cis	rs1499972	0.941	rs62263123	chr3:117632263	G/A	cg07612923	chr3:117604196	NA	1.08	7.1	0.5	4.55e-11	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2731664	0.792	rs2630763	chr5:176901005	T/A	cg23176889	chr5:176863531	GRK6	-0.84	-9.41	-0.61	7.31e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.67	-0.53	1.95e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	1.09	12.09	0.7	5.31e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.76	7.83	0.54	7.73e-13	Breast cancer;
PAAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13102973	0.645	rs6535055	chr4:135886101	A/C	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg26031613	chr14:104095156	KLC1	-0.55	-5.78	-0.42	4.2e-8	Schizophrenia;
PAAD	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.38	-4.42	-0.34	1.87e-5	Red blood cell traits;
PAAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	1.16	9.58	0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-5.23	-0.39	5.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg23283495	chr1:209979779	IRF6	0.61	5.43	0.4	2.18e-7	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4889911	1.000	rs4889792	chr17:77839845	G/A	cg26037614	chr17:77751273	CBX2	0.58	4.29	0.33	3.11e-5	Electroencephalogram traits;
PAAD	cis	rs6693295	0.605	rs4396095	chr1:246213270	A/G	cg26013412	chr1:247094486	AHCTF1	-0.59	-4.38	-0.33	2.22e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg00080972	chr5:178986291	RUFY1	-0.64	-6.32	-0.46	2.74e-9	Lung cancer;
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.79	8.74	0.58	3.97e-15	Lung cancer;
PAAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs4676482	0.577	rs4676615	chr3:39271524	G/A	cg02254461	chr3:39195904	CSRNP1	0.72	4.46	0.34	1.61e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06972998	chr10:76585851	MYST4	0.63	6.48	0.47	1.21e-9	Pancreatic cancer;
PAAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.91	-7.96	-0.54	3.68e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.0	0.44	1.4e-8	Menarche (age at onset);
PAAD	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.79	-0.48	2.34e-10	Atrioventricular conduction;
PAAD	cis	rs6424115	0.594	rs7519640	chr1:24069637	G/C	cg24699146	chr1:24152579	HMGCL	0.47	5.17	0.39	7.39e-7	Immature fraction of reticulocytes;
PAAD	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg22134325	chr11:66188745	NPAS4	0.29	4.62	0.35	8.16e-6	Airway imaging phenotypes;
PAAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.63	-6.38	-0.46	2.03e-9	Monocyte count;
PAAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg05338066	chr1:7812865	CAMTA1	-0.6	-4.78	-0.36	4.16e-6	Inflammatory bowel disease;
PAAD	cis	rs12714314	0.756	rs10181146	chr2:1948645	A/G	cg22350835	chr2:1868857	MYT1L	-0.44	-4.62	-0.35	8.29e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs12760731	0.720	rs12022185	chr1:178279653	A/G	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.34	-0.33	2.56e-5	Life satisfaction;
PAAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09758869	chr16:12010052	GSPT1	-0.56	-6.32	-0.46	2.77e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs2147959	0.883	rs7529055	chr1:228636824	T/G	cg00655913	chr1:228633920	NA	0.5	4.57	0.35	9.95e-6	Adult asthma;
PAAD	cis	rs617219	0.671	rs1316753	chr5:78531337	G/C	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03543731	chr15:50474621	SLC27A2	0.56	6.31	0.46	2.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-12.87	-0.72	4.28e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg06883089	chr1:45254480	BEST4	0.34	4.28	0.33	3.28e-5	High light scatter reticulocyte count;
PAAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg15017067	chr4:17643749	FAM184B	0.4	4.61	0.35	8.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg10591111	chr5:226296	SDHA	0.67	5.19	0.39	6.5e-7	Breast cancer;
PAAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg03037974	chr15:76606532	NA	0.55	6.54	0.47	8.74e-10	Blood metabolite levels;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.03e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	6.72	0.48	3.52e-10	Total body bone mineral density;
PAAD	cis	rs9677476	0.517	rs60664562	chr2:232060843	T/A	cg07929768	chr2:232055508	NA	0.46	5.23	0.39	5.41e-7	Food antigen IgG levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08739233	chr1:201857947	SHISA4	-0.75	-6.44	-0.46	1.5e-9	Neuroticism;
PAAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.2e-14	Bone mineral density;
PAAD	cis	rs13273891	1.000	rs13273891	chr8:58986459	G/A	cg05901852	chr8:59757290	TOX	-0.51	-4.68	-0.36	6.22e-6	Pit-and-Fissure caries;
PAAD	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.56	5.4	0.4	2.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7771547	0.603	rs9357218	chr6:36549858	G/A	cg07856975	chr6:36356162	ETV7	0.56	5.75	0.42	4.76e-8	Platelet distribution width;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.95	-10.41	-0.65	1.74e-19	Headache;
PAAD	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.84	-8.91	-0.59	1.51e-15	Ulcerative colitis;
PAAD	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	7.34	0.51	1.19e-11	Response to antipsychotic treatment;
PAAD	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	0.98	6.32	0.46	2.74e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-6.81	-0.48	2.09e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg12700464	chr11:78128424	GAB2	-0.58	-4.39	-0.34	2.08e-5	Alzheimer's disease (survival time);
PAAD	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg18082788	chr6:149806339	ZC3H12D	-0.31	-4.33	-0.33	2.65e-5	Dupuytren's disease;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.57	5.65	0.42	7.65e-8	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18709144	chr3:110803068	PVRL3	-0.57	-6.49	-0.47	1.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	10.64	0.65	4.15e-20	Prudent dietary pattern;
PAAD	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg27511599	chr7:32358540	NA	0.89	4.7	0.36	5.86e-6	Body mass index;
PAAD	cis	rs5753037	0.809	rs5997530	chr22:30203599	C/G	cg01021169	chr22:30184971	ASCC2	-0.44	-4.51	-0.34	1.26e-5	Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg25124228	chr12:125621409	AACS	-0.65	-6.2	-0.45	5.12e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	6.59	0.47	6.81e-10	IgG glycosylation;
PAAD	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.73	6.42	0.46	1.66e-9	Dilated cardiomyopathy;
PAAD	trans	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg01620082	chr3:125678407	NA	-1.15	-6.59	-0.47	6.9e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.62	5.74	0.42	4.9e-8	Refractive astigmatism;
PAAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs337161	0.765	rs365398	chr1:220938228	G/A	cg09023136	chr1:220959637	MOSC1	-0.56	-4.3	-0.33	3.04e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.6	6.11	0.44	8.2e-9	Red blood cell count;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg11508406	chr4:1595515	NA	0.45	4.65	0.35	7.18e-6	Obesity-related traits;
PAAD	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.51	-5.17	-0.39	7.33e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4979906	1.000	rs2048787	chr10:79462793	C/T	cg07817648	chr10:79422355	NA	-0.65	-5.84	-0.43	3.01e-8	Mortality in heart failure;
PAAD	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.47	-0.57	2e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	8.48	0.57	1.87e-14	Electrocardiographic conduction measures;
PAAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg15061591	chr7:98625706	SMURF1	-0.48	-4.34	-0.33	2.54e-5	Breast cancer;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.73	0.42	5.33e-8	Prudent dietary pattern;
PAAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg09017928	chr7:158110068	PTPRN2	0.44	4.33	0.33	2.67e-5	Calcium levels;
PAAD	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.26	-0.67	9e-22	Height;
PAAD	cis	rs7631605	0.875	rs4678925	chr3:37078506	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11168618	0.967	rs1895996	chr12:48955571	A/C	cg11037512	chr12:49182566	ADCY6	-0.51	-4.26	-0.33	3.55e-5	Adiponectin levels;
PAAD	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.57	-5.33	-0.4	3.47e-7	Lung cancer;
PAAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.71	11.12	0.67	2.14e-21	Breast cancer;
PAAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg11843238	chr5:131593191	PDLIM4	0.5	4.58	0.35	9.66e-6	Acylcarnitine levels;
PAAD	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg20243544	chr17:37824526	PNMT	-0.55	-5.02	-0.38	1.43e-6	Self-reported allergy;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.52	4.82	0.36	3.49e-6	Schizophrenia;
PAAD	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg06795125	chr2:108905320	SULT1C2	-0.46	-4.52	-0.34	1.22e-5	Lobe size;
PAAD	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.69	7.02	0.49	6.9e-11	Obesity-related traits;
PAAD	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg03098721	chr1:84464084	TTLL7	0.48	4.52	0.34	1.22e-5	Obesity-related traits;
PAAD	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.72	8.35	0.56	4.03e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.78	8.25	0.56	6.89e-14	Renal function-related traits (BUN);
PAAD	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.67	6.61	0.47	6.19e-10	Uric acid levels;
PAAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7897654	0.651	rs12780134	chr10:104646443	C/A	cg14737131	chr10:104680354	CNNM2	0.42	4.27	0.33	3.47e-5	Schizophrenia;
PAAD	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	0.95	4.36	0.33	2.42e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.34	-0.33	2.59e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg00262122	chr8:11665843	FDFT1	-0.56	-4.86	-0.37	2.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.88	10.91	0.66	7.74e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.71	7.12	0.5	4.04e-11	Obesity-related traits;
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.76	-0.36	4.45e-6	Initial pursuit acceleration;
PAAD	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.26	0.39	4.9e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.5	-5.61	-0.41	9.22e-8	Obesity-related traits;
PAAD	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19671926	chr4:122722719	EXOSC9	0.51	4.99	0.38	1.64e-6	Type 2 diabetes;
PAAD	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-6.48	-0.46	1.24e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs12541635	0.899	rs1429676	chr8:107065790	G/A	cg10147462	chr8:107024639	NA	-0.44	-4.61	-0.35	8.59e-6	Age of smoking initiation;
PAAD	cis	rs818427	0.826	rs153565	chr5:112250376	A/T	cg07820702	chr5:112228657	REEP5	-0.52	-4.4	-0.34	2.02e-5	Total body bone mineral density;
PAAD	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.44	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.49	-5.69	-0.42	6.32e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.07	0.38	1.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.93e-10	Bipolar disorder;
PAAD	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.66	5.49	0.41	1.63e-7	Schizophrenia;
PAAD	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.08	0.5	5e-11	Lung cancer in ever smokers;
PAAD	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg19217778	chr13:113420270	ATP11A	0.61	4.3	0.33	3.07e-5	Glycated hemoglobin levels;
PAAD	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.43	-5.56	-0.41	1.19e-7	Prostate cancer;
PAAD	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.07	0.59	5.6e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.92	-10.76	-0.66	1.93e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg21300403	chr2:198650112	BOLL	0.49	4.29	0.33	3.22e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg23254163	chr1:152506842	NA	0.57	6.58	0.47	7.34e-10	Hair morphology;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-5.86	-0.43	2.73e-8	Lung cancer;
PAAD	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.94	8.26	0.56	6.68e-14	Bipolar disorder;
PAAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.8	-8.39	-0.56	3.19e-14	DNA methylation (variation);
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.48	5.28	0.39	4.43e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs877529	0.605	rs139394	chr22:39538214	A/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.89	-0.49	1.35e-10	Multiple myeloma;
PAAD	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.34	-0.4	3.34e-7	Daytime sleep phenotypes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21614408	chr6:52228023	PAQR8	0.58	6.89	0.49	1.39e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg08125733	chr17:73851984	WBP2	0.92	8.01	0.54	2.75e-13	Psoriasis;
PAAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-4.76	-0.36	4.47e-6	Height;
PAAD	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.7	7.05	0.5	6e-11	Schizophrenia;
PAAD	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg03037974	chr15:76606532	NA	0.58	6.97	0.49	8.97e-11	Blood metabolite levels;
PAAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg21033440	chr11:65409861	SIPA1	-0.44	-4.96	-0.37	1.86e-6	Blood pressure (age interaction);
PAAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.14	-0.5	3.69e-11	Body mass index;
PAAD	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.51	0.57	1.54e-14	Dupuytren's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03033080	chr12:118454561	RFC5	0.57	6.43	0.46	1.55e-9	Monocyte percentage of white cells;
PAAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.57	0.47	7.75e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg07061783	chr6:25882402	NA	0.51	4.82	0.36	3.39e-6	Blood metabolite levels;
PAAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg20933634	chr6:27740509	NA	0.68	6.53	0.47	9.41e-10	Parkinson's disease;
PAAD	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg04369109	chr6:150039330	LATS1	0.47	4.56	0.35	1.02e-5	Lung cancer;
PAAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.69	0.42	6.43e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08897759	chr5:178415944	GRM6	0.61	6.5	0.47	1.1e-9	Smoking initiation;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.83	10.17	0.64	7.53e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Parkinson's disease;
PAAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.73	-7.44	-0.52	6.74e-12	Neuroticism;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35955747	0.934	rs5997981	chr22:31808827	A/G	cg02404636	chr22:31891804	SFI1	-0.56	-5.49	-0.41	1.64e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg18302933	chr2:88491318	NA	-0.36	-4.27	-0.33	3.44e-5	Response to metformin (IC50);
PAAD	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.26	-0.33	3.55e-5	Blood protein levels;
PAAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Blood metabolite levels;
PAAD	cis	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg14275095	chr12:52828633	KRT75	-0.75	-5.22	-0.39	5.89e-7	Red blood cell count;
PAAD	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg13397359	chr6:42928475	GNMT	-0.6	-4.88	-0.37	2.64e-6	Blood protein levels;
PAAD	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.7	-7.06	-0.5	5.63e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-4.75	-0.36	4.75e-6	QT interval;
PAAD	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.22	-0.45	4.61e-9	Monocyte count;
PAAD	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.46	4.6	0.35	8.95e-6	Metabolite levels;
PAAD	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.39	0.56	3.14e-14	Monocyte percentage of white cells;
PAAD	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg17749961	chr2:30669863	LCLAT1	0.63	4.98	0.37	1.68e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-5.89	-0.43	2.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs77880822	0.562	rs56031085	chr20:1232221	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.62	5.3	0.4	3.95e-7	QRS duration;
PAAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.81	8.51	0.57	1.57e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.57	-5.26	-0.39	4.83e-7	Diisocyanate-induced asthma;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.49	-5.59	-0.41	1.02e-7	Cardiovascular disease risk factors;
PAAD	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.62	6.3	0.46	3.01e-9	Migraine;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.12	-0.38	9.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg01475377	chr6:109611718	NA	-0.56	-6.28	-0.45	3.33e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	6.29	0.45	3.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	trans	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.54	-0.35	1.14e-5	Height;
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.68	7.74	0.53	1.27e-12	Age at first birth;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs4281086	0.603	rs6601475	chr8:10354972	A/G	cg01072821	chr8:10382165	T-SP1	-0.43	-4.65	-0.35	7.13e-6	Obesity-related traits;
PAAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.59	5.56	0.41	1.16e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11378619	chr6:12164359	HIVEP1	-0.64	-6.73	-0.48	3.18e-10	Obesity-related traits;
PAAD	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg26205652	chr12:48591994	NA	0.86	7.78	0.53	1.04e-12	Longevity (90 years and older);
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.78	8.11	0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.72	-7.86	-0.54	6.66e-13	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.79	8.93	0.59	1.27e-15	Lung cancer;
PAAD	cis	rs939584	1.000	rs4854347	chr2:641159	A/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.74	7.56	0.52	3.48e-12	Prostate cancer;
PAAD	cis	rs3760982	0.747	rs62116990	chr19:44301608	G/A	cg12072164	chr19:44306565	LYPD5	-0.47	-5.03	-0.38	1.38e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.75	7.27	0.51	1.72e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.23	-0.45	4.37e-9	Body mass index;
PAAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg09796270	chr17:17721594	SREBF1	0.44	4.68	0.36	6.22e-6	Total body bone mineral density;
PAAD	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg06217245	chr20:33103252	DYNLRB1	0.43	4.85	0.37	3.04e-6	Height;
PAAD	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.66	0.42	7.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs12476592	0.602	rs262484	chr2:63878015	A/G	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.49	-0.61	4.7e-17	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25789201	chr7:72395803	POM121	0.63	7.29	0.51	1.55e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11615916	0.790	rs73135240	chr12:62661522	T/C	cg11441379	chr12:63026424	NA	0.7	4.54	0.35	1.15e-5	Pulmonary function decline;
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg05457628	chr5:178986728	RUFY1	0.48	4.65	0.35	7.14e-6	Lung cancer;
PAAD	cis	rs939584	1.000	rs4613321	chr2:650647	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.59	-4.88	-0.37	2.71e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-1.12	-10.25	-0.64	4.43e-19	Blood trace element (Zn levels);
PAAD	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	cis	rs9517302	0.615	rs4772081	chr13:99100262	T/C	cg22223119	chr13:99095684	FARP1	-0.72	-7.29	-0.51	1.59e-11	Obesity-related traits;
PAAD	cis	rs863345	0.935	rs10797026	chr1:158519710	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs9815354	1.000	rs1717033	chr3:41910216	C/T	cg03022575	chr3:42003672	ULK4	0.84	6.12	0.44	7.66e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg20893579	chr22:38215064	NA	0.53	4.91	0.37	2.34e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg25204440	chr1:209979598	IRF6	0.63	5.28	0.39	4.47e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.76	8.78	0.58	3.12e-15	Total body bone mineral density;
PAAD	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02743256	chr7:2109353	MAD1L1	-0.72	-6.15	-0.45	6.46e-9	Bipolar disorder;
PAAD	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	5.38	0.4	2.83e-7	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.81e-7	Life satisfaction;
PAAD	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg20891558	chr2:74357851	NA	0.96	11.0	0.67	4.56e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-4.96	-0.37	1.84e-6	Systemic lupus erythematosus;
PAAD	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	8.34	0.56	4.18e-14	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.61	0.69	1.04e-22	Menopause (age at onset);
PAAD	cis	rs4867766	0.585	rs10043212	chr5:173949740	C/T	cg20434911	chr5:173954559	NA	0.63	5.65	0.42	7.78e-8	Stroke;
PAAD	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg11657440	chr19:46296263	DMWD	-0.66	-5.75	-0.42	4.79e-8	Coronary artery disease;
PAAD	cis	rs5746492	0.539	rs4819642	chr22:18353910	A/G	cg06148736	chr22:18985691	NA	-0.38	-4.43	-0.34	1.8e-5	Eotaxin levels;
PAAD	cis	rs1419980	0.730	rs11054543	chr12:7726765	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.64	6.85	0.49	1.7e-10	Longevity;
PAAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg03264133	chr6:25882463	NA	0.52	4.45	0.34	1.62e-5	Iron status biomarkers;
PAAD	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.4	-4.4	-0.34	2.05e-5	Mean arterial pressure;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.61	6.87	0.49	1.57e-10	Lymphocyte counts;
PAAD	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.61	5.43	0.4	2.19e-7	White matter hyperintensity burden;
PAAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.62	-0.35	8.08e-6	Alcohol dependence;
PAAD	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.9	-9.63	-0.62	1.96e-17	Blood metabolite levels;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg26060667	chr1:247681242	NA	0.46	5.48	0.41	1.76e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg23920097	chr1:209922102	NA	0.52	4.75	0.36	4.63e-6	Red blood cell count;
PAAD	cis	rs17002988	0.568	rs4156	chr4:79080556	C/T	cg07442568	chr4:78980533	FRAS1	0.53	4.4	0.34	1.99e-5	Uric acid levels;
PAAD	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.56	5.2	0.39	6.33e-7	Primary sclerosing cholangitis;
PAAD	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	1.1	6.68	0.48	4.3e-10	Body mass index;
PAAD	cis	rs939584	1.000	rs7576624	chr2:625029	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg23283495	chr1:209979779	IRF6	0.66	6.43	0.46	1.56e-9	Coronary artery disease;
PAAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.7	5.77	0.42	4.41e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.05	12.05	0.7	6.8e-24	Obesity-related traits;
PAAD	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg02344993	chr17:57696989	CLTC	0.58	5.37	0.4	2.83e-7	Hemoglobin concentration;
PAAD	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.82	-0.36	3.44e-6	Lymphocyte counts;
PAAD	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14169450	chr9:139327907	INPP5E	-0.56	-5.62	-0.41	9.09e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg08601574	chr20:25228251	PYGB	0.65	7.23	0.51	2.17e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2637266	0.765	rs2395391	chr10:78359932	G/A	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.46e-6	Pulmonary function;
PAAD	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.41	-4.68	-0.35	6.44e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.67	-5.75	-0.42	4.76e-8	Cognitive test performance;
PAAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs6537837	0.701	rs2304355	chr1:110155524	T/C	cg05049280	chr1:110155535	GNAT2	0.77	7.25	0.51	2.01e-11	Major depressive disorder;
PAAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg02733842	chr7:1102375	C7orf50	-0.75	-6.0	-0.44	1.39e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg15193198	chr20:60906057	LAMA5	0.53	5.44	0.4	2.11e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.23	18.62	0.83	4.63e-41	IgG glycosylation;
PAAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs62435770	0.615	rs2224645	chr6:169509800	C/T	cg15038512	chr6:170123185	PHF10	0.48	4.38	0.33	2.19e-5	Loneliness;
PAAD	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.51	0.34	1.29e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27426500	chr17:38327194	CASC3	-0.71	-7.16	-0.5	3.3e-11	Obesity-related traits;
PAAD	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg09659197	chr4:152720779	NA	0.46	6.11	0.44	8.11e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg22587600	chr2:46883368	NA	0.33	4.59	0.35	9.39e-6	Height;
PAAD	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg07636037	chr3:49044803	WDR6	-0.56	-4.42	-0.34	1.84e-5	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.75	0.53	1.21e-12	Alzheimer's disease;
PAAD	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.82	9.58	0.61	2.71e-17	Breast cancer;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg07969918	chr22:31682909	PIK3IP1	0.38	4.96	0.37	1.89e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2659067	1.000	rs1654523	chr19:51485194	C/T	cg26241993	chr19:51487245	KLK7	-0.75	-4.84	-0.37	3.19e-6	Blood protein levels;
PAAD	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg23463467	chr20:60627584	TAF4	0.42	4.5	0.34	1.34e-5	Body mass index;
PAAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg18200150	chr17:30822561	MYO1D	0.71	10.46	0.65	1.29e-19	Schizophrenia;
PAAD	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg17178900	chr1:205818956	PM20D1	0.58	4.7	0.36	5.67e-6	Prostate-specific antigen levels;
PAAD	cis	rs10214930	0.813	rs6415252	chr7:27668860	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22117172	chr7:91764530	CYP51A1	0.33	4.38	0.33	2.18e-5	Breast cancer;
PAAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.59	-0.57	9.94e-15	Gut microbiome composition (summer);
PAAD	cis	rs244293	0.672	rs9901526	chr17:53012379	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-4.53	-0.34	1.21e-5	Menarche (age at onset);
PAAD	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.17	-0.5	2.98e-11	Response to antipsychotic treatment;
PAAD	cis	rs7172971	0.688	rs78313382	chr15:42375683	A/C	cg07013680	chr15:42186124	SPTBN5	0.54	4.54	0.35	1.12e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg20243544	chr17:37824526	PNMT	-0.52	-4.56	-0.35	1.06e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3753841	0.832	rs61812153	chr1:103219928	C/T	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg16928487	chr17:17741425	SREBF1	0.35	4.79	0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs12432203	1.000	rs72622429	chr14:51732672	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg03999872	chr20:62272968	STMN3	0.57	5.07	0.38	1.15e-6	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.05e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs902774	1.000	rs17689987	chr12:53275746	T/C	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg18302933	chr2:88491318	NA	-0.42	-4.97	-0.37	1.75e-6	Response to metformin (IC50);
PAAD	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.63	-6.99	-0.49	7.99e-11	Corneal astigmatism;
PAAD	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.45	-4.48	-0.34	1.46e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg24687543	chr11:63912206	MACROD1	0.58	4.65	0.35	7.22e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg10547527	chr2:198650123	BOLL	-0.75	-5.17	-0.39	7.32e-7	Ulcerative colitis;
PAAD	cis	rs1539053	0.899	rs12029004	chr1:58118080	G/A	cg20292791	chr1:58089357	DAB1	-0.52	-4.86	-0.37	2.92e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-4.82	-0.36	3.4e-6	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18888687	chr14:38400115	NA	0.56	6.55	0.47	8.23e-10	Myopia (pathological);
PAAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg08029281	chr1:67600428	NA	0.49	6.08	0.44	9.18e-9	Psoriasis;
PAAD	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-5.25	-0.39	5.06e-7	Personality dimensions;
PAAD	cis	rs6074578	0.740	rs1858598	chr20:147915	C/T	cg16931068	chr20:139680	DEFB127	0.4	5.26	0.39	4.78e-7	Hirschsprung disease;
PAAD	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.03	0.59	7.34e-16	Motion sickness;
PAAD	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg01270228	chr10:1369114	ADARB2	0.56	5.65	0.42	7.64e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs501120	0.925	rs1746050	chr10:44777188	C/A	cg09554077	chr10:44749378	NA	0.47	5.82	0.43	3.38e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09256448	chr16:638327	NA	0.41	4.28	0.33	3.31e-5	Height;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.57	-6.41	-0.46	1.73e-9	Lymphocyte counts;
PAAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg12623918	chr2:306882	NA	0.47	4.97	0.37	1.82e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg04450456	chr4:17643702	FAM184B	0.49	5.22	0.39	5.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23362687	chr7:883564	UNC84A	0.67	7.01	0.49	7.23e-11	Smoking initiation;
PAAD	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg22587600	chr2:46883368	NA	0.36	4.64	0.35	7.32e-6	Height;
PAAD	cis	rs17534004	1.000	rs17534109	chr13:31470937	C/G	cg00570269	chr13:31480942	C13orf33	-0.58	-4.57	-0.35	9.99e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.5	5.27	0.39	4.64e-7	Male-pattern baldness;
PAAD	cis	rs1020064	0.636	rs2576726	chr2:105936412	A/G	cg02543470	chr2:105862877	NA	-0.47	-5.22	-0.39	5.9e-7	AIDS;
PAAD	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	8.0	0.54	3.01e-13	Schizophrenia;
PAAD	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9810890	1.000	rs73196970	chr3:128443193	A/G	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13984492	chr9:104031694	LPPR1	-0.6	-6.37	-0.46	2.08e-9	Obesity-related traits;
PAAD	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg24881330	chr22:46731750	TRMU	1.17	6.43	0.46	1.54e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	1.13	12.39	0.71	8.21e-25	Eosinophil percentage of granulocytes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14300568	chr18:57567149	PMAIP1	-0.59	-6.62	-0.47	5.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.4	10.5	0.65	9.6e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg19429281	chr19:53496738	ZNF702P	-0.58	-6.13	-0.45	7.17e-9	Psoriasis;
PAAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg15691649	chr6:25882328	NA	-0.49	-4.44	-0.34	1.73e-5	Blood metabolite levels;
PAAD	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.49	4.57	0.35	1.01e-5	Red blood cell count;
PAAD	cis	rs705471	0.762	rs7919625	chr10:3669970	A/G	cg14308648	chr10:3568949	NA	0.54	5.53	0.41	1.39e-7	Capecitabine sensitivity;
PAAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19784903	chr17:45786737	TBKBP1	0.53	5.65	0.42	7.82e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.74	7.02	0.49	6.88e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg10729496	chr3:10149963	C3orf24	0.88	7.31	0.51	1.42e-11	Alzheimer's disease;
PAAD	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.64	-0.35	7.33e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.61	5.97	0.44	1.64e-8	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs10214930	0.697	rs6462034	chr7:27628584	T/A	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg04315214	chr1:2043799	PRKCZ	-0.47	-5.67	-0.42	7.11e-8	Coronary artery disease;
PAAD	cis	rs10274279	1.000	rs6459798	chr7:157381735	C/T	cg26886268	chr7:157387156	PTPRN2	-0.78	-6.02	-0.44	1.23e-8	Myopia (pathological);
PAAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.62	-6.64	-0.47	5.16e-10	Height;
PAAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-15.33	-0.78	1.14e-32	Height;
PAAD	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2217332	1.000	rs247607	chr16:56963322	C/T	cg05686118	chr16:57610170	GPR114	-0.61	-4.38	-0.33	2.2e-5	Metabolic syndrome;
PAAD	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.44	-4.51	-0.34	1.28e-5	Response to statin therapy;
PAAD	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.56	-5.31	-0.4	3.79e-7	Retinal vascular caliber;
PAAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.06	-0.38	1.2e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.45	-5.93	-0.43	2e-8	Myeloid white cell count;
PAAD	cis	rs859767	0.501	rs4954160	chr2:135431692	A/C	cg12500956	chr2:135428796	TMEM163	-0.32	-4.66	-0.35	6.75e-6	Neuroticism;
PAAD	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.57	-4.37	-0.33	2.29e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.36	0.4	3.04e-7	Monocyte percentage of white cells;
PAAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.62	-4.96	-0.37	1.88e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg21269045	chr12:125625041	AACS	-0.43	-4.25	-0.33	3.66e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03532422	chr3:47844653	DHX30	0.61	6.99	0.49	8.33e-11	Monocyte percentage of white cells;
PAAD	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.41e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18706228	chr17:45094513	NA	0.66	7.65	0.53	2.11e-12	Smoking initiation;
PAAD	cis	rs75757892	0.621	rs77690503	chr6:7285545	C/G	cg02954307	chr6:7269328	NA	0.6	4.65	0.35	7.11e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	6.12	0.44	7.59e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg14219918	chr9:127249562	NR5A1	-0.35	-4.62	-0.35	8.19e-6	Menarche (age at onset);
PAAD	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg19827787	chr1:23763612	ASAP3	0.56	4.6	0.35	8.88e-6	Total cholesterol levels;
PAAD	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.08	0.38	1.11e-6	Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12992689	chr12:121015354	RNF10	-0.64	-6.51	-0.47	1.01e-9	Obesity-related traits;
PAAD	trans	rs901683	0.850	rs113588255	chr10:46067333	C/G	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs58521262	0.556	rs289299	chr19:23175751	A/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs6028335	0.610	rs73108583	chr20:37527939	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.64	-4.86	-0.37	2.93e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg14092988	chr3:52407081	DNAH1	0.45	5.71	0.42	5.85e-8	Bipolar disorder;
PAAD	cis	rs1692120	0.669	rs10897172	chr11:61427469	G/A	cg23038520	chr11:61406508	RPLP0P2	0.52	5.86	0.43	2.72e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg13444538	chr7:158905317	VIPR2	0.52	4.81	0.36	3.66e-6	Facial morphology (factor 20);
PAAD	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg03538708	chr1:25844672	NA	-0.49	-5.02	-0.38	1.45e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs12935418	0.672	rs9923948	chr16:81047419	A/G	cg16651780	chr16:81037892	C16orf61	0.66	6.17	0.45	5.96e-9	Mean corpuscular volume;
PAAD	cis	rs9535307	0.929	rs1547623	chr13:50348187	G/A	cg04663916	chr13:50265991	EBPL	0.59	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.33	-0.46	2.65e-9	Hip circumference;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18447950	chr17:79073781	BAIAP2	0.55	6.78	0.48	2.48e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12432203	0.748	rs61987306	chr14:51750167	G/A	cg23942311	chr14:51606299	NA	-0.78	-4.45	-0.34	1.65e-5	Cancer;
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg15729578	chr3:195576390	NA	-0.42	-4.26	-0.33	3.55e-5	Pancreatic cancer;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg04352962	chr1:209979756	IRF6	0.53	4.73	0.36	5.03e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.85	-9.92	-0.63	3.32e-18	Tuberculosis;
PAAD	cis	rs375066	0.935	rs11673020	chr19:44374631	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.67	0.48	4.36e-10	Breast cancer;
PAAD	cis	rs2506028	1.000	rs788260	chr10:43438490	G/A	cg20628663	chr10:43360327	NA	-0.37	-4.44	-0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg02228675	chr17:40259724	DHX58	-0.44	-5.05	-0.38	1.27e-6	Fibrinogen levels;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.65	5.46	0.4	1.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.37	7.3	0.51	1.47e-11	Skin colour saturation;
PAAD	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg04254540	chr16:71951199	KIAA0174	-0.52	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs501120	1.000	rs620356	chr10:44761073	A/C	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.36	-0.46	2.29e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg12373951	chr3:133503437	NA	0.39	4.83	0.36	3.3e-6	Ankle injury;
PAAD	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg14631576	chr9:95140430	CENPP	-0.56	-5.54	-0.41	1.33e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.67	-4.37	-0.33	2.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg01585852	chr22:24235823	MIF	-0.46	-4.77	-0.36	4.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20419410	chr7:155089803	INSIG1	0.65	7.42	0.52	7.86e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.74	-5.83	-0.43	3.27e-8	Orofacial clefts;
PAAD	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.48	5.03	0.38	1.38e-6	Mean corpuscular volume;
PAAD	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg15660573	chr17:549704	VPS53	-0.76	-7.67	-0.53	1.94e-12	Prostate cancer;
PAAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg07153921	chr17:41440717	NA	-0.4	-4.31	-0.33	2.98e-5	Menopause (age at onset);
PAAD	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg00101154	chr16:420108	MRPL28	-0.71	-6.76	-0.48	2.82e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg12143784	chr7:64541923	NA	-0.39	-4.96	-0.37	1.9e-6	Calcium levels;
PAAD	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.58	6.53	0.47	9.53e-10	Testicular germ cell tumor;
PAAD	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.61	-5.54	-0.41	1.3e-7	Total body bone mineral density;
PAAD	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg09242541	chr1:10490025	APITD1	0.44	5.55	0.41	1.24e-7	Prostate cancer;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs714515	0.586	rs4916265	chr1:172450774	A/G	cg13446689	chr1:172328377	DNM3	0.44	5.36	0.4	3.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs6540	0.793	rs523040	chr11:256161	T/C	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Electroencephalogram traits;
PAAD	cis	rs16975963	0.843	rs73029180	chr19:38420406	C/T	cg25793785	chr19:38281423	NA	0.57	4.66	0.35	6.88e-6	Longevity;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.52	-5.48	-0.41	1.71e-7	Life satisfaction;
PAAD	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	1.03	13.0	0.73	1.89e-26	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.76	-6.04	-0.44	1.12e-8	Initial pursuit acceleration;
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg22442454	chr1:209979470	IRF6	-0.51	-4.52	-0.34	1.25e-5	Coronary artery disease;
PAAD	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.57	6.3	0.46	3.08e-9	Diastolic blood pressure;
PAAD	cis	rs7816613	0.764	rs10099482	chr8:102690192	G/A	cg20585841	chr8:102729926	NCALD	-0.57	-4.81	-0.36	3.65e-6	Age-related hearing impairment;
PAAD	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs72960926	0.661	rs62437458	chr6:75242852	T/C	cg03266952	chr6:74778945	NA	-1.16	-5.12	-0.38	8.92e-7	Metabolite levels (MHPG);
PAAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.46	-0.4	1.94e-7	Personality dimensions;
PAAD	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg19423196	chr10:82049429	MAT1A	0.49	5.07	0.38	1.12e-6	Borderline personality disorder;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.76e-5	Cognitive function;
PAAD	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg17326555	chr1:119535693	NA	-0.39	-4.59	-0.35	9.28e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg14146966	chr2:61757674	XPO1	0.42	5.13	0.38	8.55e-7	Tuberculosis;
PAAD	cis	rs300774	0.925	rs437409	chr2:142137	G/A	cg23649280	chr2:140451	NA	-0.46	-4.36	-0.33	2.37e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.59	-6.55	-0.47	8.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.85	6.46	0.46	1.37e-9	Axial length;
PAAD	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	-0.41	-4.38	-0.33	2.24e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	4.77	0.36	4.34e-6	Bone mineral density;
PAAD	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.5	4.62	0.35	7.98e-6	Breast cancer;
PAAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg13444538	chr7:158905317	VIPR2	-0.59	-4.68	-0.35	6.26e-6	Facial morphology (factor 20);
PAAD	cis	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg21546286	chr11:48923668	NA	-0.44	-4.56	-0.35	1.05e-5	HDL cholesterol;
PAAD	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg18769074	chr3:133464867	TF	-0.42	-4.79	-0.36	3.94e-6	Iron status biomarkers;
PAAD	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.57	-6.24	-0.45	4.22e-9	Eye color traits;
PAAD	cis	rs11871801	0.918	rs34527783	chr17:40568094	A/G	cg21692620	chr17:40835849	CNTNAP1	-0.49	-4.87	-0.37	2.83e-6	Crohn's disease;
PAAD	cis	rs6025261	0.761	rs6099360	chr20:55511902	C/T	cg04763273	chr20:55502381	NA	-0.47	-5.36	-0.4	3.02e-7	Verbal memory performance (delayed recall level);
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg15193198	chr20:60906057	LAMA5	0.47	4.64	0.35	7.45e-6	Colorectal cancer;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-7.26	-0.51	1.86e-11	Menarche (age at onset);
PAAD	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.68	-6.52	-0.47	9.73e-10	Plateletcrit;Platelet count;
PAAD	cis	rs12760731	0.641	rs11590951	chr1:178322757	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	7.07	0.5	5.16e-11	Coronary artery disease;
PAAD	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg26750617	chr12:132293702	NA	0.5	5.48	0.41	1.74e-7	Migraine;
PAAD	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs6694672	0.867	rs10737687	chr1:197108693	C/T	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg27394845	chr17:28928406	LRRC37B2	0.63	4.46	0.34	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs593531	0.513	rs7947911	chr11:74023751	G/A	cg23327896	chr11:73669290	DNAJB13	0.33	4.44	0.34	1.75e-5	Neuroticism;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.11	0.44	7.89e-9	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21014972	chr2:241380248	GPC1	-0.63	-6.66	-0.48	4.78e-10	Obesity-related traits;
PAAD	cis	rs2236267	0.693	rs6574993	chr14:88606993	G/A	cg18078958	chr14:88630771	NA	-0.51	-6.59	-0.47	6.64e-10	Food antigen IgG levels;
PAAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.65	-0.35	7.14e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.86	6.5	0.47	1.07e-9	Prostate cancer;
PAAD	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg02493740	chr2:85810744	VAMP5	-0.42	-4.73	-0.36	5.15e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1656368	0.690	rs73154314	chr3:158225517	A/C	cg16708174	chr3:158430962	RARRES1	0.59	5.34	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16958440	0.581	rs11082564	chr18:44659149	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-5.13	-0.38	8.54e-7	Sitting height ratio;
PAAD	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg27246729	chr12:121163418	ACADS	0.43	4.38	0.33	2.18e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14882291	chr10:92663320	RPP30	-0.52	-6.29	-0.45	3.13e-9	Energy expenditure (24h);
PAAD	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.47	-4.68	-0.36	6.22e-6	Schizophrenia;
PAAD	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.54	5.24	0.39	5.17e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16288579	chr7:5643055	FSCN1	0.59	6.68	0.48	4.34e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg07969918	chr22:31682909	PIK3IP1	0.34	4.45	0.34	1.67e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.54	6.45	0.46	1.38e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.56	6.58	0.47	7.05e-10	Multiple sclerosis;
PAAD	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.73	6.44	0.46	1.52e-9	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs9422658	chr10:46059667	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62238980	0.808	rs78293816	chr22:32598529	C/T	cg02631450	chr22:32366979	NA	1.0	4.67	0.35	6.71e-6	Childhood ear infection;
PAAD	cis	rs151997	0.629	rs27288	chr5:50194920	T/A	cg06027927	chr5:50259733	NA	0.66	6.62	0.47	5.8e-10	Callous-unemotional behaviour;
PAAD	cis	rs59104589	0.617	rs56663202	chr2:242262311	A/G	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	trans	rs11794666	0.872	rs11790798	chr9:31714403	A/G	cg05628366	chr6:35744188	C6orf126	0.93	6.51	0.47	1.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.55	-0.35	1.08e-5	Height;
PAAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.3e-19	Bone mineral density;
PAAD	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg08244522	chr20:23030533	THBD	-0.58	-6.51	-0.47	1.03e-9	Coronary artery disease;
PAAD	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg23024343	chr7:107201750	COG5	0.57	4.62	0.35	8e-6	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12946690	chr17:2206740	SMG6;SRR	0.58	6.83	0.48	1.88e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.83	6.38	0.46	2.02e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.61	5.92	0.43	2.05e-8	Subjective well-being;
PAAD	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.55	5.1	0.38	9.98e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg07636037	chr3:49044803	WDR6	0.56	4.39	0.34	2.1e-5	Menarche (age at onset);
PAAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg00206168	chr11:65308501	LTBP3	0.54	5.52	0.41	1.43e-7	Bone mineral density;
PAAD	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg01426195	chr3:39028469	NA	0.63	6.25	0.45	3.97e-9	Handedness;
PAAD	cis	rs6604026	0.656	rs12074608	chr1:93411781	T/C	cg17283838	chr1:93427260	FAM69A	0.61	5.69	0.42	6.39e-8	Multiple sclerosis;
PAAD	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.68	7.4	0.51	8.42e-12	Longevity;
PAAD	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06530742	chr19:41223047	ITPKC;ADCK4	-0.59	-6.9	-0.49	1.3100000000000001e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15435718	chr19:36132263	ETV2	-0.73	-7.51	-0.52	4.63e-12	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	4.94	0.37	2.07e-6	Lung cancer in ever smokers;
PAAD	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg10587741	chr22:38071170	LGALS1	0.42	4.57	0.35	9.84e-6	Fat distribution (HIV);
PAAD	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	5.96	0.44	1.67e-8	Body mass index;
PAAD	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.5	5.06	0.38	1.21e-6	Menopause (age at onset);
PAAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.44	-4.34	-0.33	2.56e-5	Tonsillectomy;
PAAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.36	-0.46	2.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg09112717	chr4:100009950	ADH5	0.42	4.26	0.33	3.51e-5	Alcohol dependence;
PAAD	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg20283391	chr11:68216788	NA	-0.52	-4.87	-0.37	2.79e-6	Total body bone mineral density;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.72	-7.2	-0.5	2.58e-11	Height;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg23298862	chr7:158159286	PTPRN2	0.57	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08439880	chr3:133502540	NA	-0.5	-5.36	-0.4	3.02e-7	Iron status biomarkers;
PAAD	cis	rs7818688	0.697	rs11776186	chr8:95971968	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.71e-15	Dupuytren's disease;
PAAD	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00152838	chr16:24741724	TNRC6A	0.53	4.46	0.34	1.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7714584	1.000	rs73282234	chr5:150195924	G/C	cg22134413	chr5:150180641	NA	0.91	6.48	0.47	1.18e-9	Crohn's disease;
PAAD	trans	rs61931739	0.577	rs78671000	chr12:33648835	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.47	-0.46	1.3e-9	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.47	6.18	0.45	5.53e-9	Ulcerative colitis;
PAAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.87	-8.82	-0.58	2.47e-15	DNA methylation (variation);
PAAD	cis	rs7631605	0.837	rs6796640	chr3:37213274	C/A	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9503598	0.644	rs10498663	chr6:3430439	C/T	cg00476032	chr6:3446245	SLC22A23	-0.49	-5.51	-0.41	1.53e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.73	-0.42	5.24e-8	Longevity;Endometriosis;
PAAD	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.75	4.87	0.37	2.77e-6	Lung cancer in ever smokers;
PAAD	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.83	-9.84	-0.62	5.57e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-4.39	-0.34	2.14e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg04450456	chr4:17643702	FAM184B	0.46	4.85	0.37	3.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00488691	chr2:25016078	CENPO;C2orf79	-0.74	-7.72	-0.53	1.48e-12	Smoking initiation;
PAAD	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	10.12	0.63	1.02e-18	Colorectal cancer;
PAAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg21300403	chr2:198650112	BOLL	-0.62	-4.32	-0.33	2.85e-5	Ulcerative colitis;
PAAD	cis	rs4660214	0.671	rs16826012	chr1:39719519	C/T	cg14018543	chr1:39659967	MACF1	0.56	4.46	0.34	1.61e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg07159951	chr1:45983175	PRDX1	0.44	4.93	0.37	2.11e-6	High light scatter reticulocyte count;
PAAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg11211951	chr8:145729740	GPT	-0.47	-5.06	-0.38	1.22e-6	Age at first birth;
PAAD	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.73	-0.36	5.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs931127	0.554	rs3372	chr11:65485218	C/T	cg02059970	chr11:65402908	PCNXL3	-0.44	-4.54	-0.35	1.15e-5	Systemic lupus erythematosus;
PAAD	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg10820045	chr2:198174542	NA	0.45	4.4	0.34	1.99e-5	Dermatomyositis;
PAAD	cis	rs6681460	1.000	rs2031478	chr1:67123742	C/A	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.85e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.71	8.49	0.57	1.75e-14	Hand grip strength;
PAAD	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg12046867	chr14:103022105	NA	-0.74	-5.48	-0.41	1.71e-7	Platelet count;
PAAD	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg16205897	chr5:131564050	P4HA2	-0.42	-4.55	-0.35	1.08e-5	Breast cancer;
PAAD	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.89	7.14	0.5	3.57e-11	Axial length;
PAAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg02117656	chr17:79614917	TSPAN10	0.54	5.46	0.41	1.88e-7	Eye color traits;
PAAD	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-7.72	-0.53	1.47e-12	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.84	8.91	0.59	1.45e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1925576	0.838	rs6480232	chr10:68636309	A/C	cg04444303	chr10:69634106	NA	-0.42	-4.26	-0.33	3.58e-5	Educational attainment (years of education);
PAAD	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.76	-7.01	-0.49	7.36e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.93	12.73	0.72	9.69e-26	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg05791153	chr7:19748676	TWISTNB	0.61	5.01	0.38	1.49e-6	Thyroid stimulating hormone;
PAAD	cis	rs17023223	0.537	rs2361270	chr1:119603322	T/C	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9650657	0.707	rs1115867	chr8:10638750	T/A	cg13293535	chr8:11597251	GATA4	0.35	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.53	5.32	0.4	3.6e-7	Platelet count;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.98	-10.02	-0.63	1.81e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.96	5.98	0.44	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg17644776	chr2:200775616	C2orf69	-0.64	-5.02	-0.38	1.42e-6	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	6.87	0.49	1.53e-10	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.79	0.36	3.94e-6	Lung cancer in ever smokers;
PAAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	5.51	0.41	1.47e-7	Coronary artery disease;
PAAD	cis	rs112990264	0.892	rs114203803	chr1:212893344	A/G	cg01785514	chr1:212988523	TATDN3	1.22	8.02	0.55	2.63e-13	Itch intensity from mosquito bite;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.99	0.54	3.19e-13	Prudent dietary pattern;
PAAD	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	11.44	0.68	2.9e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg15660573	chr17:549704	VPS53	-0.75	-7.68	-0.53	1.8e-12	Prostate cancer;
PAAD	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.55	5.25	0.39	5.13e-7	Red blood cell count;
PAAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg20503657	chr10:835505	NA	-0.66	-5.85	-0.43	2.85e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Electroencephalogram traits;
PAAD	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg01324507	chr7:1177794	C7orf50	0.57	4.53	0.35	1.18e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg10006428	chr1:248814059	OR2T27	0.4	4.72	0.36	5.21e-6	Common traits (Other);
PAAD	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg21452805	chr1:244014465	NA	0.47	4.36	0.33	2.4e-5	RR interval (heart rate);
PAAD	cis	rs78761021	0.514	rs4791906	chr17:9795452	A/G	cg26853458	chr17:9805074	RCVRN	-0.58	-7.34	-0.51	1.2e-11	Type 2 diabetes;
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.32	-0.33	2.75e-5	Eotaxin levels;
PAAD	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.46	4.3	0.33	3.07e-5	Endometrial cancer;
PAAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.73	8.61	0.57	8.4e-15	Emphysema distribution in smoking;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.31	0.6	1.33e-16	Prudent dietary pattern;
PAAD	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.59	-0.47	6.77e-10	Aortic root size;
PAAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	cis	rs288326	0.561	rs17265859	chr2:183724612	A/T	cg09997497	chr2:183902928	NCKAP1	0.85	4.8	0.36	3.73e-6	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04842215	chr14:24899033	CBLN3;KHNYN	0.63	7.12	0.5	3.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.53	5.58	0.41	1.09e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.55	5.49	0.41	1.68e-7	Homocysteine levels;
PAAD	cis	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg21546286	chr11:48923668	NA	0.55	5.79	0.43	3.86e-8	HDL cholesterol;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg04520793	chr17:42248056	ASB16	0.42	4.67	0.35	6.45e-6	Total body bone mineral density;
PAAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg14393609	chr7:65229607	NA	0.48	4.9	0.37	2.44e-6	Aortic root size;
PAAD	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.79	7.83	0.54	7.63e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.72	-9.02	-0.59	7.87e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.52	-8.22	-0.55	8.53e-14	Urinary metabolites;
PAAD	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.88	-10.85	-0.66	1.15e-20	Heart rate;
PAAD	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.85	10.62	0.65	4.71e-20	Mean corpuscular volume;
PAAD	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.85	-9.41	-0.61	7.66e-17	Type 2 diabetes;
PAAD	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08109568	chr15:31115862	NA	-0.67	-7.08	-0.5	4.86e-11	Huntington's disease progression;
PAAD	cis	rs11105468	0.701	rs11105483	chr12:90399351	C/T	cg16962463	chr12:89968675	NA	0.48	4.57	0.35	1.02e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	8.84	0.58	2.18e-15	IgG glycosylation;
PAAD	cis	rs116175783	0.557	rs10490567	chr2:162173778	T/C	cg08807892	chr2:162101083	NA	-0.67	-4.93	-0.37	2.13e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.83	-9.53	-0.61	3.64e-17	Height;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	2.99e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13821490	chr7:100798061	AP1S1	0.66	7.26	0.51	1.89e-11	Myopia (pathological);
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.94e-6	Breast cancer;
PAAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.82	-9.34	-0.6	1.15e-16	Lung cancer;
PAAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs3112530	1.000	rs2964820	chr5:152715435	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg14683738	chr19:37701593	ZNF585B	0.63	4.48	0.34	1.44e-5	Coronary artery calcification;
PAAD	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-8.08	-0.55	1.87e-13	Coronary artery disease;
PAAD	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg24747557	chr10:131355152	MGMT	-0.44	-4.5	-0.34	1.36e-5	Response to temozolomide;
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg12143784	chr7:64541923	NA	-0.33	-4.26	-0.33	3.55e-5	Aortic root size;
PAAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.81	5.89	0.43	2.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.55	6.64	0.47	5.12e-10	Lung cancer;
PAAD	cis	rs11807834	0.505	rs7530960	chr1:230234084	C/T	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.49e-13	Schizophrenia;
PAAD	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.88	-6.75	-0.48	2.92e-10	Axial length;
PAAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2637266	0.783	rs2588334	chr10:78518504	C/T	cg18941641	chr10:78392320	NA	0.37	4.48	0.34	1.45e-5	Pulmonary function;
PAAD	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.76	6.34	0.46	2.45e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.34	4.6	0.35	8.66e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.7	5.92	0.43	2.05e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7608623	1.000	rs918814	chr2:23948466	A/C	cg08917208	chr2:24149416	ATAD2B	-0.44	-4.34	-0.33	2.63e-5	Obesity-related traits;
PAAD	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg26904215	chr21:47823096	PCNT	0.79	4.29	0.33	3.13e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs8112211	0.554	rs7256575	chr19:38840805	C/T	cg14299480	chr19:38876666	GGN	-0.7	-5.92	-0.43	2.1e-8	Blood protein levels;
PAAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg27494647	chr7:150038898	RARRES2	0.45	4.91	0.37	2.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg27478167	chr7:817139	HEATR2	-0.64	-4.97	-0.37	1.79e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.63	-5.96	-0.44	1.66e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.48	-4.37	-0.33	2.31e-5	Tuberculosis;
PAAD	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.62	0.35	7.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	1.06	14.85	0.77	2.22e-31	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.47	-5.11	-0.38	9.52e-7	Educational attainment;
PAAD	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg15841412	chr13:111365552	ING1	0.52	4.32	0.33	2.76e-5	Coronary artery disease;
PAAD	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.29	-0.51	1.56e-11	Blood metabolite levels;
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.14	-0.6	3.79e-16	Mean platelet volume;
PAAD	cis	rs73416724	0.544	rs45564136	chr6:43251880	C/G	cg00507679	chr6:43251876	TTBK1	0.68	5.27	0.39	4.59e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28655083	0.550	rs598340	chr16:77102504	A/G	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg16419906	chr5:132167176	NA	-0.66	-5.23	-0.39	5.6e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg22153407	chr1:230290089	GALNT2	0.5	5.2	0.39	6.47e-7	Coronary artery disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21395723	chr22:39101663	GTPBP1	-0.66	-6.58	-0.47	7.08e-10	Lung cancer in ever smokers;
PAAD	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg16386425	chr10:429943	DIP2C	-0.45	-4.66	-0.35	6.75e-6	Psychosis in Alzheimer's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23101091	chr17:38296248	CASC3	0.6	6.94	0.49	1.05e-10	Metabolite levels  (X-11787);
PAAD	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.69	-0.36	6.13e-6	Type 1 diabetes;
PAAD	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.59	-0.35	9.4e-6	Resting heart rate;
PAAD	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs7598759	0.679	rs10202701	chr2:232328681	C/T	cg19187155	chr2:232395269	NMUR1	-0.52	-5.57	-0.41	1.13e-7	Noise-induced hearing loss;
PAAD	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.8	9.56	0.61	3.06e-17	White blood cell count (basophil);
PAAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.15	0.39	8.04e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.53	-4.73	-0.36	5.18e-6	Mean corpuscular volume;
PAAD	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg00531865	chr16:30841666	NA	-0.52	-4.94	-0.37	2.07e-6	Dementia with Lewy bodies;
PAAD	cis	rs2692947	0.628	rs1997257	chr2:96429625	A/G	cg22654517	chr2:96458247	NA	0.38	4.47	0.34	1.51e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02071572	chr4:1403502	NA	0.5	6.43	0.46	1.57e-9	Longevity;
PAAD	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.56	6.36	0.46	2.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg22875332	chr1:76189707	ACADM	-0.46	-4.68	-0.35	6.3e-6	Daytime sleep phenotypes;
PAAD	cis	rs12431939	0.571	rs12589840	chr14:51720038	A/G	cg23942311	chr14:51606299	NA	0.53	4.69	0.36	6.15e-6	Cancer;
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.06	0.44	1.04e-8	Lung cancer;
PAAD	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg05150608	chr14:102990211	NA	0.39	4.58	0.35	9.42e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22084460	chr19:13348050	CACNA1A	-0.68	-7.08	-0.5	4.99e-11	Obesity-related traits;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg00049323	chr5:472564	LOC25845	-0.46	-4.74	-0.36	4.93e-6	Cystic fibrosis severity;
PAAD	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.66	-6.06	-0.44	1.02e-8	Crohn's disease;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.52	5.52	0.41	1.45e-7	Longevity;Endometriosis;
PAAD	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24155025	chr17:78803179	RPTOR	-0.72	-7.69	-0.53	1.67e-12	Obesity-related traits;
PAAD	cis	rs89107	0.688	rs283086	chr6:118596941	C/T	cg18833306	chr6:118973337	C6orf204	0.49	5.75	0.42	4.8e-8	Cardiac structure and function;
PAAD	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.56	7.36	0.51	1.08e-11	Ewing sarcoma;
PAAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.3e-22	Coronary artery disease;
PAAD	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-4.48	-0.34	1.45e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.72	-5.38	-0.4	2.83e-7	Initial pursuit acceleration;
PAAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-7.67	-0.53	1.91e-12	Coffee consumption (cups per day);
PAAD	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.26e-5	Total body bone mineral density;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	8.63	0.57	7.51e-15	Longevity;
PAAD	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.65	-5.17	-0.39	7.34e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01297674	chr2:122406765	CLASP1	0.61	6.85	0.49	1.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6604026	0.630	rs2391177	chr1:93353943	G/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.72	-10.09	-0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.89	10.85	0.66	1.16e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.08	0.44	9.51e-9	Colorectal cancer;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg09835421	chr16:68378352	PRMT7	-1.04	-7.81	-0.53	8.83e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.97	13.32	0.73	2.67e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs4739066	0.579	rs12541047	chr8:63879476	T/G	cg12194929	chr8:63776755	NKAIN3	0.73	4.54	0.35	1.13e-5	Myocardial infarction;
PAAD	cis	rs11264213	1.000	rs11264213	chr1:36283954	A/G	cg27506609	chr1:36549197	TEKT2	0.71	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.54	5.66	0.42	7.5e-8	Red blood cell count;
PAAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3126085	0.515	rs2275264	chr1:152331533	T/G	cg26876637	chr1:152193138	HRNR	-0.72	-5.36	-0.4	3.06e-7	Atopic dermatitis;
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-7.78	-0.53	1.02e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.37	-0.4	2.88e-7	Bladder cancer;
PAAD	cis	rs10214930	0.706	rs4722726	chr7:27694208	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.41	0.34	1.92e-5	Hypospadias;
PAAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.7	7.75	0.53	1.21e-12	Melanoma;
PAAD	cis	rs3136441	0.681	rs4752927	chr11:46702160	C/T	cg19486271	chr11:47235900	DDB2	0.62	4.25	0.33	3.69e-5	HDL cholesterol;
PAAD	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.61	4.64	0.35	7.52e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg26174226	chr8:58114915	NA	-0.56	-4.41	-0.34	1.97e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119038	0.818	rs2155433	chr11:118612921	G/A	cg19308663	chr11:118741387	NA	0.54	4.52	0.34	1.25e-5	Sjögren's syndrome;
PAAD	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.58	-0.35	9.42e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg21929781	chr1:2537748	MMEL1	-0.49	-5.11	-0.38	9.57e-7	Ulcerative colitis;
PAAD	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.67	-6.6	-0.47	6.57e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.59	6.91	0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06028605	chr16:24865363	SLC5A11	0.47	5.69	0.42	6.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.63	4.52	0.34	1.23e-5	Obesity-related traits;
PAAD	cis	rs7583236	0.500	rs7565597	chr2:70336070	T/G	cg19638749	chr2:70312615	NA	1.03	7.48	0.52	5.66e-12	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs71496620	chr10:46074329	G/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs8112211	1.000	rs7253960	chr19:38814725	C/T	cg14299480	chr19:38876666	GGN	-0.56	-7.13	-0.5	3.85e-11	Blood protein levels;
PAAD	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg14343924	chr8:8086146	FLJ10661	0.51	4.71	0.36	5.57e-6	Mood instability;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.45	4.29	0.33	3.16e-5	Mean corpuscular volume;
PAAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.8e-13	Blood protein levels;
PAAD	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.59	-4.32	-0.33	2.78e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg16988970	chr17:42248062	ASB16	0.37	5.27	0.39	4.53e-7	Total body bone mineral density;
PAAD	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.37	-0.4	2.87e-7	Pulmonary function;
PAAD	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26306683	chr17:18585705	ZNF286B	0.58	5.85	0.43	2.88e-8	Educational attainment (years of education);
PAAD	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg11367502	chr7:22862612	TOMM7	0.52	5.13	0.38	8.9e-7	Fibrinogen;
PAAD	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.57	-5.65	-0.42	7.61e-8	Height;
PAAD	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	Cognitive function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02643184	chr17:882549	NXN	-0.54	-6.45	-0.46	1.42e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9880772	0.747	rs7621606	chr3:27819783	C/T	cg21473142	chr3:27762095	EOMES	-0.33	-5.81	-0.43	3.61e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs332507	0.830	rs3821532	chr3:124402618	G/T	cg05980111	chr3:124395277	KALRN	0.43	4.34	0.33	2.61e-5	Plateletcrit;
PAAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.76	0.66	1.98e-20	Menopause (age at onset);
PAAD	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.57	5.04	0.38	1.31e-6	Life satisfaction;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.33	0.56	4.42e-14	Lung cancer;
PAAD	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg17650747	chr5:1873721	NA	0.44	4.51	0.34	1.27e-5	Cardiovascular disease risk factors;
PAAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-5.41	-0.4	2.44e-7	Monocyte count;
PAAD	cis	rs2790216	1.000	rs2993834	chr10:59971616	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.67	-8.45	-0.57	2.16e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-6.63	-0.47	5.44e-10	Morning vs. evening chronotype;
PAAD	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg23188684	chr11:67383651	NA	-0.42	-4.31	-0.33	2.95e-5	Mean corpuscular volume;
PAAD	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.76	7.5	0.52	4.96e-12	Schizophrenia;
PAAD	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg11900509	chr10:81946545	ANXA11	-0.76	-4.28	-0.33	3.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg14146966	chr2:61757674	XPO1	-0.35	-4.51	-0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.81	10.19	0.64	6.41e-19	N-glycan levels;
PAAD	cis	rs1572438	0.929	rs9378520	chr6:861685	C/T	cg13447295	chr6:887704	NA	-0.55	-5.01	-0.38	1.53e-6	Aging;
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.6	10.06	0.63	1.43e-18	IgG glycosylation;
PAAD	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.54	4.48	0.34	1.46e-5	Mean platelet volume;
PAAD	cis	rs11671653	1.000	rs7257661	chr19:10833132	C/G	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.69	-6.93	-0.49	1.14e-10	Retinal vascular caliber;
PAAD	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	6.1	0.44	8.6e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7714584	1.000	rs11740172	chr5:150300278	A/G	cg22134413	chr5:150180641	NA	0.98	6.63	0.47	5.43e-10	Crohn's disease;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	4.75	0.36	4.63e-6	Bipolar disorder;
PAAD	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs28489187	0.706	rs173026	chr1:85804249	G/A	cg16011679	chr1:85725395	C1orf52	0.53	4.97	0.37	1.75e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.63	-8.0	-0.54	2.98e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs73206853	0.841	rs3026486	chr12:110782532	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.49	4.27	0.33	3.37e-5	Lymphocyte counts;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg10862848	chr6:42927986	GNMT	-0.5	-7.88	-0.54	5.76e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.34	16.32	0.8	3.13e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	5.19	0.39	6.73e-7	Prudent dietary pattern;
PAAD	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	5.34	0.4	3.32e-7	Depressive symptoms;
PAAD	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.52	-5.66	-0.42	7.27e-8	Migraine;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03655662	chr1:202977077	TMEM183A;TMEM183B	0.57	6.71	0.48	3.68e-10	Monocyte percentage of white cells;
PAAD	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg11439826	chr17:76250004	NA	0.45	4.55	0.35	1.11e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.51	-4.69	-0.36	6.15e-6	Blood metabolite levels;
PAAD	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg21775007	chr8:11205619	TDH	-0.52	-4.69	-0.36	6.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs9826463	0.757	rs75100831	chr3:142244647	T/C	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg12658694	chr1:38397304	INPP5B	0.47	4.36	0.33	2.35e-5	Hypothyroidism;
PAAD	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.99e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.42	0.4	2.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.57	6.64	0.47	5.29e-10	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26856494	chr15:27300396	GABRG3	-0.67	-7.49	-0.52	5.09e-12	Obesity-related traits;
PAAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.73	7.49	0.52	5.36e-12	Schizophrenia;
PAAD	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg26384229	chr12:38710491	ALG10B	0.7	7.11	0.5	4.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	5.73	0.42	5.18e-8	Renal function-related traits (BUN);
PAAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.48	5.83	0.43	3.17e-8	Vitiligo;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	0.63	7.15	0.5	3.42e-11	Response to antipsychotic treatment;
PAAD	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg01270228	chr10:1369114	ADARB2	0.56	5.62	0.41	9e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.38	-0.33	2.21e-5	Plateletcrit;Platelet count;
PAAD	cis	rs17155006	0.664	rs401487	chr7:107743409	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-7.09	-0.5	4.6e-11	Pneumococcal bacteremia;
PAAD	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg08898775	chr15:59042684	ADAM10	-0.37	-4.59	-0.35	9.15e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs7580658	0.963	rs12991768	chr2:128146245	A/G	cg09760422	chr2:128146352	NA	-0.45	-7.64	-0.53	2.23e-12	Protein C levels;
PAAD	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.69	0.42	6.28e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.53	0.35	1.16e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7577696	0.785	rs11683842	chr2:32364131	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-4.67	-0.35	6.56e-6	Inflammatory biomarkers;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg05338066	chr1:7812865	CAMTA1	0.67	5.13	0.38	8.78e-7	Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg07703079	chr11:430292	ANO9	1.01	6.29	0.45	3.26e-9	Body mass index;
PAAD	cis	rs735539	0.521	rs2818995	chr13:21420964	T/G	cg27499820	chr13:21296301	IL17D	0.52	4.62	0.35	8.02e-6	Dental caries;
PAAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	4.34	0.33	2.58e-5	Total body bone mineral density;
PAAD	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.45	-4.99	-0.38	1.62e-6	Pneumonia;
PAAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.96	12.42	0.71	6.88e-25	Menopause (age at onset);
PAAD	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.74	7.25	0.51	1.94e-11	Mosquito bite size;
PAAD	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.15	-0.39	7.9e-7	Monocyte count;
PAAD	cis	rs4239252	0.769	rs4796105	chr17:34085967	A/C	cg19411729	chr17:34207663	CCL5	-0.58	-5.17	-0.39	7.35e-7	Blood protein levels;
PAAD	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg21466736	chr12:48725269	NA	0.46	4.29	0.33	3.16e-5	Glycated hemoglobin levels;
PAAD	cis	rs1413885	0.549	rs10889546	chr1:65851759	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.72	0.36	5.25e-6	Anticoagulant levels;
PAAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.94	-10.05	-0.63	1.52e-18	Blood metabolite levels;
PAAD	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-1.02	-11.29	-0.68	7.67e-22	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg05082376	chr22:42548792	NA	0.55	5.86	0.43	2.8e-8	Cognitive function;
PAAD	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05088677	chr10:21785733	C10orf114;MIR1915	0.51	5.61	0.41	9.45e-8	Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg07202610	chr7:1142643	C7orf50	-0.76	-5.24	-0.39	5.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8062405	0.625	rs8060365	chr16:28911309	C/A	cg09754948	chr16:28834200	ATXN2L	-0.49	-4.44	-0.34	1.73e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.32	0.68	6.14e-22	Smoking behavior;
PAAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs10450586	0.799	rs10835148	chr11:27266037	A/G	cg10370305	chr11:27303972	NA	0.37	4.47	0.34	1.55e-5	Total body bone mineral density;
PAAD	cis	rs3136739	0.614	rs34361836	chr8:42026968	A/T	cg17828057	chr8:42037527	PLAT	0.7	4.84	0.37	3.19e-6	Plasma plasminogen activator levels;
PAAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.85	8.18	0.55	1.05e-13	Cognitive function;
PAAD	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg02640540	chr1:67518911	SLC35D1	0.56	4.88	0.37	2.63e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-1.02	-14.12	-0.75	1.84e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg01388757	chr2:102091195	RFX8	-0.67	-8.41	-0.56	2.83e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg14709524	chr16:89940631	TCF25	0.9	4.61	0.35	8.43e-6	Skin colour saturation;
PAAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.12e-6	Total body bone mineral density;
PAAD	cis	rs35955747	0.807	rs9619169	chr22:31537342	T/G	cg02404636	chr22:31891804	SFI1	-0.51	-5.19	-0.39	6.76e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.51	6.48	0.47	1.18e-9	Schizophrenia;
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs16975963	0.793	rs73027418	chr19:38361020	C/T	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.32	-0.33	2.77e-5	Caffeine consumption;
PAAD	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.81e-7	Bipolar disorder;
PAAD	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.27	-0.6	1.68e-16	Caffeine consumption;
PAAD	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg05627522	chr15:75251581	NA	-0.4	-4.86	-0.37	2.92e-6	Systemic lupus erythematosus;
PAAD	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg27449745	chr7:23145252	KLHL7	-0.52	-4.54	-0.35	1.15e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02353448	chr8:103439648	NA	-0.66	-6.53	-0.47	9.34e-10	Obesity-related traits;
PAAD	cis	rs6663390	0.510	rs1932819	chr1:208078238	C/T	cg00387621	chr1:208086895	NA	0.7	4.35	0.33	2.46e-5	Facial morphology (factor 18);
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	6.49	0.47	1.15e-9	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.49	-0.41	1.68e-7	Life satisfaction;
PAAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg23947450	chr7:900037	UNC84A	-0.52	-4.37	-0.33	2.27e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.67	5.77	0.42	4.3e-8	Breast cancer;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg00280220	chr17:61926910	NA	0.43	4.61	0.35	8.46e-6	Prudent dietary pattern;
PAAD	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.56	-4.65	-0.35	7.03e-6	Pursuit maintenance gain;
PAAD	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg27490568	chr2:178487706	NA	0.4	4.27	0.33	3.44e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.49	7.82	0.54	8.27e-13	Neuroticism;
PAAD	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg03871329	chr12:110338662	TCHP	-0.64	-4.66	-0.35	6.91e-6	Neuroticism;
PAAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.78	8.95	0.59	1.17e-15	DNA methylation (variation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08785274	chr1:161068252	KLHDC9	0.57	6.36	0.46	2.29e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-4.45	-0.34	1.68e-5	Plateletcrit;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.56	-5.06	-0.38	1.2e-6	Mosquito bite size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17436327	chr6:170863443	PSMB1;TBP	0.6	6.39	0.46	1.9e-9	Myopia (pathological);
PAAD	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.54	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-4.27	-0.33	3.48e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.5	5.32	0.4	3.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.58	-5.77	-0.42	4.3e-8	Height;
PAAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg16205897	chr5:131564050	P4HA2	0.52	5.86	0.43	2.79e-8	Blood metabolite levels;
PAAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.4	4.5	0.34	1.35e-5	High light scatter reticulocyte count;
PAAD	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.57	5.76	0.42	4.57e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11811982	0.793	rs11809113	chr1:227374357	C/T	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg23205692	chr1:25664452	TMEM50A	0.51	4.82	0.36	3.4e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9659323	1.000	rs56897173	chr1:119515732	G/A	cg17326555	chr1:119535693	NA	-0.41	-5.4	-0.4	2.55e-7	Body mass index;
PAAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.62	-5.55	-0.41	1.26e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs59888335	0.799	rs7621523	chr3:80963671	T/C	cg21735741	chr3:80819488	NA	-0.53	-4.58	-0.35	9.67e-6	Schizophrenia;
PAAD	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.4	4.37	0.33	2.32e-5	Calcium levels;
PAAD	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg23950597	chr19:37808831	NA	-0.77	-5.23	-0.39	5.49e-7	Coronary artery calcification;
PAAD	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.46	4.76	0.36	4.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.28	-0.56	5.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	5.87	0.43	2.6e-8	Mean platelet volume;
PAAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-4.72	-0.36	5.3e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.69	9.42	0.61	6.93e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.35	-0.68	5.11e-22	Chronic sinus infection;
PAAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.6	-6.7	-0.48	3.76e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.7	9.22	0.6	2.38e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4704187	0.687	rs10066946	chr5:74508021	T/A	cg03227963	chr5:74354835	NA	0.53	5.09	0.38	1.04e-6	Response to amphetamines;
PAAD	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	11.93	0.7	1.41e-23	Body mass index (adult);
PAAD	cis	rs7172971	0.566	rs117999754	chr15:42384292	A/C	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.81	5.34	0.4	3.36e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6715793	0.901	rs4670928	chr2:33417110	T/C	cg26672287	chr2:33391915	LTBP1	-0.41	-4.75	-0.36	4.74e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs4782309	0.544	rs6500488	chr16:88753865	A/G	cg27099511	chr16:88729703	MGC23284;MVD	-0.86	-4.53	-0.34	1.18e-5	Hair color;
PAAD	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Educational attainment (college completion);
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg07341007	chr3:195489909	MUC4	0.64	4.87	0.37	2.81e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.55	5.59	0.41	1.01e-7	Menopause (age at onset);
PAAD	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.78	9.18	0.6	2.89e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4795519	0.849	rs11658968	chr17:22144986	G/T	cg22648282	chr17:21454238	C17orf51	-0.54	-5.53	-0.41	1.38e-7	Chronic myeloid leukemia;
PAAD	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.82	-0.48	1.98e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6708331	0.517	rs12617812	chr2:70359471	A/G	cg01613454	chr2:70366299	NA	0.44	4.63	0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg09835421	chr16:68378352	PRMT7	1.0	6.46	0.46	1.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg06606381	chr12:133084897	FBRSL1	1.04	6.46	0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.59	5.66	0.42	7.33e-8	Prudent dietary pattern;
PAAD	cis	rs9395066	0.509	rs11967188	chr6:44956925	C/T	cg18551225	chr6:44695536	NA	-0.42	-4.41	-0.34	1.99e-5	Height;
PAAD	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.71	8.9	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.94	0.37	2.03e-6	Oropharynx cancer;
PAAD	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg11939631	chr5:178977406	RUFY1	0.6	4.7	0.36	5.82e-6	Lung cancer;
PAAD	cis	rs11252926	0.732	rs10904542	chr10:744013	G/A	cg08603382	chr10:743973	NA	-0.48	-4.72	-0.36	5.33e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	4.32	0.33	2.83e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26095694	chr13:26789271	RNF6	-0.73	-7.11	-0.5	4.16e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg25251562	chr2:3704773	ALLC	-0.44	-5.06	-0.38	1.18e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.57	5.75	0.42	4.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.58	-7.83	-0.54	7.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1075265	0.669	rs805317	chr2:54135004	T/A	cg04546899	chr2:54196757	PSME4	0.33	4.88	0.37	2.64e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs1499972	0.941	rs62263119	chr3:117630175	T/G	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.65	-8.05	-0.55	2.26e-13	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09979956	chr2:190648634	ORMDL1;PMS1	-0.77	-7.01	-0.49	7.41e-11	Neuroticism;
PAAD	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	1.42	9.04	0.59	6.92e-16	Prostate cancer;
PAAD	cis	rs17655565	1.000	rs60696802	chr12:52693176	C/T	cg02645295	chr12:52705424	NA	-0.48	-4.38	-0.34	2.16e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.12	0.75	1.87e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs72960926	1.000	rs72956962	chr6:75100904	T/C	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11051970	0.655	rs10771942	chr12:32528488	G/A	cg02745156	chr12:32552066	NA	0.38	4.28	0.33	3.34e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.62	1.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.95	-11.19	-0.67	1.37e-21	Calcium levels;
PAAD	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.43	-0.34	1.76e-5	Height;
PAAD	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.69	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs72901758	0.768	rs55730737	chr17:76250777	T/A	cg11439826	chr17:76250004	NA	0.47	4.68	0.35	6.26e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg10920065	chr6:169824652	NA	-0.47	-4.65	-0.35	7.02e-6	Obesity-related traits;
PAAD	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27518047	chr12:68647590	IL22	-0.63	-6.32	-0.46	2.78e-9	Obesity-related traits;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05977900	chr3:182512126	ATP11B	0.58	6.36	0.46	2.22e-9	Metabolite levels  (X-11787);
PAAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3996993	0.573	rs11759734	chr6:52724146	A/G	cg00536792	chr6:53530503	KLHL31	-0.42	-4.43	-0.34	1.8e-5	Hemoglobin concentration;
PAAD	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.89	-9.31	-0.6	1.32e-16	Systemic lupus erythematosus;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg22225219	chr6:113941344	NA	0.57	6.84	0.49	1.81e-10	Body fat percentage;
PAAD	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.85	0.62	5.34e-18	Chronic sinus infection;
PAAD	cis	rs1499972	0.503	rs1909590	chr3:117815843	A/T	cg07612923	chr3:117604196	NA	-0.72	-5.13	-0.38	8.54e-7	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.66	-7.04	-0.5	6.33e-11	Iron status biomarkers;
PAAD	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg14993813	chr1:46806288	NSUN4	-0.55	-4.94	-0.37	2e-6	Menopause (age at onset);
PAAD	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs4605213	0.510	rs11651110	chr17:49299066	A/G	cg22932220	chr17:49244634	NME2;NME1-NME2	0.44	5.49	0.41	1.69e-7	Height;
PAAD	cis	rs2637266	0.818	rs7894799	chr10:78392012	T/C	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.65e-5	Pulmonary function;
PAAD	cis	rs6466055	0.661	rs68004394	chr7:104788261	G/C	cg04380332	chr7:105027541	SRPK2	0.49	4.76	0.36	4.47e-6	Schizophrenia;
PAAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs2969070	1.000	rs2969070	chr7:2512545	C/T	cg03277898	chr7:2518824	NA	-0.35	-4.5	-0.34	1.36e-5	Diastolic blood pressure;
PAAD	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg19486271	chr11:47235900	DDB2	0.52	5.38	0.4	2.82e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1499972	0.609	rs62264957	chr3:117532595	A/C	cg07612923	chr3:117604196	NA	0.85	6.07	0.44	9.88e-9	Schizophrenia;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs62025270	0.688	rs7182210	chr15:86265782	A/C	cg13263323	chr15:86062960	AKAP13	0.47	4.25	0.33	3.76e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs78707713	0.841	rs10998780	chr10:71201735	A/T	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.31	-0.4	3.76e-7	Venous thromboembolism;
PAAD	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg08999081	chr20:33150536	PIGU	-0.53	-5.71	-0.42	5.69e-8	Height;
PAAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg10167378	chr1:228756711	NA	0.43	4.26	0.33	3.57e-5	Diastolic blood pressure;
PAAD	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs3857067	1.000	rs1588381	chr4:95017558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-5.42	-0.4	2.34e-7	QT interval;
PAAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg07371521	chr5:154026371	NA	0.54	6.88	0.49	1.43e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.97	-9.91	-0.63	3.57e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs17407555	0.909	rs11732729	chr4:10300316	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-4.25	-0.33	3.67e-5	Schizophrenia (age at onset);
PAAD	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs10768122	0.642	rs7942698	chr11:35363078	A/G	cg13971030	chr11:35366721	SLC1A2	0.41	4.77	0.36	4.34e-6	Vitiligo;
PAAD	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-4.52	-0.34	1.22e-5	Ulcerative colitis;
PAAD	cis	rs11618113	0.634	rs9588187	chr13:111183528	G/A	cg11688093	chr13:111178359	RAB20	-0.73	-4.57	-0.35	1.02e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs2807544	0.652	rs4661308	chr1:15196673	C/G	cg23645831	chr1:15944060	DDI2	-0.49	-4.4	-0.34	2.02e-5	Interleukin-2 levels;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg19673125	chr6:150240577	RAET1G	0.41	5.74	0.42	5.07e-8	Testicular germ cell tumor;
PAAD	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg05925327	chr15:68127851	NA	-0.55	-4.83	-0.36	3.3e-6	Restless legs syndrome;
PAAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.93	8.72	0.58	4.61e-15	Gut microbiome composition (summer);
PAAD	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg00806126	chr19:22604979	ZNF98	0.4	5.02	0.38	1.4e-6	Pain;
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg06714761	chr1:201096289	NA	0.31	4.55	0.35	1.09e-5	Permanent tooth development;
PAAD	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.6	-7.01	-0.49	7.18e-11	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.03	0.67	3.74e-21	Parkinson's disease;
PAAD	cis	rs965469	0.857	rs1922990	chr20:3252348	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.57	-0.35	1e-5	IgG glycosylation;
PAAD	cis	rs35740288	0.731	rs11638407	chr15:86094655	A/C	cg07943548	chr15:86304357	KLHL25	-0.57	-5.01	-0.38	1.47e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg25811867	chr2:3488468	NA	0.43	4.51	0.34	1.31e-5	Neurofibrillary tangles;
PAAD	cis	rs9810890	1.000	rs13323787	chr3:128602135	G/T	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg27113419	chr16:58533979	NDRG4	-0.76	-4.67	-0.35	6.65e-6	Schizophrenia;
PAAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27318635	chr16:3781749	CREBBP	0.57	6.98	0.49	8.77e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg05768032	chr16:30646687	NA	0.52	5.04	0.38	1.33e-6	Multiple myeloma;
PAAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.6	-6.7	-0.48	3.76e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg01763666	chr17:80159506	CCDC57	0.44	4.51	0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.45	5.41	0.4	2.39e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	trans	rs10500871	1.000	rs4757042	chr11:20223936	A/G	cg02956962	chr6:161097311	NA	0.62	6.36	0.46	2.2e-9	Educational attainment;
PAAD	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12136530	0.593	rs881247	chr1:19733320	A/G	cg03321592	chr1:19991676	HTR6	0.54	4.91	0.37	2.32e-6	Lead levels in blood;
PAAD	cis	rs818427	0.684	rs351771	chr5:112164561	G/A	cg06941702	chr5:112196734	SRP19	-0.52	-4.73	-0.36	5.09e-6	Total body bone mineral density;
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.63	-4.4	-0.34	2.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg08648136	chr8:956695	NA	0.42	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09703004	chr6:42788080	KIAA0240	0.6	6.75	0.48	2.95e-10	Smoking initiation;
PAAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg26727032	chr16:67993705	SLC12A4	-0.6	-4.38	-0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs4343996	0.934	rs4495320	chr7:3369936	G/A	cg21248987	chr7:3385318	SDK1	-0.47	-5.1	-0.38	9.98e-7	Motion sickness;
PAAD	cis	rs17592366	0.517	rs4981250	chr14:35254473	A/C	cg09327582	chr14:35236912	BAZ1A	0.56	4.66	0.35	6.98e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.35	5.28	0.39	4.43e-7	IgG glycosylation;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg00988841	chr10:134556463	INPP5A	0.47	4.3	0.33	3.09e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs35123781	0.580	rs355163	chr5:138958078	T/C	cg11459648	chr5:138714337	SLC23A1	-0.61	-5.55	-0.41	1.26e-7	Schizophrenia;
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg05554000	chr7:158905015	VIPR2	-0.66	-5.29	-0.39	4.28e-7	Facial morphology (factor 20);
PAAD	cis	rs939584	1.000	rs13386964	chr2:650828	A/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.78	-0.42	4.12e-8	Life satisfaction;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08677398	chr8:58056175	NA	0.65	4.39	0.34	2.13e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.59	0.41	1.02e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs256277	0.657	rs154120	chr5:111375061	G/A	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs507080	0.961	rs642497	chr11:118550784	C/A	cg08498647	chr11:118550644	TREH	-0.37	-4.33	-0.33	2.73e-5	Serum metabolite levels;
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.44	4.85	0.37	3.04e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.13	14.62	0.76	8.78e-31	Cortisol levels (saliva);
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10214930	0.813	rs2391445	chr7:27648871	C/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.83	-9.48	-0.61	4.96e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.71	7.13	0.5	3.7e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7101378	0.538	rs7942258	chr11:108899569	T/C	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.71	-5.84	-0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg14703610	chr5:56206110	C5orf35	0.58	5.48	0.41	1.75e-7	Coronary artery disease;
PAAD	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.1	0.38	9.8e-7	HDL cholesterol;
PAAD	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	1.2	10.22	0.64	5.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg10818794	chr15:86012489	AKAP13	0.46	4.78	0.36	4.06e-6	Bulimia nervosa;
PAAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs6466055	0.615	rs1204061	chr7:104964249	A/G	cg04380332	chr7:105027541	SRPK2	-0.49	-4.75	-0.36	4.64e-6	Schizophrenia;
PAAD	cis	rs988913	1.000	rs9396011	chr6:54836739	C/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.89	-0.37	2.53e-6	Menarche (age at onset);
PAAD	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.53	6.69	0.48	3.95e-10	Sitting height ratio;
PAAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.88	-13.3	-0.73	2.9e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.52	4.31	0.33	2.9e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg25364880	chr3:44379878	C3orf23	0.57	5.22	0.39	5.88e-7	Depressive symptoms;
PAAD	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.73	-7.89	-0.54	5.5e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7567389	0.677	rs10850	chr2:128063945	T/C	cg11380483	chr2:127933992	NA	-0.48	-4.71	-0.36	5.48e-6	Self-rated health;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07520141	chr5:10564205	ANKRD33B	0.6	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6922632	0.867	rs6934526	chr6:24114746	G/C	cg26194775	chr6:24126114	NRSN1	-0.67	-5.21	-0.39	6.11e-7	Information processing speed;
PAAD	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg00262122	chr8:11665843	FDFT1	0.5	4.35	0.33	2.44e-5	Retinal vascular caliber;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg14926445	chr8:58193284	C8orf71	0.61	4.47	0.34	1.53e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.57	-0.47	7.74e-10	Triglycerides;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.88	0.54	5.76e-13	Lung cancer in ever smokers;
PAAD	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.64	-6.78	-0.48	2.54e-10	Menarche (age at onset);
PAAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg14393609	chr7:65229607	NA	0.47	5.0	0.38	1.55e-6	Aortic root size;
PAAD	cis	rs13102973	0.720	rs7687641	chr4:135885739	C/T	cg14419869	chr4:135874104	NA	0.44	4.37	0.33	2.26e-5	Subjective well-being;
PAAD	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.62	5.78	0.42	4.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg13877915	chr19:58951672	ZNF132	0.47	4.37	0.33	2.25e-5	Uric acid clearance;
PAAD	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.98	10.77	0.66	1.9e-20	Corneal astigmatism;
PAAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.9	-5.9	-0.43	2.33e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.54	5.0	0.38	1.58e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.95	0.54	3.96e-13	Coronary artery disease;
PAAD	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg04370829	chr17:406249	NA	-0.56	-5.6	-0.41	9.59e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2117029	0.554	rs2334930	chr12:49569311	T/C	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8105895	0.935	rs7247041	chr19:22249790	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.16	16.64	0.8	4.75e-36	Cognitive function;
PAAD	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg06131755	chr6:160182447	ACAT2	0.51	4.48	0.34	1.48e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.86	-9.28	-0.6	1.65e-16	Obesity-related traits;
PAAD	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg08135965	chr6:41755394	TOMM6	0.49	5.06	0.38	1.22e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.51	-6.0	-0.44	1.38e-8	Mean arterial pressure;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.89	10.89	0.66	9.12e-21	Prudent dietary pattern;
PAAD	cis	rs2017305	0.667	rs117657934	chr10:70643836	A/G	cg25290552	chr10:70751067	KIAA1279	-0.83	-4.8	-0.36	3.72e-6	Depression (quantitative trait);
PAAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.61	-6.61	-0.47	6.24e-10	Coronary artery disease;
PAAD	cis	rs346785	0.692	rs6501880	chr17:74289705	A/G	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs2271400	0.556	rs6474012	chr8:56659467	C/T	cg08894788	chr8:56792171	LYN	-0.54	-5.15	-0.39	8.1e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02466933	chr2:9770529	YWHAQ	0.51	6.29	0.45	3.2e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg07395648	chr5:131743802	NA	-0.62	-6.4	-0.46	1.83e-9	Blood metabolite levels;
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg04154034	chr17:28927549	LRRC37B2	0.71	4.74	0.36	4.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs5746492	0.539	rs28700195	chr22:18349948	T/C	cg06148736	chr22:18985691	NA	-0.37	-4.29	-0.33	3.22e-5	Eotaxin levels;
PAAD	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.52	6.34	0.46	2.53e-9	Endometriosis;
PAAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.81	7.41	0.52	8.06e-12	Psoriasis;
PAAD	cis	rs8067287	0.688	rs11651187	chr17:16845402	T/A	cg26910001	chr17:16838321	NA	-0.53	-5.04	-0.38	1.3e-6	Diabetic kidney disease;
PAAD	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.09	-0.38	1.07e-6	Schizophrenia;
PAAD	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-6.24	-0.45	4.13e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-8.22	-0.55	8.42e-14	Response to antipsychotic treatment;
PAAD	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.13	-0.38	8.64e-7	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg05342682	chr7:94953680	PON1	-0.56	-4.72	-0.36	5.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-13.45	-0.74	1.16e-27	Schizophrenia;
PAAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.88	-9.06	-0.59	5.93e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1075265	0.870	rs7569370	chr2:54216349	C/T	cg04546899	chr2:54196757	PSME4	0.38	5.74	0.42	4.93e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg17524180	chr13:113633600	MCF2L	-0.49	-5.37	-0.4	2.86e-7	Systolic blood pressure;
PAAD	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	1.2	10.22	0.64	5.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg18612461	chr15:75251733	NA	0.59	7.24	0.51	2.07e-11	Breast cancer;
PAAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.35	-0.33	2.47e-5	Obesity-related traits;
PAAD	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26926768	chr12:34528122	NA	0.4	4.85	0.37	3.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg05342682	chr7:94953680	PON1	0.55	5.01	0.38	1.49e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11252926	0.732	rs10904542	chr10:744013	G/A	cg05336292	chr10:466338	DIP2C	0.42	4.41	0.34	1.96e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.69	-8.02	-0.55	2.6e-13	Diastolic blood pressure;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11245990	chr11:68621969	NA	0.38	4.98	0.37	1.72e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.65	7.06	0.5	5.43e-11	Blood protein levels;
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.74	7.56	0.52	3.48e-12	Prostate cancer;
PAAD	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.57	-0.41	1.14e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.62	5.85	0.43	2.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg16419906	chr5:132167176	NA	-0.63	-5.03	-0.38	1.35e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs1012068	0.881	rs5998168	chr22:32297296	T/C	cg01338084	chr22:32026380	PISD	0.63	5.58	0.41	1.06e-7	Chronic hepatitis C infection;
PAAD	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.75	-9.7	-0.62	1.29e-17	Educational attainment;
PAAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.54	-4.6	-0.35	9.01e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg11266682	chr4:10021025	SLC2A9	0.49	4.26	0.33	3.5e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.91	-0.37	2.35e-6	Menopause (age at onset);
PAAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23463467	chr20:60627584	TAF4	-0.43	-4.81	-0.36	3.59e-6	Body mass index;
PAAD	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.42	-5.28	-0.39	4.42e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg11601000	chr22:42348013	LOC339674	0.41	4.79	0.36	3.99e-6	Cognitive function;
PAAD	cis	rs62577244	0.645	rs111342974	chr9:138434448	G/A	cg14097499	chr9:138441348	OBP2A	0.57	5.6	0.41	9.76e-8	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
PAAD	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs258892	0.895	rs34782328	chr5:72060974	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs6748734	0.581	rs4234092	chr2:241866389	T/C	cg26818257	chr2:241905806	NA	0.45	4.42	0.34	1.85e-5	Urinary metabolites;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14554176	chr9:139360056	SEC16A	-0.71	-7.35	-0.51	1.12e-11	Obesity-related traits;
PAAD	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.74	8.32	0.56	4.59e-14	Colorectal cancer;
PAAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.57	-6.51	-0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.06	0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.59	-0.41	1.05e-7	Neuroticism;
PAAD	cis	rs16852403	0.583	rs12071903	chr1:178095804	C/T	cg00404053	chr1:178313656	RASAL2	0.44	4.28	0.33	3.27e-5	Childhood ear infection;
PAAD	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.56	-5.29	-0.39	4.1e-7	Gut microbiome composition (summer);
PAAD	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg06042504	chr8:55087323	NA	-0.77	-8.72	-0.58	4.56e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs900145	0.861	rs10832007	chr11:13270052	A/T	cg15603424	chr11:13300592	ARNTL	0.5	4.36	0.33	2.38e-5	Menarche (age at onset);
PAAD	cis	rs7487075	0.619	rs10467214	chr12:46841210	A/G	cg14671384	chr12:47219920	SLC38A4	0.45	4.52	0.34	1.21e-5	Itch intensity from mosquito bite;
PAAD	cis	rs66696671	0.806	rs11199050	chr10:121377046	T/C	cg13975098	chr10:121303635	RGS10	0.4	4.79	0.36	3.88e-6	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
PAAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.74	7.84	0.54	7.52e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg07336987	chr11:625147	MUPCDH	-0.36	-4.48	-0.34	1.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg10978503	chr1:24200527	CNR2	0.51	6.06	0.44	1.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.67	-6.25	-0.45	3.93e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23708337	chr7:1209742	NA	0.45	4.93	0.37	2.1e-6	Longevity;Endometriosis;
PAAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg25155006	chr6:37138205	PIM1	-0.51	-4.42	-0.34	1.86e-5	QRS duration;
PAAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.21	-0.39	6.13e-7	Mean corpuscular volume;
PAAD	cis	rs1867982	0.822	rs7896487	chr10:73563839	A/C	cg07131093	chr10:72648379	PCBD1	0.67	4.38	0.33	2.17e-5	Age at smoking initiation in chronic obstructive pulmonary disease;Pulmonary function decline;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14937543	chr3:20081518	KAT2B	-0.66	-6.54	-0.47	9.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg10223061	chr2:219282414	VIL1	0.38	4.39	0.34	2.15e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg00999904	chr2:3704751	ALLC	-0.51	-5.87	-0.43	2.64e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	4.39	0.34	2.12e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.68	5.0	0.38	1.55e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg03318428	chr22:46971703	NA	0.36	4.36	0.33	2.43e-5	Urate levels in obese individuals;
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg09471204	chr22:42347991	LOC339674	-0.38	-5.18	-0.39	6.87e-7	Intelligence;
PAAD	cis	rs1414896	1.000	rs1414896	chr1:95692310	G/A	cg20701556	chr1:95698924	RWDD3	-0.29	-4.39	-0.34	2.08e-5	Non-alcoholic fatty liver disease histology (AST);
PAAD	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg00750074	chr16:89608354	SPG7	0.56	5.42	0.4	2.32e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs11168618	0.904	rs7135125	chr12:48926268	A/T	cg01881778	chr12:48919444	OR8S1	-0.48	-4.89	-0.37	2.57e-6	Adiponectin levels;
PAAD	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.66	6.1	0.44	8.48e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.17	-8.4	-0.56	2.89e-14	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.83	6.18	0.45	5.63e-9	Tuberculosis;
PAAD	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	6.0	0.44	1.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.54	-4.38	-0.33	2.19e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.7	-5.68	-0.42	6.69e-8	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg27411982	chr8:10470053	RP1L1	-0.51	-5.6	-0.41	1e-7	Retinal vascular caliber;
PAAD	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.56	-6.07	-0.44	9.83e-9	Red blood cell count;
PAAD	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg06067394	chr11:133789110	IGSF9B	0.43	4.73	0.36	5.06e-6	Parkinson's disease;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg09699651	chr6:150184138	LRP11	0.4	4.27	0.33	3.47e-5	Lung cancer;
PAAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.57	-5.99	-0.44	1.45e-8	Type 2 diabetes;
PAAD	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg08886695	chr4:3369023	RGS12	-0.51	-4.83	-0.36	3.31e-6	Mean platelet volume;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.51	0.41	1.47e-7	Platelet count;
PAAD	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.67	0.35	6.66e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg02117656	chr17:79614917	TSPAN10	0.7	8.05	0.55	2.19e-13	Eye color traits;
PAAD	cis	rs3753841	0.832	rs12136992	chr1:103220808	G/A	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.94	11.26	0.67	9.07e-22	Menarche (age at onset);
PAAD	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.59	-7.58	-0.52	3.18e-12	Lewy body disease;
PAAD	cis	rs11209002	0.876	rs7517744	chr1:67570879	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg07150166	chr2:30669952	LCLAT1	0.87	6.23	0.45	4.26e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg13722127	chr7:150037890	RARRES2	0.52	5.41	0.4	2.42e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg07202610	chr7:1142643	C7orf50	-0.69	-4.97	-0.37	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4757319	0.515	rs7126103	chr11:15337892	T/C	cg03245590	chr11:15329459	NA	0.44	5.27	0.39	4.55e-7	Breast cancer;
PAAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg26497354	chr6:109612229	NA	-0.42	-4.25	-0.33	3.7e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.79	0.36	3.85e-6	Depressive symptoms;
PAAD	cis	rs9810890	1.000	rs116835720	chr3:128547280	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs8053891	0.673	rs35338546	chr16:72022156	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-4.75	-0.36	4.63e-6	Coronary artery disease;
PAAD	cis	rs988913	1.000	rs9370345	chr6:54825167	C/T	cg03513858	chr6:54763001	FAM83B	-0.41	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.84	8.91	0.59	1.45e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg03871329	chr12:110338662	TCHP	0.68	4.99	0.38	1.64e-6	Neuroticism;
PAAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17341933	chr17:79008687	BAIAP2;FLJ90757	0.68	6.94	0.49	1.08e-10	Obesity-related traits;
PAAD	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg11214348	chr21:47283868	PCBP3	-0.49	-4.42	-0.34	1.85e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs12776336	chr10:46063911	G/C	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs863345	0.933	rs10797015	chr1:158468265	T/G	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02743256	chr7:2109353	MAD1L1	-0.73	-6.08	-0.44	9.33e-9	Bipolar disorder;
PAAD	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg26597838	chr10:835615	NA	0.49	5.27	0.39	4.5e-7	Survival in rectal cancer;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-5.82	-0.43	3.4e-8	Crohn's disease;
PAAD	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs858239	0.899	rs1881203	chr7:23292808	T/C	cg27449745	chr7:23145252	KLHL7	-0.52	-4.61	-0.35	8.61e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs490234	0.545	rs10117700	chr9:128250651	C/T	cg14078157	chr9:128172775	NA	-0.4	-4.43	-0.34	1.77e-5	Mean arterial pressure;
PAAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.32	-0.4	3.67e-7	Blood metabolite levels;
PAAD	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.23	0.51	2.14e-11	Lung cancer in ever smokers;
PAAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-8.42	-0.56	2.61e-14	Gut microbiome composition (summer);
PAAD	cis	rs12453935	0.708	rs72843735	chr17:59934862	A/G	cg01765249	chr17:59476334	TBX2	-0.48	-4.44	-0.34	1.74e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg14393609	chr7:65229607	NA	-0.45	-4.63	-0.35	7.8e-6	Aortic root size;
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs11807834	0.522	rs754666	chr1:230250182	T/C	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	10.66	0.65	3.63e-20	Platelet count;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg00738919	chr7:1100172	C7orf50	0.54	4.5	0.34	1.36e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg16576597	chr16:28551801	NUPR1	0.71	7.64	0.53	2.29e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs735539	0.517	rs3809357	chr13:21140781	T/A	cg27234864	chr13:21295941	IL17D	0.59	5.06	0.38	1.19e-6	Dental caries;
PAAD	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.81	-0.36	3.65e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg23033748	chr14:75592666	NEK9	-0.45	-5.58	-0.41	1.07e-7	Height;
PAAD	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.74	4.91	0.37	2.35e-6	HDL cholesterol;
PAAD	cis	rs8062405	0.573	rs6565300	chr16:28993049	G/T	cg16576597	chr16:28551801	NUPR1	0.56	5.31	0.4	3.74e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04294625	chr17:45727224	KPNB1	0.65	6.86	0.49	1.65e-10	Myopia (pathological);
PAAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.12e-8	Blood metabolite levels;
PAAD	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.62	6.04	0.44	1.16e-8	Breast cancer;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.78	7.08	0.5	4.9e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.71	-0.42	5.81e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7577696	0.568	rs115985725	chr2:32335807	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-4.76	-0.36	4.55e-6	Inflammatory biomarkers;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24056307	chr19:19932543	ZNF506	0.55	6.35	0.46	2.35e-9	Metabolite levels  (X-11787);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25654301	chr17:73511699	TSEN54;CASKIN2	-0.49	-6.43	-0.46	1.6e-9	Body fat percentage;
PAAD	cis	rs1925576	0.686	rs61866188	chr10:68636450	A/C	cg04444303	chr10:69634106	NA	-0.42	-4.26	-0.33	3.58e-5	Educational attainment (years of education);
PAAD	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-4.56	-0.35	1.03e-5	Educational attainment (years of education);
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.84	-0.43	3.02e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg10820045	chr2:198174542	NA	0.48	4.97	0.37	1.81e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.55	-5.17	-0.39	7.2e-7	Retinal vascular caliber;
PAAD	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.15	0.39	7.94e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.75	8.81	0.58	2.64e-15	Colorectal cancer;
PAAD	cis	rs1497828	0.956	rs2646828	chr1:217542361	C/T	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.75	-8.37	-0.56	3.4e-14	Colorectal cancer;
PAAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg05895507	chr15:77155635	SCAPER	0.36	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.36	0.64	2.36e-19	Smoking behavior;
PAAD	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.72	0.42	5.45e-8	Menarche (age at onset);
PAAD	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg11995313	chr8:8860691	ERI1	0.45	4.26	0.33	3.61e-5	Joint mobility (Beighton score);
PAAD	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg08198773	chr8:1697536	NA	0.47	5.16	0.39	7.5e-7	Systolic blood pressure;
PAAD	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.78	7.91	0.54	5.04e-13	Coronary artery disease;
PAAD	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg15309053	chr8:964076	NA	0.56	6.36	0.46	2.21e-9	Schizophrenia;
PAAD	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg16386425	chr10:429943	DIP2C	0.41	4.3	0.33	3.04e-5	Psychosis in Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01149259	chr3:47021396	NBEAL2	0.67	7.17	0.5	3.02e-11	Myopia (pathological);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13021479	chr17:8380298	MYH10	0.66	6.9	0.49	1.3e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.88	6.8	0.48	2.3e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg19337854	chr7:99768885	GPC2	0.48	4.43	0.34	1.77e-5	Platelet count;
PAAD	cis	rs375066	0.868	rs378109	chr19:44421937	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	trans	rs4324798	1	rs4324798	chr6:28776117	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.97	-0.63	2.47e-18	Lung adenocarcinoma;
PAAD	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.39	0.34	2.14e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs375066	0.762	rs239938	chr19:44390305	T/C	cg21496419	chr19:44306685	LYPD5	0.42	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.8	0.36	3.72e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg01422370	chr2:73384389	NA	-0.35	-4.75	-0.36	4.76e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg27490568	chr2:178487706	NA	0.41	4.47	0.34	1.52e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.55e-5	Life satisfaction;
PAAD	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.06	-0.44	1.01e-8	Bipolar disorder;
PAAD	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg02135003	chr7:105160482	PUS7	-0.67	-6.04	-0.44	1.13e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.65	6.38	0.46	2.03e-9	Corneal astigmatism;
PAAD	cis	rs4845552	0.716	rs16835382	chr1:153475660	C/T	cg15998505	chr1:153479701	NA	-0.5	-4.41	-0.34	1.94e-5	Hippocampal atrophy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00778059	chr13:24734742	SPATA13	-0.64	-6.71	-0.48	3.6e-10	Smoking initiation;
PAAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg11232448	chr19:2858854	NA	-0.5	-4.99	-0.38	1.6e-6	Total cholesterol levels;
PAAD	cis	rs1204798	0.617	rs6909152	chr6:116601557	A/G	cg00470183	chr6:116575913	TSPYL4	-0.48	-4.34	-0.33	2.64e-5	Dental caries;
PAAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.72	0.36	5.23e-6	Breast cancer;
PAAD	trans	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg08566640	chr11:64091735	NA	0.58	6.55	0.47	8.51e-10	Height;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg09876464	chr15:85330779	ZNF592	0.43	4.28	0.33	3.34e-5	P wave terminal force;
PAAD	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.47	5.91	0.43	2.17e-8	Crohn's disease;
PAAD	cis	rs12753569	0.720	rs4381138	chr1:76509783	G/A	cg00791851	chr1:76518896	NA	0.4	4.5	0.34	1.32e-5	Personality dimensions;
PAAD	cis	rs6142102	0.961	rs4911392	chr20:32570518	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	4.38	0.33	2.2e-5	Skin pigmentation;
PAAD	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg03264133	chr6:25882463	NA	0.43	4.25	0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg09658497	chr7:2847517	GNA12	-0.4	-4.26	-0.33	3.54e-5	Height;
PAAD	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.86	7.7	0.53	1.62e-12	Coronary artery disease;
PAAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.47	-6.02	-0.44	1.22e-8	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05595602	chr1:1343077	MRPL20	0.67	6.84	0.49	1.81e-10	Obesity-related traits;
PAAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg09796270	chr17:17721594	SREBF1	-0.52	-5.82	-0.43	3.35e-8	Total body bone mineral density;
PAAD	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17376030	chr22:41985996	PMM1	0.69	4.78	0.36	4.08e-6	Vitiligo;
PAAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.11	14.98	0.77	1e-31	Cognitive function;
PAAD	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.77	-6.11	-0.44	7.99e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg04545296	chr12:48745243	ZNF641	0.37	4.53	0.34	1.21e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.72	-7.09	-0.5	4.61e-11	Cognitive function;
PAAD	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.36e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs1364705	1.000	rs6986732	chr8:120225428	A/C	cg09273054	chr8:120220131	MAL2	0.41	4.7	0.36	5.79e-6	Hippocampal atrophy;
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.63	5.26	0.39	4.71e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19671926	chr4:122722719	EXOSC9	-0.58	-5.57	-0.41	1.14e-7	Type 2 diabetes;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg16434002	chr17:42200994	HDAC5	0.67	6.74	0.48	3.01e-10	Total body bone mineral density;
PAAD	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.84	7.09	0.5	4.76e-11	Neutrophil percentage of white cells;
PAAD	cis	rs1043515	1.000	rs1043515	chr17:36922196	C/T	cg20826740	chr17:37024042	NA	-0.38	-4.46	-0.34	1.61e-5	Height;
PAAD	cis	rs755249	0.532	rs61779278	chr1:39834617	A/G	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.54	-5.91	-0.43	2.17e-8	Testicular germ cell tumor;
PAAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg23283495	chr1:209979779	IRF6	0.81	7.46	0.52	6.12e-12	Coronary artery disease;
PAAD	cis	rs12153243	0.714	rs72806723	chr5:142930282	G/T	cg13907255	chr5:142895549	NA	-0.56	-4.9	-0.37	2.42e-6	Migraine;
PAAD	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.26	-0.39	4.73e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.21	0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg17401720	chr7:158221031	PTPRN2	-0.43	-4.93	-0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.52	-5.66	-0.42	7.27e-8	Migraine;
PAAD	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.55	5.69	0.42	6.27e-8	Multiple sclerosis;
PAAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.78	-8.87	-0.58	1.89e-15	DNA methylation (variation);
PAAD	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-6.25	-0.45	3.98e-9	Blood protein levels;
PAAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.93	0.43	2e-8	Dupuytren's disease;
PAAD	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg14219918	chr9:127249562	NR5A1	-0.35	-4.62	-0.35	8.19e-6	Menarche (age at onset);
PAAD	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg15556689	chr8:8085844	FLJ10661	0.53	4.75	0.36	4.57e-6	Systolic blood pressure;
PAAD	cis	rs9527	0.518	rs11191530	chr10:104800044	C/T	cg14737131	chr10:104680354	CNNM2	-0.69	-6.3	-0.45	3.09e-9	Arsenic metabolism;
PAAD	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs72960926	0.744	rs2352083	chr6:75023176	A/G	cg03266952	chr6:74778945	NA	-1.13	-6.3	-0.46	3.02e-9	Metabolite levels (MHPG);
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.25	-0.45	3.98e-9	Lung cancer;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.59	-0.41	1.01e-7	Ulcerative colitis;
PAAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	5.35	0.4	3.24e-7	Tonsillectomy;
PAAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg03983715	chr16:68378420	PRMT7	-0.95	-6.73	-0.48	3.23e-10	Schizophrenia;
PAAD	cis	rs62408225	0.888	rs58453446	chr6:90948093	G/C	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg20731937	chr12:48336164	NA	-0.51	-4.29	-0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg22189786	chr22:42395067	WBP2NL	0.51	4.35	0.33	2.47e-5	Birth weight;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg00450029	chr8:599525	NA	-0.82	-5.04	-0.38	1.33e-6	IgG glycosylation;
PAAD	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.74	7.6	0.52	2.82e-12	Colorectal cancer;
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.54	5.88	0.43	2.55e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs7608623	0.935	rs13387530	chr2:23943729	T/C	cg08917208	chr2:24149416	ATAD2B	-0.45	-4.46	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs58521262	0.530	rs289315	chr19:23161973	C/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg03822858	chr10:4066499	NA	0.8	5.0	0.38	1.56e-6	Major depressive disorder;
PAAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.94	-8.9	-0.59	1.59e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2283228	1.000	rs2283228	chr11:2849530	A/C	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	0.63	4.85	0.37	2.98e-6	Type 2 diabetes;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	5.61	0.41	9.54e-8	Height;
PAAD	cis	rs1570884	0.539	rs7999363	chr13:50111368	A/G	cg03651054	chr13:50194643	NA	0.34	4.34	0.33	2.58e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06850241	chr22:41845214	NA	-0.52	-4.73	-0.36	5.06e-6	Vitiligo;
PAAD	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg15192750	chr16:69999425	NA	-0.53	-4.45	-0.34	1.66e-5	Sjögren's syndrome;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.6	-0.35	8.83e-6	Triglycerides;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11115005	chr3:25728479	NA	0.57	6.46	0.46	1.33e-9	Pancreatic cancer;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg24879335	chr3:133465180	TF	0.6	7.14	0.5	3.69e-11	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	1.11	12.66	0.72	1.55e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.9	-5.77	-0.42	4.33e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9535307	0.584	rs61961502	chr13:50393700	G/A	cg03658251	chr13:50265850	EBPL	-0.76	-4.65	-0.35	7.14e-6	Obesity-related traits;
PAAD	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.92	-0.37	2.25e-6	Body mass index;
PAAD	cis	rs9616064	0.813	rs28448546	chr22:46971294	G/T	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.54	-0.35	1.14e-5	Urate levels in obese individuals;
PAAD	cis	rs1372356	0.788	rs12884100	chr14:88529291	A/C	cg18078958	chr14:88630771	NA	0.5	6.23	0.45	4.42e-9	Food antigen IgG levels;
PAAD	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.75	8.92	0.59	1.4e-15	Alcohol dependence;
PAAD	cis	rs3809912	0.527	rs571002	chr18:13090667	A/C	cg03156904	chr18:13801143	NA	0.47	4.53	0.34	1.19e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg01064725	chr1:204461714	NA	-0.5	-4.75	-0.36	4.76e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01207010	chr5:14664662	FAM105B	0.61	6.81	0.48	2.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.81	9.71	0.62	1.19e-17	Methadone dose in opioid dependence;
PAAD	cis	rs939584	1.000	rs939584	chr2:621558	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs59888335	1.000	rs59888335	chr3:80660050	C/T	cg21735741	chr3:80819488	NA	0.57	5.08	0.38	1.09e-6	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26658471	chr20:25677673	ZNF337	-0.75	-6.49	-0.47	1.13e-9	Neuroticism;
PAAD	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.9	0.37	2.4e-6	Lymphocyte counts;
PAAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg14847009	chr1:175162515	KIAA0040	-0.32	-5.06	-0.38	1.2e-6	Alcohol dependence;
PAAD	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.51	6.15	0.45	6.56e-9	Height;
PAAD	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.84	-7.94	-0.54	4.22e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg19582115	chr14:103436037	CDC42BPB	0.47	4.41	0.34	1.98e-5	Blood metabolite levels;
PAAD	cis	rs12449964	0.524	rs7224756	chr17:17572342	G/A	cg04398451	chr17:18023971	MYO15A	0.49	4.83	0.36	3.36e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.06	0.38	1.21e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs2529218	0.551	rs2529206	chr7:101421979	G/T	cg09205156	chr7:101991189	SPDYE6	0.55	4.7	0.36	5.79e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg15192750	chr16:69999425	NA	0.74	5.74	0.42	4.99e-8	IgE levels;
PAAD	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg20487152	chr13:99095054	FARP1	-0.5	-4.82	-0.36	3.52e-6	Longevity;
PAAD	cis	rs96067	0.607	rs274134	chr1:36580554	T/C	cg27506609	chr1:36549197	TEKT2	-0.82	-5.03	-0.38	1.38e-6	Corneal structure;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg10729496	chr3:10149963	C3orf24	0.67	5.9	0.43	2.31e-8	Alzheimer's disease;
PAAD	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.08	-11.56	-0.68	1.38e-22	Blood pressure (smoking interaction);
PAAD	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.77	-0.36	4.33e-6	Obesity-related traits;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18710985	chr20:16554249	KIF16B	0.57	6.32	0.46	2.72e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.51	-0.41	1.49e-7	Mean platelet volume;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.45	-0.34	1.64e-5	Response to amphetamines;
PAAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19784903	chr17:45786737	TBKBP1	0.52	5.55	0.41	1.24e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg03732007	chr1:2071316	PRKCZ	-0.47	-5.13	-0.38	8.77e-7	Height;
PAAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.43	4.75	0.36	4.75e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg01283332	chr5:1856932	NA	-0.47	-4.87	-0.37	2.75e-6	Cardiovascular disease risk factors;
PAAD	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.85e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.58	5.94	0.43	1.87e-8	Huntington's disease progression;
PAAD	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg11494091	chr17:61959527	GH2	0.55	4.7	0.36	5.83e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6494488	0.500	rs72741337	chr15:64760964	C/T	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg14388049	chr10:71211838	TSPAN15	-0.54	-5.46	-0.4	1.91e-7	Venous thromboembolism;
PAAD	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-1.04	-12.16	-0.7	3.5e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6499755	0.712	rs31108	chr16:55377999	T/G	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.78	7.94	0.54	4.05e-13	Retinal vascular caliber;
PAAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.94	-0.43	1.89e-8	Ulcerative colitis;
PAAD	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.9	11.17	0.67	1.62e-21	Dental caries;
PAAD	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.72	7.21	0.5	2.46e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9463078	0.546	rs1284975	chr6:45079345	T/A	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg10729496	chr3:10149963	C3orf24	0.81	6.76	0.48	2.72e-10	Alzheimer's disease;
PAAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg05110241	chr16:68378359	PRMT7	-0.99	-5.88	-0.43	2.54e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11023332	0.706	rs11023379	chr11:14929960	C/T	cg03486485	chr11:14927004	NA	0.43	4.3	0.33	3.06e-5	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.48	-4.36	-0.33	2.37e-5	Mean corpuscular volume;
PAAD	cis	rs6782025	0.837	rs601567	chr3:120718287	C/A	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg08601574	chr20:25228251	PYGB	0.66	7.27	0.51	1.76e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg27490568	chr2:178487706	NA	0.39	4.41	0.34	1.93e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7714584	1.000	rs7724036	chr5:150284808	A/G	cg22134413	chr5:150180641	NA	-0.66	-5.08	-0.38	1.11e-6	Crohn's disease;
PAAD	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.51	-4.76	-0.36	4.48e-6	Response to antidepressants and depression;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.54	-5.71	-0.42	5.79e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.73	7.62	0.53	2.58e-12	Lung cancer;
PAAD	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.62	-0.41	9.07e-8	Neuroticism;
PAAD	cis	rs183266	0.736	rs113537777	chr14:77486390	T/C	cg01682506	chr14:77422843	NA	-0.93	-4.49	-0.34	1.4e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg14191688	chr11:70257035	CTTN	0.58	5.18	0.39	7.03e-7	Coronary artery disease;
PAAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg00901687	chr17:48585270	MYCBPAP	0.62	6.82	0.48	2.04e-10	Visceral fat;
PAAD	cis	rs476633	0.708	rs2928155	chr15:41432187	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-7.9	-0.54	5.17e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.56	5.62	0.41	8.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs2124910	0.717	rs8102707	chr19:52008754	A/G	cg14953197	chr19:52005651	SIGLEC12	0.49	5.24	0.39	5.2e-7	Blood protein levels;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.65	-7.25	-0.51	1.95e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21796825	chr12:64173751	TMEM5	0.57	6.46	0.46	1.31e-9	Metabolite levels  (X-11787);
PAAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.74	-6.32	-0.46	2.76e-9	Exhaled nitric oxide output;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg10034588	chr2:232392055	NMUR1	-0.36	-4.38	-0.33	2.23e-5	Height;
PAAD	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg26876637	chr1:152193138	HRNR	-0.82	-5.97	-0.44	1.64e-8	Atopic dermatitis;
PAAD	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg03938978	chr2:103052716	IL18RAP	0.65	8.2	0.55	9.29e-14	Asthma;
PAAD	cis	rs6496932	0.865	rs4843049	chr15:85874372	G/A	cg19183879	chr15:85880815	NA	0.53	4.27	0.33	3.49e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08555112	chr17:48942811	TOB1	0.59	6.35	0.46	2.37e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg19680485	chr15:31195859	MTMR15	-0.45	-4.37	-0.33	2.26e-5	Huntington's disease progression;
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.4	0.61	7.96e-17	Menopause (age at onset);
PAAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg24053715	chr22:38214548	NA	-0.58	-5.62	-0.41	9.01e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	4.42	0.34	1.84e-5	Diisocyanate-induced asthma;
PAAD	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg23024343	chr7:107201750	COG5	0.57	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg24737193	chr18:12778029	NA	-0.63	-5.33	-0.4	3.43e-7	Inflammatory skin disease;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.56	5.94	0.43	1.89e-8	Menopause (age at onset);
PAAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.52	-6.1	-0.44	8.54e-9	Mean arterial pressure;
PAAD	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.11	15.04	0.77	6.76e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg21994712	chr19:21861136	NA	0.45	4.44	0.34	1.7e-5	Pain;
PAAD	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-4.72	-0.36	5.29e-6	Reticulocyte count;
PAAD	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg11143131	chr5:131608246	PDLIM4	0.51	5.16	0.39	7.7e-7	Blood metabolite levels;
PAAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.5	6.03	0.44	1.22e-8	Height;
PAAD	cis	rs733175	0.951	rs7669090	chr4:10028131	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	5.08	0.38	1.1e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.03	0.55	2.54e-13	Schizophrenia;
PAAD	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.57	-7.74	-0.53	1.26e-12	Renal cell carcinoma;
PAAD	cis	rs2718812	0.935	rs1006097	chr3:133411478	T/C	cg08439880	chr3:133502540	NA	0.43	4.96	0.37	1.87e-6	Iron status biomarkers;
PAAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.56	6.05	0.44	1.06e-8	Menopause (age at onset);
PAAD	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.73	6.54	0.47	8.79e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-4.48	-0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	10.57	0.65	6.54e-20	Menopause (age at onset);
PAAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24549020	chr5:56110836	MAP3K1	0.51	4.42	0.34	1.83e-5	Initial pursuit acceleration;
PAAD	cis	rs4979906	1.000	rs4979908	chr10:79452127	C/T	cg07817648	chr10:79422355	NA	-0.53	-4.87	-0.37	2.79e-6	Mortality in heart failure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10171557	chr20:34256821	NFS1	0.62	6.4	0.46	1.83e-9	Smoking initiation;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.71	-7.92	-0.54	4.69e-13	Renal function-related traits (BUN);
PAAD	cis	rs7727544	0.548	rs2069616	chr5:131408077	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.76	0.36	4.46e-6	Blood metabolite levels;
PAAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.57	-5.12	-0.38	9.04e-7	Schizophrenia;
PAAD	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg10578991	chr7:12443926	VWDE	-0.64	-4.54	-0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-8.01	-0.54	2.77e-13	Total body bone mineral density;
PAAD	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.75	9.09	0.59	5.02e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg10183150	chr4:120222239	C4orf3	0.36	5.16	0.39	7.64e-7	Corneal astigmatism;
PAAD	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.59	-5.35	-0.4	3.21e-7	Personality dimensions;
PAAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.55	4.33	0.33	2.74e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg09654669	chr8:57350985	NA	-0.54	-5.09	-0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.76e-6	Menarche (age at onset);
PAAD	cis	rs35160687	0.712	rs4832030	chr2:86478869	A/C	cg10973622	chr2:86423274	IMMT	-0.44	-4.9	-0.37	2.41e-6	Night sleep phenotypes;
PAAD	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg24565620	chr2:194026	NA	-0.68	-5.22	-0.39	5.7e-7	Blood protein levels;
PAAD	cis	rs11208691	0.513	rs60466849	chr1:66107714	A/G	cg04111102	chr1:66153794	NA	0.48	4.55	0.35	1.09e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs950881	0.932	rs72823646	chr2:102954213	G/A	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.64	-8.25	-0.56	6.81e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.88	-8.66	-0.57	6.36e-15	Neurofibrillary tangles;
PAAD	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.62	6.0	0.44	1.38e-8	Menopause (age at onset);
PAAD	cis	rs847577	0.550	rs6465654	chr7:97786282	G/A	cg19930314	chr7:98593876	TRRAP	-0.46	-4.6	-0.35	8.86e-6	Breast cancer;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Body mass index;
PAAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.86	-9.48	-0.61	4.94e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg06375148	chr1:209958343	C1orf74	0.62	4.96	0.37	1.83e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.33	5.19	0.39	6.49e-7	Alcohol dependence;
PAAD	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-1.06	-9.79	-0.62	7.39e-18	Prostate cancer;
PAAD	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-4.86	-0.37	2.9e-6	Testicular germ cell tumor;
PAAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.66	-8.9	-0.59	1.54e-15	Eye color traits;
PAAD	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.69	7.2	0.5	2.66e-11	Tonsillectomy;
PAAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-1.05	-14.69	-0.77	5.67e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2290416	0.710	rs61005957	chr8:144669512	T/G	cg13191508	chr8:144600686	ZC3H3	-0.87	-5.11	-0.38	9.64e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.34e-7	Bipolar disorder;
PAAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.59	5.8	0.43	3.68e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg26506288	chr17:46804123	HOXB13	-0.34	-4.32	-0.33	2.85e-5	Type 2 diabetes;
PAAD	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg19407955	chr1:165599744	MGST3	-0.59	-5.13	-0.38	8.89e-7	Total ventricular volume;
PAAD	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.88	7.06	0.5	5.54e-11	Axial length;
PAAD	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs501120	0.713	rs676966	chr10:44739594	A/G	cg09554077	chr10:44749378	NA	-0.44	-5.25	-0.39	5.1e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-4.61	-0.35	8.34e-6	Educational attainment;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.74e-7	Monocyte count;
PAAD	cis	rs2229238	0.911	rs73020232	chr1:154482669	C/T	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.91e-6	Coronary heart disease;
PAAD	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.12	0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.12	14.7	0.77	5.33e-31	Cognitive function;
PAAD	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	11.93	0.7	1.44e-23	Cognitive ability;
PAAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.7	-6.94	-0.49	1.08e-10	Callous-unemotional behaviour;
PAAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.82	7.4	0.51	8.6e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg21565972	chr17:80109576	CCDC57	0.5	5.52	0.41	1.45e-7	Life satisfaction;
PAAD	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	5.14	0.38	8.36e-7	Renal function-related traits (BUN);
PAAD	cis	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg18809830	chr7:99032528	PTCD1	-1.04	-4.56	-0.35	1.06e-5	Blood metabolite levels;
PAAD	cis	rs988913	0.624	rs980821	chr6:54854439	T/C	cg03513858	chr6:54763001	FAM83B	-0.42	-4.69	-0.36	6.11e-6	Menarche (age at onset);
PAAD	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.94	6.62	0.47	5.86e-10	Opioid sensitivity;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.34	0.4	3.33e-7	Bipolar disorder;
PAAD	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.35	9.33	0.6	1.22e-16	Diabetic retinopathy;
PAAD	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg22467129	chr15:76604101	ETFA	0.51	4.77	0.36	4.36e-6	Blood metabolite levels;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.89	-9.82	-0.62	6.25e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.74	-0.48	3.04e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.5	5.32	0.4	3.71e-7	Carotid intima media thickness;
PAAD	cis	rs13242816	1.000	rs3779513	chr7:116178992	T/C	cg16553024	chr7:116138462	CAV2	-0.64	-4.47	-0.34	1.55e-5	P wave duration;
PAAD	cis	rs12533831	0.518	rs6979015	chr7:150852393	T/A	cg25403974	chr7:150105495	LOC728743	0.52	4.49	0.34	1.43e-5	Childhood ear infection;
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	cis	rs2562456	0.833	rs8102783	chr19:21538553	T/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	5.58	0.41	1.06e-7	Blood protein levels;
PAAD	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg19640130	chr10:64028056	RTKN2	-0.36	-4.32	-0.33	2.82e-5	Rheumatoid arthritis;
PAAD	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.7	9.06	0.59	6.1e-16	Asthma (childhood onset);
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08677398	chr8:58056175	NA	0.68	4.76	0.36	4.45e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg20893579	chr22:38215064	NA	-0.57	-6.13	-0.45	7.26e-9	Glioblastoma;Glioma;
PAAD	cis	rs889122	0.836	rs56053932	chr19:10003011	G/T	cg03494634	chr19:9238958	OR7G3	0.39	4.41	0.34	1.91e-5	Menarche (age at onset);
PAAD	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg27411982	chr8:10470053	RP1L1	0.47	4.98	0.37	1.68e-6	Retinal vascular caliber;
PAAD	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21239572	chr9:111617595	ACTL7B	0.64	6.83	0.48	1.94e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.01	-0.38	1.53e-6	Coronary artery disease;
PAAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.17	-0.55	1.14e-13	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.75e-5	Morning vs. evening chronotype;
PAAD	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs859767	0.626	rs842354	chr2:135343934	C/G	cg12500956	chr2:135428796	TMEM163	0.32	4.53	0.34	1.2e-5	Neuroticism;
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.63	-5.48	-0.41	1.7e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2275731	0.723	rs12218061	chr10:16540239	C/T	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs793571	0.505	rs16940589	chr15:58898684	C/T	cg05156742	chr15:59063176	FAM63B	0.62	4.58	0.35	9.47e-6	Schizophrenia;
PAAD	cis	rs375066	0.901	rs372491	chr19:44401793	G/A	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.49	-5.23	-0.39	5.49e-7	Eosinophil percentage of white cells;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg11508406	chr4:1595515	NA	0.49	4.7	0.36	5.7e-6	Obesity-related traits;
PAAD	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.52	-4.61	-0.35	8.65e-6	Red blood cell traits;
PAAD	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg15309053	chr8:964076	NA	0.61	7.08	0.5	4.9e-11	Schizophrenia;
PAAD	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.06	-0.5	5.5e-11	Neuroticism;
PAAD	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.53	5.85	0.43	2.85e-8	Testicular germ cell tumor;
PAAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.77	-10.14	-0.64	8.84e-19	Bone mineral density;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.88	10.9	0.66	8.34e-21	Prudent dietary pattern;
PAAD	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg16434002	chr17:42200994	HDAC5	0.5	5.15	0.39	7.91e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs11264213	0.901	rs2765013	chr1:36374101	C/T	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26852971	chr16:4365424	NA	0.44	4.27	0.33	3.44e-5	Body mass index (adult);
PAAD	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4427176	0.825	rs6601355	chr8:9574783	G/C	cg03024720	chr8:9765601	NA	0.48	4.61	0.35	8.35e-6	Mosquito bite size;
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-7.15	-0.5	3.45e-11	Colorectal cancer;
PAAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.88	-7.24	-0.51	2.13e-11	Gut microbiome composition (summer);
PAAD	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg14926445	chr8:58193284	C8orf71	-0.67	-5.36	-0.4	3.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.62	5.24	0.39	5.38e-7	IgG glycosylation;
PAAD	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.9e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg27490568	chr2:178487706	NA	0.45	5.02	0.38	1.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8112211	0.689	rs4802326	chr19:38793227	C/T	cg01275006	chr19:38876250	GGN	-0.81	-5.08	-0.38	1.07e-6	Blood protein levels;
PAAD	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.4	0.34	2.02e-5	Personality dimensions;
PAAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.76	-8.72	-0.58	4.49e-15	Lung cancer in ever smokers;
PAAD	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.6	5.77	0.42	4.32e-8	Height;
PAAD	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.81	8.34	0.56	4.16e-14	Response to diuretic therapy;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11700980	0.551	rs8127818	chr21:30117123	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.97	-7.78	-0.53	1.01e-12	Blood protein levels;
PAAD	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg08027265	chr7:2291960	NA	-0.54	-5.45	-0.4	2.04e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	1.22	15.56	0.78	2.85e-33	Longevity;
PAAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-4.41	-0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.78	7.76	0.53	1.17e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03605463	chr16:89740564	NA	-0.5	-4.76	-0.36	4.5e-6	Vitiligo;
PAAD	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.19	-10.14	-0.64	8.82e-19	Vitiligo;
PAAD	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.2	0.45	5.19e-9	Coffee consumption (cups per day);
PAAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.7	-9.76	-0.62	8.91e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.5	5.03	0.38	1.36e-6	Menopause (age at onset);
PAAD	cis	rs11700980	0.551	rs2832045	chr21:30116753	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs362296	0.530	rs3129316	chr4:3287906	A/G	cg08886695	chr4:3369023	RGS12	-0.55	-5.38	-0.4	2.8e-7	Parental longevity (mother's age at death);
PAAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.63	6.65	0.47	5.03e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg25233709	chr10:116636983	FAM160B1	-0.36	-4.35	-0.33	2.52e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.69	-5.16	-0.39	7.47e-7	Resting heart rate;
PAAD	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg23954153	chr1:44402353	ARTN	-0.47	-4.46	-0.34	1.56e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-4.9	-0.37	2.39e-6	Blood metabolite levels;
PAAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg12639453	chr1:2035780	PRKCZ	-0.47	-5.15	-0.39	7.88e-7	Height;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.98e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05317498	chr16:1425256	UNKL	0.71	6.92	0.49	1.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.81	8.59	0.57	9.47e-15	Lewy body disease;
PAAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.99	11.76	0.69	4.12e-23	Cognitive function;
PAAD	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-5.65	-0.42	7.7e-8	Vitiligo;
PAAD	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg04851639	chr8:1020857	NA	-0.53	-6.0	-0.44	1.36e-8	Schizophrenia;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg11062466	chr8:58055876	NA	0.68	4.79	0.36	3.97e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.4	-4.56	-0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs9463078	0.546	rs1324532	chr6:45075795	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.59	-5.48	-0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2882667	0.690	rs6877187	chr5:138159344	T/C	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.649	rs10929683	chr2:10732208	C/T	cg12757816	chr2:10669957	NA	0.42	4.29	0.33	3.2e-5	Prostate cancer;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.33	0.56	4.39e-14	Platelet count;
PAAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.47	-4.57	-0.35	1.02e-5	Height;
PAAD	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.68	6.77	0.48	2.6200000000000003e-10	Tourette syndrome;
PAAD	cis	rs72960926	1.000	rs72960926	chr6:75158266	C/A	cg13997649	chr6:74171430	MTO1	0.88	4.42	0.34	1.87e-5	Metabolite levels (MHPG);
PAAD	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.34	-0.51	1.23e-11	Coronary artery disease;
PAAD	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11078597	0.697	rs3976	chr17:1653091	G/A	cg18436246	chr17:1640651	WDR81	0.81	7.16	0.5	3.16e-11	Serum albumin level;
PAAD	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.84	6.48	0.47	1.21e-9	Axial length;
PAAD	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.84	-0.54	7.48e-13	Colorectal cancer;
PAAD	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.44	-0.34	1.73e-5	Diastolic blood pressure;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg15117754	chr3:10150083	C3orf24	0.72	6.27	0.45	3.61e-9	Alzheimer's disease;
PAAD	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.65	-6.35	-0.46	2.32e-9	Itch intensity from mosquito bite;
PAAD	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.69	4.71	0.36	5.62e-6	Iron status biomarkers;
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.85	-10.39	-0.64	1.88e-19	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.53	4.95	0.37	1.93e-6	Uric acid clearance;
PAAD	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg19254793	chr6:44695348	NA	-0.45	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs1879734	1.000	rs1879734	chr1:54138854	T/C	cg14659662	chr1:54151053	GLIS1	-0.39	-5.96	-0.44	1.65e-8	Mitral valve prolapse;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13363640	chr11:2985302	SNORA54;NAP1L4	0.61	6.61	0.47	6.12e-10	Smoking initiation;
PAAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs3857067	0.550	rs12502748	chr4:94999939	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.23	-0.39	5.56e-7	QT interval;
PAAD	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg26954736	chr11:73693896	UCP2	1.05	4.68	0.36	6.19e-6	Obesity-related traits;
PAAD	cis	rs10861342	0.892	rs12322134	chr12:105646804	G/C	cg23923672	chr12:105501055	KIAA1033	0.74	4.41	0.34	1.97e-5	IgG glycosylation;
PAAD	cis	rs59888335	0.964	rs11127707	chr3:80705570	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.44	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26456999	chr2:236900867	AGAP1	0.62	6.3	0.46	3.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg01620082	chr3:125678407	NA	-1.09	-6.3	-0.46	3.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27294431	chr1:186344717	TPR;C1orf27;MIR548F1	0.57	6.42	0.46	1.63e-9	Metabolite levels  (X-11787);
PAAD	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs6421571	0.564	rs11216972	chr11:118585826	C/T	cg04176122	chr11:118779835	BCL9L	0.38	4.3	0.33	3.01e-5	Primary biliary cholangitis;
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.65	-0.53	2.08e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.6	-6.13	-0.45	7.3e-9	Ankylosing spondylitis;
PAAD	cis	rs2051773	0.539	rs6486345	chr11:17038777	A/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-4.71	-0.36	5.43e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.41	0.61	7.26e-17	Chronic sinus infection;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs617219	0.698	rs7445125	chr5:78507417	A/G	cg24856658	chr5:78533917	JMY	-0.38	-4.35	-0.33	2.52e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.54	-4.26	-0.33	3.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg07257824	chr6:170732353	NA	0.66	4.29	0.33	3.15e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3136739	0.681	rs7014440	chr8:41993474	C/T	cg17828057	chr8:42037527	PLAT	0.63	4.38	0.33	2.21e-5	Plasma plasminogen activator levels;
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.12	0.55	1.46e-13	Lung function (FEV1/FVC);
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.49	6.58	0.47	7.04e-10	Thyroid hormone levels;
PAAD	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-1.0	-17.44	-0.82	4.15e-38	Urate levels in lean individuals;
PAAD	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs900145	0.773	rs4757141	chr11:13307095	A/G	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.6	6.77	0.48	2.58e-10	Height;
PAAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs12127944	1.000	rs17419037	chr1:205479770	C/T	cg08473693	chr1:205342340	NA	-0.71	-4.61	-0.35	8.37e-6	IgG glycosylation;
PAAD	cis	rs2944755	0.723	rs13250299	chr8:141589584	A/G	cg18491938	chr8:141590271	EIF2C2	-0.54	-5.06	-0.38	1.21e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg21775007	chr8:11205619	TDH	0.5	4.8	0.36	3.74e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13988995	chr13:111340350	CARS2	-0.63	-6.53	-0.47	9.32e-10	Obesity-related traits;
PAAD	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg26497354	chr6:109612229	NA	-0.45	-4.56	-0.35	1.04e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.68	-0.35	6.3e-6	Lung cancer in ever smokers;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg05861140	chr6:150128134	PCMT1	-0.52	-6.17	-0.45	6.04e-9	Lung cancer;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.8	-8.98	-0.59	9.52e-16	Iron status biomarkers;
PAAD	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg14458575	chr2:238380390	NA	0.47	4.27	0.33	3.44e-5	Prostate cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18668503	chr20:57466137	GNAS	-0.56	-6.52	-0.47	9.68e-10	Body fat percentage;
PAAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.4	-0.34	2.06e-5	Aortic root size;
PAAD	cis	rs2235573	0.868	rs4821737	chr22:38500382	G/T	cg19070798	chr22:38240558	ANKRD54;MIR658	-0.48	-4.26	-0.33	3.62e-5	Glioblastoma;Glioma;
PAAD	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.92	-0.59	1.38e-15	Bone mineral density;
PAAD	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.78	6.66	0.48	4.68e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.51	0.34	1.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.95	-11.53	-0.68	1.7e-22	Longevity;
PAAD	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.42e-5	Resting heart rate;
PAAD	cis	rs7631605	0.905	rs6550457	chr3:37182198	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.4	0.34	2e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1413885	0.551	rs11208643	chr1:65852310	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.44	4.59	0.35	9.37e-6	Anticoagulant levels;
PAAD	cis	rs11583200	0.785	rs12743369	chr1:50564416	A/G	cg09846084	chr1:50888024	DMRTA2	0.43	4.31	0.33	2.86e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.08	8.05	0.55	2.25e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg15017067	chr4:17643749	FAM184B	0.41	4.76	0.36	4.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12935418	0.616	rs62054213	chr16:80968203	G/C	cg16651780	chr16:81037892	C16orf61	0.57	4.66	0.35	6.94e-6	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09459146	chr3:195595813	TNK2	-0.74	-7.3	-0.51	1.48e-11	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs17157832	chr10:45961761	T/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06620762	chr15:76136437	UBE2Q2	0.62	6.71	0.48	3.69e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26651784	chr16:67062934	CBFB	-0.63	-6.59	-0.47	6.89e-10	Smoking initiation;
PAAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6604026	0.656	rs2811596	chr1:93341223	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.93	-0.49	1.12e-10	Body mass index;
PAAD	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.52	4.89	0.37	2.5e-6	Cancer;
PAAD	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg10934807	chr2:113191815	RGPD8;RGPD5	0.97	7.42	0.52	7.58e-12	Yeast infection;
PAAD	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-6.29	-0.45	3.22e-9	Schizophrenia (age at onset);
PAAD	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-11.04	-0.67	3.52e-21	Cognitive function;
PAAD	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg10556349	chr10:835070	NA	0.61	4.38	0.33	2.24e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.23	0.6	2.14e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35300120	0.757	rs6696955	chr1:233654929	G/A	cg23054119	chr1:233659267	NA	-0.54	-4.88	-0.37	2.61e-6	Cognitive function;
PAAD	cis	rs1797885	0.714	rs299640	chr3:12532057	A/G	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.02e-5	Immature fraction of reticulocytes;
PAAD	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	6.33	0.46	2.6e-9	Monocyte count;
PAAD	cis	rs1723838	0.826	rs1531001	chr11:73606963	G/A	cg26954736	chr11:73693896	UCP2	1.09	4.75	0.36	4.64e-6	Obesity-related traits;
PAAD	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg23752985	chr2:85803571	VAMP8	0.52	6.01	0.44	1.3e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.62	-5.69	-0.42	6.35e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs72960926	1.000	rs56168999	chr6:75121136	A/G	cg03266952	chr6:74778945	NA	-1.08	-5.73	-0.42	5.28e-8	Metabolite levels (MHPG);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25621037	chr22:30988221	PES1	0.56	6.38	0.46	1.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8105895	0.935	rs8111854	chr19:22240213	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.32	-0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.95	6.51	0.47	1.04e-9	IgG glycosylation;
PAAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.95	-9.69	-0.62	1.41e-17	Bronchopulmonary dysplasia;
PAAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg09796270	chr17:17721594	SREBF1	-0.49	-5.46	-0.41	1.88e-7	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10333701	chr4:17811979	NCAPG;DCAF16	-0.73	-6.91	-0.49	1.26e-10	Neuroticism;
PAAD	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.52	4.42	0.34	1.87e-5	Menopause (age at onset);
PAAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg19337854	chr7:99768885	GPC2	-0.49	-5.11	-0.38	9.59e-7	Coronary artery disease;
PAAD	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.73	7.7	0.53	1.61e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-5.14	-0.38	8.34e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg01966878	chr4:90757139	SNCA	0.47	4.59	0.35	9.27e-6	Dementia with Lewy bodies;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02711976	chr1:36023590	NCDN;KIAA0319L	0.62	7.65	0.53	2.19e-12	Immature fraction of reticulocytes;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg21237687	chr17:6899380	ALOX12	0.58	6.0	0.44	1.4e-8	Blood metabolite levels;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-5.93	-0.43	1.96e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg09659197	chr4:152720779	NA	0.45	6.02	0.44	1.25e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6681460	0.510	rs6682534	chr1:67166666	T/C	cg02459107	chr1:67143332	SGIP1	0.59	5.45	0.4	2.03e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.05	-0.7	6.63e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg24881330	chr22:46731750	TRMU	1.08	5.26	0.39	4.81e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.52	-0.41	1.42e-7	Osteoporosis;
PAAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg14393609	chr7:65229607	NA	0.48	4.9	0.37	2.44e-6	Aortic root size;
PAAD	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg21523528	chr20:32077966	CBFA2T2	0.59	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg14847009	chr1:175162515	KIAA0040	-0.29	-4.44	-0.34	1.73e-5	Alcohol dependence;
PAAD	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.65	6.23	0.45	4.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.8e-7	Interstitial lung disease;
PAAD	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg02986806	chr22:18893533	DGCR6	0.57	6.49	0.47	1.16e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs1997066	0.831	rs59644304	chr10:106816249	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.52	0.34	1.24e-5	Diabetic kidney disease;
PAAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg20933634	chr6:27740509	NA	0.66	6.29	0.45	3.26e-9	Parkinson's disease;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08677398	chr8:58056175	NA	0.66	4.66	0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.84	6.46	0.46	1.32e-9	Axial length;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.560	rs12027445	chr1:152344787	A/T	cg26876637	chr1:152193138	HRNR	-0.68	-5.15	-0.39	8.05e-7	Atopic dermatitis;
PAAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.51e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs4668356	0.730	rs58307585	chr2:171925897	T/C	cg13882835	chr2:172017928	TLK1	0.92	5.23	0.39	5.42e-7	Cognitive performance;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.39	-0.34	2.11e-5	Life satisfaction;
PAAD	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	IgG glycosylation;
PAAD	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.53	4.58	0.35	9.67e-6	Corneal astigmatism;
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.36	-0.33	2.39e-5	Lung cancer;
PAAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg03808351	chr9:123631620	PHF19	0.47	5.06	0.38	1.17e-6	Rheumatoid arthritis;
PAAD	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.67	6.41	0.46	1.75e-9	Mosquito bite size;
PAAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.56	6.28	0.45	3.31e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6908034	0.607	rs73376651	chr6:19805559	C/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs939584	0.932	rs2867131	chr2:610603	T/C	cg03610516	chr2:642275	NA	0.58	4.92	0.37	2.19e-6	Body mass index;
PAAD	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.53	-0.41	1.37e-7	Total body bone mineral density;
PAAD	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.87	10.13	0.63	9.5e-19	Monocyte count;
PAAD	cis	rs4751006	0.543	rs12240532	chr10:128768446	G/A	cg05702161	chr10:128779687	DOCK1	-1.24	-6.92	-0.49	1.16e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg20933634	chr6:27740509	NA	0.68	6.53	0.47	9.41e-10	Parkinson's disease;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg08699206	chr4:1595414	NA	-0.46	-4.58	-0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.84	8.18	0.55	1.08e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.69	-4.55	-0.35	1.1e-5	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01283332	chr5:1856932	NA	-0.46	-4.86	-0.37	2.95e-6	Cardiovascular disease risk factors;
PAAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg01059385	chr22:42394853	WBP2NL	0.46	5.05	0.38	1.25e-6	Intelligence;
PAAD	cis	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg22134413	chr5:150180641	NA	0.71	5.15	0.39	7.87e-7	Crohn's disease;
PAAD	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6558530	0.836	rs7461159	chr8:1716616	A/T	cg02000426	chr8:1759815	NA	-0.41	-4.37	-0.33	2.31e-5	Systolic blood pressure;
PAAD	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg03538708	chr1:25844672	NA	-0.52	-5.39	-0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.42	-4.86	-0.37	2.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6062788	0.870	rs8116033	chr20:61699635	T/C	cg01771885	chr20:60882801	ADRM1	-0.27	-4.36	-0.33	2.43e-5	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03381304	chr8:6263789	MCPH1	0.61	6.63	0.47	5.53e-10	Myopia (pathological);
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.78	4.51	0.34	1.27e-5	Schizophrenia;
PAAD	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.67	-7.17	-0.5	3.06e-11	Dementia with Lewy bodies;
PAAD	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg03315344	chr16:75512273	CHST6	-0.63	-5.31	-0.4	3.86e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-15.32	-0.78	1.22e-32	Height;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.0	0.38	1.56e-6	Colorectal cancer;
PAAD	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg20913747	chr6:44695427	NA	-0.63	-6.15	-0.45	6.42e-9	Total body bone mineral density;
PAAD	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg05484376	chr2:27715224	FNDC4	-0.45	-4.59	-0.35	9.26e-6	Oral cavity cancer;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2798269	0.604	rs1200034	chr13:22165262	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.55	-4.95	-0.37	1.98e-6	PR segment;
PAAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg04398451	chr17:18023971	MYO15A	-0.78	-8.94	-0.59	1.23e-15	Total body bone mineral density;
PAAD	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.16	17.47	0.82	3.44e-38	Cognitive function;
PAAD	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.55	5.73	0.42	5.2e-8	Multiple sclerosis;
PAAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	4.77	0.36	4.31e-6	Platelet count;
PAAD	cis	rs6681460	0.932	rs2146904	chr1:67160336	C/T	cg02459107	chr1:67143332	SGIP1	-0.69	-6.34	-0.46	2.43e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.88	-8.49	-0.57	1.71e-14	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs10500871	1.000	rs4757905	chr11:20226556	T/G	cg02956962	chr6:161097311	NA	0.62	6.31	0.46	2.93e-9	Educational attainment;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04509559	chr14:69864994	ERH;SLC39A9	0.7	6.44	0.46	1.49e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	1.03	7.09	0.5	4.62e-11	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25894985	chr4:83294101	HNRNPD	0.73	7.53	0.52	4.29e-12	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.29	-0.68	7.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg07362569	chr17:61921086	SMARCD2	0.43	4.93	0.37	2.16e-6	Height;
PAAD	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg02196655	chr2:10830764	NOL10	0.63	6.82	0.48	1.97e-10	Prostate cancer;
PAAD	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg05425664	chr17:57184151	TRIM37	-0.49	-4.26	-0.33	3.5e-5	Testicular germ cell tumor;
PAAD	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13870426	chr17:30244630	NA	0.54	4.98	0.37	1.67e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13606994	chr1:44402422	ARTN	0.53	5.35	0.4	3.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.8	-9.0	-0.59	8.76e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg04289385	chr6:36355825	ETV7	0.44	4.42	0.34	1.87e-5	Platelet distribution width;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.49	-4.56	-0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg08562672	chr19:21860753	NA	0.45	4.79	0.36	3.85e-6	Pain;
PAAD	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-7.99	-0.54	3.05e-13	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.48	4.86	0.37	2.93e-6	Schizophrenia;
PAAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.28	0.39	4.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	5.31	0.4	3.84e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26009944	chr1:52210504	OSBPL9	0.54	6.42	0.46	1.67e-9	Body fat percentage;
PAAD	cis	rs78761021	0.867	rs62067560	chr17:9785427	G/A	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.12e-13	Type 2 diabetes;
PAAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.15e-11	Rheumatoid arthritis;
PAAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.85e-17	Cognitive function;
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.83	6.77	0.48	2.69e-10	Lung function (FEV1/FVC);
PAAD	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg07559730	chr19:53497048	ZNF702P	-0.54	-5.81	-0.43	3.55e-8	Psoriasis;
PAAD	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.77	9.56	0.61	2.96e-17	Bladder cancer;
PAAD	cis	rs17123764	0.710	rs11169109	chr12:50088363	A/T	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.79	-8.03	-0.55	2.5e-13	Anterior chamber depth;
PAAD	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	5.28	0.39	4.35e-7	Height;
PAAD	trans	rs4272720	0.855	rs11816318	chr10:50236368	C/T	cg15329866	chr3:171455826	PLD1	0.74	6.57	0.47	7.38e-10	Platelet count;Plateletcrit;
PAAD	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs72960926	0.744	rs72950506	chr6:74895922	A/G	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.76e-10	Metabolite levels (MHPG);
PAAD	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.88	-0.54	5.83e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs59888335	0.798	rs6766472	chr3:80651423	A/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.72e-6	Schizophrenia;
PAAD	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.94	-14.17	-0.75	1.4e-29	Height;
PAAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg24253500	chr15:84953950	NA	-0.47	-5.2	-0.39	6.45e-7	P wave terminal force;
PAAD	cis	rs4750440	0.702	rs4748068	chr10:14030692	T/A	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.26	-0.33	3.53e-5	Adiponectin levels;
PAAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg14393609	chr7:65229607	NA	-0.48	-4.9	-0.37	2.44e-6	Aortic root size;
PAAD	cis	rs2013441	0.613	rs7215803	chr17:19998377	C/T	cg13482628	chr17:19912719	NA	0.51	5.12	0.38	8.96e-7	Obesity-related traits;
PAAD	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg07159951	chr1:45983175	PRDX1	-0.41	-4.57	-0.35	9.89e-6	High light scatter reticulocyte count;
PAAD	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.95	-9.73	-0.62	1.05e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11159840	0.565	rs4899940	chr14:88553868	C/T	cg18078958	chr14:88630771	NA	-0.4	-4.73	-0.36	5.17e-6	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg01759136	chr6:27242945	NA	0.42	4.57	0.35	9.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.3	0.33	2.99e-5	Bipolar disorder;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg26338869	chr17:61819248	STRADA	0.49	4.66	0.35	6.79e-6	Height;
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.19	-0.5	2.72e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.49	-5.88	-0.43	2.54e-8	Mean corpuscular volume;
PAAD	cis	rs943466	1.000	rs7755323	chr6:33761159	A/G	cg04704449	chr6:33738291	NA	-0.46	-4.86	-0.37	2.96e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.56	-5.73	-0.42	5.27e-8	Facial morphology (factor 20);
PAAD	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.43	4.63	0.35	7.81e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.89	-8.09	-0.55	1.74e-13	Recombination rate (females);
PAAD	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-6.53	-0.47	9.53e-10	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs608114	0.623	rs1415190	chr6:96364732	A/G	cg03043157	chr6:97010903	FHL5	0.84	4.55	0.35	1.11e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.47	4.68	0.35	6.37e-6	Type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg05791153	chr7:19748676	TWISTNB	0.54	4.51	0.34	1.3e-5	Thyroid stimulating hormone;
PAAD	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.8	-0.48	2.28e-10	Retinal vascular caliber;
PAAD	cis	rs7688540	0.760	rs2883229	chr4:231744	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.4	0.34	2e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg21231944	chr12:82153410	PPFIA2	-0.54	-4.62	-0.35	8.12e-6	Resting heart rate;
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.84e-11	Interstitial lung disease;
PAAD	cis	rs12949688	0.651	rs4793915	chr17:55838163	C/T	cg12582317	chr17:55822272	NA	0.44	4.99	0.38	1.63e-6	Schizophrenia;
PAAD	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.64	5.98	0.44	1.5e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.68	6.59	0.47	6.92e-10	Coronary artery disease;
PAAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.8	7.97	0.54	3.42e-13	Vitiligo;
PAAD	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-5.21	-0.39	6.01e-7	Daytime sleep phenotypes;
PAAD	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-4.93	-0.37	2.12e-6	Schizophrenia (age at onset);
PAAD	trans	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg01620082	chr3:125678407	NA	-1.12	-6.4	-0.46	1.87e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.52	-4.96	-0.37	1.9e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2085601	0.518	rs2670629	chr4:89968290	G/C	cg17769793	chr4:89976368	FAM13A	-0.44	-5.5	-0.41	1.6e-7	Hair greying;
PAAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg19163074	chr7:65112434	INTS4L2	0.48	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.6	6.14	0.45	6.88e-9	Multiple sclerosis;
PAAD	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg09344028	chr17:70110421	NA	0.49	6.51	0.47	1.02e-9	Thyroid hormone levels;
PAAD	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	0.95	6.7	0.48	3.8e-10	Pulse pressure;
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02850689	chr1:2391347	NA	-0.45	-4.35	-0.33	2.48e-5	Non-obstructive azoospermia;
PAAD	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg08992911	chr2:238395768	MLPH	0.6	5.11	0.38	9.36e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs7714584	1.000	rs75294883	chr5:150196503	T/C	cg22134413	chr5:150180641	NA	1.03	6.27	0.45	3.64e-9	Crohn's disease;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	6.51	0.47	1.05e-9	Renal function-related traits (BUN);
PAAD	cis	rs914615	0.552	rs4276914	chr1:155142229	G/A	cg20311333	chr1:155197753	GBAP1	0.43	4.26	0.33	3.56e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg10818794	chr15:86012489	AKAP13	0.47	5.02	0.38	1.43e-6	Interstitial lung disease;
PAAD	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.49e-12	Childhood ear infection;
PAAD	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.5	-0.34	1.37e-5	Mood instability;
PAAD	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-5.84	-0.43	3.07e-8	Bipolar disorder;
PAAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26277730	chr18:60988085	BCL2	0.64	6.43	0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.86	10.94	0.66	6.39e-21	Body mass index;
PAAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg18446336	chr7:2847575	GNA12	0.4	4.5	0.34	1.33e-5	Loneliness (linear analysis);
PAAD	cis	rs9810890	1.000	rs73198862	chr3:128524945	C/T	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-1.0	-5.77	-0.42	4.26e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.32	0.71	1.25e-24	Menopause (age at onset);
PAAD	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.68	-4.45	-0.34	1.65e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	8.17	0.55	1.14e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.27e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg04575393	chr19:53496094	ZNF702P	-0.48	-5.18	-0.39	6.91e-7	Psoriasis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24587056	chr17:40306979	RAB5C	0.62	7.15	0.5	3.32e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73416724	0.858	rs4466248	chr6:43279652	T/C	cg26312998	chr6:43337775	ZNF318	-0.68	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.28	-0.33	3.3e-5	Red blood cell count;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	1.06	15.26	0.78	1.8e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2455826	0.521	rs6442546	chr3:15789996	C/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.58	-0.35	9.76e-6	Daytime sleep phenotypes;
PAAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg17366294	chr4:99064904	C4orf37	0.59	6.3	0.45	3.12e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg09659197	chr4:152720779	NA	0.46	6.27	0.45	3.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05680085	chr2:227700568	RHBDD1	-0.56	-6.34	-0.46	2.44e-9	Body fat percentage;
PAAD	cis	rs929596	0.564	rs2741029	chr2:234530160	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.61	-6.48	-0.47	1.22e-9	Brugada syndrome;
PAAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg14349672	chr11:133703707	NA	-0.56	-6.08	-0.44	9.31e-9	Childhood ear infection;
PAAD	cis	rs498136	0.966	rs2046493	chr11:69379188	G/A	cg24388239	chr11:68438018	NA	-0.42	-4.48	-0.34	1.47e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs2274459	0.841	rs34778247	chr6:33658552	C/A	cg06253072	chr6:33679850	C6orf125	0.66	4.82	0.36	3.49e-6	Obesity (extreme);
PAAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg09796270	chr17:17721594	SREBF1	0.44	5.08	0.38	1.07e-6	Total body bone mineral density;
PAAD	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs311392	0.715	rs311394	chr8:55083332	C/A	cg20636351	chr8:55087400	NA	-0.71	-7.66	-0.53	2.07e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-8.56	-0.57	1.17e-14	Prostate cancer;
PAAD	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.55	5.68	0.42	6.58e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg18888403	chr1:24152774	HMGCL	0.4	4.53	0.35	1.17e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg14196790	chr5:131705035	SLC22A5	-0.42	-4.61	-0.35	8.55e-6	Breast cancer;
PAAD	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.7	-0.42	5.93e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.49	-4.46	-0.34	1.61e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg27094323	chr7:1216898	NA	-0.45	-5.36	-0.4	2.97e-7	Longevity;Endometriosis;
PAAD	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg19337854	chr7:99768885	GPC2	0.58	5.29	0.39	4.27e-7	Lung function (FEV1/FVC);
PAAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23158103	chr7:148848205	ZNF398	-0.6	-5.89	-0.43	2.4e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9646944	0.501	rs12712144	chr2:102995600	C/G	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.71	-5.12	-0.38	9.17e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.81	-0.43	3.61e-8	Retinal vascular caliber;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16110411	chr5:1286162	TERT	-0.67	-6.54	-0.47	8.62e-10	Obesity-related traits;
PAAD	cis	rs8016982	1.000	rs8016982	chr14:81707057	C/T	cg01989461	chr14:81687754	GTF2A1	0.67	5.76	0.42	4.51e-8	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09744435	chr15:43425949	TMEM62	0.59	6.61	0.47	5.99e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.75e-5	Calcium levels;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01585852	chr22:24235823	MIF	-0.45	-4.92	-0.37	2.22e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg03771185	chr4:775700	NA	0.6	6.91	0.49	1.26e-10	Response to antipsychotic treatment;
PAAD	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.49	-7.08	-0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.72	7.06	0.5	5.67e-11	Total body bone mineral density;
PAAD	cis	rs6136489	0.710	rs4144201	chr20:1923623	T/G	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs2109514	1.000	rs2270188	chr7:116140524	G/T	cg19719915	chr7:115928094	NA	-0.47	-4.42	-0.34	1.85e-5	Prevalent atrial fibrillation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09116932	chr22:31477245	SMTN	0.58	6.43	0.46	1.56e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg03885332	chr11:832357	CD151	-0.45	-5.29	-0.39	4.2e-7	Mean platelet volume;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg27417659	chr7:98567827	TRRAP	-0.46	-4.38	-0.33	2.2e-5	Breast cancer;
PAAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.72	6.68	0.48	4.23e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	6.14	0.45	7.01e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.65	10.14	0.64	9.16e-19	Asthma (sex interaction);
PAAD	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg04165759	chr1:150448943	RPRD2	-0.54	-5.69	-0.42	6.3e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs9463078	0.510	rs1329714	chr6:45003335	T/A	cg18551225	chr6:44695536	NA	-0.43	-4.5	-0.34	1.33e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26850624	chr5:429559	AHRR	-0.8	-9.38	-0.61	8.68e-17	Cystic fibrosis severity;
PAAD	cis	rs10737909	1.000	rs10737909	chr1:15548636	A/C	cg21012057	chr1:15538911	TMEM51	0.58	6.23	0.45	4.38e-9	Migraine;
PAAD	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	10.15	0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs55823223	0.648	rs9894383	chr17:73865657	T/G	cg08125733	chr17:73851984	WBP2	0.93	8.15	0.55	1.23e-13	Psoriasis;
PAAD	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.57	-5.18	-0.39	6.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26160492	chr3:38009911	CTDSPL;MIR26A1	-0.62	-6.88	-0.49	1.48e-10	Monocyte percentage of white cells;
PAAD	cis	rs12136530	0.593	rs12121242	chr1:19740609	G/C	cg01468656	chr1:19991678	HTR6	0.5	4.47	0.34	1.54e-5	Lead levels in blood;
PAAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg02398342	chr17:80708632	TBCD;FN3K	0.7	4.99	0.38	1.63e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.72	-6.08	-0.44	9.47e-9	Neuroticism;
PAAD	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.31	0.4	3.88e-7	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24822001	chr3:43732329	ABHD5	0.6	6.98	0.49	8.44e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs375066	0.762	rs1073653	chr19:44411543	G/A	cg08633290	chr19:44405433	NA	0.54	5.16	0.39	7.61e-7	Breast cancer;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs256277	0.597	rs166263	chr5:111393231	G/A	cg17919331	chr5:112312406	DCP2	0.57	4.34	0.33	2.61e-5	Coronary artery disease;
PAAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22906224	chr7:99728672	NA	-0.61	-5.26	-0.39	4.74e-7	Coronary artery disease;
PAAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	8.61	0.57	8.67e-15	Cognitive test performance;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14142627	chr13:111301379	CARS2	0.6	7.07	0.5	5.32e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	4.83	0.36	3.34e-6	Breast cancer;
PAAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg20243544	chr17:37824526	PNMT	0.52	4.56	0.35	1.06e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.79	-7.97	-0.54	3.6e-13	Menopause (age at onset);
PAAD	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.72	6.65	0.47	4.93e-10	Mean platelet volume;
PAAD	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.53	-4.81	-0.36	3.65e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02528389	chr5:143550332	YIPF5;KCTD16	0.6	6.8	0.48	2.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.4	4.76	0.36	4.48e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg02475695	chr16:616220	NHLRC4	0.47	5.52	0.41	1.42e-7	Height;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg27644672	chr7:1858694	MAD1L1	-0.42	-4.64	-0.35	7.31e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs12304921	1.000	rs12306808	chr12:51354803	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg08501292	chr6:25962987	TRIM38	0.84	4.76	0.36	4.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	6.31	0.46	2.87e-9	Calcium levels;
PAAD	cis	rs3996993	0.597	rs12529923	chr6:52736056	C/T	cg00536792	chr6:53530503	KLHL31	-0.42	-4.43	-0.34	1.8e-5	Hemoglobin concentration;
PAAD	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg04990556	chr1:26633338	UBXN11	-0.52	-4.26	-0.33	3.56e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.55	5.59	0.41	1.01e-7	Menopause (age at onset);
PAAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.31e-5	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg02404636	chr22:31891804	SFI1	0.64	5.99	0.44	1.44e-8	Colorectal cancer;
PAAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2834902	0.578	rs2834898	chr21:36685144	C/A	cg04915566	chr21:36421472	RUNX1	-0.33	-4.51	-0.34	1.3e-5	Corneal curvature;
PAAD	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg14092571	chr14:90743983	NA	-0.58	-5.66	-0.42	7.3900000000000007e-08	Mortality in heart failure;
PAAD	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.77	8.08	0.55	1.85e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg03101763	chr11:65319844	LTBP3	-0.92	-5.06	-0.38	1.22e-6	Height;
PAAD	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg27398547	chr14:60952738	C14orf39	-0.81	-5.3	-0.39	4.04e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.72	7.82	0.54	8.39e-13	Lung cancer;
PAAD	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg10818794	chr15:86012489	AKAP13	-0.46	-5.11	-0.38	9.46e-7	Interstitial lung disease;
PAAD	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg27490568	chr2:178487706	NA	0.39	4.37	0.33	2.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg20333904	chr2:240724165	NA	-0.39	-4.73	-0.36	5.15e-6	Obesity-related traits;
PAAD	cis	rs3892630	0.558	rs4588103	chr19:33352770	G/A	cg22980127	chr19:33182716	NUDT19	0.91	7.71	0.53	1.55e-12	Red blood cell traits;
PAAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.05	0.38	1.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs11811982	0.793	rs78061959	chr1:227303004	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-4.34	-0.33	2.57e-5	Asthma;
PAAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg10556349	chr10:835070	NA	0.58	4.64	0.35	7.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.16	-16.83	-0.81	1.54e-36	Exhaled nitric oxide levels;
PAAD	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.55	5.91	0.43	2.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg21399703	chr1:247681439	NA	0.69	7.09	0.5	4.8e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg26174226	chr8:58114915	NA	-0.66	-5.93	-0.43	1.94e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.34e-9	Lung cancer;
PAAD	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.51	5.36	0.4	3.05e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs12799264	0.915	rs2120113	chr11:19975790	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.58	-5.42	-0.4	2.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8179	0.761	rs42035	chr7:92239531	A/G	cg03496780	chr7:92466842	CDK6	0.48	4.32	0.33	2.82e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.22	13.08	0.73	1.11e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs7823896	0.722	rs16879288	chr8:110304747	T/A	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg15654264	chr1:150340011	RPRD2	0.52	5.09	0.38	1.02e-6	Migraine;
PAAD	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg09667013	chr22:42394590	WBP2NL	0.54	5.41	0.4	2.43e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2562456	0.833	rs1781872	chr19:21477403	T/G	cg08562672	chr19:21860753	NA	-0.46	-4.8	-0.36	3.69e-6	Pain;
PAAD	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.71	4.87	0.37	2.82e-6	Major depressive disorder;
PAAD	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	6.38	0.46	2.04e-9	Body mass index;
PAAD	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg17652424	chr22:38574118	PLA2G6	0.28	4.42	0.34	1.85e-5	Cutaneous nevi;
PAAD	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.67	-4.91	-0.37	2.37e-6	Vitiligo;
PAAD	cis	rs73568641	0.546	rs6899940	chr6:154085465	A/C	cg15658985	chr6:154448740	OPRM1	0.56	4.62	0.35	8e-6	Methadone dose in opioid dependence;
PAAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.51	-5.33	-0.4	3.46e-7	Type 2 diabetes;
PAAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg07153921	chr17:41440717	NA	-0.42	-4.46	-0.34	1.59e-5	Menopause (age at onset);
PAAD	cis	rs28595532	0.720	rs72670233	chr4:119316237	C/G	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.67	-6.22	-0.45	4.56e-9	Vitamin D levels;
PAAD	cis	rs4454254	0.814	rs7815937	chr8:141065441	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.34	-4.79	-0.36	3.94e-6	Pulse pressure;
PAAD	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.91	5.15	0.39	7.89e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12667521	chr19:29218732	NA	0.63	5.5	0.41	1.58e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.07	-0.5	5.25e-11	Mood instability;
PAAD	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg09491104	chr22:46646882	C22orf40	-0.96	-6.0	-0.44	1.42e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs755249	0.567	rs72637906	chr1:39708302	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs3106136	0.843	rs1991316	chr4:95268272	G/T	cg11021082	chr4:95130006	SMARCAD1	0.59	5.73	0.42	5.24e-8	Capecitabine sensitivity;
PAAD	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.92	-12.0	-0.7	9.29e-24	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7941600	0.786	rs956517	chr11:9201995	C/G	cg19415743	chr11:9336845	TMEM41B	0.67	4.37	0.33	2.25e-5	Coronary artery disease;
PAAD	cis	rs78761021	0.867	rs17681708	chr17:9792872	T/C	cg26853458	chr17:9805074	RCVRN	0.72	8.38	0.56	3.23e-14	Type 2 diabetes;
PAAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.45	0.4	2.03e-7	Aortic root size;
PAAD	cis	rs10793968	0.688	rs2583849	chr9:133635211	A/G	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.89	9.85	0.62	5.09e-18	Monocyte count;
PAAD	cis	rs4679121	0.642	rs78537496	chr3:126164721	G/A	cg05485589	chr3:126194908	ZXDC	-0.92	-4.56	-0.35	1.03e-5	Pursuit maintenance gain;
PAAD	cis	rs7818688	0.697	rs60003497	chr8:95983423	A/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.66	7.06	0.5	5.47e-11	Crohn's disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00900124	chr2:69969033	ANXA4	0.57	6.55	0.47	8.34e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg11335335	chr11:637885	DRD4	-0.38	-5.17	-0.39	7.29e-7	Systemic lupus erythematosus;
PAAD	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-8.38	-0.56	3.24e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg19445457	chr11:5799446	OR52N5	0.52	4.71	0.36	5.55e-6	DNA methylation (variation);
PAAD	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.64	0.53	2.32e-12	Resting heart rate;
PAAD	cis	rs6466055	0.636	rs6466049	chr7:104896929	A/G	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs9900972	0.851	rs62077283	chr17:76868135	T/C	cg20937029	chr17:76870563	TIMP2	0.53	4.75	0.36	4.67e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09376238	chr14:96830058	ATG2B	0.64	7.01	0.49	7.11e-11	Myopia (pathological);
PAAD	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.85	-5.32	-0.4	3.67e-7	Response to metformin (IC50);
PAAD	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.76	-6.36	-0.46	2.23e-9	Type 2 diabetes;
PAAD	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.72	6.62	0.47	5.96e-10	Obesity-related traits;
PAAD	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.73e-7	Crohn's disease;
PAAD	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.57	0.61	2.87e-17	Response to antipsychotic treatment;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg22663859	chr13:21900854	NA	0.59	6.36	0.46	2.25e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg06042504	chr8:55087323	NA	-0.69	-7.02	-0.49	6.81e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Height;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg16606324	chr3:10149918	C3orf24	0.64	4.87	0.37	2.83e-6	Alzheimer's disease;
PAAD	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg10208897	chr5:178548229	ADAMTS2	0.53	4.72	0.36	5.26e-6	Pubertal anthropometrics;
PAAD	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.65	-7.54	-0.52	3.97e-12	Colorectal cancer;
PAAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.66	-6.42	-0.46	1.68e-9	Urate levels in lean individuals;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13198984	chr17:80129470	CCDC57	-0.39	-4.92	-0.37	2.27e-6	Life satisfaction;
PAAD	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.89	9.98	0.63	2.35e-18	Breast cancer;
PAAD	cis	rs494459	0.964	rs576283	chr11:118573894	A/G	cg08498647	chr11:118550644	TREH	-0.42	-5.21	-0.39	6.01e-7	Height;
PAAD	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.62	-0.35	8.26e-6	Renal cell carcinoma;
PAAD	cis	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg26467538	chr3:125486086	NA	-0.46	-4.32	-0.33	2.86e-5	Blood pressure (smoking interaction);
PAAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.57	-6.81	-0.48	2.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10885582	0.781	rs10885571	chr10:116293421	T/G	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.13	-0.38	8.69e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.13	-7.35	-0.51	1.11e-11	Plateletcrit;
PAAD	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.78	-0.36	4.14e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	1.07	16.07	0.79	1.42e-34	Menarche (age at onset);
PAAD	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.97	13.99	0.75	4.06e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg14019695	chr9:139328340	INPP5E	0.51	5.08	0.38	1.08e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	1.13	12.34	0.71	1.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.45	4.44	0.34	1.73e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.47	-6.84	-0.48	1.85e-10	Schizophrenia;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18621852	chr3:10150065	C3orf24	0.73	6.49	0.47	1.16e-9	Alzheimer's disease;
PAAD	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.75	5.42	0.4	2.28e-7	Major depressive disorder;
PAAD	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.76e-14	Triglycerides;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.67e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11998497	chr2:131688028	ARHGEF4	0.63	6.94	0.49	1.04e-10	Smoking initiation;
PAAD	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	1.03	5.36	0.4	3.08e-7	Body mass index;
PAAD	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg00277334	chr10:82204260	NA	0.54	6.19	0.45	5.45e-9	Sarcoidosis;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.77e-7	Life satisfaction;
PAAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	4.61	0.35	8.46e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg01299579	chr2:10830716	NOL10	0.44	4.41	0.34	1.95e-5	Prostate cancer;
PAAD	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs943466	1.000	rs2395400	chr6:33770076	G/A	cg04704449	chr6:33738291	NA	-0.52	-5.6	-0.41	9.55e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs17152411	1.000	rs11245440	chr10:126634572	C/T	cg07906193	chr10:126599966	NA	0.71	5.56	0.41	1.16e-7	Height;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	5.99e-8	Life satisfaction;
PAAD	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.89	-0.37	2.5e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.61e-6	Cognitive function;
PAAD	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.45	4.61	0.35	8.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg10183150	chr4:120222239	C4orf3	-0.37	-5.2	-0.39	6.47e-7	Corneal astigmatism;
PAAD	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.87	0.43	2.62e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.55	5.56	0.41	1.19e-7	Lung cancer;
PAAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.29	-0.45	3.14e-9	Bone mineral density;
PAAD	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.53	5.49	0.41	1.67e-7	Male-pattern baldness;
PAAD	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.53	-0.34	1.2e-5	Platelet count;
PAAD	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	1.1	13.01	0.73	1.73e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg08992911	chr2:238395768	MLPH	0.73	5.42	0.4	2.3e-7	Prostate cancer;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg10729496	chr3:10149963	C3orf24	0.67	5.95	0.43	1.76e-8	Alzheimer's disease;
PAAD	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2290402	0.536	rs3775129	chr4:875155	G/A	cg09237302	chr4:906077	GAK	-0.44	-4.59	-0.35	9.3e-6	Type 2 diabetes;
PAAD	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.8	-8.96	-0.59	1.11e-15	Mean platelet volume;
PAAD	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.38	-0.4	2.79e-7	Cognitive function;
PAAD	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.64	5.74	0.42	4.98e-8	Mean platelet volume;
PAAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.78	-7.5	-0.52	5.08e-12	Urate levels in lean individuals;
PAAD	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg04165759	chr1:150448943	RPRD2	0.5	5.19	0.39	6.58e-7	Migraine;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25273799	chr10:105198564	PDCD11	-0.59	-7.15	-0.5	3.48e-11	Monocyte percentage of white cells;
PAAD	cis	rs2997447	0.846	rs61775422	chr1:26395898	C/T	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.71	10.16	0.64	8.11e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.86	-7.81	-0.54	8.77e-13	Coronary artery disease;
PAAD	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs337161	0.719	rs337150	chr1:220941281	A/C	cg09023136	chr1:220959637	MOSC1	-0.6	-4.51	-0.34	1.28e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg25193494	chr16:90016004	DEF8	0.45	4.43	0.34	1.83e-5	Squamous cell carcinoma;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs11718455	0.503	rs6441813	chr3:44041323	C/T	cg21419209	chr3:44054225	NA	-0.61	-6.93	-0.49	1.12e-10	Coronary artery disease;
PAAD	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.5	-5.14	-0.38	8.26e-7	Tonsillectomy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21548464	chr13:50707937	NA	0.57	6.5	0.47	1.07e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.56	-4.44	-0.34	1.74e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg16928487	chr17:17741425	SREBF1	0.37	4.83	0.37	3.25e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.6	0.41	9.87e-8	Caffeine consumption;
PAAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-9.3	-0.6	1.48e-16	Height;
PAAD	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.28	0.39	4.38e-7	Heart rate;
PAAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.7	-7.68	-0.53	1.78e-12	Bone mineral density;
PAAD	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.78	8.52	0.57	1.44e-14	Colorectal cancer;
PAAD	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.4	0.4	2.56e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.72e-5	Systolic blood pressure;
PAAD	cis	rs6894268	0.762	rs4701137	chr5:179026192	C/A	cg26135573	chr5:179059668	NA	0.7	6.04	0.44	1.13e-8	Eating disorders;
PAAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.51	-4.65	-0.35	7.26e-6	Life satisfaction;
PAAD	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Vitiligo;
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg18904891	chr8:8559673	CLDN23	-0.49	-4.27	-0.33	3.42e-5	Mood instability;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.38	-0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.32	-0.33	2.78e-5	Depression;
PAAD	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.93e-11	Mosquito bite size;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.67	8.74	0.58	3.93e-15	Lymphocyte counts;
PAAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.85	-0.37	3.04e-6	Recombination rate (females);
PAAD	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	6.59	0.47	6.86e-10	Response to antipsychotic treatment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13138952	chr17:236013	NA	-0.54	-6.42	-0.46	1.64e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs26528	0.584	rs153103	chr16:28528623	A/G	cg16576597	chr16:28551801	NUPR1	-0.55	-5.57	-0.41	1.13e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg06740227	chr12:86229804	RASSF9	-0.5	-4.55	-0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs847851	0.833	rs3817473	chr6:34949451	C/T	cg05379947	chr6:35436047	RPL10A	-0.51	-4.28	-0.33	3.34e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17032980	0.956	rs7600954	chr2:67321682	G/A	cg06994420	chr2:66672553	MEIS1	-0.51	-4.5	-0.34	1.35e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg09127314	chr1:152161683	NA	-0.75	-5.4	-0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs8105895	0.935	rs7259971	chr19:22237319	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.68	-7.81	-0.54	8.71e-13	Bone mineral density;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.42	-0.34	1.84e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg05110241	chr16:68378359	PRMT7	1.18	8.17	0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9463078	0.845	rs2396425	chr6:45177025	A/G	cg25276700	chr6:44698697	NA	-0.48	-5.57	-0.41	1.12e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.36	0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs300774	0.925	rs409572	chr2:153302	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.27	0.33	3.39e-5	Asthma;
PAAD	cis	rs7719624	0.756	rs13168506	chr5:135396452	A/G	cg16684184	chr5:135415129	NA	0.39	4.9	0.37	2.42e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg10591111	chr5:226296	SDHA	-0.69	-5.2	-0.39	6.25e-7	Breast cancer;
PAAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.69	8.09	0.55	1.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg14393609	chr7:65229607	NA	0.48	4.9	0.37	2.44e-6	Aortic root size;
PAAD	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs1015213	0.609	rs77277680	chr8:52881125	G/A	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs2916733	0.752	rs2515581	chr8:6321203	C/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.25	-0.33	3.65e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.74	-8.3	-0.56	5.28e-14	Prostate cancer;
PAAD	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.29e-16	Asthma;
PAAD	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Crohn's disease;
PAAD	trans	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg26939375	chr7:64535504	NA	0.75	9.02	0.59	7.72e-16	Aortic root size;
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.75	7.69	0.53	1.73e-12	DNA methylation (variation);
PAAD	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg23957660	chr17:17878224	LRRC48	-0.37	-4.28	-0.33	3.32e-5	Total body bone mineral density;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.64	0.69	8.37e-23	Platelet count;
PAAD	cis	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-5.03	-0.38	1.36e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9287719	0.614	rs6711473	chr2:10723374	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg19767477	chr5:127420684	SLC12A2	0.54	4.38	0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.83	-5.73	-0.42	5.17e-8	Coronary artery disease;
PAAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.72	5.25	0.39	4.96e-7	Tuberculosis;
PAAD	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs11811982	0.744	rs114772174	chr1:227564515	T/G	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.65	-4.74	-0.36	4.84e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.7	6.86	0.49	1.65e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.59	6.23	0.45	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-6.43	-0.46	1.57e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26471467	chr22:38669073	TMEM184B	0.58	6.33	0.46	2.56e-9	Monocyte percentage of white cells;
PAAD	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-0.93	-9.16	-0.6	3.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18621852	chr3:10150065	C3orf24	0.68	6.21	0.45	4.89e-9	Alzheimer's disease;
PAAD	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs41311933	0.656	rs72758201	chr9:123828217	G/C	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg26174226	chr8:58114915	NA	-0.64	-5.33	-0.4	3.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg08200582	chr11:442649	ANO9	0.57	4.81	0.36	3.67e-6	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.84	-0.37	3.2e-6	Life satisfaction;
PAAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg10589385	chr1:150898437	SETDB1	-0.38	-4.57	-0.35	9.88e-6	Melanoma;
PAAD	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.67	6.7	0.48	3.86e-10	Multiple sclerosis;
PAAD	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs564309	0.681	rs1188483	chr1:228618088	A/C	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg06917450	chr1:38156652	C1orf109	-0.5	-4.51	-0.34	1.31e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7688540	0.511	rs6845131	chr4:200147	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.95	0.37	1.91e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg19930314	chr7:98593876	TRRAP	-0.48	-4.53	-0.34	1.19e-5	Breast cancer;
PAAD	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg00122941	chr17:4613640	ARRB2	0.83	8.23	0.56	7.99e-14	Lymphocyte counts;
PAAD	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg07486100	chr7:132562508	CHCHD3	0.38	4.26	0.33	3.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17741873	0.720	rs2227568	chr10:75673879	C/T	cg01368488	chr10:75493387	NA	-0.57	-4.42	-0.34	1.88e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg07475973	chr22:42306951	NA	0.47	4.4	0.34	2.04e-5	Neuroticism;
PAAD	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.85	10.58	0.65	5.97e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.37	-4.57	-0.35	1.02e-5	Schizophrenia;
PAAD	cis	rs17095355	0.818	rs11194981	chr10:111861054	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.87	-0.37	2.81e-6	Biliary atresia;
PAAD	cis	rs77774742	0.887	rs6911701	chr6:145350949	C/T	cg02758840	chr6:146285544	SHPRH	-0.68	-4.34	-0.33	2.55e-5	Loneliness (multivariate analysis);
PAAD	cis	rs11785693	0.730	rs62489552	chr8:4956801	T/C	cg26367366	chr8:4980734	NA	0.64	4.71	0.36	5.55e-6	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.68	-5.97	-0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.55	5.74	0.42	5.02e-8	Mean corpuscular volume;
PAAD	cis	rs16975963	0.843	rs11672163	chr19:38373856	G/A	cg25793785	chr19:38281423	NA	0.6	4.95	0.37	1.92e-6	Longevity;
PAAD	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.41	0.34	1.95e-5	Lung cancer;
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-8.48	-0.57	1.82e-14	Prostate cancer;
PAAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25833597	chr17:30823145	MYO1D	-0.48	-4.63	-0.35	7.93e-6	Schizophrenia;
PAAD	cis	rs4662592	0.590	rs36084105	chr2:128868432	C/T	cg17144508	chr2:128283727	IWS1	-0.54	-4.25	-0.33	3.67e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.72	8.55	0.57	1.23e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.7	5.23	0.39	5.41e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3784262	0.565	rs8041644	chr15:58266833	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-5.12	-0.38	9.16e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.89e-7	HDL cholesterol;
PAAD	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.47	4.48	0.34	1.44e-5	Longevity;
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.43	-4.61	-0.35	8.56e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.76	0.36	4.43e-6	Asthma;
PAAD	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.96	0.54	3.63e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs564309	0.681	rs1150917	chr1:228607395	T/C	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27096759	chr10:101770090	DNMBP	-0.65	-6.43	-0.46	1.53e-9	Lung cancer in ever smokers;
PAAD	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12304921	0.748	rs12580097	chr12:51500886	G/T	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.53	0.34	1.2e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12304921	0.748	rs61005916	chr12:51357946	T/A	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.16	-0.39	7.54e-7	Type 2 diabetes;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.83e-7	Obesity-related traits;
PAAD	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-4.44	-0.34	1.71e-5	Diabetic retinopathy;
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg13444538	chr7:158905317	VIPR2	0.55	5.18	0.39	7.09e-7	Facial morphology (factor 20);
PAAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg20893579	chr22:38215064	NA	0.52	5.18	0.39	6.88e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg21605333	chr4:119757512	SEC24D	1.91	10.98	0.66	5.25e-21	Cannabis dependence symptom count;
PAAD	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.37	-0.33	2.29e-5	Neuroticism;
PAAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.54	4.75	0.36	4.68e-6	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg15693483	chr7:1102177	C7orf50	0.46	5.12	0.38	8.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.54	5.55	0.41	1.22e-7	Diastolic blood pressure;
PAAD	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg26554054	chr8:600488	NA	-0.99	-6.24	-0.45	4.09e-9	IgG glycosylation;
PAAD	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.44	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.75	7.65	0.53	2.1e-12	Retinal vascular caliber;
PAAD	cis	rs6585424	1.000	rs61860024	chr10:81925363	G/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.76	-6.97	-0.49	9.08e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg04450456	chr4:17643702	FAM184B	-0.5	-4.9	-0.37	2.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.68	6.54	0.47	9.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-1.03	-13.79	-0.75	1.41e-28	Uric acid levels;
PAAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-6.07	-0.44	9.86e-9	Neuroticism;
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg21929781	chr1:2537748	MMEL1	-0.53	-5.6	-0.41	9.66e-8	Ulcerative colitis;
PAAD	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.59	5.35	0.4	3.15e-7	Obesity-related traits;
PAAD	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.64	-0.62	1.91e-17	Height;
PAAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.71	6.96	0.49	9.31e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.55	5.67	0.42	6.96e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02196655	chr2:10830764	NOL10	0.67	7.58	0.52	3.2e-12	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.02	0.81	4.86e-37	Prudent dietary pattern;
PAAD	cis	rs1499972	0.938	rs2925312	chr3:117720473	C/T	cg07612923	chr3:117604196	NA	-0.98	-6.67	-0.48	4.45e-10	Schizophrenia;
PAAD	cis	rs6496932	0.663	rs11074169	chr15:85918952	A/G	cg19183879	chr15:85880815	NA	-0.58	-5.36	-0.4	2.97e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs375066	0.935	rs422457	chr19:44409411	A/T	cg21496419	chr19:44306685	LYPD5	0.44	5.27	0.39	4.69e-7	Breast cancer;
PAAD	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.55	-4.8	-0.36	3.69e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg19847866	chr10:1019161	NA	-0.75	-7.61	-0.53	2.7e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1468333	0.538	rs13182414	chr5:137639838	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg20406979	chr6:167373233	NA	0.37	5.0	0.38	1.53e-6	Crohn's disease;
PAAD	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.66	6.31	0.46	2.88e-9	Corneal astigmatism;
PAAD	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.42	0.4	2.32e-7	Height;
PAAD	cis	rs17095355	0.792	rs2273738	chr10:111648659	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.37	-0.33	2.25e-5	Biliary atresia;
PAAD	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24738475	chr1:89149492	PKN2	-0.75	-6.67	-0.48	4.54e-10	Hip circumference;
PAAD	cis	rs714515	0.569	rs9425628	chr1:172451442	A/T	cg13446689	chr1:172328377	DNM3	-0.44	-5.36	-0.4	3.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg06917634	chr15:78832804	PSMA4	-0.46	-4.52	-0.34	1.26e-5	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg19000871	chr14:103996768	TRMT61A	-0.51	-5.79	-0.43	3.9e-8	Coronary artery disease;
PAAD	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg03264133	chr6:25882463	NA	-0.52	-4.37	-0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23158103	chr7:148848205	ZNF398	-0.6	-5.99	-0.44	1.46e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.59	5.88	0.43	2.47e-8	Multiple myeloma (IgH translocation);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg20626144	chr17:157107	RPH3AL	-0.66	-6.72	-0.48	3.39e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs721399	0.583	rs4646267	chr8:18247913	A/G	cg18736775	chr8:18248649	NAT2	-0.8	-6.77	-0.48	2.61e-10	Blood metabolite levels;
PAAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.72	-9.97	-0.63	2.54e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.53	-5.16	-0.39	7.6e-7	Schizophrenia;
PAAD	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg27449745	chr7:23145252	KLHL7	0.52	4.54	0.35	1.15e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs357618	1.000	rs357625	chr5:150848874	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.57	-0.35	1.02e-5	Basophil percentage of white cells;
PAAD	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.15	-0.5	3.34e-11	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01161138	chr12:977854	HSN2;WNK1	-0.63	-6.53	-0.47	9.4e-10	Obesity-related traits;
PAAD	cis	rs3736485	0.966	rs4775944	chr15:51775610	T/C	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.72	7.05	0.5	5.79e-11	Uric acid levels;
PAAD	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs35096708	0.525	rs34177108	chr16:89893375	C/A	cg02875869	chr16:89901417	SPIRE2	-0.55	-5.25	-0.39	5.09e-7	Skin aging (microtopography measurement);
PAAD	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.61	4.86	0.37	2.85e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	5.06	0.38	1.18e-6	Cognitive ability;
PAAD	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg05338066	chr1:7812865	CAMTA1	0.52	4.41	0.34	1.94e-5	Inflammatory bowel disease;
PAAD	cis	rs4751006	0.543	rs17692028	chr10:128783983	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.11e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01727434	chr2:152118530	RBM43	0.61	6.7	0.48	3.88e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs45430	0.635	rs398800	chr21:42742212	A/C	cg22778903	chr21:42741698	MX2	-0.66	-7.25	-0.51	2.01e-11	Melanoma;
PAAD	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-8.01	-0.54	2.8e-13	Hemoglobin concentration;
PAAD	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.84	-9.88	-0.63	4.28e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg20887711	chr4:1340912	KIAA1530	0.51	5.17	0.39	7.42e-7	Obesity-related traits;
PAAD	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg05528293	chr18:74961138	GALR1	0.56	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.57	6.58	0.47	7.04e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg25233709	chr10:116636983	FAM160B1	0.36	4.29	0.33	3.11e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.8	-0.36	3.72e-6	Ulcerative colitis;
PAAD	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.35	4.35	0.33	2.53e-5	Body mass index;
PAAD	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg02869306	chr7:64672164	INTS4L1	-0.52	-6.26	-0.45	3.73e-9	Calcium levels;
PAAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.78	-8.17	-0.55	1.11e-13	DNA methylation (variation);
PAAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.34	0.33	2.63e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg15571903	chr15:79123663	NA	0.47	6.11	0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs35160687	0.623	rs11127021	chr2:86474919	C/T	cg10973622	chr2:86423274	IMMT	-0.49	-5.56	-0.41	1.18e-7	Night sleep phenotypes;
PAAD	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs256277	0.657	rs469316	chr5:111366581	A/C	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.84	10.36	0.64	2.33e-19	Dental caries;
PAAD	cis	rs7523050	0.908	rs12405585	chr1:109397229	C/A	cg08274380	chr1:109419600	GPSM2	0.76	5.35	0.4	3.13e-7	Fat distribution (HIV);
PAAD	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg08601574	chr20:25228251	PYGB	-0.54	-5.63	-0.42	8.4e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.49	-4.61	-0.35	8.45e-6	Coronary artery disease;
PAAD	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg19554555	chr3:13937349	NA	0.57	5.75	0.42	4.66e-8	Ovarian reserve;
PAAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.11e-20	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	0.850	rs35081812	chr10:45995789	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.64	-6.48	-0.47	1.21e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg10547527	chr2:198650123	BOLL	-0.66	-4.61	-0.35	8.62e-6	Ulcerative colitis;
PAAD	cis	rs6604026	0.656	rs2481710	chr1:93337494	T/C	cg13858687	chr1:93297071	RPL5	-0.48	-4.34	-0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.93	10.51	0.65	9.25e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.48	4.52	0.34	1.22e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13443122	chr2:70142154	MXD1	0.66	6.68	0.48	4.34e-10	Obesity-related traits;
PAAD	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.51	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.72	-0.8	2.9e-36	Height;
PAAD	cis	rs75920871	0.925	rs4936359	chr11:116893724	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg00383909	chr3:49044727	WDR6	0.53	4.44	0.34	1.71e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20202505	chr21:47706161	MCM3AP;C21orf57	0.59	6.44	0.46	1.46e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.82	8.76	0.58	3.47e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9677476	0.632	rs6437008	chr2:232091948	C/G	cg07929768	chr2:232055508	NA	0.4	4.8	0.36	3.75e-6	Food antigen IgG levels;
PAAD	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg24076588	chr1:18808559	KLHDC7A	-0.41	-4.85	-0.37	3.03e-6	Breast cancer;
PAAD	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4906172	1.000	rs1678033	chr14:102435852	G/A	cg23904247	chr14:102554826	HSP90AA1	0.41	4.56	0.35	1.06e-5	Menopause (age at onset);
PAAD	cis	rs7786877	0.953	rs7457024	chr7:100215220	A/G	cg20848291	chr7:100343083	ZAN	-0.7	-6.27	-0.45	3.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg07685180	chr8:600429	NA	-1.01	-6.42	-0.46	1.64e-9	IgG glycosylation;
PAAD	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.34	-0.4	3.27e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2415984	0.519	rs2642102	chr14:46965502	A/G	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.62	7.02	0.5	6.75e-11	Testicular germ cell tumor;
PAAD	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.5	8.01	0.54	2.73e-13	Neuroticism;
PAAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19784903	chr17:45786737	TBKBP1	-0.68	-7.57	-0.52	3.34e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.88	7.19	0.5	2.8e-11	Axial length;
PAAD	cis	rs831571	0.876	rs56363381	chr3:64056677	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.6	-4.59	-0.35	9.3e-6	Type 2 diabetes;
PAAD	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.59	-5.79	-0.42	3.99e-8	Primary sclerosing cholangitis;
PAAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18621852	chr3:10150065	C3orf24	0.64	5.46	0.4	1.89e-7	Alzheimer's disease;
PAAD	cis	rs6494488	0.500	rs72744763	chr15:65076652	C/T	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs1977876	0.852	rs12405155	chr1:211713414	A/G	cg01575408	chr1:211752895	SLC30A1	0.55	4.56	0.35	1.04e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs11825685	1.000	rs11825685	chr11:134573810	C/T	cg02089395	chr11:134479357	NA	-0.69	-4.5	-0.34	1.32e-5	IgG glycosylation;
PAAD	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.68	-7.82	-0.54	8.03e-13	High light scatter reticulocyte count;
PAAD	cis	rs10857712	0.504	rs2265907	chr10:135218844	G/T	cg17796960	chr10:135278976	LOC619207	0.34	4.33	0.33	2.68e-5	Systemic lupus erythematosus;
PAAD	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4343996	0.870	rs6974075	chr7:3392071	A/G	cg21248987	chr7:3385318	SDK1	-0.46	-4.9	-0.37	2.41e-6	Motion sickness;
PAAD	cis	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.65	7.06	0.5	5.61e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7631605	0.623	rs4535177	chr3:36977460	A/G	cg17445812	chr3:36986805	TRANK1	0.33	4.46	0.34	1.56e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs3736485	0.873	rs7162563	chr15:51775067	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.28	-0.33	3.32e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.98	-11.3	-0.68	6.94e-22	Tonsillectomy;
PAAD	cis	rs11700980	0.551	rs12481819	chr21:30113901	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg20848291	chr7:100343083	ZAN	-0.93	-7.85	-0.54	6.88e-13	Other erythrocyte phenotypes;
PAAD	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg10547527	chr2:198650123	BOLL	-0.66	-4.49	-0.34	1.4e-5	Ulcerative colitis;
PAAD	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.98e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.69	7.78	0.53	1.05e-12	Height;
PAAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-6.06	-0.44	1.04e-8	Schizophrenia;
PAAD	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg00455402	chr19:21769736	NA	-0.51	-4.67	-0.35	6.53e-6	Pain;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.95	8.32	0.56	4.68e-14	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.8	0.58	2.89e-15	Lung cancer;
PAAD	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-5.72	-0.42	5.4e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.62	5.39	0.4	2.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs704	0.726	rs2073867	chr17:26678960	G/C	cg10342447	chr17:26645325	TMEM97	-0.36	-4.54	-0.35	1.13e-5	Osteoprotegerin levels;
PAAD	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.74	7.75	0.53	1.25e-12	Height;
PAAD	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg21929781	chr1:2537748	MMEL1	0.43	4.57	0.35	1.01e-5	Ulcerative colitis;
PAAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg22517653	chr1:2918612	NA	-0.63	-4.98	-0.37	1.69e-6	Plateletcrit;
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.66	6.51	0.47	1.03e-9	Prostate cancer;
PAAD	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg26816564	chr1:7831052	VAMP3	0.86	7.27	0.51	1.79e-11	Inflammatory bowel disease;
PAAD	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg08345082	chr10:99160200	RRP12	-0.31	-4.32	-0.33	2.83e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.88	-10.84	-0.66	1.22e-20	Body mass index;
PAAD	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-4.75	-0.36	4.74e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Gut microbiome composition (summer);
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.61	-0.47	6.13e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg17764715	chr19:33622953	WDR88	0.66	6.22	0.45	4.61e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-4.9	-0.37	2.39e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.66	-6.12	-0.44	7.8e-9	Diisocyanate-induced asthma;
PAAD	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.61	6.18	0.45	5.52e-9	Migraine;
PAAD	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.6	-6.02	-0.44	1.24e-8	Waist circumference adjusted for body mass index;
PAAD	cis	rs17032980	0.910	rs1921280	chr2:67329905	A/C	cg06994420	chr2:66672553	MEIS1	-0.51	-4.46	-0.34	1.56e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.6	5.51	0.41	1.48e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2073300	1.000	rs6048827	chr20:23458080	T/C	cg12062639	chr20:23401060	NAPB	0.85	4.54	0.35	1.16e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4605213	0.528	rs17574887	chr17:49332744	G/A	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.58	0.41	1.06e-7	Height;
PAAD	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.55	5.24	0.39	5.29e-7	Night sleep phenotypes;
PAAD	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg00536532	chr6:33561449	C6orf227	-0.43	-4.61	-0.35	8.44e-6	Height;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg21724239	chr8:58056113	NA	0.72	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.33	0.33	2.66e-5	Plateletcrit;
PAAD	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05647906	chr6:168378810	HGC6.3	0.63	6.44	0.46	1.46e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs16958440	0.581	rs12386097	chr18:44673268	G/A	cg17192377	chr18:44677553	HDHD2	0.65	4.38	0.33	2.21e-5	Sitting height ratio;
PAAD	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.62	-5.82	-0.43	3.36e-8	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.69	-0.42	6.45e-8	Personality dimensions;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19626725	chr5:178986131	RUFY1	-0.47	-4.94	-0.37	2.03e-6	Lung cancer;
PAAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.69	-6.03	-0.44	1.18e-8	Neuroticism;
PAAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.31	0.4	3.8e-7	Diabetic kidney disease;
PAAD	cis	rs802075	0.967	rs360562	chr6:49658441	G/T	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.44	5.5	0.41	1.6e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg27395922	chr11:50257633	LOC441601	-0.42	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs4774830	0.744	rs12900655	chr15:56151306	T/A	cg24530489	chr15:56299380	NA	1.09	4.65	0.35	7.16e-6	Delta-5 desaturase activity;
PAAD	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg20406979	chr6:167373233	NA	-0.37	-5.07	-0.38	1.14e-6	Crohn's disease;
PAAD	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg02153855	chr1:11041070	C1orf127	-0.37	-4.52	-0.34	1.23e-5	Hepatocellular carcinoma;
PAAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg25809561	chr17:30822961	MYO1D	0.56	5.72	0.42	5.53e-8	Schizophrenia;
PAAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg14829360	chr17:73884958	NA	-0.67	-5.83	-0.43	3.18e-8	Psoriasis;
PAAD	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs61861422	0.543	rs34309159	chr10:134419166	C/T	cg20090690	chr10:134436459	INPP5A	0.59	4.94	0.37	2.08e-6	Primary sclerosing cholangitis;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg05457628	chr5:178986728	RUFY1	-0.54	-5.54	-0.41	1.32e-7	Lung cancer;
PAAD	cis	rs876084	0.505	rs7459865	chr8:121115611	A/T	cg06265175	chr8:121136014	COL14A1	0.47	4.62	0.35	8.01e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08219700	chr8:58056026	NA	0.66	5.11	0.38	9.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg12072164	chr19:44306565	LYPD5	0.48	5.02	0.38	1.43e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs569214	0.648	rs576016	chr8:27513473	T/C	cg04264299	chr8:27491209	SCARA3	0.52	4.74	0.36	4.89e-6	Alzheimer's disease;
PAAD	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.6	7.1	0.5	4.43e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.48	6.46	0.46	1.33e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs904092	1.000	rs1229987	chr4:100217127	T/C	cg12011299	chr4:100065546	ADH4	-0.56	-4.69	-0.36	6.01e-6	Alcohol dependence;
PAAD	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.45	-4.37	-0.33	2.3e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.37	-5.61	-0.41	9.53e-8	Educational attainment (years of education);
PAAD	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-6.94	-0.49	1.05e-10	Gut microbiome composition (summer);
PAAD	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs925642	0.669	rs11721685	chr4:187672074	A/G	cg20274950	chr4:187647402	NA	-0.38	-4.35	-0.33	2.54e-5	Obesity;
PAAD	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg26149184	chr10:133730230	NA	-0.73	-6.34	-0.46	2.5e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.32	0.33	2.79e-5	Breast cancer;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.85	6.48	0.46	1.24e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.9	-10.85	-0.66	1.17e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg11993925	chr19:44307056	LYPD5	-0.5	-6.66	-0.48	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.49	6.25	0.45	3.93e-9	Prostate cancer;
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.51	-5.0	-0.38	1.59e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.66	0.42	7.28e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.75	8.82	0.58	2.53e-15	Lewy body disease;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.84	8.26	0.56	6.53e-14	Body mass index;
PAAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	6.05	0.44	1.1e-8	Personality dimensions;
PAAD	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg24519413	chr1:26490540	NA	0.52	4.81	0.36	3.57e-6	Height;
PAAD	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg12756303	chr2:74692479	MOGS	-0.48	-4.32	-0.33	2.79e-5	Metabolite levels;
PAAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.85	-0.37	3.04e-6	Recombination rate (females);
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.35	-0.4	3.23e-7	Life satisfaction;
PAAD	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-7.1	-0.5	4.44e-11	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.09	0.67	2.59e-21	Platelet count;
PAAD	cis	rs2229238	0.911	rs12405637	chr1:154501285	C/T	cg21262032	chr1:154437693	IL6R	-0.45	-4.77	-0.36	4.27e-6	Coronary heart disease;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24526587	chr1:164587676	PBX1	-0.55	-7.05	-0.5	5.76e-11	Monocyte percentage of white cells;
PAAD	cis	rs12580194	0.593	rs12296692	chr12:55756851	A/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.36	0.33	2.39e-5	Cancer;
PAAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs1372356	0.816	rs10873389	chr14:88532403	G/A	cg18078958	chr14:88630771	NA	0.5	6.33	0.46	2.6e-9	Food antigen IgG levels;
PAAD	cis	rs9916302	0.560	rs3764352	chr17:37790939	C/T	cg20243544	chr17:37824526	PNMT	0.63	5.4	0.4	2.47e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg10183150	chr4:120222239	C4orf3	-0.41	-5.63	-0.42	8.52e-8	Corneal astigmatism;
PAAD	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-5.17	-0.39	7.12e-7	Cystic fibrosis severity;
PAAD	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.75	8.42	0.56	2.62e-14	Longevity;
PAAD	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.98	0.37	1.7e-6	Personality dimensions;
PAAD	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg01766943	chr2:54829624	SPTBN1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.75	-8.87	-0.58	1.88e-15	Body mass index;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.1	-0.44	8.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-5.97	-0.44	1.64e-8	Lymphocyte counts;
PAAD	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.72	7.28	0.51	1.65e-11	Morning vs. evening chronotype;
PAAD	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg14440974	chr22:39074834	NA	0.49	5.91	0.43	2.19e-8	Menopause (age at onset);
PAAD	cis	rs12760731	0.668	rs12727134	chr1:178266794	T/C	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08047338	chr2:75873982	MRPL19	0.59	6.61	0.47	6.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17467752	chr17:38218738	THRA	0.49	4.44	0.34	1.74e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.8	8.54	0.57	1.32e-14	Calcium levels;
PAAD	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.62e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.52	-5.15	-0.39	8.03e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04045327	chr4:905805	GAK	0.39	5.02	0.38	1.46e-6	Systemic sclerosis;
PAAD	cis	rs9361491	0.608	rs7766791	chr6:79458753	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg18279126	chr7:2041391	MAD1L1	0.61	6.18	0.45	5.54e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg21775007	chr8:11205619	TDH	0.47	4.27	0.33	3.39e-5	Neuroticism;
PAAD	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.47	-0.41	1.84e-7	Airway imaging phenotypes;
PAAD	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg21775007	chr8:11205619	TDH	-0.57	-4.92	-0.37	2.26e-6	Neuroticism;
PAAD	cis	rs308971	0.563	rs394945	chr3:12075117	T/C	cg15873301	chr3:12045459	SYN2	0.63	4.46	0.34	1.56e-5	Fasting blood insulin (BMI interaction);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21211866	chr9:35111727	KIAA1539	0.64	7.36	0.51	1.06e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.67	-8.35	-0.56	3.85e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.75	5.92	0.43	2.05e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.65	6.66	0.48	4.72e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.36	-0.33	2.4e-5	Height;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg14660784	chr6:106773188	ATG5	-0.57	-6.76	-0.48	2.72e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.49	-5.27	-0.39	4.66e-7	Vitiligo;
PAAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.7	-5.75	-0.42	4.72e-8	Non-small cell lung cancer;
PAAD	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg13206674	chr6:150067644	NUP43	0.59	5.42	0.4	2.27e-7	Lung cancer;
PAAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2555155	0.806	rs10769697	chr11:6547407	A/G	cg10208301	chr11:6592745	DNHD1	-0.42	-4.31	-0.33	2.87e-5	DNA methylation (variation);
PAAD	cis	rs72901758	0.768	rs56046325	chr17:76251998	G/T	cg11439826	chr17:76250004	NA	0.48	4.73	0.36	4.99e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.53	5.68	0.42	6.51e-8	Major depressive disorder;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs72843506	0.656	rs56138907	chr17:19989045	G/C	cg12246644	chr17:19995277	CYTSB	0.58	4.3	0.33	3.01e-5	Schizophrenia;
PAAD	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg12310025	chr6:25882481	NA	0.44	4.32	0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs4787951	0.605	rs4360944	chr16:27307687	T/G	cg08008352	chr16:27322356	NA	0.5	4.58	0.35	9.55e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1144333	0.655	rs77244403	chr1:76304872	A/G	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.81	9.81	0.62	6.69e-18	Colorectal cancer;
PAAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	6.76	0.48	2.76e-10	Schizophrenia;
PAAD	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.18	0.5	2.84e-11	Neuroticism;
PAAD	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.78	7.74	0.53	1.28e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg14388049	chr10:71211838	TSPAN15	-0.47	-4.67	-0.35	6.49e-6	Venous thromboembolism;
PAAD	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.9	9.66	0.62	1.7e-17	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg18944383	chr4:111397179	ENPEP	0.65	7.15	0.5	3.42e-11	Coronary artery disease;
PAAD	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-4.43	-0.34	1.83e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.99	-10.45	-0.65	1.36e-19	Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.47	-5.68	-0.42	6.81e-8	Menopause (age at onset);
PAAD	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs7009110	0.593	rs4739744	chr8:81312920	A/G	cg21158561	chr8:81178149	NA	0.45	4.28	0.33	3.24e-5	Asthma and hay fever;
PAAD	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.55	-5.22	-0.39	5.73e-7	Dental caries;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.96	8.39	0.56	3.13e-14	Alzheimer's disease;
PAAD	cis	rs12754538	0.777	rs12029303	chr1:8638666	T/C	cg06159269	chr1:8767347	RERE	0.42	4.85	0.37	3.03e-6	Subjective well-being;
PAAD	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.43	-4.73	-0.36	4.99e-6	Platelet count;
PAAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	trans	rs4382726	0.548	rs6674807	chr1:209414935	C/A	cg14042241	chr19:1474872	C19orf25	0.53	6.36	0.46	2.22e-9	Response to amphetamines;
PAAD	cis	rs7301016	1.000	rs11174504	chr12:62877036	A/G	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs2017305	0.915	rs80180159	chr10:70749756	G/A	cg25290552	chr10:70751067	KIAA1279	-0.88	-4.94	-0.37	2e-6	Depression (quantitative trait);
PAAD	cis	rs13256369	0.671	rs59003218	chr8:8554921	G/A	cg17143192	chr8:8559678	CLDN23	0.69	6.55	0.47	8.35e-10	Obesity-related traits;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg21280320	chr1:152162025	NA	0.55	5.62	0.41	8.99e-8	Inflammatory skin disease;
PAAD	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.63	5.99	0.44	1.43e-8	Menopause (age at onset);
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg27413539	chr10:131576096	NA	-0.57	-5.8	-0.43	3.79e-8	Vitamin D levels;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg11271282	chr2:238384023	NA	0.51	4.78	0.36	4.16e-6	Prostate cancer;
PAAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-8.82	-0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg21929781	chr1:2537748	MMEL1	0.43	4.57	0.35	1.01e-5	Ulcerative colitis;
PAAD	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.64	-0.65	4.15e-20	Platelet distribution width;
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.74	-7.7	-0.53	1.58e-12	Prostate cancer;
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08214693	chr8:144885540	SCRIB	0.58	6.77	0.48	2.69e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12660364	chr7:44788915	ZMIZ2	-0.72	-7.72	-0.53	1.46e-12	Smoking initiation;
PAAD	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.54	-4.62	-0.35	8e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs732765	0.734	rs9323602	chr14:75182008	A/G	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	8.39	0.56	3.1e-14	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.38	4.43	0.34	1.76e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg17330251	chr7:94953956	PON1	0.53	4.41	0.34	1.93e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.36	8.3	0.56	5.1e-14	Cognitive function;
PAAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.83	-9.28	-0.6	1.64e-16	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04839219	chr2:234684024	NA	-0.54	-6.54	-0.47	8.84e-10	Obesity-related traits;
PAAD	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg25828445	chr12:7781288	NA	0.77	5.51	0.41	1.47e-7	HDL cholesterol levels;
PAAD	cis	rs76866386	1.000	rs11887534	chr2:44066247	G/C	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.83	-5.25	-0.39	5.15e-7	Cholesterol, total;
PAAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.75	-8.9	-0.59	1.6e-15	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05134775	chr10:98273510	TLL2	0.64	7.43	0.52	7.23e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.74	8.0	0.54	2.98e-13	Aortic root size;
PAAD	cis	rs2236267	0.726	rs2755075	chr14:88579279	A/G	cg18078958	chr14:88630771	NA	-0.5	-6.32	-0.46	2.78e-9	Food antigen IgG levels;
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.84	10.69	0.65	3.13e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.31	5.4	0.4	2.48e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4740619	0.648	rs752489	chr9:16032679	G/C	cg14451791	chr9:16040625	NA	-0.48	-5.58	-0.41	1.1e-7	Body mass index;
PAAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-5.15	-0.39	7.98e-7	Lymphocyte counts;
PAAD	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.91	11.35	0.68	5.15e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05671241	chr3:126373822	NA	0.64	7.2	0.5	2.58e-11	Myopia (pathological);
PAAD	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg19904058	chr10:135279010	LOC619207	-0.48	-5.82	-0.43	3.44e-8	Systemic lupus erythematosus;
PAAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10556349	chr10:835070	NA	0.67	5.2	0.39	6.22e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.93	11.7	0.69	5.95e-23	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.23	-0.39	5.64e-7	Life satisfaction;
PAAD	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-9.27	-0.6	1.73e-16	Body mass index;
PAAD	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg09168692	chr1:7887560	PER3	-0.43	-4.44	-0.34	1.7e-5	Inflammatory bowel disease;
PAAD	cis	rs354033	0.759	rs67512364	chr7:149331604	C/A	cg06920324	chr7:149264011	ZNF767	-0.57	-4.44	-0.34	1.7e-5	Multiple sclerosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17050049	chr20:61904214	ARFGAP1	-0.72	-6.3	-0.46	3.06e-9	Neuroticism;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.01	0.81	5.21e-37	Prudent dietary pattern;
PAAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22482690	chr17:47019901	SNF8	0.47	5.11	0.38	9.5e-7	Type 2 diabetes;
PAAD	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.21	-0.45	4.83e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.76	8.64	0.57	7.2e-15	Type 2 diabetes;
PAAD	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg20406979	chr6:167373233	NA	-0.36	-4.93	-0.37	2.13e-6	Crohn's disease;
PAAD	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg19847866	chr10:1019161	NA	-0.56	-4.43	-0.34	1.82e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.55	5.03	0.38	1.35e-6	Interleukin-17 levels;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.06	0.44	1.04e-8	Lung cancer;
PAAD	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.96	11.91	0.69	1.63e-23	Bone mineral density;
PAAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg24842760	chr6:133561719	EYA4	0.9	6.81	0.48	2.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.41	4.69	0.36	6.04e-6	Cystic fibrosis severity;
PAAD	cis	rs1075265	0.933	rs7573491	chr2:54343012	C/A	cg04546899	chr2:54196757	PSME4	0.32	4.53	0.34	1.21e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs4819143	0.517	rs439145	chr21:47373995	G/A	cg13695288	chr21:47294981	PCBP3	0.55	4.73	0.36	5.16e-6	Insulin resistance/response;
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.86	11.06	0.67	3.09e-21	Vitiligo;
PAAD	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6762644	0.507	rs13075137	chr3:4765093	C/T	cg11584376	chr3:4789075	ITPR1	-0.4	-4.43	-0.34	1.79e-5	Breast cancer;
PAAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.49	-4.48	-0.34	1.44e-5	Coronary artery disease;
PAAD	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.73	-0.58	4.31e-15	Exhaled nitric oxide output;
PAAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg23346134	chr3:49453900	TCTA	0.46	4.96	0.37	1.9e-6	Menarche (age at onset);
PAAD	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.71	6.41	0.46	1.69e-9	Intraocular pressure;
PAAD	cis	rs10090774	0.965	rs11778798	chr8:141918880	A/G	cg02508881	chr8:142216119	NA	0.4	4.25	0.33	3.77e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.52e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.76	-7.67	-0.53	1.95e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg05484376	chr2:27715224	FNDC4	0.47	4.67	0.35	6.7e-6	Total body bone mineral density;
PAAD	cis	rs10044254	0.537	rs6862949	chr5:15691746	G/A	cg07238450	chr5:15720153	FBXL7	-0.53	-5.02	-0.38	1.45e-6	Asthma (corticosteroid response);
PAAD	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-6.76	-0.48	2.78e-10	Myopia (pathological);
PAAD	cis	rs4742903	0.875	rs7037174	chr9:106924871	C/T	cg14250997	chr9:106856677	SMC2	0.47	5.11	0.38	9.56e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.04	19.13	0.84	2.69e-42	Birth weight;
PAAD	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.15	-0.6	3.45e-16	Response to antipsychotic treatment;
PAAD	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg08743896	chr10:65200160	JMJD1C	-0.44	-4.3	-0.33	3.07e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1371614	0.566	rs1440042	chr2:27187814	G/A	cg00617064	chr2:27272375	NA	-0.51	-5.41	-0.4	2.43e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.33	-4.85	-0.37	3.04e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.73e-5	Calcium levels;
PAAD	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.54	5.33	0.4	3.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.89	-7.95	-0.54	3.98e-13	IgG glycosylation;
PAAD	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.18	0.45	5.56e-9	Alzheimer's disease;
PAAD	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg10820045	chr2:198174542	NA	0.56	5.71	0.42	5.65e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg06714761	chr1:201096289	NA	0.3	4.57	0.35	1.01e-5	Permanent tooth development;
PAAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.63	-4.8	-0.36	3.7e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.54	-5.63	-0.42	8.44e-8	Inflammatory bowel disease;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.05	0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	cis	rs2131877	0.913	rs58434965	chr3:194846096	C/G	cg21937377	chr3:194868750	C3orf21	0.4	4.25	0.33	3.74e-5	Non-small cell lung cancer;
PAAD	cis	rs17213078	0.505	rs737101	chr2:106732545	C/T	cg16099169	chr2:106886729	NA	0.45	4.25	0.33	3.78e-5	Facial morphology (factor 23);
PAAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.36	-0.46	2.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.57	-0.35	1.02e-5	Height;
PAAD	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg21823605	chr1:152486609	CRCT1	0.49	6.14	0.45	6.82e-9	Hair morphology;
PAAD	cis	rs17601876	0.545	rs61018102	chr15:51533530	G/C	cg21478137	chr15:51532386	CYP19A1	0.49	4.83	0.36	3.26e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-5.23	-0.39	5.44e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1539053	0.932	rs7548317	chr1:58106514	A/G	cg00026909	chr1:58089001	DAB1	-0.65	-7.66	-0.53	1.99e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg07153921	chr17:41440717	NA	-0.4	-4.28	-0.33	3.32e-5	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03301075	chr11:3254240	MRGPRE	0.71	9.02	0.59	7.57e-16	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.69	7.12	0.5	4.01e-11	Melanoma;
PAAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs904092	0.720	rs1230019	chr4:100172691	A/G	cg12011299	chr4:100065546	ADH4	0.6	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.62	10.45	0.65	1.3e-19	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg07202610	chr7:1142643	C7orf50	-0.78	-5.47	-0.41	1.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.77	-7.41	-0.51	8.37e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.64	5.83	0.43	3.2e-8	Trans fatty acid levels;
PAAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg10818794	chr15:86012489	AKAP13	-0.47	-5.16	-0.39	7.54e-7	Interstitial lung disease;
PAAD	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.76	-0.48	2.81e-10	Exhaled nitric oxide output;
PAAD	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.01	13.89	0.75	7.61e-29	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg25155006	chr6:37138205	PIM1	-0.52	-4.61	-0.35	8.59e-6	QRS duration;
PAAD	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-1.05	-11.07	-0.67	2.85e-21	Platelet distribution width;
PAAD	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.93	6.06	0.44	1.02e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03044149	chr1:228327742	GUK1	0.54	6.34	0.46	2.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7580658	0.680	rs12468304	chr2:128193812	A/G	cg09760422	chr2:128146352	NA	0.42	6.98	0.49	8.39e-11	Protein C levels;
PAAD	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.77	7.9	0.54	5.21e-13	Alzheimer's disease (late onset);
PAAD	cis	rs863345	0.565	rs2051665	chr1:158507157	A/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.25e-6	Pneumococcal bacteremia;
PAAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.49	4.26	0.33	3.62e-5	Height;
PAAD	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.26	0.33	3.51e-5	Migraine;
PAAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs9314614	0.872	rs2977794	chr8:6710357	A/G	cg27319216	chr8:6693540	XKR5	-0.34	-4.66	-0.35	6.81e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.48	6.21	0.45	4.94e-9	Crohn's disease;
PAAD	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg08134877	chr2:44394819	PPM1B	0.44	4.44	0.34	1.69e-5	Height;
PAAD	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-4.53	-0.35	1.17e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg00206168	chr11:65308501	LTBP3	0.53	5.5	0.41	1.54e-7	Bone mineral density;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.93	12.45	0.71	5.72e-25	Prudent dietary pattern;
PAAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.82	0.36	3.38e-6	Multiple sclerosis;
PAAD	cis	rs8133932	0.701	rs2150454	chr21:47288142	T/C	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.53	-0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg01489032	chr8:143877656	NA	-0.48	-5.06	-0.38	1.18e-6	Urinary tract infection frequency;
PAAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.97	5.0	0.38	1.57e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-4.88	-0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.38e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs3829109	0.564	rs11789379	chr9:139285260	T/C	cg21253087	chr9:139290292	SNAPC4	0.52	4.68	0.36	6.23e-6	Peak insulin response;Acute insulin response;
PAAD	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.53	-5.97	-0.44	1.61e-8	Metabolite levels;
PAAD	cis	rs9337951	0.579	rs2505083	chr10:30335122	C/T	cg11771529	chr10:31047686	NA	-0.36	-4.3	-0.33	3.09e-5	Pulse pressure;Coronary artery disease;
PAAD	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs72960926	1.000	rs72960934	chr6:75161902	T/A	cg03266952	chr6:74778945	NA	-1.28	-6.46	-0.46	1.36e-9	Metabolite levels (MHPG);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13393195	chr12:113659153	TPCN1;IQCD	0.63	7.09	0.5	4.77e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.7	-7.83	-0.54	7.8e-13	Eosinophil percentage of white cells;
PAAD	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.86	-4.63	-0.35	7.67e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg14146966	chr2:61757674	XPO1	-0.4	-5.02	-0.38	1.41e-6	Tuberculosis;
PAAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.4	-5.88	-0.43	2.54e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg18357526	chr6:26021779	HIST1H4A	0.66	6.63	0.47	5.43e-10	Height;
PAAD	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg07150166	chr2:30669952	LCLAT1	0.81	5.78	0.42	4.12e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs10943724	0.679	rs953499	chr6:81266456	C/T	cg19323245	chr6:80716898	TTK	-0.43	-4.54	-0.35	1.14e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06850241	chr22:41845214	NA	-0.61	-5.28	-0.39	4.31e-7	Vitiligo;
PAAD	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12304921	0.549	rs66781280	chr12:51461912	A/G	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.58	-0.35	9.71e-6	Type 2 diabetes;
PAAD	cis	rs7714584	1.000	rs3900064	chr5:150264414	C/G	cg22134413	chr5:150180641	NA	-0.69	-5.05	-0.38	1.26e-6	Crohn's disease;
PAAD	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg02877791	chr2:177005403	NA	0.44	4.33	0.33	2.64e-5	IgG glycosylation;
PAAD	cis	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.76	-0.36	4.56e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.23	0.39	5.41e-7	Bipolar disorder;
PAAD	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-5.77	-0.42	4.34e-8	Bone mineral density;
PAAD	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.7	7.63	0.53	2.43e-12	Morning vs. evening chronotype;
PAAD	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg12395012	chr8:11607386	GATA4	0.48	4.47	0.34	1.5e-5	Alcohol dependence;Nicotine use;
PAAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.75	-8.76	-0.58	3.56e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Magnesium levels;
PAAD	cis	rs3812111	0.677	rs1204804	chr6:116546924	C/T	cg18828861	chr6:116576566	TSPYL4	0.4	4.31	0.33	2.93e-5	Age-related macular degeneration;
PAAD	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg17749961	chr2:30669863	LCLAT1	0.67	4.93	0.37	2.09e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.17	0.5	3.08e-11	Obesity-related traits;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg21211367	chr2:162094118	NA	-0.6	-6.94	-0.49	1.08e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-8.19	-0.55	9.74e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.39	-0.34	2.15e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg08698997	chr16:88989212	CBFA2T3	-0.39	-4.73	-0.36	4.98e-6	Social autistic-like traits;
PAAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg12940439	chr1:67600707	NA	0.37	4.38	0.34	2.17e-5	Crohn's disease;
PAAD	cis	rs2124910	0.689	rs3810110	chr19:52004743	G/A	cg14953197	chr19:52005651	SIGLEC12	0.45	4.84	0.37	3.16e-6	Blood protein levels;
PAAD	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.79	0.62	7.63e-18	Chronic sinus infection;
PAAD	cis	rs4462272	0.557	rs3904036	chr10:101998414	T/C	cg11888571	chr10:102027403	CWF19L1	-0.49	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1468734	1.000	rs1468733	chr16:5001481	G/C	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.57	-4.56	-0.35	1.03e-5	Cancer;
PAAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62247992	0.686	rs834175	chr3:43104848	C/A	cg12239580	chr3:43073058	FAM198A	-0.52	-4.48	-0.34	1.48e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg20487152	chr13:99095054	FARP1	0.45	4.74	0.36	4.79e-6	Longevity;
PAAD	cis	rs1642645	0.831	rs11210563	chr1:42494633	G/T	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12799264	0.915	rs894550	chr11:19977001	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-1.01	-6.97	-0.49	8.83e-11	Coronary artery disease;
PAAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.92	0.37	2.18e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.9	0.69	1.67e-23	Smoking behavior;
PAAD	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.26	-0.51	1.82e-11	Leprosy;
PAAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	10.89	0.66	8.94e-21	Monocyte count;
PAAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.52	-6.88	-0.49	1.44e-10	Diastolic blood pressure;
PAAD	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg16083429	chr3:49237500	CCDC36	0.46	4.54	0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.7	0.36	5.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.86	9.78	0.62	7.78e-18	Cognitive function;
PAAD	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-5.97	-0.44	1.59e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.38	0.33	2.17e-5	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13370280	chr6:137539688	IFNGR1	0.6	6.51	0.47	1.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-5.12	-0.38	9.19e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.01	-0.38	1.48e-6	Schizophrenia;
PAAD	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.35	4.29	0.33	3.13e-5	Body mass index in non-asthmatics;
PAAD	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	9.11	0.59	4.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.78	0.42	4.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.74e-13	Monocyte percentage of white cells;
PAAD	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.8	-5.47	-0.41	1.8e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs2235544	0.554	rs7540270	chr1:54484682	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.23	-4.25	-0.33	3.66e-5	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
PAAD	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg12893428	chr3:195717962	SDHAP1	0.46	4.54	0.35	1.15e-5	Pancreatic cancer;
PAAD	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.99	6.41	0.46	1.7e-9	LDL cholesterol;
PAAD	cis	rs4356203	0.933	rs12801545	chr11:17266176	C/A	cg15432903	chr11:17409602	KCNJ11	0.41	4.27	0.33	3.48e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.7	-0.48	3.88e-10	Life satisfaction;
PAAD	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.59	-5.57	-0.41	1.12e-7	Malaria;
PAAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.73	-0.48	3.27e-10	IgG glycosylation;
PAAD	cis	rs787274	0.681	rs787270	chr9:115549092	C/T	cg13803584	chr9:115635662	SNX30	-0.99	-6.54	-0.47	8.98e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.86	9.3	0.6	1.43e-16	Bone mineral density;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.95	-8.59	-0.57	9.53e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075265	0.527	rs959285	chr2:54306101	C/A	cg04546899	chr2:54196757	PSME4	0.32	4.69	0.36	6.09e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.19	0.6	2.74e-16	Hemoglobin concentration;
PAAD	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.62	0.35	8.14e-6	Skin pigmentation;
PAAD	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10577284	chr10:81838377	LOC219347;C10orf57	0.62	6.39	0.46	1.9e-9	Myopia (pathological);
PAAD	trans	rs1442089	0.764	rs74803484	chr18:51138212	C/T	cg24118715	chr10:70232072	DNA2	0.75	6.42	0.46	1.63e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg07153921	chr17:41440717	NA	-0.42	-4.38	-0.33	2.21e-5	Menopause (age at onset);
PAAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg03808351	chr9:123631620	PHF19	0.46	5.01	0.38	1.51e-6	Rheumatoid arthritis;
PAAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	9.04	0.59	6.96e-16	Colorectal cancer;
PAAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.62	6.93	0.49	1.13e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs62179067	0.708	rs62175987	chr2:179876514	A/G	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Urinary tract infection frequency;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.7	8.68	0.58	5.88e-15	Dupuytren's disease;
PAAD	cis	rs28830936	0.934	rs2412641	chr15:42124399	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.73	-0.48	3.23e-10	Diastolic blood pressure;
PAAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg00999904	chr2:3704751	ALLC	0.49	5.71	0.42	5.64e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9287719	0.649	rs6722126	chr2:10721642	A/G	cg12757816	chr2:10669957	NA	-0.42	-4.29	-0.33	3.22e-5	Prostate cancer;
PAAD	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.31	-0.56	4.97e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00142150	chr22:38071001	LGALS1	0.78	8.61	0.57	8.5e-15	Fat distribution (HIV);
PAAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.19e-7	Ulcerative colitis;
PAAD	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.4	-0.34	2.02e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.93	12.06	0.7	6.48e-24	Methadone dose in opioid dependence;
PAAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.57	-5.75	-0.42	4.68e-8	Personality dimensions;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21083709	chr3:129035520	H1FX;C3orf47	-0.74	-6.34	-0.46	2.49e-9	Neuroticism;
PAAD	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg22875332	chr1:76189707	ACADM	-0.49	-4.82	-0.36	3.4e-6	Daytime sleep phenotypes;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11037575	1.000	rs11037575	chr11:43728330	T/C	cg24662154	chr11:44118094	EXT2	0.42	4.32	0.33	2.85e-5	Neuroblastoma;
PAAD	cis	rs1371614	0.632	rs3739085	chr2:27163044	T/C	cg00617064	chr2:27272375	NA	-0.42	-4.5	-0.34	1.36e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.84	9.51	0.61	4.1e-17	Prudent dietary pattern;
PAAD	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.87e-6	Myopia (pathological);
PAAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.61	5.05	0.38	1.28e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.63	6.74	0.48	3.11e-10	Mean platelet volume;
PAAD	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	0.96	6.14	0.45	7.05e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.57	5.96	0.44	1.71e-8	Menopause (age at onset);
PAAD	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.01	7.06	0.5	5.61e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs16857609	0.529	rs2373058	chr2:218250549	G/C	cg15335768	chr2:218268053	DIRC3	-0.48	-4.8	-0.36	3.73e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19615174	chr19:4558545	SEMA6B	0.68	6.75	0.48	2.88e-10	Obesity-related traits;
PAAD	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	6.29	0.45	3.16e-9	Initial pursuit acceleration;
PAAD	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.75	7.08	0.5	5.01e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.36	4.27	0.33	3.44e-5	Schizophrenia;
PAAD	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	4.33	0.33	2.67e-5	Educational attainment;
PAAD	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg18551225	chr6:44695536	NA	-0.77	-7.54	-0.52	3.91e-12	Total body bone mineral density;
PAAD	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg09399716	chr2:46890238	NA	-0.73	-5.95	-0.43	1.74e-8	Height;
PAAD	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.91e-13	Coronary artery disease;
PAAD	cis	rs10885582	0.809	rs10787538	chr10:116315951	A/C	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.16	-0.39	7.44e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-4.77	-0.36	4.21e-6	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg18357526	chr6:26021779	HIST1H4A	0.53	4.78	0.36	4.16e-6	Height;
PAAD	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs6442522	0.678	rs3732722	chr3:15507761	G/A	cg16303742	chr3:15540471	COLQ	0.48	5.15	0.39	7.94e-7	Uric acid levels;
PAAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg01287884	chr10:130110330	NA	-0.38	-4.33	-0.33	2.65e-5	Vitamin D levels;
PAAD	cis	rs76917914	0.561	rs73492791	chr9:100833925	T/C	cg21225548	chr9:100864335	TRIM14	-0.46	-5.04	-0.38	1.32e-6	Immature fraction of reticulocytes;
PAAD	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.95	0.43	1.79e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.58	-0.68	1.23e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.38	-5.14	-0.38	8.36e-7	Schizophrenia;
PAAD	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs939421	0.521	rs2280411	chr3:46599984	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.34	-5.13	-0.38	8.7e-7	Blood protein levels;
PAAD	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.41	-5.14	-0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15235096	chr8:22014439	LGI3	0.57	6.67	0.48	4.51e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12139190	chr11:3014171	NAP1L4	0.61	6.9	0.49	1.3100000000000001e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg10985347	chr2:127963512	CYP27C1	0.48	4.47	0.34	1.52e-5	Protein C levels;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs11892454	0.544	rs7582924	chr2:25997020	T/C	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	cis	rs2730260	0.537	rs3793222	chr7:158863536	A/C	cg13444538	chr7:158905317	VIPR2	0.63	4.79	0.36	3.96e-6	Myopia (pathological);
PAAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg14895029	chr7:2775587	GNA12	0.46	4.47	0.34	1.52e-5	Height;
PAAD	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10207060	0.500	rs28640956	chr2:240714001	G/C	cg07506560	chr2:240697449	NA	0.56	5.81	0.43	3.58e-8	Obesity-related traits;
PAAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-9.99	-0.63	2.29e-18	Bone mineral density;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13830393	chr12:108079615	PWP1	0.63	7.49	0.52	5.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg22546130	chr22:19950026	COMT	-0.32	-5.08	-0.38	1.09e-6	Blood metabolite levels;
PAAD	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.27	-0.33	3.42e-5	Total body bone mineral density;
PAAD	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.63	0.47	5.42e-10	Atopic dermatitis;
PAAD	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs74544699	1.000	rs353029	chr4:74776804	C/T	cg05509609	chr4:74847829	PF4	1.14	4.4	0.34	2.04e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.7	-6.28	-0.45	3.31e-9	Diabetic retinopathy;
PAAD	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs10411696	0.868	rs3829687	chr19:1053299	C/T	cg18950617	chr19:1066959	HMHA1	-0.46	-4.57	-0.35	9.93e-6	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.8	5.37	0.4	2.96e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9361491	0.608	rs9448540	chr6:79441675	G/T	cg05283184	chr6:79620031	NA	-0.41	-4.91	-0.37	2.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs112990264	0.541	rs113753058	chr1:212877202	T/G	cg01785514	chr1:212988523	TATDN3	1.13	6.72	0.48	3.48e-10	Itch intensity from mosquito bite;
PAAD	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.1	-0.38	1e-6	Pulmonary function;
PAAD	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-4.86	-0.37	2.87e-6	Osteoarthritis;
PAAD	cis	rs7121446	0.521	rs11218490	chr11:121862691	A/G	cg13820391	chr11:121835505	NA	0.46	4.29	0.33	3.2e-5	Cardiovascular risk factors (age interaction);
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg04257695	chr17:30186438	C17orf79	-0.53	-4.36	-0.33	2.43e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs34779708	0.801	rs12255409	chr10:35535425	G/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.68	-4.95	-0.37	1.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs6499129	1.000	rs7185709	chr16:67529349	T/G	cg10189135	chr16:67516162	ATP6V0D1	-0.56	-4.29	-0.33	3.14e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg10621924	chr7:39171070	POU6F2	0.27	4.51	0.34	1.29e-5	IgG glycosylation;
PAAD	cis	rs527409	1.000	rs6668411	chr1:58746316	A/G	cg26345888	chr1:58716257	DAB1	-0.62	-4.76	-0.36	4.45e-6	Kawasaki disease;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.59	5.88	0.43	2.5e-8	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23358589	chr6:56958631	ZNF451	-0.64	-6.43	-0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs96067	0.772	rs6664471	chr1:36606757	A/G	cg24686825	chr1:36642396	MAP7D1	-0.5	-4.29	-0.33	3.19e-5	Corneal structure;
PAAD	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.42	4.64	0.35	7.62e-6	Depression;
PAAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg10547527	chr2:198650123	BOLL	0.63	4.29	0.33	3.18e-5	Ulcerative colitis;
PAAD	cis	rs735539	0.521	rs9552280	chr13:21365361	T/A	cg27499820	chr13:21296301	IL17D	0.51	4.65	0.35	7.22e-6	Dental caries;
PAAD	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.35	-0.46	2.41e-9	Alcohol dependence;
PAAD	cis	rs8040855	0.627	rs12905036	chr15:85637788	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.59	4.96	0.37	1.88e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg25452165	chr22:42524984	CYP2D6	0.62	5.77	0.42	4.39e-8	Schizophrenia;
PAAD	cis	rs501120	0.584	rs11238925	chr10:44703730	A/G	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6604026	0.656	rs9651257	chr1:93385136	A/G	cg17283838	chr1:93427260	FAM69A	0.61	5.48	0.41	1.71e-7	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13053817	0.904	rs13053624	chr22:29838203	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.14	-0.38	8.27e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.81	5.6	0.41	9.55e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Gut microbiome composition (summer);
PAAD	cis	rs10804591	0.666	rs4688807	chr3:129309263	C/T	cg18548199	chr3:129281892	PLXND1	-0.51	-4.39	-0.34	2.09e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.59	5.31	0.4	3.87e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg03482866	chr13:111040579	COL4A2	-0.45	-4.35	-0.33	2.46e-5	White matter hyperintensity burden;
PAAD	cis	rs9659323	1.000	rs9658899	chr1:119504543	G/A	cg17326555	chr1:119535693	NA	-0.42	-5.5	-0.41	1.55e-7	Body mass index;
PAAD	cis	rs2671540	0.574	rs884242	chr10:65650779	C/T	cg19573236	chr10:65733388	NA	-0.56	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.95	0.37	1.98e-6	Colorectal cancer;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.82	7.89	0.54	5.61e-13	Response to hepatitis C treatment;
PAAD	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.83	9.94	0.63	2.98e-18	Coronary artery disease;
PAAD	cis	rs3745672	0.590	rs79770870	chr19:12175358	C/A	cg11321965	chr19:12780562	MORG1;C19orf56	-1.03	-4.66	-0.35	6.79e-6	Multiple sclerosis;
PAAD	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg05250797	chr16:70222502	NA	0.88	6.81	0.48	2.16e-10	IgE levels;
PAAD	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.81	8.35	0.56	3.91e-14	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.8	9.0	0.59	8.64e-16	Lung cancer;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg05697835	chr1:2722811	NA	-0.41	-4.66	-0.35	6.98e-6	Ulcerative colitis;
PAAD	cis	rs72960926	1.000	rs72958991	chr6:75130440	T/C	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.74	-7.33	-0.51	1.28e-11	White matter hyperintensity burden;
PAAD	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg20356878	chr3:121714668	ILDR1	0.48	4.58	0.35	9.72e-6	Cognitive performance;
PAAD	cis	rs3779195	0.929	rs4268041	chr7:98005538	C/T	cg21770322	chr7:97807741	LMTK2	-0.57	-5.58	-0.41	1.1e-7	Sex hormone-binding globulin levels;
PAAD	cis	rs55986470	0.670	rs6704902	chr2:239417161	G/C	cg18131467	chr2:239335373	ASB1	-0.62	-4.54	-0.35	1.13e-5	Chronotype;
PAAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.63	-7.65	-0.53	2.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09524271	chr5:38596129	LIFR	-0.7	-7.32	-0.51	1.38e-11	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs17155006	0.711	rs377007	chr7:107750446	T/A	cg05962710	chr7:107745446	LAMB4	-0.58	-7.62	-0.53	2.47e-12	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-6.14	-0.45	6.75e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2744375	0.600	rs2744372	chr6:7554466	C/T	cg27023638	chr6:7288726	SSR1	0.4	4.26	0.33	3.51e-5	Resting heart rate;
PAAD	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.42	4.97	0.37	1.8e-6	Uric acid levels;
PAAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.45	0.52	6.53e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6991838	0.778	rs7843724	chr8:66462816	G/T	cg15971335	chr8:66515592	ARMC1	0.45	4.6	0.35	8.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.53	5.27	0.39	4.61e-7	Colorectal adenoma (advanced);
PAAD	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.58	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs10887741	0.532	rs791889	chr10:89413057	A/G	cg13926569	chr10:89418898	PAPSS2	0.52	5.35	0.4	3.23e-7	Exercise (leisure time);
PAAD	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg10818794	chr15:86012489	AKAP13	0.51	5.69	0.42	6.2e-8	Coronary artery disease;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.77	-10.87	-0.66	1.01e-20	Psoriasis;
PAAD	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-4.35	-0.33	2.48e-5	Morning vs. evening chronotype;
PAAD	cis	rs965604	1.000	rs11637656	chr15:78751961	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-4.41	-0.34	1.92e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs757081	0.658	rs190046	chr11:17293356	T/C	cg15432903	chr11:17409602	KCNJ11	-0.53	-5.67	-0.42	7.14e-8	Systolic blood pressure;
PAAD	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.85	-10.15	-0.64	8.54e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg19418318	chr19:17219073	MYO9B	0.41	4.95	0.37	1.98e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	5.75	0.42	4.8e-8	Monocyte count;
PAAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.39e-10	Life satisfaction;
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Electroencephalogram traits;
PAAD	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-7.14	-0.5	3.56e-11	Chronic sinus infection;
PAAD	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.58	5.96	0.44	1.71e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs116248771	0.690	rs16829314	chr3:158416409	C/T	cg16708174	chr3:158430962	RARRES1	0.75	5.65	0.42	7.76e-8	diarrhoeal disease at age 2;
PAAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.14	-0.5	3.55e-11	Coronary artery disease;
PAAD	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.42	-0.34	1.89e-5	Primary biliary cholangitis;
PAAD	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg23024343	chr7:107201750	COG5	0.62	5.15	0.39	7.81e-7	Coronary artery disease;
PAAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs4740619	0.592	rs2987079	chr9:16010931	C/T	cg14451791	chr9:16040625	NA	0.4	4.72	0.36	5.3e-6	Body mass index;
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs9361491	0.657	rs9343804	chr6:79468052	G/A	cg05283184	chr6:79620031	NA	-0.36	-4.34	-0.33	2.63e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.56	4.82	0.36	3.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	4.98	0.37	1.68e-6	Mean platelet volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23572578	chr14:102975895	ANKRD9	-0.57	-7.02	-0.49	7.07e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.94	6.89	0.49	1.38e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.89	12.79	0.72	7.05e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7072216	0.687	rs11189587	chr10:100154545	G/A	cg19567339	chr10:100142640	NA	0.42	4.41	0.34	1.93e-5	Metabolite levels;
PAAD	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.9	-4.6	-0.35	8.94e-6	Toenail selenium levels;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.53	0.41	1.35e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-4.69	-0.36	5.96e-6	Systemic lupus erythematosus;
PAAD	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.39e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg27565382	chr3:53032988	SFMBT1	0.78	4.53	0.34	1.2e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs881827	0.962	rs12483634	chr21:47992401	G/A	cg14789911	chr21:47582049	C21orf56	-0.5	-4.83	-0.36	3.25e-6	Lymphocyte counts;
PAAD	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.76	7.9	0.54	5.17e-13	Schizophrenia;
PAAD	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.7	7.93	0.54	4.42e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06850241	chr22:41845214	NA	-0.52	-4.61	-0.35	8.61e-6	Vitiligo;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12872686	chr3:36902601	TRANK1	-0.63	-6.44	-0.46	1.47e-9	Obesity-related traits;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg10864074	chr7:100318194	EPO	-0.48	-4.72	-0.36	5.4e-6	Other erythrocyte phenotypes;
PAAD	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.92	-12.16	-0.7	3.41e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg22963979	chr7:1858916	MAD1L1	0.55	5.35	0.4	3.24e-7	Schizophrenia;
PAAD	cis	rs9913156	0.517	rs11868227	chr17:4614539	G/A	cg23387401	chr17:4582204	PELP1	0.41	4.52	0.34	1.25e-5	Lymphocyte counts;
PAAD	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.67	-8.73	-0.58	4.29e-15	Schizophrenia;
PAAD	cis	rs2242116	0.501	rs936184	chr3:46938247	A/C	cg27129171	chr3:47204927	SETD2	0.68	5.9	0.43	2.23e-8	Birth weight;
PAAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.13	-0.38	8.91e-7	Monocyte count;
PAAD	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.81	10.03	0.63	1.76e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg14709524	chr16:89940631	TCF25	0.74	4.37	0.33	2.33e-5	Skin colour saturation;
PAAD	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.35	6.34	0.46	2.52e-9	Type 2 diabetes;
PAAD	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-5.79	-0.43	3.92e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.63	0.35	7.65e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.94	9.95	0.63	2.89e-18	Height;
PAAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.63	5.68	0.42	6.77e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.56	6.3	0.45	3.07e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	1.12	8.8	0.58	2.83e-15	Post bronchodilator FEV1;
PAAD	cis	rs6494488	0.500	rs72741379	chr15:64804763	T/C	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.0	0.38	1.57e-6	White blood cell count;
PAAD	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg10705379	chr10:99080932	FRAT1	0.39	4.51	0.34	1.28e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.75	-0.42	4.83e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs116175783	0.557	rs7349280	chr2:162210631	C/T	cg08807892	chr2:162101083	NA	-0.65	-4.66	-0.35	6.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24387347	chr12:56661247	COQ10A	0.58	6.9	0.49	1.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.48	-5.46	-0.41	1.88e-7	Migraine;
PAAD	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-5.42	-0.4	2.24e-7	Response to antipsychotic treatment;
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	-0.53	-4.74	-0.36	4.8e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg18551225	chr6:44695536	NA	-0.7	-7.03	-0.5	6.65e-11	Total body bone mineral density;
PAAD	cis	rs4343996	0.719	rs10254665	chr7:3483504	T/G	cg21248987	chr7:3385318	SDK1	0.44	4.75	0.36	4.64e-6	Motion sickness;
PAAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.85	-9.21	-0.6	2.47e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	6.57	0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.66	-8.32	-0.56	4.67e-14	Schizophrenia;
PAAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.46	-4.33	-0.33	2.67e-5	Breast cancer;
PAAD	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.73	0.48	3.33e-10	Height;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.79	8.9	0.59	1.6e-15	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23617786	chr4:159644614	PPID	0.58	6.68	0.48	4.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.54	5.33	0.4	3.5e-7	Prudent dietary pattern;
PAAD	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-1.1	-11.8	-0.69	3.16e-23	Longevity;
PAAD	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.76e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12612619	0.732	rs13032059	chr2:27233789	T/C	cg00617064	chr2:27272375	NA	-0.47	-4.99	-0.38	1.61e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21178979	chr7:1889533	MAD1L1	0.4	4.42	0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	-0.5	-4.41	-0.34	1.96e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.45	4.72	0.36	5.22e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg20007245	chr22:24372913	LOC391322	-0.67	-5.13	-0.38	8.9e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.73	0.36	5.03e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.67	0.35	6.64e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg02297831	chr4:17616191	MED28	0.54	5.29	0.39	4.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.79	-0.36	3.93e-6	Renal cell carcinoma;
PAAD	cis	rs2798269	0.604	rs2798277	chr13:22155781	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.54	-4.87	-0.37	2.78e-6	PR segment;
PAAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.35	-0.33	2.47e-5	Obesity-related traits;
PAAD	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.88	-0.37	2.61e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.56	7.44	0.52	6.79e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg01075559	chr1:2537774	MMEL1	0.47	5.04	0.38	1.32e-6	Ulcerative colitis;
PAAD	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.42	-0.52	7.8e-12	Eosinophil percentage of white cells;
PAAD	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.19	0.64	6.75e-19	Cognitive test performance;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04102734	chr1:209406725	NA	-0.56	-6.35	-0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg23587288	chr2:27483067	SLC30A3	0.69	6.53	0.47	9.34e-10	Blood metabolite levels;
PAAD	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs9810890	1.000	rs73198811	chr3:128470749	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs17076896	0.520	rs73155763	chr13:19728346	C/T	cg20227530	chr10:79085138	KCNMA1	0.82	6.42	0.46	1.62e-9	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg26618903	chr10:100175079	PYROXD2	-0.49	-5.07	-0.38	1.15e-6	Metabolite levels;
PAAD	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg25452165	chr22:42524984	CYP2D6	0.58	5.3	0.39	4.01e-7	Schizophrenia;
PAAD	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.54	-0.52	3.93e-12	Height;
PAAD	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.4	10.66	0.65	3.59e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.49	-4.43	-0.34	1.79e-5	P wave terminal force;
PAAD	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	9.02e-6	Menarche (age at onset);
PAAD	cis	rs2131877	0.871	rs62290352	chr3:194864191	G/A	cg24618514	chr3:194868507	C3orf21	0.49	4.36	0.33	2.4e-5	Non-small cell lung cancer;
PAAD	trans	rs9409082	0.677	rs10453225	chr9:108920220	G/T	cg07010948	chr13:79181613	NA	-0.35	-6.65	-0.47	4.84e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2491441	1.000	rs2491440	chr1:183806691	C/T	cg08905629	chr1:183188297	LAMC2	-0.45	-4.3	-0.33	3e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.56	-5.41	-0.4	2.46e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09667134	chr7:98550922	TRRAP	-0.7	-7.03	-0.5	6.42e-11	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg14926445	chr8:58193284	C8orf71	-0.67	-4.8	-0.36	3.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.54	6.27	0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.6	5.09	0.38	1.07e-6	Common traits (Other);
PAAD	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.9	7.29	0.51	1.58e-11	Vitiligo;
PAAD	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg18551225	chr6:44695536	NA	-0.73	-7.44	-0.52	7.09e-12	Total body bone mineral density;
PAAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.66	7.65	0.53	2.14e-12	Bone mineral density;
PAAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	6.86	0.49	1.59e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg02462569	chr6:150064036	NUP43	-0.45	-4.99	-0.38	1.63e-6	Lung cancer;
PAAD	cis	rs7567389	0.677	rs72846002	chr2:128118147	G/A	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.85	5.53	0.41	1.35e-7	Gout;
PAAD	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.98	-12.17	-0.7	3.13e-24	Refractive error;
PAAD	cis	rs12714314	0.756	rs13389573	chr2:1936113	G/T	cg22350835	chr2:1868857	MYT1L	-0.48	-4.68	-0.35	6.32e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs75920871	0.920	rs61907605	chr11:116820071	T/A	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg25364880	chr3:44379878	C3orf23	0.6	5.46	0.4	1.91e-7	Depressive symptoms;
PAAD	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg20826740	chr17:37024042	NA	0.48	5.29	0.39	4.19e-7	Height;
PAAD	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.46	6.82	0.48	1.99e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.02	-0.55	2.7e-13	Blood metabolite levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26477387	chr6:87973166	ZNF292	-0.55	-6.4	-0.46	1.87e-9	Energy expenditure (24h);
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs57244997	0.685	rs1954916	chr6:162447612	A/G	cg17173639	chr6:162384350	PARK2	-0.65	-4.93	-0.37	2.09e-6	Mosquito bite size;
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2617583	0.599	rs2975226	chr5:1445616	A/T	cg07151155	chr5:1473589	LPCAT1	-0.47	-4.68	-0.35	6.4e-6	Breast cancer;
PAAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	cis	rs727479	0.962	rs2414095	chr15:51524292	A/G	cg21478137	chr15:51532386	CYP19A1	0.62	6.95	0.49	1.03e-10	Estradiol levels;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.89	10.79	0.66	1.63e-20	Ulcerative colitis;
PAAD	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs8105895	1.000	rs8104559	chr19:22205167	T/C	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs9914578	1.000	rs62067978	chr17:2013058	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-5.16	-0.39	7.72e-7	Body mass index;
PAAD	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg02135003	chr7:105160482	PUS7	-0.8	-6.45	-0.46	1.44e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg20406979	chr6:167373233	NA	0.36	4.8	0.36	3.7e-6	Crohn's disease;
PAAD	cis	rs367943	0.698	rs2115206	chr5:112999058	A/T	cg12552261	chr5:112820674	MCC	0.62	6.59	0.47	6.75e-10	Type 2 diabetes;
PAAD	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.5	4.5	0.34	1.36e-5	Height;
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.61	-0.41	9.33e-8	Iron status biomarkers;
PAAD	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.69	5.33	0.4	3.46e-7	Alzheimer's disease (survival time);
PAAD	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.65	-7.99	-0.54	3.05e-13	Schizophrenia;
PAAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.73	5.74	0.42	5.03e-8	Vitiligo;
PAAD	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	cis	rs939584	0.935	rs10865551	chr2:641863	T/A	cg03610516	chr2:642275	NA	0.58	5.4	0.4	2.56e-7	Body mass index;
PAAD	cis	rs1385374	0.920	rs34785537	chr12:129273094	C/T	cg09035930	chr12:129282057	SLC15A4	-0.79	-4.57	-0.35	1.02e-5	Systemic lupus erythematosus;
PAAD	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg15841412	chr13:111365552	ING1	-0.5	-4.38	-0.33	2.22e-5	Coronary artery disease;
PAAD	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9652601	0.665	rs17805769	chr16:11185873	A/G	cg04616529	chr16:11181986	CLEC16A	0.38	4.65	0.35	7.07e-6	Systemic lupus erythematosus;
PAAD	cis	rs375066	0.935	rs413093	chr19:44426265	A/G	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs831571	0.915	rs6797912	chr3:64058240	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.62	5.12	0.38	8.94e-7	Type 2 diabetes;
PAAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	trans	rs3020418	1.000	rs3020418	chr6:152345162	G/A	cg09520904	chr11:69462943	CCND1	-0.53	-6.68	-0.48	4.33e-10	Height;
PAAD	cis	rs1413885	0.549	rs9436725	chr1:65852870	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.72	0.36	5.25e-6	Anticoagulant levels;
PAAD	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.55	-6.06	-0.44	1.04e-8	Body mass index;
PAAD	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.58	-7.9	-0.54	5.15e-13	Primary biliary cholangitis;
PAAD	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg09998033	chr7:158218633	PTPRN2	-0.77	-7.96	-0.54	3.77e-13	Obesity-related traits;
PAAD	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.6	5.09	0.38	1.07e-6	Common traits (Other);
PAAD	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg24053715	chr22:38214548	NA	-0.61	-6.28	-0.45	3.41e-9	Glioblastoma;Glioma;
PAAD	cis	rs4704187	0.687	rs4389672	chr5:74368642	G/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg19486271	chr11:47235900	DDB2	-0.61	-5.97	-0.44	1.58e-8	Acne (severe);
PAAD	cis	rs6942407	0.744	rs10273853	chr7:86863060	A/G	cg02420886	chr7:86849541	C7orf23	-0.54	-4.3	-0.33	3.04e-5	Food allergy;
PAAD	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.59	4.46	0.34	1.58e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.5	-0.34	1.32e-5	Platelet count;
PAAD	cis	rs11168618	0.875	rs7972785	chr12:48877056	T/C	cg01881778	chr12:48919444	OR8S1	-0.49	-4.92	-0.37	2.19e-6	Adiponectin levels;
PAAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.04	-0.44	1.15e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-4.58	-0.35	9.53e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg15212455	chr7:39170539	POU6F2	0.42	7.06	0.5	5.65e-11	IgG glycosylation;
PAAD	cis	rs2531992	0.800	rs1045476	chr16:4015313	A/G	cg05927578	chr16:4029543	ADCY9	0.71	6.13	0.44	7.38e-9	Waist circumference;
PAAD	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg09876464	chr15:85330779	ZNF592	0.44	4.33	0.33	2.65e-5	P wave terminal force;
PAAD	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13939156	chr17:80058883	NA	-0.42	-4.52	-0.34	1.23e-5	Life satisfaction;
PAAD	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-1.11	-10.48	-0.65	1.14e-19	Corneal structure;
PAAD	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.71	8.03	0.55	2.41e-13	Airway imaging phenotypes;
PAAD	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg12615879	chr12:58013172	SLC26A10	-0.61	-7.68	-0.53	1.84e-12	Multiple sclerosis;
PAAD	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.79	8.59	0.57	9.75e-15	Body mass index;
PAAD	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.74	6.47	0.46	1.27e-9	Dilated cardiomyopathy;
PAAD	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.67	-7.5	-0.52	5.03e-12	White blood cell count (basophil);
PAAD	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.65	5.86	0.43	2.79e-8	Late-onset Alzheimer's disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13411897	chr3:12526166	TSEN2	0.57	6.56	0.47	8.12e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.61	6.41	0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs375066	0.935	rs423765	chr19:44416199	C/T	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.57	-5.05	-0.38	1.24e-6	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16490096	chr1:40367661	MYCL1	0.57	6.33	0.46	2.65e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	6.42	0.46	1.65e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs939584	1.000	rs7570198	chr2:648198	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.4	4.77	0.36	4.21e-6	Intraocular pressure;
PAAD	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.5	-4.81	-0.36	3.68e-6	Inflammatory biomarkers;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.9	-11.46	-0.68	2.64e-22	Total body bone mineral density;
PAAD	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.49	-5.86	-0.43	2.8e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg00319359	chr11:70116639	PPFIA1	0.64	4.63	0.35	7.93e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09437460	chr10:119042696	PDZD8	-0.53	-6.34	-0.46	2.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.96	9.66	0.62	1.65e-17	Corneal astigmatism;
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.7	-6.86	-0.49	1.6e-10	Blood metabolite levels;
PAAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.55	-5.73	-0.42	5.19e-8	Blood metabolite levels;
PAAD	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.72	5.09	0.38	1.05e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.78	5.64	0.42	8.16e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.69	-5.68	-0.42	6.57e-8	Neuroticism;
PAAD	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.49	4.43	0.34	1.77e-5	Corneal astigmatism;
PAAD	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs6466055	0.720	rs4730082	chr7:105027509	A/G	cg04380332	chr7:105027541	SRPK2	-0.66	-7.45	-0.52	6.47e-12	Schizophrenia;
PAAD	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.88	-5.84	-0.43	3.01e-8	LDL cholesterol;
PAAD	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg21300403	chr2:198650112	BOLL	-0.49	-4.33	-0.33	2.67e-5	Dermatomyositis;
PAAD	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs4662750	0.580	rs4662742	chr2:128350744	C/A	cg09760422	chr2:128146352	NA	0.34	5.08	0.38	1.07e-6	Renal cell carcinoma;
PAAD	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.63	5.54	0.41	1.32e-7	Corneal astigmatism;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg26554054	chr8:600488	NA	0.87	5.73	0.42	5.15e-8	IgG glycosylation;
PAAD	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.5	5.59	0.41	1.01e-7	Heart rate;
PAAD	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.2	-0.39	6.47e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.54e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6594713	0.837	rs13180516	chr5:112732998	G/A	cg12552261	chr5:112820674	MCC	0.6	4.35	0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	cis	rs35160687	0.798	rs11127029	chr2:86554625	C/G	cg10973622	chr2:86423274	IMMT	-0.43	-4.57	-0.35	1e-5	Night sleep phenotypes;
PAAD	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg02475695	chr16:616220	NHLRC4	0.47	5.35	0.4	3.1e-7	Height;
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg14259594	chr22:18958660	DGCR5	0.62	4.38	0.33	2.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.64	6.17	0.45	5.78e-9	Asthma;
PAAD	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.3	-0.46	2.98e-9	Menopause (age at onset);
PAAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-5.61	-0.41	9.26e-8	Gut microbiome composition (summer);
PAAD	cis	rs7594192	0.744	rs4356658	chr2:199369404	G/A	cg07835424	chr2:200327334	NA	0.34	4.36	0.33	2.43e-5	Educational attainment;
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg07777115	chr5:623756	CEP72	-0.53	-4.55	-0.35	1.11e-5	Cystic fibrosis severity;
PAAD	cis	rs6499755	0.712	rs31100	chr16:55371523	A/G	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.53	0.61	3.52e-17	Cognitive function;
PAAD	cis	rs453193	0.597	rs3111416	chr2:8452313	G/A	cg12167548	chr2:8464763	NA	0.44	4.29	0.33	3.17e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg00614314	chr15:82944287	LOC80154	0.52	5.17	0.39	7.38e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.91	-11.21	-0.67	1.23e-21	Obesity-related traits;
PAAD	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg01966878	chr4:90757139	SNCA	-0.47	-4.42	-0.34	1.88e-5	Dementia with Lewy bodies;
PAAD	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg10856724	chr12:34555212	NA	-0.42	-4.35	-0.33	2.45e-5	Morning vs. evening chronotype;
PAAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	4.94	0.37	2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	6.05	0.44	1.08e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg06484146	chr7:12443880	VWDE	-0.81	-5.45	-0.4	2.01e-7	Coronary artery disease;
PAAD	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg01422370	chr2:73384389	NA	0.33	4.52	0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg09168692	chr1:7887560	PER3	-0.46	-4.61	-0.35	8.57e-6	Inflammatory bowel disease;
PAAD	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.74	5.26	0.39	4.88e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg18135555	chr8:22132992	PIWIL2	0.6	8.78	0.58	3.11e-15	Hypertriglyceridemia;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.81	-11.1	-0.67	2.41e-21	Vitiligo;
PAAD	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.5	4.84	0.37	3.18e-6	High light scatter reticulocyte count;
PAAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.46	5.59	0.41	1e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.82	-0.43	3.3e-8	Tonsillectomy;
PAAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg21929781	chr1:2537748	MMEL1	-0.49	-5.13	-0.38	8.55e-7	Ulcerative colitis;
PAAD	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.57	-7.63	-0.53	2.43e-12	Renal cell carcinoma;
PAAD	cis	rs6942407	0.592	rs6958626	chr7:86751525	A/G	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs1109501	0.734	rs28492877	chr4:71419199	A/G	cg25553522	chr4:71388589	AMTN	0.53	4.59	0.35	9.37e-6	Alcoholism (heaviness of drinking);
PAAD	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg08648136	chr8:956695	NA	0.41	4.4	0.34	2.05e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs79752400	chr10:46072088	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs642743	0.967	rs581686	chr10:105983356	C/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.56	0.35	1.04e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.78	8.18	0.55	1.04e-13	Prostate cancer;
PAAD	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg23331303	chr5:5135948	NA	0.45	6.49	0.47	1.15e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg26338869	chr17:61819248	STRADA	0.5	4.81	0.36	3.63e-6	Height;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25791773	chr11:129910324	NA	0.63	6.33	0.46	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.02	0.38	1.46e-6	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.57	4.45	0.34	1.67e-5	Resting heart rate;
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.63	6.21	0.45	4.92e-9	Monocyte count;
PAAD	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.58	-6.29	-0.45	3.25e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.66	-7.1	-0.5	4.57e-11	Blood protein levels;
PAAD	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg15571903	chr15:79123663	NA	-0.48	-6.1	-0.44	8.34e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.63	-0.35	7.79e-6	Eotaxin levels;
PAAD	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.5	-5.71	-0.42	5.88e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11264799	0.539	rs2779160	chr1:157550950	C/T	cg18268488	chr1:157545234	FCRL4	0.56	6.34	0.46	2.44e-9	IgA nephropathy;
PAAD	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.59	5.63	0.42	8.6e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg15208524	chr1:10270712	KIF1B	0.46	4.32	0.33	2.82e-5	Hepatocellular carcinoma;
PAAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.64	6.6	0.47	6.38e-10	Aortic root size;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.69	-7.73	-0.53	1.38e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.63	-4.52	-0.34	1.24e-5	Mosquito bite size;
PAAD	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2290416	0.534	rs35846341	chr8:144632591	C/T	cg13191508	chr8:144600686	ZC3H3	-0.96	-6.98	-0.49	8.59e-11	Attention deficit hyperactivity disorder;
PAAD	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg09659197	chr4:152720779	NA	0.36	5.12	0.38	8.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.06	-0.5	5.62e-11	Aortic root size;
PAAD	cis	rs1510510	0.757	rs907109	chr2:239566309	C/T	cg23517743	chr2:238623585	LRRFIP1	0.39	4.31	0.33	2.88e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-4.43	-0.34	1.79e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.3	0.45	3.1e-9	Initial pursuit acceleration;
PAAD	cis	rs9815354	1.000	rs10865914	chr3:41919499	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10768122	0.642	rs4756212	chr11:35362311	G/T	cg13971030	chr11:35366721	SLC1A2	-0.43	-5.02	-0.38	1.44e-6	Vitiligo;
PAAD	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.0	0.38	1.55e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.48	-4.96	-0.37	1.89e-6	Iron status biomarkers;
PAAD	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	6.49	0.47	1.12e-9	Schizophrenia;
PAAD	trans	rs9409082	0.748	rs7028916	chr9:108927068	C/A	cg07010948	chr13:79181613	NA	-0.35	-6.47	-0.46	1.29e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg14159672	chr1:205819179	PM20D1	0.69	5.78	0.42	4.16e-8	Prostate-specific antigen levels;
PAAD	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.02e-8	Electrocardiographic conduction measures;
PAAD	cis	rs17461620	1.000	rs11792804	chr9:88925774	A/G	cg13456106	chr9:88897068	ISCA1	0.61	4.38	0.33	2.22e-5	Diisocyanate-induced asthma;
PAAD	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg06207120	chr15:45996521	NA	0.3	4.43	0.34	1.78e-5	Waist circumference;Weight;
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.65	-5.51	-0.41	1.52e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.74	-0.48	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	8.16e-9	Lung cancer;
PAAD	cis	rs863345	0.604	rs11264981	chr1:158455890	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg12705353	chr12:122356852	WDR66	-0.45	-4.65	-0.35	7.17e-6	Mean corpuscular volume;
PAAD	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.01	12.32	0.71	1.25e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7577696	0.752	rs12614686	chr2:32363171	A/G	cg02381751	chr2:32503542	YIPF4	-0.47	-4.67	-0.35	6.56e-6	Inflammatory biomarkers;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	6.09	0.44	8.99e-9	Prudent dietary pattern;
PAAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.85	-10.74	-0.66	2.24e-20	Heart rate;
PAAD	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg08099141	chr12:7053170	C12orf57	0.43	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs11811982	0.793	rs11808696	chr1:227563680	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs9397240	0.789	rs9384303	chr6:155557068	T/C	cg26934881	chr6:155569291	TIAM2	-0.53	-4.32	-0.33	2.85e-5	Life satisfaction;
PAAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg18892244	chr7:807596	HEATR2	-0.72	-5.44	-0.4	2.04e-7	Initial pursuit acceleration;
PAAD	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.64	6.95	0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.02	-0.67	4.11e-21	Coronary artery disease;
PAAD	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.68	6.26	0.45	3.81e-9	Lung cancer;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-1.05	-7.47	-0.52	5.88e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg17372223	chr3:52568218	NT5DC2	0.56	5.45	0.4	2e-7	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg20243544	chr17:37824526	PNMT	-0.5	-4.27	-0.33	3.42e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs13102973	0.640	rs6857995	chr4:135834193	G/A	cg14419869	chr4:135874104	NA	0.45	4.59	0.35	9.21e-6	Subjective well-being;
PAAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.64	-6.66	-0.48	4.82e-10	Body mass index;
PAAD	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.64	5.7	0.42	6.12e-8	Corneal astigmatism;
PAAD	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg21775007	chr8:11205619	TDH	0.8	7.95	0.54	4.01e-13	Retinal vascular caliber;
PAAD	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs4704187	0.712	rs7701262	chr5:74365986	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.82	9.35	0.6	1.04e-16	Age at first birth;
PAAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.81	8.1	0.55	1.65e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg14343924	chr8:8086146	FLJ10661	0.49	4.45	0.34	1.67e-5	Mood instability;
PAAD	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.68e-5	Skin colour saturation;
PAAD	cis	rs6484218	1.000	rs10770107	chr11:10391880	A/G	cg06686058	chr11:10326672	ADM	-0.56	-4.26	-0.33	3.5e-5	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg08890418	chr1:21044141	KIF17	0.43	4.27	0.33	3.41e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.49	5.65	0.42	7.54e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.52	-5.07	-0.38	1.15e-6	Essential tremor;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.4	-5.87	-0.43	2.58e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.71	-6.85	-0.49	1.73e-10	White matter hyperintensity burden;
PAAD	cis	rs7799006	0.895	rs3800938	chr7:2267442	C/G	cg08027265	chr7:2291960	NA	-0.61	-5.84	-0.43	3.05e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08100565	chr3:140660748	SLC25A36	-0.64	-6.42	-0.46	1.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg11663144	chr21:46675770	NA	-0.53	-6.36	-0.46	2.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-4.88	-0.37	2.65e-6	Bipolar disorder;
PAAD	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.19	-0.5	2.73e-11	Triglycerides;
PAAD	cis	rs412658	0.504	rs17769372	chr19:22114704	T/C	cg07498013	chr19:22123504	NA	-0.42	-4.52	-0.34	1.23e-5	Telomere length;
PAAD	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg04398451	chr17:18023971	MYO15A	0.77	8.61	0.57	8.71e-15	Total body bone mineral density;
PAAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.3	-0.46	3.06e-9	Neuroticism;
PAAD	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.65	-9.41	-0.61	7.43e-17	Airflow obstruction;
PAAD	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.47	-5.23	-0.39	5.41e-7	Heart rate;
PAAD	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.58	-0.47	7.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg24250549	chr1:154909240	PMVK	0.5	4.89	0.37	2.53e-6	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12165864	chr7:66369176	NA	0.76	5.04	0.38	1.32e-6	Diabetic kidney disease;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.19	0.45	5.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg26939375	chr7:64535504	NA	-0.76	-9.02	-0.59	7.55e-16	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25316856	chr2:64925436	NA	0.57	6.37	0.46	2.18e-9	Smoking initiation;
PAAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2164068	0.547	rs61435657	chr2:198825506	G/C	cg10820045	chr2:198174542	NA	0.43	4.38	0.33	2.23e-5	Allergy;
PAAD	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.63	6.64	0.47	5.2400000000000005e-10	Testicular germ cell tumor;
PAAD	cis	rs12136530	0.550	rs904964	chr1:19697065	T/C	cg25104613	chr1:20649108	VWA5B1	-0.46	-5.09	-0.38	1.03e-6	Lead levels in blood;
PAAD	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.11	6.38	0.46	2.02e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2885056	0.843	rs35769432	chr19:10695824	G/A	cg04833646	chr19:10679720	CDKN2D	0.96	9.34	0.6	1.16e-16	Red cell distribution width;
PAAD	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.91	0.37	2.36e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.75	0.36	4.65e-6	Neuroticism;
PAAD	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg05250797	chr16:70222502	NA	-0.59	-4.8	-0.36	3.7e-6	Sjögren's syndrome;
PAAD	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.81	-7.82	-0.54	8.39e-13	Prostate cancer;
PAAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.98	11.69	0.69	6.13e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.81	-8.9	-0.59	1.52e-15	Menopause (age at onset);
PAAD	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs621942	0.718	rs585480	chr11:85662846	T/A	cg07180834	chr11:85838833	NA	-0.47	-4.66	-0.35	6.85e-6	Tourette syndrome;
PAAD	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg02683114	chr2:24398427	C2orf84	-0.46	-4.83	-0.36	3.35e-6	Sjögren's syndrome;
PAAD	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.04	-0.44	1.11e-8	Menarche (age at onset);
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg00976097	chr5:421733	AHRR	-0.5	-4.82	-0.36	3.47e-6	Cystic fibrosis severity;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg16606324	chr3:10149918	C3orf24	0.79	6.28	0.45	3.4e-9	Alzheimer's disease;
PAAD	cis	rs2302729	0.789	rs876503	chr12:2797179	A/G	cg19945202	chr12:2788847	CACNA1C	-0.61	-4.81	-0.36	3.56e-6	Sleep quality;
PAAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.9	-10.85	-0.66	1.11e-20	Ulcerative colitis;
PAAD	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg04342483	chr1:7259290	CAMTA1	-0.41	-4.42	-0.34	1.85e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.49	-0.34	1.4e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19341344	chr11:57335140	UBE2L6	-0.67	-7.81	-0.54	8.82e-13	Body fat percentage;
PAAD	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.37	-0.33	2.26e-5	Lung cancer in ever smokers;
PAAD	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.3	11.28	0.68	8.02e-22	Uric acid levels;
PAAD	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.54	-0.35	1.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.47	4.8	0.36	3.84e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.82	-10.48	-0.65	1.11e-19	Bone mineral density;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.35	0.4	3.15e-7	Multiple sclerosis;
PAAD	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg12661370	chr5:149340060	SLC26A2	0.65	5.48	0.41	1.75e-7	HIV-1 control;
PAAD	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.65	4.9	0.37	2.48e-6	Exhaled nitric oxide output;
PAAD	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg18551225	chr6:44695536	NA	-0.55	-5.77	-0.42	4.34e-8	Total body bone mineral density;
PAAD	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg10437265	chr15:77819839	NA	0.39	4.32	0.33	2.86e-5	Type 2 diabetes;
PAAD	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.25	-0.33	3.66e-5	Arsenic metabolism;
PAAD	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs11264799	0.817	rs17676026	chr1:157666336	C/G	cg18268488	chr1:157545234	FCRL4	-0.57	-5.46	-0.41	1.87e-7	IgA nephropathy;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg15212455	chr7:39170539	POU6F2	0.49	6.91	0.49	1.22e-10	IgG glycosylation;
PAAD	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.54	5.18	0.39	6.96e-7	Multiple myeloma;
PAAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.7	5.84	0.43	3.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg23346134	chr3:49453900	TCTA	0.47	4.72	0.36	5.33e-6	Menarche (age at onset);
PAAD	cis	rs11892454	0.544	rs6753192	chr2:25986729	C/A	cg25181710	chr2:26045287	ASXL2	0.43	4.92	0.37	2.22e-6	Heschl's gyrus morphology;
PAAD	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-1.06	-9.86	-0.62	4.85e-18	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg19630374	chr17:18023558	MYO15A	-0.42	-4.47	-0.34	1.52e-5	Total body bone mineral density;
PAAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19804182	chr18:13262750	C18orf1	0.64	6.37	0.46	2.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg06569542	chr10:98946673	SLIT1	0.43	4.29	0.33	3.19e-5	Monocyte count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18807030	chr7:931980	C7orf20	0.71	6.3	0.46	3.01e-9	Neuroticism;
PAAD	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	5.28	0.39	4.45e-7	Body mass index;
PAAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg05272587	chr13:111038400	COL4A2	-0.49	-4.56	-0.35	1.05e-5	White matter hyperintensity burden;
PAAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg17644776	chr2:200775616	C2orf69	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.11	0.38	9.37e-7	Bone mineral density;
PAAD	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg25037394	chr1:24152592	HMGCL	-0.43	-4.65	-0.35	7.12e-6	Immature fraction of reticulocytes;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.41	-4.98	-0.37	1.7e-6	Iron status biomarkers;
PAAD	cis	rs2950393	0.777	rs2926747	chr12:57109931	A/T	cg02954252	chr12:57119365	NACA	0.46	4.27	0.33	3.47e-5	Platelet distribution width;
PAAD	cis	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg00400743	chr4:148603008	PRMT10	-0.71	-4.46	-0.34	1.61e-5	Pulse pressure;
PAAD	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.62	0.47	5.75e-10	Response to antipsychotic treatment;
PAAD	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.73	4.53	0.35	1.17e-5	IgG glycosylation;
PAAD	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.66	6.64	0.47	5.16e-10	Coronary artery disease;
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.37	-5.32	-0.4	3.73e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.43	-4.26	-0.33	3.63e-5	Breast cancer;
PAAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.73	-0.36	5.18e-6	Alcohol dependence;
PAAD	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.75	5.31	0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg05528293	chr18:74961138	GALR1	0.61	4.86	0.37	2.95e-6	Obesity-related traits;
PAAD	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.81	6.39	0.46	1.96e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.13	-0.45	7.2e-9	Height;
PAAD	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg10578991	chr7:12443926	VWDE	-0.5	-4.39	-0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs9463078	0.683	rs1418433	chr6:44752568	C/T	cg25276700	chr6:44698697	NA	0.51	5.97	0.44	1.62e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.71	-8.79	-0.58	2.99e-15	Breast cancer;
PAAD	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.59	-0.52	2.92e-12	Hemoglobin concentration;
PAAD	cis	rs9361491	0.608	rs9350774	chr6:79461603	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.45	5.54	0.41	1.3e-7	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
PAAD	cis	rs1642645	0.872	rs348139	chr1:42470901	C/T	cg01990334	chr1:42801334	FOXJ3	-0.66	-5.78	-0.42	4e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04362095	chr11:63592001	C11orf84	-0.5	-4.46	-0.34	1.6e-5	Platelet count;
PAAD	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.83	0.36	3.32e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.62	-0.35	8.22e-6	Testicular germ cell tumor;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg05697835	chr1:2722811	NA	0.39	4.37	0.33	2.26e-5	Ulcerative colitis;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.87e-10	Lymphocyte counts;
PAAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg02917321	chr22:38215204	NA	0.45	4.52	0.34	1.22e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.63	6.48	0.47	1.18e-9	Caffeine consumption;
PAAD	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.74	-7.93	-0.54	4.47e-13	Blood metabolite levels;
PAAD	cis	rs9916302	0.560	rs907094	chr17:37790371	G/A	cg00129232	chr17:37814104	STARD3	-0.77	-6.61	-0.47	6.22e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg03476357	chr21:30257390	N6AMT1	0.45	4.28	0.33	3.28e-5	Cognitive test performance;
PAAD	cis	rs238295	0.843	rs238288	chr20:5591903	T/G	cg15842884	chr20:5591925	RP5-1022P6.2	-0.5	-5.29	-0.39	4.27e-7	Occipital cortical area (total cortical area interaction);
PAAD	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.54	6.68	0.48	4.2e-10	Schizophrenia;
PAAD	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.83	-9.41	-0.61	7.41e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs3779195	0.520	rs17169479	chr7:97868033	A/G	cg21770322	chr7:97807741	LMTK2	0.54	4.56	0.35	1.05e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.74	8.27	0.56	6.29e-14	Prostate cancer;
PAAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.58	6.34	0.46	2.44e-9	Age at first birth;
PAAD	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.67	7.72	0.53	1.43e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10073892	0.625	rs9327814	chr5:101617905	T/C	cg17280723	chr5:101634495	NA	0.41	4.42	0.34	1.85e-5	Cognitive decline (age-related);
PAAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs2133450	0.526	rs17047062	chr3:7343383	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.28	-0.45	3.39e-9	Hip circumference;
PAAD	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg09010748	chr1:235293032	TOMM20	-0.39	-4.27	-0.33	3.38e-5	Adiposity;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2255932	0.735	rs10513793	chr3:183224103	C/T	cg12326526	chr3:183209927	KLHL6	0.6	4.34	0.33	2.54e-5	Interleukin-1-beta levels;
PAAD	cis	rs4280164	0.578	rs17184689	chr14:24794440	A/C	cg07162820	chr14:24837146	NFATC4	0.36	4.78	0.36	4.06e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.43	-0.46	1.56e-9	Aortic root size;
PAAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs73416724	1.000	rs77529883	chr6:43364634	C/G	cg17076780	chr6:43251928	TTBK1	0.58	4.59	0.35	9.27e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26072327	chr5:98104276	RGMB	0.67	7.14	0.5	3.6e-11	Obesity-related traits;
PAAD	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.87	0.37	2.79e-6	HDL cholesterol;
PAAD	cis	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs9649465	0.967	rs1506642	chr7:123390058	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.78	-0.36	4.14e-6	Migraine;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03413328	chr12:8851234	RIMKLB	-0.6	-6.31	-0.46	2.89e-9	Smoking initiation;
PAAD	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13870426	chr17:30244630	NA	-0.7	-6.9	-0.49	1.29e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.91	-6.93	-0.49	1.12e-10	Initial pursuit acceleration;
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13012494	chr21:47604986	C21orf56	0.47	4.86	0.37	2.96e-6	Testicular germ cell tumor;
PAAD	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg26668828	chr6:292823	DUSP22	0.66	6.97	0.49	8.9e-11	Menopause (age at onset);
PAAD	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs73416724	0.610	rs111981370	chr6:43255380	G/T	cg17502394	chr6:43251710	TTBK1	0.61	4.41	0.34	1.92e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24176009	chr12:49580217	TUBA1A	0.6	6.34	0.46	2.54e-9	Smoking initiation;
PAAD	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.5	-4.81	-0.36	3.68e-6	Inflammatory biomarkers;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg05562828	chr17:3906858	NA	-0.54	-6.05	-0.44	1.09e-8	Type 2 diabetes;
PAAD	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.32	-0.33	2.85e-5	Tonsillectomy;
PAAD	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg00277334	chr10:82204260	NA	-0.61	-6.01	-0.44	1.35e-8	Post bronchodilator FEV1;
PAAD	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	9.69	0.62	1.35e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs300774	0.925	rs300720	chr2:134472	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.58	0.74	5.23e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.74	8.51	0.57	1.54e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-7.66	-0.53	1.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.89	-15.2	-0.78	2.55e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs887829	0.694	rs6725478	chr2:234615400	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-5.14	-0.39	8.21e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs2790216	1.000	rs1199108	chr10:59942324	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00815214	chr21:47717953	NA	-0.44	-4.42	-0.34	1.86e-5	Testicular germ cell tumor;
PAAD	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.9	-8.16	-0.55	1.15e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.59	4.57	0.35	1.02e-5	Menarche (age at onset);
PAAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.11	0.38	9.4e-7	Rheumatoid arthritis;
PAAD	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.58e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	1.15	7.24	0.51	2.09e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs4704187	0.687	rs115403098	chr5:74397384	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs42648	0.508	rs39204	chr7:89734318	C/A	cg27367526	chr7:89841692	STEAP2	-0.33	-4.58	-0.35	9.8e-6	Homocysteine levels;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.51	5.32	0.4	3.66e-7	Blood metabolite levels;
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg08676812	chr11:65308423	LTBP3	1.44	8.05	0.55	2.22e-13	Height;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.67	-0.35	6.61e-6	Testicular germ cell tumor;
PAAD	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg01953289	chr20:60874239	NA	-0.69	-5.16	-0.39	7.71e-7	Obesity-related traits;
PAAD	cis	rs3764400	0.567	rs12946208	chr17:46312129	G/A	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.95	0.37	1.98e-6	Vitiligo;
PAAD	cis	rs6922632	0.867	rs62400307	chr6:24114249	C/A	cg26194775	chr6:24126114	NRSN1	-0.67	-5.21	-0.39	6.11e-7	Information processing speed;
PAAD	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg03030879	chr14:75389066	RPS6KL1	0.43	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.62	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg08219700	chr8:58056026	NA	0.66	5.11	0.38	9.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11124272	0.951	rs1510917	chr2:31928899	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-4.71	-0.36	5.65e-6	Interleukin-18 levels;
PAAD	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.47	4.53	0.34	1.19e-5	High light scatter reticulocyte count;
PAAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg12215294	chr3:40350768	EIF1B	-0.48	-4.77	-0.36	4.23e-6	Renal cell carcinoma;
PAAD	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs56804039	0.524	rs11783173	chr8:8362710	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.36	-0.33	2.39e-5	Cervical cancer;
PAAD	cis	rs12431939	0.947	rs56026555	chr14:51649066	G/T	cg23942311	chr14:51606299	NA	-0.71	-5.74	-0.42	4.98e-8	Cancer;
PAAD	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19784903	chr17:45786737	TBKBP1	-0.59	-6.47	-0.46	1.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.42	-5.34	-0.4	3.35e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs61884328	0.777	rs17790420	chr11:47169555	G/A	cg23433285	chr11:47201945	PACSIN3	0.81	4.62	0.35	8.17e-6	Total body bone mineral density (age over 60);
PAAD	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg12395012	chr8:11607386	GATA4	0.43	4.65	0.35	7.14e-6	Retinal vascular caliber;
PAAD	cis	rs7554547	0.818	rs4993566	chr1:11969994	T/G	cg07603449	chr1:11986842	KIAA2013	-0.28	-4.32	-0.33	2.81e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.65	-0.42	7.61e-8	Triglycerides;
PAAD	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.71	-7.06	-0.5	5.57e-11	Heart rate;
PAAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	5.47	0.41	1.78e-7	Monocyte count;
PAAD	cis	rs1879734	0.681	rs12076192	chr1:54157742	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.82	-0.43	3.37e-8	Mitral valve prolapse;
PAAD	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.56	4.88	0.37	2.65e-6	Itch intensity from mosquito bite;
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00431813	chr7:1051703	C7orf50	-0.46	-4.37	-0.33	2.31e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg01244601	chr4:120671846	NA	-0.49	-4.27	-0.33	3.47e-5	Corneal astigmatism;
PAAD	cis	rs367943	0.712	rs26969	chr5:112742436	A/G	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs58521262	0.556	rs435715	chr19:23126086	G/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.9	7.79	0.53	9.69e-13	Triglycerides;
PAAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.71	8.05	0.55	2.17e-13	Cisplatin-induced ototoxicity;
PAAD	cis	rs113779084	0.690	rs13247118	chr7:11983362	C/T	cg15090509	chr7:11872073	THSD7A	0.44	5.28	0.39	4.42e-7	Educational attainment (years of education);
PAAD	cis	rs6466055	0.589	rs9918494	chr7:104681649	T/A	cg04380332	chr7:105027541	SRPK2	-0.49	-4.59	-0.35	9.35e-6	Schizophrenia;
PAAD	cis	rs6604026	0.740	rs7536563	chr1:93349046	A/G	cg17283838	chr1:93427260	FAM69A	-0.65	-5.86	-0.43	2.82e-8	Multiple sclerosis;
PAAD	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.61	0.47	6.25e-10	Body mass index;
PAAD	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg10985347	chr2:127963512	CYP27C1	0.49	4.91	0.37	2.34e-6	Protein C levels;
PAAD	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg03651054	chr13:50194643	NA	0.4	5.43	0.4	2.16e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21160192	chr5:180229544	MGAT1	0.55	6.34	0.46	2.46e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4287000	0.934	rs7870000	chr9:96453315	A/T	cg13787134	chr9:96362102	PHF2	0.39	4.42	0.34	1.88e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6700896	0.864	rs7515766	chr1:66167452	G/A	cg04111102	chr1:66153794	NA	-0.41	-4.67	-0.35	6.49e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.55	7.8	0.53	9.38e-13	Diastolic blood pressure;
PAAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.57	-6.15	-0.45	6.45e-9	Schizophrenia;
PAAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg13312174	chr5:178288687	ZNF354B	-0.6	-6.17	-0.45	5.81e-9	Sleep duration;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2.03e-5	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	1.08	15.2	0.78	2.63e-32	Breast cancer;
PAAD	cis	rs4704187	0.687	rs10050948	chr5:74484275	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-4.61	-0.35	8.54e-6	Bipolar disorder;
PAAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02244288	chr16:89573955	SPG7	-0.34	-4.51	-0.34	1.31e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.36	0.33	2.36e-5	Breast cancer;
PAAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg20003494	chr4:90757398	SNCA	-0.74	-7.1	-0.5	4.51e-11	Neuroticism;
PAAD	cis	rs863345	0.967	rs11264998	chr1:158488766	G/A	cg12129480	chr1:158549410	OR10X1	-0.45	-5.23	-0.39	5.48e-7	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14461511	chr9:127993113	RABEPK	-0.63	-6.72	-0.48	3.5e-10	Obesity-related traits;
PAAD	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.35	-5.57	-0.41	1.11e-7	Urate levels in overweight individuals;
PAAD	cis	rs9896052	0.614	rs9890461	chr17:73452479	G/A	cg25649188	chr17:73499917	CASKIN2	0.59	4.6	0.35	8.84e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg04156016	chr5:1868137	NA	0.49	5.0	0.38	1.54e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7631605	0.905	rs9817219	chr3:37139888	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.68	0.35	6.43e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6460942	0.597	rs4721108	chr7:12535247	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg13206674	chr6:150067644	NUP43	-0.55	-4.99	-0.37	1.67e-6	Lung cancer;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.7	-5.6	-0.41	9.74e-8	Neuroticism;
PAAD	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.74	7.75	0.53	1.19e-12	Height;
PAAD	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.55	-5.02	-0.38	1.41e-6	Total body bone mineral density;
PAAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.97	-12.85	-0.72	4.86e-26	Menopause (age at onset);
PAAD	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.89	-10.26	-0.64	4.36e-19	Refractive error;
PAAD	cis	rs11958404	0.615	rs10061079	chr5:157449968	G/C	cg05962755	chr5:157440814	NA	0.57	5.42	0.4	2.34e-7	IgG glycosylation;
PAAD	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.03	0.44	1.19e-8	Platelet count;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg26354017	chr1:205819088	PM20D1	-0.55	-5.39	-0.4	2.68e-7	Parkinson's disease;
PAAD	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.79	8.08	0.55	1.87e-13	Coronary artery disease;
PAAD	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.6	0.41	9.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.95	-8.6	-0.57	9.12e-15	Body mass index;
PAAD	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.75	5.75	0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.83e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2036707	0.744	rs79922539	chr13:108476193	G/A	cg22302985	chr13:108520945	FAM155A	-1.01	-4.48	-0.34	1.47e-5	Obesity-related traits;
PAAD	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg04218760	chr10:45406644	TMEM72	-0.28	-4.79	-0.36	3.85e-6	Mean corpuscular volume;
PAAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	11.79	0.69	3.43e-23	Menopause (age at onset);
PAAD	cis	rs7809950	0.798	rs2701687	chr7:107304628	C/T	cg23024343	chr7:107201750	COG5	0.76	8.78	0.58	3.22e-15	Coronary artery disease;
PAAD	cis	rs28647808	0.881	rs3739894	chr9:136270871	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.7	5.84	0.43	3.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.06	-0.59	6.07e-16	Exhaled nitric oxide output;
PAAD	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg10431340	chr1:161279108	MPZ	-0.62	-5.67	-0.42	7e-8	Rheumatoid arthritis;
PAAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	4.27	0.33	3.41e-5	Coronary artery disease;
PAAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg25276700	chr6:44698697	NA	0.42	4.35	0.33	2.5e-5	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs10949834	0.689	rs2269081	chr7:73519887	T/G	cg07137043	chr7:73588983	EIF4H	-0.6	-4.43	-0.34	1.76e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.19	17.75	0.82	6.82e-39	Cognitive function;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.13	15.91	0.79	3.56e-34	Schizophrenia;
PAAD	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.66	-6.18	-0.45	5.59e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06850241	chr22:41845214	NA	-0.53	-4.98	-0.37	1.74e-6	Vitiligo;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.91	0.54	4.8e-13	Alzheimer's disease;
PAAD	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.76	-0.53	1.17e-12	Morning vs. evening chronotype;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.98	-0.37	1.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.92	-0.37	2.19e-6	Self-reported allergy;
PAAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg20003494	chr4:90757398	SNCA	-0.64	-5.92	-0.43	2.08e-8	Neuroticism;
PAAD	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	7.25	0.51	1.96e-11	Migraine;Coronary artery disease;
PAAD	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.15e-5	Coronary artery disease;
PAAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02244288	chr16:89573955	SPG7	0.34	4.39	0.34	2.15e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg18279126	chr7:2041391	MAD1L1	-0.55	-5.54	-0.41	1.3e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg15628303	chr1:26608928	UBXN11	0.73	7.31	0.51	1.45e-11	Obesity-related traits;
PAAD	cis	rs911555	0.603	rs11626562	chr14:103845362	C/A	cg12935359	chr14:103987150	CKB	-0.61	-5.7	-0.42	6.02e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg24642844	chr7:1081250	C7orf50	-0.7	-6.22	-0.45	4.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.52	-5.14	-0.38	8.35e-7	High light scatter reticulocyte count;
PAAD	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg26876637	chr1:152193138	HRNR	-0.87	-6.5	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg07362569	chr17:61921086	SMARCD2	0.59	6.95	0.49	9.85e-11	Prudent dietary pattern;
PAAD	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg10223061	chr2:219282414	VIL1	0.38	4.59	0.35	9.04e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.68	-7.69	-0.53	1.67e-12	White blood cell count (basophil);
PAAD	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.72	0.62	1.12e-17	Total body bone mineral density;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg09760422	chr2:128146352	NA	0.36	4.67	0.35	6.58e-6	Protein C levels;
PAAD	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.62	5.91	0.43	2.2e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.5	4.33	0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.7	-8.46	-0.57	2.08e-14	Dupuytren's disease;
PAAD	cis	rs10861661	0.856	rs4964190	chr12:107216359	C/T	cg15890332	chr12:107067104	RFX4	0.46	4.75	0.36	4.71e-6	Triglyceride levels;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13732083	chr21:47605072	C21orf56	0.48	4.61	0.35	8.42e-6	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.64	-7.1	-0.5	4.38e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs965469	0.779	rs2207994	chr20:3294304	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.39	-5.39	-0.4	2.6e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.57	-4.9	-0.37	2.38e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs714031	0.934	rs5757764	chr22:40067818	C/T	cg21377881	chr22:40064566	CACNA1I	-0.47	-4.61	-0.35	8.61e-6	Schizophrenia;
PAAD	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg05784532	chr1:230284198	GALNT2	0.7	6.13	0.45	7.31e-9	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	1.09	15.3	0.78	1.45e-32	Breast cancer;
PAAD	cis	rs7180079	1.000	rs2062248	chr15:64672319	C/T	cg18210365	chr15:65066710	RBPMS2	0.68	4.93	0.37	2.12e-6	Monocyte count;
PAAD	cis	rs1372356	0.816	rs8014682	chr14:88535240	T/C	cg18078958	chr14:88630771	NA	0.49	6.19	0.45	5.23e-9	Food antigen IgG levels;
PAAD	cis	rs5751901	0.614	rs2070477	chr22:24990916	G/A	cg08808123	chr22:24999002	GGT1	-0.46	-4.68	-0.35	6.26e-6	Protein quantitative trait loci;
PAAD	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.45	5.14	0.38	8.39e-7	Inflammatory bowel disease;
PAAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg14349672	chr11:133703707	NA	-0.55	-5.97	-0.44	1.63e-8	Childhood ear infection;
PAAD	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.03	-0.44	1.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1035491	0.715	rs2366902	chr5:63923702	T/C	cg01791865	chr5:63954708	NA	0.51	5.47	0.41	1.79e-7	Body mass index;
PAAD	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Breast cancer;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.56	-5.13	-0.38	8.68e-7	Educational attainment;
PAAD	cis	rs7172971	0.688	rs4923924	chr15:42365668	T/G	cg07013680	chr15:42186124	SPTBN5	0.52	4.38	0.33	2.17e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg23024343	chr7:107201750	COG5	0.54	4.5	0.34	1.32e-5	Osteoarthritis;
PAAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22117172	chr7:91764530	CYP51A1	0.34	4.58	0.35	9.64e-6	Breast cancer;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg04352962	chr1:209979756	IRF6	-0.52	-4.46	-0.34	1.6e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.12	0.44	7.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.74	8.22	0.55	8.38e-14	Menopause (age at onset);
PAAD	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg22654517	chr2:96458247	NA	0.37	4.32	0.33	2.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	7.96	0.54	3.8e-13	Menopause (age at onset);
PAAD	cis	rs2290402	0.536	rs45486093	chr4:875671	T/C	cg09237302	chr4:906077	GAK	-0.43	-4.5	-0.34	1.37e-5	Type 2 diabetes;
PAAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs4704187	0.687	rs4447963	chr5:74376309	A/C	cg03227963	chr5:74354835	NA	0.49	4.79	0.36	3.85e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.4	-0.34	2.04e-5	Neuroticism;
PAAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.63	5.76	0.42	4.45e-8	Corneal astigmatism;
PAAD	cis	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.66	-0.35	7e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg22903657	chr4:1355424	KIAA1530	0.42	4.48	0.34	1.46e-5	Obesity-related traits;
PAAD	cis	rs6466055	0.669	rs6948885	chr7:104664879	C/T	cg04380332	chr7:105027541	SRPK2	-0.62	-6.57	-0.47	7.68e-10	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.83	9.44	0.61	6.13e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3736485	0.966	rs62016017	chr15:51897402	A/G	cg19558802	chr15:51695713	GLDN	-0.43	-4.42	-0.34	1.84e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.87	-0.37	2.78e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.29	-0.33	3.19e-5	Crohn's disease;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	10.21	0.64	5.68e-19	Platelet count;
PAAD	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.48	5.49	0.41	1.62e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6908034	0.607	rs112599867	chr6:19805532	A/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7772697	0.635	rs1316376	chr6:149410549	T/C	cg21368479	chr6:149415018	NA	0.44	4.68	0.36	6.19e-6	Diabetic retinopathy;
PAAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3764400	0.567	rs16953941	chr17:46296204	C/A	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg14515779	chr1:101123966	NA	0.49	6.26	0.45	3.73e-9	Monocyte count;
PAAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00149659	chr3:10157352	C3orf10	0.79	6.18	0.45	5.71e-9	Alzheimer's disease;
PAAD	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg07541023	chr7:19748670	TWISTNB	0.57	4.32	0.33	2.79e-5	Thyroid stimulating hormone;
PAAD	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.18	-0.45	5.52e-9	Schizophrenia;
PAAD	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs1468734	1.000	rs34122066	chr16:5003288	G/A	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20775508	chr20:44996230	ELMO2	-0.63	-6.46	-0.46	1.35e-9	Obesity-related traits;
PAAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.56	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.81	10.03	0.63	1.73e-18	Metabolite levels;
PAAD	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg02070205	chr10:30722105	MAP3K8	0.48	4.26	0.33	3.6e-5	Inflammatory bowel disease;
PAAD	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg21466736	chr12:48725269	NA	0.52	4.86	0.37	2.94e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg24032752	chr3:50388670	TUSC4;CYB561D2	-0.7	-5.44	-0.4	2.12e-7	Schizophrenia;
PAAD	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.18	-0.39	7.04e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09463466	chr15:77925892	LINGO1	0.64	6.8	0.48	2.28e-10	Myopia (pathological);
PAAD	cis	rs3106136	0.649	rs6532486	chr4:95300390	C/T	cg11021082	chr4:95130006	SMARCAD1	0.51	4.91	0.37	2.3e-6	Capecitabine sensitivity;
PAAD	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.63	0.35	7.89e-6	Height;
PAAD	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs10888329	0.744	rs6587433	chr1:248355279	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Autism spectrum disorder;
PAAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	8.35	0.56	4.02e-14	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06850241	chr22:41845214	NA	-0.5	-4.78	-0.36	4.15e-6	Vitiligo;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.908	rs6978768	chr7:12232366	G/A	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.57	4.81	0.36	3.64e-6	RR interval (heart rate);
PAAD	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.47	6.03	0.44	1.19e-8	Renal cell carcinoma;
PAAD	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.66	-7.7	-0.53	1.59e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11051970	0.559	rs11051973	chr12:32541912	G/T	cg24626660	chr12:32551988	NA	0.43	4.43	0.34	1.76e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19077271	chr20:37063995	LOC388796;SNORA71D	0.58	6.46	0.46	1.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg14343924	chr8:8086146	FLJ10661	-0.53	-4.69	-0.36	6.16e-6	Joint mobility (Beighton score);
PAAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg13722127	chr7:150037890	RARRES2	0.62	6.59	0.47	6.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg11196182	chr7:1989412	MAD1L1	0.41	4.37	0.33	2.33e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.48	5.18	0.39	6.99e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg16576597	chr16:28551801	NUPR1	0.74	7.6	0.52	2.88e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08850400	chr17:18231786	SHMT1	0.66	6.7	0.48	3.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg21565972	chr17:80109576	CCDC57	-0.56	-6.54	-0.47	8.74e-10	Life satisfaction;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-0.75	-7.75	-0.53	1.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	4.88	0.37	2.65e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs2133450	0.712	rs1396403	chr3:7365357	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-5.24	-0.39	5.2e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25262866	chr7:16686311	BZW2;ANKMY2	0.59	6.7	0.48	3.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72960926	1.000	rs11756716	chr6:75097407	T/C	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg25124228	chr12:125621409	AACS	-0.64	-6.12	-0.44	7.69e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg04632378	chr13:21900426	NA	0.69	7.44	0.52	6.74e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.38	4.68	0.35	6.31e-6	Intraocular pressure;
PAAD	cis	rs4740619	0.592	rs2987018	chr9:15984937	G/A	cg14451791	chr9:16040625	NA	0.39	4.62	0.35	8.17e-6	Body mass index;
PAAD	cis	rs112990264	1.000	rs111371878	chr1:213018132	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.76	-8.74	-0.58	4.06e-15	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	trans	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg06606381	chr12:133084897	FBRSL1	1.01	6.38	0.46	2.05e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.78e-5	Platelet count;
PAAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.94e-6	Triglycerides;
PAAD	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs7766436	0.614	rs7775936	chr6:22566151	T/C	cg13666174	chr6:22585274	NA	-0.5	-4.45	-0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs6066835	1.000	rs6125446	chr20:47348161	C/G	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.11	0.55	1.53e-13	Alzheimer's disease;
PAAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.61	5.99	0.44	1.47e-8	Menopause (age at onset);
PAAD	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg16579770	chr16:72058938	DHODH	0.38	4.35	0.33	2.51e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg04087571	chr11:116723030	SIK3	-0.35	-4.6	-0.35	8.97e-6	Subjective well-being;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.11	-15.98	-0.79	2.38e-34	Height;
PAAD	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs2320952	0.790	rs11654242	chr17:10488774	T/C	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	9.97	0.63	2.51e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs4523957	0.890	rs12941621	chr17:2194852	C/T	cg16513277	chr17:2031491	SMG6	0.44	4.42	0.34	1.9e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.4	0.46	1.82e-9	IgG glycosylation;
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg26174226	chr8:58114915	NA	-0.57	-4.38	-0.33	2.2e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg06046430	chr4:77819534	ANKRD56	0.78	9.14	0.6	3.75e-16	Emphysema distribution in smoking;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.84	7.0	0.49	7.61e-11	Alzheimer's disease;
PAAD	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs1012068	0.686	rs5994451	chr22:32323511	A/C	cg01338084	chr22:32026380	PISD	0.54	4.88	0.37	2.61e-6	Chronic hepatitis C infection;
PAAD	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg18806716	chr10:30721971	MAP3K8	0.37	4.29	0.33	3.14e-5	Inflammatory bowel disease;
PAAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.66	5.44	0.4	2.04e-7	Schizophrenia;
PAAD	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.46	0.57	2.1e-14	Rheumatoid arthritis;
PAAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.73	-0.48	3.21e-10	Lung cancer;
PAAD	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.61	6.95	0.49	9.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg13468214	chr4:1046988	NA	-0.51	-4.58	-0.35	9.53e-6	Recombination rate (females);
PAAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg11204139	chr17:3907470	NA	0.79	5.89	0.43	2.37e-8	Type 2 diabetes;
PAAD	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.07	-0.5	5.32e-11	Neuroticism;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs4523957	0.788	rs11651451	chr17:2098417	C/T	cg16513277	chr17:2031491	SMG6	-0.49	-5.06	-0.38	1.19e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.58	-5.26	-0.39	4.76e-7	Menarche (age at onset);
PAAD	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.63	5.7	0.42	6.04e-8	Platelet count;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16606324	chr3:10149918	C3orf24	0.74	6.12	0.44	7.63e-9	Alzheimer's disease;
PAAD	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.6	4.84	0.37	3.14e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7503168	1.000	rs9894057	chr17:33889923	G/A	cg05299278	chr17:33885742	SLFN14	-0.49	-4.26	-0.33	3.59e-5	Plateletcrit;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Colorectal cancer;
PAAD	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.68	-4.65	-0.35	7.3e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.34	-0.33	2.6e-5	Neuroticism;
PAAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.34	0.56	4.27e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.78	8.96	0.59	1.06e-15	Menopause (age at onset);
PAAD	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg02569219	chr17:2266849	SGSM2	0.57	5.54	0.41	1.31e-7	Proinsulin levels;
PAAD	cis	rs533581	0.789	rs7404039	chr16:88975954	A/G	cg05579598	chr16:88989069	CBFA2T3	0.65	10.13	0.63	9.7e-19	Social autistic-like traits;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.51	5.2	0.39	6.46e-7	Longevity;Endometriosis;
PAAD	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.91	8.89	0.59	1.61e-15	Exhaled nitric oxide output;
PAAD	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.9	0.49	1.34e-10	Cognitive ability;
PAAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.45	5.87	0.43	2.6e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.51	-6.02	-0.44	1.26e-8	Mean arterial pressure;
PAAD	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.09e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.81	-7.13	-0.5	3.86e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg20243544	chr17:37824526	PNMT	0.51	4.63	0.35	7.94e-6	Self-reported allergy;
PAAD	cis	rs9659323	0.700	rs10923746	chr1:119616278	A/G	cg26570165	chr1:119541833	NA	-0.48	-5.2	-0.39	6.31e-7	Body mass index;
PAAD	cis	rs12773846	0.537	rs60812935	chr10:126273414	T/C	cg04949429	chr10:126290192	LHPP	0.66	5.68	0.42	6.57e-8	Subcutaneous adipose tissue;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.42	-5.01	-0.38	1.47e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs78761021	0.755	rs62064480	chr17:9794251	G/A	cg26853458	chr17:9805074	RCVRN	0.73	8.58	0.57	1.06e-14	Type 2 diabetes;
PAAD	cis	rs4740619	0.619	rs1410450	chr9:16037123	A/C	cg14451791	chr9:16040625	NA	-0.43	-4.94	-0.37	2.06e-6	Body mass index;
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.65	7.71	0.53	1.55e-12	Vitiligo;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08769276	chr4:186347048	UFSP2	0.72	6.76	0.48	2.83e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg05333889	chr7:157238977	NA	-0.43	-4.52	-0.34	1.24e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg10150615	chr22:24372951	LOC391322	-0.59	-4.44	-0.34	1.69e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.44	-0.34	1.7e-5	Ileal carcinoids;
PAAD	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.63	-5.37	-0.4	2.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg11464842	chr2:97427975	CNNM4	0.81	4.44	0.34	1.69e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.71	-6.86	-0.49	1.64e-10	Hip circumference;
PAAD	cis	rs11997175	0.609	rs4733459	chr8:33663793	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	5.34	0.4	3.29e-7	Body mass index;
PAAD	cis	rs34734847	0.750	rs3915	chr12:121176679	C/T	cg21892295	chr12:121157589	UNC119B	-0.4	-4.7	-0.36	5.76e-6	Mean corpuscular volume;
PAAD	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.69	-6.66	-0.48	4.75e-10	Retinal vascular caliber;
PAAD	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg20636351	chr8:55087400	NA	-0.8	-9.08	-0.59	5.5e-16	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs72752223	0.541	rs12438772	chr15:93753488	T/C	cg01959025	chr15:93749169	NA	0.78	6.5	0.47	1.11e-9	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
PAAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.87	9.41	0.61	7.38e-17	Tuberculosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05798608	chr1:202317770	PPP1R12B	0.61	7.05	0.5	5.9e-11	Monocyte percentage of white cells;
PAAD	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04327947	chr19:55795380	BRSK1	0.65	6.3	0.46	3.12e-9	Obesity-related traits;
PAAD	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.5	4.54	0.35	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.83	10.13	0.63	9.25e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2555155	0.837	rs2723631	chr11:6537730	A/G	cg24637308	chr11:6592297	DNHD1	0.5	5.17	0.39	7.29e-7	DNA methylation (variation);
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.5	-0.47	1.11e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg11630242	chr17:19881632	AKAP10	-0.47	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.7	-7.81	-0.54	8.69e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62400317	0.859	rs12205905	chr6:45178498	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.56	-0.47	7.97e-10	Total body bone mineral density;
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01616529	chr11:638424	DRD4	-0.63	-5.64	-0.42	8.11e-8	Systemic lupus erythematosus;
PAAD	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.9	8.6	0.57	8.88e-15	Response to diuretic therapy;
PAAD	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-10.31	-0.64	3.08e-19	Vitiligo;
PAAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg03161606	chr19:29218774	NA	-0.73	-5.47	-0.41	1.79e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9677476	0.909	rs13408391	chr2:232124127	G/T	cg07929768	chr2:232055508	NA	0.38	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Gut microbiome composition (summer);
PAAD	cis	rs1997066	0.831	rs73342205	chr10:106816790	A/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13394990	chr13:113537737	ATP11A	0.61	7.07	0.5	5.14e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10046574	0.831	rs10250306	chr7:135165275	G/A	cg27474649	chr7:135195673	CNOT4	0.8	4.3	0.33	3e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.85	-9.26	-0.6	1.85e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg04775059	chr7:64541387	NA	0.57	5.94	0.43	1.87e-8	Calcium levels;
PAAD	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.64	-5.57	-0.41	1.15e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6782025	0.832	rs7615712	chr3:120884717	T/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12165864	chr7:66369176	NA	-0.8	-4.96	-0.37	1.89e-6	Diabetic kidney disease;
PAAD	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.35	4.65	0.35	7.24e-6	Schizophrenia;
PAAD	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.64	5.92	0.43	2.08e-8	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.94	-5.32	-0.4	3.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2637266	0.935	rs2637265	chr10:78326104	A/G	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.42e-6	Pulmonary function;
PAAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.1e-6	Type 2 diabetes;
PAAD	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.67	7.55	0.52	3.84e-12	Resting heart rate;
PAAD	cis	rs28595532	0.720	rs72670228	chr4:119309516	T/C	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03762994	chr17:6899332	ALOX12	0.49	4.97	0.37	1.75e-6	Tonsillectomy;
PAAD	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.92	-7.85	-0.54	6.97e-13	Gut microbiome composition (summer);
PAAD	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg06565975	chr8:143823917	SLURP1	-0.22	-4.9	-0.37	2.42e-6	Urinary tract infection frequency;
PAAD	cis	rs2882667	0.690	rs288030	chr5:138216283	A/G	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.6	5.7	0.42	6.09e-8	Alcohol dependence;
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-6.61	-0.47	6.27e-10	Lymphocyte counts;
PAAD	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg23973274	chr1:155060172	NA	0.46	4.81	0.36	3.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg16928487	chr17:17741425	SREBF1	-0.34	-4.66	-0.35	6.86e-6	Total body bone mineral density;
PAAD	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26897989	chr16:1907736	C16orf73	-0.55	-4.92	-0.37	2.26e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11926012	chr5:115299828	LVRN	0.59	6.3	0.46	3.01e-9	Smoking initiation;
PAAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03676636	chr4:99064102	C4orf37	0.33	6.02	0.44	1.24e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.21	-7.92	-0.54	4.75e-13	Lung cancer in ever smokers;
PAAD	cis	rs2017305	0.915	rs79606412	chr10:70777891	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg01798341	chr17:80842262	TBCD	0.45	4.78	0.36	4.07e-6	Breast cancer;
PAAD	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.6	4.48	0.34	1.43e-5	Alzheimer's disease (survival time);
PAAD	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-7.05	-0.5	5.98e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12808519	0.605	rs3893155	chr11:69597881	T/C	cg26765567	chr11:69587473	NA	-0.46	-4.29	-0.33	3.13e-5	Urate levels in overweight individuals;
PAAD	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg24747557	chr10:131355152	MGMT	0.46	4.62	0.35	8.09e-6	Response to temozolomide;
PAAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.81	8.24	0.56	7.47e-14	Vitiligo;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02909866	chr10:101152469	CNNM1	-0.57	-6.46	-0.46	1.33e-9	Body fat percentage;
PAAD	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.72	7.12	0.5	4.03e-11	Corneal astigmatism;
PAAD	cis	rs10958369	0.836	rs2376145	chr8:54399343	G/C	cg12485204	chr8:54507357	NA	0.45	4.42	0.34	1.89e-5	Response to antineoplastic agents;
PAAD	cis	rs6785206	0.614	rs6771177	chr3:128510137	C/G	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.74	-7.4	-0.51	8.57e-12	Resistin levels;
PAAD	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11112613	0.680	rs12231332	chr12:106046030	G/A	cg03607813	chr12:105948248	NA	0.62	5.06	0.38	1.19e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.6	-6.2	-0.45	5.07e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4740619	0.557	rs1328296	chr9:16046292	G/C	cg14451791	chr9:16040625	NA	-0.43	-4.84	-0.37	3.13e-6	Body mass index;
PAAD	cis	rs2790216	0.950	rs1115435	chr10:60008611	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs2694528	0.620	rs79524768	chr5:59930164	C/A	cg11474532	chr5:59995715	DEPDC1B	0.95	4.83	0.36	3.34e-6	Parkinson's disease;
PAAD	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.49	-0.47	1.12e-9	Chronic sinus infection;
PAAD	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.65	-5.41	-0.4	2.38e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.52	4.91	0.37	2.3e-6	Hirschsprung disease;
PAAD	cis	rs564309	0.681	rs1188488	chr1:228621626	G/T	cg01200585	chr1:228362443	C1orf69	0.63	4.5	0.34	1.33e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.79	10.19	0.64	6.41e-19	Bone mineral density;
PAAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.75	-7.87	-0.54	6.09e-13	Colorectal cancer;
PAAD	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.64	7.66	0.53	2.02e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.81	-10.01	-0.63	1.94e-18	Bone mineral density;
PAAD	cis	rs62238980	0.901	rs62238999	chr22:32584787	C/T	cg00543991	chr22:32367038	NA	1.15	6.37	0.46	2.1e-9	Childhood ear infection;
PAAD	cis	rs3206736	0.548	rs167893	chr7:35042733	A/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.42	-6.34	-0.46	2.54e-9	Serum sulfate level;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.76	-9.3	-0.6	1.47e-16	Lymphocyte counts;
PAAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.81	6.96	0.49	9.3e-11	Recombination rate (females);
PAAD	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.29	0.6	1.5e-16	Bipolar disorder;
PAAD	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs3764400	0.507	rs56161855	chr17:46288649	A/T	cg10706073	chr17:46328419	SKAP1	-0.68	-4.42	-0.34	1.91e-5	Body mass index;
PAAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.64	7.71	0.53	1.52e-12	Weight;
PAAD	cis	rs2421770	0.701	rs7105545	chr11:35257588	A/T	cg13971030	chr11:35366721	SLC1A2	0.48	4.96	0.37	1.89e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	3.43e-18	Cognitive function;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs3106136	0.710	rs7694491	chr4:95290250	C/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.84	-9.56	-0.61	3.01e-17	Ulcerative colitis;
PAAD	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg01388757	chr2:102091195	RFX8	0.66	7.77	0.53	1.08e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.92	6.29	0.45	3.27e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.48	5.89	0.43	2.38e-8	Sitting height ratio;
PAAD	cis	rs10793968	0.681	rs4740363	chr9:133629184	A/G	cg21207741	chr9:134148648	FAM78A	-0.44	-4.25	-0.33	3.72e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-5.0	-0.38	1.56e-6	Homocysteine levels;
PAAD	cis	rs3736485	0.966	rs11634180	chr15:51895757	G/C	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2.03e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs57920188	0.658	rs7548273	chr1:4078945	G/C	cg20703997	chr1:4087676	NA	0.49	4.41	0.34	1.97e-5	Interleukin-17 levels;
PAAD	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	5.33	0.4	3.55e-7	Menarche (age at onset);
PAAD	cis	rs2882667	0.690	rs160398	chr5:138063439	T/G	cg09476006	chr5:138032270	NA	0.47	6.1	0.44	8.33e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9880772	0.747	rs4680868	chr3:27829161	C/G	cg21473142	chr3:27762095	EOMES	0.33	5.84	0.43	3.04e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.48	3.13e-10	Longevity;Endometriosis;
PAAD	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.45	-0.46	1.42e-9	Neuroticism;
PAAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.27	-0.39	4.62e-7	Glomerular filtration rate;
PAAD	cis	rs9646944	0.501	rs2293223	chr2:103035468	C/T	cg20060108	chr2:102954350	IL1RL1	0.53	4.31	0.33	2.9e-5	Blood protein levels;
PAAD	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.51	-4.71	-0.36	5.43e-6	Red cell distribution width;
PAAD	cis	rs9395066	0.545	rs6925467	chr6:44998038	T/A	cg18551225	chr6:44695536	NA	-0.4	-4.27	-0.33	3.44e-5	Height;
PAAD	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.47e-21	Blood protein levels;
PAAD	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.67	9.4	0.61	7.8e-17	Breast size;
PAAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg03714773	chr7:91764589	CYP51A1	-0.32	-4.49	-0.34	1.37e-5	Breast cancer;
PAAD	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.93	-7.11	-0.5	4.2e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg12292205	chr6:26970375	C6orf41	-0.53	-4.79	-0.36	3.91e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.67	4.95	0.37	1.99e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg27644672	chr7:1858694	MAD1L1	-0.42	-4.58	-0.35	9.43e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.73	5.86	0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6942407	0.542	rs1981535	chr7:86747375	A/G	cg14887563	chr7:86849180	C7orf23	0.49	4.27	0.33	3.45e-5	Food allergy;
PAAD	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.87	6.99	0.49	8.19e-11	Chronic kidney disease;
PAAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg10705379	chr10:99080932	FRAT1	-0.44	-4.99	-0.38	1.64e-6	Monocyte count;
PAAD	cis	rs7715811	1.000	rs10050673	chr5:13761643	G/A	cg07548982	chr5:13769939	DNAH5	-0.65	-6.33	-0.46	2.62e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs4946900	1.000	rs4946902	chr6:108418008	G/A	cg13435432	chr6:108489292	NR2E1	0.41	4.35	0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.37	0.4	2.88e-7	Obesity-related traits;
PAAD	cis	rs3996993	0.686	rs2749007	chr6:52625963	A/T	cg00536792	chr6:53530503	KLHL31	0.47	4.95	0.37	1.94e-6	Hemoglobin concentration;
PAAD	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.27e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.81	0.54	8.7e-13	Lung cancer in ever smokers;
PAAD	cis	rs2229238	0.911	rs60760897	chr1:154504849	C/T	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.59	6.94	0.49	1.07e-10	Height;
PAAD	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg02297831	chr4:17616191	MED28	0.58	5.39	0.4	2.63e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6748734	0.548	rs4441463	chr2:241872597	A/G	cg26818257	chr2:241905806	NA	0.49	5.01	0.38	1.47e-6	Urinary metabolites;
PAAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.73	7.77	0.53	1.07e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.79	6.98	0.49	8.33e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	5.45	0.4	2.02e-7	Joint mobility (Beighton score);
PAAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-4.28	-0.33	3.3e-5	Renal cell carcinoma;
PAAD	cis	rs375066	0.967	rs441344	chr19:44404682	T/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg07384165	chr1:10488281	NA	-0.53	-5.2	-0.39	6.3e-7	Prostate cancer;
PAAD	cis	rs9810890	0.717	rs73210625	chr3:128668246	G/A	cg18531004	chr3:128564980	NA	-0.93	-5.2	-0.39	6.44e-7	Dental caries;
PAAD	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg19217778	chr13:113420270	ATP11A	0.62	4.45	0.34	1.68e-5	Glycated hemoglobin levels;
PAAD	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs55883249	1.000	rs17362902	chr2:9768564	C/T	cg23886495	chr2:9695866	ADAM17	-0.55	-4.7	-0.36	5.72e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg01765077	chr12:122356316	WDR66	-0.49	-4.79	-0.36	3.98e-6	Mean corpuscular volume;
PAAD	trans	rs17076896	0.520	rs73155758	chr13:19727092	C/T	cg20227530	chr10:79085138	KCNMA1	0.82	6.41	0.46	1.7e-9	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4294134	0.608	rs11767351	chr7:135243837	A/G	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.58	-5.92	-0.43	2.04e-8	Testicular germ cell tumor;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25583086	chr18:74209008	NA	-0.54	-6.39	-0.46	1.91e-9	Obesity-related traits;
PAAD	cis	rs73019876	0.869	rs11670558	chr19:22171249	T/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg05554000	chr7:158905015	VIPR2	-0.74	-5.49	-0.41	1.66e-7	Facial morphology (factor 20);
PAAD	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg06484146	chr7:12443880	VWDE	-0.61	-4.39	-0.34	2.08e-5	Coronary artery disease;
PAAD	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.61	4.82	0.36	3.46e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	4.35	0.33	2.53e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-7.85	-0.54	6.96e-13	Lung cancer;
PAAD	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Lymphocyte counts;
PAAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.76	8.41	0.56	2.71e-14	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs12042052	1.000	rs72752168	chr1:232922800	G/A	cg02191044	chr1:232940990	KIAA1383	0.91	4.48	0.34	1.44e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.2e-18	Electrocardiographic conduction measures;
PAAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg07648498	chr16:89883185	FANCA	0.5	4.75	0.36	4.72e-6	Vitiligo;
PAAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.45	-6.16	-0.45	6.13e-9	Height;
PAAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.71	-0.48	3.68e-10	Joint mobility (Beighton score);
PAAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg23957660	chr17:17878224	LRRC48	-0.37	-4.38	-0.33	2.18e-5	Total body bone mineral density;
PAAD	cis	rs59888335	0.858	rs35446432	chr3:80924324	C/T	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg21269045	chr12:125625041	AACS	-0.45	-4.36	-0.33	2.36e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.92	-9.17	-0.6	3.09e-16	Obesity-related traits;
PAAD	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.58	-5.11	-0.38	9.73e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	6.16	0.45	6.16e-9	Blood metabolite levels;
PAAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.61	-8.31	-0.56	4.94e-14	Renal cell carcinoma;
PAAD	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11811982	0.793	rs77317375	chr1:227511926	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.78	-7.33	-0.51	1.29e-11	Vitamin D levels;
PAAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.65	6.3	0.46	3.03e-9	Refractive astigmatism;
PAAD	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.56	-0.35	1.06e-5	Arsenic metabolism;
PAAD	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.67	4.67	0.35	6.46e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.89	-0.54	5.55e-13	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04432377	chr3:45017297	EXOSC7;ZDHHC3	0.67	6.69	0.48	4.01e-10	Obesity-related traits;
PAAD	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.7	0.48	3.83e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs617219	0.659	rs13182512	chr5:78573790	A/T	cg24856658	chr5:78533917	JMY	0.4	4.38	0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg08632701	chr21:37451849	NA	-0.61	-6.65	-0.47	4.97e-10	Mitral valve prolapse;
PAAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg06883089	chr1:45254480	BEST4	0.33	4.26	0.33	3.51e-5	High light scatter reticulocyte count;
PAAD	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.38	-4.62	-0.35	8.24e-6	Rheumatoid arthritis;
PAAD	cis	rs2031532	0.587	rs7995283	chr13:50044585	A/C	cg03651054	chr13:50194643	NA	0.32	4.69	0.36	5.93e-6	Cardiac hypertrophy;
PAAD	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	4.6	0.35	8.69e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg05305434	chr11:1874049	LSP1	0.47	5.32	0.4	3.71e-7	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.63	-6.98	-0.49	8.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.66	-6.6	-0.47	6.49e-10	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4343996	0.902	rs4719894	chr7:3381789	C/T	cg21248987	chr7:3385318	SDK1	-0.48	-5.28	-0.39	4.32e-7	Motion sickness;
PAAD	cis	rs12780845	1.000	rs17140062	chr10:17202840	T/A	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.76	-7.82	-0.54	8.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs7678296	1.000	rs1342999	chr4:37217990	A/G	cg06805348	chr4:37245195	KIAA1239	0.65	4.83	0.36	3.34e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7009516	0.604	rs13259526	chr8:24263957	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.47	-5.31	-0.4	3.9e-7	Hair greying;
PAAD	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-1.07	-9.37	-0.61	9.53e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7619427	0.544	rs9866639	chr3:43990450	G/A	cg16646616	chr3:44040527	NA	-0.56	-4.55	-0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs7224737	1.000	rs8072215	chr17:40271970	A/G	cg20291162	chr17:40259547	DHX58	-0.61	-6.45	-0.46	1.41e-9	Fibrinogen levels;
PAAD	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-8.7	-0.58	5.03e-15	Gut microbiome composition (summer);
PAAD	cis	rs11022131	0.960	rs10765918	chr11:12071855	A/G	cg17400947	chr11:11645841	NA	0.36	4.43	0.34	1.81e-5	Warfarin maintenance dose;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09300980	chr6:17601309	FAM8A1	0.62	6.6	0.47	6.3e-10	Myopia (pathological);
PAAD	cis	rs9914578	0.943	rs3760231	chr17:2014984	T/C	cg16513277	chr17:2031491	SMG6	-0.6	-5.45	-0.4	1.99e-7	Body mass index;
PAAD	cis	rs9916302	0.560	rs3764353	chr17:37790781	T/C	cg20243544	chr17:37824526	PNMT	0.63	5.4	0.4	2.47e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.77	-0.42	4.4e-8	Psoriasis;
PAAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg12215294	chr3:40350768	EIF1B	-0.44	-4.29	-0.33	3.18e-5	Renal cell carcinoma;
PAAD	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	5.12	0.38	8.99e-7	Thyroid stimulating hormone;
PAAD	cis	rs2980439	0.517	rs712253	chr8:8103782	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.41	-0.46	1.75e-9	Neuroticism;
PAAD	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.85	9.62	0.62	2.06e-17	Resting heart rate;
PAAD	cis	rs8018808	1.000	rs12432247	chr14:77856321	T/C	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs4845459	0.935	rs4845449	chr1:152591024	A/T	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-7.22	-0.51	2.33e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg07150166	chr2:30669952	LCLAT1	0.68	5.09	0.38	1.04e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25869295	chr11:70433086	SHANK2	0.64	6.46	0.46	1.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.84	-0.37	3.16e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6496932	0.635	rs4356428	chr15:85929580	C/A	cg19183879	chr15:85880815	NA	-0.62	-5.69	-0.42	6.24e-8	Central corneal thickness;Corneal structure;
PAAD	cis	rs28830936	0.966	rs3743024	chr15:42118971	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.04	-0.5	6.27e-11	Diastolic blood pressure;
PAAD	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.67	9.81	0.62	6.5e-18	Breast cancer;
PAAD	cis	rs642743	0.934	rs611372	chr10:105958464	G/A	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.39	0.34	2.12e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.52	-0.34	1.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7696796	0.613	rs7661740	chr4:183167560	G/A	cg04638710	chr4:183167912	NA	0.44	4.33	0.33	2.75e-5	Neuroticism;
PAAD	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03115019	chr17:80708279	FN3K	0.47	4.32	0.33	2.78e-5	Glycated hemoglobin levels;
PAAD	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg08992911	chr2:238395768	MLPH	0.66	5.42	0.4	2.34e-7	Prostate cancer;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.77	-10.87	-0.66	1.01e-20	Psoriasis;
PAAD	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	10.47	0.65	1.17e-19	Smoking behavior;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg13264159	chr8:625131	ERICH1	-0.7	-4.72	-0.36	5.23e-6	IgG glycosylation;
PAAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.91	10.52	0.65	8.64e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.41	0.34	1.93e-5	Educational attainment (years of education);
PAAD	cis	rs17095355	0.818	rs2501575	chr10:111849864	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-5.08	-0.38	1.09e-6	Biliary atresia;
PAAD	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs28595532	0.841	rs115080469	chr4:119720501	C/T	cg21605333	chr4:119757512	SEC24D	1.92	9.76	0.62	9.09e-18	Cannabis dependence symptom count;
PAAD	cis	rs721399	0.568	rs7816847	chr8:18275189	A/C	cg18736775	chr8:18248649	NAT2	-0.66	-4.94	-0.37	2e-6	Blood metabolite levels;
PAAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.58	6.0	0.44	1.36e-8	Personality dimensions;
PAAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.47	0.52	5.99e-12	IgG glycosylation;
PAAD	cis	rs10516089	0.504	rs1897549	chr5:171137737	G/A	cg21066063	chr5:171570130	STK10	0.34	4.25	0.33	3.68e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg12310025	chr6:25882481	NA	-0.52	-4.32	-0.33	2.86e-5	Iron status biomarkers;
PAAD	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.52	-5.08	-0.38	1.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg16230307	chr14:35515116	FAM177A1	0.74	6.9	0.49	1.28e-10	Psoriasis;
PAAD	trans	rs901683	0.850	rs76879426	chr10:46044857	G/A	cg11747279	chr17:21096632	NA	0.88	6.71	0.48	3.53e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6960043	0.738	rs12540947	chr7:15059326	T/C	cg19272540	chr7:15055459	NA	0.35	6.1	0.44	8.54e-9	Type 2 diabetes;
PAAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9364554	0.691	rs2063347	chr6:160882029	G/A	cg25313204	chr6:160768801	SLC22A3	0.51	4.49	0.34	1.42e-5	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs41311933	0.803	rs41312871	chr9:123733630	C/T	cg13567360	chr9:123745713	C5	-0.69	-4.29	-0.33	3.14e-5	Coronary artery disease;
PAAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.62	-8.26	-0.56	6.75e-14	Renal cell carcinoma;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg24585817	chr7:64895279	NA	-0.39	-4.39	-0.34	2.11e-5	Calcium levels;
PAAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.96	-14.69	-0.77	5.68e-31	Height;
PAAD	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	1.05	6.06	0.44	1.01e-8	Type 2 diabetes nephropathy;
PAAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4604732	0.588	rs4356092	chr1:247632668	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	5.69	0.42	6.3e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2124910	0.808	rs2124909	chr19:52037704	C/A	cg12008991	chr19:52034861	SIGLEC6	0.33	4.33	0.33	2.71e-5	Blood protein levels;
PAAD	cis	rs7567389	0.504	rs5937	chr2:128184770	T/C	cg09760422	chr2:128146352	NA	0.4	5.88	0.43	2.51e-8	Self-rated health;
PAAD	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22857025	chr5:266934	NA	-1.15	-5.27	-0.39	4.51e-7	Breast cancer;
PAAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg08994789	chr17:28903642	LRRC37B2	0.55	4.65	0.35	7.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.7	-6.96	-0.49	9.44e-11	Blood metabolite levels;
PAAD	cis	rs9646944	0.501	rs10210176	chr2:103079516	A/C	cg20060108	chr2:102954350	IL1RL1	-0.55	-4.49	-0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs11078597	0.636	rs4790821	chr17:1654048	A/G	cg17514665	chr17:1657533	SERPINF2	0.76	7.05	0.5	5.96e-11	Serum albumin level;
PAAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.6	-6.28	-0.45	3.4e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.21	0.55	8.91e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.45	0.34	1.67e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs73198271	0.628	rs74433718	chr8:8591546	A/C	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.22	0.7	2.41e-24	Prudent dietary pattern;
PAAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09099965	chr7:99036501	CPSF4;PTCD1	0.66	7.44	0.52	7.09e-12	Monocyte percentage of white cells;
PAAD	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	1.02	7.92	0.54	4.72e-13	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.03	0.38	1.38e-6	Breast cancer;
PAAD	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.4	-0.51	8.45e-12	Response to antipsychotic treatment;
PAAD	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	trans	rs901683	1.000	rs901683	chr10:45966422	C/T	cg23720331	chr10:123873670	TACC2	-0.8	-6.45	-0.46	1.43e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.51	-0.34	1.27e-5	Fear of minor pain;
PAAD	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-5.92	-0.43	2.04e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.66	8.12	0.55	1.51e-13	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg21890820	chr11:65308645	LTBP3	1.0	7.9	0.54	5.22e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-9.49	-0.61	4.72e-17	Blood trace element (Zn levels);
PAAD	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.57	4.9	0.37	2.44e-6	RR interval (heart rate);
PAAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.73	-7.67	-0.53	1.88e-12	Neurofibrillary tangles;
PAAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs12949688	0.682	rs11871658	chr17:55839058	G/A	cg12582317	chr17:55822272	NA	0.41	4.77	0.36	4.27e-6	Schizophrenia;
PAAD	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg07725925	chr16:89976287	TCF25	0.77	4.28	0.33	3.26e-5	Interleukin-17 levels;
PAAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Coronary artery disease;
PAAD	cis	rs11677203	0.756	rs873715	chr2:12559864	A/G	cg01085830	chr2:11774354	GREB1	-0.52	-4.62	-0.35	8.13e-6	Electroencephalogram traits;
PAAD	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.81	-7.34	-0.51	1.2e-11	Pancreatic cancer;
PAAD	cis	rs12900413	0.687	rs12911126	chr15:90315380	T/C	cg24249390	chr15:90295951	MESP1	-0.52	-5.62	-0.41	8.89e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9463078	0.585	rs10456552	chr6:45313952	G/A	cg25276700	chr6:44698697	NA	0.51	5.68	0.42	6.63e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.25e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs340029	0.798	rs339991	chr15:60913637	A/G	cg00200653	chr15:60883225	RORA	0.49	4.32	0.33	2.84e-5	C-reactive protein levels;
PAAD	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.81	7.69	0.53	1.71e-12	Asthma;
PAAD	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.82	6.66	0.48	4.73e-10	Lung function (FEV1/FVC);
PAAD	cis	rs4343996	0.869	rs10266047	chr7:3476501	C/G	cg21248987	chr7:3385318	SDK1	0.5	5.51	0.41	1.49e-7	Motion sickness;
PAAD	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg10223061	chr2:219282414	VIL1	-0.37	-4.44	-0.34	1.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16333971	chr13:30424821	UBL3	0.61	7.05	0.5	5.93e-11	Monocyte percentage of white cells;
PAAD	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg15654264	chr1:150340011	RPRD2	-0.61	-6.38	-0.46	1.99e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.59	0.47	6.76e-10	Blood protein levels;
PAAD	cis	rs490234	0.841	rs7863341	chr9:128449085	A/G	cg14078157	chr9:128172775	NA	0.45	5.26	0.39	4.81e-7	Mean arterial pressure;
PAAD	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs202065757	1	rs202065757	chr6:28766359	C/CAT	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.58	0.35	9.61e-6	Tuberculosis;
PAAD	cis	rs1468333	0.537	rs13184188	chr5:137789519	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	4.78	0.36	4.17e-6	Resting heart rate;
PAAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.42	4.28	0.33	3.23e-5	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.49	4.89	0.37	2.55e-6	QT interval;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01765077	chr12:122356316	WDR66	-0.65	-6.8	-0.48	2.19e-10	Mean corpuscular volume;
PAAD	cis	rs7173419	0.953	rs7170989	chr15:28200408	A/G	cg20906524	chr15:28200668	OCA2	-0.46	-5.01	-0.38	1.5e-6	Eye color;
PAAD	cis	rs876084	0.505	rs12546625	chr8:121155225	C/T	cg06265175	chr8:121136014	COL14A1	0.45	4.43	0.34	1.77e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.37	-0.33	2.25e-5	Red blood cell count;
PAAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7301016	0.948	rs12369985	chr12:62918780	A/G	cg19781863	chr12:62918364	MON2	0.74	4.37	0.33	2.28e-5	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17662584	chr22:40440687	TNRC6B	0.61	6.93	0.49	1.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.99	10.63	0.65	4.32e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg03538708	chr1:25844672	NA	-0.5	-5.13	-0.38	8.87e-7	Plateletcrit;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08920068	chr5:121414076	LOX	0.58	6.52	0.47	9.93e-10	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.32e-8	Alzheimer's disease;
PAAD	cis	rs9815354	1.000	rs6801343	chr3:41767234	C/T	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02243437	chr10:61469599	SLC16A9	-0.76	-6.84	-0.49	1.8e-10	Neuroticism;
PAAD	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg23531748	chr20:60969906	CABLES2	0.45	4.43	0.34	1.83e-5	Colorectal cancer;
PAAD	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg08934286	chr12:123463762	ARL6IP4;OGFOD2	-0.45	-4.37	-0.33	2.32e-5	Platelet count;
PAAD	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.6	-5.3	-0.4	3.95e-7	Schizophrenia;
PAAD	cis	rs6585424	1.000	rs12763392	chr10:81934995	C/T	cg19423196	chr10:82049429	MAT1A	-0.42	-4.46	-0.34	1.55e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg16926213	chr1:1841314	NA	0.37	4.42	0.34	1.89e-5	Body mass index;
PAAD	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.71	9.64	0.62	1.87e-17	Eosinophil percentage of white cells;
PAAD	cis	rs2019216	0.500	rs7502283	chr17:21878561	G/C	cg22648282	chr17:21454238	C17orf51	-0.59	-6.04	-0.44	1.15e-8	Pelvic organ prolapse;
PAAD	cis	rs113779084	0.711	rs4568516	chr7:11989864	C/G	cg15090509	chr7:11872073	THSD7A	0.39	4.71	0.36	5.57e-6	Educational attainment (years of education);
PAAD	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs655641	0.520	rs480781	chr11:85795950	A/G	cg07180834	chr11:85838833	NA	-0.51	-5.24	-0.39	5.35e-7	Platelet count;
PAAD	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02598441	chr17:62777298	LOC146880	-0.54	-4.42	-0.34	1.9e-5	Joint mobility (Beighton score);
PAAD	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.52	5.56	0.41	1.19e-7	Dupuytren's disease;
PAAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	4.3	0.33	3.05e-5	Acne (severe);
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.49	-4.82	-0.36	3.39e-6	Male sexual orientation;
PAAD	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg15017067	chr4:17643749	FAM184B	0.44	4.86	0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7651511	1.000	rs720663	chr3:141233105	T/C	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-4.84	-0.37	3.15e-6	Subjective well-being;
PAAD	cis	rs28647808	1.000	rs28690644	chr9:136269669	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg08886695	chr4:3369023	RGS12	-0.47	-4.38	-0.33	2.21e-5	Serum sulfate level;
PAAD	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17208502	chr2:37948491	NA	0.64	7.22	0.51	2.33e-11	Smoking initiation;
PAAD	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.55	-5.16	-0.39	7.5e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-6.25	-0.45	3.88e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg21929781	chr1:2537748	MMEL1	0.44	4.66	0.35	6.85e-6	Ulcerative colitis;
PAAD	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	6.7	0.48	3.9e-10	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11958404	0.546	rs10475647	chr5:157443489	A/G	cg05962755	chr5:157440814	NA	0.55	5.19	0.39	6.76e-7	IgG glycosylation;
PAAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.65	6.62	0.47	5.88e-10	Blood protein levels;
PAAD	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer;
PAAD	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.43	5.28	0.39	4.36e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg10096100	chr1:26503862	CNKSR1	0.3	4.25	0.33	3.66e-5	Height;
PAAD	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1497828	0.956	rs2810784	chr1:217546406	A/T	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20685352	chr3:47823121	SMARCC1	0.7	7.07	0.5	5.39e-11	Obesity-related traits;
PAAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg00031303	chr3:195681400	NA	0.56	4.98	0.37	1.67e-6	Pancreatic cancer;
PAAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.94	8.48	0.57	1.83e-14	Gut microbiome composition (summer);
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs4908768	0.629	rs4908517	chr1:8887005	T/A	cg00590817	chr1:8272081	NA	-0.36	-4.37	-0.33	2.31e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23544223	chr18:12777786	NA	0.69	6.09	0.44	8.98e-9	Inflammatory skin disease;
PAAD	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.69	-4.67	-0.35	6.47e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	7.39	0.51	9.37e-12	Monocyte percentage of white cells;
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg14789911	chr21:47582049	C21orf56	-0.51	-5.07	-0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.54	-4.93	-0.37	2.12e-6	Asthma;
PAAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-9.02	-0.59	7.73e-16	Total body bone mineral density;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.07	0.44	9.99e-9	Height;
PAAD	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.87	10.49	0.65	1.04e-19	Menopause (age at onset);
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.79	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09916155	chr16:1728187	HN1L	0.61	6.84	0.49	1.84e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.79	-9.47	-0.61	5.32e-17	White blood cell count (basophil);
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.6	-10.18	-0.64	6.91e-19	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-5.75	-0.42	4.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg16928487	chr17:17741425	SREBF1	0.38	5.0	0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	4.66	0.35	6.89e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg21929781	chr1:2537748	MMEL1	0.53	5.62	0.41	8.92e-8	Ulcerative colitis;
PAAD	cis	rs59888335	0.964	rs34982420	chr3:80765874	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs3127553	0.526	rs1766377	chr1:49917084	C/T	cg09846084	chr1:50888024	DMRTA2	0.54	4.68	0.36	6.19e-6	Waist circumference;
PAAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.71	4.76	0.36	4.39e-6	Yeast infection;
PAAD	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg03252829	chr6:39282164	KCNK17	-0.55	-5.82	-0.43	3.3e-8	Type 2 diabetes;
PAAD	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.52	-5.53	-0.41	1.36e-7	Mitral valve prolapse;
PAAD	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-8.52	-0.57	1.44e-14	Vitiligo;
PAAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.72	6.39	0.46	1.94e-9	Menarche (age at onset);
PAAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.59	-4.94	-0.37	2.03e-6	Coronary artery disease;
PAAD	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.11	-0.5	4.14e-11	Cognitive function;
PAAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4455778	0.580	rs56191832	chr7:49128223	C/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.64	5.39	0.4	2.67e-7	Lymphocyte counts;
PAAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg25319279	chr11:5960081	NA	-0.63	-5.86	-0.43	2.78e-8	DNA methylation (variation);
PAAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.59	6.3	0.45	3.1e-9	Mean corpuscular volume;
PAAD	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.6	-5.33	-0.4	3.45e-7	Height;
PAAD	cis	rs2019216	0.500	rs7359613	chr17:21944028	T/C	cg22648282	chr17:21454238	C17orf51	-0.51	-4.59	-0.35	9.35e-6	Pelvic organ prolapse;
PAAD	cis	rs5009270	0.524	rs11763053	chr7:112262623	C/T	cg25550468	chr7:112262557	NA	0.58	5.08	0.38	1.07e-6	Osteoarthritis (hip);
PAAD	cis	rs2694528	0.844	rs4541610	chr5:60065941	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.69	-4.31	-0.33	2.95e-5	Parkinson's disease;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg25937216	chr8:58172855	NA	-0.86	-7.76	-0.53	1.18e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.44	-4.34	-0.33	2.6e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs3112530	1.000	rs3112530	chr5:152639677	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.94	-5.25	-0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg15181151	chr6:150070149	PCMT1	0.59	6.38	0.46	2.01e-9	Lung cancer;
PAAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01200585	chr1:228362443	C1orf69	-0.49	-5.53	-0.41	1.35e-7	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.77	7.62	0.53	2.5e-12	Coronary artery disease;
PAAD	cis	rs4716602	0.898	rs10275754	chr7:156161763	A/G	cg04090468	chr7:156181990	NA	0.5	4.91	0.37	2.28e-6	Anti-saccade response;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs7551345	1.000	rs34400805	chr1:31826396	C/T	cg17086398	chr1:31896392	SERINC2	-0.48	-4.38	-0.33	2.2e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg07747251	chr5:1868357	NA	0.57	6.46	0.46	1.32e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg07701084	chr6:150067640	NUP43	-0.54	-4.69	-0.36	6.16e-6	Lung cancer;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs73019876	0.901	rs417628	chr19:22230794	C/A	cg11619707	chr19:22235551	ZNF257	-0.42	-4.57	-0.35	9.95e-6	Testicular germ cell tumor;
PAAD	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs183266	0.736	rs10483880	chr14:77502118	A/G	cg01682506	chr14:77422843	NA	0.92	4.61	0.35	8.44e-6	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg05294307	chr14:35346193	BAZ1A	-0.66	-5.32	-0.4	3.62e-7	Psoriasis;
PAAD	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.38	-0.33	2.24e-5	Ovarian reserve;
PAAD	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02419362	chr12:121203948	SPPL3	0.53	5.79	0.43	3.84e-8	Systemic lupus erythematosus;
PAAD	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg23860436	chr12:58378763	NA	0.5	4.82	0.36	3.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg12568669	chr8:11666485	FDFT1	-0.28	-4.43	-0.34	1.8e-5	Monocyte count;
PAAD	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg21174375	chr14:64681225	SYNE2	-0.34	-4.63	-0.35	7.74e-6	Atrial fibrillation;
PAAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg08641963	chr20:44451973	TNNC2	0.29	4.25	0.33	3.71e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08113639	chr17:17061915	MPRIP	0.56	6.3	0.46	3.1e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg10374248	chr10:99083645	NA	0.5	4.57	0.35	1e-5	Monocyte count;
PAAD	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg08992911	chr2:238395768	MLPH	0.49	4.99	0.38	1.6e-6	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05614058	chr19:48949061	GRWD1	0.64	6.74	0.48	3.11e-10	Myopia (pathological);
PAAD	cis	rs11264213	0.786	rs72659696	chr1:36313665	G/A	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs2070677	0.866	rs2987796	chr10:135379688	C/T	cg20169779	chr10:135381914	SYCE1	0.78	7.51	0.52	4.68e-12	Gout;
PAAD	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg25703541	chr22:24373054	LOC391322	-0.93	-10.57	-0.65	6.25e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.81	-8.86	-0.58	1.93e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6025261	0.735	rs6099357	chr20:55508611	A/G	cg11868041	chr20:55503363	NA	0.41	4.68	0.35	6.31e-6	Verbal memory performance (delayed recall level);
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.74	7.52	0.52	4.36e-12	Prostate cancer;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg10411590	chr13:21900810	NA	0.63	7.05	0.5	5.92e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg23093090	chr10:104574429	C10orf26	-0.42	-4.45	-0.34	1.63e-5	Colorectal cancer;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.49	5.16	0.39	7.64e-7	Longevity;Endometriosis;
PAAD	cis	rs9463078	0.547	rs2038555	chr6:44744033	A/G	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7624766	0.555	rs718757	chr3:160534225	A/G	cg22637730	chr3:160473554	PPM1L	-0.54	-4.68	-0.35	6.26e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg10137597	chr8:22132714	PIWIL2	0.49	5.81	0.43	3.57e-8	Hypertriglyceridemia;
PAAD	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.26	-0.39	4.85e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.55	5.38	0.4	2.82e-7	Fibrinogen levels;
PAAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg02683114	chr2:24398427	C2orf84	0.56	6.05	0.44	1.06e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs375066	0.762	rs171238	chr19:44379554	A/C	cg11993925	chr19:44307056	LYPD5	0.51	6.25	0.45	3.97e-9	Breast cancer;
PAAD	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.56	-0.52	3.64e-12	Morning vs. evening chronotype;
PAAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.68	7.51	0.52	4.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.46	5.78	0.42	4.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.58	-0.41	1.1e-7	Vitiligo;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.3	0.33	2.99e-5	Bipolar disorder;
PAAD	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.05	0.38	1.26e-6	Childhood ear infection;
PAAD	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg03367679	chr17:38183553	MED24;SNORD124	-0.34	-4.35	-0.33	2.44e-5	White blood cell count;
PAAD	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.54	0.41	1.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088813	0.961	rs6088791	chr20:33907909	A/G	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.56	-8.06	-0.55	2.06e-13	Huntington's disease progression;
PAAD	cis	rs4523957	0.855	rs1231206	chr17:2125605	G/A	cg16513277	chr17:2031491	SMG6	-0.49	-4.97	-0.37	1.81e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1075232	1.000	rs72722829	chr15:31639114	G/A	cg06530883	chr15:30699977	NA	0.96	4.46	0.34	1.56e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs3743102	0.591	rs76037357	chr15:83399490	A/G	cg00614314	chr15:82944287	LOC80154	-0.66	-4.41	-0.34	1.96e-5	Colorectal adenoma (advanced);
PAAD	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.44	0.4	2.05e-7	Type 2 diabetes;
PAAD	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg07168214	chr17:7380112	ZBTB4	-0.64	-5.83	-0.43	3.14e-8	Androgen levels;
PAAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-5.76	-0.42	4.44e-8	Monocyte count;
PAAD	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.59	6.93	0.49	1.09e-10	Lung cancer;
PAAD	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.82	7.9	0.54	5.24e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12042052	0.590	rs12048236	chr1:232942251	A/G	cg02903907	chr1:232941055	KIAA1383	0.8	4.56	0.35	1.04e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.67	-7.28	-0.51	1.64e-11	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg10729496	chr3:10149963	C3orf24	0.87	6.16	0.45	6.37e-9	Alzheimer's disease;
PAAD	cis	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg22101045	chr11:47927509	NA	0.57	4.38	0.33	2.21e-5	Intraocular pressure;
PAAD	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.39	-5.0	-0.38	1.55e-6	Prostate cancer;
PAAD	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.64	5.78	0.42	4.11e-8	Height;
PAAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg21775007	chr8:11205619	TDH	-0.51	-4.75	-0.36	4.72e-6	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.72	-0.36	5.32e-6	Joint mobility (Beighton score);
PAAD	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.66	5.73	0.42	5.2e-8	Advanced age-related macular degeneration;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.8	-8.71	-0.58	4.92e-15	Menopause (age at onset);
PAAD	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9395066	0.545	rs4711805	chr6:44870102	T/C	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.64	6.52	0.47	9.76e-10	Adiposity;
PAAD	cis	rs986417	0.686	rs6573322	chr14:61117882	T/C	cg27398547	chr14:60952738	C14orf39	0.97	5.32	0.4	3.68e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.46	-0.46	1.33e-9	Response to antipsychotic treatment;
PAAD	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg21479132	chr6:26055353	NA	0.7	4.49	0.34	1.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs16854884	1.000	rs2370171	chr3:143765177	C/T	cg06585982	chr3:143692056	C3orf58	0.61	5.93	0.43	2.01e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.17	16.85	0.81	1.32e-36	Body mass index;
PAAD	cis	rs57244997	0.582	rs73030424	chr6:162434298	T/A	cg17173639	chr6:162384350	PARK2	-0.7	-5.29	-0.39	4.23e-7	Mosquito bite size;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.8	-8.35	-0.56	3.95e-14	Paraoxonase activity;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.81	-0.48	2.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.72	8.05	0.55	2.25e-13	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11342046	chr2:242641489	ING5	0.67	7.6	0.52	2.77e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.56	5.67	0.42	6.99e-8	Resistin levels;
PAAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.32e-6	Mood instability;
PAAD	trans	rs1442089	0.764	rs77904651	chr18:51140186	T/C	cg24118715	chr10:70232072	DNA2	0.75	6.42	0.46	1.63e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.7	4.85	0.37	3.06e-6	Iron status biomarkers;
PAAD	cis	rs6256	0.929	rs10832053	chr11:13550209	T/G	cg11976911	chr11:13509032	NA	-0.67	-5.18	-0.39	7.06e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg11251234	chr10:101825055	CPN1	0.3	4.33	0.33	2.7e-5	Bone mineral density;
PAAD	cis	rs2790216	1.000	rs1199104	chr10:59946781	T/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	4.86	0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.6	-5.6	-0.41	9.86e-8	Height;
PAAD	cis	rs9815354	0.903	rs9822598	chr3:41954587	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.78	-0.42	4.13e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg02683114	chr2:24398427	C2orf84	0.55	5.68	0.42	6.55e-8	Asthma;
PAAD	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg11657817	chr20:23433608	CST11	0.52	5.29	0.39	4.2e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12599982	chr1:44399894	ARTN	0.43	4.61	0.35	8.35e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-6.36	-0.46	2.27e-9	Coronary artery disease;
PAAD	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.81	-9.59	-0.61	2.54e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.62	-5.97	-0.44	1.61e-8	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.6	-5.99	-0.44	1.49e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6976053	0.935	rs4727469	chr7:100509163	C/T	cg22425096	chr7:100417404	EPHB4	0.51	4.36	0.33	2.37e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.16	15.48	0.78	4.78e-33	Triglycerides;
PAAD	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg11214348	chr21:47283868	PCBP3	-0.49	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.38	-0.51	9.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg10547527	chr2:198650123	BOLL	-0.72	-4.78	-0.36	4.02e-6	Ulcerative colitis;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01616529	chr11:638424	DRD4	-0.58	-5.68	-0.42	6.8e-8	Systemic lupus erythematosus;
PAAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06451957	chr5:158758139	IL12B	0.57	6.44	0.46	1.48e-9	Smoking initiation;
PAAD	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.7	-7.13	-0.5	3.73e-11	Body mass index;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.11	0.55	1.56e-13	Prudent dietary pattern;
PAAD	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.55	-5.45	-0.4	1.96e-7	Capecitabine sensitivity;
PAAD	cis	rs5751901	0.575	rs2154611	chr22:24989920	C/T	cg08808123	chr22:24999002	GGT1	-0.47	-4.84	-0.37	3.2e-6	Protein quantitative trait loci;
PAAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.45	-5.44	-0.4	2.13e-7	Height;
PAAD	cis	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg06375148	chr1:209958343	C1orf74	0.65	4.85	0.37	3.02e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.71	7.76	0.53	1.13e-12	Mean corpuscular volume;
PAAD	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg16558253	chr16:72132732	DHX38	-0.68	-4.35	-0.33	2.5e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg04156016	chr5:1868137	NA	0.48	4.79	0.36	3.99e-6	Cardiovascular disease risk factors;
PAAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg26939375	chr7:64535504	NA	0.76	9.04	0.59	6.97e-16	Aortic root size;
PAAD	cis	rs7172971	0.688	rs74909369	chr15:42382241	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20597494	chr11:126136113	SRPR	0.62	6.34	0.46	2.55e-9	Smoking initiation;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg07061783	chr6:25882402	NA	-0.49	-4.68	-0.35	6.37e-6	Blood metabolite levels;
PAAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.43	-0.34	1.81e-5	Height;
PAAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2421770	0.927	rs7929900	chr11:35312583	C/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-6.63	-0.47	5.41e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.78	9.26	0.6	1.83e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs9422441	chr10:46048053	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2147904	0.867	rs1408947	chr1:42364198	C/T	cg16685388	chr1:42384056	HIVEP3	0.4	4.75	0.36	4.75e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg20913747	chr6:44695427	NA	-0.66	-6.61	-0.47	6.03e-10	Total body bone mineral density;
PAAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs12780845	1.000	rs7072634	chr10:17240918	C/A	cg00857480	chr10:17188594	TRDMT1	0.35	4.34	0.33	2.63e-5	Homocysteine levels;
PAAD	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-4.38	-0.33	2.17e-5	Ovarian reserve;
PAAD	cis	rs17221829	0.965	rs12292340	chr11:89461273	C/A	cg02982614	chr11:89391479	FOLH1B	-0.43	-4.39	-0.34	2.12e-5	Anxiety in major depressive disorder;
PAAD	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.37	4.58	0.35	9.46e-6	Carotid intima media thickness;
PAAD	cis	rs11997175	0.531	rs113627999	chr8:33737335	G/T	ch.8.33884649F	chr8:33765107	NA	0.58	5.62	0.42	8.68e-8	Body mass index;
PAAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.42	5.42	0.4	2.32e-7	Monocyte count;
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg20821713	chr7:1055600	C7orf50	-0.44	-4.73	-0.36	5.06e-6	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02071572	chr4:1403502	NA	-0.44	-5.68	-0.42	6.68e-8	Obesity-related traits;
PAAD	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.46	-4.41	-0.34	1.98e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.71	-6.34	-0.46	2.44e-9	Vitamin D levels;
PAAD	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.2	10.29	0.64	3.51e-19	Night sleep phenotypes;
PAAD	cis	rs7692976	0.503	rs62325265	chr4:110923592	T/C	cg06981781	chr4:110842888	EGF	-0.41	-4.63	-0.35	7.84e-6	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-5.8	-0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg12034118	chr1:209979487	IRF6	0.48	4.35	0.33	2.48e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg11271282	chr2:238384023	NA	0.54	4.97	0.37	1.78e-6	Prostate cancer;
PAAD	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.69	4.84	0.37	3.22e-6	Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.52	-5.64	-0.42	8e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	1.000	rs372492	chr5:112198015	A/G	cg06941702	chr5:112196734	SRP19	-0.47	-4.47	-0.34	1.51e-5	Total body bone mineral density;
PAAD	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs7009516	0.625	rs17799264	chr8:24257137	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.5	6.04	0.44	1.13e-8	Hair greying;
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg19761014	chr17:28927070	LRRC37B2	0.87	5.9	0.43	2.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg25487775	chr2:162093969	NA	-0.52	-5.13	-0.38	8.75e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-6.97	-0.49	9.05e-11	Bipolar disorder;
PAAD	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.74	-7.63	-0.53	2.41e-12	Retinal vascular caliber;
PAAD	cis	rs876084	0.505	rs35529075	chr8:121143623	C/G	cg06265175	chr8:121136014	COL14A1	0.46	4.49	0.34	1.39e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.83	5.56	0.41	1.2e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.4	-4.31	-0.33	2.9e-5	Facial morphology (factor 20);
PAAD	cis	rs4662592	0.554	rs13012263	chr2:128930883	G/A	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23513784	chr8:22550797	EGR3	0.7	7.07	0.5	5.2e-11	Obesity-related traits;
PAAD	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.65	5.53	0.41	1.34e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg13468214	chr4:1046988	NA	0.64	8.95	0.59	1.13e-15	Recombination rate (males);
PAAD	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.97	-0.37	1.75e-6	Pulmonary function;
PAAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg00540400	chr15:79124168	NA	0.69	8.78	0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg05784532	chr1:230284198	GALNT2	0.69	5.78	0.42	4.13e-8	Coronary artery disease;
PAAD	cis	rs2952768	1.000	rs2551941	chr2:208492143	A/T	cg22329743	chr2:208688774	PLEKHM3	0.23	4.48	0.34	1.45e-5	Opioid sensitivity;
PAAD	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.69	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.44	-4.46	-0.34	1.57e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12612619	0.732	rs11681562	chr2:27250603	A/G	cg00617064	chr2:27272375	NA	-0.52	-5.49	-0.41	1.66e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	6.76	0.48	2.73e-10	Mood instability;
PAAD	cis	rs9581857	0.579	rs9581838	chr13:27966127	G/A	cg22138327	chr13:27999177	GTF3A	0.87	5.42	0.4	2.3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.52	-0.41	1.42e-7	Lung cancer;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03605463	chr16:89740564	NA	0.53	5.14	0.38	8.3e-7	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09507643	chr6:70506719	LMBRD1	0.64	6.44	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.83e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.89	10.43	0.65	1.55e-19	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.74	6.01	0.44	1.31e-8	Mean platelet volume;
PAAD	cis	rs77956314	0.792	rs117924143	chr12:117440958	T/C	cg02017074	chr12:117425053	FBXW8	-1.08	-5.17	-0.39	7.3e-7	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs10901513	0.861	rs10794047	chr10:127671038	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-7.98	-0.54	3.27e-13	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26395828	chr5:14665166	FAM105B	0.66	6.38	0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg04738700	chr2:239367308	NA	0.45	4.88	0.37	2.6e-6	Multiple system atrophy;
PAAD	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-4.42	-0.34	1.88e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg06375148	chr1:209958343	C1orf74	0.62	4.92	0.37	2.24e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9535307	0.929	rs6561550	chr13:50249423	C/T	cg03658251	chr13:50265850	EBPL	0.78	5.5	0.41	1.59e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.82	-5.73	-0.42	5.23e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.82	-0.54	8.08e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs863345	0.565	rs2220633	chr1:158445272	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.27e-6	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10307595	chr11:70330927	SHANK2	-0.67	-6.45	-0.46	1.44e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.76	8.47	0.57	1.93e-14	Lewy body disease;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg00035636	chr13:21900591	NA	0.6	6.09	0.44	8.87e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7508	0.512	rs6981130	chr8:17892518	C/T	cg08627089	chr8:17753878	FGL1	-0.44	-4.33	-0.33	2.65e-5	Atrial fibrillation;
PAAD	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs73019876	0.712	rs1859092	chr19:22143441	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.26	-0.33	3.57e-5	Testicular germ cell tumor;
PAAD	cis	rs9309711	0.813	rs11690865	chr2:3471950	C/T	cg10845886	chr2:3471009	TTC15	-0.91	-8.87	-0.58	1.84e-15	Neurofibrillary tangles;
PAAD	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg14250997	chr9:106856677	SMC2	0.48	5.12	0.38	9.05e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg09835421	chr16:68378352	PRMT7	-1.22	-8.79	-0.58	3.04e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-4.52	-0.34	1.23e-5	Type 2 diabetes;
PAAD	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.66	5.94	0.43	1.83e-8	Response to metformin (IC50);
PAAD	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-6.55	-0.47	8.53e-10	Morning vs. evening chronotype;
PAAD	cis	rs17641971	0.700	rs113263275	chr8:50048558	C/G	cg00325661	chr8:49890786	NA	-0.48	-4.51	-0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs863345	0.565	rs6679056	chr1:158450314	A/G	cg12129480	chr1:158549410	OR10X1	-0.38	-4.42	-0.34	1.88e-5	Pneumococcal bacteremia;
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg15193198	chr20:60906057	LAMA5	0.59	6.73	0.48	3.2e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg16596103	chr2:233749413	NGEF	0.41	4.43	0.34	1.78e-5	Schizophrenia;
PAAD	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-5.04	-0.38	1.33e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs28647808	1.000	rs28540113	chr9:136273463	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.61	0.35	8.48e-6	Homocysteine levels;
PAAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.58	-0.41	1.06e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg26898376	chr11:64110657	CCDC88B	0.43	4.6	0.35	8.76e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.52	-4.89	-0.37	2.58e-6	Kawasaki disease;
PAAD	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg03037974	chr15:76606532	NA	0.55	6.54	0.47	8.74e-10	Blood metabolite levels;
PAAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.63	-7.06	-0.5	5.58e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.66	-7.25	-0.51	1.92e-11	Huntington's disease progression;
PAAD	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.76	8.05	0.55	2.25e-13	Colorectal cancer;
PAAD	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.55	4.93	0.37	2.16e-6	RR interval (heart rate);
PAAD	cis	rs1941184	0.500	rs1893390	chr18:29017382	C/G	cg03238162	chr18:29027701	DSG3	0.42	4.62	0.35	8.11e-6	Parkinson's disease (age of onset);
PAAD	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.37	-0.51	1.02e-11	Chronic sinus infection;
PAAD	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	6.31	0.46	2.9e-9	Response to antipsychotic treatment;
PAAD	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02419362	chr12:121203948	SPPL3	-0.49	-5.4	-0.4	2.51e-7	Systemic lupus erythematosus;
PAAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.66	9.03	0.59	7.15e-16	Eye color traits;
PAAD	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg19090574	chr1:205240910	TMCC2	-0.41	-4.28	-0.33	3.3e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg19847866	chr10:1019161	NA	-0.59	-4.68	-0.35	6.34e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6669119	0.759	rs116404531	chr1:19112851	T/C	cg19637330	chr1:19110922	NA	0.83	5.13	0.38	8.63e-7	Percentage gas trapping;
PAAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.33	0.46	2.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg22875332	chr1:76189707	ACADM	-0.5	-4.99	-0.37	1.67e-6	Daytime sleep phenotypes;
PAAD	cis	rs7688540	0.511	rs61794991	chr4:198207	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-1.19	-10.34	-0.64	2.58e-19	Height;
PAAD	cis	rs62229266	0.625	rs2051395	chr21:37431265	A/C	cg12218747	chr21:37451666	NA	0.47	5.23	0.39	5.46e-7	Mitral valve prolapse;
PAAD	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.35	-4.6	-0.35	8.99e-6	Myeloid white cell count;
PAAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10322419	chr1:4470956	LOC284661	-0.58	-6.3	-0.46	3.12e-9	Obesity-related traits;
PAAD	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.96e-6	Cognitive ability;
PAAD	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.52	-6.8	-0.48	2.19e-10	Height;
PAAD	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.54	4.81	0.36	3.62e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.76	-6.97	-0.49	9.08e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.34	4.87	0.37	2.8e-6	Migraine;
PAAD	cis	rs4594175	0.962	rs4254242	chr14:51599184	A/C	cg23942311	chr14:51606299	NA	0.7	6.86	0.49	1.64e-10	Cancer;
PAAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.17e-7	Ulcerative colitis;
PAAD	cis	rs11615916	0.790	rs11615693	chr12:62693635	C/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.54	-5.49	-0.41	1.61e-7	Iron status biomarkers;
PAAD	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs7009110	0.786	rs10957978	chr8:81285139	G/T	cg21158561	chr8:81178149	NA	0.41	4.33	0.33	2.66e-5	Asthma and hay fever;
PAAD	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.49	-0.41	1.65e-7	Monocyte percentage of white cells;
PAAD	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg23112188	chr14:24563095	PCK2	-0.51	-5.39	-0.4	2.6e-7	IgG glycosylation;
PAAD	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15814675	chr11:105880605	KIAA1826	0.66	6.9	0.49	1.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.55	-0.35	1.08e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs11133665	0.683	rs7719875	chr5:1190088	A/G	cg17633683	chr5:1225331	SLC6A18	0.41	4.63	0.35	7.71e-6	Urinary metabolites;
PAAD	cis	rs89107	0.603	rs414091	chr6:118613398	T/C	cg21191810	chr6:118973309	C6orf204	0.47	6.57	0.47	7.47e-10	Cardiac structure and function;
PAAD	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.53	5.47	0.41	1.78e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs4668356	0.773	rs59301982	chr2:172050675	G/T	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	8.99	0.59	9.17e-16	Cognitive test performance;
PAAD	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.86	-5.47	-0.41	1.77e-7	Lung cancer in ever smokers;
PAAD	cis	rs2284367	0.769	rs4756153	chr11:34507879	G/A	cg20406267	chr11:34377921	ABTB2	0.43	4.44	0.34	1.69e-5	Blood protein levels;
PAAD	cis	rs1953600	0.521	rs7067644	chr10:81924245	A/G	cg00277334	chr10:82204260	NA	-0.47	-5.09	-0.38	1.03e-6	Sarcoidosis;
PAAD	cis	rs6687430	0.967	rs12741973	chr1:10638604	C/T	cg17425144	chr1:10567563	PEX14	-0.42	-4.46	-0.34	1.55e-5	Hand grip strength;
PAAD	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.39	0.34	2.15e-5	Total body bone mineral density;
PAAD	cis	rs2594989	0.943	rs9877694	chr3:11418873	A/C	cg01796438	chr3:11312864	ATG7	-0.63	-4.95	-0.37	1.92e-6	Circulating chemerin levels;
PAAD	cis	rs11997175	0.625	rs4268088	chr8:33599343	A/T	ch.8.33884649F	chr8:33765107	NA	0.58	6.39	0.46	1.9e-9	Body mass index;
PAAD	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg18302933	chr2:88491318	NA	-0.36	-4.27	-0.33	3.44e-5	Response to metformin (IC50);
PAAD	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14019695	chr9:139328340	INPP5E	0.5	4.53	0.34	1.19e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg15017067	chr4:17643749	FAM184B	0.46	5.3	0.39	4.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.17	-0.45	5.9e-9	Lung cancer;
PAAD	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-6.16	-0.45	6.2e-9	Gallbladder cancer;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.86	0.54	6.7e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.41	-0.34	1.92e-5	Blood metabolite levels;
PAAD	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.64	7.16	0.5	3.25e-11	Coronary artery disease;
PAAD	cis	rs11051970	0.918	rs73084099	chr12:32539751	C/T	cg24626660	chr12:32551988	NA	0.42	4.59	0.35	9.36e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs16867321	0.901	rs2368168	chr2:181355888	G/T	cg23363182	chr2:181467187	NA	-0.48	-4.33	-0.33	2.64e-5	Obesity;
PAAD	cis	rs9314323	0.558	rs58153210	chr8:26271120	C/T	cg11498726	chr8:26250323	BNIP3L	-0.44	-4.3	-0.33	3e-5	Red cell distribution width;
PAAD	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10991689	chr13:111164367	COL4A2	-0.73	-6.55	-0.47	8.27e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Body mass index;
PAAD	trans	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17712092	chr4:129076599	LARP1B	0.87	11.24	0.67	1e-21	Eosinophil percentage of white cells;
PAAD	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.5	-5.17	-0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.62	0.35	8.22e-6	Asthma;
PAAD	cis	rs7719624	0.756	rs6880837	chr5:135396669	A/G	cg16684184	chr5:135415129	NA	0.37	4.62	0.35	8.12e-6	Response to cytidine analogues (gemcitabine);
PAAD	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.95	0.49	9.8e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2904967	0.636	rs184734	chr11:64982203	T/C	cg21890820	chr11:65308645	LTBP3	-0.55	-5.34	-0.4	3.28e-7	Mean corpuscular volume;
PAAD	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg27411982	chr8:10470053	RP1L1	-0.5	-5.39	-0.4	2.58e-7	Retinal vascular caliber;
PAAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.63	-7.33	-0.51	1.26e-11	Longevity;Endometriosis;
PAAD	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.52	5.39	0.4	2.62e-7	Diastolic blood pressure;
PAAD	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg10820045	chr2:198174542	NA	-0.48	-4.88	-0.37	2.71e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.63	6.07	0.44	9.94e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.64	5.19	0.39	6.53e-7	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23428725	chr14:36278532	RALGAPA1	0.69	6.4	0.46	1.85e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10044254	0.587	rs13180702	chr5:15736320	A/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.83	8.82	0.58	2.48e-15	Anterior chamber depth;
PAAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg10589385	chr1:150898437	SETDB1	0.39	4.74	0.36	4.88e-6	Melanoma;
PAAD	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	1.16	12.78	0.72	7.43e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg20406979	chr6:167373233	NA	0.39	5.1	0.38	1.02e-6	Crohn's disease;
PAAD	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg09127314	chr1:152161683	NA	-0.7	-5.03	-0.38	1.39e-6	Atopic dermatitis;
PAAD	cis	rs5751901	0.614	rs5760489	chr22:24990646	A/G	cg08808123	chr22:24999002	GGT1	-0.45	-4.59	-0.35	9.32e-6	Protein quantitative trait loci;
PAAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.91	-6.24	-0.45	4.2e-9	IgG glycosylation;
PAAD	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.54	-5.94	-0.43	1.88e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.97	-7.88	-0.54	5.8e-13	Bipolar disorder;
PAAD	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.14e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18728316	chr6:157241162	ARID1B	0.61	6.4	0.46	1.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg07469887	chr10:131262384	NA	-0.39	-4.36	-0.33	2.43e-5	Response to temozolomide;
PAAD	cis	rs4668356	1.000	rs56155601	chr2:171954471	G/A	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg01305830	chr4:1604576	NA	-0.46	-4.57	-0.35	9.91e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg25837213	chr17:80849375	TBCD	-0.46	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg22771759	chr13:24902376	NA	0.48	4.72	0.36	5.34e-6	Obesity-related traits;
PAAD	cis	rs17534004	1.000	rs35955426	chr13:31471381	A/G	cg00570269	chr13:31480942	C13orf33	0.58	4.27	0.33	3.43e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.09	-0.55	1.77e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.75	-9.21	-0.6	2.39e-16	Lymphocyte counts;
PAAD	cis	rs27434	0.583	rs149544	chr5:96157854	C/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.64	-0.35	7.33e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.5	4.81	0.36	3.55e-6	Hepatocellular carcinoma;
PAAD	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs939584	1.000	rs10190313	chr2:647577	A/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.62	7.47	0.52	5.76e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.58	5.37	0.4	2.89e-7	Cognitive test performance;
PAAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.47	5.85	0.43	2.9e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.88	7.52	0.52	4.55e-12	Alzheimer's disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22944662	chr1:178062847	LOC100302401;RASAL2	0.54	6.29	0.45	3.22e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg15764593	chr10:829463	NA	-0.93	-4.74	-0.36	4.78e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.82	-5.02	-0.38	1.43e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.52	5.17	0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg00450029	chr8:599525	NA	-0.88	-5.62	-0.41	9.06e-8	IgG glycosylation;
PAAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.48	-0.57	1.83e-14	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11824304	chr4:37688119	RELL1	0.53	6.32	0.46	2.73e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.09	-0.38	1.03e-6	Lung cancer;
PAAD	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.31	5.98	0.44	1.56e-8	Skin colour saturation;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg12757816	chr2:10669957	NA	0.56	6.03	0.44	1.18e-8	Prostate cancer;
PAAD	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg02100629	chr10:71892760	AIFM2	-0.36	-4.37	-0.33	2.26e-5	Blood protein levels;
PAAD	cis	rs8070740	0.898	rs8074617	chr17:5323989	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	4.94	0.37	2.01e-6	Menopause (age at onset);
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs9398803	0.687	rs9375450	chr6:126985351	G/A	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.14e-6	Male-pattern baldness;
PAAD	trans	rs6732189	0.559	rs584526	chr2:161603829	G/A	cg02628561	chr17:18061605	MYO15A	0.59	6.52	0.47	1.01e-9	Educational attainment;
PAAD	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg10591111	chr5:226296	SDHA	-0.67	-4.99	-0.38	1.63e-6	Breast cancer;
PAAD	cis	rs6782228	0.606	rs6807019	chr3:128405934	G/A	cg16766828	chr3:128327626	NA	-0.46	-6.33	-0.46	2.56e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17655565	0.581	rs2298794	chr12:52760732	G/A	cg15701111	chr12:52685334	KRT81	0.5	4.28	0.33	3.26e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg01612440	chr4:3296283	NA	0.47	4.57	0.35	9.95e-6	Serum sulfate level;
PAAD	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.87	10.02	0.63	1.8e-18	Gout;
PAAD	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg12907477	chr18:56117327	MIR122	0.61	4.77	0.36	4.3e-6	Platelet count;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg26060667	chr1:247681242	NA	0.46	5.46	0.41	1.87e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	7.43	0.52	7.49e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14895029	chr7:2775587	GNA12	0.45	4.26	0.33	3.58e-5	Height;
PAAD	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-6.25	-0.45	3.85e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs11168618	0.561	rs4075258	chr12:48919659	T/C	cg01881778	chr12:48919444	OR8S1	-0.52	-5.59	-0.41	1.05e-7	Adiponectin levels;
PAAD	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.48	-4.74	-0.36	4.93e-6	Immature fraction of reticulocytes;
PAAD	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07685180	chr8:600429	NA	0.88	5.47	0.41	1.83e-7	IgG glycosylation;
PAAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg00206168	chr11:65308501	LTBP3	0.5	5.18	0.39	7.1e-7	Bone mineral density;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.67	8.17	0.55	1.08e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.47	-0.34	1.52e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.52	4.93	0.37	2.1e-6	Acylcarnitine levels;
PAAD	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg06242599	chr12:132069077	NA	0.64	6.35	0.46	2.41e-9	Cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13775575	chr19:48018329	NAPA	0.67	7.28	0.51	1.65e-11	Myopia (pathological);
PAAD	trans	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg01620082	chr3:125678407	NA	-1.41	-7.82	-0.54	8.25e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs868943	0.582	rs34001069	chr6:116483014	T/C	cg18764771	chr6:116381957	FRK	0.28	4.56	0.35	1.06e-5	Total cholesterol levels;
PAAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.78	-7.79	-0.53	9.91e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.83	-9.38	-0.61	9.16e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.27	0.45	3.51e-9	Lung cancer in ever smokers;
PAAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.24	0.39	5.4e-7	Bone mineral density;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg03732007	chr1:2071316	PRKCZ	-0.46	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.5	5.16	0.39	7.78e-7	Schizophrenia;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16262614	chr3:133464971	TF	0.46	5.07	0.38	1.16e-6	Iron status biomarkers;
PAAD	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg08648136	chr8:956695	NA	0.48	4.83	0.37	3.24e-6	Schizophrenia;
PAAD	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.48	5.18	0.39	6.99e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.42	4.59	0.35	9.29e-6	Platelet count;
PAAD	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.14	-0.45	6.94e-9	Schizophrenia;
PAAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.55	5.47	0.41	1.77e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.77	-0.36	4.35e-6	Smoking behavior;
PAAD	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs2229238	0.911	rs59239860	chr1:154492107	G/T	cg21262032	chr1:154437693	IL6R	-0.44	-4.57	-0.35	9.95e-6	Coronary heart disease;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-5.21	-0.39	5.97e-7	Testicular germ cell tumor;
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.54	5.76	0.42	4.58e-8	Age at first birth;
PAAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.3	0.6	1.4e-16	Rheumatoid arthritis;
PAAD	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.31	-0.33	2.88e-5	Cystic fibrosis severity;
PAAD	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg26528668	chr16:1614120	IFT140	0.52	4.86	0.37	2.86e-6	Coronary artery disease;
PAAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs11997175	0.838	rs10954934	chr8:33669637	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	6.53	0.47	9.25e-10	Body mass index;
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg19337854	chr7:99768885	GPC2	-0.5	-4.63	-0.35	7.7e-6	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19711553	chr22:20850288	KLHL22	0.62	7.11	0.5	4.22e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg00944433	chr1:107599041	PRMT6	-0.43	-4.92	-0.37	2.27e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg20503657	chr10:835505	NA	0.52	5.46	0.41	1.87e-7	Survival in rectal cancer;
PAAD	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg04254540	chr16:71951199	KIAA0174	-0.52	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	5.04	0.38	1.31e-6	Hirschsprung disease;
PAAD	cis	rs4343996	0.902	rs7798672	chr7:3342334	A/T	cg21248987	chr7:3385318	SDK1	0.47	5.14	0.38	8.41e-7	Motion sickness;
PAAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.47	-6.06	-0.44	1.03e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs8067354	0.958	rs8081468	chr17:57836924	A/G	cg02344993	chr17:57696989	CLTC	0.54	4.96	0.37	1.86e-6	Hemoglobin concentration;
PAAD	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.51	5.57	0.41	1.1e-7	Heart rate;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.52	5.31	0.4	3.82e-7	Testicular germ cell tumor;
PAAD	cis	rs2997447	0.846	rs3008429	chr1:26390833	A/G	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg16300553	chr8:8131077	NA	-0.36	-4.36	-0.33	2.35e-5	Joint mobility (Beighton score);
PAAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.75	0.42	4.75e-8	Schizophrenia;
PAAD	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg26205652	chr12:48591994	NA	0.86	7.78	0.53	1.04e-12	Longevity (90 years and older);
PAAD	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.89	-7.53	-0.52	4.25e-12	Lymphocyte percentage of white cells;
PAAD	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.1	0.67	2.4e-21	Breast cancer;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.45	-0.68	2.87e-22	Total body bone mineral density;
PAAD	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg22705602	chr4:152727874	NA	-0.43	-4.3	-0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	7.14	0.5	3.63e-11	IgG glycosylation;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg17325771	chr7:75508891	RHBDD2	-0.34	-4.82	-0.36	3.38e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs75757892	0.542	rs55716008	chr6:7324523	C/T	cg02954307	chr6:7269328	NA	0.5	4.27	0.33	3.44e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.09e-8	Life satisfaction;
PAAD	cis	rs2964802	0.505	rs7728436	chr5:10814464	T/A	cg14521931	chr5:10832172	NA	-0.46	-4.74	-0.36	4.81e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg16579770	chr16:72058938	DHODH	0.37	4.27	0.33	3.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg14440974	chr22:39074834	NA	-0.54	-6.86	-0.49	1.65e-10	Menopause (age at onset);
PAAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.76	-0.48	2.73e-10	Body mass index;
PAAD	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.84	7.18	0.5	2.93e-11	Pulmonary function decline;
PAAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg00253185	chr1:247542119	NA	0.53	4.31	0.33	2.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg13512537	chr8:22265999	SLC39A14	-0.44	-4.54	-0.35	1.16e-5	Verbal declarative memory;
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09256448	chr16:638327	NA	0.42	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.8e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.49	-7.78	-0.53	1.03e-12	Urinary metabolites;
PAAD	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9567406	1.000	rs2031996	chr13:44875173	C/T	cg08635097	chr13:44833857	NA	-0.63	-4.34	-0.33	2.55e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.71	7.86	0.54	6.62e-13	Longevity;
PAAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs12044355	0.927	rs12040182	chr1:231839165	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	5.36	0.4	3.06e-7	Alzheimer's disease;
PAAD	trans	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg00717180	chr2:96193071	NA	-0.61	-6.37	-0.46	2.12e-9	Migraine - clinic-based;
PAAD	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.8	8.0	0.54	2.96e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7598759	0.679	rs6437018	chr2:232327691	A/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.53	-0.34	1.2e-5	Noise-induced hearing loss;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06484986	chr15:42841099	LRRC57;HAUS2	0.72	7.17	0.5	3.11e-11	Primary biliary cholangitis;
PAAD	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.69	-5.04	-0.38	1.28e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-6.09	-0.44	8.74e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	0.97	6.82	0.48	2.06e-10	IgG glycosylation;
PAAD	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.73	6.91	0.49	1.23e-10	Methadone dose in opioid dependence;
PAAD	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg07159951	chr1:45983175	PRDX1	-0.44	-4.7	-0.36	5.89e-6	High light scatter reticulocyte count;
PAAD	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.38	-4.54	-0.35	1.12e-5	Rheumatoid arthritis;
PAAD	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.49	4.58	0.35	9.59e-6	Motion sickness;
PAAD	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg07943548	chr15:86304357	KLHL25	-0.71	-6.0	-0.44	1.38e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.39	4.26	0.33	3.62e-5	High light scatter reticulocyte count;
PAAD	trans	rs1442089	1.000	rs80098921	chr18:51127968	G/A	cg24118715	chr10:70232072	DNA2	0.74	6.47	0.46	1.27e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs12780845	1.000	rs61517255	chr10:17208918	G/A	cg00857480	chr10:17188594	TRDMT1	0.37	4.72	0.36	5.32e-6	Homocysteine levels;
PAAD	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg18084798	chr19:33555255	RHPN2	0.46	4.73	0.36	5.14e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6466055	0.661	rs17640472	chr7:104813097	T/C	cg04380332	chr7:105027541	SRPK2	0.51	5.0	0.38	1.57e-6	Schizophrenia;
PAAD	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.55	-0.35	1.11e-5	Height;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg01059385	chr22:42394853	WBP2NL	0.47	5.13	0.38	8.67e-7	Intelligence;
PAAD	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg11266682	chr4:10021025	SLC2A9	-0.64	-5.99	-0.44	1.45e-8	Schizophrenia (age at onset);
PAAD	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg01338084	chr22:32026380	PISD	0.49	4.42	0.34	1.85e-5	Intelligence;
PAAD	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs72627123	1.000	rs17093141	chr14:74326903	G/T	cg19860245	chr14:74300557	NA	-0.73	-5.12	-0.38	9.01e-7	Morning vs. evening chronotype;
PAAD	cis	rs6681460	0.671	rs628655	chr1:67213573	T/G	cg02459107	chr1:67143332	SGIP1	-0.71	-6.64	-0.47	5.1e-10	Presence of antiphospholipid antibodies;
PAAD	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.74	6.92	0.49	1.19e-10	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg22143635	chr11:980567	AP2A2	0.52	5.49	0.41	1.68e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.21	0.51	2.41e-11	Multiple sclerosis;
PAAD	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.72	6.33	0.46	2.68e-9	Inflammatory skin disease;
PAAD	cis	rs2030114	1.000	rs11639662	chr16:51609435	A/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.55	-5.75	-0.42	4.71e-8	Blood metabolite levels;
PAAD	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.21	0.45	4.71e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.91	0.37	2.3e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2290402	0.536	rs73207791	chr4:865941	A/G	cg09237302	chr4:906077	GAK	-0.42	-4.38	-0.33	2.21e-5	Type 2 diabetes;
PAAD	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg22705602	chr4:152727874	NA	-0.5	-5.41	-0.4	2.4e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.55	-0.35	1.11e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-1.23	-6.72	-0.48	3.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-5.82	-0.43	3.43e-8	Longevity;
PAAD	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	8.18	0.55	1.08e-13	Lung cancer in ever smokers;
PAAD	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.32	-0.33	2.81e-5	Height;
PAAD	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.76	-7.72	-0.53	1.43e-12	Monocyte count;
PAAD	cis	rs59191668	0.515	rs2439717	chr15:62777399	T/C	cg12918536	chr15:62891943	NA	0.33	4.3	0.33	3.04e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-5.37	-0.4	2.95e-7	Monocyte count;
PAAD	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.6	-5.89	-0.43	2.34e-8	Red cell distribution width;
PAAD	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.61	5.88	0.43	2.57e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-5.31	-0.4	3.9e-7	Personality dimensions;
PAAD	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.51	5.31	0.4	3.78e-7	Resting heart rate;
PAAD	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.51e-8	Coronary artery disease;
PAAD	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg05585544	chr11:47624801	NA	-0.45	-4.91	-0.37	2.35e-6	Subjective well-being;
PAAD	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg09184832	chr6:79620586	NA	-0.42	-4.26	-0.33	3.62e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08857478	chr17:74722826	JMJD6;C17orf95	0.69	7.98	0.54	3.33e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2455826	0.544	rs2455848	chr3:15771372	C/T	cg13420985	chr3:16524424	RFTN1	0.45	4.27	0.33	3.4e-5	Inflammatory skin disease;
PAAD	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.41	4.3	0.33	3.07e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg17974515	chr1:2252516	NA	-0.58	-6.16	-0.45	6.31e-9	Coronary artery disease;
PAAD	cis	rs1419980	0.730	rs11054581	chr12:7730276	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg12092346	chr18:77659572	KCNG2	-0.65	-4.56	-0.35	1.04e-5	Opioid sensitivity;
PAAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.72	-6.45	-0.46	1.4e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs4795519	0.784	rs8079151	chr17:22164221	A/C	cg22648282	chr17:21454238	C17orf51	-0.51	-5.42	-0.4	2.27e-7	Chronic myeloid leukemia;
PAAD	cis	rs6679454	0.801	rs852791	chr1:58308335	G/A	cg17491850	chr1:57888480	DAB1	-0.41	-4.38	-0.33	2.21e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg15676125	chr6:33679581	C6orf125	0.46	4.43	0.34	1.79e-5	Height;
PAAD	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.39	4.41	0.34	1.92e-5	Longevity;
PAAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12667521	chr19:29218732	NA	0.68	6.66	0.48	4.75e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.85	10.13	0.63	9.37e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.52	-0.41	1.46e-7	Obesity-related traits;
PAAD	cis	rs11997175	0.625	rs2882300	chr8:33585323	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.82	5.34	0.4	3.37e-7	Diabetic kidney disease;
PAAD	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg18898632	chr2:242989856	NA	-0.81	-6.03	-0.44	1.22e-8	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.69	7.33	0.51	1.3e-11	Platelet distribution width;
PAAD	cis	rs11718455	0.548	rs9824340	chr3:43902170	A/G	cg00181669	chr3:44000978	NA	-0.54	-5.92	-0.43	2.04e-8	Coronary artery disease;
PAAD	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg23024343	chr7:107201750	COG5	0.61	4.66	0.35	6.84e-6	Coronary artery disease;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.52	5.67	0.42	7.06e-8	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.99	-14.97	-0.77	1.05e-31	Prudent dietary pattern;
PAAD	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	4.49	0.34	1.39e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg02462569	chr6:150064036	NUP43	-0.45	-4.84	-0.37	3.21e-6	Lung cancer;
PAAD	cis	rs35160687	0.623	rs11127019	chr2:86467618	G/A	cg10973622	chr2:86423274	IMMT	-0.51	-5.72	-0.42	5.57e-8	Night sleep phenotypes;
PAAD	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.6	6.04	0.44	1.15e-8	Crohn's disease;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.35	6.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7742824	1.000	rs7773700	chr6:44097472	T/C	cg21657043	chr6:44035552	NA	0.5	5.15	0.39	7.83e-7	Major depressive disorder;
PAAD	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.62	-0.35	7.97e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7580658	0.864	rs3088374	chr2:128062048	T/C	cg09760422	chr2:128146352	NA	-0.27	-4.38	-0.33	2.17e-5	Protein C levels;
PAAD	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.51	-0.34	1.29e-5	Primary biliary cholangitis;
PAAD	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg06917450	chr1:38156652	C1orf109	-0.51	-4.48	-0.34	1.49e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11191205	0.685	rs1374471	chr10:103659601	C/A	cg15320455	chr10:103880129	LDB1	0.55	4.55	0.35	1.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs2153904	0.609	rs4951254	chr1:205642390	T/C	cg23034840	chr1:205782522	SLC41A1	0.69	5.53	0.41	1.35e-7	Prostate-specific antigen levels;
PAAD	cis	rs3112530	0.551	rs2446429	chr5:152716207	T/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.8	9.56	0.61	2.94e-17	Monocyte percentage of white cells;
PAAD	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg08523384	chr5:141488047	NDFIP1	-0.51	-4.89	-0.37	2.57e-6	Asthma;
PAAD	trans	rs901683	0.850	rs77876088	chr10:46094121	T/C	cg07567308	chr20:3149320	ProSAPiP1	0.76	6.45	0.46	1.41e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs17534004	1.000	rs12870594	chr13:31462909	T/C	cg00570269	chr13:31480942	C13orf33	0.59	4.42	0.34	1.9e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.95	7.58	0.52	3.09e-12	Type 2 diabetes;
PAAD	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.49	5.14	0.38	8.23e-7	Coronary heart disease;
PAAD	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	0.88	5.51	0.41	1.49e-7	Autism spectrum disorder-related traits;
PAAD	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.7	-5.83	-0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.73	-0.36	5.1e-6	Lung cancer;
PAAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.77	8.05	0.55	2.22e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs728616	0.681	rs12413174	chr10:82062404	G/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-4.42	-0.34	1.9e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.76	7.53	0.52	4.22e-12	Breast cancer;
PAAD	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.47	-0.34	1.51e-5	Myopia;Myopia (pathological);
PAAD	cis	rs10982213	1.000	rs10817607	chr9:117179222	A/G	cg00078025	chr9:117159975	NA	0.57	4.58	0.35	9.52e-6	Interleukin-6 levels;
PAAD	cis	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg27411982	chr8:10470053	RP1L1	0.45	4.73	0.36	5.09e-6	Neuroticism;
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.3	-0.6	1.44e-16	Systemic lupus erythematosus;
PAAD	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.46	-4.25	-0.33	3.66e-5	Menopause (age at onset);
PAAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg04106633	chr4:1044584	NA	0.62	5.3	0.4	3.97e-7	Recombination rate (females);
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.9	12.33	0.71	1.16e-24	Prudent dietary pattern;
PAAD	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg00262122	chr8:11665843	FDFT1	-0.55	-5.4	-0.4	2.55e-7	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg27394845	chr17:28928406	LRRC37B2	0.63	4.46	0.34	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg04575393	chr19:53496094	ZNF702P	0.5	5.48	0.41	1.76e-7	Psoriasis;
PAAD	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.63	6.5	0.47	1.06e-9	Crohn's disease;
PAAD	cis	rs16910800	0.731	rs35725172	chr11:23185968	G/A	cg20040320	chr11:23191996	NA	-0.82	-6.93	-0.49	1.09e-10	Cancer;
PAAD	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.4	0.64	1.77e-19	Smoking behavior;
PAAD	cis	rs1535500	0.935	rs34247110	chr6:39282371	G/A	cg08315770	chr6:39281885	KCNK17	-0.61	-6.44	-0.46	1.51e-9	Type 2 diabetes;
PAAD	trans	rs9810890	1.000	rs73207976	chr3:128569020	C/T	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.46	4.47	0.34	1.49e-5	Attention deficit hyperactivity disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12138346	chr1:15851107	CASP9	0.57	6.75	0.48	2.91e-10	Monocyte percentage of white cells;
PAAD	cis	rs4605213	0.528	rs12951858	chr17:49328627	C/G	cg22932220	chr17:49244634	NME2;NME1-NME2	-0.45	-5.62	-0.41	8.84e-8	Height;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.79	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.46	4.67	0.35	6.48e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.65	-6.41	-0.46	1.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.71	7.88	0.54	5.79e-13	Corneal astigmatism;
PAAD	cis	rs72960926	0.744	rs67945212	chr6:74891678	C/T	cg03266952	chr6:74778945	NA	-1.04	-6.0	-0.44	1.38e-8	Metabolite levels (MHPG);
PAAD	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-5.2	-0.39	6.48e-7	Chronic sinus infection;
PAAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.61	6.35	0.46	2.37e-9	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.57	-0.57	1.07e-14	Body mass index;
PAAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-1.11	-11.82	-0.69	2.88e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.96	0.37	1.83e-6	Ovarian reserve;
PAAD	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.18	0.39	6.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs1941184	0.500	rs7234091	chr18:29019829	C/T	cg03238162	chr18:29027701	DSG3	0.43	4.65	0.35	7.25e-6	Parkinson's disease (age of onset);
PAAD	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.45	5.24	0.39	5.29e-7	Atrioventricular conduction;
PAAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg06346307	chr22:19949965	COMT	-0.3	-4.61	-0.35	8.6e-6	Blood metabolite levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02711190	chr6:150244288	RAET1G	-0.64	-6.7	-0.48	3.78e-10	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2070729	0.523	rs743562	chr5:131872383	C/T	cg21138405	chr5:131827807	IRF1	-0.36	-4.99	-0.38	1.62e-6	Platelet count;
PAAD	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.67	7.22	0.51	2.29e-11	Resting heart rate;
PAAD	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg16417436	chr16:28758564	NA	0.43	4.32	0.33	2.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7219021	0.961	rs3901705	chr17:46865760	T/C	cg12314713	chr17:47074576	IGF2BP1	-0.38	-4.66	-0.35	6.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18099408	chr3:52552593	STAB1	0.51	5.77	0.42	4.22e-8	Electroencephalogram traits;
PAAD	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.46	4.74	0.36	4.88e-6	Type 2 diabetes;
PAAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.66	-0.35	6.73e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.57e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.64	7.0	0.49	7.52e-11	Myopia (pathological);
PAAD	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg19090574	chr1:205240910	TMCC2	-0.41	-4.46	-0.34	1.61e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	trans	rs61931739	0.629	rs17637821	chr12:33701108	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-5.16	-0.39	7.54e-7	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg02071572	chr4:1403502	NA	0.4	4.9	0.37	2.39e-6	Obesity-related traits;
PAAD	cis	rs354033	1.000	rs3735320	chr7:149246680	A/T	cg06920324	chr7:149264011	ZNF767	-0.57	-4.9	-0.37	2.42e-6	Multiple sclerosis;
PAAD	cis	rs3781663	1.000	rs10160639	chr11:69999122	A/C	cg11157765	chr11:69982996	ANO1	0.49	4.31	0.33	2.96e-5	Survival in rectal cancer;
PAAD	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.7	6.85	0.49	1.7e-10	Mean platelet volume;
PAAD	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg03989125	chr22:38214979	NA	0.6	5.69	0.42	6.3e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	4.33	0.33	2.73e-5	Ileal carcinoids;
PAAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.39	-0.4	2.61e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.31	-0.33	2.96e-5	Obesity-related traits;
PAAD	cis	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg07549590	chr16:15018862	NA	-0.46	-4.85	-0.37	3.08e-6	Triglycerides;
PAAD	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.51	4.85	0.37	3.07e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.9e-13	Response to antipsychotic treatment;
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.16	0.55	1.18e-13	Height;
PAAD	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.78	-7.06	-0.5	5.46e-11	Body mass index (adult);
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.65	-7.44	-0.52	6.83e-12	Iron status biomarkers;
PAAD	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.81	6.84	0.49	1.78e-10	Alzheimer's disease;
PAAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg13870426	chr17:30244630	NA	0.71	6.05	0.44	1.08e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs8027181	0.682	rs11637168	chr15:73100694	C/A	cg25632853	chr15:73088954	NA	0.4	4.3	0.33	3.01e-5	Triglyceride levels;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.38	-0.51	9.48e-12	Cognitive function;
PAAD	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17554472	chr22:41940697	POLR3H	0.59	4.27	0.33	3.48e-5	Vitiligo;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11669133	1.000	rs78686811	chr19:11128063	G/A	cg25243385	chr19:11167475	SMARCA4	0.98	4.59	0.35	9.11e-6	LDL cholesterol;
PAAD	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.6	-0.52	2.76e-12	Colorectal cancer;
PAAD	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.05e-6	Resting heart rate;
PAAD	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.52	6.03	0.44	1.19e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3125734	0.529	rs4979770	chr10:63921697	A/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.53	-0.35	1.17e-5	Rheumatoid arthritis;
PAAD	cis	rs6541297	0.757	rs600845	chr1:230322708	C/T	cg05784532	chr1:230284198	GALNT2	0.57	4.31	0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.66	6.93	0.49	1.12e-10	Systemic lupus erythematosus;
PAAD	cis	rs10885582	0.781	rs10159811	chr10:116293820	G/A	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.27	-0.39	4.62e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.59	6.03	0.44	1.22e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg20891558	chr2:74357851	NA	0.88	8.66	0.57	6.34e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.77	0.36	4.24e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.24	-0.39	5.35e-7	Obesity-related traits;
PAAD	cis	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg10301338	chr18:24129315	KCTD1	-0.54	-5.07	-0.38	1.12e-6	Dental caries;
PAAD	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-1.02	-13.82	-0.75	1.21e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg19930314	chr7:98593876	TRRAP	-0.49	-4.71	-0.36	5.55e-6	Breast cancer;
PAAD	cis	rs58521262	0.519	rs56791875	chr19:22942973	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.33e-5	Testicular germ cell tumor;
PAAD	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs1198430	0.562	rs7522616	chr1:23794914	A/G	cg24580199	chr1:23763081	ASAP3	0.5	4.4	0.34	2.06e-5	Total cholesterol levels;
PAAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.76	-0.36	4.43e-6	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19388446	chr12:6715730	CHD4	0.71	7.25	0.51	2.01e-11	Obesity-related traits;
PAAD	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-20.57	-0.86	8.77e-46	Myeloid white cell count;
PAAD	cis	rs1797885	0.646	rs299652	chr3:12547657	G/A	cg07775309	chr3:12595852	NA	0.41	4.33	0.33	2.74e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6681460	0.966	rs7542924	chr1:67143055	C/T	cg02459107	chr1:67143332	SGIP1	0.74	7.3	0.51	1.51e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07362569	chr17:61921086	SMARCD2	-0.44	-4.96	-0.37	1.83e-6	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.68	0.42	6.61e-8	Tonsillectomy;
PAAD	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.74	6.08	0.44	9.16e-9	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.6	0.52	2.81e-12	Alzheimer's disease;
PAAD	cis	rs501120	0.564	rs1704214	chr10:44682729	A/G	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg06207120	chr15:45996521	NA	0.3	4.43	0.34	1.78e-5	Waist circumference;Weight;
PAAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.96	11.8	0.69	3.28e-23	Bone mineral density;
PAAD	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg10137597	chr8:22132714	PIWIL2	0.5	6.01	0.44	1.35e-8	Hypertriglyceridemia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23843414	chr1:8484310	RERE	0.63	6.31	0.46	2.87e-9	Obesity-related traits;
PAAD	cis	rs7487075	0.619	rs4768123	chr12:46852093	G/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.44	0.34	1.71e-5	Itch intensity from mosquito bite;
PAAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	8.13	0.55	1.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs10865541	0.571	rs4854187	chr2:3384196	C/G	cg21040360	chr2:3383326	TTC15	0.41	4.63	0.35	7.83e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06850241	chr22:41845214	NA	0.47	4.27	0.33	3.5e-5	Vitiligo;
PAAD	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.9	-10.94	-0.66	6.38e-21	Dental caries;
PAAD	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg08079166	chr15:68083412	MAP2K5	-0.6	-5.6	-0.41	9.84e-8	Restless legs syndrome;
PAAD	cis	rs12432203	1.000	rs72622432	chr14:51733810	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.78	9.5	0.61	4.22e-17	Bone mineral density;
PAAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg14895029	chr7:2775587	GNA12	-0.46	-4.4	-0.34	2.06e-5	Height;
PAAD	cis	rs9438901	0.655	rs609320	chr1:25717365	C/G	cg12421513	chr1:25599066	RHD	-0.67	-5.13	-0.38	8.82e-7	Red cell distribution width;
PAAD	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.54	5.45	0.4	2.01e-7	Red blood cell count;
PAAD	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.82	10.32	0.64	2.97e-19	Height;
PAAD	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg24519413	chr1:26490540	NA	0.52	4.81	0.36	3.57e-6	Height;
PAAD	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.79	0.36	3.86e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.2	-0.45	4.97e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.671	rs10951172	chr7:27614111	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.35	0.33	2.49e-5	Hypospadias;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.9	10.83	0.66	1.3e-20	Prudent dietary pattern;
PAAD	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.48	-5.56	-0.41	1.17e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg25797454	chr6:150327115	RAET1K	0.31	4.73	0.36	5.09e-6	Alopecia areata;
PAAD	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.61	6.53	0.47	9.26e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.93	10.5	0.65	1e-19	Total cholesterol levels;
PAAD	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-7.44	-0.52	6.96e-12	Body mass index;
PAAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.5	6.67e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.46	4.57	0.35	1.02e-5	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.99	10.61	0.65	4.97e-20	Corneal astigmatism;
PAAD	cis	rs10267417	0.603	rs2390196	chr7:19864026	G/A	cg05791153	chr7:19748676	TWISTNB	0.74	5.0	0.38	1.55e-6	Night sleep phenotypes;
PAAD	cis	rs30380	1.000	rs469758	chr5:96121715	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.51	0.34	1.26e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg00540400	chr15:79124168	NA	-0.71	-8.91	-0.59	1.45e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg26149184	chr10:133730230	NA	0.78	6.86	0.49	1.64e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23588161	chr11:65729143	SART1	0.59	6.64	0.47	5.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-5.68	-0.42	6.51e-8	Mean platelet volume;
PAAD	cis	rs10463316	0.817	rs7708940	chr5:150789051	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.83	-0.43	3.2e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8014252	0.803	rs56328037	chr14:71045341	A/C	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg08601574	chr20:25228251	PYGB	0.55	5.55	0.41	1.26e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs12738007	0.901	rs755294	chr1:29460759	C/T	cg05667379	chr2:115920764	DPP10	0.37	6.31	0.46	2.97e-9	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08377924	chr17:41363628	NBR1;TMEM106A	-0.66	-6.4	-0.46	1.86e-9	Lung cancer in ever smokers;
PAAD	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	1.07	8.09	0.55	1.78e-13	Dental caries;
PAAD	cis	rs30380	0.734	rs27044	chr5:96118852	G/C	cg17330273	chr5:96107758	CAST;ERAP1	0.54	5.38	0.4	2.77e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs728616	0.614	rs61859209	chr10:82128309	G/A	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.95	-16.09	-0.79	1.22e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.47	4.82	0.36	3.46e-6	Red blood cell count;
PAAD	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.39	-4.31	-0.33	2.87e-5	Type 2 diabetes;
PAAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg16147221	chr4:10020634	SLC2A9	0.48	4.42	0.34	1.84e-5	Bone mineral density;
PAAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.63	7.5	0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs12474201	0.816	rs35809007	chr2:47019521	G/A	cg06386533	chr2:46925753	SOCS5	0.7	7.4	0.51	8.69e-12	Height;
PAAD	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg04317338	chr11:64019027	PLCB3	0.64	4.52	0.34	1.22e-5	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00210204	chr6:10748101	TMEM14B	0.57	6.34	0.46	2.48e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg08501292	chr6:25962987	TRIM38	0.98	5.33	0.4	3.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73195822	0.542	rs79439779	chr12:111093995	G/A	cg12870014	chr12:110450643	ANKRD13A	0.92	4.37	0.33	2.27e-5	Itch intensity from mosquito bite;
PAAD	cis	rs4823006	0.874	rs2179129	chr22:29450923	C/T	cg23896685	chr22:29451551	ZNRF3	-0.54	-5.64	-0.42	7.92e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.88	9.68	0.62	1.45e-17	Height;
PAAD	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.53	4.97	0.37	1.82e-6	Schizophrenia;
PAAD	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	7.98	0.54	3.24e-13	Cognitive test performance;
PAAD	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.98	-14.08	-0.75	2.4e-29	Post bronchodilator FEV1;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14608422	chr10:75634225	CAMK2G	-0.63	-6.33	-0.46	2.58e-9	Smoking initiation;
PAAD	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.18	-0.39	6.92e-7	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21865039	chr13:31773952	B3GALTL	0.63	6.71	0.48	3.64e-10	Myopia (pathological);
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-4.88	-0.37	2.69e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.45	4.64	0.35	7.52e-6	Corneal astigmatism;
PAAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.76	-8.24	-0.56	7.41e-14	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1891275	0.506	rs4933214	chr10:93417761	A/G	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs225245	0.817	rs225302	chr17:33922396	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.42	-0.46	1.67e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg15507776	chr3:136538369	TMEM22	0.5	4.91	0.37	2.3e-6	Neuroticism;
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg04520793	chr17:42248056	ASB16	0.47	6.39	0.46	1.95e-9	Total body bone mineral density;
PAAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.53	-0.41	1.35e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1355223	0.768	rs11032806	chr11:34692305	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-4.25	-0.33	3.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2422052	0.566	rs2161829	chr2:118856914	A/G	cg22545206	chr2:118617499	NA	0.46	4.89	0.37	2.5e-6	Mosquito bite size;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.53	-5.87	-0.43	2.58e-8	Facial morphology (factor 20);
PAAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg15145965	chr22:50218605	BRD1	-0.6	-5.28	-0.39	4.42e-7	Schizophrenia;
PAAD	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.45	-7.36	-0.51	1.05e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.54	5.32	0.4	3.64e-7	Rheumatoid arthritis;
PAAD	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.11	0.5	4.34e-11	Coffee consumption (cups per day);
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.68	0.58	5.8e-15	Platelet count;
PAAD	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	trans	rs9345521	0.967	rs9363235	chr6:65507611	C/T	cg26414000	chr1:85721327	C1orf52	0.52	6.35	0.46	2.39e-9	Iris color (a* coordinate);
PAAD	cis	rs258892	0.895	rs394274	chr5:72135955	C/T	cg21869765	chr5:72125136	TNPO1	0.77	5.25	0.39	5.03e-7	Small cell lung carcinoma;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.87	-0.37	2.74e-6	Bipolar disorder;
PAAD	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.38	-0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.47e-6	HDL cholesterol levels;
PAAD	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg11262906	chr1:85462892	MCOLN2	0.6	4.76	0.36	4.41e-6	Serum sulfate level;
PAAD	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg02493740	chr2:85810744	VAMP5	-0.46	-5.12	-0.38	9.14e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.93e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.61	6.24	0.45	4.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg26528668	chr16:1614120	IFT140	0.53	5.03	0.38	1.35e-6	Coronary artery disease;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.72	7.77	0.53	1.07e-12	Cystic fibrosis severity;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg07061783	chr6:25882402	NA	0.46	4.3	0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1620921	0.756	rs783163	chr6:161182401	A/T	cg01280913	chr6:161186852	NA	-0.49	-5.44	-0.4	2.09e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-7.09	-0.5	4.66e-11	Parkinson's disease;
PAAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs216026	0.689	rs61907987	chr12:2768017	G/A	cg19945202	chr12:2788847	CACNA1C	-0.61	-4.73	-0.36	5.19e-6	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.54	-5.21	-0.39	6.12e-7	Mortality in heart failure;
PAAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.55	7.35	0.51	1.12e-11	Renal cell carcinoma;
PAAD	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.47	-5.1	-0.38	1.02e-6	Educational attainment;
PAAD	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs17125944	0.686	rs2025634	chr14:53336017	C/T	cg00686598	chr14:53173677	PSMC6	-0.91	-5.61	-0.41	9.47e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.64	-5.83	-0.43	3.24e-8	Cognitive test performance;
PAAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.85	0.58	2.07e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg17346650	chr17:80929145	B3GNTL1	0.45	5.48	0.41	1.73e-7	Glycated hemoglobin levels;
PAAD	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg24699146	chr1:24152579	HMGCL	0.48	5.03	0.38	1.37e-6	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25944130	chr21:47851470	PCNT	-0.64	-6.49	-0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg04362095	chr11:63592001	C11orf84	0.51	4.65	0.35	7.22e-6	Platelet count;
PAAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg00105475	chr2:10696890	NA	0.71	7.91	0.54	5.06e-13	Prostate cancer;
PAAD	cis	rs7960581	0.585	rs35263167	chr12:99169649	C/G	cg17109042	chr12:99139387	ANKS1B	-0.65	-4.39	-0.34	2.1e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.58	6.54	0.47	8.97e-10	Coronary artery disease;
PAAD	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs16858210	0.529	rs10937154	chr3:183569489	C/T	cg25686905	chr3:183603175	PARL	-0.39	-4.51	-0.34	1.31e-5	Menopause (age at onset);
PAAD	cis	rs4867766	0.789	rs17725606	chr5:173956965	A/C	cg20434911	chr5:173954559	NA	-0.66	-6.7	-0.48	3.82e-10	Stroke;
PAAD	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg00571178	chr13:114841904	RASA3	-0.57	-4.81	-0.36	3.63e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	1.13	12.31	0.71	1.33e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.64	5.63	0.42	8.4e-8	Resistin levels;
PAAD	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-6.74	-0.48	3.15e-10	High light scatter reticulocyte count;
PAAD	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.9e-7	Ulcerative colitis;
PAAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg21433313	chr16:3507492	NAT15	0.91	7.74	0.53	1.28e-12	Tuberculosis;
PAAD	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.5	5.09	0.38	1.03e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.46	5.09	0.38	1.05e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs77633900	0.730	rs2456054	chr15:76474217	C/T	cg05412396	chr15:76631569	ISL2	-0.61	-4.29	-0.33	3.23e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.52	5.39	0.4	2.62e-7	Diastolic blood pressure;
PAAD	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.02	7.54	0.52	4.07e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9815354	0.672	rs12107296	chr3:41892503	C/G	cg03022575	chr3:42003672	ULK4	0.84	6.12	0.44	7.66e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg11204139	chr17:3907470	NA	0.64	5.81	0.43	3.53e-8	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.44	4.81	0.36	3.59e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12592111	1	rs12592111	chr15:78767346	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-4.34	-0.33	2.62e-5	Parental longevity (combined parental age at death);Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs617219	0.684	rs2896766	chr5:78586493	A/G	cg24856658	chr5:78533917	JMY	0.39	4.33	0.33	2.66e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg12623918	chr2:306882	NA	0.51	4.35	0.33	2.48e-5	Blood protein levels;
PAAD	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs838147	0.844	rs2307018	chr19:49244219	C/A	cg13540341	chr19:49222985	MAMSTR	0.44	4.98	0.37	1.69e-6	Dietary macronutrient intake;
PAAD	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg16810054	chr20:33298113	TP53INP2	-0.59	-4.62	-0.35	8.17e-6	Neuroticism;
PAAD	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.62	6.82	0.48	2.02e-10	Body mass index;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg09471204	chr22:42347991	LOC339674	-0.39	-5.31	-0.4	3.8e-7	Intelligence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07287682	chr7:2281772	NUDT1;FTSJ2	-0.74	-6.44	-0.46	1.51e-9	Neuroticism;
PAAD	cis	rs75920871	0.920	rs61905687	chr11:116862144	T/C	cg04087571	chr11:116723030	SIK3	-0.43	-4.54	-0.35	1.13e-5	Subjective well-being;
PAAD	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-7.7	-0.53	1.65e-12	Bladder cancer;
PAAD	cis	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.54	0.41	1.28e-7	Alzheimer's disease;
PAAD	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg00717180	chr2:96193071	NA	0.6	6.68	0.48	4.13e-10	HDL cholesterol;
PAAD	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.82	8.69	0.58	5.36e-15	Itch intensity from mosquito bite;
PAAD	cis	rs4742903	0.935	rs7026246	chr9:106955686	A/C	cg14250997	chr9:106856677	SMC2	0.44	4.72	0.36	5.36e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6782025	0.752	rs1615325	chr3:120664458	C/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs654384	0.507	rs2342505	chr7:4175710	C/T	cg08447571	chr7:4743074	FOXK1	-0.46	-4.34	-0.33	2.57e-5	Positive affect;
PAAD	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.67	0.62	1.53e-17	Post bronchodilator FEV1;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.65	-8.15	-0.55	1.24e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.47	4.77	0.36	4.25e-6	Lymphocyte counts;
PAAD	cis	rs7577696	0.512	rs9789593	chr2:32381110	T/G	cg02381751	chr2:32503542	YIPF4	-0.51	-4.87	-0.37	2.79e-6	Inflammatory biomarkers;
PAAD	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs8040855	0.860	rs6496775	chr15:85708141	A/G	cg08123816	chr15:85640762	PDE8A	0.37	4.29	0.33	3.14e-5	Bulimia nervosa;
PAAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-4.9	-0.37	2.42e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg10556349	chr10:835070	NA	-0.58	-4.75	-0.36	4.68e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.87	11.03	0.67	3.86e-21	Breast cancer;
PAAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.02	0.38	1.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.74	-0.36	4.94e-6	Dilated cardiomyopathy;
PAAD	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26876637	chr1:152193138	HRNR	-0.87	-6.91	-0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.6	-7.06	-0.5	5.65e-11	Aortic root size;
PAAD	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.75	-8.34	-0.56	4.17e-14	Body mass index;
PAAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.92	8.04	0.55	2.35e-13	IgG glycosylation;
PAAD	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.85	8.62	0.57	7.97e-15	Cognitive function;
PAAD	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg20933634	chr6:27740509	NA	0.64	6.07	0.44	9.68e-9	Parkinson's disease;
PAAD	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.15	-10.49	-0.65	1.04e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.58	-6.07	-0.44	9.94e-9	Total body bone mineral density;
PAAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.73	-8.22	-0.55	8.12e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.41	-4.55	-0.35	1.1e-5	Mean arterial pressure;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.46	0.57	2.06e-14	Schizophrenia;
PAAD	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.62	4.6	0.35	8.78e-6	Exhaled nitric oxide output;
PAAD	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg21191810	chr6:118973309	C6orf204	0.47	6.05	0.44	1.06e-8	Electrocardiographic conduction measures;
PAAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.49	0.34	1.39e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.71	-0.42	5.76e-8	Schizophrenia;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg00563768	chr17:34174170	TAF15	-0.61	-6.86	-0.49	1.63e-10	Iris heterochromicity;
PAAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg15192750	chr16:69999425	NA	0.76	5.99	0.44	1.48e-8	IgE levels;
PAAD	cis	rs4835937	0.633	rs6595796	chr5:127316331	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	4.36	0.33	2.36e-5	Cancer;
PAAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-6.16	-0.45	6.12e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.94	-0.43	1.85e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs595018	0.789	rs931861	chr11:60559805	A/G	cg21152628	chr11:60704616	TMEM132A;SLC15A3	-0.44	-4.57	-0.35	1.02e-5	Wegener's granulomatosis;
PAAD	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.8	-8.95	-0.59	1.13e-15	Idiopathic membranous nephropathy;
PAAD	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.54	-5.17	-0.39	7.33e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs314370	0.570	rs314313	chr7:100423365	C/T	cg10426581	chr7:100472382	SRRT	-0.58	-5.77	-0.42	4.37e-8	Resting heart rate;
PAAD	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs1532557	1.000	rs969025	chr1:224766955	G/A	cg09988837	chr1:224811939	CNIH3	0.62	4.54	0.35	1.15e-5	Cancer;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.46	0.57	2.09e-14	Alzheimer's disease;
PAAD	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.41	-4.76	-0.36	4.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg26897989	chr16:1907736	C16orf73	0.44	4.55	0.35	1.07e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.72e-5	Prostate cancer;
PAAD	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.58	-0.35	9.75e-6	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg08099141	chr12:7053170	C12orf57	0.44	4.5	0.34	1.37e-5	IgG glycosylation;
PAAD	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.97	0.54	3.6e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs793571	0.915	rs12916751	chr15:59221741	T/C	cg05156742	chr15:59063176	FAM63B	-0.64	-5.39	-0.4	2.58e-7	Schizophrenia;
PAAD	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg04575393	chr19:53496094	ZNF702P	-0.44	-4.74	-0.36	4.89e-6	Psoriasis;
PAAD	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.12	0.55	1.46e-13	Menarche (age at onset);
PAAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13871588	chr6:42981948	MEA1;KLHDC3	0.64	7.27	0.51	1.8e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs288326	0.561	rs75466155	chr2:183706804	T/G	cg09997497	chr2:183902928	NCKAP1	0.81	4.45	0.34	1.64e-5	Blood protein levels;
PAAD	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.73	0.69	5e-23	Smoking behavior;
PAAD	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.93	11.22	0.67	1.15e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg03268063	chr7:1337281	NA	-0.52	-4.53	-0.35	1.17e-5	Neuroticism;
PAAD	cis	rs501120	0.525	rs1704229	chr10:44689529	G/A	cg09554077	chr10:44749378	NA	0.43	5.58	0.41	1.07e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg01176363	chr20:62369445	LIME1	0.56	5.57	0.41	1.12e-7	Prostate cancer;
PAAD	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs6137287	0.889	rs6047278	chr20:21139382	C/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg02297831	chr4:17616191	MED28	-0.61	-5.93	-0.43	1.95e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.42	0.4	2.25e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.54	-5.5	-0.41	1.56e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	1.01	7.11	0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.19	-0.7	2.93e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg00531865	chr16:30841666	NA	-0.56	-4.26	-0.33	3.62e-5	Dementia with Lewy bodies;
PAAD	cis	rs6604026	0.656	rs6604028	chr1:93378033	C/T	cg13858687	chr1:93297071	RPL5	0.48	4.33	0.33	2.71e-5	Multiple sclerosis;
PAAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.51	-5.07	-0.38	1.14e-6	Menopause (age at onset);
PAAD	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15225657	chr3:57542469	PDE12	-0.73	-6.52	-0.47	1e-9	Neuroticism;
PAAD	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg18518183	chr2:172544446	DYNC1I2	0.49	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	1.09	7.71	0.53	1.54e-12	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	1.17	11.88	0.69	1.91e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.6	-6.28	-0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.14	10.5	0.65	1.01e-19	Initial pursuit acceleration;
PAAD	cis	rs2019216	0.605	rs907705	chr17:21981887	C/G	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs367943	0.698	rs6594746	chr5:112995895	A/C	cg12552261	chr5:112820674	MCC	-0.63	-6.71	-0.48	3.55e-10	Type 2 diabetes;
PAAD	cis	rs7707921	0.752	rs34981833	chr5:81272732	T/C	cg21483461	chr5:81570383	RPS23	-0.51	-4.27	-0.33	3.38e-5	Breast cancer;
PAAD	cis	rs7893279	0.556	rs11595529	chr10:18759047	C/T	cg24128066	chr10:18689503	CACNB2	0.66	4.36	0.33	2.37e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg03342759	chr3:160939853	NMD3	-0.74	-7.74	-0.53	1.3e-12	Morning vs. evening chronotype;
PAAD	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.62	5.89	0.43	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.43	4.48	0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.89	-7.34	-0.51	1.23e-11	Obesity-related traits;
PAAD	cis	rs12906542	0.544	rs35472584	chr15:78266727	C/T	cg15889649	chr15:79055693	ADAMTS7	-0.55	-4.5	-0.34	1.33e-5	Breast cancer;
PAAD	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.59	0.41	1.03e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.69	-0.36	6.1e-6	Neuroticism;
PAAD	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs4740619	0.630	rs2860316	chr9:15986768	T/C	cg14451791	chr9:16040625	NA	0.39	4.62	0.35	8.17e-6	Body mass index;
PAAD	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.54	5.83	0.43	3.16e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs4144027	0.967	rs72712857	chr14:104362673	T/C	cg12183467	chr14:104352244	NA	0.34	4.27	0.33	3.42e-5	Blood metabolite levels;
PAAD	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg25547332	chr5:131281432	NA	0.54	4.33	0.33	2.72e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg18338521	chr10:69995036	NA	0.34	4.48	0.34	1.45e-5	Optic disc area;
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.51	-6.18	-0.45	5.58e-9	Iron status biomarkers;
PAAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	cis	rs965469	0.779	rs6037528	chr20:3260978	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.51	-5.86	-0.43	2.74e-8	Breast cancer;
PAAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.03	0.5	6.69e-11	Rheumatoid arthritis;
PAAD	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg13263323	chr15:86062960	AKAP13	-0.65	-7.52	-0.52	4.45e-12	Coronary artery disease;
PAAD	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg07856975	chr6:36356162	ETV7	0.48	5.5	0.41	1.55e-7	Platelet distribution width;
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.56	5.95	0.43	1.78e-8	Schizophrenia;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12826942	0.879	rs7312066	chr12:42766380	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	4.96	0.37	1.89e-6	Coronary artery disease;
PAAD	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.47	6.08	0.44	9.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.63	7.94	0.54	4.17e-13	Hypertriglyceridemia;
PAAD	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.73	9.43	0.61	6.74e-17	Asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22733438	chr5:169529408	NA	-0.63	-6.62	-0.47	5.96e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.27	0.39	4.56e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9810890	1.000	rs73196999	chr3:128460581	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.25	-6.73	-0.48	3.33e-10	Body mass index;
PAAD	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.76	7.72	0.53	1.43e-12	Coronary artery disease;
PAAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.54	0.35	1.12e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.63	-6.29	-0.45	3.14e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2034650	0.506	rs1984793	chr15:40699373	G/T	cg05276125	chr15:40653601	DISP2	0.44	4.35	0.33	2.46e-5	Interstitial lung disease;
PAAD	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.71	-0.42	5.73e-8	Total cholesterol levels;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	5.77	0.42	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4417704	0.551	rs60677070	chr2:241900494	A/G	cg26818257	chr2:241905806	NA	0.52	5.28	0.39	4.34e-7	Joint mobility (Beighton score);
PAAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.75	-7.73	-0.53	1.36e-12	Neurofibrillary tangles;
PAAD	cis	rs258892	0.895	rs465388	chr5:72135899	C/T	cg21869765	chr5:72125136	TNPO1	0.77	5.25	0.39	5.03e-7	Small cell lung carcinoma;
PAAD	cis	rs13242816	1.000	rs62471184	chr7:116090300	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-4.88	-0.37	2.7e-6	P wave duration;
PAAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.61	6.39	0.46	1.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.01	-0.63	1.98e-18	Chronic sinus infection;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg13047869	chr3:10149882	C3orf24	0.64	5.12	0.38	9.17e-7	Alzheimer's disease;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.68	7.35	0.51	1.14e-11	Platelet distribution width;
PAAD	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg03700679	chr2:178418002	TTC30B	0.54	4.37	0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.51	-5.38	-0.4	2.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11051970	0.918	rs12229856	chr12:32531220	C/T	cg02745156	chr12:32552066	NA	0.46	4.8	0.36	3.7e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg22134325	chr11:66188745	NPAS4	0.29	4.3	0.33	2.99e-5	Airway imaging phenotypes;
PAAD	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-5.6	-0.41	9.99e-8	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.63	6.25	0.45	3.85e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg24585817	chr7:64895279	NA	0.44	4.38	0.33	2.23e-5	Aortic root size;
PAAD	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.3e-7	Monocyte percentage of white cells;
PAAD	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.65	6.7	0.48	3.77e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.53e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs8044995	0.636	rs12596500	chr16:68299771	G/A	cg05110241	chr16:68378359	PRMT7	-1.31	-7.73	-0.53	1.35e-12	Schizophrenia;
PAAD	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.31	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs6686423	0.543	rs7525271	chr1:157389885	C/T	cg24251193	chr1:156676542	CRABP2	-0.45	-4.35	-0.33	2.44e-5	Renal sinus fat;
PAAD	cis	rs7119167	0.851	rs7122560	chr11:73091913	G/A	cg17517138	chr11:73019481	ARHGEF17	0.65	4.26	0.33	3.62e-5	Blood protein levels;
PAAD	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.23	-10.05	-0.63	1.51e-18	Breast cancer;
PAAD	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg04520793	chr17:42248056	ASB16	-0.47	-6.43	-0.46	1.56e-9	Total body bone mineral density;
PAAD	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg20673841	chr7:107026890	COG5	-0.53	-4.64	-0.35	7.57e-6	Coronary artery disease;
PAAD	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	8.65	0.57	6.88e-15	Cognitive test performance;
PAAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg07952391	chr2:88470173	THNSL2	-0.49	-4.78	-0.36	4.12e-6	Response to metformin (IC50);
PAAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg23283495	chr1:209979779	IRF6	0.51	6.23	0.45	4.32e-9	Monobrow;
PAAD	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs2834902	0.633	rs2834893	chr21:36682285	T/C	cg04915566	chr21:36421472	RUNX1	-0.33	-4.47	-0.34	1.53e-5	Corneal curvature;
PAAD	cis	rs7127900	0.950	rs7123299	chr11:2232344	A/G	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	9.92	0.63	3.38e-18	Prudent dietary pattern;
PAAD	cis	rs8077577	0.747	rs1925	chr17:18177715	G/A	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.73	6.68	0.48	4.24e-10	Obesity-related traits;
PAAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.8	7.79	0.53	9.49e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg21253087	chr9:139290292	SNAPC4	0.51	4.52	0.34	1.22e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.27	-0.33	3.49e-5	Red blood cell count;
PAAD	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	9.27e-7	Motion sickness;
PAAD	cis	rs55788414	0.725	rs13339033	chr16:81189034	G/A	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.54	-0.57	1.3e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-4.39	-0.34	2.07e-5	Blood protein levels;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.82	6.64	0.47	5.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.31	-0.4	3.75e-7	Schizophrenia;
PAAD	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg10483660	chr13:112241077	NA	0.54	4.94	0.37	2e-6	Menarche (age at onset);
PAAD	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg10556349	chr10:835070	NA	0.58	4.91	0.37	2.37e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.98e-8	Alzheimer's disease;
PAAD	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.83	-9.23	-0.6	2.24e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg20673841	chr7:107026890	COG5	0.5	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg12705353	chr12:122356852	WDR66	0.48	5.14	0.38	8.4e-7	Mean corpuscular volume;
PAAD	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.86	-0.37	2.94e-6	Bipolar disorder;
PAAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04045327	chr4:905805	GAK	-0.42	-5.38	-0.4	2.78e-7	Systemic sclerosis;
PAAD	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.54	4.65	0.35	7.3e-6	Acylcarnitine levels;
PAAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg05313129	chr8:58192883	C8orf71	-0.55	-4.7	-0.36	5.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.81	9.63	0.62	1.99e-17	Menopause (age at onset);
PAAD	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	4.33	0.33	2.74e-5	Menarche (age at onset);
PAAD	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.78	-0.48	2.52e-10	Total cholesterol levels;
PAAD	cis	rs7635838	0.963	rs35834806	chr3:11414100	C/T	cg00170343	chr3:11313890	ATG7	0.48	4.47	0.34	1.52e-5	HDL cholesterol;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg22903657	chr4:1355424	KIAA1530	0.43	4.46	0.34	1.57e-5	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg01244601	chr4:120671846	NA	-0.5	-4.28	-0.33	3.23e-5	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27067269	chr10:48355070	ZNF488	0.58	6.36	0.46	2.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72828912	0.831	rs2176934	chr6:24094194	A/T	cg27524988	chr6:24583477	KIAA0319	-0.48	-4.39	-0.34	2.11e-5	Squamous cell lung carcinoma;
PAAD	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.85	-0.43	2.91e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg04482110	chr17:41364121	TMEM106A	0.41	4.62	0.35	8.02e-6	Menopause (age at onset);
PAAD	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.71	-7.1	-0.5	4.57e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs12612619	0.761	rs34732613	chr2:27254796	T/C	cg00617064	chr2:27272375	NA	-0.55	-5.81	-0.43	3.62e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg12408990	chr5:179634671	RASGEF1C	0.64	4.65	0.35	7.23e-6	LDL cholesterol;
PAAD	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.47	-4.39	-0.34	2.12e-5	Urinary tract infection frequency;
PAAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg16590910	chr6:42928470	GNMT	0.55	5.55	0.41	1.23e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	5.14	0.39	8.21e-7	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.53	-0.52	4.23e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.57	-6.73	-0.48	3.31e-10	Aortic root size;
PAAD	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg19980929	chr12:42632907	YAF2	0.63	7.49	0.52	5.31e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03812309	chr1:46938281	NA	0.33	4.46	0.34	1.6e-5	High light scatter reticulocyte count;
PAAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6142102	0.625	rs4911384	chr20:32555807	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.72	-11.63	-0.69	9.18e-23	Urate levels in overweight individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17400634	chr5:139944476	APBB3;SLC35A4	0.6	6.31	0.46	2.83e-9	Obesity-related traits;
PAAD	cis	rs10207060	0.500	rs72992168	chr2:240712932	G/A	cg07506560	chr2:240697449	NA	0.56	5.81	0.43	3.58e-8	Obesity-related traits;
PAAD	cis	rs2273156	0.500	rs17103120	chr14:35703839	C/T	cg14523979	chr14:35838413	NA	0.67	4.83	0.36	3.32e-6	Immunoglobulin light chain (AL) amyloidosis;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.88	-15.08	-0.77	5.2e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.72	7.76	0.53	1.13e-12	Coronary artery disease;
PAAD	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Lymphocyte counts;
PAAD	cis	rs1497828	0.956	rs2646822	chr1:217535860	A/G	cg04411442	chr1:217543379	NA	-0.48	-4.69	-0.36	6.12e-6	Dialysis-related mortality;
PAAD	cis	rs2061333	0.557	rs8105860	chr19:44606928	A/G	cg20607764	chr19:44506953	ZNF230	-0.69	-4.91	-0.37	2.37e-6	Alzheimer's disease;
PAAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.36	4.29	0.33	3.11e-5	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Depression;
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.45	7.28	0.51	1.7e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg05084668	chr3:125655381	ALG1L	-1.04	-8.6	-0.57	9.19e-15	Blood pressure (smoking interaction);
PAAD	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.71	-0.58	4.72e-15	Extrinsic epigenetic age acceleration;
PAAD	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.53	6.34	0.46	2.5e-9	Alcohol dependence;
PAAD	cis	rs377457	0.821	rs755464	chr16:85738795	T/A	cg02758499	chr16:85682440	KIAA0182	0.37	4.57	0.35	9.99e-6	Type 2 diabetes;
PAAD	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.58	-0.35	9.7e-6	Educational attainment (years of education);
PAAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.43	4.86	0.37	2.9e-6	Breast cancer;
PAAD	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg00792783	chr2:198669748	PLCL1	0.46	4.26	0.33	3.59e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs61677309	0.964	rs56020103	chr11:118172132	C/T	cg15548380	chr1:19984784	NBL1	-0.64	-6.53	-0.47	9.25e-10	Lung cancer in ever smokers;
PAAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16055075	chr10:135209199	MTG1	-0.66	-6.45	-0.46	1.38e-9	Obesity-related traits;
PAAD	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-5.51	-0.41	1.53e-7	Personality dimensions;
PAAD	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.58	5.48	0.41	1.7e-7	Schizophrenia;
PAAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.42	7.59	0.52	3.03e-12	Multiple system atrophy;
PAAD	cis	rs12282928	0.876	rs1158898	chr11:48273246	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.22	-0.45	4.61e-9	Migraine - clinic-based;
PAAD	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.62	6.93	0.49	1.1e-10	Colorectal cancer;
PAAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19784903	chr17:45786737	TBKBP1	-0.47	-4.88	-0.37	2.61e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs258892	0.895	rs4254881	chr5:72031360	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23158103	chr7:148848205	ZNF398	-0.59	-5.59	-0.41	1.02e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26926768	chr12:34528122	NA	0.4	4.95	0.37	1.95e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7833986	0.530	rs72653972	chr8:57006809	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	4.33	0.33	2.73e-5	Height;
PAAD	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-1.1	-5.55	-0.41	1.25e-7	Inflammatory biomarkers;
PAAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg27494647	chr7:150038898	RARRES2	0.42	4.27	0.33	3.38e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	8.07e-9	Blood metabolite levels;
PAAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.16	17.83	0.82	4.27e-39	Cognitive function;
PAAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21511925	chr5:175788234	KIAA1191	-0.81	-7.11	-0.5	4.29e-11	Neuroticism;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6782025	0.837	rs3856575	chr3:120816217	A/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.99	-6.75	-0.48	3e-10	Coronary artery disease;
PAAD	cis	rs6688613	0.840	rs6669886	chr1:166956710	T/C	cg07049167	chr1:166818506	POGK	0.62	6.09	0.44	8.77e-9	Refractive astigmatism;
PAAD	cis	rs16975963	0.843	rs2382624	chr19:38419025	A/G	cg25793785	chr19:38281423	NA	0.57	4.66	0.35	6.88e-6	Longevity;
PAAD	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.89	11.05	0.67	3.41e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.61	0.47	6.19e-10	Schizophrenia;
PAAD	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-6.86	-0.49	1.65e-10	Response to antipsychotic treatment;
PAAD	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	6.04e-6	Plateletcrit;
PAAD	cis	rs72827839	0.779	rs16955073	chr17:46381746	T/C	cg23391107	chr17:45924227	SP6	0.55	5.19	0.39	6.52e-7	Ease of getting up in the morning;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.37	-4.45	-0.34	1.67e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg03760483	chr17:6899297	ALOX12	0.46	5.01	0.38	1.49e-6	Blood metabolite levels;
PAAD	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06762969	chr11:93474102	C11orf54;TAF1D	0.7	6.36	0.46	2.27e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.97	0.37	1.75e-6	Myopia (pathological);
PAAD	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.67	7.36	0.51	1.08e-11	Menarche (age at onset);
PAAD	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.89	-4.63	-0.35	7.78e-6	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10499166	chr1:23345815	KDM1A	-0.58	-6.68	-0.48	4.21e-10	Body fat percentage;
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.49	-4.39	-0.34	2.11e-5	Multiple sclerosis;
PAAD	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.51	0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs4679121	0.642	rs114997767	chr3:126195140	A/C	cg05485589	chr3:126194908	ZXDC	-0.88	-4.39	-0.34	2.09e-5	Pursuit maintenance gain;
PAAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.54	5.76	0.42	4.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.96	-8.58	-0.57	1e-14	Bipolar disorder;
PAAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg21395723	chr22:39101663	GTPBP1	0.44	4.58	0.35	9.81e-6	Menopause (age at onset);
PAAD	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.94	-11.3	-0.68	6.87e-22	Rheumatoid arthritis;
PAAD	cis	rs1371614	0.632	rs6707735	chr2:27166822	T/C	cg00617064	chr2:27272375	NA	-0.42	-4.35	-0.33	2.52e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.66	7.03	0.5	6.48e-11	Morning vs. evening chronotype;
PAAD	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.46	-0.46	1.33e-9	Response to antipsychotic treatment;
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg19337854	chr7:99768885	GPC2	0.5	4.72	0.36	5.31e-6	Platelet count;
PAAD	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	4.61	0.35	8.42e-6	Lymphocyte counts;
PAAD	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.58	-0.41	1.08e-7	Colorectal cancer;
PAAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg20933634	chr6:27740509	NA	0.65	6.19	0.45	5.38e-9	Parkinson's disease;
PAAD	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.52	-5.35	-0.4	3.19e-7	Platelet count;
PAAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.22	-0.45	4.66e-9	Height;
PAAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg27411982	chr8:10470053	RP1L1	0.51	5.75	0.42	4.86e-8	Neuroticism;
PAAD	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	4.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.39	-4.34	-0.33	2.57e-5	Prostate cancer;
PAAD	cis	rs6088813	1.000	rs4911178	chr20:33952620	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.35	-0.56	3.86e-14	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg17366294	chr4:99064904	C4orf37	0.65	6.02	0.44	1.25e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg01620082	chr3:125678407	NA	-1.43	-8.54	-0.57	1.33e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.83	7.76	0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg11843238	chr5:131593191	PDLIM4	0.5	4.58	0.35	9.66e-6	Acylcarnitine levels;
PAAD	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.73	5.65	0.42	7.66e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.91	7.1	0.5	4.49e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2594989	0.616	rs6442255	chr3:11474492	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-4.54	-0.35	1.13e-5	Circulating chemerin levels;
PAAD	cis	rs8014252	0.803	rs57598551	chr14:71068401	G/A	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	trans	rs2112743	0.704	rs1450333	chr5:144729692	C/T	cg16512364	chr13:50513235	NA	0.42	6.31	0.46	2.96e-9	Acoustic startle blink response;
PAAD	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg07943548	chr15:86304357	KLHL25	0.63	5.57	0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.25e-20	Heart rate;
PAAD	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.78	8.43	0.56	2.44e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-5.48	-0.41	1.7e-7	Mood instability;
PAAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-7.39	-0.51	9.37e-12	Blood pressure (smoking interaction);
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.57	-6.42	-0.46	1.64e-9	Tonsillectomy;
PAAD	cis	rs2271400	0.529	rs4738457	chr8:56657801	C/T	cg08894788	chr8:56792171	LYN	-0.55	-5.28	-0.39	4.37e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06850241	chr22:41845214	NA	-0.55	-5.26	-0.39	4.84e-7	Vitiligo;
PAAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	12.01	0.7	8.44e-24	Smoking behavior;
PAAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs6137287	0.889	rs1884762	chr20:21124667	C/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.46	0.34	1.56e-5	Height;
PAAD	cis	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.68	-0.42	6.74e-8	HDL cholesterol;
PAAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4690686	0.769	rs7656505	chr4:177274867	A/T	cg17059388	chr4:177262070	NA	0.54	5.29	0.39	4.15e-7	Essential tremor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15480897	chr4:151505467	LRBA;MAB21L2	-0.64	-6.36	-0.46	2.28e-9	Obesity-related traits;
PAAD	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.88	-0.49	1.43e-10	Morning vs. evening chronotype;
PAAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.92	-8.25	-0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs17407555	0.909	rs76748344	chr4:10311985	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-4.33	-0.33	2.7e-5	Schizophrenia (age at onset);
PAAD	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22267597	chr17:8534187	MYH10	0.61	6.41	0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg19630374	chr17:18023558	MYO15A	-0.47	-4.97	-0.37	1.78e-6	Total body bone mineral density;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12143110	chr17:79146738	LOC388428	-0.67	-6.95	-0.49	9.9e-11	Lung cancer in ever smokers;
PAAD	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.45	5.36	0.4	2.97e-7	Tonsillectomy;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.71	7.44	0.52	6.89e-12	Renal function-related traits (BUN);
PAAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg24053715	chr22:38214548	NA	0.57	5.54	0.41	1.33e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg10356904	chr22:49881777	NA	-0.52	-5.06	-0.38	1.21e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs797680	0.856	rs6541404	chr1:93743434	A/T	cg04535902	chr1:92947332	GFI1	-0.42	-4.49	-0.34	1.38e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg22134325	chr11:66188745	NPAS4	0.42	5.23	0.39	5.46e-7	Airway imaging phenotypes;
PAAD	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg01489256	chr8:11204017	TDH	0.44	4.39	0.34	2.09e-5	Retinal vascular caliber;
PAAD	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.25e-31	Chronic sinus infection;
PAAD	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.72	5.8	0.43	3.71e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs4743820	0.620	rs10991787	chr9:93917218	A/G	cg14446406	chr9:93919335	NA	0.5	6.03	0.44	1.21e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg06375148	chr1:209958343	C1orf74	0.6	4.79	0.36	4.01e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7591163	0.959	rs10933217	chr2:228716226	T/C	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.38	0.33	2.21e-5	Blood pressure;
PAAD	cis	rs10885582	0.754	rs10787533	chr10:116288063	A/T	cg17056676	chr10:116301354	ABLIM1	0.38	5.16	0.39	7.61e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10574202	chr15:63246079	NA	0.52	6.82	0.48	1.97e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14264380	chr17:79651103	ARL16;HGS	0.71	8.41	0.56	2.75e-14	Myopia (pathological);
PAAD	cis	rs9788721	0.775	rs12914385	chr15:78898723	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-4.53	-0.35	1.17e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-4.79	-0.36	3.91e-6	Neuroticism;
PAAD	cis	rs936229	0.724	rs4886406	chr15:75057203	G/T	cg14664628	chr15:75095509	CSK	-1.03	-11.08	-0.67	2.71e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-5.92	-0.43	2.02e-8	Homocysteine levels;
PAAD	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg00122941	chr17:4613640	ARRB2	0.84	8.03	0.55	2.44e-13	Lymphocyte counts;
PAAD	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg26816564	chr1:7831052	VAMP3	0.74	5.67	0.42	6.84e-8	Inflammatory bowel disease;
PAAD	cis	rs776905	0.540	rs510335	chr13:113759755	G/T	cg09069900	chr13:113776964	F10	-0.59	-4.73	-0.36	5.01e-6	Blood protein levels;
PAAD	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg21191810	chr6:118973309	C6orf204	0.51	7.07	0.5	5.39e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	0.97	11.36	0.68	5.03e-22	Schizophrenia;
PAAD	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	7.48	0.52	5.55e-12	Lymphocyte percentage of white cells;
PAAD	cis	rs4073582	0.964	rs801742	chr11:65914766	C/A	cg16950941	chr11:66035639	RAB1B	0.68	5.78	0.42	4.06e-8	Gout;
PAAD	cis	rs2882667	0.690	rs700620	chr5:138097936	C/T	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.75	-7.84	-0.54	7.47e-13	Blood metabolite levels;
PAAD	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg19792802	chr11:65647270	CTSW	0.55	6.13	0.45	7.37e-9	Crohn's disease;
PAAD	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.62	8.09	0.55	1.79e-13	Crohn's disease;
PAAD	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.63	-7.37	-0.51	1e-11	Sense of smell;
PAAD	cis	rs7260538	0.808	rs2086785	chr19:41527085	T/C	cg13322449	chr19:42300200	CEACAM3	0.4	4.53	0.34	1.19e-5	DDT metabolite (p,p'-DDE levels);
PAAD	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.4	-0.46	1.79e-9	Leprosy;
PAAD	cis	rs1007738	0.507	rs61897857	chr11:47233458	G/A	cg19486271	chr11:47235900	DDB2	0.64	5.85	0.43	2.96e-8	Bone mineral density (hip);
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22442454	chr1:209979470	IRF6	0.59	5.33	0.4	3.51e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18708744	chr15:63406185	NA	-0.4	-4.51	-0.34	1.26e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11614333	0.920	rs767842	chr12:15003707	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.29	-0.33	3.21e-5	Hand grip strength;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26083396	chr7:128049885	IMPDH1	-0.65	-7.71	-0.53	1.52e-12	Body fat percentage;
PAAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg03477792	chr4:77819574	ANKRD56	0.83	11.06	0.67	3.05e-21	Emphysema distribution in smoking;
PAAD	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.45	-4.99	-0.38	1.64e-6	Pneumonia;
PAAD	cis	rs10186876	0.762	rs7568481	chr2:44145374	G/T	cg26828767	chr2:44457733	PPM1B	-0.46	-4.46	-0.34	1.62e-5	Hand grip strength;
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.73	-5.38	-0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.84	10.34	0.64	2.61e-19	Menopause (age at onset);
PAAD	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.14	-9.27	-0.6	1.69e-16	Post bronchodilator FEV1;
PAAD	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.29	-0.39	4.25e-7	Neuroticism;
PAAD	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.48	5.86	0.43	2.76e-8	Sitting height ratio;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg17372223	chr3:52568218	NT5DC2	0.56	5.51	0.41	1.47e-7	Bipolar disorder;
PAAD	cis	rs6489882	0.669	rs1293759	chr12:113431643	A/G	cg20102336	chr12:113376681	OAS3	-0.47	-4.43	-0.34	1.77e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg27395922	chr11:50257633	LOC441601	0.41	4.36	0.33	2.43e-5	Coronary artery disease;
PAAD	cis	rs728616	0.614	rs35395602	chr10:81906770	A/G	cg19423196	chr10:82049429	MAT1A	0.46	4.32	0.33	2.79e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg21823605	chr1:152486609	CRCT1	0.47	5.21	0.39	6.02e-7	Hair morphology;
PAAD	cis	rs72960926	0.744	rs55962148	chr6:74962021	G/T	cg03266952	chr6:74778945	NA	-1.2	-6.59	-0.47	6.77e-10	Metabolite levels (MHPG);
PAAD	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs58804349	0.581	rs2744081	chr10:43352400	C/A	cg20628663	chr10:43360327	NA	0.74	4.37	0.33	2.31e-5	Pediatric bone mineral content (radius);
PAAD	cis	rs742132	0.545	rs11969981	chr6:25650817	T/A	cg03517284	chr6:25882590	NA	0.65	4.3	0.33	2.99e-5	Uric acid levels;
PAAD	cis	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg15590007	chr10:45870220	ALOX5	0.51	5.38	0.4	2.74e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg23461800	chr14:103021989	NA	-0.63	-4.84	-0.37	3.17e-6	Platelet count;
PAAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.65	-6.09	-0.44	9.05e-9	DNA methylation (variation);
PAAD	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg15733309	chr7:157513707	PTPRN2	0.63	7.74	0.53	1.29e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	6.57	0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs2242420	0.920	rs16825746	chr1:21958909	G/A	cg04297819	chr1:22260125	HSPG2	0.49	4.33	0.33	2.72e-5	Hematological and biochemical traits;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg03605226	chr16:87637261	JPH3	0.39	4.32	0.33	2.78e-5	Menopause (age at onset);
PAAD	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.68	5.45	0.4	2.03e-7	Mammographic density (dense area);
PAAD	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.96	-0.44	1.65e-8	Menopause (age at onset);
PAAD	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg00383909	chr3:49044727	WDR6	0.82	5.4	0.4	2.53e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.04	-0.77	6.63e-32	Height;
PAAD	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	cis	rs11811982	0.793	rs79611117	chr1:227339435	A/G	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs1497828	0.956	rs2646834	chr1:217545202	G/C	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.59	5.76	0.42	4.5e-8	Lung cancer;
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg25487775	chr2:162093969	NA	0.56	5.47	0.41	1.81e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs990171	0.955	rs11465583	chr2:102982466	C/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.88e-5	Lymphocyte counts;
PAAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.46	7.37	0.51	1.04e-11	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs12979813	0.901	rs10421382	chr19:11344973	G/C	cg03333546	chr19:13263065	IER2	-0.88	-6.53	-0.47	9.4e-10	HDL cholesterol;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-4.86	-0.37	2.84e-6	Acylcarnitine levels;
PAAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg24733560	chr20:60626293	TAF4	0.48	6.07	0.44	9.88e-9	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05596149	chr1:169337205	BLZF1;NME7	0.64	6.36	0.46	2.24e-9	Obesity-related traits;
PAAD	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	5.39	0.4	2.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.89	11.93	0.7	1.46e-23	Vitiligo;
PAAD	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.87	7.8	0.53	9.09e-13	Coronary artery disease;
PAAD	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.39	0.51	9.37e-12	Multiple sclerosis;
PAAD	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4234284	1.000	rs4234284	chr3:126950126	C/T	cg27326032	chr3:127006922	NA	-0.49	-5.02	-0.38	1.44e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.61	6.34	0.46	2.49e-9	Glomerular filtration rate;
PAAD	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg24053715	chr22:38214548	NA	0.63	5.8	0.43	3.7e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.88	12.19	0.7	2.91e-24	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01998146	chr9:15511358	PSIP1	0.57	6.31	0.46	2.95e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.54	-6.17	-0.45	5.81e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6723162	1.000	rs6723162	chr2:71102286	A/T	cg06142537	chr2:71114785	NA	0.41	4.36	0.33	2.35e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg27565382	chr3:53032988	SFMBT1	-0.8	-4.65	-0.35	7.01e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07232711	chr11:85859878	NA	0.6	7.23	0.51	2.17e-11	Smoking initiation;
PAAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg02683114	chr2:24398427	C2orf84	-0.51	-4.96	-0.37	1.9e-6	Asthma;
PAAD	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg02580895	chr19:2754563	NA	-0.52	-4.32	-0.33	2.8e-5	Total cholesterol levels;
PAAD	cis	rs9944275	0.860	rs71396873	chr15:97203130	T/C	cg23969200	chr15:97326567	SPATA8	0.68	4.45	0.34	1.66e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.54e-17	White blood cell count (basophil);
PAAD	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.94	9.87	0.62	4.71e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.05	0.63	1.53e-18	Cognitive test performance;
PAAD	cis	rs6496932	0.635	rs8023859	chr15:85904771	A/T	cg19183879	chr15:85880815	NA	-0.5	-4.71	-0.36	5.6e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.34	-0.33	2.62e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg01796438	chr3:11312864	ATG7	-0.67	-5.07	-0.38	1.14e-6	Circulating chemerin levels;
PAAD	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.44	-0.34	1.7e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00097573	chr1:202830495	LOC148709	-0.6	-6.94	-0.49	1.08e-10	Body fat percentage;
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg04844267	chr4:1394941	NA	0.44	5.09	0.38	1.06e-6	Longevity;
PAAD	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.77	8.47	0.57	1.92e-14	Blood protein levels;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.72	5.31	0.4	3.89e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	0.88	5.12	0.38	9.16e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.73	-7.68	-0.53	1.81e-12	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.94	0.54	4.17e-13	Prudent dietary pattern;
PAAD	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.5	-5.46	-0.4	1.9e-7	Major depressive disorder;
PAAD	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	9.55	0.61	3.14e-17	Electrocardiographic conduction measures;
PAAD	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.78	7.06	0.5	5.57e-11	Obesity-related traits;
PAAD	cis	rs859767	0.501	rs12691869	chr2:135407641	T/C	cg12500956	chr2:135428796	TMEM163	-0.32	-4.57	-0.35	1e-5	Neuroticism;
PAAD	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg14440974	chr22:39074834	NA	-0.54	-6.5	-0.47	1.07e-9	Menopause (age at onset);
PAAD	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.74	8.05	0.55	2.19e-13	Corneal astigmatism;
PAAD	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg14393609	chr7:65229607	NA	-0.51	-4.75	-0.36	4.77e-6	Aortic root size;
PAAD	cis	rs28830936	0.841	rs4923914	chr15:42119603	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.71	-0.48	3.62e-10	Diastolic blood pressure;
PAAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09695851	chr17:3907499	NA	0.59	5.58	0.41	1.08e-7	Type 2 diabetes;
PAAD	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	0.91	5.75	0.42	4.81e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg26816564	chr1:7831052	VAMP3	-0.61	-5.21	-0.39	6.09e-7	Inflammatory bowel disease;
PAAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.73	-7.42	-0.52	7.68e-12	Monocyte count;
PAAD	cis	rs35150201	0.818	rs7810260	chr7:135311120	G/A	cg23117316	chr7:135346802	PL-5283	-0.39	-6.1	-0.44	8.34e-9	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
PAAD	cis	rs75920871	0.720	rs4938340	chr11:116980622	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.68	-0.35	6.38e-6	Subjective well-being;
PAAD	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.8	0.53	9.26e-13	Motion sickness;
PAAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.79	7.01	0.49	7.13e-11	Cisplatin-induced ototoxicity;
PAAD	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-1.12	-12.21	-0.7	2.56e-24	Blood pressure (smoking interaction);
PAAD	cis	rs1468333	0.824	rs10952	chr5:137588340	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.57	5.93	0.43	2e-8	Resting heart rate;
PAAD	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	4.34	0.33	2.57e-5	Refractive astigmatism;
PAAD	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	5.96	0.44	1.67e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg08898775	chr15:59042684	ADAM10	0.42	5.58	0.41	1.08e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10556349	chr10:835070	NA	0.66	5.15	0.39	7.99e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg12143784	chr7:64541923	NA	-0.33	-4.26	-0.33	3.51e-5	Corneal structure;
PAAD	cis	rs7188861	0.768	rs62023624	chr16:11399603	C/A	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs10918270	0.710	rs2340723	chr1:161940254	A/G	cg25774098	chr1:161359705	NA	0.54	5.26	0.39	4.75e-7	Parkinson's disease (age of onset);
PAAD	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.9	-0.49	1.33e-10	Migraine;Coronary artery disease;
PAAD	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.34	-0.4	3.31e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg14752227	chr20:34000481	UQCC	-0.52	-5.22	-0.39	5.83e-7	Height;
PAAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg25506879	chr20:3388711	C20orf194	0.5	4.28	0.33	3.3e-5	IFN-related cytopenia;
PAAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.77	-8.15	-0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	5.91	0.43	2.15e-8	Schizophrenia;
PAAD	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.36	5.48	0.41	1.7e-7	IgG glycosylation;
PAAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg00717180	chr2:96193071	NA	-0.61	-6.7	-0.48	3.82e-10	HDL cholesterol;
PAAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg07148914	chr20:33460835	GGT7	0.47	4.64	0.35	7.32e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.62	6.68	0.48	4.3e-10	High light scatter reticulocyte count;
PAAD	cis	rs7580658	0.637	rs4560059	chr2:127972228	T/C	cg10985347	chr2:127963512	CYP27C1	0.48	4.69	0.36	5.94e-6	Protein C levels;
PAAD	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg08992911	chr2:238395768	MLPH	0.94	6.65	0.47	4.99e-10	Prostate cancer;
PAAD	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.73	-0.42	5.22e-8	Menopause (age at onset);
PAAD	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg19336497	chr11:14380999	RRAS2	-0.48	-5.19	-0.39	6.73e-7	Vitamin D levels;
PAAD	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-7.07	-0.5	5.17e-11	Eye color traits;
PAAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg14180030	chr9:123475675	MEGF9	-0.39	-4.62	-0.35	8.08e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg01489256	chr8:11204017	TDH	0.45	4.84	0.37	3.17e-6	Neuroticism;
PAAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.78	7.89	0.54	5.62e-13	Vitiligo;
PAAD	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.1	0.38	9.85e-7	Mood instability;
PAAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	11.5	0.68	2.06e-22	Tonsillectomy;
PAAD	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.43	4.65	0.35	7.21e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.38	-0.33	2.18e-5	Initial pursuit acceleration;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.16	0.55	1.18e-13	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16851699	chr7:5938193	C7orf28A	-0.8	-7.4	-0.51	8.62e-12	Neuroticism;
PAAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg03289416	chr15:75166202	SCAMP2	0.58	6.13	0.45	7.18e-9	Breast cancer;
PAAD	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15210612	chr3:98312534	CPOX	0.58	6.3	0.46	2.99e-9	Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.93	10.76	0.66	2.04e-20	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13560548	chr3:10150139	C3orf24	0.61	5.45	0.4	2.01e-7	Alzheimer's disease;
PAAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.74e-6	Menarche (age at onset);
PAAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg21929781	chr1:2537748	MMEL1	0.53	5.45	0.4	1.97e-7	Ulcerative colitis;
PAAD	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-11.39	-0.68	3.93e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs6066835	0.867	rs73144586	chr20:47360454	G/A	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72772787	1.000	rs72772787	chr1:248016378	C/T	cg20507276	chr1:248100600	OR2L13	0.56	4.82	0.36	3.5e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.55	6.3	0.45	3.11e-9	Aortic root size;
PAAD	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.58	-5.18	-0.39	6.9e-7	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11678423	chr1:17380834	SDHB	0.59	6.5	0.47	1.11e-9	Monocyte percentage of white cells;
PAAD	cis	rs12936587	0.601	rs7212538	chr17:17554587	T/G	cg04398451	chr17:18023971	MYO15A	0.48	4.46	0.34	1.57e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.69	5.67	0.42	6.95e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-5.66	-0.42	7.3900000000000007e-08	Fear of minor pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24816578	chr7:102389892	FAM185A	-0.71	-6.3	-0.46	3.06e-9	Neuroticism;
PAAD	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg00181669	chr3:44000978	NA	-0.55	-5.85	-0.43	2.9e-8	Coronary artery disease;
PAAD	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs2147959	0.714	rs6659690	chr1:228628170	A/G	cg02753203	chr1:228287806	NA	-0.59	-4.76	-0.36	4.39e-6	Adult asthma;
PAAD	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11588062	0.660	rs12738055	chr1:46701222	T/A	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.52	4.67	0.35	6.56e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	4.25	0.33	3.66e-5	Neuroticism;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04156016	chr5:1868137	NA	0.46	4.76	0.36	4.57e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.934	rs454813	chr19:44408973	A/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg22089800	chr15:90895588	ZNF774	0.53	5.02	0.38	1.44e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs7077446	0.733	rs6584467	chr10:103748333	G/A	cg19008088	chr10:102890038	TLX1;TLX1NB	-0.48	-4.55	-0.35	1.09e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9467160	1.000	rs9461010	chr6:24440206	T/C	cg16211469	chr6:24423932	MRS2	0.47	4.71	0.36	5.53e-6	Liver enzyme levels;
PAAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.51	-4.48	-0.34	1.43e-5	P wave terminal force;
PAAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.69	6.57	0.47	7.49e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg12935359	chr14:103987150	CKB	-0.73	-8.51	-0.57	1.51e-14	Body mass index;
PAAD	cis	rs6684428	0.706	rs61774839	chr1:56336609	G/A	cg11651538	chr1:56320950	NA	-0.51	-4.43	-0.34	1.77e-5	Airflow obstruction;
PAAD	cis	rs6782025	0.794	rs589682	chr3:120689958	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg09509183	chr1:209979624	IRF6	0.54	5.05	0.38	1.23e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.49	-4.5	-0.34	1.35e-5	Tuberculosis;
PAAD	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	4.48	0.34	1.46e-5	Menarche (age at onset);
PAAD	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg17346650	chr17:80929145	B3GNTL1	0.46	5.65	0.42	7.54e-8	Glycated hemoglobin levels;
PAAD	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg02072170	chr3:194406190	FAM43A	0.54	5.49	0.41	1.67e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg20607287	chr7:12443886	VWDE	-0.63	-5.01	-0.38	1.47e-6	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	trans	rs901683	1.000	rs76469200	chr10:46080033	C/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-4.72	-0.36	5.22e-6	Menarche (age at onset);
PAAD	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.44	-6.73	-0.48	3.25e-10	Subjective well-being;
PAAD	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg18281939	chr5:77783895	LHFPL2	0.51	6.57	0.47	7.37e-10	Triglycerides;
PAAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg22338127	chr1:209979572	IRF6	0.54	4.36	0.33	2.35e-5	Coronary artery disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08838602	chr8:65483645	NA	0.59	6.8	0.48	2.2e-10	Body fat percentage;
PAAD	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg14768367	chr16:72042858	DHODH	-0.73	-5.93	-0.43	2.01e-8	Blood protein levels;
PAAD	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg07220939	chr11:64358617	SLC22A12	-0.45	-4.73	-0.36	5.07e-6	Urate levels in obese individuals;
PAAD	cis	rs1667255	1.000	rs1667244	chr18:29167905	C/T	cg18808318	chr18:29669225	NA	-0.42	-4.25	-0.33	3.65e-5	Retinol levels;
PAAD	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg27068330	chr11:65405492	SIPA1	0.47	4.38	0.33	2.2e-5	Acne (severe);
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-6.08	-0.44	9.47e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg03989125	chr22:38214979	NA	0.6	5.48	0.41	1.76e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2131877	0.871	rs62290354	chr3:194867296	A/G	cg11177333	chr3:195857752	NA	0.52	4.28	0.33	3.3e-5	Non-small cell lung cancer;
PAAD	cis	rs2131877	0.830	rs1874104	chr3:194845226	A/C	cg21937377	chr3:194868750	C3orf21	-0.49	-4.78	-0.36	4.17e-6	Non-small cell lung cancer;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.96	12.27	0.71	1.76e-24	Menopause (age at onset);
PAAD	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg00042356	chr1:8021962	PARK7	0.66	4.63	0.35	7.9e-6	Inflammatory bowel disease;
PAAD	cis	rs3764400	0.567	rs1452662	chr17:46293310	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.6	-0.35	8.72e-6	Glomerular filtration rate;
PAAD	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.39	-4.42	-0.34	1.9e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2051773	0.567	rs7130826	chr11:17037793	T/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.85	-0.37	3.01e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.48	4.67	0.35	6.52e-6	Menopause (age at onset);
PAAD	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-7.22	-0.51	2.32e-11	Body mass index (adult);
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs377457	0.623	rs1053328	chr16:85711860	A/G	cg02758499	chr16:85682440	KIAA0182	-0.35	-4.27	-0.33	3.46e-5	Type 2 diabetes;
PAAD	cis	rs6604026	0.630	rs10874753	chr1:93429087	A/C	cg17283838	chr1:93427260	FAM69A	-0.62	-5.87	-0.43	2.66e-8	Multiple sclerosis;
PAAD	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.76	-4.9	-0.37	2.44e-6	Body mass index;
PAAD	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.69	4.74	0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17467752	chr17:38218738	THRA	0.5	4.54	0.35	1.12e-5	Asthma;
PAAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06544989	chr22:39130855	UNC84B	0.48	4.69	0.36	6.14e-6	Menopause (age at onset);
PAAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.63	-6.75	-0.48	2.91e-10	Schizophrenia;
PAAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-0.65	-6.02	-0.44	1.26e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs881827	1.000	rs881827	chr21:48019868	C/T	cg11766577	chr21:47581405	C21orf56	-0.43	-4.53	-0.34	1.19e-5	Lymphocyte counts;
PAAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.54	5.94	0.43	1.84e-8	Diastolic blood pressure;
PAAD	cis	rs76917914	0.589	rs10985065	chr9:100866903	C/T	cg03040243	chr9:100819229	NANS	0.51	4.33	0.33	2.69e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1816752	0.679	rs8181826	chr13:24970708	A/T	cg02811702	chr13:24901961	NA	-0.49	-4.91	-0.37	2.37e-6	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.84	-10.76	-0.66	1.93e-20	Height;
PAAD	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	5.35	0.4	3.18e-7	Mean platelet volume;
PAAD	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.46e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23158103	chr7:148848205	ZNF398	-0.59	-5.77	-0.42	4.34e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1468734	1.000	rs873645	chr16:5005280	A/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs9943465	0.688	rs318929	chr10:132071772	T/A	cg11951218	chr10:131825678	NA	0.84	4.44	0.34	1.71e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	7.17	0.5	3.09e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7260598	0.539	rs73525891	chr19:24069933	A/G	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg21395723	chr22:39101663	GTPBP1	0.44	4.49	0.34	1.4e-5	Menopause (age at onset);
PAAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.5	5.36	0.4	2.99e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	trans	rs10767971	1.000	rs9943661	chr11:32893777	A/G	cg03700492	chr17:73874623	TRIM47	0.62	6.47	0.46	1.25e-9	Parkinson's disease (age of onset);
PAAD	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.4e-6	Depressive symptoms;
PAAD	cis	rs10435719	0.540	rs804267	chr8:11629241	G/A	cg00262122	chr8:11665843	FDFT1	0.59	5.69	0.42	6.32e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg12215294	chr3:40350768	EIF1B	0.47	4.89	0.37	2.58e-6	Renal cell carcinoma;
PAAD	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg13870426	chr17:30244630	NA	-0.73	-6.84	-0.48	1.84e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12582317	chr17:55822272	NA	0.71	8.7	0.58	5.07e-15	Schizophrenia;
PAAD	cis	rs2882667	0.690	rs288028	chr5:138221989	C/G	cg09476006	chr5:138032270	NA	0.44	5.63	0.42	8.39e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg16576597	chr16:28551801	NUPR1	0.52	5.76	0.42	4.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.46	4.31	0.33	2.96e-5	Endometrial cancer;
PAAD	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-8.16	-0.55	1.19e-13	Colorectal cancer;
PAAD	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg21351543	chr2:191399470	TMEM194B	-0.63	-4.63	-0.35	7.84e-6	Diastolic blood pressure;
PAAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	5.03	0.38	1.38e-6	Rheumatoid arthritis;
PAAD	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.62	-6.02	-0.44	1.25e-8	Systolic blood pressure;
PAAD	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.46	-4.84	-0.37	3.13e-6	Response to antidepressants in depression;
PAAD	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg20742385	chr13:113633654	MCF2L	-0.46	-4.72	-0.36	5.26e-6	Systolic blood pressure;
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.92	7.54	0.52	4.07e-12	Gut microbiome composition (summer);
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg10137597	chr8:22132714	PIWIL2	0.5	5.96	0.44	1.66e-8	Hypertriglyceridemia;
PAAD	cis	rs2594989	0.943	rs1391903	chr3:11423271	C/G	cg01796438	chr3:11312864	ATG7	0.64	4.89	0.37	2.58e-6	Circulating chemerin levels;
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs1387259	0.759	rs7960122	chr12:48777000	C/T	cg04545296	chr12:48745243	ZNF641	-0.36	-4.33	-0.33	2.72e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.84	9.76	0.62	8.95e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg16031515	chr1:205743344	RAB7L1	-0.41	-4.68	-0.35	6.28e-6	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10230308	chr17:61678218	TACO1	0.73	7.44	0.52	6.76e-12	Obesity-related traits;
PAAD	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.74	8.04	0.55	2.33e-13	Lewy body disease;
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-6.87	-0.49	1.55e-10	Body mass index;
PAAD	cis	rs6141769	0.569	rs6119935	chr20:31270570	C/A	cg13636640	chr20:31349939	DNMT3B	-0.54	-4.97	-0.37	1.77e-6	Subjective well-being;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19687152	chr14:102968497	TECPR2	0.57	6.66	0.48	4.65e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1847202	1.000	rs7651022	chr3:72924564	T/C	cg25664220	chr3:72788482	NA	-0.46	-4.87	-0.37	2.78e-6	Motion sickness;
PAAD	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27416749	chr17:49008786	NA	0.59	6.8	0.48	2.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72960926	0.661	rs11752031	chr6:75249198	A/G	cg03266952	chr6:74778945	NA	-1.06	-4.89	-0.37	2.52e-6	Metabolite levels (MHPG);
PAAD	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg15309053	chr8:964076	NA	0.4	4.25	0.33	3.68e-5	Schizophrenia;
PAAD	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.89	5.95	0.43	1.79e-8	Body mass index;
PAAD	cis	rs12042052	0.793	rs7534632	chr1:232910796	G/A	cg02191044	chr1:232940990	KIAA1383	0.91	4.47	0.34	1.51e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg06108461	chr20:60628389	TAF4	-0.63	-6.16	-0.45	6.07e-9	Body mass index;
PAAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Birth weight;
PAAD	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.19	6.77	0.48	2.64e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.7	8.09	0.55	1.74e-13	Colorectal cancer;
PAAD	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg01329690	chr21:38580129	DSCR9	0.33	4.45	0.34	1.67e-5	Eye color traits;
PAAD	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.49	5.09	0.38	1.04e-6	Plasma plasminogen activator levels;
PAAD	cis	rs735539	0.593	rs35584557	chr13:21366557	T/C	cg27234864	chr13:21295941	IL17D	0.61	5.31	0.4	3.88e-7	Dental caries;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs11671653	1.000	rs11671653	chr19:10838486	A/G	cg18582342	chr19:11591989	ELAVL3	0.52	4.47	0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4742903	0.904	rs4373581	chr9:106977463	C/T	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.37	-4.27	-0.33	3.39e-5	Blood protein levels;
PAAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg10556349	chr10:835070	NA	0.56	4.99	0.38	1.62e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.77	0.62	8.58e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs282587	0.502	rs382758	chr13:113400169	C/T	cg04656015	chr13:113407548	ATP11A	0.54	4.45	0.34	1.68e-5	Glycated hemoglobin levels;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13732083	chr21:47605072	C21orf56	0.44	4.32	0.33	2.84e-5	Testicular germ cell tumor;
PAAD	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.66	5.21	0.39	6e-7	Mammographic density (dense area);
PAAD	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.65	-4.8	-0.36	3.76e-6	Response to haloperidol in psychosis;
PAAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	1.1	11.26	0.67	8.92e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.38	-0.4	2.75e-7	Educational attainment (years of education);
PAAD	cis	rs62238980	0.731	rs62239005	chr22:32593371	A/G	cg02631450	chr22:32366979	NA	0.98	4.64	0.35	7.48e-6	Childhood ear infection;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.55	5.13	0.38	8.59e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.72	8.98	0.59	9.93e-16	Dupuytren's disease;
PAAD	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.45	0.46	1.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.66	6.35	0.46	2.41e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14094447	chr9:74383399	TMEM2	0.53	6.56	0.47	8.05e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2882667	0.690	rs288004	chr5:138231645	C/T	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs12956009	0.518	rs1347343	chr18:44818996	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.69	-0.36	5.99e-6	Educational attainment (years of education);
PAAD	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg04833646	chr19:10679720	CDKN2D	1.0	9.81	0.62	6.46e-18	Red cell distribution width;
PAAD	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.68	7.23	0.51	2.22e-11	Schizophrenia;
PAAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	0.95	6.5	0.47	1.11e-9	Thyroid stimulating hormone;
PAAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg12458913	chr13:53173898	NA	0.56	5.45	0.4	1.99e-7	Lewy body disease;
PAAD	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg14092571	chr14:90743983	NA	-0.53	-4.87	-0.37	2.74e-6	Mortality in heart failure;
PAAD	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg08847533	chr14:75593920	NEK9	0.46	4.51	0.34	1.27e-5	Neuroticism;
PAAD	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.48	-4.47	-0.34	1.53e-5	Putamen volume;
PAAD	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg27234864	chr13:21295941	IL17D	0.61	5.17	0.39	7.16e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg07777115	chr5:623756	CEP72	-0.52	-4.63	-0.35	7.77e-6	Cystic fibrosis severity;
PAAD	cis	rs5757949	0.578	rs133056	chr22:41051324	C/T	cg14701072	chr22:41075428	MCHR1	-0.44	-4.35	-0.33	2.45e-5	Height;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23731591	chr2:71222556	TEX261	-0.68	-6.64	-0.47	5.16e-10	Lung cancer in ever smokers;
PAAD	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20181325	chr3:126009688	NA	0.58	6.35	0.46	2.32e-9	Smoking initiation;
PAAD	cis	rs9463078	0.546	rs1284987	chr6:45063721	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.21	-0.39	6.14e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs151997	1.000	rs373030	chr5:50215836	G/A	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg24565620	chr2:194026	NA	-0.66	-5.03	-0.38	1.39e-6	Blood protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00523224	chr17:16310862	NA	-0.64	-6.5	-0.47	1.07e-9	Neuroticism;
PAAD	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg24692254	chr21:30365293	RNF160	-0.62	-5.12	-0.38	9.28e-7	Cognitive test performance;
PAAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.29	-0.56	5.62e-14	Eye color traits;
PAAD	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg27565382	chr3:53032988	SFMBT1	0.96	4.74	0.36	4.88e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs6604026	0.698	rs2492294	chr1:93346566	C/G	cg17283838	chr1:93427260	FAM69A	-0.61	-5.63	-0.42	8.64e-8	Multiple sclerosis;
PAAD	cis	rs13424612	0.965	rs4149544	chr2:240943162	C/T	cg01812947	chr2:240904978	NDUFA10	0.57	4.98	0.37	1.74e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.96	-0.44	1.68e-8	Calcium levels;
PAAD	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	6.92	0.49	1.19e-10	Systolic blood pressure;
PAAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg20805835	chr1:248005719	OR11L1	0.54	4.91	0.37	2.37e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.33	0.56	4.29e-14	Monocyte percentage of white cells;
PAAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs6844506	0.901	rs13135534	chr4:185219305	A/G	cg12654155	chr4:185238627	NA	-0.5	-4.41	-0.34	1.96e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.6	-0.35	8.75e-6	Breast cancer;
PAAD	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-5.86	-0.43	2.82e-8	Monocyte percentage of white cells;
PAAD	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.11	-0.38	9.6e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg07202610	chr7:1142643	C7orf50	-0.76	-5.24	-0.39	5.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.81	4.9	0.37	2.41e-6	Psoriasis;
PAAD	cis	rs11605275	0.792	rs2568131	chr11:20046407	G/T	cg14835545	chr11:20032148	NAV2	0.69	4.38	0.33	2.24e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.76	8.0	0.54	2.88e-13	Height;
PAAD	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.67	0.35	6.47e-6	Height;
PAAD	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.78	-5.46	-0.41	1.86e-7	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg04398451	chr17:18023971	MYO15A	0.77	8.58	0.57	1e-14	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03309786	chr2:232574968	PTMA	0.57	6.62	0.47	5.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10957961	0.586	rs13280432	chr8:81066654	A/T	cg10609868	chr8:81963379	PAG1	0.35	4.27	0.33	3.48e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg00825309	chr19:58991885	ZNF446	-0.77	-8.04	-0.55	2.3e-13	Uric acid clearance;
PAAD	cis	rs11615916	0.790	rs73135251	chr12:62665540	A/G	cg11441379	chr12:63026424	NA	0.7	4.53	0.34	1.19e-5	Pulmonary function decline;
PAAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.93	0.37	2.11e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg23352942	chr3:46931381	PTH1R	0.48	4.9	0.37	2.45e-6	Birth weight;
PAAD	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.78	0.58	3.17e-15	Lung cancer;
PAAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg00334542	chr7:100209784	MOSPD3	-0.63	-4.51	-0.34	1.28e-5	Other erythrocyte phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08235889	chr16:1660574	IFT140	-0.73	-6.45	-0.46	1.4e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22152446	chr4:48754953	FRYL	-0.6	-6.65	-0.47	5e-10	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs36053776	chr10:46088145	C/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	cis	rs10792830	0.900	rs580887	chr11:85831433	A/T	cg07180834	chr11:85838833	NA	-0.58	-6.9	-0.49	1.34e-10	Psychosis and Alzheimer's disease;
PAAD	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg22437258	chr11:111473054	SIK2	0.62	6.03	0.44	1.17e-8	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs282587	0.569	rs432522	chr13:113400015	A/G	cg04656015	chr13:113407548	ATP11A	0.54	4.31	0.33	2.88e-5	Glycated hemoglobin levels;
PAAD	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg17524180	chr13:113633600	MCF2L	-0.52	-5.68	-0.42	6.79e-8	Systolic blood pressure;
PAAD	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	0.85	5.75	0.42	4.66e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.57	5.71	0.42	5.88e-8	Prostate cancer;
PAAD	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.59	5.49	0.41	1.68e-7	Breast size;
PAAD	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03576123	chr11:487126	PTDSS2	-1.13	-5.79	-0.43	3.88e-8	Body mass index;
PAAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.66	7.45	0.52	6.47e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.54	5.09	0.38	1.05e-6	Eosinophilic esophagitis;
PAAD	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg04826882	chr13:114838756	RASA3	-0.71	-5.85	-0.43	2.86e-8	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.49	-0.47	1.16e-9	Longevity;Endometriosis;
PAAD	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg24687543	chr11:63912206	MACROD1	-0.55	-4.92	-0.37	2.27e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.51	-4.92	-0.37	2.21e-6	Mean platelet volume;
PAAD	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.63	0.35	7.93e-6	Refractive astigmatism;
PAAD	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	10.22	0.64	5.53e-19	Monocyte percentage of white cells;
PAAD	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg16898833	chr6:26189333	HIST1H4D	0.5	4.42	0.34	1.85e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.6	5.23	0.39	5.53e-7	Neutrophil percentage of white cells;
PAAD	cis	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.8	-8.63	-0.57	7.76e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17679824	chr5:65018933	SGTB;NLN	0.65	6.58	0.47	7.1e-10	Obesity-related traits;
PAAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14215459	chr19:10764813	ILF3;LOC147727	0.55	6.64	0.47	5.1e-10	Immature fraction of reticulocytes;
PAAD	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg02683114	chr2:24398427	C2orf84	-0.46	-4.83	-0.36	3.33e-6	Sjögren's syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05702851	chr4:110481083	CCDC109B	0.64	6.44	0.46	1.45e-9	Obesity-related traits;
PAAD	trans	rs4272720	0.805	rs17700388	chr10:50218092	A/G	cg15329866	chr3:171455826	PLD1	0.76	6.89	0.49	1.38e-10	Platelet count;Plateletcrit;
PAAD	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09597638	chr17:3907349	NA	-0.66	-6.35	-0.46	2.33e-9	Type 2 diabetes;
PAAD	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.47	4.63	0.35	7.79e-6	Systemic lupus erythematosus;
PAAD	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg18279126	chr7:2041391	MAD1L1	-0.6	-6.11	-0.44	8.11e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15388430	chr22:43010952	POLDIP3;RNU12	0.63	7.24	0.51	2.13e-11	Monocyte percentage of white cells;
PAAD	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	5.12	0.38	8.99e-7	Thyroid stimulating hormone;
PAAD	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg24565620	chr2:194026	NA	0.65	4.81	0.36	3.54e-6	Blood protein levels;
PAAD	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	High light scatter reticulocyte count;
PAAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.48	4.58	0.35	9.75e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs3784262	0.740	rs2119859	chr15:58254745	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.52	-5.92	-0.43	2.08e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg04291430	chr17:48206283	SAMD14	-0.34	-4.58	-0.35	9.6e-6	Temporomandibular joint disorder;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4800452	0.956	rs4239436	chr18:20731930	A/G	cg26136497	chr18:20735537	CABLES1	-0.47	-4.48	-0.34	1.48e-5	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.65	6.36	0.46	2.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20060928	chr8:135708851	ZFAT	-0.66	-6.57	-0.47	7.53e-10	Obesity-related traits;
PAAD	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-6.46	-0.46	1.37e-9	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.57	-5.59	-0.41	1.02e-7	Heschl's gyrus morphology;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03923535	chr7:1197113	ZFAND2A	0.47	4.91	0.37	2.29e-6	Longevity;Endometriosis;
PAAD	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.34e-6	Pulmonary function;
PAAD	cis	rs6076065	0.723	rs2424537	chr20:23382026	T/C	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg04374321	chr14:90722782	PSMC1	-0.8	-8.48	-0.57	1.82e-14	Mortality in heart failure;
PAAD	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	5.94	0.43	1.86e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg26385993	chr17:80788710	TBCD;ZNF750	-0.44	-4.34	-0.33	2.64e-5	Glycated hemoglobin levels;
PAAD	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.22	0.39	5.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-5.04	-0.38	1.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg21438018	chr1:76262537	MSH4	0.48	4.45	0.34	1.68e-5	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05677402	chr11:57335051	UBE2L6	0.61	6.73	0.48	3.19e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1198430	0.562	rs504145	chr1:23788310	C/T	cg19827787	chr1:23763612	ASAP3	0.53	4.88	0.37	2.71e-6	Total cholesterol levels;
PAAD	cis	rs8133932	0.736	rs11089025	chr21:47281579	C/A	cg13695288	chr21:47294981	PCBP3	-0.49	-4.82	-0.36	3.47e-6	Schizophrenia;
PAAD	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.39	-0.46	1.92e-9	Hip circumference;
PAAD	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs427941	0.632	rs201471	chr7:101744145	T/G	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg26668828	chr6:292823	DUSP22	-0.86	-9.13	-0.6	3.94e-16	Menopause (age at onset);
PAAD	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-7.82	-0.54	8.21e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg01657329	chr11:68192670	LRP5	-0.74	-6.82	-0.48	2.07e-10	Total body bone mineral density;
PAAD	cis	rs6545883	0.860	rs4671399	chr2:61458518	C/T	cg14146966	chr2:61757674	XPO1	-0.4	-4.99	-0.38	1.63e-6	Tuberculosis;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.62	-5.29	-0.39	4.24e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9463078	0.585	rs1748231	chr6:45133354	T/G	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg14671328	chr17:61934042	TCAM1	-0.55	-4.42	-0.34	1.9e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.62e-5	Platelet count;
PAAD	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.37	-0.4	2.84e-7	Cognitive function;
PAAD	cis	rs9356171	0.572	rs13198847	chr6:164326504	T/C	cg25752492	chr6:164341247	NA	-0.47	-5.18	-0.39	7.01e-7	Diisocyanate-induced asthma;
PAAD	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.53	-5.06	-0.38	1.18e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg20913747	chr6:44695427	NA	-0.72	-7.25	-0.51	1.93e-11	Total body bone mineral density;
PAAD	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.18	-0.45	5.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg03910582	chr17:19030146	GRAPL	0.45	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.5	-0.34	1.37e-5	Height;
PAAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg14393609	chr7:65229607	NA	0.46	4.45	0.34	1.63e-5	Aortic root size;
PAAD	cis	rs730532	0.556	rs1032578	chr14:52523900	C/T	cg10149976	chr14:52535953	NID2	-0.68	-5.13	-0.38	8.83e-7	Pulmonary function;
PAAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08893839	chr5:154027129	NA	0.79	6.1	0.44	8.53e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-4.8	-0.36	3.83e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs282587	0.569	rs282598	chr13:113384331	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.88	10.32	0.64	2.96e-19	Tuberculosis;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg01652476	chr7:809048	HEATR2	-0.65	-7.34	-0.51	1.21e-11	Subjective well-being;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.46	4.67	0.35	6.44e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.43	-5.43	-0.4	2.21e-7	Lewy body disease;
PAAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.88	0.37	2.64e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.53	-6.06	-0.44	1.04e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg12573674	chr2:1569213	NA	-0.69	-4.53	-0.34	1.2e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.51	8.31	0.56	4.91e-14	IgG glycosylation;
PAAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18404041	chr3:52824283	ITIH1	0.42	4.49	0.34	1.4e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.44	4.31	0.33	2.91e-5	Trans fatty acid levels;
PAAD	cis	rs89107	0.603	rs399844	chr6:118613435	A/G	cg21191810	chr6:118973309	C6orf204	0.46	6.47	0.46	1.26e-9	Cardiac structure and function;
PAAD	cis	rs7187365	0.935	rs34108883	chr16:86504658	C/A	cg06866187	chr16:86489453	NA	0.49	4.29	0.33	3.16e-5	Obesity (early onset extreme);
PAAD	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.14	0.38	8.49e-7	Prostate cancer;
PAAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.93	0.37	2.09e-6	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09161592	chr10:91405006	PANK1	-0.75	-6.76	-0.48	2.8e-10	Neuroticism;
PAAD	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	1.05	15.2	0.78	2.61e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.61	0.41	9.29e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.935	rs11673020	chr19:44374631	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.85	-0.43	2.88e-8	Breast cancer;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.75	6.53	0.47	9.23e-10	Pediatric autoimmune diseases;
PAAD	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.47	-0.46	1.28e-9	Mood instability;
PAAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg11663144	chr21:46675770	NA	-0.46	-5.51	-0.41	1.51e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg13385521	chr17:29058706	SUZ12P	-0.63	-4.32	-0.33	2.75e-5	Body mass index;
PAAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.58	6.86	0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.79	8.68	0.58	5.7e-15	Obesity-related traits;
PAAD	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.58	6.66	0.48	4.71e-10	Schizophrenia;
PAAD	cis	rs1903068	0.853	rs10012589	chr4:56002689	A/T	cg09978860	chr4:56023921	NA	0.38	4.34	0.33	2.61e-5	Endometriosis;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.58	-5.92	-0.43	2.02e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.83	8.8	0.58	2.87e-15	Itch intensity from mosquito bite;
PAAD	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-5.07	-0.38	1.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.58	5.12	0.38	9.08e-7	Sudden cardiac arrest;
PAAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs61931739	0.592	rs708140	chr12:33719563	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11887884	chr17:79486500	NA	-0.75	-6.56	-0.47	8e-10	Neuroticism;
PAAD	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	5.23	0.39	5.42e-7	Iron status biomarkers;
PAAD	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs9485372	1.000	rs58489510	chr6:149600991	T/C	cg14417099	chr6:150073879	PCMT1	-0.53	-4.25	-0.33	3.72e-5	Breast cancer;
PAAD	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-1.03	-13.37	-0.74	1.91e-27	Schizophrenia;
PAAD	cis	rs7577696	0.962	rs67157050	chr2:32271364	C/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.69	-0.36	6.13e-6	Inflammatory biomarkers;
PAAD	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.49	-4.73	-0.36	5.07e-6	Mortality in heart failure;
PAAD	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.26e-6	Lung cancer;
PAAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.02	0.5	6.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23779106	chr1:161719820	DUSP12	0.64	6.69	0.48	4.05e-10	Myopia (pathological);
PAAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg12072164	chr19:44306565	LYPD5	0.48	5.02	0.38	1.43e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.74	9.21	0.6	2.41e-16	Prudent dietary pattern;
PAAD	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55728055	0.661	rs10428007	chr22:31646653	C/T	cg01338084	chr22:32026380	PISD	1.16	5.94	0.43	1.91e-8	Age-related hearing impairment;
PAAD	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.71	-7.15	-0.5	3.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.98	5.64	0.42	8.26e-8	Schizophrenia;
PAAD	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg00262122	chr8:11665843	FDFT1	0.5	4.67	0.35	6.6e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.46	5.29	0.39	4.28e-7	Mean arterial pressure;
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg01612440	chr4:3296283	NA	0.45	4.47	0.34	1.51e-5	Serum sulfate level;
PAAD	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	trans	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.33	-0.46	2.61e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.87	7.08	0.5	4.99e-11	Initial pursuit acceleration;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs75920871	1.000	rs7125788	chr11:116883396	T/C	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-10.95	-0.66	5.99e-21	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00867273	chr16:4852936	ROGDI	-0.76	-6.57	-0.47	7.65e-10	Neuroticism;
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.56	0.35	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12453935	0.708	rs11652477	chr17:59899840	G/A	cg01765249	chr17:59476334	TBX2	-0.52	-4.59	-0.35	9.05e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.68	5.74	0.42	4.87e-8	Menarche (age at onset);
PAAD	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs758324	0.704	rs31480	chr5:131396332	C/T	cg06307176	chr5:131281290	NA	-0.53	-4.53	-0.35	1.17e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg18944383	chr4:111397179	ENPEP	0.76	8.32	0.56	4.73e-14	Coronary artery disease;
PAAD	cis	rs17761864	0.555	rs11654636	chr17:2008904	G/A	cg16513277	chr17:2031491	SMG6	0.43	4.25	0.33	3.73e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.57	6.78	0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.98	13.85	0.75	9.87e-29	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01704862	chr7:150780657	TMUB1	0.6	6.39	0.46	1.93e-9	Myopia (pathological);
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg00450029	chr8:599525	NA	0.94	6.36	0.46	2.24e-9	IgG glycosylation;
PAAD	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19882132	chr14:106167949	NA	-0.55	-4.91	-0.37	2.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg07862535	chr7:139043722	LUC7L2	0.62	4.77	0.36	4.35e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	4.59	0.35	9.4e-6	Height;
PAAD	cis	rs9826463	0.757	rs77081474	chr3:142294634	T/C	cg20824294	chr3:142316082	PLS1	0.43	4.87	0.37	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.7	-7.08	-0.5	5.07e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.53	5.8	0.43	3.79e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg05791153	chr7:19748676	TWISTNB	0.63	4.52	0.34	1.24e-5	Thyroid stimulating hormone;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.61	-0.41	9.28e-8	Life satisfaction;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg21237687	chr17:6899380	ALOX12	-0.59	-5.94	-0.43	1.88e-8	Tonsillectomy;
PAAD	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg10523679	chr1:76189770	ACADM	-0.51	-4.87	-0.37	2.83e-6	Daytime sleep phenotypes;
PAAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.52	4.99	0.38	1.64e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.62	-6.43	-0.46	1.55e-9	Primary sclerosing cholangitis;
PAAD	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	4.38	0.33	2.21e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs288326	0.561	rs76304059	chr2:183779555	C/G	cg09997497	chr2:183902928	NCKAP1	0.97	5.7	0.42	5.93e-8	Blood protein levels;
PAAD	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg14829360	chr17:73884958	NA	-0.53	-5.57	-0.41	1.14e-7	White matter hyperintensity burden;
PAAD	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.56	-5.25	-0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.72	0.42	5.42e-8	Ileal carcinoids;
PAAD	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.44	0.34	1.72e-5	IgG glycosylation;
PAAD	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.95	-0.59	1.13e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.51	5.06	0.38	1.22e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.68	0.42	6.74e-8	Body mass index;
PAAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg06271696	chr7:157225062	NA	-0.77	-9.55	-0.61	3.23e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs11825064	0.666	rs61393915	chr11:134496330	C/T	cg06603561	chr11:134479413	NA	-0.96	-6.33	-0.46	2.59e-9	Seasonality;
PAAD	cis	rs730532	0.556	rs2173145	chr14:52518485	T/C	cg10149976	chr14:52535953	NID2	0.64	4.95	0.37	1.97e-6	Pulmonary function;
PAAD	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-4.64	-0.35	7.57e-6	Primary biliary cholangitis;
PAAD	cis	rs4356203	0.870	rs10832751	chr11:17274016	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.32	-0.33	2.84e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg20636351	chr8:55087400	NA	-0.66	-6.35	-0.46	2.4e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.61	6.17	0.45	6.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17155006	0.746	rs429252	chr7:107745554	T/C	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg15557168	chr22:42548783	NA	-0.55	-6.14	-0.45	6.98e-9	Cognitive function;
PAAD	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	5.7	0.42	6.18e-8	Schizophrenia;
PAAD	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.46	-5.09	-0.38	1.02e-6	Pneumonia;
PAAD	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.75	0.36	4.68e-6	Eosinophil percentage of white cells;
PAAD	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.55	5.79	0.42	3.96e-8	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12334911	chr13:114290059	TFDP1	-0.56	-6.44	-0.46	1.48e-9	Monocyte percentage of white cells;
PAAD	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs7551222	0.646	rs4951384	chr1:204452514	A/T	cg01064725	chr1:204461714	NA	-0.52	-4.64	-0.35	7.51e-6	Schizophrenia;
PAAD	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.21e-5	Educational attainment (years of education);
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15128208	chr22:42549153	NA	-0.45	-4.66	-0.35	6.77e-6	Cognitive function;
PAAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.85	10.29	0.64	3.5e-19	Ulcerative colitis;
PAAD	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg10072921	chr12:121022843	NA	0.4	4.89	0.37	2.58e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg10494973	chr17:80897199	TBCD	0.54	4.57	0.35	1.01e-5	Breast cancer;
PAAD	cis	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.94	-8.98	-0.59	9.96e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.47	4.67	0.35	6.61e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg18721089	chr20:30220636	NA	-0.59	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg18171855	chr10:2543474	NA	0.66	8.09	0.55	1.73e-13	Age-related hearing impairment;
PAAD	cis	rs2712381	0.517	rs62273237	chr3:128310107	T/C	cg16766828	chr3:128327626	NA	-0.46	-5.87	-0.43	2.6e-8	Monocyte count;
PAAD	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.53	0.34	1.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11825064	0.666	rs73596940	chr11:134495250	G/A	cg06603561	chr11:134479413	NA	-0.94	-6.25	-0.45	4.02e-9	Seasonality;
PAAD	cis	rs939584	1.000	rs1320338	chr2:649347	T/G	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4073221	0.789	rs35630651	chr3:18224286	G/C	cg07694806	chr3:18168406	NA	-0.81	-5.13	-0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19623624	chr10:135278901	LOC619207	-0.54	-5.48	-0.41	1.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.551	rs10500287	chr19:44331970	C/G	cg11993925	chr19:44307056	LYPD5	-0.4	-4.33	-0.33	2.74e-5	Breast cancer;
PAAD	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.49	5.66	0.42	7.19e-8	Prostate cancer;
PAAD	cis	rs959770	0.822	rs58069885	chr4:2377316	T/C	cg08330972	chr4:2403930	ZFYVE28	0.57	4.52	0.34	1.22e-5	Schizophrenia;
PAAD	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.92	-0.37	2.22e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.54	5.52	0.41	1.43e-7	Schizophrenia;
PAAD	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.48	-4.39	-0.34	2.11e-5	Red blood cell count;
PAAD	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg12560992	chr17:57184187	TRIM37	0.69	5.32	0.4	3.59e-7	Vitamin D levels;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg15117754	chr3:10150083	C3orf24	0.64	5.57	0.41	1.12e-7	Alzheimer's disease;
PAAD	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.87	-0.37	2.76e-6	Eotaxin levels;
PAAD	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.67	8.73	0.58	4.18e-15	Hypertriglyceridemia;
PAAD	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg07703079	chr11:430292	ANO9	0.79	4.4	0.34	1.99e-5	Body mass index;
PAAD	cis	rs9463078	0.585	rs1629542	chr6:45158485	A/G	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.64	6.93	0.49	1.11e-10	Mean platelet volume;
PAAD	cis	rs6256	1.000	rs12418203	chr11:13560725	A/T	cg11976911	chr11:13509032	NA	-0.67	-5.18	-0.39	7.06e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg07813855	chr1:200183606	FAM58B	-0.46	-4.43	-0.34	1.77e-5	Permanent tooth development;
PAAD	cis	rs3126085	0.667	rs12747821	chr1:152240424	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.51	0.47	1.04e-9	Atopic dermatitis;
PAAD	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.41	0.46	1.71e-9	Lung cancer in ever smokers;
PAAD	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg10820045	chr2:198174542	NA	0.53	5.3	0.39	4e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1075265	0.626	rs805320	chr2:54138442	G/T	cg04546899	chr2:54196757	PSME4	0.33	4.98	0.37	1.74e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.56	5.52	0.41	1.45e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.48e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4845552	0.767	rs6660055	chr1:153467074	C/T	cg15998505	chr1:153479701	NA	-0.51	-4.49	-0.34	1.42e-5	Hippocampal atrophy;
PAAD	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg15128208	chr22:42549153	NA	-0.46	-4.65	-0.35	7.21e-6	Cognitive function;
PAAD	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.65	-6.16	-0.45	6.07e-9	Primary sclerosing cholangitis;
PAAD	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.37	0.46	2.12e-9	Mean platelet volume;
PAAD	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.4	0.4	2.51e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.6	-0.41	9.75e-8	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02642223	chr17:38109030	NA	0.58	6.39	0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.67	0.35	6.51e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg13399544	chr8:144649678	C8orf73	-0.58	-6.0	-0.44	1.36e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs10214930	0.723	rs6948814	chr7:27633401	C/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.62	5.27	0.39	4.51e-7	Common traits (Other);
PAAD	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.08	0.63	1.26e-18	Smoking behavior;
PAAD	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg09796270	chr17:17721594	SREBF1	0.47	5.31	0.4	3.85e-7	Total body bone mineral density;
PAAD	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.48	-0.34	1.49e-5	Height;
PAAD	cis	rs2944755	0.686	rs11997913	chr8:141588660	C/G	cg18491938	chr8:141590271	EIF2C2	-0.51	-4.8	-0.36	3.76e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.64	-0.62	1.84e-17	Lung cancer;
PAAD	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.71	-9.16	-0.6	3.27e-16	Asthma;
PAAD	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.31	0.73	2.74e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg01059385	chr22:42394853	WBP2NL	0.46	4.33	0.33	2.69e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.87	10.27	0.64	4.01e-19	Menarche (age at onset);
PAAD	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25314111	chr5:178204356	AACSL	0.63	6.33	0.46	2.66e-9	Smoking initiation;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.3e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.75	-8.84	-0.58	2.27e-15	Childhood ear infection;
PAAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	1.01	13.87	0.75	8.93e-29	Menopause (age at onset);
PAAD	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.24	-0.45	4.24e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg10207240	chr12:122356781	WDR66	0.62	6.66	0.48	4.8e-10	Mean corpuscular volume;
PAAD	cis	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg27395922	chr11:50257633	LOC441601	-0.45	-4.53	-0.34	1.2e-5	Coronary artery disease;
PAAD	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.98	0.49	8.7e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20957382	chr12:105501358	KIAA1033	0.62	7.1	0.5	4.52e-11	Myopia (pathological);
PAAD	cis	rs367943	0.698	rs11741887	chr5:112959315	T/C	cg12552261	chr5:112820674	MCC	0.49	4.94	0.37	2.07e-6	Type 2 diabetes;
PAAD	cis	rs12311304	1.000	rs7297771	chr12:15376420	A/G	cg08258403	chr12:15378311	NA	0.35	4.38	0.33	2.17e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	9.78	0.62	7.83e-18	Menopause (age at onset);
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Electroencephalogram traits;
PAAD	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg11441379	chr12:63026424	NA	0.85	6.13	0.45	7.19e-9	IgG glycosylation;
PAAD	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.61	6.17	0.45	5.91e-9	Eosinophil percentage of white cells;
PAAD	cis	rs858239	0.614	rs10229956	chr7:23402936	C/G	cg23682824	chr7:23144976	KLHL7	-0.46	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17407555	0.955	rs11734209	chr4:10170371	T/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-5.07	-0.38	1.12e-6	Schizophrenia (age at onset);
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg26060667	chr1:247681242	NA	0.46	5.46	0.41	1.87e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs16975963	0.843	rs77895245	chr19:38419780	G/C	cg14218481	chr19:38281219	NA	0.48	5.01	0.38	1.49e-6	Longevity;
PAAD	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg25811867	chr2:3488468	NA	0.47	4.32	0.33	2.83e-5	Neurofibrillary tangles;
PAAD	cis	rs3737883	1.000	rs11579055	chr1:203031315	G/T	cg03900565	chr1:203031815	PPFIA4	0.34	5.81	0.43	3.55e-8	Early onset atrial fibrillation;
PAAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs35326978	chr10:45997712	A/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11638815	0.581	rs783537	chr15:83252807	A/G	cg00614314	chr15:82944287	LOC80154	0.52	5.1	0.38	9.9e-7	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg23024343	chr7:107201750	COG5	0.56	4.46	0.34	1.59e-5	Coronary artery disease;
PAAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.47	0.61	5.34e-17	Rheumatoid arthritis;
PAAD	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.67	6.8	0.48	2.19e-10	Cancer;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs17407555	0.657	rs12505144	chr4:10270919	G/C	cg11266682	chr4:10021025	SLC2A9	0.41	4.3	0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.7	5.16	0.39	7.51e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.83	0.43	3.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7264396	0.887	rs224347	chr20:34037523	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02359409	chr6:42947317	PEX6	0.52	5.37	0.4	2.87e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.53	-5.26	-0.39	4.78e-7	Crohn's disease;
PAAD	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.95	-0.37	1.99e-6	Diastolic blood pressure;
PAAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.75	-6.88	-0.49	1.43e-10	Coronary artery disease;
PAAD	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg16211469	chr6:24423932	MRS2	0.53	5.32	0.4	3.66e-7	Liver enzyme levels;
PAAD	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	6.86	0.49	1.61e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.95	11.47	0.68	2.4e-22	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.59e-8	Life satisfaction;
PAAD	cis	rs10090774	0.965	rs13250787	chr8:141916932	A/C	cg02508881	chr8:142216119	NA	0.41	4.4	0.34	2.01e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.72	0.36	5.21e-6	Cognitive ability;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.01	-0.44	1.33e-8	Longevity;Endometriosis;
PAAD	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4597304	1	rs4597304	chr16:85055741	G/C	cg01715842	chr16:85045600	ZDHHC7	-0.55	-4.81	-0.36	3.63e-6	Dysphagia;
PAAD	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07176514	chr1:185126191	C1orf25;C1orf26	-0.57	-6.31	-0.46	2.93e-9	Myopia (pathological);
PAAD	cis	rs6700896	0.500	rs4655575	chr1:66135668	C/T	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7929679	0.521	rs10768094	chr11:34792189	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs7165102	1.000	rs6494529	chr15:65902922	G/A	cg22900193	chr15:65823441	PTPLAD1	0.48	4.47	0.34	1.54e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.55	-5.63	-0.42	8.4e-8	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11807834	0.505	rs1967707	chr1:230241456	A/G	cg09847368	chr1:230250326	GALNT2	0.73	8.81	0.58	2.61e-15	Schizophrenia;
PAAD	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.88e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9463078	0.585	rs1285022	chr6:45111012	C/T	cg25276700	chr6:44698697	NA	-0.45	-4.98	-0.37	1.73e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04492929	chr16:2155436	PKD1	-0.62	-6.32	-0.46	2.69e-9	Metabolite levels (lipid measures);
PAAD	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg14349672	chr11:133703707	NA	0.6	6.67	0.48	4.47e-10	Childhood ear infection;
PAAD	cis	rs933117	0.892	rs113019625	chr21:31079343	C/T	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.29	-0.33	3.18e-5	Body mass index;
PAAD	cis	rs12257961	0.549	rs1955342	chr10:15377871	A/G	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs13102973	0.899	rs13119071	chr4:135909862	G/T	cg14419869	chr4:135874104	NA	0.48	4.86	0.37	2.84e-6	Subjective well-being;
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg07068956	chr7:100330872	ZAN	0.69	5.34	0.4	3.37e-7	Other erythrocyte phenotypes;
PAAD	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg23587288	chr2:27483067	SLC30A3	-0.71	-6.69	-0.48	4.08e-10	Blood metabolite levels;
PAAD	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.66	6.58	0.47	7.21e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs28830936	0.966	rs2277535	chr15:42119711	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.84	-0.49	1.83e-10	Diastolic blood pressure;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg10396713	chr8:602097	NA	0.69	4.61	0.35	8.43e-6	IgG glycosylation;
PAAD	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.88	-8.66	-0.57	6.36e-15	Neurofibrillary tangles;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs10957961	0.586	rs1834521	chr8:81072315	A/G	cg10609868	chr8:81963379	PAG1	-0.36	-4.32	-0.33	2.83e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.65	-4.66	-0.35	6.92e-6	Smoking behavior;
PAAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.77	6.27	0.45	3.59e-9	Gut microbiome composition (summer);
PAAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.45	4.88	0.37	2.63e-6	HDL cholesterol levels;
PAAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs863345	0.526	rs863931	chr1:158612236	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.87	-0.37	2.78e-6	Pneumococcal bacteremia;
PAAD	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.69	6.91	0.49	1.23e-10	Lymphocyte percentage of white cells;
PAAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.75	-7.15	-0.5	3.45e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.64	6.14	0.45	7.04e-9	Schizophrenia;
PAAD	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs9815354	1.000	rs9865780	chr3:41895802	A/G	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.39	-0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs78761021	0.755	rs17744048	chr17:9794996	A/G	cg26853458	chr17:9805074	RCVRN	0.73	8.65	0.57	6.9e-15	Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg25811867	chr2:3488468	NA	0.45	4.73	0.36	5.16e-6	Neurofibrillary tangles;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22043720	chr17:17399726	RASD1	-0.72	-6.39	-0.46	1.89e-9	Neuroticism;
PAAD	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.26	-0.39	4.76e-7	Vitamin D levels;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.28e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.54	-5.55	-0.41	1.27e-7	Menarche (age at onset);
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.56	-6.31	-0.46	2.94e-9	Longevity;Endometriosis;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.85	9.88	0.63	4.3e-18	Menarche (age at onset);
PAAD	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.9	-10.91	-0.66	8.03e-21	Eosinophil percentage of white cells;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.68	-0.35	6.39e-6	Bipolar disorder;
PAAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.85	-0.43	2.95e-8	Personality dimensions;
PAAD	cis	rs6089829	0.692	rs62197304	chr20:61656064	C/T	cg08564027	chr20:61660810	NA	-0.77	-6.96	-0.49	9.49e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs732765	0.734	rs17782707	chr14:75179102	T/A	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26240231	chr7:1148101	C7orf50	-0.48	-4.25	-0.33	3.7e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.39	0.61	8.36e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.82	6.7	0.48	3.82e-10	Chronic kidney disease;
PAAD	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.54	0.35	1.13e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg10932868	chr11:921992	NA	-0.5	-6.02	-0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.2	0.39	6.36e-7	Life satisfaction;
PAAD	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.18	-0.5	2.85e-11	Diastolic blood pressure;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.52	5.06	0.38	1.21e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.87	-0.37	2.78e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg23024343	chr7:107201750	COG5	0.53	4.42	0.34	1.84e-5	Coronary artery disease;
PAAD	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.6	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs12620999	0.941	rs1986830	chr2:237978320	C/T	cg23555395	chr2:238036564	NA	0.5	5.9	0.43	2.26e-8	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.71	-0.36	5.62e-6	Testicular germ cell tumor;
PAAD	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.52	4.8	0.36	3.8e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.68	7.2	0.5	2.58e-11	Vitiligo;
PAAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	7.07	0.5	5.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	1.04	6.92	0.49	1.21e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs4742903	0.875	rs7041529	chr9:106991539	G/A	cg14250997	chr9:106856677	SMC2	0.46	5.0	0.38	1.59e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	9.21	0.6	2.46e-16	Cognitive test performance;
PAAD	cis	rs1903068	0.925	rs1551642	chr4:55994210	T/C	cg01777861	chr4:56023843	NA	0.36	4.26	0.33	3.54e-5	Endometriosis;
PAAD	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.48	-5.38	-0.4	2.75e-7	Breast cancer;
PAAD	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg12218747	chr21:37451666	NA	-0.45	-4.9	-0.37	2.47e-6	Mitral valve prolapse;
PAAD	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.09	-0.5	4.63e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg19281693	chr22:42666674	NA	0.58	6.49	0.47	1.14e-9	Morning vs. evening chronotype;
PAAD	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.92e-6	Oral cavity cancer;
PAAD	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.61	-5.26	-0.39	4.72e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-1.02	-9.23	-0.6	2.22e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.97	8.41	0.56	2.71e-14	Triglycerides;
PAAD	cis	rs743757	0.938	rs2027854	chr3:50521177	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	5.06	0.38	1.2e-6	Diastolic blood pressure;
PAAD	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.57	-7.3	-0.51	1.49e-11	Lewy body disease;
PAAD	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-6.02	-0.44	1.25e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.89	-0.59	1.61e-15	Longevity;Endometriosis;
PAAD	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.5	-0.47	1.11e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg02745156	chr12:32552066	NA	0.42	4.36	0.33	2.35e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs10450586	0.932	rs10082678	chr11:27320448	C/T	cg10370305	chr11:27303972	NA	-0.38	-4.39	-0.34	2.13e-5	Total body bone mineral density;
PAAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.5	0.34	1.35e-5	Trans fatty acid levels;
PAAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs78761021	0.720	rs874175	chr17:9798595	T/G	cg26853458	chr17:9805074	RCVRN	0.74	8.44	0.56	2.39e-14	Type 2 diabetes;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg27094323	chr7:1216898	NA	-0.45	-5.42	-0.4	2.34e-7	Longevity;Endometriosis;
PAAD	cis	rs4141404	0.604	rs5753625	chr22:31854846	C/T	cg02404636	chr22:31891804	SFI1	-0.53	-5.1	-0.38	9.95e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg11143131	chr5:131608246	PDLIM4	-0.51	-5.13	-0.38	8.72e-7	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg14709524	chr16:89940631	TCF25	1.01	4.73	0.36	5.1e-6	Skin colour saturation;
PAAD	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg06569542	chr10:98946673	SLIT1	-0.48	-5.19	-0.39	6.55e-7	Monocyte count;
PAAD	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-7.42	-0.52	7.6e-12	IgG glycosylation;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-1.2	-9.93	-0.63	3.18e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs10483554	0.671	rs2816741	chr14:49811002	A/T	cg24879595	chr14:50359859	ARF6	-0.57	-4.42	-0.34	1.86e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.7	7.91	0.54	4.88e-13	Educational attainment;
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.51	5.4	0.4	2.47e-7	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9463078	0.809	rs57020561	chr6:44862734	T/C	cg25276700	chr6:44698697	NA	-0.49	-5.65	-0.42	7.71e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24432295	chr17:70101836	NA	-0.68	-6.86	-0.49	1.63e-10	Obesity-related traits;
PAAD	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg23587288	chr2:27483067	SLC30A3	-0.65	-6.07	-0.44	1e-8	Blood metabolite levels;
PAAD	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg05528293	chr18:74961138	GALR1	0.61	5.08	0.38	1.1e-6	Obesity-related traits;
PAAD	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg15192750	chr16:69999425	NA	0.73	5.65	0.42	7.71e-8	IgE levels;
PAAD	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.71	6.45	0.46	1.42e-9	Body mass index;
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg14393609	chr7:65229607	NA	-0.67	-7.43	-0.52	7.49e-12	Aortic root size;
PAAD	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.59	-4.88	-0.37	2.71e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.1	-0.38	1.02e-6	Asthma;
PAAD	trans	rs61677309	1.000	rs4938494	chr11:118150735	G/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.82	-9.69	-0.62	1.38e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6076065	0.692	rs6083111	chr20:23374667	A/G	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.63	6.08	0.44	9.11e-9	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg24330906	chr2:85765176	MAT2A	0.44	4.45	0.34	1.65e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.8	10.4	0.64	1.8e-19	Vitiligo;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07744562	chr6:90539506	CASP8AP2	0.48	5.23	0.39	5.42e-7	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01585852	chr22:24235823	MIF	-0.45	-4.87	-0.37	2.73e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg17674042	chr6:34482479	PACSIN1	-1.25	-7.38	-0.51	9.39e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.83	-6.82	-0.48	2.05e-10	Schizophrenia;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-4.43	-0.34	1.82e-5	Lung cancer in ever smokers;
PAAD	cis	rs9463078	0.585	rs1284961	chr6:45172621	T/C	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.74e-19	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24593630	chr1:26496180	ZNF593	-0.69	-7.26	-0.51	1.82e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg07099767	chr17:78039528	CCDC40	0.52	5.03	0.38	1.37e-6	Yeast infection;
PAAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.59	-6.94	-0.49	1.04e-10	Dementia with Lewy bodies;
PAAD	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.39	0.4	2.6e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg24220031	chr2:73402428	NA	-0.29	-4.35	-0.33	2.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7786877	1.000	rs7786877	chr7:100214015	A/G	cg16850897	chr7:100343110	ZAN	-0.55	-4.87	-0.37	2.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.46	-0.34	1.58e-5	Glomerular filtration rate;
PAAD	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg11518657	chr1:67396239	MIER1	0.68	5.11	0.38	9.43e-7	Lymphocyte percentage of white cells;
PAAD	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.32	-0.51	1.33e-11	Neuroticism;
PAAD	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.54	-5.0	-0.38	1.56e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg26205652	chr12:48591994	NA	0.78	7.04	0.5	6.33e-11	Longevity (90 years and older);
PAAD	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.54	-4.72	-0.36	5.4e-6	Facial morphology (factor 19);
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-5.9	-0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.44	-4.36	-0.33	2.37e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.58	-4.85	-0.37	2.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.9	8.79	0.58	3.07e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.66	-6.44	-0.46	1.49e-9	Body mass index;
PAAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.97	12.41	0.71	7.1e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.48	-4.53	-0.34	1.2e-5	Endometrial cancer;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.62	6.48	0.47	1.18e-9	Resting heart rate;
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg12705353	chr12:122356852	WDR66	0.51	5.04	0.38	1.31e-6	Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.53	5.8	0.43	3.79e-8	Obesity-related traits;
PAAD	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.74	7.41	0.52	8.28e-12	Alcohol dependence;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.48	6.19	0.45	5.39e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.56	-5.74	-0.42	4.9e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.62	-6.75	-0.48	2.87e-10	Cognitive function;
PAAD	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs6663390	0.510	rs2267897	chr1:208075378	C/T	cg00387621	chr1:208086895	NA	0.75	4.41	0.34	1.94e-5	Facial morphology (factor 18);
PAAD	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06782748	chr10:35416372	CREM	0.58	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.66	6.99	0.49	8.11e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs941408	0.964	rs1736195	chr19:2786557	C/T	cg06609049	chr19:2785107	THOP1	0.97	11.32	0.68	6.3e-22	Total cholesterol levels;
PAAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.52	-6.07	-0.44	9.71e-9	Blood pressure (smoking interaction);
PAAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23544223	chr18:12777786	NA	-0.7	-5.97	-0.44	1.59e-8	Inflammatory skin disease;
PAAD	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-8.38	-0.56	3.24e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.47	4.78	0.36	4.17e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs3112530	0.591	rs2560245	chr5:152715538	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.75	8.02	0.55	2.65e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	7.21	0.5	2.52e-11	Leprosy;
PAAD	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.48	4.43	0.34	1.76e-5	Red blood cell count;
PAAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg23947450	chr7:900037	UNC84A	-0.52	-4.32	-0.33	2.76e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.39	-0.46	1.94e-9	Retinal vascular caliber;
PAAD	cis	rs943466	0.793	rs59137082	chr6:33732365	C/T	cg04704449	chr6:33738291	NA	-0.45	-4.52	-0.34	1.22e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg10518543	chr12:38710700	ALG10B	0.52	5.01	0.38	1.51e-6	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.07	14.43	0.76	2.86e-30	Testicular germ cell tumor;
PAAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.59	-7.93	-0.54	4.47e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.62	6.86	0.49	1.64e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4450131	0.522	rs61870535	chr10:126382431	G/C	cg20435097	chr10:126320824	FAM53B	0.47	4.54	0.35	1.15e-5	White blood cell count (basophil);
PAAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg11802864	chr11:65308245	LTBP3	0.47	4.78	0.36	4.14e-6	Bone mineral density;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26752657	chr1:75199075	CRYZ;TYW3	0.57	5.48	0.41	1.72e-7	Resistin levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09947881	chr4:178363729	AGA	-0.63	-7.46	-0.52	6.35e-12	Body fat percentage;
PAAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg01306824	chr17:77834118	NA	0.58	4.43	0.34	1.77e-5	Electroencephalogram traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01243992	chr20:31378276	DNMT3B	-0.56	-6.35	-0.46	2.34e-9	Monocyte percentage of white cells;
PAAD	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.96	0.44	1.72e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	6.76	0.48	2.79e-10	Renal function-related traits (BUN);
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg19337854	chr7:99768885	GPC2	0.53	4.98	0.37	1.71e-6	Platelet count;
PAAD	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6565180	1.000	rs68051857	chr16:30360011	A/G	cg05085585	chr16:30420623	ZNF771	0.44	4.4	0.34	2.02e-5	Tonsillectomy;
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg00277334	chr10:82204260	NA	-0.64	-6.7	-0.48	3.83e-10	Post bronchodilator FEV1;
PAAD	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.56	5.25	0.39	5.12e-7	Cognitive test performance;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02429656	chr12:26275311	BHLHE41	-0.8	-6.85	-0.49	1.71e-10	Neuroticism;
PAAD	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg02421172	chr7:1938701	MAD1L1	0.61	4.3	0.33	2.99e-5	Bipolar disorder;
PAAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.46	4.36	0.33	2.42e-5	Menopause (age at onset);
PAAD	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	4.91	0.37	2.33e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08618113	chr15:41523882	CHP;EXD1	0.61	6.56	0.47	8.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.72	7.69	0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	1.01	11.63	0.69	8.91e-23	Multiple myeloma;
PAAD	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg18833306	chr6:118973337	C6orf204	0.43	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.39	4.76	0.36	4.4e-6	Blood pressure;
PAAD	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg14709524	chr16:89940631	TCF25	1.01	4.73	0.36	5.1e-6	Skin colour saturation;
PAAD	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.96	-6.41	-0.46	1.76e-9	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	5.09	0.38	1.06e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.21e-8	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.38	-0.33	2.23e-5	Aortic root size;
PAAD	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg12615879	chr12:58013172	SLC26A10	0.45	4.82	0.36	3.52e-6	Multiple sclerosis;
PAAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14895029	chr7:2775587	GNA12	-0.47	-4.84	-0.37	3.13e-6	Height;
PAAD	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.99	11.68	0.69	6.82e-23	Bone mineral density;
PAAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.63	5.6	0.41	9.67e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4668356	0.881	rs73017262	chr2:172031464	C/T	cg13882835	chr2:172017928	TLK1	0.93	4.52	0.34	1.23e-5	Cognitive performance;
PAAD	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.67	-6.87	-0.49	1.58e-10	Body mass index;
PAAD	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg13010199	chr12:38710504	ALG10B	0.58	5.08	0.38	1.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs2075671	0.818	rs10953302	chr7:100365567	C/T	cg16850897	chr7:100343110	ZAN	-0.55	-4.4	-0.34	2.05e-5	Other erythrocyte phenotypes;
PAAD	cis	rs329674	0.516	rs329650	chr11:133765897	C/T	cg06766960	chr11:133703094	NA	-0.7	-4.58	-0.35	9.71e-6	Bipolar disorder;
PAAD	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.8	-9.04	-0.59	6.94e-16	Colorectal cancer;
PAAD	cis	rs10886094	0.922	rs7909732	chr10:119263864	A/G	cg09660043	chr10:118395444	PNLIPRP2	-0.43	-4.27	-0.33	3.49e-5	Photic sneeze reflex;
PAAD	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-8.33	-0.56	4.53e-14	Bladder cancer;
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.88	-0.37	2.63e-6	Primary sclerosing cholangitis;
PAAD	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.76	-8.06	-0.55	2.14e-13	Menarche (age at onset);
PAAD	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.52	5.1	0.38	9.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs427941	1.000	rs423452	chr7:101848790	G/A	cg06721601	chr7:101762633	CUX1	-0.42	-4.31	-0.33	2.91e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg19413350	chr8:57351067	NA	-0.48	-4.57	-0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.76	8.73	0.58	4.14e-15	Total body bone mineral density;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.87	10.84	0.66	1.25e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7714584	1.000	rs73284126	chr5:150261307	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.71	-8.1	-0.55	1.71e-13	White blood cell count (basophil);
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.64	-6.81	-0.48	2.14e-10	Longevity;
PAAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs11966931	1.000	rs17589215	chr6:108147664	C/T	cg10566610	chr6:108093680	SCML4	0.47	4.39	0.34	2.15e-5	Neutrophil percentage of white cells;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	1.1	9.82	0.62	6.23e-18	Orofacial clefts;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg00738919	chr7:1100172	C7orf50	0.67	5.06	0.38	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.46	-7.37	-0.51	1.04e-11	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	6.11	0.44	8.19e-9	Alzheimer's disease (late onset);
PAAD	cis	rs89107	0.641	rs431115	chr6:118612615	C/T	cg18833306	chr6:118973337	C6orf204	0.48	5.65	0.42	7.71e-8	Cardiac structure and function;
PAAD	cis	rs8049634	0.720	rs11864916	chr16:84228305	C/G	cg26466773	chr16:84211947	TAF1C	0.55	5.09	0.38	1.04e-6	Small cell lung carcinoma;
PAAD	cis	rs2061333	0.894	rs2284981	chr19:44633558	G/C	cg18700516	chr19:44507157	ZNF230	-0.65	-4.83	-0.36	3.27e-6	Alzheimer's disease;
PAAD	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06634786	chr22:41940651	POLR3H	-0.64	-4.45	-0.34	1.67e-5	Vitiligo;
PAAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.61	6.16	0.45	6.32e-9	Longevity;
PAAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg03808351	chr9:123631620	PHF19	0.47	5.15	0.39	8.09e-7	Rheumatoid arthritis;
PAAD	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg02404636	chr22:31891804	SFI1	0.49	4.89	0.37	2.5e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg05144285	chr7:158935647	VIPR2	-0.53	-4.66	-0.35	6.92e-6	Height;
PAAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.81	-10.29	-0.64	3.58e-19	Height;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-4.3	-0.33	3e-5	Resting heart rate;
PAAD	cis	rs1042026	0.848	rs7669776	chr4:100177342	G/A	cg21548116	chr4:100009993	ADH5	-0.49	-4.29	-0.33	3.21e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.73	0.62	1.06e-17	Cognitive function;
PAAD	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.65	6.99	0.49	7.98e-11	Testicular germ cell tumor;
PAAD	cis	rs6496932	0.874	rs2003294	chr15:85817372	A/G	cg19183879	chr15:85880815	NA	0.51	4.42	0.34	1.84e-5	Central corneal thickness;Corneal structure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06538757	chr5:177631493	HNRNPAB	0.62	7.18	0.5	2.94e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs528301	0.868	rs518853	chr2:45141218	A/G	cg15393275	chr2:45165193	NA	0.52	5.61	0.41	9.25e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg06307176	chr5:131281290	NA	-0.53	-4.61	-0.35	8.43e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.66	5.0	0.38	1.54e-6	Hip geometry;
PAAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs8040855	0.627	rs2304418	chr15:85640983	T/C	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11614333	0.839	rs725444	chr12:15029443	C/G	cg00431549	chr12:15039025	MGP	-0.36	-4.3	-0.33	3.03e-5	Hand grip strength;
PAAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.82	-7.63	-0.53	2.35e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14983362	chr11:118901610	SLC37A4	0.66	6.91	0.49	1.23e-10	Myopia (pathological);
PAAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg19337854	chr7:99768885	GPC2	0.54	5.03	0.38	1.4e-6	Platelet count;
PAAD	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.13	10.73	0.66	2.42e-20	Lymphocyte percentage of white cells;
PAAD	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.44	0.46	1.51e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.24	-0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs1190596	0.525	rs4601978	chr14:102751077	C/T	cg23904247	chr14:102554826	HSP90AA1	0.43	4.91	0.37	2.34e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.83	8.8	0.58	2.87e-15	Itch intensity from mosquito bite;
PAAD	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg22532475	chr10:104410764	TRIM8	0.41	4.83	0.36	3.32e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs901683	1.000	rs71494790	chr10:45972611	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.37	0.4	2.92e-7	Breast cancer;
PAAD	cis	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.94e-7	HDL cholesterol;
PAAD	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.59	7.89	0.54	5.42e-13	Crohn's disease;
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.43	4.49	0.34	1.42e-5	Caffeine consumption;
PAAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs2790216	1.000	rs2790185	chr10:60041840	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9649465	1.000	rs3807640	chr7:123338713	G/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	cis	rs7084921	0.578	rs7474935	chr10:101875936	G/C	cg04359915	chr10:101825029	CPN1	-0.34	-5.21	-0.39	6.18e-7	Bone mineral density;
PAAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.75	-4.47	-0.34	1.53e-5	Tuberculosis;
PAAD	cis	rs527409	0.677	rs490671	chr1:58749602	C/G	cg26345888	chr1:58716257	DAB1	-0.66	-4.48	-0.34	1.46e-5	Kawasaki disease;
PAAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-8.26	-0.56	6.47e-14	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.59	0.35	9.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6995541	0.737	rs17152576	chr8:10683988	C/T	cg14855657	chr8:10587604	SOX7	0.46	4.26	0.33	3.62e-5	Triglyceride levels;
PAAD	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.75	9.19	0.6	2.78e-16	Alcohol dependence;
PAAD	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.69	-6.37	-0.46	2.13e-9	Mean corpuscular volume;
PAAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.65	7.45	0.52	6.5e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg05294307	chr14:35346193	BAZ1A	-0.54	-5.26	-0.39	4.82e-7	Psoriasis;
PAAD	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.79	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.93	-7.83	-0.54	7.7e-13	Dupuytren's disease;
PAAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.43	-4.55	-0.35	1.07e-5	Type 2 diabetes;
PAAD	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-7.65	-0.53	2.17e-12	Bladder cancer;
PAAD	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.62	6.68	0.48	4.31e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-7.27	-0.51	1.73e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.55	-5.78	-0.42	4.02e-8	Metabolic syndrome;
PAAD	cis	rs12580194	0.593	rs11832308	chr12:55755506	C/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.35	0.33	2.52e-5	Cancer;
PAAD	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	6.52	0.47	9.75e-10	Colorectal cancer;
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Body mass index;
PAAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.47	-4.63	-0.35	7.88e-6	Cancer;
PAAD	cis	rs501120	1.000	rs634963	chr10:44760033	T/C	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	5.01e-14	Prudent dietary pattern;
PAAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.61	7.95	0.54	3.84e-13	Renal cell carcinoma;
PAAD	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg04117972	chr1:227635322	NA	0.61	4.27	0.33	3.41e-5	Major depressive disorder;
PAAD	cis	rs1957429	0.614	rs78603758	chr14:65396648	C/G	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.79	9.15	0.6	3.43e-16	Blood metabolite ratios;
PAAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg14346243	chr4:90757452	SNCA	-0.51	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.68	-0.35	6.42e-6	Cognitive function;
PAAD	cis	rs72772787	1.000	rs72761021	chr1:248012975	T/A	cg00785941	chr1:248100591	OR2L13	0.44	4.39	0.34	2.11e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7849585	1.000	rs12338076	chr9:139121740	A/C	cg13435263	chr9:139143522	NA	0.37	4.38	0.33	2.21e-5	Height;
PAAD	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10501293	0.917	rs10768914	chr11:43102263	G/A	cg03447554	chr11:43094025	NA	-0.48	-4.86	-0.37	2.94e-6	Cognitive performance;
PAAD	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-0.97	-9.5	-0.61	4.22e-17	Platelet distribution width;
PAAD	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	0.58	6.42	0.46	1.64e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg19760965	chr3:194868843	C3orf21	0.45	4.74	0.36	4.96e-6	Non-small cell lung cancer;
PAAD	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.63	-7.21	-0.5	2.47e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs76866386	0.786	rs9753033	chr2:44084600	A/T	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.75	-4.64	-0.35	7.52e-6	Cholesterol, total;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00049323	chr5:472564	LOC25845	0.42	4.93	0.37	2.14e-6	Cystic fibrosis severity;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-5.36	-0.4	3.02e-7	Obesity (extreme);
PAAD	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg01620082	chr3:125678407	NA	1.39	8.86	0.58	1.95e-15	Depression;
PAAD	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-6.86	-0.49	1.64e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs7567389	0.710	rs72848618	chr2:128135325	A/C	cg09760422	chr2:128146352	NA	0.39	6.02	0.44	1.29e-8	Self-rated health;
PAAD	cis	rs939584	1.000	rs6711254	chr2:624210	G/A	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg24881330	chr22:46731750	TRMU	1.17	6.4	0.46	1.85e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.85e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2236267	0.518	rs12878664	chr14:88549799	G/T	cg18078958	chr14:88630771	NA	0.49	6.19	0.45	5.23e-9	Food antigen IgG levels;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg06521852	chr22:38141419	TRIOBP	0.44	4.66	0.35	6.98e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17737263	chr12:64537067	SRGAP1	-0.66	-6.46	-0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs757978	1.000	rs73116394	chr2:242367915	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.77	-4.67	-0.35	6.62e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs10768122	0.966	rs10768118	chr11:35267855	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.34	-0.33	2.59e-5	Vitiligo;
PAAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.71	-6.96	-0.49	9.77e-11	Plateletcrit;Platelet count;
PAAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	5.36	0.4	3.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg09659197	chr4:152720779	NA	-0.45	-5.97	-0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg03186972	chr10:5931880	ANKRD16;FBXO18	0.6	6.47	0.46	1.3e-9	Iris heterochromicity;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04206329	chr16:30597253	ZNF785	0.59	6.62	0.47	5.78e-10	Metabolite levels  (X-11787);
PAAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07648498	chr16:89883185	FANCA	0.68	6.84	0.49	1.77e-10	Vitiligo;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.75	0.36	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg00149659	chr3:10157352	C3orf10	0.86	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg17178900	chr1:205818956	PM20D1	0.64	6.46	0.46	1.35e-9	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.79	0.43	3.88e-8	Schizophrenia;
PAAD	cis	rs950037	0.710	rs7554456	chr1:89344649	C/T	cg13109106	chr1:89333529	GTF2B	0.5	4.77	0.36	4.28e-6	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg14440974	chr22:39074834	NA	-0.58	-6.75	-0.48	2.89e-10	Menopause (age at onset);
PAAD	cis	rs77688320	1.000	rs78053840	chr2:202367568	G/T	cg02738983	chr2:202315807	TRAK2;STRADB	-0.61	-4.38	-0.33	2.17e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22633769	chr20:60982531	CABLES2	-0.49	-4.76	-0.36	4.47e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.14	15.88	0.79	4.24e-34	Exhaled nitric oxide output;
PAAD	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.85	10.0	0.63	2.04e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.28	-0.45	3.47e-9	Menarche (age at onset);
PAAD	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg26571870	chr16:85723150	GINS2	-0.47	-5.28	-0.39	4.31e-7	Platelet distribution width;
PAAD	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	10.44	0.65	1.41e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.45	-0.34	1.68e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg08601574	chr20:25228251	PYGB	0.53	5.3	0.39	4.04e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg02569823	chr6:5851330	NA	0.63	6.65	0.47	4.84e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4704187	0.687	rs4704196	chr5:74537606	A/G	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs2645694	1.000	rs2645694	chr4:77833947	C/T	cg06046430	chr4:77819534	ANKRD56	0.81	8.87	0.58	1.85e-15	Emphysema distribution in smoking;
PAAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.15	0.55	1.22e-13	Schizophrenia;
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg06632027	chr4:90757378	SNCA	-0.61	-5.56	-0.41	1.19e-7	Neuroticism;
PAAD	cis	rs9463078	0.546	rs969211	chr6:45022378	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-10.49	-0.65	1.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs76917914	0.820	rs7034147	chr9:100821691	T/G	cg03040243	chr9:100819229	NANS	0.59	4.8	0.36	3.77e-6	Immature fraction of reticulocytes;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.47	-4.56	-0.35	1.03e-5	Iron status biomarkers;
PAAD	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg15208524	chr1:10270712	KIF1B	0.48	4.34	0.33	2.6e-5	Hepatocellular carcinoma;
PAAD	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	1.17	17.06	0.81	4e-37	Gut microbiome composition (winter);
PAAD	cis	rs28489187	0.683	rs11161607	chr1:85855855	T/C	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.64	0.47	5.34e-10	IgG glycosylation;
PAAD	cis	rs6088813	1.000	rs6060401	chr20:34005214	C/T	cg14752227	chr20:34000481	UQCC	-0.51	-5.18	-0.39	6.79e-7	Height;
PAAD	cis	rs3809060	0.959	rs2301254	chr11:32457675	A/G	cg27259320	chr11:32460587	WIT1	0.36	4.58	0.35	9.81e-6	Inguinal hernia;
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs62045844	0.510	rs7201122	chr16:89167140	G/C	cg03605463	chr16:89740564	NA	-0.92	-4.83	-0.37	3.23e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.7	6.06	0.44	1.03e-8	Radiation response;
PAAD	cis	rs662064	0.748	rs2506892	chr1:10598216	G/A	cg17425144	chr1:10567563	PEX14	-0.39	-4.31	-0.33	2.87e-5	Asthma;
PAAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg06521852	chr22:38141419	TRIOBP	0.41	4.33	0.33	2.74e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.81	9.29	0.6	1.54e-16	Caffeine consumption;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16087267	chr5:32313494	MTMR12	0.74	6.79	0.48	2.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09460712	chr2:1793435	MYT1L	-0.61	-6.76	-0.48	2.82e-10	Obesity-related traits;
PAAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	7.95	0.54	4.02e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs76866386	1.000	rs75331444	chr2:44069772	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.77	-4.92	-0.37	2.22e-6	Cholesterol, total;
PAAD	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.84	-9.59	-0.61	2.45e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	4.43	0.34	1.77e-5	Thyroid stimulating hormone;
PAAD	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	5.88	0.43	2.46e-8	Schizophrenia;
PAAD	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg21479132	chr6:26055353	NA	0.92	5.83	0.43	3.28e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9462027	0.539	rs2814963	chr6:34708908	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.3	-0.39	4.02e-7	Systemic lupus erythematosus;
PAAD	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.34	-0.33	2.62e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.47	-7.15	-0.5	3.4e-11	Cutaneous nevi;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26778807	chr12:118498675	WSB2	0.59	6.42	0.46	1.62e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.65	6.37	0.46	2.1e-9	Blood metabolite levels;
PAAD	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.64	6.03	0.44	1.21e-8	Coronary artery disease;
PAAD	cis	rs8105895	0.935	rs8103518	chr19:22246952	G/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs8077577	0.895	rs1563373	chr17:18114228	G/A	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs11203032	1.000	rs17117124	chr10:90963997	C/G	cg16672925	chr10:90967113	CH25H	0.75	6.01	0.44	1.29e-8	Heart failure;
PAAD	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg25753631	chr6:25732923	NA	-0.4	-4.37	-0.33	2.29e-5	Iron status biomarkers;
PAAD	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg16576597	chr16:28551801	NUPR1	0.68	7.7	0.53	1.57e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7077446	0.733	rs4919606	chr10:103743852	C/G	cg19008088	chr10:102890038	TLX1;TLX1NB	-0.48	-4.55	-0.35	1.09e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.92	-8.03	-0.55	2.49e-13	Vitiligo;
PAAD	cis	rs3812111	0.641	rs1547030	chr6:116418158	G/A	cg05304507	chr6:116381966	FRK	-0.28	-5.0	-0.38	1.55e-6	Age-related macular degeneration;
PAAD	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg22517653	chr1:2918612	NA	-0.63	-5.17	-0.39	7.13e-7	Plateletcrit;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg08677398	chr8:58056175	NA	0.6	4.32	0.33	2.83e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg16928487	chr17:17741425	SREBF1	0.38	5.04	0.38	1.32e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27553231	chr19:17797533	UNC13A	0.67	6.99	0.49	8.25e-11	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18946373	chr6:155582926	TFB1M	-0.7	-6.93	-0.49	1.09e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27020941	chr19:10679777	CDKN2D	0.66	6.47	0.46	1.24e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.47	-0.41	1.85e-7	Lung cancer;
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.37	0.4	2.94e-7	Menarche (age at onset);
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg21237687	chr17:6899380	ALOX12	0.58	5.89	0.43	2.35e-8	Tonsillectomy;
PAAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.7	-6.21	-0.45	4.78e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.89	8.94	0.59	1.22e-15	Corneal astigmatism;
PAAD	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg23254163	chr1:152506842	NA	0.49	4.75	0.36	4.62e-6	Hair morphology;
PAAD	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.59	-5.28	-0.39	4.38e-7	Monocyte count;
PAAD	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg05347473	chr6:146136440	FBXO30	0.53	5.09	0.38	1.03e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.91	7.74	0.53	1.27e-12	Alzheimer's disease;
PAAD	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.69	6.95	0.49	1.01e-10	Retinal vascular caliber;
PAAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg10556349	chr10:835070	NA	0.69	5.25	0.39	5.13e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.15	-0.39	7.83e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.9	11.32	0.68	6.12e-22	Metabolic syndrome;
PAAD	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.7	-4.95	-0.37	1.98e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.44	4.85	0.37	2.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.74	5.41	0.4	2.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.83	-5.16	-0.39	7.57e-7	Response to metformin (IC50);
PAAD	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.39	4.45	0.34	1.66e-5	High light scatter reticulocyte count;
PAAD	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg02376097	chr19:46275166	DMPK	0.66	8.19	0.55	9.98e-14	Coronary artery disease;
PAAD	cis	rs8181588	1.000	rs8181588	chr11:2831541	A/G	cg10890346	chr11:2207660	NA	0.61	4.26	0.33	3.55e-5	Type 2 diabetes;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.73	0.48	3.33e-10	Lung cancer in ever smokers;
PAAD	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg01489032	chr8:143877656	NA	0.45	4.76	0.36	4.5e-6	Urinary tract infection frequency;
PAAD	cis	rs4144743	1.000	rs7224990	chr17:45326878	C/T	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg08601574	chr20:25228251	PYGB	0.45	4.37	0.33	2.26e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	4.73	0.36	5.04e-6	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg13798780	chr7:105162888	PUS7	0.62	4.48	0.34	1.45e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs16975963	0.644	rs11083427	chr19:38074152	G/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg12215294	chr3:40350768	EIF1B	0.44	4.28	0.33	3.27e-5	Renal cell carcinoma;
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg10729496	chr3:10149963	C3orf24	-0.85	-6.44	-0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-5.1	-0.38	9.89e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.935	rs398964	chr19:44413884	G/A	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs258892	0.895	rs10070210	chr5:72046042	A/G	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	trans	rs459193	0.529	rs245142	chr5:55810449	G/A	cg17928895	chr20:57583091	CTSZ	-0.44	-6.43	-0.46	1.52e-9	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.22	19.46	0.84	4.23e-43	Gut microbiome composition (winter);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26606064	chr11:125439070	EI24	-0.67	-6.44	-0.46	1.51e-9	Lung cancer in ever smokers;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	9.58	0.61	2.68e-17	Lymphocyte counts;
PAAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08677398	chr8:58056175	NA	0.7	4.89	0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1451882	0.748	rs12546596	chr8:1052672	G/T	cg07395941	chr8:1078200	NA	0.61	4.56	0.35	1.05e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06514371	chr3:152880982	RAP2B	0.64	6.59	0.47	6.88e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.79	9.78	0.62	8.13e-18	Vitiligo;
PAAD	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.42	-5.09	-0.38	1.04e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.87e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12432203	1.000	rs72622425	chr14:51731227	A/G	cg23942311	chr14:51606299	NA	-0.69	-4.65	-0.35	7.08e-6	Cancer;
PAAD	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.48	-4.39	-0.34	2.1e-5	Tuberculosis;
PAAD	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs3771514	0.502	rs9284774	chr2:70670873	C/A	cg18150120	chr2:71134936	VAX2	-0.4	-4.68	-0.35	6.39e-6	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7627468	0.770	rs2134221	chr3:121962246	A/G	cg17240004	chr3:121949083	CASR	-0.49	-4.62	-0.35	7.96e-6	Kidney stones;
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-8.97	-0.59	1e-15	Age at first birth;
PAAD	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg04607699	chr11:48328132	OR4S1	0.52	5.0	0.38	1.54e-6	Migraine - clinic-based;
PAAD	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.04	0.38	1.3e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.58	0.35	9.56e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7301826	0.651	rs7956851	chr12:131319099	C/T	cg11011512	chr12:131303247	STX2	0.43	4.49	0.34	1.39e-5	Plasma plasminogen activator levels;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg14132834	chr19:41945861	ATP5SL	0.53	5.06	0.38	1.2e-6	Height;
PAAD	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg00031303	chr3:195681400	NA	0.81	7.97	0.54	3.43e-13	Pancreatic cancer;
PAAD	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.73	8.49	0.57	1.74e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7638995	0.774	rs2872690	chr3:69171803	T/C	cg26574240	chr3:69171822	LMOD3	-0.74	-5.77	-0.42	4.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg19847866	chr10:1019161	NA	-0.59	-4.49	-0.34	1.4e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.6	5.84	0.43	3.1e-8	Blood metabolite levels;
PAAD	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.35	-4.36	-0.33	2.41e-5	Inflammatory bowel disease;
PAAD	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-5.06	-0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08645402	chr16:4508243	NA	0.59	5.52	0.41	1.4e-7	Schizophrenia;
PAAD	cis	rs7594192	0.744	rs1014226	chr2:199412464	A/C	cg03163783	chr2:200326591	SATB2	0.34	4.66	0.35	6.73e-6	Educational attainment;
PAAD	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.61	-4.98	-0.37	1.71e-6	Osteoarthritis;
PAAD	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.81	5.68	0.42	6.68e-8	Blood protein levels;
PAAD	cis	rs4740619	0.839	rs4740622	chr9:15665602	G/C	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.11e-5	Body mass index;
PAAD	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00864171	chr11:67383662	NA	-0.52	-5.24	-0.39	5.4e-7	Mean corpuscular volume;
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg19337854	chr7:99768885	GPC2	-0.41	-4.4	-0.34	2.05e-5	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs3733418	0.858	rs11100583	chr4:165877645	C/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.62	-0.41	8.87e-8	Obesity-related traits;
PAAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-4.63	-0.35	7.83e-6	Coronary artery disease;
PAAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.82	9.55	0.61	3.25e-17	Schizophrenia;
PAAD	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.57	5.43	0.4	2.2e-7	Educational attainment;
PAAD	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.69	-7.86	-0.54	6.37e-13	White blood cell count (basophil);
PAAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14180030	chr9:123475675	MEGF9	-0.41	-4.55	-0.35	1.08e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg17105886	chr17:28927953	LRRC37B2	-0.71	-4.78	-0.36	4.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg09677638	chr11:61582810	MIR1908;FADS1	0.56	4.94	0.37	2.07e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs28489187	0.706	rs1498375	chr1:85787323	T/A	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1510510	0.757	rs907109	chr2:239566309	C/T	cg27144223	chr2:240114898	HDAC4	0.54	4.43	0.34	1.82e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-4.66	-0.35	6.74e-6	Facial morphology (factor 19);
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.07	8.64	0.57	7.05e-15	Corneal structure;
PAAD	cis	rs6076065	0.723	rs2275787	chr20:23338486	A/G	cg11657817	chr20:23433608	CST11	0.51	5.25	0.39	4.93e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs8062405	0.789	rs28676837	chr16:28627063	C/T	cg16576597	chr16:28551801	NUPR1	-0.71	-7.33	-0.51	1.28e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.16	0.5	3.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.71	6.27	0.45	3.51e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06324021	chr1:156770381	PRCC	-0.64	-6.73	-0.48	3.25e-10	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.59	-0.35	9.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg23460851	chr4:1604456	NA	-0.42	-4.26	-0.33	3.6e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1144333	0.655	rs5745465	chr1:76346832	A/G	cg22875332	chr1:76189707	ACADM	0.78	4.79	0.36	4e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs17095355	0.605	rs58154613	chr10:111633966	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.49	-0.34	1.41e-5	Biliary atresia;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg09737314	chr17:6899359	ALOX12	-0.5	-5.24	-0.39	5.16e-7	Tonsillectomy;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg15841412	chr13:111365552	ING1	0.52	4.32	0.33	2.76e-5	Coronary artery disease;
PAAD	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.86	6.12	0.44	7.42e-9	Initial pursuit acceleration;
PAAD	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.01	0.44	1.33e-8	Rheumatoid arthritis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17520314	chr17:79604207	NPLOC4	-0.59	-7.07	-0.5	5.14e-11	Body fat percentage;
PAAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg09324608	chr17:30823087	MYO1D	0.48	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.48	4.84	0.37	3.22e-6	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.64	-7.02	-0.49	6.94e-11	Diastolic blood pressure;
PAAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.49	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.51	6.62	0.47	5.76e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.96	-7.95	-0.54	3.96e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg08079166	chr15:68083412	MAP2K5	0.52	5.06	0.38	1.18e-6	Restless legs syndrome;
PAAD	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.55e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2964802	0.505	rs1438714	chr5:10811422	G/A	cg14521931	chr5:10832172	NA	-0.48	-4.95	-0.37	1.94e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.7	-8.2	-0.55	9.45e-14	Lung cancer;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs3736757	1.000	rs9425341	chr1:184659318	T/A	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.76	-8.16	-0.55	1.18e-13	Cognitive function;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13939156	chr17:80058883	NA	0.45	4.94	0.37	2.07e-6	Life satisfaction;
PAAD	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg10072921	chr12:121022843	NA	-0.37	-4.88	-0.37	2.68e-6	High light scatter reticulocyte count;
PAAD	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.46	5.02	0.38	1.42e-6	Diastolic blood pressure;
PAAD	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.92	-12.84	-0.72	5.13e-26	Height;
PAAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.04	0.55	2.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg07617317	chr6:118971624	C6orf204	0.55	4.56	0.35	1.05e-5	Diastolic blood pressure;
PAAD	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg14631576	chr9:95140430	CENPP	-0.6	-5.78	-0.42	4.1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.02	-6.59	-0.47	6.82e-10	Body mass index;
PAAD	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.34	-10.22	-0.64	5.47e-19	Breast cancer;
PAAD	cis	rs55986470	0.670	rs10204157	chr2:239422669	C/G	cg18131467	chr2:239335373	ASB1	-0.59	-4.38	-0.33	2.24e-5	Chronotype;
PAAD	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Bladder cancer;
PAAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.16	17.57	0.82	1.94e-38	Cognitive function;
PAAD	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs6494488	0.500	rs112691501	chr15:64919260	T/C	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs12431939	0.626	rs8015848	chr14:51715021	G/A	cg23942311	chr14:51606299	NA	0.53	4.8	0.36	3.79e-6	Cancer;
PAAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.45	-4.81	-0.36	3.53e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.73	-4.52	-0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05676450	chr17:6459368	PITPNM3	0.58	6.63	0.47	5.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg18850127	chr7:39170497	POU6F2	0.54	7.79	0.53	9.59e-13	IgG glycosylation;
PAAD	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.22	0.55	8.55e-14	Morning vs. evening chronotype;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10009056	chr4:187475841	MTNR1A	-0.6	-6.36	-0.46	2.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.17	-0.39	7.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.54	-0.35	1.13e-5	Depression;
PAAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.63e-6	Renal cell carcinoma;
PAAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg13870426	chr17:30244630	NA	-0.73	-6.54	-0.47	8.87e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.93	12.11	0.7	4.78e-24	Menarche (age at onset);
PAAD	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs16989760	1.000	rs3761430	chr22:31538002	C/T	cg01338084	chr22:32026380	PISD	1.28	7.67	0.53	1.87e-12	Age-related hearing impairment;
PAAD	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs78707713	0.841	rs78677622	chr10:71196698	C/T	cg12610070	chr10:71211762	TSPAN15	-0.57	-5.29	-0.39	4.22e-7	Venous thromboembolism;
PAAD	cis	rs6893807	0.778	rs13162708	chr5:87943345	C/T	cg02225085	chr5:87975992	LOC645323	-0.69	-4.93	-0.37	2.11e-6	Body mass index;
PAAD	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg12458913	chr13:53173898	NA	0.43	4.4	0.34	2.03e-5	Lewy body disease;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg15117754	chr3:10150083	C3orf24	0.65	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.61	-0.41	9.53e-8	Coronary artery disease;
PAAD	cis	rs7119	0.651	rs12902449	chr15:77850926	A/G	cg10437265	chr15:77819839	NA	0.41	4.67	0.35	6.61e-6	Type 2 diabetes;
PAAD	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.05e-6	Diastolic blood pressure;
PAAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00049323	chr5:472564	LOC25845	0.42	4.92	0.37	2.18e-6	Cystic fibrosis severity;
PAAD	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.48	-6.11	-0.44	7.94e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg08677398	chr8:58056175	NA	0.61	4.32	0.33	2.86e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.38	-5.76	-0.42	4.43e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.08	-0.38	1.11e-6	Subjective well-being;
PAAD	cis	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	0.702	rs113019116	chr10:46093939	A/G	cg07567308	chr20:3149320	ProSAPiP1	0.74	6.5	0.47	1.09e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	5.93	0.43	1.99e-8	Total body bone mineral density;
PAAD	cis	rs669446	0.591	rs574736	chr1:44106266	C/T	cg12908607	chr1:44402522	ARTN	-0.41	-4.37	-0.33	2.26e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.92	-0.59	1.39e-15	Total body bone mineral density;
PAAD	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg26174226	chr8:58114915	NA	-0.63	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.61	-6.22	-0.45	4.58e-9	Visceral fat;
PAAD	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.52	5.26	0.39	4.71e-7	Schizophrenia;
PAAD	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.36	-0.4	3.04e-7	Reticulocyte count;
PAAD	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.47	-4.27	-0.33	3.43e-5	Schizophrenia;
PAAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.63	-6.19	-0.45	5.28e-9	DNA methylation (variation);
PAAD	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.77	7.67	0.53	1.94e-12	Resting heart rate;
PAAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.51	-4.59	-0.35	9.28e-6	IgG glycosylation;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg17541715	chr7:1216824	NA	-0.51	-5.75	-0.42	4.81e-8	Longevity;Endometriosis;
PAAD	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg11161011	chr14:65562177	MAX	-0.52	-4.57	-0.35	9.9e-6	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26381592	chr2:190649278	PMS1;ORMDL1	0.64	6.49	0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.45	-0.52	6.46e-12	Neuroticism;
PAAD	cis	rs2916733	0.530	rs2515576	chr8:6313206	C/A	cg02465761	chr8:6735510	DEFB1	-0.47	-4.39	-0.34	2.08e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.54	5.32	0.4	3.67e-7	Systolic blood pressure;
PAAD	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg01631408	chr1:248437212	OR2T33	0.54	5.41	0.4	2.36e-7	Common traits (Other);
PAAD	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.69	5.77	0.42	4.22e-8	Schizophrenia;
PAAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.62	4.38	0.33	2.2e-5	Depression;
PAAD	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	5.21	0.39	6.01e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.16	15.51	0.78	3.92e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.18	-0.6	2.94e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-4.67	-0.35	6.45e-6	Lung cancer;
PAAD	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg23460851	chr4:1604456	NA	-0.42	-4.56	-0.35	1.04e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs3106136	0.681	rs11097422	chr4:95302982	C/G	cg11021082	chr4:95130006	SMARCAD1	0.52	4.9	0.37	2.42e-6	Capecitabine sensitivity;
PAAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.55	6.02	0.44	1.28e-8	Major depressive disorder;
PAAD	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.57	5.47	0.41	1.82e-7	Educational attainment (years of education);
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.44	-4.59	-0.35	9.18e-6	Breast cancer;
PAAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg20673091	chr1:2541236	MMEL1	0.84	10.27	0.64	3.95e-19	Ulcerative colitis;
PAAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.54	-6.58	-0.47	7.23e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-5.66	-0.42	7.23e-8	Breast cancer;
PAAD	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.36	-0.46	2.28e-9	Neuroticism;
PAAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.78	0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg19052272	chr2:3704530	ALLC	-0.53	-6.28	-0.45	3.31e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg00280220	chr17:61926910	NA	-0.43	-4.38	-0.33	2.21e-5	Prudent dietary pattern;
PAAD	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs370915	0.578	rs28627789	chr4:187788774	T/C	cg12892747	chr4:187813459	NA	-0.45	-4.57	-0.35	9.8200000000000008e-06	Gout;
PAAD	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg10915739	chr21:34405733	NA	0.32	4.43	0.34	1.8e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg25566285	chr7:158114605	PTPRN2	-0.81	-7.38	-0.51	9.91e-12	Calcium levels;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg03303774	chr4:1407052	NA	-0.33	-4.26	-0.33	3.64e-5	Obesity-related traits;
PAAD	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg18093559	chr17:18951025	GRAP	0.47	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.83	-0.48	1.89e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3996993	0.809	rs6910581	chr6:52735825	T/C	cg20803780	chr6:52668592	GSTA1	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;
PAAD	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg08632701	chr21:37451849	NA	-0.52	-5.48	-0.41	1.69e-7	Mitral valve prolapse;
PAAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.63	-4.66	-0.35	7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.57	5.89	0.43	2.41e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg08992911	chr2:238395768	MLPH	0.73	5.55	0.41	1.24e-7	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.69	0.36	5.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.5	5.11	0.38	9.34e-7	Glycated hemoglobin levels;
PAAD	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.74	4.87	0.37	2.78e-6	Major depressive disorder;
PAAD	cis	rs34845616	0.551	rs12576074	chr11:133686324	A/G	cg06067394	chr11:133789110	IGSF9B	-0.45	-4.66	-0.35	6.89e-6	Hand grip strength;
PAAD	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg10820045	chr2:198174542	NA	0.5	5.15	0.39	7.92e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg19660806	chr8:588740	NA	-0.64	-4.31	-0.33	2.89e-5	IgG glycosylation;
PAAD	cis	rs3112530	0.688	rs304857	chr5:152718051	C/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.74	-4.65	-0.35	7.15e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg11459648	chr5:138714337	SLC23A1	-0.64	-5.86	-0.43	2.71e-8	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs4740619	0.967	rs7049176	chr9:15677427	T/C	cg14451791	chr9:16040625	NA	-0.38	-4.46	-0.34	1.59e-5	Body mass index;
PAAD	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.75	-10.01	-0.63	1.97e-18	Height;
PAAD	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.92	7.62	0.53	2.6e-12	Cerebrospinal P-tau181p levels;
PAAD	trans	rs61677309	1.000	rs61677309	chr11:118168086	A/T	cg15548380	chr1:19984784	NBL1	-0.61	-6.29	-0.45	3.29e-9	Lung cancer in ever smokers;
PAAD	cis	rs9649465	0.688	rs34967330	chr7:123318560	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25319992	chr2:232119957	ARMC9	-0.58	-7.01	-0.49	7.3e-11	Monocyte percentage of white cells;
PAAD	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-5.55	-0.41	1.22e-7	Colorectal cancer;
PAAD	cis	rs12808519	0.646	rs12361755	chr11:69602646	C/T	cg27032427	chr11:69587568	NA	-0.63	-5.02	-0.38	1.44e-6	Urate levels in overweight individuals;
PAAD	cis	rs4764124	0.557	rs2195199	chr12:14927994	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	5.49	0.41	1.63e-7	Pubertal anthropometrics;
PAAD	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.22	-5.04	-0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.68	-4.82	-0.36	3.5e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.45	5.35	0.4	3.2e-7	Tonsillectomy;
PAAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg09796270	chr17:17721594	SREBF1	-0.49	-5.46	-0.41	1.87e-7	Total body bone mineral density;
PAAD	cis	rs6688613	0.959	rs112416021	chr1:166944745	T/C	cg07049167	chr1:166818506	POGK	0.48	4.73	0.36	4.98e-6	Refractive astigmatism;
PAAD	cis	rs41311933	0.521	rs7465958	chr9:123719335	G/A	cg21241889	chr9:123690658	TRAF1	-0.68	-4.29	-0.33	3.17e-5	Coronary artery disease;
PAAD	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-8.59	-0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.92	6.29	0.45	3.27e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.23	-15.91	-0.79	3.53e-34	Ulcerative colitis;
PAAD	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg11266682	chr4:10021025	SLC2A9	0.51	4.37	0.33	2.3e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg24596788	chr1:163392923	NA	-0.46	-4.59	-0.35	9.26e-6	Motion sickness;
PAAD	cis	rs990171	1.000	rs3860444	chr2:103007623	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.4	0.34	2.01e-5	Lymphocyte counts;
PAAD	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.56	-0.41	1.17e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg15117754	chr3:10150083	C3orf24	0.71	6.18	0.45	5.56e-9	Alzheimer's disease;
PAAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.79	6.9	0.49	1.35e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg24238205	chr11:58912174	FAM111A	-0.49	-4.25	-0.33	3.73e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg01304814	chr3:48885189	PRKAR2A	-0.99	-5.23	-0.39	5.61e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs11871801	1.000	rs12938856	chr17:40570649	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.49	-4.8	-0.36	3.79e-6	Crohn's disease;
PAAD	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.48	-5.67	-0.42	6.93e-8	Graves' disease;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.91e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.3	0.4	3.98e-7	Monocyte percentage of white cells;
PAAD	cis	rs35110281	0.517	rs11701973	chr21:44979671	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.92	-0.37	2.19e-6	Mean corpuscular volume;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01616529	chr11:638424	DRD4	-0.61	-5.94	-0.43	1.82e-8	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs59888335	0.964	rs35267048	chr3:80793056	C/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.57	4.73	0.36	5.15e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.94	12.25	0.7	1.92e-24	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.48	4.4	0.34	2.01e-5	Hypospadias;
PAAD	cis	rs8025118	0.583	rs7173511	chr15:79550410	C/T	cg11862246	chr15:78730200	IREB2	-0.54	-4.49	-0.34	1.41e-5	Cognitive function;
PAAD	cis	rs804280	0.544	rs804276	chr8:11625008	G/A	cg12395012	chr8:11607386	GATA4	-0.65	-8.42	-0.56	2.6e-14	Myopia (pathological);
PAAD	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.67	0.42	7.01e-8	Prudent dietary pattern;
PAAD	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.04	-5.69	-0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.43	-4.63	-0.35	7.63e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11825685	0.887	rs76812821	chr11:134564628	G/A	cg02089395	chr11:134479357	NA	-0.72	-4.54	-0.35	1.15e-5	IgG glycosylation;
PAAD	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.14	16.6	0.8	5.7e-36	Primary sclerosing cholangitis;
PAAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg05342682	chr7:94953680	PON1	-0.52	-4.65	-0.35	7.26e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02607605	chr16:88729149	MGC23284;MVD	-0.66	-6.62	-0.47	5.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10657547	chr5:150632246	GM2A	0.54	6.33	0.46	2.58e-9	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg21479132	chr6:26055353	NA	0.95	6.13	0.45	7.23e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.77	-6.79	-0.48	2.42e-10	Vitiligo;
PAAD	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.56	4.28	0.33	3.27e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.81	-9.39	-0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.4	-4.96	-0.37	1.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.63	6.5	0.47	1.07e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.92	0.59	1.41e-15	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.59	0.52	2.92e-12	Alzheimer's disease;
PAAD	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10439144	chr5:173315308	CPEB4	-0.79	-6.72	-0.48	3.39e-10	Neuroticism;
PAAD	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg14388049	chr10:71211838	TSPAN15	-0.56	-5.61	-0.41	9.26e-8	Venous thromboembolism;
PAAD	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.5	-6.23	-0.45	4.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.96	-13.61	-0.74	4.2e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg23281280	chr6:28129359	ZNF389	0.62	5.06	0.38	1.2e-6	Depression;
PAAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.71	7.92	0.54	4.68e-13	Melanoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18737534	chr17:1800702	RPA1	-0.66	-6.93	-0.49	1.12e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.75	0.42	4.83e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.67	7.63	0.53	2.46e-12	High light scatter reticulocyte count;
PAAD	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg21523528	chr20:32077966	CBFA2T2	0.5	4.25	0.33	3.66e-5	Height;
PAAD	cis	rs2281636	1.000	rs10786569	chr10:101513585	G/A	cg05149213	chr10:101381631	SLC25A28	0.48	4.71	0.36	5.46e-6	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.19	-0.5	2.8e-11	Gut microbiome composition (summer);
PAAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.54	5.81	0.43	3.59e-8	Menopause (age at onset);
PAAD	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.09	10.55	0.65	7.19e-20	Orofacial clefts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14542554	chr14:61122327	NA	0.57	6.77	0.48	2.57e-10	Myopia (pathological);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg00599163	chr2:162100495	NA	0.38	4.75	0.36	4.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg07362569	chr17:61921086	SMARCD2	0.44	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs3857067	1.000	rs2199603	chr4:95016174	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.7	5.97	0.44	1.57e-8	Breast cancer;
PAAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.46	4.46	0.34	1.55e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.74	-6.22	-0.45	4.58e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg13047869	chr3:10149882	C3orf24	0.71	6.25	0.45	3.86e-9	Alzheimer's disease;
PAAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.54	0.35	1.12e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14080254	chr11:46722302	ZNF408;ARHGAP1	-0.73	-6.38	-0.46	1.99e-9	Neuroticism;
PAAD	trans	rs901683	1.000	rs17157880	chr10:46014488	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25436985	chr22:42016998	XRCC6;PPPDE2	-0.63	-6.65	-0.47	5.03e-10	Smoking initiation;
PAAD	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6142102	0.886	rs4911147	chr20:32667607	C/A	cg06115741	chr20:33292138	TP53INP2	0.53	4.41	0.34	1.92e-5	Skin pigmentation;
PAAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.93	11.38	0.68	4.38e-22	Rheumatoid arthritis;
PAAD	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.86	9.78	0.62	7.78e-18	Cognitive function;
PAAD	cis	rs4740619	0.766	rs7034781	chr9:15753528	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.52	-0.34	1.22e-5	Body mass index;
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg15691649	chr6:25882328	NA	0.66	6.17	0.45	6.03e-9	Blood metabolite levels;
PAAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.65	-0.35	7.3e-6	Type 2 diabetes;
PAAD	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg06606381	chr12:133084897	FBRSL1	-1.17	-7.59	-0.52	2.94e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02697246	chr12:117187890	RNFT2	0.66	6.53	0.47	9.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg10978503	chr1:24200527	CNR2	-0.38	-4.28	-0.33	3.32e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9677476	0.587	rs3731779	chr2:232158885	C/T	cg07929768	chr2:232055508	NA	0.41	4.83	0.37	3.24e-6	Food antigen IgG levels;
PAAD	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-4.6	-0.35	8.92e-6	Breast cancer;
PAAD	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.49	-4.91	-0.37	2.37e-6	Mean corpuscular volume;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg18850127	chr7:39170497	POU6F2	0.54	7.93	0.54	4.3e-13	IgG glycosylation;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.3	4.29	0.33	3.12e-5	Asthma;
PAAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.65	-6.48	-0.47	1.2e-9	Urate levels in lean individuals;
PAAD	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.73	-0.42	5.22e-8	Colorectal cancer;
PAAD	cis	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg15676455	chr3:128564943	NA	-0.8	-4.62	-0.35	8.2e-6	Dental caries;
PAAD	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.31	-0.33	2.88e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.81	-8.35	-0.56	3.96e-14	Corneal astigmatism;
PAAD	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg06935464	chr4:38784597	TLR10	0.45	4.33	0.33	2.71e-5	Asthma;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.75	7.28	0.51	1.69e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.86	-10.5	-0.65	9.63e-20	Body mass index;
PAAD	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.15	-0.6	3.59e-16	Mean platelet volume;
PAAD	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs16970672	0.501	rs28607457	chr17:76053160	G/A	cg15618347	chr17:76503643	DNAH17	-0.45	-4.75	-0.36	4.59e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.88	0.37	2.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg04025307	chr7:1156635	C7orf50	0.6	4.33	0.33	2.64e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs5756391	0.568	rs10222232	chr22:37317970	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12395012	chr8:11607386	GATA4	-0.6	-6.69	-0.48	4.08e-10	Myopia (pathological);
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg13444538	chr7:158905317	VIPR2	0.5	4.54	0.35	1.13e-5	Facial morphology (factor 20);
PAAD	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-6.62	-0.47	5.85e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.81	-0.36	3.68e-6	Renal cell carcinoma;
PAAD	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg13263323	chr15:86062960	AKAP13	-0.61	-6.9	-0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg16083429	chr3:49237500	CCDC36	-0.43	-4.46	-0.34	1.59e-5	Parkinson's disease;
PAAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.37	-0.56	3.41e-14	Height;
PAAD	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg13468214	chr4:1046988	NA	-0.52	-5.59	-0.41	1.03e-7	Recombination rate (males);
PAAD	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs6466055	0.516	rs7784126	chr7:104731338	T/A	cg04380332	chr7:105027541	SRPK2	-0.51	-4.98	-0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg02250501	chr15:90694978	NA	-0.46	-4.25	-0.33	3.66e-5	Rheumatoid arthritis;
PAAD	cis	rs4704187	0.687	rs2112874	chr5:74525165	G/A	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs10073892	0.703	rs9327825	chr5:101638179	C/T	cg17280723	chr5:101634495	NA	0.41	4.41	0.34	1.98e-5	Cognitive decline (age-related);
PAAD	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.66	-0.35	6.84e-6	Mean corpuscular volume;
PAAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.56	4.8	0.36	3.82e-6	Fat distribution (HIV);
PAAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25833597	chr17:30823145	MYO1D	0.51	4.95	0.37	1.93e-6	Schizophrenia;
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	6.27	0.45	3.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg10578991	chr7:12443926	VWDE	-0.68	-4.29	-0.33	3.23e-5	Coronary artery disease;
PAAD	cis	rs300774	1.000	rs300772	chr2:117230	C/T	cg23649280	chr2:140451	NA	-0.49	-4.51	-0.34	1.28e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs3106136	0.814	rs10020236	chr4:95277993	A/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.03	0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.54	4.67	0.35	6.57e-6	Red blood cell count;
PAAD	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.73	0.36	4.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs9463078	0.546	rs2186062	chr6:45023732	T/C	cg25276700	chr6:44698697	NA	0.45	5.04	0.38	1.31e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg08222618	chr4:941054	TMEM175	0.81	10.61	0.65	4.9e-20	Sjögren's syndrome;
PAAD	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.98	-7.82	-0.54	8.38e-13	Blood protein levels;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg21479132	chr6:26055353	NA	0.9	5.05	0.38	1.22e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.91	-9.83	-0.62	5.8e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg08390786	chr10:135334061	NA	-0.62	-4.96	-0.37	1.86e-6	Gout;
PAAD	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.72	7.25	0.51	2.02e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-6.67	-0.48	4.58e-10	Prudent dietary pattern;
PAAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg03286735	chr4:906491	GAK	0.32	4.36	0.33	2.34e-5	Systemic sclerosis;
PAAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.91	9.83	0.62	5.95e-18	Corneal astigmatism;
PAAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.6	-4.8	-0.36	3.82e-6	Type 2 diabetes;
PAAD	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.58	-5.67	-0.42	7.08e-8	Personality dimensions;
PAAD	cis	rs59888335	0.929	rs13100828	chr3:80741599	G/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22541911	chr12:51785465	GALNT6	-0.73	-7.59	-0.52	2.92e-12	Smoking initiation;
PAAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-6.32	-0.46	2.7e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06858150	chr19:7977647	MAP2K7	0.57	6.32	0.46	2.79e-9	Body fat percentage;
PAAD	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.77	5.4	0.4	2.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.52	0.41	1.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10899021	0.920	rs12287097	chr11:74332664	A/G	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.58	-5.45	-0.4	1.99e-7	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.77	0.58	3.36e-15	Lung cancer;
PAAD	cis	rs7941600	0.708	rs4537761	chr11:9323353	T/C	cg19415743	chr11:9336845	TMEM41B	0.96	5.89	0.43	2.44e-8	Coronary artery disease;
PAAD	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg27373749	chr11:63775612	MACROD1	0.44	5.03	0.38	1.35e-6	Pulse pressure;
PAAD	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg26874164	chr19:58962979	ZNF324B	0.5	4.7	0.36	5.85e-6	Uric acid clearance;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09519462	chr10:75007181	DNAJC9	-0.6	-6.66	-0.48	4.62e-10	Body fat percentage;
PAAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg26752657	chr1:75199075	CRYZ;TYW3	0.54	5.2	0.39	6.46e-7	Resistin levels;
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.6	-0.35	8.93e-6	Type 2 diabetes;
PAAD	cis	rs7873102	0.654	rs56884355	chr9:38004859	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.0	-0.38	1.58e-6	Brain structure;
PAAD	cis	rs6746082	0.570	rs61671081	chr2:25761103	A/C	cg23192403	chr2:25781496	DTNB	-0.28	-4.31	-0.33	2.95e-5	Multiple myeloma;
PAAD	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-8.07	-0.55	2e-13	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs1468333	0.537	rs4317313	chr5:137699592	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs2290419	0.730	rs75158992	chr11:68944759	A/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.85	-5.74	-0.42	5.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.09	0.55	1.77e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.92	11.88	0.69	1.95e-23	Morning vs. evening chronotype;
PAAD	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg04287289	chr16:89883240	FANCA	0.62	6.93	0.49	1.13e-10	Vitiligo;
PAAD	cis	rs2555155	0.840	rs10839576	chr11:6552107	C/T	cg10208301	chr11:6592745	DNHD1	-0.44	-4.51	-0.34	1.27e-5	DNA methylation (variation);
PAAD	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs35740288	0.770	rs34058174	chr15:86174462	G/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2286379	0.594	rs10848550	chr12:1787240	G/A	cg05227549	chr12:1770782	NA	-0.39	-4.4	-0.34	2.02e-5	Blood pressure (smoking interaction);
PAAD	trans	rs4272720	0.755	rs11813727	chr10:50216449	T/C	cg15329866	chr3:171455826	PLD1	0.78	6.88	0.49	1.49e-10	Platelet count;Plateletcrit;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11614333	0.920	rs4764133	chr12:15064363	A/G	cg00431549	chr12:15039025	MGP	0.36	4.41	0.34	1.98e-5	Hand grip strength;
PAAD	cis	rs2548003	0.518	rs2548006	chr5:28732126	C/T	cg22863700	chr5:28928346	NA	-0.53	-5.15	-0.39	7.87e-7	Hip geometry;
PAAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.28	0.51	1.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.69	5.6	0.41	9.64e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4662592	0.628	rs71420828	chr2:128906797	G/A	cg03222009	chr2:129077232	HS6ST1	-0.5	-4.68	-0.35	6.39e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.77	8.95	0.59	1.18e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.53	-6.6	-0.47	6.61e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35160687	0.644	rs4832272	chr2:86516211	A/G	cg10973622	chr2:86423274	IMMT	-0.45	-4.93	-0.37	2.12e-6	Night sleep phenotypes;
PAAD	trans	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg20686313	chr15:44039057	PDIA3;CATSPER2P1	0.69	6.33	0.46	2.65e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.5	-5.26	-0.39	4.8e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.88	0.43	2.48e-8	Prudent dietary pattern;
PAAD	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.69	-8.23	-0.56	8.02e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	4.89	0.37	2.54e-6	Body mass index;
PAAD	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.13	0.38	8.78e-7	Personality dimensions;
PAAD	cis	rs4605213	0.528	rs11079950	chr17:49332866	A/G	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.37	-4.67	-0.35	6.51e-6	Height;
PAAD	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.39	4.76	0.36	4.39e-6	Colorectal cancer;
PAAD	cis	rs12432203	1.000	rs72622431	chr14:51732854	G/T	cg23942311	chr14:51606299	NA	-0.71	-4.89	-0.37	2.56e-6	Cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21232956	chr9:129677782	RALGPS1	0.58	6.63	0.47	5.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.42e-8	Height;
PAAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.84e-19	Coronary artery disease;
PAAD	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.97	12.65	0.72	1.63e-25	Menopause (age at onset);
PAAD	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg06243866	chr13:111019493	COL4A2	-0.56	-4.96	-0.37	1.9e-6	White matter hyperintensity burden;
PAAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14169450	chr9:139327907	INPP5E	0.52	4.59	0.35	9.29e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-1.1	-12.08	-0.7	5.66e-24	Longevity;
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.61	-5.7	-0.42	6.17e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs17227506	0.529	rs13258748	chr8:13470909	A/T	cg02718516	chr8:13424094	C8orf48	0.36	4.83	0.37	3.24e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs59104589	0.521	rs2240482	chr2:242405021	C/T	cg04488487	chr2:242709673	NA	0.58	4.62	0.35	7.98e-6	Fibrinogen levels;
PAAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.81	7.14	0.5	3.65e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs2790216	1.000	rs1339580	chr10:60027122	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs11807834	0.522	rs12565365	chr1:230251507	G/A	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs35955747	0.633	rs5998012	chr22:31889844	G/A	cg02404636	chr22:31891804	SFI1	-0.51	-5.2	-0.39	6.33e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08532870	chr1:8086308	ERRFI1	0.66	6.92	0.49	1.2e-10	Myopia (pathological);
PAAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	cis	rs6563943	1.000	rs9934609	chr16:83638578	C/T	cg01935413	chr16:83636749	CDH13	0.59	5.5	0.41	1.6e-7	Height;
PAAD	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs12136530	0.593	rs12136926	chr1:19710794	G/A	cg25104613	chr1:20649108	VWA5B1	-0.38	-4.53	-0.34	1.21e-5	Lead levels in blood;
PAAD	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.69	-7.35	-0.51	1.13e-11	Neuroticism;
PAAD	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	1.0	10.31	0.64	3.22e-19	Platelet distribution width;
PAAD	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.56	-5.31	-0.4	3.9e-7	Cancer;
PAAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23158103	chr7:148848205	ZNF398	-0.6	-5.9	-0.43	2.3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg01798341	chr17:80842262	TBCD	0.41	4.47	0.34	1.54e-5	Breast cancer;
PAAD	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.83	6.38	0.46	1.98e-9	Mean platelet volume;
PAAD	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg24747557	chr10:131355152	MGMT	-0.47	-4.92	-0.37	2.18e-6	Response to temozolomide;
PAAD	cis	rs34734847	0.777	rs555404	chr12:121175984	T/C	cg27246729	chr12:121163418	ACADS	0.41	4.25	0.33	3.77e-5	Mean corpuscular volume;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.68	-7.53	-0.52	4.29e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.61	0.41	9.34e-8	Prudent dietary pattern;
PAAD	cis	rs747650	0.504	rs923324	chr11:47164208	G/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.65	-0.42	7.65e-8	Acne (severe);
PAAD	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.63	-5.99	-0.44	1.45e-8	Breast size;
PAAD	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg23153227	chr6:27725408	NA	0.44	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-4.42	-0.34	1.9e-5	Schizophrenia;
PAAD	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.35	-4.46	-0.34	1.55e-5	Height;
PAAD	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs12144049	0.662	rs941933	chr1:152397413	T/C	cg25605289	chr1:151974222	NA	-0.35	-4.45	-0.34	1.65e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs6684428	0.706	rs12118218	chr1:56320445	C/T	cg11651538	chr1:56320950	NA	-0.51	-4.48	-0.34	1.46e-5	Airflow obstruction;
PAAD	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.46	-6.41	-0.46	1.73e-9	Congenital heart disease (maternal effect);
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg07291445	chr7:39015928	NA	0.29	4.34	0.33	2.59e-5	IgG glycosylation;
PAAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.74	-8.13	-0.55	1.39e-13	Personality dimensions;
PAAD	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-4.72	-0.36	5.29e-6	Height;
PAAD	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg26031613	chr14:104095156	KLC1	0.43	4.42	0.34	1.84e-5	Coronary artery disease;
PAAD	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.5	-5.56	-0.41	1.19e-7	Menarche (age at onset);
PAAD	cis	rs6804624	0.892	rs34614397	chr3:99160635	A/G	cg02646433	chr3:99218170	NA	0.46	4.63	0.35	7.83e-6	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.3	10.05	0.63	1.55e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6718203	1.000	rs56199502	chr2:60641604	C/G	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
PAAD	cis	rs6088813	1.000	rs6141546	chr20:33949282	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.69	6.89	0.49	1.38e-10	Schizophrenia;
PAAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs12432203	1.000	rs61064202	chr14:51747067	G/A	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs11807834	0.522	rs10864688	chr1:230237167	C/T	cg09847368	chr1:230250326	GALNT2	-0.67	-8.19	-0.55	1.01e-13	Schizophrenia;
PAAD	cis	rs10121009	0.565	rs10972462	chr9:35427324	C/T	cg11846315	chr9:35647073	NA	0.49	4.42	0.34	1.86e-5	Parkinson's disease;
PAAD	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	6.05	0.44	1.06e-8	Mean platelet volume;
PAAD	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14019695	chr9:139328340	INPP5E	0.59	4.99	0.38	1.6e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9583531	0.760	rs1887200	chr13:111393137	A/C	cg24331049	chr13:111365604	ING1	-0.74	-5.16	-0.39	7.51e-7	Coronary artery disease;
PAAD	cis	rs6782025	0.837	rs571545	chr3:120640425	C/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.42	4.27	0.33	3.36e-5	Red cell distribution width;
PAAD	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.42	-6.24	-0.45	4.23e-9	Subjective well-being;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.79	5.66	0.42	7.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19671926	chr4:122722719	EXOSC9	-0.53	-4.31	-0.33	2.95e-5	Type 2 diabetes;
PAAD	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg08345082	chr10:99160200	RRP12	-0.32	-4.6	-0.35	8.74e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2645424	0.635	rs62495697	chr8:11709007	G/A	cg21281001	chr8:11725306	CTSB	0.54	4.87	0.37	2.79e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.95	10.01	0.63	2.02e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	7.83	0.54	7.67e-13	Eosinophilic esophagitis;
PAAD	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12599982	chr1:44399894	ARTN	0.44	4.82	0.36	3.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.77	6.26	0.45	3.84e-9	Prostate cancer;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg11416102	chr8:651193	ERICH1	0.89	5.54	0.41	1.32e-7	IgG glycosylation;
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13732083	chr21:47605072	C21orf56	0.46	4.55	0.35	1.09e-5	Testicular germ cell tumor;
PAAD	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg00614314	chr15:82944287	LOC80154	0.52	5.17	0.39	7.38e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.54	-4.93	-0.37	2.17e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg18402987	chr7:1209562	NA	1.05	5.35	0.4	3.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	5.45	0.4	2.03e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg04165759	chr1:150448943	RPRD2	-0.54	-5.69	-0.42	6.3e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.61	5.43	0.4	2.16e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.59	-5.28	-0.39	4.38e-7	Monocyte count;
PAAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.56	6.61	0.47	6.25e-10	Monobrow;
PAAD	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.89	4.75	0.36	4.66e-6	Plasma clusterin levels;
PAAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.49	-4.75	-0.36	4.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg12165864	chr7:66369176	NA	0.78	5.76	0.42	4.58e-8	Diabetic kidney disease;
PAAD	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg11477892	chr4:106580295	NA	-0.54	-4.31	-0.33	2.93e-5	Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08039050	chr6:11094291	LOC221710	0.65	6.91	0.49	1.26e-10	Myopia (pathological);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06161720	chr14:35099471	SNX6	0.61	6.67	0.48	4.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2017305	0.915	rs1125054	chr10:70762513	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.0	-0.38	1.57e-6	Depression (quantitative trait);
PAAD	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.75	6.71	0.48	3.66e-10	Large artery stroke;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01258499	chr20:30540016	PDRG1	0.58	6.81	0.48	2.08e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9810890	1.000	rs73198855	chr3:128512664	G/A	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg02683114	chr2:24398427	C2orf84	0.6	6.51	0.47	1.01e-9	Asthma;
PAAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.66	-6.11	-0.44	8.2e-9	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg04398451	chr17:18023971	MYO15A	0.73	7.71	0.53	1.56e-12	Total body bone mineral density;
PAAD	cis	rs11997175	0.546	rs4733448	chr8:33628575	G/A	ch.8.33884649F	chr8:33765107	NA	0.6	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.54	4.91	0.37	2.36e-6	Mood instability;
PAAD	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg23587288	chr2:27483067	SLC30A3	-0.68	-6.05	-0.44	1.08e-8	Blood metabolite levels;
PAAD	cis	rs11809230	0.541	rs72938999	chr1:70186689	T/G	cg01791338	chr1:70606906	NA	0.75	4.55	0.35	1.07e-5	Cannabis use (initiation);
PAAD	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14180030	chr9:123475675	MEGF9	-0.41	-4.66	-0.35	6.83e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg09324608	chr17:30823087	MYO1D	0.51	5.47	0.41	1.84e-7	Schizophrenia;
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg15691649	chr6:25882328	NA	0.51	4.61	0.35	8.52e-6	Blood metabolite levels;
PAAD	cis	rs9362426	0.524	rs61731441	chr6:88125542	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.48	-4.32	-0.33	2.79e-5	Depressive episodes in bipolar disorder;
PAAD	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg13897122	chr2:103039542	IL18RAP	0.37	4.56	0.35	1.07e-5	Asthma;
PAAD	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg11812906	chr14:75593930	NEK9	-0.49	-4.79	-0.36	3.96e-6	Caffeine consumption;
PAAD	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	4.83	0.36	3.29e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.53	-4.78	-0.36	4.08e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg00280220	chr17:61926910	NA	0.42	4.55	0.35	1.08e-5	Prudent dietary pattern;
PAAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg25452165	chr22:42524984	CYP2D6	-0.46	-4.45	-0.34	1.63e-5	Cognitive function;
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.73	8.29	0.56	5.43e-14	Colorectal cancer;
PAAD	cis	rs72627123	1.000	rs72627130	chr14:74374897	C/T	cg19860245	chr14:74300557	NA	-0.72	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs6585424	1.000	rs10466226	chr10:81924055	C/T	cg19423196	chr10:82049429	MAT1A	-0.44	-4.56	-0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.94	0.66	6.43e-21	Chronic sinus infection;
PAAD	trans	rs901683	0.850	rs113588255	chr10:46067333	C/G	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	5.01	0.38	1.48e-6	Educational attainment;
PAAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.1	0.63	1.16e-18	Platelet count;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.56	-5.78	-0.42	4.12e-8	Testicular germ cell tumor;
PAAD	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.54	-0.47	8.62e-10	Total body bone mineral density;
PAAD	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg10596483	chr8:143751796	JRK	-0.48	-4.43	-0.34	1.76e-5	Urinary tract infection frequency;
PAAD	cis	rs2279817	0.775	rs34357655	chr1:18009415	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.56	-6.1	-0.44	8.36e-9	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18211447	chr14:102771717	RAGE	0.66	7.78	0.53	1.02e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-5.9	-0.43	2.28e-8	Body mass index (adult);
PAAD	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.72	-5.63	-0.42	8.49e-8	Ileal carcinoids;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16262614	chr3:133464971	TF	0.49	5.42	0.4	2.25e-7	Iron status biomarkers;
PAAD	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.61	7.24	0.51	2.05e-11	HDL cholesterol levels;
PAAD	cis	rs11997175	0.520	rs4733449	chr8:33628652	G/T	ch.8.33884649F	chr8:33765107	NA	0.6	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.66	6.26	0.45	3.7e-9	Parkinson's disease;
PAAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.82	9.62	0.62	2.13e-17	Aortic root size;
PAAD	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.5	-0.47	1.07e-9	Monocyte count;
PAAD	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.01e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.31	0.64	3.1400000000000002e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7638995	0.628	rs4855550	chr3:69185740	C/A	cg26574240	chr3:69171822	LMOD3	-0.82	-5.05	-0.38	1.24e-6	Alzheimer's disease (late onset);
PAAD	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.43	4.47	0.34	1.54e-5	Plateletcrit;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.3	0.33	3.01e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.09	0.38	1.06e-6	Lung cancer in ever smokers;
PAAD	cis	rs4704187	0.687	rs6885071	chr5:74460045	A/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs7084783	0.500	rs9521	chr10:105358458	C/G	cg00126946	chr10:105363258	SH3PXD2A	-0.45	-4.66	-0.35	6.94e-6	Fear of pain;
PAAD	cis	rs16958440	0.867	rs12326457	chr18:44678425	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.39	0.4	2.59e-7	Sitting height ratio;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	4.37	0.33	2.26e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs8084125	1.000	rs62105167	chr18:74944594	G/A	cg05528293	chr18:74961138	GALR1	0.61	5.04	0.38	1.32e-6	Obesity-related traits;
PAAD	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.83	-0.43	3.22e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg13880726	chr7:1868755	MAD1L1	-0.48	-4.59	-0.35	9.21e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.47	-4.3	-0.33	3.04e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2286379	0.837	rs2286383	chr12:1891372	C/T	cg05227549	chr12:1770782	NA	0.42	4.77	0.36	4.23e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg20673841	chr7:107026890	COG5	0.51	4.42	0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs9346649	0.967	rs6920748	chr6:168490047	T/G	cg09211372	chr6:168490623	NA	0.39	4.35	0.33	2.45e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.66	6.48	0.47	1.22e-9	White matter hyperintensity burden;
PAAD	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.52	-0.41	1.45e-7	Personality dimensions;
PAAD	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.77	-0.36	4.21e-6	Height;
PAAD	cis	rs12956009	0.583	rs7240132	chr18:44858634	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	4.85	0.37	2.97e-6	Educational attainment (years of education);
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.7	6.73	0.48	3.33e-10	Cystic fibrosis severity;
PAAD	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.75	4.76	0.36	4.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs16958440	0.708	rs57468764	chr18:44624856	T/C	cg17192377	chr18:44677553	HDHD2	0.62	4.37	0.33	2.28e-5	Sitting height ratio;
PAAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.63	-5.21	-0.39	5.96e-7	Diastolic blood pressure;
PAAD	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	4.79	0.36	3.9e-6	Educational attainment;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg20821713	chr7:1055600	C7orf50	-0.39	-4.36	-0.33	2.4e-5	Longevity;Endometriosis;
PAAD	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg27499820	chr13:21296301	IL17D	-0.51	-5.02	-0.38	1.45e-6	Dental caries;
PAAD	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.23	0.55	8.09e-14	Schizophrenia;
PAAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12963246	chr6:28129442	ZNF389	0.56	4.52	0.34	1.21e-5	Parkinson's disease;
PAAD	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.45	-4.7	-0.36	5.88e-6	Gut microbiome composition (winter);
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.82	-8.99	-0.59	9.07e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11871801	1.000	rs12951549	chr17:40593502	C/T	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.62	-0.35	8.12e-6	Crohn's disease;
PAAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg07870213	chr5:140052090	DND1	-0.7	-6.82	-0.48	2.04e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.49	-5.69	-0.42	6.32e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.66	6.98	0.49	8.37e-11	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.41	-0.34	1.98e-5	Mood instability;
PAAD	cis	rs370915	0.542	rs13124558	chr4:187794175	T/C	cg12892747	chr4:187813459	NA	-0.43	-4.26	-0.33	3.6e-5	Gout;
PAAD	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs66530629	0.837	rs12439	chr1:25169634	A/G	cg22509179	chr1:25234806	RUNX3	0.48	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg21977766	chr11:1107580	NA	0.44	4.32	0.33	2.77e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9296095	0.607	rs10947409	chr6:33515191	G/C	cg14003231	chr6:33640908	ITPR3	0.44	5.67	0.42	6.94e-8	Platelet count;
PAAD	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.15e-6	Childhood ear infection;
PAAD	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg07395648	chr5:131743802	NA	-0.57	-5.11	-0.38	9.57e-7	Breast cancer;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg10589385	chr1:150898437	SETDB1	0.39	4.88	0.37	2.67e-6	Melanoma;
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg02353165	chr6:42928485	GNMT	0.77	9.14	0.6	3.66e-16	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.8	8.01	0.54	2.8e-13	Tuberculosis;
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.93	9.83	0.62	5.76e-18	Blood metabolite levels;
PAAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	8.02	0.55	2.69e-13	Homoarginine levels;
PAAD	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.51	-0.34	1.27e-5	Fear of minor pain;
PAAD	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.54	-5.35	-0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs793571	0.502	rs688756	chr15:59076272	A/C	cg05156742	chr15:59063176	FAM63B	0.77	8.33	0.56	4.36e-14	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73198824	chr3:128486699	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs11588062	0.660	rs12738055	chr1:46701222	T/A	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.51	5.23	0.39	5.5e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-4.61	-0.35	8.3e-6	Bipolar disorder;
PAAD	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.11	0.55	1.5700000000000001e-13	Alzheimer's disease;
PAAD	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.84	9.94	0.63	3.06e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7742824	0.576	rs1138991	chr6:44058579	G/T	cg21657043	chr6:44035552	NA	0.41	4.54	0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs10865541	0.571	rs7601188	chr2:3382440	G/T	cg21040360	chr2:3383326	TTC15	0.43	4.81	0.36	3.66e-6	Obesity-related traits;
PAAD	cis	rs1075265	0.568	rs10865278	chr2:54302039	A/G	cg04546899	chr2:54196757	PSME4	0.35	5.15	0.39	7.85e-7	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13850887	chr2:241993303	SNED1	-0.67	-6.72	-0.48	3.49e-10	Obesity-related traits;
PAAD	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.83	-5.07	-0.38	1.14e-6	Cholesterol, total;
PAAD	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.55	5.8	0.43	3.81e-8	Bladder cancer;
PAAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.64e-6	Breast cancer;
PAAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg22143856	chr6:28129313	ZNF389	0.67	5.31	0.4	3.81e-7	Depression;
PAAD	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.69	5.45	0.4	2.02e-7	Neuroticism;
PAAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-6.6	-0.47	6.48e-10	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg23708337	chr7:1209742	NA	0.71	5.52	0.41	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7925523	0.891	rs883724	chr11:61457857	A/G	cg12472022	chr11:61462803	DAGLA	-0.62	-5.11	-0.38	9.33e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4450131	1.000	rs4450131	chr10:126383363	C/T	cg20435097	chr10:126320824	FAM53B	0.47	5.47	0.41	1.8e-7	White blood cell count (basophil);
PAAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	5.12	0.38	9.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg21130718	chr4:1044621	NA	0.57	4.81	0.36	3.6e-6	Recombination rate (females);
PAAD	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs507080	0.922	rs12788848	chr11:118553788	C/T	cg08498647	chr11:118550644	TREH	-0.38	-4.42	-0.34	1.87e-5	Serum metabolite levels;
PAAD	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	5.0	0.38	1.56e-6	Height;
PAAD	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.89	10.46	0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.74	-6.39	-0.46	1.91e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg05925327	chr15:68127851	NA	-0.64	-5.68	-0.42	6.62e-8	Restless legs syndrome;
PAAD	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg25364880	chr3:44379878	C3orf23	0.58	5.4	0.4	2.55e-7	Depressive symptoms;
PAAD	cis	rs2790216	1.000	rs2590330	chr10:60008219	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs13424612	1.000	rs10206993	chr2:240900919	C/A	cg01812947	chr2:240904978	NDUFA10	0.58	5.09	0.38	1.03e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs12940923	0.529	rs3744102	chr17:56383187	C/T	cg26072851	chr17:56296444	MKS1	-0.59	-5.03	-0.38	1.38e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg14851346	chr12:38532713	NA	-0.46	-4.37	-0.33	2.33e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg21452805	chr1:244014465	NA	0.53	4.73	0.36	5.07e-6	RR interval (heart rate);
PAAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg20673091	chr1:2541236	MMEL1	0.84	10.27	0.64	3.95e-19	Ulcerative colitis;
PAAD	cis	rs11212260	0.678	rs11212203	chr11:107267629	A/G	cg25435332	chr11:107328525	CWF19L2	1.33	6.43	0.46	1.53e-9	IgG glycosylation;
PAAD	cis	rs939584	0.935	rs13022164	chr2:632536	A/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs1997066	0.831	rs73342299	chr10:106823351	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs2061333	0.901	rs3172	chr19:44609846	C/G	cg18700516	chr19:44507157	ZNF230	-0.63	-4.88	-0.37	2.66e-6	Alzheimer's disease;
PAAD	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.69	7.14	0.5	3.65e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs1497828	1.000	rs2810765	chr1:217565100	T/C	cg04411442	chr1:217543379	NA	0.5	4.89	0.37	2.51e-6	Dialysis-related mortality;
PAAD	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4787491	0.704	rs12447915	chr16:30089908	C/T	cg06015834	chr16:30021696	DOC2A	-0.44	-4.47	-0.34	1.5e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.11	0.44	8.03e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.82	-0.36	3.51e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs11794666	1.000	rs4879532	chr9:31678203	A/C	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg13932035	chr19:11266624	SPC24	-0.61	-6.73	-0.48	3.23e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg16928487	chr17:17741425	SREBF1	-0.36	-4.88	-0.37	2.65e-6	Total body bone mineral density;
PAAD	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06002616	chr8:101225028	SPAG1	0.46	5.47	0.41	1.83e-7	Atrioventricular conduction;
PAAD	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.57	-6.6	-0.47	6.63e-10	Dementia with Lewy bodies;
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.64	6.54	0.47	8.81e-10	Type 2 diabetes;
PAAD	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21646471	chr2:242523971	THAP4	0.65	5.02	0.38	1.44e-6	Prostate cancer;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.88	0.37	2.7e-6	Bipolar disorder;
PAAD	cis	rs34929064	0.525	rs1880243	chr7:22759655	C/A	cg05472934	chr7:22766657	IL6	0.54	4.61	0.35	8.62e-6	Major depression and alcohol dependence;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.61e-7	Monocyte count;
PAAD	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg01362358	chr17:58117360	NA	0.42	5.02	0.38	1.43e-6	Hemoglobin concentration;
PAAD	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs61744385	chr3:41756986	A/T	cg03022575	chr3:42003672	ULK4	0.84	6.09	0.44	8.73e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7631605	0.623	rs13421	chr3:36985879	T/C	cg10333520	chr3:36987040	TRANK1	0.33	4.43	0.34	1.81e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-1.11	-8.22	-0.55	8.22e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00821051	chr10:131592591	NA	0.52	6.4	0.46	1.86e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.95	-10.91	-0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.51	5.46	0.4	1.94e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.76	-0.42	4.53e-8	QT interval;
PAAD	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.64	-5.73	-0.42	5.23e-8	Mean corpuscular volume;
PAAD	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.7	7.36	0.51	1.07e-11	Colorectal cancer;
PAAD	cis	rs4965869	0.824	rs4965867	chr15:101976039	G/A	cg12371147	chr15:101978424	PCSK6	-0.5	-4.42	-0.34	1.9e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs9346353	0.762	rs1902655	chr6:70499187	C/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16762979	chr20:50387214	NA	-0.59	-6.56	-0.47	7.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.62	6.2	0.45	5.15e-9	Monocyte count;
PAAD	cis	rs4740619	0.661	rs10962227	chr9:15944352	G/T	cg14451791	chr9:16040625	NA	-0.44	-5.06	-0.38	1.18e-6	Body mass index;
PAAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.75	6.59	0.47	6.82e-10	Coronary artery disease;
PAAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.63	6.52	0.47	9.68e-10	Coronary artery disease;
PAAD	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.5	0.41	1.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9810890	1.000	rs56000731	chr3:128647141	T/C	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.34	-0.56	4.22e-14	Hemoglobin concentration;
PAAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.83	-11.39	-0.68	4.15e-22	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg21698718	chr17:80085957	CCDC57	0.39	4.26	0.33	3.62e-5	Life satisfaction;
PAAD	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg15211996	chr1:2936768	ACTRT2	0.47	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	trans	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.17	0.5	3.04e-11	Diastolic blood pressure;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.64	5.95	0.43	1.81e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs2882667	0.690	rs288041	chr5:138204011	T/C	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1419980	0.730	rs11054546	chr12:7727059	G/T	cg25828445	chr12:7781288	NA	-0.84	-4.35	-0.33	2.53e-5	HDL cholesterol levels;
PAAD	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.55	-5.01	-0.38	1.52e-6	Obesity-related traits;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21147944	chr13:114264438	TFDP1	-0.67	-6.79	-0.48	2.35e-10	Obesity-related traits;
PAAD	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs11615916	0.790	rs55642112	chr12:62680896	A/T	cg11441379	chr12:63026424	NA	0.65	4.41	0.34	1.93e-5	Pulmonary function decline;
PAAD	cis	rs2236521	0.632	rs35265388	chr20:60894278	C/T	cg06026331	chr20:60912101	LAMA5	0.59	5.45	0.4	1.96e-7	Pelvic organ prolapse;
PAAD	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg15309053	chr8:964076	NA	0.54	6.23	0.45	4.31e-9	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg08316699	chr6:150357289	NA	0.41	4.53	0.35	1.17e-5	Alopecia areata;
PAAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-1.4	-10.47	-0.65	1.2e-19	Schizophrenia;
PAAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.73	0.62	1.06e-17	Total body bone mineral density;
PAAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.81	-7.97	-0.54	3.53e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.72	8.21	0.55	8.61e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.52	-4.98	-0.37	1.71e-6	Itch intensity from mosquito bite;
PAAD	cis	rs597480	0.857	rs644972	chr11:85476235	A/G	cg11817631	chr11:85522609	SYTL2	-0.45	-4.48	-0.34	1.47e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs17155006	0.664	rs378962	chr7:107739538	A/C	cg05962710	chr7:107745446	LAMB4	-0.52	-6.83	-0.48	1.96e-10	Pneumococcal bacteremia;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg12757816	chr2:10669957	NA	0.56	6.09	0.44	8.96e-9	Prostate cancer;
PAAD	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.85e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs714031	0.730	rs5757766	chr22:40069490	T/C	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.51	-0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-5.39	-0.4	2.63e-7	Joint mobility (Beighton score);
PAAD	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.61	7.04	0.5	6.23e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08893839	chr5:154027129	NA	0.79	6.1	0.44	8.53e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.21	-0.39	5.93e-7	Lung cancer;
PAAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.53	4.76	0.36	4.54e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg19442545	chr10:75533431	FUT11	-0.5	-5.28	-0.39	4.46e-7	Inflammatory bowel disease;
PAAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.98	-0.44	1.52e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.47	-5.31	-0.4	3.76e-7	Cognitive function;
PAAD	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg01329690	chr21:38580129	DSCR9	0.39	5.32	0.4	3.72e-7	Eye color traits;
PAAD	cis	rs1941184	0.759	rs7240892	chr18:29029474	C/T	cg03238162	chr18:29027701	DSG3	-0.42	-4.88	-0.37	2.65e-6	Parkinson's disease (age of onset);
PAAD	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg09709951	chr12:54017699	ATF7	0.56	4.93	0.37	2.13e-6	Height;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg27644672	chr7:1858694	MAD1L1	-0.44	-4.86	-0.37	2.87e-6	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.74e-27	Height;
PAAD	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.78	-9.84	-0.62	5.55e-18	Prudent dietary pattern;
PAAD	trans	rs7172971	0.688	rs79897861	chr15:42381832	T/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg15847926	chr7:2749597	AMZ1	-0.4	-4.81	-0.36	3.64e-6	Height;
PAAD	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.75	-7.99	-0.54	3.07e-13	Eosinophil percentage of white cells;
PAAD	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.57	-5.62	-0.42	8.69e-8	Pulse pressure;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg12419862	chr22:24373484	LOC391322	-0.81	-6.57	-0.47	7.47e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg08992911	chr2:238395768	MLPH	0.65	6.52	0.47	9.81e-10	Prostate cancer;
PAAD	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg22601191	chr20:60968625	CABLES2	0.55	5.42	0.4	2.25e-7	Colorectal cancer;
PAAD	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.66	6.85	0.49	1.69e-10	Height;
PAAD	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg25801113	chr15:45476975	SHF	0.39	4.59	0.35	9.3e-6	Uric acid levels;
PAAD	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg10523679	chr1:76189770	ACADM	0.48	4.53	0.34	1.19e-5	Daytime sleep phenotypes;
PAAD	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs1620921	0.524	rs7450979	chr6:161186889	A/C	cg01280913	chr6:161186852	NA	0.49	5.44	0.4	2.07e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02985541	chr2:219472218	PLCD4	0.29	4.49	0.34	1.4e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.48	-5.15	-0.39	7.78e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4765905	0.713	rs7297582	chr12:2355806	A/G	cg27485368	chr12:1485704	ERC1	-0.49	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs80346118	0.673	rs2869675	chr20:47420680	C/T	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.58	-4.37	-0.33	2.29e-5	Diastolic blood pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19832322	chr15:52311484	MAPK6	-0.54	-6.3	-0.46	3.11e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.42	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.81	-0.36	3.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.58	5.75	0.42	4.7e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.55	-0.41	1.24e-7	Schizophrenia;
PAAD	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	7.29	0.51	1.56e-11	LDL cholesterol;
PAAD	cis	rs7072216	0.770	rs942810	chr10:100167860	G/C	cg26618903	chr10:100175079	PYROXD2	-0.41	-4.63	-0.35	7.85e-6	Metabolite levels;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg10729496	chr3:10149963	C3orf24	0.82	6.07	0.44	9.72e-9	Alzheimer's disease;
PAAD	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-1.25	-9.98	-0.63	2.32e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg00522288	chr12:125625016	AACS	-0.53	-5.84	-0.43	3.08e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.1e-13	Diastolic blood pressure;
PAAD	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg15047889	chr8:124780837	FAM91A1	-0.63	-4.92	-0.37	2.21e-6	Pancreatic cancer;
PAAD	cis	rs3736485	0.844	rs28878886	chr15:51760892	T/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.27	-0.33	3.44e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg14851346	chr12:38532713	NA	-0.46	-4.45	-0.34	1.68e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.48	4.46	0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.5	-5.5	-0.41	1.61e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-6.23	-0.45	4.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.19	-0.5	2.78e-11	Response to antipsychotic treatment;
PAAD	cis	rs2769264	0.593	rs4971040	chr1:151366494	A/C	cg18801370	chr1:151430492	POGZ	0.98	7.76	0.53	1.18e-12	Blood trace element (Cu levels);
PAAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.25	-0.39	4.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.54	5.53	0.41	1.37e-7	Resting heart rate;
PAAD	cis	rs6782025	0.837	rs234995	chr3:121019414	C/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs7729723	0.653	rs7703010	chr5:137711716	C/A	cg26069252	chr5:137800343	EGR1	-0.45	-4.25	-0.33	3.76e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.67	-5.67	-0.42	6.86e-8	Menarche (age at onset);
PAAD	cis	rs12760731	0.565	rs6701832	chr1:178156775	A/G	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg19847866	chr10:1019161	NA	-0.53	-4.25	-0.33	3.7e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs899997	0.906	rs72625802	chr15:78992811	G/A	cg16602846	chr15:78114278	NA	-0.43	-4.4	-0.34	1.99e-5	Coronary artery disease or large artery stroke;
PAAD	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.87	-6.73	-0.48	3.24e-10	Axial length;
PAAD	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.43	4.27	0.33	3.38e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.97	7.68	0.53	1.76e-12	Eosinophilic esophagitis;
PAAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg25452165	chr22:42524984	CYP2D6	0.6	5.85	0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.38	-4.74	-0.36	4.97e-6	Pubertal anthropometrics;
PAAD	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.48	-5.33	-0.4	3.43e-7	Mean arterial pressure;
PAAD	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg02683114	chr2:24398427	C2orf84	-0.56	-5.76	-0.42	4.45e-8	Asthma;
PAAD	cis	rs12122100	0.696	rs12752148	chr1:146557073	T/C	cg19022274	chr1:146715514	CHD1L	-0.55	-4.26	-0.33	3.51e-5	HIV-1 control;
PAAD	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.4	-4.34	-0.33	2.55e-5	Calcium levels;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	6.62	0.47	5.92e-10	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs757081	0.579	rs11024221	chr11:17274550	T/A	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.5	-0.41	1.61e-7	Systolic blood pressure;
PAAD	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.5	-6.26	-0.45	3.71e-9	Crohn's disease;
PAAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.91	4.73	0.36	5.1e-6	Plasma clusterin levels;
PAAD	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.62	0.47	5.68e-10	Systemic lupus erythematosus;
PAAD	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.55	4.84	0.37	3.11e-6	Life satisfaction;
PAAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg22029157	chr1:209979665	IRF6	0.71	6.62	0.47	5.9e-10	Coronary artery disease;
PAAD	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.54e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18181496	chr7:107642539	LAMB1	0.48	4.51	0.34	1.29e-5	Ulcerative colitis;
PAAD	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	11.32	0.68	6.42e-22	Ulcerative colitis;
PAAD	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.97e-5	Age-related disease endophenotypes;
PAAD	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	9.89	0.63	4.14e-18	Smoking behavior;
PAAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg05484376	chr2:27715224	FNDC4	0.49	5.0	0.38	1.58e-6	Total body bone mineral density;
PAAD	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.07	8.65	0.57	6.99e-15	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs901683	0.850	rs76395348	chr10:46082064	T/C	cg12869334	chr8:37699360	GPR124	1.07	7.26	0.51	1.91e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.62	5.46	0.4	1.91e-7	Blood metabolite levels;
PAAD	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01200585	chr1:228362443	C1orf69	0.56	6.24	0.45	4.08e-9	Diastolic blood pressure;
PAAD	cis	rs7577696	0.962	rs212746	chr2:32413067	T/C	cg02381751	chr2:32503542	YIPF4	0.41	4.41	0.34	1.91e-5	Inflammatory biomarkers;
PAAD	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2594989	1.000	rs2594990	chr3:11317897	G/T	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg04920474	chr2:44395004	PPM1B	0.45	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.57	4.97	0.37	1.79e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.0	-0.49	7.63e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.15	16.59	0.8	6.39e-36	Cognitive function;
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg13374026	chr7:158955107	NA	0.47	4.36	0.33	2.4e-5	Facial morphology (factor 20);
PAAD	cis	rs12940923	0.554	rs12953025	chr17:56369569	T/C	cg26072851	chr17:56296444	MKS1	-0.58	-4.94	-0.37	2.02e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg12568669	chr8:11666485	FDFT1	0.27	4.61	0.35	8.44e-6	Monocyte count;
PAAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.6	5.72	0.42	5.47e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs9535307	0.719	rs1570353	chr13:50385967	G/T	cg03658251	chr13:50265850	EBPL	-0.82	-5.61	-0.41	9.14e-8	Obesity-related traits;
PAAD	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg03277515	chr1:153321198	PGLYRP4	0.42	5.01	0.38	1.52e-6	Psoriasis;
PAAD	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.31	-0.33	2.97e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs72681920	1.000	rs28730619	chr4:99999225	T/C	cg12011299	chr4:100065546	ADH4	-0.72	-4.43	-0.34	1.82e-5	Alcohol dependence;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.52	0.34	1.21e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.41	-5.07	-0.38	1.15e-6	Menopause (age at onset);
PAAD	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.72	6.93	0.49	1.12e-10	Obesity-related traits;
PAAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg02012338	chr4:187126139	CYP4V2	0.66	4.63	0.35	7.83e-6	Activated partial thromboplastin time;
PAAD	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.4	4.54	0.35	1.15e-5	Calcium levels;
PAAD	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg18084798	chr19:33555255	RHPN2	0.45	4.75	0.36	4.6e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.03	-0.5	6.66e-11	Menarche (age at onset);
PAAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Depression;
PAAD	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.86e-7	Bladder cancer;
PAAD	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.55	0.57	1.23e-14	Colorectal cancer;
PAAD	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.49	-5.44	-0.4	2.11e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2274459	0.722	rs67854583	chr6:33649648	T/A	cg06253072	chr6:33679850	C6orf125	0.63	5.03	0.38	1.4e-6	Obesity (extreme);
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.07	-0.38	1.14e-6	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs752010	0.543	rs7545381	chr1:42044183	T/A	cg06885757	chr1:42089581	HIVEP3	0.45	4.89	0.37	2.5e-6	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.65	-6.09	-0.44	9.05e-9	DNA methylation (variation);
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg18279126	chr7:2041391	MAD1L1	0.55	5.38	0.4	2.72e-7	Schizophrenia;
PAAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.75e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12300511	chr20:2854049	PTPRA	-0.61	-6.33	-0.46	2.61e-9	Warfarin maintenance dose;
PAAD	cis	rs116248771	0.739	rs1051109	chr3:158415344	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.91	-10.93	-0.66	6.81e-21	Schizophrenia;
PAAD	cis	rs4919087	0.926	rs945189	chr10:99091766	C/G	cg10705379	chr10:99080932	FRAT1	-0.46	-5.15	-0.39	8.09e-7	Monocyte count;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.62	6.89	0.49	1.36e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.61	-5.78	-0.42	4.03e-8	Cancer;
PAAD	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg11204139	chr17:3907470	NA	0.85	9.08	0.59	5.29e-16	Type 2 diabetes;
PAAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg24154853	chr7:158122151	PTPRN2	0.72	7.58	0.52	3.16e-12	Calcium levels;
PAAD	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-4.35	-0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	8.01	0.54	2.85e-13	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19545348	chr1:211434133	RCOR3	0.62	6.99	0.49	8.08e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.7	-7.35	-0.51	1.14e-11	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs300774	0.925	rs447775	chr2:106413	T/A	cg21211680	chr2:198530	NA	-0.61	-5.33	-0.4	3.51e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	4.62	0.35	8.21e-6	Mean platelet volume;
PAAD	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs62025270	0.632	rs7181796	chr15:86233009	C/G	cg13263323	chr15:86062960	AKAP13	0.51	4.52	0.34	1.21e-5	Idiopathic pulmonary fibrosis;
PAAD	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.65	8.16	0.55	1.18e-13	Weight;
PAAD	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg06917634	chr15:78832804	PSMA4	0.47	4.66	0.35	6.74e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2221894	0.922	rs2203209	chr8:28788033	G/A	cg20212339	chr8:28908912	HMBOX1	0.52	5.47	0.41	1.77e-7	Obesity-related traits;
PAAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs28489187	0.706	rs233120	chr1:85788490	A/C	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.62	-6.06	-0.44	1.01e-8	Schizophrenia;
PAAD	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.01	7.02	0.49	7.07e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs15676	0.947	rs10988124	chr9:131569345	G/A	cg00228799	chr9:131580591	ENDOG	0.62	6.09	0.44	8.83e-9	Blood metabolite levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09059988	chr1:150693299	HORMAD1	0.58	6.29	0.45	3.2e-9	Myopia (pathological);
PAAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.87	9.68	0.62	1.43e-17	Cognitive function;
PAAD	cis	rs2526932	0.623	rs2803963	chr14:73084761	G/A	cg13588403	chr14:73209128	DPF3	0.4	4.55	0.35	1.11e-5	C-reactive protein and white blood cell count;
PAAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.76	7.19	0.5	2.69e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21862992	chr11:68658383	NA	0.44	4.92	0.37	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-1.02	-6.7	-0.48	3.91e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg08888203	chr3:10149979	C3orf24	0.8	6.78	0.48	2.44e-10	Alzheimer's disease;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.66	-0.48	4.75e-10	Longevity;Endometriosis;
PAAD	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	5.55	0.41	1.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg14664628	chr15:75095509	CSK	-0.48	-4.64	-0.35	7.53e-6	Caffeine consumption;
PAAD	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.5	0.52	4.84e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.11	15.0	0.77	8.79e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg08886695	chr4:3369023	RGS12	-0.5	-4.7	-0.36	5.74e-6	Serum sulfate level;
PAAD	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7922314	0.571	rs61865718	chr10:64740407	C/A	cg08989932	chr10:65390526	NA	-0.89	-4.31	-0.33	2.92e-5	Cutaneous psoriasis;
PAAD	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	4.98	0.37	1.74e-6	Cervical cancer;
PAAD	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.57	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.53	5.2	0.39	6.41e-7	Rheumatoid arthritis;
PAAD	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.34	4.45	0.34	1.64e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.49	4.54	0.35	1.13e-5	Renal cell carcinoma;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15064873	chr2:99953016	EIF5B;TXNDC9	-0.56	-6.44	-0.46	1.5e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.6	-0.35	8.74e-6	Neuroticism;
PAAD	cis	rs12257961	0.710	rs10906883	chr10:15335808	A/T	cg10616319	chr10:15468812	NA	-0.48	-4.46	-0.34	1.58e-5	Selective IgA deficiency;
PAAD	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg04877966	chr15:75135169	ULK3	0.45	4.33	0.33	2.72e-5	Systemic lupus erythematosus;
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg25452165	chr22:42524984	CYP2D6	0.58	5.3	0.39	4.01e-7	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12229597	chr3:135914755	MSL2	0.58	6.45	0.46	1.44e-9	Monocyte percentage of white cells;
PAAD	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.03e-11	Lung cancer in ever smokers;
PAAD	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg20607287	chr7:12443886	VWDE	-0.71	-5.49	-0.41	1.62e-7	Coronary artery disease;
PAAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.88	8.59	0.57	9.43e-15	Eosinophil percentage of granulocytes;
PAAD	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.46	4.36	0.33	2.38e-5	Breast cancer;
PAAD	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg12184421	chr1:167409136	CD247	0.38	4.3	0.33	2.99e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09902332	chr16:27280434	NSMCE1	-0.52	-6.31	-0.46	2.92e-9	Body fat percentage;
PAAD	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.64	6.88	0.49	1.5e-10	N-glycan levels;
PAAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg14349672	chr11:133703707	NA	-0.59	-6.73	-0.48	3.27e-10	Childhood ear infection;
PAAD	cis	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Urinary tract infection frequency;
PAAD	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg11993925	chr19:44307056	LYPD5	-0.46	-6.17	-0.45	5.99e-9	Breast cancer;
PAAD	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.5	6.16e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs4794202	0.579	rs9904503	chr17:45884372	T/C	cg02219949	chr17:45927392	SP6	0.6	4.74	0.36	4.98e-6	Alzheimer's disease (cognitive decline);
PAAD	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.47	-5.4	-0.4	2.52e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.83	9.91	0.63	3.53e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.72	-9.01	-0.59	8.03e-16	Educational attainment;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.53	0.41	1.37e-7	Total body bone mineral density;
PAAD	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.59	6.43	0.46	1.54e-9	Insulin-like growth factors;
PAAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.57	-5.74	-0.42	4.97e-8	Total body bone mineral density;
PAAD	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg20900008	chr2:392811	NA	-0.58	-4.93	-0.37	2.09e-6	Blood protein levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04456036	chr1:94375027	GCLM	0.6	6.81	0.48	2.07e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2671540	0.501	rs7077109	chr10:65637680	C/T	cg19573236	chr10:65733388	NA	-0.57	-4.51	-0.34	1.29e-5	Coronary artery disease;
PAAD	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs4343996	0.870	rs4722712	chr7:3389147	C/T	cg21248987	chr7:3385318	SDK1	-0.46	-4.9	-0.37	2.41e-6	Motion sickness;
PAAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg25124228	chr12:125621409	AACS	-0.6	-5.85	-0.43	2.93e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.47e-10	Lung cancer;
PAAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.31	-0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs7260598	0.605	rs78358879	chr19:24087236	C/A	cg09235885	chr19:23456588	NA	-0.64	-4.47	-0.34	1.5e-5	Response to taxane treatment (placlitaxel);
PAAD	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.51	-0.57	1.55e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.47e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.52	-5.08	-0.38	1.1e-6	Blood osmolality (transformed sodium);
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.59	5.29	0.39	4.26e-7	Corneal astigmatism;
PAAD	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	7.09e-7	Pulmonary function;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4704187	0.687	rs6869345	chr5:74378742	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg27489772	chr12:121021490	NA	-0.58	-5.19	-0.39	6.79e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.05	-0.38	1.27e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	7.06	0.5	5.63e-11	Response to antipsychotic treatment;
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.58	5.9	0.43	2.33e-8	Menarche (age at onset);
PAAD	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg12568669	chr8:11666485	FDFT1	0.28	4.88	0.37	2.62e-6	Neuroticism;
PAAD	cis	rs4743820	0.503	rs4437763	chr9:93913579	C/T	cg14446406	chr9:93919335	NA	-0.37	-5.06	-0.38	1.22e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.08	0.44	9.17e-9	Height;
PAAD	cis	rs56011263	0.532	rs17164964	chr4:745053	T/C	cg05835009	chr4:710272	PCGF3	0.62	5.03	0.38	1.34e-6	White blood cell count;
PAAD	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.71	-6.91	-0.49	1.27e-10	Hip circumference;
PAAD	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.66	4.94	0.37	2.07e-6	Hip geometry;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg12766815	chr9:135230515	SETX	0.64	6.41	0.46	1.77e-9	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22394119	chr7:99869529	GATS	0.56	6.3	0.46	3.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.48	5.13	0.38	8.91e-7	Schizophrenia;
PAAD	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.56	5.59	0.41	1e-7	Resting heart rate;
PAAD	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg04851639	chr8:1020857	NA	-0.63	-8.0	-0.54	2.98e-13	Schizophrenia;
PAAD	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.52	4.89	0.37	2.54e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg25204440	chr1:209979598	IRF6	0.6	5.4	0.4	2.48e-7	Coronary artery disease;
PAAD	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.74	-8.52	-0.57	1.48e-14	Personality dimensions;
PAAD	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg20933634	chr6:27740509	NA	0.44	4.25	0.33	3.76e-5	Parkinson's disease;
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg02555727	chr12:129281546	SLC15A4	0.5	5.34	0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.36	4.48	0.34	1.47e-5	Mean corpuscular volume;
PAAD	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg27234864	chr13:21295941	IL17D	0.63	5.49	0.41	1.69e-7	Dental caries;
PAAD	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.63	6.11	0.44	8.11e-9	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06850241	chr22:41845214	NA	-0.47	-4.26	-0.33	3.63e-5	Vitiligo;
PAAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.44	-0.34	1.72e-5	Initial pursuit acceleration;
PAAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg15017067	chr4:17643749	FAM184B	0.42	4.98	0.37	1.73e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3787159	0.573	rs528802	chr20:56907103	C/T	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.1e-5	Systolic blood pressure;
PAAD	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	7.39	0.51	9.1e-12	Electrocardiographic conduction measures;
PAAD	cis	rs11696501	0.688	rs6130894	chr20:44322673	G/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.66	-5.95	-0.43	1.82e-8	Diabetic retinopathy;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg11416102	chr8:651193	ERICH1	0.91	5.51	0.41	1.49e-7	IgG glycosylation;
PAAD	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.53	-5.75	-0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	5.56	0.41	1.18e-7	Lung cancer in ever smokers;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg21890820	chr11:65308645	LTBP3	0.63	7.61	0.53	2.64e-12	Bone mineral density;
PAAD	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs8077577	0.708	rs3862147	chr17:18133713	G/T	cg03916694	chr17:18150707	FLII	-0.39	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg23024343	chr7:107201750	COG5	0.57	4.7	0.36	5.89e-6	Coronary artery disease;
PAAD	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg21037935	chr19:58911965	NA	0.57	4.48	0.34	1.47e-5	Mean platelet volume;
PAAD	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.41	-0.76	3.17e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs5756391	0.509	rs2075727	chr22:37310217	C/T	cg16356956	chr22:37317934	CSF2RB	0.37	4.68	0.36	6.2e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7081476	0.737	rs74544016	chr10:27482395	T/C	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7517847	0.540	rs7543633	chr1:67691772	A/G	cg16314899	chr1:68516101	DIRAS3	-0.46	-4.54	-0.35	1.12e-5	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14559799	chr22:20760090	ZNF74	0.63	6.37	0.46	2.1e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs901683	1.000	rs34539215	chr10:46087378	C/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	7.86	0.54	6.42e-13	Height;
PAAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.21	-10.17	-0.64	7.61e-19	Breast cancer;
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.64	7.19	0.5	2.68e-11	Vitiligo;
PAAD	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.33	-7.78	-0.53	1.05e-12	Psoriasis vulgaris;
PAAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-5.58	-0.41	1.07e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.23	-0.39	5.62e-7	Menarche (age at onset);
PAAD	cis	rs6679454	1.000	rs61770282	chr1:58367643	C/T	cg17491850	chr1:57888480	DAB1	-0.4	-4.48	-0.34	1.46e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.35	-0.33	2.47e-5	Schizophrenia;
PAAD	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	1.09	7.41	0.52	8.25e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.69	7.27	0.51	1.81e-11	Morning vs. evening chronotype;
PAAD	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-4.52	-0.34	1.22e-5	Lung cancer;
PAAD	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.46	6.16	0.45	6.33e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12138061	0.954	rs12137651	chr1:50353130	G/A	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.75	-8.72	-0.58	4.49e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg19090574	chr1:205240910	TMCC2	-0.43	-4.64	-0.35	7.55e-6	Red blood cell count;
PAAD	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg00806126	chr19:22604979	ZNF98	0.43	5.52	0.41	1.42e-7	Pain;
PAAD	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4388249	0.687	rs2416217	chr5:109072211	G/T	cg17395555	chr5:108820864	NA	0.31	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg09941381	chr10:64027924	RTKN2	-0.37	-4.49	-0.34	1.43e-5	Rheumatoid arthritis;
PAAD	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs59191668	0.809	rs7176966	chr15:62817568	A/G	cg12918536	chr15:62891943	NA	0.34	4.49	0.34	1.42e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.52	-4.67	-0.35	6.44e-6	Educational attainment (years of education);
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.48	4.93	0.37	2.15e-6	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs863345	0.604	rs1342953	chr1:158464499	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-5.08	-0.38	1.1e-6	Pneumococcal bacteremia;
PAAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg05785598	chr3:49045655	WDR6	0.42	4.87	0.37	2.78e-6	Parkinson's disease;
PAAD	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg26394196	chr10:1453818	ADARB2	-0.6	-6.75	-0.48	2.89e-10	Radiation response;
PAAD	cis	rs10982213	1.000	rs4979386	chr9:117186592	T/A	cg00078025	chr9:117159975	NA	0.63	4.7	0.36	5.71e-6	Interleukin-6 levels;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.7	7.14	0.5	3.64e-11	Schizophrenia;
PAAD	cis	rs73416724	1.000	rs112870457	chr6:43280714	T/G	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11250714	0.845	rs7916773	chr10:1679197	G/C	cg10435618	chr10:838112	NA	-0.5	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.96	9.21	0.6	2.47e-16	Monocyte percentage of white cells;
PAAD	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.89	-0.43	2.41e-8	Mood instability;
PAAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.47	5.88	0.43	2.47e-8	Childhood ear infection;
PAAD	cis	rs73198271	0.515	rs78600128	chr8:8628706	C/A	cg01851573	chr8:8652454	MFHAS1	0.93	6.95	0.49	1.01e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.13	0.5	3.83e-11	Coffee consumption (cups per day);
PAAD	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg15181151	chr6:150070149	PCMT1	0.56	5.64	0.42	7.92e-8	Lung cancer;
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-5.95	-0.43	1.8e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.86	9.34	0.6	1.14e-16	Cognitive function;
PAAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.5	-6.16	-0.45	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.67	-0.42	6.89e-8	Mood instability;
PAAD	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	10.51	0.65	9.34e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26926768	chr12:34528122	NA	0.38	4.51	0.34	1.28e-5	Morning vs. evening chronotype;
PAAD	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.57	4.89	0.37	2.5e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg06917634	chr15:78832804	PSMA4	-0.47	-4.63	-0.35	7.89e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.51	5.01	0.38	1.51e-6	Corneal astigmatism;
PAAD	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.29	0.56	5.49e-14	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.57	-5.46	-0.41	1.87e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.47	-4.96	-0.37	1.83e-6	Body mass index;
PAAD	cis	rs1535500	0.756	rs3807042	chr6:39290834	G/T	cg03252829	chr6:39282164	KCNK17	0.57	5.8	0.43	3.73e-8	Type 2 diabetes;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg17820247	chr12:6579852	VAMP1	-0.57	-6.84	-0.49	1.8e-10	Blood protein levels;
PAAD	cis	rs7853377	0.800	rs1982151	chr9:86617265	A/G	cg03531853	chr9:86535572	KIF27	-0.44	-4.62	-0.35	8.09e-6	Height;
PAAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg27129171	chr3:47204927	SETD2	0.72	8.1	0.55	1.65e-13	Birth weight;
PAAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.29e-5	Renal cell carcinoma;
PAAD	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.56	5.69	0.42	6.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.51	-4.86	-0.37	2.93e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.12	0.59	4.33e-16	Menopause (age at onset);
PAAD	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.77	8.77	0.58	3.33e-15	Height;
PAAD	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03198275	chr3:126423056	CHCHD6	-0.64	-6.62	-0.47	5.95e-10	Smoking initiation;
PAAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.44	5.87	0.43	2.64e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.8	7.69	0.53	1.75e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.55	5.87	0.43	2.61e-8	Lung cancer;
PAAD	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.42	-4.33	-0.33	2.72e-5	Resting heart rate;
PAAD	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21385522	chr1:16154831	NA	0.52	4.48	0.34	1.47e-5	Systolic blood pressure;
PAAD	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg27411982	chr8:10470053	RP1L1	-0.5	-5.46	-0.4	1.89e-7	Retinal vascular caliber;
PAAD	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.48	4.81	0.36	3.61e-6	Trans fatty acid levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23233673	chr19:54693846	MBOAT7;TSEN34	0.73	7.38	0.51	9.5e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.72e-5	Schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11867599	chr4:128887130	MFSD8;C4orf29	0.66	6.93	0.49	1.09e-10	Primary biliary cholangitis;
PAAD	cis	rs2271001	0.615	rs1863383	chr11:19134500	C/T	cg00161556	chr11:19138045	ZDHHC13	0.49	5.51	0.41	1.51e-7	Gut microbiome composition (winter);
PAAD	cis	rs2279463	0.667	rs3101822	chr6:160628590	G/A	cg09900253	chr6:160186100	ACAT2	-0.65	-4.29	-0.33	3.13e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
PAAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg24053715	chr22:38214548	NA	0.61	6.05	0.44	1.09e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs6464929	0.531	rs10224999	chr7:148695980	G/T	cg16844053	chr7:148404978	CUL1	0.42	4.37	0.33	2.33e-5	Pediatric bone mineral content (hip);
PAAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1075265	0.749	rs6738369	chr2:53983684	T/C	cg04546899	chr2:54196757	PSME4	0.29	4.43	0.34	1.81e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg26557270	chr6:116382179	FRK	0.28	5.03	0.38	1.34e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.62	-0.35	7.97e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg10591111	chr5:226296	SDHA	-0.93	-4.34	-0.33	2.61e-5	Breast cancer;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.71	7.02	0.5	6.74e-11	Menarche (age at onset);
PAAD	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.73	6.93	0.49	1.15e-10	Obesity-related traits;
PAAD	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.89	10.95	0.66	5.99e-21	Dental caries;
PAAD	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.52	0.34	1.26e-5	Educational attainment (years of education);
PAAD	cis	rs1499972	0.590	rs1456196	chr3:117654553	C/A	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.93	0.43	1.92e-8	Coffee consumption (cups per day);
PAAD	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.8	-10.07	-0.63	1.36e-18	Hemoglobin concentration;
PAAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.62	-0.35	8.05e-6	Aortic root size;
PAAD	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.93	10.75	0.66	2.13e-20	Colorectal adenoma (advanced);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07583091	chr11:18343626	GTF2H1;HPS5	-0.7	-6.29	-0.45	3.19e-9	Neuroticism;
PAAD	cis	rs6504950	0.720	rs9895901	chr17:52984885	A/G	cg18040354	chr17:53800484	TMEM100	0.49	4.43	0.34	1.82e-5	Breast cancer;
PAAD	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.63	9.06	0.59	5.95e-16	Airflow obstruction;
PAAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	1.06	6.31	0.46	2.96e-9	Schizophrenia;
PAAD	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.93	9.78	0.62	8.08e-18	Height;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg21665744	chr7:39171113	POU6F2	0.36	6.11	0.44	8.17e-9	IgG glycosylation;
PAAD	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg05085585	chr16:30420623	ZNF771	-0.44	-4.46	-0.34	1.59e-5	Tonsillectomy;
PAAD	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.61	-5.7	-0.42	5.99e-8	White matter hyperintensity burden;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07362569	chr17:61921086	SMARCD2	0.63	8.0	0.54	2.94e-13	Prudent dietary pattern;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg18769074	chr3:133464867	TF	0.42	4.84	0.37	3.18e-6	Iron status biomarkers;
PAAD	cis	rs820218	0.728	rs820152	chr17:73616088	T/C	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.28	-0.33	3.24e-5	Rotator cuff tears;
PAAD	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.54	0.52	3.88e-12	Platelet distribution width;
PAAD	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-5.86	-0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.47	4.81	0.36	3.59e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.88	10.69	0.66	2.98e-20	Menopause (age at onset);
PAAD	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.19	-0.45	5.3300000000000004e-09	Monocyte count;
PAAD	cis	rs12935418	0.672	rs11866803	chr16:81051203	T/G	cg16651780	chr16:81037892	C16orf61	0.69	6.33	0.46	2.64e-9	Mean corpuscular volume;
PAAD	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.55	-5.52	-0.41	1.44e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs7567389	0.576	rs2069902	chr2:128174863	C/G	cg11380483	chr2:127933992	NA	0.52	4.9	0.37	2.45e-6	Self-rated health;
PAAD	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.4	0.34	2.07e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs375066	0.623	rs239948	chr19:44356887	A/T	cg11993925	chr19:44307056	LYPD5	0.41	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs728616	0.867	rs56271768	chr10:81837051	T/G	cg05935833	chr10:81318306	SFTPA2	-0.65	-4.97	-0.37	1.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.66	-6.05	-0.44	1.11e-8	Platelet count;
PAAD	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.76	9.23	0.6	2.24e-16	Monocyte percentage of white cells;
PAAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.86	0.37	2.85e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.62	-7.41	-0.52	8.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.97	-0.37	1.8e-6	Bipolar disorder;
PAAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.28e-10	Coronary artery disease;
PAAD	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.75	-0.36	4.72e-6	Height;
PAAD	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.56	-4.94	-0.37	2.05e-6	P wave terminal force;
PAAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.45	0.34	1.66e-5	Breast cancer;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-7.84	-0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2908197	0.762	rs2908192	chr7:75949617	C/T	cg22830091	chr7:75961684	YWHAG	-0.63	-7.66	-0.53	1.98e-12	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.91	-9.98	-0.63	2.29e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.71	-0.36	5.55e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.93	11.46	0.68	2.64e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.661	rs17640508	chr7:104842643	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.15e-6	Schizophrenia;
PAAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.91	-10.41	-0.65	1.7e-19	Cancer (pleiotropy);
PAAD	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	5.0	0.38	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2882667	0.619	rs6861556	chr5:138188040	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.08	0.44	9.26e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.4	0.34	2.03e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7816613	0.516	rs2387626	chr8:102637195	G/T	cg20585841	chr8:102729926	NCALD	-0.66	-4.94	-0.37	2.03e-6	Age-related hearing impairment;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.07	0.55	1.95e-13	Height;
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg09667013	chr22:42394590	WBP2NL	0.55	4.63	0.35	7.76e-6	Birth weight;
PAAD	trans	rs4427176	0.507	rs11783635	chr8:9587803	T/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27269427	chr8:143472474	TSNARE1	0.59	6.53	0.47	9.26e-10	Smoking initiation;
PAAD	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	5.2	0.39	6.25e-7	Height;
PAAD	cis	rs67385638	1.000	rs67385638	chr11:5290370	C/G	cg12559170	chr11:5275217	HBG2	0.48	4.68	0.35	6.27e-6	Hemoglobin levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17396989	chr4:2011427	WHSC2	0.54	6.29	0.45	3.14e-9	Metabolite levels  (X-11787);
PAAD	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs245880	0.740	rs245898	chr7:29194143	G/A	cg17163760	chr7:29186267	CPVL	-0.52	-6.18	-0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.83	11.37	0.68	4.72e-22	Vitiligo;
PAAD	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.35e-13	Coronary artery disease;
PAAD	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-5.59	-0.41	1.05e-7	Coronary artery disease;
PAAD	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.9	-0.43	2.29e-8	Acne (severe);
PAAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.93	0.43	2e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg05528293	chr18:74961138	GALR1	0.61	4.87	0.37	2.77e-6	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.74	-0.36	4.88e-6	Daytime sleep phenotypes;
PAAD	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.62	-6.05	-0.44	1.06e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs4919087	0.532	rs61861850	chr10:99073874	C/A	cg25902810	chr10:99078978	FRAT1	-0.57	-5.35	-0.4	3.16e-7	Monocyte count;
PAAD	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg19197139	chr17:4613644	ARRB2	-0.81	-8.34	-0.56	4.1e-14	Lymphocyte counts;
PAAD	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg00531865	chr16:30841666	NA	0.6	4.5	0.34	1.36e-5	Dementia with Lewy bodies;
PAAD	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	5.0	0.38	1.56e-6	Myopia (pathological);
PAAD	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	9.89	0.63	4.02e-18	Response to antipsychotic treatment;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.76	0.36	4.46e-6	Electroencephalogram traits;
PAAD	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg10985347	chr2:127963512	CYP27C1	-0.5	-4.45	-0.34	1.66e-5	Protein C levels;
PAAD	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.91	9.83	0.62	5.95e-18	Corneal astigmatism;
PAAD	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9.3e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.75	7.35	0.51	1.15e-11	Urate levels in lean individuals;
PAAD	cis	rs2147959	0.700	rs12725863	chr1:228630986	C/T	cg18477163	chr1:228402036	OBSCN	-0.43	-4.49	-0.34	1.43e-5	Adult asthma;
PAAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-5.2	-0.39	6.33e-7	Aortic root size;
PAAD	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs28489187	0.706	rs3087894	chr1:85787118	G/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.78	4.48	0.34	1.48e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg20933634	chr6:27740509	NA	0.76	6.86	0.49	1.66e-10	Parkinson's disease;
PAAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.52	-4.62	-0.35	8.08e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.7	7.1	0.5	4.4e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.74	7.52	0.52	4.36e-12	Prostate cancer;
PAAD	cis	rs35785195	0.593	rs35304519	chr12:114236677	C/T	cg08193681	chr12:114234200	NA	0.6	4.65	0.35	7.12e-6	Daytime sleep phenotypes;
PAAD	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg08758996	chr17:66097529	LOC651250	0.52	4.34	0.33	2.6e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-5.64	-0.42	8.01e-8	Platelet count;
PAAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.62	5.07	0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs7811528	0.656	rs58091069	chr7:2705879	C/T	cg11411865	chr7:2701802	TTYH3	0.52	4.39	0.34	2.15e-5	Schizophrenia;
PAAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.7	-7.09	-0.5	4.82e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg11508081	chr17:41442227	NA	0.41	4.32	0.33	2.78e-5	Menopause (age at onset);
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.45	-4.9	-0.37	2.46e-6	Vitiligo;
PAAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	1.03	16.66	0.8	4.02e-36	Height;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-6.22	-0.45	4.48e-9	Pancreatic cancer;
PAAD	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.77	7.77	0.53	1.12e-12	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg06197492	chr11:2016605	H19	0.41	4.34	0.33	2.58e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.71	4.92	0.37	2.19e-6	Vitiligo;
PAAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.55	7.42	0.52	7.58e-12	Renal cell carcinoma;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	0.98	6.05	0.44	1.08e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs4478858	0.684	rs17440445	chr1:31722562	C/T	cg18939081	chr1:31884902	SERINC2	-0.49	-5.4	-0.4	2.57e-7	Alcohol dependence;
PAAD	cis	rs2147959	0.941	rs6426503	chr1:228651011	A/G	cg00655913	chr1:228633920	NA	0.51	4.67	0.35	6.51e-6	Adult asthma;
PAAD	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.19	-0.39	6.54e-7	Breast cancer;
PAAD	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg02811702	chr13:24901961	NA	0.51	5.42	0.4	2.31e-7	Obesity-related traits;
PAAD	trans	rs7594645	1.000	rs114031213	chr2:207619463	C/T	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg15211996	chr1:2936768	ACTRT2	0.47	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07652213	chr2:48010362	MSH6	0.61	6.3	0.46	3.04e-9	Obesity-related traits;
PAAD	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg08601574	chr20:25228251	PYGB	0.57	5.79	0.42	3.99e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg00277334	chr10:82204260	NA	-0.58	-5.67	-0.42	6.92e-8	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.59	-6.46	-0.46	1.37e-9	Post bronchodilator FEV1;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg07308232	chr7:1071921	C7orf50	-0.43	-4.36	-0.33	2.43e-5	Longevity;Endometriosis;
PAAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6449957	1.000	rs6449956	chr5:67483070	G/T	cg23036683	chr5:67512108	NA	0.53	5.21	0.39	5.99e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01942863	chr7:99769432	GPC2	0.51	4.28	0.33	3.24e-5	Platelet count;
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg19337854	chr7:99768885	GPC2	0.5	4.53	0.34	1.2e-5	Lung function (FEV1/FVC);
PAAD	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.41	0.65	1.75e-19	Smoking behavior;
PAAD	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.49	5.36	0.4	3.04e-7	Urate levels in lean individuals;
PAAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.59	6.28	0.45	3.36e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg00631329	chr6:26305371	NA	-0.45	-4.7	-0.36	5.87e-6	Educational attainment;
PAAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.67	6.02	0.44	1.25e-8	Breast cancer;
PAAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.56	7.07	0.5	5.28e-11	Urate levels in overweight individuals;
PAAD	cis	rs1864585	0.806	rs12156345	chr8:10752537	T/G	cg21775007	chr8:11205619	TDH	-0.57	-4.27	-0.33	3.37e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg11995313	chr8:8860691	ERI1	0.51	5.29	0.39	4.15e-7	Joint mobility (Beighton score);
PAAD	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.97	-0.37	1.75e-6	Menarche (age at onset);
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	6.99	0.49	8.04e-11	Renal function-related traits (BUN);
PAAD	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg10437265	chr15:77819839	NA	0.4	4.54	0.35	1.16e-5	Type 2 diabetes;
PAAD	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg20169779	chr10:135381914	SYCE1	-0.45	-4.66	-0.35	7e-6	Obesity-related traits;
PAAD	cis	rs7580658	0.711	rs12469035	chr2:127984917	A/G	cg09760422	chr2:128146352	NA	-0.33	-5.54	-0.41	1.33e-7	Protein C levels;
PAAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg06521852	chr22:38141419	TRIOBP	0.43	4.55	0.35	1.11e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9395066	0.545	rs10456119	chr6:44889045	C/T	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.26	-0.45	3.77e-9	IgG glycosylation;
PAAD	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg20636351	chr8:55087400	NA	-0.8	-9.08	-0.59	5.5e-16	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.63	-0.53	2.44e-12	Height;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg21724239	chr8:58056113	NA	0.65	4.96	0.37	1.83e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.72	4.79	0.36	3.98e-6	Body mass index;
PAAD	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.22	0.55	8.55e-14	Morning vs. evening chronotype;
PAAD	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.99	13.46	0.74	1.07e-27	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.75	8.06	0.55	2.09e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.87	7.07	0.5	5.26e-11	Axial length;
PAAD	cis	rs1015291	0.708	rs2731614	chr12:19999688	T/C	cg25401612	chr12:20009446	NA	-0.57	-5.67	-0.42	6.92e-8	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19884546	chr22:38082237	NOL12	0.6	6.53	0.47	9.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs847851	1.000	rs847851	chr6:34904584	A/G	cg13196216	chr6:34231128	NA	0.61	5.02	0.38	1.44e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.52	6.21	0.45	4.94e-9	Height;
PAAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.67	5.19	0.39	6.78e-7	Fat distribution (HIV);
PAAD	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.52	-0.34	1.23e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.28	-0.33	3.27e-5	Systemic lupus erythematosus;
PAAD	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.06	-0.7	6.53e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62408225	1.000	rs2089126	chr6:90970212	A/G	cg03795776	chr6:90687632	BACH2	0.43	4.3	0.33	3.09e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23323827	chr2:121108755	INHBB	-0.66	-7.34	-0.51	1.24e-11	Obesity-related traits;
PAAD	trans	rs7132746	0.808	rs61930131	chr12:86236903	G/A	cg13084525	chr11:34642463	EHF	0.67	6.32	0.46	2.77e-9	Lewy body disease;
PAAD	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7264396	0.887	rs6060431	chr20:34059337	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg23153227	chr6:27725408	NA	0.43	4.3	0.33	3.05e-5	Depression;
PAAD	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg15017067	chr4:17643749	FAM184B	0.44	5.16	0.39	7.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg16898833	chr6:26189333	HIST1H4D	0.66	4.91	0.37	2.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg18769074	chr3:133464867	TF	0.41	4.62	0.35	8.18e-6	Iron status biomarkers;
PAAD	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.49	4.55	0.35	1.1e-5	Endometrial cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25619106	chr3:52321767	GLYCTK	0.64	6.33	0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs11124272	0.857	rs11683744	chr2:31985308	C/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.57	-0.35	9.86e-6	Interleukin-18 levels;
PAAD	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg03098721	chr1:84464084	TTLL7	0.45	4.33	0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.74	-7.81	-0.54	8.48e-13	Prostate cancer;
PAAD	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.77	-6.73	-0.48	3.2e-10	Blood pressure (smoking interaction);
PAAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg09796270	chr17:17721594	SREBF1	0.44	4.74	0.36	4.9100000000000004e-06	Total body bone mineral density;
PAAD	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.71	-0.48	3.62e-10	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7766436	0.767	rs13215709	chr6:22604121	A/G	cg13666174	chr6:22585274	NA	-0.52	-5.75	-0.42	4.65e-8	Coronary artery disease;
PAAD	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-5.24	-0.39	5.19e-7	Mood instability;
PAAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.43	4.64	0.35	7.61e-6	Longevity;Endometriosis;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11716160	chr12:7342787	PEX5	-0.58	-6.45	-0.46	1.44e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg03037974	chr15:76606532	NA	0.52	6.1	0.44	8.6e-9	Blood metabolite levels;
PAAD	cis	rs2271400	0.556	rs9657059	chr8:56650652	T/C	cg08894788	chr8:56792171	LYN	-0.5	-4.68	-0.35	6.34e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg13870426	chr17:30244630	NA	-0.74	-6.56	-0.47	8e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6066835	1.000	rs6095244	chr20:47318774	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs354033	1.000	rs354043	chr7:149297332	C/T	cg06920324	chr7:149264011	ZNF767	-0.62	-5.1	-0.38	9.97e-7	Multiple sclerosis;
PAAD	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.43e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs2271404	0.506	rs12989775	chr2:111998827	C/G	cg23466623	chr2:111982296	NA	-0.51	-4.95	-0.37	1.92e-6	Atopic dermatitis;
PAAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.95	8.26	0.56	6.54e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg25401027	chr5:176370377	UIMC1	0.54	5.33	0.4	3.41e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.52	-4.91	-0.37	2.3e-6	Glomerular filtration rate;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.72	7.24	0.51	2.11e-11	Migraine;
PAAD	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg23153227	chr6:27725408	NA	0.43	4.41	0.34	1.94e-5	Cardiac Troponin-T levels;
PAAD	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	6.15	0.45	6.66e-9	Blood protein levels;
PAAD	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs508970	0.556	rs677303	chr11:60924738	T/C	cg24692310	chr11:60915630	VPS37C	0.34	4.71	0.36	5.56e-6	Rheumatoid arthritis;
PAAD	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.44	4.77	0.36	4.26e-6	HDL cholesterol levels;
PAAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.61	-0.88	1.74e-50	Myeloid white cell count;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2211560	0.752	rs1399164	chr1:61315473	A/C	cg00575674	chr1:61314297	NA	-0.5	-4.39	-0.34	2.1e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-8.46	-0.57	2.06e-14	Asthma;
PAAD	cis	rs2882667	0.690	rs311602	chr5:138053059	A/G	cg09476006	chr5:138032270	NA	0.51	6.58	0.47	7e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.74	-8.55	-0.57	1.23e-14	Bipolar disorder and schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15895505	chr14:105903354	MTA1	0.66	7.35	0.51	1.16e-11	Smoking initiation;
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.48	4.93	0.37	2.09e-6	Eosinophil percentage of white cells;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.59	5.93	0.43	1.97e-8	Longevity;Endometriosis;
PAAD	cis	rs4646404	0.544	rs1108579	chr17:17422354	C/T	cg07083043	chr17:17397972	RASD1	-0.39	-4.5	-0.34	1.36e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
PAAD	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.92	8.88	0.58	1.74e-15	Breast cancer;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11245990	chr11:68621969	NA	0.38	4.8	0.36	3.74e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.85	10.98	0.67	5.09e-21	Aortic root size;
PAAD	cis	rs2221894	0.959	rs1487969	chr8:28885661	A/G	cg20212339	chr8:28908912	HMBOX1	-0.49	-5.08	-0.38	1.1e-6	Obesity-related traits;
PAAD	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.49	4.51	0.34	1.31e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10712623	chr3:25469577	RARB	0.56	6.39	0.46	1.96e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg01262667	chr19:19385393	TM6SF2	0.45	5.04	0.38	1.33e-6	Tonsillectomy;
PAAD	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.54	5.9	0.43	2.25e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.96	8.41	0.56	2.82e-14	Bipolar disorder;
PAAD	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs939584	0.935	rs6752706	chr2:629831	T/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg13540341	chr19:49222985	MAMSTR	0.45	5.14	0.38	8.25e-7	Urinary metabolites (H-NMR features);
PAAD	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.6	6.47	0.46	1.28e-9	Mean corpuscular volume;
PAAD	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.63e-5	Coronary artery disease;
PAAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.47	-4.66	-0.35	6.96e-6	Multiple sclerosis;
PAAD	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg14343924	chr8:8086146	FLJ10661	-0.61	-5.1	-0.38	9.88e-7	Mood instability;
PAAD	cis	rs11264799	0.731	rs76782071	chr1:157684532	T/C	cg18268488	chr1:157545234	FCRL4	0.64	5.63	0.42	8.38e-8	IgA nephropathy;
PAAD	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.52	0.34	1.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg07841815	chr7:100318223	EPO	-0.5	-4.68	-0.35	6.34e-6	Other erythrocyte phenotypes;
PAAD	cis	rs72843506	0.586	rs76886618	chr17:19878796	T/C	cg05625806	chr17:19284432	MAPK7	0.66	4.31	0.33	2.94e-5	Schizophrenia;
PAAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.6	7.9	0.54	5.17e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13393754	chr6:114292725	HDAC2	-0.39	-4.28	-0.33	3.33e-5	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-5.73	-0.42	5.19e-8	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22120852	chr5:3932145	NA	-0.65	-6.59	-0.47	6.76e-10	Obesity-related traits;
PAAD	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.52	-5.39	-0.4	2.58e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg08886695	chr4:3369023	RGS12	-0.48	-4.54	-0.35	1.15e-5	Serum sulfate level;
PAAD	trans	rs11675636	0.520	rs11688896	chr2:136986460	T/C	cg27075654	chr16:1503444	CLCN7	0.73	6.35	0.46	2.31e-9	Alcohol dependence;
PAAD	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.32	0.56	4.58e-14	Rheumatoid arthritis;
PAAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.65	-7.45	-0.52	6.39e-12	Huntington's disease progression;
PAAD	cis	rs9810890	1.000	rs73198811	chr3:128470749	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.3	-0.51	1.5e-11	Response to antipsychotic treatment;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22785750	chr14:23067727	ABHD4	-0.71	-6.3	-0.46	3.06e-9	Neuroticism;
PAAD	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg04398451	chr17:18023971	MYO15A	-0.79	-8.41	-0.56	2.82e-14	Total body bone mineral density;
PAAD	cis	rs1359582	0.793	rs860949	chr10:90414939	A/G	cg15661332	chr10:90342814	RNLS	0.55	4.84	0.37	3.19e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.91	5.11	0.38	9.46e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.76	7.84	0.54	7.29e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16447950	chr5:562315	NA	-0.67	-5.93	-0.43	1.99e-8	Obesity-related traits;
PAAD	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs7243821	0.842	rs57710994	chr18:52630130	G/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	10.24	0.64	4.91e-19	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.53	4.56	0.35	1.04e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10510102	0.935	rs11200203	chr10:123633529	A/G	cg09536375	chr10:123735128	NSMCE4A	-0.4	-4.27	-0.33	3.41e-5	Breast cancer;
PAAD	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.62	-5.11	-0.38	9.47e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg21929781	chr1:2537748	MMEL1	-0.44	-4.69	-0.36	6.05e-6	Ulcerative colitis;
PAAD	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.54	6.45	0.46	1.38e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg12560992	chr17:57184187	TRIM37	0.67	4.93	0.37	2.15e-6	Vitamin D levels;
PAAD	cis	rs2340727	0.668	rs3767636	chr1:161817031	T/A	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg19784903	chr17:45786737	TBKBP1	-0.55	-5.82	-0.43	3.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	1.08	5.21	0.39	5.96e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs7101378	0.599	rs7927284	chr11:108899563	C/G	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.59	5.06	0.38	1.22e-6	Common traits (Other);
PAAD	cis	rs7326068	0.610	rs2772169	chr13:21314725	T/C	cg27234864	chr13:21295941	IL17D	0.59	4.94	0.37	2.04e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.46	-4.49	-0.34	1.41e-5	Mean platelet volume;
PAAD	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.78	7.5	0.52	4.93e-12	Macular telangiectasia type 2;
PAAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.49	4.49	0.34	1.39e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.0	-0.38	1.59e-6	Diastolic blood pressure;
PAAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.78	-9.09	-0.59	5.06e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-4.88	-0.37	2.65e-6	Morning vs. evening chronotype;
PAAD	cis	rs5742933	0.857	rs7571089	chr2:190561793	G/A	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.57	5.38	0.4	2.78e-7	Primary sclerosing cholangitis;
PAAD	cis	rs516243	0.806	rs7545228	chr1:10740303	G/C	cg02903756	chr1:10750680	CASZ1	-0.5	-5.6	-0.41	9.69e-8	Migraine - clinic-based;
PAAD	cis	rs4908768	0.555	rs55939938	chr1:8863664	A/T	cg06780032	chr1:8272277	NA	-0.33	-4.28	-0.33	3.24e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.92	-0.37	2.2e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14597492	chr8:125487571	RNF139	-0.67	-6.6	-0.47	6.5e-10	Smoking initiation;
PAAD	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg11995313	chr8:8860691	ERI1	0.5	5.03	0.38	1.35e-6	Myopia;Myopia (pathological);
PAAD	cis	rs10121009	0.610	rs7866794	chr9:35283368	C/T	cg11846315	chr9:35647073	NA	0.48	4.49	0.34	1.39e-5	Parkinson's disease;
PAAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.84	10.32	0.64	2.88e-19	Height;
PAAD	cis	rs2908197	0.843	rs2961041	chr7:75945944	C/T	cg22830091	chr7:75961684	YWHAG	-0.59	-6.69	-0.48	3.95e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14487039	chr6:5145161	LYRM4	-0.61	-6.34	-0.46	2.43e-9	Obesity-related traits;
PAAD	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	1.09	11.25	0.67	9.8e-22	Platelet distribution width;
PAAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg01503450	chr10:980765	NA	-0.56	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg14003231	chr6:33640908	ITPR3	0.37	4.74	0.36	4.8e-6	Plateletcrit;
PAAD	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs5015933	0.734	rs10126025	chr9:128146064	C/G	cg13590414	chr9:128173245	NA	-0.41	-4.33	-0.33	2.74e-5	Body mass index;
PAAD	cis	rs8044868	0.512	rs12935266	chr16:72157000	C/G	cg04254540	chr16:71951199	KIAA0174	-0.41	-4.27	-0.33	3.39e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.04	0.5	6.35e-11	Life satisfaction;
PAAD	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	4.35	0.33	2.45e-5	IgG glycosylation;
PAAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01200585	chr1:228362443	C1orf69	-0.51	-5.59	-0.41	1.04e-7	Diastolic blood pressure;
PAAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs590121	0.876	rs653724	chr11:75276467	G/A	cg26104986	chr11:75275303	SERPINH1	-0.46	-4.62	-0.35	8.09e-6	Coronary artery disease;
PAAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.84	7.92	0.54	4.7e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg01304814	chr3:48885189	PRKAR2A	0.64	4.35	0.33	2.53e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.55e-5	Depression;
PAAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.5	-7.31	-0.51	1.43e-11	Diastolic blood pressure;
PAAD	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.15	0.39	7.94e-7	Lung cancer in ever smokers;
PAAD	cis	rs4690686	0.500	rs72623907	chr4:177261965	C/G	cg17059388	chr4:177262070	NA	0.61	6.01	0.44	1.31e-8	Essential tremor;
PAAD	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.79	-9.21	-0.6	2.47e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.42	0.4	2.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6782025	0.737	rs1588538	chr3:121050612	A/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.85	8.18	0.55	1.05e-13	Cognitive function;
PAAD	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg20422242	chr11:95976579	MAML2	-0.6	-6.36	-0.46	2.26e-9	Coronary artery disease;
PAAD	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.7	-5.58	-0.41	1.08e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs8032158	1.000	rs8024944	chr15:56125135	C/A	cg02198044	chr15:56286336	NEDD4	-0.52	-5.49	-0.41	1.68e-7	Keloid;
PAAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.47	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.53	-5.27	-0.39	4.58e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.63	7.2	0.5	2.57e-11	Emphysema distribution in smoking;
PAAD	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg06917634	chr15:78832804	PSMA4	0.43	4.29	0.33	3.2e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg12035532	chr1:1886765	KIAA1751	-0.4	-4.39	-0.34	2.13e-5	Severe influenza A (H1N1) infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09110634	chr2:232758445	MIR1471	-0.63	-7.03	-0.5	6.67e-11	Obesity-related traits;
PAAD	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs2571445	0.813	rs1991161	chr2:218676890	A/G	cg10147666	chr2:219646481	CYP27A1	-0.44	-4.46	-0.34	1.57e-5	Pulmonary function;Coronary artery disease;Lung function (FEV1);High light scatter reticulocyte count;Pulmonary function (smoking interaction);High light scatter reticulocyte percentage of red cells;Lung function (FEV1/FVC);Lung function (FVC);Immature fraction of reticulocytes;
PAAD	cis	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.88	-0.37	2.62e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.62	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.92	7.04	0.5	6.03e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.49	-4.5	-0.34	1.32e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg02450064	chr17:40260053	DHX58	-0.38	-4.42	-0.34	1.89e-5	Fibrinogen levels;
PAAD	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-5.49	-0.41	1.62e-7	Neuroticism;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.71	5.52	0.41	1.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.61	6.2	0.45	5.19e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7260598	0.539	rs7250219	chr19:24095611	A/T	cg09235885	chr19:23456588	NA	-0.63	-4.31	-0.33	2.97e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.79	-0.53	1e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.9e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.86	10.31	0.64	3.1400000000000002e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg19264203	chr11:92714893	MTNR1B	0.39	4.44	0.34	1.71e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs73815153	0.546	rs6869019	chr5:180483973	G/T	cg00050152	chr5:180479829	BTNL9	0.7	4.44	0.34	1.74e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg12568669	chr8:11666485	FDFT1	-0.31	-5.24	-0.39	5.26e-7	Monocyte count;
PAAD	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-6.7	-0.48	3.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.54	-0.47	9.02e-10	Glomerular filtration rate;
PAAD	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg25324976	chr17:61989376	CSHL1	0.55	4.56	0.35	1.03e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	1.16	9.81	0.62	6.62e-18	Height;
PAAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.75	8.87	0.58	1.88e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.51	-5.24	-0.39	5.33e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-1.01	-6.97	-0.49	8.83e-11	Coronary artery disease;
PAAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.78	7.76	0.53	1.16e-12	Urate levels in lean individuals;
PAAD	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.41	4.64	0.35	7.59e-6	Inflammatory bowel disease;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg03983715	chr16:68378420	PRMT7	-0.7	-5.18	-0.39	6.97e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg08999081	chr20:33150536	PIGU	0.45	4.28	0.33	3.35e-5	Skin pigmentation;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.89	-12.11	-0.7	4.8e-24	Menopause (age at onset);
PAAD	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.79	-6.64	-0.47	5.16e-10	Cancer;
PAAD	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.85	9.85	0.62	5.25e-18	Height;
PAAD	cis	rs939584	1.000	rs939582	chr2:622723	A/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs6708413	0.528	rs7567885	chr2:103108852	G/T	cg13897122	chr2:103039542	IL18RAP	0.45	5.01	0.38	1.51e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04081257	chr3:148706325	NA	0.58	6.64	0.47	5.23e-10	Smoking initiation;
PAAD	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg05754148	chr16:3507555	NAT15	0.7	4.98	0.37	1.73e-6	Tuberculosis;
PAAD	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg05425664	chr17:57184151	TRIM37	0.52	4.54	0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg25650185	chr19:21324782	ZNF431	0.48	4.42	0.34	1.83e-5	Pain;
PAAD	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg08917208	chr2:24149416	ATAD2B	0.5	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg14709524	chr16:89940631	TCF25	0.99	4.6	0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.79	6.5	0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16417436	chr16:28758564	NA	0.45	4.64	0.35	7.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.85	-8.19	-0.55	1.01e-13	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-4.41	-0.34	1.98e-5	Height;
PAAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.05	-0.38	1.24e-6	Monocyte percentage of white cells;
PAAD	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg15654264	chr1:150340011	RPRD2	0.51	4.84	0.37	3.18e-6	Migraine;
PAAD	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	8.06	0.55	2.1e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg02574844	chr11:5959923	NA	0.54	5.5	0.41	1.59e-7	DNA methylation (variation);
PAAD	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03105603	chr7:39772936	LOC349114	0.69	7.57	0.52	3.4e-12	Myopia (pathological);
PAAD	cis	rs2067615	0.831	rs1922437	chr12:107058045	C/T	cg19260189	chr12:106995001	RFX4	0.35	4.25	0.33	3.73e-5	Heart rate;
PAAD	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs346785	0.692	rs2279052	chr17:74287204	C/G	cg09812376	chr17:74270190	QRICH2	-0.47	-5.91	-0.43	2.17e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-1.05	-14.31	-0.76	5.69e-30	Breast cancer;
PAAD	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg19640130	chr10:64028056	RTKN2	-0.37	-4.53	-0.34	1.21e-5	Rheumatoid arthritis;
PAAD	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs55728055	0.661	rs73158601	chr22:31790417	C/A	cg01338084	chr22:32026380	PISD	1.4	7.05	0.5	5.87e-11	Age-related hearing impairment;
PAAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.61	5.55	0.41	1.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs17014483	0.822	rs3017895	chr4:89649491	C/T	cg13081009	chr1:8430745	RERE	-0.9	-6.61	-0.47	6.26e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.55	5.24	0.39	5.18e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.54	-4.79	-0.36	4e-6	Obesity;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg05042697	chr2:10830656	NOL10	-0.45	-4.43	-0.34	1.81e-5	Prostate cancer;
PAAD	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.76e-8	Eye color traits;
PAAD	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26897989	chr16:1907736	C16orf73	-0.55	-4.92	-0.37	2.26e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs507080	0.733	rs4486664	chr11:118569067	A/C	cg08498647	chr11:118550644	TREH	-0.38	-4.33	-0.33	2.71e-5	Serum metabolite levels;
PAAD	cis	rs7975161	0.520	rs9739833	chr12:104737430	A/T	cg25273343	chr12:104657179	TXNRD1	-0.87	-4.7	-0.36	5.88e-6	Toenail selenium levels;
PAAD	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.92	-0.43	2.03e-8	Menarche (age at onset);
PAAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.36	-0.51	1.07e-11	Coffee consumption (cups per day);
PAAD	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.65	0.35	7.19e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg05333889	chr7:157238977	NA	0.48	4.68	0.35	6.32e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-5.01	-0.38	1.46e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.13	-0.6	3.89e-16	Schizophrenia;
PAAD	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6e-9	Subjective well-being;
PAAD	cis	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg18531004	chr3:128564980	NA	-0.89	-5.02	-0.38	1.43e-6	Dental caries;
PAAD	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.4	0.4	2.54e-7	Bipolar disorder;
PAAD	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.41	0.4	2.4e-7	Lung cancer in ever smokers;
PAAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg06970076	chr16:1560791	IFT140	0.62	4.99	0.37	1.66e-6	Coronary artery disease;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.43	-4.63	-0.35	7.71e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.68	4.76	0.36	4.41e-6	Hip geometry;
PAAD	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.46	-0.34	1.6e-5	Plateletcrit;Platelet count;
PAAD	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.67	7.45	0.52	6.47e-12	Coronary artery disease;
PAAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.52	-6.89	-0.49	1.36e-10	Height;
PAAD	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9880772	0.776	rs4450763	chr3:27806852	A/G	cg21473142	chr3:27762095	EOMES	0.35	6.58	0.47	7.11e-10	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs12042052	1.000	rs72754230	chr1:232935071	A/G	cg02191044	chr1:232940990	KIAA1383	0.9	4.43	0.34	1.78e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	1.1	16.87	0.81	1.19e-36	Menarche (age at onset);
PAAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.49	-0.57	1.73e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg02254261	chr7:158964346	NA	-0.61	-4.72	-0.36	5.42e-6	Myopia (pathological);
PAAD	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.12	-0.38	9.01e-7	Morning vs. evening chronotype;
PAAD	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.64	-5.88	-0.43	2.46e-8	Breast size;
PAAD	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.77	6.71	0.48	3.69e-10	Chronic kidney disease;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.9	10.98	0.67	5.07e-21	Menarche (age at onset);
PAAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.49	-5.07	-0.38	1.13e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7671266	0.532	rs28730480	chr4:10048867	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	4.99	0.38	1.63e-6	Cardiovascular disease risk factors;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04771938	chr2:97405809	LMAN2L	-0.64	-6.39	-0.46	1.94e-9	Lung cancer in ever smokers;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg08677398	chr8:58056175	NA	0.61	4.54	0.35	1.13e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.6	5.61	0.41	9.31e-8	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg26174226	chr8:58114915	NA	-0.67	-4.78	-0.36	4.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.65	-4.61	-0.35	8.32e-6	Parkinson's disease;
PAAD	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg01763666	chr17:80159506	CCDC57	-0.45	-4.56	-0.35	1.06e-5	Life satisfaction;
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.44	-4.87	-0.37	2.73e-6	Platelet distribution width;
PAAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.37	-0.4	2.84e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.96	5.98	0.44	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg02301978	chr19:7069707	ZNF557	-0.63	-6.71	-0.48	3.62e-10	Blood protein levels;
PAAD	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.21e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs75595592	chr10:46039930	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14128259	chr12:27848523	REP15	-0.64	-7.1	-0.5	4.41e-11	Obesity-related traits;
PAAD	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.38	5.14	0.38	8.36e-7	Schizophrenia;
PAAD	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.45	7.15	0.5	3.5e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg26818257	chr2:241905806	NA	0.42	4.5	0.34	1.36e-5	Urinary metabolites;
PAAD	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.73	-5.87	-0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.71	-9.47	-0.61	5.17e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25551661	chr18:11851326	GNAL;CHMP1B	0.63	7.38	0.51	9.47e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.6	5.98	0.44	1.51e-8	Monocyte count;
PAAD	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.78	8.1	0.55	1.68e-13	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg20592124	chr2:65290738	CEP68	-0.47	-4.6	-0.35	8.76e-6	Pulse pressure;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.59	6.56	0.47	8.17e-10	Iron status biomarkers;
PAAD	cis	rs11209002	0.956	rs11209000	chr1:67578514	C/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg19254793	chr6:44695348	NA	-0.45	-4.37	-0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.24	21.01	0.86	8.44e-47	Testicular germ cell tumor;
PAAD	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.8	8.3	0.56	5.23e-14	Uric acid levels;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.63	-0.42	8.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg00750074	chr16:89608354	SPG7	-0.57	-5.66	-0.42	7.4e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27297192	chr10:134578999	INPP5A	0.61	5.48	0.41	1.69e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.64	0.53	2.32e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.53	4.82	0.36	3.39e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.58	-0.52	3.23e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22162314	chr17:61951766	CSH2	-0.58	-5.95	-0.43	1.8e-8	Height;
PAAD	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.41	-0.34	1.92e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg23912435	chr1:150601613	ENSA	0.49	4.51	0.34	1.27e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.47	5.02	0.38	1.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.61	4.48	0.34	1.44e-5	Exhaled nitric oxide output;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13990065	chr11:73468824	RAB6A	0.59	6.46	0.46	1.37e-9	Smoking initiation;
PAAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07701084	chr6:150067640	NUP43	0.64	6.4	0.46	1.86e-9	Testicular germ cell tumor;
PAAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.72	8.42	0.56	2.54e-14	Multiple sclerosis;
PAAD	cis	rs1577917	0.559	rs2223788	chr6:86811920	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.58	-0.41	1.06e-7	Response to antipsychotic treatment;
PAAD	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.62e-7	Bladder cancer;
PAAD	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg17076780	chr6:43251928	TTBK1	0.55	4.25	0.33	3.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7752195	0.730	rs62392365	chr6:25371369	A/T	cg26336265	chr6:25042955	NA	0.86	4.81	0.36	3.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16958440	0.737	rs16950096	chr18:44745546	T/C	cg17192377	chr18:44677553	HDHD2	1.02	5.43	0.4	2.15e-7	Sitting height ratio;
PAAD	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-7.04	-0.5	6.03e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-1.03	-7.93	-0.54	4.3e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.64	-0.35	7.34e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.82	-7.4	-0.51	8.47e-12	Homoarginine levels;
PAAD	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	1.04	13.92	0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.65	-6.48	-0.47	1.21e-9	Prostate cancer;
PAAD	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.88	0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg10820045	chr2:198174542	NA	0.48	4.86	0.37	2.88e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg12310025	chr6:25882481	NA	0.49	4.54	0.35	1.13e-5	Iron status biomarkers;
PAAD	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.61	0.35	8.3e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7896471	0.655	rs4919415	chr10:101789817	A/C	cg09956859	chr10:101293089	NKX2-3	-0.8	-4.5	-0.34	1.34e-5	Blood protein levels;
PAAD	cis	rs746265	0.938	rs12595668	chr15:39573535	A/G	cg10099207	chr15:39544144	C15orf54	0.55	4.3	0.33	3.01e-5	PR interval;
PAAD	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.36e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	6.07	0.44	9.58e-9	Prudent dietary pattern;
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.91	9.75	0.62	9.78e-18	Blood metabolite levels;
PAAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.8	8.15	0.55	1.26e-13	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg10950924	chr17:47092072	IGF2BP1	-0.61	-8.8	-0.58	2.74e-15	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.65	7.37	0.51	1.02e-11	Huntington's disease progression;
PAAD	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg23958373	chr8:599963	NA	-1.13	-7.32	-0.51	1.37e-11	IgG glycosylation;
PAAD	cis	rs7202877	0.561	rs2865532	chr16:75350975	A/G	cg03315344	chr16:75512273	CHST6	0.62	5.08	0.38	1.08e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg18888403	chr1:24152774	HMGCL	0.39	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.68	0.35	6.27e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.78	0.42	4.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.76	7.93	0.54	4.43e-13	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322817	0.691	rs2499652	chr6:105269959	G/A	cg02098413	chr6:105308735	HACE1	0.43	5.4	0.4	2.56e-7	Thyroid stimulating hormone;
PAAD	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.83	-6.01	-0.44	1.33e-8	Coronary artery disease;
PAAD	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs933117	0.892	rs112364845	chr21:31070537	T/A	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.29	-0.33	3.18e-5	Body mass index;
PAAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.34	-0.4	3.39e-7	Diastolic blood pressure;
PAAD	cis	rs9462027	0.517	rs2744973	chr6:34580221	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.38	-4.42	-0.34	1.84e-5	Systemic lupus erythematosus;
PAAD	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.62	5.58	0.41	1.1e-7	Blood metabolite levels;
PAAD	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.98	-0.44	1.55e-8	Menarche (age at onset);
PAAD	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.57	-5.5	-0.41	1.59e-7	Lymphocyte counts;
PAAD	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-9.13	-0.6	3.88e-16	Dental caries;
PAAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.16	-0.45	6.11e-9	Total body bone mineral density;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.41e-8	Life satisfaction;
PAAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg21724239	chr8:58056113	NA	0.68	5.42	0.4	2.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg07703079	chr11:430292	ANO9	0.89	5.66	0.42	7.19e-8	Body mass index;
PAAD	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.58	5.94	0.43	1.91e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.62	7.41	0.51	8.37e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.49	5.05	0.38	1.28e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.66	6.25	0.45	3.88e-9	Refractive astigmatism;
PAAD	cis	rs727479	0.962	rs12595627	chr15:51517100	A/G	cg21478137	chr15:51532386	CYP19A1	0.61	6.49	0.47	1.16e-9	Estradiol levels;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg00166722	chr3:10149974	C3orf24	0.71	6.36	0.46	2.29e-9	Alzheimer's disease;
PAAD	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg15654264	chr1:150340011	RPRD2	0.53	5.19	0.39	6.63e-7	Migraine;
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.81	-7.78	-0.53	1.06e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg01064725	chr1:204461714	NA	-0.54	-5.07	-0.38	1.15e-6	Schizophrenia;
PAAD	cis	rs17407555	0.789	rs4348091	chr4:10115363	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-5.8	-0.43	3.72e-8	Schizophrenia (age at onset);
PAAD	cis	rs315934	1.000	rs315934	chr2:113883706	T/C	cg24553058	chr2:113831203	IL1F10	-0.54	-4.36	-0.33	2.36e-5	Dysmenorrheic pain;
PAAD	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.95	-8.57	-0.57	1.1e-14	Bipolar disorder;
PAAD	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.7	6.99	0.49	8.14e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.61	-5.87	-0.43	2.7e-8	Psoriasis;
PAAD	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.41	-5.08	-0.38	1.1e-6	Menopause (age at onset);
PAAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.61	-7.67	-0.53	1.93e-12	Diastolic blood pressure;
PAAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg25204440	chr1:209979598	IRF6	-0.56	-4.54	-0.35	1.16e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.89	-0.37	2.57e-6	Mean corpuscular volume;
PAAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.69e-10	Lung cancer;
PAAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-1.02	-14.27	-0.76	7.6e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07415687	chr6:7910841	TXNDC5	-0.61	-6.31	-0.46	2.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs12936587	0.807	rs9913096	chr17:17546826	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-4.63	-0.35	7.86e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg16205897	chr5:131564050	P4HA2	-0.38	-4.32	-0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg12573674	chr2:1569213	NA	-0.67	-5.28	-0.39	4.39e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-5.74	-0.42	4.97e-8	Total body bone mineral density;
PAAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs73082363	0.609	rs73082357	chr3:49083566	G/A	cg19401529	chr3:49056140	DALRD3	1.0	6.81	0.48	2.11e-10	Coronary artery disease;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.72	0.58	4.51e-15	Lung cancer;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08219700	chr8:58056026	NA	0.63	4.93	0.37	2.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg07154921	chr7:157260426	NA	0.45	4.41	0.34	1.91e-5	Body mass index;
PAAD	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.7	-7.0	-0.49	7.68e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs11811982	0.793	rs75606178	chr1:227421821	A/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.46	-6.93	-0.49	1.13e-10	Cutaneous nevi;
PAAD	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.52	5.4	0.4	2.53e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.15	16.59	0.8	6.39e-36	Cognitive function;
PAAD	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg10208897	chr5:178548229	ADAMTS2	0.53	4.72	0.36	5.26e-6	Pubertal anthropometrics;
PAAD	cis	rs12138061	0.954	rs6588355	chr1:50113591	T/C	cg09846084	chr1:50888024	DMRTA2	0.54	4.55	0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.47	-0.34	1.49e-5	Joint mobility (Beighton score);
PAAD	cis	rs10934631	1.000	rs7619630	chr3:122696958	T/A	cg04830808	chr3:122712224	SEMA5B	0.47	4.6	0.35	8.83e-6	Vascular endothelial growth factor levels;
PAAD	cis	rs17023223	0.537	rs2361272	chr1:119603417	T/C	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.62	5.83	0.43	3.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.82	-8.83	-0.58	2.41e-15	Mortality in heart failure;
PAAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg03959625	chr15:84868606	LOC388152	0.49	5.43	0.4	2.22e-7	Schizophrenia;
PAAD	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.48	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs6942407	0.592	rs1024457	chr7:86764142	T/G	cg02420886	chr7:86849541	C7orf23	0.59	4.61	0.35	8.46e-6	Food allergy;
PAAD	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-5.33	-0.4	3.44e-7	Vitiligo;
PAAD	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg24220031	chr2:73402428	NA	0.44	6.78	0.48	2.53e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7168592	1.000	rs35086434	chr15:101743925	A/C	cg24254196	chr15:101719523	CHSY1	-0.68	-4.83	-0.37	3.24e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-5.24	-0.39	5.37e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.34	-0.46	2.51e-9	Schizophrenia;
PAAD	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg14181355	chr19:12984996	MAST1	-0.45	-4.45	-0.34	1.66e-5	Mean corpuscular volume;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma;
PAAD	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.48	-5.91	-0.43	2.18e-8	Atrioventricular conduction;
PAAD	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.75	-8.22	-0.55	8.52e-14	Schizophrenia;
PAAD	cis	rs1879734	0.731	rs6694399	chr1:54159198	C/T	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.24	-0.8	5.06e-35	Ulcerative colitis;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.71	-7.12	-0.5	3.92e-11	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.56	5.77	0.42	4.32e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg22437258	chr11:111473054	SIK2	0.64	6.48	0.47	1.21e-9	Primary sclerosing cholangitis;
PAAD	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.55	-0.57	1.22e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4843185	0.731	rs10514608	chr16:85713173	C/G	cg26571870	chr16:85723150	GINS2	-0.45	-5.55	-0.41	1.22e-7	Platelet distribution width;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-5.98	-0.44	1.56e-8	Lymphocyte counts;
PAAD	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.72	6.68	0.48	4.28e-10	Obesity-related traits;
PAAD	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.23	0.51	2.21e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.43	0.68	3.07e-22	Smoking behavior;
PAAD	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg10547527	chr2:198650123	BOLL	-0.7	-4.73	-0.36	5.07e-6	Ulcerative colitis;
PAAD	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	0.68	4.99	0.38	1.6e-6	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg24530489	chr15:56299380	NA	-0.92	-4.39	-0.34	2.07e-5	Delta-5 desaturase activity;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.75	7.81	0.54	8.79e-13	Neuroticism;
PAAD	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	trans	rs992005	0.894	rs7601948	chr2:199520605	G/A	cg12456799	chr10:106441036	SORCS3	-0.38	-6.41	-0.46	1.73e-9	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9638182	0.848	rs55747707	chr7:73037366	G/A	cg07467649	chr7:72856462	BAZ1B	0.52	4.69	0.36	5.94e-6	Triglycerides;
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.52	-0.41	1.45e-7	Atopic dermatitis;
PAAD	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg10395934	chr14:104002654	TRMT61A	0.47	4.61	0.35	8.53e-6	Body mass index;
PAAD	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.57	-0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg19192590	chr2:178524533	PDE11A	0.39	4.33	0.33	2.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.03	0.55	2.44e-13	Colorectal cancer;
PAAD	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.74	7.96	0.54	3.77e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg18884388	chr7:190334	NA	0.53	4.25	0.33	3.72e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2479106	0.963	rs1778900	chr9:126549420	T/G	cg16191174	chr9:126692580	DENND1A	0.53	4.93	0.37	2.14e-6	Polycystic ovary syndrome;
PAAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs6089829	0.632	rs62197308	chr20:61660705	T/C	cg08564027	chr20:61660810	NA	-0.8	-7.33	-0.51	1.26e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17155006	0.655	rs94604	chr7:107733856	C/T	cg05962710	chr7:107745446	LAMB4	-0.46	-5.75	-0.42	4.67e-8	Pneumococcal bacteremia;
PAAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-1.22	-12.07	-0.7	5.9e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.68e-6	Cognitive function;
PAAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.45	-4.82	-0.36	3.46e-6	Major depressive disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01722343	chr4:25235437	PI4K2B	0.57	6.34	0.46	2.43e-9	Monocyte percentage of white cells;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.59	0.35	9.28e-6	Bipolar disorder;
PAAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-9.76	-0.62	8.82e-18	Total body bone mineral density;
PAAD	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs2242420	0.920	rs829406	chr1:21949462	A/G	cg26362272	chr1:22108717	USP48	0.56	4.43	0.34	1.77e-5	Hematological and biochemical traits;
PAAD	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg11262906	chr1:85462892	MCOLN2	0.63	5.01	0.38	1.53e-6	Serum sulfate level;
PAAD	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg09682330	chr6:28411287	ZSCAN23	0.41	5.0	0.38	1.55e-6	Pubertal anthropometrics;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09963654	chr16:2806322	SRRM2	0.63	6.38	0.46	1.99e-9	Smoking initiation;
PAAD	cis	rs6142102	0.602	rs10485503	chr20:32557842	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.67	0.35	6.54e-6	Skin pigmentation;
PAAD	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg09835421	chr16:68378352	PRMT7	-0.64	-4.78	-0.36	4.06e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-1.01	-12.84	-0.72	4.95e-26	Refractive error;
PAAD	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.65	5.96	0.44	1.68e-8	Height;
PAAD	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.65	5.88	0.43	2.52e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.49	6.28	0.45	3.33e-9	Schizophrenia;
PAAD	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-5.84	-0.43	3.12e-8	Prevalent atrial fibrillation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00861635	chr16:3285425	ZNF200	-0.59	-7.06	-0.5	5.62e-11	Body fat percentage;
PAAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.64	-6.15	-0.45	6.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2790216	1.000	rs2790174	chr10:60031931	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.78	-8.47	-0.57	1.98e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.57	-0.35	1.01e-5	Type 2 diabetes;
PAAD	cis	rs288326	0.561	rs80099669	chr2:183776981	G/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.7	0.42	5.93e-8	Blood protein levels;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs3779195	0.697	rs13232861	chr7:97929081	A/G	cg24562669	chr7:97807699	LMTK2	0.51	4.54	0.35	1.13e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.49	4.8	0.36	3.74e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg14345882	chr6:26364793	BTN3A2	-0.72	-5.1	-0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3112530	1.000	rs982494	chr5:152645213	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	0.68	4.8	0.36	3.77e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.83	4.92	0.37	2.19e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13560548	chr3:10150139	C3orf24	0.59	5.26	0.39	4.83e-7	Alzheimer's disease;
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg14926445	chr8:58193284	C8orf71	-0.6	-4.65	-0.35	7.16e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.78	-6.64	-0.47	5.2400000000000005e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg01200585	chr1:228362443	C1orf69	0.57	6.29	0.45	3.15e-9	Diastolic blood pressure;
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg17986701	chr20:44574422	PCIF1	0.59	6.09	0.44	8.99e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	1.07	14.13	0.75	1.74e-29	Testicular germ cell tumor;
PAAD	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.75	-0.48	2.85e-10	Glomerular filtration rate;
PAAD	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-4.49	-0.34	1.4e-5	Blood protein levels;
PAAD	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.54	-4.79	-0.36	3.89e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.69	8.06	0.55	2.08e-13	Colorectal cancer;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.7	-0.42	6.17e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.77	-8.0	-0.54	2.89e-13	Blood metabolite levels;
PAAD	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg08917208	chr2:24149416	ATAD2B	0.5	4.47	0.34	1.5e-5	Asthma;
PAAD	cis	rs3925075	0.500	rs3764327	chr16:31273129	T/C	cg02846316	chr16:31340340	ITGAM	0.49	5.71	0.42	5.78e-8	IgA nephropathy;
PAAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.25e-16	Aortic root size;
PAAD	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06850241	chr22:41845214	NA	-0.58	-5.13	-0.38	8.8e-7	Vitiligo;
PAAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.86	10.36	0.64	2.29e-19	Menopause (age at onset);
PAAD	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg14343924	chr8:8086146	FLJ10661	-0.54	-4.42	-0.34	1.86e-5	Neuroticism;
PAAD	cis	rs11264799	0.603	rs12730818	chr1:157575630	T/A	cg18268488	chr1:157545234	FCRL4	0.43	4.9	0.37	2.42e-6	IgA nephropathy;
PAAD	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	5.98e-6	Plateletcrit;
PAAD	cis	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg01990334	chr1:42801334	FOXJ3	-0.58	-5.46	-0.41	1.88e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg18538332	chr22:24372958	LOC391322	-0.61	-4.62	-0.35	8.29e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22442454	chr1:209979470	IRF6	0.38	4.25	0.33	3.69e-5	Monobrow;
PAAD	cis	rs6604026	0.630	rs2263247	chr1:93364067	T/C	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg04362960	chr10:104952993	NT5C2	0.5	4.53	0.35	1.16e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg14829360	chr17:73884958	NA	-0.57	-5.97	-0.44	1.57e-8	White matter hyperintensity burden;
PAAD	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs7264396	0.667	rs224368	chr20:34070380	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	4.29	0.33	3.14e-5	Total cholesterol levels;
PAAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14585907	chr11:94497474	NA	-0.6	-6.75	-0.48	2.91e-10	Obesity-related traits;
PAAD	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.75	-8.27	-0.56	6.23e-14	Inflammatory bowel disease;
PAAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.49	-6.13	-0.45	7.16e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs11771526	0.551	rs6462344	chr7:32254889	T/C	cg13207630	chr7:32358064	NA	-0.7	-4.55	-0.35	1.09e-5	Body mass index;
PAAD	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg17325771	chr7:75508891	RHBDD2	0.3	4.26	0.33	3.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs704	0.739	rs2027993	chr17:26706946	G/T	cg10342447	chr17:26645325	TMEM97	-0.36	-4.43	-0.34	1.8e-5	Osteoprotegerin levels;
PAAD	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg19980929	chr12:42632907	YAF2	-0.58	-7.0	-0.49	7.6e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.68	-8.05	-0.55	2.18e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.85	-6.39	-0.46	1.92e-9	Hair shape;
PAAD	cis	rs7567389	0.599	rs6430938	chr2:128162623	A/G	cg09760422	chr2:128146352	NA	-0.41	-6.01	-0.44	1.35e-8	Self-rated health;
PAAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg14703610	chr5:56206110	C5orf35	0.56	5.22	0.39	5.66e-7	Coronary artery disease;
PAAD	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.94	-7.91	-0.54	5.04e-13	Dupuytren's disease;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.69	0.48	4.11e-10	Height;
PAAD	trans	rs12137025	1.000	rs56017959	chr1:223848541	G/T	cg18879828	chr11:46942432	NA	-0.77	-6.46	-0.46	1.33e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.62	5.07	0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.8	-8.78	-0.58	3.17e-15	Body mass index;
PAAD	cis	rs58521262	0.585	rs1645766	chr19:23209241	C/A	cg02350677	chr19:23254381	NA	0.26	4.61	0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs9462027	0.883	rs6941110	chr6:34791334	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.0	-0.38	1.59e-6	Systemic lupus erythematosus;
PAAD	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.53	-5.35	-0.4	3.22e-7	Mean platelet volume;
PAAD	cis	rs7577696	0.814	rs479333	chr2:32489158	C/G	cg02381751	chr2:32503542	YIPF4	-0.44	-4.79	-0.36	3.95e-6	Inflammatory biomarkers;
PAAD	cis	rs3764400	0.567	rs1979897	chr17:46309546	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs54211	0.572	rs137626	chr22:39716271	A/G	cg05872129	chr22:39784769	NA	-0.65	-4.34	-0.33	2.58e-5	Sudden cardiac arrest;
PAAD	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.94	-11.02	-0.67	3.98e-21	Monocyte count;
PAAD	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.67	-6.96	-0.49	9.34e-11	Capecitabine sensitivity;
PAAD	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	4.36	0.33	2.42e-5	Mood instability;
PAAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.94	6.95	0.49	1.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg05110241	chr16:68378359	PRMT7	-0.98	-5.08	-0.38	1.08e-6	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs4676482	0.577	rs57365951	chr3:39264532	C/A	cg02254461	chr3:39195904	CSRNP1	0.63	4.46	0.34	1.58e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.43	5.12	0.38	9.17e-7	Psoriasis;
PAAD	cis	rs6466055	0.661	rs7782673	chr7:104917508	G/C	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.5	-5.81	-0.43	3.53e-8	Mean corpuscular volume;
PAAD	cis	rs2992756	0.663	rs12750779	chr1:18805048	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.48e-9	Breast cancer;
PAAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.51	4.31	0.33	2.94e-5	Height;
PAAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg19592336	chr6:28129416	ZNF389	0.62	4.4	0.34	2.05e-5	Parkinson's disease;
PAAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14169450	chr9:139327907	INPP5E	0.53	4.77	0.36	4.2e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs11669133	1.000	rs117068342	chr19:11096610	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.03	-6.28	-0.45	3.36e-9	Mitochondrial DNA levels;
PAAD	cis	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.88	9.35	0.6	1.09e-16	Corneal astigmatism;
PAAD	cis	rs4294134	0.608	rs35956223	chr7:135245054	C/T	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs11203032	1.000	rs17117126	chr10:90964026	A/G	cg16672925	chr10:90967113	CH25H	0.75	6.01	0.44	1.29e-8	Heart failure;
PAAD	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.57	-6.68	-0.48	4.19e-10	Schizophrenia;
PAAD	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.46	4.27	0.33	3.39e-5	HDL cholesterol;
PAAD	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.83	-5.97	-0.44	1.65e-8	Facial morphology (factor 23);
PAAD	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg05625103	chr10:2543513	NA	0.5	4.94	0.37	2.04e-6	Age-related hearing impairment;
PAAD	cis	rs874460	1.000	rs78320072	chr19:47182842	G/A	cg13467550	chr19:47212573	PRKD2	-0.72	-4.25	-0.33	3.64e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg00576331	chr11:65640516	EFEMP2	-0.5	-5.02	-0.38	1.43e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg03909863	chr11:638404	DRD4	-0.68	-6.03	-0.44	1.17e-8	Systemic lupus erythematosus;
PAAD	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-5.24	-0.39	5.32e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6496932	0.755	rs4842876	chr15:85889322	T/C	cg19183879	chr15:85880815	NA	-0.54	-4.82	-0.36	3.42e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg26174226	chr8:58114915	NA	-0.63	-4.5	-0.34	1.32e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.88	10.73	0.66	2.45e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg05519781	chr21:40033154	ERG	0.5	5.89	0.43	2.41e-8	Coronary artery disease;
PAAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg11764359	chr7:65958608	NA	0.74	4.86	0.37	2.94e-6	Diabetic kidney disease;
PAAD	cis	rs863345	0.604	rs10908654	chr1:158455790	A/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16886045	chr19:1269073	CIRBP;C19orf23	0.71	7.26	0.51	1.86e-11	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs73196964	chr3:128436391	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs288326	0.561	rs17265866	chr2:183822374	G/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs9815354	0.951	rs6599167	chr3:41750260	A/G	cg03022575	chr3:42003672	ULK4	0.87	6.29	0.45	3.2e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10821973	0.527	rs4115469	chr10:64018865	T/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.64	8.65	0.57	6.89e-15	Eye color traits;
PAAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg02781088	chr2:113192302	RGPD8;RGPD5	0.91	6.56	0.47	7.98e-10	Yeast infection;
PAAD	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg07395648	chr5:131743802	NA	-0.53	-4.49	-0.34	1.41e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs3736485	0.934	rs12442803	chr15:51898754	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.77e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.97	15.03	0.77	7.21e-32	Height;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg24879335	chr3:133465180	TF	0.57	5.99	0.44	1.47e-8	Iron status biomarkers;
PAAD	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.8	-0.43	3.75e-8	P wave terminal force;
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.54	5.04	0.38	1.3e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg04522676	chr10:134968826	NA	0.47	4.49	0.34	1.38e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs375066	0.935	rs407731	chr19:44418077	A/G	cg08633290	chr19:44405433	NA	0.53	5.32	0.4	3.58e-7	Breast cancer;
PAAD	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg18649319	chr8:144631768	NA	-0.3	-4.71	-0.36	5.45e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-1.0	-6.88	-0.49	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4742903	0.904	rs10761015	chr9:107007200	C/T	cg14250997	chr9:106856677	SMC2	0.43	4.64	0.35	7.62e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	5.94	0.43	1.86e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13278732	0.500	rs12550104	chr8:99017665	G/A	cg16297171	chr8:99017690	MATN2	-0.5	-4.29	-0.33	3.15e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.34	0.6	1.16e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg01528321	chr10:82214614	TSPAN14	1.19	12.58	0.71	2.5e-25	Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05010219	chr10:134210111	PWWP2B	0.68	7.5	0.52	5.06e-12	Myopia (pathological);
PAAD	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.78	9.12	0.59	4.13e-16	Eosinophil percentage of white cells;
PAAD	cis	rs9395066	0.545	rs6925467	chr6:44998038	T/A	cg25276700	chr6:44698697	NA	0.48	5.59	0.41	1.02e-7	Height;
PAAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.65	6.71	0.48	3.57e-10	Height;
PAAD	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg07884673	chr3:53033167	SFMBT1	-0.65	-4.3	-0.33	3.09e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg16685388	chr1:42384056	HIVEP3	0.38	4.25	0.33	3.69e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7668190	0.924	rs28622224	chr4:55088093	C/T	cg17187183	chr4:55093834	PDGFRA	0.45	4.4	0.34	2.07e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.65	5.38	0.4	2.81e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg14631576	chr9:95140430	CENPP	-0.63	-6.26	-0.45	3.79e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22442454	chr1:209979470	IRF6	0.43	4.88	0.37	2.7e-6	Monobrow;
PAAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs28472312	0.762	rs62037423	chr16:28964716	A/G	cg16576597	chr16:28551801	NUPR1	-0.47	-4.63	-0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.41	0.4	2.45e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg02056144	chr12:54070517	ATP5G2	-0.46	-4.79	-0.36	4.01e-6	Height;
PAAD	cis	rs11568819	1.000	rs11568819	chr11:102401633	C/T	cg01813071	chr11:102401616	MMP7	1.16	6.45	0.46	1.39e-9	Blood protein levels;
PAAD	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg22189786	chr22:42395067	WBP2NL	-0.47	-5.13	-0.38	8.52e-7	Cognitive function;
PAAD	cis	rs3774830	0.685	rs73212741	chr4:5464450	G/C	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.22e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg01815783	chr4:1047043	NA	-0.41	-4.45	-0.34	1.68e-5	Recombination rate (males);
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg17879804	chr3:44752500	NA	0.62	6.42	0.46	1.65e-9	Initial pursuit acceleration in psychotic disorders;
PAAD	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	8.09	0.55	1.75e-13	Prudent dietary pattern;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07685180	chr8:600429	NA	-0.9	-5.42	-0.4	2.28e-7	IgG glycosylation;
PAAD	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.61	-5.67	-0.42	7.01e-8	Malaria;
PAAD	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg18721089	chr20:30220636	NA	0.63	5.08	0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-4.5	-0.34	1.34e-5	QRS complex (12-leadsum);
PAAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.92	10.89	0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg14789911	chr21:47582049	C21orf56	-0.53	-5.61	-0.41	9.47e-8	Testicular germ cell tumor;
PAAD	cis	rs12304921	1.000	rs7397068	chr12:51401904	C/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.56	7.97	0.54	3.47e-13	Homoarginine levels;
PAAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg15793417	chr19:38573135	SIPA1L3	-0.64	-6.41	-0.46	1.71e-9	Survival in colon cancer;
PAAD	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.77	6.56	0.47	8.14e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-4.58	-0.35	9.62e-6	Obesity-related traits;
PAAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.36	0.56	3.66e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.62	0.47	5.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11209002	0.738	rs1321154	chr1:67570703	T/C	cg02640540	chr1:67518911	SLC35D1	0.7	4.68	0.35	6.27e-6	Crohn's disease;
PAAD	cis	rs6565189	1.000	rs6565189	chr16:30507265	A/C	cg17640201	chr16:30407289	ZNF48	0.45	4.38	0.33	2.21e-5	Tonsillectomy;
PAAD	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.42e-5	Calcium levels;
PAAD	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.68	-7.79	-0.53	9.78e-13	Alcohol dependence;
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.79	-6.82	-0.48	2.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs340029	0.760	rs1647990	chr15:60916622	G/T	cg00200653	chr15:60883225	RORA	0.51	4.45	0.34	1.64e-5	C-reactive protein levels;
PAAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.64	6.21	0.45	4.72e-9	Breast cancer;
PAAD	cis	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00708844	chr14:60558039	C14orf135	-0.63	-7.51	-0.52	4.82e-12	Body fat percentage;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg07336987	chr11:625147	MUPCDH	-0.38	-4.73	-0.36	5.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.46	4.34	0.33	2.62e-5	Hip circumference;
PAAD	cis	rs1190596	0.830	rs2298877	chr14:102548224	T/C	cg23289024	chr14:102554846	HSP90AA1	-0.44	-4.72	-0.36	5.4e-6	Behavioural disinhibition (generation interaction);
PAAD	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.73	0.48	3.25e-10	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.88	-7.16	-0.5	3.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.49	0.34	1.41e-5	Bipolar disorder;
PAAD	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs863345	0.564	rs7515245	chr1:158494110	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs7737355	0.773	rs1019122	chr5:131099227	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	trans	rs61931739	0.583	rs1873010	chr12:33756375	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.28	0.51	1.66e-11	Morning vs. evening chronotype;
PAAD	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg01868782	chr6:126071099	HEY2	0.46	5.44	0.4	2.1e-7	Brugada syndrome;
PAAD	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.98	10.46	0.65	1.22e-19	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.73	8.39	0.56	3.06e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.35	-4.32	-0.33	2.85e-5	Longevity;Endometriosis;
PAAD	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg07242267	chr20:33460843	GGT7	-0.54	-5.21	-0.39	5.96e-7	Coronary artery disease;
PAAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.74	6.65	0.47	4.96e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9815354	0.953	rs1716655	chr3:41918706	A/G	cg03022575	chr3:42003672	ULK4	-0.81	-5.69	-0.42	6.21e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.87	0.49	1.52e-10	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-4.96	-0.37	1.85e-6	Lung cancer;
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.63	-7.33	-0.51	1.27e-11	Lymphocyte counts;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01176538	chr2:97405546	LMAN2L	0.56	6.35	0.46	2.36e-9	Metabolite levels  (X-11787);
PAAD	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.5	-0.34	1.35e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.64	-0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1334894	1.000	rs72913427	chr6:35581803	G/C	cg07213720	chr6:35227408	ZNF76	-0.89	-4.88	-0.37	2.65e-6	Coronary artery disease;
PAAD	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg14664628	chr15:75095509	CSK	-1.1	-12.68	-0.72	1.32e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.43	-4.35	-0.33	2.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.49	4.43	0.34	1.81e-5	Sudden cardiac arrest;
PAAD	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.74e-13	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs35000415	0.873	rs13246321	chr7:128701331	T/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg12610070	chr10:71211762	TSPAN15	-0.62	-8.88	-0.58	1.78e-15	Thrombosis;
PAAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12311346	chr5:56204834	C5orf35	-0.54	-4.39	-0.34	2.15e-5	Coronary artery disease;
PAAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06544989	chr22:39130855	UNC84B	-0.44	-4.47	-0.34	1.53e-5	Menopause (age at onset);
PAAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.95	-9.88	-0.63	4.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg07168214	chr17:7380112	ZBTB4	-0.65	-6.06	-0.44	1e-8	Androgen levels;
PAAD	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg20302533	chr7:39170763	POU6F2	0.5	7.0	0.49	7.65e-11	IgG glycosylation;
PAAD	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg12661370	chr5:149340060	SLC26A2	0.64	5.39	0.4	2.65e-7	HIV-1 control;
PAAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.48	5.06	0.38	1.18e-6	Major depressive disorder;
PAAD	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg26248373	chr2:1572462	NA	-1.09	-7.55	-0.52	3.72e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11608355	0.508	rs2075434	chr12:109797051	G/A	cg19025524	chr12:109796872	NA	-0.63	-5.82	-0.43	3.41e-8	Neuroticism;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.74	-10.25	-0.64	4.65e-19	Iron status biomarkers;
PAAD	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs60154123	1.000	rs60154123	chr1:210468999	C/T	cg23283495	chr1:209979779	IRF6	0.62	5.34	0.4	3.38e-7	Coronary artery disease;
PAAD	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.99	7.91	0.54	4.8e-13	Eosinophilic esophagitis;
PAAD	cis	rs6547631	0.622	rs10192752	chr2:85926142	T/G	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs2952768	0.965	rs2551969	chr2:208510965	G/T	cg22329743	chr2:208688774	PLEKHM3	0.22	4.36	0.33	2.34e-5	Opioid sensitivity;
PAAD	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.46	-5.77	-0.42	4.22e-8	Crohn's disease;
PAAD	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.63	6.97	0.49	9.19e-11	Leprosy;
PAAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.78e-5	Tonsillectomy;
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg00035636	chr13:21900591	NA	0.59	6.18	0.45	5.72e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00166722	chr3:10149974	C3orf24	0.9	6.74	0.48	3.04e-10	Alzheimer's disease;
PAAD	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02285477	chr13:28196059	POLR1D;LNX2	0.58	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.63	6.03	0.44	1.2e-8	Ovarian reserve;
PAAD	cis	rs8032158	0.702	rs11630780	chr15:56128445	G/T	cg02198044	chr15:56286336	NEDD4	0.41	4.3	0.33	3e-5	Keloid;
PAAD	cis	rs2274459	1.000	rs877187	chr6:33706211	A/G	cg06253072	chr6:33679850	C6orf125	-0.56	-4.53	-0.34	1.2e-5	Obesity (extreme);
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg04257695	chr17:30186438	C17orf79	-0.59	-4.69	-0.36	6.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6547631	0.622	rs2366807	chr2:85926598	G/A	cg24620635	chr2:85921963	GNLY	0.41	5.39	0.4	2.59e-7	Blood protein levels;
PAAD	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg20283391	chr11:68216788	NA	-0.55	-5.28	-0.39	4.29e-7	Total body bone mineral density;
PAAD	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06998765	chr14:75389618	RPS6KL1	0.28	4.98	0.37	1.71e-6	Caffeine consumption;
PAAD	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg09659197	chr4:152720779	NA	0.36	5.12	0.38	8.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg20302533	chr7:39170763	POU6F2	0.43	5.83	0.43	3.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.89	-8.94	-0.59	1.27e-15	Asthma;
PAAD	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg07469887	chr10:131262384	NA	0.46	5.66	0.42	7.43e-8	Response to temozolomide;
PAAD	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.68	5.85	0.43	2.86e-8	Common traits (Other);
PAAD	cis	rs10768122	0.932	rs10836369	chr11:35322427	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.31	-0.33	2.88e-5	Vitiligo;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg02725872	chr8:58115012	NA	-0.57	-4.75	-0.36	4.69e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	8.89	0.58	1.66e-15	Ulcerative colitis;
PAAD	cis	rs10958605	0.761	rs1961481	chr8:40038181	C/G	cg14545590	chr8:40388592	ZMAT4	0.43	4.82	0.36	3.49e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.77	0.36	4.26e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-5.15	-0.39	8.13e-7	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14544983	chr19:47248940	FKRP;STRN4	0.61	6.34	0.46	2.52e-9	Myopia (pathological);
PAAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs375066	0.935	rs371875	chr19:44393257	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-4.85	-0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.85	-10.05	-0.63	1.53e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Menopause (age at onset);
PAAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.74	-8.66	-0.57	6.54e-15	Childhood ear infection;
PAAD	cis	rs732765	0.689	rs8019690	chr14:75135142	A/T	cg17347104	chr14:75034677	LTBP2	0.57	5.03	0.38	1.34e-6	Non-small cell lung cancer;
PAAD	cis	rs12799264	1.000	rs2707086	chr11:19978073	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.66	0.48	4.59e-10	Schizophrenia;
PAAD	cis	rs863345	0.604	rs2317970	chr1:158504770	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs35164067	1.000	rs11879191	chr19:10512911	G/A	cg24189696	chr19:10585866	NA	0.42	4.66	0.35	6.82e-6	Inflammatory bowel disease;
PAAD	cis	rs11585357	0.501	rs72646775	chr1:17592121	T/C	cg08277548	chr1:17600880	PADI3	-0.9	-6.49	-0.47	1.12e-9	Hair shape;
PAAD	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.56	-6.7	-0.48	3.91e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12530845	0.943	rs3800762	chr7:135347601	T/A	cg23117316	chr7:135346802	PL-5283	-0.39	-4.5	-0.34	1.32e-5	Red blood cell traits;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.57e-8	Menopause (age at onset);
PAAD	cis	rs375066	0.935	rs428505	chr19:44428911	G/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg03388025	chr16:89894329	SPIRE2	0.49	6.51	0.47	1.01e-9	Schizophrenia;
PAAD	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg12568669	chr8:11666485	FDFT1	-0.28	-4.33	-0.33	2.69e-5	Retinal vascular caliber;
PAAD	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.5	-5.36	-0.4	3.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-4.93	-0.37	2.1e-6	Educational attainment (years of education);
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.34	-0.33	2.59e-5	Longevity;Endometriosis;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.73e-9	Height;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.44	4.85	0.37	3.05e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	1.13	11.82	0.69	2.78e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08219700	chr8:58056026	NA	0.67	5.11	0.38	9.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.05	0.5	5.9e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg08992911	chr2:238395768	MLPH	0.63	5.84	0.43	3.13e-8	Prostate cancer;
PAAD	cis	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg25886479	chr11:50257625	LOC441601	-0.44	-4.84	-0.37	3.12e-6	Height;
PAAD	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.49	-4.51	-0.34	1.28e-5	Height;
PAAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12165864	chr7:66369176	NA	-0.84	-5.52	-0.41	1.4e-7	Diabetic kidney disease;
PAAD	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.61	-5.96	-0.43	1.73e-8	Systolic blood pressure;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01077841	chr13:99228499	STK24	0.62	6.56	0.47	8.1e-10	Iris heterochromicity;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.62	4.99	0.38	1.63e-6	Alzheimer's disease;
PAAD	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.72	-7.09	-0.5	4.6e-11	Plateletcrit;Platelet count;
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.64	-7.02	-0.49	6.93e-11	Colorectal cancer;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg10207240	chr12:122356781	WDR66	0.54	5.97	0.44	1.64e-8	Mean corpuscular volume;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.64	-7.94	-0.54	4.19e-13	Body mass index;
PAAD	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.98	-14.04	-0.75	3.14e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs6066835	0.572	rs6066809	chr20:47273119	T/C	cg18078177	chr20:47281410	PREX1	1.1	5.08	0.38	1.11e-6	Multiple myeloma;
PAAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	5.26	0.39	4.71e-7	Obesity-related traits;
PAAD	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.71	7.27	0.51	1.75e-11	Uric acid levels;
PAAD	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg25204440	chr1:209979598	IRF6	-0.57	-4.85	-0.37	3.04e-6	Coronary artery disease;
PAAD	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.78	-0.48	2.49e-10	Total body bone mineral density;
PAAD	cis	rs2016586	0.895	rs5750162	chr22:36114551	T/C	cg26342177	chr22:36113512	APOL5	-0.48	-4.73	-0.36	5.03e-6	Body mass index;
PAAD	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	11.0	0.67	4.43e-21	Cognitive test performance;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08839770	chr4:95373309	PDLIM5	0.64	6.68	0.48	4.15e-10	Obesity-related traits;
PAAD	cis	rs76917914	0.780	rs1059273	chr9:100849500	G/T	cg03040243	chr9:100819229	NANS	0.61	4.6	0.35	8.99e-6	Immature fraction of reticulocytes;
PAAD	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.88e-7	Bladder cancer;
PAAD	cis	rs12474201	0.569	rs13411633	chr2:46932666	A/G	cg06386533	chr2:46925753	SOCS5	0.57	5.83	0.43	3.14e-8	Height;
PAAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.81	-0.36	3.68e-6	Biliary atresia;
PAAD	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg11764359	chr7:65958608	NA	-0.78	-5.17	-0.39	7.13e-7	Diabetic kidney disease;
PAAD	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.26	10.02	0.63	1.82e-18	Hemostatic factors and hematological phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11156230	chr4:83351251	HNRPDL;ENOPH1	0.59	6.62	0.47	5.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.2	-0.64	6.32e-19	Obesity-related traits;
PAAD	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.58	0.35	9.79e-6	Lung cancer;
PAAD	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.3	-0.33	3e-5	Diastolic blood pressure;
PAAD	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-5.52	-0.41	1.42e-7	Schizophrenia (age at onset);
PAAD	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg19486271	chr11:47235900	DDB2	-0.58	-5.83	-0.43	3.22e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00540400	chr15:79124168	NA	0.59	6.7	0.48	3.9e-10	Coronary artery disease;
PAAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.36	16.94	0.81	7.81e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.38	-0.4	2.73e-7	Height;
PAAD	cis	rs111327216	1	rs111327216	chr3:49525218	C/T	cg19401529	chr3:49056140	DALRD3	0.89	5.95	0.43	1.74e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.09	-10.17	-0.64	7.57e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	6.39	0.46	1.92e-9	Blood protein levels;
PAAD	trans	rs12127679	0.614	rs12064447	chr1:244171765	T/C	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg04450456	chr4:17643702	FAM184B	-0.51	-5.42	-0.4	2.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg01249072	chr7:66147992	NA	-0.73	-6.61	-0.47	6.12e-10	Photic sneeze reflex;
PAAD	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.61	5.56	0.41	1.18e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg08293408	chr5:1077731	SLC12A7	1.04	4.54	0.35	1.13e-5	Asthma (childhood onset);
PAAD	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	1.02	12.17	0.7	3.31e-24	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.51	-0.41	1.49e-7	Vitamin D levels;
PAAD	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.69	7.18	0.5	2.89e-11	Morning vs. evening chronotype;
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22601191	chr20:60968625	CABLES2	-0.55	-5.35	-0.4	3.11e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-10.7	-0.66	2.94e-20	Schizophrenia;
PAAD	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.48	-4.3	-0.33	3.02e-5	Acne (severe);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19027571	chr12:133463885	CHFR	0.61	6.65	0.47	5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg05562828	chr17:3906858	NA	0.59	6.31	0.46	2.91e-9	Type 2 diabetes;
PAAD	cis	rs4704187	0.687	rs9918293	chr5:74514828	T/C	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08633850	chr15:42867590	STARD9	-0.73	-6.29	-0.45	3.22e-9	Neuroticism;
PAAD	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.51	-4.83	-0.36	3.28e-6	Hypospadias;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.9	10.05	0.63	1.54e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.61	7.46	0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-8.77	-0.58	3.39e-15	Body mass index;
PAAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.92	7.54	0.52	4.07e-12	Gut microbiome composition (summer);
PAAD	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-1.1	-15.39	-0.78	7.99e-33	Caffeine consumption;
PAAD	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.47	4.33	0.33	2.74e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.51	-5.92	-0.43	2.08e-8	Migraine;
PAAD	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.77	8.41	0.56	2.74e-14	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23281280	chr6:28129359	ZNF389	-0.71	-5.55	-0.41	1.24e-7	Depression;
PAAD	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	5.23	0.39	5.64e-7	Type 2 diabetes;
PAAD	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-5.5	-0.41	1.55e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs899997	0.906	rs6495318	chr15:78992137	G/C	cg04896959	chr15:78267971	NA	-0.59	-5.33	-0.4	3.43e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg19901468	chr14:105411992	AHNAK2	-0.91	-10.58	-0.65	5.95e-20	Rheumatoid arthritis;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.67	-7.21	-0.5	2.51e-11	Menopause (age at onset);
PAAD	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg11995313	chr8:8860691	ERI1	0.49	4.62	0.35	8.09e-6	Joint mobility (Beighton score);
PAAD	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg04087571	chr11:116723030	SIK3	-0.4	-4.77	-0.36	4.27e-6	Subjective well-being;
PAAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg15017067	chr4:17643749	FAM184B	0.39	4.41	0.34	1.97e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	1.19	8.79	0.58	3.01e-15	Lymphocyte counts;
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	5.79	0.43	3.82e-8	Coronary artery disease;
PAAD	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	5.05	0.38	1.24e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg11783602	chr8:55087084	NA	-0.58	-6.3	-0.45	3.12e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	8.01	0.54	2.84e-13	Prudent dietary pattern;
PAAD	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg11062466	chr8:58055876	NA	0.69	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg07220939	chr11:64358617	SLC22A12	-0.41	-4.32	-0.33	2.8e-5	Urate levels in obese individuals;
PAAD	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-6.28	-0.45	3.45e-9	Blood trace element (Zn levels);
PAAD	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg09179987	chr1:167433047	CD247	0.48	5.53	0.41	1.34e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs490234	0.615	rs2819625	chr9:128156648	A/G	cg14078157	chr9:128172775	NA	-0.54	-6.33	-0.46	2.6e-9	Mean arterial pressure;
PAAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.56	-5.68	-0.42	6.8e-8	IgG glycosylation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09183840	chr4:48138347	TEC	0.64	7.83	0.54	7.67e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.89	0.37	2.52e-6	Lung cancer in ever smokers;
PAAD	cis	rs2271001	0.955	rs10500841	chr11:19143383	C/A	cg00161556	chr11:19138045	ZDHHC13	0.5	5.32	0.4	3.67e-7	Gut microbiome composition (winter);
PAAD	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	trans	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg26501369	chr6:133561814	EYA4	0.89	6.59	0.47	6.69e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg23346134	chr3:49453900	TCTA	0.46	5.2	0.39	6.21e-7	Menarche (age at onset);
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.41	13.79	0.75	1.47e-28	Corneal structure;
PAAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2885056	0.891	rs892082	chr19:10680478	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.44	4.54	0.35	1.15e-5	Red cell distribution width;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07677032	chr17:61819896	STRADA	-0.59	-5.67	-0.42	6.84e-8	Prudent dietary pattern;
PAAD	cis	rs539096	0.671	rs513862	chr1:44114405	A/T	cg12908607	chr1:44402522	ARTN	-0.41	-4.31	-0.33	2.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.81	0.54	8.51e-13	Prudent dietary pattern;
PAAD	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.48	4.73	0.36	4.98e-6	Schizophrenia;
PAAD	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg01966878	chr4:90757139	SNCA	-0.46	-4.51	-0.34	1.31e-5	Dementia with Lewy bodies;
PAAD	trans	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg10616974	chr17:74511719	NA	0.41	6.3	0.46	3.01e-9	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs11848070	1.000	rs11848070	chr14:71507601	C/T	cg22864613	chr14:71067440	MED6	-0.5	-4.38	-0.33	2.24e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.65e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.51	5.14	0.38	8.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg16006841	chr5:176797999	RGS14	0.73	7.03	0.5	6.7e-11	Urate levels in lean individuals;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.16	17.57	0.82	1.93e-38	Prudent dietary pattern;
PAAD	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.63	6.41	0.46	1.77e-9	Ease of getting up in the morning;
PAAD	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.67	-5.5	-0.41	1.55e-7	Coronary artery disease;
PAAD	cis	rs16895831	0.531	rs56302029	chr6:42522409	T/G	cg10605015	chr6:42532144	UBR2	-0.7	-4.92	-0.37	2.25e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg12072164	chr19:44306565	LYPD5	0.46	4.99	0.38	1.61e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.57	4.98	0.37	1.73e-6	Height;
PAAD	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.67	-0.48	4.55e-10	Eye color traits;
PAAD	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.94	7.8	0.53	9.38e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.99	7.51	0.52	4.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.5	5.29	0.39	4.2e-7	Menopause (age at onset);
PAAD	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg01305830	chr4:1604576	NA	-0.49	-4.73	-0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.78	8.31	0.56	4.82e-14	Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg25730555	chr22:47059586	GRAMD4	0.46	4.47	0.34	1.52e-5	Urate levels in obese individuals;
PAAD	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24110177	chr3:50126178	RBM5	-0.61	-6.86	-0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg09127314	chr1:152161683	NA	-0.67	-4.32	-0.33	2.84e-5	Atopic dermatitis;
PAAD	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg13207630	chr7:32358064	NA	0.96	4.91	0.37	2.28e-6	Body mass index;
PAAD	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9463078	0.546	rs1284973	chr6:45078163	C/T	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs939584	1.000	rs6739303	chr2:628749	C/T	cg14515364	chr2:636606	NA	0.49	4.46	0.34	1.57e-5	Body mass index;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27287166	chr8:71315034	NCOA2	0.73	6.34	0.46	2.44e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.61	5.21	0.39	5.94e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.21	0.45	4.85e-9	Body mass index;
PAAD	cis	rs9399135	0.682	rs9402684	chr6:135419305	T/C	cg24558204	chr6:135376177	HBS1L	0.45	4.38	0.33	2.18e-5	Red blood cell count;
PAAD	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg06131755	chr6:160182447	ACAT2	0.53	4.36	0.33	2.35e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.4	4.89	0.37	2.54e-6	Electrocardiographic conduction measures;
PAAD	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs561655	0.525	rs10792831	chr11:85852979	A/G	cg07180834	chr11:85838833	NA	0.45	4.94	0.37	2.02e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.65	-6.5	-0.47	1.06e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26549601	chr10:134560360	INPP5A	-0.51	-4.92	-0.37	2.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3736757	1.000	rs6663178	chr1:184661642	G/A	cg05045817	chr1:184633523	NA	0.44	4.73	0.36	5.19e-6	Obesity-related traits;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg27121462	chr16:89883253	FANCA	0.5	5.29	0.39	4.14e-7	Vitiligo;
PAAD	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.73	5.62	0.41	9.01e-8	Crohn's disease;
PAAD	cis	rs3784262	0.565	rs2899613	chr15:58347260	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.44	-5.39	-0.4	2.69e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.46	5.23	0.39	5.42e-7	Height;
PAAD	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg13512537	chr8:22265999	SLC39A14	-0.44	-4.26	-0.33	3.61e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.24	-0.39	5.38e-7	Pulmonary function;
PAAD	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.53	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.7	7.51	0.52	4.74e-12	Testicular germ cell tumor;
PAAD	cis	rs1075265	0.870	rs10207537	chr2:54328837	G/A	cg04546899	chr2:54196757	PSME4	0.33	4.52	0.34	1.25e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.25	-0.33	3.67e-5	Eotaxin levels;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.5	5.43	0.4	2.19e-7	Obesity-related traits;
PAAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-5.97	-0.44	1.6e-8	Neuroticism;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg17650747	chr5:1873721	NA	0.43	4.39	0.34	2.14e-5	Cardiovascular disease risk factors;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08677398	chr8:58056175	NA	0.59	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.83	-8.92	-0.59	1.36e-15	Type 2 diabetes;
PAAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Life satisfaction;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.94	7.47	0.52	5.81e-12	Initial pursuit acceleration;
PAAD	cis	rs617219	0.710	rs16876598	chr5:78573970	T/C	cg24856658	chr5:78533917	JMY	0.4	4.38	0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.76	-6.41	-0.46	1.78e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.79	6.28	0.45	3.46e-9	Prostate cancer;
PAAD	cis	rs60154123	0.730	rs12034871	chr1:210475701	T/C	cg23283495	chr1:209979779	IRF6	0.63	5.5	0.41	1.56e-7	Coronary artery disease;
PAAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.65	0.35	7.29e-6	Calcium levels;
PAAD	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg18265118	chr7:2139243	MAD1L1	0.52	4.25	0.33	3.71e-5	Neuroticism;
PAAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg06740227	chr12:86229804	RASSF9	0.59	5.27	0.39	4.66e-7	Major depressive disorder;
PAAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg01815783	chr4:1047043	NA	-0.44	-4.27	-0.33	3.4e-5	Recombination rate (females);
PAAD	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2414856	0.504	rs72742986	chr15:64987229	T/C	cg16425858	chr15:64791681	ZNF609	0.96	4.85	0.37	3.02e-6	Pulse pressure;Systolic blood pressure;
PAAD	cis	rs863345	0.625	rs4575081	chr1:158504837	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.91	10.67	0.65	3.43e-20	Total body bone mineral density;
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg21589280	chr1:85930151	DDAH1	-0.56	-4.25	-0.33	3.68e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg20913747	chr6:44695427	NA	-0.66	-6.65	-0.47	5.07e-10	Total body bone mineral density;
PAAD	cis	rs1507153	0.549	rs699182	chr6:79327328	T/G	cg05283184	chr6:79620031	NA	0.36	4.32	0.33	2.86e-5	Sjögren's syndrome;
PAAD	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg02910952	chr12:132569714	EP400NL	0.58	4.35	0.33	2.5e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs4774830	0.744	rs62046397	chr15:56321302	G/A	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg25753631	chr6:25732923	NA	-0.37	-4.6	-0.35	8.89e-6	Blood metabolite levels;
PAAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.59	5.8	0.43	3.72e-8	Longevity;
PAAD	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.54	8.29	0.56	5.47e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.44	0.34	1.71e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.81	-0.36	3.64e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.61	-5.46	-0.41	1.88e-7	Schizophrenia;
PAAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.75	7.33	0.51	1.26e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.48	0.34	1.44e-5	Mean corpuscular volume;
PAAD	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.61	-5.71	-0.42	5.68e-8	Mean corpuscular volume;
PAAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.38	0.33	2.22e-5	Electroencephalogram traits;
PAAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.75	7.49	0.52	5.14e-12	Tonsillectomy;
PAAD	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.96	-6.7	-0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3540	0.960	rs11857092	chr15:90960115	T/C	cg22089800	chr15:90895588	ZNF774	0.6	5.8	0.43	3.65e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	6.97	0.49	8.96e-11	IgG glycosylation;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.53	5.67	0.42	7.1e-8	Life satisfaction;
PAAD	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.71	7.4	0.51	8.6e-12	Height;
PAAD	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.51	-6.15	-0.45	6.5e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg00262122	chr8:11665843	FDFT1	-0.64	-5.64	-0.42	7.89e-8	Neuroticism;
PAAD	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-5.37	-0.4	2.94e-7	Obesity (extreme);
PAAD	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg01868782	chr6:126071099	HEY2	0.38	4.42	0.34	1.89e-5	Brugada syndrome;
PAAD	cis	rs4450131	0.618	rs897306	chr10:126337060	T/C	cg20435097	chr10:126320824	FAM53B	-0.54	-5.74	-0.42	4.9e-8	White blood cell count (basophil);
PAAD	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.61	0.47	6.13e-10	Subjective well-being;
PAAD	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg26904215	chr21:47823096	PCNT	-0.83	-4.53	-0.34	1.21e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.7	-0.36	5.74e-6	Breast cancer;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg26338869	chr17:61819248	STRADA	0.49	4.78	0.36	4.09e-6	Height;
PAAD	cis	rs4907240	0.961	rs12471390	chr2:97322958	C/T	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.62	-0.35	8.18e-6	Event-related brain oscillations;
PAAD	cis	rs1419980	0.730	rs11054845	chr12:7768130	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg10183150	chr4:120222239	C4orf3	-0.38	-5.27	-0.39	4.59e-7	Corneal astigmatism;
PAAD	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.03	0.38	1.36e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.63	0.42	8.49e-8	Immature fraction of reticulocytes;
PAAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.82	-0.36	3.44e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs1372356	0.816	rs10130801	chr14:88528910	T/C	cg18078958	chr14:88630771	NA	0.5	6.38	0.46	2.03e-9	Food antigen IgG levels;
PAAD	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg01064725	chr1:204461714	NA	-0.52	-4.85	-0.37	2.96e-6	Schizophrenia;
PAAD	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg25620797	chr2:55921863	PNPT1	-0.47	-4.28	-0.33	3.33e-5	Metabolic syndrome;
PAAD	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.68	5.85	0.43	2.86e-8	Common traits (Other);
PAAD	cis	rs12447180	0.527	rs4782365	chr16:88516171	C/G	cg01649317	chr16:87719201	JPH3	-0.4	-4.25	-0.33	3.75e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.56	7.06	0.5	5.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.06	-7.68	-0.53	1.83e-12	Alzheimer's disease;
PAAD	cis	rs7811528	0.656	rs7783760	chr7:2707822	G/T	cg11411865	chr7:2701802	TTYH3	-0.55	-4.77	-0.36	4.22e-6	Schizophrenia;
PAAD	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.72	-0.36	5.32e-6	Body mass index;
PAAD	cis	rs590121	0.876	rs652054	chr11:75275532	C/A	cg26104986	chr11:75275303	SERPINH1	-0.47	-4.64	-0.35	7.38e-6	Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs7301016	1.000	rs11614022	chr12:62891329	A/G	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs829661	1.000	rs829672	chr2:30712016	C/T	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.42	0.34	1.87e-5	Tonsillectomy;
PAAD	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg10631289	chr15:39006617	NA	0.46	4.41	0.34	1.93e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.27	-0.33	3.47e-5	Educational attainment (years of education);
PAAD	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.55	-6.89	-0.49	1.36e-10	Crohn's disease;
PAAD	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.45	-0.52	6.68e-12	Total body bone mineral density;
PAAD	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.7	7.68	0.53	1.83e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg17201900	chr20:34330562	RBM39	0.62	4.31	0.33	2.9e-5	Total cholesterol levels;
PAAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.74	-0.36	4.88e-6	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	10.32	0.64	3.04e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.68	7.14	0.5	3.69e-11	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08677398	chr8:58056175	NA	0.67	4.53	0.34	1.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs9810890	1.000	rs73207974	chr3:128568455	T/C	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.49	-4.52	-0.34	1.25e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.7	6.41	0.46	1.7e-9	Menarche (age at onset);
PAAD	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.41	0.71	7.08e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.72	6.62	0.47	5.69e-10	Endometrial cancer;
PAAD	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg06636001	chr8:8085503	FLJ10661	0.5	4.74	0.36	4.8e-6	Parkinson's disease;
PAAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.43	0.4	2.2e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.86	-0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg25364880	chr3:44379878	C3orf23	0.6	5.46	0.4	1.91e-7	Depressive symptoms;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.55	-5.17	-0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22455342	chr2:225449267	CUL3	0.6	5.49	0.41	1.66e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.86	-9.54	-0.61	3.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.57	-7.9	-0.54	5.17e-13	Asthma (sex interaction);
PAAD	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.38	4.45	0.34	1.64e-5	Endometriosis;
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg10978503	chr1:24200527	CNR2	-0.45	-5.14	-0.38	8.45e-7	Immature fraction of reticulocytes;
PAAD	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.75	5.69	0.42	6.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15664640	chr17:80829946	TBCD	-0.62	-4.42	-0.34	1.84e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.09	-0.38	1.05e-6	Pulmonary function;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.64	6.46	0.46	1.32e-9	Obesity-related traits;
PAAD	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.43	-4.46	-0.34	1.59e-5	Response to antidepressants in depression;
PAAD	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg01851573	chr8:8652454	MFHAS1	0.68	5.63	0.42	8.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.67	5.64	0.42	8.23e-8	Iron status biomarkers;
PAAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg16928487	chr17:17741425	SREBF1	0.37	4.83	0.37	3.25e-6	Total body bone mineral density;
PAAD	trans	rs2249625	0.708	rs1384389	chr6:72780595	G/C	cg04413069	chr12:9800446	LOC374443	0.59	6.62	0.47	5.81e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs4795519	0.784	rs1606915	chr17:22182010	A/C	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs7172689	0.908	rs4076201	chr15:81572303	C/T	cg05624577	chr15:81411055	NA	0.56	4.27	0.33	3.41e-5	Inattentive symptoms;
PAAD	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.54	-4.65	-0.35	7.28e-6	Obesity-related traits;
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.97	-0.37	1.79e-6	Menarche (age at onset);
PAAD	cis	rs3136441	1.000	rs12574512	chr11:46768405	G/A	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs1878047	0.665	rs34589735	chr19:51775380	T/C	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20490015	chr17:62336680	TEX2	-0.69	-6.86	-0.49	1.6e-10	Obesity-related traits;
PAAD	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-6.06	-0.44	1.04e-8	Subjective well-being;
PAAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.08e-23	Smoking behavior;
PAAD	cis	rs73416724	0.688	rs10498755	chr6:43330756	C/T	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	0.55	6.07	0.44	9.75e-9	Hypothyroidism;
PAAD	cis	rs258892	0.895	rs155426	chr5:72117128	G/T	cg21869765	chr5:72125136	TNPO1	-0.78	-5.15	-0.39	8.02e-7	Small cell lung carcinoma;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.74	8.54	0.57	1.33e-14	Height;
PAAD	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg07671805	chr5:74907694	NA	0.57	4.33	0.33	2.64e-5	Coronary artery disease;
PAAD	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg18551225	chr6:44695536	NA	-0.73	-7.44	-0.52	7.09e-12	Total body bone mineral density;
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.57	6.66	0.48	4.81e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	1.08	9.32	0.6	1.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.54	-5.31	-0.4	3.85e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg20302533	chr7:39170763	POU6F2	0.4	6.3	0.46	3.01e-9	IgG glycosylation;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.38	-4.99	-0.38	1.62e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.86	-7.48	-0.52	5.54e-12	Alzheimer's disease;
PAAD	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.89	-5.8	-0.43	3.75e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs7577696	0.925	rs11683931	chr2:32304068	G/A	cg02381751	chr2:32503542	YIPF4	-0.41	-4.37	-0.33	2.33e-5	Inflammatory biomarkers;
PAAD	cis	rs12532960	0.642	rs2190515	chr7:42378095	T/C	cg27332053	chr7:42446175	NA	0.62	4.3	0.33	3.07e-5	Inflammatory biomarkers;
PAAD	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.32	-6.05	-0.44	1.1e-8	Type 2 diabetes;
PAAD	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	1.0	8.75	0.58	3.75e-15	Alzheimer's disease;
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.65	-6.23	-0.45	4.41e-9	Blood metabolite levels;
PAAD	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.68	7.52	0.52	4.35e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs3736485	0.966	rs4774596	chr15:51910975	C/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs89107	0.675	rs283080	chr6:118606000	C/A	cg21191810	chr6:118973309	C6orf204	0.46	6.34	0.46	2.52e-9	Cardiac structure and function;
PAAD	cis	rs4478858	0.624	rs10914333	chr1:31701491	A/G	cg00250761	chr1:31883323	NA	-0.39	-4.29	-0.33	3.18e-5	Alcohol dependence;
PAAD	cis	rs10512697	0.772	rs62336078	chr5:3516966	T/G	cg19473799	chr5:3511975	NA	-0.97	-4.53	-0.35	1.17e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs72960926	0.744	rs55764691	chr6:74924388	T/C	cg03266952	chr6:74778945	NA	-1.17	-6.5	-0.47	1.07e-9	Metabolite levels (MHPG);
PAAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg26497354	chr6:109612229	NA	-0.44	-4.7	-0.36	5.7e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4959799	1.000	rs4959797	chr6:3290720	G/A	cg04716048	chr6:3732797	C6orf145	0.8	4.45	0.34	1.66e-5	Survival in rectal cancer;
PAAD	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.7	9.57	0.61	2.77e-17	Crohn's disease;
PAAD	cis	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg25246084	chr19:4971487	KDM4B	-0.46	-5.71	-0.42	5.65e-8	Monocyte percentage of white cells;
PAAD	cis	rs12949688	0.575	rs10083864	chr17:55837910	C/T	cg12582317	chr17:55822272	NA	-0.4	-4.61	-0.35	8.56e-6	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.06	-8.09	-0.55	1.79e-13	Diabetic kidney disease;
PAAD	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.58	-5.15	-0.39	8.13e-7	Mean corpuscular volume;
PAAD	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg01620082	chr3:125678407	NA	-1.25	-7.51	-0.52	4.72e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.06	-0.55	2.05e-13	Coffee consumption (cups per day);
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.66	-5.51	-0.41	1.53e-7	Menarche (age at onset);
PAAD	cis	rs7301016	0.948	rs11174537	chr12:62929827	G/C	cg11441379	chr12:63026424	NA	0.85	6.17	0.45	5.8e-9	IgG glycosylation;
PAAD	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-6.37	-0.46	2.09e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.56	-5.89	-0.43	2.42e-8	Hepatitis;
PAAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.46	6.29	0.45	3.16e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17347941	chr15:79387269	NA	0.38	4.33	0.33	2.73e-5	Refractive error;
PAAD	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-4.26	-0.33	3.53e-5	Prevalent atrial fibrillation;
PAAD	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg16589663	chr20:23618590	CST3	0.85	7.26	0.51	1.85e-11	Chronic kidney disease;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg18279126	chr7:2041391	MAD1L1	0.58	5.61	0.41	9.29e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.67	6.71	0.48	3.61e-10	Caffeine consumption;
PAAD	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs786425	0.601	rs67178535	chr12:124196299	C/A	cg16237390	chr12:124156159	TCTN2	0.46	4.26	0.33	3.52e-5	Pubertal anthropometrics;
PAAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.5	-0.34	1.37e-5	Height;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg15691649	chr6:25882328	NA	0.51	5.03	0.38	1.37e-6	Blood metabolite levels;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12550012	chr3:106959716	LOC344595;LOC100302640	0.57	6.47	0.46	1.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.32	-0.33	2.77e-5	Vitiligo;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg00080972	chr5:178986291	RUFY1	0.5	4.76	0.36	4.47e-6	Lung cancer;
PAAD	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.41	-4.86	-0.37	2.9e-6	HIV-1 susceptibility;
PAAD	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.54	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg09760422	chr2:128146352	NA	0.44	7.59	0.52	2.96e-12	Protein C levels;
PAAD	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.43	-0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.82	-9.69	-0.62	1.38e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17376030	chr22:41985996	PMM1	0.68	4.61	0.35	8.4e-6	Vitiligo;
PAAD	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.23	9.84	0.62	5.51e-18	Alzheimer's disease (late onset);
PAAD	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg23995914	chr4:10459228	ZNF518B	-0.4	-4.82	-0.36	3.45e-6	Schizophrenia (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18745217	chr4:56215882	SRD5A3	-0.72	-7.43	-0.52	7.35e-12	Obesity-related traits;
PAAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.91	0.37	2.34e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.95	10.6	0.65	5.23e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg08562672	chr19:21860753	NA	0.41	4.25	0.33	3.69e-5	Pain;
PAAD	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.85	-0.43	2.97e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg18279126	chr7:2041391	MAD1L1	-0.57	-5.49	-0.41	1.66e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6009527	1.000	rs6009527	chr22:49570587	C/T	cg12746016	chr22:49560550	NA	0.48	4.83	0.37	3.23e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.23	-16.33	-0.8	2.92e-35	IgG glycosylation;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06112835	chr11:68658793	MRPL21	0.61	6.02	0.44	1.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg01059385	chr22:42394853	WBP2NL	0.56	4.46	0.34	1.61e-5	Birth weight;
PAAD	cis	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10329334	chr7:128767475	LOC407835	-0.73	-7.39	-0.51	9.05e-12	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.62	-7.75	-0.53	1.22e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.58	6.96	0.49	9.37e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg00319359	chr11:70116639	PPFIA1	0.77	4.34	0.33	2.54e-5	Coronary artery disease;
PAAD	cis	rs755249	0.567	rs2018212	chr1:39905588	T/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.68	-0.35	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.64	-6.83	-0.48	1.89e-10	Dementia with Lewy bodies;
PAAD	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.68	7.43	0.52	7.2e-12	Prostate cancer;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg07212818	chr11:638076	DRD4	-0.7	-6.94	-0.49	1.07e-10	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.53	4.66	0.35	6.84e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg00717180	chr2:96193071	NA	0.59	6.5	0.47	1.09e-9	HDL cholesterol;
PAAD	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg26597838	chr10:835615	NA	0.47	4.99	0.37	1.66e-6	Survival in rectal cancer;
PAAD	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.67	-6.33	-0.46	2.55e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9463078	0.683	rs227851	chr6:44699209	A/C	cg25276700	chr6:44698697	NA	0.51	5.97	0.44	1.62e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.72	8.84	0.58	2.16e-15	Vitiligo;
PAAD	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.04	0.44	1.14e-8	Rheumatoid arthritis;
PAAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-1.02	-17.07	-0.81	3.65e-37	Height;
PAAD	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.79	0.58	3.06e-15	Colorectal cancer;
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	5.86	0.43	2.73e-8	Lung cancer in ever smokers;
PAAD	cis	rs1468333	0.514	rs10515498	chr5:137586330	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.54	4.54	0.35	1.15e-5	Resting heart rate;
PAAD	cis	rs35160687	0.901	rs10200186	chr2:86527423	C/T	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg03315344	chr16:75512273	CHST6	-0.66	-8.15	-0.55	1.26e-13	Dupuytren's disease;
PAAD	trans	rs901683	0.850	rs76294334	chr10:45964279	T/C	cg11747279	chr17:21096632	NA	0.91	6.75	0.48	2.98e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg15510373	chr7:100224934	TFR2	-0.52	-4.25	-0.33	3.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.47	-4.44	-0.34	1.75e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12136530	0.593	rs12121189	chr1:19740421	G/A	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	4.31	0.33	2.91e-5	Personality dimensions;
PAAD	cis	rs4823006	1.000	rs4823006	chr22:29451671	C/T	cg23896685	chr22:29451551	ZNRF3	-0.56	-5.8	-0.43	3.75e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.9	6.05	0.44	1.07e-8	Diabetic kidney disease;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.61	6.58	0.47	7.3e-10	Lung cancer;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-7.63	-0.53	2.45e-12	Morning vs. evening chronotype;
PAAD	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.58	-0.35	9.67e-6	Height;
PAAD	cis	rs787274	1.000	rs885387	chr9:115596390	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.9	-10.3	-0.64	3.29e-19	Obesity-related traits;
PAAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.93	13.35	0.73	2.18e-27	Dental caries;
PAAD	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.53	-5.25	-0.39	5.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg00901687	chr17:48585270	MYCBPAP	-0.56	-5.58	-0.41	1.06e-7	Visceral fat;
PAAD	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.46	-4.49	-0.34	1.42e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg16586182	chr3:47516702	SCAP	-0.59	-6.37	-0.46	2.17e-9	Granulocyte count;Sum neutrophil eosinophil counts;
PAAD	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11995313	chr8:8860691	ERI1	0.52	5.29	0.39	4.17e-7	Joint mobility (Beighton score);
PAAD	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg15590007	chr10:45870220	ALOX5	0.6	6.01	0.44	1.3e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-7.26	-0.51	1.85e-11	Blood pressure (smoking interaction);
PAAD	cis	rs1497828	0.956	rs1497834	chr1:217535731	G/T	cg04411442	chr1:217543379	NA	-0.48	-4.69	-0.36	6.12e-6	Dialysis-related mortality;
PAAD	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.35	-0.33	2.5e-5	Tuberculosis;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	8.49	0.57	1.75e-14	Platelet count;
PAAD	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Osteoarthritis;
PAAD	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg21969647	chr13:114767023	RASA3	-0.54	-4.32	-0.33	2.79e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9815354	0.904	rs62258655	chr3:41932330	G/A	cg03022575	chr3:42003672	ULK4	-0.9	-6.62	-0.47	5.92e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg14515779	chr1:101123966	NA	-0.5	-6.29	-0.45	3.27e-9	Monocyte count;
PAAD	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.5	-0.47	1.1e-9	Monocyte count;
PAAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-1.0	-7.0	-0.49	7.49e-11	Dupuytren's disease;
PAAD	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg11812906	chr14:75593930	NEK9	0.48	4.74	0.36	4.94e-6	Caffeine consumption;
PAAD	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg03233332	chr7:66118400	NA	-0.4	-4.31	-0.33	2.97e-5	Aortic root size;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.09	-0.38	1.04e-6	Daytime sleep phenotypes;
PAAD	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.91	-9.46	-0.61	5.6e-17	Response to antineoplastic agents;
PAAD	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.53	4.7	0.36	5.76e-6	P wave terminal force;
PAAD	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs617219	0.737	rs6453431	chr5:78493873	G/C	cg24856658	chr5:78533917	JMY	-0.4	-4.5	-0.34	1.36e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.72	5.2	0.39	6.23e-7	Plateletcrit;
PAAD	cis	rs757081	0.648	rs11024231	chr11:17287250	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-5.99	-0.44	1.49e-8	Systolic blood pressure;
PAAD	cis	rs76917914	0.780	rs6478556	chr9:100842005	A/G	cg03040243	chr9:100819229	NANS	-0.56	-4.52	-0.34	1.23e-5	Immature fraction of reticulocytes;
PAAD	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg26318627	chr11:63887540	MACROD1	-0.47	-4.63	-0.35	7.8e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg02725872	chr8:58115012	NA	-0.6	-5.2	-0.39	6.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.6	-0.35	8.99e-6	Toenail selenium levels;
PAAD	cis	rs501120	0.584	rs58129751	chr10:44706720	G/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.28	-0.33	3.34e-5	Joint mobility (Beighton score);
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27165667	chr12:131129133	NA	-0.75	-7.74	-0.53	1.31e-12	Obesity-related traits;
PAAD	trans	rs11794666	0.652	rs17179862	chr9:31629459	A/G	cg05628366	chr6:35744188	C6orf126	1.01	7.2	0.5	2.64e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs4740619	0.689	rs1590749	chr9:15953344	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs2221894	0.922	rs983365	chr8:28750429	A/C	cg20212339	chr8:28908912	HMBOX1	0.5	5.29	0.39	4.17e-7	Obesity-related traits;
PAAD	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.46	-5.21	-0.39	6.1e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.15	11.41	0.68	3.48e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.33	-5.75	-0.42	4.8e-8	Type 2 diabetes;
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.91	5.88	0.43	2.46e-8	Body mass index;
PAAD	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg20406979	chr6:167373233	NA	0.32	4.42	0.34	1.88e-5	Crohn's disease;
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.53	-5.14	-0.38	8.38e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs732765	0.644	rs10483860	chr14:75119507	G/C	cg01090926	chr14:75137805	KIAA0317	0.49	4.29	0.33	3.22e-5	Non-small cell lung cancer;
PAAD	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12500973	chr10:43951159	ZNF487	0.61	6.88	0.49	1.47e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.56	-6.72	-0.48	3.37e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg26205652	chr12:48591994	NA	0.87	7.8	0.53	9.04e-13	Longevity (90 years and older);
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05209534	chr15:45021761	NA	-0.64	-6.15	-0.45	6.55e-9	Lung cancer in ever smokers;
PAAD	cis	rs1400816	0.850	rs2028672	chr2:172798804	T/C	cg23624723	chr2:173292262	ITGA6	-0.76	-4.45	-0.34	1.62e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg14631576	chr9:95140430	CENPP	-0.46	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg05717871	chr11:638507	DRD4	-0.6	-5.41	-0.4	2.42e-7	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6494488	0.500	rs72741399	chr15:64825036	A/G	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03538504	chr15:66581018	NA	0.58	6.34	0.46	2.5e-9	Smoking initiation;
PAAD	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.4	-0.34	2.07e-5	Educational attainment;
PAAD	cis	rs2030114	0.948	rs56377292	chr16:51607895	C/G	cg03758633	chr16:51611768	NA	0.6	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.97	0.49	8.8e-11	Rheumatoid arthritis;
PAAD	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.52	-4.95	-0.37	1.94e-6	Schizophrenia;
PAAD	cis	rs8133932	0.701	rs2330327	chr21:47305177	A/G	cg13695288	chr21:47294981	PCBP3	-0.46	-4.49	-0.34	1.41e-5	Schizophrenia;
PAAD	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.96	11.17	0.67	1.54e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	1.15	11.21	0.67	1.27e-21	Post bronchodilator FEV1;
PAAD	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.49	-5.28	-0.39	4.49e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-6.78	-0.48	2.49e-10	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26120584	chr12:50795366	LARP4	0.62	7.1	0.5	4.38e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.98	-6.82	-0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.43	0.4	2.21e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02071572	chr4:1403502	NA	0.51	6.54	0.47	8.65e-10	Longevity;
PAAD	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.61	-5.24	-0.39	5.36e-7	Common traits (Other);
PAAD	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg10820045	chr2:198174542	NA	-0.44	-4.35	-0.33	2.49e-5	Dermatomyositis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13074795	chr12:53996158	ATF7	0.54	6.4	0.46	1.79e-9	Smoking initiation;
PAAD	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg16342193	chr10:102329863	NA	-0.8	-8.51	-0.57	1.58e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.92	8.24	0.56	7.39e-14	Body mass index;
PAAD	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	1.07	6.47	0.46	1.26e-9	Plateletcrit;
PAAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.52	-4.87	-0.37	2.76e-6	Glomerular filtration rate;
PAAD	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1519814	0.696	rs7832657	chr8:121036632	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-4.89	-0.37	2.53e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13198984	chr17:80129470	CCDC57	0.45	5.7	0.42	5.98e-8	Life satisfaction;
PAAD	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.37	4.78	0.36	4.13e-6	Plateletcrit;
PAAD	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg13897122	chr2:103039542	IL18RAP	0.37	4.59	0.35	9.09e-6	Asthma;
PAAD	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.51	-4.38	-0.33	2.19e-5	Cocaine dependence;
PAAD	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.52	-4.62	-0.35	8.28e-6	Total body bone mineral density;
PAAD	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.77	8.21	0.55	9.03e-14	Corneal astigmatism;
PAAD	trans	rs10238623	0.962	rs6959280	chr7:28805323	A/G	cg01031251	chr1:26855423	RPS6KA1	0.64	6.38	0.46	2.03e-9	Anxiety in major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15546232	chr2:99771159	LIPT1;TSGA10	0.6	6.38	0.46	1.99e-9	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs4835937	0.681	rs10068883	chr5:127331614	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	4.43	0.34	1.79e-5	Cancer;
PAAD	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs9535307	0.522	rs55732704	chr13:50414205	G/A	cg04663916	chr13:50265991	EBPL	-0.59	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.19e-8	Lung cancer;
PAAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg22143856	chr6:28129313	ZNF389	0.69	5.51	0.41	1.5e-7	Depression;
PAAD	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.82	7.55	0.52	3.81e-12	Corneal astigmatism;
PAAD	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg06569542	chr10:98946673	SLIT1	0.47	4.79	0.36	3.88e-6	Monocyte count;
PAAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.78	-9.48	-0.61	4.8e-17	Metabolite levels;
PAAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.64	-5.27	-0.39	4.5e-7	Tuberculosis;
PAAD	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.53	5.08	0.38	1.07e-6	Motion sickness;
PAAD	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg26668713	chr11:65405903	SIPA1	0.64	4.44	0.34	1.69e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.5	5.45	0.4	1.98e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg16259171	chr11:73660510	DNAJB13	-0.65	-4.37	-0.33	2.32e-5	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg15193198	chr20:60906057	LAMA5	-0.54	-5.46	-0.4	1.94e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg21300403	chr2:198650112	BOLL	0.48	4.33	0.33	2.67e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.07	9.43	0.61	6.49e-17	Cannabis dependence symptom count;
PAAD	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.5	4.25	0.33	3.7e-5	Lymphocyte counts;
PAAD	cis	rs1413885	1.000	rs7354899	chr1:65818709	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-4.95	-0.37	1.93e-6	Anticoagulant levels;
PAAD	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg10018233	chr7:150070692	REPIN1	0.67	7.69	0.53	1.72e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg07943548	chr15:86304357	KLHL25	-0.75	-6.23	-0.45	4.29e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.59e-8	Height;
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg09359103	chr1:154839909	KCNN3	-0.81	-8.58	-0.57	1e-14	Prostate cancer;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11245990	chr11:68621969	NA	0.39	4.82	0.36	3.43e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg12310025	chr6:25882481	NA	0.45	4.25	0.33	3.76e-5	Blood metabolite levels;
PAAD	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.67	6.78	0.48	2.46e-10	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	1.09	11.9	0.69	1.67e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.96	8.02	0.55	2.71e-13	Alzheimer's disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06296570	chr7:130792605	FLJ43663	-0.68	-6.72	-0.48	3.44e-10	Primary biliary cholangitis;
PAAD	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.76	8.19	0.55	9.75e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.79	10.13	0.63	9.37e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.84	6.67	0.48	4.4e-10	Mean platelet volume;
PAAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg10556349	chr10:835070	NA	0.52	4.32	0.33	2.84e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2790216	0.951	rs1769041	chr10:59956642	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs4443100	0.958	rs5996459	chr22:23391131	G/A	cg14186256	chr22:23484241	RTDR1	0.51	4.54	0.35	1.16e-5	Serum parathyroid hormone levels;
PAAD	cis	rs11761408	0.585	rs7800507	chr7:5257297	G/C	cg02820836	chr7:4652842	NA	-0.73	-4.36	-0.33	2.35e-5	Mean corpuscular volume;
PAAD	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.83	9.03	0.59	7.05e-16	Mortality in heart failure;
PAAD	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg02900213	chr11:20385756	HTATIP2	0.47	4.41	0.34	1.95e-5	Pursuit maintenance gain;
PAAD	cis	rs939584	1.000	rs74676797	chr2:633063	G/A	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.59	-0.65	5.64e-20	Platelet distribution width;
PAAD	cis	rs7246760	0.500	rs7250760	chr19:9989298	C/T	cg07515324	chr19:10461336	TYK2	-0.89	-4.62	-0.35	8.13e-6	Pursuit maintenance gain;
PAAD	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg25150519	chr12:98850993	NA	0.52	5.2	0.39	6.24e-7	Colorectal adenoma (advanced);
PAAD	cis	rs75920871	1.000	rs1473324	chr11:116821918	T/G	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs3790455	0.610	rs1171548	chr1:156471998	G/T	cg14087168	chr1:156450669	MEF2D	-0.4	-4.36	-0.33	2.38e-5	Migraine;
PAAD	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg02683114	chr2:24398427	C2orf84	-0.53	-5.19	-0.39	6.52e-7	Asthma;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg19418458	chr7:158789849	NA	0.54	4.4	0.34	2.03e-5	Facial morphology (factor 20);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15604693	chr1:52832160	CC2D1B	-0.6	-6.38	-0.46	2.08e-9	Smoking initiation;
PAAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.65	7.39	0.51	9.18e-12	Height;
PAAD	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-4.26	-0.33	3.53e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6499755	0.712	rs31087	chr16:55363238	G/A	cg02859129	chr16:55357253	IRX6	0.36	5.01	0.38	1.46e-6	Hypospadias;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg21215323	chr15:41220556	DLL4	-0.67	-6.32	-0.46	2.77e-9	Survival in colon cancer;
PAAD	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.83	-9.61	-0.61	2.16e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22601191	chr20:60968625	CABLES2	0.5	4.56	0.35	1.05e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08400120	chr3:169940839	PRKCI	0.61	6.56	0.47	8.07e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg24375607	chr4:120327624	NA	0.43	4.48	0.34	1.44e-5	Diastolic blood pressure;
PAAD	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.49	4.36	0.33	2.34e-5	Pursuit maintenance gain;
PAAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg07959070	chr22:50026188	C22orf34	-0.36	-4.47	-0.34	1.49e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7101378	0.540	rs10890933	chr11:108902934	G/A	cg10610482	chr11:108093212	ATM;NPAT	-0.46	-4.4	-0.34	2.04e-5	IgG glycosylation;
PAAD	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	8.27	0.56	6.3e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.61	-0.35	8.42e-6	Glomerular filtration rate;
PAAD	cis	rs9913156	0.748	rs56364707	chr17:4562579	A/T	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	4.49	0.34	1.41e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	0.83	9.66	0.62	1.65e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.79	-6.83	-0.48	1.95e-10	Platelet distribution width;
PAAD	cis	rs12354486	1	rs12354486	chr10:104124055	C/G	cg15320455	chr10:103880129	LDB1	0.59	4.99	0.38	1.61e-6	Educational attainment (college completion);
PAAD	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.65	7.31	0.51	1.44e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.05e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.66	7.19	0.5	2.73e-11	Type 2 diabetes;
PAAD	cis	rs6687840	0.544	rs6427482	chr1:159499258	G/A	cg13968061	chr1:159557257	APCS	-0.47	-4.48	-0.34	1.45e-5	Chemerin levels;
PAAD	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg04117972	chr1:227635322	NA	0.77	4.95	0.37	1.98e-6	Major depressive disorder;
PAAD	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.5	5.49	0.41	1.68e-7	Menarche (age at onset);
PAAD	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg03684893	chr10:554711	DIP2C	0.44	4.78	0.36	4.12e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.41	0.61	7.26e-17	Chronic sinus infection;
PAAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	cis	rs16910800	0.954	rs2449440	chr11:23200335	T/G	cg20040320	chr11:23191996	NA	0.57	4.81	0.36	3.66e-6	Cancer;
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg20821713	chr7:1055600	C7orf50	-0.51	-4.31	-0.33	2.87e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg09796270	chr17:17721594	SREBF1	0.42	4.67	0.35	6.54e-6	Total body bone mineral density;
PAAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.93	-8.08	-0.55	1.85e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.9	0.37	2.44e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.94	-10.1	-0.63	1.16e-18	Parkinson's disease;
PAAD	cis	rs1198430	0.639	rs1767147	chr1:23770516	A/G	cg19827787	chr1:23763612	ASAP3	0.58	4.79	0.36	3.84e-6	Total cholesterol levels;
PAAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg25837213	chr17:80849375	TBCD	0.46	4.37	0.33	2.26e-5	Breast cancer;
PAAD	cis	rs10885582	0.904	rs12357781	chr10:116343076	C/T	cg17056676	chr10:116301354	ABLIM1	0.37	4.82	0.36	3.52e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11811982	0.793	rs77464064	chr1:227301610	C/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.83	-8.48	-0.57	1.85e-14	Corneal astigmatism;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg05861140	chr6:150128134	PCMT1	0.49	5.65	0.42	7.59e-8	Lung cancer;
PAAD	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.29	-0.51	1.59e-11	Neuroticism;
PAAD	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.31	0.33	2.96e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01200585	chr1:228362443	C1orf69	-0.48	-5.47	-0.41	1.77e-7	Diastolic blood pressure;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg19223190	chr17:80058835	NA	-0.54	-5.58	-0.41	1.07e-7	Life satisfaction;
PAAD	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.64	-7.0	-0.49	7.62e-11	Schizophrenia;
PAAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.07	13.42	0.74	1.43e-27	Cognitive function;
PAAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.12	0.38	9.11e-7	Rheumatoid arthritis;
PAAD	cis	rs6088813	1.000	rs224329	chr20:34019579	C/T	cg14752227	chr20:34000481	UQCC	0.49	5.0	0.38	1.56e-6	Height;
PAAD	cis	rs7824557	0.527	rs4841495	chr8:10958824	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-4.98	-0.37	1.7e-6	Retinal vascular caliber;
PAAD	cis	rs11887277	0.557	rs828257	chr2:26976712	C/T	cg12368169	chr2:27073192	DPYSL5	-0.39	-4.27	-0.33	3.39e-5	Obesity-related traits;
PAAD	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.49	-4.69	-0.36	6.15e-6	Obesity-related traits;
PAAD	cis	rs4740619	0.544	rs2153727	chr9:15829503	A/G	cg14451791	chr9:16040625	NA	0.38	4.31	0.33	2.97e-5	Body mass index;
PAAD	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.73	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.85	0.37	3.01e-6	Breast cancer;
PAAD	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-7.42	-0.52	7.91e-12	Heart rate;
PAAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.69	-6.0	-0.44	1.39e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.49	-0.47	1.15e-9	Morning vs. evening chronotype;
PAAD	cis	rs375066	0.762	rs17713001	chr19:44421225	C/T	cg21496419	chr19:44306685	LYPD5	-0.4	-4.65	-0.35	7.04e-6	Breast cancer;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	1.17	8.22	0.55	8.32e-14	IgG glycosylation;
PAAD	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.76	7.53	0.52	4.22e-12	Corneal astigmatism;
PAAD	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.87	9.45	0.61	5.85e-17	Colorectal cancer;
PAAD	cis	rs863345	0.967	rs863360	chr1:158549264	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.72	-5.71	-0.42	5.83e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11411865	chr7:2701802	TTYH3	0.65	4.65	0.35	7.23e-6	Bipolar disorder;
PAAD	cis	rs13253111	0.766	rs56232071	chr8:28063230	A/T	cg26534493	chr8:28060551	NA	0.45	4.95	0.37	1.91e-6	Childhood body mass index;
PAAD	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg04450456	chr4:17643702	FAM184B	0.51	5.48	0.41	1.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs138918	1.000	rs3937387	chr22:43555194	C/G	cg08909806	chr22:43548696	TSPO	-0.44	-4.45	-0.34	1.62e-5	Monocyte count;
PAAD	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.82	-0.48	2.06e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs4965869	0.866	rs2412012	chr15:101974653	C/T	cg20742182	chr15:101629240	NA	-0.52	-4.59	-0.35	9.06e-6	Platelet-derived growth factor BB levels;
PAAD	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg14004232	chr6:26401691	BTN3A1	-0.49	-4.27	-0.33	3.48e-5	Height;
PAAD	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg16230307	chr14:35515116	FAM177A1	0.41	4.36	0.33	2.43e-5	Psoriasis;
PAAD	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs7187994	0.651	rs12933163	chr16:84798300	G/C	cg07647771	chr16:84786436	USP10	-0.35	-4.26	-0.33	3.62e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg19847866	chr10:1019161	NA	0.73	7.89	0.54	5.62e-13	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg03948781	chr1:205179583	DSTYK	0.47	4.32	0.33	2.86e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs3764400	0.508	rs978263	chr17:46180664	A/G	cg24322968	chr17:46507895	SKAP1	-0.87	-5.3	-0.39	4.06e-7	Body mass index;
PAAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.78	-8.19	-0.55	9.81e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.46	-4.84	-0.37	3.13e-6	Dilated cardiomyopathy;
PAAD	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.96	13.36	0.73	2.07e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2885056	0.830	rs10409805	chr19:10691445	A/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg26097391	chr2:54893211	SPTBN1	0.45	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.08	0.5	4.96e-11	Rheumatoid arthritis;
PAAD	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	trans	rs4427176	0.507	rs7462910	chr8:9579986	C/T	cg01912921	chr6:1611712	FOXC1	-0.79	-6.33	-0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Body mass index;
PAAD	cis	rs12304921	0.626	rs73105025	chr12:51508406	A/G	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.64	6.49	0.47	1.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7537052	0.646	rs795045	chr1:36650055	T/C	cg24686825	chr1:36642396	MAP7D1	-0.6	-6.05	-0.44	1.06e-8	Schizophrenia;
PAAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs793571	0.822	rs11630160	chr15:59213678	A/G	cg05156742	chr15:59063176	FAM63B	-0.59	-4.8	-0.36	3.68e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01987515	chr2:232651086	COPS7B	0.63	6.43	0.46	1.56e-9	Obesity-related traits;
PAAD	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.72	8.93	0.59	1.27e-15	Dupuytren's disease;
PAAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg00579200	chr11:133705235	NA	-0.47	-5.49	-0.41	1.68e-7	Childhood ear infection;
PAAD	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg00262122	chr8:11665843	FDFT1	-0.48	-4.31	-0.33	2.96e-5	Retinal vascular caliber;
PAAD	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.59	5.6	0.41	9.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs12760731	0.565	rs6701848	chr1:178156816	A/C	cg00404053	chr1:178313656	RASAL2	0.67	5.17	0.39	7.34e-7	Obesity-related traits;
PAAD	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.01	0.38	1.48e-6	Axial length;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.89	-8.67	-0.58	5.95e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg17633681	chr16:88106987	BANP	0.6	7.08	0.5	5.05e-11	Menopause (age at onset);
PAAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.86	-9.62	-0.62	2.1e-17	Paraoxonase activity;
PAAD	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-12.2	-0.7	2.7e-24	Chronic sinus infection;
PAAD	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg25200586	chr1:148000763	NA	-0.61	-6.47	-0.46	1.27e-9	Hip geometry;
PAAD	cis	rs2867695	0.789	rs72656514	chr4:81104643	G/A	cg27211120	chr4:81307781	C4orf22	0.81	4.3	0.33	3.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-5.38	-0.4	2.72e-7	Schizophrenia;
PAAD	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg17326555	chr1:119535693	NA	-0.35	-4.37	-0.33	2.24e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	9.19	0.6	2.85e-16	Nonalcoholic fatty liver disease;
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg12310025	chr6:25882481	NA	-0.52	-4.32	-0.33	2.86e-5	Iron status biomarkers;
PAAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.58	-5.96	-0.44	1.68e-8	Body mass index;
PAAD	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	1.14	6.98	0.49	8.43e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs11811982	0.793	rs116647640	chr1:227408696	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.58	7.17	0.5	3.12e-11	Multiple system atrophy;
PAAD	cis	rs7951870	0.673	rs13448	chr11:46695414	T/C	cg19486271	chr11:47235900	DDB2	0.56	5.28	0.39	4.37e-7	Schizophrenia;
PAAD	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg24053715	chr22:38214548	NA	0.58	5.62	0.41	9.08e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg18281939	chr5:77783895	LHFPL2	0.5	5.57	0.41	1.12e-7	Triglycerides;
PAAD	cis	rs7551222	0.752	rs12566957	chr1:204556958	C/T	cg01064725	chr1:204461714	NA	-0.54	-5.18	-0.39	6.93e-7	Schizophrenia;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.66	0.42	7.46e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.49	-6.06	-0.44	1.05e-8	Crohn's disease;
PAAD	cis	rs1400816	0.850	rs35881445	chr2:172913957	C/T	cg23624723	chr2:173292262	ITGA6	0.89	4.89	0.37	2.53e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-9.85	-0.62	5.24e-18	Cognitive function;
PAAD	cis	rs9810890	1.000	rs116142295	chr3:128447372	G/C	cg18531004	chr3:128564980	NA	-0.84	-4.75	-0.36	4.72e-6	Dental caries;
PAAD	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.5	-0.41	1.54e-7	Bladder cancer;
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	4.48	0.34	1.49e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg16591659	chr17:78472290	NA	0.51	4.88	0.37	2.67e-6	Fractional excretion of uric acid;
PAAD	cis	rs790123	0.842	rs2650958	chr3:122396187	A/T	cg15604389	chr3:122379662	NA	0.57	6.09	0.44	8.86e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08677398	chr8:58056175	NA	0.67	4.57	0.35	9.85e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg14250997	chr9:106856677	SMC2	-0.42	-4.48	-0.34	1.46e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg19630374	chr17:18023558	MYO15A	-0.45	-4.77	-0.36	4.34e-6	Total body bone mineral density;
PAAD	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg16766828	chr3:128327626	NA	-0.49	-6.73	-0.48	3.19e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg08619932	chr19:49200058	FUT2	0.57	6.29	0.45	3.22e-9	Dietary macronutrient intake;
PAAD	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.52	6.0	0.44	1.38e-8	Schizophrenia;
PAAD	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.36	4.77	0.36	4.29e-6	Mean corpuscular volume;
PAAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.26e-6	Lung cancer;
PAAD	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.36	-0.6	1.01e-16	Venous thromboembolism;
PAAD	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.75	6.18	0.45	5.48e-9	Blood protein levels;
PAAD	cis	rs735539	0.521	rs9552281	chr13:21365407	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.65	0.35	7.22e-6	Dental caries;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.49	-0.41	1.63e-7	Lung cancer;
PAAD	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.44	0.65	1.42e-19	Cannabis dependence symptom count;
PAAD	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.85	-7.01	-0.49	7.26e-11	Triglycerides;
PAAD	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.74	-7.6	-0.52	2.87e-12	Prostate cancer;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.26	-0.51	1.85e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs795484	0.633	rs904661	chr12:118581860	C/T	cg16572268	chr12:118583242	PEBP1	0.53	4.99	0.38	1.64e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.82	-0.36	3.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg17724175	chr1:150552817	MCL1	-0.49	-5.63	-0.42	8.38e-8	Tonsillectomy;
PAAD	cis	rs2885056	0.891	rs11085739	chr19:10694239	A/G	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.53	5.64	0.42	8.24e-8	Testicular germ cell tumor;
PAAD	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg12963866	chr19:57752005	ZNF805	-0.47	-4.54	-0.35	1.12e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg04588774	chr16:3207967	NA	0.79	6.38	0.46	2.01e-9	Atopic dermatitis;
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6545883	0.562	rs777588	chr2:61426820	G/A	cg14146966	chr2:61757674	XPO1	0.35	4.36	0.33	2.35e-5	Tuberculosis;
PAAD	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg08835956	chr7:39171034	POU6F2	0.26	4.67	0.35	6.47e-6	IgG glycosylation;
PAAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.28	-0.39	4.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg24097872	chr10:5724021	NA	-0.58	-4.79	-0.36	3.91e-6	Childhood ear infection;
PAAD	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.54	-5.05	-0.38	1.25e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6499755	0.712	rs31115	chr16:55380735	T/C	cg02859129	chr16:55357253	IRX6	0.33	4.58	0.35	9.43e-6	Hypospadias;
PAAD	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11235843	0.853	rs7119528	chr11:73514762	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.18e-5	Hand grip strength;
PAAD	cis	rs9715521	0.645	rs9312120	chr4:59844036	A/T	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22307029	chr19:49891270	CCDC155	0.63	4.87	0.37	2.8e-6	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.75	6.29	0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg14343924	chr8:8086146	FLJ10661	-0.52	-4.31	-0.33	2.9e-5	Neuroticism;
PAAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17335440	chr11:48161380	PTPRJ	-0.67	-6.85	-0.49	1.72e-10	Obesity-related traits;
PAAD	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.61	7.0	0.49	7.68e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	5.43	0.4	2.17e-7	Blood metabolite levels;
PAAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.65	-8.42	-0.56	2.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.59	5.58	0.41	1.1e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.86	-9.32	-0.6	1.24e-16	Obesity-related traits;
PAAD	cis	rs11105468	1.000	rs56391951	chr12:90274621	G/A	cg16962463	chr12:89968675	NA	0.44	4.31	0.33	2.94e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.42	-4.68	-0.35	6.34e-6	Itch intensity from mosquito bite;
PAAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg18764771	chr6:116381957	FRK	0.34	5.92	0.43	2.09e-8	Total cholesterol levels;
PAAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	4.98	0.37	1.69e-6	Height;
PAAD	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg11650704	chr1:154556575	ADAR	-0.39	-4.26	-0.33	3.52e-5	Blood protein levels;
PAAD	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs75920871	0.660	rs7930783	chr11:116959039	G/A	cg04087571	chr11:116723030	SIK3	-0.42	-5.92	-0.43	2.08e-8	Subjective well-being;
PAAD	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.72	8.32	0.56	4.56e-14	Age-related hearing impairment;
PAAD	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.71	6.72	0.48	3.38e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg14159672	chr1:205819179	PM20D1	0.55	4.31	0.33	2.93e-5	Prostate-specific antigen levels;
PAAD	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Alcohol dependence;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-1.14	-7.96	-0.54	3.76e-13	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.55	-4.96	-0.37	1.83e-6	White blood cell count;
PAAD	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.66	-0.35	6.92e-6	Menarche (age at onset);
PAAD	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.6	5.56	0.41	1.19e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg17507749	chr15:85114479	UBE2QP1	0.55	4.77	0.36	4.3e-6	Alzheimer's disease (age of onset);
PAAD	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.49	4.88	0.37	2.64e-6	Asthma;
PAAD	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.76	8.84	0.58	2.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg23573665	chr14:55907122	TBPL2	-0.33	-4.44	-0.34	1.75e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.17e-10	Life satisfaction;
PAAD	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.23	0.64	5.22e-19	Cognitive test performance;
PAAD	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.51	5.54	0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.2	0.39	6.24e-7	Parkinson's disease;
PAAD	cis	rs2289328	0.882	rs7164606	chr15:40645133	G/A	cg13931752	chr15:40660718	DISP2	0.57	5.22	0.39	5.66e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14895029	chr7:2775587	GNA12	-0.48	-4.62	-0.35	8.25e-6	Height;
PAAD	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.61	7.92	0.54	4.74e-13	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08851591	chr19:44259152	C19orf61	0.63	7.15	0.5	3.43e-11	Monocyte percentage of white cells;
PAAD	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7771547	0.521	rs2180929	chr6:36394087	G/A	cg07856975	chr6:36356162	ETV7	0.53	5.45	0.4	1.96e-7	Platelet distribution width;
PAAD	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs4073221	0.585	rs34630061	chr3:18318863	T/G	cg07694806	chr3:18168406	NA	-0.62	-4.58	-0.35	9.43e-6	Parkinson's disease;
PAAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg03076319	chr2:238395764	MLPH	0.47	4.27	0.33	3.49e-5	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.79	8.16	0.55	1.17e-13	Height;
PAAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.59	6.05	0.44	1.09e-8	Multiple sclerosis;
PAAD	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.73	-8.8	-0.58	2.74e-15	Motion sickness;
PAAD	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg25620797	chr2:55921863	PNPT1	-0.47	-4.28	-0.33	3.33e-5	Metabolic syndrome;
PAAD	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12311304	1.000	rs11056409	chr12:15382567	T/C	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.86e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs16975963	0.843	rs60731897	chr19:38269259	C/A	cg14218481	chr19:38281219	NA	0.44	4.6	0.35	8.92e-6	Longevity;
PAAD	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-5.9	-0.43	2.32e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2786865	0.529	rs2744782	chr1:26025810	A/G	cg02327719	chr1:26185386	C1orf135	-0.82	-4.76	-0.36	4.4e-6	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.75	6.92	0.49	1.17e-10	Total body bone mineral density;
PAAD	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.69	6.91	0.49	1.23e-10	Testicular germ cell tumor;
PAAD	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.64	-0.35	7.46e-6	Mean corpuscular volume;
PAAD	cis	rs28489187	0.643	rs997251	chr1:85845367	T/C	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.52	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.73	0.42	5.35e-8	Urate levels;
PAAD	cis	rs3126085	0.736	rs12747962	chr1:152240456	G/A	cg09127314	chr1:152161683	NA	0.68	4.59	0.35	9.18e-6	Atopic dermatitis;
PAAD	cis	rs329648	1.000	rs329648	chr11:133765367	A/G	cg15485101	chr11:133734466	NA	0.37	4.31	0.33	2.91e-5	Parkinson's disease;
PAAD	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	1.13	6.36	0.46	2.25e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.36e-10	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs72829446	0.505	rs72842824	chr17:7352910	G/A	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.45	-0.4	1.99e-7	Androgen levels;
PAAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg08132940	chr7:1081526	C7orf50	0.6	4.42	0.34	1.89e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4731207	0.596	rs11767649	chr7:124637517	C/T	cg14311320	chr7:124405732	GPR37	0.43	4.51	0.34	1.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs2117029	0.521	rs58336603	chr12:49556888	C/T	cg05368762	chr12:50135785	TMBIM6	0.42	4.3	0.33	3.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-7.71	-0.53	1.5e-12	Prostate cancer;
PAAD	cis	rs7765175	0.598	rs2801438	chr6:113631900	A/G	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.78e-18	Cognitive function;
PAAD	cis	rs6504622	0.557	rs197912	chr17:44989888	A/T	cg23825231	chr17:45054460	NA	-0.43	-4.28	-0.33	3.23e-5	Orofacial clefts;
PAAD	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg14196790	chr5:131705035	SLC22A5	0.42	4.6	0.35	9e-6	Breast cancer;
PAAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15145965	chr22:50218605	BRD1	-0.6	-5.1	-0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	6.22	0.45	4.66e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs256277	0.657	rs34927	chr5:111358740	C/T	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11563648	0.517	rs2269729	chr7:127032663	A/T	cg13381984	chr7:127881344	LEP	-0.29	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.79	9.32	0.6	1.29e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9928842	0.771	rs8059190	chr16:75260797	T/A	cg09066997	chr16:75300724	BCAR1	0.6	4.49	0.34	1.43e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg00262122	chr8:11665843	FDFT1	0.5	4.66	0.35	6.86e-6	Retinal vascular caliber;
PAAD	cis	rs900145	0.906	rs2279285	chr11:13298687	G/T	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-6.73	-0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.6	-6.08	-0.44	9.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.68	-7.39	-0.51	9.13e-12	Coronary artery disease;
PAAD	cis	rs2790216	0.950	rs1199102	chr10:59947303	C/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-5.03	-0.38	1.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg02683114	chr2:24398427	C2orf84	0.62	6.85	0.49	1.69e-10	Asthma;
PAAD	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.7	9.57	0.61	2.77e-17	Crohn's disease;
PAAD	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.95	-0.37	1.96e-6	Body mass index;
PAAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.16	-0.55	1.21e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs7705042	0.826	rs11749731	chr5:141500436	A/C	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.09	-0.38	1.06e-6	Asthma;
PAAD	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg11601000	chr22:42348013	LOC339674	0.47	5.56	0.41	1.2e-7	Cognitive function;
PAAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.59	5.86	0.43	2.8e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12438356	1.000	rs28640063	chr15:69589663	A/G	cg02375503	chr15:69591110	PAQR5	-0.62	-4.3	-0.33	3.06e-5	CTACK levels;
PAAD	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg26695010	chr11:65641043	EFEMP2	0.57	5.03	0.38	1.34e-6	DNA methylation (variation);
PAAD	trans	rs57506017	0.585	rs6460900	chr7:12253088	C/T	cg25841539	chr7:103086474	SLC26A5	-0.64	-6.65	-0.47	5.05e-10	Neuroticism;
PAAD	cis	rs7873102	0.654	rs7037371	chr9:38016247	T/C	cg03528946	chr9:38069800	SHB	-0.53	-5.37	-0.4	2.92e-7	Brain structure;
PAAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.96	-12.54	-0.71	3.32e-25	Height;
PAAD	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.87	0.49	1.51e-10	Lung cancer in ever smokers;
PAAD	cis	rs357618	1.000	rs357628	chr5:150850352	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs9535307	0.719	rs9535341	chr13:50363304	C/T	cg04663916	chr13:50265991	EBPL	-0.6	-4.46	-0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.46	4.51	0.34	1.27e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg20893579	chr22:38215064	NA	-0.57	-6.08	-0.44	9.12e-9	Glioblastoma;Glioma;
PAAD	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.49	-5.34	-0.4	3.38e-7	Migraine;
PAAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.46	-0.46	1.35e-9	Glomerular filtration rate;
PAAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.13	-13.17	-0.73	6.47e-27	Cognitive function;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	1.05	8.69	0.58	5.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-5.02	-0.38	1.41e-6	Neurofibrillary tangles;
PAAD	cis	rs4523957	0.928	rs216190	chr17:2187457	C/T	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	trans	rs7689240	0.818	rs12503142	chr4:35275589	A/G	cg14214685	chr1:26799841	HMGN2	0.88	6.34	0.46	2.54e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9463078	0.656	rs227843	chr6:44691703	A/G	cg25276700	chr6:44698697	NA	0.52	5.81	0.43	3.48e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Bladder cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23360967	chr6:11210562	NEDD9	-0.58	-6.98	-0.49	8.5e-11	Obesity-related traits;
PAAD	cis	rs2790216	1.000	rs1769047	chr10:59963046	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.39	-0.34	2.13e-5	Inflammatory bowel disease;
PAAD	cis	rs7705042	0.828	rs10875596	chr5:141495715	T/C	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.26	-0.39	4.89e-7	Asthma;
PAAD	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.37	-0.51	1.02e-11	Colorectal cancer;
PAAD	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.44	-0.34	1.7e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg14703610	chr5:56206110	C5orf35	0.61	5.68	0.42	6.56e-8	Coronary artery disease;
PAAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.24e-22	Parkinson's disease;
PAAD	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.49	0.34	1.38e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.29	0.33	3.15e-5	Bipolar disorder;
PAAD	cis	rs11634944	0.676	rs220027	chr15:25196960	C/G	cg14481604	chr15:25334117	SNORD116-22	-0.42	-4.25	-0.33	3.66e-5	Interleukin-8 levels;
PAAD	trans	rs9428104	0.920	rs35182733	chr1:118917956	C/T	cg18701660	chr19:34012935	PEPD	0.67	6.29	0.45	3.17e-9	Height;
PAAD	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-1.12	-4.97	-0.37	1.77e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	6.42	0.46	1.61e-9	Neuroticism;
PAAD	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-4.28	-0.33	3.3e-5	Systolic blood pressure;
PAAD	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg05627522	chr15:75251581	NA	-0.4	-4.27	-0.33	3.4e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9814567	0.574	rs1391695	chr3:134171376	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.29	-0.39	4.11e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16641000	chr16:4848176	ROGDI	0.61	7.32	0.51	1.32e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7765175	0.651	rs1074618	chr6:113667638	C/T	cg19037598	chr6:113666021	NA	-0.41	-4.38	-0.33	2.24e-5	Coronary artery calcification;
PAAD	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-4.55	-0.35	1.09e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.33	0.4	3.52e-7	Bipolar disorder;
PAAD	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1;
PAAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2109514	1.000	rs2109514	chr7:116159961	G/A	cg19719915	chr7:115928094	NA	-0.45	-4.3	-0.33	3.06e-5	Prevalent atrial fibrillation;
PAAD	cis	rs5756391	0.568	rs2075941	chr22:37318515	T/C	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.35e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs776905	0.598	rs6041	chr13:113772707	G/A	cg09069900	chr13:113776964	F10	-0.58	-4.58	-0.35	9.47e-6	Blood protein levels;
PAAD	cis	rs9534288	0.699	rs2146884	chr13:46660392	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-5.88	-0.43	2.53e-8	Blood protein levels;
PAAD	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.56	6.02	0.44	1.24e-8	Bladder cancer;
PAAD	trans	rs3758141	0.858	rs1116018	chr8:18717226	G/A	cg02479022	chr8:22250005	SLC39A14	-1.07	-6.64	-0.47	5.33e-10	Body mass index (change over time) in gastrointestinal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15773744	chr18:33160866	NA	0.61	6.69	0.48	3.96e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.45	5.65	0.42	7.73e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2790216	1.000	rs2790191	chr10:60045091	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg15105011	chr4:940614	TMEM175	0.67	7.6	0.52	2.79e-12	Sjögren's syndrome;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22368307	chr11:75110460	SNORD15A;RPS3	0.61	6.43	0.46	1.6e-9	Pancreatic cancer;
PAAD	cis	rs622217	0.837	rs2665357	chr6:160848167	A/C	cg25313204	chr6:160768801	SLC22A3	0.43	4.52	0.34	1.25e-5	Type 2 diabetes;
PAAD	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.7	0.66	2.89e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.55	-5.82	-0.43	3.3e-8	Metabolic syndrome;
PAAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg07617317	chr6:118971624	C6orf204	0.53	4.49	0.34	1.43e-5	Diastolic blood pressure;
PAAD	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.25	-0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs4742903	1.000	rs4743687	chr9:106856910	C/T	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.17	0.55	1.13e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg25204440	chr1:209979598	IRF6	0.64	5.67	0.42	6.93e-8	Coronary artery disease;
PAAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.45	6.24	0.45	4.09e-9	Vitiligo;
PAAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg13606994	chr1:44402422	ARTN	-0.48	-4.39	-0.34	2.09e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.23	0.39	5.62e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.52	-5.97	-0.44	1.61e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.5	-7.22	-0.51	2.31e-11	Diastolic blood pressure;
PAAD	cis	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg21775007	chr8:11205619	TDH	0.5	4.55	0.35	1.08e-5	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.17	-0.55	1.13e-13	Hemoglobin concentration;
PAAD	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.57	0.41	1.11e-7	Educational attainment;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.44	0.4	2.07e-7	Menarche (age at onset);
PAAD	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg09127314	chr1:152161683	NA	-0.64	-4.47	-0.34	1.52e-5	Atopic dermatitis;
PAAD	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.94	-0.43	1.87e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-5.2	-0.39	6.25e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.86	-10.16	-0.64	7.98e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.54	0.41	1.32e-7	Lung cancer;
PAAD	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.83	-10.02	-0.63	1.81e-18	Coronary artery disease;
PAAD	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.68	-7.44	-0.52	6.86e-12	Dilated cardiomyopathy;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg04810063	chr16:88703634	IL17C	-0.47	-4.46	-0.34	1.6e-5	Menopause (age at onset);
PAAD	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.5	5.86	0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.63	6.67	0.48	4.38e-10	Crohn's disease;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg26554054	chr8:600488	NA	0.84	5.34	0.4	3.29e-7	IgG glycosylation;
PAAD	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.19	0.64	6.76e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7326068	0.610	rs2762999	chr13:21445243	G/A	cg27499820	chr13:21296301	IL17D	0.48	4.4	0.34	2.06e-5	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.77	5.43	0.4	2.18e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.04	0.38	1.29e-6	Aortic root size;
PAAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.19	0.64	6.5e-19	Menopause (age at onset);
PAAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.58	5.25	0.39	4.97e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.59	5.59	0.41	1.01e-7	Cognitive test performance;
PAAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	1.0	10.02	0.63	1.84e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.7	-7.92	-0.54	4.79e-13	Motion sickness;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg17595323	chr11:93583763	C11orf90	0.34	4.33	0.33	2.66e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.52	5.19	0.39	6.67e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.45	5.16	0.39	7.76e-7	Testicular germ cell tumor;
PAAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.97	12.48	0.71	4.83e-25	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.75	-0.48	2.9e-10	Lung cancer;
PAAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg15443732	chr18:74961078	GALR1	0.73	5.99	0.44	1.48e-8	Obesity-related traits;
PAAD	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.8	8.22	0.55	8.31e-14	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17437033	chr5:132072786	KIF3A	0.66	6.38	0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs863345	0.604	rs4373761	chr1:158464634	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.4	-5.87	-0.43	2.65e-8	Subjective well-being;
PAAD	cis	rs17023223	0.537	rs3936018	chr1:119682370	T/C	cg17326555	chr1:119535693	NA	-0.41	-4.66	-0.35	6.94e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg13444538	chr7:158905317	VIPR2	-0.55	-5.15	-0.39	8.03e-7	Facial morphology (factor 20);
PAAD	cis	rs684232	0.623	rs117314378	chr17:521672	C/T	cg15660573	chr17:549704	VPS53	-0.76	-7.48	-0.52	5.57e-12	Prostate cancer;
PAAD	cis	rs73206853	0.841	rs17625767	chr12:111102627	A/C	cg12870014	chr12:110450643	ANKRD13A	0.75	4.66	0.35	6.83e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg19423196	chr10:82049429	MAT1A	0.53	4.94	0.37	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg21929781	chr1:2537748	MMEL1	0.54	5.61	0.41	9.34e-8	Ulcerative colitis;
PAAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs16895831	0.549	rs12204274	chr6:42607841	C/T	cg10605015	chr6:42532144	UBR2	-0.68	-4.88	-0.37	2.67e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg01851573	chr8:8652454	MFHAS1	0.63	5.11	0.38	9.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.3e-5	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.66	-7.93	-0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg22143856	chr6:28129313	ZNF389	0.54	4.95	0.37	1.98e-6	Parkinson's disease;
PAAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.15	-0.5	3.48e-11	Personality dimensions;
PAAD	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-1.0	-8.13	-0.55	1.4e-13	Smoking behavior;
PAAD	cis	rs8005677	0.798	rs4982713	chr14:23404102	C/T	cg01529538	chr14:23388837	RBM23	0.48	4.79	0.36	3.86e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.91	-0.79	3.56e-34	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.86	9.78	0.62	7.97e-18	Resting heart rate;
PAAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.56	6.86	0.49	1.63e-10	Monobrow;
PAAD	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.6	-5.13	-0.38	8.72e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Mosquito bite size;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.54	5.92	0.43	2.02e-8	Tonsillectomy;
PAAD	cis	rs863345	0.604	rs1342945	chr1:158512912	C/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.8	-0.36	3.75e-6	Pneumococcal bacteremia;
PAAD	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.86	-0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.07	5.19	0.39	6.52e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg23024343	chr7:107201750	COG5	0.56	4.59	0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.78	-0.36	4.05e-6	Eotaxin levels;
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14132884	chr14:75230010	YLPM1	0.67	6.65	0.47	5.07e-10	Obesity-related traits;
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg15181151	chr6:150070149	PCMT1	0.61	6.58	0.47	7.05e-10	Lung cancer;
PAAD	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg25364880	chr3:44379878	C3orf23	0.62	6.01	0.44	1.33e-8	Depressive symptoms;
PAAD	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.99	11.96	0.7	1.21e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.05	-0.38	1.24e-6	Schizophrenia;
PAAD	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.8	9.24	0.6	2.02e-16	Breast cancer;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.41	0.56	2.7e-14	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.93	8.01	0.54	2.84e-13	Alzheimer's disease;
PAAD	cis	rs7249921	0.802	rs35746990	chr19:35666857	C/T	cg11856182	chr19:35264148	ZNF599	-0.54	-4.78	-0.36	4.03e-6	Platelet count;
PAAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.58	4.94	0.37	2.08e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26329020	chr12:32909488	YARS2	0.62	6.99	0.49	8.06e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.67	7.09	0.5	4.73e-11	Mean corpuscular volume;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg22254299	chr17:77772001	CBX8	0.61	6.42	0.46	1.65e-9	Primary biliary cholangitis;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg15693483	chr7:1102177	C7orf50	0.47	5.15	0.39	7.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs939584	1.000	rs13386517	chr2:650479	G/C	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.52	-5.2	-0.39	6.46e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs12599426	0.852	rs3853178	chr16:34597543	C/T	cg08331635	chr16:34430078	NA	-0.65	-5.02	-0.38	1.45e-6	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.72e-6	Oral cavity cancer;
PAAD	cis	rs10073892	0.625	rs59648644	chr5:101618975	A/T	cg17280723	chr5:101634495	NA	0.41	4.42	0.34	1.85e-5	Cognitive decline (age-related);
PAAD	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.62e-17	White blood cell count (basophil);
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs73019876	0.836	rs548059	chr19:22228091	A/G	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg24881330	chr22:46731750	TRMU	1.14	5.62	0.42	8.71e-8	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.15e-9	HDL cholesterol;
PAAD	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs77633900	0.772	rs157788	chr15:76806011	T/C	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs12137025	1.000	rs12137149	chr1:223867965	G/A	cg18879828	chr11:46942432	NA	-0.77	-6.46	-0.46	1.33e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.66	7.59	0.52	3.03e-12	Rheumatoid arthritis;
PAAD	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.85e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	1.04	13.71	0.74	2.37e-28	Breast cancer;
PAAD	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg00522288	chr12:125625016	AACS	-0.42	-4.36	-0.33	2.35e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs17407555	0.865	rs115163648	chr4:10331926	G/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.44	-0.34	1.69e-5	Schizophrenia (age at onset);
PAAD	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.99	6.98	0.49	8.79e-11	Major depressive disorder;
PAAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.58	5.35	0.4	3.21e-7	Self-reported allergy;
PAAD	cis	rs4740619	0.967	rs4741527	chr9:15643065	T/A	cg14451791	chr9:16040625	NA	-0.37	-4.25	-0.33	3.72e-5	Body mass index;
PAAD	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.54	-6.44	-0.46	1.5e-9	Systemic lupus erythematosus;
PAAD	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.52	6.78	0.48	2.51e-10	Urate levels in overweight individuals;
PAAD	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4787951	0.580	rs1805010	chr16:27356203	A/G	cg00632019	chr16:27217587	JMJD5	0.43	4.3	0.33	3.02e-5	Eosinophil percentage of white cells;
PAAD	cis	rs4727012	1	rs4727012	chr7:148740493	C/T	cg23583168	chr7:148888333	NA	0.71	4.7	0.36	5.91e-6	Colorectal or endometrial cancer;
PAAD	cis	rs4666360	1.000	rs4666294	chr2:20336753	C/G	cg23291376	chr2:20336282	NA	0.41	4.61	0.35	8.58e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs5753037	0.630	rs140111	chr22:30131570	A/G	cg01021169	chr22:30184971	ASCC2	-0.46	-4.74	-0.36	4.9100000000000004e-06	Type 1 diabetes;
PAAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.6	-7.19	-0.5	2.67e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19346786	chr7:2764209	NA	-0.38	-5.29	-0.39	4.12e-7	Height;
PAAD	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.37	0.33	2.31e-5	Asthma;
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.79	-8.33	-0.56	4.4e-14	Tuberculosis;
PAAD	cis	rs9397240	0.789	rs10499303	chr6:155615239	G/A	cg26934881	chr6:155569291	TIAM2	-0.51	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs2016586	0.929	rs8136429	chr22:36111828	C/G	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25730138	chr19:5903868	NDUFA11;VMAC	0.65	6.33	0.46	2.57e-9	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.78	-8.25	-0.56	7.19e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10792830	0.706	rs2508381	chr11:85731982	A/C	cg07180834	chr11:85838833	NA	-0.48	-5.38	-0.4	2.78e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.49	-0.34	1.41e-5	Biliary atresia;
PAAD	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-4.62	-0.35	8.08e-6	Ulcerative colitis;
PAAD	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.62	-7.06	-0.5	5.43e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	1.21	7.28	0.51	1.7e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.56	6.83	0.48	1.95e-10	Renal cell carcinoma;
PAAD	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg23254163	chr1:152506842	NA	0.61	6.98	0.49	8.64e-11	Hair morphology;
PAAD	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	4.87	0.37	2.78e-6	Schizophrenia;
PAAD	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	5.45	0.4	1.98e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg15212455	chr7:39170539	POU6F2	-0.41	-5.62	-0.41	8.88e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.26	-0.33	3.64e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.49	-4.26	-0.33	3.57e-5	Triglycerides;
PAAD	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Educational attainment;
PAAD	cis	rs990171	1.000	rs6755786	chr2:103048103	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.42	4.71	0.36	5.57e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-5.91	-0.43	2.12e-8	Obesity (extreme);
PAAD	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.42	-6.56	-0.47	7.98e-10	Mean corpuscular volume;
PAAD	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.6	-7.07	-0.5	5.26e-11	Monocyte count;
PAAD	cis	rs9462027	0.628	rs2744961	chr6:34655000	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.38	-4.47	-0.34	1.53e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.08	-0.44	9.2e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg04034577	chr2:241836375	C2orf54	-0.33	-4.95	-0.37	1.94e-6	Urinary metabolites;
PAAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg16479474	chr6:28041457	NA	0.45	4.48	0.34	1.47e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs842828	1.000	rs842827	chr2:201246868	C/T	cg26842802	chr2:202125212	CASP8	-0.67	-4.81	-0.36	3.56e-6	Urate levels in lean individuals;
PAAD	cis	rs16958440	0.867	rs3809965	chr18:44676872	G/A	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg04287289	chr16:89883240	FANCA	0.63	6.81	0.48	2.13e-10	Vitiligo;
PAAD	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.82	-8.98	-0.59	9.72e-16	Body mass index;
PAAD	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg14895029	chr7:2775587	GNA12	-0.45	-4.43	-0.34	1.78e-5	Height;
PAAD	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.98	6.04	0.44	1.15e-8	Parkinson's disease;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.75	-8.76	-0.58	3.67e-15	Lung cancer;
PAAD	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.97	-0.49	8.91e-11	Eye color traits;
PAAD	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.09	-11.79	-0.69	3.45e-23	Blood pressure (smoking interaction);
PAAD	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg19413350	chr8:57351067	NA	-0.46	-4.33	-0.33	2.68e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.75	-0.36	4.6e-6	Obesity-related traits;
PAAD	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg01631408	chr1:248437212	OR2T33	-0.6	-5.36	-0.4	3.09e-7	Common traits (Other);
PAAD	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-8.24	-0.56	7.53e-14	Neuroticism;
PAAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.57	-5.7	-0.42	6.15e-8	Urate levels;
PAAD	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs62025270	0.747	rs17639314	chr15:86309909	A/G	cg13263323	chr15:86062960	AKAP13	0.6	5.59	0.41	1.04e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.47	4.69	0.36	6.1e-6	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs36070902	chr10:45983977	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9913156	0.748	rs72835626	chr17:4560326	C/A	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.71	0.48	3.54e-10	Life satisfaction;
PAAD	cis	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.87	4.43	0.34	1.76e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg06375148	chr1:209958343	C1orf74	0.65	5.39	0.4	2.69e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.67	8.38	0.56	3.21e-14	Dupuytren's disease;
PAAD	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg09462578	chr12:12878428	APOLD1	-0.9	-9.1	-0.59	4.85e-16	Lymphocyte counts;
PAAD	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg10729496	chr3:10149963	C3orf24	0.73	6.4	0.46	1.81e-9	Alzheimer's disease;
PAAD	cis	rs13201294	1	rs13201294	chr6:27556141	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.71	0.36	5.49e-6	Squamous cell lung carcinoma;
PAAD	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.59	-6.92	-0.49	1.15e-10	Dementia with Lewy bodies;
PAAD	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-5.32	-0.4	3.62e-7	Common traits (Other);
PAAD	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.75	-7.16	-0.5	3.25e-11	Pancreatic cancer;
PAAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.52	0.47	9.9e-10	Alzheimer's disease;
PAAD	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg08495239	chr10:135273341	LOC619207	-0.41	-4.28	-0.33	3.28e-5	Systemic lupus erythematosus;
PAAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg26138144	chr22:38071188	LGALS1	0.51	5.57	0.41	1.12e-7	Fat distribution (HIV);
PAAD	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21644669	chr17:8649170	CCDC42	0.62	6.53	0.47	9.49e-10	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19287320	chr4:169796855	PALLD	-0.56	-7.19	-0.5	2.74e-11	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10707110	chr22:38227306	ANKRD54	-0.71	-7.08	-0.5	4.88e-11	Obesity-related traits;
PAAD	trans	rs875971	0.660	rs801192	chr7:66031952	C/G	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg24147428	chr11:65409760	SIPA1	0.34	4.38	0.33	2.18e-5	Urate levels;
PAAD	cis	rs10750165	0.692	rs67007544	chr11:119651554	T/G	cg24085502	chr11:119066850	CCDC153	-0.35	-4.43	-0.34	1.78e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	7.64	0.53	2.33e-12	Response to antipsychotic treatment;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.6	5.74	0.42	5.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg15510373	chr7:100224934	TFR2	-0.53	-4.3	-0.33	3.02e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	6.76	0.48	2.82e-10	Renal function-related traits (BUN);
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.71	5.48	0.41	1.7e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs7216064	0.817	rs12601921	chr17:65825354	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-5.66	-0.42	7.48e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs73416724	1.000	rs76823934	chr6:43359424	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.79	0.42	3.99e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.58	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs2617583	0.679	rs2652511	chr5:1446389	A/G	cg07151155	chr5:1473589	LPCAT1	-0.46	-4.52	-0.34	1.21e-5	Breast cancer;
PAAD	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg25811867	chr2:3488468	NA	0.47	4.89	0.37	2.52e-6	Neurofibrillary tangles;
PAAD	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.27e-20	Electrocardiographic conduction measures;
PAAD	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.46	4.57	0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs6578985	0.636	rs734351	chr11:2156213	A/G	cg12383159	chr11:1262597	MUC5B	0.43	4.9	0.37	2.48e-6	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2544527	0.819	rs2693018	chr2:15921554	A/G	cg26669897	chr2:15909070	NA	0.46	4.57	0.35	9.93e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg15674680	chr20:60982522	CABLES2	-0.5	-4.64	-0.35	7.52e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2133450	0.526	rs12489404	chr3:7346698	C/T	cg19930620	chr3:7340148	GRM7	-0.47	-5.04	-0.38	1.28e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.27	16.54	0.8	8.57e-36	Schizophrenia;
PAAD	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg03938978	chr2:103052716	IL18RAP	0.51	5.21	0.39	6.15e-7	Blood protein levels;
PAAD	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.59	-5.84	-0.43	3.11e-8	Pulse pressure;
PAAD	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.84	9.24	0.6	2.04e-16	Mortality in heart failure;
PAAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg25204440	chr1:209979598	IRF6	0.58	4.58	0.35	9.76e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg10864074	chr7:100318194	EPO	-0.48	-4.72	-0.36	5.22e-6	Other erythrocyte phenotypes;
PAAD	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.46	-0.34	1.56e-5	Triglycerides;
PAAD	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.5	-5.99	-0.44	1.49e-8	Systemic lupus erythematosus;
PAAD	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg00945666	chr1:160990265	F11R	-0.42	-4.84	-0.37	3.2e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg02462569	chr6:150064036	NUP43	-0.48	-5.11	-0.38	9.56e-7	Lung cancer;
PAAD	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.39e-6	Diastolic blood pressure;
PAAD	cis	rs6669119	1.000	rs79433889	chr1:19111355	T/G	cg26220594	chr1:19110978	NA	0.73	4.52	0.34	1.25e-5	Percentage gas trapping;
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.44	-5.54	-0.41	1.33e-7	Prostate cancer;
PAAD	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06850241	chr22:41845214	NA	-0.59	-5.05	-0.38	1.22e-6	Vitiligo;
PAAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg27490568	chr2:178487706	NA	0.43	4.58	0.35	9.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16083429	chr3:49237500	CCDC36	-0.48	-5.34	-0.4	3.28e-7	Menarche (age at onset);
PAAD	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-7.43	-0.52	7.39e-12	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05933224	chr14:81609977	TSHR	0.63	7.59	0.52	2.97e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.52	4.29	0.33	3.21e-5	Morning vs. evening chronotype;
PAAD	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.32	-0.4	3.65e-7	Subjective well-being;
PAAD	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.8	9.33	0.6	1.21e-16	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg05709478	chr1:6581295	PLEKHG5	0.73	4.7	0.36	5.72e-6	Body mass index;
PAAD	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg08758996	chr17:66097529	LOC651250	0.53	4.27	0.33	3.47e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg25838818	chr2:108905173	SULT1C2	-0.5	-5.09	-0.38	1.02e-6	Blood pressure;
PAAD	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg03482866	chr13:111040579	COL4A2	0.44	4.33	0.33	2.65e-5	White matter hyperintensity burden;
PAAD	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg14906510	chr12:7781169	NA	-0.65	-4.68	-0.35	6.36e-6	HDL cholesterol levels;
PAAD	cis	rs4478858	0.718	rs10914329	chr1:31688441	T/A	cg00250761	chr1:31883323	NA	0.41	4.55	0.35	1.1e-5	Alcohol dependence;
PAAD	cis	rs10875746	0.768	rs12305182	chr12:48421407	G/T	cg26205652	chr12:48591994	NA	0.84	8.04	0.55	2.31e-13	Longevity (90 years and older);
PAAD	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-4.5	-0.34	1.35e-5	Educational attainment;
PAAD	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	1.0	12.31	0.71	1.36e-24	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11355319	chr5:89825117	LYSMD3	0.65	7.44	0.52	6.91e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26549601	chr10:134560360	INPP5A	-0.49	-4.81	-0.36	3.57e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs3026101	0.624	rs1806261	chr17:5317008	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.81	0.43	3.48e-8	Body mass index;
PAAD	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg19787841	chr12:53845606	PCBP2	0.43	4.26	0.33	3.51e-5	Height;
PAAD	trans	rs9375185	0.941	rs9401599	chr6:123120403	C/T	cg17396305	chr6:1594275	NA	0.87	6.3	0.46	3.11e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13003239	chr3:49044627	WDR6	-0.57	-6.76	-0.48	2.74e-10	Body fat percentage;
PAAD	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs13082711	0.522	rs537674	chr3:27361901	G/T	cg02860705	chr3:27208620	NA	0.53	5.2	0.39	6.29e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9810890	1.000	rs73198828	chr3:128489894	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.66	0.48	4.69e-10	Height;
PAAD	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.85	9.34	0.6	1.12e-16	Prostate cancer;
PAAD	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.45	4.76	0.36	4.5e-6	Longevity;Endometriosis;
PAAD	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.56	-0.35	1.05e-5	Mean corpuscular volume;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.79	-0.48	2.31e-10	Life satisfaction;
PAAD	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.52	5.63	0.42	8.58e-8	Major depressive disorder;
PAAD	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg11498726	chr8:26250323	BNIP3L	0.46	4.92	0.37	2.18e-6	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02339418	chr12:123717776	C12orf65	-0.64	-6.57	-0.47	7.39e-10	Smoking initiation;
PAAD	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.38	5.54	0.41	1.3e-7	Educational attainment (years of education);
PAAD	cis	rs2481665	0.904	rs2457817	chr1:62604570	T/C	cg18591186	chr1:62594603	INADL	-0.63	-5.52	-0.41	1.44e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.45	6.54	0.47	8.87e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.45	-6.87	-0.49	1.58e-10	Subjective well-being;
PAAD	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.46	0.34	1.59e-5	Neuroticism;
PAAD	cis	rs10028187	0.865	rs713248	chr4:154408454	A/G	cg24020152	chr4:154419554	KIAA0922	0.49	5.33	0.4	3.54e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg26513180	chr16:89883248	FANCA	-0.45	-4.47	-0.34	1.54e-5	Vitiligo;
PAAD	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg25753631	chr6:25732923	NA	-0.47	-5.24	-0.39	5.29e-7	Iron status biomarkers;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.78	7.61	0.53	2.62e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.82	-9.15	-0.6	3.46e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.77	-6.17	-0.45	5.98e-9	Lung function (FEV1/FVC);
PAAD	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.61	-8.56	-0.57	1.16e-14	Endometriosis;
PAAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.46	-0.34	1.57e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs6842047	0.611	rs4253421	chr4:187204937	C/T	cg09526685	chr4:187126073	CYP4V2	-0.68	-5.17	-0.39	7.14e-7	Blood protein levels;
PAAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	5.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11892454	0.544	rs11894959	chr2:25997821	C/T	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	6.13	0.45	7.35e-9	Aortic root size;
PAAD	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.68	8.99	0.59	9.01e-16	Hemoglobin concentration;
PAAD	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.6	5.85	0.43	2.92e-8	Eye color traits;
PAAD	cis	rs10899021	0.920	rs11236171	chr11:74317518	C/T	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.75	0.36	4.63e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3816788	0.792	rs10097055	chr8:21872328	A/G	cg17168535	chr8:21777572	XPO7	0.83	9.71	0.62	1.24e-17	Lung cancer in ever smokers;
PAAD	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.88	11.27	0.67	8.75e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.25	-0.39	5.03e-7	Coronary artery calcification;
PAAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg27511599	chr7:32358540	NA	0.72	4.38	0.33	2.23e-5	Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15890852	chr7:64362320	ZNF273	0.56	6.52	0.47	9.76e-10	Body fat percentage;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12538369	chr19:40932019	SERTAD1	-0.65	-6.52	-0.47	9.73e-10	Smoking initiation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27310827	chr1:1163671	SDF4	0.62	7.4	0.51	8.51e-12	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg25200586	chr1:148000763	NA	-0.61	-6.35	-0.46	2.36e-9	Hip geometry;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg00280220	chr17:61926910	NA	0.44	4.65	0.35	7.23e-6	Prudent dietary pattern;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.62	-7.29	-0.51	1.54e-11	Lung cancer;
PAAD	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg15571903	chr15:79123663	NA	-0.47	-6.11	-0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.48	-5.37	-0.4	2.86e-7	Menarche (age at onset);
PAAD	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.41	4.49	0.34	1.4e-5	Mean platelet volume;
PAAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.5	4.7	0.36	5.77e-6	Height;
PAAD	cis	rs73416724	1.000	rs77626494	chr6:43286886	C/T	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.91	-11.77	-0.69	3.91e-23	Menarche (age at onset);
PAAD	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.11	0.5	4.34e-11	Coffee consumption (cups per day);
PAAD	cis	rs4691139	0.619	rs2139218	chr4:165922427	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.42	-4.44	-0.34	1.71e-5	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs639012	0.570	rs519961	chr11:85832424	T/C	cg07180834	chr11:85838833	NA	-0.42	-4.49	-0.34	1.4e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg00800038	chr16:89945340	TCF25	-0.83	-4.29	-0.33	3.21e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.47	4.88	0.37	2.71e-6	Menopause (age at onset);
PAAD	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.6	6.18	0.45	5.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.68e-13	Motion sickness;
PAAD	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.74	0.58	4.1e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.86	5.84	0.43	3.11e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg24699146	chr1:24152579	HMGCL	0.44	4.5	0.34	1.34e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	ch.8.33884649F	chr8:33765107	NA	0.57	5.84	0.43	2.99e-8	Body mass index;
PAAD	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.75	0.53	1.22e-12	Personality dimensions;
PAAD	cis	rs6495122	0.662	rs11632414	chr15:75061916	A/G	cg14664628	chr15:75095509	CSK	-0.72	-6.55	-0.47	8.5e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23158103	chr7:148848205	ZNF398	-0.58	-5.52	-0.41	1.44e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg20246863	chr2:73402720	NA	-0.4	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg20019720	chr6:154832845	CNKSR3	0.64	8.2	0.55	9.32e-14	Lipoprotein (a) levels;
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs2300603	0.922	rs2300605	chr14:76010981	T/C	cg01624173	chr14:75981868	NA	0.57	5.87	0.43	2.62e-8	Multiple sclerosis;
PAAD	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg27094323	chr7:1216898	NA	-0.36	-4.27	-0.33	3.45e-5	Longevity;Endometriosis;
PAAD	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg09579323	chr1:150459698	TARS2	0.45	4.28	0.33	3.25e-5	Migraine;
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg08088566	chr11:430123	ANO9	0.79	4.5	0.34	1.32e-5	Body mass index;
PAAD	cis	rs8040855	0.627	rs4843019	chr15:85644459	G/T	cg08123816	chr15:85640762	PDE8A	0.44	5.29	0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg05185573	chr6:26598237	ABT1	-0.48	-4.88	-0.37	2.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs6908034	0.547	rs35185749	chr6:19754511	C/T	cg02682789	chr6:19804855	NA	0.79	4.35	0.33	2.46e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg11143131	chr5:131608246	PDLIM4	-0.46	-4.69	-0.36	5.98e-6	Blood metabolite levels;
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.43	0.4	2.15e-7	Total body bone mineral density;
PAAD	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.41	-5.84	-0.43	3.13e-8	Information processing speed;
PAAD	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg16579770	chr16:72058938	DHODH	0.37	4.27	0.33	3.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.47	4.62	0.35	8.27e-6	Testicular germ cell tumor;
PAAD	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.56	-0.41	1.21e-7	Sjögren's syndrome;
PAAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.68	0.69	6.76e-23	Menopause (age at onset);
PAAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-4.28	-0.33	3.33e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg23205692	chr1:25664452	TMEM50A	0.49	4.69	0.36	6.08e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg26071806	chr7:100318239	EPO	-0.49	-4.86	-0.37	2.89e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg02344993	chr17:57696989	CLTC	-0.58	-5.42	-0.4	2.3e-7	Hemoglobin concentration;
PAAD	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.71	8.42	0.56	2.56e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.11	9.42	0.61	6.97e-17	Red blood cell traits;
PAAD	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.93	0.43	1.95e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs2899832	0.866	rs8004236	chr14:35737035	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	4.62	0.35	8.03e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs2279817	0.780	rs35588575	chr1:18007045	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg08992911	chr2:238395768	MLPH	0.69	6.95	0.49	1.03e-10	Prostate cancer;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.67	6.42	0.46	1.62e-9	Obesity-related traits;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg25124228	chr12:125621409	AACS	-0.7	-7.09	-0.5	4.85e-11	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10813644	chr19:2271093	OAZ1	0.69	6.71	0.48	3.59e-10	Obesity-related traits;
PAAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.07	15.02	0.77	7.47e-32	Multiple system atrophy;
PAAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.73	7.27	0.51	1.73e-11	Tonsillectomy;
PAAD	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.94	-5.99	-0.44	1.43e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3925075	0.500	rs10438639	chr16:31267698	A/G	cg02846316	chr16:31340340	ITGAM	0.47	5.54	0.41	1.3e-7	IgA nephropathy;
PAAD	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg12623918	chr2:306882	NA	0.47	4.84	0.37	3.11e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg02462569	chr6:150064036	NUP43	0.41	4.44	0.34	1.72e-5	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01877967	chr7:56148907	PHKG1	-0.56	-6.37	-0.46	2.15e-9	Monocyte percentage of white cells;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.53	5.78	0.42	4.01e-8	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-1.14	-9.42	-0.61	7.03e-17	Initial pursuit acceleration;
PAAD	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.83	9.64	0.62	1.82e-17	Blood metabolite ratios;
PAAD	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg20003494	chr4:90757398	SNCA	-0.4	-4.32	-0.33	2.82e-5	Dementia with Lewy bodies;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.64	-7.08	-0.5	5.04e-11	Facial morphology (factor 20);
PAAD	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.46	-4.37	-0.33	2.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.93	9.77	0.62	8.36e-18	Parkinson's disease;
PAAD	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-1.11	-7.69	-0.53	1.69e-12	Post bronchodilator FEV1;
PAAD	cis	rs7922314	0.571	rs61865717	chr10:64739190	G/A	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs2252790	0.899	rs2501052	chr6:116658955	A/G	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.72	8.72	0.58	4.54e-15	Monocyte percentage of white cells;
PAAD	cis	rs1126510	0.823	rs4803987	chr19:47131924	C/T	cg07844738	chr19:47129343	PTGIR	0.42	4.85	0.37	3.07e-6	Ulcerative colitis;
PAAD	cis	rs1561176	0.943	rs12667735	chr7:155003753	G/C	cg08570118	chr7:155025533	NA	-0.51	-4.69	-0.36	6.06e-6	Personality dimensions;
PAAD	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.53	13.24	0.73	4.14e-27	Atopic dermatitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12616745	chr2:191273000	MFSD6	0.65	6.97	0.49	9.04e-11	Myopia (pathological);
PAAD	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg27638815	chr19:15662578	CYP4F22	0.73	4.57	0.35	9.95e-6	Inflammatory biomarkers;
PAAD	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg19090574	chr1:205240910	TMCC2	-0.44	-4.81	-0.36	3.56e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg26597838	chr10:835615	NA	0.46	4.94	0.37	2.05e-6	Survival in rectal cancer;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.28	-0.6	1.61e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6066825	0.555	rs717709	chr20:47305959	G/A	cg18078177	chr20:47281410	PREX1	0.44	4.25	0.33	3.7e-5	Colorectal cancer;
PAAD	cis	rs6499244	0.552	rs7196917	chr16:69896527	A/G	cg15192750	chr16:69999425	NA	0.48	4.37	0.33	2.25e-5	Menarche (age at onset);
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.51	4.49	0.34	1.39e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12311304	1.000	rs6488766	chr12:15374630	A/G	cg08258403	chr12:15378311	NA	0.34	4.4	0.34	2.04e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs7247513	1.000	rs12459123	chr19:12689741	T/C	cg01871581	chr19:12707946	ZNF490	-0.85	-10.39	-0.64	1.87e-19	Bipolar disorder;
PAAD	cis	rs2275731	0.723	rs11254033	chr10:16543919	T/C	cg04254609	chr10:16479192	PTER	-0.42	-4.44	-0.34	1.75e-5	Bone fracture in osteoporosis;
PAAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.83	7.87	0.54	6.17e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.5	4.32	0.33	2.78e-5	Height;
PAAD	cis	rs3781663	1.000	rs10751194	chr11:70001637	T/A	cg06393558	chr11:69982916	ANO1	-0.45	-4.83	-0.37	3.23e-6	Survival in rectal cancer;
PAAD	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.93	7.3	0.51	1.48e-11	Monocyte percentage of white cells;
PAAD	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.61	0.35	8.61e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.36	16.94	0.81	7.81e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.85	0.58	2.09e-15	Lung cancer;
PAAD	cis	rs10044254	0.563	rs12153463	chr5:15693370	G/A	cg07238450	chr5:15720153	FBXL7	-0.53	-5.02	-0.38	1.45e-6	Asthma (corticosteroid response);
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.08	0.38	1.08e-6	Restless legs syndrome;
PAAD	cis	rs9487051	0.597	rs9400265	chr6:109594932	A/C	cg21918786	chr6:109611834	NA	-0.47	-4.95	-0.37	1.97e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs939584	1.000	rs7604609	chr2:643303	C/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.87	-0.49	1.58e-10	Atrioventricular conduction;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.63	6.84	0.49	1.79e-10	Renal function-related traits (BUN);
PAAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg05697835	chr1:2722811	NA	-0.43	-4.82	-0.36	3.45e-6	Ulcerative colitis;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	7.29	0.51	1.58e-11	Prudent dietary pattern;
PAAD	cis	rs8005172	0.653	rs1816776	chr14:88520236	T/C	cg18078958	chr14:88630771	NA	0.35	4.38	0.33	2.18e-5	Parkinson's disease;
PAAD	cis	rs4455778	0.580	rs4543492	chr7:49097005	C/T	cg26309511	chr7:48887640	NA	0.37	4.49	0.34	1.38e-5	Lung cancer in never smokers;
PAAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.81	8.85	0.58	2.1e-15	Obesity-related traits;
PAAD	cis	rs9900972	0.918	rs4789942	chr17:76877495	T/C	cg20937029	chr17:76870563	TIMP2	0.59	5.35	0.4	3.2e-7	Obesity-related traits;
PAAD	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.54	0.61	3.32e-17	Total body bone mineral density;
PAAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.49	4.98	0.37	1.7e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg00717180	chr2:96193071	NA	0.58	6.55	0.47	8.18e-10	HDL cholesterol;
PAAD	cis	rs116175783	0.557	rs3769963	chr2:162207510	A/G	cg08807892	chr2:162101083	NA	-0.66	-4.68	-0.36	6.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18621852	chr3:10150065	C3orf24	0.68	5.98	0.44	1.56e-8	Alzheimer's disease;
PAAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.86	9.52	0.61	3.74e-17	Mortality in heart failure;
PAAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg25319279	chr11:5960081	NA	-0.66	-6.21	-0.45	4.79e-9	DNA methylation (variation);
PAAD	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.6	5.91	0.43	2.2e-8	Myeloid white cell count;
PAAD	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.4	-4.25	-0.33	3.67e-5	Calcium levels;
PAAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg25204440	chr1:209979598	IRF6	0.58	4.64	0.35	7.34e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25809561	chr17:30822961	MYO1D	0.58	6.04	0.44	1.15e-8	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg18551225	chr6:44695536	NA	-0.7	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.49	-4.78	-0.36	4.09e-6	Lung cancer;
PAAD	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-1.03	-13.82	-0.75	1.22e-28	Rheumatoid arthritis;
PAAD	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.33	0.33	2.74e-5	Breast cancer;
PAAD	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.29e-16	Asthma;
PAAD	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.55	-0.35	1.11e-5	Lung cancer in ever smokers;
PAAD	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg05041596	chr11:89867385	NAALAD2	0.66	4.84	0.37	3.22e-6	Trans fatty acid levels;
PAAD	cis	rs1879734	0.731	rs6661728	chr1:54162471	G/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg02580895	chr19:2754563	NA	0.62	5.43	0.4	2.16e-7	Total cholesterol levels;
PAAD	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.48	4.3	0.33	3.08e-5	Height;
PAAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.64	-6.13	-0.45	7.36e-9	Resistin levels;
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11167764	0.895	rs891986	chr5:141466080	C/G	cg23435118	chr5:141488016	NDFIP1	-0.52	-5.05	-0.38	1.23e-6	Crohn's disease;
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg02462569	chr6:150064036	NUP43	-0.54	-5.92	-0.43	2.05e-8	Lung cancer;
PAAD	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.66	7.97	0.54	3.51e-13	Mean arterial pressure;
PAAD	cis	rs12776158	0.901	rs57028689	chr10:71216345	G/A	cg12610070	chr10:71211762	TSPAN15	-0.51	-5.0	-0.38	1.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg14926445	chr8:58193284	C8orf71	-0.65	-4.55	-0.35	1.11e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg17650747	chr5:1873721	NA	0.45	4.51	0.34	1.29e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4742903	0.791	rs6479226	chr9:106972872	T/G	cg14250997	chr9:106856677	SMC2	0.47	5.02	0.38	1.46e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-1.14	-11.94	-0.7	1.36e-23	Platelet distribution width;
PAAD	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.74	-0.36	4.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs655641	0.520	rs676733	chr11:85734010	C/T	cg07180834	chr11:85838833	NA	-0.45	-4.92	-0.37	2.21e-6	Platelet count;
PAAD	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-4.62	-0.35	8.22e-6	Mood instability;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs12449964	0.524	rs7225934	chr17:17572544	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-5.26	-0.39	4.92e-7	Coronary artery disease or ischemic stroke;
PAAD	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg21951975	chr1:209979733	IRF6	0.52	5.04	0.38	1.3e-6	Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.92	8.25	0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg24562669	chr7:97807699	LMTK2	-0.45	-6.64	-0.47	5.34e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs59888335	0.858	rs7642419	chr3:80924490	G/A	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs251130	0.540	rs251131	chr5:110859740	G/T	cg11925263	chr5:110849104	STARD4	0.38	4.31	0.33	2.98e-5	Menarche (age at onset);
PAAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.81	-7.68	-0.53	1.79e-12	DNA methylation (variation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26586710	chr10:134216688	PWWP2B	-0.64	-6.37	-0.46	2.12e-9	Obesity-related traits;
PAAD	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg21823605	chr1:152486609	CRCT1	0.49	5.75	0.42	4.75e-8	Hair morphology;
PAAD	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.03	-0.5	6.65e-11	Alcohol dependence;
PAAD	cis	rs13359291	0.841	rs6890251	chr5:122486419	C/T	cg16368670	chr5:122501738	PRDM6	-0.52	-4.29	-0.33	3.21e-5	Systolic blood pressure;
PAAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.48	4.55	0.35	1.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.27	0.39	4.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg03938978	chr2:103052716	IL18RAP	0.5	4.98	0.37	1.72e-6	Blood protein levels;
PAAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23281280	chr6:28129359	ZNF389	0.7	5.42	0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.68	-7.41	-0.52	8.25e-12	DNA methylation (variation);
PAAD	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1419980	0.730	rs11054611	chr12:7733774	T/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs111342015	0.772	rs77379690	chr6:43186775	A/T	cg17076780	chr6:43251928	TTBK1	0.66	4.29	0.33	3.21e-5	Breast cancer;
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.77	-9.41	-0.61	7.24e-17	Lymphocyte counts;
PAAD	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.49	5.72	0.42	5.57e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg21546286	chr11:48923668	NA	-0.52	-5.34	-0.4	3.3e-7	HDL cholesterol;
PAAD	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9910055	0.550	rs377963	chr17:42158310	T/G	cg16434002	chr17:42200994	HDAC5	0.61	4.9	0.37	2.44e-6	Total body bone mineral density;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-4.98	-0.37	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs10411262	0.935	rs314661	chr19:47172473	C/T	cg13467550	chr19:47212573	PRKD2	0.49	4.97	0.37	1.82e-6	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12995162	chr2:129079641	NA	0.64	6.97	0.49	8.89e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg23708337	chr7:1209742	NA	0.66	5.0	0.38	1.54e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.32	0.4	3.71e-7	Fat distribution (HIV);
PAAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.72	-6.23	-0.45	4.42e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	6.99	0.49	8.05e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg11335335	chr11:637885	DRD4	-0.37	-5.45	-0.4	2.01e-7	Systemic lupus erythematosus;
PAAD	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg07159951	chr1:45983175	PRDX1	0.42	4.64	0.35	7.38e-6	High light scatter reticulocyte count;
PAAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7092929	0.941	rs705477	chr10:3582161	A/G	cg14308648	chr10:3568949	NA	0.71	5.09	0.38	1.02e-6	Coronary artery calcification;
PAAD	cis	rs7534824	0.625	rs58234233	chr1:101510440	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.52	0.34	1.24e-5	Refractive astigmatism;
PAAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg24747557	chr10:131355152	MGMT	-0.43	-4.29	-0.33	3.12e-5	Response to temozolomide;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.02e-5	Platelet count;
PAAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs3764563	0.935	rs623700	chr19:15698544	C/T	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	1.1	12.04	0.7	7.29e-24	Hair shape;
PAAD	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.55	-0.41	1.24e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11871801	0.560	rs8074296	chr17:40583421	A/G	cg09776463	chr17:40836087	CNTNAP1	-0.55	-5.08	-0.38	1.07e-6	Crohn's disease;
PAAD	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg23352942	chr3:46931381	PTH1R	-0.45	-4.81	-0.36	3.65e-6	Birth weight;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.85e-7	Life satisfaction;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg26516362	chr5:178986906	RUFY1	0.55	6.1	0.44	8.37e-9	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03524461	chr10:21823437	MLLT10	0.69	6.82	0.48	2.07e-10	Obesity-related traits;
PAAD	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs72843506	0.656	rs73984559	chr17:19946516	C/A	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs2649	0.518	rs6494412	chr15:63856544	C/A	cg22599514	chr15:63798201	USP3	0.59	4.97	0.37	1.82e-6	Aortic root size;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.7	8.23	0.56	7.8e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs7236492	0.872	rs78538334	chr18:77223322	G/A	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg24375607	chr4:120327624	NA	0.53	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs337161	0.935	rs17008613	chr1:220943581	A/G	cg09023136	chr1:220959637	MOSC1	-0.61	-4.36	-0.33	2.4e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.97	-14.55	-0.76	1.33e-30	Height;
PAAD	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Colorectal cancer;
PAAD	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.87	-5.86	-0.43	2.8e-8	Schizophrenia;
PAAD	cis	rs8084125	1.000	rs72981154	chr18:74944135	C/T	cg15443732	chr18:74961078	GALR1	0.72	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.58	-5.56	-0.41	1.16e-7	Monocyte count;
PAAD	cis	rs2814331	0.830	rs2446016	chr10:88002711	T/C	cg08962038	chr10:88022859	GRID1	-0.58	-4.5	-0.34	1.34e-5	Balding;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-6.64	-0.47	5.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-5.78	-0.42	4.07e-8	Schizophrenia;
PAAD	cis	rs73416724	0.925	rs79641366	chr6:43279144	T/C	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7189233	1.000	rs16952251	chr16:53483138	A/G	cg00221382	chr16:54322308	NA	-0.28	-4.34	-0.33	2.58e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03820205	chr10:76970516	VDAC2	0.57	6.47	0.46	1.3e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5751901	0.614	rs874852	chr22:24987964	G/A	cg15363607	chr22:24998974	GGT1	-0.45	-4.58	-0.35	9.56e-6	Protein quantitative trait loci;
PAAD	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg22875332	chr1:76189707	ACADM	-0.52	-5.09	-0.38	1.03e-6	Daytime sleep phenotypes;
PAAD	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-1.14	-14.3	-0.76	6.11e-30	Height;
PAAD	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg08660999	chr19:1592898	MBD3	0.65	6.38	0.46	2.07e-9	Primary biliary cholangitis;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.31	0.56	4.82e-14	Homoarginine levels;
PAAD	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.29	-0.33	3.2e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.89	10.85	0.66	1.12e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg20356878	chr3:121714668	ILDR1	0.47	4.46	0.34	1.56e-5	Cognitive performance;
PAAD	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.72	0.36	5.4e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.61	5.84	0.43	3.06e-8	Sleep duration;
PAAD	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg13332499	chr17:408570	NA	0.67	7.44	0.52	7.1e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs7705042	0.828	rs7737631	chr5:141506615	T/G	cg08523384	chr5:141488047	NDFIP1	-0.56	-5.37	-0.4	2.83e-7	Asthma;
PAAD	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.63	6.88	0.49	1.45e-10	Resting heart rate;
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.61	-8.19	-0.55	1.01e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.56	-6.16	-0.45	6.12e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	1.09	9.7	0.62	1.27e-17	Orofacial clefts;
PAAD	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-4.71	-0.36	5.6e-6	Menopause (age at onset);
PAAD	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	cis	rs7631605	0.935	rs9831084	chr3:37025661	T/C	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9463078	0.845	rs9349303	chr6:44792579	C/T	cg25276700	chr6:44698697	NA	0.51	5.93	0.43	1.95e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06674436	chr5:1278864	TERT	-0.66	-6.71	-0.48	3.66e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg14851468	chr5:179071604	C5orf60	0.56	5.63	0.42	8.44e-8	Lung cancer;
PAAD	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	5.9	0.43	2.32e-8	Joint mobility (Beighton score);
PAAD	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs2555155	1.000	rs11040899	chr11:6520015	A/C	cg24637308	chr11:6592297	DNHD1	-0.49	-5.16	-0.39	7.5e-7	DNA methylation (variation);
PAAD	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs9314614	0.714	rs2980949	chr8:6713250	C/G	cg27319216	chr8:6693540	XKR5	-0.4	-5.36	-0.4	3.01e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg20573242	chr4:122745356	CCNA2	-0.58	-5.17	-0.39	7.4e-7	Type 2 diabetes;
PAAD	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.57	6.22	0.45	4.61e-9	Bladder cancer;
PAAD	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg23024343	chr7:107201750	COG5	0.54	4.48	0.34	1.45e-5	Coronary artery disease;
PAAD	cis	rs1529711	0.568	rs11880504	chr19:10957733	A/G	cg16667279	chr19:11591998	ELAVL3	-0.56	-4.57	-0.35	1.02e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg24253500	chr15:84953950	NA	0.56	6.54	0.47	9.05e-10	Schizophrenia;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.79	-6.72	-0.48	3.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	1.1	15.37	0.78	9.27e-33	Menarche (age at onset);
PAAD	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.81e-7	Interstitial lung disease;
PAAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.59	5.35	0.4	3.25e-7	Monocyte count;
PAAD	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg08992911	chr2:238395768	MLPH	0.69	6.84	0.49	1.78e-10	Prostate cancer;
PAAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg10556349	chr10:835070	NA	0.58	4.7	0.36	5.79e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.65	-0.35	7.06e-6	Joint mobility (Beighton score);
PAAD	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.6	-5.3	-0.4	3.94e-7	Coronary heart disease;
PAAD	cis	rs9815354	1.000	rs1717000	chr3:41930219	A/C	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.19	0.5	2.8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05665937	chr4:1216051	CTBP1	0.4	4.42	0.34	1.88e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.5	5.21	0.39	6.11e-7	Corneal astigmatism;
PAAD	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.65	7.02	0.49	6.83e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.84	0.37	3.1e-6	HDL cholesterol;
PAAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.75	-5.34	-0.4	3.32e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	6.1	0.44	8.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00300879	chr1:26503847	CNKSR1	0.3	4.69	0.36	5.93e-6	Height;
PAAD	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-15.5	-0.78	4.15e-33	Height;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg10437265	chr15:77819839	NA	0.43	4.8	0.36	3.77e-6	Type 2 diabetes;
PAAD	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg26816564	chr1:7831052	VAMP3	0.81	6.2	0.45	5.16e-9	Inflammatory bowel disease;
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg11335335	chr11:637885	DRD4	-0.31	-4.43	-0.34	1.76e-5	Systemic lupus erythematosus;
PAAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.43	4.51	0.34	1.28e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6710503	0.574	rs76979480	chr2:24795883	T/C	cg21151432	chr2:25142229	ADCY3	-0.36	-4.3	-0.33	3.07e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs1018836	0.544	rs2142145	chr8:91460670	A/G	cg16814680	chr8:91681699	NA	-0.72	-6.96	-0.49	9.48e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg11965913	chr1:205819406	PM20D1	0.54	4.99	0.37	1.66e-6	White blood cell types;
PAAD	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.91	9.72	0.62	1.18e-17	Corneal astigmatism;
PAAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg14343924	chr8:8086146	FLJ10661	-0.57	-4.98	-0.37	1.69e-6	Mood instability;
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-1.08	-5.84	-0.43	3.06e-8	Hair color;
PAAD	cis	rs35160687	0.901	rs35762338	chr2:86513553	G/A	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.56	-5.41	-0.4	2.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg07469887	chr10:131262384	NA	-0.47	-5.88	-0.43	2.49e-8	Response to temozolomide;
PAAD	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg05562828	chr17:3906858	NA	-0.41	-4.28	-0.33	3.31e-5	Type 2 diabetes;
PAAD	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.43	-5.08	-0.38	1.1e-6	Uric acid levels;
PAAD	cis	rs6466055	0.720	rs3801999	chr7:105027646	G/A	cg04380332	chr7:105027541	SRPK2	0.65	7.28	0.51	1.69e-11	Schizophrenia;
PAAD	cis	rs11671005	0.656	rs55928441	chr19:59009674	T/C	cg25952890	chr19:58913133	NA	0.65	4.71	0.36	5.43e-6	Mean platelet volume;
PAAD	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg07617317	chr6:118971624	C6orf204	0.58	4.81	0.36	3.65e-6	Renal cell carcinoma;
PAAD	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.84	9.37	0.61	9.41e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14421180	chr9:132804510	FNBP1	-0.65	-6.35	-0.46	2.31e-9	Lung cancer in ever smokers;
PAAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.56	5.93	0.43	1.98e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	6.57	0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg25070565	chr17:20044324	CYTSB	0.45	4.35	0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs12935418	0.616	rs1469123	chr16:81029549	A/G	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg00738919	chr7:1100172	C7orf50	0.52	4.35	0.33	2.52e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg12072164	chr19:44306565	LYPD5	0.4	4.34	0.33	2.56e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13524819	chr12:123921146	RILPL2	0.6	6.5	0.47	1.11e-9	Myopia (pathological);
PAAD	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-10.61	-0.65	5.12e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.89	8.41	0.56	2.71e-14	Breast cancer;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.84	-9.39	-0.61	8.16e-17	Prostate cancer;
PAAD	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	4.93e-20	Heart rate;
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.24	0.39	5.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12042938	0.571	rs1030711	chr1:231755461	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-4.7	-0.36	5.81e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg05373962	chr22:49881684	NA	-0.47	-4.56	-0.35	1.05e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6942407	0.592	rs739711	chr7:86746741	G/C	cg02420886	chr7:86849541	C7orf23	0.51	4.3	0.33	3.1e-5	Food allergy;
PAAD	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.93	11.11	0.67	2.32e-21	Alcohol dependence;
PAAD	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg22654517	chr2:96458247	NA	0.37	4.32	0.33	2.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.15	-8.31	-0.56	5e-14	Height;
PAAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg21433313	chr16:3507492	NAT15	0.93	7.62	0.53	2.58e-12	Tuberculosis;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14756332	chr5:64920198	TRIM23;C5orf44	-0.62	-6.35	-0.46	2.38e-9	Warfarin maintenance dose;
PAAD	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.45e-8	Triglycerides;
PAAD	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg13859433	chr6:33739653	LEMD2	-0.64	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs1642645	0.915	rs6696291	chr1:42500421	C/T	cg01990334	chr1:42801334	FOXJ3	0.63	5.75	0.42	4.77e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg09835421	chr16:68378352	PRMT7	-0.98	-5.97	-0.44	1.64e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21117768	chr2:85829779	TMEM150A	0.57	6.43	0.46	1.56e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.58	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg08916839	chr5:415575	AHRR	0.49	4.32	0.33	2.76e-5	Fat distribution (HIV);
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-6.69	-0.48	4.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.26e-8	Alcohol dependence;
PAAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.83	-8.54	-0.57	1.27e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	1.08	12.76	0.72	8.08e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.78	-6.01	-0.44	1.3e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.54	5.98	0.44	1.57e-8	Schizophrenia;
PAAD	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.2	10.6	0.65	5.23e-20	Uric acid levels;
PAAD	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg21300403	chr2:198650112	BOLL	0.49	4.36	0.33	2.38e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg12072164	chr19:44306565	LYPD5	-0.41	-4.55	-0.35	1.09e-5	Breast cancer;
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.13	-0.5	3.76e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	4.3	0.33	3.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	6.92	0.49	1.17e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7873102	0.654	rs7033326	chr9:37962799	T/C	cg03528946	chr9:38069800	SHB	0.55	5.48	0.41	1.7e-7	Brain structure;
PAAD	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg08315770	chr6:39281885	KCNK17	-0.55	-5.66	-0.42	7.43e-8	Type 2 diabetes;
PAAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.45	4.5	0.34	1.34e-5	Schizophrenia;
PAAD	cis	rs10849915	0.667	rs17192160	chr12:111353161	A/G	cg10833066	chr12:111807467	FAM109A	0.53	4.39	0.34	2.08e-5	Alcohol consumption (drinkers vs non-drinkers);Alcohol consumption;
PAAD	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.62	-6.98	-0.49	8.77e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2120243	0.539	rs1840668	chr3:157098721	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.53	0.35	1.16e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03698729	chr19:2328812	SPPL2B;LSM7	0.67	7.23	0.51	2.24e-11	Myopia (pathological);
PAAD	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.45	-4.82	-0.36	3.43e-6	Fibrinogen levels;
PAAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg12658694	chr1:38397304	INPP5B	-0.71	-7.36	-0.51	1.1e-11	Coronary artery disease;
PAAD	cis	rs151997	0.630	rs26064	chr5:50217806	T/C	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.49	-4.51	-0.34	1.28e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg00277334	chr10:82204260	NA	-0.49	-4.78	-0.36	4.11e-6	Post bronchodilator FEV1;
PAAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.6	0.47	6.42e-10	Rheumatoid arthritis;
PAAD	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg06780032	chr1:8272277	NA	-0.34	-4.37	-0.33	2.31e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.8	-7.37	-0.51	1.04e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg03351412	chr1:154909251	PMVK	0.72	7.11	0.5	4.18e-11	Prostate cancer;
PAAD	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9346353	0.737	rs3799112	chr6:70424299	C/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.95e-5	Sleep duration;
PAAD	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2006771	0.818	rs8142376	chr22:32001037	C/T	cg02404636	chr22:31891804	SFI1	-0.54	-5.15	-0.39	7.95e-7	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg21535247	chr6:8435926	SLC35B3	-0.45	-4.5	-0.34	1.34e-5	Motion sickness;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.51	5.57	0.41	1.13e-7	Life satisfaction;
PAAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.35e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.16	10.02	0.63	1.84e-18	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs58521262	0.585	rs461390	chr19:23130419	G/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg24879335	chr3:133465180	TF	0.41	4.37	0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.59	-6.62	-0.47	5.94e-10	Schizophrenia;
PAAD	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs863345	0.967	rs7511912	chr1:158531808	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.89	-0.37	2.57e-6	Pneumococcal bacteremia;
PAAD	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.11	-0.38	9.49e-7	Body mass index;
PAAD	cis	rs2403221	1.000	rs2403221	chr11:9852475	G/A	cg06875754	chr11:10328428	ADM	-0.37	-4.36	-0.33	2.43e-5	Smoking initiation;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05074645	chr13:101327922	TMTC4	-0.73	-7.53	-0.52	4.18e-12	Lung cancer in ever smokers;
PAAD	cis	rs501120	0.584	rs11238894	chr10:44671851	T/C	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.72	6.79	0.48	2.43e-10	Obesity-related traits;
PAAD	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg23024343	chr7:107201750	COG5	-0.66	-4.4	-0.34	2.02e-5	Osteoarthritis;
PAAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.89	-8.19	-0.55	9.74e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	1.91	10.98	0.66	5.25e-21	Cannabis dependence symptom count;
PAAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09835421	chr16:68378352	PRMT7	-1.1	-8.13	-0.55	1.41e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs11989843	0.636	rs868651	chr8:118074726	A/G	cg24636944	chr5:92615296	NA	0.49	6.4	0.46	1.82e-9	Obesity-related traits;
PAAD	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.6	-4.9	-0.37	2.46e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.23	16.6	0.8	5.83e-36	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.7	10.38	0.64	2.07e-19	Breast cancer;
PAAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg25452165	chr22:42524984	CYP2D6	0.58	5.21	0.39	6.1e-7	Schizophrenia;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.08e-7	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.29	0.45	3.26e-9	Mean platelet volume;
PAAD	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	8.19	0.55	9.88e-14	Lung cancer in ever smokers;
PAAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.32	0.46	2.78e-9	Height;
PAAD	cis	rs9303280	0.818	rs9747973	chr17:37905107	C/T	cg20243544	chr17:37824526	PNMT	-0.59	-5.62	-0.41	8.87e-8	Self-reported allergy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14460953	chr17:7835493	TRAPPC1;CNTROB	0.7	7.5	0.52	4.93e-12	Obesity-related traits;
PAAD	cis	rs1035491	1.000	rs1035491	chr5:63962177	A/G	cg01791865	chr5:63954708	NA	0.56	5.86	0.43	2.8e-8	Body mass index;
PAAD	cis	rs3026101	0.671	rs57085931	chr17:5305370	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.93	-9.2	-0.6	2.58e-16	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.48	-4.99	-0.37	1.67e-6	Iron status biomarkers;
PAAD	cis	rs713587	0.776	rs2118826	chr2:25191745	A/T	cg01884057	chr2:25150051	NA	-0.47	-5.37	-0.4	2.96e-7	Body mass index in non-asthmatics;
PAAD	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23158103	chr7:148848205	ZNF398	0.64	5.92	0.43	2.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.79	8.4	0.56	2.94e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12379764	chr21:47803548	PCNT	0.46	4.28	0.33	3.27e-5	Testicular germ cell tumor;
PAAD	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg26685658	chr5:74633012	HMGCR	-0.51	-4.41	-0.34	1.95e-5	Age-related disease endophenotypes;
PAAD	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg22532475	chr10:104410764	TRIM8	-0.41	-4.67	-0.35	6.45e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2790216	1.000	rs1416763	chr10:60029163	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg08992911	chr2:238395768	MLPH	-0.56	-4.94	-0.37	2.07e-6	Prostate cancer;
PAAD	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.73	0.48	3.33e-10	Lung cancer in ever smokers;
PAAD	cis	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg00495515	chr3:169490965	MYNN	0.66	4.43	0.34	1.77e-5	Lung function (FEV1/FVC);
PAAD	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.79	10.14	0.64	8.91e-19	Iron status biomarkers (transferrin levels);
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg10705379	chr10:99080932	FRAT1	-0.38	-4.51	-0.34	1.28e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07930192	chr7:1003750	NA	0.42	5.3	0.39	4.06e-7	Longevity;Endometriosis;
PAAD	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-9.99	-0.63	2.17e-18	Homoarginine levels;
PAAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.51	5.67	0.42	7.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.84	9.07	0.59	5.76e-16	Corneal astigmatism;
PAAD	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.61	6.41	0.46	1.74e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.44	6.19	0.45	5.24e-9	Vitiligo;
PAAD	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.77	7.49	0.52	5.35e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25889944	chr7:72299890	SBDSP;TYW1B	0.66	6.7	0.48	3.87e-10	Obesity-related traits;
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-1.02	-10.76	-0.66	2e-20	Platelet distribution width;
PAAD	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.44	6.34	0.46	2.44e-9	Educational attainment;
PAAD	cis	rs10885582	0.874	rs10885586	chr10:116357563	A/G	cg17056676	chr10:116301354	ABLIM1	-0.37	-5.0	-0.38	1.59e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.28	-0.39	4.48e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4740619	0.935	rs10810439	chr9:15754393	C/T	cg14451791	chr9:16040625	NA	0.4	4.72	0.36	5.34e-6	Body mass index;
PAAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.24e-22	Parkinson's disease;
PAAD	cis	rs2085601	0.566	rs1795721	chr4:89943473	C/G	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs375066	0.934	rs440784	chr19:44404342	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs6700896	0.931	rs4655743	chr1:66087301	G/C	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.53e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	5.94	0.43	1.91e-8	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22251048	chr13:111314707	CARS2	-0.65	-6.44	-0.46	1.46e-9	Obesity-related traits;
PAAD	cis	rs496300	0.691	rs2073428	chr21:44783600	T/G	cg18342814	chr21:45755740	C21orf2	-0.49	-4.66	-0.35	6.82e-6	Metabolic syndrome;
PAAD	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.24	8.04	0.55	2.33e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg00738919	chr7:1100172	C7orf50	0.72	5.53	0.41	1.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18621852	chr3:10150065	C3orf24	0.73	6.49	0.47	1.16e-9	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.59	0.57	9.44e-15	Lung cancer;
PAAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.29e-5	Renal cell carcinoma;
PAAD	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1359582	0.661	rs814633	chr10:90416756	A/T	cg15661332	chr10:90342814	RNLS	-0.55	-4.84	-0.37	3.19e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.41	5.12	0.38	9.25e-7	Pulmonary function;
PAAD	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.14	-0.55	1.29e-13	Brugada syndrome;
PAAD	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.7	6.91	0.49	1.24e-10	Lymphocyte counts;
PAAD	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.38	-0.51	9.57e-12	Mosquito bite size;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	6.99	0.49	8.16e-11	Lymphocyte counts;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14580859	chr9:123691850	NA	0.38	4.37	0.33	2.3e-5	Rheumatoid arthritis;
PAAD	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26836793	chr7:32982953	RP9P	-0.81	-7.83	-0.54	7.59e-13	Neuroticism;
PAAD	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.4	5.07	0.38	1.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg26816564	chr1:7831052	VAMP3	0.75	5.75	0.42	4.86e-8	Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.21	0.8	5.83e-35	Prudent dietary pattern;
PAAD	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg11204139	chr17:3907470	NA	-0.69	-7.06	-0.5	5.65e-11	Type 2 diabetes;
PAAD	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg16447950	chr5:562315	NA	-0.62	-5.47	-0.41	1.8e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.88	7.1	0.5	4.47e-11	Axial length;
PAAD	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.48	6.89	0.49	1.4e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5753618	0.539	rs5753596	chr22:31787472	C/T	cg02404636	chr22:31891804	SFI1	-0.6	-6.06	-0.44	1.04e-8	Colorectal cancer;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-7.68	-0.53	1.79e-12	Renal function-related traits (BUN);
PAAD	cis	rs4917300	0.626	rs1388796	chr8:143096437	A/G	cg26003909	chr8:143102224	NA	-0.35	-5.61	-0.41	9.11e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs1042026	0.848	rs3819197	chr4:100200509	C/T	cg21548116	chr4:100009993	ADH5	-0.48	-4.25	-0.33	3.78e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.79	-0.43	3.88e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg22256960	chr15:77711686	NA	-0.56	-4.76	-0.36	4.42e-6	Type 2 diabetes;
PAAD	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	4.74	0.36	4.92e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg06636001	chr8:8085503	FLJ10661	0.74	7.33	0.51	1.3e-11	Retinal vascular caliber;
PAAD	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg19792802	chr11:65647270	CTSW	0.52	6.76	0.48	2.79e-10	Crohn's disease;
PAAD	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.89	11.03	0.67	3.8e-21	Coronary artery disease;
PAAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.45	-4.41	-0.34	1.94e-5	Height;
PAAD	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.61	-5.77	-0.42	4.39e-8	Neuroticism;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13560548	chr3:10150139	C3orf24	0.61	5.56	0.41	1.19e-7	Alzheimer's disease;
PAAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg21951975	chr1:209979733	IRF6	0.43	5.37	0.4	2.87e-7	Monobrow;
PAAD	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-0.73	-4.73	-0.36	5.02e-6	Lung cancer;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg24879335	chr3:133465180	TF	0.52	5.56	0.41	1.17e-7	Iron status biomarkers;
PAAD	cis	rs10901513	0.932	rs35451781	chr10:127667881	A/C	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg01759136	chr6:27242945	NA	0.42	4.5	0.34	1.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.94	7.09	0.5	4.68e-11	Prostate cancer;
PAAD	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10510891	chr14:50159699	KLHDC1	-0.63	-6.4	-0.46	1.84e-9	Warfarin maintenance dose;
PAAD	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.98	13.18	0.73	6.08e-27	Heart rate;
PAAD	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.31	0.6	1.37e-16	Diabetic retinopathy;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs67257959	1.000	rs67257959	chr19:17158145	T/C	cg19418318	chr19:17219073	MYO9B	0.33	4.64	0.35	7.59e-6	Selective IgA deficiency;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.73	8.7	0.58	5.22e-15	Lung cancer;
PAAD	cis	rs35123781	0.502	rs440662	chr5:139003472	T/C	cg11459648	chr5:138714337	SLC23A1	-0.6	-5.42	-0.4	2.27e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	0.66	4.36	0.33	2.36e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg00944433	chr1:107599041	PRMT6	-0.43	-5.02	-0.38	1.45e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.33	0.64	2.71e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.6	-6.58	-0.47	7.21e-10	Tonsillectomy;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.27	-0.33	3.41e-5	Prostate cancer;
PAAD	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg11650704	chr1:154556575	ADAR	-0.39	-4.27	-0.33	3.37e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg00531865	chr16:30841666	NA	0.52	4.94	0.37	2.02e-6	Dementia with Lewy bodies;
PAAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.61	5.85	0.43	2.95e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg12215294	chr3:40350768	EIF1B	0.47	4.72	0.36	5.42e-6	Renal cell carcinoma;
PAAD	cis	rs7534824	0.625	rs12565777	chr1:101485794	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10274279	0.688	rs4716762	chr7:157403939	C/T	cg26886268	chr7:157387156	PTPRN2	-0.65	-4.78	-0.36	4.09e-6	Myopia (pathological);
PAAD	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg10547527	chr2:198650123	BOLL	0.49	4.25	0.33	3.71e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.81	6.82	0.48	2.06e-10	Alzheimer's disease;
PAAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg10547527	chr2:198650123	BOLL	-0.66	-4.49	-0.34	1.4e-5	Ulcerative colitis;
PAAD	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.45e-6	Plateletcrit;
PAAD	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.62	-4.8	-0.36	3.73e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg08264704	chr1:228270414	ARF1	0.5	4.57	0.35	1.02e-5	Myeloid white cell count;
PAAD	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg04721828	chr11:48285200	OR4X1	-0.48	-5.96	-0.44	1.69e-8	Migraine - clinic-based;
PAAD	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg05791153	chr7:19748676	TWISTNB	0.64	4.91	0.37	2.34e-6	Thyroid stimulating hormone;
PAAD	cis	rs900145	0.823	rs12361893	chr11:13301114	C/G	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	6.1	0.44	8.37e-9	Height;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg15693483	chr7:1102177	C7orf50	0.45	5.05	0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.12	-0.55	1.44e-13	Brugada syndrome;
PAAD	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg23024343	chr7:107201750	COG5	0.59	4.91	0.37	2.34e-6	Coronary artery disease;
PAAD	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.8	-9.49	-0.61	4.67e-17	White blood cell count (basophil);
PAAD	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.41	-6.04	-0.44	1.11e-8	Subjective well-being;
PAAD	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-1.01	-12.96	-0.72	2.38e-26	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.56	-5.59	-0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-4.65	-0.35	7.28e-6	Height;
PAAD	cis	rs1879734	0.863	rs3013770	chr1:54155959	C/T	cg14659662	chr1:54151053	GLIS1	0.42	6.76	0.48	2.72e-10	Mitral valve prolapse;
PAAD	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.04e-8	Electrocardiographic conduction measures;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs7923609	0.871	rs10761787	chr10:65353755	A/T	cg01631684	chr10:65280961	REEP3	-0.42	-4.29	-0.33	3.11e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg09127314	chr1:152161683	NA	-0.69	-4.81	-0.36	3.64e-6	Atopic dermatitis;
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.61	6.75	0.48	2.93e-10	Coronary artery disease;
PAAD	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.24	-4.45	-0.34	1.67e-5	Type 2 diabetes;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.66	-7.08	-0.5	5.11e-11	Iron status biomarkers;
PAAD	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.65	-0.42	7.85e-8	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16631682	chr2:114388878	RABL2A	-0.61	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs13631	0.791	rs7390710	chr9:139973629	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.41	-4.3	-0.33	3.07e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-1.05	-6.9	-0.49	1.35e-10	Plateletcrit;
PAAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.65	4.61	0.35	8.5e-6	Parkinson's disease;
PAAD	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.66	5.5	0.41	1.61e-7	HIV-1 control;
PAAD	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs9361491	0.508	rs10943567	chr6:79402451	A/G	cg05283184	chr6:79620031	NA	-0.4	-5.0	-0.38	1.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs11051970	0.636	rs325424	chr12:32570193	C/T	cg02745156	chr12:32552066	NA	0.42	4.36	0.33	2.35e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.53	5.04	0.38	1.33e-6	Pancreatic cancer;
PAAD	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.12	9.52	0.61	3.85e-17	Vitiligo;
PAAD	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg09579323	chr1:150459698	TARS2	-0.45	-4.25	-0.33	3.67e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.31	-0.4	3.85e-7	Other erythrocyte phenotypes;
PAAD	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24110177	chr3:50126178	RBM5	-0.58	-6.32	-0.46	2.76e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.69	7.06	0.5	5.52e-11	Glycated hemoglobin levels;
PAAD	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	0.84	5.91	0.43	2.19e-8	Gut microbiota (bacterial taxa);
PAAD	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.49	-5.65	-0.42	7.86e-8	Tonsillectomy;
PAAD	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	High light scatter reticulocyte count;
PAAD	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.85e-11	Interstitial lung disease;
PAAD	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.55	4.44	0.34	1.75e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs4356203	0.519	rs214092	chr11:17295046	G/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.38	-0.33	2.18e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg14851346	chr12:38532713	NA	0.45	4.49	0.34	1.4e-5	Bladder cancer;
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.64	-6.72	-0.48	3.44e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7577696	0.785	rs7592356	chr2:32370344	C/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.74	-0.36	4.9e-6	Inflammatory biomarkers;
PAAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.64	-0.57	7.38e-15	Bone mineral density;
PAAD	cis	rs12425451	0.518	rs10848767	chr12:3142630	A/C	cg05389053	chr12:3131226	TEAD4	0.73	6.12	0.44	7.78e-9	Narcolepsy with cataplexy;
PAAD	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.7	-6.9	-0.49	1.3e-10	Type 2 diabetes;
PAAD	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.56	5.11	0.38	9.36e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs863345	0.604	rs12123305	chr1:158498955	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.56	4.67	0.35	6.55e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2882667	0.690	rs274119	chr5:138064219	G/A	cg09476006	chr5:138032270	NA	0.49	6.4	0.46	1.86e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.26	0.45	3.77e-9	Mean platelet volume;
PAAD	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-6.4	-0.46	1.82e-9	Testicular germ cell tumor;
PAAD	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-5.79	-0.42	3.95e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs13382275	0.632	rs6548283	chr2:941534	A/C	cg02924234	chr2:420061	NA	0.51	4.54	0.35	1.12e-5	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs151997	1.000	rs72758246	chr5:50246783	G/C	cg06027927	chr5:50259733	NA	0.68	6.74	0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.43	-0.34	1.78e-5	Red blood cell count;
PAAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg17105886	chr17:28927953	LRRC37B2	0.67	4.47	0.34	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg11995313	chr8:8860691	ERI1	0.48	4.82	0.36	3.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.56	-6.65	-0.47	4.91e-10	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14164252	chr22:51066919	ARSA	0.62	6.51	0.47	1.03e-9	Obesity-related traits;
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21862992	chr11:68658383	NA	0.45	4.9	0.37	2.41e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.69	6.67	0.48	4.47e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.46	-5.58	-0.41	1.08e-7	Colorectal cancer;
PAAD	cis	rs6604026	0.630	rs4847378	chr1:93324634	G/T	cg17283838	chr1:93427260	FAM69A	-0.59	-5.58	-0.41	1.08e-7	Multiple sclerosis;
PAAD	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs300774	1.000	rs300782	chr2:110345	C/T	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg14458575	chr2:238380390	NA	0.59	5.07	0.38	1.16e-6	Prostate cancer;
PAAD	cis	rs11669133	1.000	rs78775018	chr19:11099609	C/T	cg25243385	chr19:11167475	SMARCA4	0.97	4.9	0.37	2.46e-6	LDL cholesterol;
PAAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg02773041	chr1:40204384	PPIE	0.75	7.47	0.52	5.94e-12	Blood protein levels;
PAAD	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg14061069	chr19:46274453	DMPK	-0.48	-5.72	-0.42	5.5e-8	Coronary artery disease;
PAAD	cis	rs6066835	1.000	rs4431002	chr20:47316585	C/T	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.54	6.95	0.49	9.84e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs9326726	0.566	rs289230	chr5:107406309	A/G	cg19779370	chr5:108084990	FER	0.58	4.63	0.35	7.63e-6	Resting heart rate;
PAAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.98	14.12	0.75	1.91e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.08	13.97	0.75	4.7e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.41	-4.79	-0.36	3.95e-6	Systemic lupus erythematosus;
PAAD	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.5	7.03	0.5	6.52e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22162314	chr17:61951766	CSH2	-0.61	-6.26	-0.45	3.79e-9	Height;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08439880	chr3:133502540	NA	-0.57	-6.31	-0.46	2.93e-9	Iron status biomarkers;
PAAD	cis	rs9472414	0.510	rs609643	chr6:44705303	A/G	cg18551225	chr6:44695536	NA	-0.5	-5.08	-0.38	1.08e-6	Height;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg16362232	chr11:430036	ANO9	-0.91	-5.56	-0.41	1.18e-7	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08734125	chr1:31769791	SNRNP40;ZCCHC17	-0.75	-8.78	-0.58	3.18e-15	Smoking initiation;
PAAD	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.35	0.6	1.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.06	-0.38	1.18e-6	Subjective well-being;
PAAD	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	7.6	0.52	2.86e-12	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14312894	chr12:57171980	HSD17B6	-0.67	-6.86	-0.49	1.64e-10	Obesity-related traits;
PAAD	cis	rs2271001	0.910	rs1503508	chr11:19141721	A/C	cg00161556	chr11:19138045	ZDHHC13	0.52	5.71	0.42	5.65e-8	Gut microbiome composition (winter);
PAAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.65	8.55	0.57	1.24e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs13382275	0.544	rs10188791	chr2:952234	T/C	cg02924234	chr2:420061	NA	0.54	4.56	0.35	1.03e-5	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg12463550	chr7:65579703	CRCP	-0.74	-5.34	-0.4	3.33e-7	Diabetic kidney disease;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.592	rs2987034	chr9:15995938	T/C	cg14451791	chr9:16040625	NA	0.38	4.59	0.35	9.35e-6	Body mass index;
PAAD	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.55	4.75	0.36	4.7e-6	Schizophrenia;
PAAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.07	-8.59	-0.57	9.76e-15	Diabetic kidney disease;
PAAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg10395934	chr14:104002654	TRMT61A	0.5	5.06	0.38	1.18e-6	Body mass index;
PAAD	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	6.18	0.45	5.63e-9	Adiposity;
PAAD	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.7	8.9	0.59	1.59e-15	Asthma;
PAAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg08632701	chr21:37451849	NA	-0.59	-6.09	-0.44	9.05e-9	Mitral valve prolapse;
PAAD	trans	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg01620082	chr3:125678407	NA	-1.12	-6.48	-0.47	1.22e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs9944715	0.954	rs4542747	chr18:43802169	C/T	cg00381974	chr18:44260357	ST8SIA5	-0.49	-4.69	-0.36	5.98e-6	Red cell distribution width;Mean corpuscular volume;
PAAD	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-7.13	-0.5	3.78e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.48	-6.78	-0.48	2.47e-10	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.77	7.94	0.54	4.06e-13	Body mass index;
PAAD	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg16512390	chr1:228756714	NA	0.62	4.63	0.35	7.66e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg15181151	chr6:150070149	PCMT1	0.55	5.84	0.43	3.02e-8	Lung cancer;
PAAD	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.34e-6	Prudent dietary pattern;
PAAD	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg19792802	chr11:65647270	CTSW	0.53	6.91	0.49	1.22e-10	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25353054	chr22:39101979	GTPBP1	0.59	6.44	0.46	1.5e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg09597638	chr17:3907349	NA	-0.72	-7.77	-0.53	1.08e-12	Type 2 diabetes;
PAAD	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.57	-5.77	-0.42	4.24e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg13859433	chr6:33739653	LEMD2	-0.66	-4.57	-0.35	1.02e-5	Schizophrenia;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.76	-8.18	-0.55	1.03e-13	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4899554	0.640	rs4899555	chr14:75719834	T/C	cg18117039	chr14:75741733	NA	0.4	4.65	0.35	7.23e-6	Inflammatory bowel disease;
PAAD	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg21366198	chr4:185655624	MLF1IP	0.54	4.83	0.36	3.31e-6	Kawasaki disease;
PAAD	cis	rs7561149	0.580	rs36051007	chr2:179545859	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.55	5.16	0.39	7.76e-7	QT interval;
PAAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	4.84	0.37	3.17e-6	Bipolar disorder;
PAAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18261144	chr6:167370276	RNASET2	0.64	7.2	0.5	2.53e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-5.18	-0.39	6.94e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg26939375	chr7:64535504	NA	0.52	5.73	0.42	5.2100000000000003e-08	Aortic root size;
PAAD	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.35	6.47	0.46	1.26e-9	Type 2 diabetes;
PAAD	cis	rs4704187	0.506	rs3935470	chr5:74352180	A/G	cg03227963	chr5:74354835	NA	0.47	4.71	0.36	5.46e-6	Response to amphetamines;
PAAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.84	-0.43	3.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.33	-0.51	1.26e-11	Heart rate;
PAAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13396716	chr1:5923309	NPHP4	-0.64	-6.5	-0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.54	5.95	0.43	1.79e-8	Diastolic blood pressure;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.2	-0.39	6.42e-7	Cognitive function;
PAAD	cis	rs2637266	0.627	rs1992396	chr10:78482228	T/C	cg18941641	chr10:78392320	NA	0.36	4.28	0.33	3.32e-5	Pulmonary function;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg08994789	chr17:28903642	LRRC37B2	0.65	4.97	0.37	1.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg03115019	chr17:80708279	FN3K	0.52	4.61	0.35	8.34e-6	Glycated hemoglobin levels;
PAAD	cis	rs7671266	0.532	rs4608811	chr4:10049675	A/C	cg00071950	chr4:10020882	SLC2A9	0.51	4.37	0.33	2.28e-5	Cardiovascular disease risk factors;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	5.9	0.43	2.28e-8	Obesity-related traits;
PAAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.36	-0.33	2.43e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.63	6.98	0.49	8.7e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07167872	chr1:205819463	PM20D1	0.45	4.26	0.33	3.62e-5	Parkinson's disease;
PAAD	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8105895	0.935	rs62111027	chr19:22269019	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.71	-6.39	-0.46	1.95e-9	Blood metabolite levels;
PAAD	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-5.57	-0.41	1.15e-7	Blood metabolite levels;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.68	6.95	0.49	9.84e-11	Menarche (age at onset);
PAAD	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg16230307	chr14:35515116	FAM177A1	0.41	4.34	0.33	2.62e-5	Psoriasis;
PAAD	cis	rs2814982	0.605	rs79379247	chr6:34489516	G/A	cg17674042	chr6:34482479	PACSIN1	-1.23	-7.45	-0.52	6.41e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs4731207	0.596	rs10247349	chr7:124607495	C/T	cg14311320	chr7:124405732	GPR37	-0.43	-4.53	-0.34	1.2e-5	Cutaneous malignant melanoma;
PAAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.28	17.61	0.82	1.54e-38	Eosinophil percentage of granulocytes;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.85	0.37	3.08e-6	Vitiligo;
PAAD	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg06697600	chr4:7070879	GRPEL1	0.88	5.39	0.4	2.69e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg07148914	chr20:33460835	GGT7	-0.46	-4.42	-0.34	1.9e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg27417659	chr7:98567827	TRRAP	-0.46	-4.44	-0.34	1.72e-5	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09133192	chr4:89205337	PPM1K	0.58	6.57	0.47	7.52e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8396	0.960	rs6839534	chr4:159637995	C/A	cg11637968	chr4:159732036	FNIP2	-0.27	-4.33	-0.33	2.7e-5	Acylcarnitine levels;Blood metabolite levels;Blood protein levels;Metabolic traits;Metabolite levels;
PAAD	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.62	5.96	0.44	1.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.96	-0.43	1.73e-8	Menarche (age at onset);
PAAD	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-5.19	-0.39	6.68e-7	Blood pressure (smoking interaction);
PAAD	cis	rs89107	0.967	rs4946333	chr6:118565665	A/G	cg18833306	chr6:118973337	C6orf204	-0.49	-5.6	-0.41	9.63e-8	Cardiac structure and function;
PAAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg03517284	chr6:25882590	NA	0.53	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.68	-7.49	-0.52	5.18e-12	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04899896	chr4:79860379	PAQR3	0.65	6.34	0.46	2.55e-9	Obesity-related traits;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.56	-6.08	-0.44	9.39e-9	Testicular germ cell tumor;
PAAD	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-8.16	-0.55	1.19e-13	Colorectal cancer;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10875746	0.551	rs10875799	chr12:48740879	C/A	cg26205652	chr12:48591994	NA	0.75	6.87	0.49	1.52e-10	Longevity (90 years and older);
PAAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.53	4.65	0.35	7.06e-6	Facial morphology (factor 20);
PAAD	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.84	0.58	2.18e-15	Menopause (age at onset);
PAAD	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.51	-0.34	1.29e-5	Mood instability;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09131844	chr2:27651398	NRBP1	0.72	7.28	0.51	1.68e-11	Obesity-related traits;
PAAD	cis	rs2929278	0.617	rs693919	chr15:44102328	C/T	cg26247942	chr15:43984922	CKMT1A	0.34	4.43	0.34	1.79e-5	Schizophrenia;
PAAD	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19859290	chr11:20618399	NA	0.32	4.5	0.34	1.33e-5	Pursuit maintenance gain;
PAAD	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg06569542	chr10:98946673	SLIT1	-0.54	-5.93	-0.43	1.95e-8	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15670394	chr6:74080260	OOEP	-0.6	-6.43	-0.46	1.6e-9	Obesity-related traits;
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	8.64	0.57	7.3e-15	Schizophrenia;
PAAD	cis	rs59888335	0.964	rs11712055	chr3:80688155	G/C	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs11696501	0.739	rs6073820	chr20:44249272	T/A	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs73206853	0.841	rs55864430	chr12:110932355	G/T	cg12870014	chr12:110450643	ANKRD13A	0.73	4.54	0.35	1.12e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg19337854	chr7:99768885	GPC2	0.48	4.43	0.34	1.77e-5	Platelet count;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-5.99	-0.44	1.49e-8	Body mass index;
PAAD	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg13263323	chr15:86062960	AKAP13	0.61	6.9	0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.81	-8.57	-0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.61	-6.17	-0.45	5.78e-9	Glioblastoma;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7833787	0.896	rs2029610	chr8:18706981	A/G	cg17701159	chr8:18705777	PSD3	-0.45	-5.23	-0.39	5.61e-7	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg15017067	chr4:17643749	FAM184B	-0.44	-4.86	-0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09473759	chr16:9057885	USP7	0.69	7.37	0.51	1.03e-11	Myopia (pathological);
PAAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg14440974	chr22:39074834	NA	-0.6	-7.14	-0.5	3.52e-11	Menopause (age at onset);
PAAD	trans	rs3129178	1	rs3129178	chr6:29075088	T/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Breast cancer;
PAAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.93	11.07	0.67	2.88e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02827336	chr4:1005033	FGFRL1	0.57	6.39	0.46	1.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.47	-0.34	1.51e-5	Mean platelet volume;
PAAD	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg23254163	chr1:152506842	NA	0.58	6.66	0.48	4.76e-10	Hair morphology;
PAAD	cis	rs375066	0.935	rs422457	chr19:44409411	A/T	cg11993925	chr19:44307056	LYPD5	0.55	6.95	0.49	9.87e-11	Breast cancer;
PAAD	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.73	0.58	4.25e-15	Corneal astigmatism;
PAAD	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.64	5.93	0.43	1.99e-8	Obesity-related traits;
PAAD	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.84	-6.8	-0.48	2.29e-10	Lymphocyte counts;
PAAD	cis	rs1227969	1.000	rs1652804	chr10:71264325	G/A	cg12610070	chr10:71211762	TSPAN15	-0.3	-4.29	-0.33	3.22e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs11250714	0.845	rs17221916	chr10:1692147	C/T	cg10435618	chr10:838112	NA	-0.49	-4.63	-0.35	7.88e-6	Gut microbiome composition (summer);
PAAD	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.6	5.46	0.4	1.91e-7	Breast cancer;
PAAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.52	5.9	0.43	2.3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.71	7.65	0.53	2.09e-12	Platelet distribution width;
PAAD	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.59	5.47	0.41	1.82e-7	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.75e-6	Height;
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.99	-0.38	1.63e-6	Obesity-related traits;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18116813	chr6:91225725	MAP3K7	0.38	4.29	0.33	3.18e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs438465	1.000	rs368028	chr6:169811294	A/G	cg11181693	chr6:169825345	NA	0.55	4.3	0.33	2.99e-5	Corneal astigmatism;
PAAD	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-6.2	-0.45	5.18e-9	Chronic sinus infection;
PAAD	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs1190596	0.689	rs2224460	chr14:102563797	A/T	cg14893857	chr14:102554969	HSP90AA1	-0.41	-4.29	-0.33	3.11e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.79	-9.11	-0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.57	0.35	1.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9397240	0.789	rs9384308	chr6:155615948	C/T	cg06694381	chr6:155569200	TIAM2	-0.47	-4.35	-0.33	2.53e-5	Life satisfaction;
PAAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg21890820	chr11:65308645	LTBP3	0.7	8.76	0.58	3.52e-15	Bone mineral density;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.81	-9.64	-0.62	1.83e-17	Monocyte percentage of white cells;
PAAD	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-5.38	-0.4	2.75e-7	Educational attainment;
PAAD	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.59	6.08	0.44	9.2e-9	Platelet count;
PAAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.55	-4.8	-0.36	3.78e-6	Pursuit maintenance gain;
PAAD	cis	rs61542988	0.797	rs4329182	chr7:22882621	C/T	cg11367502	chr7:22862612	TOMM7	0.52	4.48	0.34	1.47e-5	Fibrinogen levels;
PAAD	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-4.65	-0.35	7.13e-6	Educational attainment (years of education);
PAAD	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg25418670	chr11:30344373	C11orf46	0.59	5.75	0.42	4.64e-8	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10323490	chr2:88469007	THNSL2	-0.61	-6.29	-0.45	3.13e-9	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18311416	chr1:151732277	MRPL9	-0.69	-6.95	-0.49	1.02e-10	Obesity-related traits;
PAAD	cis	rs863345	0.933	rs12041380	chr1:158482138	A/G	cg12129480	chr1:158549410	OR10X1	-0.45	-5.26	-0.39	4.78e-7	Pneumococcal bacteremia;
PAAD	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.42	4.61	0.35	8.42e-6	HDL cholesterol levels;
PAAD	cis	rs2562456	0.833	rs62110416	chr19:21584726	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs12681288	0.782	rs6559213	chr8:1030923	A/G	cg08648136	chr8:956695	NA	0.43	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs6840360	0.593	rs4696103	chr4:152564611	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.83	-0.43	3.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-4.62	-0.35	8.27e-6	Post bronchodilator FEV1;
PAAD	cis	rs375066	0.935	rs430667	chr19:44413253	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.73	7.2	0.5	2.58e-11	Body mass index;
PAAD	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.91	11.68	0.69	6.63e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.19	0.55	9.82e-14	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.55	-4.53	-0.35	1.17e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26031613	chr14:104095156	KLC1	1.16	15.6	0.78	2.35e-33	Body mass index;
PAAD	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.56	-6.19	-0.45	5.25e-9	Metabolite levels;
PAAD	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg03528137	chr13:111589969	NA	0.64	6.31	0.46	2.85e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2457480	0.850	rs61855743	chr10:44681729	A/G	cg09554077	chr10:44749378	NA	0.43	5.04	0.38	1.32e-6	Coronary artery disease;
PAAD	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2031532	0.587	rs721457	chr13:50035151	G/C	cg03651054	chr13:50194643	NA	0.33	4.41	0.34	1.98e-5	Cardiac hypertrophy;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg07212818	chr11:638076	DRD4	-0.7	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg03938978	chr2:103052716	IL18RAP	0.6	5.48	0.41	1.76e-7	Blood protein levels;
PAAD	cis	rs2562456	0.833	rs55920089	chr19:21520693	A/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.52	5.51	0.41	1.53e-7	Menopause (age at onset);
PAAD	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.74	0.36	4.93e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.65	4.5	0.34	1.33e-5	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.73	0.53	1.33e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.7	8.22	0.55	8.31e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg27121462	chr16:89883253	FANCA	0.48	4.97	0.37	1.8e-6	Vitiligo;
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.69	-0.36	5.98e-6	Body mass index;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg09324608	chr17:30823087	MYO1D	0.47	4.77	0.36	4.26e-6	Schizophrenia;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.73	-13.09	-0.73	1.07e-26	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.57	5.12	0.38	9.22e-7	Lymphocyte counts;
PAAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.69	-6.03	-0.44	1.18e-8	Neuroticism;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg07212818	chr11:638076	DRD4	-0.7	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.51	4.56	0.35	1.06e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs990171	1.000	rs6750020	chr2:102994714	G/A	cg03938978	chr2:103052716	IL18RAP	0.44	4.37	0.33	2.31e-5	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.86	0.43	2.83e-8	Platelet count;
PAAD	cis	rs78761021	0.829	rs17810376	chr17:9787845	A/G	cg26853458	chr17:9805074	RCVRN	0.69	8.0	0.54	2.91e-13	Type 2 diabetes;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg17372223	chr3:52568218	NT5DC2	0.56	5.43	0.4	2.18e-7	Bipolar disorder;
PAAD	cis	rs62158211	0.565	rs57611236	chr2:114103804	A/T	cg17784749	chr2:114082611	LOC440839	0.55	5.37	0.4	2.88e-7	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03228407	chr17:5392363	MIS12	0.69	6.35	0.46	2.34e-9	Neuroticism;
PAAD	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg09978860	chr4:56023921	NA	-0.38	-4.31	-0.33	2.9e-5	Endometriosis;
PAAD	cis	rs7638995	0.878	rs9844987	chr3:69170012	T/C	cg26574240	chr3:69171822	LMOD3	-0.69	-4.79	-0.36	3.87e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.51	-5.26	-0.39	4.74e-7	Menarche (age at onset);
PAAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.94	11.23	0.67	1.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4343996	0.840	rs1917689	chr7:3317586	G/A	cg21248987	chr7:3385318	SDK1	0.5	5.56	0.41	1.17e-7	Motion sickness;
PAAD	cis	rs10958605	0.761	rs2925036	chr8:40044109	G/A	cg14545590	chr8:40388592	ZMAT4	0.41	4.58	0.35	9.47e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-4.7	-0.36	5.78e-6	Blood protein levels;
PAAD	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.68	-7.31	-0.51	1.43e-11	IgG glycosylation;
PAAD	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	4.4	0.34	2.02e-5	Depressive symptoms;
PAAD	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.63	6.6	0.47	6.61e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs597480	0.929	rs290191	chr11:85427641	T/C	cg11817631	chr11:85522609	SYTL2	-0.46	-4.3	-0.33	3.06e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.01	-0.44	1.33e-8	Longevity;Endometriosis;
PAAD	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.33e-6	Tuberculosis;
PAAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.6	-5.77	-0.42	4.24e-8	Glaucoma (primary open-angle);
PAAD	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06156847	chr2:113672199	IL1F7	0.56	5.91	0.43	2.2e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2885056	0.891	rs892082	chr19:10680478	A/G	cg06392426	chr19:10676186	KRI1	0.6	5.94	0.43	1.85e-8	Red cell distribution width;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	7.69	0.53	1.7e-12	Prudent dietary pattern;
PAAD	cis	rs6540	1.000	rs548551	chr11:255048	A/T	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg08926642	chr1:7887455	PER3	0.5	4.38	0.33	2.24e-5	Inflammatory bowel disease;
PAAD	cis	rs1270639	0.818	rs1079358	chr7:157462544	A/C	cg13357408	chr7:157437802	PTPRN2	1.07	8.78	0.58	3.11e-15	Colorectal cancer;
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs332507	0.601	rs7618562	chr3:124363001	A/G	cg05980111	chr3:124395277	KALRN	0.4	4.26	0.33	3.57e-5	Plateletcrit;
PAAD	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	1.69	10.47	0.65	1.19e-19	Height;
PAAD	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.38	5.59	0.41	1.01e-7	Educational attainment (years of education);
PAAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.87	8.15	0.55	1.23e-13	Menarche (age at onset);
PAAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.45	4.86	0.37	2.89e-6	Cystic fibrosis severity;
PAAD	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg02580895	chr19:2754563	NA	-0.62	-5.48	-0.41	1.72e-7	Total cholesterol levels;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24893123	chr2:200669039	NA	-0.51	-6.47	-0.46	1.3e-9	Monocyte percentage of white cells;
PAAD	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.54	4.33	0.33	2.7e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.71	5.85	0.43	2.92e-8	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.86	-0.43	2.78e-8	Retinal vascular caliber;
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-4.97	-0.37	1.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg07725925	chr16:89976287	TCF25	0.69	4.56	0.35	1.03e-5	Skin colour saturation;
PAAD	cis	rs258892	0.895	rs3846643	chr5:72023038	T/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.88	10.24	0.64	4.75e-19	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs4750440	0.702	rs4748066	chr10:14029313	A/T	cg27542038	chr10:14027202	FRMD4A	0.42	4.32	0.33	2.84e-5	Adiponectin levels;
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.62	-5.89	-0.43	2.44e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-7.03	-0.5	6.43e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.18	0.6	3.02e-16	Hemoglobin concentration;
PAAD	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.55	5.31	0.4	3.75e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg19257562	chr1:2043853	PRKCZ	0.39	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.89	-0.43	2.43e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10848704	0.525	rs4073984	chr12:2885780	G/A	cg19995117	chr12:2880862	NA	0.51	5.31	0.4	3.9e-7	Quantitative traits;
PAAD	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg22711741	chr19:57742444	AURKC	-0.43	-4.62	-0.35	8.03e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg23024343	chr7:107201750	COG5	0.56	4.31	0.33	2.94e-5	Coronary artery disease;
PAAD	cis	rs12893597	0.580	rs2278687	chr14:76838336	G/C	cg20290672	chr14:76816747	NA	-0.5	-4.43	-0.34	1.8e-5	Maximal oxygen uptake response;
PAAD	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg20487152	chr13:99095054	FARP1	-0.62	-5.58	-0.41	1.08e-7	Neuroticism;
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg19337854	chr7:99768885	GPC2	0.5	4.7	0.36	5.68e-6	Lung function (FEV1/FVC);
PAAD	trans	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	6.5	0.47	1.08e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10929159	0.928	rs12053257	chr2:236920174	C/T	cg14226755	chr2:236923322	AGAP1	0.29	4.58	0.35	9.79e-6	Parkinson's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00236831	chr12:14518751	ATF7IP	0.61	6.6	0.47	6.33e-10	Monocyte percentage of white cells;
PAAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg04154034	chr17:28927549	LRRC37B2	0.71	4.76	0.36	4.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	6.07	0.44	9.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.54	5.14	0.38	8.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg10362426	chr1:54518856	TMEM59;C1orf83	0.44	4.34	0.33	2.64e-5	Hand grip strength;
PAAD	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.77	5.28	0.39	4.42e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.66	6.05	0.44	1.1e-8	Androgen levels;
PAAD	cis	rs863345	0.604	rs6663277	chr1:158495001	A/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs5753037	0.809	rs2074707	chr22:30210356	G/A	cg01021169	chr22:30184971	ASCC2	-0.45	-4.51	-0.34	1.32e-5	Type 1 diabetes;
PAAD	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.63	-6.86	-0.49	1.66e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.69	5.27	0.39	4.53e-7	Body mass index;
PAAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-1.04	-17.48	-0.82	3.42e-38	Height;
PAAD	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.42	-4.25	-0.33	3.73e-5	Resting heart rate;
PAAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.6	-0.35	8.77e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs71557345	1	rs71557345	chr6:26680698	G/A	cg01620082	chr3:125678407	NA	-1.34	-6.81	-0.48	2.15e-10	Breast cancer;
PAAD	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.6	-6.52	-0.47	9.66e-10	High light scatter reticulocyte count;
PAAD	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.89	6.67	0.48	4.39e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4343996	0.935	rs10276190	chr7:3348663	C/T	cg21248987	chr7:3385318	SDK1	0.47	5.2	0.39	6.32e-7	Motion sickness;
PAAD	cis	rs308971	0.635	rs310761	chr3:12221429	A/G	cg03310376	chr3:12229001	SYN2	-0.5	-4.33	-0.33	2.66e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-1.34	-10.72	-0.66	2.52e-20	Obesity-related traits;
PAAD	cis	rs11811982	0.655	rs114683993	chr1:227383157	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-4.49	-0.34	1.39e-5	Vitiligo;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10681256	chr3:47324572	KIF9;KLHL18	0.59	6.64	0.47	5.3e-10	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02071572	chr4:1403502	NA	-0.44	-5.92	-0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.39	0.4	2.63e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.62	-5.24	-0.39	5.35e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.59	6.48	0.47	1.22e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs1190596	0.526	rs8003556	chr14:102659667	T/C	cg23289024	chr14:102554846	HSP90AA1	0.36	4.36	0.33	2.36e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24147428	chr11:65409760	SIPA1	-0.5	-5.26	-0.39	4.71e-7	Blood pressure (age interaction);
PAAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.47	-4.52	-0.34	1.25e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg20913747	chr6:44695427	NA	-0.63	-5.9	-0.43	2.32e-8	Total body bone mineral density;
PAAD	cis	rs11563648	0.535	rs1946108	chr7:127050778	T/C	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-11.87	-0.69	2.02e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs797680	0.894	rs7418101	chr1:93756192	G/A	cg04535902	chr1:92947332	GFI1	-0.46	-4.48	-0.34	1.48e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7631605	0.809	rs3774327	chr3:37099367	G/A	cg17445812	chr3:36986805	TRANK1	0.33	4.37	0.33	2.31e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1507153	0.851	rs9352610	chr6:79389398	A/G	cg05283184	chr6:79620031	NA	-0.37	-4.43	-0.34	1.77e-5	Sjögren's syndrome;
PAAD	cis	rs9810890	1.000	rs73196979	chr3:128450276	T/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs10214930	0.697	rs12535844	chr7:27689824	G/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg15798862	chr7:76129360	DTX2	-0.52	-6.96	-0.49	9.54e-11	Multiple sclerosis;
PAAD	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg26022315	chr17:47021804	SNF8	0.42	4.38	0.33	2.22e-5	Type 2 diabetes;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.82	9.18	0.6	3e-16	Menarche (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23272098	chr11:77185129	PAK1	0.66	6.68	0.48	4.2e-10	Myopia (pathological);
PAAD	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg21546286	chr11:48923668	NA	-0.42	-4.54	-0.35	1.12e-5	Height;
PAAD	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs322458	0.550	rs488416	chr3:120630345	G/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-6.59	-0.47	6.75e-10	Blood pressure (smoking interaction);
PAAD	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.59	-5.08	-0.38	1.08e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.57	5.41	0.4	2.39e-7	Electroencephalogram traits;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.91	-0.37	2.35e-6	Lung cancer;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	7.11	0.5	4.23e-11	Renal function-related traits (BUN);
PAAD	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg00031303	chr3:195681400	NA	0.63	6.16	0.45	6.2e-9	Pancreatic cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15203333	chr10:43280976	BMS1	-0.75	-7.97	-0.54	3.44e-13	Obesity-related traits;
PAAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02725872	chr8:58115012	NA	-0.66	-5.4	-0.4	2.47e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	6.71	0.48	3.55e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.92	-0.37	2.25e-6	Obesity-related traits;
PAAD	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.91	-0.37	2.34e-6	Recombination measurement;
PAAD	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.48	0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20254251	chr8:144557206	ZC3H3	-0.58	-6.46	-0.46	1.36e-9	Monocyte percentage of white cells;
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.57	-5.93	-0.43	1.97e-8	Immature fraction of reticulocytes;
PAAD	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg26097391	chr2:54893211	SPTBN1	0.45	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.44	4.68	0.35	6.37e-6	Age of smoking initiation;
PAAD	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	8.84	0.58	2.18e-15	IgG glycosylation;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26549601	chr10:134560360	INPP5A	-0.49	-4.81	-0.36	3.57e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10887741	0.532	rs791881	chr10:89408246	C/T	cg13926569	chr10:89418898	PAPSS2	-0.54	-5.55	-0.41	1.27e-7	Exercise (leisure time);
PAAD	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	trans	rs61931739	0.658	rs708142	chr12:33719872	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-0.7	-5.49	-0.41	1.66e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg08992911	chr2:238395768	MLPH	0.67	6.58	0.47	7.11e-10	Prostate cancer;
PAAD	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.54	5.14	0.38	8.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg21951975	chr1:209979733	IRF6	0.41	5.15	0.39	8e-7	Monobrow;
PAAD	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.4	0.34	1.99e-5	Breast cancer;
PAAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg03060546	chr3:49711283	APEH	-0.63	-4.8	-0.36	3.74e-6	Cognitive function;
PAAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.45	-4.37	-0.33	2.32e-5	Renal cell carcinoma;
PAAD	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.76	8.08	0.55	1.91e-13	Colorectal cancer;
PAAD	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.6	7.08	0.5	5.12e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg13171406	chr11:92712998	MTNR1B	-0.57	-4.89	-0.37	2.51e-6	Pulmonary function decline;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg06752163	chr3:170588210	RPL22L1	-0.65	-6.9	-0.49	1.34e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00142150	chr22:38071001	LGALS1	0.81	9.09	0.59	5.15e-16	Fat distribution (HIV);
PAAD	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg03938978	chr2:103052716	IL18RAP	0.67	8.43	0.56	2.49e-14	Asthma;
PAAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs12913538	0.962	rs4775517	chr15:62885173	A/G	cg09983546	chr15:62884068	NA	0.73	8.3	0.56	5.3e-14	Sleep depth;
PAAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.48	-0.52	5.67e-12	Morning vs. evening chronotype;
PAAD	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	10.22	0.64	5.39e-19	Post bronchodilator FEV1;
PAAD	cis	rs6256	1.000	rs80103568	chr11:13603741	C/T	cg11976911	chr11:13509032	NA	-0.65	-5.06	-0.38	1.22e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs6107516	0.645	rs6107515	chr20:4671381	T/G	cg02413285	chr20:4668134	PRNP	-0.63	-5.91	-0.43	2.12e-8	Creutzfeldt-Jakob disease (variant);Creutzfeldt-Jakob disease (sporadic);
PAAD	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.82	9.58	0.61	2.59e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12193833	chr17:30244370	NA	-0.58	-4.78	-0.36	4.17e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3112530	0.901	rs2926288	chr5:152643969	G/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg25022915	chr17:49243257	NME2;NME1-NME2	0.38	4.65	0.35	7.29e-6	Height;
PAAD	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.69	-0.36	6.12e-6	Height;
PAAD	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.63	-6.33	-0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19346786	chr7:2764209	NA	-0.37	-5.13	-0.38	8.6e-7	Height;
PAAD	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.67	-7.24	-0.51	2.13e-11	Schizophrenia;
PAAD	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.72	6.66	0.48	4.59e-10	Obesity-related traits;
PAAD	cis	rs71520386	0.583	rs28799344	chr7:22845266	T/C	cg04907244	chr7:22894795	SNORD93	0.45	4.8	0.36	3.83e-6	Fibrinogen levels;
PAAD	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-11.06	-0.67	3.07e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg06671706	chr8:8559999	CLDN23	0.56	5.29	0.39	4.17e-7	Obesity-related traits;
PAAD	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	1.16	13.18	0.73	5.98e-27	Hair shape;
PAAD	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-4.7	-0.36	5.85e-6	Self-reported allergy;
PAAD	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.69	-0.42	6.32e-8	Mean corpuscular volume;
PAAD	cis	rs2645694	0.569	rs11097584	chr4:77836059	C/T	cg06046430	chr4:77819534	ANKRD56	0.67	5.24	0.39	5.22e-7	Emphysema distribution in smoking;
PAAD	cis	rs6960043	0.620	rs11760782	chr7:15064788	A/T	cg19272540	chr7:15055459	NA	0.3	5.31	0.4	3.85e-7	Type 2 diabetes;
PAAD	cis	rs863345	0.604	rs1894038	chr1:158455947	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs17539620	0.529	rs11753075	chr6:154875085	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.03	0.44	1.19e-8	Lipoprotein (a) levels;
PAAD	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.93	8.01	0.54	2.84e-13	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.72	-8.45	-0.57	2.18e-14	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-7.59	-0.52	3.07e-12	Menarche (age at onset);
PAAD	cis	rs13223928	0.542	rs12540595	chr7:3131792	G/A	cg19214707	chr7:3157722	NA	-0.64	-6.07	-0.44	9.54e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.49	4.9	0.37	2.45e-6	Mean corpuscular volume;
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg10137597	chr8:22132714	PIWIL2	0.5	6.01	0.44	1.35e-8	Hypertriglyceridemia;
PAAD	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.67e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1997066	0.831	rs57634638	chr10:106826307	G/T	cg17321814	chr10:106440892	SORCS3	0.64	4.25	0.33	3.74e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg14345882	chr6:26364793	BTN3A2	0.38	4.31	0.33	2.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg16818395	chr3:128274084	NA	0.54	4.77	0.36	4.25e-6	Dental caries;
PAAD	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg09491104	chr22:46646882	C22orf40	-0.96	-5.99	-0.44	1.43e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.73	-7.45	-0.52	6.62e-12	Cognitive function;
PAAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg14440974	chr22:39074834	NA	-0.57	-6.58	-0.47	7.02e-10	Menopause (age at onset);
PAAD	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.75	-6.9	-0.49	1.3e-10	Primary sclerosing cholangitis;
PAAD	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.83	9.51	0.61	4.12e-17	Metabolic syndrome;
PAAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg26338869	chr17:61819248	STRADA	-0.48	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-1.01	-8.28	-0.56	6e-14	Blood protein levels;
PAAD	cis	rs17135859	1.000	rs10059373	chr5:113002991	G/A	cg12552261	chr5:112820674	MCC	0.67	4.46	0.34	1.61e-5	F-cell distribution;
PAAD	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.24	0.51	2.07e-11	Morning vs. evening chronotype;
PAAD	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg02016764	chr4:38805732	TLR1	-0.54	-4.26	-0.33	3.64e-5	Breast cancer;
PAAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01267941	chr12:57623452	SHMT2	0.56	6.58	0.47	7.36e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg06028605	chr16:24865363	SLC5A11	-0.36	-4.75	-0.36	4.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.720	rs6466064	chr7:105024217	T/C	cg04380332	chr7:105027541	SRPK2	-0.66	-7.43	-0.52	7.13e-12	Schizophrenia;
PAAD	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.8	-5.63	-0.42	8.45e-8	Blood protein levels;
PAAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs2242420	0.920	rs6658321	chr1:21968660	C/T	cg26362272	chr1:22108717	USP48	0.62	4.81	0.36	3.55e-6	Hematological and biochemical traits;
PAAD	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.53	5.06	0.38	1.22e-6	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.38	-0.51	9.57e-12	Coronary artery disease;
PAAD	cis	rs7922314	0.571	rs11814927	chr10:64722248	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs1800469	0.598	rs8103493	chr19:41874339	T/G	cg09537434	chr19:41945824	ATP5SL	-0.62	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.04e-5	Pubertal anthropometrics;
PAAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.19	-0.39	6.77e-7	Diastolic blood pressure;
PAAD	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.58	6.12	0.44	7.54e-9	Mean corpuscular volume;
PAAD	cis	rs6908034	0.607	rs74559916	chr6:19818717	G/T	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.67	5.52	0.41	1.4e-7	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg00864171	chr11:67383662	NA	-0.49	-5.12	-0.38	9.15e-7	Mean corpuscular volume;
PAAD	cis	rs1880828	0.500	rs1458987	chr3:55103700	C/T	cg08225137	chr3:54915807	CACNA2D3	-0.52	-4.27	-0.33	3.36e-5	Lung cancer in ever smokers;
PAAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg09324608	chr17:30823087	MYO1D	0.55	5.73	0.42	5.17e-8	Schizophrenia;
PAAD	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Blood protein levels;
PAAD	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.33e-5	Life satisfaction;
PAAD	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg12963246	chr6:28129442	ZNF389	0.56	4.53	0.34	1.18e-5	Cardiac Troponin-T levels;
PAAD	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.67	5.37	0.4	2.85e-7	Obesity (extreme);
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13939156	chr17:80058883	NA	-0.39	-4.25	-0.33	3.76e-5	Life satisfaction;
PAAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg06740227	chr12:86229804	RASSF9	0.59	5.37	0.4	2.95e-7	Major depressive disorder;
PAAD	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-0.95	-9.34	-0.6	1.14e-16	Exhaled nitric oxide output;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	1.05	13.07	0.73	1.23e-26	Breast cancer;
PAAD	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.7	6.12	0.44	7.7e-9	Pubertal anthropometrics;
PAAD	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.64	-0.47	5.3e-10	Systolic blood pressure;
PAAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	6.98	0.49	8.7e-11	Height;
PAAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.75	7.56	0.52	3.48e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.57	7.64	0.53	2.23e-12	Renal cell carcinoma;
PAAD	cis	rs9633740	0.685	rs10749608	chr10:82243986	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	6.1	0.44	8.49e-9	Post bronchodilator FEV1;
PAAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.78	7.92	0.54	4.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.25	8.56	0.57	1.17e-14	Opioid sensitivity;
PAAD	cis	rs10792830	0.706	rs3016786	chr11:85774562	T/G	cg07180834	chr11:85838833	NA	-0.47	-5.22	-0.39	5.79e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs2077212	0.837	rs10103097	chr8:5984498	T/C	cg17754742	chr8:6400956	ANGPT2;MCPH1	-0.35	-4.26	-0.33	3.63e-5	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs3931020	0.745	rs1980851	chr1:75268971	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.55	5.34	0.4	3.35e-7	Resistin levels;
PAAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.83e-13	Motion sickness;
PAAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.46	4.46	0.34	1.6e-5	Pulse pressure;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.29	0.33	3.11e-5	Mean corpuscular volume;
PAAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.57	6.14	0.45	6.98e-9	Menopause (age at onset);
PAAD	cis	rs5753037	0.640	rs131260	chr22:30132964	A/C	cg01021169	chr22:30184971	ASCC2	-0.46	-4.79	-0.36	3.84e-6	Type 1 diabetes;
PAAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.52	0.41	1.42e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10426930	0.816	rs2602728	chr19:5046318	C/T	cg08036796	chr19:5034282	KDM4B	0.47	4.66	0.35	6.79e-6	Monocyte percentage of white cells;
PAAD	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.21	18.79	0.84	1.76e-41	Exhaled nitric oxide output;
PAAD	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg10616300	chr11:66138557	SLC29A2	-0.33	-4.31	-0.33	2.96e-5	Educational attainment (years of education);
PAAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.1	-0.38	9.85e-7	Life satisfaction;
PAAD	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg27489772	chr12:121021490	NA	-0.57	-5.07	-0.38	1.16e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18906283	chr4:39771913	UBE2K	-0.58	-6.61	-0.47	6.01e-10	Myopia (pathological);
PAAD	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg08888203	chr3:10149979	C3orf24	1.0	7.64	0.53	2.22e-12	Alzheimer's disease;
PAAD	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.66	6.67	0.48	4.54e-10	Depressive symptoms;
PAAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.73	-0.48	3.27e-10	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17347400	chr20:633844	SRXN1	0.62	7.43	0.52	7.12e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.34e-13	Alzheimer's disease;
PAAD	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg04289385	chr6:36355825	ETV7	0.43	4.52	0.34	1.25e-5	Platelet distribution width;
PAAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.87	8.55	0.57	1.23e-14	Methadone dose in opioid dependence;
PAAD	cis	rs8112211	0.637	rs4804046	chr19:38839732	G/T	cg14299480	chr19:38876666	GGN	-0.64	-6.09	-0.44	8.95e-9	Blood protein levels;
PAAD	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg23461800	chr14:103021989	NA	-0.58	-4.57	-0.35	1.02e-5	Platelet count;
PAAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Height;
PAAD	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg05484376	chr2:27715224	FNDC4	0.45	4.44	0.34	1.7e-5	Oral cavity cancer;
PAAD	cis	rs9902453	0.730	rs3794808	chr17:28531793	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.52	0.41	1.42e-7	Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs2147959	0.941	rs7524236	chr1:228630395	C/T	cg18477163	chr1:228402036	OBSCN	0.43	4.72	0.36	5.29e-6	Adult asthma;
PAAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg01503450	chr10:980765	NA	-0.54	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-4.52	-0.34	1.26e-5	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.73	-0.48	3.24e-10	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.11e-9	Life satisfaction;
PAAD	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg10072921	chr12:121022843	NA	-0.34	-4.42	-0.34	1.9e-5	High light scatter reticulocyte count;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg24213567	chr19:53496664	ZNF702P	-0.45	-4.58	-0.35	9.7e-6	Psoriasis;
PAAD	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-5.02	-0.38	1.44e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg16434002	chr17:42200994	HDAC5	0.61	5.56	0.41	1.21e-7	Total body bone mineral density;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg16680214	chr1:154839983	KCNN3	-0.4	-4.48	-0.34	1.44e-5	Schizophrenia;
PAAD	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.96	7.77	0.53	1.1e-12	Axial length;
PAAD	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.5	-7.01	-0.49	7.23e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs58521262	0.560	rs60687221	chr19:22990509	T/C	cg07749055	chr19:23076870	NA	-0.57	-4.41	-0.34	1.91e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg04117972	chr1:227635322	NA	0.76	4.84	0.37	3.2e-6	Major depressive disorder;
PAAD	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs7640424	0.649	rs35710439	chr3:107913059	C/A	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-7.83	-0.54	7.7e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	4.36	0.33	2.43e-5	Blood metabolite levels;
PAAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.82	-9.95	-0.63	2.87e-18	Menopause (age at onset);
PAAD	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg01970496	chr2:177005398	NA	-0.51	-4.26	-0.33	3.53e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg06740227	chr12:86229804	RASSF9	0.59	5.2	0.39	6.35e-7	Major depressive disorder;
PAAD	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg16589663	chr20:23618590	CST3	0.79	6.88	0.49	1.5e-10	Chronic kidney disease;
PAAD	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg25456477	chr12:86230367	RASSF9	0.49	4.33	0.33	2.65e-5	Major depressive disorder;
PAAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.52	5.85	0.43	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.56	-5.21	-0.39	5.95e-7	Obesity-related traits;
PAAD	cis	rs1035491	0.715	rs7726365	chr5:63922274	T/C	cg01791865	chr5:63954708	NA	0.52	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg05341575	chr12:125625032	AACS	-0.47	-4.47	-0.34	1.5e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2579500	0.807	rs7584930	chr2:97298290	C/T	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.41	-5.1	-0.38	9.83e-7	Electrocardiographic conduction measures;
PAAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.74	-0.36	4.79e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg05861140	chr6:150128134	PCMT1	-0.57	-6.49	-0.47	1.12e-9	Lung cancer;
PAAD	cis	rs2969070	1.000	rs1548594	chr7:2513281	G/C	cg03277898	chr7:2518824	NA	-0.34	-4.29	-0.33	3.14e-5	Diastolic blood pressure;
PAAD	cis	rs10899021	0.790	rs10899022	chr11:74339386	C/T	cg25880958	chr11:74394337	NA	-0.76	-4.79	-0.36	3.9e-6	Response to metformin (IC50);
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11245990	chr11:68621969	NA	0.38	4.79	0.36	3.88e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13253111	0.624	rs13277389	chr8:28100234	G/T	cg26534493	chr8:28060551	NA	0.41	4.48	0.34	1.46e-5	Childhood body mass index;
PAAD	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06156847	chr2:113672199	IL1F7	0.57	6.08	0.44	9.36e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4478858	0.746	rs7544003	chr1:31689088	C/T	cg00250761	chr1:31883323	NA	0.4	4.46	0.34	1.61e-5	Alcohol dependence;
PAAD	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg18898632	chr2:242989856	NA	-0.73	-5.71	-0.42	5.65e-8	Obesity-related traits;
PAAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21028142	chr17:79581711	NPLOC4	-0.49	-5.7	-0.42	6.07e-8	Eye color traits;
PAAD	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.12	-10.55	-0.65	7.3e-20	Lymphocyte percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18796523	chr13:52586133	ALG11;ATP7B	-0.73	-6.5	-0.47	1.1e-9	Neuroticism;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.43	-4.63	-0.35	7.71e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.38	4.59	0.35	9.31e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg25233709	chr10:116636983	FAM160B1	0.4	4.92	0.37	2.23e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.56	-7.56	-0.52	3.55e-12	Renal cell carcinoma;
PAAD	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs7094131	0.556	rs4748818	chr10:22877953	T/G	cg19500236	chr10:22911537	PIP4K2A	0.44	4.81	0.36	3.6e-6	Obesity-related traits;
PAAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.53	5.22	0.39	5.9e-7	Trans fatty acid levels;
PAAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.71	7.89	0.54	5.55e-13	Cisplatin-induced ototoxicity;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.81	0.58	2.63e-15	Lung cancer;
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.52	4.9	0.37	2.44e-6	Prostate-specific antigen levels;
PAAD	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7631605	0.875	rs11714125	chr3:37024256	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22392857	chr1:151129088	TNFAIP8L2	0.62	7.09	0.5	4.74e-11	Smoking initiation;
PAAD	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.57	6.19	0.45	5.43e-9	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.84	-8.51	-0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7727544	0.545	rs3916443	chr5:131369079	T/C	cg14196790	chr5:131705035	SLC22A5	0.42	4.47	0.34	1.51e-5	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25564144	chr22:36135459	RBM9	0.59	6.32	0.46	2.8e-9	Smoking initiation;
PAAD	cis	rs2274459	0.659	rs35095444	chr6:33651975	C/G	cg06253072	chr6:33679850	C6orf125	0.63	4.49	0.34	1.41e-5	Obesity (extreme);
PAAD	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-4.32	-0.33	2.84e-5	Morning vs. evening chronotype;
PAAD	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg15123519	chr2:136567270	LCT	0.37	4.56	0.35	1.04e-5	Mosquito bite size;
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg07648498	chr16:89883185	FANCA	0.46	4.37	0.33	2.27e-5	Vitiligo;
PAAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6921919	0.789	rs6912584	chr6:28309590	T/C	cg23153227	chr6:27725408	NA	0.55	4.69	0.36	5.94e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35955747	0.902	rs5997932	chr22:31668154	C/G	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.02	-6.37	-0.46	2.09e-9	Lung cancer in ever smokers;
PAAD	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.59	-4.32	-0.33	2.8e-5	Vitiligo;
PAAD	cis	rs7551222	0.646	rs6594015	chr1:204461622	C/T	cg01064725	chr1:204461714	NA	-0.5	-4.4	-0.34	2.03e-5	Schizophrenia;
PAAD	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.02	0.5	6.72e-11	Lung cancer in ever smokers;
PAAD	cis	rs12625057	0.541	rs12624906	chr20:57784525	G/T	cg17286326	chr20:57796491	ZNF831	0.72	4.43	0.34	1.8e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.81	-6.47	-0.46	1.29e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg16810054	chr20:33298113	TP53INP2	0.57	4.66	0.35	6.79e-6	Neuroticism;
PAAD	cis	rs2797685	0.735	rs56204811	chr1:7895069	A/G	cg04725166	chr1:7887271	PER3	-0.63	-5.3	-0.39	3.99e-7	Crohn's disease;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.55e-7	Prudent dietary pattern;
PAAD	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg05805236	chr11:65401703	PCNXL3	0.41	4.3	0.33	3.1e-5	Acne (severe);
PAAD	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.86	0.43	2.71e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg15117754	chr3:10150083	C3orf24	0.76	6.81	0.48	2.09e-10	Alzheimer's disease;
PAAD	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.37	1.85e-6	Morning vs. evening chronotype;
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.53	0.41	1.34e-7	Platelet count;
PAAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs354225	0.584	rs9677089	chr2:54794927	A/C	cg01766943	chr2:54829624	SPTBN1	0.5	4.68	0.36	6.25e-6	Schizophrenia;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg18357526	chr6:26021779	HIST1H4A	0.63	6.01	0.44	1.32e-8	Blood metabolite levels;
PAAD	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg21252483	chr19:49399788	TULP2	-0.61	-6.23	-0.45	4.32e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.5	-5.09	-0.38	1.04e-6	Schizophrenia;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.03	-0.38	1.39e-6	Mood instability;
PAAD	cis	rs3734905	1.000	rs3817869	chr6:170024736	T/C	cg11181693	chr6:169825345	NA	-0.83	-5.2	-0.39	6.28e-7	HIV-1 control;
PAAD	cis	rs6681460	0.634	rs4142763	chr1:66998036	A/G	cg02459107	chr1:67143332	SGIP1	0.61	5.44	0.4	2.07e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.53	-6.0	-0.44	1.39e-8	Prostate cancer;
PAAD	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.68	-0.42	6.77e-8	Crohn's disease;
PAAD	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.41	-0.4	2.4e-7	Systolic blood pressure;
PAAD	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs11250464	0.517	rs2387667	chr10:1430761	T/C	cg08668359	chr10:1443807	ADARB2	0.49	4.33	0.33	2.67e-5	Radiation response;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg00738919	chr7:1100172	C7orf50	0.59	4.35	0.33	2.46e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2004318	1.000	rs77568158	chr19:55078544	A/G	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs9857275	0.788	rs6789653	chr3:141150990	G/A	cg00789793	chr3:141329863	RASA2	0.51	4.43	0.34	1.8e-5	Prion diseases;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg22907277	chr7:1156413	C7orf50	0.63	4.56	0.35	1.06e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg03910582	chr17:19030146	GRAPL	-0.5	-4.66	-0.35	6.86e-6	Schizophrenia;
PAAD	cis	rs4455778	0.580	rs7808387	chr7:49125122	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg22875332	chr1:76189707	ACADM	0.77	4.56	0.35	1.03e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	0.87	5.07	0.38	1.12e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.22	7.14	0.5	3.63e-11	Cognitive function;
PAAD	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-6.25	-0.45	3.96e-9	Coronary artery disease;
PAAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	4.92	0.37	2.23e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9826463	0.702	rs56397702	chr3:142304764	C/T	cg20824294	chr3:142316082	PLS1	0.44	4.99	0.38	1.6e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg07636037	chr3:49044803	WDR6	0.6	4.53	0.34	1.2e-5	Menarche (age at onset);
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.7	-7.95	-0.54	3.92e-13	Renal function-related traits (BUN);
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg25487775	chr2:162093969	NA	0.52	5.13	0.38	8.75e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	ch.11.42038R	chr11:967971	AP2A2	0.62	5.94	0.43	1.87e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9905704	0.633	rs2632506	chr17:56467408	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.82	-7.66	-0.53	2.02e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.585	rs462900	chr19:23123663	G/T	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.52	5.29	0.39	4.21e-7	Myeloid white cell count;
PAAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg14349672	chr11:133703707	NA	-0.55	-6.37	-0.46	2.18e-9	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19405718	chr4:7764996	AFAP1;LOC84740	0.52	6.51	0.47	1.05e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7896691	0.777	rs7917172	chr10:3147926	C/T	cg15228268	chr10:3146741	PFKP	0.88	4.6	0.35	8.66e-6	Disc degeneration (lumbar);
PAAD	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg05895507	chr15:77155635	SCAPER	-0.38	-4.28	-0.33	3.31e-5	Blood metabolite levels;
PAAD	cis	rs17138114	1.000	rs7747061	chr6:4381445	C/T	cg05411199	chr6:3749715	C6orf145	0.42	4.32	0.33	2.84e-5	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.63	5.98	0.44	1.54e-8	Neuroticism;
PAAD	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg03417191	chr3:183542750	MAP6D1	-0.58	-5.06	-0.38	1.21e-6	Menopause (age at onset);
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.94	-16.21	-0.8	5.95e-35	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19347576	chr18:9136711	ANKRD12	0.61	6.65	0.47	4.88e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	4.76	0.36	4.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg20744362	chr22:50050164	C22orf34	0.68	8.3	0.56	5.32e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg02781088	chr2:113192302	RGPD8;RGPD5	0.91	6.56	0.47	7.98e-10	Yeast infection;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.79	6.0	0.44	1.38e-8	Mean platelet volume;
PAAD	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.61	5.43	0.4	2.19e-7	White matter hyperintensity burden;
PAAD	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.63	-0.72	1.9e-25	Longevity;Endometriosis;
PAAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg18765565	chr5:669397	TPPP	0.44	4.78	0.36	4.18e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.57	-0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg11380483	chr2:127933992	NA	0.49	4.73	0.36	5.12e-6	Self-rated health;
PAAD	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.0	0.49	7.73e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21186775	chr2:173941045	ZAK	-0.64	-6.39	-0.46	1.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9616064	0.962	rs875778	chr22:46984306	T/C	cg05621596	chr22:47072043	GRAMD4	0.54	5.04	0.38	1.28e-6	Urate levels in obese individuals;
PAAD	cis	rs1075265	0.548	rs2542575	chr2:54048358	G/A	cg04546899	chr2:54196757	PSME4	0.3	4.4	0.34	1.99e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79387448	0.745	rs72993754	chr2:103151136	A/G	cg09003973	chr2:102972529	NA	0.66	4.27	0.33	3.39e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs9857275	0.527	rs13088429	chr3:141181790	G/A	cg25967872	chr3:141205623	RASA2	0.51	4.38	0.33	2.19e-5	Prion diseases;
PAAD	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.63	-6.65	-0.47	5.02e-10	Calcium levels;
PAAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg18225595	chr11:63971243	STIP1	-0.5	-4.98	-0.37	1.74e-6	Platelet count;
PAAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.76	7.52	0.52	4.39e-12	Mood instability;
PAAD	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.73	-5.27	-0.39	4.59e-7	Iron status biomarkers;
PAAD	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg03938978	chr2:103052716	IL18RAP	0.6	5.55	0.41	1.24e-7	Blood protein levels;
PAAD	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg22256960	chr15:77711686	NA	-0.52	-4.25	-0.33	3.76e-5	Type 2 diabetes;
PAAD	cis	rs7631605	0.623	rs7619689	chr3:36981363	A/C	cg10333520	chr3:36987040	TRANK1	0.33	4.43	0.34	1.82e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg03959625	chr15:84868606	LOC388152	0.5	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg08885076	chr2:99613938	TSGA10	-0.54	-5.2	-0.39	6.3e-7	Chronic sinus infection;
PAAD	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg14825688	chr5:132208181	LEAP2	-0.59	-4.37	-0.33	2.26e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg21175976	chr8:11421337	BLK	-0.39	-4.26	-0.33	3.6e-5	Triglycerides;
PAAD	cis	rs56104184	0.779	rs73061627	chr19:49360418	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.19	-8.45	-0.57	2.22e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17948627	chr1:36107295	PSMB2	0.59	6.72	0.48	3.37e-10	Metabolite levels  (X-11787);
PAAD	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg01420254	chr6:26195488	NA	-0.9	-5.07	-0.38	1.14e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs10090774	0.965	rs11777839	chr8:141917894	G/T	cg02508881	chr8:142216119	NA	-0.4	-4.26	-0.33	3.6e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs950037	0.710	rs6698181	chr1:89143305	C/T	cg25104671	chr1:89149378	PKN2	-0.48	-4.5	-0.34	1.35e-5	Coronary artery disease;
PAAD	cis	rs11811982	0.793	rs77311509	chr1:227459097	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.97	-10.11	-0.63	1.05e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13256369	0.671	rs57506062	chr8:8554535	G/A	cg18904891	chr8:8559673	CLDN23	0.64	5.66	0.42	7.35e-8	Obesity-related traits;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.5	-5.08	-0.38	1.07e-6	Testicular germ cell tumor;
PAAD	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	4.85	0.37	3.03e-6	Birth weight;
PAAD	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.65	6.33	0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.72	6.37	0.46	2.18e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.74	-0.36	4.78e-6	High light scatter reticulocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19529604	chr2:153246184	FMNL2	0.55	6.57	0.47	7.73e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg23947450	chr7:900037	UNC84A	-0.54	-4.5	-0.34	1.34e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs13092825	1.000	rs7613948	chr3:113279698	T/G	cg18753928	chr3:113234510	CCDC52	-0.46	-4.42	-0.34	1.88e-5	Dental caries;
PAAD	cis	rs4740619	0.935	rs7032877	chr9:15640047	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.01	-0.38	1.51e-6	Body mass index;
PAAD	cis	rs8108269	0.518	rs12972158	chr19:46158473	C/T	cg04683509	chr19:45885800	PPP1R13L	0.53	4.29	0.33	3.22e-5	Type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.5	4.99	0.37	1.66e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.65e-17	Lymphocyte counts;
PAAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	7.33	0.51	1.29e-11	Tonsillectomy;
PAAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg16205897	chr5:131564050	P4HA2	-0.46	-4.81	-0.36	3.55e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.73	-6.98	-0.49	8.4e-11	Blood protein levels;
PAAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.89	7.03	0.5	6.68e-11	Tuberculosis;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.72	-0.42	5.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.4e-8	Subjective well-being;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01585852	chr22:24235823	MIF	-0.46	-4.93	-0.37	2.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.52	-6.3	-0.45	3.13e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2415984	0.600	rs61990993	chr14:46850479	C/G	cg14871534	chr14:47121158	RPL10L	-0.46	-5.08	-0.38	1.09e-6	Number of children ever born;
PAAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20180092	chr3:39425780	SLC25A38	0.66	6.68	0.48	4.2e-10	Obesity-related traits;
PAAD	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.31	8.63	0.57	7.55e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs3206736	0.548	rs328939	chr7:35050227	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs7631605	0.905	rs6787539	chr3:37164647	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.69	-7.1	-0.5	4.51e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs990171	0.538	rs11687071	chr2:103111920	G/A	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.27	-0.39	4.58e-7	Lymphocyte counts;
PAAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.33	-0.33	2.71e-5	Retinal vascular caliber;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17243582	chr15:59969081	BNIP2	-0.65	-6.46	-0.46	1.37e-9	Primary biliary cholangitis;
PAAD	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.62	6.1	0.44	8.28e-9	Colorectal cancer;
PAAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.28e-11	Menopause (age at onset);
PAAD	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.5	-0.61	4.26e-17	Blood trace element (Zn levels);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25395653	chr11:69455731	CCND1	0.65	7.17	0.5	3.01e-11	Myopia (pathological);
PAAD	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.79	8.22	0.55	8.34e-14	Body mass index;
PAAD	cis	rs6748734	0.519	rs9973362	chr2:241898198	T/C	cg26818257	chr2:241905806	NA	0.48	4.5	0.34	1.35e-5	Urinary metabolites;
PAAD	cis	rs818427	0.858	rs469827	chr5:112242139	C/A	cg07820702	chr5:112228657	REEP5	-0.54	-4.83	-0.36	3.31e-6	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg14709524	chr16:89940631	TCF25	0.73	4.25	0.33	3.73e-5	Skin colour saturation;
PAAD	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.42	-0.34	1.87e-5	Life satisfaction;
PAAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12044355	0.892	rs12048349	chr1:231850323	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.09	0.38	1.05e-6	Alzheimer's disease;
PAAD	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-10.34	-0.64	2.6e-19	Response to antipsychotic treatment;
PAAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg10587741	chr22:38071170	LGALS1	0.61	6.84	0.49	1.82e-10	Fat distribution (HIV);
PAAD	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.48	7.01	0.49	7.28e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg06492744	chr11:65406254	SIPA1	0.45	5.37	0.4	2.85e-7	Blood pressure (age interaction);
PAAD	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.62	-0.41	8.92e-8	Mean corpuscular volume;
PAAD	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-6.76	-0.48	2.74e-10	Body mass index (adult);
PAAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.78e-7	Body mass index;
PAAD	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.31e-7	Noise-induced hearing loss;
PAAD	cis	rs258892	0.895	rs16901131	chr5:72054836	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.09	-0.38	1.03e-6	Lung cancer;
PAAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg10589385	chr1:150898437	SETDB1	-0.44	-5.36	-0.4	2.99e-7	Tonsillectomy;
PAAD	cis	rs11614333	0.959	rs10492150	chr12:15043897	G/A	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	cis	rs11264213	0.591	rs274745	chr1:36538282	G/A	cg27506609	chr1:36549197	TEKT2	-1.15	-6.89	-0.49	1.38e-10	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18166636	chr5:178956931	NA	-0.66	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs12136530	0.636	rs4244001	chr1:19734368	C/T	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg00206168	chr11:65308501	LTBP3	0.51	5.32	0.4	3.73e-7	Bone mineral density;
PAAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	6.81	0.48	2.17e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12136530	0.593	rs881247	chr1:19733320	A/G	cg01468656	chr1:19991678	HTR6	0.49	4.43	0.34	1.77e-5	Lead levels in blood;
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg14008862	chr17:28927542	LRRC37B2	0.73	5.13	0.38	8.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg07371521	chr5:154026371	NA	0.54	6.84	0.49	1.82e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18858717	chr14:90863402	CALM1	-0.6	-6.39	-0.46	1.95e-9	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16046261	chr12:1602312	ERC1	-0.64	-6.57	-0.47	7.44e-10	Obesity-related traits;
PAAD	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg19337854	chr7:99768885	GPC2	0.42	4.37	0.33	2.31e-5	Coronary artery disease;
PAAD	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg17842918	chr13:113540400	ATP11A	0.42	4.52	0.34	1.25e-5	Glycated hemoglobin levels;
PAAD	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg18171855	chr10:2543474	NA	-0.59	-6.48	-0.47	1.19e-9	Age-related hearing impairment;
PAAD	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg16950941	chr11:66035639	RAB1B	0.67	5.84	0.43	3.03e-8	Gout;
PAAD	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.93	10.07	0.63	1.37e-18	Breast cancer;
PAAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-1.04	-14.62	-0.76	8.81e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg23205692	chr1:25664452	TMEM50A	0.51	5.02	0.38	1.41e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.65	-7.02	-0.49	6.9e-11	Iron status biomarkers;
PAAD	cis	rs10090774	0.830	rs62521902	chr8:141911774	T/C	cg24251448	chr8:141577100	EIF2C2	-0.43	-4.26	-0.33	3.55e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9810890	1.000	rs73198824	chr3:128486699	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs16845107	1.000	rs11929418	chr3:113115770	C/T	cg02556155	chr3:114052269	NA	0.74	4.33	0.33	2.7e-5	Colorectal cancer;
PAAD	cis	rs9796	0.562	rs3959554	chr15:41443924	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-6.85	-0.49	1.71e-10	Menopause (age at onset);
PAAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-5.83	-0.43	3.17e-8	Menarche (age at onset);
PAAD	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg00262122	chr8:11665843	FDFT1	-0.5	-4.64	-0.35	7.59e-6	Systolic blood pressure;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs7809615	0.636	rs12538826	chr7:99030228	T/C	cg12290671	chr7:99195819	NA	-0.65	-4.36	-0.33	2.39e-5	Blood metabolite ratios;
PAAD	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.02	0.49	6.78e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-15.58	-0.78	2.64e-33	Exhaled nitric oxide output;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08886695	chr4:3369023	RGS12	-0.51	-4.83	-0.36	3.31e-6	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07450135	chr3:13521524	HDAC11	0.59	6.55	0.47	8.18e-10	Monocyte percentage of white cells;
PAAD	cis	rs7839488	0.823	rs4644306	chr8:121574174	C/G	cg14806103	chr8:121457329	MTBP;MRPL13	-0.47	-4.58	-0.35	9.56e-6	Myopia (pathological);
PAAD	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.22	0.39	5.71e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-4.39	-0.34	2.08e-5	Metabolite levels;
PAAD	cis	rs7711186	0.786	rs7736565	chr5:178020240	A/G	cg17371294	chr5:178012716	COL23A1	-0.86	-4.51	-0.34	1.3e-5	Urate levels in obese individuals;
PAAD	cis	rs7255045	0.665	rs2014639	chr19:12975021	G/C	cg09980403	chr19:12975529	MAST1	0.31	4.74	0.36	4.9e-6	Mean corpuscular volume;
PAAD	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.13	14.84	0.77	2.24e-31	Cortisol levels (saliva);
PAAD	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.66	8.43	0.56	2.46e-14	Hemoglobin concentration;
PAAD	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-5.25	-0.39	5.02e-7	Daytime sleep phenotypes;
PAAD	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.59	5.79	0.43	3.86e-8	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.41	5.26	0.39	4.73e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs933688	0.652	rs4916856	chr5:90596403	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.69	-5.38	-0.4	2.82e-7	Smoking behavior;
PAAD	cis	rs66530629	0.837	rs4306080	chr1:25135004	C/T	cg01905478	chr1:25040257	NA	0.49	5.42	0.4	2.27e-7	Plateletcrit;
PAAD	cis	rs183266	0.800	rs79405382	chr14:77482578	G/A	cg01682506	chr14:77422843	NA	-0.92	-4.46	-0.34	1.6e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.73	-7.73	-0.53	1.33e-12	Blood metabolite levels;
PAAD	cis	rs12760731	0.720	rs35781686	chr1:178261262	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.69	5.82	0.43	3.34e-8	Height;
PAAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	7.1	0.5	4.58e-11	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17771610	chr13:45011050	TSC22D1	-0.78	-7.2	-0.5	2.62e-11	Neuroticism;
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.62	7.03	0.5	6.71e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs12304921	0.622	rs67466786	chr12:51505336	C/T	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.47	-0.34	1.51e-5	Mood instability;
PAAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg09060608	chr5:178986726	RUFY1	0.46	4.45	0.34	1.68e-5	Lung cancer;
PAAD	trans	rs61931739	0.649	rs12424046	chr12:33714374	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs66731853	0.557	rs477190	chr1:20898514	C/A	cg04087271	chr1:20915334	CDA	-0.52	-6.26	-0.45	3.67e-9	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs4740619	1.000	rs4740621	chr9:15640404	C/T	cg14451791	chr9:16040625	NA	-0.41	-4.85	-0.37	3.05e-6	Body mass index;
PAAD	cis	rs988913	1.000	rs9475081	chr6:54813738	G/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.81	-7.45	-0.52	6.48e-12	Body mass index (adult);
PAAD	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg27029450	chr22:50098074	NA	0.67	4.48	0.34	1.44e-5	Natriuretic peptide levels;
PAAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.49	0.65	1.06e-19	Menopause (age at onset);
PAAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.53	-6.33	-0.46	2.63e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg07979401	chr6:33739406	LEMD2	-0.53	-4.53	-0.35	1.18e-5	Schizophrenia;
PAAD	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.41	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	trans	rs11794666	1.000	rs80119354	chr9:31670755	T/G	cg05628366	chr6:35744188	C6orf126	1.0	6.41	0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.29	-0.33	3.19e-5	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23063879	chr4:89881374	FAM13A	-0.67	-6.99	-0.49	8.33e-11	Obesity-related traits;
PAAD	cis	rs10901513	0.932	rs2176097	chr10:127668487	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.92	7.47	0.52	5.83e-12	D-dimer levels;
PAAD	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.66	-0.35	6.84e-6	Height;
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.45	0.57	2.15e-14	Lung cancer;
PAAD	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.58	5.51	0.41	1.48e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3748682	0.861	rs28625842	chr1:38310786	G/A	cg12658694	chr1:38397304	INPP5B	0.48	4.5	0.34	1.37e-5	Hypothyroidism;
PAAD	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.6	4.69	0.36	6.01e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7651511	0.926	rs77603484	chr3:141320351	G/T	cg25967872	chr3:141205623	RASA2	0.51	4.53	0.34	1.19e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14251936	chr19:44417025	ZNF45	-0.72	-7.54	-0.52	3.87e-12	Obesity-related traits;
PAAD	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.55	0.47	8.23e-10	Bladder cancer;
PAAD	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs667920	0.557	rs35849216	chr3:136327569	C/T	cg15507776	chr3:136538369	TMEM22	-0.66	-4.25	-0.33	3.68e-5	Coronary artery disease;
PAAD	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.46	-5.34	-0.4	3.32e-7	Blood pressure (smoking interaction);
PAAD	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.86	-10.35	-0.64	2.48e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.27	-0.39	4.67e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-4.39	-0.34	2.08e-5	Educational attainment (years of education);
PAAD	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg03934865	chr2:198174659	NA	-0.47	-4.73	-0.36	5.08e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg00253185	chr1:247542119	NA	0.54	4.49	0.34	1.4e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.47	-5.42	-0.4	2.31e-7	Migraine;
PAAD	cis	rs7873102	0.654	rs2244207	chr9:37986978	G/A	cg03528946	chr9:38069800	SHB	0.52	5.21	0.39	6.01e-7	Brain structure;
PAAD	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.43	-0.52	7.25e-12	Migraine;Coronary artery disease;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg11900509	chr10:81946545	ANXA11	-0.76	-4.3	-0.33	3.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg00614314	chr15:82944287	LOC80154	-0.59	-6.18	-0.45	5.65e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg21300403	chr2:198650112	BOLL	0.49	4.35	0.33	2.5e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs899997	1.000	rs1814880	chr15:79021140	T/C	cg12645284	chr15:79092878	ADAMTS7	0.49	4.36	0.33	2.4e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs4148087	1.000	rs9975740	chr21:43620485	A/T	cg08841829	chr21:43638893	ABCG1	-0.64	-4.33	-0.33	2.71e-5	Eating disorder in bipolar disorder;
PAAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10924309	1.000	rs10924309	chr1:245863222	A/G	cg00036263	chr1:245852353	KIF26B	0.53	4.4	0.34	2.02e-5	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs9463078	0.547	rs4714819	chr6:44735285	G/C	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.05e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.59	-5.72	-0.42	5.46e-8	YKL-40 levels;
PAAD	cis	rs1468734	1.000	rs34630219	chr16:5003436	C/T	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	1.02	7.92	0.54	4.72e-13	IgG glycosylation;
PAAD	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg12696750	chr1:38022466	DNALI1	0.47	4.49	0.34	1.41e-5	Axial length;
PAAD	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg26513180	chr16:89883248	FANCA	0.73	8.51	0.57	1.58e-14	Vitiligo;
PAAD	cis	rs7301016	0.895	rs11174514	chr12:62895074	G/C	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg19787841	chr12:53845606	PCBP2	0.45	4.36	0.33	2.38e-5	Height;
PAAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.65	4.47	0.34	1.5e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.45	4.69	0.36	6.14e-6	Motion sickness;
PAAD	cis	rs72627123	1.000	rs72627125	chr14:74369623	G/C	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.7	-8.16	-0.55	1.16e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.42	-4.47	-0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg19630374	chr17:18023558	MYO15A	-0.4	-4.35	-0.33	2.52e-5	Total body bone mineral density;
PAAD	cis	rs735539	0.593	rs4463942	chr13:21367434	C/T	cg27499820	chr13:21296301	IL17D	0.54	5.14	0.39	8.17e-7	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13236679	chr6:37467396	C6orf129	0.59	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs288326	0.561	rs75139715	chr2:183890660	T/A	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs877529	0.625	rs714016	chr22:39532554	G/T	cg18708252	chr22:39545030	CBX7	0.68	7.24	0.51	2.04e-11	Multiple myeloma;
PAAD	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.79	0.36	3.92e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05665937	chr4:1216051	CTBP1	0.4	4.42	0.34	1.88e-5	Obesity-related traits;
PAAD	cis	rs9652601	0.649	rs7403919	chr16:11085968	C/T	cg04616529	chr16:11181986	CLEC16A	-0.41	-4.5	-0.34	1.36e-5	Systemic lupus erythematosus;
PAAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.26	0.39	4.72e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.35	0.6	1.09e-16	Bipolar disorder;
PAAD	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg05338066	chr1:7812865	CAMTA1	0.58	4.61	0.35	8.4e-6	Inflammatory bowel disease;
PAAD	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.38e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.03	-0.38	1.36e-6	Mood instability;
PAAD	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	trans	rs901683	1.000	rs34879733	chr10:45997761	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00992913	chr1:156698515	C1orf66;ISG20L2	0.76	8.4	0.56	2.9e-14	Myopia (pathological);
PAAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.51e-38	Height;
PAAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg17552801	chr10:99332121	ANKRD2	-0.46	-4.64	-0.35	7.39e-6	Metabolite levels;
PAAD	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs1144333	1.000	rs12082448	chr1:76353225	C/T	cg22875332	chr1:76189707	ACADM	0.62	4.5	0.34	1.34e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.59	6.27	0.45	3.62e-9	Mean corpuscular volume;
PAAD	cis	rs36715	0.868	rs2546147	chr5:127552590	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.22	0.45	4.59e-9	Breast cancer;
PAAD	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg12927641	chr6:109611667	NA	-0.41	-4.37	-0.33	2.32e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.55	-4.86	-0.37	2.86e-6	Squamous cell lung carcinoma;
PAAD	cis	rs8014252	0.518	rs58919501	chr14:71069022	G/A	cg11204974	chr14:71022665	NA	-0.59	-4.31	-0.33	2.92e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs6137287	0.924	rs2876596	chr20:21158371	T/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.27	11.75	0.69	4.27e-23	Corneal structure;
PAAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.85	5.53	0.41	1.35e-7	Gout;
PAAD	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.26	0.51	1.86e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16447276	chr2:204306494	RAPH1	0.58	6.39	0.46	1.9e-9	Smoking initiation;
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.93	0.37	2.17e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs747650	0.532	rs10838658	chr11:47130778	G/A	cg19486271	chr11:47235900	DDB2	0.67	6.23	0.45	4.31e-9	Acne (severe);
PAAD	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.9	8.91	0.59	1.49e-15	Pulmonary function decline;
PAAD	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg01953289	chr20:60874239	NA	0.67	4.91	0.37	2.3e-6	Obesity-related traits;
PAAD	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.68	7.55	0.52	3.81e-12	Melanoma;
PAAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.81e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35740288	0.822	rs17636864	chr15:86234589	A/C	cg07943548	chr15:86304357	KLHL25	-0.65	-5.58	-0.41	1.08e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11051970	1.000	rs1872829	chr12:32535100	C/T	cg24626660	chr12:32551988	NA	0.44	5.15	0.39	7.99e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-7.46	-0.52	6.25e-12	Total body bone mineral density;
PAAD	cis	rs17539620	0.624	rs56737784	chr6:154848694	C/T	cg20019720	chr6:154832845	CNKSR3	0.64	7.33	0.51	1.26e-11	Lipoprotein (a) levels;
PAAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.61	-6.29	-0.45	3.24e-9	IgG glycosylation;
PAAD	cis	rs10512697	0.655	rs35093298	chr5:3460454	T/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg00717180	chr2:96193071	NA	0.59	6.56	0.47	7.9e-10	HDL cholesterol;
PAAD	trans	rs62179067	0.708	rs17362972	chr2:179909467	C/T	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg14440974	chr22:39074834	NA	-0.57	-6.55	-0.47	8.27e-10	Menopause (age at onset);
PAAD	cis	rs4073221	0.585	rs35441238	chr3:18316117	T/A	cg07694806	chr3:18168406	NA	-0.62	-4.58	-0.35	9.43e-6	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1816752	0.638	rs9578730	chr13:24999683	G/A	cg02811702	chr13:24901961	NA	0.52	5.47	0.41	1.82e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.39	-0.51	8.95e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg25029533	chr12:50188891	NCKAP5L	0.62	6.42	0.46	1.67e-9	Body mass index;
PAAD	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg26910651	chr8:30669848	PPP2CB	0.42	4.42	0.34	1.89e-5	Metabolite levels  (X-11787);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26125787	chr4:164415830	C4orf43	-0.63	-8.12	-0.55	1.44e-13	Body fat percentage;
PAAD	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.81	8.18	0.55	1.03e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg27170260	chr1:38156575	C1orf109	-0.45	-4.28	-0.33	3.25e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg15557168	chr22:42548783	NA	-0.44	-4.56	-0.35	1.05e-5	Cognitive function;
PAAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.7	5.02	0.38	1.45e-6	Breast cancer;
PAAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.5	-6.03	-0.44	1.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.78	5.98	0.44	1.5e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.76	-0.42	4.54e-8	Psoriasis;
PAAD	cis	rs7178572	0.789	rs4886869	chr15:77799657	A/G	cg22256960	chr15:77711686	NA	-0.6	-5.85	-0.43	2.96e-8	Type 2 diabetes;
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg24690094	chr11:67383802	NA	0.45	4.25	0.33	3.65e-5	Mean corpuscular volume;
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg09473613	chr1:24152604	HMGCL	0.54	5.73	0.42	5.35e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.19	0.39	6.67e-7	Schizophrenia;
PAAD	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	0.8	5.87	0.43	2.62e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg06375148	chr1:209958343	C1orf74	0.67	5.64	0.42	8.16e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs569214	0.515	rs542794	chr8:27520773	C/T	cg04264299	chr8:27491209	SCARA3	0.54	5.37	0.4	2.86e-7	Alzheimer's disease;
PAAD	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs829661	0.739	rs829635	chr2:30736811	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.46	0.34	1.57e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg04132472	chr17:19861366	AKAP10	0.47	5.29	0.39	4.21e-7	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16282339	chr11:47927019	NA	0.55	6.78	0.48	2.56e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs2735839	0.573	rs2659124	chr19:51354597	A/T	cg03162314	chr19:51600935	CTU1	-0.52	-4.3	-0.33	2.99e-5	Prostate-specific antigen levels;Prostate cancer (SNP x SNP interaction);Elevated serum prostate-specific antigen levels in healthy men;Prostate cancer;
PAAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.62	-7.58	-0.52	3.1e-12	Immature fraction of reticulocytes;
PAAD	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.87	-8.07	-0.55	2.01e-13	Neurofibrillary tangles;
PAAD	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.2	-0.5	2.64e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs11700980	0.636	rs73190119	chr21:30303685	C/A	cg08807101	chr21:30365312	RNF160	-0.73	-4.4	-0.34	2.07e-5	QRS complex (12-leadsum);
PAAD	cis	rs7766436	0.614	rs12660580	chr6:22564428	C/G	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.77e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.85	-10.74	-0.66	2.26e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7705819	0.955	rs10058978	chr5:172876851	C/G	cg25070803	chr5:172483131	C5orf41	-0.55	-4.99	-0.37	1.66e-6	Stroke;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.62	6.3	0.45	3.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11586313	0.935	rs4845496	chr1:152888178	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-4.38	-0.33	2.18e-5	Vitamin D levels;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.55	5.95	0.43	1.79e-8	Longevity;Endometriosis;
PAAD	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.57	-5.9	-0.43	2.32e-8	Hypospadias;
PAAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.6	0.57	9.06e-15	Schizophrenia;
PAAD	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9677476	0.909	rs7562116	chr2:232108246	A/G	cg07929768	chr2:232055508	NA	0.38	4.31	0.33	2.97e-5	Food antigen IgG levels;
PAAD	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.5	4.44	0.34	1.72e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.63	-4.82	-0.36	3.51e-6	Diastolic blood pressure;
PAAD	cis	rs2968864	1.000	rs2968864	chr7:150622162	T/C	cg06221570	chr7:150558377	ABP1	0.49	5.64	0.42	8.02e-8	QT interval;
PAAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.59	6.22	0.45	4.52e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	12.51	0.71	3.82e-25	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.77	-6.69	-0.48	3.99e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg18721089	chr20:30220636	NA	-0.6	-5.01	-0.38	1.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.85	0.75	9.99e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.85	0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg07212818	chr11:638076	DRD4	-0.74	-6.87	-0.49	1.54e-10	Systemic lupus erythematosus;
PAAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs6011002	0.550	rs6010634	chr20:62363838	T/C	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg16964102	chr10:135390573	NA	0.41	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs9398803	0.687	rs7740134	chr6:127009669	T/A	cg19875578	chr6:126661172	C6orf173	-0.44	-4.59	-0.35	9.14e-6	Male-pattern baldness;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg20893717	chr7:100318190	EPO	-0.47	-4.36	-0.33	2.35e-5	Other erythrocyte phenotypes;
PAAD	trans	rs6694672	1.000	rs7516700	chr1:197110331	T/G	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.93	-7.93	-0.54	4.48e-13	Diastolic blood pressure;
PAAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.81	-8.66	-0.57	6.52e-15	DNA methylation (variation);
PAAD	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg07747251	chr5:1868357	NA	0.58	6.34	0.46	2.48e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.47	-4.65	-0.35	7.07e-6	Diastolic blood pressure;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02071572	chr4:1403502	NA	0.43	5.69	0.42	6.24e-8	Obesity-related traits;
PAAD	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	9.55	0.61	3.14e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg20813462	chr7:2646259	IQCE	0.66	4.65	0.35	7.21e-6	Urate levels in lean individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24833569	chr3:25426534	NA	-0.62	-6.78	-0.48	2.52e-10	Obesity-related traits;
PAAD	cis	rs3787159	0.523	rs4811982	chr20:56875059	T/C	cg15032960	chr20:56888536	RAB22A	0.41	4.4	0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs11825685	0.579	rs948044	chr11:134539404	A/T	cg06603561	chr11:134479413	NA	-0.57	-5.03	-0.38	1.36e-6	IgG glycosylation;
PAAD	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg06740227	chr12:86229804	RASSF9	-0.53	-4.86	-0.37	2.92e-6	Major depressive disorder;
PAAD	cis	rs66515854	1.000	rs9866810	chr3:3893723	C/G	cg03930929	chr3:3862703	LRRN1	0.58	4.53	0.34	1.21e-5	beta-nerve growth factor levels;
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg05132306	chr1:1846340	CALML6	-0.42	-4.98	-0.37	1.73e-6	Body mass index;
PAAD	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.58	-0.41	1.06e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg21419209	chr3:44054225	NA	-0.74	-7.72	-0.53	1.45e-12	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21549333	chr12:57623775	SHMT2	0.7	7.84	0.54	7.16e-13	Myopia (pathological);
PAAD	cis	rs11651753	0.598	rs4794286	chr17:45990597	T/C	cg24458315	chr17:46148407	CBX1	0.42	4.66	0.35	6.81e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg05980111	chr3:124395277	KALRN	0.44	4.51	0.34	1.26e-5	Plateletcrit;
PAAD	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17347941	chr15:79387269	NA	0.38	4.33	0.33	2.73e-5	Refractive error;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.52	-5.11	-0.38	9.37e-7	Testicular germ cell tumor;
PAAD	cis	rs1842579	0.596	rs12727784	chr1:86268032	C/T	cg14090374	chr1:85667233	SYDE2	0.49	4.33	0.33	2.73e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20050194	chr10:116046732	VWA2	-0.62	-6.36	-0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-6.67	-0.48	4.36e-10	Lymphocyte counts;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.4	4.31	0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.6	5.74	0.42	5.03e-8	Endometrial cancer;
PAAD	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.67	-0.72	1.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs58521262	0.585	rs2548898	chr19:23212933	G/A	cg03433597	chr19:22806448	NA	0.24	4.36	0.33	2.39e-5	Testicular germ cell tumor;
PAAD	cis	rs12304921	0.683	rs17125346	chr12:51471152	C/T	cg18059802	chr12:51347058	HIGD1C	0.64	5.14	0.38	8.24e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg16342193	chr10:102329863	NA	-0.79	-8.58	-0.57	1.05e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg04315214	chr1:2043799	PRKCZ	-0.56	-7.24	-0.51	2.09e-11	Height;
PAAD	cis	rs12304921	1.000	rs4768942	chr12:51355701	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.74	6.33	0.46	2.64e-9	Alzheimer's disease;
PAAD	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.88	10.93	0.66	7e-21	Body mass index;
PAAD	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg21479132	chr6:26055353	NA	0.95	5.52	0.41	1.45e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg05110241	chr16:68378359	PRMT7	-1.44	-9.87	-0.63	4.58e-18	Magnesium levels;
PAAD	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.38	-9.61	-0.61	2.2e-17	Diabetic retinopathy;
PAAD	trans	rs6828577	0.729	rs35604604	chr4:119421152	C/A	cg26518628	chr1:97050305	NA	-0.74	-6.79	-0.48	2.35e-10	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.72	-6.79	-0.48	2.32e-10	Body mass index;
PAAD	cis	rs11945232	0.624	rs35607673	chr4:88363217	C/T	cg23841344	chr4:88312519	HSD17B11	-0.59	-4.74	-0.36	4.78e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.86	-8.42	-0.56	2.61e-14	Coronary artery disease;
PAAD	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.55	-6.71	-0.48	3.68e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-8.88	-0.58	1.76e-15	Colorectal cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05358183	chr16:85112625	KIAA0513	0.56	6.46	0.46	1.31e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg20962211	chr2:183580829	DNAJC10	0.66	6.49	0.47	1.13e-9	Primary biliary cholangitis;
PAAD	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11700980	0.551	rs2832020	chr21:30112231	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg07202610	chr7:1142643	C7orf50	-0.68	-5.68	-0.42	6.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	1.03	11.49	0.68	2.2e-22	Bone mineral density;
PAAD	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	10.73	0.66	2.37e-20	Primary sclerosing cholangitis;
PAAD	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.95e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg25755851	chr1:9335794	NA	-0.54	-6.45	-0.46	1.41e-9	Eosinophil percentage of white cells;
PAAD	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs9768139	0.512	rs1121014	chr7:158081769	T/C	cg02855558	chr7:158107723	PTPRN2	0.45	4.39	0.34	2.09e-5	Calcium levels;
PAAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23477849	chr19:5698492	LONP1	0.56	6.48	0.47	1.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.65	-4.84	-0.37	3.2e-6	Vitiligo;
PAAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg18551225	chr6:44695536	NA	0.74	7.22	0.51	2.37e-11	Total body bone mineral density;
PAAD	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg26752657	chr1:75199075	CRYZ;TYW3	0.53	4.42	0.34	1.85e-5	Resistin levels;
PAAD	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00079375	chr15:79125835	NA	-0.43	-4.55	-0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.23	-0.6	2.23e-16	Type 2 diabetes;
PAAD	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-6.34	-0.46	2.55e-9	Triglycerides;
PAAD	trans	rs1015213	0.609	rs76288806	chr8:52877169	T/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-5.04	-0.38	1.33e-6	Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3136441	1.000	rs4752940	chr11:46847715	G/C	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.67	-6.34	-0.46	2.48e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00703019	chr1:7831811	VAMP3	0.59	6.83	0.48	1.92e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.74	-8.36	-0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg00262122	chr8:11665843	FDFT1	-0.53	-5.13	-0.38	8.82e-7	Neuroticism;
PAAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.17	-0.39	7.43e-7	Common traits (Other);
PAAD	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg27113419	chr16:58533979	NDRG4	-0.76	-4.75	-0.36	4.69e-6	Schizophrenia;
PAAD	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.77	7.13	0.5	3.88e-11	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs73196999	chr3:128460581	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg10820045	chr2:198174542	NA	0.51	5.26	0.39	4.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.23	-0.39	5.41e-7	Tonsillectomy;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.66e-10	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18446701	chr14:105357477	KIAA0284	-0.53	-6.64	-0.47	5.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg20913747	chr6:44695427	NA	-0.66	-6.53	-0.47	9.28e-10	Total body bone mineral density;
PAAD	cis	rs600550	0.588	rs2304933	chr11:60102507	G/T	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.56	-5.13	-0.38	8.53e-7	Interleukin-17 levels;
PAAD	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.49	4.59	0.35	9.39e-6	Airway imaging phenotypes;
PAAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs13177180	0.671	rs10055339	chr5:114973120	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.44	-4.78	-0.36	4.19e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.81	5.91	0.43	2.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs3857067	0.550	rs72663751	chr4:95001794	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.55	-4.83	-0.37	3.24e-6	QT interval;
PAAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.55	6.21	0.45	4.92e-9	Tumor biomarkers;
PAAD	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.81	-0.36	3.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6066825	0.666	rs6019374	chr20:47303812	A/G	cg18078177	chr20:47281410	PREX1	0.45	4.31	0.33	2.9e-5	Colorectal cancer;
PAAD	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg02038168	chr22:39784481	NA	-0.49	-4.77	-0.36	4.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg14343924	chr8:8086146	FLJ10661	0.56	5.03	0.38	1.39e-6	Mood instability;
PAAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.47	4.98	0.37	1.72e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6499129	0.558	rs9934328	chr16:67573367	G/C	cg05110241	chr16:68378359	PRMT7	-0.78	-5.21	-0.39	6.08e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3112530	1.000	rs300327	chr5:152703974	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.02	-0.55	2.7e-13	Blood metabolite levels;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg07159951	chr1:45983175	PRDX1	-0.42	-4.54	-0.35	1.15e-5	High light scatter reticulocyte count;
PAAD	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg26312998	chr6:43337775	ZNF318	0.66	5.29	0.39	4.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.26	-0.45	3.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.77	-0.53	1.07e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.91	-12.1	-0.7	5.07e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3853824	0.636	rs9911560	chr17:54939715	C/T	cg14266156	chr17:54829018	NA	-0.41	-4.25	-0.33	3.68e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10992471	0.580	rs13284106	chr9:95433845	G/A	cg14631576	chr9:95140430	CENPP	-0.49	-4.59	-0.35	9.33e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.84	-0.37	3.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg17644776	chr2:200775616	C2orf69	-0.68	-5.88	-0.43	2.56e-8	Schizophrenia;
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg08888203	chr3:10149979	C3orf24	0.69	6.29	0.45	3.18e-9	Alzheimer's disease;
PAAD	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg06740227	chr12:86229804	RASSF9	-0.55	-5.27	-0.39	4.57e-7	Major depressive disorder;
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.39	-0.34	2.11e-5	Life satisfaction;
PAAD	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.39	-0.34	2.09e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.42	-0.34	1.89e-5	Primary biliary cholangitis;
PAAD	cis	rs2790216	1.000	rs2590311	chr10:59983565	A/G	cg20442379	chr10:60024634	IPMK	-0.56	-4.25	-0.33	3.75e-5	Inflammatory bowel disease;
PAAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg09695851	chr17:3907499	NA	0.8	6.02	0.44	1.29e-8	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.95	12.52	0.71	3.61e-25	Menopause (age at onset);
PAAD	cis	rs7524258	0.900	rs4908606	chr1:7259321	A/C	cg07173049	chr1:7289937	CAMTA1	0.75	11.13	0.67	1.98e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2997447	0.748	rs2802346	chr1:26434354	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.38	-0.56	3.34e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10982886	chr11:82868462	PCF11	-0.78	-6.81	-0.48	2.12e-10	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18797950	chr3:12856746	CAND2	0.55	6.3	0.46	3.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.38	4.26	0.33	3.6e-5	High light scatter reticulocyte count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11347955	chr5:141079463	NA	0.58	6.42	0.46	1.61e-9	Smoking initiation;
PAAD	cis	rs617219	0.710	rs2255913	chr5:78562399	G/C	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.55	5.41	0.4	2.4e-7	Corneal astigmatism;
PAAD	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.7	7.14	0.5	3.64e-11	Schizophrenia;
PAAD	cis	rs6585424	0.925	rs11201964	chr10:81931367	A/G	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.73	0.42	5.35e-8	Immature fraction of reticulocytes;
PAAD	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.75	8.61	0.57	8.4e-15	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12993477	chr11:506911	RNH1	0.62	6.84	0.49	1.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.32	0.81	8.35e-38	Height;
PAAD	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.31	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.78	6.47	0.46	1.3e-9	Monocyte percentage of white cells;
PAAD	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg23024343	chr7:107201750	COG5	0.56	4.52	0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs6681460	0.932	rs602513	chr1:67177270	G/A	cg02459107	chr1:67143332	SGIP1	0.73	6.85	0.49	1.72e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.81	-6.18	-0.45	5.68e-9	Coronary artery calcification;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10000312	chr16:4801404	ZNF500	-0.7	-6.92	-0.49	1.16e-10	Obesity-related traits;
PAAD	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-5.17	-0.39	7.31e-7	Response to antipsychotic treatment;
PAAD	trans	rs2817937	0.892	rs79613291	chr6:121107110	G/C	cg22125214	chr7:135612081	LUZP6;MTPN	1.11	6.51	0.47	1.01e-9	Primary tooth development (number of teeth);
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.71	8.03	0.55	2.5e-13	Longevity;Endometriosis;
PAAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg10556349	chr10:835070	NA	0.68	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9311474	0.775	rs352163	chr3:52247110	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-5.15	-0.39	8.03e-7	Electroencephalogram traits;
PAAD	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg07154921	chr7:157260426	NA	0.44	4.35	0.33	2.5e-5	Body mass index;
PAAD	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg18736775	chr8:18248649	NAT2	-0.57	-5.27	-0.39	4.66e-7	Total cholesterol levels;
PAAD	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.82	-9.8	-0.62	6.93e-18	Brugada syndrome;
PAAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.51	-0.61	3.98e-17	Colorectal cancer;
PAAD	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg04415270	chr2:102091202	RFX8	0.51	6.35	0.46	2.4e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9322817	0.583	rs6571202	chr6:105182644	G/T	cg02098413	chr6:105308735	HACE1	-0.45	-5.72	-0.42	5.54e-8	Thyroid stimulating hormone;
PAAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.63	6.6	0.47	6.38e-10	Mood instability;
PAAD	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.51	-4.7	-0.36	5.72e-6	Menopause (age at onset);
PAAD	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	5.68	0.42	6.68e-8	Blood protein levels;
PAAD	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.6	-5.47	-0.41	1.79e-7	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.76	7.55	0.52	3.7e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26370608	chr17:40831365	NA	0.55	6.43	0.46	1.55e-9	Monocyte percentage of white cells;
PAAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.68	-5.21	-0.39	6.13e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs2637030	0.559	rs256117	chr5:52916684	G/A	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg12639453	chr1:2035780	PRKCZ	0.49	5.11	0.38	9.52e-7	Height;
PAAD	cis	rs12476592	0.571	rs10171223	chr2:63687700	A/G	cg10828910	chr2:63850056	LOC388955	0.52	4.49	0.34	1.42e-5	Childhood ear infection;
PAAD	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.84	10.71	0.66	2.69e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.28	-0.39	4.48e-7	Migraine - clinic-based;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.76	5.89	0.43	2.35e-8	Left atrial antero-posterior diameter;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23989516	chr11:65554385	OVOL1	0.6	6.63	0.47	5.39e-10	Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.56	5.45	0.4	1.99e-7	Menopause (age at onset);
PAAD	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.81	8.63	0.57	7.8e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg10932868	chr11:921992	NA	0.44	4.81	0.36	3.59e-6	Alzheimer's disease (late onset);
PAAD	cis	rs877529	0.934	rs139425	chr22:39559742	G/C	cg18708252	chr22:39545030	CBX7	-0.47	-4.45	-0.34	1.65e-5	Multiple myeloma;
PAAD	cis	rs13102973	0.640	rs13140829	chr4:135838818	T/C	cg14419869	chr4:135874104	NA	0.44	4.51	0.34	1.28e-5	Subjective well-being;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00997424	chr10:99400181	PI4K2A	-0.69	-6.69	-0.48	4.09e-10	Lung cancer in ever smokers;
PAAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg13263323	chr15:86062960	AKAP13	-0.62	-7.27	-0.51	1.76e-11	Interstitial lung disease;
PAAD	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg15508401	chr2:239997380	HDAC4	0.5	4.37	0.33	2.33e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.71	8.71	0.58	4.8e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7829975	0.627	rs876954	chr8:8310923	G/A	cg06636001	chr8:8085503	FLJ10661	0.72	7.41	0.52	8.18e-12	Mood instability;
PAAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.75	-0.36	4.68e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.63	6.07	0.44	9.93e-9	Asthma;
PAAD	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg24375607	chr4:120327624	NA	0.54	5.44	0.4	2.06e-7	Corneal astigmatism;
PAAD	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	4.4	0.34	2.06e-5	Systolic blood pressure;
PAAD	cis	rs1891275	0.551	rs10881941	chr10:93414911	G/A	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.26	0.56	6.56e-14	Height;
PAAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg12215294	chr3:40350768	EIF1B	0.49	4.77	0.36	4.29e-6	Renal cell carcinoma;
PAAD	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs722208	0.565	rs2982705	chr6:152347858	C/G	cg02897527	chr10:88699338	MMRN2	0.6	6.34	0.46	2.48e-9	Developmental language disorder;
PAAD	cis	rs13242816	0.881	rs35210394	chr7:116104911	C/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12282928	0.885	rs1503176	chr11:48269191	C/T	cg22827986	chr11:48284249	OR4X1	-0.41	-5.2	-0.39	6.28e-7	Migraine - clinic-based;
PAAD	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-4.71	-0.36	5.62e-6	Colorectal cancer;
PAAD	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg25079218	chr10:134836799	NA	-0.47	-4.31	-0.33	2.92e-5	Gout;
PAAD	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.97e-10	Platelet distribution width;
PAAD	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg27170260	chr1:38156575	C1orf109	0.49	4.5	0.34	1.34e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.34	0.4	3.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6142102	0.602	rs11696338	chr20:32687611	T/C	cg06115741	chr20:33292138	TP53INP2	0.58	5.22	0.39	5.8e-7	Skin pigmentation;
PAAD	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-8.62	-0.57	8.07e-15	Morning vs. evening chronotype;
PAAD	cis	rs7829975	0.627	rs876954	chr8:8310923	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	6.68	0.48	4.27e-10	Mood instability;
PAAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.69	-6.81	-0.48	2.17e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02827336	chr4:1005033	FGFRL1	0.62	6.51	0.47	1.02e-9	Myopia (pathological);
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg01097406	chr16:89675127	NA	0.38	4.73	0.36	5.17e-6	Vitiligo;
PAAD	cis	rs959260	1.000	rs2033608	chr17:73367208	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.65	0.42	7.82e-8	Prostate cancer;
PAAD	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.37	9.39	0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	11.19	0.67	1.36e-21	Smoking behavior;
PAAD	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg19567339	chr10:100142640	NA	0.42	4.44	0.34	1.72e-5	Metabolite levels;
PAAD	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.66	7.19	0.5	2.73e-11	Body mass index;
PAAD	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.75	9.56	0.61	3.08e-17	Cancer;
PAAD	cis	rs12799264	1.000	rs2707087	chr11:19978194	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.56	-4.57	-0.35	9.86e-6	Coronary artery disease;
PAAD	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.6	5.65	0.42	7.71e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.52	4.89	0.37	2.55e-6	Eosinophilic esophagitis;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg25204440	chr1:209979598	IRF6	0.63	5.62	0.41	8.78e-8	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.61	6.46	0.46	1.32e-9	Crohn's disease;
PAAD	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.94e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg23665729	chr3:49977591	RBM6	0.6	4.59	0.35	9.3e-6	Schizophrenia;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg10864074	chr7:100318194	EPO	-0.48	-4.72	-0.36	5.4e-6	Other erythrocyte phenotypes;
PAAD	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Birth weight;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02943769	chr6:35310542	PPARD	0.68	7.2	0.5	2.59e-11	Myopia (pathological);
PAAD	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.7	5.2	0.39	6.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Myopia (pathological);
PAAD	cis	rs73416724	0.688	rs76514175	chr6:43347125	A/G	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02543470	chr2:105862877	NA	-0.54	-5.12	-0.38	9.05e-7	Obesity-related traits;
PAAD	cis	rs227833	0.729	rs687878	chr6:44706790	T/C	cg20913747	chr6:44695427	NA	0.46	4.71	0.36	5.6e-6	Monobrow;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06799790	chr17:61951754	CSH2	0.44	4.43	0.34	1.77e-5	Height;
PAAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-5.39	-0.4	2.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.72	0.36	5.33e-6	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12940558	chr6:109703017	CD164	0.67	6.96	0.49	9.75e-11	Obesity-related traits;
PAAD	cis	rs347685	0.554	rs6440059	chr3:141755344	C/T	cg00217306	chr3:141681567	TFDP2	0.64	4.55	0.35	1.07e-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg23417306	chr2:180868811	CWC22	-0.47	-4.33	-0.33	2.65e-5	Schizophrenia;
PAAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg00944433	chr1:107599041	PRMT6	-0.44	-5.08	-0.38	1.1e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.29	-0.45	3.18e-9	Triglycerides;
PAAD	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.57	5.8	0.43	3.79e-8	Cognitive function;
PAAD	cis	rs12220238	0.841	rs11000952	chr10:76037336	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg11062466	chr8:58055876	NA	0.69	5.17	0.39	7.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.6	5.62	0.41	9.03e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13968717	chr6:4954232	CDYL	-0.68	-7.25	-0.51	1.99e-11	Obesity-related traits;
PAAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.77	-0.48	2.63e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.86	6.59	0.47	6.95e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.51	-4.92	-0.37	2.27e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.49	5.05	0.38	1.28e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1497828	0.956	rs2646814	chr1:217523440	A/G	cg04411442	chr1:217543379	NA	-0.52	-4.92	-0.37	2.22e-6	Dialysis-related mortality;
PAAD	cis	rs111342015	1.000	rs74371173	chr6:43203583	T/C	cg17076780	chr6:43251928	TTBK1	0.7	4.69	0.36	5.96e-6	Breast cancer;
PAAD	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.79	0.48	2.38e-10	Exhaled nitric oxide levels;
PAAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.7	0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.76e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2133450	0.712	rs9811489	chr3:7370789	G/A	cg19930620	chr3:7340148	GRM7	-0.47	-5.31	-0.4	3.84e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg26248373	chr2:1572462	NA	-1.01	-8.08	-0.55	1.83e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs500891	0.574	rs1112482	chr6:84112019	G/C	cg08257003	chr6:84140564	ME1	0.35	4.27	0.33	3.47e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	6.71	0.48	3.62e-10	Educational attainment;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.16	0.39	7.72e-7	Prostate cancer;
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.58	6.84	0.49	1.79e-10	Aortic root size;
PAAD	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.63	-5.29	-0.39	4.27e-7	Pubertal anthropometrics;
PAAD	cis	rs6500550	0.636	rs2158443	chr16:3685782	C/G	cg01678580	chr16:4674018	MGRN1	0.47	4.51	0.34	1.3e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
PAAD	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.97	6.7	0.48	3.79e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg16664915	chr8:10907788	XKR6	-0.43	-4.41	-0.34	1.98e-5	Neuroticism;
PAAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg19680485	chr15:31195859	MTMR15	-0.43	-4.43	-0.34	1.78e-5	Huntington's disease progression;
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.73	7.43	0.52	7.38e-12	Height;
PAAD	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.61	-0.88	1.74e-50	Myeloid white cell count;
PAAD	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg17326555	chr1:119535693	NA	-0.35	-4.37	-0.33	2.24e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg03983715	chr16:68378420	PRMT7	-0.89	-6.37	-0.46	2.18e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.67	4.76	0.36	4.38e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	9.08	0.59	5.43e-16	Bone mineral density;
PAAD	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.88	0.37	2.62e-6	Myopia (pathological);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13626774	chr8:68256266	ARFGEF1	-0.81	-7.23	-0.51	2.18e-11	Neuroticism;
PAAD	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.42	5.12	0.38	9.25e-7	Total body bone mineral density;
PAAD	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.18	-0.39	6.86e-7	Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.49	0.47	1.12e-9	Personality dimensions;
PAAD	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg14301190	chr16:31159704	PRSS36	-0.4	-4.31	-0.33	2.87e-5	Diastolic blood pressure;
PAAD	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg25025879	chr12:53359317	NA	-0.89	-5.57	-0.41	1.11e-7	Prostate cancer;
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Electroencephalogram traits;
PAAD	cis	rs735539	0.593	rs35584557	chr13:21366557	T/C	cg27499820	chr13:21296301	IL17D	0.54	5.14	0.39	8.17e-7	Dental caries;
PAAD	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.71	-0.48	3.61e-10	Morning vs. evening chronotype;
PAAD	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg24053715	chr22:38214548	NA	0.61	6.37	0.46	2.16e-9	Glioblastoma;Glioma;
PAAD	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.05	11.4	0.68	3.91e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.49	4.83	0.36	3.26e-6	Vitiligo;
PAAD	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg23024343	chr7:107201750	COG5	0.56	4.59	0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg27121462	chr16:89883253	FANCA	0.48	5.04	0.38	1.3e-6	Vitiligo;
PAAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs881375	0.501	rs10739591	chr9:123885728	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	7.33	0.51	1.25e-11	Rheumatoid arthritis;
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	11.17	0.67	1.6e-21	Platelet count;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-5.08	-0.38	1.11e-6	Vitiligo;
PAAD	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.27e-6	Lung cancer;
PAAD	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs7598759	0.548	rs6750795	chr2:232378231	T/C	cg19187155	chr2:232395269	NMUR1	0.73	8.56	0.57	1.14e-14	Noise-induced hearing loss;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19195609	chr12:123464932	ARL6IP4	-0.77	-6.79	-0.48	2.41e-10	Neuroticism;
PAAD	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs17688076	0.558	rs12446418	chr16:68290200	G/A	cg03983715	chr16:68378420	PRMT7	-0.84	-5.06	-0.38	1.2e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs755249	0.567	rs3818806	chr1:39748271	G/A	cg14018543	chr1:39659967	MACF1	-0.53	-4.49	-0.34	1.4e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.52	5.02	0.38	1.4e-6	Hepatocellular carcinoma;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.85	9.88	0.63	4.3e-18	Menarche (age at onset);
PAAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg19930314	chr7:98593876	TRRAP	-0.49	-4.75	-0.36	4.62e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs838147	0.815	rs12981072	chr19:49241006	C/G	cg13540341	chr19:49222985	MAMSTR	0.44	5.03	0.38	1.35e-6	Dietary macronutrient intake;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.57	0.65	6.39e-20	Platelet count;
PAAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.91	9.56	0.61	3.05e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.52	-4.73	-0.36	5.19e-6	Menarche (age at onset);
PAAD	cis	rs12476592	0.602	rs6708804	chr2:63807269	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg10434728	chr15:90938212	IQGAP1	-0.44	-4.55	-0.35	1.08e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.84e-8	Personality dimensions;
PAAD	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.56e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2412208	0.796	rs4287204	chr1:7076184	G/A	cg26570804	chr1:6352357	ACOT7	0.57	5.34	0.4	3.33e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.74	8.72	0.58	4.4e-15	Bladder cancer;
PAAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	trans	rs3130834	1	rs3130834	chr6:29248149	T/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Breast cancer;
PAAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg16176600	chr6:116381609	FRK	0.28	4.35	0.33	2.52e-5	Total cholesterol levels;
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-8.09	-0.55	1.78e-13	Prostate cancer;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.33	-0.33	2.65e-5	Mood instability;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-6.0	-0.44	1.36e-8	Electroencephalogram traits;
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07701084	chr6:150067640	NUP43	0.62	6.24	0.45	4.19e-9	Testicular germ cell tumor;
PAAD	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg18551225	chr6:44695536	NA	-0.61	-5.45	-0.4	2.02e-7	Total body bone mineral density;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg27546065	chr7:4923383	RADIL	-0.58	-4.49	-0.34	1.38e-5	Borderline personality disorder;
PAAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-5.1	-0.38	9.99e-7	Menarche (age at onset);
PAAD	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.6	7.39	0.51	9.1e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09738193	chr16:67926317	PSKH1	-0.58	-6.29	-0.45	3.29e-9	Obesity-related traits;
PAAD	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.01	-0.38	1.5e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73416724	1.000	rs111882537	chr6:43366075	C/A	cg17076780	chr6:43251928	TTBK1	0.59	4.65	0.35	7.19e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15581365	chr11:88071006	CTSC	-0.79	-7.64	-0.53	2.32e-12	Neuroticism;
PAAD	cis	rs7594192	0.744	rs62179794	chr2:199377994	C/T	cg01558212	chr2:200327336	NA	-0.34	-4.32	-0.33	2.79e-5	Educational attainment;
PAAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs4740619	0.592	rs2987086	chr9:16013072	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.53	-0.34	1.19e-5	Body mass index;
PAAD	cis	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	4.69	0.36	6.07e-6	Schizophrenia;
PAAD	cis	rs2814982	0.514	rs73405691	chr6:34468767	A/G	cg17674042	chr6:34482479	PACSIN1	-0.95	-7.28	-0.51	1.71e-11	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs9584850	0.794	rs17470961	chr13:99135314	A/G	cg20487152	chr13:99095054	FARP1	0.58	5.09	0.38	1.02e-6	Neuroticism;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg05250797	chr16:70222502	NA	0.87	6.55	0.47	8.27e-10	IgE levels;
PAAD	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.7	5.84	0.43	3.02e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24998145	chr1:150550761	MCL1	-0.67	-6.46	-0.46	1.31e-9	Lung cancer in ever smokers;
PAAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14343924	chr8:8086146	FLJ10661	0.5	4.64	0.35	7.53e-6	Mood instability;
PAAD	cis	rs2274459	1.000	rs34869648	chr6:33724059	G/A	cg06253072	chr6:33679850	C6orf125	0.68	4.85	0.37	3.08e-6	Obesity (extreme);
PAAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.62	5.47	0.41	1.82e-7	Lymphocyte counts;
PAAD	cis	rs939584	0.935	rs7567710	chr2:645372	T/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg17759274	chr19:39260954	NA	0.4	4.3	0.33	3.07e-5	Heart rate;
PAAD	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.38	4.39	0.34	2.14e-5	IgG glycosylation;
PAAD	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.54	0.52	3.9e-12	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.52	5.34	0.4	3.34e-7	Personality dimensions;
PAAD	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-5.9	-0.43	2.3e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08374291	chr11:108338329	C11orf65	-0.74	-6.46	-0.46	1.33e-9	Neuroticism;
PAAD	cis	rs1371614	0.635	rs12714002	chr2:27134925	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.72	-7.35	-0.51	1.14e-11	Cognitive function;
PAAD	cis	rs3026101	0.671	rs28409881	chr17:5319100	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.56	5.96	0.44	1.67e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.83	-9.04	-0.59	6.89e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs288342	0.797	rs442044	chr2:183615193	T/A	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.52	-4.8	-0.36	3.72e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.41	-0.34	1.96e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg02734326	chr4:10020555	SLC2A9	0.5	4.99	0.38	1.63e-6	Bone mineral density;
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.83	10.74	0.66	2.27e-20	Vitiligo;
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.68	7.39	0.51	9.19e-12	Longevity;
PAAD	cis	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg21546286	chr11:48923668	NA	0.56	5.89	0.43	2.44e-8	HDL cholesterol;
PAAD	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-5.14	-0.39	8.17e-7	Longevity;Endometriosis;
PAAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.21	0.45	4.75e-9	Lung cancer in ever smokers;
PAAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg05392440	chr1:2478653	NA	0.55	5.87	0.43	2.64e-8	Ulcerative colitis;
PAAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg18370025	chr7:2749541	AMZ1	-0.39	-4.73	-0.36	5e-6	Height;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.47	0.41	1.83e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.31	-0.33	2.93e-5	Joint mobility (Beighton score);
PAAD	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26421448	chr1:224622516	WDR26	0.58	6.38	0.46	2.03e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.97	12.92	0.72	3.14e-26	Menopause (age at onset);
PAAD	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg00310523	chr12:86230176	RASSF9	-0.47	-5.24	-0.39	5.2e-7	Major depressive disorder;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg20790798	chr5:1857306	NA	-0.49	-5.53	-0.41	1.38e-7	Cardiovascular disease risk factors;
PAAD	cis	rs1539053	1.000	rs57982718	chr1:58100694	T/C	cg00026909	chr1:58089001	DAB1	-0.7	-8.09	-0.55	1.76e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg05805236	chr11:65401703	PCNXL3	-0.6	-6.31	-0.46	2.87e-9	Acne (severe);
PAAD	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	7.53	0.52	4.26e-12	Multiple sclerosis;
PAAD	cis	rs258892	0.947	rs266448	chr5:72182229	G/A	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-11.72	-0.69	5.28e-23	Height;
PAAD	cis	rs6681460	0.528	rs10889629	chr1:67032098	T/A	cg02459107	chr1:67143332	SGIP1	0.66	7.09	0.5	4.82e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.33	4.75	0.36	4.64e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Gout;
PAAD	cis	rs11590090	1.000	rs10857975	chr1:113321594	A/G	cg25707805	chr1:113285387	NA	-0.33	-4.5	-0.34	1.36e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs4073221	0.789	rs35051749	chr3:18217673	T/C	cg07694806	chr3:18168406	NA	-0.83	-4.96	-0.37	1.86e-6	Parkinson's disease;
PAAD	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	10.16	0.64	7.93e-19	Tonsillectomy;
PAAD	cis	rs59888335	0.825	rs7621618	chr3:80993873	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10899021	0.920	rs7112664	chr11:74348426	T/C	cg25880958	chr11:74394337	NA	-0.82	-5.19	-0.39	6.6e-7	Response to metformin (IC50);
PAAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg14440974	chr22:39074834	NA	-0.57	-6.66	-0.48	4.77e-10	Menopause (age at onset);
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg18833306	chr6:118973337	C6orf204	0.49	5.71	0.42	5.89e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.82	-6.11	-0.44	8.01e-9	Type 2 diabetes;
PAAD	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.51	5.21	0.39	6.16e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.1	0.38	1.02e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.76	5.61	0.41	9.37e-8	Vitiligo;
PAAD	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05145649	chr17:73127468	NT5C	0.58	6.74	0.48	3.16e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.97	11.02	0.67	4.03e-21	Parkinson's disease;
PAAD	cis	rs820218	0.728	rs820151	chr17:73615983	G/A	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.28	-0.33	3.24e-5	Rotator cuff tears;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05889321	chr10:97416837	ALDH18A1	0.58	6.84	0.49	1.77e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11696501	0.793	rs1883520	chr20:44130777	T/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-5.73	-0.42	5.25e-8	Brain structure;
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg20821713	chr7:1055600	C7orf50	-0.41	-4.51	-0.34	1.28e-5	Longevity;Endometriosis;
PAAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.57	6.12	0.44	7.65e-9	Menopause (age at onset);
PAAD	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.55	7.39	0.51	8.93e-12	Primary biliary cholangitis;
PAAD	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg08886695	chr4:3369023	RGS12	0.47	4.55	0.35	1.11e-5	Parental longevity (mother's age at death);
PAAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.79	-10.03	-0.63	1.78e-18	Height;
PAAD	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.55	-6.21	-0.45	4.92e-9	Cognitive function;
PAAD	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg07959070	chr22:50026188	C22orf34	-0.36	-4.3	-0.33	3.04e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.49	5.12	0.38	9.19e-7	Obesity-related traits;
PAAD	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg10925829	chr20:60860984	OSBPL2	-0.42	-4.31	-0.33	2.97e-5	Colorectal cancer;
PAAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.42	0.65	1.62e-19	Menopause (age at onset);
PAAD	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.65e-5	Schizophrenia;
PAAD	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg15192750	chr16:69999425	NA	0.76	5.99	0.44	1.48e-8	IgE levels;
PAAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg15193198	chr20:60906057	LAMA5	-0.45	-5.07	-0.38	1.17e-6	Colorectal cancer;
PAAD	cis	rs11645898	0.687	rs6499558	chr16:72102813	G/C	cg03805757	chr16:71968109	PKD1L3	-0.51	-4.39	-0.34	2.15e-5	Blood protein levels;
PAAD	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg02887458	chr19:19495540	GATAD2A	-0.6	-5.43	-0.4	2.19e-7	Bipolar disorder;
PAAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg21929781	chr1:2537748	MMEL1	0.54	5.61	0.41	9.42e-8	Ulcerative colitis;
PAAD	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.82	-12.14	-0.7	3.84e-24	Endometriosis;
PAAD	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.57e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.52	-5.62	-0.41	8.87e-8	Vitamin D levels;
PAAD	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.69	-5.96	-0.44	1.68e-8	Diabetic retinopathy;
PAAD	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-4.48	-0.34	1.49e-5	Rheumatoid arthritis;
PAAD	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	5.81	0.43	3.56e-8	Adiposity;
PAAD	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.64	6.51	0.47	1.05e-9	Testicular germ cell tumor;
PAAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg19413350	chr8:57351067	NA	-0.49	-4.73	-0.36	5.04e-6	Obesity-related traits;
PAAD	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg27499820	chr13:21296301	IL17D	-0.5	-4.98	-0.37	1.71e-6	Dental caries;
PAAD	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.63	8.32	0.56	4.72e-14	Crohn's disease;
PAAD	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.15	0.67	1.78e-21	Cognitive test performance;
PAAD	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg20893579	chr22:38215064	NA	-0.48	-4.76	-0.36	4.46e-6	Glioblastoma;Glioma;
PAAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22878469	chr5:235427	SDHA	0.66	6.63	0.47	5.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg15841412	chr13:111365552	ING1	0.52	4.44	0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg08498647	chr11:118550644	TREH	-0.44	-4.31	-0.33	2.95e-5	Rheumatoid arthritis;
PAAD	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.62	5.14	0.38	8.42e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1198430	0.683	rs1077514	chr1:23766233	A/G	cg27447006	chr1:23763279	ASAP3	-0.64	-5.1	-0.38	9.91e-7	Total cholesterol levels;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs7188861	0.768	rs12925649	chr16:11390445	T/C	cg16532467	chr16:11454386	NA	-0.54	-4.32	-0.33	2.76e-5	HDL cholesterol;
PAAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg07395648	chr5:131743802	NA	-0.47	-4.3	-0.33	3.09e-5	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.14	0.45	6.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.57	5.83	0.43	3.14e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg26939375	chr7:64535504	NA	0.76	9.08	0.59	5.41e-16	Aortic root size;
PAAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4324798	1	rs4324798	chr6:28776117	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.56	4.69	0.36	5.94e-6	Lung adenocarcinoma;
PAAD	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-8.36	-0.56	3.62e-14	Monocyte percentage of white cells;
PAAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg24737193	chr18:12778029	NA	0.63	5.58	0.41	1.09e-7	Inflammatory skin disease;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs881827	0.888	rs3804040	chr21:48015322	C/G	cg14789911	chr21:47582049	C21orf56	-0.45	-4.34	-0.33	2.58e-5	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20759823	chr20:43849786	SEMG2	-0.71	-7.14	-0.5	3.67e-11	Obesity-related traits;
PAAD	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs137699	0.500	rs137646	chr22:39728714	T/C	cg05872129	chr22:39784769	NA	-0.64	-4.37	-0.33	2.28e-5	IgG glycosylation;
PAAD	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.45	-6.95	-0.49	1e-10	Breast cancer;
PAAD	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14169450	chr9:139327907	INPP5E	0.56	5.6	0.41	9.83e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11264213	0.786	rs72659690	chr1:36291750	G/A	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6496932	1.000	rs28374025	chr15:85827338	A/G	cg19183879	chr15:85880815	NA	0.52	4.47	0.34	1.53e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg22903657	chr4:1355424	KIAA1530	-0.46	-5.0	-0.38	1.57e-6	Obesity-related traits;
PAAD	cis	rs13102973	0.965	rs4331828	chr4:135849100	C/G	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs597583	1.000	rs597583	chr11:117421799	C/G	cg27161313	chr11:117392002	DSCAML1	-0.52	-4.7	-0.36	5.74e-6	Putamen volume;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg08317243	chr16:87101592	NA	-0.54	-5.07	-0.38	1.13e-6	Menopause (age at onset);
PAAD	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11644478	chr21:40555479	PSMG1	0.78	7.12	0.5	4.05e-11	Cognitive function;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg11062466	chr8:58055876	NA	0.68	5.11	0.38	9.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7213347	0.707	rs216196	chr17:2202943	T/C	cg15816464	chr17:2026533	SMG6	-0.51	-5.62	-0.41	8.79e-8	Total body bone mineral density;
PAAD	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.53	-5.11	-0.38	9.6e-7	Cancer;
PAAD	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg04132472	chr17:19861366	AKAP10	0.45	4.98	0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.34	0.51	1.22e-11	Educational attainment;
PAAD	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg10395934	chr14:104002654	TRMT61A	0.56	5.72	0.42	5.49e-8	Body mass index;
PAAD	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.97	-13.26	-0.73	3.8e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.49	0.52	5.18e-12	Platelet count;
PAAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg08992911	chr2:238395768	MLPH	0.85	6.03	0.44	1.2e-8	Prostate cancer;
PAAD	cis	rs12450239	0.732	rs35133947	chr17:77444512	G/A	cg09567646	chr17:76962761	NA	-0.52	-4.96	-0.37	1.9e-6	Body mass index;
PAAD	cis	rs10490913	0.932	rs12246334	chr10:120150985	G/A	cg04126427	chr10:120840676	EIF3A	-0.46	-4.87	-0.37	2.78e-6	Cancer;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1570155	1.000	rs1998222	chr6:20383519	A/C	cg03881924	chr6:20404342	E2F3	0.44	4.47	0.34	1.54e-5	Obesity-related traits;
PAAD	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg04370829	chr17:406249	NA	-0.55	-5.54	-0.41	1.31e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02071572	chr4:1403502	NA	0.38	4.9	0.37	2.45e-6	Longevity;
PAAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.31	-0.56	5.03e-14	Coronary artery disease;
PAAD	cis	rs6088813	1.000	rs1570004	chr20:33958253	A/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs3795579	0.517	rs7549807	chr1:204079268	C/T	cg20634475	chr1:203652385	ATP2B4	-0.51	-5.1	-0.38	9.98e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	4.7	0.36	5.79e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg19930314	chr7:98593876	TRRAP	-0.46	-4.38	-0.34	2.16e-5	Breast cancer;
PAAD	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.99	8.89	0.58	1.67e-15	Vitiligo;
PAAD	cis	rs10214930	0.813	rs759270	chr7:27646461	T/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	trans	rs11212737	0.765	rs2062116	chr11:108514951	C/T	cg13462821	chr8:86214814	NA	-0.58	-6.66	-0.48	4.68e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg01796438	chr3:11312864	ATG7	-0.64	-5.01	-0.38	1.49e-6	Circulating chemerin levels;
PAAD	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.55	4.42	0.34	1.86e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.13e-9	Alzheimer's disease;
PAAD	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.7	0.53	1.61e-12	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.67	-0.42	6.98e-8	Gut microbiome composition (summer);
PAAD	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.6	6.44	0.46	1.48e-9	N-glycan levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18291085	chr7:77236596	PTPN12	0.57	6.36	0.46	2.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.16	-10.12	-0.63	1.02e-18	Initial pursuit acceleration;
PAAD	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg23860436	chr12:58378763	NA	0.47	4.48	0.34	1.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-6.08	-0.44	9.48e-9	Atopic dermatitis;
PAAD	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.65	6.98	0.49	8.55e-11	Morning vs. evening chronotype;
PAAD	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7809615	0.748	rs11973173	chr7:99032399	A/G	cg12290671	chr7:99195819	NA	-0.93	-5.2	-0.39	6.29e-7	Blood metabolite ratios;
PAAD	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg05425664	chr17:57184151	TRIM37	-0.51	-4.94	-0.37	2.04e-6	Testicular germ cell tumor;
PAAD	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs881827	0.962	rs2839329	chr21:47984563	A/G	cg11766577	chr21:47581405	C21orf56	0.43	4.53	0.35	1.17e-5	Lymphocyte counts;
PAAD	cis	rs6460942	0.597	rs4721107	chr7:12535105	T/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02985541	chr2:219472218	PLCD4	0.3	4.67	0.35	6.46e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg01090926	chr14:75137805	KIAA0317	0.54	4.84	0.37	3.17e-6	Non-small cell lung cancer;
PAAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg14092988	chr3:52407081	DNAH1	-0.44	-5.55	-0.41	1.24e-7	Bipolar disorder;
PAAD	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.14	0.45	6.92e-9	Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13198984	chr17:80129470	CCDC57	0.4	4.82	0.36	3.39e-6	Life satisfaction;
PAAD	cis	rs731174	0.802	rs609437	chr1:38184316	T/C	cg06917450	chr1:38156652	C1orf109	-0.5	-4.35	-0.33	2.45e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.48	-4.62	-0.35	8.3e-6	Cancer;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.55	-4.91	-0.37	2.28e-6	Depressive symptoms;
PAAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.63	5.48	0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.65	-0.35	7.04e-6	Lung cancer;
PAAD	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs68170813	1.000	rs7785962	chr7:107243995	A/C	cg23024343	chr7:107201750	COG5	-0.53	-4.32	-0.33	2.77e-5	Coronary artery disease;
PAAD	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg20406979	chr6:167373233	NA	-0.38	-5.24	-0.39	5.29e-7	Crohn's disease;
PAAD	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.56	5.36	0.4	3.07e-7	Night sleep phenotypes;
PAAD	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg06241208	chr11:30344200	C11orf46	0.51	4.57	0.35	9.98e-6	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14284889	chr11:65122212	TIGD3	0.62	6.95	0.49	1e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg27395922	chr11:50257633	LOC441601	0.42	4.54	0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.5	6.55	0.47	8.44e-10	Thyroid hormone levels;
PAAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs35791980	0.820	rs11764672	chr7:76949191	C/T	cg02756451	chr7:76178720	LOC100133091	0.47	4.29	0.33	3.14e-5	Pursuit maintenance gain;
PAAD	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs62037427	1	rs62037427	chr16:29002706	G/A	cg16576597	chr16:28551801	NUPR1	-0.45	-4.59	-0.35	9.25e-6	Tonsillectomy;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13560548	chr3:10150139	C3orf24	0.56	5.01	0.38	1.53e-6	Alzheimer's disease;
PAAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.53	-5.5	-0.41	1.56e-7	Height;
PAAD	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.81	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.78	-8.06	-0.55	2.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs41271473	0.687	rs10916364	chr1:228884405	A/G	cg10167378	chr1:228756711	NA	-0.51	-4.37	-0.33	2.27e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg21479132	chr6:26055353	NA	-0.8	-4.27	-0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.5	5.19	0.39	6.74e-7	Social autistic-like traits;
PAAD	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.74	5.98	0.44	1.5e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.77	9.26	0.6	1.79e-16	Bladder cancer;
PAAD	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg01059385	chr22:42394853	WBP2NL	0.48	4.37	0.33	2.28e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg19090574	chr1:205240910	TMCC2	-0.41	-4.47	-0.34	1.54e-5	Red blood cell count;
PAAD	cis	rs2004318	1.000	rs77522659	chr19:55125533	A/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.83	-8.96	-0.59	1.11e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.48	5.21	0.39	5.93e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Vitiligo;
PAAD	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.36	0.33	2.34e-5	Lung cancer in ever smokers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05794227	chr16:56484937	OGFOD1;NUDT21	0.65	6.67	0.48	4.49e-10	Myopia (pathological);
PAAD	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.69	6.66	0.48	4.61e-10	Lymphocyte counts;
PAAD	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg24220031	chr2:73402428	NA	0.43	6.46	0.46	1.37e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg09695851	chr17:3907499	NA	0.84	9.03	0.59	7.11e-16	Type 2 diabetes;
PAAD	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	1.03	13.69	0.74	2.69e-28	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs12612619	0.732	rs11679069	chr2:27270311	G/A	cg00617064	chr2:27272375	NA	-0.54	-5.75	-0.42	4.86e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.56	7.59	0.52	2.92e-12	Electrocardiographic conduction measures;
PAAD	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.47	-4.3	-0.33	3.07e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12599982	chr1:44399894	ARTN	0.46	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.72	-7.63	-0.53	2.46e-12	Verbal declarative memory;
PAAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.77	9.17	0.6	3.19e-16	Emphysema distribution in smoking;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.73e-6	Coronary artery disease;
PAAD	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-5.69	-0.42	6.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.3	-4.26	-0.33	3.55e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11966931	0.790	rs12665630	chr6:108101358	C/T	cg10566610	chr6:108093680	SCML4	0.47	4.37	0.33	2.26e-5	Neutrophil percentage of white cells;
PAAD	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	7.15	0.5	3.48e-11	Menarche (age at onset);
PAAD	cis	rs3736485	0.934	rs1077361	chr15:51880919	T/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.83	-10.36	-0.64	2.26e-19	Height;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.76	0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg01338255	chr20:30176054	NA	0.44	4.25	0.33	3.72e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.36e-6	Liver enzyme levels;
PAAD	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.26	0.56	6.72e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05592996	chr3:47823995	SMARCC1	-0.69	-6.59	-0.47	6.89e-10	Lung cancer in ever smokers;
PAAD	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.8	-0.48	2.2e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.68e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9557237	0.510	rs77119468	chr13:100063855	G/A	cg21788972	chr13:99853209	UBAC2	0.79	4.77	0.36	4.29e-6	Periodontal disease-related phenotypes;
PAAD	cis	rs116248771	0.696	rs16847123	chr3:158416137	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs34845616	0.514	rs4937835	chr11:133691060	G/C	cg14349672	chr11:133703707	NA	0.57	5.18	0.39	6.89e-7	Hand grip strength;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg03286735	chr4:906491	GAK	0.36	4.98	0.37	1.69e-6	Systemic sclerosis;
PAAD	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-6.78	-0.48	2.43e-10	Hemoglobin concentration;
PAAD	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs1035491	0.715	rs2366901	chr5:63923514	T/C	cg01791865	chr5:63954708	NA	0.51	5.47	0.41	1.79e-7	Body mass index;
PAAD	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg27205649	chr11:78285834	NARS2	0.59	4.25	0.33	3.67e-5	Alzheimer's disease (survival time);
PAAD	cis	rs642743	0.967	rs556292	chr10:105961957	C/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.65	0.35	7.06e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg15660573	chr17:549704	VPS53	-0.6	-5.61	-0.41	9.44e-8	Prostate cancer;
PAAD	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.58	5.51	0.41	1.51e-7	HDL cholesterol;
PAAD	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.61	-9.14	-0.6	3.77e-16	Asthma (sex interaction);
PAAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs3015497	0.646	rs2172673	chr14:51115807	A/G	cg26011998	chr14:51135199	SAV1	-0.46	-4.32	-0.33	2.75e-5	Mean platelet volume;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.92	7.15	0.5	3.33e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4751058	0.526	rs10829563	chr10:130859036	A/G	cg00118712	chr10:131686819	EBF3	-0.51	-4.71	-0.36	5.61e-6	Vitamin D levels;
PAAD	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg22852734	chr6:133119734	C6orf192	1.1	6.08	0.44	9.24e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.39	0.46	1.96e-9	Body mass index;
PAAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.46	-0.34	1.58e-5	Aortic root size;
PAAD	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.34	6.18	0.45	5.51e-9	Skin colour saturation;
PAAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17554472	chr22:41940697	POLR3H	0.61	4.42	0.34	1.88e-5	Vitiligo;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.48	-7.91	-0.54	4.87e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.54	5.37	0.4	2.91e-7	Parkinson's disease;
PAAD	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-0.86	-8.8	-0.58	2.84e-15	Exhaled nitric oxide output;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04640194	chr12:56754023	STAT2	0.58	6.29	0.45	3.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6132905	0.590	rs7264710	chr20:2622574	C/T	cg24848351	chr20:2622020	TMC2	-0.76	-5.53	-0.41	1.36e-7	Mumps;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.41	-0.61	7.55e-17	Schizophrenia;
PAAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.68	0.65	3.29e-20	Smoking behavior;
PAAD	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg14631576	chr9:95140430	CENPP	-0.57	-5.65	-0.42	7.54e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.63	5.24	0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs10887741	0.646	rs7903568	chr10:89433931	T/A	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07617163	chr11:71185649	NADSYN1	-0.61	-6.39	-0.46	1.94e-9	Obesity-related traits;
PAAD	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.48	4.4	0.34	2.02e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.7	6.14	0.45	7.04e-9	Triglycerides;
PAAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	1.24	12.11	0.7	4.81e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg19630374	chr17:18023558	MYO15A	0.47	4.86	0.37	2.91e-6	Total body bone mineral density;
PAAD	trans	rs7333764	0.793	rs7993044	chr13:34203051	A/G	cg27659903	chr2:236514471	AGAP1	0.67	6.87	0.49	1.52e-10	CTACK levels;
PAAD	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg13736514	chr6:26305472	NA	-0.59	-6.27	-0.45	3.63e-9	Educational attainment;
PAAD	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.84	6.62	0.47	5.85e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.41	0.34	1.95e-5	Chronic sinus infection;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg02005375	chr2:118572176	DDX18	0.64	6.82	0.48	2.04e-10	Hand grip strength;
PAAD	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.72	7.78	0.53	1.01e-12	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.53	5.3	0.39	4.01e-7	Anterior chamber depth;
PAAD	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.57	6.87	0.49	1.52e-10	Multiple sclerosis;
PAAD	cis	rs34375054	1.000	rs3751178	chr12:125664357	C/T	cg00522288	chr12:125625016	AACS	0.41	4.36	0.33	2.4e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.57	4.81	0.36	3.6e-6	Schizophrenia;
PAAD	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-8.66	-0.57	6.56e-15	Exhaled nitric oxide output;
PAAD	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg14393609	chr7:65229607	NA	-0.46	-4.47	-0.34	1.51e-5	Aortic root size;
PAAD	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.04	0.38	1.31e-6	Restless legs syndrome;
PAAD	cis	rs4751006	0.543	rs78526511	chr10:128769686	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs713587	0.571	rs2917916	chr2:25316336	A/C	cg01884057	chr2:25150051	NA	-0.37	-4.48	-0.34	1.43e-5	Body mass index in non-asthmatics;
PAAD	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg10820045	chr2:198174542	NA	-0.45	-4.53	-0.34	1.21e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.59	-6.08	-0.44	9.28e-9	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16868776	chr4:976565	SLC26A1	-0.57	-6.49	-0.47	1.17e-9	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.22	0.55	8.57e-14	Prudent dietary pattern;
PAAD	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-1.14	-16.0	-0.79	2.15e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs66530629	0.958	rs4024244	chr1:25050228	G/A	cg01905478	chr1:25040257	NA	0.54	5.85	0.43	2.84e-8	Plateletcrit;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04156016	chr5:1868137	NA	0.46	4.67	0.35	6.46e-6	Cardiovascular disease risk factors;
PAAD	cis	rs288342	0.832	rs288280	chr2:183593697	C/T	cg02625481	chr2:183667124	NA	-0.45	-4.61	-0.35	8.44e-6	Recurrent major depressive disorder;
PAAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg27539214	chr16:67997921	SLC12A4	0.63	4.78	0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16447950	chr5:562315	NA	-0.64	-5.65	-0.42	7.65e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.63	7.44	0.52	6.74e-12	Lung cancer;
PAAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg25204440	chr1:209979598	IRF6	0.66	5.63	0.42	8.64e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.62e-16	Mortality in heart failure;
PAAD	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06634786	chr22:41940651	POLR3H	0.69	4.83	0.36	3.37e-6	Vitiligo;
PAAD	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg09998033	chr7:158218633	PTPRN2	-0.77	-7.98	-0.54	3.34e-13	Obesity-related traits;
PAAD	cis	rs74181299	0.684	rs6713746	chr2:65324492	G/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.33	-0.33	2.68e-5	Pulse pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22302626	chr19:10196930	C19orf66	0.6	6.33	0.46	2.63e-9	Myopia (pathological);
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00280220	chr17:61926910	NA	0.44	4.53	0.35	1.16e-5	Prudent dietary pattern;
PAAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.44	-4.41	-0.34	1.98e-5	Vitiligo;
PAAD	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.91	0.37	2.34e-6	Axial length;
PAAD	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.51	-4.9	-0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.82	-7.54	-0.52	3.88e-12	Response to diuretic therapy;
PAAD	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.48	-4.4	-0.34	1.99e-5	Tuberculosis;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg14926445	chr8:58193284	C8orf71	-0.69	-5.61	-0.41	9.44e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12681288	0.782	rs2600497	chr8:1026220	A/G	cg08648136	chr8:956695	NA	0.41	4.3	0.33	2.98e-5	Schizophrenia;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg19223190	chr17:80058835	NA	0.55	5.6	0.41	9.8e-8	Life satisfaction;
PAAD	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.54	4.36	0.33	2.38e-5	Mosquito bite size;
PAAD	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.96	9.0	0.59	8.48e-16	Migraine;
PAAD	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.53	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.6	-5.88	-0.43	2.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs12042052	1.000	rs72752168	chr1:232922800	G/A	cg02903907	chr1:232941055	KIAA1383	0.85	4.6	0.35	8.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg23093090	chr10:104574429	C10orf26	-0.41	-4.58	-0.35	9.69e-6	Arsenic metabolism;
PAAD	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02711726	chr17:80685570	FN3KRP	-0.57	-5.05	-0.38	1.23e-6	Glycated hemoglobin levels;
PAAD	cis	rs17169635	0.879	rs3800737	chr7:134537875	A/G	cg02516134	chr7:134575187	CALD1	0.51	4.87	0.37	2.75e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.6	-6.49	-0.47	1.16e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.84	-7.36	-0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.78	6.0	0.44	1.36e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg23254163	chr1:152506842	NA	0.57	6.59	0.47	6.92e-10	Hair morphology;
PAAD	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg00922110	chr4:57842668	C4orf14	-0.45	-4.33	-0.33	2.69e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.62	-0.35	8.18e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.76	5.8	0.43	3.79e-8	Small cell lung carcinoma;
PAAD	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02891332	chr18:9334497	TWSG1	0.61	6.88	0.49	1.46e-10	Monocyte percentage of white cells;
PAAD	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.54	-0.35	1.14e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6074578	0.679	rs12480299	chr20:140171	A/G	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04318546	chr15:101147087	ASB7	0.53	6.43	0.46	1.58e-9	Body fat percentage;
PAAD	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg09017928	chr7:158110068	PTPRN2	0.45	4.42	0.34	1.89e-5	Calcium levels;
PAAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12165864	chr7:66369176	NA	-0.72	-4.54	-0.35	1.14e-5	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09449449	chr16:14357888	MKL2	-0.63	-6.49	-0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.81	-9.34	-0.6	1.11e-16	Bipolar disorder;
PAAD	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.94	5.6	0.41	9.65e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.61	-8.44	-0.56	2.33e-14	Height;
PAAD	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05875032	chr22:18593364	TUBA8	-0.61	-6.44	-0.46	1.49e-9	Smoking initiation;
PAAD	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs9815354	0.857	rs794894	chr3:42032483	C/T	cg03022575	chr3:42003672	ULK4	-0.71	-4.98	-0.37	1.68e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs34845616	0.813	rs36086419	chr11:133761715	G/C	cg06067394	chr11:133789110	IGSF9B	0.52	5.01	0.38	1.51e-6	Hand grip strength;
PAAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.56	-5.55	-0.41	1.26e-7	Childhood ear infection;
PAAD	cis	rs2790216	0.950	rs2590322	chr10:59999931	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg14393609	chr7:65229607	NA	-0.5	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.55	6.36	0.46	2.25e-9	Total body bone mineral density;
PAAD	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs7173743	0.525	rs7402877	chr15:79132814	T/C	cg00540400	chr15:79124168	NA	0.45	4.66	0.35	6.97e-6	Coronary artery disease;
PAAD	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.79e-5	Blood protein levels;
PAAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14801290	chr10:27793116	RAB18	0.69	7.34	0.51	1.18e-11	Myopia (pathological);
PAAD	cis	rs6784615	0.744	rs34385735	chr3:52299737	G/A	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs7168353	0.519	rs11074140	chr15:93635244	C/G	cg02918577	chr15:93633145	RGMA	-0.37	-4.98	-0.37	1.7e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs8040855	0.659	rs8037886	chr15:85686764	C/A	cg08123816	chr15:85640762	PDE8A	0.45	5.31	0.4	3.79e-7	Bulimia nervosa;
PAAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.09	12.34	0.71	1.13e-24	IgG glycosylation;
PAAD	cis	rs727505	0.583	rs17147421	chr7:124383948	C/T	cg23710748	chr7:124431027	NA	-0.47	-5.3	-0.39	4.1e-7	Lewy body disease;
PAAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.34	-0.33	2.59e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg07148914	chr20:33460835	GGT7	0.5	4.58	0.35	9.54e-6	Height;
PAAD	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.8	8.25	0.56	6.91e-14	Body mass index;
PAAD	cis	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg15956490	chr3:53032818	SFMBT1	-0.75	-4.66	-0.35	6.85e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.61	4.86	0.37	2.95e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12612619	0.695	rs4665935	chr2:27229892	C/A	cg00617064	chr2:27272375	NA	0.51	5.49	0.41	1.67e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.2	0.6	2.65e-16	Parkinson's disease;
PAAD	cis	rs2555155	0.967	rs2555161	chr11:6515853	C/T	cg24637308	chr11:6592297	DNHD1	0.48	4.96	0.37	1.88e-6	DNA methylation (variation);
PAAD	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-1.12	-6.04	-0.44	1.13e-8	Inflammatory biomarkers;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.6	5.81	0.43	3.47e-8	Acylcarnitine levels;
PAAD	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg06071746	chr17:57297518	GDPD1	0.29	4.36	0.33	2.42e-5	Cognitive test performance;
PAAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.43	4.45	0.34	1.63e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg00262122	chr8:11665843	FDFT1	0.52	4.62	0.35	8.03e-6	Neuroticism;
PAAD	cis	rs5757949	0.553	rs133040	chr22:41018165	T/C	cg14701072	chr22:41075428	MCHR1	-0.47	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.35	-0.33	2.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-10.04	-0.63	1.68e-18	Response to antipsychotic treatment;
PAAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs939584	1.000	rs4854344	chr2:638144	G/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg05564831	chr3:52568323	NT5DC2	0.43	4.33	0.33	2.73e-5	Bipolar disorder;
PAAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.88	12.19	0.7	2.76e-24	Vitiligo;
PAAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.59	6.37	0.46	2.18e-9	Lung cancer;
PAAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.3	-10.25	-0.64	4.65e-19	Breast cancer;
PAAD	cis	rs10186876	0.631	rs4952693	chr2:44151808	C/T	cg09541576	chr2:44873248	C2orf34	-0.49	-4.94	-0.37	2.07e-6	Hand grip strength;
PAAD	cis	rs58521262	0.556	rs2963060	chr19:23192539	C/T	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-1.13	-12.41	-0.71	7.16e-25	Hair shape;
PAAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs89107	0.576	rs114951787	chr6:118839081	C/G	cg21191810	chr6:118973309	C6orf204	0.38	4.48	0.34	1.47e-5	Cardiac structure and function;
PAAD	cis	rs6681460	1.000	rs1562217	chr1:67073566	C/T	cg02459107	chr1:67143332	SGIP1	-0.77	-7.87	-0.54	6.34e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs11159086	0.793	rs10139122	chr14:74959056	C/T	cg10195687	chr14:74926396	NA	-0.47	-5.25	-0.39	5.15e-7	Advanced glycation end-product levels;
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.04	0.38	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13102973	0.932	rs7656273	chr4:135852678	G/A	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.36	0.56	3.61e-14	Prudent dietary pattern;
PAAD	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg24747557	chr10:131355152	MGMT	0.46	4.93	0.37	2.14e-6	Response to temozolomide;
PAAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.52	-5.09	-0.38	1.02e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.68	7.04	0.5	6.05e-11	Mean corpuscular volume;
PAAD	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.76	5.61	0.41	9.37e-8	Vitiligo;
PAAD	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.81	6.89	0.49	1.37e-10	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13870426	chr17:30244630	NA	-0.57	-5.77	-0.42	4.26e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs73206853	0.764	rs3026468	chr12:110758081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.54	-6.31	-0.46	2.97e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04558112	chr16:69788908	NOB1	0.64	7.11	0.5	4.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.62	5.76	0.42	4.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.61	-6.64	-0.47	5.15e-10	Colorectal cancer;
PAAD	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.53	0.35	1.17e-5	Educational attainment;
PAAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg03808351	chr9:123631620	PHF19	0.48	5.19	0.39	6.52e-7	Rheumatoid arthritis;
PAAD	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-7.48	-0.52	5.41e-12	Heart rate;
PAAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.28	7.78	0.53	1.02e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-1.08	-15.68	-0.79	1.44e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.39	0.64	1.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg15573783	chr19:45927056	ERCC1	-0.72	-6.51	-0.47	1.02e-9	Blood protein levels;
PAAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs12612619	0.732	rs10865461	chr2:27292651	T/C	cg00617064	chr2:27272375	NA	-0.56	-6.05	-0.44	1.1e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.98	8.29	0.56	5.59e-14	Dupuytren's disease;
PAAD	cis	rs2274459	1.000	rs35274562	chr6:33716831	C/T	cg06253072	chr6:33679850	C6orf125	0.67	4.7	0.36	5.7e-6	Obesity (extreme);
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg21972741	chr5:435613	AHRR	0.4	4.42	0.34	1.9e-5	Cystic fibrosis severity;
PAAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.72	0.36	5.28e-6	Schizophrenia;
PAAD	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-5.78	-0.42	4.11e-8	Itch intensity from mosquito bite;
PAAD	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg00792783	chr2:198669748	PLCL1	-0.48	-4.29	-0.33	3.2e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs11113894	0.901	rs34990412	chr12:108859453	G/A	cg06834313	chr12:108851556	NA	-0.75	-4.59	-0.35	9.14e-6	Obesity-related traits;
PAAD	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg02880119	chr16:3481970	NA	0.51	4.32	0.33	2.8e-5	Body mass index (adult);
PAAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.83	8.31	0.56	5.07e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.87	0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg21823605	chr1:152486609	CRCT1	0.52	6.81	0.48	2.09e-10	Hair morphology;
PAAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.49	4.76	0.36	4.55e-6	HDL cholesterol;
PAAD	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.9	-0.37	2.43e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg03909863	chr11:638404	DRD4	-0.65	-5.64	-0.42	8.06e-8	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg02683114	chr2:24398427	C2orf84	-0.55	-5.87	-0.43	2.62e-8	Asthma;
PAAD	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.73	-7.0	-0.49	7.68e-11	QRS duration;
PAAD	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.56	4.54	0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.48	4.35	0.33	2.52e-5	Sudden cardiac arrest;
PAAD	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg07159951	chr1:45983175	PRDX1	0.43	4.53	0.34	1.2e-5	High light scatter reticulocyte count;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg17420218	chr2:20102066	TTC32	-0.62	-6.29	-0.45	3.23e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7646881	0.812	rs7624408	chr3:158460058	G/A	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs12753569	0.748	rs1013630	chr1:76513819	G/T	cg00791851	chr1:76518896	NA	0.41	4.52	0.34	1.25e-5	Personality dimensions;
PAAD	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.52	5.45	0.4	1.99e-7	Male-pattern baldness;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08298757	chr22:40390734	FAM83F	-0.64	-6.45	-0.46	1.43e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs669446	0.561	rs571862	chr1:44083110	C/T	cg12908607	chr1:44402522	ARTN	-0.41	-4.33	-0.33	2.67e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs17155006	0.664	rs411396	chr7:107744759	A/G	cg05962710	chr7:107745446	LAMB4	-0.58	-7.8	-0.53	9.39e-13	Pneumococcal bacteremia;
PAAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.23	18.2	0.83	5.25e-40	Ulcerative colitis;
PAAD	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.69	7.2	0.5	2.57e-11	Osteoporosis;
PAAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02071572	chr4:1403502	NA	0.36	4.4	0.34	2.04e-5	Longevity;
PAAD	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2712184	0.683	rs2541406	chr2:217635847	C/G	cg05032264	chr2:217675019	NA	-0.47	-5.17	-0.39	7.4e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.63	-7.65	-0.53	2.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17135859	1.000	rs13435951	chr5:112994003	C/G	cg12552261	chr5:112820674	MCC	-0.69	-4.44	-0.34	1.73e-5	F-cell distribution;
PAAD	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg08999081	chr20:33150536	PIGU	0.6	6.63	0.47	5.45e-10	Height;
PAAD	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.56	-5.33	-0.4	3.46e-7	Systemic sclerosis;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs900145	0.814	rs7120247	chr11:13278612	T/C	cg15603424	chr11:13300592	ARNTL	0.5	4.31	0.33	2.97e-5	Menarche (age at onset);
PAAD	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg08501292	chr6:25962987	TRIM38	1.0	5.92	0.43	2.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.34	0.4	3.31e-7	Lung function (FEV1/FVC);
PAAD	cis	rs17750015	0.733	rs12454362	chr18:54396186	G/A	cg18434998	chr18:54306185	TXNL1	-0.54	-5.27	-0.39	4.56e-7	Depression and alcohol dependence;
PAAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg16928487	chr17:17741425	SREBF1	0.35	4.58	0.35	9.62e-6	Total body bone mineral density;
PAAD	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.56	6.1	0.44	8.31e-9	Bladder cancer;
PAAD	cis	rs4727443	0.769	rs12673005	chr7:99576068	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.48	4.92	0.37	2.25e-6	Interstitial lung disease;
PAAD	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg24565620	chr2:194026	NA	-0.63	-5.37	-0.4	2.95e-7	Blood protein levels;
PAAD	cis	rs6908034	0.607	rs75110577	chr6:19814523	C/T	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9361491	0.608	rs9448536	chr6:79437672	G/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.584	rs11238892	chr10:44671194	A/G	cg09554077	chr10:44749378	NA	-0.43	-4.95	-0.37	1.94e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6466055	0.612	rs68113831	chr7:104860104	G/C	cg04380332	chr7:105027541	SRPK2	0.48	4.62	0.35	8.03e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01213928	chr14:20923277	APEX1;OSGEP	0.69	6.91	0.49	1.27e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.53	-0.47	9.44e-10	Lung cancer;
PAAD	cis	rs3738772	1.000	rs3738772	chr1:110048436	A/C	cg08704217	chr1:110036942	CYB561D1	-0.47	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg21269045	chr12:125625041	AACS	-0.5	-4.71	-0.36	5.47e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg09659197	chr4:152720779	NA	-0.36	-5.37	-0.4	2.89e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.87	10.83	0.66	1.31e-20	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-6.53	-0.47	9.43e-10	Gut microbiome composition (summer);
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Body mass index;
PAAD	cis	rs8027181	0.606	rs4777548	chr15:73105863	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.66	6.45	0.46	1.41e-9	Triglyceride levels;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.1	0.55	1.7e-13	Alzheimer's disease;
PAAD	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg27411982	chr8:10470053	RP1L1	0.46	4.92	0.37	2.27e-6	Neuroticism;
PAAD	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg16586182	chr3:47516702	SCAP	-0.63	-7.14	-0.5	3.64e-11	Colorectal cancer;
PAAD	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg27478167	chr7:817139	HEATR2	-0.62	-4.92	-0.37	2.18e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15559909	chr3:57678603	FAM116A	0.6	6.68	0.48	4.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.72	9.0	0.59	8.66e-16	Dupuytren's disease;
PAAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.76	8.07	0.55	1.97e-13	Coronary artery disease;
PAAD	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6540	1.000	rs7131008	chr11:260834	T/C	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05364829	chr1:21671910	ECE1	0.6	6.43	0.46	1.55e-9	Myopia (pathological);
PAAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs2882667	0.537	rs7704790	chr5:138410096	A/C	cg22797968	chr5:138629998	MATR3	0.47	4.71	0.36	5.53e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.45	4.87	0.37	2.82e-6	Post-traumatic stress disorder;
PAAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.19	-0.5	2.78e-11	Neuroticism;
PAAD	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.44	-5.95	-0.43	1.75e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.8	-0.36	3.8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3996993	0.752	rs2749026	chr6:52630635	A/G	cg00536792	chr6:53530503	KLHL31	0.43	4.47	0.34	1.52e-5	Hemoglobin concentration;
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.49	6.18	0.45	5.59e-9	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.87	7.13	0.5	3.82e-11	Alzheimer's disease;
PAAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.67	6.33	0.46	2.67e-9	Platelet count;
PAAD	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg26528668	chr16:1614120	IFT140	0.56	5.22	0.39	5.86e-7	Coronary artery disease;
PAAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.59	5.22	0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.71	4.32	0.33	2.82e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.86	-0.37	2.88e-6	Prevalent atrial fibrillation;
PAAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.98	-0.44	1.53e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg17325771	chr7:75508891	RHBDD2	0.3	4.26	0.33	3.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8112211	0.637	rs2270094	chr19:38840139	T/C	cg14299480	chr19:38876666	GGN	-0.6	-6.61	-0.47	6.01e-10	Blood protein levels;
PAAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg06131755	chr6:160182447	ACAT2	0.55	4.88	0.37	2.68e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3784262	0.565	rs12595410	chr15:58293040	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	4.62	0.35	7.97e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.58	6.01	0.44	1.31e-8	Testicular germ cell tumor;
PAAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7631605	0.905	rs61489663	chr3:37261734	T/A	cg17445812	chr3:36986805	TRANK1	0.34	4.37	0.33	2.31e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.75	-8.42	-0.56	2.63e-14	Childhood ear infection;
PAAD	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.41	-4.84	-0.37	3.16e-6	Uric acid levels;
PAAD	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs3764400	0.567	rs36071506	chr17:46279772	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.74	6.12	0.44	7.68e-9	Schizophrenia;
PAAD	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.5	5.64	0.42	8.23e-8	QRS complex (12-leadsum);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03362329	chr13:50265524	EBPL	-0.8	-7.07	-0.5	5.36e-11	Neuroticism;
PAAD	cis	rs9364554	0.718	rs9355288	chr6:160867159	G/A	cg25313204	chr6:160768801	SLC22A3	0.54	4.87	0.37	2.72e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.6	-0.41	9.8e-8	Longevity;Endometriosis;
PAAD	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs4455778	0.580	rs4270911	chr7:49112131	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg03700679	chr2:178418002	TTC30B	-0.6	-4.69	-0.36	6.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs75920871	0.925	rs4938333	chr11:116930888	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4704187	0.687	rs6889372	chr5:74531150	A/T	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.41	-0.4	2.42e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.68	6.82	0.48	2.07e-10	DNA methylation (variation);
PAAD	cis	rs9810890	1.000	rs73198891	chr3:128553841	T/G	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg27411982	chr8:10470053	RP1L1	-0.49	-5.35	-0.4	3.19e-7	Retinal vascular caliber;
PAAD	cis	rs17407555	0.909	rs34521641	chr4:10306300	A/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.42	-0.34	1.84e-5	Schizophrenia (age at onset);
PAAD	cis	rs7172971	0.688	rs4923926	chr15:42378826	G/A	cg07013680	chr15:42186124	SPTBN5	0.53	4.29	0.33	3.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10885997	0.626	rs7910135	chr10:118398046	C/A	cg09194742	chr10:118576158	NA	0.44	4.34	0.33	2.61e-5	Phospholipid levels (plasma);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14684375	chr19:45540895	SFRS16;RELB	-0.7	-6.48	-0.47	1.24e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.74e-13	Monocyte percentage of white cells;
PAAD	cis	rs9463078	0.585	rs6905396	chr6:45169165	C/T	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.85e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg14343924	chr8:8086146	FLJ10661	0.66	5.44	0.4	2.07e-7	Mood instability;
PAAD	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.1	-0.75	2.14e-29	Primary sclerosing cholangitis;
PAAD	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.64	6.17	0.45	5.86e-9	Cognitive test performance;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.44	-0.46	1.48e-9	Chronic sinus infection;
PAAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.94	-8.65	-0.57	6.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.46	-5.03	-0.38	1.34e-6	Fibrinogen levels;
PAAD	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.31	7.42	0.52	7.63e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs4906332	1.000	rs8004501	chr14:103981662	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-4.56	-0.35	1.03e-5	Coronary artery disease;
PAAD	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	4.87	0.37	2.8e-6	Educational attainment;
PAAD	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.92	0.37	2.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg18765565	chr5:669397	TPPP	0.43	4.65	0.35	7.07e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs302972	0.826	rs79738691	chr6:25148560	A/G	cg26336265	chr6:25042955	NA	1.0	5.56	0.41	1.18e-7	Creatinine levels in ischemic stroke;
PAAD	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26926768	chr12:34528122	NA	0.4	4.85	0.37	3.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg14393609	chr7:65229607	NA	0.46	4.89	0.37	2.53e-6	Aortic root size;
PAAD	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs12935418	0.616	rs2549857	chr16:81026958	A/G	cg16651780	chr16:81037892	C16orf61	0.65	6.09	0.44	8.7e-9	Mean corpuscular volume;
PAAD	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg20406979	chr6:167373233	NA	0.34	4.52	0.34	1.25e-5	Crohn's disease;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg16506815	chr2:162101123	NA	0.6	6.46	0.46	1.36e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.47	4.44	0.34	1.7e-5	Renal cell carcinoma;
PAAD	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.76	7.61	0.53	2.7e-12	Alzheimer's disease (late onset);
PAAD	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.87	-10.67	-0.65	3.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs743757	1.000	rs762898	chr3:50480863	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.67	4.53	0.34	1.18e-5	Diastolic blood pressure;
PAAD	cis	rs62025270	0.631	rs55968154	chr15:86268630	G/A	cg13263323	chr15:86062960	AKAP13	0.5	4.39	0.34	2.08e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-4.89	-0.37	2.56e-6	Intelligence;
PAAD	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.57	6.75	0.48	2.93e-10	Total body bone mineral density;
PAAD	cis	rs1982963	0.572	rs61971549	chr14:52478541	A/G	cg20550154	chr14:52487779	NID2	0.61	5.0	0.38	1.6e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg14343924	chr8:8086146	FLJ10661	-0.66	-6.01	-0.44	1.31e-8	Mood instability;
PAAD	cis	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg04809787	chr17:7348339	CHRNB1	0.39	4.37	0.33	2.29e-5	Height;
PAAD	cis	rs2242116	0.501	rs936184	chr3:46938247	A/C	cg02527881	chr3:46936655	PTH1R	-0.61	-6.31	-0.46	2.92e-9	Birth weight;
PAAD	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg01090926	chr14:75137805	KIAA0317	0.53	4.73	0.36	5.15e-6	Non-small cell lung cancer;
PAAD	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.85	10.9	0.66	8.25e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7246865	0.510	rs7253742	chr19:17171689	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.57	-5.77	-0.42	4.34e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.35	-0.51	1.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg15017067	chr4:17643749	FAM184B	0.41	4.86	0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.6	-6.65	-0.47	5.07e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.93	10.05	0.63	1.57e-18	Blood metabolite levels;
PAAD	trans	rs901683	0.850	rs73291121	chr10:46097404	A/G	cg07567308	chr20:3149320	ProSAPiP1	0.74	6.5	0.47	1.09e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25057861	chr10:72142518	LRRC20	0.61	6.85	0.49	1.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.77	-5.26	-0.39	4.84e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1619661	0.530	rs1509929	chr10:44682829	A/C	cg09554077	chr10:44749378	NA	0.32	4.76	0.36	4.39e-6	QT interval (ambient particulate matter interaction);
PAAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg10932868	chr11:921992	NA	0.45	4.78	0.36	4.14e-6	Alzheimer's disease (late onset);
PAAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg19630374	chr17:18023558	MYO15A	-0.53	-5.55	-0.41	1.22e-7	Total body bone mineral density;
PAAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg04738700	chr2:239367308	NA	0.41	4.43	0.34	1.82e-5	Multiple system atrophy;
PAAD	cis	rs2278796	0.639	rs12139426	chr1:204970708	A/G	cg17947172	chr1:204966197	NFASC	-0.43	-4.7	-0.36	5.86e-6	Mean platelet volume;
PAAD	cis	rs3736485	0.966	rs6493513	chr15:51910174	G/A	cg19558802	chr15:51695713	GLDN	-0.44	-4.37	-0.33	2.32e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg08501292	chr6:25962987	TRIM38	0.98	5.32	0.4	3.59e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.69	0.36	6.07e-6	Menopause (age at onset);
PAAD	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg01489032	chr8:143877656	NA	-0.46	-5.3	-0.39	4.03e-7	Urinary tract infection frequency;
PAAD	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.64	6.12	0.44	7.43e-9	Corneal astigmatism;
PAAD	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg09760422	chr2:128146352	NA	0.32	5.33	0.4	3.51e-7	Protein C levels;
PAAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.88	-7.79	-0.53	9.84e-13	Coronary artery disease;
PAAD	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.47	-4.8	-0.36	3.69e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.61	-5.91	-0.43	2.13e-8	Diastolic blood pressure;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.83	-7.97	-0.54	3.49e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.87	-0.37	2.82e-6	Recombination rate (females);
PAAD	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg20487152	chr13:99095054	FARP1	0.58	4.91	0.37	2.34e-6	Neuroticism;
PAAD	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.95	-7.7	-0.53	1.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg09526685	chr4:187126073	CYP4V2	-0.64	-5.17	-0.39	7.31e-7	Blood protein levels;
PAAD	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg21479132	chr6:26055353	NA	0.99	6.01	0.44	1.31e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	6.38	0.46	2.05e-9	Initial pursuit acceleration;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg11802864	chr11:65308245	LTBP3	1.35	6.8	0.48	2.3e-10	Height;
PAAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.91	4.73	0.36	5.1e-6	Plasma clusterin levels;
PAAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.56	-0.52	3.46e-12	Triglycerides;
PAAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.8	7.11	0.5	4.23e-11	Obesity-related traits;
PAAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.79	-9.64	-0.62	1.91e-17	Height;
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.51	-4.97	-0.37	1.75e-6	Facial morphology (factor 20);
PAAD	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs17496827	0.727	rs7581707	chr2:223360730	C/T	cg25565276	chr2:223520875	FARSB	0.42	4.44	0.34	1.71e-5	Anorexia nervosa;
PAAD	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg13919466	chr1:32135498	COL16A1	0.4	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.54	-6.97	-0.49	8.98e-11	Renal cell carcinoma;
PAAD	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg26554054	chr8:600488	NA	0.91	6.0	0.44	1.4e-8	IgG glycosylation;
PAAD	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.82	-0.36	3.43e-6	Daytime sleep phenotypes;
PAAD	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.33	-0.46	2.66e-9	Exhaled nitric oxide output;
PAAD	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg01969543	chr11:61895209	INCENP	0.52	4.61	0.35	8.63e-6	Breast cancer;
PAAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.86	9.78	0.62	7.78e-18	Cognitive function;
PAAD	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	5.08	0.38	1.08e-6	Platelet count;
PAAD	cis	rs2061333	0.557	rs10420143	chr19:44608082	A/G	cg18700516	chr19:44507157	ZNF230	-0.84	-5.69	-0.42	6.23e-8	Alzheimer's disease;
PAAD	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs500891	0.553	rs1112483	chr6:84112033	G/A	cg08257003	chr6:84140564	ME1	0.35	4.27	0.33	3.47e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.54	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg08125733	chr17:73851984	WBP2	0.91	8.0	0.54	2.89e-13	Psoriasis;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg20169779	chr10:135381914	SYCE1	-0.44	-4.75	-0.36	4.67e-6	Obesity-related traits;
PAAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.73	-0.42	5.28e-8	Personality dimensions;
PAAD	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg26248373	chr2:1572462	NA	-1.09	-7.65	-0.53	2.13e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs56145559	1	rs56145559	chr2:73623439	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-4.32	-0.33	2.79e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg07150166	chr2:30669952	LCLAT1	0.78	5.58	0.41	1.08e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg05084668	chr3:125655381	ALG1L	-0.53	-5.45	-0.4	1.98e-7	Blood pressure (smoking interaction);
PAAD	trans	rs901683	0.702	rs75758972	chr10:46081598	C/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.78	0.48	2.46e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.98	-12.66	-0.72	1.55e-25	Coronary artery disease;
PAAD	cis	rs2211560	0.762	rs10493297	chr1:61291122	C/A	cg00575674	chr1:61314297	NA	-0.51	-4.55	-0.35	1.11e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.73	-9.23	-0.6	2.2e-16	Dupuytren's disease;
PAAD	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg09168692	chr1:7887560	PER3	-0.43	-4.4	-0.34	2.05e-5	Inflammatory bowel disease;
PAAD	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg05562828	chr17:3906858	NA	-0.5	-5.25	-0.39	5.14e-7	Type 2 diabetes;
PAAD	cis	rs13242816	0.892	rs34645128	chr7:116078382	T/A	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.6	-7.94	-0.54	4.24e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-8.14	-0.55	1.31e-13	Schizophrenia;
PAAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-6.62	-0.47	5.73e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.16	-0.39	7.61e-7	Menarche (age at onset);
PAAD	cis	rs7792596	1.000	rs2027983	chr7:94004513	A/T	cg20814616	chr7:94014465	NA	-0.44	-4.5	-0.34	1.37e-5	Intelligence;
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg16926213	chr1:1841314	NA	-0.39	-4.92	-0.37	2.23e-6	Body mass index;
PAAD	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg09476006	chr5:138032270	NA	0.38	4.88	0.37	2.66e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.6	8.19	0.55	9.87e-14	Eye color traits;
PAAD	trans	rs71557345	1	rs71557345	chr6:26680698	G/A	cg06606381	chr12:133084897	FBRSL1	-1.21	-6.53	-0.47	9.41e-10	Breast cancer;
PAAD	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.67	-7.47	-0.52	5.86e-12	Menopause (age at onset);
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs939584	1.000	rs7588007	chr2:631255	T/C	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	1.03	6.3	0.46	2.99e-9	Axial length;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.49	-4.38	-0.34	2.16e-5	Menarche (age at onset);
PAAD	cis	rs340029	1.000	rs340005	chr15:60878030	G/A	cg00200653	chr15:60883225	RORA	0.53	4.96	0.37	1.85e-6	C-reactive protein levels;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.61	6.71	0.48	3.61e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.53	5.55	0.41	1.26e-7	Red blood cell count;
PAAD	cis	rs6867913	0.556	rs6580218	chr5:141463497	A/G	cg23435118	chr5:141488016	NDFIP1	0.5	4.26	0.33	3.57e-5	Asthma;
PAAD	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.88	9.22	0.6	2.37e-16	Prostate cancer;
PAAD	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.42	4.59	0.35	9.29e-6	Platelet count;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23708337	chr7:1209742	NA	0.45	4.91	0.37	2.28e-6	Longevity;Endometriosis;
PAAD	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.96	0.37	1.91e-6	Lung cancer in ever smokers;
PAAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.38	4.25	0.33	3.71e-5	Melanoma;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.49	-4.91	-0.37	2.32e-6	Testicular germ cell tumor;
PAAD	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg00700412	chr12:58011837	NA	0.46	4.85	0.37	2.98e-6	Multiple sclerosis;
PAAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.38	4.44	0.34	1.74e-5	Fat distribution (HIV);
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12121587	chr11:66025327	KLC2	0.56	6.52	0.47	9.68e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4740619	0.588	rs1328278	chr9:16030535	G/A	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16417436	chr16:28758564	NA	0.47	4.35	0.33	2.46e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.37	-0.51	1.03e-11	Chronic sinus infection;
PAAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10267417	0.603	rs10281428	chr7:19857374	G/A	cg05791153	chr7:19748676	TWISTNB	0.79	5.02	0.38	1.44e-6	Night sleep phenotypes;
PAAD	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.49	4.52	0.34	1.21e-5	Neutrophil percentage of white cells;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg17644870	chr7:36407243	KIAA0895	-0.64	-6.45	-0.46	1.44e-9	Dental caries;
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg16362232	chr11:430036	ANO9	0.81	5.03	0.38	1.37e-6	Body mass index;
PAAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.78	-8.5	-0.57	1.61e-14	DNA methylation (variation);
PAAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-4.84	-0.37	3.13e-6	Gut microbiome composition (summer);
PAAD	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.28	0.33	3.29e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.35	-0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1559088	0.512	rs36085438	chr19:33562145	G/A	cg27124370	chr19:33622961	WDR88	0.54	4.36	0.33	2.38e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.01	-0.59	8.17e-16	Calcium levels;
PAAD	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.68	10.35	0.64	2.46e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs11892454	0.515	rs3731638	chr2:26046845	T/C	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.82	-0.43	3.37e-8	Lung cancer;
PAAD	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.14	0.38	8.3e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.8	-0.36	3.8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08677398	chr8:58056175	NA	0.66	4.65	0.35	7.25e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549260	0.753	rs4943794	chr13:41173408	G/C	cg21288729	chr13:41239152	FOXO1	0.6	4.95	0.37	1.93e-6	Red blood cell count;
PAAD	cis	rs6801605	0.894	rs6445608	chr3:53877233	G/C	cg15798837	chr3:54122146	NA	0.34	4.41	0.34	1.96e-5	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12595990	chr12:49351331	ARF3	0.64	6.95	0.49	9.83e-11	Myopia (pathological);
PAAD	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.56	-7.05	-0.5	5.8e-11	Atrioventricular conduction;
PAAD	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-1.03	-7.33	-0.51	1.28e-11	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs1359582	0.801	rs2576167	chr10:90345671	A/C	cg15661332	chr10:90342814	RNLS	0.53	4.6	0.35	8.73e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.73	-8.41	-0.56	2.82e-14	Total body bone mineral density;
PAAD	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.59	-0.41	1.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.53	4.93	0.37	2.12e-6	Red blood cell count;
PAAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg09421083	chr10:134358535	INPP5A	-0.51	-4.52	-0.34	1.26e-5	Primary sclerosing cholangitis;
PAAD	cis	rs7816613	0.850	rs16868132	chr8:102662195	C/G	cg20585841	chr8:102729926	NCALD	-0.57	-4.97	-0.37	1.8e-6	Age-related hearing impairment;
PAAD	cis	rs9857275	0.527	rs9837202	chr3:141187097	A/G	cg25967872	chr3:141205623	RASA2	0.5	4.4	0.34	2.04e-5	Prion diseases;
PAAD	cis	rs501120	0.657	rs1619661	chr10:44733383	T/C	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.52	0.57	1.47e-14	Colorectal cancer;
PAAD	trans	rs901683	0.850	rs79319916	chr10:46073980	C/T	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-1.17	-9.63	-0.62	2e-17	Obesity-related traits;
PAAD	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg05535760	chr7:792225	HEATR2	-0.93	-7.63	-0.53	2.4e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.91	-9.85	-0.62	5.3e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.64	0.35	7.54e-6	Breast cancer;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.2	9.77	0.62	8.69e-18	Corneal structure;
PAAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.61	-6.23	-0.45	4.46e-9	Red blood cell count;
PAAD	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.63	6.57	0.47	7.58e-10	Crohn's disease;
PAAD	cis	rs11264799	0.520	rs2777965	chr1:157550417	A/C	cg18268488	chr1:157545234	FCRL4	0.56	6.39	0.46	1.93e-9	IgA nephropathy;
PAAD	cis	rs73019876	0.901	rs507994	chr19:22233059	G/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	1.99e-5	Testicular germ cell tumor;
PAAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.35	-0.33	2.5e-5	Life satisfaction;
PAAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.79	9.19	0.6	2.7e-16	Diastolic blood pressure;
PAAD	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.4	-0.4	2.53e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18683875	chr3:49977380	RBM6	-0.79	-7.19	-0.5	2.68e-11	Neuroticism;
PAAD	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.2e-5	Life satisfaction;
PAAD	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.1	0.59	4.65e-16	Post bronchodilator FEV1;
PAAD	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	5.96	0.44	1.7e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02725872	chr8:58115012	NA	-0.76	-6.04	-0.44	1.13e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs6694672	0.702	rs6685259	chr1:197093098	A/T	cg26994526	chr18:47719735	MYO5B	-0.93	-6.6	-0.47	6.57e-10	Asthma;
PAAD	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg04374321	chr14:90722782	PSMC1	0.53	4.37	0.33	2.33e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs877426	0.681	rs56352545	chr13:114839620	A/G	cg00571178	chr13:114841904	RASA3	-0.55	-4.62	-0.35	8.02e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.55	5.91	0.43	2.13e-8	Menopause (age at onset);
PAAD	cis	rs6604026	0.698	rs2492294	chr1:93346566	C/G	cg13858687	chr1:93297071	RPL5	-0.48	-4.4	-0.34	2e-5	Multiple sclerosis;
PAAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg21951975	chr1:209979733	IRF6	0.43	5.37	0.4	2.87e-7	Monobrow;
PAAD	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01616529	chr11:638424	DRD4	-0.59	-5.79	-0.43	3.82e-8	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg27396498	chr16:55794478	CES4	0.69	5.45	0.4	2e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	4.95e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12986413	0.846	rs12609327	chr19:2183000	A/C	cg09261902	chr19:2140048	AP3D1	0.45	4.47	0.34	1.53e-5	Height;
PAAD	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.87	8.75	0.58	3.71e-15	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00605358	chr12:89747739	DUSP6	0.66	7.35	0.51	1.13e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	4.79	0.36	3.97e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08567021	chr5:16701387	MYO10	0.55	6.35	0.46	2.4e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6681460	0.932	rs523956	chr1:67188276	A/G	cg02459107	chr1:67143332	SGIP1	-0.7	-6.5	-0.47	1.11e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg22437258	chr11:111473054	SIK2	-0.59	-5.65	-0.42	7.51e-8	Primary sclerosing cholangitis;
PAAD	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	4.64	0.35	7.53e-6	Height;
PAAD	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.48	4.67	0.35	6.48e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.43	-0.4	2.19e-7	Heart rate;
PAAD	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.6	6.09	0.44	8.72e-9	Menopause (age at onset);
PAAD	cis	rs8077577	0.633	rs12939851	chr17:18131585	T/A	cg16794390	chr17:18148240	FLII	-0.59	-5.18	-0.39	6.98e-7	Obesity-related traits;
PAAD	cis	rs6088813	0.961	rs2425062	chr20:33923566	A/G	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg23024343	chr7:107201750	COG5	0.54	4.33	0.33	2.72e-5	Osteoarthritis;
PAAD	cis	rs8060686	0.844	rs73597581	chr16:67682234	G/A	cg05110241	chr16:68378359	PRMT7	-0.98	-5.02	-0.38	1.46e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.59	-6.55	-0.47	8.29e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2882667	0.690	rs12186373	chr5:138248574	T/A	cg09476006	chr5:138032270	NA	0.44	5.45	0.4	2.01e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.62	6.13	0.45	7.1e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg05315796	chr3:52349193	DNAH1	0.41	4.41	0.34	1.96e-5	Bipolar disorder;
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.72	-6.39	-0.46	1.91e-9	Obesity-related traits;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.07	-0.38	1.14e-6	Mood instability;
PAAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg12645284	chr15:79092878	ADAMTS7	0.49	4.25	0.33	3.67e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg00750074	chr16:89608354	SPG7	-0.5	-4.43	-0.34	1.82e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg23463467	chr20:60627584	TAF4	0.4	4.34	0.33	2.62e-5	Body mass index;
PAAD	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg08079166	chr15:68083412	MAP2K5	0.59	4.48	0.34	1.46e-5	Obesity;
PAAD	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.6	5.6	0.41	9.84e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08550205	chr17:45786854	TBKBP1	-0.4	-4.52	-0.34	1.22e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.64	-7.0	-0.49	7.78e-11	Testicular germ cell tumor;
PAAD	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09672890	chr17:70536484	NA	0.6	6.99	0.49	8.12e-11	Metabolite levels  (X-11787);
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.52	0.34	1.21e-5	Body mass index;
PAAD	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	5.23	0.39	5.53e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.89	9.98	0.63	2.35e-18	Breast cancer;
PAAD	cis	rs2659067	0.527	rs2659065	chr19:51484553	G/A	cg19471655	chr19:51487109	KLK7	-0.89	-4.91	-0.37	2.28e-6	Blood protein levels;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg00738919	chr7:1100172	C7orf50	0.53	4.42	0.34	1.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-1.21	-13.84	-0.75	1.08e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.41e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.6	-6.67	-0.48	4.5e-10	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.93	-10.39	-0.64	1.9e-19	Testicular germ cell tumor;
PAAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.61	-5.18	-0.39	7e-7	Coronary artery disease;
PAAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.95	-9.09	-0.59	4.91e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10450586	0.932	rs10742174	chr11:27332291	A/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg02743256	chr7:2109353	MAD1L1	-0.62	-4.73	-0.36	5.01e-6	Bipolar disorder;
PAAD	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg14092988	chr3:52407081	DNAH1	0.39	4.81	0.36	3.53e-6	Electroencephalogram traits;
PAAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.55	6.87	0.49	1.53e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.82	-7.95	-0.54	3.82e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg22827986	chr11:48284249	OR4X1	0.42	5.34	0.4	3.29e-7	Migraine - clinic-based;
PAAD	trans	rs901683	1.000	rs71496611	chr10:46021732	G/A	cg23720331	chr10:123873670	TACC2	-0.84	-6.5	-0.47	1.1e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.5	-4.72	-0.36	5.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.82	-0.43	3.43e-8	Primary biliary cholangitis;
PAAD	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.98	12.01	0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	6.7	0.48	3.82e-10	Retinal vascular caliber;
PAAD	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21782712	chr6:33257137	WDR46;PFDN6	0.6	6.38	0.46	1.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11159086	0.793	rs10148268	chr14:74950964	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.14	-0.38	8.25e-7	Advanced glycation end-product levels;
PAAD	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.62	-5.66	-0.42	7.38e-8	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs4986811	0.500	rs72893553	chr11:32462695	C/A	cg16078836	chr3:185081374	MAP3K13	-0.95	-6.51	-0.47	1.03e-9	Rubella-specific interleukin-6 secretion;
PAAD	cis	rs3106136	0.618	rs6853674	chr4:95309190	T/C	cg11021082	chr4:95130006	SMARCAD1	0.54	5.09	0.38	1.07e-6	Capecitabine sensitivity;
PAAD	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg02574844	chr11:5959923	NA	-0.66	-6.39	-0.46	1.89e-9	DNA methylation (variation);
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7631605	0.905	rs748766	chr3:37082874	A/G	cg17445812	chr3:36986805	TRANK1	0.35	4.67	0.35	6.47e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-7.63	-0.53	2.36e-12	Response to antipsychotic treatment;
PAAD	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.85	-4.65	-0.35	7.26e-6	Toenail selenium levels;
PAAD	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.51	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.59	-0.82	1.73e-38	Height;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2340727	0.668	rs10494357	chr1:161788348	G/T	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg07469887	chr10:131262384	NA	-0.43	-4.96	-0.37	1.89e-6	Response to temozolomide;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14348828	chr7:142985245	CASP2	-0.81	-7.03	-0.5	6.49e-11	Neuroticism;
PAAD	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg14952266	chr13:112191215	NA	0.48	5.54	0.41	1.27e-7	Hepatitis;
PAAD	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.82	7.9	0.54	5.24e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.24e-7	Multiple sclerosis;
PAAD	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.57	4.26	0.33	3.57e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20584918	chr3:196295759	WDR53;FBXO45	-0.65	-6.47	-0.46	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08887952	chr4:16257948	FLJ39653	-0.62	-6.89	-0.49	1.43e-10	Myopia (pathological);
PAAD	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.77	-0.36	4.2e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs66530629	0.917	rs11249177	chr1:25171088	A/G	cg22509179	chr1:25234806	RUNX3	0.48	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00831633	chr12:34174976	ALG10	-0.59	-6.7	-0.48	3.79e-10	Body fat percentage;
PAAD	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-5.81	-0.43	3.48e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg26695010	chr11:65641043	EFEMP2	-0.57	-5.47	-0.41	1.79e-7	Eosinophil percentage of white cells;
PAAD	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg14092571	chr14:90743983	NA	-0.52	-5.07	-0.38	1.16e-6	Mortality in heart failure;
PAAD	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.55	-4.99	-0.38	1.61e-6	White blood cell count;
PAAD	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg08823186	chr16:347294	AXIN1	0.45	4.3	0.33	2.99e-5	Morning vs. evening chronotype;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg14092988	chr3:52407081	DNAH1	0.41	5.16	0.39	7.45e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.58	-0.52	3.09e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs2455826	0.521	rs11128763	chr3:15898390	C/G	cg13420985	chr3:16524424	RFTN1	-0.46	-4.37	-0.33	2.33e-5	Inflammatory skin disease;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.41e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.84	8.18	0.55	1.06e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.28	0.39	4.39e-7	Colorectal cancer;
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg26513180	chr16:89883248	FANCA	0.63	7.4	0.51	8.43e-12	Vitiligo;
PAAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.71	-0.48	3.59e-10	Retinal vascular caliber;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02359409	chr6:42947317	PEX6	-0.48	-4.71	-0.36	5.48e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6762644	0.507	rs9311400	chr3:4764171	A/G	cg11584376	chr3:4789075	ITPR1	-0.41	-4.62	-0.35	8.07e-6	Breast cancer;
PAAD	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.44	-5.05	-0.38	1.28e-6	Blood pressure (smoking interaction);
PAAD	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.13	-0.55	1.44e-13	Hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04598251	chr12:132628980	NOC4L;DDX51	0.73	7.31	0.51	1.38e-11	Obesity-related traits;
PAAD	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg10356904	chr22:49881777	NA	-0.46	-4.97	-0.37	1.77e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.71e-15	Dupuytren's disease;
PAAD	cis	rs9287719	0.624	rs10187659	chr2:10726960	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.77	0.36	4.21e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6688613	1.000	rs7554962	chr1:166956297	C/T	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg19949948	chr17:19361230	NA	0.46	4.52	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.58	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs2721811	0.782	rs874540	chr7:24758161	A/G	cg17569154	chr7:24781545	DFNA5	0.46	4.76	0.36	4.5e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg27396498	chr16:55794478	CES4	0.69	5.46	0.4	1.92e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg10356904	chr22:49881777	NA	-0.47	-4.76	-0.36	4.48e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9657904	0.738	rs4894954	chr3:105532497	C/T	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg09796270	chr17:17721594	SREBF1	0.39	4.3	0.33	3.04e-5	Total body bone mineral density;
PAAD	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.94	-5.89	-0.43	2.35e-8	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs28795989	0.795	rs4696779	chr4:7919375	T/C	cg18538662	chr4:7941764	AFAP1	0.43	4.51	0.34	1.27e-5	Intraocular pressure;
PAAD	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.64	0.42	8.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs35123781	0.518	rs72790986	chr5:138973081	A/G	cg11459648	chr5:138714337	SLC23A1	-0.59	-5.06	-0.38	1.21e-6	Schizophrenia;
PAAD	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.61	-5.96	-0.44	1.71e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-0.98	-5.03	-0.38	1.39e-6	Stem cell growth factor beta levels;
PAAD	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg10587741	chr22:38071170	LGALS1	0.46	5.06	0.38	1.21e-6	Fat distribution (HIV);
PAAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.6	5.95	0.43	1.79e-8	Blood metabolite levels;
PAAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-6.69	-0.48	4.08e-10	Colorectal cancer;
PAAD	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.25	-0.33	3.78e-5	Body mass index;
PAAD	cis	rs6604026	0.740	rs7536563	chr1:93349046	A/G	cg13858687	chr1:93297071	RPL5	-0.48	-4.3	-0.33	3.06e-5	Multiple sclerosis;
PAAD	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.02	-0.49	7.06e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3112530	0.818	rs10073797	chr5:152715445	C/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg16083429	chr3:49237500	CCDC36	0.45	4.41	0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.49	-0.52	5.36e-12	Neuroticism;
PAAD	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.58e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35740288	0.770	rs35447727	chr15:86174399	C/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.41	5.68	0.42	6.68e-8	Alcohol dependence;
PAAD	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-4.46	-0.34	1.56e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.58	4.87	0.37	2.8e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.76	-6.84	-0.48	1.85e-10	Schizophrenia;
PAAD	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-4.45	-0.34	1.68e-5	Plateletcrit;
PAAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	5.16	0.39	7.55e-7	Schizophrenia;
PAAD	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.58	-5.71	-0.42	5.75e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg25566285	chr7:158114605	PTPRN2	0.85	8.84	0.58	2.2e-15	Calcium levels;
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg17105886	chr17:28927953	LRRC37B2	0.88	5.39	0.4	2.68e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.82	8.65	0.57	6.98e-15	Uric acid levels;
PAAD	cis	rs6537837	1.000	rs3768486	chr1:110123971	A/G	cg05049280	chr1:110155535	GNAT2	0.46	4.61	0.35	8.43e-6	Major depressive disorder;
PAAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg10193763	chr2:225306901	NA	0.55	4.75	0.36	4.74e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs490234	0.783	rs937481	chr9:128194443	C/G	cg14078157	chr9:128172775	NA	-0.46	-5.11	-0.38	9.44e-7	Mean arterial pressure;
PAAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	4.97	0.37	1.79e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs59888335	0.964	rs12633023	chr3:80779148	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-7.46	-0.52	6.31e-12	Primary sclerosing cholangitis;
PAAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Birth weight;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg00738919	chr7:1100172	C7orf50	0.51	4.28	0.33	3.36e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66530629	0.837	rs4306080	chr1:25135004	C/T	cg22509179	chr1:25234806	RUNX3	0.51	4.73	0.36	5.11e-6	Plateletcrit;
PAAD	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.02e-11	Corneal astigmatism;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.74	-7.44	-0.52	6.9e-12	Menopause (age at onset);
PAAD	cis	rs6460942	0.597	rs13232817	chr7:12551909	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-4.71	-0.36	5.59e-6	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg14926445	chr8:58193284	C8orf71	-0.65	-5.3	-0.39	4.01e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.34	-0.33	2.56e-5	Cystic fibrosis severity;
PAAD	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.38	-0.34	2.17e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg18128536	chr17:47092178	IGF2BP1	0.47	5.44	0.4	2.1e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.44	-4.92	-0.37	2.23e-6	Mean arterial pressure;
PAAD	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg27234864	chr13:21295941	IL17D	0.6	5.19	0.39	6.74e-7	Dental caries;
PAAD	cis	rs1797885	0.738	rs2264371	chr3:12562413	C/T	cg07775309	chr3:12595852	NA	0.4	4.39	0.34	2.12e-5	Immature fraction of reticulocytes;
PAAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg05643964	chr20:62369504	LIME1	-0.5	-4.61	-0.35	8.44e-6	Prostate cancer;
PAAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.56	5.43	0.4	2.21e-7	Aortic root size;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg03894339	chr8:19674705	INTS10	0.6	5.43	0.4	2.15e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.49	-8.12	-0.55	1.51e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.87	6.43	0.46	1.54e-9	Alzheimer's disease;
PAAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.67	-0.35	6.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-1.2	-9.84	-0.62	5.59e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs3736485	0.932	rs2124879	chr15:51916833	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.35	-0.33	2.52e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs72960926	0.744	rs56020332	chr6:75030022	C/G	cg03266952	chr6:74778945	NA	-1.14	-6.41	-0.46	1.74e-9	Metabolite levels (MHPG);
PAAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.95e-6	Coronary artery disease;
PAAD	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.48e-6	Menarche (age at onset);
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.7	-0.36	5.71e-6	Lung cancer;
PAAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.83	0.43	3.21e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.63	8.91	0.59	1.43e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9549328	0.837	rs9549330	chr13:113648404	G/T	cg17524180	chr13:113633600	MCF2L	-0.49	-5.16	-0.39	7.7e-7	Systolic blood pressure;
PAAD	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1376877	0.538	rs12474416	chr2:204226003	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.6	4.91	0.37	2.37e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9913156	0.670	rs7219606	chr17:4561928	T/C	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg20406979	chr6:167373233	NA	0.34	4.49	0.34	1.4e-5	Crohn's disease;
PAAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg27539214	chr16:67997921	SLC12A4	0.58	4.75	0.36	4.7e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg04717802	chr22:42394638	WBP2NL	-0.58	-4.88	-0.37	2.63e-6	Birth weight;
PAAD	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg06287003	chr12:125626642	AACS	0.45	4.5	0.34	1.35e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg18068537	chr15:74660088	CYP11A1	-0.5	-4.47	-0.34	1.54e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs3112530	1.000	rs159978	chr5:152737575	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.58	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg18209359	chr17:80159595	CCDC57	0.43	4.29	0.33	3.22e-5	Life satisfaction;
PAAD	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.64	5.02	0.38	1.45e-6	Blood protein levels;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.73	-7.36	-0.51	1.09e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.42e-5	Resting heart rate;
PAAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02444810	chr17:27055702	NEK8	-0.76	-6.75	-0.48	3e-10	Neuroticism;
PAAD	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg10595753	chr17:80898281	TBCD	0.5	4.55	0.35	1.11e-5	Glycated hemoglobin levels;
PAAD	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg09659197	chr4:152720779	NA	-0.47	-6.32	-0.46	2.75e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22633769	chr20:60982531	CABLES2	0.51	4.66	0.35	6.9e-6	Colorectal cancer;
PAAD	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-7.24	-0.51	2.06e-11	Morning vs. evening chronotype;
PAAD	cis	rs7274811	0.744	rs6119395	chr20:32244711	G/T	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.54	5.97	0.44	1.6e-8	Mean corpuscular volume;
PAAD	cis	rs2798269	0.763	rs4769169	chr13:22171158	A/G	cg17543804	chr13:22179073	EFHA1	0.53	5.01	0.38	1.48e-6	PR segment;
PAAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.61	5.86	0.43	2.74e-8	Refractive astigmatism;
PAAD	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	6.02	0.44	1.25e-8	Platelet count;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.62	5.25	0.39	4.97e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	6.13	0.45	7.06e-9	Cognitive test performance;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.8	9.7	0.62	1.33e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.43	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg06115741	chr20:33292138	TP53INP2	0.58	4.94	0.37	2.05e-6	Skin pigmentation;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.34	0.56	4.28e-14	Prudent dietary pattern;
PAAD	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.8	-8.95	-0.59	1.13e-15	Idiopathic membranous nephropathy;
PAAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.63	-8.47	-0.57	1.94e-14	Renal cell carcinoma;
PAAD	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7714584	1.000	rs59043558	chr5:150334662	T/C	cg22134413	chr5:150180641	NA	0.76	5.22	0.39	5.84e-7	Crohn's disease;
PAAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	1.24	11.34	0.68	5.51e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs2479106	0.892	rs2479102	chr9:126683955	T/C	cg16191174	chr9:126692580	DENND1A	0.5	4.47	0.34	1.52e-5	Polycystic ovary syndrome;
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.07e-6	Testicular germ cell tumor;
PAAD	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.35	0.33	2.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg01851573	chr8:8652454	MFHAS1	-0.47	-4.76	-0.36	4.38e-6	Parkinson's disease;
PAAD	cis	rs2030114	0.948	rs56183762	chr16:51607640	G/T	cg03758633	chr16:51611768	NA	0.6	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09103073	chr17:39019724	KRT12	-0.72	-7.36	-0.51	1.1e-11	Obesity-related traits;
PAAD	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.72	6.9	0.49	1.33e-10	Obesity-related traits;
PAAD	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	5.04e-14	Prudent dietary pattern;
PAAD	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.52	-4.65	-0.35	7.23e-6	Triglycerides;
PAAD	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg04851639	chr8:1020857	NA	-0.62	-7.79	-0.53	9.55e-13	Schizophrenia;
PAAD	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	1.23	13.55	0.74	6.26e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs62264129	0.500	rs56294743	chr3:112028863	G/A	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4450131	0.618	rs7075794	chr10:126338093	A/G	cg20435097	chr10:126320824	FAM53B	0.54	5.83	0.43	3.26e-8	White blood cell count (basophil);
PAAD	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.51	-5.09	-0.38	1.04e-6	Schizophrenia;
PAAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.28	0.6	1.62e-16	Colorectal cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07802900	chr17:80009465	GPS1;RFNG	-0.64	-6.49	-0.47	1.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.54	0.41	1.32e-7	Lung cancer;
PAAD	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	4.27	0.33	3.41e-5	Recombination measurement;
PAAD	cis	rs2120991	0.967	rs7306498	chr12:54259701	A/G	cg23795217	chr12:54812000	ITGA5	0.3	4.31	0.33	2.97e-5	Biliary atresia;
PAAD	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg19567339	chr10:100142640	NA	0.42	4.59	0.35	9.41e-6	Metabolite levels;
PAAD	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.57	6.24	0.45	4.23e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01585852	chr22:24235823	MIF	-0.46	-5.02	-0.38	1.42e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg04810063	chr16:88703634	IL17C	-0.5	-4.42	-0.34	1.83e-5	Menopause (age at onset);
PAAD	cis	rs7127900	0.950	rs6579002	chr11:2232229	A/G	cg25635251	chr11:2234043	NA	0.84	7.36	0.51	1.09e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8070740	0.838	rs57745425	chr17:5327528	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.32	0.33	2.79e-5	Menopause (age at onset);
PAAD	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.6	-5.68	-0.42	6.73e-8	IgG glycosylation;
PAAD	cis	rs3112530	1.000	rs2973149	chr5:152645408	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.62	5.61	0.41	9.18e-8	Mean platelet volume;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.57	-6.31	-0.46	2.96e-9	Systemic lupus erythematosus;
PAAD	cis	rs2073499	1.000	rs57462170	chr3:50239803	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.6	4.68	0.35	6.36e-6	Schizophrenia;
PAAD	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.45	-4.78	-0.36	4.07e-6	Type 2 diabetes;
PAAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.43	5.73	0.42	5.32e-8	Childhood ear infection;
PAAD	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.57	5.68	0.42	6.69e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.89	9.6	0.61	2.38e-17	Cognitive function;
PAAD	cis	rs3126085	0.560	rs11803108	chr1:152344386	G/A	cg26876637	chr1:152193138	HRNR	-0.68	-5.06	-0.38	1.2e-6	Atopic dermatitis;
PAAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.7	7.4	0.51	8.72e-12	IgG glycosylation;
PAAD	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg20856181	chr7:2632371	IQCE	-0.57	-4.36	-0.33	2.39e-5	Multiple sclerosis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00419759	chr1:114301964	PHTF1	0.58	6.62	0.47	5.78e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg23283495	chr1:209979779	IRF6	0.77	7.06	0.5	5.58e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg07153921	chr17:41440717	NA	-0.42	-4.44	-0.34	1.69e-5	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.62	8.18	0.55	1.07e-13	Renal cell carcinoma;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.62	-6.59	-0.47	6.69e-10	Dementia with Lewy bodies;
PAAD	cis	rs1912528	0.778	rs769656	chr4:140878643	T/C	cg11128457	chr4:140864437	MAML3	-0.34	-4.44	-0.34	1.7e-5	Educational attainment (years of education);
PAAD	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg11673840	chr17:47092156	IGF2BP1	-0.41	-4.62	-0.35	8.11e-6	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs10508895	chr10:45967768	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23158103	chr7:148848205	ZNF398	-0.52	-4.79	-0.36	3.95e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg02543470	chr2:105862877	NA	0.48	5.32	0.4	3.7e-7	AIDS;
PAAD	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg24747557	chr10:131355152	MGMT	-0.45	-4.9	-0.37	2.45e-6	Response to temozolomide;
PAAD	cis	rs71520386	0.634	rs13240023	chr7:22867493	C/A	cg04907244	chr7:22894795	SNORD93	0.51	5.53	0.41	1.36e-7	Fibrinogen levels;
PAAD	cis	rs7771547	0.723	rs9366908	chr6:36550488	G/A	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg21130718	chr4:1044621	NA	0.47	4.53	0.34	1.21e-5	Recombination rate (males);
PAAD	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg23995914	chr4:10459228	ZNF518B	-0.36	-4.37	-0.33	2.27e-5	Schizophrenia (age at onset);
PAAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.72	-7.62	-0.53	2.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs4950322	0.570	rs17360443	chr1:146751410	G/T	cg22381352	chr1:146742008	CHD1L	-0.49	-4.32	-0.33	2.8e-5	Protein quantitative trait loci;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.8	8.41	0.56	2.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.6	-0.52	2.88e-12	Mosquito bite size;
PAAD	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.86	-0.43	2.79e-8	Eye color traits;
PAAD	cis	rs6908034	0.660	rs12525506	chr6:19794234	G/T	cg02682789	chr6:19804855	NA	0.81	4.49	0.34	1.42e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	5.19	0.39	6.69e-7	Educational attainment;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18621852	chr3:10150065	C3orf24	0.7	5.93	0.43	1.99e-8	Alzheimer's disease;
PAAD	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg04450456	chr4:17643702	FAM184B	0.54	5.47	0.41	1.82e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.48	-5.07	-0.38	1.17e-6	Plateletcrit;
PAAD	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg21918786	chr6:109611834	NA	0.44	4.86	0.37	2.89e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.44	-4.52	-0.34	1.23e-5	Platelet distribution width;
PAAD	cis	rs66530629	0.917	rs6665083	chr1:25148291	G/T	cg01905478	chr1:25040257	NA	-0.48	-5.24	-0.39	5.38e-7	Plateletcrit;
PAAD	cis	rs630539	0.744	rs7218635	chr17:40828206	T/C	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs136211	0.965	rs933224	chr22:36766003	A/G	cg11153328	chr22:36877737	TXN2	-0.5	-4.58	-0.35	9.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs12304921	1.000	rs224446	chr12:51381718	A/G	cg18059802	chr12:51347058	HIGD1C	0.65	5.23	0.39	5.64e-7	Type 2 diabetes;
PAAD	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.69	6.01	0.44	1.35e-8	Menarche (age at onset);
PAAD	trans	rs901683	1.000	rs35713143	chr10:46088159	G/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs950881	0.932	rs72823635	chr2:102931612	T/C	cg03938978	chr2:103052716	IL18RAP	0.54	4.39	0.34	2.14e-5	Allergy;
PAAD	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	1.0	9.76	0.62	8.82e-18	Psoriasis;
PAAD	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.78	-0.42	4.17e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1468333	0.704	rs4835675	chr5:137623683	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	5.45	0.4	2e-7	Resting heart rate;
PAAD	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg04811205	chr2:55563533	CCDC88A	-0.48	-4.46	-0.34	1.56e-5	Alcohol dependence;
PAAD	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.83	8.8	0.58	2.75e-15	Schizophrenia;
PAAD	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.46	4.28	0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.79	8.36	0.56	3.61e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.47	4.91	0.37	2.31e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg21832896	chr7:23629908	NA	0.39	4.63	0.35	7.88e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg15193198	chr20:60906057	LAMA5	-0.49	-5.65	-0.42	7.56e-8	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.9	0.63	3.82e-18	Platelet count;
PAAD	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.48	5.15	0.39	7.96e-7	Diastolic blood pressure;
PAAD	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg00024416	chr22:24240387	NA	-0.56	-6.13	-0.45	7.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg23346134	chr3:49453900	TCTA	-0.47	-4.99	-0.38	1.63e-6	Menarche (age at onset);
PAAD	cis	rs375066	0.935	rs399098	chr19:44418824	C/T	cg08633290	chr19:44405433	NA	-0.55	-5.42	-0.4	2.31e-7	Breast cancer;
PAAD	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg01256987	chr12:42539512	GXYLT1	-0.4	-4.6	-0.35	8.68e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2835872	0.861	rs67739865	chr21:39049101	G/A	cg06728970	chr21:39037746	KCNJ6	-0.43	-4.64	-0.35	7.37e-6	Electroencephalographic traits in alcoholism;
PAAD	trans	rs3733631	1.000	rs4141203	chr4:104638435	A/G	cg21490444	chr5:171095097	NA	0.75	6.4	0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg26205652	chr12:48591994	NA	0.46	4.4	0.34	2e-5	Plateletcrit;
PAAD	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.49	4.5	0.34	1.32e-5	Red cell distribution width;
PAAD	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg02459107	chr1:67143332	SGIP1	0.73	7.13	0.5	3.84e-11	Presence of antiphospholipid antibodies;
PAAD	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-8.14	-0.55	1.34e-13	Neuroticism;
PAAD	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	6.42	0.46	1.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs7552393	0.636	rs12135529	chr1:84293113	C/T	cg10977910	chr1:84465055	TTLL7	0.58	5.51	0.41	1.48e-7	Select biomarker traits;
PAAD	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.89	7.41	0.52	8.21e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.87	0.43	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg11764359	chr7:65958608	NA	0.8	5.23	0.39	5.44e-7	Diabetic kidney disease;
PAAD	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg17380795	chr3:122379686	NA	0.52	5.55	0.41	1.27e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.41	-0.52	8.21e-12	Personality dimensions;
PAAD	cis	rs6681460	0.773	rs515944	chr1:67219980	C/A	cg02459107	chr1:67143332	SGIP1	-0.71	-6.57	-0.47	7.54e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.17e-8	Height;
PAAD	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg21918786	chr6:109611834	NA	-0.46	-4.95	-0.37	1.92e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg11416102	chr8:651193	ERICH1	0.82	5.5	0.41	1.56e-7	IgG glycosylation;
PAAD	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.39	-4.34	-0.33	2.57e-5	Prostate cancer;
PAAD	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.8	0.81	1.82e-36	Schizophrenia;
PAAD	cis	rs2000999	0.573	rs34139543	chr16:72158477	C/T	cg00207534	chr16:71929512	KIAA0174	0.72	4.31	0.33	2.92e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-4.42	-0.34	1.88e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12689227	chr10:123970158	TACC2	0.64	7.92	0.54	4.59e-13	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07192240	chr11:3829780	PGAP2	0.6	7.24	0.51	2.08e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg11271282	chr2:238384023	NA	0.52	4.73	0.36	5e-6	Prostate cancer;
PAAD	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4795519	0.557	rs12451105	chr17:22179841	T/A	cg22648282	chr17:21454238	C17orf51	-0.5	-4.62	-0.35	8.1e-6	Chronic myeloid leukemia;
PAAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.6	5.37	0.4	2.86e-7	Retinal vascular caliber;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.3	0.46	3e-9	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22032292	chr6:24876193	FAM65B	-0.63	-7.22	-0.51	2.35e-11	Obesity-related traits;
PAAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.93	-0.43	1.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.87	-10.37	-0.64	2.22e-19	Ulcerative colitis;
PAAD	cis	rs4812048	0.503	rs6070690	chr20:57574816	G/C	cg23907860	chr20:57583709	CTSZ	0.66	4.45	0.34	1.64e-5	Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.58	-6.21	-0.45	4.93e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs76533333	0.646	rs71446625	chr13:113390285	G/T	cg02820901	chr13:113351484	ATP11A	-0.79	-4.69	-0.36	5.98e-6	Red cell distribution width;
PAAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	trans	rs76010824	0.892	rs74429267	chr3:67443246	C/CTT	cg20414749	chr1:205181261	DSTYK	-0.96	-6.84	-0.49	1.8e-10	Prostate cancer (survival);
PAAD	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.8e-10	Response to antipsychotic treatment;
PAAD	cis	rs76793172	0.920	rs77588767	chr19:46326472	G/C	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.74	-8.46	-0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.92	8.11	0.55	1.58e-13	Alzheimer's disease;
PAAD	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg07166546	chr14:35805898	NA	-0.35	-5.22	-0.39	5.88e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.66	7.33	0.51	1.24e-11	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.61	-0.47	5.99e-10	Mood instability;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg02869306	chr7:64672164	INTS4L1	-0.45	-5.16	-0.39	7.52e-7	Calcium levels;
PAAD	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17274428	chr5:157170601	LSM11	0.6	6.98	0.49	8.73e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg13266496	chr6:110720918	DDO	-0.46	-4.93	-0.37	2.11e-6	Platelet distribution width;
PAAD	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg01942863	chr7:99769432	GPC2	0.49	4.61	0.35	8.48e-6	Coronary artery disease;
PAAD	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.57	6.58	0.47	7e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.38	-0.33	2.2e-5	Plateletcrit;
PAAD	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs10850408	1.000	rs10850408	chr12:115380393	C/T	cg05726002	chr12:115341178	NA	-0.4	-4.74	-0.36	4.84e-6	Alzheimer's disease;
PAAD	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.49	-0.47	1.13e-9	Blood metabolite levels;
PAAD	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-6.29	-0.45	3.17e-9	Neuroticism;
PAAD	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.75	5.7	0.42	5.97e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.47	-7.15	-0.5	3.4e-11	Cutaneous nevi;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11620074	chr11:33722319	C11orf91	-0.59	-6.62	-0.47	5.88e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6604026	0.922	rs12750269	chr1:93311661	T/C	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg23172400	chr8:95962367	TP53INP1	-0.44	-4.34	-0.33	2.58e-5	Type 2 diabetes;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg24562669	chr7:97807699	LMTK2	0.44	4.91	0.37	2.31e-6	Breast cancer;
PAAD	cis	rs9398803	0.671	rs1155939	chr6:126866133	C/A	cg19875578	chr6:126661172	C6orf173	0.48	4.94	0.37	2.02e-6	Male-pattern baldness;
PAAD	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.51	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.57	6.56	0.47	8.1e-10	Mean corpuscular volume;
PAAD	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-8.23	-0.56	7.75e-14	Chronic sinus infection;
PAAD	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.52	-5.04	-0.38	1.28e-6	Red blood cell count;
PAAD	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Blood protein levels;
PAAD	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.85	-8.6	-0.57	9.21e-15	Breast cancer;
PAAD	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg06917634	chr15:78832804	PSMA4	-0.47	-4.6	-0.35	8.98e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.64	-6.48	-0.47	1.2e-9	Monocyte count;
PAAD	cis	rs11168618	0.743	rs12815151	chr12:48874836	A/C	cg01881778	chr12:48919444	OR8S1	-0.49	-4.92	-0.37	2.19e-6	Adiponectin levels;
PAAD	cis	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg02356786	chr1:243265016	LOC731275	1.01	6.42	0.46	1.62e-9	Obesity (early onset extreme);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09252528	chr19:42901252	NA	0.61	6.8	0.48	2.29e-10	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg17372657	chr7:1216933	NA	-0.36	-4.63	-0.35	7.86e-6	Longevity;Endometriosis;
PAAD	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.21	-0.39	6.09e-7	Breast cancer;
PAAD	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-7.64	-0.53	2.22e-12	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs9810890	1.000	rs73198899	chr3:128566430	A/G	cg18531004	chr3:128564980	NA	-0.91	-4.89	-0.37	2.51e-6	Dental caries;
PAAD	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.77	8.04	0.55	2.36e-13	Corneal astigmatism;
PAAD	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.71	4.62	0.35	8.28e-6	Major depressive disorder;
PAAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.47	-6.75	-0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.76	-0.36	4.55e-6	Testicular germ cell tumor;
PAAD	cis	rs7082209	0.938	rs11238983	chr10:44810205	C/T	cg13191911	chr10:44806660	NA	-0.93	-5.39	-0.4	2.7e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.1	0.63	1.14e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs6748734	0.779	rs11680800	chr2:241793977	A/G	cg26818257	chr2:241905806	NA	0.41	4.29	0.33	3.2e-5	Urinary metabolites;
PAAD	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg26685658	chr5:74633012	HMGCR	0.5	4.35	0.33	2.44e-5	Age-related disease endophenotypes;
PAAD	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.97	7.07	0.5	5.24e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.7	0.48	3.84e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg08926642	chr1:7887455	PER3	0.5	4.46	0.34	1.57e-5	Inflammatory bowel disease;
PAAD	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.05	-0.38	1.25e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06436655	chr19:9938652	UBL5	0.67	6.96	0.49	9.73e-11	Obesity-related traits;
PAAD	cis	rs9652601	0.779	rs11648679	chr16:11175984	A/G	cg04616529	chr16:11181986	CLEC16A	0.44	5.02	0.38	1.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1497828	0.956	rs2646829	chr1:217542801	T/C	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.48	5.13	0.38	8.59e-7	Tonsillectomy;
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2.03e-5	Blood metabolite levels;
PAAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02071572	chr4:1403502	NA	0.36	4.69	0.36	6.02e-6	Longevity;
PAAD	cis	rs367943	0.665	rs4401566	chr5:112963356	A/G	cg12552261	chr5:112820674	MCC	0.53	5.52	0.41	1.42e-7	Type 2 diabetes;
PAAD	cis	rs58521262	0.519	rs62122416	chr19:22990522	C/G	cg07749055	chr19:23076870	NA	-0.61	-4.57	-0.35	9.86e-6	Testicular germ cell tumor;
PAAD	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg02016764	chr4:38805732	TLR1	-0.61	-4.65	-0.35	7.23e-6	Breast cancer;
PAAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.37	0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg11416102	chr8:651193	ERICH1	-0.87	-4.96	-0.37	1.84e-6	IgG glycosylation;
PAAD	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.63	-0.42	8.49e-8	Urate levels in overweight individuals;
PAAD	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg09127314	chr1:152161683	NA	-0.73	-5.04	-0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs6681460	0.800	rs693272	chr1:67221552	A/G	cg02459107	chr1:67143332	SGIP1	-0.71	-6.5	-0.47	1.12e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.54	5.58	0.41	1.07e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.42	-0.34	1.9e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.42	4.73	0.36	5.17e-6	Platelet count;
PAAD	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.0	-12.07	-0.7	5.88e-24	Dilated cardiomyopathy;
PAAD	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg09876464	chr15:85330779	ZNF592	0.44	4.41	0.34	1.91e-5	P wave terminal force;
PAAD	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	1.03	12.41	0.71	7.04e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.63	7.09	0.5	4.84e-11	Longevity;Endometriosis;
PAAD	cis	rs2387326	0.951	rs7919668	chr10:129931541	A/C	cg16087940	chr10:129947807	NA	-0.54	-4.58	-0.35	9.48e-6	Select biomarker traits;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27656074	chr7:157414580	PTPRN2	0.68	6.64	0.47	5.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.76	8.09	0.55	1.74e-13	Hemoglobin concentration;
PAAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.48e-6	Lung cancer;
PAAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	4.36	0.33	2.36e-5	Aortic root size;
PAAD	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	4.8	0.36	3.71e-6	Lung cancer in ever smokers;
PAAD	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg01191920	chr7:158217561	PTPRN2	0.75	8.0	0.54	2.9e-13	Obesity-related traits;
PAAD	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs790110	1.000	rs790130	chr3:122384661	C/G	cg16054280	chr3:122517974	DIRC2	0.86	4.53	0.34	1.21e-5	Acoustic startle blink response;
PAAD	cis	rs2594989	0.943	rs2442785	chr3:11521828	C/T	cg01796438	chr3:11312864	ATG7	-0.56	-4.34	-0.33	2.56e-5	Circulating chemerin levels;
PAAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.93	8.9	0.59	1.53e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.21	-0.39	6.03e-7	Pulmonary function;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.35e-7	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16260438	chr19:10259657	DNMT1	-0.68	-6.76	-0.48	2.83e-10	Obesity-related traits;
PAAD	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.68	6.88	0.49	1.46e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.65	7.07	0.5	5.18e-11	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26293830	chr11:66512047	C11orf80	-0.75	-6.42	-0.46	1.63e-9	Neuroticism;
PAAD	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.54	5.63	0.42	8.59e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26099943	chr3:186524574	RFC4	-0.58	-6.6	-0.47	6.31e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.61	5.86	0.43	2.74e-8	Eye color traits;
PAAD	cis	rs13424612	1.000	rs4149547	chr2:240933308	C/T	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.86	-0.37	2.9e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.48	-4.54	-0.35	1.15e-5	Bipolar disorder;
PAAD	cis	rs7703051	0.707	rs1115091	chr5:74575801	A/G	cg00601450	chr5:74908170	NA	0.43	4.38	0.33	2.19e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.93e-10	Bipolar disorder;
PAAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.51	-5.43	-0.4	2.2e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg06740227	chr12:86229804	RASSF9	-0.5	-4.55	-0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-4.85	-0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18621852	chr3:10150065	C3orf24	0.73	6.52	0.47	1e-9	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13818243	chr13:114789734	RASA3	0.71	9.37	0.61	9.5e-17	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs990171	1.000	rs6543134	chr2:103050458	T/G	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-4.91	-0.37	2.37e-6	Blood pressure;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg23708337	chr7:1209742	NA	0.62	4.37	0.33	2.26e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg11057378	chr10:81107060	PPIF	0.52	6.24	0.45	4.07e-9	Height;
PAAD	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg09021430	chr5:549028	NA	-0.86	-7.28	-0.51	1.7e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs735539	0.555	rs2922799	chr13:21302347	C/T	cg27499820	chr13:21296301	IL17D	0.57	5.25	0.39	4.93e-7	Dental caries;
PAAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.48	4.87	0.37	2.78e-6	Trans fatty acid levels;
PAAD	cis	rs6681460	1.000	rs7532173	chr1:67086111	A/G	cg02459107	chr1:67143332	SGIP1	0.75	7.62	0.53	2.6e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.8	8.86	0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.95	-9.9	-0.63	3.88e-18	Blood pressure (smoking interaction);
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg13560548	chr3:10150139	C3orf24	0.67	5.38	0.4	2.82e-7	Alzheimer's disease;
PAAD	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.76	7.72	0.53	1.45e-12	Resting heart rate;
PAAD	cis	rs2944755	0.723	rs13274321	chr8:141588206	A/G	cg18491938	chr8:141590271	EIF2C2	-0.52	-4.92	-0.37	2.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.93	-8.76	-0.58	3.51e-15	Body mass index;
PAAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.82	5.47	0.41	1.79e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.82	0.48	2.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs9346455	0.614	rs1322759	chr6:72013023	A/G	cg27238071	chr6:71998145	OGFRL1	0.75	4.38	0.33	2.18e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13901737	chr5:34656566	RAI14	0.67	7.68	0.53	1.84e-12	Myopia (pathological);
PAAD	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg15017067	chr4:17643749	FAM184B	-0.43	-4.7	-0.36	5.72e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.32	-0.4	3.67e-7	Blood metabolite levels;
PAAD	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.26	0.56	6.72e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.77	7.58	0.52	3.18e-12	Coronary artery disease;
PAAD	cis	rs36715	0.953	rs42916	chr5:127560659	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.85	0.43	2.93e-8	Breast cancer;
PAAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs75920871	0.925	rs76523703	chr11:116749509	T/G	cg04087571	chr11:116723030	SIK3	-0.46	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25833597	chr17:30823145	MYO1D	0.49	4.58	0.35	9.78e-6	Schizophrenia;
PAAD	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg25274157	chr19:19626576	NDUFA13;TSSK6	-0.43	-4.4	-0.34	2.04e-5	Bipolar disorder;
PAAD	cis	rs863345	1.000	rs863345	chr1:158534982	A/G	cg12129480	chr1:158549410	OR10X1	0.44	4.97	0.37	1.82e-6	Pneumococcal bacteremia;
PAAD	cis	rs2139634	0.965	rs2280407	chr3:46539963	G/A	cg23009419	chr3:46618597	LRRC2;TDGF1	0.32	4.55	0.35	1.07e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6782228	0.606	rs2001703	chr3:128383097	A/G	cg16766828	chr3:128327626	NA	-0.47	-6.31	-0.46	2.95e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6142102	0.602	rs4911399	chr20:32623418	C/A	cg06115741	chr20:33292138	TP53INP2	0.56	5.08	0.38	1.09e-6	Skin pigmentation;
PAAD	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs1499972	0.941	rs73168378	chr3:117636234	G/T	cg07612923	chr3:117604196	NA	1.08	7.1	0.5	4.55e-11	Schizophrenia;
PAAD	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg25902810	chr10:99078978	FRAT1	-0.64	-5.96	-0.44	1.68e-8	Monocyte count;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.73	6.64	0.47	5.11e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	6.61	0.47	6.1e-10	Renal function-related traits (BUN);
PAAD	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	1.04	8.98	0.59	9.92e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg14515779	chr1:101123966	NA	-0.47	-5.11	-0.38	9.51e-7	Breast cancer;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.17	0.5	3.11e-11	Alzheimer's disease;
PAAD	cis	rs11264799	0.639	rs12064217	chr1:157736431	C/A	cg18268488	chr1:157545234	FCRL4	0.6	5.14	0.38	8.25e-7	IgA nephropathy;
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg14019146	chr3:50243930	SLC38A3	0.43	4.42	0.34	1.87e-5	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	trans	rs4751058	0.607	rs4750732	chr10:130864640	C/T	cg14515250	chr17:18086444	ALKBH5	0.68	6.46	0.46	1.34e-9	Vitamin D levels;
PAAD	cis	rs1413885	0.526	rs4575118	chr1:65857457	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.41	4.25	0.33	3.67e-5	Anticoagulant levels;
PAAD	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-4.68	-0.35	6.41e-6	Personality dimensions;
PAAD	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.48	-0.34	1.47e-5	Educational attainment;
PAAD	cis	rs918959	0.793	rs77000181	chr2:181608415	T/C	cg05113709	chr2:182521874	CERKL	-0.95	-4.38	-0.33	2.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs6850606	0.577	rs35188871	chr4:42868563	C/T	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.34	0.4	3.3e-7	Total body bone mineral density;
PAAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-4.89	-0.37	2.57e-6	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15837879	chr17:36905998	PCGF2	-0.6	-7.6	-0.52	2.85e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.75	-0.36	4.73e-6	Breast cancer;
PAAD	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-7.14	-0.5	3.69e-11	Depression;
PAAD	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg05895507	chr15:77155635	SCAPER	-0.4	-4.4	-0.34	2.06e-5	Blood metabolite levels;
PAAD	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	6.66	0.48	4.74e-10	Lung cancer in ever smokers;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25757740	chr10:72647938	PCBD1	0.55	6.48	0.47	1.2e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg06131755	chr6:160182447	ACAT2	0.54	4.82	0.36	3.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.76	-8.2	-0.55	9.45e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs17123764	0.710	rs12315224	chr12:50109517	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.53	5.83	0.43	3.15e-8	Bladder cancer;
PAAD	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.81	5.47	0.41	1.81e-7	Diisocyanate-induced asthma;
PAAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10203711	0.509	rs10175606	chr2:239599255	C/T	cg03761885	chr2:238707879	RBM44	0.45	4.33	0.33	2.72e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	5.01	0.38	1.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs438465	0.629	rs9406322	chr6:169739733	A/C	cg00289362	chr6:170482788	NA	0.48	4.27	0.33	3.42e-5	Corneal astigmatism;
PAAD	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.82	10.33	0.64	2.85e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg03684893	chr10:554711	DIP2C	0.54	5.21	0.39	6.06e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.91	-5.69	-0.42	6.19e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.59	-4.76	-0.36	4.55e-6	Platelet count;
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg24503407	chr1:205819492	PM20D1	0.55	5.49	0.41	1.63e-7	Parkinson's disease;
PAAD	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.67	7.22	0.51	2.27e-11	Age at first birth;
PAAD	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg04896959	chr15:78267971	NA	-0.64	-6.13	-0.45	7.25e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.7	8.17	0.55	1.09e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg27565382	chr3:53032988	SFMBT1	-0.73	-4.56	-0.35	1.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg12623918	chr2:306882	NA	0.47	4.8	0.36	3.75e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-1.15	-7.74	-0.53	1.31e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.01	-0.44	1.29e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.64	-7.08	-0.5	5.04e-11	Facial morphology (factor 20);
PAAD	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	10.8	0.66	1.59e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg14393609	chr7:65229607	NA	-0.64	-6.84	-0.49	1.78e-10	Aortic root size;
PAAD	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg18551225	chr6:44695536	NA	0.71	7.14	0.5	3.69e-11	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07667813	chr19:7985168	SNAPC2	-0.58	-6.51	-0.47	1.01e-9	Body fat percentage;
PAAD	cis	rs12136530	0.669	rs10917449	chr1:19756869	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.1e-6	Lead levels in blood;
PAAD	cis	rs595018	0.505	rs7106391	chr11:60608443	A/G	cg23904249	chr11:60608951	CCDC86	0.67	4.89	0.37	2.49e-6	Wegener's granulomatosis;
PAAD	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.41	-0.34	1.92e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg12395012	chr8:11607386	GATA4	0.44	4.55	0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	10.89	0.66	8.82e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg21573476	chr21:45109991	RRP1B	-0.48	-4.3	-0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs35160687	0.644	rs4832264	chr2:86486834	A/G	cg10973622	chr2:86423274	IMMT	-0.48	-5.35	-0.4	3.19e-7	Night sleep phenotypes;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	9.04	0.59	6.71e-16	Alzheimer's disease;
PAAD	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.77	5.4	0.4	2.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.76	8.18	0.55	1.06e-13	Obesity-related traits;
PAAD	cis	rs17032980	0.956	rs13397289	chr2:67321213	T/C	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.01e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.32	0.64	2.95e-19	Smoking behavior;
PAAD	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-5.34	-0.4	3.27e-7	Schizophrenia;
PAAD	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.2	-0.39	6.29e-7	Fear of minor pain;
PAAD	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.67	-4.7	-0.36	5.69e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	0.830	rs1716698	chr3:41957466	T/G	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.91e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.53	-5.34	-0.4	3.25e-7	Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.3	-0.46	2.98e-9	Menopause (age at onset);
PAAD	cis	rs8040855	1.000	rs6496768	chr15:85702932	A/G	cg08123816	chr15:85640762	PDE8A	0.4	4.93	0.37	2.1e-6	Bulimia nervosa;
PAAD	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.78	8.04	0.55	2.35e-13	Body mass index;
PAAD	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.6	5.5	0.41	1.57e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.45	-4.58	-0.35	9.64e-6	Colorectal cancer;
PAAD	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.37	4.47	0.34	1.51e-5	Pulmonary function;
PAAD	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.44	4.55	0.35	1.07e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg16964102	chr10:135390573	NA	0.41	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs288342	0.832	rs288303	chr2:183655230	G/T	cg02625481	chr2:183667124	NA	-0.46	-4.75	-0.36	4.74e-6	Recurrent major depressive disorder;
PAAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-5.54	-0.41	1.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs258892	0.895	rs34653	chr5:72146480	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	trans	rs72700829	0.517	rs113833990	chr1:150162158	C/T	cg26950652	chr16:70416101	ST3GAL2	0.66	6.32	0.46	2.81e-9	Schizophrenia;
PAAD	cis	rs11998649	0.640	rs6557592	chr8:22631047	C/T	cg02046552	chr8:21914287	EPB49	-0.41	-4.25	-0.33	3.74e-5	Visceral fat;
PAAD	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-5.01	-0.38	1.49e-6	Metabolite levels;
PAAD	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.76e-5	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07981822	chr2:26568781	SELI;GPR113	0.64	7.36	0.51	1.05e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.01e-18	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg04154034	chr17:28927549	LRRC37B2	0.62	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.53	-4.51	-0.34	1.28e-5	Dementia with Lewy bodies;
PAAD	trans	rs901683	1.000	rs71496619	chr10:46068095	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg20913747	chr6:44695427	NA	-0.69	-6.89	-0.49	1.39e-10	Total body bone mineral density;
PAAD	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-5.41	-0.4	2.35e-7	Body mass index;
PAAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17095355	0.901	rs6584964	chr10:111759160	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.43	-0.34	1.8e-5	Biliary atresia;
PAAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg02038168	chr22:39784481	NA	-0.51	-4.95	-0.37	1.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg14926445	chr8:58193284	C8orf71	-0.62	-4.53	-0.35	1.17e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs113779084	0.632	rs2355145	chr7:11931567	G/A	cg15090509	chr7:11872073	THSD7A	0.37	4.83	0.36	3.28e-6	Educational attainment (years of education);
PAAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg17366294	chr4:99064904	C4orf37	0.56	5.97	0.44	1.64e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10274279	1.000	rs2021742	chr7:157381671	T/A	cg26886268	chr7:157387156	PTPRN2	-0.78	-6.02	-0.44	1.23e-8	Myopia (pathological);
PAAD	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-4.58	-0.35	9.74e-6	Neuroticism;
PAAD	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs9463078	0.585	rs1284969	chr6:45153881	T/C	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs59888335	0.862	rs10428193	chr3:80505674	G/A	cg21735741	chr3:80819488	NA	0.57	5.01	0.38	1.5e-6	Schizophrenia;
PAAD	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.37	0.46	2.16e-9	Body mass index;
PAAD	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	0.86	5.29	0.39	4.25e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.47	5.14	0.38	8.34e-7	Longevity;Endometriosis;
PAAD	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.56e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	1.2	9.95	0.63	2.83e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs7984522	1.000	rs7993264	chr13:109346013	C/T	cg11693848	chr13:109793698	MYO16	0.43	4.38	0.33	2.23e-5	Blood pressure;
PAAD	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.63	0.47	5.6e-10	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg25427524	chr10:38739819	LOC399744	0.51	5.0	0.38	1.55e-6	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg12215294	chr3:40350768	EIF1B	0.47	4.68	0.36	6.24e-6	Renal cell carcinoma;
PAAD	cis	rs4690686	0.836	rs10027831	chr4:177256699	T/C	cg17059388	chr4:177262070	NA	0.5	4.95	0.37	1.98e-6	Essential tremor;
PAAD	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.4	5.0	0.38	1.58e-6	Pulmonary function;
PAAD	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.73	-7.49	-0.52	5.22e-12	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	4.26	0.33	3.64e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.62	4.94	0.37	2.03e-6	Cholesterol, total;
PAAD	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.08	-11.29	-0.68	7.68e-22	Blood pressure (smoking interaction);
PAAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.86	-9.76	-0.62	8.9e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4819052	0.540	rs7282639	chr21:46491155	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.7	-6.4	-0.46	1.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.7	5.33	0.4	3.44e-7	Vitiligo;
PAAD	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12935418	0.583	rs2244452	chr16:81025372	A/T	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	trans	rs9409082	0.834	rs7032974	chr9:108918627	T/C	cg07010948	chr13:79181613	NA	-0.34	-6.37	-0.46	2.14e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.77	6.17	0.45	5.92e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-4.46	-0.34	1.58e-5	Platelet count;
PAAD	cis	rs7631605	0.905	rs60490177	chr3:37254925	G/C	cg17445812	chr3:36986805	TRANK1	0.35	4.58	0.35	9.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.46	5.79	0.43	3.82e-8	Renal cell carcinoma;
PAAD	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg17724175	chr1:150552817	MCL1	-0.52	-5.93	-0.43	2.01e-8	Tonsillectomy;
PAAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs508970	0.541	rs10792302	chr11:60896165	T/C	cg24692310	chr11:60915630	VPS37C	0.32	4.38	0.33	2.2e-5	Rheumatoid arthritis;
PAAD	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg00071950	chr4:10020882	SLC2A9	0.52	4.33	0.33	2.69e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.05	-0.38	1.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.48e-10	Uric acid levels;
PAAD	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07930192	chr7:1003750	NA	0.39	4.78	0.36	4.13e-6	Longevity;Endometriosis;
PAAD	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	1.04	7.11	0.5	4.15e-11	Mitochondrial DNA levels;
PAAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19784903	chr17:45786737	TBKBP1	0.54	5.66	0.42	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.49	5.58	0.41	1.09e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg08824895	chr13:115047677	UPF3A	0.47	4.41	0.34	1.95e-5	Schizophrenia;
PAAD	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.7	-6.15	-0.45	6.64e-9	Radiation response;
PAAD	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.74	7.52	0.52	4.43e-12	Cognitive function;
PAAD	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.76	-7.8	-0.53	9.31e-13	Itch intensity from mosquito bite;
PAAD	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.9	-10.28	-0.64	3.74e-19	Height;
PAAD	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06149389	chr14:77499875	NA	0.57	6.36	0.46	2.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.32	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.88	-0.43	2.56e-8	Prostate cancer;
PAAD	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.99	-0.44	1.47e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg21775007	chr8:11205619	TDH	-0.54	-4.89	-0.37	2.58e-6	Neuroticism;
PAAD	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-1.14	-16.15	-0.79	8.74e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3126085	0.560	rs6693160	chr1:152341321	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	1.08	12.5	0.71	4.23e-25	Obesity-related traits;
PAAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.71	-7.32	-0.51	1.36e-11	Colorectal cancer;
PAAD	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12908607	chr1:44402522	ARTN	-0.43	-4.76	-0.36	4.44e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09256448	chr16:638327	NA	0.42	4.31	0.33	2.95e-5	Height;
PAAD	cis	rs1519814	0.956	rs7827008	chr8:121130281	A/T	cg22335954	chr8:121166405	COL14A1	-0.61	-5.35	-0.4	3.14e-7	Breast cancer;
PAAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.7	5.63	0.42	8.64e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs6547631	0.622	rs10180451	chr2:85926238	G/T	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.06	0.55	2.07e-13	Height;
PAAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.28	0.67	8.06e-22	Breast cancer;
PAAD	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.7e-13	Coronary artery disease;
PAAD	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.99	12.13	0.7	4e-24	Primary sclerosing cholangitis;
PAAD	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg15128208	chr22:42549153	NA	-0.43	-4.27	-0.33	3.44e-5	Cognitive function;
PAAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg09796270	chr17:17721594	SREBF1	0.44	5.04	0.38	1.31e-6	Total body bone mineral density;
PAAD	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg10183150	chr4:120222239	C4orf3	-0.31	-4.43	-0.34	1.76e-5	Diastolic blood pressure;
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.63	7.97	0.54	3.43e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg10819733	chr22:24237672	NA	-0.57	-4.67	-0.35	6.45e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.97	-9.89	-0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs732505	1.000	rs8111720	chr19:5585823	A/G	cg26242866	chr19:5711310	LONP1	1.03	5.49	0.41	1.67e-7	vWF and FVIII levels;
PAAD	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg25072359	chr17:41440525	NA	0.56	5.94	0.43	1.84e-8	Menopause (age at onset);
PAAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.69	7.94	0.54	4.19e-13	Colorectal cancer;
PAAD	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10885582	0.754	rs10885576	chr10:116298843	G/A	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.64	-6.49	-0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2030114	0.531	rs1909338	chr16:51605142	C/T	cg03758633	chr16:51611768	NA	-0.51	-4.98	-0.37	1.68e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-8.6	-0.57	9.31e-15	Vitiligo;
PAAD	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg26138144	chr22:38071188	LGALS1	0.41	4.62	0.35	8.04e-6	Fat distribution (HIV);
PAAD	cis	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg18582342	chr19:11591989	ELAVL3	-0.74	-5.85	-0.43	2.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs375066	0.935	rs399098	chr19:44418824	C/T	cg11993925	chr19:44307056	LYPD5	0.5	6.36	0.46	2.2e-9	Breast cancer;
PAAD	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-12.28	-0.71	1.6e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg06915872	chr16:87998081	BANP	0.46	4.3	0.33	3e-5	Menopause (age at onset);
PAAD	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-4.95	-0.37	1.99e-6	Coronary artery disease;
PAAD	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg22777020	chr22:31556080	RNF185	0.53	4.58	0.35	9.78e-6	Colorectal cancer;
PAAD	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.8	-0.36	3.74e-6	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12365397	0.926	rs11037273	chr11:43170714	C/A	cg03447554	chr11:43094025	NA	0.42	4.25	0.33	3.76e-5	Migraine;
PAAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.56	-7.36	-0.51	1.08e-11	Renal cell carcinoma;
PAAD	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.57	5.96	0.44	1.65e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.84	0.43	3.01e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-6.05	-0.44	1.1e-8	Diabetic retinopathy;
PAAD	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.94	-0.59	1.23e-15	Exhaled nitric oxide output;
PAAD	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22947322	chr17:47091978	IGF2BP1	0.43	5.1	0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.71e-8	Dementia with Lewy bodies;
PAAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.38	-0.33	2.22e-5	Aortic root size;
PAAD	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg14343924	chr8:8086146	FLJ10661	-0.54	-4.74	-0.36	4.88e-6	Joint mobility (Beighton score);
PAAD	cis	rs4906332	1.000	rs4906332	chr14:103980134	A/T	cg26031613	chr14:104095156	KLC1	-0.46	-4.67	-0.35	6.5e-6	Coronary artery disease;
PAAD	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg05373962	chr22:49881684	NA	-0.43	-4.38	-0.33	2.23e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.46	0.46	1.32e-9	Crohn's disease;
PAAD	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs9896052	0.614	rs9892171	chr17:73452529	C/T	cg25649188	chr17:73499917	CASKIN2	0.59	4.6	0.35	8.84e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs13102973	0.645	rs7692242	chr4:135886041	A/G	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	6.49	0.47	1.16e-9	Bipolar disorder;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.63	-6.72	-0.48	3.4e-10	Iron status biomarkers;
PAAD	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg19554555	chr3:13937349	NA	-0.48	-4.38	-0.33	2.23e-5	Ovarian reserve;
PAAD	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-9.09	-0.59	5e-16	Exhaled nitric oxide output;
PAAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.87	8.16	0.55	1.16e-13	Menarche (age at onset);
PAAD	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg06565975	chr8:143823917	SLURP1	-0.23	-5.09	-0.38	1.04e-6	Urinary tract infection frequency;
PAAD	cis	rs2415984	0.622	rs1761027	chr14:46929611	G/A	cg14871534	chr14:47121158	RPL10L	0.51	5.26	0.39	4.85e-7	Number of children ever born;
PAAD	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.88	-5.32	-0.4	3.71e-7	Hypertriglyceridemia;
PAAD	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.4	-4.63	-0.35	7.91e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01004641	chr2:39406099	CDKL4	-0.51	-6.69	-0.48	4.08e-10	Monocyte percentage of white cells;
PAAD	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs1879734	0.731	rs12041221	chr1:54164165	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	0.93	7.86	0.54	6.55e-13	Blood protein levels;
PAAD	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg21253087	chr9:139290292	SNAPC4	0.51	4.43	0.34	1.82e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3734905	0.614	rs78919990	chr6:170011741	C/T	cg11181693	chr6:169825345	NA	-0.85	-5.17	-0.39	7.2e-7	HIV-1 control;
PAAD	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.49	-7.82	-0.54	8.24e-13	Urinary metabolites;
PAAD	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg25649188	chr17:73499917	CASKIN2	0.46	4.63	0.35	7.84e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.62	5.55	0.41	1.24e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.3	-0.33	3e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	6.84	0.49	1.81e-10	Body mass index (adult);
PAAD	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	10.87	0.66	9.83e-21	Chronic sinus infection;
PAAD	cis	rs713477	1.000	rs28604440	chr14:55911324	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs988913	1.000	rs9382404	chr6:54835218	C/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.63	-0.35	7.84e-6	Menarche (age at onset);
PAAD	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.52	-5.11	-0.38	9.71e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.96	-11.45	-0.68	2.76e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg09060608	chr5:178986726	RUFY1	0.53	5.16	0.39	7.55e-7	Lung cancer;
PAAD	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg18085866	chr17:45331354	ITGB3	-0.99	-5.7	-0.42	6.12e-8	Left atrial antero-posterior diameter;
PAAD	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg25233709	chr10:116636983	FAM160B1	0.45	5.68	0.42	6.53e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.87	-8.03	-0.55	2.47e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.21	0.39	6.07e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	7.08	0.5	5.11e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs7904519	1.000	rs7904519	chr10:114773927	A/G	cg17116091	chr10:114807157	TCF7L2	0.42	4.5	0.34	1.35e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.3	0.33	3.05e-5	Menarche (age at onset);
PAAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs863345	0.604	rs4584390	chr1:158505975	T/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.61	6.48	0.47	1.2e-9	Lung cancer;
PAAD	cis	rs16867321	0.803	rs1453064	chr2:181316534	G/T	cg23363182	chr2:181467187	NA	-0.51	-4.32	-0.33	2.81e-5	Obesity;
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.53	0.57	1.38e-14	Lung cancer;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.96	-12.95	-0.72	2.52e-26	Height;
PAAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg09112613	chr19:8563861	PRAM1	-0.56	-6.35	-0.46	2.34e-9	Alzheimer's disease (survival time);
PAAD	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00142150	chr22:38071001	LGALS1	0.7	7.87	0.54	6.1e-13	Fat distribution (HIV);
PAAD	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.69	-0.42	6.38e-8	Primary biliary cholangitis;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19253612	chr13:96239899	DZIP1	-0.64	-6.44	-0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	6.77	0.48	2.69e-10	Monocyte count;
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg08436684	chr16:88034427	BANP	0.51	4.52	0.34	1.25e-5	Menopause (age at onset);
PAAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs829661	0.793	rs829637	chr2:30737910	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	4.4	0.34	2.03e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6676180	0.555	rs947430	chr1:119778734	G/A	cg05756136	chr1:119680316	WARS2	-0.46	-4.64	-0.35	7.54e-6	Monobrow;
PAAD	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.91	5.83	0.43	3.27e-8	Prostate cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03564166	chr16:70380888	DDX19A	0.61	6.98	0.49	8.53e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg04160749	chr8:58172571	NA	0.69	4.69	0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.81	8.36	0.56	3.8e-14	Cognitive function;
PAAD	cis	rs7561273	0.717	rs10185680	chr2:24275306	C/T	cg04809136	chr2:24300158	SF3B14	-0.47	-5.25	-0.39	4.98e-7	Quantitative traits;
PAAD	cis	rs2882667	0.537	rs7701116	chr5:138406078	C/T	cg22797968	chr5:138629998	MATR3	0.46	4.57	0.35	9.88e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.51e-5	Life satisfaction;
PAAD	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.47	4.35	0.33	2.52e-5	Tuberculosis;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg27588902	chr6:42928151	GNMT	-0.42	-4.5	-0.34	1.32e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.69	7.3	0.51	1.53e-11	Osteoporosis;
PAAD	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg05805236	chr11:65401703	PCNXL3	0.46	4.86	0.37	2.86e-6	Systemic lupus erythematosus;
PAAD	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.56	0.52	3.62e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.65	-7.8	-0.53	9.37e-13	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.55	-5.78	-0.42	4.12e-8	Lung cancer;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.66	7.42	0.52	7.58e-12	Mean corpuscular volume;
PAAD	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.5	-4.81	-0.36	3.65e-6	Psoriasis;
PAAD	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.7	6.92	0.49	1.17e-10	Coronary artery disease;
PAAD	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.6	-0.41	9.55e-8	Myopia (pathological);
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.34	6.22	0.45	4.59e-9	Type 2 diabetes;
PAAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	1.27	11.98	0.7	1.04e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7532866	0.885	rs7552065	chr1:26731951	G/T	cg17456097	chr1:26900765	RPS6KA1	-0.53	-4.56	-0.35	1.06e-5	Height;
PAAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg04330084	chr7:123175371	IQUB	-0.52	-4.62	-0.35	8.24e-6	Plateletcrit;Platelet count;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.67	-6.24	-0.45	4.16e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	0.661	rs72969239	chr6:75066475	A/G	cg13997649	chr6:74171430	MTO1	0.8	4.47	0.34	1.53e-5	Metabolite levels (MHPG);
PAAD	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg05555928	chr11:63887634	MACROD1	-0.62	-4.6	-0.35	8.94e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.46	5.64	0.42	7.89e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2139634	0.929	rs12490169	chr3:46547400	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.48	0.34	1.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.7	9.41	0.61	7.52e-17	Hemoglobin concentration;
PAAD	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-7.03	-0.5	6.48e-11	Hemoglobin concentration;
PAAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg22800045	chr5:56110881	MAP3K1	0.7	5.78	0.42	4e-8	Coronary artery disease;
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.47	5.0	0.38	1.53e-6	Vitiligo;
PAAD	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.08	0.59	5.29e-16	Cognitive test performance;
PAAD	cis	rs11264213	0.681	rs72659694	chr1:36301803	G/A	cg27506609	chr1:36549197	TEKT2	0.85	4.35	0.33	2.46e-5	Schizophrenia;
PAAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs642743	0.967	rs515910	chr10:105966404	A/G	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.64	0.35	7.6e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs425535	0.702	rs352029	chr4:74791795	G/A	cg01447579	chr4:74847100	PF4	0.67	4.57	0.35	1.01e-5	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11183000	chr6:122720825	HSF2	0.58	6.34	0.46	2.55e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.82	9.1	0.59	4.63e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg19254793	chr6:44695348	NA	-0.49	-4.58	-0.35	9.81e-6	Total body bone mineral density;
PAAD	cis	rs7582720	1.000	rs72932770	chr2:203680954	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1997066	0.831	rs73340298	chr10:106815470	C/G	cg17321814	chr10:106440892	SORCS3	0.65	4.47	0.34	1.54e-5	Diabetic kidney disease;
PAAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-6.58	-0.47	7.06e-10	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.37	0.33	2.28e-5	Bipolar disorder;
PAAD	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.7	0.36	5.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	cg25843174	chr11:12811716	TEAD1	-0.37	-5.15	-0.39	7.99e-7	Educational attainment (years of education);
PAAD	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.53	-0.35	1.16e-5	Red blood cell traits;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg07212818	chr11:638076	DRD4	-0.68	-6.58	-0.47	7.05e-10	Systemic lupus erythematosus;
PAAD	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.85	-9.54	-0.61	3.4e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.57	6.36	0.46	2.2e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.65	-8.23	-0.56	7.84e-14	Schizophrenia;
PAAD	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg09163369	chr1:210001066	C1orf107	0.52	5.47	0.41	1.8e-7	Orofacial clefts;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13515894	chr19:47290659	SLC1A5	0.62	6.95	0.49	1.01e-10	Monocyte percentage of white cells;
PAAD	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg05925327	chr15:68127851	NA	0.64	5.86	0.43	2.71e-8	Restless legs syndrome;
PAAD	cis	rs4073221	0.520	rs66569729	chr3:18189623	A/C	cg07694806	chr3:18168406	NA	-1.07	-6.29	-0.45	3.24e-9	Parkinson's disease;
PAAD	cis	rs863345	0.967	rs10797027	chr1:158523232	T/C	cg12129480	chr1:158549410	OR10X1	-0.45	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs7772697	0.635	rs4454159	chr6:149411908	A/C	cg21368479	chr6:149415018	NA	0.44	4.48	0.34	1.43e-5	Diabetic retinopathy;
PAAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	trans	rs10177924	1.000	rs10177924	chr2:156933553	A/G	cg13601739	chr11:74875013	SLCO2B1	-0.57	-6.65	-0.47	4.9e-10	Smoking initiation;
PAAD	cis	rs7539542	0.516	rs10920517	chr1:202856469	A/T	cg10327424	chr1:202611933	SYT2	-0.43	-4.34	-0.33	2.54e-5	Mean platelet volume;
PAAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg25833597	chr17:30823145	MYO1D	0.49	4.67	0.35	6.52e-6	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg24699146	chr1:24152579	HMGCL	0.54	5.76	0.42	4.47e-8	Immature fraction of reticulocytes;
PAAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg20893579	chr22:38215064	NA	0.5	4.86	0.37	2.93e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.58	7.4	0.51	8.78e-12	Hypertriglyceridemia;
PAAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.14	15.58	0.78	2.64e-33	Exhaled nitric oxide output;
PAAD	cis	rs4704187	0.687	rs9293642	chr5:74365026	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.89	0.54	5.61e-13	Corneal astigmatism;
PAAD	cis	rs4074493	1.000	rs4378192	chr1:231173379	C/T	cg22172038	chr1:231176991	FAM89A	0.51	4.8	0.36	3.84e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg24053715	chr22:38214548	NA	-0.49	-5.3	-0.4	3.98e-7	Glioblastoma;Glioma;
PAAD	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.01	0.63	1.97e-18	Bladder cancer;
PAAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.33	-0.33	2.74e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg01815783	chr4:1047043	NA	-0.41	-4.41	-0.34	1.98e-5	Recombination rate (males);
PAAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.58	0.61	2.63e-17	Menarche (age at onset);
PAAD	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg02683114	chr2:24398427	C2orf84	-0.57	-5.85	-0.43	2.93e-8	Asthma;
PAAD	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.73	8.21	0.55	8.99e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.59	6.48	0.47	1.22e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg25551287	chr1:205649424	SLC45A3	-0.52	-4.48	-0.34	1.44e-5	Mean platelet volume;
PAAD	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-7.07	-0.5	5.27e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.32	-0.33	2.86e-5	Subjective well-being;
PAAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	1.1	8.4	0.56	2.88e-14	Iron status biomarkers;
PAAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg05697835	chr1:2722811	NA	0.44	4.9	0.37	2.38e-6	Ulcerative colitis;
PAAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.18	-0.5	2.92e-11	Blood pressure (smoking interaction);
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs6132905	0.590	rs76990741	chr20:2606746	A/G	cg24848351	chr20:2622020	TMC2	-0.7	-4.98	-0.37	1.72e-6	Mumps;
PAAD	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.94	0.37	2.04e-6	Post bronchodilator FEV1;
PAAD	cis	rs3127573	0.534	rs3127575	chr6:160644012	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.65	-4.32	-0.33	2.84e-5	Creatinine levels;
PAAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs425535	0.757	rs352024	chr4:74797139	G/T	cg01447579	chr4:74847100	PF4	-0.64	-4.28	-0.33	3.33e-5	Blood protein levels;
PAAD	cis	rs1075265	0.870	rs1363062	chr2:54281762	C/T	cg04546899	chr2:54196757	PSME4	0.33	4.68	0.35	6.26e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg14631576	chr9:95140430	CENPP	-0.53	-5.31	-0.4	3.86e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00134340	chr10:47966590	NA	0.54	6.52	0.47	9.75e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.51	-4.38	-0.33	2.19e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.8	-0.36	3.74e-6	Life satisfaction;
PAAD	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg12923728	chr3:195709715	SDHAP1	-0.87	-8.38	-0.56	3.28e-14	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.63	-5.41	-0.4	2.4e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.2	0.6	2.7e-16	Bipolar disorder;
PAAD	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.59	-4.34	-0.33	2.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg17372223	chr3:52568218	NT5DC2	0.53	5.34	0.4	3.33e-7	Bipolar disorder;
PAAD	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.99	-0.59	9.33e-16	Morning vs. evening chronotype;
PAAD	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg24519413	chr1:26490540	NA	-0.49	-4.42	-0.34	1.9e-5	QRS complex (12-leadsum);
PAAD	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.14	18.29	0.83	3.11e-40	Platelet distribution width;
PAAD	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.72	0.62	1.12e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.69	5.75	0.42	4.74e-8	Coronary artery disease;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs2882667	0.893	rs13180851	chr5:138290607	C/G	cg09476006	chr5:138032270	NA	0.36	4.46	0.34	1.58e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7561149	1.000	rs7600330	chr2:179689985	C/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.48	4.65	0.35	7.1e-6	QT interval;
PAAD	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg24739098	chr15:79297159	RASGRF1	0.36	4.82	0.36	3.39e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs375066	0.934	rs440784	chr19:44404342	T/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-1.11	-15.7	-0.79	1.29e-33	Total body bone mineral density;
PAAD	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.52	-7.65	-0.53	2.18e-12	Diastolic blood pressure;
PAAD	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.31e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-4.6	-0.35	8.95e-6	Triglycerides;
PAAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs2662368	0.542	rs10805914	chr5:77113097	A/G	cg02570643	chr5:77531473	AP3B1	0.41	4.54	0.35	1.15e-5	Platelet distribution width;
PAAD	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg00717180	chr2:96193071	NA	-0.6	-6.82	-0.48	2.04e-10	HDL cholesterol;
PAAD	cis	rs8049634	0.732	rs2303243	chr16:84230500	A/C	cg26466773	chr16:84211947	TAF1C	0.59	5.51	0.41	1.51e-7	Small cell lung carcinoma;
PAAD	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-5.34	-0.4	3.32e-7	Schizophrenia (age at onset);
PAAD	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	4.63	0.35	7.67e-6	Lung disease severity in cystic fibrosis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27368533	chr7:38791870	VPS41	-0.65	-6.34	-0.46	2.53e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.78	-5.85	-0.43	2.92e-8	Mean platelet volume;
PAAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02711726	chr17:80685570	FN3KRP	-0.49	-4.44	-0.34	1.7e-5	Glycated hemoglobin levels;
PAAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg21625146	chr5:486483	SLC9A3	0.37	5.42	0.4	2.27e-7	Cystic fibrosis severity;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.05	-0.7	6.63e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.65	-7.14	-0.5	3.54e-11	Blood protein levels;
PAAD	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.63e-11	Eye color traits;
PAAD	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg03938978	chr2:103052716	IL18RAP	0.52	5.2	0.39	6.35e-7	Blood protein levels;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7301016	1.000	rs11174504	chr12:62877036	A/G	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg14219918	chr9:127249562	NR5A1	-0.35	-4.62	-0.35	8.19e-6	Menarche (age at onset);
PAAD	cis	rs7932354	0.682	rs7118404	chr11:46908730	G/A	cg19486271	chr11:47235900	DDB2	-0.56	-5.89	-0.43	2.41e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.87	0.58	1.84e-15	Lung cancer;
PAAD	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.84	-7.03	-0.5	6.66e-11	Triglycerides;
PAAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.51	6.2	0.45	5.07e-9	Monobrow;
PAAD	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	5.08	0.38	1.11e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg01378222	chr16:28622494	SULT1A1	-0.62	-4.99	-0.37	1.67e-6	Platelet distribution width;
PAAD	trans	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg18543610	chr13:100627929	NA	0.64	6.43	0.46	1.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.67	6.42	0.46	1.62e-9	Cognitive ability;
PAAD	cis	rs2180233	0.635	rs12729813	chr1:30664232	C/T	cg06703062	chr1:31191648	MATN1	-0.56	-5.07	-0.38	1.16e-6	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09065629	chr16:1709722	CRAMP1L	0.49	5.28	0.39	4.31e-7	Coronary artery disease;
PAAD	cis	rs58521262	0.556	rs2935441	chr19:23211195	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg01388757	chr2:102091195	RFX8	-0.62	-8.02	-0.55	2.68e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs35955747	0.902	rs5997919	chr22:31623442	A/G	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.36	-0.33	2.41e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	Cognitive function;
PAAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.89	-9.7	-0.62	1.27e-17	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7711186	0.786	rs11748909	chr5:178021743	A/G	cg07427642	chr5:177944298	COL23A1	0.68	4.41	0.34	1.93e-5	Urate levels in obese individuals;
PAAD	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	4.91	0.37	2.31e-6	Height;
PAAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.77	-0.53	1.11e-12	Hemoglobin concentration;
PAAD	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.92	10.58	0.65	6.05e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.57	-7.37	-0.51	1.04e-11	Menopause (age at onset);
PAAD	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.57	-0.52	3.28e-12	Diastolic blood pressure;
PAAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.52	-6.98	-0.49	8.77e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.55	-6.02	-0.44	1.29e-8	Facial morphology (factor 20);
PAAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2882667	0.628	rs10076629	chr5:138255961	G/C	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10737625	chr4:76439436	RCHY1;THAP6	0.59	6.34	0.46	2.43e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.58	0.57	1.03e-14	Menopause (age at onset);
PAAD	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg00262122	chr8:11665843	FDFT1	0.53	4.62	0.35	8.13e-6	Retinal vascular caliber;
PAAD	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg05393297	chr12:53359155	NA	-0.96	-10.3	-0.64	3.44e-19	Cancer (pleiotropy);
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.42	-0.34	1.87e-5	Fear of minor pain;
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg08501292	chr6:25962987	TRIM38	0.87	4.7	0.36	5.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.53	5.44	0.4	2.06e-7	Major depressive disorder;
PAAD	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-5.67	-0.42	7.1e-8	Rheumatoid arthritis;
PAAD	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg15628303	chr1:26608928	UBXN11	0.71	7.13	0.5	3.72e-11	Obesity-related traits;
PAAD	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-8.59	-0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.65	-0.35	7.17e-6	Neuroticism;
PAAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg20913747	chr6:44695427	NA	-0.65	-6.41	-0.46	1.75e-9	Total body bone mineral density;
PAAD	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.14	0.45	7.01e-9	Breast cancer;
PAAD	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-6.5	-0.47	1.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.62	0.41	8.78e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14180030	chr9:123475675	MEGF9	-0.45	-4.88	-0.37	2.69e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2017305	0.915	rs76210299	chr10:70747052	T/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs12118280	0.921	rs72693452	chr1:108740482	G/A	cg11967332	chr1:108735228	SLC25A24	0.61	4.66	0.35	6.74e-6	Myeloid white cell count;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24376286	chr2:198245629	NA	0.59	6.44	0.46	1.45e-9	Pancreatic cancer;
PAAD	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.73	6.95	0.49	9.97e-11	Sum neutrophil eosinophil counts;
PAAD	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6681460	1.000	rs964574	chr1:67062885	T/C	cg02459107	chr1:67143332	SGIP1	0.76	7.45	0.52	6.6e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.67	9.97	0.63	2.46e-18	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.61	-5.74	-0.42	4.98e-8	Glaucoma (primary open-angle);
PAAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	7.31	0.51	1.44e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg12705353	chr12:122356852	WDR66	0.49	4.98	0.37	1.68e-6	Mean platelet volume;
PAAD	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.57	5.27	0.39	4.57e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.42	4.43	0.34	1.82e-5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg00988841	chr10:134556463	INPP5A	0.51	4.71	0.36	5.62e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.71	8.16	0.55	1.16e-13	Colorectal cancer;
PAAD	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.58	-0.41	1.07e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.73	-6.97	-0.49	8.94e-11	Cognitive function;
PAAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.48	4.57	0.35	9.86e-6	HDL cholesterol;
PAAD	cis	rs16975963	0.843	rs75802547	chr19:38393321	C/T	cg14218481	chr19:38281219	NA	0.48	5.01	0.38	1.49e-6	Longevity;
PAAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23463467	chr20:60627584	TAF4	0.43	4.64	0.35	7.57e-6	Body mass index;
PAAD	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.72	9.25	0.6	1.96e-16	Cancer;
PAAD	cis	rs2070632	0.668	rs4498037	chr3:186341263	C/T	cg25162301	chr3:186330055	AHSG	-0.46	-4.29	-0.33	3.23e-5	Blood protein levels;
PAAD	cis	rs4979906	1.000	rs11002242	chr10:79445873	G/C	cg07817648	chr10:79422355	NA	-0.57	-5.07	-0.38	1.14e-6	Mortality in heart failure;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg03909863	chr11:638404	DRD4	-0.59	-5.43	-0.4	2.14e-7	Systemic lupus erythematosus;
PAAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.9	-8.05	-0.55	2.17e-13	Diastolic blood pressure;
PAAD	cis	rs12935418	0.634	rs9934940	chr16:81049626	A/G	cg16651780	chr16:81037892	C16orf61	0.69	6.65	0.47	4.92e-10	Mean corpuscular volume;
PAAD	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg18765565	chr5:669397	TPPP	-0.42	-4.55	-0.35	1.07e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg01200585	chr1:228362443	C1orf69	0.57	6.29	0.45	3.15e-9	Diastolic blood pressure;
PAAD	cis	rs6494488	0.500	rs72741387	chr15:64816334	A/G	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.82	-7.1	-0.5	4.45e-11	Blood pressure (smoking interaction);
PAAD	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-4.41	-0.34	1.96e-5	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg05156850	chr2:88355134	KRCC1	-0.64	-6.33	-0.46	2.65e-9	Primary biliary cholangitis;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.42	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs4704187	0.687	rs1903839	chr5:74421397	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4073221	0.654	rs7373125	chr3:18297522	A/G	cg07694806	chr3:18168406	NA	-0.64	-4.68	-0.35	6.33e-6	Parkinson's disease;
PAAD	cis	rs12311304	1.000	rs12310061	chr12:15390019	A/T	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Mosquito bite size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25336634	chr7:6388601	C7orf70	-0.75	-6.71	-0.48	3.54e-10	Neuroticism;
PAAD	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.69	10.2	0.64	6.21e-19	Breast cancer;
PAAD	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg16341495	chr8:142228727	SLC45A4	0.5	4.66	0.35	6.79e-6	Immature fraction of reticulocytes;
PAAD	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-6.14	-0.45	6.88e-9	Schizophrenia (age at onset);
PAAD	cis	rs2275731	0.723	rs7917386	chr10:16542705	C/G	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7853377	0.723	rs7020300	chr9:86550647	A/G	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.68	6.7	0.48	3.77e-10	Platelet distribution width;
PAAD	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.42	-0.46	1.62e-9	Retinal vascular caliber;
PAAD	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs621942	0.635	rs34191396	chr11:85833460	A/G	cg07180834	chr11:85838833	NA	-0.48	-5.03	-0.38	1.38e-6	Tourette syndrome;
PAAD	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.11	0.44	8.19e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7084921	0.521	rs12782269	chr10:101875210	T/C	cg04359915	chr10:101825029	CPN1	-0.28	-4.37	-0.33	2.3e-5	Bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08803571	chr3:58292201	RPP14	0.59	6.52	0.47	9.89e-10	Monocyte percentage of white cells;
PAAD	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16489895	chr1:156890244	C1orf92	0.58	6.3	0.46	3.04e-9	Myopia (pathological);
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.27e-5	Menopause (age at onset);
PAAD	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	5.71	0.42	5.82e-8	Lung cancer in ever smokers;
PAAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg09324608	chr17:30823087	MYO1D	0.48	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg04111992	chr7:158790115	NA	-0.46	-4.37	-0.33	2.34e-5	Facial morphology (factor 20);
PAAD	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg13206674	chr6:150067644	NUP43	0.62	5.64	0.42	8.2e-8	Lung cancer;
PAAD	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.67	-7.14	-0.5	3.51e-11	Type 2 diabetes;
PAAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.5	-4.94	-0.37	2.02e-6	Multiple sclerosis;
PAAD	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.19	0.64	6.75e-19	Cognitive test performance;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.9	12.23	0.7	2.19e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.61	6.32	0.46	2.74e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.48	0.52	5.68e-12	Coffee consumption (cups per day);
PAAD	cis	rs10512697	0.655	rs36117475	chr5:3478502	T/C	cg19473799	chr5:3511975	NA	-1.01	-4.5	-0.34	1.33e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1015291	0.708	rs1492125	chr12:20007550	T/C	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	6.77	0.48	2.57e-10	Resting heart rate;
PAAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.09	-0.38	1.05e-6	Mean corpuscular volume;
PAAD	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.76	-0.48	2.84e-10	Capecitabine sensitivity;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-7.01	-0.49	7.27e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg15193198	chr20:60906057	LAMA5	-0.45	-4.93	-0.37	2.09e-6	Colorectal cancer;
PAAD	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.55	4.58	0.35	9.72e-6	Body mass index;
PAAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.41	-0.4	2.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg02917321	chr22:38215204	NA	0.48	4.81	0.36	3.65e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-5.38	-0.4	2.75e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2479106	0.892	rs549779	chr9:126613028	A/G	cg16191174	chr9:126692580	DENND1A	-0.54	-4.93	-0.37	2.12e-6	Polycystic ovary syndrome;
PAAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg03517284	chr6:25882590	NA	-0.52	-4.34	-0.33	2.57e-5	Iron status biomarkers;
PAAD	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg19767477	chr5:127420684	SLC12A2	-0.59	-4.78	-0.36	4.15e-6	Ileal carcinoids;
PAAD	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	5.56	0.41	1.21e-7	Joint mobility (Beighton score);
PAAD	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.85	7.89	0.54	5.62e-13	Rheumatoid arthritis;
PAAD	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.54	5.06	0.38	1.19e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.77	8.05	0.55	2.22e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.62	8.91	0.59	1.44e-15	Breast cancer;
PAAD	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.44	4.3	0.33	3.01e-5	Chronic sinus infection;
PAAD	cis	rs10875746	0.551	rs12322348	chr12:48707699	T/A	cg26205652	chr12:48591994	NA	0.79	7.23	0.51	2.19e-11	Longevity (90 years and older);
PAAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg26513180	chr16:89883248	FANCA	0.7	8.23	0.56	7.97e-14	Vitiligo;
PAAD	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.34	-0.33	2.61e-5	Joint mobility (Beighton score);
PAAD	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.54	0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs508970	0.556	rs628327	chr11:60919145	T/C	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg21724239	chr8:58056113	NA	0.71	5.47	0.41	1.81e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.34	-0.46	2.49e-9	Longevity;
PAAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg24733560	chr20:60626293	TAF4	-0.52	-6.64	-0.47	5.33e-10	Body mass index;
PAAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg02961798	chr16:67687392	RLTPR	-0.38	-4.28	-0.33	3.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg09659197	chr4:152720779	NA	0.36	5.3	0.39	3.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19671926	chr4:122722719	EXOSC9	0.59	5.72	0.42	5.55e-8	Type 2 diabetes;
PAAD	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-8.16	-0.55	1.15e-13	Lung function (FVC);
PAAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.71	8.31	0.56	4.96e-14	Multiple sclerosis;
PAAD	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.98	-11.28	-0.68	8e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.78	7.77	0.53	1.11e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs3774830	0.714	rs55816120	chr4:5463350	C/T	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.2e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg07671805	chr5:74907694	NA	0.57	4.44	0.34	1.75e-5	Coronary artery disease;
PAAD	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.87e-5	Dermatomyositis;
PAAD	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg09839279	chr12:125627357	AACS	-0.51	-4.94	-0.37	2.06e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs412658	0.670	rs1912576	chr19:22121293	T/C	cg07498013	chr19:22123504	NA	-0.44	-4.83	-0.36	3.34e-6	Telomere length;
PAAD	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.47	-5.0	-0.38	1.54e-6	Breast cancer;
PAAD	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.95	-0.43	1.74e-8	Fear of minor pain;
PAAD	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.88	-0.37	2.61e-6	Menopause (age at onset);
PAAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.91	-0.37	2.37e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.54	-5.16	-0.39	7.66e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.66	-0.35	6.85e-6	Type 1 diabetes;
PAAD	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.49	4.39	0.34	2.15e-5	Morning vs. evening chronotype;
PAAD	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10751667	0.558	rs12276666	chr11:1022119	G/A	cg21977766	chr11:1107580	NA	0.44	4.45	0.34	1.65e-5	Alzheimer's disease (late onset);
PAAD	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg02555727	chr12:129281546	SLC15A4	0.46	4.74	0.36	4.85e-6	Systemic lupus erythematosus;
PAAD	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.67	6.35	0.46	2.31e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1903068	0.785	rs10013228	chr4:55997340	A/G	cg09978860	chr4:56023921	NA	0.41	4.41	0.34	1.95e-5	Endometriosis;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13560548	chr3:10150139	C3orf24	0.62	5.66	0.42	7.23e-8	Alzheimer's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08563677	chr9:37080373	NA	-0.54	-6.31	-0.46	2.91e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg22705602	chr4:152727874	NA	0.48	5.13	0.38	8.63e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.81	-7.88	-0.54	6.01e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	5.82	0.43	3.36e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg13468214	chr4:1046988	NA	-0.54	-5.01	-0.38	1.49e-6	Recombination rate (females);
PAAD	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg10253484	chr15:75165896	SCAMP2	0.59	5.09	0.38	1.02e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg19413350	chr8:57351067	NA	-0.48	-4.57	-0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.92	7.38	0.51	9.59e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg02683114	chr2:24398427	C2orf84	0.45	5.22	0.39	5.69e-7	Asthma;
PAAD	cis	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg11619707	chr19:22235551	ZNF257	-0.58	-5.82	-0.43	3.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg03989125	chr22:38214979	NA	-0.66	-6.91	-0.49	1.25e-10	Glioblastoma;Glioma;
PAAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg09796270	chr17:17721594	SREBF1	-0.48	-5.33	-0.4	3.51e-7	Total body bone mineral density;
PAAD	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.59e-5	Life satisfaction;
PAAD	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg27205649	chr11:78285834	NARS2	0.62	4.45	0.34	1.65e-5	Alzheimer's disease (survival time);
PAAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg09455208	chr3:40491958	NA	-0.55	-6.78	-0.48	2.55e-10	Renal cell carcinoma;
PAAD	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.61	5.86	0.43	2.83e-8	Subjective well-being;
PAAD	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.46	-0.46	1.31e-9	Triglycerides;
PAAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.81	8.33	0.56	4.46e-14	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.63	8.19	0.55	1.02e-13	Renal cell carcinoma;
PAAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.26	0.33	3.51e-5	Type 2 diabetes;
PAAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs12476592	0.636	rs262493	chr2:63845066	G/T	cg10828910	chr2:63850056	LOC388955	0.51	4.36	0.33	2.34e-5	Childhood ear infection;
PAAD	cis	rs11811982	0.793	rs75972256	chr1:227605097	C/T	cg24860534	chr1:227506868	CDC42BPA	0.51	4.69	0.36	6.08e-6	Optic disc area;
PAAD	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	6.9	0.49	1.34e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs11024102	1.000	rs4141194	chr11:17011176	A/C	cg15084286	chr11:17036142	PLEKHA7	-0.52	-4.8	-0.36	3.77e-6	Glaucoma (primary angle closure);
PAAD	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.5	5.62	0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.28	-0.51	1.7e-11	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09739036	chr11:67211315	CORO1B	-0.64	-6.79	-0.48	2.36e-10	Smoking initiation;
PAAD	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.76	7.96	0.54	3.74e-13	Retinal vascular caliber;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.95	10.72	0.66	2.55e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg05697835	chr1:2722811	NA	0.43	4.85	0.37	2.99e-6	Ulcerative colitis;
PAAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.5	-5.0	-0.38	1.57e-6	Blood metabolite levels;
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.52e-8	Body mass index;
PAAD	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.38	0.33	2.23e-5	Iron status biomarkers;
PAAD	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.8	-6.04	-0.44	1.12e-8	Coronary artery disease;
PAAD	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.64	6.82	0.48	2.01e-10	Colorectal cancer;
PAAD	cis	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00166722	chr3:10149974	C3orf24	0.85	7.27	0.51	1.76e-11	Alzheimer's disease;
PAAD	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.54	-0.41	1.31e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01428454	chr8:11696232	FDFT1	0.63	6.78	0.48	2.55e-10	Smoking initiation;
PAAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.7	-6.82	-0.48	2.04e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.79	8.85	0.58	2.07e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg07810366	chr2:100720526	AFF3	0.37	4.69	0.36	6.15e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs16975963	0.793	rs59616348	chr19:38447753	G/A	cg25793785	chr19:38281423	NA	0.6	4.96	0.37	1.85e-6	Longevity;
PAAD	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.21	0.45	4.85e-9	Mean platelet volume;
PAAD	cis	rs887829	0.508	rs1104892	chr2:234620272	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.86	-0.37	2.86e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2278796	0.639	rs12145998	chr1:204969419	C/T	cg17947172	chr1:204966197	NFASC	0.43	4.7	0.36	5.86e-6	Mean platelet volume;
PAAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07587117	chr16:2239488	CASKIN1	0.49	5.24	0.39	5.39e-7	Height;
PAAD	cis	rs2562456	0.678	rs7260140	chr19:21523525	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17305672	chr8:101871420	NA	-0.65	-6.96	-0.49	9.41e-11	Obesity-related traits;
PAAD	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.67	6.38	0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.52	-5.57	-0.41	1.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.69	-7.82	-0.54	8.04e-13	Systemic lupus erythematosus;
PAAD	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg27644672	chr7:1858694	MAD1L1	-0.43	-4.68	-0.35	6.38e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25193384	chr7:39837692	NA	-0.6	-6.31	-0.46	2.86e-9	Obesity-related traits;
PAAD	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.54	-5.3	-0.4	3.95e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs16910800	1.000	rs2449442	chr11:23197362	C/T	cg20040320	chr11:23191996	NA	0.56	4.74	0.36	4.84e-6	Cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03123822	chr22:24199866	SLC2A11	0.66	7.32	0.51	1.32e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21502999	chr12:96588203	ELK3	-0.66	-6.95	-0.49	1.01e-10	Smoking initiation;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.43	4.28	0.33	3.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8112211	0.834	rs11881305	chr19:38804218	A/G	cg14299480	chr19:38876666	GGN	-0.53	-6.96	-0.49	9.32e-11	Blood protein levels;
PAAD	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.94	7.35	0.51	1.11e-11	Eotaxin levels;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.77	10.07	0.63	1.38e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17397135	chr2:28789816	PLB1	0.69	6.93	0.49	1.14e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg04160749	chr8:58172571	NA	-0.71	-4.89	-0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.85	10.16	0.64	7.69e-19	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.96	-0.54	3.7e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.22	0.39	5.89e-7	Tonsillectomy;
PAAD	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.6	7.05	0.5	5.78e-11	Aortic root size;
PAAD	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	5.14	0.38	8.31e-7	Cognitive ability;
PAAD	cis	rs89107	0.544	rs11968176	chr6:118900940	C/A	cg21191810	chr6:118973309	C6orf204	0.37	4.44	0.34	1.71e-5	Cardiac structure and function;
PAAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg02313495	chr15:40398007	BMF	-0.56	-4.58	-0.35	9.75e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.53e-7	Plateletcrit;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.8	8.06	0.55	2.15e-13	Vitiligo;
PAAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg01621132	chr19:10221146	PPAN-P2RY11;P2RY11;PPAN	-0.58	-5.87	-0.43	2.62e-8	Narcolepsy;
PAAD	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.1	0.67	2.4e-21	Breast cancer;
PAAD	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.11	-0.38	9.49e-7	Inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22685226	chr1:143743939	LOC100286793;FLJ39739	-0.78	-6.94	-0.49	1.06e-10	Neuroticism;
PAAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg10556349	chr10:835070	NA	0.66	5.24	0.39	5.26e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg13444538	chr7:158905317	VIPR2	-0.58	-4.78	-0.36	4.16e-6	Facial morphology (factor 20);
PAAD	cis	rs863345	0.625	rs10908655	chr1:158460899	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.62	-4.85	-0.37	2.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs793571	0.784	rs28800895	chr15:59085036	T/C	cg05156742	chr15:59063176	FAM63B	0.61	4.55	0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg24296786	chr1:45957014	TESK2	0.52	4.97	0.37	1.81e-6	Homocysteine levels;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.66e-7	Blood metabolite levels;
PAAD	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-1.0	-12.37	-0.71	9.12e-25	Coronary artery disease;
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg02462569	chr6:150064036	NUP43	-0.46	-4.85	-0.37	3.06e-6	Testicular germ cell tumor;
PAAD	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg23024343	chr7:107201750	COG5	0.59	4.9	0.37	2.44e-6	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08084454	chr3:176915592	TBL1XR1	0.64	7.21	0.5	2.5e-11	Monocyte percentage of white cells;
PAAD	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg16576597	chr16:28551801	NUPR1	0.62	6.59	0.47	6.89e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.88	7.05	0.5	5.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg22777020	chr22:31556080	RNF185	-0.51	-4.28	-0.33	3.25e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg04045327	chr4:905805	GAK	-0.37	-4.66	-0.35	6.79e-6	Systemic sclerosis;
PAAD	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.54e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00166722	chr3:10149974	C3orf24	0.62	5.46	0.41	1.87e-7	Alzheimer's disease;
PAAD	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.34	0.33	2.54e-5	Iron status biomarkers;
PAAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg23506979	chr15:79090958	ADAMTS7	0.25	4.3	0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg14851346	chr12:38532713	NA	0.49	4.6	0.35	8.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.61	-6.25	-0.45	3.89e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-0.97	-6.47	-0.46	1.3e-9	Post bronchodilator FEV1;
PAAD	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg17960426	chr8:142067321	NA	0.54	4.9	0.37	2.42e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg05585544	chr11:47624801	NA	0.47	5.22	0.39	5.89e-7	Subjective well-being;
PAAD	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.05	0.38	1.27e-6	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.9	0.59	1.6e-15	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.96	-0.37	1.86e-6	Menarche (age at onset);
PAAD	cis	rs12893597	0.580	rs35068962	chr14:76818804	G/A	cg20290672	chr14:76816747	NA	-0.48	-4.43	-0.34	1.83e-5	Maximal oxygen uptake response;
PAAD	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.56	-0.35	1.03e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs12304921	0.882	rs67106267	chr12:51352452	T/C	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.94	11.38	0.68	4.27e-22	Coronary artery disease;
PAAD	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.43	-6.43	-0.46	1.59e-9	Subjective well-being;
PAAD	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.74	8.04	0.55	2.36e-13	Lewy body disease;
PAAD	cis	rs427941	0.703	rs10953358	chr7:101738226	T/C	cg06246474	chr7:101738831	CUX1	-0.45	-4.64	-0.35	7.48e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.99	0.44	1.48e-8	Lung cancer;
PAAD	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.66	0.57	6.55e-15	Morning vs. evening chronotype;
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-7.6	-0.52	2.8e-12	Systemic lupus erythematosus;
PAAD	trans	rs9409082	0.715	rs4273906	chr9:108983662	C/G	cg07010948	chr13:79181613	NA	-0.35	-6.51	-0.47	1.01e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.69	4.8	0.36	3.82e-6	Hip geometry;
PAAD	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs66530629	1.000	rs2153125	chr1:25070230	A/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.6	-0.35	8.84e-6	Plateletcrit;
PAAD	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.55	4.8	0.36	3.69e-6	Myopia;
PAAD	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg08345082	chr10:99160200	RRP12	-0.31	-4.46	-0.34	1.58e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01409793	chr4:106394821	PPA2	0.62	6.58	0.47	7.33e-10	Myopia (pathological);
PAAD	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg06713675	chr4:122721982	EXOSC9	0.46	4.49	0.34	1.38e-5	Type 2 diabetes;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg23119463	chr10:134592391	INPP5A	-0.47	-4.42	-0.34	1.89e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	8.34	0.56	4.18e-14	Monocyte percentage of white cells;
PAAD	cis	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.58	-0.41	1.07e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10512697	0.541	rs62336074	chr5:3513171	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.06	-0.38	1.2e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.69	-0.36	5.92e-6	Height;
PAAD	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg03115019	chr17:80708279	FN3K	0.5	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.83	-0.36	3.34e-6	Large artery stroke;
PAAD	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg05697835	chr1:2722811	NA	-0.41	-4.71	-0.36	5.59e-6	Ulcerative colitis;
PAAD	cis	rs13242816	1.000	rs55803834	chr7:116103141	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs288326	0.561	rs74564500	chr2:183786420	C/A	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.92	7.72	0.53	1.45e-12	Inflammatory bowel disease;
PAAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8192917	0.832	rs10148494	chr14:25105891	G/T	cg00962125	chr14:24616485	PSME2;RNF31	0.55	4.31	0.33	2.93e-5	Vitiligo;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.5	-0.47	1.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21016266	chr12:122356598	WDR66	0.63	6.67	0.48	4.45e-10	Mean corpuscular volume;
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.77	-9.27	-0.6	1.72e-16	Cystic fibrosis severity;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.77	8.15	0.55	1.24e-13	Brugada syndrome;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg11965913	chr1:205819406	PM20D1	0.89	11.01	0.67	4.18e-21	Menarche (age at onset);
PAAD	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-5.52	-0.41	1.43e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.15	0.45	6.4e-9	Rheumatoid arthritis;
PAAD	cis	rs3126085	0.515	rs2146119	chr1:152368898	G/A	cg26876637	chr1:152193138	HRNR	-0.59	-4.38	-0.33	2.21e-5	Atopic dermatitis;
PAAD	cis	rs72960926	1.000	rs1830595	chr6:75176836	G/A	cg03266952	chr6:74778945	NA	-1.28	-6.61	-0.47	6.06e-10	Metabolite levels (MHPG);
PAAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg00647820	chr17:40259828	DHX58	-0.44	-5.19	-0.39	6.51e-7	Fibrinogen levels;
PAAD	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-10.71	-0.66	2.72e-20	Height;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.64	6.85	0.49	1.73e-10	Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.98	-0.44	1.54e-8	Cystic fibrosis severity;
PAAD	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.5	4.71	0.36	5.46e-6	Eosinophilic esophagitis;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18337363	chr3:52569053	NT5DC2	0.41	4.36	0.33	2.4e-5	Bipolar disorder;
PAAD	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.38	-0.4	2.79e-7	Metabolite levels;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-5.43	-0.4	2.23e-7	Height;
PAAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.68	-7.84	-0.54	7.15e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.48	-0.34	1.46e-5	IgG glycosylation;
PAAD	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg01529538	chr14:23388837	RBM23	0.55	5.56	0.41	1.18e-7	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.8	9.0	0.59	8.64e-16	Lung cancer;
PAAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.8	-8.35	-0.56	4e-14	Glaucoma (primary open-angle);
PAAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg18769074	chr3:133464867	TF	0.48	5.92	0.43	2.08e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.62	5.56	0.41	1.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.5	-4.75	-0.36	4.68e-6	Endometrial cancer;
PAAD	cis	rs12780845	1.000	rs35062783	chr10:17202869	A/C	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs6689263	0.615	rs112456461	chr1:20873804	C/A	cg25104613	chr1:20649108	VWA5B1	0.51	4.27	0.33	3.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg21226059	chr5:178986404	RUFY1	0.51	5.59	0.41	1.01e-7	Lung cancer;
PAAD	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.65	-7.08	-0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.55	-4.76	-0.36	4.47e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6494488	0.500	rs72742954	chr15:64903039	G/T	cg16425858	chr15:64791681	ZNF609	0.82	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg07622451	chr1:3079886	PRDM16	0.39	4.69	0.36	6.14e-6	Migraine;
PAAD	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-7.03	-0.5	6.43e-11	Morning vs. evening chronotype;
PAAD	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.87	-9.81	-0.62	6.63e-18	DNA methylation (variation);
PAAD	cis	rs2252865	0.517	rs2587513	chr1:8447237	T/C	cg23262827	chr1:8395557	SLC45A1	-0.46	-4.29	-0.33	3.13e-5	Optic cup area;Schizophrenia;Total body bone mineral density;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg14686297	chr22:46650375	NA	-0.48	-4.89	-0.37	2.55e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12935418	0.616	rs13332890	chr16:81005733	T/A	cg16651780	chr16:81037892	C16orf61	0.62	5.5	0.41	1.61e-7	Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03647581	chr2:242660564	ING5	0.63	7.59	0.52	2.97e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7172971	0.688	rs112413693	chr15:42383864	C/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg21479132	chr6:26055353	NA	0.89	5.29	0.39	4.28e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.43	4.51	0.34	1.28e-5	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg05110241	chr16:68378359	PRMT7	-1.14	-8.06	-0.55	2.13e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01942863	chr7:99769432	GPC2	0.52	4.28	0.33	3.25e-5	Platelet count;
PAAD	cis	rs7487075	0.619	rs4427617	chr12:46794502	A/G	cg14671384	chr12:47219920	SLC38A4	0.44	4.31	0.33	2.88e-5	Itch intensity from mosquito bite;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.69	-6.37	-0.46	2.19e-9	IgG glycosylation;
PAAD	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs1620921	0.505	rs1549741	chr6:161204783	G/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7246760	1.000	rs2081066	chr19:9928044	C/T	cg16876255	chr19:9731953	ZNF561	0.94	4.46	0.34	1.6e-5	Pursuit maintenance gain;
PAAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.48	-4.6	-0.35	8.86e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.24	-0.39	5.38e-7	Pulmonary function;
PAAD	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg21589460	chr7:45850481	NA	-0.74	-5.51	-0.41	1.49e-7	Subjective response to lithium treatment in bipolar disorder;
PAAD	cis	rs58521262	0.556	rs10418414	chr19:23185163	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.03	-0.55	2.48e-13	Type 2 diabetes;
PAAD	cis	rs2241685	0.850	rs58404476	chr2:1936998	C/T	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.75	-8.54	-0.57	1.31e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg27411982	chr8:10470053	RP1L1	0.48	5.36	0.4	3.04e-7	Neuroticism;
PAAD	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.59	-5.48	-0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.76	8.54	0.57	1.3e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.46e-6	Asthma;
PAAD	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.51	-5.52	-0.41	1.41e-7	Obesity-related traits;
PAAD	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.6	6.99	0.49	8.31e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg14906510	chr12:7781169	NA	0.63	4.54	0.35	1.15e-5	HDL cholesterol levels;
PAAD	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.88	5.7	0.42	6.19e-8	Schizophrenia;
PAAD	cis	rs12461016	1	rs12461016	chr19:17161687	G/A	cg19418318	chr19:17219073	MYO9B	0.35	4.92	0.37	2.25e-6	Diastolic blood pressure;
PAAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1499972	0.887	rs55718530	chr3:117534125	T/C	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-1.08	-11.68	-0.69	6.63e-23	Longevity;
PAAD	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.48	-4.26	-0.33	3.51e-5	Acne (severe);
PAAD	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg00750074	chr16:89608354	SPG7	-0.59	-5.58	-0.41	1.1e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg11779900	chr17:80519722	FOXK2	-0.48	-4.96	-0.37	1.85e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg06735111	chr7:14031037	ETV1	-0.65	-6.6	-0.47	6.43e-10	Dental caries;
PAAD	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.69	6.61	0.47	6.22e-10	Lymphocyte counts;
PAAD	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	0.96	7.79	0.53	9.86e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.55	5.25	0.39	5.13e-7	Breast cancer;
PAAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.52	5.11	0.38	9.37e-7	Parkinson's disease;
PAAD	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg22517653	chr1:2918612	NA	-0.6	-4.91	-0.37	2.37e-6	Plateletcrit;
PAAD	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.91	-0.63	3.67e-18	Response to antipsychotic treatment;
PAAD	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.46	-4.59	-0.35	9.27e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs35955841	0.569	rs2828	chr14:65336050	T/G	cg23373153	chr14:65346875	NA	0.53	4.92	0.37	2.26e-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7188861	0.861	rs7197188	chr16:11443424	C/A	cg01510278	chr16:11456238	NA	-0.44	-4.36	-0.33	2.38e-5	HDL cholesterol;
PAAD	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.02	0.63	1.9e-18	Cognitive test performance;
PAAD	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg21798802	chr22:38057573	PDXP	0.49	5.2	0.39	6.31e-7	Fat distribution (HIV);
PAAD	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg23033748	chr14:75592666	NEK9	0.4	4.84	0.37	3.12e-6	Height;
PAAD	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9677476	0.587	rs59886973	chr2:232137284	T/C	cg07929768	chr2:232055508	NA	0.39	4.58	0.35	9.71e-6	Food antigen IgG levels;
PAAD	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.79	9.14	0.6	3.8e-16	Hemoglobin concentration;
PAAD	cis	rs2270968	0.542	rs7611381	chr3:182649203	T/A	cg17054674	chr3:182697310	DCUN1D1	0.53	5.17	0.39	7.22e-7	Blood metabolite levels;Parkinson's disease;
PAAD	cis	rs7487075	0.619	rs4768719	chr12:46840838	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.56	0.35	1.07e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg16928487	chr17:17741425	SREBF1	-0.35	-4.62	-0.35	8.07e-6	Total body bone mineral density;
PAAD	cis	rs9815354	1.000	rs1717031	chr3:41905791	G/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27537453	chr16:2732578	KCTD5	0.59	6.62	0.47	5.69e-10	Metabolite levels  (X-11787);
PAAD	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs7219021	0.926	rs11657940	chr17:46852616	G/A	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs7896729	1.000	rs11253088	chr10:5346684	C/T	cg07902545	chr10:6194255	PFKFB3	-0.43	-4.48	-0.34	1.47e-5	Intelligence;
PAAD	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.58	-5.81	-0.43	3.56e-8	Pulse pressure;
PAAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg04450456	chr4:17643702	FAM184B	-0.56	-6.39	-0.46	1.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.48	-0.41	1.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-4.59	-0.35	9.28e-6	Fat distribution (HIV);
PAAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.89	11.12	0.67	2.1e-21	Coronary artery disease;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs688181	0.550	rs588277	chr6:158114365	T/C	cg10378795	chr6:158080676	ZDHHC14	0.47	4.57	0.35	1e-5	Platelet distribution width;
PAAD	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-5.88	-0.43	2.47e-8	Monocyte count;
PAAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-1.0	-10.78	-0.66	1.81e-20	Platelet count;
PAAD	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg06375148	chr1:209958343	C1orf74	0.69	5.77	0.42	4.38e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.6	7.27	0.51	1.75e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.51	4.97	0.37	1.75e-6	Mean corpuscular volume;
PAAD	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.83	10.1	0.63	1.11e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.5	-4.76	-0.36	4.55e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs962856	0.756	rs13016812	chr2:67624302	C/T	cg09028215	chr2:67624308	ETAA1	0.54	4.73	0.36	4.98e-6	Pancreatic cancer;
PAAD	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.37	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs41563	0.674	rs2192932	chr7:104653265	A/G	cg04380332	chr7:105027541	SRPK2	0.61	6.31	0.46	2.9e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.82	-9.74	-0.62	9.9e-18	Coronary artery disease;
PAAD	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg17264618	chr3:40429014	ENTPD3	0.35	4.32	0.33	2.83e-5	Renal cell carcinoma;
PAAD	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.97	-10.55	-0.65	7.21e-20	Asthma;
PAAD	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.79e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg14926445	chr8:58193284	C8orf71	-0.6	-4.65	-0.35	7.16e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.5	0.61	4.22e-17	Cognitive function;
PAAD	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg06042504	chr8:55087323	NA	-0.64	-6.06	-0.44	1.02e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-4.96	-0.37	1.86e-6	Mean platelet volume;
PAAD	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.62e-17	White blood cell count (basophil);
PAAD	cis	rs6496044	0.507	rs7175731	chr15:86154346	C/T	cg13263323	chr15:86062960	AKAP13	0.53	5.58	0.41	1.09e-7	Interstitial lung disease;
PAAD	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.34	-6.05	-0.44	1.08e-8	Type 2 diabetes;
PAAD	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg22467129	chr15:76604101	ETFA	0.56	5.16	0.39	7.52e-7	Blood metabolite levels;
PAAD	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg17385448	chr1:15911702	AGMAT	-0.39	-4.52	-0.34	1.23e-5	Systolic blood pressure;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	1.11	15.74	0.79	9.66e-34	Systemic lupus erythematosus;
PAAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2514805	0.803	rs2514796	chr8:95156145	A/G	cg25183890	chr8:94929275	PDP1	0.7	4.52	0.34	1.24e-5	Diisocyanate-induced asthma;
PAAD	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.3	0.33	3.06e-5	Educational attainment;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.48	5.16	0.39	7.74e-7	Tonsillectomy;
PAAD	cis	rs2278796	0.528	rs4951151	chr1:204970302	T/C	cg04862289	chr1:204966208	NFASC	0.47	4.53	0.34	1.18e-5	Mean platelet volume;
PAAD	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.54	0.57	1.29e-14	Exhaled nitric oxide output;
PAAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs2286379	0.682	rs12316367	chr12:1850146	G/A	cg05227549	chr12:1770782	NA	-0.44	-5.1	-0.38	9.95e-7	Blood pressure (smoking interaction);
PAAD	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg01075559	chr1:2537774	MMEL1	0.47	5.04	0.38	1.32e-6	Ulcerative colitis;
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.65	-4.63	-0.35	7.68e-6	Body mass index;
PAAD	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg01064725	chr1:204461714	NA	-0.51	-4.87	-0.37	2.76e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18363668	chr6:26026694	NA	0.58	6.31	0.46	2.9e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9409082	0.715	rs11999547	chr9:108940214	G/C	cg07010948	chr13:79181613	NA	-0.35	-6.6	-0.47	6.36e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6782025	0.837	rs234997	chr3:121001757	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg20913747	chr6:44695427	NA	-0.66	-6.33	-0.46	2.59e-9	Total body bone mineral density;
PAAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg14092988	chr3:52407081	DNAH1	0.4	5.11	0.38	9.72e-7	Electroencephalogram traits;
PAAD	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs939584	0.932	rs2867108	chr2:650143	T/C	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs859767	0.887	rs842348	chr2:135342391	T/G	cg12500956	chr2:135428796	TMEM163	0.33	4.84	0.37	3.2e-6	Neuroticism;
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2139634	0.965	rs11130093	chr3:46540612	A/T	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.33	-4.92	-0.37	2.24e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.58	-5.66	-0.42	7.5e-8	Sjögren's syndrome;
PAAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.5	4.93	0.37	2.11e-6	Obesity-related traits;
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.66	-7.23	-0.51	2.21e-11	Lung cancer;
PAAD	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg14583973	chr4:3374767	RGS12	-0.38	-5.7	-0.42	5.92e-8	Parental longevity (mother's age at death);
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.39	-5.77	-0.42	4.34e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg08601574	chr20:25228251	PYGB	0.56	5.96	0.44	1.66e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.34	-0.33	2.63e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.69	6.65	0.47	5.05e-10	Lymphocyte counts;
PAAD	cis	rs427941	1.000	rs10808119	chr7:101840716	G/A	cg06721601	chr7:101762633	CUX1	0.42	4.41	0.34	1.94e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs8014252	0.803	rs10135356	chr14:71030355	T/C	cg11204974	chr14:71022665	NA	-0.69	-4.58	-0.35	9.5e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	11.23	0.67	1.11e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs2133450	0.712	rs1396404	chr3:7365390	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-5.24	-0.39	5.2e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs965469	0.895	rs6051729	chr20:3290615	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.32	-0.33	2.86e-5	IFN-related cytopenia;
PAAD	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg08926642	chr1:7887455	PER3	0.5	4.39	0.34	2.13e-5	Inflammatory bowel disease;
PAAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.52	-5.08	-0.38	1.1e-6	Menopause (age at onset);
PAAD	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.73	11.04	0.67	3.46e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.5	5.12	0.38	9.21e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg10985347	chr2:127963512	CYP27C1	0.46	4.28	0.33	3.26e-5	Protein C levels;
PAAD	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.73	8.3	0.56	5.18e-14	Huntington's disease progression;
PAAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg13263323	chr15:86062960	AKAP13	-0.6	-6.68	-0.48	4.29e-10	Interstitial lung disease;
PAAD	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.47	4.74	0.36	4.79e-6	Mean corpuscular volume;
PAAD	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.77e-11	Eye color traits;
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.52	5.34	0.4	3.35e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg00599163	chr2:162100495	NA	0.52	7.38	0.51	9.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg00806126	chr19:22604979	ZNF98	0.39	4.94	0.37	2.05e-6	Pain;
PAAD	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.47	-4.44	-0.34	1.72e-5	Neuroticism;
PAAD	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.43	4.25	0.33	3.64e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01996304	chr16:31085596	ZNF668;ZNF646	-0.67	-6.99	-0.49	8.27e-11	Smoking initiation;
PAAD	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-6.97	-0.49	9.18e-11	Total cholesterol levels;
PAAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg04330084	chr7:123175371	IQUB	-0.49	-4.63	-0.35	7.72e-6	Migraine;
PAAD	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg20283391	chr11:68216788	NA	-0.54	-5.18	-0.39	7.09e-7	Total body bone mineral density;
PAAD	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg00631329	chr6:26305371	NA	-0.48	-4.84	-0.37	3.15e-6	Educational attainment;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs9473924	0.542	rs2894780	chr6:50924527	T/G	cg14470998	chr6:50812995	TFAP2B	0.8	5.34	0.4	3.38e-7	Body mass index;
PAAD	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	8.7	0.58	5.18e-15	Ulcerative colitis;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25155679	chr13:67479146	PCDH9	-0.55	-6.36	-0.46	2.29e-9	Energy expenditure (24h);
PAAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.61	6.73	0.48	3.24e-10	Tumor biomarkers;
PAAD	cis	rs4356203	0.905	rs10832733	chr11:17111272	A/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.31	-0.33	2.92e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.51	4.33	0.33	2.74e-5	Cocaine dependence;
PAAD	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.75	-7.56	-0.52	3.55e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg00310523	chr12:86230176	RASSF9	0.43	4.54	0.35	1.14e-5	Major depressive disorder;
PAAD	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.44e-13	Eotaxin levels;
PAAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.54	6.03	0.44	1.17e-8	Total body bone mineral density;
PAAD	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg01305830	chr4:1604576	NA	-0.46	-4.55	-0.35	1.1e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1499972	0.504	rs1995245	chr3:117776020	A/G	cg07612923	chr3:117604196	NA	0.62	4.57	0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.08	8.16	0.55	1.17e-13	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16256065	chr11:68216328	LRP5	0.56	7.15	0.5	3.34e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg14758556	chr20:62440591	NA	0.52	4.46	0.34	1.56e-5	Glioblastoma;
PAAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg19254793	chr6:44695348	NA	-0.46	-4.4	-0.34	2.04e-5	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10108612	chr1:19203999	ALDH4A1	0.57	6.42	0.46	1.63e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.48	0.41	1.73e-7	Life satisfaction;
PAAD	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.76	8.19	0.55	9.75e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.87	-0.43	2.6e-8	Type 2 diabetes;
PAAD	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26876637	chr1:152193138	HRNR	0.88	6.87	0.49	1.57e-10	Atopic dermatitis;
PAAD	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.09	15.99	0.79	2.19e-34	Chronic sinus infection;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg18769074	chr3:133464867	TF	0.41	4.84	0.37	3.15e-6	Iron status biomarkers;
PAAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.73	6.95	0.49	1.02e-10	Pancreatic cancer;
PAAD	cis	rs89107	0.549	rs17427116	chr6:118986198	G/A	cg21191810	chr6:118973309	C6orf204	0.37	4.44	0.34	1.71e-5	Cardiac structure and function;
PAAD	cis	rs4740619	0.846	rs950234	chr9:15755645	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.49	-0.34	1.41e-5	Body mass index;
PAAD	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.34	6.3	0.45	3.11e-9	Type 2 diabetes;
PAAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.16	-0.39	7.52e-7	Cystic fibrosis severity;
PAAD	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.43	0.46	1.6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.35	-10.59	-0.65	5.58e-20	Obesity-related traits;
PAAD	cis	rs8040855	0.791	rs8042888	chr15:85695591	G/A	cg08123816	chr15:85640762	PDE8A	0.4	4.66	0.35	6.94e-6	Bulimia nervosa;
PAAD	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.72	5.19	0.39	6.56e-7	Breast cancer;
PAAD	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.36	4.45	0.34	1.65e-5	Systolic blood pressure;
PAAD	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg21427119	chr20:30132790	HM13	-0.64	-5.14	-0.38	8.37e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.54	4.73	0.36	4.98e-6	Coronary artery disease;
PAAD	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.1	14.27	0.76	7.29e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14169450	chr9:139327907	INPP5E	0.53	4.68	0.35	6.42e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.47	-4.59	-0.35	9.22e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.31	-0.4	3.78e-7	Initial pursuit acceleration;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10997500	chr13:113974988	LAMP1	0.64	6.72	0.48	3.42e-10	Smoking initiation;
PAAD	trans	rs901683	1.000	rs34516867	chr10:46081737	T/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-6.28	-0.45	3.41e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.48	-0.34	1.47e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs3779195	1.000	rs3779195	chr7:97993362	T/A	cg21770322	chr7:97807741	LMTK2	-0.51	-4.54	-0.35	1.12e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg13264159	chr8:625131	ERICH1	-0.75	-5.06	-0.38	1.22e-6	IgG glycosylation;
PAAD	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg07784872	chr16:85687041	KIAA0182	-0.56	-5.06	-0.38	1.18e-6	Platelet distribution width;
PAAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg03959625	chr15:84868606	LOC388152	-0.43	-4.62	-0.35	8.22e-6	P wave terminal force;
PAAD	cis	rs9810890	1.000	rs73196983	chr3:128452500	G/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.31	7.42	0.52	7.63e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg02462569	chr6:150064036	NUP43	-0.57	-6.33	-0.46	2.65e-9	Lung cancer;
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-8.55	-0.57	1.23e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	1.05	10.52	0.65	8.89e-20	Post bronchodilator FEV1;
PAAD	cis	rs939584	0.778	rs62105304	chr2:632925	A/G	cg14515364	chr2:636606	NA	0.49	4.51	0.34	1.31e-5	Body mass index;
PAAD	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	6.3	0.45	3.11e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22175943	chr7:80329687	NA	0.62	6.45	0.46	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.58	-6.12	-0.44	7.62e-9	Lung cancer;
PAAD	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.89	5.01	0.38	1.51e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7176527	1.000	rs3762169	chr15:85141959	C/T	cg24253500	chr15:84953950	NA	-0.63	-5.2	-0.39	6.26e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15145965	chr22:50218605	BRD1	0.56	4.77	0.36	4.25e-6	Schizophrenia;
PAAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.56	-7.52	-0.52	4.37e-12	Height;
PAAD	cis	rs7217780	0.569	rs2305959	chr17:15234232	G/A	cg20358362	chr17:14248304	HS3ST3B1	-0.57	-4.75	-0.36	4.73e-6	Preterm birth (maternal effect);
PAAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg15604389	chr3:122379662	NA	0.56	6.04	0.44	1.12e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	cis	rs7570971	1.000	rs1375131	chr2:135954797	T/C	cg07169764	chr2:136633963	MCM6	0.64	5.81	0.43	3.49e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs9816226	0.591	rs75160594	chr3:185810481	C/G	cg00760338	chr3:185826511	ETV5	-0.72	-5.55	-0.41	1.26e-7	Obesity;Body mass index;
PAAD	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.81	-7.6	-0.52	2.81e-12	Blood metabolite levels;
PAAD	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.49	-4.78	-0.36	4.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg06074448	chr4:187884817	NA	-0.63	-7.85	-0.54	6.77e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg11993925	chr19:44307056	LYPD5	-0.5	-6.66	-0.48	4.78e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg02917321	chr22:38215204	NA	-0.44	-4.75	-0.36	4.74e-6	Glioblastoma;Glioma;
PAAD	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.43	-4.54	-0.35	1.13e-5	Personality dimensions;
PAAD	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.66e-6	Educational attainment;
PAAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg06632027	chr4:90757378	SNCA	-0.51	-4.51	-0.34	1.26e-5	Neuroticism;
PAAD	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg26570165	chr1:119541833	NA	-0.46	-4.28	-0.33	3.3e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.53	-0.57	1.41e-14	Homoarginine levels;
PAAD	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg04705435	chr11:17411270	KCNJ11	0.62	6.34	0.46	2.5e-9	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.84	8.94	0.59	1.21e-15	Osteoporosis;
PAAD	cis	rs7631605	0.875	rs3821823	chr3:37158827	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.85	5.38	0.4	2.71e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6669919	0.647	rs10863900	chr1:211675597	A/G	cg10512769	chr1:211675356	NA	-0.33	-4.28	-0.33	3.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.77	-6.12	-0.44	7.65e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19784903	chr17:45786737	TBKBP1	-0.47	-4.9	-0.37	2.45e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.77	-6.2	-0.45	5.02e-9	Cancer;
PAAD	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.64	7.12	0.5	4.08e-11	Coronary artery disease;
PAAD	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.63	6.29	0.45	3.26e-9	Capecitabine sensitivity;
PAAD	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.53e-6	Vitiligo;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.48	-4.94	-0.37	2.05e-6	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.81	-0.54	8.91e-13	Height;
PAAD	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-7.03	-0.5	6.48e-11	Hemoglobin concentration;
PAAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.77	-5.48	-0.41	1.74e-7	Yeast infection;
PAAD	trans	rs901683	0.850	rs80222863	chr10:46016975	C/T	cg12869334	chr8:37699360	GPR124	0.98	6.78	0.48	2.44e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg19192590	chr2:178524533	PDE11A	0.4	4.63	0.35	7.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs62392365	0.536	rs114354133	chr6:25157902	G/A	cg26336265	chr6:25042955	NA	0.96	5.4	0.4	2.48e-7	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs2899832	1.000	rs2899832	chr14:35740941	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	4.62	0.35	8.03e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg01448562	chr3:133502909	NA	-0.47	-4.75	-0.36	4.72e-6	Iron status biomarkers;
PAAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-9.04	-0.59	6.6e-16	Bone mineral density;
PAAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.57	7.73	0.53	1.36e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg16606324	chr3:10149918	C3orf24	0.55	4.73	0.36	4.99e-6	Alzheimer's disease;
PAAD	cis	rs4294134	0.580	rs11760731	chr7:135244179	C/T	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.35	0.46	2.34e-9	Lung cancer in ever smokers;
PAAD	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.66	6.44	0.46	1.49e-9	Schizophrenia;
PAAD	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg18084798	chr19:33555255	RHPN2	0.48	5.01	0.38	1.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	1.05	15.3	0.78	1.43e-32	Menarche (age at onset);
PAAD	cis	rs10501293	1.000	rs1559762	chr11:43128541	C/T	cg03447554	chr11:43094025	NA	0.5	4.95	0.37	1.94e-6	Cognitive performance;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02700478	chr2:12856717	TRIB2	0.59	6.56	0.47	7.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.64	6.86	0.49	1.59e-10	Leprosy;
PAAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19346786	chr7:2764209	NA	-0.38	-5.22	-0.39	5.7e-7	Height;
PAAD	cis	rs346785	0.666	rs9902690	chr17:74295140	A/G	cg09812376	chr17:74270190	QRICH2	-0.48	-6.06	-0.44	1.02e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs9325144	0.794	rs7963855	chr12:38914187	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-5.97	-0.44	1.62e-8	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg13722127	chr7:150037890	RARRES2	-0.6	-6.25	-0.45	3.89e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.29	-0.33	3.13e-5	Dupuytren's disease;
PAAD	cis	rs13102973	0.863	rs11099307	chr4:135908104	T/C	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg10494973	chr17:80897199	TBCD	-0.49	-4.91	-0.37	2.34e-6	Breast cancer;
PAAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.58	5.35	0.4	3.18e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09597638	chr17:3907349	NA	0.87	9.32	0.6	1.29e-16	Type 2 diabetes;
PAAD	cis	rs13242816	1.000	rs56382464	chr7:116040828	C/G	cg16553024	chr7:116138462	CAV2	-0.66	-4.49	-0.34	1.4e-5	P wave duration;
PAAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.87	6.46	0.46	1.32e-9	Gut microbiome composition (summer);
PAAD	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.69	4.32	0.33	2.8e-5	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27298559	chr17:57785523	PTRH2;TMEM49	0.62	7.1	0.5	4.39e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.5	-6.55	-0.47	8.19e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	1.21	7.41	0.51	8.34e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg13012494	chr21:47604986	C21orf56	0.43	4.41	0.34	1.96e-5	Testicular germ cell tumor;
PAAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	5.79	0.43	3.91e-8	Lung cancer in ever smokers;
PAAD	cis	rs4795519	0.922	rs8076631	chr17:22172118	C/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.17	-0.5	3.02e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.84	6.45	0.46	1.44e-9	Axial length;
PAAD	cis	rs2051773	0.567	rs4255517	chr11:17043209	C/G	cg15378786	chr11:17036137	PLEKHA7	0.53	4.54	0.35	1.14e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.46	0.34	1.57e-5	Breast cancer;
PAAD	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.55	4.54	0.35	1.12e-5	RR interval (heart rate);
PAAD	cis	rs740474	1.000	rs740474	chr5:140925362	A/G	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.29	-4.27	-0.33	3.42e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg08923669	chr16:420230	MRPL28	-0.68	-6.48	-0.47	1.18e-9	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg10494973	chr17:80897199	TBCD	-0.49	-4.91	-0.37	2.34e-6	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09351254	chr2:242088885	PASK;PPP1R7	-0.59	-6.35	-0.46	2.37e-9	Smoking initiation;
PAAD	cis	rs914615	0.507	rs4971085	chr1:155138222	T/C	cg20311333	chr1:155197753	GBAP1	0.44	4.26	0.33	3.61e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.41	-0.4	2.38e-7	Initial pursuit acceleration;
PAAD	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg02353165	chr6:42928485	GNMT	0.61	4.81	0.36	3.59e-6	Blood protein levels;
PAAD	cis	rs7707921	0.914	rs4081859	chr5:81466669	G/A	cg21483461	chr5:81570383	RPS23	0.51	4.32	0.33	2.83e-5	Breast cancer;
PAAD	cis	rs4907240	0.961	rs60959055	chr2:97313450	C/G	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.61	-0.35	8.39e-6	Event-related brain oscillations;
PAAD	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg05538161	chr7:4242769	SDK1	0.4	4.31	0.33	2.97e-5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.51e-9	Bipolar disorder;
PAAD	cis	rs4746818	0.579	rs118014923	chr10:70932108	T/C	cg11621586	chr10:70884670	VPS26A	-1.17	-5.85	-0.43	2.92e-8	Left atrial antero-posterior diameter;
PAAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.67	-6.93	-0.49	1.09e-10	Schizophrenia;
PAAD	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg07777115	chr5:623756	CEP72	-0.67	-4.28	-0.33	3.27e-5	Obesity-related traits;
PAAD	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg18551225	chr6:44695536	NA	-0.69	-6.96	-0.49	9.41e-11	Total body bone mineral density;
PAAD	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.58	6.51	0.47	1.03e-9	Coronary artery disease;
PAAD	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg17764715	chr19:33622953	WDR88	0.66	6.21	0.45	4.73e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs35000415	0.938	rs13239597	chr7:128695983	C/A	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg05484376	chr2:27715224	FNDC4	0.46	4.47	0.34	1.52e-5	Oral cavity cancer;
PAAD	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg22815214	chr1:201083145	CACNA1S	0.53	4.31	0.33	2.96e-5	Permanent tooth development;
PAAD	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.15	0.39	8.12e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.53	4.86	0.37	2.88e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.59	-0.41	1.03e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.31	0.33	2.94e-5	Aortic root size;
PAAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.77	7.67	0.53	1.91e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.54	5.4	0.4	2.51e-7	Menarche (age at onset);
PAAD	cis	rs4588572	0.779	rs3088102	chr5:77654679	G/A	cg11547950	chr5:77652471	NA	0.96	8.66	0.57	6.48e-15	Triglycerides;
PAAD	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg16898833	chr6:26189333	HIST1H4D	1.08	5.85	0.43	2.92e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1419980	0.730	rs11559770	chr12:7764642	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.72	8.95	0.59	1.15e-15	Dupuytren's disease;
PAAD	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	4.54	0.35	1.14e-5	Personality dimensions;
PAAD	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs4740619	0.556	rs1359954	chr9:16039223	A/G	cg14451791	chr9:16040625	NA	-0.43	-4.95	-0.37	1.94e-6	Body mass index;
PAAD	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg16342193	chr10:102329863	NA	-0.76	-8.06	-0.55	2.09e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	1.0	6.09	0.44	9.03e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg25233709	chr10:116636983	FAM160B1	0.43	5.38	0.4	2.73e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg12923728	chr3:195709715	SDHAP1	0.79	5.79	0.42	3.95e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.28	-4.27	-0.33	3.46e-5	Urate levels in overweight individuals;
PAAD	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg09184832	chr6:79620586	NA	-0.42	-4.29	-0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.09	8.47	0.57	1.96e-14	Vitiligo;
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.52e-20	Ulcerative colitis;
PAAD	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg26205652	chr12:48591994	NA	0.95	9.6	0.61	2.35e-17	Longevity (90 years and older);
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.55	0.35	1.11e-5	Personality dimensions;
PAAD	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.69	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs58521262	0.585	rs289302	chr19:23169954	G/A	cg03433597	chr19:22806448	NA	0.24	4.26	0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg21419209	chr3:44054225	NA	0.58	5.7	0.42	6.15e-8	Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs4740619	0.590	rs4247294	chr9:16030960	C/T	cg14451791	chr9:16040625	NA	-0.45	-5.37	-0.4	2.87e-7	Body mass index;
PAAD	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	5.41	0.4	2.42e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.27e-5	Renal cell carcinoma;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.59	-0.61	2.5e-17	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.57e-5	Life satisfaction;
PAAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg07148914	chr20:33460835	GGT7	0.49	4.63	0.35	7.65e-6	Coronary artery disease;
PAAD	cis	rs7713065	0.802	rs111280764	chr5:131785789	G/C	cg14196790	chr5:131705035	SLC22A5	-0.47	-4.4	-0.34	2e-5	Lung function (FEV1/FVC);
PAAD	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.49	4.99	0.38	1.64e-6	Colorectal cancer;
PAAD	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg21181453	chr9:130700954	DPM2	0.41	4.59	0.35	9.32e-6	Glaucoma (primary angle closure);
PAAD	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.18e-10	Blood protein levels;
PAAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg24849736	chr1:201084428	NA	0.47	4.59	0.35	9.28e-6	Permanent tooth development;
PAAD	cis	rs9463078	0.715	rs7768521	chr6:45060938	C/G	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.88	10.01	0.63	1.95e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.52	-6.26	-0.45	3.81e-9	Alcohol dependence;
PAAD	cis	rs735539	0.521	rs2763002	chr13:21369982	T/C	cg27234864	chr13:21295941	IL17D	0.56	4.6	0.35	8.68e-6	Dental caries;
PAAD	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.29e-6	Blood metabolite levels;
PAAD	cis	rs3736485	0.932	rs2124879	chr15:51916833	T/C	cg19558802	chr15:51695713	GLDN	-0.44	-4.41	-0.34	1.97e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13870426	chr17:30244630	NA	0.59	5.66	0.42	7.44e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.69	5.96	0.44	1.67e-8	Common traits (Other);
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.86	-9.27	-0.6	1.76e-16	Paraoxonase activity;
PAAD	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg01966878	chr4:90757139	SNCA	-0.46	-4.32	-0.33	2.82e-5	Dementia with Lewy bodies;
PAAD	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14019695	chr9:139328340	INPP5E	0.48	4.51	0.34	1.27e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg02917321	chr22:38215204	NA	-0.43	-4.55	-0.35	1.08e-5	Glioblastoma;Glioma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23675362	chr1:180601130	XPR1	-0.61	-6.41	-0.46	1.78e-9	Smoking initiation;
PAAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.3e-5	Menopause (age at onset);
PAAD	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.87	-9.65	-0.62	1.79e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg09796270	chr17:17721594	SREBF1	0.43	4.58	0.35	9.5e-6	Total body bone mineral density;
PAAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg09399716	chr2:46890238	NA	-0.72	-5.72	-0.42	5.42e-8	Height;
PAAD	cis	rs7084921	0.809	rs12412869	chr10:101797412	A/G	cg04359915	chr10:101825029	CPN1	-0.37	-5.33	-0.4	3.54e-7	Bone mineral density;
PAAD	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.65	-6.09	-0.44	9.01e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg14036092	chr11:66035641	RAB1B	0.64	5.34	0.4	3.36e-7	Gout;
PAAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.92	7.85	0.54	7.07e-13	Total cholesterol levels;
PAAD	cis	rs7561273	0.545	rs6733127	chr2:24325805	G/A	cg04809136	chr2:24300158	SF3B14	0.46	5.24	0.39	5.28e-7	Quantitative traits;
PAAD	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg15440763	chr7:158190612	PTPRN2	0.43	4.38	0.33	2.19e-5	Obesity-related traits;
PAAD	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.2	0.45	5.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.76	0.69	4.18e-23	Smoking behavior;
PAAD	cis	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01585723	chr16:33734837	NA	0.41	4.32	0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.57	4.41	0.34	1.93e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg00814883	chr7:100076585	TSC22D4	-0.64	-5.19	-0.39	6.77e-7	Platelet count;
PAAD	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.75	5.57	0.41	1.14e-7	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20560906	chr3:47459876	SCAP	0.68	6.64	0.47	5.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17123764	0.605	rs7954994	chr12:50068089	C/T	cg14846292	chr12:49726500	C1QL4	-0.69	-4.54	-0.35	1.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	5.22	0.39	5.78e-7	Menarche (age at onset);
PAAD	cis	rs2594989	0.943	rs62245870	chr3:11439838	G/A	cg01796438	chr3:11312864	ATG7	-0.58	-4.5	-0.34	1.35e-5	Circulating chemerin levels;
PAAD	cis	rs3736757	1.000	rs9658937	chr1:184667371	C/A	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs2299116	0.785	rs35010731	chr7:28793405	C/G	cg06647007	chr7:28747836	CREB5	0.51	4.99	0.38	1.65e-6	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-1.14	-15.16	-0.78	3.36e-32	Longevity;
PAAD	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg02404636	chr22:31891804	SFI1	-0.49	-4.94	-0.37	2.03e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.9	-0.43	2.32e-8	Menopause (age at onset);
PAAD	cis	rs1975974	0.574	rs59896566	chr17:21733621	C/T	cg18423549	chr17:21743878	NA	-0.54	-5.22	-0.39	5.79e-7	Psoriasis;
PAAD	cis	rs501120	0.564	rs2802482	chr10:44675851	A/G	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2120991	0.901	rs9919682	chr12:54293218	G/C	cg25640699	chr12:54070114	ATP5G2	-0.43	-4.52	-0.34	1.23e-5	Biliary atresia;
PAAD	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.69	0.58	5.5e-15	Rheumatoid arthritis;
PAAD	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.66	7.12	0.5	4.03e-11	Longevity;
PAAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.93	0.37	2.12e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg20917491	chr3:195578259	NA	0.53	4.88	0.37	2.62e-6	Pancreatic cancer;
PAAD	cis	rs1879734	0.731	rs6588487	chr1:54166790	G/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.91	-0.43	2.17e-8	Mitral valve prolapse;
PAAD	cis	rs56046484	0.956	rs34076898	chr15:85664800	A/C	cg08123816	chr15:85640762	PDE8A	-0.5	-5.15	-0.39	7.93e-7	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12858701	chr10:114894792	TCF7L2	0.57	6.4	0.46	1.83e-9	Smoking initiation;
PAAD	cis	rs1642645	0.915	rs10890177	chr1:42506381	T/C	cg01990334	chr1:42801334	FOXJ3	-0.62	-5.53	-0.41	1.34e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.97e-6	Neuroticism;
PAAD	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06530960	chr19:49140787	SEC1;DBP	-0.63	-5.22	-0.39	5.83e-7	Myeloid white cell count;
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg21269045	chr12:125625041	AACS	-0.48	-4.65	-0.35	7.06e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12379764	chr21:47803548	PCNT	0.45	4.27	0.33	3.49e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09060316	chr2:26467451	HADHB;HADHA	0.57	6.42	0.46	1.62e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.49	-4.26	-0.33	3.63e-5	Aortic root size;
PAAD	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	trans	rs4382726	0.585	rs6419460	chr1:209412567	C/T	cg14042241	chr19:1474872	C19orf25	0.53	6.38	0.46	2.04e-9	Response to amphetamines;
PAAD	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg04165759	chr1:150448943	RPRD2	0.5	5.19	0.39	6.58e-7	Migraine;
PAAD	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs6782025	0.837	rs338979	chr3:120950098	A/C	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23544223	chr18:12777786	NA	-0.73	-6.24	-0.45	4.22e-9	Inflammatory skin disease;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg23743428	chr13:21893420	NA	-0.51	-7.33	-0.51	1.3e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg27236539	chr20:62289627	RTEL1	0.66	5.93	0.43	2e-8	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.87	10.87	0.66	1.03e-20	Prudent dietary pattern;
PAAD	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.29e-6	Airway imaging phenotypes;
PAAD	cis	rs6782029	0.583	rs11128561	chr3:11677427	A/T	cg07643000	chr3:11666825	VGLL4	-0.62	-4.49	-0.34	1.4e-5	Anorexia nervosa;
PAAD	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.8	-0.36	3.84e-6	Tuberculosis;
PAAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.93	8.08	0.55	1.82e-13	Alzheimer's disease;
PAAD	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg23920097	chr1:209922102	NA	-0.49	-4.46	-0.34	1.6e-5	Red blood cell count;
PAAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-4.38	-0.33	2.21e-5	Personality dimensions;
PAAD	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.51	4.31	0.33	2.93e-5	Body mass index;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.56	-5.02	-0.38	1.45e-6	Coronary artery disease;
PAAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.5	5.06	0.38	1.19e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.08	0.55	1.9e-13	Monocyte percentage of white cells;
PAAD	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.12	0.55	1.51e-13	Lung cancer in ever smokers;
PAAD	cis	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25952510	chr10:116055721	AFAP1L2	-0.64	-6.32	-0.46	2.79e-9	Obesity-related traits;
PAAD	cis	rs1358748	0.522	rs2092911	chr1:67574319	T/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.16	-7.74	-0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.68	-8.99	-0.59	9.06e-16	Hemoglobin concentration;
PAAD	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg11288833	chr15:55489084	RSL24D1	0.58	4.7	0.36	5.9e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.47	4.61	0.35	8.31e-6	Inflammatory bowel disease;
PAAD	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.86	-9.42	-0.61	6.8e-17	Body mass index;
PAAD	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.44	6.3	0.46	2.98e-9	Information processing speed;
PAAD	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.47	4.7	0.36	5.78e-6	Schizophrenia;
PAAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg06740227	chr12:86229804	RASSF9	0.59	5.2	0.39	6.35e-7	Major depressive disorder;
PAAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-1.1	-8.2	-0.55	9.25e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.63	7.44	0.52	6.79e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs10121009	0.635	rs513002	chr9:35321690	G/T	cg11846315	chr9:35647073	NA	-0.47	-4.3	-0.33	3.07e-5	Parkinson's disease;
PAAD	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg24044776	chr19:53454761	ZNF816A	-0.45	-4.92	-0.37	2.26e-6	Psoriasis;
PAAD	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg25801113	chr15:45476975	SHF	0.42	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.79	8.45	0.57	2.21e-14	Mean corpuscular volume;
PAAD	cis	rs988913	0.697	rs9475159	chr6:54995517	A/G	cg03513858	chr6:54763001	FAM83B	0.4	4.35	0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.62	0.41	8.92e-8	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg15105011	chr4:940614	TMEM175	-0.44	-4.73	-0.36	5.04e-6	Parkinson's disease;
PAAD	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.79	-6.1	-0.44	8.52e-9	Uric acid levels;
PAAD	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.84	-8.79	-0.58	2.99e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.6	6.24	0.45	4.15e-9	Lung cancer;
PAAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg13606994	chr1:44402422	ARTN	-0.49	-4.48	-0.34	1.48e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-4.5	-0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.49	-5.21	-0.39	6.15e-7	Menarche (age at onset);
PAAD	cis	rs8077577	0.895	rs62072464	chr17:18108314	T/C	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs3747547	0.710	rs7864512	chr9:37949638	G/A	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg00450029	chr8:599525	NA	-0.82	-5.04	-0.38	1.33e-6	IgG glycosylation;
PAAD	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13023536	chr11:94226537	MRE11A;ANKRD49	0.7	6.61	0.47	6.06e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs59104589	0.521	rs3771584	chr2:242399493	C/G	cg04488487	chr2:242709673	NA	0.58	4.7	0.36	5.84e-6	Fibrinogen levels;
PAAD	cis	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs939584	0.825	rs7564711	chr2:639061	T/G	cg03610516	chr2:642275	NA	0.61	5.47	0.41	1.77e-7	Body mass index;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	7.33	0.51	1.27e-11	Lymphocyte counts;
PAAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.68	7.57	0.52	3.4e-12	Systemic lupus erythematosus;
PAAD	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.41	4.83	0.37	3.25e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17376030	chr22:41985996	PMM1	-0.64	-4.39	-0.34	2.09e-5	Cannabis dependence symptom count;
PAAD	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg10631289	chr15:39006617	NA	0.44	4.28	0.33	3.25e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg20243544	chr17:37824526	PNMT	-0.53	-4.65	-0.35	7.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	5.05	0.38	1.24e-6	Systolic blood pressure;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg17372223	chr3:52568218	NT5DC2	-0.49	-5.02	-0.38	1.42e-6	Electroencephalogram traits;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06915872	chr16:87998081	BANP	0.56	5.07	0.38	1.17e-6	Menopause (age at onset);
PAAD	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.88	-7.26	-0.51	1.92e-11	Diastolic blood pressure;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg20007245	chr22:24372913	LOC391322	-0.88	-9.75	-0.62	9.8e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-4.99	-0.37	1.67e-6	Mean platelet volume;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02071572	chr4:1403502	NA	0.36	4.6	0.35	8.76e-6	Obesity-related traits;
PAAD	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.52	4.36	0.33	2.41e-5	Homoarginine levels;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.47	4.55	0.35	1.07e-5	Cognitive ability;
PAAD	cis	rs12476592	0.571	rs2028883	chr2:63804531	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.54	5.61	0.41	9.5e-8	Bladder cancer;
PAAD	cis	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.83	-5.5	-0.41	1.58e-7	Mononucleosis;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.64	5.4	0.4	2.49e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12931267	0.561	rs34395984	chr16:89659511	C/T	cg07984980	chr16:89898383	SPIRE2	0.82	4.47	0.34	1.52e-5	Skin sensitivity to sun;Freckling;Hair color;
PAAD	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.74	8.31	0.56	4.97e-14	Corneal astigmatism;
PAAD	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.39	4.87	0.37	2.78e-6	Sitting height ratio;
PAAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg06766960	chr11:133703094	NA	-0.66	-7.27	-0.51	1.78e-11	Childhood ear infection;
PAAD	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.52	5.3	0.39	4.07e-7	Interleukin-18 levels;
PAAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2916733	0.530	rs2442516	chr8:6291558	C/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.51	-0.34	1.31e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg25364880	chr3:44379878	C3orf23	0.59	5.55	0.41	1.24e-7	Depressive symptoms;
PAAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02244288	chr16:89573955	SPG7	0.32	4.42	0.34	1.83e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12612619	0.695	rs11126806	chr2:27225144	C/A	cg00617064	chr2:27272375	NA	0.5	5.3	0.39	4.06e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.41	4.88	0.37	2.64e-6	Intraocular pressure;
PAAD	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.61	4.49	0.34	1.39e-5	Neuroblastoma;
PAAD	cis	rs9896052	0.580	rs8078577	chr17:73464294	G/T	cg25649188	chr17:73499917	CASKIN2	0.61	4.66	0.35	6.77e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs838147	0.844	rs8111288	chr19:49247900	G/A	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.93	-12.67	-0.72	1.46e-25	Prudent dietary pattern;
PAAD	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg10595753	chr17:80898281	TBCD	-0.47	-4.28	-0.33	3.3e-5	Glycated hemoglobin levels;
PAAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.03	0.38	1.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.63	5.04	0.38	1.29e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7577696	0.722	rs466125	chr2:32462092	G/A	cg02381751	chr2:32503542	YIPF4	0.44	4.75	0.36	4.61e-6	Inflammatory biomarkers;
PAAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.8	-0.43	3.67e-8	Monocyte count;
PAAD	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.75	-0.48	2.88e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24225147	chr10:81107889	PPIF	-0.51	-5.07	-0.38	1.14e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.44	4.98	0.37	1.68e-6	Electroencephalogram traits;
PAAD	cis	rs11700980	0.551	rs8132111	chr21:30117206	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	7.79	0.53	9.62e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs740474	0.831	rs3828677	chr5:140993623	C/T	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.29	-4.28	-0.33	3.31e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4722166	0.508	rs4506102	chr7:22747152	A/T	cg05472934	chr7:22766657	IL6	0.45	4.5	0.34	1.32e-5	Lung cancer;
PAAD	cis	rs7742824	1.000	rs7742030	chr6:44065062	C/T	cg21657043	chr6:44035552	NA	0.53	5.42	0.4	2.32e-7	Major depressive disorder;
PAAD	cis	rs4975616	0.686	rs37009	chr5:1350339	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.68	-6.84	-0.49	1.83e-10	Lung cancer;
PAAD	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg03983715	chr16:68378420	PRMT7	0.96	6.77	0.48	2.61e-10	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.84e-9	Blood metabolite levels;
PAAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.65	0.57	6.67e-15	Corneal astigmatism;
PAAD	cis	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs59888335	0.858	rs4856307	chr3:80961100	G/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg14703610	chr5:56206110	C5orf35	0.63	5.95	0.43	1.77e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs7219021	1.000	rs11868085	chr17:46847575	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.41	-4.69	-0.36	6.16e-6	Height;
PAAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg09017928	chr7:158110068	PTPRN2	-0.44	-4.26	-0.33	3.64e-5	Calcium levels;
PAAD	cis	rs7624766	0.508	rs1598495	chr3:160497731	G/A	cg22637730	chr3:160473554	PPM1L	0.55	4.74	0.36	4.9e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.6	-5.52	-0.41	1.4e-7	Schizophrenia;
PAAD	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg02577049	chr1:1851347	TMEM52	0.36	4.47	0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs2236267	0.726	rs2208547	chr14:88604515	C/T	cg18078958	chr14:88630771	NA	-0.51	-6.55	-0.47	8.24e-10	Food antigen IgG levels;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.74	-0.36	4.92e-6	Lymphocyte counts;
PAAD	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.61	-6.82	-0.48	2.02e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.72	-7.3	-0.51	1.54e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1334894	1.000	rs16878812	chr6:35569562	A/G	cg07213720	chr6:35227408	ZNF76	-0.72	-4.31	-0.33	2.86e-5	Coronary artery disease;
PAAD	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-7.47	-0.52	5.81e-12	Colorectal cancer;
PAAD	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.36	0.4	3.1e-7	Personality dimensions;
PAAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg18402987	chr7:1209562	NA	1.06	5.52	0.41	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7714584	1.000	rs1428555	chr5:150257391	A/G	cg22134413	chr5:150180641	NA	-0.7	-4.92	-0.37	2.18e-6	Crohn's disease;
PAAD	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg01942863	chr7:99769432	GPC2	0.51	4.71	0.36	5.61e-6	Coronary artery disease;
PAAD	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	4.42	0.34	1.9e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg27129171	chr3:47204927	SETD2	-0.64	-6.74	-0.48	3.09e-10	Colorectal cancer;
PAAD	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg06569542	chr10:98946673	SLIT1	0.45	4.59	0.35	9.05e-6	Monocyte count;
PAAD	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-5.09	-0.38	1.06e-6	Personality dimensions;
PAAD	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg19257562	chr1:2043853	PRKCZ	-0.4	-4.55	-0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs7678296	0.649	rs6831699	chr4:37237387	A/G	cg06805348	chr4:37245195	KIAA1239	0.69	4.52	0.34	1.21e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.81	-8.13	-0.55	1.43e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7594645	1.000	rs10490541	chr2:207587173	C/T	cg25244921	chr15:65342634	OSTBETA	-1.17	-6.4	-0.46	1.81e-9	Episodic memory;
PAAD	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.71	5.66	0.42	7.31e-8	Height;
PAAD	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs9912789	0.875	rs9892075	chr17:79186737	T/C	cg14413466	chr17:79170920	AZI1	-0.5	-7.07	-0.5	5.27e-11	Frontotemporal dementia;
PAAD	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.97	8.04	0.55	2.29e-13	Triglycerides;
PAAD	cis	rs2284367	1.000	rs942223	chr11:34510681	C/T	cg20406267	chr11:34377921	ABTB2	0.42	4.3	0.33	3.04e-5	Blood protein levels;
PAAD	cis	rs1692580	0.807	rs263535	chr1:2177727	T/C	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.28e-5	Coronary artery disease;
PAAD	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg01953289	chr20:60874239	NA	-0.61	-4.48	-0.34	1.43e-5	Obesity-related traits;
PAAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg00262122	chr8:11665843	FDFT1	0.51	4.31	0.33	2.91e-5	Retinal vascular caliber;
PAAD	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.32	-0.33	2.77e-5	Aortic root size;
PAAD	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.64	7.16	0.5	3.25e-11	Airway imaging phenotypes;
PAAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14425796	chr6:37321643	RNF8	-0.72	-7.16	-0.5	3.23e-11	Lung cancer in ever smokers;
PAAD	cis	rs2421770	0.594	rs7104693	chr11:35266191	A/G	cg13971030	chr11:35366721	SLC1A2	-0.44	-5.32	-0.4	3.73e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg09659197	chr4:152720779	NA	0.46	6.16	0.45	6.15e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg06042504	chr8:55087323	NA	-0.61	-5.91	-0.43	2.15e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.52	4.91	0.37	2.37e-6	Aortic root size;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25756129	chr3:185655915	TRA2B	0.53	5.22	0.39	5.82e-7	Myopia (pathological);
PAAD	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.64	-0.57	7.28e-15	Electrocardiographic conduction measures;
PAAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2085601	0.566	rs2458545	chr4:89955369	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.73	10.25	0.64	4.5e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.55	-6.09	-0.44	9.02e-9	Total body bone mineral density;
PAAD	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg00262122	chr8:11665843	FDFT1	-0.64	-5.46	-0.4	1.9e-7	Neuroticism;
PAAD	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.06e-5	Systolic blood pressure;
PAAD	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs9810890	1.000	rs73196971	chr3:128443606	G/C	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	4.89	0.37	2.52e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg21827317	chr3:136751795	NA	0.5	5.32	0.4	3.69e-7	Gestational age at birth (child effect);
PAAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs7577696	0.711	rs385076	chr2:32489851	T/C	cg02381751	chr2:32503542	YIPF4	0.46	4.96	0.37	1.87e-6	Inflammatory biomarkers;
PAAD	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.53	5.03	0.38	1.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.07	0.5	5.4e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.59	6.98	0.49	8.51e-11	Aortic root size;
PAAD	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.85	-10.08	-0.63	1.29e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs288326	0.561	rs80231765	chr2:183745777	C/T	cg09997497	chr2:183902928	NCKAP1	0.87	4.86	0.37	2.95e-6	Blood protein levels;
PAAD	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.44	4.37	0.33	2.32e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.91	-7.47	-0.52	5.91e-12	Orofacial clefts;
PAAD	cis	rs3764400	0.567	rs2229369	chr17:46136133	G/C	cg24322968	chr17:46507895	SKAP1	0.83	5.26	0.39	4.9e-7	Body mass index;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg15249106	chr17:27277861	PHF12	-0.64	-6.34	-0.46	2.55e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg13658921	chr2:136499517	UBXN4	0.92	6.33	0.46	2.6e-9	Lung function (FEV1/FVC);
PAAD	cis	rs12799264	0.915	rs2585776	chr11:19974286	T/C	cg17303119	chr11:19974895	NAV2	0.73	4.98	0.37	1.73e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.5	-5.19	-0.39	6.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6976053	0.875	rs7783543	chr7:100468398	T/C	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.62e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.82	-8.85	-0.58	2.04e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg21698718	chr17:80085957	CCDC57	-0.48	-5.43	-0.4	2.18e-7	Life satisfaction;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27297192	chr10:134578999	INPP5A	0.61	5.65	0.42	7.55e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg13002189	chr3:66846049	NA	-0.47	-4.54	-0.35	1.15e-5	Type 2 diabetes;
PAAD	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg18898632	chr2:242989856	NA	-0.78	-5.53	-0.41	1.35e-7	Obesity-related traits;
PAAD	cis	rs9346455	0.614	rs58732838	chr6:72000496	C/T	cg27238071	chr6:71998145	OGFRL1	0.76	4.54	0.35	1.13e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.46	-6.07	-0.44	9.79e-9	Height;
PAAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg00310523	chr12:86230176	RASSF9	-0.47	-5.19	-0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	6.29	0.45	3.16e-9	Initial pursuit acceleration;
PAAD	cis	rs507080	0.922	rs12796373	chr11:118554939	G/A	cg08498647	chr11:118550644	TREH	-0.38	-4.42	-0.34	1.87e-5	Serum metabolite levels;
PAAD	cis	rs10501293	0.917	rs7951266	chr11:43110728	C/T	cg03447554	chr11:43094025	NA	0.48	4.86	0.37	2.94e-6	Cognitive performance;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.8	-8.87	-0.58	1.87e-15	Iron status biomarkers;
PAAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	4.36	0.33	2.39e-5	Schizophrenia;
PAAD	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.68	-4.99	-0.38	1.65e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.22	0.45	4.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19815871	chr13:114861689	RASA3	0.52	6.53	0.47	9.28e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.79	9.11	0.59	4.62e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg00738919	chr7:1100172	C7orf50	0.71	5.03	0.38	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11696501	0.688	rs6130897	chr20:44330004	C/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs6494488	0.500	rs55644048	chr15:64752167	G/T	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.74	7.83	0.54	7.81e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.57	-0.83	6.11e-41	Ulcerative colitis;
PAAD	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg21724239	chr8:58056113	NA	0.68	5.23	0.39	5.45e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.5	-5.1	-0.38	9.79e-7	Monocyte count;
PAAD	cis	rs965469	0.779	rs2207995	chr20:3294484	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.52	5.08	0.38	1.11e-6	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg08132940	chr7:1081526	C7orf50	-0.73	-5.33	-0.4	3.49e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.43	-0.4	2.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs62179067	0.708	rs1473577	chr2:179872750	G/T	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.8	0.62	7.22e-18	Menopause (age at onset);
PAAD	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg15571903	chr15:79123663	NA	0.4	4.88	0.37	2.7e-6	Coronary artery disease;
PAAD	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.63	6.02	0.44	1.26e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19821804	chr19:49401915	TULP2	-0.59	-6.37	-0.46	2.16e-9	Obesity-related traits;
PAAD	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.75	-5.28	-0.39	4.34e-7	Carotid intima media thickness;
PAAD	cis	rs6137287	0.668	rs6082329	chr20:21100138	G/T	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.93	-0.37	2.11e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21861644	chr18:13726504	C18orf19;RNMT	0.69	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	cis	rs35160687	0.644	rs7595785	chr2:86556405	T/C	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.72	7.17	0.5	3.12e-11	Prostate cancer;
PAAD	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.6	-5.15	-0.39	8.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg23127183	chr11:57508653	C11orf31	-0.53	-4.49	-0.34	1.38e-5	Schizophrenia;
PAAD	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg00206168	chr11:65308501	LTBP3	-0.62	-6.49	-0.47	1.14e-9	Plateletcrit;
PAAD	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.55	5.44	0.4	2.1e-7	Monocyte count;
PAAD	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.7	-5.7	-0.42	6.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.92	8.25	0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.55	-5.51	-0.41	1.49e-7	Multiple myeloma;
PAAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg03538708	chr1:25844672	NA	0.51	5.03	0.38	1.39e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-5.17	-0.39	7.16e-7	Bipolar disorder;
PAAD	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.49	0.34	1.37e-5	Multiple sclerosis;
PAAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.6	-7.35	-0.51	1.11e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4455778	0.580	rs10242641	chr7:49085748	G/A	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	1.07	9.58	0.61	2.71e-17	Red blood cell traits;
PAAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.98	7.26	0.51	1.88e-11	Recombination rate (females);
PAAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	10.77	0.66	1.87e-20	Menopause (age at onset);
PAAD	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.11	0.44	7.92e-9	Rheumatoid arthritis;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg26338869	chr17:61819248	STRADA	0.51	4.89	0.37	2.52e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05323904	chr16:691677	FAM195A	0.62	7.16	0.5	3.26e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.68	-0.36	6.21e-6	Total body bone mineral density;
PAAD	cis	rs6694270	1.000	rs12139558	chr1:19121246	G/A	cg19637330	chr1:19110922	NA	-0.63	-5.32	-0.4	3.66e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.69	-5.48	-0.41	1.69e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.31	0.33	2.89e-5	Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	7.89	0.54	5.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	4.27	0.33	3.43e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg00976097	chr5:421733	AHRR	-0.62	-5.54	-0.41	1.31e-7	Cystic fibrosis severity;
PAAD	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg00228799	chr9:131580591	ENDOG	-0.64	-6.33	-0.46	2.58e-9	Blood metabolite levels;
PAAD	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.65	-5.94	-0.43	1.89e-8	Red blood cell count;
PAAD	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.67	0.35	6.48e-6	Colorectal cancer;
PAAD	cis	rs17152411	0.652	rs1036676	chr10:126654184	A/G	cg04726013	chr10:126223236	LHPP	-0.3	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.41	-5.9	-0.43	2.25e-8	QT interval;
PAAD	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.56	5.9	0.43	2.27e-8	Dupuytren's disease;
PAAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.52	4.74	0.36	4.94e-6	Height;
PAAD	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.67	5.96	0.44	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg25686905	chr3:183603175	PARL	-0.32	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	trans	rs6532374	0.872	rs17019530	chr4:93466887	G/C	cg01163837	chr2:31457287	EHD3	-0.72	-6.31	-0.46	2.86e-9	Interleukin-12p70 levels;
PAAD	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.51	-4.87	-0.37	2.75e-6	Psoriasis;
PAAD	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg10253484	chr15:75165896	SCAMP2	0.58	5.04	0.38	1.32e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs4356203	0.875	rs680205	chr11:17207757	C/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.37	-0.33	2.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7224685	0.731	rs35514092	chr17:4183041	G/A	cg09597638	chr17:3907349	NA	0.65	5.51	0.41	1.5e-7	Type 2 diabetes;
PAAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg14349672	chr11:133703707	NA	-0.56	-6.37	-0.46	2.16e-9	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12734838	chr11:1227807	NA	0.51	6.34	0.46	2.49e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg22467129	chr15:76604101	ETFA	0.5	4.77	0.36	4.29e-6	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.93e-6	Life satisfaction;
PAAD	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg16558253	chr16:72132732	DHX38	-0.52	-5.28	-0.39	4.35e-7	Fibrinogen levels;
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.47	4.93	0.37	2.11e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2268241	0.877	rs9975473	chr21:34776441	T/G	cg14850771	chr21:34775459	IFNGR2	0.83	5.99	0.44	1.43e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-1.03	-8.73	-0.58	4.31e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.43	4.26	0.33	3.6e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
PAAD	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	trans	rs4427176	0.507	rs7006785	chr8:9580970	T/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg06375148	chr1:209958343	C1orf74	0.6	4.58	0.35	9.51e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.25	-0.51	2.01e-11	Diastolic blood pressure;
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg04154034	chr17:28927549	LRRC37B2	0.68	4.59	0.35	9.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.37	-4.28	-0.33	3.31e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.62	7.74	0.53	1.27e-12	Multiple system atrophy;
PAAD	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg16456728	chr7:65580328	CRCP	0.43	4.3	0.33	3.04e-5	Aortic root size;
PAAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs17152411	1.000	rs11245432	chr10:126616861	G/A	cg07906193	chr10:126599966	NA	0.73	5.6	0.41	9.94e-8	Height;
PAAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.52	5.11	0.38	9.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.77	6.89	0.49	1.39e-10	Bronchopulmonary dysplasia;
PAAD	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.84	-6.0	-0.44	1.37e-8	Atopic dermatitis;
PAAD	cis	rs35955747	0.902	rs7288643	chr22:31679669	C/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg11783602	chr8:55087084	NA	-0.51	-5.41	-0.4	2.35e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg21479132	chr6:26055353	NA	0.92	5.66	0.42	7.17e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28489187	0.683	rs6671599	chr1:85858857	T/C	cg16011679	chr1:85725395	C1orf52	-0.54	-5.16	-0.39	7.53e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg10290764	chr8:4849399	CSMD1	-0.37	-6.37	-0.46	2.1e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg09226986	chr6:160852328	SLC22A3	-0.48	-4.49	-0.34	1.41e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.63	6.38	0.46	2.03e-9	Testicular germ cell tumor;
PAAD	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.75	0.36	4.59e-6	Depressive symptoms;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.9	-0.49	1.29e-10	Life satisfaction;
PAAD	cis	rs12304921	0.935	rs67646958	chr12:51354625	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg27411982	chr8:10470053	RP1L1	-0.5	-5.62	-0.42	8.67e-8	Neuroticism;
PAAD	cis	rs10901513	0.932	rs10901492	chr10:127669761	C/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07371452	chr16:139780	C16orf35	0.63	7.63	0.53	2.34e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	cis	rs17155006	0.612	rs435361	chr7:107738552	C/T	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6893807	0.667	rs7733438	chr5:87986284	T/G	cg02225085	chr5:87975992	LOC645323	-0.72	-5.26	-0.39	4.87e-7	Body mass index;
PAAD	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	1.14	7.99	0.54	3.09e-13	Hippocampal volume;
PAAD	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.65	6.69	0.48	4e-10	Blood protein levels;
PAAD	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg16589663	chr20:23618590	CST3	0.85	7.26	0.51	1.85e-11	Chronic kidney disease;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg20003494	chr4:90757398	SNCA	-0.67	-6.25	-0.45	3.86e-9	Neuroticism;
PAAD	cis	rs308971	0.656	rs307578	chr3:12084158	A/G	cg02700894	chr3:12045449	SYN2	0.6	5.07	0.38	1.12e-6	Fasting blood insulin (BMI interaction);
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01616529	chr11:638424	DRD4	-0.63	-5.86	-0.43	2.73e-8	Systemic lupus erythematosus;
PAAD	cis	rs527409	1.000	rs651663	chr1:58749004	G/A	cg26345888	chr1:58716257	DAB1	-0.66	-4.48	-0.34	1.46e-5	Kawasaki disease;
PAAD	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2764208	0.535	rs7763832	chr6:34693960	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.41	4.45	0.34	1.62e-5	Systemic lupus erythematosus;
PAAD	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.54	5.13	0.38	8.59e-7	Mood instability;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	5.04e-14	Prudent dietary pattern;
PAAD	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.52	4.68	0.35	6.32e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg04809136	chr2:24300158	SF3B14	-0.4	-4.75	-0.36	4.69e-6	Quantitative traits;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg26338869	chr17:61819248	STRADA	0.49	4.73	0.36	5e-6	Height;
PAAD	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg13512537	chr8:22265999	SLC39A14	-0.42	-4.33	-0.33	2.69e-5	Verbal declarative memory;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.77	-7.67	-0.53	1.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.27	-0.56	6.12e-14	Alcohol dependence;
PAAD	cis	rs4073221	0.654	rs35320569	chr3:18289750	T/C	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7243821	1.000	rs7242681	chr18:52646348	G/A	cg16669619	chr18:52630472	NA	-0.44	-4.37	-0.33	2.25e-5	Chin dimples;
PAAD	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.6	-5.56	-0.41	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.53	-4.51	-0.34	1.29e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.01e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6496667	0.586	rs7162687	chr15:90889323	C/T	cg22089800	chr15:90895588	ZNF774	-0.57	-5.13	-0.38	8.73e-7	Rheumatoid arthritis;
PAAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.1	-0.44	8.27e-9	Prostate cancer;
PAAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.89	-10.46	-0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.76	-8.56	-0.57	1.13e-14	Lung function (FVC);
PAAD	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs35160687	0.623	rs13005014	chr2:86487216	T/C	cg10973622	chr2:86423274	IMMT	-0.48	-5.35	-0.4	3.19e-7	Night sleep phenotypes;
PAAD	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg24848339	chr3:12840334	CAND2	0.46	4.99	0.38	1.61e-6	QRS complex (12-leadsum);
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg20821713	chr7:1055600	C7orf50	-0.57	-5.75	-0.42	4.84e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.39	-0.46	1.93e-9	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73198822	chr3:128480061	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.76	-0.36	4.46e-6	Dental caries;
PAAD	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg02795151	chr17:7402630	POLR2A	0.6	5.36	0.4	3.06e-7	Androgen levels;
PAAD	cis	rs732505	0.764	rs7255573	chr19:5575148	T/C	cg26242866	chr19:5711310	LONP1	0.98	5.47	0.41	1.8e-7	vWF and FVIII levels;
PAAD	cis	rs73019876	0.869	rs8108093	chr19:22147450	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs7707921	0.881	rs7733122	chr5:81351443	C/T	cg21483461	chr5:81570383	RPS23	-0.51	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg14829155	chr15:31115871	NA	-0.63	-6.86	-0.49	1.62e-10	Huntington's disease progression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13520373	chr11:108463818	EXPH5	-0.64	-6.4	-0.46	1.83e-9	Smoking initiation;
PAAD	cis	rs12935418	0.552	rs2113196	chr16:81025490	A/C	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs776905	1.000	rs776905	chr13:113781942	G/T	cg09069900	chr13:113776964	F10	0.6	4.49	0.34	1.41e-5	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15553911	chr19:54641084	CNOT3	0.57	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12315302	chr6:26189340	HIST1H4D	0.56	4.3	0.33	2.99e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25023717	chr11:8077914	TUB	0.56	6.61	0.47	6.25e-10	Smoking initiation;
PAAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-5.45	-0.4	2.02e-7	Lymphocyte counts;
PAAD	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs9487051	0.621	rs446974	chr6:109525589	A/C	cg21918786	chr6:109611834	NA	-0.42	-4.4	-0.34	2.07e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg20356878	chr3:121714668	ILDR1	0.51	4.88	0.37	2.71e-6	Cognitive performance;
PAAD	cis	rs9463078	0.585	rs1285023	chr6:45111749	G/A	cg25276700	chr6:44698697	NA	-0.45	-4.98	-0.37	1.73e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1014246	0.784	rs4751610	chr10:118473730	T/C	cg14471191	chr10:117818509	GFRA1	0.39	4.51	0.34	1.29e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg05768032	chr16:30646687	NA	0.51	4.91	0.37	2.33e-6	Multiple myeloma;
PAAD	cis	rs7631605	0.905	rs1046512	chr3:37032296	A/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs76419734	0.558	rs2305212	chr4:106534691	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.61	0.35	8.4e-6	Post bronchodilator FEV1;
PAAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.89	-7.8	-0.53	9.24e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs41271473	0.687	rs4391637	chr1:228878379	A/C	cg16512390	chr1:228756714	NA	0.57	4.82	0.36	3.52e-6	Chronic lymphocytic leukemia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05957736	chr3:111579326	PHLDB2	0.68	7.26	0.51	1.9e-11	Obesity-related traits;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg16606324	chr3:10149918	C3orf24	0.7	4.89	0.37	2.56e-6	Alzheimer's disease;
PAAD	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.72	-5.55	-0.41	1.22e-7	Resting heart rate;
PAAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.34	0.6	1.14e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23917638	chr1:567501	MIR1977	-0.62	-6.39	-0.46	1.9e-9	Smoking initiation;
PAAD	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.87	10.08	0.63	1.28e-18	White blood cell count;
PAAD	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.72	9.3	0.6	1.42e-16	Weight;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1823874	0.962	rs12906206	chr15:100359126	A/T	cg16400843	chr15:100339927	C15orf51	0.4	4.94	0.37	2.03e-6	IgG glycosylation;
PAAD	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg23728669	chr11:63258734	HRASLS5	-0.43	-4.27	-0.33	3.42e-5	Platelet count;
PAAD	cis	rs7793919	0.691	rs4077986	chr7:4766676	A/G	cg09789173	chr7:4769017	FOXK1	0.67	7.04	0.5	6.08e-11	Mosquito bite size;
PAAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.81	-9.62	-0.62	2.08e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-1.03	-12.23	-0.7	2.2e-24	Breast cancer;
PAAD	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.77	-5.38	-0.4	2.78e-7	Monocyte percentage of white cells;
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg21859623	chr20:33103246	DYNLRB1	0.48	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.91	9.96	0.63	2.61e-18	Testicular germ cell tumor;
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg07527105	chr16:88053339	BANP	-0.46	-4.58	-0.35	9.54e-6	Menopause (age at onset);
PAAD	cis	rs904092	0.810	rs1693457	chr4:100236762	A/G	cg12011299	chr4:100065546	ADH4	0.51	4.37	0.33	2.27e-5	Alcohol dependence;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	4.28	0.33	3.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg24220031	chr2:73402428	NA	-0.35	-5.25	-0.39	5.13e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg05341670	chr1:54518153	TMEM59;C1orf83	-0.57	-6.38	-0.46	2.04e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.53	-0.41	1.36e-7	Personality dimensions;
PAAD	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26926768	chr12:34528122	NA	0.38	4.67	0.35	6.67e-6	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06847283	chr2:217277082	SMARCAL1	0.7	6.88	0.49	1.47e-10	Obesity-related traits;
PAAD	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.72	0.58	4.6e-15	Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs755249	0.567	rs61782157	chr1:39762889	C/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.75	6.46	0.46	1.31e-9	Morning vs. evening chronotype;
PAAD	cis	rs9469913	0.799	rs28567450	chr6:34747409	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.92	11.07	0.67	2.99e-21	Prudent dietary pattern;
PAAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg24733560	chr20:60626293	TAF4	0.52	6.86	0.49	1.6e-10	Body mass index;
PAAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.64	5.62	0.42	8.7e-8	Pulmonary function decline;
PAAD	cis	rs939584	1.000	rs11127483	chr2:623691	G/A	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg02683114	chr2:24398427	C2orf84	0.53	5.29	0.39	4.16e-7	Asthma;
PAAD	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.73	7.36	0.51	1.1e-11	Alcohol dependence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02513392	chr12:112601463	C12orf51	-0.61	-6.64	-0.47	5.27e-10	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.76	0.36	4.56e-6	Bipolar disorder;
PAAD	cis	rs7577696	0.606	rs212747	chr2:32414704	A/G	cg02381751	chr2:32503542	YIPF4	0.49	4.63	0.35	7.82e-6	Inflammatory biomarkers;
PAAD	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg23587288	chr2:27483067	SLC30A3	-0.72	-6.86	-0.49	1.67e-10	Blood metabolite levels;
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1015291	0.605	rs1388678	chr12:19994151	A/C	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13939156	chr17:80058883	NA	-0.42	-4.57	-0.35	9.85e-6	Life satisfaction;
PAAD	cis	rs294958	0.680	rs294956	chr5:151548621	C/T	cg04453665	chr5:151504455	NA	-0.42	-4.54	-0.35	1.16e-5	Periodontitis (PAL4Q3);
PAAD	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg00666640	chr1:248458726	OR2T12	-0.59	-5.0	-0.38	1.54e-6	Common traits (Other);
PAAD	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	6.09	0.44	8.67e-9	Renal function-related traits (BUN);
PAAD	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.45	-0.46	1.4e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Urate levels;
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.5	-5.18	-0.39	6.96e-7	Type 2 diabetes;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.77	0.48	2.57e-10	Menarche (age at onset);
PAAD	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg00280922	chr14:74226427	C14orf43	0.67	6.74	0.48	3.11e-10	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
PAAD	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg02415014	chr8:143852576	LYNX1	0.39	4.55	0.35	1.07e-5	Urinary tract infection frequency;
PAAD	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	9.58	0.61	2.7e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs300774	0.925	rs408074	chr2:150853	T/C	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg04731861	chr2:219085781	ARPC2	0.35	4.27	0.33	3.46e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg24110177	chr3:50126178	RBM5	-0.58	-4.52	-0.34	1.22e-5	Menarche (age at onset);
PAAD	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg20503657	chr10:835505	NA	0.51	5.38	0.4	2.82e-7	Survival in rectal cancer;
PAAD	cis	rs2790216	1.000	rs2095894	chr10:59968671	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.89	10.22	0.64	5.5e-19	Sudden cardiac arrest;
PAAD	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg09339527	chr5:178322752	ZFP2	-0.43	-4.52	-0.34	1.24e-5	Sleep duration;
PAAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg12486944	chr17:80159399	CCDC57	0.53	4.69	0.36	6.05e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg21775007	chr8:11205619	TDH	-0.48	-4.36	-0.33	2.43e-5	Neuroticism;
PAAD	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg18867708	chr6:26865862	GUSBL1	-0.44	-4.48	-0.34	1.48e-5	Schizophrenia;
PAAD	cis	rs9487051	0.621	rs566164	chr6:109506461	C/T	cg21918786	chr6:109611834	NA	-0.4	-4.25	-0.33	3.78e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg05393424	chr1:91403111	ZNF644	-0.55	-6.33	-0.46	2.59e-9	Alcohol dependence;
PAAD	cis	rs7577696	0.962	rs212745	chr2:32412832	C/G	cg02381751	chr2:32503542	YIPF4	0.42	4.43	0.34	1.8e-5	Inflammatory biomarkers;
PAAD	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.21	-9.66	-0.62	1.64e-17	Breast cancer;
PAAD	cis	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg22134413	chr5:150180641	NA	0.71	5.15	0.39	7.87e-7	Crohn's disease;
PAAD	cis	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg05299278	chr17:33885742	SLFN14	0.43	5.16	0.39	7.65e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22618164	chr12:122356400	WDR66	0.67	6.94	0.49	1.05e-10	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18530251	chr8:22409574	SORBS3	0.64	6.54	0.47	8.92e-10	Obesity-related traits;
PAAD	cis	rs914615	0.552	rs11264337	chr1:155138450	C/T	cg18645493	chr1:154167437	MIR190B	0.45	4.29	0.33	3.13e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg02640540	chr1:67518911	SLC35D1	0.61	4.53	0.34	1.19e-5	Neutrophil percentage of white cells;
PAAD	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.73	-5.99	-0.44	1.46e-8	Gallbladder cancer;
PAAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.71	-0.42	5.83e-8	Schizophrenia;
PAAD	cis	rs113779084	0.531	rs4401740	chr7:11974825	G/C	cg15090509	chr7:11872073	THSD7A	0.38	4.7	0.36	5.8e-6	Educational attainment (years of education);
PAAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.75	8.69	0.58	5.46e-15	Prostate cancer;
PAAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20167471	chr1:16528984	ARHGEF19	0.46	4.49	0.34	1.4e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12681963	0.688	rs73234780	chr8:30059755	G/A	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg10595753	chr17:80898281	TBCD	0.5	4.55	0.35	1.11e-5	Glycated hemoglobin levels;
PAAD	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.81	5.34	0.4	3.36e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.68	-6.77	-0.48	2.7e-10	Pubertal anthropometrics;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg01097406	chr16:89675127	NA	-0.38	-4.61	-0.35	8.49e-6	Vitiligo;
PAAD	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.52	-0.41	1.45e-7	Common traits (Other);
PAAD	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg21770322	chr7:97807741	LMTK2	0.49	6.77	0.48	2.64e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7107174	0.688	rs3740677	chr11:77928036	A/C	cg02023728	chr11:77925099	USP35	0.44	4.93	0.37	2.16e-6	Testicular germ cell tumor;
PAAD	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.46	4.44	0.34	1.73e-5	Pneumonia;
PAAD	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg21823605	chr1:152486609	CRCT1	0.52	6.58	0.47	7.03e-10	Hair morphology;
PAAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	4.65	0.35	7.06e-6	Joint mobility (Beighton score);
PAAD	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg27490568	chr2:178487706	NA	0.45	4.99	0.37	1.66e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.59	5.56	0.41	1.16e-7	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014252	0.803	rs60555424	chr14:71041502	T/C	cg11204974	chr14:71022665	NA	-0.72	-4.74	-0.36	4.97e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.86e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg04111992	chr7:158790115	NA	-0.5	-4.91	-0.37	2.29e-6	Facial morphology (factor 20);
PAAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg26897989	chr16:1907736	C16orf73	-0.45	-4.59	-0.35	9.27e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs959260	1.000	rs4789185	chr17:73383368	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs7260598	0.539	rs10418417	chr19:24080807	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.68	-6.43	-0.46	1.54e-9	Sleep quality;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.65	-6.23	-0.45	4.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.85	0.58	2.13e-15	Lung cancer;
PAAD	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.09	-10.17	-0.64	7.57e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.9	-6.23	-0.45	4.34e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg02696790	chr15:75250997	RPP25	-0.41	-4.78	-0.36	4.11e-6	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	4.45	0.34	1.66e-5	Mosquito bite size;
PAAD	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-7.78	-0.53	1.03e-12	Urinary metabolites;
PAAD	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.94	-7.74	-0.53	1.33e-12	Triglycerides;
PAAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg18370025	chr7:2749541	AMZ1	-0.37	-4.52	-0.34	1.25e-5	Height;
PAAD	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg23973274	chr1:155060172	NA	0.43	4.43	0.34	1.81e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.08e-7	Tonsillectomy;
PAAD	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.56	-6.18	-0.45	5.58e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs3736485	0.966	rs8031903	chr15:51838161	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.33	-0.33	2.7e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00387107	chr7:101845057	CUX1	0.65	6.64	0.47	5.17e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18090894	chr14:75227656	NA	-0.53	-6.48	-0.47	1.21e-9	Obesity-related traits;
PAAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.73	6.77	0.48	2.65e-10	Asthma;
PAAD	cis	rs28489187	0.706	rs423105	chr1:85796427	A/G	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs13177918	0.734	rs6579791	chr5:149844003	G/A	cg04670168	chr5:150039249	MYOZ3	-0.46	-4.49	-0.34	1.42e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.5	-0.57	1.64e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs1864585	0.520	rs56046029	chr8:10693803	A/C	cg21775007	chr8:11205619	TDH	-0.58	-4.28	-0.33	3.28e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26651784	chr16:67062934	CBFB	0.65	6.73	0.48	3.34e-10	Obesity-related traits;
PAAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg09417038	chr21:47716443	C21orf57	0.41	4.36	0.33	2.38e-5	Testicular germ cell tumor;
PAAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg04106633	chr4:1044584	NA	0.64	5.39	0.4	2.66e-7	Recombination rate (females);
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.5	4.76	0.36	4.52e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9361491	0.608	rs9352616	chr6:79441503	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.62	6.8	0.48	2.24e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.63	7.06	0.5	5.59e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs1559088	0.847	rs7255968	chr19:33601902	A/T	cg18084798	chr19:33555255	RHPN2	0.47	4.68	0.35	6.43e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.73	7.39	0.51	9.24e-12	Colorectal cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19915181	chr14:81905381	NA	0.63	6.9	0.49	1.3100000000000001e-10	Smoking initiation;
PAAD	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg21775007	chr8:11205619	TDH	-0.46	-4.32	-0.33	2.81e-5	Neuroticism;
PAAD	cis	rs787274	1.000	rs787274	chr9:115550363	A/C	cg13803584	chr9:115635662	SNX30	-0.99	-6.54	-0.47	8.98e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.5	-5.1	-0.38	1.01e-6	Tonsillectomy;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.43	-0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.26	-0.51	1.9e-11	Response to amphetamines;
PAAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.14	0.39	8.15e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9810890	1.000	rs73198875	chr3:128540286	C/T	cg18531004	chr3:128564980	NA	-0.87	-5.18	-0.39	7.09e-7	Dental caries;
PAAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.71	9.5	0.61	4.22e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.77	6.71	0.48	3.61e-10	Obesity-related traits;
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.12	-0.44	7.59e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg14500267	chr11:67383377	NA	0.47	4.67	0.35	6.71e-6	Mean corpuscular volume;
PAAD	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.84	9.85	0.62	5.34e-18	Selective IgA deficiency;
PAAD	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	1.06	8.27	0.56	6.09e-14	Menopause (age at onset);
PAAD	cis	rs9325144	0.747	rs34246358	chr12:39179841	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-4.78	-0.36	4.08e-6	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.37	4.46	0.34	1.61e-5	Prostate cancer;
PAAD	cis	rs939584	1.000	rs2867112	chr2:651349	T/G	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs28719689	0.541	rs6994475	chr8:1273426	T/G	cg22761795	chr8:1265118	NA	0.83	6.19	0.45	5.46e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.27	-0.39	4.62e-7	Glomerular filtration rate;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.53	-7.02	-0.5	6.76e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4427176	0.660	rs35468013	chr8:9578208	G/T	cg03024720	chr8:9765601	NA	-0.48	-4.61	-0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.52	-0.34	1.23e-5	Joint mobility (Beighton score);
PAAD	cis	rs4547160	0.821	rs877898	chr12:63483535	G/A	cg26727693	chr12:63544175	AVPR1A	-0.36	-4.27	-0.33	3.4e-5	Morning vs. evening chronotype;
PAAD	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg17644776	chr2:200775616	C2orf69	-0.7	-5.9	-0.43	2.31e-8	Schizophrenia;
PAAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg13482628	chr17:19912719	NA	0.66	6.72	0.48	3.38e-10	Schizophrenia;
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg04733989	chr22:42467013	NAGA	0.49	5.03	0.38	1.39e-6	Cognitive function;
PAAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.64	6.48	0.47	1.21e-9	Schizophrenia;
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg12143784	chr7:64541923	NA	-0.34	-4.37	-0.33	2.25e-5	Aortic root size;
PAAD	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.25	-0.39	5.03e-7	Joint mobility (Beighton score);
PAAD	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.98	10.64	0.65	4.05e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.96	14.21	0.76	1.08e-29	Age-related hearing impairment;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg13374026	chr7:158955107	NA	0.45	4.25	0.33	3.75e-5	Facial morphology (factor 20);
PAAD	cis	rs66530629	0.917	rs66519614	chr1:25164778	G/T	cg22509179	chr1:25234806	RUNX3	0.49	4.58	0.35	9.43e-6	Plateletcrit;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.64	6.7	0.48	3.72e-10	Mean platelet volume;
PAAD	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.56	5.46	0.41	1.89e-7	Breast cancer;
PAAD	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.75	-8.97	-0.59	1.01e-15	Body mass index;
PAAD	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.61	-5.72	-0.42	5.51e-8	Mean corpuscular volume;
PAAD	cis	rs6681460	0.834	rs2916	chr1:67216697	G/A	cg02459107	chr1:67143332	SGIP1	-0.72	-6.75	-0.48	2.91e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg09945482	chr18:12777974	NA	0.61	5.28	0.39	4.35e-7	Inflammatory skin disease;
PAAD	cis	rs2120243	0.539	rs1456105	chr3:157123461	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.8	-6.12	-0.44	7.72e-9	Yeast infection;
PAAD	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg14593290	chr7:50529359	DDC	-0.47	-4.89	-0.37	2.53e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs17095355	1.000	rs7083619	chr10:111755762	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-5.02	-0.38	1.41e-6	Biliary atresia;
PAAD	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.46	-0.34	1.57e-5	Reticulocyte count;
PAAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs62392365	0.686	rs115989354	chr6:25208585	C/T	cg26336265	chr6:25042955	NA	0.68	4.74	0.36	4.83e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Lymphocyte counts;
PAAD	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg01489032	chr8:143877656	NA	-0.39	-4.33	-0.33	2.65e-5	Urinary tract infection frequency;
PAAD	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs863345	1.000	rs863351	chr1:158538663	G/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.89	-0.37	2.57e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs818427	0.548	rs153544	chr5:112248466	T/C	cg06941702	chr5:112196734	SRP19	0.57	5.25	0.39	4.99e-7	Total body bone mineral density;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.59	-6.36	-0.46	2.24e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.55	-0.35	1.07e-5	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17322935	chr7:91570297	AKAP9	-0.6	-6.75	-0.48	2.95e-10	Body fat percentage;
PAAD	cis	rs11971779	0.774	rs7785906	chr7:139122652	T/C	cg07862535	chr7:139043722	LUC7L2	0.7	5.47	0.41	1.84e-7	Diisocyanate-induced asthma;
PAAD	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.6	-0.47	6.34e-10	Obesity-related traits;
PAAD	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.27	0.39	4.6e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.44	-0.34	1.69e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.81	7.89	0.54	5.65e-13	Corneal astigmatism;
PAAD	cis	rs75920871	0.841	rs77250716	chr11:116877353	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs7213347	0.610	rs8077194	chr17:2119475	A/G	cg15816464	chr17:2026533	SMG6	0.5	5.35	0.4	3.22e-7	Total body bone mineral density;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-6.67	-0.48	4.38e-10	Lymphocyte counts;
PAAD	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg12458913	chr13:53173898	NA	0.62	6.15	0.45	6.53e-9	Lewy body disease;
PAAD	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17376030	chr22:41985996	PMM1	0.69	4.66	0.35	6.78e-6	Vitiligo;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.92	-10.89	-0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg18833306	chr6:118973337	C6orf204	0.45	5.01	0.38	1.5e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs9810890	1.000	rs79217699	chr3:128445585	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.75	-0.36	4.72e-6	Dental caries;
PAAD	cis	rs96067	0.652	rs7553155	chr1:36568236	A/T	cg27506609	chr1:36549197	TEKT2	0.86	5.52	0.41	1.44e-7	Corneal structure;
PAAD	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.12	-0.38	9.32e-7	Pulmonary function;
PAAD	cis	rs459571	0.920	rs2157770	chr9:136921464	A/G	cg13789015	chr9:136890014	NCRNA00094	0.56	5.81	0.43	3.54e-8	Platelet distribution width;
PAAD	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	4.84	0.37	3.19e-6	Lung cancer in ever smokers;
PAAD	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.77	6.69	0.48	4.09e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	trans	rs228916	1.000	rs1961437	chr22:37511033	A/G	cg14326991	chr6:46889760	GPR116	-0.66	-6.49	-0.47	1.16e-9	Iron status biomarkers (iron levels);
PAAD	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.82	-0.36	3.49e-6	Dupuytren's disease;
PAAD	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.57	-5.2	-0.39	6.4e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg22153463	chr1:85462885	MCOLN2	0.64	4.97	0.37	1.81e-6	Serum sulfate level;
PAAD	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg16938614	chr7:106685021	PRKAR2B	-0.54	-4.41	-0.34	1.95e-5	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg14440974	chr22:39074834	NA	-0.57	-6.49	-0.47	1.16e-9	Menopause (age at onset);
PAAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.47	-4.78	-0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.69	7.52	0.52	4.41e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.72	6.57	0.47	7.67e-10	Inflammatory bowel disease;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg09471204	chr22:42347991	LOC339674	-0.38	-5.17	-0.39	7.3e-7	Intelligence;
PAAD	cis	rs76793172	1.000	rs77756656	chr19:46320718	C/G	cg13320842	chr19:46175254	GIPR	0.64	4.89	0.37	2.52e-6	Eosinophil counts;
PAAD	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.49	4.6	0.35	8.9e-6	HDL cholesterol;
PAAD	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.34e-5	Longevity (90 years and older);
PAAD	cis	rs375066	0.935	rs448823	chr19:44406291	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.95	0.37	1.92e-6	Breast cancer;
PAAD	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.86	-5.26	-0.39	4.76e-7	Alzheimer's disease (late onset);
PAAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	6.22	0.45	4.58e-9	Personality dimensions;
PAAD	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	1.16	13.18	0.73	5.98e-27	Hair shape;
PAAD	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.14	11.04	0.67	3.62e-21	Corneal structure;
PAAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Depression;
PAAD	cis	rs13242816	1.000	rs67982517	chr7:116075363	A/G	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14395537	chr12:133349744	GOLGA3	-0.67	-6.55	-0.47	8.26e-10	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.52	-5.71	-0.42	5.68e-8	Migraine;
PAAD	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg05110241	chr16:68378359	PRMT7	-0.99	-7.82	-0.54	8.36e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg06217245	chr20:33103252	DYNLRB1	0.44	5.14	0.38	8.23e-7	Height;
PAAD	cis	rs8040855	0.658	rs12909111	chr15:85604326	A/G	cg08123816	chr15:85640762	PDE8A	-0.41	-4.93	-0.37	2.15e-6	Bulimia nervosa;
PAAD	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6074578	0.509	rs6039198	chr20:144899	T/C	cg16931068	chr20:139680	DEFB127	-0.4	-5.55	-0.41	1.25e-7	Hirschsprung disease;
PAAD	cis	rs3736757	1.000	rs10752941	chr1:184695571	C/T	cg05045817	chr1:184633523	NA	0.44	4.73	0.36	5.19e-6	Obesity-related traits;
PAAD	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.75	-0.42	4.68e-8	YKL-40 levels;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07293736	chr12:132670858	NA	0.35	5.14	0.38	8.45e-7	Anti-saccade response;
PAAD	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-1.51	-9.85	-0.62	5.32e-18	Depression;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19158176	chr1:1510364	SSU72	0.62	6.74	0.48	3.08e-10	Myopia (pathological);
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00166722	chr3:10149974	C3orf24	0.8	5.76	0.42	4.42e-8	Alzheimer's disease;
PAAD	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.41	-4.9	-0.37	2.45e-6	Uric acid levels;
PAAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg02117656	chr17:79614917	TSPAN10	0.54	5.38	0.4	2.82e-7	Eye color traits;
PAAD	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg01214346	chr17:406501	NA	0.49	4.31	0.33	2.93e-5	Prostate cancer;
PAAD	cis	rs643506	0.934	rs4936690	chr11:111646915	T/A	cg09085632	chr11:111637200	PPP2R1B	0.8	7.4	0.51	8.45e-12	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg26338869	chr17:61819248	STRADA	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.59	-5.37	-0.4	2.84e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg04627240	chr19:42746847	GSK3A	-0.76	-6.89	-0.49	1.39e-10	Blood protein levels;
PAAD	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-8.95	-0.59	1.19e-15	Morning vs. evening chronotype;
PAAD	cis	rs870825	0.860	rs2696052	chr4:185604356	G/A	cg04058563	chr4:185651563	MLF1IP	-0.67	-4.98	-0.37	1.74e-6	Blood protein levels;
PAAD	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.65	7.05	0.5	5.84e-11	Obesity-related traits;
PAAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16447950	chr5:562315	NA	-0.66	-5.73	-0.42	5.22e-8	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg03983476	chr2:10830698	NOL10	0.57	5.72	0.42	5.56e-8	Prostate cancer;
PAAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg10356904	chr22:49881777	NA	-0.47	-4.67	-0.35	6.62e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.78	-7.81	-0.54	8.79e-13	Menopause (age at onset);
PAAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg13722127	chr7:150037890	RARRES2	0.66	6.5	0.47	1.11e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3764400	0.508	rs757353	chr17:46122270	A/G	cg10706073	chr17:46328419	SKAP1	-1.0	-6.14	-0.45	6.74e-9	Body mass index;
PAAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.72	7.69	0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg00982548	chr2:198649783	BOLL	-0.78	-5.51	-0.41	1.49e-7	Ulcerative colitis;
PAAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg22517653	chr1:2918612	NA	-0.59	-4.86	-0.37	2.93e-6	Plateletcrit;
PAAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.62	6.1	0.44	8.36e-9	Blood protein levels;
PAAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg07943548	chr15:86304357	KLHL25	-0.61	-5.37	-0.4	2.84e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3764400	0.567	rs16953941	chr17:46296204	C/A	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12955076	chr3:186389477	HRG	0.63	6.36	0.46	2.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.07	6.91	0.49	1.27e-10	Plateletcrit;
PAAD	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.5	-6.23	-0.45	4.46e-9	Lewy body disease;
PAAD	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg25753631	chr6:25732923	NA	-0.36	-4.44	-0.34	1.75e-5	Blood metabolite levels;
PAAD	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs59888335	0.964	rs34267339	chr3:80692753	G/A	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs73195822	0.614	rs56259130	chr12:111225650	C/T	cg09298818	chr12:111181546	PPP1CC	-0.52	-4.37	-0.33	2.26e-5	Itch intensity from mosquito bite;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.62	0.57	8.32e-15	Prudent dietary pattern;
PAAD	cis	rs4751058	0.526	rs10764842	chr10:130861658	A/C	cg05596517	chr10:131320214	MGMT	0.49	4.69	0.36	5.99e-6	Vitamin D levels;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.65	-6.49	-0.47	1.16e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.69	-5.96	-0.44	1.68e-8	Diabetic retinopathy;
PAAD	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.6	-5.59	-0.41	1.05e-7	Multiple myeloma;
PAAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg03037974	chr15:76606532	NA	0.52	5.94	0.43	1.91e-8	Blood metabolite levels;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg26071806	chr7:100318239	EPO	-0.49	-4.88	-0.37	2.62e-6	Other erythrocyte phenotypes;
PAAD	cis	rs11811982	0.793	rs76132272	chr1:227456065	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs965469	0.532	rs6115865	chr20:3359303	A/G	cg25506879	chr20:3388711	C20orf194	0.49	4.3	0.33	3.05e-5	IFN-related cytopenia;
PAAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.75	8.4	0.56	2.96e-14	Longevity;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04852103	chr1:180471378	ACBD6	0.58	6.4	0.46	1.81e-9	Morning vs. evening chronotype;
PAAD	cis	rs2131877	0.827	rs6784890	chr3:194842145	A/C	cg21937377	chr3:194868750	C3orf21	0.39	4.35	0.33	2.51e-5	Non-small cell lung cancer;
PAAD	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg09835421	chr16:68378352	PRMT7	-1.03	-7.56	-0.52	3.46e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6782228	1.000	rs34890930	chr3:128329223	T/C	cg07730360	chr3:128845626	NA	-0.49	-4.53	-0.35	1.17e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.44	0.46	1.45e-9	Tonsillectomy;
PAAD	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.45	4.43	0.34	1.77e-5	Schizophrenia;
PAAD	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg18209359	chr17:80159595	CCDC57	-0.49	-5.02	-0.38	1.42e-6	Life satisfaction;
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.5e-15	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06876040	chr16:1462119	UNKL	-0.59	-6.87	-0.49	1.55e-10	Monocyte percentage of white cells;
PAAD	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.77	-5.26	-0.39	4.74e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	7.61	0.53	2.72e-12	HIV-1 control;
PAAD	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg14500798	chr7:98100126	NA	0.43	4.56	0.35	1.03e-5	Breast cancer;
PAAD	trans	rs901683	0.850	rs73291122	chr10:46099403	G/C	cg07567308	chr20:3149320	ProSAPiP1	0.71	6.37	0.46	2.17e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7619427	0.544	rs62252204	chr3:43965558	G/A	cg16646616	chr3:44040527	NA	-0.56	-4.57	-0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.72	7.92	0.54	4.77e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.44	0.56	2.32e-14	Menopause (age at onset);
PAAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.63	-6.24	-0.45	4.11e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.86	0.49	1.59e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.62	-6.12	-0.44	7.67e-9	Monocyte count;
PAAD	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.99	-12.35	-0.71	1.06e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg22963979	chr7:1858916	MAD1L1	0.77	9.06	0.59	5.87e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.16	13.36	0.73	1.98e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12623107	chr11:18346401	GTF2H1	0.57	6.31	0.46	2.97e-9	Smoking initiation;
PAAD	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.52	4.6	0.35	9e-6	Corneal astigmatism;
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg23018236	chr17:30244563	NA	-0.63	-5.39	-0.4	2.65e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg23461800	chr14:103021989	NA	-0.58	-4.38	-0.33	2.18e-5	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17367243	chr17:70801709	SLC39A11	-0.67	-6.55	-0.47	8.55e-10	Obesity-related traits;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.58	5.29	0.39	4.24e-7	Acylcarnitine levels;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02071572	chr4:1403502	NA	-0.48	-6.17	-0.45	5.81e-9	Obesity-related traits;
PAAD	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.69	-6.85	-0.49	1.75e-10	Post bronchodilator FEV1;
PAAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.72	0.58	4.65e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.59	-5.66	-0.42	7.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-6.56	-0.47	7.95e-10	Coronary artery disease;
PAAD	cis	rs11718455	0.767	rs13075535	chr3:43954612	G/A	cg08738300	chr3:44038990	NA	0.66	6.21	0.45	4.8e-9	Coronary artery disease;
PAAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.5	-4.82	-0.36	3.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg11764359	chr7:65958608	NA	0.8	5.24	0.39	5.37e-7	Diabetic kidney disease;
PAAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg14346243	chr4:90757452	SNCA	-0.53	-4.65	-0.35	7.27e-6	Neuroticism;
PAAD	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.97	11.02	0.67	3.97e-21	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-7.49	-0.52	5.35e-12	Colorectal cancer;
PAAD	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs9810890	1.000	rs28675843	chr3:128575353	T/C	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg09654669	chr8:57350985	NA	-0.55	-5.18	-0.39	7.09e-7	Obesity-related traits;
PAAD	trans	rs6474412	0.664	rs2217732	chr8:42618446	A/G	cg07164722	chr1:247587378	NLRP3	0.61	6.64	0.47	5.11e-10	Smoking behavior;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.75	-0.88	8.21e-51	Myeloid white cell count;
PAAD	cis	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg00614314	chr15:82944287	LOC80154	0.45	4.68	0.35	6.4e-6	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13686104	chr1:202927632	ADIPOR1	0.6	6.99	0.49	8.27e-11	Monocyte percentage of white cells;
PAAD	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg11650704	chr1:154556575	ADAR	-0.39	-4.25	-0.33	3.7e-5	Blood protein levels;
PAAD	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.54	5.92	0.43	2.03e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs73416724	1.000	rs77529883	chr6:43364634	C/G	cg26312998	chr6:43337775	ZNF318	0.7	5.79	0.42	3.99e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.4	5.7	0.42	6.12e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05535760	chr7:792225	HEATR2	-0.65	-5.87	-0.43	2.63e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs656319	0.702	rs477860	chr8:9811765	T/C	cg27411982	chr8:10470053	RP1L1	-0.48	-5.04	-0.38	1.29e-6	Myopia (pathological);
PAAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg06108461	chr20:60628389	TAF4	-0.63	-6.0	-0.44	1.38e-8	Body mass index;
PAAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg20003494	chr4:90757398	SNCA	-0.74	-7.17	-0.5	3.13e-11	Neuroticism;
PAAD	cis	rs4676482	0.577	rs17038578	chr3:39262863	T/C	cg02254461	chr3:39195904	CSRNP1	0.63	4.46	0.34	1.58e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-5.19	-0.39	6.49e-7	Blood pressure;
PAAD	cis	rs933688	0.532	rs4916851	chr5:90536300	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.56	-5.07	-0.38	1.14e-6	Smoking behavior;
PAAD	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.55	-0.47	8.31e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs617219	0.726	rs955897	chr5:78431486	A/C	cg24856658	chr5:78533917	JMY	-0.39	-4.3	-0.33	3.1e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs258892	0.895	rs13159570	chr5:72045109	A/T	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.79	9.04	0.59	6.98e-16	Lung cancer;
PAAD	cis	rs55728055	0.661	rs16989274	chr22:31955908	G/A	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-5.59	-0.41	1.02e-7	Intelligence;
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.72	-0.36	5.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.66	5.73	0.42	5.2e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.83	-8.99	-0.59	9.3e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs13720	0.673	rs163802	chr20:57578852	C/G	cg23907860	chr20:57583709	CTSZ	-0.58	-4.28	-0.33	3.23e-5	Platelet distribution width;
PAAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg07168214	chr17:7380112	ZBTB4	-0.65	-6.06	-0.44	1e-8	Androgen levels;
PAAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.87	8.31	0.56	4.9e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19181244	chr15:78237003	NA	0.58	6.41	0.46	1.7e-9	Monocyte percentage of white cells;
PAAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.16	17.57	0.82	1.94e-38	Cognitive function;
PAAD	cis	rs2286379	0.837	rs10848571	chr12:1882472	G/T	cg05227549	chr12:1770782	NA	0.39	4.5	0.34	1.35e-5	Blood pressure (smoking interaction);
PAAD	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.88	-10.49	-0.65	1.05e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.83	6.38	0.46	2.02e-9	Axial length;
PAAD	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	0.99	7.31	0.51	1.45e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	7.14	0.5	3.63e-11	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs62025270	0.576	rs62022947	chr15:86271322	G/C	cg13263323	chr15:86062960	AKAP13	0.49	4.38	0.33	2.17e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.41	-4.83	-0.36	3.27e-6	Mean arterial pressure;
PAAD	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg14703610	chr5:56206110	C5orf35	0.61	5.68	0.42	6.67e-8	Coronary artery disease;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg01097406	chr16:89675127	NA	0.39	4.82	0.36	3.38e-6	Vitiligo;
PAAD	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg08992911	chr2:238395768	MLPH	0.74	5.53	0.41	1.34e-7	Prostate cancer;
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.54	-5.26	-0.39	4.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-4.91	-0.37	2.33e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06799790	chr17:61951754	CSH2	-0.47	-4.9	-0.37	2.41e-6	Height;
PAAD	cis	rs11122449	1	rs11122449	chr1:230300481	C/T	cg03144619	chr1:230415668	GALNT2	-0.47	-4.33	-0.33	2.74e-5	Red cell distribution width;
PAAD	cis	rs6787172	0.628	rs58363161	chr3:158258312	T/A	cg16708174	chr3:158430962	RARRES1	0.42	4.44	0.34	1.7e-5	Subjective well-being;
PAAD	cis	rs863345	0.604	rs11264977	chr1:158447852	G/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.27e-6	Pneumococcal bacteremia;
PAAD	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg10932868	chr11:921992	NA	0.45	4.81	0.36	3.62e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg27411982	chr8:10470053	RP1L1	0.46	4.68	0.36	6.23e-6	Triglycerides;
PAAD	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg18964960	chr10:1102726	WDR37	-0.88	-4.51	-0.34	1.31e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs501120	0.584	rs673354	chr10:44733816	C/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs78761021	0.597	rs4791903	chr17:9783566	G/C	cg26853458	chr17:9805074	RCVRN	0.41	4.84	0.37	3.2e-6	Type 2 diabetes;
PAAD	cis	rs12986413	0.935	rs36065733	chr19:2163771	T/G	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.15e-6	Height;
PAAD	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg24253500	chr15:84953950	NA	0.57	6.52	0.47	9.75e-10	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.38	4.46	0.34	1.58e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.6	4.34	0.33	2.56e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg25233709	chr10:116636983	FAM160B1	0.43	5.37	0.4	2.83e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs9409082	0.798	rs7020240	chr9:108924941	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.41	-0.46	1.75e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg00179576	chr16:74483694	GLG1	-0.42	-4.6	-0.35	8.76e-6	Testicular germ cell tumor;
PAAD	cis	rs1376877	0.519	rs13416670	chr2:204285774	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.58	4.74	0.36	4.94e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.51	-5.63	-0.42	8.41e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.53	4.94	0.37	2.01e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15664640	chr17:80829946	TBCD	0.55	5.6	0.41	9.86e-8	Breast cancer;
PAAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.74	10.39	0.64	1.87e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12903563	0.505	rs12898861	chr15:77983802	A/G	cg25212270	chr15:78015279	NA	0.37	4.32	0.33	2.79e-5	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs1468333	0.667	rs6886388	chr5:137733423	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.42	0.4	2.26e-7	Resting heart rate;
PAAD	cis	rs138918	1.000	rs138918	chr22:43559451	G/A	cg00343092	chr22:43547974	TSPO	0.55	6.23	0.45	4.29e-9	Monocyte count;
PAAD	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg01420254	chr6:26195488	NA	0.82	6.13	0.45	7.18e-9	Gout;Renal underexcretion gout;
PAAD	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.06	-0.38	1.18e-6	Total body bone mineral density;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.45	-4.59	-0.35	9.14e-6	Iron status biomarkers;
PAAD	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs11615916	0.790	rs1074956	chr12:62664224	A/G	cg11441379	chr12:63026424	NA	0.7	4.54	0.35	1.15e-5	Pulmonary function decline;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07705912	chr1:154155363	TPM3	-0.74	-6.4	-0.46	1.87e-9	Neuroticism;
PAAD	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg06643013	chr6:134217242	NA	-0.53	-5.85	-0.43	2.87e-8	Coronary artery disease;
PAAD	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	10.91	0.66	8.09e-21	Primary sclerosing cholangitis;
PAAD	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.33	-0.33	2.65e-5	Neuroticism;
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Body mass index;
PAAD	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	5.26	0.39	4.92e-7	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg13047869	chr3:10149882	C3orf24	0.76	5.55	0.41	1.23e-7	Alzheimer's disease;
PAAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.46	0.46	1.35e-9	Mood instability;
PAAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.74	-7.26	-0.51	1.86e-11	Dilated cardiomyopathy;
PAAD	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.79	6.27	0.45	3.56e-9	Prostate cancer;
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.55	-0.41	1.26e-7	Prostate cancer;
PAAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg22633769	chr20:60982531	CABLES2	0.53	4.81	0.36	3.55e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.31	0.56	4.85e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28655083	0.529	rs4544253	chr16:77104774	T/C	cg06128999	chr16:77247126	NA	-0.37	-4.38	-0.33	2.18e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10450586	0.796	rs7948420	chr11:27276450	C/T	cg10370305	chr11:27303972	NA	0.38	4.53	0.34	1.21e-5	Total body bone mineral density;
PAAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg01815783	chr4:1047043	NA	-0.49	-4.76	-0.36	4.51e-6	Recombination rate (females);
PAAD	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs4668356	0.773	rs73017286	chr2:172048632	G/C	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.77	8.91	0.59	1.45e-15	Hemoglobin concentration;
PAAD	cis	rs736801	0.538	rs2548998	chr5:131832514	G/A	cg00255919	chr5:131827918	IRF1	-0.46	-5.8	-0.43	3.73e-8	Breast cancer;Mosquito bite size;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.67	7.4	0.51	8.39e-12	Blood metabolite levels;
PAAD	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-4.78	-0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.46	-0.34	1.57e-5	Joint mobility (Beighton score);
PAAD	cis	rs1468734	0.929	rs59640658	chr16:5006541	T/C	cg06510647	chr16:5006106	NA	0.61	5.69	0.42	6.3e-8	Cancer;
PAAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg11584989	chr19:19387371	SF4	0.45	4.55	0.35	1.1e-5	Tonsillectomy;
PAAD	cis	rs7729723	0.653	rs982085	chr5:137775581	C/G	cg26069252	chr5:137800343	EGR1	-0.47	-4.32	-0.33	2.85e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.24	-9.8	-0.62	7.2e-18	Breast cancer;
PAAD	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16270571	chr7:6746599	ZNF12	0.57	6.41	0.46	1.73e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.75	-0.42	4.7e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.9	-8.97	-0.59	1.03e-15	Corneal astigmatism;
PAAD	cis	rs6494488	0.500	rs72742957	chr15:64905227	A/C	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs1126510	0.860	rs10416000	chr19:47130774	G/A	cg07844738	chr19:47129343	PTGIR	0.43	4.99	0.38	1.62e-6	Ulcerative colitis;
PAAD	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg21948783	chr12:49372474	WNT1	0.43	4.86	0.37	2.96e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.73	-9.74	-0.62	1.04e-17	Iron status biomarkers;
PAAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14895029	chr7:2775587	GNA12	-0.47	-4.61	-0.35	8.33e-6	Height;
PAAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg02734326	chr4:10020555	SLC2A9	0.46	4.55	0.35	1.1e-5	Bone mineral density;
PAAD	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg10729496	chr3:10149963	C3orf24	0.82	6.62	0.47	5.71e-10	Alzheimer's disease;
PAAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg18892244	chr7:807596	HEATR2	-0.67	-5.08	-0.38	1.11e-6	Initial pursuit acceleration;
PAAD	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs58521262	0.585	rs462900	chr19:23123663	G/T	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg12623918	chr2:306882	NA	0.47	4.78	0.36	4.03e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	5.98	0.44	1.56e-8	Blood protein levels;
PAAD	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-5.58	-0.41	1.1e-7	Platelet count;
PAAD	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg17541715	chr7:1216824	NA	-0.6	-6.67	-0.48	4.54e-10	Longevity;Endometriosis;
PAAD	cis	rs6499755	0.712	rs31091	chr16:55363818	T/C	cg02859129	chr16:55357253	IRX6	0.35	4.87	0.37	2.79e-6	Hypospadias;
PAAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	10.48	0.65	1.11e-19	Menopause (age at onset);
PAAD	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-11.86	-0.69	2.25e-23	Primary sclerosing cholangitis;
PAAD	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.37	5.34	0.4	3.37e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs282587	0.569	rs282593	chr13:113378882	T/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg10790723	chr22:36903033	FOXRED2	0.44	4.45	0.34	1.63e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	4.8	0.36	3.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg07810366	chr2:100720526	AFF3	0.42	5.18	0.39	7.09e-7	Educational attainment (years of education);
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg18892244	chr7:807596	HEATR2	-0.62	-6.63	-0.47	5.61e-10	Subjective well-being;
PAAD	trans	rs111756027	0.522	rs72800050	chr16:77277067	A/G	cg17418387	chr1:17761802	RCC2	-0.79	-6.39	-0.46	1.93e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg01320130	chr1:67600311	NA	-0.56	-5.9	-0.43	2.25e-8	Psoriasis;
PAAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg01320130	chr1:67600311	NA	0.54	5.96	0.44	1.66e-8	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21077245	chr14:104191469	ZFYVE21	-0.64	-6.37	-0.46	2.08e-9	Obesity-related traits;
PAAD	trans	rs11794666	1.000	rs16917279	chr9:31675800	A/T	cg05628366	chr6:35744188	C6orf126	1.0	6.41	0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.51	-0.34	1.29e-5	Primary biliary cholangitis;
PAAD	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.72	5.76	0.42	4.48e-8	Methadone dose in opioid dependence;
PAAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.74	7.17	0.5	3e-11	Cognitive function;
PAAD	trans	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.34	0.46	2.46e-9	Calcium levels;
PAAD	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2882667	0.654	rs4835704	chr5:138151325	G/A	cg09476006	chr5:138032270	NA	-0.45	-5.67	-0.42	7.05e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.77	-0.36	4.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs72960926	0.744	rs55867620	chr6:75038763	G/A	cg03266952	chr6:74778945	NA	-1.18	-6.55	-0.47	8.34e-10	Metabolite levels (MHPG);
PAAD	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.66	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg20130138	chr11:64956067	CAPN1	0.62	4.47	0.34	1.5e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.56	5.46	0.41	1.86e-7	Obesity;
PAAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.88	-14.05	-0.75	2.81e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg23283495	chr1:209979779	IRF6	0.81	7.41	0.51	8.36e-12	Coronary artery disease;
PAAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs12949688	0.682	rs7503947	chr17:55838518	C/A	cg12582317	chr17:55822272	NA	0.43	4.85	0.37	2.98e-6	Schizophrenia;
PAAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg23281280	chr6:28129359	ZNF389	0.47	4.28	0.33	3.24e-5	Parkinson's disease;
PAAD	cis	rs1925576	0.935	rs1916381	chr10:68656451	C/T	cg04444303	chr10:69634106	NA	-0.44	-4.41	-0.34	1.97e-5	Educational attainment (years of education);
PAAD	cis	rs12447180	0.527	rs4782365	chr16:88516171	C/G	cg01690119	chr16:88511822	NA	-0.38	-4.38	-0.33	2.23e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.71	5.78	0.42	4.18e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.13	0.45	7.11e-9	Height;
PAAD	cis	rs13102973	0.611	rs4298187	chr4:135886186	G/A	cg14419869	chr4:135874104	NA	0.43	4.32	0.33	2.83e-5	Subjective well-being;
PAAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg23018236	chr17:30244563	NA	-0.57	-4.35	-0.33	2.53e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-5.45	-0.4	1.99e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg24879335	chr3:133465180	TF	0.55	5.86	0.43	2.8e-8	Iron status biomarkers;
PAAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg04450456	chr4:17643702	FAM184B	0.52	5.87	0.43	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs901683	1.000	rs71494793	chr10:45985092	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.54	5.92	0.43	2.03e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.58	-5.71	-0.42	5.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Lymphocyte counts;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04622620	chr7:127032509	ZNF800	-0.67	-6.91	-0.49	1.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg13699009	chr12:122356056	WDR66	-0.46	-6.61	-0.47	6.08e-10	Mean corpuscular volume;
PAAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg06740227	chr12:86229804	RASSF9	-0.49	-4.9	-0.37	2.48e-6	Major depressive disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06080267	chr1:25943116	MAN1C1	0.63	7.12	0.5	4.04e-11	Monocyte percentage of white cells;
PAAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg25833597	chr17:30823145	MYO1D	0.51	5.0	0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs6466055	0.777	rs41562	chr7:104845094	C/T	cg04380332	chr7:105027541	SRPK2	0.64	7.3	0.51	1.53e-11	Schizophrenia;
PAAD	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.6	5.85	0.43	2.97e-8	Type 2 diabetes;
PAAD	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs900145	0.725	rs11022754	chr11:13313243	G/A	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.96	-0.44	1.67e-8	QT interval;
PAAD	cis	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	4.65	0.35	7.06e-6	Coronary artery disease;
PAAD	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.5	6.16e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.36	0.46	2.25e-9	Schizophrenia;
PAAD	cis	rs470119	0.966	rs140523	chr22:50962782	C/G	cg12969734	chr22:50962224	SCO2	0.53	5.48	0.41	1.77e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.88	7.28	0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs6011674	1.000	rs41282998	chr20:61875513	A/G	cg12002882	chr20:62461365	NA	-0.79	-4.73	-0.36	5.04e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.87	9.3	0.6	1.42e-16	Corneal astigmatism;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18247638	chr13:103451366	KDELC1;BIVM	0.6	6.82	0.48	2.02e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.7	0.36	5.89e-6	Electroencephalogram traits;
PAAD	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.61	-8.52	-0.57	1.42e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.54	7.21	0.5	2.47e-11	Prostate cancer;
PAAD	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	1.0	7.3	0.51	1.47e-11	Dental caries;
PAAD	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.66	0.48	4.59e-10	Schizophrenia;
PAAD	cis	rs11563648	0.553	rs9656363	chr7:127056042	C/T	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.98	10.53	0.65	8.4e-20	Blood metabolite levels;
PAAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.89	-9.41	-0.61	7.34e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs762407	0.560	rs2838362	chr21:45189165	A/T	cg11815682	chr21:44486381	CBS	-0.54	-5.3	-0.4	3.95e-7	Systolic blood pressure change trajectories;
PAAD	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.91	-10.67	-0.65	3.38e-20	Refractive error;
PAAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg02734326	chr4:10020555	SLC2A9	-0.51	-4.91	-0.37	2.28e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9900062	0.586	rs35018407	chr17:62690181	A/C	cg02598441	chr17:62777298	LOC146880	-0.57	-4.7	-0.36	5.83e-6	QT interval;
PAAD	cis	rs10214930	0.781	rs12700823	chr7:27659221	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03839934	chr5:95997987	CAST	-0.77	-6.3	-0.46	3.03e-9	Neuroticism;
PAAD	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.63	5.79	0.43	3.83e-8	Alcohol dependence;
PAAD	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.61	6.0	0.44	1.38e-8	Primary sclerosing cholangitis;
PAAD	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24120800	chr3:100455446	TFG	-0.64	-6.85	-0.49	1.68e-10	Obesity-related traits;
PAAD	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	8.05	0.55	2.25e-13	Eotaxin levels;
PAAD	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.53	-5.81	-0.43	3.56e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.69	7.53	0.52	4.26e-12	Melanoma;
PAAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.76	-6.65	-0.47	5.08e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg04160749	chr8:58172571	NA	-0.65	-4.49	-0.34	1.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs2446066	0.872	rs34148420	chr12:53798808	T/C	cg20591337	chr12:53693442	C12orf10	-0.64	-4.51	-0.34	1.31e-5	Red blood cell count;
PAAD	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg08501292	chr6:25962987	TRIM38	0.86	5.25	0.39	5.14e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	6.5	0.47	1.07e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.55	-0.57	1.25e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08219700	chr8:58056026	NA	0.63	4.93	0.37	2.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg00536532	chr6:33561449	C6orf227	-0.42	-4.44	-0.34	1.73e-5	Height;
PAAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.62	5.46	0.41	1.88e-7	Initial pursuit acceleration;
PAAD	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.4	4.97	0.37	1.76e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.7	-0.36	5.68e-6	Recombination measurement;
PAAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.05	-0.44	1.08e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.8	-7.6	-0.52	2.86e-12	DNA methylation (variation);
PAAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg04287289	chr16:89883240	FANCA	0.61	6.7	0.48	3.83e-10	Vitiligo;
PAAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.79	-8.77	-0.58	3.33e-15	Vitiligo;
PAAD	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg17517138	chr11:73019481	ARHGEF17	0.83	4.54	0.35	1.12e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.98	-10.49	-0.65	1.06e-19	Longevity;
PAAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.58	5.28	0.39	4.29e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.69	7.54	0.52	3.92e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.58	5.75	0.42	4.86e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.59	7.34	0.51	1.18e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg15061591	chr7:98625706	SMURF1	-0.5	-4.69	-0.36	6.12e-6	Breast cancer;
PAAD	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg25566285	chr7:158114605	PTPRN2	0.75	6.42	0.46	1.63e-9	Response to amphetamines;
PAAD	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.31	0.46	2.84e-9	Breast cancer;
PAAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.98	-6.88	-0.49	1.47e-10	Lung cancer in ever smokers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04358685	chr3:12598421	MKRN2	0.56	6.29	0.45	3.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg10290764	chr8:4849399	CSMD1	0.38	6.35	0.46	2.36e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12304921	1.000	rs73090647	chr12:51345465	G/C	cg18059802	chr12:51347058	HIGD1C	-0.72	-5.94	-0.43	1.88e-8	Type 2 diabetes;
PAAD	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.72	-0.48	3.39e-10	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.92	-0.37	2.21e-6	Bipolar disorder;
PAAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg03999872	chr20:62272968	STMN3	0.48	4.37	0.33	2.31e-5	Prostate cancer;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg20849893	chr7:64541193	NA	0.5	4.87	0.37	2.77e-6	Calcium levels;
PAAD	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg09491104	chr22:46646882	C22orf40	-0.98	-5.89	-0.43	2.34e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.67	6.9	0.49	1.32e-10	Response to antidepressants and depression;
PAAD	cis	rs508970	0.556	rs663920	chr11:60914533	A/G	cg24692310	chr11:60915630	VPS37C	0.32	4.45	0.34	1.67e-5	Rheumatoid arthritis;
PAAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22601191	chr20:60968625	CABLES2	0.7	6.42	0.46	1.67e-9	Colorectal cancer;
PAAD	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.55	-6.79	-0.48	2.34e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.47	4.87	0.37	2.81e-6	Major depressive disorder;
PAAD	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.57	-6.0	-0.44	1.41e-8	Response to antidepressants and depression;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs4555772	1.000	rs10473971	chr5:74302241	T/C	cg03227963	chr5:74354835	NA	0.44	4.47	0.34	1.52e-5	Stearic acid (18:0) levels;
PAAD	cis	rs377457	0.857	rs11644122	chr16:85740750	C/T	cg07784872	chr16:85687041	KIAA0182	-0.74	-6.76	-0.48	2.72e-10	Type 2 diabetes;
PAAD	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.52	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9815354	0.953	rs1613233	chr3:41945144	A/G	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.86e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.84	6.2	0.45	5e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg14346243	chr4:90757452	SNCA	-0.51	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11245990	chr11:68621969	NA	0.39	5.24	0.39	5.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.67	4.57	0.35	9.87e-6	IgG glycosylation;
PAAD	cis	rs7168592	1.000	rs36082322	chr15:101749641	T/C	cg24254196	chr15:101719523	CHSY1	-0.59	-4.32	-0.33	2.81e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg10605766	chr3:121512184	IQCB1	-0.63	-6.31	-0.46	2.93e-9	Alcohol dependence;
PAAD	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.64	-5.31	-0.4	3.76e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs6782025	0.837	rs6775842	chr3:120805772	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.66	-0.35	7e-6	Lung cancer;
PAAD	cis	rs17125944	0.686	rs2025634	chr14:53336017	C/T	cg13660082	chr14:53194042	PSMC6	0.71	4.44	0.34	1.72e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7558233	0.614	rs763456	chr2:23675180	A/G	cg00747342	chr2:23700632	KLHL29	0.67	4.27	0.33	3.45e-5	Cannabis use (initiation);
PAAD	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-4.91	-0.37	2.29e-6	Common traits (Other);
PAAD	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	1.1	16.19	0.8	6.71e-35	Platelet distribution width;
PAAD	cis	rs2555155	0.935	rs2723645	chr11:6519363	C/G	cg24637308	chr11:6592297	DNHD1	0.48	4.91	0.37	2.33e-6	DNA methylation (variation);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05539622	chr2:73298971	SFXN5	-0.65	-6.44	-0.46	1.47e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.33	0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs9810890	1.000	rs73196967	chr3:128437236	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.66	7.13	0.5	3.7e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.43	-4.37	-0.33	2.28e-5	Mean corpuscular volume;
PAAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18297960	chr7:1142765	C7orf50	-0.6	-4.99	-0.38	1.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.53	4.95	0.37	1.91e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.51	4.71	0.36	5.46e-6	Total body bone mineral density;
PAAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg05342682	chr7:94953680	PON1	-0.51	-4.44	-0.34	1.69e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.59	4.25	0.33	3.67e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.72	7.7	0.53	1.65e-12	Cognitive test performance;
PAAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg07338119	chr7:157211683	NA	-0.43	-4.4	-0.34	2.02e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6499129	0.558	rs13334205	chr16:67581883	A/G	cg09835421	chr16:68378352	PRMT7	-0.66	-4.36	-0.33	2.38e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.85	7.35	0.51	1.12e-11	Recombination rate (females);
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.62	7.03	0.5	6.71e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs282587	0.502	rs408476	chr13:113400056	A/C	cg02820901	chr13:113351484	ATP11A	-0.66	-5.02	-0.38	1.4e-6	Glycated hemoglobin levels;
PAAD	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.54	5.54	0.41	1.31e-7	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg03098721	chr1:84464084	TTLL7	0.45	4.25	0.33	3.69e-5	Obesity-related traits;
PAAD	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.51	5.29	0.39	4.21e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.97	11.85	0.69	2.41e-23	Breast cancer;
PAAD	cis	rs731174	0.802	rs609437	chr1:38184316	T/C	cg10090792	chr1:38198142	EPHA10	-0.44	-4.54	-0.35	1.14e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.33	0.4	3.46e-7	Lung cancer in ever smokers;
PAAD	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg20913747	chr6:44695427	NA	-0.7	-6.96	-0.49	9.52e-11	Total body bone mineral density;
PAAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg14829360	chr17:73884958	NA	-0.64	-6.14	-0.45	6.86e-9	Psoriasis;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg11062466	chr8:58055876	NA	0.68	5.09	0.38	1.02e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.62	4.63	0.35	7.81e-6	Thyroid stimulating hormone;
PAAD	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.55	4.5	0.34	1.36e-5	Heschl's gyrus morphology;
PAAD	cis	rs1730008	0.719	rs827188	chr3:158047753	C/T	cg01557547	chr3:157823089	SHOX2	0.42	4.3	0.33	3.05e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.83	-8.81	-0.58	2.63e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.532	rs75392670	chr5:74394968	A/G	cg03227963	chr5:74354835	NA	0.5	4.86	0.37	2.94e-6	Response to amphetamines;
PAAD	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs354033	1.000	rs56707870	chr7:149265728	T/C	cg06920324	chr7:149264011	ZNF767	-0.62	-5.16	-0.39	7.75e-7	Multiple sclerosis;
PAAD	cis	rs863345	0.967	rs10797014	chr1:158468202	C/T	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.54	-4.66	-0.35	6.95e-6	Obesity-related traits;
PAAD	cis	rs2031532	0.565	rs1543513	chr13:50034684	C/A	cg08779649	chr13:50194554	NA	0.36	4.77	0.36	4.2e-6	Cardiac hypertrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26366347	chr17:73008860	ICT1	0.62	6.46	0.46	1.33e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg03030879	chr14:75389066	RPS6KL1	0.41	4.36	0.33	2.35e-5	Height;
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.66	-0.35	6.79e-6	Lung cancer;
PAAD	cis	rs4604732	0.588	rs4925552	chr1:247631749	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.62	5.85	0.43	2.86e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.95	12.31	0.71	1.38e-24	Menopause (age at onset);
PAAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.75	-7.11	-0.5	4.24e-11	Pancreatic cancer;
PAAD	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.16e-8	Total body bone mineral density;
PAAD	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg12310025	chr6:25882481	NA	0.43	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs7766436	0.621	rs2294825	chr6:22597820	G/T	cg13666174	chr6:22585274	NA	0.5	5.96	0.44	1.67e-8	Coronary artery disease;
PAAD	cis	rs6880778	0.505	rs7730693	chr5:40373105	A/G	cg05240017	chr5:40756081	TTC33	0.5	4.31	0.33	2.94e-5	Inflammatory bowel disease;
PAAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg19980929	chr12:42632907	YAF2	0.57	6.78	0.48	2.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.48	0.47	1.21e-9	Total body bone mineral density;
PAAD	cis	rs12935418	0.616	rs11863536	chr16:80969674	C/T	cg16651780	chr16:81037892	C16orf61	0.57	4.61	0.35	8.33e-6	Mean corpuscular volume;
PAAD	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.64	6.17	0.45	5.85e-9	Uric acid clearance;
PAAD	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.85	5.88	0.43	2.47e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg14847009	chr1:175162515	KIAA0040	0.32	4.99	0.37	1.66e-6	Alcohol dependence;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.4	0.34	2.02e-5	Personality dimensions;
PAAD	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.5	-4.72	-0.36	5.41e-6	Type 2 diabetes;
PAAD	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs6466055	0.589	rs111595825	chr7:104649037	A/G	cg04380332	chr7:105027541	SRPK2	0.48	4.58	0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.73	7.53	0.52	4.16e-12	Handedness;
PAAD	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg03959625	chr15:84868606	LOC388152	-0.51	-4.92	-0.37	2.23e-6	P wave terminal force;
PAAD	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg04733911	chr16:78082701	NA	0.53	5.05	0.38	1.24e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg21770322	chr7:97807741	LMTK2	-0.69	-9.26	-0.6	1.79e-16	Breast cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19562499	chr20:43595488	STK4	-0.73	-7.18	-0.5	2.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18621852	chr3:10150065	C3orf24	0.59	5.23	0.39	5.5e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.95	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.57	-7.0	-0.49	7.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28472312	0.723	rs1137843	chr16:28977713	T/C	cg16576597	chr16:28551801	NUPR1	-0.45	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.68	5.09	0.38	1.03e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	4.47	0.34	1.53e-5	Eosinophil percentage of white cells;
PAAD	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.69	-0.36	6.16e-6	Glomerular filtration rate;
PAAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg11673840	chr17:47092156	IGF2BP1	0.48	6.04	0.44	1.15e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18490616	chr2:88469792	THNSL2	-0.48	-4.51	-0.34	1.29e-5	Response to metformin (IC50);
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.74	5.55	0.41	1.26e-7	Alzheimer's disease;
PAAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.89	10.3	0.64	3.43e-19	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01820262	chr20:36322484	CTNNBL1	-0.75	-6.29	-0.45	3.2e-9	Neuroticism;
PAAD	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg22189786	chr22:42395067	WBP2NL	0.52	4.38	0.33	2.21e-5	Birth weight;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.89	-0.37	2.51e-6	Lung cancer;
PAAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-7.1	-0.5	4.54e-11	Personality dimensions;
PAAD	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.93	-13.32	-0.73	2.56e-27	Heart rate;
PAAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.93	7.49	0.52	5.24e-12	Initial pursuit acceleration;
PAAD	cis	rs11700980	0.551	rs77334403	chr21:30109398	A/G	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.89	-7.34	-0.51	1.23e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.87	-0.49	1.53e-10	Life satisfaction;
PAAD	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs3126085	0.736	rs12747962	chr1:152240456	G/A	cg26876637	chr1:152193138	HRNR	0.9	6.49	0.47	1.14e-9	Atopic dermatitis;
PAAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.09e-5	Homoarginine levels;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg11995313	chr8:8860691	ERI1	0.43	4.31	0.33	2.93e-5	Mood instability;
PAAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.83	8.75	0.58	3.81e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg03885332	chr11:832357	CD151	-0.45	-5.34	-0.4	3.32e-7	Mean platelet volume;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.06e-6	Lung cancer;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05025164	chr4:1340916	KIAA1530	-0.55	-5.5	-0.41	1.59e-7	Obesity-related traits;
PAAD	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	4.47	0.34	1.52e-5	Refractive astigmatism;
PAAD	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg00262122	chr8:11665843	FDFT1	0.49	4.3	0.33	3.06e-5	Retinal vascular caliber;
PAAD	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.84e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6604026	0.656	rs2774950	chr1:93353527	T/C	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.82	6.72	0.48	3.46e-10	Alzheimer's disease;
PAAD	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg17509989	chr5:176798049	RGS14	0.76	7.19	0.5	2.69e-11	Urate levels in lean individuals;
PAAD	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12746016	chr22:49560550	NA	0.65	6.98	0.49	8.76e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.64	6.91	0.49	1.25e-10	Longevity;
PAAD	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.55	5.14	0.38	8.42e-7	Obesity-related traits;
PAAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14895029	chr7:2775587	GNA12	0.47	4.71	0.36	5.44e-6	Height;
PAAD	cis	rs4605213	0.510	rs11658506	chr17:49326433	G/A	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.48e-8	Height;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg05717871	chr11:638507	DRD4	-0.58	-5.44	-0.4	2.09e-7	Systemic lupus erythematosus;
PAAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2077654	0.822	rs12279699	chr11:17443348	G/A	cg25308976	chr11:17434268	ABCC8	0.9	4.99	0.38	1.65e-6	Gout;
PAAD	cis	rs10090774	0.965	rs11167012	chr8:141968408	C/A	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.72	6.44	0.46	1.49e-9	Childhood ear infection;
PAAD	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.67	7.47	0.52	5.78e-12	Menopause (age at onset);
PAAD	cis	rs12220238	0.915	rs10824164	chr10:76137032	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.51	-4.53	-0.35	1.16e-5	Red blood cell traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg00114008	chr1:27114423	PIGV	0.62	6.43	0.46	1.59e-9	Primary biliary cholangitis;
PAAD	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg23920097	chr1:209922102	NA	-0.48	-4.26	-0.33	3.6e-5	Red blood cell count;
PAAD	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg11995313	chr8:8860691	ERI1	0.5	5.03	0.38	1.35e-6	Joint mobility (Beighton score);
PAAD	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.06	-0.38	1.18e-6	Height;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.66	-0.35	6.89e-6	Testicular germ cell tumor;
PAAD	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.81	9.81	0.62	6.69e-18	Colorectal cancer;
PAAD	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	4.49	0.34	1.38e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.55	5.98	0.44	1.56e-8	Testicular germ cell tumor;
PAAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.62	6.5	0.47	1.1e-9	Coronary artery disease;
PAAD	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.75e-5	Monobrow;
PAAD	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.67	6.81	0.48	2.08e-10	Menarche (age at onset);
PAAD	cis	rs4523957	0.713	rs9906500	chr17:2129210	C/A	cg16513277	chr17:2031491	SMG6	-0.52	-5.39	-0.4	2.66e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg05250797	chr16:70222502	NA	0.79	5.89	0.43	2.39e-8	IgE levels;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg00531865	chr16:30841666	NA	-0.51	-4.82	-0.36	3.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	-0.36	-4.29	-0.33	3.12e-5	Longevity;
PAAD	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.72	0.77	4.64e-31	Chronic sinus infection;
PAAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.08	0.59	5.46e-16	Menopause (age at onset);
PAAD	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08564027	chr20:61660810	NA	-1.08	-12.78	-0.72	7.1e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Melanoma;
PAAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.76	5.8	0.43	3.75e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.92	-10.75	-0.66	2.16e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs778371	0.788	rs2675955	chr2:233753281	G/A	cg08000102	chr2:233561755	GIGYF2	-0.66	-5.98	-0.44	1.57e-8	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.69	-4.74	-0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.64	5.08	0.38	1.08e-6	Osteoarthritis;
PAAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.65	7.93	0.54	4.38e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs7957197	0.628	rs692902	chr12:121197124	A/G	cg16175725	chr12:121416796	HNF1A	-0.38	-4.63	-0.35	7.93e-6	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00938305	chr16:30569736	ZNF764	-0.72	-6.38	-0.46	2.01e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27376548	chr3:32338292	CMTM8	0.65	6.31	0.46	2.86e-9	Obesity-related traits;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.75	-7.88	-0.54	5.68e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17418252	chr10:8559030	NA	-0.61	-6.34	-0.46	2.47e-9	Obesity-related traits;
PAAD	cis	rs593531	0.513	rs4944887	chr11:74029883	G/A	cg15851278	chr11:73669449	DNAJB13	0.39	4.96	0.37	1.9e-6	Neuroticism;
PAAD	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.98	-14.18	-0.75	1.28e-29	Post bronchodilator FEV1;
PAAD	cis	rs75920871	0.843	rs61905713	chr11:116909429	C/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg09060608	chr5:178986726	RUFY1	0.53	5.16	0.39	7.55e-7	Lung cancer;
PAAD	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg06307176	chr5:131281290	NA	0.46	4.31	0.33	2.92e-5	Blood metabolite levels;
PAAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23158103	chr7:148848205	ZNF398	0.64	6.43	0.46	1.56e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg17372223	chr3:52568218	NT5DC2	-0.45	-4.36	-0.33	2.42e-5	Electroencephalogram traits;
PAAD	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.48	-8.08	-0.55	1.86e-13	Mean corpuscular volume;
PAAD	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg16306870	chr3:194868790	C3orf21	0.48	4.4	0.34	2.01e-5	Non-small cell lung cancer;
PAAD	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.93	12.53	0.71	3.38e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.61	6.76	0.48	2.75e-10	Lung cancer;
PAAD	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs2117029	0.586	rs11168882	chr12:49537343	G/A	cg05368762	chr12:50135785	TMBIM6	0.46	4.63	0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.64	-5.45	-0.4	2.02e-7	Lung cancer;
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg04369109	chr6:150039330	LATS1	0.47	4.49	0.34	1.39e-5	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg00431813	chr7:1051703	C7orf50	-0.36	-4.53	-0.34	1.19e-5	Longevity;Endometriosis;
PAAD	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.19	-0.39	6.75e-7	Myopia (pathological);
PAAD	cis	rs76419734	0.558	rs10516520	chr4:106534110	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.66	0.35	6.98e-6	Post bronchodilator FEV1;
PAAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	9.98	0.63	2.36e-18	Platelet count;
PAAD	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-1.0	-9.2	-0.6	2.59e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg21479132	chr6:26055353	NA	0.98	5.48	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.48	4.91	0.37	2.31e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.56	-0.57	1.17e-14	Thrombosis;
PAAD	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-6.41	-0.46	1.71e-9	Breast cancer;
PAAD	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	trans	rs901683	1.000	rs34539215	chr10:46087378	C/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.15	-0.64	8.25e-19	Response to antipsychotic treatment;
PAAD	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg16558253	chr16:72132732	DHX38	-0.56	-5.12	-0.38	9.26e-7	Coronary artery disease;
PAAD	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.17	11.65	0.69	7.88e-23	Corneal structure;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09695851	chr17:3907499	NA	0.6	5.48	0.41	1.7e-7	Type 2 diabetes;
PAAD	cis	rs422249	0.634	rs174616	chr11:61629122	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.39	4.38	0.33	2.23e-5	Trans fatty acid levels;
PAAD	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.45	-0.34	1.64e-5	Joint mobility (Beighton score);
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg07701084	chr6:150067640	NUP43	0.65	6.35	0.46	2.35e-9	Testicular germ cell tumor;
PAAD	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.51	-5.15	-0.39	7.9e-7	Subjective well-being;
PAAD	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.52	-0.52	4.35e-12	Psoriasis vulgaris;
PAAD	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg09760422	chr2:128146352	NA	-0.44	-7.6	-0.52	2.81e-12	Protein C levels;
PAAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2019216	0.500	rs12938673	chr17:21941987	C/G	cg22648282	chr17:21454238	C17orf51	-0.51	-4.59	-0.35	9.35e-6	Pelvic organ prolapse;
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg04257695	chr17:30186438	C17orf79	-0.62	-4.93	-0.37	2.16e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24456592	chr4:185434033	NA	-0.59	-6.37	-0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.71	7.72	0.53	1.44e-12	Hemoglobin concentration;
PAAD	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg14092571	chr14:90743983	NA	-0.46	-4.6	-0.35	8.96e-6	Mortality in heart failure;
PAAD	cis	rs9815354	1.000	rs2625667	chr3:41900951	C/A	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.91	-0.43	2.13e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg14349672	chr11:133703707	NA	-0.49	-5.24	-0.39	5.34e-7	Childhood ear infection;
PAAD	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg27449745	chr7:23145252	KLHL7	-0.58	-5.21	-0.39	6.11e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.31	0.4	3.86e-7	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18732064	chr14:23356059	REM2	0.59	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12760731	0.565	rs78577576	chr1:178141982	A/G	cg00404053	chr1:178313656	RASAL2	0.64	4.75	0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.99	8.0	0.54	2.93e-13	Eosinophilic esophagitis;
PAAD	cis	rs2564921	0.513	rs12638195	chr3:52876639	G/A	cg11645453	chr3:52864694	ITIH4	-0.31	-4.4	-0.34	2.05e-5	Height;
PAAD	trans	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg07211511	chr3:129823064	LOC729375	-1.18	-11.21	-0.67	1.26e-21	Blood pressure (smoking interaction);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.57	-4.38	-0.33	2.21e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs863345	0.604	rs1342946	chr1:158453187	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.27e-6	Pneumococcal bacteremia;
PAAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.95	-8.96	-0.59	1.12e-15	Bronchopulmonary dysplasia;
PAAD	trans	rs9409082	0.677	rs1516881	chr9:108913054	C/G	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.6	-6.18	-0.45	5.66e-9	Neuroticism;
PAAD	cis	rs4842666	0.850	rs11105328	chr12:89942390	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.63	-4.29	-0.33	3.2e-5	Blood pressure;
PAAD	cis	rs4454254	0.589	rs9987138	chr8:141076623	C/G	cg07454640	chr8:140990901	TRAPPC9	0.49	4.67	0.35	6.49e-6	Pulse pressure;
PAAD	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2278796	0.881	rs11240325	chr1:204955329	A/G	cg04862289	chr1:204966208	NFASC	0.43	4.33	0.33	2.71e-5	Mean platelet volume;
PAAD	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-6.08	-0.44	9.24e-9	Multiple myeloma (IgH translocation);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01419670	chr5:115696151	NA	0.55	6.49	0.47	1.16e-9	Body fat percentage;
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg02555727	chr12:129281546	SLC15A4	-0.46	-4.96	-0.37	1.84e-6	Systemic lupus erythematosus;
PAAD	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-5.09	-0.38	1.06e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.51	-4.5	-0.34	1.32e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	6.47	0.46	1.26e-9	HIV-1 control;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	6.6	0.47	6.56e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs757081	0.658	rs214075	chr11:17300417	G/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-5.62	-0.41	8.96e-8	Systolic blood pressure;
PAAD	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.68	6.7	0.48	3.89e-10	Lymphocyte counts;
PAAD	cis	rs308971	0.611	rs387152	chr3:12076032	G/C	cg02700894	chr3:12045449	SYN2	0.62	5.32	0.4	3.63e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.76	7.19	0.5	2.74e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.12e-6	Cognitive function;
PAAD	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.72	-0.48	3.46e-10	Platelet distribution width;
PAAD	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10768122	1.000	rs4755394	chr11:35290365	G/A	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.29	-0.33	3.13e-5	Vitiligo;
PAAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg08601574	chr20:25228251	PYGB	0.47	4.56	0.35	1.02e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg01075559	chr1:2537774	MMEL1	-0.5	-5.2	-0.39	6.36e-7	Ulcerative colitis;
PAAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg14851346	chr12:38532713	NA	0.49	4.62	0.35	8.23e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.81	9.32	0.6	1.28e-16	Aortic root size;
PAAD	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.61	-5.93	-0.43	1.98e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.7	6.75	0.48	2.9e-10	Platelet distribution width;
PAAD	cis	rs755249	0.532	rs17343193	chr1:39881468	T/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.53	5.03	0.38	1.37e-6	Crohn's disease;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg26516362	chr5:178986906	RUFY1	-0.56	-6.79	-0.48	2.37e-10	Lung cancer;
PAAD	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg10820045	chr2:198174542	NA	-0.44	-4.35	-0.33	2.49e-5	Dermatomyositis;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.19	-0.7	2.93e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26926768	chr12:34528122	NA	0.4	4.84	0.37	3.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs10044254	0.563	rs10866514	chr5:15689507	A/G	cg07238450	chr5:15720153	FBXL7	0.52	4.98	0.37	1.69e-6	Asthma (corticosteroid response);
PAAD	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.98	6.65	0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs375066	0.762	rs239943	chr19:44374716	A/T	cg11993925	chr19:44307056	LYPD5	0.51	6.28	0.45	3.33e-9	Breast cancer;
PAAD	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.67	-0.42	7.13e-8	Lung cancer in ever smokers;
PAAD	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.35	-0.64	2.39e-19	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.75	-8.07	-0.55	1.93e-13	Aortic root size;
PAAD	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-7.98	-0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs12935418	0.552	rs2549838	chr16:81023210	C/T	cg16651780	chr16:81037892	C16orf61	-0.66	-6.2	-0.45	5.15e-9	Mean corpuscular volume;
PAAD	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.68	0.48	4.17e-10	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg10137597	chr8:22132714	PIWIL2	0.48	5.75	0.42	4.7e-8	Hypertriglyceridemia;
PAAD	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.98	0.44	1.51e-8	Lung cancer in ever smokers;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg19318889	chr4:1322082	MAEA	-0.43	-4.51	-0.34	1.26e-5	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.43	-0.61	6.43e-17	Response to antipsychotic treatment;
PAAD	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.67	7.86	0.54	6.72e-13	Weight;
PAAD	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.85	-7.95	-0.54	4.03e-13	Exhaled nitric oxide output;
PAAD	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.43	4.41	0.34	1.96e-5	Sarcoidosis;
PAAD	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs300774	0.925	rs405258	chr2:145646	T/A	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.42	0.34	1.9e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs17127529	0.596	rs1570872	chr1:65808508	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	5.26	0.39	4.77e-7	Idiopathic osteonecrosis of the femoral head;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15177315	chr10:102046452	BLOC1S2	0.69	7.26	0.51	1.86e-11	Myopia (pathological);
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Body mass index;
PAAD	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26876637	chr1:152193138	HRNR	-0.87	-7.01	-0.49	7.12e-11	Atopic dermatitis;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg16300553	chr8:8131077	NA	0.36	4.27	0.33	3.46e-5	Mood instability;
PAAD	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg09226986	chr6:160852328	SLC22A3	-0.5	-4.67	-0.35	6.63e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg13870426	chr17:30244630	NA	-0.56	-5.99	-0.44	1.44e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.7	6.61	0.47	6.19e-10	Mosquito bite size;
PAAD	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.55	-4.36	-0.33	2.34e-5	Blood protein levels;
PAAD	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.39	5.33	0.4	3.48e-7	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12327666	1.000	rs117465815	chr19:14134379	A/G	cg09538921	chr19:14142201	IL27RA	-0.77	-4.25	-0.33	3.65e-5	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.36	0.6	1.02e-16	Schizophrenia;
PAAD	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	7.82	0.54	8.13e-13	Type 2 diabetes;
PAAD	cis	rs10274279	0.660	rs10278007	chr7:157372906	C/G	cg09270525	chr7:157391030	PTPRN2	0.7	6.44	0.46	1.45e-9	Myopia (pathological);
PAAD	cis	rs2279817	0.820	rs13376112	chr1:18016441	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-6.03	-0.44	1.17e-8	Neuroticism;
PAAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.57	6.79	0.48	2.38e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.9	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	8.63	0.57	7.62e-15	Total body bone mineral density;
PAAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.65	0.42	7.82e-8	Prostate cancer;
PAAD	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.8	7.11	0.5	4.16e-11	Coronary artery disease;
PAAD	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.71	6.86	0.49	1.67e-10	Platelet count;
PAAD	cis	rs2964802	0.505	rs13179252	chr5:10805662	A/G	cg14521931	chr5:10832172	NA	-0.47	-4.76	-0.36	4.41e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-5.67	-0.42	6.93e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	7.67	0.53	1.91e-12	Electrocardiographic conduction measures;
PAAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg13918804	chr1:2043761	PRKCZ	-0.37	-4.89	-0.37	2.5e-6	Height;
PAAD	trans	rs61931739	0.620	rs745608	chr12:33711564	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.55	5.57	0.41	1.11e-7	Myeloid white cell count;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.53	5.59	0.41	1.04e-7	Longevity;Endometriosis;
PAAD	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.7	5.57	0.41	1.13e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16761131	chr22:38142377	TRIOBP	0.63	7.39	0.51	9.11e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7941600	0.655	rs61875699	chr11:9360940	G/A	cg19415743	chr11:9336845	TMEM41B	0.92	5.77	0.42	4.27e-8	Coronary artery disease;
PAAD	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs7315621	0.965	rs7954562	chr12:132082528	T/C	cg05851493	chr12:132142067	NA	-0.33	-4.32	-0.33	2.85e-5	Longevity;
PAAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.5	-0.57	1.66e-14	Type 2 diabetes;
PAAD	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.7	-5.8	-0.43	3.66e-8	Exhaled nitric oxide output;
PAAD	cis	rs12136530	0.593	rs12125806	chr1:19734781	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg05785598	chr3:49045655	WDR6	0.44	5.15	0.39	8.08e-7	Parkinson's disease;
PAAD	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.6	-5.87	-0.43	2.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.55	-5.42	-0.4	2.25e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs733175	0.599	rs6856396	chr4:10031163	A/T	cg11266682	chr4:10021025	SLC2A9	0.57	4.5	0.34	1.35e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs7260329	0.670	rs4803413	chr19:41485977	G/A	cg06653635	chr19:40910092	PRX	-0.49	-4.36	-0.33	2.34e-5	Smoking behavior;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs911119	1.000	rs911119	chr20:23612737	C/T	cg16589663	chr20:23618590	CST3	-0.85	-6.98	-0.49	8.41e-11	Chronic kidney disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24481381	chr1:27339413	FAM46B	0.56	6.36	0.46	2.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.65	6.58	0.47	7.05e-10	Liver enzyme levels;
PAAD	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.36	0.46	2.25e-9	Mean platelet volume;
PAAD	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.83	6.22	0.45	4.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2085601	0.519	rs1708679	chr4:89976963	T/C	cg17769793	chr4:89976368	FAM13A	-0.44	-5.5	-0.41	1.6e-7	Hair greying;
PAAD	cis	rs939584	1.000	rs10188334	chr2:653874	C/T	cg03610516	chr2:642275	NA	-0.67	-6.01	-0.44	1.31e-8	Body mass index;
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.72	8.08	0.55	1.82e-13	Height;
PAAD	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-1.0	-12.94	-0.72	2.71e-26	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.67	-0.48	4.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.48	4.45	0.34	1.67e-5	Uric acid clearance;
PAAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.32	0.33	2.84e-5	Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.53	5.32	0.4	3.61e-7	Prudent dietary pattern;
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Electroencephalogram traits;
PAAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.92	11.29	0.68	7.43e-22	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07148879	chr3:32443279	CMTM7	0.57	6.44	0.46	1.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs288326	0.561	rs75473200	chr2:183762165	C/T	cg09997497	chr2:183902928	NCKAP1	1.03	5.16	0.39	7.53e-7	Blood protein levels;
PAAD	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg06217245	chr20:33103252	DYNLRB1	0.41	4.62	0.35	8.27e-6	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07202532	chr17:29814621	RAB11FIP4	0.59	6.71	0.48	3.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9367125	0.583	rs80211614	chr6:41996699	C/T	cg12151296	chr6:42013349	CCND3	-0.62	-4.68	-0.35	6.26e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.61	-6.43	-0.46	1.53e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.51	-5.33	-0.4	3.54e-7	Ulcerative colitis;
PAAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs6604026	0.656	rs2811590	chr1:93367166	C/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs7873102	0.654	rs4878726	chr9:37975555	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.37	-5.19	-0.39	6.53e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.62	5.07	0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.68	-0.35	6.37e-6	Height;
PAAD	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.63	9.72	0.62	1.18e-17	Asthma (sex interaction);
PAAD	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg26816564	chr1:7831052	VAMP3	0.75	5.78	0.42	4.14e-8	Inflammatory bowel disease;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-5.88	-0.43	2.49e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-9.73	-0.62	1.09e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.46	-5.54	-0.41	1.31e-7	Colorectal cancer;
PAAD	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.53e-6	Vitiligo;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.59	-5.93	-0.43	2e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.7	6.8	0.48	2.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs35160687	1.000	rs35160687	chr2:86472114	C/T	cg10973622	chr2:86423274	IMMT	0.45	5.28	0.39	4.32e-7	Night sleep phenotypes;
PAAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg20712883	chr12:51590929	POU6F1	0.44	4.46	0.34	1.61e-5	Cisplatin-induced ototoxicity;
PAAD	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.95	-8.28	-0.56	5.79e-14	Vitiligo;
PAAD	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.85	8.91	0.59	1.49e-15	Lewy body disease;
PAAD	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.89	-0.49	1.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.77	-6.48	-0.47	1.23e-9	Bipolar disorder;
PAAD	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs11168854	0.719	rs11168902	chr12:49568266	C/T	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.5e-5	Body mass index;
PAAD	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg25614726	chr1:10490058	APITD1	0.37	4.35	0.33	2.45e-5	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg00738919	chr7:1100172	C7orf50	0.73	5.55	0.41	1.26e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.54	5.78	0.42	4.08e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg22101045	chr11:47927509	NA	0.53	4.25	0.33	3.67e-5	Axial length;
PAAD	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.59	-7.32	-0.51	1.35e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8044995	0.636	rs77517043	chr16:68301410	G/A	cg03983715	chr16:68378420	PRMT7	-0.98	-5.96	-0.44	1.72e-8	Schizophrenia;
PAAD	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.47	4.54	0.35	1.15e-5	Crohn's disease;
PAAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg21929781	chr1:2537748	MMEL1	0.54	5.65	0.42	7.85e-8	Ulcerative colitis;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04156016	chr5:1868137	NA	0.44	4.51	0.34	1.28e-5	Cardiovascular disease risk factors;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.86	9.7	0.62	1.25e-17	Prudent dietary pattern;
PAAD	cis	rs1997066	0.667	rs75638929	chr10:106820107	T/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg13206674	chr6:150067644	NUP43	0.54	4.41	0.34	1.96e-5	Lung cancer;
PAAD	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.4	4.4	0.34	2.05e-5	Mean arterial pressure;
PAAD	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.52	-4.9	-0.37	2.39e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg09127314	chr1:152161683	NA	0.63	4.76	0.36	4.51e-6	Atopic dermatitis;
PAAD	cis	rs17227506	0.543	rs13282808	chr8:13416650	A/G	cg02718516	chr8:13424094	C8orf48	-0.36	-4.74	-0.36	4.85e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.63	4.78	0.36	4.05e-6	Breast cancer;
PAAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.35	4.29	0.33	3.21e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-7.89	-0.54	5.57e-13	Chronic sinus infection;
PAAD	cis	rs58521262	0.556	rs289324	chr19:23156905	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs329648	0.534	rs4937850	chr11:133764891	G/C	cg03392386	chr11:133800800	IGSF9B	0.55	6.04	0.44	1.14e-8	Parkinson's disease;
PAAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg26528668	chr16:1614120	IFT140	0.51	4.81	0.36	3.62e-6	Coronary artery disease;
PAAD	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.51	4.77	0.36	4.27e-6	Mean platelet volume;
PAAD	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.91	-10.8	-0.66	1.59e-20	Schizophrenia;
PAAD	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.47	4.54	0.35	1.12e-5	Proinsulin levels;
PAAD	cis	rs7951870	0.617	rs7932354	chr11:46722221	T/C	cg19486271	chr11:47235900	DDB2	-0.59	-5.95	-0.43	1.8e-8	Schizophrenia;
PAAD	cis	rs1619661	0.530	rs1623851	chr10:44691241	C/T	cg09554077	chr10:44749378	NA	-0.34	-5.18	-0.39	7.1e-7	QT interval (ambient particulate matter interaction);
PAAD	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.46	-0.34	1.56e-5	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.78	5.77	0.42	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-5.45	-0.4	1.96e-7	Aortic root size;
PAAD	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-9.0	-0.59	8.76e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20033557	chr15:63414489	LACTB	0.48	5.08	0.38	1.09e-6	Immature fraction of reticulocytes;
PAAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.53	5.37	0.4	2.89e-7	Resting heart rate;
PAAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg07371521	chr5:154026371	NA	0.54	6.88	0.49	1.43e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-4.51	-0.34	1.27e-5	Height;
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	5.02	0.38	1.45e-6	Vitiligo;
PAAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.75	-6.09	-0.44	8.91e-9	Coronary artery disease;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg26554054	chr8:600488	NA	1.06	7.49	0.52	5.11e-12	IgG glycosylation;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20250396	chr14:65880036	FUT8;LOC645431	0.54	6.3	0.46	3.04e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-4.68	-0.35	6.42e-6	Homocysteine levels;
PAAD	cis	rs6715793	0.901	rs6707904	chr2:33405332	A/G	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.62	6.6	0.47	6.51e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.4	-0.61	7.69e-17	Calcium levels;
PAAD	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.62	5.65	0.42	7.74e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.8	9.18	0.6	2.97e-16	Lung cancer;
PAAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.88	-7.86	-0.54	6.58e-13	Diastolic blood pressure;
PAAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg21130718	chr4:1044621	NA	0.56	4.76	0.36	4.46e-6	Recombination rate (females);
PAAD	cis	rs6782228	0.876	rs34198449	chr3:128381270	G/A	cg07730360	chr3:128845626	NA	-0.48	-4.27	-0.33	3.42e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	1.12	18.12	0.83	8.29e-40	Menarche (age at onset);
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02359409	chr6:42947317	PEX6	-0.47	-4.67	-0.35	6.47e-6	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.76	9.41	0.61	7.33e-17	Lymphocyte counts;
PAAD	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.53	4.74	0.36	4.87e-6	Depression;
PAAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5756391	0.568	rs4821569	chr22:37316873	A/G	cg16356956	chr22:37317934	CSF2RB	0.39	4.77	0.36	4.28e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.91	8.35	0.56	4e-14	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg20302533	chr7:39170763	POU6F2	0.38	5.29	0.39	4.12e-7	IgG glycosylation;
PAAD	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.78	6.05	0.44	1.1e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19671926	chr4:122722719	EXOSC9	-0.72	-6.96	-0.49	9.72e-11	Type 2 diabetes;
PAAD	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg00590817	chr1:8272081	NA	0.37	4.53	0.35	1.17e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.68	0.35	6.35e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs62408225	1.000	rs1504215	chr6:91006227	G/A	cg24360137	chr6:90598826	NA	-0.43	-4.3	-0.33	3.05e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11718455	0.503	rs1554654	chr3:44044344	C/T	cg08738300	chr3:44038990	NA	0.42	4.33	0.33	2.65e-5	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.7	6.02	0.44	1.26e-8	Interstitial lung disease;
PAAD	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-7.84	-0.54	7.48e-13	Colorectal cancer;
PAAD	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg11177333	chr3:195857752	NA	0.45	4.3	0.33	3.07e-5	Non-small cell lung cancer;
PAAD	cis	rs351855	0.642	rs2546095	chr5:176509584	G/T	cg19956155	chr5:176511416	NA	0.44	5.07	0.38	1.12e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs498136	0.503	rs17318844	chr11:69402981	A/G	cg24388239	chr11:68438018	NA	-0.4	-4.31	-0.33	2.98e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.86	6.39	0.46	1.97e-9	Tuberculosis;
PAAD	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06850241	chr22:41845214	NA	-0.5	-4.79	-0.36	3.96e-6	Vitiligo;
PAAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.42	-5.14	-0.38	8.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs3018712	0.605	rs2513297	chr11:68446144	T/C	cg02340541	chr11:68451699	GAL	-0.63	-5.25	-0.39	4.98e-7	Total body bone mineral density;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg01238044	chr22:24384105	GSTT1	-0.5	-4.8	-0.36	3.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.5	5.1	0.38	9.9e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.87	9.5	0.61	4.29e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6684428	0.706	rs11206673	chr1:56326340	C/T	cg11651538	chr1:56320950	NA	0.5	4.35	0.33	2.46e-5	Airflow obstruction;
PAAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.66	6.9	0.49	1.28e-10	Multiple sclerosis;
PAAD	trans	rs61931739	0.817	rs11053125	chr12:34265417	C/T	cg26384229	chr12:38710491	ALG10B	0.69	6.97	0.49	8.86e-11	Morning vs. evening chronotype;
PAAD	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.88	7.01	0.49	7.4e-11	Axial length;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	0.99	6.58	0.47	7.12e-10	IgG glycosylation;
PAAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg00024989	chr19:17902242	NA	0.43	4.68	0.35	6.29e-6	Tumor biomarkers;
PAAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.72e-5	Parkinson's disease;
PAAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.31	-0.33	2.9e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16576597	chr16:28551801	NUPR1	0.67	7.5	0.52	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.68	6.19	0.45	5.4e-9	DNA methylation (variation);
PAAD	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg17644776	chr2:200775616	C2orf69	-0.65	-4.35	-0.33	2.48e-5	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg14583973	chr4:3374767	RGS12	0.4	6.31	0.46	2.93e-9	Parental longevity (mother's age at death);
PAAD	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-6.0	-0.44	1.42e-8	Schizophrenia (age at onset);
PAAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.78	6.29	0.45	3.16e-9	Gut microbiome composition (summer);
PAAD	cis	rs59888335	0.858	rs6774442	chr3:80999094	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs8025118	0.583	rs7177417	chr15:79547515	A/C	cg11862246	chr15:78730200	IREB2	0.5	4.25	0.33	3.78e-5	Cognitive function;
PAAD	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-4.97	-0.37	1.82e-6	QT interval;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg00183340	chr1:120838644	FAM72B	-0.71	-6.34	-0.46	2.55e-9	Blood protein levels;
PAAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.6	6.3	0.45	3.1e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg14903685	chr15:70391316	TLE3	-0.67	-6.7	-0.48	3.9e-10	Body mass index;
PAAD	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg27182935	chr16:89790473	ZNF276	-0.81	-4.44	-0.34	1.75e-5	Skin colour saturation;
PAAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2627282	0.664	rs2604133	chr8:2774784	A/C	cg21769514	chr8:2743697	NA	-0.41	-4.29	-0.33	3.18e-5	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs6466055	0.669	rs10808141	chr7:104715490	T/G	cg04380332	chr7:105027541	SRPK2	-0.65	-7.15	-0.5	3.38e-11	Schizophrenia;
PAAD	cis	rs58521262	0.585	rs176456	chr19:23166966	G/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.63	4.42	0.34	1.9e-5	Depression;
PAAD	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.65	6.99	0.49	8.16e-11	Mean corpuscular volume;
PAAD	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.82	-9.92	-0.63	3.35e-18	Coronary artery disease;
PAAD	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.46	4.54	0.35	1.13e-5	Aortic root size;
PAAD	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg20761395	chr17:511517	VPS53	0.59	6.26	0.45	3.71e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4838594	0.549	rs11101333	chr10:49668179	A/G	cg17291251	chr10:49678358	ARHGAP22	0.49	4.53	0.34	1.18e-5	Daytime sleep phenotypes;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg04025307	chr7:1156635	C7orf50	0.64	4.54	0.35	1.14e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.87	0.37	2.73e-6	Major depressive disorder;
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg14433983	chr11:636460	DRD4	-0.47	-4.95	-0.37	1.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.16	8.63	0.57	7.73e-15	Alzheimer's disease;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06753367	chr22:24256600	NA	-0.43	-4.51	-0.34	1.27e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21646471	chr2:242523971	THAP4	0.56	4.43	0.34	1.76e-5	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg03094675	chr11:5960213	NA	-0.53	-4.71	-0.36	5.57e-6	DNA methylation (variation);
PAAD	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg07689907	chr11:61582574	FADS1	0.47	4.67	0.35	6.58e-6	Trans fatty acid levels;
PAAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.98	0.54	3.32e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs72960926	0.744	rs3846756	chr6:75061918	A/T	cg09257923	chr6:74303635	SLC17A5	-0.76	-4.44	-0.34	1.75e-5	Metabolite levels (MHPG);
PAAD	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.6	6.19	0.45	5.4e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	-0.5	-4.41	-0.34	1.98e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs16975963	0.843	rs113690074	chr19:38375393	G/A	cg08679971	chr19:38281047	NA	0.55	5.17	0.39	7.38e-7	Longevity;
PAAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.24	-0.39	5.27e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	1.16	7.91	0.54	4.95e-13	IgG glycosylation;
PAAD	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg17644776	chr2:200775616	C2orf69	0.58	5.64	0.42	7.92e-8	Osteoporosis;
PAAD	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.53	5.47	0.41	1.78e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.91	-10.2	-0.64	6.22e-19	Obesity-related traits;
PAAD	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.84	-8.12	-0.55	1.53e-13	Body mass index;
PAAD	cis	rs11825685	0.607	rs1944893	chr11:134551700	T/C	cg06603561	chr11:134479413	NA	-0.61	-5.21	-0.39	6.06e-7	IgG glycosylation;
PAAD	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.66	5.38	0.4	2.82e-7	Obesity (extreme);
PAAD	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.03	11.5	0.68	2.05e-22	Breast cancer;
PAAD	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs939584	1.000	rs1320331	chr2:622161	G/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.39	5.05	0.38	1.23e-6	Multiple sclerosis;
PAAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.98	0.59	9.75e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg18867708	chr6:26865862	GUSBL1	0.5	5.13	0.38	8.82e-7	Schizophrenia;
PAAD	cis	rs3753841	0.832	rs4908262	chr1:103225699	C/T	cg24495344	chr1:103574097	COL11A1	0.4	4.73	0.36	5.13e-6	Glaucoma (primary angle closure);
PAAD	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.64	0.8	4.72e-36	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13327859	chr12:104359478	TDG	0.64	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg14581129	chr12:53358946	NA	-1.2	-7.37	-0.51	1e-11	Prostate cancer;
PAAD	cis	rs7210086	0.808	rs6501558	chr17:70639488	T/C	cg04206342	chr17:70636940	NA	-0.48	-6.27	-0.45	3.62e-9	Ulcerative colitis;
PAAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.84	-0.37	3.15e-6	Blood pressure;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.7	0.36	5.89e-6	Electroencephalogram traits;
PAAD	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.58	0.61	2.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.67	-7.38	-0.51	9.79e-12	Childhood ear infection;
PAAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.84	13.04	0.73	1.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-5.35	-0.4	3.25e-7	Renal function-related traits (BUN);
PAAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.62	7.3	0.51	1.52e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.76	8.44	0.56	2.37e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.94	-8.81	-0.58	2.66e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2117029	0.586	rs10783308	chr12:49531458	T/C	cg05368762	chr12:50135785	TMBIM6	0.44	4.39	0.34	2.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20436533	chr2:202746623	CDK15	0.58	6.31	0.46	2.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.91	8.55	0.57	1.25e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06307176	chr5:131281290	NA	0.49	4.49	0.34	1.41e-5	Life satisfaction;
PAAD	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg05925327	chr15:68127851	NA	-0.54	-4.74	-0.36	4.84e-6	Obesity;
PAAD	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg12623918	chr2:306882	NA	0.48	5.01	0.38	1.52e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7823896	0.722	rs67650612	chr8:110246852	G/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.27	-0.39	4.61e-7	Schizophrenia;
PAAD	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.35	9.33	0.6	1.22e-16	Diabetic retinopathy;
PAAD	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.9	-9.98	-0.63	2.32e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.6	-0.35	8.99e-6	Toenail selenium levels;
PAAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg25833597	chr17:30823145	MYO1D	0.55	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.79	9.66	0.62	1.65e-17	Breast cancer;
PAAD	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	4.72	0.36	5.4e-6	Iron status biomarkers;
PAAD	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16447950	chr5:562315	NA	-0.69	-5.98	-0.44	1.5e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.51	4.83	0.36	3.29e-6	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.0	-0.38	1.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.520	rs479044	chr17:42158613	A/G	cg19774624	chr17:42201019	HDAC5	0.7	5.78	0.42	4.13e-8	Total body bone mineral density;
PAAD	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg06307176	chr5:131281290	NA	0.56	4.97	0.37	1.77e-6	Life satisfaction;
PAAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.52	5.34	0.4	3.33e-7	Multiple myeloma (IgH translocation);
PAAD	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg05562828	chr17:3906858	NA	0.53	5.83	0.43	3.2e-8	Type 2 diabetes;
PAAD	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg08601574	chr20:25228251	PYGB	-0.6	-6.67	-0.48	4.5e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.7	0.36	5.85e-6	Bipolar disorder;
PAAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.51	5.63	0.42	8.32e-8	Height;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.5	5.0	0.38	1.59e-6	Height;
PAAD	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-5.88	-0.43	2.53e-8	Testicular germ cell tumor;
PAAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.71	-8.38	-0.56	3.26e-14	Educational attainment;
PAAD	cis	rs9535307	0.719	rs1198322	chr13:50380404	G/A	cg03658251	chr13:50265850	EBPL	-0.82	-5.62	-0.42	8.68e-8	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19808841	chr7:131012535	MKLN1	-0.75	-6.37	-0.46	2.17e-9	Neuroticism;
PAAD	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg05250797	chr16:70222502	NA	0.93	6.74	0.48	3.14e-10	IgE levels;
PAAD	cis	rs11615916	0.790	rs1586916	chr12:62664274	G/A	cg11441379	chr12:63026424	NA	0.7	4.54	0.35	1.15e-5	Pulmonary function decline;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg26536354	chr8:144654954	C8orf73	-0.47	-4.39	-0.34	2.15e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg06606381	chr12:133084897	FBRSL1	0.99	6.4	0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs75920871	0.925	rs56134734	chr11:116833055	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Body mass index;
PAAD	cis	rs797680	0.820	rs10874773	chr1:93798496	T/G	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7260598	0.539	rs10418377	chr19:24081344	G/T	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.8	-9.18	-0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg09491104	chr22:46646882	C22orf40	-1.06	-5.87	-0.43	2.64e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.92	9.16	0.6	3.39e-16	Orofacial clefts;
PAAD	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg16342193	chr10:102329863	NA	0.75	8.31	0.56	4.98e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.35	4.58	0.35	9.71e-6	Schizophrenia;
PAAD	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.41	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg11177333	chr3:195857752	NA	0.44	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg06375148	chr1:209958343	C1orf74	0.68	5.27	0.39	4.57e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.95	-11.07	-0.67	3e-21	Refractive error;
PAAD	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg26727032	chr16:67993705	SLC12A4	-0.64	-5.58	-0.41	1.06e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.89	11.07	0.67	2.91e-21	Metabolic syndrome;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.93	-13.45	-0.74	1.13e-27	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15247372	chr17:26684730	TMEM199;POLDIP2	0.64	6.47	0.46	1.28e-9	Obesity-related traits;
PAAD	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-5.5	-0.41	1.59e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1476670	0.690	rs6677372	chr1:44505789	G/A	cg09470012	chr1:44509516	NA	0.46	4.5	0.34	1.33e-5	Eotaxin levels;
PAAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23028631	chr1:2335500	RER1	0.62	6.37	0.46	2.1e-9	Smoking initiation;
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.77	8.29	0.56	5.72e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.71	7.85	0.54	6.77e-13	Melanoma;
PAAD	cis	rs1270639	0.778	rs2952650	chr7:157450939	C/T	cg14404164	chr7:157455790	PTPRN2	-0.63	-4.4	-0.34	2.02e-5	Colorectal cancer;
PAAD	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.43	-0.4	2.24e-7	Atrioventricular conduction;
PAAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14853989	chr20:37101489	RALGAPB	-0.75	-6.51	-0.47	1.04e-9	Neuroticism;
PAAD	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	9.52	0.61	3.79e-17	Electrocardiographic conduction measures;
PAAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	7.9	0.54	5.26e-13	Menopause (age at onset);
PAAD	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	6.39	0.46	1.91e-9	Type 2 diabetes;
PAAD	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15412815	chr11:93271088	C11orf75	-0.42	-4.49	-0.34	1.4e-5	Pulmonary function decline;
PAAD	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.68	-6.98	-0.49	8.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg11271282	chr2:238384023	NA	0.65	4.36	0.33	2.38e-5	Prostate cancer;
PAAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.85	9.33	0.6	1.23e-16	Prostate cancer;
PAAD	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Mean corpuscular volume;
PAAD	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.27	-0.33	3.37e-5	Recombination measurement;
PAAD	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	1.02	12.56	0.71	2.81e-25	Breast cancer;
PAAD	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg18898632	chr2:242989856	NA	-0.81	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.51	-0.34	1.31e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.07	-0.44	9.59e-9	Hypospadias;
PAAD	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg04415270	chr2:102091202	RFX8	-0.67	-8.57	-0.57	1.11e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg08817983	chr4:3391423	RGS12	-0.39	-4.43	-0.34	1.8e-5	Mean platelet volume;
PAAD	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.72	7.35	0.51	1.11e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg25214090	chr10:38739885	LOC399744	0.6	6.57	0.47	7.37e-10	Diastolic blood pressure;
PAAD	cis	rs9469913	0.799	rs9469860	chr6:34724815	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg14092988	chr3:52407081	DNAH1	-0.43	-5.35	-0.4	3.2e-7	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23958118	chr5:132574472	FSTL4	-0.68	-6.79	-0.48	2.34e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11977500	chr17:66416767	ARSG	-0.72	-7.36	-0.51	1.1e-11	Obesity-related traits;
PAAD	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.78	9.4	0.61	7.85e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg23417306	chr2:180868811	CWC22	-0.49	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg01620082	chr3:125678407	NA	-1.07	-7.26	-0.51	1.89e-11	Depression;
PAAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12165864	chr7:66369176	NA	-0.79	-5.07	-0.38	1.12e-6	Diabetic kidney disease;
PAAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-4.91	-0.37	2.35e-6	Blood metabolite levels;
PAAD	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.72	6.42	0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.19	0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02452435	chr17:71188192	COG1	-0.45	-4.73	-0.36	5e-6	Smoking initiation;
PAAD	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg19254793	chr6:44695348	NA	-0.44	-4.25	-0.33	3.68e-5	Total body bone mineral density;
PAAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.72	-7.3	-0.51	1.51e-11	DNA methylation (variation);
PAAD	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	10.44	0.65	1.46e-19	Smoking behavior;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07699235	chr13:39260309	FREM2	0.59	6.69	0.48	3.95e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.51	-0.34	1.29e-5	Type 2 diabetes;
PAAD	cis	rs4742903	0.904	rs7048676	chr9:106998349	G/A	cg14250997	chr9:106856677	SMC2	0.45	4.84	0.37	3.23e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg08835956	chr7:39171034	POU6F2	0.37	5.94	0.43	1.89e-8	IgG glycosylation;
PAAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg16540259	chr10:75572220	NDST2	0.42	4.27	0.33	3.39e-5	Inflammatory bowel disease;
PAAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg07148914	chr20:33460835	GGT7	0.5	4.87	0.37	2.72e-6	Coronary artery disease;
PAAD	cis	rs4356203	0.519	rs214097	chr11:17291499	G/T	cg15432903	chr11:17409602	KCNJ11	-0.45	-4.67	-0.35	6.68e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12315302	chr6:26189340	HIST1H4D	0.59	4.72	0.36	5.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-1.08	-9.59	-0.61	2.58e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg09127314	chr1:152161683	NA	-0.68	-4.59	-0.35	9.22e-6	Atopic dermatitis;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	1.11	17.6	0.82	1.69e-38	Menarche (age at onset);
PAAD	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg01798341	chr17:80842262	TBCD	-0.4	-4.43	-0.34	1.79e-5	Breast cancer;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg17063962	chr7:91808500	NA	1.02	11.92	0.7	1.51e-23	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14969806	chr1:5919854	NA	0.56	6.46	0.46	1.32e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12304921	0.683	rs12582592	chr12:51513608	C/T	cg18059802	chr12:51347058	HIGD1C	-0.64	-5.2	-0.39	6.48e-7	Type 2 diabetes;
PAAD	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14180030	chr9:123475675	MEGF9	0.46	5.08	0.38	1.1e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs778371	0.722	rs2102788	chr2:233805812	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	5.77	0.42	4.25e-8	Schizophrenia;
PAAD	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs988913	0.957	rs9367597	chr6:54784652	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13792233	chr3:56591045	CCDC66	0.56	6.37	0.46	2.09e-9	Monocyte percentage of white cells;
PAAD	cis	rs9657904	0.865	rs4894962	chr3:105600699	G/A	cg16975614	chr3:105601834	NA	-0.46	-4.62	-0.35	7.98e-6	Multiple sclerosis;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	5.01	0.38	1.5e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.68	5.74	0.42	4.87e-8	Menarche (age at onset);
PAAD	cis	rs2492906	0.600	rs2637324	chr10:28075973	A/C	cg25523538	chr10:28031957	MKX	-0.47	-4.38	-0.33	2.2e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs58521262	0.615	rs2645881	chr19:23213414	C/G	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs1035491	0.753	rs4700645	chr5:63929649	A/G	cg01791865	chr5:63954708	NA	0.44	4.51	0.34	1.28e-5	Body mass index;
PAAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.5	0.41	1.6e-7	Depression;
PAAD	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.57	-0.47	7.48e-10	Glomerular filtration rate;
PAAD	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg13660082	chr14:53194042	PSMC6	0.75	4.57	0.35	1.01e-5	Alzheimer's disease (late onset);
PAAD	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.72	0.36	5.4e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs7070678	0.638	rs61849289	chr10:29796378	T/C	cg05086789	chr10:29701805	LOC387647	-0.49	-4.63	-0.35	7.64e-6	Platelet thrombus formation;
PAAD	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.79	6.45	0.46	1.44e-9	Gastritis;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.52	4.8	0.36	3.71e-6	Airway imaging phenotypes;
PAAD	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	6.73	0.48	3.19e-10	Educational attainment;
PAAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.52	-4.3	-0.33	3.04e-5	Schizophrenia;
PAAD	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.51	-6.32	-0.46	2.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.58	-0.35	9.77e-6	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg14346243	chr4:90757452	SNCA	-0.51	-4.46	-0.34	1.59e-5	Neuroticism;
PAAD	cis	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg18582342	chr19:11591989	ELAVL3	-0.74	-5.89	-0.43	2.44e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs2271404	0.506	rs12329287	chr2:111995287	A/T	cg23466623	chr2:111982296	NA	-0.51	-4.95	-0.37	1.92e-6	Atopic dermatitis;
PAAD	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Cannabis dependence symptom count;
PAAD	cis	rs1519814	0.616	rs28885745	chr8:121012458	T/C	cg22335954	chr8:121166405	COL14A1	-0.64	-4.9	-0.37	2.39e-6	Breast cancer;
PAAD	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg22467129	chr15:76604101	ETFA	0.51	4.89	0.37	2.57e-6	Blood metabolite levels;
PAAD	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg20003494	chr4:90757398	SNCA	-0.4	-4.28	-0.33	3.23e-5	Dementia with Lewy bodies;
PAAD	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.49	4.73	0.36	5.07e-6	Pancreatic cancer;
PAAD	cis	rs4742903	0.875	rs1857980	chr9:106992265	G/T	cg14250997	chr9:106856677	SMC2	0.46	5.0	0.38	1.57e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2882667	0.964	rs67296915	chr5:138301599	C/T	cg09476006	chr5:138032270	NA	0.36	4.46	0.34	1.6e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.92	8.25	0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	5.72	0.42	5.46e-8	Testicular germ cell tumor;
PAAD	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs11671005	0.571	rs56243535	chr19:59006150	C/T	cg25952890	chr19:58913133	NA	0.71	5.51	0.41	1.52e-7	Mean platelet volume;
PAAD	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg15193198	chr20:60906057	LAMA5	-0.56	-5.9	-0.43	2.27e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg07703079	chr11:430292	ANO9	0.89	5.0	0.38	1.56e-6	Body mass index;
PAAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.9	-9.66	-0.62	1.68e-17	Obesity-related traits;
PAAD	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.66	6.4	0.46	1.82e-9	Itch intensity from mosquito bite;
PAAD	cis	rs7210086	0.606	rs72849437	chr17:70631124	T/C	cg04206342	chr17:70636940	NA	-0.37	-4.32	-0.33	2.84e-5	Ulcerative colitis;
PAAD	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg00750074	chr16:89608354	SPG7	-0.46	-4.38	-0.33	2.23e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.61	7.06	0.5	5.5e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.22	-0.6	2.26e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.34	-0.4	3.33e-7	Retinal vascular caliber;
PAAD	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.49	-0.34	1.43e-5	Mean corpuscular volume;
PAAD	cis	rs62025270	0.688	rs76902341	chr15:86280290	T/C	cg13263323	chr15:86062960	AKAP13	0.48	4.25	0.33	3.75e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	9.37	0.61	9.23e-17	Parkinson's disease;
PAAD	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.85	10.41	0.65	1.71e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.62	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg19760965	chr3:194868843	C3orf21	0.44	4.66	0.35	6.99e-6	Non-small cell lung cancer;
PAAD	cis	rs7814319	0.838	rs4598220	chr8:97232832	C/G	cg20787634	chr8:97240163	UQCRB	-0.61	-6.29	-0.45	3.22e-9	Lung function (FVC);
PAAD	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.63	-7.98	-0.54	3.36e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.92	12.25	0.7	2.01e-24	Body mass index;
PAAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.7	6.22	0.45	4.53e-9	Platelet distribution width;
PAAD	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg08885076	chr2:99613938	TSGA10	-0.55	-5.38	-0.4	2.74e-7	Chronic sinus infection;
PAAD	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.51	5.05	0.38	1.25e-6	HDL cholesterol;
PAAD	cis	rs9652601	0.691	rs12928726	chr16:11191572	G/A	cg04616529	chr16:11181986	CLEC16A	0.39	4.65	0.35	7.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.54	0.35	1.12e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.68	-7.05	-0.5	5.98e-11	DNA methylation (variation);
PAAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg02820901	chr13:113351484	ATP11A	0.7	4.52	0.34	1.26e-5	Glycated hemoglobin levels;
PAAD	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg09659197	chr4:152720779	NA	-0.47	-6.53	-0.47	9.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.13	7.56	0.52	3.46e-12	Parkinson's disease;
PAAD	cis	rs2271001	0.955	rs12273085	chr11:19138511	G/C	cg00161556	chr11:19138045	ZDHHC13	0.53	5.85	0.43	2.98e-8	Gut microbiome composition (winter);
PAAD	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.59	4.46	0.34	1.6e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.57	6.75	0.48	2.93e-10	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13542817	chr10:104154499	NFKB2	-0.66	-6.93	-0.49	1.14e-10	Smoking initiation;
PAAD	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.83	9.43	0.61	6.45e-17	Metabolic syndrome;
PAAD	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.55	0.57	1.23e-14	Colorectal cancer;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.0	-0.38	1.57e-6	Cystic fibrosis severity;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg07202610	chr7:1142643	C7orf50	-0.68	-5.69	-0.42	6.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg08213375	chr14:104286397	PPP1R13B	0.48	6.17	0.45	6.03e-9	Schizophrenia;
PAAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-6.1	-0.44	8.47e-9	Body mass index;
PAAD	cis	rs3857067	0.967	rs899135	chr4:95019816	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg02993010	chr8:124780839	FAM91A1	-0.83	-6.91	-0.49	1.25e-10	Pancreatic cancer;
PAAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.65	-7.45	-0.52	6.39e-12	Huntington's disease progression;
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs943466	1.000	rs11755593	chr6:33740325	G/C	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	trans	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg15655154	chr3:113604241	GRAMD1C	-0.67	-7.25	-0.51	2.02e-11	Diastolic blood pressure;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.25e-9	Lymphocyte counts;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15428792	chr12:11151430	PRR4;TAS2R20;PRH1	0.56	6.37	0.46	2.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-7.51	-0.52	4.67e-12	Cognitive function;
PAAD	cis	rs8063160	0.667	rs79139787	chr16:89795360	C/T	cg07984980	chr16:89898383	SPIRE2	0.92	4.99	0.38	1.63e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	trans	rs3129178	1	rs3129178	chr6:29075088	T/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Breast cancer;
PAAD	cis	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.43	4.26	0.33	3.57e-5	Depression;
PAAD	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.78	-6.39	-0.46	1.91e-9	HDL cholesterol;
PAAD	cis	rs243505	0.762	rs1019218	chr7:148488964	C/T	cg09806900	chr7:148480153	CUL1	0.53	4.94	0.37	2.01e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.7	0.36	5.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.5	-5.0	-0.38	1.57e-6	Yeast infection;
PAAD	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg05784532	chr1:230284198	GALNT2	0.71	6.16	0.45	6.13e-9	Coronary artery disease;
PAAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.24	0.45	4.11e-9	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.86	9.95	0.63	2.83e-18	Prudent dietary pattern;
PAAD	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg22710661	chr11:17411071	KCNJ11	0.46	4.69	0.36	5.94e-6	Type 2 diabetes;
PAAD	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.96	9.14	0.6	3.83e-16	Psoriasis;
PAAD	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18364779	chr6:26104403	HIST1H4C	0.46	4.52	0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.43	4.78	0.36	4.03e-6	Testicular germ cell tumor;
PAAD	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.46	0.34	1.61e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg12524338	chr4:183729343	NA	0.6	4.55	0.35	1.07e-5	Pediatric autoimmune diseases;
PAAD	cis	rs6028335	0.825	rs66477659	chr20:37765693	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.28	-0.33	3.29e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs2555155	1.000	rs11604149	chr11:6519642	G/A	cg11185456	chr11:6592066	DNHD1	0.43	4.61	0.35	8.63e-6	DNA methylation (variation);
PAAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg05697835	chr1:2722811	NA	-0.43	-4.86	-0.37	2.93e-6	Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.34e-13	Alzheimer's disease;
PAAD	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.93	-7.13	-0.5	3.72e-11	Blood protein levels;
PAAD	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs73195822	0.667	rs60184376	chr12:111229975	T/C	cg09298818	chr12:111181546	PPP1CC	-0.56	-4.36	-0.33	2.36e-5	Itch intensity from mosquito bite;
PAAD	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9810890	1.000	rs9825119	chr3:128595514	C/G	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.93	11.58	0.68	1.29e-22	Ulcerative colitis;
PAAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.67	6.25	0.45	3.89e-9	Initial pursuit acceleration;
PAAD	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.89	10.42	0.65	1.62e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg21698718	chr17:80085957	CCDC57	-0.45	-5.1	-0.38	1.01e-6	Life satisfaction;
PAAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-4.61	-0.35	8.41e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg26939375	chr7:64535504	NA	-0.71	-8.17	-0.55	1.08e-13	Calcium levels;
PAAD	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg01267373	chr18:77410094	NA	-0.41	-4.47	-0.34	1.51e-5	Monocyte count;
PAAD	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.79	0.58	2.99e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs818427	0.684	rs465899	chr5:112177171	G/A	cg06941702	chr5:112196734	SRP19	-0.52	-4.72	-0.36	5.31e-6	Total body bone mineral density;
PAAD	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg26597838	chr10:835615	NA	0.46	4.88	0.37	2.69e-6	Survival in rectal cancer;
PAAD	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg05250797	chr16:70222502	NA	0.79	5.95	0.43	1.82e-8	IgE levels;
PAAD	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg27335600	chr3:53528857	CACNA1D	-0.38	-4.25	-0.33	3.65e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.94	-12.18	-0.7	3.06e-24	Coronary artery disease;
PAAD	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.6	6.29	0.45	3.22e-9	Type 2 diabetes;
PAAD	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.7e-5	Pulmonary function;
PAAD	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.83	8.77	0.58	3.3e-15	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21039563	chr11:64323816	SLC22A11	0.57	6.61	0.47	5.99e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.76	8.23	0.56	7.69e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	1.19	15.54	0.78	3.23e-33	Longevity;
PAAD	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.49e-5	Electrocardiographic conduction measures;
PAAD	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.77	8.49	0.57	1.75e-14	Lung cancer;
PAAD	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.79	-0.36	3.99e-6	Prevalent atrial fibrillation;
PAAD	cis	rs9834373	0.593	rs11127621	chr3:78500847	G/C	cg06138941	chr3:78371609	NA	-0.39	-4.41	-0.34	1.97e-5	Protein quantitative trait loci;
PAAD	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg18898632	chr2:242989856	NA	-0.74	-5.28	-0.39	4.48e-7	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	cis	rs1032355	0.643	rs12152646	chr4:100539297	G/A	cg03025880	chr4:100572172	NA	-0.49	-4.26	-0.33	3.64e-5	Celiac disease;
PAAD	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.76	-0.62	9.16e-18	Total body bone mineral density;
PAAD	cis	rs12760731	0.565	rs12028023	chr1:178087408	G/A	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs13396519	1.000	rs13400660	chr2:11041643	T/C	cg04169469	chr2:10588434	ODC1;SNORA80B	-0.7	-4.42	-0.34	1.87e-5	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
PAAD	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg20933634	chr6:27740509	NA	0.57	5.56	0.41	1.19e-7	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14672709	chr17:48133110	ITGA3	0.64	6.41	0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs10450586	0.932	rs7110026	chr11:27337526	A/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22162314	chr17:61951766	CSH2	-0.61	-6.29	-0.45	3.15e-9	Height;
PAAD	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg02910952	chr12:132569714	EP400NL	0.63	4.75	0.36	4.58e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.76	6.47	0.46	1.27e-9	Pulmonary function decline;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-6.21	-0.45	4.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.51	5.11	0.38	9.48e-7	Testicular germ cell tumor;
PAAD	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg09659197	chr4:152720779	NA	0.35	5.13	0.38	8.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.74	0.36	4.9e-6	Breast cancer;
PAAD	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.68	6.35	0.46	2.39e-9	Lymphocyte counts;
PAAD	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.52	-4.84	-0.37	3.15e-6	Subjective well-being;
PAAD	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.8	-6.17	-0.45	5.99e-9	Type 2 diabetes;
PAAD	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-4.99	-0.38	1.63e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-1.07	-11.09	-0.67	2.56e-21	Platelet distribution width;
PAAD	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg10932868	chr11:921992	NA	0.52	6.26	0.45	3.76e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.84	0.37	3.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.32	-0.51	1.35e-11	Heart rate;
PAAD	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.91	-0.43	2.13e-8	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg15181151	chr6:150070149	PCMT1	0.57	6.22	0.45	4.62e-9	Lung cancer;
PAAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.9	11.17	0.67	1.61e-21	Blood protein levels;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg18279126	chr7:2041391	MAD1L1	0.61	6.3	0.45	3.08e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-5.41	-0.4	2.36e-7	QRS duration;
PAAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-4.93	-0.37	2.1e-6	Glomerular filtration rate;
PAAD	cis	rs2120243	0.874	rs2316709	chr3:157150247	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	5.6	0.41	9.96e-8	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08235883	chr12:122238836	LOC338799	0.59	6.42	0.46	1.65e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.7	-0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs1043763	0.826	rs3741452	chr12:122628429	A/T	cg26218692	chr12:122497826	BCL7A	-0.52	-5.03	-0.38	1.36e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg20673091	chr1:2541236	MMEL1	0.84	10.27	0.64	3.95e-19	Ulcerative colitis;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg15117754	chr3:10150083	C3orf24	0.68	5.81	0.43	3.46e-8	Alzheimer's disease;
PAAD	cis	rs2133450	0.712	rs17697853	chr3:7366195	A/G	cg19930620	chr3:7340148	GRM7	0.48	5.25	0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs939584	1.000	rs7563362	chr2:620297	A/G	cg03610516	chr2:642275	NA	0.71	6.12	0.44	7.78e-9	Body mass index;
PAAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.69	7.34	0.51	1.23e-11	Pancreatic cancer;
PAAD	cis	rs116248771	0.690	rs4459938	chr3:158406075	G/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs988913	0.533	rs980822	chr6:54854504	G/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg13919466	chr1:32135498	COL16A1	-0.4	-4.46	-0.34	1.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14019695	chr9:139328340	INPP5E	0.62	5.57	0.41	1.15e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.68	0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.81	8.5	0.57	1.69e-14	Anterior chamber depth;
PAAD	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.42	4.69	0.36	6.09e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1957429	0.808	rs1957428	chr14:65354058	T/C	cg23373153	chr14:65346875	NA	1.04	7.25	0.51	1.96e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg24466277	chr1:23519622	HTR1D	-0.56	-5.28	-0.39	4.41e-7	Height;
PAAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg03989125	chr22:38214979	NA	0.61	5.83	0.43	3.15e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg21951975	chr1:209979733	IRF6	0.59	5.4	0.4	2.56e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg16419906	chr5:132167176	NA	-0.61	-4.87	-0.37	2.8e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg19131313	chr8:1704013	NA	-0.41	-4.46	-0.34	1.59e-5	Systolic blood pressure;
PAAD	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.48	-0.34	1.47e-5	Body mass index;
PAAD	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg21191810	chr6:118973309	C6orf204	-0.52	-5.13	-0.38	8.86e-7	Diastolic blood pressure;
PAAD	cis	rs8067287	0.762	rs11649835	chr17:16823541	C/G	cg26910001	chr17:16838321	NA	-0.68	-6.21	-0.45	4.95e-9	Diabetic kidney disease;
PAAD	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.9	8.43	0.56	2.41e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg14019146	chr3:50243930	SLC38A3	0.47	4.96	0.37	1.87e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35955747	0.838	rs7285171	chr22:31598367	C/T	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.36	-0.33	2.41e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18214930	chr14:53254659	GNPNAT1	-0.65	-6.32	-0.46	2.81e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.62	5.96	0.44	1.7e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg01573162	chr19:1940828	CSNK1G2	-0.58	-4.45	-0.34	1.65e-5	Bipolar disorder;
PAAD	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg24565620	chr2:194026	NA	0.58	4.76	0.36	4.52e-6	Blood protein levels;
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg19337854	chr7:99768885	GPC2	0.52	4.85	0.37	3.06e-6	Platelet count;
PAAD	trans	rs1075265	0.587	rs2949812	chr2:54024327	C/G	cg16115072	chr17:25938812	KSR1	0.6	6.35	0.46	2.4e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7707921	0.667	rs111549985	chr5:81268070	C/G	cg21483461	chr5:81570383	RPS23	-0.55	-4.57	-0.35	9.93e-6	Breast cancer;
PAAD	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.71	-0.36	5.45e-6	Subjective well-being;
PAAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.51	5.61	0.41	9.37e-8	Height;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.53	6.05	0.44	1.05e-8	Lung cancer;
PAAD	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.81	8.32	0.56	4.69e-14	Alzheimer's disease (late onset);
PAAD	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.56	-6.89	-0.49	1.39e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.66	4.94	0.37	2.07e-6	Hip geometry;
PAAD	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.97	11.26	0.67	9.06e-22	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08886695	chr4:3369023	RGS12	-0.51	-4.83	-0.36	3.31e-6	Mean platelet volume;
PAAD	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg18171855	chr10:2543474	NA	0.41	4.29	0.33	3.17e-5	Age-related hearing impairment;
PAAD	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.77	7.2	0.5	2.61e-11	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg18281939	chr5:77783895	LHFPL2	0.51	6.57	0.47	7.42e-10	Triglycerides;
PAAD	cis	rs9649465	1.000	rs7803287	chr7:123354807	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg20406979	chr6:167373233	NA	0.38	4.99	0.38	1.6e-6	Crohn's disease;
PAAD	cis	rs66515854	0.602	rs4349487	chr3:3960052	G/T	cg03930929	chr3:3862703	LRRN1	-0.54	-4.52	-0.34	1.24e-5	beta-nerve growth factor levels;
PAAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.81	9.54	0.61	3.38e-17	Methadone dose in opioid dependence;
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.9	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.43e-12	Calcium levels;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.7	7.69	0.53	1.74e-12	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20316304	chr1:150981039	FAM63A;PRUNE	-0.67	-7.22	-0.51	2.38e-11	Smoking initiation;
PAAD	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-4.64	-0.35	7.62e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	11.24	0.67	1.02e-21	Platelet count;
PAAD	cis	rs5753037	0.615	rs131279	chr22:30155251	G/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.7	6.79	0.48	2.32e-10	Mean platelet volume;
PAAD	cis	rs2252790	0.859	rs1204826	chr6:116564388	A/G	cg26893134	chr6:116381904	FRK	-0.29	-4.53	-0.35	1.17e-5	Fast beta electroencephalogram;
PAAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg09796270	chr17:17721594	SREBF1	-0.48	-5.38	-0.4	2.75e-7	Total body bone mineral density;
PAAD	cis	rs7101378	0.577	rs2136533	chr11:108900072	G/A	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22614265	chr7:100425456	EPHB4	0.62	6.76	0.48	2.79e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg01815783	chr4:1047043	NA	0.46	4.37	0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.57	-5.46	-0.41	1.87e-7	Breast size;
PAAD	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.07	-0.67	3.02e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg14703610	chr5:56206110	C5orf35	0.63	5.78	0.42	4.12e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs7113874	0.802	rs4272783	chr11:8685393	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.64	-0.35	7.54e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg04415270	chr2:102091202	RFX8	-0.51	-6.46	-0.46	1.34e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs2085601	0.542	rs1708675	chr4:89973400	G/A	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.15	0.55	1.24e-13	Coffee consumption (cups per day);
PAAD	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg07741184	chr6:167504864	NA	-0.35	-4.53	-0.34	1.2e-5	Primary biliary cholangitis;
PAAD	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.92	-0.37	2.26e-6	Resting heart rate;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18883852	chr13:45965548	LOC100190939	-0.72	-6.6	-0.47	6.48e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1879734	0.731	rs12044337	chr1:54160558	C/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.53	-4.27	-0.33	3.49e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs3733631	1.000	rs3796951	chr4:104628158	A/T	cg21490444	chr5:171095097	NA	-0.79	-6.68	-0.48	4.25e-10	Menarche (age at onset);
PAAD	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg00806126	chr19:22604979	ZNF98	0.4	4.95	0.37	1.94e-6	Pain;
PAAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg03989125	chr22:38214979	NA	-0.51	-4.83	-0.36	3.31e-6	Glioblastoma;Glioma;
PAAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.51	-5.17	-0.39	7.17e-7	Breast size;
PAAD	cis	rs2997447	0.846	rs17257086	chr1:26392535	C/T	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119038	0.865	rs7117261	chr11:118741157	T/C	cg19308663	chr11:118741387	NA	-0.63	-4.85	-0.37	2.99e-6	Sjögren's syndrome;
PAAD	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs7172971	0.688	rs7180420	chr15:42372872	A/G	cg07013680	chr15:42186124	SPTBN5	0.51	4.25	0.33	3.78e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.5	0.52	4.84e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.43	-0.52	7.35e-12	Hemoglobin concentration;
PAAD	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.45	-4.59	-0.35	9.14e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs41271473	0.687	rs4391637	chr1:228878379	A/C	cg10167378	chr1:228756711	NA	0.54	4.61	0.35	8.42e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg01191920	chr7:158217561	PTPRN2	0.69	7.45	0.52	6.51e-12	Obesity-related traits;
PAAD	cis	rs2455826	0.521	rs1447648	chr3:15857574	G/A	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21238812	chr9:126143023	DENND1A	-0.61	-6.3	-0.46	3.12e-9	Obesity-related traits;
PAAD	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.89	-4.63	-0.35	7.78e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg24881330	chr22:46731750	TRMU	1.08	5.55	0.41	1.27e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13268919	chr11:842945	TSPAN4;POLR2L	-0.7	-7.42	-0.52	7.93e-12	Smoking initiation;
PAAD	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.7	-0.53	1.66e-12	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00933542	chr6:150070202	PCMT1	0.58	5.9	0.43	2.25e-8	Lung cancer;
PAAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.56	0.57	1.13e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Body mass index;
PAAD	cis	rs939584	1.000	rs5017300	chr2:631099	C/G	cg14515364	chr2:636606	NA	0.5	4.59	0.35	9.27e-6	Body mass index;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12683085	chr13:112690689	NA	0.48	6.51	0.47	1.03e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10702113	chr3:196664466	NCBP2	0.56	6.48	0.47	1.18e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.44	4.61	0.35	8.36e-6	Heart rate;
PAAD	cis	rs4716602	0.513	rs13237220	chr7:156169727	G/A	cg04090468	chr7:156181990	NA	-0.97	-9.47	-0.61	5.19e-17	Anti-saccade response;
PAAD	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg10818794	chr15:86012489	AKAP13	-0.59	-4.71	-0.36	5.46e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.14e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	1.16	13.08	0.73	1.17e-26	Eosinophil percentage of granulocytes;
PAAD	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs863345	0.526	rs857676	chr1:158615702	G/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.72	-0.36	5.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg00277334	chr10:82204260	NA	0.48	5.09	0.38	1.02e-6	Sarcoidosis;
PAAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.71	8.3	0.56	5.18e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg10621924	chr7:39171070	POU6F2	-0.33	-5.05	-0.38	1.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4668356	0.730	rs10490606	chr2:171909189	C/T	cg13882835	chr2:172017928	TLK1	-0.92	-5.37	-0.4	2.83e-7	Cognitive performance;
PAAD	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.46	4.68	0.35	6.42e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs17102423	0.896	rs8004805	chr14:65579720	T/C	cg11161011	chr14:65562177	MAX	-0.49	-4.31	-0.33	2.9e-5	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26027482	chr12:1100598	ERC1	0.65	7.59	0.52	2.95e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13606994	chr1:44402422	ARTN	-0.44	-4.73	-0.36	5.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg00262122	chr8:11665843	FDFT1	0.47	4.39	0.34	2.1e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg14146966	chr2:61757674	XPO1	0.42	5.2	0.39	6.4e-7	Tuberculosis;
PAAD	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg23033748	chr14:75592666	NEK9	-0.4	-4.84	-0.37	3.11e-6	Height;
PAAD	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.13	0.6	4.03e-16	Colorectal cancer;
PAAD	cis	rs10901513	0.932	rs2366349	chr10:127674675	G/A	cg22975853	chr10:127789788	ADAM12	0.45	4.8	0.36	3.71e-6	Visceral fat;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23588161	chr11:65729143	SART1	0.66	7.25	0.51	2.03e-11	Myopia (pathological);
PAAD	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.48	4.41	0.34	1.96e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13002353	chr6:36823013	PPIL1	-0.56	-6.31	-0.46	2.97e-9	Monocyte percentage of white cells;
PAAD	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg08992911	chr2:238395768	MLPH	0.94	6.88	0.49	1.48e-10	Prostate cancer;
PAAD	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg13859433	chr6:33739653	LEMD2	-0.64	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.82	10.24	0.64	4.89e-19	N-glycan levels;
PAAD	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.31	-0.4	3.8e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg07148914	chr20:33460835	GGT7	-0.45	-4.43	-0.34	1.76e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.49	-0.47	1.15e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.72	7.43	0.52	7.48e-12	Corneal astigmatism;
PAAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.57e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg26220594	chr1:19110978	NA	-0.6	-5.05	-0.38	1.27e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.91	-12.1	-0.7	4.83e-24	Prudent dietary pattern;
PAAD	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	-0.44	-4.5	-0.34	1.34e-5	Height;
PAAD	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.6	6.29	0.45	3.27e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs876084	0.505	rs11988495	chr8:121128487	A/G	cg06265175	chr8:121136014	COL14A1	0.49	4.77	0.36	4.3e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09563617	chr6:134374917	SLC2A12	-0.7	-7.58	-0.52	3.09e-12	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.71	0.53	1.57e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1997066	0.831	rs73344311	chr10:106825591	C/T	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04438595	chr1:16176425	SPEN	-0.58	-6.94	-0.49	1.09e-10	Body fat percentage;
PAAD	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17554472	chr22:41940697	POLR3H	0.59	4.27	0.33	3.48e-5	Vitiligo;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg01283332	chr5:1856932	NA	-0.42	-4.27	-0.33	3.41e-5	Cardiovascular disease risk factors;
PAAD	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg16386425	chr10:429943	DIP2C	0.51	5.09	0.38	1.03e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.4	-0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22455342	chr2:225449267	CUL3	0.6	5.49	0.41	1.66e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg02135003	chr7:105160482	PUS7	-0.7	-5.57	-0.41	1.12e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-7.79	-0.53	9.82e-13	Morning vs. evening chronotype;
PAAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg03268063	chr7:1337281	NA	-0.52	-4.53	-0.35	1.17e-5	Neuroticism;
PAAD	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.96	11.4	0.68	3.87e-22	Breast cancer;
PAAD	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.59	6.85	0.49	1.74e-10	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.81	-8.17	-0.55	1.09e-13	Pancreatic cancer;
PAAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.82	0.58	2.46e-15	Menopause (age at onset);
PAAD	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg18612461	chr15:75251733	NA	-0.58	-7.2	-0.5	2.56e-11	Caffeine consumption;
PAAD	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.77	-0.53	1.1e-12	Morning vs. evening chronotype;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26164151	chr11:44749353	NA	-0.74	-6.76	-0.48	2.74e-10	Blood protein levels;
PAAD	cis	rs59888335	0.858	rs7427096	chr3:80986105	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg02404636	chr22:31891804	SFI1	-0.58	-5.22	-0.39	5.85e-7	Colorectal cancer;
PAAD	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.6	5.44	0.4	2.08e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21643547	chr1:205240462	TMCC2	-0.41	-4.67	-0.35	6.51e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.22	-0.39	5.72e-7	Monocyte count;
PAAD	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.04	0.55	2.29e-13	Exhaled nitric oxide output;
PAAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.64	-6.15	-0.45	6.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg21132104	chr15:45694354	SPATA5L1	0.87	8.09	0.55	1.8e-13	Homoarginine levels;
PAAD	cis	rs3736485	0.932	rs10519313	chr15:51915812	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.4	-0.34	2.01e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.71	-7.34	-0.51	1.18e-11	Colorectal cancer;
PAAD	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11677203	1.000	rs11685890	chr2:12564292	C/T	cg01085830	chr2:11774354	GREB1	0.48	4.77	0.36	4.34e-6	Electroencephalogram traits;
PAAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs757081	0.648	rs1488933	chr11:17267029	C/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.76	-0.42	4.59e-8	Systolic blood pressure;
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg07689907	chr11:61582574	FADS1	0.56	5.0	0.38	1.59e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.66	8.8	0.58	2.84e-15	Eye color traits;
PAAD	cis	rs6499755	0.768	rs116563840	chr16:55362376	G/A	cg02859129	chr16:55357253	IRX6	0.37	5.12	0.38	9.15e-7	Hypospadias;
PAAD	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg25783544	chr11:47291846	MADD	0.54	4.34	0.33	2.6e-5	HDL cholesterol;
PAAD	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg16898833	chr6:26189333	HIST1H4D	0.87	4.69	0.36	5.96e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs1358748	0.522	rs6588239	chr1:67572361	G/A	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg06917450	chr1:38156652	C1orf109	-0.49	-4.35	-0.33	2.44e-5	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14238478	chr2:219433113	RQCD1;USP37	0.66	6.46	0.46	1.33e-9	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27249178	chr3:138067404	MRAS	-0.62	-6.57	-0.47	7.59e-10	Smoking initiation;
PAAD	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.7	-7.21	-0.5	2.48e-11	Type 2 diabetes;
PAAD	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26172385	chr10:120840446	EIF3A	0.65	6.68	0.48	4.21e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg14008862	chr17:28927542	LRRC37B2	0.84	6.04	0.44	1.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.89	-7.68	-0.53	1.84e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.91	-10.67	-0.65	3.4e-20	Total body bone mineral density;
PAAD	cis	rs7923609	0.846	rs7098181	chr10:65027143	G/T	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3736485	0.966	rs7170444	chr15:51890500	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.84e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4704187	0.687	rs4360021	chr5:74421962	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05269546	chr19:50098360	PRR12	0.56	6.39	0.46	1.94e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-5.91	-0.43	2.14e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs28472312	0.667	rs9937676	chr16:28969480	A/G	cg16576597	chr16:28551801	NUPR1	-0.46	-4.81	-0.36	3.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.25	0.39	5.01e-7	Renal function-related traits (BUN);
PAAD	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg23649088	chr2:200775458	C2orf69	-0.71	-5.81	-0.43	3.56e-8	Schizophrenia;
PAAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73206853	0.764	rs16940909	chr12:111054591	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	4.73	0.36	5.16e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-7.95	-0.54	3.9e-13	Blood protein levels;
PAAD	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg07828024	chr6:149772892	ZC3H12D	0.32	4.26	0.33	3.51e-5	Dupuytren's disease;
PAAD	cis	rs11825685	0.887	rs76812821	chr11:134564628	G/A	cg06603561	chr11:134479413	NA	-0.88	-5.51	-0.41	1.47e-7	IgG glycosylation;
PAAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg13266496	chr6:110720918	DDO	-0.47	-4.95	-0.37	1.91e-6	Platelet distribution width;
PAAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3736485	0.932	rs11633395	chr15:51917957	G/T	cg08986416	chr15:51914746	DMXL2	-0.47	-4.54	-0.35	1.16e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.7	5.77	0.42	4.41e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.81	6.22	0.45	4.53e-9	Crohn's disease;
PAAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-4.94	-0.37	2.08e-6	Height;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg14789911	chr21:47582049	C21orf56	0.53	5.67	0.42	6.92e-8	Testicular germ cell tumor;
PAAD	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg06606381	chr12:133084897	FBRSL1	-0.98	-6.61	-0.47	6.12e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-4.58	-0.35	9.54e-6	Schizophrenia;
PAAD	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg20592124	chr2:65290738	CEP68	0.47	4.51	0.34	1.29e-5	Pulse pressure;
PAAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.42	4.31	0.33	2.91e-5	Vitiligo;
PAAD	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.67	7.29	0.51	1.55e-11	Menarche (age at onset);
PAAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10556349	chr10:835070	NA	0.72	5.86	0.43	2.81e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg12639453	chr1:2035780	PRKCZ	-0.51	-4.99	-0.38	1.62e-6	Height;
PAAD	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06850241	chr22:41845214	NA	-0.55	-4.62	-0.35	8.09e-6	Vitiligo;
PAAD	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-4.94	-0.37	2.07e-6	Triglycerides;
PAAD	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs12580194	0.593	rs79104523	chr12:55749220	T/C	cg06899799	chr12:56650233	ANKRD52	0.33	4.36	0.33	2.39e-5	Cancer;
PAAD	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21545522	chr1:205238299	TMCC2	0.48	4.38	0.33	2.17e-5	Red blood cell count;
PAAD	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.74	8.04	0.55	2.39e-13	Prostate cancer;
PAAD	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg00536532	chr6:33561449	C6orf227	0.43	4.59	0.35	9.18e-6	Height;
PAAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.78	7.43	0.52	7.4e-12	Birth weight;
PAAD	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg00717180	chr2:96193071	NA	0.57	6.37	0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs12425451	0.544	rs7961302	chr12:3146436	G/C	cg05389053	chr12:3131226	TEAD4	-0.63	-5.45	-0.4	1.98e-7	Narcolepsy with cataplexy;
PAAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21747090	chr2:27597821	SNX17	-0.44	-4.3	-0.33	3.08e-5	Total body bone mineral density;
PAAD	cis	rs4742903	0.875	rs4543600	chr9:106939884	A/G	cg14250997	chr9:106856677	SMC2	0.44	4.66	0.35	6.98e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.35	4.93	0.37	2.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg16083429	chr3:49237500	CCDC36	0.45	4.41	0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.55	-5.64	-0.42	7.92e-8	Tonsillectomy;
PAAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.76	-8.15	-0.55	1.24e-13	Blood metabolite levels;
PAAD	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.08	7.48	0.52	5.43e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg08917208	chr2:24149416	ATAD2B	-0.5	-4.67	-0.35	6.69e-6	Asthma;
PAAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.5	-4.68	-0.35	6.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg14092988	chr3:52407081	DNAH1	0.57	7.27	0.51	1.81e-11	Bipolar disorder;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.44	0.34	1.71e-5	Bipolar disorder;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.73	9.25	0.6	1.95e-16	Cardiovascular disease risk factors;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.34	0.56	4.28e-14	Prudent dietary pattern;
PAAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg03538708	chr1:25844672	NA	0.48	4.95	0.37	1.97e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs10849004	1.000	rs10849002	chr12:4291829	G/A	cg03803796	chr12:3575061	NA	0.57	4.69	0.36	6.08e-6	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.55	5.87	0.43	2.61e-8	Lung cancer;
PAAD	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.98	-12.71	-0.72	1.1e-25	Coronary artery disease;
PAAD	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	6.56	0.47	8.06e-10	Schizophrenia;
PAAD	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.2	0.5	2.6e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.74	-0.48	3.09e-10	Lung cancer;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.88	-6.68	-0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg03264133	chr6:25882463	NA	0.44	4.38	0.33	2.24e-5	Schizophrenia;
PAAD	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.38	0.34	2.16e-5	Multiple sclerosis;
PAAD	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.67	7.2	0.5	2.6e-11	Testicular germ cell tumor;
PAAD	cis	rs11761441	1.000	rs11761441	chr7:82377	G/A	cg22368281	chr7:82270	NA	-0.33	-4.44	-0.34	1.69e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs78472555	1.000	rs78472555	chr15:100267322	G/C	cg18869061	chr15:100272053	LYSMD4	-0.71	-5.83	-0.43	3.15e-8	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1619661	0.530	rs7909598	chr10:44688935	T/C	cg09554077	chr10:44749378	NA	0.33	4.91	0.37	2.32e-6	QT interval (ambient particulate matter interaction);
PAAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7941600	0.708	rs11042290	chr11:9357059	G/A	cg19415743	chr11:9336845	TMEM41B	0.93	5.88	0.43	2.46e-8	Coronary artery disease;
PAAD	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.44	-4.25	-0.33	3.68e-5	Height;
PAAD	cis	rs54211	0.831	rs137649	chr22:39730700	T/C	cg24399712	chr22:39784796	NA	-0.77	-4.35	-0.33	2.47e-5	Sudden cardiac arrest;
PAAD	cis	rs1144333	1.000	rs76192904	chr1:76359995	C/T	cg22875332	chr1:76189707	ACADM	0.61	4.35	0.33	2.5e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3126085	0.560	rs11588022	chr1:152316952	A/T	cg26876637	chr1:152193138	HRNR	-0.63	-4.58	-0.35	9.42e-6	Atopic dermatitis;
PAAD	cis	rs11811982	1.000	rs11811982	chr1:227581520	C/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.33e-7	Optic disc area;
PAAD	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.5	4.75	0.36	4.74e-6	Hip circumference;
PAAD	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.94	-0.43	1.88e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08359347	chr11:86667175	FZD4	0.56	6.43	0.46	1.55e-9	Monocyte percentage of white cells;
PAAD	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	6.91	0.49	1.24e-10	Type 2 diabetes;
PAAD	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.9	-10.64	-0.65	4.09e-20	Total body bone mineral density;
PAAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg24399712	chr22:39784796	NA	-0.77	-7.8	-0.53	9.17e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7714584	1.000	rs10052606	chr5:150272217	T/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-9.99	-0.63	2.29e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	6.37	0.46	2.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6076065	0.723	rs4813495	chr20:23391617	A/G	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7593730	0.636	rs10181181	chr2:161087411	C/T	cg22609984	chr2:161126801	NA	-0.52	-4.52	-0.34	1.23e-5	Type 2 diabetes;
PAAD	cis	rs762407	0.560	rs11089096	chr21:45188955	C/G	cg11815682	chr21:44486381	CBS	-0.56	-5.44	-0.4	2.06e-7	Systolic blood pressure change trajectories;
PAAD	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg01942863	chr7:99769432	GPC2	0.47	4.4	0.34	2.02e-5	Coronary artery disease;
PAAD	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg05585544	chr11:47624801	NA	0.46	5.13	0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg08699206	chr4:1595414	NA	0.41	4.25	0.33	3.65e-5	Obesity-related traits;
PAAD	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg08523384	chr5:141488047	NDFIP1	0.51	4.94	0.37	2.08e-6	Asthma;
PAAD	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.94	10.55	0.65	7.02e-20	Multiple sclerosis;
PAAD	cis	rs16958440	0.581	rs72907280	chr18:44681130	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-4.61	-0.35	8.51e-6	Sitting height ratio;
PAAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg22710661	chr11:17411071	KCNJ11	0.45	4.62	0.35	8.07e-6	Type 2 diabetes;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg17810781	chr1:201082982	CACNA1S	0.45	5.23	0.39	5.63e-7	Permanent tooth development;
PAAD	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg03522150	chr11:46969673	C11orf49	0.43	5.19	0.39	6.72e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.67	-0.48	4.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2051773	0.567	rs7934608	chr11:17038917	A/C	cg15084286	chr11:17036142	PLEKHA7	0.55	4.93	0.37	2.14e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs258892	0.895	rs57787613	chr5:72047278	C/A	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-5.05	-0.38	1.25e-6	Chronic sinus infection;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07648498	chr16:89883185	FANCA	0.75	7.55	0.52	3.7e-12	Schizophrenia;
PAAD	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg10820045	chr2:198174542	NA	-0.44	-4.35	-0.33	2.49e-5	Dermatomyositis;
PAAD	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.68	6.61	0.47	6.09e-10	Hip circumference;
PAAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	1.08	7.41	0.51	8.32e-12	IgG glycosylation;
PAAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg14343924	chr8:8086146	FLJ10661	-0.52	-4.55	-0.35	1.08e-5	Joint mobility (Beighton score);
PAAD	cis	rs755249	0.567	rs2296172	chr1:39835817	A/G	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.55	5.05	0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg01176363	chr20:62369445	LIME1	-0.56	-5.49	-0.41	1.63e-7	Prostate cancer;
PAAD	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.64	-0.35	7.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg21130718	chr4:1044621	NA	0.57	4.81	0.36	3.53e-6	Recombination rate (females);
PAAD	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg05341575	chr12:125625032	AACS	-0.47	-4.27	-0.33	3.5e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.57e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4343996	0.935	rs4385365	chr7:3360860	C/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg23346134	chr3:49453900	TCTA	0.45	4.89	0.37	2.58e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg19223190	chr17:80058835	NA	-0.54	-5.44	-0.4	2.07e-7	Life satisfaction;
PAAD	cis	rs8112211	0.911	rs2286475	chr19:38847431	T/C	cg14299480	chr19:38876666	GGN	-0.59	-6.85	-0.49	1.68e-10	Blood protein levels;
PAAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.65	-4.79	-0.36	3.91e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg20406979	chr6:167373233	NA	-0.37	-5.1	-0.38	9.94e-7	Crohn's disease;
PAAD	cis	rs6782025	0.837	rs2701057	chr3:120958914	C/G	cg16417163	chr3:121280760	NA	-0.44	-4.59	-0.35	9.41e-6	Aging (facial);
PAAD	cis	rs2882667	0.587	rs1848506	chr5:138182457	A/T	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.82	-8.64	-0.57	7.11e-15	Prostate cancer;
PAAD	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg15123519	chr2:136567270	LCT	-0.37	-4.43	-0.34	1.79e-5	Mosquito bite size;
PAAD	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.8e-10	Resting heart rate;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	5.08e-8	Life satisfaction;
PAAD	cis	rs1975974	1.000	rs17052337	chr17:21710774	A/T	cg18423549	chr17:21743878	NA	-0.52	-4.83	-0.36	3.26e-6	Psoriasis;
PAAD	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.06	6.95	0.49	1.03e-10	Plateletcrit;
PAAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.61	6.76	0.48	2.76e-10	Testicular germ cell tumor;
PAAD	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.08	-0.44	9.5e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.18	-0.5	2.9e-11	Personality dimensions;
PAAD	cis	rs62408225	1.000	rs62408225	chr6:90956409	A/G	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Height;
PAAD	cis	rs2286503	0.839	rs2270108	chr7:22862131	A/C	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08833010	chr4:1684739	FAM53A	0.6	6.82	0.48	2.01e-10	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08110718	chr16:2827420	TCEB2	0.65	6.43	0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.35	-0.33	2.46e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.48	-0.41	1.74e-7	Bladder cancer;
PAAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg18833306	chr6:118973337	C6orf204	-0.53	-4.35	-0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.71	-8.17	-0.55	1.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06745235	chr1:180471494	ACBD6	0.64	7.22	0.51	2.34e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17323393	chr14:92136722	CATSPERB	-0.69	-7.22	-0.51	2.31e-11	Obesity-related traits;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.67	7.25	0.51	1.99e-11	Longevity;
PAAD	cis	rs7714584	1.000	rs7716903	chr5:150258574	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26206990	chr15:63569719	APH1B	0.6	6.93	0.49	1.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg21625146	chr5:486483	SLC9A3	-0.37	-5.44	-0.4	2.07e-7	Cystic fibrosis severity;
PAAD	cis	rs72827839	1.000	rs78250051	chr17:46545826	G/A	cg23391107	chr17:45924227	SP6	0.61	5.12	0.38	9.29e-7	Ease of getting up in the morning;
PAAD	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.86	8.65	0.57	6.9e-15	Corneal astigmatism;
PAAD	cis	rs73206853	0.841	rs73191828	chr12:110946121	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.44	0.34	1.73e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.12	-0.44	7.63e-9	Bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26296941	chr15:93114062	LOC100144604	0.62	6.53	0.47	9.11e-10	Smoking initiation;
PAAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.69	7.23	0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16262614	chr3:133464971	TF	0.49	5.55	0.41	1.24e-7	Iron status biomarkers;
PAAD	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2286379	0.684	rs4765844	chr12:1874853	A/G	cg05227549	chr12:1770782	NA	-0.45	-5.16	-0.39	7.76e-7	Blood pressure (smoking interaction);
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	15.04	0.77	6.86e-32	Height;
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.5	-4.91	-0.37	2.29e-6	Facial morphology (factor 20);
PAAD	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg01620082	chr3:125678407	NA	-1.41	-7.82	-0.54	8.25e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.4	4.83	0.36	3.25e-6	Thyroid stimulating hormone;
PAAD	trans	rs901683	1.000	rs9422442	chr10:46048078	C/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.33	-0.46	2.67e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg04315214	chr1:2043799	PRKCZ	-0.46	-5.44	-0.4	2.13e-7	Coronary artery disease;
PAAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.62	6.25	0.45	3.93e-9	Multiple myeloma (IgH translocation);
PAAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.64	-5.56	-0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs11966931	0.817	rs2883361	chr6:108090328	G/A	cg10566610	chr6:108093680	SCML4	-0.5	-4.71	-0.36	5.54e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2004318	1.000	rs78629820	chr19:55134631	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.69	6.92	0.49	1.17e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs58521262	0.556	rs462446	chr19:23125344	T/G	cg02350677	chr19:23254381	NA	-0.26	-4.47	-0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.34	0.4	3.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.53e-8	Mean corpuscular volume;
PAAD	cis	rs8099014	0.816	rs8099343	chr18:56110071	C/T	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15441629	chr19:16582551	EPS15L1	0.6	6.46	0.46	1.37e-9	Myopia (pathological);
PAAD	trans	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.35	-0.46	2.33e-9	Mean corpuscular volume;
PAAD	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.65	4.35	0.33	2.44e-5	Skin colour saturation;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs832187	0.813	rs704370	chr3:63868250	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.46	4.4	0.34	2.07e-5	Schizophrenia;
PAAD	cis	rs7301016	0.948	rs73141045	chr12:62931083	C/G	cg11441379	chr12:63026424	NA	0.84	6.07	0.44	9.66e-9	IgG glycosylation;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg24879335	chr3:133465180	TF	0.53	5.74	0.42	4.96e-8	Iron status biomarkers;
PAAD	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.59e-7	Monocyte percentage of white cells;
PAAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg02297831	chr4:17616191	MED28	0.6	6.12	0.44	7.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.45	4.87	0.37	2.73e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.64	5.95	0.43	1.77e-8	Proinsulin levels;
PAAD	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.7	7.63	0.53	2.43e-12	Colorectal cancer;
PAAD	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.4	4.29	0.33	3.13e-5	Longevity;
PAAD	cis	rs11264799	0.731	rs41479249	chr1:157694013	C/T	cg18268488	chr1:157545234	FCRL4	0.61	5.42	0.4	2.34e-7	IgA nephropathy;
PAAD	cis	rs59191668	0.780	rs1822201	chr15:62812655	G/T	cg12918536	chr15:62891943	NA	-0.33	-4.32	-0.33	2.83e-5	Immature fraction of reticulocytes;
PAAD	trans	rs11794666	1.000	rs79711279	chr9:31666894	G/A	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg26528668	chr16:1614120	IFT140	0.57	5.34	0.4	3.38e-7	Coronary artery disease;
PAAD	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg00546117	chr1:8445545	RERE	-0.47	-4.9	-0.37	2.41e-6	Crohn's disease;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	1.57	9.43	0.61	6.71e-17	Age-related hearing impairment;
PAAD	cis	rs3736485	0.934	rs17609666	chr15:51858038	G/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	5.8	0.43	3.65e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.72	-8.33	-0.56	4.3e-14	Body mass index;
PAAD	cis	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg07689907	chr11:61582574	FADS1	0.48	4.64	0.35	7.56e-6	Trans fatty acid levels;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.83	7.14	0.5	3.66e-11	Alzheimer's disease;
PAAD	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs6141769	0.542	rs6057632	chr20:31319841	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg10587741	chr22:38071170	LGALS1	0.61	6.84	0.49	1.82e-10	Fat distribution (HIV);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06932451	chr19:36869880	NA	0.58	6.67	0.48	4.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.62	6.08	0.44	9.44e-9	Testicular germ cell tumor;
PAAD	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02598441	chr17:62777298	LOC146880	-0.55	-4.49	-0.34	1.43e-5	QT interval;
PAAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg15017067	chr4:17643749	FAM184B	0.44	5.16	0.39	7.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.83	-5.54	-0.41	1.33e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
PAAD	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs2180233	0.712	rs12742054	chr1:30664122	T/G	cg06703062	chr1:31191648	MATN1	-0.56	-5.03	-0.38	1.34e-6	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs1816752	0.875	rs17384871	chr13:25059097	T/C	cg01628528	chr13:24882594	C1QTNF9	-0.46	-4.32	-0.33	2.83e-5	Obesity-related traits;
PAAD	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.71	7.58	0.52	3.13e-12	Platelet distribution width;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12277888	chr11:35723985	TRIM44	-0.67	-6.83	-0.48	1.9e-10	Smoking initiation;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.64	-6.84	-0.49	1.77e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.54	-0.35	1.15e-5	Colorectal cancer;
PAAD	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.46	4.69	0.36	5.99e-6	Corneal astigmatism;
PAAD	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.69	7.53	0.52	4.3e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.08	0.59	5.52e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs61931739	0.649	rs815037	chr12:33725193	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.76	9.14	0.6	3.71e-16	Lung cancer;
PAAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075265	0.568	rs805416	chr2:54125258	C/T	cg04546899	chr2:54196757	PSME4	-0.31	-4.69	-0.36	5.92e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg09304653	chr7:141251275	AGK	-0.67	-6.67	-0.48	4.44e-10	Body mass index;
PAAD	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.85	6.42	0.46	1.69e-9	Axial length;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.55	-6.06	-0.44	1.01e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.86	-9.28	-0.6	1.65e-16	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.83	0.36	3.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.64	-6.09	-0.44	9e-9	Schizophrenia;
PAAD	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs12612619	0.732	rs11680032	chr2:27198148	C/T	cg00617064	chr2:27272375	NA	-0.48	-5.05	-0.38	1.27e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12612619	0.732	rs11687536	chr2:27199754	C/T	cg00617064	chr2:27272375	NA	0.46	5.07	0.38	1.17e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06156847	chr2:113672199	IL1F7	0.57	5.91	0.43	2.13e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-5.8	-0.43	3.8e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg02743256	chr7:2109353	MAD1L1	-0.6	-4.3	-0.33	3.02e-5	Bipolar disorder;
PAAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.09	0.5	4.64e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg05372495	chr19:1063624	ABCA7	-0.5	-4.4	-0.34	2.04e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Tonsillectomy;
PAAD	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08267141	chr4:110354820	SEC24B	-0.66	-6.68	-0.48	4.34e-10	Smoking initiation;
PAAD	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.8	-4.44	-0.34	1.72e-5	Cholesterol, total;
PAAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	trans	rs901683	1.000	rs76805415	chr10:46026163	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.84	-7.15	-0.5	3.48e-11	Blood protein levels;
PAAD	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-5.28	-0.39	4.36e-7	Axial length;
PAAD	cis	rs656900	0.740	rs644315	chr15:80113549	C/T	cg02196730	chr15:80188777	MTHFS	-0.43	-4.51	-0.34	1.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.38	0.34	2.16e-5	Multiple sclerosis;
PAAD	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg05309399	chr4:106552544	FLJ20184	-0.57	-4.69	-0.36	5.93e-6	Post bronchodilator FEV1;
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.76	-0.36	4.55e-6	Testicular germ cell tumor;
PAAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.58	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs3760982	0.520	rs425578	chr19:44302256	A/T	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2131877	0.830	rs60922537	chr3:194842785	C/G	cg24618514	chr3:194868507	C3orf21	0.49	4.73	0.36	5.14e-6	Non-small cell lung cancer;
PAAD	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.55	5.29	0.39	4.18e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg27490568	chr2:178487706	NA	-0.42	-4.62	-0.35	8.13e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.81	9.96	0.63	2.62e-18	Height;
PAAD	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.52	6.63	0.47	5.4e-10	Thyroid hormone levels;
PAAD	cis	rs7132746	0.553	rs11830880	chr12:86192583	C/T	cg18827107	chr12:86230957	RASSF9	0.48	4.71	0.36	5.43e-6	Lewy body disease;
PAAD	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.81	9.09	0.59	4.95e-16	Metabolic syndrome;
PAAD	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.56	5.29	0.39	4.11e-7	Tonsillectomy;
PAAD	cis	rs863345	0.604	rs10908666	chr1:158500098	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs3960554	0.696	rs10952869	chr7:75846453	A/G	cg17325771	chr7:75508891	RHBDD2	-0.37	-4.44	-0.34	1.72e-5	Eotaxin levels;
PAAD	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25632853	chr15:73088954	NA	0.42	4.84	0.37	3.1e-6	Triglyceride levels;
PAAD	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg22153463	chr1:85462885	MCOLN2	0.71	5.25	0.39	4.99e-7	Serum sulfate level;
PAAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.54	5.3	0.4	3.92e-7	Menarche (age at onset);
PAAD	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.72	8.56	0.57	1.14e-14	Huntington's disease progression;
PAAD	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.32e-13	Prostate cancer;
PAAD	cis	rs4889855	0.530	rs4890047	chr17:78549439	A/G	cg16591659	chr17:78472290	NA	-0.45	-4.37	-0.33	2.31e-5	Fractional excretion of uric acid;
PAAD	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	5.4	0.4	2.5e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.68	6.73	0.48	3.22e-10	Breast cancer;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.74	-7.93	-0.54	4.47e-13	Blood metabolite levels;
PAAD	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg14440974	chr22:39074834	NA	-0.59	-7.15	-0.5	3.46e-11	Menopause (age at onset);
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.51	4.89	0.37	2.57e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6604026	0.656	rs2774949	chr1:93352553	T/C	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	7.61	0.53	2.75e-12	Bone mineral density;
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.66	7.78	0.53	1.03e-12	Vitiligo;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	1.07	6.43	0.46	1.6e-9	Body mass index;
PAAD	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg14055004	chr2:241860995	NA	-0.28	-4.46	-0.34	1.62e-5	Joint mobility (Beighton score);
PAAD	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-4.27	-0.33	3.44e-5	Morning vs. evening chronotype;
PAAD	cis	rs5751901	0.929	rs2330805	chr22:24998619	A/G	cg15363607	chr22:24998974	GGT1	-0.54	-5.59	-0.41	1e-7	Protein quantitative trait loci;
PAAD	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	1.0	8.82	0.58	2.45e-15	Bipolar disorder;
PAAD	cis	rs12449964	0.524	rs4925093	chr17:17568946	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.47	5.06	0.38	1.22e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs59888335	0.858	rs6548735	chr3:81010258	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2790216	1.000	rs2440845	chr10:59971884	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs112990264	1.000	rs75313819	chr1:213016923	C/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs7998202	0.667	rs388382	chr13:113353999	G/T	cg02820901	chr13:113351484	ATP11A	0.74	4.85	0.37	3.08e-6	Glycated hemoglobin levels;
PAAD	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg08898775	chr15:59042684	ADAM10	0.4	5.2	0.39	6.32e-7	Schizophrenia;
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.48	5.41	0.4	2.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10886094	0.881	rs10886090	chr10:119270787	C/T	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs2555155	0.870	rs2723652	chr11:6534081	C/T	cg24637308	chr11:6592297	DNHD1	-0.47	-4.73	-0.36	5e-6	DNA methylation (variation);
PAAD	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.93	-0.49	1.12e-10	Body mass index;
PAAD	cis	rs4621152	0.672	rs6435956	chr2:217867564	G/A	cg21875423	chr2:217559867	IGFBP5	-0.42	-4.26	-0.33	3.61e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.59	7.54	0.52	3.92e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19213242	chr20:55966434	RBM38	-0.79	-8.64	-0.57	7.28e-15	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7608623	1.000	rs2113422	chr2:23939007	A/G	cg08917208	chr2:24149416	ATAD2B	-0.44	-4.34	-0.33	2.63e-5	Obesity-related traits;
PAAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.72	7.69	0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.71e-7	Vitiligo;
PAAD	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.57	-5.96	-0.44	1.68e-8	Lung cancer;
PAAD	cis	rs3087591	0.553	rs2854334	chr17:29715500	A/G	cg24425628	chr17:29625626	OMG;NF1	0.51	4.82	0.36	3.51e-6	Hip circumference;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-4.93	-0.37	2.17e-6	Hip circumference;
PAAD	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.92	11.97	0.7	1.08e-23	Mean corpuscular volume;
PAAD	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.11	-0.5	4.2e-11	Neuroticism;
PAAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg03367679	chr17:38183553	MED24;SNORD124	-0.38	-4.97	-0.37	1.76e-6	Myeloid white cell count;
PAAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	4.95	0.37	1.91e-6	Schizophrenia;
PAAD	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg17178900	chr1:205818956	PM20D1	0.46	4.58	0.35	9.67e-6	Parkinson's disease;
PAAD	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg10453019	chr3:16216215	GALNTL2	0.39	4.35	0.33	2.44e-5	Mean platelet volume;
PAAD	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.79	7.75	0.53	1.23e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg17524180	chr13:113633600	MCF2L	-0.44	-4.69	-0.36	6.16e-6	Systolic blood pressure;
PAAD	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.55	5.78	0.42	4.17e-8	Lung cancer;
PAAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.5	-6.34	-0.46	2.43e-9	Childhood ear infection;
PAAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.47	0.34	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00292662	chr22:38071168	LGALS1	0.53	5.58	0.41	1.07e-7	Fat distribution (HIV);
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2637266	0.756	rs846621	chr10:78545171	G/T	cg18941641	chr10:78392320	NA	0.36	4.41	0.34	1.92e-5	Pulmonary function;
PAAD	cis	rs797680	0.930	rs2295423	chr1:93581024	T/C	cg04535902	chr1:92947332	GFI1	0.45	4.3	0.33	3.04e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.82	9.22	0.6	2.31e-16	Ulcerative colitis;
PAAD	cis	rs2051773	0.567	rs12293395	chr11:17047661	C/G	cg15432903	chr11:17409602	KCNJ11	0.57	5.2	0.39	6.37e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.49	5.09	0.38	1.02e-6	Life satisfaction;
PAAD	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.65	-6.97	-0.49	9.13e-11	Brugada syndrome;
PAAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.61	6.37	0.46	2.11e-9	Ease of getting up in the morning;
PAAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.64	-6.57	-0.47	7.5e-10	Childhood ear infection;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg04287289	chr16:89883240	FANCA	0.61	6.62	0.47	5.91e-10	Vitiligo;
PAAD	cis	rs939584	1.000	rs11127488	chr2:646061	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.63	8.84	0.58	2.2e-15	Height;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg23119463	chr10:134592391	INPP5A	0.46	4.29	0.33	3.12e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19402405	chr10:64576514	EGR2	0.67	7.88	0.54	5.97e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg27121462	chr16:89883253	FANCA	0.48	5.01	0.38	1.47e-6	Vitiligo;
PAAD	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.75	8.53	0.57	1.34e-14	Breast cancer;
PAAD	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg14593290	chr7:50529359	DDC	-0.47	-4.53	-0.34	1.2e-5	Malaria;
PAAD	cis	rs9659323	0.670	rs10157346	chr1:119633547	T/C	cg17326555	chr1:119535693	NA	-0.38	-5.23	-0.39	5.65e-7	Body mass index;
PAAD	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg21253087	chr9:139290292	SNAPC4	0.46	4.56	0.35	1.03e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.44	-5.11	-0.38	9.48e-7	Testicular germ cell tumor;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.96	11.66	0.69	7.52e-23	Longevity;
PAAD	cis	rs2777491	0.872	rs11267024	chr15:41576241	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.87	-9.94	-0.63	3.1e-18	Ulcerative colitis;
PAAD	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.87	9.12	0.59	4.32e-16	Prostate cancer;
PAAD	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	1.12	8.58	0.57	1.04e-14	Inflammatory bowel disease;
PAAD	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.54	-6.99	-0.49	8.26e-11	Menopause (age at onset);
PAAD	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.81	8.87	0.58	1.83e-15	Mortality in heart failure;
PAAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	6.57	0.47	7.47e-10	Initial pursuit acceleration;
PAAD	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.65	9.97	0.63	2.47e-18	Asthma (sex interaction);
PAAD	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.15	-0.5	3.43e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg00012203	chr2:219082015	ARPC2	0.6	5.79	0.43	3.82e-8	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18323710	chr12:67660403	NA	-0.7	-7.24	-0.51	2.13e-11	Obesity-related traits;
PAAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.55	-5.34	-0.4	3.35e-7	Motion sickness;
PAAD	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.72	8.51	0.57	1.55e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs9322817	0.691	rs6929352	chr6:105204621	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-5.39	-0.4	2.6e-7	Thyroid stimulating hormone;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10023613	chr17:42248099	ASB16	-0.3	-4.26	-0.33	3.61e-5	Total body bone mineral density;
PAAD	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.65	-6.76	-0.48	2.75e-10	Height;
PAAD	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg15017067	chr4:17643749	FAM184B	0.43	4.96	0.37	1.88e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.46	4.39	0.34	2.07e-5	HDL cholesterol;
PAAD	cis	rs11816922	0.655	rs17401052	chr10:6909353	C/T	cg10119075	chr10:7709738	ITIH5	-0.57	-4.36	-0.33	2.39e-5	Migraine;
PAAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg05896902	chr15:45671018	LOC145663;GATM	0.49	4.26	0.33	3.62e-5	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.89	10.99	0.67	4.83e-21	Aortic root size;
PAAD	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.33	-0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-5.78	-0.42	4.06e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	1.0	7.31	0.51	1.39e-11	Dental caries;
PAAD	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg24466448	chr17:1505159	SLC43A2	0.66	4.27	0.33	3.41e-5	Type 2 diabetes;
PAAD	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.36	4.34	0.33	2.61e-5	Pulmonary function;
PAAD	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.62	4.57	0.35	1.01e-5	Vitiligo;
PAAD	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.71	8.26	0.56	6.69e-14	Bladder cancer;
PAAD	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.32e-5	Skin colour saturation;
PAAD	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg11949866	chr1:10754891	CASZ1	0.53	4.27	0.33	3.39e-5	Ewing sarcoma;
PAAD	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.3	4.47	0.34	1.52e-5	Alopecia areata;
PAAD	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06771106	chr2:113671356	IL1F7	-0.61	-6.6	-0.47	6.58e-10	Pulmonary function;
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	6.18	0.45	5.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg20406979	chr6:167373233	NA	-0.37	-5.2	-0.39	6.42e-7	Crohn's disease;
PAAD	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.85e-8	Coronary artery disease;
PAAD	cis	rs7084783	0.967	rs10748844	chr10:105325170	C/T	cg00126946	chr10:105363258	SH3PXD2A	-0.43	-4.51	-0.34	1.29e-5	Fear of pain;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg19223190	chr17:80058835	NA	0.52	5.38	0.4	2.79e-7	Life satisfaction;
PAAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22442454	chr1:209979470	IRF6	0.56	5.1	0.38	1.01e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.25	-0.33	3.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	0.935	rs7579427	chr2:631183	C/A	cg14515364	chr2:636606	NA	0.5	4.59	0.35	9.27e-6	Body mass index;
PAAD	cis	rs8025118	0.583	rs7173546	chr15:79549789	T/C	cg11862246	chr15:78730200	IREB2	-0.51	-4.26	-0.33	3.54e-5	Cognitive function;
PAAD	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.53	4.93	0.37	2.16e-6	Total body bone mineral density;
PAAD	cis	rs10982256	0.817	rs10817631	chr9:117267942	G/T	cg12877860	chr9:117266580	DFNB31	0.47	4.91	0.37	2.33e-6	Bipolar disorder;
PAAD	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs4843185	0.764	rs12149210	chr16:85700481	G/A	cg07784872	chr16:85687041	KIAA0182	0.57	4.86	0.37	2.91e-6	Platelet distribution width;
PAAD	trans	rs41264869	1.000	rs41264869	chr1:205030862	C/T	cg08840230	chr19:15622718	CYP4F22	0.49	6.41	0.46	1.7e-9	Blood protein levels;
PAAD	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15815730	chr19:52491114	ZNF350	0.64	6.51	0.47	1.04e-9	Smoking initiation;
PAAD	cis	rs9463078	0.691	rs6938177	chr6:45271834	T/C	cg25276700	chr6:44698697	NA	-0.53	-6.0	-0.44	1.38e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg02264943	chr11:130785842	SNX19	0.38	4.5	0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs113779084	0.660	rs35505991	chr7:11969520	T/G	cg15090509	chr7:11872073	THSD7A	0.37	4.53	0.34	1.18e-5	Educational attainment (years of education);
PAAD	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.44	-5.99	-0.44	1.49e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.59	-6.23	-0.45	4.37e-9	Body mass index;
PAAD	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg00864171	chr11:67383662	NA	-0.45	-4.69	-0.36	6.16e-6	Mean corpuscular volume;
PAAD	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg19486271	chr11:47235900	DDB2	-0.53	-5.41	-0.4	2.44e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.73	-0.42	5.15e-8	Coronary artery disease;
PAAD	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.26	-0.45	3.77e-9	IgG glycosylation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10516465	chr14:102695515	RAGE	0.6	7.11	0.5	4.2e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs988913	0.957	rs12525787	chr6:54789072	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg21724239	chr8:58056113	NA	0.72	5.64	0.42	7.99e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16652790	chr16:776895	HAGHL;CCDC78	0.67	7.6	0.52	2.88e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg18005901	chr6:33739558	LEMD2	-0.55	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-1.07	-7.51	-0.52	4.7e-12	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs904092	0.935	rs3133155	chr4:100227212	C/G	cg12011299	chr4:100065546	ADH4	-0.54	-4.58	-0.35	9.66e-6	Alcohol dependence;
PAAD	cis	rs2290416	0.892	rs2278898	chr8:144691512	G/C	cg01494348	chr8:144660395	NAPRT1	0.96	4.64	0.35	7.55e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs8053891	0.507	rs12920844	chr16:72029304	G/A	cg16558253	chr16:72132732	DHX38	-0.44	-4.57	-0.35	1e-5	Coronary artery disease;
PAAD	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.53	6.5	0.47	1.07e-9	Dupuytren's disease;
PAAD	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.89	-9.36	-0.6	1.01e-16	Inhibitory control;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12098015	chr19:38270616	ZNF573	0.61	6.49	0.47	1.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.08	-0.38	1.08e-6	Obesity-related traits;
PAAD	trans	rs901683	0.850	rs17157931	chr10:46054359	T/C	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg00280220	chr17:61926910	NA	0.46	4.77	0.36	4.24e-6	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.62	4.58	0.35	9.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3106136	0.843	rs4282187	chr4:95273145	T/C	cg11021082	chr4:95130006	SMARCAD1	0.6	5.83	0.43	3.21e-8	Capecitabine sensitivity;
PAAD	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg23024343	chr7:107201750	COG5	0.56	4.49	0.34	1.39e-5	Osteoarthritis;
PAAD	cis	rs932143	0.645	rs11179770	chr12:74134612	C/G	cg25356621	chr12:74686282	NA	-0.38	-4.4	-0.34	2.04e-5	Neuroticism;
PAAD	cis	rs11892454	0.515	rs6741640	chr2:26068509	C/T	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	4.39	0.34	2.15e-5	Obesity-related traits;
PAAD	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.99	11.96	0.7	1.21e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs2133450	0.712	rs10510357	chr3:7367528	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs4474465	0.562	rs7130503	chr11:78272226	G/A	cg27205649	chr11:78285834	NARS2	0.66	4.8	0.36	3.79e-6	Alzheimer's disease (survival time);
PAAD	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg21951975	chr1:209979733	IRF6	-0.53	-5.07	-0.38	1.17e-6	Coronary artery disease;
PAAD	cis	rs4646404	0.562	rs4646403	chr17:17420793	C/T	cg07083043	chr17:17397972	RASD1	-0.4	-4.53	-0.35	1.17e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.49	5.12	0.38	9.19e-7	Obesity-related traits;
PAAD	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.44	6.88	0.49	1.48e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1075265	0.729	rs7571086	chr2:54235036	A/C	cg04546899	chr2:54196757	PSME4	0.38	5.61	0.41	9.13e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.74	-5.81	-0.43	3.47e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.54	-5.21	-0.39	6.12e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg05861140	chr6:150128134	PCMT1	-0.54	-6.17	-0.45	5.9e-9	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09049417	chr8:28421125	FZD3	0.54	6.36	0.46	2.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.17	0.39	7.42e-7	Obesity-related traits;
PAAD	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg27411982	chr8:10470053	RP1L1	0.5	5.51	0.41	1.5e-7	Retinal vascular caliber;
PAAD	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.05	-0.44	1.11e-8	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.45	4.94	0.37	2.03e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.71	6.8	0.48	2.2e-10	Obesity-related traits;
PAAD	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.68	-7.49	-0.52	5.18e-12	Alcohol dependence;
PAAD	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.16	-0.6	3.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg13266496	chr6:110720918	DDO	-0.46	-4.9	-0.37	2.39e-6	Platelet distribution width;
PAAD	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.5	-4.28	-0.33	3.3e-5	Extraversion;
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.65	-5.99	-0.44	1.42e-8	Blood metabolite levels;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3106136	0.609	rs12500027	chr4:95107918	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.69	-6.16	-0.45	6.23e-9	Capecitabine sensitivity;
PAAD	cis	rs4711350	0.862	rs597723	chr6:33694079	C/T	cg13859433	chr6:33739653	LEMD2	0.79	5.39	0.4	2.64e-7	Schizophrenia;
PAAD	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.46	5.11	0.38	9.7e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26549601	chr10:134560360	INPP5A	0.51	5.13	0.38	8.9e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.57	-7.68	-0.53	1.78e-12	Renal cell carcinoma;
PAAD	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg15226751	chr1:10001911	LZIC	0.39	4.47	0.34	1.51e-5	Hepatocellular carcinoma;
PAAD	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.57	5.8	0.43	3.81e-8	Schizophrenia;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.88	10.43	0.65	1.52e-19	Menarche (age at onset);
PAAD	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.41	4.3	0.33	3.09e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7873102	0.654	rs7047276	chr9:37962592	C/T	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	8.05e-8	Brain structure;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg21546286	chr11:48923668	NA	0.55	5.71	0.42	5.84e-8	HDL cholesterol;
PAAD	cis	rs17169634	1.000	rs17169630	chr7:34087546	T/G	cg24927974	chr7:35078269	DPY19L1	-0.6	-5.06	-0.38	1.21e-6	Alzheimer's disease;
PAAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.53	4.86	0.37	2.91e-6	Blood metabolite levels;
PAAD	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	1.01	8.39	0.56	3.04e-14	Left atrial antero-posterior diameter;
PAAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.81	9.05	0.59	6.47e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4862307	0.514	rs62340075	chr4:185014889	C/G	cg06737308	chr4:185021514	ENPP6	0.89	10.02	0.63	1.9e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg09163369	chr1:210001066	C1orf107	-0.51	-5.09	-0.38	1.06e-6	Orofacial clefts;
PAAD	cis	rs929596	0.518	rs13401281	chr2:234628679	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-5.99	-0.44	1.46e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs7246865	0.510	rs34833670	chr19:17172983	T/C	cg19418318	chr19:17219073	MYO9B	0.35	5.03	0.38	1.35e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg09760422	chr2:128146352	NA	-0.34	-5.97	-0.44	1.63e-8	Protein C levels;
PAAD	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg01200585	chr1:228362443	C1orf69	0.66	6.82	0.48	2.01e-10	Diastolic blood pressure;
PAAD	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.55	-5.44	-0.4	2.05e-7	Metabolic syndrome;
PAAD	cis	rs7765004	1.000	rs9372374	chr6:114074659	G/A	cg13100190	chr6:114053961	NA	0.35	4.32	0.33	2.84e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.42	4.28	0.33	3.28e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-11.92	-0.7	1.53e-23	Longevity;Endometriosis;
PAAD	cis	rs860295	0.580	rs10908461	chr1:155275727	C/T	cg02153340	chr1:155202674	NA	-0.51	-4.58	-0.35	9.45e-6	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13229655	chr1:10532570	DFFA	0.79	9.08	0.59	5.48e-16	Myopia (pathological);
PAAD	cis	rs6604026	0.616	rs17380789	chr1:93387519	C/T	cg13858687	chr1:93297071	RPL5	0.5	4.56	0.35	1.06e-5	Multiple sclerosis;
PAAD	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.19	16.64	0.8	4.71e-36	Total cholesterol levels;
PAAD	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs4704187	0.687	rs4704176	chr5:74420596	G/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs7809615	0.901	rs10230784	chr7:99113672	G/A	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	6.31	0.46	2.91e-9	Lung cancer in ever smokers;
PAAD	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-1.0	-8.68	-0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.73	5.9	0.43	2.29e-8	Alzheimer's disease;
PAAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.71	-9.47	-0.61	5.17e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2988277	0.713	rs10800313	chr1:167429985	C/T	cg22356347	chr1:167427500	CD247	0.56	6.29	0.45	3.2e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4356203	0.905	rs11024148	chr11:17096059	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.4	-0.34	2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.56	-5.28	-0.39	4.34e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg01689657	chr7:91764605	CYP51A1	0.37	5.3	0.4	3.91e-7	Breast cancer;
PAAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg19131313	chr8:1704013	NA	-0.38	-4.34	-0.33	2.62e-5	Systolic blood pressure;
PAAD	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18355067	chr10:114206661	ZDHHC6;VTI1A	-0.76	-6.55	-0.47	8.37e-10	Neuroticism;
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.73	-7.36	-0.51	1.09e-11	Prostate cancer;
PAAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg07813855	chr1:200183606	FAM58B	0.47	4.53	0.34	1.18e-5	Permanent tooth development;
PAAD	cis	rs9356171	0.540	rs2207441	chr6:164325217	G/A	cg25752492	chr6:164341247	NA	-0.46	-5.01	-0.38	1.5e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg23759393	chr7:158110405	PTPRN2	0.35	4.25	0.33	3.67e-5	Response to amphetamines;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11817309	chr1:249152443	ZNF692	0.59	6.44	0.46	1.46e-9	Myopia (pathological);
PAAD	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.84	9.64	0.62	1.87e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.7	-5.69	-0.42	6.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.52	5.12	0.38	8.97e-7	Parkinson's disease;
PAAD	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.91	-9.41	-0.61	7.64e-17	Parkinson's disease;
PAAD	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.65	-6.44	-0.46	1.45e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs863345	0.604	rs11264997	chr1:158485482	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.76	-6.9	-0.49	1.29e-10	Neuroticism;
PAAD	cis	rs112990264	0.892	rs73079886	chr1:212894357	T/C	cg01785514	chr1:212988523	TATDN3	1.22	8.28	0.56	6.04e-14	Itch intensity from mosquito bite;
PAAD	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs35955747	0.677	rs4820974	chr22:31869467	A/C	cg02404636	chr22:31891804	SFI1	-0.52	-5.22	-0.39	5.75e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09583839	chr1:228297145	MRPL55	0.63	6.33	0.46	2.67e-9	Obesity-related traits;
PAAD	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg10616300	chr11:66138557	SLC29A2	-0.33	-4.47	-0.34	1.52e-5	Educational attainment (years of education);
PAAD	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26306683	chr17:18585705	ZNF286B	0.6	6.02	0.44	1.27e-8	Educational attainment (years of education);
PAAD	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg01494348	chr8:144660395	NAPRT1	0.98	6.95	0.49	9.82e-11	Attention deficit hyperactivity disorder;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08439880	chr3:133502540	NA	-0.5	-5.34	-0.4	3.29e-7	Iron status biomarkers;
PAAD	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg18643199	chr10:82363313	SH2D4B	-0.6	-4.66	-0.35	6.92e-6	Post bronchodilator FEV1;
PAAD	trans	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg17646765	chr4:40631741	RBM47	0.59	6.29	0.45	3.15e-9	IgG glycosylation;
PAAD	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.86	-7.5	-0.52	5.09e-12	Vitiligo;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06287288	chr1:21763415	NA	-0.53	-6.59	-0.47	6.64e-10	Warfarin maintenance dose;
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.61	-6.36	-0.46	2.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg25025879	chr12:53359317	NA	-0.8	-9.03	-0.59	7.36e-16	Prostate cancer;
PAAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-9.31	-0.6	1.36e-16	Cognitive function;
PAAD	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg08390786	chr10:135334061	NA	0.61	5.32	0.4	3.66e-7	Gout;
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.99e-9	Lung cancer;
PAAD	cis	rs2131877	0.956	rs6775431	chr3:194859194	G/T	cg11177333	chr3:195857752	NA	0.45	4.37	0.33	2.3e-5	Non-small cell lung cancer;
PAAD	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg24375607	chr4:120327624	NA	0.6	5.62	0.41	8.9e-8	Corneal astigmatism;
PAAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.09	0.44	8.88e-9	Height;
PAAD	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.18e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.34	0.56	4.11e-14	Mean corpuscular volume;
PAAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg01299579	chr2:10830716	NOL10	0.52	5.37	0.4	2.85e-7	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.56	5.25	0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs2997447	0.761	rs2783622	chr1:26458990	A/T	cg24519413	chr1:26490540	NA	0.55	4.9	0.37	2.38e-6	QRS complex (12-leadsum);
PAAD	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.52	0.47	9.87e-10	Response to antipsychotic treatment;
PAAD	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.97	10.3	0.64	3.43e-19	Platelet distribution width;
PAAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	1.03e-18	Response to antipsychotic treatment;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.79	0.36	3.89e-6	Electroencephalogram traits;
PAAD	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-4.42	-0.34	1.9e-5	Monocyte percentage of white cells;
PAAD	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.37	4.87	0.37	2.72e-6	Calcium levels;
PAAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Vitiligo;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg15193198	chr20:60906057	LAMA5	-0.45	-5.11	-0.38	9.75e-7	Colorectal cancer;
PAAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg10589385	chr1:150898437	SETDB1	0.39	4.63	0.35	7.89e-6	Melanoma;
PAAD	cis	rs4072705	0.557	rs1886124	chr9:127233207	A/G	cg13476313	chr9:127244764	NR5A1	0.33	4.97	0.37	1.81e-6	Menarche (age at onset);
PAAD	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs12304921	1.000	rs58999537	chr12:51357104	A/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs793571	0.822	rs1078001	chr15:59167865	G/A	cg05156742	chr15:59063176	FAM63B	-0.59	-4.84	-0.37	3.15e-6	Schizophrenia;
PAAD	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-4.65	-0.35	7.18e-6	Coronary artery disease;
PAAD	cis	rs4739066	0.579	rs12547848	chr8:63879389	G/A	cg20602954	chr8:63776762	NKAIN3	0.82	5.32	0.4	3.69e-7	Myocardial infarction;
PAAD	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.32	-0.4	3.72e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.59	5.8	0.43	3.79e-8	Tonsillectomy;
PAAD	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg26695010	chr11:65641043	EFEMP2	0.66	6.01	0.44	1.32e-8	DNA methylation (variation);
PAAD	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.78	6.34	0.46	2.45e-9	Gastritis;
PAAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg25452165	chr22:42524984	CYP2D6	0.51	4.64	0.35	7.45e-6	Schizophrenia;
PAAD	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	1.13	12.91	0.72	3.29e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs10186876	0.833	rs7594526	chr2:44173422	T/G	cg09541576	chr2:44873248	C2orf34	-0.47	-4.99	-0.38	1.65e-6	Hand grip strength;
PAAD	cis	rs6466055	0.661	rs17640623	chr7:104913312	G/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12963246	chr6:28129442	ZNF389	0.56	4.43	0.34	1.81e-5	Cardiac Troponin-T levels;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.26	6.15	0.45	6.41e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.01	11.82	0.69	2.83e-23	Breast cancer;
PAAD	cis	rs2070997	0.607	rs2772028	chr9:133707940	C/T	cg11464064	chr9:133710261	ABL1	0.61	4.26	0.33	3.57e-5	Response to amphetamines;
PAAD	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.09	-0.38	1.06e-6	Height;
PAAD	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs758324	0.898	rs10037928	chr5:131142046	T/C	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	4.65	0.35	7.07e-6	Cognitive test performance;
PAAD	cis	rs58521262	0.530	rs289310	chr19:23165414	C/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg15571903	chr15:79123663	NA	0.48	6.27	0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2564921	0.513	rs12638195	chr3:52876639	G/A	cg20626645	chr3:53528846	CACNA1D	-0.5	-4.51	-0.34	1.3e-5	Height;
PAAD	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.69	5.74	0.42	4.93e-8	Common traits (Other);
PAAD	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	0.96	6.31	0.46	2.83e-9	Plateletcrit;
PAAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg06236206	chr7:66120395	NA	-0.54	-4.27	-0.33	3.44e-5	Diabetic kidney disease;
PAAD	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.64	-6.93	-0.49	1.11e-10	Ulcerative colitis;
PAAD	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.69	-6.38	-0.46	1.99e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.21	-0.45	4.86e-9	IgG glycosylation;
PAAD	cis	rs72901758	0.774	rs72901750	chr17:76243453	C/T	cg26068271	chr17:76253126	NA	0.58	5.72	0.42	5.55e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1620921	0.505	rs12214254	chr6:161195932	C/A	cg01280913	chr6:161186852	NA	-0.48	-5.31	-0.4	3.86e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs6074578	0.679	rs6086352	chr20:140695	C/T	cg16931068	chr20:139680	DEFB127	-0.38	-5.19	-0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs1075265	0.704	rs10181999	chr2:54252497	A/C	cg04546899	chr2:54196757	PSME4	0.3	4.36	0.33	2.37e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.17	-0.5	3.07e-11	Response to antipsychotic treatment;
PAAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.3	-4.35	-0.33	2.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg01075559	chr1:2537774	MMEL1	0.5	5.29	0.39	4.16e-7	Ulcerative colitis;
PAAD	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	0.9	6.36	0.46	2.27e-9	Opioid sensitivity;
PAAD	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg20607287	chr7:12443886	VWDE	-0.74	-5.73	-0.42	5.2e-8	Coronary artery disease;
PAAD	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18357526	chr6:26021779	HIST1H4A	0.53	4.64	0.35	7.61e-6	Height;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg27094323	chr7:1216898	NA	-0.56	-6.68	-0.48	4.13e-10	Longevity;Endometriosis;
PAAD	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg23261102	chr5:138775214	DNAJC18	-0.57	-6.41	-0.46	1.71e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg07689907	chr11:61582574	FADS1	0.54	4.9	0.37	2.46e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.6	-0.52	2.88e-12	Mosquito bite size;
PAAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	cis	rs4144743	0.702	rs7208055	chr17:45330827	C/A	cg18085866	chr17:45331354	ITGB3	-0.77	-5.27	-0.39	4.59e-7	Body mass index;
PAAD	cis	rs17162190	0.698	rs4970498	chr1:26844195	G/A	cg17456097	chr1:26900765	RPS6KA1	0.58	4.7	0.36	5.71e-6	Mean corpuscular volume;
PAAD	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.83	-7.64	-0.53	2.3e-12	Neurofibrillary tangles;
PAAD	cis	rs6942407	0.546	rs4728686	chr7:86814784	G/A	cg02420886	chr7:86849541	C7orf23	0.65	5.02	0.38	1.45e-6	Food allergy;
PAAD	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg00262122	chr8:11665843	FDFT1	0.48	4.57	0.35	9.86e-6	Myopia (pathological);
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg14820908	chr5:178986412	RUFY1	0.55	5.44	0.4	2.07e-7	Lung cancer;
PAAD	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.93	-12.69	-0.72	1.3e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg15181151	chr6:150070149	PCMT1	0.57	6.23	0.45	4.28e-9	Lung cancer;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg08888203	chr3:10149979	C3orf24	0.88	7.71	0.53	1.53e-12	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08106708	chr3:118923449	UPK1B	0.61	6.38	0.46	2.05e-9	Smoking initiation;
PAAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.2	0.5	2.53e-11	Rheumatoid arthritis;
PAAD	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	5.95	0.43	1.78e-8	Body mass index (adult);
PAAD	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.01	-0.38	1.49e-6	Height;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg10862848	chr6:42927986	GNMT	-0.53	-8.67	-0.58	6.01e-15	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.65e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.44	4.93	0.37	2.15e-6	Age of smoking initiation;
PAAD	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs7715811	1.000	rs1502052	chr5:13774908	G/A	cg07548982	chr5:13769939	DNAH5	-0.57	-5.46	-0.4	1.9e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs785830	0.558	rs573860	chr9:257034	A/G	cg17093826	chr7:138458720	ATP6V0A4	0.52	6.8	0.48	2.2e-10	Platelet distribution width;
PAAD	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-7.99	-0.54	3.18e-13	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25211013	chr20:19998037	NAA20	0.62	6.71	0.48	3.63e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs901683	0.850	rs12765244	chr10:46032041	A/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11955175	1.000	rs79132719	chr5:40668525	T/C	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.36	0.4	2.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.78	0.36	4.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.1	-0.38	9.81e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg05754148	chr16:3507555	NAT15	0.65	5.02	0.38	1.42e-6	Tuberculosis;
PAAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg25930673	chr12:123319894	HIP1R	1.21	6.08	0.44	9.3e-9	Adiponectin levels;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg10006428	chr1:248814059	OR2T27	0.37	4.45	0.34	1.66e-5	Common traits (Other);
PAAD	cis	rs17209837	1.000	rs59934297	chr7:87116469	T/G	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.07	-0.5	5.32e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs564309	0.867	rs56174824	chr1:228564884	G/A	cg01328119	chr1:228783545	DUSP5P	0.71	4.48	0.34	1.47e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg11650704	chr1:154556575	ADAR	-0.39	-4.28	-0.33	3.34e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs757110	0.524	rs214095	chr11:17293462	T/A	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.73	-0.36	5.19e-6	Type 2 diabetes;
PAAD	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg06713675	chr4:122721982	EXOSC9	-0.71	-5.99	-0.44	1.43e-8	Type 2 diabetes;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg22963979	chr7:1858916	MAD1L1	0.63	6.67	0.48	4.46e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg25233709	chr10:116636983	FAM160B1	0.37	4.54	0.35	1.16e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs607987	0.967	rs605765	chr11:30217503	C/T	cg16820616	chr11:30605581	MPPED2	0.42	4.39	0.34	2.14e-5	Body mass index;
PAAD	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.61	5.63	0.42	8.27e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.68	6.78	0.48	2.55e-10	Obesity-related traits;
PAAD	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg03371404	chr2:241525653	CAPN10	-0.54	-4.93	-0.37	2.17e-6	Bipolar disorder;
PAAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	7.75e-7	Aortic root size;
PAAD	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs6137287	0.813	rs6082353	chr20:21217456	A/C	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35160687	0.644	rs57270703	chr2:86516873	T/C	cg10973622	chr2:86423274	IMMT	-0.45	-4.93	-0.37	2.12e-6	Night sleep phenotypes;
PAAD	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	5.49	0.41	1.68e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3760982	0.776	rs62116991	chr19:44303447	G/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.4	-0.46	1.81e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg15208524	chr1:10270712	KIF1B	0.46	4.26	0.33	3.61e-5	Hepatocellular carcinoma;
PAAD	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.19	-0.45	5.47e-9	Neuroticism;
PAAD	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	0.69	4.7	0.36	5.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.69	6.64	0.47	5.15e-10	Lymphocyte counts;
PAAD	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	5.9	0.43	2.31e-8	Lung cancer in ever smokers;
PAAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.41	-0.34	1.94e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13380717	0.657	rs4335778	chr16:86914742	A/G	cg16630791	chr16:86543538	FOXF1	-0.53	-4.31	-0.33	2.9e-5	Sepsis in extremely premature infants;
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg07689907	chr11:61582574	FADS1	0.55	4.91	0.37	2.37e-6	Bipolar disorder;
PAAD	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.42	-0.34	1.87e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25551661	chr18:11851326	GNAL;CHMP1B	0.77	8.99	0.59	9.03e-16	Myopia (pathological);
PAAD	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.97	-0.44	1.65e-8	Alcohol dependence;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg20003494	chr4:90757398	SNCA	-0.4	-4.45	-0.34	1.64e-5	Dementia with Lewy bodies;
PAAD	cis	rs7243821	0.921	rs62094063	chr18:52629128	T/G	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs17135859	0.715	rs34699212	chr5:113055307	C/T	cg12552261	chr5:112820674	MCC	0.74	4.5	0.34	1.37e-5	F-cell distribution;
PAAD	cis	rs6132905	0.590	rs7271340	chr20:2628109	T/C	cg24848351	chr20:2622020	TMC2	-0.7	-5.32	-0.4	3.73e-7	Mumps;
PAAD	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.52e-6	Height;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg09559163	chr10:130298860	NA	-0.38	-4.55	-0.35	1.1e-5	Vitamin D levels;
PAAD	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21984481	chr17:79567631	NPLOC4	-0.55	-5.8	-0.43	3.66e-8	Myopia;
PAAD	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.77	-0.36	4.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.57	-5.59	-0.41	1.01e-7	Coronary artery disease;
PAAD	cis	rs943466	0.955	rs2894342	chr6:33774394	C/A	cg04704449	chr6:33738291	NA	-0.55	-5.75	-0.42	4.72e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs2514805	0.803	rs2513795	chr8:95133647	C/T	cg25183890	chr8:94929275	PDP1	0.7	4.52	0.34	1.24e-5	Diisocyanate-induced asthma;
PAAD	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs112990264	0.657	rs115121570	chr1:213014308	G/T	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs1144	0.537	rs2470949	chr7:104590780	C/T	cg04380332	chr7:105027541	SRPK2	-0.64	-6.86	-0.49	1.66e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15063753	chr1:145139679	NA	-0.62	-6.36	-0.46	2.26e-9	Smoking initiation;
PAAD	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-6.51	-0.47	1.02e-9	Menarche (age at onset);
PAAD	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs6701037	0.522	rs12094153	chr1:175094025	G/A	cg14847009	chr1:175162515	KIAA0040	-0.28	-4.31	-0.33	2.91e-5	Alcohol dependence;
PAAD	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.35	-0.33	2.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs4272720	0.901	rs72785084	chr10:50359962	G/A	cg15329866	chr3:171455826	PLD1	0.77	6.3	0.46	2.99e-9	Platelet count;Plateletcrit;
PAAD	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.56	-5.72	-0.42	5.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6088813	0.961	rs3795159	chr20:33896262	C/G	cg14752227	chr20:34000481	UQCC	0.51	5.14	0.39	8.2e-7	Height;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.62	5.21	0.39	6.03e-7	Mammographic density (dense area);
PAAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.78	-5.88	-0.43	2.49e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.52	-0.52	4.51e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.6	-5.89	-0.43	2.41e-8	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.14e-18	Electrocardiographic conduction measures;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22249338	chr20:52824393	PFDN4	-0.77	-7.08	-0.5	5.08e-11	Neuroticism;
PAAD	cis	rs7301016	1.000	rs11174495	chr12:62864931	A/G	cg11441379	chr12:63026424	NA	0.85	6.11	0.44	8.06e-9	IgG glycosylation;
PAAD	cis	rs11700980	0.551	rs2832033	chr21:30114841	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26344250	chr1:39336014	MYCBP	0.6	6.38	0.46	2e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs1499972	0.618	rs56255439	chr3:117651366	C/A	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.99	11.62	0.69	9.53e-23	Breast cancer;
PAAD	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs797680	0.856	rs687394	chr1:93713917	G/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.32	-0.33	2.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.7	10.38	0.64	2.07e-19	Breast cancer;
PAAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs11020478	0.681	rs10765623	chr11:93404924	G/A	cg10523193	chr11:93463762	SNORA25	0.43	4.44	0.34	1.71e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.9	10.77	0.66	1.91e-20	Tonsillectomy;
PAAD	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.38	-0.33	2.21e-5	Depression;
PAAD	cis	rs427941	0.575	rs201520	chr7:101770677	G/A	cg06246474	chr7:101738831	CUX1	0.44	4.3	0.33	3.04e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg16341495	chr8:142228727	SLC45A4	-0.49	-4.72	-0.36	5.21e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	1.17	17.85	0.82	3.99e-39	Gut microbiome composition (winter);
PAAD	cis	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.41	4.38	0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs10988449	0.891	rs10988452	chr9:132376859	C/T	cg18327994	chr9:132372705	NA	-0.6	-4.4	-0.34	2.05e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs75757892	0.621	rs111582393	chr6:7291433	C/A	cg02954307	chr6:7269328	NA	0.59	4.56	0.35	1.04e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs12311304	1.000	rs34562067	chr12:15375929	A/G	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.87e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg23034840	chr1:205782522	SLC41A1	0.66	6.58	0.47	7.31e-10	Menarche (age at onset);
PAAD	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg03094675	chr11:5960213	NA	-0.46	-4.31	-0.33	2.88e-5	DNA methylation (variation);
PAAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-6.41	-0.46	1.7e-9	Gut microbiome composition (summer);
PAAD	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.5	-5.04	-0.38	1.3e-6	Visceral fat;
PAAD	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-4.89	-0.37	2.49e-6	Cervical cancer;
PAAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.75	-7.13	-0.5	3.84e-11	Obesity-related traits;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22251879	chr2:242144684	ANO7	0.69	7.16	0.5	3.18e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg03959625	chr15:84868606	LOC388152	0.42	4.3	0.33	3.06e-5	Schizophrenia;
PAAD	cis	rs34421088	0.603	rs10086064	chr8:11583841	A/G	cg00262122	chr8:11665843	FDFT1	0.54	4.78	0.36	4.08e-6	Neuroticism;
PAAD	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	15.98	0.79	2.39e-34	Prudent dietary pattern;
PAAD	cis	rs6074578	0.771	rs964794	chr20:148703	G/A	cg16931068	chr20:139680	DEFB127	0.35	4.57	0.35	1.01e-5	Hirschsprung disease;
PAAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg19636519	chr7:99541626	NA	0.38	4.3	0.33	3.09e-5	Coronary artery disease;
PAAD	cis	rs10170846	0.572	rs12620873	chr2:223419528	A/C	cg25565276	chr2:223520875	FARSB	0.91	8.49	0.57	1.74e-14	Schizophrenia (inflammation and infection response interaction);
PAAD	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.87	10.48	0.65	1.13e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.94	7.79	0.53	9.74e-13	Eotaxin levels;
PAAD	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.62	-6.43	-0.46	1.53e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12714314	0.681	rs4853753	chr2:1941381	T/C	cg22350835	chr2:1868857	MYT1L	0.5	4.78	0.36	4.08e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-4.55	-0.35	1.09e-5	Metabolite levels;
PAAD	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg05925327	chr15:68127851	NA	-0.54	-4.98	-0.37	1.72e-6	Obesity;
PAAD	cis	rs7532866	0.848	rs12401866	chr1:26726967	C/G	cg17456097	chr1:26900765	RPS6KA1	-0.53	-4.61	-0.35	8.55e-6	Height;
PAAD	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.47	-4.85	-0.37	3.09e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs11853189	0.938	rs77056929	chr15:78588517	A/G	cg22935921	chr15:78556834	DNAJA4	0.76	5.14	0.39	8.2e-7	Red cell distribution width;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07384136	chr5:1115158	NA	0.63	6.82	0.48	1.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg00531865	chr16:30841666	NA	-0.52	-5.08	-0.38	1.09e-6	Dementia with Lewy bodies;
PAAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.38	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.71	7.65	0.53	2.18e-12	Mean corpuscular volume;
PAAD	cis	rs6710503	0.574	rs749046	chr2:24815624	A/G	cg21151432	chr2:25142229	ADCY3	-0.37	-4.41	-0.34	1.98e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg03233332	chr7:66118400	NA	0.4	4.3	0.33	3.09e-5	Aortic root size;
PAAD	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg02795151	chr17:7402630	POLR2A	0.58	5.34	0.4	3.35e-7	Androgen levels;
PAAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs4740619	0.619	rs1410454	chr9:16042193	C/A	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.84	-0.49	1.81e-10	Schizophrenia;
PAAD	cis	rs2031532	0.524	rs2057414	chr13:50057287	C/T	cg08779649	chr13:50194554	NA	-0.34	-4.58	-0.35	9.52e-6	Cardiac hypertrophy;
PAAD	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.8	-8.53	-0.57	1.34e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.48	0.52	5.62e-12	Hemoglobin concentration;
PAAD	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.49	-4.5	-0.34	1.36e-5	Tonsillectomy;
PAAD	cis	rs12098973	0.591	rs80169597	chr11:131799759	G/A	cg13055484	chr11:132662455	OPCML	0.52	4.38	0.34	2.16e-5	Cardiac Troponin-T levels;
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.41	5.12	0.38	9.1e-7	Pulmonary function;
PAAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg22134325	chr11:66188745	NPAS4	0.31	4.68	0.35	6.31e-6	Airway imaging phenotypes;
PAAD	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg25902810	chr10:99078978	FRAT1	-0.6	-5.44	-0.4	2.08e-7	Monocyte count;
PAAD	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.65	6.97	0.49	8.89e-11	Alcohol dependence;
PAAD	cis	rs9649465	0.935	rs3815458	chr7:123304323	A/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7591163	1.000	rs6436741	chr2:228714598	G/A	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25632853	chr15:73088954	NA	0.4	4.55	0.35	1.09e-5	Triglyceride levels;
PAAD	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg09654669	chr8:57350985	NA	-0.52	-4.81	-0.36	3.64e-6	Obesity-related traits;
PAAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg10556349	chr10:835070	NA	0.63	4.43	0.34	1.82e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs1045902	0.532	rs10185579	chr2:73456342	C/T	cg24220031	chr2:73402428	NA	-0.32	-4.31	-0.33	2.96e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02244288	chr16:89573955	SPG7	-0.33	-4.37	-0.33	2.29e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.56	-5.91	-0.43	2.19e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18357526	chr6:26021779	HIST1H4A	0.64	5.93	0.43	1.98e-8	Blood metabolite levels;
PAAD	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.7	6.56	0.47	7.93e-10	Uric acid levels;
PAAD	cis	rs10450586	0.932	rs10767630	chr11:27314069	A/T	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs6466055	0.661	rs6967753	chr7:104787971	T/C	cg04380332	chr7:105027541	SRPK2	0.49	4.76	0.36	4.47e-6	Schizophrenia;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.87	0.49	1.51e-10	Renal function-related traits (BUN);
PAAD	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-5.8	-0.43	3.64e-8	Blood pressure (smoking interaction);
PAAD	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg15733309	chr7:157513707	PTPRN2	0.6	7.49	0.52	5.22e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs329648	1.000	rs329648	chr11:133765367	A/G	cg12362517	chr11:133800685	IGSF9B	0.54	5.61	0.41	9.41e-8	Parkinson's disease;
PAAD	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg25401027	chr5:176370377	UIMC1	0.53	5.24	0.39	5.17e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.54	-5.49	-0.41	1.64e-7	Menarche (age at onset);
PAAD	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg09163369	chr1:210001066	C1orf107	0.59	6.29	0.45	3.19e-9	Orofacial clefts;
PAAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18490616	chr2:88469792	THNSL2	-0.48	-4.51	-0.34	1.29e-5	Response to metformin (IC50);
PAAD	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-12.49	-0.71	4.31e-25	Myeloid white cell count;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.44	4.92	0.37	2.27e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.59	6.89	0.49	1.39e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	1.11	9.39	0.61	8.45e-17	Red blood cell traits;
PAAD	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg02264943	chr11:130785842	SNX19	0.38	4.37	0.33	2.26e-5	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.11e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	1.14	16.73	0.81	2.73e-36	Breast cancer;
PAAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.85	4.29	0.33	3.12e-5	Plasma clusterin levels;
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.5e-8	Life satisfaction;
PAAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg08179530	chr6:36648295	CDKN1A	0.59	4.49	0.34	1.41e-5	QRS duration;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5753037	0.653	rs140129	chr22:30150549	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.7	-0.36	5.72e-6	Type 1 diabetes;
PAAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg17366294	chr4:99064904	C4orf37	-0.55	-5.89	-0.43	2.4e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.8	-5.03	-0.38	1.39e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2885056	1.000	rs2885056	chr19:10693628	C/A	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs9463078	0.770	rs9296453	chr6:45227432	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.48	-0.41	1.72e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg03022575	chr3:42003672	ULK4	0.78	5.47	0.41	1.81e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6141769	0.542	rs28456308	chr20:31273747	C/T	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.67	-0.35	6.51e-6	Subjective well-being;
PAAD	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg08648136	chr8:956695	NA	0.41	4.38	0.33	2.2e-5	Schizophrenia;
PAAD	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg15507776	chr3:136538369	TMEM22	-0.47	-4.61	-0.35	8.63e-6	Neuroticism;
PAAD	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg27236539	chr20:62289627	RTEL1	0.58	4.69	0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.97e-6	Mononucleosis;
PAAD	cis	rs362296	0.671	rs1006798	chr4:3258373	A/G	cg08886695	chr4:3369023	RGS12	0.53	4.97	0.37	1.8e-6	Parental longevity (mother's age at death);
PAAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	1.07	14.87	0.77	1.86e-31	Breast cancer;
PAAD	cis	rs896623	0.597	rs6856825	chr4:122065557	T/G	cg19463078	chr4:122099598	TNIP3	-0.49	-4.32	-0.33	2.83e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs11168618	0.740	rs10875826	chr12:48921160	C/T	cg01881778	chr12:48919444	OR8S1	-0.52	-5.59	-0.41	1.05e-7	Adiponectin levels;
PAAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-4.89	-0.37	2.53e-6	Personality dimensions;
PAAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg22981736	chr15:31284413	MTMR10	-0.48	-4.42	-0.34	1.84e-5	Huntington's disease progression;
PAAD	cis	rs6987853	0.563	rs7004796	chr8:42450170	T/G	cg09913449	chr8:42400586	C8orf40	0.51	5.73	0.42	5.17e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	6.55	0.47	8.4e-10	Height;
PAAD	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1012068	0.541	rs11703587	chr22:32322414	A/C	cg01338084	chr22:32026380	PISD	0.54	4.48	0.34	1.44e-5	Chronic hepatitis C infection;
PAAD	cis	rs375066	0.935	rs108775	chr19:44405922	G/C	cg21496419	chr19:44306685	LYPD5	0.42	5.18	0.39	7.05e-7	Breast cancer;
PAAD	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg15309053	chr8:964076	NA	0.44	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.93	-8.75	-0.58	3.72e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06850241	chr22:41845214	NA	-0.55	-5.06	-0.38	1.2e-6	Vitiligo;
PAAD	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	cis	rs7561273	0.722	rs12713161	chr2:24280682	T/C	cg04809136	chr2:24300158	SF3B14	-0.44	-5.05	-0.38	1.24e-6	Quantitative traits;
PAAD	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg20913747	chr6:44695427	NA	0.64	6.24	0.45	4.09e-9	Total body bone mineral density;
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.78	10.97	0.66	5.53e-21	Psoriasis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05464172	chr8:97247954	UQCRB	0.58	6.35	0.46	2.34e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2229238	0.911	rs57783436	chr1:154511709	A/G	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg01851573	chr8:8652454	MFHAS1	0.63	5.11	0.38	9.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6066835	0.867	rs6095277	chr20:47363257	A/G	cg18078177	chr20:47281410	PREX1	-0.89	-4.35	-0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24031277	chr7:33102336	NT5C3	0.6	6.43	0.46	1.54e-9	Myopia (pathological);
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs8112211	0.689	rs4802326	chr19:38793227	C/T	cg14299480	chr19:38876666	GGN	-0.5	-4.27	-0.33	3.46e-5	Blood protein levels;
PAAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14119001	chr9:139324193	INPP5E	-0.61	-5.49	-0.41	1.68e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2997447	0.723	rs2802336	chr1:26473758	A/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.87e-6	QRS complex (12-leadsum);
PAAD	cis	rs6496932	0.802	rs67928464	chr15:85881766	C/G	cg19183879	chr15:85880815	NA	0.52	4.67	0.35	6.54e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg17541715	chr7:1216824	NA	-0.39	-4.34	-0.33	2.6e-5	Longevity;Endometriosis;
PAAD	cis	rs9397240	1.000	rs9397240	chr6:155648579	C/G	cg06694381	chr6:155569200	TIAM2	0.49	4.47	0.34	1.5e-5	Life satisfaction;
PAAD	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.58	5.67	0.42	6.98e-8	Cognitive test performance;
PAAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17647095	chr5:150603697	CCDC69	0.66	7.64	0.53	2.32e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7554547	0.755	rs6662295	chr1:11967905	G/C	cg07603449	chr1:11986842	KIAA2013	-0.37	-5.83	-0.43	3.26e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg09659197	chr4:152720779	NA	-0.36	-5.29	-0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12042107	0.818	rs6428600	chr1:91192297	C/G	cg13456504	chr1:91191583	NA	0.45	4.9	0.37	2.38e-6	Educational attainment;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.96	6.58	0.47	7.05e-10	Eosinophilic esophagitis;
PAAD	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.63	-6.31	-0.46	2.89e-9	Systemic sclerosis;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg24004447	chr1:52883346	PRPF38A	-0.52	-6.59	-0.47	6.75e-10	Energy expenditure (24h);
PAAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs4705952	0.832	rs2706390	chr5:131842280	C/A	cg05209330	chr5:131550942	P4HA2	0.52	4.28	0.33	3.29e-5	C-reactive protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16535332	chr7:17338557	AHR	0.6	6.39	0.46	1.88e-9	Myopia (pathological);
PAAD	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.88	10.11	0.63	1.07e-18	Schizophrenia;
PAAD	cis	rs3136739	0.681	rs35416565	chr8:42000350	G/A	cg17828057	chr8:42037527	PLAT	0.62	4.27	0.33	3.41e-5	Plasma plasminogen activator levels;
PAAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.78	0.36	4.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.87	7.77	0.53	1.11e-12	Migraine;Coronary artery disease;
PAAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.66	6.86	0.49	1.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg14329783	chr7:75779857	NA	0.79	4.72	0.36	5.35e-6	Mononucleosis;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	1.05	7.08	0.5	5.1e-11	IgG glycosylation;
PAAD	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.78e-7	Motion sickness;
PAAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01200585	chr1:228362443	C1orf69	-0.52	-5.81	-0.43	3.48e-8	Diastolic blood pressure;
PAAD	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	6.61	0.47	6.2e-10	Gastritis;
PAAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.58	-7.21	-0.51	2.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05778739	chr2:96676295	LOC729234	0.63	6.96	0.49	9.42e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs78761021	0.898	rs17810279	chr17:9774057	T/G	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg10556349	chr10:835070	NA	0.52	4.31	0.33	2.92e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg26816564	chr1:7831052	VAMP3	0.62	4.84	0.37	3.22e-6	Inflammatory bowel disease;
PAAD	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg18939081	chr1:31884902	SERINC2	0.47	5.32	0.4	3.57e-7	Alcohol dependence;
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg21890820	chr11:65308645	LTBP3	1.45	9.21	0.6	2.52e-16	Height;
PAAD	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.37	0.46	2.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg13512537	chr8:22265999	SLC39A14	-0.42	-4.33	-0.33	2.69e-5	Verbal declarative memory;
PAAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg22532475	chr10:104410764	TRIM8	-0.39	-4.65	-0.35	7.19e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.59	6.35	0.46	2.4e-9	Tonsillectomy;
PAAD	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.79	-7.86	-0.54	6.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg02475695	chr16:616220	NHLRC4	0.47	5.5	0.41	1.56e-7	Height;
PAAD	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.34	-0.33	2.55e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1;
PAAD	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.86	-6.65	-0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.86	0.37	2.89e-6	Oropharynx cancer;
PAAD	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.12e-6	Cognitive function;
PAAD	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.54	-4.92	-0.37	2.18e-6	Menopause (age at onset);
PAAD	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.69	6.8	0.48	2.26e-10	Depressive symptoms;
PAAD	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg23306229	chr2:178417860	TTC30B	0.62	4.41	0.34	1.96e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs151997	0.509	rs11744954	chr5:50296729	A/G	cg06027927	chr5:50259733	NA	-0.79	-6.69	-0.48	4.12e-10	Callous-unemotional behaviour;
PAAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.58	5.84	0.43	3.09e-8	Mean corpuscular volume;
PAAD	cis	rs3787159	0.573	rs527991	chr20:56911344	G/A	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.1e-5	Systolic blood pressure;
PAAD	cis	rs10267417	0.603	rs10215844	chr7:19909227	T/C	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.41	-5.17	-0.39	7.42e-7	Pulmonary function;
PAAD	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-9.25	-0.6	1.93e-16	Height;
PAAD	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.49	5.12	0.38	9.07e-7	Type 2 diabetes;
PAAD	cis	rs11048434	0.518	rs34533518	chr12:9177898	T/C	cg04548204	chr12:9162872	KLRG1	0.39	4.38	0.33	2.23e-5	Sjögren's syndrome;
PAAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-5.24	-0.39	5.23e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg19623624	chr10:135278901	LOC619207	-0.42	-5.09	-0.38	1.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.81	-0.36	3.61e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs6076960	0.684	rs6054041	chr20:6247288	C/T	cg21095983	chr6:86352623	SYNCRIP	0.67	6.53	0.47	9.26e-10	Smooth-surface caries;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.67	-6.12	-0.44	7.71e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-5.2	-0.39	6.27e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2019216	0.570	rs908996	chr17:22005671	A/G	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.25	-0.33	3.76e-5	Pelvic organ prolapse;
PAAD	cis	rs427941	0.703	rs1734879	chr7:101740610	C/A	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	1.02	8.72	0.58	4.5e-15	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg23682824	chr7:23144976	KLHL7	-0.5	-4.43	-0.34	1.79e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.62	-4.79	-0.36	3.95e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs900145	0.906	rs11022735	chr11:13292727	A/C	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg11143131	chr5:131608246	PDLIM4	0.48	4.74	0.36	4.95e-6	Blood metabolite levels;
PAAD	cis	rs9907295	0.818	rs2280789	chr17:34207003	A/G	cg16983627	chr17:34238386	NA	-0.54	-4.28	-0.33	3.31e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.77	-5.59	-0.41	1.01e-7	Vitiligo;
PAAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg03808351	chr9:123631620	PHF19	0.44	4.75	0.36	4.76e-6	Rheumatoid arthritis;
PAAD	cis	rs863345	0.604	rs11265003	chr1:158490631	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg03037974	chr15:76606532	NA	0.5	5.73	0.42	5.14e-8	Blood metabolite levels;
PAAD	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg20607287	chr7:12443886	VWDE	-0.82	-5.15	-0.39	7.89e-7	Coronary artery disease;
PAAD	cis	rs6074578	0.516	rs751596	chr20:151330	T/C	cg16931068	chr20:139680	DEFB127	-0.42	-5.6	-0.41	9.67e-8	Hirschsprung disease;
PAAD	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	13.32	0.73	2.51e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg05627522	chr15:75251581	NA	0.47	5.8	0.43	3.71e-8	Breast cancer;
PAAD	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.23e-14	Colorectal cancer;
PAAD	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.72	-7.58	-0.52	3.13e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg15212455	chr7:39170539	POU6F2	0.36	5.33	0.4	3.56e-7	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg16928487	chr17:17741425	SREBF1	0.35	4.64	0.35	7.45e-6	Total body bone mineral density;
PAAD	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg02353165	chr6:42928485	GNMT	0.6	5.03	0.38	1.38e-6	Blood protein levels;
PAAD	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.76	0.53	1.15e-12	Coronary artery disease;
PAAD	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.78	8.41	0.56	2.8e-14	Calcium levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06538998	chr16:28503160	CLN3	0.61	6.29	0.45	3.14e-9	Myopia (pathological);
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.64	5.4	0.4	2.49e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9788721	0.504	rs12899135	chr15:78954379	A/G	cg00540400	chr15:79124168	NA	-0.46	-5.11	-0.38	9.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7123876	0.587	rs55765314	chr11:72360935	C/A	cg03713592	chr11:72463424	ARAP1	0.64	4.3	0.33	3e-5	Body mass index;
PAAD	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22987188	chr3:101559865	NFKBIZ	-0.6	-6.41	-0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs35883536	1.000	rs6681906	chr1:101086414	C/T	cg14515779	chr1:101123966	NA	-0.52	-6.28	-0.45	3.3e-9	Monocyte count;
PAAD	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg00631329	chr6:26305371	NA	-0.49	-4.94	-0.37	2.07e-6	Educational attainment;
PAAD	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.64	-0.35	7.45e-6	Resting heart rate;
PAAD	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.43	4.67	0.35	6.44e-6	Post-traumatic stress disorder;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg20982606	chr12:109535391	UNG	0.68	6.94	0.49	1.08e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg23024343	chr7:107201750	COG5	0.57	4.8	0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.61	5.88	0.43	2.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6815814	0.861	rs4833095	chr4:38799710	T/C	cg02016764	chr4:38805732	TLR1	-0.53	-4.28	-0.33	3.36e-5	Breast cancer;
PAAD	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-5.55	-0.41	1.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.95	0.43	1.82e-8	Eosinophil percentage of white cells;
PAAD	cis	rs13065560	0.659	rs6776510	chr3:38887253	C/T	cg01426195	chr3:39028469	NA	-0.5	-5.19	-0.39	6.76e-7	Interleukin-18 levels;
PAAD	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-5.39	-0.4	2.6e-7	Schizophrenia;
PAAD	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.57	5.53	0.41	1.39e-7	Osteoporosis;
PAAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.52	-5.44	-0.4	2.12e-7	Major depressive disorder;
PAAD	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	6.28	0.45	3.37e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg26554054	chr8:600488	NA	0.91	6.0	0.44	1.4e-8	IgG glycosylation;
PAAD	cis	rs354033	1.000	rs354042	chr7:149297104	A/G	cg06920324	chr7:149264011	ZNF767	-0.61	-5.06	-0.38	1.17e-6	Multiple sclerosis;
PAAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg17328665	chr1:7887199	PER3	0.48	4.57	0.35	9.97e-6	Crohn's disease;
PAAD	cis	rs72960926	0.744	rs7755776	chr6:74967405	C/G	cg03266952	chr6:74778945	NA	1.14	6.54	0.47	8.82e-10	Metabolite levels (MHPG);
PAAD	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.58	0.47	7.06e-10	Hip circumference;
PAAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg02117656	chr17:79614917	TSPAN10	-0.59	-6.46	-0.46	1.37e-9	Eye color traits;
PAAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.62	8.42	0.56	2.62e-14	Renal cell carcinoma;
PAAD	cis	rs9635231	1	rs9635231	chr14:55887703	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.37	-0.33	2.31e-5	Pediatric bone mineral density (femoral neck);
PAAD	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg00750074	chr16:89608354	SPG7	-0.49	-4.57	-0.35	9.9e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg21869046	chr19:41225005	ITPKC	0.5	5.18	0.39	6.9e-7	Kawasaki disease;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg08888203	chr3:10149979	C3orf24	0.68	6.22	0.45	4.5e-9	Alzheimer's disease;
PAAD	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.27	0.33	3.46e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.98	12.41	0.71	7.11e-25	Bone mineral density;
PAAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg23033748	chr14:75592666	NEK9	0.42	4.97	0.37	1.82e-6	Height;
PAAD	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.77	6.2	0.45	5.12e-9	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-4.29	-0.33	3.11e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg00166722	chr3:10149974	C3orf24	0.71	6.36	0.46	2.29e-9	Alzheimer's disease;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.76	7.65	0.53	2.19e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg21770322	chr7:97807741	LMTK2	0.37	4.34	0.33	2.55e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4908760	0.965	rs10864353	chr1:8549716	A/G	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Vitiligo;
PAAD	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-5.24	-0.39	5.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.49e-7	Subjective well-being;
PAAD	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.7	-0.8	3.19e-36	Height;
PAAD	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg00864171	chr11:67383662	NA	-0.48	-5.11	-0.38	9.42e-7	Mean corpuscular volume;
PAAD	cis	rs4378999	0.623	rs6796642	chr3:51091392	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.55	-4.31	-0.33	2.9e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4731207	0.596	rs2170351	chr7:124642197	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.51	-0.34	1.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.93	4.86	0.37	2.83e-6	Plasma clusterin levels;
PAAD	trans	rs901683	1.000	rs34268168	chr10:45988526	G/A	cg14076390	chr17:34947837	DHRS11	0.92	6.81	0.48	2.15e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.67	4.67	0.35	6.46e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.4	0.64	1.83e-19	Menopause (age at onset);
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.17	-0.39	7.24e-7	Mood instability;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6867913	0.556	rs75041269	chr5:141464114	G/A	cg23435118	chr5:141488016	NDFIP1	0.52	4.51	0.34	1.27e-5	Asthma;
PAAD	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-5.04	-0.38	1.3e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.61	-5.4	-0.4	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg09021430	chr5:549028	NA	-0.85	-6.29	-0.45	3.29e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg03684893	chr10:554711	DIP2C	0.54	5.18	0.39	6.83e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg25922125	chr7:127225783	GCC1	0.68	4.93	0.37	2.11e-6	Type 2 diabetes;
PAAD	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.51	4.9	0.37	2.44e-6	Breast cancer;
PAAD	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.84	-7.43	-0.52	7.17e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs9535307	0.929	rs6561552	chr13:50260905	A/G	cg03658251	chr13:50265850	EBPL	0.78	5.51	0.41	1.51e-7	Obesity-related traits;
PAAD	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.78	-0.36	4.17e-6	Menopause (age at onset);
PAAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.09	0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.83	-0.36	3.37e-6	Mood instability;
PAAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.36	-0.4	3.05e-7	Neuroticism;
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-8.34	-0.56	4.16e-14	Platelet distribution width;
PAAD	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.3	0.33	3.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02072899	chr5:865605	BRD9	0.64	7.09	0.5	4.67e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.58	-0.35	9.6e-6	IgG glycosylation;
PAAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs16910800	1.000	rs2468655	chr11:23197060	G/A	cg20040320	chr11:23191996	NA	0.57	4.81	0.36	3.66e-6	Cancer;
PAAD	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.23	-0.7	2.18e-24	Urate levels in overweight individuals;
PAAD	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.93	13.03	0.73	1.53e-26	Height;
PAAD	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.61	-4.4	-0.34	2.02e-5	Inhibitory control;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12372477	chr20:57465915	GNAS	0.57	6.32	0.46	2.69e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2147959	0.941	rs12131962	chr1:228631641	G/A	cg00655913	chr1:228633920	NA	0.49	4.56	0.35	1.06e-5	Adult asthma;
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.39	4.42	0.34	1.84e-5	High light scatter reticulocyte count;
PAAD	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7646881	0.812	rs79303235	chr3:158444793	C/T	cg19483011	chr3:158453295	NA	-0.71	-5.92	-0.43	2.03e-8	Tetralogy of Fallot;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg26939375	chr7:64535504	NA	0.7	8.03	0.55	2.45e-13	Calcium levels;
PAAD	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.82	-8.84	-0.58	2.2e-15	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7091957	0.875	rs4880419	chr10:134456109	C/T	cg04522676	chr10:134968826	NA	-0.43	-4.64	-0.35	7.47e-6	Gait speed in old age;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26058965	chr1:28559558	DNAJC8	-0.71	-7.19	-0.5	2.81e-11	Lung cancer in ever smokers;
PAAD	cis	rs6460942	0.597	rs4721108	chr7:12535247	C/T	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs1912528	0.783	rs6536588	chr4:140862671	C/T	cg11128457	chr4:140864437	MAML3	-0.32	-4.31	-0.33	2.95e-5	Educational attainment (years of education);
PAAD	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg21573476	chr21:45109991	RRP1B	0.65	5.72	0.42	5.4e-8	Mean corpuscular volume;
PAAD	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.66	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg15847926	chr7:2749597	AMZ1	-0.39	-4.74	-0.36	4.92e-6	Height;
PAAD	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.55	-0.35	1.08e-5	Height;
PAAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.63	7.16	0.5	3.18e-11	Emphysema distribution in smoking;
PAAD	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.0	-0.38	1.55e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9815354	1.000	rs6763829	chr3:41897046	A/G	cg03022575	chr3:42003672	ULK4	0.84	6.12	0.44	7.66e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2421770	0.532	rs7119430	chr11:35345085	C/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.31	0.64	3.18e-19	White blood cell count;
PAAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.77	8.57	0.57	1.06e-14	Total body bone mineral density;
PAAD	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.46	-0.34	1.61e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	1.03	8.0	0.54	2.98e-13	IgG glycosylation;
PAAD	cis	rs116248771	0.739	rs2291595	chr3:158378847	A/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.17	8.12	0.55	1.48e-13	Schizophrenia;
PAAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs11235843	0.929	rs11235864	chr11:73408272	A/G	cg18195628	chr11:73498948	MRPL48	-0.78	-4.29	-0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs955333	0.540	rs62434185	chr6:154889016	T/G	cg20019720	chr6:154832845	CNKSR3	0.47	5.44	0.4	2.11e-7	Diabetic kidney disease;
PAAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.34	-0.33	2.56e-5	Initial pursuit acceleration;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs4073221	0.860	rs13071572	chr3:18259222	G/T	cg07694806	chr3:18168406	NA	-0.76	-5.04	-0.38	1.28e-6	Parkinson's disease;
PAAD	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.82	6.82	0.48	2.03e-10	Pulmonary function decline;
PAAD	cis	rs9346353	0.815	rs3799113	chr6:70439471	C/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.47	-0.34	1.51e-5	Sleep duration;
PAAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.55	-5.64	-0.42	7.94e-8	Monocyte count;
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.52	-6.61	-0.47	6.08e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.18	-0.55	1.07e-13	Response to antipsychotic treatment;
PAAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg01102307	chr1:9340416	NA	-0.42	-4.38	-0.33	2.19e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6907629	0.704	rs879840	chr6:167558739	C/T	cg13805183	chr6:167554790	NA	-0.32	-4.85	-0.37	3.01e-6	Asthma (childhood onset);
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.73	8.2	0.55	9.3e-14	Height;
PAAD	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.85	0.43	2.9e-8	Eosinophil percentage of white cells;
PAAD	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.53	5.69	0.42	6.49e-8	Major depressive disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24085468	chr7:76009472	NA	-0.75	-6.36	-0.46	2.28e-9	Neuroticism;
PAAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.49	0.41	1.65e-7	Tonsillectomy;
PAAD	cis	rs427941	0.703	rs201452	chr7:101739663	C/T	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-4.55	-0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.84	11.07	0.67	2.89e-21	Vitiligo;
PAAD	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.45	5.12	0.38	9.19e-7	Testicular germ cell tumor;
PAAD	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	1.03	7.25	0.51	2e-11	Alzheimer's disease;
PAAD	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.05e-6	Resting heart rate;
PAAD	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.66	7.82	0.54	8.17e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs7213347	0.581	rs7209460	chr17:2048713	C/T	cg15816464	chr17:2026533	SMG6	0.52	5.72	0.42	5.47e-8	Total body bone mineral density;
PAAD	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.55	5.4	0.4	2.49e-7	Type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.46	-0.4	1.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17332484	chr14:24811893	NA	0.62	6.51	0.47	1.02e-9	Smoking initiation;
PAAD	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.56	-4.87	-0.37	2.8e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg04673462	chr1:38461896	NA	-0.38	-4.75	-0.36	4.73e-6	Coronary artery disease;
PAAD	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs3736485	0.966	rs4144941	chr15:51796806	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.26	-0.33	3.52e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs66731853	0.557	rs477190	chr1:20898514	C/A	cg24502330	chr1:20914028	CDA	0.35	4.38	0.33	2.2e-5	Mean corpuscular volume;
PAAD	cis	rs1372356	0.816	rs4904421	chr14:88538685	C/T	cg18078958	chr14:88630771	NA	0.5	6.33	0.46	2.6e-9	Food antigen IgG levels;
PAAD	cis	rs1903068	0.785	rs28584303	chr4:55997622	C/T	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.71e-5	Endometriosis;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg18209359	chr17:80159595	CCDC57	0.46	4.69	0.36	6.01e-6	Life satisfaction;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg24705254	chr5:96098115	CAST;ERAP1	-0.57	-6.48	-0.47	1.21e-9	Energy expenditure (24h);
PAAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.91	9.63	0.62	2.01e-17	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.65	-6.19	-0.45	5.37e-9	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	4.95e-8	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg16147221	chr4:10020634	SLC2A9	-0.48	-4.31	-0.33	2.97e-5	Bone mineral density;
PAAD	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.65	-0.35	7.23e-6	Testicular germ cell tumor;
PAAD	cis	rs5742933	0.652	rs10210345	chr2:190619486	G/C	cg04003228	chr2:190539410	ANKAR	-0.52	-4.32	-0.33	2.83e-5	Ferritin levels;
PAAD	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	0.94	6.01	0.44	1.32e-8	Crohn's disease;
PAAD	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs1716692	chr3:41983786	G/A	cg03022575	chr3:42003672	ULK4	-0.85	-5.94	-0.43	1.82e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.45	-0.34	1.64e-5	Mean platelet volume;
PAAD	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	1.11	12.19	0.7	2.89e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs4074493	1.000	rs10864655	chr1:231172810	A/G	cg22172038	chr1:231176991	FAM89A	0.51	4.73	0.36	5.15e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs939584	1.000	rs7571970	chr2:646849	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg15654264	chr1:150340011	RPRD2	-0.5	-4.85	-0.37	2.99e-6	Migraine;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.95	11.6	0.69	1.1e-22	Longevity;
PAAD	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.5	-0.34	1.34e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs62408225	1.000	rs11752685	chr6:90966415	A/C	cg03795776	chr6:90687632	BACH2	0.43	4.29	0.33	3.23e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.84	-0.48	1.85e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.98	10.49	0.65	1.06e-19	Corneal astigmatism;
PAAD	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.78	0.53	1.03e-12	Coronary artery disease;
PAAD	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-7.97	-0.54	3.42e-13	Brugada syndrome;
PAAD	cis	rs11723261	0.545	rs6812799	chr4:197334	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	0.46	4.26	0.33	3.53e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.52	-5.02	-0.38	1.45e-6	Migraine;
PAAD	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24364908	chr17:34897161	NA	0.62	6.36	0.46	2.22e-9	Smoking initiation;
PAAD	cis	rs2717559	0.541	rs34497317	chr8:143889053	T/A	cg02415014	chr8:143852576	LYNX1	0.42	5.46	0.4	1.89e-7	Urinary tract infection frequency;
PAAD	cis	rs2080501	0.601	rs12919799	chr16:49668955	C/T	cg27618369	chr16:49636483	ZNF423	-0.53	-5.66	-0.42	7.26e-8	IgG glycosylation;
PAAD	cis	rs2562456	0.754	rs112195516	chr19:21593651	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.59	0.35	9.36e-6	Eosinophil percentage of white cells;
PAAD	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.87	-9.57	-0.61	2.9e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.7	0.48	3.83e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg03098721	chr1:84464084	TTLL7	0.46	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg23352942	chr3:46931381	PTH1R	-0.61	-6.82	-0.48	2.04e-10	Birth weight;
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs55692468	0.771	rs6744391	chr2:153334614	T/C	cg24749089	chr2:153322823	FMNL2	0.27	4.46	0.34	1.6e-5	Intraocular pressure;
PAAD	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg19254793	chr6:44695348	NA	-0.45	-4.36	-0.33	2.42e-5	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.43e-7	Psoriasis vulgaris;Psoriasis;
PAAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.87	-10.06	-0.63	1.45e-18	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-5.14	-0.38	8.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.72	-8.23	-0.56	7.93e-14	Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05063616	chr17:42147940	G6PC3	0.59	6.57	0.47	7.61e-10	Monocyte percentage of white cells;
PAAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs12780845	0.931	rs2884039	chr10:17252241	T/C	cg00857480	chr10:17188594	TRDMT1	0.34	4.3	0.33	3.09e-5	Homocysteine levels;
PAAD	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.82	-9.69	-0.62	1.38e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg21452805	chr1:244014465	NA	0.59	5.1	0.38	9.85e-7	RR interval (heart rate);
PAAD	cis	rs12144049	0.662	rs1923500	chr1:152413025	G/A	cg25605289	chr1:151974222	NA	-0.34	-4.37	-0.33	2.33e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-5.97	-0.44	1.63e-8	Crohn's disease;
PAAD	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg10978503	chr1:24200527	CNR2	-0.39	-4.47	-0.34	1.5e-5	Immature fraction of reticulocytes;
PAAD	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg23018236	chr17:30244563	NA	-0.63	-5.44	-0.4	2.13e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13658921	chr2:136499517	UBXN4	0.63	6.44	0.46	1.52e-9	Myopia (pathological);
PAAD	cis	rs76917914	0.820	rs7846880	chr9:100822940	G/A	cg21225548	chr9:100864335	TRIM14	-0.55	-5.86	-0.43	2.82e-8	Immature fraction of reticulocytes;
PAAD	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-5.63	-0.42	8.37e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.49	-5.5	-0.41	1.59e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3981351	0.763	rs4595501	chr10:115491565	A/T	cg24846397	chr10:115438155	CASP7	0.49	4.73	0.36	5.05e-6	Obesity-related traits;
PAAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.92	7.84	0.54	7.23e-13	Gut microbiome composition (summer);
PAAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.58	-6.28	-0.45	3.45e-9	Blood metabolite levels;
PAAD	cis	rs74181299	0.570	rs10197530	chr2:65355604	T/A	cg20592124	chr2:65290738	CEP68	-0.47	-4.37	-0.33	2.27e-5	Pulse pressure;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.23	0.56	7.98e-14	Prudent dietary pattern;
PAAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.61	-8.31	-0.56	4.94e-14	Renal cell carcinoma;
PAAD	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.83	-10.22	-0.64	5.36e-19	Monocyte percentage of white cells;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.51	0.41	1.47e-7	Platelet count;
PAAD	cis	rs7945705	0.935	rs2568064	chr11:8852685	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.64	6.75	0.48	2.94e-10	Hemoglobin concentration;
PAAD	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.57	5.57	0.41	1.12e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.45	0.4	1.95e-7	Ileal carcinoids;
PAAD	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg13206674	chr6:150067644	NUP43	0.6	6.39	0.46	1.93e-9	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	5.33	0.4	3.54e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.13e-6	Life satisfaction;
PAAD	cis	rs818427	0.593	rs351768	chr5:112200028	T/A	cg06941702	chr5:112196734	SRP19	-0.53	-5.16	-0.39	7.56e-7	Total body bone mineral density;
PAAD	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.95	-12.34	-0.71	1.09e-24	Height;
PAAD	cis	rs10870270	0.564	rs45519634	chr10:133782616	C/T	cg27353308	chr10:133796559	BNIP3	-0.59	-4.28	-0.33	3.31e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs131777	0.563	rs5770927	chr22:51028945	C/T	cg00083937	chr22:51039805	MAPK8IP2	0.48	4.41	0.34	1.94e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10851478	0.500	rs36023246	chr15:49699311	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.57	5.39	0.4	2.62e-7	Oral cavity cancer;
PAAD	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.25	-0.6	1.96e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.13	14.79	0.77	3.15e-31	Cortisol levels (saliva);
PAAD	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg10556349	chr10:835070	NA	0.58	4.7	0.36	5.79e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11208691	0.513	rs72480644	chr1:66159417	C/G	cg04111102	chr1:66153794	NA	0.5	4.69	0.36	5.98e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.03	11.12	0.67	2.2e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs6782228	0.606	rs58977394	chr3:128337917	C/T	cg16766828	chr3:128327626	NA	-0.48	-6.59	-0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg25547332	chr5:131281432	NA	0.59	4.58	0.35	9.7e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.41	-0.52	8.04e-12	Total body bone mineral density;
PAAD	cis	rs2835872	0.758	rs1787398	chr21:39037504	A/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg24220031	chr2:73402428	NA	-0.33	-5.1	-0.38	9.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.1	-0.59	4.85e-16	Blood trace element (Zn levels);
PAAD	cis	rs559928	0.692	rs12146487	chr11:64026639	G/A	cg26898376	chr11:64110657	CCDC88B	0.55	4.61	0.35	8.42e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6693295	0.729	rs10737782	chr1:246215358	C/T	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.71	0.69	5.48e-23	Platelet count;
PAAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.68	-7.0	-0.49	7.77e-11	Schizophrenia;
PAAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg18612461	chr15:75251733	NA	0.56	7.16	0.5	3.25e-11	Breast cancer;
PAAD	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.71	-0.36	5.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.31	0.46	2.85e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs9644630	0.745	rs7816777	chr8:19371767	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.37	-4.62	-0.35	8.3e-6	Oropharynx cancer;
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg15181151	chr6:150070149	PCMT1	0.59	6.09	0.44	8.98e-9	Lung cancer;
PAAD	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.22	0.55	8.47e-14	Coffee consumption (cups per day);
PAAD	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.93	11.46	0.68	2.64e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2133450	0.712	rs62237081	chr3:7366057	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.51	5.07	0.38	1.16e-6	Menopause (age at onset);
PAAD	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.88	4.72	0.36	5.29e-6	Plasma clusterin levels;
PAAD	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.54	4.52	0.34	1.22e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg11802864	chr11:65308245	LTBP3	0.8	5.5	0.41	1.61e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4751006	0.543	rs61875512	chr10:128789622	G/A	cg05702161	chr10:128779687	DOCK1	-1.2	-5.89	-0.43	2.38e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs9850225	0.719	rs4856616	chr3:80466481	A/C	cg15692687	chr8:27950300	ELP3	0.63	7.35	0.51	1.13e-11	Erectile dysfunction in type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	10.19	0.64	6.77e-19	Prudent dietary pattern;
PAAD	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.41	4.75	0.36	4.58e-6	Sarcoidosis;
PAAD	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg17052926	chr7:915758	C7orf20	-0.52	-5.13	-0.38	8.68e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.29	-0.33	3.19e-5	Neuroticism;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	1.14	15.61	0.78	2.23e-33	Body mass index;
PAAD	trans	rs901683	0.702	rs75758972	chr10:46081598	C/T	cg11747279	chr17:21096632	NA	0.9	6.5	0.47	1.08e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg03115019	chr17:80708279	FN3K	0.66	7.12	0.5	4.01e-11	Glycated hemoglobin levels;
PAAD	cis	rs12042938	0.935	rs823167	chr1:231767230	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.7	0.36	5.8e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.72	6.33	0.46	2.68e-9	Inflammatory skin disease;
PAAD	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.17	16.8	0.81	1.75e-36	Cognitive function;
PAAD	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg20129853	chr10:51489980	NA	0.5	4.75	0.36	4.62e-6	Prostate-specific antigen levels;
PAAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.36	-0.33	2.39e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.89	12.03	0.7	7.9e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.01	-0.38	1.46e-6	Blood metabolite levels;
PAAD	cis	rs6976053	0.791	rs314377	chr7:100458049	A/G	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.65	0.57	6.77e-15	Lung cancer;
PAAD	cis	rs2797685	0.735	rs56204811	chr1:7895069	A/G	cg17328665	chr1:7887199	PER3	-0.55	-4.72	-0.36	5.37e-6	Crohn's disease;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-4.43	-0.34	1.81e-5	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00982548	chr2:198649783	BOLL	0.63	4.29	0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.8	-0.62	7.17e-18	Height;
PAAD	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.57	-6.68	-0.48	4.19e-10	Schizophrenia;
PAAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg20003494	chr4:90757398	SNCA	-0.67	-6.25	-0.45	3.86e-9	Neuroticism;
PAAD	cis	rs7567389	0.504	rs5937	chr2:128184770	T/C	cg11380483	chr2:127933992	NA	0.5	4.8	0.36	3.84e-6	Self-rated health;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-7.8	-0.53	9.25e-13	Bone mineral density;
PAAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.53	5.57	0.41	1.12e-7	Menopause (age at onset);
PAAD	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.67	0.35	6.52e-6	Self-reported allergy;
PAAD	cis	rs9395066	0.545	rs3799979	chr6:44845514	A/G	cg25276700	chr6:44698697	NA	0.43	4.93	0.37	2.1e-6	Height;
PAAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.7	7.41	0.52	7.97e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs11807834	0.522	rs910498	chr1:230243837	G/C	cg00566187	chr1:230250356	GALNT2	-0.65	-6.88	-0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.63	-5.75	-0.42	4.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg07159951	chr1:45983175	PRDX1	0.42	4.7	0.36	5.74e-6	High light scatter reticulocyte count;
PAAD	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.78	-0.36	4.19e-6	Bipolar disorder;
PAAD	cis	rs61542988	0.756	rs5013587	chr7:22882660	C/T	cg11367502	chr7:22862612	TOMM7	0.52	4.49	0.34	1.37e-5	Fibrinogen levels;
PAAD	cis	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-4.35	-0.33	2.52e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.34	6.17	0.45	5.83e-9	Skin colour saturation;
PAAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.65	-6.56	-0.47	7.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2327429	0.821	rs1967917	chr6:134198175	C/T	cg06643013	chr6:134217242	NA	0.4	4.43	0.34	1.79e-5	Coronary artery disease;
PAAD	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.45	4.43	0.34	1.82e-5	Kawasaki disease;
PAAD	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.49	-5.45	-0.4	2.01e-7	Heart rate;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg17541715	chr7:1216824	NA	-0.4	-4.42	-0.34	1.85e-5	Longevity;Endometriosis;
PAAD	cis	rs7577696	0.888	rs652978	chr2:32286411	A/T	cg02381751	chr2:32503542	YIPF4	-0.44	-4.63	-0.35	7.76e-6	Inflammatory biomarkers;
PAAD	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.56	-4.48	-0.34	1.47e-5	Type 2 diabetes;
PAAD	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	1.18	18.36	0.83	2.06e-40	Gut microbiome composition (winter);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01803125	chr7:75157456	PMS2L3	-0.75	-6.3	-0.46	3.01e-9	Neuroticism;
PAAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.82	-10.48	-0.65	1.11e-19	Bone mineral density;
PAAD	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg08564027	chr20:61660810	NA	0.82	7.59	0.52	2.98e-12	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.64	8.84	0.58	2.26e-15	Airflow obstruction;
PAAD	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	1.01	6.28	0.45	3.46e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12667521	chr19:29218732	NA	0.77	7.22	0.51	2.27e-11	Methadone dose in opioid dependence;
PAAD	trans	rs901683	0.850	rs17157931	chr10:46054359	T/C	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-5.29	-0.39	4.23e-7	Diastolic blood pressure;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg13198984	chr17:80129470	CCDC57	0.46	5.83	0.43	3.22e-8	Life satisfaction;
PAAD	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.51	5.05	0.38	1.23e-6	Motion sickness;
PAAD	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg21775007	chr8:11205619	TDH	0.54	5.05	0.38	1.22e-6	Neuroticism;
PAAD	cis	rs35955747	0.902	rs12166373	chr22:31700508	A/G	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-1.02	-9.35	-0.6	1.04e-16	IgG glycosylation;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg04369109	chr6:150039330	LATS1	-0.5	-4.83	-0.36	3.31e-6	Testicular germ cell tumor;
PAAD	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4774830	0.744	rs76851035	chr15:56165642	G/A	cg24530489	chr15:56299380	NA	-1.1	-4.67	-0.35	6.46e-6	Delta-5 desaturase activity;
PAAD	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.89	-10.8	-0.66	1.58e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.86	6.61	0.47	6.05e-10	Alzheimer's disease;
PAAD	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg10434728	chr15:90938212	IQGAP1	-0.44	-4.45	-0.34	1.65e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.51	-0.34	1.3e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.8	7.98	0.54	3.22e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.52	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs4742903	0.967	rs2122577	chr9:106866703	C/T	cg14250997	chr9:106856677	SMC2	0.48	5.21	0.39	6.01e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2456568	0.808	rs7942236	chr11:93685031	T/G	cg19264203	chr11:92714893	MTNR1B	-0.4	-4.59	-0.35	9.38e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.78	0.36	4.05e-6	Hip circumference;
PAAD	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.17	-0.39	7.17e-7	Systemic lupus erythematosus;
PAAD	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.84	-5.31	-0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs639012	0.825	rs2508696	chr11:85717923	A/C	cg07180834	chr11:85838833	NA	-0.47	-5.16	-0.39	7.47e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.54	0.41	1.31e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs56133113	0.710	rs4578418	chr11:72691692	G/T	cg25124030	chr11:73498278	MRPL48	0.51	4.57	0.35	9.97e-6	Mean platelet volume;
PAAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.93	9.73	0.62	1.09e-17	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05212510	chr18:77623544	KCNG2	-0.45	-4.6	-0.35	8.89e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	6.86e-11	Life satisfaction;
PAAD	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.87	-0.54	6.12e-13	Schizophrenia;
PAAD	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.44	0.61	6.15e-17	Platelet count;
PAAD	cis	rs3126085	0.560	rs72698932	chr1:152355520	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.71	6.55	0.47	8.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.4	4.73	0.36	5.17e-6	Total body bone mineral density;
PAAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.84	-9.26	-0.6	1.81e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.59	-0.35	9.22e-6	Prevalent atrial fibrillation;
PAAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg15598662	chr11:61582890	MIR1908;FADS1	0.5	4.34	0.33	2.6e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.39	4.4	0.34	2.02e-5	Aortic root size;
PAAD	cis	rs12612619	0.732	rs3806520	chr2:27276202	G/A	cg00617064	chr2:27272375	NA	-0.54	-5.75	-0.42	4.86e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1992660	0.523	rs7707395	chr5:40343533	G/C	cg05240017	chr5:40756081	TTC33	0.49	4.25	0.33	3.72e-5	Crohn's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26614262	chr16:2961799	FLYWCH1	-0.55	-6.51	-0.47	1.01e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.78	-0.42	4.18e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg00289084	chr20:3828030	MAVS	0.56	6.56	0.47	7.94e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg04662567	chr6:169592167	NA	0.56	4.76	0.36	4.48e-6	Pulse pressure;
PAAD	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg09357268	chr20:43379437	KCNK15	-0.43	-4.66	-0.35	6.78e-6	Obesity-related traits;
PAAD	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.55	-5.27	-0.39	4.69e-7	QT interval;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg14926445	chr8:58193284	C8orf71	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26820641	chr20:30326728	TPX2	0.61	6.95	0.49	1.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14180030	chr9:123475675	MEGF9	0.44	5.21	0.39	6.14e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs4924935	0.748	rs9915894	chr17:18752778	T/C	cg26378065	chr17:18585709	ZNF286B	0.66	4.89	0.37	2.54e-6	Pancreatic cancer;
PAAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg11995313	chr8:8860691	ERI1	0.48	4.72	0.36	5.31e-6	Joint mobility (Beighton score);
PAAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.27	0.33	3.41e-5	Iron status biomarkers;
PAAD	cis	rs2004318	1.000	rs77812912	chr19:55078054	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg27539214	chr16:67997921	SLC12A4	-0.73	-4.84	-0.37	3.1e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2290419	0.730	rs75139917	chr11:68944768	A/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	1.19	8.77	0.58	3.46e-15	Lymphocyte counts;
PAAD	cis	rs2281636	0.540	rs7913583	chr10:101436718	G/A	cg05149213	chr10:101381631	SLC25A28	-0.55	-5.39	-0.4	2.64e-7	Obesity-related traits;
PAAD	cis	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg15798862	chr7:76129360	DTX2	0.38	4.53	0.34	1.21e-5	Eotaxin levels;
PAAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs17381785	0.586	rs1874205	chr4:14971155	T/C	cg12377275	chr4:15005593	CPEB2	0.76	8.12	0.55	1.45e-13	Urate levels in overweight individuals;
PAAD	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg18436246	chr17:1640651	WDR81	0.86	7.97	0.54	3.59e-13	Serum albumin level;
PAAD	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.72	6.94	0.49	1.04e-10	Anterior chamber depth;
PAAD	cis	rs5743890	0.545	rs34410363	chr11:1375606	C/T	cg15607277	chr11:1312923	TOLLIP	-0.63	-4.25	-0.33	3.66e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.73	-6.7	-0.48	3.75e-10	Homoarginine levels;
PAAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg14440974	chr22:39074834	NA	-0.58	-6.72	-0.48	3.48e-10	Menopause (age at onset);
PAAD	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.34	-0.33	2.61e-5	Bipolar disorder;
PAAD	cis	rs795484	0.926	rs191626	chr12:118629470	G/A	cg16572268	chr12:118583242	PEBP1	-0.47	-4.64	-0.35	7.44e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs8049603	0.812	rs4494543	chr16:23197115	A/G	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.57	0.35	1.01e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg04876069	chr12:132293656	NA	0.52	5.38	0.4	2.72e-7	Migraine;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.44	-4.53	-0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.68	-0.35	6.36e-6	Refractive error;
PAAD	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	1.14	13.4	0.74	1.61e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-4.46	-0.34	1.56e-5	Red blood cell count;
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	7.03	0.5	6.37e-11	Renal function-related traits (BUN);
PAAD	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.65	6.79	0.48	2.43e-10	Obesity-related traits;
PAAD	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.41	4.44	0.34	1.71e-5	Height;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.46	4.57	0.35	9.86e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg10589385	chr1:150898437	SETDB1	-0.4	-5.01	-0.38	1.52e-6	Melanoma;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg11062466	chr8:58055876	NA	0.7	4.9	0.37	2.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.89	0.37	2.5e-6	Lung cancer in ever smokers;
PAAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.8	0.58	2.75e-15	Menopause (age at onset);
PAAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	0.81	6.3	0.46	3.1e-9	Obesity-related traits;
PAAD	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.68e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs116248771	0.739	rs2082158	chr3:158359791	G/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg20673841	chr7:107026890	COG5	0.47	4.3	0.33	3.02e-5	Coronary artery disease;
PAAD	cis	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg13821571	chr21:34406537	NA	-0.48	-4.64	-0.35	7.36e-6	Gastritis;
PAAD	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.72	5.14	0.38	8.39e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.09	8.45	0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.77	8.07	0.55	2.03e-13	Gout;
PAAD	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.47	-4.28	-0.33	3.34e-5	Mean corpuscular volume;
PAAD	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.71	6.03	0.44	1.18e-8	Inflammatory skin disease;
PAAD	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.94	10.7	0.66	2.89e-20	Colorectal adenoma (advanced);
PAAD	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.56	-4.85	-0.37	3.06e-6	Schizophrenia;
PAAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.01	-0.38	1.5e-6	Electroencephalogram traits;
PAAD	cis	rs1422189	0.619	rs12655172	chr5:88010829	C/T	cg23136275	chr5:88188704	MEF2C	0.53	4.49	0.34	1.37e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-4.29	-0.33	3.1e-5	Total body bone mineral density;
PAAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.78	4.62	0.35	8.24e-6	Body mass index;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.17	-0.39	7.29e-7	Retinal vascular caliber;
PAAD	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs7577696	0.597	rs375050	chr2:32413765	C/T	cg02381751	chr2:32503542	YIPF4	0.49	4.63	0.35	7.82e-6	Inflammatory biomarkers;
PAAD	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg15571903	chr15:79123663	NA	-0.47	-6.4	-0.46	1.82e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12304921	1.000	rs73090649	chr12:51349641	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10797726	chr6:82957093	IBTK	0.68	8.04	0.55	2.3e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.69	6.59	0.47	6.82e-10	Subjective well-being;
PAAD	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-5.63	-0.42	8.45e-8	Cognitive test performance;
PAAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg14703610	chr5:56206110	C5orf35	0.56	5.32	0.4	3.69e-7	Initial pursuit acceleration;
PAAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06850241	chr22:41845214	NA	0.57	5.0	0.38	1.58e-6	Vitiligo;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4704187	0.687	rs922390	chr5:74401269	A/G	cg03227963	chr5:74354835	NA	0.5	4.86	0.37	2.95e-6	Response to amphetamines;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26545983	chr19:18632784	ELL	0.68	6.75	0.48	2.96e-10	Obesity-related traits;
PAAD	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.71	5.02	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19105961	chr17:4046223	CYB5D2;ZZEF1	0.63	6.38	0.46	1.99e-9	Primary biliary cholangitis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg22162010	chr1:113249994	RHOC	0.66	6.6	0.47	6.36e-10	Primary biliary cholangitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24348823	chr19:5680464	HSD11B1L;C19orf70	0.66	6.67	0.48	4.55e-10	Obesity-related traits;
PAAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg09796270	chr17:17721594	SREBF1	0.47	5.35	0.4	3.14e-7	Total body bone mineral density;
PAAD	cis	rs9659323	0.931	rs113197996	chr1:119522426	G/A	cg26570165	chr1:119541833	NA	-0.47	-4.7	-0.36	5.76e-6	Body mass index;
PAAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	4.76	0.36	4.5e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.91	-9.17	-0.6	3.14e-16	Asthma;
PAAD	cis	rs557074	0.749	rs9505060	chr6:7172946	T/G	cg01785233	chr6:7260807	NA	0.48	4.38	0.33	2.18e-5	Monocyte count;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.52	4.94	0.37	2e-6	Metabolic traits;
PAAD	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.05	-0.38	1.23e-6	Mean platelet volume;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg13047869	chr3:10149882	C3orf24	0.56	4.99	0.38	1.61e-6	Alzheimer's disease;
PAAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.04	0.55	2.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1879734	0.731	rs4927029	chr1:54169455	C/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.83	-0.43	3.15e-8	Mitral valve prolapse;
PAAD	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7714584	1.000	rs74955473	chr5:150174558	T/A	cg22134413	chr5:150180641	NA	0.95	6.39	0.46	1.92e-9	Crohn's disease;
PAAD	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.99	10.4	0.64	1.76e-19	Pulmonary function decline;
PAAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.0	0.38	1.58e-6	Bone mineral density;
PAAD	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.49	-4.8	-0.36	3.81e-6	Breast cancer;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg05861140	chr6:150128134	PCMT1	-0.56	-6.39	-0.46	1.94e-9	Lung cancer;
PAAD	cis	rs12209128	0.893	rs9369756	chr6:47885216	A/G	cg20497205	chr6:47754005	OPN5	-0.36	-4.29	-0.33	3.18e-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.36	4.82	0.36	3.4e-6	Schizophrenia;
PAAD	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg05874882	chr4:1763078	NA	-0.36	-5.01	-0.38	1.49e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs8133932	0.736	rs2839030	chr21:47292007	A/C	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg10513866	chr5:139070639	NA	0.73	6.27	0.45	3.55e-9	Schizophrenia;
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.8	9.18	0.6	3.03e-16	Emphysema distribution in smoking;
PAAD	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg05272587	chr13:111038400	COL4A2	-0.51	-4.62	-0.35	8.1e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.88	6.69	0.48	4.06e-10	Alzheimer's disease;
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.48	5.83	0.43	3.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs287982	1.000	rs56154233	chr2:9969227	C/T	cg01119585	chr2:10571959	NA	0.39	4.43	0.34	1.78e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-1.03	-12.6	-0.71	2.18e-25	Obesity-related traits;
PAAD	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.45	0.34	1.67e-5	Myopia (pathological);
PAAD	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	5.69	0.42	6.3e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-4.66	-0.35	6.77e-6	Fear of minor pain;
PAAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-5.72	-0.42	5.4e-8	Alzheimer's disease (late onset);
PAAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg04087571	chr11:116723030	SIK3	-0.34	-4.42	-0.34	1.86e-5	Blood protein levels;
PAAD	cis	rs4423214	0.524	rs4944046	chr11:71123794	C/G	cg05163923	chr11:71159392	DHCR7	0.48	4.43	0.34	1.79e-5	Vitamin D levels;
PAAD	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.22	0.39	5.77e-7	Mean platelet volume;
PAAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.7	-5.84	-0.43	3.04e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08754654	chr5:154026448	NA	-0.36	-5.26	-0.39	4.91e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg15571903	chr15:79123663	NA	0.46	6.05	0.44	1.1e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-7.51	-0.52	4.75e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg09127314	chr1:152161683	NA	-0.71	-4.91	-0.37	2.3e-6	Atopic dermatitis;
PAAD	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.84	6.08	0.44	9.24e-9	Pulse pressure;
PAAD	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11811982	0.793	rs75261338	chr1:227510379	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1903068	0.819	rs10517343	chr4:56002267	T/A	cg09978860	chr4:56023921	NA	0.39	4.39	0.34	2.14e-5	Endometriosis;
PAAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.46e-5	Blood metabolite levels;
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg06375148	chr1:209958343	C1orf74	-0.49	-5.14	-0.38	8.49e-7	Monobrow;
PAAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-6.36	-0.46	2.26e-9	Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17039936	chr5:89769860	MBLAC2;POLR3G	-0.76	-6.43	-0.46	1.58e-9	Neuroticism;
PAAD	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.51	5.15	0.39	7.81e-7	Schizophrenia;
PAAD	cis	rs116175783	0.557	rs62197081	chr2:162193325	G/A	cg08807892	chr2:162101083	NA	-0.67	-4.89	-0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg08648136	chr8:956695	NA	0.42	4.47	0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg05425664	chr17:57184151	TRIM37	0.55	5.27	0.39	4.66e-7	Testicular germ cell tumor;
PAAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg07153921	chr17:41440717	NA	-0.4	-4.28	-0.33	3.32e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11625262	chr3:156393772	TIPARP;LOC100287227	0.68	6.36	0.46	2.24e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs113779084	0.632	rs17180695	chr7:11934368	G/C	cg15090509	chr7:11872073	THSD7A	0.39	5.04	0.38	1.31e-6	Educational attainment (years of education);
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.79	-10.26	-0.64	4.21e-19	Prudent dietary pattern;
PAAD	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg03938978	chr2:103052716	IL18RAP	0.66	8.21	0.55	8.74e-14	Asthma;
PAAD	cis	rs2834188	0.521	rs9984454	chr21:34684534	C/T	cg04842828	chr21:34696676	IFNAR1	0.48	5.04	0.38	1.3e-6	Narcolepsy;
PAAD	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.47	4.55	0.35	1.1e-5	Blood pressure;
PAAD	cis	rs4727443	0.866	rs35228488	chr7:99617852	G/C	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.61	0.35	8.59e-6	Interstitial lung disease;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg04154034	chr17:28927549	LRRC37B2	0.69	4.64	0.35	7.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.51	-0.47	1.04e-9	Plateletcrit;Platelet count;
PAAD	cis	rs939584	0.825	rs13028252	chr2:632529	T/C	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg06632027	chr4:90757378	SNCA	-0.5	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.68	-0.62	1.44e-17	Blood trace element (Zn levels);
PAAD	cis	rs5498	0.809	rs2228615	chr19:10403368	G/A	cg10604476	chr19:10403908	ICAM5	0.35	4.43	0.34	1.78e-5	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-6.57	-0.47	7.63e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg04089426	chr11:65307791	LTBP3	1.1	5.13	0.38	8.84e-7	Height;
PAAD	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.56	-5.12	-0.38	9.28e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12727513	chr3:42632622	SS18L2	0.72	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.57	5.36	0.4	3.07e-7	Corneal astigmatism;
PAAD	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	5.82	0.43	3.36e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.06e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10158711	chr7:148725822	PDIA4	0.6	6.55	0.47	8.34e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.98	-0.44	1.55e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.92	0.37	2.19e-6	Corneal astigmatism;
PAAD	cis	rs13256369	0.737	rs34194904	chr8:8554553	C/T	cg06671706	chr8:8559999	CLDN23	0.61	5.86	0.43	2.84e-8	Obesity-related traits;
PAAD	cis	rs6750047	0.541	rs162330	chr2:38319496	C/A	cg19753864	chr2:38320028	NA	0.44	4.93	0.37	2.11e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.73	-7.38	-0.51	9.8e-12	Neurofibrillary tangles;
PAAD	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.85	8.28	0.56	5.95e-14	Vitamin D levels;
PAAD	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.77	-0.53	1.07e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.74	8.7	0.58	5.01e-15	Height;
PAAD	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	trans	rs790110	1.000	rs60226894	chr3:122384152	C/T	cg15869492	chr17:36907295	NA	-1.05	-6.52	-0.47	9.94e-10	Acoustic startle blink response;
PAAD	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg08619932	chr19:49200058	FUT2	0.52	5.7	0.42	6.18e-8	Dietary macronutrient intake;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14120224	chr2:219575507	TTLL4	0.62	6.37	0.46	2.09e-9	Obesity-related traits;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	4.8	0.36	3.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg02917321	chr22:38215204	NA	0.44	4.56	0.35	1.07e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.05	0.38	1.27e-6	Colorectal cancer;
PAAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.41	-0.34	1.94e-5	Menopause (age at onset);
PAAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08219700	chr8:58056026	NA	0.67	5.47	0.41	1.84e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.48	0.8	1.17e-35	Prudent dietary pattern;
PAAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.65	0.35	7.12e-6	Coronary artery disease;
PAAD	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.62	4.99	0.38	1.6e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg18944383	chr4:111397179	ENPEP	0.63	7.07	0.5	5.24e-11	Coronary artery disease;
PAAD	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.15	14.21	0.76	1.1e-29	Schizophrenia;
PAAD	cis	rs1468734	1.000	rs35659917	chr16:5003592	G/A	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.98e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.28	0.6	1.62e-16	Colorectal cancer;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg26174226	chr8:58114915	NA	-0.67	-4.78	-0.36	4.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg07841815	chr7:100318223	EPO	-0.47	-4.62	-0.35	8.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg03605463	chr16:89740564	NA	-0.5	-4.82	-0.36	3.43e-6	Vitiligo;
PAAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.83	-8.43	-0.56	2.47e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg16898833	chr6:26189333	HIST1H4D	1.08	5.85	0.43	2.92e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg14343924	chr8:8086146	FLJ10661	-0.65	-5.93	-0.43	1.92e-8	Mood instability;
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2997447	0.653	rs56134135	chr1:26440718	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.49	-0.52	5.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg14631576	chr9:95140430	CENPP	-0.45	-4.44	-0.34	1.73e-5	Height;
PAAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11897517	chr6:109761938	SMPD2;PPIL6	-0.55	-6.35	-0.46	2.33e-9	Body fat percentage;
PAAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg26497354	chr6:109612229	NA	-0.42	-4.33	-0.33	2.7e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.58	5.02	0.38	1.41e-6	Life satisfaction;
PAAD	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.57	5.46	0.4	1.9e-7	Type 2 diabetes;
PAAD	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg08886695	chr4:3369023	RGS12	0.52	5.07	0.38	1.16e-6	Parental longevity (mother's age at death);
PAAD	cis	rs1113500	0.541	rs11185241	chr1:108583025	T/C	cg06207961	chr1:108661230	NA	0.48	5.09	0.38	1.07e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg24253500	chr15:84953950	NA	0.43	4.58	0.35	9.78e-6	Schizophrenia;
PAAD	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.11	-0.38	9.47e-7	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.38	4.25	0.33	3.71e-5	Melanoma;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09860653	chr1:19970708	NBL1	0.58	6.83	0.48	1.91e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9595066	0.627	rs4941486	chr13:44749157	G/A	cg04068111	chr13:44716778	NA	-0.5	-5.49	-0.41	1.65e-7	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08551088	chr10:121631655	C10orf119	-0.63	-7.22	-0.51	2.27e-11	Body fat percentage;
PAAD	cis	rs863345	0.604	rs10908674	chr1:158503920	A/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.63	6.31	0.46	2.83e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.59	-4.31	-0.33	2.97e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08886695	chr4:3369023	RGS12	-0.47	-4.63	-0.35	7.87e-6	Parental longevity (mother's age at death);
PAAD	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	8.02	0.55	2.62e-13	Response to antipsychotic treatment;
PAAD	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	9.41	0.61	7.54e-17	Ulcerative colitis;
PAAD	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.57	-7.19	-0.5	2.71e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs375066	0.901	rs368316	chr19:44431894	C/A	cg08633290	chr19:44405433	NA	-0.57	-5.66	-0.42	7.18e-8	Breast cancer;
PAAD	cis	rs12304921	1.000	rs67420027	chr12:51349847	T/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.07e-6	Cognitive function;
PAAD	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg12633918	chr20:23549525	CST9L	-0.43	-4.66	-0.35	7e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.55	6.04	0.44	1.13e-8	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14360444	chr9:129643082	ZBTB34	-0.66	-6.31	-0.46	2.85e-9	Obesity-related traits;
PAAD	cis	rs9810890	0.702	rs73207972	chr3:128568186	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2000999	0.514	rs16970719	chr16:72252104	G/C	cg16558253	chr16:72132732	DHX38	-0.66	-4.27	-0.33	3.41e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs790123	0.842	rs2650957	chr3:122396097	C/G	cg17380795	chr3:122379686	NA	0.52	5.39	0.4	2.68e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg27094323	chr7:1216898	NA	-0.37	-4.37	-0.33	2.29e-5	Longevity;Endometriosis;
PAAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.54	6.25	0.45	3.86e-9	Breast cancer;
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18621852	chr3:10150065	C3orf24	0.74	5.76	0.42	4.62e-8	Alzheimer's disease;
PAAD	cis	rs4409675	0.826	rs17257252	chr1:28220484	A/C	cg23691781	chr1:28212827	C1orf38	-0.45	-4.95	-0.37	1.98e-6	Corneal astigmatism;
PAAD	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.6	-0.57	9.17e-15	Coffee consumption (cups per day);
PAAD	cis	rs2544527	0.819	rs2544523	chr2:15920323	T/C	cg26669897	chr2:15909070	NA	0.47	4.69	0.36	6.05e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs988913	0.918	rs7739399	chr6:54855538	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.97	-0.37	1.79e-6	Menarche (age at onset);
PAAD	cis	rs12600121	0.622	rs9937465	chr16:72021638	A/T	cg03379631	chr16:72873149	ZFHX3	0.37	4.34	0.33	2.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	-0.44	-4.35	-0.33	2.5e-5	Trans fatty acid levels;
PAAD	cis	rs16958440	1.000	rs62096469	chr18:44638298	A/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.98	0.49	8.5e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.24	-0.45	4.05e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.75	0.42	4.75e-8	Schizophrenia;
PAAD	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs66478310	0.793	rs55813925	chr12:108718333	G/A	cg04872675	chr12:108983234	NA	0.83	5.15	0.39	7.85e-7	Plasma clusterin levels;
PAAD	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.53	4.36	0.33	2.43e-5	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14210321	chr2:106509881	NCK2	-0.69	-6.85	-0.49	1.7e-10	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs13424612	0.864	rs4854071	chr2:240885050	C/T	cg12807937	chr2:240965920	NDUFA10	-0.46	-4.69	-0.36	6.09e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.66	-6.57	-0.47	7.5e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg05585544	chr11:47624801	NA	0.51	5.83	0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs17095355	0.792	rs72828203	chr10:111649343	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.31	-0.33	2.87e-5	Biliary atresia;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.76	8.46	0.57	2.07e-14	Menopause (age at onset);
PAAD	trans	rs6686842	0.798	rs12037263	chr1:41482500	C/G	cg04009860	chr15:101853297	PCSK6	-0.59	-6.39	-0.46	1.9e-9	Height;
PAAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.94	11.23	0.67	1.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg24881330	chr22:46731750	TRMU	1.17	5.3	0.39	3.99e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.7	7.42	0.52	7.94e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg08601574	chr20:25228251	PYGB	0.51	5.18	0.39	6.93e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.36	-0.4	3e-7	Joint mobility (Beighton score);
PAAD	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.75	8.85	0.58	2.06e-15	Morning vs. evening chronotype;
PAAD	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.58	-7.46	-0.52	6.14e-12	Lewy body disease;
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	4.35	0.33	2.48e-5	Height;
PAAD	cis	rs7678296	1.000	rs73142757	chr4:37205169	C/T	cg06805348	chr4:37245195	KIAA1239	0.62	4.64	0.35	7.47e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06006401	chr6:168482421	NA	-0.7	-7.01	-0.49	7.19e-11	Obesity-related traits;
PAAD	cis	rs11811982	0.793	rs77487289	chr1:227562721	C/A	cg24860534	chr1:227506868	CDC42BPA	0.58	4.79	0.36	4.01e-6	Optic disc area;
PAAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.41e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15990800	chr14:55738852	FBXO34	0.65	7.34	0.51	1.18e-11	Monocyte percentage of white cells;
PAAD	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg00717180	chr2:96193071	NA	-0.63	-7.74	-0.53	1.28e-12	HDL cholesterol;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14930269	chr3:49142045	QARS	0.68	7.11	0.5	4.22e-11	Myopia (pathological);
PAAD	cis	rs7631605	0.905	rs7651033	chr3:37116042	A/G	cg17445812	chr3:36986805	TRANK1	-0.34	-4.57	-0.35	9.85e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs4427176	0.507	rs11989409	chr8:9581766	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg14393609	chr7:65229607	NA	-0.47	-4.77	-0.36	4.22e-6	Aortic root size;
PAAD	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.57	5.59	0.41	1.04e-7	Mortality in heart failure;
PAAD	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.82	-12.58	-0.71	2.59e-25	Lymphocyte counts;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg04160749	chr8:58172571	NA	-0.64	-4.65	-0.35	7.07e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.97	10.57	0.65	6.24e-20	Corneal astigmatism;
PAAD	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.96e-6	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg01320130	chr1:67600311	NA	0.53	5.86	0.43	2.83e-8	Psoriasis;
PAAD	cis	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.97	6.25	0.45	3.98e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.4	5.42	0.4	2.31e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.79	-8.95	-0.59	1.19e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.64	4.29	0.33	3.11e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs55823223	0.504	rs2034946	chr17:73863589	T/G	cg14829360	chr17:73884958	NA	-0.66	-6.27	-0.45	3.52e-9	Psoriasis;
PAAD	cis	rs7071247	0.915	rs3014205	chr10:105262185	G/A	cg18199807	chr10:106074281	ITPRIP	0.67	4.39	0.34	2.09e-5	Platelet aggregation;
PAAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg15017067	chr4:17643749	FAM184B	0.45	5.38	0.4	2.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg00626422	chr7:22894849	SNORD93	-0.55	-6.33	-0.46	2.57e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.73	7.07	0.5	5.36e-11	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01829450	chr3:135914745	MSL2	0.57	6.35	0.46	2.36e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-7.42	-0.52	7.91e-12	Heart rate;
PAAD	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.82	8.81	0.58	2.63e-15	Mortality in heart failure;
PAAD	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.17	-0.5	3.06e-11	Colorectal cancer;
PAAD	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.92	0.37	2.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg16211469	chr6:24423932	MRS2	-0.46	-4.41	-0.34	1.92e-5	Liver enzyme levels;
PAAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.54	0.52	3.88e-12	Platelet distribution width;
PAAD	cis	rs4294134	0.608	rs11532803	chr7:135245734	T/A	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.81e-6	Myopia (pathological);
PAAD	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.48	5.04	0.38	1.33e-6	QRS complex (12-leadsum);
PAAD	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.43	-0.4	2.21e-7	Reticulocyte count;
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-4.52	-0.34	1.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.59	0.35	9.41e-6	Depression;
PAAD	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	0.96	6.07	0.44	9.85e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6942407	0.543	rs739712	chr7:86746798	G/A	cg02420886	chr7:86849541	C7orf23	0.51	4.3	0.33	3.1e-5	Food allergy;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	5.21	0.39	6.14e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg25037394	chr1:24152592	HMGCL	0.43	4.38	0.34	2.16e-5	Immature fraction of reticulocytes;
PAAD	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.54	0.35	1.14e-5	Calcium levels;
PAAD	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs501120	0.564	rs1704231	chr10:44691543	C/T	cg09554077	chr10:44749378	NA	0.41	5.1	0.38	1.01e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.67	0.53	1.89e-12	IgG glycosylation;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02725872	chr8:58115012	NA	-0.62	-5.26	-0.39	4.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.47	4.42	0.34	1.85e-5	Educational attainment (years of education);
PAAD	cis	rs288326	0.561	rs77496277	chr2:183761706	C/T	cg09997497	chr2:183902928	NCKAP1	1.03	5.12	0.38	9.29e-7	Blood protein levels;
PAAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs6142102	0.812	rs6059574	chr20:32523172	C/G	cg08999081	chr20:33150536	PIGU	-0.46	-4.36	-0.33	2.42e-5	Skin pigmentation;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs7101446	0.545	rs4466837	chr11:63217222	G/A	cg10713715	chr11:63533656	C11orf95	0.36	4.28	0.33	3.33e-5	Economic and political preferences;
PAAD	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg00531865	chr16:30841666	NA	0.52	4.94	0.37	2.02e-6	Dementia with Lewy bodies;
PAAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg05082376	chr22:42548792	NA	-0.55	-5.66	-0.42	7.19e-8	Cognitive function;
PAAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs75920871	0.800	rs59266239	chr11:116911077	C/T	cg04087571	chr11:116723030	SIK3	-0.44	-5.56	-0.41	1.17e-7	Subjective well-being;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07187069	chr13:28404269	NA	0.66	7.22	0.51	2.38e-11	Myopia (pathological);
PAAD	cis	rs939584	1.000	rs11127483	chr2:623691	G/A	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.4	0.46	1.83e-9	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg01762785	chr22:42226837	NA	-0.43	-4.85	-0.37	3.09e-6	Intelligence;
PAAD	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	1.35	7.93	0.54	4.29e-13	Corneal curvature;
PAAD	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.88	-8.73	-0.58	4.16e-15	Corneal astigmatism;
PAAD	cis	rs9880772	0.776	rs4680852	chr3:27805204	G/A	cg21473142	chr3:27762095	EOMES	0.36	6.72	0.48	3.34e-10	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg18769074	chr3:133464867	TF	0.43	4.93	0.37	2.14e-6	Iron status biomarkers;
PAAD	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.85	10.98	0.67	5.16e-21	Breast cancer;
PAAD	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.55e-5	Systolic blood pressure;
PAAD	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.96	-8.69	-0.58	5.44e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.63	6.23	0.45	4.43e-9	Type 2 diabetes;
PAAD	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.46	4.7	0.36	5.75e-6	Type 2 diabetes;
PAAD	cis	rs4321325	0.733	rs75834205	chr2:127947237	G/T	cg11380483	chr2:127933992	NA	0.71	5.3	0.39	4.05e-7	Protein C levels;
PAAD	trans	rs3733631	0.696	rs7672658	chr4:104631530	G/A	cg21490444	chr5:171095097	NA	0.79	6.62	0.47	5.74e-10	Menarche (age at onset);
PAAD	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.8	-7.55	-0.52	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg26248373	chr2:1572462	NA	-1.08	-7.69	-0.53	1.7e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.97	11.23	0.67	1.06e-21	Cannabis dependence symptom count;
PAAD	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1420338	1.000	rs1420338	chr7:34143256	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-4.89	-0.37	2.58e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs427941	0.632	rs201507	chr7:101764141	T/C	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg00262122	chr8:11665843	FDFT1	-0.64	-5.48	-0.41	1.71e-7	Neuroticism;
PAAD	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg27436995	chr16:743998	FBXL16	-0.38	-4.54	-0.35	1.14e-5	Height;
PAAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.71	-4.25	-0.33	3.68e-5	Tuberculosis;
PAAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.23	-0.39	5.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03412946	chr2:38029124	NA	-0.67	-6.71	-0.48	3.54e-10	Obesity-related traits;
PAAD	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.47	-0.46	1.29e-9	Morning vs. evening chronotype;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.59	6.29	0.45	3.14e-9	Lung cancer;
PAAD	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.82	-0.43	3.4e-8	Menopause (age at onset);
PAAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.15	-8.62	-0.57	7.92e-15	Diabetic kidney disease;
PAAD	cis	rs7707921	1.000	rs1543911	chr5:81504841	C/T	cg21483461	chr5:81570383	RPS23	0.57	4.74	0.36	4.94e-6	Breast cancer;
PAAD	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg06236206	chr7:66120395	NA	0.51	4.29	0.33	3.21e-5	Diabetic kidney disease;
PAAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg03037974	chr15:76606532	NA	0.55	6.54	0.47	8.74e-10	Blood metabolite levels;
PAAD	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.33	0.6	1.2e-16	Response to antipsychotic treatment;
PAAD	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-4.43	-0.34	1.79e-5	Common traits (Other);
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.0	-0.44	1.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg25418670	chr11:30344373	C11orf46	-0.65	-6.29	-0.45	3.13e-9	Morning vs. evening chronotype;
PAAD	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs10929159	0.928	rs10200358	chr2:236935791	A/G	cg14226755	chr2:236923322	AGAP1	0.3	4.72	0.36	5.33e-6	Parkinson's disease;
PAAD	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg24553058	chr2:113831203	IL1F10	-0.46	-5.16	-0.39	7.6e-7	Protein quantitative trait loci;
PAAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-6.78	-0.48	2.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23517469	chr6:36164058	BRPF3	0.6	6.52	0.47	9.72e-10	Monocyte percentage of white cells;
PAAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg05484376	chr2:27715224	FNDC4	0.48	4.9	0.37	2.44e-6	Total body bone mineral density;
PAAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs73198271	0.595	rs117424193	chr8:8591377	T/C	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.57	-6.91	-0.49	1.22e-10	Blood pressure (smoking interaction);
PAAD	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.52	-5.22	-0.39	5.87e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.51	-5.2	-0.39	6.26e-7	Motion sickness;
PAAD	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	7.05	0.5	5.84e-11	Renal function-related traits (BUN);
PAAD	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg14196790	chr5:131705035	SLC22A5	0.48	5.05	0.38	1.26e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.77	-8.37	-0.56	3.56e-14	Coronary artery disease;
PAAD	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.6	-0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.83	8.28	0.56	5.78e-14	Response to antineoplastic agents;
PAAD	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg05338066	chr1:7812865	CAMTA1	-0.47	-4.26	-0.33	3.5e-5	Inflammatory bowel disease;
PAAD	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg08807892	chr2:162101083	NA	0.53	5.57	0.41	1.11e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25021893	chr21:47856140	PCNT	0.65	7.75	0.53	1.19e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs58521262	0.585	rs289290	chr19:23178873	C/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.89	6.83	0.48	1.93e-10	Eosinophilic esophagitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02998281	chr1:92683454	C1orf146	0.57	6.62	0.47	5.92e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg20628663	chr10:43360327	NA	0.66	4.78	0.36	4.15e-6	Blood protein levels;
PAAD	cis	rs36093844	0.948	rs7128854	chr11:85552167	C/T	cg25872744	chr11:85566296	CCDC83	-0.54	-4.36	-0.33	2.38e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg18939081	chr1:31884902	SERINC2	0.47	5.38	0.4	2.71e-7	Alcohol dependence;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.02e-9	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12780845	0.964	rs56314943	chr10:17193632	T/A	cg00857480	chr10:17188594	TRDMT1	0.38	4.94	0.37	2.07e-6	Homocysteine levels;
PAAD	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg08601574	chr20:25228251	PYGB	0.54	5.56	0.41	1.19e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.66	10.63	0.65	4.36e-20	Diastolic blood pressure;
PAAD	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-4.51	-0.34	1.31e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07685180	chr8:600429	NA	0.82	5.13	0.38	8.57e-7	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.55	-0.35	1.1e-5	Aortic root size;
PAAD	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	4.71	0.36	5.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs2730260	0.673	rs56236179	chr7:158843088	G/A	cg02254261	chr7:158964346	NA	-0.6	-4.64	-0.35	7.4e-6	Myopia (pathological);
PAAD	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg08992911	chr2:238395768	MLPH	0.91	6.58	0.47	7.34e-10	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11807492	chr7:99870057	GATS	0.62	6.94	0.49	1.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	cis	rs9581857	0.512	rs9652091	chr13:28073509	G/A	cg22138327	chr13:27999177	GTF3A	0.79	5.49	0.41	1.67e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2791553	0.562	rs12034581	chr1:219694903	C/A	cg09060784	chr1:220324033	RAB3GAP2	0.45	4.28	0.33	3.34e-5	Adiponectin levels;
PAAD	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.7	6.83	0.48	1.94e-10	Hip circumference;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg11416102	chr8:651193	ERICH1	0.95	5.58	0.41	1.07e-7	IgG glycosylation;
PAAD	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.87	6.98	0.49	8.42e-11	Axial length;
PAAD	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.57	5.92	0.43	2.02e-8	Multiple myeloma (IgH translocation);
PAAD	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg03805757	chr16:71968109	PKD1L3	-0.51	-4.34	-0.33	2.56e-5	Blood protein levels;
PAAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	trans	rs8042680	0.688	rs28404354	chr15:91539050	C/TT	cg03852144	chr5:95159639	GLRX	-0.81	-6.3	-0.46	3.06e-9	Type 2 diabetes;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg02869306	chr7:64672164	INTS4L1	-0.43	-5.0	-0.38	1.54e-6	Calcium levels;
PAAD	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.96	0.37	1.9e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2230307	0.908	rs17121827	chr1:100537564	C/G	cg24955406	chr1:100503596	HIAT1	0.91	4.52	0.34	1.25e-5	Carotid intima media thickness;
PAAD	cis	rs55794721	0.611	rs74937936	chr1:25747646	G/A	cg03538708	chr1:25844672	NA	-0.48	-4.91	-0.37	2.31e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.77	5.2	0.39	6.47e-7	Red cell distribution width;
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg27094323	chr7:1216898	NA	-0.47	-5.61	-0.41	9.22e-8	Longevity;Endometriosis;
PAAD	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-4.57	-0.35	9.98e-6	Vitiligo;
PAAD	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.97	0.49	8.8e-11	Rheumatoid arthritis;
PAAD	cis	rs7487075	0.578	rs4768119	chr12:46807902	G/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.41	0.34	1.92e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs62179067	0.708	rs17363006	chr2:179915541	T/C	cg13380624	chr19:7735426	NA	-0.73	-6.9	-0.49	1.32e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs73198271	1.000	rs4840356	chr8:8607527	A/G	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.53	-5.82	-0.43	3.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs75920871	0.623	rs7932655	chr11:116962563	T/A	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.23e-6	Bipolar disorder;
PAAD	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.4	-0.4	2.48e-7	QT interval;
PAAD	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.56	6.47	0.46	1.29e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg27121462	chr16:89883253	FANCA	0.46	4.91	0.37	2.3e-6	Vitiligo;
PAAD	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg15181151	chr6:150070149	PCMT1	0.59	6.45	0.46	1.38e-9	Lung cancer;
PAAD	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.74	8.46	0.57	2.05e-14	Age-related hearing impairment;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg19700328	chr14:106028568	NA	-0.64	-6.05	-0.44	1.09e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.7	0.36	5.77e-6	Educational attainment;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26658471	chr20:25677673	ZNF337	0.57	6.32	0.46	2.79e-9	Monocyte percentage of white cells;
PAAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7742824	0.843	rs7743249	chr6:44072863	G/A	cg21657043	chr6:44035552	NA	0.44	4.78	0.36	4.03e-6	Major depressive disorder;
PAAD	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.45	-0.4	1.95e-7	Schizophrenia;
PAAD	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.85	-0.37	3.07e-6	Depression;
PAAD	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg01620082	chr3:125678407	NA	-0.91	-6.63	-0.47	5.46e-10	Depression;
PAAD	cis	rs258892	0.895	rs34066594	chr5:72030627	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.49	5.11	0.38	9.5e-7	Menopause (age at onset);
PAAD	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg02683114	chr2:24398427	C2orf84	-0.59	-6.28	-0.45	3.43e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.2	10.6	0.65	5.23e-20	Uric acid levels;
PAAD	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4959799	1.000	rs61417737	chr6:3291251	G/A	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.82e-5	Survival in rectal cancer;
PAAD	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg24053715	chr22:38214548	NA	-0.62	-6.57	-0.47	7.71e-10	Glioblastoma;Glioma;
PAAD	cis	rs3106136	0.678	rs7674215	chr4:95294145	C/A	cg11021082	chr4:95130006	SMARCAD1	0.5	4.75	0.36	4.6e-6	Capecitabine sensitivity;
PAAD	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg09237302	chr4:906077	GAK	-0.43	-4.41	-0.34	1.99e-5	Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14915854	chr11:46722264	ZNF408;ARHGAP1	-0.69	-6.67	-0.48	4.56e-10	Lung cancer in ever smokers;
PAAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.94	7.64	0.53	2.29e-12	Gut microbiome composition (summer);
PAAD	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs539096	0.624	rs499257	chr1:44078384	T/C	cg12908607	chr1:44402522	ARTN	-0.42	-4.5	-0.34	1.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs894157	0.920	rs6496588	chr15:90189758	A/C	cg06792126	chr15:90365488	NA	-0.69	-4.25	-0.33	3.66e-5	Obesity-related traits;
PAAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	1.21	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.59	-7.86	-0.54	6.57e-13	Longevity;
PAAD	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.77	-7.85	-0.54	6.96e-13	Colorectal adenoma (advanced);
PAAD	cis	rs1519814	0.956	rs6995843	chr8:121159867	C/T	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.83	-10.74	-0.66	2.28e-20	Breast cancer;
PAAD	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.79	8.16	0.55	1.16e-13	Lewy body disease;
PAAD	trans	rs3749237	0.964	rs2276864	chr3:49894030	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.44	0.46	1.46e-9	Resting heart rate;
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg02462569	chr6:150064036	NUP43	-0.56	-6.24	-0.45	4.25e-9	Lung cancer;
PAAD	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	1.03	12.44	0.71	5.9e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg02743256	chr7:2109353	MAD1L1	-0.55	-4.34	-0.33	2.57e-5	Bipolar disorder;
PAAD	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg23346134	chr3:49453900	TCTA	0.44	4.8	0.36	3.84e-6	Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25685761	chr2:121453389	NA	-0.76	-6.98	-0.49	8.61e-11	Neuroticism;
PAAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	7.81	0.54	8.78e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg10434728	chr15:90938212	IQGAP1	0.44	4.55	0.35	1.08e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg02555727	chr12:129281546	SLC15A4	0.49	5.21	0.39	6.16e-7	Systemic lupus erythematosus;
PAAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg00944433	chr1:107599041	PRMT6	-0.44	-5.08	-0.38	1.12e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6681460	1.000	rs1445575	chr1:67052164	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.46	0.52	6.1e-12	Presence of antiphospholipid antibodies;
PAAD	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg00717180	chr2:96193071	NA	0.61	7.18	0.5	2.82e-11	Height;
PAAD	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.58	5.88	0.43	2.54e-8	Red cell distribution width;
PAAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs3733418	0.929	rs1401399	chr4:165927906	G/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.61	-5.42	-0.4	2.28e-7	Obesity-related traits;
PAAD	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-5.41	-0.4	2.46e-7	Monocyte count;
PAAD	cis	rs12580194	0.593	rs61957885	chr12:55720876	C/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.29	0.33	3.13e-5	Cancer;
PAAD	cis	rs60154123	1.000	rs60154123	chr1:210468999	C/T	cg21951975	chr1:209979733	IRF6	0.5	4.44	0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06753367	chr22:24256600	NA	-0.42	-4.48	-0.34	1.44e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.82e-16	Parkinson's disease;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg16031515	chr1:205743344	RAB7L1	0.39	4.6	0.35	8.7e-6	Monocyte percentage of white cells;
PAAD	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.48	-0.47	1.22e-9	Leprosy;
PAAD	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg02297831	chr4:17616191	MED28	-0.64	-5.84	-0.43	3.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.58e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.41	-0.46	1.7e-9	HDL cholesterol;
PAAD	cis	rs11718455	0.548	rs11918413	chr3:43902518	C/A	cg00181669	chr3:44000978	NA	0.55	6.05	0.44	1.09e-8	Coronary artery disease;
PAAD	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg24289452	chr6:170231220	NA	-1.06	-4.36	-0.33	2.4e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6594713	0.885	rs6594716	chr5:112745118	G/A	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.43	-5.09	-0.38	1.04e-6	Type 2 diabetes;
PAAD	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.6	4.73	0.36	5.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-5.64	-0.42	8e-8	Coronary artery disease;
PAAD	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg12486944	chr17:80159399	CCDC57	0.53	4.69	0.36	6.05e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.79	-0.43	3.87e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	1.07	5.73	0.42	5.26e-8	Body mass index;
PAAD	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.71	7.6	0.52	2.85e-12	Morning vs. evening chronotype;
PAAD	cis	rs8077577	0.747	rs57697650	chr17:18224695	G/A	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg26695010	chr11:65641043	EFEMP2	0.63	6.17	0.45	6.06e-9	Eosinophil percentage of white cells;
PAAD	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.8	9.08	0.59	5.21e-16	Lung cancer;
PAAD	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.54	5.2	0.39	6.32e-7	Multiple myeloma;
PAAD	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg08632701	chr21:37451849	NA	-0.57	-5.96	-0.44	1.69e-8	Mitral valve prolapse;
PAAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.91	6.49	0.47	1.16e-9	Initial pursuit acceleration;
PAAD	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.5	4.36	0.33	2.35e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.75	-5.26	-0.39	4.74e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6929137	0.632	rs67413479	chr6:151960929	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.53	-0.34	1.21e-5	Bone mineral density (spine);
PAAD	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.54	8.35	0.56	3.98e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs300774	0.925	rs441469	chr2:129028	C/T	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg12908607	chr1:44402522	ARTN	-0.43	-4.67	-0.35	6.66e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.81	9.62	0.62	2.11e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.38	-0.61	8.87e-17	Aortic root size;
PAAD	cis	rs6137287	0.924	rs2145099	chr20:21159152	T/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs1903068	0.853	rs9312657	chr4:56003502	G/A	cg09978860	chr4:56023921	NA	0.38	4.34	0.33	2.61e-5	Endometriosis;
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.62	6.48	0.47	1.2e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs227833	1.000	rs227835	chr6:44682316	A/G	cg20913747	chr6:44695427	NA	0.57	5.98	0.44	1.57e-8	Monobrow;
PAAD	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.7	6.91	0.49	1.25e-10	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16786661	chr2:234160315	ATG16L1	0.59	7.07	0.5	5.23e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs300774	0.925	rs300737	chr2:170576	A/G	cg21211680	chr2:198530	NA	-0.65	-5.85	-0.43	2.9e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg24330906	chr2:85765176	MAT2A	0.45	4.48	0.34	1.47e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.36	4.91	0.37	2.3e-6	Blood protein levels;
PAAD	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.49	4.95	0.37	1.99e-6	Longevity;Endometriosis;
PAAD	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.63	-6.01	-0.44	1.29e-8	Cognitive function;
PAAD	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	1.01	7.19	0.5	2.74e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.69	5.76	0.42	4.43e-8	Schizophrenia;
PAAD	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8179	0.648	rs42036	chr7:92241451	C/G	cg03496780	chr7:92466842	CDK6	0.48	4.32	0.33	2.82e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg02917321	chr22:38215204	NA	0.49	4.72	0.36	5.2e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.6	-7.11	-0.5	4.29e-11	Iron status biomarkers;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.9	-10.18	-0.64	6.84e-19	Paraoxonase activity;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.53	-6.35	-0.46	2.42e-9	Mean corpuscular volume;
PAAD	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.44	-4.25	-0.33	3.71e-5	Mean platelet volume;
PAAD	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs950881	0.932	rs72823646	chr2:102954213	G/A	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.45	0.34	1.68e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs732765	0.734	rs6574189	chr14:75166493	C/T	cg01090926	chr14:75137805	KIAA0317	-0.51	-4.74	-0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.67	-6.12	-0.44	7.44e-9	White matter hyperintensity burden;
PAAD	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.81	-9.95	-0.63	2.84e-18	Height;
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01616529	chr11:638424	DRD4	-0.58	-5.74	-0.42	4.89e-8	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg00181669	chr3:44000978	NA	0.46	4.63	0.35	7.83e-6	Coronary artery disease;
PAAD	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2790216	0.950	rs2790149	chr10:59956556	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg18551225	chr6:44695536	NA	-0.73	-7.29	-0.51	1.54e-11	Total body bone mineral density;
PAAD	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.59	5.38	0.4	2.73e-7	Mean platelet volume;
PAAD	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.7	-9.16	-0.6	3.34e-16	Hemoglobin concentration;
PAAD	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.55	-5.4	-0.4	2.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs427941	0.632	rs201498	chr7:101756262	G/A	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg20933634	chr6:27740509	NA	-0.7	-6.74	-0.48	3.01e-10	Parkinson's disease;
PAAD	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg21300403	chr2:198650112	BOLL	0.49	4.36	0.33	2.38e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg26876637	chr1:152193138	HRNR	-0.8	-5.6	-0.41	9.89e-8	Atopic dermatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	0.66	7.86	0.54	6.62e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34375054	0.573	rs34579346	chr12:125658174	T/C	cg09839279	chr12:125627357	AACS	-0.49	-4.49	-0.34	1.38e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg22827986	chr11:48284249	OR4X1	0.37	4.8	0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs6594713	0.717	rs2972689	chr5:112945966	C/T	cg12552261	chr5:112820674	MCC	0.67	4.79	0.36	3.95e-6	Brain cytoarchitecture;
PAAD	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.87	5.56	0.41	1.2e-7	Diabetic kidney disease;
PAAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-14.94	-0.77	1.21e-31	Coronary artery disease;
PAAD	cis	rs9430161	0.611	rs2003046	chr1:11032827	C/A	cg27631724	chr1:11040367	C1orf127	0.54	7.0	0.49	7.64e-11	Ewing sarcoma;
PAAD	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17691542	chr6:26056736	HIST1H1C	1.11	8.9	0.59	1.58e-15	Iron status biomarkers;
PAAD	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-6.41	-0.46	1.74e-9	Monocyte percentage of white cells;
PAAD	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.9	5.65	0.42	7.58e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	Cognitive function;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.72	-0.42	5.44e-8	Daytime sleep phenotypes;
PAAD	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg18031326	chr11:68079681	LRP5	-0.34	-4.34	-0.33	2.6e-5	Mean corpuscular volume;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.83	-0.43	3.15e-8	Lung cancer;
PAAD	cis	rs12612619	0.542	rs6710065	chr2:27076557	C/T	cg12368169	chr2:27073192	DPYSL5	-0.42	-4.39	-0.34	2.15e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg24687543	chr11:63912206	MACROD1	0.58	4.65	0.35	7.22e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-4.87	-0.37	2.78e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-8.18	-0.55	1.07e-13	Colorectal cancer;
PAAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4740619	0.619	rs4741559	chr9:16041982	G/A	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10252235	chr14:102508959	DYNC1H1	-0.62	-6.37	-0.46	2.14e-9	Myopia (pathological);
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08048268	chr3:133502702	NA	-0.52	-6.22	-0.45	4.55e-9	Iron status biomarkers;
PAAD	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.29	8.05	0.55	2.16e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.46	6.03	0.44	1.18e-8	Childhood ear infection;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.49	-4.84	-0.37	3.18e-6	Breast size;
PAAD	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.58	0.35	9.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.45	-4.47	-0.34	1.51e-5	Body mass index;
PAAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs1419980	0.730	rs12229540	chr12:7776578	A/C	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	6.13	0.45	7.22e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.9	11.87	0.69	2.08e-23	Body mass index;
PAAD	cis	rs1329189	1.000	rs10829355	chr10:129996768	T/C	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.58e-6	Orofacial clefts;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.57e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.55	-5.45	-0.4	1.95e-7	Height;
PAAD	cis	rs12935418	0.672	rs78895138	chr16:81048425	A/G	cg16651780	chr16:81037892	C16orf61	0.64	5.95	0.43	1.81e-8	Mean corpuscular volume;
PAAD	cis	rs9310709	0.538	rs822770	chr3:23032988	T/C	cg00327796	chr3:23032191	NA	0.48	4.7	0.36	5.88e-6	Chronic kidney disease and serum creatinine levels;
PAAD	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg23815491	chr16:72088622	HP	0.41	4.44	0.34	1.71e-5	Fibrinogen levels;
PAAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg22022671	chr5:83253023	EDIL3	-0.52	-6.31	-0.46	2.97e-9	Energy expenditure (24h);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23568552	chr17:73105988	ARMC7	0.65	7.03	0.5	6.51e-11	Myopia (pathological);
PAAD	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs714031	0.934	rs5757768	chr22:40071322	G/A	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.29	-0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7092929	1.000	rs7097515	chr10:3539690	A/G	cg14308648	chr10:3568949	NA	0.57	4.52	0.34	1.25e-5	Coronary artery calcification;
PAAD	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.62	-0.35	8.01e-6	Triglycerides;
PAAD	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg12935359	chr14:103987150	CKB	-0.61	-6.42	-0.46	1.64e-9	Body mass index;
PAAD	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.52	5.2	0.39	6.25e-7	Breast cancer;
PAAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.82	-0.36	3.47e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg07153921	chr17:41440717	NA	-0.42	-4.48	-0.34	1.47e-5	Menopause (age at onset);
PAAD	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.42	4.33	0.33	2.65e-5	Longevity;Endometriosis;
PAAD	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.49	-7.02	-0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg07883600	chr3:53528162	CACNA1D	0.4	4.25	0.33	3.65e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.82	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg09796270	chr17:17721594	SREBF1	0.44	4.72	0.36	5.31e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.8	-6.66	-0.48	4.83e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs317865	0.867	rs7668729	chr4:16180391	A/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	-0.81	-5.91	-0.43	2.22e-8	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.67	5.86	0.43	2.72e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs939584	0.877	rs62105307	chr2:633661	A/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02574952	chr11:65104563	DPF2	-0.55	-6.51	-0.47	1.01e-9	Monocyte percentage of white cells;
PAAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.16	0.55	1.15e-13	Schizophrenia;
PAAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.96	6.46	0.46	1.36e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.7	-7.25	-0.51	1.97e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3857067	1.000	rs4693364	chr4:95012284	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.51	8.07	0.55	2.03e-13	IgG glycosylation;
PAAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03290511	chr15:28457389	HERC2	-0.68	-6.7	-0.48	3.74e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg16205897	chr5:131564050	P4HA2	-0.42	-4.61	-0.35	8.63e-6	Breast cancer;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg00601450	chr5:74908170	NA	0.49	4.4	0.34	2.05e-5	Coronary artery disease;
PAAD	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.7	5.71	0.42	5.7e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg08345082	chr10:99160200	RRP12	-0.31	-4.36	-0.33	2.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-4.46	-0.34	1.6e-5	Schizophrenia;
PAAD	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.69	-7.31	-0.51	1.44e-11	Metabolic syndrome;
PAAD	cis	rs2882667	0.690	rs700624	chr5:138099021	C/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg05697835	chr1:2722811	NA	-0.42	-4.81	-0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.67	8.76	0.58	3.67e-15	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg01475377	chr6:109611718	NA	0.4	4.46	0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8105895	1.000	rs62112917	chr19:22226580	C/T	cg20662725	chr19:22235022	ZNF257	-0.56	-4.37	-0.33	2.25e-5	Body mass index (change over time);
PAAD	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg09659197	chr4:152720779	NA	0.37	5.29	0.39	4.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.73	-0.42	5.22e-8	Menopause (age at onset);
PAAD	cis	rs6494488	0.500	rs72741327	chr15:64730822	G/C	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01013738	chr7:1149705	C7orf50	0.64	7.64	0.53	2.22e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg05791153	chr7:19748676	TWISTNB	0.74	4.99	0.38	1.63e-6	Night sleep phenotypes;
PAAD	cis	rs2479106	0.963	rs7850870	chr9:126509996	C/T	cg16191174	chr9:126692580	DENND1A	0.48	4.4	0.34	2.05e-5	Polycystic ovary syndrome;
PAAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg03037974	chr15:76606532	NA	-0.48	-5.49	-0.41	1.63e-7	Blood metabolite levels;
PAAD	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.38	5.21	0.39	6.1e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs215088	0.879	rs182482	chr16:16071020	G/A	cg08996506	chr16:16070868	ABCC1	0.36	4.27	0.33	3.46e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg20936604	chr3:58311152	NA	-0.77	-4.39	-0.34	2.15e-5	Cholesterol, total;
PAAD	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg19337854	chr7:99768885	GPC2	0.44	4.56	0.35	1.06e-5	Coronary artery disease;
PAAD	cis	rs9487051	0.621	rs9374076	chr6:109597826	G/T	cg21918786	chr6:109611834	NA	-0.47	-4.95	-0.37	1.97e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.82	-0.36	3.49e-6	Large artery stroke;
PAAD	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg26816564	chr1:7831052	VAMP3	-0.75	-6.19	-0.45	5.37e-9	Inflammatory bowel disease;
PAAD	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.59	5.39	0.4	2.7e-7	Lymphocyte counts;
PAAD	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.51	5.31	0.4	3.84e-7	Menopause (age at onset);
PAAD	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-0.91	-7.32	-0.51	1.31e-11	Dupuytren's disease;
PAAD	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.77	9.22	0.6	2.31e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.48	-4.45	-0.34	1.68e-5	Endometrial cancer;
PAAD	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.65	6.65	0.47	4.95e-10	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23511169	chr19:55851260	SUV420H2	0.59	6.44	0.46	1.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg08282784	chr12:121454133	C12orf43	0.68	6.65	0.47	5.07e-10	Primary biliary cholangitis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12229505	chr15:80351983	ZFAND6	0.68	6.46	0.46	1.32e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.06	-0.55	2.05e-13	Coffee consumption (cups per day);
PAAD	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg06713675	chr4:122721982	EXOSC9	0.45	4.38	0.34	2.16e-5	Type 2 diabetes;
PAAD	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.77	-0.36	4.36e-6	Inflammatory biomarkers;
PAAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg14709524	chr16:89940631	TCF25	0.99	4.6	0.35	8.84e-6	Skin colour saturation;
PAAD	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.99	5.36	0.4	2.98e-7	Childhood ear infection;
PAAD	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12304921	0.872	rs17122760	chr12:51519106	A/G	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.55	-0.35	1.08e-5	Type 2 diabetes;
PAAD	cis	rs877529	1.000	rs139413	chr22:39553772	C/T	cg13455509	chr22:39551605	NA	0.44	4.25	0.33	3.76e-5	Multiple myeloma;
PAAD	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.57	5.06	0.38	1.18e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.71	6.09	0.44	8.65e-9	Migraine;Coronary artery disease;
PAAD	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg02250501	chr15:90694978	NA	0.5	4.32	0.33	2.85e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-7.81	-0.53	8.88e-13	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg07148914	chr20:33460835	GGT7	0.54	5.06	0.38	1.18e-6	Coronary artery disease;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg02706910	chr19:24269975	ZNF254	0.63	6.37	0.46	2.1e-9	Body mass index;
PAAD	cis	rs2730260	0.736	rs7784586	chr7:158836379	T/C	cg02254261	chr7:158964346	NA	-0.6	-4.75	-0.36	4.74e-6	Myopia (pathological);
PAAD	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.56	-5.21	-0.39	5.95e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs832187	0.640	rs3774729	chr3:63982082	C/T	cg11558850	chr10:99695981	CRTAC1	0.69	6.46	0.46	1.32e-9	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg17127132	chr2:85788382	GGCX	-0.46	-4.53	-0.35	1.18e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs469568	0.543	rs11249618	chr5:178670507	T/C	cg08999896	chr5:178685787	ADAMTS2	0.55	5.75	0.42	4.85e-8	Stroke (pediatric);
PAAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.57	-5.34	-0.4	3.26e-7	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.48e-8	Prudent dietary pattern;
PAAD	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14447606	chr2:72370328	CYP26B1	-0.61	-6.42	-0.46	1.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.81	-0.43	3.61e-8	Schizophrenia;
PAAD	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg14343924	chr8:8086146	FLJ10661	-0.5	-4.37	-0.33	2.27e-5	Joint mobility (Beighton score);
PAAD	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Mosquito bite size;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21604972	chr3:115118067	NA	0.62	6.56	0.47	7.77e-10	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264213	0.892	rs6661867	chr1:36195809	C/A	cg27506609	chr1:36549197	TEKT2	0.63	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.69	-0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs6594713	0.921	rs7731231	chr5:112717546	C/A	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs12304921	1.000	rs7973904	chr12:51333424	T/C	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.24	-0.39	5.16e-7	Type 2 diabetes;
PAAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.96	8.58	0.57	1.06e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35995292	1.000	rs9638944	chr7:38947417	T/C	cg19327137	chr7:38886074	VPS41	0.42	4.35	0.33	2.53e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg02071572	chr4:1403502	NA	0.38	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg00262122	chr8:11665843	FDFT1	-0.52	-4.61	-0.35	8.62e-6	Neuroticism;
PAAD	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg07166546	chr14:35805898	NA	-0.3	-4.54	-0.35	1.12e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08082908	chr7:1067951	C7orf50	-0.79	-6.84	-0.49	1.8e-10	Neuroticism;
PAAD	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7929679	0.551	rs11032849	chr11:34785740	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.54	5.07	0.38	1.16e-6	Tonsillectomy;
PAAD	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.22	0.6	2.26e-16	Post bronchodilator FEV1;
PAAD	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.76	7.9	0.54	5.11e-13	Mean corpuscular volume;
PAAD	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-10.31	-0.64	3.08e-19	Vitiligo;
PAAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.72	-7.23	-0.51	2.2e-11	Menarche (age at onset);
PAAD	cis	rs818427	0.593	rs2545170	chr5:112204170	G/A	cg06941702	chr5:112196734	SRP19	-0.55	-5.47	-0.41	1.85e-7	Total body bone mineral density;
PAAD	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.62	5.9	0.43	2.3e-8	Height;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.01	-17.56	-0.82	2.09e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg14926445	chr8:58193284	C8orf71	-0.78	-6.13	-0.44	7.37e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.63	7.18	0.5	2.84e-11	High light scatter reticulocyte count;
PAAD	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.96e-6	Cognitive ability;
PAAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-6.0	-0.44	1.36e-8	Personality dimensions;
PAAD	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	1.01	7.1	0.5	4.37e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs72079386	1	rs72079386	chr2:97231618	ATGCT/A	cg09304357	chr2:97220596	NA	0.39	4.35	0.33	2.52e-5	Sum eosinophil basophil counts;
PAAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg12639453	chr1:2035780	PRKCZ	-0.56	-6.05	-0.44	1.06e-8	Height;
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	1.28	10.87	0.66	1.02e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg26312998	chr6:43337775	ZNF318	0.66	5.29	0.39	4.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs988913	0.957	rs1393774	chr6:54838449	G/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.77	-0.36	4.21e-6	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14765337	chr11:45931715	PEX16	-0.71	-7.63	-0.53	2.33e-12	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg00945038	chr17:61921165	SMARCD2	0.51	5.94	0.43	1.86e-8	Prudent dietary pattern;
PAAD	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.64	7.27	0.51	1.78e-11	Platelet distribution width;
PAAD	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.48	5.35	0.4	3.25e-7	Menarche (age at onset);
PAAD	cis	rs7873102	0.654	rs6476668	chr9:37975104	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs4740619	0.619	rs1410452	chr9:16042120	G/C	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg22764044	chr5:178986830	RUFY1	0.48	4.86	0.37	2.86e-6	Lung cancer;
PAAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg26816564	chr1:7831052	VAMP3	0.93	6.99	0.49	7.98e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs3812762	0.833	rs35670750	chr11:8782444	T/C	cg11156914	chr11:8892616	ST5	0.53	4.62	0.35	8.3e-6	Hypospadias;
PAAD	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.55	5.28	0.39	4.3e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg17372223	chr3:52568218	NT5DC2	-0.62	-6.37	-0.46	2.17e-9	Electroencephalogram traits;
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11245990	chr11:68621969	NA	0.38	4.81	0.36	3.61e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.31	-0.33	2.93e-5	Educational attainment (years of education);
PAAD	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.47	-4.58	-0.35	9.8e-6	Cognitive function;
PAAD	cis	rs6909834	0.636	rs1572000	chr6:12769487	G/A	cg17869960	chr6:12718530	PHACTR1	0.36	4.34	0.33	2.59e-5	Gait speed in old age;
PAAD	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.41	-0.34	1.93e-5	Systolic blood pressure;
PAAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14119001	chr9:139324193	INPP5E	-0.62	-5.58	-0.41	1.09e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.47	0.41	1.79e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg17325771	chr7:75508891	RHBDD2	0.39	4.54	0.35	1.15e-5	Eotaxin levels;
PAAD	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg00531865	chr16:30841666	NA	-0.65	-4.83	-0.36	3.29e-6	Diastolic blood pressure;
PAAD	cis	rs9907295	0.551	rs4795090	chr17:34123597	A/G	cg19411729	chr17:34207663	CCL5	-0.5	-4.45	-0.34	1.68e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs10901513	0.932	rs2366342	chr10:127671466	G/C	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg10985347	chr2:127963512	CYP27C1	0.48	4.83	0.36	3.34e-6	Protein C levels;
PAAD	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.18	0.39	7.04e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg15448220	chr1:150897856	SETDB1	0.64	6.7	0.48	3.72e-10	Tonsillectomy;
PAAD	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg27411982	chr8:10470053	RP1L1	0.42	4.39	0.34	2.11e-5	Neuroticism;
PAAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	1.08	15.14	0.78	3.6e-32	Breast cancer;
PAAD	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.54	-5.18	-0.39	6.8e-7	P wave terminal force;
PAAD	cis	rs748404	0.578	rs2584701	chr15:43684939	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.42	0.4	2.32e-7	Lung cancer;
PAAD	cis	rs372883	0.564	rs13051579	chr21:30589840	C/T	cg24692254	chr21:30365293	RNF160	0.5	5.32	0.4	3.68e-7	Pancreatic cancer;
PAAD	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg14440974	chr22:39074834	NA	0.59	7.26	0.51	1.82e-11	Menopause (age at onset);
PAAD	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.09	0.5	4.83e-11	Colorectal cancer;
PAAD	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.75	5.25	0.39	4.98e-7	Phospholipid levels (plasma);
PAAD	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.52	-0.41	1.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg14393609	chr7:65229607	NA	-0.53	-4.53	-0.34	1.21e-5	Aortic root size;
PAAD	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.81	-7.88	-0.54	5.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg19401529	chr3:49056140	DALRD3	0.55	4.55	0.35	1.07e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg16964102	chr10:135390573	NA	0.43	4.61	0.35	8.37e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.57	-6.79	-0.48	2.38e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02527881	chr3:46936655	PTH1R	0.42	5.1	0.38	9.85e-7	Colorectal cancer;
PAAD	cis	rs367943	0.712	rs26961	chr5:112736779	A/G	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.76	4.98	0.37	1.67e-6	Lung cancer in ever smokers;
PAAD	cis	rs75757892	0.504	rs9505165	chr6:7327436	A/C	cg02954307	chr6:7269328	NA	0.5	4.29	0.33	3.13e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.8	-0.53	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.59	-6.66	-0.48	4.64e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-0.83	-4.28	-0.33	3.28e-5	Skin colour saturation;
PAAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	5.85	0.43	2.94e-8	Alcohol dependence;
PAAD	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.49	5.07	0.38	1.13e-6	Red blood cell count;
PAAD	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.87e-13	Extrinsic epigenetic age acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22776125	chr6:167041314	RPS6KA2	0.64	7.2	0.5	2.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.79	0.58	3.06e-15	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02578557	chr2:198175821	NA	0.62	6.31	0.46	2.91e-9	Obesity-related traits;
PAAD	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg01270228	chr10:1369114	ADARB2	0.56	5.65	0.42	7.64e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7975161	0.572	rs11111919	chr12:104569918	C/A	cg25273343	chr12:104657179	TXNRD1	-0.88	-4.5	-0.34	1.36e-5	Toenail selenium levels;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.41	-0.46	1.77e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	6.86	0.49	1.59e-10	Leprosy;
PAAD	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.71	7.75	0.53	1.19e-12	Longevity;
PAAD	cis	rs9810890	1.000	rs73196972	chr3:128443796	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.71	-0.36	5.61e-6	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-1.11	-7.69	-0.53	1.69e-12	Post bronchodilator FEV1;
PAAD	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.58	-5.95	-0.43	1.79e-8	Hypospadias;
PAAD	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg10820045	chr2:198174542	NA	-0.44	-4.4	-0.34	2.03e-5	Dermatomyositis;
PAAD	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg19192590	chr2:178524533	PDE11A	0.4	4.63	0.35	7.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.78	5.53	0.41	1.4e-7	Gut microbiome composition (summer);
PAAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.7	-7.54	-0.52	3.92e-12	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.88	-0.63	4.22e-18	Blood trace element (Zn levels);
PAAD	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg02887458	chr19:19495540	GATAD2A	0.61	5.56	0.41	1.18e-7	Bipolar disorder;
PAAD	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.76	-7.86	-0.54	6.7e-13	Corneal structure;
PAAD	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg19102993	chr5:1523610	LPCAT1	0.6	6.38	0.46	2.01e-9	Iris heterochromicity;
PAAD	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.67e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.85	-0.49	1.68e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg20283391	chr11:68216788	NA	0.54	5.27	0.39	4.58e-7	Total body bone mineral density;
PAAD	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.46	-5.11	-0.38	9.58e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.95	11.9	0.69	1.68e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.79	7.86	0.54	6.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.6e-5	Platelet count;
PAAD	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg01620082	chr3:125678407	NA	-1.44	-8.61	-0.57	8.47e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.67e-19	Tonsillectomy;
PAAD	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.87	10.83	0.66	1.28e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.92	7.43	0.52	7.45e-12	Migraine;Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg07959490	chr17:80112427	CCDC57	-0.37	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg20435097	chr10:126320824	FAM53B	-0.47	-4.53	-0.34	1.2e-5	Cocaine dependence;
PAAD	cis	rs6604026	0.643	rs1360366	chr1:93330987	A/C	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs6539288	0.677	rs4964509	chr12:107357058	C/T	cg22764639	chr12:106532701	NUAK1	0.44	4.37	0.33	2.27e-5	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03247675	chr19:10812111	QTRT1	-0.72	-6.31	-0.46	2.87e-9	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26542501	chr3:124449238	UMPS	-0.57	-7.02	-0.49	7.03e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.97	0.44	1.58e-8	Alzheimer's disease;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.35	4.65	0.35	7.28e-6	Vitiligo;
PAAD	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg21479132	chr6:26055353	NA	0.92	5.66	0.42	7.17e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg02376097	chr19:46275166	DMPK	-0.57	-5.81	-0.43	3.52e-8	Coronary artery disease;
PAAD	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs6604026	0.656	rs10493863	chr1:93399694	T/C	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-4.59	-0.35	9.08e-6	Dementia with Lewy bodies;
PAAD	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.45	-5.64	-0.42	8.25e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04238871	chr10:126431886	FAM53B	0.65	7.24	0.51	2.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.72	7.3	0.51	1.47e-11	Mood instability;
PAAD	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.85	9.57	0.61	2.92e-17	Mortality in heart failure;
PAAD	cis	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg03400443	chr2:74347616	NA	0.55	4.3	0.33	3.02e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs3748682	0.861	rs28411034	chr1:38276997	G/A	cg12658694	chr1:38397304	INPP5B	0.47	4.43	0.34	1.78e-5	Hypothyroidism;
PAAD	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-0.99	-5.46	-0.41	1.87e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-4.63	-0.35	7.77e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg27499820	chr13:21296301	IL17D	-0.52	-5.12	-0.38	9.19e-7	Dental caries;
PAAD	cis	rs1351164	1.000	rs10181989	chr2:218294915	T/C	cg15335768	chr2:218268053	DIRC3	-0.5	-5.59	-0.41	1.03e-7	Height;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01283332	chr5:1856932	NA	-0.45	-4.73	-0.36	5.03e-6	Cardiovascular disease risk factors;
PAAD	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.28	0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs13424612	0.839	rs4149548	chr2:240933241	A/G	cg01812947	chr2:240904978	NDUFA10	-0.53	-5.02	-0.38	1.42e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs8028182	0.636	rs11637586	chr15:75791112	G/C	cg20655648	chr15:75932815	IMP3	0.5	4.41	0.34	1.92e-5	Sudden cardiac arrest;
PAAD	cis	rs735539	0.598	rs745680	chr13:21269314	T/G	cg27499820	chr13:21296301	IL17D	0.5	4.92	0.37	2.23e-6	Dental caries;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01927065	chr2:97001301	NCAPH	0.62	7.11	0.5	4.26e-11	Monocyte percentage of white cells;
PAAD	cis	rs7224685	0.815	rs8070159	chr17:4073447	A/G	cg05562828	chr17:3906858	NA	0.43	4.39	0.34	2.15e-5	Type 2 diabetes;
PAAD	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26306683	chr17:18585705	ZNF286B	0.57	5.74	0.42	5.03e-8	Educational attainment (years of education);
PAAD	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	1.27	7.44	0.52	6.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs9322817	0.607	rs9404572	chr6:105149439	T/C	cg02098413	chr6:105308735	HACE1	-0.45	-5.8	-0.43	3.76e-8	Thyroid stimulating hormone;
PAAD	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.37	-4.66	-0.35	6.72e-6	Menarche (age at onset);
PAAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg09796270	chr17:17721594	SREBF1	-0.5	-5.47	-0.41	1.82e-7	Total body bone mineral density;
PAAD	cis	rs9659323	0.613	rs72705339	chr1:119471869	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.25	-0.33	3.7e-5	Body mass index;
PAAD	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1519814	1.000	rs7818027	chr8:121158662	G/C	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg21479132	chr6:26055353	NA	0.98	5.48	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	5.53	0.41	1.38e-7	Monocyte count;
PAAD	cis	rs7922314	0.571	rs79416716	chr10:64727030	T/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.93	9.41	0.61	7.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.5	4.76	0.36	4.38e-6	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12980019	chr19:42724343	ZNF526	0.7	7.64	0.53	2.29e-12	Myopia (pathological);
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg04844267	chr4:1394941	NA	0.41	4.54	0.35	1.14e-5	Obesity-related traits;
PAAD	cis	rs7176527	0.579	rs366717	chr15:85088079	G/A	cg24253500	chr15:84953950	NA	-0.54	-4.69	-0.36	6.09e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.76	-0.42	4.5e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs642743	0.934	rs614406	chr10:105954650	G/C	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.63	0.35	7.86e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.48	0.57	1.79e-14	Menarche (age at onset);
PAAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.6	0.35	8.9e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7091957	0.875	rs4880419	chr10:134456109	C/T	cg27286337	chr10:134555280	INPP5A	-0.58	-5.75	-0.42	4.67e-8	Gait speed in old age;
PAAD	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.69	5.79	0.43	3.87e-8	Common traits (Other);
PAAD	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.9	-9.78	-0.62	7.98e-18	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs10768122	1.000	rs1570214	chr11:35289819	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2e-5	Vitiligo;
PAAD	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.56	-5.39	-0.4	2.67e-7	QT interval;
PAAD	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.55	5.85	0.43	2.93e-8	Mean corpuscular volume;
PAAD	cis	rs8060686	0.764	rs73599521	chr16:67733322	G/A	cg09835421	chr16:68378352	PRMT7	-0.93	-5.32	-0.4	3.69e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg05338066	chr1:7812865	CAMTA1	0.61	4.75	0.36	4.62e-6	Inflammatory bowel disease;
PAAD	cis	rs6547631	0.527	rs55665393	chr2:85927727	T/C	cg24620635	chr2:85921963	GNLY	0.41	5.32	0.4	3.6e-7	Blood protein levels;
PAAD	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.64	6.14	0.45	6.85e-9	Aortic root size;
PAAD	cis	rs6065	0.529	rs113183521	chr17:4930115	G/A	cg02990439	chr17:4875527	CAMTA2	-0.87	-4.76	-0.36	4.4e-6	Platelet count;
PAAD	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs11112613	0.609	rs7966960	chr12:106032152	G/A	cg03607813	chr12:105948248	NA	0.77	5.51	0.41	1.51e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.2	0.45	5.05e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs600550	0.588	rs10897049	chr11:60100581	C/T	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.68	0.72	1.37e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.62	-7.0	-0.49	7.89e-11	Longevity;Endometriosis;
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.43	0.56	2.51e-14	Homoarginine levels;
PAAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02161503	chr7:157955692	PTPRN2	0.55	6.49	0.47	1.15e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11696501	0.688	rs6073862	chr20:44331705	T/C	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.63	-0.47	5.52e-10	Brain structure;
PAAD	cis	rs9567406	1.000	rs9567404	chr13:44869808	T/A	cg08635097	chr13:44833857	NA	-0.64	-4.47	-0.34	1.52e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.01	-17.81	-0.82	4.82e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.47	-5.09	-0.38	1.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3753841	0.832	rs4381210	chr1:103247297	C/T	cg24495344	chr1:103574097	COL11A1	0.38	4.41	0.34	1.96e-5	Glaucoma (primary angle closure);
PAAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg00579200	chr11:133705235	NA	-0.51	-5.72	-0.42	5.4e-8	Childhood ear infection;
PAAD	cis	rs643506	0.874	rs618421	chr11:111648809	T/C	cg09085632	chr11:111637200	PPP2R1B	0.56	4.97	0.37	1.81e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg20129853	chr10:51489980	NA	0.45	4.33	0.33	2.7e-5	Prostate-specific antigen levels;
PAAD	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Lung cancer;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.41	-0.4	2.41e-7	Life satisfaction;
PAAD	cis	rs8070740	0.898	rs11078562	chr17:5326857	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.62	0.35	8.25e-6	Menopause (age at onset);
PAAD	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg11630242	chr17:19881632	AKAP10	0.48	4.4	0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	cis	rs8040855	0.627	rs11637512	chr15:85648759	T/C	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs10901513	0.932	rs2366341	chr10:127669318	C/T	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16931807	chr17:73452755	KIAA0195	-0.63	-6.4	-0.46	1.8e-9	Smoking initiation;
PAAD	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg02389323	chr16:88786976	FAM38A	1.05	6.87	0.49	1.58e-10	Plateletcrit;
PAAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Lymphocyte counts;
PAAD	cis	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg23087877	chr10:22022646	MLLT10	0.54	4.41	0.34	1.98e-5	Photic sneeze reflex;
PAAD	trans	rs61931739	0.510	rs2200158	chr12:33648538	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-6.47	-0.46	1.3e-9	Morning vs. evening chronotype;
PAAD	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.55	4.65	0.35	7.05e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs3925075	0.509	rs11574631	chr16:31363977	C/T	cg02846316	chr16:31340340	ITGAM	0.46	5.29	0.39	4.11e-7	IgA nephropathy;
PAAD	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.95	-9.13	-0.6	3.88e-16	Longevity;
PAAD	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg02404636	chr22:31891804	SFI1	-0.61	-5.48	-0.41	1.71e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.34	4.98	0.37	1.68e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.73	6.29	0.45	3.2e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg10621924	chr7:39171070	POU6F2	0.27	4.52	0.34	1.24e-5	IgG glycosylation;
PAAD	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.03	-0.44	1.18e-8	Fear of minor pain;
PAAD	cis	rs735539	0.645	rs9552248	chr13:21159200	G/A	cg27499820	chr13:21296301	IL17D	0.52	4.9	0.37	2.39e-6	Dental caries;
PAAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.36	17.32	0.81	8.59e-38	Eosinophil percentage of granulocytes;
PAAD	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.55	-4.5	-0.34	1.33e-5	Vitiligo;
PAAD	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	13.93	0.75	5.86e-29	Schizophrenia;
PAAD	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg04719120	chr6:96025338	MANEA	0.55	4.33	0.33	2.68e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.71	-8.57	-0.57	1.08e-14	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.52	-4.81	-0.36	3.57e-6	Strep throat;
PAAD	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs7714584	1.000	rs3857422	chr5:150268609	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02949469	chr2:219135266	PNKD;AAMP	0.57	6.48	0.47	1.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.53	5.19	0.39	6.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.98	-7.67	-0.53	1.88e-12	Initial pursuit acceleration;
PAAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	4.95	0.37	1.91e-6	Bone mineral density;
PAAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.77	0.66	1.9e-20	Smoking behavior;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.63	6.05	0.44	1.06e-8	Lung cancer;
PAAD	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.62	0.35	8.04e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Body mass index;
PAAD	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.35	-0.4	3.17e-7	Subjective well-being;
PAAD	cis	rs28655083	0.509	rs285024	chr16:77099844	G/A	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05793409	chr1:35658810	SFPQ	0.6	6.66	0.48	4.74e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg20312557	chr2:97357134	FER1L5	-0.83	-4.43	-0.34	1.77e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	5.17	0.39	7.17e-7	Personality dimensions;
PAAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13647721	chr17:30228624	UTP6	0.58	4.46	0.34	1.56e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.58	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs4580973	1	rs4580973	chr7:104903659	A/G	cg04380332	chr7:105027541	SRPK2	0.49	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg10820045	chr2:198174542	NA	0.44	4.36	0.33	2.42e-5	Dermatomyositis;
PAAD	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.59	5.16	0.39	7.5e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg09324608	chr17:30823087	MYO1D	0.5	5.26	0.39	4.92e-7	Schizophrenia;
PAAD	cis	rs216303	0.642	rs216324	chr12:6145225	A/G	cg12895370	chr12:6755816	ACRBP	-0.59	-4.66	-0.35	6.8e-6	Low vWF levels;
PAAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg20673091	chr1:2541236	MMEL1	0.86	10.59	0.65	5.63e-20	Ulcerative colitis;
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.57	-0.47	7.59e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	5.0	0.38	1.54e-6	Platelet count;Platelet distribution width;Mean platelet volume;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs755249	0.567	rs1126313	chr1:39639744	A/C	cg14018543	chr1:39659967	MACF1	0.55	4.6	0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9398803	0.661	rs853985	chr6:127020173	C/T	cg19875578	chr6:126661172	C6orf173	-0.44	-4.59	-0.35	9.14e-6	Male-pattern baldness;
PAAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg17595323	chr11:93583763	C11orf90	0.36	4.52	0.34	1.24e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg09835421	chr16:68378352	PRMT7	-1.4	-9.57	-0.61	2.86e-17	Magnesium levels;
PAAD	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs72627123	1.000	rs72627129	chr14:74374805	T/C	cg19860245	chr14:74300557	NA	-0.72	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs4561483	0.603	rs11639888	chr16:11934623	G/A	cg08843971	chr16:11963173	GSPT1	0.43	4.66	0.35	7.01e-6	Testicular germ cell tumor;
PAAD	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-1.0	-10.15	-0.64	8.34e-19	Menarche (age at onset);
PAAD	cis	rs2271400	0.556	rs7837821	chr8:56738256	A/G	cg08894788	chr8:56792171	LYN	-0.54	-4.97	-0.37	1.77e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.59e-13	Coronary artery disease;
PAAD	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10132987	chr3:171757307	FNDC3B	0.65	6.76	0.48	2.81e-10	Obesity-related traits;
PAAD	cis	rs4740619	0.689	rs10810501	chr9:15951954	G/C	cg14451791	chr9:16040625	NA	-0.43	-4.83	-0.37	3.24e-6	Body mass index;
PAAD	cis	rs11811982	0.793	rs11807068	chr1:227514908	T/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg15117754	chr3:10150083	C3orf24	0.66	5.67	0.42	7.07e-8	Alzheimer's disease;
PAAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.93	9.83	0.62	6.03e-18	Cognitive function;
PAAD	cis	rs6596100	0.500	rs35534543	chr5:132160057	C/T	cg16419906	chr5:132167176	NA	-0.58	-4.38	-0.33	2.22e-5	Breast cancer;
PAAD	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg22356347	chr1:167427500	CD247	-0.46	-5.39	-0.4	2.58e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	11.04	0.67	3.57e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.93	6.4	0.46	1.85e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24105744	chr5:138993362	UBE2D2	-0.52	-6.46	-0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.44	0.46	1.47e-9	Lung cancer in ever smokers;
PAAD	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	1.01	5.64	0.42	8.13e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.69	-0.36	6.01e-6	Lung cancer in ever smokers;
PAAD	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg16205897	chr5:131564050	P4HA2	-0.49	-5.41	-0.4	2.45e-7	Blood metabolite levels;
PAAD	cis	rs2241685	0.570	rs2195905	chr2:1907728	C/T	cg22511877	chr2:1942942	MYT1L	-0.74	-5.08	-0.38	1.11e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9905704	0.633	rs2526368	chr17:56470310	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs722599	0.501	rs10139347	chr14:75390135	T/C	cg06637938	chr14:75390232	RPS6KL1	0.63	6.22	0.45	4.55e-9	IgG glycosylation;
PAAD	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg27542038	chr10:14027202	FRMD4A	-0.44	-4.3	-0.33	3.08e-5	Adiponectin levels;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05665937	chr4:1216051	CTBP1	0.54	5.93	0.43	2.01e-8	Obesity-related traits;
PAAD	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg22907277	chr7:1156413	C7orf50	0.75	7.14	0.5	3.62e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.45	-0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9888739	1.000	rs36055763	chr16:31299775	C/T	cg02256631	chr16:31342952	ITGAM	-0.55	-4.32	-0.33	2.78e-5	Systemic lupus erythematosus;
PAAD	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	1.22	13.58	0.74	5.16e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	4.63	0.35	7.75e-6	Blood protein levels;
PAAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg11833968	chr6:79620685	NA	-0.42	-4.29	-0.33	3.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16976116	0.901	rs11852763	chr15:55494606	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	5.16	0.39	7.72e-7	Height;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7873102	0.630	rs12347935	chr9:38001073	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.04	-0.38	1.28e-6	Brain structure;
PAAD	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.6	-6.97	-0.49	8.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10924309	0.855	rs2008766	chr1:245860205	C/A	cg00036263	chr1:245852353	KIF26B	-0.68	-5.9	-0.43	2.24e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.83	-9.65	-0.62	1.72e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9810890	1.000	rs74961584	chr3:128567032	T/C	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	10.75	0.66	2.13e-20	Monocyte count;
PAAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.53	5.96	0.44	1.71e-8	Major depressive disorder;
PAAD	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.68	0.58	5.8e-15	Platelet count;
PAAD	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.79	-7.67	-0.53	1.94e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Body mass index;
PAAD	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.72	7.36	0.51	1.07e-11	Alcohol dependence;
PAAD	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs3736485	0.932	rs2278988	chr15:51915234	A/C	cg19558802	chr15:51695713	GLDN	-0.44	-4.41	-0.34	1.97e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.55	5.02	0.38	1.44e-6	Facial morphology (factor 20);
PAAD	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg17333051	chr19:2783644	SGTA	0.43	4.76	0.36	4.38e-6	Total cholesterol levels;
PAAD	cis	rs9506514	0.509	rs9506515	chr13:21132009	T/G	cg27234864	chr13:21295941	IL17D	-0.49	-4.62	-0.35	8.05e-6	Coronary artery calcification;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.54e-7	Breast cancer;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22162314	chr17:61951766	CSH2	-0.56	-5.76	-0.42	4.49e-8	Height;
PAAD	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-4.42	-0.34	1.89e-5	Red blood cell count;
PAAD	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.78	8.73	0.58	4.26e-15	Bladder cancer;
PAAD	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.36	3.63e-6	Coronary artery disease;
PAAD	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.63	-5.61	-0.41	9.23e-8	Mean corpuscular volume;
PAAD	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	4.71	0.36	5.56e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20893717	chr7:100318190	EPO	0.43	4.73	0.36	4.99e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.57	6.72	0.48	3.52e-10	Schizophrenia;
PAAD	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg04907244	chr7:22894795	SNORD93	-0.38	-4.35	-0.33	2.46e-5	Fibrinogen;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.85	0.43	2.84e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg10495392	chr1:46806563	NSUN4	0.59	5.83	0.43	3.2e-8	Menopause (age at onset);
PAAD	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg18551225	chr6:44695536	NA	-0.71	-7.26	-0.51	1.86e-11	Total body bone mineral density;
PAAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.31	4.32	0.33	2.76e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	9.44	0.61	6.33e-17	Electrocardiographic conduction measures;
PAAD	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00142150	chr22:38071001	LGALS1	0.69	7.73	0.53	1.39e-12	Fat distribution (HIV);
PAAD	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.75	-8.53	-0.57	1.38e-14	Menopause (age at onset);
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.78	-0.42	4.12e-8	Life satisfaction;
PAAD	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.71	8.38	0.56	3.34e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.59	-6.25	-0.45	4.02e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg09471204	chr22:42347991	LOC339674	0.33	4.33	0.33	2.74e-5	Cognitive function;
PAAD	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs2051773	0.567	rs77545208	chr11:17047747	G/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-4.54	-0.35	1.13e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg19680485	chr15:31195859	MTMR15	-0.43	-4.35	-0.33	2.49e-5	Huntington's disease progression;
PAAD	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg18700516	chr19:44507157	ZNF230	0.48	4.42	0.34	1.85e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg11271282	chr2:238384023	NA	0.53	4.87	0.37	2.8e-6	Prostate cancer;
PAAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.6	6.08	0.44	9.32e-9	Coronary artery disease;
PAAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.88	-10.07	-0.63	1.4e-18	Ulcerative colitis;
PAAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.69	5.09	0.38	1.07e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08704884	chr19:59070524	UBE2M;LOC100131691	0.67	7.75	0.53	1.2e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17374677	chr20:2489892	ZNF343	-0.6	-7.02	-0.49	7.01e-11	Body fat percentage;
PAAD	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg09998033	chr7:158218633	PTPRN2	-0.76	-7.92	-0.54	4.57e-13	Obesity-related traits;
PAAD	cis	rs8040855	0.597	rs994989	chr15:85660716	G/C	cg08123816	chr15:85640762	PDE8A	-0.46	-5.54	-0.41	1.3e-7	Bulimia nervosa;
PAAD	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs12780845	1.000	rs34434809	chr10:17187634	G/C	cg00857480	chr10:17188594	TRDMT1	0.38	4.89	0.37	2.51e-6	Homocysteine levels;
PAAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-4.39	-0.34	2.1e-5	Coronary artery disease;
PAAD	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg02404636	chr22:31891804	SFI1	0.64	5.93	0.43	1.99e-8	Colorectal cancer;
PAAD	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	trans	rs901683	1.000	rs77204970	chr10:46034949	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7113874	0.797	rs4503528	chr11:8664454	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	4.8	0.36	3.76e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9826463	0.818	rs9858204	chr3:142299855	C/T	cg20824294	chr3:142316082	PLS1	0.42	4.67	0.35	6.47e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-1.2	-10.86	-0.66	1.06e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.77	8.97	0.59	1.05e-15	Heart rate;
PAAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.76	-8.52	-0.57	1.43e-14	Childhood ear infection;
PAAD	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg27449745	chr7:23145252	KLHL7	-0.52	-4.41	-0.34	1.97e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg16606324	chr3:10149918	C3orf24	0.63	5.03	0.38	1.35e-6	Alzheimer's disease;
PAAD	cis	rs1996152	0.543	rs11077747	chr17:72385894	G/C	cg23221732	chr17:72383708	NA	-0.61	-5.21	-0.39	6.01e-7	Interleukin-12p70 levels;
PAAD	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg22134325	chr11:66188745	NPAS4	0.29	4.3	0.33	2.99e-5	Airway imaging phenotypes;
PAAD	cis	rs7243821	0.921	rs57718472	chr18:52628757	A/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs6715793	0.901	rs17566780	chr2:33410088	G/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.39e-7	Monocyte count;
PAAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.6	6.99	0.49	8.05e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs939584	1.000	rs6728726	chr2:623976	A/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.61	-0.35	8.35e-6	Recombination measurement;
PAAD	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.83	0.48	1.89e-10	Yeast infection;
PAAD	cis	rs1190596	0.525	rs10134693	chr14:102733324	A/T	cg23904247	chr14:102554826	HSP90AA1	0.43	4.97	0.37	1.81e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.64	-5.57	-0.41	1.1e-7	Exhaled nitric oxide output;
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg19761014	chr17:28927070	LRRC37B2	0.74	5.16	0.39	7.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9345521	0.967	rs924029	chr6:65494938	G/A	cg26414000	chr1:85721327	C1orf52	0.54	6.6	0.47	6.51e-10	Iris color (a* coordinate);
PAAD	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	6.59	0.47	6.78e-10	Menarche (age at onset);
PAAD	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-1.03	-11.43	-0.68	3.14e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg25204440	chr1:209979598	IRF6	-0.62	-4.89	-0.37	2.51e-6	Coronary artery disease;
PAAD	cis	rs2252790	1.000	rs12213442	chr6:116636907	G/A	cg18764771	chr6:116381957	FRK	0.25	4.33	0.33	2.75e-5	Fast beta electroencephalogram;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24136288	chr17:43183150	NMT1	0.69	8.12	0.55	1.49e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.18	0.73	6.33e-27	Platelet count;
PAAD	cis	rs7904985	1.000	rs7904985	chr10:88116479	A/G	cg07322936	chr10:88137208	NA	0.5	4.51	0.34	1.28e-5	Barrett's esophagus;
PAAD	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.59	6.05	0.44	1.06e-8	Lung disease severity in cystic fibrosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14431266	chr11:67057003	ANKRD13D	0.58	6.5	0.47	1.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11871801	0.846	rs4792923	chr17:40690118	G/C	cg21692620	chr17:40835849	CNTNAP1	0.48	4.95	0.37	1.93e-6	Crohn's disease;
PAAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg16147221	chr4:10020634	SLC2A9	0.48	4.37	0.33	2.26e-5	Bone mineral density;
PAAD	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-7.31	-0.51	1.4e-11	Asthma;
PAAD	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.41	4.43	0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs11892454	0.515	rs11888036	chr2:26063775	C/T	cg25181710	chr2:26045287	ASXL2	-0.45	-5.17	-0.39	7.34e-7	Heschl's gyrus morphology;
PAAD	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.49	-0.34	1.41e-5	Biliary atresia;
PAAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg16926213	chr1:1841314	NA	0.38	4.63	0.35	7.66e-6	Body mass index;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.36	5.51e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.45	5.32	0.4	3.64e-7	P wave duration;
PAAD	cis	rs9815354	0.556	rs73073276	chr3:42025354	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10768122	1.000	rs4756204	chr11:35292312	G/A	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.26	-0.33	3.55e-5	Vitiligo;
PAAD	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs13006833	0.668	rs291461	chr2:191181644	T/G	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.11	0.5	4.13e-11	Lung cancer in ever smokers;
PAAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.09	0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.72	7.02	0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg15017067	chr4:17643749	FAM184B	0.45	5.27	0.39	4.62e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.9	-10.38	-0.64	2.09e-19	Cognitive function;
PAAD	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.59	-8.05	-0.55	2.18e-13	Endometriosis;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-9.35	-0.6	1.06e-16	Gut microbiome composition (summer);
PAAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.01	-0.44	1.34e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.87	-10.8	-0.66	1.54e-20	Body mass index;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.53	-0.47	9.07e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.81	10.04	0.63	1.65e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.8	6.16	0.45	6.12e-9	Diisocyanate-induced asthma;
PAAD	cis	rs13024765	0.550	rs6753509	chr2:225183305	C/A	cg22455342	chr2:225449267	CUL3	0.49	4.59	0.35	9.06e-6	Platelet-derived growth factor BB levels;
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.87	0.69	2.06e-23	Smoking behavior;
PAAD	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.47	4.46	0.34	1.62e-5	Type 2 diabetes;
PAAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-6.12	-0.44	7.42e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg21601837	chr3:125900065	ALDH1L1	-0.5	-5.44	-0.4	2.1e-7	Metabolite levels;
PAAD	cis	rs7487075	0.619	rs6582646	chr12:46813857	T/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.41	0.34	1.92e-5	Itch intensity from mosquito bite;
PAAD	cis	rs72827839	0.740	rs10514938	chr17:46322604	A/T	cg23391107	chr17:45924227	SP6	0.63	5.34	0.4	3.39e-7	Ease of getting up in the morning;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg23920097	chr1:209922102	NA	-0.5	-4.53	-0.34	1.18e-5	Red blood cell count;
PAAD	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.55	-6.1	-0.44	8.44e-9	Longevity;
PAAD	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg23281280	chr6:28129359	ZNF389	0.5	4.38	0.33	2.23e-5	Parkinson's disease;
PAAD	cis	rs112591243	0.685	rs2839294	chr21:47917664	T/C	cg26904215	chr21:47823096	PCNT	-0.82	-4.31	-0.33	2.87e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg22101045	chr11:47927509	NA	0.57	4.38	0.33	2.21e-5	Intraocular pressure;
PAAD	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.31	0.33	2.94e-5	Longevity;
PAAD	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg00806126	chr19:22604979	ZNF98	0.4	5.02	0.38	1.4e-6	Pain;
PAAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	5.01	0.38	1.49e-6	Mood instability;
PAAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19346786	chr7:2764209	NA	-0.36	-4.77	-0.36	4.21e-6	Height;
PAAD	cis	rs9398803	0.687	rs9491653	chr6:126943630	A/G	cg19875578	chr6:126661172	C6orf173	0.45	4.66	0.35	6.89e-6	Male-pattern baldness;
PAAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.72	-8.45	-0.57	2.18e-14	Diastolic blood pressure;
PAAD	cis	rs4740619	0.619	rs1359956	chr9:16044097	A/G	cg14451791	chr9:16040625	NA	-0.45	-4.96	-0.37	1.86e-6	Body mass index;
PAAD	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.54	-6.9	-0.49	1.35e-10	Height;
PAAD	cis	rs1419980	0.730	rs9634074	chr12:7734180	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.41	-4.66	-0.35	6.99e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.93	0.49	1.11e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.53	-5.48	-0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.88	-13.2	-0.73	5.42e-27	Dental caries;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg13198984	chr17:80129470	CCDC57	-0.38	-4.58	-0.35	9.77e-6	Life satisfaction;
PAAD	cis	rs593531	0.513	rs7947911	chr11:74023751	G/A	cg15851278	chr11:73669449	DNAJB13	0.4	5.07	0.38	1.16e-6	Neuroticism;
PAAD	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.99	9.32	0.6	1.27e-16	Triglycerides;
PAAD	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.72e-6	Oral cavity cancer;
PAAD	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.72	7.42	0.52	7.88e-12	Colorectal cancer;
PAAD	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-5.37	-0.4	2.86e-7	Daytime sleep phenotypes;
PAAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.85	10.94	0.66	6.68e-21	Aortic root size;
PAAD	cis	rs12304921	0.810	rs73092534	chr12:51358380	C/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.29	-0.33	3.21e-5	Type 2 diabetes;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg00738919	chr7:1100172	C7orf50	0.7	5.32	0.4	3.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg05554000	chr7:158905015	VIPR2	-0.71	-5.07	-0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.65	7.42	0.52	7.89e-12	High light scatter reticulocyte count;
PAAD	cis	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.58	-4.34	-0.33	2.61e-5	Hypertriglyceridemia;
PAAD	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03191565	chr19:47987374	KPTN	0.6	6.45	0.46	1.43e-9	Monocyte percentage of white cells;
PAAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg19847866	chr10:1019161	NA	-0.49	-4.28	-0.33	3.25e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.55	5.31	0.4	3.81e-7	Parkinson's disease;
PAAD	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.28	-0.39	4.3e-7	Mean platelet volume;
PAAD	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg14146966	chr2:61757674	XPO1	0.37	4.67	0.35	6.57e-6	Tuberculosis;
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.54	-5.6	-0.41	9.84e-8	Iron status biomarkers;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.55	0.41	1.27e-7	Alzheimer's disease;
PAAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.62	-7.6	-0.52	2.82e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4663969	0.839	rs7572563	chr2:234617236	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.86	-0.37	2.86e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.52	5.18	0.39	6.91e-7	Stem cell growth factor beta levels;
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs7539409	0.915	rs6576945	chr1:84252882	A/G	cg10977910	chr1:84465055	TTLL7	1.03	5.81	0.43	3.51e-8	Alzheimer's disease;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg14820908	chr5:178986412	RUFY1	0.49	4.85	0.37	3.08e-6	Lung cancer;
PAAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg21130718	chr4:1044621	NA	0.51	4.89	0.37	2.49e-6	Recombination rate (males);
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.8	8.68	0.58	5.84e-15	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.56	-5.26	-0.39	4.82e-7	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs61123157	0.895	rs9398069	chr6:106601165	A/G	cg03875496	chr6:106335674	NA	-0.26	-4.25	-0.33	3.76e-5	Monobrow;Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.43	0.46	1.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9472414	0.689	rs1402599	chr6:44799657	C/T	cg20913747	chr6:44695427	NA	0.44	4.27	0.33	3.4e-5	Height;
PAAD	cis	rs7582720	1.000	rs72932731	chr2:203650410	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.47	0.52	5.81e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg21546286	chr11:48923668	NA	-0.51	-5.03	-0.38	1.36e-6	HDL cholesterol;
PAAD	cis	rs7711186	0.655	rs75315590	chr5:178020818	A/T	cg17371294	chr5:178012716	COL23A1	-0.86	-4.52	-0.34	1.24e-5	Urate levels in obese individuals;
PAAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs7539409	0.831	rs6663583	chr1:84223168	A/G	cg10977910	chr1:84465055	TTLL7	0.7	4.58	0.35	9.76e-6	Alzheimer's disease;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7894051	1.000	rs7070635	chr10:135190127	T/C	cg24905316	chr10:135186343	ECHS1	-0.67	-4.34	-0.33	2.59e-5	Lifespan;
PAAD	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.61	4.7	0.36	5.68e-6	QT interval;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.71	0.62	1.22e-17	Prudent dietary pattern;
PAAD	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.47	0.76	2.24e-30	Headache;
PAAD	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg18281939	chr5:77783895	LHFPL2	0.51	5.7	0.42	6.18e-8	Triglycerides;
PAAD	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.43	-4.76	-0.36	4.54e-6	Testicular germ cell tumor;
PAAD	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.57	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.33	-0.4	3.53e-7	Glaucoma (primary open-angle);
PAAD	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.89	-9.71	-0.62	1.2e-17	Gut microbiota (bacterial taxa);
PAAD	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg05731713	chr7:157510257	PTPRN2	0.55	5.82	0.43	3.39e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.96	11.01	0.67	4.38e-21	IgG glycosylation;
PAAD	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26306683	chr17:18585705	ZNF286B	0.56	5.86	0.43	2.78e-8	Educational attainment (years of education);
PAAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg13918804	chr1:2043761	PRKCZ	0.42	5.64	0.42	8.11e-8	Height;
PAAD	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg14458575	chr2:238380390	NA	0.58	4.94	0.37	2.03e-6	Prostate cancer;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg17541715	chr7:1216824	NA	-0.47	-5.34	-0.4	3.37e-7	Longevity;Endometriosis;
PAAD	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-4.63	-0.35	7.92e-6	Menopause (age at onset);
PAAD	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.79	8.99	0.59	9.3e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg10925829	chr20:60860984	OSBPL2	-0.42	-4.3	-0.33	3.02e-5	Colorectal cancer;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.77	-7.91	-0.54	4.9e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2279817	0.780	rs12737453	chr1:18006107	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg01620082	chr3:125678407	NA	-1.28	-7.6	-0.52	2.79e-12	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.43	-0.46	1.55e-9	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12780845	1.000	rs10490958	chr10:17233450	A/G	cg00857480	chr10:17188594	TRDMT1	-0.34	-4.27	-0.33	3.45e-5	Homocysteine levels;
PAAD	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	1.2	7.85	0.54	7.09e-13	Prostate cancer;
PAAD	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.74	5.77	0.42	4.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7300001	0.510	rs73205064	chr12:110512546	A/G	cg12870014	chr12:110450643	ANKRD13A	0.87	4.77	0.36	4.28e-6	Headache;
PAAD	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.75	8.56	0.57	1.13e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.04e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg03407747	chr17:6899364	ALOX12	0.54	5.82	0.43	3.34e-8	Blood metabolite levels;
PAAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	5.27	0.39	4.58e-7	Schizophrenia;
PAAD	trans	rs6694672	1.000	rs6677082	chr1:197112533	G/A	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg14851346	chr12:38532713	NA	-0.44	-4.26	-0.33	3.61e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.86e-9	Bladder cancer;
PAAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.43	0.34	1.83e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.36	-0.33	2.34e-5	Coronary artery disease;
PAAD	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg14092571	chr14:90743983	NA	0.76	8.0	0.54	2.88e-13	Gut microbiota (bacterial taxa);
PAAD	cis	rs12533831	0.518	rs4725394	chr7:150851566	T/C	cg25403974	chr7:150105495	LOC728743	0.52	4.55	0.35	1.1e-5	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.65	4.82	0.36	3.5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg08992911	chr2:238395768	MLPH	0.61	5.76	0.42	4.49e-8	Prostate cancer;
PAAD	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	6.12	0.44	7.59e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	4.56	0.35	1.07e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6496044	0.507	rs8034676	chr15:86159262	C/T	cg13263323	chr15:86062960	AKAP13	-0.54	-5.75	-0.42	4.68e-8	Interstitial lung disease;
PAAD	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg18898632	chr2:242989856	NA	-0.85	-6.83	-0.48	1.92e-10	Obesity-related traits;
PAAD	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.7	9.57	0.61	2.77e-17	Crohn's disease;
PAAD	cis	rs9810890	1.000	rs73198868	chr3:128529111	T/C	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-7.74	-0.53	1.31e-12	Colorectal cancer;
PAAD	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg09066997	chr16:75300724	BCAR1	0.63	4.58	0.35	9.76e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg12559170	chr11:5275217	HBG2	0.44	4.28	0.33	3.24e-5	Hemoglobin levels;
PAAD	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19671926	chr4:122722719	EXOSC9	-0.61	-5.81	-0.43	3.49e-8	Type 2 diabetes;
PAAD	cis	rs73019876	0.836	rs8103368	chr19:22174872	A/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg08048268	chr3:133502702	NA	0.42	4.83	0.36	3.26e-6	Iron status biomarkers;
PAAD	cis	rs9463078	0.669	rs9381364	chr6:45069673	T/C	cg25276700	chr6:44698697	NA	-0.52	-5.72	-0.42	5.39e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg08501292	chr6:25962987	TRIM38	0.98	5.33	0.4	3.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.55	-5.56	-0.41	1.21e-7	Iron status biomarkers;
PAAD	cis	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.89	-0.43	2.44e-8	HDL cholesterol;
PAAD	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.92e-7	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg04125373	chr11:65430610	RELA	-0.65	-7.68	-0.53	1.77e-12	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09140693	chr7:54794760	NA	-0.56	-6.8	-0.48	2.29e-10	Energy expenditure (24h);
PAAD	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	10.6	0.65	5.35e-20	Chronic sinus infection;
PAAD	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg16230307	chr14:35515116	FAM177A1	-0.41	-4.36	-0.33	2.38e-5	Psoriasis;
PAAD	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs939584	0.932	rs13013021	chr2:632723	C/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.29	-0.56	5.67e-14	Schizophrenia;
PAAD	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.14	11.04	0.67	3.62e-21	Corneal structure;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg01181863	chr3:195395398	SDHAP2	0.65	4.41	0.34	1.98e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.62	6.86	0.49	1.6e-10	Lung cancer;
PAAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.79	-0.36	4.01e-6	Type 2 diabetes;
PAAD	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.75	-7.56	-0.52	3.63e-12	Retinal vascular caliber;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs58521262	0.729	rs12460438	chr19:23075779	C/A	cg07749055	chr19:23076870	NA	-0.68	-4.83	-0.36	3.28e-6	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.66	-8.24	-0.56	7.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3745621	1.000	rs34159938	chr19:47690811	G/A	cg24326880	chr19:47634349	SAE1	-0.53	-4.39	-0.34	2.12e-5	Lymphocyte counts;
PAAD	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.39	-5.51	-0.41	1.48e-7	Educational attainment (years of education);
PAAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg27234864	chr13:21295941	IL17D	-0.54	-4.76	-0.36	4.54e-6	Dental caries;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.47	-4.43	-0.34	1.78e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg19223190	chr17:80058835	NA	0.53	5.44	0.4	2.06e-7	Life satisfaction;
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	8.92	0.59	1.38e-15	Platelet count;
PAAD	cis	rs2648708	1.000	rs2648708	chr10:12601439	A/G	cg08360820	chr10:11652640	USP6NL	-0.74	-4.71	-0.36	5.51e-6	Calcium levels;
PAAD	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.36	0.51	1.1e-11	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	9.86	0.62	4.83e-18	Smoking behavior;
PAAD	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.75	-5.98	-0.44	1.51e-8	Uric acid levels;
PAAD	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17430781	chr7:4014989	SDK1	-0.7	-7.5	-0.52	4.9e-12	Obesity-related traits;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg00024416	chr22:24240387	NA	-0.57	-5.84	-0.43	3.04e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.22e-15	Diabetic kidney disease;
PAAD	cis	rs761746	0.584	rs62238892	chr22:32161549	C/A	cg01338084	chr22:32026380	PISD	0.6	5.27	0.39	4.51e-7	Intelligence;
PAAD	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	7.36	0.51	1.1e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1395	0.925	rs1659689	chr2:27393030	A/G	cg23587288	chr2:27483067	SLC30A3	0.61	5.56	0.41	1.18e-7	Blood metabolite levels;
PAAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	1.23	11.56	0.68	1.42e-22	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15554898	chr3:101498198	FAM55C	0.63	6.29	0.45	3.17e-9	Obesity-related traits;
PAAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.95	9.29	0.6	1.52e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-1.22	-6.67	-0.48	4.46e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	5.96	0.44	1.67e-8	Body mass index;
PAAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.8	7.38	0.51	9.4e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs9467603	0.925	rs1892251	chr6:25769349	T/C	cg23465465	chr6:26364728	BTN3A2	-0.69	-4.47	-0.34	1.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg09127314	chr1:152161683	NA	0.55	5.51	0.41	1.51e-7	Inflammatory skin disease;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-5.95	-0.43	1.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.79	8.98	0.59	9.84e-16	Heart rate;
PAAD	cis	rs3736485	0.934	rs28410165	chr15:51875019	C/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs59888335	0.964	rs66478528	chr3:80689872	C/G	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.07	6.98	0.49	8.73e-11	Body mass index;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.72	-8.32	-0.56	4.71e-14	Iron status biomarkers;
PAAD	cis	rs1539053	1.000	rs11207076	chr1:58097024	G/A	cg20292791	chr1:58089357	DAB1	-0.55	-5.45	-0.4	2e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.51e-21	Ulcerative colitis;
PAAD	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1371614	0.635	rs10196691	chr2:27141359	T/A	cg00617064	chr2:27272375	NA	0.45	4.74	0.36	4.86e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.77	8.68	0.58	5.83e-15	Lung cancer;
PAAD	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12776158	0.685	rs60677596	chr10:71216880	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-4.63	-0.35	7.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.59	-4.57	-0.35	1.01e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs2221894	1.000	rs10111019	chr8:28830300	C/G	cg20212339	chr8:28908912	HMBOX1	0.52	5.49	0.41	1.62e-7	Obesity-related traits;
PAAD	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.64	-0.35	7.33e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.51	-4.96	-0.37	1.84e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.81	-0.54	8.8e-13	Coronary artery disease;
PAAD	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16576597	chr16:28551801	NUPR1	0.66	7.4	0.51	8.86e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg09876464	chr15:85330779	ZNF592	0.45	4.49	0.34	1.39e-5	P wave terminal force;
PAAD	cis	rs7786877	0.723	rs62482237	chr7:100213476	A/G	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.36	-0.4	3.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.59	5.54	0.41	1.32e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13177180	0.671	rs9326970	chr5:114965602	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.46	-4.84	-0.37	3.11e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg06217245	chr20:33103252	DYNLRB1	0.4	4.48	0.34	1.49e-5	Height;
PAAD	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9652601	0.691	rs3893661	chr16:11193880	C/G	cg04616529	chr16:11181986	CLEC16A	0.37	4.49	0.34	1.41e-5	Systemic lupus erythematosus;
PAAD	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.13e-9	Educational attainment;
PAAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg24253500	chr15:84953950	NA	0.56	6.54	0.47	8.87e-10	Schizophrenia;
PAAD	cis	rs8077577	0.895	rs6502640	chr17:18122485	G/A	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg09654669	chr8:57350985	NA	-0.56	-5.38	-0.4	2.72e-7	Obesity-related traits;
PAAD	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg05043794	chr9:111880884	C9orf5	-0.33	-4.28	-0.33	3.31e-5	Menarche (age at onset);
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.56	-6.54	-0.47	8.64e-10	Prostate cancer;
PAAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08893839	chr5:154027129	NA	0.75	5.8	0.43	3.75e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9810890	1.000	rs73198894	chr3:128562396	T/C	cg18531004	chr3:128564980	NA	-0.9	-4.82	-0.36	3.39e-6	Dental caries;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20060178	chr11:119039643	NLRX1	0.62	6.77	0.48	2.64e-10	Myopia (pathological);
PAAD	cis	rs6681460	0.898	rs1032635	chr1:67195184	C/G	cg02459107	chr1:67143332	SGIP1	-0.7	-6.74	-0.48	3.03e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.53	5.03	0.38	1.35e-6	Mortality in heart failure;
PAAD	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.36	0.46	2.2e-9	Hip circumference;
PAAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.45e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs755249	0.567	rs41270821	chr1:39923732	T/C	cg14018543	chr1:39659967	MACF1	-0.54	-4.54	-0.35	1.15e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.4	4.41	0.34	1.91e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.8	-7.69	-0.53	1.73e-12	DNA methylation (variation);
PAAD	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.91	-6.94	-0.49	1.04e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg09835421	chr16:68378352	PRMT7	-0.67	-5.22	-0.39	5.76e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.54	-0.47	8.84e-10	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg07703079	chr11:430292	ANO9	0.77	4.43	0.34	1.82e-5	Body mass index;
PAAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg05484376	chr2:27715224	FNDC4	0.49	4.79	0.36	3.9e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.19	-0.39	6.5e-7	Menarche (age at onset);
PAAD	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.87	6.76	0.48	2.83e-10	Migraine;Coronary artery disease;
PAAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.57	-7.34	-0.51	1.19e-11	Longevity;
PAAD	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	0.81	9.71	0.62	1.19e-17	Breast cancer;
PAAD	cis	rs7714584	1.000	rs1816256	chr5:150272853	T/C	cg22134413	chr5:150180641	NA	0.73	5.21	0.39	5.93e-7	Crohn's disease;
PAAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.7	-6.7	-0.48	3.78e-10	Schizophrenia;
PAAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9314614	0.789	rs4840642	chr8:6712765	T/A	cg27319216	chr8:6693540	XKR5	-0.4	-5.34	-0.4	3.26e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs7627468	0.770	rs1979869	chr3:121963285	T/C	cg17240004	chr3:121949083	CASR	0.5	4.77	0.36	4.33e-6	Kidney stones;
PAAD	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.67	7.09	0.5	4.71e-11	Dupuytren's disease;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07648498	chr16:89883185	FANCA	0.69	7.17	0.5	3.02e-11	Vitiligo;
PAAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg24737193	chr18:12778029	NA	-0.68	-5.72	-0.42	5.48e-8	Inflammatory skin disease;
PAAD	cis	rs4481887	0.508	rs7349159	chr1:248386242	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-4.6	-0.35	8.88e-6	Common traits (Other);
PAAD	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.83	9.85	0.62	5.14e-18	Fuchs's corneal dystrophy;
PAAD	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	7.13	0.5	3.81e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.48	-0.34	1.43e-5	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg14926445	chr8:58193284	C8orf71	-0.77	-5.92	-0.43	2.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2414856	0.510	rs112523289	chr15:64905835	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Pulse pressure;Systolic blood pressure;
PAAD	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.53	-5.83	-0.43	3.26e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-8.71	-0.58	4.74e-15	Longevity;Endometriosis;
PAAD	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg03309721	chr19:2236316	PLEKHJ1;SF3A2	-0.56	-4.36	-0.33	2.37e-5	Bipolar disorder;
PAAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10698984	chr13:30424281	UBL3	-0.62	-6.32	-0.46	2.74e-9	Smoking initiation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01879437	chr15:78913683	CHRNA3	-0.66	-6.83	-0.48	1.89e-10	Smoking initiation;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg04160749	chr8:58172571	NA	0.72	4.83	0.36	3.37e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.64	-5.91	-0.43	2.2e-8	Cognitive test performance;
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.69	-7.6	-0.52	2.78e-12	Aortic root size;
PAAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-4.69	-0.36	5.93e-6	Coronary artery disease;
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg20821713	chr7:1055600	C7orf50	0.52	4.41	0.34	1.95e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3026101	0.671	rs1806239	chr17:5295528	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs2882667	0.690	rs160405	chr5:138084076	A/G	cg09476006	chr5:138032270	NA	0.46	5.92	0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.73	6.74	0.48	3.14e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs2073300	1.000	rs6137984	chr20:23469864	T/A	cg12062639	chr20:23401060	NAPB	0.95	4.7	0.36	5.72e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.07	-0.38	1.16e-6	Reticulocyte count;
PAAD	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.72	0.48	3.36e-10	Resting heart rate;
PAAD	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg27246729	chr12:121163418	ACADS	0.42	4.41	0.34	1.92e-5	Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.72	-0.36	5.32e-6	Joint mobility (Beighton score);
PAAD	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg19486271	chr11:47235900	DDB2	-0.55	-5.43	-0.4	2.15e-7	Acne (severe);
PAAD	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg01657329	chr11:68192670	LRP5	-0.74	-6.82	-0.48	2.07e-10	Total body bone mineral density;
PAAD	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	1.11	12.66	0.72	1.55e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs6494488	0.500	rs111793398	chr15:65079354	C/T	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.55	-6.22	-0.45	4.66e-9	Blood metabolite levels;
PAAD	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.24	0.51	2.08e-11	Lung cancer in ever smokers;
PAAD	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.51	4.61	0.35	8.47e-6	Lung cancer;
PAAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.51	5.83	0.43	3.15e-8	Tuberculosis;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.58	0.47	7.27e-10	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.28	0.39	4.4e-7	Resting heart rate;
PAAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.51	4.58	0.35	9.58e-6	Mood instability;
PAAD	cis	rs11209002	0.695	rs10889653	chr1:67560897	A/G	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Crohn's disease;
PAAD	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.74	-0.42	4.98e-8	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22947322	chr17:47091978	IGF2BP1	0.38	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.47	4.38	0.33	2.23e-5	Tuberculosis;
PAAD	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.47	-4.73	-0.36	5.18e-6	Type 1 diabetes;
PAAD	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg20913747	chr6:44695427	NA	-0.7	-6.86	-0.49	1.62e-10	Total body bone mineral density;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.51	6.02	0.44	1.24e-8	Testicular germ cell tumor;
PAAD	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg18944383	chr4:111397179	ENPEP	0.54	6.45	0.46	1.39e-9	Coronary artery disease;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.58	6.77	0.48	2.7e-10	Aortic root size;
PAAD	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-5.72	-0.42	5.45e-8	Vitiligo;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg02462569	chr6:150064036	NUP43	-0.51	-5.75	-0.42	4.69e-8	Lung cancer;
PAAD	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.24	-0.39	5.32e-7	Glomerular filtration rate;
PAAD	cis	rs7677751	0.943	rs9991165	chr4:55124591	A/G	cg23664174	chr4:54357316	LNX1	0.57	4.59	0.35	9.09e-6	Corneal astigmatism;
PAAD	cis	rs7072216	0.687	rs10786417	chr10:100153904	C/T	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.73	7.12	0.5	3.98e-11	Recombination rate (males);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07677396	chr7:143078637	ZYX	0.58	6.42	0.46	1.65e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.27	-0.33	3.4e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.39	-0.34	2.11e-5	Breast cancer;
PAAD	cis	rs7119038	0.629	rs11216994	chr11:118603520	C/T	cg04176122	chr11:118779835	BCL9L	0.43	4.62	0.35	8.08e-6	Sjögren's syndrome;
PAAD	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.36	0.33	2.35e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg21698718	chr17:80085957	CCDC57	-0.45	-5.1	-0.38	1.01e-6	Life satisfaction;
PAAD	cis	rs11168618	0.846	rs7974213	chr12:48881492	C/T	cg01881778	chr12:48919444	OR8S1	0.46	4.41	0.34	1.93e-5	Adiponectin levels;
PAAD	cis	rs7932354	0.583	rs10734548	chr11:46787573	T/C	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.24	-0.39	5.26e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg26554054	chr8:600488	NA	1.04	6.91	0.49	1.24e-10	IgG glycosylation;
PAAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg15117754	chr3:10150083	C3orf24	0.67	5.56	0.41	1.2e-7	Alzheimer's disease;
PAAD	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.59	-8.19	-0.55	1.01e-13	Breast cancer;
PAAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14472251	chr14:55493991	SOCS4;WDHD1	0.68	6.69	0.48	3.96e-10	Primary biliary cholangitis;
PAAD	cis	rs939584	1.000	rs12714414	chr2:651407	A/G	cg03610516	chr2:642275	NA	-0.63	-5.85	-0.43	2.9e-8	Body mass index;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	1.69	10.47	0.65	1.19e-19	Height;
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.15	-0.39	8.04e-7	Platelet count;
PAAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.58	5.79	0.43	3.89e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18404041	chr3:52824283	ITIH1	0.42	4.5	0.34	1.32e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.16	0.39	7.74e-7	Tonsillectomy;
PAAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Cleft lip with or without cleft palate;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg07791578	chr6:24358308	KAAG1;DCDC2	-0.66	-6.53	-0.47	9.32e-10	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02380278	chr5:71756236	ZNF366	-0.62	-6.4	-0.46	1.85e-9	Myopia (pathological);
PAAD	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.64	4.67	0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg03910582	chr17:19030146	GRAPL	-0.44	-4.32	-0.33	2.81e-5	Schizophrenia;
PAAD	cis	rs58521262	0.556	rs289333	chr19:23153042	C/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs6748734	0.625	rs4675792	chr2:241819526	A/G	cg04034577	chr2:241836375	C2orf54	0.34	4.99	0.38	1.64e-6	Urinary metabolites;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.1	0.5	4.51e-11	Renal function-related traits (BUN);
PAAD	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-7.08	-0.5	5.05e-11	Eye color traits;
PAAD	cis	rs2790216	0.950	rs2590351	chr10:60016075	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.29	-0.39	4.12e-7	Blood metabolite levels;
PAAD	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.8	8.44	0.56	2.27e-14	Corneal astigmatism;
PAAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.49	-4.26	-0.33	3.63e-5	Aortic root size;
PAAD	cis	rs6066835	0.850	rs3827042	chr20:47319307	G/A	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg08224773	chr8:11311868	FAM167A	0.38	4.49	0.34	1.43e-5	Rheumatoid arthritis;
PAAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg20821713	chr7:1055600	C7orf50	0.52	4.34	0.33	2.62e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9644630	0.745	rs7816777	chr8:19371767	T/C	cg10121113	chr8:20112959	LZTS1	-0.42	-4.41	-0.34	1.97e-5	Oropharynx cancer;
PAAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.77	12.09	0.7	5.35e-24	Breast cancer;
PAAD	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg21351543	chr2:191399470	TMEM194B	-0.69	-5.15	-0.39	7.91e-7	Diastolic blood pressure;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01585852	chr22:24235823	MIF	-0.44	-4.88	-0.37	2.66e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.61	-6.57	-0.47	7.48e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg16989719	chr2:238392110	NA	-0.4	-5.12	-0.38	8.95e-7	Prostate cancer;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg07648498	chr16:89883185	FANCA	0.55	5.31	0.4	3.9e-7	Vitiligo;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.56	6.41	0.46	1.75e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg21665744	chr7:39171113	POU6F2	-0.35	-5.3	-0.4	3.94e-7	IgG glycosylation;
PAAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.95	-13.51	-0.74	7.8e-28	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1455213	0.544	rs2604555	chr4:15168236	C/T	cg12377275	chr4:15005593	CPEB2	0.49	4.68	0.35	6.35e-6	Parental longevity (mother's age at death);
PAAD	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.72	-5.96	-0.44	1.72e-8	Gallbladder cancer;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.858	rs9931366	chr16:67725347	C/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.81	-0.36	3.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.57	-5.63	-0.42	8.35e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.76	-7.8	-0.53	9.2e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.88	7.17	0.5	3.01e-11	Gut microbiome composition (summer);
PAAD	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.66	5.75	0.42	4.75e-8	Educational attainment;
PAAD	cis	rs2916733	0.530	rs2251956	chr8:6288879	A/T	cg02465761	chr8:6735510	DEFB1	-0.42	-4.33	-0.33	2.64e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.96	-0.79	2.7200000000000002e-34	Schizophrenia;
PAAD	cis	rs4906332	1.000	rs911549	chr14:103984537	T/C	cg19000871	chr14:103996768	TRMT61A	0.51	5.73	0.42	5.15e-8	Coronary artery disease;
PAAD	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.53	5.14	0.38	8.48e-7	Cognitive ability;
PAAD	cis	rs6445967	1.000	rs11713627	chr3:58306946	T/G	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.26e-7	Diabetic kidney disease;
PAAD	cis	rs2635047	0.604	rs1434527	chr18:44742868	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-4.3	-0.33	3.07e-5	Educational attainment;
PAAD	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.39	0.51	9.36e-12	HIV-1 control;
PAAD	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg10515125	chr16:89437361	ANKRD11	0.45	4.31	0.33	2.97e-5	Squamous cell carcinoma;
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.97	-0.59	1e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.47	-4.73	-0.36	5.18e-6	Type 1 diabetes;
PAAD	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1190596	0.578	rs12887161	chr14:102706918	T/C	cg23904247	chr14:102554826	HSP90AA1	0.44	5.02	0.38	1.45e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg05627522	chr15:75251581	NA	-0.4	-4.68	-0.35	6.41e-6	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.74	-5.9	-0.43	2.3e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.74	6.05	0.44	1.08e-8	Alzheimer's disease;
PAAD	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg27511599	chr7:32358540	NA	-0.75	-4.53	-0.34	1.21e-5	Body mass index;
PAAD	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	6.07	0.44	9.69e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.85	8.65	0.57	6.88e-15	Corneal astigmatism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01082422	chr5:179224751	MGAT4B	-0.63	-6.88	-0.49	1.46e-10	Myopia (pathological);
PAAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.793	rs78469866	chr1:227575024	G/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.71	-8.79	-0.58	2.99e-15	Breast cancer;
PAAD	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.63	-5.58	-0.41	1.06e-7	Coronary artery disease;
PAAD	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.51	-6.2	-0.45	5.15e-9	Psoriasis;
PAAD	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.71	-6.27	-0.45	3.5e-9	Triglycerides;
PAAD	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.37	-5.21	-0.39	6.18e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg08677398	chr8:58056175	NA	0.61	4.34	0.33	2.57e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg17595323	chr11:93583763	C11orf90	-0.35	-4.46	-0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.69	-0.36	6.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.84	8.55	0.57	1.2e-14	Height;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26651784	chr16:67062934	CBFB	-0.64	-6.67	-0.48	4.42e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.67	-0.53	1.93e-12	Neuroticism;
PAAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.57	5.43	0.4	2.17e-7	Height;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs6489785	0.522	rs2701177	chr12:121344490	G/T	cg02419362	chr12:121203948	SPPL3	-0.49	-5.49	-0.41	1.68e-7	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4740619	0.592	rs2987035	chr9:15995946	A/G	cg14451791	chr9:16040625	NA	0.38	4.59	0.35	9.35e-6	Body mass index;
PAAD	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.42	-0.4	2.3e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs10821973	0.527	rs4590753	chr10:63976449	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg10018233	chr7:150070692	REPIN1	0.67	6.88	0.49	1.43e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg07153921	chr17:41440717	NA	-0.42	-4.49	-0.34	1.42e-5	Menopause (age at onset);
PAAD	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.18e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg13870426	chr17:30244630	NA	-0.73	-7.39	-0.51	9.23e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs56309584	0.755	rs66582670	chr17:8139339	T/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.44	-4.43	-0.34	1.76e-5	Initial pursuit acceleration;
PAAD	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs2734839	0.964	rs12800853	chr11:113302514	C/T	cg14159747	chr11:113255604	NA	0.44	6.67	0.48	4.39e-10	Information processing speed;
PAAD	cis	rs1468333	0.964	rs2967785	chr5:137543713	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.37	0.46	2.12e-9	Resting heart rate;
PAAD	cis	rs10916814	0.959	rs12037522	chr1:20900184	A/T	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg26939375	chr7:64535504	NA	-0.74	-8.9	-0.59	1.59e-15	Aortic root size;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.75	-0.36	4.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.75	-0.48	2.97e-10	Neuroticism;
PAAD	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg25401027	chr5:176370377	UIMC1	0.47	4.78	0.36	4.15e-6	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	5.4	0.4	2.55e-7	Mean platelet volume;
PAAD	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.2	-0.39	6.34e-7	Subjective well-being;
PAAD	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg23024343	chr7:107201750	COG5	0.58	4.75	0.36	4.61e-6	Coronary artery disease;
PAAD	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.62	-5.8	-0.43	3.72e-8	Cognitive function;
PAAD	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.53	4.96	0.37	1.88e-6	Multiple sclerosis;
PAAD	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg07944420	chr16:89185293	ACSF3	0.48	4.52	0.34	1.23e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg04160749	chr8:58172571	NA	-0.71	-4.89	-0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7804356	0.651	rs2189016	chr7:26785016	A/T	cg03456212	chr7:26904342	SKAP2	0.58	5.02	0.38	1.42e-6	Type 1 diabetes;
PAAD	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs714031	0.902	rs4820388	chr22:40070642	C/G	cg21377881	chr22:40064566	CACNA1I	-0.48	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.62	-6.85	-0.49	1.74e-10	Neuroticism;
PAAD	cis	rs11113894	0.901	rs12425076	chr12:108863470	A/C	cg06834313	chr12:108851556	NA	-0.77	-4.64	-0.35	7.54e-6	Obesity-related traits;
PAAD	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg23460851	chr4:1604456	NA	-0.41	-4.39	-0.34	2.09e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.74	7.96	0.54	3.71e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.04	0.44	1.13e-8	Menopause (age at onset);
PAAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.56	6.94	0.49	1.09e-10	Multiple system atrophy;
PAAD	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.94	8.26	0.56	6.68e-14	Bipolar disorder;
PAAD	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-5.87	-0.43	2.64e-8	Schizophrenia;
PAAD	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.37	12.7	0.72	1.18e-25	Corneal structure;
PAAD	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.69	-5.23	-0.39	5.57e-7	Vitiligo;
PAAD	cis	rs732765	0.819	rs714788	chr14:75320043	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.63	-5.14	-0.38	8.48e-7	Non-small cell lung cancer;
PAAD	cis	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.72	6.15	0.45	6.51e-9	Inflammatory skin disease;
PAAD	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.55	-5.95	-0.43	1.74e-8	Rheumatoid arthritis;
PAAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg20933634	chr6:27740509	NA	0.79	7.2	0.5	2.6e-11	Parkinson's disease;
PAAD	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.7	6.34	0.46	2.48e-9	Mean platelet volume;
PAAD	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.74	7.69	0.53	1.67e-12	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg21466736	chr12:48725269	NA	0.51	4.72	0.36	5.35e-6	Glycated hemoglobin levels;
PAAD	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	8.19	0.55	1.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.69	-7.11	-0.5	4.27e-11	Pulse pressure;
PAAD	cis	rs6084352	0.564	rs2326084	chr20:3251356	A/C	cg06251395	chr20:3663186	ADAM33	0.38	4.3	0.33	3.09e-5	Asthma;
PAAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.82	-9.07	-0.59	5.78e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.5	4.88	0.37	2.63e-6	Lung cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16134607	chr12:56512091	ZC3H10	0.58	6.44	0.46	1.45e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1497828	0.956	rs2646820	chr1:217526479	A/T	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg16040993	chr19:53496440	ZNF702P	-0.46	-4.61	-0.35	8.53e-6	Psoriasis;
PAAD	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4474465	0.920	rs10128743	chr11:78214673	C/T	cg27205649	chr11:78285834	NARS2	-0.63	-4.57	-0.35	1.02e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4731207	0.596	rs10269342	chr7:124693845	C/G	cg14311320	chr7:124405732	GPR37	0.41	4.26	0.33	3.55e-5	Cutaneous malignant melanoma;
PAAD	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.47	4.94	0.37	2.05e-6	Diastolic blood pressure;
PAAD	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg18265118	chr7:2139243	MAD1L1	0.54	4.5	0.34	1.34e-5	Neuroticism;
PAAD	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg00277334	chr10:82204260	NA	-0.6	-5.43	-0.4	2.21e-7	Post bronchodilator FEV1;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08788819	chr21:16437740	NRIP1	-0.6	-6.89	-0.49	1.38e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	0.54	6.11	0.44	8.11e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs507080	0.885	rs4938530	chr11:118560570	G/T	cg08498647	chr11:118550644	TREH	-0.37	-4.27	-0.33	3.49e-5	Serum metabolite levels;
PAAD	trans	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg04682977	chr7:1062711	C7orf50;MIR339	1.01	6.29	0.45	3.23e-9	Atopic dermatitis;
PAAD	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	7.38	0.51	9.65e-12	Lymphocyte counts;
PAAD	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.68	-6.11	-0.44	7.86e-9	Response to antineoplastic agents;
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.23	-0.39	5.41e-7	Tonsillectomy;
PAAD	cis	rs787274	1.000	rs787295	chr9:115541606	C/G	cg13803584	chr9:115635662	SNX30	1.03	6.99	0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs2131877	0.871	rs28569214	chr3:194871488	A/G	cg16306870	chr3:194868790	C3orf21	0.41	4.37	0.33	2.29e-5	Non-small cell lung cancer;
PAAD	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg17401720	chr7:158221031	PTPRN2	0.47	4.93	0.37	2.14e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.57	4.98	0.37	1.69e-6	Corneal astigmatism;
PAAD	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.86	-0.43	2.76e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.42	5.29	0.39	4.2e-7	Psoriasis;
PAAD	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.26	-0.64	4.17e-19	Response to antipsychotic treatment;
PAAD	cis	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg16818395	chr3:128274084	NA	0.54	4.77	0.36	4.25e-6	Dental caries;
PAAD	cis	rs13024765	0.550	rs35160719	chr2:225177666	C/T	cg22455342	chr2:225449267	CUL3	-0.49	-4.61	-0.35	8.32e-6	Platelet-derived growth factor BB levels;
PAAD	cis	rs11880706	0.667	rs8109482	chr19:6113453	G/T	cg22563182	chr19:5680756	HSD11B1L;C19orf70	0.75	4.25	0.33	3.71e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.62	-5.6	-0.41	9.65e-8	Total body bone mineral density;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-5.95	-0.43	1.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg19949948	chr17:19361230	NA	0.43	4.67	0.35	6.56e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.72	6.72	0.48	3.35e-10	Neuroticism;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.26	-0.33	3.53e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg27638815	chr19:15662578	CYP4F22	0.74	4.8	0.36	3.75e-6	Inflammatory biomarkers;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg12757816	chr2:10669957	NA	-0.51	-5.24	-0.39	5.39e-7	Prostate cancer;
PAAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs6743376	0.556	rs3820738	chr2:113819439	A/G	cg24553058	chr2:113831203	IL1F10	0.38	4.25	0.33	3.77e-5	Inflammatory biomarkers;
PAAD	cis	rs3106136	0.678	rs6818255	chr4:95283266	T/A	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.19	-0.39	6.65e-7	Ulcerative colitis;
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg20848291	chr7:100343083	ZAN	-0.93	-7.85	-0.54	6.88e-13	Other erythrocyte phenotypes;
PAAD	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.58	4.61	0.35	8.53e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2422052	0.639	rs11676728	chr2:118654927	T/C	cg22545206	chr2:118617499	NA	0.45	4.44	0.34	1.75e-5	Mosquito bite size;
PAAD	cis	rs73198271	0.562	rs76960788	chr8:8674049	C/T	cg01851573	chr8:8652454	MFHAS1	0.96	7.39	0.51	8.98e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.16	-0.39	7.68e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.62	-6.98	-0.49	8.66e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg15693483	chr7:1102177	C7orf50	0.39	4.7	0.36	5.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg20302533	chr7:39170763	POU6F2	0.47	7.09	0.5	4.67e-11	IgG glycosylation;
PAAD	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.52	-0.52	4.53e-12	Neuroticism;
PAAD	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.6	-5.41	-0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs1982963	0.572	rs61971551	chr14:52479975	C/G	cg20550154	chr14:52487779	NID2	0.57	4.55	0.35	1.11e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg24112000	chr20:60950667	NA	-0.69	-8.72	-0.58	4.48e-15	Colorectal cancer;
PAAD	cis	rs16867321	0.806	rs16867314	chr2:181336471	C/A	cg23363182	chr2:181467187	NA	-0.52	-4.28	-0.33	3.36e-5	Obesity;
PAAD	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.49	-4.77	-0.36	4.2e-6	Platelet count;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.47	0.41	1.82e-7	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.84	7.33	0.51	1.26e-11	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18182039	chr12:93165808	PLEKHG7	0.61	7.19	0.5	2.74e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3764400	0.567	rs2109983	chr17:46207148	A/G	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.94	-7.68	-0.53	1.8e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15832905	chr11:1707625	HCCA2;FAM99B	-0.55	-6.8	-0.48	2.23e-10	Obesity-related traits;
PAAD	cis	rs5751901	0.614	rs5760489	chr22:24990646	A/G	cg15363607	chr22:24998974	GGT1	-0.44	-4.45	-0.34	1.64e-5	Protein quantitative trait loci;
PAAD	cis	rs12780845	1.000	rs12773642	chr10:17196055	T/C	cg00857480	chr10:17188594	TRDMT1	0.38	4.89	0.37	2.51e-6	Homocysteine levels;
PAAD	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.61	-0.35	8.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.63	-6.86	-0.49	1.6e-10	Coronary artery disease;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg19000871	chr14:103996768	TRMT61A	-0.51	-5.71	-0.42	5.64e-8	Coronary artery disease;
PAAD	cis	rs4774830	0.744	rs7167999	chr15:56167667	T/C	cg24530489	chr15:56299380	NA	1.1	4.67	0.35	6.46e-6	Delta-5 desaturase activity;
PAAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg15145965	chr22:50218605	BRD1	0.57	4.84	0.37	3.17e-6	Schizophrenia;
PAAD	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.46	-4.27	-0.33	3.42e-5	Red blood cell count;
PAAD	cis	rs3126085	0.515	rs12760712	chr1:152355550	G/A	cg26876637	chr1:152193138	HRNR	-0.59	-4.37	-0.33	2.29e-5	Atopic dermatitis;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-8.86	-0.58	1.93e-15	Lung function (FVC);
PAAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg21191810	chr6:118973309	C6orf204	0.52	4.66	0.35	6.76e-6	Diastolic blood pressure;
PAAD	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg08132940	chr7:1081526	C7orf50	0.6	4.5	0.34	1.37e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg16083429	chr3:49237500	CCDC36	0.45	4.41	0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19500275	chr17:80737654	TBCD	-0.52	-4.28	-0.33	3.28e-5	Glycated hemoglobin levels;
PAAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9462027	1.000	rs9689160	chr6:34749849	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.46	-4.97	-0.37	1.76e-6	Systemic lupus erythematosus;
PAAD	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22641632	chr7:48017789	HUS1	0.62	6.42	0.46	1.66e-9	Smoking initiation;
PAAD	cis	rs2637266	0.846	rs2583051	chr10:78403542	T/C	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.67e-5	Pulmonary function;
PAAD	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.78	8.42	0.56	2.66e-14	Total body bone mineral density;
PAAD	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-1.0	-6.67	-0.48	4.37e-10	Mitochondrial DNA levels;
PAAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.58	-5.89	-0.43	2.35e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.07	0.59	5.64e-16	Platelet count;
PAAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs11811982	0.793	rs115516662	chr1:227418455	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg10705379	chr10:99080932	FRAT1	0.45	5.3	0.4	3.92e-7	Monocyte count;
PAAD	cis	rs2835872	0.733	rs1709822	chr21:39035485	A/G	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.63	-5.07	-0.38	1.12e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.69	7.61	0.53	2.75e-12	Longevity;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg01997529	chr19:913524	C19orf22	-0.62	-6.34	-0.46	2.54e-9	Primary biliary cholangitis;
PAAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg17633681	chr16:88106987	BANP	0.62	7.92	0.54	4.56e-13	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.64	-0.47	5.11e-10	Neuroticism;
PAAD	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.65	-6.13	-0.45	7.34e-9	Cognitive test performance;
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg23708337	chr7:1209742	NA	0.39	4.29	0.33	3.11e-5	Longevity;Endometriosis;
PAAD	cis	rs1468333	1.000	rs4835669	chr5:137473391	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.36	0.46	2.27e-9	Resting heart rate;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.56	-6.95	-0.49	9.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.63	-6.54	-0.47	8.68e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	6.53	0.47	9.15e-10	Renal function-related traits (BUN);
PAAD	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.43	0.52	7.39e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.97	-0.37	1.82e-6	Total cholesterol levels;
PAAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.51	5.4	0.4	2.52e-7	Longevity;
PAAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg17848003	chr1:3704513	LRRC47	0.39	4.35	0.33	2.47e-5	Red cell distribution width;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-5.08	-0.38	1.09e-6	Longevity;Endometriosis;
PAAD	cis	rs377457	0.503	rs929865	chr16:85703627	T/G	cg07784872	chr16:85687041	KIAA0182	-0.78	-9.15	-0.6	3.63e-16	Type 2 diabetes;
PAAD	cis	rs4378999	0.800	rs4582086	chr3:51110521	A/G	cg21075593	chr3:50426605	CACNA2D2	0.63	4.26	0.33	3.64e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.09e-15	Lung cancer;
PAAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.45	0.46	1.43e-9	Body mass index;
PAAD	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg04450456	chr4:17643702	FAM184B	0.46	4.79	0.36	3.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.1	-0.44	8.4e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.38	4.6	0.35	8.89e-6	Iron status biomarkers;
PAAD	cis	rs6601450	0.522	rs10095190	chr8:10239612	C/G	cg27411982	chr8:10470053	RP1L1	0.44	4.67	0.35	6.46e-6	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.5	5.15	0.39	7.87e-7	Tonsillectomy;
PAAD	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.69	-4.32	-0.33	2.86e-5	Body mass index;
PAAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.53	5.68	0.42	6.51e-8	Major depressive disorder;
PAAD	trans	rs228916	0.901	rs228924	chr22:37507250	A/G	cg14326991	chr6:46889760	GPR116	-0.66	-6.62	-0.47	5.85e-10	Iron status biomarkers (iron levels);
PAAD	trans	rs901683	1.000	rs35326978	chr10:45997712	A/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.73	-0.48	3.24e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22488486	chr2:46612964	EPAS1	0.62	6.46	0.46	1.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.16e-5	Blood metabolite levels;
PAAD	cis	rs797680	0.856	rs6680107	chr1:93770880	G/A	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.91	-11.04	-0.67	3.45e-21	Diastolic blood pressure;
PAAD	cis	rs12476592	0.500	rs78152709	chr2:64235780	A/G	cg10828910	chr2:63850056	LOC388955	-0.55	-4.64	-0.35	7.35e-6	Childhood ear infection;
PAAD	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.86	-9.36	-0.6	1.02e-16	Colorectal cancer;
PAAD	cis	rs10962181	0.510	rs1885917	chr9:1663954	T/C	cg00250430	chr9:1051579	DMRT2	-0.55	-4.36	-0.33	2.37e-5	Superior frontal gyrus grey matter volume;
PAAD	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg14146966	chr2:61757674	XPO1	0.38	4.71	0.36	5.43e-6	Tuberculosis;
PAAD	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.57	6.99	0.49	8.14e-11	Crohn's disease;
PAAD	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Diabetic kidney disease;
PAAD	cis	rs10887741	0.546	rs7903516	chr10:89441102	T/C	cg13926569	chr10:89418898	PAPSS2	0.44	4.27	0.33	3.43e-5	Exercise (leisure time);
PAAD	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.34	-0.64	2.6e-19	Dental caries;
PAAD	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-1.09	-10.91	-0.66	8.11e-21	Platelet distribution width;
PAAD	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.78	0.53	1.05e-12	Coronary artery disease;
PAAD	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg11459648	chr5:138714337	SLC23A1	0.66	6.09	0.44	8.69e-9	Schizophrenia;
PAAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.81	-9.21	-0.6	2.5e-16	Aortic root size;
PAAD	trans	rs901683	1.000	rs71494797	chr10:45997458	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1419980	0.730	rs11054872	chr12:7770908	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg02820901	chr13:113351484	ATP11A	-0.7	-4.55	-0.35	1.09e-5	Glycated hemoglobin levels;
PAAD	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.31	0.4	3.79e-7	HIV-1 control;
PAAD	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8.13e-6	Blood metabolite levels;
PAAD	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.37	0.33	2.26e-5	P wave terminal force;
PAAD	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03552401	chr19:54974983	LENG9	0.54	6.36	0.46	2.27e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.53	5.64	0.42	8.15e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06850241	chr22:41845214	NA	-0.61	-5.41	-0.4	2.39e-7	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25753841	chr19:3500584	DOHH	0.6	6.37	0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6142102	0.527	rs1015362	chr20:32738612	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.48	-4.71	-0.36	5.47e-6	Skin pigmentation;
PAAD	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.34	-0.4	3.34e-7	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09227533	chr4:186945339	NA	0.62	6.3	0.46	3.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1865721	0.728	rs7232269	chr18:73219023	G/A	cg26385618	chr18:73139727	C18orf62	-0.45	-5.25	-0.39	4.98e-7	Intelligence;
PAAD	cis	rs7957197	0.506	rs66947454	chr12:121350922	T/C	cg02419362	chr12:121203948	SPPL3	-0.53	-4.34	-0.33	2.56e-5	Type 2 diabetes;
PAAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-8.63	-0.57	7.78e-15	Coronary artery disease;
PAAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.94	0.37	2.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg00945038	chr17:61921165	SMARCD2	-0.37	-4.46	-0.34	1.56e-5	Prudent dietary pattern;
PAAD	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg20333904	chr2:240724165	NA	-0.41	-4.5	-0.34	1.33e-5	Obesity-related traits;
PAAD	cis	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg27411982	chr8:10470053	RP1L1	0.4	4.36	0.33	2.34e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.55	5.11	0.38	9.51e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	4.99	0.38	1.62e-6	Menarche (age at onset);
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.67	5.54	0.41	1.3e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.09	-0.44	9.05e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg10729496	chr3:10149963	C3orf24	0.91	7.49	0.52	5.2e-12	Alzheimer's disease;
PAAD	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.76	-0.42	4.56e-8	Tonsillectomy;
PAAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.65	-5.16	-0.39	7.5e-7	IgG glycosylation;
PAAD	cis	rs7678296	1.000	rs16993308	chr4:37196057	A/T	cg06805348	chr4:37245195	KIAA1239	0.6	4.7	0.36	5.82e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg00806126	chr19:22604979	ZNF98	0.39	5.07	0.38	1.15e-6	Pain;
PAAD	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg16898833	chr6:26189333	HIST1H4D	1.03	5.18	0.39	6.91e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg04369109	chr6:150039330	LATS1	0.44	4.3	0.33	3.1e-5	Lung cancer;
PAAD	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.92	9.25	0.6	1.98e-16	Corneal astigmatism;
PAAD	cis	rs10788264	0.716	rs7091348	chr10:124016160	C/T	cg09507567	chr10:124027408	NA	0.43	5.16	0.39	7.7e-7	Total body bone mineral density;
PAAD	cis	rs60733400	0.509	rs56814247	chr1:2622489	A/G	cg18854424	chr1:2615690	NA	-0.48	-6.07	-0.44	9.99e-9	Multiple sclerosis;
PAAD	cis	rs11997175	0.558	rs6468207	chr8:33798095	G/A	ch.8.33884649F	chr8:33765107	NA	-0.62	-6.31	-0.46	2.93e-9	Body mass index;
PAAD	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.569	rs3008727	chr9:16009213	C/T	cg14451791	chr9:16040625	NA	-0.39	-4.54	-0.35	1.13e-5	Body mass index;
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.73	-0.36	5.12e-6	Mean corpuscular volume;
PAAD	cis	rs9859260	0.689	rs3817672	chr3:195800811	C/T	cg12923728	chr3:195709715	SDHAP1	-0.52	-4.7	-0.36	5.67e-6	Mean corpuscular volume;
PAAD	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.99	11.6	0.69	1.08e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.72e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.7	0.53	1.62e-12	Melanoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11861389	chr8:145626443	CPSF1;MIR1234	-0.62	-6.38	-0.46	2.05e-9	Obesity-related traits;
PAAD	cis	rs2414095	0.527	rs11632036	chr15:51542162	A/C	cg21478137	chr15:51532386	CYP19A1	0.54	5.53	0.41	1.36e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs4662592	0.554	rs13026746	chr2:128933224	G/C	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg05554000	chr7:158905015	VIPR2	0.57	5.09	0.38	1.04e-6	Facial morphology (factor 20);
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.76	-0.36	4.41e-6	Personality dimensions;
PAAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-4.8	-0.36	3.73e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.18	-0.5	2.93e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs7616330	0.887	rs1474305	chr3:71043496	A/G	cg01511742	chr3:71112437	FOXP1	0.72	5.17	0.39	7.15e-7	QT interval;
PAAD	cis	rs7646881	0.812	rs73015665	chr3:158453934	A/T	cg19483011	chr3:158453295	NA	-0.71	-5.99	-0.44	1.49e-8	Tetralogy of Fallot;
PAAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.63	-8.35	-0.56	3.9e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4523957	0.928	rs216201	chr17:2198800	C/T	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.93e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.56	-0.41	1.21e-7	Lung cancer;
PAAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.27	-0.39	4.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.76	-12.08	-0.7	5.8e-24	Body mass index;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.67	0.42	6.82e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.75	-8.85	-0.58	2.09e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-4.6	-0.35	8.92e-6	Breast cancer;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs319204	0.527	rs2125443	chr5:146229428	A/G	cg02760293	chr5:146258785	PPP2R2B	-0.53	-4.39	-0.34	2.14e-5	Schizophrenia;
PAAD	cis	rs7385804	0.895	rs4729597	chr7:100221849	C/T	cg20848291	chr7:100343083	ZAN	0.51	4.92	0.37	2.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.48	5.08	0.38	1.1e-6	Electroencephalogram traits;
PAAD	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg24699146	chr1:24152579	HMGCL	0.45	4.3	0.33	2.99e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.06	-0.38	1.18e-6	Subjective well-being;
PAAD	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.62	6.1	0.44	8.56e-9	Schizophrenia;
PAAD	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg16205897	chr5:131564050	P4HA2	-0.42	-4.62	-0.35	8.04e-6	Breast cancer;
PAAD	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg10223061	chr2:219282414	VIL1	0.38	4.59	0.35	9.04e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.78	4.82	0.36	3.41e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.34	-0.64	2.6e-19	Dental caries;
PAAD	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.41	-4.91	-0.37	2.31e-6	Total body bone mineral density;
PAAD	cis	rs9913156	0.748	rs55981776	chr17:4561401	T/C	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg13446199	chr8:143762866	PSCA	0.37	4.36	0.33	2.34e-5	Urinary tract infection frequency;
PAAD	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg19131313	chr8:1704013	NA	-0.38	-4.33	-0.33	2.7e-5	Systolic blood pressure;
PAAD	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg12661370	chr5:149340060	SLC26A2	-0.7	-5.85	-0.43	2.92e-8	HIV-1 control;
PAAD	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.57	5.77	0.42	4.31e-8	Menopause (age at onset);
PAAD	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg02404636	chr22:31891804	SFI1	0.61	5.79	0.42	3.94e-8	Colorectal cancer;
PAAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.87e-6	Life satisfaction;
PAAD	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.28	10.39	0.64	1.9e-19	Uric acid levels;
PAAD	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg26247942	chr15:43984922	CKMT1A	0.36	4.28	0.33	3.28e-5	Schizophrenia;
PAAD	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.39	4.87	0.37	2.78e-6	Sitting height ratio;
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg11335335	chr11:637885	DRD4	-0.37	-4.91	-0.37	2.36e-6	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.87	4.6	0.35	8.97e-6	Childhood ear infection;
PAAD	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73198846	chr3:128505472	A/C	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4605213	0.528	rs8069453	chr17:49261750	T/C	cg22932220	chr17:49244634	NME2;NME1-NME2	-0.44	-5.41	-0.4	2.36e-7	Height;
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.64	6.7	0.48	3.82e-10	Obesity-related traits;
PAAD	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg27121462	chr16:89883253	FANCA	0.75	4.43	0.34	1.82e-5	Skin colour saturation;
PAAD	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.72	-0.48	3.36e-10	Capecitabine sensitivity;
PAAD	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs3753841	0.752	rs1841837	chr1:103384044	G/A	cg24495344	chr1:103574097	COL11A1	0.39	4.29	0.33	3.21e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.44e-7	Life satisfaction;
PAAD	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17507749	chr15:85114479	UBE2QP1	0.58	5.88	0.43	2.51e-8	Schizophrenia;
PAAD	cis	rs28830936	1.000	rs28444909	chr15:41953105	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.61	-7.51	-0.52	4.59e-12	Diastolic blood pressure;
PAAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	0.79	7.13	0.5	3.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.6	0.57	9.15e-15	Rheumatoid arthritis;
PAAD	cis	rs4668356	1.000	rs10173931	chr2:171857695	T/G	cg13882835	chr2:172017928	TLK1	0.94	4.89	0.37	2.52e-6	Cognitive performance;
PAAD	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.31	4.79	0.36	4.01e-6	Alcohol dependence;
PAAD	cis	rs13053817	1.000	rs71329487	chr22:29833469	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.09	-0.38	1.03e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg03951180	chr7:72742151	TRIM50;FKBP6	0.67	6.33	0.46	2.58e-9	Blood protein levels;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7833986	1.000	rs56699713	chr8:57096670	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	4.26	0.33	3.62e-5	Height;
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04733989	chr22:42467013	NAGA	-0.47	-4.83	-0.36	3.3e-6	Cognitive function;
PAAD	cis	rs2790216	0.901	rs2590363	chr10:60024712	C/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg10578991	chr7:12443926	VWDE	-0.66	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.49	-4.35	-0.33	2.52e-5	Vitiligo;
PAAD	cis	rs9361491	0.508	rs9341739	chr6:79419076	C/G	cg05283184	chr6:79620031	NA	-0.4	-5.03	-0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1419980	0.643	rs7296689	chr12:7779241	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.99	6.99	0.49	7.96e-11	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg16205897	chr5:131564050	P4HA2	-0.49	-5.48	-0.41	1.76e-7	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02731540	chr11:31391568	DCDC1;DNAJC24	0.59	6.8	0.48	2.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.49	-4.32	-0.33	2.82e-5	Height;
PAAD	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.91	-0.37	2.34e-6	Retinal vascular caliber;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.61	6.73	0.48	3.22e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg18621852	chr3:10150065	C3orf24	0.63	5.39	0.4	2.59e-7	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10450586	0.830	rs10450590	chr11:27310339	G/A	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg10183150	chr4:120222239	C4orf3	-0.37	-5.2	-0.39	6.47e-7	Corneal astigmatism;
PAAD	cis	rs6137287	0.924	rs1072271	chr20:21151377	G/A	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.02	0.38	1.42e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.52	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	12.29	0.71	1.55e-24	Menopause (age at onset);
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.62	5.05	0.38	1.27e-6	Birth weight;
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.96	10.9	0.66	8.14e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1499972	0.887	rs9842435	chr3:117517339	A/G	cg07612923	chr3:117604196	NA	-1.03	-6.64	-0.47	5.32e-10	Schizophrenia;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.9	13.12	0.73	8.85e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.29	-0.51	1.56e-11	Longevity;
PAAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	7.03	0.5	6.58e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg02524346	chr8:600233	NA	1.13	7.26	0.51	1.91e-11	IgG glycosylation;
PAAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg02071572	chr4:1403502	NA	0.37	4.4	0.34	2.06e-5	Obesity-related traits;
PAAD	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.43	-0.34	1.78e-5	IgG glycosylation;
PAAD	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.68e-13	Motion sickness;
PAAD	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg04111992	chr7:158790115	NA	-0.56	-5.65	-0.42	7.87e-8	Facial morphology (factor 20);
PAAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	9.18e-15	Homoarginine levels;
PAAD	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.76	-6.4	-0.46	1.87e-9	Monocyte percentage of white cells;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg19335943	chr6:35419979	FANCE	0.58	6.74	0.48	3.16e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs10512697	0.541	rs35183718	chr5:3498590	A/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs8105895	0.935	rs7251884	chr19:22245530	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs735539	0.521	rs7336905	chr13:21447278	T/C	cg27499820	chr13:21296301	IL17D	0.51	4.51	0.34	1.27e-5	Dental caries;
PAAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg13468214	chr4:1046988	NA	0.54	5.18	0.39	7.07e-7	Recombination rate (females);
PAAD	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg25838465	chr1:92012736	NA	-0.72	-9.0	-0.59	8.87e-16	Breast cancer;
PAAD	cis	rs9810890	1.000	rs73198839	chr3:128500442	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09266468	chr1:45241580	SNORD46;SNORD55;RPS8	-0.61	-6.51	-0.47	1.01e-9	Smoking initiation;
PAAD	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg15432903	chr11:17409602	KCNJ11	0.88	10.36	0.64	2.38e-19	Type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23857200	chr19:39882127	MED29;PAF1	0.59	6.63	0.47	5.43e-10	Metabolite levels  (X-11787);
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.4	-0.34	2.04e-5	Longevity;Endometriosis;
PAAD	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.72	8.81	0.58	2.71e-15	Obesity (extreme);
PAAD	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08212713	chr7:77428059	PHTF2;TMEM60	0.59	6.72	0.48	3.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg03871329	chr12:110338662	TCHP	-0.56	-4.52	-0.34	1.25e-5	Neuroticism;
PAAD	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg09760422	chr2:128146352	NA	-0.4	-6.8	-0.48	2.26e-10	Protein C levels;
PAAD	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19145272	chr2:180613571	ZNF385B	-0.54	-6.85	-0.49	1.68e-10	Monocyte percentage of white cells;
PAAD	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.71	6.15	0.45	6.41e-9	Type 2 diabetes;
PAAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg05342682	chr7:94953680	PON1	-0.51	-4.44	-0.34	1.73e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11817453	chr19:8464850	RAB11B	0.75	6.46	0.46	1.33e-9	Neuroticism;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.84	-0.37	3.2e-6	Life satisfaction;
PAAD	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.06	-0.38	1.21e-6	Mean platelet volume;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.7	-0.36	5.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.49	-4.37	-0.33	2.28e-5	Asthma;
PAAD	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.53	-8.13	-0.55	1.39e-13	Urinary metabolites;
PAAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.69	-6.73	-0.48	3.18e-10	Initial pursuit acceleration;
PAAD	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg17385448	chr1:15911702	AGMAT	0.39	4.72	0.36	5.41e-6	Systolic blood pressure;
PAAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs797680	0.856	rs7526112	chr1:93747683	T/G	cg04535902	chr1:92947332	GFI1	-0.47	-4.67	-0.35	6.67e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24243429	chr4:148653539	ARHGAP10	0.67	7.71	0.53	1.5e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.06	9.79	0.62	7.57e-18	Red blood cell traits;
PAAD	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.56	5.05	0.38	1.23e-6	Testicular germ cell tumor;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-5.39	-0.4	2.68e-7	Testicular germ cell tumor;
PAAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg03989125	chr22:38214979	NA	0.58	5.57	0.41	1.11e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	6.96	0.49	9.31e-11	Schizophrenia;
PAAD	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.77	6.71	0.48	3.54e-10	Coronary artery disease;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	1.04	14.21	0.76	1.08e-29	Menarche (age at onset);
PAAD	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-4.66	-0.35	6.72e-6	Lung cancer;
PAAD	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg17326555	chr1:119535693	NA	-0.4	-4.9	-0.37	2.43e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.62	-5.9	-0.43	2.3e-8	Monocyte count;
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13870426	chr17:30244630	NA	-0.73	-6.4	-0.46	1.83e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.81	5.92	0.43	2.09e-8	Height;
PAAD	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.18	-0.39	6.88e-7	Schizophrenia;
PAAD	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	4.97	0.37	1.75e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-4.28	-0.33	3.32e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.76	6.77	0.48	2.59e-10	Obesity-related traits;
PAAD	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9926296	0.632	rs8048331	chr16:89793042	G/T	cg04287289	chr16:89883240	FANCA	-0.61	-6.52	-0.47	9.74e-10	Vitiligo;
PAAD	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg15676125	chr6:33679581	C6orf125	0.47	4.52	0.34	1.24e-5	Height;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs300774	0.858	rs300718	chr2:136579	G/A	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04733989	chr22:42467013	NAGA	0.48	4.92	0.37	2.27e-6	Cognitive function;
PAAD	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg14254433	chr6:34482411	PACSIN1	-1.11	-6.09	-0.44	8.64e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.88	-0.49	1.47e-10	Glomerular filtration rate;
PAAD	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.13	-0.5	3.79e-11	Neuroticism;
PAAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.47	-0.61	5.09e-17	Colorectal cancer;
PAAD	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg08648136	chr8:956695	NA	0.43	4.73	0.36	5.19e-6	Schizophrenia;
PAAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.47	-5.1	-0.38	1e-6	Breast cancer;
PAAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg21395723	chr22:39101663	GTPBP1	0.43	4.38	0.33	2.18e-5	Menopause (age at onset);
PAAD	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.78e-6	Type 2 diabetes;
PAAD	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs654384	0.798	rs12701426	chr7:4176315	A/G	cg27574739	chr7:4176374	SDK1	0.51	4.98	0.37	1.68e-6	Positive affect;
PAAD	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.54	-6.71	-0.48	3.59e-10	Crohn's disease;
PAAD	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg05484376	chr2:27715224	FNDC4	0.49	5.02	0.38	1.42e-6	Total body bone mineral density;
PAAD	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.44	6.89	0.49	1.37e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.54	-4.76	-0.36	4.47e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09778919	chr12:40019907	C12orf40	-0.68	-6.95	-0.49	9.91e-11	Obesity-related traits;
PAAD	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.58	-0.65	5.97e-20	Heart rate;
PAAD	cis	rs2019872	0.810	rs9892559	chr17:2067737	C/A	cg15816464	chr17:2026533	SMG6	0.53	4.73	0.36	5.13e-6	Schizophrenia;
PAAD	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg08382946	chr5:1082689	SLC12A7	-0.47	-4.47	-0.34	1.51e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.84	9.85	0.62	5.34e-18	Selective IgA deficiency;
PAAD	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.34e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.81	-9.24	-0.6	2.03e-16	Bipolar disorder;
PAAD	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg21433313	chr16:3507492	NAT15	0.92	7.86	0.54	6.42e-13	Tuberculosis;
PAAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.68	-6.07	-0.44	9.74e-9	Hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12927153	chr9:125133318	PTGS1	0.58	6.3	0.46	3.09e-9	Monocyte percentage of white cells;
PAAD	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.47	-4.94	-0.37	2e-6	Age of smoking initiation;
PAAD	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.67	6.02	0.44	1.25e-8	Platelet count;
PAAD	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.43	5.02	0.38	1.41e-6	Total body bone mineral density;
PAAD	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg23244877	chr17:73518230	TSEN54	0.73	6.78	0.48	2.45e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg03517284	chr6:25882590	NA	0.47	4.37	0.33	2.26e-5	Blood metabolite levels;
PAAD	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.42	-4.6	-0.35	8.87e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg16685388	chr1:42384056	HIVEP3	0.38	4.25	0.33	3.69e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.41	-4.46	-0.34	1.58e-5	Aortic root size;
PAAD	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs258892	0.895	rs34672	chr5:72165389	G/A	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.74	-6.62	-0.47	5.79e-10	Triglycerides;
PAAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs3026101	0.671	rs56061343	chr17:5318502	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.68	6.56	0.47	8.04e-10	Plateletcrit;Platelet count;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07685180	chr8:600429	NA	-0.83	-5.57	-0.41	1.11e-7	IgG glycosylation;
PAAD	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.52	-5.11	-0.38	9.71e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9891119	0.663	rs709631	chr17:40555939	A/T	cg14558262	chr17:40713999	COASY	-0.47	-4.28	-0.33	3.27e-5	Multiple sclerosis;Crohn's disease;
PAAD	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg00280220	chr17:61926910	NA	0.42	4.28	0.33	3.29e-5	Prudent dietary pattern;
PAAD	cis	rs7616330	0.775	rs6794619	chr3:71039895	A/G	cg01511742	chr3:71112437	FOXP1	-0.71	-5.04	-0.38	1.31e-6	QT interval;
PAAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.53	-0.34	1.19e-5	Caffeine consumption;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.17	-0.39	7.34e-7	Mood instability;
PAAD	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.53	4.76	0.36	4.39e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10991814	1.000	rs78826784	chr9:93944200	G/A	cg14446406	chr9:93919335	NA	0.49	4.29	0.33	3.23e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg04705435	chr11:17411270	KCNJ11	0.68	7.85	0.54	6.76e-13	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15027466	chr6:170893729	PDCD2	0.62	6.41	0.46	1.74e-9	Myopia (pathological);
PAAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.63	5.35	0.4	3.17e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg02415014	chr8:143852576	LYNX1	0.39	4.52	0.34	1.24e-5	Urinary tract infection frequency;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.52	-0.34	1.25e-5	Obesity-related traits;
PAAD	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.98	0.49	8.62e-11	Coronary artery disease;
PAAD	cis	rs10916814	0.546	rs10799644	chr1:20903195	G/T	cg04087271	chr1:20915334	CDA	0.37	4.49	0.34	1.37e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.6	-5.71	-0.42	5.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.08	15.6	0.78	2.31e-33	Body mass index (adult);
PAAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg02696790	chr15:75250997	RPP25	0.4	4.68	0.35	6.33e-6	Breast cancer;
PAAD	cis	rs7627468	0.739	rs9874845	chr3:121954304	A/T	cg17240004	chr3:121949083	CASR	0.5	4.75	0.36	4.67e-6	Kidney stones;
PAAD	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg10534938	chr5:1868639	NA	0.47	6.15	0.45	6.55e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4605213	0.686	rs8076111	chr17:49302782	C/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.55	-4.87	-0.37	2.82e-6	Height;
PAAD	cis	rs10274279	1.000	rs73163816	chr7:157388126	C/G	cg09270525	chr7:157391030	PTPRN2	0.72	5.6	0.41	9.65e-8	Myopia (pathological);
PAAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.42	4.41	0.34	1.94e-5	Psoriasis;
PAAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-5.51	-0.41	1.48e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.69	5.59	0.41	1.01e-7	Chronic lymphocytic leukemia;
PAAD	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	6.27	0.45	3.63e-9	Platelet count;
PAAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg02038168	chr22:39784481	NA	-0.59	-4.81	-0.36	3.67e-6	IgG glycosylation;
PAAD	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.89	-8.85	-0.58	2.12e-15	Ulcerative colitis;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg18279126	chr7:2041391	MAD1L1	-0.56	-5.45	-0.4	1.97e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.84	8.28	0.56	5.92e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6585424	1.000	rs35180576	chr10:81922971	G/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.85	0.54	6.92e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.78	-5.08	-0.38	1.11e-6	Platelet distribution width;
PAAD	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.59	5.63	0.42	8.38e-8	HDL cholesterol;
PAAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Gut microbiome composition (summer);
PAAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.63	7.76	0.53	1.15e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18805835	chr5:138775054	DNAJC18	0.65	7.57	0.52	3.33e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2236267	0.693	rs2755080	chr14:88595886	A/G	cg18078958	chr14:88630771	NA	-0.52	-6.6	-0.47	6.57e-10	Food antigen IgG levels;
PAAD	cis	rs7551222	0.752	rs12130686	chr1:204554057	G/C	cg01064725	chr1:204461714	NA	-0.54	-5.18	-0.39	6.93e-7	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9815354	1.000	rs9864217	chr3:41762206	G/A	cg03022575	chr3:42003672	ULK4	0.83	5.81	0.43	3.55e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.54	-5.44	-0.4	2.08e-7	Iron status biomarkers;
PAAD	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.92e-16	Motion sickness;
PAAD	cis	rs4679121	0.642	rs79482777	chr3:126170693	C/T	cg05485589	chr3:126194908	ZXDC	-0.88	-4.4	-0.34	2.02e-5	Pursuit maintenance gain;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg23119463	chr10:134592391	INPP5A	-0.5	-4.64	-0.35	7.53e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs75920871	1.000	rs61905681	chr11:116836209	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.25	-0.39	5.14e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg09579323	chr1:150459698	TARS2	0.45	4.27	0.33	3.41e-5	Migraine;
PAAD	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg09163369	chr1:210001066	C1orf107	-0.53	-4.67	-0.35	6.71e-6	Orofacial clefts;
PAAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27436995	chr16:743998	FBXL16	-0.38	-4.59	-0.35	9.28e-6	Height;
PAAD	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.81	8.87	0.58	1.83e-15	Mortality in heart failure;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.61	6.79	0.48	2.35e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg06214716	chr4:10118677	WDR1	0.48	4.74	0.36	4.96e-6	Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.31	4.75	0.36	4.74e-6	Alcohol dependence;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05348768	chr1:202936122	CYB5R1	0.62	6.33	0.46	2.57e-9	Obesity-related traits;
PAAD	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.37	-5.82	-0.43	3.4e-8	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg26939375	chr7:64535504	NA	0.76	9.15	0.6	3.49e-16	Aortic root size;
PAAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.63	0.35	7.79e-6	Total body bone mineral density;
PAAD	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.57	5.51	0.41	1.49e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01053463	chr1:26186087	C1orf135	0.62	6.87	0.49	1.53e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg23254163	chr1:152506842	NA	0.61	7.03	0.5	6.38e-11	Hair morphology;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.65	-0.47	5.07e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	7.25	0.51	1.96e-11	Neuroticism;
PAAD	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.54	5.81	0.43	3.57e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7776786	0.934	rs13243526	chr7:18812917	C/T	cg13420273	chr7:18810212	HDAC9	-0.41	-4.41	-0.34	1.97e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.05	0.38	1.23e-6	Lung cancer;
PAAD	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.9	10.76	0.66	1.98e-20	Sudden cardiac arrest;
PAAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	1.02	9.18	0.6	2.94e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg03700679	chr2:178418002	TTC30B	0.54	4.37	0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02725872	chr8:58115012	NA	-0.62	-5.26	-0.39	4.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg18551225	chr6:44695536	NA	-0.68	-7.91	-0.54	5e-13	Total body bone mineral density;
PAAD	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	0.88	6.26	0.45	3.66e-9	Pulse pressure;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.81	-0.43	3.46e-8	Lung cancer;
PAAD	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg27394845	chr17:28928406	LRRC37B2	0.63	4.46	0.34	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2688419	0.545	rs1849478	chr3:23067010	C/G	cg00327796	chr3:23032191	NA	-0.49	-4.9	-0.37	2.41e-6	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	0.9	6.49	0.47	1.15e-9	Pulse pressure;
PAAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg18370025	chr7:2749541	AMZ1	-0.42	-5.09	-0.38	1.06e-6	Height;
PAAD	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.72	5.22	0.39	5.72e-7	Major depressive disorder;
PAAD	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.59	5.36	0.4	3.1e-7	Breast cancer;
PAAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg23460851	chr4:1604456	NA	0.46	4.64	0.35	7.56e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.67	-6.12	-0.44	7.44e-9	White matter hyperintensity burden;
PAAD	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-5.33	-0.4	3.5e-7	Crohn's disease;
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg14830002	chr1:247616686	OR2B11	-0.65	-5.41	-0.4	2.42e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.3	-5.81	-0.43	3.47e-8	Urinary metabolites;
PAAD	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs754423	0.600	rs754424	chr14:52527188	T/G	cg16066272	chr14:52535949	NID2	-0.61	-5.21	-0.39	6e-7	Craniofacial microsomia;
PAAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.89	0.37	2.54e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.91	9.78	0.62	8.02e-18	Breast cancer;
PAAD	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.73	-0.42	5.22e-8	Colorectal cancer;
PAAD	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.73	7.33	0.51	1.25e-11	Obesity-related traits;
PAAD	cis	rs13278732	0.500	rs12549802	chr8:99022171	G/A	cg27313044	chr8:99903985	NA	0.52	4.27	0.33	3.48e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.4	-0.51	8.86e-12	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10696724	chr3:13937557	NA	0.65	6.42	0.46	1.66e-9	Obesity-related traits;
PAAD	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.49	4.62	0.35	8.16e-6	Uric acid levels;
PAAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.83	11.06	0.67	3.05e-21	Emphysema distribution in smoking;
PAAD	cis	rs2735413	0.875	rs8045975	chr16:78090187	C/G	cg04733911	chr16:78082701	NA	0.56	5.92	0.43	2.04e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs1561176	0.830	rs2873382	chr7:154994122	C/G	cg08570118	chr7:155025533	NA	-0.48	-4.42	-0.34	1.84e-5	Personality dimensions;
PAAD	cis	rs8113142	0.614	rs2108771	chr19:29187422	C/T	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.08e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.86	0.58	1.95e-15	Motion sickness;
PAAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.59	-0.35	9.31e-6	Alcohol dependence;
PAAD	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.56	6.43	0.46	1.58e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg23947450	chr7:900037	UNC84A	-0.5	-4.25	-0.33	3.73e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.79	-0.42	3.94e-8	Life satisfaction;
PAAD	cis	rs10044254	0.587	rs4568364	chr5:15732533	T/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg25952890	chr19:58913133	NA	0.67	5.71	0.42	5.73e-8	Mean platelet volume;
PAAD	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs6844506	0.763	rs2703739	chr4:185214145	A/T	cg12654155	chr4:185238627	NA	0.6	5.68	0.42	6.52e-8	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg10729496	chr3:10149963	C3orf24	0.78	6.33	0.46	2.59e-9	Alzheimer's disease;
PAAD	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20270762	chr11:117014891	PAFAH1B2	-0.46	-4.27	-0.33	3.49e-5	Blood protein levels;
PAAD	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.26	-0.33	3.53e-5	Joint mobility (Beighton score);
PAAD	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-12.54	-0.71	3.27e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Coronary artery disease;
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.84	6.98	0.49	8.66e-11	Recombination rate (females);
PAAD	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg17077180	chr1:38461687	NA	-0.67	-8.39	-0.56	3.06e-14	Coronary artery disease;
PAAD	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg10495392	chr1:46806563	NSUN4	0.58	5.66	0.42	7.35e-8	Menopause (age at onset);
PAAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.96	-0.44	1.68e-8	Calcium levels;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg21782813	chr7:2030301	MAD1L1	0.61	6.13	0.45	7.19e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.35	-0.4	3.19e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04731861	chr2:219085781	ARPC2	0.37	4.37	0.33	2.31e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg04398451	chr17:18023971	MYO15A	0.76	8.16	0.55	1.15e-13	Total body bone mineral density;
PAAD	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg24747557	chr10:131355152	MGMT	-0.48	-5.2	-0.39	6.44e-7	Response to temozolomide;
PAAD	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-7.06	-0.5	5.52e-11	Breast cancer;
PAAD	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg00206168	chr11:65308501	LTBP3	0.8	5.61	0.41	9.18e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs12912251	0.947	rs36094159	chr15:38998395	G/A	cg01338139	chr15:38987640	C15orf53	-0.48	-4.65	-0.35	7.28e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg08200582	chr11:442649	ANO9	0.57	4.77	0.36	4.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.63	5.82	0.43	3.44e-8	Obesity-related traits;
PAAD	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-6.73	-0.48	3.25e-10	Blood pressure (smoking interaction);
PAAD	cis	rs4780401	0.567	rs8191279	chr16:11764329	G/C	cg01061890	chr16:11836724	TXNDC11	-0.46	-4.25	-0.33	3.69e-5	Rheumatoid arthritis;
PAAD	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16431687	chr12:89919797	GALNT4;WDR51B	-0.71	-6.39	-0.46	1.96e-9	Neuroticism;
PAAD	cis	rs7719624	0.811	rs17689879	chr5:135393138	C/T	cg16684184	chr5:135415129	NA	-0.35	-4.43	-0.34	1.79e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.96	7.74	0.53	1.27e-12	Vitiligo;
PAAD	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-4.51	-0.34	1.28e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.69	5.29	0.39	4.26e-7	Body mass index;
PAAD	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.56	4.95	0.37	1.99e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg16596103	chr2:233749413	NGEF	0.43	4.48	0.34	1.48e-5	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12600695	chr5:137513806	BRD8;KIF20A	0.59	6.98	0.49	8.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-16.22	-0.8	5.75e-35	Schizophrenia;
PAAD	cis	rs2555155	0.870	rs10839575	chr11:6551635	G/C	cg11185456	chr11:6592066	DNHD1	-0.42	-4.4	-0.34	2.04e-5	DNA methylation (variation);
PAAD	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.53	0.61	3.7e-17	Rheumatoid arthritis;
PAAD	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-5.52	-0.41	1.45e-7	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs115643064	chr1:227416153	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.74	7.47	0.52	6.02e-12	Prostate cancer;
PAAD	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg25972092	chr12:117363249	FBXW8	-0.83	-5.15	-0.39	7.85e-7	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-4.79	-0.36	3.88e-6	Rheumatoid arthritis;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs300774	0.800	rs393008	chr2:125639	A/G	cg23649280	chr2:140451	NA	-0.47	-4.33	-0.33	2.74e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.58	4.86	0.37	2.84e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.94	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs6141769	0.542	rs6058833	chr20:31316767	T/G	cg13636640	chr20:31349939	DNMT3B	-0.49	-4.64	-0.35	7.32e-6	Subjective well-being;
PAAD	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13798912	chr7:905769	UNC84A	0.59	4.28	0.33	3.32e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg20129853	chr10:51489980	NA	0.5	4.75	0.36	4.62e-6	Prostate-specific antigen levels;
PAAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.09	0.44	9.02e-9	Schizophrenia;
PAAD	cis	rs1559473	0.659	rs1364389	chr2:222892007	C/A	cg15825116	chr2:223169586	CCDC140	-0.31	-4.26	-0.33	3.64e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6460942	0.597	rs6968664	chr7:12515493	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.87	-0.37	2.74e-6	Coronary artery disease;
PAAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.32	4.94	0.37	2.06e-6	Blood metabolite levels;
PAAD	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg10589385	chr1:150898437	SETDB1	-0.39	-4.52	-0.34	1.24e-5	Tonsillectomy;
PAAD	cis	rs1903068	0.853	rs12331471	chr4:56001509	T/C	cg01777861	chr4:56023843	NA	0.35	4.39	0.34	2.14e-5	Endometriosis;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.71	7.31	0.51	1.43e-11	Resistin levels;
PAAD	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	5.97	0.44	1.65e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg26875137	chr12:53738046	NA	-0.49	-4.86	-0.37	2.94e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs73568641	0.546	rs1937637	chr6:154101847	G/A	cg15658985	chr6:154448740	OPRM1	0.55	4.68	0.35	6.36e-6	Methadone dose in opioid dependence;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	6.06	0.44	1.05e-8	Alzheimer's disease;
PAAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.15	0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg23306229	chr2:178417860	TTC30B	0.66	4.48	0.34	1.46e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1015291	0.836	rs1352902	chr12:19990847	A/G	cg25401612	chr12:20009446	NA	-0.48	-4.74	-0.36	4.92e-6	Diastolic blood pressure;
PAAD	cis	rs7119038	0.509	rs11216964	chr11:118581895	G/A	cg08498647	chr11:118550644	TREH	0.4	4.43	0.34	1.81e-5	Sjögren's syndrome;
PAAD	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.74	-9.65	-0.62	1.7e-17	Cancer;
PAAD	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.58	-5.15	-0.39	8.13e-7	Mean corpuscular volume;
PAAD	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg01362358	chr17:58117360	NA	0.39	4.36	0.33	2.35e-5	Hemoglobin concentration;
PAAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	7.64	0.53	2.23e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs590121	0.830	rs615896	chr11:75275301	T/C	cg26104986	chr11:75275303	SERPINH1	-0.47	-4.64	-0.35	7.38e-6	Coronary artery disease;
PAAD	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1371614	0.635	rs877273	chr2:27140022	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs12195424	0.558	rs76569072	chr6:56299479	G/T	cg10030658	chr6:56298004	NA	-0.73	-4.27	-0.33	3.43e-5	Cerebrospinal fluid clusterin levels;
PAAD	cis	rs13242816	1.000	rs35538349	chr7:116117896	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.01	-0.38	1.52e-6	P wave duration;
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.7	6.78	0.48	2.48e-10	Blood metabolite levels;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06799790	chr17:61951754	CSH2	-0.45	-4.52	-0.34	1.24e-5	Height;
PAAD	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs9815354	0.859	rs9822288	chr3:41954588	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.78	-0.42	4.13e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs1667255	1.000	rs7243588	chr18:29160612	C/T	cg18808318	chr18:29669225	NA	0.46	4.42	0.34	1.83e-5	Retinol levels;
PAAD	cis	rs1371614	0.523	rs7585127	chr2:27179371	A/G	cg00617064	chr2:27272375	NA	-0.41	-4.32	-0.33	2.84e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg20761395	chr17:511517	VPS53	0.51	5.0	0.38	1.57e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg16342193	chr10:102329863	NA	-0.81	-8.67	-0.58	5.9e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.19	-0.5	2.78e-11	Colorectal cancer;
PAAD	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	4.32	0.33	2.82e-5	Height;
PAAD	cis	rs10991814	1.000	rs74508579	chr9:93959594	C/T	cg14446406	chr9:93919335	NA	0.57	4.73	0.36	5.01e-6	Neutrophil percentage of granulocytes;
PAAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.14	-11.47	-0.68	2.43e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg12046867	chr14:103022105	NA	-0.74	-5.5	-0.41	1.55e-7	Platelet count;
PAAD	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19671926	chr4:122722719	EXOSC9	0.51	5.01	0.38	1.48e-6	Type 2 diabetes;
PAAD	cis	rs4742903	0.935	rs1580014	chr9:106933625	A/C	cg14250997	chr9:106856677	SMC2	0.44	4.7	0.36	5.86e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.48	-5.1	-0.38	9.77e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.77	-5.83	-0.43	3.16e-8	Mean platelet volume;
PAAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	7.06	0.5	5.44e-11	Total body bone mineral density;
PAAD	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.59	-6.37	-0.46	2.11e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg08717414	chr16:71523259	ZNF19	-0.87	-5.14	-0.38	8.22e-7	Post bronchodilator FEV1;
PAAD	cis	rs6748734	0.779	rs11680800	chr2:241793977	A/G	cg07537917	chr2:241836409	C2orf54	-0.27	-5.26	-0.39	4.72e-7	Urinary metabolites;
PAAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.83	10.03	0.63	1.7e-18	Menopause (age at onset);
PAAD	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-7.48	-0.52	5.55e-12	Heart rate;
PAAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg00926285	chr3:122398533	PARP14	-0.42	-4.33	-0.33	2.72e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10426930	0.816	rs8101347	chr19:5044620	C/T	cg08036796	chr19:5034282	KDM4B	0.49	4.88	0.37	2.64e-6	Monocyte percentage of white cells;
PAAD	cis	rs2555155	0.870	rs2555145	chr11:6534192	T/C	cg24637308	chr11:6592297	DNHD1	0.48	4.87	0.37	2.83e-6	DNA methylation (variation);
PAAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.82	-10.01	-0.63	1.99e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.32	-0.4	3.67e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3996993	0.809	rs62412906	chr6:52736685	T/C	cg20803780	chr6:52668592	GSTA1	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;
PAAD	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21643547	chr1:205240462	TMCC2	-0.43	-4.91	-0.37	2.31e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1997066	0.831	rs73340302	chr10:106815717	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.47	0.34	1.54e-5	Diabetic kidney disease;
PAAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg06618935	chr21:46677482	NA	-0.59	-6.99	-0.49	8.17e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	5.33	0.4	3.44e-7	Renal function-related traits (BUN);
PAAD	cis	rs7922314	0.557	rs61865713	chr10:64737184	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.57	-5.37	-0.4	2.83e-7	White matter hyperintensity burden;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg24503407	chr1:205819492	PM20D1	-0.51	-5.04	-0.38	1.32e-6	Parkinson's disease;
PAAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.81	9.27	0.6	1.71e-16	Schizophrenia;
PAAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg14711859	chr11:8959438	ASCL3	0.37	4.68	0.35	6.39e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.69	-6.78	-0.48	2.53e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg23346134	chr3:49453900	TCTA	0.42	4.45	0.34	1.68e-5	Menarche (age at onset);
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.56	5.7	0.42	6.01e-8	Testicular germ cell tumor;
PAAD	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.58	-0.35	9.75e-6	Testicular germ cell tumor;
PAAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg01815783	chr4:1047043	NA	-0.4	-4.31	-0.33	2.93e-5	Recombination rate (males);
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13870426	chr17:30244630	NA	-0.71	-6.97	-0.49	8.8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.78	8.06	0.55	2.06e-13	Morning vs. evening chronotype;
PAAD	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.71	6.76	0.48	2.77e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.25	0.51	2e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg05484376	chr2:27715224	FNDC4	0.49	4.91	0.37	2.3e-6	Total body bone mineral density;
PAAD	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.57	-5.26	-0.39	4.74e-7	Primary biliary cholangitis;
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.48	-0.34	1.49e-5	Tonsillectomy;
PAAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs7829975	0.539	rs35571782	chr8:8141823	A/C	cg06636001	chr8:8085503	FLJ10661	0.76	7.4	0.51	8.77e-12	Mood instability;
PAAD	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg14664628	chr15:75095509	CSK	0.51	4.91	0.37	2.35e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23022344	chr1:24969466	SRRM1	0.62	6.36	0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.55e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs939584	1.000	rs7570993	chr2:652565	A/G	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3857067	1.000	rs115969971	chr4:95023550	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.76	8.97	0.59	1.01e-15	Emphysema distribution in smoking;
PAAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.46	-4.68	-0.35	6.36e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.13	-0.38	8.74e-7	Vitiligo;
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6597981	0.592	rs28625355	chr11:736334	G/T	cg21775979	chr11:780331	NA	-0.57	-5.4	-0.4	2.56e-7	Breast cancer;
PAAD	cis	rs72772787	1.000	rs74152846	chr1:248013318	G/T	cg03748376	chr1:248100585	OR2L13	0.52	4.25	0.33	3.78e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-1.07	-8.77	-0.58	3.39e-15	Blood trace element (Zn levels);
PAAD	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.73	7.63	0.53	2.34e-12	Alcohol dependence;
PAAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.31	0.46	2.85e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.92	-4.92	-0.37	2.2e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.62	-6.61	-0.47	6e-10	Lymphocyte counts;
PAAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.12	-0.38	9.31e-7	Mood instability;
PAAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.52	5.06	0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.36	7.07	0.5	5.39e-11	Skin colour saturation;
PAAD	cis	rs11887277	0.557	rs828270	chr2:26970109	C/G	cg12368169	chr2:27073192	DPYSL5	0.39	4.25	0.33	3.77e-5	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17612148	chr17:26898533	PIGS	-0.72	-6.33	-0.46	2.6e-9	Neuroticism;
PAAD	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11168618	0.605	rs2731102	chr12:48884535	G/C	cg05152354	chr12:48152931	RAPGEF3	0.54	4.78	0.36	4.15e-6	Adiponectin levels;
PAAD	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.52	-5.54	-0.41	1.29e-7	Lung cancer;
PAAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg10556349	chr10:835070	NA	0.58	4.64	0.35	7.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.61	7.49	0.52	5.35e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.87	0.37	2.73e-6	Diisocyanate-induced asthma;
PAAD	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.8	-5.03	-0.38	1.39e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.66	-0.42	7.46e-8	Prudent dietary pattern;
PAAD	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.76	0.42	4.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.03	-0.38	1.37e-6	Height;
PAAD	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.52e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.77	9.01	0.59	8.15e-16	Blood metabolite ratios;
PAAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.48	-5.09	-0.38	1.03e-6	Platelet distribution width;
PAAD	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2117029	0.521	rs11168885	chr12:49539987	C/T	cg05368762	chr12:50135785	TMBIM6	0.42	4.26	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.44	4.87	0.37	2.83e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.47	5.87	0.43	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18453904	chr3:105088217	ALCAM	-0.56	-6.46	-0.46	1.33e-9	Body fat percentage;
PAAD	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg00919237	chr7:87102261	ABCB4	-0.78	-6.32	-0.46	2.72e-9	Gallbladder cancer;
PAAD	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs76793172	0.660	rs4803852	chr19:46238926	G/T	cg14061069	chr19:46274453	DMPK	0.61	5.48	0.41	1.76e-7	Eosinophil counts;
PAAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.83	-7.97	-0.54	3.49e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg14458575	chr2:238380390	NA	0.54	4.64	0.35	7.57e-6	Prostate cancer;
PAAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg20003494	chr4:90757398	SNCA	-0.64	-5.92	-0.43	2.08e-8	Neuroticism;
PAAD	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.76	0.42	4.52e-8	Menopause (age at onset);
PAAD	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07540629	chr19:46277811	DMPK	-0.58	-6.65	-0.47	4.92e-10	Monocyte percentage of white cells;
PAAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.7	-6.61	-0.47	6.16e-10	DNA methylation (variation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03105603	chr7:39772936	LOC349114	0.61	7.01	0.49	7.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	cis	rs73072330	0.555	rs77580994	chr3:47935727	T/C	cg04507495	chr3:47563649	NA	1.35	6.15	0.45	6.55e-9	Stem cell growth factor beta levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02562519	chr16:85202632	NA	0.7	7.21	0.5	2.42e-11	Obesity-related traits;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13556491	chr19:19739414	LPAR2	0.61	7.1	0.5	4.42e-11	Metabolite levels  (X-11787);
PAAD	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.81	0.36	3.55e-6	Red blood cell count;
PAAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.65	7.52	0.52	4.48e-12	Schizophrenia;
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.26	-0.39	4.9e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-6.07	-0.44	9.86e-9	Schizophrenia;
PAAD	cis	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.91	-0.43	2.14e-8	HDL cholesterol;
PAAD	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.63	0.53	2.42e-12	HIV-1 control;
PAAD	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116175783	0.557	rs3731768	chr2:162107320	G/A	cg08807892	chr2:162101083	NA	-0.71	-5.1	-0.38	9.89e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12826209	chr6:26865740	GUSBL1	0.58	4.83	0.36	3.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25809561	chr17:30822961	MYO1D	0.74	8.34	0.56	4.05e-14	Schizophrenia;
PAAD	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.45	4.5	0.34	1.37e-5	Cardiovascular disease risk factors;
PAAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg05484376	chr2:27715224	FNDC4	0.5	4.95	0.37	1.95e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.97	-0.37	1.8e-6	Blood metabolite levels;
PAAD	trans	rs7569716	1.000	rs7569716	chr2:22568713	A/T	cg21402071	chr15:78933902	CHRNB4	-0.61	-6.35	-0.46	2.37e-9	Chronic obstructive pulmonary disease (moderate to severe);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03433549	chr12:56498817	PA2G4	0.6	6.69	0.48	4.03e-10	Metabolite levels  (X-11787);
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg00450029	chr8:599525	NA	0.82	5.38	0.4	2.79e-7	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg01763666	chr17:80159506	CCDC57	0.44	4.51	0.34	1.29e-5	Life satisfaction;
PAAD	trans	rs1015213	0.609	rs75550511	chr8:52868406	C/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.73	-7.5	-0.52	4.87e-12	Neurofibrillary tangles;
PAAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg20920097	chr3:127057149	NA	-0.39	-5.38	-0.4	2.79e-7	Interleukin-10 levels;Interleukin-13 levels;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.72	0.53	1.42e-12	Prudent dietary pattern;
PAAD	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.6	-6.18	-0.45	5.68e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs76866386	0.786	rs9753033	chr2:44084600	A/T	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.91	-5.26	-0.39	4.72e-7	Cholesterol, total;
PAAD	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.76	-7.18	-0.5	2.95e-11	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.9	-7.74	-0.53	1.29e-12	Alzheimer's disease;
PAAD	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-5.66	-0.42	7.5e-8	Longevity;Endometriosis;
PAAD	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.15	-0.39	7.98e-7	Subjective well-being;
PAAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.34	-0.33	2.57e-5	Mood instability;
PAAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09695851	chr17:3907499	NA	0.83	8.45	0.57	2.17e-14	Type 2 diabetes;
PAAD	cis	rs6496932	0.755	rs56909106	chr15:85864048	A/C	cg19183879	chr15:85880815	NA	0.52	4.76	0.36	4.56e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.79	11.74	0.69	4.72e-23	Birth weight;
PAAD	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg09021430	chr5:549028	NA	-0.85	-6.92	-0.49	1.19e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg13264159	chr8:625131	ERICH1	-0.74	-5.0	-0.38	1.53e-6	IgG glycosylation;
PAAD	cis	rs7577696	0.785	rs6723154	chr2:32365161	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-4.7	-0.36	5.67e-6	Inflammatory biomarkers;
PAAD	cis	rs1015291	0.701	rs2417810	chr12:20008461	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.51	-5.87	-0.43	2.64e-8	Breast cancer;
PAAD	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg14146966	chr2:61757674	XPO1	-0.37	-4.78	-0.36	4.18e-6	Tuberculosis;
PAAD	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg14146966	chr2:61757674	XPO1	0.42	5.22	0.39	5.87e-7	Tuberculosis;
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.41	-4.48	-0.34	1.43e-5	Mean platelet volume;
PAAD	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7082209	0.877	rs3740084	chr10:44813432	T/C	cg13191911	chr10:44806660	NA	-0.88	-5.23	-0.39	5.48e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs6743376	0.556	rs957201	chr2:113821200	T/C	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs9810890	1.000	rs73210622	chr3:128659748	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg20849893	chr7:64541193	NA	-0.49	-4.79	-0.36	3.95e-6	Calcium levels;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.79	-6.54	-0.47	8.85e-10	Alzheimer's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg14939300	chr17:8199012	SLC25A35	-0.62	-7.42	-0.52	7.6e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg27094323	chr7:1216898	NA	-0.42	-4.7	-0.36	5.87e-6	Longevity;Endometriosis;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg07157834	chr1:205819609	PM20D1	0.6	5.72	0.42	5.46e-8	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.58	7.35	0.51	1.15e-11	Hypertriglyceridemia;
PAAD	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2300603	0.881	rs1990564	chr14:76023346	G/A	cg01624173	chr14:75981868	NA	0.56	5.56	0.41	1.21e-7	Multiple sclerosis;
PAAD	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	trans	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg17712092	chr4:129076599	LARP1B	-0.63	-6.59	-0.47	6.8e-10	Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24442661	chr7:36192818	EEPD1	0.64	7.31	0.51	1.38e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9652601	0.779	rs12708716	chr16:11179873	C/T	cg04616529	chr16:11181986	CLEC16A	-0.46	-5.21	-0.39	5.97e-7	Systemic lupus erythematosus;
PAAD	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg20243544	chr17:37824526	PNMT	0.59	5.42	0.4	2.24e-7	Self-reported allergy;
PAAD	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg12362517	chr11:133800685	IGSF9B	-0.7	-6.67	-0.48	4.56e-10	Parkinson's disease;
PAAD	cis	rs1879734	0.689	rs6695509	chr1:54161112	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs10982213	1.000	rs10982203	chr9:117171209	G/A	cg00078025	chr9:117159975	NA	0.58	4.29	0.33	3.2e-5	Interleukin-6 levels;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg01097406	chr16:89675127	NA	0.37	4.5	0.34	1.35e-5	Vitiligo;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.56	-7.04	-0.5	6.22e-11	Lewy body disease;
PAAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg07959070	chr22:50026188	C22orf34	-0.38	-4.46	-0.34	1.58e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg23514324	chr3:12329213	PPARG	0.73	6.52	0.47	1e-9	LDL cholesterol;
PAAD	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.67	-5.66	-0.42	7.2e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20400955	chr10:130828973	NA	-0.63	-6.56	-0.47	7.81e-10	Obesity-related traits;
PAAD	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.38	-0.4	2.8e-7	Retinal vascular caliber;
PAAD	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg04289385	chr6:36355825	ETV7	-0.45	-4.47	-0.34	1.54e-5	Platelet distribution width;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.77	6.2	0.45	5.08e-9	Alzheimer's disease;
PAAD	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.52	-6.21	-0.45	4.84e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-1.03	-6.99	-0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg05555928	chr11:63887634	MACROD1	-0.44	-4.91	-0.37	2.37e-6	Platelet count;
PAAD	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg01214346	chr17:406501	NA	-0.43	-4.8	-0.36	3.83e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.65	0.42	7.78e-8	Alcohol dependence;
PAAD	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.53	-5.2	-0.39	6.37e-7	Multiple myeloma;
PAAD	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.84	6.71	0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg04374321	chr14:90722782	PSMC1	-0.53	-4.39	-0.34	2.12e-5	Longevity;
PAAD	cis	rs1451882	0.719	rs12544411	chr8:1052594	A/C	cg07395941	chr8:1078200	NA	0.62	4.62	0.35	8.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.67	-9.29	-0.6	1.49e-16	Birth weight;
PAAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.61	5.7	0.42	6.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.39	-0.4	2.59e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.54	-0.57	1.28e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1730008	0.533	rs73172114	chr3:158176191	A/G	cg16708174	chr3:158430962	RARRES1	0.55	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13047869	chr3:10149882	C3orf24	0.86	7.13	0.5	3.71e-11	Alzheimer's disease;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg13264159	chr8:625131	ERICH1	-0.75	-5.06	-0.38	1.22e-6	IgG glycosylation;
PAAD	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg27490568	chr2:178487706	NA	0.44	4.8	0.36	3.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03295096	chr2:173292268	ITGA6	-0.62	-6.34	-0.46	2.52e-9	Smoking initiation;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.49	-4.81	-0.36	3.67e-6	Cognitive function;
PAAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.41	0.34	1.96e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9659323	0.622	rs28653656	chr1:119486430	A/C	cg17326555	chr1:119535693	NA	-0.35	-4.25	-0.33	3.7e-5	Body mass index;
PAAD	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg05373962	chr22:49881684	NA	-0.45	-4.69	-0.36	6.04e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg17366294	chr4:99064904	C4orf37	0.55	5.81	0.43	3.51e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16504939	chr2:10263023	RRM2	-0.7	-6.64	-0.47	5.19e-10	Neuroticism;
PAAD	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.7	-7.01	-0.49	7.22e-11	Urate levels in lean individuals;
PAAD	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.68	-0.36	6.22e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03900353	chr1:212732456	NA	0.57	6.4	0.46	1.81e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.6	-5.95	-0.43	1.78e-8	Red cell distribution width;
PAAD	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.21	-0.39	5.96e-7	Monocyte percentage of white cells;
PAAD	cis	rs4742903	1.000	rs10761010	chr9:106858788	G/A	cg14250997	chr9:106856677	SMC2	0.48	5.21	0.39	6.01e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19104462	chr2:216392197	NA	-0.55	-6.48	-0.47	1.22e-9	Monocyte percentage of white cells;
PAAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26796135	chr15:45671001	LOC145663;GATM	0.49	4.39	0.34	2.12e-5	Homoarginine levels;
PAAD	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.61	-6.67	-0.48	4.59e-10	Coronary artery disease;
PAAD	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.45	4.59	0.35	9.04e-6	Type 2 diabetes;
PAAD	cis	rs9463078	0.774	rs9369558	chr6:45274021	A/C	cg25276700	chr6:44698697	NA	-0.46	-5.36	-0.4	3.09e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.58	-5.32	-0.4	3.7e-7	Corneal structure;
PAAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.46	0.34	1.56e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg27398640	chr15:77910606	LINGO1	0.5	4.72	0.36	5.2e-6	Type 2 diabetes;
PAAD	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg12395012	chr8:11607386	GATA4	0.44	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.63	-4.67	-0.35	6.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg19761014	chr17:28927070	LRRC37B2	0.94	6.43	0.46	1.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00506402	chr20:56754700	NA	0.65	6.33	0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs28489187	0.617	rs233112	chr1:85785751	C/T	cg16011679	chr1:85725395	C1orf52	-0.48	-4.5	-0.34	1.32e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3996993	0.568	rs2749043	chr6:52646065	T/C	cg00536792	chr6:53530503	KLHL31	0.45	4.73	0.36	5.08e-6	Hemoglobin concentration;
PAAD	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg26816564	chr1:7831052	VAMP3	0.66	5.37	0.4	2.92e-7	Inflammatory bowel disease;
PAAD	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.77	-0.36	4.34e-6	Type 2 diabetes;
PAAD	cis	rs740698	0.511	rs1012268	chr17:60812041	A/G	cg13195520	chr17:60813227	MARCH10	-0.56	-5.85	-0.43	2.95e-8	Pulse pressure;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.87	11.05	0.67	3.31e-21	Prudent dietary pattern;
PAAD	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.95	11.84	0.69	2.42e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg27490568	chr2:178487706	NA	0.41	4.25	0.33	3.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg13770153	chr20:60521292	NA	-0.46	-4.37	-0.33	2.33e-5	Body mass index;
PAAD	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg07777115	chr5:623756	CEP72	-0.67	-4.28	-0.33	3.27e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.85	-9.62	-0.62	2.09e-17	Prostate cancer;
PAAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg02490460	chr8:1365502	NA	-0.52	-4.46	-0.34	1.61e-5	Triglycerides;
PAAD	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.0	-0.54	2.91e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12257961	0.640	rs7897087	chr10:15376516	C/T	cg10616319	chr10:15468812	NA	-0.48	-4.63	-0.35	7.91e-6	Selective IgA deficiency;
PAAD	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.42	5.03	0.38	1.36e-6	Colorectal cancer;
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs621559	0.636	rs615350	chr1:43681806	T/C	cg14851383	chr1:43888477	KIAA0467	0.55	4.33	0.33	2.66e-5	Telomere length;
PAAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.69	-7.61	-0.53	2.73e-12	Melanoma;
PAAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.87	7.63	0.53	2.33e-12	Pulmonary function decline;
PAAD	cis	rs16854884	0.582	rs35211123	chr3:143640171	A/T	cg06585982	chr3:143692056	C3orf58	0.73	7.95	0.54	4e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs9447004	0.966	rs997765	chr6:74506914	A/G	cg22208108	chr6:74363775	SLC17A5	-0.45	-4.38	-0.34	2.17e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs261532	0.906	rs355162	chr5:138956241	T/C	cg26929925	chr5:138714136	SLC23A1	-0.51	-4.72	-0.36	5.24e-6	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg20913747	chr6:44695427	NA	-0.58	-6.47	-0.46	1.29e-9	Total body bone mineral density;
PAAD	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.56	0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	1.09	12.26	0.71	1.79e-24	Blood trace element (Zn levels);
PAAD	cis	rs6691722	1.000	rs6691722	chr1:24673866	A/G	cg18323236	chr1:24743029	NIPAL3	0.39	4.58	0.35	9.72e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg23033748	chr14:75592666	NEK9	-0.41	-5.03	-0.38	1.34e-6	Height;
PAAD	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	1.24	12.51	0.71	3.86e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12391174	chr12:48167505	SLC48A1	0.67	6.53	0.47	9.49e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12462858	chr1:16810776	CROCCL2	-0.62	-6.56	-0.47	7.79e-10	Obesity-related traits;
PAAD	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg01620082	chr3:125678407	NA	-1.42	-8.22	-0.55	8.56e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-6.04	-0.44	1.15e-8	Pancreatic cancer;
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg11262906	chr1:85462892	MCOLN2	0.61	4.47	0.34	1.49e-5	Serum sulfate level;
PAAD	cis	rs4748857	0.947	rs10764395	chr10:23511697	G/A	cg18853376	chr10:23633759	C10orf67	0.54	4.93	0.37	2.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.65	-5.76	-0.42	4.43e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.49	0.61	4.53e-17	Rheumatoid arthritis;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg23119463	chr10:134592391	INPP5A	-0.48	-4.87	-0.37	2.72e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.08	-0.5	5.07e-11	Breast cancer;
PAAD	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.6	-6.24	-0.45	4.15e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.56	-0.35	1.06e-5	Neuroticism;
PAAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.62	7.5	0.52	4.95e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.52	-5.64	-0.42	8e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs12760731	0.668	rs12073428	chr1:178427933	G/A	cg00404053	chr1:178313656	RASAL2	0.64	5.39	0.4	2.6e-7	Obesity-related traits;
PAAD	cis	rs59888335	1.000	rs35937069	chr3:80681696	T/A	cg21735741	chr3:80819488	NA	0.57	5.08	0.38	1.08e-6	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.6	-0.35	9.02e-6	Dupuytren's disease;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	6.33	0.46	2.56e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.7	5.77	0.42	4.41e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.92	-11.95	-0.7	1.22e-23	Ulcerative colitis;
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02071572	chr4:1403502	NA	-0.47	-6.19	-0.45	5.3e-9	Longevity;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.55	5.39	0.4	2.65e-7	Lung cancer;
PAAD	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg07884673	chr3:53033167	SFMBT1	-0.65	-4.32	-0.33	2.85e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.7	7.09	0.5	4.78e-11	Morning vs. evening chronotype;
PAAD	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.25	0.33	3.78e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg19536664	chr17:6899085	ALOX12	0.53	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg12568669	chr8:11666485	FDFT1	0.29	4.45	0.34	1.67e-5	Retinal vascular caliber;
PAAD	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg23815491	chr16:72088622	HP	0.55	5.84	0.43	3.11e-8	Fibrinogen levels;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.08	-0.55	1.88e-13	Longevity;Endometriosis;
PAAD	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.42	-4.51	-0.34	1.27e-5	Aortic root size;
PAAD	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.57	5.15	0.39	8.01e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.65	0.47	5.08e-10	Blood protein levels;
PAAD	cis	rs758324	0.812	rs2088718	chr5:131179189	C/T	cg06307176	chr5:131281290	NA	0.52	4.54	0.35	1.13e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.57	-5.84	-0.43	3.04e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg23093090	chr10:104574429	C10orf26	-0.43	-5.08	-0.38	1.11e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs7301826	0.627	rs61937256	chr12:131302645	G/A	cg11011512	chr12:131303247	STX2	-0.41	-4.28	-0.33	3.29e-5	Plasma plasminogen activator levels;
PAAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg25753631	chr6:25732923	NA	-0.47	-5.27	-0.39	4.6e-7	Iron status biomarkers;
PAAD	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.47	4.78	0.36	4.17e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg07384165	chr1:10488281	NA	-0.47	-5.01	-0.38	1.53e-6	Breast size;
PAAD	cis	rs965604	0.965	rs36146269	chr15:78779510	T/A	cg18825076	chr15:78729989	IREB2	-0.45	-4.46	-0.34	1.6e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	9.08e-7	Motion sickness;
PAAD	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.57	-6.23	-0.45	4.44e-9	Motion sickness;
PAAD	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg01631408	chr1:248437212	OR2T33	-0.6	-5.83	-0.43	3.25e-8	Common traits (Other);
PAAD	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg09127314	chr1:152161683	NA	0.59	4.36	0.33	2.38e-5	Atopic dermatitis;
PAAD	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.57	4.93	0.37	2.16e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	10.57	0.65	6.41e-20	Smoking behavior;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19657201	chr12:69139816	SLC35E3	0.62	6.75	0.48	2.97e-10	Myopia (pathological);
PAAD	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.4	-4.42	-0.34	1.85e-5	Inflammatory bowel disease;
PAAD	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.53	-5.68	-0.42	6.54e-8	Migraine;
PAAD	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.54	-5.38	-0.4	2.73e-7	Blood metabolite levels;
PAAD	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg14169450	chr9:139327907	INPP5E	0.67	7.39	0.51	9.14e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20406540	chr10:95720748	PIPSL	-0.61	-6.47	-0.46	1.29e-9	Obesity-related traits;
PAAD	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.8	-5.67	-0.42	7.12e-8	Coronary artery calcification;
PAAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg16850897	chr7:100343110	ZAN	-0.73	-6.12	-0.44	7.65e-9	Other erythrocyte phenotypes;
PAAD	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	9.96	0.63	2.64e-18	Colorectal cancer;
PAAD	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	4.06e-10	Total body bone mineral density;
PAAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.47	-4.58	-0.35	9.44e-6	Prostate-specific antigen levels;
PAAD	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-4.76	-0.36	4.5e-6	Height;
PAAD	cis	rs2662368	0.542	rs13170774	chr5:77117759	A/G	cg09660878	chr5:77142695	NA	0.45	4.26	0.33	3.5e-5	Platelet distribution width;
PAAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-4.44	-0.34	1.69e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg23958373	chr8:599963	NA	-1.13	-7.22	-0.51	2.31e-11	IgG glycosylation;
PAAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg05042697	chr2:10830656	NOL10	0.43	4.25	0.33	3.71e-5	Prostate cancer;
PAAD	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.42	-5.61	-0.41	9.16e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg05299278	chr17:33885742	SLFN14	-0.43	-5.16	-0.39	7.5e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.97	6.39	0.46	1.91e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14019695	chr9:139328340	INPP5E	0.58	4.99	0.38	1.62e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.27	0.64	4.11e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	5.15e-7	Coronary artery disease;
PAAD	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-4.36	-0.33	2.4e-5	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg23587288	chr2:27483067	SLC30A3	-0.7	-6.59	-0.47	6.67e-10	Blood metabolite levels;
PAAD	cis	rs4908768	0.501	rs910581	chr1:8529524	T/C	cg20416874	chr1:8611966	RERE	-0.48	-4.64	-0.35	7.53e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.42	0.46	1.66e-9	Lung cancer in ever smokers;
PAAD	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.85	10.1	0.63	1.15e-18	Selective IgA deficiency;
PAAD	cis	rs79911532	0.515	rs10245109	chr7:75846115	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.73	-4.83	-0.36	3.36e-6	Mononucleosis;
PAAD	cis	rs35740288	0.770	rs75039806	chr15:86105044	C/T	cg07943548	chr15:86304357	KLHL25	-0.66	-5.83	-0.43	3.28e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-9.03	-0.59	7.04e-16	Headache;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.49	4.53	0.34	1.19e-5	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27292417	chr3:53850724	CHDH	-0.55	-6.86	-0.49	1.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs939584	0.867	rs34119520	chr2:632760	T/C	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	1.01	10.72	0.66	2.54e-20	Platelet count;
PAAD	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.12	-0.59	4.1e-16	Response to antipsychotic treatment;
PAAD	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.42	4.6	0.35	8.93e-6	Platelet distribution width;
PAAD	cis	rs829661	0.894	rs1252624	chr2:30747083	G/T	cg12454169	chr2:30669597	LCLAT1	0.64	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg14345882	chr6:26364793	BTN3A2	0.59	4.71	0.36	5.48e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.01	0.38	1.48e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04751069	chr16:89787483	ZNF276;C16orf7	0.7	6.99	0.49	8.13e-11	Obesity-related traits;
PAAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg11673840	chr17:47092156	IGF2BP1	0.45	5.46	0.41	1.88e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	0.93	10.42	0.65	1.59e-19	Intracerebral hemorrhage;White matter hyperintensity burden;
PAAD	cis	rs6466055	0.739	rs6943183	chr7:104819479	T/C	cg04380332	chr7:105027541	SRPK2	-0.66	-7.41	-0.52	8.14e-12	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13794334	chr9:110045982	RAD23B	-0.66	-6.32	-0.46	2.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12476592	0.602	rs6724160	chr2:63786423	G/C	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs55823223	0.504	rs2034946	chr17:73863589	T/G	cg10935138	chr17:73851978	WBP2	0.86	7.54	0.52	4.05e-12	Psoriasis;
PAAD	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.12	7.98	0.54	3.26e-13	Type 2 diabetes;
PAAD	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21862992	chr11:68658383	NA	0.44	4.72	0.36	5.36e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.75	-5.29	-0.39	4.18e-7	Lung cancer;
PAAD	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg25401027	chr5:176370377	UIMC1	0.53	5.21	0.39	6.08e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.69	8.63	0.57	7.58e-15	Cardiovascular disease risk factors;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22684387	chr10:105916443	C10orf79	0.59	6.71	0.48	3.64e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.76	9.09	0.59	4.98e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.89	12.47	0.71	4.87e-25	Vitiligo;
PAAD	cis	rs7593730	0.636	rs7583157	chr2:161114552	A/G	cg22609984	chr2:161126801	NA	0.51	4.4	0.34	2.02e-5	Type 2 diabetes;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg14789911	chr21:47582049	C21orf56	-0.51	-5.07	-0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.93	9.15	0.6	3.54e-16	Post bronchodilator FEV1;
PAAD	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.68	7.02	0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.77	-0.42	4.36e-8	Tonsillectomy;
PAAD	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	trans	rs901683	1.000	rs34011467	chr10:46059758	T/C	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.63	-6.18	-0.45	5.55e-9	Obesity-related traits;
PAAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.62	6.55	0.47	8.44e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.99	-10.56	-0.65	6.96e-20	Blood pressure (smoking interaction);
PAAD	cis	rs7594192	0.744	rs12998934	chr2:199366955	T/C	cg01558212	chr2:200327336	NA	-0.35	-4.49	-0.34	1.38e-5	Educational attainment;
PAAD	cis	rs863345	0.933	rs1157523	chr1:158457638	G/T	cg12129480	chr1:158549410	OR10X1	-0.41	-4.54	-0.35	1.16e-5	Pneumococcal bacteremia;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.23	9.84	0.62	5.51e-18	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.51	-5.12	-0.38	8.94e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22664307	chr6:144471564	STX11	0.63	7.25	0.51	1.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg00071950	chr4:10020882	SLC2A9	-0.68	-6.55	-0.47	8.6e-10	Schizophrenia (age at onset);
PAAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.36	4.78	0.36	4.07e-6	Blood protein levels;
PAAD	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg24623649	chr8:11872141	NA	0.45	4.61	0.35	8.59e-6	Monocyte count;
PAAD	trans	rs2919917	1.000	rs1466526	chr8:79555474	C/G	cg08882882	chr6:84937375	KIAA1009	0.65	7.03	0.5	6.69e-11	Lymphocyte counts;
PAAD	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.4	-0.34	2.03e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.67	6.77	0.48	2.61e-10	Menarche (age at onset);
PAAD	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.7	-6.79	-0.48	2.38e-10	Coronary artery disease;
PAAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.44	4.39	0.34	2.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs11825685	0.775	rs115695236	chr11:134569427	A/T	cg06603561	chr11:134479413	NA	-0.81	-5.31	-0.4	3.8e-7	IgG glycosylation;
PAAD	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.94	-10.1	-0.63	1.11e-18	Parkinson's disease;
PAAD	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg05110241	chr16:68378359	PRMT7	-0.68	-5.05	-0.38	1.23e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-4.57	-0.35	1e-5	Blood protein levels;
PAAD	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3790455	0.610	rs746527	chr1:156460511	C/T	cg14087168	chr1:156450669	MEF2D	-0.43	-5.14	-0.38	8.45e-7	Migraine;
PAAD	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.97	13.72	0.74	2.22e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05981247	chr2:8821346	ID2	0.58	6.57	0.47	7.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.56	-0.41	1.16e-7	Metabolite levels;
PAAD	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.73	-0.48	3.25e-10	Blood pressure (smoking interaction);
PAAD	cis	rs877529	0.967	rs139414	chr22:39553819	G/A	cg13455509	chr22:39551605	NA	-0.45	-4.46	-0.34	1.59e-5	Multiple myeloma;
PAAD	cis	rs4765663	1.000	rs4765663	chr12:2178760	C/G	cg24952640	chr12:3108225	TEAD4	-0.64	-4.85	-0.37	3.07e-6	Aortic root size;
PAAD	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.48	-7.99	-0.54	3.19e-13	Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.85	0.37	2.96e-6	Life satisfaction;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.61	6.38	0.46	2.07e-9	Lung cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04362369	chr14:21905501	CHD8	-0.57	-6.36	-0.46	2.2e-9	Body fat percentage;
PAAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.49	-0.34	1.4e-5	Mean platelet volume;
PAAD	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-4.36	-0.33	2.43e-5	Subjective well-being;
PAAD	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.86	-6.96	-0.49	9.29e-11	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Height;
PAAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.57	7.03	0.5	6.56e-11	Monobrow;
PAAD	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg12623918	chr2:306882	NA	0.62	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.66	0.48	4.71e-10	IgG glycosylation;
PAAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg05895507	chr15:77155635	SCAPER	0.36	4.41	0.34	1.97e-5	Blood metabolite levels;
PAAD	cis	rs6500395	0.554	rs2355302	chr16:48738428	C/T	cg04672837	chr16:48644449	N4BP1	0.56	4.54	0.35	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.76	5.61	0.41	9.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.98e-19	Response to antipsychotic treatment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19343871	chr19:48103651	NA	0.6	6.55	0.47	8.26e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	19.41	0.84	5.52e-43	IgG glycosylation;
PAAD	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.68	-6.29	-0.45	3.25e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24555468	chr13:114820315	RASA3	-0.6	-6.36	-0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.86	8.77	0.58	3.44e-15	Uric acid levels;
PAAD	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.61	5.34	0.4	3.4e-7	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs2712184	0.875	rs2541382	chr2:217680034	C/A	cg05032264	chr2:217675019	NA	-0.58	-6.35	-0.46	2.39e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.57	-6.78	-0.48	2.48e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.25	-0.56	7.2e-14	Brugada syndrome;
PAAD	cis	rs6558530	0.836	rs7461600	chr8:1714642	G/T	cg19131313	chr8:1704013	NA	-0.39	-4.26	-0.33	3.52e-5	Systolic blood pressure;
PAAD	cis	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg25886479	chr11:50257625	LOC441601	-0.42	-4.58	-0.35	9.54e-6	Coronary artery disease;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.72	-7.89	-0.54	5.67e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6256	1.000	rs12362225	chr11:13548274	G/A	cg11976911	chr11:13509032	NA	-0.66	-5.11	-0.38	9.6e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.9	-11.31	-0.68	6.63e-22	Monocyte percentage of white cells;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.5	5.0	0.38	1.56e-6	Fibrinogen levels;
PAAD	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg02820901	chr13:113351484	ATP11A	0.72	4.83	0.36	3.33e-6	Glycated hemoglobin levels;
PAAD	cis	rs7714584	1.000	rs11167518	chr5:150258920	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg00455402	chr19:21769736	NA	-0.48	-4.3	-0.33	3.06e-5	Pain;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-5.95	-0.43	1.77e-8	Obesity (extreme);
PAAD	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.4	8.13	0.55	1.38e-13	Mean corpuscular volume;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.89	9.76	0.62	8.85e-18	Blood metabolite levels;
PAAD	cis	rs8005172	0.750	rs3844024	chr14:88429304	C/T	cg18078958	chr14:88630771	NA	0.47	5.4	0.4	2.5e-7	Parkinson's disease;
PAAD	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.962	rs13094687	chr3:52450043	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-4.6	-0.35	8.94e-6	Bipolar disorder;
PAAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-9.42	-0.61	6.92e-17	Response to antipsychotic treatment;
PAAD	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.72	5.83	0.43	3.26e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.4	-0.4	2.48e-7	Personality dimensions;
PAAD	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.69	9.61	0.61	2.25e-17	Breast size;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.63	-7.13	-0.5	3.78e-11	Systemic lupus erythematosus;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04571355	chr1:201489142	RPS10P7	0.53	6.97	0.49	8.9e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs863345	0.604	rs10908661	chr1:158466990	T/A	cg12129480	chr1:158549410	OR10X1	-0.4	-4.58	-0.35	9.65e-6	Pneumococcal bacteremia;
PAAD	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.62	5.68	0.42	6.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.88	-8.36	-0.56	3.66e-14	Bone mineral density;
PAAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4953404	0.613	rs897532	chr2:46893225	G/A	cg12784625	chr2:46524557	EPAS1	-0.48	-4.26	-0.33	3.62e-5	Pulse pressure (alcohol consumption interaction);
PAAD	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-4.92	-0.37	2.23e-6	Height;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg03909863	chr11:638404	DRD4	-0.6	-5.45	-0.4	1.94e-7	Systemic lupus erythematosus;
PAAD	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.9	-13.17	-0.73	6.4e-27	Dental caries;
PAAD	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.85	0.62	5.34e-18	Chronic sinus infection;
PAAD	cis	rs73019876	0.869	rs11085506	chr19:22181939	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.41	-0.34	1.91e-5	Testicular germ cell tumor;
PAAD	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.31	12.02	0.7	7.98e-24	Uric acid levels;
PAAD	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.66	-4.8	-0.36	3.77e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.57	-7.3	-0.51	1.53e-11	Schizophrenia;
PAAD	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.43	4.33	0.33	2.75e-5	Type 2 diabetes;
PAAD	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg02404636	chr22:31891804	SFI1	0.64	6.17	0.45	5.91e-9	Colorectal cancer;
PAAD	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs258892	0.895	rs34155124	chr5:72060249	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4740619	0.933	rs10738405	chr9:15704787	T/C	cg14451791	chr9:16040625	NA	-0.39	-4.52	-0.34	1.21e-5	Body mass index;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08439880	chr3:133502540	NA	-0.52	-5.68	-0.42	6.75e-8	Iron status biomarkers;
PAAD	trans	rs901683	1.000	rs76805415	chr10:46026163	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.1	6.74	0.48	3.17e-10	Blood protein levels;
PAAD	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15908909	chr7:56894857	NA	-0.63	-6.84	-0.49	1.81e-10	Lung cancer in ever smokers;
PAAD	cis	rs375066	0.935	rs388685	chr19:44418680	C/G	cg21496419	chr19:44306685	LYPD5	0.41	4.95	0.37	1.97e-6	Breast cancer;
PAAD	cis	rs4343996	1.000	rs4298408	chr7:3358731	T/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-9.42	-0.61	7.1e-17	Alzheimer's disease (late onset);
PAAD	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.79	9.26	0.6	1.87e-16	Morning vs. evening chronotype;
PAAD	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.61	-6.61	-0.47	6.12e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs3116813	1	rs3116813	chr6:29660816	C/A	cg01620082	chr3:125678407	NA	-1.6	-9.47	-0.61	5.28e-17	Breast cancer;
PAAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.68	-6.27	-0.45	3.54e-9	DNA methylation (variation);
PAAD	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg21565972	chr17:80109576	CCDC57	0.59	6.77	0.48	2.68e-10	Life satisfaction;
PAAD	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.74	-7.87	-0.54	6.04e-13	Blood metabolite levels;
PAAD	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg15105011	chr4:940614	TMEM175	0.67	7.62	0.53	2.57e-12	Sjögren's syndrome;
PAAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.75	9.33	0.6	1.22e-16	Body mass index;
PAAD	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.5	5.1	0.38	9.89e-7	Red blood cell count;
PAAD	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-6.45	-0.46	1.43e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Coronary artery disease;
PAAD	cis	rs258892	1.000	rs26577	chr5:72299039	C/T	cg21869765	chr5:72125136	TNPO1	-0.65	-4.56	-0.35	1.03e-5	Small cell lung carcinoma;
PAAD	trans	rs1991867	0.541	rs8046292	chr16:82493473	T/G	cg24029050	chr5:141691561	SPRY4	0.74	6.62	0.47	5.73e-10	D-dimer levels;White matter microstructure (global fractional anisotropy);
PAAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	9.75	0.62	9.56e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21525449	chr1:156571403	GPATCH4	0.58	6.42	0.46	1.68e-9	Monocyte percentage of white cells;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12715266	chr12:60812459	NA	-0.5	-6.39	-0.46	1.96e-9	Energy expenditure (24h);
PAAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg08345082	chr10:99160200	RRP12	-0.31	-4.43	-0.34	1.82e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.79	7.86	0.54	6.7e-13	Corneal astigmatism;
PAAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-8.03	-0.55	2.51e-13	Height;
PAAD	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	trans	rs61677309	0.929	rs58983315	chr11:118167759	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.73	-8.22	-0.55	8.54e-14	Renal function-related traits (BUN);
PAAD	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.71	7.4	0.51	8.76e-12	Schizophrenia;
PAAD	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6782025	0.837	rs13067941	chr3:121054605	A/G	cg16417163	chr3:121280760	NA	0.46	4.79	0.36	3.98e-6	Aging (facial);
PAAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02020650	chr2:88991579	RPIA	-0.65	-7.14	-0.5	3.6e-11	Smoking initiation;
PAAD	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11615916	0.722	rs73136863	chr12:62764400	G/A	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-5.12	-0.38	8.94e-7	Reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17165432	chr2:230222630	DNER	-0.68	-6.76	-0.48	2.76e-10	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03893346	chr12:4598353	C12orf4	0.52	6.79	0.48	2.41e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg16606324	chr3:10149918	C3orf24	0.64	4.43	0.34	1.78e-5	Alzheimer's disease;
PAAD	cis	rs934734	0.511	rs62141115	chr2:65672192	A/G	cg16178603	chr2:66667101	MEIS1	-0.44	-4.41	-0.34	1.95e-5	Rheumatoid arthritis;
PAAD	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-1.0	-8.01	-0.55	2.72e-13	Blood protein levels;
PAAD	cis	rs950037	0.710	rs634683	chr1:89232337	G/T	cg13109106	chr1:89333529	GTF2B	-0.47	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.53	5.59	0.41	1.03e-7	Red blood cell count;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg18128536	chr17:47092178	IGF2BP1	0.5	5.57	0.41	1.15e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11853189	0.938	rs74894101	chr15:78597405	G/A	cg22935921	chr15:78556834	DNAJA4	0.76	5.13	0.38	8.54e-7	Red cell distribution width;
PAAD	cis	rs112990264	1.000	rs115370728	chr1:213019196	T/C	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs2077654	0.556	rs11024284	chr11:17444590	C/T	cg25308976	chr11:17434268	ABCC8	0.7	5.07	0.38	1.14e-6	Gout;
PAAD	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.68	5.16	0.39	7.78e-7	Body mass index;
PAAD	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg08886695	chr4:3369023	RGS12	-0.5	-4.83	-0.36	3.33e-6	Mean platelet volume;
PAAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.44	-0.34	1.72e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.5	0.57	1.62e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.76	-0.42	4.57e-8	Androgen levels;
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.56	-5.28	-0.39	4.46e-7	Cognitive test performance;
PAAD	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.85	9.62	0.62	2.06e-17	Resting heart rate;
PAAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-5.36	-0.4	3.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13144136	0.786	rs10938921	chr4:10666960	C/T	cg10242279	chr4:10666415	CLNK	-0.36	-4.41	-0.34	1.92e-5	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs1879734	0.731	rs10888803	chr1:54160235	C/T	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.71	-7.75	-0.53	1.21e-12	Mean platelet volume;
PAAD	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.53	5.58	0.41	1.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.75	8.12	0.55	1.47e-13	Gout;
PAAD	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	4.7	0.36	5.78e-6	Hip circumference;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg09471204	chr22:42347991	LOC339674	0.33	4.39	0.34	2.11e-5	Cognitive function;
PAAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19346786	chr7:2764209	NA	-0.35	-5.0	-0.38	1.53e-6	Height;
PAAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18364779	chr6:26104403	HIST1H4C	0.53	5.23	0.39	5.49e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26926768	chr12:34528122	NA	0.39	4.63	0.35	7.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.78	-6.23	-0.45	4.32e-9	Neutrophil percentage of white cells;
PAAD	cis	rs7301016	1.000	rs10877856	chr12:62870536	C/G	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg10556349	chr10:835070	NA	0.67	5.12	0.38	9.2e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs11624221	0.896	rs7144257	chr14:21138005	C/G	cg00657582	chr14:21904906	CHD8	0.43	4.32	0.33	2.75e-5	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs1468333	1.000	rs10479179	chr5:137564115	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07225547	chr2:211035530	C2orf67	0.58	6.91	0.49	1.24e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28489187	0.706	rs233127	chr1:85793801	A/G	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.76	-0.53	1.14e-12	Hemoglobin concentration;
PAAD	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.62	6.0	0.44	1.37e-8	Acylcarnitine levels;
PAAD	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.87	7.02	0.5	6.75e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs9810890	1.000	rs73196972	chr3:128443796	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs7772697	0.632	rs9498217	chr6:149422098	C/G	cg21368479	chr6:149415018	NA	0.41	4.3	0.33	3.01e-5	Diabetic retinopathy;
PAAD	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg17764715	chr19:33622953	WDR88	0.66	6.21	0.45	4.73e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg21823605	chr1:152486609	CRCT1	0.51	6.48	0.47	1.23e-9	Hair morphology;
PAAD	cis	rs6494488	0.500	rs72741325	chr15:64730384	T/C	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.57	-0.41	1.14e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.17e-10	Lymphocyte counts;
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16497277	chr3:49208875	KLHDC8B	-0.59	-5.46	-0.41	1.87e-7	Menarche (age at onset);
PAAD	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.66	0.53	2.04e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.35	-0.33	2.47e-5	Daytime sleep phenotypes;
PAAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.71	7.04	0.5	6.3e-11	Menarche (age at onset);
PAAD	cis	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.78	-0.36	4.05e-6	Eotaxin levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25499769	chr12:128245397	NA	-0.67	-6.59	-0.47	6.91e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2147959	0.825	rs12746910	chr1:228658133	G/A	cg00655913	chr1:228633920	NA	-0.5	-4.52	-0.34	1.23e-5	Adult asthma;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.69	0.48	4.07e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.69	4.82	0.36	3.43e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs16958440	0.541	rs13547	chr18:44634756	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-5.04	-0.38	1.33e-6	Sitting height ratio;
PAAD	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-5.31	-0.4	3.74e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-6.97	-0.49	9.05e-11	Bipolar disorder;
PAAD	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg27535305	chr1:53392650	SCP2	-0.52	-5.71	-0.42	5.86e-8	Monocyte count;
PAAD	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.41e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.42	-4.65	-0.35	7.06e-6	Aortic root size;
PAAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg14146966	chr2:61757674	XPO1	0.4	4.9	0.37	2.44e-6	Tuberculosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00807877	chr14:70095319	KIAA0247	0.59	6.85	0.49	1.73e-10	Smoking initiation;
PAAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.69	7.23	0.51	2.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.35	0.51	1.13e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.26	-0.45	3.82e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg23898951	chr10:4511903	NA	0.75	4.53	0.35	1.16e-5	Major depressive disorder;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.96	-10.71	-0.66	2.65e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-5.04	-0.38	1.31e-6	Neuroticism;
PAAD	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.25e-31	Chronic sinus infection;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.97e-8	Lymphocyte counts;
PAAD	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs939584	0.935	rs6732471	chr2:629914	G/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.56	-6.56	-0.47	8.13e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.88	-10.15	-0.64	8.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.75	6.75	0.48	2.97e-10	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.56	2.93e-14	Morning vs. evening chronotype;
PAAD	trans	rs12127679	0.614	rs1607071	chr1:244170183	A/C	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.8	8.09	0.55	1.8e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.49	4.66	0.35	6.8e-6	Airway imaging phenotypes;
PAAD	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14119001	chr9:139324193	INPP5E	-0.49	-4.75	-0.36	4.75e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.23	-0.45	4.37e-9	Body mass index;
PAAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg14773178	chr5:1868261	NA	0.36	4.75	0.36	4.59e-6	Cardiovascular disease risk factors;
PAAD	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.44	4.45	0.34	1.63e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs798766	0.903	rs811316	chr4:1689377	T/C	cg05874882	chr4:1763078	NA	-0.33	-4.49	-0.34	1.39e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	1.02	12.38	0.71	8.9e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.93e-7	Motion sickness;
PAAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.8	-0.43	3.69e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13560548	chr3:10150139	C3orf24	0.61	5.6	0.41	9.87e-8	Alzheimer's disease;
PAAD	cis	rs288342	0.832	rs288304	chr2:183653727	C/A	cg02625481	chr2:183667124	NA	-0.46	-4.62	-0.35	8.18e-6	Recurrent major depressive disorder;
PAAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.83	10.04	0.63	1.64e-18	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.19	0.45	5.25e-9	Lung cancer;
PAAD	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.84	-9.27	-0.6	1.7e-16	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg09399716	chr2:46890238	NA	-0.62	-5.6	-0.41	9.95e-8	Height;
PAAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.56	-7.63	-0.53	2.43e-12	Renal cell carcinoma;
PAAD	cis	rs1468734	0.963	rs35051265	chr16:5002903	T/C	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.96	10.79	0.66	1.69e-20	Tonsillectomy;
PAAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.8	6.1	0.44	8.24e-9	Gut microbiome composition (summer);
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.71	7.64	0.53	2.31e-12	Renal function-related traits (BUN);
PAAD	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.54	-0.35	1.16e-5	Height;
PAAD	cis	rs790123	0.749	rs1355562	chr3:122397064	G/T	cg15604389	chr3:122379662	NA	0.57	5.98	0.44	1.51e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg25837213	chr17:80849375	TBCD	-0.52	-4.28	-0.33	3.36e-5	Breast cancer;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16417436	chr16:28758564	NA	0.43	4.44	0.34	1.74e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2278796	0.558	rs35288741	chr1:204928155	A/G	cg04862289	chr1:204966208	NFASC	0.43	4.71	0.36	5.62e-6	Mean platelet volume;
PAAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.88	0.37	2.69e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.42	5.38	0.4	2.73e-7	Panic disorder;
PAAD	cis	rs2092319	0.649	rs2786875	chr1:26061266	C/A	cg12446045	chr1:25857419	NA	-0.47	-4.31	-0.33	2.96e-5	Nose morphology;
PAAD	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg20003494	chr4:90757398	SNCA	-0.41	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs7084921	0.809	rs11594585	chr10:101811166	C/G	cg04359915	chr10:101825029	CPN1	-0.36	-5.12	-0.38	8.95e-7	Bone mineral density;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.59	6.32	0.46	2.75e-9	Lung cancer;
PAAD	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg00262122	chr8:11665843	FDFT1	-0.56	-4.87	-0.37	2.81e-6	Neuroticism;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg11218175	chr11:495084	RNH1	0.76	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg06453172	chr10:134556979	INPP5A	-0.49	-4.25	-0.33	3.66e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-5.95	-0.43	1.79e-8	Mean corpuscular volume;
PAAD	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.7	6.91	0.49	1.27e-10	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.68	7.11	0.5	4.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-8.57	-0.57	1.07e-14	Total body bone mineral density;
PAAD	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.13e-13	Dupuytren's disease;
PAAD	cis	rs11785693	0.730	rs62489549	chr8:4954185	G/C	cg26367366	chr8:4980734	NA	0.65	4.71	0.36	5.66e-6	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg03131358	chr22:42195972	CCDC134	-0.49	-5.07	-0.38	1.17e-6	Birth weight;
PAAD	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.72	0.62	1.15e-17	Chronic sinus infection;
PAAD	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg04398451	chr17:18023971	MYO15A	0.73	7.73	0.53	1.37e-12	Total body bone mineral density;
PAAD	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.78	8.22	0.55	8.47e-14	Aortic root size;
PAAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg05110241	chr16:68378359	PRMT7	-1.12	-8.19	-0.55	1.01e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.24	0.39	5.28e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9333029	0.524	rs4333799	chr1:47411548	G/A	cg08644498	chr1:46502608	NA	-0.49	-4.51	-0.34	1.31e-5	Blood metabolite levels;
PAAD	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs1730008	0.507	rs73172119	chr3:158178856	G/A	cg16708174	chr3:158430962	RARRES1	0.55	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg10591111	chr5:226296	SDHA	0.56	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.3	-0.39	4e-7	Mood instability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04872869	chr1:28908637	SNORA16A;SNHG12	0.68	8.22	0.55	8.56e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg14391382	chr7:866102	UNC84A	0.46	4.3	0.33	3.1e-5	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02631286	chr1:32281722	SPOCD1	0.65	6.54	0.47	8.67e-10	Obesity-related traits;
PAAD	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	7.13	0.5	3.89e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.55e-7	Prudent dietary pattern;
PAAD	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg19442545	chr10:75533431	FUT11	-0.49	-5.03	-0.38	1.35e-6	Inflammatory bowel disease;
PAAD	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs17155006	0.746	rs419031	chr7:107750157	G/A	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	cis	rs9810890	1.000	rs73198838	chr3:128498292	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06956232	chr14:78432436	NA	-0.59	-6.3	-0.46	3.06e-9	Myopia (pathological);
PAAD	trans	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg03021296	chr7:158060614	PTPRN2	-0.58	-6.32	-0.46	2.69e-9	Breast cancer;
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg26174226	chr8:58114915	NA	-0.63	-5.07	-0.38	1.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9659323	0.717	rs61806238	chr1:119536378	G/A	cg17326555	chr1:119535693	NA	-0.4	-4.97	-0.37	1.76e-6	Body mass index;
PAAD	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg20742385	chr13:113633654	MCF2L	-0.45	-4.55	-0.35	1.1e-5	Systolic blood pressure;
PAAD	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.65	7.4	0.51	8.45e-12	Mean corpuscular volume;
PAAD	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg11380483	chr2:127933992	NA	0.72	5.68	0.42	6.76e-8	Protein C levels;
PAAD	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.31	0.46	2.94e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.53	-4.9	-0.37	2.48e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.51	4.35	0.33	2.47e-5	Cocaine dependence;
PAAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.91	11.1	0.67	2.44e-21	Alcohol dependence;
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.9e-7	Blood metabolite levels;
PAAD	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.49	5.61	0.41	9.37e-8	Coronary artery disease;
PAAD	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	0.96	8.64	0.57	7.3e-15	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16799961	chr2:99953048	EIF5B;TXNDC9	0.72	6.38	0.46	2.08e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg12439432	chr8:145163960	KIAA1875	0.39	4.35	0.33	2.44e-5	Age at first birth;
PAAD	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.84	0.37	3.15e-6	Testicular germ cell tumor;
PAAD	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg16205897	chr5:131564050	P4HA2	-0.41	-4.46	-0.34	1.59e-5	Blood metabolite levels;
PAAD	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.86	-0.37	2.96e-6	Neuroticism;
PAAD	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.6	-6.38	-0.46	2e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.76	-9.09	-0.59	4.98e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs735539	0.517	rs7325243	chr13:21133294	G/A	cg27234864	chr13:21295941	IL17D	0.62	5.54	0.41	1.31e-7	Dental caries;
PAAD	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.91	11.75	0.69	4.48e-23	Mean corpuscular volume;
PAAD	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg00700412	chr12:58011837	NA	0.4	4.26	0.33	3.61e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.7	7.57	0.52	3.35e-12	Platelet distribution width;
PAAD	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.8	9.06	0.59	5.98e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs73196974	chr3:128449006	A/C	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.86	-0.49	1.64e-10	Life satisfaction;
PAAD	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg26205652	chr12:48591994	NA	0.98	9.91	0.63	3.57e-18	Longevity (90 years and older);
PAAD	cis	rs9815354	1.000	rs7622259	chr3:41881351	A/T	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs7081476	0.737	rs113681814	chr10:27489683	C/T	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.4	4.5	0.34	1.35e-5	High light scatter reticulocyte count;
PAAD	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.61	-6.0	-0.44	1.36e-8	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.5	-0.41	1.57e-7	Neuroticism;
PAAD	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.9	0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.58	4.71	0.36	5.64e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs73416724	0.688	rs77241311	chr6:43364043	C/T	cg17502394	chr6:43251710	TTBK1	0.71	4.41	0.34	1.91e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.76	-8.7	-0.58	5.15e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.36	0.46	2.2e-9	Hip circumference;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19510038	chr1:113044860	WNT2B	0.61	6.94	0.49	1.06e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.53	-4.7	-0.36	5.69e-6	Schizophrenia;
PAAD	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.64	-6.32	-0.46	2.76e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.65	6.36	0.46	2.26e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.44	-5.05	-0.38	1.24e-6	Rheumatoid arthritis;
PAAD	cis	rs1365505	0.587	rs4238382	chr15:50484746	T/A	cg26188685	chr15:50540269	HDC	-0.41	-4.43	-0.34	1.8e-5	Blood metabolite ratios;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg15117754	chr3:10150083	C3orf24	0.75	6.21	0.45	4.89e-9	Alzheimer's disease;
PAAD	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.72	6.93	0.49	1.13e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg26703956	chr19:39260304	NA	-0.42	-5.43	-0.4	2.14e-7	Heart rate;
PAAD	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-4.56	-0.35	1.06e-5	Vitiligo;
PAAD	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	1.11	12.62	0.72	2.01e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.47	-4.81	-0.36	3.65e-6	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.56	-5.36	-0.4	3e-7	Blood metabolite levels;
PAAD	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.67	-7.31	-0.51	1.39e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg24739098	chr15:79297159	RASGRF1	0.34	4.35	0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7308134	0.709	rs78723906	chr12:2017576	G/A	cg08762603	chr12:2031417	NA	0.78	4.69	0.36	5.92e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.84	-0.37	3.19e-6	Coronary artery disease;
PAAD	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs7260538	0.509	rs10420194	chr19:41529781	A/T	cg27089200	chr19:41531976	NA	0.43	4.91	0.37	2.34e-6	DDT metabolite (p,p'-DDE levels);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg21407906	chr20:61427925	C20orf20	0.63	6.7	0.48	3.76e-10	Primary biliary cholangitis;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg18612461	chr15:75251733	NA	0.63	7.85	0.54	6.76e-13	Breast cancer;
PAAD	cis	rs2133450	0.683	rs9849706	chr3:7370444	C/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.31	-0.4	3.84e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	1.02	14.21	0.76	1.05e-29	Menarche (age at onset);
PAAD	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6691722	0.583	rs7532539	chr1:24694427	A/G	cg18323236	chr1:24743029	NIPAL3	0.41	4.4	0.34	2e-5	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg10011062	chr15:43941034	CATSPER2	-0.87	-5.29	-0.39	4.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.82	5.91	0.43	2.18e-8	Height;
PAAD	cis	rs7187994	0.848	rs16974535	chr16:84783473	G/A	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Coronary artery disease;
PAAD	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.82	9.73	0.62	1.11e-17	Total body bone mineral density;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg22907277	chr7:1156413	C7orf50	0.49	4.94	0.37	2.03e-6	Longevity;Endometriosis;
PAAD	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.45	4.66	0.35	6.86e-6	Gut microbiome composition (winter);
PAAD	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-5.51	-0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.44	-5.08	-0.38	1.1e-6	Age at first birth;
PAAD	cis	rs1007738	0.580	rs2279439	chr11:47196982	C/T	cg19486271	chr11:47235900	DDB2	0.68	6.32	0.46	2.8e-9	Bone mineral density (hip);
PAAD	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.22	-0.67	1.13e-21	Total body bone mineral density;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.52	5.11	0.38	9.35e-7	Resistin levels;
PAAD	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6442522	0.615	rs13060973	chr3:15500933	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-5.33	-0.4	3.56e-7	Uric acid levels;
PAAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-4.76	-0.36	4.39e-6	Total body bone mineral density;
PAAD	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.39e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.68	-6.75	-0.48	2.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg16558253	chr16:72132732	DHX38	0.47	5.01	0.38	1.52e-6	Fibrinogen levels;
PAAD	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.84	10.29	0.64	3.51e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.61	-5.43	-0.4	2.14e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.54	-0.47	8.87e-10	Life satisfaction;
PAAD	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.42	-0.46	1.65e-9	Triglycerides;
PAAD	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.71	5.06	0.38	1.18e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.94	12.78	0.72	7.52e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg26818257	chr2:241905806	NA	0.42	4.28	0.33	3.34e-5	Urinary metabolites;
PAAD	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs11853189	0.938	rs2280364	chr15:78585106	C/T	cg22935921	chr15:78556834	DNAJA4	0.78	5.36	0.4	3.03e-7	Red cell distribution width;
PAAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.77	9.17	0.6	3.19e-16	Emphysema distribution in smoking;
PAAD	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.78	-5.83	-0.43	3.16e-8	Mean platelet volume;
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg19673125	chr6:150240577	RAET1G	0.4	5.59	0.41	1.03e-7	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-1.01	-8.75	-0.58	3.72e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs3935740	0.649	rs28529299	chr15:81620361	A/G	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6565180	1.000	rs6565180	chr16:30361341	G/T	cg05085585	chr16:30420623	ZNF771	0.45	4.48	0.34	1.46e-5	Tonsillectomy;
PAAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.22	0.39	5.89e-7	Parkinson's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21375511	chr3:53523981	NA	0.57	6.29	0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.04e-6	Itch intensity from mosquito bite;
PAAD	trans	rs901683	1.000	rs901682	chr10:45965861	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.89	-8.68	-0.58	5.88e-15	Bone mineral density;
PAAD	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.46	4.36	0.33	2.42e-5	Red blood cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10781704	chr10:64905996	NRBF2	-0.6	-7.2	-0.5	2.59e-11	Monocyte percentage of white cells;
PAAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.56	4.72	0.36	5.3e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.15	-0.39	7.97e-7	Daytime sleep phenotypes;
PAAD	cis	rs2421770	0.929	rs2421766	chr11:35320946	A/G	cg13971030	chr11:35366721	SLC1A2	-0.52	-6.12	-0.44	7.44e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3206736	0.529	rs1649225	chr7:34991676	C/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg26816564	chr1:7831052	VAMP3	0.6	4.49	0.34	1.4e-5	Inflammatory bowel disease;
PAAD	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg00806126	chr19:22604979	ZNF98	-0.4	-5.11	-0.38	9.36e-7	Pain;
PAAD	cis	rs1903068	0.853	rs12331597	chr4:55997914	T/C	cg01777861	chr4:56023843	NA	0.37	4.49	0.34	1.37e-5	Endometriosis;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg08390786	chr10:135334061	NA	0.64	5.2	0.39	6.24e-7	Gout;
PAAD	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg00922110	chr4:57842668	C4orf14	-0.4	-4.38	-0.33	2.23e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg07395648	chr5:131743802	NA	-0.49	-4.26	-0.33	3.59e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12438356	0.881	rs883767	chr15:69572763	G/T	cg02375503	chr15:69591110	PAQR5	-0.62	-4.46	-0.34	1.59e-5	CTACK levels;
PAAD	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.52	-5.4	-0.4	2.48e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.64	-7.08	-0.5	4.96e-11	Bone mineral density;
PAAD	cis	rs10501293	0.746	rs4755691	chr11:43054865	C/T	cg03447554	chr11:43094025	NA	0.46	4.28	0.33	3.24e-5	Cognitive performance;
PAAD	cis	rs58521262	0.505	rs289343	chr19:23150196	C/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-5.35	-0.4	3.11e-7	Reticulocyte count;
PAAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg13736514	chr6:26305472	NA	-0.59	-6.24	-0.45	4.1e-9	Educational attainment;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.58	-7.13	-0.5	3.78e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg18099408	chr3:52552593	STAB1	0.41	4.59	0.35	9.1e-6	Electroencephalogram traits;
PAAD	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg19882132	chr14:106167949	NA	-0.56	-4.88	-0.37	2.61e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg13902645	chr11:5959945	NA	-0.74	-7.42	-0.52	7.54e-12	DNA methylation (variation);
PAAD	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.73	-8.49	-0.57	1.76e-14	Lung function (FVC);
PAAD	cis	rs9815354	0.767	rs11917248	chr3:41885723	T/C	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs62025270	0.632	rs62022943	chr15:86259470	G/T	cg13263323	chr15:86062960	AKAP13	0.49	4.47	0.34	1.55e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs821931	1.000	rs821951	chr10:108460153	T/A	cg16415058	chr10:108923781	SORCS1	0.37	4.34	0.33	2.57e-5	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
PAAD	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg18302933	chr2:88491318	NA	-0.36	-4.3	-0.33	3.06e-5	Response to metformin (IC50);
PAAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.36	0.4	2.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.38	9.7	0.62	1.28e-17	Atopic dermatitis;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.73	-0.48	3.3e-10	Personality dimensions;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg11874272	chr3:121773564	CD86	-0.42	-4.33	-0.33	2.69e-5	Multiple sclerosis;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs7188861	0.597	rs12918017	chr16:11402350	G/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.71	8.45	0.57	2.24e-14	Lewy body disease;
PAAD	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.72	7.62	0.53	2.48e-12	Triglyceride levels;
PAAD	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg25364880	chr3:44379878	C3orf23	0.57	5.16	0.39	7.47e-7	Depressive symptoms;
PAAD	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2902440	0.502	rs7556198	chr1:67665543	A/G	cg03340356	chr1:67600835	NA	0.44	4.88	0.37	2.66e-6	Crohn's disease;
PAAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.49	4.65	0.35	7.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.4	4.36	0.33	2.36e-5	HDL cholesterol levels;
PAAD	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.49	-4.86	-0.37	2.94e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg04106633	chr4:1044584	NA	-0.66	-5.46	-0.4	1.9e-7	Recombination rate (females);
PAAD	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg25952890	chr19:58913133	NA	0.66	5.61	0.41	9.52e-8	Mean platelet volume;
PAAD	cis	rs746265	0.818	rs11633545	chr15:39590488	T/G	cg10099207	chr15:39544144	C15orf54	0.55	4.31	0.33	2.98e-5	PR interval;
PAAD	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs758324	0.773	rs40819	chr5:131305384	G/T	cg06307176	chr5:131281290	NA	-0.53	-4.56	-0.35	1.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.58	-6.65	-0.47	5.09e-10	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-7.92	-0.54	4.64e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg16701003	chr16:89028210	CBFA2T3	0.57	5.65	0.42	7.67e-8	Social autistic-like traits;
PAAD	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.72	-0.42	5.58e-8	Mean corpuscular volume;
PAAD	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs7129556	0.954	rs6592738	chr11:77323126	C/T	cg24456632	chr11:77314957	AQP11	-0.53	-4.62	-0.35	8.15e-6	Weight loss (gastric bypass surgery);
PAAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	trans	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg00626422	chr7:22894849	SNORD93	-0.54	-6.35	-0.46	2.41e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs6549438	1.000	rs6798993	chr3:72161623	A/C	cg10452974	chr3:71398091	FOXP1	0.45	5.04	0.38	1.3e-6	Migraine - clinic-based;
PAAD	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.91	0.37	2.34e-6	Total body bone mineral density;
PAAD	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg06728252	chr6:26598149	ABT1	-0.38	-4.46	-0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.23	0.51	2.14e-11	Lung cancer in ever smokers;
PAAD	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg14181355	chr19:12984996	MAST1	-0.49	-4.81	-0.36	3.63e-6	Mean corpuscular volume;
PAAD	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.77	8.98	0.59	9.76e-16	Total body bone mineral density;
PAAD	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg07617317	chr6:118971624	C6orf204	0.5	4.28	0.33	3.31e-5	Diastolic blood pressure;
PAAD	cis	rs6141769	0.542	rs9421	chr20:31291161	C/T	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.69	-0.36	6e-6	Subjective well-being;
PAAD	trans	rs992005	0.894	rs13393754	chr2:199518159	C/T	cg12456799	chr10:106441036	SORCS3	-0.37	-6.34	-0.46	2.46e-9	Cognitive ability (multi-trait analysis);
PAAD	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.55	5.01	0.38	1.52e-6	Type 2 diabetes;
PAAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.95	12.32	0.71	1.24e-24	Menopause (age at onset);
PAAD	cis	rs10450586	0.897	rs7480191	chr11:27330098	A/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg23346134	chr3:49453900	TCTA	0.41	4.35	0.33	2.51e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11825685	0.579	rs3016428	chr11:134544301	G/A	cg06603561	chr11:134479413	NA	-0.59	-5.15	-0.39	7.86e-7	IgG glycosylation;
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.5e-9	Bipolar disorder;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg10729496	chr3:10149963	C3orf24	0.9	7.5	0.52	4.92e-12	Alzheimer's disease;
PAAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg24253500	chr15:84953950	NA	-0.47	-5.18	-0.39	7.05e-7	P wave terminal force;
PAAD	cis	rs67311347	0.521	rs6769540	chr3:40357904	G/A	cg12215294	chr3:40350768	EIF1B	-0.47	-4.76	-0.36	4.47e-6	Renal cell carcinoma;
PAAD	cis	rs6942407	0.744	rs6968640	chr7:86862783	T/G	cg02420886	chr7:86849541	C7orf23	0.55	4.34	0.33	2.56e-5	Food allergy;
PAAD	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.75	0.36	4.64e-6	Educational attainment;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.93	-11.05	-0.67	3.32e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.12	17.44	0.82	4.12e-38	Menarche (age at onset);
PAAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.84	-10.9	-0.66	8.55e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7326068	0.610	rs4769128	chr13:21322682	A/G	cg27499820	chr13:21296301	IL17D	-0.56	-5.2	-0.39	6.2e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg05805236	chr11:65401703	PCNXL3	-0.42	-4.4	-0.34	2.01e-5	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	5.01	0.38	1.47e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2302729	0.727	rs10848684	chr12:2793478	G/A	cg19945202	chr12:2788847	CACNA1C	-0.71	-6.79	-0.48	2.32e-10	Sleep quality;
PAAD	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-1.0	-11.0	-0.67	4.46e-21	Breast cancer;
PAAD	cis	rs11892454	0.515	rs2176181	chr2:26030339	A/G	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23099349	chr6:26032281	HIST1H3B	0.59	6.59	0.47	6.85e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.97	-0.44	1.65e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.46	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs7922314	0.571	rs34827384	chr10:64733028	A/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.91	-0.37	2.34e-6	Body mass index;
PAAD	cis	rs1499972	0.648	rs62264764	chr3:117639575	G/A	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.48	-0.34	1.49e-5	Height;
PAAD	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	6.59	0.47	6.79e-10	Lymphocyte counts;
PAAD	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.69	-5.72	-0.42	5.52e-8	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06544989	chr22:39130855	UNC84B	0.49	4.79	0.36	3.86e-6	Menopause (age at onset);
PAAD	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg16898833	chr6:26189333	HIST1H4D	0.6	4.59	0.35	9.12e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.59	-4.27	-0.33	3.37e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2085601	0.542	rs9307062	chr4:89949228	T/G	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.47	-4.25	-0.33	3.78e-5	Triglycerides;
PAAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.63	6.31	0.46	2.87e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg15654264	chr1:150340011	RPRD2	-0.49	-4.77	-0.36	4.33e-6	Migraine;
PAAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.85	7.63	0.53	2.4e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-6.6	-0.47	6.55e-10	Schizophrenia;
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.18	-0.39	6.91e-7	Other erythrocyte phenotypes;
PAAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg20805835	chr1:248005719	OR11L1	-0.5	-4.41	-0.34	1.94e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.77	-8.08	-0.55	1.88e-13	Type 2 diabetes;
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.44	0.34	1.69e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.47	4.77	0.36	4.31e-6	Electroencephalogram traits;
PAAD	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.39	-4.3	-0.33	2.99e-5	Inflammatory bowel disease;
PAAD	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg04289385	chr6:36355825	ETV7	0.44	4.36	0.33	2.34e-5	Platelet distribution width;
PAAD	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.45	4.41	0.34	1.95e-5	Chronic sinus infection;
PAAD	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.86	-0.43	2.78e-8	Retinal vascular caliber;
PAAD	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.53	0.34	1.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.81e-6	Lymphocyte counts;
PAAD	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.83	9.92	0.63	3.31e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06850241	chr22:41845214	NA	0.58	5.05	0.38	1.24e-6	Vitiligo;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.07e-5	Eye color traits;
PAAD	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.74	-8.76	-0.58	3.52e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	7.52	0.52	4.39e-12	Mood instability;
PAAD	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.07	0.55	1.95e-13	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg05253283	chr3:195717344	SDHAP1	-0.55	-6.46	-0.46	1.36e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.73	5.09	0.38	1.03e-6	Phospholipid levels (plasma);
PAAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg26897989	chr16:1907736	C16orf73	0.44	4.55	0.35	1.07e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13198984	chr17:80129470	CCDC57	0.41	5.03	0.38	1.35e-6	Life satisfaction;
PAAD	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-5.73	-0.42	5.1e-8	Cognitive test performance;
PAAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-4.69	-0.36	6.16e-6	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs55692468	0.771	rs6744391	chr2:153334614	T/C	cg04681845	chr2:153283485	FMNL2	-0.42	-5.03	-0.38	1.39e-6	Intraocular pressure;
PAAD	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs56046484	0.956	rs12904410	chr15:85609788	C/T	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.32	-0.33	2.76e-5	Recombination measurement;
PAAD	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg13446199	chr8:143762866	PSCA	0.35	4.27	0.33	3.36e-5	Urinary tract infection frequency;
PAAD	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.55	5.62	0.41	8.93e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.74	7.13	0.5	3.7e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7119038	0.509	rs10892259	chr11:118583002	G/A	cg08498647	chr11:118550644	TREH	0.4	4.43	0.34	1.81e-5	Sjögren's syndrome;
PAAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	1.1	14.06	0.75	2.74e-29	Breast cancer;
PAAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	6.16	0.45	6.24e-9	Schizophrenia;
PAAD	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg00383909	chr3:49044727	WDR6	0.54	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs501120	0.584	rs966161	chr10:44712574	C/T	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14533206	chr13:110439006	IRS2	-0.79	-6.99	-0.49	8.27e-11	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27426824	chr10:70426930	TET1	-0.65	-6.48	-0.47	1.18e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	7.67	0.53	1.95e-12	Alzheimer's disease;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg10207240	chr12:122356781	WDR66	0.59	6.05	0.44	1.09e-8	Mean corpuscular volume;
PAAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.83	6.88	0.49	1.44e-10	Crohn's disease;
PAAD	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.2	-0.39	6.37e-7	Schizophrenia (age at onset);
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-4.71	-0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs10861342	1.000	rs1444608	chr12:105559157	A/G	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.48	4.33	0.33	2.74e-5	Educational attainment;
PAAD	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.97	-13.25	-0.73	3.92e-27	Height;
PAAD	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	0.95	6.86	0.49	1.6e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.44	0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg23283495	chr1:209979779	IRF6	0.78	7.07	0.5	5.37e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.46	0.46	1.31e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.64	4.98	0.37	1.72e-6	Gut microbiome composition (summer);
PAAD	cis	rs2072883	0.669	rs5759111	chr22:43442599	C/T	cg16973406	chr22:43265991	NA	-0.35	-4.25	-0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg09127314	chr1:152161683	NA	0.73	5.21	0.39	6.02e-7	Atopic dermatitis;
PAAD	cis	rs3112530	0.688	rs2927584	chr5:152715355	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs12432203	1.000	rs72622437	chr14:51735708	A/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg11952622	chr19:58962976	ZNF324B	0.44	4.31	0.33	2.87e-5	Uric acid clearance;
PAAD	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg05082376	chr22:42548792	NA	0.48	5.17	0.39	7.31e-7	Cognitive function;
PAAD	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12767760	0.669	rs7902642	chr10:99329081	C/T	cg25247692	chr10:99313390	UBTD1	0.56	5.47	0.41	1.83e-7	Obesity-related traits;
PAAD	cis	rs11811982	0.793	rs55643926	chr1:227575629	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.13	0.38	8.71e-7	Optic disc area;
PAAD	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.51	4.58	0.35	9.55e-6	Depression;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg18764771	chr6:116381957	FRK	-0.44	-7.59	-0.52	3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2133450	0.712	rs17697928	chr3:7367771	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.22	-0.39	5.72e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.43	-5.14	-0.38	8.42e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.51	-4.39	-0.34	2.09e-5	Cocaine dependence;
PAAD	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg15841412	chr13:111365552	ING1	0.56	4.74	0.36	4.98e-6	Coronary artery disease;
PAAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.51	0.61	3.98e-17	Rheumatoid arthritis;
PAAD	cis	rs10450586	0.863	rs6484283	chr11:27298776	C/G	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg09060608	chr5:178986726	RUFY1	0.46	4.45	0.34	1.68e-5	Lung cancer;
PAAD	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-5.81	-0.43	3.5e-8	Schizophrenia;
PAAD	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.37	-7.07	-0.5	5.35e-11	Psoriasis vulgaris;
PAAD	cis	rs13100165	0.966	rs13096980	chr3:73269710	A/C	cg07385778	chr3:72320634	NA	-0.28	-4.37	-0.33	2.34e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.65	-0.35	7.19e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	0.79	5.6	0.41	9.55e-8	Body mass index;
PAAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs9616064	0.778	rs9616050	chr22:46966536	G/A	cg05621596	chr22:47072043	GRAMD4	-0.54	-4.39	-0.34	2.15e-5	Urate levels in obese individuals;
PAAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	4.31	0.33	2.87e-5	Menopause (age at onset);
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.53	-5.5	-0.41	1.55e-7	Lung cancer;
PAAD	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.59	-5.26	-0.39	4.74e-7	Menarche (age at onset);
PAAD	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
PAAD	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs939584	0.867	rs34119520	chr2:632760	T/C	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.75	8.35	0.56	3.92e-14	Magnesium levels;
PAAD	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs6604026	0.656	rs2774954	chr1:93363525	G/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09436067	chr3:185689507	NA	-0.45	-4.59	-0.35	9.2e-6	Myopia (pathological);
PAAD	cis	rs642743	1.000	rs642743	chr10:105933417	C/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.62	0.35	8.27e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06796806	chr11:66313538	ZDHHC24;ACTN3	-0.71	-6.42	-0.46	1.62e-9	Neuroticism;
PAAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.48	-4.91	-0.37	2.29e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.67	4.57	0.35	9.87e-6	IgG glycosylation;
PAAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg18402987	chr7:1209562	NA	1.11	5.59	0.41	1.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg17366294	chr4:99064904	C4orf37	0.55	5.89	0.43	2.4e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg23281280	chr6:28129359	ZNF389	0.54	4.86	0.37	2.88e-6	Parkinson's disease;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg27094323	chr7:1216898	NA	-0.56	-6.51	-0.47	1.06e-9	Longevity;Endometriosis;
PAAD	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.54	5.94	0.43	1.9e-8	Urate levels in lean individuals;
PAAD	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg13256891	chr4:100009986	ADH5	-0.76	-7.69	-0.53	1.7e-12	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs454510	0.726	rs347909	chr1:120184212	C/T	cg11530693	chr1:120165357	ZNF697	0.58	5.07	0.38	1.13e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.89	-7.34	-0.51	1.23e-11	Obesity-related traits;
PAAD	cis	rs2790216	0.950	rs2790182	chr10:60039877	A/G	cg20442379	chr10:60024634	IPMK	0.6	4.6	0.35	8.68e-6	Inflammatory bowel disease;
PAAD	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg05338066	chr1:7812865	CAMTA1	0.63	4.71	0.36	5.55e-6	Inflammatory bowel disease;
PAAD	cis	rs11581903	0.929	rs34275176	chr1:53056063	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.93	6.38	0.46	2.04e-9	Joint mobility (Beighton score);
PAAD	cis	rs35160687	0.644	rs1863061	chr2:86512907	C/T	cg10973622	chr2:86423274	IMMT	-0.45	-4.93	-0.37	2.12e-6	Night sleep phenotypes;
PAAD	cis	rs1043763	0.826	rs4075625	chr12:122610593	A/T	cg26218692	chr12:122497826	BCL7A	-0.66	-6.65	-0.47	4.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg24375607	chr4:120327624	NA	0.55	5.19	0.39	6.64e-7	Corneal astigmatism;
PAAD	cis	rs3743102	0.527	rs117959961	chr15:83339895	C/T	cg00614314	chr15:82944287	LOC80154	-0.77	-5.45	-0.4	1.99e-7	Colorectal adenoma (advanced);
PAAD	cis	rs732765	0.657	rs10148524	chr14:75226002	C/T	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs12476592	0.636	rs196123	chr2:63841712	T/C	cg10828910	chr2:63850056	LOC388955	0.52	4.28	0.33	3.28e-5	Childhood ear infection;
PAAD	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.99	-0.44	1.47e-8	Prostate cancer;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.97	-0.54	3.47e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.68	7.06	0.5	5.71e-11	Caffeine consumption;
PAAD	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.72	-0.36	5.36e-6	Neuroticism;
PAAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg03983715	chr16:68378420	PRMT7	-0.96	-6.81	-0.48	2.1e-10	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.07	0.44	9.99e-9	Height;
PAAD	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.63	-0.35	7.87e-6	Prevalent atrial fibrillation;
PAAD	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg04705435	chr11:17411270	KCNJ11	0.49	4.58	0.35	9.74e-6	Body mass index;Social communication problems;
PAAD	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg11262906	chr1:85462892	MCOLN2	0.6	4.6	0.35	8.89e-6	Serum sulfate level;
PAAD	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.56	5.38	0.4	2.82e-7	Mood instability;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05671347	chr6:44355199	CDC5L	-0.61	-6.63	-0.47	5.38e-10	Smoking initiation;
PAAD	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.68	7.35	0.51	1.15e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.12e-6	Skin colour saturation;
PAAD	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	11.06	0.67	3.11e-21	Menopause (age at onset);
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg09417038	chr21:47716443	C21orf57	0.61	6.63	0.47	5.55e-10	Testicular germ cell tumor;
PAAD	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.67	0.35	6.57e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg21698718	chr17:80085957	CCDC57	0.46	5.16	0.39	7.52e-7	Life satisfaction;
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.59	-5.72	-0.42	5.5e-8	Acylcarnitine levels;
PAAD	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg19630374	chr17:18023558	MYO15A	-0.57	-6.17	-0.45	5.81e-9	Total body bone mineral density;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg08498647	chr11:118550644	TREH	-0.44	-4.31	-0.33	2.95e-5	Sjögren's syndrome;
PAAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.48	4.77	0.36	4.35e-6	Corneal structure;
PAAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg21395723	chr22:39101663	GTPBP1	0.44	4.48	0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs508970	0.578	rs60905595	chr11:60924896	C/A	cg24692310	chr11:60915630	VPS37C	0.34	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.66	-6.7	-0.48	3.87e-10	Blood metabolite levels;
PAAD	cis	rs72772090	0.908	rs76539796	chr5:96038675	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.32	-0.46	2.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18364678	chr10:103586829	KCNIP2	0.65	6.62	0.47	5.68e-10	Smoking initiation;
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.83	-9.09	-0.59	4.97e-16	Prostate cancer;
PAAD	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.61	7.47	0.52	5.91e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1419980	0.730	rs12229550	chr12:7745968	T/C	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.31	-0.33	2.97e-5	Resting heart rate;
PAAD	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg07943548	chr15:86304357	KLHL25	-0.74	-6.01	-0.44	1.32e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.93	7.49	0.52	5.24e-12	Initial pursuit acceleration;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.55	-5.15	-0.39	7.95e-7	Brugada syndrome;
PAAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	5.03	0.38	1.38e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs4981053	0.553	rs12897278	chr14:20487504	T/A	cg10560561	chr2:122187299	CLASP1	0.56	6.5	0.47	1.06e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.58	-7.62	-0.53	2.59e-12	Longevity;
PAAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.43	4.97	0.37	1.79e-6	Immature fraction of reticulocytes;
PAAD	cis	rs911119	0.955	rs1011226	chr20:23605833	G/T	cg16589663	chr20:23618590	CST3	-0.76	-6.66	-0.48	4.77e-10	Chronic kidney disease;
PAAD	cis	rs3206736	0.548	rs10265125	chr7:35061136	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg20821713	chr7:1055600	C7orf50	-0.38	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Bladder cancer;
PAAD	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06307176	chr5:131281290	NA	-0.52	-4.64	-0.35	7.33e-6	Life satisfaction;
PAAD	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.92	0.37	2.19e-6	Ovarian reserve;
PAAD	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.55	-0.41	1.23e-7	Monocyte percentage of white cells;
PAAD	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.16e-10	Cutaneous nevi;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-1.17	-11.21	-0.67	1.23e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg19423196	chr10:82049429	MAT1A	0.61	4.65	0.35	7.02e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23305440	chr4:99529282	TSPAN5	-0.62	-6.49	-0.47	1.13e-9	Obesity-related traits;
PAAD	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.56	-0.41	1.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.46	-0.34	1.55e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-1.14	-4.8	-0.36	3.76e-6	Asthma (childhood onset);
PAAD	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.48	-5.65	-0.42	7.71e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-5.75	-0.42	4.66e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs77880822	0.562	rs7271372	chr20:1233893	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	1.01	7.61	0.53	2.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg06131755	chr6:160182447	ACAT2	-0.55	-4.96	-0.37	1.9e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg14146966	chr2:61757674	XPO1	0.38	4.56	0.35	1.03e-5	Tuberculosis;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27297192	chr10:134578999	INPP5A	0.61	5.57	0.41	1.12e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.31	-0.4	3.88e-7	Daytime sleep phenotypes;
PAAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.83	10.05	0.63	1.56e-18	Coronary artery disease;
PAAD	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.48	5.12	0.38	9.19e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.89	-7.29	-0.51	1.61e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.47	0.52	5.77e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg06728252	chr6:26598149	ABT1	-0.36	-4.26	-0.33	3.59e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.18	0.39	7e-7	Tonsillectomy;
PAAD	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.35	-6.53	-0.47	9.48e-10	Type 2 diabetes;
PAAD	cis	rs4455778	0.538	rs7796590	chr7:49124983	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.63	-7.88	-0.54	5.89e-13	Prostate cancer;
PAAD	cis	rs12760731	0.720	rs1510266	chr1:178346771	A/T	cg00404053	chr1:178313656	RASAL2	-0.74	-5.77	-0.42	4.3e-8	Obesity-related traits;
PAAD	trans	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg00626422	chr7:22894849	SNORD93	-0.54	-6.38	-0.46	2.04e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs9810890	1.000	rs6778057	chr3:128647823	A/G	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs227833	0.739	rs663933	chr6:44660748	A/G	cg18551225	chr6:44695536	NA	0.41	4.29	0.33	3.23e-5	Monobrow;
PAAD	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.57	-5.96	-0.43	1.73e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg00206168	chr11:65308501	LTBP3	0.5	5.25	0.39	5.09e-7	Bone mineral density;
PAAD	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.7e-13	Coronary artery disease;
PAAD	cis	rs7236492	0.572	rs76694706	chr18:77236006	T/C	cg15644404	chr18:77186268	NFATC1	-0.93	-6.08	-0.44	9.44e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg23461800	chr14:103021989	NA	-0.65	-4.81	-0.36	3.62e-6	Platelet count;
PAAD	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.68	6.7	0.48	3.73e-10	Lymphocyte counts;
PAAD	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-7.13	-0.5	3.8e-11	Coffee consumption (cups per day);
PAAD	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.61	4.48	0.34	1.44e-5	Exhaled nitric oxide output;
PAAD	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg21605333	chr4:119757512	SEC24D	1.97	9.97	0.63	2.57e-18	Cannabis dependence symptom count;
PAAD	cis	rs11997175	0.624	rs66475930	chr8:33752570	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	5.44	0.4	2.1e-7	Body mass index;
PAAD	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.65	-0.35	7.22e-6	Glomerular filtration rate;
PAAD	cis	rs10905065	0.930	rs10795485	chr10:5755047	T/C	cg11519256	chr10:5708881	ASB13	0.51	4.31	0.33	2.91e-5	Menopause (age at onset);
PAAD	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22633769	chr20:60982531	CABLES2	0.51	4.57	0.35	1.01e-5	Colorectal cancer;
PAAD	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.25	0.33	3.78e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.86	-10.35	-0.64	2.52e-19	Sudden cardiac arrest;
PAAD	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs757081	0.533	rs56030184	chr11:17067849	C/T	cg15084286	chr11:17036142	PLEKHA7	0.57	4.82	0.36	3.37e-6	Systolic blood pressure;
PAAD	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg06636001	chr8:8085503	FLJ10661	-0.81	-8.6	-0.57	9.41e-15	Neuroticism;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.9	11.19	0.67	1.43e-21	Prudent dietary pattern;
PAAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.97	11.24	0.67	9.9700000000000009e-22	Menopause (age at onset);
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.41	-4.38	-0.33	2.22e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg00206168	chr11:65308501	LTBP3	0.84	5.88	0.43	2.56e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.82	6.73	0.48	3.21e-10	Pulmonary function decline;
PAAD	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-6.45	-0.46	1.38e-9	Monocyte count;
PAAD	cis	rs1912528	0.783	rs809955	chr4:140874760	G/A	cg11128457	chr4:140864437	MAML3	-0.32	-4.31	-0.33	2.94e-5	Educational attainment (years of education);
PAAD	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	4.95	0.37	1.99e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.27e-15	Emphysema distribution in smoking;
PAAD	cis	rs4658101	0.906	rs1192404	chr1:92068967	A/G	cg06318676	chr1:92077357	NA	0.41	4.59	0.35	9.04e-6	Optic disc area;Vertical cup-disc ratio;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.81	-9.11	-0.59	4.35e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg19337854	chr7:99768885	GPC2	0.44	4.48	0.34	1.45e-5	Coronary artery disease;
PAAD	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg20283391	chr11:68216788	NA	-0.53	-5.08	-0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs6594713	0.533	rs34817468	chr5:112953168	G/A	cg12552261	chr5:112820674	MCC	0.74	4.72	0.36	5.27e-6	Brain cytoarchitecture;
PAAD	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.81	6.09	0.44	9.03e-9	Mean platelet volume;
PAAD	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg08601574	chr20:25228251	PYGB	0.49	5.0	0.38	1.59e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.57e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.7	7.1	0.5	4.58e-11	Coronary artery disease;
PAAD	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.56	-4.87	-0.37	2.76e-6	Breast cancer;
PAAD	cis	rs2271001	0.955	rs4757758	chr11:19155035	A/G	cg00161556	chr11:19138045	ZDHHC13	-0.51	-5.32	-0.4	3.57e-7	Gut microbiome composition (winter);
PAAD	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.88	-9.2	-0.6	2.64e-16	Response to antineoplastic agents;
PAAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	1.05	6.58	0.47	7.1e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.69	5.74	0.42	4.94e-8	Alzheimer's disease;
PAAD	cis	rs308971	0.656	rs2648347	chr3:12057200	T/G	cg15873301	chr3:12045459	SYN2	0.63	5.19	0.39	6.77e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06636551	chr8:101224915	SPAG1	0.58	7.36	0.51	1.06e-11	Atrioventricular conduction;
PAAD	cis	rs1198430	0.599	rs10917382	chr1:23780639	G/A	cg24580199	chr1:23763081	ASAP3	0.55	4.79	0.36	4e-6	Total cholesterol levels;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg14926445	chr8:58193284	C8orf71	-0.67	-4.85	-0.37	3.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6076065	0.723	rs6132607	chr20:23390373	C/G	cg11657817	chr20:23433608	CST11	-0.5	-5.14	-0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-8.09	-0.55	1.71e-13	Urinary metabolites;
PAAD	cis	rs6594713	0.642	rs6867579	chr5:112899573	T/C	cg12552261	chr5:112820674	MCC	0.74	5.08	0.38	1.1e-6	Brain cytoarchitecture;
PAAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.1	-0.55	1.66e-13	Bone mineral density;
PAAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.98	11.56	0.68	1.38e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs6466055	0.661	rs6950104	chr7:104877373	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.6	5.69	0.42	6.23e-8	Cystic fibrosis severity;
PAAD	cis	rs8076220	1.000	rs9891347	chr17:11088287	G/T	cg18156845	chr17:11985185	MIR744;MAP2K4	0.62	4.25	0.33	3.73e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg11946769	chr3:48343235	NME6	-0.52	-4.96	-0.37	1.87e-6	Educational attainment (years of education);
PAAD	cis	rs12257961	0.549	rs11259613	chr10:15382515	A/C	cg10616319	chr10:15468812	NA	0.46	4.42	0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs7173743	0.525	rs8028410	chr15:79134267	C/T	cg00540400	chr15:79124168	NA	0.45	4.69	0.36	6.06e-6	Coronary artery disease;
PAAD	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg26031613	chr14:104095156	KLC1	-0.48	-5.24	-0.39	5.38e-7	Schizophrenia;
PAAD	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg13198984	chr17:80129470	CCDC57	-0.38	-4.57	-0.35	9.84e-6	Life satisfaction;
PAAD	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg15208524	chr1:10270712	KIF1B	0.48	4.38	0.33	2.21e-5	Hepatocellular carcinoma;
PAAD	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg07741184	chr6:167504864	NA	0.42	4.93	0.37	2.14e-6	Crohn's disease;
PAAD	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs1322639	0.592	rs7743597	chr6:169591678	T/C	cg03254818	chr6:169586852	NA	0.4	4.33	0.33	2.69e-5	Pulse pressure;
PAAD	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg09659197	chr4:152720779	NA	0.31	4.4	0.34	2.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs630539	0.793	rs2855484	chr17:40712811	T/A	cg20669292	chr17:40823420	PLEKHH3	-0.44	-4.25	-0.33	3.69e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs12422267	0.536	rs61944635	chr12:132575652	C/T	cg05134918	chr12:132603531	EP400NL	-0.66	-4.7	-0.36	5.8e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.6	5.37	0.4	2.86e-7	Retinal vascular caliber;
PAAD	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.67	-5.94	-0.43	1.85e-8	Coronary artery disease;
PAAD	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.14e-6	Airway imaging phenotypes;
PAAD	cis	rs17824933	0.848	rs74860834	chr11:60778513	T/C	cg27098804	chr11:60776124	CD6	0.44	4.33	0.33	2.71e-5	Multiple sclerosis;
PAAD	cis	rs2899832	0.866	rs1884715	chr14:35743573	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	4.62	0.35	8.03e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.55	5.9	0.43	2.27e-8	Menopause (age at onset);
PAAD	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-1.01	-12.96	-0.72	2.45e-26	Refractive error;
PAAD	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.6	-0.57	9.17e-15	Monocyte count;
PAAD	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-4.92	-0.37	2.23e-6	Menarche (age at onset);
PAAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.45	5.52	0.41	1.42e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.54	-5.27	-0.39	4.62e-7	White matter hyperintensity burden;
PAAD	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.52	-4.65	-0.35	7.02e-6	Total body bone mineral density;
PAAD	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-6.88	-0.49	1.44e-10	Acylcarnitine levels;
PAAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.6e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.56	-0.41	1.21e-7	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22869660	chr8:101965413	YWHAZ	0.61	6.79	0.48	2.31e-10	Monocyte percentage of white cells;
PAAD	cis	rs6835098	0.692	rs1316411	chr4:174075143	A/G	cg08422745	chr4:174089978	GALNT7	-0.58	-5.49	-0.41	1.67e-7	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2718812	1.000	rs2718815	chr3:133398786	A/G	cg08439880	chr3:133502540	NA	0.41	4.62	0.35	8.2e-6	Iron status biomarkers;
PAAD	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg18068537	chr15:74660088	CYP11A1	-0.49	-4.38	-0.33	2.19e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.96	10.53	0.65	7.96e-20	Multiple sclerosis;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg08446989	chr11:66036511	RAB1B	-0.46	-4.72	-0.36	5.33e-6	Eosinophil percentage of white cells;
PAAD	cis	rs73206853	0.841	rs73191815	chr12:110914698	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.81	-10.16	-0.64	7.86e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.65	6.99	0.49	8.16e-11	Mean corpuscular volume;
PAAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg26897989	chr16:1907736	C16orf73	0.46	4.76	0.36	4.38e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs42648	0.564	rs39283	chr7:89788806	C/A	cg27367526	chr7:89841692	STEAP2	-0.31	-4.33	-0.33	2.75e-5	Homocysteine levels;
PAAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.53	0.47	9.17e-10	Morning vs. evening chronotype;
PAAD	cis	rs990171	0.538	rs1523201	chr2:103107064	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs6601530	0.557	rs2409676	chr8:10722058	T/C	cg00262122	chr8:11665843	FDFT1	-0.52	-4.58	-0.35	9.61e-6	Carotid intima media thickness;
PAAD	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg20936604	chr3:58311152	NA	-0.77	-4.39	-0.34	2.15e-5	Cholesterol, total;
PAAD	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg21937377	chr3:194868750	C3orf21	0.46	4.85	0.37	2.97e-6	Non-small cell lung cancer;
PAAD	cis	rs75920871	0.623	rs56227539	chr11:116964469	T/C	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-4.37	-0.33	2.29e-5	Neuroticism;
PAAD	cis	rs1569175	1.000	rs3115424	chr2:200932296	A/G	cg23649088	chr2:200775458	C2orf69	-0.79	-4.49	-0.34	1.39e-5	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.52	5.14	0.39	8.18e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg27411982	chr8:10470053	RP1L1	-0.48	-4.91	-0.37	2.28e-6	Triglycerides;
PAAD	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.02	-0.38	1.41e-6	Cervical cancer;
PAAD	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs8031341	0.712	rs1063147	chr15:91354505	C/T	cg02722434	chr15:91362469	NA	0.53	4.44	0.34	1.7e-5	Delta-5 desaturase activity;
PAAD	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.44	4.6	0.35	8.92e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.91	-0.54	4.8e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg16417436	chr16:28758564	NA	0.45	4.41	0.34	1.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs593531	0.571	rs35170680	chr11:74085420	T/G	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.48	-0.34	1.47e-5	Neuroticism;
PAAD	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.41	-0.52	8.02e-12	Body mass index;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.5	5.14	0.38	8.4e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.3	-0.33	2.99e-5	Daytime sleep phenotypes;
PAAD	cis	rs9487051	0.646	rs11153166	chr6:109622494	C/T	cg01475377	chr6:109611718	NA	0.39	4.43	0.34	1.76e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg02555727	chr12:129281546	SLC15A4	0.5	5.34	0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-5.95	-0.43	1.77e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg15123519	chr2:136567270	LCT	0.37	4.53	0.35	1.18e-5	Mosquito bite size;
PAAD	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg14752227	chr20:34000481	UQCC	0.55	5.5	0.41	1.55e-7	Height;
PAAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00290607	chr11:67383545	NA	-0.57	-5.61	-0.41	9.45e-8	Mean corpuscular volume;
PAAD	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.53	4.73	0.36	5.06e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.85	-10.74	-0.66	2.26e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.51	-4.28	-0.33	3.34e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14560775	chr19:14952078	OR7A10	-0.48	-6.32	-0.46	2.72e-9	Energy expenditure (24h);
PAAD	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg03885332	chr11:832357	CD151	-0.45	-5.24	-0.39	5.27e-7	Mean platelet volume;
PAAD	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg00228799	chr9:131580591	ENDOG	0.64	6.43	0.46	1.58e-9	Blood metabolite levels;
PAAD	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.4	-4.87	-0.37	2.78e-6	Lewy body disease;
PAAD	cis	rs8005172	0.663	rs7141184	chr14:88512761	C/T	cg18078958	chr14:88630771	NA	0.35	4.43	0.34	1.78e-5	Parkinson's disease;
PAAD	cis	rs1045714	0.943	rs56063345	chr7:2653504	C/G	cg20813462	chr7:2646259	IQCE	0.62	4.25	0.33	3.71e-5	Urate levels in lean individuals;
PAAD	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg19131313	chr8:1704013	NA	-0.43	-4.58	-0.35	9.67e-6	Systolic blood pressure;
PAAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04362095	chr11:63592001	C11orf84	-0.52	-4.64	-0.35	7.57e-6	Platelet count;
PAAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg01796438	chr3:11312864	ATG7	-0.56	-4.36	-0.33	2.35e-5	Circulating chemerin levels;
PAAD	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.29	-0.33	3.2e-5	Acylcarnitine levels;
PAAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg10167378	chr1:228756711	NA	0.43	4.27	0.33	3.43e-5	Diastolic blood pressure;
PAAD	cis	rs10899021	1.000	rs61900636	chr11:74359591	G/T	cg25880958	chr11:74394337	NA	-0.86	-5.58	-0.41	1.08e-7	Response to metformin (IC50);
PAAD	cis	rs7771547	0.603	rs7743396	chr6:36579252	C/T	cg07856975	chr6:36356162	ETV7	0.55	5.86	0.43	2.83e-8	Platelet distribution width;
PAAD	cis	rs6596100	0.538	rs34592321	chr5:132181675	G/C	cg14825688	chr5:132208181	LEAP2	-0.68	-4.84	-0.37	3.15e-6	Breast cancer;
PAAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.62	-8.25	-0.56	7.18e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.08	14.54	0.76	1.43e-30	Primary sclerosing cholangitis;
PAAD	cis	rs2117029	0.619	rs9325145	chr12:49525884	A/G	cg05368762	chr12:50135785	TMBIM6	0.43	4.26	0.33	3.59e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.73	7.96	0.54	3.62e-13	Longevity;
PAAD	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.39	0.46	1.88e-9	Personality dimensions;
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg11062466	chr8:58055876	NA	0.67	4.71	0.36	5.55e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7616330	0.623	rs926023	chr3:71027733	G/C	cg01511742	chr3:71112437	FOXP1	-0.79	-4.84	-0.37	3.17e-6	QT interval;
PAAD	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.99	-0.49	8.17e-11	Response to antipsychotic treatment;
PAAD	cis	rs9826463	0.757	rs2229032	chr3:142178144	A/G	cg20824294	chr3:142316082	PLS1	-0.47	-5.42	-0.4	2.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.74	-5.5	-0.41	1.61e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg04359915	chr10:101825029	CPN1	-0.35	-5.27	-0.39	4.68e-7	Bone mineral density;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.9	6.63	0.47	5.6e-10	Pulse pressure;
PAAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg25838465	chr1:92012736	NA	-0.77	-9.47	-0.61	5.04e-17	Breast cancer;
PAAD	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.59e-7	Lung cancer;
PAAD	cis	rs6489785	0.521	rs668622	chr12:121198299	G/A	cg02419362	chr12:121203948	SPPL3	0.52	5.69	0.42	6.23e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20607769	chr12:53491735	IGFBP6	0.61	6.83	0.48	1.88e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03762994	chr17:6899332	ALOX12	-0.49	-5.01	-0.38	1.47e-6	Tonsillectomy;
PAAD	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.73	-9.17	-0.6	3.11e-16	Educational attainment;
PAAD	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-6.02	-0.44	1.26e-8	Parkinson's disease;
PAAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.39	-0.34	2.12e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.73	7.61	0.53	2.72e-12	Type 2 diabetes;
PAAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg03808351	chr9:123631620	PHF19	0.46	5.0	0.38	1.55e-6	Rheumatoid arthritis;
PAAD	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	4.54	0.35	1.14e-5	Educational attainment;
PAAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	5.19	0.39	6.73e-7	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.47	0.57	1.93e-14	Alzheimer's disease;
PAAD	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg16211469	chr6:24423932	MRS2	0.52	5.26	0.39	4.74e-7	Liver enzyme levels;
PAAD	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-4.72	-0.36	5.27e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.77	0.62	8.44e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.56	5.51	0.41	1.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.72	4.74	0.36	4.83e-6	HDL cholesterol;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.35	-0.33	2.47e-5	Daytime sleep phenotypes;
PAAD	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19882132	chr14:106167949	NA	-0.55	-4.92	-0.37	2.21e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.81	-8.38	-0.56	3.34e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.42	5.14	0.38	8.42e-7	Corneal astigmatism;
PAAD	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg06217071	chr17:408420	NA	0.48	5.03	0.38	1.34e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1891275	0.588	rs6583782	chr10:93425779	G/A	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.86	7.12	0.5	3.92e-11	Alzheimer's disease;
PAAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg01503450	chr10:980765	NA	-0.57	-5.03	-0.38	1.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.82	8.22	0.55	8.11e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.9	13.12	0.73	8.85e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.94	10.59	0.65	5.8e-20	Parkinson's disease;
PAAD	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-5.23	-0.39	5.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg15017067	chr4:17643749	FAM184B	-0.39	-4.29	-0.33	3.2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs290268	0.803	rs2780701	chr9:93567281	A/G	cg02608019	chr9:93564028	SYK	0.61	5.83	0.43	3.24e-8	Platelet count;
PAAD	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.51	-0.52	4.75e-12	Blood metabolite levels;
PAAD	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.72	-8.65	-0.57	6.99e-15	Body mass index;
PAAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg15691649	chr6:25882328	NA	0.5	4.54	0.35	1.11e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg00825309	chr19:58991885	ZNF446	-0.77	-8.02	-0.55	2.58e-13	Uric acid clearance;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg07469887	chr10:131262384	NA	-0.43	-5.02	-0.38	1.43e-6	Response to temozolomide;
PAAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.86	0.54	6.59e-13	Personality dimensions;
PAAD	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.23	0.56	7.79e-14	Alzheimer's disease (late onset);
PAAD	cis	rs939584	1.000	rs4854345	chr2:638190	C/T	cg03610516	chr2:642275	NA	-0.6	-5.4	-0.4	2.52e-7	Body mass index;
PAAD	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.61	6.18	0.45	5.52e-9	Migraine;
PAAD	cis	rs73206853	0.841	rs6606683	chr12:110712212	T/G	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.35e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg23283495	chr1:209979779	IRF6	0.63	6.01	0.44	1.33e-8	Coronary artery disease;
PAAD	cis	rs78761021	0.720	rs79348078	chr17:9795771	T/A	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs4281086	1.000	rs62490637	chr8:10348217	A/T	cg01072821	chr8:10382165	T-SP1	0.46	4.45	0.34	1.63e-5	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg19442545	chr10:75533431	FUT11	-0.49	-5.19	-0.39	6.67e-7	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.76	5.45	0.4	2.03e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.56	6.52	0.47	9.73e-10	Mean corpuscular volume;
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21963583	chr11:68658836	MRPL21	0.54	5.89	0.43	2.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs818427	0.656	rs818426	chr5:112226192	G/A	cg05511853	chr5:112182657	NA	-0.47	-4.45	-0.34	1.63e-5	Total body bone mineral density;
PAAD	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.52	-0.61	3.74e-17	Monocyte percentage of white cells;
PAAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg17328964	chr8:145687451	CYHR1	0.52	5.61	0.41	9.5e-8	Age at first birth;
PAAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Aortic root size;
PAAD	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Graves' disease;
PAAD	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.8	-9.0	-0.59	8.44e-16	Idiopathic membranous nephropathy;
PAAD	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	1.06	10.28	0.64	3.88e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.5	-4.45	-0.34	1.66e-5	Pubertal anthropometrics;
PAAD	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.49	0.41	1.64e-7	Body mass index;
PAAD	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24655899	chr17:79519568	C17orf70	0.7	7.85	0.54	7.04e-13	Myopia (pathological);
PAAD	cis	rs1879734	0.731	rs12059719	chr1:54190333	A/C	cg14659662	chr1:54151053	GLIS1	-0.31	-4.46	-0.34	1.56e-5	Mitral valve prolapse;
PAAD	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.71	7.47	0.52	6.01e-12	Brugada syndrome;
PAAD	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08409687	chr2:201936025	NDUFB3;FAM126B	0.65	7.49	0.52	5.14e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.62	-5.66	-0.42	7.38e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.95	9.58	0.61	2.59e-17	Corneal astigmatism;
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.4	-6.04	-0.44	1.11e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	7.04	0.5	6.25e-11	Resting heart rate;
PAAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg10556349	chr10:835070	NA	0.67	5.16	0.39	7.55e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg05585544	chr11:47624801	NA	-0.47	-5.24	-0.39	5.3e-7	Subjective well-being;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg08835956	chr7:39171034	POU6F2	0.31	5.06	0.38	1.19e-6	IgG glycosylation;
PAAD	cis	rs988913	0.958	rs9475078	chr6:54809589	T/A	cg03513858	chr6:54763001	FAM83B	-0.42	-4.59	-0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.44	-4.35	-0.33	2.51e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-4.39	-0.34	2.14e-5	Self-reported allergy;
PAAD	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg24737193	chr18:12778029	NA	0.61	5.34	0.4	3.31e-7	Inflammatory skin disease;
PAAD	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs901683	0.850	rs71494794	chr10:45985284	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.58e-9	Morning vs. evening chronotype;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs58521262	0.519	rs62122419	chr19:22996998	T/C	cg07749055	chr19:23076870	NA	-0.59	-4.64	-0.35	7.36e-6	Testicular germ cell tumor;
PAAD	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24110177	chr3:50126178	RBM5	-0.62	-7.08	-0.5	4.89e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg08898775	chr15:59042684	ADAM10	0.45	5.88	0.43	2.57e-8	Asperger disorder;
PAAD	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg00536532	chr6:33561449	C6orf227	-0.41	-4.43	-0.34	1.8e-5	Height;
PAAD	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.6	-6.23	-0.45	4.37e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs1018697	0.966	rs1953930	chr10:104549461	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.81e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2882667	0.599	rs288008	chr5:138229321	G/A	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7487075	0.619	rs4768718	chr12:46834336	G/C	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.57e-5	Itch intensity from mosquito bite;
PAAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.5	5.35	0.4	3.23e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.65	-0.35	7.13e-6	Neuroticism;
PAAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.91	-0.37	2.31e-6	Bipolar disorder;
PAAD	cis	rs1497828	0.956	rs2810787	chr1:217549038	A/G	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.63	-5.58	-0.41	1.07e-7	Mean corpuscular volume;
PAAD	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg00629941	chr15:75287862	SCAMP5	-0.55	-4.26	-0.33	3.6e-5	Blood trace element (Zn levels);
PAAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	1.08	12.49	0.71	4.56e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs78761021	0.867	rs17681738	chr17:9793240	C/T	cg26853458	chr17:9805074	RCVRN	0.68	7.69	0.53	1.7e-12	Type 2 diabetes;
PAAD	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg23024343	chr7:107201750	COG5	0.55	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs7523050	0.908	rs12036331	chr1:109398707	A/T	cg08274380	chr1:109419600	GPSM2	0.64	4.86	0.37	2.95e-6	Fat distribution (HIV);
PAAD	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg11204139	chr17:3907470	NA	-0.69	-7.07	-0.5	5.2e-11	Type 2 diabetes;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg17372657	chr7:1216933	NA	-0.35	-4.41	-0.34	1.93e-5	Longevity;Endometriosis;
PAAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.63	6.64	0.47	5.3e-10	Platelet distribution width;
PAAD	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg11650704	chr1:154556575	ADAR	-0.39	-4.28	-0.33	3.34e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.58	5.23	0.39	5.57e-7	Total body bone mineral density;
PAAD	cis	rs3106136	0.678	rs2195001	chr4:95281946	G/A	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.65	-5.24	-0.39	5.37e-7	Alzheimer's disease;
PAAD	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.81	0.36	3.67e-6	Height;
PAAD	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.14	5.58	0.41	1.07e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4757319	0.553	rs10766252	chr11:15443714	A/C	cg03245590	chr11:15329459	NA	0.46	5.52	0.41	1.41e-7	Breast cancer;
PAAD	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	5.44	0.4	2.12e-7	Mean platelet volume;
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.64	6.83	0.48	1.89e-10	Mean corpuscular volume;
PAAD	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7260329	0.628	rs35659050	chr19:41493603	A/G	cg22249281	chr19:41082756	SHKBP1	-0.61	-4.7	-0.36	5.77e-6	Smoking behavior;
PAAD	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.87	-0.79	4.54e-34	Schizophrenia;
PAAD	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.66e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs73206853	0.841	rs73191851	chr12:111032305	G/A	cg12870014	chr12:110450643	ANKRD13A	0.71	4.52	0.34	1.23e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg02415014	chr8:143852576	LYNX1	0.5	6.05	0.44	1.09e-8	Urinary tract infection frequency;
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg12757816	chr2:10669957	NA	-0.54	-5.79	-0.43	3.82e-8	Prostate cancer;
PAAD	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg25482853	chr8:67687455	SGK3	0.98	7.25	0.51	1.99e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.79	6.81	0.48	2.17e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4343996	1.000	rs6461993	chr7:3356463	G/A	cg21248987	chr7:3385318	SDK1	-0.48	-5.27	-0.39	4.53e-7	Motion sickness;
PAAD	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg04398451	chr17:18023971	MYO15A	-0.83	-9.55	-0.61	3.19e-17	Total body bone mineral density;
PAAD	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.43	-5.33	-0.4	3.56e-7	Sitting height ratio;
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.48	4.69	0.36	6.12e-6	Breast cancer;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	1.01	7.29	0.51	1.58e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg09317036	chr8:144635547	GSDMD	0.47	4.34	0.33	2.58e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.48	-4.71	-0.36	5.47e-6	Type 1 diabetes;
PAAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	1.01	13.38	0.74	1.81e-27	Gestational age at birth (maternal effect);
PAAD	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.15e-11	Corneal astigmatism;
PAAD	cis	rs908922	0.962	rs4240882	chr1:152456358	G/C	cg23254163	chr1:152506842	NA	0.54	5.58	0.41	1.07e-7	Hair morphology;
PAAD	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.29	-0.33	3.23e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.63	-0.35	7.66e-6	Lung cancer;
PAAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.48	-5.36	-0.4	3e-7	Platelet distribution width;
PAAD	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.52	5.45	0.4	2.02e-7	Lung cancer;
PAAD	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.45	4.6	0.35	8.85e-6	Type 2 diabetes;
PAAD	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.51	4.97	0.37	1.8e-6	Endometrial cancer;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11141652	chr22:24348549	GSTTP1	-0.48	-4.26	-0.33	3.59e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.59	5.26	0.39	4.75e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10426930	0.816	rs2602727	chr19:5052107	G/A	cg08036796	chr19:5034282	KDM4B	-0.48	-4.79	-0.36	3.95e-6	Monocyte percentage of white cells;
PAAD	cis	rs4588572	0.774	rs4072853	chr5:77656402	G/C	cg18281939	chr5:77783895	LHFPL2	-0.46	-5.28	-0.39	4.46e-7	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14458509	chr22:39066904	CBY1	-0.64	-6.47	-0.46	1.29e-9	Obesity-related traits;
PAAD	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg15211996	chr1:2936768	ACTRT2	-0.48	-5.03	-0.38	1.37e-6	Plateletcrit;
PAAD	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs2421770	0.865	rs1321677	chr11:35315538	G/T	cg13971030	chr11:35366721	SLC1A2	-0.5	-5.78	-0.42	4.01e-8	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs755249	0.567	rs61779285	chr1:39867055	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1190596	0.525	rs6575901	chr14:102691854	A/G	cg23904247	chr14:102554826	HSP90AA1	0.44	5.21	0.39	6.01e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.24	-0.45	4.05e-9	Body mass index;
PAAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg09654669	chr8:57350985	NA	-0.57	-5.24	-0.39	5.2e-7	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26926768	chr12:34528122	NA	0.38	4.78	0.36	4.08e-6	Morning vs. evening chronotype;
PAAD	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.53	5.49	0.41	1.66e-7	Hemostatic factors and hematological phenotypes;
PAAD	trans	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg15770106	chr1:208133116	NA	-0.68	-6.63	-0.47	5.45e-10	Corneal structure;
PAAD	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg23788917	chr6:8435910	SLC35B3	-0.59	-6.31	-0.46	2.95e-9	Motion sickness;
PAAD	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.67	5.66	0.42	7.29e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7308134	0.766	rs7966806	chr12:1988167	T/C	cg08762603	chr12:2031417	NA	0.65	4.26	0.33	3.5e-5	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6499755	0.965	rs9889178	chr16:55353110	G/T	cg02859129	chr16:55357253	IRX6	0.34	4.55	0.35	1.07e-5	Hypospadias;
PAAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.46	-4.37	-0.33	2.33e-5	Breast cancer;
PAAD	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06026331	chr20:60912101	LAMA5	0.5	4.66	0.35	6.97e-6	Colorectal cancer;
PAAD	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.57	8.89	0.58	1.63e-15	IgG glycosylation;
PAAD	cis	rs66530629	0.917	rs11249178	chr1:25171719	G/C	cg01905478	chr1:25040257	NA	0.51	5.6	0.41	9.63e-8	Plateletcrit;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07685180	chr8:600429	NA	0.89	6.13	0.44	7.42e-9	IgG glycosylation;
PAAD	cis	rs6547631	0.682	rs4832186	chr2:85929674	C/T	cg24620635	chr2:85921963	GNLY	0.43	5.77	0.42	4.4e-8	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27047577	chr1:1473193	C1orf70	-0.58	-6.64	-0.47	5.13e-10	Monocyte percentage of white cells;
PAAD	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg06637938	chr14:75390232	RPS6KL1	0.48	4.68	0.35	6.3e-6	Height;
PAAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg05697835	chr1:2722811	NA	0.42	4.69	0.36	6.14e-6	Ulcerative colitis;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-6.08	-0.44	9.47e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs16910800	1.000	rs73479585	chr11:23197391	T/C	cg20040320	chr11:23191996	NA	-0.59	-5.03	-0.38	1.35e-6	Cancer;
PAAD	cis	rs140633572	1	rs140633572	chr6:107279935	A/G	cg25263140	chr6:106959651	AIM1	0.85	4.45	0.34	1.67e-5	Alzheimer disease and age of onset;
PAAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12098973	0.591	rs7107547	chr11:131804013	G/A	cg13055484	chr11:132662455	OPCML	0.51	4.45	0.34	1.65e-5	Cardiac Troponin-T levels;
PAAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.59	-0.35	9.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2030114	1.000	rs56391038	chr16:51611887	G/A	cg03758633	chr16:51611768	NA	0.58	4.86	0.37	2.84e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs7255045	0.913	rs10419408	chr19:12942750	C/T	cg08897044	chr19:12950850	MAST1	0.37	4.65	0.35	7.01e-6	Mean corpuscular volume;
PAAD	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg13263323	chr15:86062960	AKAP13	-0.61	-6.87	-0.49	1.51e-10	Coronary artery disease;
PAAD	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.69	5.64	0.42	8.13e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg07527105	chr16:88053339	BANP	-0.46	-4.63	-0.35	7.94e-6	Menopause (age at onset);
PAAD	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg00990874	chr7:1149470	C7orf50	-0.55	-4.74	-0.36	4.77e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg14092571	chr14:90743983	NA	-0.99	-10.35	-0.64	2.5e-19	Gut microbiota (bacterial taxa);
PAAD	cis	rs7113874	0.802	rs11042030	chr11:8690718	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-4.52	-0.34	1.25e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-4.86	-0.37	2.92e-6	Subjective well-being;
PAAD	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7568458	0.783	rs7591175	chr2:85738374	G/T	cg02493740	chr2:85810744	VAMP5	-0.43	-4.7	-0.36	5.84e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs258892	0.895	rs34660	chr5:72151858	T/A	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg13877915	chr19:58951672	ZNF132	0.47	4.3	0.33	3e-5	Uric acid clearance;
PAAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg07979401	chr6:33739406	LEMD2	-0.53	-4.43	-0.34	1.78e-5	Schizophrenia;
PAAD	cis	rs7646881	0.767	rs73015629	chr3:158433840	C/A	cg19483011	chr3:158453295	NA	-0.71	-5.95	-0.43	1.74e-8	Tetralogy of Fallot;
PAAD	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg25686905	chr3:183603175	PARL	-0.32	-4.28	-0.33	3.27e-5	Menopause (age at onset);
PAAD	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-4.82	-0.36	3.42e-6	Coronary artery disease;
PAAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-7.19	-0.5	2.75e-11	Body mass index;
PAAD	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.69	-6.97	-0.49	8.91e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs4713118	0.500	rs9461434	chr6:28102465	A/C	cg01620082	chr3:125678407	NA	-0.86	-6.33	-0.46	2.63e-9	Parkinson's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22909138	chr17:79803493	P4HB	0.56	6.5	0.47	1.1e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2479106	0.963	rs10818864	chr9:126502619	G/T	cg16191174	chr9:126692580	DENND1A	-0.47	-4.26	-0.33	3.54e-5	Polycystic ovary syndrome;
PAAD	cis	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg16667279	chr19:11591998	ELAVL3	-0.64	-4.7	-0.36	5.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08392591	chr16:89556376	ANKRD11	0.48	4.56	0.35	1.03e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.6	6.84	0.49	1.81e-10	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs9810890	1.000	rs73198887	chr3:128546426	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.99	0.44	1.43e-8	Parkinson's disease;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.8	-0.43	3.63e-8	Life satisfaction;
PAAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs2131877	0.830	rs62290329	chr3:194843634	G/A	cg21937377	chr3:194868750	C3orf21	0.52	4.91	0.37	2.34e-6	Non-small cell lung cancer;
PAAD	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.22	0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg26097391	chr2:54893211	SPTBN1	0.45	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg21724239	chr8:58056113	NA	0.71	5.53	0.41	1.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg13397359	chr6:42928475	GNMT	0.61	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg06138931	chr13:21896616	NA	-0.64	-4.36	-0.33	2.39e-5	White matter hyperintensity burden;
PAAD	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Lymphocyte counts;
PAAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.54	7.26	0.51	1.88e-11	Renal cell carcinoma;
PAAD	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.85	9.92	0.63	3.51e-18	Monocyte count;
PAAD	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.85	6.59	0.47	6.85e-10	Axial length;
PAAD	cis	rs9810890	1.000	rs73196989	chr3:128454638	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.74	5.77	0.42	4.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg27490568	chr2:178487706	NA	0.41	4.47	0.34	1.49e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-4.53	-0.35	1.16e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.6	6.5	0.47	1.11e-9	Longevity;Endometriosis;
PAAD	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.82	9.64	0.62	1.91e-17	Bladder cancer;
PAAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-9.68	-0.62	1.5e-17	Personality dimensions;
PAAD	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.7	-8.28	-0.56	5.76e-14	Educational attainment;
PAAD	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.63	7.06	0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.54	-5.29	-0.39	4.11e-7	Squamous cell lung carcinoma;
PAAD	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08583059	chr17:37887002	C17orf37	0.64	6.33	0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-8.11	-0.55	1.5700000000000001e-13	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.21	0.67	1.23e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg05110241	chr16:68378359	PRMT7	-1.18	-8.58	-0.57	1e-14	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.88	9.91	0.63	3.65e-18	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs755249	0.567	rs67886352	chr1:39708703	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.49	-5.23	-0.39	5.63e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1160297	0.552	rs6732467	chr2:53223652	C/T	cg07782112	chr2:53107842	NA	-0.36	-4.25	-0.33	3.67e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.54	4.52	0.34	1.22e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg27490568	chr2:178487706	NA	-0.45	-4.98	-0.37	1.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4662592	0.857	rs13021583	chr2:128832000	G/C	cg17144508	chr2:128283727	IWS1	-0.63	-4.37	-0.33	2.25e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.53	-5.11	-0.38	9.59e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs116175783	0.557	rs16845829	chr2:162256471	C/T	cg08807892	chr2:162101083	NA	-0.65	-4.66	-0.35	6.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs527409	0.510	rs664999	chr1:58749719	G/C	cg26345888	chr1:58716257	DAB1	-0.66	-4.48	-0.34	1.46e-5	Kawasaki disease;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.39	-4.28	-0.33	3.34e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg10395934	chr14:104002654	TRMT61A	0.46	4.46	0.34	1.61e-5	Body mass index;
PAAD	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.97	-0.37	1.82e-6	Total cholesterol levels;
PAAD	cis	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11411107	chr3:160473611	PPM1L	0.48	4.57	0.35	9.97e-6	Primary biliary cholangitis;
PAAD	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.69	-10.11	-0.63	1.05e-18	Huntington's disease progression;
PAAD	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	7.25	0.51	2e-11	Retinal vascular caliber;
PAAD	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.63	5.79	0.43	3.89e-8	Prostate cancer;
PAAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.58	-0.35	9.62e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg21361702	chr7:150065534	REPIN1	0.59	4.73	0.36	5.13e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-5.31	-0.4	3.74e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg25452165	chr22:42524984	CYP2D6	-0.61	-4.53	-0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg21969647	chr13:114767023	RASA3	-0.54	-4.28	-0.33	3.3e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg03700679	chr2:178418002	TTC30B	0.59	4.76	0.36	4.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs9810890	0.850	rs79042456	chr3:128517917	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg26818257	chr2:241905806	NA	0.48	5.14	0.38	8.36e-7	Joint mobility (Beighton score);
PAAD	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs9810890	1.000	rs73196980	chr3:128451396	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14898116	chr10:17272764	VIM	0.66	6.93	0.49	1.14e-10	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17988709	chr1:117889680	NA	0.62	7.04	0.5	6.35e-11	Smoking initiation;
PAAD	cis	rs9913156	0.517	rs2326118	chr17:4611851	C/T	cg00122941	chr17:4613640	ARRB2	0.66	7.02	0.5	6.75e-11	Lymphocyte counts;
PAAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-4.66	-0.35	7e-6	Type 2 diabetes;
PAAD	cis	rs78411303	0.673	rs16833346	chr3:122377788	T/C	cg17380795	chr3:122379686	NA	0.75	5.53	0.41	1.36e-7	Periodontitis (CDC/AAP);
PAAD	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.61	0.35	8.48e-6	Homocysteine levels;
PAAD	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.5	-6.32	-0.46	2.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg25620797	chr2:55921863	PNPT1	-0.52	-5.09	-0.38	1.03e-6	Metabolic syndrome;
PAAD	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.81	-0.36	3.57e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72634258	0.945	rs3766606	chr1:8022197	G/T	cg26816564	chr1:7831052	VAMP3	0.78	5.93	0.43	1.93e-8	Inflammatory bowel disease;
PAAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg16205897	chr5:131564050	P4HA2	0.54	6.07	0.44	9.79e-9	Blood metabolite levels;
PAAD	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.63	-7.59	-0.52	3.01e-12	Coronary artery disease;
PAAD	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.86	0.43	2.71e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.59	-5.94	-0.43	1.88e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg07167872	chr1:205819463	PM20D1	0.52	4.67	0.35	6.46e-6	White blood cell types;
PAAD	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-5.64	-0.42	8.21e-8	Schizophrenia;
PAAD	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.39	-4.89	-0.37	2.59e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-1.03	-10.94	-0.66	6.54e-21	Platelet distribution width;
PAAD	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.69	0.69	6.2e-23	Corneal structure;
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.58	6.92	0.49	1.15e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.54	4.94	0.37	2.06e-6	Mortality in heart failure;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	15.96	0.79	2.66e-34	Prudent dietary pattern;
PAAD	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-1.34	-10.73	-0.66	2.4e-20	Schizophrenia;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.26	-0.51	1.9e-11	Response to amphetamines;
PAAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.58	5.25	0.39	4.98e-7	Serum sulfate level;
PAAD	cis	rs2117029	0.554	rs12579015	chr12:49556431	T/G	cg05368762	chr12:50135785	TMBIM6	0.44	4.41	0.34	1.92e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03601098	chr7:127228532	ARF5	0.62	7.11	0.5	4.13e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08109568	chr15:31115862	NA	-0.7	-7.9	-0.54	5.16e-13	Huntington's disease progression;
PAAD	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg08917208	chr2:24149416	ATAD2B	0.49	4.27	0.33	3.5e-5	Asthma;
PAAD	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.59	-6.48	-0.47	1.21e-9	Fibrinogen levels;
PAAD	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-11.83	-0.69	2.69e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.45	4.3	0.33	3.03e-5	Morning vs. evening chronotype;
PAAD	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.47	4.55	0.35	1.1e-5	Blood pressure;
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.07	-19.64	-0.85	1.5e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg03959625	chr15:84868606	LOC388152	0.43	4.28	0.33	3.26e-5	Schizophrenia;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02463440	chr8:22132932	PIWIL2	0.61	7.8	0.53	8.97e-13	Hypertriglyceridemia;
PAAD	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.87	-8.7	-0.58	5.2e-15	Response to hepatitis C treatment;
PAAD	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.6	-6.67	-0.48	4.52e-10	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.4	-4.82	-0.36	3.52e-6	Menarche (age at onset);
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg10207240	chr12:122356781	WDR66	0.55	5.8	0.43	3.71e-8	Mean corpuscular volume;
PAAD	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg21253087	chr9:139290292	SNAPC4	0.44	4.45	0.34	1.63e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2885056	0.843	rs1821280	chr19:10693007	G/A	cg06392426	chr19:10676186	KRI1	0.55	5.31	0.4	3.83e-7	Red cell distribution width;
PAAD	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.84	10.67	0.65	3.54e-20	Height;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg01053087	chr8:637909	ERICH1	0.63	4.36	0.33	2.36e-5	IgG glycosylation;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg08501292	chr6:25962987	TRIM38	0.98	5.33	0.4	3.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00670742	chr2:87034831	CD8A	0.68	7.33	0.51	1.29e-11	Myopia (pathological);
PAAD	cis	rs72848980	0.512	rs11191749	chr10:105378840	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.55	4.87	0.37	2.79e-6	White matter hyperintensity burden;
PAAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg25204440	chr1:209979598	IRF6	0.62	4.92	0.37	2.25e-6	Coronary artery disease;
PAAD	cis	rs1032355	0.558	rs113911713	chr4:100523366	T/C	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs76917914	0.820	rs4743158	chr9:100821275	T/C	cg21225548	chr9:100864335	TRIM14	-0.55	-5.8	-0.43	3.72e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.8	9.12	0.59	4.29e-16	Lung cancer;
PAAD	cis	rs3747547	0.892	rs56408868	chr9:38003124	G/T	cg13774184	chr9:37916125	SHB	-0.6	-4.3	-0.33	2.99e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.55	-4.75	-0.36	4.69e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.8	-7.07	-0.5	5.26e-11	Coronary artery disease;
PAAD	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg25922239	chr6:33757077	LEMD2	0.63	6.57	0.47	7.47e-10	Crohn's disease;
PAAD	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.6	5.55	0.41	1.25e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.65	6.3	0.46	3.02e-9	Lymphocyte counts;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg02060408	chr1:150898663	SETDB1	-0.61	-6.42	-0.46	1.64e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.84	8.32	0.56	4.81e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15901199	chr1:151433350	POGZ	-0.63	-6.73	-0.48	3.3e-10	Obesity-related traits;
PAAD	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg00536532	chr6:33561449	C6orf227	-0.41	-4.31	-0.33	2.93e-5	Height;
PAAD	cis	rs12148477	0.602	rs2470189	chr15:51662629	G/T	cg25905881	chr15:51634250	GLDN	-0.43	-4.71	-0.36	5.47e-6	Follicule stimulating hormone;
PAAD	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-1.04	-14.78	-0.77	3.27e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10768122	1.000	rs10836361	chr11:35291328	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2e-5	Vitiligo;
PAAD	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg11822372	chr1:151115635	SEMA6C	0.61	5.71	0.42	5.63e-8	Childhood ear infection;
PAAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.94	-7.28	-0.51	1.67e-11	Smoking behavior;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.89	-0.37	2.52e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6466055	0.661	rs2079340	chr7:104897964	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.64	5.69	0.42	6.3e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs829661	1.000	rs829642	chr2:30699970	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2271404	0.506	rs4848426	chr2:112002130	T/G	cg23466623	chr2:111982296	NA	-0.5	-4.93	-0.37	2.08e-6	Atopic dermatitis;
PAAD	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.53	-5.54	-0.41	1.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.97	7.86	0.54	6.7e-13	Vitiligo;
PAAD	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg04851639	chr8:1020857	NA	-0.64	-7.97	-0.54	3.56e-13	Schizophrenia;
PAAD	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.91	-11.42	-0.68	3.47e-22	Bipolar disorder;
PAAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg07959070	chr22:50026188	C22orf34	-0.38	-4.47	-0.34	1.51e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-8.15	-0.55	1.26e-13	Coronary artery disease;
PAAD	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.11	0.81	2.86e-37	Height;
PAAD	cis	rs6137287	0.924	rs6035791	chr20:21135718	G/T	cg04219410	chr20:21106687	PLK1S1	0.4	4.61	0.35	8.34e-6	Height;
PAAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.91	0.37	2.32e-6	Menopause (age at onset);
PAAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.94	10.16	0.64	7.67e-19	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg11271282	chr2:238384023	NA	0.65	4.38	0.33	2.17e-5	Prostate cancer;
PAAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	5.98	0.44	1.5e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.46	-0.57	2.03e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg10351095	chr21:47802916	PCNT	0.49	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.79	9.15	0.6	3.55e-16	Menopause (age at onset);
PAAD	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.33	-0.33	2.69e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.45	6.58	0.47	7.09e-10	Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00149659	chr3:10157352	C3orf10	0.78	5.82	0.43	3.43e-8	Alzheimer's disease;
PAAD	cis	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.97e-6	Mononucleosis;
PAAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.94	9.87	0.63	4.52e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg10820045	chr2:198174542	NA	0.49	5.04	0.38	1.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.33	0.4	3.41e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.45	0.71	5.5e-25	Cognitive ability;
PAAD	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.73	-0.58	4.23e-15	Vitiligo;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	10.34	0.64	2.61e-19	Platelet count;
PAAD	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs2070633	0.532	rs7635884	chr3:186341191	C/T	cg25162301	chr3:186330055	AHSG	0.4	4.37	0.33	2.27e-5	Blood protein levels;
PAAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg21361702	chr7:150065534	REPIN1	0.63	5.16	0.39	7.47e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.69	-0.36	6.16e-6	Glomerular filtration rate;
PAAD	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg18833306	chr6:118973337	C6orf204	0.5	5.67	0.42	6.88e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	4.57	0.35	9.8200000000000008e-06	Thyroid stimulating hormone;
PAAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00142150	chr22:38071001	LGALS1	0.81	9.09	0.59	5.15e-16	Fat distribution (HIV);
PAAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.4	-0.83	1.66e-40	Ulcerative colitis;
PAAD	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.82	6.06	0.44	1.05e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.66	-7.13	-0.5	3.77e-11	Menarche (age at onset);
PAAD	cis	rs10073892	0.830	rs28864102	chr5:101615894	G/A	cg17280723	chr5:101634495	NA	0.42	4.39	0.34	2.11e-5	Cognitive decline (age-related);
PAAD	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	0.95	5.79	0.42	3.98e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.68	-7.22	-0.51	2.3e-11	Obesity-related traits;
PAAD	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.54	5.31	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs17824933	0.887	rs12790976	chr11:60767420	T/G	cg16817237	chr11:60793675	NA	0.49	6.0	0.44	1.41e-8	Multiple sclerosis;
PAAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	9.71	0.62	1.2e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6141769	0.542	rs6058813	chr20:31270861	C/T	cg13636640	chr20:31349939	DNMT3B	-0.54	-4.97	-0.37	1.77e-6	Subjective well-being;
PAAD	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.52	-5.16	-0.39	7.59e-7	Mortality in heart failure;
PAAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.6	-6.47	-0.46	1.28e-9	Blood metabolite levels;
PAAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg22800045	chr5:56110881	MAP3K1	-0.9	-7.09	-0.5	4.63e-11	Initial pursuit acceleration;
PAAD	cis	rs6887276	0.538	rs35897671	chr5:127349745	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.46	-4.5	-0.34	1.35e-5	Height;
PAAD	cis	rs58521262	0.556	rs290583	chr19:23198437	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.95	12.3	0.71	1.48e-24	Menopause (age at onset);
PAAD	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg08198773	chr8:1697536	NA	-0.45	-4.96	-0.37	1.85e-6	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7165102	1.000	rs662099	chr15:65726693	G/A	cg22900193	chr15:65823441	PTPLAD1	0.46	4.41	0.34	1.91e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.88	-10.24	-0.64	4.97e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.54	5.28	0.39	4.41e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.76	7.63	0.53	2.36e-12	Cognitive function;
PAAD	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.72	-7.58	-0.52	3.13e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg23281280	chr6:28129359	ZNF389	0.52	4.63	0.35	7.7e-6	Parkinson's disease;
PAAD	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	6.7	0.48	3.9e-10	Lung cancer in ever smokers;
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.7	7.81	0.53	8.86e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10861342	1.000	rs7968711	chr12:105447921	G/A	cg23923672	chr12:105501055	KIAA1033	0.73	4.5	0.34	1.36e-5	IgG glycosylation;
PAAD	cis	rs6596100	0.538	rs34626261	chr5:132174880	A/C	cg16419906	chr5:132167176	NA	-0.58	-4.41	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs8077577	0.747	rs11078415	chr17:18255498	C/T	cg16794390	chr17:18148240	FLII	0.51	4.26	0.33	3.55e-5	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg05250797	chr16:70222502	NA	0.84	6.39	0.46	1.89e-9	IgE levels;
PAAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs12961799	0.719	rs2222138	chr18:12889217	A/C	cg07510885	chr18:12896951	NA	-0.43	-4.72	-0.36	5.29e-6	Body mass index;
PAAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs8101881	1.000	rs10412219	chr19:33413246	G/C	cg16524284	chr19:33353338	SLC7A9	-0.44	-4.28	-0.33	3.33e-5	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
PAAD	cis	rs9314614	0.872	rs2951861	chr8:6711693	G/C	cg27319216	chr8:6693540	XKR5	-0.37	-4.95	-0.37	1.96e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs2649	0.518	rs4556742	chr15:63864433	C/T	cg22599514	chr15:63798201	USP3	0.59	4.92	0.37	2.19e-6	Aortic root size;
PAAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg07395648	chr5:131743802	NA	-0.44	-4.25	-0.33	3.71e-5	Asthma (sex interaction);
PAAD	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.02	0.38	1.46e-6	Eye color traits;
PAAD	cis	rs13177918	0.734	rs6579790	chr5:149843942	C/T	cg04670168	chr5:150039249	MYOZ3	-0.47	-4.48	-0.34	1.47e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.88	0.58	1.74e-15	Chronic sinus infection;
PAAD	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.46	-6.25	-0.45	3.87e-9	Height;
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.66	6.98	0.49	8.36e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.75	6.68	0.48	4.22e-10	Asthma;
PAAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.71	7.18	0.5	2.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.47	-4.37	-0.33	2.25e-5	Multiple sclerosis;
PAAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs13082711	0.519	rs13091103	chr3:27229122	G/C	cg02860705	chr3:27208620	NA	0.79	6.27	0.45	3.51e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	Schizophrenia;
PAAD	cis	rs7580658	0.613	rs12478656	chr2:128196520	G/T	cg09760422	chr2:128146352	NA	-0.44	-7.19	-0.5	2.71e-11	Protein C levels;
PAAD	cis	rs7786877	0.545	rs73156234	chr7:100234744	C/T	cg26071806	chr7:100318239	EPO	-0.46	-4.58	-0.35	9.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.51	4.95	0.37	1.91e-6	High light scatter reticulocyte count;
PAAD	cis	rs877529	0.967	rs139407	chr22:39552075	G/A	cg18708252	chr22:39545030	CBX7	-0.45	-4.37	-0.33	2.3e-5	Multiple myeloma;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04289163	chr16:11351165	SOCS1	0.56	6.3	0.46	3.11e-9	Immature fraction of reticulocytes;
PAAD	cis	rs863345	0.625	rs950487	chr1:158460130	A/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.8	-0.36	3.73e-6	Pneumococcal bacteremia;
PAAD	cis	rs9217	1.000	rs9217	chr17:7363088	T/C	cg24479590	chr17:7348322	CHRNB1	-0.43	-4.68	-0.35	6.34e-6	Height;
PAAD	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06026331	chr20:60912101	LAMA5	0.5	4.66	0.35	6.97e-6	Colorectal cancer;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs59888335	0.929	rs7621529	chr3:80824878	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.5	-5.5	-0.41	1.6e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs3774830	0.748	rs7698146	chr4:5465476	G/A	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.2e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg21775007	chr8:11205619	TDH	0.82	8.14	0.55	1.3e-13	Retinal vascular caliber;
PAAD	cis	rs4963124	0.886	rs10902216	chr11:739392	G/C	cg01741372	chr11:783889	NA	0.5	5.68	0.42	6.8e-8	Proteinuria and chronic kidney disease;
PAAD	trans	rs12979813	0.901	rs10421795	chr19:11344406	C/T	cg03333546	chr19:13263065	IER2	-0.86	-6.46	-0.46	1.32e-9	HDL cholesterol;
PAAD	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg20045696	chr14:77926864	AHSA1	0.59	4.34	0.33	2.55e-5	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
PAAD	cis	rs17152411	0.744	rs10901835	chr10:126589712	G/T	cg04726013	chr10:126223236	LHPP	-0.31	-4.46	-0.34	1.56e-5	Height;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.66	-6.57	-0.47	7.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.89	-7.83	-0.54	7.67e-13	Body mass index;
PAAD	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.62	5.94	0.43	1.91e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11696501	0.688	rs6073851	chr20:44306978	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.73	-0.36	5.09e-6	Educational attainment (years of education);
PAAD	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.7	-6.62	-0.47	5.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg04844267	chr4:1394941	NA	0.45	5.15	0.39	8.14e-7	Longevity;
PAAD	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.48	6.06	0.44	1.02e-8	Prostate cancer;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.76	-12.33	-0.71	1.19e-24	Body mass index;
PAAD	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg16584676	chr17:46985605	UBE2Z	-0.57	-5.63	-0.42	8.46e-8	Type 2 diabetes;
PAAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg25452165	chr22:42524984	CYP2D6	0.61	5.8	0.43	3.75e-8	Schizophrenia;
PAAD	cis	rs8077059	1.000	rs4793565	chr17:55809518	C/G	cg12582317	chr17:55822272	NA	0.51	4.7	0.36	5.67e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg18597434	chr13:76055871	TBC1D4	-0.56	-6.55	-0.47	8.33e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg03517284	chr6:25882590	NA	-0.55	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg26816564	chr1:7831052	VAMP3	0.63	5.16	0.39	7.48e-7	Inflammatory bowel disease;
PAAD	cis	rs12799264	0.915	rs2707088	chr11:19978210	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs34845616	0.514	rs4937835	chr11:133691060	G/C	cg06766960	chr11:133703094	NA	0.63	5.25	0.39	4.97e-7	Hand grip strength;
PAAD	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15924577	chr11:120039917	NA	0.61	6.5	0.47	1.08e-9	Myopia (pathological);
PAAD	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.5	-6.11	-0.44	8.18e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg00982548	chr2:198649783	BOLL	-0.73	-5.21	-0.39	6.09e-7	Ulcerative colitis;
PAAD	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.63	6.02	0.44	1.29e-8	Hip circumference;
PAAD	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-5.03	-0.38	1.34e-6	Height;
PAAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg18370025	chr7:2749541	AMZ1	-0.42	-4.87	-0.37	2.82e-6	Height;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	7.26	0.51	1.89e-11	Renal function-related traits (BUN);
PAAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.27	0.45	3.55e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11966931	0.948	rs72933169	chr6:108090799	A/G	cg10566610	chr6:108093680	SCML4	0.48	4.48	0.34	1.45e-5	Neutrophil percentage of white cells;
PAAD	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg04721828	chr11:48285200	OR4X1	-0.41	-5.41	-0.4	2.4e-7	Migraine - clinic-based;
PAAD	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.8	-0.36	3.7e-6	Asthma;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg26939375	chr7:64535504	NA	-0.6	-6.45	-0.46	1.42e-9	Calcium levels;
PAAD	cis	rs7562790	0.697	rs2023549	chr2:36679795	G/A	cg01206211	chr2:36825736	FEZ2	0.46	4.5	0.34	1.35e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.69	-7.94	-0.54	4.11e-13	Body mass index;
PAAD	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg05697835	chr1:2722811	NA	0.4	4.58	0.35	9.47e-6	Multiple sclerosis;
PAAD	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7188861	0.813	rs2867936	chr16:11398698	C/T	cg01510278	chr16:11456238	NA	0.44	4.54	0.35	1.15e-5	HDL cholesterol;
PAAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.57	0.82	1.94e-38	Cognitive function;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7213347	0.581	rs4790881	chr17:2068932	C/A	cg15816464	chr17:2026533	SMG6	0.53	5.95	0.43	1.75e-8	Total body bone mineral density;
PAAD	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2051773	0.539	rs6486345	chr11:17038777	A/G	cg15084286	chr11:17036142	PLEKHA7	0.55	4.93	0.37	2.14e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15370732	chr17:47892591	MYST2	0.73	8.23	0.56	7.95e-14	Smoking initiation;
PAAD	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2120991	0.967	rs10876514	chr12:54282853	C/T	cg25640699	chr12:54070114	ATP5G2	-0.43	-4.55	-0.35	1.1e-5	Biliary atresia;
PAAD	cis	rs7089973	0.668	rs11196962	chr10:116646827	A/C	cg25233709	chr10:116636983	FAM160B1	0.45	5.66	0.42	7.38e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg10395934	chr14:104002654	TRMT61A	0.48	4.65	0.35	7.18e-6	Body mass index;
PAAD	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.789	rs68107602	chr7:150054146	C/T	cg21361702	chr7:150065534	REPIN1	0.56	4.71	0.36	5.54e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg18769074	chr3:133464867	TF	0.39	4.42	0.34	1.9e-5	Iron status biomarkers;
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg09197432	chr4:183729176	NA	0.62	5.33	0.4	3.51e-7	Pediatric autoimmune diseases;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21097640	chr13:28195548	POLR1D;LNX2	0.72	7.73	0.53	1.36e-12	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg19223190	chr17:80058835	NA	0.51	5.25	0.39	4.94e-7	Life satisfaction;
PAAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg18404041	chr3:52824283	ITIH1	0.41	4.46	0.34	1.57e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.23e-14	Colorectal cancer;
PAAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs11871801	0.918	rs2006141	chr17:40679718	C/T	cg21692620	chr17:40835849	CNTNAP1	0.49	5.02	0.38	1.44e-6	Crohn's disease;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.67	5.71	0.42	5.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.81	-9.24	-0.6	2.1e-16	Height;
PAAD	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg09835421	chr16:68378352	PRMT7	-0.72	-5.55	-0.41	1.27e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04077077	chr17:47841656	FAM117A	0.6	6.5	0.47	1.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9687846	0.877	rs9687832	chr5:55861595	G/A	cg15001016	chr5:55860904	NA	-0.47	-4.53	-0.34	1.18e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.46	-0.34	1.6e-5	Arsenic metabolism;
PAAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.88	8.03	0.55	2.55e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg20159608	chr7:32802032	NA	-0.59	-6.11	-0.44	8.17e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.11	15.21	0.78	2.46e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs72960926	0.744	rs7776273	chr6:74967693	T/C	cg03266952	chr6:74778945	NA	-1.12	-6.44	-0.46	1.48e-9	Metabolite levels (MHPG);
PAAD	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs11907546	1	rs11907546	chr20:32719797	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.36	0.33	2.37e-5	Cancer;Cancer (pleiotropy);
PAAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.8	8.65	0.57	6.66e-15	IgG glycosylation;
PAAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg02264943	chr11:130785842	SNX19	-0.35	-4.52	-0.34	1.26e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.92	7.06	0.5	5.59e-11	Alzheimer's disease;
PAAD	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.64	0.47	5.23e-10	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-5.27	-0.39	4.51e-7	Personality dimensions;
PAAD	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.71	6.72	0.48	3.52e-10	Corneal astigmatism;
PAAD	cis	rs4676482	0.577	rs4676616	chr3:39271581	C/T	cg02254461	chr3:39195904	CSRNP1	0.71	4.38	0.33	2.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4676380	0.855	rs1583261	chr2:241644740	T/C	cg21930842	chr2:241631663	AQP12A	0.55	5.51	0.41	1.51e-7	Response to metformin (IC50);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16248795	chr3:182698009	DCUN1D1	0.65	6.53	0.47	9.23e-10	Obesity-related traits;
PAAD	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01110552	chr10:103578627	MGEA5	0.63	7.13	0.5	3.74e-11	Metabolite levels  (X-11787);
PAAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg22143856	chr6:28129313	ZNF389	0.64	4.94	0.37	2.06e-6	Depression;
PAAD	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg02459107	chr1:67143332	SGIP1	0.74	7.4	0.51	8.63e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.75	8.2	0.55	9.14e-14	Total body bone mineral density;
PAAD	cis	rs12431939	1.000	rs7160729	chr14:51637241	C/T	cg23942311	chr14:51606299	NA	-0.72	-5.66	-0.42	7.26e-8	Cancer;
PAAD	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-4.79	-0.36	3.93e-6	Mean corpuscular volume;
PAAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6494488	0.500	rs72744738	chr15:65048334	C/G	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.62	4.76	0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.52	-5.23	-0.39	5.44e-7	Glomerular filtration rate;
PAAD	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.52	5.46	0.41	1.86e-7	Menopause (age at onset);
PAAD	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.96	-0.43	1.73e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg12419862	chr22:24373484	LOC391322	-1.01	-12.71	-0.72	1.15e-25	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.81	5.81	0.43	3.59e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg10395934	chr14:104002654	TRMT61A	-0.54	-5.75	-0.42	4.75e-8	Body mass index;
PAAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.14	-0.6	3.69e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg23024343	chr7:107201750	COG5	0.59	4.91	0.37	2.34e-6	Coronary artery disease;
PAAD	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg16205897	chr5:131564050	P4HA2	-0.4	-4.35	-0.33	2.47e-5	Blood metabolite levels;
PAAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-5.82	-0.43	3.32e-8	Mean corpuscular volume;
PAAD	cis	rs4908768	0.555	rs11582339	chr1:8898807	A/C	cg06972019	chr1:8937448	ENO1	0.47	5.49	0.41	1.67e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.7	-4.68	-0.35	6.3e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.99	0.67	4.82e-21	Smoking behavior;
PAAD	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg00614314	chr15:82944287	LOC80154	0.54	5.49	0.41	1.69e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs9535307	0.858	rs6561553	chr13:50261089	A/G	cg03658251	chr13:50265850	EBPL	0.77	5.34	0.4	3.26e-7	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.57e-6	Bipolar disorder;
PAAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.88e-9	Tonsillectomy;
PAAD	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs78761021	0.823	rs57690042	chr17:9786783	T/C	cg26853458	chr17:9805074	RCVRN	0.69	8.01	0.54	2.84e-13	Type 2 diabetes;
PAAD	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02543470	chr2:105862877	NA	0.52	4.99	0.38	1.63e-6	Obesity-related traits;
PAAD	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.88	-0.43	2.5e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.31	0.64	3.17e-19	Menopause (age at onset);
PAAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg15017067	chr4:17643749	FAM184B	0.38	4.29	0.33	3.2e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3996993	0.597	rs62412888	chr6:52702026	G/A	cg00536792	chr6:53530503	KLHL31	-0.4	-4.39	-0.34	2.11e-5	Hemoglobin concentration;
PAAD	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.89	-0.43	2.38e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs258892	0.947	rs258894	chr5:72332060	A/T	cg21869765	chr5:72125136	TNPO1	-0.7	-5.1	-0.38	1.01e-6	Small cell lung carcinoma;
PAAD	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg08601574	chr20:25228251	PYGB	-0.58	-6.37	-0.46	2.16e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.93	0.37	2.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.49	5.45	0.4	2.01e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs57502260	0.790	rs7128942	chr11:68387984	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-4.27	-0.33	3.47e-5	Total body bone mineral density (age 45-60);
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg05082376	chr22:42548792	NA	0.41	4.27	0.33	3.45e-5	Intelligence;
PAAD	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.85	5.73	0.42	5.1e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.24e-5	Cognitive function;
PAAD	trans	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg00717180	chr2:96193071	NA	-0.61	-6.37	-0.46	2.12e-9	Migraine - clinic-based;
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.61	-5.76	-0.42	4.43e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	4.53	0.34	1.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.82	-9.27	-0.6	1.71e-16	Height;
PAAD	cis	rs2885056	0.891	rs12979033	chr19:10691618	G/A	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg18833306	chr6:118973337	C6orf204	-0.53	-4.34	-0.33	2.55e-5	Renal cell carcinoma;
PAAD	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.94	-0.37	2.02e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.7	-4.4	-0.34	2.03e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	8.65	0.57	6.78e-15	Lymphocyte counts;
PAAD	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.93	-7.4	-0.51	8.59e-12	Orofacial clefts;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg05717871	chr11:638507	DRD4	-0.58	-4.98	-0.37	1.67e-6	Systemic lupus erythematosus;
PAAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	1.11	8.74	0.58	4.05e-15	Iron status biomarkers;
PAAD	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg05110241	chr16:68378359	PRMT7	-0.74	-5.73	-0.42	5.28e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.58	5.86	0.43	2.77e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs943466	1.000	rs943462	chr6:33769578	G/A	cg04704449	chr6:33738291	NA	-0.48	-4.88	-0.37	2.7e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.56	5.43	0.4	2.22e-7	Parkinson's disease;
PAAD	cis	rs7072216	0.922	rs942813	chr10:100153608	A/C	cg19567339	chr10:100142640	NA	0.44	4.83	0.36	3.34e-6	Metabolite levels;
PAAD	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.94	-0.37	2e-6	Neuroticism;
PAAD	cis	rs28489187	0.706	rs233115	chr1:85786977	G/A	cg16011679	chr1:85725395	C1orf52	0.53	4.97	0.37	1.75e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.76	-7.42	-0.52	7.8e-12	Retinal vascular caliber;
PAAD	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg27205649	chr11:78285834	NARS2	0.59	4.37	0.33	2.25e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.49	4.6	0.35	8.93e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs367943	0.649	rs255866	chr5:112748532	A/T	cg12552261	chr5:112820674	MCC	0.66	6.74	0.48	3.17e-10	Type 2 diabetes;
PAAD	cis	rs688181	0.621	rs9347482	chr6:158099736	A/G	cg17310882	chr6:158066609	ZDHHC14	0.35	4.37	0.33	2.33e-5	Platelet distribution width;
PAAD	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.63	-7.59	-0.52	3.01e-12	HDL cholesterol;
PAAD	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg23024343	chr7:107201750	COG5	0.57	4.38	0.33	2.18e-5	Osteoarthritis;
PAAD	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.7	6.53	0.47	9.2e-10	Obesity-related traits;
PAAD	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.74	-7.57	-0.52	3.31e-12	Uric acid clearance;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13047869	chr3:10149882	C3orf24	0.64	5.19	0.39	6.52e-7	Alzheimer's disease;
PAAD	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.26	-8.91	-0.59	1.44e-15	Plateletcrit;
PAAD	cis	rs7247513	0.856	rs2162863	chr19:12699777	G/T	cg01871581	chr19:12707946	ZNF490	-0.83	-9.96	-0.63	2.64e-18	Bipolar disorder;
PAAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.75e-5	Monobrow;
PAAD	cis	rs1334894	1.000	rs10498734	chr6:35559773	A/C	cg07213720	chr6:35227408	ZNF76	-0.84	-4.64	-0.35	7.33e-6	Coronary artery disease;
PAAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.52	-4.68	-0.35	6.31e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg14458575	chr2:238380390	NA	0.66	5.28	0.39	4.49e-7	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg00792783	chr2:198669748	PLCL1	-0.46	-4.25	-0.33	3.76e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.07	0.59	5.76e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.56	5.51	0.41	1.47e-7	Menarche (age at onset);
PAAD	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06002616	chr8:101225028	SPAG1	0.47	5.58	0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs354033	1.000	rs354033	chr7:149289464	A/G	cg06920324	chr7:149264011	ZNF767	0.61	5.08	0.38	1.11e-6	Multiple sclerosis;
PAAD	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.6	-6.38	-0.46	2e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.16	14.31	0.76	5.89e-30	Schizophrenia;
PAAD	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg07954423	chr9:130741881	FAM102A	-0.62	-5.83	-0.43	3.14e-8	Glaucoma (primary angle closure);
PAAD	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg02135003	chr7:105160482	PUS7	-0.7	-5.77	-0.42	4.23e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.75	7.49	0.52	5.37e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.94	0.37	2.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.67	-8.31	-0.56	4.85e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.72	6.34	0.46	2.46e-9	Platelet count;
PAAD	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg17410650	chr12:54324560	NA	-0.4	-5.79	-0.43	3.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs10878977	0.542	rs73339619	chr12:69797628	C/G	cg13322954	chr12:69198953	NA	0.68	4.35	0.33	2.46e-5	Colorectal cancer;
PAAD	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.72	-8.21	-0.55	8.78e-14	Airway imaging phenotypes;
PAAD	cis	rs9283706	0.608	rs10053537	chr5:66332543	T/C	cg11590213	chr5:66331682	MAST4	0.62	4.96	0.37	1.87e-6	Coronary artery disease;
PAAD	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg10208897	chr5:178548229	ADAMTS2	0.55	4.98	0.37	1.72e-6	Pubertal anthropometrics;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	8.57	0.57	1.07e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg14393609	chr7:65229607	NA	0.6	6.39	0.46	1.89e-9	Aortic root size;
PAAD	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-6.16	-0.45	6.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs3812111	0.510	rs4946151	chr6:116595289	G/C	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs7714584	1.000	rs3906527	chr5:150266392	T/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.48	-4.82	-0.36	3.42e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11886014	chr5:41904500	C5orf51	0.59	6.44	0.46	1.46e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg10589385	chr1:150898437	SETDB1	0.39	4.88	0.37	2.67e-6	Melanoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03332314	chr8:146278003	C8orf33	0.65	6.35	0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12612619	0.732	rs12613822	chr2:27217102	A/T	cg00617064	chr2:27272375	NA	-0.52	-5.48	-0.41	1.73e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.69	5.11	0.38	9.64e-7	Vitiligo;
PAAD	cis	rs3812111	0.677	rs1204846	chr6:116522021	C/A	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.31	-0.33	2.97e-5	Age-related macular degeneration;
PAAD	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg04749549	chr19:17459798	NA	-0.5	-5.49	-0.41	1.66e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	1.06	5.83	0.43	3.28e-8	Body mass index;
PAAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg18892244	chr7:807596	HEATR2	-0.67	-5.14	-0.38	8.51e-7	Initial pursuit acceleration;
PAAD	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg04315214	chr1:2043799	PRKCZ	-0.47	-5.65	-0.42	7.66e-8	Coronary artery disease;
PAAD	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg03315344	chr16:75512273	CHST6	0.56	4.75	0.36	4.73e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7554547	1.000	rs7554547	chr1:11973888	A/G	cg07603449	chr1:11986842	KIAA2013	-0.28	-4.25	-0.33	3.72e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-6.19	-0.45	5.45e-9	Lymphocyte counts;
PAAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.62	6.45	0.46	1.4e-9	Diastolic blood pressure;
PAAD	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.41	-0.61	7.34e-17	White blood cell count (basophil);
PAAD	cis	rs2401	0.643	rs1060542	chr11:126210862	A/G	cg05055844	chr11:126275997	ST3GAL4	-0.54	-4.31	-0.33	2.89e-5	LDL cholesterol levels;
PAAD	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12961656	chr3:193853443	HES1	0.65	7.55	0.52	3.65e-12	Monocyte percentage of white cells;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.98	13.01	0.73	1.8e-26	Menarche (age at onset);
PAAD	cis	rs3764400	0.567	rs9890691	chr17:46192936	G/T	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg17595323	chr11:93583763	C11orf90	-0.36	-4.52	-0.34	1.26e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23158103	chr7:148848205	ZNF398	0.54	4.92	0.37	2.18e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.86	5.54	0.41	1.31e-7	Systolic blood pressure;
PAAD	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.73	7.08	0.5	5.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg04154034	chr17:28927549	LRRC37B2	-0.65	-4.63	-0.35	7.68e-6	Body mass index;
PAAD	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg23004174	chr6:74404879	CD109	0.5	5.19	0.39	6.6e-7	Blood protein levels;Calcium levels;
PAAD	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.43	-4.6	-0.35	8.9e-6	Platelet count;
PAAD	cis	rs959260	1.000	rs4789189	chr17:73397985	C/G	cg20590849	chr17:73267439	MIF4GD	-0.55	-4.45	-0.34	1.68e-5	Systemic lupus erythematosus;
PAAD	cis	rs6977660	0.652	rs2072187	chr7:19747915	A/G	cg05791153	chr7:19748676	TWISTNB	0.94	6.27	0.45	3.49e-9	Thyroid stimulating hormone;
PAAD	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg08099141	chr12:7053170	C12orf57	0.43	4.39	0.34	2.12e-5	IgG glycosylation;
PAAD	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.85	6.96	0.49	9.76e-11	Axial length;
PAAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.87	0.54	6.03e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02463440	chr8:22132932	PIWIL2	0.6	7.59	0.52	3.04e-12	Hypertriglyceridemia;
PAAD	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.59	5.01	0.38	1.49e-6	Common traits (Other);
PAAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs3131337	1	rs3131337	chr6:28796071	G/C	cg01620082	chr3:125678407	NA	-1.53	-9.61	-0.61	2.25e-17	Cold sores;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs757978	0.810	rs35319025	chr2:242402463	C/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.76	-4.53	-0.34	1.19e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs12541635	0.967	rs4734896	chr8:107075454	T/C	cg10147462	chr8:107024639	NA	-0.44	-4.64	-0.35	7.54e-6	Age of smoking initiation;
PAAD	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	10.48	0.65	1.14e-19	Monocyte count;
PAAD	trans	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg14171944	chr9:126323477	DENND1A	0.53	6.38	0.46	2.08e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.51	5.51	0.41	1.51e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.59	4.95	0.37	1.98e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg03098721	chr1:84464084	TTLL7	0.46	4.33	0.33	2.68e-5	Obesity-related traits;
PAAD	cis	rs7922314	0.571	rs4746776	chr10:64730674	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.48	4.69	0.36	6.15e-6	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.51	-4.97	-0.37	1.78e-6	Lung cancer;
PAAD	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.08	-0.44	9.5e-9	Bipolar disorder;
PAAD	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg21775007	chr8:11205619	TDH	-0.58	-4.93	-0.37	2.16e-6	Neuroticism;
PAAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg05895507	chr15:77155635	SCAPER	-0.37	-4.59	-0.35	9.2e-6	Blood metabolite levels;
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.14e-6	Testicular germ cell tumor;
PAAD	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg13312174	chr5:178288687	ZNF354B	-0.6	-6.17	-0.45	5.81e-9	Sleep duration;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.83	-7.92	-0.54	4.76e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.71	8.71	0.58	4.8e-15	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.63	-7.16	-0.5	3.28e-11	Coronary artery disease;
PAAD	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.77	7.66	0.53	2e-12	Asthma;
PAAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg19636519	chr7:99541626	NA	-0.39	-4.59	-0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.51	4.97	0.37	1.8e-6	Brain structure;
PAAD	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.7	-7.83	-0.54	7.6e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6710503	0.574	rs59615345	chr2:24778897	G/A	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.71e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg18265118	chr7:2139243	MAD1L1	0.52	4.26	0.33	3.64e-5	Neuroticism;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.54	-4.84	-0.37	3.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20273697	chr2:8977583	KIDINS220	-0.72	-6.3	-0.46	3.1e-9	Neuroticism;
PAAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs6724465	1.000	rs868945	chr2:219924439	C/A	cg25908985	chr2:219925065	IHH	0.63	4.28	0.33	3.25e-5	Height;
PAAD	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.99	-10.56	-0.65	6.96e-20	Blood pressure (smoking interaction);
PAAD	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg24053715	chr22:38214548	NA	-0.6	-6.28	-0.45	3.45e-9	Glioblastoma;Glioma;
PAAD	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-7.29	-0.51	1.56e-11	Urate levels in overweight individuals;
PAAD	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.42	4.3	0.33	3.04e-5	Pancreatic cancer;
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.55	-5.53	-0.41	1.37e-7	Menarche (age at onset);
PAAD	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.06	-6.88	-0.49	1.48e-10	Mitochondrial DNA levels;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	1.03	7.07	0.5	5.18e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.43	6.32	0.46	2.71e-9	Information processing speed;
PAAD	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg17076780	chr6:43251928	TTBK1	0.55	4.26	0.33	3.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.55	5.07	0.38	1.15e-6	Resting heart rate;
PAAD	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs1144333	0.655	rs4949681	chr1:76409828	C/T	cg22875332	chr1:76189707	ACADM	0.78	4.75	0.36	4.74e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.64	5.21	0.39	6.19e-7	Diastolic blood pressure;
PAAD	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg18217622	chr6:170732253	NA	0.7	4.64	0.35	7.49e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs35740288	0.787	rs2291048	chr15:86225658	A/T	cg07943548	chr15:86304357	KLHL25	0.67	5.75	0.42	4.8e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.19	0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs16975963	0.843	rs73041022	chr19:38272394	C/T	cg25793785	chr19:38281423	NA	0.57	4.75	0.36	4.69e-6	Longevity;
PAAD	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7487075	0.619	rs12822345	chr12:46834677	G/C	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.57e-5	Itch intensity from mosquito bite;
PAAD	cis	rs516243	0.688	rs284307	chr1:10739255	T/C	cg02903756	chr1:10750680	CASZ1	-0.43	-4.64	-0.35	7.32e-6	Migraine - clinic-based;
PAAD	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.41	-5.29	-0.39	4.21e-7	Colorectal cancer;
PAAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.6	-4.81	-0.36	3.62e-6	Gut microbiome composition (summer);
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.47	5.01	0.38	1.51e-6	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs1539053	1.000	rs1983454	chr1:58096379	G/T	cg20292791	chr1:58089357	DAB1	-0.55	-5.45	-0.4	2e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2252790	1.000	rs2232470	chr6:116575083	C/A	cg18764771	chr6:116381957	FRK	-0.27	-4.62	-0.35	8.25e-6	Fast beta electroencephalogram;
PAAD	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg17401720	chr7:158221031	PTPRN2	-0.43	-4.91	-0.37	2.28e-6	Obesity-related traits;
PAAD	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.59	8.72	0.58	4.42e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.62	-9.89	-0.63	4.2e-18	Migraine;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs6601327	0.613	rs10104032	chr8:9616664	C/A	cg27411982	chr8:10470053	RP1L1	0.41	4.44	0.34	1.71e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10929159	0.928	rs7598567	chr2:236920673	A/G	cg14226755	chr2:236923322	AGAP1	0.28	4.5	0.34	1.33e-5	Parkinson's disease;
PAAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.46	-0.82	3.85e-38	Height;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg07202610	chr7:1142643	C7orf50	-0.68	-5.69	-0.42	6.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.98	9.57	0.61	2.84e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.56	-0.35	1.06e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3026101	0.671	rs17636147	chr17:5315299	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.88	0.43	2.54e-8	Body mass index;
PAAD	cis	rs8112211	0.554	rs11666449	chr19:38853659	C/T	cg01275006	chr19:38876250	GGN	-0.69	-4.87	-0.37	2.76e-6	Blood protein levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25817788	chr6:21589024	NA	0.57	6.49	0.47	1.14e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.25	-0.39	5.14e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.33	5.23	0.39	5.56e-7	Alcohol dependence;
PAAD	cis	rs2139634	0.965	rs883739	chr3:46538018	A/C	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.33	-4.91	-0.37	2.34e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	1.03	12.6	0.71	2.18e-25	Obesity-related traits;
PAAD	cis	rs1941184	0.759	rs12185303	chr18:29024329	A/G	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.96	12.69	0.72	1.28e-25	Menarche (age at onset);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07762761	chr8:104033118	ATP6V1C1	0.73	6.82	0.48	1.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg02683114	chr2:24398427	C2orf84	-0.57	-5.5	-0.41	1.57e-7	Asthma;
PAAD	cis	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.59	5.24	0.39	5.31e-7	Height;
PAAD	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.69	-5.69	-0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.64	-8.03	-0.55	2.48e-13	Prostate cancer;
PAAD	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs758324	0.812	rs12653237	chr5:131241778	C/T	cg06307176	chr5:131281290	NA	0.54	4.7	0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg10705379	chr10:99080932	FRAT1	0.39	4.37	0.33	2.34e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg27411982	chr8:10470053	RP1L1	-0.47	-5.24	-0.39	5.25e-7	Systolic blood pressure;
PAAD	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.56	6.51	0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.46	-0.46	1.36e-9	Monocyte count;
PAAD	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.85	8.69	0.58	5.42e-15	Schizophrenia;
PAAD	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.51	4.78	0.36	4.03e-6	Total body bone mineral density;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.64	7.57	0.52	3.38e-12	Lung cancer;
PAAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.85	9.57	0.61	2.92e-17	Mortality in heart failure;
PAAD	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg18765565	chr5:669397	TPPP	-0.45	-4.84	-0.37	3.16e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs61677309	0.964	rs59138930	chr11:118173783	C/T	cg15548380	chr1:19984784	NBL1	-0.64	-6.53	-0.47	9.25e-10	Lung cancer in ever smokers;
PAAD	cis	rs288342	0.832	rs288285	chr2:183639766	T/G	cg02625481	chr2:183667124	NA	-0.45	-4.47	-0.34	1.52e-5	Recurrent major depressive disorder;
PAAD	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.62	5.58	0.41	1.08e-7	Red blood cell count;
PAAD	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.67	5.31	0.4	3.91e-7	Mammographic density (dense area);
PAAD	cis	rs9880772	0.747	rs10049011	chr3:27815942	C/T	cg21473142	chr3:27762095	EOMES	0.34	6.0	0.44	1.38e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7853377	0.800	rs296893	chr9:86598190	C/T	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs13418717	0.793	rs6733255	chr2:127662386	C/T	cg25501666	chr2:127640322	NA	-0.83	-4.25	-0.33	3.71e-5	Heart failure;
PAAD	cis	rs8005172	0.676	rs2269312	chr14:88410434	G/A	cg18078958	chr14:88630771	NA	0.46	5.53	0.41	1.35e-7	Parkinson's disease;
PAAD	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs11700980	0.551	rs57066619	chr21:30118948	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-4.99	-0.38	1.6e-6	QRS complex (12-leadsum);
PAAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.62	-4.57	-0.35	9.96e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.47	4.9	0.37	2.39e-6	Testicular germ cell tumor;
PAAD	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.64	0.47	5.29e-10	Lung cancer in ever smokers;
PAAD	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg12963866	chr19:57752005	ZNF805	-0.46	-4.47	-0.34	1.51e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.47	-4.93	-0.37	2.09e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.02	-0.49	6.8e-11	Retinal vascular caliber;
PAAD	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.49	0.61	4.64e-17	Bladder cancer;
PAAD	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg00717180	chr2:96193071	NA	0.6	6.74	0.48	3.1e-10	HDL cholesterol;
PAAD	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6136489	0.710	rs6132106	chr20:1924127	G/A	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs1819043	1.000	rs705747	chr1:202505283	C/T	cg26755539	chr1:201924899	TIMM17A	-0.47	-4.41	-0.34	1.99e-5	Sex ratio;
PAAD	cis	rs6693295	0.536	rs6662962	chr1:246226180	T/A	cg11798871	chr1:246315928	SMYD3	-0.79	-5.71	-0.42	5.86e-8	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.71	-0.62	1.25e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg09796270	chr17:17721594	SREBF1	0.46	4.91	0.37	2.33e-6	Total body bone mineral density;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.68	-7.15	-0.5	3.41e-11	Schizophrenia;
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.75	7.6	0.52	2.9e-12	Prostate cancer;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.51	-5.03	-0.38	1.35e-6	Testicular germ cell tumor;
PAAD	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.64	-6.03	-0.44	1.21e-8	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.59	0.57	9.74e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.8	0.43	3.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg11995313	chr8:8860691	ERI1	0.46	4.35	0.33	2.53e-5	Joint mobility (Beighton score);
PAAD	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2916733	0.530	rs2440424	chr8:6289937	C/T	cg02465761	chr8:6735510	DEFB1	0.4	4.25	0.33	3.7e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.13	-0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.88	0.69	1.95e-23	Corneal structure;
PAAD	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.68e-7	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12172753	chr19:1228888	NA	0.55	6.39	0.46	1.89e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9652601	0.649	rs12599402	chr16:11189888	T/C	cg04616529	chr16:11181986	CLEC16A	0.38	4.58	0.35	9.72e-6	Systemic lupus erythematosus;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg10546176	chr5:34929404	DNAJC21	0.62	6.67	0.48	4.56e-10	Primary biliary cholangitis;
PAAD	cis	rs3857067	1.000	rs1588384	chr4:95001354	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	5.4	0.4	2.52e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg21300403	chr2:198650112	BOLL	-0.66	-4.52	-0.34	1.24e-5	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25750363	chr12:133156565	FBRSL1	-0.66	-6.84	-0.49	1.79e-10	Obesity-related traits;
PAAD	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.58	-6.0	-0.44	1.36e-8	Systolic blood pressure;
PAAD	cis	rs1499972	0.941	rs2860308	chr3:117690309	T/G	cg07612923	chr3:117604196	NA	-1.08	-7.2	-0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs2282978	0.557	rs42045	chr7:92250354	C/T	cg06556290	chr7:92222188	NA	-0.44	-4.43	-0.34	1.79e-5	Height;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.47	-4.63	-0.35	7.86e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg25456477	chr12:86230367	RASSF9	0.48	4.32	0.33	2.82e-5	Major depressive disorder;
PAAD	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.23	7.75	0.53	1.23e-12	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs1436294	0.704	rs640676	chr4:20204617	C/T	cg18206137	chr4:20811042	KCNIP4	-0.45	-4.28	-0.33	3.23e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg05596517	chr10:131320214	MGMT	-0.48	-4.7	-0.36	5.85e-6	Vitamin D levels;
PAAD	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.06e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.44	4.69	0.36	5.95e-6	Red cell distribution width;
PAAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg11601000	chr22:42348013	LOC339674	-0.41	-4.55	-0.35	1.1e-5	Cognitive function;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.44	-4.71	-0.36	5.46e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.94	12.9	0.72	3.49e-26	Menarche (age at onset);
PAAD	cis	rs2712184	0.729	rs2541390	chr2:217664020	A/G	cg05032264	chr2:217675019	NA	-0.58	-6.56	-0.47	8.02e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.54	5.38	0.4	2.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.09	8.81	0.58	2.6e-15	Diabetic kidney disease;
PAAD	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-4.46	-0.34	1.6e-5	Schizophrenia;
PAAD	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.52	-4.79	-0.36	3.94e-6	Asthma;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg02440177	chr19:53496695	ZNF702P	-0.62	-6.56	-0.47	8.13e-10	Psoriasis;
PAAD	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09695851	chr17:3907499	NA	-0.68	-6.97	-0.49	9.11e-11	Type 2 diabetes;
PAAD	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg07153921	chr17:41440717	NA	-0.44	-4.74	-0.36	4.93e-6	Menopause (age at onset);
PAAD	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.62	-6.4	-0.46	1.82e-9	Body mass index;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.76	-8.29	-0.56	5.62e-14	Lung cancer;
PAAD	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	0.79	4.8	0.36	3.74e-6	Obesity-related traits;
PAAD	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg15211996	chr1:2936768	ACTRT2	0.48	4.96	0.37	1.86e-6	Plateletcrit;
PAAD	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg05673287	chr15:77411982	SGK269	0.5	5.11	0.38	9.68e-7	Type 2 diabetes;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06044117	chr11:95523445	FAM76B;CEP57	-0.55	-6.53	-0.47	9.13e-10	Body fat percentage;
PAAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg02117656	chr17:79614917	TSPAN10	0.54	5.43	0.4	2.17e-7	Eye color traits;
PAAD	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.49	-0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.12	-0.38	9.08e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.62	-6.2	-0.45	5.14e-9	Morning vs. evening chronotype;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25045972	chr14:101405842	SNORD113-6	-0.49	-6.37	-0.46	2.14e-9	Energy expenditure (24h);
PAAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg21395723	chr22:39101663	GTPBP1	-0.48	-4.96	-0.37	1.83e-6	Menopause (age at onset);
PAAD	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-1.14	-14.23	-0.76	9.32e-30	Height;
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.59	6.46	0.46	1.36e-9	Menopause (age at onset);
PAAD	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg17366294	chr4:99064904	C4orf37	-0.45	-4.93	-0.37	2.1e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4711350	0.723	rs6915136	chr6:33651322	A/G	cg07979401	chr6:33739406	LEMD2	0.62	4.58	0.35	9.79e-6	Schizophrenia;
PAAD	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.47	4.97	0.37	1.76e-6	Breast cancer;
PAAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.6	-8.23	-0.56	7.81e-14	Renal cell carcinoma;
PAAD	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.53	-5.15	-0.39	8.02e-7	Body mass index;
PAAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs939584	1.000	rs7576624	chr2:625029	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.87	0.43	2.59e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.76	8.76	0.58	3.55e-15	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg11204139	chr17:3907470	NA	-0.69	-6.99	-0.49	8.29e-11	Type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09466277	chr19:50321458	MED25	0.75	6.59	0.47	6.68e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.51	-0.34	1.3e-5	Tonsillectomy;
PAAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35955747	0.869	rs7286648	chr22:31539614	A/T	cg02404636	chr22:31891804	SFI1	0.46	4.45	0.34	1.67e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs622217	0.595	rs547176	chr6:160729393	C/T	cg19643109	chr6:160697625	NA	-0.37	-4.64	-0.35	7.36e-6	Type 2 diabetes;
PAAD	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs7932354	0.583	rs7480140	chr11:46856335	A/G	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06850241	chr22:41845214	NA	0.58	5.05	0.38	1.24e-6	Vitiligo;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21690979	chr1:234744308	IRF2BP2	0.66	7.01	0.49	7.28e-11	Myopia (pathological);
PAAD	cis	rs76419734	0.614	rs17035951	chr4:106527613	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.56	0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg20333904	chr2:240724165	NA	-0.4	-4.34	-0.33	2.62e-5	Obesity-related traits;
PAAD	cis	rs977987	0.732	rs999675	chr16:75306402	C/T	cg03315344	chr16:75512273	CHST6	0.65	7.23	0.51	2.18e-11	Dupuytren's disease;
PAAD	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-5.67	-0.42	7.13e-8	Vitiligo;
PAAD	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.96	-8.86	-0.58	1.97e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.7	5.02	0.38	1.44e-6	Iron status biomarkers;
PAAD	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg25124228	chr12:125621409	AACS	-0.66	-6.45	-0.46	1.38e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.46	5.15	0.39	7.84e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.66	-5.72	-0.42	5.5e-8	HIV-1 control;
PAAD	cis	rs116175783	0.557	rs62194490	chr2:162200798	T/C	cg08807892	chr2:162101083	NA	-0.65	-4.77	-0.36	4.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.42	0.4	2.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	1.06	14.37	0.76	4.15e-30	Menarche (age at onset);
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.12e-6	Cognitive function;
PAAD	cis	rs2242420	0.920	rs829413	chr1:21956050	C/G	cg26362272	chr1:22108717	USP48	0.55	4.27	0.33	3.47e-5	Hematological and biochemical traits;
PAAD	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg07278332	chr7:94294290	PEG10	-0.68	-6.66	-0.48	4.83e-10	Primary biliary cholangitis;
PAAD	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs4979906	1.000	rs7098023	chr10:79449665	A/C	cg07817648	chr10:79422355	NA	-0.57	-5.14	-0.38	8.4e-7	Mortality in heart failure;
PAAD	cis	rs11159086	1.000	rs11626856	chr14:74936368	G/C	cg10195687	chr14:74926396	NA	-0.46	-5.04	-0.38	1.32e-6	Advanced glycation end-product levels;
PAAD	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	1.07	9.62	0.62	2.07e-17	Monocyte percentage of white cells;
PAAD	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.59	4.45	0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-9.0	-0.59	8.76e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.64	-7.23	-0.51	2.18e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.8	8.98	0.59	9.96e-16	Height;
PAAD	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg19640130	chr10:64028056	RTKN2	-0.37	-4.47	-0.34	1.5e-5	Rheumatoid arthritis;
PAAD	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.96	0.37	1.91e-6	Lung cancer in ever smokers;
PAAD	cis	rs35000415	0.882	rs17424921	chr7:128708122	G/C	cg19972273	chr7:128594194	NA	0.93	5.34	0.4	3.39e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15014069	chr17:80540666	FOXK2	-0.69	-7.16	-0.5	3.15e-11	Obesity-related traits;
PAAD	cis	rs4561483	0.583	rs11075027	chr16:11948895	T/C	cg08843971	chr16:11963173	GSPT1	0.45	5.16	0.39	7.63e-7	Testicular germ cell tumor;
PAAD	cis	rs62005083	0.867	rs56220902	chr14:74665393	G/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.72	4.34	0.33	2.62e-5	Mean corpuscular volume;
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.51	-0.57	1.55e-14	Body mass index;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.56	-0.41	1.2e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.39	-0.4	2.59e-7	Coronary artery disease;
PAAD	cis	rs7523050	0.908	rs17621644	chr1:109399023	C/T	cg08274380	chr1:109419600	GPSM2	0.76	5.38	0.4	2.72e-7	Fat distribution (HIV);
PAAD	cis	rs867529	0.722	rs13014673	chr2:88989001	C/G	cg26627705	chr2:89060884	NA	-0.45	-4.43	-0.34	1.77e-5	Height;
PAAD	cis	rs2790216	0.755	rs11006090	chr10:60005211	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Menopause (age at onset);
PAAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.69	4.89	0.37	2.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.72	-6.55	-0.47	8.29e-10	Platelet distribution width;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg11416102	chr8:651193	ERICH1	0.89	5.62	0.41	9.08e-8	IgG glycosylation;
PAAD	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.99	-9.52	-0.61	3.78e-17	Dilated cardiomyopathy;
PAAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.49	-0.78	4.35e-33	Height;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.67	7.72	0.53	1.43e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16024904	chr19:17905718	B3GNT3	0.44	4.29	0.33	3.11e-5	Tumor biomarkers;
PAAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs28493229	0.500	rs45545932	chr19:41190875	G/A	cg21869046	chr19:41225005	ITPKC	0.54	5.94	0.43	1.91e-8	Kawasaki disease;
PAAD	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.44	-0.4	2.11e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs11671653	1.000	rs76291634	chr19:10836545	T/C	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	cg13376598	chr11:24518225	LUZP2	-0.54	-4.6	-0.35	8.9e-6	Response to Homoharringtonine (cytotoxicity);
PAAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.73	6.98	0.49	8.69e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.39	4.31	0.33	2.91e-5	High light scatter reticulocyte count;
PAAD	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.78	0.36	4.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.79	8.52	0.57	1.49e-14	Body mass index;
PAAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg14440974	chr22:39074834	NA	-0.54	-6.55	-0.47	8.45e-10	Menopause (age at onset);
PAAD	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.92	9.01	0.59	7.98e-16	Post bronchodilator FEV1;
PAAD	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg27478167	chr7:817139	HEATR2	0.7	5.35	0.4	3.18e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg03213289	chr20:61660250	NA	0.51	7.01	0.49	7.27e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg04450456	chr4:17643702	FAM184B	0.46	4.85	0.37	3.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6942407	0.546	rs765968	chr7:86794724	G/A	cg02420886	chr7:86849541	C7orf23	0.63	4.79	0.36	3.85e-6	Food allergy;
PAAD	cis	rs787274	1.000	rs787286	chr9:115534336	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.45	-0.34	1.68e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4605213	0.869	rs8079266	chr17:49246726	A/C	cg25022915	chr17:49243257	NME2;NME1-NME2	0.37	5.11	0.38	9.46e-7	Height;
PAAD	cis	rs11168618	0.740	rs7299323	chr12:48921533	C/T	cg01881778	chr12:48919444	OR8S1	-0.52	-5.59	-0.41	1.04e-7	Adiponectin levels;
PAAD	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.53	4.32	0.33	2.76e-5	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.55	6.04	0.44	1.16e-8	Lung cancer;
PAAD	cis	rs7219021	0.926	rs10468517	chr17:46862114	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.43	-0.34	1.77e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.58	-0.41	1.07e-7	Schizophrenia;
PAAD	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.81	9.34	0.6	1.14e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg08355456	chr11:67383691	NA	-0.46	-4.33	-0.33	2.64e-5	Mean corpuscular volume;
PAAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.61	7.12	0.5	4e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.47	-4.25	-0.33	3.67e-5	Tuberculosis;
PAAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.41	-4.96	-0.37	1.84e-6	Menarche (age at onset);
PAAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.61	0.41	9.33e-8	Personality dimensions;
PAAD	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.51	0.34	1.31e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg24879335	chr3:133465180	TF	0.55	5.86	0.43	2.8e-8	Iron status biomarkers;
PAAD	cis	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg02723904	chr3:160167768	TRIM59	0.61	6.06	0.44	1.05e-8	Primary biliary cholangitis;
PAAD	cis	rs4782309	0.544	rs6500488	chr16:88753865	A/G	cg27087555	chr16:88793112	FAM38A	-1.03	-5.69	-0.42	6.35e-8	Hair color;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01942863	chr7:99769432	GPC2	0.52	4.26	0.33	3.51e-5	Platelet count;
PAAD	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs7249921	0.833	rs73044054	chr19:35666661	C/A	cg11856182	chr19:35264148	ZNF599	-0.55	-4.82	-0.36	3.49e-6	Platelet count;
PAAD	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.75	6.91	0.49	1.25e-10	Response to hepatitis C treatment;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.77e-8	Migraine;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07772537	chr12:51464515	CSRNP2	0.61	6.55	0.47	8.51e-10	Smoking initiation;
PAAD	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.88	6.65	0.47	4.99e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	1.03	7.07	0.5	5.18e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.69	5.42	0.4	2.34e-7	Blood protein levels;
PAAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg17759274	chr19:39260954	NA	0.37	4.26	0.33	3.51e-5	Heart rate;
PAAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.52	5.32	0.4	3.67e-7	Menopause (age at onset);
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.8	9.07	0.59	5.77e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.04	0.59	6.73e-16	Cognitive test performance;
PAAD	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg21892295	chr12:121157589	UNC119B	-0.43	-4.26	-0.33	3.55e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg00522288	chr12:125625016	AACS	-0.42	-4.36	-0.33	2.35e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8013055	0.846	rs35590487	chr14:105989599	C/T	cg19700328	chr14:106028568	NA	-0.61	-5.38	-0.4	2.75e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	cg13376598	chr11:24518225	LUZP2	-0.54	-4.6	-0.35	8.9e-6	Response to Homoharringtonine (cytotoxicity);
PAAD	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.49	6.94	0.49	1.04e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-10.99	-0.67	4.77e-21	Total body bone mineral density;
PAAD	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.43	5.19	0.39	6.75e-7	Systolic blood pressure;
PAAD	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg07168214	chr17:7380112	ZBTB4	-0.65	-6.1	-0.44	8.55e-9	Androgen levels;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12512545	chr10:3214326	PITRM1	0.63	7.38	0.51	9.4e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs593531	0.592	rs598869	chr11:74046975	C/T	cg15851278	chr11:73669449	DNAJB13	-0.35	-4.25	-0.33	3.75e-5	Neuroticism;
PAAD	cis	rs11615916	0.656	rs73139037	chr12:62824742	C/T	cg11441379	chr12:63026424	NA	0.76	4.77	0.36	4.28e-6	Pulmonary function decline;
PAAD	cis	rs72827839	0.696	rs77244957	chr17:46325577	T/C	cg23391107	chr17:45924227	SP6	0.81	5.59	0.41	1.01e-7	Ease of getting up in the morning;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg20848291	chr7:100343083	ZAN	-0.88	-7.54	-0.52	3.93e-12	Other erythrocyte phenotypes;
PAAD	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.56	-0.47	7.85e-10	Retinal vascular caliber;
PAAD	cis	rs9462846	0.960	rs12194860	chr6:42862934	C/T	cg13397359	chr6:42928475	GNMT	0.56	4.52	0.34	1.26e-5	Blood protein levels;
PAAD	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.68	4.99	0.37	1.66e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.37e-6	Type 2 diabetes;
PAAD	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.61	5.98	0.44	1.54e-8	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7246865	0.510	rs2305756	chr19:17169936	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.57	5.62	0.41	8.79e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.42	6.42	0.46	1.61e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs72772090	1.000	rs11738135	chr5:96048336	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.71	-5.69	-0.42	6.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13881513	chr18:2652797	NA	-0.38	-4.3	-0.33	2.98e-5	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.56	-0.41	1.19e-7	Sjögren's syndrome;
PAAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.04e-15	Personality dimensions;
PAAD	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.5	-0.34	1.37e-5	Tonsillectomy;
PAAD	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.61	0.35	8.6e-6	Hepatocellular carcinoma;
PAAD	cis	rs2302729	0.545	rs3794291	chr12:2769665	C/T	cg19945202	chr12:2788847	CACNA1C	-0.74	-7.44	-0.52	7.04e-12	Sleep quality;
PAAD	cis	rs7191751	0.543	rs57705566	chr16:86306431	A/C	cg13441891	chr16:85648370	KIAA0182	0.51	4.33	0.33	2.65e-5	Response to platinum-based chemotherapy (cisplatin);
PAAD	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.76	7.96	0.54	3.73e-13	Blood protein levels;
PAAD	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.32	0.33	2.75e-5	Bipolar disorder;
PAAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.34	-0.33	2.58e-5	Daytime sleep phenotypes;
PAAD	trans	rs34787248	1	rs34787248	chr6:28197886	C/T	cg01620082	chr3:125678407	NA	-0.84	-6.47	-0.46	1.3e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.98	-0.37	1.73e-6	Menarche (age at onset);
PAAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.17	-0.39	7.21e-7	Glomerular filtration rate;
PAAD	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg08886695	chr4:3369023	RGS12	-0.53	-5.06	-0.38	1.21e-6	Mean platelet volume;
PAAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg15061591	chr7:98625706	SMURF1	-0.49	-4.58	-0.35	9.45e-6	Breast cancer;
PAAD	cis	rs793571	0.694	rs12910580	chr15:59272053	A/G	cg05156742	chr15:59063176	FAM63B	0.59	4.99	0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs4924935	0.581	rs8070669	chr17:18774708	A/T	cg26378065	chr17:18585709	ZNF286B	0.67	4.99	0.38	1.61e-6	Pancreatic cancer;
PAAD	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	cis	rs959260	0.614	rs930297	chr17:73404537	C/T	cg14668889	chr17:73230827	NUP85	-0.75	-4.84	-0.37	3.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs72901758	0.768	rs11650317	chr17:76251306	A/T	cg26068271	chr17:76253126	NA	0.53	5.07	0.38	1.16e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21644669	chr17:8649170	CCDC42	-0.71	-6.55	-0.47	8.23e-10	Neuroticism;
PAAD	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.29	0.39	4.18e-7	Colorectal cancer;
PAAD	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg18551225	chr6:44695536	NA	-0.75	-7.55	-0.52	3.69e-12	Total body bone mineral density;
PAAD	trans	rs12706411	1.000	rs11973627	chr7:122056001	A/G	cg06154544	chr16:764854	METRN	-1.33	-6.39	-0.46	1.97e-9	Alzheimer disease and age of onset;
PAAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06850241	chr22:41845214	NA	-0.49	-4.26	-0.33	3.55e-5	Vitiligo;
PAAD	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.71	5.78	0.42	4.18e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-6.5	-0.47	1.12e-9	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.93	0.37	2.12e-6	Depressive symptoms;
PAAD	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	4.28	0.33	3.34e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.52	4.62	0.35	8.1e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs375066	0.934	rs411803	chr19:44432840	C/T	cg11993925	chr19:44307056	LYPD5	-0.49	-6.31	-0.46	2.88e-9	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15732812	chr1:206808946	DYRK3	-0.72	-6.37	-0.46	2.17e-9	Neuroticism;
PAAD	cis	rs412658	0.670	rs1912576	chr19:22121293	T/C	cg23859931	chr19:22123797	NA	-0.46	-4.8	-0.36	3.75e-6	Telomere length;
PAAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.61	7.34	0.51	1.18e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs9463078	0.677	rs1324537	chr6:45114791	A/G	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg05861140	chr6:150128134	PCMT1	-0.49	-5.58	-0.41	1.05e-7	Lung cancer;
PAAD	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.73	-6.96	-0.49	9.35e-11	Body mass index;
PAAD	cis	rs28489187	0.617	rs233124	chr1:85791658	A/G	cg16011679	chr1:85725395	C1orf52	0.5	4.63	0.35	7.95e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg10818794	chr15:86012489	AKAP13	0.49	5.23	0.39	5.53e-7	Bulimia nervosa;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.58	4.3	0.33	3.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg11952622	chr19:58962976	ZNF324B	0.45	4.37	0.33	2.26e-5	Uric acid clearance;
PAAD	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg10411590	chr13:21900810	NA	0.6	6.49	0.47	1.16e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.8	-0.43	3.64e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.2	-0.39	6.24e-7	Schizophrenia;
PAAD	cis	rs7082209	0.702	rs61856383	chr10:44812186	C/T	cg13191911	chr10:44806660	NA	-0.94	-4.53	-0.34	1.21e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.71	-4.41	-0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg04632378	chr13:21900426	NA	0.69	7.47	0.52	5.92e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg21665744	chr7:39171113	POU6F2	0.39	5.88	0.43	2.53e-8	IgG glycosylation;
PAAD	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.76	7.91	0.54	5.02e-13	Total body bone mineral density;
PAAD	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.49	5.61	0.41	9.37e-8	Coronary artery disease;
PAAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.04	-0.38	1.28e-6	Electroencephalogram traits;
PAAD	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	4.43	0.34	1.79e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.53	-5.08	-0.38	1.08e-6	Psoriasis;
PAAD	cis	rs375066	0.935	rs425217	chr19:44393975	C/T	cg08633290	chr19:44405433	NA	-0.58	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg03233332	chr7:66118400	NA	0.46	4.61	0.35	8.37e-6	Aortic root size;
PAAD	cis	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg27411982	chr8:10470053	RP1L1	0.43	4.51	0.34	1.28e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4588572	0.688	rs4590164	chr5:77671870	A/G	cg18281939	chr5:77783895	LHFPL2	0.51	6.3	0.45	3.08e-9	Triglycerides;
PAAD	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10886094	0.922	rs7084690	chr10:119270489	A/G	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg18612461	chr15:75251733	NA	0.56	6.57	0.47	7.41e-10	Caffeine consumption;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.49	0.41	1.61e-7	Alzheimer's disease;
PAAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg00717180	chr2:96193071	NA	-0.66	-8.0	-0.54	2.87e-13	Coronary artery disease;
PAAD	cis	rs11811982	0.793	rs78707022	chr1:227574765	A/G	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	Cognitive function;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13556604	chr1:203274688	BTG2	0.61	6.6	0.47	6.46e-10	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.64	0.62	1.9e-17	Total body bone mineral density;
PAAD	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg26248373	chr2:1572462	NA	-1.04	-9.33	-0.6	1.18e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg14440974	chr22:39074834	NA	0.5	5.9	0.43	2.25e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.97	12.48	0.71	4.83e-25	Menopause (age at onset);
PAAD	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg20673091	chr1:2541236	MMEL1	-0.64	-6.55	-0.47	8.59e-10	Ulcerative colitis;
PAAD	cis	rs2070677	0.736	rs12261564	chr10:135354594	C/T	cg20169779	chr10:135381914	SYCE1	-0.8	-6.76	-0.48	2.8e-10	Gout;
PAAD	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg20848291	chr7:100343083	ZAN	-0.93	-7.85	-0.54	6.88e-13	Other erythrocyte phenotypes;
PAAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg03808351	chr9:123631620	PHF19	-0.56	-4.85	-0.37	3.04e-6	Birth weight;
PAAD	cis	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.53	5.31	0.4	3.82e-7	Longevity;Endometriosis;
PAAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg10018233	chr7:150070692	REPIN1	0.58	6.2	0.45	5e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.57	-5.61	-0.41	9.54e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7336332	0.941	rs9579097	chr13:28084337	C/T	cg22138327	chr13:27999177	GTF3A	0.85	5.42	0.4	2.27e-7	Weight;
PAAD	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27511599	chr7:32358540	NA	0.86	4.86	0.37	2.88e-6	Body mass index;
PAAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg13312174	chr5:178288687	ZNF354B	-0.6	-5.88	-0.43	2.53e-8	Sleep duration;
PAAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6743376	0.556	rs4849146	chr2:113824840	A/T	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.4	4.75	0.36	4.64e-6	Urate levels;
PAAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.75	9.33	0.6	1.2e-16	Bone mineral density;
PAAD	cis	rs1730008	0.533	rs6806967	chr3:158178245	C/T	cg16708174	chr3:158430962	RARRES1	0.55	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.55	-4.92	-0.37	2.26e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2153535	0.518	rs1328868	chr6:8652578	C/T	cg07606381	chr6:8435919	SLC35B3	0.44	4.43	0.34	1.83e-5	Motion sickness;
PAAD	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.27	0.64	3.92e-19	Smoking behavior;
PAAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.78	9.23	0.6	2.25e-16	Eye color traits;
PAAD	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg26685658	chr5:74633012	HMGCR	0.51	4.41	0.34	1.95e-5	Age-related disease endophenotypes;
PAAD	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs714031	1.000	rs5750869	chr22:40065332	T/C	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.45	-0.34	1.66e-5	Schizophrenia;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg21724239	chr8:58056113	NA	-0.8	-5.35	-0.4	3.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.71	-0.36	5.55e-6	Menarche (age at onset);
PAAD	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg05082376	chr22:42548792	NA	-0.55	-5.66	-0.42	7.48e-8	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22274473	chr13:107687147	NA	-0.69	-7.15	-0.5	3.41e-11	Obesity-related traits;
PAAD	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.55	-5.72	-0.42	5.44e-8	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09327610	chr1:7847797	PER3	-0.61	-6.29	-0.45	3.28e-9	Obesity-related traits;
PAAD	cis	rs6088813	0.702	rs2425060	chr20:33914701	T/C	cg14752227	chr20:34000481	UQCC	0.5	4.48	0.34	1.46e-5	Height;
PAAD	cis	rs75920871	0.843	rs17120111	chr11:116744018	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.85	-4.76	-0.36	4.44e-6	Subjective well-being;
PAAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg14349672	chr11:133703707	NA	-0.54	-6.24	-0.45	4.24e-9	Childhood ear infection;
PAAD	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg12184421	chr1:167409136	CD247	-0.38	-4.44	-0.34	1.7e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.55	5.3	0.4	3.97e-7	Tonsillectomy;
PAAD	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs4455778	0.580	rs4285433	chr7:49114185	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.84	-0.37	3.15e-6	Eotaxin levels;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg03808351	chr9:123631620	PHF19	0.45	4.91	0.37	2.34e-6	Rheumatoid arthritis;
PAAD	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.64	-6.25	-0.45	3.96e-9	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27191207	chr4:124320678	SPRY1	0.63	6.41	0.46	1.71e-9	Obesity-related traits;
PAAD	cis	rs9361491	0.608	rs9343794	chr6:79444925	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.13	-0.38	8.86e-7	Bipolar disorder;
PAAD	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg22134325	chr11:66188745	NPAS4	0.31	4.71	0.36	5.65e-6	Airway imaging phenotypes;
PAAD	cis	rs595018	0.505	rs72916916	chr11:60604224	C/T	cg07588442	chr11:60673866	PRPF19	0.65	4.56	0.35	1.04e-5	Wegener's granulomatosis;
PAAD	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10547527	chr2:198650123	BOLL	0.49	4.25	0.33	3.71e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.7	0.42	6.1e-8	Lung cancer;
PAAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs11076805	0.510	rs365010	chr16:4152190	A/C	cg01959050	chr16:4170088	NA	0.52	5.19	0.39	6.56e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg22674798	chr1:3096360	PRDM16	-0.43	-5.52	-0.41	1.45e-7	Migraine;
PAAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.47	-4.66	-0.35	6.8e-6	Multiple sclerosis;
PAAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.68	-6.99	-0.49	7.92e-11	Schizophrenia;
PAAD	cis	rs11741688	0.720	rs4700981	chr5:178389116	A/T	cg13312174	chr5:178288687	ZNF354B	0.42	4.35	0.33	2.47e-5	Sleep duration;
PAAD	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.83	0.58	2.42e-15	Lung cancer;
PAAD	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	1.15	12.72	0.72	1.09e-25	Post bronchodilator FEV1;
PAAD	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs569214	0.515	rs519311	chr8:27519587	A/G	cg04264299	chr8:27491209	SCARA3	0.58	5.58	0.41	1.09e-7	Alzheimer's disease;
PAAD	cis	rs7953249	0.791	rs10774579	chr12:121405210	T/C	cg02403541	chr12:121454288	C12orf43	-0.44	-4.78	-0.36	4.08e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg27565382	chr3:53032988	SFMBT1	0.78	4.52	0.34	1.24e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7633770	0.643	rs58413466	chr3:46689154	G/T	cg11219411	chr3:46661640	NA	-0.53	-6.01	-0.44	1.32e-8	Coronary artery disease;
PAAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6496667	0.600	rs9806361	chr15:91073867	G/A	cg22089800	chr15:90895588	ZNF774	0.61	4.79	0.36	3.87e-6	Rheumatoid arthritis;
PAAD	cis	rs12304921	0.748	rs17125375	chr12:51499719	T/C	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.41	-0.4	2.35e-7	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11909064	chr6:155578034	TIAM2	-0.64	-6.79	-0.48	2.32e-10	Obesity-related traits;
PAAD	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-1.09	-12.1	-0.7	4.96e-24	Gut microbiota (bacterial taxa);
PAAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.58	-5.64	-0.42	7.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07701084	chr6:150067640	NUP43	0.62	6.11	0.44	8.08e-9	Lung cancer;
PAAD	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs12612619	0.732	rs2289360	chr2:27302165	T/C	cg00617064	chr2:27272375	NA	-0.51	-5.36	-0.4	3.09e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg01305830	chr4:1604576	NA	-0.48	-4.69	-0.36	6.07e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.83	-9.01	-0.59	7.93e-16	Obesity-related traits;
PAAD	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-4.73	-0.36	5.03e-6	Thyroid stimulating hormone;
PAAD	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg15654264	chr1:150340011	RPRD2	0.52	5.03	0.38	1.37e-6	Migraine;
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.63	-5.87	-0.43	2.67e-8	White matter hyperintensity burden;
PAAD	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.56	-5.48	-0.41	1.72e-7	Obesity-related traits;
PAAD	cis	rs2004318	1.000	rs7258275	chr19:55080756	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs6594713	0.679	rs17388260	chr5:112764578	C/A	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-5.46	-0.41	1.86e-7	Schizophrenia;
PAAD	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg09184832	chr6:79620586	NA	-0.42	-4.26	-0.33	3.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.56	4.96	0.37	1.89e-6	Smoking behavior;
PAAD	cis	rs1997066	0.831	rs73342223	chr10:106820999	G/T	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg00024416	chr22:24240387	NA	-0.55	-5.74	-0.42	5.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.87	10.57	0.65	6.48e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.24	-0.56	7.37e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.8	4.82	0.36	3.45e-6	Obesity-related traits;
PAAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.45	4.61	0.35	8.58e-6	Type 2 diabetes;
PAAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs4690686	0.510	rs10520348	chr4:177261738	T/A	cg17059388	chr4:177262070	NA	0.61	6.01	0.44	1.31e-8	Essential tremor;
PAAD	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg15841412	chr13:111365552	ING1	0.52	4.42	0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg19847866	chr10:1019161	NA	0.73	7.89	0.54	5.62e-13	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9652601	0.959	rs9652582	chr16:11174564	G/A	cg04616529	chr16:11181986	CLEC16A	0.48	5.11	0.38	9.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.5	-0.41	1.55e-7	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.48	4.41	0.34	1.97e-5	Dialysis-related mortality;
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.67	6.52	0.47	9.81e-10	Blood metabolite levels;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg26554054	chr8:600488	NA	-0.97	-5.69	-0.42	6.46e-8	IgG glycosylation;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.44	0.4	2.13e-7	Prudent dietary pattern;
PAAD	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.87	10.15	0.64	8.21e-19	Bladder cancer;
PAAD	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs288326	0.561	rs78528869	chr2:183815502	C/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg18612461	chr15:75251733	NA	0.61	7.67	0.53	1.88e-12	Breast cancer;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22358708	chr1:185126161	C1orf25;C1orf26	0.63	6.4	0.46	1.8e-9	Obesity-related traits;
PAAD	cis	rs564309	0.764	rs35155240	chr1:228550426	C/T	cg01328119	chr1:228783545	DUSP5P	0.69	4.37	0.33	2.28e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs17655565	0.553	rs7956996	chr12:52724938	C/T	cg22980804	chr12:52818037	KRT75	-0.51	-4.52	-0.34	1.24e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg02475695	chr16:616220	NHLRC4	0.45	5.22	0.39	5.85e-7	Height;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25671716	chr12:96441714	NA	-0.65	-6.59	-0.47	6.63e-10	Lung cancer in ever smokers;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg20821713	chr7:1055600	C7orf50	-0.38	-4.34	-0.33	2.6e-5	Longevity;Endometriosis;
PAAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg16083429	chr3:49237500	CCDC36	-0.43	-4.56	-0.35	1.06e-5	Parkinson's disease;
PAAD	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.22	0.45	4.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.24	-0.45	4.11e-9	Longevity;Endometriosis;
PAAD	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.7	4.67	0.35	6.69e-6	Inflammatory bowel disease;
PAAD	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.79	-7.09	-0.5	4.72e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.86	5.83	0.43	3.27e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.53	-0.52	4.09e-12	Total body bone mineral density;
PAAD	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg00800038	chr16:89945340	TCF25	-0.71	-4.41	-0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.72	-7.24	-0.51	2.11e-11	Morning vs. evening chronotype;
PAAD	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.97e-10	Resting heart rate;
PAAD	cis	rs1105228	0.885	rs524081	chr6:165711829	A/G	cg20535254	chr6:165714960	C6orf118	-0.5	-4.93	-0.37	2.09e-6	Number of pregnancies;Number of children;
PAAD	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg05250797	chr16:70222502	NA	0.88	6.7	0.48	3.72e-10	IgE levels;
PAAD	cis	rs7766436	0.561	rs1342206	chr6:22593676	G/A	cg13666174	chr6:22585274	NA	-0.51	-5.36	-0.4	3.07e-7	Coronary artery disease;
PAAD	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.72	-8.42	-0.56	2.57e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	3.98e-27	Heart rate;
PAAD	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.65	7.53	0.52	4.2e-12	Vitamin D levels;
PAAD	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.44	-6.78	-0.48	2.5e-10	Subjective well-being;
PAAD	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.58	-6.62	-0.47	5.95e-10	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.75e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.59	5.35	0.4	3.25e-7	Monocyte count;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg07747251	chr5:1868357	NA	0.57	6.2	0.45	5.02e-9	Cardiovascular disease risk factors;
PAAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg15838173	chr10:75533400	FUT11	-0.43	-4.28	-0.33	3.31e-5	Inflammatory bowel disease;
PAAD	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.56	-6.11	-0.44	7.81e-9	Breast cancer;
PAAD	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.41	-0.56	2.8e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4356203	0.543	rs214093	chr11:17294788	C/G	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.38	-0.33	2.18e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.87	7.02	0.5	6.75e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-0.9	-10.55	-0.65	7.11e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.89	-0.54	5.68e-13	Hemoglobin concentration;
PAAD	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.04	0.5	6.24e-11	Chronic sinus infection;
PAAD	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.63	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs4889911	1.000	rs4889911	chr17:77839811	C/T	cg26037614	chr17:77751273	CBX2	0.58	4.29	0.33	3.11e-5	Electroencephalogram traits;
PAAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.2	0.45	5.09e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.72	7.43	0.52	7.11e-12	Tourette syndrome;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.18e-8	Lung cancer;
PAAD	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg12568669	chr8:11666485	FDFT1	-0.27	-4.42	-0.34	1.85e-5	Neuroticism;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs7714584	1.000	rs11955172	chr5:150254378	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.82	-5.91	-0.43	2.16e-8	Diisocyanate-induced asthma;
PAAD	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg00999904	chr2:3704751	ALLC	-0.49	-5.72	-0.42	5.42e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.54	5.83	0.43	3.26e-8	Menopause (age at onset);
PAAD	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.67	-7.54	-0.52	3.88e-12	Colorectal cancer;
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.44	0.61	6.39e-17	Cognitive test performance;
PAAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg15510373	chr7:100224934	TFR2	-0.53	-4.3	-0.33	3.02e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.83	-10.51	-0.65	9e-20	Height;
PAAD	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.78e-6	Mortality in heart failure;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.84	-7.64	-0.53	2.24e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.41	-0.34	1.96e-5	Bipolar disorder;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg08204369	chr17:73150733	HN1	0.61	6.61	0.47	6.05e-10	Response to antipsychotic treatment;
PAAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-1.25	-12.98	-0.73	2.11e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs818427	0.508	rs2546112	chr5:112183157	A/G	cg06941702	chr5:112196734	SRP19	-0.51	-4.78	-0.36	4.04e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12425292	chr2:69372988	ANTXR1	-0.61	-6.87	-0.49	1.54e-10	Obesity-related traits;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg24846343	chr22:24311635	DDTL	0.71	5.89	0.43	2.44e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.72	6.21	0.45	4.79e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04779191	chr16:69166964	CHTF8;CIRH1A	0.6	6.82	0.48	2.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg08316699	chr6:150357289	NA	0.38	4.29	0.33	3.2e-5	Alopecia areata;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.5	4.85	0.37	2.99e-6	Parkinson's disease;
PAAD	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg04450456	chr4:17643702	FAM184B	0.48	5.17	0.39	7.13e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg14008862	chr17:28927542	LRRC37B2	0.82	5.79	0.43	3.86e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.57	-7.07	-0.5	5.3e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs367943	0.608	rs6859352	chr5:113007384	A/C	cg12552261	chr5:112820674	MCC	0.57	5.61	0.41	9.43e-8	Type 2 diabetes;
PAAD	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.85	10.27	0.64	4.06e-19	Body mass index;
PAAD	cis	rs17095355	0.818	rs17126936	chr10:111757126	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-4.26	-0.33	3.5e-5	Biliary atresia;
PAAD	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	1.0	14.09	0.75	2.21e-29	Heart rate;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.37	-0.33	2.26e-5	Lung cancer;
PAAD	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg21419209	chr3:44054225	NA	-0.73	-7.71	-0.53	1.55e-12	Coronary artery disease;
PAAD	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.67	0.42	7.15e-8	Joint mobility (Beighton score);
PAAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.49	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg01489256	chr8:11204017	TDH	-0.43	-4.3	-0.33	3.05e-5	Retinal vascular caliber;
PAAD	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.71	8.21	0.55	8.65e-14	Colorectal cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21577007	chr18:55315848	ATP8B1	0.6	6.37	0.46	2.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-6.56	-0.47	7.77e-10	Crohn's disease;
PAAD	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg15017067	chr4:17643749	FAM184B	0.41	4.85	0.37	2.98e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.97	-14.55	-0.76	1.33e-30	Height;
PAAD	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg07943548	chr15:86304357	KLHL25	-0.73	-5.94	-0.43	1.91e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.53	-5.83	-0.43	3.15e-8	Testicular germ cell tumor;
PAAD	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.83	0.36	3.36e-6	Breast cancer;
PAAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.72	-7.86	-0.54	6.65e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg06569542	chr10:98946673	SLIT1	0.5	5.58	0.41	1.08e-7	Monocyte count;
PAAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg09754948	chr16:28834200	ATXN2L	0.47	4.74	0.36	4.93e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.11	0.38	9.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs950880	0.710	rs67723747	chr2:102969807	C/T	cg23450938	chr2:102972792	NA	0.43	4.41	0.34	1.96e-5	Serum protein levels (sST2);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24677321	chr3:25116377	NA	-0.59	-6.56	-0.47	7.84e-10	Obesity-related traits;
PAAD	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.5	5.09	0.38	1.03e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.47	-5.41	-0.4	2.45e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.0	-8.29	-0.56	5.42e-14	Alzheimer's disease;
PAAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg05785598	chr3:49045655	WDR6	0.41	4.68	0.36	6.22e-6	Parkinson's disease;
PAAD	trans	rs901683	0.850	rs117582049	chr10:46050228	C/A	cg13065504	chr15:42448234	PLA2G4F	0.81	6.49	0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.87	-0.58	1.86e-15	Longevity;Endometriosis;
PAAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg11143131	chr5:131608246	PDLIM4	0.51	5.22	0.39	5.75e-7	Blood metabolite levels;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-6.55	-0.47	8.46e-10	Electroencephalogram traits;
PAAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg23346134	chr3:49453900	TCTA	-0.46	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.56	6.08	0.44	9.24e-9	Menopause (age at onset);
PAAD	cis	rs11051970	0.918	rs73084099	chr12:32539751	C/T	cg02745156	chr12:32552066	NA	0.47	4.82	0.36	3.47e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs6782025	0.802	rs1397824	chr3:121043980	T/G	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.35	6.3e-6	Aging (facial);
PAAD	cis	rs58521262	0.556	rs289294	chr19:23176773	A/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.88	0.37	2.69e-6	Blood metabolite levels;
PAAD	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.85	-0.37	3.08e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg21253087	chr9:139290292	SNAPC4	-0.43	-4.5	-0.34	1.34e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06392451	chr2:27994816	MRPL33	-0.74	-6.72	-0.48	3.35e-10	Neuroticism;
PAAD	cis	rs6445967	1.000	rs6791748	chr3:58308519	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.34	0.33	2.59e-5	Platelet count;
PAAD	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg00277334	chr10:82204260	NA	-0.76	-8.9	-0.59	1.55e-15	Post bronchodilator FEV1;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg02696790	chr15:75250997	RPP25	0.49	5.85	0.43	2.84e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.36	6.28	0.45	3.3e-9	Skin colour saturation;
PAAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.61	4.8	0.36	3.83e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9346455	0.614	rs2273888	chr6:72006512	C/T	cg27238071	chr6:71998145	OGFRL1	-0.75	-4.38	-0.33	2.18e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg18612461	chr15:75251733	NA	-0.44	-4.65	-0.35	7.23e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10198271	chr20:55966838	RBM38	0.56	6.46	0.46	1.35e-9	Immature fraction of reticulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04661747	chr11:46264818	NA	0.58	6.35	0.46	2.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.55	0.41	1.26e-7	Immature fraction of reticulocytes;
PAAD	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.81	8.57	0.57	1.1e-14	Sudden cardiac arrest;
PAAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg08648136	chr8:956695	NA	0.41	4.4	0.34	2.01e-5	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2133450	0.679	rs28378912	chr3:7365156	G/A	cg19930620	chr3:7340148	GRM7	-0.43	-4.74	-0.36	4.79e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6076065	0.723	rs2051093	chr20:23371349	G/A	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13144136	0.687	rs12511309	chr4:10657137	A/G	cg10242279	chr4:10666415	CLNK	-0.46	-5.82	-0.43	3.45e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Gout;
PAAD	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.71	7.24	0.51	2.11e-11	Platelet distribution width;
PAAD	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25820220	chr8:107282481	OXR1	0.61	6.94	0.49	1.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg06026331	chr20:60912101	LAMA5	-0.53	-4.71	-0.36	5.62e-6	Colorectal cancer;
PAAD	trans	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg16973527	chr15:70767570	NA	0.4	6.36	0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2124910	0.624	rs61742108	chr19:52004795	G/T	cg14953197	chr19:52005651	SIGLEC12	0.45	4.84	0.37	3.16e-6	Blood protein levels;
PAAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.49	-5.43	-0.4	2.24e-7	Major depressive disorder;
PAAD	cis	rs11756438	0.572	rs1844963	chr6:119002679	C/G	cg18833306	chr6:118973337	C6orf204	0.43	4.29	0.33	3.23e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7567389	0.719	rs11890243	chr2:127958041	C/A	cg09760422	chr2:128146352	NA	-0.47	-7.4	-0.51	8.79e-12	Self-rated health;
PAAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs669446	0.527	rs72883034	chr1:44112379	T/C	cg12908607	chr1:44402522	ARTN	-0.43	-4.56	-0.35	1.04e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg02404636	chr22:31891804	SFI1	0.61	5.51	0.41	1.47e-7	Colorectal cancer;
PAAD	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg10705379	chr10:99080932	FRAT1	-0.39	-4.48	-0.34	1.47e-5	Monocyte count;
PAAD	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg01620082	chr3:125678407	NA	-1.28	-7.6	-0.52	2.79e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-10.78	-0.66	1.78e-20	Cognitive function;
PAAD	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.99	0.75	4.1e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs10794720	0.867	rs78029387	chr10:1138589	C/T	cg05228244	chr10:1102351	WDR37	1.0	4.25	0.33	3.66e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
PAAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.09	0.5	4.66e-11	Rheumatoid arthritis;
PAAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg05207973	chr5:176823642	SLC34A1	-0.38	-4.51	-0.34	1.3e-5	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.55	-4.86	-0.37	2.85e-6	Lung cancer;
PAAD	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg17633681	chr16:88106987	BANP	0.63	8.14	0.55	1.32e-13	Menopause (age at onset);
PAAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.14	0.67	1.95e-21	Menopause (age at onset);
PAAD	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg27490568	chr2:178487706	NA	0.44	4.8	0.36	3.74e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4280164	0.830	rs2144494	chr14:24773387	T/C	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.85	6.51	0.47	1.03e-9	Axial length;
PAAD	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg06569542	chr10:98946673	SLIT1	-0.53	-5.97	-0.44	1.58e-8	Monocyte count;
PAAD	cis	rs899997	1.000	rs1904920	chr15:79029587	C/T	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.46	0.4	1.94e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.51	-5.04	-0.38	1.28e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-4.73	-0.36	5.16e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3736485	0.934	rs114641722	chr15:51863572	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.64	5.08	0.38	1.08e-6	Osteoarthritis;
PAAD	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.68	7.5	0.52	4.84e-12	Schizophrenia;
PAAD	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17507749	chr15:85114479	UBE2QP1	0.7	7.18	0.5	2.9100000000000002e-11	Schizophrenia;
PAAD	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.45	-0.34	1.68e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2296225	0.722	rs74840517	chr1:21049848	G/A	cg24673385	chr1:21051448	SH2D5	0.49	4.54	0.35	1.13e-5	Eosinophilic esophagitis;
PAAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg04844267	chr4:1394941	NA	0.44	5.04	0.38	1.29e-6	Longevity;
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg10072921	chr12:121022843	NA	0.41	5.11	0.38	9.7e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg27411982	chr8:10470053	RP1L1	-0.51	-5.63	-0.42	8.41e-8	Retinal vascular caliber;
PAAD	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg15193198	chr20:60906057	LAMA5	-0.48	-5.43	-0.4	2.2e-7	Colorectal cancer;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.7	-7.98	-0.54	3.38e-13	Iron status biomarkers;
PAAD	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.73	7.31	0.51	1.44e-11	Cognitive function;
PAAD	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg07741184	chr6:167504864	NA	-0.46	-5.51	-0.41	1.5e-7	Crohn's disease;
PAAD	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.54	4.99	0.37	1.66e-6	Resting heart rate;
PAAD	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6500395	0.926	rs8057164	chr16:48563466	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.39	0.4	2.65e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.71	8.9	0.59	1.56e-15	Bone mineral density;
PAAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.46	-4.67	-0.35	6.52e-6	Body mass index;
PAAD	cis	rs2120243	0.539	rs1563420	chr3:157119326	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs11771526	0.681	rs6953542	chr7:32418466	C/T	cg27511599	chr7:32358540	NA	0.7	4.39	0.34	2.15e-5	Body mass index;
PAAD	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	-0.48	-4.45	-0.34	1.68e-5	Inflammatory bowel disease;
PAAD	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg05373962	chr22:49881684	NA	-0.43	-4.38	-0.33	2.23e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg21890820	chr11:65308645	LTBP3	0.65	7.8	0.53	9.23e-13	Bone mineral density;
PAAD	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg02917321	chr22:38215204	NA	-0.46	-4.97	-0.37	1.81e-6	Glioblastoma;Glioma;
PAAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.59	7.16	0.5	3.24e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.97	-0.37	1.8e-6	Blood metabolite levels;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.21	-0.39	6.12e-7	Monocyte count;
PAAD	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg00101154	chr16:420108	MRPL28	-0.67	-6.39	-0.46	1.97e-9	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.4	-4.9	-0.37	2.39e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9810890	0.717	rs73210625	chr3:128668246	G/A	cg16818395	chr3:128274084	NA	0.52	4.53	0.34	1.18e-5	Dental caries;
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	1.01	8.26	0.56	6.69e-14	Initial pursuit acceleration;
PAAD	trans	rs1326986	0.702	rs12776678	chr10:20019851	A/G	cg04724540	chr1:166916762	ILDR2	-0.94	-6.31	-0.46	2.92e-9	Ankylosing spondylitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23747525	chr20:37064089	LOC388796;SNORA71D	0.68	6.59	0.47	6.67e-10	Obesity-related traits;
PAAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.47	-5.0	-0.38	1.55e-6	Platelet distribution width;
PAAD	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.54	-4.62	-0.35	8.18e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg24851651	chr11:66362959	CCS	-0.47	-4.26	-0.33	3.51e-5	Airway imaging phenotypes;
PAAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.42	0.34	1.87e-5	Tonsillectomy;
PAAD	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg16898833	chr6:26189333	HIST1H4D	0.88	4.77	0.36	4.2e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4253772	0.505	rs111280202	chr22:46646063	C/A	cg09491104	chr22:46646882	C22orf40	-0.79	-4.27	-0.33	3.46e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.76	5.53	0.41	1.39e-7	White matter hyperintensity burden;
PAAD	cis	rs2637266	0.807	rs2256413	chr10:78315334	C/T	cg18941641	chr10:78392320	NA	-0.36	-4.44	-0.34	1.69e-5	Pulmonary function;
PAAD	cis	rs2414095	0.527	rs767199	chr15:51540387	G/A	cg21478137	chr15:51532386	CYP19A1	0.54	5.52	0.41	1.46e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.01e-11	Diastolic blood pressure;
PAAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.58	-7.13	-0.5	3.77e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28647808	1.000	rs6597629	chr9:136270841	A/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.55	5.21	0.39	5.94e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1419980	0.730	rs11054588	chr12:7731148	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs16958440	0.867	rs77599321	chr18:44689642	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs4742903	0.935	rs12351370	chr9:106928940	G/A	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.95e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7688540	0.511	rs77815676	chr4:189869	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.3	-0.45	3.09e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg05697835	chr1:2722811	NA	0.39	4.28	0.33	3.28e-5	Ulcerative colitis;
PAAD	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.89	0.66	9.11e-21	Menopause (age at onset);
PAAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg01851573	chr8:8652454	MFHAS1	-0.49	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.52	5.11	0.38	9.7e-7	Mean corpuscular volume;
PAAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.43	0.46	1.52e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.48	-0.71	4.65e-25	Ulcerative colitis;
PAAD	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg27494647	chr7:150038898	RARRES2	0.52	5.24	0.39	5.39e-7	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.81	10.14	0.64	8.77e-19	Morning vs. evening chronotype;
PAAD	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.81	-9.46	-0.61	5.64e-17	DNA methylation (variation);
PAAD	cis	rs66478310	0.793	rs1399822	chr12:108712781	C/A	cg04872675	chr12:108983234	NA	0.89	5.74	0.42	5.08e-8	Plasma clusterin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18183014	chr1:47779854	STIL	0.59	6.29	0.45	3.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.79	6.15	0.45	6.41e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120991	0.901	rs6580966	chr12:54260941	T/C	cg21845580	chr12:53472882	SPRYD3	-0.46	-4.34	-0.33	2.55e-5	Biliary atresia;
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg21130718	chr4:1044621	NA	0.53	4.62	0.35	8.26e-6	Recombination rate (females);
PAAD	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs2526932	0.625	rs2526944	chr14:73059828	A/G	cg13588403	chr14:73209128	DPF3	-0.4	-5.44	-0.4	2.06e-7	C-reactive protein and white blood cell count;
PAAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-6.02	-0.44	1.29e-8	IgG glycosylation;
PAAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.78e-13	Blood protein levels;
PAAD	cis	rs6804624	0.654	rs2700662	chr3:99175428	A/G	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10037758	0.618	rs2577394	chr5:128286806	C/T	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.97	-0.44	1.64e-8	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1941184	0.526	rs116175575	chr18:29029430	T/C	cg03238162	chr18:29027701	DSG3	0.42	4.81	0.36	3.65e-6	Parkinson's disease (age of onset);
PAAD	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.73	5.71	0.42	5.76e-8	Diisocyanate-induced asthma;
PAAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.23	0.64	4.99e-19	Smoking behavior;
PAAD	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.68	-6.7	-0.48	3.8e-10	Uric acid levels;
PAAD	cis	rs4343996	0.747	rs1403158	chr7:3464896	A/G	cg21248987	chr7:3385318	SDK1	0.47	5.09	0.38	1.04e-6	Motion sickness;
PAAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.15	-0.5	3.34e-11	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg14926445	chr8:58193284	C8orf71	-0.78	-6.0	-0.44	1.38e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	1.25	12.98	0.73	2.11e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.17	-0.39	7.2e-7	Morning vs. evening chronotype;
PAAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.98	-14.04	-0.75	2.98e-29	Post bronchodilator FEV1;
PAAD	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg04990556	chr1:26633338	UBXN11	0.64	4.69	0.36	5.95e-6	Obesity-related traits;
PAAD	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg00700412	chr12:58011837	NA	0.46	4.85	0.37	2.98e-6	Multiple sclerosis;
PAAD	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs364477	0.818	rs279890	chr9:978108	T/C	cg13952963	chr9:998547	NA	0.64	5.16	0.39	7.68e-7	Major depressive disorder;
PAAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs6499755	0.862	rs2588994	chr16:55357681	G/A	cg02859129	chr16:55357253	IRX6	0.36	4.85	0.37	3.01e-6	Hypospadias;
PAAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.42	-5.05	-0.38	1.26e-6	Psoriasis;
PAAD	cis	rs4676406	0.608	rs6749767	chr2:241588985	A/G	cg21930842	chr2:241631663	AQP12A	0.47	5.34	0.4	3.25e-7	Ulcerative colitis;
PAAD	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.82	7.84	0.54	7.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs941898	0.574	rs8006662	chr14:100577890	C/T	cg21146428	chr14:101498343	MIR543	0.65	4.62	0.35	8.28e-6	White matter hyperintensity burden;
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg07061783	chr6:25882402	NA	-0.48	-4.64	-0.35	7.5e-6	Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	trans	rs901683	1.000	rs71496624	chr10:46085949	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.56	5.7	0.42	5.92e-8	Testicular germ cell tumor;
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg13282195	chr8:144660772	NAPRT1	-0.82	-4.3	-0.33	3.1e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg18833306	chr6:118973337	C6orf204	0.43	4.45	0.34	1.68e-5	Electrocardiographic conduction measures;
PAAD	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg20487152	chr13:99095054	FARP1	-0.47	-4.58	-0.35	9.77e-6	Longevity;
PAAD	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.27	16.54	0.8	8.57e-36	Schizophrenia;
PAAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	4.34	0.33	2.54e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.56	2.93e-14	Morning vs. evening chronotype;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg07841815	chr7:100318223	EPO	0.45	5.1	0.38	1.02e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs732505	0.764	rs73920020	chr19:5583514	T/C	cg26242866	chr19:5711310	LONP1	0.98	5.41	0.4	2.35e-7	vWF and FVIII levels;
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg15181151	chr6:150070149	PCMT1	0.6	6.54	0.47	8.96e-10	Lung cancer;
PAAD	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg08999081	chr20:33150536	PIGU	0.46	4.4	0.34	2.06e-5	Skin pigmentation;
PAAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.81	-7.99	-0.54	3.03e-13	Schizophrenia;
PAAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.85	10.53	0.65	8.08e-20	Height;
PAAD	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg10871876	chr19:53194124	ZNF83	0.64	5.7	0.42	5.9e-8	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs6708331	0.517	rs6546570	chr2:70350033	G/C	cg15408734	chr2:70369140	NA	-0.4	-4.26	-0.33	3.52e-5	Obesity-related traits;
PAAD	cis	rs709400	0.633	rs10135868	chr14:104004147	T/C	cg12935359	chr14:103987150	CKB	-0.74	-8.8	-0.58	2.85e-15	Body mass index;
PAAD	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.71	7.32	0.51	1.33e-11	Monocyte count;
PAAD	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg08992911	chr2:238395768	MLPH	0.59	5.63	0.42	8.49e-8	Prostate cancer;
PAAD	cis	rs16867321	1.000	rs4289138	chr2:181364220	T/G	cg23363182	chr2:181467187	NA	-0.48	-4.33	-0.33	2.64e-5	Obesity;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.99	10.69	0.66	3.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11664223	chr3:141868409	NA	0.69	6.82	0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.63	-6.55	-0.47	8.19e-10	Body mass index;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.93e-6	Life satisfaction;
PAAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.49	-5.25	-0.39	4.98e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-1.0	-6.88	-0.49	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12311304	1.000	rs11056410	chr12:15382815	T/C	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg08992911	chr2:238395768	MLPH	0.69	6.84	0.49	1.78e-10	Prostate cancer;
PAAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.57	-6.51	-0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.66	-6.09	-0.44	8.77e-9	Multiple myeloma;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs375066	0.762	rs17713001	chr19:44421225	C/T	cg11993925	chr19:44307056	LYPD5	-0.49	-5.98	-0.44	1.57e-8	Breast cancer;
PAAD	cis	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	4.53	0.34	1.2e-5	Resistin levels;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.78	5.66	0.42	7.22e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	6.9	0.49	1.32e-10	Type 2 diabetes;
PAAD	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg26174226	chr8:58114915	NA	-0.61	-4.71	-0.36	5.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.46	-5.02	-0.38	1.44e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs1421334	0.703	rs12114357	chr8:30833427	A/G	cg00964221	chr8:30240029	NA	0.43	4.28	0.33	3.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs4548	chr3:128525253	C/T	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.36	0.6	1e-16	Hemoglobin concentration;
PAAD	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	4.72	0.36	5.2e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.64	0.47	5.29e-10	Lung cancer in ever smokers;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	1.01	7.46	0.52	6.02e-12	IgG glycosylation;
PAAD	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs3112530	1.000	rs2560229	chr5:152677993	A/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	1.06	11.17	0.67	1.56e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.11e-8	Coronary artery disease;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-7.46	-0.52	6.26e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.55	4.4	0.34	1.99e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2278796	0.639	rs6661192	chr1:204971413	A/G	cg04862289	chr1:204966208	NFASC	0.5	5.16	0.39	7.67e-7	Mean platelet volume;
PAAD	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.31	11.62	0.69	1e-22	Uric acid levels;
PAAD	cis	rs1371614	0.611	rs7557229	chr2:27130891	T/C	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6700896	0.900	rs7524581	chr1:66166499	T/C	cg04111102	chr1:66153794	NA	-0.44	-5.01	-0.38	1.52e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg04352962	chr1:209979756	IRF6	0.53	4.51	0.34	1.27e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.31	-0.4	3.78e-7	Mononucleosis;
PAAD	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.46	-7.49	-0.52	5.21e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.85	10.0	0.63	2.05e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg23649088	chr2:200775458	C2orf69	-0.69	-5.15	-0.39	7.98e-7	Schizophrenia;
PAAD	cis	rs9832740	1.000	rs9832740	chr3:72393141	G/C	cg07881171	chr3:72988159	GXYLT2	0.48	4.68	0.35	6.35e-6	Height;
PAAD	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.37	5.01	0.38	1.52e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2299587	0.710	rs62498202	chr8:17876573	T/G	cg08627089	chr8:17753878	FGL1	-0.47	-4.7	-0.36	5.75e-6	Economic and political preferences;
PAAD	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.7	-0.36	5.66e-6	Height;
PAAD	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.73	4.61	0.35	8.49e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11209002	1.000	rs10732838	chr1:67577955	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.41	-6.0	-0.44	1.41e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.53	5.56	0.41	1.2e-7	Diastolic blood pressure;
PAAD	cis	rs7945718	0.621	rs10765984	chr11:12672669	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.38	0.33	2.19e-5	Educational attainment (years of education);
PAAD	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg00206168	chr11:65308501	LTBP3	0.78	5.54	0.41	1.3e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg19413350	chr8:57351067	NA	-0.48	-4.6	-0.35	8.93e-6	Obesity-related traits;
PAAD	cis	rs7279771	0.561	rs9980846	chr21:35841300	G/A	cg16756527	chr21:35891075	RCAN1	0.42	4.37	0.33	2.25e-5	Cancer;
PAAD	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.76	8.92	0.59	1.38e-15	Blood metabolite ratios;
PAAD	cis	rs11615916	0.790	rs17716876	chr12:62726983	A/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.82	8.28	0.56	5.82e-14	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.38	-0.33	2.21e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.57	12.45	0.71	5.72e-25	Atopic dermatitis;
PAAD	cis	rs16966918	0.579	rs1253841	chr13:106269751	T/C	cg17388689	chr13:107140685	NA	0.72	4.37	0.33	2.29e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg01815783	chr4:1047043	NA	-0.47	-4.34	-0.33	2.56e-5	Recombination rate (females);
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14895029	chr7:2775587	GNA12	-0.47	-4.45	-0.34	1.67e-5	Height;
PAAD	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.69	7.57	0.52	3.38e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.51	5.5	0.41	1.59e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg22162314	chr17:61951766	CSH2	0.56	5.57	0.41	1.15e-7	Height;
PAAD	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg14388049	chr10:71211838	TSPAN15	-0.43	-4.41	-0.34	1.94e-5	Venous thromboembolism;
PAAD	cis	rs818427	0.737	rs433429	chr5:112182232	A/T	cg06941702	chr5:112196734	SRP19	-0.48	-4.35	-0.33	2.46e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19232395	chr11:8550221	STK33	-0.59	-6.54	-0.47	9.03e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.3	0.64	3.25e-19	Prudent dietary pattern;
PAAD	cis	rs7619427	0.544	rs9877020	chr3:43992455	A/G	cg16646616	chr3:44040527	NA	0.56	4.52	0.34	1.25e-5	Schizophrenia;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg02524346	chr8:600233	NA	-1.05	-6.51	-0.47	1.04e-9	IgG glycosylation;
PAAD	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.47	4.74	0.36	4.98e-6	Type 1 diabetes;
PAAD	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.6	5.49	0.41	1.66e-7	Narcolepsy with cataplexy;
PAAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.47	4.84	0.37	3.11e-6	Total body bone mineral density;
PAAD	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs609418	1.000	rs9315451	chr13:37410696	A/C	cg14962159	chr13:37441585	SMAD9	-0.46	-4.25	-0.33	3.7e-5	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09725962	chr7:75268827	HIP1	-0.59	-6.53	-0.47	9.34e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg10432947	chr4:2062441	NAT8L	0.48	4.38	0.33	2.21e-5	Systolic blood pressure;
PAAD	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.74	7.31	0.51	1.43e-11	Sudden cardiac arrest;
PAAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg20003494	chr4:90757398	SNCA	-0.65	-6.07	-0.44	9.86e-9	Neuroticism;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg03989125	chr22:38214979	NA	0.64	5.69	0.42	6.4e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.83	8.56	0.57	1.19e-14	Heart rate;
PAAD	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg23112188	chr14:24563095	PCK2	-0.58	-6.16	-0.45	6.32e-9	IgG glycosylation;
PAAD	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.63	6.56	0.47	7.83e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs2229238	0.911	rs73023331	chr1:154508210	G/A	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg09835421	chr16:68378352	PRMT7	-0.91	-7.08	-0.5	4.91e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg24110177	chr3:50126178	RBM5	-0.67	-7.27	-0.51	1.79e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.61	6.08	0.44	9.36e-9	Essential tremor;
PAAD	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs838147	0.844	rs12611211	chr19:49248331	G/A	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.61	6.43	0.46	1.53e-9	Huntington's disease progression;
PAAD	cis	rs2010672	0.500	rs4932351	chr15:91143720	C/G	cg15547629	chr15:90437138	AP3S2	-0.51	-4.42	-0.34	1.9e-5	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.75	-0.36	4.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3736485	0.934	rs11634999	chr15:51871461	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.72	7.0	0.49	7.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs72827839	1.000	rs1472966	chr17:46430145	A/G	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg05025164	chr4:1340916	KIAA1530	0.49	4.31	0.33	2.94e-5	Obesity-related traits;
PAAD	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg05272587	chr13:111038400	COL4A2	-0.49	-4.48	-0.34	1.47e-5	White matter hyperintensity burden;
PAAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.49	-5.92	-0.43	2.03e-8	Height;
PAAD	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.65	6.57	0.47	7.7e-10	Monocyte count;
PAAD	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	1.02	12.3	0.71	1.4e-24	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.33	6.14	0.45	6.8e-9	Type 2 diabetes;
PAAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg19131313	chr8:1704013	NA	0.43	4.59	0.35	9.04e-6	Systolic blood pressure;
PAAD	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06850241	chr22:41845214	NA	0.57	4.92	0.37	2.22e-6	Vitiligo;
PAAD	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.55	-0.41	1.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06498398	chr8:11627480	NEIL2	0.66	7.47	0.52	5.85e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.16	16.6	0.8	5.87e-36	Cognitive function;
PAAD	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	1.0	8.27	0.56	6.41e-14	LDL cholesterol;
PAAD	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg14952266	chr13:112191215	NA	-0.44	-5.05	-0.38	1.25e-6	Hepatitis;
PAAD	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	6.41	0.46	1.73e-9	Menarche (age at onset);
PAAD	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.85	-0.37	3.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.45	6.2	0.45	5.09e-9	Vitiligo;
PAAD	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg25364880	chr3:44379878	C3orf23	0.55	5.42	0.4	2.27e-7	Depressive symptoms;
PAAD	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.72	6.98	0.49	8.62e-11	Hip circumference;
PAAD	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg12935359	chr14:103987150	CKB	-0.57	-5.98	-0.44	1.54e-8	Body mass index;
PAAD	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06327596	chr16:79634583	MAF	0.66	7.76	0.53	1.12e-12	Metabolite levels  (X-11787);
PAAD	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.53	-4.69	-0.36	6.17e-6	Schizophrenia;
PAAD	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg24296786	chr1:45957014	TESK2	-0.52	-4.79	-0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.51	-6.26	-0.45	3.78e-9	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06640718	chr6:91417950	NA	-0.53	-6.36	-0.46	2.24e-9	Obesity-related traits;
PAAD	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.15e-10	Atrioventricular conduction;
PAAD	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-5.27	-0.39	4.57e-7	Schizophrenia;
PAAD	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs4751006	0.543	rs7899778	chr10:128780419	A/C	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.11e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.9	-0.37	2.43e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs728616	0.867	rs61858980	chr10:81816618	G/A	cg05935833	chr10:81318306	SFTPA2	-0.6	-4.73	-0.36	5.1e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.78	-8.34	-0.56	4.12e-14	Cognitive function;
PAAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg06131755	chr6:160182447	ACAT2	0.57	5.06	0.38	1.18e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg00945038	chr17:61921165	SMARCD2	0.46	5.44	0.4	2.07e-7	Prudent dietary pattern;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.89	7.03	0.5	6.68e-11	Tuberculosis;
PAAD	cis	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.57	-6.17	-0.45	5.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg21483415	chr3:195448197	MUC20	-0.44	-4.38	-0.34	2.17e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12582317	chr17:55822272	NA	0.69	8.37	0.56	3.47e-14	Schizophrenia;
PAAD	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg05250797	chr16:70222502	NA	0.85	6.8	0.48	2.26e-10	IgE levels;
PAAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.17	-0.39	7.25e-7	Glomerular filtration rate;
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.69	7.22	0.51	2.36e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2718812	0.935	rs1006097	chr3:133411478	T/C	cg08048268	chr3:133502702	NA	0.43	5.33	0.4	3.46e-7	Iron status biomarkers;
PAAD	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3e-7	Heart rate;
PAAD	cis	rs4561483	0.815	rs7198817	chr16:11945778	C/A	cg08843971	chr16:11963173	GSPT1	0.49	5.33	0.4	3.41e-7	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	1.19	8.79	0.58	3.01e-15	Lymphocyte counts;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg21665744	chr7:39171113	POU6F2	0.39	5.88	0.43	2.53e-8	IgG glycosylation;
PAAD	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13065560	0.659	rs4676476	chr3:38882009	C/T	cg01426195	chr3:39028469	NA	-0.57	-5.9	-0.43	2.32e-8	Interleukin-18 levels;
PAAD	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.2	-0.64	6.32e-19	Obesity-related traits;
PAAD	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg26031613	chr14:104095156	KLC1	-0.47	-5.21	-0.39	6.18e-7	Schizophrenia;
PAAD	cis	rs4720118	0.660	rs1009355	chr7:33218763	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.49	4.28	0.33	3.28e-5	Leprosy;
PAAD	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.03	8.95	0.59	1.16e-15	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.52	4.64	0.35	7.54e-6	Systemic lupus erythematosus;
PAAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.33	0.33	2.68e-5	Platelet count;
PAAD	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg06632027	chr4:90757378	SNCA	-0.48	-4.44	-0.34	1.73e-5	Neuroticism;
PAAD	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	10.41	0.65	1.68e-19	Lymphocyte percentage of white cells;
PAAD	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg02493740	chr2:85810744	VAMP5	-0.43	-4.79	-0.36	3.93e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	0.93	6.19	0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.73	9.04	0.59	6.89e-16	Sjögren's syndrome;
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg23018236	chr17:30244563	NA	-0.63	-5.31	-0.4	3.81e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.68	8.95	0.59	1.19e-15	Hemoglobin concentration;
PAAD	cis	rs7577696	0.512	rs212736	chr2:32473126	T/C	cg02381751	chr2:32503542	YIPF4	0.54	5.2	0.39	6.44e-7	Inflammatory biomarkers;
PAAD	cis	rs73058052	0.597	rs10404887	chr19:50096421	C/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.59	-5.13	-0.38	8.75e-7	Fibrinogen levels;
PAAD	cis	rs6076065	0.755	rs3746734	chr20:23349765	C/T	cg11657817	chr20:23433608	CST11	0.5	5.16	0.39	7.56e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9462027	0.651	rs7752390	chr6:34790624	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.69	7.04	0.5	6.25e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.06	-0.55	2.15e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.55	-0.47	8.29e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06564803	chr16:70100193	PDXDC2	0.68	7.33	0.51	1.31e-11	Myopia (pathological);
PAAD	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.74	-8.29	-0.56	5.53e-14	Total body bone mineral density;
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg05717871	chr11:638507	DRD4	-0.57	-5.47	-0.41	1.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.74	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.85	0.49	1.72e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.52	8.81	0.58	2.68e-15	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.49	-0.47	1.15e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.56	-5.39	-0.4	2.6e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg19131313	chr8:1704013	NA	-0.42	-4.68	-0.35	6.35e-6	Systolic blood pressure;
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.37	0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg03037974	chr15:76606532	NA	0.49	5.65	0.42	7.59e-8	Blood metabolite levels;
PAAD	cis	rs7873102	0.654	rs2244713	chr9:37983434	T/C	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.94e-6	Breast cancer;
PAAD	cis	rs10090774	0.965	rs1031262	chr8:141985905	T/G	cg02508881	chr8:142216119	NA	-0.41	-4.36	-0.33	2.43e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs6076065	1.000	rs2424538	chr20:23382076	A/G	cg11657817	chr20:23433608	CST11	0.41	4.49	0.34	1.38e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	9.9	0.63	3.91e-18	Cognitive test performance;
PAAD	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.53	0.41	1.36e-7	Joint mobility (Beighton score);
PAAD	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg09324608	chr17:30823087	MYO1D	-0.4	-4.49	-0.34	1.42e-5	Schizophrenia;
PAAD	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.68	6.65	0.47	4.86e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11588062	0.745	rs5019033	chr1:46735072	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.49	4.59	0.35	9.1e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10256972	0.680	rs7784708	chr7:1003049	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.85e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.35	-0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.9	0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg21605333	chr4:119757512	SEC24D	1.91	10.98	0.66	5.25e-21	Cannabis dependence symptom count;
PAAD	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg00369613	chr2:3483100	TTC15	0.63	4.64	0.35	7.52e-6	Type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.63	0.53	2.37e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.58	7.7	0.53	1.58e-12	Obesity (extreme);
PAAD	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg05785598	chr3:49045655	WDR6	0.41	5.06	0.38	1.18e-6	Parkinson's disease;
PAAD	cis	rs3026101	0.578	rs55747983	chr17:5297742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.99	0.44	1.42e-8	Body mass index;
PAAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.64	6.48	0.47	1.23e-9	Calcium levels;
PAAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.49	-5.18	-0.39	7.05e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.62	-0.41	8.79e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.58	-6.41	-0.46	1.71e-9	Sense of smell;
PAAD	cis	rs1570884	0.539	rs3794377	chr13:50111135	T/C	cg08779649	chr13:50194554	NA	0.34	4.29	0.33	3.19e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	1.0	13.85	0.75	1.02e-28	Rheumatoid arthritis;
PAAD	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs11037575	0.654	rs6485451	chr11:43743302	T/C	cg24662154	chr11:44118094	EXT2	-0.43	-4.33	-0.33	2.73e-5	Neuroblastoma;
PAAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.94	-10.24	-0.64	4.88e-19	Blood metabolite levels;
PAAD	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.6	-6.42	-0.46	1.62e-9	Calcium levels;
PAAD	cis	rs11997175	0.625	rs17698353	chr8:33592241	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	6.39	0.46	1.9e-9	Body mass index;
PAAD	cis	rs8005172	0.594	rs7145963	chr14:88513124	C/A	cg18078958	chr14:88630771	NA	0.36	4.52	0.34	1.23e-5	Parkinson's disease;
PAAD	cis	rs35160687	0.842	rs7593440	chr2:86550657	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-4.52	-0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23708337	chr7:1209742	NA	0.63	4.51	0.34	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	7.95	0.54	3.85e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg02569823	chr6:5851330	NA	0.61	6.76	0.48	2.77e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.41	0.46	1.7e-9	IgG glycosylation;
PAAD	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.88	10.84	0.66	1.24e-20	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04901821	chr1:235507088	GGPS1	-0.51	-6.42	-0.46	1.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.52	5.27	0.39	4.65e-7	Lewy body disease;
PAAD	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.63	6.1	0.44	8.54e-9	Breast cancer;
PAAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.67	5.02	0.38	1.4e-6	Breast cancer;
PAAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.94	12.06	0.7	6.28e-24	Menopause (age at onset);
PAAD	cis	rs2133450	0.679	rs7610696	chr3:7368565	T/C	cg19930620	chr3:7340148	GRM7	-0.44	-4.98	-0.37	1.69e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg14219918	chr9:127249562	NR5A1	0.35	4.67	0.35	6.53e-6	Menarche (age at onset);
PAAD	trans	rs901683	1.000	rs17451208	chr10:46051905	C/G	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs61759167	1.000	rs11587518	chr1:3096925	T/A	cg22396632	chr1:3079212	PRDM16	-0.55	-5.19	-0.39	6.65e-7	Motion sickness;
PAAD	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.05	-0.75	2.85e-29	Headache;
PAAD	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.6	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.42	0.4	2.28e-7	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	-0.5	-4.41	-0.34	1.96e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs757081	0.658	rs214076	chr11:17300257	T/C	cg04705435	chr11:17411270	KCNJ11	-0.56	-6.01	-0.44	1.35e-8	Systolic blood pressure;
PAAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	4.36	0.33	2.41e-5	Tonsillectomy;
PAAD	cis	rs508970	0.556	rs672162	chr11:60922110	A/G	cg24692310	chr11:60915630	VPS37C	0.33	4.54	0.35	1.14e-5	Rheumatoid arthritis;
PAAD	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.3	-0.39	4.1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	8.16	0.55	1.16e-13	Rheumatoid arthritis;
PAAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.66	7.46	0.52	6.15e-12	Height;
PAAD	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.21	4.93	0.37	2.15e-6	Urinary tract infection frequency;
PAAD	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.7e-13	Coronary artery disease;
PAAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	Schizophrenia;
PAAD	cis	rs1190552	0.706	rs2146426	chr14:102995068	A/G	cg18135206	chr14:102964638	TECPR2	0.59	4.81	0.36	3.62e-6	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00456348	chr12:52463677	C12orf44	-0.63	-6.51	-0.47	1.03e-9	Smoking initiation;
PAAD	cis	rs2031532	0.587	rs7995283	chr13:50044585	A/C	cg08779649	chr13:50194554	NA	0.32	4.62	0.35	8.06e-6	Cardiac hypertrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00770008	chr3:20081585	KAT2B	0.66	6.74	0.48	3.1e-10	Obesity-related traits;
PAAD	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.57	5.28	0.39	4.49e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg02736288	chr16:86012573	NA	-0.57	-4.64	-0.35	7.61e-6	Multiple sclerosis;
PAAD	cis	rs41311933	0.656	rs41308026	chr9:123792989	A/G	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg15930145	chr14:90864542	CALM1	-0.63	-6.6	-0.47	6.56e-10	Educational attainment (years of education);
PAAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg04450456	chr4:17643702	FAM184B	0.5	5.44	0.4	2.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-5.04	-0.38	1.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Calcium levels;
PAAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.52	-5.67	-0.42	7.1e-8	Major depressive disorder;
PAAD	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg05084668	chr3:125655381	ALG1L	-0.51	-5.25	-0.39	5.12e-7	Blood pressure (smoking interaction);
PAAD	cis	rs35164067	1.000	rs11085730	chr19:10497976	G/A	cg24189696	chr19:10585866	NA	0.42	4.59	0.35	9.03e-6	Inflammatory bowel disease;
PAAD	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.94	-0.49	1.06e-10	Triglycerides;
PAAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.82	8.41	0.56	2.82e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4144743	1.000	rs2037150	chr17:45328718	G/A	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.5	-4.35	-0.33	2.44e-5	Obesity-related traits;
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg15193198	chr20:60906057	LAMA5	-0.44	-4.78	-0.36	4.14e-6	Colorectal cancer;
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.38	0.46	2.05e-9	Platelet count;
PAAD	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg13002189	chr3:66846049	NA	0.54	5.25	0.39	5.08e-7	Type 2 diabetes;
PAAD	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09960727	chr20:39765952	PLCG1	0.61	6.73	0.48	3.18e-10	Monocyte percentage of white cells;
PAAD	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg24881330	chr22:46731750	TRMU	1.08	5.53	0.41	1.34e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.76	-9.94	-0.63	2.93e-18	Bone mineral density;
PAAD	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.18e-10	Blood protein levels;
PAAD	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Vitiligo;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg24633833	chr3:10029261	TMEM111	0.58	4.31	0.33	2.96e-5	Alzheimer's disease;
PAAD	cis	rs831571	1.000	rs17069791	chr3:64052279	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.63	-4.81	-0.36	3.62e-6	Type 2 diabetes;
PAAD	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.93	7.96	0.54	3.62e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg02631450	chr22:32366979	NA	1.03	5.61	0.41	9.46e-8	Childhood ear infection;
PAAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.91	-0.37	2.33e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.71	6.82	0.48	2.01e-10	Coronary artery disease;
PAAD	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.5	0.61	4.39e-17	Psoriasis;
PAAD	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-5.37	-0.4	2.94e-7	Obesity (extreme);
PAAD	cis	rs4668356	0.892	rs1863679	chr2:172017906	C/T	cg13882835	chr2:172017928	TLK1	0.73	4.44	0.34	1.74e-5	Cognitive performance;
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14180030	chr9:123475675	MEGF9	-0.46	-5.04	-0.38	1.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.67	6.48	0.47	1.19e-9	Blood metabolite levels;
PAAD	cis	rs10490913	1.000	rs7916520	chr10:120145747	C/G	cg04126427	chr10:120840676	EIF3A	-0.47	-4.86	-0.37	2.91e-6	Cancer;
PAAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg13312174	chr5:178288687	ZNF354B	-0.6	-6.17	-0.45	5.81e-9	Sleep duration;
PAAD	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.77	9.38	0.61	8.77e-17	Metabolite levels;
PAAD	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.54	-4.74	-0.36	4.86e-6	Fibrinogen levels;
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs2594989	0.623	rs6802055	chr3:11470642	T/A	cg01796438	chr3:11312864	ATG7	-0.85	-4.97	-0.37	1.81e-6	Circulating chemerin levels;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.47	5.29	0.39	4.17e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.53	-5.64	-0.42	7.92e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.52	4.29	0.33	3.17e-5	Glycated hemoglobin levels;
PAAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.37	-4.39	-0.34	2.11e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	4.42	0.34	1.83e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.53	-4.96	-0.37	1.9e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.48	5.05	0.38	1.27e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg18769074	chr3:133464867	TF	-0.44	-5.13	-0.38	8.86e-7	Iron status biomarkers;
PAAD	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg26528668	chr16:1614120	IFT140	0.53	4.97	0.37	1.78e-6	Coronary artery disease;
PAAD	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg14515779	chr1:101123966	NA	0.43	4.64	0.35	7.6e-6	Monocyte count;
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.49	4.89	0.37	2.52e-6	Height;
PAAD	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9535307	0.929	rs1581745	chr13:50330957	T/C	cg03658251	chr13:50265850	EBPL	0.83	5.68	0.42	6.7e-8	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16520101	chr14:24769033	DHRS1;C14orf21	-0.76	-7.02	-0.49	6.79e-11	Neuroticism;
PAAD	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.52	-5.27	-0.39	4.57e-7	Inflammatory bowel disease;
PAAD	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg16006841	chr5:176797999	RGS14	0.73	7.17	0.5	3.04e-11	Urate levels in lean individuals;
PAAD	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.58	5.87	0.43	2.69e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.79	12.79	0.72	6.93e-26	Breast cancer;
PAAD	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17410650	chr12:54324560	NA	-0.44	-6.99	-0.49	7.91e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27553231	chr19:17797533	UNC13A	0.57	6.55	0.47	8.29e-10	Monocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13560548	chr3:10150139	C3orf24	0.61	5.56	0.41	1.19e-7	Alzheimer's disease;
PAAD	cis	rs743757	1.000	rs2236968	chr3:50465975	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.62	0.35	8e-6	Diastolic blood pressure;
PAAD	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.56	0.35	1.03e-5	Lung cancer;
PAAD	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-5.8	-0.43	3.66e-8	Bladder cancer;
PAAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.76	-0.36	4.48e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs350729	0.592	rs7585428	chr2:53164401	A/T	cg07782112	chr2:53107842	NA	-0.37	-4.29	-0.33	3.22e-5	Bronchodilator response in asthma;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03665000	chr5:109051593	MAN2A1	-0.66	-6.98	-0.49	8.72e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.44e-19	Menopause (age at onset);
PAAD	trans	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg11034861	chr16:67194079	TRADD;FBXL8	0.64	6.59	0.47	6.87e-10	Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-5.47	-0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg18135206	chr14:102964638	TECPR2	0.65	5.26	0.39	4.9e-7	Blood protein levels;
PAAD	cis	rs600626	0.529	rs10899113	chr11:75468464	T/A	cg24262691	chr11:75473276	NA	0.74	6.1	0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.71	6.02e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.94	12.37	0.71	9.43e-25	Menopause (age at onset);
PAAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00982548	chr2:198649783	BOLL	-0.79	-5.77	-0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.75	-8.74	-0.58	3.93e-15	Eye color traits;
PAAD	cis	rs11945232	0.624	rs112791869	chr4:88369598	A/G	cg23841344	chr4:88312519	HSD17B11	-0.56	-4.51	-0.34	1.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01585723	chr16:33734837	NA	0.41	4.31	0.33	2.87e-5	Menopause (age at onset);
PAAD	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.8	8.3	0.56	5.23e-14	Uric acid levels;
PAAD	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs7620363	0.859	rs12485304	chr3:34088287	G/A	cg02064073	chr3:33155252	CRTAP	-0.51	-4.38	-0.33	2.2e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.93	-5.4	-0.4	2.5e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg16211469	chr6:24423932	MRS2	0.49	4.95	0.37	1.93e-6	Liver enzyme levels;
PAAD	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09806900	chr7:148480153	CUL1	0.72	7.4	0.51	8.8e-12	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs77633900	0.772	rs284901	chr15:76747761	C/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.53	8.88	0.58	1.71e-15	Cutaneous nevi;
PAAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-7.75	-0.53	1.22e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.46	0.65	1.26e-19	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.86	8.16	0.55	1.2e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg12458913	chr13:53173898	NA	0.51	5.17	0.39	7.25e-7	Lewy body disease;
PAAD	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg14036092	chr11:66035641	RAB1B	0.78	8.18	0.55	1.03e-13	Gout;
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg18279126	chr7:2041391	MAD1L1	0.56	5.63	0.42	8.32e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.86	9.95	0.63	2.83e-18	Prudent dietary pattern;
PAAD	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.65	6.98	0.49	8.55e-11	Morning vs. evening chronotype;
PAAD	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01454528	chr17:49243444	NME2;NME1-NME2	-0.62	-6.36	-0.46	2.2e-9	Lung cancer in ever smokers;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.68	-7.78	-0.53	1.04e-12	Melanoma;
PAAD	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.54	0.52	4.05e-12	Mean platelet volume;
PAAD	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.38	5.14	0.38	8.36e-7	Schizophrenia;
PAAD	cis	rs787274	0.764	rs787281	chr9:115538568	C/T	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.48	5.0	0.38	1.54e-6	Body mass index;
PAAD	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.61	-0.88	1.74e-50	Myeloid white cell count;
PAAD	cis	rs9888739	0.844	rs41476751	chr16:31335906	T/C	cg15817542	chr16:31343056	ITGAM	-0.45	-4.4	-0.34	1.99e-5	Systemic lupus erythematosus;
PAAD	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.7	4.54	0.35	1.13e-5	Glycated hemoglobin levels;
PAAD	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg20246863	chr2:73402720	NA	-0.4	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.45	4.69	0.36	6.15e-6	Corneal astigmatism;
PAAD	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Dermatomyositis;
PAAD	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.96	9.99	0.63	2.24e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.51	-4.68	-0.36	6.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.4	-4.41	-0.34	1.94e-5	Prostate cancer;
PAAD	cis	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg25972092	chr12:117363249	FBXW8	-0.83	-6.36	-0.46	2.21e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs11825064	0.673	rs79389752	chr11:134496974	A/T	cg06603561	chr11:134479413	NA	-1.1	-6.6	-0.47	6.57e-10	Seasonality;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg05110241	chr16:68378359	PRMT7	-0.78	-5.15	-0.39	7.97e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg02770688	chr6:168491649	NA	0.46	4.79	0.36	3.92e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.67	-7.68	-0.53	1.84e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2292096	0.850	rs6663728	chr1:200815179	G/A	cg07580975	chr1:200843333	NA	0.5	4.66	0.35	6.8e-6	Epilepsy;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg11062466	chr8:58055876	NA	0.65	4.67	0.35	6.67e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg14343924	chr8:8086146	FLJ10661	-0.54	-5.25	-0.39	5.01e-7	Joint mobility (Beighton score);
PAAD	cis	rs350729	0.568	rs7577197	chr2:53174956	C/T	cg07782112	chr2:53107842	NA	-0.37	-4.31	-0.33	2.97e-5	Bronchodilator response in asthma;
PAAD	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.58	6.02	0.44	1.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.47	4.3	0.33	3.05e-5	Red blood cell count;
PAAD	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11971779	0.651	rs74368518	chr7:139004327	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.57	0.35	1.02e-5	Diisocyanate-induced asthma;
PAAD	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-0.93	-9.23	-0.6	2.13e-16	Exhaled nitric oxide output;
PAAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.82	7.26	0.51	1.86e-11	Psoriasis;
PAAD	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.63	-6.38	-0.46	2.02e-9	Proinsulin levels;
PAAD	cis	rs939584	0.877	rs7559547	chr2:615627	C/T	cg03610516	chr2:642275	NA	0.65	5.89	0.43	2.38e-8	Body mass index;
PAAD	cis	rs8077577	0.633	rs12939851	chr17:18131585	T/A	cg03916694	chr17:18150707	FLII	-0.4	-4.33	-0.33	2.64e-5	Obesity-related traits;
PAAD	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs28489187	0.629	rs2012683	chr1:85841485	C/T	cg16011679	chr1:85725395	C1orf52	0.54	5.16	0.39	7.53e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs337161	0.719	rs10863562	chr1:220929155	A/T	cg09023136	chr1:220959637	MOSC1	-0.59	-4.39	-0.34	2.08e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg21191810	chr6:118973309	C6orf204	-0.52	-5.01	-0.38	1.51e-6	Diastolic blood pressure;
PAAD	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg26924012	chr15:45694286	SPATA5L1	0.47	4.38	0.33	2.19e-5	Uric acid levels;
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg01831904	chr17:28903510	LRRC37B2	0.89	6.21	0.45	4.76e-9	Body mass index;
PAAD	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg23254163	chr1:152506842	NA	0.49	4.65	0.35	7.1e-6	Hair morphology;
PAAD	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.7	-0.48	3.71e-10	Retinal vascular caliber;
PAAD	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.59	-7.02	-0.49	6.89e-11	Aortic root size;
PAAD	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg14440974	chr22:39074834	NA	-0.56	-6.81	-0.48	2.15e-10	Menopause (age at onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23987876	chr1:29562838	PTPRU	-0.65	-6.42	-0.46	1.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.71	0.48	3.66e-10	IgG glycosylation;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.45	-5.12	-0.38	9.23e-7	Longevity;Endometriosis;
PAAD	cis	rs4737010	0.644	rs522407	chr8:41610969	G/A	cg17182837	chr8:41585554	ANK1	0.48	4.74	0.36	4.83e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs600626	0.588	rs10793124	chr11:75452267	C/G	cg24262691	chr11:75473276	NA	0.74	6.1	0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19749445	chr14:92493378	TRIP11	-0.68	-6.68	-0.48	4.33e-10	Obesity-related traits;
PAAD	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg20673841	chr7:107026890	COG5	-0.54	-4.73	-0.36	5.15e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.33	-0.33	2.73e-5	Testicular germ cell tumor;
PAAD	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.45	-5.15	-0.39	8.06e-7	Mean arterial pressure;
PAAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs8077577	0.689	rs16961114	chr17:18215339	G/C	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg26554054	chr8:600488	NA	-1.07	-7.03	-0.5	6.5500000000000006e-11	IgG glycosylation;
PAAD	cis	rs10849893	0.538	rs10744762	chr12:121839701	A/C	cg01154721	chr12:121881891	KDM2B	0.51	4.63	0.35	7.63e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs10915437	0.605	rs4654492	chr1:4201815	A/G	cg27165836	chr1:4193882	NA	-0.51	-5.21	-0.39	6.06e-7	Migraine - clinic-based;
PAAD	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.84	-8.43	-0.56	2.47e-14	Cisplatin-induced ototoxicity;
PAAD	cis	rs13191362	0.576	rs9356070	chr6:163273021	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.99	0.38	1.62e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.59	-6.6	-0.47	6.45e-10	Platelet distribution width;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07172036	chr6:15663356	DTNBP1	-0.76	-6.77	-0.48	2.6e-10	Neuroticism;
PAAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg04398451	chr17:18023971	MYO15A	-0.78	-8.94	-0.59	1.23e-15	Total body bone mineral density;
PAAD	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.52	0.47	9.95e-10	Smoking initiation;
PAAD	cis	rs2061333	0.557	rs10410306	chr19:44601537	T/C	cg20607764	chr19:44506953	ZNF230	-0.67	-4.59	-0.35	9.06e-6	Alzheimer's disease;
PAAD	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg24053715	chr22:38214548	NA	-0.48	-4.67	-0.35	6.45e-6	Glioblastoma;Glioma;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg16606324	chr3:10149918	C3orf24	-0.75	-5.93	-0.43	1.95e-8	Alzheimer's disease;
PAAD	cis	rs6604026	0.740	rs10874746	chr1:93323971	A/G	cg17283838	chr1:93427260	FAM69A	-0.6	-5.36	-0.4	3.07e-7	Multiple sclerosis;
PAAD	trans	rs901683	1.000	rs35902429	chr10:46024335	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.52	-0.47	9.84e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs950881	0.932	rs3771180	chr2:102953617	G/T	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	6.23	0.45	4.27e-9	Hip circumference;
PAAD	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.72	-0.36	5.41e-6	Type 2 diabetes;
PAAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.89	-0.49	1.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs3026101	0.671	rs1806242	chr17:5304763	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs2952768	1.000	rs2709390	chr2:208506371	G/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.36	0.33	2.34e-5	Opioid sensitivity;
PAAD	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg08390786	chr10:135334061	NA	0.48	4.64	0.35	7.5e-6	Obesity-related traits;
PAAD	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.94	-6.55	-0.47	8.25e-10	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg03676636	chr4:99064102	C4orf37	-0.25	-4.4	-0.34	2.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3996993	0.509	rs55695953	chr6:52652649	C/T	cg00536792	chr6:53530503	KLHL31	-0.42	-4.48	-0.34	1.49e-5	Hemoglobin concentration;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg15557168	chr22:42548783	NA	0.42	4.49	0.34	1.41e-5	Intelligence;
PAAD	cis	rs939584	0.877	rs11687052	chr2:623740	A/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13469180	chr3:47324151	KIF9;KLHL18	0.67	6.46	0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-5.62	-0.41	8.96e-8	Monocyte count;
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.04e-8	Electrocardiographic conduction measures;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19504661	chr2:239542427	NA	0.6	6.39	0.46	1.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.26	0.39	4.86e-7	Coronary artery disease;
PAAD	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.65	4.9	0.37	2.39e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.67	-8.37	-0.56	3.45e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.61	-5.67	-0.42	7.01e-8	Malaria;
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-4.55	-0.35	1.1e-5	Tonsillectomy;
PAAD	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg24687543	chr11:63912206	MACROD1	0.58	4.66	0.35	6.8e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.52	-5.14	-0.39	8.17e-7	Mean corpuscular volume;
PAAD	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg20933634	chr6:27740509	NA	-0.74	-4.63	-0.35	7.95e-6	Depression;
PAAD	cis	rs16975963	0.843	rs73027451	chr19:38375666	C/T	cg14218481	chr19:38281219	NA	0.43	4.45	0.34	1.63e-5	Longevity;
PAAD	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.7	-7.98	-0.54	3.38e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg14019146	chr3:50243930	SLC38A3	0.44	4.48	0.34	1.44e-5	Menarche (age at onset);
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg16040993	chr19:53496440	ZNF702P	-0.44	-4.38	-0.33	2.23e-5	Psoriasis;
PAAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.16	16.6	0.8	5.87e-36	Cognitive function;
PAAD	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-7.02	-0.49	7.04e-11	Body mass index (adult);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05779081	chr10:93683588	BTAF1	-0.71	-6.46	-0.46	1.34e-9	Neuroticism;
PAAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.07	13.1	0.73	9.86e-27	Cognitive function;
PAAD	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg10664184	chr19:17420304	DDA1	0.46	4.29	0.33	3.15e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.68	0.58	5.69e-15	Rheumatoid arthritis;
PAAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg14711859	chr11:8959438	ASCL3	0.5	5.97	0.44	1.59e-8	Hematocrit;
PAAD	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.56	5.02	0.38	1.42e-6	Retinal vascular caliber;
PAAD	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.64	6.73	0.48	3.25e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg10290764	chr8:4849399	CSMD1	-0.39	-6.56	-0.47	7.79e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.2e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08677398	chr8:58056175	NA	0.58	4.3	0.33	3.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2236918	0.932	rs1635501	chr1:242040775	C/T	cg17736920	chr1:242011382	EXO1	0.69	7.98	0.54	3.36e-13	Menopause (age at onset);
PAAD	cis	rs12453935	0.708	rs11654581	chr17:59904796	T/A	cg01765249	chr17:59476334	TBX2	-0.52	-4.59	-0.35	9.05e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	ch.11.42038R	chr11:967971	AP2A2	0.63	6.15	0.45	6.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.83	-8.13	-0.55	1.44e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9393777	0.668	rs72839449	chr6:27261661	A/C	cg16479474	chr6:28041457	NA	0.52	4.4	0.34	2.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.82	6.34	0.46	2.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg19787841	chr12:53845606	PCBP2	0.44	4.37	0.33	2.33e-5	Height;
PAAD	cis	rs10821973	0.527	rs4381270	chr10:63995658	G/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.69	6.84	0.49	1.83e-10	Coronary artery disease;
PAAD	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.53	8.28	0.56	5.83e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs7570971	0.583	rs1375132	chr2:135954405	A/G	cg07169764	chr2:136633963	MCM6	0.69	6.7	0.48	3.87e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.52	4.8	0.36	3.71e-6	Airway imaging phenotypes;
PAAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.76	-8.13	-0.55	1.39e-13	Aortic root size;
PAAD	cis	rs360071	0.528	rs360100	chr1:226067382	G/A	cg25552768	chr1:226077287	LEFTY1	0.44	4.52	0.34	1.22e-5	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs802075	0.765	rs3799678	chr6:49603016	C/A	cg20364632	chr6:49636226	NA	-0.48	-5.38	-0.4	2.71e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg15693483	chr7:1102177	C7orf50	0.41	5.1	0.38	9.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.94	8.42	0.56	2.61e-14	Body mass index;
PAAD	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg22903471	chr2:27725779	GCKR	-0.39	-4.28	-0.33	3.33e-5	Total body bone mineral density;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03674076	chr20:524243	CSNK2A1	0.56	6.44	0.46	1.47e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73210622	chr3:128659748	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg18265608	chr11:44087367	ACCS	-0.81	-4.99	-0.38	1.62e-6	IgA nephropathy;
PAAD	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-7.8	-0.53	8.94e-13	Menarche (age at onset);
PAAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.64	-5.18	-0.39	6.83e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18297960	chr7:1142765	C7orf50	-0.55	-4.37	-0.33	2.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16975963	0.843	rs73027451	chr19:38375666	C/T	cg25793785	chr19:38281423	NA	0.6	4.95	0.37	1.92e-6	Longevity;
PAAD	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg00083206	chr6:110721305	DDO	-0.48	-5.06	-0.38	1.17e-6	Platelet distribution width;
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Electroencephalogram traits;
PAAD	cis	rs12432203	0.915	rs12434713	chr14:51743378	C/A	cg23942311	chr14:51606299	NA	-0.75	-4.73	-0.36	5.12e-6	Cancer;
PAAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg26031613	chr14:104095156	KLC1	-0.47	-5.15	-0.39	7.89e-7	Schizophrenia;
PAAD	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg12072164	chr19:44306565	LYPD5	-0.42	-4.63	-0.35	7.82e-6	Breast cancer;
PAAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs6466055	1.000	rs6466055	chr7:104929064	A/C	cg04380332	chr7:105027541	SRPK2	0.64	7.03	0.5	6.59e-11	Schizophrenia;
PAAD	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg06609049	chr19:2785107	THOP1	0.87	9.7	0.62	1.28e-17	Total cholesterol levels;
PAAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg09659197	chr4:152720779	NA	0.36	5.11	0.38	9.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg14440974	chr22:39074834	NA	-0.59	-6.88	-0.49	1.45e-10	Menopause (age at onset);
PAAD	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg23531748	chr20:60969906	CABLES2	0.44	4.42	0.34	1.88e-5	Colorectal cancer;
PAAD	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-4.37	-0.33	2.31e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.6	-0.41	9.75e-8	Schizophrenia;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10467557	chr13:21893662	NA	-0.39	-4.48	-0.34	1.46e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.79	10.08	0.63	1.32e-18	Vitiligo;
PAAD	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg09127314	chr1:152161683	NA	-0.63	-4.58	-0.35	9.45e-6	Atopic dermatitis;
PAAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.46	-5.94	-0.43	1.89e-8	Ulcerative colitis;
PAAD	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-4.7	-0.36	5.67e-6	Schizophrenia;
PAAD	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.38	4.62	0.35	8.27e-6	Pulmonary function;
PAAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-1.06	-14.93	-0.77	1.35e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.51	4.88	0.37	2.71e-6	Pancreatic cancer;
PAAD	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg14078157	chr9:128172775	NA	0.63	7.45	0.52	6.65e-12	Resting heart rate;
PAAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs7688540	0.511	rs61794969	chr4:188031	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.38	-0.33	2.19e-5	Life satisfaction;
PAAD	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.16	0.39	7.59e-7	Lung cancer;
PAAD	cis	rs721399	0.512	rs4560828	chr8:18276294	A/T	cg18736775	chr8:18248649	NAT2	-0.65	-4.87	-0.37	2.74e-6	Blood metabolite levels;
PAAD	trans	rs12738007	0.933	rs61783707	chr1:29543700	A/T	cg05667379	chr2:115920764	DPP10	0.38	6.3	0.46	3.08e-9	Schizophrenia;
PAAD	cis	rs12134245	0.527	rs36048657	chr1:92022364	T/C	cg25838465	chr1:92012736	NA	-0.45	-4.59	-0.35	9.04e-6	Breast cancer;
PAAD	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7624766	0.555	rs6794047	chr3:160523531	T/C	cg22637730	chr3:160473554	PPM1L	0.51	4.38	0.34	2.16e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg05484376	chr2:27715224	FNDC4	0.46	4.47	0.34	1.52e-5	Oral cavity cancer;
PAAD	cis	rs12612619	0.659	rs12997235	chr2:27229079	A/C	cg00617064	chr2:27272375	NA	0.48	4.88	0.37	2.69e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.44	4.49	0.34	1.39e-5	Longevity;Endometriosis;
PAAD	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.8	9.76	0.62	9.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.89	5.85	0.43	2.95e-8	Body mass index;
PAAD	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg10705379	chr10:99080932	FRAT1	-0.44	-4.99	-0.38	1.64e-6	Monocyte count;
PAAD	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-0.92	-8.83	-0.58	2.37e-15	Exhaled nitric oxide output;
PAAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-6.03	-0.44	1.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs9657904	0.865	rs4447799	chr3:105584684	A/G	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.73	4.45	0.34	1.67e-5	Response to cognitive-behavioural therapy in anxiety disorder;
PAAD	cis	rs7202877	0.610	rs3784936	chr16:75337583	C/G	cg03315344	chr16:75512273	CHST6	0.62	5.23	0.39	5.47e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.53	-5.44	-0.4	2.07e-7	Body mass index;
PAAD	cis	rs62025270	0.688	rs10163064	chr15:86277520	A/G	cg13263323	chr15:86062960	AKAP13	0.49	4.38	0.33	2.17e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg22467129	chr15:76604101	ETFA	0.51	4.79	0.36	3.99e-6	Blood metabolite levels;
PAAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-9.12	-0.59	4.34e-16	Gut microbiome composition (summer);
PAAD	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.63	7.53	0.52	4.29e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9815354	1.000	rs6805880	chr3:41865397	A/G	cg03022575	chr3:42003672	ULK4	0.84	6.32	0.46	2.78e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.78	0.42	4.02e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.51	-5.02	-0.38	1.41e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.56	4.6	0.35	8.92e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7247513	0.964	rs4414604	chr19:12702437	C/G	cg01871581	chr19:12707946	ZNF490	-0.86	-10.73	-0.66	2.38e-20	Bipolar disorder;
PAAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg23346134	chr3:49453900	TCTA	0.4	4.3	0.33	3.09e-5	Menarche (age at onset);
PAAD	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-1.15	-16.8	-0.81	1.81e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.87	10.76	0.66	1.98e-20	Heart rate;
PAAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.6	5.61	0.41	9.31e-8	Prostate cancer;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.45	0.61	5.97e-17	Prudent dietary pattern;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg17541715	chr7:1216824	NA	-0.5	-5.77	-0.42	4.22e-8	Longevity;Endometriosis;
PAAD	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.82	-8.44	-0.56	2.36e-14	Paraoxonase activity;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg16606324	chr3:10149918	C3orf24	0.54	4.7	0.36	5.85e-6	Alzheimer's disease;
PAAD	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.61	-8.95	-0.59	1.15e-15	Huntington's disease progression;
PAAD	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12935418	0.583	rs2098726	chr16:81025275	C/T	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs12550646	0.652	rs12680139	chr8:41666355	G/T	cg19997384	chr8:41685595	ANK1	-0.32	-4.37	-0.33	2.32e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6141769	0.569	rs11905501	chr20:31270962	C/A	cg13636640	chr20:31349939	DNMT3B	-0.54	-4.97	-0.37	1.77e-6	Subjective well-being;
PAAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.59	7.53	0.52	4.24e-12	Diastolic blood pressure;
PAAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-8.46	-0.57	2.12e-14	Gut microbiome composition (summer);
PAAD	cis	rs75920871	0.609	rs11216187	chr11:116787148	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.83	-4.49	-0.34	1.4e-5	Subjective well-being;
PAAD	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.56	5.57	0.41	1.15e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.65	-6.85	-0.49	1.72e-10	DNA methylation (variation);
PAAD	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.32	-0.4	3.67e-7	Height;
PAAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.75	7.01	0.49	7.24e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs258892	0.895	rs266437	chr5:72167441	G/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.77	7.66	0.53	2.07e-12	Resting heart rate;
PAAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.57	-6.14	-0.45	6.86e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg00579200	chr11:133705235	NA	-0.46	-4.98	-0.37	1.7e-6	Childhood ear infection;
PAAD	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.56	5.4	0.4	2.57e-7	Corneal astigmatism;
PAAD	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.37	4.44	0.34	1.72e-5	Pulmonary function;
PAAD	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.7	-8.12	-0.55	1.51e-13	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.88	-9.65	-0.62	1.75e-17	Chronic sinus infection;
PAAD	cis	rs1476670	0.683	rs813642	chr1:44506420	A/C	cg09470012	chr1:44509516	NA	0.5	4.96	0.37	1.84e-6	Eotaxin levels;
PAAD	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-11.6	-0.69	1.09e-22	Chronic sinus infection;
PAAD	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.11	-0.7	4.69e-24	Obesity-related traits;
PAAD	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.79	6.03	0.44	1.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.62	6.79	0.48	2.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	1.0	8.14	0.55	1.34e-13	Triglycerides;
PAAD	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.71	4.97	0.37	1.76e-6	HDL cholesterol levels;
PAAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg13057898	chr1:3703894	LRRC47	0.46	4.86	0.37	2.89e-6	Red cell distribution width;
PAAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.64	6.44	0.46	1.5e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg07148914	chr20:33460835	GGT7	-0.48	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.84	-7.7	-0.53	1.59e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg11196182	chr7:1989412	MAD1L1	0.42	4.47	0.34	1.51e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.69	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12066905	chr13:25497207	CENPJ	-0.55	-6.35	-0.46	2.36e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10819733	chr22:24237672	NA	-0.62	-6.97	-0.49	8.94e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg09658497	chr7:2847517	GNA12	-0.62	-6.07	-0.44	9.78e-9	Height;
PAAD	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.55	5.05	0.38	1.23e-6	Airway imaging phenotypes;
PAAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.64	6.2	0.45	5.19e-9	Mood instability;
PAAD	cis	rs4676482	0.577	rs4676484	chr3:39267352	C/T	cg02254461	chr3:39195904	CSRNP1	0.66	4.29	0.33	3.19e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.39	-0.34	2.08e-5	Obesity-related traits;
PAAD	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.59	5.39	0.4	2.62e-7	Platelet count;
PAAD	cis	rs2952768	0.932	rs2551645	chr2:208450788	C/T	cg22329743	chr2:208688774	PLEKHM3	-0.23	-4.54	-0.35	1.15e-5	Opioid sensitivity;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg21523564	chr15:75251491	NA	0.47	4.93	0.37	2.11e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.29	0.39	4.22e-7	Gut microbiome composition (summer);
PAAD	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	6.29	0.45	3.17e-9	Neuroticism;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.65	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	5.61	0.41	9.28e-8	Mood instability;
PAAD	cis	rs6604026	0.698	rs4420089	chr1:93391043	G/T	cg17283838	chr1:93427260	FAM69A	0.61	5.59	0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.58	5.65	0.42	7.66e-8	Asthma;
PAAD	cis	rs10943724	0.679	rs541037	chr6:81231852	G/C	cg19323245	chr6:80716898	TTK	-0.46	-4.79	-0.36	3.93e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs59698941	0.882	rs6871970	chr5:132189594	G/A	cg14825688	chr5:132208181	LEAP2	-0.66	-4.89	-0.37	2.59e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.61	-0.35	8.49e-6	Prevalent atrial fibrillation;
PAAD	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.76	-7.76	-0.53	1.16e-12	Osteoporosis;
PAAD	cis	rs2997447	0.761	rs2783639	chr1:26429437	C/G	cg24519413	chr1:26490540	NA	-0.48	-4.51	-0.34	1.31e-5	QRS complex (12-leadsum);
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg09417038	chr21:47716443	C21orf57	-0.6	-6.42	-0.46	1.65e-9	Testicular germ cell tumor;
PAAD	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg09876464	chr15:85330779	ZNF592	0.44	4.37	0.33	2.28e-5	P wave terminal force;
PAAD	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.5	-5.48	-0.41	1.69e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2885056	0.843	rs2360745	chr19:10693836	G/T	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs11113894	0.901	rs10861928	chr12:108862616	G/A	cg06834313	chr12:108851556	NA	-0.68	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs13053817	1.000	rs34305567	chr22:29853562	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.55	-4.76	-0.36	4.41e-6	Carotid atherosclerosis in HIV infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24668618	chr5:177165350	FAM153A	-0.6	-6.53	-0.47	9.28e-10	Obesity-related traits;
PAAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.71	7.18	0.5	2.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.88	-0.72	3.91e-26	Dental caries;
PAAD	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg06569542	chr10:98946673	SLIT1	0.5	5.06	0.38	1.2e-6	Monocyte count;
PAAD	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs7766436	0.767	rs62391062	chr6:22598736	G/A	cg13666174	chr6:22585274	NA	-0.5	-5.28	-0.39	4.45e-7	Coronary artery disease;
PAAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.47	-4.73	-0.36	5.14e-6	Menopause (age at onset);
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.61	6.32	0.46	2.82e-9	Iron status biomarkers;
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg16718678	chr11:64490633	NRXN2	0.91	6.69	0.48	4.07e-10	Lung function (FEV1/FVC);
PAAD	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.87	-9.64	-0.62	1.82e-17	Tonsillectomy;
PAAD	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg06287003	chr12:125626642	AACS	-0.46	-4.54	-0.35	1.15e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11671653	1.000	rs7256743	chr19:10833131	G/C	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg26516362	chr5:178986906	RUFY1	-0.63	-7.82	-0.54	8.21e-13	Lung cancer;
PAAD	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.64	6.97	0.49	9.14e-11	Blood protein levels;
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.08	0.55	1.83e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.73	7.12	0.5	4.03e-11	Mood instability;
PAAD	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.73	8.18	0.55	1.06e-13	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21244253	chr9:102879586	INVS	-0.68	-6.46	-0.46	1.36e-9	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04042914	chr22:36786722	NA	0.6	6.76	0.48	2.79e-10	Smoking initiation;
PAAD	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg16810054	chr20:33298113	TP53INP2	-0.59	-4.62	-0.35	8.17e-6	Neuroticism;
PAAD	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.5	5.34	0.4	3.34e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.62	-4.51	-0.34	1.27e-5	Blood protein levels;
PAAD	cis	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg21546286	chr11:48923668	NA	-0.6	-6.24	-0.45	4.06e-9	HDL cholesterol;
PAAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10724425	chr4:83932168	LIN54	0.56	6.75	0.48	2.94e-10	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09852008	chr1:10092689	UBE4B	0.69	6.82	0.48	2.04e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg21698718	chr17:80085957	CCDC57	0.47	5.26	0.39	4.85e-7	Life satisfaction;
PAAD	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg00750074	chr16:89608354	SPG7	-0.64	-6.65	-0.47	4.96e-10	Multiple myeloma (IgH translocation);
PAAD	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs2016586	0.929	rs5750161	chr22:36113236	T/C	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	trans	rs10895275	0.606	rs2846837	chr11:102105605	A/G	cg15692862	chr11:116734453	SIK3	-0.62	-6.39	-0.46	1.88e-9	Migraine;
PAAD	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.51	-4.46	-0.34	1.57e-5	IgG glycosylation;
PAAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.59	0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.73	-6.17	-0.45	5.82e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.65	7.44	0.52	7.01e-12	Height;
PAAD	cis	rs7216064	0.859	rs7502307	chr17:65989961	C/G	cg12091567	chr17:66097778	LOC651250	-0.71	-5.77	-0.42	4.3e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.38	-7.57	-0.52	3.43e-12	Mean corpuscular volume;
PAAD	cis	rs11700980	0.551	rs909329	chr21:30108262	G/A	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.9	-10.27	-0.64	4.11e-19	Refractive error;
PAAD	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.78	-0.53	1.02e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7523050	0.908	rs17621621	chr1:109398917	G/T	cg08274380	chr1:109419600	GPSM2	0.76	5.38	0.4	2.72e-7	Fat distribution (HIV);
PAAD	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.79	9.41	0.61	7.23e-17	Eosinophil percentage of white cells;
PAAD	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.47	4.4	0.34	2.05e-5	Urate levels;
PAAD	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.77	6.14	0.45	6.74e-9	Type 2 diabetes;
PAAD	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.55	-5.85	-0.43	2.91e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg00738919	chr7:1100172	C7orf50	0.73	5.3	0.39	4.09e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00540400	chr15:79124168	NA	-0.57	-6.66	-0.48	4.74e-10	Coronary artery disease;
PAAD	cis	rs12767760	0.669	rs7475470	chr10:99310503	C/T	cg25247692	chr10:99313390	UBTD1	0.56	5.46	0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07701084	chr6:150067640	NUP43	0.62	6.15	0.45	6.42e-9	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.66	6.34	0.46	2.54e-9	Corneal astigmatism;
PAAD	cis	rs621942	0.664	rs693458	chr11:85733065	A/C	cg07180834	chr11:85838833	NA	-0.52	-5.16	-0.39	7.58e-7	Tourette syndrome;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg15117754	chr3:10150083	C3orf24	0.7	6.01	0.44	1.34e-8	Alzheimer's disease;
PAAD	cis	rs7188861	0.681	rs66718203	chr16:11428643	C/G	cg16532467	chr16:11454386	NA	-0.55	-4.28	-0.33	3.26e-5	HDL cholesterol;
PAAD	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.35	0.51	1.11e-11	Lung function (FEV1/FVC);
PAAD	cis	rs12304921	1.000	rs73090629	chr12:51335777	T/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.4	-0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg11900509	chr10:81946545	ANXA11	-0.61	-4.27	-0.33	3.38e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.59	-7.1	-0.5	4.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs11264213	0.591	rs619666	chr1:36488956	C/T	cg27506609	chr1:36549197	TEKT2	-0.81	-5.96	-0.44	1.71e-8	Schizophrenia;
PAAD	trans	rs901683	1.000	rs35036712	chr10:46046710	C/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg07593977	chr8:11735419	NA	-0.42	-6.32	-0.46	2.69e-9	Monocyte count;
PAAD	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.78	6.65	0.47	5.02e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	trans	rs901683	1.000	rs35187216	chr10:45986620	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.71	-0.42	5.82e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-5.15	-0.39	8.1e-7	Lung cancer;
PAAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	1.08	11.4	0.68	3.71e-22	Longevity;
PAAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.92	7.74	0.53	1.31e-12	Psoriasis;
PAAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg10871876	chr19:53194124	ZNF83	0.57	4.83	0.36	3.36e-6	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs59901009	0.577	rs61877043	chr11:10044629	T/C	cg06876053	chr11:9810051	SBF2	-0.33	-4.36	-0.33	2.39e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.6	5.85	0.43	2.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-4.39	-0.34	2.14e-5	Asthma;
PAAD	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.86	0.62	4.78e-18	Smoking behavior;
PAAD	cis	rs2415984	0.579	rs2100337	chr14:46966088	T/C	cg14871534	chr14:47121158	RPL10L	-0.47	-4.89	-0.37	2.49e-6	Number of children ever born;
PAAD	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.8	9.32	0.6	1.26e-16	Lung cancer;
PAAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.74	8.48	0.57	1.87e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.71	7.65	0.53	2.1e-12	Menarche (age at onset);
PAAD	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.42	-4.3	-0.33	2.99e-5	Obesity-related traits;
PAAD	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg00647317	chr7:50633725	DDC	0.42	4.35	0.33	2.48e-5	Systemic sclerosis;
PAAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg02421172	chr7:1938701	MAD1L1	0.67	5.14	0.38	8.43e-7	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.4	4.92	0.37	2.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.66	5.92	0.43	2.07e-8	Mortality in heart failure;
PAAD	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg19337854	chr7:99768885	GPC2	0.45	4.33	0.33	2.75e-5	Lung function (FEV1/FVC);
PAAD	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg18200150	chr17:30822561	MYO1D	0.79	11.88	0.69	1.97e-23	Schizophrenia;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg01700524	chr14:24803014	ADCY4	-0.69	-6.29	-0.45	3.17e-9	Blood protein levels;
PAAD	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg10820045	chr2:198174542	NA	-0.44	-4.36	-0.33	2.39e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.57	6.45	0.46	1.41e-9	Urate levels;
PAAD	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09650158	chr5:137911165	HSPA9	0.65	7.42	0.52	7.71e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.52	5.72	0.42	5.52e-8	Bladder cancer;
PAAD	cis	rs7896729	0.943	rs11253086	chr10:5345926	T/C	cg07902545	chr10:6194255	PFKFB3	-0.43	-4.48	-0.34	1.47e-5	Intelligence;
PAAD	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.82	8.95	0.59	1.15e-15	Body mass index;
PAAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.85	9.42	0.61	6.97e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.55	6.01	0.44	1.33e-8	Schizophrenia;
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs9900972	0.721	rs11656224	chr17:76867996	A/G	cg00961940	chr17:76876995	TIMP2	0.54	5.12	0.38	9.13e-7	Obesity-related traits;
PAAD	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-4.51	-0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.74	5.44	0.4	2.13e-7	Alzheimer's disease;
PAAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.68	7.73	0.53	1.39e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	1.13	6.36	0.46	2.25e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.74	0.42	4.92e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs6604026	0.883	rs77741804	chr1:93324038	C/T	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.56	5.01	0.38	1.48e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg10864074	chr7:100318194	EPO	-0.48	-4.69	-0.36	5.95e-6	Other erythrocyte phenotypes;
PAAD	cis	rs4698775	0.924	rs6533442	chr4:110553141	C/G	cg05791136	chr4:110223969	COL25A1	-0.32	-4.29	-0.33	3.14e-5	Age-related macular degeneration;
PAAD	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	0.98	11.27	0.67	8.26e-22	Testicular germ cell tumor;
PAAD	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg02640540	chr1:67518911	SLC35D1	0.56	4.8	0.36	3.69e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	0.98	10.26	0.64	4.26e-19	Nonalcoholic fatty liver disease;
PAAD	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg12290671	chr7:99195819	NA	-0.99	-5.35	-0.4	3.16e-7	Blood metabolite ratios;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	15.86	0.79	4.88e-34	Prudent dietary pattern;
PAAD	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg26031613	chr14:104095156	KLC1	0.5	5.53	0.41	1.37e-7	Schizophrenia;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.54	5.41	0.4	2.43e-7	Parkinson's disease;
PAAD	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.46	-0.34	1.58e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7551345	0.901	rs35068862	chr1:31834173	G/A	cg17086398	chr1:31896392	SERINC2	-0.54	-4.75	-0.36	4.6e-6	Schizophrenia;
PAAD	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg24555670	chr8:18244502	NA	0.56	4.62	0.35	8.01e-6	Blood metabolite levels;
PAAD	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg09659197	chr4:152720779	NA	0.4	5.04	0.38	1.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg21523528	chr20:32077966	CBFA2T2	0.51	4.3	0.33	3.07e-5	Height;
PAAD	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.51	-4.83	-0.36	3.29e-6	Daytime sleep phenotypes;
PAAD	cis	rs12760731	0.565	rs16852576	chr1:178192371	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.2	12.32	0.71	1.27e-24	Corneal structure;
PAAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.71	7.61	0.53	2.66e-12	Colorectal cancer;
PAAD	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.69	-0.36	5.92e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.85	0.58	2.07e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg00431813	chr7:1051703	C7orf50	-0.35	-4.44	-0.34	1.73e-5	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.73	0.36	5.18e-6	Obesity-related traits;
PAAD	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.8	5.37	0.4	2.96e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08532870	chr1:8086308	ERRFI1	0.61	6.75	0.48	2.86e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.49	-5.2	-0.39	6.48e-7	Daytime sleep phenotypes;
PAAD	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.74e-9	Coffee consumption (cups per day);
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21300561	chr12:49525534	TUBA1B	0.63	7.05	0.5	5.99e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.52	-5.14	-0.38	8.26e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.51	-0.57	1.55e-14	Obesity-related traits;
PAAD	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.52	4.47	0.34	1.54e-5	Systolic blood pressure;
PAAD	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.05	11.47	0.68	2.4e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.79	-7.64	-0.53	2.25e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs3996993	0.772	rs3957356	chr6:52668670	T/C	cg20803780	chr6:52668592	GSTA1	-0.34	-4.31	-0.33	2.94e-5	Hemoglobin concentration;
PAAD	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	5.86	0.43	2.75e-8	Response to antipsychotic treatment;
PAAD	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.49	-5.59	-0.41	1.04e-7	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03577350	chr2:46293123	PRKCE	0.58	6.36	0.46	2.21e-9	Smoking initiation;
PAAD	cis	rs6076065	0.692	rs2424549	chr20:23394563	C/A	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.88	-0.58	1.8e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs9434723	0.920	rs9434725	chr1:9293861	C/T	cg04199779	chr1:9294473	H6PD	0.58	4.94	0.37	2.06e-6	Height;
PAAD	cis	rs10090774	0.965	rs7005909	chr8:141983699	A/G	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg18551225	chr6:44695536	NA	-0.69	-7.01	-0.49	7.39e-11	Total body bone mineral density;
PAAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg09835421	chr16:68378352	PRMT7	-1.15	-8.25	-0.56	6.98e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs3764563	0.935	rs585680	chr19:15687802	T/G	cg20725493	chr19:15740067	CYP4F8	0.95	5.23	0.39	5.42e-7	Inflammatory biomarkers;
PAAD	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs2242420	0.920	rs853480	chr1:21949537	A/G	cg04297819	chr1:22260125	HSPG2	0.5	4.4	0.34	1.99e-5	Hematological and biochemical traits;
PAAD	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	trans	rs3733631	1.000	rs28878597	chr4:104591916	A/G	cg21490444	chr5:171095097	NA	0.77	6.29	0.45	3.16e-9	Menarche (age at onset);
PAAD	cis	rs288342	0.832	rs288254	chr2:183608627	G/A	cg02625481	chr2:183667124	NA	-0.43	-4.25	-0.33	3.77e-5	Recurrent major depressive disorder;
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg24879335	chr3:133465180	TF	-0.62	-7.02	-0.49	6.84e-11	Iron status biomarkers;
PAAD	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.53	-5.94	-0.43	1.89e-8	Mean arterial pressure;
PAAD	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg25233709	chr10:116636983	FAM160B1	-0.36	-4.25	-0.33	3.72e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg21665744	chr7:39171113	POU6F2	0.34	5.73	0.42	5.2e-8	IgG glycosylation;
PAAD	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.95	0.49	1.02e-10	Rheumatoid arthritis;
PAAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9659323	1.000	rs9658899	chr1:119504543	G/A	cg26570165	chr1:119541833	NA	-0.46	-4.63	-0.35	7.9e-6	Body mass index;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.64	-0.42	8.09e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg15660573	chr17:549704	VPS53	-0.76	-7.71	-0.53	1.55e-12	Prostate cancer;
PAAD	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.99	-12.82	-0.72	5.62e-26	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15500929	chr1:85666720	SYDE2	0.58	6.4	0.46	1.79e-9	Monocyte percentage of white cells;
PAAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.6e-13	Rheumatoid arthritis;
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg00522288	chr12:125625016	AACS	-0.56	-6.02	-0.44	1.26e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.05	-0.38	1.27e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg21479132	chr6:26055353	NA	0.96	6.18	0.45	5.68e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg17372223	chr3:52568218	NT5DC2	0.5	4.89	0.37	2.53e-6	Bipolar disorder;
PAAD	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg08645402	chr16:4508243	NA	0.51	4.27	0.33	3.42e-5	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-1.22	-12.02	-0.7	8.1e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.91	-11.9	-0.69	1.77e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7714584	1.000	rs11741861	chr5:150277909	C/T	cg22134413	chr5:150180641	NA	-0.99	-6.32	-0.46	2.78e-9	Crohn's disease;
PAAD	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-4.54	-0.35	1.12e-5	Mood instability;
PAAD	cis	rs12467812	0.682	rs10181220	chr2:20035567	C/T	cg04561332	chr2:20550539	NA	0.46	4.3	0.33	2.99e-5	Monobrow;
PAAD	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-11.57	-0.68	1.33e-22	Height;
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg27565382	chr3:53032988	SFMBT1	0.78	4.51	0.34	1.29e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10450586	0.863	rs7481148	chr11:27298139	A/T	cg10370305	chr11:27303972	NA	0.36	4.32	0.33	2.84e-5	Total body bone mineral density;
PAAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.88	9.48	0.61	4.83e-17	Cognitive function;
PAAD	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.56	0.57	1.18e-14	Bipolar disorder;
PAAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.45	-4.42	-0.34	1.88e-5	Body mass index;
PAAD	cis	rs2006771	0.836	rs7285777	chr22:31982241	C/G	cg02404636	chr22:31891804	SFI1	-0.55	-5.31	-0.4	3.77e-7	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs9430161	0.611	rs72644044	chr1:11034347	C/G	cg02454025	chr1:11042201	C1orf127	1.23	14.99	0.77	9.07e-32	Ewing sarcoma;
PAAD	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.97e-7	Educational attainment;
PAAD	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.21	-0.39	6.16e-7	Monocyte percentage of white cells;
PAAD	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg21496419	chr19:44306685	LYPD5	0.39	4.97	0.37	1.76e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg18892244	chr7:807596	HEATR2	-0.61	-6.43	-0.46	1.6e-9	Subjective well-being;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg21565972	chr17:80109576	CCDC57	-0.58	-6.69	-0.48	4.1e-10	Life satisfaction;
PAAD	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.03	11.94	0.7	1.37e-23	Breast cancer;
PAAD	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.64	6.51	0.47	1.05e-9	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.28e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.48	4.98	0.37	1.71e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07362569	chr17:61921086	SMARCD2	0.58	6.76	0.48	2.84e-10	Prudent dietary pattern;
PAAD	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.73	-9.13	-0.6	3.88e-16	Dental caries;
PAAD	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10885582	0.810	rs1333690	chr10:116347790	G/T	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.12	-0.38	8.94e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs732765	0.734	rs17183132	chr14:75153818	C/A	cg17347104	chr14:75034677	LTBP2	0.63	5.38	0.4	2.78e-7	Non-small cell lung cancer;
PAAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg14440974	chr22:39074834	NA	-0.57	-6.81	-0.48	2.18e-10	Menopause (age at onset);
PAAD	trans	rs1015213	0.609	rs74435722	chr8:52870839	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00513467	chr9:21335551	KLHL9	-0.55	-6.36	-0.46	2.27e-9	Body fat percentage;
PAAD	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.7e-8	Schizophrenia;
PAAD	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.64	6.69	0.48	4.01e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg04257695	chr17:30186438	C17orf79	-0.71	-5.19	-0.39	6.53e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs74181299	0.684	rs2302631	chr2:65331659	T/G	cg20592124	chr2:65290738	CEP68	-0.46	-4.33	-0.33	2.68e-5	Pulse pressure;
PAAD	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.41	-4.63	-0.35	7.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.44	4.28	0.33	3.31e-5	Platelet count;
PAAD	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.5	5.03	0.38	1.36e-6	Menopause (age at onset);
PAAD	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.6	-0.78	2.36e-33	Schizophrenia;
PAAD	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.56e-11	Retinal vascular caliber;
PAAD	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	5.0	0.38	1.53e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.12	-10.55	-0.65	7.3e-20	Lymphocyte percentage of white cells;
PAAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.6	-6.48	-0.47	1.23e-9	Eye color traits;
PAAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.8	-5.1	-0.38	9.84e-7	Tuberculosis;
PAAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.97	10.57	0.65	6.21e-20	Parkinson's disease;
PAAD	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg18057887	chr11:133800913	IGSF9B	0.57	5.97	0.44	1.62e-8	Parkinson's disease;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	7.98	0.54	3.33e-13	Prudent dietary pattern;
PAAD	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.62	6.09	0.44	8.79e-9	Refractive astigmatism;
PAAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.52	-4.28	-0.33	3.33e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.14	6.88	0.49	1.46e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.46	-0.57	2.04e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.61	6.5	0.47	1.06e-9	Menarche (age at onset);
PAAD	cis	rs59191668	0.809	rs12441323	chr15:62816101	G/A	cg12918536	chr15:62891943	NA	0.33	4.28	0.33	3.32e-5	Immature fraction of reticulocytes;
PAAD	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg13918804	chr1:2043761	PRKCZ	0.43	5.77	0.42	4.26e-8	Height;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12675942	chr10:71160999	HK1	-0.66	-6.31	-0.46	2.87e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22867315	chr6:153476415	NA	0.61	6.7	0.48	3.82e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs773506	0.628	rs10733740	chr9:93933158	G/T	cg14446406	chr9:93919335	NA	0.39	5.45	0.4	1.95e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.08	-0.38	1.09e-6	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg08235883	chr12:122238836	LOC338799	0.63	7.12	0.5	4.01e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.4	0.46	1.83e-9	Morning vs. evening chronotype;
PAAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06544989	chr22:39130855	UNC84B	0.51	4.94	0.37	2.04e-6	Menopause (age at onset);
PAAD	cis	rs990171	0.538	rs7566063	chr2:103112565	C/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg07157834	chr1:205819609	PM20D1	0.58	4.37	0.33	2.26e-5	Parkinson's disease;
PAAD	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg09455208	chr3:40491958	NA	-0.45	-5.82	-0.43	3.32e-8	Renal cell carcinoma;
PAAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg05484376	chr2:27715224	FNDC4	0.5	5.13	0.38	8.63e-7	Total body bone mineral density;
PAAD	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07683663	chr4:147096828	LSM6	0.63	7.1	0.5	4.48e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.36	-10.89	-0.66	8.92e-21	Obesity-related traits;
PAAD	cis	rs863345	0.604	rs11265015	chr1:158503252	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.34e-7	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg24634471	chr8:143751801	JRK	-0.49	-4.25	-0.33	3.77e-5	Urinary tract infection frequency;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.12e-6	Cognitive function;
PAAD	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.7	-0.48	3.72e-10	Coffee consumption (cups per day);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14345012	chr20:26189240	MIR663	0.36	6.31	0.46	2.91e-9	Myopia (pathological);
PAAD	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.92	9.78	0.62	7.89e-18	Testicular germ cell tumor;
PAAD	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07156097	chr12:42720006	PPHLN1;ZCRB1	-0.55	-6.3	-0.46	2.99e-9	Body fat percentage;
PAAD	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.65	6.32	0.46	2.8e-9	Hemoglobin concentration;
PAAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.77	-8.15	-0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-1.01	-8.75	-0.58	3.72e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg02770688	chr6:168491649	NA	0.46	4.71	0.36	5.52e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.5	-5.02	-0.38	1.43e-6	Menarche (age at onset);
PAAD	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.5	4.83	0.37	3.24e-6	Endometrial cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21903221	chr14:105851981	PACS2	0.62	6.53	0.47	9.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17766062	chr2:75062663	HK2	0.51	6.31	0.46	2.9e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12304921	0.748	rs77433345	chr12:51335582	C/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.29	-0.33	3.16e-5	Type 2 diabetes;
PAAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.53	4.93	0.37	2.12e-6	Schizophrenia;
PAAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00300879	chr1:26503847	CNKSR1	0.32	5.02	0.38	1.44e-6	Height;
PAAD	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.73	-0.36	5.12e-6	High light scatter reticulocyte count;
PAAD	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2902440	0.502	rs7556198	chr1:67665543	A/G	cg08029281	chr1:67600428	NA	0.44	5.07	0.38	1.14e-6	Crohn's disease;
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.45	4.82	0.36	3.47e-6	Cystic fibrosis severity;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.79	8.22	0.55	8.38e-14	Menopause (age at onset);
PAAD	cis	rs990171	1.000	rs6727306	chr2:102981644	A/C	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.88e-5	Lymphocyte counts;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg06740227	chr12:86229804	RASSF9	0.47	4.44	0.34	1.73e-5	Major depressive disorder;
PAAD	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.52	4.93	0.37	2.1e-6	Hypospadias;
PAAD	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.08	-6.78	-0.48	2.54e-10	Plateletcrit;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01111558	chr17:423281	VPS53	0.53	6.64	0.47	5.37e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01485165	chr20:49411421	BCAS4	0.65	7.71	0.53	1.53e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.7	-8.16	-0.55	1.15e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg10395934	chr14:104002654	TRMT61A	0.48	4.7	0.36	5.75e-6	Body mass index;
PAAD	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.67	6.35	0.46	2.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.71	-6.37	-0.46	2.14e-9	Type 2 diabetes;
PAAD	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg25811867	chr2:3488468	NA	-0.46	-4.3	-0.33	2.99e-5	Neurofibrillary tangles;
PAAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-5.39	-0.4	2.61e-7	Tonsillectomy;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg07685180	chr8:600429	NA	-0.79	-5.16	-0.39	7.49e-7	IgG glycosylation;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.23	-0.39	5.57e-7	Longevity;Endometriosis;
PAAD	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00864171	chr11:67383662	NA	-0.47	-4.98	-0.37	1.68e-6	Mean corpuscular volume;
PAAD	cis	rs4743820	0.651	rs73494920	chr9:93923153	G/C	cg14446406	chr9:93919335	NA	0.45	5.41	0.4	2.39e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs72636617	0.867	rs58463079	chr13:95064145	A/T	cg07907493	chr13:95480448	NA	0.65	4.35	0.33	2.48e-5	Pelvic organ prolapse;
PAAD	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.59	-4.69	-0.36	6e-6	Type 2 diabetes;
PAAD	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.71	8.21	0.55	8.68e-14	Colorectal cancer;
PAAD	cis	rs12282928	1.000	rs2134554	chr11:48262351	C/T	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg03522150	chr11:46969673	C11orf49	0.43	5.21	0.39	6.03e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.46	5.43	0.4	2.22e-7	Height;
PAAD	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.78	8.82	0.58	2.5e-15	Corneal astigmatism;
PAAD	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg15478930	chr2:27652102	NRBP1	0.53	4.38	0.33	2.24e-5	Blood metabolite levels;
PAAD	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.58	0.47	6.99e-10	Hair morphology;
PAAD	cis	rs1577917	0.523	rs1413724	chr6:86814549	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.58	-0.41	1.06e-7	Response to antipsychotic treatment;
PAAD	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.5	-6.39	-0.46	1.88e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.6	-6.16	-0.45	6.14e-9	Height;
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.43	-0.46	1.57e-9	Lung cancer;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs11887277	0.684	rs2082610	chr2:27033440	G/A	cg12368169	chr2:27073192	DPYSL5	-0.42	-4.4	-0.34	2.04e-5	Obesity-related traits;
PAAD	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg24553058	chr2:113831203	IL1F10	0.73	8.26	0.56	6.6e-14	Protein quantitative trait loci;
PAAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.79	8.25	0.56	7.09e-14	Tuberculosis;
PAAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg14019146	chr3:50243930	SLC38A3	0.43	4.42	0.34	1.87e-5	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01872447	chr12:96336980	AMDHD1;CCDC38	-0.65	-6.46	-0.46	1.35e-9	Smoking initiation;
PAAD	cis	rs4356203	0.875	rs527810	chr11:17201066	A/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.28	-0.33	3.34e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg05110241	chr16:68378359	PRMT7	-1.14	-8.15	-0.55	1.26e-13	HDL cholesterol;
PAAD	cis	rs17209837	1.000	rs12673662	chr7:87110351	C/G	cg00919237	chr7:87102261	ABCB4	0.76	4.95	0.37	1.92e-6	Gallbladder cancer;
PAAD	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.52	4.57	0.35	9.97e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg10820045	chr2:198174542	NA	0.51	5.08	0.38	1.1e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15318007	chr21:47406806	COL6A1	-0.61	-6.52	-0.47	9.83e-10	Obesity-related traits;
PAAD	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.5	5.26	0.39	4.86e-7	Body mass index;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg16606324	chr3:10149918	C3orf24	0.56	4.75	0.36	4.68e-6	Alzheimer's disease;
PAAD	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg16590910	chr6:42928470	GNMT	-0.53	-5.32	-0.4	3.69e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.6	-6.1	-0.44	8.22e-9	Coronary artery disease;
PAAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg18265118	chr7:2139243	MAD1L1	0.52	4.27	0.33	3.42e-5	Neuroticism;
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.92	-10.32	-0.64	3.02e-19	Height;
PAAD	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.7	-0.53	1.62e-12	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.93e-9	Lung cancer;
PAAD	cis	rs12138061	0.954	rs10749685	chr1:50125628	C/T	cg09846084	chr1:50888024	DMRTA2	0.57	4.79	0.36	3.98e-6	Schizophrenia;
PAAD	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.37	2.41e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.57	-5.78	-0.42	4.09e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg09796270	chr17:17721594	SREBF1	0.42	4.66	0.35	6.93e-6	Total body bone mineral density;
PAAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.47	-5.41	-0.4	2.42e-7	Body mass index;
PAAD	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg26205652	chr12:48591994	NA	0.73	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg13870426	chr17:30244630	NA	-0.71	-6.95	-0.49	9.8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg03517284	chr6:25882590	NA	-0.51	-4.79	-0.36	3.9e-6	Blood metabolite levels;
PAAD	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.28	0.33	3.31e-5	Menopause (age at onset);
PAAD	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg09237302	chr4:906077	GAK	-0.41	-5.14	-0.39	8.19e-7	Systemic sclerosis;
PAAD	cis	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg21546286	chr11:48923668	NA	-0.46	-4.77	-0.36	4.31e-6	Height;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.27	0.71	1.72e-24	Prudent dietary pattern;
PAAD	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.55	5.18	0.39	7.04e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg00147172	chr22:46423604	NA	0.4	5.33	0.4	3.56e-7	Dupuytren's disease;
PAAD	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg06569542	chr10:98946673	SLIT1	-0.54	-5.93	-0.43	1.96e-8	Monocyte count;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.96	-12.28	-0.71	1.67e-24	Menopause (age at onset);
PAAD	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.42	-0.56	2.67e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1912528	0.814	rs769671	chr4:140883618	C/T	cg11128457	chr4:140864437	MAML3	-0.33	-4.43	-0.34	1.83e-5	Educational attainment (years of education);
PAAD	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg23352942	chr3:46931381	PTH1R	-0.61	-6.82	-0.48	2.04e-10	Birth weight;
PAAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	5.21	0.39	6.18e-7	Monocyte percentage of white cells;
PAAD	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs859767	0.741	rs6759065	chr2:135389197	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-4.46	-0.34	1.6e-5	Neuroticism;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	6.92	0.49	1.17e-10	Systemic lupus erythematosus;
PAAD	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg15841412	chr13:111365552	ING1	-0.54	-4.57	-0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs10924309	0.737	rs1122734	chr1:245853336	A/T	cg00036263	chr1:245852353	KIF26B	-0.61	-5.94	-0.43	1.83e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26119740	chr11:73881915	C2CD3;PPME1	-0.53	-4.41	-0.34	1.94e-5	Blood protein levels;
PAAD	cis	rs6460942	0.908	rs6978877	chr7:12232690	A/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06209143	chr10:131448811	MGMT	0.54	6.48	0.47	1.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg19254793	chr6:44695348	NA	-0.47	-4.37	-0.33	2.27e-5	Total body bone mineral density;
PAAD	cis	rs71520386	0.632	rs10224419	chr7:22870016	A/G	cg04907244	chr7:22894795	SNORD93	-0.52	-5.56	-0.41	1.2e-7	Fibrinogen levels;
PAAD	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg16230307	chr14:35515116	FAM177A1	0.41	4.34	0.33	2.62e-5	Psoriasis;
PAAD	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg02344993	chr17:57696989	CLTC	0.6	4.96	0.37	1.9e-6	Hemoglobin concentration;
PAAD	trans	rs901683	1.000	rs12781186	chr10:46013438	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg05585544	chr11:47624801	NA	-0.47	-5.23	-0.39	5.41e-7	Subjective well-being;
PAAD	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.81	-5.06	-0.38	1.2e-6	Hypertriglyceridemia;
PAAD	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg00164583	chr16:88554420	ZFPM1	-0.3	-4.27	-0.33	3.38e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-7.51	-0.52	4.6e-12	Menarche (age at onset);
PAAD	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-7.81	-0.54	8.76e-13	Monocyte percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05227111	chr16:75512979	CHST6	0.64	6.75	0.48	2.99e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.78	8.3	0.56	5.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.97	10.96	0.66	5.85e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs9409082	0.652	rs13294242	chr9:108933647	G/A	cg07010948	chr13:79181613	NA	-0.35	-6.71	-0.48	3.62e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg05313129	chr8:58192883	C8orf71	-0.61	-5.28	-0.39	4.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.6	6.34	0.46	2.43e-9	Caffeine consumption;
PAAD	cis	rs11669133	1.000	rs17001074	chr19:11104121	C/T	cg25243385	chr19:11167475	SMARCA4	0.96	4.76	0.36	4.46e-6	LDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22583711	chr7:154795321	PAXIP1;LOC202781	0.6	6.78	0.48	2.49e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.46	4.88	0.37	2.65e-6	Lung cancer;
PAAD	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg22482690	chr17:47019901	SNF8	-0.47	-5.02	-0.38	1.4e-6	Type 2 diabetes;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.94	12.53	0.71	3.5e-25	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg07423050	chr13:99094983	FARP1	0.38	4.28	0.33	3.34e-5	Longevity;
PAAD	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.78	-7.81	-0.54	8.7e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg20607287	chr7:12443886	VWDE	-0.61	-5.65	-0.42	7.71e-8	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14829378	chr9:33167077	B4GALT1	0.66	7.6	0.52	2.8e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.15	-12.67	-0.72	1.43e-25	Hip circumference adjusted for BMI;
PAAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.99	0.54	3.19e-13	Prudent dietary pattern;
PAAD	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.75	-7.43	-0.52	7.16e-12	White matter hyperintensity burden;
PAAD	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.87	-9.73	-0.62	1.05e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11958404	0.932	rs10045597	chr5:157451963	T/C	cg05962755	chr5:157440814	NA	0.93	8.29	0.56	5.7e-14	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg04990556	chr1:26633338	UBXN11	0.66	4.85	0.37	3.02e-6	Obesity-related traits;
PAAD	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.93	-9.31	-0.6	1.34e-16	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.78	9.14	0.6	3.83e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.59e-12	Height;
PAAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.96	7.54	0.52	3.9e-12	Gut microbiome composition (summer);
PAAD	cis	rs7264396	0.887	rs224344	chr20:34036865	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.76	8.29	0.56	5.44e-14	Body mass index;
PAAD	cis	rs10951983	0.750	rs12536544	chr7:6435901	A/G	cg13912435	chr7:6750462	NA	-0.44	-4.29	-0.33	3.17e-5	Coronary artery disease;
PAAD	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg00409905	chr10:38381863	ZNF37A	-0.59	-4.41	-0.34	1.91e-5	Obesity (extreme);
PAAD	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.24e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.69	7.67	0.53	1.97e-12	Lung cancer;
PAAD	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.37	-0.51	1.02e-11	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8.17e-6	Life satisfaction;
PAAD	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.41	4.35	0.33	2.48e-5	Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg22467129	chr15:76604101	ETFA	0.5	5.36	0.4	3.09e-7	Blood metabolite levels;
PAAD	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.88	-0.37	2.61e-6	Menopause (age at onset);
PAAD	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.57	7.54	0.52	4.04e-12	Endometriosis;
PAAD	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.9	0.54	5.35e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs9888739	1.000	rs9745421	chr16:31326081	G/A	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02384565	chr11:64578173	MEN1	0.61	6.52	0.47	9.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-6.85	-0.49	1.75e-10	Lymphocyte counts;
PAAD	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.41	0.61	7.63e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7678296	1.000	rs73140737	chr4:37172922	A/G	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.6e-10	Hair morphology;
PAAD	cis	rs829661	0.843	rs829632	chr2:30733617	G/A	cg12454169	chr2:30669597	LCLAT1	0.65	4.47	0.34	1.53e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs73206853	0.686	rs73194021	chr12:111131893	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.4	0.34	1.99e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.79	-0.36	3.93e-6	High light scatter reticulocyte count;
PAAD	cis	rs35160687	0.901	rs11127026	chr2:86531748	C/T	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08608762	chr6:107348430	C6orf203	-0.62	-6.38	-0.46	2e-9	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04468334	chr7:149414901	KRBA1	0.56	6.41	0.46	1.76e-9	Body fat percentage;
PAAD	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.35e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.01	0.38	1.47e-6	Migraine;
PAAD	cis	rs2061333	0.842	rs7253485	chr19:44625042	A/G	cg23489630	chr19:44645078	ZNF234	-0.58	-4.38	-0.33	2.19e-5	Alzheimer's disease;
PAAD	cis	rs1797885	0.714	rs299638	chr3:12534327	C/T	cg07775309	chr3:12595852	NA	0.4	4.42	0.34	1.89e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.66	-0.35	6.76e-6	Blood metabolite levels;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.23e-5	Testicular germ cell tumor;
PAAD	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg10977910	chr1:84465055	TTLL7	0.48	4.36	0.33	2.42e-5	Obesity-related traits;
PAAD	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg09796270	chr17:17721594	SREBF1	0.46	4.94	0.37	2.05e-6	Total body bone mineral density;
PAAD	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg26597838	chr10:835615	NA	0.51	5.78	0.42	4.19e-8	Survival in rectal cancer;
PAAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.77	0.42	4.41e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs1015213	0.609	rs116867982	chr8:52873855	G/C	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	trans	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg00717180	chr2:96193071	NA	0.61	6.45	0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs4740619	0.630	rs1927701	chr9:15986552	C/T	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-6.62	-0.47	5.83e-10	Monocyte percentage of white cells;
PAAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.63	6.25	0.45	4.03e-9	Mood instability;
PAAD	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Bone mineral density;
PAAD	cis	rs7766436	0.767	rs6456496	chr6:22599386	G/C	cg13666174	chr6:22585274	NA	-0.52	-5.75	-0.42	4.65e-8	Coronary artery disease;
PAAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.5	-4.95	-0.37	1.95e-6	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23977821	chr2:24270452	C2orf44	0.66	6.55	0.47	8.34e-10	Obesity-related traits;
PAAD	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.59	-5.07	-0.38	1.13e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg23465465	chr6:26364728	BTN3A2	0.75	4.43	0.34	1.79e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.65	-0.47	4.91e-10	Neuroticism;
PAAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs7487075	0.619	rs67249026	chr12:46835768	T/C	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.57e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17358307	chr2:235951453	SH3BP4	0.65	6.8	0.48	2.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.92	7.1	0.5	4.58e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg21130718	chr4:1044621	NA	0.48	4.64	0.35	7.42e-6	Recombination rate (males);
PAAD	cis	rs62264129	0.500	rs11923402	chr3:112050148	G/T	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.91	-0.37	2.29e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.74	8.46	0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7168353	0.519	rs8028642	chr15:93638128	G/A	cg12595281	chr15:93633172	RGMA	0.39	5.19	0.39	6.7e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg05341575	chr12:125625032	AACS	-0.49	-4.59	-0.35	9.38e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg10978503	chr1:24200527	CNR2	-0.46	-5.27	-0.39	4.65e-7	Immature fraction of reticulocytes;
PAAD	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg11764359	chr7:65958608	NA	0.8	5.51	0.41	1.51e-7	Diabetic kidney disease;
PAAD	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg27234864	chr13:21295941	IL17D	-0.6	-5.42	-0.4	2.34e-7	Dental caries;
PAAD	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg10437265	chr15:77819839	NA	0.43	4.79	0.36	3.92e-6	Type 2 diabetes;
PAAD	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.76	8.21	0.55	8.61e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.51	6.87	0.49	1.55e-10	Life satisfaction;
PAAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.43	-4.27	-0.33	3.42e-5	Body mass index;
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.16	-0.39	7.77e-7	Tonsillectomy;
PAAD	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.37	-4.48	-0.34	1.46e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4281086	0.561	rs4997498	chr8:10352622	G/C	cg01072821	chr8:10382165	T-SP1	-0.4	-4.38	-0.33	2.21e-5	Obesity-related traits;
PAAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-1.07	-10.4	-0.64	1.85e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.34	0.68	5.46e-22	Cannabis dependence symptom count;
PAAD	cis	rs72960926	0.744	rs72952273	chr6:74926284	C/T	cg03266952	chr6:74778945	NA	-1.1	-6.46	-0.46	1.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs256277	0.657	rs2456907	chr5:111371462	G/A	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.53	5.24	0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.89	-7.34	-0.51	1.23e-11	Obesity-related traits;
PAAD	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.73	-7.3	-0.51	1.51e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24843246	chr19:7621952	PNPLA6	-0.57	-6.31	-0.46	2.85e-9	Monocyte percentage of white cells;
PAAD	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg09389931	chr14:103748217	NA	0.4	4.3	0.33	3.01e-5	Coronary artery disease;
PAAD	cis	rs12935418	0.552	rs2549835	chr16:81022610	G/C	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.34e-8	Mean corpuscular volume;
PAAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.55	5.87	0.43	2.6e-8	Menopause (age at onset);
PAAD	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.81	9.09	0.59	4.95e-16	Metabolic syndrome;
PAAD	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.54	-4.36	-0.33	2.4e-5	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06251068	chr11:910944	CHID1	0.67	6.43	0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs6850606	0.537	rs12508134	chr4:42868769	T/C	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.59	-6.05	-0.44	1.07e-8	Menopause (age at onset);
PAAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.33	0.4	3.42e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg09695851	chr17:3907499	NA	-0.68	-7.05	-0.5	5.74e-11	Type 2 diabetes;
PAAD	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg16898833	chr6:26189333	HIST1H4D	0.68	5.22	0.39	5.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg10756475	chr4:1757242	NA	0.46	4.44	0.34	1.74e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.75	-6.25	-0.45	4.02e-9	Neuroticism;
PAAD	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.84	6.0	0.44	1.36e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09597638	chr17:3907349	NA	-0.7	-7.52	-0.52	4.5e-12	Type 2 diabetes;
PAAD	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.39	4.3	0.33	3.05e-5	Dilated cardiomyopathy;
PAAD	cis	rs11955175	1.000	rs73080591	chr5:40634687	T/C	cg17351974	chr5:40835760	RPL37	0.79	4.64	0.35	7.51e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18297960	chr7:1142765	C7orf50	-0.55	-4.4	-0.34	2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg15226275	chr6:116381976	FRK	-0.28	-4.46	-0.34	1.56e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26850624	chr5:429559	AHRR	0.47	5.85	0.43	2.88e-8	Cystic fibrosis severity;
PAAD	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs2834188	0.669	rs1467845	chr21:34666376	A/G	cg04842828	chr21:34696676	IFNAR1	0.5	5.16	0.39	7.56e-7	Narcolepsy;
PAAD	cis	rs11811982	0.744	rs79392739	chr1:227459572	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.06	-0.38	1.2e-6	Platelet count;
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.71	5.4	0.4	2.5e-7	Type 2 diabetes;
PAAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg03676636	chr4:99064102	C4orf37	-0.25	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.62	4.76	0.36	4.53e-6	Osteoarthritis;
PAAD	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg03315344	chr16:75512273	CHST6	-0.67	-5.55	-0.41	1.23e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs6129846	1.000	rs6129846	chr20:40107314	A/G	cg23060191	chr20:39666765	PRO0628;TOP1	0.74	4.35	0.33	2.53e-5	Verbal declarative memory;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-5.87	-0.43	2.58e-8	Prudent dietary pattern;
PAAD	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg11077631	chr22:50617003	PANX2	0.52	4.98	0.37	1.7e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27436995	chr16:743998	FBXL16	-0.36	-4.28	-0.33	3.24e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04705907	chr1:169764193	C1orf112;C1orf156	0.68	6.73	0.48	3.28e-10	Obesity-related traits;
PAAD	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-5.62	-0.41	8.87e-8	Schizophrenia;
PAAD	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.04	0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg02631450	chr22:32366979	NA	0.99	5.28	0.39	4.45e-7	Childhood ear infection;
PAAD	cis	rs6137287	0.883	rs6047319	chr20:21218345	A/G	cg04219410	chr20:21106687	PLK1S1	-0.42	-4.76	-0.36	4.51e-6	Height;
PAAD	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg03264133	chr6:25882463	NA	-0.49	-4.68	-0.35	6.36e-6	Blood metabolite levels;
PAAD	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg00409905	chr10:38381863	ZNF37A	-0.59	-4.41	-0.34	1.91e-5	Obesity (extreme);
PAAD	cis	rs6681460	0.549	rs1373909	chr1:67040875	A/G	cg02459107	chr1:67143332	SGIP1	0.66	7.1	0.5	4.42e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.63	8.59	0.57	9.52e-15	Airflow obstruction;
PAAD	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12165864	chr7:66369176	NA	-0.79	-5.29	-0.39	4.19e-7	Diabetic kidney disease;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.89	11.17	0.67	1.61e-21	Monocyte percentage of white cells;
PAAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.91	5.96	0.44	1.68e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.65	6.22	0.45	4.51e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs11811982	0.793	rs115632182	chr1:227510459	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09392381	chr15:63114897	MIR190;TLN2	-0.57	-6.26	-0.45	3.66e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9287719	0.649	rs2024432	chr2:10731474	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs10861661	0.963	rs11113118	chr12:107199142	G/A	cg15890332	chr12:107067104	RFX4	0.51	5.14	0.38	8.25e-7	Triglyceride levels;
PAAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.74	-8.51	-0.57	1.58e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg15212455	chr7:39170539	POU6F2	0.39	5.68	0.42	6.6e-8	IgG glycosylation;
PAAD	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg11995313	chr8:8860691	ERI1	0.48	4.85	0.37	3.02e-6	Joint mobility (Beighton score);
PAAD	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.66	5.15	0.39	7.78e-7	Vitiligo;
PAAD	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs500891	0.574	rs3798890	chr6:84119361	G/A	cg08257003	chr6:84140564	ME1	0.35	4.27	0.33	3.47e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.29	0.33	3.1e-5	Adiposity;
PAAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.4	7.48	0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg02527881	chr3:46936655	PTH1R	0.38	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.51	6.15	0.45	6.56e-9	Height;
PAAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg07856975	chr6:36356162	ETV7	-0.49	-5.72	-0.42	5.49e-8	Platelet distribution width;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.85	13.14	0.73	7.75e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.83	-9.23	-0.6	2.17e-16	Blood protein levels;
PAAD	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg13206674	chr6:150067644	NUP43	0.58	6.22	0.45	4.61e-9	Testicular germ cell tumor;
PAAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.69	-7.85	-0.54	6.91e-13	Height;
PAAD	cis	rs1879734	0.731	rs4927028	chr1:54161545	T/C	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19417588	chr11:68529067	CPT1A	0.53	6.44	0.46	1.49e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03067192	chr7:72300134	SBDSP;TYW1B	0.61	6.71	0.48	3.57e-10	Myopia (pathological);
PAAD	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.66	-6.11	-0.44	8.05e-9	Blood metabolite levels;
PAAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg14709524	chr16:89940631	TCF25	0.74	4.37	0.33	2.33e-5	Skin colour saturation;
PAAD	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.91	12.22	0.7	2.41e-24	Body mass index;
PAAD	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg06714761	chr1:201096289	NA	0.29	4.29	0.33	3.22e-5	Permanent tooth development;
PAAD	cis	rs10426930	0.651	rs759993	chr19:5080200	C/T	cg25246084	chr19:4971487	KDM4B	0.37	4.59	0.35	9.31e-6	Monocyte percentage of white cells;
PAAD	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.86	-7.66	-0.53	2.02e-12	Obesity;Body mass index;
PAAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3.02e-7	Heart rate;
PAAD	cis	rs78761021	0.720	rs55740146	chr17:9796599	G/A	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.67	-6.52	-0.47	9.76e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9644630	0.864	rs4339658	chr8:19347059	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.9	0.37	2.42e-6	Oropharynx cancer;
PAAD	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.73	7.63	0.53	2.38e-12	Body mass index;
PAAD	cis	rs6594713	0.572	rs6898400	chr5:112678005	C/A	cg12552261	chr5:112820674	MCC	0.61	5.06	0.38	1.19e-6	Brain cytoarchitecture;
PAAD	cis	rs7567389	0.511	rs61185143	chr2:128165478	T/C	cg09760422	chr2:128146352	NA	-0.51	-9.28	-0.6	1.67e-16	Self-rated health;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.75	-6.91	-0.49	1.23e-10	Coronary artery disease;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.67	-7.22	-0.51	2.3e-11	Iron status biomarkers;
PAAD	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.46	0.34	1.58e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.62	6.3	0.46	2.99e-9	Motion sickness;
PAAD	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.29	-0.64	3.58e-19	Obesity-related traits;
PAAD	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.72	-7.26	-0.51	1.89e-11	Itch intensity from mosquito bite;
PAAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.71	6.04	0.44	1.13e-8	Inflammatory skin disease;
PAAD	cis	rs2997447	0.761	rs60404932	chr1:26454881	C/T	cg24519413	chr1:26490540	NA	0.58	5.08	0.38	1.1e-6	QRS complex (12-leadsum);
PAAD	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.56e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.42	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25018208	chr6:37338607	RNF8	0.57	6.29	0.45	3.22e-9	Smoking initiation;
PAAD	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	1.15	12.72	0.72	1.09e-25	Post bronchodilator FEV1;
PAAD	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.28	-5.39	-0.4	2.65e-7	Urinary metabolites;
PAAD	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15084286	chr11:17036142	PLEKHA7	0.54	5.19	0.39	6.55e-7	Glaucoma (primary angle closure);
PAAD	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.37	5.01	0.38	1.5e-6	Blood protein levels;
PAAD	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.6	6.34	0.46	2.5e-9	Schizophrenia;
PAAD	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-10.71	-0.66	2.78e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6710503	0.574	rs62142283	chr2:24787912	C/T	cg21151432	chr2:25142229	ADCY3	-0.36	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs17776563	0.959	rs28687418	chr15:89115862	G/A	cg27664085	chr15:89157815	NA	0.32	4.28	0.33	3.33e-5	Thyroid hormone levels;
PAAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.67	0.62	1.53e-17	Cognitive function;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12233386	chr17:38464679	RARA	-0.52	-7.35	-0.51	1.15e-11	Monocyte percentage of white cells;
PAAD	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	4.38	0.34	2.16e-5	Aortic root size;
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg11601000	chr22:42348013	LOC339674	-0.4	-4.66	-0.35	6.84e-6	Cognitive function;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.78	-7.52	-0.52	4.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.45	-0.4	2.02e-7	Morning vs. evening chronotype;
PAAD	cis	rs9649465	1.000	rs1073670	chr7:123345029	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg03781084	chr7:26191726	NFE2L3	0.48	4.65	0.35	7.23e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02071572	chr4:1403502	NA	0.49	6.25	0.45	3.97e-9	Longevity;
PAAD	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs28647808	1.000	rs13940	chr9:136271546	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.79	-8.2	-0.55	9.52e-14	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25401754	chr6:153304305	FBXO5	0.6	6.46	0.46	1.31e-9	Myopia (pathological);
PAAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.7	8.11	0.55	1.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg05784532	chr1:230284198	GALNT2	-0.67	-5.9	-0.43	2.25e-8	Coronary artery disease;
PAAD	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg19640130	chr10:64028056	RTKN2	-0.37	-4.53	-0.34	1.21e-5	Rheumatoid arthritis;
PAAD	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.61	6.71	0.48	3.54e-10	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.77	9.17	0.6	3.19e-16	Emphysema distribution in smoking;
PAAD	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.48	-4.84	-0.37	3.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg19257562	chr1:2043853	PRKCZ	-0.39	-4.38	-0.33	2.18e-5	Coronary artery disease;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg01815783	chr4:1047043	NA	-0.45	-5.87	-0.43	2.58e-8	Recombination rate (males);
PAAD	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg16964102	chr10:135390573	NA	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs2594989	0.943	rs4684070	chr3:11437551	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-4.5	-0.34	1.35e-5	Circulating chemerin levels;
PAAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.51	-5.27	-0.39	4.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2992756	0.519	rs2992740	chr1:18810344	G/T	cg14356550	chr1:18808102	KLHDC7A	-0.45	-4.76	-0.36	4.52e-6	Breast cancer;
PAAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-4.83	-0.37	3.25e-6	Morning vs. evening chronotype;
PAAD	cis	rs41271473	0.687	rs35832347	chr1:228883738	G/C	cg16512390	chr1:228756714	NA	0.56	4.82	0.36	3.47e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.76	7.84	0.54	7.16e-13	Sleep quality;
PAAD	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24179065	chr6:35888551	SRPK1	0.69	7.99	0.54	3.1400000000000003e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.8	-7.18	-0.5	2.94e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.57	-6.5	-0.47	1.08e-9	Migraine;
PAAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs469568	0.523	rs11741111	chr5:178666752	G/C	cg08999896	chr5:178685787	ADAMTS2	0.51	5.3	0.4	3.96e-7	Stroke (pediatric);
PAAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.01	-0.38	1.5e-6	Electroencephalogram traits;
PAAD	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg07943548	chr15:86304357	KLHL25	-0.78	-6.32	-0.46	2.69e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg01815783	chr4:1047043	NA	-0.46	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs3784262	0.565	rs9635346	chr15:58298118	C/G	cg12031962	chr15:58353849	ALDH1A2	0.38	4.55	0.35	1.1e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.65	6.34	0.46	2.51e-9	Menarche (age at onset);
PAAD	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	0.98	7.15	0.5	3.5e-11	Lung disease severity in cystic fibrosis;
PAAD	trans	rs9942416	0.715	rs2112347	chr5:75015242	T/G	cg03931927	chr7:65215969	CCT6P1	-0.63	-6.3	-0.46	3.1e-9	Age-related disease endophenotypes;
PAAD	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs3736485	0.966	rs12372948	chr15:51894311	A/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.31	-0.33	2.94e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22042144	chr1:211432745	RCOR3	0.64	6.36	0.46	2.2e-9	Obesity-related traits;
PAAD	cis	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg01099526	chr6:26124504	HIST1H2AC;HIST1H2BC	0.78	4.42	0.34	1.9e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.8	9.6	0.61	2.33e-17	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg07362569	chr17:61921086	SMARCD2	-0.42	-4.78	-0.36	4.04e-6	Height;
PAAD	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.3	0.6	1.42e-16	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	4.79	0.36	3.97e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.82	-0.43	3.34e-8	Menopause (age at onset);
PAAD	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.54	4.86	0.37	2.92e-6	Anterior chamber depth;
PAAD	cis	rs639012	0.503	rs7114401	chr11:85839935	C/T	cg07180834	chr11:85838833	NA	-0.37	-4.26	-0.33	3.5e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.59	-5.17	-0.39	7.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg13282195	chr8:144660772	NAPRT1	0.77	5.74	0.42	4.91e-8	Attention deficit hyperactivity disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16652790	chr16:776895	HAGHL;CCDC78	0.62	6.32	0.46	2.8e-9	Myopia (pathological);
PAAD	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.71	8.32	0.56	4.75e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.12	0.5	4.09e-11	Lung cancer in ever smokers;
PAAD	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.9	-0.43	2.25e-8	Rheumatoid arthritis;
PAAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.6	-7.43	-0.52	7.13e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6604026	0.656	rs11164843	chr1:93416142	A/C	cg17283838	chr1:93427260	FAM69A	0.61	5.64	0.42	8.07e-8	Multiple sclerosis;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1371614	0.523	rs12468721	chr2:27183751	G/A	cg00617064	chr2:27272375	NA	0.5	5.23	0.39	5.45e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.63	-6.93	-0.49	1.12e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg02454025	chr1:11042201	C1orf127	1.26	15.5	0.78	4.24e-33	Ewing sarcoma;
PAAD	cis	rs4713118	0.550	rs9368527	chr6:27679445	C/A	cg23153227	chr6:27725408	NA	0.43	4.48	0.34	1.45e-5	Parkinson's disease;
PAAD	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.64	-0.57	7.34e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.8	8.41	0.56	2.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg15654264	chr1:150340011	RPRD2	0.52	5.09	0.38	1.06e-6	Migraine;
PAAD	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg07338119	chr7:157211683	NA	-0.45	-4.51	-0.34	1.26e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8067354	0.574	rs2531898	chr17:58012351	G/C	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.31	-0.51	1.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg21929781	chr1:2537748	MMEL1	0.48	5.08	0.38	1.1e-6	Ulcerative colitis;
PAAD	cis	rs2718812	1.000	rs2718812	chr3:133399702	C/T	cg08048268	chr3:133502702	NA	0.43	5.24	0.39	5.18e-7	Iron status biomarkers;
PAAD	cis	rs116139393	0.505	rs3801033	chr7:6734103	A/G	cg09896999	chr7:6746977	ZNF12	0.49	4.29	0.33	3.16e-5	Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.28	-0.39	4.34e-7	Monocyte count;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.33	4.41	0.34	1.91e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.81	7.23	0.51	2.23e-11	Cancer;
PAAD	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs1883415	0.534	rs2760145	chr6:24478813	T/C	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.75	8.56	0.57	1.14e-14	Lung cancer;
PAAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09695851	chr17:3907499	NA	0.84	8.53	0.57	1.41e-14	Type 2 diabetes;
PAAD	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg02077977	chr1:231376624	GNPAT;C1orf131	-0.44	-4.35	-0.33	2.49e-5	Hemoglobin concentration;
PAAD	cis	rs73198271	0.628	rs11776981	chr8:8589459	C/T	cg01851573	chr8:8652454	MFHAS1	0.65	4.9	0.37	2.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.3	0.46	3e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.46	4.35	0.33	2.52e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.65	-0.42	7.77e-8	Mood instability;
PAAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.51	0.65	9.11e-20	Menopause (age at onset);
PAAD	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.01	0.38	1.52e-6	Common traits (Other);
PAAD	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs346785	0.692	rs6501882	chr17:74289875	C/T	cg09812376	chr17:74270190	QRICH2	-0.48	-6.03	-0.44	1.17e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.74	-7.81	-0.54	8.75e-13	Obesity-related traits;
PAAD	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.54	-0.35	1.13e-5	Neuroticism;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg17650747	chr5:1873721	NA	0.45	4.57	0.35	1.01e-5	Cardiovascular disease risk factors;
PAAD	cis	rs10078	0.559	rs6893791	chr5:430413	T/C	cg08916839	chr5:415575	AHRR	0.58	4.36	0.33	2.42e-5	Fat distribution (HIV);
PAAD	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg25457927	chr22:38595422	NA	-0.39	-5.6	-0.41	9.96e-8	Breast cancer;
PAAD	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.27	0.45	3.63e-9	Bladder cancer;
PAAD	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.95	9.1	0.59	4.65e-16	Psoriasis;
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.4	-4.98	-0.37	1.72e-6	Prostate cancer;
PAAD	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg12661370	chr5:149340060	SLC26A2	0.64	5.44	0.4	2.06e-7	HIV-1 control;
PAAD	cis	rs9633835	0.519	rs10766073	chr11:13317964	A/G	cg15603424	chr11:13300592	ARNTL	0.55	4.8	0.36	3.77e-6	Body mass index;
PAAD	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg00105475	chr2:10696890	NA	-0.62	-6.39	-0.46	1.94e-9	Prostate cancer;
PAAD	cis	rs77880822	0.562	rs77258412	chr20:1249168	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.95	0.37	1.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9810890	1.000	rs73198881	chr3:128542760	T/G	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg23033748	chr14:75592666	NEK9	-0.45	-5.59	-0.41	1.03e-7	Height;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.89	12.21	0.7	2.57e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg19442545	chr10:75533431	FUT11	-0.56	-5.75	-0.42	4.72e-8	Inflammatory bowel disease;
PAAD	cis	rs1891275	0.551	rs4933684	chr10:93407562	C/T	cg07889827	chr10:93443413	NA	-0.4	-4.31	-0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg21191810	chr6:118973309	C6orf204	0.47	5.94	0.43	1.9e-8	Electrocardiographic conduction measures;
PAAD	cis	rs7255045	0.711	rs2077544	chr19:12963285	C/T	cg09980403	chr19:12975529	MAST1	0.29	4.25	0.33	3.76e-5	Mean corpuscular volume;
PAAD	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.88	7.34	0.51	1.22e-11	Neutrophil percentage of white cells;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg00149659	chr3:10157352	C3orf10	0.54	4.25	0.33	3.69e-5	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03664139	chr6:101329504	ASCC3	0.66	7.81	0.54	8.69e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8044995	0.929	rs3743739	chr16:68293320	T/C	cg05110241	chr16:68378359	PRMT7	-1.0	-7.71	-0.53	1.55e-12	Schizophrenia;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.65	4.76	0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.81	8.54	0.57	1.27e-14	Mortality in heart failure;
PAAD	cis	rs9463078	0.764	rs6904015	chr6:44785502	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.05	-0.38	1.26e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13826154	chr19:45754942	MARK4	0.43	4.27	0.33	3.38e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26539736	chr2:10666585	NA	0.64	6.49	0.47	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20060928	chr8:135708851	ZFAT	0.67	6.73	0.48	3.17e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6960043	0.584	rs2189724	chr7:15041822	G/A	cg19272540	chr7:15055459	NA	0.32	5.66	0.42	7.48e-8	Type 2 diabetes;
PAAD	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.58	-5.49	-0.41	1.63e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.8	8.19	0.55	9.93e-14	Tuberculosis;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03605463	chr16:89740564	NA	0.47	4.37	0.33	2.26e-5	Vitiligo;
PAAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.62	8.0	0.54	3e-13	Renal cell carcinoma;
PAAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	5.59	0.41	1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs959260	1.000	rs4789186	chr17:73386086	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.71	0.48	3.67e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12304921	0.639	rs1112391	chr12:51475963	C/T	cg18059802	chr12:51347058	HIGD1C	0.63	5.19	0.39	6.55e-7	Type 2 diabetes;
PAAD	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg07967677	chr1:161008977	TSTD1	0.5	4.41	0.34	1.96e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs75920871	1.000	rs7934763	chr11:116792357	T/G	cg04087571	chr11:116723030	SIK3	-0.47	-4.79	-0.36	3.98e-6	Subjective well-being;
PAAD	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg08999081	chr20:33150536	PIGU	-0.48	-5.16	-0.39	7.7e-7	Height;
PAAD	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.52	7.02	0.5	6.75e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.43e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-22.31	-0.88	8.47e-50	Myeloid white cell count;
PAAD	cis	rs2862774	0.598	rs721870	chr2:113805806	T/G	cg06156847	chr2:113672199	IL1F7	-0.59	-5.21	-0.39	6.13e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.71	-6.12	-0.44	7.53e-9	Obesity (extreme);
PAAD	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.48	-5.09	-0.38	1.03e-6	Platelet distribution width;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	0.744	rs4385272	chr6:75063124	G/A	cg13435101	chr6:74171350	MTO1	0.85	4.55	0.35	1.11e-5	Metabolite levels (MHPG);
PAAD	cis	rs6496932	1.000	rs2002642	chr15:85827744	T/C	cg19183879	chr15:85880815	NA	0.55	4.64	0.35	7.45e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs6782025	0.837	rs338969	chr3:120944355	G/A	cg16417163	chr3:121280760	NA	-0.46	-4.73	-0.36	5.08e-6	Aging (facial);
PAAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs1497828	1.000	rs2818967	chr1:217568218	T/G	cg04411442	chr1:217543379	NA	0.5	4.89	0.37	2.51e-6	Dialysis-related mortality;
PAAD	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.3	0.39	4.03e-7	Ovarian reserve;
PAAD	cis	rs2882667	0.690	rs7722965	chr5:138100455	T/C	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs16958440	1.000	rs62096468	chr18:44637566	C/A	cg17192377	chr18:44677553	HDHD2	1.07	6.69	0.48	3.96e-10	Sitting height ratio;
PAAD	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.45	4.97	0.37	1.77e-6	Age of smoking initiation;
PAAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg24519413	chr1:26490540	NA	-0.44	-5.64	-0.42	8.04e-8	Height;
PAAD	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.4	-6.01	-0.44	1.33e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.59	0.47	6.84e-10	Educational attainment;
PAAD	cis	rs847851	0.833	rs3817473	chr6:34949451	C/T	cg13196216	chr6:34231128	NA	0.61	5.0	0.38	1.59e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3826795	0.569	rs73059722	chr19:46796418	G/A	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs4759375	0.667	rs28376696	chr12:123849863	T/C	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24360513	chr1:249120106	SH3BP5L	0.63	6.68	0.48	4.21e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg05042697	chr2:10830656	NOL10	0.42	4.3	0.33	3.02e-5	Prostate cancer;
PAAD	cis	rs6494488	0.500	rs8029243	chr15:64921736	G/A	cg16425858	chr15:64791681	ZNF609	0.94	5.1	0.38	9.86e-7	Coronary artery disease;
PAAD	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.73	-0.58	4.31e-15	Exhaled nitric oxide output;
PAAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg18128536	chr17:47092178	IGF2BP1	0.41	4.61	0.35	8.39e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg12362517	chr11:133800685	IGSF9B	0.68	6.5	0.47	1.1e-9	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg22482690	chr17:47019901	SNF8	0.5	5.43	0.4	2.19e-7	Type 2 diabetes;
PAAD	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-6.97	-0.49	8.98e-11	Body mass index (adult);
PAAD	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.67	-0.42	7.12e-8	Coronary artery calcification;
PAAD	cis	rs3026101	0.671	rs3026128	chr17:5293962	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.44	-0.34	1.7e-5	Dupuytren's disease;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.01e-8	Tonsillectomy;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg19500098	chr13:21900506	NA	0.58	5.99	0.44	1.49e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.54	4.78	0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.93e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14968838	chr1:11724397	FBXO6	0.6	6.51	0.47	1.05e-9	Myopia (pathological);
PAAD	cis	rs2412776	0.673	rs7659866	chr4:57954901	G/A	cg26099281	chr4:57773868	REST	-0.5	-4.3	-0.33	3.07e-5	Blood protein levels;
PAAD	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg10523679	chr1:76189770	ACADM	-0.51	-4.86	-0.37	2.95e-6	Daytime sleep phenotypes;
PAAD	cis	rs3809060	0.878	rs5030179	chr11:32448255	T/C	cg27259320	chr11:32460587	WIT1	0.35	4.38	0.33	2.19e-5	Inguinal hernia;
PAAD	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg16898833	chr6:26189333	HIST1H4D	0.76	4.28	0.33	3.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs950881	0.799	rs72823669	chr2:102982033	G/T	cg20060108	chr2:102954350	IL1RL1	0.57	4.5	0.34	1.34e-5	Allergy;
PAAD	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.86	8.66	0.57	6.54e-15	Uric acid levels;
PAAD	cis	rs73019876	0.869	rs7247121	chr19:22161490	T/C	cg11619707	chr19:22235551	ZNF257	-0.4	-4.38	-0.33	2.22e-5	Testicular germ cell tumor;
PAAD	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg01868782	chr6:126071099	HEY2	0.45	5.32	0.4	3.71e-7	Brugada syndrome;
PAAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg19723775	chr5:179050963	HNRNPH1	0.59	5.46	0.4	1.93e-7	Lung cancer;
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9361491	0.508	rs4706718	chr6:79416883	G/A	cg05283184	chr6:79620031	NA	-0.4	-5.03	-0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9395066	0.545	rs1831310	chr6:44976725	G/A	cg25276700	chr6:44698697	NA	0.49	5.62	0.41	8.85e-8	Height;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.31	-0.33	2.96e-5	Longevity;Endometriosis;
PAAD	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.77	6.18	0.45	5.53e-9	Height;
PAAD	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.24	-0.39	5.37e-7	Mood instability;
PAAD	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.74	7.75	0.53	1.19e-12	Height;
PAAD	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.67	-4.73	-0.36	5.17e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.8	-0.36	3.78e-6	Body mass index;
PAAD	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density (age over 60);Total body bone mineral density;
PAAD	cis	rs17169634	1.000	rs75353220	chr7:34094036	A/G	cg24927974	chr7:35078269	DPY19L1	-0.63	-5.23	-0.39	5.59e-7	Alzheimer's disease;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.5	5.25	0.39	5.14e-7	Obesity-related traits;
PAAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg21366198	chr4:185655624	MLF1IP	0.5	4.41	0.34	1.98e-5	Kawasaki disease;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07930192	chr7:1003750	NA	0.39	4.91	0.37	2.32e-6	Longevity;Endometriosis;
PAAD	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.58	-6.47	-0.46	1.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-6.58	-0.47	7.02e-10	Menarche (age at onset);
PAAD	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.1	-9.8	-0.62	7.07e-18	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg18964960	chr10:1102726	WDR37	0.95	4.73	0.36	5.15e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.0	11.83	0.69	2.62e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12304921	0.810	rs73092534	chr12:51358380	C/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.16	-0.39	7.54e-7	Type 2 diabetes;
PAAD	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.66	-4.56	-0.35	1.05e-5	LDL cholesterol levels;
PAAD	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.56	0.41	1.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg01426195	chr3:39028469	NA	-0.63	-6.2	-0.45	5.19e-9	Handedness;
PAAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.85	9.42	0.61	6.97e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs501120	0.657	rs114070077	chr10:44742911	A/G	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg11995313	chr8:8860691	ERI1	0.51	5.15	0.39	8.1e-7	Joint mobility (Beighton score);
PAAD	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01689892	chr11:207412	BET1L;RIC8A	0.62	6.88	0.49	1.45e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.94	6.57	0.47	7.47e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00603274	chr11:61596626	FADS2	-0.59	-4.57	-0.35	9.92e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs499368	0.519	rs216245	chr12:310419	G/T	cg24087681	chr12:298268	NA	0.42	4.31	0.33	2.94e-5	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs939584	1.000	rs10865548	chr2:631606	A/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs17534004	1.000	rs17505772	chr13:31456002	G/C	cg00570269	chr13:31480942	C13orf33	0.58	4.4	0.34	1.99e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.51	4.77	0.36	4.23e-6	Endometrial cancer;
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.99e-9	Lung cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01263691	chr6:52535928	TMEM14A	0.61	6.36	0.46	2.22e-9	Myopia (pathological);
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.62	-6.71	-0.48	3.71e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.94	-6.79	-0.48	2.31e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.86	-5.54	-0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02244288	chr16:89573955	SPG7	-0.33	-4.26	-0.33	3.6e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg27471124	chr11:109292789	C11orf87	-0.24	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs4621152	0.737	rs4435428	chr2:217886970	G/A	cg21875423	chr2:217559867	IGFBP5	-0.46	-4.57	-0.35	1.01e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2544527	0.586	rs2544532	chr2:15904993	C/T	cg26669897	chr2:15909070	NA	-0.46	-4.56	-0.35	1.06e-5	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs10901513	0.932	rs12356665	chr10:127663380	G/A	cg22975853	chr10:127789788	ADAM12	0.4	4.32	0.33	2.82e-5	Visceral fat;
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg19761014	chr17:28927070	LRRC37B2	0.92	5.59	0.41	1.05e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg21209356	chr22:37319042	CSF2RB	-0.36	-4.49	-0.34	1.39e-5	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
PAAD	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-4.63	-0.35	7.91e-6	Mean corpuscular volume;
PAAD	cis	rs1519814	1.000	rs1519814	chr8:121115024	T/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.44	-0.4	2.09e-7	Breast cancer;
PAAD	cis	rs8060686	0.858	rs7191129	chr16:67801391	A/G	cg09835421	chr16:68378352	PRMT7	-0.62	-4.63	-0.35	7.91e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs13242816	0.881	rs13235183	chr7:116140149	G/T	cg16553024	chr7:116138462	CAV2	-0.7	-5.1	-0.38	9.81e-7	P wave duration;
PAAD	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-4.73	-0.36	5.16e-6	Joint mobility (Beighton score);
PAAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg25319279	chr11:5960081	NA	-0.63	-5.86	-0.43	2.74e-8	DNA methylation (variation);
PAAD	trans	rs1585440	0.962	rs7992861	chr13:66415462	G/T	cg16023991	chr13:45140260	TSC22D1	0.64	6.59	0.47	6.87e-10	Pancreatic cancer;
PAAD	cis	rs7534824	0.625	rs72736234	chr1:101526098	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.69	0.36	6.06e-6	Refractive astigmatism;
PAAD	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg15017067	chr4:17643749	FAM184B	0.41	4.39	0.34	2.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.48	5.05	0.38	1.27e-6	Bladder cancer;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	1.06	8.51	0.57	1.51e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs76917914	0.589	rs7022455	chr9:100866872	C/T	cg03040243	chr9:100819229	NANS	-0.5	-4.35	-0.33	2.48e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg16950941	chr11:66035639	RAB1B	0.67	5.87	0.43	2.68e-8	Gout;
PAAD	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg09592244	chr17:37024020	NA	0.41	4.31	0.33	2.92e-5	Height;
PAAD	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.69	7.18	0.5	2.88e-11	Brugada syndrome;
PAAD	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg19582115	chr14:103436037	CDC42BPB	-0.47	-4.61	-0.35	8.43e-6	Blood metabolite levels;
PAAD	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs12760731	0.720	rs16852717	chr1:178309723	T/C	cg00404053	chr1:178313656	RASAL2	0.68	4.86	0.37	2.86e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18023558	chr4:10118459	WDR1	0.71	7.84	0.54	7.22e-13	Myopia (pathological);
PAAD	trans	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg15770106	chr1:208133116	NA	-0.64	-6.31	-0.46	2.88e-9	Corneal structure;
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg27094323	chr7:1216898	NA	-0.42	-4.6	-0.35	8.68e-6	Longevity;Endometriosis;
PAAD	cis	rs6142102	0.961	rs6087557	chr20:32698275	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	4.79	0.36	3.84e-6	Skin pigmentation;
PAAD	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.17	-0.39	7.22e-7	Reticulocyte count;
PAAD	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg17947172	chr1:204966197	NFASC	0.41	4.42	0.34	1.9e-5	Mean platelet volume;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.91	9.81	0.62	6.75e-18	Cleft lip with or without cleft palate;
PAAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.92	11.85	0.69	2.31e-23	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.54	5.83	0.43	3.26e-8	Menopause (age at onset);
PAAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs17824933	1.000	rs12797044	chr11:60768018	T/A	cg16817237	chr11:60793675	NA	0.49	5.75	0.42	4.85e-8	Multiple sclerosis;
PAAD	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Electroencephalogram traits;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.85e-7	Life satisfaction;
PAAD	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.34	0.6	1.13e-16	Bipolar disorder;
PAAD	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.35	0.4	3.16e-7	Ovarian reserve;
PAAD	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4513299	0.601	rs1948882	chr2:115012396	C/G	cg12978357	chr2:114426529	NA	-0.44	-4.4	-0.34	2.03e-5	Inflammatory biomarkers;
PAAD	cis	rs58521262	1.000	rs58521262	chr19:23205184	G/A	cg22640819	chr19:22990650	NA	0.36	4.3	0.33	2.99e-5	Testicular germ cell tumor;
PAAD	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-6.39	-0.46	1.93e-9	Total cholesterol levels;
PAAD	cis	rs6442522	0.643	rs7620149	chr3:15500896	A/G	cg16303742	chr3:15540471	COLQ	-0.48	-5.18	-0.39	6.81e-7	Uric acid levels;
PAAD	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.65e-8	Coronary artery disease;
PAAD	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.92	-11.97	-0.7	1.12e-23	Ulcerative colitis;
PAAD	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.49	-4.97	-0.37	1.77e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs6531209	0.926	rs11678155	chr2:20339792	C/A	cg18868357	chr2:20425395	SDC1	-0.51	-4.26	-0.33	3.62e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg24848339	chr3:12840334	CAND2	0.46	4.99	0.38	1.61e-6	QRS complex (12-leadsum);
PAAD	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.76	-6.78	-0.48	2.44e-10	Blood pressure (smoking interaction);
PAAD	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-7.44	-0.52	7.03e-12	Morning vs. evening chronotype;
PAAD	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.67	-5.77	-0.42	4.29e-8	Common traits (Other);
PAAD	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.87	-8.01	-0.55	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.52	5.19	0.39	6.58e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.22	-0.39	5.72e-7	Monocyte count;
PAAD	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg16964102	chr10:135390573	NA	0.42	4.54	0.35	1.14e-5	Obesity-related traits;
PAAD	cis	rs73058052	0.542	rs10414643	chr19:50097784	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.56	-4.77	-0.36	4.2e-6	Fibrinogen levels;
PAAD	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.66	4.94	0.37	2.07e-6	Hip geometry;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10994639	chr1:167789455	ADCY10	0.58	6.32	0.46	2.78e-9	Pancreatic cancer;
PAAD	cis	rs2718812	0.904	rs2718809	chr3:133409418	A/G	cg08439880	chr3:133502540	NA	0.42	4.8	0.36	3.7e-6	Iron status biomarkers;
PAAD	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg20487152	chr13:99095054	FARP1	-0.5	-4.83	-0.36	3.32e-6	Neuroticism;
PAAD	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	4.47	0.34	1.49e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg15211996	chr1:2936768	ACTRT2	0.47	4.61	0.35	8.42e-6	Plateletcrit;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg07899956	chr17:74261249	FAM100B	-0.72	-6.61	-0.47	6.08e-10	Blood protein levels;
PAAD	cis	rs11671653	1.000	rs78162577	chr19:10839195	C/T	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.63	5.1	0.38	1.01e-6	Alzheimer's disease;
PAAD	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.76	-8.05	-0.55	2.21e-13	Type 2 diabetes;
PAAD	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.71	7.18	0.5	2.95e-11	Schizophrenia;
PAAD	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.27	-0.39	4.69e-7	Blood pressure;
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.21	-0.39	5.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11009175	0.556	rs10763905	chr10:33305096	G/A	cg00146027	chr10:33299147	NA	-0.38	-4.47	-0.34	1.53e-5	Depression (quantitative trait);
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg22029157	chr1:209979665	IRF6	0.68	6.33	0.46	2.65e-9	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	1.02	7.29	0.51	1.59e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.6	-7.15	-0.5	3.46e-11	Dementia with Lewy bodies;
PAAD	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.44e-6	Depressive symptoms;
PAAD	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg18357526	chr6:26021779	HIST1H4A	0.57	4.46	0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.04	-0.38	1.3e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs72627123	0.881	rs28548133	chr14:74309154	A/G	cg19860245	chr14:74300557	NA	0.76	5.47	0.41	1.8e-7	Morning vs. evening chronotype;
PAAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-1.03	-14.49	-0.76	1.97e-30	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17023223	0.537	rs2765532	chr1:119591546	T/C	cg17326555	chr1:119535693	NA	-0.42	-5.11	-0.38	9.62e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	1.0	13.85	0.75	9.72e-29	Rheumatoid arthritis;
PAAD	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-4.34	-0.33	2.6e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg18093559	chr17:18951025	GRAP	0.46	4.71	0.36	5.62e-6	Schizophrenia;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg22242926	chr17:73627717	RECQL5	0.62	6.36	0.46	2.26e-9	Body mass index;
PAAD	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.86	10.24	0.64	4.86e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1372356	0.780	rs11159840	chr14:88556525	G/T	cg18078958	chr14:88630771	NA	0.49	6.24	0.45	4.11e-9	Food antigen IgG levels;
PAAD	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.49	4.96	0.37	1.84e-6	Multiple myeloma (IgH translocation);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15473325	chr12:133137087	FBRSL1	0.63	6.59	0.47	6.84e-10	Myopia (pathological);
PAAD	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08556938	chr17:58512855	NA	0.55	6.33	0.46	2.63e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg10820045	chr2:198174542	NA	0.51	5.16	0.39	7.46e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	5.14	0.39	8.16e-7	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg00147160	chr1:26503991	CNKSR1	0.38	4.41	0.34	1.95e-5	QRS complex (12-leadsum);
PAAD	cis	rs7953508	0.700	rs11107126	chr12:93997373	A/T	cg18151635	chr12:93972918	NA	-0.53	-5.29	-0.39	4.2e-7	Pubertal anthropometrics;
PAAD	cis	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.49	0.34	1.41e-5	Depression;
PAAD	cis	rs793571	0.822	rs11858989	chr15:59175228	C/T	cg05156742	chr15:59063176	FAM63B	0.54	4.39	0.34	2.12e-5	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg04809136	chr2:24300158	SF3B14	-0.38	-4.42	-0.34	1.88e-5	Quantitative traits;
PAAD	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg14345882	chr6:26364793	BTN3A2	0.64	5.3	0.4	3.97e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg21399703	chr1:247681439	NA	0.6	4.58	0.35	9.57e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2718812	1.000	rs2953740	chr3:133406351	T/C	cg11941060	chr3:133502564	NA	0.48	4.99	0.38	1.6e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.82	-5.87	-0.43	2.62e-8	Breast cancer;
PAAD	cis	rs300774	0.925	rs7562639	chr2:117690	G/T	cg23649280	chr2:140451	NA	-0.46	-4.25	-0.33	3.71e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	5.52	0.41	1.4e-7	Schizophrenia;
PAAD	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.85	9.89	0.63	4e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.91	7.82	0.54	8.38e-13	Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2030114	0.768	rs7194955	chr16:51596669	A/C	cg03758633	chr16:51611768	NA	-0.5	-4.46	-0.34	1.56e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.82	5.92	0.43	2.08e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.49	5.04	0.38	1.29e-6	Bladder cancer;
PAAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg15443732	chr18:74961078	GALR1	0.73	5.99	0.44	1.48e-8	Obesity-related traits;
PAAD	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.55	-5.18	-0.39	6.81e-7	Dental caries;
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.91	-10.21	-0.64	5.96e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.73	-5.03	-0.38	1.37e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	5.0	0.38	1.56e-6	Iron status biomarkers;
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.77	-0.36	4.33e-6	Obesity-related traits;
PAAD	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.76	7.31	0.51	1.39e-11	Retinal vascular caliber;
PAAD	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.48e-6	Daytime sleep phenotypes;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.75	-0.42	4.69e-8	Lung cancer;
PAAD	cis	rs7243821	0.921	rs8089609	chr18:52634441	T/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs501916	0.634	rs3803349	chr15:48064867	T/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.54	-4.41	-0.34	1.98e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.46	-0.34	1.6e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.77	-0.42	4.3e-8	Blood trace element (Zn levels);
PAAD	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-4.66	-0.35	6.96e-6	Monocyte percentage of white cells;
PAAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.67	-6.73	-0.48	3.24e-10	Body mass index;
PAAD	cis	rs4692589	0.581	rs34149802	chr4:170960284	A/G	cg19918862	chr4:170955249	NA	0.51	4.47	0.34	1.5e-5	Anxiety disorder;
PAAD	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	7.09	0.5	4.64e-11	Response to antipsychotic treatment;
PAAD	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg24846680	chr1:228362309	C1orf69	0.45	4.31	0.33	2.96e-5	Diastolic blood pressure;
PAAD	cis	rs6604026	0.671	rs6697543	chr1:93312295	C/A	cg17283838	chr1:93427260	FAM69A	-0.63	-5.86	-0.43	2.72e-8	Multiple sclerosis;
PAAD	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.81	-8.17	-0.55	1.09e-13	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.9	11.78	0.69	3.69e-23	Total body bone mineral density;
PAAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs6604026	0.656	rs11164845	chr1:93416685	A/G	cg17283838	chr1:93427260	FAM69A	0.61	5.64	0.42	8.07e-8	Multiple sclerosis;
PAAD	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.49	4.88	0.37	2.64e-6	Asthma;
PAAD	cis	rs2067615	0.831	rs1922437	chr12:107058045	C/T	cg15890332	chr12:107067104	RFX4	0.38	4.28	0.33	3.27e-5	Heart rate;
PAAD	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.64	-0.42	7.98e-8	Longevity;Endometriosis;
PAAD	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs62408225	1.000	rs905670	chr6:90958502	G/A	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11696501	0.895	rs6130855	chr20:44148515	T/C	cg11783356	chr20:44313418	WFDC10B	-0.65	-6.03	-0.44	1.18e-8	Brain structure;
PAAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02725872	chr8:58115012	NA	-0.55	-4.59	-0.35	9.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg20406979	chr6:167373233	NA	0.35	4.89	0.37	2.53e-6	Crohn's disease;
PAAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.56	6.2	0.45	5.04e-9	Major depressive disorder;
PAAD	cis	rs1011018	0.955	rs10952511	chr7:139431351	A/C	cg03224163	chr7:139420300	HIPK2	-0.61	-4.36	-0.33	2.41e-5	Systolic blood pressure;
PAAD	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg22875332	chr1:76189707	ACADM	-0.51	-5.12	-0.38	9.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-7.41	-0.52	8.1e-12	Total body bone mineral density;
PAAD	cis	rs1144333	0.510	rs1144328	chr1:76266601	G/A	cg22875332	chr1:76189707	ACADM	-0.77	-4.73	-0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.86	9.88	0.63	4.37e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.81	-9.14	-0.6	3.64e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	6.66	0.48	4.83e-10	Body mass index (adult);
PAAD	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.65	-5.95	-0.43	1.81e-8	Crohn's disease;
PAAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.51	-5.56	-0.41	1.19e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8112211	0.637	rs2270093	chr19:38839859	T/C	cg14299480	chr19:38876666	GGN	-0.6	-6.61	-0.47	6.01e-10	Blood protein levels;
PAAD	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.75	7.48	0.52	5.48e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	4.78	0.36	4.04e-6	Mood instability;
PAAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.52	5.08	0.38	1.12e-6	Trans fatty acid levels;
PAAD	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.44	6.93	0.49	1.1e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.7	6.88	0.49	1.5e-10	Lymphocyte counts;
PAAD	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg08099141	chr12:7053170	C12orf57	0.43	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	8.44	0.57	2.27e-14	Monocyte percentage of white cells;
PAAD	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs758324	0.773	rs4705901	chr5:131146993	T/C	cg06307176	chr5:131281290	NA	0.49	4.31	0.33	2.88e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg06057569	chr22:50219754	BRD1	-0.69	-5.41	-0.4	2.43e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg02951883	chr7:2050386	MAD1L1	0.64	5.63	0.42	8.64e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18830013	chr6:14082604	NA	-0.67	-6.58	-0.47	7.24e-10	Obesity-related traits;
PAAD	cis	rs11955175	0.717	rs112304996	chr5:40867592	A/T	cg05478818	chr5:40835740	RPL37	0.97	4.86	0.37	2.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.7	-7.01	-0.49	7.45e-11	Retinal vascular caliber;
PAAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg16205897	chr5:131564050	P4HA2	-0.49	-5.5	-0.41	1.56e-7	Blood metabolite levels;
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-4.71	-0.36	5.48e-6	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg13535736	chr9:111863775	C9orf5	-0.36	-4.62	-0.35	8.12e-6	Menarche (age at onset);
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-9.37	-0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs7737355	0.773	rs192166	chr5:130852525	T/C	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.44	7.48	0.52	5.39e-12	Multiple system atrophy;
PAAD	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg07784872	chr16:85687041	KIAA0182	0.52	4.32	0.33	2.84e-5	Platelet distribution width;
PAAD	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.97	13.99	0.75	4.06e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.69	4.91	0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.97e-6	Mononucleosis;
PAAD	cis	rs3774830	0.714	rs73212742	chr4:5464915	A/G	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.2e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg11111859	chr10:97686634	C10orf131	-0.53	-6.37	-0.46	2.16e-9	Energy expenditure (24h);
PAAD	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg24053715	chr22:38214548	NA	-0.5	-5.19	-0.39	6.73e-7	Glioblastoma;Glioma;
PAAD	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.6	-0.52	2.76e-12	Morning vs. evening chronotype;
PAAD	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	6.77	0.48	2.59e-10	Blood protein levels;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg19673125	chr6:150240577	RAET1G	0.42	5.9	0.43	2.26e-8	Testicular germ cell tumor;
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.56	-5.22	-0.39	5.85e-7	Menarche (age at onset);
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	1.04	8.59	0.57	9.46e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg01267373	chr18:77410094	NA	0.4	4.28	0.33	3.31e-5	Monocyte count;
PAAD	cis	rs3112530	1.000	rs300335	chr5:152723633	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2718812	1.000	rs2718811	chr3:133399738	T/A	cg08439880	chr3:133502540	NA	0.42	4.69	0.36	5.94e-6	Iron status biomarkers;
PAAD	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.69	-7.58	-0.52	3.23e-12	Aortic root size;
PAAD	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg14092571	chr14:90743983	NA	0.44	4.28	0.33	3.27e-5	Mortality in heart failure;
PAAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg16083429	chr3:49237500	CCDC36	-0.42	-4.45	-0.34	1.64e-5	Parkinson's disease;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.45	-7.0	-0.49	7.76e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.04	-0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-1.06	-14.93	-0.77	1.35e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.51	5.19	0.39	6.72e-7	Lung cancer;
PAAD	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.41	-0.4	2.35e-7	HDL cholesterol;
PAAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.55	-0.41	1.21e-7	Bipolar disorder;
PAAD	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.52	-4.6	-0.35	8.96e-6	Migraine;
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.75	5.57	0.41	1.14e-7	Initial pursuit acceleration;
PAAD	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.66	-8.23	-0.56	7.65e-14	Schizophrenia;
PAAD	cis	rs4679121	0.643	rs74892038	chr3:126142583	C/T	cg05485589	chr3:126194908	ZXDC	-0.99	-4.77	-0.36	4.26e-6	Pursuit maintenance gain;
PAAD	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.4	-0.34	2.07e-5	Morning vs. evening chronotype;
PAAD	cis	rs1018697	1.000	rs7080587	chr10:104545274	C/T	cg25123470	chr10:103603722	KCNIP2	-0.32	-4.34	-0.33	2.57e-5	Colorectal adenoma (advanced);
PAAD	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.76e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.39	0.34	2.12e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.62	5.82	0.43	3.31e-8	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs61677309	1.000	rs67462512	chr11:118155336	G/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.64	6.12	0.44	7.71e-9	Schizophrenia;
PAAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg27417659	chr7:98567827	TRRAP	-0.47	-4.42	-0.34	1.91e-5	Breast cancer;
PAAD	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg27205649	chr11:78285834	NARS2	0.6	4.32	0.33	2.83e-5	Alzheimer's disease (survival time);
PAAD	cis	rs412658	0.535	rs1651558	chr19:22089575	A/G	cg23859931	chr19:22123797	NA	0.44	4.46	0.34	1.6e-5	Telomere length;
PAAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.78	7.17	0.5	2.98e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.83	9.03	0.59	7.05e-16	Mortality in heart failure;
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02071572	chr4:1403502	NA	0.5	6.66	0.48	4.67e-10	Longevity;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.95	7.38	0.51	9.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.59	6.18	0.45	5.76e-9	Testicular germ cell tumor;
PAAD	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.42	-0.4	2.26e-7	Response to temozolomide;
PAAD	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg23029597	chr12:123009494	RSRC2	-0.82	-7.11	-0.5	4.25e-11	Body mass index;
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.83	0.58	2.42e-15	Lung cancer;
PAAD	cis	rs73019876	0.901	rs2666440	chr19:22139345	G/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs6582630	0.555	rs7956782	chr12:38603641	C/G	cg26384229	chr12:38710491	ALG10B	0.88	9.88	0.63	4.27e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg00383909	chr3:49044727	WDR6	0.54	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.52	7.0	0.49	7.61e-11	Ewing sarcoma;
PAAD	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.61	-5.96	-0.44	1.69e-8	Subjective well-being;
PAAD	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.61	7.15	0.5	3.49e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6494488	0.500	rs79866634	chr15:64818621	C/T	cg16425858	chr15:64791681	ZNF609	0.9	4.38	0.33	2.22e-5	Coronary artery disease;
PAAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg14092988	chr3:52407081	DNAH1	0.4	5.13	0.38	8.74e-7	Electroencephalogram traits;
PAAD	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.96	0.37	1.9e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9810890	1.000	rs78460081	chr3:128446113	A/G	cg19129842	chr3:128565090	NA	-0.86	-5.4	-0.4	2.48e-7	Dental caries;
PAAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.71	8.05	0.55	2.21e-13	Colorectal cancer;
PAAD	cis	rs9944275	0.860	rs12902211	chr15:97201877	G/A	cg23969200	chr15:97326567	SPATA8	0.66	4.37	0.33	2.27e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg14092988	chr3:52407081	DNAH1	0.4	4.28	0.33	3.28e-5	Schizophrenia;
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg16926213	chr1:1841314	NA	0.37	4.48	0.34	1.46e-5	Body mass index;
PAAD	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg03538708	chr1:25844672	NA	-0.54	-5.46	-0.4	1.94e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg10820045	chr2:198174542	NA	0.46	4.5	0.34	1.34e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.53	-0.34	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.61	-6.68	-0.48	4.24e-10	High light scatter reticulocyte count;
PAAD	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.51	-5.87	-0.43	2.7e-8	Testicular germ cell tumor;
PAAD	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs17655565	1.000	rs17126647	chr12:52706194	C/T	cg02645295	chr12:52705424	NA	-0.46	-4.39	-0.34	2.14e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7714584	1.000	rs11746108	chr5:150264622	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.49	-5.31	-0.4	3.74e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.69	7.22	0.51	2.35e-11	Mean corpuscular volume;
PAAD	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.67	-0.53	1.93e-12	Morning vs. evening chronotype;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg15331088	chr8:600555	NA	0.75	4.57	0.35	1e-5	IgG glycosylation;
PAAD	cis	rs586313	1.000	rs586802	chr11:133874656	G/A	cg19966618	chr11:134123407	THYN1;ACAD8	0.57	4.58	0.35	9.51e-6	Granulocyte-colony stimulating factor levels;
PAAD	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.56	6.23	0.45	4.43e-9	Sense of smell;
PAAD	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-5.34	-0.4	3.25e-7	Itch intensity from mosquito bite;
PAAD	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.38	0.46	2.03e-9	Hip circumference;
PAAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs5742933	0.857	rs10931430	chr2:190542186	T/C	cg04003228	chr2:190539410	ANKAR	-0.52	-4.32	-0.33	2.83e-5	Ferritin levels;
PAAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.46	4.75	0.36	4.59e-6	Longevity;
PAAD	cis	rs1497828	0.956	rs2815239	chr1:217546728	G/A	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs10934753	0.609	rs2077523	chr3:125905389	A/C	cg20988073	chr3:125900093	ALDH1L1	-0.4	-4.51	-0.34	1.28e-5	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg26939375	chr7:64535504	NA	-0.72	-8.19	-0.55	1e-13	Aortic root size;
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg17105886	chr17:28927953	LRRC37B2	-0.87	-5.3	-0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg23306229	chr2:178417860	TTC30B	0.76	5.06	0.38	1.21e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs600626	0.529	rs2004638	chr11:75471012	C/T	cg24262691	chr11:75473276	NA	0.74	6.18	0.45	5.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.66	6.34	0.46	2.52e-9	Pulse pressure;
PAAD	cis	rs9652601	0.691	rs7198004	chr16:11207617	A/G	cg04616529	chr16:11181986	CLEC16A	0.36	4.44	0.34	1.73e-5	Systemic lupus erythematosus;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.28	0.68	7.81e-22	Platelet count;
PAAD	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.51	-4.47	-0.34	1.55e-5	Obesity;
PAAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.69	0.53	1.67e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.7	7.53	0.52	4.25e-12	Renal function-related traits (BUN);
PAAD	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	1.21	11.77	0.69	3.9699999999999997e-23	Corneal structure;
PAAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.46e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.78	-4.66	-0.35	6.74e-6	Cholesterol, total;
PAAD	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg23860436	chr12:58378763	NA	0.51	4.8	0.36	3.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.51	-5.17	-0.39	7.41e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2117029	0.587	rs57853986	chr12:49518395	T/G	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.687	rs13360638	chr5:74433258	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs4604234	0.708	rs11966262	chr6:81004584	A/G	cg23115158	chr6:80341412	SH3BGRL2	-1.08	-4.25	-0.33	3.72e-5	Cancer;
PAAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.54	5.01	0.38	1.5e-6	Schizophrenia;
PAAD	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-1.09	-6.72	-0.48	3.38e-10	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.91	-11.3	-0.68	6.91e-22	Dental caries;
PAAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4919087	0.715	rs793520	chr10:99032375	G/A	cg06569542	chr10:98946673	SLIT1	0.5	4.91	0.37	2.3e-6	Monocyte count;
PAAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg14003231	chr6:33640908	ITPR3	-0.35	-4.41	-0.34	1.97e-5	Plateletcrit;
PAAD	cis	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24011531	chr6:114180173	MARCKS	-0.42	-4.92	-0.37	2.2e-6	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.48	-4.51	-0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.73	8.91	0.59	1.46e-15	Breast cancer;
PAAD	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.56	-4.47	-0.34	1.5e-5	Metabolite levels;
PAAD	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.74	-7.74	-0.53	1.29e-12	Cognitive function;
PAAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.38e-12	Height;
PAAD	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.25	-0.45	3.86e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg22947322	chr17:47091978	IGF2BP1	0.44	5.36	0.4	3.05e-7	Type 2 diabetes;
PAAD	cis	rs818427	0.669	rs2952615	chr5:112138888	G/C	cg06941702	chr5:112196734	SRP19	-0.52	-4.68	-0.35	6.28e-6	Total body bone mineral density;
PAAD	trans	rs61931739	0.546	rs61927758	chr12:33712017	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-7.42	-0.52	7.77e-12	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg17456097	chr1:26900765	RPS6KA1	0.51	4.28	0.33	3.3e-5	Glucose homeostasis traits;
PAAD	cis	rs2730260	0.673	rs56236179	chr7:158843088	G/A	cg13444538	chr7:158905317	VIPR2	-0.63	-4.52	-0.34	1.24e-5	Myopia (pathological);
PAAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg20893579	chr22:38215064	NA	0.47	4.66	0.35	6.81e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.49	5.5	0.41	1.61e-7	QRS complex (12-leadsum);
PAAD	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.84	6.57	0.47	7.59e-10	Prostate cancer;
PAAD	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg09127314	chr1:152161683	NA	-0.7	-4.74	-0.36	4.87e-6	Atopic dermatitis;
PAAD	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.6	-5.85	-0.43	2.87e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg22138327	chr13:27999177	GTF3A	0.86	5.38	0.4	2.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.35	-0.4	3.23e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.9	-0.37	2.45e-6	Schizophrenia;
PAAD	trans	rs901683	1.000	rs36100685	chr10:46086854	G/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.46	0.34	1.62e-5	Bipolar disorder;
PAAD	cis	rs4243830	1.000	rs4243831	chr1:6577915	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.04	-5.46	-0.41	1.86e-7	Body mass index;
PAAD	cis	rs2492906	0.515	rs1907391	chr10:27982710	C/T	cg25523538	chr10:28031957	MKX	0.51	4.35	0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.63	5.5	0.41	1.56e-7	Menarche (age at onset);
PAAD	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-1.14	-15.55	-0.78	3.04e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg01966878	chr4:90757139	SNCA	-0.64	-5.36	-0.4	3.05e-7	Neuroticism;
PAAD	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.62	0.47	5.68e-10	Primary sclerosing cholangitis;
PAAD	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.31	0.4	3.84e-7	Monocyte percentage of white cells;
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.99	8.34	0.56	4.09e-14	Initial pursuit acceleration;
PAAD	cis	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.67	-6.45	-0.46	1.42e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3206736	0.548	rs6971363	chr7:34953681	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.51	-4.87	-0.37	2.8e-6	Diastolic blood pressure;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg10191248	chr10:134441085	INPP5A	-0.45	-4.25	-0.33	3.67e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.62	0.57	8.35e-15	Alzheimer's disease;
PAAD	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.89	-8.36	-0.56	3.61e-14	Bone mineral density;
PAAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg01612440	chr4:3296283	NA	0.47	4.67	0.35	6.67e-6	Serum sulfate level;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06041567	chr3:194991685	C3orf21	-0.69	-8.52	-0.57	1.47e-14	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs75920871	0.925	rs11823918	chr11:116960497	G/C	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	cis	rs11203032	0.831	rs4511206	chr10:90968759	C/T	cg16672925	chr10:90967113	CH25H	0.79	6.19	0.45	5.3e-9	Heart failure;
PAAD	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.47	-0.78	4.97e-33	Height;
PAAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.4	-0.34	2.05e-5	Fibrinogen levels;
PAAD	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.46	4.54	0.35	1.13e-5	Breast cancer;
PAAD	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg04370829	chr17:406249	NA	-0.52	-5.2	-0.39	6.28e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.26	-0.39	4.78e-7	Menopause (age at onset);
PAAD	cis	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg18196295	chr10:418757	DIP2C	0.44	4.8	0.36	3.79e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.35	-0.4	3.24e-7	Mean corpuscular volume;
PAAD	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.42	-0.4	2.26e-7	Response to temozolomide;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.88	-7.12	-0.5	3.94e-11	Initial pursuit acceleration;
PAAD	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.32	0.4	3.67e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs786425	0.676	rs4930708	chr12:124145697	T/C	cg16237390	chr12:124156159	TCTN2	0.45	4.25	0.33	3.72e-5	Pubertal anthropometrics;
PAAD	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.5	-4.42	-0.34	1.84e-5	Testicular germ cell tumor;
PAAD	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.79	-0.43	3.91e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02244288	chr16:89573955	SPG7	-0.33	-4.28	-0.33	3.34e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.52	5.19	0.39	6.64e-7	Pulmonary function;
PAAD	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.34	-0.33	2.62e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg16205897	chr5:131564050	P4HA2	0.4	4.37	0.33	2.32e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7719624	0.680	rs1442	chr5:135382989	G/C	cg16684184	chr5:135415129	NA	-0.45	-5.4	-0.4	2.53e-7	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.63	0.35	7.65e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.94	10.8	0.66	1.56e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.65	5.44	0.4	2.1e-7	Common traits (Other);
PAAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg04398451	chr17:18023971	MYO15A	0.75	7.96	0.54	3.69e-13	Total body bone mineral density;
PAAD	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.68	7.38	0.51	9.8e-12	Blood protein levels;
PAAD	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg01851573	chr8:8652454	MFHAS1	0.95	7.25	0.51	2.02e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11617484	chr10:135113459	TUBGCP2	0.56	6.31	0.46	2.97e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.87	5.57	0.41	1.12e-7	Diabetic kidney disease;
PAAD	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg10495392	chr1:46806563	NSUN4	0.56	5.48	0.41	1.71e-7	Menopause (age at onset);
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.55	5.63	0.42	8.61e-8	Parkinson's disease;
PAAD	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-4.95	-0.37	1.94e-6	Schizophrenia;
PAAD	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.74	-7.19	-0.5	2.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.71	6.11	0.44	8e-9	Interstitial lung disease;
PAAD	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg22040403	chr1:23858016	E2F2	0.82	5.06	0.38	1.22e-6	Total cholesterol levels;
PAAD	cis	rs6784615	1.000	rs164636	chr3:52265259	G/C	cg27565382	chr3:53032988	SFMBT1	1.06	4.65	0.35	7.13e-6	Waist-hip ratio;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25798026	chr22:32149910	DEPDC5	0.56	6.53	0.47	9.12e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg00071950	chr4:10020882	SLC2A9	-0.71	-6.71	-0.48	3.67e-10	Schizophrenia (age at onset);
PAAD	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.57	-4.79	-0.36	4.01e-6	Total body bone mineral density;
PAAD	cis	rs1620921	0.505	rs1344730	chr6:161204995	G/A	cg01280913	chr6:161186852	NA	-0.48	-5.33	-0.4	3.48e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.32	0.33	2.86e-5	P wave terminal force;
PAAD	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.29	0.33	3.22e-5	Aortic root size;
PAAD	cis	rs11958404	1.000	rs72816523	chr5:157403168	G/C	cg05962755	chr5:157440814	NA	1.03	8.15	0.55	1.25e-13	IgG glycosylation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21509457	chr7:157053606	UBE3C	0.56	6.63	0.47	5.38e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.63	-7.71	-0.53	1.5e-12	Lung cancer;
PAAD	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.63	-0.35	7.89e-6	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.22	0.45	4.5e-9	Bladder cancer;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.72	7.77	0.53	1.07e-12	Cystic fibrosis severity;
PAAD	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	4.68	0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.67	-0.35	6.56e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg09177884	chr7:1199841	ZFAND2A	-0.65	-5.15	-0.39	7.96e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.53	6.51	0.47	1.05e-9	Migraine;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.45	4.89	0.37	2.58e-6	Calcium levels;
PAAD	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.53	-4.64	-0.35	7.37e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-5.05	-0.38	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.66	-7.42	-0.52	7.8e-12	Iron status biomarkers;
PAAD	cis	rs7766436	0.614	rs16886471	chr6:22567379	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.45	-0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg01262667	chr19:19385393	TM6SF2	0.45	5.04	0.38	1.33e-6	Tonsillectomy;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg13903179	chr13:21900392	NA	0.57	5.85	0.43	2.87e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.57	5.68	0.42	6.69e-8	Testicular germ cell tumor;
PAAD	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg09695851	chr17:3907499	NA	0.67	6.76	0.48	2.78e-10	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.81	6.23	0.45	4.44e-9	Alzheimer's disease;
PAAD	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.96	-10.68	-0.65	3.15e-20	Gut microbiome composition (winter);
PAAD	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	5.38	0.4	2.76e-7	Cognitive test performance;
PAAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.53	5.32	0.4	3.57e-7	Testicular germ cell tumor;
PAAD	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg10183150	chr4:120222239	C4orf3	-0.3	-4.35	-0.33	2.5e-5	Diastolic blood pressure;
PAAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.55	7.66	0.53	2.07e-12	Height;
PAAD	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg07671805	chr5:74907694	NA	0.56	4.34	0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17850984	chr19:4246870	CCDC94	0.61	7.42	0.52	7.56e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg26149184	chr10:133730230	NA	0.79	6.76	0.48	2.83e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs28830936	0.966	rs28451764	chr15:42126583	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.99e-10	Diastolic blood pressure;
PAAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.52	-5.39	-0.4	2.61e-7	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs9283706	0.623	rs10041624	chr5:66314861	T/A	cg11590213	chr5:66331682	MAST4	0.55	4.56	0.35	1.03e-5	Coronary artery disease;
PAAD	cis	rs3857067	0.509	rs72663769	chr4:95017716	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.55	-4.83	-0.37	3.24e-6	QT interval;
PAAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg14780466	chr2:20870812	GDF7	-0.34	-4.3	-0.33	3.06e-5	Abdominal aortic aneurysm;
PAAD	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21241219	chr9:139965163	C9orf140	0.83	10.17	0.64	7.25e-19	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2051773	0.567	rs7935677	chr11:17039832	A/G	cg15084286	chr11:17036142	PLEKHA7	0.55	4.87	0.37	2.72e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-11.8	-0.69	3.22e-23	Height;
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.54	6.11	0.44	7.84e-9	Mean corpuscular volume;
PAAD	cis	rs7922314	0.571	rs16917979	chr10:64730192	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.53	5.55	0.41	1.26e-7	Red blood cell count;
PAAD	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.52	6.03	0.44	1.2e-8	Aortic root size;
PAAD	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.65	6.87	0.49	1.59e-10	Corneal astigmatism;
PAAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.47	4.82	0.36	3.4e-6	Major depressive disorder;
PAAD	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.48	-5.13	-0.38	8.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg00738919	chr7:1100172	C7orf50	0.68	4.76	0.36	4.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.920	rs4474673	chr16:67758778	C/T	cg05110241	chr16:68378359	PRMT7	-0.96	-5.45	-0.4	1.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-5.72	-0.42	5.42e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6687430	0.512	rs34575776	chr1:10621061	A/G	cg17425144	chr1:10567563	PEX14	-0.42	-4.67	-0.35	6.71e-6	Hand grip strength;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg00250761	chr1:31883323	NA	-0.54	-6.24	-0.45	4.14e-9	Alcohol dependence;
PAAD	cis	rs7071247	0.915	rs3740474	chr10:105274941	C/T	cg14553436	chr10:104822996	CNNM2	0.67	4.99	0.37	1.67e-6	Platelet aggregation;
PAAD	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg25155006	chr6:37138205	PIM1	-0.52	-4.6	-0.35	8.88e-6	QRS duration;
PAAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.23	0.6	2.17e-16	Parkinson's disease;
PAAD	cis	rs2033908	0.558	rs6486064	chr11:12869509	T/C	cg25843174	chr11:12811716	TEAD1	-0.35	-4.95	-0.37	1.98e-6	Sitting height ratio;
PAAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg09324608	chr17:30823087	MYO1D	0.57	5.95	0.43	1.8e-8	Schizophrenia;
PAAD	cis	rs4795519	0.500	rs12165036	chr17:22169878	C/G	cg22648282	chr17:21454238	C17orf51	-0.55	-5.46	-0.41	1.88e-7	Chronic myeloid leukemia;
PAAD	cis	rs6841948	0.698	rs28447132	chr4:7979514	T/C	cg14959746	chr4:7987834	ABLIM2	0.58	4.4	0.34	2.05e-5	Post bronchodilator FEV1 in COPD;
PAAD	cis	rs73019876	0.901	rs399990	chr19:22232796	G/A	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs12304921	1.000	rs73092537	chr12:51358517	G/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.43	-0.4	2.22e-7	Type 2 diabetes;
PAAD	cis	rs2275565	0.872	rs7536446	chr1:237023442	G/A	cg17297354	chr1:237056641	MTR	-0.52	-4.57	-0.35	1.01e-5	Homocysteine levels;
PAAD	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-8.11	-0.55	1.55e-13	Colorectal cancer;
PAAD	cis	rs7119038	0.865	rs7951740	chr11:118740418	G/C	cg19308663	chr11:118741387	NA	-0.63	-4.85	-0.37	2.99e-6	Sjögren's syndrome;
PAAD	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.28	-0.33	3.28e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.46e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6466055	0.720	rs10227302	chr7:105021829	C/G	cg04380332	chr7:105027541	SRPK2	-0.66	-7.43	-0.52	7.13e-12	Schizophrenia;
PAAD	cis	rs9287719	0.649	rs10166765	chr2:10725673	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs12714314	0.756	rs4481014	chr2:1948892	C/T	cg22350835	chr2:1868857	MYT1L	0.48	4.69	0.36	6.02e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7824557	0.679	rs6601579	chr8:11138098	T/A	cg21775007	chr8:11205619	TDH	-0.59	-5.24	-0.39	5.23e-7	Retinal vascular caliber;
PAAD	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.59	4.76	0.36	4.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg21951975	chr1:209979733	IRF6	0.55	4.96	0.37	1.85e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25303396	chr1:59282018	NA	0.65	7.0	0.49	7.68e-11	Obesity-related traits;
PAAD	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	4.59	0.35	9.24e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-1.0	-12.89	-0.72	3.76e-26	Refractive error;
PAAD	cis	rs17824933	0.848	rs74860834	chr11:60778513	T/C	cg16817237	chr11:60793675	NA	0.53	6.32	0.46	2.76e-9	Multiple sclerosis;
PAAD	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg03264133	chr6:25882463	NA	-0.53	-4.45	-0.34	1.62e-5	Iron status biomarkers;
PAAD	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.94	8.13	0.55	1.44e-13	Red blood cell traits;
PAAD	cis	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg08224773	chr8:11311868	FAM167A	0.41	4.71	0.36	5.6e-6	Rheumatoid arthritis;
PAAD	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.92	-7.7	-0.53	1.65e-12	Total cholesterol levels;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01114163	chr5:1856713	NA	-0.41	-4.37	-0.33	2.32e-5	Cardiovascular disease risk factors;
PAAD	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-5.12	-0.38	9.14e-7	Schizophrenia;
PAAD	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.85	-6.8	-0.48	2.23e-10	Initial pursuit acceleration;
PAAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.52	5.85	0.43	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	1.03	12.66	0.72	1.54e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.53	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	cis	rs329648	0.571	rs510306	chr11:133774863	G/T	cg03392386	chr11:133800800	IGSF9B	-0.52	-5.84	-0.43	3.13e-8	Parkinson's disease;
PAAD	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2492906	0.600	rs2637323	chr10:28075908	C/T	cg25523538	chr10:28031957	MKX	-0.46	-4.25	-0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.42	-0.56	2.67e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg03338584	chr11:507455	RNH1	0.61	4.74	0.36	4.8e-6	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.53	-5.31	-0.4	3.79e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.65	0.35	7.18e-6	Body mass index;
PAAD	cis	rs4417704	0.551	rs10169544	chr2:241899356	A/C	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.89e-7	Joint mobility (Beighton score);
PAAD	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg09659197	chr4:152720779	NA	0.36	5.28	0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01483505	chr11:975446	AP2A2	0.58	6.55	0.47	8.39e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18561899	chr14:53162556	ERO1L	0.66	6.93	0.49	1.12e-10	Obesity-related traits;
PAAD	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg02569219	chr17:2266849	SGSM2	-0.52	-4.4	-0.34	2.05e-5	Total body bone mineral density;
PAAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.23e-6	Bipolar disorder;
PAAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg08562672	chr19:21860753	NA	0.46	4.77	0.36	4.36e-6	Pain;
PAAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.64e-6	Childhood ear infection;
PAAD	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg11288833	chr15:55489084	RSL24D1	0.57	4.53	0.34	1.21e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.31	-0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.44	-0.34	1.7e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg11416102	chr8:651193	ERICH1	0.91	5.51	0.41	1.49e-7	IgG glycosylation;
PAAD	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Dermatomyositis;
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.29	0.6	1.54e-16	Post bronchodilator FEV1;
PAAD	cis	rs458685	0.636	rs456784	chr21:31184827	A/G	cg24620508	chr21:31310605	GRIK1	-0.5	-4.64	-0.35	7.44e-6	Breast cancer;
PAAD	cis	rs881827	0.962	rs12483634	chr21:47992401	G/A	cg08742575	chr21:47604166	C21orf56	0.45	4.26	0.33	3.6e-5	Lymphocyte counts;
PAAD	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg23024343	chr7:107201750	COG5	0.58	4.82	0.36	3.46e-6	Coronary artery disease;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg19598514	chr11:442149	ANO9	-0.52	-4.32	-0.33	2.84e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8014252	0.803	rs73282126	chr14:70986041	T/C	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg22134413	chr5:150180641	NA	0.73	5.04	0.38	1.28e-6	Crohn's disease;
PAAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.62	8.03	0.55	2.46e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.84	-9.22	-0.6	2.28e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.05	12.8	0.72	6.58e-26	Schizophrenia;
PAAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.56	5.32	0.4	3.65e-7	Total body bone mineral density;
PAAD	cis	rs72636617	0.867	rs61962228	chr13:95064746	T/A	cg07907493	chr13:95480448	NA	0.64	4.29	0.33	3.2e-5	Pelvic organ prolapse;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15212038	chr4:7032128	TBC1D14	0.56	6.33	0.46	2.57e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg19264203	chr11:92714893	MTNR1B	0.37	4.31	0.33	2.88e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9583531	0.714	rs76166228	chr13:111343774	T/C	cg24331049	chr13:111365604	ING1	-0.87	-4.63	-0.35	7.78e-6	Coronary artery disease;
PAAD	cis	rs988913	0.624	rs3105254	chr6:54846043	T/C	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.42	7.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075265	0.722	rs7596349	chr2:53936260	T/C	cg04546899	chr2:54196757	PSME4	0.3	4.42	0.34	1.85e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg14348967	chr4:10160060	NA	-0.38	-4.54	-0.35	1.14e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs17318866	1.000	rs2326364	chr6:3830849	G/A	cg23955161	chr6:3737956	C6orf145	-0.49	-4.45	-0.34	1.67e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11039072	chr15:35280907	ZNF770	0.66	7.52	0.52	4.53e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4074493	1.000	rs4074494	chr1:231172249	G/A	cg22172038	chr1:231176991	FAM89A	0.5	4.71	0.36	5.62e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs9487051	0.646	rs55677234	chr6:109621974	G/A	cg01475377	chr6:109611718	NA	-0.4	-4.3	-0.33	2.98e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1891275	0.576	rs2000178	chr10:93413044	A/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.65	-6.38	-0.46	2.05e-9	Pubertal anthropometrics;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03685910	chr17:39844834	EIF1	0.6	6.77	0.48	2.67e-10	Metabolite levels  (X-11787);
PAAD	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.58	-6.74	-0.48	3.09e-10	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08762653	chr20:56293564	NA	0.6	6.5	0.47	1.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.55	5.37	0.4	2.84e-7	Itch intensity from mosquito bite;
PAAD	cis	rs7989332	0.890	rs35891640	chr13:21050174	C/T	cg06710890	chr13:21477865	XPO4	0.44	4.41	0.34	1.95e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.49	6.12	0.44	7.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs527409	0.737	rs553382	chr1:58733178	C/T	cg26345888	chr1:58716257	DAB1	-0.69	-4.73	-0.36	4.98e-6	Kawasaki disease;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-6.28	-0.45	3.39e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.67	-7.03	-0.5	6.52e-11	White blood cell count (basophil);
PAAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	4.58	0.35	9.6e-6	Coronary artery disease;
PAAD	cis	rs6466055	0.589	rs888086	chr7:104626690	G/A	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg08648136	chr8:956695	NA	0.47	5.08	0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	1.1	15.64	0.79	1.82e-33	Breast cancer;
PAAD	cis	rs7577696	0.886	rs659239	chr2:32484569	T/C	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.68e-6	Inflammatory biomarkers;
PAAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.27	0.39	4.5e-7	Rheumatoid arthritis;
PAAD	cis	rs1519814	0.702	rs4871032	chr8:121042074	C/T	cg22335954	chr8:121166405	COL14A1	0.62	5.28	0.39	4.42e-7	Breast cancer;
PAAD	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg14146966	chr2:61757674	XPO1	0.37	4.47	0.34	1.49e-5	Tuberculosis;
PAAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26240231	chr7:1148101	C7orf50	-0.48	-4.25	-0.33	3.71e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs755249	0.567	rs61779284	chr1:39855177	G/A	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.58	-8.6	-0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.5	5.21	0.39	6.17e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08073142	chr16:24740747	TNRC6A	-0.67	-6.61	-0.47	6.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.57	-4.95	-0.37	1.94e-6	Pursuit maintenance gain;
PAAD	cis	rs950776	0.678	rs12910237	chr15:78956338	C/T	cg06917634	chr15:78832804	PSMA4	0.56	5.24	0.39	5.25e-7	Sudden cardiac arrest;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.07	0.44	9.99e-9	Height;
PAAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-6.68	-0.48	4.21e-10	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9361491	0.579	rs9352615	chr6:79441493	C/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18434673	chr17:40333360	KCNH4	0.58	6.76	0.48	2.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28719689	0.892	rs28415621	chr8:1270475	C/T	cg22761795	chr8:1265118	NA	0.92	6.84	0.49	1.81e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.620	rs61927757	chr12:33710109	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-7.42	-0.52	7.77e-12	Morning vs. evening chronotype;
PAAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	6.14e-7	Ulcerative colitis;
PAAD	cis	rs818427	1.000	rs2545166	chr5:112213805	C/G	cg06941702	chr5:112196734	SRP19	-0.46	-4.33	-0.33	2.72e-5	Total body bone mineral density;
PAAD	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.74	-7.43	-0.52	7.38e-12	Alcohol dependence;
PAAD	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg07159951	chr1:45983175	PRDX1	0.43	4.67	0.35	6.64e-6	High light scatter reticulocyte count;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg01652476	chr7:809048	HEATR2	-0.66	-7.54	-0.52	3.89e-12	Subjective well-being;
PAAD	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg15676125	chr6:33679581	C6orf125	0.46	4.43	0.34	1.79e-5	Plateletcrit;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.8	5.43	0.4	2.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1190596	0.526	rs1190572	chr14:102634589	A/G	cg23904247	chr14:102554826	HSP90AA1	-0.4	-4.98	-0.37	1.71e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2816062	0.786	rs2816059	chr1:18902977	G/A	cg18795169	chr1:18902165	NA	-1.08	-19.8	-0.85	6.37e-44	Urate levels in lean individuals;
PAAD	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg22705602	chr4:152727874	NA	-0.49	-5.07	-0.38	1.15e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.72	7.45	0.52	6.61e-12	Type 2 diabetes;
PAAD	cis	rs4740619	0.630	rs1576171	chr9:15981144	A/T	cg14451791	chr9:16040625	NA	0.37	4.36	0.33	2.34e-5	Body mass index;
PAAD	cis	rs7792596	0.861	rs57900160	chr7:93986265	C/G	cg20814616	chr7:94014465	NA	-0.66	-7.05	-0.5	5.76e-11	Intelligence;
PAAD	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg19486271	chr11:47235900	DDB2	-0.59	-6.02	-0.44	1.27e-8	Acne (severe);
PAAD	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.26e-6	Hepatitis;
PAAD	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs11264799	0.817	rs72708359	chr1:157666256	T/C	cg18268488	chr1:157545234	FCRL4	0.57	5.33	0.4	3.51e-7	IgA nephropathy;
PAAD	cis	rs829661	0.843	rs866680	chr2:30720191	C/A	cg12454169	chr2:30669597	LCLAT1	0.63	4.42	0.34	1.89e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-1.35	-9.93	-0.63	3.25e-18	Schizophrenia;
PAAD	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.28	0.81	1.06e-37	Height;
PAAD	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.99	-0.49	8.24e-11	Neuroticism;
PAAD	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.97	10.05	0.63	1.52e-18	Platelet distribution width;
PAAD	trans	rs883115	0.846	rs1566388	chr1:224795474	A/T	cg20784531	chr11:134534456	NA	-0.56	-6.36	-0.46	2.22e-9	Cancer;
PAAD	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs881827	0.821	rs1047221	chr21:48003193	A/G	cg12016809	chr21:47604291	C21orf56	0.46	4.34	0.33	2.59e-5	Lymphocyte counts;
PAAD	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs6942407	0.592	rs2057984	chr7:86826540	C/T	cg02420886	chr7:86849541	C7orf23	0.58	4.38	0.33	2.24e-5	Food allergy;
PAAD	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg25309567	chr17:79516362	C17orf70	-0.43	-4.31	-0.33	2.96e-5	Eye color traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09762907	chr6:42290256	TRERF1	-0.68	-7.2	-0.5	2.61e-11	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs58653258	0.730	rs2802982	chr1:234966544	T/C	cg03518729	chr1:235147744	NA	0.48	4.51	0.34	1.29e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg21361702	chr7:150065534	REPIN1	0.54	4.59	0.35	9.38e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs9832625	1.000	rs9832625	chr3:29329020	C/A	cg06712285	chr3:29990487	RBMS3	-0.73	-4.69	-0.36	6.06e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.63	-6.73	-0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19197652	chr11:94602456	AMOTL1	-0.7	-7.16	-0.5	3.15e-11	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.87	8.85	0.58	2.13e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg03060546	chr3:49711283	APEH	-0.58	-4.25	-0.33	3.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4638749	1.000	rs7586308	chr2:108882824	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.93	-0.37	2.14e-6	Blood pressure;
PAAD	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2882667	0.654	rs2351247	chr5:138185145	A/G	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	1.32	8.14	0.55	1.32e-13	Skin colour saturation;
PAAD	cis	rs757081	0.667	rs214933	chr11:17194584	C/T	cg15432903	chr11:17409602	KCNJ11	-0.6	-6.2	-0.45	5.01e-9	Systolic blood pressure;
PAAD	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	5.52	0.41	1.45e-7	Lung cancer in ever smokers;
PAAD	cis	rs59104589	0.521	rs60988810	chr2:242430084	C/A	cg19488206	chr2:242435732	STK25	0.45	4.45	0.34	1.65e-5	Fibrinogen levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27624381	chr4:77917883	SEPT11	0.57	6.47	0.46	1.29e-9	Smoking initiation;
PAAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3126085	0.560	rs12403031	chr1:152343394	T/C	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.83	9.69	0.62	1.38e-17	Gout;
PAAD	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	0.78	5.27	0.39	4.7e-7	Body mass index;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.91	7.82	0.54	8.38e-13	Alzheimer's disease;
PAAD	cis	rs9715521	0.573	rs7683444	chr4:59810939	G/T	cg11281224	chr4:60001000	NA	-0.66	-5.82	-0.43	3.45e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.64	-5.92	-0.43	2.11e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg14703610	chr5:56206110	C5orf35	0.61	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.57	5.47	0.41	1.77e-7	Economic and political preferences (feminism/equality);
PAAD	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.32	-0.51	1.31e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.94	-7.55	-0.52	3.74e-12	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg07384165	chr1:10488281	NA	-0.45	-4.62	-0.35	8.22e-6	Breast cancer;
PAAD	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.28	-0.39	4.4e-7	Mood instability;
PAAD	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26897989	chr16:1907736	C16orf73	-0.58	-4.94	-0.37	2.06e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.76	8.2	0.55	9.21e-14	Magnesium levels;
PAAD	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.65	7.72	0.53	1.42e-12	Dupuytren's disease;
PAAD	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg19196401	chr6:110721138	DDO	-0.49	-5.41	-0.4	2.36e-7	Platelet distribution width;
PAAD	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg09491104	chr22:46646882	C22orf40	-0.92	-5.99	-0.44	1.45e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.7	4.69	0.36	5.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1358748	0.522	rs4655675	chr1:67576075	C/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.48	6.19	0.45	5.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.48	-0.41	1.72e-7	HDL cholesterol;
PAAD	cis	rs6804624	0.963	rs55942440	chr3:99177281	T/A	cg02646433	chr3:99218170	NA	0.41	4.35	0.33	2.46e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.9	-9.94	-0.63	3.03e-18	Tonsillectomy;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7786877	1.000	rs7786877	chr7:100214015	A/G	cg20848291	chr7:100343083	ZAN	-0.7	-6.24	-0.45	4.09e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	7.52	0.52	4.48e-12	Schizophrenia;
PAAD	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.6	-5.72	-0.42	5.42e-8	Endometrial cancer;
PAAD	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19671926	chr4:122722719	EXOSC9	-0.57	-4.58	-0.35	9.64e-6	Type 2 diabetes;
PAAD	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.92	7.6	0.52	2.81e-12	Alzheimer's disease;
PAAD	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.56	5.03	0.38	1.36e-6	Neutrophil percentage of white cells;
PAAD	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.56	-6.15	-0.45	6.6e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs943466	0.955	rs3763253	chr6:33772761	C/T	cg04704449	chr6:33738291	NA	0.53	5.51	0.41	1.47e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	7.37	0.51	1.01e-11	Tonsillectomy;
PAAD	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.57	6.49	0.47	1.13e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg18370025	chr7:2749541	AMZ1	-0.39	-4.66	-0.35	6.73e-6	Height;
PAAD	cis	rs10998941	0.561	rs1381937	chr10:71464834	C/A	cg26770870	chr10:71561502	COL13A1	0.49	4.46	0.34	1.57e-5	CSF tryptophan concentration in tuberculous meningitis;
PAAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.79	-0.43	3.91e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs3784262	0.740	rs12898976	chr15:58276358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.52	-5.97	-0.44	1.61e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04696391	chr16:3021794	PAQR4	0.52	6.31	0.46	2.9e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-8.0	-0.54	2.97e-13	Bladder cancer;
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs73019876	0.869	rs58270321	chr19:22146299	G/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs3136739	0.558	rs7000303	chr8:41993563	T/G	cg17828057	chr8:42037527	PLAT	0.62	4.38	0.33	2.17e-5	Plasma plasminogen activator levels;
PAAD	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg03959625	chr15:84868606	LOC388152	0.49	5.36	0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.7	-0.42	6.06e-8	Mood instability;
PAAD	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg21937377	chr3:194868750	C3orf21	0.46	4.85	0.37	2.97e-6	Non-small cell lung cancer;
PAAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-4.73	-0.36	5.01e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.68	-7.84	-0.54	7.4e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	4.01e-6	Life satisfaction;
PAAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg00579200	chr11:133705235	NA	0.48	5.35	0.4	3.12e-7	Childhood ear infection;
PAAD	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.74	-9.59	-0.61	2.55e-17	Educational attainment;
PAAD	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.55	5.84	0.43	3.09e-8	Menopause (age at onset);
PAAD	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.9	-7.53	-0.52	4.23e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg16590910	chr6:42928470	GNMT	0.5	4.99	0.37	1.66e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19671926	chr4:122722719	EXOSC9	-0.74	-7.3	-0.51	1.51e-11	Type 2 diabetes;
PAAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Bladder cancer;
PAAD	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg10820045	chr2:198174542	NA	0.5	5.16	0.39	7.44e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-4.25	-0.33	3.72e-5	Barrett's esophagus  or Esophageal adenocarcinoma;
PAAD	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg25730555	chr22:47059586	GRAMD4	0.48	4.86	0.37	2.93e-6	Urate levels in obese individuals;
PAAD	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.53	4.96	0.37	1.89e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.54	-4.72	-0.36	5.34e-6	Life satisfaction;
PAAD	cis	rs300774	0.925	rs432750	chr2:147456	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.5	5.9	0.43	2.24e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	6.09e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg13256891	chr4:100009986	ADH5	-0.53	-5.44	-0.4	2.12e-7	Alcohol dependence;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	4.54	0.35	1.13e-5	IgG glycosylation;
PAAD	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	1.11	8.66	0.57	6.39e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs10214930	0.752	rs1015265	chr7:27639609	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2.02e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.51	-0.8	9.93e-36	Height;
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg22705602	chr4:152727874	NA	-0.48	-5.19	-0.39	6.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13034020	0.522	rs12996059	chr2:61245551	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.48	4.31	0.33	2.96e-5	Homoarginine levels;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.63	8.22	0.55	8.38e-14	Hypertriglyceridemia;
PAAD	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.68	-0.48	4.22e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6710503	0.547	rs62142285	chr2:24793097	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.3	-0.33	3.07e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.7	0.53	1.65e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13006833	0.694	rs291444	chr2:191176223	T/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg08917208	chr2:24149416	ATAD2B	1.18	8.35	0.56	3.93e-14	Lymphocyte counts;
PAAD	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.61	-7.67	-0.53	1.93e-12	Diastolic blood pressure;
PAAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs901683	0.867	rs35356752	chr10:45980106	G/A	cg23720331	chr10:123873670	TACC2	-0.87	-6.57	-0.47	7.53e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg16950941	chr11:66035639	RAB1B	0.67	5.79	0.43	3.82e-8	Gout;
PAAD	cis	rs13070279	0.786	rs13079034	chr3:71813219	C/T	cg03457142	chr3:71804859	EIF4E3	-0.55	-4.34	-0.33	2.56e-5	Monocyte count;
PAAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg02549819	chr16:58548995	SETD6	0.95	4.68	0.36	6.21e-6	Schizophrenia;
PAAD	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg03805757	chr16:71968109	PKD1L3	-0.51	-4.39	-0.34	2.15e-5	Blood protein levels;
PAAD	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg02795151	chr17:7402630	POLR2A	0.59	5.39	0.4	2.61e-7	Androgen levels;
PAAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs595018	0.505	rs2074421	chr11:60610056	G/C	cg07588442	chr11:60673866	PRPF19	0.65	4.49	0.34	1.4e-5	Wegener's granulomatosis;
PAAD	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.15	0.39	7.94e-7	Lung cancer in ever smokers;
PAAD	cis	rs303386	0.501	rs4908302	chr1:99583122	A/C	cg03593336	chr1:99471295	LPPR5	0.55	5.21	0.39	5.98e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.49	5.86	0.43	2.75e-8	Sitting height ratio;
PAAD	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.46	4.5	0.34	1.37e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.06	-0.38	1.19e-6	Asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05760393	chr11:2466141	KCNQ1	-0.73	-6.31	-0.46	2.88e-9	Neuroticism;
PAAD	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs4867766	0.871	rs11747479	chr5:173955389	C/T	cg20434911	chr5:173954559	NA	-0.66	-6.74	-0.48	3.15e-10	Stroke;
PAAD	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg05299278	chr17:33885742	SLFN14	0.42	5.04	0.38	1.32e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.27	-7.5	-0.52	4.83e-12	Body mass index;
PAAD	cis	rs380904	0.519	rs12541790	chr8:144643321	A/G	cg13399544	chr8:144649678	C8orf73	-0.62	-6.19	-0.45	5.32e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg16176600	chr6:116381609	FRK	0.3	4.33	0.33	2.73e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs2718812	1.000	rs7626210	chr3:133398099	G/A	cg11941060	chr3:133502564	NA	0.47	4.98	0.37	1.73e-6	Iron status biomarkers;
PAAD	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs12714314	0.834	rs4241293	chr2:1953555	A/G	cg17170872	chr1:91487911	ZNF644	-0.76	-6.3	-0.46	3.12e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg08835956	chr7:39171034	POU6F2	-0.32	-4.89	-0.37	2.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.8	0.48	2.28e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.41	-8.6	-0.57	9.03e-15	Mean corpuscular volume;
PAAD	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04403917	chr7:37960974	EPDR1	0.61	6.7	0.48	3.85e-10	Monocyte percentage of white cells;
PAAD	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.72	7.45	0.52	6.48e-12	Aortic root size;
PAAD	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.66	5.31	0.4	3.8e-7	Morning vs. evening chronotype;
PAAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.53	8.18	0.55	1.08e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.53	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26876637	chr1:152193138	HRNR	0.89	6.91	0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs10274279	1.000	rs55941863	chr7:157372989	C/G	cg09270525	chr7:157391030	PTPRN2	0.73	5.56	0.41	1.17e-7	Myopia (pathological);
PAAD	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	trans	rs75583333	0.502	rs2080951	chr5:159623296	G/A	cg14222307	chr15:61097246	RORA	-0.82	-6.45	-0.46	1.4e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.62	0.41	8.78e-8	Prudent dietary pattern;
PAAD	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.59	-6.15	-0.45	6.51e-9	Hypospadias;
PAAD	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg19337854	chr7:99768885	GPC2	-0.45	-4.77	-0.36	4.37e-6	Coronary artery disease;
PAAD	cis	rs12900413	0.959	rs12902793	chr15:90304402	G/A	cg24249390	chr15:90295951	MESP1	-0.44	-4.28	-0.33	3.24e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.77	8.27	0.56	6.13e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.89	0.49	1.41e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	4.73	0.36	5.03e-6	Schizophrenia;
PAAD	cis	rs829661	1.000	rs2692035	chr2:30672835	T/A	cg12454169	chr2:30669597	LCLAT1	0.68	5.1	0.38	9.78e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs12612619	0.732	rs11679681	chr2:27298479	C/A	cg00617064	chr2:27272375	NA	-0.55	-5.93	-0.43	1.97e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2968864	1.000	rs2907948	chr7:150638484	G/A	cg06221570	chr7:150558377	ABP1	0.49	5.59	0.41	1.01e-7	QT interval;
PAAD	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.5	-5.53	-0.41	1.34e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.0	-0.44	1.4e-8	Prostate cancer;
PAAD	cis	rs17407555	1.000	rs6833988	chr4:10295586	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-4.69	-0.36	6.02e-6	Schizophrenia (age at onset);
PAAD	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg18436246	chr17:1640651	WDR81	0.86	7.97	0.54	3.59e-13	Serum albumin level;
PAAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.89	7.15	0.5	3.48e-11	Tuberculosis;
PAAD	trans	rs7965364	0.591	rs11047951	chr12:25470557	T/C	cg23940241	chr17:250070	NA	0.81	6.31	0.46	2.86e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9463078	0.546	rs1937046	chr6:45048243	A/G	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg27094323	chr7:1216898	NA	-0.37	-4.39	-0.34	2.13e-5	Longevity;Endometriosis;
PAAD	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-4.36	-0.33	2.36e-5	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25021590	chr1:183774742	RGL1	0.65	6.32	0.46	2.71e-9	Obesity-related traits;
PAAD	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg15838173	chr10:75533400	FUT11	-0.43	-4.3	-0.33	3.04e-5	Inflammatory bowel disease;
PAAD	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg23947450	chr7:900037	UNC84A	-0.55	-4.47	-0.34	1.51e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2073300	1.000	rs59283536	chr20:23457575	A/T	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs757081	0.684	rs214071	chr11:17305294	T/G	cg04705435	chr11:17411270	KCNJ11	-0.57	-6.08	-0.44	9.35e-9	Systolic blood pressure;
PAAD	cis	rs7616330	0.790	rs2140131	chr3:71044545	A/G	cg01511742	chr3:71112437	FOXP1	-0.74	-5.23	-0.39	5.5e-7	QT interval;
PAAD	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs72901758	0.810	rs61740716	chr17:76244648	G/A	cg11439826	chr17:76250004	NA	0.44	4.32	0.33	2.83e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10741243	0.702	rs10829910	chr10:132929949	C/T	cg07037374	chr10:132873708	NA	0.59	4.3	0.33	3.01e-5	Type 2 diabetes;
PAAD	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg03812309	chr1:46938281	NA	0.32	4.29	0.33	3.13e-5	High light scatter reticulocyte count;
PAAD	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg01426195	chr3:39028469	NA	0.6	5.84	0.43	3.03e-8	Handedness;
PAAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.53	-4.51	-0.34	1.27e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg01966878	chr4:90757139	SNCA	-0.69	-5.48	-0.41	1.75e-7	Neuroticism;
PAAD	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.73	8.32	0.56	4.78e-14	Metabolic syndrome;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.74	8.31	0.56	5.08e-14	Corneal astigmatism;
PAAD	cis	rs2252790	1.000	rs12214926	chr6:116643292	C/T	cg18764771	chr6:116381957	FRK	0.26	4.36	0.33	2.42e-5	Fast beta electroencephalogram;
PAAD	cis	rs28489187	0.597	rs10489513	chr1:85855622	C/T	cg16011679	chr1:85725395	C1orf52	-0.52	-5.05	-0.38	1.27e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs12153243	0.659	rs72806725	chr5:142936181	T/C	cg13907255	chr5:142895549	NA	-0.58	-4.98	-0.37	1.73e-6	Migraine;
PAAD	trans	rs901683	0.850	rs79022473	chr10:46101768	C/T	cg11747279	chr17:21096632	NA	0.85	6.35	0.46	2.36e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg04705435	chr11:17411270	KCNJ11	0.6	6.09	0.44	8.72e-9	Type 2 diabetes;
PAAD	cis	rs58521262	0.556	rs289297	chr19:23176140	T/C	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2221894	1.000	rs4559202	chr8:28816852	G/A	cg20212339	chr8:28908912	HMBOX1	0.53	5.63	0.42	8.56e-8	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.41e-13	Height;
PAAD	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.57	0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.43	-0.34	1.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.41	5.07	0.38	1.12e-6	Iron status biomarkers;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg19223190	chr17:80058835	NA	-0.53	-5.4	-0.4	2.55e-7	Life satisfaction;
PAAD	cis	rs1113500	0.524	rs11185270	chr1:108654362	G/A	cg06207961	chr1:108661230	NA	0.45	4.68	0.35	6.26e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg27319216	chr8:6693540	XKR5	-0.33	-4.41	-0.34	1.98e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-4.59	-0.35	9.31e-6	Joint mobility (Beighton score);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17541965	chr7:148844604	ZNF398	-0.63	-7.49	-0.52	5.22e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg06375148	chr1:209958343	C1orf74	0.64	4.7	0.36	5.78e-6	Coronary artery disease;
PAAD	cis	rs9535307	0.745	rs1407440	chr13:50286218	T/C	cg03658251	chr13:50265850	EBPL	0.81	5.61	0.41	9.52e-8	Obesity-related traits;
PAAD	cis	rs988913	0.581	rs1354288	chr6:54856623	T/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.9	11.6	0.69	1.1e-22	Menarche (age at onset);
PAAD	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.97e-8	Lymphocyte counts;
PAAD	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.61e-6	Cognitive function;
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.34	0.51	1.22e-11	Obesity-related traits;
PAAD	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.23	0.81	1.41e-37	Prudent dietary pattern;
PAAD	cis	rs4072705	0.615	rs10986355	chr9:127248299	G/A	cg14219918	chr9:127249562	NR5A1	0.35	4.84	0.37	3.21e-6	Menarche (age at onset);
PAAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.52	-4.77	-0.36	4.35e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7922314	0.571	rs16917985	chr10:64732314	T/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20825994	chr4:25448682	NA	-0.63	-6.48	-0.47	1.22e-9	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.4	-0.34	2.05e-5	Height;
PAAD	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	4.96	0.37	1.89e-6	Serum sulfate level;
PAAD	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.73	-4.52	-0.34	1.23e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg14343924	chr8:8086146	FLJ10661	-0.5	-4.52	-0.34	1.24e-5	Mood instability;
PAAD	cis	rs3826795	0.569	rs76909958	chr19:46795799	G/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.61	-5.68	-0.42	6.51e-8	White matter hyperintensity burden;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8105895	0.935	rs8104144	chr19:22246913	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs12311304	0.965	rs1382803	chr12:15372662	A/G	cg08258403	chr12:15378311	NA	0.37	4.73	0.36	5.13e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.74	-0.42	4.94e-8	Total cholesterol levels;
PAAD	cis	rs1982963	0.627	rs8020559	chr14:52490690	T/G	cg20550154	chr14:52487779	NID2	0.6	5.02	0.38	1.46e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs2637266	0.626	rs2588329	chr10:78552782	C/T	cg18941641	chr10:78392320	NA	0.36	4.28	0.33	3.25e-5	Pulmonary function;
PAAD	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg19217778	chr13:113420270	ATP11A	0.62	4.27	0.33	3.39e-5	Glycated hemoglobin levels;
PAAD	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Breast cancer;
PAAD	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg05768032	chr16:30646687	NA	0.54	5.08	0.38	1.07e-6	Multiple myeloma;
PAAD	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.61	5.84	0.43	3.11e-8	Height;
PAAD	cis	rs73416724	1.000	rs111408004	chr6:43326139	T/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2526932	0.625	rs2214651	chr14:73054440	T/C	cg13588403	chr14:73209128	DPF3	-0.41	-5.55	-0.41	1.24e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6585424	1.000	rs61860045	chr10:81947397	C/T	cg19423196	chr10:82049429	MAT1A	0.46	4.76	0.36	4.56e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	-0.64	-7.75	-0.53	1.19e-12	Menopause (age at onset);
PAAD	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg04851639	chr8:1020857	NA	-0.65	-7.97	-0.54	3.54e-13	Schizophrenia;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.35	-0.4	3.13e-7	Obesity-related traits;
PAAD	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg27478167	chr7:817139	HEATR2	0.74	5.4	0.4	2.49e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.95	-13.73	-0.74	2.05e-28	Dental caries;
PAAD	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.91	-0.54	5.05e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.77	5.51	0.41	1.52e-7	Yeast infection;
PAAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.52	6.86	0.49	1.63e-10	Body mass index;
PAAD	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg07395648	chr5:131743802	NA	-0.51	-4.56	-0.35	1.05e-5	Breast cancer;
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.49	-4.77	-0.36	4.26e-6	Menarche (age at onset);
PAAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg13452994	chr2:3699195	NA	0.52	4.59	0.35	9.39e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg00945038	chr17:61921165	SMARCD2	-0.37	-4.44	-0.34	1.74e-5	Prudent dietary pattern;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.89	5.85	0.43	2.95e-8	Body mass index;
PAAD	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.68	9.06	0.59	5.86e-16	Hemoglobin concentration;
PAAD	cis	rs1018697	1.000	rs4919678	chr10:104554363	C/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.67	6.0	0.44	1.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.48	6.06	0.44	1.02e-8	Prostate cancer;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg05627522	chr15:75251581	NA	0.5	5.96	0.43	1.73e-8	Breast cancer;
PAAD	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-5.81	-0.43	3.59e-8	Bipolar disorder;
PAAD	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg21483461	chr5:81570383	RPS23	-0.59	-5.26	-0.39	4.91e-7	Breast cancer;
PAAD	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	4.89	0.37	2.55e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.49	-5.41	-0.4	2.36e-7	Platelet distribution width;
PAAD	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.45	-0.34	1.67e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg22961107	chr3:194096808	NA	0.37	4.79	0.36	3.92e-6	Platelet distribution width;
PAAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg12463550	chr7:65579703	CRCP	-0.87	-5.31	-0.4	3.86e-7	Diabetic kidney disease;
PAAD	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg23752985	chr2:85803571	VAMP8	0.54	6.03	0.44	1.17e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-10.39	-0.64	1.93e-19	Height;
PAAD	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg26816564	chr1:7831052	VAMP3	0.81	6.17	0.45	5.84e-9	Inflammatory bowel disease;
PAAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.25	0.67	9.57e-22	Menopause (age at onset);
PAAD	trans	rs7172971	0.688	rs7162019	chr15:42385617	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.56	-5.66	-0.42	7.3900000000000007e-08	Childhood ear infection;
PAAD	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.86	-10.96	-0.66	5.66e-21	Aortic root size;
PAAD	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.77e-8	Migraine;
PAAD	cis	rs73416724	0.688	rs77688577	chr6:43328629	A/G	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27026673	chr2:39664343	MAP4K3	0.65	6.44	0.46	1.47e-9	Obesity-related traits;
PAAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg10356904	chr22:49881777	NA	-0.52	-5.51	-0.41	1.52e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.4	0.34	2.02e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17407555	1.000	rs17407324	chr4:10273043	A/C	cg11266682	chr4:10021025	SLC2A9	0.59	5.24	0.39	5.37e-7	Schizophrenia (age at onset);
PAAD	cis	rs9810890	1.000	rs73198868	chr3:128529111	T/C	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.72	10.21	0.64	5.86e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4731207	1.000	rs4731207	chr7:124396645	G/A	cg14311320	chr7:124405732	GPR37	0.43	4.71	0.36	5.62e-6	Cutaneous malignant melanoma;
PAAD	cis	rs16966918	0.579	rs974126	chr13:106268824	A/G	cg14363981	chr13:107186561	EFNB2	-0.79	-4.34	-0.33	2.58e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.9	-7.62	-0.53	2.53e-12	Diastolic blood pressure;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.62	-0.35	8e-6	Testicular germ cell tumor;
PAAD	cis	rs288326	0.561	rs76829215	chr2:183894452	A/G	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	4.59	0.35	9.26e-6	Height;
PAAD	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg22467129	chr15:76604101	ETFA	0.53	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs6494488	0.500	rs76625439	chr15:65018904	G/C	cg16425858	chr15:64791681	ZNF609	1.01	4.73	0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17507749	chr15:85114479	UBE2QP1	0.57	5.72	0.42	5.4e-8	P wave terminal force;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg03983476	chr2:10830698	NOL10	-0.62	-6.18	-0.45	5.57e-9	Prostate cancer;
PAAD	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.6	-5.44	-0.4	2.08e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg16386425	chr10:429943	DIP2C	0.47	4.46	0.34	1.62e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg22681709	chr2:178499509	PDE11A	-0.55	-5.16	-0.39	7.72e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.39	5.61	0.41	9.3e-8	Neuroticism;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-4.28	-0.33	3.28e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.56	5.9	0.43	2.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.7	-8.3	-0.56	5.22e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.2	-0.39	6.21e-7	Schizophrenia;
PAAD	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg18265118	chr7:2139243	MAD1L1	0.52	4.28	0.33	3.36e-5	Neuroticism;
PAAD	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.91	4.87	0.37	2.79e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.76	-7.72	-0.53	1.43e-12	Monocyte count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14433247	chr12:14923044	NA	0.65	6.64	0.47	5.21e-10	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05898928	chr22:22090066	YPEL1	-0.56	-6.65	-0.47	4.94e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28374715	0.510	rs28478807	chr15:41558620	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-7.05	-0.5	5.94e-11	Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.51	0.57	1.58e-14	Alzheimer's disease;
PAAD	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.81	-9.24	-0.6	2.05e-16	Eosinophil percentage of white cells;
PAAD	cis	rs6988985	0.678	rs28571827	chr8:144003207	G/A	cg23588384	chr8:144684634	NA	-0.3	-4.26	-0.33	3.58e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.65	-5.07	-0.38	1.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.83	-10.25	-0.64	4.45e-19	Obesity-related traits;
PAAD	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.66e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.61	-6.74	-0.48	3.02e-10	Motion sickness;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg12705353	chr12:122356852	WDR66	0.47	4.71	0.36	5.64e-6	Mean corpuscular volume;
PAAD	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.96	8.14	0.55	1.32e-13	Bipolar disorder;
PAAD	cis	rs3764400	0.567	rs8071879	chr17:46217457	G/A	cg24322968	chr17:46507895	SKAP1	-0.85	-5.27	-0.39	4.5e-7	Body mass index;
PAAD	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.24	0.45	4.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	1.04	7.21	0.5	2.51e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4795519	0.594	rs12452982	chr17:22216558	A/C	cg22648282	chr17:21454238	C17orf51	-0.55	-5.32	-0.4	3.6e-7	Chronic myeloid leukemia;
PAAD	cis	rs72634258	0.786	rs7537362	chr1:8177564	C/T	cg26816564	chr1:7831052	VAMP3	0.59	4.94	0.37	2.08e-6	Inflammatory bowel disease;
PAAD	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.63	-0.35	7.83e-6	Resting heart rate;
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11950805	chr1:43824379	CDC20	0.59	6.91	0.49	1.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg08371190	chr1:87598514	LOC339524	0.44	6.0	0.44	1.4e-8	Smoking behavior;
PAAD	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.85	-9.41	-0.61	7.5e-17	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.78	-0.36	4.09e-6	Lung cancer;
PAAD	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9535307	0.522	rs9596200	chr13:50416370	G/A	cg03658251	chr13:50265850	EBPL	-0.76	-4.91	-0.37	2.33e-6	Obesity-related traits;
PAAD	cis	rs183266	0.734	rs75583835	chr14:77475669	T/G	cg01682506	chr14:77422843	NA	-0.94	-4.51	-0.34	1.31e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs2398893	1.000	rs1411861	chr9:96763614	A/G	cg14459158	chr9:96720562	NA	0.34	4.35	0.33	2.53e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg23033748	chr14:75592666	NEK9	-0.43	-5.26	-0.39	4.83e-7	Height;
PAAD	cis	rs9810890	1.000	rs73198838	chr3:128498292	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.26	0.39	4.88e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-4.96	-0.37	1.86e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg04415270	chr2:102091202	RFX8	-0.65	-8.38	-0.56	3.3e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.49	5.8	0.43	3.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06287003	chr12:125626642	AACS	-0.56	-5.47	-0.41	1.77e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2671540	0.518	rs1916449	chr10:65643717	A/G	cg19573236	chr10:65733388	NA	-0.57	-4.51	-0.34	1.29e-5	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.71	0.42	5.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.67	6.24	0.45	4.1e-9	Coronary artery disease;
PAAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg04018474	chr16:31008003	STX1B	-0.29	-4.48	-0.34	1.47e-5	Dementia with Lewy bodies;
PAAD	cis	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg00262122	chr8:11665843	FDFT1	-0.52	-4.63	-0.35	7.88e-6	Neuroticism;
PAAD	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.46	-4.41	-0.34	1.97e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6976053	0.905	rs13232524	chr7:100512824	A/G	cg22425096	chr7:100417404	EPHB4	-0.49	-4.3	-0.33	3.03e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02364276	chr19:9271301	ZNF317	0.51	6.41	0.46	1.77e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs58521262	0.556	rs289303	chr19:23169015	A/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs6494488	0.500	rs1133357	chr15:64987570	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.85	0.37	3.02e-6	Coronary artery disease;
PAAD	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.76	-0.48	2.74e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.74	7.16	0.5	3.15e-11	Asthma;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00166722	chr3:10149974	C3orf24	0.97	7.98	0.54	3.38e-13	Alzheimer's disease;
PAAD	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs73206853	0.614	rs117546059	chr12:110508632	T/C	cg12870014	chr12:110450643	ANKRD13A	0.87	4.8	0.36	3.78e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.48	5.83	0.43	3.22e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.6	-0.35	8.9e-6	Testicular germ cell tumor;
PAAD	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.05	-0.38	1.25e-6	Interstitial lung disease;
PAAD	cis	rs16975963	0.644	rs11083428	chr19:38083967	A/C	cg08679971	chr19:38281047	NA	0.46	4.61	0.35	8.58e-6	Longevity;
PAAD	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg21366198	chr4:185655624	MLF1IP	-0.5	-4.61	-0.35	8.54e-6	Kawasaki disease;
PAAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7071247	0.915	rs10883875	chr10:105259917	T/C	cg18199807	chr10:106074281	ITPRIP	0.67	4.39	0.34	2.14e-5	Platelet aggregation;
PAAD	cis	rs112990264	1.000	rs80050938	chr1:213021027	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.61	4.87	0.37	2.83e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg18543610	chr13:100627929	NA	-0.64	-6.43	-0.46	1.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01066212	chr17:40729653	PSMC3IP	0.67	8.13	0.55	1.36e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg14393609	chr7:65229607	NA	0.63	6.72	0.48	3.41e-10	Aortic root size;
PAAD	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs7976059	0.824	rs12230839	chr12:52249405	A/G	cg13698196	chr12:52257893	NA	0.59	7.14	0.5	3.53e-11	Urate levels;
PAAD	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.65	4.34	0.33	2.62e-5	Systolic blood pressure;
PAAD	cis	rs4740619	0.933	rs10738404	chr9:15704715	A/G	cg14451791	chr9:16040625	NA	-0.38	-4.37	-0.33	2.25e-5	Body mass index;
PAAD	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.96	-10.78	-0.66	1.71e-20	Chronic sinus infection;
PAAD	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.75	-6.61	-0.47	6.07e-10	Body mass index;
PAAD	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.37	-0.4	2.92e-7	Myeloid white cell count;
PAAD	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.95	-0.37	1.93e-6	Bipolar disorder;
PAAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg05484376	chr2:27715224	FNDC4	0.48	4.88	0.37	2.69e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.42	-4.45	-0.34	1.62e-5	Birth weight;
PAAD	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.61	6.33	0.46	2.68e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	ch.8.33884649F	chr8:33765107	NA	0.56	6.37	0.46	2.13e-9	Body mass index;
PAAD	cis	rs11191205	0.697	rs11191117	chr10:103558261	G/A	cg15320455	chr10:103880129	LDB1	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.65	-0.42	7.71e-8	QT interval;
PAAD	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.14	-0.45	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.82	6.24	0.45	4.19e-9	Alzheimer's disease;
PAAD	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7567389	0.719	rs6733478	chr2:127995989	C/A	cg11380483	chr2:127933992	NA	-0.47	-4.68	-0.36	6.23e-6	Self-rated health;
PAAD	cis	rs3812111	0.545	rs1931895	chr6:116572971	C/G	cg18828861	chr6:116576566	TSPYL4	0.46	4.75	0.36	4.67e-6	Age-related macular degeneration;
PAAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg24253500	chr15:84953950	NA	0.57	6.62	0.47	5.74e-10	Schizophrenia;
PAAD	cis	rs838147	0.844	rs12611201	chr19:49248255	G/A	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs2239785	0.920	rs78523	chr22:36663248	C/T	cg15716373	chr22:36655542	APOL1	0.5	4.4	0.34	2.05e-5	Glomerulosclerosis;
PAAD	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.44	-5.09	-0.38	1.03e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7818688	0.614	rs79487086	chr8:95875513	G/A	cg16049864	chr8:95962084	TP53INP1	0.55	4.25	0.33	3.73e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.81	0.43	3.49e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs8050755	0.649	rs1800720	chr16:2105400	C/T	cg04515572	chr16:2107413	TSC2	-1.17	-7.88	-0.54	5.9e-13	Major depressive disorder;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01704862	chr7:150780657	TMUB1	0.61	6.43	0.46	1.58e-9	Iris heterochromicity;
PAAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.56	-6.69	-0.48	4.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.42	-4.25	-0.33	3.78e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.94	-0.37	2.03e-6	Menopause (age at onset);
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg23018236	chr17:30244563	NA	-0.63	-5.31	-0.4	3.75e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.67	6.01	0.44	1.31e-8	Mean platelet volume;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg17541715	chr7:1216824	NA	0.42	4.68	0.36	6.21e-6	Longevity;Endometriosis;
PAAD	cis	rs716804	0.654	rs7924499	chr11:10140797	T/C	cg06875754	chr11:10328428	ADM	-0.34	-4.25	-0.33	3.78e-5	Neuroticism;
PAAD	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.93	12.66	0.72	1.5e-25	Prudent dietary pattern;
PAAD	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg05313129	chr8:58192883	C8orf71	-0.44	-4.31	-0.33	2.95e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.66	-0.35	6.97e-6	Joint mobility (Beighton score);
PAAD	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-4.95	-0.37	1.95e-6	Mean corpuscular volume;
PAAD	cis	rs9506514	0.722	rs4769124	chr13:21226845	C/T	cg27234864	chr13:21295941	IL17D	0.44	4.42	0.34	1.86e-5	Coronary artery calcification;
PAAD	cis	rs743757	1.000	rs2236971	chr3:50473349	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.62	0.35	8e-6	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.96	9.56	0.61	3.08e-17	Post bronchodilator FEV1;
PAAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg23346134	chr3:49453900	TCTA	-0.47	-4.94	-0.37	2.07e-6	Menarche (age at onset);
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg15117754	chr3:10150083	C3orf24	0.61	5.89	0.43	2.4e-8	Alzheimer's disease;
PAAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.81	6.59	0.47	6.84e-10	Gastritis;
PAAD	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.41	-0.46	1.73e-9	Chronic sinus infection;
PAAD	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg14583973	chr4:3374767	RGS12	0.35	4.94	0.37	2.03e-6	Mean platelet volume;
PAAD	cis	rs950881	0.932	rs13408661	chr2:102955082	G/A	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	trans	rs7957197	0.628	rs692902	chr12:121197124	A/G	cg26392924	chr5:138718812	SLC23A1	-0.67	-6.35	-0.46	2.34e-9	Type 2 diabetes;
PAAD	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	1.25	10.27	0.64	3.96e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-14.06	-0.75	2.64e-29	Ulcerative colitis;
PAAD	cis	rs6074578	0.541	rs1578637	chr20:167431	G/A	cg16931068	chr20:139680	DEFB127	-0.41	-5.52	-0.41	1.44e-7	Hirschsprung disease;
PAAD	cis	rs12472274	0.646	rs34989058	chr2:239074698	C/T	cg17459225	chr2:239074497	NA	0.73	5.07	0.38	1.15e-6	Phospholipid levels (plasma);
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg12143784	chr7:64541923	NA	0.34	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.14	-0.38	8.25e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.63	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg02071572	chr4:1403502	NA	0.35	4.25	0.33	3.67e-5	Longevity;
PAAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs6089829	0.643	rs6011545	chr20:61660038	G/A	cg08045932	chr20:61659980	NA	0.58	6.29	0.45	3.26e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01114163	chr5:1856713	NA	-0.41	-4.27	-0.33	3.44e-5	Cardiovascular disease risk factors;
PAAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-6.71	-0.48	3.61e-10	Glomerular filtration rate;
PAAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.78	-9.25	-0.6	1.95e-16	Parkinson's disease;
PAAD	cis	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg17325771	chr7:75508891	RHBDD2	-0.43	-5.19	-0.39	6.77e-7	Eotaxin levels;
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11932746	chr7:23571818	TRA2A	-0.42	-4.31	-0.33	2.91e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg13207630	chr7:32358064	NA	0.82	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs6442522	0.678	rs3773452	chr3:15509954	C/A	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.25	-0.33	3.68e-5	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.86	-0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.66	4.56	0.35	1.06e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.19	16.68	0.8	3.65e-36	Total cholesterol levels;
PAAD	cis	rs282587	0.569	rs7987086	chr13:113409889	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-5.01	-0.38	1.52e-6	Glycated hemoglobin levels;
PAAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg16928487	chr17:17741425	SREBF1	0.35	4.79	0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.85	6.72	0.48	3.37e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs300774	0.844	rs300728	chr2:131828	G/A	cg21211680	chr2:198530	NA	-0.6	-5.62	-0.41	9e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg13207630	chr7:32358064	NA	0.91	4.49	0.34	1.39e-5	Body mass index;
PAAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs11892454	0.604	rs7564034	chr2:25941633	A/G	cg25181710	chr2:26045287	ASXL2	0.39	4.49	0.34	1.43e-5	Heschl's gyrus morphology;
PAAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.76	-0.36	4.56e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.27e-7	Life satisfaction;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00512023	chr15:34396328	PGBD4	0.56	6.43	0.46	1.57e-9	Body fat percentage;
PAAD	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.49	5.85	0.43	2.93e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs11811982	0.793	rs79025417	chr1:227579428	G/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs7713065	0.765	rs11242112	chr5:131767888	C/T	cg14196790	chr5:131705035	SLC22A5	-0.44	-4.31	-0.33	2.91e-5	Lung function (FEV1/FVC);
PAAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg12046867	chr14:103022105	NA	0.64	4.86	0.37	2.9e-6	Platelet count;
PAAD	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.48	-5.13	-0.38	8.61e-7	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.93	6.57	0.47	7.52e-10	Initial pursuit acceleration;
PAAD	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.82	-0.36	3.44e-6	Lymphocyte counts;
PAAD	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.44	4.31	0.33	2.95e-5	Blood pressure;
PAAD	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.38	-0.34	2.17e-5	Total body bone mineral density;
PAAD	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg10820045	chr2:198174542	NA	0.45	4.4	0.34	1.99e-5	Intracranial aneurysm;
PAAD	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.88e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg03989125	chr22:38214979	NA	0.59	5.61	0.41	9.4e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs1569019	0.915	rs1569020	chr12:131574485	A/C	cg01056242	chr12:131622739	GPR133	0.6	4.27	0.33	3.49e-5	Height;
PAAD	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg21479132	chr6:26055353	NA	0.8	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg01612440	chr4:3296283	NA	0.44	4.42	0.34	1.85e-5	Serum sulfate level;
PAAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-4.57	-0.35	1.02e-5	Parkinson's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00095276	chr5:1068111	SLC12A7	0.65	7.61	0.53	2.75e-12	Body fat percentage;
PAAD	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.93	6.08	0.44	9.49e-9	Major depressive disorder;
PAAD	cis	rs11700980	0.551	rs2832016	chr21:30111397	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.61	5.72	0.42	5.54e-8	Mood instability;
PAAD	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.59	-7.15	-0.5	3.35e-11	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.62	6.9	0.49	1.3100000000000001e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6942407	0.592	rs6465092	chr7:86750925	A/T	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg05313129	chr8:58192883	C8orf71	-0.65	-5.37	-0.4	2.91e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25072359	chr17:41440525	NA	0.54	5.22	0.39	5.67e-7	Menopause (age at onset);
PAAD	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.45	-4.39	-0.34	2.1e-5	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.68	-7.58	-0.52	3.2e-12	Motion sickness;
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg16926213	chr1:1841314	NA	0.38	4.63	0.35	7.89e-6	Body mass index;
PAAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg21929781	chr1:2537748	MMEL1	0.53	5.71	0.42	5.81e-8	Multiple sclerosis;
PAAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	4.33	0.33	2.67e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.75	9.24	0.6	2.04e-16	Bone mineral density;
PAAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.57	-5.17	-0.39	7.34e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.99	0.38	1.61e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs273909	0.622	rs2662314	chr5:131625169	C/T	cg11143131	chr5:131608246	PDLIM4	0.6	4.25	0.33	3.76e-5	Coronary artery disease;
PAAD	cis	rs3981351	0.752	rs12762208	chr10:115492303	A/G	cg24846397	chr10:115438155	CASP7	-0.5	-4.82	-0.36	3.42e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11789864	chr1:229694784	ABCB10	0.64	6.93	0.49	1.1e-10	Myopia (pathological);
PAAD	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.71	9.53	0.61	3.62e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.74	6.78	0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.81	0.48	2.11e-10	Systemic lupus erythematosus;
PAAD	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.53	5.47	0.41	1.83e-7	Response to antipsychotic treatment;
PAAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.52	-5.54	-0.41	1.33e-7	Schizophrenia;
PAAD	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.68	-6.41	-0.46	1.77e-9	Serum sulfate level;
PAAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.47	-0.34	1.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.61	6.16	0.45	6.15e-9	Height;
PAAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.61	6.45	0.46	1.38e-9	Monocyte count;
PAAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.59	0.35	9.25e-6	Educational attainment;
PAAD	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.77	8.02	0.55	2.7e-13	Neuroticism;
PAAD	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg09695851	chr17:3907499	NA	-0.68	-7.06	-0.5	5.69e-11	Type 2 diabetes;
PAAD	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg03938978	chr2:103052716	IL18RAP	0.67	8.43	0.56	2.49e-14	Asthma;
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg11416102	chr8:651193	ERICH1	0.95	6.03	0.44	1.2e-8	IgG glycosylation;
PAAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.84	-0.37	3.19e-6	Neuroticism;
PAAD	cis	rs11252688	1.000	rs11252688	chr10:4774565	T/C	cg26552733	chr10:5542941	CALML5	0.8	4.46	0.34	1.56e-5	Major depressive disorder;
PAAD	cis	rs78761021	0.755	rs79379978	chr17:9794488	G/A	cg26853458	chr17:9805074	RCVRN	0.73	8.65	0.57	6.9e-15	Type 2 diabetes;
PAAD	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs3996993	0.597	rs72938158	chr6:52735179	T/A	cg00536792	chr6:53530503	KLHL31	-0.42	-4.46	-0.34	1.6e-5	Hemoglobin concentration;
PAAD	cis	rs7707921	1.000	rs1019806	chr5:81551659	G/A	cg21483461	chr5:81570383	RPS23	0.55	4.63	0.35	7.74e-6	Breast cancer;
PAAD	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg09066997	chr16:75300724	BCAR1	0.58	4.26	0.33	3.58e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.31	-0.33	2.94e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg06375148	chr1:209958343	C1orf74	0.45	4.57	0.35	1.01e-5	Monobrow;
PAAD	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg01942863	chr7:99769432	GPC2	0.5	4.71	0.36	5.57e-6	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.72	0.36	5.23e-6	Breast cancer;
PAAD	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg04176122	chr11:118779835	BCL9L	-0.43	-4.46	-0.34	1.57e-5	Sjögren's syndrome;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg10864074	chr7:100318194	EPO	-0.47	-4.62	-0.35	8.21e-6	Other erythrocyte phenotypes;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.78	9.14	0.6	3.77e-16	Eosinophil percentage of white cells;
PAAD	cis	rs2117029	0.586	rs7957998	chr12:49574023	A/C	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.66	6.36	0.46	2.21e-9	Blood metabolite levels;
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	5.84	0.43	3.07e-8	Renal function-related traits (BUN);
PAAD	cis	rs10208940	1.000	rs10208940	chr2:68733389	C/T	cg12452813	chr2:68675892	NA	-0.64	-4.41	-0.34	1.93e-5	Urate levels in lean individuals;
PAAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.43e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.25	7.9	0.54	5.19e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11771526	0.579	rs58993780	chr7:32385244	A/T	cg27511599	chr7:32358540	NA	0.73	4.31	0.33	2.94e-5	Body mass index;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.27	0.45	3.57e-9	Systolic blood pressure;
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg22868518	chr11:507468	RNH1	-0.91	-4.75	-0.36	4.66e-6	Body mass index;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg00738919	chr7:1100172	C7orf50	0.58	5.19	0.39	6.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26095694	chr13:26789271	RNF6	-0.53	-6.35	-0.46	2.35e-9	Energy expenditure (24h);
PAAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.88	5.58	0.41	1.1e-7	Information processing speed;
PAAD	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.4	4.9	0.37	2.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs57994353	0.540	rs12379380	chr9:139279981	C/T	cg21253087	chr9:139290292	SNAPC4	0.46	4.38	0.33	2.18e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs6494488	0.500	rs72741369	chr15:64797048	C/T	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg26394196	chr10:1453818	ADARB2	-0.6	-6.75	-0.48	2.89e-10	Radiation response;
PAAD	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.62e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg17031739	chr1:67600172	NA	0.38	4.25	0.33	3.78e-5	Psoriasis;
PAAD	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.09	-0.5	4.61e-11	Cognitive function;
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs58653258	0.554	rs822841	chr1:234972552	G/A	cg03518729	chr1:235147744	NA	-0.45	-4.26	-0.33	3.5e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.71	8.3	0.56	5.18e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg08501292	chr6:25962987	TRIM38	0.91	5.45	0.4	1.95e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg24220031	chr2:73402428	NA	-0.3	-4.46	-0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16262614	chr3:133464971	TF	0.47	5.37	0.4	2.91e-7	Iron status biomarkers;
PAAD	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.69	5.39	0.4	2.64e-7	Blood protein levels;
PAAD	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.38	4.81	0.36	3.64e-6	Metabolite levels (MHPG);
PAAD	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs7766436	0.621	rs9348527	chr6:22604319	C/T	cg13666174	chr6:22585274	NA	-0.5	-6.17	-0.45	5.81e-9	Coronary artery disease;
PAAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.58	0.35	9.67e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.69	-7.4	-0.51	8.77e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.7	9.21	0.6	2.54e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg13263691	chr18:77568018	NA	0.6	6.3	0.46	3.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg03808351	chr9:123631620	PHF19	0.47	5.06	0.38	1.17e-6	Rheumatoid arthritis;
PAAD	cis	rs2274459	0.841	rs13204162	chr6:33696131	C/T	cg06253072	chr6:33679850	C6orf125	0.62	4.73	0.36	5.19e-6	Obesity (extreme);
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00166722	chr3:10149974	C3orf24	0.91	8.15	0.55	1.26e-13	Alzheimer's disease;
PAAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.8e-13	Height;
PAAD	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.66	-4.83	-0.36	3.34e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs735539	0.521	rs7984503	chr13:21448486	T/C	cg27234864	chr13:21295941	IL17D	0.64	5.42	0.4	2.25e-7	Dental caries;
PAAD	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.7	4.96	0.37	1.86e-6	Type 2 diabetes;
PAAD	cis	rs6782228	1.000	rs12635488	chr3:128352378	C/T	cg15607142	chr3:128420513	NA	-0.51	-5.23	-0.39	5.56e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs829661	0.793	rs829684	chr2:30708123	G/C	cg12454169	chr2:30669597	LCLAT1	0.63	4.37	0.33	2.27e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg00147160	chr1:26503991	CNKSR1	0.46	5.14	0.38	8.35e-7	Height;
PAAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.5	4.44	0.34	1.7e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.47	4.81	0.36	3.55e-6	Red blood cell count;
PAAD	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-1.36	-7.97	-0.54	3.53e-13	Corneal curvature;
PAAD	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.45	-0.4	1.98e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13006227	chr2:62132614	COMMD1	-0.65	-6.73	-0.48	3.22e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.68	-8.59	-0.57	9.59e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.22e-17	Electrocardiographic conduction measures;
PAAD	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.45	5.1	0.38	9.89e-7	Urinary metabolites (H-NMR features);
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.61	-5.76	-0.42	4.43e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg20503657	chr10:835505	NA	0.48	4.92	0.37	2.25e-6	Survival in rectal cancer;
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.71	5.4	0.4	2.5e-7	Initial pursuit acceleration;
PAAD	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg02404636	chr22:31891804	SFI1	0.64	5.93	0.43	1.99e-8	Colorectal cancer;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.75	6.8	0.48	2.3e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs13242816	1.000	rs2052105	chr7:116187979	T/C	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.84	-0.62	5.61e-18	Coronary artery disease;
PAAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.67	-6.27	-0.45	3.56e-9	Neurofibrillary tangles;
PAAD	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	5.56	0.41	1.2e-7	Birth weight;
PAAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.66	7.34	0.51	1.23e-11	Melanoma;
PAAD	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.36	4.67	0.35	6.57e-6	Calcium levels;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.81	-7.25	-0.51	1.98e-11	Body mass index;
PAAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.37	0.33	2.33e-5	Height;
PAAD	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg08875078	chr22:50639485	SELO	0.48	4.42	0.34	1.89e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.73	-5.41	-0.4	2.4e-7	Body mass index;
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04108811	chr1:246670728	SMYD3	0.72	7.67	0.53	1.88e-12	Obesity-related traits;
PAAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs1335587	1.000	rs1335587	chr13:102145560	C/T	cg09276445	chr13:102106423	ITGBL1	-0.37	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs6681460	0.549	rs1156618	chr1:67031564	T/C	cg02459107	chr1:67143332	SGIP1	0.62	6.52	0.47	9.58e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs7624766	0.518	rs9815499	chr3:160491722	T/A	cg22637730	chr3:160473554	PPM1L	0.56	4.86	0.37	2.85e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs9657904	0.813	rs2099892	chr3:105557340	T/C	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs7873102	0.654	rs7048063	chr9:37957229	C/T	cg03528946	chr9:38069800	SHB	-0.57	-5.69	-0.42	6.21e-8	Brain structure;
PAAD	cis	rs12282928	0.851	rs4980421	chr11:48301482	G/A	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9346353	0.689	rs1031631	chr6:70442866	C/T	cg03001484	chr6:70507230	LMBRD1	-0.34	-4.76	-0.36	4.52e-6	Sleep duration;
PAAD	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.3	-4.6	-0.35	9.02e-6	Red cell distribution width;
PAAD	cis	rs818427	0.684	rs2545164	chr5:112153665	C/T	cg06941702	chr5:112196734	SRP19	-0.52	-4.84	-0.37	3.16e-6	Total body bone mineral density;
PAAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs7870753	0.634	rs9299370	chr9:99101845	C/T	cg04728584	chr9:99329474	CDC14B	0.55	4.32	0.33	2.77e-5	Height;
PAAD	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.83	5.36	0.4	2.97e-7	Systolic blood pressure;
PAAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.58	-0.57	1e-14	HDL cholesterol;
PAAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	1.28	11.83	0.69	2.68e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg15123519	chr2:136567270	LCT	-0.38	-4.6	-0.35	8.87e-6	Mosquito bite size;
PAAD	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	4.29	0.33	3.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.51	4.65	0.35	7.06e-6	Breast cancer;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.69	6.57	0.47	7.55e-10	Blood metabolite levels;
PAAD	cis	rs1032355	0.558	rs76819189	chr4:100528381	C/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs2227564	1	rs2227564	chr10:75673101	C/T	cg16540259	chr10:75572220	NDST2	-0.49	-4.37	-0.33	2.26e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.94e-7	HDL cholesterol;
PAAD	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg20503657	chr10:835505	NA	0.52	5.32	0.4	3.63e-7	Survival in rectal cancer;
PAAD	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg24747557	chr10:131355152	MGMT	-0.44	-4.76	-0.36	4.48e-6	Response to temozolomide;
PAAD	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26926768	chr12:34528122	NA	0.36	4.55	0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-8.4	-0.56	2.97e-14	Body mass index;
PAAD	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-1.22	-6.67	-0.48	4.46e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	7.61	0.53	2.7e-12	Menopause (age at onset);
PAAD	cis	rs6466055	0.661	rs73186041	chr7:104916716	G/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.39	-0.34	2.12e-5	Ovarian reserve;
PAAD	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.38	-0.4	2.73e-7	Post bronchodilator FEV1;
PAAD	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.51	-7.29	-0.51	1.56e-11	Homoarginine levels;
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg05717871	chr11:638507	DRD4	-0.6	-5.4	-0.4	2.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-4.83	-0.36	3.31e-6	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.57	4.26	0.33	3.61e-5	Systolic blood pressure;
PAAD	cis	rs10861661	0.963	rs7977765	chr12:107205390	A/G	cg15890332	chr12:107067104	RFX4	0.47	4.44	0.34	1.72e-5	Triglyceride levels;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs2051773	0.567	rs77545208	chr11:17047747	G/T	cg15378786	chr11:17036137	PLEKHA7	0.52	4.34	0.33	2.57e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs740474	0.831	rs1479585	chr5:140976528	G/C	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.43	5.23	0.39	5.62e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg06375148	chr1:209958343	C1orf74	0.44	4.43	0.34	1.82e-5	Monobrow;
PAAD	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg15654264	chr1:150340011	RPRD2	0.49	4.78	0.36	4.05e-6	Migraine;
PAAD	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg05082376	chr22:42548792	NA	-0.42	-4.4	-0.34	2e-5	Cognitive function;
PAAD	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.94	-0.37	2.06e-6	Height;
PAAD	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.62	-0.41	8.82e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.56	0.47	7.95e-10	Resting heart rate;
PAAD	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg22467129	chr15:76604101	ETFA	0.51	4.89	0.37	2.57e-6	Blood metabolite levels;
PAAD	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.64	6.78	0.48	2.55e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg05434287	chr7:2030229	MAD1L1	0.44	4.87	0.37	2.83e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7219021	0.798	rs11652858	chr17:46844996	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.97	-0.37	1.77e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.15	-0.67	1.8e-21	Rheumatoid arthritis;
PAAD	cis	rs7804356	0.871	rs212850	chr7:26724279	G/T	cg03456212	chr7:26904342	SKAP2	-0.55	-4.51	-0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs17032980	0.956	rs7569503	chr2:67325858	A/G	cg06994420	chr2:66672553	MEIS1	-0.51	-4.46	-0.34	1.56e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14019695	chr9:139328340	INPP5E	0.58	4.96	0.37	1.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.38	-4.7	-0.36	5.81e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11584989	chr19:19387371	SF4	-0.72	-5.73	-0.42	5.29e-8	Bipolar disorder;
PAAD	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg05791153	chr7:19748676	TWISTNB	0.64	4.91	0.37	2.34e-6	Thyroid stimulating hormone;
PAAD	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.97	8.41	0.56	2.71e-14	Triglycerides;
PAAD	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.49	-4.49	-0.34	1.4e-5	Tuberculosis;
PAAD	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04479354	chr3:160118184	SMC4;IFT80	0.64	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs863345	0.604	rs6697656	chr1:158520737	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.75	-0.36	4.76e-6	Pneumococcal bacteremia;
PAAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.63	-6.33	-0.46	2.62e-9	Ear protrusion;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg07202610	chr7:1142643	C7orf50	-0.78	-5.47	-0.41	1.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	1.96	11.2	0.67	1.34e-21	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.71	-4.65	-0.35	7.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.2	0.55	9.46e-14	Menopause (age at onset);
PAAD	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.86	-4.62	-0.35	8.13e-6	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01074643	chr2:3337709	TSSC1	0.66	7.1	0.5	4.36e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.51	0.41	1.47e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.31e-5	Aortic root size;
PAAD	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16676472	chr19:42363949	RPS19	0.57	6.67	0.48	4.55e-10	Monocyte percentage of white cells;
PAAD	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.43	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.88	-4.79	-0.36	3.88e-6	Cholesterol, total;
PAAD	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg01766943	chr2:54829624	SPTBN1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.47	-5.43	-0.4	2.17e-7	Mean arterial pressure;
PAAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.9	11.09	0.67	2.64e-21	Methadone dose in opioid dependence;
PAAD	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-1.06	-7.5	-0.52	4.86e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs7874142	0.546	rs10776906	chr9:137692089	A/T	cg13803559	chr9:137684506	COL5A1	0.46	5.03	0.38	1.35e-6	Longevity;
PAAD	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.6	-6.45	-0.46	1.43e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.65	7.28	0.51	1.71e-11	Iron status biomarkers;
PAAD	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg16735072	chr8:11994639	FAM66D	0.44	4.46	0.34	1.56e-5	Triglycerides;
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.51	6.39	0.46	1.92e-9	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.85	9.08	0.59	5.4e-16	Coronary artery disease;
PAAD	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13047869	chr3:10149882	C3orf24	0.79	6.65	0.47	5.02e-10	Alzheimer's disease;
PAAD	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.4	-0.34	2e-5	Platelet count;
PAAD	cis	rs10078545	0.649	rs4703920	chr5:82128879	C/A	cg20697188	chr5:82360356	TMEM167A;SCARNA18	0.51	4.71	0.36	5.66e-6	Chin dimples;
PAAD	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg23534315	chr17:78082725	GAA	0.48	4.78	0.36	4.08e-6	Yeast infection;
PAAD	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09035552	chr10:86001241	LRIT1	-0.59	-6.57	-0.47	7.51e-10	Obesity-related traits;
PAAD	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.99	-10.75	-0.66	2.08e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.35	0.33	2.49e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.69	6.96	0.49	9.67e-11	Cardiac Troponin-T levels;
PAAD	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.8	7.93	0.54	4.41e-13	Corneal astigmatism;
PAAD	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.94	5.91	0.43	2.17e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.36	-0.33	2.38e-5	Resting heart rate;
PAAD	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.45	4.56	0.35	1.06e-5	Primary biliary cholangitis;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg04025307	chr7:1156635	C7orf50	0.68	4.79	0.36	3.87e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.75	-0.88	8.21e-51	Myeloid white cell count;
PAAD	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.23	0.39	5.59e-7	HIV-1 control;
PAAD	cis	rs375066	0.868	rs378112	chr19:44421929	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.04	0.55	2.28e-13	Lipoprotein (a) levels;
PAAD	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.81	-9.76	-0.62	8.82e-18	Coronary artery disease;
PAAD	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg08992911	chr2:238395768	MLPH	0.73	5.55	0.41	1.24e-7	Prostate cancer;
PAAD	cis	rs4664293	0.605	rs7556888	chr2:160540261	T/C	cg04215213	chr2:159602169	NA	0.4	4.42	0.34	1.84e-5	Monocyte percentage of white cells;
PAAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13606994	chr1:44402422	ARTN	-0.45	-4.67	-0.35	6.47e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg21523528	chr20:32077966	CBFA2T2	0.5	4.25	0.33	3.66e-5	Height;
PAAD	cis	rs6466055	0.611	rs3213742	chr7:104643230	C/A	cg04380332	chr7:105027541	SRPK2	-0.61	-6.31	-0.46	2.9e-9	Schizophrenia;
PAAD	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.23	0.56	7.73e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.96	-7.56	-0.52	3.59e-12	Multiple sclerosis;
PAAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg05038881	chr1:10490043	APITD1	0.45	5.25	0.39	5.02e-7	Prostate cancer;
PAAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs3136739	0.614	rs113455175	chr8:42007622	C/T	cg12054981	chr8:42037387	PLAT	0.66	4.78	0.36	4.08e-6	Plasma plasminogen activator levels;
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.84	0.58	2.21e-15	Lung cancer;
PAAD	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.73	-7.73	-0.53	1.33e-12	Blood metabolite levels;
PAAD	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.43	-0.34	1.78e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1499972	0.878	rs817513	chr3:117733823	A/T	cg07612923	chr3:117604196	NA	-1.08	-7.02	-0.49	6.99e-11	Schizophrenia;
PAAD	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13910715	chr3:63901000	ATXN7	-0.64	-7.25	-0.51	1.92e-11	Monocyte percentage of white cells;
PAAD	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2555155	0.935	rs10769693	chr11:6520346	C/G	cg24637308	chr11:6592297	DNHD1	0.49	5.11	0.38	9.46e-7	DNA methylation (variation);
PAAD	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	5.47	0.41	1.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06998765	chr14:75389618	RPS6KL1	0.28	4.98	0.37	1.69e-6	Caffeine consumption;
PAAD	cis	rs2594989	1.000	rs346077	chr3:11326102	A/C	cg01796438	chr3:11312864	ATG7	-0.7	-5.59	-0.41	1.03e-7	Circulating chemerin levels;
PAAD	trans	rs2309322	0.623	rs1996387	chr4:181255535	T/C	cg24124977	chr17:78010277	CCDC40;TBC1D16	0.75	6.51	0.47	1.06e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	10.42	0.65	1.56e-19	Prudent dietary pattern;
PAAD	cis	rs311392	0.715	rs311394	chr8:55083332	C/A	cg11783602	chr8:55087084	NA	-0.56	-6.49	-0.47	1.13e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg24747557	chr10:131355152	MGMT	-0.5	-5.16	-0.39	7.52e-7	Response to temozolomide;
PAAD	cis	rs1678618	0.615	rs4148950	chr10:73771706	G/A	cg20897136	chr10:74034667	DDIT4	0.37	4.35	0.33	2.5e-5	Smoking behavior;
PAAD	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.81	-7.88	-0.54	6.01e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7975161	0.572	rs4964228	chr12:104572759	T/C	cg25273343	chr12:104657179	TXNRD1	-0.88	-4.5	-0.34	1.36e-5	Toenail selenium levels;
PAAD	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg02580895	chr19:2754563	NA	-0.51	-4.42	-0.34	1.88e-5	Total cholesterol levels;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg10621924	chr7:39171070	POU6F2	0.37	5.74	0.42	4.95e-8	IgG glycosylation;
PAAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs9815354	1.000	rs9854833	chr3:41775577	C/T	cg03022575	chr3:42003672	ULK4	0.84	5.87	0.43	2.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9815354	1.000	rs6796210	chr3:41851718	T/C	cg03022575	chr3:42003672	ULK4	0.75	5.59	0.41	1.02e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg20626645	chr3:53528846	CACNA1D	-0.45	-4.32	-0.33	2.79e-5	Height;
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.73	-11.1	-0.67	2.4e-21	Body mass index;
PAAD	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.57	5.74	0.42	4.99e-8	Hemoglobin levels;
PAAD	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	6.33	0.46	2.6e-9	Schizophrenia;
PAAD	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.4	0.46	1.83e-9	Lung cancer in ever smokers;
PAAD	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg10011062	chr15:43941034	CATSPER2	-0.75	-4.3	-0.33	2.99e-5	Lung cancer in ever smokers;
PAAD	cis	rs732765	0.689	rs10139925	chr14:75123076	C/T	cg01090926	chr14:75137805	KIAA0317	0.51	4.61	0.35	8.45e-6	Non-small cell lung cancer;
PAAD	cis	rs9888739	1.000	rs9928372	chr16:31312053	A/G	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs7562790	0.651	rs2049367	chr2:36668219	G/T	cg01206211	chr2:36825736	FEZ2	0.45	4.57	0.35	9.92e-6	QRS duration;QRS complex (Cornell);
PAAD	cis	rs6066835	0.702	rs6122709	chr20:47278938	C/A	cg18078177	chr20:47281410	PREX1	1.11	5.12	0.38	9.3e-7	Multiple myeloma;
PAAD	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.79	8.68	0.58	5.82e-15	Caffeine consumption;
PAAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.31	-0.4	3.85e-7	Mood instability;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20799095	chr1:225924665	NA	0.68	7.44	0.52	6.83e-12	Smoking initiation;
PAAD	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.53	-5.35	-0.4	3.23e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg02023728	chr11:77925099	USP35	-0.43	-4.46	-0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.94	6.79	0.48	2.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1003645	1.000	rs9908216	chr17:34346018	A/C	cg07880005	chr17:34842371	ZNHIT3	-0.57	-4.29	-0.33	3.12e-5	Blood protein levels;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg21951975	chr1:209979733	IRF6	0.57	5.74	0.42	4.93e-8	Coronary artery disease;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg09491104	chr22:46646882	C22orf40	-0.96	-9.08	-0.59	5.51e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.78	-9.51	-0.61	4.13e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs12935418	0.523	rs2549846	chr16:81024127	A/T	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.85	5.73	0.42	5.1e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs755249	0.567	rs16826000	chr1:39713860	G/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-1.29	-7.07	-0.5	5.3e-11	Prostate cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14460003	chr20:31173015	NA	0.65	6.36	0.46	2.2e-9	Primary biliary cholangitis;
PAAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.83	0.48	1.87e-10	Schizophrenia;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.6	5.23	0.39	5.56e-7	Dialysis-related mortality;
PAAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.92	-0.43	2.08e-8	IgG glycosylation;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg18641463	chr7:2144579	MAD1L1	-0.46	-4.54	-0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.54	0.61	3.36e-17	Lymphocyte counts;
PAAD	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg22189786	chr22:42395067	WBP2NL	0.51	4.33	0.33	2.74e-5	Birth weight;
PAAD	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.55	5.91	0.43	2.13e-8	Menopause (age at onset);
PAAD	cis	rs5015933	0.801	rs11999662	chr9:128143928	T/A	cg14078157	chr9:128172775	NA	-0.39	-4.44	-0.34	1.73e-5	Body mass index;
PAAD	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-1.04	-10.87	-0.66	1e-20	Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01733783	chr9:128003852	HSPA5	0.57	6.34	0.46	2.55e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	9.51	0.61	4.14e-17	Platelet count;
PAAD	cis	rs2036402	0.955	rs34250800	chr5:156418363	C/T	cg21915449	chr5:156456672	HAVCR1	-0.37	-4.27	-0.33	3.37e-5	Hypertriglyceridemia;
PAAD	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg06484146	chr7:12443880	VWDE	-0.61	-4.39	-0.34	2.08e-5	Coronary artery disease;
PAAD	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.78	-7.65	-0.53	2.13e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2070997	0.607	rs72765060	chr9:133712404	T/C	cg11464064	chr9:133710261	ABL1	0.63	4.39	0.34	2.11e-5	Response to amphetamines;
PAAD	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.41	0.34	1.97e-5	Lung cancer;
PAAD	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.33	0.33	2.7e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.57	-7.06	-0.5	5.63e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07361580	chr16:29874914	LOC440356;CDIPT	0.62	6.47	0.46	1.24e-9	Myopia (pathological);
PAAD	cis	rs16910800	1.000	rs12420544	chr11:23200505	A/C	cg20040320	chr11:23191996	NA	-0.57	-4.87	-0.37	2.79e-6	Cancer;
PAAD	cis	rs11971779	0.588	rs2003531	chr7:139126578	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg24296786	chr1:45957014	TESK2	0.52	4.81	0.36	3.63e-6	Homocysteine levels;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	cis	rs617219	0.551	rs2131978	chr5:78613986	G/A	cg24856658	chr5:78533917	JMY	0.38	4.28	0.33	3.29e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	10.76	0.66	2.03e-20	Total body bone mineral density;
PAAD	cis	rs13242816	1.000	rs35595472	chr7:116122306	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	trans	rs901683	1.000	rs79490183	chr10:46080241	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg04160749	chr8:58172571	NA	-0.59	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1957429	1.000	rs1957429	chr14:65354033	C/T	cg23373153	chr14:65346875	NA	1.04	7.25	0.51	1.96e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	0.52	4.61	0.35	8.54e-6	Testicular germ cell tumor;
PAAD	cis	rs11641365	0.651	rs2879902	chr16:88778133	C/A	cg00034003	chr16:88779146	CTU2	-0.44	-4.5	-0.34	1.32e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-5.4	-0.4	2.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2730260	0.736	rs73169215	chr7:158833701	T/C	cg13444538	chr7:158905317	VIPR2	-0.62	-4.47	-0.34	1.55e-5	Myopia (pathological);
PAAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.87	-9.87	-0.62	4.73e-18	Coronary artery disease;
PAAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg10556349	chr10:835070	NA	0.71	5.35	0.4	3.15e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs2445762	0.600	rs12148492	chr15:51653193	A/C	cg25905881	chr15:51634250	GLDN	-0.54	-4.73	-0.36	5.17e-6	Hormone measurements;
PAAD	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.53	-6.1	-0.44	8.58e-9	Systemic lupus erythematosus;
PAAD	cis	rs67311347	0.521	rs6769540	chr3:40357904	G/A	cg09455208	chr3:40491958	NA	0.45	5.71	0.42	5.81e-8	Renal cell carcinoma;
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	trans	rs6694672	1.000	rs4915345	chr1:197102839	A/C	cg26994526	chr18:47719735	MYO5B	-0.83	-6.4	-0.46	1.82e-9	Asthma;
PAAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg10591111	chr5:226296	SDHA	-0.72	-5.44	-0.4	2.05e-7	Breast cancer;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01283332	chr5:1856932	NA	-0.46	-4.86	-0.37	2.95e-6	Cardiovascular disease risk factors;
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.29	0.33	3.15e-5	Bipolar disorder;
PAAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13012494	chr21:47604986	C21orf56	-0.46	-4.81	-0.36	3.56e-6	Testicular germ cell tumor;
PAAD	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.6	5.43	0.4	2.15e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7173419	0.601	rs9788702	chr15:28207095	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.31	-0.4	3.89e-7	Eye color;
PAAD	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3026101	0.534	rs57303034	chr17:5319003	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07017636	chr1:165567312	NA	0.6	6.44	0.46	1.5e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.85e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.45	4.68	0.35	6.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs3206736	0.548	rs17793929	chr7:35068980	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.49	-4.63	-0.35	7.71e-6	Diastolic blood pressure;
PAAD	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg08648136	chr8:956695	NA	0.44	4.8	0.36	3.81e-6	Schizophrenia;
PAAD	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.77	9.46	0.61	5.51e-17	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00953282	chr9:139606849	FAM69B	0.57	6.32	0.46	2.77e-9	Monocyte percentage of white cells;
PAAD	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs8077577	0.708	rs2290502	chr17:18133495	G/A	cg03916694	chr17:18150707	FLII	-0.39	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs2281636	1.000	rs11190263	chr10:101506383	A/G	cg05149213	chr10:101381631	SLC25A28	0.46	4.39	0.34	2.09e-5	Obesity-related traits;
PAAD	cis	rs921968	0.541	rs72965147	chr2:219341827	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-7.91	-0.54	4.98e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg23435118	chr5:141488016	NDFIP1	-0.56	-5.5	-0.41	1.54e-7	Crohn's disease;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.68	7.57	0.52	3.36e-12	Total body bone mineral density;
PAAD	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs72799341	1.000	rs7185007	chr16:30927509	C/T	cg00531865	chr16:30841666	NA	-0.68	-5.01	-0.38	1.49e-6	Diastolic blood pressure;
PAAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18075040	chr12:96337100	AMDHD1;CCDC38	0.56	6.36	0.46	2.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7539409	0.667	rs55824969	chr1:84182205	G/A	cg10977910	chr1:84465055	TTLL7	-0.88	-4.83	-0.36	3.28e-6	Alzheimer's disease;
PAAD	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17214737	chr10:75757811	VCL	0.67	7.7	0.53	1.58e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4356203	0.905	rs656623	chr11:17219179	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.4	-0.34	2.07e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg23024343	chr7:107201750	COG5	0.57	4.69	0.36	6.01e-6	Coronary artery disease;
PAAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg14983838	chr19:29218262	NA	0.72	6.22	0.45	4.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	4.54	0.35	1.15e-5	Menarche (age at onset);
PAAD	cis	rs6066835	0.718	rs60028924	chr20:47359415	A/G	cg18078177	chr20:47281410	PREX1	0.86	4.59	0.35	9.29e-6	Multiple myeloma;
PAAD	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.54	-6.99	-0.49	8.26e-11	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.38	0.4	2.79e-7	Prudent dietary pattern;
PAAD	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.41	-5.16	-0.39	7.52e-7	Lewy body disease;
PAAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg03983715	chr16:68378420	PRMT7	-0.83	-5.95	-0.43	1.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg14703610	chr5:56206110	C5orf35	0.57	5.38	0.4	2.74e-7	Initial pursuit acceleration;
PAAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.61	7.96	0.54	3.62e-13	Renal cell carcinoma;
PAAD	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg26876637	chr1:152193138	HRNR	-0.87	-6.5	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg16898833	chr6:26189333	HIST1H4D	0.63	4.99	0.38	1.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.73	-7.73	-0.53	1.33e-12	Blood metabolite levels;
PAAD	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.62	5.79	0.42	3.97e-8	Menopause (age at onset);
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02071572	chr4:1403502	NA	0.49	6.33	0.46	2.61e-9	Longevity;
PAAD	cis	rs12826942	0.959	rs34507359	chr12:42736831	A/G	cg19980929	chr12:42632907	YAF2	0.55	4.96	0.37	1.85e-6	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.86	7.4	0.51	8.59e-12	Recombination rate (females);
PAAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14119001	chr9:139324193	INPP5E	-0.62	-5.58	-0.41	1.09e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg14515779	chr1:101123966	NA	-0.54	-6.4	-0.46	1.81e-9	Monocyte count;
PAAD	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg22852734	chr6:133119734	C6orf192	0.91	4.87	0.37	2.82e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	cis	rs688181	0.585	rs674060	chr6:158101113	A/G	cg17310882	chr6:158066609	ZDHHC14	0.35	4.31	0.33	2.87e-5	Platelet distribution width;
PAAD	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-4.57	-0.35	1.01e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13560548	chr3:10150139	C3orf24	0.6	5.34	0.4	3.29e-7	Alzheimer's disease;
PAAD	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg02780029	chr10:43622663	RET	-0.48	-4.82	-0.36	3.46e-6	Hirschsprung disease;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs818427	0.896	rs351770	chr5:112199199	C/A	cg07820702	chr5:112228657	REEP5	0.53	4.76	0.36	4.47e-6	Total body bone mineral density;
PAAD	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13939156	chr17:80058883	NA	-0.41	-4.46	-0.34	1.59e-5	Life satisfaction;
PAAD	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.67	-6.71	-0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg08315770	chr6:39281885	KCNK17	-0.6	-6.2	-0.45	5.11e-9	Type 2 diabetes;
PAAD	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.53	5.6	0.41	9.55e-8	Eye color traits;
PAAD	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg00278107	chr5:1061253	SLC12A7	0.48	4.55	0.35	1.09e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.91	6.49	0.47	1.16e-9	Initial pursuit acceleration;
PAAD	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.46	-4.34	-0.33	2.58e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.89	-7.28	-0.51	1.66e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.49e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	8.68	0.58	5.66e-15	Age at first birth;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.64	6.84	0.49	1.77e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.81	0.48	2.08e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg00800038	chr16:89945340	TCF25	-0.83	-4.29	-0.33	3.21e-5	Skin colour saturation;
PAAD	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg10818794	chr15:86012489	AKAP13	0.5	5.26	0.39	4.74e-7	Bulimia nervosa;
PAAD	cis	rs2290419	0.667	rs11228537	chr11:68927358	A/G	cg17042914	chr11:68898666	NA	-0.63	-4.31	-0.33	2.93e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg10437265	chr15:77819839	NA	-0.38	-4.3	-0.33	3.01e-5	Type 2 diabetes;
PAAD	cis	rs9677476	0.542	rs6437009	chr2:232110483	C/T	cg07929768	chr2:232055508	NA	-0.36	-4.3	-0.33	3.07e-5	Food antigen IgG levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12026095	chr19:49468461	FTL	-0.56	-6.62	-0.47	5.95e-10	Body fat percentage;
PAAD	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.41	0.34	1.94e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.79	8.22	0.55	8.26e-14	Diastolic blood pressure;
PAAD	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.75	0.36	4.68e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2968864	1.000	rs1547958	chr7:150640285	C/T	cg06221570	chr7:150558377	ABP1	0.49	5.59	0.41	1.01e-7	QT interval;
PAAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.31	0.33	2.9e-5	Mean corpuscular volume;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.7	5.46	0.4	1.92e-7	Alzheimer's disease;
PAAD	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg21770322	chr7:97807741	LMTK2	0.49	6.77	0.48	2.66e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20167471	chr1:16528984	ARHGEF19	0.47	4.65	0.35	7.21e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg26209169	chr5:1316264	NA	0.38	4.34	0.33	2.62e-5	Lung cancer;
PAAD	cis	rs773506	0.589	rs773507	chr9:93974553	G/T	cg14446406	chr9:93919335	NA	-0.32	-4.36	-0.33	2.43e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.42	6.37	0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6446731	0.568	rs732869	chr4:3286801	C/G	cg00060484	chr4:3287598	NA	0.58	5.07	0.38	1.16e-6	Mean platelet volume;
PAAD	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.77	6.2	0.45	5.12e-9	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.77	-5.38	-0.4	2.78e-7	Monocyte percentage of white cells;
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.28	-0.51	1.7e-11	Longevity;
PAAD	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg15841412	chr13:111365552	ING1	0.52	4.32	0.33	2.76e-5	Coronary artery disease;
PAAD	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.27	-0.33	3.43e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-8.69	-0.58	5.54e-15	Body mass index;
PAAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.59	-7.22	-0.51	2.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg18944383	chr4:111397179	ENPEP	0.74	8.08	0.55	1.91e-13	Height;
PAAD	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.43	4.68	0.35	6.38e-6	HDL cholesterol levels;
PAAD	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.45	4.62	0.35	8.04e-6	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.37	-0.4	2.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12986413	0.967	rs4807211	chr19:2174643	G/A	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.13e-6	Height;
PAAD	cis	rs13278732	0.500	rs2290467	chr8:99040154	G/T	cg27313044	chr8:99903985	NA	-0.53	-4.39	-0.34	2.14e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-5.62	-0.41	8.99e-8	Schizophrenia;
PAAD	cis	rs4742903	0.904	rs966390	chr9:106944031	A/G	cg14250997	chr9:106856677	SMC2	0.42	4.42	0.34	1.89e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.04	0.44	1.16e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	1.08	11.83	0.69	2.66e-23	Cisplatin-induced ototoxicity;
PAAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10821973	0.527	rs7896953	chr10:64025653	C/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.52	-5.59	-0.41	1.05e-7	Testicular germ cell tumor;
PAAD	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.47	-5.15	-0.39	7.83e-7	Testicular germ cell tumor;
PAAD	cis	rs17127529	0.570	rs6588132	chr1:65805554	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.5	0.34	1.36e-5	Idiopathic osteonecrosis of the femoral head;
PAAD	cis	rs13424612	0.860	rs34277046	chr2:240897331	G/A	cg01812947	chr2:240904978	NDUFA10	0.61	5.37	0.4	2.91e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7651511	1.000	rs11717842	chr3:141208684	A/C	cg25967872	chr3:141205623	RASA2	0.5	4.29	0.33	3.19e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-4.41	-0.34	1.97e-5	Resting heart rate;
PAAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16048239	chr19:1924679	SCAMP4	0.53	6.73	0.48	3.34e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.61	4.57	0.35	1.01e-5	Neuroblastoma;
PAAD	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.3	-0.39	4e-7	Pulmonary function;
PAAD	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	0.96	6.68	0.48	4.18e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.93e-7	Red blood cell count;
PAAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04520396	chr17:1585312	PRPF8	-0.56	-6.72	-0.48	3.51e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg27411982	chr8:10470053	RP1L1	-0.49	-5.47	-0.41	1.84e-7	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13053783	chr1:1334803	CCNL2;LOC148413	-0.64	-6.3	-0.46	3.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.75	-0.48	2.95e-10	Menopause (age at onset);
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.18	-0.39	6.91e-7	Other erythrocyte phenotypes;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08561442	chr16:49891857	NA	-0.6	-7.01	-0.49	7.27e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11694441	0.618	rs1866409	chr2:119573604	C/A	cg14634534	chr2:119616825	NA	-0.45	-4.83	-0.36	3.27e-6	Monobrow;
PAAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.57	6.24	0.45	4.07e-9	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg26752657	chr1:75199075	CRYZ;TYW3	0.56	5.46	0.4	1.91e-7	Resistin levels;
PAAD	cis	rs4343996	0.934	rs4607498	chr7:3368197	C/T	cg21248987	chr7:3385318	SDK1	-0.48	-5.17	-0.39	7.15e-7	Motion sickness;
PAAD	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.49	5.46	0.4	1.9e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.67e-19	Tonsillectomy;
PAAD	cis	rs2594989	0.943	rs9836989	chr3:11463637	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-4.36	-0.33	2.35e-5	Circulating chemerin levels;
PAAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs13144136	0.775	rs13136927	chr4:10669522	A/C	cg10242279	chr4:10666415	CLNK	-0.37	-4.58	-0.35	9.68e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs4862307	0.514	rs77116912	chr4:185014978	T/C	cg06737308	chr4:185021514	ENPP6	0.84	9.47	0.61	5.32e-17	Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg22691776	chr3:15032403	NR2C2	0.31	4.59	0.35	9.41e-6	Mean platelet volume;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg17372657	chr7:1216933	NA	-0.35	-4.44	-0.34	1.71e-5	Longevity;Endometriosis;
PAAD	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.56	5.11	0.38	9.71e-7	Testicular germ cell tumor;
PAAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.56	5.62	0.41	8.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.7	0.36	5.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3809060	0.959	rs3930513	chr11:32455527	G/T	cg27259320	chr11:32460587	WIT1	0.35	4.49	0.34	1.37e-5	Inguinal hernia;
PAAD	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.6	6.19	0.45	5.41e-9	Pancreatic cancer;
PAAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg17796960	chr10:135278976	LOC619207	-0.57	-6.36	-0.46	2.24e-9	Systemic lupus erythematosus;
PAAD	cis	rs13102973	0.640	rs10434071	chr4:135842080	C/G	cg14419869	chr4:135874104	NA	0.45	4.56	0.35	1.04e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.57	6.41	0.46	1.73e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2286379	0.544	rs10773980	chr12:1798718	C/T	cg11558135	chr12:861715	WNK1	-0.46	-4.47	-0.34	1.54e-5	Blood pressure (smoking interaction);
PAAD	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.21	0.6	2.47e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg02980000	chr4:1222292	CTBP1	0.57	4.26	0.33	3.61e-5	Systolic blood pressure;
PAAD	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs2302729	0.790	rs10505724	chr12:2782070	C/T	cg19945202	chr12:2788847	CACNA1C	-0.65	-5.17	-0.39	7.36e-7	Sleep quality;
PAAD	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-7.93	-0.54	4.39e-13	Dental caries;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11608355	0.538	rs10850074	chr12:109800531	T/C	cg19025524	chr12:109796872	NA	-0.58	-6.2	-0.45	4.98e-9	Neuroticism;
PAAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg10556349	chr10:835070	NA	0.71	5.39	0.4	2.58e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs61931739	0.592	rs61927750	chr12:33696070	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-7.48	-0.52	5.62e-12	Morning vs. evening chronotype;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.57	6.93	0.49	1.1e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg13798912	chr7:905769	UNC84A	0.59	4.51	0.34	1.3e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07685180	chr8:600429	NA	-0.89	-5.73	-0.42	5.35e-8	IgG glycosylation;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.59	5.06	0.38	1.17e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6466055	0.576	rs2106500	chr7:104616744	G/A	cg04380332	chr7:105027541	SRPK2	-0.48	-4.54	-0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.9	6.83	0.48	1.92e-10	Alzheimer's disease;
PAAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.63	0.47	5.45e-10	Personality dimensions;
PAAD	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.64	6.21	0.45	4.92e-9	White matter hyperintensity burden;
PAAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-4.34	-0.33	2.59e-5	Selective IgA deficiency;
PAAD	cis	rs955333	0.685	rs1022403	chr6:154899713	C/G	cg20019720	chr6:154832845	CNKSR3	-0.36	-4.57	-0.35	1e-5	Diabetic kidney disease;
PAAD	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg05084668	chr3:125655381	ALG1L	-0.39	-4.35	-0.33	2.52e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg15693483	chr7:1102177	C7orf50	0.44	4.81	0.36	3.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.01	-0.49	7.36e-11	Leprosy;
PAAD	cis	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.44	5.1	0.38	9.97e-7	Coronary artery disease;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07930192	chr7:1003750	NA	0.37	4.47	0.34	1.53e-5	Longevity;Endometriosis;
PAAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg03959625	chr15:84868606	LOC388152	0.48	5.19	0.39	6.62e-7	Schizophrenia;
PAAD	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.97	-0.44	1.63e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1279750	0.651	rs2546421	chr5:180586879	A/G	cg06965003	chr5:180616570	NA	-0.64	-4.31	-0.33	2.89e-5	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18966810	chr2:134368695	NA	-0.58	-6.97	-0.49	9.15e-11	Obesity-related traits;
PAAD	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.77	6.2	0.45	5.08e-9	Alzheimer's disease;
PAAD	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-1.53	-8.48	-0.57	1.84e-14	Atopic dermatitis;
PAAD	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.75	5.99	0.44	1.49e-8	Crohn's disease;
PAAD	cis	rs528301	0.833	rs540606	chr2:45138507	A/G	cg15393275	chr2:45165193	NA	-0.49	-5.34	-0.4	3.37e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.43	-4.29	-0.33	3.19e-5	Height;
PAAD	cis	rs12474201	0.887	rs35158352	chr2:46953763	C/T	cg06386533	chr2:46925753	SOCS5	0.88	9.27	0.6	1.73e-16	Height;
PAAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.62	6.4	0.46	1.84e-9	Crohn's disease;
PAAD	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.71	-0.48	3.54e-10	Morning vs. evening chronotype;
PAAD	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-10.25	-0.64	4.68e-19	Height;
PAAD	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-5.0	-0.38	1.55e-6	Pubertal anthropometrics;
PAAD	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.9	7.85	0.54	6.93e-13	Alzheimer's disease;
PAAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg02135003	chr7:105160482	PUS7	-0.84	-5.53	-0.41	1.35e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg17759274	chr19:39260954	NA	0.39	4.29	0.33	3.22e-5	Heart rate;
PAAD	cis	rs11235843	0.853	rs60020777	chr11:73482496	T/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	cis	rs7623687	0.579	rs78807522	chr3:49056150	C/A	cg19401529	chr3:49056140	DALRD3	1.0	6.81	0.48	2.11e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs10073892	0.830	rs13355136	chr5:101607291	A/G	cg17280723	chr5:101634495	NA	0.44	4.55	0.35	1.1e-5	Cognitive decline (age-related);
PAAD	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.87	-0.37	2.76e-6	Schizophrenia;
PAAD	cis	rs375066	0.901	rs374307	chr19:44404398	G/T	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-10.97	-0.66	5.31e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.44	-0.56	2.39e-14	Diabetic kidney disease;
PAAD	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.46	-4.43	-0.34	1.81e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.85	9.13	0.6	3.94e-16	Cognitive function;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.57	0.65	6.39e-20	Platelet count;
PAAD	trans	rs6694672	0.867	rs1332662	chr1:197108427	A/G	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.64	7.18	0.5	2.9100000000000002e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs59698941	0.943	rs59634464	chr5:132178735	A/G	cg16419906	chr5:132167176	NA	-0.58	-4.41	-0.34	1.99e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2092319	0.649	rs807266	chr1:26070184	G/A	cg12446045	chr1:25857419	NA	-0.44	-4.37	-0.33	2.29e-5	Nose morphology;
PAAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	6.43	0.46	1.53e-9	Initial pursuit acceleration;
PAAD	cis	rs4605213	0.869	rs8079266	chr17:49246726	A/C	cg00965052	chr17:49230932	NME1;NME1-NME2	0.48	4.92	0.37	2.27e-6	Height;
PAAD	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg16586182	chr3:47516702	SCAP	-0.75	-8.78	-0.58	3.18e-15	Colorectal cancer;
PAAD	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16417436	chr16:28758564	NA	0.45	4.33	0.33	2.74e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.4	-0.4	2.58e-7	Asthma;
PAAD	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.51	-4.88	-0.37	2.65e-6	Morning vs. evening chronotype;
PAAD	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg02743256	chr7:2109353	MAD1L1	-0.63	-5.74	-0.42	4.9e-8	Neuroticism;
PAAD	cis	rs6547631	0.622	rs1437743	chr2:85924989	A/G	cg24620635	chr2:85921963	GNLY	-0.41	-5.43	-0.4	2.17e-7	Blood protein levels;
PAAD	cis	rs4144027	0.875	rs6576010	chr14:104349602	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.39	-4.8	-0.36	3.72e-6	Blood metabolite levels;
PAAD	cis	rs6537837	0.838	rs71657105	chr1:110114122	G/A	cg05049280	chr1:110155535	GNAT2	0.46	4.75	0.36	4.61e-6	Major depressive disorder;
PAAD	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.74	0.36	4.98e-6	Menopause (age at onset);
PAAD	trans	rs61677309	1.000	rs4938501	chr11:118166497	A/G	cg15548380	chr1:19984784	NBL1	-0.62	-6.79	-0.48	2.32e-10	Lung cancer in ever smokers;
PAAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg09796270	chr17:17721594	SREBF1	-0.49	-5.44	-0.4	2.08e-7	Total body bone mineral density;
PAAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.86	8.6	0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.0	0.49	7.71e-11	Lung cancer in ever smokers;
PAAD	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg25686905	chr3:183603175	PARL	-0.33	-4.35	-0.33	2.5e-5	Menopause (age at onset);
PAAD	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.53	5.19	0.39	6.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.65	-5.17	-0.39	7.34e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11406216	chr6:158497842	SYNJ2	-0.65	-6.88	-0.49	1.5e-10	Obesity-related traits;
PAAD	cis	rs80346118	0.673	rs6012536	chr20:47423563	C/T	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	0.63	4.66	0.35	6.97e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg10621924	chr7:39171070	POU6F2	0.29	4.71	0.36	5.56e-6	IgG glycosylation;
PAAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.48	4.69	0.36	6.03e-6	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09994773	chr1:9212514	MIR34A	-0.63	-6.44	-0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.15	-8.62	-0.57	7.92e-15	Diabetic kidney disease;
PAAD	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs7534824	0.625	rs61782078	chr1:101498212	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.71	0.36	5.52e-6	Refractive astigmatism;
PAAD	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3026101	0.671	rs8077472	chr17:5299359	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17159098	chr11:120196353	TMEM136	0.56	6.7	0.48	3.91e-10	Monocyte percentage of white cells;
PAAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.51	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.3	0.56	5.23e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.6	6.69	0.48	3.96e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg06057569	chr22:50219754	BRD1	0.72	5.17	0.39	7.11e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg11494091	chr17:61959527	GH2	0.53	4.4	0.34	2.06e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11037575	0.739	rs938942	chr11:43712390	A/T	cg24662154	chr11:44118094	EXT2	0.43	4.4	0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.55	-6.43	-0.46	1.57e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-4.28	-0.33	3.32e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.48	4.38	0.33	2.19e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00463171	chr13:100741364	PCCA	-0.69	-7.19	-0.5	2.68e-11	Smoking initiation;
PAAD	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg15890332	chr12:107067104	RFX4	-0.42	-4.77	-0.36	4.24e-6	Total body bone mineral density;
PAAD	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12136530	0.593	rs12125806	chr1:19734781	A/G	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs13424612	0.764	rs66550334	chr2:240889517	G/A	cg01812947	chr2:240904978	NDUFA10	0.59	5.61	0.41	9.52e-8	Odorant perception (isobutyraldehyde);
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.68	7.82	0.54	8.31e-13	Longevity;Endometriosis;
PAAD	cis	rs6594713	0.577	rs6883547	chr5:112916853	A/G	cg12552261	chr5:112820674	MCC	-0.63	-5.44	-0.4	2.1e-7	Brain cytoarchitecture;
PAAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.57	6.02	0.44	1.26e-8	Obesity-related traits;
PAAD	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.7	6.86	0.49	1.62e-10	Coronary artery disease;
PAAD	cis	rs6010044	0.609	rs8142140	chr22:51091914	C/T	cg07576525	chr22:51146088	SHANK3	0.5	4.37	0.33	2.27e-5	Fibrinogen levels;Fibrinogen;
PAAD	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-8.83	-0.58	2.42e-15	Morning vs. evening chronotype;
PAAD	cis	rs8044995	0.563	rs79543001	chr16:68387341	C/T	cg03983715	chr16:68378420	PRMT7	-0.97	-6.38	-0.46	2.07e-9	Schizophrenia;
PAAD	cis	rs920915	0.967	rs443401	chr15:58692095	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.43	-0.34	1.77e-5	Age-related macular degeneration;
PAAD	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.76e-8	Adiposity;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg16342193	chr10:102329863	NA	-0.78	-8.46	-0.57	2.04e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg19044706	chr2:241829685	C2orf54	0.48	4.6	0.35	8.91e-6	Urinary metabolites;
PAAD	cis	rs11716531	0.510	rs513546	chr3:27348920	A/G	cg02860705	chr3:27208620	NA	0.53	5.17	0.39	7.16e-7	Diastolic blood pressure;
PAAD	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-5.52	-0.41	1.44e-7	Vitiligo;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg11995313	chr8:8860691	ERI1	0.43	4.31	0.33	2.93e-5	Mood instability;
PAAD	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.05	0.38	1.23e-6	Morning vs. evening chronotype;
PAAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.7	9.13	0.59	4.08e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.44	-0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs282587	0.502	rs371150	chr13:113397815	C/T	cg02820901	chr13:113351484	ATP11A	-0.65	-4.96	-0.37	1.89e-6	Glycated hemoglobin levels;
PAAD	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg18084798	chr19:33555255	RHPN2	0.46	4.76	0.36	4.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9652601	0.779	rs9929994	chr16:11178245	A/G	cg04616529	chr16:11181986	CLEC16A	0.46	5.18	0.39	6.99e-7	Systemic lupus erythematosus;
PAAD	cis	rs282587	0.569	rs399569	chr13:113398464	A/T	cg02820901	chr13:113351484	ATP11A	-0.65	-4.96	-0.37	1.89e-6	Glycated hemoglobin levels;
PAAD	cis	rs12935418	0.616	rs874053	chr16:81006107	A/G	cg16651780	chr16:81037892	C16orf61	0.66	6.1	0.44	8.57e-9	Mean corpuscular volume;
PAAD	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg22189786	chr22:42395067	WBP2NL	0.59	5.75	0.42	4.85e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.1	13.38	0.74	1.82e-27	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg23024343	chr7:107201750	COG5	0.51	4.25	0.33	3.69e-5	Coronary artery disease;
PAAD	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35785195	0.593	rs12831240	chr12:114243590	A/G	cg08193681	chr12:114234200	NA	0.56	4.31	0.33	2.97e-5	Daytime sleep phenotypes;
PAAD	cis	rs16975963	0.843	rs112628349	chr19:38268238	G/C	cg08679971	chr19:38281047	NA	0.5	4.88	0.37	2.68e-6	Longevity;
PAAD	cis	rs564309	0.764	rs61825312	chr1:228530748	G/A	cg01328119	chr1:228783545	DUSP5P	0.71	4.41	0.34	1.98e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg22875332	chr1:76189707	ACADM	0.47	4.76	0.36	4.4e-6	Daytime sleep phenotypes;
PAAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-5.05	-0.38	1.26e-6	Mean platelet volume;
PAAD	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg18357526	chr6:26021779	HIST1H4A	0.5	4.45	0.34	1.63e-5	Height;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.56	0.57	1.19e-14	Prudent dietary pattern;
PAAD	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg09913449	chr8:42400586	C8orf40	0.48	5.14	0.39	8.17e-7	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.78	8.02	0.55	2.65e-13	Body mass index;
PAAD	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-1.0	-12.37	-0.71	9.12e-25	Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg19337854	chr7:99768885	GPC2	0.53	4.98	0.37	1.71e-6	Platelet count;
PAAD	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.95	-7.24	-0.51	2.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.94	-13.03	-0.73	1.59e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4679121	0.643	rs16837468	chr3:126153792	C/G	cg05485589	chr3:126194908	ZXDC	-1.0	-4.89	-0.37	2.55e-6	Pursuit maintenance gain;
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.6	0.35	8.76e-6	Electroencephalogram traits;
PAAD	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.0	0.38	1.55e-6	Restless legs syndrome;
PAAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.81	-0.48	2.11e-10	Breast cancer;
PAAD	cis	rs3136441	0.901	rs3136499	chr11:46758290	G/A	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.72	7.44	0.52	7.07e-12	Lung cancer;
PAAD	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	5.55	0.41	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg08436684	chr16:88034427	BANP	0.53	4.73	0.36	5.02e-6	Menopause (age at onset);
PAAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19784903	chr17:45786737	TBKBP1	0.53	5.65	0.42	7.82e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg23018236	chr17:30244563	NA	-0.6	-4.77	-0.36	4.19e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11024102	0.962	rs12575487	chr11:17019317	C/T	cg15084286	chr11:17036142	PLEKHA7	0.51	4.6	0.35	8.92e-6	Glaucoma (primary angle closure);
PAAD	cis	rs939584	1.000	rs2947411	chr2:614168	A/G	cg03610516	chr2:642275	NA	0.64	5.82	0.43	3.4e-8	Body mass index;
PAAD	cis	rs2286379	0.596	rs7296521	chr12:1802988	C/T	cg11558135	chr12:861715	WNK1	-0.44	-4.3	-0.33	3.02e-5	Blood pressure (smoking interaction);
PAAD	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.45	-5.19	-0.39	6.63e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg18357526	chr6:26021779	HIST1H4A	0.67	6.43	0.46	1.57e-9	Blood metabolite levels;
PAAD	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-7.75	-0.53	1.22e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06850241	chr22:41845214	NA	0.62	5.5	0.41	1.59e-7	Vitiligo;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.85	6.4	0.46	1.86e-9	Alzheimer's disease;
PAAD	cis	rs112990264	0.656	rs6540756	chr1:212878828	C/T	cg01785514	chr1:212988523	TATDN3	1.14	7.25	0.51	2e-11	Itch intensity from mosquito bite;
PAAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs12612619	0.704	rs10185736	chr2:27321224	T/C	cg00617064	chr2:27272375	NA	0.49	4.79	0.36	3.95e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg20673841	chr7:107026890	COG5	0.5	4.37	0.33	2.29e-5	Coronary artery disease;
PAAD	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-4.7	-0.36	5.72e-6	Colorectal cancer;
PAAD	cis	rs62027291	0.950	rs17465482	chr15:77262489	A/G	cg17802220	chr15:77601643	NA	-0.63	-4.36	-0.33	2.41e-5	Plateletcrit;
PAAD	cis	rs776905	0.831	rs474810	chr13:113780910	T/C	cg09069900	chr13:113776964	F10	-0.64	-4.79	-0.36	3.93e-6	Blood protein levels;
PAAD	cis	rs600550	0.588	rs2304936	chr11:60102156	T/C	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.24e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs3762637	0.941	rs74467988	chr3:122083140	C/T	cg24169773	chr3:122142474	KPNA1	-0.65	-4.45	-0.34	1.69e-5	LDL cholesterol levels;
PAAD	cis	rs9815354	1.000	rs6791806	chr3:41889995	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.98	8.42	0.56	2.57e-14	Gut microbiome composition (summer);
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.5	5.43	0.4	2.17e-7	Longevity;Endometriosis;
PAAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.92	-11.53	-0.68	1.72e-22	Coronary artery disease;
PAAD	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.72	6.59	0.47	6.77e-10	Alcohol dependence;Nicotine use;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.78	-7.53	-0.52	4.08e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.57	-6.54	-0.47	8.69e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs901683	1.000	rs71496603	chr10:46005649	A/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.77	6.01	0.44	1.31e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg01059385	chr22:42394853	WBP2NL	0.48	4.39	0.34	2.11e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-5.27	-0.39	4.63e-7	Eosinophil percentage of white cells;
PAAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.92	5.87	0.43	2.67e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9832740	1.000	rs4677151	chr3:72394027	G/A	cg07881171	chr3:72988159	GXYLT2	0.44	4.31	0.33	2.96e-5	Height;
PAAD	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-4.58	-0.35	9.74e-6	Fat distribution (HIV);
PAAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.52	6.67	0.48	4.48e-10	Schizophrenia;
PAAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.34	-0.4	3.32e-7	Monocyte count;
PAAD	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-6.57	-0.47	7.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg00253185	chr1:247542119	NA	-0.55	-4.54	-0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11264799	0.765	rs6427389	chr1:157632011	C/A	cg18268488	chr1:157545234	FCRL4	0.41	4.63	0.35	7.66e-6	IgA nephropathy;
PAAD	cis	rs4838594	0.590	rs1867579	chr10:49671394	A/G	cg17291251	chr10:49678358	ARHGAP22	-0.49	-4.59	-0.35	9.33e-6	Daytime sleep phenotypes;
PAAD	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs12753920	0.735	rs12403751	chr1:92673203	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.47	-4.44	-0.34	1.75e-5	Systemic lupus erythematosus;
PAAD	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4740619	0.585	rs1359949	chr9:15987538	G/T	cg14451791	chr9:16040625	NA	0.39	4.71	0.36	5.61e-6	Body mass index;
PAAD	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.46	6.65	0.47	4.9e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.8	8.41	0.56	2.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.81	0.36	3.6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs832187	0.813	rs704368	chr3:63868337	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.46	4.4	0.34	2.07e-5	Schizophrenia;
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg06145435	chr7:1022769	CYP2W1	0.33	4.42	0.34	1.9e-5	Longevity;Endometriosis;
PAAD	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.64	0.42	7.9e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.33	-4.48	-0.34	1.43e-5	Mean corpuscular volume;
PAAD	cis	rs6894268	1.000	rs6894268	chr5:179032488	A/G	cg26135573	chr5:179059668	NA	0.59	5.38	0.4	2.79e-7	Eating disorders;
PAAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.83	6.18	0.45	5.63e-9	Tuberculosis;
PAAD	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg08601574	chr20:25228251	PYGB	0.49	5.0	0.38	1.59e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.94	-12.38	-0.71	8.72e-25	Prudent dietary pattern;
PAAD	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.45	-4.45	-0.34	1.68e-5	Crohn's disease;
PAAD	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.66	6.23	0.45	4.26e-9	Subjective well-being;
PAAD	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.63	7.36	0.51	1.1e-11	Aortic root size;
PAAD	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.58	5.23	0.39	5.59e-7	Mean platelet volume;
PAAD	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg09491104	chr22:46646882	C22orf40	-0.95	-5.79	-0.43	3.89e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12808519	0.688	rs3740640	chr11:69587583	C/T	cg27032427	chr11:69587568	NA	0.66	5.33	0.4	3.45e-7	Urate levels in overweight individuals;
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.13	13.31	0.73	2.71e-27	Cognitive function;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.46	0.57	2.09e-14	Alzheimer's disease;
PAAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.62	-6.88	-0.49	1.43e-10	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16497018	chr10:102133035	C10orf75	0.59	7.61	0.53	2.67e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg20607287	chr7:12443886	VWDE	-0.71	-5.57	-0.41	1.15e-7	Coronary artery disease;
PAAD	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg13870426	chr17:30244630	NA	-0.72	-5.05	-0.38	1.23e-6	Height;
PAAD	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.57	-0.35	1.02e-5	Lung cancer;
PAAD	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	1.38	7.03	0.5	6.6e-11	Prostate cancer;
PAAD	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.57	5.09	0.38	1.05e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.62	5.95	0.43	1.77e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs732765	0.734	rs2270424	chr14:75159007	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.53	-0.34	1.2e-5	Non-small cell lung cancer;
PAAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg12935359	chr14:103987150	CKB	-0.52	-5.6	-0.41	9.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.86	-7.95	-0.54	4.03e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg14008862	chr17:28927542	LRRC37B2	0.95	5.31	0.4	3.86e-7	Body mass index;
PAAD	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1797885	0.714	rs709161	chr3:12526188	G/T	cg07775309	chr3:12595852	NA	0.41	4.45	0.34	1.62e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg09491104	chr22:46646882	C22orf40	-0.92	-4.91	-0.37	2.33e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.65e-13	Eye color traits;
PAAD	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg12454169	chr2:30669597	LCLAT1	0.73	5.58	0.41	1.07e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.75	-0.42	4.8e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.67	7.16	0.5	3.21e-11	Schizophrenia;
PAAD	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg03098721	chr1:84464084	TTLL7	0.48	4.64	0.35	7.6e-6	Obesity-related traits;
PAAD	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg08562672	chr19:21860753	NA	-0.46	-4.93	-0.37	2.12e-6	Pain;
PAAD	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.5	4.49	0.34	1.4e-5	Mean corpuscular volume;
PAAD	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg19337854	chr7:99768885	GPC2	0.59	5.43	0.4	2.24e-7	Lung function (FEV1/FVC);
PAAD	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg22800045	chr5:56110881	MAP3K1	0.71	5.93	0.43	2e-8	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.63	7.56	0.52	3.47e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.31	-0.4	3.79e-7	Vitamin D levels;
PAAD	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg01426195	chr3:39028469	NA	-0.77	-8.52	-0.57	1.46e-14	Handedness;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.72	-8.9	-0.59	1.54e-15	Lymphocyte counts;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.87	10.16	0.64	7.79e-19	Blood protein levels;
PAAD	cis	rs11966931	0.857	rs4391294	chr6:108090454	G/A	cg10566610	chr6:108093680	SCML4	-0.5	-4.71	-0.36	5.54e-6	Neutrophil percentage of white cells;
PAAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.73	7.5	0.52	5.09e-12	Body mass index;
PAAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.53	-0.34	1.19e-5	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.6	5.79	0.42	3.95e-8	Prudent dietary pattern;
PAAD	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg14196790	chr5:131705035	SLC22A5	0.42	4.61	0.35	8.55e-6	Breast cancer;
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg19729930	chr2:74357872	NA	0.98	10.82	0.66	1.4e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg18551225	chr6:44695536	NA	-0.74	-7.47	-0.52	5.93e-12	Total body bone mineral density;
PAAD	cis	rs6963495	0.818	rs1721500	chr7:105219233	T/G	cg19920283	chr7:105172520	RINT1	0.74	5.39	0.4	2.64e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.5	4.5	0.34	1.35e-5	P wave terminal force;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.54	6.78	0.48	2.55e-10	Atrioventricular conduction;
PAAD	cis	rs30380	0.922	rs246453	chr5:96123336	T/C	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.76	7.91	0.54	4.91e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.68	7.74	0.53	1.27e-12	Testicular germ cell tumor;
PAAD	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs300703	0.655	rs300798	chr2:105917	A/G	cg21211680	chr2:198530	NA	-0.88	-7.29	-0.51	1.61e-11	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg20003494	chr4:90757398	SNCA	-0.4	-4.43	-0.34	1.77e-5	Dementia with Lewy bodies;
PAAD	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.68	6.39	0.46	1.96e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26850624	chr5:429559	AHRR	-0.45	-5.61	-0.41	9.15e-8	Cystic fibrosis severity;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.98	0.54	3.39e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg21399703	chr1:247681439	NA	0.66	6.39	0.46	1.94e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7818688	0.697	rs74633621	chr8:95981037	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.79	10.09	0.63	1.19e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.56	-5.69	-0.42	6.49e-8	Immature fraction of reticulocytes;
PAAD	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg09508736	chr19:41385865	CYP2A7	-0.54	-5.69	-0.42	6.46e-8	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.85	5.53	0.41	1.35e-7	Diabetic kidney disease;
PAAD	cis	rs13256369	0.671	rs57506062	chr8:8554535	G/A	cg06671706	chr8:8559999	CLDN23	0.6	5.83	0.43	3.23e-8	Obesity-related traits;
PAAD	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.61	-5.86	-0.43	2.74e-8	Refractive astigmatism;
PAAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-4.57	-0.35	1e-5	Huntington's disease progression;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.43	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9842133	0.587	rs1524517	chr3:179647365	C/T	cg18765712	chr3:179670323	PEX5L	0.52	4.58	0.35	9.55e-6	Blood metabolite levels;
PAAD	cis	rs4704187	0.625	rs11947996	chr5:74545548	A/T	cg03227963	chr5:74354835	NA	0.48	4.69	0.36	5.92e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg01966878	chr4:90757139	SNCA	-0.45	-4.37	-0.33	2.33e-5	Dementia with Lewy bodies;
PAAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg13722127	chr7:150037890	RARRES2	-0.52	-5.2	-0.39	6.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-1.01	-13.72	-0.74	2.2e-28	Breast cancer;
PAAD	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.84	-9.4	-0.61	8.07e-17	Prudent dietary pattern;
PAAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs955333	0.685	rs17539620	chr6:154896235	G/T	cg20019720	chr6:154832845	CNKSR3	0.44	5.13	0.38	8.83e-7	Diabetic kidney disease;
PAAD	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg21681030	chr2:46777652	RHOQ	0.46	4.26	0.33	3.6e-5	Height;
PAAD	cis	rs911119	0.657	rs2104005	chr20:23630761	G/A	cg16589663	chr20:23618590	CST3	0.95	6.24	0.45	4.25e-9	Chronic kidney disease;
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.28	-0.39	4.37e-7	Life satisfaction;
PAAD	cis	rs13242816	0.881	rs55930206	chr7:116172850	C/T	cg16553024	chr7:116138462	CAV2	-0.61	-4.29	-0.33	3.18e-5	P wave duration;
PAAD	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.38	-0.4	2.73e-7	Post bronchodilator FEV1;
PAAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs6466055	0.639	rs3823752	chr7:104624626	C/T	cg04380332	chr7:105027541	SRPK2	-0.61	-6.31	-0.46	2.9e-9	Schizophrenia;
PAAD	cis	rs28647808	0.881	rs7852803	chr9:136245903	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.97	5.79	0.43	3.92e-8	Blood protein levels;
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.75	-0.36	4.73e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	6.68	0.48	4.31e-10	Body mass index;
PAAD	cis	rs136211	0.929	rs5750254	chr22:36774449	G/A	cg11153328	chr22:36877737	TXN2	0.48	4.3	0.33	3.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg13191508	chr8:144600686	ZC3H3	0.83	4.51	0.34	1.31e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6011674	1.000	rs59784306	chr20:61859596	C/T	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.74	-4.54	-0.35	1.15e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.88e-6	Breast cancer;
PAAD	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg14146966	chr2:61757674	XPO1	0.38	4.78	0.36	4.11e-6	Tuberculosis;
PAAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg10495392	chr1:46806563	NSUN4	0.57	5.69	0.42	6.33e-8	Menopause (age at onset);
PAAD	cis	rs28580297	1	rs28580297	chr4:119427957	C/G	cg21605333	chr4:119757512	SEC24D	0.7	4.31	0.33	2.94e-5	Body mass index;
PAAD	cis	rs8040855	0.547	rs17611171	chr15:85572699	T/A	cg08123816	chr15:85640762	PDE8A	-0.45	-5.46	-0.41	1.87e-7	Bulimia nervosa;
PAAD	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.96	8.07	0.55	1.99e-13	Triglycerides;
PAAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg04106633	chr4:1044584	NA	-0.72	-6.33	-0.46	2.67e-9	Recombination rate (females);
PAAD	cis	rs1018836	0.537	rs13251501	chr8:91458796	G/A	cg16814680	chr8:91681699	NA	-0.85	-9.0	-0.59	8.44e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.32	4.35	0.33	2.48e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg15654264	chr1:150340011	RPRD2	-0.51	-4.9	-0.37	2.46e-6	Migraine;
PAAD	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.81	-7.59	-0.52	3.07e-12	Body mass index;
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.97	-10.72	-0.66	2.51e-20	Blood metabolite levels;
PAAD	cis	rs758324	0.812	rs7709934	chr5:131145210	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17467752	chr17:38218738	THRA	0.49	4.44	0.34	1.74e-5	Asthma;
PAAD	cis	rs7101378	0.599	rs7938927	chr11:108899180	A/G	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-7.83	-0.54	7.66e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.89	9.5	0.61	4.22e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14497545	chr4:140754475	MAML3	-0.51	-6.54	-0.47	8.98e-10	Immature fraction of reticulocytes;
PAAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.37	-0.33	2.28e-5	Glomerular filtration rate;
PAAD	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-5.48	-0.41	1.72e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6074578	0.740	rs6086552	chr20:145853	C/A	cg16931068	chr20:139680	DEFB127	0.41	5.6	0.41	9.9e-8	Hirschsprung disease;
PAAD	cis	rs1577917	0.559	rs7763210	chr6:86808618	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-7.07	-0.5	5.13e-11	Response to antipsychotic treatment;
PAAD	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg08088566	chr11:430123	ANO9	0.81	4.39	0.34	2.07e-5	Body mass index;
PAAD	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.44	0.34	1.72e-5	IgG glycosylation;
PAAD	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg00277334	chr10:82204260	NA	-0.44	-4.81	-0.36	3.59e-6	Sarcoidosis;
PAAD	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	8.14	0.55	1.32e-13	Cognitive test performance;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.58	-5.64	-0.42	8.23e-8	Eye color traits;
PAAD	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.76	10.1	0.63	1.16e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.8	8.33	0.56	4.32e-14	Corneal astigmatism;
PAAD	cis	rs4668356	0.892	rs966181	chr2:171796255	A/G	cg13882835	chr2:172017928	TLK1	-0.87	-4.35	-0.33	2.45e-5	Cognitive performance;
PAAD	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.76	-6.93	-0.49	1.12e-10	Blood protein levels;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.59	6.38	0.46	2e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.55	-0.52	3.77e-12	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.91	6.4	0.46	1.79e-9	Pulse pressure;
PAAD	cis	rs10861342	1.000	rs115224406	chr12:105578060	C/T	cg23923672	chr12:105501055	KIAA1033	0.75	4.56	0.35	1.04e-5	IgG glycosylation;
PAAD	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.78	7.71	0.53	1.56e-12	Corneal astigmatism;
PAAD	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg05627522	chr15:75251581	NA	-0.4	-4.39	-0.34	2.14e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.22	10.47	0.65	1.2e-19	Uric acid levels;
PAAD	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	1.22	7.33	0.51	1.24e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.44	-6.26	-0.45	3.74e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs9397240	0.846	rs9384310	chr6:155630653	G/A	cg06694381	chr6:155569200	TIAM2	-0.48	-4.29	-0.33	3.19e-5	Life satisfaction;
PAAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.75e-9	Cognitive function;
PAAD	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg15654264	chr1:150340011	RPRD2	0.48	4.69	0.36	6.15e-6	Migraine;
PAAD	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.73	7.39	0.51	9.22e-12	Colorectal cancer;
PAAD	cis	rs17095355	0.710	rs2150211	chr10:111855414	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.73	-0.36	5.04e-6	Biliary atresia;
PAAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.49	-5.36	-0.4	2.97e-7	Platelet distribution width;
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.73	-0.36	5.04e-6	Obesity-related traits;
PAAD	cis	rs6500395	0.584	rs9922553	chr16:48739059	A/G	cg04672837	chr16:48644449	N4BP1	0.56	4.54	0.35	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.11	0.59	4.43e-16	Asthma;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg22535103	chr8:58192502	C8orf71	-1.22	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.33	-4.26	-0.33	3.58e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16579770	chr16:72058938	DHODH	0.39	4.51	0.34	1.29e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.93	9.41	0.61	7.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	4.91	0.37	2.32e-6	Joint mobility (Beighton score);
PAAD	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.63	5.69	0.42	6.27e-8	HIV-1 control;
PAAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.53	-0.47	9.4e-10	Aortic root size;
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg05299278	chr17:33885742	SLFN14	0.42	5.02	0.38	1.45e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	Cognitive function;
PAAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg08027265	chr7:2291960	NA	-0.59	-5.8	-0.43	3.65e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg10094624	chr16:18813259	ARL6IP1	-0.63	-5.15	-0.39	7.94e-7	Parkinson's disease;
PAAD	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-1.11	-7.87	-0.54	6.16e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	4.98	0.37	1.74e-6	Systolic blood pressure;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21899138	chr3:52720056	GNL3;PBRM1	-0.61	-6.41	-0.46	1.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2735413	0.802	rs5008070	chr16:78096404	T/C	cg04733911	chr16:78082701	NA	0.55	5.67	0.42	7.1e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg19254793	chr6:44695348	NA	-0.47	-4.48	-0.34	1.44e-5	Total body bone mineral density;
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.55	5.24	0.39	5.16e-7	Vitiligo;
PAAD	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.71	7.42	0.52	7.63e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg07810366	chr2:100720526	AFF3	-0.36	-4.51	-0.34	1.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.4	-4.58	-0.35	9.43e-6	Breast cancer;
PAAD	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.48	-0.57	1.83e-14	Gut microbiome composition (summer);
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.53	-4.4	-0.34	2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-9.9	-0.63	3.89e-18	Obesity-related traits;
PAAD	cis	rs62229266	0.654	rs62230787	chr21:37376480	A/G	cg12218747	chr21:37451666	NA	-0.49	-5.23	-0.39	5.54e-7	Mitral valve prolapse;
PAAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.87	-7.64	-0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs2229238	0.911	rs58881140	chr1:154515193	C/T	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.29e-6	Coronary heart disease;
PAAD	cis	rs6508941	0.959	rs79576994	chr19:41016935	A/C	cg25811527	chr19:40791102	AKT2	0.52	4.33	0.33	2.71e-5	Antibody level in response to infection;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.56	-5.79	-0.43	3.92e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11582617	chr6:158589302	SERAC1;GTF2H5	0.58	6.29	0.45	3.29e-9	Primary biliary cholangitis;
PAAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.78	0.62	8.13e-18	Platelet count;
PAAD	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.83	9.14	0.6	3.81e-16	Corneal astigmatism;
PAAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.63	6.18	0.45	5.66e-9	Pancreatic cancer;
PAAD	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-4.94	-0.37	2.04e-6	Testicular germ cell tumor;
PAAD	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.52	-0.47	9.96e-10	Crohn's disease;
PAAD	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.83	-7.88	-0.54	5.99e-13	Breast cancer;
PAAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.01	0.67	4.16e-21	Parkinson's disease;
PAAD	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs488248	0.574	rs7329547	chr13:106588236	C/G	cg03898952	chr13:107069935	NA	0.7	4.45	0.34	1.66e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.97	-10.14	-0.64	8.92e-19	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.93	-7.92	-0.54	4.75e-13	Vitiligo;
PAAD	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.46	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.48	-5.4	-0.4	2.48e-7	Platelet distribution width;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.22	0.55	8.51e-14	Alzheimer's disease;
PAAD	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	1.31	10.89	0.66	8.78e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03939054	chr11:96076473	MAML2	0.56	6.44	0.46	1.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg09760422	chr2:128146352	NA	-0.42	-6.85	-0.49	1.73e-10	Protein C levels;
PAAD	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.37	0.33	2.31e-5	Educational attainment (years of education);
PAAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg01475735	chr3:40494733	NA	-0.45	-4.36	-0.33	2.37e-5	Renal cell carcinoma;
PAAD	cis	rs877529	0.967	rs139386	chr22:39530859	T/C	cg18708252	chr22:39545030	CBX7	-0.46	-4.53	-0.34	1.2e-5	Multiple myeloma;
PAAD	cis	rs1329189	0.798	rs1952470	chr10:129997681	A/G	cg17972361	chr10:130010134	NA	-0.48	-4.83	-0.36	3.28e-6	Orofacial clefts;
PAAD	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.52	4.86	0.37	2.86e-6	Red blood cell count;
PAAD	cis	rs4740619	0.681	rs10738420	chr9:15966656	C/G	cg14451791	chr9:16040625	NA	-0.42	-4.84	-0.37	3.1e-6	Body mass index;
PAAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.28	0.33	3.27e-5	Total body bone mineral density;
PAAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06115741	chr20:33292138	TP53INP2	0.59	6.12	0.44	7.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10121009	0.635	rs572527	chr9:35307408	C/A	cg11846315	chr9:35647073	NA	-0.49	-4.46	-0.34	1.6e-5	Parkinson's disease;
PAAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2278796	1.000	rs2278796	chr1:204951209	C/T	cg04862289	chr1:204966208	NFASC	0.45	4.77	0.36	4.21e-6	Mean platelet volume;
PAAD	cis	rs4144743	1.000	rs2317384	chr17:45329770	G/A	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg11584989	chr19:19387371	SF4	-0.77	-6.41	-0.46	1.73e-9	Bipolar disorder;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18337363	chr3:52569053	NT5DC2	0.42	4.36	0.33	2.42e-5	Bipolar disorder;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg04717802	chr22:42394638	WBP2NL	0.42	4.54	0.35	1.11e-5	Intelligence;
PAAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg23346134	chr3:49453900	TCTA	0.47	4.99	0.38	1.63e-6	Menarche (age at onset);
PAAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	9.97	0.63	2.58e-18	Platelet count;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.85	6.86	0.49	1.67e-10	Axial length;
PAAD	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg19192590	chr2:178524533	PDE11A	0.42	4.28	0.33	3.24e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.16	0.45	6.36e-9	Electrocardiographic conduction measures;
PAAD	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.55	-5.87	-0.43	2.69e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	1.0	13.92	0.75	6.46e-29	Heart rate;
PAAD	cis	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg21546286	chr11:48923668	NA	-0.58	-6.08	-0.44	9.44e-9	HDL cholesterol;
PAAD	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg24553058	chr2:113831203	IL1F10	0.46	5.16	0.39	7.47e-7	Protein quantitative trait loci;
PAAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg25204440	chr1:209979598	IRF6	0.67	5.73	0.42	5.33e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.34	4.25	0.33	3.76e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.31	0.64	3.11e-19	Monocyte percentage of white cells;
PAAD	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg05393297	chr12:53359155	NA	-0.94	-10.3	-0.64	3.43e-19	Prostate cancer;
PAAD	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg12126869	chr10:346505	DIP2C	-0.81	-4.34	-0.33	2.54e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.65	0.35	7.27e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.15	-16.3	-0.8	3.53e-35	Primary sclerosing cholangitis;
PAAD	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.75	-5.51	-0.41	1.49e-7	Vitiligo;
PAAD	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.8	9.51	0.61	4.09e-17	Graves' disease;
PAAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13012494	chr21:47604986	C21orf56	0.47	4.96	0.37	1.83e-6	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.71e-15	Lung cancer;
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.99	11.96	0.7	1.21e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg03885332	chr11:832357	CD151	-0.45	-5.29	-0.39	4.2e-7	Mean platelet volume;
PAAD	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.52	5.04	0.38	1.3e-6	Psoriasis;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg01262667	chr19:19385393	TM6SF2	-0.43	-4.66	-0.35	6.92e-6	Tonsillectomy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14593867	chr5:65018177	NLN;SGTB	-0.75	-6.46	-0.46	1.33e-9	Neuroticism;
PAAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg26513180	chr16:89883248	FANCA	-0.44	-4.43	-0.34	1.82e-5	Vitiligo;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg11335335	chr11:637885	DRD4	-0.38	-5.48	-0.41	1.76e-7	Systemic lupus erythematosus;
PAAD	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.56	-0.47	7.85e-10	Retinal vascular caliber;
PAAD	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.71	-8.24	-0.56	7.43e-14	Refractive error;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.93	-0.59	1.28e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4604234	0.518	rs73463537	chr6:80985031	A/T	cg23115158	chr6:80341412	SH3BGRL2	-1.09	-4.41	-0.34	1.94e-5	Cancer;
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2073300	1.000	rs6036423	chr20:23459810	A/C	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs73019876	0.869	rs402281	chr19:22231312	G/C	cg11619707	chr19:22235551	ZNF257	-0.42	-4.59	-0.35	9.22e-6	Testicular germ cell tumor;
PAAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg02574844	chr11:5959923	NA	0.6	5.87	0.43	2.69e-8	DNA methylation (variation);
PAAD	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs12986413	0.651	rs2238609	chr19:2146629	C/T	cg09261902	chr19:2140048	AP3D1	0.61	6.06	0.44	1.04e-8	Height;
PAAD	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07157834	chr1:205819609	PM20D1	0.52	5.01	0.38	1.51e-6	Parkinson's disease;
PAAD	cis	rs6987853	0.814	rs1349471	chr8:42454011	C/T	cg09913449	chr8:42400586	C8orf40	0.55	6.2	0.45	5.14e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.8	5.39	0.4	2.67e-7	Gut microbiome composition (summer);
PAAD	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.75	-8.97	-0.59	1.01e-15	Body mass index;
PAAD	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.69	-0.36	6.08e-6	Height;
PAAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-5.16	-0.39	7.47e-7	Personality dimensions;
PAAD	trans	rs901683	1.000	rs36074276	chr10:46055741	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.51	-4.59	-0.35	9.28e-6	IgG glycosylation;
PAAD	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.85	-0.37	3.07e-6	Height;
PAAD	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg14092988	chr3:52407081	DNAH1	0.44	5.52	0.41	1.42e-7	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.69	6.53	0.47	9.23e-10	Subjective well-being;
PAAD	cis	rs10274279	0.660	rs10278007	chr7:157372906	C/G	cg26886268	chr7:157387156	PTPRN2	-0.49	-4.32	-0.33	2.83e-5	Myopia (pathological);
PAAD	cis	rs939584	1.000	rs10173167	chr2:646767	G/A	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.89	-7.54	-0.52	4.02e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-11.74	-0.69	4.76e-23	Longevity;Endometriosis;
PAAD	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.89e-9	Lung cancer;
PAAD	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	1.07	13.63	0.74	3.78e-28	Breast cancer;
PAAD	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18302933	chr2:88491318	NA	-0.45	-5.28	-0.39	4.41e-7	Response to metformin (IC50);
PAAD	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.58	-4.69	-0.36	6.08e-6	QRS complex (12-leadsum);
PAAD	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.51	-5.27	-0.39	4.57e-7	Resting heart rate;
PAAD	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg19680485	chr15:31195859	MTMR15	-0.48	-4.86	-0.37	2.94e-6	Huntington's disease progression;
PAAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs6800768	0.663	rs59911620	chr3:24092004	G/C	cg10674438	chr3:24145617	LOC152024	-0.47	-4.35	-0.33	2.46e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.83	6.86	0.49	1.65e-10	Total cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21231550	chr9:103116118	TEX10	0.56	6.29	0.45	3.28e-9	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.54	4.53	0.34	1.19e-5	Depression;
PAAD	cis	rs818427	0.737	rs2545165	chr5:112153119	C/T	cg06941702	chr5:112196734	SRP19	-0.52	-4.84	-0.37	3.16e-6	Total body bone mineral density;
PAAD	cis	rs17169635	0.579	rs4732066	chr7:134569177	A/G	cg02516134	chr7:134575187	CALD1	-0.47	-4.54	-0.35	1.14e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.75	-0.42	4.67e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6674970	0.777	rs12087892	chr1:151118500	T/C	cg11822372	chr1:151115635	SEMA6C	-0.89	-8.56	-0.57	1.17e-14	Childhood ear infection;
PAAD	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg24053715	chr22:38214548	NA	0.58	5.64	0.42	8.16e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7188861	0.768	rs7184969	chr16:11397206	C/A	cg16532467	chr16:11454386	NA	-0.55	-4.37	-0.33	2.3e-5	HDL cholesterol;
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs1075265	0.692	rs805358	chr2:54162022	C/T	cg04546899	chr2:54196757	PSME4	0.33	5.06	0.38	1.21e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.4	4.9	0.37	2.42e-6	Sitting height ratio;
PAAD	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	6.29	0.45	3.19e-9	Schizophrenia;
PAAD	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs11614333	0.839	rs11056227	chr12:15032020	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.29	-0.33	3.2e-5	Hand grip strength;
PAAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg10935138	chr17:73851978	WBP2	0.88	7.28	0.51	1.67e-11	Psoriasis;
PAAD	cis	rs2031532	0.679	rs7329078	chr13:50092486	T/C	cg08779649	chr13:50194554	NA	0.37	4.77	0.36	4.26e-6	Cardiac hypertrophy;
PAAD	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg02254261	chr7:158964346	NA	-0.61	-4.72	-0.36	5.42e-6	Myopia (pathological);
PAAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-6.08	-0.44	9.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	4.37	0.33	2.34e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.81	-0.36	3.62e-6	Renal cell carcinoma;
PAAD	cis	rs55955238	0.605	rs10048170	chr17:35282302	C/T	cg13677415	chr17:35291900	NA	-0.32	-4.39	-0.34	2.16e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.97	11.96	0.7	1.18e-23	Longevity;
PAAD	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.84	7.4	0.51	8.43e-12	Schizophrenia;
PAAD	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.45	0.4	2.04e-7	Bipolar disorder;
PAAD	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg13902645	chr11:5959945	NA	-0.83	-8.09	-0.55	1.78e-13	DNA methylation (variation);
PAAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs7219021	0.926	rs9912856	chr17:46861667	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.43	-0.34	1.77e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs17407555	0.837	rs10939710	chr4:10116801	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.16	-0.39	7.61e-7	Schizophrenia (age at onset);
PAAD	cis	rs6604026	0.656	rs11578986	chr1:93402823	G/T	cg13858687	chr1:93297071	RPL5	0.47	4.28	0.33	3.28e-5	Multiple sclerosis;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.55	0.61	3.24e-17	Platelet count;
PAAD	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg00686598	chr14:53173677	PSMC6	-0.83	-4.9	-0.37	2.4e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.59	-5.57	-0.41	1.12e-7	Malaria;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03064080	chr19:14800596	ZNF333	0.62	6.41	0.46	1.77e-9	Obesity-related traits;
PAAD	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.6	-6.36	-0.46	2.26e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs59918340	0.738	rs3739240	chr8:142221414	G/A	cg16341495	chr8:142228727	SLC45A4	-0.56	-5.55	-0.41	1.21e-7	Immature fraction of reticulocytes;
PAAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Coronary artery disease;
PAAD	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg23461800	chr14:103021989	NA	-0.63	-4.53	-0.34	1.19e-5	Platelet count;
PAAD	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20154865	chr11:111957432	SDHD;TIMM8B	0.59	6.95	0.49	1e-10	Monocyte percentage of white cells;
PAAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg15017067	chr4:17643749	FAM184B	0.38	4.26	0.33	3.61e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6138152	0.841	rs8182947	chr20:23811186	C/T	cg03403719	chr20:23335483	NA	0.55	4.38	0.33	2.19e-5	Blood protein levels;
PAAD	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg05554000	chr7:158905015	VIPR2	-0.62	-5.07	-0.38	1.14e-6	Facial morphology (factor 20);
PAAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.59	7.56	0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.74	-6.82	-0.48	2.07e-10	Obesity-related traits;
PAAD	cis	rs10943724	0.731	rs10447325	chr6:81276447	A/C	cg19323245	chr6:80716898	TTK	-0.41	-4.3	-0.33	3.06e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg22705602	chr4:152727874	NA	-0.48	-5.18	-0.39	7.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs73568641	0.508	rs73572679	chr6:154101173	C/A	cg15658985	chr6:154448740	OPRM1	0.55	4.68	0.35	6.36e-6	Methadone dose in opioid dependence;
PAAD	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.53	4.26	0.33	3.5e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.805	rs4721142	chr7:1918079	T/C	cg00035074	chr7:2701567	TTYH3	0.62	4.63	0.35	7.89e-6	Bipolar disorder;
PAAD	cis	rs1997066	0.831	rs73340286	chr10:106812295	G/A	cg17321814	chr10:106440892	SORCS3	0.64	4.36	0.33	2.38e-5	Diabetic kidney disease;
PAAD	cis	rs1667255	0.830	rs11662311	chr18:29160783	T/C	cg18808318	chr18:29669225	NA	0.51	4.74	0.36	4.9e-6	Retinol levels;
PAAD	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.68	-6.18	-0.45	5.74e-9	Mean corpuscular volume;
PAAD	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-4.65	-0.35	7.02e-6	Left atrial antero-posterior diameter;
PAAD	cis	rs490234	0.841	rs950534	chr9:128225881	C/G	cg14078157	chr9:128172775	NA	-0.42	-4.62	-0.35	8.14e-6	Mean arterial pressure;
PAAD	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.89	7.86	0.54	6.58e-13	IgG glycosylation;
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg16898833	chr6:26189333	HIST1H4D	0.59	4.93	0.37	2.13e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.44	6.54	0.47	8.9e-10	Mean corpuscular volume;
PAAD	cis	rs621559	0.636	rs585275	chr1:43680680	T/A	cg14851383	chr1:43888477	KIAA0467	0.55	4.33	0.33	2.66e-5	Telomere length;
PAAD	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.68	-0.48	4.28e-10	Retinal vascular caliber;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.63	7.06	0.5	5.66e-11	Metabolite levels  (X-11787);
PAAD	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs2668423	1.000	rs2668419	chr19:1366994	A/G	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.74	-0.48	3.16e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.21	-0.39	6.02e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1146751	0.674	rs515207	chr3:84926866	A/G	cg21856205	chr7:94953877	PON1	0.71	6.81	0.48	2.18e-10	Photic sneeze reflex;
PAAD	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg12555334	chr7:56120290	CCT6A;PSPH	-0.39	-5.44	-0.4	2.07e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs7100689	0.890	rs7086627	chr10:82220597	C/T	cg00277334	chr10:82204260	NA	-0.68	-7.07	-0.5	5.14e-11	Post bronchodilator FEV1;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs7178572	0.688	rs12591335	chr15:77774894	A/G	cg22256960	chr15:77711686	NA	0.62	4.5	0.34	1.35e-5	Type 2 diabetes;
PAAD	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	5.95	0.43	1.76e-8	Blood protein levels;
PAAD	cis	rs11209002	0.911	rs2815346	chr1:67531646	G/A	cg02640540	chr1:67518911	SLC35D1	0.68	4.74	0.36	4.96e-6	Crohn's disease;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.67	-0.53	1.91e-12	Coronary artery disease;
PAAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.35	4.27	0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg25886479	chr11:50257625	LOC441601	0.39	4.37	0.33	2.29e-5	Height;
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg07313626	chr1:247681931	NA	-0.47	-4.9	-0.37	2.43e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.94	-6.94	-0.49	1.05e-10	Alzheimer's disease;
PAAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg00431813	chr7:1051703	C7orf50	0.74	4.54	0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.71	4.62	0.35	8.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs516243	0.703	rs544722	chr1:10743042	T/C	cg02903756	chr1:10750680	CASZ1	-0.48	-5.22	-0.39	5.91e-7	Migraine - clinic-based;
PAAD	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.17e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.68	-7.23	-0.51	2.15e-11	Multiple sclerosis;
PAAD	cis	rs10896609	0.550	rs2003065	chr11:57116707	A/T	cg25492363	chr11:57319872	UBE2L6	-0.43	-4.8	-0.36	3.81e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.45	-4.67	-0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg12560992	chr17:57184187	TRIM37	0.59	4.6	0.35	8.66e-6	Vitamin D levels;
PAAD	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	7.75	0.53	1.23e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.71	0.42	5.67e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.6	6.34	0.46	2.43e-9	Caffeine consumption;
PAAD	trans	rs901683	0.850	rs73291113	chr10:46095065	G/C	cg13065504	chr15:42448234	PLA2G4F	0.78	6.4	0.46	1.78e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12474201	0.589	rs76089707	chr2:47013899	G/A	cg06386533	chr2:46925753	SOCS5	0.68	7.42	0.52	7.76e-12	Height;
PAAD	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.4	-0.34	2.06e-5	IgG glycosylation;
PAAD	cis	rs1879734	0.636	rs12080903	chr1:54178270	G/A	cg14659662	chr1:54151053	GLIS1	-0.39	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.31	0.73	2.74e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6065	0.867	rs79843668	chr17:4849627	A/T	cg02990439	chr17:4875527	CAMTA2	-0.85	-4.38	-0.33	2.19e-5	Platelet count;
PAAD	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-5.14	-0.38	8.28e-7	Daytime sleep phenotypes;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.44e-19	Menopause (age at onset);
PAAD	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.3	-0.33	3.08e-5	Educational attainment;
PAAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.52	6.67	0.48	4.36e-10	Childhood ear infection;
PAAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.3	0.68	7.28e-22	Menopause (age at onset);
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg07841815	chr7:100318223	EPO	-0.5	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7554547	0.600	rs2180180	chr1:12019369	A/G	cg13216073	chr1:12042593	MFN2	-0.44	-4.99	-0.38	1.62e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg02811702	chr13:24901961	NA	0.54	5.79	0.43	3.89e-8	Obesity-related traits;
PAAD	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16447950	chr5:562315	NA	-0.61	-5.4	-0.4	2.47e-7	Obesity-related traits;
PAAD	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2072732	0.861	rs55863899	chr1:2955245	C/G	cg15211996	chr1:2936768	ACTRT2	0.48	4.25	0.33	3.65e-5	Plateletcrit;
PAAD	cis	rs3852527	0.736	rs11024175	chr11:2830565	C/T	cg03571121	chr11:2832861	KCNQ1	-0.59	-4.36	-0.33	2.38e-5	Bacterial meningitis;
PAAD	cis	rs10792830	1.000	rs10792830	chr11:85838808	G/A	cg07180834	chr11:85838833	NA	-0.63	-7.66	-0.53	2e-12	Psychosis and Alzheimer's disease;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-1.0	-6.53	-0.47	9.21e-10	IgG glycosylation;
PAAD	cis	rs950881	1.000	rs950881	chr2:102932512	G/T	cg03938978	chr2:103052716	IL18RAP	0.54	4.39	0.34	2.14e-5	Allergy;
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg04267008	chr7:1944627	MAD1L1	0.76	7.91	0.54	4.93e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-4.81	-0.36	3.55e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1008126	0.609	rs6465920	chr7:103084770	G/A	cg04218035	chr7:103086829	SLC26A5	0.35	4.78	0.36	4.1e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9926296	0.632	rs4785590	chr16:89790167	G/C	cg03605463	chr16:89740564	NA	0.55	5.15	0.39	7.95e-7	Vitiligo;
PAAD	cis	rs516243	0.841	rs6540944	chr1:10740405	C/T	cg02903756	chr1:10750680	CASZ1	-0.51	-5.74	-0.42	4.98e-8	Migraine - clinic-based;
PAAD	cis	rs375066	0.935	rs432454	chr19:44398831	C/G	cg11993925	chr19:44307056	LYPD5	0.55	6.95	0.49	9.93e-11	Breast cancer;
PAAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.42	4.72	0.36	5.29e-6	Type 2 diabetes;
PAAD	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg05425664	chr17:57184151	TRIM37	0.5	4.28	0.33	3.26e-5	Testicular germ cell tumor;
PAAD	trans	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg06606381	chr12:133084897	FBRSL1	-1.16	-7.42	-0.52	7.65e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg07636037	chr3:49044803	WDR6	-0.58	-4.59	-0.35	9.2e-6	Menarche (age at onset);
PAAD	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.82	7.04	0.5	6.08e-11	Waist circumference;
PAAD	cis	rs7925908	0.686	rs1557483	chr11:131155806	G/A	cg13391028	chr11:130657123	NA	0.36	4.26	0.33	3.64e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);Glucocorticoid-induced osteonecrosis (time dependent analysis);
PAAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg19784903	chr17:45786737	TBKBP1	0.56	6.21	0.45	4.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg08436684	chr16:88034427	BANP	-0.51	-4.47	-0.34	1.54e-5	Menopause (age at onset);
PAAD	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg12721952	chr1:2337711	PEX10	-0.5	-4.42	-0.34	1.86e-5	Plateletcrit;
PAAD	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.62	8.28	0.56	5.73e-14	Crohn's disease;
PAAD	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.71	4.74	0.36	4.93e-6	HDL cholesterol;
PAAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg16557858	chr17:37879740	ERBB2	-0.43	-4.26	-0.33	3.56e-5	Asthma;
PAAD	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2051773	0.539	rs34902253	chr11:17049380	T/A	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.93	9.23	0.6	2.21e-16	Corneal astigmatism;
PAAD	cis	rs490234	0.966	rs542974	chr9:128373218	G/A	cg14078157	chr9:128172775	NA	0.4	4.36	0.33	2.43e-5	Mean arterial pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24826236	chr12:102506848	NUP37	0.61	6.64	0.47	5.26e-10	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16423265	chr20:60697137	LSM14B	0.63	7.23	0.51	2.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.77	5.46	0.4	1.93e-7	Cannabis dependence symptom count;
PAAD	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-1.35	-10.59	-0.65	5.58e-20	Obesity-related traits;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17038397	chr1:43637937	EBNA1BP2;WDR65	0.59	6.53	0.47	9.29e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	4.69	0.36	6.08e-6	Cognitive ability;
PAAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.64	-0.35	7.56e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12714314	0.756	rs1469646	chr2:1950180	T/C	cg22350835	chr2:1868857	MYT1L	0.48	4.64	0.35	7.51e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.58	5.13	0.38	8.61e-7	Life satisfaction;
PAAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	4.51	0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg00129232	chr17:37814104	STARD3	-0.56	-4.89	-0.37	2.56e-6	Self-reported allergy;
PAAD	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.89	10.22	0.64	5.5e-19	Sudden cardiac arrest;
PAAD	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg02404636	chr22:31891804	SFI1	0.64	5.93	0.43	1.99e-8	Colorectal cancer;
PAAD	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22880518	chr1:46152302	GPBP1L1	-0.74	-6.46	-0.46	1.31e-9	Neuroticism;
PAAD	cis	rs10450586	0.932	rs899303	chr11:27309681	A/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs6191	0.901	rs33388	chr5:142697295	A/T	cg08845721	chr5:142780693	NR3C1	0.39	4.25	0.33	3.78e-5	Night sleep phenotypes;
PAAD	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg26528668	chr16:1614120	IFT140	0.55	5.26	0.39	4.78e-7	Coronary artery disease;
PAAD	cis	rs2415984	0.622	rs12434073	chr14:46921265	G/A	cg14871534	chr14:47121158	RPL10L	-0.53	-5.48	-0.41	1.76e-7	Number of children ever born;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.84	-9.44	-0.61	6.33e-17	Prudent dietary pattern;
PAAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg12623918	chr2:306882	NA	0.44	4.47	0.34	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.88	-10.85	-0.66	1.14e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.82	7.93	0.54	4.35e-13	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13945301	chr2:157190182	NR4A2	0.54	6.3	0.46	3.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.31	0.33	2.94e-5	Cancer;
PAAD	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs7765175	0.598	rs2130850	chr6:113649375	C/T	cg19037598	chr6:113666021	NA	-0.42	-4.66	-0.35	6.77e-6	Coronary artery calcification;
PAAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.58	6.51	0.47	1.04e-9	Coronary artery disease;
PAAD	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-4.46	-0.34	1.61e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg18989491	chr10:6185502	PFKFB3	0.49	4.41	0.34	1.98e-5	Menopause (age at onset);
PAAD	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.31	-0.4	3.75e-7	Common traits (Other);
PAAD	cis	rs303386	0.734	rs3911435	chr1:99590454	T/C	cg03593336	chr1:99471295	LPPR5	0.48	4.6	0.35	8.89e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-6.76	-0.48	2.85e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.65	7.08	0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs863345	0.604	rs2054992	chr1:158506015	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00339695	chr16:24857497	SLC5A11	0.49	4.61	0.35	8.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	5.44	0.4	2.04e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13198984	chr17:80129470	CCDC57	0.39	4.9	0.37	2.4e-6	Life satisfaction;
PAAD	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.64	7.11	0.5	4.32e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs7843479	0.898	rs13282562	chr8:21869727	G/A	cg10400843	chr16:29915329	ASPHD1	-0.48	-6.32	-0.46	2.76e-9	Mean corpuscular volume;
PAAD	cis	rs2421770	0.532	rs10768128	chr11:35361518	C/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.3	-0.4	3.92e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.38e-8	QT interval;
PAAD	cis	rs747650	0.504	rs34340483	chr11:46953154	T/G	cg19486271	chr11:47235900	DDB2	-0.62	-5.91	-0.43	2.21e-8	Acne (severe);
PAAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg22143856	chr6:28129313	ZNF389	-0.65	-5.15	-0.39	8.05e-7	Depression;
PAAD	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.25	-0.39	5.06e-7	Schizophrenia;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.0	-0.38	1.57e-6	Cystic fibrosis severity;
PAAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.81	-7.99	-0.54	3.03e-13	Schizophrenia;
PAAD	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.22	-0.51	2.36e-11	Total cholesterol levels;
PAAD	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	7.7	0.53	1.65e-12	Eotaxin levels;
PAAD	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.91	-0.37	2.28e-6	Type 1 diabetes;
PAAD	cis	rs9534288	0.619	rs9526146	chr13:46680854	C/T	cg15192986	chr13:46630673	CPB2	-0.71	-6.01	-0.44	1.34e-8	Blood protein levels;
PAAD	cis	rs855965	0.517	rs10886116	chr10:119477832	A/G	cg17249170	chr10:119305798	EMX2;EMX2OS	0.32	4.29	0.33	3.2e-5	Ovarian disease with few adhesions;
PAAD	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg02745156	chr12:32552066	NA	0.5	5.39	0.4	2.66e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg03808351	chr9:123631620	PHF19	0.44	4.88	0.37	2.63e-6	Rheumatoid arthritis;
PAAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.73	-8.65	-0.57	6.81e-15	Height;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.53	-4.98	-0.37	1.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs10916814	0.546	rs7547998	chr1:20903192	C/T	cg04087271	chr1:20915334	CDA	0.37	4.49	0.34	1.37e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg23281280	chr6:28129359	ZNF389	0.48	4.26	0.33	3.56e-5	Parkinson's disease;
PAAD	cis	rs10872587	0.598	rs10457057	chr6:146542320	G/T	cg23711669	chr6:146136114	FBXO30	0.69	5.96	0.44	1.7e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.27	0.45	3.55e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.51	5.09	0.38	1.06e-6	Temperament;
PAAD	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg23417306	chr2:180868811	CWC22	0.49	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg24565620	chr2:194026	NA	0.6	5.14	0.39	8.18e-7	Blood protein levels;
PAAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.69	-8.16	-0.55	1.17e-13	Huntington's disease progression;
PAAD	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.62	-6.5	-0.47	1.09e-9	DNA methylation (variation);
PAAD	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg22256960	chr15:77711686	NA	-0.53	-4.29	-0.33	3.1e-5	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	7.18	0.5	2.82e-11	Renal function-related traits (BUN);
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08219700	chr8:58056026	NA	0.73	5.82	0.43	3.33e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2286503	0.901	rs2286505	chr7:22854840	G/A	cg04907244	chr7:22894795	SNORD93	-0.43	-5.33	-0.4	3.51e-7	Fibrinogen;
PAAD	cis	rs755249	0.567	rs4660690	chr1:39819503	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8105895	0.867	rs62111037	chr19:22286563	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg13263323	chr15:86062960	AKAP13	-0.61	-6.9	-0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.48	4.85	0.37	3.04e-6	Colorectal cancer;
PAAD	cis	rs7101378	0.577	rs10789708	chr11:108894875	A/G	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	IgG glycosylation;
PAAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.93	9.74	0.62	1.02e-17	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01753966	chr4:3531945	LRPAP1	-0.66	-6.54	-0.47	8.68e-10	Obesity-related traits;
PAAD	cis	rs73416724	0.688	rs79761807	chr6:43341088	C/A	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10821973	0.527	rs2393869	chr10:63999263	G/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg03871329	chr12:110338662	TCHP	-0.56	-4.35	-0.33	2.49e-5	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg02795151	chr17:7402630	POLR2A	0.62	5.81	0.43	3.6e-8	Androgen levels;
PAAD	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.63	-0.35	7.69e-6	Dupuytren's disease;
PAAD	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.53	5.44	0.4	2.06e-7	Major depressive disorder;
PAAD	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.62	-6.38	-0.46	1.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.36	-0.33	2.35e-5	Tuberculosis;
PAAD	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg21062780	chr6:887772	NA	-0.45	-4.44	-0.34	1.69e-5	Aging;
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.69	7.21	0.5	2.5e-11	Menarche (age at onset);
PAAD	cis	rs59888335	0.823	rs13089360	chr3:80922827	G/A	cg21735741	chr3:80819488	NA	0.53	4.61	0.35	8.39e-6	Schizophrenia;
PAAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.85e-10	Glomerular filtration rate;
PAAD	cis	rs4740619	0.933	rs10756694	chr9:15710636	C/T	cg14451791	chr9:16040625	NA	-0.39	-4.44	-0.34	1.7e-5	Body mass index;
PAAD	cis	rs10916814	0.704	rs4655221	chr1:20899265	C/A	cg04087271	chr1:20915334	CDA	0.38	4.7	0.36	5.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	4.4	0.34	1.99e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.66	7.28	0.51	1.69e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-5.12	-0.38	9.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	cis	rs7301826	0.580	rs12821464	chr12:131322719	T/G	cg11011512	chr12:131303247	STX2	-0.44	-4.33	-0.33	2.66e-5	Plasma plasminogen activator levels;
PAAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.16	0.7	3.43e-24	Smoking behavior;
PAAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.93	10.07	0.63	1.37e-18	Breast cancer;
PAAD	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg27565382	chr3:53032988	SFMBT1	0.78	4.51	0.34	1.28e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	1.03	9.88	0.63	4.31e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs2415984	0.579	rs12147941	chr14:46972907	A/G	cg14871534	chr14:47121158	RPL10L	-0.5	-5.2	-0.39	6.4e-7	Number of children ever born;
PAAD	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg10820045	chr2:198174542	NA	-0.44	-4.48	-0.34	1.49e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-6.39	-0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs11825685	0.790	rs80204957	chr11:134545553	A/T	cg02089395	chr11:134479357	NA	-0.78	-5.46	-0.41	1.87e-7	IgG glycosylation;
PAAD	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg08898775	chr15:59042684	ADAM10	0.37	4.48	0.34	1.45e-5	Schizophrenia;
PAAD	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.46	-0.34	1.57e-5	IgG glycosylation;
PAAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg23346134	chr3:49453900	TCTA	0.47	4.99	0.38	1.63e-6	Menarche (age at onset);
PAAD	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.63	-6.73	-0.48	3.23e-10	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02095752	chr6:150262961	ULBP2	0.64	6.59	0.47	6.75e-10	Obesity-related traits;
PAAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.25	4.27	0.33	3.39e-5	IgG glycosylation;
PAAD	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.51	-5.4	-0.4	2.46e-7	Non-response to antidepressants and depression;
PAAD	cis	rs59888335	0.964	rs68149058	chr3:80693369	T/C	cg21735741	chr3:80819488	NA	0.57	5.08	0.38	1.09e-6	Schizophrenia;
PAAD	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.7	6.37	0.46	2.09e-9	Asthma;
PAAD	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs8112211	0.731	rs2368484	chr19:38825447	T/G	cg14299480	chr19:38876666	GGN	-0.57	-4.74	-0.36	4.97e-6	Blood protein levels;
PAAD	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.81	9.73	0.62	1.06e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.67	-5.73	-0.42	5.16e-8	Menarche (age at onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19701246	chr3:39508314	MOBP	-0.57	-6.94	-0.49	1.05e-10	Energy expenditure (24h);
PAAD	cis	rs288342	0.797	rs288336	chr2:183619141	G/T	cg02625481	chr2:183667124	NA	-0.46	-4.61	-0.35	8.3e-6	Recurrent major depressive disorder;
PAAD	cis	rs6074578	0.679	rs1858594	chr20:138555	A/G	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07701084	chr6:150067640	NUP43	0.62	6.34	0.46	2.44e-9	Lung cancer;
PAAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg09177884	chr7:1199841	ZFAND2A	0.64	5.09	0.38	1.07e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2278796	0.697	rs4951150	chr1:204952849	C/A	cg17947172	chr1:204966197	NFASC	0.45	5.32	0.4	3.61e-7	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15324256	chr3:113775233	QTRTD1;KIAA1407	0.64	6.32	0.46	2.75e-9	Obesity-related traits;
PAAD	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.1	-0.38	9.81e-7	Monocyte percentage of white cells;
PAAD	cis	rs1075265	0.589	rs2253760	chr2:54033988	C/G	cg04546899	chr2:54196757	PSME4	0.29	4.3	0.33	3.02e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-7.12	-0.5	4.1e-11	Hemoglobin concentration;
PAAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg09945482	chr18:12777974	NA	-0.63	-5.47	-0.41	1.85e-7	Inflammatory skin disease;
PAAD	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg07856975	chr6:36356162	ETV7	-0.57	-6.38	-0.46	2.03e-9	Platelet distribution width;
PAAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg22143856	chr6:28129313	ZNF389	0.6	4.66	0.35	6.96e-6	Parkinson's disease;
PAAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.45	-6.54	-0.47	8.77e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.55	0.35	1.08e-5	Electrocardiographic conduction measures;
PAAD	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg15501526	chr10:2543763	NA	-0.88	-9.24	-0.6	2.08e-16	Age-related hearing impairment;
PAAD	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.8	7.99	0.54	3.15e-13	Retinal vascular caliber;
PAAD	cis	rs9595066	0.667	rs3809350	chr13:44736179	T/C	cg04068111	chr13:44716778	NA	-0.5	-5.55	-0.41	1.24e-7	Schizophrenia;
PAAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12963246	chr6:28129442	ZNF389	0.56	4.44	0.34	1.7e-5	Cardiac Troponin-T levels;
PAAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg00990874	chr7:1149470	C7orf50	-0.78	-6.23	-0.45	4.32e-9	Bronchopulmonary dysplasia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00044463	chr1:184006933	GLT25D2	-0.65	-6.54	-0.47	8.82e-10	Lung cancer in ever smokers;
PAAD	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-7.13	-0.5	3.72e-11	Urate levels in overweight individuals;
PAAD	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg12395012	chr8:11607386	GATA4	0.43	4.32	0.33	2.78e-5	Triglycerides;
PAAD	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.81	7.84	0.54	7.32e-13	Coronary artery disease;
PAAD	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.67	6.36	0.46	2.22e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.21	-0.39	6.18e-7	Personality dimensions;
PAAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.61	0.35	8.34e-6	Height;
PAAD	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	4.97	0.37	1.8e-6	Birth weight;
PAAD	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.02e-13	Blood metabolite levels;
PAAD	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg00531865	chr16:30841666	NA	0.5	4.64	0.35	7.42e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.39	-4.46	-0.34	1.6e-5	Pubertal anthropometrics;
PAAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.78	6.95	0.49	1.01e-10	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.19	6.5	0.47	1.07e-9	Blood protein levels;
PAAD	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg17252645	chr8:143867129	LY6D	0.5	4.85	0.37	3.05e-6	Urinary tract infection frequency;
PAAD	cis	rs3736485	0.966	rs2414113	chr15:51903896	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.71e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1561176	0.830	rs4620236	chr7:154986897	C/T	cg08570118	chr7:155025533	NA	-0.48	-4.53	-0.34	1.19e-5	Personality dimensions;
PAAD	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.67	-0.42	6.83e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15797843	chr17:40761348	FAM134C;TUBG1	0.64	6.39	0.46	1.88e-9	Obesity-related traits;
PAAD	cis	rs6466055	0.661	rs2299305	chr7:104791075	A/G	cg04380332	chr7:105027541	SRPK2	0.49	4.76	0.36	4.47e-6	Schizophrenia;
PAAD	cis	rs4906332	0.933	rs4906330	chr14:103971202	T/G	cg26031613	chr14:104095156	KLC1	-0.46	-4.57	-0.35	9.85e-6	Coronary artery disease;
PAAD	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.93	5.49	0.41	1.61e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.75	0.62	9.4e-18	Platelet count;
PAAD	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.83	-10.16	-0.64	7.87e-19	Brugada syndrome;
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.44	6.24	0.45	4.19e-9	Mean corpuscular volume;
PAAD	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	1.07	6.79	0.48	2.42e-10	Skin colour saturation;
PAAD	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg01444501	chr16:343706	AXIN1	0.55	4.73	0.36	5.03e-6	Mean corpuscular volume;
PAAD	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.54	4.96	0.37	1.88e-6	Self-reported allergy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07040161	chr21:48084674	PRMT2	0.57	6.62	0.47	5.93e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.8	0.48	2.21e-10	Total body bone mineral density;
PAAD	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg06115741	chr20:33292138	TP53INP2	0.69	6.7	0.48	3.77e-10	Coronary artery disease;
PAAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg11663144	chr21:46675770	NA	-0.52	-6.23	-0.45	4.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.77	-8.34	-0.56	4.07e-14	Aortic root size;
PAAD	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-11.62	-0.69	1e-22	Height;
PAAD	cis	rs4759375	0.667	rs11057266	chr12:123807545	A/G	cg05908960	chr12:123472150	PITPNM2	0.61	4.41	0.34	1.94e-5	HDL cholesterol;
PAAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-9.56	-0.61	2.96e-17	Total body bone mineral density;
PAAD	cis	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg15590007	chr10:45870220	ALOX5	0.54	5.17	0.39	7.2e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.71	-7.02	-0.49	6.9e-11	Neurofibrillary tangles;
PAAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19825600	chr2:3704501	ALLC	-0.51	-4.4	-0.34	2.03e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.51	0.34	1.29e-5	Self-reported allergy;
PAAD	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg21399703	chr1:247681439	NA	0.6	4.58	0.35	9.57e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.65	5.78	0.42	4.01e-8	Mean platelet volume;
PAAD	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.82	10.25	0.64	4.56e-19	Methadone dose in opioid dependence;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg05313129	chr8:58192883	C8orf71	-0.54	-4.87	-0.37	2.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs597480	0.889	rs485485	chr11:85495269	C/T	cg11817631	chr11:85522609	SYTL2	0.46	4.37	0.33	2.26e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg22437258	chr11:111473054	SIK2	-0.45	-4.5	-0.34	1.33e-5	Primary sclerosing cholangitis;
PAAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.24	-6.68	-0.48	4.22e-10	Body mass index;
PAAD	cis	rs867529	0.695	rs335115	chr2:89027647	C/T	cg26627705	chr2:89060884	NA	0.46	4.5	0.34	1.34e-5	Height;
PAAD	cis	rs8258	0.927	rs560355	chr11:117256384	C/G	cg15227623	chr11:117232454	CEP164	0.59	5.43	0.4	2.14e-7	Pulse pressure;
PAAD	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg16586182	chr3:47516702	SCAP	-0.69	-7.28	-0.51	1.71e-11	Colorectal cancer;
PAAD	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.72	-6.31	-0.46	2.87e-9	Triglycerides;
PAAD	cis	rs1126510	0.897	rs2229129	chr19:47124714	T/G	cg07844738	chr19:47129343	PTGIR	0.45	5.38	0.4	2.78e-7	Ulcerative colitis;
PAAD	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.48	4.53	0.34	1.18e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs901683	1.000	rs35934513	chr10:46059781	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs141060743	1	rs141060743	chr6:55492653	T/C	cg15259904	chr6:55559213	NA	0.38	4.42	0.34	1.86e-5	Cold sores;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.67	7.43	0.52	7.16e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.57	6.4	0.46	1.87e-9	Blood metabolite levels;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00166722	chr3:10149974	C3orf24	0.97	8.28	0.56	5.81e-14	Alzheimer's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01538982	chr3:48481510	CCDC51;CCDC72	-0.56	-6.7	-0.48	3.82e-10	Body fat percentage;
PAAD	cis	rs7765175	0.698	rs6904981	chr6:113668106	G/A	cg19037598	chr6:113666021	NA	-0.41	-4.38	-0.33	2.24e-5	Coronary artery calcification;
PAAD	cis	rs57244997	0.544	rs77182940	chr6:162443721	T/C	cg17173639	chr6:162384350	PARK2	-0.67	-4.93	-0.37	2.1e-6	Mosquito bite size;
PAAD	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-5.52	-0.41	1.45e-7	Coronary artery disease;
PAAD	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg05084668	chr3:125655381	ALG1L	-0.39	-4.35	-0.33	2.52e-5	Blood pressure (smoking interaction);
PAAD	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.57e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.52	12.91	0.72	3.36e-26	Atopic dermatitis;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	6.03	0.44	1.19e-8	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs3136441	1.000	rs11038977	chr11:46734384	C/T	cg19486271	chr11:47235900	DDB2	0.63	4.68	0.35	6.36e-6	HDL cholesterol;
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg18888403	chr1:24152774	HMGCL	-0.4	-4.54	-0.35	1.15e-5	Immature fraction of reticulocytes;
PAAD	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18867708	chr6:26865862	GUSBL1	0.45	4.54	0.35	1.16e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs10934631	1.000	rs7652165	chr3:122696901	C/G	cg04830808	chr3:122712224	SEMA5B	0.47	4.6	0.35	8.83e-6	Vascular endothelial growth factor levels;
PAAD	cis	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg03989125	chr22:38214979	NA	0.63	5.6	0.41	9.57e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs73416724	0.535	rs61729324	chr6:43258994	G/A	cg17502394	chr6:43251710	TTBK1	0.82	4.4	0.34	1.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.43	4.35	0.33	2.48e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.49	4.64	0.35	7.51e-6	Hepatocellular carcinoma;
PAAD	cis	rs7246865	0.510	rs3816549	chr19:17173937	G/A	cg19418318	chr19:17219073	MYO9B	0.35	5.03	0.38	1.35e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.2	0.45	5.02e-9	Vitiligo;
PAAD	cis	rs12145833	0.538	rs9803701	chr1:243391634	T/C	cg02356786	chr1:243265016	LOC731275	-0.96	-6.23	-0.45	4.33e-9	Obesity (early onset extreme);
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.84	6.45	0.46	1.44e-9	Axial length;
PAAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.45	5.11	0.38	9.58e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.46	0.34	1.6e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3126085	0.515	rs9633410	chr1:152363922	G/T	cg26876637	chr1:152193138	HRNR	-0.63	-4.7	-0.36	5.8e-6	Atopic dermatitis;
PAAD	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.13	16.42	0.8	1.73e-35	Schizophrenia;
PAAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.3	0.45	3.1e-9	Initial pursuit acceleration;
PAAD	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.57	-6.73	-0.48	3.19e-10	Dilated cardiomyopathy;
PAAD	cis	rs2885056	0.891	rs2304161	chr19:10692117	T/C	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25029022	chr1:185126088	C1orf25;C1orf26	-0.67	-6.69	-0.48	3.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.83	0.43	3.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.54	-6.2	-0.45	5.01e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg05528293	chr18:74961138	GALR1	0.61	5.02	0.38	1.4e-6	Obesity-related traits;
PAAD	cis	rs73206853	0.841	rs17187412	chr12:110766767	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.67	-4.4	-0.34	2.05e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg01267373	chr18:77410094	NA	0.44	4.85	0.37	2.97e-6	Monocyte count;
PAAD	cis	rs9888739	0.841	rs12102791	chr16:31303946	C/T	cg02256631	chr16:31342952	ITGAM	-0.55	-4.45	-0.34	1.64e-5	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09974205	chr1:222638972	NA	0.61	6.61	0.47	6.16e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg05585544	chr11:47624801	NA	-0.52	-5.87	-0.43	2.7e-8	Subjective well-being;
PAAD	cis	rs7264396	0.887	rs4911503	chr20:34063095	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.3	0.33	3.08e-5	Total cholesterol levels;
PAAD	cis	rs17318866	1.000	rs2326364	chr6:3830849	G/A	cg11393995	chr6:2842359	SERPINB1	0.47	4.27	0.33	3.47e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.95	13.34	0.73	2.32e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.85	10.4	0.64	1.87e-19	Mean corpuscular volume;
PAAD	cis	rs929596	0.531	rs2741021	chr2:234511883	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	4.46	0.34	1.58e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.66	4.72	0.36	5.32e-6	Depression;
PAAD	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg00531865	chr16:30841666	NA	-0.53	-5.25	-0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22442454	chr1:209979470	IRF6	0.38	4.25	0.33	3.69e-5	Monobrow;
PAAD	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.6	-5.95	-0.43	1.75e-8	Morning vs. evening chronotype;
PAAD	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.98e-6	Cognitive ability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17342916	chr3:104556025	NA	0.54	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.49	-5.1	-0.38	1.01e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.97	0.44	1.65e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19434433	chr17:44849214	WNT3	0.62	7.08	0.5	4.89e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.03	-0.38	1.36e-6	Personality dimensions;
PAAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg04013166	chr16:89971882	TCF25	0.67	4.39	0.34	2.14e-5	Interleukin-17 levels;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10819733	chr22:24237672	NA	-0.61	-6.8	-0.48	2.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-4.98	-0.37	1.74e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg02555727	chr12:129281546	SLC15A4	0.44	4.71	0.36	5.63e-6	Systemic lupus erythematosus;
PAAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs11807834	0.522	rs4846832	chr1:230250676	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.64	0.47	5.2400000000000005e-10	Coffee consumption (cups per day);
PAAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg02917321	chr22:38215204	NA	0.44	4.5	0.34	1.33e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs757081	0.648	rs10832752	chr11:17285487	G/A	cg04705435	chr11:17411270	KCNJ11	-0.56	-5.58	-0.41	1.06e-7	Systolic blood pressure;
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Body mass index;
PAAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	cis	rs9361491	0.608	rs9359343	chr6:79456731	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4523957	0.552	rs2760742	chr17:2019037	A/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	14.47	0.76	2.2e-30	Testicular germ cell tumor;
PAAD	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.6	-0.47	6.55e-10	Neuroticism;
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs287982	1.000	rs287980	chr2:9971366	G/A	cg01119585	chr2:10571959	NA	-0.38	-4.39	-0.34	2.08e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.98	6.84	0.49	1.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4389656	0.857	rs274719	chr5:6720916	A/G	cg10857441	chr5:6722123	POLS	-0.41	-4.52	-0.34	1.24e-5	Coronary artery disease;
PAAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.88	10.29	0.64	3.65e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11807834	0.522	rs10864687	chr1:230237142	C/T	cg00566187	chr1:230250356	GALNT2	-0.63	-6.57	-0.47	7.58e-10	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.79	7.62	0.53	2.6e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7260598	0.539	rs10425498	chr19:24081671	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.57	5.43	0.4	2.2e-7	Diastolic blood pressure;
PAAD	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7247513	0.964	rs2042946	chr19:12705354	A/G	cg01871581	chr19:12707946	ZNF490	-0.86	-10.6	-0.65	5.47e-20	Bipolar disorder;
PAAD	cis	rs308971	0.563	rs307560	chr3:12093405	A/G	cg15873301	chr3:12045459	SYN2	0.63	4.41	0.34	1.92e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.28	-7.15	-0.5	3.42e-11	Body mass index;
PAAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.38	-0.33	2.18e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg14171486	chr1:155139557	NA	-0.32	-4.41	-0.34	1.98e-5	Serum magnesium levels;
PAAD	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.8	7.65	0.53	2.12e-12	Neuroticism;
PAAD	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.62	6.55	0.47	8.49e-10	Bladder cancer;
PAAD	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.49	-6.04	-0.44	1.12e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-4.49	-0.34	1.41e-5	Dental caries;
PAAD	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.52	5.41	0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.61	8.86	0.58	1.96e-15	Asthma (sex interaction);
PAAD	cis	rs17155006	0.664	rs451252	chr7:107738948	G/A	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg03983715	chr16:68378420	PRMT7	-0.97	-6.68	-0.48	4.26e-10	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs11921456	chr3:128581001	A/T	cg15676455	chr3:128564943	NA	0.69	4.47	0.34	1.49e-5	Dental caries;
PAAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg17366294	chr4:99064904	C4orf37	-0.49	-5.3	-0.4	3.94e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2019216	0.605	rs907706	chr17:21982191	G/A	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs793571	0.822	rs28538484	chr15:59201222	T/C	cg05156742	chr15:59063176	FAM63B	0.59	4.73	0.36	5.17e-6	Schizophrenia;
PAAD	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.65	-6.19	-0.45	5.43e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-5.53	-0.41	1.38e-7	Sjögren's syndrome;
PAAD	cis	rs4356203	0.519	rs214082	chr11:17299390	T/C	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.5	-0.34	1.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.77	5.92	0.43	2.1e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg03264133	chr6:25882463	NA	0.52	4.49	0.34	1.38e-5	Iron status biomarkers;
PAAD	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg05309399	chr4:106552544	FLJ20184	-0.54	-4.28	-0.33	3.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.7	-7.69	-0.53	1.73e-12	Alcohol dependence;
PAAD	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg09579323	chr1:150459698	TARS2	0.45	4.27	0.33	3.41e-5	Migraine;
PAAD	cis	rs6066835	0.867	rs6090901	chr20:47370788	T/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg02404636	chr22:31891804	SFI1	0.64	6.17	0.45	5.91e-9	Colorectal cancer;
PAAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.44	4.93	0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.95	-9.35	-0.6	1.05e-16	Asthma;
PAAD	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg12458913	chr13:53173898	NA	0.6	5.85	0.43	2.89e-8	Lewy body disease;
PAAD	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg22601191	chr20:60968625	CABLES2	-0.55	-5.38	-0.4	2.76e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.63	6.04	0.44	1.14e-8	Uric acid clearance;
PAAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg06521852	chr22:38141419	TRIOBP	0.42	4.38	0.33	2.19e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4356203	0.870	rs7936310	chr11:17270288	C/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.24e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06898199	chr7:128502890	ATP6V1F	0.58	7.22	0.51	2.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-7.04	-0.5	6.15e-11	Parkinson's disease;
PAAD	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg14393609	chr7:65229607	NA	-0.48	-4.86	-0.37	2.93e-6	Aortic root size;
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.05	-0.38	1.28e-6	Total body bone mineral density;
PAAD	cis	rs1997066	0.831	rs73340283	chr10:106811305	C/A	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg04154034	chr17:28927549	LRRC37B2	0.72	4.27	0.33	3.4e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.46	5.27	0.39	4.58e-7	Major depressive disorder;
PAAD	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg10113582	chr4:905918	GAK	0.38	4.44	0.34	1.7e-5	Systemic sclerosis;
PAAD	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs4908768	0.555	rs11582339	chr1:8898807	A/C	cg13432294	chr1:8937640	ENO1	0.36	4.28	0.33	3.29e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.35	0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7301826	0.967	rs4759792	chr12:131296631	G/A	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.54e-5	Plasma plasminogen activator levels;
PAAD	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg23331303	chr5:5135948	NA	0.46	6.57	0.47	7.61e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1468333	0.824	rs9327809	chr5:137587806	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.57	5.93	0.43	2e-8	Resting heart rate;
PAAD	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.46	5.06	0.38	1.19e-6	Age of smoking initiation;
PAAD	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24035218	chr20:61847643	YTHDF1	-0.76	-6.41	-0.46	1.74e-9	Neuroticism;
PAAD	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.83	-7.68	-0.53	1.77e-12	Breast cancer;
PAAD	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.91	-6.44	-0.46	1.47e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-4.76	-0.36	4.4e-6	Metabolite levels;
PAAD	cis	rs58521262	0.556	rs435715	chr19:23126086	G/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.93	-0.37	2.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11096990	0.892	rs3733288	chr4:39218569	G/T	cg16714752	chr4:39368184	RFC1	0.49	4.26	0.33	3.56e-5	Cognitive function;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08017156	chr16:21611107	METTL9	0.59	6.55	0.47	8.42e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.84	10.33	0.64	2.76e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg16579770	chr16:72058938	DHODH	0.37	4.27	0.33	3.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.49	-5.77	-0.42	4.41e-8	Intelligence;
PAAD	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg09175582	chr1:161736000	ATF6	0.7	4.79	0.36	3.86e-6	IgG glycosylation;
PAAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.56	-5.43	-0.4	2.18e-7	Vitiligo;
PAAD	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.58	5.12	0.38	9.16e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg00579200	chr11:133705235	NA	-0.45	-4.9	-0.37	2.43e-6	Childhood ear infection;
PAAD	cis	rs2133450	0.745	rs7642946	chr3:7365494	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-5.24	-0.39	5.2e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-5.48	-0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs12999616	0.817	rs55933640	chr2:98328721	C/T	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg08994789	chr17:28903642	LRRC37B2	0.62	4.63	0.35	7.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-10.31	-0.64	3.2e-19	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg12458913	chr13:53173898	NA	0.56	5.56	0.41	1.17e-7	Lewy body disease;
PAAD	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19700328	chr14:106028568	NA	-0.65	-6.18	-0.45	5.68e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs6088813	1.000	rs6142358	chr20:33960308	A/G	cg14752227	chr20:34000481	UQCC	0.53	5.35	0.4	3.14e-7	Height;
PAAD	cis	rs4144743	1.000	rs3809861	chr17:45330066	A/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs79839061	0.732	rs56852661	chr4:826257	G/A	cg07828340	chr4:882639	GAK	1.22	6.41	0.46	1.74e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14650005	chr6:111195812	AMD1	0.62	6.53	0.47	9.19e-10	Myopia (pathological);
PAAD	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	1.3	7.77	0.53	1.1e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-5.89	-0.43	2.42e-8	Monocyte count;
PAAD	cis	rs2514805	0.614	rs2446825	chr8:95126377	G/T	cg25183890	chr8:94929275	PDP1	0.67	4.75	0.36	4.66e-6	Diisocyanate-induced asthma;
PAAD	cis	rs35300120	0.796	rs7533955	chr1:233667338	C/T	cg23054119	chr1:233659267	NA	-0.5	-4.26	-0.33	3.6e-5	Cognitive function;
PAAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	trans	rs9409082	0.684	rs7862972	chr9:108981418	A/C	cg07010948	chr13:79181613	NA	0.35	6.57	0.47	7.39e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.99	0.38	1.63e-6	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg14580859	chr9:123691850	NA	0.38	4.32	0.33	2.76e-5	Rheumatoid arthritis;
PAAD	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.84	-7.15	-0.5	3.48e-11	Blood protein levels;
PAAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg02038168	chr22:39784481	NA	-0.51	-4.95	-0.37	1.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.62	-6.68	-0.48	4.17e-10	IgG glycosylation;
PAAD	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-4.39	-0.34	2.14e-5	Morning vs. evening chronotype;
PAAD	cis	rs12940923	0.507	rs16942914	chr17:56373071	T/C	cg14843216	chr17:56064736	VEZF1	-0.51	-4.25	-0.33	3.78e-5	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs9463078	0.510	rs1329714	chr6:45003335	T/A	cg25276700	chr6:44698697	NA	0.46	5.32	0.4	3.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.19	-0.39	6.68e-7	Migraine - clinic-based;
PAAD	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.71	7.62	0.53	2.47e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.4	-0.51	8.43e-12	Diastolic blood pressure;
PAAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg04738700	chr2:239367308	NA	0.4	4.4	0.34	2.06e-5	Multiple system atrophy;
PAAD	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg06042504	chr8:55087323	NA	-0.77	-8.67	-0.58	6.01e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05585630	chr7:157510462	PTPRN2	-0.79	-9.19	-0.6	2.84e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.55	4.65	0.35	7.05e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg00024416	chr22:24240387	NA	0.45	4.38	0.33	2.22e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg02951883	chr7:2050386	MAD1L1	0.58	5.67	0.42	6.96e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05665937	chr4:1216051	CTBP1	0.53	5.75	0.42	4.67e-8	Obesity-related traits;
PAAD	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.41	4.61	0.35	8.31e-6	Urate levels in lean individuals;
PAAD	cis	rs16975963	0.843	rs113690074	chr19:38375393	G/A	cg14218481	chr19:38281219	NA	0.47	4.75	0.36	4.75e-6	Longevity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25877054	chr1:95700082	RWDD3	0.61	6.46	0.46	1.37e-9	Myopia (pathological);
PAAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.69e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12580194	0.593	rs11171432	chr12:55757696	G/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.35	0.33	2.52e-5	Cancer;
PAAD	cis	rs2281636	0.929	rs7913190	chr10:101498396	T/G	cg05149213	chr10:101381631	SLC25A28	0.47	4.54	0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg21625146	chr5:486483	SLC9A3	0.43	5.24	0.39	5.38e-7	Cystic fibrosis severity;
PAAD	cis	rs757081	0.658	rs105290	chr11:17292068	T/C	cg04705435	chr11:17411270	KCNJ11	-0.56	-6.0	-0.44	1.38e-8	Systolic blood pressure;
PAAD	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.49	4.82	0.36	3.43e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs9581857	0.512	rs2057523	chr13:28073816	T/C	cg22138327	chr13:27999177	GTF3A	0.75	5.22	0.39	5.89e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs12311304	1.000	rs11056404	chr12:15378291	C/T	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.72e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.5	7.98	0.54	3.39e-13	Neuroticism;
PAAD	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.9	9.71	0.62	1.19e-17	Breast cancer;
PAAD	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Gout;
PAAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs682748	0.846	rs13187032	chr5:17135535	A/G	cg23987134	chr5:17158319	LOC285696	-0.35	-4.33	-0.33	2.7e-5	Hippocampal atrophy;
PAAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-6.28	-0.45	3.32e-9	Eye color traits;
PAAD	cis	rs1800795	0.530	rs7805828	chr7:22758562	A/G	cg05472934	chr7:22766657	IL6	-0.56	-5.99	-0.44	1.49e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.71	0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.52	5.06	0.38	1.17e-6	Cognitive function;
PAAD	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg19008133	chr3:123124015	ADCY5	0.6	4.54	0.35	1.12e-5	LDL cholesterol levels;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.58	5.88	0.43	2.49e-8	Lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23715237	chr8:145018300	PLEC1	-0.73	-6.35	-0.46	2.37e-9	Neuroticism;
PAAD	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.57	-5.53	-0.41	1.36e-7	Platelet count;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.74	6.63	0.47	5.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-5.01	-0.38	1.49e-6	Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4851254	0.626	rs115581542	chr2:100717725	T/A	cg22139774	chr2:100720529	AFF3	-0.45	-4.4	-0.34	2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg21361702	chr7:150065534	REPIN1	0.59	5.1	0.38	9.84e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.07	0.44	9.79e-9	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-5.36	-0.4	2.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11615916	0.790	rs11613953	chr12:62711199	T/C	cg11441379	chr12:63026424	NA	0.64	4.33	0.33	2.72e-5	Pulmonary function decline;
PAAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.53	4.85	0.37	3.09e-6	Monocyte count;
PAAD	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.64	-7.48	-0.52	5.67e-12	Schizophrenia;
PAAD	cis	rs4356203	0.905	rs662711	chr11:17206188	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg08975724	chr8:8085496	FLJ10661	0.68	6.83	0.48	1.87e-10	Triglycerides;
PAAD	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-5.69	-0.42	6.35e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2229238	0.955	rs4072391	chr1:154438880	A/G	cg21262032	chr1:154437693	IL6R	0.46	4.72	0.36	5.29e-6	Coronary heart disease;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg11062466	chr8:58055876	NA	0.84	5.13	0.38	8.71e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg19254793	chr6:44695348	NA	-0.49	-4.71	-0.36	5.62e-6	Total body bone mineral density;
PAAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.84	10.47	0.65	1.21e-19	Bladder cancer;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.61	-5.08	-0.38	1.1e-6	Monocyte count;
PAAD	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	5.17	0.39	7.18e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12612091	chr3:52279902	PPM1M	-0.62	-7.09	-0.5	4.8e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.67	6.21	0.45	4.73e-9	Alcohol dependence;
PAAD	cis	rs1468333	0.567	rs12514520	chr5:137778068	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.07	0.38	1.14e-6	Resting heart rate;
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-1.08	-7.77	-0.53	1.09e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10450586	0.932	rs10767637	chr11:27336082	G/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs7172677	1.000	rs11072525	chr15:75419110	G/A	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.69	-0.36	6.09e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-4.54	-0.35	1.13e-5	Circulating chemerin levels;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.57	0.41	1.13e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg22764044	chr5:178986830	RUFY1	0.48	4.86	0.37	2.96e-6	Lung cancer;
PAAD	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.46	-4.25	-0.33	3.72e-5	Multiple sclerosis;
PAAD	cis	rs11811982	0.793	rs78292385	chr1:227295064	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs7727544	0.647	rs7721882	chr5:131418948	A/G	cg16205897	chr5:131564050	P4HA2	-0.49	-5.3	-0.4	3.92e-7	Blood metabolite levels;
PAAD	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg16447950	chr5:562315	NA	0.64	5.91	0.43	2.21e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg10589385	chr1:150898437	SETDB1	0.39	4.88	0.37	2.67e-6	Melanoma;
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13870426	chr17:30244630	NA	-0.7	-6.9	-0.49	1.29e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg19197139	chr17:4613644	ARRB2	0.86	8.93	0.59	1.32e-15	Lymphocyte counts;
PAAD	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.68	-0.35	6.39e-6	Refractive error;
PAAD	cis	rs16975963	0.644	rs73031321	chr19:38040858	C/T	cg08679971	chr19:38281047	NA	0.46	4.53	0.34	1.19e-5	Longevity;
PAAD	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg24565620	chr2:194026	NA	0.58	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs6142102	0.625	rs6142061	chr20:32548335	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	cis	rs12714314	0.957	rs2060196	chr2:1955972	T/A	cg22350835	chr2:1868857	MYT1L	0.48	4.76	0.36	4.47e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg00277334	chr10:82204260	NA	-0.57	-5.78	-0.42	4.05e-8	Post bronchodilator FEV1;
PAAD	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9880772	0.602	rs12493245	chr3:27797810	C/T	cg21473142	chr3:27762095	EOMES	0.3	4.99	0.38	1.6e-6	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.71	9.32	0.6	1.29e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs258892	0.895	rs13166571	chr5:72039858	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg00262122	chr8:11665843	FDFT1	-0.52	-4.72	-0.36	5.36e-6	Retinal vascular caliber;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg24519413	chr1:26490540	NA	0.52	4.84	0.37	3.22e-6	Height;
PAAD	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg02297831	chr4:17616191	MED28	0.59	5.82	0.43	3.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.83	6.63	0.47	5.59e-10	Lung function (FEV1/FVC);
PAAD	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-7.6	-0.52	2.77e-12	Heart rate;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg10207240	chr12:122356781	WDR66	0.53	6.09	0.44	8.74e-9	Mean corpuscular volume;
PAAD	cis	rs6460942	0.597	rs17277369	chr7:12536192	A/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.58	5.09	0.38	1.04e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	8.14	0.55	1.33e-13	Cognitive test performance;
PAAD	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.47	5.24	0.39	5.26e-7	Total cholesterol levels;
PAAD	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	cis	rs2637030	0.559	rs549131	chr5:52902238	T/C	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg06636001	chr8:8085503	FLJ10661	0.85	8.9	0.59	1.6e-15	Mood instability;
PAAD	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.51	5.23	0.39	5.44e-7	Heart rate;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	trans	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg17712092	chr4:129076599	LARP1B	-0.62	-6.56	-0.47	8.09e-10	Eosinophil percentage of white cells;
PAAD	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.47	4.37	0.33	2.26e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.67	0.35	6.55e-6	Resting heart rate;
PAAD	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.57	5.14	0.38	8.28e-7	Mean platelet volume;
PAAD	cis	rs1642645	0.872	rs10890170	chr1:42409522	A/C	cg01990334	chr1:42801334	FOXJ3	-0.62	-5.4	-0.4	2.47e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.61	4.52	0.34	1.23e-5	Neuroblastoma;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.92	11.78	0.69	3.73e-23	Menarche (age at onset);
PAAD	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg15571903	chr15:79123663	NA	0.48	6.17	0.45	5.97e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11264213	0.901	rs614235	chr1:36450565	G/A	cg27506609	chr1:36549197	TEKT2	0.72	5.08	0.38	1.09e-6	Schizophrenia;
PAAD	cis	rs7567389	0.573	rs11541137	chr2:128145771	C/T	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs6594713	0.921	rs6887482	chr5:112741433	G/T	cg12552261	chr5:112820674	MCC	-0.67	-5.37	-0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.65	7.75	0.53	1.24e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.33	-0.4	3.44e-7	Mood instability;
PAAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs11871801	1.000	rs7223784	chr17:40577580	A/C	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.6	-0.35	8.98e-6	Crohn's disease;
PAAD	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg26816564	chr1:7831052	VAMP3	-0.6	-5.15	-0.39	7.84e-7	Inflammatory bowel disease;
PAAD	cis	rs10901513	0.932	rs11244744	chr10:127668317	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.43	-0.52	7.18e-12	Neuroticism;
PAAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-5.21	-0.39	6e-7	Electroencephalogram traits;
PAAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-7.99	-0.54	3.07e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.17	0.5	3.07e-11	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.32	0.56	4.57e-14	Platelet count;
PAAD	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.65	-7.0	-0.49	7.68e-11	Longevity;
PAAD	cis	rs8060686	0.858	rs7191129	chr16:67801391	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-5.28	-0.39	4.37e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.1	-0.59	4.73e-16	Colorectal cancer;
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg18357526	chr6:26021779	HIST1H4A	0.63	6.01	0.44	1.32e-8	Blood metabolite levels;
PAAD	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg19131313	chr8:1704013	NA	0.39	4.4	0.34	2.04e-5	Systolic blood pressure;
PAAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.48	0.65	1.13e-19	Total body bone mineral density;
PAAD	cis	rs12681963	0.688	rs2958746	chr8:30089070	C/T	cg23406830	chr8:30012838	DCTN6	0.69	4.49	0.34	1.39e-5	Migraine;
PAAD	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.11	0.38	9.44e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg16558253	chr16:72132732	DHX38	-0.59	-5.02	-0.38	1.4e-6	Coronary artery disease;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg26516362	chr5:178986906	RUFY1	0.47	5.21	0.39	6.09e-7	Lung cancer;
PAAD	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.44	4.28	0.33	3.31e-5	Neutrophil percentage of white cells;
PAAD	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.21	-0.39	6.16e-7	Monocyte percentage of white cells;
PAAD	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg27449745	chr7:23145252	KLHL7	-0.5	-4.31	-0.33	2.92e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs600550	0.588	rs11230239	chr11:60072149	C/T	cg18570331	chr11:60101691	MS4A6E	0.47	4.25	0.33	3.76e-5	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs375066	0.544	rs12462507	chr19:44310391	G/A	cg11993925	chr19:44307056	LYPD5	-0.44	-4.71	-0.36	5.46e-6	Breast cancer;
PAAD	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.37	0.33	2.31e-5	Eosinophil percentage of white cells;
PAAD	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.71	-8.34	-0.56	4.19e-14	Educational attainment;
PAAD	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.77	-8.04	-0.55	2.31e-13	Cognitive test performance;
PAAD	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg23912435	chr1:150601613	ENSA	0.5	4.65	0.35	7.24e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg02903104	chr8:1507517	DLGAP2	0.34	4.32	0.33	2.77e-5	Lung cancer;
PAAD	cis	rs7187994	0.848	rs12922556	chr16:84784290	C/T	cg07647771	chr16:84786436	USP10	0.35	4.41	0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs9434723	0.844	rs9434729	chr1:9303940	G/C	cg04199779	chr1:9294473	H6PD	0.57	5.01	0.38	1.51e-6	Height;
PAAD	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	8.62	0.57	8.16e-15	Multiple sclerosis;
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00166722	chr3:10149974	C3orf24	0.85	6.18	0.45	5.72e-9	Alzheimer's disease;
PAAD	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.33	0.6	1.21e-16	Smoking behavior;
PAAD	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg12935359	chr14:103987150	CKB	-0.62	-6.72	-0.48	3.46e-10	Body mass index;
PAAD	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.67	6.96	0.49	9.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg27129171	chr3:47204927	SETD2	0.72	8.09	0.55	1.81e-13	Birth weight;
PAAD	cis	rs6662572	1.000	rs11585275	chr1:46095989	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	4.45	0.34	1.62e-5	Blood protein levels;
PAAD	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.79	7.79	0.53	1e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs114540395	0.858	rs78446856	chr10:103119815	T/A	cg19499884	chr10:102760724	LZTS2	-0.75	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.74	0.58	4.1e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4938330	0.608	rs4938358	chr11:117084091	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.29	-0.51	1.55e-11	Testicular germ cell tumor;
PAAD	cis	rs9628987	1.000	rs9628987	chr1:8386730	A/C	cg14413262	chr1:8384046	SLC45A1	-0.56	-4.27	-0.33	3.37e-5	Breast cancer;
PAAD	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg18964960	chr10:1102726	WDR37	0.93	4.79	0.36	3.99e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2133450	0.526	rs56129834	chr3:7345582	A/T	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.75	8.77	0.58	3.32e-15	Methadone dose in opioid dependence;
PAAD	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	6.36	0.46	2.25e-9	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.56	-4.91	-0.37	2.31e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg20628663	chr10:43360327	NA	0.58	4.49	0.34	1.41e-5	Blood protein levels;
PAAD	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg27565382	chr3:53032988	SFMBT1	0.96	4.72	0.36	5.25e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.13	0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg17178900	chr1:205818956	PM20D1	-0.62	-4.62	-0.35	8.07e-6	Prostate-specific antigen levels;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.75	-7.88	-0.54	5.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.65	5.8	0.43	3.71e-8	Airflow obstruction;
PAAD	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg04330084	chr7:123175371	IQUB	-0.54	-4.81	-0.36	3.55e-6	Plateletcrit;Platelet count;
PAAD	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.46	-5.39	-0.4	2.64e-7	Colorectal cancer;
PAAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.95	10.42	0.65	1.64e-19	Diastolic blood pressure;
PAAD	cis	rs4356203	0.519	rs214083	chr11:17298859	G/C	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.5	-0.34	1.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs11037575	0.739	rs1320168	chr11:43714849	A/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.18	0.5	2.82e-11	Colorectal cancer;
PAAD	cis	rs1519814	0.696	rs7821842	chr8:121033982	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-4.89	-0.37	2.53e-6	Breast cancer;
PAAD	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg23254163	chr1:152506842	NA	-0.49	-4.96	-0.37	1.88e-6	Hair morphology;
PAAD	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.57	5.42	0.4	2.32e-7	Corneal astigmatism;
PAAD	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg22517653	chr1:2918612	NA	-0.59	-4.56	-0.35	1.06e-5	Plateletcrit;
PAAD	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg18898632	chr2:242989856	NA	-0.61	-4.79	-0.36	3.96e-6	Obesity-related traits;
PAAD	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg26031613	chr14:104095156	KLC1	0.51	4.73	0.36	4.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg15017067	chr4:17643749	FAM184B	0.41	4.41	0.34	1.91e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	1.14	12.44	0.71	6.04e-25	Post bronchodilator FEV1;
PAAD	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs73416724	0.535	rs61729324	chr6:43258994	G/A	cg00507679	chr6:43251876	TTBK1	0.84	4.92	0.37	2.22e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Body mass index;
PAAD	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg23024343	chr7:107201750	COG5	0.61	4.66	0.35	6.84e-6	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.88	0.63	4.31e-18	Platelet count;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.8	-5.17	-0.39	7.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3753841	0.832	rs1812682	chr1:103210619	A/T	cg24495344	chr1:103574097	COL11A1	0.41	4.76	0.36	4.43e-6	Glaucoma (primary angle closure);
PAAD	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.83	-8.72	-0.58	4.46e-15	Body mass index;
PAAD	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.57	-0.52	3.31e-12	Blood metabolite levels;
PAAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg18666930	chr2:3658894	COLEC11	-0.43	-4.35	-0.33	2.44e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.52	4.66	0.35	6.79e-6	Height;
PAAD	cis	rs7487075	0.619	rs12832777	chr12:46831129	T/C	cg14671384	chr12:47219920	SLC38A4	0.46	4.58	0.35	9.73e-6	Itch intensity from mosquito bite;
PAAD	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.64	-6.09	-0.44	8.7e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.61	6.17	0.45	5.93e-9	Menopause (age at onset);
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.82	-9.23	-0.6	2.2e-16	Height;
PAAD	cis	rs73019876	0.869	rs10418541	chr19:22177814	T/C	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs17739794	0.502	rs3860879	chr8:809489	C/T	cg10454879	chr8:602158	NA	0.42	4.47	0.34	1.51e-5	Clozapine-induced cytotoxicity;
PAAD	cis	rs7554547	0.668	rs2038028	chr1:11979556	A/G	cg07603449	chr1:11986842	KIAA2013	-0.38	-5.77	-0.42	4.35e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17309711	chr11:45826527	SLC35C1	0.6	6.55	0.47	8.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg02555727	chr12:129281546	SLC15A4	0.47	4.95	0.37	1.99e-6	Systemic lupus erythematosus;
PAAD	cis	rs6141769	0.866	rs79384779	chr20:31214944	C/T	cg13636640	chr20:31349939	DNMT3B	0.55	4.48	0.34	1.48e-5	Subjective well-being;
PAAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg25204440	chr1:209979598	IRF6	-0.63	-5.63	-0.42	8.32e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19784903	chr17:45786737	TBKBP1	0.5	5.35	0.4	3.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.91	0.37	2.37e-6	Cognitive ability;
PAAD	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg11965913	chr1:205819406	PM20D1	0.63	4.91	0.37	2.34e-6	Parkinson's disease;
PAAD	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg23346134	chr3:49453900	TCTA	-0.49	-5.06	-0.38	1.19e-6	Menarche (age at onset);
PAAD	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg16147221	chr4:10020634	SLC2A9	0.5	4.44	0.34	1.73e-5	Bone mineral density;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.76	8.83	0.58	2.34e-15	Lung cancer;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.57e-8	Lung cancer;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.86	7.02	0.5	6.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg15181151	chr6:150070149	PCMT1	-0.55	-5.63	-0.42	8.54e-8	Lung cancer;
PAAD	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg19008133	chr3:123124015	ADCY5	0.67	4.76	0.36	4.54e-6	LDL cholesterol levels;
PAAD	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1050846	0.603	rs1050847	chr16:87443734	A/G	cg00512563	chr16:87398040	FBXO31	0.41	5.38	0.4	2.71e-7	Neuroticism;
PAAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg03999872	chr20:62272968	STMN3	0.53	4.81	0.36	3.57e-6	Prostate cancer;
PAAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-7.08	-0.5	4.94e-11	Personality dimensions;
PAAD	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.42	-6.34	-0.46	2.45e-9	Subjective well-being;
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07648498	chr16:89883185	FANCA	0.68	7.2	0.5	2.58e-11	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13820589	chr18:3013400	LPIN2	0.68	7.91	0.54	4.92e-13	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21522636	chr3:50374980	RASSF1	-0.68	-7.09	-0.5	4.66e-11	Smoking initiation;
PAAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.97	12.71	0.72	1.13e-25	Menopause (age at onset);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg19803976	chr18:11850907	CHMP1B;GNAL	-0.62	-6.39	-0.46	1.88e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4733781	1.000	rs4733781	chr8:131296767	A/C	ch.8.2598327F	chr8:131124146	ASAP1	-0.46	-4.38	-0.33	2.19e-5	Tuberculosis;
PAAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.6	-6.71	-0.48	3.64e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.93	0.63	3.18e-18	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09161592	chr10:91405006	PANK1	0.58	6.52	0.47	9.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg24250549	chr1:154909240	PMVK	-0.47	-4.67	-0.35	6.52e-6	Schizophrenia;
PAAD	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	4.76	0.36	4.43e-6	Educational attainment (years of education);
PAAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.63	8.47	0.57	1.92e-14	Renal cell carcinoma;
PAAD	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg16558253	chr16:72132732	DHX38	-0.59	-4.92	-0.37	2.22e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg25124228	chr12:125621409	AACS	-0.69	-6.91	-0.49	1.28e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1499972	0.838	rs7644473	chr3:117520833	G/T	cg07612923	chr3:117604196	NA	-1.06	-7.0	-0.49	7.85e-11	Schizophrenia;
PAAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg19636519	chr7:99541626	NA	0.38	4.28	0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-7.95	-0.54	4.03e-13	Hemoglobin concentration;
PAAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.41	-4.52	-0.34	1.24e-5	Mean platelet volume;
PAAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg10432947	chr4:2062441	NAT8L	-0.48	-4.38	-0.33	2.17e-5	Systolic blood pressure;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg13852536	chr9:32567045	NDUFB6	-0.61	-6.81	-0.48	2.14e-10	Iris heterochromicity;
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg14789911	chr21:47582049	C21orf56	-0.47	-4.79	-0.36	3.99e-6	Testicular germ cell tumor;
PAAD	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-6.29	-0.45	3.16e-9	Systolic blood pressure;
PAAD	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.95	0.54	3.87e-13	Motion sickness;
PAAD	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.81	9.13	0.6	3.93e-16	Crohn's disease;
PAAD	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg12458913	chr13:53173898	NA	-0.51	-5.03	-0.38	1.35e-6	Lewy body disease;
PAAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.52	5.88	0.43	2.57e-8	Breast cancer;
PAAD	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.35	0.4	3.2e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06671706	chr8:8559999	CLDN23	0.73	7.14	0.5	3.68e-11	Obesity-related traits;
PAAD	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.06	0.38	1.18e-6	Blood protein levels;
PAAD	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.79	8.63	0.57	7.46e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.68	6.56	0.47	7.98e-10	Prostate cancer;
PAAD	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13560548	chr3:10150139	C3orf24	0.63	5.51	0.41	1.53e-7	Alzheimer's disease;
PAAD	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.78	7.83	0.54	7.64e-13	Uric acid levels;
PAAD	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.48	-0.41	1.69e-7	Prevalent atrial fibrillation;
PAAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.13	16.42	0.8	1.73e-35	Schizophrenia;
PAAD	cis	rs4938330	0.608	rs2239011	chr11:117088994	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.72	-0.36	5.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.95	-10.04	-0.63	1.62e-18	Platelet count;
PAAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg08284496	chr17:37894027	GRB7	0.25	4.26	0.33	3.59e-5	Asthma;
PAAD	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs9506514	0.617	rs9509352	chr13:21295149	A/G	cg27499820	chr13:21296301	IL17D	-0.53	-5.8	-0.43	3.79e-8	Coronary artery calcification;
PAAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05025164	chr4:1340916	KIAA1530	0.57	5.72	0.42	5.5e-8	Obesity-related traits;
PAAD	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00292662	chr22:38071168	LGALS1	0.52	5.49	0.41	1.66e-7	Fat distribution (HIV);
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-5.87	-0.43	2.7e-8	Longevity;Endometriosis;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.91	-0.37	2.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.94	-9.66	-0.62	1.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.53	-0.35	1.17e-5	Diastolic blood pressure;
PAAD	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg20312557	chr2:97357134	FER1L5	-0.86	-4.4	-0.34	2.04e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7714584	1.000	rs4958852	chr5:150330631	C/T	cg22134413	chr5:150180641	NA	1.04	6.37	0.46	2.11e-9	Crohn's disease;
PAAD	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.51	-5.0	-0.38	1.58e-6	High light scatter reticulocyte count;
PAAD	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg13160058	chr8:26243215	BNIP3L	0.34	4.65	0.35	7.08e-6	Height;
PAAD	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg15192750	chr16:69999425	NA	0.78	6.06	0.44	1.04e-8	IgE levels;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.75	-0.42	4.77e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg05528293	chr18:74961138	GALR1	0.61	4.93	0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.62	-5.87	-0.43	2.62e-8	Aortic root size;
PAAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.61	6.51	0.47	1.06e-9	Glomerular filtration rate;
PAAD	cis	rs2327429	0.541	rs12193973	chr6:134151297	A/G	cg06296503	chr6:134217401	NA	-0.43	-4.55	-0.35	1.08e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.64	-5.32	-0.4	3.65e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.59	6.15	0.45	6.4e-9	Crohn's disease;
PAAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.41	0.34	1.98e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg17802220	chr15:77601643	NA	-0.65	-4.82	-0.36	3.4e-6	Risky sexual behaviors (alcohol dependence interaction);
PAAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.89	0.43	2.37e-8	Coronary artery disease;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg05457628	chr5:178986728	RUFY1	-0.64	-6.79	-0.48	2.41e-10	Lung cancer;
PAAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.84	8.12	0.55	1.5e-13	Colorectal cancer;
PAAD	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg10483660	chr13:112241077	NA	0.55	5.04	0.38	1.28e-6	Menarche (age at onset);
PAAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.69	7.23	0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.17	0.6	3.16e-16	Motion sickness;
PAAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.78	8.85	0.58	2.05e-15	Hemoglobin concentration;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.61	0.35	8.46e-6	Electroencephalogram traits;
PAAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.96	8.19	0.55	1.02e-13	IgG glycosylation;
PAAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.53	-5.86	-0.43	2.77e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.64	-4.95	-0.37	1.98e-6	Birth weight;
PAAD	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.64	5.98	0.44	1.56e-8	Obesity-related traits;
PAAD	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs9888739	0.920	rs7190807	chr16:31301910	G/C	cg02256631	chr16:31342952	ITGAM	-0.55	-4.45	-0.34	1.64e-5	Systemic lupus erythematosus;
PAAD	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.1	-0.38	9.79e-7	Fear of minor pain;
PAAD	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg02421172	chr7:1938701	MAD1L1	0.62	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg04721828	chr11:48285200	OR4X1	-0.48	-6.0	-0.44	1.41e-8	Migraine - clinic-based;
PAAD	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.57	-6.16	-0.45	6.24e-9	Tonsillectomy;
PAAD	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg08648136	chr8:956695	NA	0.42	4.62	0.35	7.98e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg04445214	chr22:31688300	PIK3IP1	0.61	7.4	0.51	8.5e-12	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs35955747	0.633	rs4541328	chr22:31896172	G/A	cg02404636	chr22:31891804	SFI1	-0.52	-5.2	-0.39	6.46e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg07959070	chr22:50026188	C22orf34	-0.37	-4.58	-0.35	9.59e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.5	-6.13	-0.45	7.09e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.68	0.36	6.19e-6	Longevity;
PAAD	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg03678062	chr6:149772716	ZC3H12D	0.32	4.31	0.33	2.93e-5	Dupuytren's disease;
PAAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg25251562	chr2:3704773	ALLC	-0.44	-5.06	-0.38	1.18e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.65	7.39	0.51	9.02e-12	Coronary artery disease;
PAAD	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-4.43	-0.34	1.81e-5	Breast cancer;
PAAD	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.73	7.72	0.53	1.45e-12	Corneal astigmatism;
PAAD	cis	rs7191439	0.522	rs4597303	chr16:88763561	T/C	cg27087555	chr16:88793112	FAM38A	-0.97	-4.99	-0.38	1.63e-6	Plateletcrit;
PAAD	cis	rs13092825	1.000	rs6808951	chr3:113274334	A/T	cg18753928	chr3:113234510	CCDC52	-0.47	-4.52	-0.34	1.22e-5	Dental caries;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02438965	chr17:31200009	MYO1D	-0.61	-7.56	-0.52	3.64e-12	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12473036	chr20:62611207	SAMD10;PRPF6	0.61	7.07	0.5	5.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.49	-4.95	-0.37	1.98e-6	Monocyte count;
PAAD	cis	rs3779195	0.929	rs2906184	chr7:97939987	T/A	cg24562669	chr7:97807699	LMTK2	-0.51	-4.54	-0.35	1.12e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.43e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.49	-5.11	-0.38	9.55e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	8.65	0.57	6.7e-15	Total body bone mineral density;
PAAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg03938978	chr2:103052716	IL18RAP	0.51	5.18	0.39	6.86e-7	Blood protein levels;
PAAD	cis	rs11671653	1.000	rs11669253	chr19:10836329	A/C	cg18582342	chr19:11591989	ELAVL3	-0.53	-4.49	-0.34	1.39e-5	LDL cholesterol;
PAAD	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg25838818	chr2:108905173	SULT1C2	-0.48	-4.91	-0.37	2.34e-6	Blood pressure;
PAAD	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.42	-4.77	-0.36	4.3e-6	Blood pressure (smoking interaction);
PAAD	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs12935418	0.616	rs55776427	chr16:81005896	T/C	cg16651780	chr16:81037892	C16orf61	0.69	6.73	0.48	3.2e-10	Mean corpuscular volume;
PAAD	cis	rs3734905	0.803	rs4451137	chr6:169986070	C/T	cg11181693	chr6:169825345	NA	-0.83	-5.2	-0.39	6.28e-7	HIV-1 control;
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.66	-0.48	4.64e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6694270	1.000	rs6694270	chr1:19120377	A/G	cg19637330	chr1:19110922	NA	-0.63	-5.3	-0.39	4.03e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg16494567	chr8:142200140	DENND3	-0.43	-4.44	-0.34	1.72e-5	Immature fraction of reticulocytes;
PAAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.6	-5.66	-0.42	7.43e-8	IgG glycosylation;
PAAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.6	-5.86	-0.43	2.79e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.44	-4.97	-0.37	1.75e-6	Electroencephalogram traits;
PAAD	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg02780029	chr10:43622663	RET	-0.46	-4.51	-0.34	1.29e-5	Hirschsprung disease;
PAAD	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.73	5.6	0.41	9.54e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	11.47	0.68	2.4e-22	Nonalcoholic fatty liver disease;
PAAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.5	4.66	0.35	6.83e-6	Red blood cell count;
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.43	0.4	2.19e-7	Total body bone mineral density;
PAAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.56	5.28	0.39	4.45e-7	Mood instability;
PAAD	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-6.8	-0.48	2.19e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg27119904	chr13:114814333	RASA3	0.41	4.67	0.35	6.46e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs716804	0.515	rs7128698	chr11:10056496	A/G	cg06875754	chr11:10328428	ADM	0.34	4.3	0.33	2.99e-5	Neuroticism;
PAAD	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg17796960	chr10:135278976	LOC619207	-0.43	-4.77	-0.36	4.29e-6	Systemic lupus erythematosus;
PAAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.86	8.46	0.57	2.12e-14	Cognitive function;
PAAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg13722127	chr7:150037890	RARRES2	0.54	5.45	0.4	1.95e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.76	7.5	0.52	4.99e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1006703	0.544	rs34713010	chr17:3834718	A/G	cg06463185	chr17:3833770	ATP2A3	-0.88	-7.22	-0.51	2.37e-11	Glucose homeostasis traits;
PAAD	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.53	5.52	0.41	1.43e-7	Longevity;
PAAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-4.58	-0.35	9.54e-6	Schizophrenia;
PAAD	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08886695	chr4:3369023	RGS12	-0.5	-4.83	-0.36	3.31e-6	Serum sulfate level;
PAAD	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.81	6.62	0.47	5.74e-10	Pulmonary function decline;
PAAD	cis	rs2562456	0.833	rs2650776	chr19:21613397	C/T	cg00806126	chr19:22604979	ZNF98	-0.41	-5.22	-0.39	5.83e-7	Pain;
PAAD	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	1.18	10.37	0.64	2.14e-19	Red blood cell traits;
PAAD	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg08885076	chr2:99613938	TSGA10	-0.46	-4.49	-0.34	1.41e-5	Chronic sinus infection;
PAAD	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.52	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16317052	chr17:61678891	TACO1	-0.68	-6.65	-0.47	4.98e-10	Lung cancer in ever smokers;
PAAD	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.57	-5.96	-0.43	1.73e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.73	8.24	0.56	7.34e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg21395723	chr22:39101663	GTPBP1	0.44	4.55	0.35	1.1e-5	Menopause (age at onset);
PAAD	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg02753203	chr1:228287806	NA	0.59	4.76	0.36	4.39e-6	Adult asthma;
PAAD	cis	rs3747547	0.710	rs16934659	chr9:37950604	T/C	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg05342682	chr7:94953680	PON1	-0.52	-4.61	-0.35	8.65e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg02463844	chr16:88152170	NA	0.29	4.78	0.36	4.15e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg03676636	chr4:99064102	C4orf37	0.31	5.77	0.42	4.28e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg23442198	chr4:187126114	CYP4V2	-0.65	-4.69	-0.36	5.95e-6	Blood protein levels;
PAAD	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.38	-4.73	-0.36	5.12e-6	Schizophrenia;
PAAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.28e-10	Coronary artery disease;
PAAD	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg27411982	chr8:10470053	RP1L1	0.46	5.16	0.39	7.57e-7	Systolic blood pressure;
PAAD	cis	rs1385374	0.920	rs61946175	chr12:129273021	G/A	cg09035930	chr12:129282057	SLC15A4	-0.77	-4.48	-0.34	1.47e-5	Systemic lupus erythematosus;
PAAD	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	4.6	0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg13397359	chr6:42928475	GNMT	0.61	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.58	-6.46	-0.46	1.32e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	9.22	0.6	2.3e-16	Ulcerative colitis;
PAAD	cis	rs9463078	0.585	rs9463075	chr6:45149650	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01091261	chr16:4029363	ADCY9	0.54	6.57	0.47	7.44e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg27499820	chr13:21296301	IL17D	0.59	5.83	0.43	3.22e-8	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	1.09	7.74	0.53	1.28e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.57	6.44	0.46	1.5e-9	Cardiovascular disease risk factors;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05367824	chr21:40817657	SH3BGR	-0.59	-6.65	-0.47	5.02e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.34	-6.91	-0.49	1.27e-10	Psoriasis vulgaris;
PAAD	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.56	-5.36	-0.4	3e-7	Blood metabolite levels;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg04520793	chr17:42248056	ASB16	-0.46	-6.3	-0.46	2.99e-9	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08219700	chr8:58056026	NA	0.68	5.28	0.39	4.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.67	7.26	0.51	1.86e-11	Heart rate;
PAAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg13207630	chr7:32358064	NA	0.96	4.91	0.37	2.28e-6	Body mass index;
PAAD	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-1.03	-9.52	-0.61	3.78e-17	Prostate cancer;
PAAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.73	7.95	0.54	3.93e-13	Longevity;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.72	-7.83	-0.54	7.75e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg16989086	chr20:62203971	PRIC285	-0.55	-4.38	-0.33	2.18e-5	Atopic dermatitis;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	0.69	4.7	0.36	5.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10476473	chr2:170681531	METTL5	0.59	6.98	0.49	8.6e-11	Monocyte percentage of white cells;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.72	7.91	0.54	4.98e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.36e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.94	10.51	0.65	9.04e-20	Coronary artery disease;
PAAD	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.81	-0.54	8.69e-13	Coronary artery disease;
PAAD	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.78	8.37	0.56	3.46e-14	Obesity-related traits;
PAAD	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg05250797	chr16:70222502	NA	0.86	6.69	0.48	4.02e-10	IgE levels;
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.3	0.56	5.37e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.48e-6	Daytime sleep phenotypes;
PAAD	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	6.54	0.47	8.65e-10	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20957975	chr19:18392540	JUND	-0.65	-7.04	-0.5	6.07e-11	Smoking initiation;
PAAD	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg13171406	chr11:92712998	MTNR1B	-0.5	-4.27	-0.33	3.37e-5	Pulmonary function decline;
PAAD	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg05555928	chr11:63887634	MACROD1	-0.45	-4.98	-0.37	1.71e-6	Platelet count;
PAAD	cis	rs2882667	0.722	rs825751	chr5:138133869	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.51	-4.65	-0.35	7.13e-6	Educational attainment (years of education);
PAAD	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.96	11.38	0.68	4.19e-22	IgG glycosylation;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22509189	chr2:225307070	NA	-0.47	-4.68	-0.36	6.17e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2814331	0.883	rs1993485	chr10:88058417	T/C	cg08962038	chr10:88022859	GRID1	-0.51	-4.38	-0.33	2.17e-5	Balding;
PAAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19346786	chr7:2764209	NA	-0.36	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg27449745	chr7:23145252	KLHL7	-0.6	-5.37	-0.4	2.85e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.42	-0.56	2.56e-14	Urate levels in overweight individuals;
PAAD	cis	rs17683430	0.681	rs12157575	chr22:32543338	T/C	cg00543991	chr22:32367038	NA	0.62	4.74	0.36	4.8e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.76	0.48	2.73e-10	IgG glycosylation;
PAAD	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.68	-8.54	-0.57	1.33e-14	Educational attainment;
PAAD	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.15	-0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.75	-6.12	-0.44	7.52e-9	Pancreatic cancer;
PAAD	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg10556349	chr10:835070	NA	0.59	4.89	0.37	2.5e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	6.43	0.46	1.55e-9	Renal function-related traits (BUN);
PAAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg04287289	chr16:89883240	FANCA	0.42	4.39	0.34	2.12e-5	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01866597	chr16:837896	RPUSD1;CHTF18	0.6	6.77	0.48	2.6e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11264799	0.594	rs72710024	chr1:157773265	C/G	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg09835421	chr16:68378352	PRMT7	-0.97	-5.8	-0.43	3.78e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.08e-15	Prostate cancer;
PAAD	cis	rs1144333	0.655	rs4949682	chr1:76443196	C/T	cg22875332	chr1:76189707	ACADM	-0.76	-4.45	-0.34	1.62e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-5.27	-0.39	4.52e-7	Hirschsprung disease;
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.44	6.54	0.47	8.9e-10	Mean corpuscular volume;
PAAD	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15447715	chr7:150725397	ABCB8	0.75	6.76	0.48	2.72e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2299587	0.553	rs2299580	chr8:17734567	C/A	cg08627089	chr8:17753878	FGL1	-0.47	-4.5	-0.34	1.36e-5	Economic and political preferences;
PAAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.67	8.05	0.55	2.24e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg03989125	chr22:38214979	NA	0.64	5.84	0.43	3.03e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg19700328	chr14:106028568	NA	-0.64	-6.18	-0.45	5.55e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	4.71	0.36	5.52e-6	Schizophrenia;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg18210722	chr7:74379144	GATSL1	-0.55	-6.48	-0.47	1.19e-9	Alzheimer's disease (survival time);
PAAD	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg21037935	chr19:58911965	NA	0.5	4.32	0.33	2.81e-5	Mean platelet volume;
PAAD	cis	rs3774830	0.714	rs12509727	chr4:5470800	T/G	cg26943120	chr4:5472116	STK32B	0.41	5.21	0.39	5.93e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs990171	0.538	rs4851014	chr2:103116276	C/T	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.26	-0.39	4.78e-7	Lymphocyte counts;
PAAD	cis	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg13446288	chr2:102313644	MAP4K4	-0.41	-4.6	-0.35	8.91e-6	Serum protein levels (sST2);
PAAD	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.62	-5.65	-0.42	7.6e-8	White blood cell count;
PAAD	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg13002189	chr3:66846049	NA	0.6	5.82	0.43	3.35e-8	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14230938	chr11:43918832	LOC729799;ALKBH3	-0.53	-6.35	-0.46	2.4e-9	Monocyte percentage of white cells;
PAAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.73	-9.17	-0.6	3.11e-16	Educational attainment;
PAAD	cis	rs7923609	0.846	rs10761739	chr10:65062008	C/G	cg08743896	chr10:65200160	JMJD1C	0.43	4.32	0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.08	-0.38	1.11e-6	Total body bone mineral density;
PAAD	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.57	-5.28	-0.39	4.48e-7	Blood metabolite levels;
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.05	-0.38	1.23e-6	Reticulocyte count;
PAAD	cis	rs1879734	0.731	rs6691833	chr1:54159079	C/G	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01600621	chr19:42681426	NA	0.67	7.01	0.49	7.17e-11	Myopia (pathological);
PAAD	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg12886812	chr5:131893301	RAD50	0.5	4.43	0.34	1.81e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg16506815	chr2:162101123	NA	-0.57	-6.13	-0.45	7.26e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.56	7.41	0.52	8.07e-12	Hypertriglyceridemia;
PAAD	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.48	4.78	0.36	4.04e-6	Obesity-related traits;
PAAD	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg26939375	chr7:64535504	NA	0.71	8.07	0.55	1.98e-13	Aortic root size;
PAAD	cis	rs7567389	0.719	rs4150402	chr2:128050134	C/T	cg09760422	chr2:128146352	NA	0.38	5.87	0.43	2.7e-8	Self-rated health;
PAAD	cis	rs2790216	0.951	rs1815610	chr10:60037985	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.41	-4.52	-0.34	1.24e-5	Mean platelet volume;
PAAD	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	1.03	6.65	0.47	4.91e-10	Major depressive disorder;
PAAD	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.6	5.44	0.4	2.08e-7	Total body bone mineral density;
PAAD	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.57	5.45	0.4	2.01e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	4.55	0.35	1.1e-5	Vitiligo;
PAAD	cis	rs77741769	0.926	rs4767941	chr12:121359586	G/A	cg02403541	chr12:121454288	C12orf43	0.49	5.18	0.39	6.96e-7	Mean corpuscular volume;
PAAD	cis	rs2688419	0.565	rs1817581	chr3:23078375	T/A	cg00327796	chr3:23032191	NA	-0.5	-4.84	-0.37	3.2e-6	Type 2 diabetes;
PAAD	cis	rs12760731	0.565	rs11583503	chr1:178169663	G/C	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg09667013	chr22:42394590	WBP2NL	0.48	4.59	0.35	9.16e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9314614	0.714	rs2980948	chr8:6713695	A/G	cg27319216	chr8:6693540	XKR5	0.39	5.23	0.39	5.65e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs595018	0.505	rs7117730	chr11:60597281	C/T	cg23904249	chr11:60608951	CCDC86	0.65	5.05	0.38	1.24e-6	Wegener's granulomatosis;
PAAD	cis	rs2797685	0.786	rs72632093	chr1:7897988	G/A	cg04725166	chr1:7887271	PER3	-0.63	-5.3	-0.39	3.99e-7	Crohn's disease;
PAAD	cis	rs77741769	0.571	rs11065311	chr12:121324115	A/T	cg02419362	chr12:121203948	SPPL3	-0.53	-5.95	-0.43	1.76e-8	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06060673	chr22:39268830	CBX6	0.64	6.51	0.47	1.01e-9	Myopia (pathological);
PAAD	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-6.09	-0.44	8.91e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.67	6.38	0.46	2.04e-9	Hip circumference;
PAAD	cis	rs12257961	0.640	rs10906887	chr10:15375654	C/T	cg10616319	chr10:15468812	NA	-0.47	-4.51	-0.34	1.27e-5	Selective IgA deficiency;
PAAD	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg18357526	chr6:26021779	HIST1H4A	0.56	5.0	0.38	1.58e-6	Educational attainment;
PAAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.6	-6.6	-0.47	6.54e-10	Hematocrit;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18827097	chr2:3522506	ADI1	0.6	6.73	0.48	3.34e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-6.75	-0.48	2.97e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg24220031	chr2:73402428	NA	0.36	5.54	0.41	1.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-8.38	-0.56	3.31e-14	Hemoglobin concentration;
PAAD	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg16342193	chr10:102329863	NA	-0.77	-8.41	-0.56	2.7e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.51	-0.8	9.93e-36	Height;
PAAD	cis	rs4655582	0.510	rs4655772	chr1:66130398	A/G	cg04111102	chr1:66153794	NA	0.45	4.76	0.36	4.41e-6	Fibrinogen levels;
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.47	-6.4	-0.46	1.85e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.2	-0.39	6.31e-7	Pulmonary function;
PAAD	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg08562672	chr19:21860753	NA	-0.44	-4.65	-0.35	7.2e-6	Pain;
PAAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.84	9.61	0.61	2.26e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg04865290	chr3:52927548	TMEM110	-0.67	-4.5	-0.34	1.34e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg05874882	chr4:1763078	NA	-0.36	-5.15	-0.39	8.13e-7	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13794334	chr9:110045982	RAD23B	0.67	7.36	0.51	1.06e-11	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.49	-4.55	-0.35	1.11e-5	Response to antidepressants and depression;
PAAD	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg14403583	chr14:105418241	AHNAK2	-0.77	-8.25	-0.56	6.97e-14	Systemic lupus erythematosus;
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg21951975	chr1:209979733	IRF6	0.58	5.7	0.42	6.12e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.81	-0.36	3.54e-6	Large artery stroke;
PAAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg03676636	chr4:99064102	C4orf37	-0.31	-5.26	-0.39	4.79e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7932354	0.537	rs3816614	chr11:46890165	C/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.68	-8.36	-0.56	3.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17678877	chr2:105654366	MRPS9	-0.55	-6.33	-0.46	2.63e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg16794390	chr17:18148240	FLII	0.6	4.94	0.37	2.04e-6	Obesity-related traits;
PAAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12463550	chr7:65579703	CRCP	0.85	5.51	0.41	1.48e-7	Diabetic kidney disease;
PAAD	cis	rs11651753	0.636	rs4793737	chr17:46042257	A/C	cg24458315	chr17:46148407	CBX1	0.42	4.46	0.34	1.6e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.58	6.3	0.46	3.03e-9	Lung cancer;
PAAD	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.46	-5.77	-0.42	4.22e-8	Crohn's disease;
PAAD	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs7737355	0.812	rs4705890	chr5:130855000	A/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs7188861	1.000	rs731774	chr16:11456266	C/T	cg01510278	chr16:11456238	NA	-0.45	-4.51	-0.34	1.28e-5	HDL cholesterol;
PAAD	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.4	-4.56	-0.35	1.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.77	-6.73	-0.48	3.26e-10	Obesity-related traits;
PAAD	trans	rs795484	0.926	rs708865	chr12:118683533	A/C	cg06703803	chr12:110811045	ANAPC7	-0.58	-6.31	-0.46	2.86e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.72	9.7	0.62	1.28e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.56	6.3	0.46	3.02e-9	Aortic root size;
PAAD	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs30380	0.690	rs27432	chr5:96119273	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.54	5.38	0.4	2.77e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs6604026	0.656	rs2811597	chr1:93341153	G/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.51	-6.71	-0.48	3.58e-10	Height;
PAAD	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.59	5.19	0.39	6.71e-7	Life satisfaction;
PAAD	cis	rs1997066	0.831	rs73342211	chr10:106818355	C/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.69	-5.12	-0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs2766692	0.957	rs2757532	chr14:100673213	A/G	cg13185188	chr14:100680334	NA	0.45	4.28	0.33	3.29e-5	Electroencephalographic traits in alcoholism;
PAAD	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg13429435	chr10:81271195	EIF5AL1	0.4	4.4	0.34	2.03e-5	Sarcoidosis;
PAAD	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs899997	1.000	rs1383635	chr15:79029511	T/C	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg20578329	chr17:80767326	TBCD	-0.87	-5.62	-0.41	9.09e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10858909	chr4:99850288	EIF4E	0.54	6.33	0.46	2.65e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg07559730	chr19:53497048	ZNF702P	-0.52	-5.59	-0.41	1.05e-7	Psoriasis;
PAAD	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs288326	0.561	rs7595898	chr2:183819892	C/A	cg09997497	chr2:183902928	NCKAP1	0.96	5.73	0.42	5.28e-8	Blood protein levels;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.57	6.24	0.45	4.2e-9	Menopause (age at onset);
PAAD	cis	rs2120243	0.539	rs2168430	chr3:157120408	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.43	0.34	1.83e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg09658497	chr7:2847517	GNA12	0.65	6.22	0.45	4.65e-9	Loneliness (linear analysis);
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6908034	0.505	rs76391302	chr6:19819116	G/A	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03605463	chr16:89740564	NA	-0.52	-4.95	-0.37	1.96e-6	Vitiligo;
PAAD	cis	rs1329189	1.000	rs7080060	chr10:130007638	G/A	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.52e-6	Orofacial clefts;
PAAD	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.54	6.15	0.45	6.58e-9	Skin aging (microtopography measurement);
PAAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.92	-11.63	-0.69	9.18e-23	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	5.53	0.41	1.34e-7	Eosinophil percentage of white cells;
PAAD	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.56	-6.44	-0.46	1.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.56	6.72	0.48	3.39e-10	Multiple sclerosis;
PAAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14895029	chr7:2775587	GNA12	-0.47	-4.84	-0.37	3.13e-6	Height;
PAAD	cis	rs12912251	0.591	rs3102119	chr15:39003601	C/T	cg01338139	chr15:38987640	C15orf53	-0.51	-4.55	-0.35	1.11e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.74	6.78	0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs877529	0.605	rs139387	chr22:39531085	G/A	cg18708252	chr22:39545030	CBX7	-0.66	-6.89	-0.49	1.35e-10	Multiple myeloma;
PAAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.51	5.81	0.43	3.59e-8	Electroencephalogram traits;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs6594713	0.642	rs13169748	chr5:112848999	C/T	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.74	7.99	0.54	3.17e-13	Longevity;
PAAD	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.71	-0.42	5.89e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4740619	0.592	rs2987019	chr9:15985498	G/A	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.48	-4.3	-0.33	3.06e-5	Testicular germ cell tumor;
PAAD	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.84	9.32	0.6	1.26e-16	Parkinson's disease;
PAAD	cis	rs9900062	0.586	rs11653958	chr17:62686730	G/A	cg02598441	chr17:62777298	LOC146880	-0.53	-4.29	-0.33	3.16e-5	QT interval;
PAAD	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.86	-7.17	-0.5	3.14e-11	Pulmonary function decline;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg26554054	chr8:600488	NA	1.03	7.13	0.5	3.73e-11	IgG glycosylation;
PAAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg07725925	chr16:89976287	TCF25	0.75	4.32	0.33	2.84e-5	Skin colour saturation;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.89	-14.6	-0.76	9.64e-31	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12993916	chr6:15553155	DTNBP1	-0.51	-6.52	-0.47	1e-9	Energy expenditure (24h);
PAAD	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.53	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg26855724	chr1:75198818	TYW3;CRYZ	0.49	4.81	0.36	3.67e-6	Resistin levels;
PAAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.66	5.7	0.42	6.19e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2117029	0.586	rs1874908	chr12:49584030	G/A	cg05368762	chr12:50135785	TMBIM6	0.46	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9395066	0.545	rs2396372	chr6:44966867	T/C	cg25276700	chr6:44698697	NA	0.49	5.61	0.41	9.29e-8	Height;
PAAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.13	-0.45	7.14e-9	Height;
PAAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	1.24	12.51	0.71	3.86e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	cis	rs910039	0.606	rs823435	chr6:17496534	A/C	cg21466042	chr6:17707449	NUP153	-0.52	-4.28	-0.33	3.23e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg12215294	chr3:40350768	EIF1B	0.45	4.37	0.33	2.31e-5	Renal cell carcinoma;
PAAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	trans	rs9969729	0.702	rs13299235	chr9:108633573	A/G	cg22780193	chr13:74825252	NA	0.82	6.37	0.46	2.18e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7707921	0.881	rs1428940	chr5:81447995	A/G	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.57	0.47	7.62e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg07944420	chr16:89185293	ACSF3	-0.47	-4.43	-0.34	1.79e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	trans	rs3733631	0.948	rs28438896	chr4:104625753	C/T	cg11176159	chr1:28213800	NA	-0.48	-6.4	-0.46	1.87e-9	Menarche (age at onset);
PAAD	cis	rs6537837	0.701	rs6680537	chr1:110155022	T/C	cg05049280	chr1:110155535	GNAT2	0.76	7.14	0.5	3.69e-11	Major depressive disorder;
PAAD	cis	rs11159086	0.838	rs10147963	chr14:74942794	G/C	cg10195687	chr14:74926396	NA	-0.49	-5.47	-0.41	1.85e-7	Advanced glycation end-product levels;
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg23985595	chr17:80112537	CCDC57	0.42	5.39	0.4	2.66e-7	Life satisfaction;
PAAD	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.69	-7.02	-0.49	7.06e-11	Menarche (age at onset);
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.53	-5.72	-0.42	5.57e-8	Longevity;Endometriosis;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.89	-0.63	4.19e-18	Total body bone mineral density;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg24043887	chr11:695896	TMEM80;DEAF1	-0.55	-6.36	-0.46	2.26e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02359409	chr6:42947317	PEX6	-0.46	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.64	-5.88	-0.43	2.46e-8	Breast size;
PAAD	cis	rs9646944	0.540	rs12712148	chr2:103025547	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.77	7.98	0.54	3.33e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.72	0.42	5.6e-8	Adiposity;
PAAD	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.57	-5.14	-0.39	8.16e-7	Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8077059	1.000	rs9916043	chr17:55813260	C/T	cg12582317	chr17:55822272	NA	0.52	4.89	0.37	2.54e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.27	0.45	3.63e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg26205652	chr12:48591994	NA	0.96	10.34	0.64	2.65e-19	Longevity (90 years and older);
PAAD	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg17788362	chr6:86352627	SYNCRIP	0.64	6.38	0.46	2.03e-9	Smooth-surface caries;
PAAD	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24580588	chr11:72505101	STARD10	-0.76	-6.38	-0.46	2.04e-9	Neuroticism;
PAAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20424065	chr6:151673357	AKAP12	-0.69	-7.42	-0.52	7.54e-12	Obesity-related traits;
PAAD	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-5.63	-0.42	8.48e-8	Total cholesterol levels;
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.48	6.37	0.46	2.08e-9	Ulcerative colitis;
PAAD	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.36	4.68	0.35	6.27e-6	Calcium levels;
PAAD	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.6	5.88	0.43	2.54e-8	Type 2 diabetes;
PAAD	cis	rs6028335	0.877	rs67917239	chr20:37779167	G/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.37	-0.33	2.29e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.43	4.33	0.33	2.68e-5	Bipolar disorder;
PAAD	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.62	-0.47	5.95e-10	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	8.8	0.58	2.89e-15	Multiple sclerosis;
PAAD	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.56	5.03	0.38	1.36e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06850241	chr22:41845214	NA	0.57	5.06	0.38	1.21e-6	Vitiligo;
PAAD	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs8102137	1.000	rs111640872	chr19:30290357	G/C	cg27475126	chr19:30303651	CCNE1	-0.45	-5.01	-0.38	1.47e-6	Bladder cancer;
PAAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.62	-6.15	-0.45	6.44e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.69	-0.36	6.15e-6	Joint mobility (Beighton score);
PAAD	cis	rs375066	0.935	rs413093	chr19:44426265	A/G	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.95	-0.37	1.99e-6	Triglycerides;
PAAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg24952224	chr10:75571601	NDST2	-0.56	-6.53	-0.47	9.13e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7714584	1.000	rs11167519	chr5:150265407	C/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs11168618	0.846	rs11168586	chr12:48854012	C/T	cg01881778	chr12:48919444	OR8S1	-0.49	-4.91	-0.37	2.3e-6	Adiponectin levels;
PAAD	cis	rs6076065	0.723	rs2424554	chr20:23415867	T/C	cg11657817	chr20:23433608	CST11	0.47	4.6	0.35	8.98e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg05627522	chr15:75251581	NA	-0.43	-4.51	-0.34	1.29e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.01	-0.38	1.49e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg20917491	chr3:195578259	NA	0.45	4.49	0.34	1.39e-5	Pancreatic cancer;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.74	-5.12	-0.38	8.94e-7	Alzheimer's disease;
PAAD	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg11941060	chr3:133502564	NA	-0.53	-5.42	-0.4	2.26e-7	Iron status biomarkers;
PAAD	cis	rs10450586	0.863	rs7105447	chr11:27306238	A/G	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.46	10.24	0.64	4.91e-19	Opioid sensitivity;
PAAD	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	1.01	11.73	0.69	4.83e-23	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.52	-0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14400246	chr14:51171483	NA	-0.64	-6.71	-0.48	3.61e-10	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.87e-5	Height;
PAAD	trans	rs4707930	0.628	rs2754050	chr6:72416458	A/C	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg10351095	chr21:47802916	PCNT	-0.46	-4.39	-0.34	2.1e-5	Testicular germ cell tumor;
PAAD	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.59	6.63	0.47	5.46e-10	Carotid intima media thickness;
PAAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.66	-7.48	-0.52	5.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9652601	0.959	rs12928537	chr16:11191400	G/A	cg04616529	chr16:11181986	CLEC16A	0.44	4.79	0.36	3.99e-6	Systemic lupus erythematosus;
PAAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg10547527	chr2:198650123	BOLL	-0.84	-5.58	-0.41	1.09e-7	Ulcerative colitis;
PAAD	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	4.81	0.36	3.55e-6	Joint mobility (Beighton score);
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16642003	chr16:30456845	SEPHS2	0.58	6.58	0.47	7.29e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs12541635	0.966	rs12550587	chr8:106978289	C/T	cg10147462	chr8:107024639	NA	0.45	4.61	0.35	8.53e-6	Age of smoking initiation;
PAAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.83	8.68	0.58	5.86e-15	Tuberculosis;
PAAD	cis	rs4930776	0.838	rs406430	chr12:5753920	C/T	cg06629086	chr12:6715057	CHD4	-0.52	-4.93	-0.37	2.11e-6	Plasma clusterin levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17836114	chr1:222628702	NA	-0.69	-6.48	-0.47	1.22e-9	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.75	0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.93	7.06	0.5	5.64e-11	Alzheimer's disease;
PAAD	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg09597638	chr17:3907349	NA	-0.53	-5.12	-0.38	9.22e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg26174226	chr8:58114915	NA	-0.65	-5.75	-0.42	4.73e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.74	-0.48	3.16e-10	Aortic root size;
PAAD	cis	rs76793172	0.841	rs111386720	chr19:46302145	G/A	cg13320842	chr19:46175254	GIPR	0.58	4.36	0.33	2.43e-5	Eosinophil counts;
PAAD	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.71	-7.34	-0.51	1.18e-11	Colorectal cancer;
PAAD	cis	rs134594	0.885	rs134636	chr22:29482221	C/T	cg01361351	chr22:29467363	NA	0.4	4.47	0.34	1.53e-5	Birth weight;
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	trans	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg26939375	chr7:64535504	NA	-0.77	-9.11	-0.59	4.37e-16	Aortic root size;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21034903	chr2:172544336	DYNC1I2	0.53	6.35	0.46	2.34e-9	Immature fraction of reticulocytes;
PAAD	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs7714584	1.000	rs73268545	chr5:150335282	C/T	cg22134413	chr5:150180641	NA	0.92	4.9	0.37	2.39e-6	Crohn's disease;
PAAD	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg24739098	chr15:79297159	RASGRF1	0.34	4.3	0.33	3.02e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00119197	chr4:103422974	NFKB1	0.6	6.74	0.48	3.15e-10	Immature fraction of reticulocytes;
PAAD	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.62	-0.41	8.88e-8	Bladder cancer;
PAAD	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.41	-4.56	-0.35	1.07e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs4417704	0.551	rs4315517	chr2:241894906	T/G	cg26818257	chr2:241905806	NA	0.51	5.27	0.39	4.7e-7	Joint mobility (Beighton score);
PAAD	cis	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg13262752	chr1:54355695	YIPF1	0.47	4.75	0.36	4.69e-6	Hand grip strength;
PAAD	cis	rs10214930	0.697	rs12672811	chr7:27684883	T/C	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.64	-7.58	-0.52	3.11e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg05250797	chr16:70222502	NA	0.84	6.5	0.47	1.06e-9	IgE levels;
PAAD	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.46	4.67	0.35	6.5e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	trans	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg14171944	chr9:126323477	DENND1A	0.53	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.05	-7.98	-0.54	3.33e-13	Diabetic kidney disease;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.8	-0.36	3.79e-6	Life satisfaction;
PAAD	cis	rs1478897	0.510	rs11786148	chr8:11423781	C/G	cg21175976	chr8:11421337	BLK	-0.51	-5.64	-0.42	8.02e-8	Systemic lupus erythematosus;
PAAD	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.86	-0.37	2.85e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.9e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	16.74	0.81	2.58e-36	Height;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg16606324	chr3:10149918	C3orf24	0.54	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17376030	chr22:41985996	PMM1	-0.67	-4.57	-0.35	1e-5	Vitiligo;
PAAD	cis	rs925642	0.669	rs11729956	chr4:187672156	A/C	cg20274950	chr4:187647402	NA	0.38	4.36	0.33	2.41e-5	Obesity;
PAAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.88	0.43	2.55e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-5.85	-0.43	2.9e-8	Total cholesterol levels;
PAAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.48	5.01	0.38	1.5e-6	Obesity-related traits;
PAAD	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg08999081	chr20:33150536	PIGU	-0.51	-5.52	-0.41	1.46e-7	Height;
PAAD	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.76	7.99	0.54	3.19e-13	Diastolic blood pressure;
PAAD	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs4073221	0.725	rs35161320	chr3:18279526	C/A	cg07694806	chr3:18168406	NA	-0.66	-4.77	-0.36	4.3e-6	Parkinson's disease;
PAAD	cis	rs853679	0.567	rs9969098	chr6:28398748	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.31	-0.33	2.9e-5	Depression;
PAAD	cis	rs2834188	1.000	rs1018742	chr21:34686381	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	4.41	0.34	1.91e-5	Narcolepsy;
PAAD	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.5	-0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10792830	0.741	rs553141	chr11:85728476	A/G	cg07180834	chr11:85838833	NA	-0.48	-5.38	-0.4	2.78e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs75920871	0.841	rs7112967	chr11:116831912	C/T	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg16205897	chr5:131564050	P4HA2	-0.52	-5.85	-0.43	2.88e-8	Blood metabolite levels;
PAAD	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg08079166	chr15:68083412	MAP2K5	-0.59	-4.39	-0.34	2.1e-5	Obesity;
PAAD	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.47	-0.34	1.51e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09604840	chr16:81991640	PLCG2	0.6	6.3	0.46	3.03e-9	Smoking initiation;
PAAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.37e-10	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-6.74	-0.48	3.14e-10	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-5.04	-0.38	1.28e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06481639	chr22:41940642	POLR3H	-0.58	-4.27	-0.33	3.42e-5	Vitiligo;
PAAD	cis	rs9367125	0.816	rs9357384	chr6:41997926	A/G	cg12151296	chr6:42013349	CCND3	0.65	4.75	0.36	4.59e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg26501369	chr6:133561814	EYA4	-0.9	-6.67	-0.48	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.73	5.11	0.38	9.66e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35955747	0.871	rs5994392	chr22:31783906	T/A	cg02404636	chr22:31891804	SFI1	-0.55	-5.42	-0.4	2.26e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg13263323	chr15:86062960	AKAP13	-0.48	-4.9	-0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.4	0.51	8.68e-12	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17055721	chr4:749157	PCGF3	0.5	6.31	0.46	2.84e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05491587	chr18:77659695	KCNG2	-0.44	-4.3	-0.33	3.04e-5	Schizophrenia;
PAAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs12432203	1.000	rs3507	chr14:51730548	G/C	cg23942311	chr14:51606299	NA	-0.7	-4.82	-0.36	3.52e-6	Cancer;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg01097406	chr16:89675127	NA	-0.35	-4.3	-0.33	2.99e-5	Vitiligo;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.7	-7.9	-0.54	5.24e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	8.37	0.56	3.4e-14	Post bronchodilator FEV1;
PAAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.53e-6	Bipolar disorder;
PAAD	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg16989719	chr2:238392110	NA	-0.35	-4.36	-0.33	2.43e-5	Prostate cancer;
PAAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.23e-6	Iron status biomarkers;
PAAD	cis	rs4731207	0.596	rs2219953	chr7:124671915	A/C	cg14311320	chr7:124405732	GPR37	-0.41	-4.26	-0.33	3.55e-5	Cutaneous malignant melanoma;
PAAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.7	-8.68	-0.58	5.62e-15	Breast cancer;
PAAD	trans	rs11794666	0.929	rs11791899	chr9:31806539	T/C	cg05628366	chr6:35744188	C6orf126	1.12	6.81	0.48	2.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01765077	chr12:122356316	WDR66	0.62	6.54	0.47	8.81e-10	Mean corpuscular volume;
PAAD	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.42	5.28	0.39	4.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg23346134	chr3:49453900	TCTA	-0.46	-4.96	-0.37	1.9e-6	Menarche (age at onset);
PAAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.82	0.36	3.5e-6	Schizophrenia;
PAAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.67	7.27	0.51	1.79e-11	Age at first birth;
PAAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.54	7.28	0.51	1.69e-11	Renal cell carcinoma;
PAAD	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.86	9.56	0.61	2.99e-17	Multiple sclerosis;
PAAD	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.15	-10.62	-0.65	4.62e-20	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg12661370	chr5:149340060	SLC26A2	0.65	5.63	0.42	8.37e-8	HIV-1 control;
PAAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg11204139	chr17:3907470	NA	-0.67	-6.88	-0.49	1.49e-10	Type 2 diabetes;
PAAD	cis	rs10155981	0.510	rs10255241	chr7:22593806	C/T	cg05062323	chr7:22590069	NA	-0.9	-5.42	-0.4	2.34e-7	Bilirubin levels;
PAAD	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26926768	chr12:34528122	NA	0.4	4.85	0.37	3e-6	Morning vs. evening chronotype;
PAAD	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.79	8.37	0.56	3.6e-14	Educational attainment;
PAAD	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.91	-10.2	-0.64	6.22e-19	Obesity-related traits;
PAAD	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg15047889	chr8:124780837	FAM91A1	-0.64	-5.07	-0.38	1.15e-6	Pancreatic cancer;
PAAD	cis	rs3764400	0.508	rs72823519	chr17:46061885	G/T	cg10706073	chr17:46328419	SKAP1	-0.77	-4.72	-0.36	5.31e-6	Body mass index;
PAAD	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.54	-4.72	-0.36	5.34e-6	Life satisfaction;
PAAD	cis	rs62025270	0.632	rs13379832	chr15:86115900	A/T	cg13263323	chr15:86062960	AKAP13	0.5	4.43	0.34	1.82e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs4523957	0.757	rs1002135	chr17:2097583	T/G	cg16513277	chr17:2031491	SMG6	-0.53	-5.57	-0.41	1.15e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg23283495	chr1:209979779	IRF6	0.77	7.05	0.5	5.97e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs6594713	0.679	rs9326890	chr5:112859994	C/T	cg12552261	chr5:112820674	MCC	0.73	5.99	0.44	1.47e-8	Brain cytoarchitecture;
PAAD	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg25233709	chr10:116636983	FAM160B1	0.42	5.31	0.4	3.86e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs16882447	0.607	rs2783	chr5:53489874	C/T	cg06461071	chr5:53490839	ARL15	-0.45	-4.85	-0.37	3.02e-6	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-5.64	-0.42	8.21e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg04359915	chr10:101825029	CPN1	-0.37	-5.68	-0.42	6.53e-8	Bone mineral density;
PAAD	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.98	-0.59	9.92e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.88	-0.58	1.75e-15	Exhaled nitric oxide output;
PAAD	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19904058	chr10:135279010	LOC619207	-0.63	-7.62	-0.53	2.56e-12	Systemic lupus erythematosus;
PAAD	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	1.13	11.7	0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.16	0.45	6.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.48	-6.17	-0.45	5.9e-9	Height;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.74	-5.89	-0.43	2.4e-8	Initial pursuit acceleration;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg17747265	chr1:1875780	NA	-0.74	-11.83	-0.69	2.63e-23	Body mass index;
PAAD	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg05373962	chr22:49881684	NA	-0.54	-5.05	-0.38	1.23e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4454254	0.901	rs10088129	chr8:141060242	A/G	cg06693505	chr8:141057453	TRAPPC9	0.34	4.63	0.35	7.71e-6	Pulse pressure;
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	5.08	0.38	1.1e-6	Joint mobility (Beighton score);
PAAD	cis	rs73621547	0.558	rs10988325	chr9:132101962	G/A	cg18217252	chr9:133027791	NA	-0.8	-4.29	-0.33	3.23e-5	Caudate activity during reward;
PAAD	cis	rs939584	0.877	rs6752470	chr2:629694	T/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10727759	chr12:50017361	PRPF40B	0.58	6.76	0.48	2.81e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs34421088	0.506	rs2572428	chr8:11146672	T/A	cg00622658	chr8:10469796	RP1L1	-0.41	-4.26	-0.33	3.51e-5	Neuroticism;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.27	0.56	6.17e-14	Lung cancer;
PAAD	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg26668713	chr11:65405903	SIPA1	0.63	4.4	0.34	1.99e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.5	-0.34	1.34e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.9	11.51	0.68	1.93e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.8	10.04	0.63	1.62e-18	Height;
PAAD	cis	rs6604026	0.656	rs2255717	chr1:93368500	G/T	cg17283838	chr1:93427260	FAM69A	-0.63	-5.82	-0.43	3.37e-8	Multiple sclerosis;
PAAD	cis	rs16975963	0.843	rs11672440	chr19:38250958	C/T	cg14218481	chr19:38281219	NA	0.47	4.81	0.36	3.55e-6	Longevity;
PAAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Depression;
PAAD	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.47	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.64	-6.08	-0.44	9.18e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs73198271	0.722	rs11785741	chr8:8605512	A/G	cg01851573	chr8:8652454	MFHAS1	0.54	4.32	0.33	2.86e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg24737193	chr18:12778029	NA	-0.68	-5.72	-0.42	5.48e-8	Inflammatory skin disease;
PAAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.58	7.19	0.5	2.8e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg15691649	chr6:25882328	NA	-0.52	-4.67	-0.35	6.48e-6	Blood metabolite levels;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.46	4.84	0.37	3.15e-6	Longevity;Endometriosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17482927	chr17:63133259	RGS9	0.62	6.85	0.49	1.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.67	-6.88	-0.49	1.47e-10	Urate levels in lean individuals;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25883261	chr11:34937992	PDHX;APIP	0.61	6.39	0.46	1.93e-9	Myopia (pathological);
PAAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.73	-0.36	5.13e-6	Bipolar disorder;
PAAD	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg08835956	chr7:39171034	POU6F2	0.26	4.7	0.36	5.87e-6	IgG glycosylation;
PAAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg05207973	chr5:176823642	SLC34A1	0.4	4.66	0.35	6.94e-6	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg18490616	chr2:88469792	THNSL2	-0.44	-4.28	-0.33	3.35e-5	Response to metformin (IC50);
PAAD	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg08284496	chr17:37894027	GRB7	0.26	4.41	0.34	1.93e-5	Asthma;
PAAD	cis	rs57709857	0.957	rs7007097	chr8:38123188	C/T	cg16625770	chr8:38300134	FGFR1	-0.47	-4.37	-0.33	2.33e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.52	-5.55	-0.41	1.24e-7	Bladder cancer;
PAAD	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg20673841	chr7:107026890	COG5	0.5	4.3	0.33	3.02e-5	Coronary artery disease;
PAAD	cis	rs8025118	0.583	rs7166607	chr15:79548995	G/A	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.27	-0.33	3.36e-5	Cognitive function;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg16988970	chr17:42248062	ASB16	0.37	5.12	0.38	9.02e-7	Total body bone mineral density;
PAAD	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg03676636	chr4:99064102	C4orf37	0.25	4.4	0.34	2.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4740619	0.592	rs1927700	chr9:15986529	C/A	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.91	0.43	2.12e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27370558	chr19:13397515	CACNA1A	0.54	6.46	0.46	1.35e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14169450	chr9:139327907	INPP5E	0.57	5.88	0.43	2.54e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.93	9.06	0.59	6.15e-16	Corneal astigmatism;
PAAD	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.74	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs496300	0.691	rs672929	chr21:44793464	A/G	cg18342814	chr21:45755740	C21orf2	-0.46	-4.26	-0.33	3.5e-5	Metabolic syndrome;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg07202610	chr7:1142643	C7orf50	-0.73	-5.23	-0.39	5.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16944613	0.510	rs8035793	chr15:91150084	C/T	cg15547629	chr15:90437138	AP3S2	-0.49	-4.26	-0.33	3.52e-5	Colorectal cancer;
PAAD	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.68	5.77	0.42	4.29e-8	Menarche (age at onset);
PAAD	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.71	-0.8	3.03e-36	Height;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.41e-7	Cognitive function;
PAAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg24829409	chr8:58192753	C8orf71	-0.72	-4.72	-0.36	5.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Weight;
PAAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg21929781	chr1:2537748	MMEL1	-0.51	-5.3	-0.39	4.07e-7	Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.78	0.62	8.02e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1891275	0.551	rs7071844	chr10:93403849	G/C	cg07889827	chr10:93443413	NA	-0.4	-4.31	-0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10186876	0.728	rs4507144	chr2:44164481	T/A	cg09541576	chr2:44873248	C2orf34	-0.44	-4.55	-0.35	1.07e-5	Hand grip strength;
PAAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.51	-5.35	-0.4	3.15e-7	Menopause (age at onset);
PAAD	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.58	-6.75	-0.48	2.9e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14694746	chr21:43239011	PRDM15	-0.67	-6.97	-0.49	9.27e-11	Obesity-related traits;
PAAD	cis	rs757081	0.658	rs214101	chr11:17289354	A/G	cg04705435	chr11:17411270	KCNJ11	-0.59	-6.24	-0.45	4.2e-9	Systolic blood pressure;
PAAD	cis	rs27434	0.583	rs151953	chr5:96157648	C/G	cg16492584	chr5:96139282	ERAP1	-0.46	-4.43	-0.34	1.8e-5	Ankylosing spondylitis;
PAAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg24147428	chr11:65409760	SIPA1	-0.44	-4.59	-0.35	9.07e-6	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg10589385	chr1:150898437	SETDB1	0.38	4.6	0.35	9e-6	Melanoma;
PAAD	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.52	4.48	0.34	1.47e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	9.92	0.63	3.43e-18	Platelet count;
PAAD	cis	rs17023223	0.537	rs1057990	chr1:119575232	T/C	cg17326555	chr1:119535693	NA	-0.41	-4.86	-0.37	2.94e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.53	5.68	0.42	6.77e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.38	4.7	0.36	5.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.6	7.03	0.5	6.51e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9913156	0.670	rs7219606	chr17:4561928	T/C	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26385074	chr7:100816740	C7orf52	0.53	6.44	0.46	1.49e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7132746	0.553	rs9788214	chr12:86175638	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-4.83	-0.36	3.31e-6	Lewy body disease;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.91	11.31	0.68	6.66e-22	Menarche (age at onset);
PAAD	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.71	6.74	0.48	3.03e-10	Gout;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06361278	chr17:25783929	NA	0.56	6.83	0.48	1.93e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs9557207	0.540	rs4605009	chr13:100064765	G/A	cg01259362	chr13:99101761	FARP1	-0.48	-4.36	-0.33	2.38e-5	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
PAAD	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.41e-6	Renal cell carcinoma;
PAAD	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg04721828	chr11:48285200	OR4X1	0.41	5.41	0.4	2.4e-7	Migraine - clinic-based;
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg19337854	chr7:99768885	GPC2	0.5	4.6	0.35	9.01e-6	Lung function (FEV1/FVC);
PAAD	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.64	-4.62	-0.35	8.3e-6	Facial morphology (factor 23);
PAAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg15017067	chr4:17643749	FAM184B	0.43	5.12	0.38	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg13565585	chr5:132299512	AFF4	0.63	4.51	0.34	1.3e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26291519	chr15:76640005	NA	-0.65	-6.65	-0.47	4.88e-10	Obesity-related traits;
PAAD	cis	rs89107	0.651	rs283084	chr6:118603999	G/A	cg18833306	chr6:118973337	C6orf204	0.48	5.51	0.41	1.47e-7	Cardiac structure and function;
PAAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.28	0.39	4.46e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.62	-6.29	-0.45	3.23e-9	Coronary artery disease;
PAAD	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1559088	0.847	rs7255968	chr19:33601902	A/T	cg17764715	chr19:33622953	WDR88	0.69	6.31	0.46	2.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1570884	0.539	rs3794377	chr13:50111135	T/C	cg03651054	chr13:50194643	NA	0.34	4.37	0.33	2.28e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.14	5.59	0.41	1.01e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs508970	0.556	rs657643	chr11:60915967	C/T	cg24692310	chr11:60915630	VPS37C	-0.33	-4.64	-0.35	7.56e-6	Rheumatoid arthritis;
PAAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.48	-5.65	-0.42	7.71e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg15212455	chr7:39170539	POU6F2	0.41	5.54	0.41	1.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.85	0.37	2.98e-6	Motion sickness;
PAAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.7	-0.42	5.99e-8	Tonsillectomy;
PAAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.86	-10.5	-0.65	1.01e-19	Body mass index;
PAAD	cis	rs13253111	0.624	rs28372101	chr8:28099384	G/T	cg26534493	chr8:28060551	NA	0.4	4.4	0.34	2.04e-5	Childhood body mass index;
PAAD	cis	rs7631605	0.905	rs11129752	chr3:37257793	A/G	cg17445812	chr3:36986805	TRANK1	-0.37	-4.92	-0.37	2.26e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg02961798	chr16:67687392	RLTPR	-0.39	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	8.31	0.56	5.1e-14	Cognitive test performance;
PAAD	cis	rs35791980	0.567	rs17805954	chr7:76942455	A/C	cg02756451	chr7:76178720	LOC100133091	-0.53	-4.55	-0.35	1.1e-5	Pursuit maintenance gain;
PAAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00252701	chr1:193091045	CDC73	0.61	6.81	0.48	2.11e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17942371	chr19:796826	PTBP1	0.58	6.31	0.46	2.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg11250194	chr11:61601937	FADS2	-0.52	-4.71	-0.36	5.47e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg23442198	chr4:187126114	CYP4V2	0.63	4.48	0.34	1.43e-5	Blood protein levels;
PAAD	cis	rs818427	0.927	rs153548	chr5:112237724	A/C	cg07820702	chr5:112228657	REEP5	-0.5	-4.27	-0.33	3.38e-5	Total body bone mineral density;
PAAD	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg26904215	chr21:47823096	PCNT	-0.83	-4.53	-0.34	1.21e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg15212455	chr7:39170539	POU6F2	0.49	6.91	0.49	1.22e-10	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg21395723	chr22:39101663	GTPBP1	0.44	4.49	0.34	1.4e-5	Menopause (age at onset);
PAAD	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	5.7	0.42	6e-8	Monocyte count;
PAAD	cis	rs13175840	0.687	rs4958200	chr5:133215213	C/T	cg18514949	chr5:133563216	PPP2CA	0.31	4.3	0.33	2.99e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.71	-8.72	-0.58	4.43e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.5	-0.47	1.11e-9	Neuroticism;
PAAD	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg13786083	chr1:19110734	NA	-0.65	-5.88	-0.43	2.52e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.24	18.89	0.84	9.91e-42	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.78	9.9	0.63	3.87e-18	Breast cancer;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.65	6.89	0.49	1.39e-10	Lung cancer;
PAAD	cis	rs10276303	0.519	rs9648355	chr7:3521676	A/G	cg24872851	chr7:4265468	SDK1	0.44	4.29	0.33	3.18e-5	Dupuytren's disease;
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.57	-6.76	-0.48	2.77e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7551345	1.000	rs4949371	chr1:31735880	A/G	cg17086398	chr1:31896392	SERINC2	-0.48	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.54	-4.75	-0.36	4.69e-6	Glycated hemoglobin levels;
PAAD	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg00806126	chr19:22604979	ZNF98	0.39	4.94	0.37	2.05e-6	Pain;
PAAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.8	9.15	0.6	3.52e-16	Aortic root size;
PAAD	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.66	6.62	0.47	5.82e-10	Height;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg20007245	chr22:24372913	LOC391322	-0.7	-7.0	-0.49	7.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.73	0.42	5.15e-8	Alzheimer's disease;
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	trans	rs901683	1.000	rs71496621	chr10:46076348	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs5753037	0.745	rs9306465	chr22:30221826	T/A	cg01021169	chr22:30184971	ASCC2	-0.45	-4.49	-0.34	1.41e-5	Type 1 diabetes;
PAAD	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	11.04	0.67	3.57e-21	Electrocardiographic conduction measures;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.55	-0.35	1.08e-5	Longevity;Endometriosis;
PAAD	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs2268667	0.597	rs1403955	chr1:85940105	G/T	cg11648968	chr1:85931116	DDAH1	-0.47	-4.9	-0.37	2.47e-6	Asymmetrical dimethylarginine levels;
PAAD	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg13468214	chr4:1046988	NA	-0.54	-5.16	-0.39	7.51e-7	Recombination rate (females);
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg07703079	chr11:430292	ANO9	0.91	5.74	0.42	5.08e-8	Body mass index;
PAAD	cis	rs629922	0.642	rs531831	chr11:114071814	A/G	cg25009965	chr11:114031120	ZBTB16	-0.49	-4.5	-0.34	1.36e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg06287003	chr12:125626642	AACS	-0.51	-4.91	-0.37	2.35e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg13397359	chr6:42928475	GNMT	0.61	4.55	0.35	1.07e-5	Blood protein levels;
PAAD	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.71	-6.09	-0.44	8.71e-9	Type 2 diabetes;
PAAD	cis	rs6132905	0.590	rs78781119	chr20:2612417	T/C	cg24848351	chr20:2622020	TMC2	-0.64	-4.46	-0.34	1.61e-5	Mumps;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.49	-0.34	1.43e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06770877	chr13:31897247	B3GALTL	-0.65	-6.57	-0.47	7.68e-10	Obesity-related traits;
PAAD	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.56	5.53	0.41	1.36e-7	Breast cancer;
PAAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs10899021	0.790	rs10899019	chr11:74335162	A/G	cg25880958	chr11:74394337	NA	-0.73	-4.65	-0.35	7.31e-6	Response to metformin (IC50);
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg04234412	chr22:24373322	LOC391322	-0.58	-4.7	-0.36	5.75e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.87	11.27	0.67	8.4e-22	Eosinophil percentage of white cells;
PAAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg13175981	chr1:150552382	MCL1	-0.44	-4.31	-0.33	2.93e-5	Tonsillectomy;
PAAD	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg06138931	chr13:21896616	NA	-0.67	-4.56	-0.35	1.04e-5	White matter hyperintensity burden;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.86	-8.1	-0.55	1.65e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.15	-12.66	-0.72	1.58e-25	Post bronchodilator FEV1;
PAAD	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-5.48	-0.41	1.7e-7	Ulcerative colitis;
PAAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.83	8.72	0.58	4.4e-15	Calcium levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10089457	chr17:73499284	CASKIN2	0.63	6.33	0.46	2.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7301016	0.947	rs10877864	chr12:62893199	T/C	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.54	0.35	1.15e-5	Iron status biomarkers;
PAAD	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	5.98	0.44	1.55e-8	Lung cancer in ever smokers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07108002	chr16:71392377	CALB2	-0.64	-7.03	-0.5	6.65e-11	Smoking initiation;
PAAD	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs4740619	0.967	rs10756689	chr9:15660904	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.49	-0.34	1.41e-5	Body mass index;
PAAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-6.33	-0.46	2.6e-9	IgG glycosylation;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.69	7.64	0.53	2.29e-12	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-7.8	-0.53	9.21e-13	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg04772947	chr11:57363540	SERPING1	-0.4	-4.25	-0.33	3.75e-5	Blood protein levels;
PAAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-1.09	-15.71	-0.79	1.18e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24549020	chr5:56110836	MAP3K1	-0.49	-4.29	-0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs11671653	1.000	rs111957218	chr19:10839089	T/C	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.8e-13	Monocyte percentage of white cells;
PAAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.66	6.47	0.46	1.3e-9	Cystic fibrosis severity;
PAAD	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.73	-5.27	-0.39	4.7e-7	Obesity;Body mass index;
PAAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg01851573	chr8:8652454	MFHAS1	0.5	4.86	0.37	2.84e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg00666640	chr1:248458726	OR2T12	0.44	4.49	0.34	1.39e-5	Common traits (Other);
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.73	5.22	0.39	5.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	4.58	0.35	9.8200000000000008e-06	Bipolar disorder and schizophrenia;
PAAD	cis	rs10901513	0.932	rs11818112	chr10:127669384	G/T	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs4588572	0.581	rs4235706	chr5:77644512	G/A	cg11547950	chr5:77652471	NA	0.92	8.65	0.57	6.66e-15	Triglycerides;
PAAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.86	-5.67	-0.42	6.94e-8	Blood protein levels;
PAAD	cis	rs1008126	0.600	rs6944123	chr7:103128824	G/T	cg04218035	chr7:103086829	SLC26A5	0.32	4.42	0.34	1.9e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg05785598	chr3:49045655	WDR6	0.43	5.09	0.38	1.04e-6	Parkinson's disease;
PAAD	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05694870	chr2:157190958	NA	0.59	6.58	0.47	7.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.17	19.89	0.85	3.67e-44	Myeloid white cell count;
PAAD	cis	rs2635047	0.615	rs1512238	chr18:44748467	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.51	0.34	1.31e-5	Educational attainment;
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg08835956	chr7:39171034	POU6F2	0.32	5.77	0.42	4.34e-8	IgG glycosylation;
PAAD	cis	rs10426930	0.816	rs2009654	chr19:5061345	A/T	cg08036796	chr19:5034282	KDM4B	-0.48	-4.69	-0.36	5.92e-6	Monocyte percentage of white cells;
PAAD	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg05625103	chr10:2543513	NA	-0.62	-6.59	-0.47	6.91e-10	Age-related hearing impairment;
PAAD	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg21929781	chr1:2537748	MMEL1	-0.44	-4.69	-0.36	6.05e-6	Ulcerative colitis;
PAAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.81	7.88	0.54	5.99e-13	Vitamin D levels;
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22633769	chr20:60982531	CABLES2	0.54	4.86	0.37	2.85e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	6.18	0.45	5.51e-9	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9395066	0.545	rs10484627	chr6:44884267	A/T	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.75	-6.89	-0.49	1.37e-10	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.69	-7.98	-0.54	3.35e-13	Parkinson's disease;
PAAD	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	4.36	0.33	2.43e-5	Post bronchodilator FEV1;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02771843	chr3:69062953	C3orf64	-0.58	-6.44	-0.46	1.48e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg04160749	chr8:58172571	NA	-0.64	-4.33	-0.33	2.65e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10688328	chr15:31684499	NA	0.62	6.87	0.49	1.52e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.37	-0.33	2.26e-5	Menopause (age at onset);
PAAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-4.76	-0.36	4.39e-6	Total body bone mineral density;
PAAD	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.61	-0.35	8.49e-6	Menarche (age at onset);
PAAD	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.52	-4.65	-0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.57	6.04	0.44	1.14e-8	Menopause (age at onset);
PAAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.43e-12	Calcium levels;
PAAD	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.65	-5.55	-0.41	1.26e-7	Menarche (age at onset);
PAAD	cis	rs12304921	0.549	rs11169691	chr12:51454952	G/C	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.62	-0.35	8.22e-6	Type 2 diabetes;
PAAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs258892	1.000	rs26576	chr5:72298256	A/C	cg21869765	chr5:72125136	TNPO1	-0.65	-4.56	-0.35	1.03e-5	Small cell lung carcinoma;
PAAD	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg20893579	chr22:38215064	NA	-0.48	-4.75	-0.36	4.58e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.25	0.39	5.13e-7	Bipolar disorder;
PAAD	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs911555	0.713	rs2765051	chr14:103972379	T/C	cg12935359	chr14:103987150	CKB	0.62	6.3	0.46	3.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.63	-6.39	-0.46	1.96e-9	Iron status biomarkers;
PAAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.58	6.0	0.44	1.37e-8	Personality dimensions;
PAAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	1.23	5.37	0.4	2.85e-7	Breast cancer;
PAAD	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	1.11	8.88	0.58	1.79e-15	Corneal structure;
PAAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.8	-0.43	3.78e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg07220939	chr11:64358617	SLC22A12	-0.41	-4.39	-0.34	2.13e-5	Urate levels in obese individuals;
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg02462569	chr6:150064036	NUP43	-0.45	-5.08	-0.38	1.09e-6	Lung cancer;
PAAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.74	7.52	0.52	4.36e-12	Prostate cancer;
PAAD	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg18939081	chr1:31884902	SERINC2	0.47	5.24	0.39	5.36e-7	Alcohol dependence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25791744	chr6:139695837	CITED2	-0.75	-6.81	-0.48	2.13e-10	Neuroticism;
PAAD	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.25e-20	Heart rate;
PAAD	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.62	7.29	0.51	1.56e-11	HDL cholesterol levels;
PAAD	cis	rs2051773	0.567	rs58047221	chr11:17056634	G/T	cg15084286	chr11:17036142	PLEKHA7	0.53	4.51	0.34	1.29e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.2	12.21	0.7	2.56e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg08501292	chr6:25962987	TRIM38	0.81	4.28	0.33	3.24e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.88	8.32	0.56	4.69e-14	Methadone dose in opioid dependence;
PAAD	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg05425664	chr17:57184151	TRIM37	0.57	4.86	0.37	2.9e-6	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.44	5.58	0.41	1.08e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.75	0.42	4.78e-8	Colorectal cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20890180	chr2:106560771	NA	-0.67	-6.36	-0.46	2.26e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13095604	chr12:12966124	DDX47	0.72	8.46	0.57	2.05e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.44	4.59	0.35	9.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.81	-0.36	3.55e-6	Blood metabolite levels;
PAAD	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg08853572	chr16:1843915	IGFALS	-0.26	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.54	5.52	0.41	1.43e-7	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.45	0.4	1.97e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.96	11.66	0.69	7.52e-23	Longevity;
PAAD	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.49	0.41	1.64e-7	Alcohol dependence;
PAAD	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.64	4.77	0.36	4.32e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Cannabis dependence symptom count;
PAAD	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.64	6.06	0.44	1.04e-8	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs2147959	0.941	rs12131962	chr1:228631641	G/A	cg02753203	chr1:228287806	NA	-0.53	-4.39	-0.34	2.15e-5	Adult asthma;
PAAD	cis	rs1075232	1.000	rs56396205	chr15:31678385	G/A	cg06530883	chr15:30699977	NA	1.04	4.63	0.35	7.74e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.03	0.55	2.44e-13	Colorectal cancer;
PAAD	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.88	-7.28	-0.51	1.67e-11	Triglycerides;
PAAD	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	10.51	0.65	9.34e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg14433983	chr11:636460	DRD4	-0.46	-4.69	-0.36	5.94e-6	Systemic lupus erythematosus;
PAAD	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg00035074	chr7:2701567	TTYH3	-0.65	-4.44	-0.34	1.74e-5	Bipolar disorder;
PAAD	cis	rs2342371	0.756	rs4916492	chr3:196106306	G/A	cg08209042	chr3:196295218	WDR53;FBXO45	-0.58	-4.64	-0.35	7.38e-6	Fat distribution (HIV);
PAAD	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg21452805	chr1:244014465	NA	0.47	4.4	0.34	2.02e-5	RR interval (heart rate);
PAAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6987853	0.686	rs7818789	chr8:42354257	A/G	cg09913449	chr8:42400586	C8orf40	0.46	5.0	0.38	1.57e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg08200582	chr11:442649	ANO9	0.52	4.49	0.34	1.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.59	6.69	0.48	4.08e-10	Cardiovascular disease risk factors;
PAAD	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg13332499	chr17:408570	NA	-0.54	-5.89	-0.43	2.43e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	4.7	0.36	5.66e-6	Obesity-related traits;
PAAD	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	1.04	11.32	0.68	6.26e-22	Ulcerative colitis;
PAAD	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-4.98	-0.37	1.71e-6	Interstitial lung disease;
PAAD	cis	rs921968	0.541	rs72965147	chr2:219341827	A/G	cg10223061	chr2:219282414	VIL1	0.39	4.52	0.34	1.22e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg22027985	chr11:4115532	RRM1	-0.45	-4.34	-0.33	2.54e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg11995313	chr8:8860691	ERI1	0.5	5.13	0.38	8.91e-7	Joint mobility (Beighton score);
PAAD	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08677398	chr8:58056175	NA	0.68	4.67	0.35	6.56e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.84e-18	Cognitive function;
PAAD	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7260598	0.539	rs114301360	chr19:24065052	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg04522676	chr10:134968826	NA	0.45	4.29	0.33	3.18e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3120667	0.789	rs11204993	chr1:152356333	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Eating disorders;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.6	6.64	0.47	5.15e-10	Testicular germ cell tumor;
PAAD	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.57	7.56	0.52	3.6e-12	Hypertriglyceridemia;
PAAD	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.41	0.56	2.81e-14	Dupuytren's disease;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.53	-5.35	-0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.54	5.07	0.38	1.14e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.31	-0.51	1.43e-11	Heart rate;
PAAD	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.56	4.58	0.35	9.43e-6	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.55	6.7	0.48	3.82e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16792613	chr17:43324609	LOC100133991;FMNL1	0.41	6.36	0.46	2.23e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.58	-7.64	-0.53	2.21e-12	Longevity;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03988675	chr1:14075428	PRDM2	-0.56	-6.55	-0.47	8.45e-10	Body fat percentage;
PAAD	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7168592	1.000	rs34748909	chr15:101731509	A/C	cg24254196	chr15:101719523	CHSY1	-0.65	-4.64	-0.35	7.4e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.86	-7.03	-0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.89	10.24	0.64	4.9e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.71	-5.28	-0.39	4.34e-7	Vitiligo;
PAAD	cis	rs8032158	0.702	rs2414444	chr15:56128117	C/T	cg02198044	chr15:56286336	NEDD4	0.43	4.48	0.34	1.48e-5	Keloid;
PAAD	cis	rs3106136	0.586	rs28474924	chr4:95086345	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.07	-0.38	1.14e-6	Capecitabine sensitivity;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg05342682	chr7:94953680	PON1	-0.53	-4.6	-0.35	8.78e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs783540	0.846	rs783534	chr15:83250243	C/T	cg00614314	chr15:82944287	LOC80154	0.44	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.69	-6.69	-0.48	3.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.51	-0.34	1.31e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.66	6.58	0.47	7.11e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs863345	0.967	rs10908664	chr1:158492629	G/A	cg12129480	chr1:158549410	OR10X1	-0.45	-5.16	-0.39	7.75e-7	Pneumococcal bacteremia;
PAAD	cis	rs12042938	0.505	rs6656080	chr1:231755265	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-4.7	-0.36	5.81e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.11	5.34	0.4	3.29e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.44	0.34	1.73e-5	Major depressive disorder;
PAAD	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg21905437	chr5:178450457	ZNF879	0.68	5.95	0.43	1.81e-8	Pubertal anthropometrics;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.87	7.39	0.51	9.2e-12	Alzheimer's disease;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg19223190	chr17:80058835	NA	-0.49	-5.18	-0.39	7.1e-7	Life satisfaction;
PAAD	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.66	0.48	4.67e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4742903	0.935	rs10120101	chr9:107000909	C/T	cg14250997	chr9:106856677	SMC2	0.44	4.76	0.36	4.39e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.48	4.79	0.36	3.88e-6	Longevity;Endometriosis;
PAAD	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	4.75	0.36	4.58e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-7.24	-0.51	2.13e-11	Total body bone mineral density;
PAAD	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.62	-0.41	8.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4363385	0.525	rs11205138	chr1:152890568	G/A	cg02711163	chr1:153330200	S100A9	-0.34	-4.38	-0.33	2.19e-5	Inflammatory skin disease;
PAAD	cis	rs621942	0.950	rs682058	chr11:85747354	G/C	cg07180834	chr11:85838833	NA	-0.46	-4.28	-0.33	3.25e-5	Tourette syndrome;
PAAD	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg22771759	chr13:24902376	NA	0.43	4.29	0.33	3.21e-5	Obesity-related traits;
PAAD	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.51	4.76	0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.65	7.27	0.51	1.77e-11	Menarche (age at onset);
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.53	5.35	0.4	3.2e-7	Menarche (age at onset);
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.74	-4.73	-0.36	5e-6	Body mass index;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.52	4.93	0.37	2.1e-6	Acylcarnitine levels;
PAAD	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg07117364	chr1:16154769	NA	-0.45	-4.28	-0.33	3.24e-5	Dilated cardiomyopathy;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.7	-5.09	-0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.68	0.42	6.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg00576331	chr11:65640516	EFEMP2	0.59	5.23	0.39	5.58e-7	DNA methylation (variation);
PAAD	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.61	-6.09	-0.44	8.76e-9	Red cell distribution width;
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25756590	chr13:50018352	CAB39L;SETDB2	0.57	6.38	0.46	1.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg14926445	chr8:58193284	C8orf71	-0.65	-4.74	-0.36	4.78e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7116495	0.609	rs567851	chr11:71592419	G/C	cg10381502	chr11:71823885	C11orf51	1.06	5.31	0.4	3.78e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4378355	1	rs4378355	chr11:34783417	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.45	4.39	0.34	2.12e-5	Prostate-specific antigen levels;
PAAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.09	-0.38	1.03e-6	Personality dimensions;
PAAD	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.83	-8.07	-0.55	1.92e-13	Cognitive function;
PAAD	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.45e-6	Plateletcrit;
PAAD	cis	rs3764400	0.507	rs16954324	chr17:46324584	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.7	6.91	0.49	1.23e-10	Uric acid levels;
PAAD	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg10518543	chr12:38710700	ALG10B	-0.47	-4.27	-0.33	3.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg15443732	chr18:74961078	GALR1	0.6	5.54	0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs3112530	1.000	rs2615176	chr5:152701153	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.58	-6.75	-0.48	2.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-1.0	-8.61	-0.57	8.86e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.89	-7.68	-0.53	1.8e-12	Cognitive test performance;
PAAD	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.48	5.0	0.38	1.55e-6	Longevity;Endometriosis;
PAAD	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.6	-6.92	-0.49	1.17e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs117623576	0.680	rs11008756	chr10:32363137	A/G	cg03047570	chr10:32398778	NA	-0.64	-4.48	-0.34	1.45e-5	Anti-saccade response;
PAAD	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg21269045	chr12:125625041	AACS	-0.48	-4.58	-0.35	9.6e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4690686	0.509	rs61482060	chr4:177264465	A/G	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.72	0.48	3.51e-10	Body mass index;
PAAD	cis	rs12136530	0.562	rs12125959	chr1:19735262	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	cis	rs11955175	1.000	rs11955175	chr5:40626753	C/T	cg17351974	chr5:40835760	RPL37	-0.8	-4.77	-0.36	4.23e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.96	8.77	0.58	3.36e-15	Psoriasis;
PAAD	cis	rs939584	1.000	rs13396935	chr2:653195	G/A	cg03610516	chr2:642275	NA	-0.64	-5.76	-0.42	4.48e-8	Body mass index;
PAAD	cis	rs7264396	0.887	rs6060435	chr20:34069370	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	5.79	0.42	4e-8	Total cholesterol levels;
PAAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Aortic root size;
PAAD	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.49	5.52	0.41	1.41e-7	Coronary artery disease;
PAAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg19052272	chr2:3704530	ALLC	-0.58	-6.58	-0.47	7.32e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.67	-7.3	-0.51	1.48e-11	Menarche (age at onset);
PAAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.75	7.52	0.52	4.32e-12	Coronary artery disease;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg26554054	chr8:600488	NA	-1.0	-6.22	-0.45	4.58e-9	IgG glycosylation;
PAAD	cis	rs6499755	0.768	rs31084	chr16:55362442	T/C	cg02859129	chr16:55357253	IRX6	0.36	4.9	0.37	2.47e-6	Hypospadias;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.58	5.52	0.41	1.45e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14409850	chr12:27091377	C12orf11;FGFR1OP2	-0.63	-6.29	-0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs17135859	0.762	rs11957573	chr5:113032714	A/C	cg12552261	chr5:112820674	MCC	0.63	4.43	0.34	1.79e-5	F-cell distribution;
PAAD	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-6.25	-0.45	3.93e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.605	rs3799984	chr6:44893640	C/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.95	-10.41	-0.65	1.74e-19	Headache;
PAAD	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	4.35	0.33	2.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.78	-9.23	-0.6	2.21e-16	Huntington's disease progression;
PAAD	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg09469691	chr10:81107165	PPIF	0.67	7.46	0.52	6.08e-12	Height;
PAAD	trans	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.34	0.46	2.46e-9	Calcium levels;
PAAD	trans	rs61931739	0.620	rs61927756	chr12:33709931	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-7.42	-0.52	7.77e-12	Morning vs. evening chronotype;
PAAD	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs818427	0.737	rs386830	chr5:112182379	G/A	cg06941702	chr5:112196734	SRP19	-0.48	-4.35	-0.33	2.46e-5	Total body bone mineral density;
PAAD	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.23	0.56	7.73e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.73	7.11	0.5	4.13e-11	Asthma;
PAAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.3	0.33	3.05e-5	Mean corpuscular volume;
PAAD	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg07636037	chr3:49044803	WDR6	0.56	4.39	0.34	2.1e-5	Menarche (age at onset);
PAAD	cis	rs9547692	1.000	rs604279	chr13:37471254	G/C	cg01493522	chr13:37497338	NA	-0.55	-5.65	-0.42	7.76e-8	Coronary artery disease;
PAAD	cis	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg25809561	chr17:30822961	MYO1D	0.57	5.66	0.42	7.31e-8	Schizophrenia;
PAAD	cis	rs58521262	0.556	rs289331	chr19:23154436	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs3733346	0.589	rs2290404	chr4:945225	A/G	cg23939001	chr4:940644	TMEM175	0.71	8.53	0.57	1.37e-14	Sjögren's syndrome;
PAAD	cis	rs4921915	0.519	rs35583283	chr8:18254509	G/C	cg18736775	chr8:18248649	NAT2	-0.63	-4.87	-0.37	2.75e-6	Iron status biomarkers (transferrin levels);
PAAD	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.56	-0.47	8.05e-10	Colorectal cancer;
PAAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	11.38	0.68	4.4e-22	Menopause (age at onset);
PAAD	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.54	5.09	0.38	1.03e-6	Mortality in heart failure;
PAAD	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.48	0.41	1.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.9	7.03	0.5	6.52e-11	Axial length;
PAAD	cis	rs11997175	0.646	rs7386741	chr8:33769709	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	5.72	0.42	5.56e-8	Body mass index;
PAAD	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-15.43	-0.78	6.27e-33	Ulcerative colitis;
PAAD	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg03115019	chr17:80708279	FN3K	0.52	4.56	0.35	1.05e-5	Glycated hemoglobin levels;
PAAD	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.94	6.02	0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg26893134	chr6:116381904	FRK	0.32	5.18	0.39	6.86e-7	Total cholesterol levels;
PAAD	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10875746	0.551	rs12322347	chr12:48707698	T/G	cg26205652	chr12:48591994	NA	0.79	7.23	0.51	2.19e-11	Longevity (90 years and older);
PAAD	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.63	-6.07	-0.44	9.76e-9	Itch intensity from mosquito bite;
PAAD	cis	rs1975974	1.000	rs1985717	chr17:21731807	T/A	cg18423549	chr17:21743878	NA	-0.51	-4.93	-0.37	2.13e-6	Psoriasis;
PAAD	cis	rs73416724	1.000	rs111882537	chr6:43366075	C/A	cg26312998	chr6:43337775	ZNF318	0.69	5.72	0.42	5.39e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	5.45	0.4	1.96e-7	Lung cancer in ever smokers;
PAAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	4.54	0.35	1.12e-5	Breast cancer;
PAAD	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg09491104	chr22:46646882	C22orf40	-0.94	-6.03	-0.44	1.2e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.44	-5.99	-0.44	1.49e-8	Congenital heart disease (maternal effect);
PAAD	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-7.24	-0.51	2.06e-11	Morning vs. evening chronotype;
PAAD	cis	rs2115386	0.932	rs4804092	chr19:7196247	C/G	cg00428638	chr19:7224713	INSR	0.47	4.89	0.37	2.49e-6	Diabetic retinopathy;
PAAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg14440974	chr22:39074834	NA	-0.57	-6.58	-0.47	7.02e-10	Menopause (age at onset);
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05222119	chr17:80211999	CSNK1D	0.59	7.24	0.51	2.09e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.57	4.87	0.37	2.79e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg23460851	chr4:1604456	NA	-0.4	-4.26	-0.33	3.59e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-6.14	-0.45	6.9e-9	Pancreatic cancer;
PAAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.48	-4.6	-0.35	8.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10929159	0.928	rs13025044	chr2:236916549	G/A	cg14226755	chr2:236923322	AGAP1	0.29	4.72	0.36	5.26e-6	Parkinson's disease;
PAAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08480854	chr16:1498490	CLCN7	-0.54	-4.97	-0.37	1.75e-6	Bone mineral density;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg16031515	chr1:205743344	RAB7L1	-0.42	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs89107	0.576	rs72952771	chr6:118883817	C/T	cg21191810	chr6:118973309	C6orf204	0.39	4.56	0.35	1.06e-5	Cardiac structure and function;
PAAD	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg19438565	chr8:143695827	ARC	-0.55	-5.37	-0.4	2.84e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs733175	0.794	rs7678211	chr4:10057583	T/G	cg00071950	chr4:10020882	SLC2A9	0.49	4.32	0.33	2.83e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs1419980	0.730	rs7980155	chr12:7739292	A/G	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg27449745	chr7:23145252	KLHL7	-0.57	-4.97	-0.37	1.77e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.46	-0.34	1.58e-5	Joint mobility (Beighton score);
PAAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.31e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg00814883	chr7:100076585	TSC22D4	-0.64	-5.19	-0.39	6.77e-7	Platelet count;
PAAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg15192750	chr16:69999425	NA	0.71	5.34	0.4	3.34e-7	IgE levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00669777	chr8:95565739	KIAA1429	0.59	6.57	0.47	7.59e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.53	5.78	0.42	4.01e-8	Testicular germ cell tumor;
PAAD	cis	rs9918079	0.560	rs7685083	chr4:15610771	G/A	cg16509355	chr4:15471240	CC2D2A	0.34	4.32	0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.39	4.45	0.34	1.66e-5	High light scatter reticulocyte count;
PAAD	cis	rs6694270	0.529	rs11261065	chr1:19106254	A/C	cg13786083	chr1:19110734	NA	-0.71	-6.23	-0.45	4.43e-9	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.75	-0.48	2.87e-10	Breast cancer;
PAAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-1.09	-9.63	-0.62	1.98e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg08885800	chr1:201084119	NA	0.67	7.4	0.51	8.68e-12	Permanent tooth development;
PAAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.78	6.79	0.48	2.32e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.49e-9	Height;
PAAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.33	-0.4	3.53e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7624766	0.555	rs9866566	chr3:160543742	G/C	cg22637730	chr3:160473554	PPM1L	0.5	4.28	0.33	3.28e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg17346650	chr17:80929145	B3GNTL1	0.5	6.58	0.47	7.22e-10	Glycated hemoglobin levels;
PAAD	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg08589418	chr20:61993913	CHRNA4	-0.5	-4.32	-0.33	2.86e-5	Atopic dermatitis;
PAAD	cis	rs6804624	0.676	rs2670322	chr3:99167401	T/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	trans	rs901683	1.000	rs9422440	chr10:46045125	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.57	-0.35	1.01e-5	Renal cell carcinoma;
PAAD	cis	rs7752195	0.558	rs77914161	chr6:25233485	T/C	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3736485	0.873	rs12442725	chr15:51874412	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-7.05	-0.5	5.94e-11	Morning vs. evening chronotype;
PAAD	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs4356203	0.870	rs214919	chr11:17238704	C/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.65	-0.35	7.3e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.0	-0.38	1.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2594989	0.887	rs7632902	chr3:11476884	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.57	-0.35	9.85e-6	Circulating chemerin levels;
PAAD	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.82	-9.99	-0.63	2.17e-18	Brugada syndrome;
PAAD	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg10818794	chr15:86012489	AKAP13	-0.58	-4.9	-0.37	2.42e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.72	-11.63	-0.69	9.18e-23	Urate levels in overweight individuals;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12217517	chr12:56522352	ESYT1	-0.66	-6.39	-0.46	1.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.71	-8.73	-0.58	4.2e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.67	6.11	0.44	7.87e-9	Platelet count;
PAAD	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.79	-0.43	3.91e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.4	5.01	0.38	1.51e-6	Pulmonary function;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-8.05	-0.55	2.18e-13	Systemic lupus erythematosus;
PAAD	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg18898632	chr2:242989856	NA	-0.65	-4.83	-0.36	3.28e-6	Obesity-related traits;
PAAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.61	-7.81	-0.54	8.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.21	0.39	6.05e-7	Multiple sclerosis;
PAAD	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.89	-8.5	-0.57	1.69e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.94	-10.94	-0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs909002	0.889	rs1061392	chr1:32118160	C/A	cg13919466	chr1:32135498	COL16A1	-0.4	-4.38	-0.34	2.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.89	-7.95	-0.54	3.9e-13	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.58	-5.97	-0.44	1.63e-8	Aortic root size;
PAAD	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.41	0.65	1.74e-19	Morning vs. evening chronotype;
PAAD	cis	rs6508941	0.550	rs10413556	chr19:41023601	A/G	cg26971411	chr19:41016501	SPTBN4	-0.44	-4.44	-0.34	1.69e-5	Antibody level in response to infection;
PAAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01866215	chr16:3150293	NA	-0.67	-7.23	-0.51	2.22e-11	Smoking initiation;
PAAD	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.42	0.65	1.6e-19	Electrocardiographic conduction measures;
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg23283495	chr1:209979779	IRF6	0.66	6.4	0.46	1.78e-9	Coronary artery disease;
PAAD	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.24	0.6	2.02e-16	Bipolar disorder;
PAAD	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.58	4.89	0.37	2.59e-6	Diastolic blood pressure;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.44	-0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26549601	chr10:134560360	INPP5A	-0.48	-4.6	-0.35	8.79e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.64	6.44	0.46	1.5e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9659323	0.622	rs11582744	chr1:119457404	G/A	cg17326555	chr1:119535693	NA	-0.36	-4.47	-0.34	1.54e-5	Body mass index;
PAAD	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg10556349	chr10:835070	NA	0.57	4.95	0.37	1.98e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24577389	chr7:2082868	MAD1L1	-0.64	-6.3	-0.46	3.12e-9	Obesity-related traits;
PAAD	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.67	-0.35	6.58e-6	Mean corpuscular volume;
PAAD	cis	rs17407555	0.560	rs73229842	chr4:10044524	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-4.62	-0.35	8.11e-6	Schizophrenia (age at onset);
PAAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg22143856	chr6:28129313	ZNF389	0.68	5.47	0.41	1.81e-7	Depression;
PAAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg20243544	chr17:37824526	PNMT	-0.5	-4.36	-0.33	2.41e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.53	-5.83	-0.43	3.14e-8	Testicular germ cell tumor;
PAAD	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.71	7.3	0.51	1.53e-11	Neuroticism;
PAAD	cis	rs4851870	0.581	rs3754806	chr2:106487382	A/G	cg21551182	chr2:106399873	NCK2	0.43	4.25	0.33	3.71e-5	Addiction;
PAAD	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg08601574	chr20:25228251	PYGB	0.44	4.75	0.36	4.61e-6	Allergic rhinitis;
PAAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg09796270	chr17:17721594	SREBF1	0.39	4.3	0.33	3.04e-5	Total body bone mineral density;
PAAD	cis	rs2286503	0.839	rs2270103	chr7:22862722	C/T	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.38	0.56	3.24e-14	Bipolar disorder;
PAAD	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs2252790	0.859	rs1204825	chr6:116563925	G/C	cg26893134	chr6:116381904	FRK	-0.29	-4.53	-0.35	1.17e-5	Fast beta electroencephalogram;
PAAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs7594192	0.744	rs62179794	chr2:199377994	C/T	cg03163783	chr2:200326591	SATB2	-0.32	-4.29	-0.33	3.22e-5	Educational attainment;
PAAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.64	-7.38	-0.51	9.4e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.88	-10.02	-0.63	1.81e-18	Morning vs. evening chronotype;
PAAD	cis	rs9876781	1.000	rs1563736	chr3:48436794	G/A	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs797680	0.856	rs797681	chr1:93717746	T/C	cg04535902	chr1:92947332	GFI1	-0.45	-4.32	-0.33	2.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg21209604	chr6:26032199	HIST1H3B	0.63	6.49	0.47	1.16e-9	Primary biliary cholangitis;
PAAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg16928487	chr17:17741425	SREBF1	0.36	4.82	0.36	3.51e-6	Total body bone mineral density;
PAAD	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3749237	0.964	rs2276864	chr3:49894030	T/C	cg02487422	chr3:49467188	NICN1	0.46	4.52	0.34	1.26e-5	Resting heart rate;
PAAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg21361702	chr7:150065534	REPIN1	0.6	5.01	0.38	1.48e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17326144	chr1:145608565	POLR3C	-0.53	-6.48	-0.47	1.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Blood metabolite levels;
PAAD	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.61	-4.61	-0.35	8.34e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22162314	chr17:61951766	CSH2	-0.57	-5.95	-0.43	1.79e-8	Height;
PAAD	cis	rs9401295	0.546	rs10457368	chr6:98259776	A/G	cg00987395	chr6:98934664	NA	0.37	4.36	0.33	2.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg12193833	chr17:30244370	NA	-0.63	-5.32	-0.4	3.68e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.5	-4.75	-0.36	4.73e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-7.65	-0.53	2.16e-12	Body mass index;
PAAD	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg24999883	chr14:99880641	SETD3	0.41	4.57	0.35	1.01e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.81	8.32	0.56	4.68e-14	Alzheimer's disease (late onset);
PAAD	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.48	5.18	0.39	6.8e-7	Hemoglobin concentration;
PAAD	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-6.35	-0.46	2.36e-9	Homocysteine levels;
PAAD	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg14515779	chr1:101123966	NA	0.4	4.45	0.34	1.65e-5	Monocyte count;
PAAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.1	-0.5	4.55e-11	Gut microbiome composition (summer);
PAAD	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-4.5	-0.34	1.33e-5	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27409770	chr7:43965942	URGCP;UBE2D4	0.57	6.34	0.46	2.47e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.23	4.28	0.33	3.31e-5	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
PAAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg26174226	chr8:58114915	NA	-0.66	-5.93	-0.43	1.94e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs9287719	0.649	rs10190774	chr2:10718746	T/A	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	1.5	9.65	0.62	1.73e-17	Age-related hearing impairment;
PAAD	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.48	-6.27	-0.45	3.52e-9	Renal cell carcinoma;
PAAD	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.55	-6.16	-0.45	6.33e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs17032980	0.956	rs10199998	chr2:67308243	T/C	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.6e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg25251562	chr2:3704773	ALLC	-0.47	-5.07	-0.38	1.15e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.26e-18	Vitiligo;
PAAD	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg21479132	chr6:26055353	NA	0.92	5.9	0.43	2.28e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.59	6.17	0.45	5.86e-9	Lung cancer;
PAAD	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.23	0.45	4.4e-9	Bladder cancer;
PAAD	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.73	-8.3	-0.56	5.12e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.79	6.34	0.46	2.46e-9	Gastritis;
PAAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.84	-0.43	3.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg03989125	chr22:38214979	NA	-0.55	-5.64	-0.42	8.15e-8	Glioblastoma;Glioma;
PAAD	trans	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.46	-4.58	-0.35	9.73e-6	Monobrow;
PAAD	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.61	-8.89	-0.59	1.62e-15	Thrombosis;
PAAD	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.24	-13.61	-0.74	4.24e-28	Hip circumference adjusted for BMI;
PAAD	cis	rs6441975	0.506	rs1001007	chr3:46428658	A/G	cg06171971	chr3:45948591	NA	-0.34	-4.53	-0.35	1.17e-5	AIDS progression;
PAAD	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg24747557	chr10:131355152	MGMT	0.47	4.82	0.36	3.42e-6	Response to temozolomide;
PAAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.35	-0.33	2.49e-5	Menarche (age at onset);
PAAD	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12799264	1.000	rs894551	chr11:19977088	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03676636	chr4:99064102	C4orf37	0.33	6.02	0.44	1.24e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6594713	0.640	rs13159509	chr5:112671519	G/A	cg12552261	chr5:112820674	MCC	0.67	4.54	0.35	1.13e-5	Brain cytoarchitecture;
PAAD	cis	rs7301016	0.707	rs11174587	chr12:63052559	A/T	cg11441379	chr12:63026424	NA	0.83	5.95	0.43	1.8e-8	IgG glycosylation;
PAAD	cis	rs758324	0.812	rs494349	chr5:131260452	C/A	cg06307176	chr5:131281290	NA	-0.53	-4.61	-0.35	8.43e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg08200582	chr11:442649	ANO9	0.55	4.47	0.34	1.54e-5	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg19223190	chr17:80058835	NA	-0.52	-5.44	-0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.3	-0.6	1.48e-16	Calcium levels;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13047869	chr3:10149882	C3orf24	0.9	7.39	0.51	9.13e-12	Alzheimer's disease;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.4	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg02459107	chr1:67143332	SGIP1	0.77	7.54	0.52	3.99e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs10501293	0.789	rs4755690	chr11:43054680	A/G	cg03447554	chr11:43094025	NA	0.46	4.28	0.33	3.24e-5	Cognitive performance;
PAAD	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg04851639	chr8:1020857	NA	-0.65	-8.43	-0.56	2.46e-14	Schizophrenia;
PAAD	cis	rs8025118	0.583	rs7173546	chr15:79549789	T/C	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.27	-0.33	3.36e-5	Cognitive function;
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg14092988	chr3:52407081	DNAH1	0.44	5.43	0.4	2.19e-7	Bipolar disorder;
PAAD	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg06728252	chr6:26598149	ABT1	-0.37	-4.36	-0.33	2.43e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.84e-29	Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.65	-0.35	7.3e-6	Ulcerative colitis;
PAAD	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.39	-0.34	2.15e-5	Neuroticism;
PAAD	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs59888335	0.929	rs34443474	chr3:80884986	G/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs17095355	0.818	rs11194997	chr10:111889779	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.78	-0.36	4.18e-6	Biliary atresia;
PAAD	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs939584	0.935	rs11127490	chr2:646110	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg04154034	chr17:28927549	LRRC37B2	0.7	4.75	0.36	4.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs66696671	0.545	rs7099126	chr10:121387549	C/T	cg26070865	chr5:959141	NA	-0.35	-6.29	-0.45	3.18e-9	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
PAAD	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg19423196	chr10:82049429	MAT1A	0.59	4.41	0.34	1.93e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.03e-6	Skin colour saturation;
PAAD	cis	rs73001065	1.000	rs73001065	chr19:19460541	G/C	cg03709012	chr19:19516395	GATAD2A	0.98	5.01	0.38	1.5e-6	LDL cholesterol;
PAAD	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	5.02	0.38	1.45e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	2.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg06483076	chr3:194406458	FAM43A	0.54	5.19	0.39	6.71e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-5.92	-0.43	2.06e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.85	0.37	3.05e-6	Vitiligo;
PAAD	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.87	10.47	0.65	1.17e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg08704250	chr15:31115839	NA	-0.62	-8.44	-0.56	2.38e-14	Huntington's disease progression;
PAAD	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	1.05	6.59	0.47	6.87e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.58	0.35	9.56e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.3	0.64	3.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs1006703	0.544	rs35443604	chr17:3833972	G/A	cg06463185	chr17:3833770	ATP2A3	-0.88	-7.2	-0.5	2.62e-11	Glucose homeostasis traits;
PAAD	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.7e-8	Schizophrenia;
PAAD	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg10705379	chr10:99080932	FRAT1	0.4	4.67	0.35	6.63e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	4.65	0.35	7.15e-6	Personality dimensions;
PAAD	cis	rs6076065	0.723	rs6137922	chr20:23363773	G/A	cg11657817	chr20:23433608	CST11	0.5	5.21	0.39	6.17e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.48	4.49	0.34	1.42e-5	Airway imaging phenotypes;
PAAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.52	-5.19	-0.39	6.53e-7	IgG glycosylation;
PAAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.41	-0.4	2.45e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.63	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.5	-0.34	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg13444538	chr7:158905317	VIPR2	0.53	4.99	0.38	1.65e-6	Facial morphology (factor 20);
PAAD	cis	rs656900	0.647	rs600671	chr15:80117232	A/G	cg02196730	chr15:80188777	MTHFS	0.41	4.39	0.34	2.11e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs490234	0.756	rs6478705	chr9:128216326	G/T	cg14078157	chr9:128172775	NA	-0.48	-5.57	-0.41	1.13e-7	Mean arterial pressure;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.45	6.24	0.45	4.04e-9	Vitiligo;
PAAD	cis	rs939584	1.000	rs7606023	chr2:638566	C/G	cg03610516	chr2:642275	NA	0.6	5.39	0.4	2.69e-7	Body mass index;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.81	5.88	0.43	2.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.51	-4.78	-0.36	4.08e-6	Height;
PAAD	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.66	-8.46	-0.57	2.12e-14	Birth weight;
PAAD	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg19486271	chr11:47235900	DDB2	-0.6	-6.06	-0.44	1.02e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	6.62	0.47	5.96e-10	Initial pursuit acceleration;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.82	-8.72	-0.58	4.65e-15	DNA methylation (variation);
PAAD	cis	rs5009270	0.524	rs11763053	chr7:112262623	C/T	cg23628563	chr7:112262597	NA	0.72	6.01	0.44	1.3e-8	Osteoarthritis (hip);
PAAD	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.96	-9.56	-0.61	2.95e-17	Corneal astigmatism;
PAAD	cis	rs7620363	0.859	rs13060380	chr3:34089019	G/A	cg02064073	chr3:33155252	CRTAP	-0.51	-4.41	-0.34	1.92e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.23	-0.6	2.14e-16	Response to antipsychotic treatment;
PAAD	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.69	-7.53	-0.52	4.16e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9649465	1.000	rs1468656	chr7:123375505	G/C	cg04330084	chr7:123175371	IQUB	-0.49	-4.52	-0.34	1.26e-5	Migraine;
PAAD	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg09667013	chr22:42394590	WBP2NL	0.53	5.17	0.39	7.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs288342	0.832	rs288241	chr2:183643905	A/T	cg02625481	chr2:183667124	NA	-0.46	-4.55	-0.35	1.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.21	-0.39	5.95e-7	Height;
PAAD	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-7.45	-0.52	6.6e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg24253500	chr15:84953950	NA	0.56	6.54	0.47	8.87e-10	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.3	-0.6	1.45e-16	Alzheimer's disease (late onset);
PAAD	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.44	0.46	1.48e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10450586	0.932	rs11029915	chr11:27311468	G/A	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.63	6.52	0.47	9.81e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9900062	0.844	rs9908143	chr17:62754586	T/C	cg02598441	chr17:62777298	LOC146880	-0.64	-4.74	-0.36	4.98e-6	QT interval;
PAAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg21827317	chr3:136751795	NA	0.52	5.55	0.41	1.22e-7	Gestational age at birth (child effect);
PAAD	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.63	5.53	0.41	1.33e-7	Mean platelet volume;
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-0.84	-9.24	-0.6	2.03e-16	Body mass index;
PAAD	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.03	-8.52	-0.57	1.46e-14	Diabetic kidney disease;
PAAD	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg03954927	chr1:10346856	KIF1B	-0.42	-4.46	-0.34	1.6e-5	Hepatocellular carcinoma;
PAAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.79	9.19	0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.53	0.41	1.35e-7	Schizophrenia;
PAAD	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.9e-7	Rheumatoid arthritis;
PAAD	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	6.46	0.46	1.34e-9	Body mass index;
PAAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg13047869	chr3:10149882	C3orf24	0.54	4.77	0.36	4.24e-6	Alzheimer's disease;
PAAD	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.72	7.44	0.52	6.88e-12	Systolic blood pressure;
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.58	5.71	0.42	5.7e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs7243821	0.921	rs59671003	chr18:52633975	G/A	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs9326726	0.566	rs288146	chr5:107392562	A/G	cg19779370	chr5:108084990	FER	-0.6	-4.75	-0.36	4.68e-6	Resting heart rate;
PAAD	cis	rs6804624	0.636	rs2670342	chr3:99163190	T/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.39	-0.34	2.14e-5	Schizophrenia;
PAAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.45	0.52	6.49e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs2070677	0.799	rs3020498	chr10:135379710	A/C	cg20169779	chr10:135381914	SYCE1	0.78	7.51	0.52	4.68e-12	Gout;
PAAD	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg11288833	chr15:55489084	RSL24D1	0.58	4.7	0.36	5.71e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.71	7.04	0.5	6.33e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.93	12.69	0.72	1.3e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs6446731	0.593	rs2858084	chr4:3272118	A/C	cg08886695	chr4:3369023	RGS12	-0.53	-4.94	-0.37	2.04e-6	Mean platelet volume;
PAAD	cis	rs7011049	1.000	rs72643583	chr8:53847269	C/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-4.66	-0.35	6.97e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.53	-4.51	-0.34	1.31e-5	Atopic dermatitis;
PAAD	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs3779195	1.000	rs3779195	chr7:97993362	T/A	cg24562669	chr7:97807699	LMTK2	-0.5	-4.61	-0.35	8.34e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg03417191	chr3:183542750	MAP6D1	-0.81	-6.71	-0.48	3.58e-10	Menopause (age at onset);
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.58	6.32	0.46	2.79e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11671653	1.000	rs1560706	chr19:10838004	C/G	cg18582342	chr19:11591989	ELAVL3	-0.48	-4.33	-0.33	2.67e-5	LDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10515332	chr4:99064459	C4orf37	-0.57	-6.41	-0.46	1.75e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02725872	chr8:58115012	NA	-0.65	-5.55	-0.41	1.23e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg20744362	chr22:50050164	C22orf34	0.68	7.49	0.52	5.37e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-1.17	-7.09	-0.5	4.7e-11	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs13336428	0.663	rs3751883	chr16:1524604	C/T	cg07835181	chr16:1525278	CLCN7	0.94	9.44	0.61	6.09e-17	Bone mineral density;
PAAD	cis	rs1656368	0.726	rs55720154	chr3:158275810	T/C	cg16708174	chr3:158430962	RARRES1	0.55	5.01	0.38	1.47e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg02135003	chr7:105160482	PUS7	-0.59	-4.89	-0.37	2.55e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg10011062	chr15:43941034	CATSPER2	-0.71	-4.45	-0.34	1.66e-5	Lung cancer in ever smokers;
PAAD	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg16205897	chr5:131564050	P4HA2	-0.41	-4.41	-0.34	1.95e-5	Blood metabolite levels;
PAAD	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.38	-0.33	2.21e-5	Post bronchodilator FEV1;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06041469	chr2:45877179	NA	-0.71	-7.35	-0.51	1.11e-11	Smoking initiation;
PAAD	cis	rs73787773	0.867	rs75705984	chr5:111487993	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.74	-4.33	-0.33	2.67e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.48	-5.1	-0.38	9.83e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7081476	0.737	rs4747592	chr10:27498757	T/C	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-7.9	-0.54	5.1e-13	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13617047	chr10:576032	DIP2C	0.57	6.71	0.48	3.71e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.62	-9.38	-0.61	8.77e-17	Asthma (sex interaction);
PAAD	cis	rs6137287	0.855	rs3790142	chr20:21182819	T/A	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-4.46	-0.34	1.56e-5	Blood metabolite levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14150915	chr11:66056828	YIF1A	0.64	7.09	0.5	4.74e-11	Myopia (pathological);
PAAD	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.72	4.85	0.37	3.09e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg15654264	chr1:150340011	RPRD2	0.5	4.81	0.36	3.67e-6	Migraine;
PAAD	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg06102954	chr21:42741788	MX2	0.49	4.91	0.37	2.28e-6	Melanoma;
PAAD	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg04359915	chr10:101825029	CPN1	-0.36	-5.59	-0.41	1.05e-7	Liver enzyme levels;
PAAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg06714761	chr1:201096289	NA	0.3	4.48	0.34	1.44e-5	Permanent tooth development;
PAAD	cis	rs12767760	0.625	rs4635019	chr10:99311058	C/T	cg25247692	chr10:99313390	UBTD1	0.56	5.46	0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.66	-7.03	-0.5	6.4e-11	Metabolic traits;LDL cholesterol;
PAAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg27490568	chr2:178487706	NA	0.43	4.61	0.35	8.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6992820	0.530	rs6985703	chr8:56785133	G/T	cg16485482	chr8:56362574	XKR4;SBF1P1	-0.35	-4.51	-0.34	1.31e-5	Mean platelet volume;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	1.05	13.96	0.75	4.94e-29	Menarche (age at onset);
PAAD	cis	rs57244997	0.725	rs73028490	chr6:162421657	T/C	cg17173639	chr6:162384350	PARK2	-0.66	-4.86	-0.37	2.85e-6	Mosquito bite size;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.75	-7.66	-0.53	2.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-4.57	-0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.23	-0.39	5.65e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.66	-0.35	6.75e-6	Lung cancer;
PAAD	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.58	-0.41	1.09e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.69	8.93	0.59	1.29e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.39	0.34	2.14e-5	Menarche (age at onset);
PAAD	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.6	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14983993	chr14:20937849	PNP	0.57	6.5	0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.43	-5.15	-0.39	7.83e-7	Total body bone mineral density;
PAAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	11.06	0.67	3.14e-21	Menopause (age at onset);
PAAD	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg14709524	chr16:89940631	TCF25	1.01	4.73	0.36	5.1e-6	Skin colour saturation;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	5.86	0.43	2.79e-8	Joint mobility (Beighton score);
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.37	-9.39	-0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27446832	chr16:88239335	NA	0.56	6.34	0.46	2.46e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23158103	chr7:148848205	ZNF398	-0.59	-5.77	-0.42	4.34e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6681460	1.000	rs6680876	chr1:67129482	G/A	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.95e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	0.79	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	10.6	0.65	5.31e-20	Tonsillectomy;
PAAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.62	8.18	0.55	1.07e-13	Renal cell carcinoma;
PAAD	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.68	7.96	0.54	3.71e-13	Metabolite levels;
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.69	-6.25	-0.45	4.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg01777861	chr4:56023843	NA	-0.39	-5.11	-0.38	9.51e-7	Endometriosis;
PAAD	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg08501292	chr6:25962987	TRIM38	0.74	4.4	0.34	2.06e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg04990556	chr1:26633338	UBXN11	0.65	4.67	0.35	6.51e-6	Obesity-related traits;
PAAD	cis	rs73526541	0.588	rs76536698	chr8:1066059	T/G	cg20458277	chr8:1053508	NA	0.59	4.45	0.34	1.63e-5	Verbal memory performance (immediate recall change);
PAAD	cis	rs1879734	0.731	rs11206195	chr1:54164156	T/C	cg14659662	chr1:54151053	GLIS1	-0.45	-5.96	-0.44	1.65e-8	Mitral valve prolapse;
PAAD	cis	rs1351164	0.591	rs9752576	chr2:218269445	G/A	cg15335768	chr2:218268053	DIRC3	-0.43	-4.78	-0.36	4.1e-6	Height;
PAAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg21433313	chr16:3507492	NAT15	0.93	7.62	0.53	2.58e-12	Tuberculosis;
PAAD	cis	rs6844506	1.000	rs1776003	chr4:185216000	A/G	cg12654155	chr4:185238627	NA	-0.49	-4.6	-0.35	8.83e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg18721089	chr20:30220636	NA	-0.6	-5.01	-0.38	1.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs8032158	0.963	rs11071231	chr15:56159118	A/C	cg02198044	chr15:56286336	NEDD4	-0.48	-5.09	-0.38	1.02e-6	Keloid;
PAAD	cis	rs7945718	0.621	rs10831891	chr11:12676140	A/G	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.54	-0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08677398	chr8:58056175	NA	0.73	4.89	0.37	2.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs854572	0.509	rs12534274	chr7:95057510	G/A	cg05342682	chr7:94953680	PON1	-0.51	-4.91	-0.37	2.31e-6	Paraoxonase activity;
PAAD	cis	rs735539	0.517	rs9552240	chr13:21126497	T/C	cg27499820	chr13:21296301	IL17D	0.53	5.12	0.38	9.01e-7	Dental caries;
PAAD	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	1.03	6.84	0.49	1.8e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.33	0.64	2.78e-19	Cognitive test performance;
PAAD	cis	rs1570884	0.714	rs2038881	chr13:50135177	A/G	cg08779649	chr13:50194554	NA	0.39	5.4	0.4	2.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg02792821	chr20:44451783	NA	0.33	4.35	0.33	2.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg07384165	chr1:10488281	NA	0.5	5.05	0.38	1.25e-6	Prostate cancer;
PAAD	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg15798862	chr7:76129360	DTX2	0.53	7.06	0.5	5.68e-11	Multiple sclerosis;
PAAD	cis	rs300774	0.925	rs300779	chr2:111486	G/A	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg21605333	chr4:119757512	SEC24D	1.24	7.69	0.53	1.74e-12	Cannabis dependence symptom count;
PAAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.96	10.26	0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17021463	0.673	rs12646467	chr4:95288819	G/A	cg11021082	chr4:95130006	SMARCAD1	0.55	5.65	0.42	7.81e-8	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg04025307	chr7:1156635	C7orf50	0.63	4.5	0.34	1.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.74	7.9	0.54	5.18e-13	Menopause (age at onset);
PAAD	cis	rs714027	0.605	rs193475	chr22:30450492	T/C	cg01021169	chr22:30184971	ASCC2	0.44	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs6466055	0.748	rs10266871	chr7:104812129	G/A	cg04380332	chr7:105027541	SRPK2	-0.64	-7.09	-0.5	4.63e-11	Schizophrenia;
PAAD	cis	rs7572263	1.000	rs7572263	chr2:209051586	A/G	cg23998903	chr2:209048830	C2orf80	-0.49	-4.68	-0.36	6.25e-6	Glioma;Non-glioblastoma glioma;
PAAD	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09880681	chr16:30538664	ZNF768	0.58	6.46	0.46	1.37e-9	Myopia (pathological);
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.5	-0.34	1.32e-5	Platelet count;
PAAD	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs6466055	0.661	rs1010340	chr7:104830695	T/C	cg04380332	chr7:105027541	SRPK2	0.52	5.19	0.39	6.5e-7	Schizophrenia;
PAAD	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg02737268	chr20:3780182	CDC25B	0.5	4.97	0.37	1.77e-6	Bipolar disorder;
PAAD	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	5.78	0.42	4.03e-8	IgG glycosylation;
PAAD	cis	rs1941184	0.759	rs958961	chr18:29024467	G/A	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg09835421	chr16:68378352	PRMT7	-1.06	-7.73	-0.53	1.35e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs35394192	chr10:46000761	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12304921	0.549	rs66781280	chr12:51461912	A/G	cg18059802	chr12:51347058	HIGD1C	-0.61	-4.82	-0.36	3.5e-6	Type 2 diabetes;
PAAD	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26031613	chr14:104095156	KLC1	0.43	4.3	0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-5.69	-0.42	6.21e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.57	4.98	0.37	1.74e-6	Life satisfaction;
PAAD	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12926503	0.502	rs16962491	chr16:84034513	C/G	cg05253165	chr16:84033146	NECAB2	0.58	4.33	0.33	2.72e-5	Body mass index (change over time);
PAAD	cis	rs9810890	1.000	rs73198901	chr3:128566520	G/A	cg19129842	chr3:128565090	NA	-0.9	-5.32	-0.4	3.64e-7	Dental caries;
PAAD	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.24	-22.99	-0.88	2.48e-51	Myeloid white cell count;
PAAD	cis	rs3763048	1.000	rs4385221	chr5:169457601	G/A	cg01585372	chr5:169931363	KCNIP1	-0.43	-4.29	-0.33	3.22e-5	IgG glycosylation;
PAAD	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4455778	0.561	rs56235551	chr7:49128132	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs1419980	0.730	rs11054566	chr12:7729524	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.52	-4.75	-0.36	4.76e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg26552638	chr8:10875534	XKR6	-0.36	-4.26	-0.33	3.54e-5	Myopia (pathological);
PAAD	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.66	6.36	0.46	2.21e-9	Schizophrenia;
PAAD	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg20243544	chr17:37824526	PNMT	-0.52	-4.52	-0.34	1.22e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.64	7.37	0.51	9.92e-12	Vitiligo;
PAAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg26394940	chr22:46449461	C22orf26;LOC150381	0.47	4.63	0.35	7.85e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs6710503	0.574	rs62142274	chr2:24764393	C/A	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.53	4.4	0.34	2.01e-5	Type 2 diabetes;
PAAD	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-6.45	-0.46	1.38e-9	Monocyte count;
PAAD	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.55	5.23	0.39	5.41e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.87	-9.84	-0.62	5.52e-18	Iron status biomarkers;
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs2548003	0.541	rs1812669	chr5:28745835	C/G	cg22863700	chr5:28928346	NA	0.48	4.66	0.35	6.73e-6	Hip geometry;
PAAD	cis	rs17032980	0.956	rs10199998	chr2:67308243	T/C	cg06994420	chr2:66672553	MEIS1	-0.51	-4.49	-0.34	1.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.87	9.36	0.6	1.02e-16	Schizophrenia;
PAAD	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.43	4.85	0.37	2.99e-6	Refractive error;
PAAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg02071572	chr4:1403502	NA	0.38	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00955682	chr5:138677338	PAIP2	0.57	6.67	0.48	4.44e-10	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs59191668	0.809	rs12915597	chr15:62819812	G/C	cg12918536	chr15:62891943	NA	0.35	4.64	0.35	7.42e-6	Immature fraction of reticulocytes;
PAAD	cis	rs859767	0.501	rs6724777	chr2:135407292	C/T	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg26685658	chr5:74633012	HMGCR	-0.53	-4.51	-0.34	1.27e-5	Age-related disease endophenotypes;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg05457628	chr5:178986728	RUFY1	0.49	4.69	0.36	6.02e-6	Lung cancer;
PAAD	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.57	0.57	1.1e-14	Lung cancer;
PAAD	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg26939375	chr7:64535504	NA	0.52	5.76	0.42	4.53e-8	Aortic root size;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06727060	chr16:30709711	SRCAP	0.55	6.42	0.46	1.63e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12913538	0.962	rs4774442	chr15:62897853	G/A	cg09983546	chr15:62884068	NA	0.71	7.91	0.54	4.8e-13	Sleep depth;
PAAD	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.52	-0.34	1.23e-5	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg20003494	chr4:90757398	SNCA	-0.74	-7.17	-0.5	3.13e-11	Neuroticism;
PAAD	cis	rs2562456	0.793	rs11667392	chr19:21472608	T/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7168592	1.000	rs7164068	chr15:101719380	G/C	cg24254196	chr15:101719523	CHSY1	-0.61	-4.33	-0.33	2.68e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.57	7.2	0.5	2.58e-11	Schizophrenia;
PAAD	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	4.5	0.34	1.36e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1419980	0.730	rs11054870	chr12:7770803	A/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.12	0.38	8.97e-7	Common traits (Other);
PAAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.81	-7.44	-0.52	6.93e-12	Body mass index;
PAAD	cis	rs7771547	0.574	rs9349001	chr6:36550681	C/T	cg07856975	chr6:36356162	ETV7	0.56	5.75	0.42	4.76e-8	Platelet distribution width;
PAAD	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.88	5.56	0.41	1.17e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.11	0.67	2.25e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs89107	0.934	rs281868	chr6:118574061	A/G	cg18833306	chr6:118973337	C6orf204	-0.47	-5.29	-0.39	4.16e-7	Cardiac structure and function;
PAAD	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-4.86	-0.37	2.93e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.42	4.3	0.33	3.1e-5	Height;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.78	-9.2	-0.6	2.61e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs507080	0.733	rs488141	chr11:118571168	A/G	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.25	-0.33	3.66e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg07541023	chr7:19748670	TWISTNB	0.62	4.35	0.33	2.53e-5	Thyroid stimulating hormone;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg06375148	chr1:209958343	C1orf74	0.68	5.76	0.42	4.49e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg10820045	chr2:198174542	NA	-0.46	-4.64	-0.35	7.46e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.92	10.78	0.66	1.8e-20	Schizophrenia;
PAAD	cis	rs17023223	0.537	rs2361271	chr1:119603405	A/G	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.61	7.16	0.5	3.17e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.0	0.49	7.86e-11	Lung cancer in ever smokers;
PAAD	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs1878047	0.665	rs59526361	chr19:51776757	A/G	cg14884932	chr19:51774451	NA	-0.4	-4.34	-0.33	2.6e-5	Body mass index;
PAAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.76	-0.42	4.46e-8	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs375066	0.935	rs384329	chr19:44423981	A/G	cg11993925	chr19:44307056	LYPD5	0.48	6.17	0.45	6.02e-9	Breast cancer;
PAAD	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.75	5.81	0.43	3.55e-8	Obesity-related traits;
PAAD	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2735413	0.957	rs2735414	chr16:78053658	C/A	cg04733911	chr16:78082701	NA	-0.52	-4.88	-0.37	2.7e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg15515095	chr1:87563710	HS2ST1	-0.62	-6.87	-0.49	1.54e-10	Alcohol dependence;
PAAD	cis	rs1884136	1.000	rs73604334	chr20:10841798	G/A	cg12909741	chr20:10199469	SNAP25	-0.64	-4.25	-0.33	3.67e-5	Information processing speed;
PAAD	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.45	-0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg19637330	chr1:19110922	NA	0.6	4.76	0.36	4.53e-6	Percentage gas trapping;
PAAD	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.65	-6.24	-0.45	4.19e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.09	0.55	1.76e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.23	-9.19	-0.6	2.77e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.6	5.97	0.44	1.58e-8	Monocyte count;
PAAD	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg06042504	chr8:55087323	NA	-0.69	-7.02	-0.49	6.81e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg26248373	chr2:1572462	NA	-1.06	-9.41	-0.61	7.34e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.72	7.33	0.51	1.28e-11	Lung cancer;
PAAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.65	-5.93	-0.43	1.97e-8	DNA methylation (variation);
PAAD	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.55	8.69	0.58	5.36e-15	IgG glycosylation;
PAAD	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg21905437	chr5:178450457	ZNF879	0.6	4.9	0.37	2.39e-6	Pubertal anthropometrics;
PAAD	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg18833306	chr6:118973337	C6orf204	0.56	6.11	0.44	7.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.61	-0.41	9.37e-8	Personality dimensions;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.5	-4.46	-0.34	1.55e-5	Lung cancer;
PAAD	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	5.87	0.43	2.65e-8	Body mass index;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg21191810	chr6:118973309	C6orf204	0.44	5.54	0.41	1.28e-7	Electrocardiographic conduction measures;
PAAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.19	0.5	2.69e-11	Eosinophil percentage of white cells;
PAAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.46	4.36	0.33	2.35e-5	Alcohol dependence;
PAAD	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg11584989	chr19:19387371	SF4	-0.77	-6.41	-0.46	1.73e-9	Bipolar disorder;
PAAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.91	-0.49	1.26e-10	Psoriasis;
PAAD	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.04	0.63	1.68e-18	Bladder cancer;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg13880726	chr7:1868755	MAD1L1	0.45	4.25	0.33	3.73e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.42	-4.51	-0.34	1.31e-5	Total body bone mineral density;
PAAD	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.59	-0.35	9.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg22162314	chr17:61951766	CSH2	0.6	4.91	0.37	2.34e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg14393609	chr7:65229607	NA	0.63	6.83	0.48	1.93e-10	Aortic root size;
PAAD	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.79	8.08	0.55	1.87e-13	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.05	-9.74	-0.62	1.02e-17	Platelet count;
PAAD	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.92	-6.63	-0.47	5.63e-10	Psoriasis vulgaris;
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.35e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs11825064	0.666	rs58623219	chr11:134494910	C/T	cg06603561	chr11:134479413	NA	-0.97	-6.42	-0.46	1.67e-9	Seasonality;
PAAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-1.02	-14.27	-0.76	7.6e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.62	4.7	0.36	5.69e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.78	8.76	0.58	3.54e-15	Heart rate;
PAAD	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11547950	chr5:77652471	NA	-0.68	-5.93	-0.43	1.94e-8	Triglycerides;
PAAD	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg06740227	chr12:86229804	RASSF9	-0.55	-5.3	-0.39	4.09e-7	Major depressive disorder;
PAAD	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.65	-6.19	-0.45	5.43e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg09659197	chr4:152720779	NA	0.37	5.4	0.4	2.51e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.49	8.01	0.54	2.74e-13	IgG glycosylation;
PAAD	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.45	0.71	5.5e-25	Cognitive ability;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.32	0.33	2.76e-5	Height;
PAAD	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg24565620	chr2:194026	NA	-0.62	-5.38	-0.4	2.78e-7	Blood protein levels;
PAAD	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.65	7.3	0.51	1.47e-11	Coronary artery disease;
PAAD	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23927002	chr1:7843618	PER3	0.57	6.32	0.46	2.69e-9	Monocyte percentage of white cells;
PAAD	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg19090574	chr1:205240910	TMCC2	-0.42	-4.44	-0.34	1.69e-5	Red blood cell count;
PAAD	cis	rs557074	0.821	rs55869891	chr6:7179751	G/A	cg01785233	chr6:7260807	NA	0.52	4.41	0.34	1.95e-5	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01294023	chr19:41816151	CCDC97	0.65	6.38	0.46	2.02e-9	Obesity-related traits;
PAAD	cis	rs7922314	0.571	rs61865690	chr10:64727346	T/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.32	0.51	1.31e-11	Obesity-related traits;
PAAD	cis	rs6782025	0.837	rs9844667	chr3:120790061	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.45	-0.34	1.63e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2242116	0.632	rs10049237	chr3:46941626	T/C	cg27129171	chr3:47204927	SETD2	0.66	5.8	0.43	3.71e-8	Birth weight;
PAAD	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-11.86	-0.69	2.25e-23	Primary sclerosing cholangitis;
PAAD	cis	rs3812111	0.545	rs9387389	chr6:116573667	G/A	cg05304507	chr6:116381966	FRK	-0.27	-4.57	-0.35	1.02e-5	Age-related macular degeneration;
PAAD	cis	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.47	0.34	1.54e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.48	-0.34	1.49e-5	Triglycerides;
PAAD	cis	rs11700980	0.551	rs2832041	chr21:30116018	C/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs1334894	0.901	rs72899796	chr6:35515436	C/G	cg07213720	chr6:35227408	ZNF76	-0.78	-4.25	-0.33	3.73e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1468333	0.667	rs2240332	chr5:137767893	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.55	-5.39	-0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg26939375	chr7:64535504	NA	0.76	9.19	0.6	2.84e-16	Calcium levels;
PAAD	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.37e-6	Type 2 diabetes;
PAAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg09222892	chr1:25734099	RHCE	0.46	4.69	0.36	6.03e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.84	-8.74	-0.58	3.9e-15	Obesity-related traits;
PAAD	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06130950	chr11:123612538	ZNF202	0.67	6.61	0.47	6.03e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.8	6.8	0.48	2.27e-10	Itch intensity from mosquito bite;
PAAD	cis	rs965469	1.000	rs6051724	chr20:3279338	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.68	-0.35	6.32e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.79	-0.36	3.99e-6	Menopause (age at onset);
PAAD	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.59	-0.35	9.4e-6	Type 2 diabetes;
PAAD	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.5	-4.77	-0.36	4.34e-6	Coronary artery disease;
PAAD	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg08999081	chr20:33150536	PIGU	-0.52	-5.69	-0.42	6.48e-8	Height;
PAAD	cis	rs1863918	0.533	rs7729756	chr5:178584302	C/T	cg05656566	chr5:178593924	ADAMTS2	-0.47	-4.8	-0.36	3.76e-6	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.61	-0.35	8.5e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.31	-0.33	2.9e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00142150	chr22:38071001	LGALS1	0.7	7.86	0.54	6.45e-13	Fat distribution (HIV);
PAAD	cis	rs2221894	0.959	rs2129784	chr8:28899997	G/A	cg20212339	chr8:28908912	HMBOX1	-0.49	-5.21	-0.39	6.06e-7	Obesity-related traits;
PAAD	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg00825309	chr19:58991885	ZNF446	-0.78	-8.22	-0.55	8.24e-14	Uric acid clearance;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg18279126	chr7:2041391	MAD1L1	0.57	5.92	0.43	2.02e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	1.07	12.32	0.71	1.3e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.21	6.96	0.49	9.35e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs427941	0.655	rs2734782	chr7:101749667	T/C	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.93	10.1	0.63	1.15e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg26205652	chr12:48591994	NA	0.83	7.51	0.52	4.73e-12	Longevity (90 years and older);
PAAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.78	-0.42	4.16e-8	Type 2 diabetes;
PAAD	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.52	4.87	0.37	2.8e-6	Hepatocellular carcinoma;
PAAD	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.61	-6.5	-0.47	1.07e-9	Hyperactive-impulsive symptoms;
PAAD	cis	rs855965	0.527	rs10787783	chr10:119474930	C/T	cg17249170	chr10:119305798	EMX2;EMX2OS	0.32	4.29	0.33	3.12e-5	Ovarian disease with few adhesions;
PAAD	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs1042026	0.808	rs1566141	chr4:100192460	A/G	cg09112717	chr4:100009950	ADH5	-0.51	-4.55	-0.35	1.09e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg01616529	chr11:638424	DRD4	-0.61	-6.22	-0.45	4.52e-9	Systemic lupus erythematosus;
PAAD	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg15212455	chr7:39170539	POU6F2	0.32	4.47	0.34	1.53e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4455778	0.600	rs4255086	chr7:49109798	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs3784262	0.565	rs3784264	chr15:58250246	T/G	cg12031962	chr15:58353849	ALDH1A2	0.4	4.64	0.35	7.35e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-5.11	-0.38	9.65e-7	Total body bone mineral density;
PAAD	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg14515779	chr1:101123966	NA	-0.54	-6.36	-0.46	2.22e-9	Monocyte count;
PAAD	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg00982548	chr2:198649783	BOLL	-0.79	-5.64	-0.42	8.25e-8	Ulcerative colitis;
PAAD	cis	rs6076065	0.513	rs13037663	chr20:23425812	A/T	cg11657817	chr20:23433608	CST11	0.51	4.83	0.36	3.32e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs13102973	0.645	rs11734870	chr4:135885118	T/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs922692	1.000	rs922692	chr15:78984214	C/A	cg00540400	chr15:79124168	NA	-0.43	-4.8	-0.36	3.73e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.8	7.12	0.5	3.96e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.12	0.44	7.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.44	0.4	2.04e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.51	-0.34	1.28e-5	Mood instability;
PAAD	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg18582342	chr19:11591989	ELAVL3	-0.73	-5.85	-0.43	2.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.59	4.75	0.36	4.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.99e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-1.37	-12.75	-0.72	9.01e-26	Obesity-related traits;
PAAD	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg23346134	chr3:49453900	TCTA	-0.54	-5.11	-0.38	9.46e-7	Menarche (age at onset);
PAAD	cis	rs507080	0.922	rs478296	chr11:118567375	T/C	cg08498647	chr11:118550644	TREH	-0.38	-4.4	-0.34	2.06e-5	Serum metabolite levels;
PAAD	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.53	4.93	0.37	2.13e-6	Resistin levels;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.77	7.45	0.52	6.58e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg21399703	chr1:247681439	NA	-0.7	-6.8	-0.48	2.3e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg14181355	chr19:12984996	MAST1	-0.49	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg04733989	chr22:42467013	NAGA	-0.71	-5.63	-0.42	8.37e-8	Schizophrenia;
PAAD	cis	rs8070740	0.617	rs1058117	chr17:5323206	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.69	0.42	6.23e-8	Menopause (age at onset);
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.67	8.71	0.58	4.78e-15	Lymphocyte counts;
PAAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.7	6.39	0.46	1.92e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.46	5.83	0.43	3.25e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg00540400	chr15:79124168	NA	-0.69	-8.78	-0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	trans	rs61931739	0.576	rs7297346	chr12:33700544	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg20607287	chr7:12443886	VWDE	-0.72	-6.48	-0.47	1.23e-9	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08664652	chr17:28804287	GOSR1	0.61	6.63	0.47	5.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2236918	0.901	rs1635502	chr1:242039382	A/G	cg17736920	chr1:242011382	EXO1	0.69	7.78	0.53	1.05e-12	Menopause (age at onset);
PAAD	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg22916017	chr11:64110731	CCDC88B	0.38	4.46	0.34	1.61e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.86	-11.13	-0.67	1.97e-21	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13474301	chr3:119748151	GSK3B	0.59	6.7	0.48	3.73e-10	Smoking initiation;
PAAD	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.75	7.59	0.52	2.92e-12	Retinal vascular caliber;
PAAD	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg04359915	chr10:101825029	CPN1	-0.36	-5.62	-0.41	8.9e-8	Bone mineral density;
PAAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs4356203	0.525	rs111416579	chr11:17249008	T/G	cg15432903	chr11:17409602	KCNJ11	-0.45	-4.75	-0.36	4.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.73	-7.51	-0.52	4.61e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	5.95	0.43	1.77e-8	Longevity;
PAAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.56	-5.56	-0.41	1.2e-7	Childhood ear infection;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10512697	0.655	rs35912980	chr5:3458039	G/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.66	-0.35	6.94e-6	Lung cancer;
PAAD	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.2	0.55	9.29e-14	Asthma;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09741851	chr10:30692665	NA	0.6	7.3	0.51	1.54e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6782228	0.606	rs2001950	chr3:128419756	A/G	cg16766828	chr3:128327626	NA	-0.45	-6.08	-0.44	9.32e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg05333889	chr7:157238977	NA	-0.44	-4.7	-0.36	5.67e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs71636778	0.722	rs71636784	chr1:27169200	T/G	cg12203394	chr1:27248618	NUDC	0.63	4.55	0.35	1.08e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg02487422	chr3:49467188	NICN1	0.46	4.72	0.36	5.28e-6	Resting heart rate;
PAAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.25	0.45	3.99e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.62	6.22	0.45	4.51e-9	Testicular germ cell tumor;
PAAD	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg05336292	chr10:466338	DIP2C	-0.41	-4.5	-0.34	1.37e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg11900509	chr10:81946545	ANXA11	-0.76	-4.3	-0.33	3.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.07	0.5	5.27e-11	Rheumatoid arthritis;
PAAD	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.13	0.59	4.06e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11793701	chr2:206547163	NRP2	-0.77	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.54	0.35	1.14e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	4.69	0.36	6.08e-6	Cognitive ability;
PAAD	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs721399	0.539	rs10088333	chr8:18267878	G/A	cg18736775	chr8:18248649	NAT2	-0.6	-4.54	-0.35	1.13e-5	Blood metabolite levels;
PAAD	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.93	9.86	0.62	4.92e-18	Testicular germ cell tumor;
PAAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.31	-0.33	2.9e-5	Bone mineral density;
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg01097406	chr16:89675127	NA	-0.35	-4.37	-0.33	2.31e-5	Vitiligo;
PAAD	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.68	-0.35	6.4e-6	Educational attainment;
PAAD	cis	rs10924309	0.924	rs10802245	chr1:245858321	G/A	cg00036263	chr1:245852353	KIF26B	-0.69	-6.12	-0.44	7.74e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs62458065	0.925	rs10243243	chr7:32460709	A/G	cg20159608	chr7:32802032	NA	-0.47	-4.83	-0.37	3.25e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22509189	chr2:225307070	NA	-0.5	-4.82	-0.36	3.42e-6	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15645491	chr20:1294311	SDCBP2	-0.55	-6.38	-0.46	1.99e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.61	-0.41	9.1e-8	Schizophrenia (age at onset);
PAAD	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.49	4.74	0.36	4.96e-6	Mean corpuscular volume;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.74	-7.41	-0.51	8.32e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg10223061	chr2:219282414	VIL1	0.37	4.45	0.34	1.67e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.49	4.55	0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	4.99	0.38	1.6e-6	Educational attainment;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs1884136	1.000	rs73604340	chr20:10857572	G/C	cg12909741	chr20:10199469	SNAP25	-0.66	-4.27	-0.33	3.4e-5	Information processing speed;
PAAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs35740288	0.742	rs4843087	chr15:86172855	A/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg01503450	chr10:980765	NA	-0.54	-4.47	-0.34	1.53e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.6	-4.61	-0.35	8.52e-6	Mosquito bite size;
PAAD	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.97	11.76	0.69	4.03e-23	Breast cancer;
PAAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-8.69	-0.58	5.55e-15	Calcium levels;
PAAD	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.1	0.44	8.22e-9	Height;
PAAD	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg22482690	chr17:47019901	SNF8	0.43	4.6	0.35	8.7e-6	Type 2 diabetes;
PAAD	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.8	9.03	0.59	7.12e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.72	0.36	5.26e-6	Depressive symptoms;
PAAD	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.39	0.46	1.93e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg08562672	chr19:21860753	NA	-0.44	-4.78	-0.36	4.19e-6	Pain;
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.73	11.5	0.68	2.07e-22	Body mass index;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-11.14	-0.67	1.94e-21	Cognitive function;
PAAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.79	7.99	0.54	3.08e-13	Vitiligo;
PAAD	cis	rs17095355	1.000	rs7068482	chr10:111729503	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.71	-0.36	5.49e-6	Biliary atresia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17521583	chr4:129474618	NA	0.65	6.86	0.49	1.63e-10	Obesity-related traits;
PAAD	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-6.25	-0.45	3.93e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.81	-0.36	3.57e-6	Schizophrenia;
PAAD	cis	rs621559	0.688	rs6670739	chr1:43668211	C/T	cg14851383	chr1:43888477	KIAA0467	-0.55	-4.37	-0.33	2.31e-5	Telomere length;
PAAD	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg22089800	chr15:90895588	ZNF774	-0.56	-5.05	-0.38	1.25e-6	Rheumatoid arthritis;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.62	-4.55	-0.35	1.07e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.16	0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.58	-5.32	-0.4	3.66e-7	Breast cancer;
PAAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.87e-5	Height;
PAAD	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma;
PAAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.73	-6.01	-0.44	1.32e-8	Neuroticism;
PAAD	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.11	-0.5	4.21e-11	Menarche (age at onset);
PAAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.61	5.55	0.41	1.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2790216	1.000	rs2790188	chr10:60042186	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs990171	0.538	rs2075192	chr2:103118228	A/G	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1519814	0.592	rs4870969	chr8:121006548	G/A	cg22335954	chr8:121166405	COL14A1	-0.61	-4.63	-0.35	7.92e-6	Breast cancer;
PAAD	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.77	-8.55	-0.57	1.25e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.59	-7.98	-0.54	3.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.78	0.42	4.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs807669	0.565	rs2000338	chr22:19155662	G/A	cg02655711	chr22:19163373	SLC25A1	0.65	7.24	0.51	2.09e-11	Metabolite levels;
PAAD	cis	rs7627468	0.837	rs9811123	chr3:121949292	G/A	cg17240004	chr3:121949083	CASR	0.52	4.83	0.36	3.33e-6	Kidney stones;
PAAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19346786	chr7:2764209	NA	-0.35	-4.71	-0.36	5.61e-6	Height;
PAAD	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg08926642	chr1:7887455	PER3	0.51	4.33	0.33	2.66e-5	Inflammatory bowel disease;
PAAD	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.96	-0.37	1.87e-6	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg23708337	chr7:1209742	NA	0.67	5.04	0.38	1.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.05	-0.44	1.11e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg16596103	chr2:233749413	NGEF	0.41	4.47	0.34	1.55e-5	Schizophrenia;
PAAD	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.62	6.12	0.44	7.55e-9	Mood instability;
PAAD	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg12655621	chr3:133380788	TOPBP1	0.73	6.45	0.46	1.4e-9	Response to platinum-based chemotherapy (carboplatin);
PAAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg18370025	chr7:2749541	AMZ1	-0.39	-4.74	-0.36	4.9e-6	Height;
PAAD	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg14433983	chr11:636460	DRD4	-0.46	-4.74	-0.36	4.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.33	-0.4	3.55e-7	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12028052	chr1:109940313	SORT1	0.62	6.92	0.49	1.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2238823	1.000	rs6007085	chr22:45936527	G/T	cg17791035	chr22:45705866	FAM118A	-0.55	-4.57	-0.35	9.88e-6	Paneth cell defects in Crohn's disease;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6141769	0.518	rs6057631	chr20:31319149	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.68	7.1	0.5	4.45e-11	Morning vs. evening chronotype;
PAAD	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg00129232	chr17:37814104	STARD3	-0.75	-5.79	-0.42	3.94e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs1359582	0.836	rs2576155	chr10:90339593	C/T	cg15661332	chr10:90342814	RNLS	0.57	5.1	0.38	1.02e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg27411982	chr8:10470053	RP1L1	-0.52	-5.4	-0.4	2.49e-7	Neuroticism;
PAAD	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	6.38	0.46	2.04e-9	Mean platelet volume;
PAAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.75	6.17	0.45	5.9e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26209169	chr5:1316264	NA	0.38	4.55	0.35	1.07e-5	Lung cancer;
PAAD	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.63	4.73	0.36	5.18e-6	Cholesterol, total;
PAAD	cis	rs73195822	1.000	rs73195822	chr12:111240951	G/C	cg12870014	chr12:110450643	ANKRD13A	0.8	4.43	0.34	1.79e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg22349387	chr12:9600060	DDX12	-0.45	-4.57	-0.35	1.02e-5	Breast size;
PAAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg03983715	chr16:68378420	PRMT7	-1.03	-7.22	-0.51	2.34e-11	Schizophrenia;
PAAD	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4819143	0.517	rs1783076	chr21:47373586	C/T	cg13695288	chr21:47294981	PCBP3	0.55	4.81	0.36	3.64e-6	Insulin resistance/response;
PAAD	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.76	-5.72	-0.42	5.49e-8	Mean platelet volume;
PAAD	cis	rs4787491	0.679	rs7204852	chr16:30040178	C/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs303386	0.501	rs6703819	chr1:99574494	T/C	cg03593336	chr1:99471295	LPPR5	0.55	5.16	0.39	7.59e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs528301	0.833	rs578584	chr2:45143175	A/T	cg15393275	chr2:45165193	NA	0.5	5.38	0.4	2.8e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs17162190	0.643	rs3811461	chr1:26759149	C/T	cg17456097	chr1:26900765	RPS6KA1	-0.56	-4.48	-0.34	1.46e-5	Mean corpuscular volume;
PAAD	trans	rs901683	0.702	rs34019727	chr10:45987751	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07685180	chr8:600429	NA	1.04	7.14	0.5	3.66e-11	IgG glycosylation;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18364779	chr6:26104403	HIST1H4C	0.5	4.69	0.36	5.98e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	1.03	14.38	0.76	3.86e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1011018	0.955	rs12703395	chr7:139427361	A/G	cg03224163	chr7:139420300	HIPK2	-0.6	-4.27	-0.33	3.47e-5	Systolic blood pressure;
PAAD	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Breast cancer;
PAAD	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs6987853	0.814	rs1947296	chr8:42452999	T/C	cg09913449	chr8:42400586	C8orf40	0.55	6.19	0.45	5.32e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.48	4.97	0.37	1.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.47	4.99	0.38	1.6e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs282587	0.569	rs408826	chr13:113415268	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-5.01	-0.38	1.47e-6	Glycated hemoglobin levels;
PAAD	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	0.54	6.11	0.44	8.11e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg25558440	chr8:11882962	NA	-0.45	-4.35	-0.33	2.5e-5	Retinal vascular caliber;
PAAD	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg06835404	chr16:988973	LMF1	0.72	7.61	0.53	2.71e-12	Non-glioblastoma glioma;Glioblastoma;Glioma;
PAAD	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.61	5.53	0.41	1.38e-7	Height;
PAAD	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.13	16.77	0.81	2.21e-36	Primary sclerosing cholangitis;
PAAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.54	-5.13	-0.38	8.65e-7	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg18888403	chr1:24152774	HMGCL	0.4	4.54	0.35	1.12e-5	Immature fraction of reticulocytes;
PAAD	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.95	-0.37	1.91e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.51	4.95	0.37	1.96e-6	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.83e-7	Motion sickness;
PAAD	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.76	-0.42	4.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.69	-0.36	6.16e-6	Glomerular filtration rate;
PAAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.99	11.24	0.67	1.03e-21	Parkinson's disease;
PAAD	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.24	7.28	0.51	1.7e-11	Skin colour saturation;
PAAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.54	-5.84	-0.43	3.04e-8	Total body bone mineral density;
PAAD	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	1.05	7.37	0.51	9.98e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.29	-0.39	4.27e-7	Triglycerides;
PAAD	cis	rs1413885	0.549	rs9436726	chr1:65853196	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.72	0.36	5.25e-6	Anticoagulant levels;
PAAD	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs72960926	1.000	rs72960934	chr6:75161902	T/A	cg13435101	chr6:74171350	MTO1	0.92	4.47	0.34	1.54e-5	Metabolite levels (MHPG);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13071326	chr7:75368332	HIP1	0.61	6.65	0.47	4.96e-10	Monocyte percentage of white cells;
PAAD	cis	rs2526932	1.000	rs2803961	chr14:73082826	T/C	cg13588403	chr14:73209128	DPF3	0.45	5.57	0.41	1.12e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14019695	chr9:139328340	INPP5E	0.48	4.48	0.34	1.45e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1355223	0.573	rs2084970	chr11:34723729	G/A	cg11622362	chr11:34938112	PDHX;APIP	0.43	4.3	0.33	3.1e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.65	-5.74	-0.42	5.07e-8	Coronary artery disease;
PAAD	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg06606381	chr12:133084897	FBRSL1	-1.18	-7.43	-0.52	7.22e-12	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg12568669	chr8:11666485	FDFT1	0.27	4.4	0.34	2.05e-5	Neuroticism;
PAAD	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.58	5.72	0.42	5.6e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.99	-0.37	1.65e-6	Neuroticism;
PAAD	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.46	4.4	0.34	2.03e-5	Menarche (age at onset);
PAAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.74	8.89	0.58	1.65e-15	Bone mineral density;
PAAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.43	4.43	0.34	1.82e-5	Red cell distribution width;
PAAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg03732007	chr1:2071316	PRKCZ	-0.45	-4.78	-0.36	4.1e-6	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22517485	chr1:150294006	PRPF3	0.56	6.42	0.46	1.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.56	5.07	0.38	1.15e-6	Testicular germ cell tumor;
PAAD	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.59	5.07	0.38	1.16e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg23283495	chr1:209979779	IRF6	0.61	5.52	0.41	1.42e-7	Coronary artery disease;
PAAD	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.5	7.12	0.5	3.94e-11	Homoarginine levels;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg04257695	chr17:30186438	C17orf79	0.71	5.19	0.39	6.53e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg20503657	chr10:835505	NA	0.5	5.29	0.39	4.17e-7	Survival in rectal cancer;
PAAD	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg01529538	chr14:23388837	RBM23	0.48	4.79	0.36	3.88e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg21665744	chr7:39171113	POU6F2	0.28	4.84	0.37	3.1e-6	IgG glycosylation;
PAAD	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-6.7	-0.48	3.72e-10	Crohn's disease;
PAAD	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg24519413	chr1:26490540	NA	0.51	4.56	0.35	1.04e-5	QRS complex (12-leadsum);
PAAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg13468214	chr4:1046988	NA	-0.56	-6.12	-0.44	7.77e-9	Recombination rate (males);
PAAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg07617317	chr6:118971624	C6orf204	0.56	4.72	0.36	5.38e-6	Diastolic blood pressure;
PAAD	cis	rs12889267	0.722	rs2319626	chr14:21565149	G/C	cg02988727	chr14:21567520	ZNF219;C14orf176	0.53	4.82	0.36	3.51e-6	Hematocrit;Resting heart rate;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12379764	chr21:47803548	PCNT	-0.45	-4.27	-0.33	3.49e-5	Testicular germ cell tumor;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg11467262	chr20:57607340	ATP5E	-0.78	-6.46	-0.46	1.33e-9	Atopic dermatitis;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	4.95e-8	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15027466	chr6:170893729	PDCD2	0.6	6.7	0.48	3.77e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02325243	chr19:19729568	PBX4	-0.62	-6.66	-0.48	4.64e-10	Smoking initiation;
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.17	-0.39	7.19e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.62	6.92	0.49	1.17e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27277034	chr3:40575533	ZNF621	-0.69	-7.61	-0.53	2.72e-12	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg23018236	chr17:30244563	NA	-0.63	-5.43	-0.4	2.2e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.49	4.66	0.35	6.87e-6	HDL cholesterol;
PAAD	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.73	-6.96	-0.49	9.59e-11	Height;
PAAD	cis	rs4919087	0.545	rs793531	chr10:99041167	G/T	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs7582720	1.000	rs78128841	chr2:203663975	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.5	0.52	4.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs3800461	0.509	rs73407707	chr6:34476644	T/G	cg14254433	chr6:34482411	PACSIN1	-1.14	-6.41	-0.46	1.76e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.47	5.14	0.38	8.34e-7	Longevity;Endometriosis;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.87	10.66	0.65	3.63e-20	Menarche (age at onset);
PAAD	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg21929781	chr1:2537748	MMEL1	-0.54	-5.67	-0.42	7.03e-8	Multiple sclerosis;
PAAD	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	6.78	0.48	2.46e-10	Leprosy;
PAAD	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg04488487	chr2:242709673	NA	0.57	4.56	0.35	1.06e-5	Fibrinogen levels;
PAAD	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg00277334	chr10:82204260	NA	-0.71	-7.46	-0.52	6.14e-12	Post bronchodilator FEV1;
PAAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.57	-6.17	-0.45	5.77e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12165864	chr7:66369176	NA	-0.8	-4.96	-0.37	1.89e-6	Diabetic kidney disease;
PAAD	cis	rs11037575	1.000	rs4620711	chr11:43713843	A/G	cg24662154	chr11:44118094	EXT2	-0.42	-4.29	-0.33	3.12e-5	Neuroblastoma;
PAAD	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	4.55	0.35	1.11e-5	Red cell distribution width;
PAAD	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg02734326	chr4:10020555	SLC2A9	0.45	4.47	0.34	1.5e-5	Bone mineral density;
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	9.2	0.6	2.56e-16	Cognitive test performance;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.63	-5.56	-0.41	1.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04850017	chr11:63683019	RCOR2	0.39	4.42	0.34	1.87e-5	Pulse pressure;
PAAD	cis	rs4262150	0.658	rs2964223	chr5:151940822	C/T	cg12297329	chr5:152029980	NA	-0.56	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9815354	1.000	rs9866759	chr3:41758418	T/C	cg03022575	chr3:42003672	ULK4	0.77	5.55	0.41	1.25e-7	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.64	-0.53	2.28e-12	Height;
PAAD	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg10547527	chr2:198650123	BOLL	0.62	4.25	0.33	3.7e-5	Ulcerative colitis;
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.66	-6.96	-0.49	9.47e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.51	5.83	0.43	3.23e-8	Obesity-related traits;
PAAD	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.79	9.14	0.6	3.8e-16	Hemoglobin concentration;
PAAD	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg22189786	chr22:42395067	WBP2NL	0.52	4.38	0.33	2.21e-5	Birth weight;
PAAD	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.34	-0.33	2.55e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4740619	0.711	rs4590533	chr9:15989766	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.64	-0.35	7.53e-6	Body mass index;
PAAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.56	-0.35	1.05e-5	Type 2 diabetes;
PAAD	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-11.5	-0.68	2.06e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.38	4.91	0.37	2.32e-6	Calcium levels;
PAAD	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.82	0.36	3.39e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.54	4.91	0.37	2.35e-6	Glycated hemoglobin levels;
PAAD	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-1.37	-12.75	-0.72	9.01e-26	Obesity-related traits;
PAAD	cis	rs116248771	0.793	rs73156465	chr3:158374535	C/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.65	-5.52	-0.41	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.34	-0.4	3.39e-7	Diastolic blood pressure;
PAAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.91	0.37	2.29e-6	Birth weight;
PAAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.47e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.34	0.46	2.47e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.91	7.1	0.5	4.49e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg15017067	chr4:17643749	FAM184B	0.39	4.4	0.34	2.05e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.53	-6.88	-0.49	1.47e-10	Height;
PAAD	cis	rs990171	0.538	rs11682754	chr2:103117095	A/G	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg13264159	chr8:625131	ERICH1	-0.64	-4.48	-0.34	1.47e-5	IgG glycosylation;
PAAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.77	6.83	0.48	1.88e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs8049603	0.739	rs4073290	chr16:23196127	A/G	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.38	0.56	3.26e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	6.66	0.48	4.78e-10	IgG glycosylation;
PAAD	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19671926	chr4:122722719	EXOSC9	-0.63	-5.36	-0.4	3.01e-7	Type 2 diabetes;
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.48	5.73	0.42	5.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.4e-5	Parkinson's disease;
PAAD	trans	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.74e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg19254793	chr6:44695348	NA	-0.45	-4.39	-0.34	2.11e-5	Total body bone mineral density;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-1.19	-11.52	-0.68	1.84e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs13242816	1.000	rs35515812	chr7:116156032	C/G	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	cis	rs11892454	0.544	rs13382805	chr2:25997569	G/A	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.46	-5.03	-0.38	1.36e-6	Heart rate;
PAAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg07617317	chr6:118971624	C6orf204	0.53	4.51	0.34	1.26e-5	Diastolic blood pressure;
PAAD	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg08999081	chr20:33150536	PIGU	0.51	5.44	0.4	2.11e-7	Height;
PAAD	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8179	0.761	rs42034	chr7:92239144	A/G	cg03496780	chr7:92466842	CDK6	0.47	4.27	0.33	3.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs7301826	0.651	rs10848209	chr12:131311272	A/G	cg11011512	chr12:131303247	STX2	0.49	5.0	0.38	1.57e-6	Plasma plasminogen activator levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08652337	chr7:127228477	ARF5	0.58	6.49	0.47	1.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs863345	0.604	rs949397	chr1:158461951	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg07169764	chr2:136633963	MCM6	0.6	5.44	0.4	2.04e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs9815354	1.000	rs9834098	chr3:41833493	A/G	cg03022575	chr3:42003672	ULK4	0.8	5.99	0.44	1.43e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.76	7.05	0.5	5.97e-11	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.27	0.56	6.29e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.3	-0.33	3.06e-5	Blood protein levels;
PAAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2882667	0.589	rs825770	chr5:138115219	T/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.51	5.15	0.39	7.79e-7	Lung cancer;
PAAD	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.63	-7.11	-0.5	4.15e-11	Platelet distribution width;
PAAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.72	8.58	0.57	1.03e-14	Bone mineral density;
PAAD	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.61	-0.35	8.35e-6	Type 2 diabetes;
PAAD	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.9e-17	Educational attainment;
PAAD	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.5	0.41	1.55e-7	Bipolar disorder;
PAAD	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg06713675	chr4:122721982	EXOSC9	0.45	4.38	0.34	2.16e-5	Type 2 diabetes;
PAAD	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.66	-6.57	-0.47	7.37e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg15181151	chr6:150070149	PCMT1	-0.63	-6.85	-0.49	1.76e-10	Lung cancer;
PAAD	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-4.58	-0.35	9.43e-6	Menopause (age at onset);
PAAD	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.93	10.63	0.65	4.4e-20	Colorectal adenoma (advanced);
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg04204118	chr10:4194429	NA	0.81	4.64	0.35	7.42e-6	Major depressive disorder;
PAAD	cis	rs2594989	0.943	rs62245869	chr3:11439820	G/A	cg01796438	chr3:11312864	ATG7	-0.6	-4.55	-0.35	1.08e-5	Circulating chemerin levels;
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.45	4.99	0.38	1.64e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.59	-4.99	-0.38	1.62e-6	Neutrophil percentage of white cells;
PAAD	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26926768	chr12:34528122	NA	0.4	4.86	0.37	2.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.83	-7.53	-0.52	4.23e-12	Pancreatic cancer;
PAAD	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.68	8.39	0.56	3.1e-14	Dupuytren's disease;
PAAD	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg16898833	chr6:26189333	HIST1H4D	0.88	5.06	0.38	1.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7567389	0.710	rs72848615	chr2:128133598	T/A	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.73	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.25	-0.51	1.99e-11	Response to antipsychotic treatment;
PAAD	cis	rs6690583	0.560	rs1561460	chr1:85545423	A/G	cg12037450	chr1:85513124	MCOLN3	-0.51	-4.52	-0.34	1.26e-5	Serum sulfate level;
PAAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs288342	0.797	rs288291	chr2:183631835	G/C	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg18939081	chr1:31884902	SERINC2	0.48	5.32	0.4	3.65e-7	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12212336	chr2:231577353	CAB39	0.65	6.82	0.48	1.99e-10	Obesity-related traits;
PAAD	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07530681	chr19:40971904	SPTBN4;BLVRB	-0.68	-7.01	-0.49	7.42e-11	Smoking initiation;
PAAD	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.99	-7.25	-0.51	2.01e-11	Alzheimer's disease;
PAAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg05754148	chr16:3507555	NAT15	-0.61	-5.38	-0.4	2.83e-7	Tuberculosis;
PAAD	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs6466055	0.686	rs56269269	chr7:104846634	G/A	cg04380332	chr7:105027541	SRPK2	0.51	4.93	0.37	2.18e-6	Schizophrenia;
PAAD	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.68	6.73	0.48	3.27e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg23331303	chr5:5135948	NA	0.45	6.49	0.47	1.15e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.7	-7.13	-0.5	3.8e-11	Neurofibrillary tangles;
PAAD	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg10978503	chr1:24200527	CNR2	0.49	5.78	0.42	4.02e-8	Immature fraction of reticulocytes;
PAAD	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.45	5.79	0.43	3.85e-8	Ulcerative colitis;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02244288	chr16:89573955	SPG7	-0.31	-4.33	-0.33	2.66e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg07689907	chr11:61582574	FADS1	0.49	4.71	0.36	5.51e-6	Trans fatty acid levels;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.86	-8.1	-0.55	1.65e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.3	-0.39	4e-7	Common traits (Other);
PAAD	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.62	5.42	0.4	2.34e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg27455613	chr17:80820699	TBCD	-0.47	-4.7	-0.36	5.84e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.72	-8.25	-0.56	6.9e-14	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs4281086	0.965	rs10105841	chr8:10380826	A/G	cg01072821	chr8:10382165	T-SP1	0.45	4.33	0.33	2.67e-5	Obesity-related traits;
PAAD	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.79	7.87	0.54	6.16e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7561149	0.934	rs13006510	chr2:179682878	C/G	cg03283842	chr2:179343803	FKBP7;PLEKHA3;MIR548N	0.43	4.34	0.33	2.6e-5	QT interval;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg04160749	chr8:58172571	NA	-0.68	-4.63	-0.35	7.73e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.77	6.09	0.44	8.85e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.46	4.56	0.35	1.06e-5	Birth weight;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.41	-0.52	7.98e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg05082376	chr22:42548792	NA	-0.48	-4.72	-0.36	5.28e-6	Schizophrenia;
PAAD	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg02555727	chr12:129281546	SLC15A4	0.44	4.62	0.35	8.12e-6	Systemic lupus erythematosus;
PAAD	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	5.32	0.4	3.67e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-1.07	-14.94	-0.77	1.23e-31	Systemic lupus erythematosus;
PAAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg19337854	chr7:99768885	GPC2	-0.46	-5.02	-0.38	1.42e-6	Coronary artery disease;
PAAD	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00079375	chr15:79125835	NA	0.43	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12988843	chr13:53029588	CKAP2	0.58	6.42	0.46	1.64e-9	Myopia (pathological);
PAAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.47	0.34	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.25	0.33	3.73e-5	Resting heart rate;
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.9	9.94	0.63	3.06e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.76	-7.95	-0.54	4.01e-13	Vitiligo;
PAAD	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.79	9.25	0.6	1.93e-16	Colorectal cancer;
PAAD	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	1.09	8.63	0.57	7.47e-15	Corneal structure;
PAAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs427941	0.703	rs201443	chr7:101737688	A/T	cg06246474	chr7:101738831	CUX1	0.45	4.64	0.35	7.48e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs1198430	0.759	rs1198438	chr1:23749557	C/G	cg19827787	chr1:23763612	ASAP3	0.55	4.68	0.36	6.2e-6	Total cholesterol levels;
PAAD	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg10556349	chr10:835070	NA	0.68	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg06131755	chr6:160182447	ACAT2	0.52	4.33	0.33	2.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20392105	chr7:150755038	CDK5	-0.72	-6.37	-0.46	2.16e-9	Neuroticism;
PAAD	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg11262906	chr1:85462892	MCOLN2	-0.59	-4.6	-0.35	8.81e-6	Serum sulfate level;
PAAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.53	0.57	1.4e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.26	-0.33	3.57e-5	Red blood cell count;
PAAD	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.39	-4.7	-0.36	5.89e-6	Lewy body disease;
PAAD	cis	rs11168618	0.509	rs2731103	chr12:48884756	C/A	cg01881778	chr12:48919444	OR8S1	0.45	4.54	0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs2790216	1.000	rs1698468	chr10:59961590	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2108225	0.749	rs4730265	chr7:107439109	G/C	cg18560240	chr7:107437656	SLC26A3	-0.48	-4.46	-0.34	1.62e-5	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg17105886	chr17:28927953	LRRC37B2	0.7	4.75	0.36	4.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.54	-6.57	-0.47	7.64e-10	Iron status biomarkers;
PAAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs499368	0.519	rs216246	chr12:310466	C/G	cg23063825	chr12:298151	NA	0.49	5.59	0.41	1.05e-7	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg08316699	chr6:150357289	NA	0.38	4.38	0.33	2.19e-5	Alopecia areata;
PAAD	trans	rs2725236	0.520	rs7685225	chr4:88906458	T/C	cg23656380	chr20:60877581	ADRM1	-0.64	-6.62	-0.47	5.81e-10	Caffeine consumption;
PAAD	cis	rs2481665	0.680	rs2481671	chr1:62611666	A/C	cg18591186	chr1:62594603	INADL	-0.49	-4.45	-0.34	1.68e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg02887458	chr19:19495540	GATAD2A	-0.61	-5.4	-0.4	2.5e-7	Bipolar disorder;
PAAD	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.82	-9.44	-0.61	6.07e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.73	-0.36	5.17e-6	Breast cancer;
PAAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.07	-8.34	-0.56	4.18e-14	Diabetic kidney disease;
PAAD	cis	rs1867485	1.000	rs1867485	chr16:86681031	A/G	cg08058434	chr16:85832378	COX4NB;COX4I1	-0.49	-4.59	-0.35	9.03e-6	Obesity-related traits;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.58	-5.94	-0.43	1.83e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05020775	chr20:1246934	SNPH	0.55	6.37	0.46	2.09e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg12437481	chr16:420112	MRPL28	-0.59	-5.12	-0.38	9.09e-7	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-15.31	-0.78	1.34e-32	Height;
PAAD	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg14343924	chr8:8086146	FLJ10661	-0.53	-4.64	-0.35	7.35e-6	Joint mobility (Beighton score);
PAAD	cis	rs7707921	0.646	rs226208	chr5:81603444	G/A	cg21483461	chr5:81570383	RPS23	0.53	5.14	0.38	8.29e-7	Breast cancer;
PAAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.71	-0.36	5.6e-6	Personality dimensions;
PAAD	cis	rs1372356	0.816	rs4144361	chr14:88533234	C/T	cg18078958	chr14:88630771	NA	-0.49	-6.17	-0.45	5.98e-9	Food antigen IgG levels;
PAAD	cis	rs11133665	0.683	rs7719875	chr5:1190088	A/G	cg18396527	chr5:1225355	SLC6A18	0.38	4.4	0.34	2e-5	Urinary metabolites;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg01371477	chr1:150207822	ANP32E	-0.48	-4.35	-0.33	2.49e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.58	-5.37	-0.4	2.89e-7	Cognitive test performance;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.93	-0.54	4.47e-13	Blood metabolite levels;
PAAD	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg14146966	chr2:61757674	XPO1	0.38	4.63	0.35	7.72e-6	Tuberculosis;
PAAD	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.7	7.14	0.5	3.64e-11	Schizophrenia;
PAAD	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.66	5.31	0.4	3.8e-7	Morning vs. evening chronotype;
PAAD	cis	rs11563648	0.517	rs2269728	chr7:127032580	A/G	cg21885361	chr7:127911034	NA	-0.42	-4.51	-0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg09796270	chr17:17721594	SREBF1	0.46	4.91	0.37	2.33e-6	Total body bone mineral density;
PAAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.92	10.89	0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1371614	0.566	rs11695406	chr2:27178129	A/G	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.28e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6908034	0.607	rs62404179	chr6:19806272	T/C	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg19423196	chr10:82049429	MAT1A	0.54	5.09	0.38	1.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20634234	chr2:223520845	FARSB	0.66	7.09	0.5	4.67e-11	Myopia (pathological);
PAAD	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.6	5.03	0.38	1.37e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4742903	0.904	rs10114234	chr9:107003646	C/T	cg14250997	chr9:106856677	SMC2	-0.42	-4.5	-0.34	1.36e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs858239	0.899	rs10262243	chr7:23290987	G/A	cg27449745	chr7:23145252	KLHL7	-0.52	-4.61	-0.35	8.61e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.8	7.31	0.51	1.41e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.47	5.41	0.4	2.41e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.51	-0.34	1.26e-5	Joint mobility (Beighton score);
PAAD	cis	rs761746	0.579	rs5998126	chr22:32178402	T/C	cg01338084	chr22:32026380	PISD	0.59	5.04	0.38	1.33e-6	Intelligence;
PAAD	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14241672	chr4:1714399	SLBP	0.58	6.58	0.47	7.31e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg19673125	chr6:150240577	RAET1G	0.32	4.27	0.33	3.48e-5	Lung cancer;
PAAD	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6929137	0.632	rs3020313	chr6:151961900	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.53	-0.34	1.21e-5	Bone mineral density (spine);
PAAD	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.78	-8.92	-0.59	1.43e-15	Age at first birth;
PAAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.9100000000000004e-06	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.41	0.65	1.72e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9715521	0.718	rs7441564	chr4:59845405	A/T	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg13119609	chr19:45449297	APOC2	-0.42	-4.77	-0.36	4.28e-6	Blood protein levels;
PAAD	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg13767294	chr17:41856619	C17orf105;DUSP3	0.5	4.26	0.33	3.6e-5	Triglycerides;
PAAD	cis	rs2637266	1.000	rs2579761	chr10:78321040	C/T	cg18941641	chr10:78392320	NA	0.4	4.98	0.37	1.69e-6	Pulmonary function;
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.57	0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.66	-6.09	-0.44	8.77e-9	Multiple myeloma;
PAAD	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.47	-4.52	-0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs13217239	0.511	rs3800314	chr6:27236048	T/G	cg12292205	chr6:26970375	C6orf41	-0.44	-4.41	-0.34	1.98e-5	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs13177918	0.717	rs6874318	chr5:149842399	C/T	cg04670168	chr5:150039249	MYOZ3	0.43	4.26	0.33	3.56e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.83	0.37	3.24e-6	Height;
PAAD	cis	rs2046867	0.908	rs28822756	chr3:72825011	C/T	cg25664220	chr3:72788482	NA	-0.72	-7.28	-0.51	1.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.89	0.49	1.4e-10	Schizophrenia;
PAAD	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-1.09	-6.02	-0.44	1.22e-8	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.87	10.81	0.66	1.43e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9463078	0.546	rs10948191	chr6:44947281	G/T	cg18551225	chr6:44695536	NA	-0.41	-4.34	-0.33	2.56e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg01831904	chr17:28903510	LRRC37B2	0.78	6.01	0.44	1.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17155006	0.746	rs402264	chr7:107748337	G/A	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.64	5.02	0.38	1.44e-6	Serum sulfate level;
PAAD	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg23024343	chr7:107201750	COG5	-0.51	-4.33	-0.33	2.67e-5	Coronary artery disease;
PAAD	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg03910582	chr17:19030146	GRAPL	0.45	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.52	-5.91	-0.43	2.15e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	10.0	0.63	2.13e-18	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.78	-7.0	-0.49	7.68e-11	Neuroticism;
PAAD	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.43	5.72	0.42	5.51e-8	Mean corpuscular volume;
PAAD	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	4.92	0.37	2.2e-6	Oropharynx cancer;
PAAD	cis	rs258892	0.843	rs16901116	chr5:72053382	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg02869306	chr7:64672164	INTS4L1	0.42	4.89	0.37	2.52e-6	Aortic root size;
PAAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.79	0.66	1.64e-20	Parkinson's disease;
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg07395648	chr5:131743802	NA	-0.76	-7.89	-0.54	5.59e-13	Blood metabolite levels;
PAAD	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.0	0.49	7.75e-11	Hemoglobin concentration;
PAAD	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.48	-5.34	-0.4	3.31e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-1.07	-19.6	-0.85	1.87e-43	Urate levels in lean individuals;
PAAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg00982548	chr2:198649783	BOLL	-0.68	-4.95	-0.37	1.92e-6	Ulcerative colitis;
PAAD	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.96	12.53	0.71	3.55e-25	Menarche (age at onset);
PAAD	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.51	5.77	0.42	4.34e-8	QRS complex (12-leadsum);
PAAD	cis	rs797680	0.822	rs6541401	chr1:93738948	G/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.43	-0.34	1.76e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg23033748	chr14:75592666	NEK9	0.41	5.04	0.38	1.33e-6	Height;
PAAD	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.58	-5.35	-0.4	3.24e-7	Corneal structure;
PAAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg18016565	chr1:150552671	MCL1	-0.52	-5.31	-0.4	3.84e-7	Tonsillectomy;
PAAD	trans	rs901683	1.000	rs9422651	chr10:46047456	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg23024343	chr7:107201750	COG5	0.56	4.59	0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs7084783	0.519	rs10879	chr10:105354556	A/G	cg09754828	chr10:105363329	SH3PXD2A	-0.46	-4.51	-0.34	1.28e-5	Fear of pain;
PAAD	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.69	7.0	0.49	7.52e-11	Prostate cancer;
PAAD	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.16	-0.5	3.16e-11	Diastolic blood pressure;
PAAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.43	0.46	1.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.49e-9	Cognitive function;
PAAD	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.83	-0.54	7.86e-13	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.43e-8	Alzheimer's disease;
PAAD	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-5.58	-0.41	1.09e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10490147	chr1:11120546	SRM	-0.67	-7.09	-0.5	4.65e-11	Smoking initiation;
PAAD	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg00262122	chr8:11665843	FDFT1	-0.62	-5.42	-0.4	2.33e-7	Neuroticism;
PAAD	cis	rs8038465	0.615	rs11637315	chr15:73944068	G/C	cg15420318	chr15:73925796	NPTN	0.51	5.02	0.38	1.45e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02228815	chr15:31685131	NA	-0.53	-6.61	-0.47	6.05e-10	Body fat percentage;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.11	0.44	7.89e-9	Alzheimer's disease;
PAAD	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs1144333	0.655	rs4949685	chr1:76463270	A/T	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg21698718	chr17:80085957	CCDC57	0.39	4.26	0.33	3.51e-5	Life satisfaction;
PAAD	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.41	4.72	0.36	5.41e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05666200	chr11:89790683	NA	-0.57	-4.42	-0.34	1.85e-5	White blood cell types;
PAAD	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg00531865	chr16:30841666	NA	-0.51	-4.68	-0.35	6.35e-6	Dementia with Lewy bodies;
PAAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13984515	chr1:86046961	CYR61	-0.57	-6.69	-0.48	4.02e-10	Body fat percentage;
PAAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg22710661	chr11:17411071	KCNJ11	0.45	4.53	0.35	1.18e-5	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17021725	chr1:178694150	RALGPS2	0.62	7.07	0.5	5.37e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg18370025	chr7:2749541	AMZ1	-0.39	-4.74	-0.36	4.9100000000000004e-06	Height;
PAAD	cis	rs7765175	0.698	rs34133524	chr6:113667078	A/T	cg19037598	chr6:113666021	NA	-0.41	-4.39	-0.34	2.1e-5	Coronary artery calcification;
PAAD	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20487152	chr13:99095054	FARP1	-0.47	-4.54	-0.35	1.12e-5	Longevity;
PAAD	cis	rs59888335	0.964	rs11716999	chr3:80688389	T/C	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	trans	rs4915077	1.000	rs78326196	chr1:108377132	C/G	cg18565342	chr10:124714098	C10orf88	-1.2	-6.4	-0.46	1.79e-9	Hypothyroidism;
PAAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg12215294	chr3:40350768	EIF1B	-0.45	-4.44	-0.34	1.72e-5	Renal cell carcinoma;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.81	6.84	0.49	1.78e-10	Alzheimer's disease;
PAAD	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg02696790	chr15:75250997	RPP25	-0.4	-4.69	-0.36	6.01e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12376770	chr5:133512872	SKP1	0.59	6.68	0.48	4.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg09163369	chr1:210001066	C1orf107	0.68	6.41	0.46	1.69e-9	Orofacial clefts;
PAAD	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg02297831	chr4:17616191	MED28	0.58	5.45	0.4	1.96e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.87e-8	Blood protein levels;
PAAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.73	7.24	0.51	2.08e-11	DNA methylation (variation);
PAAD	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.71	-5.2	-0.39	6.41e-7	Type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg26816564	chr1:7831052	VAMP3	0.81	6.15	0.45	6.63e-9	Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-1.14	-6.29	-0.45	3.26e-9	Inflammatory biomarkers;
PAAD	cis	rs300774	0.925	rs300708	chr2:140449	A/G	cg23649280	chr2:140451	NA	-0.5	-4.8	-0.36	3.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.81	5.23	0.39	5.42e-7	Height;
PAAD	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg24330906	chr2:85765176	MAT2A	0.43	4.34	0.33	2.57e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.72	5.03	0.38	1.37e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg25937216	chr8:58172855	NA	-0.83	-7.53	-0.52	4.17e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg02725872	chr8:58115012	NA	-0.6	-5.16	-0.39	7.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.42	-5.53	-0.41	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg21905437	chr5:178450457	ZNF879	0.6	5.0	0.38	1.57e-6	Pubertal anthropometrics;
PAAD	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.51	0.41	1.52e-7	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02207312	chr11:60674164	PRPF19	0.57	6.37	0.46	2.14e-9	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg22705602	chr4:152727874	NA	-0.5	-5.33	-0.4	3.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.53	-6.35	-0.46	2.32e-9	Lewy body disease;
PAAD	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3136441	1.000	rs4752932	chr11:46773354	T/C	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.46	5.09	0.38	1.04e-6	Blood protein levels;
PAAD	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg16928487	chr17:17741425	SREBF1	0.38	5.06	0.38	1.22e-6	Total body bone mineral density;
PAAD	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.39	-0.4	2.63e-7	Total cholesterol levels;
PAAD	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.65	7.43	0.52	7.12e-12	Dupuytren's disease;
PAAD	cis	rs10483554	0.671	rs2816748	chr14:49812198	C/T	cg24879595	chr14:50359859	ARF6	-0.55	-4.31	-0.33	2.9e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite levels;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg16606324	chr3:10149918	C3orf24	0.57	4.81	0.36	3.53e-6	Alzheimer's disease;
PAAD	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.56	-7.12	-0.5	3.96e-11	Longevity;
PAAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg00149659	chr3:10157352	C3orf10	0.54	4.25	0.33	3.69e-5	Alzheimer's disease;
PAAD	cis	rs7487075	0.578	rs4072304	chr12:46826187	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.58	0.35	9.73e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs1999930	0.505	rs1416190	chr6:116240514	T/A	cg18764771	chr6:116381957	FRK	0.32	4.95	0.37	1.96e-6	Age-related macular degeneration;
PAAD	cis	rs62025270	0.688	rs62025272	chr15:86313622	G/A	cg13263323	chr15:86062960	AKAP13	0.56	5.01	0.38	1.49e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs35082559	1	rs35082559	chr2:23896606	CA/C	cg08917208	chr2:24149416	ATAD2B	0.64	5.81	0.43	3.54e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg10494973	chr17:80897199	TBCD	0.57	4.58	0.35	9.52e-6	Breast cancer;
PAAD	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg23254163	chr1:152506842	NA	-0.57	-6.6	-0.47	6.45e-10	Hair morphology;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.4	4.64	0.35	7.58e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.74	-5.65	-0.42	7.8e-8	Crohn's disease;
PAAD	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.59	6.09	0.44	8.81e-9	Coronary artery disease;
PAAD	cis	rs7547997	0.615	rs34591069	chr1:158316990	G/C	cg26014409	chr1:158324471	CD1E	0.37	4.63	0.35	7.65e-6	QRS duration;
PAAD	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.53	6.17	0.45	5.84e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg05562828	chr17:3906858	NA	0.54	5.99	0.44	1.47e-8	Type 2 diabetes;
PAAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.45	8.16	0.55	1.16e-13	Multiple system atrophy;
PAAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	9.48	0.61	5.01e-17	Total body bone mineral density;
PAAD	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.64	0.42	8.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs8105895	0.935	rs75025987	chr19:22230669	T/A	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg03676636	chr4:99064102	C4orf37	0.27	4.55	0.35	1.08e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.66	7.06	0.5	5.46e-11	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.23e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.72	5.84	0.43	3.04e-8	Common traits (Other);
PAAD	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.71	7.23	0.51	2.23e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.55	-5.03	-0.38	1.37e-6	Obesity-related traits;
PAAD	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.59	5.66	0.42	7.46e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg08926642	chr1:7887455	PER3	0.5	4.34	0.33	2.63e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs727479	0.962	rs4775935	chr15:51519276	T/G	cg21478137	chr15:51532386	CYP19A1	0.62	6.94	0.49	1.07e-10	Estradiol levels;
PAAD	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26876637	chr1:152193138	HRNR	-0.85	-6.8	-0.48	2.3e-10	Atopic dermatitis;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.79	8.18	0.55	1.03e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.75	-5.12	-0.38	9.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.65	-4.72	-0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.93	9.83	0.62	6.03e-18	Cognitive function;
PAAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.19	-0.39	6.77e-7	Diastolic blood pressure;
PAAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg03983715	chr16:68378420	PRMT7	-0.84	-6.19	-0.45	5.43e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.69	-8.46	-0.57	2.09e-14	Bone mineral density;
PAAD	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-5.31	-0.4	3.89e-7	Electroencephalogram traits;
PAAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.12	0.38	9.16e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.55	-5.01	-0.38	1.52e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21515243	chr18:21033072	RIOK3	0.63	6.91	0.49	1.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.53	4.4	0.34	2.01e-5	Type 2 diabetes;
PAAD	cis	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	1.000	rs36054203	chr10:46037861	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19671926	chr4:122722719	EXOSC9	0.59	5.72	0.42	5.55e-8	Type 2 diabetes;
PAAD	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-4.51	-0.34	1.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg12623918	chr2:306882	NA	0.45	4.59	0.35	9.4e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1065656	0.581	rs2575351	chr16:1836709	G/C	cg26897989	chr16:1907736	C16orf73	0.52	4.81	0.36	3.6e-6	Insulin-like growth factors;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.94	12.14	0.7	3.9e-24	Prudent dietary pattern;
PAAD	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg23127183	chr11:57508653	C11orf31	-0.5	-4.39	-0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.05e-5	Platelet count;
PAAD	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg03684893	chr10:554711	DIP2C	-0.4	-4.36	-0.33	2.38e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs10736390	0.538	rs12410550	chr1:55107306	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.81	-8.64	-0.57	7.22e-15	Survival in pancreatic cancer;
PAAD	cis	rs75920871	0.841	rs112151056	chr11:116919368	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00811796	chr7:129073727	FAM40B	0.59	6.54	0.47	8.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6787391	0.545	rs9876432	chr3:4761185	G/A	cg11584376	chr3:4789075	ITPR1	-0.44	-4.93	-0.37	2.11e-6	Breast cancer;
PAAD	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.67	6.71	0.48	3.62e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4594175	0.707	rs4901096	chr14:51722826	G/C	cg23942311	chr14:51606299	NA	0.56	5.19	0.39	6.6e-7	Cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13690588	chr1:28415118	EYA3	0.66	6.6	0.47	6.33e-10	Primary biliary cholangitis;
PAAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.83	8.1	0.55	1.63e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.34	-4.55	-0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.67	-0.48	4.39e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-6.0	-0.44	1.4e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg00540400	chr15:79124168	NA	-0.5	-5.49	-0.41	1.69e-7	Coronary artery disease;
PAAD	cis	rs1349882	0.560	rs1454382	chr2:52918929	C/T	cg08239893	chr2:52221668	NA	-0.38	-4.39	-0.34	2.11e-5	Asymmetrical dimethylarginine levels;
PAAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg26174226	chr8:58114915	NA	0.66	5.93	0.43	1.94e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.97	-7.33	-0.51	1.26e-11	Multiple sclerosis;
PAAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.54	5.03	0.38	1.35e-6	Airway imaging phenotypes;
PAAD	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.9	-10.76	-0.66	2.02e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-8.03	-0.55	2.54e-13	Total body bone mineral density;
PAAD	cis	rs7101378	0.577	rs6589047	chr11:108902062	T/C	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14159672	chr1:205819179	PM20D1	-0.47	-4.31	-0.33	2.86e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.74	-0.36	4.88e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.16	-0.45	6.34e-9	Glioblastoma;
PAAD	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.55	-4.9	-0.37	2.42e-6	Testicular germ cell tumor;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg11416102	chr8:651193	ERICH1	0.98	5.91	0.43	2.14e-8	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg21724239	chr8:58056113	NA	0.7	5.18	0.39	6.87e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs16944613	0.510	rs4932353	chr15:91145838	T/C	cg15547629	chr15:90437138	AP3S2	-0.5	-4.32	-0.33	2.82e-5	Colorectal cancer;
PAAD	cis	rs7264396	0.887	rs58458373	chr20:34045611	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21659725	chr3:3221576	CRBN	0.74	7.18	0.5	2.9e-11	Resting heart rate;
PAAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg10556349	chr10:835070	NA	0.53	4.35	0.33	2.51e-5	Eosinophil percentage of granulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19370980	chr7:94537747	PPP1R9A	0.62	6.94	0.49	1.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	1.0	8.18	0.55	1.03e-13	Initial pursuit acceleration;
PAAD	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10426930	0.816	rs2620809	chr19:5062488	A/G	cg08036796	chr19:5034282	KDM4B	-0.46	-4.66	-0.35	6.81e-6	Monocyte percentage of white cells;
PAAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-4.98	-0.37	1.71e-6	Self-reported allergy;
PAAD	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.73	7.71	0.53	1.55e-12	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.79	5.74	0.42	5.05e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.74	6.95	0.49	1.03e-10	Obesity-related traits;
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	4.93	0.37	2.15e-6	Eosinophil percentage of white cells;
PAAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.47	-0.52	5.94e-12	Coronary artery disease;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.24	12.35	0.71	1.08e-24	Platelet count;
PAAD	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg10556349	chr10:835070	NA	0.54	4.26	0.33	3.58e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.6	5.86	0.43	2.8e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg00262122	chr8:11665843	FDFT1	-0.55	-4.54	-0.35	1.15e-5	Neuroticism;
PAAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.66	0.35	6.8e-6	Blood metabolite levels;
PAAD	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.56	-0.35	1.05e-5	Atopic dermatitis;
PAAD	cis	rs758324	0.812	rs6893957	chr5:131198780	T/C	cg06307176	chr5:131281290	NA	0.52	4.54	0.35	1.13e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-1.24	-12.27	-0.71	1.78e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.67	-6.59	-0.47	6.79e-10	Total body bone mineral density;
PAAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs11825685	0.887	rs35430067	chr11:134561893	G/A	cg02089395	chr11:134479357	NA	-0.72	-4.53	-0.34	1.21e-5	IgG glycosylation;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.84	-0.37	3.12e-6	Bipolar disorder;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg07202610	chr7:1142643	C7orf50	-0.63	-4.44	-0.34	1.71e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs6539288	0.705	rs1053051	chr12:107367225	T/C	cg22764639	chr12:106532701	NUAK1	0.46	4.71	0.36	5.56e-6	Total body bone mineral density;
PAAD	cis	rs303386	0.651	rs303387	chr1:99589424	C/T	cg03593336	chr1:99471295	LPPR5	0.52	4.87	0.37	2.78e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.84	-7.17	-0.5	3.01e-11	Alzheimer's disease;
PAAD	cis	rs8005172	0.750	rs12587119	chr14:88443665	A/G	cg18078958	chr14:88630771	NA	0.47	5.39	0.4	2.67e-7	Parkinson's disease;
PAAD	trans	rs61677309	1.000	rs1945765	chr11:118182829	T/A	cg15548380	chr1:19984784	NBL1	-0.62	-6.43	-0.46	1.57e-9	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg16606324	chr3:10149918	C3orf24	0.6	4.49	0.34	1.37e-5	Alzheimer's disease;
PAAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.75	0.42	4.84e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg22875332	chr1:76189707	ACADM	-0.49	-4.95	-0.37	1.94e-6	Daytime sleep phenotypes;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.79	0.58	2.98e-15	Lung cancer;
PAAD	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-1.07	-15.19	-0.78	2.77e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.77	9.28	0.6	1.67e-16	Bladder cancer;
PAAD	cis	rs1870584	0.524	rs62062052	chr17:11899977	T/C	cg18951537	chr17:11950516	MAP2K4	0.47	4.46	0.34	1.59e-5	Response to amphetamines;
PAAD	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.68	7.46	0.52	6.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.46	4.82	0.36	3.38e-6	Motion sickness;
PAAD	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg01426195	chr3:39028469	NA	-0.71	-7.23	-0.51	2.14e-11	Handedness;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.81e-15	Lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24265806	chr7:23053737	FAM126A	0.56	6.81	0.48	2.12e-10	Metabolite levels  (X-11787);
PAAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg02016764	chr4:38805732	TLR1	-0.55	-4.35	-0.33	2.53e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21704491	chr20:388519	RBCK1	0.67	6.62	0.47	5.79e-10	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg18867708	chr6:26865862	GUSBL1	-0.44	-4.48	-0.34	1.48e-5	Schizophrenia;
PAAD	cis	rs16958440	0.708	rs62096462	chr18:44625179	C/G	cg17192377	chr18:44677553	HDHD2	0.62	4.37	0.33	2.28e-5	Sitting height ratio;
PAAD	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-4.94	-0.37	2.01e-6	Asthma;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg00024416	chr22:24240387	NA	-0.49	-4.89	-0.37	2.51e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-1.09	-8.48	-0.57	1.79e-14	Post bronchodilator FEV1;
PAAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg25452165	chr22:42524984	CYP2D6	0.51	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs28830936	0.966	rs28680296	chr15:42121538	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.84	-0.49	1.83e-10	Diastolic blood pressure;
PAAD	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.93	-9.78	-0.62	7.78e-18	Urate levels in obese individuals;
PAAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg00990874	chr7:1149470	C7orf50	-0.73	-5.69	-0.42	6.22e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19663209	chr19:14116533	RFX1	0.69	7.99	0.54	3.04e-13	Monocyte percentage of white cells;
PAAD	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.7	-7.04	-0.5	6.36e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.54	6.24	0.45	4.17e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg21300403	chr2:198650112	BOLL	-0.64	-4.43	-0.34	1.79e-5	Ulcerative colitis;
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.63	6.68	0.48	4.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.18	-0.45	5.7e-9	Monocyte count;
PAAD	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.74	8.31	0.56	4.89e-14	Corneal astigmatism;
PAAD	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg09659197	chr4:152720779	NA	0.46	6.13	0.45	7.23e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs490234	0.841	rs476819	chr9:128362737	C/T	cg14078157	chr9:128172775	NA	-0.44	-4.97	-0.37	1.81e-6	Mean arterial pressure;
PAAD	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.71	-0.48	3.7e-10	Neuroticism;
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg27394845	chr17:28928406	LRRC37B2	0.63	4.46	0.34	1.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4704187	0.640	rs1600075	chr5:74418304	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.47	0.74	1.05e-27	Platelet count;
PAAD	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21545522	chr1:205238299	TMCC2	0.46	4.3	0.33	3.06e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10450586	0.932	rs10160456	chr11:27336704	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.95	6.12	0.44	7.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7934083	0.935	rs10897829	chr11:81202696	C/G	cg25314284	chr11:80998251	NA	-0.45	-4.5	-0.34	1.32e-5	Schizophrenia;
PAAD	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.54	7.59	0.52	2.96e-12	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.63	5.43	0.4	2.2e-7	Corneal structure;
PAAD	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.48	5.31	0.4	3.79e-7	Heart rate;
PAAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7009110	0.706	rs13272328	chr8:81280496	T/C	cg21158561	chr8:81178149	NA	0.44	4.69	0.36	5.94e-6	Asthma and hay fever;
PAAD	cis	rs2120243	0.539	rs10936086	chr3:157099859	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.53	0.35	1.16e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.57	-5.26	-0.39	4.82e-7	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06896044	chr16:2222637	TRAF7	0.58	6.5	0.47	1.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.76	6.11	0.44	8.19e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7737355	0.773	rs10040578	chr5:130950232	C/T	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.78e-5	Life satisfaction;
PAAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg23346134	chr3:49453900	TCTA	0.4	4.27	0.33	3.4e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.38	-5.46	-0.4	1.92e-7	Educational attainment (years of education);
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.56	6.86	0.49	1.62e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.72	7.9	0.54	5.14e-13	Eye color traits;
PAAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.74	8.47	0.57	1.92e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.54	-5.99	-0.44	1.45e-8	Mean corpuscular volume;
PAAD	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.67	-7.23	-0.51	2.17e-11	Morning vs. evening chronotype;
PAAD	cis	rs16910800	1.000	rs1531808	chr11:23194465	C/A	cg20040320	chr11:23191996	NA	-0.6	-5.12	-0.38	9.22e-7	Cancer;
PAAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.26e-8	Alcohol dependence;
PAAD	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg07828024	chr6:149772892	ZC3H12D	-0.36	-4.76	-0.36	4.47e-6	Dupuytren's disease;
PAAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.35	0.46	2.41e-9	Height;
PAAD	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.73	-8.22	-0.55	8.18e-14	Dental caries;
PAAD	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.9	7.2	0.5	2.65e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.93	0.37	2.15e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg22705602	chr4:152727874	NA	-0.48	-5.18	-0.39	7.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	7.08	0.5	4.98e-11	Body mass index;
PAAD	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.71	6.98	0.49	8.6e-11	Uric acid levels;
PAAD	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-1.14	-7.71	-0.53	1.53e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg19640130	chr10:64028056	RTKN2	0.38	4.62	0.35	8.24e-6	Rheumatoid arthritis;
PAAD	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.54	-0.41	1.27e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg23173402	chr1:227635558	NA	0.72	4.71	0.36	5.65e-6	Major depressive disorder;
PAAD	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.69	-6.69	-0.48	4.09e-10	Parkinson's disease;
PAAD	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg19039313	chr2:136634366	MCM6	-0.51	-4.33	-0.33	2.74e-5	Corneal structure;
PAAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg23463467	chr20:60627584	TAF4	0.44	4.85	0.37	3e-6	Body mass index;
PAAD	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.58	6.32	0.46	2.72e-9	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-0.96	-6.41	-0.46	1.73e-9	Breast cancer;
PAAD	cis	rs1185460	1.000	rs4614	chr11:118952371	A/G	cg23280166	chr11:118938394	VPS11	0.54	5.5	0.41	1.6e-7	Coronary artery disease;
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.29	-0.33	3.14e-5	Tonsillectomy;
PAAD	cis	rs12989701	0.877	rs13029812	chr2:127872622	A/G	cg00091827	chr2:127863656	BIN1	0.6	4.54	0.35	1.14e-5	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15148028	chr1:245755268	KIF26B	-0.56	-6.52	-0.47	9.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.18	-10.17	-0.64	7.45e-19	Vitiligo;
PAAD	cis	rs4711350	0.862	rs688209	chr6:33700376	G/T	cg07979401	chr6:33739406	LEMD2	-0.59	-4.31	-0.33	2.91e-5	Schizophrenia;
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.55	5.73	0.42	5.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.45	4.8	0.36	3.73e-6	Age of smoking initiation;
PAAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.17	0.6	3.18e-16	Asthma;
PAAD	cis	rs72960926	0.744	rs72950563	chr6:74912043	G/C	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.51	-6.03	-0.44	1.17e-8	Mean arterial pressure;
PAAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	1.17	11.88	0.69	1.91e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.79	0.36	3.94e-6	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.49e-5	Life satisfaction;
PAAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.83	9.18	0.6	3.01e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg12757816	chr2:10669957	NA	-0.42	-4.46	-0.34	1.61e-5	Prostate cancer;
PAAD	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02743256	chr7:2109353	MAD1L1	-0.72	-5.06	-0.38	1.19e-6	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09595537	chr4:668144	ATP5I	-0.77	-7.12	-0.5	4.03e-11	Neuroticism;
PAAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-9.95	-0.63	2.76e-18	Electrocardiographic conduction measures;
PAAD	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	0.99	11.13	0.67	2.06e-21	Testicular germ cell tumor;
PAAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.79	9.18	0.6	2.93e-16	Diastolic blood pressure;
PAAD	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-5.28	-0.39	4.36e-7	Type 2 diabetes;
PAAD	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.77	-7.16	-0.5	3.31e-11	Platelet distribution width;
PAAD	trans	rs12545912	0.909	rs12676827	chr8:9581432	C/G	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10887741	0.646	rs2077773	chr10:89435501	G/A	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.72	0.48	3.47e-10	Coffee consumption (cups per day);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10354859	chr13:53024439	VPS36	0.6	6.34	0.46	2.54e-9	Myopia (pathological);
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg07469887	chr10:131262384	NA	-0.47	-5.82	-0.43	3.37e-8	Response to temozolomide;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16355531	chr10:126370306	FAM53B	0.68	8.53	0.57	1.39e-14	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg22437258	chr11:111473054	SIK2	-0.59	-5.82	-0.43	3.41e-8	Primary sclerosing cholangitis;
PAAD	cis	rs11671653	0.688	rs112508627	chr19:10842063	A/G	cg18582342	chr19:11591989	ELAVL3	-0.64	-4.27	-0.33	3.48e-5	LDL cholesterol;
PAAD	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg15192750	chr16:69999425	NA	0.74	5.8	0.43	3.72e-8	IgE levels;
PAAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg21395723	chr22:39101663	GTPBP1	0.44	4.56	0.35	1.05e-5	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.6	6.37	0.46	2.14e-9	Bladder cancer;
PAAD	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.51	-4.9	-0.37	2.39e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.29	-0.39	4.17e-7	Monocyte count;
PAAD	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.81	7.32	0.51	1.33e-11	Exhaled nitric oxide levels;
PAAD	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	6.83	0.48	1.88e-10	Multiple sclerosis;
PAAD	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg09127314	chr1:152161683	NA	-0.63	-4.32	-0.33	2.78e-5	Atopic dermatitis;
PAAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.18	0.45	5.55e-9	Lung cancer;
PAAD	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg10820045	chr2:198174542	NA	-0.52	-5.32	-0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs300774	0.925	rs300709	chr2:139743	C/T	cg21211680	chr2:198530	NA	0.6	5.72	0.42	5.44e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1371614	0.588	rs10181727	chr2:27171245	C/T	cg00617064	chr2:27272375	NA	0.45	4.6	0.35	8.67e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg15181151	chr6:150070149	PCMT1	0.51	5.28	0.39	4.49e-7	Lung cancer;
PAAD	cis	rs4974559	0.947	rs28678404	chr4:1374919	G/A	cg02980000	chr4:1222292	CTBP1	0.66	4.4	0.34	1.99e-5	Systolic blood pressure;
PAAD	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg27490568	chr2:178487706	NA	0.45	4.99	0.37	1.66e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg14019146	chr3:50243930	SLC38A3	0.47	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.9	-9.66	-0.62	1.68e-17	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.38	-0.33	2.17e-5	Osteoarthritis;
PAAD	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg11232448	chr19:2858854	NA	-0.48	-4.73	-0.36	5.02e-6	Total cholesterol levels;
PAAD	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.99	-15.48	-0.78	4.61e-33	Height;
PAAD	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs7264396	0.887	rs8116304	chr20:34054409	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.87	-9.37	-0.6	9.63e-17	Prudent dietary pattern;
PAAD	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-4.49	-0.34	1.41e-5	Ulcerative colitis;
PAAD	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.55	-0.47	8.53e-10	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.72	5.29	0.39	4.26e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.5	0.57	1.66e-14	Schizophrenia;
PAAD	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	9.13	0.6	3.88e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg03885332	chr11:832357	CD151	-0.45	-5.29	-0.39	4.2e-7	Mean platelet volume;
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.2	0.45	5.19e-9	Coffee consumption (cups per day);
PAAD	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.32	-0.51	1.31e-11	Triglycerides;
PAAD	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.65	-4.71	-0.36	5.55e-6	Vitiligo;
PAAD	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.56	-7.61	-0.53	2.64e-12	Primary biliary cholangitis;
PAAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs9857275	0.788	rs13067032	chr3:141095372	A/G	cg00789793	chr3:141329863	RASA2	0.48	4.27	0.33	3.43e-5	Prion diseases;
PAAD	cis	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg00262122	chr8:11665843	FDFT1	0.6	4.9	0.37	2.48e-6	Neuroticism;
PAAD	cis	rs6681849	0.843	rs10399820	chr1:94876282	C/G	cg17801055	chr1:95285809	SLC44A3	-0.45	-4.56	-0.35	1.04e-5	Platelet distribution width;
PAAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.62	-6.17	-0.45	5.89e-9	Eosinophil percentage of white cells;
PAAD	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg26031613	chr14:104095156	KLC1	0.53	5.47	0.41	1.81e-7	Reticulocyte count;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.620	rs349049	chr19:44301400	T/C	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer;
PAAD	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	7.22	0.51	2.26e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.57	6.02	0.44	1.26e-8	Obesity-related traits;
PAAD	cis	rs12431939	0.948	rs12435916	chr14:51665858	T/G	cg23942311	chr14:51606299	NA	-0.61	-4.94	-0.37	2.05e-6	Cancer;
PAAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg17366294	chr4:99064904	C4orf37	0.46	5.04	0.38	1.31e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10910200	0.583	rs780208	chr1:233651277	T/C	cg23054119	chr1:233659267	NA	-0.54	-5.29	-0.39	4.18e-7	Diabetic retinopathy;
PAAD	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.59	5.6	0.41	9.62e-8	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03361067	chr7:30066623	FKBP14	0.65	6.32	0.46	2.76e-9	Obesity-related traits;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-6.02	-0.44	1.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg10589385	chr1:150898437	SETDB1	0.38	4.69	0.36	6.14e-6	Melanoma;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06718723	chr19:15236813	ILVBL	-0.71	-6.74	-0.48	3.16e-10	Lung cancer in ever smokers;
PAAD	cis	rs12136530	0.593	rs12403041	chr1:19730927	A/G	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.75	-0.36	4.68e-6	Lead levels in blood;
PAAD	cis	rs600626	0.755	rs656095	chr11:75445338	A/G	cg24262691	chr11:75473276	NA	0.47	4.49	0.34	1.37e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.83	5.67	0.42	7.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs41311933	0.901	rs76481162	chr9:123740526	A/G	cg13567360	chr9:123745713	C5	-0.71	-4.42	-0.34	1.87e-5	Coronary artery disease;
PAAD	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs7651511	0.890	rs2312194	chr3:141210420	T/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	5.46	0.4	1.94e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6473252	0.546	rs7834840	chr8:81822519	T/C	cg08595989	chr8:81827712	NA	-0.33	-4.51	-0.34	1.31e-5	Breast cancer;
PAAD	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.56	4.84	0.37	3.14e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7714584	1.000	rs76433514	chr5:150306532	C/G	cg22134413	chr5:150180641	NA	1.01	6.63	0.47	5.64e-10	Crohn's disease;
PAAD	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.48	4.62	0.35	8.27e-6	Hip circumference;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs6710503	0.574	rs56001375	chr2:24850724	A/T	cg21151432	chr2:25142229	ADCY3	-0.36	-4.35	-0.33	2.5e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs6718203	1.000	rs79659409	chr2:60607636	G/C	cg10480506	chr2:60280451	NA	0.82	4.55	0.35	1.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.37	-0.33	2.34e-5	Resting heart rate;
PAAD	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.7	-6.87	-0.49	1.54e-10	Retinal vascular caliber;
PAAD	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg12935359	chr14:103987150	CKB	-0.66	-7.02	-0.49	6.96e-11	Body mass index;
PAAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg08885800	chr1:201084119	NA	-0.69	-7.92	-0.54	4.77e-13	Permanent tooth development;
PAAD	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-5.45	-0.4	2.02e-7	Mean corpuscular volume;
PAAD	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	9.02	0.59	7.76e-16	Nonalcoholic fatty liver disease;
PAAD	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.6	-6.08	-0.44	9.08e-9	Glioblastoma;
PAAD	cis	rs7941600	0.581	rs7103596	chr11:9338052	T/C	cg19415743	chr11:9336845	TMEM41B	0.96	5.97	0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.04	-12.91	-0.72	3.34e-26	Schizophrenia;
PAAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg23283495	chr1:209979779	IRF6	0.79	7.0	0.49	7.65e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.26	0.39	4.86e-7	Coronary artery disease;
PAAD	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg01090926	chr14:75137805	KIAA0317	0.54	4.84	0.37	3.17e-6	Non-small cell lung cancer;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.46	-6.6	-0.47	6.31e-10	Mean corpuscular volume;
PAAD	cis	rs7707921	0.881	rs112355050	chr5:81386035	C/T	cg21483461	chr5:81570383	RPS23	-0.51	-4.32	-0.33	2.83e-5	Breast cancer;
PAAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg11764359	chr7:65958608	NA	0.78	5.17	0.39	7.13e-7	Diabetic kidney disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09818520	chr1:151162600	VPS72	-0.69	-6.55	-0.47	8.32e-10	Lung cancer in ever smokers;
PAAD	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg20936604	chr3:58311152	NA	-0.79	-4.83	-0.36	3.37e-6	Cholesterol, total;
PAAD	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.73e-7	Daytime sleep phenotypes;
PAAD	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.94	13.06	0.73	1.32e-26	Intelligence (multi-trait analysis);
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg02555727	chr12:129281546	SLC15A4	0.5	5.3	0.39	4.04e-7	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27306034	chr1:155224863	FAM189B	0.68	7.79	0.53	9.5e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg09796270	chr17:17721594	SREBF1	-0.44	-5.04	-0.38	1.29e-6	Total body bone mineral density;
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.66	-5.72	-0.42	5.53e-8	Systemic lupus erythematosus;
PAAD	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	4.79	0.36	4e-6	Platelet distribution width;
PAAD	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.55	4.73	0.36	5.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg04034577	chr2:241836375	C2orf54	-0.34	-5.1	-0.38	1.02e-6	Urinary metabolites;
PAAD	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg08209042	chr3:196295218	WDR53;FBXO45	0.54	4.3	0.33	3.1e-5	Fat distribution (HIV);
PAAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg26022315	chr17:47021804	SNF8	0.45	4.69	0.36	6.05e-6	Type 2 diabetes;
PAAD	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.44	-10.22	-0.64	5.51e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs4711350	0.723	rs549652	chr6:33686103	G/A	cg13859433	chr6:33739653	LEMD2	0.83	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.72	7.12	0.5	4.02e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4141404	0.651	rs5753723	chr22:32002294	T/C	cg02404636	chr22:31891804	SFI1	-0.53	-4.47	-0.34	1.51e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.77	6.18	0.45	5.53e-9	Height;
PAAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.93e-10	Bipolar disorder;
PAAD	cis	rs11123610	0.698	rs72769388	chr2:3725964	C/T	cg25251562	chr2:3704773	ALLC	-0.53	-5.57	-0.41	1.13e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.52	0.34	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.67	8.74	0.58	3.93e-15	Lymphocyte counts;
PAAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.45	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs1372356	0.816	rs4904411	chr14:88510255	C/T	cg18078958	chr14:88630771	NA	0.5	6.37	0.46	2.14e-9	Food antigen IgG levels;
PAAD	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs7804356	0.626	rs9648019	chr7:26793927	A/G	cg03456212	chr7:26904342	SKAP2	0.57	4.94	0.37	1.99e-6	Type 1 diabetes;
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-5.24	-0.39	5.3e-7	Total body bone mineral density;
PAAD	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg11209218	chr8:92086451	OTUD6B	-0.55	-6.63	-0.47	5.49e-10	Energy expenditure (24h);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17837792	chr4:83273357	NA	-0.62	-6.35	-0.46	2.41e-9	Obesity-related traits;
PAAD	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.56	-5.41	-0.4	2.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.97	10.42	0.65	1.61e-19	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27654529	chr19:35418345	ZNF30	0.59	6.74	0.48	3.13e-10	Metabolite levels  (X-11787);
PAAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14895029	chr7:2775587	GNA12	0.45	4.66	0.35	6.93e-6	Height;
PAAD	cis	rs4150161	0.656	rs3785032	chr16:84216257	A/G	cg10106505	chr16:84220380	TAF1C	-1.15	-6.01	-0.44	1.3e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs564309	0.681	rs1188487	chr1:228620247	A/G	cg13099616	chr1:227751251	ZNF678	-0.72	-4.45	-0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg09659197	chr4:152720779	NA	0.35	5.1	0.38	9.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2080501	0.628	rs1344530	chr16:49665122	T/C	cg27618369	chr16:49636483	ZNF423	0.56	5.87	0.43	2.62e-8	IgG glycosylation;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg05895507	chr15:77155635	SCAPER	0.41	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs10490913	0.583	rs853921	chr10:120151128	C/T	cg04126427	chr10:120840676	EIF3A	0.43	4.39	0.34	2.11e-5	Cancer;
PAAD	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg10845886	chr2:3471009	TTC15	-0.88	-8.21	-0.55	8.86e-14	Neurofibrillary tangles;
PAAD	cis	rs16975963	0.644	rs2290999	chr19:38138887	T/C	cg25793785	chr19:38281423	NA	0.51	4.27	0.33	3.39e-5	Longevity;
PAAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.63	6.38	0.46	2.02e-9	Multiple sclerosis;
PAAD	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.7	6.93	0.49	1.12e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.5	4.36	0.33	2.37e-5	Height;
PAAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-1.04	-17.48	-0.82	3.42e-38	Height;
PAAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.8	0.43	3.8e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs13424612	0.864	rs4854071	chr2:240885050	C/T	cg15508401	chr2:239997380	HDAC4	-0.49	-4.35	-0.33	2.49e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs2274459	1.000	rs12193658	chr6:33705528	G/T	cg06253072	chr6:33679850	C6orf125	0.63	4.66	0.35	6.98e-6	Obesity (extreme);
PAAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2286379	0.626	rs10848560	chr12:1839492	C/T	cg11558135	chr12:861715	WNK1	-0.45	-4.32	-0.33	2.76e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.37	4.87	0.37	2.74e-6	Calcium levels;
PAAD	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs72827839	0.948	rs72827882	chr17:46532624	G/T	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.77	8.29	0.56	5.72e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.37	-0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.58	5.18	0.39	7.03e-7	Common traits (Other);
PAAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.04	0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.44	-0.65	1.44e-19	Ulcerative colitis;
PAAD	cis	rs4946717	0.716	rs4478446	chr6:106472120	T/A	cg02270332	chr6:106475062	NA	0.59	6.03	0.44	1.22e-8	Inflammatory bowel disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04558112	chr16:69788908	NOB1	0.73	8.01	0.54	2.86e-13	Myopia (pathological);
PAAD	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.47	4.62	0.35	8.28e-6	Schizophrenia;
PAAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.71	7.67	0.53	1.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg21918786	chr6:109611834	NA	0.44	4.64	0.35	7.36e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7555006	0.671	rs72692228	chr1:51476705	G/A	cg06082920	chr1:51796003	TTC39A	-0.46	-4.55	-0.35	1.11e-5	Headache;
PAAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg02896835	chr1:92012615	NA	-0.59	-6.71	-0.48	3.58e-10	Breast cancer;
PAAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg23957660	chr17:17878224	LRRC48	0.37	4.31	0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs2944591	0.505	rs2004202	chr2:233790289	C/G	cg08000102	chr2:233561755	GIGYF2	-0.47	-4.53	-0.34	1.18e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs498136	0.966	rs3903268	chr11:69383988	A/C	cg24454109	chr11:69520271	FGF19	0.5	4.44	0.34	1.72e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.84	-0.43	3.01e-8	Pulmonary function;
PAAD	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.3	0.33	3.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg14458575	chr2:238380390	NA	0.63	5.23	0.39	5.43e-7	Prostate cancer;
PAAD	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.75	-7.92	-0.54	4.75e-13	Cognitive test performance;
PAAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg10589385	chr1:150898437	SETDB1	0.38	4.58	0.35	9.61e-6	Melanoma;
PAAD	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.9	0.43	2.24e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.49	4.65	0.35	7.19e-6	Self-reported allergy;
PAAD	cis	rs9322817	0.691	rs2486135	chr6:105282263	C/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09888156	chr4:140222272	NAA15	0.61	6.81	0.48	2.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8017423	0.605	rs2149652	chr14:90813429	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-5.79	-0.43	3.86e-8	Mortality in heart failure;
PAAD	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg00540400	chr15:79124168	NA	-0.68	-8.5	-0.57	1.68e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18139254	chr14:100751903	NA	-0.63	-6.34	-0.46	2.5e-9	Smoking initiation;
PAAD	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.79	0.36	3.94e-6	Lung cancer in ever smokers;
PAAD	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg24053715	chr22:38214548	NA	-0.6	-6.28	-0.45	3.45e-9	Glioblastoma;Glioma;
PAAD	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.94	-0.37	2e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-8.5	-0.57	1.64e-14	Schizophrenia;
PAAD	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.76	7.0	0.49	7.77e-11	Corneal astigmatism;
PAAD	cis	rs7132746	0.620	rs61928911	chr12:86195973	A/G	cg18827107	chr12:86230957	RASSF9	-0.55	-4.57	-0.35	1.02e-5	Lewy body disease;
PAAD	cis	rs2282300	0.956	rs1717773	chr11:30383154	T/C	cg25418670	chr11:30344373	C11orf46	-0.61	-5.87	-0.43	2.68e-8	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.66	6.34	0.46	2.54e-9	Corneal astigmatism;
PAAD	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg06375148	chr1:209958343	C1orf74	-0.68	-4.87	-0.37	2.79e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg08975724	chr8:8085496	FLJ10661	0.44	4.33	0.33	2.68e-5	Mood instability;
PAAD	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg22601191	chr20:60968625	CABLES2	0.51	5.05	0.38	1.27e-6	Colorectal cancer;
PAAD	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg21823605	chr1:152486609	CRCT1	-0.54	-6.23	-0.45	4.26e-9	Hair morphology;
PAAD	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.26	0.39	4.82e-7	IgG glycosylation;
PAAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs205391	0.544	rs398889	chr16:28043497	C/T	cg00359511	chr16:28509413	APOB48R	-0.52	-4.28	-0.33	3.35e-5	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg21466736	chr12:48725269	NA	0.55	5.12	0.38	9.32e-7	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.53	0.65	8.3e-20	Electrocardiographic conduction measures;
PAAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg07943548	chr15:86304357	KLHL25	-0.71	-5.93	-0.43	1.99e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.9	5.71	0.42	5.83e-8	Body mass index;
PAAD	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg08079166	chr15:68083412	MAP2K5	0.6	4.47	0.34	1.52e-5	Obesity;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.81	5.6	0.41	9.55e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg08632701	chr21:37451849	NA	-0.6	-6.08	-0.44	9.25e-9	Mitral valve prolapse;
PAAD	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg09226986	chr6:160852328	SLC22A3	-0.51	-4.74	-0.36	4.96e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs11264799	0.655	rs59306424	chr1:157654721	G/T	cg18268488	chr1:157545234	FCRL4	0.5	5.17	0.39	7.34e-7	IgA nephropathy;
PAAD	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	cg13376598	chr11:24518225	LUZP2	0.54	4.5	0.34	1.37e-5	Response to Homoharringtonine (cytotoxicity);
PAAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.26	0.39	4.85e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.67	-7.29	-0.51	1.55e-11	Menarche (age at onset);
PAAD	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.75	-5.31	-0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs73206853	0.764	rs73191812	chr12:110910279	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.51	-0.41	1.48e-7	Mean corpuscular volume;
PAAD	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.99	-11.18	-0.67	1.51e-21	Blood pressure (smoking interaction);
PAAD	cis	rs16958440	0.867	rs79231363	chr18:44665087	T/C	cg17192377	chr18:44677553	HDHD2	0.95	5.13	0.38	8.64e-7	Sitting height ratio;
PAAD	cis	rs73019876	0.869	rs2188971	chr19:22152182	T/C	cg11619707	chr19:22235551	ZNF257	-0.42	-4.45	-0.34	1.68e-5	Testicular germ cell tumor;
PAAD	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg17644776	chr2:200775616	C2orf69	-0.52	-4.3	-0.33	3e-5	Schizophrenia;
PAAD	cis	rs425535	0.757	rs164615	chr4:74801525	A/G	cg01447579	chr4:74847100	PF4	0.66	4.32	0.33	2.86e-5	Blood protein levels;
PAAD	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.82	-6.63	-0.47	5.55e-10	Blood protein levels;
PAAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.53	0.35	1.16e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7577696	0.889	rs212733	chr2:32472640	T/C	cg02381751	chr2:32503542	YIPF4	0.42	4.53	0.34	1.2e-5	Inflammatory biomarkers;
PAAD	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.56	5.72	0.42	5.53e-8	Ulcerative colitis;
PAAD	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.69	6.24	0.45	4.13e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2085601	0.542	rs35006100	chr4:89983742	C/G	cg17769793	chr4:89976368	FAM13A	0.44	5.5	0.41	1.6e-7	Hair greying;
PAAD	cis	rs62238980	0.614	rs9609388	chr22:32334739	G/A	cg00543991	chr22:32367038	NA	0.83	4.89	0.37	2.54e-6	Childhood ear infection;
PAAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg16147221	chr4:10020634	SLC2A9	0.49	4.4	0.34	2e-5	Bone mineral density;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.51	-5.07	-0.38	1.15e-6	Lung cancer;
PAAD	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7580658	0.613	rs12463538	chr2:128196854	G/T	cg09760422	chr2:128146352	NA	-0.44	-7.17	-0.5	3e-11	Protein C levels;
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg05313129	chr8:58192883	C8orf71	-0.54	-4.87	-0.37	2.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00290607	chr11:67383545	NA	-0.43	-4.34	-0.33	2.58e-5	Mean corpuscular volume;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg26071806	chr7:100318239	EPO	-0.49	-4.79	-0.36	3.85e-6	Other erythrocyte phenotypes;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.59	7.08	0.5	5.11e-11	Lung cancer;
PAAD	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.2	-0.39	6.36e-7	Mean platelet volume;
PAAD	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.54	-0.47	8.75e-10	Mood instability;
PAAD	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.65	-5.77	-0.42	4.37e-8	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-6.62	-0.47	5.83e-10	Monocyte percentage of white cells;
PAAD	cis	rs7192380	0.651	rs12447326	chr16:69630853	C/T	cg05250797	chr16:70222502	NA	0.65	5.72	0.42	5.43e-8	Sjögren's syndrome;
PAAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.61	-5.42	-0.4	2.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.11	-8.47	-0.57	1.99e-14	Diabetic kidney disease;
PAAD	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg25902810	chr10:99078978	FRAT1	-0.58	-5.37	-0.4	2.95e-7	Monocyte count;
PAAD	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.62	-0.35	7.96e-6	Body mass index;
PAAD	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg23024343	chr7:107201750	COG5	0.58	4.72	0.36	5.36e-6	Coronary artery disease;
PAAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Breast cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06143244	chr16:22435202	RRN3P3	-0.65	-6.38	-0.46	2.01e-9	Primary biliary cholangitis;
PAAD	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-12.3	-0.71	1.39e-24	Primary sclerosing cholangitis;
PAAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.9	-0.43	2.26e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs375066	0.806	rs415168	chr19:44402574	C/G	cg21496419	chr19:44306685	LYPD5	0.43	5.18	0.39	6.96e-7	Breast cancer;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.94	0.43	1.84e-8	Prudent dietary pattern;
PAAD	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.78	-8.4	-0.56	2.97e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.73	8.24	0.56	7.6e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg21479132	chr6:26055353	NA	0.69	4.41	0.34	1.96e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg02071572	chr4:1403502	NA	0.45	5.69	0.42	6.41e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.25	-0.33	3.64e-5	IFN-related cytopenia;
PAAD	cis	rs6494488	0.500	rs72741345	chr15:64767979	C/T	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.67	-5.43	-0.4	2.19e-7	Obesity (extreme);
PAAD	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg26816564	chr1:7831052	VAMP3	0.67	5.29	0.39	4.12e-7	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.06	0.5	5.41e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg22532475	chr10:104410764	TRIM8	-0.41	-4.66	-0.35	7e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.61	-6.32	-0.46	2.74e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.59e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg04359915	chr10:101825029	CPN1	-0.35	-5.14	-0.38	8.34e-7	Bone mineral density;
PAAD	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-1.03	-8.8	-0.58	2.75e-15	Red blood cell traits;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.86	-9.47	-0.61	5.21e-17	Menarche (age at onset);
PAAD	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	0.850	rs77364880	chr10:45996100	G/A	cg12869334	chr8:37699360	GPR124	0.98	6.53	0.47	9.52e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg15942720	chr14:51706980	TMX1	0.5	4.26	0.33	3.62e-5	Cancer;
PAAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22633769	chr20:60982531	CABLES2	0.49	4.84	0.37	3.17e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03104758	chr16:57219801	RSPRY1;FAM192A	0.71	6.81	0.48	2.09e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06076054	chr21:19191045	C21orf91	0.61	6.93	0.49	1.12e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg16664915	chr8:10907788	XKR6	-0.4	-4.32	-0.33	2.84e-5	Triglycerides;
PAAD	cis	rs3857067	0.934	rs899132	chr4:95040022	A/C	cg11021082	chr4:95130006	SMARCAD1	0.46	4.47	0.34	1.5e-5	QT interval;
PAAD	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.6	-5.81	-0.43	3.5e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg09835421	chr16:68378352	PRMT7	-0.86	-6.93	-0.49	1.15e-10	Schizophrenia;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.24e-17	Lymphocyte counts;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16262614	chr3:133464971	TF	0.41	4.28	0.33	3.32e-5	Iron status biomarkers;
PAAD	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg14393609	chr7:65229607	NA	0.5	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	6.48	0.47	1.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	4.31	0.33	2.86e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.44	-7.09	-0.5	4.84e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.84	-6.33	-0.46	2.56e-9	Coronary artery calcification;
PAAD	trans	rs11818629	1.000	rs11818629	chr10:130137105	A/G	cg15656834	chr11:116578399	NA	-0.94	-6.46	-0.46	1.31e-9	HIV-1 control;
PAAD	cis	rs9646944	0.501	rs741284	chr2:103083324	G/C	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.61	-6.19	-0.45	5.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.35	1.1e-5	Triglycerides;
PAAD	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs4478858	0.602	rs4949370	chr1:31723889	G/C	cg00250761	chr1:31883323	NA	-0.48	-5.34	-0.4	3.38e-7	Alcohol dependence;
PAAD	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.6	-5.04	-0.38	1.29e-6	Lung cancer;
PAAD	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg14393609	chr7:65229607	NA	0.48	4.58	0.35	9.76e-6	Aortic root size;
PAAD	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.91	8.3	0.56	5.22e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg10621924	chr7:39171070	POU6F2	0.37	5.74	0.42	4.95e-8	IgG glycosylation;
PAAD	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.67	5.68	0.42	6.5e-8	Height;
PAAD	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-5.63	-0.42	8.61e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9900972	0.918	rs8082041	chr17:76876542	A/G	cg20937029	chr17:76870563	TIMP2	0.59	5.24	0.39	5.32e-7	Obesity-related traits;
PAAD	cis	rs7786877	0.679	rs10953301	chr7:100264893	A/G	cg07841815	chr7:100318223	EPO	-0.45	-4.38	-0.33	2.23e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg05393297	chr12:53359155	NA	-1.05	-6.28	-0.45	3.33e-9	Prostate cancer;
PAAD	cis	rs3206736	0.548	rs17793874	chr7:35065558	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.54	-0.35	1.12e-5	Diastolic blood pressure;
PAAD	cis	rs9826463	0.757	rs73240309	chr3:142240223	A/G	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.85	9.18	0.6	3e-16	Schizophrenia;
PAAD	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg23387401	chr17:4582204	PELP1	0.49	4.87	0.37	2.78e-6	Lymphocyte counts;
PAAD	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	4.98e-7	Pulmonary function;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.73	-5.34	-0.4	3.4e-7	Initial pursuit acceleration;
PAAD	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14092988	chr3:52407081	DNAH1	-0.41	-5.27	-0.39	4.69e-7	Bipolar disorder;
PAAD	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	5.38	0.4	2.71e-7	Type 2 diabetes;
PAAD	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.88	6.41	0.46	1.78e-9	IgG glycosylation;
PAAD	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-1.17	-6.08	-0.44	9.44e-9	Inflammatory biomarkers;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.77	-8.34	-0.56	4.05e-14	Breast cancer;
PAAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg16205897	chr5:131564050	P4HA2	-0.44	-4.76	-0.36	4.48e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs1997066	0.667	rs73342222	chr10:106820881	A/T	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.51	0.61	4.03e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg15816464	chr17:2026533	SMG6	-0.53	-5.84	-0.43	3.05e-8	Total body bone mineral density;
PAAD	cis	rs728616	0.614	rs1538818	chr10:82122793	G/A	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73198271	0.751	rs55816468	chr8:8605876	C/A	cg01851573	chr8:8652454	MFHAS1	0.56	4.61	0.35	8.4e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14580859	chr9:123691850	NA	0.39	4.36	0.33	2.42e-5	Rheumatoid arthritis;
PAAD	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.75	-0.42	4.65e-8	Tonsillectomy;
PAAD	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.55	-0.47	8.18e-10	HDL cholesterol;
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg14515779	chr1:101123966	NA	0.48	6.01	0.44	1.35e-8	Monocyte count;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.63	6.25	0.45	3.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg26939375	chr7:64535504	NA	-0.73	-8.05	-0.55	2.26e-13	Aortic root size;
PAAD	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.52	5.26	0.39	4.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.32	0.33	2.84e-5	Lung cancer;
PAAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg06766960	chr11:133703094	NA	-0.65	-6.66	-0.48	4.76e-10	Childhood ear infection;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.75	-10.57	-0.65	6.4e-20	Psoriasis;
PAAD	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs2712381	0.797	rs62270806	chr3:128376269	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.61	-0.47	6.25e-10	Monocyte count;
PAAD	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.63	5.38	0.4	2.77e-7	Red blood cell count;
PAAD	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg03989125	chr22:38214979	NA	0.64	5.84	0.43	3.03e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs62264129	0.500	rs13316383	chr3:112039067	C/G	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.51	5.53	0.41	1.34e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.66	-0.53	2.06e-12	Migraine;Coronary artery disease;
PAAD	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.85	0.49	1.76e-10	Exhaled nitric oxide levels;
PAAD	cis	rs9487051	0.698	rs13202939	chr6:109649655	A/G	cg21918786	chr6:109611834	NA	-0.53	-5.63	-0.42	8.54e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.4	-0.4	2.47e-7	Schizophrenia;
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs7873102	0.544	rs735741	chr9:37944489	A/G	cg03528946	chr9:38069800	SHB	0.45	4.87	0.37	2.73e-6	Brain structure;
PAAD	cis	rs11696845	0.787	rs6017408	chr20:43363529	A/G	cg25301532	chr20:43378953	KCNK15	0.49	5.62	0.41	9.04e-8	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26614578	chr12:113623930	C12orf52;DDX54	0.67	7.87	0.54	6.35e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.85	9.81	0.62	6.74e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.7	-5.75	-0.42	4.72e-8	Non-small cell lung cancer;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.63	4.85	0.37	2.99e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs2061333	0.948	rs4803681	chr19:44609485	G/A	cg18700516	chr19:44507157	ZNF230	-0.63	-4.87	-0.37	2.78e-6	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.71	0.58	4.89e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.14	-0.38	8.22e-7	Pulmonary function;
PAAD	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg19486271	chr11:47235900	DDB2	-0.59	-6.03	-0.44	1.21e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg11941060	chr3:133502564	NA	-0.53	-5.42	-0.4	2.26e-7	Iron status biomarkers;
PAAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg12639453	chr1:2035780	PRKCZ	-0.62	-6.77	-0.48	2.67e-10	Height;
PAAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.69	-8.07	-0.55	2.01e-13	Huntington's disease progression;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-7.06	-0.5	5.51e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.5	0.61	4.39e-17	Rheumatoid arthritis;
PAAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.58	5.05	0.38	1.25e-6	RR interval (heart rate);
PAAD	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg08477640	chr19:41863820	B9D2	0.65	6.8	0.48	2.25e-10	Colorectal cancer;
PAAD	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-0.93	-6.19	-0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg18944383	chr4:111397179	ENPEP	0.73	8.09	0.55	1.78e-13	Coronary artery disease;
PAAD	cis	rs4759375	0.588	rs10846521	chr12:123825157	C/G	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.55	0.57	1.26e-14	Lung cancer;
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.86	-9.66	-0.62	1.61e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12311346	chr5:56204834	C5orf35	-0.55	-4.52	-0.34	1.25e-5	Coronary artery disease;
PAAD	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg25838818	chr2:108905173	SULT1C2	-0.59	-5.63	-0.42	8.59e-8	Lobe size;
PAAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.24	-0.51	2.07e-11	Personality dimensions;
PAAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.5	4.89	0.37	2.59e-6	Morning vs. evening chronotype;
PAAD	cis	rs11718455	0.591	rs6765212	chr3:43931484	C/T	cg21419209	chr3:44054225	NA	-0.57	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21680979	chr1:204485559	MDM4	0.56	6.52	0.47	9.95e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.59	5.29	0.39	4.26e-7	Corneal astigmatism;
PAAD	cis	rs2274459	0.818	rs13206228	chr6:33719383	C/G	cg06253072	chr6:33679850	C6orf125	0.67	4.77	0.36	4.31e-6	Obesity (extreme);
PAAD	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.88	6.87	0.49	1.59e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs9463078	0.669	rs17288334	chr6:45351391	A/G	cg25276700	chr6:44698697	NA	0.52	5.82	0.43	3.41e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg05250797	chr16:70222502	NA	0.88	6.81	0.48	2.16e-10	IgE levels;
PAAD	cis	rs10214930	0.697	rs28429439	chr7:27633799	G/A	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg05805236	chr11:65401703	PCNXL3	-0.62	-6.58	-0.47	7.14e-10	Acne (severe);
PAAD	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.99	-0.38	1.6e-6	Blood pressure;
PAAD	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg00262122	chr8:11665843	FDFT1	-0.64	-5.46	-0.4	1.9e-7	Neuroticism;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.61	7.23	0.51	2.18e-11	Tonsillectomy;
PAAD	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.44	4.36	0.33	2.34e-5	Dupuytren's disease;
PAAD	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.94	-0.37	2e-6	Mean corpuscular volume;
PAAD	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg14191688	chr11:70257035	CTTN	0.58	5.39	0.4	2.67e-7	Coronary artery disease;
PAAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.61	-0.41	9.5e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg10820045	chr2:198174542	NA	0.47	4.76	0.36	4.52e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg22189786	chr22:42395067	WBP2NL	0.48	5.22	0.39	5.87e-7	Cognitive function;
PAAD	cis	rs58521262	0.585	rs289368	chr19:23114428	C/A	cg22640819	chr19:22990650	NA	-0.28	-4.25	-0.33	3.69e-5	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg26876637	chr1:152193138	HRNR	0.87	6.52	0.47	9.61e-10	Atopic dermatitis;
PAAD	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.81	8.87	0.58	1.83e-15	Mortality in heart failure;
PAAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.63	-9.41	-0.61	7.44e-17	Asthma (sex interaction);
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg07559730	chr19:53497048	ZNF702P	-0.57	-6.16	-0.45	6.32e-9	Psoriasis;
PAAD	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg23920097	chr1:209922102	NA	-0.5	-4.51	-0.34	1.26e-5	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg24565620	chr2:194026	NA	0.67	5.17	0.39	7.15e-7	Blood protein levels;
PAAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg23281280	chr6:28129359	ZNF389	0.5	4.27	0.33	3.38e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Height;
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.11	0.63	1.06e-18	Response to antipsychotic treatment;
PAAD	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg10705379	chr10:99080932	FRAT1	0.39	4.48	0.34	1.46e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg24531977	chr5:56204891	C5orf35	-0.49	-4.38	-0.33	2.18e-5	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	8.46	0.57	2.11e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.97	9.12	0.59	4.21e-16	Psoriasis;
PAAD	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-4.33	-0.33	2.66e-5	Ulcerative colitis;
PAAD	cis	rs1499972	0.938	rs843854	chr3:117757755	A/G	cg07612923	chr3:117604196	NA	1.06	7.06	0.5	5.57e-11	Schizophrenia;
PAAD	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg20085588	chr10:81316188	SFTPA2	0.38	4.29	0.33	3.22e-5	Post bronchodilator FEV1;
PAAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.41	-0.34	1.96e-5	Magnesium levels;
PAAD	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg20312557	chr2:97357134	FER1L5	0.88	4.46	0.34	1.62e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-0.87	-4.5	-0.34	1.35e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs8040855	0.627	rs17540307	chr15:85633845	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.67e-9	Prostate cancer;
PAAD	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.35	0.4	3.23e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1335587	0.518	rs9513904	chr13:102107582	G/A	cg03165014	chr13:102106348	ITGBL1	-0.46	-4.49	-0.34	1.41e-5	Obesity-related traits;
PAAD	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.51	5.03	0.38	1.39e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-7.62	-0.53	2.54e-12	Exhaled nitric oxide output;
PAAD	cis	rs2882667	0.690	rs10078079	chr5:138256139	C/T	cg09476006	chr5:138032270	NA	0.45	5.64	0.42	8.06e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-4.61	-0.35	8.45e-6	Lung cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20478390	chr14:99733000	BCL11B	-0.66	-6.41	-0.46	1.78e-9	Lung cancer in ever smokers;
PAAD	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.83	7.19	0.5	2.69e-11	Recombination rate (females);
PAAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.36	6.23e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7577696	0.962	rs2235134	chr2:32332543	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-4.62	-0.35	8.17e-6	Inflammatory biomarkers;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01774158	chr5:133562094	PPP2CA	-0.56	-6.58	-0.47	7.3e-10	Body fat percentage;
PAAD	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.68	8.81	0.58	2.68e-15	Hemoglobin concentration;
PAAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.36e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.19	0.55	1.01e-13	Alzheimer's disease;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg05627522	chr15:75251581	NA	0.59	7.22	0.51	2.38e-11	Breast cancer;
PAAD	cis	rs6011674	0.803	rs6011692	chr20:61867828	G/A	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.79	-4.73	-0.36	5.14e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs59888335	0.858	rs6807149	chr3:81027551	C/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08219700	chr8:58056026	NA	0.69	5.16	0.39	7.53e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07002382	chr15:44116782	MFAP1	-0.62	-6.2	-0.45	5.19e-9	Lung cancer in ever smokers;
PAAD	cis	rs1642645	0.831	rs10736422	chr1:42480320	C/T	cg01990334	chr1:42801334	FOXJ3	-0.58	-5.37	-0.4	2.92e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.5	0.71	4.04e-25	Breast cancer;
PAAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.29	-0.33	3.14e-5	Dupuytren's disease;
PAAD	cis	rs300774	1.000	rs300782	chr2:110345	C/T	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.36	4.97	0.37	1.8e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.57	0.41	1.12e-7	Ileal carcinoids;
PAAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs16975963	0.644	rs11083430	chr19:38139488	A/G	cg14218481	chr19:38281219	NA	0.42	4.43	0.34	1.76e-5	Longevity;
PAAD	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.5	-4.37	-0.33	2.27e-5	Menarche (age at onset);
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.44	0.65	1.41e-19	Platelet count;
PAAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg27113419	chr16:58533979	NDRG4	-0.73	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg18888403	chr1:24152774	HMGCL	-0.4	-4.42	-0.34	1.84e-5	Immature fraction of reticulocytes;
PAAD	cis	rs75920871	0.623	rs7930409	chr11:116958943	A/G	cg04087571	chr11:116723030	SIK3	-0.42	-5.92	-0.43	2.08e-8	Subjective well-being;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg18559697	chr2:208519559	NA	-0.66	-6.5	-0.47	1.07e-9	Survival in colon cancer;
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5.07e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.61	6.75	0.48	2.93e-10	Coronary artery disease;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	5.35	0.4	3.18e-7	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.21	-0.55	8.76e-14	Inflammatory bowel disease;
PAAD	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.64	-6.42	-0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.72	7.45	0.52	6.51e-12	Body mass index;
PAAD	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.72	6.53	0.47	9.07e-10	Obesity-related traits;
PAAD	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.72	7.15	0.5	3.34e-11	Obesity-related traits;
PAAD	cis	rs9815354	1.000	rs6802340	chr3:41894034	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02540021	chr10:75002811	DNAJC9	0.61	6.65	0.47	4.98e-10	Smoking initiation;
PAAD	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.44	4.28	0.33	3.31e-5	Platelet count;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.54	0.35	1.16e-5	Electroencephalogram traits;
PAAD	cis	rs2797685	0.735	rs56204811	chr1:7895069	A/G	cg00546117	chr1:8445545	RERE	-0.53	-4.78	-0.36	4.19e-6	Crohn's disease;
PAAD	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.92	-0.43	2.09e-8	Androgen levels;
PAAD	cis	rs10214930	0.697	rs7789788	chr7:27622611	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.79	6.98	0.49	8.33e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.89	14.93	0.77	1.31e-31	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs12760731	0.720	rs6702625	chr1:178339206	G/A	cg00404053	chr1:178313656	RASAL2	0.74	5.77	0.42	4.3e-8	Obesity-related traits;
PAAD	trans	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg04492929	chr16:2155436	PKD1	-0.68	-6.36	-0.46	2.23e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.53	5.85	0.43	2.98e-8	Major depressive disorder;
PAAD	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	1.1	12.77	0.72	7.81e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.44	4.36	0.33	2.38e-5	Mean corpuscular volume;
PAAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.75	-6.62	-0.47	5.72e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.52	5.77	0.42	4.25e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg23465465	chr6:26364728	BTN3A2	-0.56	-4.51	-0.34	1.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.53	0.34	1.2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg10934807	chr2:113191815	RGPD8;RGPD5	0.91	6.51	0.47	1.01e-9	Yeast infection;
PAAD	cis	rs28489187	0.617	rs11161606	chr1:85853902	T/C	cg16011679	chr1:85725395	C1orf52	0.45	4.46	0.34	1.57e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.66	7.79	0.53	9.62e-13	Sjögren's syndrome;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.33	-0.46	2.56e-9	Longevity;Endometriosis;
PAAD	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg25837213	chr17:80849375	TBCD	-0.47	-4.5	-0.34	1.35e-5	Breast cancer;
PAAD	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.9	-9.84	-0.62	5.53e-18	Obesity-related traits;
PAAD	cis	rs4705952	0.832	rs72797338	chr5:131866408	A/G	cg05209330	chr5:131550942	P4HA2	0.51	4.3	0.33	3.09e-5	C-reactive protein levels;
PAAD	cis	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg21546286	chr11:48923668	NA	-0.44	-4.63	-0.35	7.76e-6	HDL cholesterol;
PAAD	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.23	0.39	5.55e-7	Morning vs. evening chronotype;
PAAD	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11101442	0.601	rs733394	chr10:49948241	G/T	cg25838091	chr10:50887934	C10orf53	0.32	4.27	0.33	3.45e-5	Systemic lupus erythematosus;
PAAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14580859	chr9:123691850	NA	0.39	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.73	-6.49	-0.47	1.17e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg00042356	chr1:8021962	PARK7	0.74	5.11	0.38	9.61e-7	Inflammatory bowel disease;
PAAD	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg00750074	chr16:89608354	SPG7	-0.62	-6.37	-0.46	2.17e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.41	-0.34	1.96e-5	Glomerular filtration rate;
PAAD	cis	rs28830936	0.966	rs3179542	chr15:42118123	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.24	-0.51	2.04e-11	Diastolic blood pressure;
PAAD	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg03714773	chr7:91764589	CYP51A1	-0.32	-4.48	-0.34	1.44e-5	Breast cancer;
PAAD	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7957197	0.873	rs7965349	chr12:121471931	C/T	cg16175725	chr12:121416796	HNF1A	0.37	4.66	0.35	6.83e-6	Type 2 diabetes;
PAAD	cis	rs4343996	0.967	rs7803993	chr7:3353057	G/A	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.5	4.86	0.37	2.88e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs35160687	0.644	rs4832274	chr2:86529084	C/G	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-4.65	-0.35	7.06e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	cis	rs9463078	0.510	rs4714832	chr6:44978183	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.85e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.91	5.45	0.4	2.03e-7	Alzheimer's disease (late onset);
PAAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg09839279	chr12:125627357	AACS	-0.51	-5.07	-0.38	1.17e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21064939	chr6:134496060	SGK1	0.57	6.32	0.46	2.71e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.86	11.01	0.67	4.29e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.8	-0.58	2.82e-15	Testicular germ cell tumor;
PAAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg05697835	chr1:2722811	NA	0.4	4.54	0.35	1.14e-5	Ulcerative colitis;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.64	4.58	0.35	9.81e-6	Alzheimer's disease;
PAAD	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg11367502	chr7:22862612	TOMM7	0.52	5.07	0.38	1.14e-6	Fibrinogen;
PAAD	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg21937377	chr3:194868750	C3orf21	0.47	4.91	0.37	2.32e-6	Non-small cell lung cancer;
PAAD	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg19423196	chr10:82049429	MAT1A	0.61	4.72	0.36	5.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18036068	chr18:73122565	C18orf62	0.59	7.16	0.5	3.23e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.62	6.16	0.45	6.24e-9	Multiple sclerosis;
PAAD	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.87	0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.46	4.28	0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs2555155	1.000	rs11604149	chr11:6519642	G/A	cg10208301	chr11:6592745	DNHD1	0.44	4.54	0.35	1.12e-5	DNA methylation (variation);
PAAD	cis	rs3787159	0.547	rs481690	chr20:56883988	C/T	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.14e-5	Systolic blood pressure;
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.62	5.73	0.42	5.14e-8	Coronary artery disease;
PAAD	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg01631684	chr10:65280961	REEP3	-0.46	-4.66	-0.35	6.86e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.82	11.2	0.67	1.34e-21	Emphysema distribution in smoking;
PAAD	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.62	-5.38	-0.4	2.75e-7	Corneal structure;
PAAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.35	-0.4	3.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.793	rs78220690	chr1:227297523	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.81	-8.66	-0.57	6.38e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	5.54	0.41	1.27e-7	Myopia (pathological);
PAAD	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg08840230	chr19:15622718	CYP4F22	-0.41	-4.27	-0.33	3.4e-5	Pulse pressure;
PAAD	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.4	-0.34	2.01e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.75	-6.78	-0.48	2.44e-10	Coronary artery disease;
PAAD	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.33	-0.46	2.66e-9	Exhaled nitric oxide output;
PAAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.51	5.13	0.38	8.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.74	0.48	3.12e-10	Schizophrenia;
PAAD	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.65	7.69	0.53	1.68e-12	Weight;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08740026	chr21:27838876	CYYR1	-0.58	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.88	7.11	0.5	4.21e-11	Lung function (FEV1/FVC);
PAAD	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg06026331	chr20:60912101	LAMA5	0.56	5.28	0.39	4.35e-7	Pelvic organ prolapse;
PAAD	cis	rs308971	0.563	rs307611	chr3:12063344	G/C	cg02700894	chr3:12045449	SYN2	0.62	4.5	0.34	1.34e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.74	0.48	3.1e-10	Lung cancer;
PAAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg20913747	chr6:44695427	NA	-0.56	-4.91	-0.37	2.31e-6	Total body bone mineral density;
PAAD	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs4148087	1.000	rs4148100	chr21:43640169	T/C	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-0.93	-5.8	-0.43	3.79e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13767494	chr2:220355154	SPEG	-0.7	-7.01	-0.49	7.45e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-6.87	-0.49	1.55e-10	Height;
PAAD	cis	rs1497828	0.956	rs2492872	chr1:217556242	C/A	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs12304921	1.000	rs17125088	chr12:51326702	C/T	cg18059802	chr12:51347058	HIGD1C	0.67	5.24	0.39	5.16e-7	Type 2 diabetes;
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.48	0.34	1.43e-5	Trans fatty acid levels;
PAAD	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	5.91	0.43	2.16e-8	Rheumatoid arthritis;
PAAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.55	5.29	0.39	4.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs730532	0.556	rs1032578	chr14:52523900	C/T	cg16066272	chr14:52535949	NID2	-0.61	-4.52	-0.34	1.24e-5	Pulmonary function;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs36093844	0.898	rs11234446	chr11:85566169	A/G	cg25872744	chr11:85566296	CCDC83	-0.56	-4.33	-0.33	2.65e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	cis	rs2882667	0.690	rs6887841	chr5:138175910	G/A	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg15733309	chr7:157513707	PTPRN2	0.63	7.98	0.54	3.35e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	4.39	0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs12612619	0.704	rs7602823	chr2:27309406	G/A	cg00617064	chr2:27272375	NA	0.52	5.35	0.4	3.21e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.72	4.3	0.33	3.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.54	5.09	0.38	1.06e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.58	6.39	0.46	1.93e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02743256	chr7:2109353	MAD1L1	-0.67	-5.95	-0.43	1.81e-8	Neuroticism;
PAAD	cis	rs17023223	0.537	rs2645301	chr1:119590420	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11037575	0.739	rs12294299	chr11:43707560	T/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg14146966	chr2:61757674	XPO1	0.37	4.53	0.34	1.2e-5	Tuberculosis;
PAAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.75	-8.58	-0.57	1.05e-14	Huntington's disease progression;
PAAD	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.5	-5.85	-0.43	2.89e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	6.32	0.46	2.78e-9	Schizophrenia;
PAAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.92	-10.63	-0.65	4.47e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg10589385	chr1:150898437	SETDB1	0.39	4.76	0.36	4.53e-6	Melanoma;
PAAD	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg08562672	chr19:21860753	NA	0.45	4.81	0.36	3.62e-6	Pain;
PAAD	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.37	4.65	0.35	7.23e-6	Prostate cancer;
PAAD	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26306683	chr17:18585705	ZNF286B	0.57	5.74	0.42	5.03e-8	Educational attainment (years of education);
PAAD	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.58	-0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13242816	1.000	rs13242816	chr7:116189376	C/T	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs4280164	0.945	rs2224122	chr14:24783414	G/C	cg07162820	chr14:24837146	NFATC4	0.39	4.43	0.34	1.82e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs360071	0.528	rs360097	chr1:226065755	C/A	cg05376267	chr1:226075388	LEFTY1	0.4	4.32	0.33	2.79e-5	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg27141850	chr2:20869434	GDF7	-0.46	-5.24	-0.39	5.35e-7	Abdominal aortic aneurysm;
PAAD	cis	rs6681460	0.546	rs10493414	chr1:67161716	A/T	cg02459107	chr1:67143332	SGIP1	0.56	5.18	0.39	6.88e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	1.1	12.03	0.7	7.56e-24	Gut microbiota (bacterial taxa);
PAAD	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9657904	0.774	rs28427229	chr3:105559032	G/A	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-4.62	-0.35	8.18e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg23024343	chr7:107201750	COG5	0.58	4.72	0.36	5.36e-6	Coronary artery disease;
PAAD	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg10616300	chr11:66138557	SLC29A2	0.35	4.79	0.36	4.01e-6	Educational attainment (years of education);
PAAD	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg08898775	chr15:59042684	ADAM10	0.41	4.98	0.37	1.71e-6	Schizophrenia;
PAAD	cis	rs4356203	0.875	rs7939614	chr11:17079620	C/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-4.48	-0.34	1.45e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs9463078	0.546	rs4412189	chr6:45023226	T/C	cg25276700	chr6:44698697	NA	0.46	5.19	0.39	6.6e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-6.98	-0.49	8.56e-11	Total cholesterol levels;
PAAD	cis	rs1198430	0.714	rs1198437	chr1:23747424	G/C	cg27447006	chr1:23763279	ASAP3	0.6	4.73	0.36	5.07e-6	Total cholesterol levels;
PAAD	cis	rs2271400	0.556	rs10958466	chr8:56654443	T/A	cg08894788	chr8:56792171	LYN	-0.52	-4.98	-0.37	1.69e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.57	7.49	0.52	5.28e-12	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
PAAD	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.55	7.35	0.51	1.16e-11	Rheumatoid arthritis;
PAAD	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.88	-11.23	-0.67	1.08e-21	Body mass index (adult);
PAAD	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04212619	chr3:14444063	SLC6A6	0.66	6.95	0.49	1.02e-10	Obesity-related traits;
PAAD	trans	rs12714314	0.957	rs6723932	chr2:1954897	T/C	cg17170872	chr1:91487911	ZNF644	-0.76	-6.3	-0.46	3.12e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.81	5.55	0.41	1.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.34	-0.33	2.56e-5	Initial pursuit acceleration;
PAAD	cis	rs643506	0.774	rs11214033	chr11:111769702	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.53	-4.45	-0.34	1.66e-5	Breast cancer;
PAAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg24253500	chr15:84953950	NA	-0.47	-5.18	-0.39	6.82e-7	P wave terminal force;
PAAD	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg22089800	chr15:90895588	ZNF774	0.73	8.77	0.58	3.31e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.72	-7.42	-0.52	7.88e-12	Colorectal cancer;
PAAD	cis	rs375066	0.762	rs10424336	chr19:44392100	C/T	cg08633290	chr19:44405433	NA	-0.55	-5.15	-0.39	8.13e-7	Breast cancer;
PAAD	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs10875746	0.551	rs11168536	chr12:48745051	C/T	cg26205652	chr12:48591994	NA	0.76	6.96	0.49	9.36e-11	Longevity (90 years and older);
PAAD	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.6	5.77	0.42	4.26e-8	Asthma;
PAAD	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.34	-0.33	2.55e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.33	-0.33	2.72e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9810890	1.000	rs73196980	chr3:128451396	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-8.4	-0.56	2.95e-14	Prion diseases;
PAAD	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs654384	0.836	rs13224986	chr7:4172109	C/T	cg27574739	chr7:4176374	SDK1	-0.5	-5.03	-0.38	1.36e-6	Positive affect;
PAAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.78	7.38	0.51	9.82e-12	Asthma;
PAAD	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.56	-0.41	1.18e-7	Educational attainment;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.55	6.08	0.44	9.28e-9	Obesity-related traits;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg09594475	chr20:60884601	LAMA5	0.51	5.57	0.41	1.15e-7	Pelvic organ prolapse;
PAAD	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.41	0.4	2.37e-7	Menarche (age at onset);
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg17541715	chr7:1216824	NA	-0.55	-6.37	-0.46	2.17e-9	Longevity;Endometriosis;
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.73	8.67	0.58	6.01e-15	Height;
PAAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.84	-8.5	-0.57	1.66e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg00522288	chr12:125625016	AACS	-0.49	-5.1	-0.38	9.9e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.48	-4.99	-0.38	1.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg26497354	chr6:109612229	NA	-0.42	-4.25	-0.33	3.7e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.86	-4.62	-0.35	8.13e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg04775059	chr7:64541387	NA	0.57	5.98	0.44	1.51e-8	Calcium levels;
PAAD	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.3	0.46	3e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26133372	chr5:1537930	NA	-0.66	-6.41	-0.46	1.75e-9	Obesity-related traits;
PAAD	cis	rs3736485	0.934	rs1902593	chr15:51882080	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs9810890	1.000	rs73196956	chr3:128430834	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs3096299	0.967	rs3102383	chr16:89411295	G/A	cg00750074	chr16:89608354	SPG7	-0.57	-5.29	-0.39	4.27e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg06740227	chr12:86229804	RASSF9	0.52	4.89	0.37	2.51e-6	Major depressive disorder;
PAAD	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.5	5.08	0.38	1.12e-6	Obesity-related traits;
PAAD	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.63	8.53	0.57	1.4e-14	Height;
PAAD	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg10006428	chr1:248814059	OR2T27	0.4	4.72	0.36	5.21e-6	Common traits (Other);
PAAD	cis	rs9463078	0.677	rs7739928	chr6:45068053	G/C	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.08e-8	Menopause (age at onset);
PAAD	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.87	0.37	2.73e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.95	13.23	0.73	4.46e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-1.04	-8.23	-0.56	7.84e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.48	-6.11	-0.44	7.94e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.51	4.31	0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-7.78	-0.53	1e-12	Colorectal cancer;
PAAD	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg14709524	chr16:89940631	TCF25	0.92	4.84	0.37	3.13e-6	Skin colour saturation;
PAAD	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg15764593	chr10:829463	NA	-0.83	-4.46	-0.34	1.6e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg21859623	chr20:33103246	DYNLRB1	0.46	4.37	0.33	2.29e-5	Height;
PAAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.39	-0.46	1.93e-9	Fibrinogen levels;
PAAD	cis	rs7793919	0.628	rs4720402	chr7:4780961	T/G	cg09789173	chr7:4769017	FOXK1	0.74	7.92	0.54	4.76e-13	Mosquito bite size;
PAAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.76	8.89	0.59	1.62e-15	Methadone dose in opioid dependence;
PAAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg00647820	chr17:40259828	DHX58	-0.44	-5.26	-0.39	4.85e-7	Fibrinogen levels;
PAAD	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02294249	chr13:34392492	RFC3	0.71	8.3	0.56	5.18e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1865721	0.761	rs36002108	chr18:73220472	C/T	cg26385618	chr18:73139727	C18orf62	-0.45	-5.25	-0.39	4.98e-7	Intelligence;
PAAD	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-4.65	-0.35	7.03e-6	Subjective well-being;
PAAD	cis	rs7009516	0.819	rs12542012	chr8:24223031	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.46	5.52	0.41	1.43e-7	Hair greying;
PAAD	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.78	10.23	0.64	5.04e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.76	5.9	0.43	2.28e-8	Lung function (FEV1/FVC);
PAAD	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.66	7.24	0.51	2.03e-11	Blood protein levels;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg03538708	chr1:25844672	NA	-0.49	-5.02	-0.38	1.45e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs1476670	0.710	rs751442	chr1:44509551	A/C	cg09470012	chr1:44509516	NA	0.49	4.89	0.37	2.51e-6	Eotaxin levels;
PAAD	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.75	-7.57	-0.52	3.35e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8112211	1.000	rs56849284	chr19:38826947	T/C	cg14299480	chr19:38876666	GGN	-0.57	-7.25	-0.51	2e-11	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg15117754	chr3:10150083	C3orf24	0.71	6.06	0.44	1.05e-8	Alzheimer's disease;
PAAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg23281280	chr6:28129359	ZNF389	0.51	4.3	0.33	3.03e-5	Parkinson's disease;
PAAD	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.56	-0.47	8.14e-10	Chronic sinus infection;
PAAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.55	-5.01	-0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.69e-10	Exhaled nitric oxide output;
PAAD	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg01064725	chr1:204461714	NA	-0.52	-4.9	-0.37	2.41e-6	Schizophrenia;
PAAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.82	8.57	0.57	1.09e-14	Cognitive function;
PAAD	cis	rs11718455	0.526	rs11720884	chr3:43941406	A/G	cg21419209	chr3:44054225	NA	-0.57	-5.26	-0.39	4.9e-7	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.02e-6	Lung cancer;
PAAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.92	11.52	0.68	1.81e-22	Pulse pressure;
PAAD	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg01304814	chr3:48885189	PRKAR2A	1.01	5.84	0.43	3.06e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.04	9.2	0.6	2.59e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-7.42	-0.52	7.85e-12	Asthma;
PAAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg19847866	chr10:1019161	NA	-0.59	-4.64	-0.35	7.58e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	5.75	0.42	4.64e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05790982	chr4:4861404	MSX1	0.56	6.33	0.46	2.56e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.42	-6.6	-0.47	6.29e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2457480	0.543	rs1482473	chr10:44707598	G/C	cg09554077	chr10:44749378	NA	0.34	4.92	0.37	2.23e-6	Coronary artery disease;
PAAD	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.57	6.52	0.47	9.79e-10	Total body bone mineral density;
PAAD	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.75	-7.19	-0.5	2.71e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg04851639	chr8:1020857	NA	-0.64	-8.11	-0.55	1.5700000000000001e-13	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.6	-7.2	-0.5	2.62e-11	Iron status biomarkers;
PAAD	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg10556349	chr10:835070	NA	0.6	4.97	0.37	1.77e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg05341575	chr12:125625032	AACS	-0.49	-4.59	-0.35	9.13e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7044106	0.655	rs1359329	chr9:123370985	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	5.97	0.44	1.58e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg19090574	chr1:205240910	TMCC2	-0.44	-4.76	-0.36	4.45e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg15847926	chr7:2749597	AMZ1	-0.39	-4.47	-0.34	1.52e-5	Height;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	1.07	15.55	0.78	3.07e-33	Systemic lupus erythematosus;
PAAD	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.37	-0.51	1.01e-11	Morning vs. evening chronotype;
PAAD	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	8.38	0.56	3.22e-14	Chronic sinus infection;
PAAD	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.63	6.08	0.44	9.45e-9	Corneal astigmatism;
PAAD	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.47	4.25	0.33	3.68e-5	White matter hyperintensity burden;
PAAD	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.5	2.47e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.65	5.14	0.38	8.45e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg19429281	chr19:53496738	ZNF702P	-0.57	-6.06	-0.44	1.04e-8	Psoriasis;
PAAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9815354	1.000	rs9876960	chr3:41985812	C/T	cg03022575	chr3:42003672	ULK4	-0.75	-5.4	-0.4	2.47e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.39	4.98	0.37	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3790455	0.610	rs1171561	chr1:156455898	G/A	cg14087168	chr1:156450669	MEF2D	-0.42	-5.0	-0.38	1.55e-6	Migraine;
PAAD	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.96	0.63	2.65e-18	Cognitive function;
PAAD	cis	rs7833787	1.000	rs34270955	chr8:18705250	G/C	cg17701159	chr8:18705777	PSD3	-0.45	-5.24	-0.39	5.26e-7	Obesity-related traits;
PAAD	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg01620082	chr3:125678407	NA	-1.07	-7.26	-0.51	1.89e-11	Depression;
PAAD	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.55	5.45	0.4	2.02e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15848147	chr4:120132554	USP53	-0.65	-6.54	-0.47	8.81e-10	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.71	9.56	0.61	2.93e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.63	5.48	0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg20639618	chr4:183729073	NA	0.68	5.42	0.4	2.34e-7	Pediatric autoimmune diseases;
PAAD	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg00717180	chr2:96193071	NA	0.58	6.51	0.47	1.01e-9	HDL cholesterol;
PAAD	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg05038881	chr1:10490043	APITD1	-0.42	-5.05	-0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12681288	0.782	rs6559213	chr8:1030923	A/G	cg04851639	chr8:1020857	NA	-0.64	-7.71	-0.53	1.55e-12	Schizophrenia;
PAAD	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.57	6.1	0.44	8.36e-9	Lung cancer;
PAAD	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.52	-4.65	-0.35	7.02e-6	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24445507	chr3:53044901	SFMBT1	-0.51	-6.52	-0.47	9.8e-10	Monocyte percentage of white cells;
PAAD	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.46	4.87	0.37	2.82e-6	Age of smoking initiation;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg13282195	chr8:144660772	NAPRT1	0.77	5.74	0.42	4.91e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.5	5.57	0.41	1.12e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.53	0.41	1.39e-7	Body mass index;
PAAD	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06850241	chr22:41845214	NA	0.51	4.47	0.34	1.5e-5	Vitiligo;
PAAD	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs7631605	0.783	rs11129744	chr3:36966449	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.69	0.36	6.04e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs35740288	0.770	rs17635450	chr15:86199049	C/G	cg07943548	chr15:86304357	KLHL25	0.58	4.74	0.36	4.8e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4757319	0.532	rs6486245	chr11:15438256	G/A	cg03245590	chr11:15329459	NA	0.38	4.52	0.34	1.23e-5	Breast cancer;
PAAD	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.44	0.4	2.07e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.55	-5.33	-0.4	3.49e-7	Corneal structure;
PAAD	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs282708	0.934	rs2642169	chr4:59508505	G/A	cg11281224	chr4:60001000	NA	0.44	4.28	0.33	3.25e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6142102	0.625	rs6141436	chr20:32554571	T/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs4273100	0.850	rs11204306	chr17:19267371	A/G	cg18093559	chr17:18951025	GRAP	-0.52	-4.38	-0.33	2.17e-5	Schizophrenia;
PAAD	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.56	-5.36	-0.4	2.97e-7	Retinal vascular caliber;
PAAD	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs797680	0.754	rs12118230	chr1:93651461	T/G	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.03	0.38	1.39e-6	Childhood ear infection;
PAAD	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg02072170	chr3:194406190	FAM43A	0.56	5.67	0.42	7.08e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.53	5.24	0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs113123495	0.510	rs2261565	chr19:5712108	C/T	cg26242866	chr19:5711310	LONP1	1.05	4.57	0.35	1.01e-5	Obsessive-compulsive symptoms;
PAAD	cis	rs9810890	1.000	rs116203743	chr3:128483210	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.95	12.68	0.72	1.38e-25	Menarche (age at onset);
PAAD	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.67	-6.95	-0.49	1.02e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg15443732	chr18:74961078	GALR1	0.74	6.0	0.44	1.42e-8	Obesity-related traits;
PAAD	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg27449745	chr7:23145252	KLHL7	-0.51	-4.35	-0.33	2.44e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.47	-4.74	-0.36	4.88e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.22	-0.45	4.66e-9	Crohn's disease;
PAAD	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.92	-9.25	-0.6	1.95e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg20848291	chr7:100343083	ZAN	-0.79	-6.63	-0.47	5.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2455826	0.521	rs1348981	chr3:15828811	G/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.52	-0.34	1.25e-5	Inflammatory skin disease;
PAAD	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs55637147	0.671	rs10896610	chr11:57119602	G/A	cg25492363	chr11:57319872	UBE2L6	-0.42	-4.72	-0.36	5.35e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19162333	chr4:16084676	PROM1	0.56	6.51	0.47	1.06e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	4.79	0.36	3.98e-6	Depressive symptoms;
PAAD	cis	rs1497828	0.956	rs2815235	chr1:217540910	C/T	cg04411442	chr1:217543379	NA	-0.48	-4.73	-0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.8	-9.75	-0.62	9.8e-18	Height;
PAAD	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	1.26	13.06	0.73	1.29e-26	Post bronchodilator FEV1;
PAAD	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs16975963	0.644	rs11083428	chr19:38083967	A/C	cg14218481	chr19:38281219	NA	0.41	4.41	0.34	1.96e-5	Longevity;
PAAD	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.73	4.55	0.35	1.1e-5	IgG glycosylation;
PAAD	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.77	0.48	2.69e-10	Morning vs. evening chronotype;
PAAD	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg17366294	chr4:99064904	C4orf37	0.44	4.84	0.37	3.18e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.5	0.34	1.33e-5	Trans fatty acid levels;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13047869	chr3:10149882	C3orf24	0.79	6.59	0.47	6.78e-10	Alzheimer's disease;
PAAD	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg03684893	chr10:554711	DIP2C	0.5	4.77	0.36	4.3e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.63	-7.74	-0.53	1.26e-12	Alcohol dependence;
PAAD	cis	rs427941	0.632	rs201480	chr7:101747575	A/G	cg06246474	chr7:101738831	CUX1	0.43	4.29	0.33	3.2e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.85	-6.24	-0.45	4.05e-9	Type 2 diabetes;
PAAD	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.43	-6.36	-0.46	2.2e-9	Breast cancer;
PAAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-4.86	-0.37	2.93e-6	Type 2 diabetes;
PAAD	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.37	-0.4	2.86e-7	Common traits (Other);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03286202	chr11:71639070	RNF121;LOC100133315	-0.64	-6.6	-0.47	6.56e-10	Lung cancer in ever smokers;
PAAD	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg14703610	chr5:56206110	C5orf35	0.58	5.42	0.4	2.32e-7	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09656405	chr15:69745057	RPLP1	0.59	6.57	0.47	7.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06544989	chr22:39130855	UNC84B	0.48	4.71	0.36	5.55e-6	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.8	-6.0	-0.44	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg13385521	chr17:29058706	SUZ12P	-0.7	-4.61	-0.35	8.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg16447950	chr5:562315	NA	-0.67	-5.95	-0.43	1.77e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.3	-0.39	4.02e-7	Bipolar disorder;
PAAD	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg15549821	chr19:49342101	PLEKHA4	-1.22	-9.08	-0.59	5.31e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.54	-5.57	-0.41	1.11e-7	Testicular germ cell tumor;
PAAD	cis	rs2997447	0.846	rs3008225	chr1:26390181	T/A	cg24519413	chr1:26490540	NA	0.48	4.44	0.34	1.72e-5	QRS complex (12-leadsum);
PAAD	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.47	-4.82	-0.36	3.47e-6	Ulcerative colitis;
PAAD	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg18093559	chr17:18951025	GRAP	0.49	5.33	0.4	3.46e-7	Schizophrenia;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.11	-14.91	-0.77	1.49e-31	Urate levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05412136	chr9:36191352	CLTA	0.58	6.86	0.49	1.65e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.42	5.09	0.38	1.06e-6	Colorectal cancer;
PAAD	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.43	4.32	0.33	2.76e-5	Longevity;Endometriosis;
PAAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.08	-0.59	5.39e-16	Type 2 diabetes;
PAAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4740619	0.630	rs1927702	chr9:15986716	T/C	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.59	6.18	0.45	5.75e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.76	-6.79	-0.48	2.35e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9900972	0.549	rs11077399	chr17:76864175	C/T	cg00961940	chr17:76876995	TIMP2	-0.42	-4.64	-0.35	7.45e-6	Obesity-related traits;
PAAD	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	7.54	0.52	4e-12	HIV-1 control;
PAAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	0.96	6.14	0.45	7.05e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.58	-7.03	-0.5	6.66e-11	Total body bone mineral density;
PAAD	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.79	7.2	0.5	2.65e-11	Breast cancer;
PAAD	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.71	-6.93	-0.49	1.11e-10	Hip circumference;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	trans	rs62179067	0.708	rs62175992	chr2:179899087	G/A	cg13380624	chr19:7735426	NA	-0.74	-7.09	-0.5	4.64e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2694528	0.841	rs78406720	chr5:60385738	G/A	cg11474532	chr5:59995715	DEPDC1B	1.0	5.46	0.4	1.91e-7	Parkinson's disease;
PAAD	cis	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26926768	chr12:34528122	NA	0.38	4.56	0.35	1.06e-5	Morning vs. evening chronotype;
PAAD	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.12	14.37	0.76	4.16e-30	Primary sclerosing cholangitis;
PAAD	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.6	-0.35	8.9e-6	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20512419	chr11:67276145	CDK2AP2	0.63	7.11	0.5	4.19e-11	Monocyte percentage of white cells;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg11196182	chr7:1989412	MAD1L1	0.4	4.28	0.33	3.31e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11825064	0.510	rs74765580	chr11:134517903	A/G	cg06603561	chr11:134479413	NA	-0.94	-5.82	-0.43	3.39e-8	Seasonality;
PAAD	cis	rs2562456	0.876	rs2562413	chr19:21602886	G/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.71	-7.8	-0.53	9.3e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs9866391	0.679	rs13065569	chr3:141077615	C/T	cg00789793	chr3:141329863	RASA2	0.52	4.38	0.34	2.16e-5	Myopia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17146352	chr2:128051828	ERCC3	0.69	8.84	0.58	2.23e-15	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg17541715	chr7:1216824	NA	-0.52	-5.82	-0.43	3.29e-8	Longevity;Endometriosis;
PAAD	cis	rs939584	0.877	rs6548240	chr2:636929	C/A	cg03610516	chr2:642275	NA	0.56	5.16	0.39	7.52e-7	Body mass index;
PAAD	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs12127679	0.614	rs12066942	chr1:244171360	G/A	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg26570165	chr1:119541833	NA	-0.47	-4.25	-0.33	3.67e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg10494973	chr17:80897199	TBCD	-0.49	-4.91	-0.37	2.34e-6	Breast cancer;
PAAD	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg19090574	chr1:205240910	TMCC2	-0.42	-4.58	-0.35	9.47e-6	Red blood cell count;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg18612461	chr15:75251733	NA	0.63	7.85	0.54	6.76e-13	Breast cancer;
PAAD	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	1.0	12.18	0.7	2.97e-24	Breast cancer;
PAAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.17	17.94	0.82	2.33e-39	Cognitive function;
PAAD	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-1.02	-6.7	-0.48	3.91e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs3112530	1.000	rs10463328	chr5:152664042	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.75	6.79	0.48	2.36e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.76	-7.87	-0.54	6.09e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs901683	0.850	rs112392416	chr10:46070466	C/T	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.64	6.92	0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg03094675	chr11:5960213	NA	-0.48	-4.49	-0.34	1.39e-5	DNA methylation (variation);
PAAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.23e-27	Height;
PAAD	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.76	-8.24	-0.56	7.23e-14	Inflammatory bowel disease;
PAAD	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg12963866	chr19:57752005	ZNF805	0.57	5.92	0.43	2.07e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg07384165	chr1:10488281	NA	-0.51	-5.15	-0.39	7.87e-7	Prostate cancer;
PAAD	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.59	5.54	0.41	1.29e-7	Height;
PAAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg19912559	chr1:40204330	PPIE	0.5	4.78	0.36	4.15e-6	Blood protein levels;
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.87e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs354033	1.000	rs11766910	chr7:149279620	C/T	cg06920324	chr7:149264011	ZNF767	-0.62	-5.16	-0.39	7.75e-7	Multiple sclerosis;
PAAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-4.28	-0.33	3.35e-5	Obesity-related traits;
PAAD	trans	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.72	6.41	0.46	1.75e-9	Mean platelet volume;
PAAD	cis	rs8060686	0.858	rs7187476	chr16:67699948	T/C	cg05110241	chr16:68378359	PRMT7	-0.72	-4.8	-0.36	3.81e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.82	-0.36	3.49e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Tonsillectomy;
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13870426	chr17:30244630	NA	-0.7	-7.07	-0.5	5.38e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.2	-14.42	-0.76	2.99e-30	Type 1 diabetes nephropathy;
PAAD	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.52	-4.8	-0.36	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.52	-5.17	-0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.82	0.54	8.19e-13	Prudent dietary pattern;
PAAD	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg25272121	chr1:152190972	HRNR	0.48	4.32	0.33	2.78e-5	Inflammatory skin disease;
PAAD	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg04415270	chr2:102091202	RFX8	0.63	8.17	0.55	1.11e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg25886479	chr11:50257625	LOC441601	0.42	4.76	0.36	4.51e-6	Coronary artery disease;
PAAD	cis	rs761746	0.960	rs14034	chr22:32015406	T/C	cg01338084	chr22:32026380	PISD	0.5	4.43	0.34	1.82e-5	Intelligence;
PAAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg01320130	chr1:67600311	NA	0.57	6.41	0.46	1.69e-9	Psoriasis;
PAAD	cis	rs7101446	0.704	rs4102216	chr11:63211933	A/G	cg26116525	chr11:62371596	EML3	0.42	4.25	0.33	3.69e-5	Economic and political preferences;
PAAD	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-5.27	-0.39	4.63e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs990171	0.687	rs10210680	chr2:103127682	G/A	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg02117656	chr17:79614917	TSPAN10	-0.59	-6.43	-0.46	1.59e-9	Eye color traits;
PAAD	cis	rs755249	0.530	rs16826087	chr1:39812518	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.99	-0.37	1.66e-6	Menarche (age at onset);
PAAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00603274	chr11:61596626	FADS2	-0.59	-4.6	-0.35	8.7e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg20821713	chr7:1055600	C7orf50	-0.54	-4.36	-0.33	2.35e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg01334972	chr11:72463230	ARAP1	0.69	5.06	0.38	1.22e-6	Type 2 diabetes;
PAAD	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.64	6.97	0.49	9.27e-11	Corneal astigmatism;
PAAD	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.87	9.74	0.62	1e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs2133450	0.508	rs17047072	chr3:7349526	A/G	cg19930620	chr3:7340148	GRM7	-0.46	-4.98	-0.37	1.73e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs300774	0.800	rs406427	chr2:146263	C/A	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7191751	0.502	rs879124	chr16:86314962	A/C	cg09395612	chr16:86018936	NA	0.56	4.33	0.33	2.72e-5	Response to platinum-based chemotherapy (cisplatin);
PAAD	cis	rs1941184	0.526	rs7240484	chr18:29029768	G/T	cg03238162	chr18:29027701	DSG3	0.42	4.76	0.36	4.46e-6	Parkinson's disease (age of onset);
PAAD	trans	rs9039	0.550	rs12924785	chr16:9219285	T/G	cg22670128	chr1:1210100	UBE2J2	-0.52	-6.38	-0.46	2.01e-9	Menopause (age at onset);
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg14789911	chr21:47582049	C21orf56	0.51	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11312980	chr14:64931897	AKAP5	0.59	6.36	0.46	2.25e-9	Pancreatic cancer;
PAAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	1.03	13.71	0.74	2.39e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.53	6.76	0.48	2.85e-10	Sitting height ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26655873	chr3:72818019	SHQ1	-0.64	-6.4	-0.46	1.79e-9	Obesity-related traits;
PAAD	cis	rs3812111	0.506	rs1204837	chr6:116514792	G/A	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.31	-0.33	2.9e-5	Age-related macular degeneration;
PAAD	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs6604026	0.541	rs6698082	chr1:93390645	G/A	cg13858687	chr1:93297071	RPL5	0.49	4.47	0.34	1.51e-5	Multiple sclerosis;
PAAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-4.59	-0.35	9.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08632001	chr20:34130163	ERGIC3	-0.71	-6.42	-0.46	1.61e-9	Lung cancer in ever smokers;
PAAD	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-5.27	-0.39	4.54e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.66	-8.9	-0.59	1.54e-15	Eye color traits;
PAAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.8	8.8	0.58	2.79e-15	Schizophrenia;
PAAD	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.14	14.09	0.75	2.22e-29	IgG glycosylation;
PAAD	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.77	7.83	0.54	7.82e-13	Body mass index;
PAAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg09491104	chr22:46646882	C22orf40	-1.01	-6.07	-0.44	9.82e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.87	9.77	0.62	8.44e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs8105895	0.932	rs12150930	chr19:22223687	G/C	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg01059385	chr22:42394853	WBP2NL	0.44	4.7	0.36	5.71e-6	Cognitive function;
PAAD	cis	rs4924935	0.581	rs8070669	chr17:18774708	A/T	cg26306683	chr17:18585705	ZNF286B	0.62	4.6	0.35	8.86e-6	Pancreatic cancer;
PAAD	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg01631408	chr1:248437212	OR2T33	-0.56	-5.26	-0.39	4.86e-7	Common traits (Other);
PAAD	cis	rs741702	0.928	rs2965214	chr19:13029188	G/A	cg15585409	chr19:12750806	NA	-0.47	-4.27	-0.33	3.42e-5	Red blood cell traits;
PAAD	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.97	10.38	0.64	2.02e-19	Corneal astigmatism;
PAAD	cis	rs6669119	0.818	rs76874970	chr1:19087065	A/G	cg19637330	chr1:19110922	NA	0.76	4.75	0.36	4.72e-6	Percentage gas trapping;
PAAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00982548	chr2:198649783	BOLL	-0.8	-5.67	-0.42	7.04e-8	Ulcerative colitis;
PAAD	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg11266682	chr4:10021025	SLC2A9	-0.63	-5.66	-0.42	7.43e-8	Schizophrenia (age at onset);
PAAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	trans	rs4707930	0.578	rs2754047	chr6:72413070	G/A	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.72	-6.04	-0.44	1.15e-8	Fibrinogen levels;
PAAD	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.54	5.49	0.41	1.62e-7	Mean corpuscular volume;
PAAD	cis	rs7714584	1.000	rs59715748	chr5:150189287	G/A	cg22134413	chr5:150180641	NA	0.95	6.41	0.46	1.71e-9	Crohn's disease;
PAAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg25204440	chr1:209979598	IRF6	0.57	4.54	0.35	1.15e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16417436	chr16:28758564	NA	-0.47	-4.33	-0.33	2.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.05	0.55	2.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	5.86	0.43	2.75e-8	Lung cancer;
PAAD	cis	rs1539053	0.932	rs12718425	chr1:58105213	G/A	cg20292791	chr1:58089357	DAB1	-0.55	-5.49	-0.41	1.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16114798	chr6:168677396	NA	0.67	6.65	0.47	5.07e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.9	7.13	0.5	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.9	-13.82	-0.75	1.21e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.86	5.83	0.43	3.27e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.61	6.36	0.46	2.26e-9	Response to antipsychotic treatment;
PAAD	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.31	-4.74	-0.36	4.79e-6	Red cell distribution width;
PAAD	cis	rs4343996	0.840	rs4131987	chr7:3380895	C/T	cg21248987	chr7:3385318	SDK1	-0.48	-5.14	-0.38	8.37e-7	Motion sickness;
PAAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.18	-0.5	2.85e-11	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02725872	chr8:58115012	NA	-0.64	-5.44	-0.4	2.12e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06156847	chr2:113672199	IL1F7	0.57	6.13	0.45	7.14e-9	Pulmonary function;
PAAD	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.67	-9.48	-0.61	4.91e-17	Venous thromboembolism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24892309	chr3:52724568	GNL3;SNORD19B	-0.63	-7.35	-0.51	1.12e-11	Monocyte percentage of white cells;
PAAD	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.63	6.07	0.44	9.66e-9	Itch intensity from mosquito bite;
PAAD	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22601191	chr20:60968625	CABLES2	0.73	6.33	0.46	2.66e-9	Colorectal cancer;
PAAD	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.33	-0.4	3.45e-7	Schizophrenia;
PAAD	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg19257562	chr1:2043853	PRKCZ	0.39	4.39	0.34	2.1e-5	Height;
PAAD	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	5.23	0.39	5.64e-7	Type 2 diabetes;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg27532560	chr4:187881888	NA	-0.56	-6.65	-0.47	5.01e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.39	4.76	0.36	4.54e-6	Sitting height ratio;
PAAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg02071572	chr4:1403502	NA	0.38	4.49	0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs950037	0.710	rs786923	chr1:89242954	C/T	cg13109106	chr1:89333529	GTF2B	-0.46	-4.34	-0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.6	6.75	0.48	2.98e-10	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Bipolar disorder;
PAAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs10737909	1.000	rs10803369	chr1:15550525	G/T	cg21012057	chr1:15538911	TMEM51	-0.55	-5.87	-0.43	2.66e-8	Migraine;
PAAD	cis	rs8032158	1.000	rs67505007	chr15:56196253	C/T	cg02198044	chr15:56286336	NEDD4	-0.52	-5.4	-0.4	2.52e-7	Keloid;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18357526	chr6:26021779	HIST1H4A	0.68	6.7	0.48	3.91e-10	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.65	6.62	0.47	5.88e-10	Blood protein levels;
PAAD	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	9.63	0.62	2.03e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg14703610	chr5:56206110	C5orf35	0.61	5.54	0.41	1.3e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg09242541	chr1:10490025	APITD1	0.36	4.55	0.35	1.08e-5	Breast cancer;
PAAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.63e-6	Personality dimensions;
PAAD	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-4.55	-0.35	1.07e-5	Menarche (age at onset);
PAAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.65	-7.15	-0.5	3.44e-11	Caffeine consumption;
PAAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.87e-5	Height;
PAAD	cis	rs6715793	0.839	rs4670836	chr2:33406372	A/G	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25706373	chr1:206858537	MAPKAPK2	0.59	6.71	0.48	3.69e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18621852	chr3:10150065	C3orf24	0.67	6.08	0.44	9.09e-9	Alzheimer's disease;
PAAD	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.55	-0.52	3.69e-12	Total body bone mineral density;
PAAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13095912	0.925	rs11922634	chr3:185349190	G/A	cg02401761	chr3:185826130	ETV5	0.46	4.29	0.33	3.16e-5	Systolic blood pressure;
PAAD	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	trans	rs4427176	0.507	rs4841206	chr8:9583627	G/A	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18621852	chr3:10150065	C3orf24	-0.49	-4.69	-0.36	6.02e-6	Alzheimer's disease;
PAAD	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs5756391	0.546	rs9607391	chr22:37314770	A/T	cg21209356	chr22:37319042	CSF2RB	-0.35	-4.35	-0.33	2.48e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs2000999	0.524	rs12933482	chr16:72189604	A/G	cg16558253	chr16:72132732	DHX38	-0.7	-4.58	-0.35	9.76e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.07	-7.04	-0.5	6.31e-11	Mitochondrial DNA levels;
PAAD	cis	rs7119038	0.818	rs6589685	chr11:118612197	T/C	cg19308663	chr11:118741387	NA	0.53	4.32	0.33	2.75e-5	Sjögren's syndrome;
PAAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-1.33	-10.66	-0.65	3.72e-20	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08255233	chr6:87607178	NA	-0.65	-6.71	-0.48	3.61e-10	Smoking initiation;
PAAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.28	-0.33	3.3e-5	Joint mobility (Beighton score);
PAAD	cis	rs11264213	0.892	rs67906703	chr1:36178590	C/T	cg27506609	chr1:36549197	TEKT2	0.63	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.85	9.09	0.59	5.16e-16	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.57	-0.35	9.99e-6	Body mass index;
PAAD	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.62	6.92	0.49	1.18e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.6	5.96	0.44	1.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg19567339	chr10:100142640	NA	0.42	4.59	0.35	9.41e-6	Metabolite levels;
PAAD	cis	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Height;
PAAD	cis	rs1966248	0.543	rs6909803	chr6:134111198	C/T	cg17736819	chr6:133783020	EYA4	0.43	4.26	0.33	3.51e-5	Coronary artery disease;
PAAD	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.68	6.41	0.46	1.72e-9	Platelet count;
PAAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.56	4.98	0.37	1.73e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs62238980	0.708	rs3986033	chr22:32589417	C/G	cg02631450	chr22:32366979	NA	1.02	5.0	0.38	1.59e-6	Childhood ear infection;
PAAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.76	7.84	0.54	7.34e-13	Breast cancer;
PAAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.4	0.46	1.82e-9	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg09324608	chr17:30823087	MYO1D	0.43	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.41	-4.31	-0.33	2.92e-5	Aortic root size;
PAAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.7	5.86	0.43	2.84e-8	Coronary artery disease;
PAAD	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.65	0.47	5.08e-10	Blood protein levels;
PAAD	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.27	-0.39	4.65e-7	Height;
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg26554054	chr8:600488	NA	0.84	5.45	0.4	1.99e-7	IgG glycosylation;
PAAD	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.8	-8.7	-0.58	5.1e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.66	6.32	0.46	2.81e-9	Parkinson's disease;
PAAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.06	-0.38	1.19e-6	Recombination rate (females);
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.66	-7.09	-0.5	4.72e-11	Iron status biomarkers;
PAAD	cis	rs910039	0.606	rs823435	chr6:17496534	A/C	cg27087525	chr6:17600386	FAM8A1	-0.56	-4.28	-0.33	3.3e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.74	-0.36	4.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.66	5.07	0.38	1.14e-6	Osteoarthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00775695	chr9:14693648	ZDHHC21	0.59	6.37	0.46	2.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.63	-6.41	-0.46	1.76e-9	Body mass index;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07211384	chr2:86668246	KDM3A	0.63	6.77	0.48	2.65e-10	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4427176	0.769	rs6997419	chr8:9587329	A/G	cg03024720	chr8:9765601	NA	0.48	4.61	0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg16590910	chr6:42928470	GNMT	0.49	4.98	0.37	1.74e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-5.42	-0.4	2.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.28	0.6	1.63e-16	Mortality in heart failure;
PAAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg03037974	chr15:76606532	NA	0.52	6.03	0.44	1.21e-8	Blood metabolite levels;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	5.9e-8	Life satisfaction;
PAAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg21153622	chr11:89784906	NA	-0.54	-6.29	-0.45	3.21e-9	HDL cholesterol;
PAAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.58	5.93	0.43	1.98e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg01064725	chr1:204461714	NA	-0.5	-4.75	-0.36	4.76e-6	Schizophrenia;
PAAD	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.69	7.83	0.54	7.75e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.36	-0.6	1.01e-16	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18854424	chr1:2615690	NA	0.42	5.34	0.4	3.34e-7	Ulcerative colitis;
PAAD	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.64	-5.12	-0.38	8.94e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg27478167	chr7:817139	HEATR2	-0.72	-5.65	-0.42	7.77e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	6.41	0.46	1.78e-9	Cognitive test performance;
PAAD	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg08601574	chr20:25228251	PYGB	-0.54	-5.48	-0.41	1.72e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.9e-5	Rheumatoid arthritis;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg03999872	chr20:62272968	STMN3	-0.75	-6.58	-0.47	6.99e-10	Atopic dermatitis;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11905131	chr22:24372483	LOC391322	0.6	5.49	0.41	1.63e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs137699	0.500	rs137646	chr22:39728714	T/C	cg11247378	chr22:39784982	NA	-0.66	-5.05	-0.38	1.26e-6	IgG glycosylation;
PAAD	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-5.87	-0.43	2.61e-8	Homocysteine levels;
PAAD	cis	rs2790216	1.000	rs1769040	chr10:59954081	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg20129853	chr10:51489980	NA	-0.45	-4.46	-0.34	1.56e-5	Prostate-specific antigen levels;
PAAD	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	1.12	18.58	0.83	5.98e-41	Colorectal adenoma (advanced);
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.5	5.21	0.39	5.96e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg14631576	chr9:95140430	CENPP	-0.61	-5.93	-0.43	1.94e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4704187	0.687	rs12653162	chr5:74391666	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs3779195	0.585	rs7777991	chr7:97865757	A/G	cg24562669	chr7:97807699	LMTK2	-0.54	-4.62	-0.35	8.15e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs1443512	0.947	rs4759309	chr12:54342786	G/A	cg25382128	chr12:54346509	NA	-0.6	-6.06	-0.44	1.01e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.51	0.34	1.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.14	0.39	8.2e-7	Coffee consumption (cups per day);
PAAD	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.54	-0.41	1.3e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00982548	chr2:198649783	BOLL	-0.78	-5.42	-0.4	2.31e-7	Ulcerative colitis;
PAAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.47	0.34	1.5e-5	Tonsillectomy;
PAAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.4	5.07	0.38	1.12e-6	Sitting height ratio;
PAAD	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1468734	0.929	rs12929716	chr16:5006600	A/G	cg06510647	chr16:5006106	NA	0.61	5.69	0.42	6.3e-8	Cancer;
PAAD	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg19486271	chr11:47235900	DDB2	-0.59	-5.93	-0.43	1.99e-8	Acne (severe);
PAAD	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg23950597	chr19:37808831	NA	-0.77	-5.21	-0.39	6.09e-7	Coronary artery calcification;
PAAD	cis	rs7616330	0.836	rs73118214	chr3:71047396	A/C	cg01511742	chr3:71112437	FOXP1	-0.78	-5.66	-0.42	7.36e-8	QT interval;
PAAD	cis	rs16975963	0.644	rs12459013	chr19:38129497	C/G	cg14218481	chr19:38281219	NA	0.44	4.72	0.36	5.25e-6	Longevity;
PAAD	cis	rs4936891	0.557	rs470242	chr11:123909342	G/A	cg22125253	chr11:123886957	OR10G4	-0.44	-4.4	-0.34	2.03e-5	Male fertility;
PAAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	10.76	0.66	1.95e-20	Tonsillectomy;
PAAD	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.91	-6.44	-0.46	1.47e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10186876	0.544	rs4347883	chr2:44185129	T/C	cg09541576	chr2:44873248	C2orf34	0.46	4.26	0.33	3.59e-5	Hand grip strength;
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.67	-0.35	6.65e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.44	4.52	0.34	1.25e-5	Age of smoking initiation;
PAAD	cis	rs1419980	0.730	rs7137688	chr12:7741057	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.6e-8	Height;
PAAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg01388757	chr2:102091195	RFX8	-0.61	-8.1	-0.55	1.62e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs10901513	0.932	rs10901501	chr10:127683640	A/G	cg22975853	chr10:127789788	ADAM12	0.44	4.77	0.36	4.2e-6	Visceral fat;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06760068	chr1:6845484	CAMTA1	0.66	7.46	0.52	6.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21646471	chr2:242523971	THAP4	0.64	5.07	0.38	1.15e-6	Prostate cancer;
PAAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg18833306	chr6:118973337	C6orf204	-0.56	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.86	9.95	0.63	2.87e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.84	-0.37	3.16e-6	Triglycerides;
PAAD	cis	rs11811982	0.793	rs76146925	chr1:227539529	C/A	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg01815783	chr4:1047043	NA	-0.46	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.59	0.47	6.65e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.47	4.56	0.35	1.03e-5	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	1.13	9.01	0.59	8.08e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	4.67	0.35	6.53e-6	Thyroid stimulating hormone;
PAAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg09168692	chr1:7887560	PER3	-0.42	-4.31	-0.33	2.87e-5	Inflammatory bowel disease;
PAAD	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg06558623	chr16:89946397	TCF25	1.13	7.14	0.5	3.59e-11	Skin colour saturation;
PAAD	cis	rs12714314	0.756	rs7355512	chr2:1948166	A/T	cg22350835	chr2:1868857	MYT1L	0.48	4.69	0.36	6.02e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7713065	0.797	rs3846729	chr5:131806768	G/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.07	-0.38	1.13e-6	Lung function (FEV1/FVC);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09281539	chr20:20693126	RALGAPA2	0.65	6.3	0.46	3.07e-9	Primary biliary cholangitis;
PAAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.78	-7.03	-0.5	6.51e-11	Cognitive function;
PAAD	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.7	0.48	3.89e-10	High light scatter reticulocyte count;
PAAD	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg12165864	chr7:66369176	NA	-0.7	-4.81	-0.36	3.65e-6	Diabetic kidney disease;
PAAD	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.74	-7.56	-0.52	3.48e-12	Uric acid clearance;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25859441	chr4:21953738	NA	-0.63	-6.61	-0.47	6.17e-10	Obesity-related traits;
PAAD	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.58	5.69	0.42	6.27e-8	Inflammatory bowel disease;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12849807	chr6:90348187	LYRM2	0.42	4.48	0.34	1.47e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs16975963	0.843	rs7254809	chr19:38365695	A/G	cg08679971	chr19:38281047	NA	0.51	4.85	0.37	3.04e-6	Longevity;
PAAD	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs4740619	0.592	rs2987081	chr9:16012046	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.07e-5	Body mass index;
PAAD	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.46	-0.34	1.56e-5	Mood instability;
PAAD	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg08999081	chr20:33150536	PIGU	0.5	5.36	0.4	2.97e-7	Height;
PAAD	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.52	4.97	0.37	1.75e-6	Eosinophilic esophagitis;
PAAD	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-1.13	-12.41	-0.71	7.17e-25	Hair shape;
PAAD	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1497828	0.956	rs2646861	chr1:217521978	G/A	cg04411442	chr1:217543379	NA	-0.5	-5.0	-0.38	1.56e-6	Dialysis-related mortality;
PAAD	cis	rs9888739	1.000	rs9888739	chr16:31313253	C/T	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg05927578	chr16:4029543	ADCY9	0.62	5.14	0.38	8.31e-7	Waist circumference;
PAAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.7	7.99	0.54	3.08e-13	Height;
PAAD	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg26003909	chr8:143102224	NA	-0.35	-5.89	-0.43	2.38e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs2080501	0.628	rs28971165	chr16:49661703	T/A	cg27618369	chr16:49636483	ZNF423	0.52	5.4	0.4	2.55e-7	IgG glycosylation;
PAAD	cis	rs7551345	0.853	rs1505571	chr1:31864797	T/C	cg17086398	chr1:31896392	SERINC2	-0.53	-4.66	-0.35	7e-6	Schizophrenia;
PAAD	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	4.64	0.35	7.47e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.81	9.49	0.61	4.48e-17	Blood metabolite ratios;
PAAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.59	5.36	0.4	2.97e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.58	5.02	0.38	1.43e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs9657904	0.774	rs7432372	chr3:105525502	C/T	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.9	-10.64	-0.65	4.14e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.87	0.54	6.17e-13	Motion sickness;
PAAD	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs9649465	0.967	rs6950373	chr7:123361773	C/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg02696790	chr15:75250997	RPP25	0.48	5.65	0.42	7.66e-8	Caffeine consumption;
PAAD	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs7816613	0.516	rs10091039	chr8:102660252	C/T	cg20585841	chr8:102729926	NCALD	-0.68	-5.38	-0.4	2.74e-7	Age-related hearing impairment;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11958404	0.615	rs6556333	chr5:157445659	T/C	cg05962755	chr5:157440814	NA	0.55	5.37	0.4	2.85e-7	IgG glycosylation;
PAAD	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	7.75	0.53	1.23e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1519814	0.696	rs7821583	chr8:121033862	A/G	cg22335954	chr8:121166405	COL14A1	-0.67	-5.12	-0.38	9.04e-7	Breast cancer;
PAAD	cis	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.48	-0.41	1.72e-7	HDL cholesterol;
PAAD	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.54	9.13	0.6	4.04e-16	Cutaneous nevi;
PAAD	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.73	7.1	0.5	4.56e-11	Asthma;
PAAD	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg22189786	chr22:42395067	WBP2NL	0.66	6.7	0.48	3.79e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg20126647	chr17:40714003	COASY	0.57	6.02	0.44	1.25e-8	Colorectal or endometrial cancer;
PAAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-5.15	-0.39	8.04e-7	Height;
PAAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09289335	chr20:42144161	L3MBTL	-0.63	-6.35	-0.46	2.34e-9	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.51	4.72	0.36	5.39e-6	Schizophrenia;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.62	5.86	0.43	2.73e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs11700980	0.591	rs73901413	chr21:30109304	T/C	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs9913156	0.748	rs55869432	chr17:4562901	A/G	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25439845	chr2:133022980	NA	0.58	6.76	0.48	2.84e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg10761708	chr20:43804764	PI3	0.54	4.6	0.35	8.81e-6	Blood protein levels;
PAAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.74	7.03	0.5	6.71e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg26174226	chr8:58114915	NA	-0.63	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.6	-0.35	8.66e-6	Height;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.55	5.4	0.4	2.52e-7	Parkinson's disease;
PAAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg11143131	chr5:131608246	PDLIM4	-0.51	-5.14	-0.38	8.4e-7	Blood metabolite levels;
PAAD	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.75	4.62	0.35	8.26e-6	Lung cancer in ever smokers;
PAAD	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.67	6.32	0.46	2.7e-9	Hip circumference;
PAAD	cis	rs11651753	0.561	rs60580012	chr17:45969808	C/T	cg24458315	chr17:46148407	CBX1	0.41	4.54	0.35	1.11e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.37	0.61	9.27e-17	Bipolar disorder;
PAAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-0.63	-4.48	-0.34	1.43e-5	Blood protein levels;
PAAD	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2236918	0.664	rs1776140	chr1:242038713	G/A	cg17736920	chr1:242011382	EXO1	0.57	5.61	0.41	9.15e-8	Menopause (age at onset);
PAAD	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.83	0.43	3.14e-8	Height;
PAAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.77	9.17	0.6	3.19e-16	Emphysema distribution in smoking;
PAAD	cis	rs1997066	0.831	rs73342294	chr10:106823130	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs1371614	0.632	rs10196501	chr2:27147272	C/T	cg00617064	chr2:27272375	NA	-0.43	-4.65	-0.35	7.29e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg09796270	chr17:17721594	SREBF1	0.43	4.59	0.35	9.33e-6	Total body bone mineral density;
PAAD	cis	rs4750440	0.706	rs4750441	chr10:14019728	A/T	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs955333	0.641	rs73003010	chr6:154903170	T/C	cg20019720	chr6:154832845	CNKSR3	0.46	5.18	0.39	7.08e-7	Diabetic kidney disease;
PAAD	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg21037935	chr19:58911965	NA	0.5	4.32	0.33	2.81e-5	Mean platelet volume;
PAAD	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.56	6.03	0.44	1.17e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg24053715	chr22:38214548	NA	-0.6	-6.2	-0.45	5e-9	Glioblastoma;Glioma;
PAAD	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15128208	chr22:42549153	NA	-0.43	-4.27	-0.33	3.41e-5	Cognitive function;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.67e-5	Life satisfaction;
PAAD	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.3	-0.39	4.01e-7	Glomerular filtration rate;
PAAD	cis	rs9815354	1.000	rs7650227	chr3:41794937	T/G	cg03022575	chr3:42003672	ULK4	0.64	4.5	0.34	1.37e-5	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08219700	chr8:58056026	NA	0.69	5.16	0.39	7.53e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg01097406	chr16:89675127	NA	-0.39	-4.74	-0.36	4.85e-6	Vitiligo;
PAAD	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs35300120	0.757	rs1553030	chr1:233652816	A/G	cg23054119	chr1:233659267	NA	-0.53	-4.94	-0.37	2.08e-6	Cognitive function;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg05658771	chr16:89884179	FANCA	0.91	4.39	0.34	2.1e-5	Skin colour saturation;
PAAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.93	7.22	0.51	2.27e-11	Initial pursuit acceleration;
PAAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg23283495	chr1:209979779	IRF6	-0.65	-6.0	-0.44	1.36e-8	Coronary artery disease;
PAAD	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-5.0	-0.38	1.58e-6	Blood protein levels;
PAAD	cis	rs2579500	0.807	rs6753926	chr2:97298949	T/C	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs2241685	0.920	rs59907143	chr2:1934163	T/C	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22874065	chr1:212540224	TMEM206	-0.52	-6.34	-0.46	2.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.43	-4.75	-0.36	4.61e-6	Pneumonia;
PAAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.43	-6.64	-0.47	5.15e-10	Mean corpuscular volume;
PAAD	cis	rs5757949	0.578	rs133035	chr22:41012134	T/C	cg14701072	chr22:41075428	MCHR1	-0.45	-4.45	-0.34	1.66e-5	Height;
PAAD	cis	rs2389339	0.773	rs1899075	chr4:117828344	T/C	cg21399832	chr4:117847410	NA	0.3	4.3	0.33	3.02e-5	IgG glycosylation;
PAAD	trans	rs2389217	0.509	rs2389219	chr12:33722185	T/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	1.07	14.49	0.76	1.92e-30	Breast cancer;
PAAD	cis	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg27395922	chr11:50257633	LOC441601	-0.39	-4.4	-0.34	2.06e-5	Height;
PAAD	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.69	-5.34	-0.4	3.4e-7	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.99	13.59	0.74	4.99e-28	Menarche (age at onset);
PAAD	cis	rs863345	0.967	rs11265029	chr1:158529281	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg04607699	chr11:48328132	OR4S1	0.52	5.0	0.38	1.54e-6	Migraine - clinic-based;
PAAD	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.54e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs375066	0.935	rs376032	chr19:44407564	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1997066	0.831	rs79939134	chr10:106814280	C/T	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27347003	chr16:28915665	ATP2A1	0.59	7.06	0.5	5.45e-11	Myopia (pathological);
PAAD	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.29	0.39	4.22e-7	Free thyroxine concentration;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs2420915	0.630	rs2243609	chr10:122874348	A/C	cg05610379	chr10:123734658	NSMCE4A	-0.57	-4.51	-0.34	1.27e-5	Fibrinogen levels;
PAAD	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.93	0.37	2.16e-6	Lymphocyte percentage of white cells;
PAAD	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg06375148	chr1:209958343	C1orf74	0.44	4.44	0.34	1.71e-5	Monobrow;
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.77	8.39	0.56	3.08e-14	Lung cancer;
PAAD	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.47e-8	Alcohol dependence;
PAAD	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.51	-4.4	-0.34	2.02e-5	Asthma;
PAAD	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg27029450	chr22:50098074	NA	0.69	4.57	0.35	1.02e-5	Natriuretic peptide levels;
PAAD	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg20636351	chr8:55087400	NA	-0.69	-6.74	-0.48	3.17e-10	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08287162	chr16:71895706	ZNF821;ATXN1L	-0.67	-6.69	-0.48	4.13e-10	Obesity-related traits;
PAAD	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-5.05	-0.38	1.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg02462569	chr6:150064036	NUP43	-0.48	-5.11	-0.38	9.36e-7	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.38	4.6	0.35	8.9e-6	Tonsillectomy;
PAAD	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.8	9.91	0.63	3.59e-18	Height;
PAAD	cis	rs4523957	0.788	rs7217687	chr17:2098272	G/C	cg16513277	chr17:2031491	SMG6	-0.5	-5.12	-0.38	9.02e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs58653258	0.667	rs2673947	chr1:234981742	G/T	cg03518729	chr1:235147744	NA	-0.46	-4.4	-0.34	1.99e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.5	5.63	0.42	8.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.84	0.37	3.11e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2070677	0.932	rs3020499	chr10:135381215	A/G	cg08390786	chr10:135334061	NA	-0.65	-5.73	-0.42	5.3e-8	Gout;
PAAD	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.3	7.97	0.54	3.46e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.59	5.36	0.4	2.99e-7	Retinal vascular caliber;
PAAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.91	-10.27	-0.64	4.03e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.43	4.3	0.33	3.01e-5	Anterior chamber depth;
PAAD	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.51	-0.34	1.28e-5	Morning vs. evening chronotype;
PAAD	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg05791153	chr7:19748676	TWISTNB	0.62	4.81	0.36	3.57e-6	Thyroid stimulating hormone;
PAAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.6	6.31	0.46	2.94e-9	Huntington's disease progression;
PAAD	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.67	-0.62	1.57e-17	Blood trace element (Zn levels);
PAAD	cis	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg14329783	chr7:75779857	NA	0.73	4.4	0.34	2.06e-5	Mononucleosis;
PAAD	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.45	-6.6	-0.47	6.57e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs1483035	0.623	rs2138742	chr4:156463003	T/A	cg00585174	chr10:134499472	INPP5A	0.5	6.7	0.48	3.81e-10	Influenza A (H1N1) severity;
PAAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	4.5	0.34	1.36e-5	Breast cancer;
PAAD	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.52	5.27	0.39	4.65e-7	Lewy body disease;
PAAD	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg04111992	chr7:158790115	NA	0.51	4.38	0.33	2.22e-5	Facial morphology (factor 20);
PAAD	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.66	5.68	0.42	6.8e-8	Common traits (Other);
PAAD	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.38	-0.51	9.9e-12	Blood metabolite levels;
PAAD	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.46	5.11	0.38	9.7e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.54	4.36	0.33	2.35e-5	Bone mineral density (spine);
PAAD	cis	rs10186876	0.728	rs13384238	chr2:44155986	A/G	cg26828767	chr2:44457733	PPM1B	-0.44	-4.28	-0.33	3.28e-5	Hand grip strength;
PAAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.86	10.32	0.64	2.9e-19	Resting heart rate;
PAAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg15571903	chr15:79123663	NA	-0.47	-6.11	-0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg08436684	chr16:88034427	BANP	-0.5	-4.29	-0.33	3.14e-5	Menopause (age at onset);
PAAD	cis	rs11023332	0.617	rs1879888	chr11:14679247	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-4.3	-0.33	3.09e-5	Adiponectin levels;Vitamin D levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25110239	chr10:75538458	NA	-0.68	-7.51	-0.52	4.81e-12	Obesity-related traits;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg15691649	chr6:25882328	NA	-0.47	-4.29	-0.33	3.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.56	4.85	0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs7255045	0.743	rs10426080	chr19:12957850	A/G	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.47	6.06	0.44	1.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg17524265	chr8:144659883	NAPRT1	0.98	7.82	0.54	8.32e-13	Attention deficit hyperactivity disorder;
PAAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg10011062	chr15:43941034	CATSPER2	-0.72	-4.27	-0.33	3.42e-5	Lung cancer in ever smokers;
PAAD	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.81	10.14	0.64	8.77e-19	Morning vs. evening chronotype;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08949854	chr16:89437501	ANKRD11	0.57	6.37	0.46	2.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs911119	0.913	rs2405392	chr20:23569186	C/T	cg16589663	chr20:23618590	CST3	0.79	6.77	0.48	2.7e-10	Chronic kidney disease;
PAAD	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs9810890	1.000	rs115356727	chr3:128558380	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.49	-5.49	-0.41	1.66e-7	Schizophrenia;
PAAD	cis	rs55788414	0.929	rs66463064	chr16:81180995	T/C	cg06400318	chr16:81190750	PKD1L2	-1.08	-7.18	-0.5	2.9e-11	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg11766577	chr21:47581405	C21orf56	-0.42	-4.75	-0.36	4.59e-6	Testicular germ cell tumor;
PAAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.17	-0.5	3.02e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	4.29	0.33	3.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs6976053	0.875	rs1054391	chr7:100468284	A/G	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.56	0.57	1.14e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.43	-0.4	2.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	1.05	13.07	0.73	1.23e-26	Breast cancer;
PAAD	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.62	0.57	8.32e-15	Prudent dietary pattern;
PAAD	trans	rs4129059	0.541	rs12563954	chr1:214701865	A/G	cg01262630	chr16:79636944	NA	0.72	6.3	0.46	3.09e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.72	-7.54	-0.52	3.89e-12	Blood metabolite levels;
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.58	-4.54	-0.35	1.14e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26209169	chr5:1316264	NA	0.38	4.48	0.34	1.46e-5	Lung cancer;
PAAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg14196790	chr5:131705035	SLC22A5	0.51	5.46	0.4	1.91e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-5.52	-0.41	1.4e-7	Immature fraction of reticulocytes;
PAAD	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.79	6.34	0.46	2.43e-9	Brain cytoarchitecture;
PAAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04445214	chr22:31688300	PIK3IP1	0.6	7.09	0.5	4.65e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.28	-0.39	4.32e-7	Systemic lupus erythematosus;
PAAD	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.05	-0.38	1.28e-6	Total body bone mineral density;
PAAD	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.79	0.36	3.86e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9479482	0.638	rs472469	chr6:150383174	T/C	cg08316699	chr6:150357289	NA	0.4	4.62	0.35	8e-6	Alopecia areata;
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.87	-0.49	1.53e-10	Blood metabolite levels;
PAAD	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	6.81	0.48	2.16e-10	Cognitive ability;
PAAD	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Life satisfaction;
PAAD	cis	rs4454254	0.736	rs7815916	chr8:141065402	G/C	cg06693505	chr8:141057453	TRAPPC9	-0.32	-4.37	-0.33	2.25e-5	Pulse pressure;
PAAD	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg16306870	chr3:194868790	C3orf21	0.42	4.34	0.33	2.56e-5	Non-small cell lung cancer;
PAAD	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-4.89	-0.37	2.51e-6	Schizophrenia;
PAAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg15557168	chr22:42548783	NA	-0.48	-4.92	-0.37	2.25e-6	Schizophrenia;
PAAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12667521	chr19:29218732	NA	-0.58	-5.17	-0.39	7.18e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.57	-5.68	-0.42	6.57e-8	Itch intensity from mosquito bite;
PAAD	cis	rs55637147	0.671	rs2013314	chr11:57128317	C/T	cg25492363	chr11:57319872	UBE2L6	0.38	4.28	0.33	3.27e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.6	-6.33	-0.46	2.64e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10851478	0.540	rs1904316	chr15:49708710	G/T	cg08060515	chr15:49448048	GALK2;COPS2	-0.47	-4.63	-0.35	7.87e-6	Oral cavity cancer;
PAAD	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.86	-10.99	-0.67	4.87e-21	Height;
PAAD	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.45	-0.34	1.68e-5	Testicular germ cell tumor;
PAAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.42	4.72	0.36	5.27e-6	Height;
PAAD	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.55	-0.41	1.24e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg09659197	chr4:152720779	NA	-0.46	-6.27	-0.45	3.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.37e-6	Type 2 diabetes;
PAAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-6.08	-0.44	9.24e-9	Breast cancer;
PAAD	cis	rs9463078	1.000	rs9463078	chr6:45181340	G/A	cg25276700	chr6:44698697	NA	-0.5	-5.85	-0.43	2.85e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg09467607	chr2:36825704	FEZ2	0.74	8.25	0.56	7.17e-14	Height;
PAAD	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.69	6.97	0.49	9.1e-11	Migraine;
PAAD	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.67	7.27	0.51	1.78e-11	Leprosy;
PAAD	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg00623015	chr16:89177293	ACSF3	-0.83	-4.32	-0.33	2.77e-5	Red blood cell count;
PAAD	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.49	-8.27	-0.56	6.19e-14	Mean corpuscular volume;
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg01214346	chr17:406501	NA	0.47	4.54	0.35	1.13e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.43	0.56	2.49e-14	Menopause (age at onset);
PAAD	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg05338066	chr1:7812865	CAMTA1	-0.47	-4.26	-0.33	3.5e-5	Inflammatory bowel disease;
PAAD	cis	rs7084783	0.622	rs61606504	chr10:105348767	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.44	4.56	0.35	1.06e-5	Fear of pain;
PAAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs6496044	0.507	rs8034676	chr15:86159262	C/T	cg10818794	chr15:86012489	AKAP13	-0.44	-4.58	-0.35	9.71e-6	Interstitial lung disease;
PAAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.47	-4.48	-0.34	1.45e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.71	-7.82	-0.54	8.06e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg03999872	chr20:62272968	STMN3	-0.77	-7.09	-0.5	4.78e-11	Atopic dermatitis;
PAAD	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.53	5.66	0.42	7.35e-8	Nonalcoholic fatty liver disease;
PAAD	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	1.17	12.88	0.72	3.95e-26	Eosinophil percentage of granulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08196128	chr2:132056469	LOC440910	-0.51	-6.29	-0.45	3.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.63	6.09	0.44	9.04e-9	Itch intensity from mosquito bite;
PAAD	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg00576331	chr11:65640516	EFEMP2	0.59	5.23	0.39	5.58e-7	DNA methylation (variation);
PAAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.43	-4.88	-0.37	2.62e-6	Height;
PAAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg25204440	chr1:209979598	IRF6	0.57	4.54	0.35	1.15e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs4845459	1.000	rs6702463	chr1:152598711	A/T	cg03277515	chr1:153321198	PGLYRP4	0.44	5.23	0.39	5.58e-7	Psoriasis;
PAAD	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.31	-0.33	2.93e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg21130718	chr4:1044621	NA	0.49	4.73	0.36	5.06e-6	Recombination rate (males);
PAAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs73416724	1.000	rs75473868	chr6:43352623	A/G	cg26312998	chr6:43337775	ZNF318	0.7	5.79	0.42	3.98e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg08619932	chr19:49200058	FUT2	0.57	6.05	0.44	1.06e-8	Dietary macronutrient intake;
PAAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6137287	0.855	rs6047299	chr20:21160164	A/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.75	-11.49	-0.68	2.13e-22	Body mass index;
PAAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.26	0.33	3.64e-5	Renal cell carcinoma;
PAAD	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Cognitive function;
PAAD	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg09127314	chr1:152161683	NA	-0.62	-4.3	-0.33	3.03e-5	Atopic dermatitis;
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	4.78	0.36	4.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11252926	0.732	rs10904541	chr10:744008	A/G	cg08603382	chr10:743973	NA	-0.46	-4.37	-0.33	2.29e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs11997175	0.625	rs11991490	chr8:33595407	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg02734326	chr4:10020555	SLC2A9	0.49	4.83	0.37	3.23e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.98	6.64	0.47	5.29e-10	Schizophrenia;
PAAD	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.9	-8.3	-0.56	5.4e-14	Body mass index;
PAAD	cis	rs9715521	0.775	rs12646141	chr4:59846130	G/C	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.61	-7.22	-0.51	2.27e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs6782025	0.837	rs338996	chr3:121009363	G/A	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg23346134	chr3:49453900	TCTA	0.46	4.93	0.37	2.15e-6	Menarche (age at onset);
PAAD	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.49	4.99	0.38	1.64e-6	Colorectal cancer;
PAAD	trans	rs901683	0.850	rs36109121	chr10:46039511	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.45e-8	Prudent dietary pattern;
PAAD	trans	rs10951933	0.632	rs6977363	chr7:47910195	C/T	cg05433557	chr7:158325024	PTPRN2	-0.56	-6.39	-0.46	1.93e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs2300603	1.000	rs2300603	chr14:76005557	C/T	cg01624173	chr14:75981868	NA	-0.56	-5.96	-0.44	1.68e-8	Multiple sclerosis;
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.55	-6.16	-0.45	6.24e-9	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg10518543	chr12:38710700	ALG10B	0.52	4.96	0.37	1.83e-6	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22648143	chr17:72772381	TMEM104;NAT9	0.7	7.21	0.5	2.46e-11	Obesity-related traits;
PAAD	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs797680	0.856	rs7547244	chr1:93781768	A/G	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs597583	0.806	rs11603366	chr11:117396505	G/T	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.25	-0.45	4e-9	Putamen volume;
PAAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg05717871	chr11:638507	DRD4	-0.59	-5.64	-0.42	8.1e-8	Systemic lupus erythematosus;
PAAD	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs2790216	1.000	rs2590307	chr10:59977161	C/T	cg20442379	chr10:60024634	IPMK	-0.6	-4.69	-0.36	6.03e-6	Inflammatory bowel disease;
PAAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs3734905	1.000	rs2075978	chr6:169812588	A/G	cg11181693	chr6:169825345	NA	0.81	5.44	0.4	2.05e-7	HIV-1 control;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg01621132	chr19:10221146	PPAN-P2RY11;P2RY11;PPAN	-0.49	-4.84	-0.37	3.17e-6	Narcolepsy;
PAAD	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.51	-5.43	-0.4	2.23e-7	Bipolar disorder;
PAAD	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.08	-0.55	1.86e-13	Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg27394845	chr17:28928406	LRRC37B2	0.65	4.68	0.36	6.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.48	5.46	0.4	1.94e-7	Pulse pressure;
PAAD	cis	rs35955747	0.902	rs12167361	chr22:31696278	G/C	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9992101	0.547	rs7674982	chr4:77412997	G/A	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.45	-4.84	-0.37	3.14e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-4.58	-0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.4	0.51	8.58e-12	Coffee consumption (cups per day);
PAAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg24977027	chr2:88469347	THNSL2	0.76	4.36	0.33	2.43e-5	Plasma clusterin levels;
PAAD	cis	rs2790457	0.833	rs1265847	chr10:28929686	G/A	cg05705492	chr10:28955341	NA	-0.45	-4.52	-0.34	1.24e-5	Multiple myeloma;
PAAD	cis	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg14329783	chr7:75779857	NA	0.79	4.72	0.36	5.35e-6	Mononucleosis;
PAAD	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.57	7.34	0.51	1.22e-11	Periodontal microbiota;
PAAD	cis	rs1642645	0.872	rs4660210	chr1:42476676	C/T	cg01990334	chr1:42801334	FOXJ3	-0.6	-5.45	-0.4	1.96e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg06970076	chr16:1560791	IFT140	0.59	5.32	0.4	3.67e-7	Coronary artery disease;
PAAD	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.49	-5.2	-0.39	6.4e-7	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.99	0.44	1.47e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg21724239	chr8:58056113	NA	0.85	5.91	0.43	2.15e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18691242	chr12:107487714	CRY1	0.63	6.89	0.49	1.35e-10	Myopia (pathological);
PAAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.51	-5.35	-0.4	3.18e-7	Major depressive disorder;
PAAD	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.48	5.99	0.44	1.45e-8	Sitting height ratio;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.91	0.37	2.33e-6	Depressive symptoms;
PAAD	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.57	-4.96	-0.37	1.86e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.64	6.08	0.44	9.1e-9	Mean platelet volume;
PAAD	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.37	-4.83	-0.36	3.26e-6	Primary biliary cholangitis;
PAAD	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs6137287	0.643	rs6047259	chr20:21098319	A/G	cg04219410	chr20:21106687	PLK1S1	-0.4	-4.74	-0.36	4.82e-6	Height;
PAAD	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.64	5.03	0.38	1.39e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9395066	0.545	rs10948197	chr6:44967490	C/T	cg18551225	chr6:44695536	NA	0.43	4.52	0.34	1.24e-5	Height;
PAAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.91	5.91	0.43	2.22e-8	Diabetic kidney disease;
PAAD	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg12046867	chr14:103022105	NA	-0.65	-5.04	-0.38	1.28e-6	Platelet count;
PAAD	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg02631450	chr22:32366979	NA	1.03	5.6	0.41	9.84e-8	Childhood ear infection;
PAAD	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.73	0.36	5.04e-6	Schizophrenia;
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg04482110	chr17:41364121	TMEM106A	0.42	4.69	0.36	6.13e-6	Menopause (age at onset);
PAAD	cis	rs787274	0.764	rs4979157	chr9:115571791	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.48	-0.34	1.48e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.75	8.05	0.55	2.22e-13	Hypertriglyceridemia;
PAAD	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.63	-6.57	-0.47	7.52e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.81e-8	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16761752	chr17:38474378	RARA	-0.77	-6.66	-0.48	4.78e-10	Neuroticism;
PAAD	trans	rs901683	0.850	rs35150810	chr10:46071142	T/G	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg12623918	chr2:306882	NA	-0.46	-4.76	-0.36	4.56e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.33	0.4	3.42e-7	HIV-1 control;
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg04520793	chr17:42248056	ASB16	0.41	4.84	0.37	3.16e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11143857	chr1:202559755	SYT2	0.57	6.55	0.47	8.43e-10	Myopia (pathological);
PAAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.55	5.3	0.39	4.01e-7	Blood metabolite levels;
PAAD	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg20312557	chr2:97357134	FER1L5	-0.83	-4.43	-0.34	1.77e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.63	-6.6	-0.47	6.62e-10	Resting heart rate;
PAAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg00944433	chr1:107599041	PRMT6	-0.42	-4.73	-0.36	5.04e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs11191270	1.000	rs55970842	chr10:104171094	C/A	cg15320455	chr10:103880129	LDB1	0.53	4.51	0.34	1.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.53	4.71	0.36	5.56e-6	Type 2 diabetes;
PAAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.25	-0.33	3.7e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.37	-5.29	-0.39	4.12e-7	Cutaneous nevi;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg15181151	chr6:150070149	PCMT1	0.61	6.57	0.47	7.63e-10	Lung cancer;
PAAD	cis	rs9395066	0.545	rs12526711	chr6:44883873	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.45	-0.34	1.64e-5	Height;
PAAD	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg16745616	chr19:8428856	ANGPTL4	-0.54	-4.95	-0.37	1.96e-6	HDL cholesterol;
PAAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.77	-0.42	4.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg02244288	chr16:89573955	SPG7	-0.32	-4.25	-0.33	3.76e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.6	4.9	0.37	2.42e-6	Height;
PAAD	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.34	0.33	2.64e-5	Neuroticism;
PAAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.9	-9.54	-0.61	3.42e-17	DNA methylation (variation);
PAAD	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-5.0	-0.38	1.54e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10861661	0.963	rs10861669	chr12:107200068	C/A	cg15890332	chr12:107067104	RFX4	0.47	4.42	0.34	1.9e-5	Triglyceride levels;
PAAD	cis	rs74367352	1.000	rs7672923	chr4:109954423	A/G	cg06981781	chr4:110842888	EGF	-0.68	-4.28	-0.33	3.35e-5	Carotid plaque burden;
PAAD	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg21395723	chr22:39101663	GTPBP1	-0.43	-4.39	-0.34	2.12e-5	Menopause (age at onset);
PAAD	cis	rs9463078	0.866	rs9395087	chr6:45238226	T/A	cg25276700	chr6:44698697	NA	-0.48	-5.55	-0.41	1.24e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.03	0.44	1.19e-8	Height;
PAAD	trans	rs1015213	0.609	rs74830652	chr8:52878496	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.75	-0.36	4.66e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.85	9.57	0.61	2.9e-17	Mortality in heart failure;
PAAD	cis	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg14329783	chr7:75779857	NA	0.73	4.28	0.33	3.26e-5	Mononucleosis;
PAAD	cis	rs12246027	0.659	rs2060138	chr10:307807	A/G	cg16386425	chr10:429943	DIP2C	-0.45	-4.4	-0.34	2.04e-5	Blood metabolite levels;
PAAD	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg00383909	chr3:49044727	WDR6	0.82	5.15	0.39	7.94e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11276198	chr12:25404189	KRAS	0.56	6.29	0.45	3.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.46	5.33	0.4	3.42e-7	Morning vs. evening chronotype;
PAAD	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.85	12.04	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-8.15	-0.55	1.23e-13	Cognitive function;
PAAD	cis	rs72687362	0.560	rs58635845	chr8:143384780	C/T	cg02224795	chr8:143363873	TSNARE1	0.35	4.35	0.33	2.47e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg09467607	chr2:36825704	FEZ2	0.61	6.35	0.46	2.41e-9	Height;
PAAD	cis	rs308971	0.656	rs307606	chr3:12067126	A/T	cg02700894	chr3:12045449	SYN2	0.62	5.24	0.39	5.33e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs6066835	0.764	rs2426097	chr20:47385467	C/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.02	0.38	1.44e-6	Breast cancer;
PAAD	cis	rs12475964	0.666	rs4670665	chr2:37382119	T/C	cg22370082	chr2:37384244	EIF2AK2	0.44	4.34	0.33	2.54e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg20761395	chr17:511517	VPS53	0.49	4.56	0.35	1.05e-5	Prostate cancer;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.49	-8.43	-0.56	2.51e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.41	4.5	0.34	1.37e-5	Mean platelet volume;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.8	0.36	3.74e-6	Vitiligo;
PAAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08893839	chr5:154027129	NA	-0.82	-6.3	-0.46	3.03e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs375066	0.935	rs396874	chr19:44397225	G/C	cg11993925	chr19:44307056	LYPD5	0.52	6.68	0.48	4.19e-10	Breast cancer;
PAAD	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20517764	chr3:9027454	SRGAP3	-0.64	-6.36	-0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs6987853	0.814	rs2923415	chr8:42455577	A/G	cg09913449	chr8:42400586	C8orf40	0.5	5.49	0.41	1.62e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7009516	0.653	rs4442155	chr8:24220787	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.4	4.75	0.36	4.62e-6	Hair greying;
PAAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg07648498	chr16:89883185	FANCA	0.51	5.01	0.38	1.52e-6	Vitiligo;
PAAD	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg27205649	chr11:78285834	NARS2	-0.6	-4.43	-0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.94	-7.97	-0.54	3.42e-13	Vitiligo;
PAAD	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.71	7.63	0.53	2.38e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg05925327	chr15:68127851	NA	-0.61	-5.5	-0.41	1.56e-7	Obesity;
PAAD	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.5	4.51	0.34	1.26e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.85	9.9	0.63	3.87e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.17	0.5	3e-11	Eye color traits;
PAAD	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs6804624	0.676	rs2700633	chr3:99160551	C/G	cg02646433	chr3:99218170	NA	0.42	4.35	0.33	2.45e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.75	-6.93	-0.49	1.11e-10	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg18200150	chr17:30822561	MYO1D	0.59	7.18	0.5	2.86e-11	Schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14806867	chr13:96329355	DNAJC3	0.66	6.52	0.47	9.72e-10	Primary biliary cholangitis;
PAAD	cis	rs10950821	0.734	rs11769236	chr7:20685786	G/A	cg21202529	chr7:20656503	ABCB5	-0.52	-5.03	-0.38	1.35e-6	Response to statin therapy;
PAAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Calcium levels;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg15212455	chr7:39170539	POU6F2	0.39	5.67	0.42	6.82e-8	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.98	10.87	0.66	1e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs1499972	0.648	rs62264767	chr3:117642005	A/C	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs59888335	0.571	rs13078331	chr3:80491840	G/T	cg21735741	chr3:80819488	NA	0.51	4.32	0.33	2.85e-5	Schizophrenia;
PAAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg16928487	chr17:17741425	SREBF1	0.35	4.55	0.35	1.09e-5	Total body bone mineral density;
PAAD	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.69	5.7	0.42	6.05e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.63	0.42	8.32e-8	Tonsillectomy;
PAAD	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.78	8.06	0.55	2.06e-13	Morning vs. evening chronotype;
PAAD	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.49	4.81	0.36	3.67e-6	Resistin levels;
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.04	0.38	1.3e-6	Electroencephalogram traits;
PAAD	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.47	-5.51	-0.41	1.52e-7	Coronary artery disease;
PAAD	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.03	-0.38	1.34e-6	Pulmonary function;
PAAD	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.38	4.57	0.35	1.02e-5	Prostate cancer;
PAAD	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.54	5.16	0.39	7.5e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6544773	0.522	rs13426210	chr2:45042089	C/G	cg13732857	chr2:45029729	NA	0.41	4.68	0.36	6.19e-6	Mosquito bite size;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg26174226	chr8:58114915	NA	-0.57	-4.38	-0.33	2.2e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.11	-0.63	1.07e-18	Chronic sinus infection;
PAAD	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.84	8.82	0.58	2.46e-15	Itch intensity from mosquito bite;
PAAD	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.54	4.86	0.37	2.93e-6	Testicular germ cell tumor;
PAAD	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	0.93	6.19	0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg09659197	chr4:152720779	NA	0.39	5.03	0.38	1.35e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg26031613	chr14:104095156	KLC1	0.5	4.69	0.36	6.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.4	5.41	0.4	2.38e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12776158	0.901	rs56979471	chr10:71216760	G/A	cg12610070	chr10:71211762	TSPAN15	-0.51	-5.0	-0.38	1.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10792830	0.741	rs529904	chr11:85693768	C/T	cg07180834	chr11:85838833	NA	-0.49	-5.7	-0.42	5.96e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg02023728	chr11:77925099	USP35	0.44	4.54	0.35	1.15e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.49	-4.91	-0.37	2.32e-6	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.63	-0.53	2.33e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg09796270	chr17:17721594	SREBF1	-0.47	-4.96	-0.37	1.9e-6	Body mass index;
PAAD	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	7.48	0.52	5.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12472274	0.529	rs11683094	chr2:239118057	G/A	cg17459225	chr2:239074497	NA	0.67	5.04	0.38	1.31e-6	Phospholipid levels (plasma);
PAAD	cis	rs7809615	0.748	rs10265385	chr7:99162687	C/T	cg12290671	chr7:99195819	NA	-0.67	-4.45	-0.34	1.68e-5	Blood metabolite ratios;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg15117754	chr3:10150083	C3orf24	0.89	6.48	0.47	1.19e-9	Alzheimer's disease;
PAAD	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.92	11.68	0.69	6.63e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.24	0.39	5.38e-7	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-6.01	-0.44	1.33e-8	Schizophrenia;
PAAD	cis	rs288342	0.835	rs17356762	chr2:183597462	C/T	cg02625481	chr2:183667124	NA	-0.42	-4.3	-0.33	3.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.1	-0.59	4.84e-16	Mean platelet volume;
PAAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs859767	0.709	rs4954154	chr2:135370656	G/A	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg05338066	chr1:7812865	CAMTA1	0.7	5.04	0.38	1.29e-6	Inflammatory bowel disease;
PAAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05002974	chr5:81574439	RPS23	-0.58	-6.38	-0.46	2.01e-9	Body fat percentage;
PAAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.35	6.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg19337854	chr7:99768885	GPC2	0.44	4.48	0.34	1.45e-5	Coronary artery disease;
PAAD	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs59104589	0.617	rs56663202	chr2:242262311	A/G	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24842740	chr1:9973750	NA	-0.77	-8.77	-0.58	3.4e-15	Obesity-related traits;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.8	8.94	0.59	1.23e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs3747547	0.892	rs16934662	chr9:37951354	A/C	cg13774184	chr9:37916125	SHB	-0.62	-4.27	-0.33	3.39e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs990171	0.538	rs6705272	chr2:103106569	A/C	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.27	-0.39	4.58e-7	Lymphocyte counts;
PAAD	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.61	-6.14	-0.45	6.81e-9	Height;
PAAD	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.85	0.49	1.67e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.69	7.68	0.53	1.84e-12	Mean corpuscular volume;
PAAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.59	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg03060546	chr3:49711283	APEH	-0.6	-4.49	-0.34	1.4e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26423677	chr2:17935206	SMC6;GEN1	0.7	6.45	0.46	1.41e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.52	6.05	0.44	1.09e-8	Schizophrenia;
PAAD	cis	rs72843506	0.586	rs75128113	chr17:19903485	A/C	cg05625806	chr17:19284432	MAPK7	0.69	4.53	0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs12612619	0.732	rs920433	chr2:27212526	A/C	cg00617064	chr2:27272375	NA	-0.45	-4.73	-0.36	5.2e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7705042	0.897	rs12515668	chr5:141496090	G/T	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.26	-0.39	4.89e-7	Asthma;
PAAD	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg23534315	chr17:78082725	GAA	0.49	4.44	0.34	1.74e-5	Yeast infection;
PAAD	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.46	4.41	0.34	1.93e-5	Fractional excretion of uric acid;
PAAD	cis	rs2131877	0.913	rs950256	chr3:194847752	C/T	cg19760965	chr3:194868843	C3orf21	0.44	4.59	0.35	9.33e-6	Non-small cell lung cancer;
PAAD	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.26	-0.39	4.71e-7	P wave terminal force;
PAAD	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs595018	0.505	rs565539	chr11:60602297	G/A	cg23904249	chr11:60608951	CCDC86	-0.7	-5.18	-0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.12	0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4372836	0.505	rs6710082	chr2:28989977	A/C	cg09009506	chr2:28216851	BRE	0.41	4.37	0.33	2.28e-5	Body mass index;
PAAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Subjective well-being;
PAAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13114166	chr1:28241026	RPA2	0.59	6.74	0.48	3.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.71	-5.9	-0.43	2.25e-8	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg16579770	chr16:72058938	DHODH	0.39	4.5	0.34	1.33e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	trans	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg00717180	chr2:96193071	NA	-0.61	-6.37	-0.46	2.12e-9	Migraine - clinic-based;
PAAD	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	6.67	0.48	4.38e-10	Schizophrenia;
PAAD	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10514237	chr2:162064025	TANK	-0.54	-6.38	-0.46	1.97e-9	Energy expenditure (24h);
PAAD	cis	rs7534824	0.625	rs55693426	chr1:101466859	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	4.72	0.36	5.38e-6	Refractive astigmatism;
PAAD	cis	rs7255045	0.788	rs10424001	chr19:12948462	A/G	cg14181355	chr19:12984996	MAST1	-0.49	-4.81	-0.36	3.63e-6	Mean corpuscular volume;
PAAD	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	5.58	0.41	1.09e-7	Type 2 diabetes;
PAAD	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.54	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.76	8.94	0.59	1.27e-15	Lung cancer;
PAAD	cis	rs2952768	1.000	rs2709379	chr2:208496182	C/G	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16083429	chr3:49237500	CCDC36	-0.47	-5.32	-0.4	3.73e-7	Menarche (age at onset);
PAAD	cis	rs2599510	0.748	rs6718214	chr2:32550485	T/C	cg02381751	chr2:32503542	YIPF4	-0.57	-5.79	-0.43	3.86e-8	Interleukin-18 levels;
PAAD	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.53	-4.59	-0.35	9.32e-6	IgG glycosylation;
PAAD	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg05925327	chr15:68127851	NA	-0.58	-4.98	-0.37	1.74e-6	Obesity;
PAAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.76	-0.36	4.41e-6	Personality dimensions;
PAAD	cis	rs4979906	0.669	rs12254219	chr10:79443520	C/T	cg07817648	chr10:79422355	NA	-0.7	-6.37	-0.46	2.15e-9	Mortality in heart failure;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.49	5.37	0.4	2.88e-7	Age at first birth;
PAAD	cis	rs11051970	0.553	rs325419	chr12:32572460	A/G	cg02745156	chr12:32552066	NA	0.43	4.45	0.34	1.64e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg13406893	chr12:131568647	GPR133	-0.43	-4.27	-0.33	3.44e-5	Longevity;
PAAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00292662	chr22:38071168	LGALS1	0.68	6.96	0.49	9.59e-11	Fat distribution (HIV);
PAAD	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.99	8.56	0.57	1.17e-14	Alzheimer's disease;
PAAD	trans	rs11794666	1.000	rs74669039	chr9:31659891	T/C	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.57e-7	Subjective well-being;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.56	0.35	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72772090	0.710	rs11745122	chr5:96060738	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.86	-6.52	-0.47	9.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg01059385	chr22:42394853	WBP2NL	0.47	5.08	0.38	1.11e-6	Intelligence;
PAAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg01621132	chr19:10221146	PPAN-P2RY11;P2RY11;PPAN	0.57	5.74	0.42	5.07e-8	Narcolepsy;
PAAD	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25997756	chr13:114198319	TMCO3	-0.66	-7.0	-0.49	7.66e-11	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs4455778	0.580	rs4598208	chr7:49084584	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.65	5.36	0.4	2.99e-7	HIV-1 control;
PAAD	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg08676812	chr11:65308423	LTBP3	-0.77	-5.39	-0.4	2.59e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.5	4.84	0.37	3.2e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.65	-6.74	-0.48	3.14e-10	Menopause (age at onset);
PAAD	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg24330906	chr2:85765176	MAT2A	-0.43	-4.35	-0.33	2.51e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs12195424	0.558	rs76037119	chr6:56294685	T/C	cg10030658	chr6:56298004	NA	-0.76	-4.38	-0.34	2.16e-5	Cerebrospinal fluid clusterin levels;
PAAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	9.03	0.59	7.37e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	7.28	0.51	1.68e-11	Obesity-related traits;
PAAD	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.99	0.38	1.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.71	7.04	0.5	6.17e-11	Lymphocyte counts;
PAAD	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.85	-0.37	2.97e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11159086	0.729	rs8015872	chr14:74942232	T/C	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.6e-9	Childhood ear infection;
PAAD	cis	rs4234284	1.000	rs13094201	chr3:126957294	A/G	cg27326032	chr3:127006922	NA	-0.49	-4.98	-0.37	1.71e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.65	0.42	7.53e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.71	8.02	0.55	2.59e-13	Lung cancer;
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg13271783	chr10:134563150	INPP5A	-0.54	-5.66	-0.42	7.34e-8	Migraine;
PAAD	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.62	5.92	0.43	2.1e-8	Coronary artery disease;
PAAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.74	9.05	0.59	6.5e-16	Methadone dose in opioid dependence;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-7.95	-0.54	3.89e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	10.84	0.66	1.22e-20	Primary sclerosing cholangitis;
PAAD	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg00717180	chr2:96193071	NA	-0.63	-6.97	-0.49	9.04e-11	HDL cholesterol;
PAAD	cis	rs11076805	0.510	rs442611	chr16:4146695	A/G	cg01959050	chr16:4170088	NA	0.45	4.41	0.34	1.97e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2120991	0.967	rs10876514	chr12:54282853	C/T	cg23795217	chr12:54812000	ITGA5	-0.3	-4.26	-0.33	3.63e-5	Biliary atresia;
PAAD	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-4.6	-0.35	8.81e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4149423	1.000	rs13410305	chr2:108912673	C/A	cg25838818	chr2:108905173	SULT1C2	-0.62	-5.82	-0.43	3.37e-8	Lobe size;
PAAD	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs595018	1.000	rs488483	chr11:60592227	A/G	cg07588442	chr11:60673866	PRPF19	-0.53	-4.45	-0.34	1.64e-5	Wegener's granulomatosis;
PAAD	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.51	-0.34	1.27e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg09796270	chr17:17721594	SREBF1	0.44	5.0	0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.56	-4.5	-0.34	1.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12780845	0.931	rs1885393	chr10:17247573	A/G	cg00857480	chr10:17188594	TRDMT1	0.35	4.35	0.33	2.52e-5	Homocysteine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25024311	chr15:41526446	CHP	-0.62	-6.39	-0.46	1.89e-9	Obesity-related traits;
PAAD	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.55	7.37	0.51	1.05e-11	Primary biliary cholangitis;
PAAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.86	-0.37	2.9e-6	Body mass index;
PAAD	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.55	-0.35	1.09e-5	Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20711408	chr13:49550299	FNDC3A	-0.77	-6.75	-0.48	2.96e-10	Neuroticism;
PAAD	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.87	-7.36	-0.51	1.1e-11	Lymphocyte counts;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09395855	chr10:120967408	GRK5	0.57	6.57	0.47	7.65e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.58	-5.23	-0.39	5.64e-7	White blood cell count;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.41	0.46	1.75e-9	Height;
PAAD	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.89	9.69	0.62	1.34e-17	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.62	0.35	8.02e-6	Self-reported allergy;
PAAD	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.41	4.88	0.37	2.64e-6	Intraocular pressure;
PAAD	cis	rs58521262	1.000	rs62124389	chr19:23179518	A/G	cg22640819	chr19:22990650	NA	0.36	4.4	0.34	2.06e-5	Testicular germ cell tumor;
PAAD	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.94	0.59	1.22e-15	Colorectal cancer;
PAAD	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-5.32	-0.4	3.67e-7	Schizophrenia;
PAAD	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg08125733	chr17:73851984	WBP2	0.82	7.5	0.52	5.05e-12	Psoriasis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05889961	chr11:44749501	NA	0.57	6.41	0.46	1.71e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6076065	0.723	rs6137905	chr20:23340938	G/A	cg11657817	chr20:23433608	CST11	0.5	5.12	0.38	9.23e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.98	5.51	0.41	1.48e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.59	-5.63	-0.42	8.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1697938	0.563	rs1376180	chr5:40939640	A/G	cg22359217	chr5:41925772	FBXO4	0.45	4.49	0.34	1.39e-5	Multiple system atrophy;
PAAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.51	5.15	0.39	8.07e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	6.42	0.46	1.66e-9	Lung cancer;
PAAD	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.48	-4.82	-0.36	3.51e-6	Blood metabolite levels;
PAAD	cis	rs6142102	0.625	rs4911138	chr20:32547699	G/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04240471	chr7:2420162	EIF3B	-0.63	-6.53	-0.47	9.39e-10	Myopia (pathological);
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg20558230	chr5:484149	SLC9A3	-0.39	-5.31	-0.4	3.9e-7	Cystic fibrosis severity;
PAAD	cis	rs72772090	0.708	rs17082200	chr5:96048604	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.73	-5.82	-0.43	3.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27577431	chr2:3606160	RNASEH1	-0.73	-6.64	-0.47	5.35e-10	Neuroticism;
PAAD	cis	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.54	0.35	1.15e-5	Neuroticism;
PAAD	cis	rs6594713	0.533	rs2115211	chr5:112966039	T/A	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.53	4.47	0.34	1.49e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs6547631	0.622	rs1561284	chr2:85924295	C/A	cg24620635	chr2:85921963	GNLY	0.42	5.44	0.4	2.05e-7	Blood protein levels;
PAAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.99	11.45	0.68	2.74e-22	Cognitive function;
PAAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg03983715	chr16:68378420	PRMT7	-0.56	-4.42	-0.34	1.88e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.5	8.29	0.56	5.44e-14	IgG glycosylation;
PAAD	trans	rs12142669	0.556	rs4517311	chr1:188252225	C/G	cg16397071	chr2:15731827	DDX1	0.91	6.33	0.46	2.68e-9	Obesity-related traits;
PAAD	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1903068	0.925	rs1551643	chr4:55994226	T/A	cg20092376	chr4:56023423	NA	0.49	4.9	0.37	2.42e-6	Endometriosis;
PAAD	cis	rs12282928	0.876	rs1158898	chr11:48273246	G/A	cg22827986	chr11:48284249	OR4X1	-0.43	-5.37	-0.4	2.92e-7	Migraine - clinic-based;
PAAD	cis	rs4629180	1.000	rs4629180	chr2:102088370	G/A	cg01388757	chr2:102091195	RFX8	-0.63	-7.75	-0.53	1.25e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.68	6.79	0.48	2.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.43	-4.3	-0.33	2.98e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg15282417	chr9:129245246	FAM125B	0.41	4.82	0.36	3.5e-6	Intraocular pressure;
PAAD	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.4	0.56	2.96e-14	Bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03941040	chr10:60145128	TFAM	-0.62	-6.36	-0.46	2.22e-9	Smoking initiation;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg00945038	chr17:61921165	SMARCD2	0.51	6.02	0.44	1.26e-8	Prudent dietary pattern;
PAAD	cis	rs1891275	0.515	rs10881945	chr10:93423583	C/A	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg08699206	chr4:1595414	NA	0.46	4.58	0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.28	0.39	4.34e-7	Lung cancer in ever smokers;
PAAD	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-1.08	-15.07	-0.77	5.77e-32	Total body bone mineral density;
PAAD	cis	rs6137287	0.643	rs6047261	chr20:21103910	T/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.74	0.36	4.79e-6	Height;
PAAD	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.69e-7	Common traits (Other);
PAAD	cis	rs17407555	1.000	rs73224414	chr4:10297679	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.2	-0.39	6.21e-7	Schizophrenia (age at onset);
PAAD	cis	rs300774	0.925	rs300740	chr2:164169	G/A	cg21211680	chr2:198530	NA	-0.65	-6.02	-0.44	1.24e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs12808519	0.605	rs3893155	chr11:69597881	T/C	cg27032427	chr11:69587568	NA	-0.66	-5.2	-0.39	6.3e-7	Urate levels in overweight individuals;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg16928487	chr17:17741425	SREBF1	0.33	4.48	0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs11252926	0.800	rs12763675	chr10:744591	C/T	cg08603382	chr10:743973	NA	-0.52	-4.99	-0.38	1.65e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg22985122	chr17:73566478	LLGL2	0.81	5.08	0.38	1.07e-6	Psoriasis;
PAAD	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg23460851	chr4:1604456	NA	0.44	4.29	0.33	3.2e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.25	0.51	1.94e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9535307	0.929	rs1547623	chr13:50348187	G/A	cg03658251	chr13:50265850	EBPL	0.83	5.68	0.42	6.7e-8	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.96	8.17	0.55	1.12e-13	Alzheimer's disease;
PAAD	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.53	-5.31	-0.4	3.91e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.65	6.38	0.46	2.03e-9	White matter hyperintensity burden;
PAAD	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.63	8.86	0.58	1.96e-15	Airflow obstruction;
PAAD	cis	rs7582720	0.503	rs72928925	chr2:203554324	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.69	4.78	0.36	4.17e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.65	0.42	7.73e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.44	-4.37	-0.33	2.34e-5	Height;
PAAD	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08912058	chr1:6313858	GPR153	-0.58	-6.68	-0.48	4.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	trans	rs9467603	0.611	rs35789010	chr6:25514179	G/A	cg01620082	chr3:125678407	NA	-1.31	-6.63	-0.47	5.42e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00982548	chr2:198649783	BOLL	-0.82	-5.92	-0.43	2.07e-8	Ulcerative colitis;
PAAD	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.19e-10	Lymphocyte counts;
PAAD	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.96	0.49	9.62e-11	Morning vs. evening chronotype;
PAAD	cis	rs78761021	0.792	rs17743140	chr17:9785594	G/A	cg26853458	chr17:9805074	RCVRN	0.69	7.95	0.54	3.84e-13	Type 2 diabetes;
PAAD	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.54	-0.47	8.85e-10	Neuroticism;
PAAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.67	-0.53	1.93e-12	Neuroticism;
PAAD	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg02072170	chr3:194406190	FAM43A	0.54	5.49	0.41	1.67e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs7598759	1.000	rs7598759	chr2:232321956	C/T	cg11669995	chr2:231691149	NA	-0.37	-4.25	-0.33	3.7e-5	Noise-induced hearing loss;
PAAD	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg01097406	chr16:89675127	NA	-0.35	-4.43	-0.34	1.82e-5	Vitiligo;
PAAD	cis	rs6782025	0.837	rs338983	chr3:121001807	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.36	6.25e-6	Aging (facial);
PAAD	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg00806126	chr19:22604979	ZNF98	-0.41	-4.95	-0.37	1.97e-6	Pain;
PAAD	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07078622	chr17:26645920	TMEM97	-0.72	-6.47	-0.46	1.27e-9	Neuroticism;
PAAD	cis	rs7260329	0.713	rs4803414	chr19:41486082	T/C	cg07907917	chr19:40949191	SERTAD3	-0.51	-4.27	-0.33	3.4e-5	Smoking behavior;
PAAD	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	0.53	5.92	0.43	2.1e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4343996	0.837	rs6462105	chr7:3514512	C/T	cg21248987	chr7:3385318	SDK1	0.49	5.48	0.41	1.74e-7	Motion sickness;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.54	-5.16	-0.39	7.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.6	-7.37	-0.51	1.02e-11	Coronary artery disease;
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.58	-4.71	-0.36	5.63e-6	Platelet count;
PAAD	cis	rs1075265	0.567	rs66773232	chr2:54201107	C/G	cg04546899	chr2:54196757	PSME4	0.32	4.81	0.36	3.57e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg18357526	chr6:26021779	HIST1H4A	0.47	4.29	0.33	3.21e-5	Height;
PAAD	cis	rs5417	0.636	rs427784	chr17:7157516	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	0.73	7.81	0.54	8.74e-13	Diastolic blood pressure;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03150409	chr4:1892317	WHSC1	-0.55	-6.33	-0.46	2.56e-9	Immature fraction of reticulocytes;
PAAD	trans	rs3905000	1.000	rs13290420	chr9:107648965	T/C	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg00262122	chr8:11665843	FDFT1	-0.5	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.81	10.31	0.64	3.21e-19	Sjögren's syndrome;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18621852	chr3:10150065	C3orf24	0.74	6.57	0.47	7.73e-10	Alzheimer's disease;
PAAD	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg12011299	chr4:100065546	ADH4	-0.93	-12.89	-0.72	3.64e-26	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.58	0.57	1.05e-14	Hip circumference adjusted for BMI;
PAAD	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.44	-0.46	1.47e-9	Triglycerides;
PAAD	cis	rs6501435	0.840	rs8068751	chr17:69081268	T/C	cg00193521	chr17:68133597	NA	0.48	4.7	0.36	5.78e-6	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	1.2	13.25	0.73	4.05e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.41	5.23	0.39	5.47e-7	Coronary artery disease;
PAAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23158103	chr7:148848205	ZNF398	-0.62	-6.07	-0.44	9.6e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs75757892	0.544	rs6919806	chr6:7319105	A/C	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.51	4.51	0.34	1.29e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg19784903	chr17:45786737	TBKBP1	-0.52	-5.51	-0.41	1.49e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs5758659	0.789	rs2413684	chr22:42574830	C/T	cg15557168	chr22:42548783	NA	-0.58	-6.05	-0.44	1.1e-8	Cognitive function;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01852244	chr16:47494711	PHKB;ITFG1	0.6	7.02	0.49	7.04e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.72	-0.36	5.23e-6	Breast cancer;
PAAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg03340356	chr1:67600835	NA	0.45	5.02	0.38	1.45e-6	Crohn's disease;
PAAD	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.59	5.19	0.39	6.71e-7	Life satisfaction;
PAAD	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs6547631	0.622	rs10180445	chr2:85926218	C/G	cg24620635	chr2:85921963	GNLY	-0.43	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09260225	chr12:69863995	FRS2	0.59	6.7	0.48	3.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	1.02	7.27	0.51	1.81e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs9361491	0.608	rs4590227	chr6:79463910	G/A	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2190422	0.677	rs2906639	chr7:103074580	T/C	cg04218035	chr7:103086829	SLC26A5	0.35	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.12	0.67	2.12e-21	Parkinson's disease;
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg06207120	chr15:45996521	NA	0.31	4.61	0.35	8.53e-6	Waist circumference;Weight;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07512313	chr14:102963438	TECPR2	-0.6	-6.51	-0.47	1.05e-9	Myopia (pathological);
PAAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg15436174	chr10:43711423	RASGEF1A	0.62	5.82	0.43	3.34e-8	Hirschsprung disease;
PAAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.56	-6.82	-0.48	1.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3996993	0.809	rs3756982	chr6:52670444	A/T	cg20803780	chr6:52668592	GSTA1	-0.35	-4.48	-0.34	1.47e-5	Hemoglobin concentration;
PAAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.54	0.57	1.3e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg25902810	chr10:99078978	FRAT1	-0.59	-5.5	-0.41	1.54e-7	Monocyte count;
PAAD	cis	rs357618	1.000	rs357627	chr5:150850260	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06811360	chr17:8089327	NA	0.59	6.58	0.47	7.1e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4474633	1	rs4474633	chr15:49260601	A/G	cg20384325	chr15:49268750	NA	0.45	4.32	0.33	2.81e-5	Major depressive disorder;
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.93	-0.59	1.34e-15	Total body bone mineral density;
PAAD	cis	rs9928842	0.882	rs4737	chr16:75238103	A/G	cg09066997	chr16:75300724	BCAR1	-0.69	-4.64	-0.35	7.34e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg03959625	chr15:84868606	LOC388152	0.41	4.34	0.33	2.58e-5	Schizophrenia;
PAAD	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg01388757	chr2:102091195	RFX8	0.51	6.39	0.46	1.94e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-7.11	-0.5	4.33e-11	Parkinson's disease;
PAAD	cis	rs16975963	0.793	rs73034946	chr19:38460493	T/C	cg25793785	chr19:38281423	NA	0.57	4.67	0.35	6.72e-6	Longevity;
PAAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg11766577	chr21:47581405	C21orf56	-0.41	-4.66	-0.35	6.75e-6	Testicular germ cell tumor;
PAAD	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.74	-0.48	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12599982	chr1:44399894	ARTN	0.46	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26517283	chr7:6198004	USP42	-0.67	-7.97	-0.54	3.55e-13	Monocyte percentage of white cells;
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg04520793	chr17:42248056	ASB16	-0.42	-4.91	-0.37	2.32e-6	Total body bone mineral density;
PAAD	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.43	-4.3	-0.33	3.08e-5	Testicular germ cell tumor;
PAAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.52	-5.18	-0.39	6.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02138806	chr2:151730502	NA	0.59	6.52	0.47	9.75e-10	Smoking initiation;
PAAD	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg10820045	chr2:198174542	NA	0.51	5.26	0.39	4.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.05	-0.75	2.85e-29	Headache;
PAAD	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg06609049	chr19:2785107	THOP1	0.92	10.37	0.64	2.25e-19	Total cholesterol levels;
PAAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11817309	chr1:249152443	ZNF692	0.56	6.38	0.46	2.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6750047	0.781	rs4670809	chr2:38277364	A/C	cg19753864	chr2:38320028	NA	0.42	4.68	0.35	6.39e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06850241	chr22:41845214	NA	-0.55	-5.0	-0.38	1.56e-6	Vitiligo;
PAAD	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg15654264	chr1:150340011	RPRD2	0.52	5.03	0.38	1.37e-6	Migraine;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg05742988	chr12:56521901	ESYT1	-0.56	-6.36	-0.46	2.3e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.28	0.45	3.41e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg26528668	chr16:1614120	IFT140	0.56	5.22	0.39	5.86e-7	Coronary artery disease;
PAAD	cis	rs12906542	0.516	rs4886989	chr15:78303748	T/C	cg23683012	chr15:78369302	TBC1D2B	0.69	5.15	0.39	8.04e-7	Breast cancer;
PAAD	cis	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24447660	chr3:127872092	EEFSEC	0.6	6.54	0.47	9.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs13006833	0.668	rs2582770	chr2:191136794	A/C	cg27211696	chr2:191398769	TMEM194B	0.45	4.54	0.35	1.12e-5	Urinary metabolites;
PAAD	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.62	-6.31	-0.46	2.94e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Diabetic kidney disease;
PAAD	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.23	-0.39	5.43e-7	Mood instability;
PAAD	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg01304814	chr3:48885189	PRKAR2A	0.64	4.35	0.33	2.53e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg06606381	chr12:133084897	FBRSL1	1.31	8.96	0.59	1.12e-15	Depression;
PAAD	cis	rs12935418	0.616	rs12446053	chr16:80964131	A/G	cg16651780	chr16:81037892	C16orf61	-0.51	-4.28	-0.33	3.32e-5	Mean corpuscular volume;
PAAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.51	-4.59	-0.35	9.19e-6	Height;
PAAD	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg06375148	chr1:209958343	C1orf74	0.67	5.25	0.39	5.14e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg16482183	chr6:26056742	HIST1H1C	0.57	5.08	0.38	1.09e-6	Height;
PAAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.6	-8.22	-0.55	8.52e-14	Renal cell carcinoma;
PAAD	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.52	5.43	0.4	2.14e-7	Lung cancer;
PAAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.5	-4.29	-0.33	3.18e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.43	0.56	2.42e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18621852	chr3:10150065	C3orf24	0.62	5.33	0.4	3.5e-7	Alzheimer's disease;
PAAD	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.26e-9	Personality dimensions;
PAAD	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	6.48	0.47	1.19e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9398803	0.687	rs3905044	chr6:126972883	A/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Menopause (age at onset);
PAAD	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.57	-0.41	1.14e-7	Vitiligo;
PAAD	cis	rs829661	0.947	rs829669	chr2:30720752	A/G	cg12454169	chr2:30669597	LCLAT1	0.63	4.99	0.38	1.65e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg12568669	chr8:11666485	FDFT1	0.29	4.47	0.34	1.49e-5	Retinal vascular caliber;
PAAD	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs4280164	0.551	rs1109152	chr14:24799024	G/C	cg07162820	chr14:24837146	NFATC4	0.35	4.6	0.35	9.01e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg09386050	chr7:809078	HEATR2	-0.67	-7.14	-0.5	3.63e-11	Subjective well-being;
PAAD	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.49	0.61	4.6e-17	Fuchs's corneal dystrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24563703	chr4:154016076	NA	-0.61	-6.29	-0.45	3.24e-9	Obesity-related traits;
PAAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg05627522	chr15:75251581	NA	0.49	5.8	0.43	3.75e-8	Breast cancer;
PAAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.56	-6.72	-0.48	3.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3e-7	Heart rate;
PAAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg03233332	chr7:66118400	NA	0.41	4.48	0.34	1.47e-5	Cotinine glucuronidation;
PAAD	trans	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg14974938	chr4:62606570	LPHN3	0.47	6.55	0.47	8.31e-10	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03605463	chr16:89740564	NA	0.46	4.25	0.33	3.7e-5	Vitiligo;
PAAD	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs28595532	0.720	rs72670230	chr4:119312490	T/C	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.6	0.52	2.76e-12	Multiple sclerosis;
PAAD	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.67	-5.83	-0.43	3.17e-8	Obesity-related traits;
PAAD	cis	rs6132905	0.590	rs2325893	chr20:2607724	C/T	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-10.71	-0.66	2.72e-20	Height;
PAAD	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.68	7.87	0.54	6.14e-13	Systemic lupus erythematosus;
PAAD	cis	rs59888335	0.858	rs17280613	chr3:80906589	A/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.78	-6.13	-0.45	7.34e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.58	7.43	0.52	7.33e-12	Hypertriglyceridemia;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.82	-7.66	-0.53	2.02e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs818427	0.964	rs151978	chr5:112234498	T/G	cg06941702	chr5:112196734	SRP19	0.45	4.27	0.33	3.48e-5	Total body bone mineral density;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.2	-0.64	6.32e-19	Obesity-related traits;
PAAD	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.75	9.33	0.6	1.22e-16	Body mass index;
PAAD	cis	rs28595532	0.920	rs114924396	chr4:119755621	A/G	cg21605333	chr4:119757512	SEC24D	2.0	10.54	0.65	7.83e-20	Cannabis dependence symptom count;
PAAD	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.58	0.8	6.69e-36	Prudent dietary pattern;
PAAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.84	0.37	3.14e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1879734	0.636	rs4927031	chr1:54183191	C/T	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs7582720	1.000	rs72932752	chr2:203667526	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.5	0.52	4.84e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.5	-0.47	1.12e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg16306870	chr3:194868790	C3orf21	0.43	4.42	0.34	1.84e-5	Non-small cell lung cancer;
PAAD	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.54	4.25	0.33	3.64e-5	QRS complex (12-leadsum);
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6137287	0.924	rs6035793	chr20:21139252	G/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	5.05	0.38	1.23e-6	Coronary artery disease;
PAAD	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.83	10.14	0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-4.9	-0.37	2.42e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg04518342	chr5:131593106	PDLIM4	0.48	4.69	0.36	6e-6	Blood metabolite levels;
PAAD	cis	rs11853189	0.938	rs113594982	chr15:78557392	C/T	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.9	0.43	2.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg24324837	chr19:49891574	CCDC155	0.65	4.87	0.37	2.77e-6	Multiple sclerosis;
PAAD	trans	rs901683	1.000	rs35001302	chr10:46068936	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg15192750	chr16:69999425	NA	0.71	5.42	0.4	2.31e-7	IgE levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09739036	chr11:67211315	CORO1B	0.57	6.57	0.47	7.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.37	-0.4	2.84e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.8	-7.86	-0.54	6.66e-13	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06270802	chr17:75277369	SEPT9	0.59	6.64	0.47	5.35e-10	Monocyte percentage of white cells;
PAAD	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg08514558	chr10:81106712	PPIF	0.52	6.28	0.45	3.44e-9	Height;
PAAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.48	4.8	0.36	3.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg03808351	chr9:123631620	PHF19	0.43	4.42	0.34	1.88e-5	Rheumatoid arthritis;
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.83	-10.45	-0.65	1.36e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.98	11.81	0.69	3.08e-23	Breast cancer;
PAAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg03959625	chr15:84868606	LOC388152	0.43	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.7	0.42	6.02e-8	Prudent dietary pattern;
PAAD	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg08898775	chr15:59042684	ADAM10	0.39	5.08	0.38	1.08e-6	Schizophrenia;
PAAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg23283495	chr1:209979779	IRF6	0.78	7.07	0.5	5.37e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.49	4.5	0.34	1.32e-5	Diastolic blood pressure;
PAAD	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.06	13.43	0.74	1.31e-27	Testicular germ cell tumor;
PAAD	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.67	-8.67	-0.58	5.9e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs8077577	0.945	rs62073609	chr17:18071843	T/C	cg16794390	chr17:18148240	FLII	0.58	4.88	0.37	2.68e-6	Obesity-related traits;
PAAD	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-4.44	-0.34	1.73e-5	Menarche (age at onset);
PAAD	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs34779708	0.832	rs6481946	chr10:35529114	A/G	cg03585969	chr10:35415529	CREM	0.52	4.75	0.36	4.6e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4764487	0.760	rs740840	chr12:6337254	G/T	cg08284733	chr12:6341482	CD9	0.4	4.37	0.33	2.26e-5	Mean platelet volume;
PAAD	cis	rs6137287	0.813	rs6082351	chr20:21213844	T/C	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.92	11.22	0.67	1.13e-21	Menarche (age at onset);
PAAD	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.34	-0.4	3.33e-7	Retinal vascular caliber;
PAAD	cis	rs7714584	1.000	rs11167515	chr5:150239471	G/T	cg22134413	chr5:150180641	NA	0.86	6.01	0.44	1.33e-8	Crohn's disease;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.5	5.09	0.38	1.04e-6	Height;
PAAD	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.53	-5.64	-0.42	8.01e-8	Height;
PAAD	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg24565620	chr2:194026	NA	-0.63	-5.41	-0.4	2.43e-7	Blood protein levels;
PAAD	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg11952622	chr19:58962976	ZNF324B	0.45	4.31	0.33	2.92e-5	Uric acid clearance;
PAAD	cis	rs62209	0.530	rs17444979	chr10:10994159	C/T	cg26901096	chr10:10994189	LOC254312	0.62	4.75	0.36	4.67e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.71	-5.81	-0.43	3.62e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs10982213	1.000	rs10982201	chr9:117169935	C/A	cg00078025	chr9:117159975	NA	0.58	4.29	0.33	3.2e-5	Interleukin-6 levels;
PAAD	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	6.87	0.49	1.51e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.34	0.46	2.45e-9	Morning vs. evening chronotype;
PAAD	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg07600127	chr13:30881527	KATNAL1	-0.63	-4.27	-0.33	3.4e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17637107	chr8:20054583	ATP6V1B2	-0.63	-6.6	-0.47	6.54e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	6.73	0.48	3.28e-10	High light scatter reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09031958	chr5:179203369	MAML1	-0.67	-7.02	-0.49	7e-11	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21484512	chr8:11189650	AMAC1L2	0.45	6.29	0.45	3.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.87	0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg23024343	chr7:107201750	COG5	0.56	4.52	0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs11651483	1.000	rs6502208	chr17:12781955	G/C	cg06766427	chr17:12877546	RICH2	0.71	4.62	0.35	8.16e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	1.09	8.27	0.56	6.22e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg10589385	chr1:150898437	SETDB1	-0.38	-4.65	-0.35	7.16e-6	Tonsillectomy;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25883261	chr11:34937992	PDHX;APIP	0.75	9.31	0.6	1.37e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg18612461	chr15:75251733	NA	0.54	6.43	0.46	1.57e-9	Caffeine consumption;
PAAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg07384165	chr1:10488281	NA	-0.56	-5.56	-0.41	1.2e-7	Prostate cancer;
PAAD	cis	rs1555895	0.656	rs4881532	chr10:845449	A/G	cg20503657	chr10:835505	NA	0.49	5.1	0.38	1.01e-6	Survival in rectal cancer;
PAAD	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12282742	1.000	rs12282742	chr11:18265799	A/G	cg21051972	chr11:18067927	NA	-0.65	-4.34	-0.33	2.6e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.58	0.68	1.24e-22	Total body bone mineral density;
PAAD	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg23241863	chr10:102295624	HIF1AN	0.46	4.27	0.33	3.41e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.99	-10.98	-0.67	5.17e-21	Homoarginine levels;
PAAD	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.33e-7	Noise-induced hearing loss;
PAAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.43e-6	White blood cell count;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04860312	chr1:209786644	CAMK1G	0.57	6.49	0.47	1.15e-9	Warfarin maintenance dose;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-1.05	-13.36	-0.73	2.06e-27	Uric acid levels;
PAAD	trans	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg19894588	chr14:64061835	NA	-0.76	-6.62	-0.47	5.68e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.86	-0.37	2.91e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.91	-0.37	2.35e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6136489	0.710	rs4814779	chr20:1923271	C/A	cg19358608	chr20:1924565	NA	-0.32	-4.34	-0.33	2.61e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg02683114	chr2:24398427	C2orf84	-0.54	-5.1	-0.38	1.02e-6	Asthma;
PAAD	cis	rs7246865	0.510	rs34833670	chr19:17172983	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.72	0.42	5.37e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs7651511	1.000	rs9823528	chr3:141206990	C/T	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs4704187	0.687	rs57646262	chr5:74527472	C/T	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs934734	0.532	rs10184881	chr2:65684152	A/G	cg16178603	chr2:66667101	MEIS1	-0.44	-4.42	-0.34	1.89e-5	Rheumatoid arthritis;
PAAD	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.83	-0.36	3.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12138061	0.954	rs11205659	chr1:50373692	A/G	cg09846084	chr1:50888024	DMRTA2	0.55	4.65	0.35	7.07e-6	Schizophrenia;
PAAD	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg06138931	chr13:21896616	NA	-0.64	-4.36	-0.33	2.39e-5	White matter hyperintensity burden;
PAAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg20821713	chr7:1055600	C7orf50	-0.54	-4.4	-0.34	2.05e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.49	-5.0	-0.38	1.58e-6	Coronary artery disease;Body mass index;
PAAD	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.15	-0.55	1.27e-13	Brugada syndrome;
PAAD	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs11676348	0.935	rs4674248	chr2:218960131	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.79e-6	Ulcerative colitis;
PAAD	cis	rs12949688	1.000	rs7212186	chr17:55818454	C/A	cg12582317	chr17:55822272	NA	0.69	8.71	0.58	4.9e-15	Schizophrenia;
PAAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.77	-9.57	-0.61	2.92e-17	Height;
PAAD	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.69	5.1	0.38	9.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.8	9.3	0.6	1.42e-16	Diastolic blood pressure;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg22189786	chr22:42395067	WBP2NL	0.46	5.06	0.38	1.2e-6	Cognitive function;
PAAD	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.5	-6.36	-0.46	2.3e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-1.19	-9.98	-0.63	2.39e-18	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.12	-0.5	4.01e-11	Life satisfaction;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26349672	chr1:39875051	KIAA0754;MACF1	-0.76	-6.35	-0.46	2.37e-9	Neuroticism;
PAAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.72	9.06	0.59	5.9e-16	Dupuytren's disease;
PAAD	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14400763	chr9:38478901	NA	-0.68	-7.13	-0.5	3.8e-11	Obesity-related traits;
PAAD	cis	rs3787159	0.573	rs472191	chr20:56880558	A/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.67	4.91	0.37	2.38e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg24633833	chr3:10029261	TMEM111	0.6	4.4	0.34	2.01e-5	Alzheimer's disease;
PAAD	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.78	-0.42	4.13e-8	Testicular germ cell tumor;
PAAD	cis	rs35740288	0.770	rs11630286	chr15:86202529	T/C	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.61	-6.61	-0.47	6.12e-10	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.46	6.35	0.46	2.35e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs2070677	0.808	rs3020500	chr10:135381276	T/C	cg08390786	chr10:135334061	NA	-0.65	-5.73	-0.42	5.3e-8	Gout;
PAAD	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg14703610	chr5:56206110	C5orf35	0.59	5.29	0.39	4.14e-7	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.53	-5.44	-0.4	2.12e-7	Alcohol dependence;
PAAD	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.37	-5.93	-0.43	2e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.41	-0.4	2.39e-7	Glaucoma (primary open-angle);
PAAD	cis	rs727479	0.543	rs8023263	chr15:51517597	G/T	cg21478137	chr15:51532386	CYP19A1	0.5	4.91	0.37	2.33e-6	Estradiol levels;
PAAD	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.46	-0.34	1.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.75e-9	Bladder cancer;
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	4.82	0.36	3.39e-6	Obesity-related traits;
PAAD	cis	rs2555155	0.633	rs2303493	chr11:6499215	A/G	cg24637308	chr11:6592297	DNHD1	0.45	4.75	0.36	4.57e-6	DNA methylation (variation);
PAAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.81	-7.58	-0.52	3.21e-12	Asthma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24631870	chr3:142297635	ATR	-0.61	-6.47	-0.46	1.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.54	-5.59	-0.41	1.01e-7	Total body bone mineral density;
PAAD	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.77	-6.73	-0.48	3.18e-10	Coronary artery disease;
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.79	-5.94	-0.43	1.9e-8	Initial pursuit acceleration;
PAAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.96	-6.99	-0.49	7.9e-11	Breast cancer;
PAAD	cis	rs6519955	0.691	rs9627447	chr22:46423928	G/C	cg00147172	chr22:46423604	NA	0.4	5.26	0.39	4.79e-7	Dupuytren's disease;
PAAD	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.35	-4.27	-0.33	3.42e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.88	-9.19	-0.6	2.82e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.63	6.47	0.46	1.27e-9	Bladder cancer;
PAAD	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.75	7.68	0.53	1.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs950881	0.932	rs10189154	chr2:102937544	C/T	cg20060108	chr2:102954350	IL1RL1	0.56	4.44	0.34	1.73e-5	Allergy;
PAAD	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26926768	chr12:34528122	NA	0.36	4.27	0.33	3.5e-5	Morning vs. evening chronotype;
PAAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.11	0.44	7.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.47	-5.85	-0.43	2.9e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24459529	chr2:183989107	NUP35	-0.67	-6.3	-0.46	3.13e-9	Neuroticism;
PAAD	cis	rs561655	0.564	rs3844143	chr11:85850243	C/T	cg07180834	chr11:85838833	NA	-0.44	-4.91	-0.37	2.29e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.94	-8.09	-0.55	1.77e-13	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg02912127	chr19:22235281	ZNF257	0.4	4.6	0.35	8.76e-6	Telomere length;
PAAD	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.55	-7.79	-0.53	9.91e-13	Homoarginine levels;
PAAD	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.62	0.41	9.04e-8	Lung cancer;
PAAD	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.82	-0.62	6.17e-18	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.39	0.34	2.09e-5	Bipolar disorder;
PAAD	cis	rs7260329	0.629	rs2873264	chr19:41505708	C/T	cg06653635	chr19:40910092	PRX	-0.53	-4.88	-0.37	2.62e-6	Smoking behavior;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg03767155	chr2:8822052	ID2	0.9	6.3	0.46	3.04e-9	Lung function (FEV1/FVC);
PAAD	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg08992911	chr2:238395768	MLPH	0.67	6.58	0.47	7.11e-10	Prostate cancer;
PAAD	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	1.06	10.67	0.65	3.52e-20	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.92	-7.79	-0.53	9.56e-13	Gut microbiome composition (summer);
PAAD	cis	rs7577696	0.924	rs11124277	chr2:32320370	T/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.65	-0.35	7.28e-6	Inflammatory biomarkers;
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.69	0.42	6.37e-8	Eosinophil percentage of white cells;
PAAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Blood metabolite levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19489797	chr2:25475140	DNMT3A	-0.66	-6.48	-0.47	1.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6011002	0.636	rs2427536	chr20:62372813	G/A	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.09e-5	Breast cancer;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-5.57	-0.41	1.1e-7	Longevity;Endometriosis;
PAAD	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18050295	chr3:12949921	IQSEC1	0.57	6.69	0.48	3.96e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.75	-7.56	-0.52	3.55e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7624766	0.743	rs1403048	chr3:160477897	C/A	cg22637730	chr3:160473554	PPM1L	0.55	4.97	0.37	1.77e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.56	-5.62	-0.41	8.78e-8	Blood protein levels;
PAAD	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs4662592	0.554	rs13009827	chr2:128912936	G/A	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs10488172	0.857	rs4731953	chr7:133103048	A/G	cg10665199	chr7:133106180	EXOC4	0.53	4.54	0.35	1.16e-5	Tonometry;
PAAD	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.01	0.38	1.47e-6	Migraine;
PAAD	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	9.07	0.59	5.84e-16	Post bronchodilator FEV1;
PAAD	cis	rs740474	0.554	rs251041	chr5:141027888	C/G	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.34	4.79	0.36	3.9e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg07559730	chr19:53497048	ZNF702P	-0.52	-5.59	-0.41	1.05e-7	Psoriasis;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	5.45	0.4	2.03e-7	Calcium levels;
PAAD	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.78	0.42	4.05e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17525856	chr2:47596787	EPCAM	0.69	7.03	0.5	6.43e-11	Obesity-related traits;
PAAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg27478167	chr7:817139	HEATR2	-0.56	-4.47	-0.34	1.54e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00648153	chr6:74364149	SLC17A5	0.68	7.72	0.53	1.47e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.66	-6.37	-0.46	2.14e-9	Refractive astigmatism;
PAAD	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.64e-9	Educational attainment;
PAAD	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg25401027	chr5:176370377	UIMC1	0.43	4.41	0.34	1.94e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.97	-10.11	-0.63	1.05e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11811982	0.793	rs79238704	chr1:227441605	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs12464483	1.000	rs12464483	chr2:30888924	G/A	cg07150166	chr2:30669952	LCLAT1	0.76	4.5	0.34	1.33e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	0.96	10.04	0.63	1.67e-18	Homoarginine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06211459	chr4:17513897	QDPR	0.73	7.33	0.51	1.29e-11	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg02754945	chr1:152161885	NA	0.46	4.74	0.36	4.78e-6	Inflammatory skin disease;
PAAD	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg21366198	chr4:185655624	MLF1IP	0.5	4.41	0.34	1.98e-5	Kawasaki disease;
PAAD	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	1.13	13.02	0.73	1.67e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg12311346	chr5:56204834	C5orf35	-0.75	-4.6	-0.35	8.93e-6	Type 2 diabetes;
PAAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.75e-6	Personality dimensions;
PAAD	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.33	0.33	2.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-7.72	-0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-1.0	-6.88	-0.49	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1863918	0.533	rs2278221	chr5:178581859	C/T	cg05656566	chr5:178593924	ADAMTS2	-0.45	-4.73	-0.36	4.99e-6	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.97	0.37	1.81e-6	Platelet count;
PAAD	cis	rs3010562	0.831	rs2981980	chr6:167757858	C/T	cg20481416	chr6:167803413	NA	-0.48	-4.77	-0.36	4.31e-6	Gut microbiome composition (summer and winter);
PAAD	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.69	7.34	0.51	1.2e-11	Platelet distribution width;
PAAD	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.5e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.09	0.44	8.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg18084798	chr19:33555255	RHPN2	-0.4	-4.27	-0.33	3.45e-5	Bone properties (heel);
PAAD	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.16	0.39	7.59e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.84	9.93	0.63	3.26e-18	Blood metabolite ratios;
PAAD	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.47	4.3	0.33	3.04e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.95	0.37	1.98e-6	Colorectal cancer;
PAAD	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.58	5.51	0.41	1.5e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.49	0.61	4.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg17346650	chr17:80929145	B3GNTL1	0.43	5.6	0.41	9.76e-8	Glycated hemoglobin levels;
PAAD	cis	rs13424612	1.000	rs10193610	chr2:240940618	A/G	cg01812947	chr2:240904978	NDUFA10	0.59	5.28	0.39	4.3e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.5	-5.12	-0.38	9.32e-7	Colorectal cancer;
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3136441	1.000	rs75185853	chr11:46751401	T/C	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg19052272	chr2:3704530	ALLC	-0.89	-8.63	-0.57	7.47e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg16329197	chr12:53359506	NA	-0.99	-6.23	-0.45	4.35e-9	Prostate cancer;
PAAD	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-4.92	-0.37	2.25e-6	Common traits (Other);
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.05	-0.38	1.26e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg26138144	chr22:38071188	LGALS1	0.42	4.67	0.35	6.7e-6	Fat distribution (HIV);
PAAD	cis	rs3784262	0.692	rs1441819	chr15:58243204	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.48	-0.41	1.73e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg11262906	chr1:85462892	MCOLN2	0.59	4.58	0.35	9.74e-6	Serum sulfate level;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg22535103	chr8:58192502	C8orf71	-1.22	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.73	7.66	0.53	1.99e-12	Prostate cancer;
PAAD	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg26031613	chr14:104095156	KLC1	1.14	14.5	0.76	1.86e-30	Body mass index;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.12	0.44	7.53e-9	Lung cancer;
PAAD	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.59	-6.34	-0.46	2.45e-9	Schizophrenia;
PAAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.08	-0.55	1.87e-13	Diabetic kidney disease;
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs943072	0.834	rs72862289	chr6:43795319	T/A	cg06892548	chr6:43243945	TTBK1	0.62	4.57	0.35	9.98e-6	Ulcerative colitis;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg12705353	chr12:122356852	WDR66	0.5	4.98	0.37	1.72e-6	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs12826942	1.000	rs12826942	chr12:42796300	A/G	cg19980929	chr12:42632907	YAF2	0.56	5.12	0.38	9.02e-7	Coronary artery disease;
PAAD	cis	rs4908768	0.657	rs4908778	chr1:8804888	C/G	cg00590817	chr1:8272081	NA	-0.36	-4.34	-0.33	2.57e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.8	-6.74	-0.48	3.06e-10	Gut microbiome composition (summer);
PAAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08893839	chr5:154027129	NA	0.77	6.22	0.45	4.57e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.62	4.36	0.33	2.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg08317243	chr16:87101592	NA	0.51	5.12	0.38	9.22e-7	Menopause (age at onset);
PAAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.9e-7	Rheumatoid arthritis;
PAAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.65	-0.42	7.84e-8	Pulmonary function;
PAAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.64	6.07	0.44	9.88e-9	Corneal astigmatism;
PAAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.74	8.03	0.55	2.46e-13	Longevity;
PAAD	cis	rs597583	0.806	rs4938397	chr11:117392337	G/T	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.27	-0.45	3.47e-9	Putamen volume;
PAAD	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26926768	chr12:34528122	NA	-0.38	-4.74	-0.36	4.82e-6	Morning vs. evening chronotype;
PAAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-4.8	-0.36	3.73e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs2898290	0.601	rs1478891	chr8:11448328	G/C	cg21175976	chr8:11421337	BLK	0.4	4.26	0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.6	-6.0	-0.44	1.38e-8	Primary sclerosing cholangitis;
PAAD	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.57	6.4	0.46	1.82e-9	Coronary artery disease;
PAAD	cis	rs3812111	0.525	rs2232472	chr6:116574455	G/A	cg05304507	chr6:116381966	FRK	-0.27	-4.57	-0.35	1.02e-5	Age-related macular degeneration;
PAAD	cis	rs4852324	0.536	rs6721042	chr2:74217283	G/T	cg19729930	chr2:74357872	NA	0.94	4.98	0.37	1.72e-6	Systemic lupus erythematosus;
PAAD	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-1.07	-15.15	-0.78	3.4e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg01320130	chr1:67600311	NA	0.52	5.8	0.43	3.79e-8	Psoriasis;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.77	8.86	0.58	2.01e-15	Type 2 diabetes;
PAAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24729792	chr2:113192114	RGPD8;RGPD5	0.55	4.27	0.33	3.48e-5	Yeast infection;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.29e-9	Cardiovascular disease risk factors;
PAAD	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.67	6.8	0.48	2.26e-10	Tourette syndrome;
PAAD	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13939156	chr17:80058883	NA	-0.42	-4.52	-0.34	1.23e-5	Life satisfaction;
PAAD	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.58	6.03	0.44	1.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	1.19	15.27	0.78	1.72e-32	Longevity;
PAAD	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.49	5.61	0.41	9.1e-8	QRS complex (12-leadsum);
PAAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg10534938	chr5:1868639	NA	0.47	6.05	0.44	1.06e-8	Cardiovascular disease risk factors;
PAAD	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg01426195	chr3:39028469	NA	-0.63	-6.2	-0.45	5.19e-9	Handedness;
PAAD	cis	rs11811982	0.793	rs74877892	chr1:227355545	T/C	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	4.9	0.37	2.45e-6	Schizophrenia;
PAAD	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.64	6.31	0.46	2.9e-9	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.6	6.16	0.45	6.12e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs12476592	0.530	rs12476786	chr2:64151723	C/T	cg20249169	chr2:64881356	SERTAD2	-0.54	-4.31	-0.33	2.91e-5	Childhood ear infection;
PAAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs2288884	0.943	rs1433089	chr19:52506985	T/C	cg24368865	chr19:51538134	KLK12	0.52	4.76	0.36	4.51e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
PAAD	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.5	5.24	0.39	5.36e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg09491104	chr22:46646882	C22orf40	-0.67	-6.12	-0.44	7.76e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.25	-0.6	1.96e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4356203	0.870	rs7949699	chr11:17247708	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.06	-0.38	1.21e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.54	0.41	1.28e-7	Educational attainment (years of education);
PAAD	cis	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.51	-6.0	-0.44	1.38e-8	Mean arterial pressure;
PAAD	cis	rs288342	0.800	rs288278	chr2:183591571	G/A	cg02625481	chr2:183667124	NA	-0.45	-4.61	-0.35	8.44e-6	Recurrent major depressive disorder;
PAAD	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg26528668	chr16:1614120	IFT140	0.56	5.49	0.41	1.64e-7	Coronary artery disease;
PAAD	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg16447950	chr5:562315	NA	-0.51	-4.83	-0.36	3.28e-6	Obesity-related traits;
PAAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs6694672	0.867	rs7534353	chr1:197096480	T/G	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.55	6.09	0.44	8.91e-9	Height;
PAAD	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.54	4.9	0.37	2.42e-6	Liver enzyme levels;
PAAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.36	6.23e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-4.36	-0.33	2.41e-5	Inflammatory bowel disease;
PAAD	cis	rs4144027	0.935	rs10139856	chr14:104354505	T/C	cg08213375	chr14:104286397	PPP1R13B	-0.37	-4.32	-0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.0	-12.64	-0.72	1.73e-25	Dilated cardiomyopathy;
PAAD	cis	rs375066	0.935	rs406968	chr19:44418343	C/T	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.74	0.66	2.29e-20	Prudent dietary pattern;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.97	10.61	0.65	5.08e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9810890	1.000	rs73198856	chr3:128513001	C/T	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg22437258	chr11:111473054	SIK2	0.62	6.05	0.44	1.1e-8	Primary sclerosing cholangitis;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.52	5.55	0.41	1.24e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg01689657	chr7:91764605	CYP51A1	0.31	4.34	0.33	2.56e-5	Breast cancer;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.58	-6.26	-0.45	3.79e-9	Schizophrenia;
PAAD	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.52	5.43	0.4	2.21e-7	Obesity-related traits;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg24879335	chr3:133465180	TF	0.55	5.75	0.42	4.65e-8	Iron status biomarkers;
PAAD	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02985541	chr2:219472218	PLCD4	0.3	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.72	9.0	0.59	8.66e-16	Dupuytren's disease;
PAAD	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs7786877	0.587	rs56328569	chr7:100202219	C/G	cg20848291	chr7:100343083	ZAN	-0.66	-5.45	-0.4	1.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg02117656	chr17:79614917	TSPAN10	0.58	6.21	0.45	4.72e-9	Eye color traits;
PAAD	cis	rs258892	0.842	rs11951999	chr5:72020144	C/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs288342	0.763	rs288292	chr2:183631597	C/G	cg02625481	chr2:183667124	NA	-0.45	-4.47	-0.34	1.52e-5	Recurrent major depressive disorder;
PAAD	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.57	-5.06	-0.38	1.22e-6	Life satisfaction;
PAAD	trans	rs10515808	0.558	rs116457817	chr5:159814276	A/G	cg04842426	chr7:136555777	CHRM2	-0.54	-6.34	-0.46	2.47e-9	Weight loss (gastric bypass surgery);
PAAD	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg08648136	chr8:956695	NA	0.42	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.9	0.49	1.3100000000000001e-10	Blood protein levels;
PAAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.41	-0.34	1.92e-5	Coronary artery disease;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.58	-5.65	-0.42	7.69e-8	Iron status biomarkers;
PAAD	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.51	5.65	0.42	7.65e-8	Obesity-related traits;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.28	-7.71	-0.53	1.53e-12	Body mass index;
PAAD	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	trans	rs225245	0.782	rs161183	chr17:33919475	G/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.47	-0.46	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg19486271	chr11:47235900	DDB2	0.6	6.13	0.44	7.37e-9	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.57	-0.41	1.14e-7	Vitiligo;
PAAD	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	4.75	0.36	4.63e-6	Hip circumference;
PAAD	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg16989719	chr2:238392110	NA	-0.39	-5.07	-0.38	1.16e-6	Prostate cancer;
PAAD	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.5	-4.92	-0.37	2.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.43	-0.34	1.78e-5	Body mass index;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg18279126	chr7:2041391	MAD1L1	0.6	5.77	0.42	4.4e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2446066	0.872	rs7133236	chr12:53790985	A/G	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg15507776	chr3:136538369	TMEM22	0.47	4.6	0.35	8.86e-6	Neuroticism;
PAAD	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg22827986	chr11:48284249	OR4X1	0.37	4.75	0.36	4.59e-6	Migraine - clinic-based;
PAAD	cis	rs6942407	0.592	rs1859128	chr7:86752171	G/C	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.69	8.06	0.55	2.08e-13	Colorectal cancer;
PAAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.41	-0.46	1.78e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.5	5.38	0.4	2.79e-7	Height;
PAAD	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-6.29	-0.45	3.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg02743256	chr7:2109353	MAD1L1	0.65	4.95	0.37	1.98e-6	Bipolar disorder;
PAAD	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg09455208	chr3:40491958	NA	-0.44	-5.76	-0.42	4.6e-8	Renal cell carcinoma;
PAAD	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	trans	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg14974938	chr4:62606570	LPHN3	0.46	6.36	0.46	2.2e-9	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg14789911	chr21:47582049	C21orf56	0.53	5.67	0.42	6.92e-8	Testicular germ cell tumor;
PAAD	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.14e-18	Electrocardiographic conduction measures;
PAAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.51	-5.77	-0.42	4.36e-8	Tonsillectomy;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.54	5.78	0.42	4.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8084125	1.000	rs72978662	chr18:74951872	G/A	cg15443732	chr18:74961078	GALR1	0.72	5.91	0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.64	7.76	0.53	1.14e-12	Dupuytren's disease;
PAAD	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-5.0	-0.38	1.54e-6	Self-reported allergy;
PAAD	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-4.67	-0.35	6.68e-6	Type 2 diabetes;
PAAD	cis	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg11783356	chr20:44313418	WFDC10B	-0.74	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.51	-4.73	-0.36	5e-6	Hypospadias;
PAAD	cis	rs66530629	0.761	rs7519508	chr1:25147750	G/A	cg01905478	chr1:25040257	NA	-0.48	-5.24	-0.39	5.38e-7	Plateletcrit;
PAAD	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs10958605	0.761	rs13270718	chr8:40039431	G/A	cg14545590	chr8:40388592	ZMAT4	-0.41	-4.61	-0.35	8.36e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs73394838	0.590	rs6006250	chr22:30182342	C/T	cg14926439	chr22:29999402	NF2	-0.88	-4.37	-0.33	2.25e-5	Telomere length;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07685180	chr8:600429	NA	0.97	6.65	0.47	5.07e-10	IgG glycosylation;
PAAD	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.45	4.31	0.33	2.88e-5	Red blood cell count;
PAAD	cis	rs4272720	0.805	rs61848124	chr10:50210710	T/C	cg01311537	chr10:50386709	C10orf128	-0.54	-4.32	-0.33	2.84e-5	Platelet count;Plateletcrit;
PAAD	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.57	7.56	0.52	3.62e-12	Primary biliary cholangitis;
PAAD	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.62	5.95	0.43	1.77e-8	Refractive astigmatism;
PAAD	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.41	-5.99	-0.44	1.49e-8	Subjective well-being;
PAAD	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.7	-7.42	-0.52	7.67e-12	Platelet distribution width;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14457918	chr22:50608509	PANX2	0.57	6.74	0.48	3.17e-10	Metabolite levels  (X-11787);
PAAD	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06850241	chr22:41845214	NA	0.62	5.49	0.41	1.66e-7	Vitiligo;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.24	-0.45	4.1e-9	Longevity;Endometriosis;
PAAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.69	-4.86	-0.37	2.84e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg09659197	chr4:152720779	NA	0.46	6.24	0.45	4.22e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.68	-7.17	-0.5	3.07e-11	Menopause (age at onset);
PAAD	cis	rs6547631	0.622	rs4240202	chr2:85925680	T/G	cg24620635	chr2:85921963	GNLY	0.42	5.55	0.41	1.23e-7	Blood protein levels;
PAAD	cis	rs16975963	0.793	rs56672492	chr19:38448231	T/C	cg25793785	chr19:38281423	NA	0.6	4.96	0.37	1.85e-6	Longevity;
PAAD	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-7.77	-0.53	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg11461308	chr20:5986712	CRLS1	0.62	6.31	0.46	2.87e-9	Iris heterochromicity;
PAAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.73	8.21	0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs564309	0.618	rs12060002	chr1:228521875	G/A	cg01328119	chr1:228783545	DUSP5P	0.73	4.55	0.35	1.11e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg14329783	chr7:75779857	NA	0.79	4.63	0.35	7.64e-6	Mononucleosis;
PAAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.47	4.84	0.37	3.16e-6	Red cell distribution width;
PAAD	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7224685	0.608	rs12602456	chr17:4273483	C/T	cg11204139	chr17:3907470	NA	0.66	5.63	0.42	8.6e-8	Type 2 diabetes;
PAAD	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.29e-6	Airway imaging phenotypes;
PAAD	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg14583973	chr4:3374767	RGS12	-0.34	-5.18	-0.39	6.96e-7	Parental longevity (mother's age at death);
PAAD	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.6	-0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.49	0.41	1.64e-7	Alcohol dependence;
PAAD	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-10.24	-0.64	4.75e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.51	5.06	0.38	1.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3826795	0.569	rs73059723	chr19:46796502	A/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.48	4.64	0.35	7.58e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.45	4.3	0.33	3.07e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6132905	0.590	rs113218623	chr20:2613606	C/T	cg24848351	chr20:2622020	TMC2	-0.64	-4.46	-0.34	1.61e-5	Mumps;
PAAD	cis	rs7771547	0.692	rs9380578	chr6:36550287	G/A	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg20988073	chr3:125900093	ALDH1L1	-0.5	-5.58	-0.41	1.07e-7	Metabolite levels;
PAAD	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.19	0.5	2.76e-11	Schizophrenia;
PAAD	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg24848339	chr3:12840334	CAND2	0.44	4.6	0.35	8.69e-6	QRS complex (12-leadsum);
PAAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg21856205	chr7:94953877	PON1	0.53	4.52	0.34	1.23e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6499129	0.867	rs8056770	chr16:67416730	A/C	cg09395969	chr16:67918001	EDC4;NRN1L	0.65	4.7	0.36	5.81e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.59	6.48	0.47	1.22e-9	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07372659	chr6:20866952	CDKAL1	-0.51	-6.38	-0.46	1.99e-9	Energy expenditure (24h);
PAAD	cis	rs6906287	0.647	rs6569014	chr6:118681539	T/G	cg18833306	chr6:118973337	C6orf204	-0.41	-4.32	-0.33	2.84e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.7	-5.84	-0.43	3.04e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2133450	0.712	rs1508708	chr3:7364572	G/A	cg19930620	chr3:7340148	GRM7	-0.46	-5.11	-0.38	9.4e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.54	5.12	0.38	9.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.47	4.72	0.36	5.4e-6	Obesity-related traits;
PAAD	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.8	9.18	0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg07810366	chr2:100720526	AFF3	-0.35	-4.46	-0.34	1.59e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-1.23	-9.18	-0.6	2.99e-16	Blood pressure (smoking interaction);
PAAD	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.42	0.4	2.25e-7	Body mass index;
PAAD	cis	rs3737883	1.000	rs10753933	chr1:203026214	T/G	cg03900565	chr1:203031815	PPFIA4	0.34	5.69	0.42	6.25e-8	Early onset atrial fibrillation;
PAAD	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-5.14	-0.38	8.47e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.48	-4.68	-0.35	6.33e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	1.02	14.21	0.76	1.05e-29	Menarche (age at onset);
PAAD	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs11669133	1.000	rs17001070	chr19:11086746	T/C	cg18582342	chr19:11591989	ELAVL3	-0.66	-4.43	-0.34	1.81e-5	LDL cholesterol;
PAAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg14686297	chr22:46650375	NA	-0.5	-4.62	-0.35	7.98e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg07202610	chr7:1142643	C7orf50	-0.76	-5.24	-0.39	5.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-6.44	-0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.65	-8.34	-0.56	4.24e-14	Schizophrenia;
PAAD	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	cis	rs842828	1.000	rs842829	chr2:201247818	C/T	cg26842802	chr2:202125212	CASP8	-0.67	-4.81	-0.36	3.56e-6	Urate levels in lean individuals;
PAAD	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.55	6.2	0.45	5.15e-9	Cognitive function;
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg02071572	chr4:1403502	NA	0.36	4.54	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg02683114	chr2:24398427	C2orf84	0.55	5.69	0.42	6.36e-8	Asthma;
PAAD	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.19	0.39	6.53e-7	Rheumatoid arthritis;
PAAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.77	-6.12	-0.44	7.65e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg00504896	chr12:9437009	LOC642846	-0.46	-4.28	-0.33	3.28e-5	Breast size;
PAAD	cis	rs501916	0.634	rs1045688	chr15:48065487	A/G	cg16110827	chr15:48056943	SEMA6D	0.5	5.38	0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg13263323	chr15:86062960	AKAP13	-0.51	-4.84	-0.37	3.18e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09695851	chr17:3907499	NA	0.67	6.77	0.48	2.67e-10	Type 2 diabetes;
PAAD	trans	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg20587970	chr11:113659929	NA	-1.09	-9.17	-0.6	3.15e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs7547997	0.615	rs73029766	chr1:158320989	G/A	cg26014409	chr1:158324471	CD1E	0.37	4.56	0.35	1.04e-5	QRS duration;
PAAD	cis	rs11690935	0.879	rs13017585	chr2:172721808	C/A	cg13550731	chr2:172543902	DYNC1I2	-1.16	-13.87	-0.75	8.92e-29	Schizophrenia;
PAAD	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.23	-7.33	-0.51	1.3e-11	Mitochondrial DNA levels;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg15117754	chr3:10150083	C3orf24	0.67	5.56	0.41	1.2e-7	Alzheimer's disease;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.65	-10.09	-0.63	1.21e-18	Longevity;Endometriosis;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.7	8.81	0.58	2.71e-15	Cardiovascular disease risk factors;
PAAD	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	8.43	0.56	2.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs16937	1.000	rs16937	chr1:205035455	A/G	cg12447744	chr1:204662452	NA	-0.46	-4.46	-0.34	1.58e-5	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg24553058	chr2:113831203	IL1F10	0.73	8.26	0.56	6.6e-14	Protein quantitative trait loci;
PAAD	cis	rs939584	1.000	rs2903489	chr2:649638	C/T	cg03610516	chr2:642275	NA	-0.61	-5.53	-0.41	1.37e-7	Body mass index;
PAAD	cis	rs11825685	0.887	rs35430067	chr11:134561893	G/A	cg06603561	chr11:134479413	NA	-0.88	-5.54	-0.41	1.29e-7	IgG glycosylation;
PAAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-5.55	-0.41	1.27e-7	Monocyte count;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.79	-0.36	3.89e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.35	-0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.43	0.46	1.54e-9	Lung cancer in ever smokers;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.5	4.44	0.34	1.76e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.54	-0.52	3.93e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.61	-8.14	-0.55	1.29e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs71496609	chr10:46021031	C/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.52	-4.56	-0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs4796354	0.556	rs9914923	chr17:6712336	T/C	cg12642237	chr17:6703447	TEKT1	-0.35	-4.29	-0.33	3.21e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.43	-0.34	1.79e-5	Lung cancer;
PAAD	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg14092988	chr3:52407081	DNAH1	-0.51	-6.68	-0.48	4.26e-10	Bipolar disorder;
PAAD	cis	rs758324	0.812	rs6893070	chr5:131237599	A/G	cg06307176	chr5:131281290	NA	-0.54	-4.69	-0.36	6e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4740619	0.819	rs954663	chr9:15695533	C/G	cg14451791	chr9:16040625	NA	0.39	4.31	0.33	2.88e-5	Body mass index;
PAAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.83	7.25	0.51	1.97e-11	Recombination rate (females);
PAAD	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs7577696	0.925	rs7573543	chr2:32342508	A/T	cg02381751	chr2:32503542	YIPF4	-0.44	-4.72	-0.36	5.2e-6	Inflammatory biomarkers;
PAAD	cis	rs11892454	0.533	rs7592985	chr2:26100227	A/C	cg03373490	chr2:26702396	OTOF	0.51	4.35	0.33	2.49e-5	Heschl's gyrus morphology;
PAAD	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.34	-0.33	2.6e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg02527881	chr3:46936655	PTH1R	0.39	4.53	0.34	1.19e-5	Colorectal cancer;
PAAD	trans	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg02569823	chr6:5851330	NA	0.6	6.75	0.48	2.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg14343924	chr8:8086146	FLJ10661	-0.67	-5.67	-0.42	7.08e-8	Mood instability;
PAAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.45	-5.77	-0.42	4.41e-8	Renal cell carcinoma;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.83	10.17	0.64	7.39e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7896691	0.925	rs7906901	chr10:3155263	T/C	cg15228268	chr10:3146741	PFKP	-0.8	-4.97	-0.37	1.76e-6	Disc degeneration (lumbar);
PAAD	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.48	-4.69	-0.36	5.92e-6	Breast cancer;
PAAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs258892	0.843	rs34455289	chr5:72053282	G/C	cg21869765	chr5:72125136	TNPO1	-0.83	-5.6	-0.41	9.66e-8	Small cell lung carcinoma;
PAAD	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg07469887	chr10:131262384	NA	-0.38	-4.32	-0.33	2.75e-5	Response to temozolomide;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08355109	chr19:56599667	ZNF787	0.64	6.47	0.46	1.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.81	7.53	0.52	4.14e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg10729496	chr3:10149963	C3orf24	0.77	6.66	0.48	4.59e-10	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05384275	chr12:56122970	CD63	-0.82	-7.04	-0.5	6.08e-11	Neuroticism;
PAAD	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.65	0.35	7.06e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs950881	0.932	rs72823635	chr2:102931612	T/C	cg20060108	chr2:102954350	IL1RL1	0.61	4.78	0.36	4.17e-6	Allergy;
PAAD	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.78	-5.97	-0.44	1.62e-8	Prostate-specific antigen levels;
PAAD	cis	rs9463078	0.817	rs2145826	chr6:44763781	G/A	cg25276700	chr6:44698697	NA	0.53	6.2	0.45	4.96e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6137287	0.855	rs1548254	chr20:21177487	C/G	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg02250501	chr15:90694978	NA	-0.46	-4.3	-0.33	3.09e-5	Rheumatoid arthritis;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.52	5.55	0.41	1.25e-7	Menarche (age at onset);
PAAD	cis	rs89107	0.640	rs281864	chr6:118576233	A/C	cg21191810	chr6:118973309	C6orf204	0.44	6.24	0.45	4.17e-9	Cardiac structure and function;
PAAD	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg19792802	chr11:65647270	CTSW	0.51	5.73	0.42	5.22e-8	Crohn's disease;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	trans	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg14171944	chr9:126323477	DENND1A	0.55	6.57	0.47	7.49e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs1997066	0.831	rs73344330	chr10:106829407	C/T	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-6.17	-0.45	5.85e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.57	5.95	0.43	1.77e-8	Dupuytren's disease;
PAAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.75	8.07	0.55	1.98e-13	Rheumatoid arthritis;
PAAD	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg10494973	chr17:80897199	TBCD	0.59	4.84	0.37	3.21e-6	Breast cancer;
PAAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	7.16	0.5	3.29e-11	Mood instability;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.82	7.36	0.51	1.08e-11	Coronary artery disease;
PAAD	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg16473166	chr22:50639996	SELO	0.62	5.68	0.42	6.68e-8	Late-onset Alzheimer's disease;
PAAD	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg27411982	chr8:10470053	RP1L1	0.5	5.52	0.41	1.44e-7	Retinal vascular caliber;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg26876637	chr1:152193138	HRNR	-0.77	-5.43	-0.4	2.19e-7	Atopic dermatitis;
PAAD	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.98	6.78	0.48	2.5e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.7	-6.98	-0.49	8.35e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2171564	0.791	rs9852197	chr3:112442538	T/A	cg06685282	chr3:112453648	NA	0.44	4.7	0.36	5.7e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.6	5.66	0.42	7.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg10437265	chr15:77819839	NA	0.43	4.8	0.36	3.77e-6	Type 2 diabetes;
PAAD	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Dermatomyositis;
PAAD	cis	rs28493229	0.708	rs10408310	chr19:41161190	T/C	cg21869046	chr19:41225005	ITPKC	0.52	5.29	0.39	4.16e-7	Kawasaki disease;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.64	5.66	0.42	7.32e-8	Lung cancer;
PAAD	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.91	12.46	0.71	5.37e-25	Superior crus of antihelix expression;
PAAD	cis	rs9677476	0.517	rs2368563	chr2:232058493	A/G	cg07929768	chr2:232055508	NA	0.45	5.27	0.39	4.6e-7	Food antigen IgG levels;
PAAD	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.96	8.88	0.58	1.75e-15	Resting heart rate;
PAAD	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.95	10.05	0.63	1.5e-18	Alcohol dependence;
PAAD	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg18551225	chr6:44695536	NA	-0.74	-7.55	-0.52	3.72e-12	Total body bone mineral density;
PAAD	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12839172	chr4:16085077	PROM1	-0.62	-7.11	-0.5	4.17e-11	Body fat percentage;
PAAD	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg05082376	chr22:42548792	NA	0.51	5.6	0.41	9.98e-8	Cognitive function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24225493	chr6:83777365	DOPEY1	-0.61	-7.6	-0.52	2.82e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.57	5.41	0.4	2.44e-7	Bone properties (heel);
PAAD	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.76	8.51	0.57	1.58e-14	Lewy body disease;
PAAD	cis	rs4523957	0.890	rs11078024	chr17:2189324	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg22338127	chr1:209979572	IRF6	0.53	4.3	0.33	3.1e-5	Coronary artery disease;
PAAD	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.26	-0.33	3.53e-5	Diabetic retinopathy;
PAAD	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.42	-0.34	1.85e-5	Testicular germ cell tumor;
PAAD	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.47	0.61	5.17e-17	Diabetic retinopathy;
PAAD	cis	rs16975963	0.644	rs111694872	chr19:38046331	T/C	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.75	7.16	0.5	3.18e-11	Asthma;
PAAD	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.96	-0.37	1.9e-6	Monocyte percentage of white cells;
PAAD	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-7.19	-0.5	2.67e-11	Bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12163131	chr10:125754386	NA	-0.72	-6.31	-0.46	2.89e-9	Neuroticism;
PAAD	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.98	-12.42	-0.71	6.84e-25	Refractive error;
PAAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg18765565	chr5:669397	TPPP	-0.42	-4.55	-0.35	1.07e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26240231	chr7:1148101	C7orf50	-0.48	-4.25	-0.33	3.7e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4481887	0.861	rs6676064	chr1:248443890	G/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.44	-0.4	2.1e-7	Common traits (Other);
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.86	-0.43	2.71e-8	Menarche (age at onset);
PAAD	cis	rs7210086	0.768	rs72849445	chr17:70637985	T/G	cg04206342	chr17:70636940	NA	-0.44	-5.42	-0.4	2.26e-7	Ulcerative colitis;
PAAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.33	-0.4	3.53e-7	Height;
PAAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.83	0.36	3.33e-6	Breast cancer;
PAAD	cis	rs1570155	1.000	rs1570155	chr6:20382600	G/A	cg03881924	chr6:20404342	E2F3	0.44	4.47	0.34	1.54e-5	Obesity-related traits;
PAAD	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-5.06	-0.38	1.19e-6	Waist circumference;Hip circumference;
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg12143784	chr7:64541923	NA	-0.37	-4.73	-0.36	5.03e-6	Calcium levels;
PAAD	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg00531865	chr16:30841666	NA	-0.56	-4.26	-0.33	3.62e-5	Dementia with Lewy bodies;
PAAD	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2131877	0.645	rs4677663	chr3:194874605	A/G	cg11177333	chr3:195857752	NA	-0.44	-4.59	-0.35	9.4e-6	Non-small cell lung cancer;
PAAD	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-4.63	-0.35	7.93e-6	Height;
PAAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.41	13.56	0.74	6.04e-28	Corneal structure;
PAAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.76	-6.91	-0.49	1.26e-10	Coronary artery disease;
PAAD	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-4.7	-0.36	5.72e-6	Menopause (age at onset);
PAAD	cis	rs3026101	0.671	rs57774467	chr17:5300205	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	Trans fatty acid levels;
PAAD	trans	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01861284	chr12:93835964	UBE2N	0.58	6.54	0.47	8.69e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs61861422	0.543	rs34309159	chr10:134419166	C/T	cg09421083	chr10:134358535	INPP5A	-0.56	-4.9	-0.37	2.42e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.54	5.87	0.43	2.7e-8	Menopause (age at onset);
PAAD	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19671926	chr4:122722719	EXOSC9	0.51	5.01	0.38	1.48e-6	Type 2 diabetes;
PAAD	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.45	5.71	0.42	5.8e-8	Panic disorder;
PAAD	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs12913538	0.715	rs955529	chr15:62881864	A/T	cg09983546	chr15:62884068	NA	-0.59	-6.04	-0.44	1.15e-8	Sleep depth;
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.31	0.4	3.82e-7	Total body bone mineral density;
PAAD	cis	rs755249	0.567	rs3118014	chr1:39914090	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.68	-0.35	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-1.05	-14.82	-0.77	2.62e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Aortic root size;
PAAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg09066997	chr16:75300724	BCAR1	0.62	4.53	0.35	1.17e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg19407955	chr1:165599744	MGST3	-0.52	-4.81	-0.36	3.56e-6	Total ventricular volume;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	7.44	0.52	6.98e-12	Lymphocyte counts;
PAAD	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg24905316	chr10:135186343	ECHS1	0.73	4.46	0.34	1.6e-5	Lifespan;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg16606324	chr3:10149918	C3orf24	0.54	4.63	0.35	7.74e-6	Alzheimer's disease;
PAAD	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.14	-0.45	6.92e-9	Height;
PAAD	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	6.16	0.45	6.36e-9	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs6942407	0.546	rs3789252	chr7:86793362	G/C	cg02420886	chr7:86849541	C7orf23	0.63	4.79	0.36	3.85e-6	Food allergy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22204453	chr7:130752096	FLJ43663	-0.71	-7.3	-0.51	1.51e-11	Obesity-related traits;
PAAD	cis	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg05805236	chr11:65401703	PCNXL3	0.49	4.7	0.36	5.86e-6	Breast cancer;
PAAD	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg09677638	chr11:61582810	MIR1908;FADS1	0.55	4.88	0.37	2.63e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs1692580	0.807	rs4648628	chr1:2203490	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.84	-0.37	3.16e-6	Coronary artery disease;
PAAD	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.71	7.17	0.5	3.03e-11	Lymphocyte percentage of white cells;
PAAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.53	-0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs58521262	0.556	rs289298	chr19:23175945	G/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.81	-9.07	-0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.43	6.32	0.46	2.71e-9	Information processing speed;
PAAD	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.26	-0.64	4.17e-19	Response to antipsychotic treatment;
PAAD	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.89e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg24103979	chr1:155829285	SYT11	0.61	6.46	0.46	1.35e-9	Positive affect;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg13939156	chr17:80058883	NA	0.49	5.35	0.4	3.12e-7	Life satisfaction;
PAAD	cis	rs6466055	0.720	rs62484712	chr7:105005741	G/A	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.55	-5.25	-0.39	5e-7	Hypertension (SNP x SNP interaction);
PAAD	cis	rs9361491	0.608	rs4706729	chr6:79467592	T/G	cg05283184	chr6:79620031	NA	-0.39	-4.73	-0.36	5.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.34	0.33	2.62e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg05333889	chr7:157238977	NA	-0.46	-4.88	-0.37	2.63e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7873102	0.654	rs10123310	chr9:37972512	T/C	cg03528946	chr9:38069800	SHB	0.53	5.34	0.4	3.38e-7	Brain structure;
PAAD	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.86	0.69	2.2e-23	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21893154	chr20:62493317	C20orf135	0.54	6.4	0.46	1.8e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg19423196	chr10:82049429	MAT1A	0.61	4.72	0.36	5.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg09017928	chr7:158110068	PTPRN2	-0.43	-4.26	-0.33	3.53e-5	Calcium levels;
PAAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs642743	0.967	rs687557	chr10:105989509	T/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.42	0.34	1.9e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12780845	1.000	rs7100163	chr10:17181177	C/T	cg00857480	chr10:17188594	TRDMT1	0.38	4.9	0.37	2.39e-6	Homocysteine levels;
PAAD	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	0.68	5.04	0.38	1.29e-6	Obesity-related traits;
PAAD	cis	rs9296095	0.519	rs6918046	chr6:33514567	T/A	cg14003231	chr6:33640908	ITPR3	0.36	4.85	0.37	3.05e-6	Platelet count;
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Body mass index;
PAAD	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg26816564	chr1:7831052	VAMP3	-0.61	-5.27	-0.39	4.54e-7	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs2637266	0.783	rs12258504	chr10:78477055	C/T	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.69e-5	Pulmonary function;
PAAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.6	6.58	0.47	7.11e-10	Tonsillectomy;
PAAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.48	5.16	0.39	7.58e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-5.84	-0.43	2.99e-8	Schizophrenia;
PAAD	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.37	-4.92	-0.37	2.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2286503	0.780	rs981792	chr7:22861639	C/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs2834188	1.000	rs2096464	chr21:34686049	G/T	cg04842828	chr21:34696676	IFNAR1	-0.46	-4.41	-0.34	1.91e-5	Narcolepsy;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.19	0.55	1.01e-13	Platelet count;
PAAD	cis	rs10044254	0.813	rs4475263	chr5:15742789	A/T	cg07238450	chr5:15720153	FBXL7	-0.55	-4.46	-0.34	1.59e-5	Asthma (corticosteroid response);
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.03e-7	Blood metabolite levels;
PAAD	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.4	-4.39	-0.34	2.15e-5	Pneumonia;
PAAD	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6547631	0.622	rs34943381	chr2:85923997	A/G	cg24620635	chr2:85921963	GNLY	0.42	5.44	0.4	2.05e-7	Blood protein levels;
PAAD	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.88	0.37	2.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3736485	0.966	rs2414109	chr15:51901015	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.82e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg05861140	chr6:150128134	PCMT1	-0.5	-5.25	-0.39	5.04e-7	Lung cancer;
PAAD	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.2e-14	Eye color traits;
PAAD	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	7.11	0.5	4.3e-11	Triglycerides;
PAAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00290607	chr11:67383545	NA	0.47	4.65	0.35	7.15e-6	Mean corpuscular volume;
PAAD	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.68	10.31	0.64	3.21e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.52	4.81	0.36	3.63e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.63	7.2	0.5	2.66e-11	Emphysema distribution in smoking;
PAAD	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	cis	rs72827839	0.894	rs112306902	chr17:46191032	C/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-6.19	-0.45	5.39e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs7714584	1.000	rs1820682	chr5:150262142	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	4.81	0.36	3.65e-6	Total cholesterol levels;
PAAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	2.01e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6604026	0.656	rs17380908	chr1:93402551	C/T	cg17283838	chr1:93427260	FAM69A	0.55	4.78	0.36	4.06e-6	Multiple sclerosis;
PAAD	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Breast cancer;
PAAD	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-4.35	-0.33	2.53e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg01890435	chr5:442385	EXOC3;C5orf55	-0.51	-4.5	-0.34	1.37e-5	Cystic fibrosis severity;
PAAD	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.54	-4.66	-0.35	6.9e-6	Fibrinogen levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03868400	chr5:179125946	CANX	0.57	6.39	0.46	1.9e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg22449745	chr1:38156939	CDCA8;C1orf109	0.36	4.83	0.36	3.32e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.49	-4.98	-0.37	1.73e-6	Type 2 diabetes;
PAAD	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-5.14	-0.38	8.45e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs77633900	0.772	rs2948703	chr15:76711751	A/G	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs12042052	0.590	rs72752167	chr1:232922414	G/A	cg02191044	chr1:232940990	KIAA1383	0.91	4.48	0.34	1.44e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg03808351	chr9:123631620	PHF19	0.45	4.99	0.37	1.66e-6	Rheumatoid arthritis;
PAAD	cis	rs3806308	0.900	rs3820330	chr1:20142413	A/C	cg09990584	chr1:19601069	AKR7L	-0.47	-4.42	-0.34	1.85e-5	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	0.69	4.27	0.33	3.47e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.7	-0.36	5.69e-6	Alzheimer's disease (late onset);
PAAD	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg17524180	chr13:113633600	MCF2L	-0.43	-4.54	-0.35	1.14e-5	Systolic blood pressure;
PAAD	cis	rs4144027	0.740	rs10150898	chr14:104354625	G/C	cg26031613	chr14:104095156	KLC1	0.44	4.35	0.33	2.53e-5	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14576291	chr9:134526136	RAPGEF1	-0.72	-7.27	-0.51	1.73e-11	Obesity-related traits;
PAAD	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg19920283	chr7:105172520	RINT1	0.77	4.86	0.37	2.94e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	6.04	0.44	1.14e-8	Schizophrenia;
PAAD	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.81	-0.36	3.63e-6	Bipolar disorder;
PAAD	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-1.03	-10.68	-0.65	3.16e-20	Platelet distribution width;
PAAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg05313129	chr8:58192883	C8orf71	-0.44	-4.26	-0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.76	-7.75	-0.53	1.23e-12	Brugada syndrome;
PAAD	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg22771759	chr13:24902376	NA	-0.48	-4.84	-0.37	3.17e-6	Obesity-related traits;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.43	-0.52	7.24e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.29	0.45	3.21e-9	Alzheimer's disease;
PAAD	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg05472934	chr7:22766657	IL6	0.57	5.67	0.42	7.14e-8	Lung cancer;
PAAD	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg24450063	chr1:156163899	SLC25A44	1.12	15.35	0.78	1.03e-32	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-5.21	-0.39	6.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg21130718	chr4:1044621	NA	0.48	4.64	0.35	7.42e-6	Recombination rate (males);
PAAD	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.61	5.93	0.43	1.98e-8	Interleukin-18 levels;
PAAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.31	0.33	2.89e-5	Aortic root size;
PAAD	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.62e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.47	-0.41	1.8e-7	Neuroticism;
PAAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1620921	0.505	rs1344729	chr6:161204841	C/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg08219700	chr8:58056026	NA	0.7	5.58	0.41	1.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.78e-8	Life satisfaction;
PAAD	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.41	0.61	7.26e-17	Chronic sinus infection;
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-8.72	-0.58	4.63e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.47	-0.46	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.46	4.42	0.34	1.86e-5	Morning vs. evening chronotype;
PAAD	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.78	6.26	0.45	3.67e-9	Monocyte count;
PAAD	cis	rs10899021	0.790	rs7932194	chr11:74327378	C/G	cg25880958	chr11:74394337	NA	-0.73	-4.65	-0.35	7.31e-6	Response to metformin (IC50);
PAAD	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.86e-5	Systemic lupus erythematosus;
PAAD	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.78	9.08	0.59	5.36e-16	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg19223190	chr17:80058835	NA	0.55	5.59	0.41	1.03e-7	Life satisfaction;
PAAD	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs2645424	0.550	rs12338	chr8:11710888	G/C	cg21281001	chr8:11725306	CTSB	0.52	4.72	0.36	5.32e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs7577696	0.962	rs4952249	chr2:32343673	A/T	cg02381751	chr2:32503542	YIPF4	-0.41	-4.39	-0.34	2.1e-5	Inflammatory biomarkers;
PAAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.56	-5.12	-0.38	9.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09256448	chr16:638327	NA	0.42	4.36	0.33	2.35e-5	Height;
PAAD	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.41e-7	Tuberculosis;
PAAD	cis	rs939584	1.000	rs6735024	chr2:630509	T/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.41	-5.99	-0.44	1.49e-8	Subjective well-being;
PAAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12963246	chr6:28129442	ZNF389	0.56	4.47	0.34	1.5e-5	Cardiac Troponin-T levels;
PAAD	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.11	-12.08	-0.7	5.54e-24	Blood pressure (smoking interaction);
PAAD	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.74	-5.48	-0.41	1.75e-7	Coronary artery calcification;
PAAD	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3951016	0.501	rs6911599	chr6:119009913	C/T	cg21191810	chr6:118973309	C6orf204	0.35	4.32	0.33	2.85e-5	Resting heart rate;
PAAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.49	5.76	0.42	4.62e-8	Psoriasis;
PAAD	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	7.06	0.5	5.56e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs740474	0.768	rs2530223	chr5:141014494	T/C	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.45	5.26	0.39	4.91e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.37	-0.33	2.26e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18621852	chr3:10150065	C3orf24	0.56	4.43	0.34	1.81e-5	Alzheimer's disease;
PAAD	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg25783544	chr11:47291846	MADD	0.54	4.35	0.33	2.51e-5	HDL cholesterol;
PAAD	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg06346307	chr22:19949965	COMT	-0.31	-4.8	-0.36	3.82e-6	Blood metabolite levels;
PAAD	cis	rs3106136	0.807	rs9997915	chr4:95278027	C/T	cg11021082	chr4:95130006	SMARCAD1	0.63	6.03	0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs28489187	0.706	rs233131	chr1:85795259	G/A	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	7.04	0.5	6.26e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg09184832	chr6:79620586	NA	-0.42	-4.25	-0.33	3.75e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23194596	chr7:36193344	EEPD1	0.63	6.73	0.48	3.26e-10	Myopia (pathological);
PAAD	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg08048268	chr3:133502702	NA	0.43	5.16	0.39	7.47e-7	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs251130	0.709	rs116071630	chr5:110849505	A/T	cg11925263	chr5:110849104	STARD4	0.37	4.68	0.35	6.26e-6	Menarche (age at onset);
PAAD	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg21448613	chr3:49828315	CDH29	0.47	4.4	0.34	2.04e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-8.67	-0.58	5.96e-15	Corneal structure;
PAAD	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.48	-0.47	1.21e-9	Retinal vascular caliber;
PAAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.35	4.46	0.34	1.56e-5	Colorectal cancer;
PAAD	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.6	0.35	8.74e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.63	-0.53	2.46e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg18265118	chr7:2139243	MAD1L1	0.52	4.26	0.33	3.64e-5	Neuroticism;
PAAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	7.76	0.53	1.13e-12	Prudent dietary pattern;
PAAD	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg20302533	chr7:39170763	POU6F2	0.37	5.25	0.39	5.15e-7	IgG glycosylation;
PAAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.22e-6	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg25246084	chr19:4971487	KDM4B	-0.46	-5.71	-0.42	5.65e-8	Monocyte percentage of white cells;
PAAD	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.82	-0.54	8.39e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.78	9.35	0.6	1.04e-16	Emphysema distribution in smoking;
PAAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.8	7.84	0.54	7.34e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs16958440	0.867	rs61689863	chr18:44669157	A/T	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03526776	chr6:41159608	TREML2	0.6	6.65	0.47	5.01e-10	Alzheimer's disease (late onset);
PAAD	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.8	-5.03	-0.38	1.39e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg05250797	chr16:70222502	NA	-0.58	-4.71	-0.36	5.64e-6	Sjögren's syndrome;
PAAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6132905	0.590	rs74765630	chr20:2606745	C/T	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.96	-8.77	-0.58	3.39e-15	Body mass index;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.59	0.41	1.05e-7	Total body bone mineral density;
PAAD	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.98	-14.18	-0.75	1.28e-29	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg14709524	chr16:89940631	TCF25	0.73	4.34	0.33	2.6e-5	Skin colour saturation;
PAAD	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg05768032	chr16:30646687	NA	0.5	4.81	0.36	3.61e-6	Multiple myeloma;
PAAD	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9411298	0.550	rs4880192	chr9:139927062	A/G	cg13592750	chr9:140003531	MAN1B1	0.44	4.27	0.33	3.48e-5	Monocyte percentage of white cells;
PAAD	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg16898833	chr6:26189333	HIST1H4D	0.67	4.92	0.37	2.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.68	5.97	0.44	1.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg01839639	chr16:202542	HBZ	-0.31	-4.86	-0.37	2.85e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.4e-8	Coronary artery disease;
PAAD	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.48	4.41	0.34	1.94e-5	Breast cancer;
PAAD	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg24747557	chr10:131355152	MGMT	-0.46	-4.71	-0.36	5.49e-6	Response to temozolomide;
PAAD	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg00543991	chr22:32367038	NA	1.19	7.24	0.51	2.03e-11	Childhood ear infection;
PAAD	cis	rs16895831	0.549	rs1028462	chr6:42616678	G/C	cg10605015	chr6:42532144	UBR2	-0.62	-4.68	-0.35	6.28e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg11204139	chr17:3907470	NA	0.67	6.31	0.46	2.87e-9	Type 2 diabetes;
PAAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.49	-4.93	-0.37	2.12e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9372498	0.505	rs62422250	chr6:118990182	T/C	cg21191810	chr6:118973309	C6orf204	-0.5	-4.51	-0.34	1.3e-5	Diastolic blood pressure;
PAAD	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.62	6.38	0.46	2.03e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6710503	0.574	rs62142275	chr2:24767649	A/C	cg21151432	chr2:25142229	ADCY3	-0.36	-4.31	-0.33	2.98e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.78e-6	Migraine;
PAAD	cis	rs11753937	0.735	rs572004	chr6:133580411	G/T	cg20611276	chr6:133561866	EYA4	0.36	4.25	0.33	3.71e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs375066	0.935	rs388706	chr19:44418693	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11713480	chr5:1081913	SLC12A7	0.68	7.05	0.5	5.85e-11	Obesity-related traits;
PAAD	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.72	-4.74	-0.36	4.94e-6	Major depressive disorder;
PAAD	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg07636037	chr3:49044803	WDR6	-0.56	-4.3	-0.33	3.08e-5	Menarche (age at onset);
PAAD	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.92e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.43	-4.31	-0.33	2.88e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.19	10.92	0.66	7.39e-21	Corneal structure;
PAAD	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg16586182	chr3:47516702	SCAP	-0.69	-7.86	-0.54	6.68e-13	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02256410	chr20:30327142	TPX2	-0.71	-6.36	-0.46	2.23e-9	Neuroticism;
PAAD	cis	rs4666360	1.000	rs4666295	chr2:20337144	C/T	cg23291376	chr2:20336282	NA	0.4	4.47	0.34	1.5e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22038928	chr6:166756117	SFT2D1	0.65	6.86	0.49	1.64e-10	Myopia (pathological);
PAAD	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.61	-8.06	-0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12602901	0.519	rs238238	chr17:4856376	A/G	cg09495303	chr17:4804838	CHRNE;C17orf107	0.38	4.74	0.36	4.8e-6	Blood metabolite levels;
PAAD	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.71	7.14	0.5	3.57e-11	Blood protein levels;
PAAD	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.68	6.94	0.49	1.06e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.69	-5.84	-0.43	3.05e-8	Serum sulfate level;
PAAD	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23083074	chr4:89202819	PPM1K	0.61	6.62	0.47	5.82e-10	Smoking initiation;
PAAD	cis	rs593531	0.614	rs623065	chr11:74071210	A/G	cg15851278	chr11:73669449	DNAJB13	-0.39	-4.62	-0.35	7.98e-6	Neuroticism;
PAAD	cis	rs9462027	0.527	rs6939600	chr6:34822176	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.35	-0.4	3.11e-7	Systemic lupus erythematosus;
PAAD	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17032980	0.910	rs7589620	chr2:67309662	T/G	cg02551743	chr2:66673428	MEIS1	-0.5	-4.49	-0.34	1.39e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg19052272	chr2:3704530	ALLC	-0.53	-6.28	-0.45	3.31e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg01620082	chr3:125678407	NA	-1.44	-8.11	-0.55	1.61e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.81	5.66	0.42	7.38e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.83	10.03	0.63	1.71e-18	Monocyte percentage of white cells;
PAAD	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg02640540	chr1:67518911	SLC35D1	0.55	4.74	0.36	4.96e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	5.51	0.41	1.52e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg19423196	chr10:82049429	MAT1A	0.59	4.49	0.34	1.42e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.79	12.79	0.72	6.93e-26	Breast cancer;
PAAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg02811702	chr13:24901961	NA	0.52	5.61	0.41	9.35e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.7	5.18	0.39	6.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16260355	chr10:72575844	SGPL1	0.56	6.36	0.46	2.21e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.84e-11	Interstitial lung disease;
PAAD	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04717802	chr22:42394638	WBP2NL	0.39	4.25	0.33	3.71e-5	Cognitive function;
PAAD	cis	rs6024905	1.000	rs6024905	chr20:36957837	C/T	cg07053727	chr20:36965646	BPI	0.45	4.86	0.37	2.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs59698941	0.765	rs66822519	chr5:132167742	C/T	cg14825688	chr5:132208181	LEAP2	-0.67	-4.78	-0.36	4.17e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.67	0.62	1.55e-17	Electrocardiographic conduction measures;
PAAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.78	-0.42	4.16e-8	Type 2 diabetes;
PAAD	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.69	6.06	0.44	1.01e-8	Cognitive test performance;
PAAD	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg05083358	chr7:2394359	EIF3B	-0.73	-5.36	-0.4	3.08e-7	Multiple sclerosis;
PAAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.47	5.02	0.38	1.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-6.17	-0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg18370025	chr7:2749541	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14458626	chr2:63834284	MDH1	-0.64	-6.55	-0.47	8.45e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.55	7.35	0.51	1.17e-11	Renal cell carcinoma;
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs116248771	0.739	rs73156496	chr3:158421162	T/C	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06799790	chr17:61951754	CSH2	-0.45	-4.65	-0.35	7.16e-6	Height;
PAAD	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.55	-5.41	-0.4	2.38e-7	Lung cancer;
PAAD	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg22719782	chr11:114310057	REXO2	-0.57	-6.61	-0.47	6.13e-10	Body fat percentage;
PAAD	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg21361702	chr7:150065534	REPIN1	0.63	5.16	0.39	7.47e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.4	-4.63	-0.35	7.63e-6	Intelligence;
PAAD	cis	rs10895547	0.681	rs1053861	chr11:103778154	C/T	cg06560282	chr11:103830847	PDGFD	0.35	4.25	0.33	3.7e-5	LDL cholesterol;
PAAD	cis	rs380904	0.519	rs10102146	chr8:144649156	G/A	cg13399544	chr8:144649678	C8orf73	0.59	5.99	0.44	1.42e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg01796438	chr3:11312864	ATG7	-0.67	-5.13	-0.38	8.85e-7	Circulating chemerin levels;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Male-pattern baldness;
PAAD	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.68	7.45	0.52	6.43e-12	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg27335999	chr10:556044	DIP2C	0.33	4.28	0.33	3.3e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.72	-6.06	-0.44	1.05e-8	Schizophrenia;
PAAD	trans	rs10500871	1.000	rs11529169	chr11:20226453	C/T	cg02956962	chr6:161097311	NA	0.62	6.31	0.46	2.93e-9	Educational attainment;
PAAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	1.57	8.95	0.59	1.18e-15	Cannabis dependence symptom count;
PAAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.55	5.19	0.39	6.72e-7	Schizophrenia;
PAAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.81	8.91	0.59	1.45e-15	Mortality in heart failure;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8025118	0.583	rs7166813	chr15:79549205	C/T	cg11862246	chr15:78730200	IREB2	-0.51	-4.26	-0.33	3.54e-5	Cognitive function;
PAAD	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs7873102	0.608	rs3802412	chr9:38015729	T/G	cg03528946	chr9:38069800	SHB	-0.5	-5.01	-0.38	1.52e-6	Brain structure;
PAAD	cis	rs2952768	1.000	rs2709383	chr2:208496742	C/T	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.82	-8.69	-0.58	5.43e-15	DNA methylation (variation);
PAAD	cis	rs12738007	0.967	rs12032470	chr1:29464954	C/A	cg03512248	chr1:28517610	PTAFR	0.44	4.39	0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs9616064	1.000	rs5768991	chr22:46983018	A/G	cg25730555	chr22:47059586	GRAMD4	-0.43	-4.34	-0.33	2.64e-5	Urate levels in obese individuals;
PAAD	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.65	-0.47	4.91e-10	Neuroticism;
PAAD	cis	rs2882667	0.690	rs288022	chr5:138224275	A/C	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs7172971	0.688	rs112154535	chr15:42381925	T/G	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13939156	chr17:80058883	NA	0.45	5.11	0.38	9.57e-7	Life satisfaction;
PAAD	cis	rs2004318	1.000	rs118181339	chr19:55134927	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs4812973	1.000	rs61241783	chr20:44524297	A/G	cg16496526	chr20:44258267	WFDC10A;WFDC9	-0.87	-4.36	-0.33	2.42e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6785206	0.614	rs35904610	chr3:128452108	T/C	cg19205850	chr3:128446370	RAB7A	0.84	5.74	0.42	5.09e-8	Lymphocyte percentage of white cells;
PAAD	cis	rs10821973	0.527	rs2116584	chr10:63979938	A/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs7577696	0.889	rs212735	chr2:32473088	C/G	cg02381751	chr2:32503542	YIPF4	0.43	4.74	0.36	4.98e-6	Inflammatory biomarkers;
PAAD	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.73	0.36	5.14e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg01631408	chr1:248437212	OR2T33	-0.55	-4.64	-0.35	7.52e-6	Autism spectrum disorder;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg27615366	chr5:131592974	PDLIM4	-0.4	-4.25	-0.33	3.68e-5	Acylcarnitine levels;
PAAD	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.78	7.88	0.54	5.77e-13	Asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16993684	chr20:57466131	GNAS	-0.77	-6.7	-0.48	3.9e-10	Neuroticism;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg25566285	chr7:158114605	PTPRN2	0.75	6.42	0.46	1.63e-9	Response to amphetamines;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13047869	chr3:10149882	C3orf24	0.84	6.98	0.49	8.52e-11	Alzheimer's disease;
PAAD	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.74	-7.38	-0.51	9.55e-12	Prostate cancer;
PAAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg05697835	chr1:2722811	NA	-0.37	-4.28	-0.33	3.33e-5	Ulcerative colitis;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg23107878	chr1:152161397	NA	0.49	4.92	0.37	2.21e-6	Inflammatory skin disease;
PAAD	cis	rs17162190	0.698	rs4659375	chr1:26804090	G/A	cg17456097	chr1:26900765	RPS6KA1	0.6	4.8	0.36	3.72e-6	Mean corpuscular volume;
PAAD	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.61	4.51	0.34	1.31e-5	Schizophrenia;
PAAD	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.63	-7.02	-0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-11.53	-0.68	1.7e-22	Height;
PAAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.51	5.3	0.39	4.08e-7	Daytime sleep phenotypes;
PAAD	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.71	-0.53	1.54e-12	Sense of smell;
PAAD	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg15764593	chr10:829463	NA	-0.88	-4.31	-0.33	2.94e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18170098	chr16:71880032	ATXN1L	-0.63	-6.33	-0.46	2.65e-9	Smoking initiation;
PAAD	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.67	7.43	0.52	7.21e-12	Menopause (age at onset);
PAAD	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.54e-10	Eye color traits;
PAAD	cis	rs55962025	0.842	rs362267	chr4:3243218	C/T	cg08886695	chr4:3369023	RGS12	0.46	4.32	0.33	2.78e-5	Parental longevity (mother's age at death);
PAAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg00758881	chr16:58534681	NDRG4	-0.89	-4.73	-0.36	5e-6	Schizophrenia;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.51	-0.41	1.52e-7	Systemic lupus erythematosus;
PAAD	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	8.13	0.55	1.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.67	-7.23	-0.51	2.16e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	cis	rs9810890	1.000	rs116203743	chr3:128483210	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg17326555	chr1:119535693	NA	-0.4	-4.89	-0.37	2.54e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	cis	rs901683	0.850	rs74500471	chr10:46031735	A/T	cg16908948	chr10:45500256	ZNF22	0.79	4.27	0.33	3.44e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg21095983	chr6:86352623	SYNCRIP	0.66	6.7	0.48	3.89e-10	Smooth-surface caries;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.85	9.47	0.61	5.09e-17	Prudent dietary pattern;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.46	-0.4	1.92e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	10.05	0.63	1.52e-18	Platelet count;
PAAD	cis	rs1006703	0.544	rs55673593	chr17:3834179	T/C	cg06463185	chr17:3833770	ATP2A3	-0.9	-7.37	-0.51	9.94e-12	Glucose homeostasis traits;
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg07075026	chr17:47091521	IGF2BP1	-0.51	-7.17	-0.5	3.06e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg25155006	chr6:37138205	PIM1	-0.51	-4.52	-0.34	1.23e-5	QRS duration;
PAAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.7	-0.36	5.81e-6	Longevity;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04787407	chr4:99916511	METAP1	0.64	7.53	0.52	4.15e-12	Metabolite levels  (X-11787);
PAAD	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg21698718	chr17:80085957	CCDC57	0.4	4.27	0.33	3.48e-5	Life satisfaction;
PAAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.77	9.42	0.61	6.91e-17	Bone mineral density;
PAAD	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27126225	chr11:8101793	TUB	-0.59	-6.76	-0.48	2.82e-10	Obesity-related traits;
PAAD	cis	rs11997175	0.626	rs12155927	chr8:33789851	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	5.97	0.44	1.63e-8	Body mass index;
PAAD	cis	rs11105468	0.695	rs73210227	chr12:90448401	T/C	cg16962463	chr12:89968675	NA	0.45	4.74	0.36	4.89e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg13722127	chr7:150037890	RARRES2	0.52	5.2	0.39	6.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12580275	chr1:205744413	RAB7L1	0.59	6.59	0.47	6.94e-10	Metabolite levels  (X-11787);
PAAD	cis	rs375066	0.935	rs421512	chr19:44415580	A/T	cg21496419	chr19:44306685	LYPD5	0.43	5.12	0.38	9.14e-7	Breast cancer;
PAAD	cis	rs2403221	0.928	rs10743119	chr11:9845830	G/A	cg06875754	chr11:10328428	ADM	-0.37	-4.35	-0.33	2.47e-5	Smoking initiation;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23821755	chr1:173684675	KLHL20	0.61	7.03	0.5	6.4e-11	Metabolite levels  (X-11787);
PAAD	cis	rs842828	0.710	rs295145	chr2:201222159	C/T	cg23649088	chr2:200775458	C2orf69	0.82	4.7	0.36	5.67e-6	Urate levels in lean individuals;
PAAD	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.94	-8.03	-0.55	2.56e-13	Diastolic blood pressure;
PAAD	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg08992911	chr2:238395768	MLPH	0.65	5.2	0.39	6.31e-7	Prostate cancer;
PAAD	cis	rs7713065	1.000	rs7713065	chr5:131788334	A/C	cg14196790	chr5:131705035	SLC22A5	0.54	5.82	0.43	3.35e-8	Lung function (FEV1/FVC);
PAAD	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-5.25	-0.39	4.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs73419609	1.000	rs7178432	chr15:54735135	A/T	cg11288833	chr15:55489084	RSL24D1	-0.98	-4.29	-0.33	3.22e-5	Post-traumatic stress disorder;
PAAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.43	0.46	1.59e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-4.62	-0.35	8.22e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4727012	1	rs4727012	chr7:148740493	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.71	-4.39	-0.34	2.09e-5	Colorectal or endometrial cancer;
PAAD	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-8.71	-0.58	4.81e-15	Blood trace element (Zn levels);
PAAD	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs72901758	0.774	rs72901750	chr17:76243453	C/T	cg11439826	chr17:76250004	NA	0.44	4.39	0.34	2.09e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.82	-0.43	3.36e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg20913747	chr6:44695427	NA	-0.68	-6.94	-0.49	1.06e-10	Total body bone mineral density;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.69	-0.36	6.08e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6785206	0.554	rs7652168	chr3:128512295	C/A	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs6715793	0.901	rs12617970	chr2:33403837	G/T	cg26672287	chr2:33391915	LTBP1	0.43	4.98	0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.69	7.17	0.5	3.14e-11	Type 2 diabetes;
PAAD	cis	rs4757319	0.512	rs4360688	chr11:15441149	A/G	cg03245590	chr11:15329459	NA	0.38	4.49	0.34	1.39e-5	Breast cancer;
PAAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg21724239	chr8:58056113	NA	0.71	5.19	0.39	6.56e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg05697835	chr1:2722811	NA	0.43	4.79	0.36	3.89e-6	Ulcerative colitis;
PAAD	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg15017067	chr4:17643749	FAM184B	0.41	4.85	0.37	3.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58521262	0.530	rs289344	chr19:23149670	G/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg26516362	chr5:178986906	RUFY1	0.55	6.19	0.45	5.34e-9	Lung cancer;
PAAD	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3206736	0.548	rs329229	chr7:35054029	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.47	-4.5	-0.34	1.34e-5	Diastolic blood pressure;
PAAD	cis	rs12304921	0.748	rs61005916	chr12:51357946	T/A	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.29	-0.33	3.21e-5	Type 2 diabetes;
PAAD	cis	rs593531	0.513	rs4944887	chr11:74029883	G/A	cg23327896	chr11:73669290	DNAJB13	0.33	4.44	0.34	1.73e-5	Neuroticism;
PAAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.25	-0.33	3.66e-5	Lewy body disease;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg01631408	chr1:248437212	OR2T33	0.58	5.44	0.4	2.1e-7	Common traits (Other);
PAAD	cis	rs294958	0.777	rs294951	chr5:151538720	G/A	cg04453665	chr5:151504455	NA	0.44	4.96	0.37	1.89e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg18898632	chr2:242989856	NA	-0.81	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.61	6.56	0.47	8.12e-10	Eye color traits;
PAAD	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg03989125	chr22:38214979	NA	-0.66	-6.91	-0.49	1.25e-10	Glioblastoma;Glioma;
PAAD	cis	rs17095355	1.000	rs12570145	chr10:111712913	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.35	-0.33	2.51e-5	Biliary atresia;
PAAD	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-1.05	-7.16	-0.5	3.18e-11	Dupuytren's disease;
PAAD	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.54	5.36	0.4	2.98e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9810890	1.000	rs73198819	chr3:128475662	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.63	5.48	0.41	1.72e-7	Mean corpuscular volume;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg16590910	chr6:42928470	GNMT	0.5	5.14	0.38	8.3e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg05925327	chr15:68127851	NA	0.55	5.03	0.38	1.36e-6	Restless legs syndrome;
PAAD	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.58e-13	Eotaxin levels;
PAAD	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg23024343	chr7:107201750	COG5	0.53	4.52	0.34	1.24e-5	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26926768	chr12:34528122	NA	-0.38	-4.68	-0.35	6.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg15890332	chr12:107067104	RFX4	0.41	4.56	0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg03910582	chr17:19030146	GRAPL	-0.5	-4.59	-0.35	9.41e-6	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs6539267	0.737	rs3851634	chr12:106812902	T/C	cg02476566	chr12:106696527	TCP11L2	0.45	4.32	0.33	2.82e-5	Tourette syndrome;
PAAD	cis	rs72772787	1.000	rs72761021	chr1:248012975	T/A	cg20507276	chr1:248100600	OR2L13	0.48	4.26	0.33	3.52e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14209344	chr4:87886892	AFF1	0.63	6.3	0.46	3.01e-9	Smoking initiation;
PAAD	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.6	-5.84	-0.43	3.07e-8	Lymphocyte counts;
PAAD	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-1.32	-8.78	-0.58	3.11e-15	Depression;
PAAD	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	cis	rs4919669	0.513	rs884825	chr10:104427616	T/G	cg05885577	chr10:104597359	CYP17A1	0.54	4.34	0.33	2.63e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
PAAD	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.66	0.48	4.63e-10	Hair morphology;
PAAD	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	5.98e-6	Plateletcrit;
PAAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.79	-5.23	-0.39	5.5e-7	Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.92	-8.31	-0.56	4.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1198430	1.000	rs1198432	chr1:23756155	C/T	cg22040403	chr1:23858016	E2F2	-0.71	-4.55	-0.35	1.09e-5	Total cholesterol levels;
PAAD	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.67	-5.81	-0.43	3.51e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.85	8.57	0.57	1.08e-14	Height;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg17372223	chr3:52568218	NT5DC2	0.46	4.6	0.35	8.75e-6	Electroencephalogram traits;
PAAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.77	7.1	0.5	4.39e-11	Obesity-related traits;
PAAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.45	0.34	1.64e-5	Trans fatty acid levels;
PAAD	cis	rs2834188	1.000	rs4408796	chr21:34698741	C/G	cg04842828	chr21:34696676	IFNAR1	-0.44	-4.29	-0.33	3.19e-5	Narcolepsy;
PAAD	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	5.45	0.4	1.96e-7	IgG glycosylation;
PAAD	cis	rs617219	0.698	rs7379187	chr5:78521354	T/C	cg24856658	chr5:78533917	JMY	-0.4	-4.5	-0.34	1.32e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg00969815	chr22:42536375	CYP2D7P1	0.5	4.31	0.33	2.88e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.42	0.4	2.29e-7	Bipolar disorder;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg12143784	chr7:64541923	NA	-0.37	-4.73	-0.36	5.03e-6	Calcium levels;
PAAD	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.62	5.57	0.41	1.12e-7	Red blood cell count;
PAAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-5.56	-0.41	1.19e-7	Calcium levels;
PAAD	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.85	5.88	0.43	2.47e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg02100629	chr10:71892760	AIFM2	-0.38	-4.63	-0.35	7.79e-6	Blood protein levels;
PAAD	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs9467711	0.516	rs1324087	chr6:25841408	A/G	cg21479132	chr6:26055353	NA	-0.68	-4.34	-0.33	2.61e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.32e-6	Mood instability;
PAAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Calcium levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26971585	chr10:72358574	PRF1	0.49	6.54	0.47	8.83e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.49	-4.6	-0.35	9.01e-6	Total body bone mineral density;
PAAD	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	0.95	10.38	0.64	1.99e-19	Menopause (age at onset);
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.77e-5	Life satisfaction;
PAAD	cis	rs300774	1.000	rs300778	chr2:111964	C/A	cg23649280	chr2:140451	NA	-0.52	-5.0	-0.38	1.57e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-4.6	-0.35	8.7e-6	Body mass index;
PAAD	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-5.5	-0.41	1.58e-7	Hypospadias;
PAAD	cis	rs7172971	0.638	rs7165458	chr15:42382864	A/G	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg16447950	chr5:562315	NA	-0.5	-4.71	-0.36	5.56e-6	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs7576635	chr2:625057	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.61	6.14	0.45	6.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.47	4.67	0.35	6.7e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.75	-5.31	-0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.75	7.07	0.5	5.19e-11	Cognitive function;
PAAD	cis	rs795943	0.527	rs7970340	chr12:78654077	A/T	cg00023351	chr12:79187938	NA	0.66	4.64	0.35	7.6e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35160687	0.623	rs11689971	chr2:86474471	A/G	cg10973622	chr2:86423274	IMMT	-0.49	-5.56	-0.41	1.18e-7	Night sleep phenotypes;
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg16316162	chr8:144660157	NAPRT1	0.91	4.38	0.33	2.21e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg05805236	chr11:65401703	PCNXL3	0.49	4.68	0.35	6.26e-6	Breast cancer;
PAAD	cis	rs621559	0.636	rs611792	chr1:43682017	T/C	cg14851383	chr1:43888477	KIAA0467	0.55	4.33	0.33	2.66e-5	Telomere length;
PAAD	cis	rs12586317	0.597	rs28452109	chr14:35653056	T/C	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.62	-0.35	8.05e-6	Psoriasis;
PAAD	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.57	-4.8	-0.36	3.79e-6	Polycystic ovary syndrome;
PAAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg21929781	chr1:2537748	MMEL1	0.51	5.29	0.39	4.14e-7	Ulcerative colitis;
PAAD	cis	rs802075	0.676	rs492855	chr6:49773727	G/A	cg20364632	chr6:49636226	NA	0.48	5.37	0.4	2.96e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.52	0.41	1.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	0.867	rs34144887	chr10:46086393	G/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.59	6.03	0.44	1.2e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg00717180	chr2:96193071	NA	-0.57	-6.35	-0.46	2.4e-9	HDL cholesterol;
PAAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.9	8.53	0.57	1.4e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg21892295	chr12:121157589	UNC119B	-0.4	-4.71	-0.36	5.44e-6	Mean corpuscular volume;
PAAD	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg21906605	chr1:21766650	NBPF3	0.44	4.27	0.33	3.39e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.23	-0.51	2.16e-11	Life satisfaction;
PAAD	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.67	-5.75	-0.42	4.63e-8	Total ventricular volume;
PAAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	0.88	9.32	0.6	1.24e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.77	-6.36	-0.46	2.25e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg16342193	chr10:102329863	NA	-0.81	-8.86	-0.58	2.03e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg08747591	chr11:789928	CEND1	-0.53	-5.25	-0.39	5.13e-7	Breast cancer;
PAAD	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-4.39	-0.34	2.09e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4478858	0.602	rs7515867	chr1:31724744	C/T	cg00250761	chr1:31883323	NA	0.49	5.5	0.41	1.59e-7	Alcohol dependence;
PAAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg24253500	chr15:84953950	NA	-0.47	-5.18	-0.39	6.82e-7	Schizophrenia;
PAAD	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.76	8.92	0.59	1.36e-15	Neutrophil percentage of white cells;
PAAD	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.6	-0.35	8.66e-6	Depression;
PAAD	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.74	-8.22	-0.55	8.14e-14	Magnesium levels;
PAAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.79	-5.94	-0.43	1.9e-8	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03922262	chr10:77868130	C10orf11	-0.68	-6.97	-0.49	8.82e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.77	5.14	0.38	8.49e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs4740619	0.630	rs2987031	chr9:15994724	C/T	cg14451791	chr9:16040625	NA	0.36	4.25	0.33	3.78e-5	Body mass index;
PAAD	trans	rs901683	1.000	rs77649955	chr10:46050689	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.82	-0.48	2.06e-10	Post bronchodilator FEV1;
PAAD	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-1.21	-12.67	-0.72	1.45e-25	Hair shape;
PAAD	cis	rs13053817	0.898	rs7291001	chr22:29857859	C/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.99	-0.37	1.66e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.85	-6.46	-0.46	1.37e-9	Coronary artery calcification;
PAAD	cis	rs35791980	0.534	rs55883949	chr7:76939020	C/T	cg02756451	chr7:76178720	LOC100133091	0.53	4.5	0.34	1.34e-5	Pursuit maintenance gain;
PAAD	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg06917450	chr1:38156652	C1orf109	-0.49	-4.35	-0.33	2.44e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.52	4.91	0.37	2.37e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs797680	0.822	rs942196	chr1:93802264	T/A	cg04535902	chr1:92947332	GFI1	0.46	4.46	0.34	1.56e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.84	-0.43	3.01e-8	Pulmonary function;
PAAD	cis	rs7582720	0.945	rs72932720	chr2:203646934	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	7.43	0.52	7.3e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.69	-0.36	6.09e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.55	-4.48	-0.34	1.47e-5	Diastolic blood pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07785726	chr13:50159788	RCBTB1	-0.55	-6.46	-0.46	1.37e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4903604	0.581	rs11159279	chr14:78036358	C/T	cg18872420	chr14:78023429	SPTLC2	0.42	4.38	0.33	2.18e-5	Gut microbiome composition (winter);
PAAD	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.05	-0.67	3.41e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg02367144	chr2:237146137	ASB18	0.42	5.42	0.4	2.24e-7	Educational attainment;
PAAD	cis	rs11811982	0.793	rs111314111	chr1:227569838	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.93	-0.37	2.13e-6	High light scatter reticulocyte count;
PAAD	cis	rs569214	0.543	rs480291	chr8:27518682	A/G	cg04264299	chr8:27491209	SCARA3	0.57	5.42	0.4	2.29e-7	Alzheimer's disease;
PAAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.68	7.29	0.51	1.6e-11	Pulse pressure;
PAAD	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11539275	chr6:116421888	NT5DC1	0.62	7.07	0.5	5.23e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.84	0.37	3.11e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.45	0.46	1.41e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9372498	0.536	rs62424198	chr6:118827247	A/G	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.16e-6	Diastolic blood pressure;
PAAD	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.83	-8.13	-0.55	1.38e-13	Prudent dietary pattern;
PAAD	trans	rs10767971	1.000	rs10767971	chr11:32895664	T/C	cg03700492	chr17:73874623	TRIM47	0.62	6.47	0.46	1.25e-9	Parkinson's disease (age of onset);
PAAD	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.56	0.47	7.93e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11718455	0.526	rs11720884	chr3:43941406	A/G	cg00181669	chr3:44000978	NA	-0.54	-5.44	-0.4	2.07e-7	Coronary artery disease;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg17749961	chr2:30669863	LCLAT1	-0.64	-5.15	-0.39	7.82e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.57	4.91	0.37	2.37e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs282587	0.597	rs12876520	chr13:113393566	C/G	cg19217778	chr13:113420270	ATP11A	-0.55	-4.34	-0.33	2.6e-5	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2292864	0.681	rs35735886	chr17:45374277	G/T	cg18085866	chr17:45331354	ITGB3	-0.94	-5.34	-0.4	3.33e-7	Left atrial antero-posterior diameter;
PAAD	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.39e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg13540341	chr19:49222985	MAMSTR	0.41	4.51	0.34	1.3e-5	Dietary macronutrient intake;
PAAD	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.84	8.17	0.55	1.13e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2834188	0.557	rs1058867	chr21:34669381	A/G	cg04842828	chr21:34696676	IFNAR1	-0.47	-5.03	-0.38	1.36e-6	Narcolepsy;
PAAD	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-5.49	-0.41	1.68e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs17407555	0.909	rs2868939	chr4:10314921	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.53	-0.34	1.18e-5	Schizophrenia (age at onset);
PAAD	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.36	0.33	2.41e-5	Menarche (age at onset);
PAAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.9	-0.59	1.6e-15	Diabetic kidney disease;
PAAD	cis	rs4605213	0.510	rs11658506	chr17:49326433	G/A	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.63	-0.35	7.9e-6	Height;
PAAD	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.82	-7.76	-0.53	1.17e-12	Neurofibrillary tangles;
PAAD	cis	rs28830936	0.966	rs8025714	chr15:42120157	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.84	-0.49	1.83e-10	Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14162927	chr1:155145774	TRIM46;KRTCAP2	0.63	6.68	0.48	4.18e-10	Myopia (pathological);
PAAD	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.45	4.61	0.35	8.55e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4740619	0.619	rs4740631	chr9:16030126	G/C	cg14451791	chr9:16040625	NA	-0.46	-5.33	-0.4	3.52e-7	Body mass index;
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg07068956	chr7:100330872	ZAN	0.5	4.4	0.34	2.04e-5	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs4936894	0.500	rs4936919	chr11:124180082	C/T	cg14887116	chr11:124293907	OR8B4	0.38	4.45	0.34	1.64e-5	Aging (time to death);
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	4.38	0.33	2.22e-5	Vitiligo;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.901	rs67903513	chr2:86512099	A/C	cg10973622	chr2:86423274	IMMT	0.42	4.85	0.37	2.98e-6	Night sleep phenotypes;
PAAD	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg06970076	chr16:1560791	IFT140	0.59	4.55	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg15017067	chr4:17643749	FAM184B	0.4	4.61	0.35	8.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10865541	0.934	rs6738333	chr2:3403404	T/C	cg12447832	chr2:3383257	TTC15	-0.36	-4.26	-0.33	3.57e-5	Obesity-related traits;
PAAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.86	9.98	0.63	2.42e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14019695	chr9:139328340	INPP5E	-0.45	-4.35	-0.33	2.46e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.8	-0.48	2.27e-10	Capecitabine sensitivity;
PAAD	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.12	6.99	0.49	8.3e-11	Plateletcrit;
PAAD	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.77	-8.52	-0.57	1.49e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg05717871	chr11:638507	DRD4	-0.57	-5.47	-0.41	1.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs11825064	0.666	rs58623219	chr11:134494910	C/T	cg02089395	chr11:134479357	NA	-0.82	-5.42	-0.4	2.33e-7	Seasonality;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26015683	chr6:29720519	NA	0.68	7.42	0.52	7.88e-12	Pancreatic cancer;
PAAD	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.7	6.09	0.44	8.66e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg25037394	chr1:24152592	HMGCL	-0.42	-4.61	-0.35	8.6e-6	Immature fraction of reticulocytes;
PAAD	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.84	-9.77	-0.62	8.6e-18	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	5.0	0.38	1.56e-6	Mood instability;
PAAD	cis	rs8044868	0.530	rs3890860	chr16:72103409	A/G	cg16579770	chr16:72058938	DHODH	0.38	4.33	0.33	2.65e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg23167506	chr7:1303302	NA	-0.38	-6.82	-0.48	1.97e-10	Menopause (age at onset);
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.65	-6.73	-0.48	3.21e-10	Paraoxonase activity;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.46	4.54	0.35	1.13e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.07	-0.55	1.97e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.53	5.43	0.4	2.16e-7	Mean corpuscular volume;
PAAD	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.9	5.63	0.42	8.48e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.56	-5.29	-0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	4.61	0.35	8.33e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.84	-0.49	1.82e-10	Menopause (age at onset);
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg21523564	chr15:75251491	NA	0.47	4.93	0.37	2.11e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg23188684	chr11:67383651	NA	0.48	4.97	0.37	1.75e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.928	rs216209	chr17:2195130	A/G	cg16513277	chr17:2031491	SMG6	0.51	4.99	0.38	1.61e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.64	-0.35	7.54e-6	Monocyte count;
PAAD	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg13565585	chr5:132299512	AFF4	-0.53	-5.14	-0.39	8.17e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg12573674	chr2:1569213	NA	-0.68	-5.35	-0.4	3.12e-7	IgG glycosylation;
PAAD	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.5	-4.56	-0.35	1.07e-5	Cancer;
PAAD	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg25930673	chr12:123319894	HIP1R	1.23	6.4	0.46	1.87e-9	Adiponectin levels;
PAAD	cis	rs527409	1.000	rs552352	chr1:58733050	A/G	cg26345888	chr1:58716257	DAB1	-0.7	-4.93	-0.37	2.1e-6	Kawasaki disease;
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg03289416	chr15:75166202	SCAMP2	0.46	4.61	0.35	8.59e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.81	-9.34	-0.6	1.14e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.52	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.67	-6.71	-0.48	3.57e-10	Monocyte count;
PAAD	cis	rs501120	1.000	rs552794	chr10:44771666	G/A	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.16	-0.39	7.7300000000000005e-07	Menarche (age at onset);
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg10729496	chr3:10149963	C3orf24	0.93	6.8	0.48	2.23e-10	Alzheimer's disease;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07733457	chr17:5095165	ZNF594	-0.59	-7.06	-0.5	5.69e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.67	7.09	0.5	4.71e-11	Dupuytren's disease;
PAAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	1.02	5.12	0.38	9.31e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs829661	0.895	rs6749074	chr2:30791152	A/G	cg12454169	chr2:30669597	LCLAT1	0.63	4.97	0.37	1.78e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.95	9.91	0.63	3.65e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs877529	0.647	rs139395	chr22:39538433	T/C	cg18708252	chr22:39545030	CBX7	-0.64	-6.61	-0.47	6.19e-10	Multiple myeloma;
PAAD	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.58	-6.22	-0.45	4.67e-9	Cognitive function;
PAAD	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.79	8.79	0.58	3e-15	Obesity-related traits;
PAAD	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg03094675	chr11:5960213	NA	-0.46	-4.26	-0.33	3.57e-5	DNA methylation (variation);
PAAD	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.65	-0.42	7.87e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg15604389	chr3:122379662	NA	0.58	6.21	0.45	4.71e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	1.69	10.47	0.65	1.19e-19	Height;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.0	-0.44	1.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.65	-8.21	-0.55	8.65e-14	Schizophrenia;
PAAD	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg16898833	chr6:26189333	HIST1H4D	1.08	5.85	0.43	2.92e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.65	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.93	-10.61	-0.65	5.12e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	6.16	0.45	6.09e-9	Menopause (age at onset);
PAAD	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg01059385	chr22:42394853	WBP2NL	0.52	4.45	0.34	1.67e-5	Birth weight;
PAAD	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.37	-0.33	2.25e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg10589385	chr1:150898437	SETDB1	0.39	4.89	0.37	2.51e-6	Melanoma;
PAAD	cis	rs2016586	0.796	rs1997884	chr22:36103778	G/A	cg26342177	chr22:36113512	APOL5	-0.43	-4.49	-0.34	1.37e-5	Body mass index;
PAAD	cis	rs7765175	0.698	rs1565528	chr6:113669875	A/G	cg19037598	chr6:113666021	NA	-0.41	-4.35	-0.33	2.5e-5	Coronary artery calcification;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg24846343	chr22:24311635	DDTL	0.83	9.55	0.61	3.16e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg01388757	chr2:102091195	RFX8	-0.59	-7.55	-0.52	3.7e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04823499	chr5:65222365	ERBB2IP	0.64	7.23	0.51	2.23e-11	Monocyte percentage of white cells;
PAAD	cis	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg18171855	chr10:2543474	NA	0.59	6.31	0.46	2.84e-9	Age-related hearing impairment;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.74	-6.34	-0.46	2.51e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg18370025	chr7:2749541	AMZ1	-0.39	-4.66	-0.35	6.73e-6	Height;
PAAD	trans	rs901683	1.000	rs113862353	chr10:46068586	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.45	-0.34	1.64e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.65	0.57	6.71e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-9.12	-0.59	4.34e-16	Gut microbiome composition (summer);
PAAD	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg14146966	chr2:61757674	XPO1	0.39	4.97	0.37	1.81e-6	Tuberculosis;
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg24699146	chr1:24152579	HMGCL	0.54	5.7	0.42	6.02e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-6.24	-0.45	4.06e-9	Bipolar disorder;
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.58	6.57	0.47	7.45e-10	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21122466	chr6:99323548	FBXL4	-0.64	-6.29	-0.45	3.29e-9	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.31	-0.46	2.88e-9	Morning vs. evening chronotype;
PAAD	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.5	4.84	0.37	3.18e-6	High light scatter reticulocyte count;
PAAD	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs11628318	0.951	rs10134794	chr14:103034195	C/A	cg23461800	chr14:103021989	NA	-0.59	-4.88	-0.37	2.68e-6	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08366952	chr3:101293020	PCNP	0.71	7.38	0.51	9.4e-12	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg01388757	chr2:102091195	RFX8	-0.55	-7.01	-0.49	7.25e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs12144049	0.705	rs2146115	chr1:152443495	A/G	cg25605289	chr1:151974222	NA	-0.33	-4.44	-0.34	1.74e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.45	6.08	0.44	9.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg26816564	chr1:7831052	VAMP3	0.66	5.29	0.39	4.11e-7	Inflammatory bowel disease;
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.26	-0.39	4.9e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17407555	1.000	rs17407555	chr4:10274994	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.18	-0.39	7.05e-7	Schizophrenia (age at onset);
PAAD	cis	rs7678555	0.520	rs11723972	chr4:120829219	G/A	cg09307838	chr4:120376055	NA	0.47	4.52	0.34	1.24e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1419980	0.730	rs7304322	chr12:7728638	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.46	5.52	0.41	1.43e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg20312557	chr2:97357134	FER1L5	-0.88	-4.58	-0.35	9.78e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	trans	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg01957732	chr6:133561716	EYA4	0.98	7.15	0.5	3.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg15123519	chr2:136567270	LCT	-0.38	-4.56	-0.35	1.03e-5	Mosquito bite size;
PAAD	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.29	-14.04	-0.75	3.1e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg13722127	chr7:150037890	RARRES2	0.61	6.35	0.46	2.33e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg15226275	chr6:116381976	FRK	-0.39	-7.17	-0.5	3e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4450131	0.897	rs10901796	chr10:126335586	T/C	cg20435097	chr10:126320824	FAM53B	-0.49	-5.49	-0.41	1.67e-7	White blood cell count (basophil);
PAAD	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.41	0.34	1.98e-5	Tonsillectomy;
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.76	7.01	0.49	7.27e-11	Calcium levels;
PAAD	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-1.36	-10.13	-0.63	9.61e-19	Schizophrenia;
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.31	0.4	3.9e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg05717871	chr11:638507	DRD4	-0.58	-5.35	-0.4	3.2e-7	Systemic lupus erythematosus;
PAAD	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg25828445	chr12:7781288	NA	-1.0	-6.11	-0.44	8.06e-9	HDL cholesterol levels;
PAAD	cis	rs11825685	1.000	rs11825685	chr11:134573810	C/T	cg06603561	chr11:134479413	NA	-0.7	-4.41	-0.34	1.96e-5	IgG glycosylation;
PAAD	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg15956490	chr3:53032818	SFMBT1	0.78	4.39	0.34	2.16e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg05338066	chr1:7812865	CAMTA1	0.64	4.8	0.36	3.8e-6	Inflammatory bowel disease;
PAAD	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.77	-0.42	4.21e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.42	0.4	2.34e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1667255	0.830	rs1375445	chr18:29156999	A/G	cg18808318	chr18:29669225	NA	-0.51	-4.91	-0.37	2.37e-6	Retinol levels;
PAAD	cis	rs728616	0.681	rs12412762	chr10:81907470	A/G	cg19423196	chr10:82049429	MAT1A	-0.46	-4.32	-0.33	2.79e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.39	-4.99	-0.37	1.67e-6	Longevity;Endometriosis;
PAAD	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.58	-6.61	-0.47	6.16e-10	Prostate cancer;
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg16584290	chr5:462447	EXOC3	-0.44	-4.88	-0.37	2.68e-6	Cystic fibrosis severity;
PAAD	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg18850127	chr7:39170497	POU6F2	0.5	7.48	0.52	5.59e-12	IgG glycosylation;
PAAD	cis	rs7260598	0.539	rs114089634	chr19:24064993	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-10.76	-0.66	1.98e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs8014252	0.803	rs77359887	chr14:70999238	A/C	cg11204974	chr14:71022665	NA	-0.76	-4.79	-0.36	3.95e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.41e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	4.52	0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg01620082	chr3:125678407	NA	-1.36	-8.49	-0.57	1.7e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2133450	0.780	rs2030155	chr3:7361473	C/T	cg19930620	chr3:7340148	GRM7	-0.43	-4.53	-0.34	1.2e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.44e-5	Ulcerative colitis;
PAAD	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.65	6.4	0.46	1.8e-9	Coronary artery disease;
PAAD	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.54e-17	White blood cell count (basophil);
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs7591163	0.959	rs13384448	chr2:228707862	C/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.44	4.48	0.34	1.44e-5	Blood pressure;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.72	6.67	0.48	4.58e-10	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.59	-0.57	9.51e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.82	0.36	3.4e-6	Breast cancer;
PAAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg19680485	chr15:31195859	MTMR15	0.45	4.34	0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs6494488	0.500	rs112698132	chr15:64906413	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg06521331	chr12:34319734	NA	-0.44	-4.58	-0.35	9.52e-6	Resting heart rate;
PAAD	cis	rs7627468	0.802	rs1354158	chr3:121941750	A/G	cg17240004	chr3:121949083	CASR	0.52	4.83	0.36	3.33e-6	Kidney stones;
PAAD	cis	rs4621152	0.775	rs10932693	chr2:217921121	C/G	cg21875423	chr2:217559867	IGFBP5	-0.44	-4.32	-0.33	2.76e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.1	0.59	4.76e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	6.42	0.46	1.66e-9	Multiple sclerosis;
PAAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.86	-7.89	-0.54	5.63e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg08999081	chr20:33150536	PIGU	0.48	5.11	0.38	9.71e-7	Height;
PAAD	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg07636037	chr3:49044803	WDR6	0.57	4.56	0.35	1.03e-5	Menarche (age at onset);
PAAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.66	7.39	0.51	9.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.49	-5.38	-0.4	2.74e-7	Major depressive disorder;
PAAD	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.52	5.17	0.39	7.28e-7	Mean corpuscular volume;
PAAD	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.86	9.63	0.62	2.03e-17	Dental caries;
PAAD	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2296225	0.722	rs900038	chr1:21057552	C/A	cg24673385	chr1:21051448	SH2D5	0.49	4.47	0.34	1.53e-5	Eosinophilic esophagitis;
PAAD	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.95	10.73	0.66	2.44e-20	Obesity;Body mass index;
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09263875	chr16:632152	PIGQ	0.69	7.88	0.54	5.84e-13	Height;
PAAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg07338119	chr7:157211683	NA	-0.44	-4.46	-0.34	1.59e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6804624	0.654	rs2458515	chr3:99171844	A/G	cg02646433	chr3:99218170	NA	0.44	4.49	0.34	1.41e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72777070	0.857	rs66484704	chr2:9795776	C/T	cg14973360	chr2:9800511	NA	-0.52	-4.35	-0.33	2.53e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.47	4.43	0.34	1.76e-5	Red cell distribution width;
PAAD	cis	rs6142102	0.961	rs973409	chr20:32536364	A/G	cg08999081	chr20:33150536	PIGU	0.46	4.26	0.33	3.56e-5	Skin pigmentation;
PAAD	cis	rs642743	0.967	rs624159	chr10:105939451	C/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.55	0.35	1.08e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12541635	0.739	rs7833595	chr8:107089603	G/T	cg10147462	chr8:107024639	NA	-0.47	-5.02	-0.38	1.44e-6	Age of smoking initiation;
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.59	-7.44	-0.52	7.02e-12	Hypertriglyceridemia;
PAAD	cis	rs6142102	0.961	rs4911408	chr20:32700566	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.36	0.33	2.37e-5	Skin pigmentation;
PAAD	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg16664915	chr8:10907788	XKR6	0.4	4.27	0.33	3.48e-5	Triglycerides;
PAAD	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.76	7.55	0.52	3.82e-12	Retinal vascular caliber;
PAAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.43	-0.52	7.23e-12	Personality dimensions;
PAAD	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.28	8.73	0.58	4.21e-15	Opioid sensitivity;
PAAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.89	7.3	0.51	1.47e-11	Cerebrospinal P-tau181p levels;
PAAD	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18785742	chr1:9318091	H6PD	-0.63	-6.36	-0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.47	5.61	0.41	9.21e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs6585424	1.000	rs12769115	chr10:81933501	G/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1419980	0.730	rs115594156	chr12:7751337	A/G	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06915872	chr16:87998081	BANP	0.46	4.31	0.33	2.87e-5	Menopause (age at onset);
PAAD	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.84	-0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2017305	0.915	rs78812335	chr10:70664011	G/C	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.08	-0.38	1.08e-6	Depression (quantitative trait);
PAAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.6	5.49	0.41	1.63e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs2017305	0.915	rs75827490	chr10:70646393	G/A	cg25290552	chr10:70751067	KIAA1279	-0.83	-4.8	-0.36	3.72e-6	Depression (quantitative trait);
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.67	-6.45	-0.46	1.42e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9857275	0.555	rs12695735	chr3:141185754	T/A	cg25967872	chr3:141205623	RASA2	0.5	4.4	0.34	2.04e-5	Prion diseases;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1883415	0.534	rs2253794	chr6:24479642	C/A	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10788264	1.000	rs10788264	chr10:124015986	G/A	cg09507567	chr10:124027408	NA	0.39	4.73	0.36	5.06e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.38	0.4	2.74e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2790216	1.000	rs1832556	chr10:60028248	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.66	-0.35	7e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.54	0.35	1.14e-5	Bipolar disorder;
PAAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.47e-11	Rheumatoid arthritis;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.57	-5.63	-0.42	8.38e-8	Paraoxonase activity;
PAAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.51	-5.83	-0.43	3.19e-8	Breast cancer;
PAAD	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg16341495	chr8:142228727	SLC45A4	-0.49	-4.67	-0.35	6.45e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.62	-6.97	-0.49	8.84e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs73416724	0.925	rs79641366	chr6:43279144	T/C	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.868	rs10738417	chr9:15870665	T/C	cg14451791	chr9:16040625	NA	-0.37	-4.25	-0.33	3.69e-5	Body mass index;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg16342193	chr10:102329863	NA	-0.78	-8.5	-0.57	1.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.67	6.12	0.44	7.68e-9	Coronary artery disease;
PAAD	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.3	-0.33	3.05e-5	Vitiligo;
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02071572	chr4:1403502	NA	0.34	4.25	0.33	3.77e-5	Longevity;
PAAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	7.59	0.52	3.08e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	trans	rs9810890	1.000	rs73210622	chr3:128659748	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.53	5.59	0.41	1.03e-7	Red blood cell count;
PAAD	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.6	5.85	0.43	2.97e-8	Type 2 diabetes;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg00166722	chr3:10149974	C3orf24	0.9	7.81	0.54	8.61e-13	Alzheimer's disease;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.44	0.34	1.71e-5	Bipolar disorder;
PAAD	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs6499755	0.768	rs79085284	chr16:55362377	C/T	cg02859129	chr16:55357253	IRX6	0.37	5.12	0.38	9.15e-7	Hypospadias;
PAAD	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	1.22	13.48	0.74	9.9e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	6.62	0.47	5.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.9	10.04	0.63	1.61e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	1.16	10.39	0.64	1.98e-19	Eosinophil percentage of granulocytes;
PAAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.83	-9.02	-0.59	7.65e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg01064725	chr1:204461714	NA	-0.5	-4.62	-0.35	8.07e-6	Schizophrenia;
PAAD	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs138249	0.527	rs138251	chr22:50570852	A/G	cg24682541	chr22:50487496	TTLL8	-0.39	-4.47	-0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);
PAAD	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.58	6.51	0.47	1.02e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.52	0.34	1.21e-5	Bipolar disorder;
PAAD	cis	rs66530629	0.917	rs12027779	chr1:25148367	G/A	cg01905478	chr1:25040257	NA	0.5	5.44	0.4	2.04e-7	Plateletcrit;
PAAD	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.38	-0.33	2.22e-5	Joint mobility (Beighton score);
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg00786201	chr11:61583134	MIR1908;FADS1	0.51	4.94	0.37	2.06e-6	Trans fatty acid levels;
PAAD	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.4	-0.46	1.84e-9	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg13870426	chr17:30244630	NA	-0.73	-6.89	-0.49	1.41e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg03999872	chr20:62272968	STMN3	0.52	4.88	0.37	2.63e-6	Prostate cancer;
PAAD	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.45	0.4	1.99e-7	Lung cancer;
PAAD	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.28	-0.51	1.7e-11	Neuroticism;
PAAD	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs35955747	0.869	rs8142988	chr22:31587158	T/C	cg07969918	chr22:31682909	PIK3IP1	-0.34	-4.43	-0.34	1.76e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg02135003	chr7:105160482	PUS7	-0.89	-6.07	-0.44	1e-8	Bipolar disorder (body mass index interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07689503	chr2:74426200	MTHFD2	0.56	6.29	0.45	3.28e-9	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10546410	chr2:239975199	HDAC4	-0.56	-6.3	-0.46	3.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.34	-4.55	-0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg09659197	chr4:152720779	NA	0.35	5.16	0.39	7.59e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg01766943	chr2:54829624	SPTBN1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs13053817	1.000	rs13053758	chr22:29855489	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.93	-0.37	2.09e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.67	-7.62	-0.53	2.55e-12	Huntington's disease progression;
PAAD	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.5	5.08	0.38	1.07e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9463078	0.565	rs4714845	chr6:45230421	G/A	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.25e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg27411982	chr8:10470053	RP1L1	-0.49	-5.47	-0.41	1.84e-7	Neuroticism;
PAAD	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs6137287	0.924	rs6035803	chr20:21153782	C/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.69	7.05	0.5	5.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg00207534	chr16:71929512	KIAA0174	0.73	4.43	0.34	1.78e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.63	7.22	0.51	2.28e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08677398	chr8:58056175	NA	0.59	4.38	0.33	2.18e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg21665744	chr7:39171113	POU6F2	0.3	4.69	0.36	6.05e-6	IgG glycosylation;
PAAD	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	4.69	0.36	6.08e-6	Cognitive ability;
PAAD	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-6.17	-0.45	6.04e-9	Hyperactive-impulsive symptoms;
PAAD	cis	rs2327429	0.827	rs7752775	chr6:134172346	C/G	cg06296503	chr6:134217401	NA	-0.49	-5.0	-0.38	1.56e-6	Coronary artery disease;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.81	6.64	0.47	5.16e-10	Gastritis;
PAAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg05725404	chr16:58534157	NDRG4	-0.77	-4.67	-0.35	6.52e-6	Schizophrenia;
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.74	8.78	0.58	3.16e-15	Height;
PAAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.45	3.06e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9398803	0.687	rs853962	chr6:127027650	G/T	cg19875578	chr6:126661172	C6orf173	-0.44	-4.59	-0.35	9.14e-6	Male-pattern baldness;
PAAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.46	4.44	0.34	1.75e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.76	-8.15	-0.55	1.22e-13	Hemoglobin concentration;
PAAD	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg24879335	chr3:133465180	TF	0.6	6.87	0.49	1.56e-10	Iron status biomarkers;
PAAD	cis	rs9463078	0.691	rs12194311	chr6:45329048	C/A	cg25276700	chr6:44698697	NA	0.53	5.88	0.43	2.54e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.52	5.62	0.42	8.69e-8	Lung cancer;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.43	0.52	7.27e-12	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs58521262	0.560	rs289295	chr19:23176367	C/T	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1270639	0.778	rs2952650	chr7:157450939	C/T	cg13357408	chr7:157437802	PTPRN2	1.09	9.61	0.61	2.27e-17	Colorectal cancer;
PAAD	cis	rs3917254	0.570	rs2310187	chr2:102750428	G/T	cg22835712	chr2:102737379	NA	-0.65	-5.03	-0.38	1.39e-6	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13560548	chr3:10150139	C3orf24	0.6	5.33	0.4	3.54e-7	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10724490	chr7:6523886	KDELR2	0.66	7.45	0.52	6.46e-12	Myopia (pathological);
PAAD	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.33	-0.51	1.3e-11	Chronic sinus infection;
PAAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	7.96	0.54	3.65e-13	Menarche (age at onset);
PAAD	cis	rs16869652	1.000	rs16869652	chr6:33851173	A/G	cg00334056	chr6:33755658	LEMD2	0.65	4.25	0.33	3.71e-5	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03899609	chr16:29911630	SEZ6L2;ASPHD1	0.68	7.91	0.54	5.01e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5756391	0.509	rs4821559	chr22:37310269	T/C	cg21209356	chr22:37319042	CSF2RB	0.35	4.43	0.34	1.77e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg21546286	chr11:48923668	NA	0.57	6.08	0.44	9.28e-9	HDL cholesterol;
PAAD	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06544989	chr22:39130855	UNC84B	0.52	5.44	0.4	2.07e-7	Menopause (age at onset);
PAAD	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg27489772	chr12:121021490	NA	-0.57	-5.07	-0.38	1.16e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.35	-4.92	-0.37	2.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.47e-6	HDL cholesterol levels;
PAAD	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6066825	0.555	rs6019378	chr20:47309716	C/T	cg18078177	chr20:47281410	PREX1	0.44	4.25	0.33	3.7e-5	Colorectal cancer;
PAAD	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	1.07	12.86	0.72	4.58e-26	Breast cancer;
PAAD	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-6.89	-0.49	1.4e-10	Extrinsic epigenetic age acceleration;
PAAD	trans	rs61677309	0.964	rs55798741	chr11:118154114	G/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs13361707	0.600	rs10078575	chr5:40704074	A/G	cg17351974	chr5:40835760	RPL37	-0.46	-4.35	-0.33	2.44e-5	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	9.06	0.59	6.2e-16	Cognitive test performance;
PAAD	cis	rs8027181	0.710	rs34117151	chr15:73097221	T/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.53	5.01	0.38	1.51e-6	Triglyceride levels;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg10207240	chr12:122356781	WDR66	0.56	5.91	0.43	2.12e-8	Mean corpuscular volume;
PAAD	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.88	9.45	0.61	5.77e-17	Anterior chamber depth;
PAAD	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	trans	rs1903068	0.853	rs12505096	chr4:56006102	C/A	cg05132782	chr7:150126392	NA	0.44	6.29	0.45	3.17e-9	Endometriosis;
PAAD	cis	rs7011049	0.908	rs79560601	chr8:53853614	C/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs16910800	1.000	rs2468646	chr11:23202166	T/C	cg20040320	chr11:23191996	NA	0.58	4.92	0.37	2.27e-6	Cancer;
PAAD	cis	rs7823896	0.858	rs58645331	chr8:110262202	G/A	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs58521262	0.556	rs771353	chr19:23187567	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs17021463	0.673	rs4699459	chr4:95292702	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.46	0.4	1.93e-7	Testicular germ cell tumor;
PAAD	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.53	5.15	0.39	7.82e-7	Fractional excretion of uric acid;
PAAD	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.5	5.97	0.44	1.64e-8	Psoriasis;
PAAD	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.74	8.1	0.55	1.71e-13	Gout;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.68	0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.35	0.33	2.45e-5	Educational attainment;
PAAD	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg15478930	chr2:27652102	NRBP1	0.54	4.44	0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.58	6.57	0.47	7.4e-10	Glycated hemoglobin levels;
PAAD	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.89	-10.52	-0.65	8.9e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.92	7.96	0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.61	-8.78	-0.58	3.23e-15	Huntington's disease progression;
PAAD	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.53	0.52	4.25e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.35	-0.33	2.44e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07167872	chr1:205819463	PM20D1	0.5	4.74	0.36	4.98e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24187253	chr7:1032865	NA	0.56	6.42	0.46	1.69e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.37	-0.33	2.32e-5	Height;
PAAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.5	5.75	0.42	4.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg26220594	chr1:19110978	NA	-0.66	-5.43	-0.4	2.21e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12583138	chr11:78053743	GAB2	-0.58	-6.29	-0.45	3.26e-9	Obesity-related traits;
PAAD	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;
PAAD	cis	rs7932354	0.583	rs6485695	chr11:46836165	C/T	cg19486271	chr11:47235900	DDB2	-0.6	-5.92	-0.43	2.09e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.51	-4.29	-0.33	3.21e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.09	16.2	0.8	6.45e-35	Height;
PAAD	cis	rs3996993	0.702	rs6458871	chr6:52665977	C/T	cg20803780	chr6:52668592	GSTA1	-0.35	-4.5	-0.34	1.37e-5	Hemoglobin concentration;
PAAD	trans	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.74e-27	Height;
PAAD	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.0	11.83	0.69	2.62e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.59	-0.82	1.73e-38	Height;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05665937	chr4:1216051	CTBP1	0.4	4.42	0.34	1.88e-5	Obesity-related traits;
PAAD	cis	rs2481665	0.817	rs2476198	chr1:62611071	C/A	cg18591186	chr1:62594603	INADL	-0.49	-4.45	-0.34	1.68e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.86	10.15	0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22038928	chr6:166756117	SFT2D1	0.64	7.23	0.51	2.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.3	-0.39	4.01e-7	Glomerular filtration rate;
PAAD	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg05250797	chr16:70222502	NA	0.84	6.25	0.45	3.85e-9	IgE levels;
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.54	-4.98	-0.37	1.67e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10421328	0.797	rs919778	chr19:19772722	A/G	cg11584989	chr19:19387371	SF4	-0.72	-5.79	-0.42	3.96e-8	Parental longevity (combined parental age at death);
PAAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg14851346	chr12:38532713	NA	0.49	4.6	0.35	8.69e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.82	-9.41	-0.61	7.62e-17	Aortic root size;
PAAD	trans	rs11794666	0.858	rs1854361	chr9:31775714	C/A	cg05628366	chr6:35744188	C6orf126	1.11	7.4	0.51	8.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs73019876	0.901	rs424460	chr19:22233692	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	1.99e-5	Testicular germ cell tumor;
PAAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17261830	chr14:75593525	NEK9	0.64	6.97	0.49	9.1e-11	Myopia (pathological);
PAAD	cis	rs1903068	0.752	rs28517654	chr4:55993468	T/C	cg20092376	chr4:56023423	NA	0.43	4.28	0.33	3.35e-5	Endometriosis;
PAAD	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.9	-10.49	-0.65	1.06e-19	Refractive error;
PAAD	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs58521262	0.556	rs289362	chr19:23118399	A/G	cg02350677	chr19:23254381	NA	-0.27	-4.78	-0.36	4.17e-6	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs4786125	0.665	rs8060329	chr16:6908864	G/A	cg03623568	chr16:6915990	A2BP1	-0.48	-4.77	-0.36	4.25e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	7.13	0.5	3.9e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs2249694	0.878	rs2480257	chr10:135352509	T/A	cg16964102	chr10:135390573	NA	-0.43	-4.48	-0.34	1.49e-5	Obesity-related traits;
PAAD	cis	rs4478858	0.735	rs12734617	chr1:31823446	G/T	cg00250761	chr1:31883323	NA	-0.54	-6.27	-0.45	3.48e-9	Alcohol dependence;
PAAD	cis	rs7823896	0.722	rs67145203	chr8:110289182	G/A	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	1.31	11.06	0.67	3.19e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.5	-0.41	1.59e-7	Schizophrenia;
PAAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.3	-0.4	3.93e-7	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23988964	chr1:212797368	FAM71A	-0.59	-6.32	-0.46	2.7e-9	Obesity-related traits;
PAAD	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.53	0.57	1.42e-14	Caffeine consumption;
PAAD	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.71	0.42	5.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.79	-7.05	-0.5	5.8e-11	Systemic lupus erythematosus;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg02524346	chr8:600233	NA	1.03	6.52	0.47	9.57e-10	IgG glycosylation;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119038	0.629	rs11217000	chr11:118604984	A/G	cg04176122	chr11:118779835	BCL9L	0.44	4.74	0.36	4.93e-6	Sjögren's syndrome;
PAAD	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.46	-4.31	-0.33	2.93e-5	Endometrial cancer;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs11887277	0.651	rs34736994	chr2:27031085	C/T	cg12368169	chr2:27073192	DPYSL5	-0.4	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-4.68	-0.36	6.19e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg03571073	chr13:113464332	ATP11A	-0.65	-6.36	-0.46	2.21e-9	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-1.02	-10.51	-0.65	9.17e-20	Blood pressure (smoking interaction);
PAAD	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.51	-5.39	-0.4	2.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1519814	1.000	rs4588897	chr8:121139142	A/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs3736485	0.844	rs62014659	chr15:51818591	G/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.3	-0.33	3.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.48	-4.9	-0.37	2.45e-6	Melanoma;
PAAD	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg08824895	chr13:115047677	UPF3A	0.46	4.4	0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs7727544	0.564	rs3852206	chr5:131415436	G/A	cg16205897	chr5:131564050	P4HA2	-0.45	-4.75	-0.36	4.68e-6	Blood metabolite levels;
PAAD	cis	rs1334894	0.901	rs6906096	chr6:35500654	C/T	cg07213720	chr6:35227408	ZNF76	-0.83	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.94	-7.67	-0.53	1.88e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg26205652	chr12:48591994	NA	0.7	4.83	0.36	3.34e-6	Prostate cancer;
PAAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9462027	0.606	rs2235569	chr6:34570070	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.52	-0.34	1.22e-5	Systemic lupus erythematosus;
PAAD	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg09324608	chr17:30823087	MYO1D	-0.43	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.6	7.07	0.5	5.13e-11	Monocyte count;
PAAD	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.66	-6.19	-0.45	5.29e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6987853	0.602	rs2974337	chr8:42390873	C/T	cg09913449	chr8:42400586	C8orf40	0.51	5.78	0.42	4.03e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg05110241	chr16:68378359	PRMT7	-0.83	-6.83	-0.48	1.94e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.44	0.4	2.06e-7	Ileal carcinoids;
PAAD	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.69	7.44	0.52	7.08e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-6.93	-0.49	1.15e-10	Menarche (age at onset);
PAAD	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17652741	chr4:13629432	BOD1L	-0.6	-6.99	-0.49	8.1e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6445967	1.000	rs62259324	chr3:58291107	T/C	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06850241	chr22:41845214	NA	0.56	5.1	0.38	9.91e-7	Vitiligo;
PAAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg03161606	chr19:29218774	NA	0.59	4.73	0.36	5.07e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.92	8.99	0.59	8.88e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9646944	0.501	rs3213733	chr2:102997884	C/A	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg19630374	chr17:18023558	MYO15A	0.47	4.86	0.37	2.86e-6	Total body bone mineral density;
PAAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs3112530	1.000	rs308270	chr5:152686944	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg08079166	chr15:68083412	MAP2K5	-0.5	-5.06	-0.38	1.2e-6	Restless legs syndrome;
PAAD	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.35	0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg19486271	chr11:47235900	DDB2	-0.59	-5.84	-0.43	3.01e-8	Acne (severe);
PAAD	cis	rs2221894	1.000	rs7842492	chr8:28869637	C/T	cg20212339	chr8:28908912	HMBOX1	0.49	5.11	0.38	9.56e-7	Obesity-related traits;
PAAD	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.28	10.39	0.64	1.9e-19	Uric acid levels;
PAAD	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg05621596	chr22:47072043	GRAMD4	-0.92	-9.6	-0.61	2.34e-17	Urate levels in obese individuals;
PAAD	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg23352942	chr3:46931381	PTH1R	-0.51	-5.37	-0.4	2.91e-7	Birth weight;
PAAD	cis	rs2286503	0.839	rs2240726	chr7:22853135	C/T	cg04907244	chr7:22894795	SNORD93	-0.39	-4.7	-0.36	5.73e-6	Fibrinogen;
PAAD	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg22985122	chr17:73566478	LLGL2	0.76	4.55	0.35	1.08e-5	Psoriasis;
PAAD	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.86	-0.54	6.68e-13	Colorectal cancer;
PAAD	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.82	6.68	0.48	4.29e-10	Gastritis;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg21496419	chr19:44306685	LYPD5	-0.34	-4.31	-0.33	2.98e-5	Breast cancer;
PAAD	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27579618	chr16:11836828	TXNDC11	0.66	6.76	0.48	2.74e-10	Obesity-related traits;
PAAD	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.37	0.33	2.33e-5	Height;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg14092988	chr3:52407081	DNAH1	0.38	4.77	0.36	4.25e-6	Electroencephalogram traits;
PAAD	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.36	0.56	3.77e-14	Bipolar disorder;
PAAD	trans	rs1326986	0.702	rs71497289	chr10:20020143	A/C	cg04724540	chr1:166916762	ILDR2	-0.94	-6.31	-0.46	2.92e-9	Ankylosing spondylitis;
PAAD	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-1.13	-11.69	-0.69	6.32e-23	Platelet distribution width;
PAAD	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs11264799	0.539	rs849825	chr1:157546762	C/T	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs76917914	0.820	rs6478539	chr9:100818720	C/T	cg21225548	chr9:100864335	TRIM14	-0.56	-5.95	-0.43	1.82e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6735179	0.688	rs2382563	chr2:1763599	T/C	cg06599209	chr2:1746509	PXDN	0.25	4.34	0.33	2.54e-5	Response to antipsychotic treatment;
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg05082376	chr22:42548792	NA	-0.46	-4.84	-0.37	3.19e-6	Cognitive function;
PAAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.25	0.51	2.02e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs62025270	0.593	rs7166540	chr15:86244085	A/G	cg13263323	chr15:86062960	AKAP13	0.52	4.63	0.35	7.66e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg10495392	chr1:46806563	NSUN4	0.59	5.82	0.43	3.4e-8	Menopause (age at onset);
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.58	-7.19	-0.5	2.75e-11	Lung cancer;
PAAD	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.1e-9	Morning vs. evening chronotype;
PAAD	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg27490568	chr2:178487706	NA	0.44	4.91	0.37	2.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3112530	0.818	rs2973152	chr5:152657105	T/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.92	5.07	0.38	1.13e-6	Aging (time to event);
PAAD	cis	rs12620999	0.774	rs7584900	chr2:237957112	T/G	cg23555395	chr2:238036564	NA	0.45	5.08	0.38	1.07e-6	Systemic lupus erythematosus;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03909902	chr12:108154529	PRDM4	-0.59	-6.86	-0.49	1.64e-10	Body fat percentage;
PAAD	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.57	-6.11	-0.44	7.93e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	7.84	0.54	7.14e-13	LDL cholesterol;
PAAD	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg13446199	chr8:143762866	PSCA	0.37	4.41	0.34	1.94e-5	Urinary tract infection frequency;
PAAD	cis	rs11159086	1.000	rs3759745	chr14:74962670	C/T	cg10195687	chr14:74926396	NA	-0.45	-4.9	-0.37	2.47e-6	Advanced glycation end-product levels;
PAAD	cis	rs10792830	0.706	rs2508690	chr11:85672522	T/C	cg07180834	chr11:85838833	NA	-0.46	-5.19	-0.39	6.78e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.64	-6.91	-0.49	1.22e-10	Facial morphology (factor 20);
PAAD	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg16341495	chr8:142228727	SLC45A4	-0.52	-4.92	-0.37	2.19e-6	Immature fraction of reticulocytes;
PAAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.48	-0.34	1.43e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.37	0.46	2.19e-9	Mean platelet volume;
PAAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg15556689	chr8:8085844	FLJ10661	-0.78	-7.43	-0.52	7.37e-12	Triglycerides;
PAAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg23033748	chr14:75592666	NEK9	0.41	4.91	0.37	2.35e-6	Height;
PAAD	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.72	-7.09	-0.5	4.6e-11	Plateletcrit;Platelet count;
PAAD	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg01191920	chr7:158217561	PTPRN2	-0.78	-7.71	-0.53	1.56e-12	Obesity-related traits;
PAAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01200585	chr1:228362443	C1orf69	-0.49	-5.54	-0.41	1.31e-7	Diastolic blood pressure;
PAAD	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.84	8.84	0.58	2.21e-15	Cognitive function;
PAAD	cis	rs2662368	0.542	rs254373	chr5:77102168	C/T	cg02570643	chr5:77531473	AP3B1	-0.42	-4.53	-0.34	1.18e-5	Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg11062466	chr8:58055876	NA	0.71	4.81	0.36	3.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21182454	chr2:112656262	MERTK	0.7	6.41	0.46	1.72e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.8e-9	Diastolic blood pressure;
PAAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	10.8	0.66	1.56e-20	Platelet count;
PAAD	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.49	-5.43	-0.4	2.18e-7	Coronary artery disease;
PAAD	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.77	-6.79	-0.48	2.42e-10	Vitiligo;
PAAD	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.68	-5.84	-0.43	3.1e-8	Serum sulfate level;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07332563	chr6:291687	DUSP22	-0.78	-8.39	-0.56	3.19e-14	Menopause (age at onset);
PAAD	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.65	6.36	0.46	2.28e-9	Type 2 diabetes;
PAAD	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1997066	0.831	rs73340274	chr10:106808562	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs4908768	0.629	rs12410886	chr1:8878809	A/C	cg00590817	chr1:8272081	NA	-0.36	-4.32	-0.33	2.8e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-1.04	-8.31	-0.56	4.83e-14	Blood protein levels;
PAAD	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-9.84	-0.62	5.63e-18	Height;
PAAD	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.79	-6.7	-0.48	3.8e-10	Type 2 diabetes;
PAAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12599982	chr1:44399894	ARTN	0.47	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg16506815	chr2:162101123	NA	0.52	5.2	0.39	6.44e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs8084125	1.000	rs62105170	chr18:74945570	A/G	cg15443732	chr18:74961078	GALR1	0.72	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg06917634	chr15:78832804	PSMA4	-0.72	-7.68	-0.53	1.85e-12	Sudden cardiac arrest;
PAAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg06028605	chr16:24865363	SLC5A11	0.48	5.82	0.43	3.42e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Height;
PAAD	cis	rs7260598	0.539	rs76305873	chr19:24069953	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.47	-4.34	-0.33	2.57e-5	Uric acid levels;
PAAD	cis	rs7577696	0.752	rs12995952	chr2:32373298	C/T	cg02381751	chr2:32503542	YIPF4	-0.46	-4.51	-0.34	1.31e-5	Inflammatory biomarkers;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.56	-7.09	-0.5	4.79e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.53e-6	Menarche (age at onset);
PAAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg10736770	chr19:49115456	FAM83E	-0.59	-4.52	-0.34	1.24e-5	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.73	7.9	0.54	5.2e-13	Melanoma;
PAAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg18892244	chr7:807596	HEATR2	-0.7	-5.28	-0.39	4.34e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08677398	chr8:58056175	NA	0.68	4.76	0.36	4.45e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg03037974	chr15:76606532	NA	0.56	6.65	0.47	4.93e-10	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.87	5.55	0.41	1.23e-7	Diabetic kidney disease;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg20849893	chr7:64541193	NA	-0.5	-4.91	-0.37	2.28e-6	Calcium levels;
PAAD	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-1.1	-9.09	-0.59	4.96e-16	Vitiligo;
PAAD	cis	rs12935418	0.672	rs9888895	chr16:81051101	C/T	cg16651780	chr16:81037892	C16orf61	0.69	6.4	0.46	1.83e-9	Mean corpuscular volume;
PAAD	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg23024343	chr7:107201750	COG5	0.55	4.4	0.34	2.05e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24647363	chr6:143857972	NA	0.57	6.49	0.47	1.17e-9	Myopia (pathological);
PAAD	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.46	5.09	0.38	1.04e-6	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.84	10.47	0.65	1.15e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26926768	chr12:34528122	NA	0.37	4.32	0.33	2.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.62	5.75	0.42	4.72e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.95	-0.37	1.94e-6	Bone mineral density;
PAAD	cis	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.59	-0.41	1.01e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.62	-6.49	-0.47	1.17e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.74	-0.36	4.78e-6	Joint mobility (Beighton score);
PAAD	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.54	6.25	0.45	3.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6142102	0.625	rs6141431	chr20:32540314	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.34	1.49e-5	Skin pigmentation;
PAAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg27478167	chr7:817139	HEATR2	-0.6	-4.74	-0.36	4.85e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg04877966	chr15:75135169	ULK3	0.55	4.65	0.35	7.07e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs12432203	1.000	rs72622445	chr14:51749407	G/A	cg23942311	chr14:51606299	NA	-0.79	-5.11	-0.38	9.53e-7	Cancer;
PAAD	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.45	7.14	0.5	3.62e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1012068	0.686	rs5753818	chr22:32313933	A/G	cg01338084	chr22:32026380	PISD	-0.56	-4.99	-0.38	1.63e-6	Chronic hepatitis C infection;
PAAD	cis	rs2315504	0.509	rs3760335	chr17:39026061	T/A	cg05063374	chr17:38953512	KRT28	-0.41	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg08835956	chr7:39171034	POU6F2	0.32	5.58	0.41	1.07e-7	IgG glycosylation;
PAAD	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg00945666	chr1:160990265	F11R	-0.39	-4.53	-0.34	1.21e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg07159951	chr1:45983175	PRDX1	0.45	4.87	0.37	2.78e-6	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00292662	chr22:38071168	LGALS1	0.52	5.49	0.41	1.66e-7	Fat distribution (HIV);
PAAD	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg26528668	chr16:1614120	IFT140	0.55	5.15	0.39	7.84e-7	Coronary artery disease;
PAAD	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.68	-6.66	-0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg18451016	chr1:38461880	NA	-0.49	-5.28	-0.39	4.48e-7	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18714712	chr19:49866917	DKKL1;TEAD2	0.59	6.83	0.48	1.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	5.07	0.38	1.12e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.3	-5.33	-0.4	3.43e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	11.26	0.67	9.25e-22	Menopause (age at onset);
PAAD	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08109568	chr15:31115862	NA	-0.7	-7.92	-0.54	4.68e-13	Huntington's disease progression;
PAAD	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.54	5.62	0.41	8.92e-8	Subjective well-being;
PAAD	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07057042	chr3:19988680	RAB5A	-0.67	-6.77	-0.48	2.68e-10	Smoking initiation;
PAAD	cis	rs1562242	0.510	rs151913	chr5:57607955	A/G	cg25655489	chr5:57484208	NA	0.31	4.36	0.33	2.43e-5	Educational attainment (years of education);
PAAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.2	0.39	6.46e-7	Rheumatoid arthritis;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.52	6.96	0.49	9.77e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08677398	chr8:58056175	NA	0.65	5.13	0.38	8.84e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8077577	0.747	rs16961153	chr17:18227101	A/G	cg16794390	chr17:18148240	FLII	-0.51	-4.45	-0.34	1.64e-5	Obesity-related traits;
PAAD	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.54	-5.86	-0.43	2.76e-8	Body mass index;
PAAD	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.93	8.32	0.56	4.57e-14	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg26071806	chr7:100318239	EPO	-0.46	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.44	-0.34	1.7e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.95	14.02	0.75	3.41e-29	Intelligence (multi-trait analysis);
PAAD	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.62	-6.55	-0.47	8.35e-10	Schizophrenia;
PAAD	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.38	0.4	2.78e-7	Lung cancer in ever smokers;
PAAD	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs2158799	0.602	rs177462	chr7:28300699	A/G	cg21004899	chr7:28452131	CREB5	-0.45	-4.42	-0.34	1.83e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Neutrophil count;White blood cell count;Granulocyte count;Sum basophil neutrophil counts;Lymphocyte percentage of white cells;Myeloid white cell count;Sum neutrophil eosinophil counts;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.43	-4.27	-0.33	3.42e-5	Ulcerative colitis;
PAAD	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-5.16	-0.39	7.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.51	-5.06	-0.38	1.2e-6	Mean platelet volume;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg19673125	chr6:150240577	RAET1G	0.4	5.62	0.41	8.99e-8	Testicular germ cell tumor;
PAAD	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	4.68	0.36	6.22e-6	Height;
PAAD	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08496503	chr17:8286586	RPL26	0.56	6.52	0.47	9.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs943466	0.956	rs1075379	chr6:33737800	T/C	cg04704449	chr6:33738291	NA	-0.46	-4.82	-0.36	3.43e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14119001	chr9:139324193	INPP5E	-0.65	-5.84	-0.43	3.03e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg15770106	chr1:208133116	NA	-0.65	-6.52	-0.47	9.79e-10	Corneal structure;
PAAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21016266	chr12:122356598	WDR66	0.67	7.3	0.51	1.51e-11	Mean corpuscular volume;
PAAD	cis	rs2880058	0.958	rs10918588	chr1:162029053	G/C	cg23260004	chr1:161736072	ATF6	-0.5	-4.46	-0.34	1.6e-5	QT interval;
PAAD	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18029407	chr2:138781947	NA	0.67	7.13	0.5	3.87e-11	Smoking initiation;
PAAD	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg26597838	chr10:835615	NA	0.46	4.94	0.37	2.05e-6	Survival in rectal cancer;
PAAD	cis	rs6785206	0.614	rs35962268	chr3:128465270	C/T	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.48	5.26	0.39	4.87e-7	Life satisfaction;
PAAD	cis	rs4795519	0.922	rs4889749	chr17:22184866	C/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg25382128	chr12:54346509	NA	-0.47	-4.79	-0.36	4.01e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18621852	chr3:10150065	C3orf24	0.63	5.29	0.39	4.24e-7	Alzheimer's disease;
PAAD	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	5.55	0.41	1.24e-7	Multiple sclerosis;
PAAD	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg00012203	chr2:219082015	ARPC2	0.59	5.63	0.42	8.67e-8	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.77	8.05	0.55	2.22e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.88	9.96	0.63	2.62e-18	Prudent dietary pattern;
PAAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg27490568	chr2:178487706	NA	0.45	4.62	0.35	8.23e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.7	4.54	0.35	1.13e-5	Glycated hemoglobin levels;
PAAD	trans	rs567508	0.539	rs600281	chr11:126014290	C/G	cg08415973	chr6:40346114	TDRG1	-0.72	-6.51	-0.47	1.05e-9	Lung function (FEV1);
PAAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg24253500	chr15:84953950	NA	0.55	6.52	0.47	9.64e-10	Schizophrenia;
PAAD	cis	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg20893579	chr22:38215064	NA	-0.43	-4.49	-0.34	1.38e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11723261	0.582	rs11733927	chr4:166828	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.27	0.39	4.65e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg15145965	chr22:50218605	BRD1	-0.61	-5.3	-0.4	3.98e-7	Schizophrenia;
PAAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.49	4.61	0.35	8.35e-6	Monocyte count;
PAAD	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.51	-4.33	-0.33	2.73e-5	Neuroticism;
PAAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg26174226	chr8:58114915	NA	-0.69	-6.17	-0.45	6.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17095355	1.000	rs6584962	chr10:111689904	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.34	-0.33	2.56e-5	Biliary atresia;
PAAD	cis	rs2250402	0.510	rs937215	chr15:40330693	C/T	cg10636054	chr15:40330586	SRP14	1.2	7.07	0.5	5.32e-11	Corneal curvature;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01334186	chr1:151372572	PSMB4	0.65	7.58	0.52	3.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs7165102	1.000	rs4366668	chr15:65903398	G/A	cg22900193	chr15:65823441	PTPLAD1	0.46	4.38	0.33	2.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.44	-5.99	-0.44	1.49e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.82	-0.48	2.02e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs8005677	0.798	rs35615180	chr14:23404389	T/C	cg01529538	chr14:23388837	RBM23	0.48	4.79	0.36	3.86e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg05373962	chr22:49881684	NA	-0.46	-4.4	-0.34	2.02e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg07810366	chr2:100720526	AFF3	-0.37	-4.71	-0.36	5.56e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.3	-0.51	1.54e-11	Response to antipsychotic treatment;
PAAD	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.49	5.11	0.38	9.63e-7	Body mass index;
PAAD	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.51	-0.47	1.02e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.77	8.08	0.55	1.81e-13	Schizophrenia;
PAAD	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.5	-4.34	-0.33	2.57e-5	Acne (severe);
PAAD	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	5.26	0.39	4.76e-7	Multiple sclerosis;
PAAD	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg10168330	chr8:27262164	PTK2B	0.36	4.31	0.33	2.91e-5	Neuroticism;
PAAD	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.93	8.04	0.55	2.3e-13	IgG glycosylation;
PAAD	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg18323236	chr1:24743029	NIPAL3	0.41	4.28	0.33	3.31e-5	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg03999872	chr20:62272968	STMN3	-0.76	-7.08	-0.5	4.94e-11	Atopic dermatitis;
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.37	9.8	0.62	7.1e-18	Prostate cancer;
PAAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.51	-5.17	-0.39	7.27e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10958369	1.000	rs10958369	chr8:54410208	G/A	cg12485204	chr8:54507357	NA	0.43	4.33	0.33	2.68e-5	Response to antineoplastic agents;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.95	-9.91	-0.63	3.67e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.89	0.43	2.39e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.57	5.77	0.42	4.29e-8	Ovarian reserve;
PAAD	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.44	-4.92	-0.37	2.23e-6	Mean arterial pressure;
PAAD	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.09	7.55	0.52	3.8e-12	Thyroid stimulating hormone;
PAAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.88	11.23	0.67	1.13e-21	Aortic root size;
PAAD	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg05082376	chr22:42548792	NA	-0.43	-4.28	-0.33	3.36e-5	Cognitive function;
PAAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg20243544	chr17:37824526	PNMT	0.52	4.56	0.35	1.06e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.86	-0.49	1.61e-10	Neuroticism;
PAAD	cis	rs758324	0.812	rs11750031	chr5:131171251	G/A	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.32	0.33	2.76e-5	Educational attainment (years of education);
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg05861140	chr6:150128134	PCMT1	-0.54	-5.88	-0.43	2.56e-8	Lung cancer;
PAAD	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.36	-0.33	2.37e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	1.0	6.07	0.44	9.79e-9	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1997066	0.831	rs76196555	chr10:106818359	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.39	0.56	3.15e-14	Lung cancer;
PAAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06656553	chr16:89960601	TCF25	-0.86	-4.78	-0.36	4.18e-6	Skin colour saturation;
PAAD	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.48	-0.47	1.22e-9	Leprosy;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.15	0.55	1.24e-13	Prudent dietary pattern;
PAAD	cis	rs6065	0.618	rs16954342	chr17:4907103	G/A	cg02990439	chr17:4875527	CAMTA2	-0.96	-4.73	-0.36	5e-6	Platelet count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22995486	chr5:75592299	SV2C	0.6	6.57	0.47	7.42e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17559213	chr10:80827237	LOC283050	-0.81	-7.25	-0.51	2e-11	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13520011	chr3:65339606	NA	-0.53	-6.42	-0.46	1.62e-9	Monocyte percentage of white cells;
PAAD	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09294077	chr14:66975599	GPHN	0.59	6.35	0.46	2.34e-9	Myopia (pathological);
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.54	-5.41	-0.4	2.43e-7	Parkinson's disease;
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1539053	0.966	rs1524707	chr1:58102540	A/G	cg20292791	chr1:58089357	DAB1	0.5	4.94	0.37	2.05e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.12	0.38	9.02e-7	Multiple sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24083817	chr19:49217255	MAMSTR	0.62	6.51	0.47	1.04e-9	Myopia (pathological);
PAAD	cis	rs2229238	0.868	rs72999422	chr1:154514942	G/A	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.29e-6	Coronary heart disease;
PAAD	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.43	4.48	0.34	1.44e-5	Breast cancer;
PAAD	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.74	-0.36	4.95e-6	Asthma;
PAAD	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.76	-5.12	-0.38	9.26e-7	Carotid intima media thickness;
PAAD	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.77	4.89	0.37	2.56e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9657904	0.813	rs7651784	chr3:105554580	A/C	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg05731713	chr7:157510257	PTPRN2	0.52	4.93	0.37	2.16e-6	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05843339	chr6:143268816	NA	0.78	8.48	0.57	1.84e-14	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs9463078	0.585	rs6905396	chr6:45169165	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg19486271	chr11:47235900	DDB2	-0.6	-6.06	-0.44	1.02e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.62	6.22	0.45	4.51e-9	Testicular germ cell tumor;
PAAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.33	-0.33	2.68e-5	Height;
PAAD	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	1.16	6.23	0.45	4.38e-9	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.23	0.39	5.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13198984	chr17:80129470	CCDC57	0.42	5.27	0.39	4.65e-7	Life satisfaction;
PAAD	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg21890820	chr11:65308645	LTBP3	0.71	8.75	0.58	3.89e-15	Bone mineral density;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg04160749	chr8:58172571	NA	-0.58	-4.3	-0.33	3.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.52	4.52	0.34	1.23e-5	IgG glycosylation;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg00118712	chr10:131686819	EBF3	-0.51	-4.97	-0.37	1.75e-6	Vitamin D levels;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg22764044	chr5:178986830	RUFY1	0.52	5.22	0.39	5.89e-7	Lung cancer;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05935833	chr10:81318306	SFTPA2	-0.4	-4.67	-0.35	6.55e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.24	12.59	0.71	2.37e-25	Post bronchodilator FEV1;
PAAD	cis	rs682748	0.846	rs7704060	chr5:17124559	C/T	cg23987134	chr5:17158319	LOC285696	-0.37	-4.6	-0.35	8.87e-6	Hippocampal atrophy;
PAAD	cis	rs3743832	0.965	rs7189960	chr16:9222607	T/C	cg08831531	chr16:9218945	NA	-0.43	-4.57	-0.35	9.83e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg18939081	chr1:31884902	SERINC2	0.5	5.71	0.42	5.66e-8	Alcohol dependence;
PAAD	cis	rs10450586	0.932	rs7480595	chr11:27316623	T/C	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.9	-11.83	-0.69	2.69e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg14926445	chr8:58193284	C8orf71	-0.65	-5.17	-0.39	7.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.74	10.39	0.64	1.87e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg24250549	chr1:154909240	PMVK	0.5	4.89	0.37	2.53e-6	Schizophrenia;
PAAD	cis	rs308971	0.656	rs307582	chr3:12085149	T/C	cg15873301	chr3:12045459	SYN2	0.65	5.42	0.4	2.25e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.64	6.88	0.49	1.5e-10	N-glycan levels;
PAAD	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.83	7.3	0.51	1.51e-11	Vitiligo;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg05434287	chr7:2030229	MAD1L1	0.41	4.48	0.34	1.46e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.79	9.0	0.59	8.39e-16	Lung cancer;
PAAD	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.99	-0.38	1.61e-6	Personality dimensions;
PAAD	cis	rs1823874	0.720	rs7162911	chr15:100355050	A/G	cg16400843	chr15:100339927	C15orf51	0.41	5.19	0.39	6.49e-7	IgG glycosylation;
PAAD	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.73	-0.58	4.31e-15	Exhaled nitric oxide output;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg22868518	chr11:507468	RNH1	-0.97	-4.98	-0.37	1.73e-6	Body mass index;
PAAD	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.8	8.15	0.55	1.25e-13	Coronary artery disease;
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg05132306	chr1:1846340	CALML6	-0.43	-5.08	-0.38	1.09e-6	Body mass index;
PAAD	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg19217778	chr13:113420270	ATP11A	0.65	4.6	0.35	8.69e-6	Glycated hemoglobin levels;
PAAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.88	10.85	0.66	1.12e-20	Methadone dose in opioid dependence;
PAAD	cis	rs13102973	0.797	rs4453983	chr4:135905424	A/C	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14862378	chr10:81965171	ANXA11	-0.48	-4.8	-0.36	3.79e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.78	8.17	0.55	1.09e-13	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16819604	chr20:47836038	DDX27	0.67	6.51	0.47	1.03e-9	Obesity-related traits;
PAAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.44	-4.36	-0.33	2.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7624766	0.594	rs12494732	chr3:160578374	C/T	cg22637730	chr3:160473554	PPM1L	0.54	4.67	0.35	6.57e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-1.29	-7.91	-0.54	5.02e-13	Skin colour saturation;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs72627123	1.000	rs58204112	chr14:74359417	G/C	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	4.67	0.35	6.63e-6	Height;
PAAD	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	4.18e-17	IgG glycosylation;
PAAD	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.62	6.16	0.45	6.08e-9	Schizophrenia;
PAAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	5.09	0.38	1.05e-6	Joint mobility (Beighton score);
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg26071806	chr7:100318239	EPO	-0.51	-4.94	-0.37	1.99e-6	Other erythrocyte phenotypes;
PAAD	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.58	6.52	0.47	9.77e-10	Platelet distribution width;
PAAD	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9430161	0.611	rs12565727	chr1:11033082	A/G	cg02454025	chr1:11042201	C1orf127	1.25	15.45	0.78	5.6e-33	Ewing sarcoma;
PAAD	cis	rs1190596	0.830	rs61992489	chr14:102553167	T/G	cg23289024	chr14:102554846	HSP90AA1	-0.45	-4.87	-0.37	2.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26926768	chr12:34528122	NA	0.39	4.66	0.35	6.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs16975963	0.644	rs7248397	chr19:38133211	A/G	cg14218481	chr19:38281219	NA	0.42	4.53	0.35	1.17e-5	Longevity;
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-6.4	-0.46	1.79e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.86	5.38	0.4	2.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs617219	0.671	rs13165414	chr5:78548873	C/T	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.54	6.14	0.45	6.95e-9	Platelet distribution width;
PAAD	cis	rs797680	0.927	rs1000607	chr1:93772001	T/C	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg14416269	chr4:6271139	WFS1	0.68	6.46	0.46	1.37e-9	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg03098721	chr1:84464084	TTLL7	0.47	4.56	0.35	1.06e-5	Obesity-related traits;
PAAD	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.76	-0.42	4.58e-8	Neuroticism;
PAAD	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg18240062	chr17:79603768	NPLOC4	0.65	7.08	0.5	5.03e-11	Eye color traits;
PAAD	cis	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.46	0.34	1.57e-5	Personality dimensions;
PAAD	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	-0.5	-4.53	-0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg03213289	chr20:61660250	NA	-0.51	-7.01	-0.49	7.27e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs600626	0.588	rs11236526	chr11:75467605	G/A	cg24262691	chr11:75473276	NA	0.74	6.18	0.45	5.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs5771040	0.560	rs5771044	chr22:50907855	C/T	cg03450049	chr22:50913555	SBF1	0.6	5.29	0.39	4.17e-7	IgG glycosylation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16260274	chr17:35849812	DUSP14	-0.66	-6.9	-0.49	1.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg00981651	chr20:44574847	PCIF1	0.43	4.68	0.35	6.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.84	9.23	0.6	2.15e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.62	5.82	0.43	3.45e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2662368	0.542	rs1949026	chr5:77114598	A/G	cg02570643	chr5:77531473	AP3B1	-0.41	-4.48	-0.34	1.48e-5	Platelet distribution width;
PAAD	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-1.35	-12.6	-0.71	2.22e-25	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.38	-0.33	2.23e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00934597	chr7:893267	UNC84A	-0.46	-4.61	-0.35	8.45e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg03959625	chr15:84868606	LOC388152	0.44	4.84	0.37	3.13e-6	Schizophrenia;
PAAD	cis	rs4953318	0.796	rs10168349	chr2:46360907	G/C	cg12428440	chr2:46370979	PRKCE	0.41	4.27	0.33	3.36e-5	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.73	7.04	0.5	6.24e-11	Blood protein levels;
PAAD	cis	rs27434	0.583	rs34760	chr5:96153491	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.53	-0.41	1.38e-7	Ankylosing spondylitis;
PAAD	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.69	7.06	0.5	5.52e-11	Glycated hemoglobin levels;
PAAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03885332	chr11:832357	CD151	-0.46	-5.37	-0.4	2.91e-7	Mean platelet volume;
PAAD	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.14e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.46	5.82	0.43	3.33e-8	Prostate cancer;
PAAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.57	5.3	0.39	4.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.79	-0.42	3.94e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.35	0.56	3.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9395066	0.545	rs35813980	chr6:44956008	C/T	cg25276700	chr6:44698697	NA	0.49	5.67	0.42	6.94e-8	Height;
PAAD	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.64e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2274459	0.841	rs13214874	chr6:33686368	G/A	cg06253072	chr6:33679850	C6orf125	0.64	4.87	0.37	2.82e-6	Obesity (extreme);
PAAD	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.58	-0.35	9.66e-6	Fibrinogen levels;
PAAD	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.93	0.66	7e-21	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.8	5.81	0.43	3.54e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.45	5.11	0.38	9.58e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs494459	0.733	rs556437	chr11:118705753	G/A	cg08498647	chr11:118550644	TREH	-0.35	-4.28	-0.33	3.3e-5	Height;
PAAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.42	-0.34	1.85e-5	Type 2 diabetes;
PAAD	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg26893134	chr6:116381904	FRK	-0.31	-4.44	-0.34	1.73e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1692580	0.807	rs260508	chr1:2187085	T/G	cg21194808	chr1:2205498	SKI	0.44	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	1.01	6.28	0.45	3.46e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.9	0.43	2.26e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg14703610	chr5:56206110	C5orf35	0.6	5.46	0.4	1.92e-7	Coronary artery disease;
PAAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg23587288	chr2:27483067	SLC30A3	-0.82	-7.13	-0.5	3.84e-11	Blood metabolite levels;
PAAD	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg25811867	chr2:3488468	NA	-0.46	-4.3	-0.33	3.1e-5	Neurofibrillary tangles;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.39	-0.34	2.13e-5	Caffeine consumption;
PAAD	cis	rs2290405	0.591	rs7687129	chr4:939883	T/C	cg04045327	chr4:905805	GAK	-0.4	-5.19	-0.39	6.65e-7	Systemic sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13432616	chr6:116575314	TSPYL4	0.57	6.56	0.47	7.77e-10	Obesity-related traits;
PAAD	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.56	-4.94	-0.37	2.03e-6	P wave terminal force;
PAAD	cis	rs6604026	0.656	rs949915	chr1:93369774	A/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.93	-9.82	-0.62	6.35e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.55	6.23	0.45	4.37e-9	Tumor biomarkers;
PAAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.34	0.68	5.6e-22	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21851282	chr13:106751175	NA	0.62	6.72	0.48	3.41e-10	Smoking initiation;
PAAD	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.57	4.97	0.37	1.77e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs76878669	0.917	rs10444359	chr11:66102807	G/A	cg10685839	chr11:66611485	RCE1	0.45	4.27	0.33	3.42e-5	Educational attainment (years of education);
PAAD	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.51	-5.43	-0.4	2.16e-7	Motion sickness;
PAAD	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.79	9.11	0.59	4.36e-16	Heart rate;
PAAD	cis	rs7127900	0.583	rs71455921	chr11:2233635	A/C	cg25635251	chr11:2234043	NA	0.8	7.68	0.53	1.81e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.37	0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19294125	chr20:25604737	NANP	-0.88	-7.71	-0.53	1.54e-12	Neuroticism;
PAAD	cis	rs35084382	1.000	rs17658229	chr5:172191052	T/C	cg09799633	chr5:172199460	DUSP1	-0.95	-4.34	-0.33	2.56e-5	Optic cup area;
PAAD	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.88	-9.86	-0.62	4.83e-18	Cognitive function;
PAAD	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg01631408	chr1:248437212	OR2T33	0.59	5.16	0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-4.84	-0.37	3.17e-6	Monocyte percentage of white cells;
PAAD	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	6.51	0.47	1.03e-9	Mean platelet volume;
PAAD	cis	rs134594	0.885	rs713861	chr22:29485794	A/G	cg25916307	chr22:29467684	KREMEN1	0.43	4.25	0.33	3.77e-5	Birth weight;
PAAD	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg20487152	chr13:99095054	FARP1	0.47	5.04	0.38	1.28e-6	Longevity;
PAAD	cis	rs939584	0.866	rs5017304	chr2:630903	A/G	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.61	-0.41	9.15e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg24879335	chr3:133465180	TF	0.55	5.92	0.43	2.08e-8	Iron status biomarkers;
PAAD	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.89	-7.25	-0.51	1.95e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.39	-4.36	-0.33	2.38e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.9	0.37	2.44e-6	Obesity-related traits;
PAAD	cis	rs12136530	0.550	rs10753560	chr1:19708577	T/C	cg25104613	chr1:20649108	VWA5B1	0.45	5.02	0.38	1.44e-6	Lead levels in blood;
PAAD	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg25838818	chr2:108905173	SULT1C2	0.51	5.19	0.39	6.49e-7	Blood pressure;
PAAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.36	0.6	1e-16	Parkinson's disease;
PAAD	cis	rs10214930	0.697	rs13308974	chr7:27652338	G/A	cg22168087	chr7:27702803	HIBADH	0.48	4.5	0.34	1.37e-5	Hypospadias;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11240594	0.512	rs3811427	chr1:205892411	T/C	cg12458003	chr1:204960826	NFASC	0.72	4.31	0.33	2.88e-5	Response to antipsychotic treatment;
PAAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.77	4.95	0.37	1.98e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs10159528	0.691	rs7914829	chr10:87469048	A/G	cg03356747	chr10:88126089	GRID1	0.41	4.82	0.36	3.47e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15358743	chr18:56807035	SEC11C	0.6	6.45	0.46	1.41e-9	Response to antipsychotic treatment;
PAAD	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg09796270	chr17:17721594	SREBF1	-0.51	-5.53	-0.41	1.38e-7	Lymphocyte counts;
PAAD	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.51	-5.44	-0.4	2.11e-7	Dementia with Lewy bodies;
PAAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs6743376	0.554	rs11123160	chr2:113836165	A/T	cg24553058	chr2:113831203	IL1F10	0.53	5.3	0.39	4.07e-7	Inflammatory biomarkers;
PAAD	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.28	0.45	3.3e-9	Skin colour saturation;
PAAD	cis	rs630539	1.000	rs629286	chr17:40679159	T/C	cg20669292	chr17:40823420	PLEKHH3	-0.48	-4.49	-0.34	1.38e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.44	-4.79	-0.36	4.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.75	8.74	0.58	3.98e-15	Lewy body disease;
PAAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-1.06	-15.21	-0.78	2.45e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg19847866	chr10:1019161	NA	-0.54	-4.36	-0.33	2.38e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.47	-4.32	-0.33	2.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg02887458	chr19:19495540	GATAD2A	0.51	4.85	0.37	3.06e-6	Bipolar disorder;
PAAD	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.81	-9.12	-0.59	4.26e-16	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18141365	chr7:33169015	BBS9	-0.64	-6.68	-0.48	4.33e-10	Smoking initiation;
PAAD	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg21466736	chr12:48725269	NA	-0.5	-4.65	-0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.61	0.65	4.86e-20	Platelet count;
PAAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.41	0.4	2.4e-7	Lung cancer in ever smokers;
PAAD	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.44	7.05	0.5	5.88e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22633769	chr20:60982531	CABLES2	0.51	4.64	0.35	7.37e-6	Colorectal cancer;
PAAD	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg15193198	chr20:60906057	LAMA5	-0.46	-5.2	-0.39	6.29e-7	Colorectal cancer;
PAAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.48	6.36	0.46	2.2e-9	Ulcerative colitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06469570	chr4:8376908	ACOX3	0.55	6.67	0.48	4.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.61	5.91	0.43	2.18e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg05554000	chr7:158905015	VIPR2	0.5	4.42	0.34	1.89e-5	Facial morphology (factor 20);
PAAD	cis	rs4305276	0.964	rs7593034	chr2:241466020	G/C	cg07929629	chr2:241523174	NA	-0.47	-4.4	-0.34	2.04e-5	Mean platelet volume;
PAAD	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.48	-4.44	-0.34	1.75e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs9907295	0.818	rs9303692	chr17:34188496	A/G	cg16983627	chr17:34238386	NA	0.52	4.29	0.33	3.16e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.7	6.02	0.44	1.28e-8	Platelet count;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.38	4.44	0.34	1.73e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg17470449	chr10:769945	NA	0.52	5.16	0.39	7.72e-7	Uric acid levels;
PAAD	cis	rs4740619	0.967	rs10962110	chr9:15658794	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.56	-0.35	1.04e-5	Body mass index;
PAAD	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.59	-5.48	-0.41	1.72e-7	Diisocyanate-induced asthma;
PAAD	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg05925327	chr15:68127851	NA	-0.57	-5.11	-0.38	9.59e-7	Restless legs syndrome;
PAAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg10207240	chr12:122356781	WDR66	0.53	5.63	0.42	8.42e-8	Mean corpuscular volume;
PAAD	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg16964102	chr10:135390573	NA	0.41	4.54	0.35	1.15e-5	Obesity-related traits;
PAAD	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.77	-8.05	-0.55	2.22e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.76	7.18	0.5	2.9e-11	Methadone dose in opioid dependence;
PAAD	cis	rs900145	0.773	rs11022753	chr11:13310854	A/G	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg15443732	chr18:74961078	GALR1	-0.59	-5.5	-0.41	1.59e-7	Obesity-related traits;
PAAD	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.71	-7.99	-0.54	3.17e-13	Airway imaging phenotypes;
PAAD	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.62	-0.47	5.74e-10	Blood pressure (smoking interaction);
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.53	-4.78	-0.36	4.19e-6	DNA methylation (variation);
PAAD	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-8.41	-0.56	2.72e-14	Platelet distribution width;
PAAD	cis	rs9463078	0.547	rs9472362	chr6:44751285	C/A	cg25276700	chr6:44698697	NA	0.45	5.29	0.39	4.25e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	1.0	9.13	0.6	3.97e-16	Triglycerides;
PAAD	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg04545296	chr12:48745243	ZNF641	0.35	4.39	0.34	2.13e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg00383909	chr3:49044727	WDR6	0.86	5.76	0.42	4.45e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.34	0.51	1.18e-11	Eosinophil percentage of white cells;
PAAD	cis	rs1823874	0.581	rs9920347	chr15:100339331	C/T	cg16400843	chr15:100339927	C15orf51	-0.52	-6.33	-0.46	2.61e-9	IgG glycosylation;
PAAD	cis	rs2790216	0.950	rs2790154	chr10:59974788	A/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.16	0.45	6.21e-9	Major depressive disorder;
PAAD	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.84	9.12	0.59	4.29e-16	Corneal astigmatism;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.42	4.27	0.33	3.44e-5	Longevity;Endometriosis;
PAAD	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg17644776	chr2:200775616	C2orf69	-0.69	-5.15	-0.39	8.08e-7	Schizophrenia;
PAAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16447950	chr5:562315	NA	-0.67	-6.02	-0.44	1.26e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.65	6.02	0.44	1.24e-8	Cognitive test performance;
PAAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.79	8.28	0.56	5.88e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.45	4.32	0.33	2.77e-5	Morning vs. evening chronotype;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.44	-5.06	-0.38	1.22e-6	Body mass index;
PAAD	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-10.67	-0.65	3.5e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.95	-16.05	-0.79	1.54e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	12.05	0.7	6.84e-24	Menopause (age at onset);
PAAD	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg26898376	chr11:64110657	CCDC88B	0.44	4.71	0.36	5.46e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.17	0.39	7.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4903031	0.697	rs2239222	chr14:73011885	A/G	cg05236446	chr14:73524740	RBM25	0.49	4.41	0.34	1.92e-5	C-reactive protein levels;
PAAD	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg09127314	chr1:152161683	NA	0.74	5.43	0.4	2.14e-7	Atopic dermatitis;
PAAD	cis	rs6743376	0.556	rs1530551	chr2:113817566	C/T	cg12858261	chr2:113808755	IL1F8	-0.45	-4.42	-0.34	1.88e-5	Inflammatory biomarkers;
PAAD	cis	rs9657904	0.813	rs7647955	chr3:105583046	T/C	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.47	-5.5	-0.41	1.59e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.66	0.57	6.61e-15	Colorectal cancer;
PAAD	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16910805	chr2:62081285	FAM161A	-0.54	-6.4	-0.46	1.84e-9	Body fat percentage;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05043032	chr1:95583073	TMEM56	0.57	6.38	0.46	2.01e-9	Immature fraction of reticulocytes;
PAAD	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.6	6.04	0.44	1.12e-8	Essential tremor;
PAAD	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.56	-4.93	-0.37	2.1e-6	Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7594192	0.606	rs12995024	chr2:199594874	A/G	cg20554277	chr14:37506088	SLC25A21	0.7	6.44	0.46	1.52e-9	Educational attainment;
PAAD	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.17	-0.55	1.14e-13	Exhaled nitric oxide output;
PAAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.98	-14.04	-0.75	2.98e-29	Post bronchodilator FEV1;
PAAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14180030	chr9:123475675	MEGF9	-0.43	-4.75	-0.36	4.66e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg04176122	chr11:118779835	BCL9L	-0.43	-4.46	-0.34	1.57e-5	Sjögren's syndrome;
PAAD	cis	rs78761021	0.860	rs79705409	chr17:9776970	T/C	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.1e-14	Lung cancer;
PAAD	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.6	-6.16	-0.45	6.35e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12304921	1.000	rs4768942	chr12:51355701	C/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.39	-0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.65	-5.41	-0.4	2.38e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2964802	0.505	rs7717266	chr5:10832134	C/G	cg14521931	chr5:10832172	NA	-0.43	-4.55	-0.35	1.07e-5	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.64	-7.03	-0.5	6.63e-11	Caffeine consumption;
PAAD	trans	rs901683	1.000	rs34011467	chr10:46059758	T/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	6.21	0.45	4.95e-9	Systolic blood pressure;
PAAD	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.01	-0.38	1.49e-6	Height;
PAAD	cis	rs883565	0.611	rs4676588	chr3:38940741	C/T	cg01426195	chr3:39028469	NA	0.62	6.1	0.44	8.5e-9	Handedness;
PAAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.73	-7.81	-0.54	8.7e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.19	-0.39	6.51e-7	Mean platelet volume;
PAAD	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.87	4.45	0.34	1.69e-5	Plasma clusterin levels;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg10729496	chr3:10149963	C3orf24	0.88	7.4	0.51	8.76e-12	Alzheimer's disease;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg14389840	chr6:72298704	NA	0.59	6.4	0.46	1.86e-9	Educational attainment (years of education);
PAAD	trans	rs9409082	0.677	rs35717861	chr9:108917581	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.56	-0.47	8.02e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs17655565	0.553	rs17713256	chr12:52724479	C/G	cg22980804	chr12:52818037	KRT75	-0.51	-4.33	-0.33	2.67e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.93	10.87	0.66	1.03e-20	IgG glycosylation;
PAAD	cis	rs6782025	0.711	rs7648360	chr3:120884709	G/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.44	4.28	0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	4.77	0.36	4.37e-6	Dilated cardiomyopathy;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-4.37	-0.33	2.33e-5	Platelet count;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg17178900	chr1:205818956	PM20D1	0.68	5.96	0.44	1.67e-8	Prostate-specific antigen levels;
PAAD	cis	rs58365266	0.727	rs4504190	chr3:195839847	G/A	cg01181863	chr3:195395398	SDHAP2	-0.75	-6.13	-0.45	7.17e-9	Red cell distribution width;
PAAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs74181299	0.684	rs60136636	chr2:65338422	G/A	cg20592124	chr2:65290738	CEP68	-0.46	-4.44	-0.34	1.75e-5	Pulse pressure;
PAAD	cis	rs490234	0.616	rs2841325	chr9:128163620	C/G	cg14078157	chr9:128172775	NA	0.52	6.07	0.44	9.82e-9	Mean arterial pressure;
PAAD	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs7619833	0.542	rs35536598	chr3:27518167	C/A	cg02860705	chr3:27208620	NA	0.45	4.74	0.36	4.93e-6	Breast cancer;
PAAD	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.99	-11.02	-0.67	4.1e-21	Headache;
PAAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.8e-7	Resting heart rate;
PAAD	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg09796270	chr17:17721594	SREBF1	-0.44	-4.84	-0.37	3.13e-6	Total body bone mineral density;
PAAD	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg00922110	chr4:57842668	C4orf14	0.46	4.58	0.35	9.64e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7121446	0.521	rs6589904	chr11:121864885	G/A	cg13820391	chr11:121835505	NA	0.46	4.25	0.33	3.7e-5	Cardiovascular risk factors (age interaction);
PAAD	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.84	-10.34	-0.64	2.56e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg27478167	chr7:817139	HEATR2	0.69	5.28	0.39	4.34e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.49	5.74	0.42	4.96e-8	Coronary artery disease;
PAAD	cis	rs8077577	0.747	rs2071242	chr17:18154510	T/C	cg16794390	chr17:18148240	FLII	0.54	4.69	0.36	5.94e-6	Obesity-related traits;
PAAD	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.86	-0.49	1.67e-10	Morning vs. evening chronotype;
PAAD	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	1.07	8.42	0.56	2.65e-14	Inflammatory bowel disease;
PAAD	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.8	7.61	0.53	2.75e-12	Vitamin D levels;
PAAD	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.57	-5.33	-0.4	3.51e-7	Mean platelet volume;
PAAD	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.31	-4.54	-0.35	1.15e-5	IgG glycosylation;
PAAD	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.41	4.81	0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.76	7.21	0.5	2.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.6	-0.47	6.3e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg21892295	chr12:121157589	UNC119B	-0.41	-4.91	-0.37	2.35e-6	Mean corpuscular volume;
PAAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12222525	chr1:109506178	CLCC1	0.61	7.48	0.52	5.68e-12	Immature fraction of reticulocytes;
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.4e-6	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09972424	chr14:92573067	ATXN3	0.58	6.39	0.46	1.94e-9	Monocyte percentage of white cells;
PAAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.13	-0.45	7.07e-9	Total body bone mineral density;
PAAD	cis	rs4795519	0.736	rs1606914	chr17:22159899	A/G	cg22648282	chr17:21454238	C17orf51	0.48	5.07	0.38	1.16e-6	Chronic myeloid leukemia;
PAAD	cis	rs9913156	0.517	rs9893958	chr17:4611388	A/G	cg00122941	chr17:4613640	ARRB2	0.66	7.02	0.5	6.75e-11	Lymphocyte counts;
PAAD	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg06883089	chr1:45254480	BEST4	0.33	4.26	0.33	3.51e-5	High light scatter reticulocyte count;
PAAD	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs9462027	1.000	rs9462027	chr6:34797241	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-4.71	-0.36	5.44e-6	Systemic lupus erythematosus;
PAAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.11	0.38	9.72e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg24747557	chr10:131355152	MGMT	-0.43	-4.29	-0.33	3.12e-5	Response to temozolomide;
PAAD	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg18898632	chr2:242989856	NA	-0.66	-5.03	-0.38	1.36e-6	Obesity-related traits;
PAAD	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.72	-6.04	-0.44	1.15e-8	Fibrinogen levels;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-7.47	-0.52	5.86e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.71	7.02	0.49	7.07e-11	Morning vs. evening chronotype;
PAAD	cis	rs4979906	1.000	rs11002248	chr10:79446961	A/G	cg07817648	chr10:79422355	NA	-0.55	-4.94	-0.37	2.01e-6	Mortality in heart failure;
PAAD	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.51	4.53	0.35	1.17e-5	Myopia (pathological);
PAAD	cis	rs3736485	0.934	rs4775953	chr15:51873173	G/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.41	-0.34	1.93e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg04829521	chr16:1839114	NUBP2	0.57	5.04	0.38	1.28e-6	Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.5	-4.29	-0.33	3.16e-5	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	1.01	12.54	0.71	3.31e-25	Breast cancer;
PAAD	cis	rs17152411	0.652	rs3845	chr10:126674093	T/C	cg04726013	chr10:126223236	LHPP	-0.32	-4.6	-0.35	8.77e-6	Height;
PAAD	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg21191810	chr6:118973309	C6orf204	0.47	6.05	0.44	1.06e-8	Electrocardiographic conduction measures;
PAAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.56	-6.96	-0.49	9.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.2	-0.5	2.6e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.85	-10.39	-0.64	1.89e-19	Aortic root size;
PAAD	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	4.32	0.33	2.85e-5	Uric acid levels;
PAAD	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.95e-8	HIV-1 control;
PAAD	cis	rs174479	0.743	rs174464	chr11:61657926	A/G	cg06781209	chr11:61594997	FADS2	0.37	4.29	0.33	3.22e-5	Sphingolipid levels;
PAAD	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	trans	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg26939375	chr7:64535504	NA	-0.74	-8.85	-0.58	2.14e-15	Aortic root size;
PAAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	6.02	0.44	1.27e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.44	0.46	1.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.45	-4.69	-0.36	6.04e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.79	8.13	0.55	1.4e-13	Prostate cancer;
PAAD	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.75	-5.28	-0.39	4.41e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.55	-6.52	-0.47	9.67e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs761746	0.577	rs5994431	chr22:32210300	A/G	cg01338084	chr22:32026380	PISD	-0.54	-4.72	-0.36	5.23e-6	Intelligence;
PAAD	cis	rs3126085	0.560	rs12031363	chr1:152350645	G/A	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.26e-6	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg14926445	chr8:58193284	C8orf71	-0.72	-5.51	-0.41	1.53e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28530618	0.500	rs1885050	chr20:31226100	G/T	cg27643859	chr20:30720887	TM9SF4	0.48	4.26	0.33	3.61e-5	Birth weight;
PAAD	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	1.22	13.56	0.74	5.79e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.7	-6.98	-0.49	8.51e-11	Uric acid levels;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.77	-6.78	-0.48	2.54e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3736485	0.966	rs4775958	chr15:51891562	G/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.76	8.77	0.58	3.27e-15	Body mass index;
PAAD	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.47	-4.57	-0.35	1.02e-5	Height;
PAAD	cis	rs6844506	0.933	rs1087299	chr4:185226221	T/C	cg12654155	chr4:185238627	NA	-0.48	-4.46	-0.34	1.62e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg01851573	chr8:8652454	MFHAS1	0.51	4.36	0.33	2.37e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-1.02	-16.43	-0.8	1.58e-35	Height;
PAAD	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg21892295	chr12:121157589	UNC119B	0.46	5.37	0.4	2.93e-7	Urinary metabolites (H-NMR features);
PAAD	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.9	11.6	0.69	1.1e-22	Menarche (age at onset);
PAAD	cis	rs58521262	0.585	rs2548887	chr19:23211317	T/C	cg03433597	chr19:22806448	NA	0.24	4.36	0.33	2.39e-5	Testicular germ cell tumor;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05025164	chr4:1340916	KIAA1530	0.57	5.83	0.43	3.21e-8	Obesity-related traits;
PAAD	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.12	-0.59	4.1e-16	Response to antipsychotic treatment;
PAAD	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg23024343	chr7:107201750	COG5	0.57	4.66	0.35	6.87e-6	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-1.03	-14.01	-0.75	3.62e-29	Breast cancer;
PAAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.67	-4.95	-0.37	1.93e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.8e-13	Height;
PAAD	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.82	10.17	0.64	7.53e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.94	-15.68	-0.79	1.42e-33	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs2020921	0.510	rs79305352	chr8:41977708	C/G	cg17828057	chr8:42037527	PLAT	0.81	4.85	0.37	3.03e-6	Plasma plasminogen activator levels;
PAAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg16083429	chr3:49237500	CCDC36	0.44	4.33	0.33	2.72e-5	Menarche (age at onset);
PAAD	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.47	-0.34	1.51e-5	Retinal vascular caliber;
PAAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.51	0.41	1.48e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.32e-12	Height;
PAAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg27494647	chr7:150038898	RARRES2	0.42	4.27	0.33	3.38e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.48	5.22	0.39	5.73e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg14092988	chr3:52407081	DNAH1	0.54	6.63	0.47	5.47e-10	Bipolar disorder;
PAAD	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg26605046	chr4:2439731	NA	-0.42	-4.62	-0.35	8.14e-6	Cognitive function;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg18621852	chr3:10150065	C3orf24	0.5	4.68	0.36	6.2e-6	Alzheimer's disease;
PAAD	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg00540400	chr15:79124168	NA	-0.69	-8.5	-0.57	1.68e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.47	-0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.46	4.9	0.37	2.39e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg12740337	chr6:28058973	ZSCAN12L1	-0.45	-4.26	-0.33	3.54e-5	Depression;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.75	-7.57	-0.52	3.35e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg02683114	chr2:24398427	C2orf84	-0.61	-6.29	-0.45	3.15e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg10494973	chr17:80897199	TBCD	0.55	4.63	0.35	7.63e-6	Breast cancer;
PAAD	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.59	-0.35	9.33e-6	Total body bone mineral density;
PAAD	cis	rs3826795	0.569	rs73059724	chr19:46796767	T/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.49	4.27	0.33	3.37e-5	Lymphocyte counts;
PAAD	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14019695	chr9:139328340	INPP5E	0.52	5.31	0.4	3.74e-7	Monocyte percentage of white cells;
PAAD	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.48	4.83	0.36	3.28e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.3	0.45	3.09e-9	Lung cancer;
PAAD	cis	rs1620921	0.505	rs4708881	chr6:161203159	C/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs939584	1.000	rs10189761	chr2:646364	A/T	cg03610516	chr2:642275	NA	-0.58	-5.07	-0.38	1.13e-6	Body mass index;
PAAD	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.35	-0.33	2.49e-5	Ovarian reserve;
PAAD	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg09812376	chr17:74270190	QRICH2	-0.48	-6.83	-0.48	1.96e-10	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs1075265	0.527	rs10167891	chr2:54230795	C/A	cg04546899	chr2:54196757	PSME4	0.32	4.8	0.36	3.78e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.74	8.31	0.56	4.89e-14	Corneal astigmatism;
PAAD	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.75	8.69	0.58	5.24e-15	Lewy body disease;
PAAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg06632027	chr4:90757378	SNCA	-0.6	-5.35	-0.4	3.12e-7	Neuroticism;
PAAD	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19448829	chr6:42531521	UBR2	-0.55	-6.36	-0.46	2.29e-9	Body fat percentage;
PAAD	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg14851346	chr12:38532713	NA	-0.45	-4.35	-0.33	2.45e-5	Morning vs. evening chronotype;
PAAD	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.68	-4.7	-0.36	5.88e-6	HDL cholesterol levels;
PAAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.74	-6.84	-0.49	1.82e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs943466	1.000	rs6933568	chr6:33751261	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	5.36	0.4	3.08e-7	Mean platelet volume;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.54	4.66	0.35	6.89e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs4662592	0.554	rs35895113	chr2:128903979	A/G	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg05132306	chr1:1846340	CALML6	-0.44	-5.17	-0.39	7.43e-7	Body mass index;
PAAD	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.68	7.3	0.51	1.46e-11	Blood protein levels;
PAAD	cis	rs28493229	0.786	rs3745213	chr19:41248009	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.41	4.49	0.34	1.4e-5	Kawasaki disease;
PAAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg26513180	chr16:89883248	FANCA	0.65	7.4	0.51	8.44e-12	Vitiligo;
PAAD	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.69	-6.3	-0.45	3.1e-9	Vitamin D levels;
PAAD	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.45	6.7	0.48	3.89e-10	Breast cancer;
PAAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23158103	chr7:148848205	ZNF398	-0.62	-6.06	-0.44	1.01e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4774830	0.744	rs62046386	chr15:56305252	G/A	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.72	-0.36	5.4e-6	Lung cancer in ever smokers;
PAAD	cis	rs7824557	0.527	rs4841495	chr8:10958824	T/C	cg16664915	chr8:10907788	XKR6	-0.4	-4.3	-0.33	3.06e-5	Retinal vascular caliber;
PAAD	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg10518543	chr12:38710700	ALG10B	0.5	4.79	0.36	3.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg16230307	chr14:35515116	FAM177A1	0.41	4.34	0.33	2.62e-5	Psoriasis;
PAAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.45	4.41	0.34	1.94e-5	Menarche (age at onset);
PAAD	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-5.86	-0.43	2.81e-8	Schizophrenia (age at onset);
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00166722	chr3:10149974	C3orf24	0.97	8.28	0.56	5.81e-14	Alzheimer's disease;
PAAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.67	-7.84	-0.54	7.27e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15851312	chr15:73076263	ADPGK	0.66	7.1	0.5	4.47e-11	Myopia (pathological);
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Body mass index;
PAAD	cis	rs59888335	0.858	rs9309867	chr3:81001776	A/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.52	-0.41	1.45e-7	Vitiligo;
PAAD	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.64	6.57	0.47	7.44e-10	Testicular germ cell tumor;
PAAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.65	-6.58	-0.47	6.99e-10	Monocyte count;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.58	-5.89	-0.43	2.42e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.32	5.54	0.41	1.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg17372223	chr3:52568218	NT5DC2	0.56	5.43	0.4	2.18e-7	Bipolar disorder;
PAAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.24e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs4740619	0.619	rs1359957	chr9:16044182	G/A	cg14451791	chr9:16040625	NA	-0.44	-4.91	-0.37	2.35e-6	Body mass index;
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.72	7.79	0.53	9.76e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg00522288	chr12:125625016	AACS	-0.51	-5.15	-0.39	8.14e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg05342945	chr12:48394962	COL2A1	0.74	5.11	0.38	9.59e-7	Lung cancer;
PAAD	cis	rs4455778	0.600	rs4244233	chr7:49130572	T/A	cg26309511	chr7:48887640	NA	0.37	4.43	0.34	1.77e-5	Lung cancer in never smokers;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg00431813	chr7:1051703	C7orf50	-0.36	-4.57	-0.35	9.87e-6	Longevity;Endometriosis;
PAAD	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg26876637	chr1:152193138	HRNR	0.77	6.05	0.44	1.08e-8	Atopic dermatitis;
PAAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.64	6.92	0.49	1.15e-10	Schizophrenia;
PAAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.51	5.13	0.38	8.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs258892	0.947	rs17606	chr5:72184098	C/T	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.15	0.45	6.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.68	4.85	0.37	3.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.36	-0.33	2.42e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-5.22	-0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg17326555	chr1:119535693	NA	-0.43	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg18279126	chr7:2041391	MAD1L1	0.66	6.65	0.47	4.91e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs73416724	1.000	rs1214762	chr6:43355151	C/T	cg26312998	chr6:43337775	ZNF318	-0.67	-5.65	-0.42	7.82e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.61	0.65	4.96e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1198430	0.639	rs2297841	chr1:23764149	C/G	cg19827787	chr1:23763612	ASAP3	0.56	4.71	0.36	5.51e-6	Total cholesterol levels;
PAAD	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg07212818	chr11:638076	DRD4	-0.77	-6.69	-0.48	3.92e-10	Systemic lupus erythematosus;
PAAD	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg10382835	chr6:42185730	MRPS10	0.79	5.54	0.41	1.3e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.89	10.95	0.66	6.32e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.76	-8.54	-0.57	1.31e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.78	9.92	0.63	3.34e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.65	0.35	7.12e-6	Coronary artery disease;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.77	-0.36	4.37e-6	Obesity-related traits;
PAAD	cis	rs2133450	0.679	rs1396405	chr3:7365432	A/G	cg19930620	chr3:7340148	GRM7	-0.44	-4.96	-0.37	1.84e-6	Early response to risperidone in schizophrenia;
PAAD	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-1.04	-11.26	-0.67	9.28e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg03605226	chr16:87637261	JPH3	-0.38	-4.38	-0.33	2.17e-5	Menopause (age at onset);
PAAD	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg11204139	chr17:3907470	NA	0.85	8.68	0.58	5.78e-15	Type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05332306	chr17:9548278	USP43	0.71	8.25	0.56	6.92e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22251401	chr17:16590232	NA	-0.67	-6.99	-0.49	8.09e-11	Obesity-related traits;
PAAD	cis	rs11203032	0.614	rs11203025	chr10:90955474	A/C	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.47	4.63	0.35	7.78e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.23	0.45	4.3e-9	Hip circumference;
PAAD	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.6	-6.57	-0.47	7.45e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.38	4.57	0.35	1.02e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.6	7.73	0.53	1.4e-12	Bipolar disorder;
PAAD	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.49	-0.34	1.38e-5	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs7809615	0.748	rs9632722	chr7:99115568	A/G	cg12290671	chr7:99195819	NA	-0.89	-5.1	-0.38	1.01e-6	Blood metabolite ratios;
PAAD	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.68	-4.78	-0.36	4.09e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1419980	0.730	rs2192240	chr12:7758265	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-4.84	-0.37	3.2e-6	Blood pressure (smoking interaction);
PAAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg04738700	chr2:239367308	NA	0.41	4.44	0.34	1.74e-5	Multiple system atrophy;
PAAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.72	-0.36	5.34e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.92	0.37	2.26e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9810890	1.000	rs73198881	chr3:128542760	T/G	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7853377	0.800	rs296889	chr9:86595571	G/A	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.39	4.42	0.34	1.9e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.77	8.93	0.59	1.29e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.84	7.16	0.5	3.28e-11	Alzheimer's disease;
PAAD	cis	rs6594713	0.570	rs35926701	chr5:112898969	A/G	cg12552261	chr5:112820674	MCC	0.74	5.08	0.38	1.1e-6	Brain cytoarchitecture;
PAAD	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	6.01	0.44	1.29e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.61	4.98	0.37	1.72e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.58	-5.8	-0.43	3.75e-8	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11298989	chr19:54960853	LENG8	-0.78	-6.7	-0.48	3.79e-10	Neuroticism;
PAAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.87	8.48	0.57	1.85e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.25	18.24	0.83	4.23e-40	Schizophrenia;
PAAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg25204440	chr1:209979598	IRF6	-0.62	-4.8	-0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.62e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.36	-0.64	2.37e-19	Multiple sclerosis;
PAAD	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg19847866	chr10:1019161	NA	-0.49	-4.28	-0.33	3.28e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7631605	0.518	rs6777217	chr3:36979042	A/G	cg10333520	chr3:36987040	TRANK1	0.41	5.65	0.42	7.57e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs639012	0.561	rs471470	chr11:85831541	C/A	cg07180834	chr11:85838833	NA	-0.41	-4.38	-0.33	2.17e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6496932	0.755	rs2344084	chr15:85899038	C/G	cg19183879	chr15:85880815	NA	0.53	4.68	0.36	6.24e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg16920238	chr17:80076378	CCDC57	-0.45	-4.28	-0.33	3.33e-5	Life satisfaction;
PAAD	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg08807101	chr21:30365312	RNF160	-0.65	-4.99	-0.38	1.64e-6	Cognitive test performance;
PAAD	cis	rs10814247	1.000	rs10972498	chr9:35514653	C/T	cg18130437	chr9:35658183	CCDC107;RMRP	-0.45	-4.52	-0.34	1.22e-5	Psoriasis;
PAAD	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg26597838	chr10:835615	NA	0.49	5.3	0.39	4e-7	Survival in rectal cancer;
PAAD	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.56	5.77	0.42	4.29e-8	Mean corpuscular volume;
PAAD	cis	rs12257961	0.646	rs10752363	chr10:15349264	C/T	cg10616319	chr10:15468812	NA	-0.44	-4.25	-0.33	3.74e-5	Selective IgA deficiency;
PAAD	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs6604026	0.656	rs12745968	chr1:93401837	C/T	cg17283838	chr1:93427260	FAM69A	-0.6	-5.57	-0.41	1.1e-7	Multiple sclerosis;
PAAD	cis	rs642743	0.967	rs569856	chr10:105942304	T/C	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.7	0.36	5.82e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9381040	0.692	rs3088370	chr6:41157670	T/C	cg03526776	chr6:41159608	TREML2	0.45	4.98	0.37	1.73e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.54	-4.52	-0.34	1.24e-5	Heschl's gyrus morphology;
PAAD	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg22143856	chr6:28129313	ZNF389	0.54	4.96	0.37	1.87e-6	Parkinson's disease;
PAAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.71	0.36	5.63e-6	Melanoma;
PAAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.45	-5.55	-0.41	1.24e-7	Systolic blood pressure;
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07648498	chr16:89883185	FANCA	0.68	7.25	0.51	2.02e-11	Vitiligo;
PAAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.49	-4.62	-0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs340029	1.000	rs340029	chr15:60894965	A/G	cg00200653	chr15:60883225	RORA	-0.6	-5.89	-0.43	2.44e-8	C-reactive protein levels;
PAAD	cis	rs13253111	0.624	rs7357359	chr8:28094835	T/C	cg26534493	chr8:28060551	NA	0.41	4.59	0.35	9.13e-6	Childhood body mass index;
PAAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg11204139	chr17:3907470	NA	0.68	6.78	0.48	2.47e-10	Type 2 diabetes;
PAAD	cis	rs1891275	0.551	rs4933691	chr10:93419957	T/A	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7766436	0.614	rs60412116	chr6:22563741	G/T	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.85	7.54	0.52	3.9e-12	Coronary artery disease;
PAAD	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.89	0.54	5.51e-13	Monocyte percentage of white cells;
PAAD	cis	rs787274	1.000	rs947609	chr9:115516562	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.48	-0.34	1.48e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg11251234	chr10:101825055	CPN1	-0.28	-4.35	-0.33	2.46e-5	Bone mineral density;
PAAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg21724239	chr8:58056113	NA	0.69	5.41	0.4	2.41e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.75e-13	Height;
PAAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-1.39	-10.33	-0.64	2.81e-19	Magnesium levels;
PAAD	cis	rs9549328	0.577	rs4907477	chr13:113618484	A/G	cg17524180	chr13:113633600	MCF2L	-0.42	-4.48	-0.34	1.49e-5	Systolic blood pressure;
PAAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg08029281	chr1:67600428	NA	-0.45	-5.32	-0.4	3.64e-7	Psoriasis;
PAAD	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs564309	1.000	rs12061642	chr1:228586236	C/A	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs457162	0.643	rs283065	chr6:118620204	C/A	cg21191810	chr6:118973309	C6orf204	0.71	4.69	0.36	5.93e-6	QT interval;
PAAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg25204440	chr1:209979598	IRF6	0.61	5.28	0.39	4.47e-7	Coronary artery disease;
PAAD	cis	rs804280	0.544	rs2740435	chr8:11628471	C/T	cg12395012	chr8:11607386	GATA4	-0.68	-8.79	-0.58	3e-15	Myopia (pathological);
PAAD	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.63	-0.53	2.41e-12	Total cholesterol levels;
PAAD	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs35955747	0.659	rs11704494	chr22:31913271	G/A	cg02404636	chr22:31891804	SFI1	-0.54	-5.41	-0.4	2.41e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9810890	1.000	rs13325671	chr3:128461047	C/T	cg18531004	chr3:128564980	NA	-0.85	-4.81	-0.36	3.59e-6	Dental caries;
PAAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.98	0.37	1.73e-6	Breast cancer;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.59	0.35	9.33e-6	Obesity-related traits;
PAAD	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.54	-8.51	-0.57	1.56e-14	Urinary metabolites;
PAAD	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05491587	chr18:77659695	KCNG2	-0.45	-4.31	-0.33	2.9e-5	Schizophrenia;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg03983715	chr16:68378420	PRMT7	-1.0	-7.03	-0.5	6.52e-11	Schizophrenia;
PAAD	cis	rs2299587	0.710	rs62498201	chr8:17876569	A/G	cg08627089	chr8:17753878	FGL1	-0.47	-4.61	-0.35	8.32e-6	Economic and political preferences;
PAAD	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg02737268	chr20:3780182	CDC25B	0.43	4.57	0.35	9.95e-6	Bipolar disorder;
PAAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg06618935	chr21:46677482	NA	-0.54	-6.7	-0.48	3.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.68	4.84	0.37	3.13e-6	Inflammatory bowel disease;
PAAD	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs7577696	0.962	rs17767988	chr2:32286826	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-4.64	-0.35	7.53e-6	Inflammatory biomarkers;
PAAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.49	-0.47	1.12e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.74	-6.25	-0.45	3.94e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg12963866	chr19:57752005	ZNF805	-0.49	-4.76	-0.36	4.54e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	0.92	10.79	0.66	1.69e-20	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg09835421	chr16:68378352	PRMT7	-0.87	-6.98	-0.49	8.58e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg25915919	chr17:74884468	MGAT5B	0.64	4.32	0.33	2.83e-5	Airflow obstruction;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23337289	chr2:27603239	ZNF513	0.59	6.95	0.49	9.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	10.05	0.63	1.54e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.81	-9.16	-0.6	3.39e-16	Birth weight;
PAAD	cis	rs7904985	1.000	rs10887586	chr10:88113521	G/A	cg07322936	chr10:88137208	NA	-0.48	-4.41	-0.34	1.94e-5	Barrett's esophagus;
PAAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg01320130	chr1:67600311	NA	0.56	5.81	0.43	3.52e-8	Psoriasis;
PAAD	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27656074	chr7:157414580	PTPRN2	-0.68	-6.62	-0.47	5.71e-10	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.87	11.23	0.67	1.1e-21	Body mass index;
PAAD	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.5	4.46	0.34	1.58e-5	Corneal astigmatism;
PAAD	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.7e-6	Plateletcrit;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19905861	chr1:180601141	XPR1	0.59	6.64	0.47	5.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.52	-5.16	-0.39	7.44e-7	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.3	-0.46	3.01e-9	Schizophrenia;
PAAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg22189786	chr22:42395067	WBP2NL	-0.46	-4.48	-0.34	1.45e-5	Cognitive function;
PAAD	trans	rs76010824	0.892	rs74429267	chr3:67443246	C/CTT	cg24637035	chr12:120445227	CCDC64	-0.9	-6.33	-0.46	2.61e-9	Prostate cancer (survival);
PAAD	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg18833306	chr6:118973337	C6orf204	-0.56	-4.51	-0.34	1.27e-5	Diastolic blood pressure;
PAAD	cis	rs6494488	0.500	rs28398966	chr15:65024126	G/T	cg16425858	chr15:64791681	ZNF609	0.92	4.95	0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.49	5.01	0.38	1.53e-6	Height;
PAAD	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	7.48	0.52	5.62e-12	Menarche (age at onset);
PAAD	cis	rs2004318	1.000	rs111992790	chr19:55078751	C/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs16976116	0.803	rs28530662	chr15:55498836	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.51	-5.94	-0.43	1.91e-8	Mean arterial pressure;
PAAD	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg26935685	chr1:15502881	TMEM51	-0.55	-4.89	-0.37	2.59e-6	Systolic blood pressure;
PAAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.61	6.24	0.45	4.12e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs12999373	0.501	rs11127496	chr2:694063	G/A	cg05676510	chr2:1311570	SNTG2	0.41	4.58	0.35	9.71e-6	Uric acid levels;Response to fenofibrate (adiponectin levels);
PAAD	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.9e-7	Blood metabolite levels;
PAAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.32	0.6	1.31e-16	Gut microbiome composition (summer);
PAAD	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.65	-8.27	-0.56	6.32e-14	Inflammatory bowel disease;
PAAD	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.82	7.42	0.52	7.63e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26850624	chr5:429559	AHRR	0.44	5.56	0.41	1.17e-7	Cystic fibrosis severity;
PAAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.87	0.43	2.64e-8	Tonsillectomy;
PAAD	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.56	5.12	0.38	9.02e-7	Mean platelet volume;
PAAD	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.66	-8.54	-0.57	1.33e-14	Lymphocyte counts;
PAAD	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.61	-5.4	-0.4	2.52e-7	Platelet count;
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13870426	chr17:30244630	NA	-0.75	-7.42	-0.52	7.61e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.96	-8.32	-0.56	4.63e-14	Bipolar disorder;
PAAD	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	10.29	0.64	3.62e-19	Smoking behavior;
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg06629702	chr1:2706960	NA	-0.36	-4.34	-0.33	2.55e-5	Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg14851346	chr12:38532713	NA	-0.47	-4.37	-0.33	2.27e-5	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs28573326	0.629	rs1438119	chr4:166348346	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.78	-6.34	-0.46	2.42e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs7551222	0.646	rs4951382	chr1:204451495	T/C	cg01064725	chr1:204461714	NA	-0.52	-4.64	-0.35	7.51e-6	Schizophrenia;
PAAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.13	8.96	0.59	1.07e-15	Iron status biomarkers;
PAAD	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.77e-8	Migraine;
PAAD	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.61	6.09	0.44	8.77e-9	Essential tremor;
PAAD	cis	rs2445762	0.518	rs7163193	chr15:51644775	G/A	cg20344442	chr15:51633704	GLDN	0.46	4.64	0.35	7.36e-6	Hormone measurements;
PAAD	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs13361707	0.600	rs10078575	chr5:40704074	A/G	cg04002187	chr5:40835754	RPL37	-0.48	-4.33	-0.33	2.67e-5	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs793571	0.822	rs35477914	chr15:59197669	A/T	cg05156742	chr15:59063176	FAM63B	0.59	4.7	0.36	5.73e-6	Schizophrenia;
PAAD	cis	rs259282	0.692	rs35972270	chr19:33128457	C/T	cg02997394	chr19:33096574	ANKRD27	-0.4	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.47	5.11	0.38	9.63e-7	Age of smoking initiation;
PAAD	cis	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.63	6.5	0.47	1.06e-9	Crohn's disease;
PAAD	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-5.89	-0.43	2.34e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.74	-7.33	-0.51	1.28e-11	White matter hyperintensity burden;
PAAD	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.62	-8.86	-0.58	1.99e-15	Rheumatoid arthritis;
PAAD	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.38	9.61	0.61	2.2e-17	Diabetic retinopathy;
PAAD	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.37	0.33	2.27e-5	Migraine;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg27317327	chr6:99963477	USP45	0.59	6.71	0.48	3.67e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg09017928	chr7:158110068	PTPRN2	-0.48	-4.34	-0.33	2.57e-5	Calcium levels;
PAAD	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.78	-7.16	-0.5	3.29e-11	Exhaled nitric oxide output;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg24879335	chr3:133465180	TF	0.55	5.91	0.43	2.22e-8	Iron status biomarkers;
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.21	-0.51	2.39e-11	Total body bone mineral density;
PAAD	cis	rs2274459	0.908	rs13207666	chr6:33707227	C/G	cg06253072	chr6:33679850	C6orf125	0.61	4.67	0.35	6.61e-6	Obesity (extreme);
PAAD	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14139375	chr10:53071348	PRKG1	-0.61	-6.5	-0.47	1.08e-9	Obesity-related traits;
PAAD	cis	rs7896729	0.943	rs10904451	chr10:5347724	T/C	cg07902545	chr10:6194255	PFKFB3	-0.44	-4.55	-0.35	1.08e-5	Intelligence;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.9	7.78	0.53	1.01e-12	Alzheimer's disease;
PAAD	cis	rs7786877	0.679	rs10953301	chr7:100264893	A/G	cg16850897	chr7:100343110	ZAN	-0.75	-6.55	-0.47	8.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.58	5.94	0.43	1.87e-8	Huntington's disease progression;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg00024416	chr22:24240387	NA	-0.62	-6.63	-0.47	5.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.6	-0.41	9.74e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-6.25	-0.45	3.95e-9	Lymphocyte counts;
PAAD	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.99	11.62	0.69	9.53e-23	Breast cancer;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08219700	chr8:58056026	NA	0.78	5.44	0.4	2.12e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.15	-12.67	-0.72	1.43e-25	Hip circumference adjusted for BMI;
PAAD	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg15061591	chr7:98625706	SMURF1	0.48	4.5	0.34	1.35e-5	Breast cancer;
PAAD	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs16975963	0.744	rs11672724	chr19:38457488	C/T	cg25793785	chr19:38281423	NA	0.58	4.74	0.36	4.95e-6	Longevity;
PAAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.87	10.1	0.63	1.11e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg25905881	chr15:51634250	GLDN	0.52	4.73	0.36	5.19e-6	Hormone measurements;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.53	4.54	0.35	1.13e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.23	-0.39	5.41e-7	Tonsillectomy;
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg22442454	chr1:209979470	IRF6	0.48	4.25	0.33	3.78e-5	Coronary artery disease;
PAAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-9.16	-0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg03277515	chr1:153321198	PGLYRP4	0.39	4.57	0.35	9.96e-6	Psoriasis;
PAAD	cis	rs804279	0.535	rs804260	chr8:11631906	A/G	cg26752888	chr8:11627280	NEIL2	-0.65	-5.94	-0.43	1.89e-8	Polycystic ovary syndrome;
PAAD	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.65	7.54	0.52	3.94e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg09998033	chr7:158218633	PTPRN2	-0.74	-7.88	-0.54	5.71e-13	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg21479132	chr6:26055353	NA	0.98	5.51	0.41	1.53e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19904666	chr5:11524895	CTNND2	0.55	6.39	0.46	1.95e-9	Smoking initiation;
PAAD	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.94	5.94	0.43	1.9e-8	Cognitive function;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13198984	chr17:80129470	CCDC57	0.4	4.97	0.37	1.77e-6	Life satisfaction;
PAAD	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg20302533	chr7:39170763	POU6F2	0.39	6.16	0.45	6.1e-9	IgG glycosylation;
PAAD	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.21	0.45	4.75e-9	Lung cancer in ever smokers;
PAAD	cis	rs9395066	0.545	rs17424547	chr6:44988970	A/G	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.02e-5	Height;
PAAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg04106633	chr4:1044584	NA	0.74	6.36	0.46	2.29e-9	Recombination rate (females);
PAAD	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-7.64	-0.53	2.25e-12	Systemic lupus erythematosus;
PAAD	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.73	-7.28	-0.51	1.71e-11	Alcohol dependence;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14895029	chr7:2775587	GNA12	-0.48	-4.71	-0.36	5.57e-6	Height;
PAAD	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18402987	chr7:1209562	NA	0.43	4.59	0.35	9.35e-6	Longevity;Endometriosis;
PAAD	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06850241	chr22:41845214	NA	0.57	5.41	0.4	2.43e-7	Vitiligo;
PAAD	cis	rs288326	0.561	rs77426227	chr2:183890678	A/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-11.76	-0.69	4.04e-23	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg08562672	chr19:21860753	NA	0.43	4.55	0.35	1.07e-5	Pain;
PAAD	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg19949948	chr17:19361230	NA	0.55	4.81	0.36	3.58e-6	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1843834	0.517	rs1908252	chr2:225484736	G/A	cg22509189	chr2:225307070	NA	-0.46	-4.44	-0.34	1.7e-5	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10149021	chr10:121484846	INPP5F	0.51	6.76	0.48	2.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-4.5	-0.34	1.33e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs469568	0.562	rs13165525	chr5:178665562	G/A	cg08999896	chr5:178685787	ADAMTS2	0.56	5.31	0.4	3.8e-7	Stroke (pediatric);
PAAD	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg14752227	chr20:34000481	UQCC	-0.54	-5.37	-0.4	2.83e-7	Height;
PAAD	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.87	10.2	0.64	6.19e-19	Monocyte count;
PAAD	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.87	-0.43	2.62e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg07677032	chr17:61819896	STRADA	0.45	4.31	0.33	2.9e-5	Height;
PAAD	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.76	-5.72	-0.42	5.49e-8	Mean platelet volume;
PAAD	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs76793172	1.000	rs7257342	chr19:46356418	C/T	cg13320842	chr19:46175254	GIPR	0.63	4.84	0.37	3.21e-6	Eosinophil counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22718071	chr11:64578277	MEN1	-0.81	-7.31	-0.51	1.39e-11	Neuroticism;
PAAD	cis	rs365132	0.902	rs353489	chr5:176461974	T/C	cg25401027	chr5:176370377	UIMC1	0.56	5.61	0.41	9.51e-8	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.37	0.46	2.13e-9	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-6.63	-0.47	5.5e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-4.59	-0.35	9.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13560548	chr3:10150139	C3orf24	0.58	5.12	0.38	9.02e-7	Alzheimer's disease;
PAAD	trans	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg20979042	chr8:144387646	NA	-0.5	-6.44	-0.46	1.5e-9	Height;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08493265	chr3:195539297	MUC4	-0.58	-4.49	-0.34	1.41e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg10556349	chr10:835070	NA	0.55	4.35	0.33	2.44e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs877529	0.967	rs139400	chr22:39545396	C/T	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs4743820	0.620	rs10991784	chr9:93917094	T/C	cg14446406	chr9:93919335	NA	0.5	6.03	0.44	1.21e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14019695	chr9:139328340	INPP5E	0.58	6.13	0.45	7.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg04473634	chr6:144605763	NA	0.53	6.3	0.46	2.99e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.12	-0.44	7.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7678296	1.000	rs73140733	chr4:37168834	T/G	cg06805348	chr4:37245195	KIAA1239	0.6	4.44	0.34	1.71e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10982213	1.000	rs7849013	chr9:117181430	A/G	cg00078025	chr9:117159975	NA	0.61	4.62	0.35	8.22e-6	Interleukin-6 levels;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.88	13.37	0.74	1.88e-27	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs17681684	0.565	rs12150167	chr17:9764244	C/A	cg26853458	chr17:9805074	RCVRN	0.73	7.76	0.53	1.18e-12	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.79	-7.6	-0.52	2.89e-12	Body mass index;
PAAD	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-5.11	-0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.49	4.49	0.34	1.4e-5	Platelet count;
PAAD	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.43	0.4	2.19e-7	Bipolar disorder;
PAAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.84	-6.04	-0.44	1.14e-8	Ulcerative colitis;
PAAD	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.91	-8.89	-0.58	1.64e-15	Post bronchodilator FEV1;
PAAD	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.84	0.54	7.19e-13	Motion sickness;
PAAD	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg10518543	chr12:38710700	ALG10B	0.51	4.85	0.37	2.98e-6	Morning vs. evening chronotype;
PAAD	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg24747557	chr10:131355152	MGMT	-0.46	-4.71	-0.36	5.49e-6	Response to temozolomide;
PAAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs476633	0.708	rs111717706	chr15:41441162	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.29	-0.56	5.65e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg15218456	chr17:25289681	NA	-0.57	-6.82	-0.48	2.03e-10	Alzheimer's disease (survival time);
PAAD	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.66e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7714584	1.000	rs2004711	chr5:150225068	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	4.97	0.37	1.78e-6	Mood instability;
PAAD	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs71494788	chr10:45972325	C/G	cg14076390	chr17:34947837	DHRS11	0.93	6.81	0.48	2.08e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg14146966	chr2:61757674	XPO1	0.42	5.21	0.39	6.16e-7	Tuberculosis;
PAAD	cis	rs621942	0.635	rs7926591	chr11:85840446	T/G	cg07180834	chr11:85838833	NA	-0.51	-5.35	-0.4	3.22e-7	Tourette syndrome;
PAAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.71	-5.19	-0.39	6.64e-7	Hand grip strength;
PAAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.95	0.37	1.93e-6	Menopause (age at onset);
PAAD	cis	rs282587	0.569	rs1278658	chr13:113386832	G/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs6494488	0.500	rs72744766	chr15:65079091	T/C	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg15181151	chr6:150070149	PCMT1	0.54	5.62	0.42	8.72e-8	Lung cancer;
PAAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg24733560	chr20:60626293	TAF4	0.58	7.48	0.52	5.56e-12	Body mass index;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10769017	chr3:48658346	TMEM89	-0.56	-6.33	-0.46	2.68e-9	Monocyte percentage of white cells;
PAAD	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.43	-5.65	-0.42	7.85e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg25197388	chr11:66278006	BBS1	-0.43	-4.3	-0.33	3.04e-5	Mean corpuscular volume;
PAAD	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Breast cancer;
PAAD	cis	rs136211	0.965	rs2899262	chr22:36768595	A/G	cg11153328	chr22:36877737	TXN2	-0.5	-4.59	-0.35	9.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs317865	0.529	rs28487914	chr4:16191303	T/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.82	6.11	0.44	8.14e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10444037	chr6:42531637	UBR2	0.57	6.48	0.47	1.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs797680	0.796	rs797661	chr1:93687091	G/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.42	-0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-7.46	-0.52	6.12e-12	Hemoglobin concentration;
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.89	0.63	4.07e-18	Platelet count;
PAAD	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.9	11.34	0.68	5.48e-22	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10516089	0.504	rs28439361	chr5:171139857	G/A	cg21066063	chr5:171570130	STK10	0.35	4.4	0.34	2e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg16989719	chr2:238392110	NA	-0.39	-4.94	-0.37	2.02e-6	Prostate cancer;
PAAD	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.84	-8.08	-0.55	1.82e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18621852	chr3:10150065	C3orf24	0.66	5.83	0.43	3.26e-8	Alzheimer's disease;
PAAD	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	6.0	0.44	1.42e-8	Parkinson's disease;
PAAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.71	-6.18	-0.45	5.62e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg11995313	chr8:8860691	ERI1	0.48	4.72	0.36	5.31e-6	Joint mobility (Beighton score);
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.88	10.62	0.65	4.64e-20	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.566	rs34595606	chr2:10722518	G/A	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.34	-4.81	-0.36	3.64e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7922314	0.571	rs2893913	chr10:64702053	T/C	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.27	-0.56	6.16e-14	Bone mineral density;
PAAD	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg08558340	chr7:100472263	SRRT	0.51	4.51	0.34	1.27e-5	Resting heart rate;
PAAD	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.54	5.95	0.43	1.79e-8	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00068622	chr5:79783654	FAM151B	0.67	6.87	0.49	1.51e-10	Obesity-related traits;
PAAD	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.9	-7.29	-0.51	1.63e-11	Orofacial clefts;
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07930192	chr7:1003750	NA	0.36	4.39	0.34	2.08e-5	Longevity;Endometriosis;
PAAD	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg11530693	chr1:120165357	ZNF697	0.61	6.73	0.48	3.27e-10	Systemic lupus erythematosus;
PAAD	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg22153463	chr1:85462885	MCOLN2	0.64	4.97	0.37	1.81e-6	Serum sulfate level;
PAAD	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg24519413	chr1:26490540	NA	0.52	4.81	0.36	3.57e-6	Height;
PAAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg14440974	chr22:39074834	NA	-0.61	-7.36	-0.51	1.07e-11	Menopause (age at onset);
PAAD	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.61	-7.41	-0.52	8.02e-12	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg04824913	chr4:887549	GAK	0.71	5.19	0.39	6.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg00083206	chr6:110721305	DDO	-0.48	-5.06	-0.38	1.17e-6	Platelet distribution width;
PAAD	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.36e-6	Bone mineral density;
PAAD	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg14440974	chr22:39074834	NA	-0.52	-6.27	-0.45	3.64e-9	Menopause (age at onset);
PAAD	cis	rs12935418	0.523	rs2549845	chr16:81024125	C/A	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.66	5.08	0.38	1.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2006771	0.846	rs6518754	chr22:32097775	C/T	cg02404636	chr22:31891804	SFI1	0.49	5.07	0.38	1.15e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs438465	0.685	rs9393169	chr6:169739798	C/T	cg00289362	chr6:170482788	NA	0.48	4.25	0.33	3.76e-5	Corneal astigmatism;
PAAD	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg16342193	chr10:102329863	NA	-0.76	-8.29	-0.56	5.6e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs56158183	0.511	rs114064870	chr2:60646491	G/C	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Educational attainment (years of education);
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.35e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03676636	chr4:99064102	C4orf37	0.32	4.76	0.36	4.44e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.73	0.48	3.2e-10	Coffee consumption (cups per day);
PAAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg03983715	chr16:68378420	PRMT7	-0.73	-5.18	-0.39	6.9e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.52	5.41	0.4	2.37e-7	Number of children ever born;
PAAD	cis	rs12711490	0.559	rs4843867	chr16:85970718	C/G	cg05709598	chr16:85699621	KIAA0182	0.43	4.46	0.34	1.61e-5	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.32	0.46	2.79e-9	Alzheimer's disease;
PAAD	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg00590817	chr1:8272081	NA	-0.36	-4.29	-0.33	3.12e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11168854	0.651	rs12227770	chr12:49576848	T/A	cg05368762	chr12:50135785	TMBIM6	0.43	4.27	0.33	3.45e-5	Body mass index;
PAAD	cis	rs4388249	0.687	rs10038829	chr5:109104703	A/G	cg17395555	chr5:108820864	NA	-0.33	-4.52	-0.34	1.24e-5	Schizophrenia;
PAAD	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg25364880	chr3:44379878	C3orf23	0.58	5.36	0.4	3.05e-7	Depressive symptoms;
PAAD	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg10072921	chr12:121022843	NA	0.39	4.86	0.37	2.86e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs10450586	0.863	rs10835150	chr11:27301061	C/G	cg10370305	chr11:27303972	NA	-0.36	-4.33	-0.33	2.73e-5	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs114366529	chr3:128564604	A/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.58	-5.33	-0.4	3.54e-7	Menarche (age at onset);
PAAD	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.38	-5.71	-0.42	5.89e-8	Glomerular filtration rate;
PAAD	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.68e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.29	-0.33	3.14e-5	Menopause (age at onset);
PAAD	cis	rs902774	1.000	rs75236700	chr12:53276938	A/G	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.56	0.41	1.18e-7	Alzheimer's disease;
PAAD	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	4.28	0.33	3.23e-5	Eosinophil percentage of white cells;
PAAD	cis	rs11686241	0.748	rs13411746	chr2:217306616	A/G	cg15830940	chr2:217278069	SMARCAL1	0.52	4.74	0.36	4.97e-6	Cancer;
PAAD	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.74	6.2	0.45	5.03e-9	Blood protein levels;
PAAD	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg24154853	chr7:158122151	PTPRN2	-0.61	-5.44	-0.4	2.04e-7	Calcium levels;
PAAD	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.31	-0.4	3.82e-7	Bipolar disorder;
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1190596	0.526	rs8003556	chr14:102659667	T/C	cg23904247	chr14:102554826	HSP90AA1	0.41	5.07	0.38	1.14e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	5.87	0.43	2.66e-8	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.64	-7.19	-0.5	2.74e-11	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20519524	chr4:8472938	C4orf23	0.56	6.6	0.47	6.43e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg00125455	chr20:44574271	PCIF1	0.42	4.31	0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18522351	chr19:48103913	NA	-0.57	-6.49	-0.47	1.13e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg18281939	chr5:77783895	LHFPL2	0.52	6.76	0.48	2.81e-10	Triglycerides;
PAAD	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.8	8.6	0.57	9.25e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs302972	0.826	rs7740534	chr6:25077179	A/C	cg01382804	chr6:25931017	SLC17A2	0.79	4.41	0.34	1.98e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg26703956	chr19:39260304	NA	-0.5	-6.24	-0.45	4.18e-9	Heart rate;
PAAD	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.64	6.18	0.45	5.69e-9	Breast cancer;
PAAD	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg15309053	chr8:964076	NA	0.43	4.71	0.36	5.59e-6	Schizophrenia;
PAAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.85	8.7	0.58	5.06e-15	Mean platelet volume;
PAAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg14515779	chr1:101123966	NA	0.49	6.29	0.45	3.24e-9	Monocyte count;
PAAD	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-5.14	-0.38	8.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.43	-0.4	2.2e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg01047959	chr19:17666446	GLT25D1	0.47	4.47	0.34	1.52e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg20703997	chr1:4087676	NA	0.62	4.96	0.37	1.9e-6	Interleukin-17 levels;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs9463078	0.803	rs2396380	chr6:45043557	T/A	cg25276700	chr6:44698697	NA	-0.47	-5.49	-0.41	1.65e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg06677660	chr19:49140777	SEC1;DBP	0.65	5.41	0.4	2.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
PAAD	cis	rs714031	1.000	rs5757765	chr22:40067840	T/C	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs6466055	0.796	rs9649275	chr7:104935801	T/G	cg04380332	chr7:105027541	SRPK2	0.64	7.03	0.5	6.59e-11	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.71	-0.48	3.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09351035	chr11:748060	TALDO1	0.68	7.84	0.54	7.18e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg10395934	chr14:104002654	TRMT61A	0.47	4.59	0.35	9.16e-6	Body mass index;
PAAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.82	10.15	0.64	8.45e-19	Methadone dose in opioid dependence;
PAAD	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-4.47	-0.34	1.51e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg05768032	chr16:30646687	NA	0.5	4.81	0.36	3.61e-6	Multiple myeloma;
PAAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.94	12.11	0.7	4.55e-24	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-0.71	-4.84	-0.37	3.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.55	5.12	0.38	9.25e-7	Monocyte count;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.58	6.06	0.44	1.01e-8	Emphysema distribution in smoking;
PAAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.53	5.7	0.42	5.97e-8	Menopause (age at onset);
PAAD	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.53	-5.08	-0.38	1.1e-6	Gut microbiome composition (summer);
PAAD	cis	rs4455778	0.580	rs12718320	chr7:49109447	A/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.28	0.39	4.45e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg09877947	chr5:131593287	PDLIM4	0.59	5.43	0.4	2.22e-7	Acylcarnitine levels;
PAAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg21395723	chr22:39101663	GTPBP1	-0.44	-4.38	-0.33	2.22e-5	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73198819	chr3:128475662	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	7.45	0.52	6.58e-12	Lymphocyte counts;
PAAD	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.51	0.61	4.06e-17	Colorectal cancer;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg00280220	chr17:61926910	NA	0.42	4.39	0.34	2.12e-5	Prudent dietary pattern;
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	5.8	0.43	3.76e-8	Longevity;
PAAD	cis	rs11853189	0.938	rs16969703	chr15:78592036	C/T	cg22935921	chr15:78556834	DNAJA4	0.74	5.18	0.39	6.87e-7	Red cell distribution width;
PAAD	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.42	-5.15	-0.39	7.84e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24549020	chr5:56110836	MAP3K1	0.5	4.36	0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.55	4.96	0.37	1.89e-6	Blood metabolite levels;
PAAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.67	-5.73	-0.42	5.31e-8	Systemic lupus erythematosus;
PAAD	cis	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.57	-7.67	-0.53	1.91e-12	Renal cell carcinoma;
PAAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-5.05	-0.38	1.26e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.77	8.3	0.56	5.33e-14	Obesity-related traits;
PAAD	cis	rs258892	0.843	rs4260644	chr5:72031375	A/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs41563	0.593	rs7807853	chr7:104597669	A/T	cg04380332	chr7:105027541	SRPK2	-0.51	-5.05	-0.38	1.27e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.38	4.94	0.37	2.04e-6	Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23337289	chr2:27603239	ZNF513	0.54	6.36	0.46	2.25e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4740619	0.933	rs2382534	chr9:15713090	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.4	-0.34	2.05e-5	Body mass index;
PAAD	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	7.54	0.52	4.03e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs11023332	0.800	rs12271890	chr11:14934686	A/G	cg16394018	chr11:14927549	NA	0.42	4.71	0.36	5.53e-6	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.62	5.64	0.42	7.96e-8	Mean platelet volume;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.59	-0.35	9.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3768644	0.607	rs2241058	chr2:72361865	C/A	cg04940582	chr2:72356976	CYP26B1	0.56	4.27	0.33	3.4e-5	Schizophrenia;
PAAD	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23158103	chr7:148848205	ZNF398	-0.6	-5.58	-0.41	1.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg05562828	chr17:3906858	NA	0.58	6.62	0.47	5.95e-10	Type 2 diabetes;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.85	0.43	2.97e-8	Body mass index;
PAAD	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12311304	0.965	rs7303595	chr12:15359063	T/A	cg08258403	chr12:15378311	NA	0.33	4.28	0.33	3.24e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs12304921	0.575	rs55938119	chr12:51511745	C/G	cg18059802	chr12:51347058	HIGD1C	-0.61	-4.92	-0.37	2.25e-6	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.7	0.42	5.96e-8	Restless legs syndrome;
PAAD	cis	rs6076065	0.644	rs1056394	chr20:23337422	G/A	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.41e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.44	4.69	0.36	6.14e-6	Coronary artery disease;
PAAD	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg18898632	chr2:242989856	NA	-0.81	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.9	-10.45	-0.65	1.3e-19	Height;
PAAD	trans	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg01075559	chr1:2537774	MMEL1	0.47	4.98	0.37	1.7e-6	Ulcerative colitis;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.85	6.88	0.49	1.5e-10	Alzheimer's disease;
PAAD	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs6596100	0.538	rs56097052	chr5:132194430	A/G	cg14825688	chr5:132208181	LEAP2	-0.66	-4.82	-0.36	3.43e-6	Breast cancer;
PAAD	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.7	-0.66	2.8e-20	Total body bone mineral density;
PAAD	cis	rs6693295	0.729	rs10399630	chr1:246212561	A/T	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-5.71	-0.42	5.82e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.45e-8	Triglycerides;
PAAD	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-7.11	-0.5	4.34e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.64	5.38	0.4	2.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg23033748	chr14:75592666	NEK9	-0.38	-4.64	-0.35	7.57e-6	Height;
PAAD	cis	rs59104589	0.521	rs7618	chr2:242434602	A/G	cg19488206	chr2:242435732	STK25	0.5	4.87	0.37	2.75e-6	Fibrinogen levels;
PAAD	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.36	-0.33	2.35e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.67	-4.73	-0.36	5.17e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1891275	0.513	rs1539041	chr10:93577141	T/G	cg07889827	chr10:93443413	NA	-0.49	-4.75	-0.36	4.74e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg15383120	chr6:291909	DUSP22	-0.64	-6.85	-0.49	1.72e-10	Menopause (age at onset);
PAAD	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg14146966	chr2:61757674	XPO1	0.38	4.79	0.36	4e-6	Tuberculosis;
PAAD	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.6	6.02	0.44	1.28e-8	Height;
PAAD	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.82	-9.36	-0.6	1.03e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg07336987	chr11:625147	MUPCDH	-0.37	-4.64	-0.35	7.62e-6	Systemic lupus erythematosus;
PAAD	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950880	0.677	rs56224165	chr2:102925223	A/T	cg23450938	chr2:102972792	NA	0.42	4.57	0.35	1.02e-5	Serum protein levels (sST2);
PAAD	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg11993925	chr19:44307056	LYPD5	0.51	6.9	0.49	1.32e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg15956490	chr3:53032818	SFMBT1	-0.8	-4.67	-0.35	6.47e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg22764044	chr5:178986830	RUFY1	-0.54	-5.79	-0.42	3.95e-8	Lung cancer;
PAAD	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.43	4.52	0.34	1.24e-5	Kawasaki disease;
PAAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg25650185	chr19:21324782	ZNF431	-0.48	-4.38	-0.33	2.18e-5	Pain;
PAAD	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.6	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	1.07	6.43	0.46	1.56e-9	Body mass index;
PAAD	cis	rs4281086	0.965	rs4531010	chr8:10381128	G/T	cg01072821	chr8:10382165	T-SP1	-0.44	-4.44	-0.34	1.71e-5	Obesity-related traits;
PAAD	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-5.97	-0.44	1.59e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	1.29	7.91	0.54	5.02e-13	Skin colour saturation;
PAAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.73	-6.96	-0.49	9.5e-11	Alcohol dependence;
PAAD	cis	rs1390897	0.524	rs7200145	chr16:77051934	C/G	cg06128999	chr16:77247126	NA	0.47	5.23	0.39	5.52e-7	beta-nerve growth factor levels;
PAAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4750440	0.706	rs4750442	chr10:14019827	A/G	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.5	-0.34	1.32e-5	Adiponectin levels;
PAAD	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg23649088	chr2:200775458	C2orf69	0.67	4.34	0.33	2.56e-5	Schizophrenia;
PAAD	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.4	-4.64	-0.35	7.36e-6	Pubertal anthropometrics;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.34e-13	Alzheimer's disease;
PAAD	cis	rs1075265	0.901	rs2112124	chr2:54364522	A/T	cg04546899	chr2:54196757	PSME4	0.34	4.86	0.37	2.85e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg14583973	chr4:3374767	RGS12	-0.42	-6.49	-0.47	1.14e-9	Serum sulfate level;
PAAD	cis	rs300774	0.925	rs437409	chr2:142137	G/A	cg21211680	chr2:198530	NA	-0.62	-5.78	-0.42	4.1e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.63	6.19	0.45	5.26e-9	Blood protein levels;
PAAD	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs965469	0.779	rs6037516	chr20:3233142	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg26384229	chr12:38710491	ALG10B	0.7	7.34	0.51	1.23e-11	Morning vs. evening chronotype;
PAAD	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.59	-4.96	-0.37	1.84e-6	Metabolite levels;
PAAD	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg11941060	chr3:133502564	NA	0.52	5.4	0.4	2.51e-7	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs73198852	chr3:128508858	A/C	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15145965	chr22:50218605	BRD1	-0.6	-4.96	-0.37	1.87e-6	Schizophrenia;
PAAD	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg17960426	chr8:142067321	NA	-0.62	-5.33	-0.4	3.47e-7	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs11247915	0.622	rs4072445	chr1:26664219	T/C	cg15628303	chr1:26608928	UBXN11	0.66	6.6	0.47	6.48e-10	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs4834770	1.000	rs6823963	chr4:120242164	A/C	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.69	7.66	0.53	2.07e-12	Granulocyte count;Sum neutrophil eosinophil counts;
PAAD	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.42	4.49	0.34	1.39e-5	Platelet count;
PAAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.52	-6.03	-0.44	1.19e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7173419	0.813	rs28795193	chr15:28217974	A/C	cg20906524	chr15:28200668	OCA2	-0.53	-5.44	-0.4	2.09e-7	Eye color;
PAAD	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg24053715	chr22:38214548	NA	-0.62	-6.57	-0.47	7.71e-10	Glioblastoma;Glioma;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-6.18	-0.45	5.52e-9	Migraine;
PAAD	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.88	-8.16	-0.55	1.19e-13	Longevity;
PAAD	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-5.72	-0.42	5.45e-8	Vitiligo;
PAAD	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.44	4.53	0.35	1.17e-5	Height;
PAAD	cis	rs3857067	0.934	rs2865336	chr4:95029357	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-4.27	-0.33	3.39e-5	QT interval;
PAAD	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1198430	0.602	rs12401753	chr1:23762679	A/G	cg24580199	chr1:23763081	ASAP3	0.58	5.17	0.39	7.37e-7	Total cholesterol levels;
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.47	-4.88	-0.37	2.69e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.46	-0.46	1.31e-9	Mood instability;
PAAD	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.29	-0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.68	-5.89	-0.43	2.39e-8	Common traits (Other);
PAAD	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.44	-0.68	2.92e-22	Chronic sinus infection;
PAAD	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg10932868	chr11:921992	NA	0.46	4.86	0.37	2.84e-6	Alzheimer's disease (late onset);
PAAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg01075559	chr1:2537774	MMEL1	0.46	4.97	0.37	1.75e-6	Ulcerative colitis;
PAAD	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.79	-7.89	-0.54	5.63e-13	Breast cancer;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.86	9.66	0.62	1.61e-17	Prudent dietary pattern;
PAAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	4.68	0.35	6.38e-6	Joint mobility (Beighton score);
PAAD	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.58	-4.73	-0.36	5.13e-6	Facial morphology (factor 19);
PAAD	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.19	0.64	6.71e-19	Bladder cancer;
PAAD	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.65	0.35	7.29e-6	Skin pigmentation;
PAAD	cis	rs75920871	1.000	rs61905681	chr11:116836209	A/C	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.58	5.11	0.38	9.53e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	6.79	0.48	2.39e-10	Lung function (FEV1/FVC);
PAAD	cis	rs8105895	1.000	rs17450788	chr19:22224755	T/C	cg20662725	chr19:22235022	ZNF257	-0.56	-4.37	-0.33	2.25e-5	Body mass index (change over time);
PAAD	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	10.07	0.63	1.4e-18	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs282587	0.569	rs390657	chr13:113415085	A/G	cg04656015	chr13:113407548	ATP11A	0.56	4.48	0.34	1.44e-5	Glycated hemoglobin levels;
PAAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.71	9.42	0.61	7.18e-17	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg23465465	chr6:26364728	BTN3A2	0.75	4.27	0.33	3.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg18357526	chr6:26021779	HIST1H4A	0.61	4.87	0.37	2.77e-6	Homocysteine levels;
PAAD	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg06606381	chr12:133084897	FBRSL1	1.04	6.74	0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00448482	chr18:13726497	C18orf19;RNMT	-0.74	-6.41	-0.46	1.71e-9	Neuroticism;
PAAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg10589385	chr1:150898437	SETDB1	0.39	4.81	0.36	3.64e-6	Melanoma;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.65	-4.39	-0.34	2.1e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	5.12	0.38	8.93e-7	Iron status biomarkers;
PAAD	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg02887458	chr19:19495540	GATAD2A	0.61	5.56	0.41	1.16e-7	Bipolar disorder;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg02524346	chr8:600233	NA	-1.05	-6.51	-0.47	1.04e-9	IgG glycosylation;
PAAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs8064454	0.764	rs11658063	chr17:36103872	C/G	cg04198914	chr17:36106025	HNF1B	0.34	4.38	0.33	2.23e-5	Prostate cancer;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.76	-7.88	-0.54	5.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12282928	0.917	rs7942804	chr11:48297076	C/A	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs10982213	1.000	rs4979382	chr9:117178722	C/T	cg00078025	chr9:117159975	NA	0.58	4.51	0.34	1.31e-5	Interleukin-6 levels;
PAAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.68e-5	Parkinson's disease;
PAAD	trans	rs3733631	0.895	rs28592258	chr4:104621036	C/A	cg21490444	chr5:171095097	NA	0.75	6.29	0.45	3.13e-9	Menarche (age at onset);
PAAD	cis	rs56133113	0.792	rs80119927	chr11:72758804	A/G	cg25124030	chr11:73498278	MRPL48	0.49	4.46	0.34	1.57e-5	Mean platelet volume;
PAAD	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.5	-4.42	-0.34	1.84e-5	Testicular germ cell tumor;
PAAD	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.45	0.65	1.36e-19	Smoking behavior;
PAAD	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.63	-0.42	8.42e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26281728	chr15:85923949	AKAP13	0.59	6.48	0.47	1.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.77	8.62	0.57	7.92e-15	Strep throat;
PAAD	cis	rs7792596	1.000	rs10263858	chr7:93995226	T/C	cg20814616	chr7:94014465	NA	-0.44	-4.58	-0.35	9.72e-6	Intelligence;
PAAD	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg03277515	chr1:153321198	PGLYRP4	0.39	4.56	0.35	1.05e-5	Psoriasis;
PAAD	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.47	4.28	0.33	3.26e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg11271282	chr2:238384023	NA	0.56	4.37	0.33	2.29e-5	Prostate cancer;
PAAD	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg14078157	chr9:128172775	NA	-0.63	-7.39	-0.51	9.09e-12	Resting heart rate;
PAAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	12.46	0.71	5.44e-25	Bone mineral density;
PAAD	cis	rs9659323	0.730	rs10802070	chr1:119541486	C/T	cg26570165	chr1:119541833	NA	-0.55	-6.02	-0.44	1.23e-8	Body mass index;
PAAD	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg21565972	chr17:80109576	CCDC57	-0.56	-6.32	-0.46	2.83e-9	Life satisfaction;
PAAD	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.48	-5.15	-0.39	7.78e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2275731	0.723	rs10466288	chr10:16544654	C/A	cg04254609	chr10:16479192	PTER	-0.44	-4.73	-0.36	5.17e-6	Bone fracture in osteoporosis;
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.7	-7.47	-0.52	5.73e-12	Age at first birth;
PAAD	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.63	-6.17	-0.45	5.89e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11958404	0.615	rs7724696	chr5:157450852	A/C	cg05962755	chr5:157440814	NA	0.55	5.3	0.4	3.96e-7	IgG glycosylation;
PAAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.51	-4.69	-0.36	5.93e-6	Migraine;
PAAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	6.41	0.46	1.73e-9	Menarche (age at onset);
PAAD	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.66	-4.41	-0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.68	-6.99	-0.49	8.21e-11	Body mass index;
PAAD	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg26174226	chr8:58114915	NA	-0.59	-4.29	-0.33	3.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.17	0.5	3e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg18755752	chr8:142205143	DENND3	-0.53	-5.38	-0.4	2.73e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10750165	0.692	rs1466052	chr11:119653781	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.57	-5.07	-0.38	1.13e-6	Response to diuretic therapy;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg04025307	chr7:1156635	C7orf50	0.62	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05875032	chr22:18593364	TUBA8	0.63	7.09	0.5	4.65e-11	Pancreatic cancer;
PAAD	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.92	12.85	0.72	4.66e-26	Height;
PAAD	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.59	8.17	0.55	1.14e-13	Primary biliary cholangitis;
PAAD	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.22	-0.55	8.38e-14	Hemoglobin concentration;
PAAD	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-6.84	-0.49	1.81e-10	Longevity;Endometriosis;
PAAD	cis	rs863345	0.534	rs10797009	chr1:158446048	T/A	cg12129480	chr1:158549410	OR10X1	-0.38	-4.42	-0.34	1.88e-5	Pneumococcal bacteremia;
PAAD	cis	rs16975963	0.843	rs241955	chr19:38278677	A/G	cg14218481	chr19:38281219	NA	0.42	4.39	0.34	2.09e-5	Longevity;
PAAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.54	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg16306870	chr3:194868790	C3orf21	0.42	4.46	0.34	1.56e-5	Non-small cell lung cancer;
PAAD	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.73	9.15	0.6	3.51e-16	Body mass index;
PAAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.56	-5.42	-0.4	2.25e-7	Esophageal squamous cell carcinoma;
PAAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7816613	0.920	rs16868133	chr8:102663410	A/G	cg20585841	chr8:102729926	NCALD	-0.63	-5.12	-0.38	9.07e-7	Age-related hearing impairment;
PAAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00982548	chr2:198649783	BOLL	-0.84	-5.8	-0.43	3.75e-8	Ulcerative colitis;
PAAD	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.62	7.08	0.5	5.09e-11	Breast cancer;
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg27234864	chr13:21295941	IL17D	0.62	5.31	0.4	3.78e-7	Dental caries;
PAAD	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs4790333	0.562	rs2429904	chr17:2260362	T/C	cg02569219	chr17:2266849	SGSM2	0.48	4.51	0.34	1.29e-5	Proinsulin levels;
PAAD	cis	rs10905065	0.898	rs4748916	chr10:5820394	A/G	cg18989491	chr10:6185502	PFKFB3	0.45	4.3	0.33	3.02e-5	Menopause (age at onset);
PAAD	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg25401027	chr5:176370377	UIMC1	0.49	4.98	0.37	1.67e-6	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02071572	chr4:1403502	NA	0.38	4.76	0.36	4.42e-6	Obesity-related traits;
PAAD	cis	rs6988985	0.678	rs10087214	chr8:143999726	G/A	cg10324643	chr8:143916377	GML	0.4	4.57	0.35	1e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14094449	chr14:60558589	C14orf135	-0.63	-6.51	-0.47	1.04e-9	Smoking initiation;
PAAD	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg01631408	chr1:248437212	OR2T33	-0.64	-5.64	-0.42	8.23e-8	Common traits (Other);
PAAD	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg20913747	chr6:44695427	NA	-0.66	-6.64	-0.47	5.13e-10	Total body bone mineral density;
PAAD	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg10495392	chr1:46806563	NSUN4	0.56	5.47	0.41	1.84e-7	Menopause (age at onset);
PAAD	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-1.03	-8.82	-0.58	2.51e-15	Blood trace element (Zn levels);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.5	0.8	1.08e-35	Prudent dietary pattern;
PAAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg14180030	chr9:123475675	MEGF9	-0.42	-4.96	-0.37	1.84e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-7.94	-0.54	4.09e-13	Lymphocyte counts;Red cell distribution width;
PAAD	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg03983715	chr16:68378420	PRMT7	-0.91	-6.44	-0.46	1.49e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4845459	1.000	rs4845459	chr1:152603842	C/A	cg03277515	chr1:153321198	PGLYRP4	0.43	5.24	0.39	5.3e-7	Psoriasis;
PAAD	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg08175591	chr14:101176152	NA	0.41	4.99	0.38	1.6e-6	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25518386	chr19:18315738	RAB3A	0.63	6.63	0.47	5.44e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.76	6.31	0.46	2.97e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07797907	chr16:2389905	ABCA17P;ABCA3	-0.55	-6.29	-0.45	3.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	11.2	0.67	1.34e-21	Smoking behavior;
PAAD	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.68	7.94	0.54	4.24e-13	Height;
PAAD	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg24220031	chr2:73402428	NA	-0.43	-6.59	-0.47	6.66e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.53	4.44	0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.44	-5.64	-0.42	8.11e-8	Psoriasis;
PAAD	cis	rs990171	0.513	rs6543152	chr2:103114043	G/A	cg13897122	chr2:103039542	IL18RAP	-0.48	-5.31	-0.4	3.91e-7	Lymphocyte counts;
PAAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg14393609	chr7:65229607	NA	-0.5	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19386169	chr12:133296477	PGAM5	-0.63	-6.47	-0.46	1.24e-9	Obesity-related traits;
PAAD	cis	rs6494488	0.500	rs68142176	chr15:64955226	C/T	cg16425858	chr15:64791681	ZNF609	0.93	5.05	0.38	1.27e-6	Coronary artery disease;
PAAD	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-5.88	-0.43	2.56e-8	Response to antipsychotic treatment;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.53	-7.07	-0.5	5.22e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07216258	chr3:101568851	NFKBIZ	0.79	8.2	0.55	9.61e-14	Obesity-related traits;
PAAD	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.67	5.37	0.4	2.85e-7	Obesity (extreme);
PAAD	trans	rs35993099	1	rs35993099	chr10:46006967	T/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell count;Mean corpuscular hemoglobin;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.46	-4.91	-0.37	2.36e-6	Tonsillectomy;
PAAD	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg23715586	chr3:58305044	RPP14	0.51	4.45	0.34	1.63e-5	Platelet count;
PAAD	cis	rs1697938	0.590	rs2250856	chr5:40948139	A/T	cg22359217	chr5:41925772	FBXO4	0.46	4.58	0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs787274	0.764	rs786965	chr9:115448195	A/C	cg13803584	chr9:115635662	SNX30	0.86	5.3	0.39	3.99e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.22e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26897989	chr16:1907736	C16orf73	-0.57	-4.99	-0.38	1.64e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs7624766	0.743	rs2886905	chr3:160492850	C/T	cg22637730	chr3:160473554	PPM1L	0.54	4.97	0.37	1.75e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs1386478	0.585	rs1487268	chr3:113682207	G/A	cg24004780	chr3:113683598	KIAA1407	-0.52	-5.08	-0.38	1.1e-6	Crohn's disease and psoriasis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11253136	chr11:70116457	PPFIA1	-0.56	-6.31	-0.46	2.87e-9	Body fat percentage;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg17372657	chr7:1216933	NA	-0.38	-4.74	-0.36	4.79e-6	Longevity;Endometriosis;
PAAD	cis	rs17824933	1.000	rs12791045	chr11:60767964	C/T	cg27098804	chr11:60776124	CD6	0.45	4.44	0.34	1.75e-5	Multiple sclerosis;
PAAD	cis	rs13088645	0.621	rs7611834	chr3:134146088	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.53	5.03	0.38	1.39e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
PAAD	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg11214348	chr21:47283868	PCBP3	-0.52	-4.75	-0.36	4.69e-6	Schizophrenia;
PAAD	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.59	-0.41	1.02e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg23205692	chr1:25664452	TMEM50A	0.5	4.71	0.36	5.66e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24549020	chr5:56110836	MAP3K1	-0.49	-4.29	-0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	7.56	0.52	3.53e-12	Menopause (age at onset);
PAAD	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg08390786	chr10:135334061	NA	0.61	5.38	0.4	2.72e-7	Gout;
PAAD	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.75	6.91	0.49	1.25e-10	Response to hepatitis C treatment;
PAAD	cis	rs6782025	0.837	rs2656043	chr3:120960792	G/T	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg05347473	chr6:146136440	FBXO30	0.53	5.18	0.39	7.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.66	6.51	0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg23254163	chr1:152506842	NA	-0.61	-6.95	-0.49	9.95e-11	Hair morphology;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.22	0.55	8.14e-14	Alzheimer's disease;
PAAD	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.58	-0.35	9.67e-6	Height;
PAAD	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25471021	chr2:42796439	MTA3	0.58	6.67	0.48	4.47e-10	Monocyte percentage of white cells;
PAAD	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.81e-5	Immature fraction of reticulocytes;
PAAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4908760	0.868	rs12131864	chr1:8591162	A/G	cg20416874	chr1:8611966	RERE	-0.46	-4.34	-0.33	2.61e-5	Vitiligo;
PAAD	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg08390786	chr10:135334061	NA	-0.64	-5.2	-0.39	6.24e-7	Gout;
PAAD	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg21479132	chr6:26055353	NA	-0.92	-5.2	-0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2730260	0.537	rs3793222	chr7:158863536	A/C	cg02254261	chr7:158964346	NA	0.56	4.44	0.34	1.72e-5	Myopia (pathological);
PAAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13421116	chr10:75910920	AP3M1;ADK	-0.65	-6.7	-0.48	3.87e-10	Lung cancer in ever smokers;
PAAD	cis	rs2637030	0.533	rs2607511	chr5:52930471	G/A	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.71	-4.4	-0.34	2.07e-5	Skin colour saturation;
PAAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.42	-6.3	-0.45	3.07e-9	Breast cancer;
PAAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.75	-7.35	-0.51	1.16e-11	Breast cancer;
PAAD	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.51	5.48	0.41	1.71e-7	Response to metformin (IC50);
PAAD	cis	rs9646944	0.501	rs9807934	chr2:103040182	T/G	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.41e-5	Blood protein levels;
PAAD	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.31	13.11	0.73	9.34e-27	Corneal structure;
PAAD	cis	rs452036	0.736	rs743567	chr14:23890982	T/G	cg23613857	chr14:23356614	REM2	0.37	4.39	0.34	2.1e-5	Resting heart rate;P wave duration;
PAAD	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.21	10.38	0.64	2.08e-19	Chin dimples;
PAAD	cis	rs13038095	1	rs13038095	chr20:46425576	A/C	cg21798815	chr20:46414765	SULF2	-0.8	-4.25	-0.33	3.65e-5	Atrial fibrillation;
PAAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.33	0.46	2.64e-9	Initial pursuit acceleration;
PAAD	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg02683114	chr2:24398427	C2orf84	-0.53	-5.22	-0.39	5.83e-7	Asthma;
PAAD	cis	rs2290419	0.730	rs77157858	chr11:68944928	A/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg18833306	chr6:118973337	C6orf204	0.51	5.91	0.43	2.13e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs1862626	0.506	rs7716644	chr5:56043426	C/T	cg14703610	chr5:56206110	C5orf35	0.48	4.56	0.35	1.06e-5	Cancer (pleiotropy);
PAAD	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg08036796	chr19:5034282	KDM4B	0.45	4.35	0.33	2.53e-5	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24189559	chr3:12851674	CAND2	0.64	6.5	0.47	1.09e-9	Smoking initiation;
PAAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.78	-6.76	-0.48	2.73e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.86	-10.96	-0.66	5.66e-21	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05581701	chr16:56666323	MT1M	-0.58	-6.66	-0.48	4.62e-10	Body fat percentage;
PAAD	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.55	-4.67	-0.35	6.48e-6	Schizophrenia;
PAAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.92	12.14	0.7	3.96e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.67	7.08	0.5	4.88e-11	Platelet distribution width;
PAAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs73195822	0.667	rs2339634	chr12:111231277	C/T	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.3	-0.33	3e-5	Itch intensity from mosquito bite;
PAAD	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	0.91	5.9	0.43	2.31e-8	Gut microbiota (bacterial taxa);
PAAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg21601837	chr3:125900065	ALDH1L1	-0.49	-5.52	-0.41	1.41e-7	Metabolite levels;
PAAD	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.54	5.94	0.43	1.9e-8	Urate levels in lean individuals;
PAAD	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs3748682	0.731	rs9729719	chr1:38298207	G/A	cg12658694	chr1:38397304	INPP5B	0.47	4.41	0.34	1.95e-5	Hypothyroidism;
PAAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg12215294	chr3:40350768	EIF1B	-0.44	-4.41	-0.34	1.97e-5	Renal cell carcinoma;
PAAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	6.34	0.46	2.49e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs113123495	0.510	rs1572491	chr19:5704691	A/C	cg26242866	chr19:5711310	LONP1	0.95	4.47	0.34	1.5e-5	Obsessive-compulsive symptoms;
PAAD	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-10.58	-0.65	5.97e-20	Electrocardiographic conduction measures;
PAAD	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg18589874	chr11:47608310	FAM180B	-0.46	-4.5	-0.34	1.33e-5	Subjective well-being;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-4.86	-0.37	2.9e-6	Psoriasis;
PAAD	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.6	-6.22	-0.45	4.69e-9	Menarche (age at onset);
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg19626725	chr5:178986131	RUFY1	-0.5	-5.28	-0.39	4.43e-7	Lung cancer;
PAAD	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-7.48	-0.52	5.56e-12	Morning vs. evening chronotype;
PAAD	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24110177	chr3:50126178	RBM5	-0.59	-6.54	-0.47	8.65e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.53	-4.88	-0.37	2.61e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1198430	0.683	rs7551124	chr1:23785760	C/T	cg27447006	chr1:23763279	ASAP3	0.64	4.91	0.37	2.3e-6	Total cholesterol levels;
PAAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.45	4.41	0.34	1.95e-5	Response to statin therapy;
PAAD	cis	rs716804	0.740	rs2083715	chr11:10253796	A/G	cg06875754	chr11:10328428	ADM	-0.34	-4.33	-0.33	2.71e-5	Neuroticism;
PAAD	cis	rs27434	0.583	rs149431	chr5:96157541	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.61	0.57	8.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs7823896	0.527	rs7836793	chr8:110290014	T/C	cg02458499	chr8:110280928	NUDCD1	0.87	4.28	0.33	3.28e-5	Myopia (pathological);
PAAD	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.38	0.33	2.23e-5	Iron status biomarkers;
PAAD	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	6.13	0.45	7.27e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs7904985	0.793	rs10788496	chr10:88121978	G/A	cg07322936	chr10:88137208	NA	-0.54	-4.88	-0.37	2.71e-6	Barrett's esophagus;
PAAD	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	0.92	5.96	0.44	1.68e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs4077468	0.963	rs17433242	chr1:205913236	G/A	cg21828629	chr1:205913422	SLC26A9	-0.44	-4.79	-0.36	3.94e-6	Cystic fibrosis-related diabetes;
PAAD	cis	rs4924590	0.513	rs4244586	chr15:42238759	T/G	cg20935245	chr15:42234343	EHD4	0.52	5.64	0.42	8.11e-8	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
PAAD	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.05	-0.38	1.27e-6	Daytime sleep phenotypes;
PAAD	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.85	9.68	0.62	1.49e-17	Body mass index;
PAAD	cis	rs1043763	0.826	rs28478029	chr12:122605519	G/A	cg26218692	chr12:122497826	BCL7A	-0.59	-5.62	-0.41	9.06e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.78	-6.79	-0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	4.42	0.34	1.85e-5	Total cholesterol levels;
PAAD	cis	rs990171	0.538	rs4851600	chr2:103116223	C/G	cg13897122	chr2:103039542	IL18RAP	0.45	5.0	0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs1419980	0.730	rs57562412	chr12:7762124	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg14829155	chr15:31115871	NA	-0.66	-7.22	-0.51	2.29e-11	Huntington's disease progression;
PAAD	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg27511599	chr7:32358540	NA	0.76	4.52	0.34	1.22e-5	Body mass index;
PAAD	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-5.06	-0.38	1.22e-6	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.31	0.46	2.86e-9	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26831811	chr1:86862111	ODF2L	-0.59	-6.93	-0.49	1.11e-10	Smoking initiation;
PAAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg05579598	chr16:88989069	CBFA2T3	0.55	8.11	0.55	1.61e-13	Social autistic-like traits;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03140557	chr16:595690	SOLH	0.55	4.85	0.37	3.07e-6	Mean corpuscular volume;
PAAD	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs9463078	0.547	rs2038557	chr6:44740471	G/A	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg12436631	chr1:155007014	DCST1;DCST2	-0.41	-5.16	-0.39	7.72e-7	Prostate cancer;
PAAD	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.57	0.52	3.37e-12	HIV-1 control;
PAAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.67	-0.42	7.03e-8	Tonsillectomy;
PAAD	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg15211996	chr1:2936768	ACTRT2	0.47	4.61	0.35	8.42e-6	Plateletcrit;
PAAD	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.71	-7.69	-0.53	1.67e-12	Prudent dietary pattern;
PAAD	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.37	-0.33	2.29e-5	Cognitive function;
PAAD	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-5.38	-0.4	2.79e-7	Schizophrenia;
PAAD	cis	rs6782025	0.837	rs2331527	chr3:120790332	C/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2034088	0.897	rs4968124	chr17:436900	T/C	cg06217071	chr17:408420	NA	0.76	8.37	0.56	3.48e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	12.21	0.7	2.51e-24	Cognitive ability;
PAAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.91	7.61	0.53	2.74e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	7.0	0.49	7.56e-11	Renal function-related traits (BUN);
PAAD	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg10845886	chr2:3471009	TTC15	-0.6	-5.8	-0.43	3.66e-8	Neurofibrillary tangles;
PAAD	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.55	-4.87	-0.37	2.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6445967	1.000	rs34611088	chr3:58312923	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.32	0.33	2.81e-5	Platelet count;
PAAD	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg00982548	chr2:198649783	BOLL	-0.75	-5.25	-0.39	5.02e-7	Ulcerative colitis;
PAAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg17775713	chr3:133465469	TF	0.5	5.65	0.42	7.62e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.39	0.34	2.09e-5	Bipolar disorder;
PAAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.57	-7.68	-0.53	1.78e-12	Renal cell carcinoma;
PAAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.59	-6.56	-0.47	7.99e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11942476	0.619	rs4521333	chr4:21489597	G/T	cg14992154	chr4:20701870	PACRGL	0.62	4.69	0.36	6e-6	IgG glycosylation;
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.37	0.4	2.96e-7	Bipolar disorder;
PAAD	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg08926642	chr1:7887455	PER3	-0.51	-4.63	-0.35	7.71e-6	Inflammatory bowel disease;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	12.7	0.72	1.23e-25	Colorectal cancer;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg15181151	chr6:150070149	PCMT1	-0.54	-5.97	-0.44	1.64e-8	Lung cancer;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.8	8.42	0.56	2.68e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg00530320	chr1:46809349	NSUN4	0.46	4.32	0.33	2.82e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg19486271	chr11:47235900	DDB2	-0.58	-5.91	-0.43	2.13e-8	Schizophrenia;
PAAD	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.64	-6.98	-0.49	8.64e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2282978	0.557	rs3731343	chr7:92273536	G/T	cg06556290	chr7:92222188	NA	0.44	4.44	0.34	1.69e-5	Height;
PAAD	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10155981	0.510	rs4719705	chr7:22592707	C/T	cg05062323	chr7:22590069	NA	-0.9	-5.55	-0.41	1.24e-7	Bilirubin levels;
PAAD	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.42	0.46	1.64e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg20893579	chr22:38215064	NA	-0.49	-5.08	-0.38	1.1e-6	Glioblastoma;Glioma;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs2455826	0.544	rs2455841	chr3:15762120	C/A	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.53	-6.41	-0.46	1.74e-9	Lewy body disease;
PAAD	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg18833306	chr6:118973337	C6orf204	0.44	4.64	0.35	7.37e-6	Electrocardiographic conduction measures;
PAAD	cis	rs4523957	0.786	rs9897624	chr17:2121745	A/G	cg16513277	chr17:2031491	SMG6	-0.49	-4.96	-0.37	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs2010099	0.759	rs116358073	chr3:124299095	G/A	cg08542804	chr2:70141812	MXD1	-1.44	-6.37	-0.46	2.1e-9	Thyroid peroxidase antibody levels;
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg14343924	chr8:8086146	FLJ10661	-0.55	-4.78	-0.36	4.08e-6	Mood instability;
PAAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.84	9.5	0.61	4.45e-17	Lung cancer;
PAAD	cis	rs10793968	0.688	rs4740365	chr9:133630410	A/G	cg01474677	chr9:133586259	NA	-0.57	-4.45	-0.34	1.64e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.86	-9.61	-0.61	2.29e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7696796	0.615	rs13116377	chr4:183178463	G/T	cg03209412	chr4:183728196	NA	-0.61	-5.12	-0.38	9.26e-7	Neuroticism;
PAAD	cis	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.97	-0.37	1.79e-6	Body mass index;
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.37	0.4	2.85e-7	Initial pursuit acceleration;
PAAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.49e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.96	8.88	0.58	1.75e-15	Resting heart rate;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs2997447	0.761	rs12088601	chr1:26445504	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.63	-0.35	7.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg08501292	chr6:25962987	TRIM38	0.84	4.71	0.36	5.64e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.62	5.3	0.39	4.1e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13174850	chr14:93673699	C14orf142;UBR7	-0.63	-6.49	-0.47	1.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.48	-4.62	-0.35	8.25e-6	Monocyte count;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15742519	chr2:190627263	OSGEPL1	-0.6	-7.27	-0.51	1.76e-11	Body fat percentage;
PAAD	cis	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg21546286	chr11:48923668	NA	-0.45	-4.8	-0.36	3.83e-6	Height;
PAAD	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.53	4.98	0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs28493229	0.708	rs80003555	chr19:41160612	C/G	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.68	5.51	0.41	1.49e-7	Weight;
PAAD	cis	rs6976053	0.935	rs7801015	chr7:100476497	T/C	cg22425096	chr7:100417404	EPHB4	0.5	4.3	0.33	3.09e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.67	-7.53	-0.52	4.2e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg07202610	chr7:1142643	C7orf50	-0.67	-5.58	-0.41	1.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.6	-5.56	-0.41	1.2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.75e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.19	0.55	1.01e-13	Platelet count;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg13444538	chr7:158905317	VIPR2	-0.61	-6.0	-0.44	1.41e-8	Facial morphology (factor 20);
PAAD	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.26	0.33	3.64e-5	Resting heart rate;
PAAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg10556349	chr10:835070	NA	0.58	4.59	0.35	9.21e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.99	6.7	0.48	3.75e-10	Prostate cancer;
PAAD	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19671926	chr4:122722719	EXOSC9	0.61	5.98	0.44	1.52e-8	Type 2 diabetes;
PAAD	cis	rs7264396	0.887	rs224343	chr20:34036699	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.84	-0.43	3.05e-8	Total cholesterol levels;
PAAD	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg05709478	chr1:6581295	PLEKHG5	0.72	4.55	0.35	1.11e-5	Body mass index;
PAAD	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.23	0.39	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.67	-0.53	1.96e-12	Total cholesterol levels;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.33	-0.51	1.27e-11	Body mass index;
PAAD	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.71	4.83	0.36	3.37e-6	Vitiligo;
PAAD	cis	rs227163	0.560	rs1040395	chr1:7952203	C/T	cg09168692	chr1:7887560	PER3	-0.44	-5.3	-0.4	3.92e-7	Rheumatoid arthritis;
PAAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.74	-6.99	-0.49	7.93e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg22134325	chr11:66188745	NPAS4	0.42	5.17	0.39	7.41e-7	Airway imaging phenotypes;
PAAD	cis	rs6604026	0.656	rs2811598	chr1:93336933	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg01305830	chr4:1604576	NA	-0.45	-4.43	-0.34	1.76e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7631605	0.967	rs9832138	chr3:37175960	A/G	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.34e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.54	5.69	0.42	6.3e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18638598	chr22:49934445	NA	-0.64	-6.31	-0.46	2.93e-9	Obesity-related traits;
PAAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.53	-5.2	-0.39	6.33e-7	Aortic root size;
PAAD	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.55	-4.53	-0.34	1.18e-5	Corneal structure;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.26	0.33	3.56e-5	Bipolar disorder;
PAAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.59	8.98	0.59	9.51e-16	IgG glycosylation;
PAAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg11663144	chr21:46675770	NA	-0.49	-6.02	-0.44	1.29e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg10932868	chr11:921992	NA	-0.5	-6.03	-0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg15117754	chr3:10150083	C3orf24	0.7	5.94	0.43	1.9e-8	Alzheimer's disease;
PAAD	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.86	-7.03	-0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg05110241	chr16:68378359	PRMT7	-0.75	-5.93	-0.43	1.95e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg24253500	chr15:84953950	NA	0.42	4.35	0.33	2.48e-5	Schizophrenia;
PAAD	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.87	10.17	0.64	7.5e-19	Multiple sclerosis;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.64	-6.69	-0.48	4.11e-10	Iron status biomarkers;
PAAD	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.49	5.23	0.39	5.51e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.01	0.59	8.08e-16	Bipolar disorder;
PAAD	cis	rs6908034	0.607	rs12526109	chr6:19820089	C/A	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.2	-17.85	-0.82	3.93e-39	Ulcerative colitis;
PAAD	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.28	-0.33	3.26e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11621710	0.557	rs799474	chr14:35516099	C/G	cg16230307	chr14:35515116	FAM177A1	0.52	5.73	0.42	5.33e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg25204440	chr1:209979598	IRF6	0.58	4.6	0.35	8.67e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.75e-6	Iron status biomarkers;
PAAD	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg10556349	chr10:835070	NA	0.6	4.96	0.37	1.88e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs448720	0.811	rs694267	chr15:68183377	C/T	cg05925327	chr15:68127851	NA	-0.38	-4.31	-0.33	2.96e-5	Cognitive performance;
PAAD	cis	rs17533156	0.729	rs12603490	chr17:75122581	T/C	cg11416367	chr17:75137675	SEC14L1	0.51	4.45	0.34	1.63e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7631605	0.905	rs3774343	chr3:37035834	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	9.02e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.93	-5.75	-0.42	4.66e-8	Alzheimer's disease (late onset);
PAAD	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.88e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.69	-7.96	-0.54	3.69e-13	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1455213	0.544	rs6449106	chr4:15170652	T/C	cg12377275	chr4:15005593	CPEB2	0.49	4.68	0.35	6.35e-6	Parental longevity (mother's age at death);
PAAD	cis	rs800160	0.858	rs800116	chr11:2361624	G/A	cg09785033	chr11:2336066	TSPAN32	-0.55	-4.64	-0.35	7.44e-6	Bacteremia;
PAAD	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg00666640	chr1:248458726	OR2T12	0.48	4.79	0.36	3.99e-6	Common traits (Other);
PAAD	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-1.01	-12.96	-0.72	2.38e-26	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.17e-10	Life satisfaction;
PAAD	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg08648136	chr8:956695	NA	0.41	4.49	0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg05044414	chr3:183734942	ABCC5	0.53	4.76	0.36	4.53e-6	Anterior chamber depth;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.89	0.37	2.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16975963	0.843	rs7254809	chr19:38365695	A/G	cg25793785	chr19:38281423	NA	0.6	4.95	0.37	1.91e-6	Longevity;
PAAD	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg14343924	chr8:8086146	FLJ10661	0.46	4.45	0.34	1.67e-5	Joint mobility (Beighton score);
PAAD	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.77	9.46	0.61	5.51e-17	Bladder cancer;
PAAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.91	12.64	0.72	1.69e-25	Vitiligo;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.56	6.08	0.44	9.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.83	9.43	0.61	6.45e-17	Metabolic syndrome;
PAAD	cis	rs61884328	1.000	rs61884328	chr11:46783435	T/C	cg23433285	chr11:47201945	PACSIN3	0.82	4.26	0.33	3.54e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs870825	0.655	rs6552812	chr4:185653568	C/T	cg04058563	chr4:185651563	MLF1IP	-0.85	-6.17	-0.45	5.95e-9	Blood protein levels;
PAAD	cis	rs329648	0.553	rs329653	chr11:133771179	G/A	cg03392386	chr11:133800800	IGSF9B	0.53	5.89	0.43	2.34e-8	Parkinson's disease;
PAAD	cis	rs7627468	1.000	rs4678188	chr3:121946355	T/C	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.81	-0.36	3.63e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.76e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.67	-6.81	-0.48	2.18e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.47	6.25	0.45	3.85e-9	Longevity;
PAAD	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs2415984	0.579	rs2642091	chr14:46972754	A/G	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg02049472	chr2:177466316	MIR1246	-0.41	-4.37	-0.33	2.32e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.06	9.87	0.62	4.68e-18	Red blood cell traits;
PAAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.79	0.48	2.31e-10	Total body bone mineral density;
PAAD	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg23387468	chr7:139079360	LUC7L2	0.38	4.29	0.33	3.17e-5	Diisocyanate-induced asthma;
PAAD	cis	rs8060686	0.777	rs73597580	chr16:67679879	G/A	cg09835421	chr16:68378352	PRMT7	-0.95	-4.88	-0.37	2.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25190573	chr4:185721490	ACSL1;SLED1	0.73	6.58	0.47	7.34e-10	Neuroticism;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg11518657	chr1:67396239	MIER1	0.68	5.13	0.38	8.84e-7	Lymphocyte percentage of white cells;
PAAD	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.77	-6.87	-0.49	1.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.7	6.9	0.49	1.34e-10	Blood protein levels;
PAAD	cis	rs10045504	0.502	rs72746054	chr5:38762351	C/T	cg15396434	chr5:38725168	NA	-0.87	-6.17	-0.45	5.9e-9	Night sleep phenotypes;
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.22	0.39	5.84e-7	Lung function (FEV1/FVC);
PAAD	cis	rs10821973	0.527	rs4979776	chr10:63981857	G/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.68	0.48	4.17e-10	Life satisfaction;
PAAD	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg19131313	chr8:1704013	NA	0.41	4.33	0.33	2.74e-5	Systolic blood pressure;
PAAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.08	-0.55	1.9e-13	Schizophrenia;
PAAD	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.37	-0.4	2.92e-7	Myeloid white cell count;
PAAD	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00166722	chr3:10149974	C3orf24	0.92	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.1	-0.38	9.81e-7	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07788451	chr12:58146524	CDK4	0.6	6.76	0.48	2.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.49	-4.41	-0.34	1.97e-5	Response to antidepressants and depression;
PAAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.45e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg19254793	chr6:44695348	NA	-0.47	-4.45	-0.34	1.65e-5	Total body bone mineral density;
PAAD	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg11608241	chr8:8085544	FLJ10661	0.45	4.27	0.33	3.46e-5	Myopia (pathological);
PAAD	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg04154034	chr17:28927549	LRRC37B2	0.69	4.35	0.33	2.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg08992911	chr2:238395768	MLPH	0.61	5.09	0.38	1.03e-6	Prostate cancer;
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg12524338	chr4:183729343	NA	0.62	4.71	0.36	5.47e-6	Pediatric autoimmune diseases;
PAAD	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg14851346	chr12:38532713	NA	0.44	4.31	0.33	2.95e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg03808351	chr9:123631620	PHF19	0.45	4.88	0.37	2.65e-6	Rheumatoid arthritis;
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.61	6.4	0.46	1.81e-9	Systemic lupus erythematosus;
PAAD	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg09760422	chr2:128146352	NA	-0.33	-5.54	-0.41	1.33e-7	Protein C levels;
PAAD	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-8.12	-0.55	1.46e-13	Depression;
PAAD	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg14515779	chr1:101123966	NA	-0.53	-6.29	-0.45	3.25e-9	Monocyte count;
PAAD	cis	rs7572263	0.959	rs12995271	chr2:209048136	T/C	cg23998903	chr2:209048830	C2orf80	-0.48	-4.55	-0.35	1.1e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs3764400	0.506	rs2036521	chr17:46328976	T/G	cg24322968	chr17:46507895	SKAP1	0.75	4.38	0.33	2.24e-5	Body mass index;
PAAD	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg19875578	chr6:126661172	C6orf173	0.43	4.44	0.34	1.75e-5	Male-pattern baldness;
PAAD	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.64	6.92	0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.8	9.29	0.6	1.53e-16	Coronary artery disease;
PAAD	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.57	-4.66	-0.35	6.94e-6	Type 2 diabetes;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg16176600	chr6:116381609	FRK	0.3	4.32	0.33	2.79e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.61	4.53	0.34	1.2e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.56	-0.35	1.06e-5	Eotaxin levels;
PAAD	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs300774	0.925	rs300719	chr2:136203	C/T	cg23649280	chr2:140451	NA	-0.47	-4.53	-0.34	1.18e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-13.61	-0.74	4.2e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.85	-0.37	3.04e-6	Magnesium levels;
PAAD	cis	rs2327429	0.541	rs12193973	chr6:134151297	A/G	cg06643013	chr6:134217242	NA	-0.41	-4.66	-0.35	6.88e-6	Coronary artery disease;
PAAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.44	-4.99	-0.38	1.65e-6	Height;
PAAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.27	0.33	3.37e-5	Depression;
PAAD	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg06375148	chr1:209958343	C1orf74	-0.59	-4.73	-0.36	5.13e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg19442545	chr10:75533431	FUT11	0.42	4.3	0.33	2.98e-5	Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.55	0.57	1.23e-14	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.63	-0.47	5.4e-10	Lung cancer;
PAAD	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.74	-6.53	-0.47	9.36e-10	Blood pressure (smoking interaction);
PAAD	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg21191810	chr6:118973309	C6orf204	0.46	5.79	0.43	3.81e-8	Electrocardiographic conduction measures;
PAAD	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg25817165	chr18:72167213	CNDP2	-0.79	-7.14	-0.5	3.55e-11	Refractive error;
PAAD	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.66	6.66	0.48	4.64e-10	Breast cancer;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg27205649	chr11:78285834	NARS2	0.61	4.35	0.33	2.51e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg19767477	chr5:127420684	SLC12A2	-0.6	-4.87	-0.37	2.75e-6	Ileal carcinoids;
PAAD	cis	rs11886999	0.812	rs72825868	chr2:96897659	A/T	cg16627346	chr2:96057706	NA	0.48	4.31	0.33	2.96e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-4.62	-0.35	8.11e-6	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs10227331	0.632	rs10215531	chr7:157301180	A/G	cg04156418	chr7:157293606	NA	0.38	4.26	0.33	3.62e-5	Inattentive symptoms;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg11416102	chr8:651193	ERICH1	-0.97	-5.86	-0.43	2.78e-8	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg09324608	chr17:30823087	MYO1D	0.56	5.93	0.43	2.01e-8	Schizophrenia;
PAAD	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	0.91	5.41	0.4	2.4e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.68	7.02	0.49	6.83e-11	Monocyte count;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.47	4.88	0.37	2.64e-6	Height;
PAAD	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.53	-4.51	-0.34	1.31e-5	Atopic dermatitis;
PAAD	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs3745621	1.000	rs7251708	chr19:47689697	G/A	cg24326880	chr19:47634349	SAE1	-0.53	-4.39	-0.34	2.12e-5	Lymphocyte counts;
PAAD	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg20003494	chr4:90757398	SNCA	0.65	5.87	0.43	2.62e-8	Neuroticism;
PAAD	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.84e-11	Interstitial lung disease;
PAAD	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.91	0.37	2.36e-6	Schizophrenia;
PAAD	cis	rs9976767	0.932	rs9981707	chr21:43827829	T/C	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.59	-0.35	9.04e-6	Type 1 diabetes;
PAAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg26570165	chr1:119541833	NA	-0.45	-4.26	-0.33	3.59e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07648498	chr16:89883185	FANCA	0.69	7.22	0.51	2.35e-11	Vitiligo;
PAAD	cis	rs6088813	0.961	rs878639	chr20:33894463	A/G	cg14752227	chr20:34000481	UQCC	0.51	5.14	0.39	8.2e-7	Height;
PAAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg06740227	chr12:86229804	RASSF9	0.52	5.24	0.39	5.28e-7	Major depressive disorder;
PAAD	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.43	-5.66	-0.42	7.36e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.48	5.12	0.38	9.16e-7	Longevity;Endometriosis;
PAAD	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg21951975	chr1:209979733	IRF6	0.55	5.08	0.38	1.1e-6	Coronary artery disease;
PAAD	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg18944383	chr4:111397179	ENPEP	0.63	7.07	0.5	5.24e-11	Coronary artery disease;
PAAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.49	-4.48	-0.34	1.47e-5	IgG glycosylation;
PAAD	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.5	-4.8	-0.36	3.68e-6	Malaria;
PAAD	cis	rs2885056	1.000	rs2885056	chr19:10693628	C/A	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25601830	chr1:19630524	AKR7A2	0.62	6.44	0.46	1.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg04775059	chr7:64541387	NA	0.59	6.07	0.44	9.58e-9	Calcium levels;
PAAD	cis	rs9398803	0.713	rs1387916	chr6:126886731	G/C	cg19875578	chr6:126661172	C6orf173	0.43	4.51	0.34	1.3e-5	Male-pattern baldness;
PAAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg16147221	chr4:10020634	SLC2A9	0.47	4.3	0.33	3.04e-5	Bone mineral density;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.66	-7.37	-0.51	1.03e-11	Childhood ear infection;
PAAD	cis	rs834603	0.965	rs700755	chr7:47445641	A/G	cg23694490	chr7:47445681	TNS3	-0.36	-4.55	-0.35	1.1e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.81	0.66	1.48e-20	Smoking behavior;
PAAD	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	7.76	0.53	1.12e-12	Alzheimer's disease;
PAAD	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg03929089	chr4:120376271	NA	-0.85	-6.66	-0.48	4.6e-10	Axial length;
PAAD	cis	rs4794202	0.579	rs9896712	chr17:45884543	G/A	cg02219949	chr17:45927392	SP6	0.6	4.74	0.36	4.98e-6	Alzheimer's disease (cognitive decline);
PAAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg05697835	chr1:2722811	NA	0.41	4.6	0.35	8.74e-6	Ulcerative colitis;
PAAD	cis	rs9659323	0.706	rs1409160	chr1:119583854	C/A	cg26570165	chr1:119541833	NA	-0.49	-5.27	-0.39	4.58e-7	Body mass index;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.96	0.63	2.61e-18	Platelet count;
PAAD	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.29	0.45	3.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg03233332	chr7:66118400	NA	-0.41	-4.35	-0.33	2.52e-5	Aortic root size;
PAAD	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.64	7.33	0.51	1.29e-11	Schizophrenia;
PAAD	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14169450	chr9:139327907	INPP5E	0.77	9.19	0.6	2.84e-16	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	7.88	0.54	5.73e-13	Alzheimer's disease;
PAAD	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.67	5.57	0.41	1.13e-7	Lymphocyte counts;
PAAD	cis	rs4740619	0.711	rs12216921	chr9:15994502	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.72	-0.36	5.39e-6	Body mass index;
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.57	-5.37	-0.4	2.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.6	5.78	0.42	4.16e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.57	-7.46	-0.52	6.09e-12	Rheumatoid arthritis;
PAAD	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.61	8.42	0.56	2.63e-14	Height;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8179	0.700	rs42039	chr7:92244422	A/G	cg03496780	chr7:92466842	CDK6	-0.48	-4.34	-0.33	2.62e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.77	9.27	0.6	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07643314	chr3:16647343	DAZL	-0.66	-7.01	-0.49	7.19e-11	Obesity-related traits;
PAAD	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.55	5.86	0.43	2.78e-8	Height;
PAAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.88	-8.55	-0.57	1.25e-14	DNA methylation (variation);
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13916266	chr17:7787658	CHD3	0.67	7.2	0.5	2.6e-11	Obesity-related traits;
PAAD	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	1.04	6.64	0.47	5.29e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.54	-6.11	-0.44	7.83e-9	Calcium levels;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4740619	0.630	rs2987017	chr9:15984735	G/A	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.45	-4.52	-0.34	1.26e-5	Body mass index;
PAAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs6681460	0.565	rs6689755	chr1:67113050	G/A	cg02459107	chr1:67143332	SGIP1	0.51	4.97	0.37	1.76e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.54	5.35	0.4	3.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.51	5.22	0.39	5.84e-7	Body mass index;
PAAD	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.15	0.39	7.84e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.75	-0.42	4.82e-8	Bipolar disorder;
PAAD	trans	rs16853722	1.000	rs10513669	chr3:169168017	A/C	cg18154567	chr15:51464013	NA	0.77	6.34	0.46	2.52e-9	Renal function-related traits (BUN);
PAAD	cis	rs4903604	0.560	rs4899659	chr14:78038642	C/G	cg18872420	chr14:78023429	SPTLC2	0.43	4.41	0.34	1.97e-5	Gut microbiome composition (winter);
PAAD	cis	rs9283706	0.608	rs10060497	chr5:66332406	A/G	cg11590213	chr5:66331682	MAST4	0.59	4.79	0.36	3.9e-6	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg08219700	chr8:58056026	NA	0.71	5.33	0.4	3.42e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.46	4.44	0.34	1.69e-5	Pulse pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22337605	chr1:12227417	TNFRSF1B	0.69	7.29	0.51	1.59e-11	Obesity-related traits;
PAAD	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.75	7.89	0.54	5.38e-13	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25241845	chr20:44519697	NEURL2;CTSA	0.58	6.77	0.48	2.6e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.34e-10	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg00042356	chr1:8021962	PARK7	0.74	5.13	0.38	8.53e-7	Inflammatory bowel disease;
PAAD	cis	rs3096299	0.730	rs3114895	chr16:89394810	C/T	cg04143805	chr16:89395205	ANKRD11	-0.39	-4.59	-0.35	9.03e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-4.67	-0.35	6.61e-6	Primary sclerosing cholangitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14443694	chr20:5107453	CDS2;PCNA	0.65	6.72	0.48	3.5e-10	Obesity-related traits;
PAAD	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.4	0.61	7.84e-17	Response to antipsychotic treatment;
PAAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.58	-4.94	-0.37	2.04e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.75	8.78	0.58	3.11e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg12140854	chr5:148520817	ABLIM3	-0.4	-4.3	-0.33	3.01e-5	Breast cancer;
PAAD	cis	rs3764400	0.508	rs12601350	chr17:46120419	T/C	cg10706073	chr17:46328419	SKAP1	-1.0	-6.14	-0.45	6.74e-9	Body mass index;
PAAD	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.71	7.21	0.5	2.44e-11	Resistin levels;
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.29	0.39	4.21e-7	Lung cancer;
PAAD	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg01426195	chr3:39028469	NA	0.64	6.02	0.44	1.23e-8	Handedness;
PAAD	cis	rs797680	0.856	rs7541687	chr1:93656588	A/G	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	1.0	13.92	0.75	6.46e-29	Heart rate;
PAAD	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.04	-7.04	-0.5	6.08e-11	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.79	8.63	0.57	7.46e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02244288	chr16:89573955	SPG7	-0.32	-4.39	-0.34	2.14e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg14895029	chr7:2775587	GNA12	-0.46	-4.78	-0.36	4.04e-6	Height;
PAAD	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.7	-7.53	-0.52	4.28e-12	DNA methylation (variation);
PAAD	cis	rs2147959	0.941	rs10916317	chr1:228645063	A/G	cg02753203	chr1:228287806	NA	-0.58	-4.63	-0.35	7.91e-6	Adult asthma;
PAAD	cis	rs9463078	0.585	rs4714847	chr6:45231074	C/T	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.25e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.69	-6.52	-0.47	9.84e-10	Parkinson's disease;
PAAD	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.47	4.34	0.33	2.59e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg07212818	chr11:638076	DRD4	-0.7	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.47	4.37	0.33	2.31e-5	Endometrial cancer;
PAAD	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.7	9.06	0.59	6.1e-16	Asthma;
PAAD	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16242888	chr9:34179479	UBAP1	0.59	6.58	0.47	7.18e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.01	-0.44	1.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg17712092	chr4:129076599	LARP1B	0.75	8.19	0.55	9.9e-14	Eosinophil percentage of white cells;
PAAD	cis	rs11615916	0.659	rs7296326	chr12:62667727	C/T	cg11441379	chr12:63026424	NA	-0.72	-4.99	-0.38	1.61e-6	Pulmonary function decline;
PAAD	cis	rs731174	0.802	rs12123842	chr1:38187989	T/C	cg10090792	chr1:38198142	EPHA10	-0.43	-4.41	-0.34	1.91e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg23119463	chr10:134592391	INPP5A	-0.49	-4.55	-0.35	1.08e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08688798	chr22:20307858	DGCR6L	-0.74	-6.46	-0.46	1.37e-9	Neuroticism;
PAAD	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16014699	chr19:33352871	SLC7A9	-0.63	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17006519	chr13:53191650	HNRNPA1L2	0.63	6.88	0.49	1.5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.55	-5.63	-0.42	8.61e-8	Parkinson's disease;
PAAD	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.61	6.32	0.46	2.74e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg00199519	chr17:18023121	MYO15A	0.59	6.83	0.48	1.92e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg26876637	chr1:152193138	HRNR	-0.83	-6.13	-0.45	7.35e-9	Atopic dermatitis;
PAAD	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.88	-10.28	-0.64	3.9e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.53	-7.25	-0.51	1.94e-11	Diastolic blood pressure;
PAAD	cis	rs60733400	0.509	rs56814247	chr1:2622489	A/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.59	-0.41	1.03e-7	Multiple sclerosis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02697246	chr12:117187890	RNFT2	-0.73	-6.67	-0.48	4.46e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.36	0.46	2.24e-9	Personality dimensions;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-4.69	-0.36	6.05e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.7	8.01	0.54	2.8e-13	Bladder cancer;
PAAD	cis	rs1144333	0.510	rs1250882	chr1:76287314	C/A	cg22875332	chr1:76189707	ACADM	-0.77	-4.73	-0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2229238	0.868	rs72999419	chr1:154514092	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	cis	rs7896729	0.943	rs7917859	chr10:5355382	A/G	cg07902545	chr10:6194255	PFKFB3	-0.41	-4.4	-0.34	2.05e-5	Intelligence;
PAAD	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.53	-5.09	-0.38	1.02e-6	Motion sickness;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18482326	chr11:1968310	MRPL23	-0.6	-6.8	-0.48	2.2e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	1.19	14.43	0.76	2.73e-30	Longevity;
PAAD	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.83	8.73	0.58	4.37e-15	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01698108	chr3:182880470	LAMP3	-0.77	-6.83	-0.48	1.9e-10	Neuroticism;
PAAD	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg05341575	chr12:125625032	AACS	-0.5	-4.46	-0.34	1.6e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg18281939	chr5:77783895	LHFPL2	0.49	5.5	0.41	1.57e-7	Triglycerides;
PAAD	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs375066	0.901	rs451945	chr19:44408753	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg14146966	chr2:61757674	XPO1	-0.39	-4.92	-0.37	2.19e-6	Tuberculosis;
PAAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.72	8.91	0.59	1.45e-15	Vitiligo;
PAAD	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.49	-5.2	-0.39	6.22e-7	Schizophrenia;
PAAD	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.72	-5.59	-0.41	1.04e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg03909863	chr11:638404	DRD4	-0.66	-5.31	-0.4	3.89e-7	Systemic lupus erythematosus;
PAAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg07959070	chr22:50026188	C22orf34	-0.37	-4.58	-0.35	9.59e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.76	5.9	0.43	2.28e-8	Lung function (FEV1/FVC);
PAAD	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg11057378	chr10:81107060	PPIF	0.51	6.02	0.44	1.26e-8	Height;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg15660573	chr17:549704	VPS53	-0.84	-8.6	-0.57	8.96e-15	Prostate cancer;
PAAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.56	-6.19	-0.45	5.25e-9	Cognitive function;
PAAD	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg06207120	chr15:45996521	NA	0.3	4.38	0.33	2.24e-5	Waist circumference;Weight;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02071572	chr4:1403502	NA	0.36	4.64	0.35	7.62e-6	Longevity;
PAAD	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.77	7.21	0.5	2.42e-11	Platelet distribution width;
PAAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg20003494	chr4:90757398	SNCA	-0.66	-6.19	-0.45	5.22e-9	Neuroticism;
PAAD	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-4.39	-0.34	2.14e-5	Asthma;
PAAD	cis	rs13053817	1.000	rs7290684	chr22:29857664	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.99	-0.37	1.66e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg07371521	chr5:154026371	NA	-0.45	-5.75	-0.42	4.74e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.5	5.9	0.43	2.27e-8	Height;
PAAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg04315214	chr1:2043799	PRKCZ	0.66	9.29	0.6	1.57e-16	Height;
PAAD	cis	rs832187	0.603	rs7615475	chr3:63926661	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.44	-4.25	-0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg10396713	chr8:602097	NA	0.67	4.28	0.33	3.32e-5	IgG glycosylation;
PAAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg19223190	chr17:80058835	NA	0.52	5.28	0.39	4.31e-7	Life satisfaction;
PAAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.74	8.44	0.56	2.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7192380	0.651	rs72783115	chr16:69702839	G/A	cg15192750	chr16:69999425	NA	0.49	4.26	0.33	3.54e-5	Sjögren's syndrome;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.7	0.42	6.02e-8	Prudent dietary pattern;
PAAD	cis	rs6813479	0.594	rs1031711	chr4:137737358	A/C	cg16185213	chr4:137733633	NA	0.41	4.59	0.35	9.13e-6	Longevity;
PAAD	cis	rs1322639	0.550	rs9505943	chr6:169592919	C/T	cg26074411	chr6:169568564	NA	0.47	4.6	0.35	8.74e-6	Pulse pressure;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg16606324	chr3:10149918	C3orf24	0.59	4.94	0.37	2.07e-6	Alzheimer's disease;
PAAD	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.78	8.99	0.59	9.22e-16	Diastolic blood pressure;
PAAD	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.86	7.33	0.51	1.25e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.79	8.25	0.56	7.17e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs367943	0.698	rs4538600	chr5:112963488	T/C	cg12552261	chr5:112820674	MCC	0.53	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs2718812	0.792	rs1867503	chr3:133410648	G/A	cg11941060	chr3:133502564	NA	0.48	5.0	0.38	1.56e-6	Iron status biomarkers;
PAAD	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.58	4.69	0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.16	-14.23	-0.76	9.45e-30	Type 1 diabetes nephropathy;
PAAD	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.04e-8	Electrocardiographic conduction measures;
PAAD	cis	rs8038465	0.638	rs62004615	chr15:73957799	C/A	cg15420318	chr15:73925796	NPTN	0.45	4.42	0.34	1.85e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.9	7.57	0.52	3.35e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Bladder cancer;
PAAD	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.44	4.9	0.37	2.38e-6	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22412850	chr7:2754101	AMZ1	-0.66	-6.52	-0.47	9.88e-10	Obesity-related traits;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.53	4.88	0.37	2.64e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg08676812	chr11:65308423	LTBP3	1.52	7.96	0.54	3.65e-13	Height;
PAAD	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.52	-5.27	-0.39	4.6e-7	Gout;
PAAD	cis	rs490234	0.805	rs517064	chr9:128348486	C/T	cg14078157	chr9:128172775	NA	0.47	5.38	0.4	2.79e-7	Mean arterial pressure;
PAAD	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg16447950	chr5:562315	NA	-0.51	-4.8	-0.36	3.71e-6	Obesity-related traits;
PAAD	cis	rs992157	0.764	rs1870124	chr2:219187740	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.72	7.28	0.51	1.68e-11	Colorectal cancer;
PAAD	cis	rs2286503	0.839	rs2270105	chr7:22862467	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.78	7.89	0.54	5.68e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.73	-5.01	-0.38	1.49e-6	Monocyte percentage of white cells;
PAAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.11	11.72	0.69	5.09e-23	Lymphocyte percentage of white cells;
PAAD	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.69	0.42	6.31e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.64	-0.35	7.54e-6	Renal cell carcinoma;
PAAD	cis	rs9815354	0.812	rs17219090	chr3:42051952	G/C	cg03022575	chr3:42003672	ULK4	0.79	5.65	0.42	7.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg13256891	chr4:100009986	ADH5	0.73	7.61	0.53	2.61e-12	Alcohol dependence;
PAAD	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.2	-18.87	-0.84	1.12e-41	IgG glycosylation;
PAAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.56	-6.2	-0.45	5.05e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg14346243	chr4:90757452	SNCA	-0.49	-4.28	-0.33	3.24e-5	Neuroticism;
PAAD	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.41	-4.48	-0.34	1.43e-5	Bipolar disorder;
PAAD	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	6.17	0.45	5.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg25952890	chr19:58913133	NA	0.66	5.61	0.41	9.52e-8	Mean platelet volume;
PAAD	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.73	8.55	0.57	1.2e-14	Dental caries;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7223966	0.810	rs2665838	chr17:61966465	C/G	cg25324976	chr17:61989376	CSHL1	0.55	4.45	0.34	1.67e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4906172	1.000	rs2169926	chr14:102425872	T/C	cg23289024	chr14:102554846	HSP90AA1	0.4	4.36	0.33	2.41e-5	Menopause (age at onset);
PAAD	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.67	7.9	0.54	5.21e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg00484396	chr16:3507460	NAT15	0.87	7.12	0.5	3.96e-11	Tuberculosis;
PAAD	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.57	-6.17	-0.45	5.83e-9	Pelvic organ prolapse;
PAAD	cis	rs10501293	1.000	rs10768913	chr11:43060750	T/C	cg03447554	chr11:43094025	NA	0.52	5.16	0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg19486271	chr11:47235900	DDB2	-0.6	-6.06	-0.44	1.02e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.18	-0.39	6.81e-7	Dental caries;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs12431939	1.000	rs56220306	chr14:51648738	A/T	cg23942311	chr14:51606299	NA	-0.71	-5.74	-0.42	4.98e-8	Cancer;
PAAD	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.46	0.65	1.26e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs34779708	0.733	rs4102764	chr10:35545392	T/C	cg03585969	chr10:35415529	CREM	0.49	4.31	0.33	2.86e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.75	-5.75	-0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg14725641	chr11:61582763	MIR1908;FADS1	0.52	4.62	0.35	7.99e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.85	9.28	0.6	1.63e-16	Mortality in heart failure;
PAAD	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.72	-0.36	5.42e-6	Asthma (childhood onset);
PAAD	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07537551	chr16:22115461	VWA3A	-0.51	-6.68	-0.48	4.19e-10	Monocyte percentage of white cells;
PAAD	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.53	4.82	0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs354033	0.649	rs1965618	chr7:149193242	G/T	cg06920324	chr7:149264011	ZNF767	-0.62	-5.28	-0.39	4.45e-7	Multiple sclerosis;
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.8	6.26	0.45	3.73e-9	Platelet count;
PAAD	cis	rs10916814	0.632	rs10916818	chr1:20897425	C/T	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-6.05	-0.44	1.06e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	trans	rs9862730	0.519	rs349535	chr3:140250708	C/G	cg17082953	chr2:12856844	TRIB2	-0.86	-6.31	-0.46	2.9e-9	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs457162	0.643	rs281859	chr6:118586459	G/A	cg21191810	chr6:118973309	C6orf204	0.74	4.8	0.36	3.8e-6	QT interval;
PAAD	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.28e-5	Total body bone mineral density;
PAAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.96	12.63	0.72	1.9e-25	Menopause (age at onset);
PAAD	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.93	-10.79	-0.66	1.66e-20	Prostate cancer;
PAAD	cis	rs17036101	0.655	rs9808956	chr3:12215656	A/G	cg02700894	chr3:12045449	SYN2	-0.82	-4.29	-0.33	3.13e-5	Type 2 diabetes;
PAAD	cis	rs4739066	0.579	rs78867188	chr8:63870128	A/G	cg25248160	chr8:63776642	NKAIN3	0.76	4.84	0.37	3.16e-6	Myocardial infarction;
PAAD	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12612619	0.557	rs1368888	chr2:27068577	G/C	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.42	-0.34	1.85e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7517847	0.567	rs11209025	chr1:67693022	A/G	cg16314899	chr1:68516101	DIRAS3	-0.45	-4.4	-0.34	2.02e-5	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.54	-5.61	-0.41	9.22e-8	Huntington's disease progression;
PAAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg24253500	chr15:84953950	NA	0.56	6.3	0.46	3e-9	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.85	9.99	0.63	2.19e-18	Resting heart rate;
PAAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg14349672	chr11:133703707	NA	-0.47	-5.02	-0.38	1.45e-6	Childhood ear infection;
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.64	6.68	0.48	4.15e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.6	6.19	0.45	5.39e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.55	5.78	0.42	4.16e-8	Migraine;Coronary artery disease;
PAAD	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.49	4.36	0.33	2.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7555523	0.832	rs7524755	chr1:165694897	A/G	cg24409356	chr1:165738333	TMCO1	0.71	4.33	0.33	2.65e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.59	6.32	0.46	2.72e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22294845	chr11:66313678	ZDHHC24;ACTN3	0.6	6.95	0.49	1.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg13045555	chr8:105342365	NA	-0.26	-4.61	-0.35	8.47e-6	Paget's disease;
PAAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.46	-5.23	-0.39	5.56e-7	Height;
PAAD	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.62	4.37	0.33	2.33e-5	Alzheimer's disease;
PAAD	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.57	-7.77	-0.53	1.09e-12	Primary biliary cholangitis;
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.75	9.92	0.63	3.41e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg20487152	chr13:99095054	FARP1	0.47	4.99	0.38	1.65e-6	Longevity;
PAAD	cis	rs6466055	0.589	rs66638610	chr7:104977023	G/C	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.48	6.27	0.45	3.51e-9	Childhood ear infection;
PAAD	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.83	-5.98	-0.44	1.55e-8	Coronary artery calcification;
PAAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.76	-8.75	-0.58	3.87e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.43	4.44	0.34	1.72e-5	Motion sickness;
PAAD	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.75	8.73	0.58	4.16e-15	Lung cancer;
PAAD	cis	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg23352003	chr18:24237245	NA	-0.55	-5.62	-0.41	8.74e-8	Dental caries;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.0	11.02	0.67	3.95e-21	Homoarginine levels;
PAAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.63	0.35	7.84e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.48	4.83	0.37	3.25e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.61	-7.21	-0.51	2.4e-11	Systolic blood pressure;
PAAD	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.57	5.81	0.43	3.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7582720	0.945	rs72932711	chr2:203639846	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.05	7.3	0.51	1.52e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg20007245	chr22:24372913	LOC391322	-0.65	-6.37	-0.46	2.1e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9810890	1.000	rs114329538	chr3:128558387	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg02734326	chr4:10020555	SLC2A9	0.51	5.2	0.39	6.28e-7	Bone mineral density;
PAAD	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-4.32	-0.33	2.83e-5	IFN-related cytopenia;
PAAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.45	0.61	5.79e-17	Parkinson's disease;
PAAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21016266	chr12:122356598	WDR66	0.62	6.82	0.48	1.99e-10	Mean corpuscular volume;
PAAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg21395723	chr22:39101663	GTPBP1	0.46	4.74	0.36	4.98e-6	Menopause (age at onset);
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.62	-6.08	-0.44	9.41e-9	Inflammatory bowel disease;
PAAD	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs4343996	0.837	rs7802250	chr7:3475820	G/C	cg21248987	chr7:3385318	SDK1	0.5	5.54	0.41	1.27e-7	Motion sickness;
PAAD	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	1.02	7.65	0.53	2.09e-12	Dental caries;
PAAD	cis	rs1075265	0.584	rs1833497	chr2:54279323	A/G	cg04546899	chr2:54196757	PSME4	0.35	5.12	0.38	8.93e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.44	9.69	0.62	1.41e-17	Prostate cancer;
PAAD	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg14515779	chr1:101123966	NA	0.43	4.97	0.37	1.79e-6	Monocyte count;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg09417038	chr21:47716443	C21orf57	-0.6	-6.47	-0.46	1.26e-9	Testicular germ cell tumor;
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg24879335	chr3:133465180	TF	0.53	5.73	0.42	5.28e-8	Iron status biomarkers;
PAAD	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg20826740	chr17:37024042	NA	-0.48	-5.16	-0.39	7.5e-7	Height;
PAAD	cis	rs12935418	0.583	rs2549839	chr16:81023235	C/T	cg16651780	chr16:81037892	C16orf61	-0.66	-6.2	-0.45	5.15e-9	Mean corpuscular volume;
PAAD	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs787274	1.000	rs7859175	chr9:115587160	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.37	4.52	0.34	1.22e-5	Intraocular pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16133943	chr11:68205926	LRP5	-0.69	-6.89	-0.49	1.36e-10	Obesity-related traits;
PAAD	cis	rs4936891	0.577	rs12225469	chr11:123902719	G/A	cg22125253	chr11:123886957	OR10G4	-0.43	-4.32	-0.33	2.8e-5	Male fertility;
PAAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.57	-6.27	-0.45	3.48e-9	High light scatter reticulocyte count;
PAAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.59	6.91	0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.75	-5.75	-0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg23173402	chr1:227635558	NA	0.72	4.71	0.36	5.65e-6	Major depressive disorder;
PAAD	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08007110	chr3:88198601	C3orf38	0.67	6.64	0.47	5.21e-10	Obesity-related traits;
PAAD	cis	rs60154123	1.000	rs60154123	chr1:210468999	C/T	cg25204440	chr1:209979598	IRF6	0.58	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs1032355	0.558	rs79194015	chr4:100518483	A/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.64	-9.51	-0.61	3.96e-17	Body mass index;
PAAD	cis	rs375066	0.806	rs415168	chr19:44402574	C/G	cg08633290	chr19:44405433	NA	-0.6	-5.86	-0.43	2.75e-8	Breast cancer;
PAAD	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.37	0.46	2.12e-9	Mean platelet volume;
PAAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.59	0.41	1.02e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.57	-7.03	-0.5	6.56e-11	Breast cancer;
PAAD	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg18621852	chr3:10150065	C3orf24	0.59	5.01	0.38	1.5e-6	Alzheimer's disease;
PAAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs4900538	0.750	rs12590618	chr14:102808330	C/T	cg18135206	chr14:102964638	TECPR2	-0.79	-8.08	-0.55	1.83e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg04717802	chr22:42394638	WBP2NL	0.52	4.97	0.37	1.75e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.39	-0.34	2.14e-5	Systemic lupus erythematosus;
PAAD	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.06	-0.38	1.2e-6	Personality dimensions;
PAAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.31	0.71	1.35e-24	Bone mineral density;
PAAD	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.52	-4.89	-0.37	2.59e-6	Essential tremor;
PAAD	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg02683114	chr2:24398427	C2orf84	-0.46	-4.83	-0.36	3.35e-6	Sjögren's syndrome;
PAAD	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg01953289	chr20:60874239	NA	0.66	4.79	0.36	3.9e-6	Obesity-related traits;
PAAD	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.53	-0.35	1.16e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.87	-10.68	-0.65	3.2e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.07	0.38	1.13e-6	Rheumatoid arthritis;
PAAD	cis	rs1419980	0.730	rs11054853	chr12:7768993	C/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	5.77	0.42	4.23e-8	Adiposity;
PAAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.72	5.39	0.4	2.69e-7	Fat distribution (HIV);
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	6.38	0.46	2.05e-9	Alzheimer's disease;
PAAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.23e-5	Tonsillectomy;
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.93e-6	Breast cancer;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg23708337	chr7:1209742	NA	0.66	4.88	0.37	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg03989125	chr22:38214979	NA	0.59	5.35	0.4	3.23e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.42	4.31	0.33	2.9e-5	Ovarian reserve;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.98	-0.37	1.71e-6	Joint mobility (Beighton score);
PAAD	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20445582	chr4:55083843	NA	0.77	7.85	0.54	6.74e-13	Obesity-related traits;
PAAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	5.51	0.41	1.52e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.53	5.98	0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.37	-0.51	1.04e-11	Neuroticism;
PAAD	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-6.63	-0.47	5.66e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.19	-0.45	5.47e-9	Bipolar disorder;
PAAD	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10276381	0.579	rs11520706	chr7:28202748	C/T	cg23620719	chr7:28220237	JAZF1	-0.82	-4.84	-0.37	3.15e-6	Crohn's disease;
PAAD	cis	rs904092	0.720	rs1229977	chr4:100202414	A/G	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.36	-10.89	-0.66	8.92e-21	Obesity-related traits;
PAAD	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg07159951	chr1:45983175	PRDX1	0.42	4.64	0.35	7.38e-6	High light scatter reticulocyte count;
PAAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.89	0.49	1.4e-10	Schizophrenia;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.56	-6.94	-0.49	1.07e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg12143784	chr7:64541923	NA	-0.44	-5.73	-0.42	5.15e-8	Calcium levels;
PAAD	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04210544	chr13:111806530	ARHGEF7	0.6	6.73	0.48	3.31e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg21191810	chr6:118973309	C6orf204	0.48	6.68	0.48	4.33e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs7561273	0.545	rs10865262	chr2:24337594	A/G	cg04809136	chr2:24300158	SF3B14	-0.49	-5.55	-0.41	1.21e-7	Quantitative traits;
PAAD	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12612619	0.704	rs6742004	chr2:27309659	A/C	cg00617064	chr2:27272375	NA	-0.52	-5.4	-0.4	2.57e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.58	5.77	0.42	4.28e-8	Blood metabolite levels;
PAAD	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.49	5.1	0.38	1.01e-6	Bipolar disorder;
PAAD	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.54	4.52	0.34	1.22e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg00579200	chr11:133705235	NA	-0.51	-5.78	-0.42	4.19e-8	Childhood ear infection;
PAAD	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.62	-6.15	-0.45	6.42e-9	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02455064	chr1:233086327	C1orf57	0.64	7.22	0.51	2.27e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.18	-0.39	6.88e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-4.32	-0.33	2.75e-5	Retinal vascular caliber;
PAAD	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-5.83	-0.43	3.22e-8	Electroencephalogram traits;
PAAD	cis	rs4455778	0.580	rs10215945	chr7:49096423	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg14926445	chr8:58193284	C8orf71	-0.66	-5.19	-0.39	6.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.7	-0.8	3.19e-36	Height;
PAAD	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg20935368	chr5:178288625	ZNF354B	0.53	5.19	0.39	6.5e-7	Sleep duration;
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.49	-0.34	1.39e-5	Educational attainment;
PAAD	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg15017067	chr4:17643749	FAM184B	-0.41	-4.39	-0.34	2.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09760836	chr7:140397266	LOC100134713;NDUFB2	0.62	7.22	0.51	2.32e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg21452805	chr1:244014465	NA	0.47	4.4	0.34	2.06e-5	RR interval (heart rate);
PAAD	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg20703997	chr1:4087676	NA	0.48	4.35	0.33	2.46e-5	Interleukin-17 levels;
PAAD	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.52	-5.08	-0.38	1.07e-6	Corneal structure;
PAAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09597638	chr17:3907349	NA	0.73	7.65	0.53	2.15e-12	Type 2 diabetes;
PAAD	cis	rs4908768	0.501	rs6577491	chr1:8574972	G/T	cg20416874	chr1:8611966	RERE	-0.45	-4.28	-0.33	3.26e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg18370025	chr7:2749541	AMZ1	-0.4	-4.65	-0.35	7.31e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12439463	chr17:79848761	ANAPC11;THOC4	0.6	6.78	0.48	2.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg10591111	chr5:226296	SDHA	-0.72	-5.53	-0.41	1.37e-7	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02030628	chr11:62554067	TMEM179B;TAF6L	0.6	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6011674	1.000	rs45469101	chr20:61875007	C/T	cg12002882	chr20:62461365	NA	-0.75	-4.38	-0.33	2.19e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.44	0.4	2.04e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.94	-8.2	-0.55	9.41e-14	Inflammatory bowel disease;
PAAD	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.41	-6.2	-0.45	5.06e-9	Subjective well-being;
PAAD	cis	rs6782025	0.802	rs338973	chr3:120941010	T/C	cg16417163	chr3:121280760	NA	-0.46	-4.73	-0.36	5.08e-6	Aging (facial);
PAAD	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.23	0.56	7.79e-14	Alzheimer's disease (late onset);
PAAD	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.63	6.07	0.44	9.75e-9	IgG glycosylation;
PAAD	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	1.1	6.76	0.48	2.81e-10	Interleukin-17 levels;
PAAD	cis	rs58521262	0.505	rs460336	chr19:23123423	C/G	cg02350677	chr19:23254381	NA	-0.26	-4.66	-0.35	6.73e-6	Testicular germ cell tumor;
PAAD	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.57	-5.28	-0.39	4.48e-7	Blood metabolite levels;
PAAD	cis	rs2288884	0.943	rs11084131	chr19:52514446	G/A	cg24368865	chr19:51538134	KLK12	0.49	4.43	0.34	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
PAAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg05564831	chr3:52568323	NT5DC2	-0.43	-4.48	-0.34	1.43e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.81	8.24	0.56	7.45e-14	Cognitive function;
PAAD	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16006141	chr1:25167475	CLIC4	-0.62	-6.77	-0.48	2.66e-10	Obesity-related traits;
PAAD	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-15.16	-0.78	3.3e-32	Ulcerative colitis;
PAAD	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs72960926	1.000	rs72969274	chr6:75089862	G/A	cg13997649	chr6:74171430	MTO1	0.79	4.38	0.33	2.2e-5	Metabolite levels (MHPG);
PAAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg01075559	chr1:2537774	MMEL1	0.52	5.46	0.4	1.93e-7	Ulcerative colitis;
PAAD	trans	rs901683	1.000	rs71496613	chr10:46032573	A/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.68	-7.01	-0.49	7.38e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs1270639	1.000	rs1270639	chr7:157455459	C/T	cg13357408	chr7:157437802	PTPRN2	-1.07	-8.78	-0.58	3.2e-15	Colorectal cancer;
PAAD	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17467752	chr17:38218738	THRA	0.49	4.44	0.34	1.74e-5	Myeloid white cell count;
PAAD	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.68	-6.1	-0.44	8.31e-9	Mortality in heart failure;
PAAD	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg19760965	chr3:194868843	C3orf21	0.45	4.69	0.36	5.95e-6	Non-small cell lung cancer;
PAAD	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.56	0.35	1.06e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-6.39	-0.46	1.87e-9	Longevity;Endometriosis;
PAAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13181826	chr7:75987607	YWHAG	0.56	6.54	0.47	8.93e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.5	-4.88	-0.37	2.66e-6	Parkinson's disease;
PAAD	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.73	-9.08	-0.59	5.35e-16	Dental caries;
PAAD	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Diabetic kidney disease;
PAAD	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg26876637	chr1:152193138	HRNR	-0.82	-6.01	-0.44	1.34e-8	Atopic dermatitis;
PAAD	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg16576597	chr16:28551801	NUPR1	-0.66	-6.72	-0.48	3.46e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3925075	0.509	rs11150614	chr16:31366016	A/G	cg02846316	chr16:31340340	ITGAM	0.41	4.7	0.36	5.67e-6	IgA nephropathy;
PAAD	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.76	7.41	0.51	8.34e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.72	0.42	5.57e-8	Schizophrenia;
PAAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.75	7.14	0.5	3.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08642814	chr1:3734907	KIAA0562	-0.66	-6.57	-0.47	7.61e-10	Obesity-related traits;
PAAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.43	4.36	0.33	2.4e-5	Type 2 diabetes;
PAAD	trans	rs2162440	0.571	rs11082015	chr18:35209716	T/C	cg18355902	chr4:154681128	RNF175	0.75	6.33	0.46	2.56e-9	Telomere length;
PAAD	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.65	7.44	0.52	7.01e-12	Height;
PAAD	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.85	0.37	2.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.48e-6	Daytime sleep phenotypes;
PAAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-4.92	-0.37	2.22e-6	Lung cancer;
PAAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.62	-7.5	-0.52	5.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4388249	0.687	rs2300998	chr5:109083122	G/A	cg17395555	chr5:108820864	NA	0.32	4.4	0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	1.1	5.73	0.42	5.22e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10203711	0.509	rs11684544	chr2:239601424	G/A	cg08825699	chr2:239983929	HDAC4	-0.48	-4.58	-0.35	9.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg16606324	chr3:10149918	C3orf24	0.67	5.4	0.4	2.51e-7	Alzheimer's disease;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.7	6.86	0.49	1.64e-10	Cancer;
PAAD	cis	rs1372356	0.816	rs1837848	chr14:88522512	G/T	cg18078958	chr14:88630771	NA	0.47	5.97	0.44	1.6e-8	Food antigen IgG levels;
PAAD	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.53	-0.41	1.36e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-17.57	-0.82	1.96e-38	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.47	-0.34	1.51e-5	Tonsillectomy;
PAAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg07153921	chr17:41440717	NA	-0.4	-4.26	-0.33	3.58e-5	Menopause (age at onset);
PAAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.86	9.64	0.62	1.86e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18337363	chr3:52569053	NT5DC2	0.43	4.49	0.34	1.38e-5	Bipolar disorder;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg15117754	chr3:10150083	C3orf24	0.81	7.11	0.5	4.14e-11	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.61	6.74	0.48	3.1e-10	Lung cancer;
PAAD	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	1.24	7.69	0.53	1.74e-12	Cannabis dependence symptom count;
PAAD	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-5.07	-0.38	1.14e-6	Diastolic blood pressure;
PAAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.64	-0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12949688	0.601	rs11079325	chr17:55834785	A/C	cg12582317	chr17:55822272	NA	0.47	5.49	0.41	1.65e-7	Schizophrenia;
PAAD	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg04289385	chr6:36355825	ETV7	0.43	4.52	0.34	1.25e-5	Platelet distribution width;
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg07212818	chr11:638076	DRD4	-0.76	-6.92	-0.49	1.19e-10	Systemic lupus erythematosus;
PAAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs3733418	0.860	rs13141887	chr4:165950921	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-4.97	-0.37	1.75e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10325398	chr1:45476990	HECTD3;UROD	0.67	7.0	0.49	7.54e-11	Myopia (pathological);
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg16205897	chr5:131564050	P4HA2	-0.43	-4.51	-0.34	1.3e-5	Acylcarnitine levels;
PAAD	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.91	11.9	0.69	1.67e-23	Body mass index;
PAAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.55	6.41	0.46	1.76e-9	Monocyte count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12866999	chr12:70636632	CNOT2	-0.74	-7.19	-0.5	2.75e-11	Neuroticism;
PAAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg04315214	chr1:2043799	PRKCZ	0.66	9.41	0.61	7.4e-17	Height;
PAAD	cis	rs9638182	1.000	rs6976930	chr7:72885810	G/A	cg07467649	chr7:72856462	BAZ1B	0.53	4.36	0.33	2.39e-5	Triglycerides;
PAAD	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00079375	chr15:79125835	NA	0.43	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.51	-0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	1.19	8.9	0.59	1.59e-15	Lymphocyte counts;
PAAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg11204139	chr17:3907470	NA	0.66	7.04	0.5	6.08e-11	Type 2 diabetes;
PAAD	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.87	11.27	0.67	8.4e-22	Eosinophil percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05648345	chr19:10662621	ATG4D;MIR1238	-0.61	-6.54	-0.47	8.7e-10	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.49	-0.47	1.16e-9	Longevity;Endometriosis;
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg12705353	chr12:122356852	WDR66	-0.46	-5.17	-0.39	7.32e-7	Mean corpuscular volume;
PAAD	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg23912435	chr1:150601613	ENSA	0.5	4.6	0.35	8.74e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.47	-7.19	-0.5	2.7e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg12215294	chr3:40350768	EIF1B	-0.42	-4.29	-0.33	3.11e-5	Renal cell carcinoma;
PAAD	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.68	-6.99	-0.49	7.92e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.14	8.43	0.56	2.48e-14	Type 2 diabetes;
PAAD	cis	rs7771547	0.723	rs61211228	chr6:36553416	T/C	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.59	5.34	0.4	3.34e-7	Corneal astigmatism;
PAAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.44	-0.34	1.69e-5	Fat distribution (HIV);
PAAD	cis	rs73416724	1.000	rs75782458	chr6:43340810	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs2229238	0.911	rs73023349	chr1:154513440	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.9	-0.37	2.39e-6	Coronary heart disease;
PAAD	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg27478167	chr7:817139	HEATR2	-0.72	-5.62	-0.41	8.73e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs2908197	0.737	rs9770303	chr7:75999357	T/C	cg22830091	chr7:75961684	YWHAG	-0.63	-7.45	-0.52	6.51e-12	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.69	8.12	0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17376030	chr22:41985996	PMM1	-0.63	-4.35	-0.33	2.46e-5	Vitiligo;
PAAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs1499972	0.941	rs817508	chr3:117685576	T/C	cg07612923	chr3:117604196	NA	-1.09	-7.22	-0.51	2.34e-11	Schizophrenia;
PAAD	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.56	5.11	0.38	9.71e-7	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg03983715	chr16:68378420	PRMT7	-0.74	-5.4	-0.4	2.54e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs59888335	0.792	rs13082407	chr3:80523653	T/G	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.63	-0.35	7.73e-6	Obesity-related traits;
PAAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.36	-0.51	1.05e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.5	4.46	0.34	1.59e-5	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.45	6.25	0.45	3.95e-9	Vitiligo;
PAAD	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg05785598	chr3:49045655	WDR6	0.43	5.06	0.38	1.2e-6	Parkinson's disease;
PAAD	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-5.22	-0.39	5.76e-7	Resting heart rate;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.33e-7	Noise-induced hearing loss;
PAAD	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg10818794	chr15:86012489	AKAP13	0.5	5.28	0.39	4.39e-7	Bulimia nervosa;
PAAD	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.54	5.53	0.41	1.34e-7	Multiple sclerosis;
PAAD	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg09597638	chr17:3907349	NA	0.64	4.45	0.34	1.67e-5	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
PAAD	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg14092988	chr3:52407081	DNAH1	0.38	4.55	0.35	1.1e-5	Electroencephalogram traits;
PAAD	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.29	-0.45	3.13e-9	Crohn's disease;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg00024416	chr22:24240387	NA	-0.58	-4.57	-0.35	1.01e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7551345	0.853	rs7542403	chr1:31749534	A/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg10547527	chr2:198650123	BOLL	-0.72	-4.81	-0.36	3.53e-6	Ulcerative colitis;
PAAD	cis	rs1451882	0.800	rs12547408	chr8:1054205	G/A	cg07395941	chr8:1078200	NA	0.61	4.58	0.35	9.59e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.52	-4.5	-0.34	1.37e-5	Airflow obstruction;
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.8	8.68	0.58	5.84e-15	Prostate cancer;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg22029157	chr1:209979665	IRF6	0.73	7.06	0.5	5.54e-11	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs4787951	0.560	rs3024548	chr16:27354531	C/G	cg08008352	chr16:27322356	NA	0.44	4.37	0.33	2.26e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.78	-6.99	-0.49	8.23e-11	Blood protein levels;
PAAD	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg02993010	chr8:124780839	FAM91A1	0.72	5.5	0.41	1.58e-7	Pancreatic cancer;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs3931020	0.745	rs1980851	chr1:75268971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.63	6.33	0.46	2.55e-9	Resistin levels;
PAAD	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.68	-7.25	-0.51	2e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.36	4.64	0.35	7.62e-6	Prostate cancer;
PAAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.61	0.35	8.5e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10633479	chr7:157333584	PTPRN2	-0.64	-6.42	-0.46	1.63e-9	Obesity-related traits;
PAAD	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04213038	chr11:6704667	MRPL17	0.65	6.63	0.47	5.54e-10	Obesity-related traits;
PAAD	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.4	0.46	1.87e-9	Bladder cancer;
PAAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg12639453	chr1:2035780	PRKCZ	-0.48	-4.54	-0.35	1.11e-5	Height;
PAAD	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8060686	0.920	rs73591955	chr16:67782568	G/T	cg09835421	chr16:68378352	PRMT7	-0.86	-4.94	-0.37	2.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs59888335	0.964	rs11712290	chr3:80682899	G/A	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	trans	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	1.13	12.5	0.71	4.09e-25	Longevity;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15682851	chr17:44076429	STH;MAPT	-0.71	-6.97	-0.49	8.99e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.86	8.58	0.57	1.04e-14	Blood protein levels;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg24879335	chr3:133465180	TF	0.58	6.38	0.46	2.06e-9	Iron status biomarkers;
PAAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.63	6.25	0.45	3.88e-9	Longevity;
PAAD	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.66	-7.83	-0.54	7.8e-13	HDL cholesterol;
PAAD	cis	rs2695743	0.592	rs1438060	chr2:178683973	C/T	cg07513188	chr2:178257585	LOC100130691;AGPS	-0.42	-4.34	-0.33	2.58e-5	Cough in response to angiotensin-converting enzyme inhibitor drugs;
PAAD	cis	rs9816226	0.591	rs4234589	chr3:185818882	A/G	cg00760338	chr3:185826511	ETV5	-0.72	-5.39	-0.4	2.61e-7	Obesity;Body mass index;
PAAD	cis	rs9463078	0.838	rs1924662	chr6:45140332	T/A	cg25276700	chr6:44698697	NA	-0.48	-5.44	-0.4	2.09e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9463078	0.715	rs9463076	chr6:45171362	C/T	cg25276700	chr6:44698697	NA	0.54	6.07	0.44	9.65e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg01298731	chr4:154711457	SFRP2	-0.37	-4.56	-0.35	1.06e-5	Electrocardiographic conduction measures;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27229962	chr1:161099900	DEDD	-0.55	-6.4	-0.46	1.8e-9	Monocyte percentage of white cells;
PAAD	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg22349387	chr12:9600060	DDX12	0.43	4.58	0.35	9.43e-6	Breast size;
PAAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.67	7.08	0.5	5.12e-11	Obesity-related traits;
PAAD	cis	rs13065560	0.534	rs6789111	chr3:38904222	G/A	cg01426195	chr3:39028469	NA	-0.46	-4.4	-0.34	2.05e-5	Interleukin-18 levels;
PAAD	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14339287	chr19:14640339	TECR;MIR639	0.67	7.11	0.5	4.27e-11	Myopia (pathological);
PAAD	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg07168214	chr17:7380112	ZBTB4	0.63	6.07	0.44	9.7e-9	Androgen levels;
PAAD	cis	rs17407555	0.657	rs1558488	chr4:10327414	A/G	cg00071950	chr4:10020882	SLC2A9	0.44	4.72	0.36	5.37e-6	Schizophrenia (age at onset);
PAAD	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.78	6.53	0.47	9.2e-10	Recombination rate (females);
PAAD	cis	rs2885056	0.891	rs892081	chr19:10680684	G/T	cg25279553	chr19:10444815	RAVER1;ICAM3	0.44	4.54	0.35	1.15e-5	Red cell distribution width;
PAAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.88	8.25	0.56	6.84e-14	Methadone dose in opioid dependence;
PAAD	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06850241	chr22:41845214	NA	0.49	4.26	0.33	3.55e-5	Vitiligo;
PAAD	cis	rs6782025	0.794	rs7643267	chr3:120808811	T/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.82	-6.77	-0.48	2.6200000000000003e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.97	12.48	0.71	4.83e-25	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.56	5.95	0.43	1.75e-8	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.63	-4.58	-0.35	9.62e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	4.52	0.34	1.24e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	7.14	0.5	3.5e-11	Migraine;Coronary artery disease;
PAAD	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.57	5.94	0.43	1.88e-8	Dupuytren's disease;
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.36	0.33	2.43e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6445525	1.000	rs6805139	chr3:66005660	G/A	cg06109867	chr3:66002991	MAGI1	-0.46	-4.68	-0.35	6.41e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg26205652	chr12:48591994	NA	0.76	6.94	0.49	1.04e-10	Longevity (90 years and older);
PAAD	cis	rs11679640	0.589	rs11124901	chr2:43132427	C/G	cg04767697	chr2:43016446	HAAO	-0.45	-4.41	-0.34	1.94e-5	White matter hyperintensity burden;
PAAD	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.53	8.0	0.54	3.01e-13	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24752028	chr2:30369779	YPEL5	0.66	6.99	0.49	8.01e-11	Myopia (pathological);
PAAD	cis	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.8	-0.43	3.76e-8	HDL cholesterol;
PAAD	cis	rs17021463	0.643	rs6841656	chr4:95300532	A/G	cg11021082	chr4:95130006	SMARCAD1	0.51	5.18	0.39	7.08e-7	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.72	8.08	0.55	1.82e-13	Lung cancer;
PAAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.55	-5.29	-0.39	4.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	0.87	9.22	0.6	2.26e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.54	0.47	8.61e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	11.53	0.68	1.69e-22	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg04002187	chr5:40835754	RPL37	0.78	4.25	0.33	3.75e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.15	9.87	0.62	4.68e-18	Vitiligo;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.5	-0.41	1.54e-7	Bipolar disorder;
PAAD	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-7.23	-0.51	2.18e-11	Asthma;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.29e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.28	0.6	1.62e-16	Bipolar disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19358568	chr6:129614126	LAMA2	0.56	6.88	0.49	1.43e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs9487051	0.646	rs11153167	chr6:109622582	A/T	cg21918786	chr6:109611834	NA	0.53	5.63	0.42	8.64e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6132905	0.590	rs74681083	chr20:2623992	A/C	cg24848351	chr20:2622020	TMC2	-0.76	-5.52	-0.41	1.43e-7	Mumps;
PAAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs400736	0.655	rs55634431	chr1:8149549	G/A	cg25007680	chr1:8021821	PARK7	-0.54	-5.0	-0.38	1.55e-6	Response to antidepressants and depression;
PAAD	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.42	-4.54	-0.35	1.12e-5	Platelet count;
PAAD	cis	rs7771547	0.574	rs11756557	chr6:36597695	A/G	cg07856975	chr6:36356162	ETV7	0.55	5.86	0.43	2.83e-8	Platelet distribution width;
PAAD	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.49	4.54	0.35	1.16e-5	Pancreatic cancer;
PAAD	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.4	-0.34	1.99e-5	Fear of minor pain;
PAAD	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.56	-5.52	-0.41	1.43e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg21994712	chr19:21861136	NA	-0.48	-4.62	-0.35	8.12e-6	Pain;
PAAD	cis	rs621942	0.948	rs7117280	chr11:85845829	C/A	cg07180834	chr11:85838833	NA	-0.53	-5.18	-0.39	6.99e-7	Tourette syndrome;
PAAD	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.83	8.8	0.58	2.79e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.62	-0.35	8.14e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21647473	chr3:136581035	NCK1	-0.64	-6.73	-0.48	3.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.45	4.88	0.37	2.64e-6	Loneliness (linear analysis);
PAAD	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.59	5.56	0.41	1.21e-7	Daytime sleep phenotypes;
PAAD	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6e-9	Subjective well-being;
PAAD	cis	rs427941	0.668	rs201461	chr7:101741625	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.14	16.6	0.8	5.7e-36	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.81e-7	Life satisfaction;
PAAD	cis	rs6466055	0.612	rs56281713	chr7:104913947	A/G	cg04380332	chr7:105027541	SRPK2	0.51	4.9	0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.73	5.21	0.39	6.17e-7	Major depressive disorder;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.87	8.05	0.55	2.17e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-4.69	-0.36	6.01e-6	Pulmonary function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23547048	chr4:698616	PCGF3	0.56	6.41	0.46	1.75e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.54	5.19	0.39	6.49e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.36e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.93	8.32	0.56	4.57e-14	Obesity-related traits;
PAAD	cis	rs10887741	0.532	rs2755432	chr10:89414779	C/T	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.13	-0.38	8.66e-7	Exercise (leisure time);
PAAD	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.54	-5.05	-0.38	1.23e-6	Red blood cell count;
PAAD	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9832625	0.582	rs1025645	chr3:29332530	A/G	cg06712285	chr3:29990487	RBMS3	0.77	5.3	0.39	4e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Educational attainment;
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg07841815	chr7:100318223	EPO	-0.48	-4.39	-0.34	2.11e-5	Other erythrocyte phenotypes;
PAAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg23465465	chr6:26364728	BTN3A2	0.79	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.61	4.52	0.34	1.23e-5	Neuroblastoma;
PAAD	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg22143856	chr6:28129313	ZNF389	0.53	4.86	0.37	2.85e-6	Parkinson's disease;
PAAD	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg26174226	chr8:58114915	NA	-0.69	-6.2	-0.45	4.95e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26549601	chr10:134560360	INPP5A	-0.49	-4.7	-0.36	5.91e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.46	4.48	0.34	1.47e-5	Dupuytren's disease;
PAAD	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.55	6.86	0.49	1.6e-10	Atrioventricular conduction;
PAAD	cis	rs4834770	0.746	rs2389747	chr4:120236102	C/T	cg09307838	chr4:120376055	NA	0.59	5.76	0.42	4.57e-8	Blood protein levels;
PAAD	cis	rs17539620	0.702	rs59388222	chr6:154877655	T/G	cg20019720	chr6:154832845	CNKSR3	0.52	7.29	0.51	1.58e-11	Lipoprotein (a) levels;
PAAD	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg15621731	chr19:5074616	KDM4B	0.32	4.56	0.35	1.07e-5	Monocyte percentage of white cells;
PAAD	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg27094323	chr7:1216898	NA	-0.54	-6.45	-0.46	1.38e-9	Longevity;Endometriosis;
PAAD	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.16	-9.26	-0.6	1.88e-16	Plateletcrit;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23103367	chr13:60970259	TDRD3	-0.59	-6.72	-0.48	3.4e-10	Body fat percentage;
PAAD	cis	rs11651753	0.561	rs7211859	chr17:45986282	C/A	cg24458315	chr17:46148407	CBX1	0.41	4.52	0.34	1.25e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs10950821	0.843	rs73684578	chr7:20665782	T/A	cg21202529	chr7:20656503	ABCB5	-0.51	-4.79	-0.36	3.87e-6	Response to statin therapy;
PAAD	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg21918786	chr6:109611834	NA	-0.42	-4.53	-0.34	1.21e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8113142	0.614	rs4805261	chr19:29213292	T/C	cg04546413	chr19:29218101	NA	0.43	4.35	0.33	2.48e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg04398451	chr17:18023971	MYO15A	-0.77	-8.58	-0.57	1e-14	Total body bone mineral density;
PAAD	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	trans	rs901683	1.000	rs34670342	chr10:46066162	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12292205	chr6:26970375	C6orf41	-0.49	-4.63	-0.35	7.68e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1406084	0.541	rs2119722	chr2:154628843	C/T	cg01088528	chr2:201753695	PPIL3;NIF3L1	0.97	6.39	0.46	1.88e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.93	-9.67	-0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.7	-6.64	-0.47	5.23e-10	Obesity-related traits;
PAAD	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.81	-6.18	-0.45	5.53e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7301016	0.948	rs11174498	chr12:62865345	T/C	cg19781863	chr12:62918364	MON2	0.75	4.44	0.34	1.7e-5	IgG glycosylation;
PAAD	trans	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.71	-0.48	3.56e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08884247	chr17:36957996	CCDC49	-0.51	-6.44	-0.46	1.51e-9	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.71	0.42	5.71e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.26e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.83	0.36	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25867650	chr15:75743273	SIN3A	0.58	6.49	0.47	1.16e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs11113894	0.901	rs12581933	chr12:108859277	C/T	cg06834313	chr12:108851556	NA	-0.75	-4.59	-0.35	9.14e-6	Obesity-related traits;
PAAD	cis	rs35260072	1	rs35260072	chr5:131630852	A/C	cg16205897	chr5:131564050	P4HA2	-0.44	-4.5	-0.34	1.37e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1799810	0.739	rs13030284	chr2:128158719	G/A	cg09760422	chr2:128146352	NA	-0.42	-6.66	-0.48	4.62e-10	Self-rated health;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.87	-0.58	1.86e-15	Type 2 diabetes;
PAAD	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.74	7.55	0.52	3.65e-12	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.23	0.39	5.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.65	-5.69	-0.42	6.4e-8	Response to metformin (IC50);
PAAD	cis	rs4740619	0.563	rs1359950	chr9:15987539	A/C	cg14451791	chr9:16040625	NA	0.37	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-7.38	-0.51	9.82e-12	Asthma;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg27490568	chr2:178487706	NA	0.43	4.78	0.36	4.06e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12044355	0.929	rs1954175	chr1:231855410	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.95	0.37	1.91e-6	Alzheimer's disease;
PAAD	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.68	7.43	0.52	7.2e-12	Prostate cancer;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11700980	0.551	rs62223676	chr21:30118000	C/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.87	11.06	0.67	3.12e-21	Methadone dose in opioid dependence;
PAAD	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	0.69	4.27	0.33	3.47e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs1075265	0.528	rs2018747	chr2:54309624	G/C	cg04546899	chr2:54196757	PSME4	0.31	4.55	0.35	1.09e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-4.93	-0.37	2.1e-6	Total body bone mineral density;
PAAD	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg14582100	chr15:45693742	SPATA5L1	0.43	6.72	0.48	3.38e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.73	0.58	4.36e-15	Homoarginine levels;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg04632378	chr13:21900426	NA	0.69	7.3	0.51	1.5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1507153	0.523	rs236884	chr6:79319525	C/G	cg05283184	chr6:79620031	NA	0.36	4.32	0.33	2.86e-5	Sjögren's syndrome;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25522149	chr19:11372842	DOCK6	-0.73	-6.74	-0.48	3.03e-10	Neuroticism;
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg09017928	chr7:158110068	PTPRN2	-0.48	-4.35	-0.33	2.51e-5	Calcium levels;
PAAD	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.05	0.38	1.27e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs35164067	1.000	rs35164067	chr19:10525181	G/A	cg24189696	chr19:10585866	NA	0.44	4.95	0.37	1.96e-6	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	5.9e-8	Life satisfaction;
PAAD	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.63	-0.47	5.61e-10	Eye color traits;
PAAD	cis	rs11167764	0.895	rs891986	chr5:141466080	C/G	cg08523384	chr5:141488047	NDFIP1	-0.58	-5.2	-0.39	6.3e-7	Crohn's disease;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg08835956	chr7:39171034	POU6F2	0.31	5.07	0.38	1.12e-6	IgG glycosylation;
PAAD	cis	rs6960043	0.905	rs10231021	chr7:15060429	T/A	cg19272540	chr7:15055459	NA	-0.35	-6.38	-0.46	1.99e-9	Type 2 diabetes;
PAAD	cis	rs2300603	0.922	rs12432467	chr14:76006573	C/T	cg01624173	chr14:75981868	NA	0.56	5.78	0.42	4.1e-8	Multiple sclerosis;
PAAD	cis	rs6025261	0.761	rs6092390	chr20:55510339	C/T	cg11868041	chr20:55503363	NA	0.44	4.93	0.37	2.12e-6	Verbal memory performance (delayed recall level);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23513095	chr15:28272148	OCA2	-0.62	-6.4	-0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.62	-6.99	-0.49	8.09e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.64e-6	Breast cancer;
PAAD	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-7.39	-0.51	9.28e-12	Total body bone mineral density;
PAAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.73	-7.41	-0.51	8.3e-12	Obesity-related traits;
PAAD	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.42	-4.26	-0.33	3.58e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	1.03	13.54	0.74	6.53e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs6076065	0.723	rs2424546	chr20:23391751	G/T	cg11657817	chr20:23433608	CST11	0.49	5.09	0.38	1.03e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.41	5.0	0.38	1.58e-6	Iron status biomarkers;
PAAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.75	4.75	0.36	4.69e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs2637030	0.515	rs439552	chr5:52978517	G/A	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.31	0.33	2.89e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.58	-6.38	-0.46	2.03e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24169248	chr11:66247869	DPP3	0.63	6.88	0.49	1.49e-10	Myopia (pathological);
PAAD	cis	rs2242420	0.920	rs72876053	chr1:21949724	A/G	cg04297819	chr1:22260125	HSPG2	0.52	4.55	0.35	1.09e-5	Hematological and biochemical traits;
PAAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.46	-0.46	1.35e-9	Glomerular filtration rate;
PAAD	cis	rs3753841	0.832	rs10747431	chr1:103218213	T/C	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs72627123	1.000	rs2302138	chr14:74363305	C/A	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.91	11.61	0.69	1.04e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17958798	chr17:7200008	NA	-0.57	-6.96	-0.49	9.3e-11	Body fat percentage;
PAAD	cis	rs914615	0.552	rs4421576	chr1:155142210	A/G	cg18645493	chr1:154167437	MIR190B	0.46	4.52	0.34	1.25e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.72	-7.41	-0.52	8.03e-12	Colorectal cancer;
PAAD	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.56	-5.0	-0.38	1.56e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10916814	0.632	rs4439331	chr1:20897091	T/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg03037974	chr15:76606532	NA	0.4	4.53	0.34	1.18e-5	Blood metabolite levels;
PAAD	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.75	-0.36	4.73e-6	Mean corpuscular volume;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22162314	chr17:61951766	CSH2	-0.52	-5.19	-0.39	6.65e-7	Height;
PAAD	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.47	4.4	0.34	2e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs883565	0.696	rs6599007	chr3:39114445	A/C	cg01426195	chr3:39028469	NA	-0.67	-7.13	-0.5	3.75e-11	Handedness;
PAAD	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs35955747	0.934	rs5997966	chr22:31776246	C/T	cg02404636	chr22:31891804	SFI1	-0.55	-5.44	-0.4	2.1e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg26149184	chr10:133730230	NA	0.77	6.76	0.48	2.71e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg23461800	chr14:103021989	NA	0.59	4.25	0.33	3.67e-5	Platelet count;
PAAD	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.55	-5.8	-0.43	3.76e-8	Coronary artery disease;
PAAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	1.96e-13	Melanoma;
PAAD	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.69	5.76	0.42	4.43e-8	Schizophrenia;
PAAD	cis	rs1335587	0.518	rs9513904	chr13:102107582	G/A	cg09276445	chr13:102106423	ITGBL1	-0.42	-4.86	-0.37	2.84e-6	Obesity-related traits;
PAAD	cis	rs425535	0.757	rs352018	chr4:74805322	T/C	cg01447579	chr4:74847100	PF4	0.65	4.27	0.33	3.41e-5	Blood protein levels;
PAAD	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.41e-6	Blood metabolite levels;
PAAD	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.62	-6.1	-0.44	8.6e-9	Itch intensity from mosquito bite;
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.72	7.16	0.5	3.24e-11	Cognitive function;
PAAD	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	0.92	6.54	0.47	8.62e-10	Pulse pressure;
PAAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04191342	chr3:62859289	CADPS	0.58	6.36	0.46	2.3e-9	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.08e-5	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23124755	chr9:33447476	SUGT1P1;AQP3	0.57	6.39	0.46	1.93e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1035491	0.715	rs12153793	chr5:63926423	C/T	cg01791865	chr5:63954708	NA	0.52	5.46	0.4	1.93e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.23	-0.45	4.35e-9	Lung cancer;
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.91	-0.54	4.84e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28489187	0.617	rs233068	chr1:85805355	G/A	cg16011679	chr1:85725395	C1orf52	0.5	4.64	0.35	7.58e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	4.28	0.33	3.23e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg05861140	chr6:150128134	PCMT1	-0.52	-5.9	-0.43	2.24e-8	Lung cancer;
PAAD	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-4.48	-0.34	1.49e-5	Rheumatoid arthritis;
PAAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.86	9.14	0.6	3.81e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.6	-4.49	-0.34	1.39e-5	Prostate cancer;
PAAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.92	9.73	0.62	1.1e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.96	6.47	0.46	1.28e-9	IgG glycosylation;
PAAD	cis	rs10768122	1.000	rs3794098	chr11:35298608	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2.03e-5	Vitiligo;
PAAD	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.7	-0.42	6.17e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.77	8.33	0.56	4.39e-14	Obesity-related traits;
PAAD	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-4.36	-0.33	2.35e-5	Inflammatory bowel disease;
PAAD	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.8e-10	Response to antipsychotic treatment;
PAAD	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	5.02	0.38	1.41e-6	Systolic blood pressure;
PAAD	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs3781458	0.803	rs7088656	chr10:126324077	G/A	cg20435097	chr10:126320824	FAM53B	0.53	5.7	0.42	6.11e-8	Male-pattern baldness;
PAAD	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs12780845	1.000	rs12771477	chr10:17209464	T/C	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.43	5.55	0.41	1.23e-7	Alcohol dependence;
PAAD	cis	rs3753841	0.832	rs12133645	chr1:103268138	T/A	cg24495344	chr1:103574097	COL11A1	0.39	4.5	0.34	1.32e-5	Glaucoma (primary angle closure);
PAAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.71	-5.14	-0.38	8.49e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs2421770	0.929	rs3847608	chr11:35321711	C/T	cg13971030	chr11:35366721	SLC1A2	-0.53	-6.41	-0.46	1.77e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.56	-6.08	-0.44	9.39e-9	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.77	7.78	0.53	1.01e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3736485	0.966	rs7174435	chr15:51895065	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.49e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-4.69	-0.36	6.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.91	-0.49	1.23e-10	IgG glycosylation;
PAAD	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.27	-0.39	4.69e-7	Blood pressure;
PAAD	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-1.02	-9.23	-0.6	2.22e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.67	7.84	0.54	7.4e-13	Metabolite levels;
PAAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.82	8.63	0.57	7.67e-15	Cognitive function;
PAAD	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.91	7.75	0.53	1.24e-12	Triglycerides;
PAAD	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.74	-7.58	-0.52	3.13e-12	Uric acid clearance;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06544989	chr22:39130855	UNC84B	0.45	4.31	0.33	2.9e-5	Menopause (age at onset);
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.15	0.7	3.65e-24	Prudent dietary pattern;
PAAD	trans	rs901683	1.000	rs12775527	chr10:46024990	G/A	cg23720331	chr10:123873670	TACC2	-0.84	-6.5	-0.47	1.1e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	7.03	0.5	6.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.49	-5.14	-0.38	8.27e-7	Systolic blood pressure;
PAAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg20003494	chr4:90757398	SNCA	-0.64	-5.92	-0.43	2.08e-8	Neuroticism;
PAAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	4.79	0.36	3.89e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg22827986	chr11:48284249	OR4X1	-0.39	-5.07	-0.38	1.14e-6	Migraine - clinic-based;
PAAD	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg04072768	chr2:54683502	SPTBN1	-0.49	-4.41	-0.34	1.91e-5	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14763972	chr10:127461256	MMP21	-0.63	-7.54	-0.52	3.96e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs6011674	0.901	rs56783811	chr20:61860505	A/G	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.68	-4.28	-0.33	3.25e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00815214	chr21:47717953	NA	-0.46	-4.86	-0.37	2.93e-6	Testicular germ cell tumor;
PAAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg07617317	chr6:118971624	C6orf204	0.51	4.29	0.33	3.14e-5	Diastolic blood pressure;
PAAD	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.6	-4.76	-0.36	4.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg21823605	chr1:152486609	CRCT1	-0.52	-6.02	-0.44	1.24e-8	Hair morphology;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.6	-6.58	-0.47	6.98e-10	Testicular germ cell tumor;
PAAD	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.47	4.88	0.37	2.7e-6	Tonsillectomy;
PAAD	trans	rs11794666	0.929	rs72719224	chr9:31783213	T/C	cg05628366	chr6:35744188	C6orf126	1.12	7.41	0.52	8.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6500395	0.584	rs4028684	chr16:48741222	A/G	cg04672837	chr16:48644449	N4BP1	0.52	4.25	0.33	3.75e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.92	0.37	2.19e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.81	10.33	0.64	2.78e-19	Breast cancer;
PAAD	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.71	0.48	3.6e-10	Hair morphology;
PAAD	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.78	7.15	0.5	3.36e-11	Body mass index;
PAAD	cis	rs8005172	0.712	rs2236362	chr14:88419374	T/C	cg18078958	chr14:88630771	NA	0.46	5.26	0.39	4.91e-7	Parkinson's disease;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.09	-14.46	-0.76	2.36e-30	Height;
PAAD	cis	rs28489187	0.756	rs233047	chr1:85830570	G/A	cg16011679	chr1:85725395	C1orf52	0.54	5.08	0.38	1.08e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs12989701	0.877	rs71414738	chr2:127876242	C/T	cg00091827	chr2:127863656	BIN1	0.59	4.32	0.33	2.78e-5	Alzheimer's disease (late onset);
PAAD	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs7580658	0.613	rs6754999	chr2:128195387	G/A	cg09760422	chr2:128146352	NA	-0.45	-7.32	-0.51	1.34e-11	Protein C levels;
PAAD	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-1.09	-8.0	-0.54	2.94e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.11	-0.38	9.44e-7	Aortic root size;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-0.87	-12.66	-0.72	1.5e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.99	12.74	0.72	9.6e-26	Systemic lupus erythematosus;
PAAD	cis	rs8105895	0.867	rs12151358	chr19:22282608	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.43	5.42	0.4	2.27e-7	Ulcerative colitis;
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.86	0.37	2.91e-6	Vitiligo;
PAAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.56	7.31	0.51	1.39e-11	Renal cell carcinoma;
PAAD	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.58	-5.35	-0.4	3.24e-7	Corneal structure;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.02	0.38	1.45e-6	Height;
PAAD	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg19401529	chr3:49056140	DALRD3	0.52	4.37	0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	4.94	0.37	2.01e-6	Yeast infection;
PAAD	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-5.15	-0.39	7.82e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-4.63	-0.35	7.86e-6	Diastolic blood pressure;
PAAD	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg27205649	chr11:78285834	NARS2	-0.56	-4.27	-0.33	3.47e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1334894	1.000	rs12527893	chr6:35585099	T/C	cg07213720	chr6:35227408	ZNF76	-0.89	-4.92	-0.37	2.27e-6	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09375672	chr6:143858639	NA	0.59	6.5	0.47	1.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg14008862	chr17:28927542	LRRC37B2	0.71	5.06	0.38	1.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.11	14.76	0.77	3.63e-31	Body mass index;
PAAD	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.51	5.3	0.39	4.08e-7	Schizophrenia;
PAAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.82	5.48	0.41	1.73e-7	Anti-saccade response;
PAAD	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.89	11.06	0.67	3.05e-21	Mean corpuscular volume;
PAAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg19445457	chr11:5799446	OR52N5	-0.52	-4.64	-0.35	7.42e-6	DNA methylation (variation);
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.53e-6	Life satisfaction;
PAAD	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25037011	chr8:42697887	THAP1	0.6	6.56	0.47	8.15e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg13918804	chr1:2043761	PRKCZ	0.43	5.83	0.43	3.19e-8	Height;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27068619	chr7:149439536	NA	0.57	6.38	0.46	2.05e-9	Metabolite levels  (X-11787);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20650035	chr12:29542837	NA	-0.7	-7.13	-0.5	3.87e-11	Smoking initiation;
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.66	6.89	0.49	1.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1864585	0.520	rs73208782	chr8:10677555	G/A	cg21775007	chr8:11205619	TDH	-0.57	-4.43	-0.34	1.79e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs10982213	1.000	rs4978584	chr9:117186712	C/T	cg00078025	chr9:117159975	NA	0.63	4.63	0.35	7.95e-6	Interleukin-6 levels;
PAAD	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	0.75	4.53	0.34	1.18e-5	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg05342682	chr7:94953680	PON1	-0.55	-4.77	-0.36	4.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.62	-6.55	-0.47	8.3e-10	Lung cancer;
PAAD	cis	rs1045902	0.532	rs2288631	chr2:73455747	C/T	cg24220031	chr2:73402428	NA	-0.32	-4.31	-0.33	2.96e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16895831	0.519	rs12196856	chr6:42554187	T/A	cg10605015	chr6:42532144	UBR2	-0.74	-5.57	-0.41	1.14e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg05373962	chr22:49881684	NA	-0.53	-5.14	-0.38	8.31e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12776158	0.901	rs60110374	chr10:71217090	C/T	cg12610070	chr10:71211762	TSPAN15	-0.49	-4.63	-0.35	7.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	8.01	0.54	2.77e-13	Response to antipsychotic treatment;
PAAD	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.82	-0.62	6.17e-18	Response to antipsychotic treatment;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21077069	chr7:99063506	ATP5J2	0.64	6.87	0.49	1.55e-10	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13400516	chr1:2159040	SKI	0.66	6.43	0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs11076805	0.510	rs399218	chr16:4151587	C/T	cg01959050	chr16:4170088	NA	-0.55	-5.51	-0.41	1.48e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.57	4.98	0.37	1.73e-6	Height;
PAAD	cis	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg00325661	chr8:49890786	NA	0.52	5.19	0.39	6.77e-7	Blood metabolite levels;
PAAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.22e-10	Blood protein levels;
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.61	-5.99	-0.44	1.44e-8	Breast cancer;
PAAD	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.46	5.29	0.39	4.28e-7	Mean arterial pressure;
PAAD	cis	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.81	9.73	0.62	1.05e-17	Bladder cancer;
PAAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.68	0.53	1.82e-12	Prudent dietary pattern;
PAAD	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg00531865	chr16:30841666	NA	0.6	4.5	0.34	1.36e-5	Dementia with Lewy bodies;
PAAD	cis	rs6089829	0.632	rs62197308	chr20:61660705	T/C	cg03213289	chr20:61660250	NA	-0.48	-6.44	-0.46	1.5e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1497828	0.956	rs1353666	chr1:217523885	A/G	cg04411442	chr1:217543379	NA	0.48	4.57	0.35	9.94e-6	Dialysis-related mortality;
PAAD	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg21951975	chr1:209979733	IRF6	0.59	5.39	0.4	2.63e-7	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.81	5.95	0.43	1.74e-8	Vitiligo;
PAAD	cis	rs13242816	1.000	rs35800776	chr7:116110069	C/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.48	-4.42	-0.34	1.86e-5	Tuberculosis;
PAAD	cis	rs17095355	0.818	rs7090570	chr10:111772798	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.7	-4.66	-0.35	6.83e-6	Biliary atresia;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.41	-0.46	1.69e-9	Lung cancer;
PAAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg05697835	chr1:2722811	NA	-0.41	-4.75	-0.36	4.66e-6	Ulcerative colitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21448554	chr6:36564272	SFRS3	-0.67	-6.69	-0.48	3.93e-10	Lung cancer in ever smokers;
PAAD	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.57	4.98	0.37	1.74e-6	Common traits (Other);
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg05313129	chr8:58192883	C8orf71	-0.7	-5.58	-0.41	1.07e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.85	6.69	0.48	3.92e-10	Axial length;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs925642	0.700	rs13140628	chr4:187670106	A/G	cg20274950	chr4:187647402	NA	-0.38	-4.4	-0.34	2.01e-5	Obesity;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg26071806	chr7:100318239	EPO	-0.46	-4.47	-0.34	1.53e-5	Other erythrocyte phenotypes;
PAAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.22	-0.45	4.53e-9	Height;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.24	0.8	5e-35	Prudent dietary pattern;
PAAD	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	4.41	0.34	1.91e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.42	-0.34	1.87e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs73019876	0.869	rs10417673	chr19:22148101	A/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.44	-0.34	1.73e-5	Testicular germ cell tumor;
PAAD	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.51	5.31	0.4	3.82e-7	Interleukin-18 levels;
PAAD	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.22	5.84	0.43	3.05e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18364779	chr6:26104403	HIST1H4C	0.46	4.62	0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-4.73	-0.36	5.01e-6	Total body bone mineral density;
PAAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.66	6.9	0.49	1.28e-10	Multiple sclerosis;
PAAD	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg25547332	chr5:131281432	NA	0.54	4.33	0.33	2.72e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.63	6.5	0.47	1.1e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.6	-5.46	-0.41	1.87e-7	White blood cell count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01186240	chr14:90085699	FOXN3	-0.75	-6.36	-0.46	2.21e-9	Neuroticism;
PAAD	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.68	-0.65	3.24e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs6604026	0.656	rs7542608	chr1:93401194	A/G	cg17283838	chr1:93427260	FAM69A	0.62	5.69	0.42	6.48e-8	Multiple sclerosis;
PAAD	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.78	-7.88	-0.54	5.83e-13	Gout;
PAAD	cis	rs10419226	0.625	rs12980154	chr19:18770119	C/T	cg14292368	chr19:18793705	CRTC1	-0.47	-4.95	-0.37	1.93e-6	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.74	11.26	0.67	8.94e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26656136	chr11:82904757	ANKRD42	0.59	6.92	0.49	1.19e-10	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.86	0.37	2.89e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21365077	chr3:42922735	NA	0.64	6.37	0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.11	-0.55	1.53e-13	Hemoglobin concentration;
PAAD	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.87	7.59	0.52	2.94e-12	Large artery stroke;
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.57	-0.61	2.9e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg09168692	chr1:7887560	PER3	0.47	4.5	0.34	1.32e-5	Inflammatory bowel disease;
PAAD	cis	rs11771526	0.681	rs17161287	chr7:32422632	G/C	cg27511599	chr7:32358540	NA	0.7	4.37	0.33	2.3e-5	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26485003	chr12:66742565	GRIP1	-0.55	-6.62	-0.47	5.68e-10	Monocyte percentage of white cells;
PAAD	cis	rs13191362	0.576	rs9356070	chr6:163273021	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.76	0.42	4.53e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg15507776	chr3:136538369	TMEM22	0.47	4.64	0.35	7.45e-6	Neuroticism;
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.43	-4.77	-0.36	4.37e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2120991	0.967	rs6580968	chr12:54261440	T/C	cg21845580	chr12:53472882	SPRYD3	-0.46	-4.33	-0.33	2.66e-5	Biliary atresia;
PAAD	cis	rs9535307	0.719	rs1211304	chr13:50381016	G/A	cg03658251	chr13:50265850	EBPL	-0.82	-5.62	-0.42	8.68e-8	Obesity-related traits;
PAAD	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Bladder cancer;
PAAD	cis	rs8010715	0.816	rs6573572	chr14:24599230	C/A	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs262150	0.566	rs2247275	chr7:158765812	A/G	cg05554000	chr7:158905015	VIPR2	-0.65	-5.1	-0.38	1e-6	Facial morphology (factor 20);
PAAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.63	-5.75	-0.42	4.74e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.66	7.15	0.5	3.41e-11	Corneal astigmatism;
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.22	-0.45	4.67e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1126510	0.823	rs4803986	chr19:47131881	G/A	cg07844738	chr19:47129343	PTGIR	0.42	4.85	0.37	3.07e-6	Ulcerative colitis;
PAAD	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22857025	chr5:266934	NA	-1.22	-5.26	-0.39	4.9e-7	Breast cancer;
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg05082376	chr22:42548792	NA	-0.54	-5.26	-0.39	4.77e-7	Cognitive function;
PAAD	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.83	-9.43	-0.61	6.7e-17	Lung cancer;
PAAD	cis	rs6191	0.935	rs852980	chr5:142700856	G/C	cg08845721	chr5:142780693	NR3C1	-0.4	-4.41	-0.34	1.93e-5	Night sleep phenotypes;
PAAD	cis	rs3134353	0.932	rs3100052	chr8:101967139	A/G	cg04962480	chr8:101962118	YWHAZ	-0.38	-4.3	-0.33	2.99e-5	Body mass index;
PAAD	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg22442454	chr1:209979470	IRF6	-0.54	-4.56	-0.35	1.04e-5	Coronary artery disease;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg06569542	chr10:98946673	SLIT1	-0.52	-5.85	-0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7094131	0.523	rs10764343	chr10:22882655	G/C	cg19500236	chr10:22911537	PIP4K2A	0.45	4.96	0.37	1.9e-6	Obesity-related traits;
PAAD	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.53	5.61	0.41	9.14e-8	Testicular germ cell tumor;
PAAD	cis	rs8105895	0.877	rs9973249	chr19:22242160	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.74	8.19	0.55	1.01e-13	Morning vs. evening chronotype;
PAAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.46	-0.41	1.86e-7	Educational attainment;
PAAD	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.83	-5.9	-0.43	2.26e-8	Gallbladder cancer;
PAAD	cis	rs2221894	0.922	rs7018244	chr8:28894991	G/A	cg20212339	chr8:28908912	HMBOX1	-0.5	-5.36	-0.4	3.1e-7	Obesity-related traits;
PAAD	cis	rs89107	0.603	rs387945	chr6:118613313	G/A	cg21191810	chr6:118973309	C6orf204	0.46	6.36	0.46	2.22e-9	Cardiac structure and function;
PAAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-7.65	-0.53	2.2e-12	Morning vs. evening chronotype;
PAAD	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs10045504	0.502	rs72746038	chr5:38753999	G/A	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-1.04	-14.51	-0.76	1.73e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg05373962	chr22:49881684	NA	-0.53	-5.14	-0.38	8.31e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.92	0.54	4.68e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.88e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg02841227	chr6:26021843	HIST1H4A	0.45	4.5	0.34	1.32e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.52	5.1	0.38	9.95e-7	IgG glycosylation;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg16414030	chr3:133502952	NA	-0.47	-4.85	-0.37	2.96e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.55	-6.83	-0.48	1.89e-10	Educational attainment;
PAAD	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg19090574	chr1:205240910	TMCC2	-0.41	-4.28	-0.33	3.3e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg25273343	chr12:104657179	TXNRD1	-0.55	-4.46	-0.34	1.56e-5	Toenail selenium levels;
PAAD	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg11439826	chr17:76250004	NA	0.45	4.48	0.34	1.47e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg20487152	chr13:99095054	FARP1	0.59	5.23	0.39	5.54e-7	Neuroticism;
PAAD	cis	rs2171564	0.791	rs9826586	chr3:112441312	C/T	cg06685282	chr3:112453648	NA	0.49	5.29	0.39	4.28e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.92	-11.41	-0.68	3.55e-22	Menopause (age at onset);
PAAD	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.34	0.33	2.62e-5	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22798984	chr14:52456142	C14orf166	-0.7	-7.26	-0.51	1.85e-11	Smoking initiation;
PAAD	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.51	4.88	0.37	2.71e-6	Selective IgA deficiency;
PAAD	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs73019876	0.869	rs1987570	chr19:22153137	A/C	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg05697835	chr1:2722811	NA	0.41	4.52	0.34	1.22e-5	Ulcerative colitis;
PAAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.97	-0.37	1.82e-6	Monocyte percentage of white cells;
PAAD	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg00262122	chr8:11665843	FDFT1	0.49	4.3	0.33	3.04e-5	Retinal vascular caliber;
PAAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20295702	chr7:70254810	AUTS2	-0.65	-6.46	-0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.04	0.5	6.09e-11	Yeast infection;
PAAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.62	8.24	0.56	7.23e-14	Bipolar disorder;
PAAD	trans	rs901683	0.702	rs77676696	chr10:45967258	A/G	cg11747279	chr17:21096632	NA	0.92	6.79	0.48	2.37e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg22143856	chr6:28129313	ZNF389	0.53	4.86	0.37	2.85e-6	Parkinson's disease;
PAAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.59	-7.11	-0.5	4.25e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.71	-6.01	-0.44	1.31e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.57	6.0	0.44	1.4e-8	Immature fraction of reticulocytes;
PAAD	cis	rs73568641	0.583	rs12527630	chr6:154064934	A/G	cg15658985	chr6:154448740	OPRM1	0.56	4.72	0.36	5.33e-6	Methadone dose in opioid dependence;
PAAD	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	1.04	7.94	0.54	4.13e-13	Inflammatory bowel disease;
PAAD	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.89	0.54	5.4e-13	Metabolite levels;
PAAD	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.56	0.35	1.04e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.16	-0.39	7.63e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.41	6.05	0.44	1.08e-8	Subjective well-being;
PAAD	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg18367735	chr17:79674897	NA	0.84	5.17	0.39	7.14e-7	Dental caries;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.01	13.8	0.75	1.32e-28	Heart rate;
PAAD	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg09455208	chr3:40491958	NA	-0.44	-5.74	-0.42	4.93e-8	Renal cell carcinoma;
PAAD	cis	rs3007168	1.000	rs3007168	chr14:51608293	G/A	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.51	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.82	-6.24	-0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-4.44	-0.34	1.72e-5	Educational attainment (years of education);
PAAD	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14169450	chr9:139327907	INPP5E	0.57	5.86	0.43	2.73e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg20933634	chr6:27740509	NA	0.76	7.04	0.5	6.25e-11	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.74	8.5	0.57	1.61e-14	Height;
PAAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.7	-8.68	-0.58	5.62e-15	Breast cancer;
PAAD	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.7e-11	Eye color traits;
PAAD	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.59	5.15	0.39	8.02e-7	Lung function (FEV1/FVC);
PAAD	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.48	-0.34	1.47e-5	Educational attainment;
PAAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg10729496	chr3:10149963	C3orf24	0.86	7.47	0.52	5.98e-12	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00661222	chr13:52343378	DHRS12	0.57	6.52	0.47	9.66e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg17385448	chr1:15911702	AGMAT	0.36	4.38	0.34	2.16e-5	Systolic blood pressure;
PAAD	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg21361702	chr7:150065534	REPIN1	0.57	4.78	0.36	4.18e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs78761021	0.597	rs4791901	chr17:9781954	A/G	cg26853458	chr17:9805074	RCVRN	0.45	5.36	0.4	2.99e-7	Type 2 diabetes;
PAAD	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-4.97	-0.37	1.77e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16206931	chr10:134503280	INPP5A	0.59	6.96	0.49	9.6e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.9	-0.37	2.42e-6	Primary sclerosing cholangitis;
PAAD	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.53	5.58	0.41	1.08e-7	Migraine;Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-4.43	-0.34	1.78e-5	Inflammatory bowel disease;
PAAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.89e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7577696	0.962	rs212739	chr2:32404703	A/G	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.68e-6	Inflammatory biomarkers;
PAAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg07689907	chr11:61582574	FADS1	-0.45	-4.4	-0.34	2.02e-5	Trans fatty acid levels;
PAAD	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.16	-0.64	7.78e-19	Response to antipsychotic treatment;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.61	7.68	0.53	1.85e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	6.81	0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg20673841	chr7:107026890	COG5	0.51	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13126279	chr21:47581558	C21orf56	-0.4	-4.44	-0.34	1.7e-5	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	1.16	10.39	0.64	1.98e-19	Eosinophil percentage of granulocytes;
PAAD	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg01796438	chr3:11312864	ATG7	0.6	4.27	0.33	3.42e-5	Circulating chemerin levels;
PAAD	cis	rs732765	0.774	rs67212334	chr14:75317699	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-5.27	-0.39	4.6e-7	Non-small cell lung cancer;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.77	5.14	0.38	8.49e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.78	0.48	2.47e-10	Life satisfaction;
PAAD	cis	rs114540395	0.777	rs9420863	chr10:103362726	C/T	cg21381511	chr10:104264849	SUFU	-0.81	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.61	6.14	0.45	6.95e-9	Proinsulin levels;
PAAD	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.6	6.33	0.46	2.63e-9	Bladder cancer;
PAAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg26138144	chr22:38071188	LGALS1	0.5	5.55	0.41	1.24e-7	Fat distribution (HIV);
PAAD	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.55	4.43	0.34	1.78e-5	Bone mineral density (spine);
PAAD	cis	rs2017305	0.831	rs75832254	chr10:70686427	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs5753037	0.809	rs2074706	chr22:30200893	G/C	cg01021169	chr22:30184971	ASCC2	-0.45	-4.52	-0.34	1.24e-5	Type 1 diabetes;
PAAD	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs7092929	1.000	rs705472	chr10:3551484	C/G	cg14308648	chr10:3568949	NA	0.65	5.02	0.38	1.41e-6	Coronary artery calcification;
PAAD	cis	rs9469913	0.740	rs2814973	chr6:34569720	C/T	cg17674042	chr6:34482479	PACSIN1	-0.54	-4.26	-0.33	3.6e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs10450586	0.863	rs6484285	chr11:27299127	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21269893	chr17:41322169	NBR1	0.65	7.45	0.52	6.43e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.88	9.93	0.63	3.27e-18	Height;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg18964960	chr10:1102726	WDR37	0.64	4.34	0.33	2.57e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.71	8.25	0.56	7.21e-14	Colorectal cancer;
PAAD	cis	rs10982213	1.000	rs7864759	chr9:117181605	T/C	cg00078025	chr9:117159975	NA	0.61	4.62	0.35	8.22e-6	Interleukin-6 levels;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg09955084	chr16:413813	NA	0.29	4.41	0.34	1.94e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7301826	1.000	rs4759787	chr12:131290180	A/C	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-0.57	-5.48	-0.41	1.76e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.5	-7.62	-0.53	2.59e-12	Mean corpuscular volume;
PAAD	cis	rs282587	0.502	rs393320	chr13:113396469	C/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.52	5.54	0.41	1.3e-7	Obesity-related traits;
PAAD	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs2457480	0.866	rs11238940	chr10:44721459	G/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;
PAAD	cis	rs8005172	0.663	rs8009007	chr14:88513293	C/T	cg18078958	chr14:88630771	NA	0.36	4.52	0.34	1.23e-5	Parkinson's disease;
PAAD	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.93	-5.87	-0.43	2.63e-8	Lung cancer in ever smokers;
PAAD	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.4	-5.87	-0.43	2.65e-8	Subjective well-being;
PAAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	1.12	6.06	0.44	1.04e-8	Skin colour saturation;
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg02841227	chr6:26021843	HIST1H4A	0.5	4.98	0.37	1.7e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.7	7.25	0.51	2.01e-11	Morning vs. evening chronotype;
PAAD	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17467752	chr17:38218738	THRA	0.7	6.81	0.48	2.17e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg05425664	chr17:57184151	TRIM37	0.51	4.78	0.36	4.09e-6	Testicular germ cell tumor;
PAAD	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.83	9.75	0.62	9.34e-18	Breast cancer;
PAAD	cis	rs597480	0.895	rs930592	chr11:85508874	C/G	cg11817631	chr11:85522609	SYTL2	0.46	4.47	0.34	1.55e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.52	-4.85	-0.37	2.97e-6	Menarche (age at onset);
PAAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.97	-8.55	-0.57	1.2e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	8.48	0.57	1.83e-14	Prudent dietary pattern;
PAAD	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs496547	0.520	rs11216963	chr11:118580814	G/A	cg08498647	chr11:118550644	TREH	0.4	4.43	0.34	1.81e-5	Hip minimal joint space width;
PAAD	cis	rs10821973	0.527	rs6479795	chr10:64015918	T/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg16386425	chr10:429943	DIP2C	0.51	5.38	0.4	2.71e-7	Psychosis in Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00719400	chr1:227915962	LOC100130093	-0.67	-6.75	-0.48	2.91e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	trans	rs901683	1.000	rs36052429	chr10:46082345	T/A	cg06308084	chr22:50493570	TTLL8	0.88	6.47	0.46	1.28e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg02743256	chr7:2109353	MAD1L1	0.65	4.95	0.37	1.98e-6	Bipolar disorder;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg07362569	chr17:61921086	SMARCD2	0.43	4.82	0.36	3.39e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12624087	chr22:32341561	C22orf24;YWHAH	0.6	6.71	0.48	3.7e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10512697	0.655	rs13173969	chr5:3487526	G/A	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg02117656	chr17:79614917	TSPAN10	-0.55	-5.56	-0.41	1.2e-7	Eye color traits;
PAAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.76	-10.16	-0.64	8.07e-19	Bone mineral density;
PAAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg14092988	chr3:52407081	DNAH1	0.44	5.44	0.4	2.11e-7	Bipolar disorder;
PAAD	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg10072921	chr12:121022843	NA	-0.42	-5.21	-0.39	6.17e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.09	0.38	1.03e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.4	-7.52	-0.52	4.35e-12	Psoriasis vulgaris;
PAAD	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03322129	chr1:1209673	UBE2J2	0.63	7.22	0.51	2.32e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11488864	chr4:8379238	ACOX3	0.59	7.03	0.5	6.46e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.81	9.52	0.61	3.75e-17	Hemoglobin concentration;
PAAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs9815354	0.953	rs1716641	chr3:41921681	C/T	cg03022575	chr3:42003672	ULK4	-0.84	-6.1	-0.44	8.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg14952266	chr13:112191215	NA	0.46	5.3	0.39	4.02e-7	Hepatitis;
PAAD	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.47	4.5	0.34	1.33e-5	Gut microbiome composition (summer);
PAAD	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg10183150	chr4:120222239	C4orf3	-0.3	-4.35	-0.33	2.5e-5	Diastolic blood pressure;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.67	0.35	6.71e-6	Bipolar disorder;
PAAD	cis	rs2555155	1.000	rs2555154	chr11:6524556	C/T	cg10208301	chr11:6592745	DNHD1	0.42	4.38	0.33	2.23e-5	DNA methylation (variation);
PAAD	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs6466055	0.669	rs2003506	chr7:104761741	A/G	cg04380332	chr7:105027541	SRPK2	-0.56	-6.02	-0.44	1.27e-8	Schizophrenia;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg14525755	chr12:132671672	NA	0.56	5.69	0.42	6.46e-8	Anti-saccade response;
PAAD	cis	rs11811982	0.546	rs74491441	chr1:227226201	G/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.75	0.36	4.71e-6	Optic disc area;
PAAD	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.51	-5.51	-0.41	1.49e-7	Bipolar disorder;
PAAD	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.83	-8.77	-0.58	3.44e-15	Breast cancer;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg20887711	chr4:1340912	KIAA1530	0.57	6.19	0.45	5.34e-9	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.91	11.71	0.69	5.51e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg24585817	chr7:64895279	NA	0.46	4.64	0.35	7.59e-6	Aortic root size;
PAAD	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Bladder cancer;
PAAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg06569542	chr10:98946673	SLIT1	-0.53	-5.88	-0.43	2.47e-8	Monocyte count;
PAAD	cis	rs5753618	0.583	rs71324184	chr22:31752061	C/G	cg02404636	chr22:31891804	SFI1	0.63	6.34	0.46	2.46e-9	Colorectal cancer;
PAAD	cis	rs6782025	0.874	rs9875808	chr3:120801653	T/C	cg16417163	chr3:121280760	NA	0.5	5.17	0.39	7.16e-7	Aging (facial);
PAAD	cis	rs13185784	1.000	rs13185784	chr5:179694068	G/A	cg02891314	chr5:179741120	GFPT2	0.51	4.3	0.33	2.99e-5	TRAIL levels;
PAAD	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg22815214	chr1:201083145	CACNA1S	0.53	4.31	0.33	2.96e-5	Permanent tooth development;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.73	8.55	0.57	1.25e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.66	6.9	0.49	1.28e-10	Multiple sclerosis;
PAAD	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg09455208	chr3:40491958	NA	-0.44	-5.74	-0.42	4.93e-8	Renal cell carcinoma;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.57	-5.57	-0.41	1.13e-7	Parkinson's disease;
PAAD	cis	rs7301016	1.000	rs10877859	chr12:62873873	G/A	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg19630374	chr17:18023558	MYO15A	-0.45	-4.77	-0.36	4.34e-6	Total body bone mineral density;
PAAD	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.57	-4.72	-0.36	5.36e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.76	7.95	0.54	4.02e-13	Body mass index;
PAAD	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.42	-6.39	-0.46	1.94e-9	Breast cancer;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.86	-0.37	2.87e-6	Obesity-related traits;
PAAD	cis	rs11209002	0.915	rs6588240	chr1:67577367	A/T	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg08198773	chr8:1697536	NA	0.45	5.01	0.38	1.49e-6	Systolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13310671	chr20:48553087	RNF114	-0.74	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg05110241	chr16:68378359	PRMT7	-1.03	-6.66	-0.48	4.76e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.3	-5.1	-0.38	1e-6	Non-small cell lung cancer (survival);
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.32e-13	Prostate cancer;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.44	5.48	0.41	1.75e-7	Life satisfaction;
PAAD	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.88	6.7	0.48	3.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00761755	chr17:1531579	SLC43A2	0.61	6.58	0.47	7.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.46	4.38	0.33	2.2e-5	Renal cell carcinoma;
PAAD	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.69	6.41	0.46	1.77e-9	Lymphocyte counts;
PAAD	cis	rs4740619	0.635	rs10810480	chr9:15930542	T/A	cg14451791	chr9:16040625	NA	-0.4	-4.51	-0.34	1.28e-5	Body mass index;
PAAD	cis	rs7932354	0.536	rs7929294	chr11:46776176	T/C	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg22325292	chr17:80708367	FN3K	-0.64	-4.44	-0.34	1.7e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.45	-0.34	1.65e-5	Height;
PAAD	cis	rs10943724	0.658	rs953500	chr6:81266567	T/G	cg19323245	chr6:80716898	TTK	-0.43	-4.54	-0.35	1.14e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	7.25	0.51	2e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg01422370	chr2:73384389	NA	-0.35	-4.66	-0.35	6.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs990171	0.538	rs1403548	chr2:103110375	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	6.18	0.45	5.57e-9	Body mass index;
PAAD	cis	rs4141404	0.577	rs2413045	chr22:31665862	A/G	cg02404636	chr22:31891804	SFI1	-0.6	-4.76	-0.36	4.5e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.9e-6	Lung cancer;
PAAD	cis	rs73206853	0.620	rs73194035	chr12:111165793	A/G	cg12870014	chr12:110450643	ANKRD13A	0.8	4.43	0.34	1.8e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	1.17	6.4	0.46	1.85e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11588062	0.687	rs3991796	chr1:46802608	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.5	4.36	0.33	2.39e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.46	-0.68	2.64e-22	Chronic sinus infection;
PAAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.6	6.07	0.44	1e-8	Obesity-related traits;
PAAD	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg02135003	chr7:105160482	PUS7	-0.64	-5.81	-0.43	3.61e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.55	-4.67	-0.35	6.65e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg16606324	chr3:10149918	C3orf24	0.59	4.62	0.35	8.01e-6	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16326819	chr2:118771837	CCDC93	-0.78	-7.13	-0.5	3.81e-11	Neuroticism;
PAAD	cis	rs4740619	0.630	rs2987022	chr9:15986221	C/T	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs965469	0.708	rs80050989	chr20:3297881	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs6547631	0.594	rs7585576	chr2:85937785	G/A	cg24620635	chr2:85921963	GNLY	0.4	5.19	0.39	6.75e-7	Blood protein levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06752594	chr1:109825964	PSRC1	-0.58	-6.88	-0.49	1.45e-10	Body fat percentage;
PAAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs10512697	0.772	rs34227872	chr5:3523512	G/T	cg19473799	chr5:3511975	NA	-1.03	-4.6	-0.35	8.95e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.62	-7.38	-0.51	9.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg00129232	chr17:37814104	STARD3	-0.5	-4.34	-0.33	2.57e-5	Self-reported allergy;
PAAD	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg02631450	chr22:32366979	NA	0.96	5.55	0.41	1.21e-7	Childhood ear infection;
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs732765	0.734	rs12895862	chr14:75126566	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.56	-4.45	-0.34	1.64e-5	Non-small cell lung cancer;
PAAD	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.72	5.84	0.43	3.04e-8	Common traits (Other);
PAAD	cis	rs3743832	0.897	rs8049976	chr16:9182268	T/C	cg08831531	chr16:9218945	NA	-0.44	-4.55	-0.35	1.08e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg03808351	chr9:123631620	PHF19	0.41	4.26	0.33	3.63e-5	Rheumatoid arthritis;
PAAD	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-8.33	-0.56	4.31e-14	Height;
PAAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.72	-0.36	5.4e-6	Bipolar disorder;
PAAD	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.56	5.72	0.42	5.53e-8	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-10.51	-0.65	9e-20	Height;
PAAD	cis	rs507080	0.922	rs493834	chr11:118567444	A/G	cg08498647	chr11:118550644	TREH	-0.38	-4.4	-0.34	2.06e-5	Serum metabolite levels;
PAAD	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg09754948	chr16:28834200	ATXN2L	-0.49	-4.44	-0.34	1.73e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.82	8.67	0.58	5.9e-15	High light scatter reticulocyte percentage of red cells;Plateletcrit;
PAAD	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg23752985	chr2:85803571	VAMP8	0.53	6.25	0.45	3.93e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs13380717	0.628	rs4581707	chr16:86913229	G/T	cg16630791	chr16:86543538	FOXF1	0.56	4.37	0.33	2.27e-5	Sepsis in extremely premature infants;
PAAD	cis	rs11811982	0.793	rs115847858	chr1:227578235	T/C	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs6499755	0.712	rs76667757	chr16:55362378	T/G	cg02859129	chr16:55357253	IRX6	0.35	4.88	0.37	2.69e-6	Hypospadias;
PAAD	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02743256	chr7:2109353	MAD1L1	-0.73	-6.08	-0.44	9.33e-9	Bipolar disorder;
PAAD	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.1	-0.55	1.63e-13	Mean corpuscular volume;
PAAD	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.64	-6.07	-0.44	9.72e-9	Hip circumference;
PAAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg07162820	chr14:24837146	NFATC4	0.34	4.52	0.34	1.22e-5	Parent of origin effect on language impairment (paternal);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09270044	chr1:186344798	TPR;C1orf27;MIR548F1	0.68	7.23	0.51	2.17e-11	Myopia (pathological);
PAAD	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg23752985	chr2:85803571	VAMP8	0.55	6.29	0.45	3.23e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg16586182	chr3:47516702	SCAP	-0.47	-4.6	-0.35	8.71e-6	Birth weight;
PAAD	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.4	4.79	0.36	3.85e-6	Uric acid levels;
PAAD	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs10392	0.850	rs725322	chr20:37563352	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.61	-0.35	8.33e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.37	-4.79	-0.36	3.87e-6	Age at first birth;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17437181	chr20:44520166	CTSA;NEURL2	0.7	8.3	0.56	5.11e-14	Myopia (pathological);
PAAD	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.87	10.93	0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.89	-7.34	-0.51	1.18e-11	Triglycerides;
PAAD	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg24687543	chr11:63912206	MACROD1	0.62	5.41	0.4	2.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13845161	chr11:12901718	TEAD1	-0.56	-6.88	-0.49	1.43e-10	Monocyte percentage of white cells;
PAAD	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg10920065	chr6:169824652	NA	-0.48	-4.7	-0.36	5.77e-6	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.07	0.38	1.13e-6	Breast cancer;
PAAD	cis	rs4740619	0.630	rs1328269	chr9:15998506	G/T	cg14451791	chr9:16040625	NA	0.37	4.41	0.34	1.91e-5	Body mass index;
PAAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg12458913	chr13:53173898	NA	0.48	4.83	0.37	3.25e-6	Lewy body disease;
PAAD	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.59	5.12	0.38	9.11e-7	Common traits (Other);
PAAD	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.62	5.85	0.43	2.86e-8	Subjective well-being;
PAAD	cis	rs7873102	0.654	rs10114348	chr9:37960693	G/T	cg03528946	chr9:38069800	SHB	0.53	5.45	0.4	2e-7	Brain structure;
PAAD	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.9e-7	Ulcerative colitis;
PAAD	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.24	4.39	0.34	2.1e-5	Schizophrenia;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.94	-16.26	-0.8	4.36e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12453935	0.621	rs56391142	chr17:59913566	G/A	cg01765249	chr17:59476334	TBX2	-0.5	-4.51	-0.34	1.3e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg05342682	chr7:94953680	PON1	-0.59	-4.72	-0.36	5.37e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg01075559	chr1:2537774	MMEL1	0.5	5.29	0.39	4.24e-7	Ulcerative colitis;
PAAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-0.59	-7.81	-0.54	8.55e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.45	-4.91	-0.37	2.28e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.25	0.45	3.84e-9	Schizophrenia;
PAAD	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.57	-0.41	1.14e-7	Vitiligo;
PAAD	cis	rs11958404	1.000	rs11958404	chr5:157410278	A/T	cg05962755	chr5:157440814	NA	0.91	7.93	0.54	4.41e-13	IgG glycosylation;
PAAD	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.59	5.17	0.39	7.18e-7	Life satisfaction;
PAAD	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs600626	0.947	rs644361	chr11:75452392	C/T	cg24262691	chr11:75473276	NA	-0.48	-4.62	-0.35	8.27e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg09659197	chr4:152720779	NA	0.46	6.14	0.45	6.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.53	5.13	0.38	8.55e-7	Metabolic traits;
PAAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs10186876	0.833	rs28394191	chr2:44172444	A/C	cg09541576	chr2:44873248	C2orf34	-0.45	-4.79	-0.36	3.89e-6	Hand grip strength;
PAAD	cis	rs8105895	0.935	rs10413784	chr19:22246191	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg06268327	chr11:63885740	FLRT1;MACROD1	0.42	4.39	0.34	2.08e-5	Platelet count;
PAAD	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7562790	0.610	rs3770895	chr2:36656471	G/A	cg01206211	chr2:36825736	FEZ2	0.45	4.44	0.34	1.7e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs11892454	0.565	rs13398541	chr2:26049123	C/G	cg25181710	chr2:26045287	ASXL2	0.41	4.51	0.34	1.28e-5	Heschl's gyrus morphology;
PAAD	cis	rs1011018	0.955	rs1541481	chr7:139465277	C/T	cg03224163	chr7:139420300	HIPK2	-0.62	-4.28	-0.33	3.32e-5	Systolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17404397	chr10:12174728	SEC61A2	-0.62	-6.8	-0.48	2.19e-10	Obesity-related traits;
PAAD	cis	rs17407555	0.683	rs6833142	chr4:10275982	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	4.43	0.34	1.76e-5	Schizophrenia (age at onset);
PAAD	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-6.0	-0.44	1.4e-8	Diabetic retinopathy;
PAAD	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	5.34	0.4	3.33e-7	Schizophrenia;
PAAD	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.32	0.51	1.37e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg10393086	chr1:210273696	SYT14	-0.66	-6.72	-0.48	3.46e-10	Alcohol dependence;
PAAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg00786201	chr11:61583134	MIR1908;FADS1	-0.49	-4.8	-0.36	3.75e-6	Trans fatty acid levels;
PAAD	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.96	7.97	0.54	3.59e-13	Bipolar disorder;
PAAD	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.72	-0.42	5.44e-8	Daytime sleep phenotypes;
PAAD	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.65	4.91	0.37	2.35e-6	Diastolic blood pressure;
PAAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.58	6.62	0.47	5.68e-10	Aortic root size;
PAAD	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.74	8.33	0.56	4.37e-14	Morning vs. evening chronotype;
PAAD	cis	rs258892	0.947	rs266435	chr5:72174432	C/G	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg00122941	chr17:4613640	ARRB2	0.84	8.3	0.56	5.21e-14	Lymphocyte counts;
PAAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs58521262	0.556	rs1908942	chr19:23184109	A/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.81	9.34	0.6	1.11e-16	Colorectal cancer;
PAAD	cis	rs7129556	0.911	rs10899394	chr11:77324261	A/G	cg24456632	chr11:77314957	AQP11	-0.52	-4.52	-0.34	1.26e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg11143131	chr5:131608246	PDLIM4	0.51	5.22	0.39	5.75e-7	Blood metabolite levels;
PAAD	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs7565124	0.909	rs6747472	chr2:20252007	C/T	cg23821541	chr2:20251993	LAPTM4A	0.52	4.54	0.35	1.15e-5	Major depressive disorder;
PAAD	cis	rs939584	0.932	rs13387091	chr2:650980	G/A	cg14515364	chr2:636606	NA	-0.47	-4.28	-0.33	3.26e-5	Body mass index;
PAAD	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.62	-7.38	-0.51	9.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23834210	chr2:39761648	NA	-0.65	-7.44	-0.52	7e-12	Obesity-related traits;
PAAD	cis	rs593531	0.550	rs592644	chr11:74053547	C/T	cg23327896	chr11:73669290	DNAJB13	-0.36	-4.57	-0.35	9.94e-6	Neuroticism;
PAAD	trans	rs61931739	0.649	rs815049	chr12:33726757	G/C	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.23e-11	Corneal astigmatism;
PAAD	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.66	-5.94	-0.43	1.91e-8	Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.52	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs10821973	0.527	rs7096738	chr10:63980874	A/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.89	10.38	0.64	2.09e-19	Coronary artery disease;
PAAD	cis	rs58521262	0.660	rs62120789	chr19:23051308	A/C	cg07749055	chr19:23076870	NA	-0.66	-4.76	-0.36	4.53e-6	Testicular germ cell tumor;
PAAD	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.45	-5.48	-0.41	1.7e-7	Colorectal cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18629132	chr10:131592435	NA	0.55	7.3	0.51	1.5e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-4.39	-0.34	2.15e-5	Mean corpuscular volume;
PAAD	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.91	-9.33	-0.6	1.21e-16	Asthma;
PAAD	cis	rs6688567	1	rs6688567	chr1:173583414	A/T	cg14047008	chr1:173887011	SERPINC1	-0.45	-4.43	-0.34	1.8e-5	Mosquito bite size;
PAAD	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg24331049	chr13:111365604	ING1	-0.82	-4.41	-0.34	1.93e-5	Coronary artery disease;
PAAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.29e-12	Height;
PAAD	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.59	-0.35	9.11e-6	Type 2 diabetes;
PAAD	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.68	-7.02	-0.5	6.76e-11	Height;
PAAD	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs7714584	1.000	rs4958848	chr5:150271122	G/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg12046867	chr14:103022105	NA	-0.63	-4.89	-0.37	2.54e-6	Platelet count;
PAAD	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg05336292	chr10:466338	DIP2C	-0.41	-4.5	-0.34	1.37e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg08029281	chr1:67600428	NA	0.48	5.51	0.41	1.47e-7	Psoriasis;
PAAD	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.78	-6.64	-0.47	5.32e-10	Other erythrocyte phenotypes;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15219393	chr5:149109878	PPARGC1B	-0.63	-6.29	-0.45	3.16e-9	Primary biliary cholangitis;
PAAD	cis	rs12989701	1.000	rs13009551	chr2:127889118	C/T	cg08168897	chr2:127865431	BIN1	0.64	5.15	0.39	8.01e-7	Alzheimer's disease (late onset);
PAAD	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs10924309	0.889	rs10802247	chr1:245858508	G/A	cg00036263	chr1:245852353	KIF26B	-0.69	-6.12	-0.44	7.74e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	6.99	0.49	8e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg13741927	chr9:139327495	INPP5E	0.44	4.41	0.34	1.91e-5	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg16928487	chr17:17741425	SREBF1	-0.32	-4.43	-0.34	1.81e-5	Total body bone mineral density;
PAAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12432903	chr7:1882776	MAD1L1	0.62	4.5	0.34	1.33e-5	Bipolar disorder;
PAAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.67	6.58	0.47	7.23e-10	Parkinson's disease;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.49	5.33	0.4	3.43e-7	Testicular germ cell tumor;
PAAD	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.69	6.71	0.48	3.71e-10	Lymphocyte counts;
PAAD	cis	rs7567389	0.719	rs4150476	chr2:128032822	A/T	cg09760422	chr2:128146352	NA	-0.38	-5.93	-0.43	1.97e-8	Self-rated health;
PAAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.75	7.64	0.53	2.29e-12	Cognitive function;
PAAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.67	-0.35	6.5e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs1497828	0.871	rs2815248	chr1:217572871	C/T	cg04411442	chr1:217543379	NA	0.49	4.69	0.36	6.09e-6	Dialysis-related mortality;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs755249	0.567	rs16825921	chr1:39649198	A/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.76	-5.02	-0.38	1.46e-6	Platelet distribution width;
PAAD	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-10.32	-0.64	2.96e-19	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.92	-0.43	2.08e-8	IgG glycosylation;
PAAD	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.7	-0.42	5.93e-8	Total cholesterol levels;
PAAD	cis	rs877529	0.967	rs139414	chr22:39553819	G/A	cg18708252	chr22:39545030	CBX7	-0.45	-4.37	-0.33	2.29e-5	Multiple myeloma;
PAAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	1.37	11.03	0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs4774830	1.000	rs62045209	chr15:56249524	T/C	cg24530489	chr15:56299380	NA	-0.97	-4.48	-0.34	1.47e-5	Delta-5 desaturase activity;
PAAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.68	7.62	0.53	2.53e-12	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20124547	chr2:175062978	OLA1	0.59	6.35	0.46	2.42e-9	Smoking initiation;
PAAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.75	8.48	0.57	1.85e-14	Longevity;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg09509183	chr1:209979624	IRF6	0.54	5.05	0.38	1.23e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7188861	0.681	rs34947566	chr16:11412926	C/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.6	-5.21	-0.39	5.96e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs364477	0.762	rs12238866	chr9:1001309	G/T	cg13952963	chr9:998547	NA	-0.59	-4.41	-0.34	1.93e-5	Major depressive disorder;
PAAD	cis	rs16975963	0.843	rs73031215	chr19:38433555	G/A	cg25793785	chr19:38281423	NA	0.57	4.62	0.35	8e-6	Longevity;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26926768	chr12:34528122	NA	-0.36	-4.46	-0.34	1.61e-5	Morning vs. evening chronotype;
PAAD	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs8051149	0.688	rs3815559	chr16:87871366	G/C	cg01412419	chr16:87856264	NA	0.74	6.34	0.46	2.51e-9	Blood metabolite levels;
PAAD	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg15556689	chr8:8085844	FLJ10661	0.65	6.58	0.47	7.27e-10	Morning vs. evening chronotype;
PAAD	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg10819733	chr22:24237672	NA	-0.45	-4.38	-0.33	2.2e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.31e-18	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.49	-5.91	-0.43	2.16e-8	Lewy body disease;
PAAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.75	7.67	0.53	1.9e-12	Schizophrenia;
PAAD	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg14248031	chr19:58907397	NA	-0.39	-4.25	-0.33	3.78e-5	Uric acid clearance;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02889418	chr18:77227672	NFATC1	0.55	6.73	0.48	3.26e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg15193198	chr20:60906057	LAMA5	-0.53	-5.66	-0.42	7.3900000000000007e-08	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.53	0.47	9.24e-10	Mood instability;
PAAD	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg08345082	chr10:99160200	RRP12	0.3	4.35	0.33	2.44e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1413885	1.000	rs1413885	chr1:65815659	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.96	0.37	1.9e-6	Anticoagulant levels;
PAAD	cis	rs59888335	0.895	rs67287064	chr3:80831892	G/A	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.79	-5.74	-0.42	5.05e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.45	5.12	0.38	9.27e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02543470	chr2:105862877	NA	-0.54	-5.12	-0.38	9.05e-7	AIDS;
PAAD	cis	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.7	-0.42	5.93e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg26205652	chr12:48591994	NA	0.72	6.63	0.47	5.53e-10	Longevity (90 years and older);
PAAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.32	0.33	2.82e-5	Major depressive disorder;
PAAD	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.59	5.86	0.43	2.78e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-6.15	-0.45	6.64e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs288342	0.797	rs288331	chr2:183625425	C/T	cg02625481	chr2:183667124	NA	-0.45	-4.47	-0.34	1.52e-5	Recurrent major depressive disorder;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.44	4.85	0.37	2.98e-6	Electroencephalogram traits;
PAAD	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.56	4.73	0.36	5.18e-6	Cystic fibrosis severity;
PAAD	cis	rs9535307	0.929	rs6561560	chr13:50339507	A/T	cg03658251	chr13:50265850	EBPL	-0.84	-5.29	-0.39	4.29e-7	Obesity-related traits;
PAAD	cis	rs4073221	0.860	rs1849477	chr3:18245719	A/G	cg07694806	chr3:18168406	NA	-0.76	-5.04	-0.38	1.28e-6	Parkinson's disease;
PAAD	cis	rs929596	0.531	rs2741012	chr2:234508963	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.56	-0.35	1.06e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.24	0.45	4.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.88	7.55	0.52	3.74e-12	Triglycerides;
PAAD	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg19418318	chr19:17219073	MYO9B	0.41	5.34	0.4	3.37e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6774280	0.656	rs62244874	chr3:6280049	A/C	cg18469270	chr3:5468035	NA	0.54	4.27	0.33	3.48e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.91	0.37	2.28e-6	Life satisfaction;
PAAD	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg10616300	chr11:66138557	SLC29A2	0.34	4.58	0.35	9.47e-6	Educational attainment (years of education);
PAAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg13057898	chr1:3703894	LRRC47	0.47	4.93	0.37	2.15e-6	Red cell distribution width;
PAAD	cis	rs282587	0.569	rs390657	chr13:113415085	A/G	cg19217778	chr13:113420270	ATP11A	-0.56	-4.49	-0.34	1.42e-5	Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02139671	chr12:123237174	DENR	0.64	7.18	0.5	2.84e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13424612	1.000	rs1465880	chr2:240932326	G/A	cg01812947	chr2:240904978	NDUFA10	0.62	5.29	0.39	4.1e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.83	0.43	3.28e-8	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21441730	chr2:33245988	LTBP1	-0.66	-6.81	-0.48	2.16e-10	Obesity-related traits;
PAAD	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.69	-7.91	-0.54	4.85e-13	White blood cell count (basophil);
PAAD	cis	rs7100689	0.890	rs7086627	chr10:82220597	C/T	cg01528321	chr10:82214614	TSPAN14	1.23	14.83	0.77	2.39e-31	Post bronchodilator FEV1;
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.78	0.62	8.13e-18	Platelet count;
PAAD	cis	rs10512697	0.649	rs34098513	chr5:3486403	G/C	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg22863700	chr5:28928346	NA	0.55	5.32	0.4	3.67e-7	Hip geometry;
PAAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	5.47	0.41	1.83e-7	Tonsillectomy;
PAAD	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs112990264	0.892	rs79041902	chr1:212894455	A/G	cg01785514	chr1:212988523	TATDN3	1.22	8.28	0.56	6.04e-14	Itch intensity from mosquito bite;
PAAD	cis	rs877282	0.741	rs35865720	chr10:753022	G/A	cg17470449	chr10:769945	NA	0.64	5.91	0.43	2.2e-8	Uric acid levels;
PAAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.52	-5.96	-0.44	1.71e-8	Blood protein levels;
PAAD	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg04370829	chr17:406249	NA	-0.55	-5.54	-0.41	1.31e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.98	8.19	0.55	9.95e-14	Neutrophil percentage of white cells;
PAAD	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg15654264	chr1:150340011	RPRD2	0.52	4.94	0.37	2e-6	Migraine;
PAAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-6.15	-0.45	6.64e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6688613	1.000	rs2296837	chr1:166958601	T/C	cg07049167	chr1:166818506	POGK	0.47	4.66	0.35	6.94e-6	Refractive astigmatism;
PAAD	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.81	8.39	0.56	3.07e-14	Corneal astigmatism;
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.67	7.55	0.52	3.73e-12	Age at first birth;
PAAD	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.48	5.11	0.38	9.7e-7	Mean corpuscular volume;
PAAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.56	5.29	0.39	4.23e-7	Type 2 diabetes;
PAAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.47	0.34	1.5e-5	Tonsillectomy;
PAAD	cis	rs28489187	0.730	rs233130	chr1:85795112	T/C	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg02631450	chr22:32366979	NA	1.07	5.76	0.42	4.45e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	10.49	0.65	1.03e-19	Cognitive test performance;
PAAD	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs901683	1.000	rs12778980	chr10:45994211	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.34	-0.33	2.58e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg06251129	chr1:155990657	SSR2	0.58	6.29	0.45	3.25e-9	Iris heterochromicity;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27322371	chr3:150329392	SELT	0.58	6.62	0.47	5.69e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	7.8	0.53	9.18e-13	Lung cancer in ever smokers;
PAAD	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26306683	chr17:18585705	ZNF286B	0.58	5.92	0.43	2.04e-8	Educational attainment (years of education);
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.84	0.58	2.27e-15	Alzheimer's disease;
PAAD	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.75	8.7	0.58	5.08e-15	Lewy body disease;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.77	0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.06	-0.55	2.05e-13	Coffee consumption (cups per day);
PAAD	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.75	7.14	0.5	3.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg26354017	chr1:205819088	PM20D1	0.61	6.46	0.46	1.31e-9	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.84	4.5	0.34	1.32e-5	Childhood ear infection;
PAAD	cis	rs7824557	0.767	rs718427	chr8:11139038	C/G	cg21775007	chr8:11205619	TDH	0.58	5.14	0.38	8.32e-7	Retinal vascular caliber;
PAAD	cis	rs9535307	0.584	rs1198328	chr13:50389885	A/G	cg03658251	chr13:50265850	EBPL	0.73	4.34	0.33	2.58e-5	Obesity-related traits;
PAAD	cis	rs4908768	0.501	rs4351668	chr1:8535818	C/T	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-6.52	-0.47	9.61e-10	Personality dimensions;
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.79	0.58	2.91e-15	Lung cancer;
PAAD	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.87	-8.63	-0.57	7.68e-15	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8105895	0.935	rs10406553	chr19:22237801	G/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg27394845	chr17:28928406	LRRC37B2	0.67	4.26	0.33	3.58e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9463078	0.546	rs1285026	chr6:45120834	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.21	-0.39	6.14e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7260329	0.670	rs4803413	chr19:41485977	G/A	cg07907917	chr19:40949191	SERTAD3	-0.51	-4.27	-0.33	3.4e-5	Smoking behavior;
PAAD	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-1.06	-18.77	-0.84	2.02e-41	Urate levels in lean individuals;
PAAD	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg25951430	chr11:57192432	SLC43A3	-0.42	-4.38	-0.33	2.22e-5	Schizophrenia;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg09017928	chr7:158110068	PTPRN2	0.59	5.35	0.4	3.25e-7	Response to amphetamines;
PAAD	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-6.97	-0.49	8.85e-11	Response to antipsychotic treatment;
PAAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.63	-5.21	-0.39	6.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05665937	chr4:1216051	CTBP1	0.45	4.87	0.37	2.79e-6	Obesity-related traits;
PAAD	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg08079166	chr15:68083412	MAP2K5	0.69	5.44	0.4	2.11e-7	Restless legs syndrome;
PAAD	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg22802167	chr1:533950	NA	0.7	6.91	0.49	1.27e-10	Blood protein levels;
PAAD	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.51	5.01	0.38	1.51e-6	Schizophrenia;
PAAD	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.3	0.33	3.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2916733	0.530	rs2440422	chr8:6290440	A/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.51	-0.34	1.31e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.55	6.2	0.45	5.15e-9	Cognitive function;
PAAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.96	-11.64	-0.69	8.85e-23	Cognitive function;
PAAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg01815783	chr4:1047043	NA	-0.46	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs9918079	0.560	rs10008376	chr4:15623955	A/G	cg16509355	chr4:15471240	CC2D2A	0.33	4.28	0.33	3.35e-5	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg20933634	chr6:27740509	NA	0.67	6.27	0.45	3.56e-9	Parkinson's disease;
PAAD	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg26897989	chr16:1907736	C16orf73	-0.55	-5.19	-0.39	6.5e-7	Insulin-like growth factors;
PAAD	cis	rs11700980	0.551	rs59945036	chr21:30118962	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-4.99	-0.38	1.6e-6	QRS complex (12-leadsum);
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs11264799	0.639	rs7543979	chr1:157741318	A/C	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	cis	rs7631605	0.905	rs4678920	chr3:37020649	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.63	0.35	7.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs787274	0.764	rs787299	chr9:115542369	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.64	-4.47	-0.34	1.52e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.93	9.67	0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.55	-6.14	-0.45	6.79e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs11638352	1.000	rs2706477	chr15:44480189	C/A	cg10011062	chr15:43941034	CATSPER2	-1.21	-4.31	-0.33	2.93e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs7246657	0.551	rs10404069	chr19:37638404	C/T	cg23950597	chr19:37808831	NA	-0.74	-5.1	-0.38	1.01e-6	Coronary artery calcification;
PAAD	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	6.01	0.44	1.32e-8	Breast cancer;
PAAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg03959625	chr15:84868606	LOC388152	0.46	4.88	0.37	2.64e-6	P wave terminal force;
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg20917491	chr3:195578259	NA	0.47	4.81	0.36	3.62e-6	Pancreatic cancer;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-5.17	-0.39	7.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg14343924	chr8:8086146	FLJ10661	-0.5	-4.48	-0.34	1.44e-5	Joint mobility (Beighton score);
PAAD	cis	rs1642645	0.872	rs4660595	chr1:42482052	T/A	cg01990334	chr1:42801334	FOXJ3	-0.6	-5.45	-0.4	1.96e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-4.57	-0.35	1.01e-5	Mean corpuscular volume;
PAAD	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.85	0.37	2.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.9	10.83	0.66	1.3e-20	Prudent dietary pattern;
PAAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg00982548	chr2:198649783	BOLL	-0.76	-5.51	-0.41	1.5e-7	Ulcerative colitis;
PAAD	cis	rs7765004	1.000	rs9387176	chr6:114074493	T/C	cg13100190	chr6:114053961	NA	0.35	4.32	0.33	2.84e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-4.84	-0.37	3.11e-6	Menopause (age at onset);
PAAD	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg06606381	chr12:133084897	FBRSL1	-0.88	-6.37	-0.46	2.18e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.57	-5.41	-0.4	2.44e-7	Cognitive test performance;
PAAD	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg16691251	chr5:66510806	NA	0.69	7.33	0.51	1.28e-11	Breast cancer;
PAAD	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-6.65	-0.47	4.88e-10	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs939584	0.866	rs13405307	chr2:650973	T/C	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.73	7.23	0.51	2.19e-11	Total body bone mineral density;
PAAD	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.67	7.21	0.5	2.46e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg00717180	chr2:96193071	NA	-0.63	-7.58	-0.52	3.22e-12	Height;
PAAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.87	9.68	0.62	1.43e-17	Cognitive function;
PAAD	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg16898833	chr6:26189333	HIST1H4D	1.06	5.72	0.42	5.54e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1144333	0.850	rs1251273	chr1:76288617	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg13565585	chr5:132299512	AFF4	0.51	4.9	0.37	2.38e-6	Apolipoprotein A-IV levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14203525	chr3:115377744	GAP43	0.59	6.79	0.48	2.42e-10	Monocyte percentage of white cells;
PAAD	cis	rs6574988	0.514	rs8010969	chr14:88626243	C/T	cg18078958	chr14:88630771	NA	-0.48	-4.27	-0.33	3.43e-5	Bipolar disorder;
PAAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs8105895	1.000	rs75167249	chr19:22128655	C/T	cg20662725	chr19:22235022	ZNF257	-0.57	-4.4	-0.34	2.01e-5	Body mass index (change over time);
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.53	-5.73	-0.42	5.1e-8	Testicular germ cell tumor;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.62	-6.61	-0.47	6e-10	Lymphocyte counts;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.48	4.68	0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg13590414	chr9:128173245	NA	-0.47	-4.8	-0.36	3.69e-6	Resting heart rate;
PAAD	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	4.6	0.35	8.98e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.3	4.52	0.34	1.22e-5	Alcohol dependence;
PAAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	4.92	0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.67	7.15	0.5	3.38e-11	Obesity-related traits;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg00431813	chr7:1051703	C7orf50	-0.35	-4.41	-0.34	1.91e-5	Longevity;Endometriosis;
PAAD	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.63	-6.33	-0.46	2.63e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg09659197	chr4:152720779	NA	-0.46	-6.15	-0.45	6.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.39	4.4	0.34	2.06e-5	High light scatter reticulocyte count;
PAAD	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.75	-0.36	4.73e-6	Joint mobility (Beighton score);
PAAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.96	0.37	1.83e-6	Schizophrenia;
PAAD	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg04995300	chr3:66848608	NA	0.42	4.45	0.34	1.67e-5	Type 2 diabetes;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.5	4.9	0.37	2.38e-6	Longevity;Endometriosis;
PAAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.49	4.54	0.35	1.15e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg27489772	chr12:121021490	NA	0.55	4.97	0.37	1.78e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg05554000	chr7:158905015	VIPR2	0.52	4.55	0.35	1.07e-5	Facial morphology (factor 20);
PAAD	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg08898775	chr15:59042684	ADAM10	0.4	5.2	0.39	6.32e-7	Schizophrenia;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	1.06	14.37	0.76	4.15e-30	Menarche (age at onset);
PAAD	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-5.19	-0.39	6.53e-7	Alzheimer's disease (survival time);
PAAD	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.62	6.31	0.46	2.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg19640130	chr10:64028056	RTKN2	0.38	4.56	0.35	1.03e-5	Rheumatoid arthritis;
PAAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19825600	chr2:3704501	ALLC	-0.51	-4.4	-0.34	2.03e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9913156	0.748	rs7217849	chr17:4562165	G/C	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.72	6.01	0.44	1.32e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.75	-8.07	-0.55	1.93e-13	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13276305	chr14:19960976	NA	-0.51	-6.62	-0.47	5.82e-10	Myopia (pathological);
PAAD	cis	rs11264213	0.901	rs72661625	chr1:36401003	T/C	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.81e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13939156	chr17:80058883	NA	-0.4	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg26031613	chr14:104095156	KLC1	-0.48	-5.25	-0.39	5.06e-7	Schizophrenia;
PAAD	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	trans	rs3130844	1	rs3130844	chr6:28916594	G/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Urinary tract infection frequency;
PAAD	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs1811103	1	rs1811103	chr22:34182889	A/T	cg20021572	chr22:34192387	LARGE	-0.6	-4.39	-0.34	2.15e-5	Neuroticism;
PAAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg19784903	chr17:45786737	TBKBP1	0.53	5.66	0.42	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11024102	0.925	rs7123383	chr11:17002985	G/A	cg15084286	chr11:17036142	PLEKHA7	0.51	4.69	0.36	6.01e-6	Glaucoma (primary angle closure);
PAAD	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-5.2	-0.39	6.35e-7	Menarche (age at onset);
PAAD	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.88	0.43	2.45e-8	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.61	-5.43	-0.4	2.17e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg27539214	chr16:67997921	SLC12A4	-0.65	-5.02	-0.38	1.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	trans	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg01620082	chr3:125678407	NA	1.09	6.34	0.46	2.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.65	-7.25	-0.51	2.02e-11	Longevity;Endometriosis;
PAAD	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-5.18	-0.39	6.8e-7	Bipolar disorder;
PAAD	cis	rs13177180	0.671	rs746566	chr5:114922047	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.46	-4.95	-0.37	1.98e-6	Conotruncal heart defects (inherited effects);
PAAD	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.73	8.51	0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6841948	0.698	rs6830083	chr4:7979904	A/G	cg14959746	chr4:7987834	ABLIM2	0.6	4.53	0.34	1.21e-5	Post bronchodilator FEV1 in COPD;
PAAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-4.98	-0.37	1.69e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.7	6.72	0.48	3.42e-10	Recombination rate (males);
PAAD	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.81	0.58	2.58e-15	Corneal astigmatism;
PAAD	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.64	6.9	0.49	1.33e-10	Crohn's disease;
PAAD	cis	rs17539620	0.808	rs17539432	chr6:154876414	G/C	cg20019720	chr6:154832845	CNKSR3	0.46	6.11	0.44	7.81e-9	Lipoprotein (a) levels;
PAAD	cis	rs988913	1.000	rs6922186	chr6:54811092	A/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.97	-6.4	-0.46	1.85e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg26554054	chr8:600488	NA	0.85	5.59	0.41	1.04e-7	IgG glycosylation;
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg00531865	chr16:30841666	NA	0.53	5.16	0.39	7.71e-7	Dementia with Lewy bodies;
PAAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.31	14.9	0.77	1.6e-31	IgG glycosylation;
PAAD	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.61	4.79	0.36	3.92e-6	Common traits (Other);
PAAD	cis	rs8037137	0.822	rs2890156	chr15:91513157	T/A	cg23684204	chr15:91497937	RCCD1	0.73	4.71	0.36	5.61e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.73	-5.19	-0.39	6.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg24330906	chr2:85765176	MAT2A	0.51	4.93	0.37	2.16e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs57709857	0.957	rs9643870	chr8:38116792	A/G	cg16625770	chr8:38300134	FGFR1	-0.47	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	5.72	0.42	5.46e-8	Body mass index;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.61	-5.78	-0.42	4.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg14393609	chr7:65229607	NA	-0.46	-4.4	-0.34	2e-5	Aortic root size;
PAAD	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-1.1	-11.16	-0.67	1.69e-21	Cognitive test performance;
PAAD	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.63	-6.66	-0.48	4.66e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg18888403	chr1:24152774	HMGCL	0.41	4.65	0.35	7.27e-6	Immature fraction of reticulocytes;
PAAD	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.56	-7.11	-0.5	4.24e-11	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	4.93e-20	Heart rate;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-5.46	-0.41	1.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs76793172	1.000	rs76793172	chr19:46359794	C/T	cg13320842	chr19:46175254	GIPR	0.63	4.68	0.35	6.36e-6	Eosinophil counts;
PAAD	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.42	-4.38	-0.33	2.2e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.43	0.34	1.83e-5	Menarche (age at onset);
PAAD	cis	rs9283706	0.608	rs1428408	chr5:66331203	T/C	cg11590213	chr5:66331682	MAST4	0.59	4.79	0.36	3.9e-6	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs2133450	0.712	rs10510358	chr3:7368190	C/T	cg19930620	chr3:7340148	GRM7	-0.47	-5.23	-0.39	5.54e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs7577696	0.568	rs462878	chr2:32438655	A/G	cg02381751	chr2:32503542	YIPF4	0.51	4.91	0.37	2.37e-6	Inflammatory biomarkers;
PAAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.65	4.37	0.33	2.27e-5	Type 2 diabetes;
PAAD	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.4	4.38	0.33	2.23e-5	Dilated cardiomyopathy;
PAAD	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.66	-5.95	-0.43	1.82e-8	Coronary heart disease;
PAAD	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.99	-0.38	1.62e-6	High light scatter reticulocyte count;
PAAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg24733560	chr20:60626293	TAF4	0.6	7.97	0.54	3.48e-13	Body mass index;
PAAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.19	0.5	2.68e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.68	0.42	6.53e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.96	11.38	0.68	4.39e-22	Breast cancer;
PAAD	cis	rs75920871	0.544	rs76868258	chr11:116993292	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.85	-4.27	-0.33	3.45e-5	Subjective well-being;
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.45	0.4	1.98e-7	Body mass index;
PAAD	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg26695010	chr11:65641043	EFEMP2	-0.64	-4.97	-0.37	1.78e-6	Glomerular filtration rate (creatinine);Chronic kidney disease;
PAAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs5750830	0.594	rs6001566	chr22:39774448	A/G	cg11247378	chr22:39784982	NA	-0.83	-10.23	-0.64	5.11e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.21	15.37	0.78	9.29e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-1.13	-16.02	-0.79	1.84e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3753841	0.771	rs1551105	chr1:103259509	G/T	cg24495344	chr1:103574097	COL11A1	0.38	4.4	0.34	2.02e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.04	-0.55	2.33e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs12999616	0.571	rs34635139	chr2:98364407	C/T	cg26665480	chr2:98280029	ACTR1B	0.67	6.37	0.46	2.09e-9	Colorectal cancer;
PAAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg26441486	chr22:50317300	CRELD2	0.4	4.68	0.35	6.3e-6	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06900676	chr2:61293330	KIAA1841	0.68	7.35	0.51	1.16e-11	Myopia (pathological);
PAAD	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	1.16	10.18	0.64	6.9e-19	Red blood cell traits;
PAAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.99	0.49	7.97e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg25319279	chr11:5960081	NA	-0.67	-6.31	-0.46	2.93e-9	DNA methylation (variation);
PAAD	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7916697	0.578	rs1900002	chr10:70004552	G/C	cg18338521	chr10:69995036	NA	-0.39	-5.07	-0.38	1.16e-6	Optic disc area;
PAAD	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg14952266	chr13:112191215	NA	-0.43	-4.88	-0.37	2.63e-6	Hepatitis;
PAAD	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.72	-8.59	-0.57	9.68e-15	Colorectal cancer;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01114163	chr5:1856713	NA	-0.42	-4.43	-0.34	1.78e-5	Cardiovascular disease risk factors;
PAAD	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.51	-7.12	-0.5	4.09e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg10495392	chr1:46806563	NSUN4	0.58	5.64	0.42	8.11e-8	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs761746	0.960	rs5753734	chr22:32028721	A/C	cg01338084	chr22:32026380	PISD	0.49	4.28	0.33	3.33e-5	Intelligence;
PAAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.91	-8.15	-0.55	1.23e-13	Diastolic blood pressure;
PAAD	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs7989332	0.961	rs4770041	chr13:21048569	C/T	cg06710890	chr13:21477865	XPO4	0.48	4.99	0.38	1.63e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.34	-5.29	-0.39	4.26e-7	Alcohol dependence;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg08888203	chr3:10149979	C3orf24	0.96	8.02	0.55	2.71e-13	Alzheimer's disease;
PAAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6998277	0.830	rs17186961	chr8:103630028	G/A	cg10187029	chr8:103597600	NA	1.06	11.39	0.68	4.04e-22	Migraine;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.79	0.48	2.38e-10	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.25	0.64	4.43e-19	White blood cell count;
PAAD	trans	rs1442089	1.000	rs7241967	chr18:51114375	G/A	cg24118715	chr10:70232072	DNA2	0.73	6.44	0.46	1.48e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs35740288	0.929	rs1978391	chr15:86311695	A/G	cg07943548	chr15:86304357	KLHL25	0.56	4.77	0.36	4.34e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg11008003	chr7:157255264	NA	0.32	4.52	0.34	1.23e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs73416724	0.544	rs111739263	chr6:43243151	G/T	cg00507679	chr6:43251876	TTBK1	0.63	4.93	0.37	2.17e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg16606324	chr3:10149918	C3orf24	0.75	5.96	0.44	1.68e-8	Alzheimer's disease;
PAAD	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.31	0.6	1.32e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.47	0.41	1.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	1.000	rs114960066	chr3:41882323	A/G	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2301888	0.962	rs2240338	chr1:17674185	C/T	cg01790353	chr1:17674483	PADI4	0.46	5.44	0.4	2.12e-7	Rheumatoid arthritis;
PAAD	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.48	6.13	0.45	7.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.85	6.74	0.48	3.07e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.69	7.49	0.52	5.31e-12	Aortic root size;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02389270	chr19:18717781	CRLF1	-0.66	-6.45	-0.46	1.43e-9	Lung cancer in ever smokers;
PAAD	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs7260329	0.670	rs8109525	chr19:41491918	A/G	cg06653635	chr19:40910092	PRX	-0.48	-4.46	-0.34	1.57e-5	Smoking behavior;
PAAD	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg17178900	chr1:205818956	PM20D1	-0.64	-4.71	-0.36	5.59e-6	Prostate-specific antigen levels;
PAAD	trans	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg01957732	chr6:133561716	EYA4	-0.98	-7.15	-0.5	3.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.69	6.14	0.45	6.87e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6539267	1.000	rs6539267	chr12:106785554	T/C	cg02476566	chr12:106696527	TCP11L2	0.47	4.54	0.35	1.15e-5	Tourette syndrome;
PAAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.61	8.31	0.56	5.02e-14	Renal cell carcinoma;
PAAD	cis	rs2882667	0.690	rs930063	chr5:138053618	C/G	cg09476006	chr5:138032270	NA	0.51	6.58	0.47	7e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6679454	0.801	rs852788	chr1:58305551	G/A	cg17491850	chr1:57888480	DAB1	-0.43	-4.53	-0.35	1.17e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs2718812	0.904	rs2718809	chr3:133409418	A/G	cg08048268	chr3:133502702	NA	0.42	5.23	0.39	5.43e-7	Iron status biomarkers;
PAAD	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.03	0.38	1.35e-6	Schizophrenia;
PAAD	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg14851346	chr12:38532713	NA	-0.45	-4.32	-0.33	2.78e-5	Bladder cancer;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.43	-6.33	-0.46	2.68e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.77	0.62	8.57e-18	Chronic sinus infection;
PAAD	cis	rs73058052	0.597	rs2288921	chr19:50092002	G/T	cg15607449	chr19:49990766	RPL13AP5;RPL13A	0.56	5.02	0.38	1.43e-6	Fibrinogen levels;
PAAD	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg26097391	chr2:54893211	SPTBN1	0.46	4.35	0.33	2.52e-5	Schizophrenia;
PAAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.97	11.84	0.69	2.53e-23	Gestational age at birth (maternal effect);
PAAD	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.53	-5.38	-0.4	2.74e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg01448562	chr3:133502909	NA	0.48	4.89	0.37	2.59e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg19682013	chr15:45996608	NA	-0.32	-4.25	-0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06753367	chr22:24256600	NA	-0.43	-4.51	-0.34	1.27e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs57244997	0.725	rs73030431	chr6:162439575	G/A	cg17173639	chr6:162384350	PARK2	-0.66	-5.1	-0.38	9.81e-7	Mosquito bite size;
PAAD	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg08648136	chr8:956695	NA	0.5	5.2	0.39	6.24e-7	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg04990556	chr1:26633338	UBXN11	0.66	4.96	0.37	1.87e-6	Obesity-related traits;
PAAD	cis	rs4534636	0.812	rs7314690	chr12:8671274	A/C	cg12193649	chr12:8324628	ZNF705A	0.43	4.36	0.33	2.41e-5	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
PAAD	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg07541023	chr7:19748670	TWISTNB	0.53	4.33	0.33	2.7e-5	Thyroid stimulating hormone;
PAAD	cis	rs11009175	0.615	rs7901543	chr10:33299313	G/A	cg00146027	chr10:33299147	NA	-0.4	-4.87	-0.37	2.81e-6	Depression (quantitative trait);
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.43	-4.3	-0.33	3.08e-5	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.67	0.48	4.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg03989125	chr22:38214979	NA	0.61	5.54	0.41	1.29e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs476633	0.679	rs561821	chr15:41427864	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.75	-7.9	-0.54	5.17e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg13444538	chr7:158905317	VIPR2	-0.72	-5.73	-0.42	5.25e-8	Facial morphology (factor 20);
PAAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg05554000	chr7:158905015	VIPR2	-0.6	-4.51	-0.34	1.29e-5	Facial morphology (factor 20);
PAAD	cis	rs35955747	0.902	rs5997938	chr22:31676992	A/G	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-5.37	-0.4	2.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-4.76	-0.36	4.47e-6	Pancreatic cancer;
PAAD	cis	rs7627468	0.770	rs3863977	chr3:121964262	T/C	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.67	-0.35	6.5e-6	Obesity-related traits;
PAAD	cis	rs7771547	0.519	rs72852340	chr6:36554804	G/A	cg07856975	chr6:36356162	ETV7	0.56	5.75	0.42	4.76e-8	Platelet distribution width;
PAAD	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.43	4.68	0.35	6.41e-6	Platelet count;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-4.78	-0.36	4.02e-6	Testicular germ cell tumor;
PAAD	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.5e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.87	10.74	0.66	2.25e-20	Aortic root size;
PAAD	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg01942863	chr7:99769432	GPC2	0.51	4.8	0.36	3.78e-6	Coronary artery disease;
PAAD	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg20607287	chr7:12443886	VWDE	-0.89	-6.5	-0.47	1.07e-9	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs3762637	0.941	rs6788746	chr3:122106743	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.55	-0.35	1.11e-5	LDL cholesterol levels;
PAAD	cis	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg00576331	chr11:65640516	EFEMP2	-0.51	-4.29	-0.33	3.23e-5	Breast cancer;
PAAD	cis	rs6076065	0.612	rs11905630	chr20:23326165	G/C	cg11657817	chr20:23433608	CST11	0.5	5.02	0.38	1.45e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.61	-0.35	8.49e-6	Menarche (age at onset);
PAAD	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.43	4.47	0.34	1.54e-5	Plateletcrit;
PAAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	4.9	0.37	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg11890956	chr21:40555474	PSMG1	1.07	13.37	0.74	1.91e-27	Cognitive function;
PAAD	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs9535307	0.584	rs61961500	chr13:50392624	G/C	cg04663916	chr13:50265991	EBPL	-0.63	-4.38	-0.33	2.17e-5	Obesity-related traits;
PAAD	cis	rs59104589	0.570	rs73006397	chr2:242415523	C/T	cg04488487	chr2:242709673	NA	0.57	4.55	0.35	1.1e-5	Fibrinogen levels;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.48e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.94	-0.37	2.07e-6	Monocyte percentage of white cells;
PAAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg24253500	chr15:84953950	NA	-0.56	-6.55	-0.47	8.49e-10	Schizophrenia;
PAAD	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.67	-6.9	-0.49	1.32e-10	Coronary artery disease;
PAAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.14	0.6	3.69e-16	Menopause (age at onset);
PAAD	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.34e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg23033748	chr14:75592666	NEK9	-0.42	-5.17	-0.39	7.22e-7	Height;
PAAD	cis	rs2980439	0.517	rs712253	chr8:8103782	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-5.33	-0.4	3.48e-7	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06831965	chr8:55527869	RP1	0.63	6.8	0.48	2.21e-10	Smoking initiation;
PAAD	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg16205897	chr5:131564050	P4HA2	-0.49	-5.5	-0.41	1.56e-7	Blood metabolite levels;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.21	0.39	6.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.67	4.57	0.35	9.87e-6	IgG glycosylation;
PAAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.81	8.57	0.57	1.1e-14	Cognitive function;
PAAD	cis	rs8112211	0.689	rs11672219	chr19:38793596	G/C	cg01275006	chr19:38876250	GGN	-0.81	-5.15	-0.39	7.9e-7	Blood protein levels;
PAAD	cis	rs621942	0.950	rs655726	chr11:85665635	G/A	cg07180834	chr11:85838833	NA	-0.46	-4.26	-0.33	3.64e-5	Tourette syndrome;
PAAD	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg10006428	chr1:248814059	OR2T27	0.4	4.71	0.36	5.58e-6	Common traits (Other);
PAAD	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.37	0.4	2.84e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.68	6.18	0.45	5.57e-9	Obesity-related traits;
PAAD	cis	rs1903068	0.886	rs1551644	chr4:55994266	A/T	cg20092376	chr4:56023423	NA	0.49	4.9	0.37	2.42e-6	Endometriosis;
PAAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22442454	chr1:209979470	IRF6	0.39	4.25	0.33	3.69e-5	Monobrow;
PAAD	cis	rs41311933	1.000	rs41311911	chr9:123743921	C/T	cg13567360	chr9:123745713	C5	-0.7	-4.5	-0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2790216	0.901	rs2790237	chr10:59984016	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg09796270	chr17:17721594	SREBF1	0.46	5.32	0.4	3.63e-7	Total body bone mineral density;
PAAD	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-13.65	-0.74	3.45e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06606381	chr12:133084897	FBRSL1	-0.98	-6.69	-0.48	4.04e-10	Depression;
PAAD	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19882132	chr14:106167949	NA	0.58	5.23	0.39	5.59e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.85	-5.48	-0.41	1.74e-7	Type 2 diabetes;
PAAD	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.67	0.42	6.82e-8	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.91	7.82	0.54	8.38e-13	Alzheimer's disease;
PAAD	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.63	0.82	1.42e-38	Height;
PAAD	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.04	0.63	1.65e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25243171	chr2:23914356	KLHL29	-0.68	-6.42	-0.46	1.65e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6442522	0.678	rs924813	chr3:15512799	A/T	cg16303742	chr3:15540471	COLQ	0.46	4.9	0.37	2.43e-6	Uric acid levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26372423	chr22:20067491	DGCR8	0.65	7.43	0.52	7.39e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs9815354	0.761	rs794896	chr3:42031902	C/T	cg03022575	chr3:42003672	ULK4	-0.72	-5.22	-0.39	5.67e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.34	5.16	0.39	7.63e-7	Schizophrenia;
PAAD	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.51	5.4	0.4	2.46e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.76	7.26	0.51	1.85e-11	Obesity-related traits;
PAAD	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.39	-0.46	1.89e-9	Triglycerides;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13110350	chr12:46383601	SFRS2IP	0.69	7.41	0.52	8.22e-12	Myopia (pathological);
PAAD	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.49	5.03	0.38	1.34e-6	Major depressive disorder;
PAAD	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.09	-0.38	1.07e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg16434002	chr17:42200994	HDAC5	0.63	5.7	0.42	6.09e-8	Total body bone mineral density;
PAAD	cis	rs55728055	0.661	rs62237763	chr22:31947392	C/G	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.63	-6.22	-0.45	4.48e-9	Blood metabolite levels;
PAAD	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.92	-0.43	2.03e-8	Schizophrenia;
PAAD	cis	rs4713118	0.500	rs9461434	chr6:28102465	A/C	cg22143856	chr6:28129313	ZNF389	0.65	4.87	0.37	2.76e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.86	11.25	0.67	9.37e-22	Vitiligo;
PAAD	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.61	-4.92	-0.37	2.23e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg10395934	chr14:104002654	TRMT61A	0.55	5.52	0.41	1.45e-7	Body mass index;
PAAD	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.99	-10.84	-0.66	1.2e-20	Lymphocyte counts;
PAAD	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.47	-5.43	-0.4	2.17e-7	Mean arterial pressure;
PAAD	cis	rs2327429	0.858	rs12524865	chr6:134196674	C/A	cg06296503	chr6:134217401	NA	0.47	4.83	0.36	3.31e-6	Coronary artery disease;
PAAD	cis	rs3733418	0.799	rs11942693	chr4:165930168	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-4.8	-0.36	3.8e-6	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.68	-0.35	6.3e-6	Dupuytren's disease;
PAAD	cis	rs9913156	0.670	rs7219606	chr17:4561928	T/C	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs1075265	0.875	rs12616212	chr2:54266246	T/C	cg26149131	chr2:54343179	ACYP2	-0.45	-4.26	-0.33	3.55e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6142102	0.517	rs6059580	chr20:32527873	T/C	cg06115741	chr20:33292138	TP53INP2	0.53	4.55	0.35	1.08e-5	Skin pigmentation;
PAAD	cis	rs6070	0.897	rs998771	chr19:51396580	A/C	cg11738530	chr19:51047879	LRRC4B	-0.42	-4.37	-0.33	2.29e-5	Prostate-specific antigen levels;Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs258892	0.895	rs13181060	chr5:72071769	T/C	cg21869765	chr5:72125136	TNPO1	-0.79	-5.3	-0.39	4.01e-7	Small cell lung carcinoma;
PAAD	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.6	-5.04	-0.38	1.32e-6	Pursuit maintenance gain;
PAAD	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.69	4.75	0.36	4.66e-6	Hip geometry;
PAAD	cis	rs6009527	1.000	rs6009188	chr22:49572751	G/A	cg12746016	chr22:49560550	NA	0.49	4.93	0.37	2.08e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.74	-10.09	-0.63	1.2e-18	Iron status biomarkers;
PAAD	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.57	4.56	0.35	1.04e-5	Optic nerve measurement (cup area);
PAAD	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.8	5.65	0.42	7.54e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.49e-8	Menopause (age at onset);
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg07061783	chr6:25882402	NA	-0.53	-5.21	-0.39	6.02e-7	Blood metabolite levels;
PAAD	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.54	5.53	0.41	1.34e-7	Multiple sclerosis;
PAAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs11191270	0.554	rs11191274	chr10:104140350	G/A	cg15320455	chr10:103880129	LDB1	0.67	5.0	0.38	1.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.93	11.47	0.68	2.55e-22	Blood protein levels;
PAAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7714584	1.000	rs17111376	chr5:150226899	T/C	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.91	-8.8	-0.58	2.79e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10011647	chr11:58892585	FAM111B	-0.62	-6.43	-0.46	1.56e-9	Obesity-related traits;
PAAD	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24275626	chr17:4608986	PELP1	-0.62	-6.71	-0.48	3.64e-10	Obesity-related traits;
PAAD	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.78	7.12	0.5	4.05e-11	Breast cancer;
PAAD	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg05484376	chr2:27715224	FNDC4	0.45	4.59	0.35	9.38e-6	Oral cavity cancer;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg08088566	chr11:430123	ANO9	0.87	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg27234864	chr13:21295941	IL17D	0.6	5.24	0.39	5.3e-7	Dental caries;
PAAD	cis	rs375066	0.762	rs1073654	chr19:44411420	T/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.28	-0.45	3.33e-9	Breast cancer;
PAAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.53	-0.34	1.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg04369109	chr6:150039330	LATS1	-0.5	-4.84	-0.37	3.11e-6	Lung cancer;
PAAD	cis	rs10982213	1.000	rs2274158	chr9:117166206	G/T	cg00078025	chr9:117159975	NA	0.58	4.32	0.33	2.76e-5	Interleukin-6 levels;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.78	-6.46	-0.46	1.36e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23656755	chr1:230203043	GALNT2	0.65	7.4	0.51	8.56e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs797680	0.930	rs12124771	chr1:93799239	A/G	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.65e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.23	0.39	5.61e-7	Monocyte percentage of white cells;
PAAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.88	9.61	0.61	2.18e-17	Cognitive function;
PAAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.55	-0.35	1.09e-5	Platelet count;
PAAD	cis	rs2923427	0.592	rs6474400	chr8:42357682	A/T	cg09913449	chr8:42400586	C8orf40	-0.47	-5.22	-0.39	5.75e-7	Mean corpuscular volume;
PAAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg03233332	chr7:66118400	NA	0.41	4.45	0.34	1.65e-5	Aortic root size;
PAAD	cis	rs28655083	0.529	rs285023	chr16:77099783	G/A	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11563648	0.553	rs10254399	chr7:127012114	G/A	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	6.32	0.46	2.73e-9	Mood instability;
PAAD	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.48	6.32	0.46	2.72e-9	Childhood ear infection;
PAAD	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Colorectal cancer;
PAAD	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.56	-5.24	-0.39	5.21e-7	Serum sulfate level;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg05025164	chr4:1340916	KIAA1530	-0.59	-6.06	-0.44	1.04e-8	Obesity-related traits;
PAAD	trans	rs4272720	0.855	rs2377692	chr10:50230347	A/T	cg15329866	chr3:171455826	PLD1	0.77	6.7	0.48	3.75e-10	Platelet count;Plateletcrit;
PAAD	cis	rs7922314	0.571	rs61865684	chr10:64721402	G/T	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20049151	chr4:101726770	NA	-0.67	-7.07	-0.5	5.19e-11	Obesity-related traits;
PAAD	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg10431340	chr1:161279108	MPZ	-0.62	-5.67	-0.42	7e-8	Rheumatoid arthritis;
PAAD	cis	rs4662592	0.590	rs36084105	chr2:128868432	C/T	cg03222009	chr2:129077232	HS6ST1	-0.5	-4.68	-0.35	6.39e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.44	-0.34	1.73e-5	Educational attainment;
PAAD	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.26e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg15798862	chr7:76129360	DTX2	-0.37	-4.39	-0.34	2.13e-5	Eotaxin levels;
PAAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg00901687	chr17:48585270	MYCBPAP	0.6	6.02	0.44	1.23e-8	Visceral fat;
PAAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	trans	rs901683	1.000	rs71494798	chr10:45998980	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg14343924	chr8:8086146	FLJ10661	0.51	4.43	0.34	1.8e-5	Mood instability;
PAAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.43	0.4	2.21e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.51	5.52	0.41	1.45e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.69	6.82	0.48	2.02e-10	Type 2 diabetes;
PAAD	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg04415270	chr2:102091202	RFX8	-0.51	-6.35	-0.46	2.37e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.53	5.77	0.42	4.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.62	-5.66	-0.42	7.29e-8	Neuroticism;
PAAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.52	7.05	0.5	5.9e-11	Ewing sarcoma;
PAAD	cis	rs8077577	0.747	rs62072540	chr17:18225228	G/A	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs7537052	0.669	rs475591	chr1:36642420	T/C	cg24686825	chr1:36642396	MAP7D1	-0.6	-6.14	-0.45	7.03e-9	Schizophrenia;
PAAD	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7250872	0.606	rs4453627	chr19:1829860	T/C	cg27263395	chr19:2199697	DOT1L	0.53	4.29	0.33	3.17e-5	Bipolar disorder;
PAAD	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.56	-6.07	-0.44	9.59e-9	Schizophrenia;
PAAD	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.06	0.38	1.2e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2694528	0.841	rs77691613	chr5:60417118	C/T	cg11474532	chr5:59995715	DEPDC1B	1.0	5.34	0.4	3.26e-7	Parkinson's disease;
PAAD	cis	rs6499129	1.000	rs7195790	chr16:67522289	A/G	cg10189135	chr16:67516162	ATP6V0D1	-0.57	-4.36	-0.33	2.34e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.65	4.55	0.35	1.1e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9581857	0.547	rs9581882	chr13:28110682	C/G	cg22138327	chr13:27999177	GTF3A	0.79	5.19	0.39	6.62e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4908768	0.501	rs4908760	chr1:8526142	G/A	cg20416874	chr1:8611966	RERE	-0.48	-4.64	-0.35	7.38e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	7.46	0.52	6.12e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.67	6.46	0.46	1.32e-9	Subjective well-being;
PAAD	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.9e-5	Total body bone mineral density;
PAAD	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.5	-4.96	-0.37	1.83e-6	Fibrinogen levels;
PAAD	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.67	6.77	0.48	2.64e-10	Primary sclerosing cholangitis;
PAAD	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.7	7.3	0.51	1.54e-11	Osteoporosis;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	1.05	6.73	0.48	3.28e-10	IgG glycosylation;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.39	-5.64	-0.42	7.96e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-8.12	-0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21747090	chr2:27597821	SNX17	-0.44	-4.32	-0.33	2.78e-5	Total body bone mineral density;
PAAD	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.66	0.35	6.75e-6	Breast cancer;
PAAD	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.44	-4.88	-0.37	2.61e-6	Mean arterial pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10977834	chr4:77996840	CCNI	0.61	6.58	0.47	7.34e-10	Myopia (pathological);
PAAD	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.8	0.77	2.97e-31	Chronic sinus infection;
PAAD	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.61	6.09	0.44	8.76e-9	Red cell distribution width;
PAAD	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs2051773	0.567	rs4456241	chr11:17043041	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.8	-0.36	3.8e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg01966878	chr4:90757139	SNCA	0.46	4.51	0.34	1.31e-5	Dementia with Lewy bodies;
PAAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.52	4.42	0.34	1.83e-5	Height;
PAAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.83	7.19	0.5	2.69e-11	Recombination rate (females);
PAAD	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.6	-6.12	-0.44	7.46e-9	Schizophrenia;
PAAD	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.76	5.35	0.4	3.16e-7	Vitiligo;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.61	6.71	0.48	3.61e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.83	-0.48	1.89e-10	Systolic blood pressure;
PAAD	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	1.07	8.37	0.56	3.59e-14	Inflammatory bowel disease;
PAAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs357618	1.000	rs357622	chr5:150848405	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.64	-0.47	5.35e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs427941	1.000	rs445646	chr7:101880566	G/A	cg06721601	chr7:101762633	CUX1	-0.44	-4.49	-0.34	1.38e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.77	-7.68	-0.53	1.81e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.2	11.48	0.68	2.28e-22	Platelet count;
PAAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.67	-8.06	-0.55	2.08e-13	Huntington's disease progression;
PAAD	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.93	8.28	0.56	5.74e-14	Breast cancer;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.24	0.56	7.33e-14	Lung cancer;
PAAD	cis	rs9308433	0.643	rs7412913	chr1:214463228	G/A	cg06198575	chr1:214491504	SMYD2	0.5	4.58	0.35	9.63e-6	IgG glycosylation;
PAAD	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05221349	chr4:100870488	LOC256880;H2AFZ	0.43	4.63	0.35	7.67e-6	Gut microbiome composition (summer);
PAAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.79	0.58	3.01e-15	Menopause (age at onset);
PAAD	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg03959625	chr15:84868606	LOC388152	-0.41	-4.26	-0.33	3.52e-5	P wave terminal force;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15979172	chr19:15490570	AKAP8	0.65	6.48	0.47	1.21e-9	Obesity-related traits;
PAAD	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.61	-0.41	9.53e-8	Coronary artery disease;
PAAD	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg26248373	chr2:1572462	NA	-1.08	-9.15	-0.6	3.44e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-5.06	-0.38	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6585424	1.000	rs35497678	chr10:81921078	C/T	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs7177699	0.534	rs56683682	chr15:79112524	G/T	cg00540400	chr15:79124168	NA	-0.68	-8.3	-0.56	5.39e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14732136	chr17:66031828	KPNA2	0.66	7.29	0.51	1.56e-11	Myopia (pathological);
PAAD	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.31	0.33	2.95e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg02781088	chr2:113192302	RGPD8;RGPD5	-0.69	-5.03	-0.38	1.35e-6	Yeast infection;
PAAD	cis	rs795544	0.564	rs61267472	chr5:13761320	T/A	cg07548982	chr5:13769939	DNAH5	-0.64	-4.77	-0.36	4.22e-6	Corneal astigmatism;
PAAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.66	-0.48	4.83e-10	Menopause (age at onset);
PAAD	cis	rs7247513	0.866	rs7247171	chr19:12706000	T/C	cg01871581	chr19:12707946	ZNF490	-0.86	-10.76	-0.66	1.99e-20	Bipolar disorder;
PAAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg27455613	chr17:80820699	TBCD	-0.44	-4.35	-0.33	2.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.61	-0.35	8.54e-6	Renal cell carcinoma;
PAAD	cis	rs17683430	0.614	rs2006233	chr22:32530848	A/G	cg00543991	chr22:32367038	NA	0.71	5.28	0.39	4.43e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg27449745	chr7:23145252	KLHL7	0.58	5.27	0.39	4.7e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	1.09	9.32	0.6	1.3e-16	Red blood cell traits;
PAAD	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.71	-0.42	5.8e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.75	4.93	0.37	2.16e-6	Vitiligo;
PAAD	cis	rs7594192	0.744	rs6736652	chr2:199368000	C/T	cg03163783	chr2:200326591	SATB2	-0.32	-4.34	-0.33	2.55e-5	Educational attainment;
PAAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20357910	chr2:160919149	PLA2R1	0.56	6.39	0.46	1.92e-9	Monocyte percentage of white cells;
PAAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg06740227	chr12:86229804	RASSF9	0.6	5.86	0.43	2.72e-8	Major depressive disorder;
PAAD	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.46	-4.54	-0.35	1.15e-5	Systemic lupus erythematosus;
PAAD	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg04482110	chr17:41364121	TMEM106A	-0.39	-4.41	-0.34	1.97e-5	Menopause (age at onset);
PAAD	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.54	-5.16	-0.39	7.7e-7	Cancer;
PAAD	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg19930314	chr7:98593876	TRRAP	-0.46	-4.37	-0.33	2.33e-5	Breast cancer;
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.51	4.85	0.37	3.05e-6	Acylcarnitine levels;
PAAD	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.47	6.02	0.44	1.27e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-6.33	-0.46	2.58e-9	Type 2 diabetes;
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.09	-0.44	8.71e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.76	-0.48	2.7e-10	Inflammatory bowel disease;
PAAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.94	-10.34	-0.64	2.62e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.89	-0.37	2.5e-6	Migraine - clinic-based;
PAAD	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	1.14	9.33	0.6	1.23e-16	Height;
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.6	0.57	8.94e-15	Menopause (age at onset);
PAAD	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs6083	0.571	rs41294813	chr15:58847807	T/C	cg05156742	chr15:59063176	FAM63B	-0.58	-5.81	-0.43	3.53e-8	Schizophrenia;
PAAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.76	6.02	0.44	1.26e-8	Methadone dose in opioid dependence;
PAAD	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	1.13	12.39	0.71	8.21e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	5.95	0.43	1.76e-8	Blood protein levels;
PAAD	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg09659197	chr4:152720779	NA	0.37	5.28	0.39	4.45e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg14393609	chr7:65229607	NA	-0.48	-4.9	-0.37	2.44e-6	Aortic root size;
PAAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg13444538	chr7:158905317	VIPR2	-0.59	-4.68	-0.35	6.26e-6	Facial morphology (factor 20);
PAAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.73	-4.73	-0.36	5.02e-6	Lung cancer;
PAAD	cis	rs10932679	0.532	rs2024488	chr2:217662968	G/A	cg05032264	chr2:217675019	NA	-0.53	-5.16	-0.39	7.51e-7	Pulse pressure;
PAAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs75920871	0.557	rs11216275	chr11:116975704	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-4.36	-0.33	2.42e-5	Subjective well-being;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06799790	chr17:61951754	CSH2	-0.47	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.57	-0.57	1.08e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00598143	chr5:90679209	LOC100129716;ARRDC3	-0.74	-6.98	-0.49	8.77e-11	Neuroticism;
PAAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.85	9.01	0.59	8.14e-16	DNA methylation (variation);
PAAD	cis	rs7633770	0.643	rs1581325	chr3:46691866	T/C	cg11219411	chr3:46661640	NA	-0.51	-5.77	-0.42	4.39e-8	Coronary artery disease;
PAAD	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.14	-0.38	8.5e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.75	-7.88	-0.54	5.74e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2307111	0.535	rs34344	chr5:74935825	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.47	-4.56	-0.35	1.03e-5	Obesity;
PAAD	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg04143805	chr16:89395205	ANKRD11	-0.35	-4.26	-0.33	3.58e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.21	0.64	5.64e-19	Bone mineral density;
PAAD	cis	rs151997	0.671	rs395557	chr5:50215832	G/T	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.46	5.28	0.39	4.38e-7	Morning vs. evening chronotype;
PAAD	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.98	0.54	3.36e-13	Response to antipsychotic treatment;
PAAD	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.79	9.15	0.6	3.57e-16	Heart rate;
PAAD	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg00522288	chr12:125625016	AACS	-0.57	-6.17	-0.45	5.84e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13354046	chr1:27216933	GPN2	0.57	6.66	0.48	4.62e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg20826740	chr17:37024042	NA	0.44	4.68	0.35	6.33e-6	Height;
PAAD	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	1.03	7.33	0.51	1.26e-11	Alzheimer's disease;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	6.25	0.45	4.02e-9	Renal function-related traits (BUN);
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.25	0.45	4.03e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.23	0.51	2.21e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg08619932	chr19:49200058	FUT2	0.57	6.05	0.44	1.06e-8	Dietary macronutrient intake;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02071572	chr4:1403502	NA	0.43	5.46	0.41	1.88e-7	Obesity-related traits;
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg18279126	chr7:2041391	MAD1L1	0.54	5.24	0.39	5.25e-7	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4664293	0.510	rs1968343	chr2:160568758	C/T	cg04215213	chr2:159602169	NA	0.39	4.28	0.33	3.3e-5	Monocyte percentage of white cells;
PAAD	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-4.38	-0.33	2.17e-5	Coronary artery disease;
PAAD	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.84	6.32	0.46	2.78e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg02117656	chr17:79614917	TSPAN10	-0.55	-5.56	-0.41	1.2e-7	Eye color traits;
PAAD	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg23358612	chr7:1275258	UNCX	-0.42	-4.69	-0.36	6e-6	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
PAAD	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	4.54	0.35	1.11e-5	Red cell distribution width;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.9	-9.94	-0.63	3.03e-18	Tonsillectomy;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.64	4.43	0.34	1.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg14440974	chr22:39074834	NA	-0.55	-6.82	-0.48	2.01e-10	Menopause (age at onset);
PAAD	cis	rs12612619	0.704	rs6754356	chr2:27315021	G/A	cg00617064	chr2:27272375	NA	-0.52	-5.4	-0.4	2.55e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.44	4.47	0.34	1.51e-5	Age of smoking initiation;
PAAD	cis	rs4072705	0.586	rs7855380	chr9:127246763	T/C	cg14219918	chr9:127249562	NR5A1	-0.36	-4.91	-0.37	2.32e-6	Menarche (age at onset);
PAAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.43e-11	Renal cell carcinoma;
PAAD	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs629922	0.642	rs655988	chr11:114072365	A/G	cg25009965	chr11:114031120	ZBTB16	0.5	4.5	0.34	1.33e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.51	-5.21	-0.39	6.12e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg23250157	chr14:64679961	SYNE2	-0.55	-5.74	-0.42	5.08e-8	Atrial fibrillation;
PAAD	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg04721828	chr11:48285200	OR4X1	0.47	5.77	0.42	4.24e-8	Migraine - clinic-based;
PAAD	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.44	4.54	0.35	1.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg22396632	chr1:3079212	PRDM16	0.44	4.55	0.35	1.08e-5	Migraine;
PAAD	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10127679	chr11:62446724	UBXN1	0.65	6.38	0.46	2.05e-9	Obesity-related traits;
PAAD	cis	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg00746515	chr4:170679019	C4orf27	-0.52	-4.28	-0.33	3.33e-5	Anxiety disorder;
PAAD	cis	rs4739066	0.579	rs77643961	chr8:63879716	A/G	cg25248160	chr8:63776642	NKAIN3	0.76	4.84	0.37	3.16e-6	Myocardial infarction;
PAAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-6.03	-0.44	1.19e-8	Idiopathic membranous nephropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07365274	chr3:114866242	ZBTB20	0.68	7.0	0.49	7.71e-11	Obesity-related traits;
PAAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg05342682	chr7:94953680	PON1	-0.57	-4.9	-0.37	2.4e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg02779429	chr16:88753010	MGC23284;SNAI3	-0.56	-6.31	-0.46	2.9e-9	Coronary artery disease;
PAAD	cis	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg13821571	chr21:34406537	NA	-0.48	-4.64	-0.35	7.36e-6	Gastritis;
PAAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg23957660	chr17:17878224	LRRC48	0.38	4.27	0.33	3.49e-5	Total body bone mineral density;
PAAD	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.99	-0.38	1.63e-6	Personality dimensions;
PAAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg10587741	chr22:38071170	LGALS1	0.61	6.83	0.48	1.92e-10	Fat distribution (HIV);
PAAD	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg14196790	chr5:131705035	SLC22A5	0.57	6.54	0.47	9e-10	Blood metabolite levels;
PAAD	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.16	-0.5	3.3e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.59	-5.86	-0.43	2.73e-8	Lymphocyte counts;
PAAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.49	4.49	0.34	1.38e-5	Renal cell carcinoma;
PAAD	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg11766577	chr21:47581405	C21orf56	-0.43	-4.82	-0.36	3.43e-6	Testicular germ cell tumor;
PAAD	cis	rs75757892	0.544	rs9505144	chr6:7318610	C/T	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19339311	chr20:42213292	SGK2	0.6	7.34	0.51	1.2e-11	Smoking initiation;
PAAD	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs740474	1.000	rs740474	chr5:140925362	A/G	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	-0.42	-5.02	-0.38	1.43e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg21951975	chr1:209979733	IRF6	0.56	5.48	0.41	1.76e-7	Coronary artery disease;
PAAD	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.6	-5.9	-0.43	2.31e-8	Menopause (age at onset);
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	11.76	0.69	4.07e-23	Platelet count;
PAAD	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg17764715	chr19:33622953	WDR88	0.66	6.21	0.45	4.73e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.92	-0.43	2.03e-8	Coronary artery disease;
PAAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg06766960	chr11:133703094	NA	-0.77	-8.8	-0.58	2.89e-15	Childhood ear infection;
PAAD	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.43	-4.37	-0.33	2.32e-5	Response to statin therapy;
PAAD	cis	rs13323323	0.842	rs56377787	chr3:44293513	A/G	cg25364880	chr3:44379878	C3orf23	0.68	5.56	0.41	1.16e-7	IgG glycosylation;
PAAD	cis	rs10044254	0.614	rs2937075	chr5:15747814	A/G	cg07238450	chr5:15720153	FBXL7	-0.55	-5.09	-0.38	1.03e-6	Asthma (corticosteroid response);
PAAD	cis	rs11023332	1.000	rs11023332	chr11:14784110	G/C	cg19336497	chr11:14380999	RRAS2	-0.5	-5.46	-0.41	1.86e-7	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.73	8.55	0.57	1.22e-14	Height;
PAAD	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs1879734	0.731	rs7539908	chr1:54177279	C/T	cg14659662	chr1:54151053	GLIS1	0.42	5.59	0.41	1.01e-7	Mitral valve prolapse;
PAAD	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09695851	chr17:3907499	NA	0.68	6.15	0.45	6.51e-9	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs2030114	0.531	rs1353788	chr16:51606021	A/G	cg03758633	chr16:51611768	NA	0.51	4.97	0.37	1.76e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs16958440	1.000	rs62096463	chr18:44628928	A/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs2283228	1.000	rs2283228	chr11:2849530	A/C	cg10890346	chr11:2207660	NA	0.59	4.42	0.34	1.9e-5	Type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.4e-7	Cognitive function;
PAAD	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7084416	0.517	rs75453629	chr10:82010658	C/T	cg01528321	chr10:82214614	TSPAN14	-0.5	-4.8	-0.36	3.81e-6	Post bronchodilator FEV1;
PAAD	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg23587288	chr2:27483067	SLC30A3	0.67	6.25	0.45	3.93e-9	Blood metabolite levels;
PAAD	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.52	5.25	0.39	5.08e-7	Prostate cancer;
PAAD	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs11264799	0.520	rs849820	chr1:157541565	G/C	cg18268488	chr1:157545234	FCRL4	0.54	6.23	0.45	4.39e-9	IgA nephropathy;
PAAD	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	trans	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.73	-5.29	-0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	4.52	0.34	1.24e-5	Thyroid stimulating hormone;
PAAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.73	7.45	0.52	6.54e-12	Neuroticism;
PAAD	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.91	0.37	2.38e-6	Height;
PAAD	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4742903	0.935	rs10820616	chr9:106945991	G/A	cg14250997	chr9:106856677	SMC2	0.42	4.49	0.34	1.41e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg05697835	chr1:2722811	NA	-0.41	-4.66	-0.35	6.98e-6	Ulcerative colitis;
PAAD	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.64	-8.91	-0.59	1.5e-15	Breast cancer;
PAAD	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs3131513	0.965	rs7513516	chr1:25193009	C/T	cg22509179	chr1:25234806	RUNX3	-0.44	-4.53	-0.34	1.19e-5	Alcohol dependence;
PAAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.66	0.57	6.59e-15	Hip circumference adjusted for BMI;
PAAD	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.64	7.21	0.5	2.5e-11	Diastolic blood pressure;
PAAD	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.37	0.46	2.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.52	-4.96	-0.37	1.85e-6	Menarche (age at onset);
PAAD	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.35	-0.33	2.44e-5	Tuberculosis;
PAAD	cis	rs925642	0.669	rs11721677	chr4:187672016	A/G	cg20274950	chr4:187647402	NA	-0.38	-4.35	-0.33	2.54e-5	Obesity;
PAAD	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.78	7.6	0.52	2.8e-12	Retinal vascular caliber;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.39	-4.34	-0.33	2.61e-5	Mean platelet volume;
PAAD	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.5	5.44	0.4	2.12e-7	Testicular germ cell tumor;
PAAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg09017928	chr7:158110068	PTPRN2	0.47	4.69	0.36	5.92e-6	Calcium levels;
PAAD	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs7897654	0.571	rs12771681	chr10:104635620	T/C	cg15744005	chr10:104629667	AS3MT	-0.5	-4.73	-0.36	5.14e-6	Schizophrenia;
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.45	0.4	1.96e-7	Total body bone mineral density;
PAAD	cis	rs2637266	0.655	rs2588335	chr10:78510229	C/G	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.65e-5	Pulmonary function;
PAAD	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg21427119	chr20:30132790	HM13	-0.64	-5.14	-0.38	8.37e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.16	-0.39	7.67e-7	High light scatter reticulocyte count;
PAAD	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.87	9.31	0.6	1.36e-16	Cognitive function;
PAAD	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	QT interval;
PAAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg26513180	chr16:89883248	FANCA	0.65	7.43	0.52	7.38e-12	Vitiligo;
PAAD	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs7765175	0.598	rs2842838	chr6:113627471	C/T	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.5	-0.47	1.11e-9	Total body bone mineral density;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.55e-9	Lymphocyte counts;
PAAD	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.9	0.59	1.6e-15	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg06740227	chr12:86229804	RASSF9	-0.5	-4.7	-0.36	5.79e-6	Major depressive disorder;
PAAD	cis	rs11220082	0.616	rs2845837	chr11:125289055	A/G	cg23156348	chr11:124981869	NA	0.49	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg11232448	chr19:2858854	NA	-0.49	-4.93	-0.37	2.13e-6	Total cholesterol levels;
PAAD	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.6	-6.4	-0.46	1.86e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.54	6.95	0.49	1.01e-10	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg27394845	chr17:28928406	LRRC37B2	0.64	4.36	0.33	2.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs2398893	0.960	rs2153791	chr9:96744928	G/A	cg14459158	chr9:96720562	NA	0.34	4.31	0.33	2.87e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.75	5.42	0.4	2.3e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.508	rs4347239	chr1:248401116	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-4.61	-0.35	8.47e-6	Common traits (Other);
PAAD	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg06569542	chr10:98946673	SLIT1	0.49	4.95	0.37	1.97e-6	Monocyte count;
PAAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.64	0.62	1.82e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11558328	chr11:46722331	ARHGAP1;ZNF408	0.59	7.32	0.51	1.34e-11	Monocyte percentage of white cells;
PAAD	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.21	-0.39	6.01e-7	Bipolar disorder;
PAAD	cis	rs7562790	0.651	rs4670557	chr2:36654580	G/A	cg01206211	chr2:36825736	FEZ2	0.45	4.45	0.34	1.66e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.63	6.9	0.49	1.33e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-5.0	-0.38	1.58e-6	Pubertal anthropometrics;
PAAD	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.03	0.55	2.52e-13	Corneal astigmatism;
PAAD	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs6604026	0.656	rs11164843	chr1:93416142	A/C	cg13858687	chr1:93297071	RPL5	0.47	4.35	0.33	2.52e-5	Multiple sclerosis;
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg05697835	chr1:2722811	NA	-0.39	-4.42	-0.34	1.9e-5	Ulcerative colitis;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg02462569	chr6:150064036	NUP43	0.49	5.29	0.39	4.14e-7	Lung cancer;
PAAD	cis	rs863345	0.967	rs10797028	chr1:158523241	T/A	cg12129480	chr1:158549410	OR10X1	-0.45	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.69	7.56	0.52	3.54e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.59	4.75	0.36	4.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6496932	0.503	rs7176605	chr15:85986722	G/A	cg19183879	chr15:85880815	NA	-0.5	-4.45	-0.34	1.65e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.37	4.85	0.37	3.04e-6	Schizophrenia;
PAAD	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.49	5.31	0.4	3.82e-7	Longevity;Endometriosis;
PAAD	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg05805236	chr11:65401703	PCNXL3	-0.59	-6.35	-0.46	2.34e-9	Acne (severe);
PAAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.6	0.35	8.82e-6	Breast cancer;
PAAD	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.57	5.74	0.42	4.95e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs7571967	chr2:646839	T/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.56	5.63	0.42	8.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.49	4.8	0.36	3.84e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.68	4.94	0.37	2.01e-6	Fat distribution (HIV);
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.05	-0.5	5.9e-11	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg11764359	chr7:65958608	NA	-0.75	-5.1	-0.38	9.8e-7	Diabetic kidney disease;
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	4.9	0.37	2.39e-6	Prostate cancer;
PAAD	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.63	5.7	0.42	5.92e-8	Mean platelet volume;
PAAD	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.54	8.35	0.56	3.98e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.47	6.31	0.46	2.92e-9	Breast cancer;Mosquito bite size;
PAAD	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs7714584	1.000	rs11748151	chr5:150226292	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs5753037	0.653	rs140107	chr22:30130516	C/A	cg01021169	chr22:30184971	ASCC2	-0.47	-4.82	-0.36	3.42e-6	Type 1 diabetes;
PAAD	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg10395934	chr14:104002654	TRMT61A	0.49	4.76	0.36	4.43e-6	Body mass index;
PAAD	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.55	5.2	0.39	6.31e-7	Red blood cell count;
PAAD	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.75	-9.25	-0.6	1.92e-16	Educational attainment;
PAAD	cis	rs10267417	0.603	rs10264784	chr7:19909530	T/C	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01809437	chr16:84695622	KLHL36	0.71	9.24	0.6	2.03e-16	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12304921	1.000	rs12315928	chr12:51355931	T/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.77	9.76	0.62	8.94e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-1.17	-9.62	-0.62	2.05e-17	Obesity-related traits;
PAAD	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.74	5.97	0.44	1.63e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg05785598	chr3:49045655	WDR6	0.41	4.88	0.37	2.62e-6	Parkinson's disease;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27436995	chr16:743998	FBXL16	-0.36	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.86	-9.09	-0.59	4.96e-16	Non-obstructive azoospermia;
PAAD	cis	rs4273100	0.688	rs1533034	chr17:19153175	G/C	cg19949948	chr17:19361230	NA	-0.42	-4.33	-0.33	2.68e-5	Schizophrenia;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.79	5.83	0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg09211372	chr6:168490623	NA	-0.46	-4.9	-0.37	2.47e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2882667	0.690	rs7736925	chr5:138154530	C/G	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3026101	0.671	rs8076560	chr17:5299527	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04077077	chr17:47841656	FAM117A	0.6	6.45	0.46	1.41e-9	Response to antipsychotic treatment;
PAAD	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.59	-7.84	-0.54	7.42e-13	Longevity;
PAAD	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.43	-6.38	-0.46	2.05e-9	Breast cancer;
PAAD	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg27449745	chr7:23145252	KLHL7	-0.57	-5.11	-0.38	9.46e-7	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12032359	chr15:40986923	RAD51	0.63	7.35	0.51	1.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg04920474	chr2:44395004	PPM1B	0.44	4.25	0.33	3.76e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7011049	1.000	rs79536146	chr8:53853526	G/A	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg14061069	chr19:46274453	DMPK	0.85	13.22	0.73	4.73e-27	Coronary artery disease;
PAAD	cis	rs4743820	0.590	rs7045796	chr9:93919427	G/C	cg14446406	chr9:93919335	NA	0.48	5.74	0.42	5.01e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.66	-5.98	-0.44	1.52e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg27234864	chr13:21295941	IL17D	0.59	4.88	0.37	2.6e-6	Dental caries;
PAAD	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg23283495	chr1:209979779	IRF6	0.66	5.99	0.44	1.42e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs3764563	0.935	rs17708232	chr19:15686744	A/G	cg20725493	chr19:15740067	CYP4F8	-0.99	-5.88	-0.43	2.54e-8	Inflammatory biomarkers;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.61	7.66	0.53	2.08e-12	Hypertriglyceridemia;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08874788	chr8:98656259	MTDH	0.71	7.17	0.5	3.05e-11	Myopia (pathological);
PAAD	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.03	0.44	1.17e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg20731937	chr12:48336164	NA	0.52	4.41	0.34	1.95e-5	Longevity (90 years and older);
PAAD	trans	rs17076896	0.520	rs73155754	chr13:19722492	G/C	cg20227530	chr10:79085138	KCNMA1	0.77	6.3	0.46	3.1e-9	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs735539	0.521	rs2762985	chr13:21384371	G/T	cg27499820	chr13:21296301	IL17D	0.53	4.8	0.36	3.78e-6	Dental caries;
PAAD	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.72	7.01	0.49	7.27e-11	Urate levels in lean individuals;
PAAD	cis	rs9810890	1.000	rs73198868	chr3:128529111	T/C	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.29	-0.33	3.19e-5	Prostate cancer;
PAAD	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.68	5.15	0.39	8.14e-7	Type 2 diabetes;
PAAD	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg00280220	chr17:61926910	NA	-0.44	-4.66	-0.35	6.91e-6	Prudent dietary pattern;
PAAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.68	4.77	0.36	4.35e-6	Breast cancer;
PAAD	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg20406979	chr6:167373233	NA	-0.36	-4.73	-0.36	5.05e-6	Crohn's disease;
PAAD	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	1.92	10.46	0.65	1.24e-19	Cannabis dependence symptom count;
PAAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.72	7.09	0.5	4.79e-11	Tonsillectomy;
PAAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg06197492	chr11:2016605	H19	0.51	5.81	0.43	3.56e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.66	-8.44	-0.56	2.37e-14	Body mass index;
PAAD	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-5.41	-0.4	2.4e-7	Common traits (Other);
PAAD	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-1.06	-18.93	-0.84	7.91e-42	Urate levels in lean individuals;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.4	-0.34	2.05e-5	Height;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg21178979	chr7:1889533	MAD1L1	-0.41	-4.43	-0.34	1.78e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-5.61	-0.41	9.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.79	0.58	3.01e-15	Menopause (age at onset);
PAAD	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.45	-5.52	-0.41	1.4e-7	Lewy body disease;
PAAD	cis	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.43	-0.34	1.8e-5	Eotaxin levels;
PAAD	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11245990	chr11:68621969	NA	0.39	5.15	0.39	8.14e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10214930	0.781	rs6943883	chr7:27692893	A/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4478858	0.735	rs12734617	chr1:31823446	G/T	cg18939081	chr1:31884902	SERINC2	0.5	5.72	0.42	5.41e-8	Alcohol dependence;
PAAD	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.41	5.08	0.38	1.1e-6	Corneal astigmatism;
PAAD	cis	rs4272720	0.855	rs11814277	chr10:50226804	C/A	cg07637213	chr10:50820604	CHAT;SLC18A3	0.4	4.31	0.33	2.96e-5	Platelet count;Plateletcrit;
PAAD	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.5	-4.43	-0.34	1.8e-5	IgG glycosylation;
PAAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg22482690	chr17:47019901	SNF8	0.47	4.99	0.38	1.61e-6	Coronary heart disease;
PAAD	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.88	7.41	0.52	8.21e-12	Obesity-related traits;
PAAD	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.61	-5.71	-0.42	5.66e-8	Total body bone mineral density;
PAAD	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-5.36	-0.4	2.97e-7	Cognitive function;
PAAD	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg15309053	chr8:964076	NA	0.46	5.12	0.38	9.15e-7	Schizophrenia;
PAAD	cis	rs114540395	0.925	rs77449307	chr10:103385599	A/C	cg21381511	chr10:104264849	SUFU	-0.81	-4.29	-0.33	3.2e-5	Schizophrenia;
PAAD	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-10.8	-0.66	1.52e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg10324643	chr8:143916377	GML	0.42	4.52	0.34	1.25e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3018712	0.590	rs4930597	chr11:68476011	C/T	cg23009355	chr11:68451396	GAL	0.44	4.27	0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12165864	chr7:66369176	NA	0.7	4.45	0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.75	8.07	0.55	2.01e-13	Lung cancer;
PAAD	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.26e-10	Eye color traits;
PAAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-6.86	-0.49	1.62e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.92	8.26	0.56	6.77e-14	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.42	0.4	2.28e-7	Schizophrenia;
PAAD	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg21798802	chr22:38057573	PDXP	0.48	5.12	0.38	9.12e-7	Fat distribution (HIV);
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.62	5.84	0.43	3.02e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg20169779	chr10:135381914	SYCE1	-0.46	-4.75	-0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs10214930	0.697	rs4140899	chr7:27625027	G/A	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg17633681	chr16:88106987	BANP	0.63	8.25	0.56	6.93e-14	Menopause (age at onset);
PAAD	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.0	-0.49	7.84e-11	Triglycerides;
PAAD	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.23	0.39	5.53e-7	Heart rate;
PAAD	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg13647721	chr17:30228624	UTP6	0.65	5.31	0.4	3.84e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	1.23	11.34	0.68	5.66e-22	Eosinophil percentage of granulocytes;
PAAD	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.89	-0.66	8.74e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg15117754	chr3:10150083	C3orf24	0.67	5.85	0.43	2.85e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs6604026	0.698	rs4420089	chr1:93391043	G/T	cg13858687	chr1:93297071	RPL5	0.5	4.56	0.35	1.06e-5	Multiple sclerosis;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.55	5.42	0.4	2.26e-7	Parkinson's disease;
PAAD	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09597638	chr17:3907349	NA	0.6	5.61	0.41	9.46e-8	Type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg02714062	chr19:18668982	C19orf50	0.59	6.91	0.49	1.25e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.62	5.46	0.41	1.88e-7	Initial pursuit acceleration;
PAAD	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-5.41	-0.4	2.43e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg17633681	chr16:88106987	BANP	0.62	8.03	0.55	2.55e-13	Menopause (age at onset);
PAAD	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg01612440	chr4:3296283	NA	0.43	4.34	0.33	2.61e-5	Serum sulfate level;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer;
PAAD	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.23	0.45	4.33e-9	Body mass index;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.09e-6	Life satisfaction;
PAAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.51	5.04	0.38	1.28e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.86	10.0	0.63	2.1e-18	Menarche (age at onset);
PAAD	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.2	10.6	0.65	5.23e-20	Uric acid levels;
PAAD	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.35	-0.4	3.11e-7	Schizophrenia;
PAAD	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.68	-8.36	-0.56	3.67e-14	Monocyte percentage of white cells;
PAAD	trans	rs901683	1.000	rs34163035	chr10:46080719	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.8	8.68	0.58	5.84e-15	Prostate cancer;
PAAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.49	-0.34	1.42e-5	Menopause (age at onset);
PAAD	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.67	-8.63	-0.57	7.87e-15	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00280220	chr17:61926910	NA	-0.46	-4.91	-0.37	2.34e-6	Prudent dietary pattern;
PAAD	cis	rs4478858	0.735	rs10914368	chr1:31847937	A/G	cg18939081	chr1:31884902	SERINC2	0.51	5.75	0.42	4.73e-8	Alcohol dependence;
PAAD	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.73	-10.0	-0.63	2.04e-18	Venous thromboembolism;
PAAD	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-0.94	-9.26	-0.6	1.79e-16	Exhaled nitric oxide output;
PAAD	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.35	-4.38	-0.34	2.17e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	1.04	7.08	0.5	5e-11	Mitochondrial DNA levels;
PAAD	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg16928487	chr17:17741425	SREBF1	-0.37	-4.81	-0.36	3.64e-6	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14536777	chr8:145665811	NFKBIL2	0.57	6.35	0.46	2.37e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-13.47	-0.74	1.05e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	8.54	0.57	1.27e-14	Bone mineral density;
PAAD	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.99	-6.2	-0.45	5.03e-9	Lung cancer in ever smokers;
PAAD	trans	rs901683	1.000	rs71494785	chr10:45964553	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg13476313	chr9:127244764	NR5A1	-0.32	-5.18	-0.39	6.97e-7	Menarche (age at onset);
PAAD	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg17595323	chr11:93583763	C11orf90	-0.37	-4.67	-0.35	6.62e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg14092988	chr3:52407081	DNAH1	0.38	4.55	0.35	1.11e-5	Hemoglobin concentration;
PAAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.78	-5.78	-0.42	4.11e-8	Coronary artery calcification;
PAAD	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.41	4.28	0.33	3.24e-5	Heart rate;
PAAD	cis	rs35570576	0.585	rs7216806	chr17:77538517	C/T	cg05749138	chr17:77536956	NA	-0.39	-4.65	-0.35	7.06e-6	Photic sneeze reflex;
PAAD	cis	rs17152411	1.000	rs2241541	chr10:126671673	T/C	cg07906193	chr10:126599966	NA	0.71	5.66	0.42	7.33e-8	Height;
PAAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06544989	chr22:39130855	UNC84B	0.5	4.97	0.37	1.82e-6	Menopause (age at onset);
PAAD	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg16964102	chr10:135390573	NA	-0.43	-4.45	-0.34	1.68e-5	Obesity-related traits;
PAAD	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.95	8.29	0.56	5.5e-14	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.59	-6.94	-0.49	1.05e-10	Lung cancer;
PAAD	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.47	-11.1	-0.67	2.46e-21	Atopic dermatitis;
PAAD	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg13332499	chr17:408570	NA	0.53	5.69	0.42	6.38e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg16898833	chr6:26189333	HIST1H4D	0.63	4.75	0.36	4.62e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.36e-14	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg15181151	chr6:150070149	PCMT1	-0.55	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs600550	0.552	rs11605466	chr11:60097461	A/T	cg05040360	chr11:60102449	MS4A6E	-0.42	-4.84	-0.37	3.23e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.58	-0.41	1.1e-7	Blood protein levels;
PAAD	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg03233332	chr7:66118400	NA	0.4	4.31	0.33	2.97e-5	Aortic root size;
PAAD	cis	rs58521262	0.556	rs289336	chr19:23152235	G/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.87	-0.37	2.74e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.36	0.46	2.2e-9	Cognitive test performance;
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg01831904	chr17:28903510	LRRC37B2	0.8	6.03	0.44	1.2e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.96e-6	Cognitive ability;
PAAD	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.23	0.39	5.62e-7	Heart rate;
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.85	11.79	0.69	3.32e-23	Vitiligo;
PAAD	cis	rs3764400	0.508	rs74412170	chr17:46117509	C/G	cg10706073	chr17:46328419	SKAP1	-1.07	-6.29	-0.45	3.19e-9	Body mass index;
PAAD	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg25952890	chr19:58913133	NA	0.65	5.42	0.4	2.32e-7	Mean platelet volume;
PAAD	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.6	-6.06	-0.44	1.03e-8	Glioblastoma;
PAAD	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.84	8.11	0.55	1.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.37e-18	Prudent dietary pattern;
PAAD	cis	rs10992471	0.580	rs10992393	chr9:95420983	A/G	cg14631576	chr9:95140430	CENPP	-0.48	-4.44	-0.34	1.75e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg11143131	chr5:131608246	PDLIM4	-0.5	-5.01	-0.38	1.51e-6	Blood metabolite levels;
PAAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg10018233	chr7:150070692	REPIN1	0.68	6.92	0.49	1.2e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.02	-0.44	1.25e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18849799	chr19:9929547	FBXL12	0.65	6.33	0.46	2.65e-9	Smoking initiation;
PAAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12999616	0.817	rs35530168	chr2:98328477	C/G	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs3784262	0.565	rs34676542	chr15:58318716	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-5.26	-0.39	4.79e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.13	-16.86	-0.81	1.23e-36	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg10556349	chr10:835070	NA	0.58	4.92	0.37	2.26e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11066679	0.765	rs10850192	chr12:114118441	T/C	cg18842598	chr12:114273539	RBM19	0.53	4.61	0.35	8.31e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.68	-6.72	-0.48	3.42e-10	Paraoxonase activity;
PAAD	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.64	-0.35	7.41e-6	Daytime sleep phenotypes;
PAAD	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6604026	0.630	rs12081675	chr1:93461495	C/G	cg17283838	chr1:93427260	FAM69A	0.64	5.82	0.43	3.42e-8	Multiple sclerosis;
PAAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.71	0.53	1.52e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4716602	0.896	rs4716427	chr7:156166490	C/T	cg04090468	chr7:156181990	NA	-0.51	-4.97	-0.37	1.8e-6	Anti-saccade response;
PAAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	9.14	0.6	3.76e-16	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16376816	chr5:163924998	NA	-0.62	-6.78	-0.48	2.52e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15983793	chr19:53075878	ZNF701	-0.69	-7.15	-0.5	3.49e-11	Obesity-related traits;
PAAD	cis	rs2006771	0.810	rs2006648	chr22:32081929	T/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.07	-0.38	1.15e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.31	0.56	4.85e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg18016565	chr1:150552671	MCL1	-0.49	-4.9	-0.37	2.46e-6	Tonsillectomy;
PAAD	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg06636001	chr8:8085503	FLJ10661	0.67	6.42	0.46	1.68e-9	Systolic blood pressure;
PAAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.85	-0.37	3.08e-6	Parkinson's disease;
PAAD	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.7	-0.36	5.69e-6	Endometrial cancer;
PAAD	cis	rs62264129	0.500	rs9837134	chr3:112047402	C/T	cg15541583	chr3:112013063	SLC9A10	-0.31	-4.95	-0.37	1.96e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11257240	chr1:2159351	SKI	0.62	7.05	0.5	6.02e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08677398	chr8:58056175	NA	-0.66	-4.54	-0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6834538	0.597	rs1471881	chr4:113557539	T/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.68	0.35	6.26e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.95	10.36	0.64	2.35e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.83	-0.36	3.29e-6	Atopic dermatitis;
PAAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.23e-8	Response to antipsychotic treatment;
PAAD	cis	rs11264213	0.901	rs811114	chr1:36345758	G/A	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	trans	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.35	-0.46	2.33e-9	Mean corpuscular volume;
PAAD	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg08898775	chr15:59042684	ADAM10	0.35	4.41	0.34	1.93e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs33997730	chr10:46068113	G/A	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs7631605	0.905	rs3821826	chr3:37074368	C/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg20490126	chr1:25870007	LDLRAP1	-0.69	-6.29	-0.45	3.24e-9	Blood protein levels;
PAAD	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.48	-4.65	-0.35	7.02e-6	Coronary artery disease;
PAAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.46	-5.34	-0.4	3.33e-7	Interleukin-10 levels;Interleukin-13 levels;
PAAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs73206853	0.609	rs7966169	chr12:111045898	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.83	0.37	3.24e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.5	4.42	0.34	1.87e-5	Corneal astigmatism;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg08088566	chr11:430123	ANO9	0.85	5.39	0.4	2.7e-7	Body mass index;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg27532560	chr4:187881888	NA	-0.53	-6.5	-0.47	1.09e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.81	9.77	0.62	8.35e-18	Blood metabolite ratios;
PAAD	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.5	5.78	0.42	4.16e-8	Coronary artery disease;
PAAD	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.46	0.4	1.94e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	5.71	0.42	5.89e-8	Lung cancer in ever smokers;
PAAD	cis	rs7172971	0.565	rs113336192	chr15:42383254	T/C	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.39	-0.51	8.87e-12	Colorectal cancer;
PAAD	trans	rs901683	1.000	rs71494791	chr10:45978331	C/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.47	-0.46	1.3e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.75	10.84	0.66	1.18e-20	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs1413885	1.000	rs7526692	chr1:65817161	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.84	0.37	3.16e-6	Anticoagulant levels;
PAAD	cis	rs9646944	0.501	rs10181785	chr2:103025274	C/T	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg21496419	chr19:44306685	LYPD5	0.37	4.7	0.36	5.69e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.51	4.79	0.36	3.99e-6	Height;
PAAD	cis	rs11615916	0.790	rs56181846	chr12:62703907	C/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs17776563	0.922	rs12148331	chr15:89110081	C/T	cg27664085	chr15:89157815	NA	0.32	4.3	0.33	3.02e-5	Thyroid hormone levels;
PAAD	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	12.42	0.71	6.62e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg19781863	chr12:62918364	MON2	0.73	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs735539	0.517	rs9552241	chr13:21127569	C/G	cg27499820	chr13:21296301	IL17D	-0.53	-5.17	-0.39	7.29e-7	Dental caries;
PAAD	cis	rs7729723	0.653	rs7737081	chr5:137758546	G/T	cg26069252	chr5:137800343	EGR1	-0.47	-4.36	-0.33	2.37e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21680645	chr2:241513716	RNPEPL1	0.54	6.29	0.45	3.26e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.09	-10.17	-0.64	7.57e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs13102973	0.720	rs13122447	chr4:135887524	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.13e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs6879260	0.682	rs12173080	chr5:179741411	A/C	cg23248424	chr5:179741104	GFPT2	-0.76	-7.83	-0.54	7.65e-13	Height;
PAAD	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.97	13.74	0.74	2e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7678296	1.000	rs7678296	chr4:37182646	T/C	cg06805348	chr4:37245195	KIAA1239	0.6	4.49	0.34	1.38e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg20893579	chr22:38215064	NA	0.49	4.61	0.35	8.39e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.69	6.41	0.46	1.71e-9	Obesity-related traits;
PAAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.52	5.06	0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.72	9.0	0.59	8.53e-16	Obesity (extreme);
PAAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-9.69	-0.62	1.34e-17	Height;
PAAD	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg02264943	chr11:130785842	SNX19	0.37	4.39	0.34	2.09e-5	Schizophrenia;
PAAD	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg23860436	chr12:58378763	NA	0.47	4.42	0.34	1.86e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs34845616	0.514	rs11822562	chr11:133690456	A/C	cg14349672	chr11:133703707	NA	0.53	4.84	0.37	3.18e-6	Hand grip strength;
PAAD	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg26220594	chr1:19110978	NA	-0.71	-5.78	-0.42	4.04e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.9	5.3	0.39	4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg01489032	chr8:143877656	NA	-0.4	-4.56	-0.35	1.05e-5	Urinary tract infection frequency;
PAAD	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-5.77	-0.42	4.37e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs375066	0.935	rs429027	chr19:44395489	G/A	cg08633290	chr19:44405433	NA	-0.58	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.51	4.73	0.36	5.06e-6	Dialysis-related mortality;
PAAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.87	-0.37	2.75e-6	Breast cancer;
PAAD	cis	rs75757892	0.500	rs2842373	chr6:7224150	C/A	cg15365232	chr6:7261319	NA	0.39	4.5	0.34	1.36e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg07341007	chr3:195489909	MUC4	0.63	5.04	0.38	1.32e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.68	-7.33	-0.51	1.25e-11	Lung cancer;
PAAD	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg15128208	chr22:42549153	NA	0.52	4.52	0.34	1.23e-5	Birth weight;
PAAD	cis	rs939584	0.867	rs74832795	chr2:632592	G/A	cg03610516	chr2:642275	NA	0.62	5.49	0.41	1.68e-7	Body mass index;
PAAD	cis	rs35955747	0.934	rs5994397	chr22:31826150	G/C	cg07969918	chr22:31682909	PIK3IP1	-0.35	-4.5	-0.34	1.33e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.56	-4.37	-0.33	2.28e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg14830002	chr1:247616686	OR2B11	0.62	5.08	0.38	1.11e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg27234864	chr13:21295941	IL17D	-0.59	-5.3	-0.39	4.07e-7	Dental caries;
PAAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg22258538	chr11:14403163	NA	-0.32	-4.3	-0.33	3.1e-5	Mitochondrial DNA levels;
PAAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.6	5.6	0.41	9.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.84	10.54	0.65	7.76e-20	Vitiligo;
PAAD	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.86e-7	Bladder cancer;
PAAD	cis	rs2286379	0.777	rs4766415	chr12:1878154	A/T	cg05227549	chr12:1770782	NA	-0.44	-5.06	-0.38	1.2e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.47	4.59	0.35	9.25e-6	HDL cholesterol;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg04160749	chr8:58172571	NA	-0.65	-4.67	-0.35	6.55e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.78	6.66	0.48	4.68e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.14	0.5	3.57e-11	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18774545	chr21:34836806	TMEM50B	-0.62	-6.29	-0.45	3.2e-9	Obesity-related traits;
PAAD	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg03989125	chr22:38214979	NA	-0.66	-6.91	-0.49	1.25e-10	Glioblastoma;Glioma;
PAAD	trans	rs16831235	0.581	rs62168899	chr2:135723715	G/A	cg06964876	chr16:1038180	NA	0.73	6.42	0.46	1.66e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs174601	0.684	rs174528	chr11:61543499	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.43	4.41	0.34	1.96e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.58	5.67	0.42	6.98e-8	Cognitive test performance;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.87	-0.49	1.54e-10	IgG glycosylation;
PAAD	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.54e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg09709951	chr12:54017699	ATF7	0.54	4.88	0.37	2.65e-6	Height;
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg16850897	chr7:100343110	ZAN	-0.77	-6.34	-0.46	2.52e-9	Other erythrocyte phenotypes;
PAAD	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-1.37	-8.57	-0.57	1.09e-14	Depression;
PAAD	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.4	-0.4	2.55e-7	Schizophrenia (age at onset);
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.8	6.59	0.47	6.73e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg05712524	chr7:100608590	NA	-0.4	-4.29	-0.33	3.12e-5	Resting heart rate;
PAAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.33	-10.47	-0.65	1.19e-19	Breast cancer;
PAAD	cis	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg21546286	chr11:48923668	NA	-0.43	-4.63	-0.35	7.64e-6	HDL cholesterol;
PAAD	cis	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg21605333	chr4:119757512	SEC24D	1.24	7.68	0.53	1.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.64	-6.17	-0.45	6.03e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9652601	0.691	rs11861236	chr16:11183626	T/C	cg04616529	chr16:11181986	CLEC16A	0.39	4.69	0.36	6.09e-6	Systemic lupus erythematosus;
PAAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.77	10.48	0.65	1.1e-19	IgG glycosylation;
PAAD	cis	rs4455778	0.580	rs5009336	chr7:49116299	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.71	8.06	0.55	2.12e-13	Corneal astigmatism;
PAAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.51	5.06	0.38	1.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1144333	1.000	rs2202019	chr1:76299181	G/A	cg22875332	chr1:76189707	ACADM	0.6	4.31	0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	5.98	0.44	1.53e-8	Height;
PAAD	cis	rs793571	0.637	rs7179456	chr15:59174539	G/T	cg05156742	chr15:59063176	FAM63B	-0.7	-7.02	-0.49	6.88e-11	Schizophrenia;
PAAD	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg05925327	chr15:68127851	NA	-0.58	-5.31	-0.4	3.79e-7	Restless legs syndrome;
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Electroencephalogram traits;
PAAD	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.1e-5	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7809615	0.748	rs35183025	chr7:99030782	A/T	cg12290671	chr7:99195819	NA	-0.99	-5.35	-0.4	3.16e-7	Blood metabolite ratios;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16931807	chr17:73452755	KIAA0195	0.72	7.58	0.52	3.25e-12	Obesity-related traits;
PAAD	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.75	9.68	0.62	1.44e-17	Metabolite levels;
PAAD	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.78	7.9	0.54	5.28e-13	Coronary artery disease;
PAAD	cis	rs4908760	0.539	rs6577528	chr1:8891032	C/T	cg20416874	chr1:8611966	RERE	-0.43	-4.25	-0.33	3.66e-5	Vitiligo;
PAAD	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.58	-5.49	-0.41	1.66e-7	Neuroticism;
PAAD	cis	rs58521262	0.517	rs2935439	chr19:23197320	A/G	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs7580717	0.785	rs6728639	chr2:232150766	C/T	cg07929768	chr2:232055508	NA	0.53	6.04	0.44	1.11e-8	Multiple myeloma;
PAAD	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs3206736	0.548	rs2526545	chr7:35020183	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs4653767	0.573	rs708770	chr1:226912135	C/T	cg05049329	chr1:226924846	ITPKB	0.39	5.2	0.39	6.43e-7	Parkinson's disease;
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg09915433	chr19:53449742	NA	-0.82	-11.79	-0.69	3.42e-23	Psoriasis;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.74	6.5	0.47	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg24044776	chr19:53454761	ZNF816A	-0.41	-4.51	-0.34	1.31e-5	Psoriasis;
PAAD	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.3	-0.46	3.03e-9	Alcohol dependence;
PAAD	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.21	-0.7	2.58e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.73	7.9	0.54	5.2e-13	Melanoma;
PAAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg14829360	chr17:73884958	NA	-0.64	-6.14	-0.45	6.86e-9	Psoriasis;
PAAD	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.02	0.5	6.72e-11	Lung cancer in ever smokers;
PAAD	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	6.12	0.44	7.43e-9	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	0.97	10.08	0.63	1.3e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg03517284	chr6:25882590	NA	-0.58	-5.23	-0.39	5.48e-7	Iron status biomarkers;
PAAD	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs9810890	1.000	rs78675391	chr3:128472470	C/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs2286503	1.000	rs17724311	chr7:22876793	G/C	cg04907244	chr7:22894795	SNORD93	-0.42	-5.1	-0.38	1.01e-6	Fibrinogen;
PAAD	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg13207630	chr7:32358064	NA	0.96	4.91	0.37	2.28e-6	Body mass index;
PAAD	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg01868782	chr6:126071099	HEY2	0.43	5.06	0.38	1.19e-6	Brugada syndrome;
PAAD	cis	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.11	-0.44	7.91e-9	Longevity;Endometriosis;
PAAD	cis	rs4356203	0.905	rs6486352	chr11:17172370	A/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.73	-8.31	-0.56	4.82e-14	Pulse pressure;
PAAD	cis	rs4841899	1.000	rs4841899	chr9:137424412	T/C	cg21123355	chr9:136844644	VAV2	0.33	4.35	0.33	2.51e-5	Stem cell factor levels;
PAAD	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg02404636	chr22:31891804	SFI1	0.55	5.54	0.41	1.31e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg04877966	chr15:75135169	ULK3	0.54	4.67	0.35	6.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	4.27	0.33	3.46e-5	Reticulocyte count;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg08882774	chr16:28875105	SH2B1	-0.63	-6.5	-0.47	1.11e-9	Primary biliary cholangitis;
PAAD	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg22947322	chr17:47091978	IGF2BP1	0.55	6.89	0.49	1.38e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg23860436	chr12:58378763	NA	0.46	4.26	0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.58	7.16	0.5	3.24e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.6	-5.27	-0.39	4.59e-7	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00357593	chr19:14530417	DDX39	0.57	6.39	0.46	1.95e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00149659	chr3:10157352	C3orf10	0.56	4.42	0.34	1.85e-5	Alzheimer's disease;
PAAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.47	-5.15	-0.39	7.9e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs2882667	0.690	rs825761	chr5:138138007	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg00262122	chr8:11665843	FDFT1	0.52	4.97	0.37	1.78e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.69	-8.07	-0.55	1.94e-13	Colorectal cancer;
PAAD	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09695851	chr17:3907499	NA	0.6	5.43	0.4	2.14e-7	Type 2 diabetes;
PAAD	cis	rs897984	0.881	rs12920259	chr16:30881299	G/A	cg02466173	chr16:30829666	NA	0.59	6.54	0.47	9.02e-10	Dementia with Lewy bodies;
PAAD	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg14191688	chr11:70257035	CTTN	0.56	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg18404041	chr3:52824283	ITIH1	-0.41	-4.41	-0.34	1.98e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10793968	0.642	rs2313530	chr9:133634948	T/C	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs11811982	0.793	rs77220222	chr1:227342972	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.4	-0.34	1.99e-5	Tuberculosis;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg23708337	chr7:1209742	NA	0.57	4.42	0.34	1.89e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.64	0.53	2.32e-12	Resting heart rate;
PAAD	cis	rs89107	0.550	rs17226667	chr6:118721628	A/G	cg21191810	chr6:118973309	C6orf204	0.38	4.36	0.33	2.35e-5	Cardiac structure and function;
PAAD	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.29	-0.33	3.19e-5	Height;
PAAD	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.45e-11	Total cholesterol levels;
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg25037394	chr1:24152592	HMGCL	0.41	4.44	0.34	1.72e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.93	-8.69	-0.58	5.45e-15	Schizophrenia;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27096572	chr18:73141041	C18orf62	-0.5	-6.01	-0.44	1.31e-8	Obesity-related traits;
PAAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.54	-5.28	-0.39	4.37e-7	Schizophrenia;
PAAD	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg19640130	chr10:64028056	RTKN2	0.37	4.42	0.34	1.84e-5	Rheumatoid arthritis;
PAAD	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.46	5.0	0.38	1.58e-6	Mean platelet volume;
PAAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg01320130	chr1:67600311	NA	0.53	5.9	0.43	2.29e-8	Psoriasis;
PAAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.49	4.55	0.35	1.07e-5	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17346426	chr2:216946392	TMEM169;PECR	0.72	7.21	0.5	2.42e-11	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.77	-6.17	-0.45	5.8e-9	Initial pursuit acceleration;
PAAD	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg19254793	chr6:44695348	NA	-0.44	-4.34	-0.33	2.57e-5	Total body bone mineral density;
PAAD	cis	rs55883249	1.000	rs57234614	chr2:9756379	T/C	cg23886495	chr2:9695866	ADAM17	0.62	5.37	0.4	2.92e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.06	0.38	1.17e-6	Electrocardiographic conduction measures;
PAAD	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.38	5.49	0.41	1.69e-7	Neuroticism;
PAAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	5.5	0.41	1.58e-7	Blood protein levels;
PAAD	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	1.1	8.36	0.56	3.74e-14	Iron status biomarkers;
PAAD	cis	rs346785	0.666	rs8072620	chr17:74283253	A/G	cg09812376	chr17:74270190	QRICH2	-0.47	-5.87	-0.43	2.59e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.88	-0.43	2.54e-8	Menarche (age at onset);
PAAD	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.57	6.37	0.46	2.17e-9	Mean corpuscular volume;
PAAD	cis	rs2030114	0.583	rs7195329	chr16:51590733	G/A	cg03758633	chr16:51611768	NA	0.56	5.17	0.39	7.43e-7	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg00976097	chr5:421733	AHRR	-0.44	-4.28	-0.33	3.34e-5	Cystic fibrosis severity;
PAAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.0	11.18	0.67	1.52e-21	Homoarginine levels;
PAAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.7	0.36	5.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14318734	chr19:7504667	ARHGEF18	-0.66	-6.4	-0.46	1.81e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.56	0.35	1.04e-5	Asthma;
PAAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11774413	chr4:56412743	CLOCK	0.61	6.94	0.49	1.07e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13560548	chr3:10150139	C3orf24	0.62	5.5	0.41	1.6e-7	Alzheimer's disease;
PAAD	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg00717180	chr2:96193071	NA	-0.61	-7.18	-0.5	2.82e-11	Height;
PAAD	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs4287000	1.000	rs4287000	chr9:96451784	A/G	cg13787134	chr9:96362102	PHF2	0.41	4.68	0.35	6.35e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.82	6.52	0.47	9.67e-10	Ulcerative colitis;
PAAD	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg01620082	chr3:125678407	NA	-1.04	-6.41	-0.46	1.71e-9	Squamous cell lung carcinoma;
PAAD	cis	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.49	4.96	0.37	1.83e-6	Lymphocyte counts;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.51	5.05	0.38	1.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	1.01	8.31	0.56	4.84e-14	Initial pursuit acceleration;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.94	0.54	4.14e-13	Prudent dietary pattern;
PAAD	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.64	7.14	0.5	3.52e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1359582	0.836	rs10788607	chr10:90377114	C/A	cg15661332	chr10:90342814	RNLS	0.55	4.97	0.37	1.79e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.54	5.05	0.38	1.22e-6	Metabolic traits;
PAAD	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.65	6.27	0.45	3.65e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.69	7.08	0.5	5.01e-11	Mosquito bite size;
PAAD	cis	rs2147904	0.934	rs783629	chr1:42363275	C/T	cg16685388	chr1:42384056	HIVEP3	0.4	4.69	0.36	6.16e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13012494	chr21:47604986	C21orf56	0.44	4.43	0.34	1.76e-5	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04120839	chr3:122134933	WDR5B	0.65	6.57	0.47	7.6e-10	Obesity-related traits;
PAAD	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.37	-4.27	-0.33	3.44e-5	Pubertal anthropometrics;
PAAD	trans	rs2309322	0.544	rs28521449	chr4:181247204	G/A	cg24124977	chr17:78010277	CCDC40;TBC1D16	0.77	6.3	0.46	3.08e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59888335	0.862	rs6765509	chr3:80568395	A/G	cg21735741	chr3:80819488	NA	-0.58	-5.07	-0.38	1.15e-6	Schizophrenia;
PAAD	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.11	15.04	0.77	6.76e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.02e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-4.48	-0.34	1.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs797680	0.856	rs12118262	chr1:93651547	C/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.45	-0.34	1.68e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.68	-6.76	-0.48	2.81e-10	Post bronchodilator FEV1;
PAAD	cis	rs797680	0.964	rs2152358	chr1:93634009	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.44	0.34	1.74e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2221894	0.922	rs9792190	chr8:28828391	T/G	cg20212339	chr8:28908912	HMBOX1	0.49	5.22	0.39	5.82e-7	Obesity-related traits;
PAAD	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.44	-0.8	1.53e-35	Myeloid white cell count;
PAAD	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.39	0.34	2.15e-5	Total body bone mineral density;
PAAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.59	-5.75	-0.42	4.74e-8	Mean platelet volume;
PAAD	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-5.67	-0.42	7.05e-8	Schizophrenia;
PAAD	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.73	0.58	4.38e-15	Chronic sinus infection;
PAAD	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg00536532	chr6:33561449	C6orf227	-0.43	-4.55	-0.35	1.1e-5	Plateletcrit;
PAAD	trans	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.8	8.15	0.55	1.26e-13	Schizophrenia;
PAAD	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.37	-0.4	2.84e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11010242	chr7:26240470	CBX3;HNRNPA2B1	0.63	7.41	0.52	8.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	7.95	0.54	3.99e-13	Mood instability;
PAAD	trans	rs75583333	0.570	rs6888761	chr5:159625610	G/T	cg14222307	chr15:61097246	RORA	-0.82	-6.37	-0.46	2.15e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg14092988	chr3:52407081	DNAH1	0.39	4.79	0.36	3.87e-6	Electroencephalogram traits;
PAAD	cis	rs6449957	0.801	rs921792	chr5:67465803	C/T	cg23036683	chr5:67512108	NA	0.49	4.51	0.34	1.31e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.87	6.95	0.49	9.82e-11	Axial length;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	1.13	6.51	0.47	1.05e-9	Body mass index;
PAAD	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17376030	chr22:41985996	PMM1	0.69	4.78	0.36	4.14e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.58	-5.95	-0.43	1.79e-8	Hypospadias;
PAAD	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.6	5.34	0.4	3.27e-7	Retinal vascular caliber;
PAAD	trans	rs9832727	0.631	rs9821138	chr3:142659837	A/G	cg03401312	chr19:18338283	PDE4C	0.58	6.34	0.46	2.51e-9	Phospholipid levels (plasma);
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg11416102	chr8:651193	ERICH1	0.87	5.97	0.44	1.65e-8	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03041860	chr2:208489911	FAM119A	0.59	6.4	0.46	1.84e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs10450586	0.965	rs10450589	chr11:27308819	A/C	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-4.38	-0.33	2.19e-5	Longevity;Endometriosis;
PAAD	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg08601574	chr20:25228251	PYGB	0.54	5.51	0.41	1.47e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.39	4.86	0.37	2.9e-6	Total body bone mineral density;
PAAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg14709524	chr16:89940631	TCF25	0.76	4.33	0.33	2.68e-5	Skin colour saturation;
PAAD	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.7	-6.59	-0.47	6.65e-10	Obesity-related traits;
PAAD	cis	rs11811982	0.793	rs35601687	chr1:227510995	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.78	-9.18	-0.6	2.98e-16	Colorectal cancer;
PAAD	cis	rs300774	0.925	rs12233125	chr2:118611	A/T	cg21211680	chr2:198530	NA	-0.62	-5.48	-0.41	1.74e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	1.02	12.54	0.71	3.17e-25	Testicular germ cell tumor;
PAAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.82	-8.07	-0.55	2.03e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21191810	chr6:118973309	C6orf204	-0.42	-5.44	-0.4	2.13e-7	Electrocardiographic conduction measures;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs7651511	1.000	rs34317570	chr3:141227451	T/G	cg25967872	chr3:141205623	RASA2	0.49	4.45	0.34	1.65e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs35160687	0.712	rs4832262	chr2:86485134	C/G	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	cis	rs9649465	0.967	rs12538876	chr7:123296320	C/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.76	-0.36	4.38e-6	Migraine;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg10729496	chr3:10149963	C3orf24	-0.65	-5.82	-0.43	3.45e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21136358	chr5:89593497	NA	-0.62	-6.54	-0.47	8.87e-10	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.82	0.43	3.35e-8	Dupuytren's disease;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg14851468	chr5:179071604	C5orf60	0.49	5.2	0.39	6.23e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs11615916	0.790	rs73135280	chr12:62689467	C/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs17162190	0.698	rs7539320	chr1:26850665	C/T	cg17456097	chr1:26900765	RPS6KA1	0.6	4.93	0.37	2.1e-6	Mean corpuscular volume;
PAAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.79	9.3	0.6	1.42e-16	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13242658	chr1:29062949	YTHDF2	0.6	6.58	0.47	7.18e-10	Monocyte percentage of white cells;
PAAD	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-5.07	-0.38	1.12e-6	Menarche (age at onset);
PAAD	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg24905316	chr10:135186343	ECHS1	0.7	4.52	0.34	1.26e-5	Lifespan;
PAAD	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.67	-0.42	7.12e-8	Menopause (age at onset);
PAAD	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	10.88	0.66	9.66e-21	Smoking behavior;
PAAD	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg26818257	chr2:241905806	NA	0.44	4.64	0.35	7.54e-6	Urinary metabolites;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-7.27	-0.51	1.74e-11	Longevity;Endometriosis;
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	5.8	0.43	3.65e-8	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00150737	chr3:131221845	MRPL3	0.74	7.81	0.54	8.89e-13	Obesity-related traits;
PAAD	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg03318428	chr22:46971703	NA	-0.36	-4.25	-0.33	3.66e-5	Urate levels in obese individuals;
PAAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.35	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.82	8.53	0.57	1.39e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08635242	chr17:28706081	CPD	0.56	6.36	0.46	2.27e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg13435101	chr6:74171350	MTO1	-0.61	-6.35	-0.46	2.4e-9	Dental caries;
PAAD	cis	rs3018712	0.700	rs2510386	chr11:68448058	T/C	cg23009355	chr11:68451396	GAL	-0.54	-4.75	-0.36	4.74e-6	Total body bone mineral density;
PAAD	cis	rs4704187	0.687	rs6896474	chr5:74453818	C/G	cg03227963	chr5:74354835	NA	-0.54	-5.39	-0.4	2.64e-7	Response to amphetamines;
PAAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg15017067	chr4:17643749	FAM184B	0.45	5.38	0.4	2.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg05647756	chr17:73805997	UNK	0.79	4.96	0.37	1.89e-6	Psoriasis;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.18e-8	Life satisfaction;
PAAD	cis	rs346785	0.692	rs2279053	chr17:74287389	C/T	cg09812376	chr17:74270190	QRICH2	0.47	6.19	0.45	5.3e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs7818688	0.697	rs11787303	chr8:95972864	C/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg10932868	chr11:921992	NA	0.44	4.66	0.35	6.86e-6	Alzheimer's disease (late onset);
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.87	-10.18	-0.64	7.09e-19	Iron status biomarkers;
PAAD	cis	rs7260329	0.590	rs1808682	chr19:41489448	C/T	cg22249281	chr19:41082756	SHKBP1	-0.56	-4.4	-0.34	2.05e-5	Smoking behavior;
PAAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.74	-8.34	-0.56	4.1e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg14349672	chr11:133703707	NA	-0.59	-6.74	-0.48	3.12e-10	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20436707	chr10:698162	DIP2C;C10orf108	-0.67	-6.91	-0.49	1.28e-10	Obesity-related traits;
PAAD	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.59	-0.41	1.01e-7	Vitiligo;
PAAD	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg15733309	chr7:157513707	PTPRN2	0.63	7.98	0.54	3.35e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs1018697	1.000	rs7092051	chr10:104559477	C/T	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.72	6.75	0.48	2.86e-10	Asthma;
PAAD	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Alcohol dependence;
PAAD	cis	rs6028335	0.674	rs974561	chr20:37591184	G/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.63	-4.71	-0.36	5.62e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.55	4.43	0.34	1.78e-5	Bone mineral density (spine);
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.84	7.13	0.5	3.82e-11	Alzheimer's disease;
PAAD	cis	rs2414095	0.527	rs11636686	chr15:51542066	C/T	cg21478137	chr15:51532386	CYP19A1	0.52	5.29	0.39	4.18e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.9	12.36	0.71	9.73e-25	Prudent dietary pattern;
PAAD	cis	rs6782228	0.883	rs11712115	chr3:128404269	G/A	cg15607142	chr3:128420513	NA	-0.39	-4.29	-0.33	3.19e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-6.08	-0.44	9.36e-9	Hypospadias;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg07362569	chr17:61921086	SMARCD2	0.43	4.79	0.36	3.98e-6	Height;
PAAD	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.55	5.46	0.41	1.86e-7	Neutrophil percentage of white cells;
PAAD	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.83	-10.36	-0.64	2.26e-19	Height;
PAAD	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.63	6.19	0.45	5.3300000000000004e-09	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
PAAD	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg03885332	chr11:832357	CD151	-0.45	-5.26	-0.39	4.91e-7	Mean platelet volume;
PAAD	cis	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.31	-0.33	2.9e-5	Depression;
PAAD	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg19781863	chr12:62918364	MON2	0.71	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.51	-5.15	-0.39	7.9e-7	Subjective well-being;
PAAD	cis	rs4448343	0.927	rs1355619	chr9:98270171	A/G	cg13428213	chr9:98267529	PTCH1	0.46	4.38	0.33	2.2e-5	Height;
PAAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.78	-8.58	-0.57	1.05e-14	Height;
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg00981651	chr20:44574847	PCIF1	0.41	4.29	0.33	3.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.55	4.99	0.38	1.61e-6	Type 2 diabetes;
PAAD	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	5.76	0.42	4.52e-8	Height;
PAAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.44e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Coronary artery disease;
PAAD	cis	rs3763048	0.889	rs6876568	chr5:169453634	A/C	cg01585372	chr5:169931363	KCNIP1	-0.42	-4.3	-0.33	3.03e-5	IgG glycosylation;
PAAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg14580859	chr9:123691850	NA	0.38	4.32	0.33	2.76e-5	Rheumatoid arthritis;
PAAD	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-4.45	-0.34	1.68e-5	Plateletcrit;
PAAD	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.59	6.19	0.45	5.39e-9	Pancreatic cancer;
PAAD	cis	rs9354951	0.783	rs9446316	chr6:71694742	A/G	cg17424859	chr6:71319002	NA	0.46	4.43	0.34	1.82e-5	Daytime sleep phenotypes;
PAAD	cis	rs4144743	1.000	rs3809862	chr17:45330428	C/T	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.81	9.88	0.63	4.45e-18	Cognitive function;
PAAD	cis	rs900145	1.000	rs900145	chr11:13293905	C/T	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.47	-5.42	-0.4	2.31e-7	Migraine;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg09417038	chr21:47716443	C21orf57	0.59	6.41	0.46	1.76e-9	Testicular germ cell tumor;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs900145	0.863	rs10832013	chr11:13295353	G/T	cg15603424	chr11:13300592	ARNTL	0.5	4.5	0.34	1.35e-5	Menarche (age at onset);
PAAD	cis	rs72960926	1.000	rs55958316	chr6:75103944	C/T	cg13997649	chr6:74171430	MTO1	0.81	4.5	0.34	1.37e-5	Metabolite levels (MHPG);
PAAD	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs2713206	0.689	rs6723509	chr2:122000745	C/T	cg06061049	chr2:17934875	GEN1;SMC6	-0.95	-6.29	-0.45	3.29e-9	Testicular germ cell tumor;
PAAD	cis	rs4751058	0.526	rs10764841	chr10:130856829	A/C	cg00118712	chr10:131686819	EBF3	-0.53	-4.97	-0.37	1.77e-6	Vitamin D levels;
PAAD	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.91	-11.79	-0.69	3.42e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.3	0.6	1.44e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.66	6.65	0.47	5.07e-10	Platelet count;
PAAD	cis	rs16958440	1.000	rs57928699	chr18:44645593	T/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.76	-0.42	4.48e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.28	-0.39	4.49e-7	IgG glycosylation;
PAAD	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg01868782	chr6:126071099	HEY2	0.46	5.44	0.4	2.07e-7	Brugada syndrome;
PAAD	cis	rs9815354	1.000	rs1629460	chr3:41927449	T/G	cg03022575	chr3:42003672	ULK4	-0.82	-5.85	-0.43	2.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs939584	0.935	rs1320330	chr2:622225	T/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg26850624	chr5:429559	AHRR	1.03	4.82	0.36	3.44e-6	Breast cancer;
PAAD	cis	rs5769765	0.720	rs138821	chr22:50166564	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.65	-5.39	-0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.73	-8.33	-0.56	4.43e-14	Dental caries;
PAAD	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.67	9.06	0.59	6.02e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.43	-4.29	-0.33	3.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9650657	0.771	rs4240670	chr8:10665848	T/A	cg00262122	chr8:11665843	FDFT1	-0.51	-4.73	-0.36	5.01e-6	Neuroticism;
PAAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.5	4.58	0.35	9.67e-6	Renal cell carcinoma;
PAAD	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.84	8.55	0.57	1.19e-14	Corneal astigmatism;
PAAD	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.92	12.07	0.7	5.93e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg15676125	chr6:33679581	C6orf125	0.46	4.43	0.34	1.79e-5	Plateletcrit;
PAAD	cis	rs9810890	1.000	rs115394279	chr3:128493714	C/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8084125	1.000	rs72981154	chr18:74944135	C/T	cg05528293	chr18:74961138	GALR1	0.61	5.04	0.38	1.32e-6	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24010988	chr6:74079677	OOEP	0.72	6.76	0.48	2.79e-10	Neuroticism;
PAAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg21132104	chr15:45694354	SPATA5L1	0.48	4.43	0.34	1.77e-5	Glomerular filtration rate;
PAAD	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg20913747	chr6:44695427	NA	-0.63	-7.18	-0.5	2.92e-11	Total body bone mineral density;
PAAD	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg10595753	chr17:80898281	TBCD	0.5	4.55	0.35	1.11e-5	Glycated hemoglobin levels;
PAAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.77	-9.57	-0.61	2.92e-17	Height;
PAAD	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg23188684	chr11:67383651	NA	0.43	4.43	0.34	1.78e-5	Mean corpuscular volume;
PAAD	cis	rs8077577	0.895	rs62073607	chr17:18071338	A/G	cg16794390	chr17:18148240	FLII	0.59	5.12	0.38	9.19e-7	Obesity-related traits;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.82e-6	Personality dimensions;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.66	6.3	0.45	3.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.55	5.96	0.44	1.66e-8	Bladder cancer;
PAAD	cis	rs6088813	0.883	rs2425055	chr20:33903636	C/T	cg14752227	chr20:34000481	UQCC	0.5	4.95	0.37	1.96e-6	Height;
PAAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg02016764	chr4:38805732	TLR1	-0.54	-4.26	-0.33	3.64e-5	Breast cancer;
PAAD	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.13	0.5	3.84e-11	Colorectal cancer;
PAAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.75	7.54	0.52	3.97e-12	Cognitive function;
PAAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg19847866	chr10:1019161	NA	-0.58	-4.51	-0.34	1.3e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	1.05	9.43	0.61	6.44e-17	Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg08648136	chr8:956695	NA	0.51	5.45	0.4	2.02e-7	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.57	5.4	0.4	2.52e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14579157	chr2:99061273	INPP4A	0.65	7.55	0.52	3.79e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	1.15	18.31	0.83	2.81e-40	Menarche (age at onset);
PAAD	cis	rs3126085	0.560	rs11204986	chr1:152342059	T/C	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs6893807	1.000	rs2304608	chr5:87962298	C/A	cg02225085	chr5:87975992	LOC645323	-0.64	-4.81	-0.36	3.61e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.560	rs42088	chr7:27701861	C/T	cg22168087	chr7:27702803	HIBADH	-0.58	-5.44	-0.4	2.11e-7	Hypospadias;
PAAD	cis	rs9398803	0.698	rs1262553	chr6:127078785	T/C	cg19875578	chr6:126661172	C6orf173	-0.46	-4.88	-0.37	2.6e-6	Male-pattern baldness;
PAAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg14092988	chr3:52407081	DNAH1	-0.46	-5.77	-0.42	4.23e-8	Bipolar disorder;
PAAD	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Androgen levels;
PAAD	cis	rs6681460	1.000	rs7521123	chr1:67121663	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.91	-8.95	-0.59	1.15e-15	Asthma;
PAAD	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.69	10.7	0.66	2.81e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.73e-5	Self-reported allergy;
PAAD	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg14500798	chr7:98100126	NA	0.42	4.48	0.34	1.44e-5	Breast cancer;
PAAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg05895507	chr15:77155635	SCAPER	0.36	4.32	0.33	2.77e-5	Blood metabolite levels;
PAAD	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg19949948	chr17:19361230	NA	0.45	4.51	0.34	1.29e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg05110241	chr16:68378359	PRMT7	-1.03	-6.66	-0.48	4.76e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg17509989	chr5:176798049	RGS14	0.87	10.26	0.64	4.32e-19	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.51	4.6	0.35	8.75e-6	Height;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02546521	chr12:132379326	ULK1	-0.61	-7.0	-0.49	7.78e-11	Body fat percentage;
PAAD	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg02404636	chr22:31891804	SFI1	0.63	5.82	0.43	3.33e-8	Colorectal cancer;
PAAD	cis	rs11133665	1.000	rs11133665	chr5:1188285	G/A	cg00080423	chr5:1144950	NA	0.48	4.81	0.36	3.58e-6	Urinary metabolites;
PAAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg02071572	chr4:1403502	NA	0.36	4.54	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2286379	0.804	rs11061971	chr12:1863728	A/T	cg05227549	chr12:1770782	NA	0.38	4.32	0.33	2.8e-5	Blood pressure (smoking interaction);
PAAD	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.7	-9.32	-0.6	1.31e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg01489256	chr8:11204017	TDH	-0.42	-4.33	-0.33	2.65e-5	Retinal vascular caliber;
PAAD	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.83	8.91	0.59	1.49e-15	Total body bone mineral density;
PAAD	trans	rs12714314	0.708	rs13385136	chr2:1968079	A/G	cg17170872	chr1:91487911	ZNF644	-0.75	-6.36	-0.46	2.24e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg15309053	chr8:964076	NA	0.54	6.23	0.45	4.31e-9	Schizophrenia;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.77	-8.95	-0.59	1.19e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg04165759	chr1:150448943	RPRD2	0.49	5.07	0.38	1.16e-6	Migraine;
PAAD	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.83	8.49	0.57	1.71e-14	Corneal astigmatism;
PAAD	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.54	5.2	0.39	6.32e-7	Multiple myeloma;
PAAD	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.89	11.44	0.68	2.99e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg00531865	chr16:30841666	NA	0.56	4.26	0.33	3.62e-5	Dementia with Lewy bodies;
PAAD	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg27490568	chr2:178487706	NA	0.44	4.8	0.36	3.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg12568669	chr8:11666485	FDFT1	0.29	4.9	0.37	2.46e-6	Monocyte count;
PAAD	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	0.79	5.34	0.4	3.28e-7	Body mass index;
PAAD	cis	rs12566888	1	rs12566888	chr1:156869047	G/T	cg00353407	chr1:156974025	ARHGEF11	0.6	4.43	0.34	1.78e-5	Platelet aggregation;
PAAD	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg02376097	chr19:46275166	DMPK	0.62	7.39	0.51	9.28e-12	Coronary artery disease;
PAAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.86	10.16	0.64	7.88e-19	Blood protein levels;
PAAD	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	4.39	0.34	2.15e-5	Multiple sclerosis;
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.88	13.21	0.73	5.11e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.54	-0.35	1.15e-5	Colorectal cancer;
PAAD	cis	rs12523822	0.872	rs9322472	chr6:154959382	T/C	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.71	-6.55	-0.47	8.4e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg27411982	chr8:10470053	RP1L1	-0.5	-5.51	-0.41	1.48e-7	Retinal vascular caliber;
PAAD	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	5.72	0.42	5.46e-8	Body mass index;
PAAD	cis	rs11871801	0.560	rs8074296	chr17:40583421	A/G	cg21692620	chr17:40835849	CNTNAP1	-0.55	-5.65	-0.42	7.73e-8	Crohn's disease;
PAAD	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.62	5.63	0.42	8.3e-8	Height;
PAAD	cis	rs9361491	0.608	rs7751066	chr6:79443088	A/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.86	-11.0	-0.67	4.39e-21	Height;
PAAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	Schizophrenia;
PAAD	cis	rs7714584	1.000	rs10058821	chr5:150226385	A/G	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.85e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8005172	0.663	rs1441808	chr14:88514740	T/C	cg18078958	chr14:88630771	NA	0.35	4.43	0.34	1.79e-5	Parkinson's disease;
PAAD	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg23024343	chr7:107201750	COG5	0.57	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.85	-0.49	1.74e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg14311320	chr7:124405732	GPR37	-0.44	-4.35	-0.33	2.49e-5	Lewy body disease;
PAAD	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.77	-10.58	-0.65	5.97e-20	Cancer;
PAAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.2	-0.39	6.2e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	1.33	7.19	0.5	2.75e-11	Skin colour saturation;
PAAD	cis	rs7264396	0.887	rs224360	chr20:34059675	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	5.57	0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.91	-0.43	2.15e-8	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26363168	chr6:79788481	PHIP	0.63	6.41	0.46	1.74e-9	Obesity-related traits;
PAAD	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.77	-8.8	-0.58	2.77e-15	Colorectal cancer;
PAAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg05373962	chr22:49881684	NA	-0.43	-4.5	-0.34	1.34e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg08676812	chr11:65308423	LTBP3	0.8	5.31	0.4	3.85e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg05185573	chr6:26598237	ABT1	-0.48	-4.88	-0.37	2.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.94	11.05	0.67	3.23e-21	Longevity;
PAAD	trans	rs901683	1.000	rs35713143	chr10:46088159	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9815354	0.812	rs794897	chr3:42031865	T/C	cg03022575	chr3:42003672	ULK4	-0.72	-5.22	-0.39	5.67e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg02404636	chr22:31891804	SFI1	0.64	5.99	0.44	1.44e-8	Colorectal cancer;
PAAD	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Contrast sensitivity;
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg07648498	chr16:89883185	FANCA	0.48	4.64	0.35	7.4e-6	Vitiligo;
PAAD	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.67	-0.48	4.55e-10	Eye color traits;
PAAD	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.81	7.91	0.54	4.98e-13	Response to hepatitis C treatment;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs716804	0.515	rs6483883	chr11:10033265	G/A	cg06875754	chr11:10328428	ADM	-0.34	-4.44	-0.34	1.72e-5	Neuroticism;
PAAD	cis	rs9487051	0.698	rs13202939	chr6:109649655	A/G	cg01475377	chr6:109611718	NA	-0.4	-4.37	-0.33	2.3e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.54	5.08	0.38	1.11e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.92	-7.87	-0.54	6.04e-13	Alzheimer's disease;
PAAD	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.21	-0.39	6.03e-7	Pulmonary function;
PAAD	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg10395934	chr14:104002654	TRMT61A	-0.56	-5.96	-0.44	1.71e-8	Body mass index;
PAAD	cis	rs11113894	0.901	rs17040595	chr12:108860743	C/G	cg06834313	chr12:108851556	NA	-0.68	-4.3	-0.33	3.06e-5	Obesity-related traits;
PAAD	cis	rs7765175	0.674	rs4945940	chr6:113670386	A/T	cg19037598	chr6:113666021	NA	-0.41	-4.35	-0.33	2.5e-5	Coronary artery calcification;
PAAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.97	-12.46	-0.71	5.21e-25	Height;
PAAD	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.6	0.41	9.6e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg02734326	chr4:10020555	SLC2A9	0.47	4.74	0.36	4.94e-6	Bone mineral density;
PAAD	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg12700464	chr11:78128424	GAB2	0.6	4.42	0.34	1.87e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg02440177	chr19:53496695	ZNF702P	-0.67	-7.07	-0.5	5.31e-11	Psoriasis;
PAAD	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs959260	1.000	rs4789181	chr17:73374640	T/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.65	-6.31	-0.46	2.85e-9	Morning vs. evening chronotype;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.51	-4.85	-0.37	3.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.19	-0.55	9.87e-14	Brugada syndrome;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.62	7.12	0.5	3.93e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.04e-5	Vitiligo;
PAAD	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.87	10.05	0.63	1.52e-18	Iron status biomarkers;
PAAD	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg08835956	chr7:39171034	POU6F2	0.26	4.63	0.35	7.8e-6	IgG glycosylation;
PAAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-4.58	-0.35	9.58e-6	Inflammatory bowel disease;
PAAD	cis	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg01499426	chr12:133417423	CHFR	1.08	4.4	0.34	2.02e-5	Cognitive function;
PAAD	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.64	-6.61	-0.47	6.22e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg00277334	chr10:82204260	NA	-0.57	-5.78	-0.42	4.17e-8	Post bronchodilator FEV1;
PAAD	cis	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.75	-0.36	4.7e-6	Eotaxin levels;
PAAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.3	0.39	4.03e-7	Multiple sclerosis;
PAAD	cis	rs17407555	0.741	rs12509713	chr4:10107069	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.24	-0.39	5.38e-7	Schizophrenia (age at onset);
PAAD	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs743757	1.000	rs2236963	chr3:50448632	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.64	0.35	7.31e-6	Diastolic blood pressure;
PAAD	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.69	5.1	0.38	9.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1144	0.537	rs916705	chr7:104589690	C/A	cg04380332	chr7:105027541	SRPK2	-0.66	-7.03	-0.5	6.42e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.68	-7.81	-0.54	8.76e-13	Vitiligo;
PAAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	5.99	0.44	1.42e-8	Personality dimensions;
PAAD	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg25364880	chr3:44379878	C3orf23	0.6	5.6	0.41	9.62e-8	Depressive symptoms;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg03732007	chr1:2071316	PRKCZ	-0.48	-5.07	-0.38	1.14e-6	Height;
PAAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.58	-5.61	-0.41	9.51e-8	Cancer;
PAAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg18944383	chr4:111397179	ENPEP	0.73	8.11	0.55	1.54e-13	Coronary artery disease;
PAAD	cis	rs308971	0.803	rs310765	chr3:12232208	T/G	cg03310376	chr3:12229001	SYN2	-0.5	-4.33	-0.33	2.66e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg02389323	chr16:88786976	FAM38A	-0.82	-4.54	-0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.46	-0.52	6.15e-12	Morning vs. evening chronotype;
PAAD	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.83	6.82	0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.42	0.52	7.94e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.36	-0.4	3.1e-7	Fibrinogen levels;
PAAD	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	trans	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg01620082	chr3:125678407	NA	-1.16	-6.71	-0.48	3.57e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27203200	chr16:67193754	TRADD;FBXL8	0.63	6.66	0.48	4.75e-10	Myopia (pathological);
PAAD	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs1364705	0.955	rs1346014	chr8:120224949	G/C	cg09273054	chr8:120220131	MAL2	0.46	5.21	0.39	5.94e-7	Hippocampal atrophy;
PAAD	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.33	-0.33	2.67e-5	Educational attainment;
PAAD	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.87	-0.43	2.6e-8	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00815440	chr19:29704028	UQCRFS1	0.54	6.37	0.46	2.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg05697835	chr1:2722811	NA	-0.42	-4.73	-0.36	5.1e-6	Ulcerative colitis;
PAAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.72	-8.23	-0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.79	8.63	0.57	7.46e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13691442	chr19:58878570	NA	-0.58	-5.83	-0.43	3.2e-8	Uric acid clearance;
PAAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.39	0.51	9e-12	Menarche (age at onset);
PAAD	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg04717802	chr22:42394638	WBP2NL	0.48	4.56	0.35	1.03e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.64	5.38	0.4	2.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg09695851	chr17:3907499	NA	0.84	8.96	0.59	1.12e-15	Type 2 diabetes;
PAAD	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg03268063	chr7:1337281	NA	-0.5	-4.41	-0.34	1.99e-5	Neuroticism;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.63	6.02	0.44	1.25e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.4	4.4	0.34	2.05e-5	Mean arterial pressure;
PAAD	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.45	4.53	0.35	1.16e-5	Height;
PAAD	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.76	7.52	0.52	4.48e-12	Schizophrenia;
PAAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg17380795	chr3:122379686	NA	0.54	5.68	0.42	6.59e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.75	-5.57	-0.41	1.1e-7	Triglycerides;
PAAD	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.52	0.41	1.41e-7	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg17346650	chr17:80929145	B3GNTL1	0.43	5.18	0.39	7.1e-7	Glycated hemoglobin levels;
PAAD	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	7.82	0.54	8.25e-13	Platelet count;
PAAD	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-6.73	-0.48	3.27e-10	Gut microbiome composition (summer);
PAAD	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg01426195	chr3:39028469	NA	-0.74	-8.54	-0.57	1.33e-14	Handedness;
PAAD	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.54	-5.59	-0.41	1.01e-7	Coronary artery disease;
PAAD	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg21918786	chr6:109611834	NA	-0.59	-6.51	-0.47	1.04e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.55	-0.35	1.07e-5	Pain;
PAAD	cis	rs57786342	0.624	rs4899262	chr14:69283545	G/A	cg03189333	chr14:69283534	NA	-0.58	-4.88	-0.37	2.64e-6	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.42	-4.45	-0.34	1.68e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1514658	0.903	rs13124454	chr4:119279431	G/A	cg23709618	chr4:119273073	PRSS12	0.31	4.37	0.33	2.31e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg04160749	chr8:58172571	NA	-0.72	-4.91	-0.37	2.38e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.46	4.47	0.34	1.5e-5	Facial morphology (factor 20);
PAAD	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6834538	1.000	rs6823117	chr4:113447354	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	4.84	0.37	3.11e-6	Free thyroxine concentration;
PAAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg07153921	chr17:41440717	NA	-0.42	-4.42	-0.34	1.87e-5	Menopause (age at onset);
PAAD	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.63	-5.14	-0.39	8.19e-7	HIV-1 control;
PAAD	cis	rs12612619	0.732	rs1866655	chr2:27208867	A/T	cg00617064	chr2:27272375	NA	0.51	5.49	0.41	1.67e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-6.99	-0.49	8.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21890820	chr11:65308645	LTBP3	0.94	7.79	0.53	9.96e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.85	6.99	0.49	8.17e-11	Alzheimer's disease;
PAAD	cis	rs4740619	0.630	rs3008736	chr9:15986878	T/C	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg01815783	chr4:1047043	NA	-0.45	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.55	5.89	0.43	2.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.48	4.54	0.35	1.12e-5	Red cell distribution width;
PAAD	cis	rs13333054	0.950	rs68143182	chr16:86005838	C/T	cg04454285	chr16:86016317	NA	0.59	5.4	0.4	2.48e-7	Multiple sclerosis;
PAAD	cis	rs3736757	0.870	rs10797987	chr1:184651822	T/C	cg05045817	chr1:184633523	NA	0.43	4.69	0.36	6.09e-6	Obesity-related traits;
PAAD	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.75	-8.94	-0.59	1.22e-15	Obesity-related traits;
PAAD	cis	rs7619427	0.908	rs7653170	chr3:44076195	T/A	cg12796028	chr3:44040206	NA	-0.53	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.69	5.92	0.43	2.1e-8	Height;
PAAD	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg17845761	chr1:175162550	KIAA0040	-0.33	-4.78	-0.36	4.19e-6	Alcohol dependence;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.28e-6	Height;
PAAD	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.17	-0.39	7.3e-7	Common traits (Other);
PAAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.83	-0.54	7.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11153730	0.544	rs7767864	chr6:118696338	T/C	cg21191810	chr6:118973309	C6orf204	0.44	5.5	0.41	1.54e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.84	0.37	3.15e-6	Testicular germ cell tumor;
PAAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.61	5.92	0.43	2.05e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.93	5.7	0.42	6.15e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs4594175	0.926	rs12323654	chr14:51630894	G/T	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.53	-5.16	-0.39	7.6e-7	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg10547527	chr2:198650123	BOLL	-0.74	-5.13	-0.38	8.91e-7	Ulcerative colitis;
PAAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4594175	0.892	rs4572305	chr14:51592095	C/T	cg23942311	chr14:51606299	NA	0.66	6.25	0.45	3.92e-9	Cancer;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs288342	0.797	rs288313	chr2:183649154	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.55	-0.35	1.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2387326	1.000	rs10764751	chr10:129926420	A/C	cg16087940	chr10:129947807	NA	-0.51	-4.3	-0.33	3.05e-5	Select biomarker traits;
PAAD	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs742132	0.520	rs4712950	chr6:25657590	A/G	cg12310025	chr6:25882481	NA	0.65	4.35	0.33	2.47e-5	Uric acid levels;
PAAD	cis	rs6681460	0.649	rs967325	chr1:67003722	C/T	cg02459107	chr1:67143332	SGIP1	0.59	5.19	0.39	6.78e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	5.32	0.4	3.72e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.44	6.23	0.45	4.39e-9	Oropharynx cancer;
PAAD	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg02135003	chr7:105160482	PUS7	-0.69	-6.34	-0.46	2.44e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.89	0.43	2.37e-8	Coronary artery disease;
PAAD	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.49	4.6	0.35	8.95e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.77	-6.69	-0.48	3.99e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1642645	0.872	rs661428	chr1:42451518	A/C	cg01990334	chr1:42801334	FOXJ3	-0.69	-6.06	-0.44	1.03e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18364779	chr6:26104403	HIST1H4C	0.44	4.33	0.33	2.65e-5	Schizophrenia;
PAAD	cis	rs4704187	0.687	rs13359143	chr5:74433360	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg03098721	chr1:84464084	TTLL7	0.48	4.56	0.35	1.06e-5	Obesity-related traits;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.59	6.41	0.46	1.77e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.78	9.04	0.59	6.68e-16	Hemoglobin concentration;
PAAD	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.49	5.57	0.41	1.14e-7	Heart rate;
PAAD	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.69	-0.53	1.67e-12	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.7	6.22	0.45	4.53e-9	Platelet count;
PAAD	cis	rs600550	0.557	rs1899572	chr11:60086024	C/A	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.08	-0.38	1.09e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.16	0.39	7.72e-7	Prostate cancer;
PAAD	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.47	-0.41	1.85e-7	Mean corpuscular volume;
PAAD	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.62	6.74	0.48	3.04e-10	Mean corpuscular volume;
PAAD	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11950562	0.540	rs157577	chr5:131563571	G/C	cg07395648	chr5:131743802	NA	-0.52	-4.97	-0.37	1.82e-6	Mean platelet volume;Blood metabolite levels;
PAAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	7.96	0.54	3.68e-13	Menarche (age at onset);
PAAD	cis	rs2457480	0.866	rs10160170	chr10:44692843	A/G	cg10233401	chr10:45192368	NA	-0.6	-4.34	-0.33	2.62e-5	Coronary artery disease;
PAAD	cis	rs10779751	0.770	rs2788543	chr1:11344629	T/C	cg08854313	chr1:11322531	MTOR	-0.85	-10.49	-0.65	1.06e-19	Body mass index;
PAAD	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-5.51	-0.41	1.48e-7	Ulcerative colitis;
PAAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.59	-7.93	-0.54	4.32e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs3126085	0.515	rs11204994	chr1:152358640	G/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg16205897	chr5:131564050	P4HA2	-0.42	-4.43	-0.34	1.76e-5	Blood metabolite levels;
PAAD	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg14254433	chr6:34482411	PACSIN1	-0.81	-5.41	-0.4	2.37e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg00383909	chr3:49044727	WDR6	0.66	5.29	0.39	4.2e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.79	-5.34	-0.4	3.31e-7	Yeast infection;
PAAD	cis	rs4073221	0.520	rs13072195	chr3:18199498	C/T	cg07694806	chr3:18168406	NA	-0.98	-5.97	-0.44	1.61e-8	Parkinson's disease;
PAAD	cis	rs3764618	1.000	rs3810176	chr19:49496786	A/G	cg12515942	chr19:49552529	CGB8	0.71	4.31	0.33	2.97e-5	Follicule stimulating hormone;
PAAD	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.65	6.32	0.46	2.7e-9	Blood metabolite levels;
PAAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.51	5.5	0.41	1.59e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07920064	chr2:220083856	ABCB6	0.57	6.46	0.46	1.33e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-4.4	-0.34	2.07e-5	Skin colour saturation;
PAAD	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.91	-11.27	-0.67	8.79e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg24053715	chr22:38214548	NA	-0.5	-5.09	-0.38	1.04e-6	Glioblastoma;Glioma;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.54	5.33	0.4	3.42e-7	Resistin levels;
PAAD	cis	rs7168353	0.519	rs11074142	chr15:93639102	A/G	cg02918577	chr15:93633145	RGMA	0.37	4.98	0.37	1.72e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07701084	chr6:150067640	NUP43	0.62	6.22	0.45	4.63e-9	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg15117754	chr3:10150083	C3orf24	0.66	5.61	0.41	9.45e-8	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24356687	chr21:33651478	C21orf45	0.57	6.48	0.47	1.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.58	-6.8	-0.48	2.19e-10	Aortic root size;
PAAD	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.46	-4.56	-0.35	1.03e-5	Primary biliary cholangitis;
PAAD	cis	rs914615	0.552	rs4971088	chr1:155142883	T/A	cg20311333	chr1:155197753	GBAP1	0.43	4.26	0.33	3.56e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.86	9.86	0.62	4.99e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.7	10.38	0.64	2.07e-19	Breast cancer;
PAAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.08	0.38	1.1e-6	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg27121462	chr16:89883253	FANCA	-0.45	-4.74	-0.36	4.81e-6	Vitiligo;
PAAD	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-5.76	-0.42	4.59e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4523957	0.553	rs2172593	chr17:2025544	G/C	cg16513277	chr17:2031491	SMG6	-0.67	-7.01	-0.49	7.19e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.62	-6.56	-0.47	8.02e-10	Brugada syndrome;
PAAD	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg20673091	chr1:2541236	MMEL1	0.71	7.77	0.53	1.09e-12	Ulcerative colitis;
PAAD	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.35	12.77	0.72	7.83e-26	Corneal structure;
PAAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.85	-9.3	-0.6	1.41e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.964	rs434090	chr5:112229523	A/G	cg06941702	chr5:112196734	SRP19	0.46	4.35	0.33	2.44e-5	Total body bone mineral density;
PAAD	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.44	0.61	6.23e-17	Post bronchodilator FEV1;
PAAD	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.97	-13.33	-0.73	2.4e-27	Height;
PAAD	cis	rs3736757	1.000	rs2207733	chr1:184687715	C/T	cg05045817	chr1:184633523	NA	0.44	4.73	0.36	5.19e-6	Obesity-related traits;
PAAD	cis	rs2730260	0.611	rs73169221	chr7:158846316	T/A	cg13444538	chr7:158905317	VIPR2	-0.63	-4.52	-0.34	1.24e-5	Myopia (pathological);
PAAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.8	8.0	0.54	3.03e-13	Cognitive function;
PAAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg25769590	chr7:158789503	NA	0.49	4.26	0.33	3.56e-5	Facial morphology (factor 20);
PAAD	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-5.14	-0.38	8.28e-7	Total body bone mineral density;
PAAD	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.48	-0.52	5.56e-12	Morning vs. evening chronotype;
PAAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.81	7.96	0.54	3.81e-13	Primary sclerosing cholangitis;
PAAD	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.76	7.54	0.52	3.91e-12	Callous-unemotional behaviour;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs6445525	0.967	rs6792662	chr3:65996707	G/C	cg06109867	chr3:66002991	MAGI1	-0.46	-4.61	-0.35	8.35e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.43	0.4	2.22e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.53	-5.72	-0.42	5.44e-8	Tonsillectomy;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg24626660	chr12:32551988	NA	0.39	4.33	0.33	2.7e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg05993574	chr11:61129284	CYBASC3;TMEM138	0.62	6.33	0.46	2.58e-9	IgG glycosylation;
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-4.98	-0.37	1.68e-6	Neuroticism;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.55	-5.56	-0.41	1.21e-7	Iron status biomarkers;
PAAD	cis	rs12767760	0.669	rs10882962	chr10:99308923	C/T	cg25247692	chr10:99313390	UBTD1	0.56	5.47	0.41	1.84e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg21724239	chr8:58056113	NA	0.7	5.17	0.39	7.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.59	5.55	0.41	1.23e-7	Height;
PAAD	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.82	5.34	0.4	3.38e-7	Systolic blood pressure;
PAAD	cis	rs1885364	0.574	rs134086	chr22:28067235	A/G	cg17187762	chr22:28070120	NA	-0.36	-5.08	-0.38	1.08e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
PAAD	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg16558253	chr16:72132732	DHX38	-0.62	-5.22	-0.39	5.81e-7	Coronary artery disease;
PAAD	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs7551345	0.853	rs12131841	chr1:31749106	A/G	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.19	-0.39	6.65e-7	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-5.75	-0.42	4.71e-8	Total cholesterol levels;
PAAD	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.76	-8.27	-0.56	6.26e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.25	0.33	3.73e-5	Lung cancer in ever smokers;
PAAD	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg10483660	chr13:112241077	NA	0.54	4.99	0.38	1.63e-6	Menarche (age at onset);
PAAD	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg08992911	chr2:238395768	MLPH	0.54	4.83	0.36	3.29e-6	Prostate cancer;
PAAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.94	11.36	0.68	4.99e-22	Blood protein levels;
PAAD	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg12564285	chr5:131593104	PDLIM4	0.47	4.86	0.37	2.92e-6	Blood metabolite levels;
PAAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14180030	chr9:123475675	MEGF9	-0.45	-4.99	-0.37	1.66e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg11650704	chr1:154556575	ADAR	-0.39	-4.27	-0.33	3.43e-5	Blood protein levels;
PAAD	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.04	-0.55	2.33e-13	Alcohol dependence;
PAAD	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	5.01	0.38	1.48e-6	Neuroticism;
PAAD	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg21351543	chr2:191399470	TMEM194B	0.59	4.6	0.35	8.96e-6	Diastolic blood pressure;
PAAD	cis	rs2120991	0.967	rs7306498	chr12:54259701	A/G	cg25640699	chr12:54070114	ATP5G2	0.42	4.49	0.34	1.42e-5	Biliary atresia;
PAAD	cis	rs35955747	0.870	rs4820969	chr22:31773573	C/G	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.75	-0.36	4.7e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17848003	chr1:3704513	LRRC47	0.44	4.69	0.36	5.95e-6	Red cell distribution width;
PAAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.64	-4.83	-0.36	3.31e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs2109514	0.711	rs58718486	chr7:116129002	A/T	cg12739419	chr7:116140593	CAV2	-0.32	-4.33	-0.33	2.71e-5	Prevalent atrial fibrillation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12782834	chr3:196439273	PIGX;C3orf34	0.69	7.28	0.51	1.67e-11	Myopia (pathological);
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-5.59	-0.41	1.02e-7	Intelligence;
PAAD	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg04990556	chr1:26633338	UBXN11	0.65	4.82	0.36	3.4e-6	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.53	-5.54	-0.41	1.29e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs3026101	0.671	rs7502643	chr17:5297009	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.2	0.45	5.02e-9	Body mass index;
PAAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg14349672	chr11:133703707	NA	-0.59	-6.74	-0.48	3.12e-10	Childhood ear infection;
PAAD	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.65	6.92	0.49	1.17e-10	Testicular germ cell tumor;
PAAD	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg18089426	chr14:101175970	NA	0.71	5.15	0.39	8.11e-7	Plateletcrit;
PAAD	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs595018	0.505	rs11822479	chr11:60597302	C/T	cg23904249	chr11:60608951	CCDC86	0.68	4.94	0.37	2.08e-6	Wegener's granulomatosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06866814	chr16:68027297	DPEP2	0.6	6.67	0.48	4.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.45	-0.46	1.4e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.43	-0.46	1.59e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11945232	0.929	rs28736552	chr4:88356111	T/C	cg23841344	chr4:88312519	HSD17B11	-0.64	-6.23	-0.45	4.27e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.76	-0.36	4.48e-6	Blood metabolite levels;
PAAD	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.59	-0.35	9.31e-6	Daytime sleep phenotypes;
PAAD	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.56	5.85	0.43	2.96e-8	Dupuytren's disease;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg20849893	chr7:64541193	NA	0.5	4.95	0.37	1.96e-6	Calcium levels;
PAAD	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.56	-5.33	-0.4	3.49e-7	Daytime sleep phenotypes;
PAAD	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.7	7.53	0.52	4.11e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.75	0.42	4.72e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg03605463	chr16:89740564	NA	0.52	4.95	0.37	1.98e-6	Vitiligo;
PAAD	cis	rs12760731	0.565	rs10494511	chr1:178094265	A/G	cg00404053	chr1:178313656	RASAL2	0.63	5.01	0.38	1.46e-6	Obesity-related traits;
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg14092988	chr3:52407081	DNAH1	0.44	5.17	0.39	7.11e-7	Electroencephalogram traits;
PAAD	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.68	-0.35	6.39e-6	Height;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	1.08	16.51	0.8	9.92e-36	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15556689	chr8:8085844	FLJ10661	-0.73	-6.85	-0.49	1.74e-10	Neuroticism;
PAAD	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.82	-0.36	3.46e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg16950941	chr11:66035639	RAB1B	-0.6	-4.72	-0.36	5.38e-6	Electroencephalogram traits;
PAAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.76	-8.54	-0.57	1.3e-14	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.71	-0.42	5.89e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.9e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.68	7.43	0.52	7.2e-12	Prostate cancer;
PAAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.49	-4.26	-0.33	3.63e-5	Aortic root size;
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg01075559	chr1:2537774	MMEL1	0.5	5.29	0.39	4.24e-7	Ulcerative colitis;
PAAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg12031962	chr15:58353849	ALDH1A2	0.45	5.29	0.39	4.13e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs4900109	0.630	rs4904868	chr14:92781001	T/C	cg14476212	chr3:127535191	MGLL	-0.47	-6.32	-0.46	2.72e-9	Iris characteristics;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.02	-0.44	1.27e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg00933542	chr6:150070202	PCMT1	0.59	6.37	0.46	2.12e-9	Lung cancer;
PAAD	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.6	4.79	0.36	3.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg24553058	chr2:113831203	IL1F10	-0.4	-4.53	-0.34	1.2e-5	Protein quantitative trait loci;
PAAD	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.7	-6.14	-0.45	7.04e-9	Triglycerides;
PAAD	cis	rs6604026	0.617	rs12059883	chr1:93381108	T/C	cg17283838	chr1:93427260	FAM69A	0.63	5.81	0.43	3.59e-8	Multiple sclerosis;
PAAD	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.85	6.48	0.46	1.24e-9	Gut microbiome composition (summer);
PAAD	cis	rs6066825	0.546	rs2598	chr20:47241618	A/G	cg18078177	chr20:47281410	PREX1	0.49	4.68	0.35	6.35e-6	Colorectal cancer;
PAAD	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.83	-7.44	-0.52	6.89e-12	Pancreatic cancer;
PAAD	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.82	-6.11	-0.44	7.94e-9	Coronary artery calcification;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07558682	chr1:43148835	YBX1	0.63	6.5	0.47	1.11e-9	Myopia (pathological);
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.46	6.32	0.46	2.71e-9	Vitiligo;
PAAD	cis	rs9649465	0.967	rs1008539	chr7:123305518	G/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs7247513	0.964	rs1007352	chr19:12722545	G/C	cg01871581	chr19:12707946	ZNF490	-0.87	-10.91	-0.66	7.83e-21	Bipolar disorder;
PAAD	cis	rs1008126	0.600	rs7808296	chr7:103127620	C/T	cg04218035	chr7:103086829	SLC26A5	0.32	4.42	0.34	1.9e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2019216	0.500	rs1356483	chr17:21934029	A/C	cg22648282	chr17:21454238	C17orf51	-0.58	-5.97	-0.44	1.62e-8	Pelvic organ prolapse;
PAAD	cis	rs12889267	0.770	rs66995536	chr14:21564859	G/A	cg02988727	chr14:21567520	ZNF219;C14orf176	0.54	4.89	0.37	2.49e-6	Hematocrit;Resting heart rate;
PAAD	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.56	-4.27	-0.33	3.42e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg19630374	chr17:18023558	MYO15A	-0.46	-4.78	-0.36	4.05e-6	Total body bone mineral density;
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.55	0.61	3.2e-17	Menopause (age at onset);
PAAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.57	-5.86	-0.43	2.78e-8	White blood cell count;
PAAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg07153921	chr17:41440717	NA	-0.4	-4.25	-0.33	3.7e-5	Menopause (age at onset);
PAAD	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.69	-4.43	-0.34	1.8e-5	Systemic lupus erythematosus;
PAAD	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.35	5.42	0.4	2.31e-7	IgG glycosylation;
PAAD	cis	rs2057149	0.776	rs1980531	chr6:110724518	C/T	cg01119278	chr6:110721349	DDO	0.44	4.29	0.33	3.13e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.32	-4.29	-0.33	3.12e-5	Dupuytren's disease;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg18279126	chr7:2041391	MAD1L1	0.53	5.12	0.38	8.99e-7	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.84	0.43	3.01e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9361491	0.608	rs7740607	chr6:79441290	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg02258303	chr16:87377426	FBXO31	-0.62	-6.35	-0.46	2.32e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.52	-4.71	-0.36	5.51e-6	Asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12392857	chr11:134237795	GLB1L2	-0.67	-6.37	-0.46	2.12e-9	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs4343996	0.837	rs10228151	chr7:3472757	G/T	cg21248987	chr7:3385318	SDK1	-0.5	-5.59	-0.41	1.03e-7	Motion sickness;
PAAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg10600917	chr12:121163489	ACADS	-0.52	-4.27	-0.33	3.37e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg27449745	chr7:23145252	KLHL7	0.5	4.37	0.33	2.32e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs9810890	1.000	rs16851607	chr3:128570263	G/C	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7688540	0.800	rs7694325	chr4:269042	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.48	0.34	1.47e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.91	7.06	0.5	5.54e-11	Monocyte percentage of white cells;
PAAD	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.55	-0.47	8.58e-10	Triglycerides;
PAAD	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg12568669	chr8:11666485	FDFT1	0.27	4.4	0.34	2.05e-5	Neuroticism;
PAAD	cis	rs2657888	0.628	rs2638285	chr12:56886361	A/G	cg23002907	chr12:56915593	RBMS2	0.45	4.42	0.34	1.86e-5	Adiponectin levels;
PAAD	cis	rs564309	0.681	rs1188489	chr1:228621772	G/A	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.03	-0.38	1.39e-6	Longevity;Endometriosis;
PAAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg23281280	chr6:28129359	ZNF389	0.52	4.63	0.35	7.7e-6	Parkinson's disease;
PAAD	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.77	7.36	0.51	1.07e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg08501292	chr6:25962987	TRIM38	0.68	4.42	0.34	1.85e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9361491	0.608	rs3918524	chr6:79459097	A/G	cg05283184	chr6:79620031	NA	0.37	4.48	0.34	1.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg03338584	chr11:507455	RNH1	0.58	4.47	0.34	1.52e-5	Systemic lupus erythematosus;
PAAD	cis	rs2790216	1.000	rs2790217	chr10:59997644	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg00814883	chr7:100076585	TSC22D4	-0.64	-5.18	-0.39	6.98e-7	Platelet count;
PAAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg13722127	chr7:150037890	RARRES2	0.64	6.79	0.48	2.32e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg00206168	chr11:65308501	LTBP3	1.48	8.59	0.57	9.95e-15	Height;
PAAD	cis	rs2446066	0.872	rs10876447	chr12:53770941	C/T	cg23431730	chr12:53887070	MAP3K12	-0.6	-4.26	-0.33	3.52e-5	Red blood cell count;
PAAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Height;
PAAD	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.61	4.89	0.37	2.51e-6	Information processing speed;
PAAD	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.85	-9.72	-0.62	1.12e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs8112211	0.648	rs111958719	chr19:38808533	T/C	cg14299480	chr19:38876666	GGN	-0.54	-4.7	-0.36	5.82e-6	Blood protein levels;
PAAD	cis	rs3026101	0.671	rs75669379	chr17:5321355	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	6.27	0.45	3.51e-9	Body mass index;
PAAD	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.55	5.81	0.43	3.55e-8	Dupuytren's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13659026	chr2:85788631	GGCX	0.62	6.56	0.47	7.98e-10	Myopia (pathological);
PAAD	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg26247942	chr15:43984922	CKMT1A	-0.34	-4.33	-0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.53	-6.57	-0.47	7.7e-10	Systemic lupus erythematosus;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg26513180	chr16:89883248	FANCA	0.67	7.82	0.54	7.98e-13	Vitiligo;
PAAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-5.24	-0.39	5.21e-7	Personality dimensions;
PAAD	trans	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg01620082	chr3:125678407	NA	-1.12	-6.4	-0.46	1.87e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg26174226	chr8:58114915	NA	-0.57	-4.38	-0.33	2.2e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg05785598	chr3:49045655	WDR6	0.4	4.71	0.36	5.57e-6	Parkinson's disease;
PAAD	cis	rs9810890	1.000	rs73198806	chr3:128465094	A/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs71520386	0.632	rs10224244	chr7:22870074	C/A	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg00452199	chr11:44088257	ACCS	-0.9	-7.49	-0.52	5.25e-12	IgA nephropathy;
PAAD	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg22437258	chr11:111473054	SIK2	0.65	6.62	0.47	5.68e-10	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26748024	chr6:42420298	TRERF1	0.62	7.06	0.5	5.58e-11	Immature fraction of reticulocytes;
PAAD	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.28	-0.33	3.32e-5	Educational attainment;
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.5	-0.34	1.35e-5	Acylcarnitine levels;
PAAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.55	-5.31	-0.4	3.87e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10768122	1.000	rs4756203	chr11:35290351	G/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2e-5	Vitiligo;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs4268898	0.582	rs1559472	chr2:24455830	A/G	cg06627628	chr2:24431161	ITSN2	0.54	5.17	0.39	7.33e-7	Asthma;
PAAD	cis	rs7567389	0.785	rs4150474	chr2:128033327	C/A	cg09760422	chr2:128146352	NA	-0.38	-6.02	-0.44	1.25e-8	Self-rated health;
PAAD	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.84e-5	Coronary artery disease;
PAAD	cis	rs7940866	0.678	rs11222394	chr11:130794272	C/T	cg12179176	chr11:130786555	SNX19	0.82	9.31	0.6	1.32e-16	Schizophrenia;
PAAD	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.8	0.48	2.21e-10	Exhaled nitric oxide levels;
PAAD	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs6750047	0.548	rs162327	chr2:38318350	G/A	cg19753864	chr2:38320028	NA	0.4	4.58	0.35	9.61e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.73	5.62	0.41	9.01e-8	Crohn's disease;
PAAD	cis	rs2286503	1.000	rs1029740	chr7:22873586	C/A	cg04907244	chr7:22894795	SNORD93	-0.4	-4.99	-0.37	1.66e-6	Fibrinogen;
PAAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.89	10.96	0.66	5.74e-21	Aortic root size;
PAAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.14	-0.38	8.42e-7	Electroencephalogram traits;
PAAD	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.47	4.49	0.34	1.4e-5	High light scatter reticulocyte count;
PAAD	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.51	-6.15	-0.45	6.5e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg00431813	chr7:1051703	C7orf50	0.67	4.32	0.33	2.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg21395723	chr22:39101663	GTPBP1	0.45	4.65	0.35	7.19e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	4.91	0.37	2.34e-6	Thyroid stimulating hormone;
PAAD	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.5	-5.2	-0.39	6.27e-7	Colorectal cancer;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-1.0	-7.8	-0.53	9.1e-13	Initial pursuit acceleration;
PAAD	trans	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg15770106	chr1:208133116	NA	-0.64	-6.42	-0.46	1.68e-9	Corneal structure;
PAAD	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg12143784	chr7:64541923	NA	0.37	4.68	0.35	6.27e-6	Calcium levels;
PAAD	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg03989125	chr22:38214979	NA	-0.52	-5.27	-0.39	4.57e-7	Glioblastoma;Glioma;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg02462569	chr6:150064036	NUP43	0.4	4.51	0.34	1.29e-5	Lung cancer;
PAAD	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg08390786	chr10:135334061	NA	0.43	4.26	0.33	3.58e-5	Obesity-related traits;
PAAD	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg14351767	chr9:37442137	ZBTB5	0.62	6.67	0.48	4.39e-10	Educational attainment (years of education);
PAAD	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg01422370	chr2:73384389	NA	0.39	5.12	0.38	9.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-4.77	-0.36	4.36e-6	Retinal vascular caliber;
PAAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg02297831	chr4:17616191	MED28	-0.6	-5.86	-0.43	2.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-5.49	-0.41	1.64e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.42	4.35	0.33	2.44e-5	Bulimia nervosa;
PAAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Depression;
PAAD	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg08079166	chr15:68083412	MAP2K5	0.58	5.45	0.4	2e-7	Restless legs syndrome;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.88	10.9	0.66	8.34e-21	Prudent dietary pattern;
PAAD	trans	rs61931739	0.555	rs1482982	chr12:33691601	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.34	-0.51	1.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2295499	0.515	rs762856	chr4:2746898	C/T	cg00231918	chr4:2819393	SH3BP2	-0.4	-4.35	-0.33	2.52e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.59	-6.34	-0.46	2.45e-9	Schizophrenia;
PAAD	cis	rs9535307	0.522	rs9316476	chr13:50409652	G/T	cg03658251	chr13:50265850	EBPL	-0.83	-5.35	-0.4	3.21e-7	Obesity-related traits;
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs73086581	1.000	rs17287822	chr20:3978536	C/T	cg02187196	chr20:3869020	PANK2	0.57	4.95	0.37	1.96e-6	Response to antidepressants in depression;
PAAD	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.53	5.67	0.42	6.93e-8	Bladder cancer;
PAAD	trans	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg26939375	chr7:64535504	NA	0.7	7.82	0.54	8.1e-13	Aortic root size;
PAAD	cis	rs2278796	0.697	rs2278795	chr1:204954993	A/G	cg04862289	chr1:204966208	NFASC	0.45	4.74	0.36	4.87e-6	Mean platelet volume;
PAAD	cis	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs8042680	0.522	rs12595616	chr15:91563513	C/T	cg08919649	chr15:91565780	VPS33B	-0.51	-4.64	-0.35	7.59e-6	Type 2 diabetes;
PAAD	cis	rs669446	0.591	rs607062	chr1:44133016	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-4.96	-0.37	1.86e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg02297831	chr4:17616191	MED28	0.62	5.77	0.42	4.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs758324	0.812	rs13165154	chr5:131155020	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg03989125	chr22:38214979	NA	-0.61	-5.79	-0.43	3.86e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg02696790	chr15:75250997	RPP25	0.45	5.21	0.39	6.02e-7	Breast cancer;
PAAD	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg24848339	chr3:12840334	CAND2	-0.47	-4.95	-0.37	1.99e-6	QRS complex (12-leadsum);
PAAD	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg20169779	chr10:135381914	SYCE1	-0.43	-4.45	-0.34	1.67e-5	Obesity-related traits;
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.63	4.41	0.34	1.93e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg11783356	chr20:44313418	WFDC10B	-0.74	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs457162	0.708	rs283058	chr6:118625225	A/T	cg21191810	chr6:118973309	C6orf204	0.75	4.79	0.36	3.91e-6	QT interval;
PAAD	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg12623918	chr2:306882	NA	0.46	4.79	0.36	3.89e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs8040855	0.627	rs4842863	chr15:85642205	T/A	cg08123816	chr15:85640762	PDE8A	-0.43	-5.2	-0.39	6.29e-7	Bulimia nervosa;
PAAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.57	-4.98	-0.37	1.69e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.47	4.39	0.34	2.12e-5	RR interval (heart rate);
PAAD	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.85	-0.37	2.97e-6	Prevalent atrial fibrillation;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg17105886	chr17:28927953	LRRC37B2	0.76	4.88	0.37	2.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-5.43	-0.4	2.22e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.7	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg16362232	chr11:430036	ANO9	0.91	5.3	0.39	4e-7	Body mass index;
PAAD	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg03871329	chr12:110338662	TCHP	0.67	4.99	0.38	1.63e-6	Neuroticism;
PAAD	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.74	-5.12	-0.38	9.2e-7	Lung cancer;
PAAD	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-6.17	-0.45	5.77e-9	Body mass index (adult);
PAAD	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.01	0.54	2.77e-13	Lymphocyte counts;
PAAD	cis	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg01990334	chr1:42801334	FOXJ3	-0.58	-5.46	-0.41	1.88e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.89	-8.19	-0.55	9.74e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg06740227	chr12:86229804	RASSF9	0.55	5.29	0.39	4.29e-7	Major depressive disorder;
PAAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22482690	chr17:47019901	SNF8	0.49	5.25	0.39	5.01e-7	Type 2 diabetes;
PAAD	cis	rs329648	0.553	rs10791337	chr11:133765127	A/C	cg12362517	chr11:133800685	IGSF9B	-0.6	-6.44	-0.46	1.47e-9	Parkinson's disease;
PAAD	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-15.44	-0.78	5.98e-33	Schizophrenia;
PAAD	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.79	-6.1	-0.44	8.52e-9	Uric acid levels;
PAAD	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.61	-0.47	6.11e-10	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20603821	chr7:157385523	PTPRN2	-0.67	-6.52	-0.47	9.7e-10	Obesity-related traits;
PAAD	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.84	6.96	0.49	9.41e-11	Brain cytoarchitecture;
PAAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg10556349	chr10:835070	NA	0.59	4.95	0.37	1.98e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.67	7.15	0.5	3.4e-11	Blood protein levels;
PAAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.49	-0.78	4.35e-33	Height;
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg08088566	chr11:430123	ANO9	0.87	5.43	0.4	2.16e-7	Body mass index;
PAAD	cis	rs8053891	0.507	rs12919469	chr16:72028612	A/G	cg16558253	chr16:72132732	DHX38	-0.45	-4.66	-0.35	6.96e-6	Coronary artery disease;
PAAD	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.72	8.28	0.56	5.74e-14	Heart rate;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12863373	chr8:27695096	PBK	-0.59	-6.5	-0.47	1.07e-9	Height;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg24846343	chr22:24311635	DDTL	-0.71	-7.34	-0.51	1.23e-11	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.6	0.47	6.47e-10	Schizophrenia;
PAAD	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.43	-4.6	-0.35	9e-6	Eosinophil percentage of white cells;
PAAD	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.48e-10	Uric acid levels;
PAAD	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.43	0.65	1.49e-19	Morning vs. evening chronotype;
PAAD	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg20019720	chr6:154832845	CNKSR3	0.65	8.25	0.56	6.99e-14	Lipoprotein (a) levels;
PAAD	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.68	5.74	0.42	4.87e-8	Menarche (age at onset);
PAAD	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.55	-0.35	1.11e-5	Diastolic blood pressure;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs2061333	0.842	rs7253485	chr19:44625042	A/G	cg18700516	chr19:44507157	ZNF230	-0.65	-4.89	-0.37	2.53e-6	Alzheimer's disease;
PAAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg14393609	chr7:65229607	NA	0.48	4.68	0.36	6.2e-6	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23973626	chr19:18451326	PGPEP1	0.55	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.72	7.13	0.5	3.71e-11	Caffeine consumption;
PAAD	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.41	5.54	0.41	1.32e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.87	-8.72	-0.58	4.65e-15	Breast cancer;
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.37	0.4	2.85e-7	Initial pursuit acceleration;
PAAD	cis	rs35955747	0.869	rs34873968	chr22:31581773	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-4.76	-0.36	4.51e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.52	5.05	0.38	1.24e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12620999	0.555	rs4663242	chr2:238102905	C/T	cg23555395	chr2:238036564	NA	-0.44	-5.07	-0.38	1.15e-6	Systemic lupus erythematosus;
PAAD	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.5	2.47e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs2790216	0.950	rs2790236	chr10:59985102	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.64	6.41	0.46	1.74e-9	Schizophrenia;
PAAD	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg14515779	chr1:101123966	NA	-0.55	-6.74	-0.48	3.03e-10	Monocyte count;
PAAD	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-5.55	-0.41	1.23e-7	Menarche (age at onset);
PAAD	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.9	11.05	0.67	3.34e-21	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25029022	chr1:185126088	C1orf25;C1orf26	0.69	6.92	0.49	1.18e-10	Obesity-related traits;
PAAD	cis	rs1891275	0.551	rs2421627	chr10:93421983	G/A	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1419980	0.730	rs11054863	chr12:7770125	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg21775007	chr8:11205619	TDH	-0.47	-4.32	-0.33	2.81e-5	Neuroticism;
PAAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg18964960	chr10:1102726	WDR37	0.6	4.25	0.33	3.75e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg16434002	chr17:42200994	HDAC5	-0.43	-4.28	-0.33	3.32e-5	Total body bone mineral density;
PAAD	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.76	-0.48	2.73e-10	Morning vs. evening chronotype;
PAAD	cis	rs863345	0.967	rs1418845	chr1:158479691	A/C	cg12129480	chr1:158549410	OR10X1	-0.45	-5.16	-0.39	7.75e-7	Pneumococcal bacteremia;
PAAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	1.09	15.11	0.77	4.47e-32	Breast cancer;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs9463078	0.647	rs6933449	chr6:45325151	G/C	cg25276700	chr6:44698697	NA	0.53	5.88	0.43	2.53e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.04	-0.44	1.12e-8	Lymphocyte counts;
PAAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.54	0.41	1.28e-7	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22808750	chr8:9123484	NA	-0.57	-6.59	-0.47	6.86e-10	Obesity-related traits;
PAAD	cis	rs7646881	0.812	rs73017539	chr3:158460743	A/G	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.59	5.85	0.43	2.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.94	8.18	0.55	1.04e-13	Red blood cell traits;
PAAD	trans	rs6722456	0.826	rs77632323	chr2:134580445	G/A	cg06476693	chr11:130283454	ADAMTS8	0.81	6.4	0.46	1.85e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg10589385	chr1:150898437	SETDB1	0.38	4.33	0.33	2.75e-5	Melanoma;
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.24	-0.51	2.09e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs490234	0.812	rs626208	chr9:128428267	A/G	cg14078157	chr9:128172775	NA	0.45	5.0	0.38	1.58e-6	Mean arterial pressure;
PAAD	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.35	6.49	0.47	1.16e-9	Type 2 diabetes;
PAAD	cis	rs2020921	0.510	rs11774517	chr8:41979110	A/G	cg12054981	chr8:42037387	PLAT	0.81	5.47	0.41	1.8e-7	Plasma plasminogen activator levels;
PAAD	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg24110177	chr3:50126178	RBM5	-0.74	-4.77	-0.36	4.19e-6	Menarche (age at onset);
PAAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12165864	chr7:66369176	NA	-0.82	-5.43	-0.4	2.21e-7	Diabetic kidney disease;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.83	8.59	0.57	9.91e-15	Educational attainment;
PAAD	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.74	8.78	0.58	3.17e-15	Lung cancer;
PAAD	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.6	5.6	0.41	9.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.57	-6.48	-0.47	1.22e-9	Prostate cancer;
PAAD	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg24110177	chr3:50126178	RBM5	-0.82	-9.14	-0.6	3.72e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.53	-5.31	-0.4	3.77e-7	Migraine;
PAAD	cis	rs35123781	0.554	rs356428	chr5:138992703	A/G	cg26929925	chr5:138714136	SLC23A1	-0.51	-4.62	-0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.86	-13.24	-0.73	4.13e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs863345	0.604	rs11264999	chr1:158488860	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-5.04	-0.38	1.29e-6	Pneumococcal bacteremia;
PAAD	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.49	-4.63	-0.35	7.65e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.36e-8	QT interval;
PAAD	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.98	11.58	0.68	1.25e-22	Bone mineral density;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs2278796	0.639	rs4951152	chr1:204970495	G/T	cg17947172	chr1:204966197	NFASC	0.43	4.7	0.36	5.86e-6	Mean platelet volume;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg00023132	chr3:69133948	ARL6IP5	-0.61	-6.47	-0.46	1.25e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18948435	chr2:203102945	SUMO1	0.62	6.33	0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.84	6.22	0.45	4.58e-9	Gut microbiome composition (summer);
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.23	17.36	0.82	6.78e-38	Triglycerides;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg23108931	chr8:105342351	NA	0.28	4.33	0.33	2.75e-5	Paget's disease;
PAAD	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg02631450	chr22:32366979	NA	1.03	5.42	0.4	2.28e-7	Childhood ear infection;
PAAD	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.85	8.75	0.58	3.7e-15	Uric acid levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20592186	chr12:54582867	SMUG1	0.55	6.71	0.48	3.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.53	4.89	0.37	2.55e-6	Liver enzyme levels;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg06815965	chr1:205818668	PM20D1	0.65	7.43	0.52	7.29e-12	Menarche (age at onset);
PAAD	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg06243866	chr13:111019493	COL4A2	-0.58	-5.39	-0.4	2.64e-7	White matter hyperintensity burden;
PAAD	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13794888	chr15:75917792	SNUPN	0.58	6.45	0.46	1.38e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.69	-0.69	6.47e-23	Cognitive function;
PAAD	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.59	6.84	0.48	1.84e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	1.02	8.22	0.55	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs2936519	0.929	rs2928605	chr8:6638241	G/A	cg22103414	chr8:6638082	NA	-0.41	-4.31	-0.33	2.91e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg12658694	chr1:38397304	INPP5B	-0.46	-4.28	-0.33	3.27e-5	Hypothyroidism;
PAAD	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.67	6.55	0.47	8.54e-10	Gastritis;
PAAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg08436684	chr16:88034427	BANP	-0.49	-4.33	-0.33	2.67e-5	Menopause (age at onset);
PAAD	cis	rs10885582	0.904	rs1333686	chr10:116342039	A/G	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.04	-0.38	1.29e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.91	-0.54	4.91e-13	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11968436	chr19:51308133	C19orf48	0.66	6.49	0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg24829409	chr8:58192753	C8orf71	-0.87	-7.94	-0.54	4.18e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs73416724	0.688	rs77241311	chr6:43364043	C/T	cg26312998	chr6:43337775	ZNF318	0.64	4.42	0.34	1.9e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs793571	0.822	rs11636723	chr15:59206518	G/C	cg05156742	chr15:59063176	FAM63B	0.59	4.8	0.36	3.68e-6	Schizophrenia;
PAAD	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.36	0.4	3.09e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7572263	0.874	rs9646836	chr2:209055610	C/A	cg23998903	chr2:209048830	C2orf80	0.49	4.51	0.34	1.31e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg11802864	chr11:65308245	LTBP3	1.25	6.6	0.47	6.39e-10	Height;
PAAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg10356904	chr22:49881777	NA	-0.46	-4.59	-0.35	9.36e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.83	10.08	0.63	1.28e-18	Menopause (age at onset);
PAAD	cis	rs10266483	0.545	rs116760071	chr7:63749460	C/G	cg24201672	chr7:64023550	ZNF680	0.56	4.41	0.34	1.94e-5	Response to statin therapy;
PAAD	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.83	6.56	0.47	7.92e-10	Mean platelet volume;
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	6.18	0.45	5.71e-9	Lung function (FEV1/FVC);
PAAD	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.89	-0.58	1.65e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12153243	0.686	rs6580292	chr5:142942241	C/G	cg13907255	chr5:142895549	NA	-0.58	-4.97	-0.37	1.76e-6	Migraine;
PAAD	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.61e-10	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs6694672	1.000	rs857017	chr1:197019055	T/C	cg26994526	chr18:47719735	MYO5B	-0.8	-6.43	-0.46	1.55e-9	Asthma;
PAAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.63	0.47	5.53e-10	Personality dimensions;
PAAD	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.49	-4.4	-0.34	2.01e-5	Testicular germ cell tumor;
PAAD	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-5.88	-0.43	2.56e-8	Personality dimensions;
PAAD	cis	rs2637266	0.935	rs1907299	chr10:78325316	T/C	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.42e-6	Pulmonary function;
PAAD	cis	rs6679454	0.920	rs6699475	chr1:58371309	G/A	cg17491850	chr1:57888480	DAB1	-0.45	-4.71	-0.36	5.43e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.19	-0.5	2.72e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.53	4.7	0.36	5.79e-6	Lung cancer;
PAAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-4.69	-0.36	6.1e-6	Neuroticism;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.87	-8.01	-0.55	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.21	-0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.51	5.65	0.42	7.8e-8	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
PAAD	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.67	7.45	0.52	6.47e-12	Coronary artery disease;
PAAD	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.59	6.34	0.46	2.46e-9	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	4.8	0.36	3.69e-6	Verbal declarative memory;
PAAD	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg11232448	chr19:2858854	NA	-0.52	-5.17	-0.39	7.31e-7	Total cholesterol levels;
PAAD	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.13	-7.35	-0.51	1.11e-11	Plateletcrit;
PAAD	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.74	-7.59	-0.52	3.05e-12	Blood metabolite levels;
PAAD	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.55	-4.91	-0.37	2.36e-6	P wave terminal force;
PAAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.97	11.12	0.67	2.2e-21	Parkinson's disease;
PAAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.39	-0.61	8.44e-17	Gut microbiome composition (summer);
PAAD	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.72e-6	Migraine;
PAAD	cis	rs10768122	0.966	rs10742341	chr11:35317717	G/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.29	-0.33	3.17e-5	Vitiligo;
PAAD	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg10547527	chr2:198650123	BOLL	-0.64	-4.31	-0.33	2.95e-5	Ulcerative colitis;
PAAD	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.82	9.85	0.62	5.19e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg13632729	chr17:80989170	B3GNTL1	0.42	4.3	0.33	3.06e-5	Glycated hemoglobin levels;
PAAD	cis	rs72960926	0.744	rs4385272	chr6:75063124	G/A	cg13997649	chr6:74171430	MTO1	0.83	4.64	0.35	7.5e-6	Metabolite levels (MHPG);
PAAD	cis	rs61759167	0.742	rs61759178	chr1:3098489	T/C	cg22674798	chr1:3096360	PRDM16	0.41	4.8	0.36	3.76e-6	Motion sickness;
PAAD	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg23860436	chr12:58378763	NA	0.48	4.44	0.34	1.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.51	-4.47	-0.34	1.55e-5	Obesity;
PAAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.94	12.4	0.71	7.6e-25	Menopause (age at onset);
PAAD	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg19930314	chr7:98593876	TRRAP	-0.47	-4.54	-0.35	1.14e-5	Breast cancer;
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.57	0.57	1.1e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-5.88	-0.43	2.51e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.52	4.74	0.36	4.85e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.31	-0.46	2.93e-9	Alcohol dependence;
PAAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg27417659	chr7:98567827	TRRAP	-0.46	-4.44	-0.34	1.72e-5	Breast cancer;
PAAD	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg08648136	chr8:956695	NA	0.49	5.18	0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg01299579	chr2:10830716	NOL10	-0.54	-5.5	-0.41	1.61e-7	Prostate cancer;
PAAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3812762	0.879	rs1079452	chr11:8779172	C/T	cg24940230	chr11:8046101	NA	-0.41	-4.36	-0.33	2.34e-5	Hypospadias;
PAAD	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.51	5.0	0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.46	4.89	0.37	2.52e-6	Age of smoking initiation;
PAAD	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs35955747	0.838	rs5997887	chr22:31543197	G/A	cg07969918	chr22:31682909	PIK3IP1	-0.33	-4.33	-0.33	2.67e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2268118	0.892	rs7968071	chr12:13858116	C/T	cg16862319	chr12:13899195	GRIN2B	0.75	4.42	0.34	1.85e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.35	-0.4	3.2e-7	P wave terminal force;
PAAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Diastolic blood pressure;
PAAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	1.1	12.19	0.7	2.89e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg02696790	chr15:75250997	RPP25	-0.43	-5.24	-0.39	5.39e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2137920	0.685	rs12770882	chr10:50234400	T/C	cg02657375	chr10:50863136	CHAT	0.54	4.39	0.34	2.15e-5	Migraine with aura;
PAAD	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.58	-5.09	-0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.76	-8.11	-0.55	1.59e-13	DNA methylation (variation);
PAAD	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg11271282	chr2:238384023	NA	0.52	4.73	0.36	5e-6	Prostate cancer;
PAAD	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg05562828	chr17:3906858	NA	-0.55	-6.31	-0.46	2.86e-9	Type 2 diabetes;
PAAD	cis	rs2120243	0.845	rs2316710	chr3:157150180	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	5.6	0.41	9.96e-8	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	0.98	6.05	0.44	1.08e-8	Gut microbiota (bacterial taxa);
PAAD	trans	rs2275606	0.920	rs71566450	chr6:146913437	G/A	cg02825511	chr16:69344779	VPS4A	0.81	6.44	0.46	1.51e-9	Leprosy;
PAAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs7766436	0.614	rs11753682	chr6:22566908	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.45	-0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13012494	chr21:47604986	C21orf56	0.49	5.2	0.39	6.45e-7	Testicular germ cell tumor;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12524338	chr4:183729343	NA	0.62	4.74	0.36	4.88e-6	Pediatric autoimmune diseases;
PAAD	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg10006428	chr1:248814059	OR2T27	0.41	4.92	0.37	2.27e-6	Common traits (Other);
PAAD	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg02795151	chr17:7402630	POLR2A	0.62	5.9	0.43	2.28e-8	Androgen levels;
PAAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.73	0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs28830936	0.966	rs1531140	chr15:42125234	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.73	-0.48	3.23e-10	Diastolic blood pressure;
PAAD	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg09578308	chr8:124780849	FAM91A1	0.56	4.26	0.33	3.51e-5	Pancreatic cancer;
PAAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12949688	0.538	rs3883321	chr17:55804006	C/G	cg12582317	chr17:55822272	NA	0.47	5.41	0.4	2.43e-7	Schizophrenia;
PAAD	cis	rs5756391	0.546	rs4239882	chr22:37314008	A/G	cg16356956	chr22:37317934	CSF2RB	0.39	4.77	0.36	4.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg06740227	chr12:86229804	RASSF9	-0.5	-4.63	-0.35	7.7e-6	Major depressive disorder;
PAAD	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-6.53	-0.47	9.38e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.73	8.38	0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.88	-10.6	-0.65	5.16e-20	Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-6.04	-0.44	1.15e-8	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.54	0.68	1.62e-22	Platelet count;
PAAD	cis	rs4900538	0.927	rs2403058	chr14:102964654	A/G	cg18135206	chr14:102964638	TECPR2	0.98	12.92	0.72	3.05e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.89	10.08	0.63	1.31e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.62	-6.27	-0.45	3.6e-9	Iron status biomarkers;
PAAD	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg04415270	chr2:102091202	RFX8	-0.66	-8.54	-0.57	1.29e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3829109	0.564	rs12378717	chr9:139286060	G/C	cg21253087	chr9:139290292	SNAPC4	0.52	4.69	0.36	5.97e-6	Peak insulin response;Acute insulin response;
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.43	4.25	0.33	3.72e-5	Eosinophil percentage of white cells;
PAAD	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-6.55	-0.47	8.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs3136441	1.000	rs3136441	chr11:46743247	T/C	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg23417306	chr2:180868811	CWC22	0.48	4.39	0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs354225	0.544	rs13399656	chr2:54802696	T/G	cg01766943	chr2:54829624	SPTBN1	0.51	4.58	0.35	9.55e-6	Schizophrenia;
PAAD	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg07689907	chr11:61582574	FADS1	0.46	4.46	0.34	1.61e-5	Trans fatty acid levels;
PAAD	cis	rs1879734	0.731	rs17383325	chr1:54126552	C/G	cg14659662	chr1:54151053	GLIS1	-0.37	-4.84	-0.37	3.14e-6	Mitral valve prolapse;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs501120	1.000	rs501120	chr10:44753867	T/C	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg20129853	chr10:51489980	NA	-0.46	-4.66	-0.35	6.81e-6	Prostate-specific antigen levels;
PAAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg20673091	chr1:2541236	MMEL1	0.72	7.58	0.52	3.25e-12	Ulcerative colitis;
PAAD	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.57	5.67	0.42	7.02e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg25452165	chr22:42524984	CYP2D6	0.58	5.3	0.39	4.01e-7	Schizophrenia;
PAAD	cis	rs35883536	0.548	rs3176860	chr1:101187219	A/G	cg14515779	chr1:101123966	NA	-0.52	-6.1	-0.44	8.29e-9	Monocyte count;
PAAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg19630374	chr17:18023558	MYO15A	-0.57	-6.06	-0.44	1.05e-8	Total body bone mineral density;
PAAD	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.52	0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.37	-0.33	2.3e-5	Fibrinogen levels;
PAAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.56	-8.06	-0.55	2.06e-13	Huntington's disease progression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18805032	chr6:3853096	NA	-0.63	-6.64	-0.47	5.2e-10	Obesity-related traits;
PAAD	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.37	-4.55	-0.35	1.09e-5	Rheumatoid arthritis;
PAAD	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.2	9.47	0.61	5.31e-17	Alzheimer's disease (late onset);
PAAD	cis	rs11590090	1.000	rs12758837	chr1:113311633	A/G	cg25707805	chr1:113285387	NA	0.35	4.63	0.35	7.9e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.83	-0.43	3.27e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.6	5.58	0.41	1.07e-7	Mean corpuscular volume;
PAAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-1.02	-5.56	-0.41	1.18e-7	Plasma clusterin levels;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.65	4.82	0.36	3.5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4742903	0.935	rs10122352	chr9:106993511	T/C	cg14250997	chr9:106856677	SMC2	0.44	4.68	0.35	6.31e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg27478167	chr7:817139	HEATR2	-0.58	-4.6	-0.35	8.88e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg22189786	chr22:42395067	WBP2NL	0.5	5.22	0.39	5.72e-7	Cognitive function;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26896818	chr15:85607233	PDE8A	0.55	6.29	0.45	3.22e-9	Smoking initiation;
PAAD	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	9.68	0.62	1.48e-17	Cognitive test performance;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10819733	chr22:24237672	NA	-0.52	-5.92	-0.43	2.05e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg00555438	chr3:195578280	NA	0.54	5.09	0.38	1.03e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg01812947	chr2:240904978	NDUFA10	0.56	4.81	0.36	3.66e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg03959625	chr15:84868606	LOC388152	0.44	4.47	0.34	1.51e-5	Schizophrenia;
PAAD	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.49	5.86	0.43	2.75e-8	Sitting height ratio;
PAAD	cis	rs7551345	1.000	rs34329423	chr1:31857177	C/T	cg17086398	chr1:31896392	SERINC2	-0.46	-4.25	-0.33	3.65e-5	Schizophrenia;
PAAD	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.66	9.73	0.62	1.11e-17	Airflow obstruction;
PAAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	4.54	0.35	1.12e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.57	6.52	0.47	1e-9	Platelet distribution width;
PAAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.51	5.32	0.4	3.62e-7	Plasma plasminogen activator levels;
PAAD	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.94	-13.96	-0.75	4.87e-29	Age-related hearing impairment;
PAAD	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.66	6.55	0.47	8.35e-10	Coronary artery disease;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.81	-0.54	8.78e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	13.01	0.73	1.71e-26	Bone mineral density;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.28	0.81	1.06e-37	Height;
PAAD	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	11.99	0.7	1e-23	Menarche (age at onset);
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.69	6.77	0.48	2.66e-10	Initial pursuit acceleration;
PAAD	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg23127183	chr11:57508653	C11orf31	-0.5	-4.39	-0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	4.51	0.34	1.29e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.32e-7	Protein quantitative trait loci;
PAAD	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7646881	0.812	rs7635704	chr3:158459720	T/C	cg19483011	chr3:158453295	NA	-0.59	-4.8	-0.36	3.8e-6	Tetralogy of Fallot;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23571288	chr13:26828759	CDK8	0.61	6.52	0.47	9.67e-10	Monocyte percentage of white cells;
PAAD	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg05562828	chr17:3906858	NA	0.59	6.32	0.46	2.72e-9	Type 2 diabetes;
PAAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13242816	0.881	rs56034786	chr7:116106360	T/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg06219351	chr7:158114137	PTPRN2	-0.79	-6.75	-0.48	3e-10	Response to amphetamines;
PAAD	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.74	-0.36	4.95e-6	Asthma (childhood onset);
PAAD	cis	rs7688540	0.800	rs6837796	chr4:272522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.48	0.34	1.46e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.39	-0.34	2.14e-5	Menopause (age at onset);
PAAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.45	-4.74	-0.36	4.93e-6	Major depressive disorder;
PAAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.81	8.57	0.57	1.1e-14	Cognitive function;
PAAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.77	7.25	0.51	1.92e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.35e-10	Monocyte count;
PAAD	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.63	6.26	0.45	3.71e-9	Height;
PAAD	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.44	0.46	1.47e-9	Lung cancer in ever smokers;
PAAD	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.41	-4.98	-0.37	1.74e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.59	5.16	0.39	7.54e-7	Response to diuretic therapy;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg04369109	chr6:150039330	LATS1	-0.5	-4.86	-0.37	2.94e-6	Testicular germ cell tumor;
PAAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.15	-0.39	7.96e-7	Ulcerative colitis;
PAAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.62	6.14	0.45	6.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.63	5.6	0.41	9.63e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11825685	0.887	rs76377465	chr11:134569562	T/G	cg02089395	chr11:134479357	NA	-0.69	-4.53	-0.34	1.19e-5	IgG glycosylation;
PAAD	cis	rs742132	0.545	rs11969981	chr6:25650817	T/A	cg03264133	chr6:25882463	NA	0.67	4.57	0.35	9.87e-6	Uric acid levels;
PAAD	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.18	-0.45	5.76e-9	Schizophrenia;
PAAD	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg26384229	chr12:38710491	ALG10B	0.7	7.11	0.5	4.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg17372657	chr7:1216933	NA	-0.38	-4.68	-0.36	6.21e-6	Longevity;Endometriosis;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07167872	chr1:205819463	PM20D1	0.45	4.36	0.33	2.41e-5	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.49	0.57	1.7e-14	Lung cancer;
PAAD	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-5.95	-0.43	1.74e-8	Menopause (age at onset);
PAAD	cis	rs10073892	0.830	rs10057361	chr5:101602741	T/G	cg17280723	chr5:101634495	NA	0.44	4.55	0.35	1.1e-5	Cognitive decline (age-related);
PAAD	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.52	-4.96	-0.37	1.89e-6	Pancreatic cancer;
PAAD	cis	rs7224685	0.608	rs12602456	chr17:4273483	C/T	cg09695851	chr17:3907499	NA	0.62	5.26	0.39	4.9e-7	Type 2 diabetes;
PAAD	cis	rs75920871	0.920	rs61907605	chr11:116820071	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.64	6.42	0.46	1.61e-9	Neuroticism;
PAAD	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.49	4.37	0.33	2.3e-5	Ulcerative colitis;
PAAD	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.88	-8.2	-0.55	9.26e-14	Blood pressure (smoking interaction);
PAAD	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.44e-5	Hepatocellular carcinoma;
PAAD	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg06740227	chr12:86229804	RASSF9	-0.53	-4.86	-0.37	2.89e-6	Major depressive disorder;
PAAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.59	-0.41	1.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs17407555	0.779	rs17250843	chr4:10127978	C/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.16	-0.45	6.36e-9	Schizophrenia (age at onset);
PAAD	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg07828340	chr4:882639	GAK	0.84	5.74	0.42	4.92e-8	Parkinson's disease;
PAAD	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.3e-6	Tuberculosis;
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.63	-4.44	-0.34	1.75e-5	Hypertriglyceridemia;
PAAD	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.83	-0.69	2.61e-23	Blood pressure (smoking interaction);
PAAD	cis	rs288342	0.832	rs288259	chr2:183602821	A/G	cg02625481	chr2:183667124	NA	-0.43	-4.25	-0.33	3.77e-5	Recurrent major depressive disorder;
PAAD	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg16342193	chr10:102329863	NA	-0.82	-8.99	-0.59	9.15e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	4.9	0.37	2.39e-6	Parkinson's disease;
PAAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg01815783	chr4:1047043	NA	-0.48	-4.6	-0.35	8.81e-6	Recombination rate (females);
PAAD	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.73	-8.36	-0.56	3.66e-14	Diastolic blood pressure;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16262614	chr3:133464971	TF	0.41	4.31	0.33	2.95e-5	Iron status biomarkers;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	8.2	0.55	9.37e-14	Lymphocyte counts;
PAAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.53	6.12	0.44	7.75e-9	Psoriasis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24311947	chr1:28286409	XKR8	0.63	6.36	0.46	2.28e-9	Myopia (pathological);
PAAD	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg05528293	chr18:74961138	GALR1	0.57	5.24	0.39	5.25e-7	Obesity-related traits;
PAAD	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg00717180	chr2:96193071	NA	0.57	6.37	0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs2031532	0.587	rs2038638	chr13:50048975	A/G	cg08779649	chr13:50194554	NA	0.35	4.77	0.36	4.26e-6	Cardiac hypertrophy;
PAAD	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg03233332	chr7:66118400	NA	-0.41	-4.52	-0.34	1.23e-5	Aortic root size;
PAAD	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.58	-6.42	-0.46	1.63e-9	Platelet distribution width;
PAAD	cis	rs1075232	1.000	rs12438318	chr15:31680445	G/A	cg06530883	chr15:30699977	NA	1.04	4.63	0.35	7.74e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg14393609	chr7:65229607	NA	-0.66	-7.28	-0.51	1.69e-11	Aortic root size;
PAAD	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.7	0.48	3.9e-10	Triglycerides;
PAAD	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg04844267	chr4:1394941	NA	0.54	5.95	0.43	1.78e-8	Obesity-related traits;
PAAD	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.46	-0.41	1.88e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs295140	0.743	rs1729412	chr2:201083598	T/C	cg23649088	chr2:200775458	C2orf69	0.48	4.82	0.36	3.51e-6	QT interval;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg18279126	chr7:2041391	MAD1L1	-0.63	-6.61	-0.47	6.18e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.74	8.22	0.55	8.5e-14	Lung cancer;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.43	0.56	2.44e-14	Lung cancer;
PAAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.35	4.83	0.36	3.3e-6	Height;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg19429281	chr19:53496738	ZNF702P	-0.47	-4.84	-0.37	3.17e-6	Psoriasis;
PAAD	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.49	4.44	0.34	1.73e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg12641515	chr19:46296257	DMWD	0.47	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05347473	chr6:146136440	FBXO30	-0.53	-5.14	-0.38	8.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-4.52	-0.34	1.25e-5	Dilated cardiomyopathy;
PAAD	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-4.41	-0.34	1.95e-5	Type 2 diabetes;
PAAD	cis	rs2120243	0.528	rs62278647	chr3:157149133	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	4.63	0.35	7.87e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4356203	0.870	rs214914	chr11:17241892	C/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.71	-6.75	-0.48	2.99e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	1.11	16.49	0.8	1.1e-35	Breast cancer;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs17095355	0.642	rs4130278	chr10:111913522	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.7	-0.36	5.83e-6	Biliary atresia;
PAAD	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.81	7.63	0.53	2.37e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2834902	0.633	rs9975485	chr21:36681216	G/A	cg04915566	chr21:36421472	RUNX1	-0.31	-4.31	-0.33	2.98e-5	Corneal curvature;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.58	0.8	6.69e-36	Prudent dietary pattern;
PAAD	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg21395723	chr22:39101663	GTPBP1	0.46	4.78	0.36	4.11e-6	Menopause (age at onset);
PAAD	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.46	-4.41	-0.34	1.98e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg01503450	chr10:980765	NA	0.56	4.98	0.37	1.72e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19005763	chr3:58225528	ABHD6	-0.69	-7.05	-0.5	5.9e-11	Obesity-related traits;
PAAD	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.43	4.25	0.33	3.65e-5	Lung cancer;
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs11615916	0.790	rs73135290	chr12:62695835	A/G	cg11441379	chr12:63026424	NA	0.65	4.4	0.34	2.06e-5	Pulmonary function decline;
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14319249	chr9:98269526	PTCH1	-0.57	-4.62	-0.35	7.97e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13293943	chr22:39264340	CBX6	-0.65	-6.49	-0.47	1.15e-9	Obesity-related traits;
PAAD	cis	rs1499972	0.668	rs4146338	chr3:117493964	C/T	cg07612923	chr3:117604196	NA	-0.96	-6.21	-0.45	4.71e-9	Schizophrenia;
PAAD	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs1109501	0.689	rs4277751	chr4:71416895	T/G	cg25553522	chr4:71388589	AMTN	0.54	4.51	0.34	1.3e-5	Alcoholism (heaviness of drinking);
PAAD	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.31e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.71	7.85	0.54	6.95e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.94	6.45	0.46	1.42e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg22496339	chr2:162101262	NA	0.49	4.88	0.37	2.68e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7709377	0.521	rs9327000	chr5:115709156	G/T	cg05931423	chr5:115697214	NA	0.48	4.54	0.35	1.11e-5	Metabolite levels  (X-11787);
PAAD	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg10395934	chr14:104002654	TRMT61A	0.55	5.76	0.42	4.62e-8	Body mass index;
PAAD	cis	rs7255045	0.743	rs10426080	chr19:12957850	A/G	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg15693483	chr7:1102177	C7orf50	0.43	4.79	0.36	4.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.9	-9.18	-0.6	3.03e-16	Asthma;
PAAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs7523050	0.730	rs67008022	chr1:109487904	G/A	cg08274380	chr1:109419600	GPSM2	0.7	4.84	0.37	3.2e-6	Fat distribution (HIV);
PAAD	cis	rs7577696	0.962	rs11681731	chr2:32345325	A/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.62	-0.35	8.11e-6	Inflammatory biomarkers;
PAAD	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg20363699	chr7:23626180	CLK2P	-0.37	-4.46	-0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg27373749	chr11:63775612	MACROD1	0.45	5.1	0.38	9.97e-7	Pulse pressure;
PAAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.43	5.08	0.38	1.1e-6	Immature fraction of reticulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23509745	chr3:184045221	EIF4G1	0.62	7.48	0.52	5.5e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.81	-6.18	-0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7487075	0.619	rs7311504	chr12:46830776	G/A	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1419980	0.730	rs6488498	chr12:7740425	C/G	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg10547527	chr2:198650123	BOLL	-0.68	-4.66	-0.35	6.98e-6	Ulcerative colitis;
PAAD	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-1.14	-16.15	-0.79	8.74e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.93	-7.96	-0.54	3.61e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.47	8.43	0.56	2.43e-14	Multiple system atrophy;
PAAD	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg26876637	chr1:152193138	HRNR	-0.82	-6.13	-0.45	7.36e-9	Atopic dermatitis;
PAAD	cis	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg21546286	chr11:48923668	NA	-0.58	-6.07	-0.44	1e-8	HDL cholesterol;
PAAD	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs6663390	0.510	rs6540445	chr1:208081467	A/G	cg03990033	chr1:208084030	CD34	-0.47	-4.38	-0.33	2.22e-5	Facial morphology (factor 18);
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.59e-7	Lung cancer;
PAAD	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.7	6.31	0.46	2.97e-9	Type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.69	-7.43	-0.52	7.38e-12	Aortic root size;
PAAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.48	-4.68	-0.35	6.28e-6	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.72	-0.48	3.39e-10	Response to antipsychotic treatment;
PAAD	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.27	-0.39	4.6e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs901683	0.850	rs80021398	chr10:46039383	A/G	cg11747279	chr17:21096632	NA	0.88	6.67	0.48	4.45e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9535307	0.929	rs1407441	chr13:50290990	T/C	cg04663916	chr13:50265991	EBPL	0.61	4.69	0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.63	6.72	0.48	3.36e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs787274	1.000	rs2796035	chr9:115515597	C/T	cg13803584	chr9:115635662	SNX30	-0.81	-4.51	-0.34	1.3e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.54	-5.08	-0.38	1.1e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1075265	0.589	rs2542571	chr2:54041983	G/T	cg04546899	chr2:54196757	PSME4	0.3	4.38	0.33	2.19e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg07703079	chr11:430292	ANO9	0.86	4.87	0.37	2.72e-6	Body mass index;
PAAD	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.57	-6.76	-0.48	2.74e-10	Aortic root size;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.43	-4.36	-0.33	2.43e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	Cognitive function;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.34	-0.4	3.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08219700	chr8:58056026	NA	0.7	5.22	0.39	5.76e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.51	5.07	0.38	1.13e-6	Menopause (age at onset);
PAAD	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg20406979	chr6:167373233	NA	-0.33	-4.56	-0.35	1.04e-5	Graves' disease;
PAAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.15e-11	Rheumatoid arthritis;
PAAD	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	cis	rs1925576	0.713	rs61866190	chr10:68636455	A/T	cg04444303	chr10:69634106	NA	-0.42	-4.25	-0.33	3.75e-5	Educational attainment (years of education);
PAAD	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-10.24	-0.64	4.75e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.68	6.45	0.46	1.43e-9	Lymphocyte counts;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.9	-0.37	2.46e-6	Bipolar disorder;
PAAD	cis	rs57786342	0.569	rs4899260	chr14:69278204	C/T	cg03189333	chr14:69283534	NA	-0.59	-5.07	-0.38	1.13e-6	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg17724175	chr1:150552817	MCL1	-0.51	-5.76	-0.42	4.56e-8	Tonsillectomy;
PAAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.8	0.43	3.78e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.85	-0.49	1.74e-10	Mood instability;
PAAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4950322	0.600	rs11240014	chr1:146852395	G/A	cg22381352	chr1:146742008	CHD1L	-0.4	-4.26	-0.33	3.54e-5	Protein quantitative trait loci;
PAAD	cis	rs11563648	0.535	rs4731354	chr7:127019101	C/A	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.71	-7.35	-0.51	1.15e-11	Coronary artery disease;
PAAD	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg14169450	chr9:139327907	INPP5E	0.5	4.69	0.36	6.13e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7534824	0.625	rs17409499	chr1:101504936	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.69	0.36	6.06e-6	Refractive astigmatism;
PAAD	cis	rs75920871	1.000	rs61907591	chr11:116796855	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg18612461	chr15:75251733	NA	0.57	6.81	0.48	2.1e-10	Caffeine consumption;
PAAD	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.7	4.54	0.35	1.14e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.28	-5.37	-0.4	2.87e-7	Urinary metabolites;
PAAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.5	0.41	1.58e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.32	0.73	2.67e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3733418	0.929	rs7657444	chr4:165886559	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.71	-0.42	5.66e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07934941	chr4:185654596	MLF1IP	0.62	6.55	0.47	8.42e-10	Obesity-related traits;
PAAD	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg03983498	chr1:55107291	C1orf175	0.48	5.05	0.38	1.22e-6	Survival in pancreatic cancer;
PAAD	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg18765753	chr7:1198926	ZFAND2A	-0.45	-4.56	-0.35	1.03e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.7	6.66	0.48	4.68e-10	Lymphocyte percentage of white cells;
PAAD	cis	rs498136	0.901	rs634812	chr11:69364305	A/C	cg24388239	chr11:68438018	NA	-0.43	-4.38	-0.33	2.22e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.71	-6.55	-0.47	8.34e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-1.4	-10.47	-0.65	1.2e-19	Magnesium levels;
PAAD	cis	rs3764400	0.567	rs2325804	chr17:46218545	G/A	cg10706073	chr17:46328419	SKAP1	1.05	6.3	0.46	3e-9	Body mass index;
PAAD	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.17	0.5	3.04e-11	Diastolic blood pressure;
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.68	-0.42	6.54e-8	Psoriasis;
PAAD	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.53	-5.4	-0.4	2.55e-7	Height;
PAAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2717559	0.515	rs55720963	chr8:143895957	T/A	cg15329936	chr8:143360109	TSNARE1	-0.38	-4.27	-0.33	3.37e-5	Urinary tract infection frequency;
PAAD	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg00614314	chr15:82944287	LOC80154	0.59	6.11	0.44	7.99e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs992157	0.764	rs2382827	chr2:219184387	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.09	0.5	4.83e-11	Colorectal cancer;
PAAD	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06753367	chr22:24256600	NA	-0.43	-4.42	-0.34	1.84e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs300774	0.844	rs300728	chr2:131828	G/A	cg23649280	chr2:140451	NA	-0.48	-4.59	-0.35	9.08e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.56	-0.52	3.53e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg05697835	chr1:2722811	NA	-0.41	-4.66	-0.35	6.98e-6	Ulcerative colitis;
PAAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg05110241	chr16:68378359	PRMT7	-0.93	-7.29	-0.51	1.61e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7627468	1.000	rs6438713	chr3:121933635	C/T	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	trans	rs901683	1.000	rs71494787	chr10:45972247	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.54	5.12	0.38	9.22e-7	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg10729496	chr3:10149963	C3orf24	0.83	6.76	0.48	2.84e-10	Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.96e-8	Personality dimensions;
PAAD	cis	rs3112530	1.000	rs150618	chr5:152727394	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-5.49	-0.41	1.63e-7	Body mass index;
PAAD	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-1.15	-12.8	-0.72	6.55e-26	Post bronchodilator FEV1;
PAAD	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.34	-0.6	1.11e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11696845	0.712	rs6130685	chr20:43366730	T/G	cg25301532	chr20:43378953	KCNK15	0.5	5.71	0.42	5.7e-8	Obesity-related traits;
PAAD	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.87	0.37	2.82e-6	Cognitive ability;
PAAD	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.16	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.7	-5.8	-0.43	3.64e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	1.01	6.28	0.45	3.46e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs258892	0.895	rs34206264	chr5:72059806	C/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09218462	chr2:38011852	NA	0.63	6.97	0.49	8.83e-11	Smoking initiation;
PAAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.28	0.33	3.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs72827839	0.846	rs72823601	chr17:46135208	C/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.76	-8.59	-0.57	9.89e-15	Childhood ear infection;
PAAD	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.62	-4.93	-0.37	2.15e-6	Breast cancer;
PAAD	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1400816	0.850	rs6433318	chr2:172797104	T/C	cg23624723	chr2:173292262	ITGA6	-0.76	-4.45	-0.34	1.62e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.77	-6.87	-0.49	1.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.39	-0.4	2.59e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	0.86	8.31	0.56	5e-14	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-11.5	-0.68	2.06e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.4	4.87	0.37	2.79e-6	Pulmonary function;
PAAD	cis	rs28595532	0.546	rs13102483	chr4:119246396	G/A	cg21605333	chr4:119757512	SEC24D	1.32	7.12	0.5	3.96e-11	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.77	4.34	0.33	2.61e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.79	5.83	0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.52	-0.34	1.25e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg27411982	chr8:10470053	RP1L1	-0.5	-5.42	-0.4	2.26e-7	Neuroticism;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.57	5.17	0.39	7.31e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.04	-0.38	1.32e-6	Coronary artery disease;
PAAD	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.7	0.62	1.26e-17	Chronic sinus infection;
PAAD	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.95	-0.43	1.82e-8	QT interval;
PAAD	cis	rs2712184	0.967	rs7587010	chr2:217674989	G/T	cg05032264	chr2:217675019	NA	-0.69	-7.86	-0.54	6.5e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-4.26	-0.33	3.52e-5	Parkinson's disease;
PAAD	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05671241	chr3:126373822	NA	0.56	6.42	0.46	1.61e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13556604	chr1:203274688	BTG2	-0.83	-7.18	-0.5	2.94e-11	Neuroticism;
PAAD	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.37	0.64	2.13e-19	Electrocardiographic conduction measures;
PAAD	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-4.64	-0.35	7.39e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.48	-6.3	-0.45	3.1e-9	Ulcerative colitis;
PAAD	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.51	-5.37	-0.4	2.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg00988841	chr10:134556463	INPP5A	0.46	4.32	0.33	2.75e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg24998770	chr7:37888106	TXNDC3	0.54	4.69	0.36	6.04e-6	Alzheimer's disease (late onset);
PAAD	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg07154921	chr7:157260426	NA	0.44	4.31	0.33	2.9e-5	Body mass index;
PAAD	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-1.01	-12.96	-0.72	2.45e-26	Refractive error;
PAAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	5.37	0.4	2.83e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg15145965	chr22:50218605	BRD1	0.62	5.26	0.39	4.85e-7	Schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12314527	chr22:19110193	DGCR2	0.54	6.43	0.46	1.53e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.64	6.95	0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.89	-8.7	-0.58	5.03e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.63	-0.35	7.69e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg07677032	chr17:61819896	STRADA	-0.53	-5.04	-0.38	1.31e-6	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs9929218	0.817	rs3114398	chr16:68706933	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.15	-0.5	3.38e-11	Colorectal cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06074774	chr11:126138802	SRPR;FOXRED1	-0.67	-6.85	-0.49	1.76e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.4	5.88	0.43	2.51e-8	Educational attainment (years of education);
PAAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-7.79	-0.53	9.69e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	1.18	9.49	0.61	4.47e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.51	-0.41	1.47e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.52	-4.25	-0.33	3.75e-5	Blood pressure (smoking interaction);
PAAD	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.43	4.31	0.33	2.89e-5	Lung cancer;
PAAD	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.81	-6.8	-0.48	2.26e-10	Cancer;
PAAD	cis	rs340029	1.000	rs339969	chr15:60883281	C/A	cg00200653	chr15:60883225	RORA	0.54	5.11	0.38	9.53e-7	C-reactive protein levels;
PAAD	cis	rs6908034	0.660	rs74795718	chr6:19782299	G/A	cg02682789	chr6:19804855	NA	0.8	4.47	0.34	1.54e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12096438	1.000	rs11806326	chr1:25899165	G/T	cg06359931	chr1:25893405	LDLRAP1	-0.37	-4.56	-0.35	1.05e-5	Platelet count;Mean platelet volume;
PAAD	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg26816564	chr1:7831052	VAMP3	0.82	6.17	0.45	6.05e-9	Inflammatory bowel disease;
PAAD	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg23018236	chr17:30244563	NA	0.67	4.99	0.38	1.64e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg05925327	chr15:68127851	NA	-0.59	-5.23	-0.39	5.48e-7	Obesity;
PAAD	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.32	-0.51	1.34e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.77	7.56	0.52	3.46e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6137287	0.924	rs4305335	chr20:21199624	G/A	cg04219410	chr20:21106687	PLK1S1	-0.43	-4.82	-0.36	3.51e-6	Height;
PAAD	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg10183150	chr4:120222239	C4orf3	0.31	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg08143003	chr3:105086143	ALCAM	-0.62	-6.46	-0.46	1.32e-9	Educational attainment (years of education);
PAAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg23346134	chr3:49453900	TCTA	0.46	4.93	0.37	2.15e-6	Menarche (age at onset);
PAAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.56	-5.58	-0.41	1.06e-7	Personality dimensions;
PAAD	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	1.98	11.84	0.69	2.5e-23	Cannabis dependence symptom count;
PAAD	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-1.17	-11.02	-0.67	4.06e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs56046484	0.956	rs34105012	chr15:85591686	C/G	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg12568669	chr8:11666485	FDFT1	0.32	5.28	0.39	4.43e-7	Monocyte count;
PAAD	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.51	-6.5	-0.47	1.09e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.88	-0.43	2.46e-8	Blood trace element (Zn levels);
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs7219021	0.926	rs7217983	chr17:46853345	A/G	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06850241	chr22:41845214	NA	0.57	5.0	0.38	1.59e-6	Vitiligo;
PAAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2070433	0.851	rs1029231	chr21:47931653	A/G	cg12379764	chr21:47803548	PCNT	0.59	5.07	0.38	1.14e-6	Lymphocyte counts;
PAAD	trans	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.55	-0.47	8.33e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.7	-4.74	-0.36	4.9100000000000004e-06	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg14393609	chr7:65229607	NA	0.5	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs6679454	1.000	rs61770283	chr1:58367691	G/A	cg17491850	chr1:57888480	DAB1	-0.39	-4.41	-0.34	1.99e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs12541635	0.902	rs13277300	chr8:107062819	C/T	cg10147462	chr8:107024639	NA	-0.45	-4.95	-0.37	1.97e-6	Age of smoking initiation;
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg21016266	chr12:122356598	WDR66	-0.47	-4.75	-0.36	4.6e-6	Mean corpuscular volume;
PAAD	cis	rs2790216	1.000	rs1339585	chr10:59936841	G/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg24747557	chr10:131355152	MGMT	-0.43	-4.29	-0.33	3.12e-5	Response to temozolomide;
PAAD	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.53	5.19	0.39	6.72e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.5	4.67	0.35	6.44e-6	Red cell distribution width;
PAAD	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	8.27	0.56	6.3e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-6.38	-0.46	2.03e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs1015213	0.609	rs115398091	chr8:52879075	G/A	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.6	5.73	0.42	5.15e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.6	-0.35	9.02e-6	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.7	6.97	0.49	8.96e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs74181299	0.648	rs6730986	chr2:65353549	C/T	cg20592124	chr2:65290738	CEP68	-0.47	-4.37	-0.33	2.27e-5	Pulse pressure;
PAAD	cis	rs7551222	0.681	rs2926533	chr1:204480742	T/A	cg01064725	chr1:204461714	NA	0.58	5.03	0.38	1.34e-6	Schizophrenia;
PAAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.97	-13.25	-0.73	3.92e-27	Height;
PAAD	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.82	-0.36	3.47e-6	Height;
PAAD	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.77	7.72	0.53	1.48e-12	Testicular germ cell tumor;
PAAD	cis	rs9549328	0.796	rs7993665	chr13:113651132	T/C	cg08614441	chr13:113633676	MCF2L	-0.43	-4.3	-0.33	3.01e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1018697	1.000	rs7086400	chr10:104562097	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2479106	0.963	rs1627536	chr9:126542704	A/T	cg16191174	chr9:126692580	DENND1A	-0.52	-4.84	-0.37	3.21e-6	Polycystic ovary syndrome;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7923609	0.967	rs10740134	chr10:65315433	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-4.34	-0.33	2.63e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg01765077	chr12:122356316	WDR66	-0.49	-4.79	-0.36	3.98e-6	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16377939	chr16:53088918	CHD9	-0.63	-7.47	-0.52	5.91e-12	Body fat percentage;
PAAD	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.73	9.12	0.59	4.26e-16	Bone mineral density;
PAAD	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg25011176	chr20:3776985	CDC25B	-0.46	-4.42	-0.34	1.85e-5	Bipolar disorder;
PAAD	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.59e-16	Morning vs. evening chronotype;
PAAD	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs12304921	0.683	rs3759406	chr12:51441751	A/G	cg04427360	chr12:51347099	HIGD1C	0.66	4.7	0.36	5.84e-6	Type 2 diabetes;
PAAD	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	0.9	5.36	0.4	3.02e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	5.24	0.39	5.31e-7	Mood instability;
PAAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13515842	chr9:127215440	GPR144	0.44	4.67	0.35	6.55e-6	Menarche (age at onset);
PAAD	cis	rs28655083	0.636	rs7194836	chr16:77066830	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-4.81	-0.36	3.65e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.54	-5.06	-0.38	1.2e-6	P wave terminal force;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg10467557	chr13:21893662	NA	-0.42	-4.56	-0.35	1.06e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg13207630	chr7:32358064	NA	-0.76	-4.25	-0.33	3.68e-5	Body mass index;
PAAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.32e-6	Parkinson's disease;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.76	6.89	0.49	1.39e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.51	-5.24	-0.39	5.3e-7	Testicular germ cell tumor;
PAAD	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg03959625	chr15:84868606	LOC388152	-0.44	-4.58	-0.35	9.66e-6	P wave terminal force;
PAAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.39	-0.4	2.62e-7	Personality dimensions;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg18769074	chr3:133464867	TF	0.42	4.9	0.37	2.4e-6	Iron status biomarkers;
PAAD	cis	rs1499972	0.618	rs62264771	chr3:117647197	G/T	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs5756391	0.568	rs4821568	chr22:37316476	T/C	cg21209356	chr22:37319042	CSF2RB	0.39	4.75	0.36	4.63e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3931020	0.745	rs1969111	chr1:75263485	A/T	cg26752657	chr1:75199075	CRYZ;TYW3	-0.49	-4.8	-0.36	3.74e-6	Resistin levels;
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.45	-4.77	-0.36	4.21e-6	Dementia with Lewy bodies;
PAAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg03651054	chr13:50194643	NA	0.41	5.54	0.41	1.32e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg08886695	chr4:3369023	RGS12	-0.45	-4.39	-0.34	2.08e-5	Parental longevity (mother's age at death);
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs12042052	0.793	rs10910625	chr1:232940447	C/T	cg02191044	chr1:232940990	KIAA1383	-0.85	-4.74	-0.36	4.96e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9649465	0.967	rs2402666	chr7:123285478	A/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.69	-0.36	5.99e-6	Migraine;
PAAD	cis	rs42648	0.564	rs6956980	chr7:89803634	T/C	cg27367526	chr7:89841692	STEAP2	-0.34	-4.76	-0.36	4.52e-6	Homocysteine levels;
PAAD	cis	rs2916733	0.530	rs2440424	chr8:6289937	C/T	cg01691696	chr8:6734962	DEFB1	0.55	4.88	0.37	2.6e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.45	-4.45	-0.34	1.68e-5	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09897416	chr1:149859252	HIST2H2AB;HIST2H2BE	0.67	6.36	0.46	2.2e-9	Obesity-related traits;
PAAD	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26926768	chr12:34528122	NA	-0.37	-4.57	-0.35	9.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.53	-5.58	-0.41	1.08e-7	Hepatitis;
PAAD	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg25174290	chr11:3078921	CARS	-0.43	-4.37	-0.33	2.28e-5	Calcium levels;
PAAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg25833597	chr17:30823145	MYO1D	0.55	5.33	0.4	3.44e-7	Schizophrenia;
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.64	6.72	0.48	3.35e-10	Aortic root size;
PAAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg06632027	chr4:90757378	SNCA	0.51	4.51	0.34	1.26e-5	Neuroticism;
PAAD	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.59	-5.52	-0.41	1.44e-7	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.55	0.68	1.55e-22	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg22711741	chr19:57742444	AURKC	0.43	4.32	0.33	2.81e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.78	5.66	0.42	7.38e-8	Initial pursuit acceleration;
PAAD	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	1.06	5.91	0.43	2.19e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-4.67	-0.35	6.67e-6	Mean corpuscular volume;
PAAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.97	-10.76	-0.66	1.97e-20	Lymphocyte counts;
PAAD	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.47	5.33	0.4	3.57e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-6.43	-0.46	1.57e-9	Coronary artery disease;
PAAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg02734326	chr4:10020555	SLC2A9	0.49	4.9	0.37	2.48e-6	Bone mineral density;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.37	5.09	0.38	1.04e-6	Height;
PAAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4523957	0.820	rs2224770	chr17:2205923	T/C	cg16513277	chr17:2031491	SMG6	0.53	5.51	0.41	1.5e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.04e-5	Vitiligo;
PAAD	cis	rs6688613	1.000	rs6695162	chr1:166953455	C/G	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg17077180	chr1:38461687	NA	-0.52	-5.64	-0.42	7.95e-8	Coronary artery disease;
PAAD	cis	rs4780401	0.933	rs4439779	chr16:11826841	A/G	cg01061890	chr16:11836724	TXNDC11	-0.53	-5.19	-0.39	6.55e-7	Rheumatoid arthritis;
PAAD	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg00262122	chr8:11665843	FDFT1	-0.71	-6.05	-0.44	1.07e-8	Neuroticism;
PAAD	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9810890	1.000	rs78675391	chr3:128472470	C/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs4234284	0.501	rs2358559	chr3:127046788	A/G	cg27326032	chr3:127006922	NA	0.49	5.06	0.38	1.21e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.66	-6.79	-0.48	2.31e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg25200586	chr1:148000763	NA	0.62	6.56	0.47	7.87e-10	Hip geometry;
PAAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.58	5.45	0.4	2e-7	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg21724239	chr8:58056113	NA	0.72	5.71	0.42	5.8e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.54	-5.22	-0.39	5.8e-7	P wave terminal force;
PAAD	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.08	15.27	0.78	1.65e-32	Multiple system atrophy;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-8.85	-0.58	2.11e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs5771225	0.563	rs6010220	chr22:50693554	A/G	cg08875078	chr22:50639485	SELO	0.48	4.42	0.34	1.89e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1957429	0.520	rs12433757	chr14:65296598	T/C	cg23373153	chr14:65346875	NA	-1.19	-6.26	-0.45	3.73e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.81	9.0	0.59	8.64e-16	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.55	-0.35	1.11e-5	LDL cholesterol levels;
PAAD	cis	rs73058052	0.597	rs16981329	chr19:50097932	G/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.57	-4.87	-0.37	2.75e-6	Fibrinogen levels;
PAAD	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg09357268	chr20:43379437	KCNK15	0.45	4.66	0.35	6.79e-6	Obesity-related traits;
PAAD	cis	rs2882667	0.722	rs4835649	chr5:138146223	T/C	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.83	-9.46	-0.61	5.55e-17	Lung cancer;
PAAD	cis	rs412050	0.547	rs76200689	chr22:22154644	G/A	cg17089214	chr22:22089827	YPEL1	0.67	4.53	0.35	1.17e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.41	4.42	0.34	1.89e-5	Prostate cancer;
PAAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs4401971	0.518	rs10960383	chr9:11934049	G/C	cg14390656	chr9:11618691	NA	0.46	4.49	0.34	1.41e-5	Obsessive-compulsive disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11486935	chr17:123951	RPH3AL	0.56	6.81	0.48	2.13e-10	Myopia (pathological);
PAAD	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10411590	chr13:21900810	NA	0.61	7.01	0.49	7.43e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg02462569	chr6:150064036	NUP43	-0.49	-5.5	-0.41	1.57e-7	Lung cancer;
PAAD	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg02493740	chr2:85810744	VAMP5	0.41	4.54	0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.84e-18	Cognitive function;
PAAD	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-1.24	-12.27	-0.71	1.78e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4838594	0.563	rs4838597	chr10:49679397	G/A	cg17291251	chr10:49678358	ARHGAP22	0.47	4.41	0.34	1.94e-5	Daytime sleep phenotypes;
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg16434002	chr17:42200994	HDAC5	0.63	5.96	0.44	1.71e-8	Total body bone mineral density;
PAAD	cis	rs16852403	0.861	rs73049336	chr1:178042298	A/T	cg00404053	chr1:178313656	RASAL2	0.43	4.25	0.33	3.66e-5	Childhood ear infection;
PAAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.62	-5.07	-0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs16883019	0.793	rs77793250	chr6:19912331	G/A	cg26817755	chr6:19812885	NA	-0.73	-4.33	-0.33	2.74e-5	Response to statin therapy;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg00181669	chr3:44000978	NA	-0.54	-5.79	-0.43	3.86e-8	Coronary artery disease;
PAAD	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.56	5.99	0.44	1.49e-8	Menopause (age at onset);
PAAD	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg07164556	chr1:145727247	PDZK1	0.65	4.48	0.34	1.49e-5	Mitochondrial DNA levels;
PAAD	cis	rs1144333	1.000	rs75399471	chr1:76339092	A/T	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Menopause (age at onset);
PAAD	cis	rs6076065	0.723	rs2275788	chr20:23338694	G/A	cg11657817	chr20:23433608	CST11	0.48	5.03	0.38	1.37e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4792901	0.729	rs72833142	chr17:41615556	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.29	-0.33	3.18e-5	Dupuytren's disease;
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.65	-5.21	-0.39	6.01e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg06217071	chr17:408420	NA	-0.78	-8.72	-0.58	4.55e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-6.67	-0.48	4.35e-10	Body mass index (adult);
PAAD	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.49	5.56	0.41	1.18e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg01176363	chr20:62369445	LIME1	-0.58	-5.5	-0.41	1.56e-7	Prostate cancer;
PAAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs17209837	0.607	rs1468615	chr7:87074964	T/C	cg00919237	chr7:87102261	ABCB4	-0.71	-5.59	-0.41	1.01e-7	Gallbladder cancer;
PAAD	cis	rs4740619	0.592	rs3008719	chr9:16011741	T/C	cg14451791	chr9:16040625	NA	-0.37	-4.37	-0.33	2.32e-5	Body mass index;
PAAD	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.59	5.24	0.39	5.24e-7	DNA methylation (variation);
PAAD	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg27005118	chr17:13972210	COX10	-0.39	-5.16	-0.39	7.52e-7	Temperament;
PAAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.6	0.41	9.93e-8	Bipolar disorder;
PAAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	1.21	11.75	0.69	4.23e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg27494647	chr7:150038898	RARRES2	0.42	4.28	0.33	3.25e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	7.12	0.5	4.07e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.35e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9398803	0.650	rs10499135	chr6:126626333	A/G	cg19875578	chr6:126661172	C6orf173	0.49	4.65	0.35	7.17e-6	Male-pattern baldness;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22442454	chr1:209979470	IRF6	0.59	5.52	0.41	1.41e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.54e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.42	-4.83	-0.36	3.28e-6	Blood protein levels;
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.51	6.21	0.45	4.78e-9	Sitting height ratio;
PAAD	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.36	4.65	0.35	7.26e-6	Calcium levels;
PAAD	cis	rs818427	0.656	rs818426	chr5:112226192	G/A	cg06941702	chr5:112196734	SRP19	0.51	4.93	0.37	2.16e-6	Total body bone mineral density;
PAAD	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.6	-7.07	-0.5	5.16e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.85	-9.98	-0.63	2.32e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs1561288	0.731	rs57794904	chr2:25346568	C/T	cg02492873	chr2:25193821	DNAJC27	0.49	4.25	0.33	3.75e-5	Body mass index;
PAAD	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.49	-4.68	-0.35	6.36e-6	Mean platelet volume;
PAAD	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.37	0.4	2.94e-7	Educational attainment;
PAAD	cis	rs10838532	0.633	rs72902484	chr11:45934889	G/A	cg02851825	chr11:46722101	ARHGAP1;ZNF408	-0.6	-4.57	-0.35	1.01e-5	Axial length;
PAAD	cis	rs62435770	1.000	rs62433599	chr6:169523563	A/C	cg07057617	chr6:170405951	NA	0.62	4.25	0.33	3.65e-5	Loneliness;
PAAD	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg14829155	chr15:31115871	NA	-0.68	-7.34	-0.51	1.19e-11	Huntington's disease progression;
PAAD	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.17	0.5	3.04e-11	Diastolic blood pressure;
PAAD	cis	rs965604	1.000	rs12916801	chr15:78769130	A/G	cg18825076	chr15:78729989	IREB2	-0.45	-4.38	-0.33	2.18e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-7.46	-0.52	6.08e-12	Neuroticism;
PAAD	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.04	13.27	0.73	3.46e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9646944	0.501	rs34946515	chr2:103043320	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	4.28	0.33	3.24e-5	Blood protein levels;
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.22	0.45	4.53e-9	Testicular germ cell tumor;
PAAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.26	-0.33	3.55e-5	Monocyte count;
PAAD	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg12395012	chr8:11607386	GATA4	-0.42	-4.64	-0.35	7.47e-6	Neuroticism;
PAAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7179456	0.610	rs650366	chr15:59061142	A/G	cg08898775	chr15:59042684	ADAM10	0.36	4.78	0.36	4.15e-6	Asperger disorder;
PAAD	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.67	-0.42	7.12e-8	Menopause (age at onset);
PAAD	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg14583973	chr4:3374767	RGS12	0.42	6.33	0.46	2.61e-9	Serum sulfate level;
PAAD	cis	rs501120	0.929	rs2576354	chr10:44750393	G/A	cg09554077	chr10:44749378	NA	0.49	6.49	0.47	1.17e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.8	-9.13	-0.6	3.87e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.57	-0.52	3.28e-12	Migraine;Coronary artery disease;
PAAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.79	-0.36	4e-6	Alcohol dependence;
PAAD	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.62	6.9	0.49	1.29e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10392	0.850	rs73108602	chr20:37537036	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.64	-4.81	-0.36	3.66e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs508970	0.556	rs948732	chr11:60918376	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.45	4.45	0.34	1.64e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2567519	0.925	rs2714018	chr17:70788857	G/A	cg26978064	chr17:70461791	NA	0.29	4.6	0.35	8.77e-6	Smoking initiation;
PAAD	cis	rs1015291	0.708	rs2694976	chr12:20007123	A/G	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg18612461	chr15:75251733	NA	0.59	7.01	0.49	7.2e-11	Caffeine consumption;
PAAD	cis	rs990171	0.687	rs11676371	chr2:103129692	G/C	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.53	-0.34	1.18e-5	Lymphocyte counts;
PAAD	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg18551225	chr6:44695536	NA	-0.75	-7.35	-0.51	1.13e-11	Total body bone mineral density;
PAAD	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.86	9.04	0.59	6.68e-16	Corneal astigmatism;
PAAD	cis	rs11129295	0.618	rs12497514	chr3:27807665	G/A	cg21473142	chr3:27762095	EOMES	0.27	4.47	0.34	1.53e-5	Multiple sclerosis;
PAAD	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-6.14	-0.45	7.01e-9	Idiopathic membranous nephropathy;
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.74	7.76	0.53	1.16e-12	Height;
PAAD	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.56	-0.47	7.89e-10	Morning vs. evening chronotype;
PAAD	cis	rs818427	0.593	rs153551	chr5:112234834	T/G	cg06941702	chr5:112196734	SRP19	0.55	5.07	0.38	1.16e-6	Total body bone mineral density;
PAAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs66530629	0.917	rs4648879	chr1:25175246	A/G	cg22509179	chr1:25234806	RUNX3	-0.49	-4.5	-0.34	1.34e-5	Plateletcrit;
PAAD	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.57	5.81	0.43	3.5e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg14703610	chr5:56206110	C5orf35	0.63	5.78	0.42	4.12e-8	Coronary artery disease;
PAAD	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg19337854	chr7:99768885	GPC2	-0.43	-4.4	-0.34	2.03e-5	Coronary artery disease;
PAAD	cis	rs11951515	0.508	rs11958046	chr5:43583389	T/C	cg01983248	chr5:43482804	C5orf28	-0.3	-4.29	-0.33	3.14e-5	Metabolite levels  (X-11787);
PAAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.1	14.72	0.77	4.85e-31	Cognitive function;
PAAD	cis	rs4742903	0.846	rs4743699	chr9:107002261	T/A	cg14250997	chr9:106856677	SMC2	0.44	4.8	0.36	3.81e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.65	-6.18	-0.45	5.63e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10819733	chr22:24237672	NA	-0.62	-6.74	-0.48	3.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs829661	0.947	rs829659	chr2:30727866	C/T	cg12454169	chr2:30669597	LCLAT1	0.66	5.07	0.38	1.14e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.16	0.39	7.7300000000000005e-07	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2290416	0.710	rs61005957	chr8:144669512	T/G	cg08017634	chr8:144659831	NAPRT1	0.75	4.31	0.33	2.89e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.95	0.49	1.02e-10	Rheumatoid arthritis;
PAAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg17372223	chr3:52568218	NT5DC2	0.49	4.55	0.35	1.09e-5	Bipolar disorder;
PAAD	cis	rs1507153	0.812	rs9359337	chr6:79389316	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.43	-0.34	1.77e-5	Sjögren's syndrome;
PAAD	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg12486944	chr17:80159399	CCDC57	0.53	4.63	0.35	7.77e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg03030879	chr14:75389066	RPS6KL1	0.46	4.72	0.36	5.29e-6	Caffeine consumption;
PAAD	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.9	-0.49	1.35e-10	Body mass index;
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27436995	chr16:743998	FBXL16	-0.38	-4.6	-0.35	8.92e-6	Height;
PAAD	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	8.01	0.54	2.78e-13	Schizophrenia;
PAAD	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16481046	chr5:1769630	NA	0.54	6.44	0.46	1.52e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs183266	0.736	rs73296016	chr14:77490257	A/G	cg01682506	chr14:77422843	NA	-1.09	-5.39	-0.4	2.68e-7	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-1.37	-10.04	-0.63	1.6e-18	Magnesium levels;
PAAD	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg06740227	chr12:86229804	RASSF9	0.59	5.37	0.4	2.95e-7	Major depressive disorder;
PAAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.73	6.44	0.46	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg17842918	chr13:113540400	ATP11A	-0.42	-4.67	-0.35	6.54e-6	Interstitial lung disease;
PAAD	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.53	0.34	1.19e-5	Total body bone mineral density;
PAAD	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.72	7.45	0.52	6.61e-12	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.79	6.29	0.45	3.19e-9	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.92	8.25	0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs6494488	0.500	rs113645218	chr15:64843582	C/T	cg16425858	chr15:64791681	ZNF609	0.99	4.63	0.35	7.93e-6	Coronary artery disease;
PAAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg13012494	chr21:47604986	C21orf56	0.44	4.56	0.35	1.04e-5	Testicular germ cell tumor;
PAAD	cis	rs75920871	1.000	rs1473325	chr11:116822034	C/T	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.77	9.03	0.59	7.03e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs74922337	0.803	rs9532792	chr13:41912655	A/T	cg11970252	chr13:42188629	KIAA0564	0.88	4.79	0.36	3.98e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.85	-10.3	-0.64	3.31e-19	Monocyte percentage of white cells;
PAAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.56	6.05	0.44	1.06e-8	Major depressive disorder;
PAAD	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	9.9	0.63	3.8e-18	Smoking behavior;
PAAD	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg14459158	chr9:96720562	NA	0.36	4.69	0.36	5.99e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.74	-8.09	-0.55	1.77e-13	Blood pressure (smoking interaction);
PAAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg11764359	chr7:65958608	NA	0.78	5.14	0.38	8.29e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.6	-6.4	-0.46	1.86e-9	Pulmonary function;
PAAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.49	4.65	0.35	7.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7301016	0.948	rs10877870	chr12:62923955	A/G	cg19781863	chr12:62918364	MON2	0.74	4.37	0.33	2.28e-5	IgG glycosylation;
PAAD	trans	rs9372498	1.000	rs1743259	chr6:118609205	C/G	cg15607664	chr12:57630422	NDUFA4L2	-0.78	-7.6	-0.52	2.81e-12	Diastolic blood pressure;
PAAD	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Lymphocyte counts;
PAAD	cis	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	4.49	0.34	1.41e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.69	-0.36	6.01e-6	Type 1 diabetes;
PAAD	trans	rs901683	0.850	rs71494794	chr10:45985284	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg21828629	chr1:205913422	SLC26A9	-0.41	-4.5	-0.34	1.32e-5	Cystic fibrosis-related diabetes;
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	5.96	0.44	1.7e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.71e-8	Coronary artery disease;
PAAD	cis	rs7523050	0.558	rs34880940	chr1:109487731	T/C	cg08274380	chr1:109419600	GPSM2	1.0	5.99	0.44	1.42e-8	Fat distribution (HIV);
PAAD	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.86	10.67	0.65	3.45e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.58	4.68	0.36	6.19e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.91	11.01	0.67	4.29e-21	Menarche (age at onset);
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.57	0.65	6.39e-20	Platelet count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08054244	chr14:88789549	KCNK10	-0.67	-6.92	-0.49	1.16e-10	Smoking initiation;
PAAD	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.56	-5.95	-0.43	1.8e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs2072732	0.821	rs12034573	chr1:2948020	C/T	cg22517653	chr1:2918612	NA	-0.65	-5.5	-0.41	1.6e-7	Plateletcrit;
PAAD	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.68	-7.84	-0.54	7.22e-13	Educational attainment;
PAAD	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg19847866	chr10:1019161	NA	-0.6	-4.64	-0.35	7.32e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6578985	0.636	rs3213221	chr11:2157044	C/G	cg12383159	chr11:1262597	MUC5B	0.41	4.65	0.35	7.15e-6	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs1413885	0.966	rs11208633	chr1:65814693	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.93	0.37	2.09e-6	Anticoagulant levels;
PAAD	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg14664628	chr15:75095509	CSK	-1.1	-12.5	-0.71	4.27e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.63	4.58	0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg00750074	chr16:89608354	SPG7	-0.52	-4.96	-0.37	1.85e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs7631605	0.905	rs2286940	chr3:37070106	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6585424	0.778	rs12257082	chr10:81922121	C/G	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.47	-4.78	-0.36	4.17e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs1656368	0.726	rs55842512	chr3:158266535	A/G	cg16708174	chr3:158430962	RARRES1	0.53	4.83	0.37	3.23e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.45	0.4	1.97e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Educational attainment;
PAAD	cis	rs11020478	0.595	rs603360	chr11:93456755	C/G	cg10523193	chr11:93463762	SNORA25	0.47	4.76	0.36	4.5e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg18736775	chr8:18248649	NAT2	-0.79	-6.93	-0.49	1.1e-10	Blood metabolite levels;
PAAD	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	1.79	10.27	0.64	4.02e-19	Cannabis dependence symptom count;
PAAD	cis	rs6074578	0.679	rs11087789	chr20:139173	A/G	cg16931068	chr20:139680	DEFB127	0.38	5.27	0.39	4.69e-7	Hirschsprung disease;
PAAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg26497354	chr6:109612229	NA	-0.44	-4.4	-0.34	2.05e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg02415014	chr8:143852576	LYNX1	0.49	5.96	0.44	1.72e-8	Urinary tract infection frequency;
PAAD	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.66	6.44	0.46	1.49e-9	Schizophrenia;
PAAD	cis	rs1925576	0.935	rs7908463	chr10:68658986	T/C	cg04444303	chr10:69634106	NA	-0.46	-4.44	-0.34	1.72e-5	Educational attainment (years of education);
PAAD	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.62	6.59	0.47	6.89e-10	Post bronchodilator FEV1;
PAAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.64	-6.58	-0.47	6.99e-10	Body mass index;
PAAD	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.86	-5.71	-0.42	5.78e-8	Body mass index;
PAAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs17125944	0.686	rs7155860	chr14:53335229	G/C	cg00686598	chr14:53173677	PSMC6	-0.91	-5.61	-0.41	9.47e-8	Alzheimer's disease (late onset);
PAAD	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.72	7.82	0.54	8.16e-13	Schizophrenia;
PAAD	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg04117972	chr1:227635322	NA	0.59	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs3764400	0.567	rs12946143	chr17:46154943	C/T	cg10706073	chr17:46328419	SKAP1	-1.08	-6.38	-0.46	2.02e-9	Body mass index;
PAAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16674323	chr3:42846108	HIGD1A	-0.75	-8.09	-0.55	1.71e-13	Smoking initiation;
PAAD	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.62	-6.31	-0.46	2.84e-9	Apolipoprotein A-IV levels;
PAAD	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-0.91	-8.99	-0.59	9.41e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg10556349	chr10:835070	NA	0.58	4.92	0.37	2.26e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.71	5.85	0.43	2.87e-8	Menarche (age at onset);
PAAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.66e-5	Aortic root size;
PAAD	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.72	0.36	5.37e-6	Breast cancer;
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg05341575	chr12:125625032	AACS	-0.54	-5.1	-0.38	1.01e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs5417	0.636	rs222851	chr17:7139238	G/A	cg15655154	chr3:113604241	GRAMD1C	0.65	6.65	0.47	4.88e-10	Diastolic blood pressure;
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg07068956	chr7:100330872	ZAN	0.5	4.48	0.34	1.47e-5	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg08589418	chr20:61993913	CHRNA4	-0.5	-4.32	-0.33	2.86e-5	Atopic dermatitis;
PAAD	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg19486271	chr11:47235900	DDB2	-0.56	-5.91	-0.43	2.13e-8	Bone mineral density (hip);Bone mineral density;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18185028	chr3:154042079	DHX36	0.7	7.25	0.51	1.98e-11	Primary biliary cholangitis;
PAAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg14580859	chr9:123691850	NA	0.38	4.32	0.33	2.76e-5	Rheumatoid arthritis;
PAAD	trans	rs2880058	0.788	rs10800278	chr1:162036269	C/T	cg22816059	chr5:422114	AHRR	-0.63	-6.31	-0.46	2.94e-9	QT interval;
PAAD	cis	rs12311304	1.000	rs12311304	chr12:15389637	T/C	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2016586	0.895	rs2899256	chr22:36114054	C/T	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.35	-0.33	2.49e-5	Height;
PAAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.97	8.32	0.56	4.62e-14	Initial pursuit acceleration;
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.83	-7.98	-0.54	3.38e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-11.03	-0.67	3.69e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs113779084	0.738	rs2355766	chr7:11961138	T/C	cg15090509	chr7:11872073	THSD7A	0.4	4.99	0.37	1.66e-6	Educational attainment (years of education);
PAAD	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg01953289	chr20:60874239	NA	0.7	5.31	0.4	3.87e-7	Obesity-related traits;
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.66	-0.35	6.73e-6	Longevity;
PAAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9832625	0.521	rs6549922	chr3:29332630	A/C	cg06712285	chr3:29990487	RBMS3	-0.74	-5.12	-0.38	9.29e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs2882667	0.690	rs423469	chr5:138234116	G/C	cg09476006	chr5:138032270	NA	0.48	6.09	0.44	8.74e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-9.27	-0.6	1.76e-16	Gut microbiome composition (summer);
PAAD	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-5.28	-0.39	4.36e-7	Axial length;
PAAD	cis	rs4668356	0.773	rs60838537	chr2:172050583	A/T	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg06074448	chr4:187884817	NA	-0.65	-8.36	-0.56	3.76e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07805959	chr17:2595004	KIAA0664	0.53	6.48	0.47	1.19e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.69	-6.81	-0.48	2.17e-10	Blood metabolite levels;
PAAD	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.82	10.15	0.64	8.36e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.89	-8.99	-0.59	9.4e-16	Asthma;
PAAD	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.47	-0.46	1.3e-9	HDL cholesterol;
PAAD	cis	rs9907295	0.591	rs2107538	chr17:34207780	C/T	cg19411729	chr17:34207663	CCL5	-0.53	-4.77	-0.36	4.33e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.86	9.87	0.62	4.69e-18	Prudent dietary pattern;
PAAD	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.57	5.01	0.38	1.48e-6	Common traits (Other);
PAAD	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.03	-0.38	1.39e-6	QT interval;
PAAD	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.48	-4.55	-0.35	1.08e-5	Neutrophil percentage of white cells;
PAAD	cis	rs332507	0.673	rs2242426	chr3:124398031	A/G	cg05980111	chr3:124395277	KALRN	0.42	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.57	5.39	0.4	2.59e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	5.87	0.43	2.58e-8	Cognitive test performance;
PAAD	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg16068336	chr17:48637367	CACNA1G	-0.52	-4.59	-0.35	9.4e-6	Type 2 diabetes;
PAAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg16205897	chr5:131564050	P4HA2	0.41	4.4	0.34	2.05e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.47	-5.81	-0.43	3.49e-8	Menopause (age at onset);
PAAD	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-5.45	-0.4	1.98e-7	Adiposity;
PAAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.57	-0.47	7.48e-10	Glomerular filtration rate;
PAAD	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.8	9.74	0.62	9.98e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.52	-4.68	-0.35	6.42e-6	Retinal vascular caliber;
PAAD	cis	rs62264129	0.500	rs9829698	chr3:112028239	A/G	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7083	0.716	rs687740	chr11:117177603	A/C	cg26034313	chr11:117110208	RNF214	-0.35	-4.41	-0.34	1.97e-5	Blood protein levels;
PAAD	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg27246729	chr12:121163418	ACADS	-0.4	-4.36	-0.33	2.42e-5	Mean corpuscular volume;
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.79	8.45	0.57	2.21e-14	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.76	8.62	0.57	7.94e-15	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.13	-0.38	8.59e-7	Mean platelet volume;
PAAD	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.79	9.17	0.6	3.09e-16	Diastolic blood pressure;
PAAD	cis	rs2252790	1.000	rs2501050	chr6:116663206	G/A	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12533599	chr20:25371665	ABHD12	0.63	7.25	0.51	2.01e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.28e-5	Total body bone mineral density;
PAAD	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.99	14.57	0.76	1.22e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.49	-6.08	-0.44	9.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs6681460	0.674	rs4134135	chr1:67012728	A/G	cg02459107	chr1:67143332	SGIP1	0.57	5.0	0.38	1.56e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	7.5	0.52	5e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Gut microbiome composition (summer);
PAAD	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02991799	chr19:35168510	ZNF302	0.75	9.24	0.6	2.05e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg04844267	chr4:1394941	NA	0.52	5.79	0.43	3.91e-8	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs12936587	0.633	rs12939598	chr17:17508878	C/G	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.45	-0.34	1.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-5.13	-0.38	8.81e-7	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg21366198	chr4:185655624	MLF1IP	-0.52	-4.66	-0.35	6.75e-6	Kawasaki disease;
PAAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.92	-8.31	-0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs35160687	0.712	rs2303359	chr2:86478670	C/T	cg10973622	chr2:86423274	IMMT	-0.43	-4.77	-0.36	4.29e-6	Night sleep phenotypes;
PAAD	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.16	17.57	0.82	1.94e-38	Cognitive function;
PAAD	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01653422	chr8:48920818	UBE2V2	-0.59	-6.37	-0.46	2.12e-9	Pancreatic cancer;
PAAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01225838	chr16:67194867	TRADD;FBXL8	0.58	6.8	0.48	2.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.77	-4.94	-0.37	2.06e-6	White matter integrity;
PAAD	cis	rs10733682	0.659	rs1887970	chr9:129464827	C/T	cg00232160	chr9:129468157	NA	0.57	6.38	0.46	2e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-1.15	-8.98	-0.59	9.61e-16	Obesity-related traits;
PAAD	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.47	4.58	0.35	9.47e-6	Urate levels in obese individuals;
PAAD	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs682748	0.782	rs12187273	chr5:17110554	A/G	cg23987134	chr5:17158319	LOC285696	-0.37	-4.63	-0.35	7.9e-6	Hippocampal atrophy;
PAAD	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.65	7.36	0.51	1.1e-11	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22727109	chr12:32112813	C12orf35	0.67	6.3	0.46	3.02e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg04492929	chr16:2155436	PKD1	-0.67	-6.44	-0.46	1.51e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.64	-6.04	-0.44	1.16e-8	Hip circumference;
PAAD	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg18898632	chr2:242989856	NA	-0.67	-5.2	-0.39	6.31e-7	Obesity-related traits;
PAAD	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg00262122	chr8:11665843	FDFT1	0.5	4.68	0.35	6.42e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.64	-0.47	5.36e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	5.28	0.39	4.31e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.41	-0.4	2.42e-7	Coronary artery disease;
PAAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg23281280	chr6:28129359	ZNF389	0.59	4.56	0.35	1.05e-5	Parkinson's disease;
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg12140854	chr5:148520817	ABLIM3	0.4	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4742903	0.904	rs7029970	chr9:107006565	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.67	0.35	6.44e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs75920871	0.589	rs7941150	chr11:117091821	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.7	-4.27	-0.33	3.45e-5	Subjective well-being;
PAAD	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg23788917	chr6:8435910	SLC35B3	-0.67	-7.29	-0.51	1.58e-11	Motion sickness;
PAAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.6	-0.35	8.75e-6	Asthma;
PAAD	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg19313758	chr11:64889193	FAU;MRPL49	0.45	4.49	0.34	1.41e-5	Eosinophil percentage of white cells;
PAAD	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg10705379	chr10:99080932	FRAT1	-0.44	-5.15	-0.39	8e-7	Monocyte count;
PAAD	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.53	5.96	0.44	1.71e-8	Major depressive disorder;
PAAD	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.86	0.43	2.74e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.45	-0.46	1.44e-9	Monocyte count;
PAAD	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.43	-4.68	-0.35	6.31e-6	Platelet count;
PAAD	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.92	-6.75	-0.48	2.87e-10	Opioid sensitivity;
PAAD	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-5.64	-0.42	8.06e-8	Lymphocyte counts;
PAAD	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.96	12.42	0.71	6.88e-25	Menopause (age at onset);
PAAD	cis	rs3736485	0.934	rs4143724	chr15:51870413	T/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.28	-0.33	3.35e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg15816464	chr17:2026533	SMG6	0.52	5.73	0.42	5.14e-8	Total body bone mineral density;
PAAD	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-0.89	-8.8	-0.58	2.77e-15	Exhaled nitric oxide output;
PAAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.93	9.75	0.62	9.75e-18	Cognitive function;
PAAD	cis	rs1012068	0.686	rs5998176	chr22:32318093	G/A	cg01338084	chr22:32026380	PISD	0.55	4.93	0.37	2.17e-6	Chronic hepatitis C infection;
PAAD	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.42	-0.34	1.85e-5	Testicular germ cell tumor;
PAAD	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Systemic lupus erythematosus;
PAAD	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.63	5.77	0.42	4.33e-8	Platelet count;
PAAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.04	0.44	1.12e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.44e-19	Menopause (age at onset);
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg24213567	chr19:53496664	ZNF702P	-0.48	-5.04	-0.38	1.32e-6	Psoriasis;
PAAD	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.82	12.62	0.72	2.01e-25	Coronary artery disease;
PAAD	cis	rs11771526	0.681	rs11767011	chr7:32420648	G/A	cg27511599	chr7:32358540	NA	0.91	4.78	0.36	4.03e-6	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18024801	chr6:24403143	MRS2	0.65	7.19	0.5	2.81e-11	Myopia (pathological);
PAAD	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg07025548	chr5:74632477	HMGCR	-0.57	-4.29	-0.33	3.16e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.49e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg12400702	chr3:12838781	CAND2	-0.35	-4.3	-0.33	3.02e-5	QRS complex (12-leadsum);
PAAD	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.65	6.46	0.46	1.37e-9	Coronary artery disease;
PAAD	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.08	0.5	4.97e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.37	4.33	0.33	2.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg17347104	chr14:75034677	LTBP2	-0.49	-4.94	-0.37	2.03e-6	Caffeine consumption;
PAAD	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.48	-0.52	5.45e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16056964	chr11:74430117	CHRDL2	-0.65	-7.08	-0.5	4.88e-11	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26859392	chr3:10143019	FANCD2;C3orf24	-0.54	-6.43	-0.46	1.54e-9	Monocyte percentage of white cells;
PAAD	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg25547332	chr5:131281432	NA	0.54	4.33	0.33	2.72e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.72	7.02	0.49	6.88e-11	Blood metabolite levels;
PAAD	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.82	-5.2	-0.39	6.45e-7	Tuberculosis;
PAAD	cis	rs793571	0.784	rs8029301	chr15:59121836	C/T	cg05156742	chr15:59063176	FAM63B	0.6	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg08807101	chr21:30365312	RNF160	-0.66	-5.17	-0.39	7.23e-7	Cognitive test performance;
PAAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.59	0.47	6.77e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs16910800	1.000	rs2468649	chr11:23200963	T/C	cg20040320	chr11:23191996	NA	0.58	4.88	0.37	2.65e-6	Cancer;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.36	4.28	0.33	3.26e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg05341575	chr12:125625032	AACS	-0.55	-5.12	-0.38	8.96e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.43	-5.08	-0.38	1.1e-6	Uric acid levels;
PAAD	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.04	12.15	0.7	3.56e-24	Schizophrenia;
PAAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg16205897	chr5:131564050	P4HA2	-0.49	-5.43	-0.4	2.15e-7	Blood metabolite levels;
PAAD	cis	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg24110177	chr3:50126178	RBM5	-0.68	-7.41	-0.51	8.39e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.63	-0.35	7.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.64	-8.19	-0.55	9.72e-14	Body mass index;
PAAD	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg17347104	chr14:75034677	LTBP2	-0.45	-4.48	-0.34	1.45e-5	Caffeine consumption;
PAAD	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14169450	chr9:139327907	INPP5E	0.57	4.99	0.38	1.64e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg05042697	chr2:10830656	NOL10	0.44	4.47	0.34	1.54e-5	Prostate cancer;
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg04257695	chr17:30186438	C17orf79	-0.6	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.75	8.19	0.55	9.91e-14	Lung cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18018530	chr2:31558544	XDH	0.57	6.49	0.47	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.65	-7.23	-0.51	2.17e-11	Platelet distribution width;
PAAD	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.2	0.55	9.62e-14	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.74	8.0	0.54	2.92e-13	Lewy body disease;
PAAD	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.65	7.44	0.52	6.77e-12	Dupuytren's disease;
PAAD	cis	rs7818688	0.674	rs74632106	chr8:95978032	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg06569542	chr10:98946673	SLIT1	-0.46	-5.13	-0.38	8.7e-7	Monocyte count;
PAAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.58	-5.3	-0.39	4.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.59	5.81	0.43	3.61e-8	Asthma;
PAAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1468734	1.000	rs36106459	chr16:5003509	C/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg15997130	chr1:24165203	NA	0.59	6.2	0.45	5.14e-9	Immature fraction of reticulocytes;
PAAD	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg10356904	chr22:49881777	NA	-0.48	-4.79	-0.36	3.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs227833	0.826	rs227854	chr6:44701035	C/T	cg20913747	chr6:44695427	NA	-0.51	-5.44	-0.4	2.13e-7	Monobrow;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19429466	chr4:87515395	PTPN13	0.56	6.39	0.46	1.9e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.7	5.37	0.4	2.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.4	4.29	0.33	3.13e-5	Life satisfaction;
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.55	5.67	0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.53	6.1	0.44	8.51e-9	Coronary artery disease;
PAAD	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg00495681	chr13:53174319	NA	0.94	11.39	0.68	4.13e-22	Lewy body disease;
PAAD	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.8	8.15	0.55	1.26e-13	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24170415	chr4:185747632	ACSL1	0.59	6.54	0.47	8.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg07168214	chr17:7380112	ZBTB4	-0.69	-6.03	-0.44	1.2e-8	Androgen levels;
PAAD	cis	rs4234284	0.931	rs35011618	chr3:126955627	A/G	cg27326032	chr3:127006922	NA	-0.52	-5.22	-0.39	5.71e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20225246	chr19:2200020	DOT1L	0.62	7.6	0.52	2.76e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.28	0.33	3.27e-5	Self-reported allergy;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg07617317	chr6:118971624	C6orf204	0.55	4.55	0.35	1.1e-5	Diastolic blood pressure;
PAAD	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.84	9.57	0.61	2.84e-17	Metabolic syndrome;
PAAD	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg15017067	chr4:17643749	FAM184B	0.43	4.72	0.36	5.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.32	-0.4	3.58e-7	Aortic root size;
PAAD	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.46	4.3	0.33	3.07e-5	Endometrial cancer;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.6	6.65	0.47	4.93e-10	Longevity;Endometriosis;
PAAD	cis	rs12327666	0.522	rs10414674	chr19:14132662	G/C	cg09538921	chr19:14142201	IL27RA	-0.73	-5.23	-0.39	5.41e-7	Obesity-related traits;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg27094323	chr7:1216898	NA	-0.51	-5.9	-0.43	2.28e-8	Longevity;Endometriosis;
PAAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.92	9.1	0.59	4.72e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg03213289	chr20:61660250	NA	-0.55	-8.03	-0.55	2.48e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs72681920	0.881	rs35882815	chr4:100062338	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-4.44	-0.34	1.72e-5	Alcohol dependence;
PAAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg19912559	chr1:40204330	PPIE	0.5	4.78	0.36	4.15e-6	Blood protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13664964	chr2:43454185	ZFP36L2;LOC100129726	-0.75	-6.56	-0.47	7.96e-10	Neuroticism;
PAAD	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26698664	chr6:149285835	UST	0.57	6.29	0.45	3.28e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-4.39	-0.34	2.12e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	4.65	0.35	7.17e-6	Prostate-specific antigen levels;
PAAD	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg13866156	chr1:1669148	SLC35E2	-0.79	-9.06	-0.59	6.16e-16	Body mass index;
PAAD	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-6.88	-0.49	1.48e-10	Morning vs. evening chronotype;
PAAD	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.08	-0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs6723108	0.603	rs10166142	chr2:135710322	A/G	cg26890182	chr2:135621176	ACMSD	0.3	4.27	0.33	3.4e-5	Type 2 diabetes;
PAAD	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg23024343	chr7:107201750	COG5	0.54	4.33	0.33	2.72e-5	Osteoarthritis;
PAAD	cis	rs2899832	0.789	rs28470932	chr14:35751843	A/G	cg09327582	chr14:35236912	BAZ1A	0.58	4.64	0.35	7.63e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	9.27	0.6	1.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.13	-0.38	8.81e-7	Subjective well-being;
PAAD	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-5.34	-0.4	3.37e-7	Schizophrenia;
PAAD	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.73	8.21	0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.1	0.5	4.51e-11	Renal function-related traits (BUN);
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs7192380	0.651	rs9940548	chr16:69624095	T/A	cg05250797	chr16:70222502	NA	0.65	5.72	0.42	5.43e-8	Sjögren's syndrome;
PAAD	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.16	0.5	3.15e-11	Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.97	-5.2	-0.39	6.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.87	7.71	0.53	1.55e-12	Migraine;Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24539500	chr6:102115051	GRIK2	-0.58	-6.51	-0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg27094323	chr7:1216898	NA	-0.45	-5.27	-0.39	4.52e-7	Longevity;Endometriosis;
PAAD	cis	rs829883	1.000	rs249819	chr12:98897265	T/A	cg25150519	chr12:98850993	NA	0.82	8.76	0.58	3.51e-15	Colorectal adenoma (advanced);
PAAD	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.45	-0.34	1.67e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.54	4.79	0.36	3.9e-6	Lung cancer;
PAAD	cis	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg11619707	chr19:22235551	ZNF257	0.57	5.69	0.42	6.36e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.71	-8.02	-0.55	2.67e-13	Total body bone mineral density;
PAAD	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg21253087	chr9:139290292	SNAPC4	-0.44	-4.56	-0.35	1.03e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.76	-7.45	-0.52	6.67e-12	Coronary artery disease;
PAAD	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.65	4.71	0.36	5.44e-6	Biliary atresia;
PAAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.91	-8.03	-0.55	2.5e-13	Gut microbiome composition (summer);
PAAD	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06307176	chr5:131281290	NA	-0.53	-4.82	-0.36	3.49e-6	Life satisfaction;
PAAD	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.45	-4.99	-0.38	1.62e-6	Pneumonia;
PAAD	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.47	-6.73	-0.48	3.18e-10	Schizophrenia;
PAAD	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs9346353	0.713	rs7771508	chr6:70422443	T/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.93e-5	Sleep duration;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg07559730	chr19:53497048	ZNF702P	-0.5	-5.48	-0.41	1.74e-7	Psoriasis;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1015291	0.708	rs1466686	chr12:19996232	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg22162314	chr17:61951766	CSH2	-0.59	-5.98	-0.44	1.56e-8	Height;
PAAD	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.9	0.43	2.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.03e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	4.34	0.33	2.64e-5	Response to antipsychotic treatment;
PAAD	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.74	7.52	0.52	4.34e-12	Retinal vascular caliber;
PAAD	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg11271282	chr2:238384023	NA	0.7	4.33	0.33	2.66e-5	Prostate cancer;
PAAD	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26876637	chr1:152193138	HRNR	0.85	6.54	0.47	9.03e-10	Atopic dermatitis;
PAAD	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg20435097	chr10:126320824	FAM53B	-0.48	-4.64	-0.35	7.58e-6	Cocaine dependence;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs7873102	0.702	rs7036836	chr9:37972400	A/G	cg03528946	chr9:38069800	SHB	0.56	5.72	0.42	5.39e-8	Brain structure;
PAAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-0.76	-7.02	-0.49	7.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10901513	0.869	rs2366344	chr10:127671692	T/C	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs9810890	1.000	rs73196993	chr3:128456755	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17848531	chr2:182756352	SSFA2	0.6	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg19223190	chr17:80058835	NA	0.53	5.57	0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.57	5.39	0.4	2.62e-7	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22277887	chr6:75994754	TMEM30A	0.67	6.84	0.49	1.78e-10	Smoking initiation;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7742824	0.917	rs12526930	chr6:44104818	C/T	cg21657043	chr6:44035552	NA	0.42	4.45	0.34	1.64e-5	Major depressive disorder;
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.78	-8.27	-0.56	6.26e-14	Prostate cancer;
PAAD	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	4.88	0.37	2.6e-6	Menarche (age at onset);
PAAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg13859433	chr6:33739653	LEMD2	-0.65	-5.09	-0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs732765	0.580	rs113868141	chr14:75233463	A/T	cg17347104	chr14:75034677	LTBP2	0.56	4.29	0.33	3.1e-5	Non-small cell lung cancer;
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg01097406	chr16:89675127	NA	-0.36	-4.36	-0.33	2.41e-5	Vitiligo;
PAAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.7	6.35	0.46	2.4e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-5.03	-0.38	1.36e-6	Bipolar disorder;
PAAD	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg21269045	chr12:125625041	AACS	0.45	4.69	0.36	6.08e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7136716	0.541	rs77093743	chr12:7723212	A/T	cg25757697	chr12:8220002	C3AR1	-0.89	-4.4	-0.34	1.99e-5	Hematological and biochemical traits;
PAAD	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg06287003	chr12:125626642	AACS	-0.47	-4.68	-0.35	6.29e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.73	-8.6	-0.57	8.9e-15	Colorectal cancer;
PAAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.72	-5.96	-0.44	1.68e-8	Coronary artery disease;
PAAD	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.86	0.58	1.98e-15	Vitiligo;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.53	5.14	0.39	8.15e-7	Blood metabolite levels;
PAAD	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.6	0.52	2.8e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg27284194	chr4:1044797	NA	0.5	4.77	0.36	4.28e-6	Obesity-related traits;
PAAD	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.76	-8.01	-0.54	2.73e-13	Type 2 diabetes;
PAAD	cis	rs939584	1.000	rs6719883	chr2:651482	T/G	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg27478167	chr7:817139	HEATR2	0.57	4.57	0.35	1e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1015291	0.708	rs1352905	chr12:19995608	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.56	-6.41	-0.46	1.72e-9	Obesity-related traits;
PAAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg20933634	chr6:27740509	NA	-0.62	-5.99	-0.44	1.46e-8	Parkinson's disease;
PAAD	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.45	-4.45	-0.34	1.64e-5	Depression;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.71	5.15	0.39	7.89e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg14349672	chr11:133703707	NA	-0.45	-4.84	-0.37	3.22e-6	Childhood ear infection;
PAAD	cis	rs4759375	0.667	rs61955088	chr12:123850541	A/G	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.72	-8.24	-0.56	7.31e-14	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06933816	chr16:70698146	MTSS1L	-0.63	-6.61	-0.47	6.02e-10	Monocyte percentage of white cells;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg01097406	chr16:89675127	NA	0.38	4.55	0.35	1.08e-5	Vitiligo;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	7.78e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.78	-8.72	-0.58	4.43e-15	Height;
PAAD	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg26597838	chr10:835615	NA	0.52	5.71	0.42	5.68e-8	Survival in rectal cancer;
PAAD	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.78	7.56	0.52	3.46e-12	Testicular germ cell tumor;
PAAD	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.62	0.35	7.98e-6	Breast cancer;
PAAD	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.69	6.61	0.47	6.22e-10	Lymphocyte counts;
PAAD	cis	rs375066	0.967	rs8104290	chr19:44367338	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.13	0.38	8.54e-7	Breast cancer;
PAAD	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.83	-0.36	3.37e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.61	0.47	6.19e-10	Schizophrenia;
PAAD	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11051970	0.559	rs56670459	chr12:32543325	G/A	cg24626660	chr12:32551988	NA	0.48	4.93	0.37	2.17e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.54	-4.63	-0.35	7.79e-6	Facial morphology (factor 19);
PAAD	cis	rs11658311	1.000	rs897456	chr17:17422608	A/G	cg19346202	chr17:18226511	SMCR8	0.58	4.48	0.34	1.45e-5	Obsessive-compulsive symptoms;
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.05	-0.38	1.26e-6	Longevity;
PAAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-6.96	-0.49	9.37e-11	Gut microbiome composition (summer);
PAAD	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs1499972	0.941	rs55864156	chr3:117664968	C/G	cg07612923	chr3:117604196	NA	1.08	7.2	0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-8.28	-0.56	5.97e-14	Hemoglobin concentration;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs714027	0.605	rs193476	chr22:30450521	G/A	cg01021169	chr22:30184971	ASCC2	0.44	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs6142102	0.625	rs6142062	chr20:32548512	C/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	cis	rs965469	0.724	rs2007022	chr20:3237674	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.54	4.99	0.37	1.66e-6	Resting heart rate;
PAAD	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.56	-0.47	7.86e-10	Total body bone mineral density;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-7.2	-0.5	2.64e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2004318	1.000	rs10425501	chr19:55116352	A/T	cg03320607	chr19:54800032	LILRA3	-0.94	-5.57	-0.41	1.15e-7	Blood protein levels;
PAAD	cis	rs4443100	0.634	rs9612209	chr22:23359454	C/G	cg14186256	chr22:23484241	RTDR1	0.5	4.37	0.33	2.31e-5	Serum parathyroid hormone levels;
PAAD	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.9100000000000004e-06	Daytime sleep phenotypes;
PAAD	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.76	7.34	0.51	1.21e-11	Breast cancer;
PAAD	cis	rs17461620	1.000	rs62573369	chr9:88878971	T/C	cg13456106	chr9:88897068	ISCA1	0.62	4.37	0.33	2.32e-5	Diisocyanate-induced asthma;
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg26554054	chr8:600488	NA	0.87	5.79	0.43	3.91e-8	IgG glycosylation;
PAAD	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-0.72	-5.64	-0.42	8.14e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.63	-4.27	-0.33	3.44e-5	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20888402	chr2:25195556	DNAJC27	-0.7	-6.42	-0.46	1.68e-9	Neuroticism;
PAAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06656553	chr16:89960601	TCF25	-0.79	-4.25	-0.33	3.7e-5	Skin colour saturation;
PAAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg25833597	chr17:30823145	MYO1D	0.53	5.02	0.38	1.43e-6	Schizophrenia;
PAAD	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg20917491	chr3:195578259	NA	0.51	4.79	0.36	3.9e-6	Pancreatic cancer;
PAAD	cis	rs600626	0.578	rs11821808	chr11:75451187	C/T	cg24262691	chr11:75473276	NA	0.71	5.79	0.43	3.92e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	1.96e-13	Melanoma;
PAAD	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.38	0.33	2.2e-5	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg11204139	chr17:3907470	NA	-0.67	-6.82	-0.48	2.01e-10	Type 2 diabetes;
PAAD	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.8	-0.36	3.8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg16512390	chr1:228756714	NA	-0.6	-4.26	-0.33	3.64e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg10251007	chr17:42015891	NA	-0.54	-4.4	-0.34	2.06e-5	Cognitive function;
PAAD	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.48	5.69	0.42	6.3e-8	Educational attainment;
PAAD	cis	rs7627468	0.770	rs12493480	chr3:121962963	G/A	cg17240004	chr3:121949083	CASR	0.5	4.77	0.36	4.33e-6	Kidney stones;
PAAD	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.58	-5.41	-0.4	2.36e-7	Cognitive test performance;
PAAD	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.62	4.47	0.34	1.52e-5	Biliary atresia;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg21518248	chr2:162101506	NA	0.55	5.96	0.44	1.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.9	-0.37	2.45e-6	Schizophrenia;
PAAD	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.69	7.17	0.5	3.1e-11	Colorectal cancer;
PAAD	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-5.72	-0.42	5.43e-8	Obesity (extreme);
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg08057985	chr22:42470123	FAM109B	-0.36	-4.26	-0.33	3.57e-5	Schizophrenia;
PAAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.64	4.79	0.36	3.87e-6	Fat distribution (HIV);
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.81	10.36	0.64	2.36e-19	Vitiligo;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg23708337	chr7:1209742	NA	0.66	4.55	0.35	1.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg09491104	chr22:46646882	C22orf40	-0.92	-5.99	-0.44	1.44e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg24812749	chr6:127587940	RNF146	0.79	9.41	0.61	7.37e-17	Breast cancer;
PAAD	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.52	-4.86	-0.37	2.95e-6	Brugada syndrome;
PAAD	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.94	8.69	0.58	5.46e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.0	-8.6	-0.57	9.31e-15	Vitiligo;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.41	-4.85	-0.37	3.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs528301	0.868	rs570436	chr2:45142673	C/T	cg15393275	chr2:45165193	NA	-0.51	-5.65	-0.42	7.85e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.49	-5.56	-0.41	1.2e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg23018236	chr17:30244563	NA	0.66	5.05	0.38	1.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.7	8.27	0.56	6.4e-14	Eye color traits;
PAAD	cis	rs11051970	1.000	rs6488051	chr12:32532733	G/C	cg24626660	chr12:32551988	NA	0.46	5.29	0.39	4.28e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2034650	0.544	rs8034217	chr15:40721700	C/T	cg05276125	chr15:40653601	DISP2	-0.51	-4.9	-0.37	2.39e-6	Interstitial lung disease;
PAAD	cis	rs1790761	0.505	rs7103713	chr11:67338242	G/A	cg00864171	chr11:67383662	NA	-0.49	-5.1	-0.38	9.99e-7	Mean corpuscular volume;
PAAD	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.35	5.19	0.39	6.54e-7	Educational attainment (years of education);
PAAD	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.84	0.43	3.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs12760731	0.565	rs77024410	chr1:178164121	A/C	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs35968565	chr10:46076196	G/T	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26548001	chr11:116655120	ZNF259	-0.59	-6.84	-0.49	1.86e-10	Monocyte percentage of white cells;
PAAD	cis	rs4321325	0.733	rs13421996	chr2:127934812	G/T	cg11380483	chr2:127933992	NA	0.74	5.58	0.41	1.06e-7	Protein C levels;
PAAD	cis	rs4273100	0.512	rs1355128	chr17:19299144	G/A	cg19949948	chr17:19361230	NA	0.45	4.75	0.36	4.72e-6	Schizophrenia;
PAAD	cis	rs4792901	0.694	rs9907819	chr17:41602865	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.28	-0.33	3.28e-5	Dupuytren's disease;
PAAD	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.16	-0.39	7.52e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg17650747	chr5:1873721	NA	0.46	4.67	0.35	6.62e-6	Cardiovascular disease risk factors;
PAAD	cis	rs4704187	0.687	rs4704197	chr5:74537751	C/T	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.76	0.42	4.51e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs39841	1	rs39841	chr5:96120170	G/A	cg17330273	chr5:96107758	CAST;ERAP1	0.55	5.4	0.4	2.57e-7	Inflammatory skin disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16415121	chr6:88299659	ORC3L;RARS2	0.66	7.19	0.5	2.81e-11	Myopia (pathological);
PAAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg16147221	chr4:10020634	SLC2A9	0.47	4.33	0.33	2.73e-5	Bone mineral density;
PAAD	cis	rs6969780	0.673	rs2301721	chr7:27196113	C/T	cg02486425	chr7:27200959	NA	0.61	4.52	0.34	1.24e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
PAAD	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.56	6.95	0.49	1e-10	Crohn's disease;
PAAD	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg06569542	chr10:98946673	SLIT1	0.45	4.59	0.35	9.05e-6	Monocyte count;
PAAD	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg17749961	chr2:30669863	LCLAT1	0.67	5.11	0.38	9.61e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg12292205	chr6:26970375	C6orf41	-0.55	-5.39	-0.4	2.69e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.38	12.21	0.7	2.47e-24	Uric acid levels;
PAAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.84	-8.51	-0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.59	-8.45	-0.57	2.25e-14	Huntington's disease progression;
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.27	-0.39	4.57e-7	Life satisfaction;
PAAD	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg08079166	chr15:68083412	MAP2K5	0.56	5.33	0.4	3.45e-7	Restless legs syndrome;
PAAD	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-5.88	-0.43	2.55e-8	Coronary artery disease;
PAAD	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-6.29	-0.45	3.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.5	0.47	1.1e-9	Schizophrenia;
PAAD	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.75	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.573	rs10888329	chr1:248404654	C/T	cg01631408	chr1:248437212	OR2T33	0.58	4.97	0.37	1.79e-6	Common traits (Other);
PAAD	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.18	-8.44	-0.56	2.34e-14	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.89e-5	Bipolar disorder;
PAAD	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg14458575	chr2:238380390	NA	0.55	6.22	0.45	4.62e-9	Prostate cancer;
PAAD	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg04315214	chr1:2043799	PRKCZ	0.66	9.29	0.6	1.57e-16	Height;
PAAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.33	0.33	2.65e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg23920097	chr1:209922102	NA	-0.45	-4.35	-0.33	2.46e-5	Red blood cell count;
PAAD	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg09835421	chr16:68378352	PRMT7	-1.18	-8.79	-0.58	2.95e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11718455	0.767	rs13075535	chr3:43954612	G/A	cg00181669	chr3:44000978	NA	-0.46	-4.53	-0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-4.28	-0.33	3.25e-5	Type 2 diabetes;
PAAD	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.85	10.12	0.63	9.92e-19	Blood metabolite ratios;
PAAD	cis	rs2275731	0.749	rs3898395	chr10:16537818	G/T	cg04254609	chr10:16479192	PTER	-0.52	-5.33	-0.4	3.49e-7	Bone fracture in osteoporosis;
PAAD	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.63	6.46	0.46	1.34e-9	Height;
PAAD	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg12310025	chr6:25882481	NA	-0.44	-4.31	-0.33	2.88e-5	Schizophrenia;
PAAD	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg11421182	chr20:36153479	BLCAP	0.53	6.35	0.46	2.32e-9	IgG glycosylation;
PAAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.71	9.96	0.63	2.64e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.51	-4.88	-0.37	2.68e-6	Mortality in heart failure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06792154	chr17:29157990	ATAD5	0.56	6.54	0.47	8.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs58521262	0.556	rs289334	chr19:23152964	C/T	cg03433597	chr19:22806448	NA	0.25	4.41	0.34	1.93e-5	Testicular germ cell tumor;
PAAD	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.64	-0.42	8.24e-8	Schizophrenia;
PAAD	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.62	6.42	0.46	1.66e-9	Kawasaki disease;
PAAD	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.69	6.64	0.47	5.32e-10	Obesity-related traits;
PAAD	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg14146966	chr2:61757674	XPO1	0.44	5.39	0.4	2.66e-7	Tuberculosis;
PAAD	cis	rs10851411	0.559	rs62019322	chr15:42897374	T/C	cg21293051	chr15:42870591	STARD9	0.59	4.72	0.36	5.32e-6	Glucose homeostasis traits;
PAAD	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09597638	chr17:3907349	NA	0.73	7.73	0.53	1.4e-12	Type 2 diabetes;
PAAD	cis	rs990171	0.913	rs2241117	chr2:103003043	T/C	cg03938978	chr2:103052716	IL18RAP	0.44	4.37	0.33	2.31e-5	Lymphocyte counts;
PAAD	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	6.33	0.46	2.61e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.44	-4.63	-0.35	7.74e-6	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.82	9.63	0.62	2.01e-17	Blood metabolite ratios;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27015207	chr6:150067738	NUP43	-0.69	-6.64	-0.47	5.25e-10	Neuroticism;
PAAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.38	0.33	2.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg11995313	chr8:8860691	ERI1	0.48	4.72	0.36	5.31e-6	Joint mobility (Beighton score);
PAAD	cis	rs9815354	1.000	rs2683696	chr3:41914898	T/C	cg03022575	chr3:42003672	ULK4	0.83	6.04	0.44	1.16e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11264799	0.603	rs12755544	chr1:157553017	C/T	cg18268488	chr1:157545234	FCRL4	0.46	5.3	0.39	4.06e-7	IgA nephropathy;
PAAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg21929781	chr1:2537748	MMEL1	0.45	4.71	0.36	5.44e-6	Ulcerative colitis;
PAAD	cis	rs9810890	1.000	rs73198819	chr3:128475662	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg15890332	chr12:107067104	RFX4	0.41	4.35	0.33	2.46e-5	Total body bone mineral density;
PAAD	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg14092988	chr3:52407081	DNAH1	0.43	5.19	0.39	6.64e-7	Bipolar disorder;
PAAD	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg27478167	chr7:817139	HEATR2	0.72	5.57	0.41	1.11e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09101235	chr7:148480326	CUL1	0.48	4.73	0.36	5.04e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.5	5.03	0.38	1.36e-6	Schizophrenia;
PAAD	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg01631684	chr10:65280961	REEP3	-0.44	-4.4	-0.34	2e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	2.04e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.51	-0.34	1.3e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.68	-0.42	6.65e-8	Mean corpuscular volume;
PAAD	cis	rs11811982	0.793	rs74688907	chr1:227568238	T/C	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.75	7.27	0.51	1.73e-11	Corneal astigmatism;
PAAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg03037974	chr15:76606532	NA	0.53	6.19	0.45	5.27e-9	Blood metabolite levels;
PAAD	cis	rs6256	0.860	rs113194319	chr11:13567042	T/C	cg11976911	chr11:13509032	NA	-0.67	-5.18	-0.39	7.06e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg09582351	chr12:29534625	ERGIC2	0.36	4.94	0.37	2.01e-6	QT interval;
PAAD	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.73	-0.48	3.23e-10	Total body bone mineral density;
PAAD	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg15145296	chr3:125709740	NA	-0.62	-4.4	-0.34	2.05e-5	Blood pressure (smoking interaction);
PAAD	cis	rs6076065	0.692	rs6083092	chr20:23348836	T/C	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	7.79e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-1.09	-14.55	-0.76	1.33e-30	Headache;
PAAD	cis	rs614367	0.818	rs661204	chr11:69330983	G/A	cg08353955	chr11:69289746	NA	-1.04	-6.13	-0.45	7.29e-9	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	6.29	0.45	3.26e-9	Mean platelet volume;
PAAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg11843238	chr5:131593191	PDLIM4	0.51	4.63	0.35	7.9e-6	Acylcarnitine levels;
PAAD	trans	rs9929218	0.817	rs3118234	chr16:68702077	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.19	-0.5	2.67e-11	Colorectal cancer;
PAAD	cis	rs56046484	0.956	rs16974820	chr15:85627306	C/A	cg08123816	chr15:85640762	PDE8A	-0.44	-4.59	-0.35	9.31e-6	Testicular germ cell tumor;
PAAD	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.71	-0.36	5.65e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11711311	0.824	rs35089588	chr3:113352580	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.35	0.46	2.33e-9	IgG glycosylation;
PAAD	cis	rs372883	0.530	rs55921835	chr21:30544623	A/G	cg24692254	chr21:30365293	RNF160	-0.51	-4.7	-0.36	5.89e-6	Pancreatic cancer;
PAAD	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.61	6.54	0.47	8.86e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.15	-0.39	8.06e-7	Asthma;
PAAD	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.52	4.76	0.36	4.48e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-4.39	-0.34	2.13e-5	Multiple sclerosis;
PAAD	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.43	0.4	2.24e-7	Total body bone mineral density;
PAAD	cis	rs795544	0.608	rs1502048	chr5:13788282	C/T	cg07548982	chr5:13769939	DNAH5	0.49	4.27	0.33	3.47e-5	Corneal astigmatism;
PAAD	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-4.69	-0.36	6.01e-6	Monocyte percentage of white cells;
PAAD	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.4	3.92e-7	Male-pattern baldness;
PAAD	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.29e-8	Menopause (age at onset);
PAAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	5.01	0.38	1.5e-6	Menarche (age at onset);
PAAD	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg00280220	chr17:61926910	NA	0.44	4.51	0.34	1.3e-5	Prudent dietary pattern;
PAAD	cis	rs859767	0.741	rs11898084	chr2:135428054	T/C	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.77	0.48	2.69e-10	Leprosy;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-6.13	-0.45	7.29e-9	Prudent dietary pattern;
PAAD	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg07701084	chr6:150067640	NUP43	0.73	7.54	0.52	3.9e-12	Lung cancer;
PAAD	cis	rs12042052	0.590	rs2357332	chr1:232948252	C/T	cg02903907	chr1:232941055	KIAA1383	-0.81	-4.42	-0.34	1.89e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-4.57	-0.35	1.02e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6669119	1.000	rs79433889	chr1:19111355	T/G	cg19637330	chr1:19110922	NA	0.81	5.09	0.38	1.03e-6	Percentage gas trapping;
PAAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3925075	0.525	rs929868	chr16:31280282	G/A	cg02846316	chr16:31340340	ITGAM	0.49	5.84	0.43	2.98e-8	IgA nephropathy;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.64	-6.29	-0.45	3.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs35993099	1	rs35993099	chr10:46006967	T/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell count;Mean corpuscular hemoglobin;
PAAD	cis	rs10121009	0.635	rs580376	chr9:35313141	A/G	cg11846315	chr9:35647073	NA	0.51	4.73	0.36	4.99e-6	Parkinson's disease;
PAAD	cis	rs62045844	0.510	rs7201122	chr16:89167140	G/C	cg26950739	chr16:89183275	ACSF3	0.66	4.31	0.33	2.94e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs61931739	0.649	rs815028	chr12:33718591	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.42	0.52	7.77e-12	Morning vs. evening chronotype;
PAAD	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.65	-5.98	-0.44	1.52e-8	QRS duration;
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	0.93	6.3	0.46	3e-9	IgG glycosylation;
PAAD	cis	rs11966931	1.000	rs6920062	chr6:108108201	A/T	cg13784235	chr6:108495865	NR2E1	-0.34	-4.3	-0.33	3.07e-5	Neutrophil percentage of white cells;
PAAD	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.67	-6.09	-0.44	9.05e-9	Mean corpuscular volume;
PAAD	cis	rs2880058	0.958	rs4657139	chr1:162029907	A/T	cg23260004	chr1:161736072	ATF6	0.49	4.43	0.34	1.77e-5	QT interval;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01629744	chr7:116758099	ST7OT2;ST7	0.6	6.36	0.46	2.19e-9	Smoking initiation;
PAAD	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.5	5.45	0.4	1.96e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.8	6.57	0.47	7.74e-10	Monocyte percentage of white cells;
PAAD	cis	rs3026101	0.671	rs62072674	chr17:5317806	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.74	8.63	0.57	7.45e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.86	6.81	0.48	2.09e-10	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.61	6.28	0.45	3.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg00590817	chr1:8272081	NA	-0.39	-4.83	-0.36	3.3e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg11764359	chr7:65958608	NA	-0.67	-7.0	-0.49	7.65e-11	Calcium levels;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.46	-4.67	-0.35	6.63e-6	Vitiligo;
PAAD	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.94	-0.37	2.06e-6	Testicular germ cell tumor;
PAAD	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.21e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs12144344	0.708	rs2392030	chr1:76784636	C/T	cg25198894	chr1:77685135	PIGK	0.48	4.79	0.36	4.01e-6	Serum vitamin D-binding protein levels;
PAAD	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.67	6.38	0.46	2.06e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.8	6.22	0.45	4.53e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	5.82	0.43	3.32e-8	Mood instability;
PAAD	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg24220031	chr2:73402428	NA	-0.42	-6.28	-0.45	3.32e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03328750	chr5:142150401	ARHGAP26	-0.59	-6.49	-0.47	1.17e-9	Immature fraction of reticulocytes;
PAAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.2	0.39	6.28e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.56	-5.43	-0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00684032	chr4:1343700	KIAA1530	0.43	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	6.45	0.46	1.43e-9	Menarche (age at onset);
PAAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg09945482	chr18:12777974	NA	0.6	5.21	0.39	6e-7	Inflammatory skin disease;
PAAD	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.8	-0.66	1.51e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.18	0.45	5.65e-9	Height;
PAAD	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17266958	0.711	rs62572814	chr9:83198655	G/A	cg13911576	chr9:84174038	NA	0.92	4.62	0.35	8.12e-6	Preschool internalizing problems;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg15331088	chr8:600555	NA	0.71	4.48	0.34	1.45e-5	IgG glycosylation;
PAAD	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.6	7.29	0.51	1.61e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.6	-6.0	-0.44	1.38e-8	Primary sclerosing cholangitis;
PAAD	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg21145140	chr5:110409467	TSLP	0.44	4.27	0.33	3.37e-5	Eosinophilic esophagitis;
PAAD	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg15676125	chr6:33679581	C6orf125	0.49	4.84	0.37	3.17e-6	Plateletcrit;
PAAD	cis	rs1891275	0.551	rs2421625	chr10:93416501	C/T	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.11	-0.59	4.43e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg12072164	chr19:44306565	LYPD5	0.6	6.53	0.47	9.23e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.4	-6.21	-0.45	4.72e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-7.48	-0.52	5.58e-12	Cognitive function;
PAAD	trans	rs2982694	0.614	rs932479	chr6:152288037	C/T	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.36	-0.46	2.27e-9	Sudden cardiac arrest;
PAAD	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg07636037	chr3:49044803	WDR6	0.57	4.56	0.35	1.03e-5	Menarche (age at onset);
PAAD	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.84	10.35	0.64	2.41e-19	Dental caries;
PAAD	cis	rs74544699	1.000	rs149611	chr4:74780396	C/A	cg16072462	chr4:74847758	PF4	1.19	4.61	0.35	8.31e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg08992911	chr2:238395768	MLPH	-0.59	-5.37	-0.4	2.87e-7	Prostate cancer;
PAAD	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.4	0.61	7.97e-17	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-6.0	-0.44	1.36e-8	Lung cancer;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg00522288	chr12:125625016	AACS	-0.53	-5.51	-0.41	1.47e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.4	0.46	1.81e-9	Bladder cancer;
PAAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-0.92	-9.02	-0.59	7.59e-16	Exhaled nitric oxide output;
PAAD	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.39	-0.34	2.11e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.88	7.09	0.5	4.74e-11	Axial length;
PAAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.62	0.57	8.31e-15	Hip circumference adjusted for BMI;
PAAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs1642645	0.566	rs1325504	chr1:42400931	A/T	cg01990334	chr1:42801334	FOXJ3	-0.67	-5.63	-0.42	8.29e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16560861	chr14:23771758	PPP1R3E	-0.77	-6.57	-0.47	7.66e-10	Neuroticism;
PAAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.57	5.28	0.39	4.44e-7	Schizophrenia;
PAAD	cis	rs3106136	0.739	rs6840409	chr4:95283088	A/G	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.74	-5.44	-0.4	2.08e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.44	5.65	0.42	7.78e-8	Panic disorder;
PAAD	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.37	-0.33	2.32e-5	Height;
PAAD	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg25401027	chr5:176370377	UIMC1	0.55	5.35	0.4	3.16e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.87	-8.02	-0.55	2.65e-13	Colorectal adenoma (advanced);
PAAD	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg04415270	chr2:102091202	RFX8	-0.58	-7.41	-0.52	8.05e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4692589	0.556	rs13133562	chr4:170965709	C/T	cg19918862	chr4:170955249	NA	0.5	4.44	0.34	1.71e-5	Anxiety disorder;
PAAD	cis	rs78707713	0.841	rs13377102	chr10:71213386	T/A	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg10018233	chr7:150070692	REPIN1	0.66	7.43	0.52	7.22e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7173419	0.607	rs34058589	chr15:28221982	C/T	cg20906524	chr15:28200668	OCA2	-0.46	-5.43	-0.4	2.16e-7	Eye color;
PAAD	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15534212	chr5:173209194	NA	-0.56	-6.33	-0.46	2.67e-9	Body fat percentage;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	8.9	0.59	1.54e-15	Lymphocyte counts;
PAAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.56	6.35	0.46	2.37e-9	Mean corpuscular volume;
PAAD	cis	rs10274279	0.614	rs12669550	chr7:157403743	G/A	cg09270525	chr7:157391030	PTPRN2	0.68	4.95	0.37	1.97e-6	Myopia (pathological);
PAAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09695851	chr17:3907499	NA	0.6	6.24	0.45	4.12e-9	Type 2 diabetes;
PAAD	cis	rs7219021	0.961	rs7215901	chr17:46858083	A/C	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.63	-0.35	7.65e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	8.98	0.59	9.75e-16	Cognitive test performance;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-1.19	-9.7	-0.62	1.26e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.9	-6.23	-0.45	4.34e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	6.61	0.47	6.02e-10	Retinal vascular caliber;
PAAD	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-4.27	-0.33	3.44e-5	Triglycerides;
PAAD	cis	rs7631605	0.905	rs11712979	chr3:37195495	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.29e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.66	7.32	0.51	1.37e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19545258	chr7:73703601	CLIP2	0.62	6.47	0.46	1.26e-9	Myopia (pathological);
PAAD	trans	rs11794666	0.929	rs72719226	chr9:31785994	G/A	cg05628366	chr6:35744188	C6orf126	1.16	7.73	0.53	1.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.6	7.18	0.5	2.9100000000000002e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg22532475	chr10:104410764	TRIM8	-0.46	-4.99	-0.38	1.63e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.4	0.34	2.01e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.63	7.2	0.5	2.66e-11	Coronary artery disease;
PAAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05025164	chr4:1340916	KIAA1530	0.64	6.25	0.45	3.99e-9	Obesity-related traits;
PAAD	cis	rs2278796	0.639	rs6661266	chr1:204971452	C/T	cg17947172	chr1:204966197	NFASC	-0.45	-4.83	-0.36	3.37e-6	Mean platelet volume;
PAAD	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.11	0.38	9.52e-7	Lung cancer in ever smokers;
PAAD	cis	rs11037575	0.739	rs7106967	chr11:43713989	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.24	-0.39	5.39e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.88	-11.08	-0.67	2.77e-21	Heart rate;
PAAD	trans	rs2982694	0.764	rs63741360	chr6:152287143	G/C	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14215459	chr19:10764813	ILF3;LOC147727	-0.65	-7.06	-0.5	5.48e-11	Smoking initiation;
PAAD	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg12661370	chr5:149340060	SLC26A2	0.59	5.03	0.38	1.4e-6	HIV-1 control;
PAAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.94	8.48	0.57	1.83e-14	Gut microbiome composition (summer);
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg09737314	chr17:6899359	ALOX12	0.55	6.02	0.44	1.26e-8	Blood metabolite levels;
PAAD	cis	rs1997066	0.831	rs73340214	chr10:106808469	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.82	6.82	0.48	2.03e-10	Pulmonary function decline;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11197563	chr11:129872003	NCRNA00167;PRDM10	-0.62	-6.37	-0.46	2.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.75	-7.84	-0.54	7.47e-13	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs4748857	0.947	rs12413144	chr10:23575249	G/C	cg18853376	chr10:23633759	C10orf67	0.51	4.55	0.35	1.08e-5	Systemic lupus erythematosus;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.37	0.4	2.96e-7	Lung function (FEV1/FVC);
PAAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.74	0.48	3.03e-10	Rheumatoid arthritis;
PAAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.69	6.13	0.45	7.06e-9	Radiation response;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13047869	chr3:10149882	C3orf24	0.89	7.32	0.51	1.34e-11	Alzheimer's disease;
PAAD	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.87	-9.41	-0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	4.67	0.35	6.54e-6	Lung cancer in ever smokers;
PAAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.51	4.85	0.37	3.03e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.9100000000000004e-06	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.556	rs290579	chr19:23221067	T/C	cg02350677	chr19:23254381	NA	0.25	4.56	0.35	1.03e-5	Testicular germ cell tumor;
PAAD	cis	rs7873102	0.702	rs10814634	chr9:37964848	A/G	cg03528946	chr9:38069800	SHB	0.54	5.57	0.41	1.12e-7	Brain structure;
PAAD	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.56	-5.37	-0.4	2.94e-7	Platelet count;
PAAD	cis	rs7243821	1.000	rs11661666	chr18:52642958	G/C	cg16669619	chr18:52630472	NA	-0.44	-4.49	-0.34	1.38e-5	Chin dimples;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27309920	chr12:6798957	ZNF384	0.59	6.45	0.46	1.38e-9	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg02493740	chr2:85810744	VAMP5	-0.41	-4.38	-0.34	2.16e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16240424	chr2:131851392	FAM168B	0.64	6.6	0.47	6.43e-10	Obesity-related traits;
PAAD	cis	rs8013055	0.796	rs28733392	chr14:105993258	G/A	cg19700328	chr14:106028568	NA	-0.61	-5.38	-0.4	2.75e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg04106633	chr4:1044584	NA	-0.63	-5.3	-0.4	3.99e-7	Recombination rate (females);
PAAD	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.82	8.94	0.59	1.2e-15	Height;
PAAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.49	4.94	0.37	2.07e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.77	7.89	0.54	5.45e-13	Obesity-related traits;
PAAD	cis	rs2117029	0.521	rs6580702	chr12:49563266	A/G	cg05368762	chr12:50135785	TMBIM6	0.42	4.3	0.33	3.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11864453	0.682	rs10852509	chr16:72026010	G/A	cg16558253	chr16:72132732	DHX38	-0.46	-4.7	-0.36	5.68e-6	Fibrinogen levels;
PAAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.77	8.56	0.57	1.17e-14	Mood instability;
PAAD	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg01064725	chr1:204461714	NA	-0.46	-4.3	-0.33	3e-5	Schizophrenia;
PAAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.63	-4.45	-0.34	1.66e-5	Depression;
PAAD	cis	rs6137287	0.889	rs6047271	chr20:21126194	C/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.46	0.34	1.56e-5	Height;
PAAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg09399716	chr2:46890238	NA	-0.52	-4.39	-0.34	2.13e-5	Height;
PAAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.73	7.29	0.51	1.55e-11	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs992157	0.764	rs3731861	chr2:219191256	T/C	cg00012203	chr2:219082015	ARPC2	-0.61	-5.78	-0.42	4.11e-8	Colorectal cancer;
PAAD	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg24747557	chr10:131355152	MGMT	0.45	4.55	0.35	1.08e-5	Response to temozolomide;
PAAD	cis	rs3736485	0.966	rs4775958	chr15:51891562	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1419980	0.730	rs7303716	chr12:7736799	A/G	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg06766960	chr11:133703094	NA	-0.74	-8.36	-0.56	3.7e-14	Childhood ear infection;
PAAD	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.49	-5.57	-0.41	1.14e-7	Coronary artery disease;
PAAD	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	1.1	10.71	0.66	2.66e-20	Red cell distribution width;
PAAD	cis	rs1032355	0.643	rs1491237	chr4:100538423	A/G	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg02917321	chr22:38215204	NA	-0.47	-5.12	-0.38	9.27e-7	Glioblastoma;Glioma;
PAAD	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.77	9.15	0.6	3.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.86	5.81	0.43	3.46e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07077115	chr13:28024429	MTIF3	0.68	7.63	0.53	2.37e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22442454	chr1:209979470	IRF6	0.59	5.52	0.41	1.41e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12311304	0.966	rs7310253	chr12:15381237	G/A	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.72e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs12431939	0.947	rs68164178	chr14:51679003	A/C	cg23942311	chr14:51606299	NA	-0.66	-5.19	-0.39	6.64e-7	Cancer;
PAAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.78	-7.76	-0.53	1.16e-12	Urate levels in lean individuals;
PAAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg04106633	chr4:1044584	NA	0.68	5.79	0.42	3.94e-8	Recombination rate (females);
PAAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg27121462	chr16:89883253	FANCA	0.85	4.27	0.33	3.38e-5	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-4.69	-0.36	6.01e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7714584	1.000	rs11746807	chr5:150300419	G/A	cg22134413	chr5:150180641	NA	0.98	6.63	0.47	5.43e-10	Crohn's disease;
PAAD	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.61	-5.86	-0.43	2.77e-8	Blood protein levels;
PAAD	cis	rs11264799	0.636	rs6696922	chr1:157491322	G/A	cg18268488	chr1:157545234	FCRL4	-0.5	-4.37	-0.33	2.26e-5	IgA nephropathy;
PAAD	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.64	6.55	0.47	8.37e-10	Hemoglobin concentration;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13626639	chr7:155917038	NA	-0.49	-6.82	-0.48	1.99e-10	Body fat percentage;
PAAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg07099767	chr17:78039528	CCDC40	-0.48	-4.56	-0.35	1.05e-5	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs7187994	0.848	rs16974532	chr16:84783310	G/A	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.64	-5.46	-0.4	1.94e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.69	-5.5	-0.41	1.55e-7	HIV-1 control;
PAAD	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg10495392	chr1:46806563	NSUN4	0.55	5.47	0.41	1.81e-7	Menopause (age at onset);
PAAD	cis	rs6191	0.935	rs258747	chr5:142656813	A/G	cg08845721	chr5:142780693	NR3C1	0.39	4.25	0.33	3.68e-5	Night sleep phenotypes;
PAAD	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs874628	0.576	rs72999466	chr19:18248499	C/T	cg02814054	chr19:18234911	MAST3	0.44	4.36	0.33	2.4e-5	Multiple sclerosis;
PAAD	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-0.95	-5.92	-0.43	2.09e-8	Alzheimer's disease (late onset);
PAAD	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.75	8.7	0.58	5.01e-15	Blood metabolite ratios;
PAAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.79	-8.33	-0.56	4.29e-14	Menarche (age at onset);
PAAD	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.32	-0.33	2.76e-5	Joint mobility (Beighton score);
PAAD	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.59	0.47	6.88e-10	Schizophrenia;
PAAD	cis	rs10992471	0.580	rs724102	chr9:95383290	T/C	cg14631576	chr9:95140430	CENPP	-0.5	-4.73	-0.36	5.07e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.37	4.83	0.36	3.35e-6	Calcium levels;
PAAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg14683738	chr19:37701593	ZNF585B	0.63	4.41	0.34	1.96e-5	Coronary artery calcification;
PAAD	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.17	0.45	5.92e-9	Personality dimensions;
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg00080972	chr5:178986291	RUFY1	0.51	4.82	0.36	3.39e-6	Lung cancer;
PAAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.89	6.12	0.44	7.77e-9	Thyroid stimulating hormone;
PAAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.93	0.49	1.15e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs3749237	1.000	rs9819511	chr3:49884261	C/T	cg02487422	chr3:49467188	NICN1	0.51	5.0	0.38	1.55e-6	Resting heart rate;
PAAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg05874882	chr4:1763078	NA	0.36	5.06	0.38	1.22e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.97	7.85	0.54	6.87e-13	Vitiligo;
PAAD	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.75	5.25	0.39	4.98e-7	Phospholipid levels (plasma);
PAAD	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.62	-0.35	8.16e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	1.0	8.2	0.55	9.56e-14	Left atrial antero-posterior diameter;
PAAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.75	-8.04	-0.55	2.41e-13	DNA methylation (variation);
PAAD	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs300774	0.925	rs375613	chr2:130618	C/G	cg23649280	chr2:140451	NA	0.46	4.28	0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs735539	0.521	rs9552280	chr13:21365361	T/A	cg27234864	chr13:21295941	IL17D	0.56	4.6	0.35	8.68e-6	Dental caries;
PAAD	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg15193198	chr20:60906057	LAMA5	-0.53	-6.22	-0.45	4.62e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2249694	1.000	rs8192781	chr10:135354251	T/G	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs7187994	0.672	rs7186685	chr16:84798781	T/C	cg07647771	chr16:84786436	USP10	-0.35	-4.26	-0.33	3.62e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.98	-5.2	-0.39	6.24e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs1035491	0.715	rs3846479	chr5:63922013	C/T	cg01791865	chr5:63954708	NA	0.52	5.59	0.41	1.04e-7	Body mass index;
PAAD	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.34	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs75920871	0.920	rs7128071	chr11:116968798	G/A	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg14500798	chr7:98100126	NA	0.42	4.27	0.33	3.4e-5	Breast cancer;
PAAD	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg13468214	chr4:1046988	NA	-0.52	-4.96	-0.37	1.9e-6	Recombination rate (females);
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.46	7.48	0.52	5.54e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.63	6.08	0.44	9.45e-9	Corneal astigmatism;
PAAD	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.84	-8.32	-0.56	4.81e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs655641	0.520	rs565719	chr11:85795524	T/C	cg07180834	chr11:85838833	NA	-0.47	-4.98	-0.37	1.75e-6	Platelet count;
PAAD	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.58	4.73	0.36	4.99e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6024905	0.722	rs2275954	chr20:36962667	C/T	cg07053727	chr20:36965646	BPI	-0.55	-6.46	-0.46	1.37e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15431576	chr10:99393007	MORN4	-0.56	-6.91	-0.49	1.24e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19919350	chr5:140070909	HARS;HARS2	-0.77	-6.69	-0.48	4.06e-10	Neuroticism;
PAAD	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	4.44	0.34	1.76e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.6	6.36	0.46	2.27e-9	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	1.18	13.24	0.73	4.29e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.15	-16.03	-0.79	1.72e-34	Schizophrenia;
PAAD	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.72	-8.03	-0.55	2.46e-13	Colorectal cancer;
PAAD	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg09667013	chr22:42394590	WBP2NL	0.52	5.11	0.38	9.72e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg08648136	chr8:956695	NA	0.54	5.76	0.42	4.58e-8	Schizophrenia;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg15181151	chr6:150070149	PCMT1	0.61	6.76	0.48	2.81e-10	Lung cancer;
PAAD	cis	rs9395066	0.545	rs7749865	chr6:44918406	T/C	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs11078597	0.731	rs8065251	chr17:1637458	G/A	cg18436246	chr17:1640651	WDR81	0.85	7.72	0.53	1.47e-12	Serum albumin level;
PAAD	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.7	7.69	0.53	1.73e-12	Hematocrit;
PAAD	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.44	-4.53	-0.34	1.19e-5	Corneal astigmatism;
PAAD	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg19875578	chr6:126661172	C6orf173	0.43	4.51	0.34	1.3e-5	Male-pattern baldness;
PAAD	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg22947322	chr17:47091978	IGF2BP1	0.43	5.12	0.38	9.08e-7	Type 2 diabetes;
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg00809820	chr17:80708513	TBCD;FN3K	0.47	4.69	0.36	6.03e-6	Glycated hemoglobin levels;
PAAD	cis	rs4668356	0.764	rs6736045	chr2:171950740	G/A	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.52	-4.53	-0.35	1.16e-5	Iron status biomarkers;
PAAD	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.47	-4.81	-0.36	3.53e-6	Platelet distribution width;
PAAD	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg09471204	chr22:42347991	LOC339674	-0.35	-4.67	-0.35	6.47e-6	Cognitive function;
PAAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg07841815	chr7:100318223	EPO	0.44	4.85	0.37	3.07e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.53	5.66	0.42	7.46e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.82	7.03	0.5	6.41e-11	Alzheimer's disease;
PAAD	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.83	-8.53	-0.57	1.36e-14	Obesity-related traits;
PAAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.73	-0.42	5.31e-8	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs7040024	0.796	rs4740933	chr9:850114	C/G	cg14021170	chr9:826657	NA	-0.46	-4.31	-0.33	2.88e-5	Testicular germ cell tumor;Testicular cancer;
PAAD	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.02	-0.49	6.8e-11	Retinal vascular caliber;
PAAD	cis	rs1371614	0.635	rs10175737	chr2:27139747	C/A	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.72	8.35	0.56	4.03e-14	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05300996	chr3:119814693	GSK3B	0.6	6.86	0.49	1.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg10616300	chr11:66138557	SLC29A2	0.33	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-6.35	-0.46	2.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.75	10.17	0.64	7.43e-19	Coronary artery disease;
PAAD	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	7.07	0.5	5.15e-11	Body mass index;
PAAD	cis	rs7923609	0.846	rs7896518	chr10:65104500	A/G	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.72	6.41	0.46	1.71e-9	Platelet count;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.71	-6.91	-0.49	1.27e-10	Blood metabolite levels;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg16606324	chr3:10149918	C3orf24	0.81	6.71	0.48	3.63e-10	Alzheimer's disease;
PAAD	cis	rs62408225	0.894	rs62408218	chr6:90931858	C/T	cg03795776	chr6:90687632	BACH2	0.47	4.73	0.36	4.98e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg07181952	chr1:1239999	ACAP3	0.44	4.53	0.35	1.18e-5	Height;
PAAD	cis	rs4455778	0.580	rs5004391	chr7:49115629	G/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.39	0.4	2.69e-7	Alzheimer's disease;
PAAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	5.77	0.42	4.27e-8	Multiple sclerosis;
PAAD	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	6.87	0.49	1.54e-10	Leprosy;
PAAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.56	-5.87	-0.43	2.64e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.65	5.45	0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.39	-0.46	1.93e-9	Schizophrenia;
PAAD	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg26816564	chr1:7831052	VAMP3	-0.61	-5.27	-0.39	4.54e-7	Inflammatory bowel disease;
PAAD	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.896	rs460832	chr5:112225148	G/A	cg06941702	chr5:112196734	SRP19	0.48	4.37	0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg20592124	chr2:65290738	CEP68	-0.46	-4.35	-0.33	2.5e-5	Pulse pressure;
PAAD	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.38	0.74	1.79e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg13736514	chr6:26305472	NA	-0.44	-4.79	-0.36	3.98e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.37e-18	Prudent dietary pattern;
PAAD	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs1507153	0.847	rs6923778	chr6:79427089	A/G	cg05283184	chr6:79620031	NA	-0.44	-5.46	-0.41	1.86e-7	Sjögren's syndrome;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg13264159	chr8:625131	ERICH1	0.74	4.63	0.35	7.65e-6	IgG glycosylation;
PAAD	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02365742	chr5:174151204	MSX2	0.65	6.56	0.47	7.79e-10	Obesity-related traits;
PAAD	cis	rs4790333	1.000	rs2003968	chr17:2266812	T/C	cg02569219	chr17:2266849	SGSM2	0.63	6.08	0.44	9.09e-9	Proinsulin levels;
PAAD	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg10818794	chr15:86012489	AKAP13	-0.45	-4.98	-0.37	1.71e-6	Interstitial lung disease;
PAAD	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg00536532	chr6:33561449	C6orf227	-0.41	-4.31	-0.33	2.93e-5	Plateletcrit;
PAAD	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg00262122	chr8:11665843	FDFT1	-0.48	-4.29	-0.33	3.17e-5	Retinal vascular caliber;
PAAD	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg25204440	chr1:209979598	IRF6	0.62	5.5	0.41	1.6e-7	Coronary artery disease;
PAAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.64	-0.53	2.28e-12	Height;
PAAD	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-5.51	-0.41	1.51e-7	Colorectal cancer;
PAAD	cis	rs3736485	0.966	rs2414111	chr15:51901357	A/G	cg19558802	chr15:51695713	GLDN	0.45	4.45	0.34	1.63e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg16316162	chr8:144660157	NAPRT1	0.91	4.26	0.33	3.59e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6466055	0.661	rs17640711	chr7:104936920	A/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg18465962	chr7:100767262	NA	0.49	5.21	0.39	5.95e-7	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg13047869	chr3:10149882	C3orf24	0.83	7.09	0.5	4.8e-11	Alzheimer's disease;
PAAD	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg10591111	chr5:226296	SDHA	0.94	4.36	0.33	2.4e-5	Breast cancer;
PAAD	cis	rs12136530	0.625	rs12726614	chr1:19730957	G/C	cg03321592	chr1:19991676	HTR6	0.54	4.91	0.37	2.32e-6	Lead levels in blood;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	trans	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg20587970	chr11:113659929	NA	-1.24	-8.58	-0.57	1.05e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11811982	0.793	rs11806721	chr1:227514987	A/T	cg24860534	chr1:227506868	CDC42BPA	-0.5	-4.85	-0.37	3e-6	Optic disc area;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.73	-7.56	-0.52	3.5e-12	Urate levels;
PAAD	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.5	-4.87	-0.37	2.76e-6	Squamous cell lung carcinoma;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	7.47	0.52	6e-12	Hemoglobin concentration;
PAAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.77e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.51	-4.48	-0.34	1.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.63	-4.52	-0.34	1.26e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11264799	0.731	rs58215884	chr1:157708335	G/T	cg18268488	chr1:157545234	FCRL4	0.68	5.96	0.44	1.69e-8	IgA nephropathy;
PAAD	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.52	4.47	0.34	1.55e-5	Sudden cardiac arrest;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg01942863	chr7:99769432	GPC2	-0.44	-4.28	-0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg22637538	chr17:7348327	CHRNB1	-0.39	-4.39	-0.34	2.13e-5	Height;
PAAD	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.81	8.97	0.59	1.06e-15	Height;
PAAD	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.66	7.08	0.5	5.1e-11	Crohn's disease;
PAAD	cis	rs68170813	1.000	rs68170813	chr7:107259721	T/C	cg23024343	chr7:107201750	COG5	0.54	4.42	0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.54	5.36	0.4	3.06e-7	Tonsillectomy;
PAAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.87e-6	Bone mineral density;
PAAD	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg27087555	chr16:88793112	FAM38A	-1.06	-5.65	-0.42	7.84e-8	Plateletcrit;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4787951	0.560	rs3024530	chr16:27350687	C/T	cg08008352	chr16:27322356	NA	-0.42	-4.33	-0.33	2.66e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.77	-8.51	-0.57	1.58e-14	Schizophrenia;
PAAD	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.34	-0.46	2.53e-9	Neuroticism;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	1.01	12.41	0.71	7.41e-25	Breast cancer;
PAAD	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.53	-5.06	-0.38	1.21e-6	Hirschsprung disease;
PAAD	cis	rs9649465	0.967	rs7809453	chr7:123301940	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.65	-0.35	7.11e-6	Migraine;
PAAD	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.02	0.49	6.78e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.27	0.39	4.6e-7	Personality dimensions;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26465547	chr7:152602179	NA	0.45	6.46	0.46	1.36e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.56	-6.54	-0.47	9.05e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.47	4.7	0.36	5.69e-6	Coronary artery disease;
PAAD	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.79	-0.87	1.3e-48	Myeloid white cell count;
PAAD	cis	rs2637266	0.875	rs2395409	chr10:78381004	A/G	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.65e-5	Pulmonary function;
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2001970	1.000	rs8046453	chr16:55250599	C/T	cg06138439	chr16:54973128	NA	0.27	4.26	0.33	3.5e-5	Visceral fat;
PAAD	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.99	-0.38	1.61e-6	Personality dimensions;
PAAD	cis	rs116175783	0.557	rs72877940	chr2:162260476	A/G	cg08807892	chr2:162101083	NA	-0.65	-4.66	-0.35	6.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.14	-0.5	3.63e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.66	6.53	0.47	9.27e-10	Gastritis;
PAAD	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.37	-4.97	-0.37	1.78e-6	Schizophrenia;
PAAD	cis	rs6988985	0.818	rs7463212	chr8:143991858	A/T	cg10324643	chr8:143916377	GML	-0.41	-4.31	-0.33	2.93e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14119001	chr9:139324193	INPP5E	-0.65	-5.83	-0.43	3.24e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.9e-5	Total body bone mineral density;
PAAD	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg13565585	chr5:132299512	AFF4	0.62	4.5	0.34	1.32e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs714031	0.967	rs5757763	chr22:40065005	A/G	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.45	-0.34	1.66e-5	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.57	-6.57	-0.47	7.72e-10	Lung cancer;
PAAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg06618935	chr21:46677482	NA	-0.56	-6.84	-0.49	1.84e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.48	-6.44	-0.46	1.46e-9	Ulcerative colitis;
PAAD	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.66	-7.4	-0.51	8.52e-12	Longevity;Endometriosis;
PAAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg10591111	chr5:226296	SDHA	-0.63	-5.06	-0.38	1.18e-6	Breast cancer;
PAAD	cis	rs1642645	0.831	rs784103	chr1:42487059	A/G	cg01990334	chr1:42801334	FOXJ3	-0.64	-5.85	-0.43	2.98e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg22963979	chr7:1858916	MAD1L1	-0.73	-8.36	-0.56	3.61e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg18612461	chr15:75251733	NA	-0.37	-4.25	-0.33	3.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.72	7.91	0.54	4.86e-13	Lung cancer;
PAAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.76	10.13	0.63	9.73e-19	Coronary artery disease;
PAAD	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg13266496	chr6:110720918	DDO	-0.46	-4.87	-0.37	2.78e-6	Platelet distribution width;
PAAD	cis	rs9535307	0.719	rs61961491	chr13:50384106	T/C	cg03658251	chr13:50265850	EBPL	-0.83	-5.68	-0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg02683114	chr2:24398427	C2orf84	0.57	5.9	0.43	2.31e-8	Asthma;
PAAD	cis	rs965604	1.000	rs8042238	chr15:78774271	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-4.47	-0.34	1.5e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.93e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	4.91	0.37	2.28e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	4.67	0.35	6.58e-6	Height;
PAAD	cis	rs13242816	1.000	rs35184471	chr7:116133246	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14749334	chr19:8455835	RAB11B	-0.69	-6.66	-0.48	4.82e-10	Lung cancer in ever smokers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14699253	chr8:141541589	EIF2C2	0.56	6.49	0.47	1.17e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17293817	0.589	rs7084367	chr10:1427548	C/T	cg02408697	chr10:1416920	ADARB2	0.49	4.54	0.35	1.13e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.88	10.23	0.64	5.28e-19	Ulcerative colitis;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.54	0.35	1.16e-5	Electroencephalogram traits;
PAAD	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.81	6.51	0.47	1.02e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg24842760	chr6:133561719	EYA4	-0.9	-6.82	-0.48	1.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs2882667	0.659	rs11750067	chr5:138256278	C/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7772697	0.632	rs12191381	chr6:149425036	G/A	cg21368479	chr6:149415018	NA	0.41	4.3	0.33	3.01e-5	Diabetic retinopathy;
PAAD	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg03098721	chr1:84464084	TTLL7	0.48	4.59	0.35	9.21e-6	Obesity-related traits;
PAAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.47	4.54	0.35	1.13e-5	Morning vs. evening chronotype;
PAAD	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg08562672	chr19:21860753	NA	0.44	4.65	0.35	7.2e-6	Pain;
PAAD	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.49	5.21	0.39	6.17e-7	Brain structure;
PAAD	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.15	10.49	0.65	1.04e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg17595323	chr11:93583763	C11orf90	-0.37	-4.61	-0.35	8.42e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10916814	0.655	rs4291476	chr1:20897019	A/G	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg13263323	chr15:86062960	AKAP13	-0.54	-5.82	-0.43	3.34e-8	Interstitial lung disease;
PAAD	cis	rs3800461	0.544	rs11754548	chr6:34504767	G/C	cg14254433	chr6:34482411	PACSIN1	-0.9	-5.88	-0.43	2.51e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.81	8.59	0.57	9.73e-15	Prostate cancer;
PAAD	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.28	0.33	3.24e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg25905881	chr15:51634250	GLDN	0.46	4.51	0.34	1.27e-5	Hormone measurements;
PAAD	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg23957660	chr17:17878224	LRRC48	0.38	4.3	0.33	3.08e-5	Total body bone mineral density;
PAAD	trans	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.7	9.13	0.59	4.08e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg16306870	chr3:194868790	C3orf21	0.42	4.46	0.34	1.56e-5	Non-small cell lung cancer;
PAAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg10820045	chr2:198174542	NA	-0.45	-4.55	-0.35	1.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.94	4.78	0.36	4.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.78	-7.94	-0.54	4.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7809615	0.748	rs28602855	chr7:99065986	C/G	cg12290671	chr7:99195819	NA	-0.89	-5.1	-0.38	1.01e-6	Blood metabolite ratios;
PAAD	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.64	6.94	0.49	1.04e-10	Lung cancer;
PAAD	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-4.86	-0.37	2.87e-6	Schizophrenia;
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs639012	0.667	rs497816	chr11:85812210	C/T	cg07180834	chr11:85838833	NA	-0.5	-5.64	-0.42	8.22e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg05207973	chr5:176823642	SLC34A1	0.41	4.85	0.37	3.07e-6	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.82	6.7	0.48	3.8e-10	Pulmonary function decline;
PAAD	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg09796270	chr17:17721594	SREBF1	-0.49	-5.33	-0.4	3.51e-7	Total body bone mineral density;
PAAD	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs4662592	0.584	rs76762592	chr2:128961008	C/T	cg03222009	chr2:129077232	HS6ST1	-0.5	-4.63	-0.35	7.77e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg11297586	chr4:3513846	NA	0.46	4.56	0.35	1.03e-5	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.35	0.33	2.52e-5	P wave terminal force;
PAAD	cis	rs7071247	0.915	rs10883875	chr10:105259917	T/C	cg06423925	chr10:105883847	C10orf78	0.62	4.69	0.36	6.09e-6	Platelet aggregation;
PAAD	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.59	-7.94	-0.54	4.15e-13	Endometriosis;
PAAD	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.6	-5.29	-0.39	4.27e-7	Type 2 diabetes;
PAAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.81	8.51	0.57	1.57e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12432203	1.000	rs72622434	chr14:51734570	C/T	cg23942311	chr14:51606299	NA	-0.7	-4.8	-0.36	3.75e-6	Cancer;
PAAD	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg04826882	chr13:114838756	RASA3	-0.7	-5.58	-0.41	1.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6774280	0.656	rs1603866	chr3:6279652	C/T	cg18469270	chr3:5468035	NA	0.54	4.27	0.33	3.48e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6922632	0.867	rs62400306	chr6:24111980	A/C	cg26194775	chr6:24126114	NRSN1	-0.77	-5.61	-0.41	9.28e-8	Information processing speed;
PAAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.8	-9.9	-0.63	3.83e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.56	-6.7	-0.48	3.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.42	6.27	0.45	3.52e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-5.12	-0.38	9.32e-7	Menarche (age at onset);
PAAD	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	0.78	5.29	0.39	4.27e-7	Body mass index;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg07841815	chr7:100318223	EPO	0.42	4.66	0.35	6.97e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14895029	chr7:2775587	GNA12	-0.47	-4.84	-0.37	3.13e-6	Height;
PAAD	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.49	5.78	0.42	4.13e-8	Coronary artery disease;
PAAD	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.85	-6.79	-0.48	2.33e-10	Blood protein levels;
PAAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg00758881	chr16:58534681	NDRG4	-0.91	-4.9	-0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.51	6.0	0.44	1.41e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4668356	0.881	rs78813494	chr2:172038070	G/A	cg13882835	chr2:172017928	TLK1	0.93	4.53	0.34	1.19e-5	Cognitive performance;
PAAD	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.79	7.08	0.5	5.08e-11	Exhaled nitric oxide levels;
PAAD	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.82	8.78	0.58	3.18e-15	Height;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg10191248	chr10:134441085	INPP5A	-0.45	-4.25	-0.33	3.67e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	4.31	0.33	2.86e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06580891	chr20:3189935	ITPA	-0.67	-7.0	-0.49	7.57e-11	Smoking initiation;
PAAD	cis	rs375066	0.935	rs365556	chr19:44408199	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg08282784	chr12:121454133	C12orf43	0.57	6.35	0.46	2.33e-9	Alzheimer's disease (survival time);
PAAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.51	5.62	0.41	8.8e-8	Height;
PAAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.89	0.63	4.16e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.69	-8.78	-0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4148087	1.000	rs9977571	chr21:43624157	G/A	cg08841829	chr21:43638893	ABCG1	-0.68	-4.59	-0.35	9.26e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.44	4.5	0.34	1.36e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.53	-5.47	-0.41	1.82e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.8	-0.48	2.28e-10	Retinal vascular caliber;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.2	-0.55	9.57e-14	Inflammatory bowel disease;
PAAD	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.76	7.64	0.53	2.32e-12	Resting heart rate;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.77	8.63	0.57	7.63e-15	Longevity;
PAAD	cis	rs6011674	1.000	rs6011691	chr20:61867454	A/G	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.68	-4.29	-0.33	3.12e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-8.01	-0.54	2.86e-13	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14420613	chr2:204082562	NBEAL1	0.68	8.07	0.55	1.96e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg01982873	chr5:490308	SLC9A3	-0.43	-4.87	-0.37	2.83e-6	Cystic fibrosis severity;
PAAD	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.88	4.84	0.37	3.12e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg05784532	chr1:230284198	GALNT2	0.71	6.16	0.45	6.13e-9	Coronary artery disease;
PAAD	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.71	7.62	0.53	2.47e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg07725925	chr16:89976287	TCF25	0.68	4.36	0.33	2.37e-5	Skin colour saturation;
PAAD	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs113779084	0.724	rs13232267	chr7:11970651	T/G	cg15090509	chr7:11872073	THSD7A	0.36	4.46	0.34	1.6e-5	Educational attainment (years of education);
PAAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg16147221	chr4:10020634	SLC2A9	0.47	4.3	0.33	3.04e-5	Bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22217807	chr16:8768618	ABAT	0.61	6.76	0.48	2.84e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1508086	0.695	rs1911694	chr8:57804484	T/C	cg10342016	chr8:57802622	NA	-0.25	-4.39	-0.34	2.13e-5	Hand grip strength;
PAAD	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.91	-7.47	-0.52	5.91e-12	Orofacial clefts;
PAAD	cis	rs2637266	0.568	rs2579758	chr10:78262202	T/C	cg18941641	chr10:78392320	NA	0.36	4.26	0.33	3.57e-5	Pulmonary function;
PAAD	cis	rs6084352	0.564	rs6084320	chr20:3244564	C/T	cg06251395	chr20:3663186	ADAM33	0.38	4.3	0.33	3.09e-5	Asthma;
PAAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.73	-6.83	-0.48	1.92e-10	Psoriasis;
PAAD	cis	rs1569175	0.522	rs3094771	chr2:200886058	A/G	cg23649088	chr2:200775458	C2orf69	-0.81	-5.72	-0.42	5.4e-8	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9463078	0.625	rs12190513	chr6:44920679	A/T	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg15847926	chr7:2749597	AMZ1	-0.39	-4.71	-0.36	5.59e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27385726	chr16:3351249	TIGD7	-0.63	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg23024343	chr7:107201750	COG5	0.57	4.63	0.35	7.68e-6	Coronary artery disease;
PAAD	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg13207630	chr7:32358064	NA	0.81	4.37	0.33	2.34e-5	Body mass index;
PAAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs72960926	0.744	rs4385272	chr6:75063124	G/A	cg03266952	chr6:74778945	NA	-1.07	-5.78	-0.42	4.01e-8	Metabolite levels (MHPG);
PAAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs288326	0.561	rs79096460	chr2:183798677	A/G	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg20582800	chr6:43612764	RSPH9	-0.56	-4.44	-0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg09509183	chr1:209979624	IRF6	-0.5	-4.65	-0.35	7.2e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.29	-0.33	3.11e-5	Myopia (pathological);
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11245990	chr11:68621969	NA	0.38	4.77	0.36	4.27e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg15181151	chr6:150070149	PCMT1	0.53	5.8	0.43	3.69e-8	Lung cancer;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg01280390	chr8:19363452	CSGALNACT1	0.38	4.98	0.37	1.69e-6	Oropharynx cancer;
PAAD	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg25204440	chr1:209979598	IRF6	0.59	4.9	0.37	2.42e-6	Coronary artery disease;
PAAD	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg06637938	chr14:75390232	RPS6KL1	1.09	15.47	0.78	4.98e-33	Caffeine consumption;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.59	-6.87	-0.49	1.51e-10	Lung cancer;
PAAD	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.5	0.34	1.35e-5	Neuroticism;
PAAD	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.96	0.37	1.89e-6	Post bronchodilator FEV1;
PAAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00142150	chr22:38071001	LGALS1	0.8	9.02	0.59	7.44e-16	Fat distribution (HIV);
PAAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-6.06	-0.44	1.04e-8	Coronary artery disease;
PAAD	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg10356904	chr22:49881777	NA	-0.48	-4.79	-0.36	3.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg24634471	chr8:143751801	JRK	-0.51	-4.61	-0.35	8.59e-6	Urinary tract infection frequency;
PAAD	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.91	10.24	0.64	4.78e-19	Obesity-related traits;
PAAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.57	-0.35	1.02e-5	Major depressive disorder;
PAAD	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg12046867	chr14:103022105	NA	-0.66	-5.32	-0.4	3.71e-7	Platelet count;
PAAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg17644776	chr2:200775616	C2orf69	-0.72	-5.38	-0.4	2.79e-7	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.72	0.53	1.43e-12	Prudent dietary pattern;
PAAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.72	0.36	5.2e-6	Breast cancer;
PAAD	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.46	-5.78	-0.42	4.13e-8	Crohn's disease;
PAAD	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9337951	0.579	rs2505083	chr10:30335122	C/T	cg27036936	chr10:30305021	KIAA1462	-0.38	-4.4	-0.34	1.99e-5	Pulse pressure;Coronary artery disease;
PAAD	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.9	11.26	0.67	9.19e-22	Dental caries;
PAAD	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	1.07	11.08	0.67	2.82e-21	Post bronchodilator FEV1;
PAAD	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.75	8.19	0.55	9.82e-14	Menopause (age at onset);
PAAD	cis	rs4751006	0.543	rs11016943	chr10:128768902	A/C	cg05702161	chr10:128779687	DOCK1	-1.24	-6.92	-0.49	1.16e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-1.01	-15.83	-0.79	5.81e-34	Post bronchodilator FEV1;
PAAD	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.97	6.84	0.49	1.79e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg15212455	chr7:39170539	POU6F2	0.49	6.91	0.49	1.22e-10	IgG glycosylation;
PAAD	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg23939001	chr4:940644	TMEM175	0.83	10.21	0.64	5.95e-19	Sjögren's syndrome;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg14440974	chr22:39074834	NA	-0.6	-7.33	-0.51	1.27e-11	Menopause (age at onset);
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.59e-8	Height;
PAAD	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.57	5.6	0.41	9.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	4.28	0.33	3.25e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg08835956	chr7:39171034	POU6F2	0.37	5.93	0.43	2.01e-8	IgG glycosylation;
PAAD	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05382772	chr11:65686513	DRAP1;C11orf68	0.59	6.37	0.46	2.13e-9	Pancreatic cancer;
PAAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6088813	1.000	rs6087698	chr20:33948919	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.54	5.46	0.4	1.91e-7	Systemic lupus erythematosus;
PAAD	cis	rs10793968	0.688	rs10793969	chr9:133631104	T/C	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.85e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg08888203	chr3:10149979	C3orf24	0.68	6.22	0.45	4.5e-9	Alzheimer's disease;
PAAD	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.35	0.6	1.05e-16	Morning vs. evening chronotype;
PAAD	trans	rs10191559	0.613	rs2368196	chr2:181967075	A/G	cg00816152	chr3:120222812	NA	0.57	6.48	0.47	1.22e-9	Red blood cell count;
PAAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.23	-21.97	-0.87	5e-49	Testicular germ cell tumor;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg05627522	chr15:75251581	NA	0.46	5.41	0.4	2.37e-7	Breast cancer;
PAAD	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.88	-11.03	-0.67	3.77e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20487152	chr13:99095054	FARP1	-0.48	-4.71	-0.36	5.48e-6	Longevity;
PAAD	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.45	4.46	0.34	1.59e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
PAAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.49	-4.71	-0.36	5.46e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	9.95	0.63	2.85e-18	Platelet count;
PAAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.75	7.8	0.53	9.19e-13	Total body bone mineral density;
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18490616	chr2:88469792	THNSL2	-0.48	-4.52	-0.34	1.25e-5	Response to metformin (IC50);
PAAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.65	7.54	0.52	3.98e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg06740227	chr12:86229804	RASSF9	-0.49	-4.9	-0.37	2.48e-6	Major depressive disorder;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12315302	chr6:26189340	HIST1H4D	0.54	4.27	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.53	4.73	0.36	5e-6	Dialysis-related mortality;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.83	9.41	0.61	7.65e-17	Menarche (age at onset);
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.66	-0.35	6.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.4	-0.61	7.97e-17	Pancreatic cancer;
PAAD	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.8	7.53	0.52	4.09e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09998801	chr12:120105695	PRKAB1	0.64	7.2	0.5	2.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.45	4.96	0.37	1.87e-6	Schizophrenia;
PAAD	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg06131755	chr6:160182447	ACAT2	0.54	4.83	0.36	3.3e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	4.88	0.37	2.65e-6	Neuroticism;
PAAD	cis	rs6519955	0.755	rs8138989	chr22:46425432	C/T	cg05468064	chr22:46423449	NA	0.55	6.82	0.48	2.07e-10	Dupuytren's disease;
PAAD	cis	rs12780845	1.000	rs12783490	chr10:17223716	T/A	cg00857480	chr10:17188594	TRDMT1	0.37	4.72	0.36	5.42e-6	Homocysteine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02941376	chr17:1613939	TLCD2	0.63	7.06	0.5	5.5e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9907295	0.591	rs6505498	chr17:34130051	T/C	cg19411729	chr17:34207663	CCL5	-0.5	-4.45	-0.34	1.68e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.35e-5	Coronary artery disease;
PAAD	cis	rs1109501	0.689	rs4389630	chr4:71419188	A/G	cg25553522	chr4:71388589	AMTN	0.53	4.51	0.34	1.29e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.73	7.82	0.54	8.05e-13	Schizophrenia;
PAAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23463467	chr20:60627584	TAF4	-0.41	-4.44	-0.34	1.69e-5	Body mass index;
PAAD	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs8060686	0.920	rs60769312	chr16:67732186	C/T	cg05110241	chr16:68378359	PRMT7	-0.96	-5.45	-0.4	1.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-6.43	-0.46	1.57e-9	Coronary artery disease;
PAAD	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.31	0.56	4.85e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs6681460	0.608	rs10889624	chr1:67005807	A/G	cg02459107	chr1:67143332	SGIP1	0.55	4.95	0.37	1.94e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.67	-7.44	-0.52	6.73e-12	Age at first birth;
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02359409	chr6:42947317	PEX6	-0.47	-4.67	-0.35	6.51e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3026101	0.671	rs1806249	chr17:5311143	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.82	-9.92	-0.63	3.35e-18	Coronary artery disease;
PAAD	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.94	8.02	0.55	2.56e-13	Blood protein levels;
PAAD	cis	rs10450586	0.932	rs899302	chr11:27309577	T/C	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.76	-0.48	2.81e-10	Exhaled nitric oxide output;
PAAD	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.54	5.85	0.43	2.86e-8	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10057843	chr12:56473559	ERBB3	0.63	7.17	0.5	3.08e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg19630374	chr17:18023558	MYO15A	0.52	5.72	0.42	5.59e-8	Total body bone mineral density;
PAAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.46	6.95	0.49	1.01e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg20965017	chr5:231967	SDHA	-0.63	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.15	-0.6	3.44e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.86	-7.34	-0.51	1.17e-11	HIV-1 control;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.66	-7.18	-0.5	2.87e-11	Menopause (age at onset);
PAAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14563165	chr9:130214037	LRSAM1;RPL12	-0.74	-6.56	-0.47	7.92e-10	Neuroticism;
PAAD	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.78	0.48	2.52e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg17328665	chr1:7887199	PER3	-0.51	-4.72	-0.36	5.32e-6	Crohn's disease;
PAAD	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72960926	0.744	rs55792900	chr6:74924010	C/A	cg03266952	chr6:74778945	NA	-1.1	-6.37	-0.46	2.13e-9	Metabolite levels (MHPG);
PAAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.67	-0.35	6.52e-6	Mood instability;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.61	-4.88	-0.37	2.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs758324	0.812	rs519240	chr5:131269453	G/A	cg06307176	chr5:131281290	NA	-0.53	-4.61	-0.35	8.43e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11958404	1.000	rs56175756	chr5:157391080	T/C	cg05962755	chr5:157440814	NA	0.92	5.7	0.42	5.97e-8	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21053147	chr12:120880522	NA	-0.65	-6.91	-0.49	1.28e-10	Obesity-related traits;
PAAD	cis	rs9479482	0.686	rs13199618	chr6:150384648	C/A	cg08316699	chr6:150357289	NA	0.39	4.58	0.35	9.79e-6	Alopecia areata;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.8	9.14	0.6	3.8e-16	Lung cancer;
PAAD	cis	rs9815354	0.951	rs1716674	chr3:41902972	G/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs900145	0.859	rs3993105	chr11:13303071	C/T	cg15603424	chr11:13300592	ARNTL	0.51	4.51	0.34	1.3e-5	Menarche (age at onset);
PAAD	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.69	0.42	6.25e-8	Response to antipsychotic treatment;
PAAD	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs9308433	0.553	rs2047445	chr1:214469962	G/A	cg06198575	chr1:214491504	SMYD2	0.6	5.64	0.42	8.07e-8	IgG glycosylation;
PAAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.9	-0.37	2.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.74	-8.31	-0.56	4.96e-14	Dental caries;
PAAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.77	8.69	0.58	5.3e-15	Total body bone mineral density;
PAAD	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.73	6.94	0.49	1.09e-10	Total body bone mineral density;
PAAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.58	-6.23	-0.45	4.32e-9	Longevity;
PAAD	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-5.23	-0.39	5.43e-7	Crohn's disease;
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	4.65	0.35	7.26e-6	Obesity-related traits;
PAAD	cis	rs35955747	0.934	rs926928	chr22:31821719	G/A	cg02404636	chr22:31891804	SFI1	-0.59	-5.78	-0.42	4.03e-8	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.2	-0.45	5.06e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.47	4.99	0.38	1.6e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.85	0.54	6.9e-13	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24390964	chr3:4345246	SETMAR	0.62	7.2	0.5	2.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Diabetic kidney disease;
PAAD	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.57	6.42	0.46	1.64e-9	Platelet distribution width;
PAAD	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.44	4.76	0.36	4.56e-6	Sarcoidosis;
PAAD	cis	rs17155006	0.711	rs379821	chr7:107751232	T/C	cg05962710	chr7:107745446	LAMB4	-0.59	-7.68	-0.53	1.77e-12	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg04160749	chr8:58172571	NA	-0.63	-4.5	-0.34	1.35e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25392384	chr7:150102268	LOC728743	0.6	6.51	0.47	1.02e-9	Myopia (pathological);
PAAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.45	0.4	2e-7	Personality dimensions;
PAAD	trans	rs901683	1.000	rs35506889	chr10:46084637	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.78	8.53	0.57	1.42e-14	Caffeine consumption;
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg18612461	chr15:75251733	NA	0.59	7.48	0.52	5.57e-12	Breast cancer;
PAAD	cis	rs914615	0.552	rs11264337	chr1:155138450	C/T	cg20311333	chr1:155197753	GBAP1	0.44	4.26	0.33	3.61e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs959260	1.000	rs6501786	chr17:73378775	A/T	cg20590849	chr17:73267439	MIF4GD	0.54	4.36	0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg00540400	chr15:79124168	NA	-0.71	-8.91	-0.59	1.45e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.77	5.64	0.42	7.88e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6005807	0.543	rs2235432	chr22:29169420	T/G	cg15103426	chr22:29168792	CCDC117	0.64	4.69	0.36	6.1e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.44	6.79	0.48	2.4e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2384207	0.818	rs7955036	chr12:113715251	T/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.59	5.24	0.39	5.33e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs727479	0.502	rs2899471	chr15:51506553	G/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.55e-5	Estradiol levels;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg17645278	chr8:357429	FBXO25	0.6	6.37	0.46	2.18e-9	Iris heterochromicity;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs6539267	1.000	rs6539267	chr12:106785554	T/C	cg00173435	chr12:106696525	TCP11L2	0.46	4.54	0.35	1.15e-5	Tourette syndrome;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg27499820	chr13:21296301	IL17D	0.59	5.83	0.43	3.22e-8	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg21929781	chr1:2537748	MMEL1	0.51	5.36	0.4	2.97e-7	Ulcerative colitis;
PAAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.75	-0.36	4.61e-6	Type 2 diabetes;
PAAD	cis	rs3177980	0.673	rs6694855	chr1:169852851	T/C	cg18229820	chr1:169693534	SELE	0.48	4.27	0.33	3.38e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.82	-0.36	3.48e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg15838173	chr10:75533400	FUT11	-0.45	-4.45	-0.34	1.64e-5	Inflammatory bowel disease;
PAAD	cis	rs7534824	0.625	rs6692186	chr1:101470217	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs66530629	0.917	rs6665083	chr1:25148291	G/T	cg22509179	chr1:25234806	RUNX3	-0.5	-4.59	-0.35	9.16e-6	Plateletcrit;
PAAD	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.87	4.71	0.36	5.5e-6	Childhood ear infection;
PAAD	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.71	7.16	0.5	3.31e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9810890	1.000	rs116203743	chr3:128483210	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	6.21	0.45	4.94e-9	IgG glycosylation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11794814	chr19:40791331	AKT2	0.65	7.01	0.49	7.46e-11	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg12458913	chr13:53173898	NA	0.48	4.85	0.37	3.05e-6	Lewy body disease;
PAAD	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.43e-5	Resting heart rate;
PAAD	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.89	7.45	0.52	6.51e-12	Myopia (pathological);
PAAD	cis	rs11563648	0.553	rs4731359	chr7:127055248	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.6	-0.35	8.94e-6	Type 2 diabetes;
PAAD	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-10.27	-0.64	3.96e-19	Height;
PAAD	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.51	5.59	0.41	1.02e-7	Sitting height ratio;
PAAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg11764359	chr7:65958608	NA	0.72	4.73	0.36	5e-6	Diabetic kidney disease;
PAAD	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg10664184	chr19:17420304	DDA1	0.48	4.34	0.33	2.55e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.31	0.4	3.8e-7	Diabetic kidney disease;
PAAD	cis	rs7941600	0.786	rs12273748	chr11:9360367	A/G	cg19415743	chr11:9336845	TMEM41B	0.94	5.91	0.43	2.18e-8	Coronary artery disease;
PAAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-7.82	-0.54	8.2e-13	Response to antipsychotic treatment;
PAAD	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	12.6	0.71	2.21e-25	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01337508	chr17:40540572	STAT3	0.59	6.33	0.46	2.69e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg25972092	chr12:117363249	FBXW8	0.83	6.33	0.46	2.6e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs735539	0.517	rs9552240	chr13:21126497	T/C	cg27234864	chr13:21295941	IL17D	0.62	5.51	0.41	1.5e-7	Dental caries;
PAAD	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg03264133	chr6:25882463	NA	0.48	4.58	0.35	9.78e-6	Blood metabolite levels;
PAAD	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	4.8	0.36	3.77e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg10351095	chr21:47802916	PCNT	0.5	4.88	0.37	2.65e-6	Testicular germ cell tumor;
PAAD	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-6.64	-0.47	5.37e-10	Colorectal cancer;
PAAD	cis	rs7165102	1.000	rs352479	chr15:65803428	C/A	cg22900193	chr15:65823441	PTPLAD1	-0.47	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.05	15.19	0.78	2.72e-32	Multiple system atrophy;
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.81	-9.24	-0.6	2.1e-16	Height;
PAAD	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.71	7.53	0.52	4.12e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.67	0.35	6.47e-6	Homoarginine levels;
PAAD	cis	rs7084783	0.519	rs10879	chr10:105354556	A/G	cg00126946	chr10:105363258	SH3PXD2A	-0.46	-4.6	-0.35	9e-6	Fear of pain;
PAAD	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.19e-11	Corneal astigmatism;
PAAD	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.52	-5.24	-0.39	5.38e-7	Breast cancer;
PAAD	cis	rs2373794	0.583	rs7570501	chr2:40386285	A/T	cg12449404	chr2:40437698	SLC8A1	0.56	4.61	0.35	8.41e-6	Asthma;
PAAD	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.77	5.72	0.42	5.52e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16576597	chr16:28551801	NUPR1	0.67	7.5	0.52	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg12700464	chr11:78128424	GAB2	-0.57	-4.32	-0.33	2.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.4	4.64	0.35	7.43e-6	Blood protein levels;
PAAD	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.61	5.36	0.4	3.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12826942	0.718	rs12827742	chr12:42542861	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	4.37	0.33	2.32e-5	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg03030879	chr14:75389066	RPS6KL1	0.4	4.25	0.33	3.67e-5	Height;
PAAD	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg24375607	chr4:120327624	NA	0.58	5.36	0.4	3.06e-7	Educational attainment;
PAAD	cis	rs4588572	0.643	rs3885254	chr5:77686468	G/A	cg11547950	chr5:77652471	NA	0.85	7.05	0.5	5.8200000000000003e-11	Triglycerides;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-1.12	-9.16	-0.6	3.36e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11593588	chr6:170863296	PSMB1;TBP	0.63	7.06	0.5	5.68e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.97	-11.83	-0.69	2.58e-23	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg11062466	chr8:58055876	NA	0.67	4.8	0.36	3.8e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23082845	chr1:1159282	SDF4	0.64	7.53	0.52	4.31e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg12215294	chr3:40350768	EIF1B	0.47	4.67	0.35	6.66e-6	Renal cell carcinoma;
PAAD	cis	rs6882716	1.000	rs4702730	chr5:10799879	T/A	cg14521931	chr5:10832172	NA	-0.82	-4.79	-0.36	3.95e-6	Alcohol consumption (maxi-drinks);
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.79	-9.24	-0.6	2.06e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	0.88	6.15	0.45	6.66e-9	Crohn's disease;
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg10137597	chr8:22132714	PIWIL2	0.5	5.96	0.44	1.68e-8	Hypertriglyceridemia;
PAAD	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.48	4.46	0.34	1.6e-5	Pancreatic cancer;
PAAD	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg02877791	chr2:177005403	NA	0.46	4.57	0.35	9.89e-6	IgG glycosylation;
PAAD	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.38	0.56	3.36e-14	Bipolar disorder;
PAAD	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg06042504	chr8:55087323	NA	-0.6	-5.76	-0.42	4.43e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.51	4.34	0.33	2.57e-5	Depression;
PAAD	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.88	0.37	2.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	0.950	rs2790165	chr10:60022675	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.68	5.81	0.43	3.61e-8	Height;
PAAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.27	0.33	3.4e-5	HDL cholesterol;
PAAD	cis	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg21546286	chr11:48923668	NA	-0.44	-4.63	-0.35	7.76e-6	HDL cholesterol;
PAAD	cis	rs2885056	0.891	rs3760648	chr19:10680103	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.44	4.54	0.35	1.15e-5	Red cell distribution width;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg15117754	chr3:10150083	C3orf24	-0.58	-5.47	-0.41	1.83e-7	Alzheimer's disease;
PAAD	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.07	-18.7	-0.83	3.04e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17155006	0.746	rs446800	chr7:107747928	A/C	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	trans	rs17073641	0.500	rs9964893	chr18:62478765	C/T	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06942197	chr17:38804076	SMARCE1	-0.59	-7.07	-0.5	5.21e-11	Body fat percentage;
PAAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs427941	0.703	rs201441	chr7:101737327	A/C	cg06246474	chr7:101738831	CUX1	0.44	4.52	0.34	1.23e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4930776	0.838	rs368436	chr12:5754618	T/C	cg06629086	chr12:6715057	CHD4	0.53	5.02	0.38	1.42e-6	Plasma clusterin levels;
PAAD	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.55	5.05	0.38	1.23e-6	Airway imaging phenotypes;
PAAD	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg10208897	chr5:178548229	ADAMTS2	0.51	4.63	0.35	7.85e-6	Pubertal anthropometrics;
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.69	7.66	0.53	2.07e-12	Lung cancer;
PAAD	cis	rs4077515	0.839	rs3812570	chr9:139275204	A/C	cg14169450	chr9:139327907	INPP5E	0.59	6.07	0.44	1e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.56	4.7	0.36	5.67e-6	Response to antidepressants in depression;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg11062466	chr8:58055876	NA	-0.77	-4.78	-0.36	4.01e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.44	-5.13	-0.38	8.52e-7	Personality dimensions;
PAAD	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	0.98	11.27	0.67	8.26e-22	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.59	5.43	0.4	2.15e-7	Coronary artery disease;
PAAD	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.75	7.06	0.5	5.6e-11	Retinal vascular caliber;
PAAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs427941	0.703	rs201455	chr7:101740212	C/T	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg14092988	chr3:52407081	DNAH1	0.41	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs4443100	0.916	rs6003494	chr22:23399461	T/C	cg14186256	chr22:23484241	RTDR1	0.51	4.54	0.35	1.12e-5	Serum parathyroid hormone levels;
PAAD	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs9900972	0.918	rs2889530	chr17:76878706	C/T	cg00961940	chr17:76876995	TIMP2	0.56	5.18	0.39	7.01e-7	Obesity-related traits;
PAAD	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.51	-0.34	1.3e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4742903	1.000	rs1026181	chr9:106893334	A/G	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-0.58	-4.37	-0.33	2.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg27411982	chr8:10470053	RP1L1	0.46	5.46	0.4	1.9e-7	Neuroticism;
PAAD	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg00079375	chr15:79125835	NA	0.42	4.38	0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg23752985	chr2:85803571	VAMP8	0.58	6.29	0.45	3.17e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.35	-0.33	2.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	0.99	9.43	0.61	6.46e-17	Monocyte percentage of white cells;
PAAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.48	4.72	0.36	5.34e-6	Visceral fat;
PAAD	cis	rs7165102	1.000	rs7178584	chr15:65795200	T/G	cg22900193	chr15:65823441	PTPLAD1	-0.47	-4.51	-0.34	1.29e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.92	-7.23	-0.51	2.21e-11	Initial pursuit acceleration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13912035	chr5:179105622	CBY3	0.59	6.38	0.46	1.98e-9	Myopia (pathological);
PAAD	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.73	8.43	0.56	2.44e-14	Metabolic syndrome;
PAAD	cis	rs7945071	0.507	rs2853000	chr11:110295227	T/G	cg04157658	chr11:110243994	NA	0.45	4.41	0.34	1.94e-5	Cognitive function;
PAAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.55	0.41	1.22e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg08501292	chr6:25962987	TRIM38	-0.43	-4.3	-0.33	2.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.65	-6.84	-0.49	1.82e-10	Corneal astigmatism;
PAAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg16083429	chr3:49237500	CCDC36	-0.43	-4.42	-0.34	1.88e-5	Menarche (age at onset);
PAAD	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21646471	chr2:242523971	THAP4	0.64	5.02	0.38	1.45e-6	Prostate cancer;
PAAD	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.73	-6.96	-0.49	9.5e-11	Neuroblastoma (high-risk);
PAAD	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	cis	rs10044254	0.813	rs6554902	chr5:15734170	A/G	cg07238450	chr5:15720153	FBXL7	-0.52	-4.36	-0.33	2.39e-5	Asthma (corticosteroid response);
PAAD	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.25e-31	Chronic sinus infection;
PAAD	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.67	-7.82	-0.54	8.12e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.63	5.87	0.43	2.6e-8	Diastolic blood pressure;
PAAD	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg20821713	chr7:1055600	C7orf50	-0.53	-4.49	-0.34	1.37e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg05785598	chr3:49045655	WDR6	0.41	4.9	0.37	2.38e-6	Parkinson's disease;
PAAD	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg10616300	chr11:66138557	SLC29A2	0.33	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg09796270	chr17:17721594	SREBF1	-0.51	-5.69	-0.42	6.48e-8	Total body bone mineral density;
PAAD	cis	rs258892	0.895	rs253169	chr5:72118987	G/A	cg21869765	chr5:72125136	TNPO1	-0.79	-5.2	-0.39	6.29e-7	Small cell lung carcinoma;
PAAD	cis	rs9659323	0.670	rs61808898	chr1:119638855	T/C	cg17326555	chr1:119535693	NA	-0.37	-5.24	-0.39	5.22e-7	Body mass index;
PAAD	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.88e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg23461800	chr14:103021989	NA	-0.61	-4.86	-0.37	2.9e-6	Platelet count;
PAAD	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.84	-9.22	-0.6	2.35e-16	Multiple sclerosis;
PAAD	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	4.84	0.37	3.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.59	4.87	0.37	2.77e-6	Iron status biomarkers;
PAAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.31	-10.09	-0.63	1.24e-18	Breast cancer;
PAAD	cis	rs17021463	0.617	rs35368920	chr4:95325588	C/T	cg11021082	chr4:95130006	SMARCAD1	0.49	4.7	0.36	5.85e-6	Testicular germ cell tumor;
PAAD	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-4.98	-0.37	1.72e-6	Mean corpuscular volume;
PAAD	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.71	-6.79	-0.48	2.38e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.51	-5.03	-0.38	1.34e-6	Testicular germ cell tumor;
PAAD	cis	rs501120	0.584	rs10900003	chr10:44698044	C/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.5	4.53	0.34	1.2e-5	Breast cancer;
PAAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.34	-0.4	3.29e-7	Longevity;
PAAD	cis	rs11159086	1.000	rs12433848	chr14:74964273	A/G	cg10195687	chr14:74926396	NA	-0.42	-4.44	-0.34	1.73e-5	Advanced glycation end-product levels;
PAAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.92	-8.8	-0.58	2.81e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.85	11.97	0.7	1.1e-23	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26157802	chr2:220042863	FAM134A;C2orf24	-0.56	-6.43	-0.46	1.53e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs61931739	0.613	rs4931773	chr12:33749131	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.38	0.51	9.89e-12	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10438487	chr15:99640813	NA	0.7	7.68	0.53	1.8e-12	Myopia (pathological);
PAAD	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg05627522	chr15:75251581	NA	-0.4	-4.87	-0.37	2.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.2	9.47	0.61	5.31e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1419980	0.730	rs11054884	chr12:7772906	A/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9810890	1.000	rs73196978	chr3:128450228	C/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.41	-0.52	7.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21080633	chr12:132263633	SFRS8	0.56	6.52	0.47	9.7e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs282587	0.569	rs408826	chr13:113415268	G/A	cg04656015	chr13:113407548	ATP11A	0.56	4.48	0.34	1.46e-5	Glycated hemoglobin levels;
PAAD	cis	rs1925576	0.745	rs61866189	chr10:68636451	C/T	cg04444303	chr10:69634106	NA	-0.42	-4.26	-0.33	3.58e-5	Educational attainment (years of education);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08436643	chr17:73257657	MRPS7;GGA3	0.65	6.35	0.46	2.35e-9	Obesity-related traits;
PAAD	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg19483011	chr3:158453295	NA	-0.63	-5.43	-0.4	2.22e-7	Tetralogy of Fallot;
PAAD	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg12317470	chr15:67143691	NA	0.76	4.45	0.34	1.67e-5	Lung cancer (smoking interaction);
PAAD	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.21	0.45	4.87e-9	Migraine - clinic-based;
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.97	12.58	0.71	2.54e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4296977	0.935	rs77589954	chr7:76976834	T/C	cg19348272	chr7:77044158	PION	0.65	4.62	0.35	8.06e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1075265	0.933	rs7562055	chr2:54339831	C/A	cg04546899	chr2:54196757	PSME4	0.33	4.58	0.35	9.59e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07611816	chr2:236760371	AGAP1	-0.65	-6.55	-0.47	8.36e-10	Obesity-related traits;
PAAD	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.71	7.53	0.52	4.16e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.34	-6.56	-0.47	8.1e-10	Mean corpuscular volume;
PAAD	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.8	8.91	0.59	1.45e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg14146966	chr2:61757674	XPO1	0.42	5.21	0.39	6.02e-7	Tuberculosis;
PAAD	cis	rs8112211	0.648	rs34989303	chr19:38817876	G/A	cg14299480	chr19:38876666	GGN	-0.53	-4.56	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.61	-0.47	6.11e-10	Lung cancer;
PAAD	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.59	0.35	9.41e-6	Depression;
PAAD	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.58	-5.6	-0.41	9.78e-8	Primary sclerosing cholangitis;
PAAD	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg25722041	chr1:8623473	RERE	0.51	4.4	0.34	2.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs114261227	chr3:128469760	A/C	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.47	-0.57	1.96e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.41	-0.4	2.43e-7	Psoriasis;
PAAD	cis	rs7260598	0.539	rs74825083	chr19:24059507	C/T	cg09235885	chr19:23456588	NA	-0.69	-4.25	-0.33	3.65e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.61	6.95	0.49	9.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs6812193	0.508	rs7676094	chr4:77412894	C/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Parkinson's disease;
PAAD	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20084434	chr4:157999344	GLRB	0.58	6.95	0.49	1.03e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs901683	1.000	rs12779204	chr10:46064255	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.4	-0.4	2.49e-7	Mononucleosis;
PAAD	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-7.99	-0.54	3.06e-13	Morning vs. evening chronotype;
PAAD	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.76	5.47	0.41	1.82e-7	Major depressive disorder;
PAAD	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.46	0.71	5.4e-25	Chronic sinus infection;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg07685180	chr8:600429	NA	-0.9	-5.48	-0.41	1.73e-7	IgG glycosylation;
PAAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	6.23	0.45	4.33e-9	Monocyte count;
PAAD	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.68	7.73	0.53	1.39e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.27	0.45	3.55e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.25	-0.33	3.7e-5	Eosinophil percentage of white cells;
PAAD	cis	rs911119	0.955	rs6048930	chr20:23592492	T/C	cg16589663	chr20:23618590	CST3	0.8	6.92	0.49	1.15e-10	Chronic kidney disease;
PAAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9659323	0.650	rs17013645	chr1:119484849	C/T	cg17326555	chr1:119535693	NA	-0.36	-4.42	-0.34	1.89e-5	Body mass index;
PAAD	cis	rs6800768	0.663	rs12492765	chr3:24091865	C/T	cg10674438	chr3:24145617	LOC152024	-0.47	-4.35	-0.33	2.46e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg19847866	chr10:1019161	NA	-0.54	-4.37	-0.33	2.32e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-1.03	-11.45	-0.68	2.73e-22	Longevity;
PAAD	cis	rs6066835	0.681	rs3092222	chr20:47387628	C/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.69	0.36	6.09e-6	Menopause (age at onset);
PAAD	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg08601574	chr20:25228251	PYGB	0.55	5.76	0.42	4.61e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	5.95	0.43	1.76e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.66	-5.4	-0.4	2.57e-7	Coronary artery disease;
PAAD	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.77	7.45	0.52	6.58e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg16850897	chr7:100343110	ZAN	-0.77	-6.34	-0.46	2.52e-9	Other erythrocyte phenotypes;
PAAD	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.89	9.44	0.61	6.23e-17	Testicular germ cell tumor;
PAAD	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.72	5.26	0.39	4.85e-7	Plateletcrit;
PAAD	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg14092988	chr3:52407081	DNAH1	-0.43	-5.39	-0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.51	-4.56	-0.35	1.03e-5	Smoking behavior;
PAAD	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.27	-0.64	3.94e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.13	-0.38	8.62e-7	Neuroticism;
PAAD	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.59	0.61	2.44e-17	Rheumatoid arthritis;
PAAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg08284496	chr17:37894027	GRB7	-0.26	-4.53	-0.35	1.17e-5	Asthma;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.48	5.02	0.38	1.4e-6	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.44	-0.46	1.48e-9	Bipolar disorder;
PAAD	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg18551225	chr6:44695536	NA	-0.74	-7.17	-0.5	2.99e-11	Total body bone mineral density;
PAAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-8.15	-0.55	1.25e-13	Total body bone mineral density;
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.89	-0.37	2.56e-6	Obesity-related traits;
PAAD	cis	rs12754538	0.715	rs12029088	chr1:8708876	T/C	cg06159269	chr1:8767347	RERE	0.42	4.95	0.37	1.99e-6	Subjective well-being;
PAAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg05785598	chr3:49045655	WDR6	0.41	4.81	0.36	3.59e-6	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20553930	chr7:120590671	ING3	0.77	8.03	0.55	2.44e-13	Obesity-related traits;
PAAD	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg15448220	chr1:150897856	SETDB1	-0.61	-6.16	-0.45	6.17e-9	Tonsillectomy;
PAAD	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-5.91	-0.43	2.17e-8	Longevity;
PAAD	cis	rs2963826	0.596	rs3111173	chr5:59117280	G/A	cg01174811	chr5:58882939	PDE4D	-0.29	-4.48	-0.34	1.43e-5	Obesity-related traits;
PAAD	cis	rs113779084	0.711	rs12699288	chr7:11975557	T/G	cg15090509	chr7:11872073	THSD7A	0.44	5.43	0.4	2.17e-7	Educational attainment (years of education);
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.68	0.36	6.2e-6	Longevity;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03568042	chr10:88471309	LDB3	-0.66	-6.51	-0.47	1.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.51	5.84	0.43	3.13e-8	Major depressive disorder;
PAAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.15	-0.39	8.1e-7	Lung cancer;
PAAD	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.95	12.29	0.71	1.51e-24	Menopause (age at onset);
PAAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.26	-0.56	6.7e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg12549451	chr6:135224345	NA	-0.41	-4.38	-0.33	2.21e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg16329197	chr12:53359506	NA	-0.85	-9.56	-0.61	3.02e-17	Prostate cancer;
PAAD	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg14393609	chr7:65229607	NA	0.46	4.89	0.37	2.53e-6	Aortic root size;
PAAD	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.43	0.34	1.8e-5	Axial length;
PAAD	cis	rs11615916	0.790	rs73137512	chr12:62706046	A/T	cg11441379	chr12:63026424	NA	0.65	4.4	0.34	2.06e-5	Pulmonary function decline;
PAAD	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.61	6.63	0.47	5.43e-10	Tonsillectomy;
PAAD	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg14343924	chr8:8086146	FLJ10661	0.48	4.6	0.35	8.93e-6	Joint mobility (Beighton score);
PAAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.32	0.33	2.86e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.47	5.3	0.39	4.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.75	0.53	1.19e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.88	9.34	0.6	1.12e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg01334972	chr11:72463230	ARAP1	0.6	4.47	0.34	1.53e-5	Type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.51	-5.01	-0.38	1.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-1.26	-7.64	-0.53	2.27e-12	Plateletcrit;
PAAD	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9283706	0.608	rs12522430	chr5:66339522	T/C	cg11590213	chr5:66331682	MAST4	0.58	4.64	0.35	7.62e-6	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09774706	chr12:125219584	NA	0.66	6.56	0.47	7.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs4538187	0.865	rs11686956	chr2:63938708	T/G	cg08613950	chr2:64719184	NA	0.66	4.38	0.33	2.18e-5	Systolic blood pressure;
PAAD	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg14825688	chr5:132208181	LEAP2	-0.72	-5.78	-0.42	4.07e-8	Apolipoprotein A-IV levels;
PAAD	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.43	5.07	0.38	1.17e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.6	6.15	0.45	6.59e-9	Testicular germ cell tumor;
PAAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.33	0.33	2.64e-5	Mean corpuscular volume;
PAAD	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg10011062	chr15:43941034	CATSPER2	-0.9	-5.56	-0.41	1.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg06217071	chr17:408420	NA	0.78	8.86	0.58	1.94e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs261360	0.642	rs4815763	chr20:5046930	G/A	cg19239041	chr20:4795444	RASSF2	-0.42	-4.3	-0.33	3.09e-5	Hair morphology;
PAAD	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02419362	chr12:121203948	SPPL3	0.53	5.79	0.43	3.84e-8	Systemic lupus erythematosus;
PAAD	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg15212455	chr7:39170539	POU6F2	0.43	7.07	0.5	5.17e-11	IgG glycosylation;
PAAD	cis	rs11168618	0.765	rs7301368	chr12:48926792	C/A	cg01881778	chr12:48919444	OR8S1	-0.51	-5.55	-0.41	1.23e-7	Adiponectin levels;
PAAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.54	5.74	0.42	4.98e-8	Menopause (age at onset);
PAAD	cis	rs9815354	1.000	rs1717011	chr3:41980199	T/C	cg03022575	chr3:42003672	ULK4	-0.81	-5.75	-0.42	4.81e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7555006	0.671	rs11205797	chr1:51474198	G/A	cg06082920	chr1:51796003	TTC39A	-0.46	-4.59	-0.35	9.32e-6	Headache;
PAAD	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.5	-0.41	1.56e-7	Reticulocyte count;
PAAD	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg12700319	chr1:8272199	NA	-0.38	-4.28	-0.33	3.26e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.58	-6.93	-0.49	1.15e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.73	-6.06	-0.44	1.03e-8	Schizophrenia;
PAAD	cis	rs11774576	0.764	rs4732785	chr8:27738440	A/G	cg26534677	chr8:27630505	CCDC25	0.32	4.52	0.34	1.25e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.48	4.68	0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs74181299	0.684	rs11126029	chr2:65338264	C/T	cg20592124	chr2:65290738	CEP68	-0.46	-4.34	-0.33	2.63e-5	Pulse pressure;
PAAD	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.77	-0.42	4.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	5.4	0.4	2.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.7	-5.49	-0.41	1.66e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg17366294	chr4:99064904	C4orf37	0.46	5.15	0.39	7.79e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11997175	0.655	rs72630922	chr8:33662401	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg14851346	chr12:38532713	NA	0.49	4.56	0.35	1.07e-5	Morning vs. evening chronotype;
PAAD	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs11168618	0.846	rs11168599	chr12:48879951	A/C	cg01881778	chr12:48919444	OR8S1	-0.49	-4.84	-0.37	3.19e-6	Adiponectin levels;
PAAD	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.87	14.29	0.76	6.75e-30	Coronary artery disease;
PAAD	cis	rs501916	0.605	rs11070612	chr15:48073174	C/G	cg16110827	chr15:48056943	SEMA6D	-0.51	-5.48	-0.41	1.71e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs1198430	0.562	rs10917388	chr1:23803138	A/G	cg27447006	chr1:23763279	ASAP3	0.62	5.45	0.4	2e-7	Total cholesterol levels;
PAAD	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg04359915	chr10:101825029	CPN1	-0.36	-5.62	-0.42	8.71e-8	Bone mineral density;
PAAD	cis	rs2221894	0.922	rs11136055	chr8:28855526	C/T	cg20212339	chr8:28908912	HMBOX1	0.48	5.05	0.38	1.28e-6	Obesity-related traits;
PAAD	cis	rs1075265	0.901	rs2048749	chr2:54357620	A/G	cg04546899	chr2:54196757	PSME4	0.32	4.57	0.35	9.96e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.51	-5.68	-0.42	6.6e-8	Prostate cancer;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.4	-0.34	2e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13894163	chr9:136932022	BRD3	0.64	6.99	0.49	8e-11	Myopia (pathological);
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs8105895	0.935	rs8108651	chr19:22251464	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.5	6.22	0.45	4.54e-9	Crohn's disease;
PAAD	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg15693483	chr7:1102177	C7orf50	0.38	4.64	0.35	7.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.92	-8.0	-0.54	2.87e-13	Gut microbiome composition (summer);
PAAD	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg20913747	chr6:44695427	NA	-0.72	-7.25	-0.51	1.93e-11	Total body bone mineral density;
PAAD	cis	rs9395066	0.545	rs10948193	chr6:44949176	G/A	cg25276700	chr6:44698697	NA	0.48	5.48	0.41	1.73e-7	Height;
PAAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.82	-9.48	-0.61	4.97e-17	DNA methylation (variation);
PAAD	trans	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs35740288	0.617	rs17633749	chr15:86140791	G/A	cg07943548	chr15:86304357	KLHL25	-0.58	-5.94	-0.43	1.84e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg06728252	chr6:26598149	ABT1	-0.37	-4.33	-0.33	2.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12519773	0.526	rs4264926	chr5:92518686	C/T	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.79e-5	Migraine;
PAAD	cis	rs2286379	0.742	rs7976827	chr12:1841939	C/T	cg05227549	chr12:1770782	NA	-0.42	-4.79	-0.36	3.9e-6	Blood pressure (smoking interaction);
PAAD	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg21253087	chr9:139290292	SNAPC4	0.43	4.38	0.33	2.19e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg23018236	chr17:30244563	NA	-0.58	-4.9	-0.37	2.39e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg07873178	chr11:65307616	LTBP3	0.97	4.52	0.34	1.24e-5	Height;
PAAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.39e-8	Height;
PAAD	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9581857	0.685	rs12584061	chr13:28024544	C/T	cg22138327	chr13:27999177	GTF3A	0.68	4.62	0.35	8.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.57	5.83	0.43	3.14e-8	Coronary artery disease;
PAAD	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.63	5.78	0.42	4.14e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.51	-6.8	-0.48	2.21e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.85	-8.79	-0.58	2.91e-15	Testicular germ cell tumor;
PAAD	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3018712	0.522	rs11228322	chr11:68445688	T/C	cg23009355	chr11:68451396	GAL	-0.51	-5.84	-0.43	3.04e-8	Total body bone mineral density;
PAAD	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.58	5.53	0.41	1.37e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.06	-0.38	1.2e-6	Chronic sinus infection;
PAAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.96	12.28	0.71	1.61e-24	Menopause (age at onset);
PAAD	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	cis	rs77216612	0.877	rs72656645	chr12:12881055	A/G	cg09462578	chr12:12878428	APOLD1	-0.9	-9.1	-0.59	4.85e-16	Lymphocyte counts;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.89e-5	Bipolar disorder;
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.64e-9	Subjective well-being;
PAAD	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg09002919	chr12:50339186	NA	0.63	4.75	0.36	4.73e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs17209837	0.527	rs4148824	chr7:87075362	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-6.5	-0.47	1.07e-9	Gallbladder cancer;
PAAD	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg05082376	chr22:42548792	NA	-0.43	-4.27	-0.33	3.37e-5	Cognitive function;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg12193833	chr17:30244370	NA	-0.66	-5.29	-0.39	4.18e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.16	-0.6	3.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs11686241	1.000	rs11686241	chr2:217298205	A/G	cg15830940	chr2:217278069	SMARCAL1	0.44	4.34	0.33	2.56e-5	Cancer;
PAAD	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.71	-0.36	5.51e-6	Lung cancer in ever smokers;
PAAD	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg23127183	chr11:57508653	C11orf31	0.49	4.29	0.33	3.21e-5	Schizophrenia;
PAAD	cis	rs1371614	0.632	rs10196501	chr2:27147272	C/T	cg07507200	chr2:27712693	IFT172	-0.45	-4.25	-0.33	3.68e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2790216	1.000	rs61366424	chr10:60004851	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2051773	0.567	rs7929927	chr11:17044358	T/A	cg15432903	chr11:17409602	KCNJ11	-0.52	-4.7	-0.36	5.75e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.1	-0.38	9.86e-7	Prudent dietary pattern;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09256448	chr16:638327	NA	0.41	4.28	0.33	3.31e-5	Height;
PAAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg18005901	chr6:33739558	LEMD2	0.58	4.69	0.36	6.07e-6	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs3852407	chr10:64016783	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.61	9.39	0.61	8.21e-17	Longevity;Endometriosis;
PAAD	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.46	-0.4	1.94e-7	Waist circumference;Hip circumference;
PAAD	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.41	-6.33	-0.46	2.68e-9	Mean corpuscular volume;
PAAD	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.47	-4.67	-0.35	6.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12432203	1.000	rs72622428	chr14:51732095	A/T	cg23942311	chr14:51606299	NA	-0.7	-4.82	-0.36	3.52e-6	Cancer;
PAAD	cis	rs727479	0.502	rs12148604	chr15:51501404	A/G	cg21478137	chr15:51532386	CYP19A1	-0.44	-4.63	-0.35	7.85e-6	Estradiol levels;
PAAD	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.25	0.33	3.72e-5	Resting heart rate;
PAAD	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6681460	0.604	rs7546825	chr1:67101802	A/G	cg02459107	chr1:67143332	SGIP1	0.54	5.06	0.38	1.22e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs71520386	0.632	rs2286509	chr7:22854451	T/C	cg04907244	chr7:22894795	SNORD93	0.51	5.51	0.41	1.48e-7	Fibrinogen levels;
PAAD	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg12633918	chr20:23549525	CST9L	-0.4	-4.44	-0.34	1.71e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg23352942	chr3:46931381	PTH1R	-0.44	-4.79	-0.36	3.86e-6	Birth weight;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.53	5.5	0.41	1.55e-7	Lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23142935	chr16:22385308	CDR2	0.6	6.72	0.48	3.38e-10	Metabolite levels  (X-11787);
PAAD	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.67	-5.96	-0.44	1.7e-8	Mean corpuscular volume;
PAAD	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.55	-0.35	1.08e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.39	0.34	2.09e-5	Immature fraction of reticulocytes;
PAAD	cis	rs16867321	1.000	rs1358520	chr2:181440081	C/T	cg23363182	chr2:181467187	NA	-0.53	-4.69	-0.36	6.15e-6	Obesity;
PAAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.52	-4.47	-0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg02683114	chr2:24398427	C2orf84	0.61	6.93	0.49	1.09e-10	Asthma;
PAAD	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg23719950	chr11:63933701	MACROD1	-0.52	-4.54	-0.35	1.16e-5	Platelet count;
PAAD	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.55	4.83	0.36	3.35e-6	Life satisfaction;
PAAD	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg06599209	chr2:1746509	PXDN	0.25	4.25	0.33	3.75e-5	Response to antipsychotic treatment;
PAAD	cis	rs7627468	0.770	rs7635354	chr3:121966638	C/A	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.69	-6.63	-0.47	5.5e-10	Platelet distribution width;
PAAD	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg11802864	chr11:65308245	LTBP3	-0.47	-4.86	-0.37	2.91e-6	Bone mineral density;
PAAD	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg19640517	chr22:41707109	ZC3H7B	-0.54	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.73	9.37	0.6	9.64e-17	Cancer;
PAAD	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg02404636	chr22:31891804	SFI1	-0.57	-5.11	-0.38	9.56e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.5	-4.38	-0.33	2.19e-5	Multiple sclerosis;
PAAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.76	8.05	0.55	2.25e-13	Colorectal cancer;
PAAD	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.48	-4.27	-0.33	3.4e-5	Sitting height ratio;
PAAD	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.57	-5.34	-0.4	3.27e-7	Coronary artery disease;
PAAD	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.63	-5.79	-0.43	3.93e-8	Breast cancer;
PAAD	cis	rs755249	0.567	rs41270811	chr1:39815344	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.78e-10	Bipolar disorder;
PAAD	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.97	9.65	0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.33	-0.33	2.71e-5	Tonsillectomy;
PAAD	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	1.02	10.83	0.66	1.27e-20	Platelet distribution width;
PAAD	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.92	9.84	0.62	5.42e-18	Corneal astigmatism;
PAAD	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg22162314	chr17:61951766	CSH2	0.54	4.29	0.33	3.22e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2627282	0.540	rs12541680	chr8:2761488	T/C	cg21769514	chr8:2743697	NA	0.5	5.03	0.38	1.34e-6	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.59	-0.47	6.9e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs17032980	0.956	rs10208188	chr2:67307672	A/C	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.6e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg01305830	chr4:1604576	NA	-0.48	-4.52	-0.34	1.26e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.74	-9.8	-0.62	7.2e-18	Rheumatoid arthritis;
PAAD	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.49	-0.41	1.65e-7	Schizophrenia;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21862992	chr11:68658383	NA	-0.41	-4.5	-0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg05805236	chr11:65401703	PCNXL3	-0.59	-6.15	-0.45	6.4e-9	Systemic lupus erythematosus;
PAAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.48	6.33	0.46	2.59e-9	Childhood ear infection;
PAAD	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg02016764	chr4:38805732	TLR1	-0.58	-4.25	-0.33	3.65e-5	Breast cancer;
PAAD	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.66	6.64	0.47	5.16e-10	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg15117754	chr3:10150083	C3orf24	-0.73	-6.32	-0.46	2.69e-9	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25725154	chr1:168050393	NA	-0.57	-6.84	-0.49	1.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.5	-4.41	-0.34	1.91e-5	P wave terminal force;
PAAD	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg00105475	chr2:10696890	NA	-0.74	-8.41	-0.56	2.84e-14	Prostate cancer;
PAAD	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26926768	chr12:34528122	NA	0.39	4.64	0.35	7.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs134594	0.844	rs134608	chr22:29475209	T/C	cg01361351	chr22:29467363	NA	-0.4	-4.46	-0.34	1.58e-5	Birth weight;
PAAD	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.85	-0.37	3.04e-6	Height;
PAAD	cis	rs362296	0.550	rs3135064	chr4:3285389	T/C	cg14583973	chr4:3374767	RGS12	0.33	4.53	0.34	1.19e-5	Parental longevity (mother's age at death);
PAAD	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.39	5.8	0.43	3.72e-8	Educational attainment (years of education);
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.75	9.4	0.61	8.1e-17	Coronary artery disease;
PAAD	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	7.46	0.52	6.35e-12	Electrocardiographic conduction measures;
PAAD	cis	rs13201877	0.591	rs2090816	chr6:137615592	G/T	cg02969422	chr6:138484687	KIAA1244	0.57	4.57	0.35	9.86e-6	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27603082	chr10:134405566	INPP5A	0.42	4.34	0.33	2.57e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16872172	chr3:49449542	TCTA;RHOA	0.71	6.36	0.46	2.25e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.9	10.81	0.66	1.49e-20	Monocyte count;
PAAD	cis	rs577948	0.627	rs592948	chr11:122034143	C/T	cg10262710	chr11:122074011	LOC399959	0.39	4.48	0.34	1.45e-5	Myopia (pathological);
PAAD	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.54	5.08	0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.52	5.18	0.39	6.91e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg00686598	chr14:53173677	PSMC6	-0.84	-4.9	-0.37	2.4e-6	Alzheimer's disease (late onset);
PAAD	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.88	-0.37	2.63e-6	Systemic lupus erythematosus;
PAAD	cis	rs11997175	0.626	rs6468189	chr8:33648189	C/A	ch.8.33884649F	chr8:33765107	NA	0.56	6.35	0.46	2.33e-9	Body mass index;
PAAD	cis	rs9361491	0.608	rs4706069	chr6:79471568	T/C	cg05283184	chr6:79620031	NA	-0.37	-4.31	-0.33	2.87e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5751901	0.614	rs4820599	chr22:24990213	A/G	cg08808123	chr22:24999002	GGT1	-0.47	-4.9	-0.37	2.45e-6	Protein quantitative trait loci;
PAAD	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg14146966	chr2:61757674	XPO1	-0.38	-4.74	-0.36	4.89e-6	Tuberculosis;
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.53	0.47	9.22e-10	Cystic fibrosis severity;
PAAD	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.55	5.5	0.41	1.57e-7	Hemoglobin levels;
PAAD	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.5	4.58	0.35	9.47e-6	Renal cell carcinoma;
PAAD	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg05250797	chr16:70222502	NA	0.86	6.69	0.48	4.02e-10	IgE levels;
PAAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg15448220	chr1:150897856	SETDB1	-0.64	-6.45	-0.46	1.38e-9	Monocyte chemoattractant protein-1 levels;
PAAD	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.46	-0.34	1.57e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13778499	chr9:35814820	HINT2	0.69	7.67	0.53	1.89e-12	Myopia (pathological);
PAAD	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs34112283	0.568	rs35981015	chr2:144231259	T/G	cg10530280	chr1:167759869	MPZL1	-0.66	-6.56	-0.47	8.13e-10	Neuroticism;
PAAD	cis	rs10214930	0.697	rs1524533	chr7:27625796	T/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs427943	0.778	rs2838797	chr21:46593248	C/T	cg06618935	chr21:46677482	NA	-0.41	-4.74	-0.36	4.9100000000000004e-06	Body mass index;
PAAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.57	-5.77	-0.42	4.3e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg06115741	chr20:33292138	TP53INP2	-0.59	-5.88	-0.43	2.55e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg02980000	chr4:1222292	CTBP1	0.66	4.41	0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg16578609	chr1:2399051	NA	-0.41	-4.68	-0.35	6.26e-6	Schizophrenia;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-5.17	-0.39	7.4e-7	Personality dimensions;
PAAD	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.71	7.11	0.5	4.22e-11	Alcohol dependence;
PAAD	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	1.15	17.7	0.82	9.35e-39	Multiple myeloma;
PAAD	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.41	-6.2	-0.45	5.06e-9	Subjective well-being;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09606015	chr3:182511586	ATP11B	0.62	6.44	0.46	1.49e-9	Pancreatic cancer;
PAAD	cis	rs9397240	0.789	rs9383746	chr6:155563435	C/T	cg06694381	chr6:155569200	TIAM2	-0.47	-4.25	-0.33	3.69e-5	Life satisfaction;
PAAD	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.69	-0.53	1.7e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3996993	0.703	rs4715322	chr6:52649209	C/G	cg20803780	chr6:52668592	GSTA1	-0.36	-4.45	-0.34	1.62e-5	Hemoglobin concentration;
PAAD	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.68	7.88	0.54	6e-13	Huntington's disease progression;
PAAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.45	-0.4	1.97e-7	Personality dimensions;
PAAD	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.8	-9.04	-0.59	6.7e-16	Caffeine consumption;
PAAD	cis	rs1075265	0.584	rs2357954	chr2:54362437	T/C	cg04546899	chr2:54196757	PSME4	0.4	5.94	0.43	1.85e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7567389	0.719	rs4662718	chr2:128015367	C/T	cg09760422	chr2:128146352	NA	-0.37	-5.8	-0.43	3.73e-8	Self-rated health;
PAAD	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs901683	0.850	rs112297763	chr10:46069436	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.5	-0.47	1.1e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.31	0.56	4.88e-14	Parkinson's disease;
PAAD	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.65	7.49	0.52	5.13e-12	Testicular germ cell tumor;
PAAD	cis	rs7260598	0.539	rs116746751	chr19:24064218	A/G	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.72	0.62	1.11e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.25	0.33	3.72e-5	Resting heart rate;
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg05697835	chr1:2722811	NA	-0.43	-4.74	-0.36	4.79e-6	Ulcerative colitis;
PAAD	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.5	-4.8	-0.36	3.71e-6	Daytime sleep phenotypes;
PAAD	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02569437	chr6:42947051	PEX6	0.64	6.8	0.48	2.3e-10	Myopia (pathological);
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.44	-0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs959260	1.000	rs7221050	chr17:73393949	A/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs11997175	0.572	rs7836230	chr8:33623250	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg17294928	chr15:75287854	SCAMP5	-0.62	-4.95	-0.37	1.96e-6	Blood trace element (Zn levels);
PAAD	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg11779900	chr17:80519722	FOXK2	-0.49	-5.04	-0.38	1.33e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.78	-6.46	-0.46	1.36e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.88	-0.37	2.7e-6	Height;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03348901	chr8:41436158	AGPAT6	0.62	6.51	0.47	1.05e-9	Pancreatic cancer;
PAAD	cis	rs10214930	0.813	rs2391444	chr7:27642420	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.46	4.29	0.33	3.12e-5	Anterior chamber depth;
PAAD	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.91	0.37	2.33e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.69	7.06	0.5	5.52e-11	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.85	-7.16	-0.5	3.27e-11	Initial pursuit acceleration;
PAAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg24253500	chr15:84953950	NA	0.56	6.55	0.47	8.57e-10	Schizophrenia;
PAAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg05207973	chr5:176823642	SLC34A1	0.41	4.77	0.36	4.23e-6	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg15192750	chr16:69999425	NA	0.79	6.18	0.45	5.58e-9	IgE levels;
PAAD	cis	rs11951515	0.508	rs10059993	chr5:43598352	A/G	cg01983248	chr5:43482804	C5orf28	-0.31	-4.42	-0.34	1.84e-5	Metabolite levels  (X-11787);
PAAD	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.76	-0.42	4.51e-8	Colorectal cancer;
PAAD	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg23024343	chr7:107201750	COG5	0.51	4.3	0.33	2.99e-5	Coronary artery disease;
PAAD	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	4.43	0.34	1.82e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.68	-6.19	-0.45	5.24e-9	Tuberculosis;
PAAD	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg00490450	chr3:139108681	COPB2	-0.65	-5.73	-0.42	5.2100000000000003e-08	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.58	-5.65	-0.42	7.7e-8	Obesity;
PAAD	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.42	4.59	0.35	9.21e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg25828445	chr12:7781288	NA	0.77	5.51	0.41	1.47e-7	HDL cholesterol levels;
PAAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.97	-5.1	-0.38	1e-6	Childhood ear infection;
PAAD	cis	rs17023223	0.537	rs1343723	chr1:119605054	A/T	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19459675	chr4:166249239	SC4MOL	0.6	6.55	0.47	8.22e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03728813	chr1:35658789	SFPQ	-0.6	-6.37	-0.46	2.14e-9	Smoking initiation;
PAAD	trans	rs9345521	1.000	rs9360076	chr6:65503952	G/A	cg26414000	chr1:85721327	C1orf52	0.52	6.32	0.46	2.77e-9	Iris color (a* coordinate);
PAAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15145965	chr22:50218605	BRD1	0.63	5.19	0.39	6.72e-7	Schizophrenia;
PAAD	cis	rs2882667	0.690	rs4835707	chr5:138174520	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.49	4.56	0.35	1.05e-5	Renal cell carcinoma;
PAAD	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.46	-4.59	-0.35	9.37e-6	Breast cancer;
PAAD	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.47	-0.41	1.8e-7	Mood instability;
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.81	-0.36	3.57e-6	Initial pursuit acceleration;
PAAD	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.21e-5	Magnesium levels;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg09699651	chr6:150184138	LRP11	0.47	5.04	0.38	1.29e-6	Lung cancer;
PAAD	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.8	6.8	0.48	2.27e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs35213789	0.768	rs6979355	chr7:69384562	A/G	cg23025562	chr15:65281826	SPG21	0.96	6.4	0.46	1.82e-9	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.49	5.06	0.38	1.21e-6	Height;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.88	9.74	0.62	1.04e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.56	5.62	0.41	8.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2133450	0.751	rs55888066	chr3:7367119	T/C	cg19930620	chr3:7340148	GRM7	-0.44	-4.67	-0.35	6.68e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18181496	chr7:107642539	LAMB1	0.48	4.57	0.35	9.89e-6	Ulcerative colitis;
PAAD	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg05484376	chr2:27715224	FNDC4	-0.48	-4.9	-0.37	2.45e-6	Total body bone mineral density;
PAAD	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02071572	chr4:1403502	NA	0.44	5.68	0.42	6.68e-8	Obesity-related traits;
PAAD	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	5.58	0.41	1.06e-7	Blood protein levels;
PAAD	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-4.34	-0.33	2.6e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs793571	0.822	rs17302045	chr15:59199937	T/G	cg05156742	chr15:59063176	FAM63B	-0.53	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs6466055	0.575	rs11981882	chr7:104673462	T/C	cg04380332	chr7:105027541	SRPK2	-0.49	-4.59	-0.35	9.35e-6	Schizophrenia;
PAAD	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.91	0.49	1.22e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3745621	0.925	rs309185	chr19:47635284	C/T	cg24326880	chr19:47634349	SAE1	0.55	4.49	0.34	1.43e-5	Lymphocyte counts;
PAAD	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.92	-11.11	-0.67	2.33e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02399900	chr10:126305320	NA	-0.55	-6.34	-0.46	2.51e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3736485	0.966	rs12372948	chr15:51894311	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.31	-0.33	2.87e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.54	-0.35	1.12e-5	Biliary atresia;
PAAD	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06637938	chr14:75390232	RPS6KL1	-1.09	-14.72	-0.77	4.86e-31	Caffeine consumption;
PAAD	cis	rs10982213	0.951	rs12002094	chr9:117190749	A/G	cg00078025	chr9:117159975	NA	-0.65	-4.72	-0.36	5.23e-6	Interleukin-6 levels;
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg02462569	chr6:150064036	NUP43	-0.51	-5.8	-0.43	3.81e-8	Lung cancer;
PAAD	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.57	5.69	0.42	6.48e-8	Systolic blood pressure;
PAAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg05585544	chr11:47624801	NA	0.45	4.93	0.37	2.14e-6	Subjective well-being;
PAAD	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-5.45	-0.4	2.02e-7	Lymphocyte counts;
PAAD	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.52	-4.83	-0.37	3.25e-6	Hypospadias;
PAAD	cis	rs7742824	0.879	rs7769540	chr6:44062899	G/C	cg21657043	chr6:44035552	NA	0.44	4.88	0.37	2.61e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-5.2	-0.39	6.26e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg19153763	chr7:27196371	HOXA7	-0.29	-4.3	-0.33	3.03e-5	Crohn's disease;
PAAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs9346353	0.737	rs1078026	chr6:70496340	G/A	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg09399716	chr2:46890238	NA	-0.63	-5.5	-0.41	1.6e-7	Height;
PAAD	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg12046867	chr14:103022105	NA	0.64	4.65	0.35	7.29e-6	Platelet count;
PAAD	cis	rs56046484	1.000	rs2304416	chr15:85618882	C/T	cg08123816	chr15:85640762	PDE8A	0.42	4.37	0.33	2.27e-5	Testicular germ cell tumor;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03605463	chr16:89740564	NA	-0.57	-5.44	-0.4	2.09e-7	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18174222	chr1:165696598	TMCO1	-0.64	-6.47	-0.46	1.28e-9	Obesity-related traits;
PAAD	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.49	4.64	0.35	7.58e-6	Pancreatic cancer;
PAAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	5.69	0.42	6.3e-8	Body mass index;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18337363	chr3:52569053	NT5DC2	0.41	4.36	0.33	2.4e-5	Bipolar disorder;
PAAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg05697835	chr1:2722811	NA	0.42	4.76	0.36	4.46e-6	Ulcerative colitis;
PAAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg23024343	chr7:107201750	COG5	0.57	4.8	0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.89	0.37	2.5e-6	Lung cancer in ever smokers;
PAAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.45	5.61	0.41	9.14e-8	Childhood ear infection;
PAAD	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs8179	0.645	rs42046	chr7:92252203	C/G	cg03496780	chr7:92466842	CDK6	0.47	4.42	0.34	1.89e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15586420	chr15:90294517	MESP1	0.65	7.15	0.5	3.41e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg13002189	chr3:66846049	NA	-0.51	-5.24	-0.39	5.39e-7	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19857361	chr1:34330000	HMGB4;CSMD2	-0.63	-6.32	-0.46	2.74e-9	Obesity-related traits;
PAAD	cis	rs2526932	0.625	rs2526942	chr14:73061519	A/C	cg13588403	chr14:73209128	DPF3	-0.4	-5.46	-0.41	1.87e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.55	7.47	0.52	5.71e-12	Renal cell carcinoma;
PAAD	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.51	4.77	0.36	4.22e-6	Self-reported allergy;
PAAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs758324	0.812	rs116369002	chr5:131242055	G/A	cg06307176	chr5:131281290	NA	-0.54	-4.7	-0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02099313	chr1:231114956	TTC13;ARV1	0.7	8.35	0.56	3.93e-14	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27654615	chr5:138674135	NA	-0.62	-6.44	-0.46	1.46e-9	Obesity-related traits;
PAAD	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2278796	0.558	rs35288741	chr1:204928155	A/G	cg17947172	chr1:204966197	NFASC	0.41	4.81	0.36	3.55e-6	Mean platelet volume;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-6.93	-0.49	1.1e-10	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03112782	chr1:37979729	MEAF6	0.57	6.64	0.47	5.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.77	-9.11	-0.59	4.35e-16	Height;
PAAD	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg00806126	chr19:22604979	ZNF98	-0.39	-4.79	-0.36	3.95e-6	Pain;
PAAD	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4729127	1.000	rs7799378	chr7:94007546	C/G	cg20814616	chr7:94014465	NA	0.6	4.48	0.34	1.44e-5	Intelligence;
PAAD	cis	rs7225151	0.522	rs56229705	chr17:5014789	G/A	cg09495303	chr17:4804838	CHRNE;C17orf107	-0.73	-5.15	-0.39	7.83e-7	Alzheimer's disease (late onset);
PAAD	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.32	-0.46	2.69e-9	Morning vs. evening chronotype;
PAAD	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.7	0.42	6.1e-8	Lung cancer;
PAAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg02117656	chr17:79614917	TSPAN10	0.58	6.34	0.46	2.52e-9	Eye color traits;
PAAD	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-4.28	-0.33	3.32e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg24112000	chr20:60950667	NA	-0.8	-9.01	-0.59	8.11e-16	Colorectal cancer;
PAAD	trans	rs7172971	0.638	rs74554336	chr15:42384521	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9287604	1.000	rs10177150	chr2:237779235	A/G	cg15065627	chr2:237796583	NA	-0.53	-4.44	-0.34	1.72e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-6.82	-0.48	2.01e-10	Body mass index;
PAAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	cis	rs7243821	0.883	rs59149496	chr18:52629495	C/G	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.85	7.73	0.53	1.37e-12	Alcohol dependence;
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg26031613	chr14:104095156	KLC1	0.48	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.53	5.8	0.43	3.79e-8	Obesity-related traits;
PAAD	cis	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.6	-0.41	9.92e-8	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.72	-7.14	-0.5	3.56e-11	Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.55	-0.35	1.07e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.66	6.86	0.49	1.59e-10	Testicular germ cell tumor;
PAAD	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.84	-8.56	-0.57	1.13e-14	Bipolar disorder;
PAAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.5	-4.34	-0.33	2.6e-5	Parkinson's disease;
PAAD	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	7.65	0.53	2.15e-12	Cognitive test performance;
PAAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.63	6.15	0.45	6.7e-9	Blood protein levels;
PAAD	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.59	-4.67	-0.35	6.59e-6	Schizophrenia;
PAAD	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.23	21.97	0.87	5e-49	Testicular germ cell tumor;
PAAD	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14019695	chr9:139328340	INPP5E	0.5	4.64	0.35	7.46e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	ch.8.33884649F	chr8:33765107	NA	0.62	6.39	0.46	1.97e-9	Body mass index;
PAAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.7	5.18	0.39	6.88e-7	Initial pursuit acceleration;
PAAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.78	0.48	2.56e-10	Schizophrenia;
PAAD	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.51	4.25	0.33	3.76e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.68	7.67	0.53	1.87e-12	White blood cell count (basophil);
PAAD	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.35	-0.51	1.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.71	4.94	0.37	2.02e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg00277334	chr10:82204260	NA	-0.59	-5.98	-0.44	1.54e-8	Post bronchodilator FEV1;
PAAD	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.73	-7.67	-0.53	1.86e-12	Sudden cardiac arrest;
PAAD	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg11088901	chr6:166572345	T	-0.52	-4.72	-0.36	5.36e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6460942	0.597	rs6961238	chr7:12535428	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1997066	0.831	rs73342225	chr10:106821593	A/T	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg21775007	chr8:11205619	TDH	-0.68	-6.63	-0.47	5.51e-10	Retinal vascular caliber;
PAAD	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg00383909	chr3:49044727	WDR6	0.99	5.69	0.42	6.32e-8	Educational attainment (years of education);
PAAD	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg04362095	chr11:63592001	C11orf84	-0.71	-8.27	-0.56	6.13e-14	Pulse pressure;
PAAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs2050203	0.614	rs6114730	chr20:24426454	C/T	cg16485975	chr20:25065418	NA	-0.65	-4.37	-0.33	2.3e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
PAAD	cis	rs6466055	0.589	rs12530690	chr7:105005566	C/A	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg13798912	chr7:905769	UNC84A	0.59	4.48	0.34	1.48e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg18279126	chr7:2041391	MAD1L1	0.58	5.63	0.42	8.46e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.71	-5.45	-0.4	1.99e-7	Initial pursuit acceleration;
PAAD	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	1.06	6.63	0.47	5.59e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.53	5.35	0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.63	-7.08	-0.5	5e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.25	-0.45	4.04e-9	Mood instability;
PAAD	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg16584676	chr17:46985605	UBE2Z	0.61	6.28	0.45	3.45e-9	Type 2 diabetes;
PAAD	cis	rs3814231	0.531	rs11196446	chr10:115471016	A/C	cg24846397	chr10:115438155	CASP7	-0.55	-5.55	-0.41	1.22e-7	Vitiligo;
PAAD	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.61	4.6	0.35	8.87e-6	Thyroid stimulating hormone;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05714563	chr13:48807179	ITM2B	0.59	6.56	0.47	7.91e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg20936604	chr3:58311152	NA	-0.79	-4.83	-0.36	3.37e-6	Cholesterol, total;
PAAD	cis	rs863345	0.604	rs12064489	chr1:158499449	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.81	7.81	0.54	8.66e-13	Neuroticism;
PAAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.74	-8.02	-0.55	2.68e-13	Eye color traits;
PAAD	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs12044355	0.858	rs12031888	chr1:231820012	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.96	-0.44	1.66e-8	Menarche (age at onset);
PAAD	cis	rs9398803	0.723	rs1262545	chr6:127074587	C/T	cg19875578	chr6:126661172	C6orf173	-0.45	-4.76	-0.36	4.52e-6	Male-pattern baldness;
PAAD	cis	rs557074	0.821	rs9505057	chr6:7171407	G/T	cg01785233	chr6:7260807	NA	-0.47	-4.35	-0.33	2.51e-5	Monocyte count;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.83	-9.08	-0.59	5.3e-16	Prostate cancer;
PAAD	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg16576597	chr16:28551801	NUPR1	0.63	7.02	0.5	6.73e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg18551225	chr6:44695536	NA	-0.69	-7.07	-0.5	5.4e-11	Total body bone mineral density;
PAAD	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.49	5.17	0.39	7.22e-7	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.53	0.57	1.37e-14	Morning vs. evening chronotype;
PAAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-1.09	-9.13	-0.6	3.88e-16	Post bronchodilator FEV1;
PAAD	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.44	6.94	0.49	1.06e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3781663	0.963	rs3781662	chr11:69999501	A/G	cg06393558	chr11:69982916	ANO1	-0.44	-4.81	-0.36	3.59e-6	Survival in rectal cancer;
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.61	-0.41	9.52e-8	Lung cancer;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12760731	0.720	rs12022731	chr1:178416358	A/G	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00257704	chr17:77903985	NA	0.67	6.66	0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg03989125	chr22:38214979	NA	-0.66	-6.94	-0.49	1.09e-10	Glioblastoma;Glioma;
PAAD	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.58	-6.22	-0.45	4.52e-9	Lung cancer;
PAAD	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg07841815	chr7:100318223	EPO	-0.5	-4.79	-0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg09127314	chr1:152161683	NA	-0.69	-5.04	-0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.6	7.09	0.5	4.7e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16976116	0.530	rs508482	chr15:55410507	G/T	cg11288833	chr15:55489084	RSL24D1	-0.56	-4.38	-0.33	2.23e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg23083516	chr15:85180758	SCAND2	0.39	4.38	0.34	2.16e-5	P wave terminal force;
PAAD	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.7	6.56	0.47	8.12e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07156959	chr12:121975669	KDM2B	0.72	7.97	0.54	3.56e-13	Myopia (pathological);
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18678067	chr19:52674854	ZNF836	0.6	6.67	0.48	4.41e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.74	0.82	7.26e-39	Height;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-4.56	-0.35	1.05e-5	Lung cancer;
PAAD	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.57	-5.34	-0.4	3.33e-7	Obesity-related traits;
PAAD	cis	rs12780845	0.931	rs72775092	chr10:17249648	C/T	cg00857480	chr10:17188594	TRDMT1	0.35	4.39	0.34	2.1e-5	Homocysteine levels;
PAAD	cis	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.79	-0.36	3.93e-6	Parkinson's disease;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10046574	0.831	rs7455447	chr7:135062056	C/T	cg27474649	chr7:135195673	CNOT4	0.84	4.44	0.34	1.75e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8062405	0.540	rs193628	chr16:28582142	G/T	cg16576597	chr16:28551801	NUPR1	-0.51	-5.74	-0.42	5.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.72	8.58	0.57	1.03e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.74	-6.37	-0.46	2.16e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4802307	1.000	rs62136099	chr19:46847901	C/T	cg22304262	chr19:47287778	SLC1A5	-0.5	-4.56	-0.35	1.04e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12304921	0.683	rs17125346	chr12:51471152	C/T	cg04427360	chr12:51347099	HIGD1C	0.59	4.4	0.34	1.99e-5	Type 2 diabetes;
PAAD	cis	rs8014252	0.708	rs74062750	chr14:71026052	C/G	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.92	-0.37	2.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.23	-9.06	-0.59	6.16e-16	Breast cancer;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-8.45	-0.57	2.19e-14	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.39e-14	Prostate cancer;
PAAD	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	0.98	5.59	0.41	1.03e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs8040855	0.627	rs3816105	chr15:85640911	G/A	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.71e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.4	-5.18	-0.39	6.97e-7	Prostate cancer;
PAAD	trans	rs901683	0.571	rs73292811	chr10:46114121	A/G	cg07935355	chr19:50391064	TBC1D17	1.34	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	6.99	0.49	8e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.1	15.94	0.79	2.91e-34	Cognitive function;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.72	7.02	0.5	6.76e-11	Prostate cancer;
PAAD	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs11022131	1.000	rs11022131	chr11:12072213	C/G	cg17400947	chr11:11645841	NA	-0.38	-4.41	-0.34	1.95e-5	Warfarin maintenance dose;
PAAD	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.82	-6.11	-0.44	7.94e-9	Coronary artery calcification;
PAAD	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.55	5.4	0.4	2.5e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11048434	0.518	rs1805669	chr12:9180251	T/C	cg04548204	chr12:9162872	KLRG1	0.4	4.45	0.34	1.67e-5	Sjögren's syndrome;
PAAD	cis	rs11264799	0.813	rs10908588	chr1:157699866	A/T	cg18268488	chr1:157545234	FCRL4	0.51	4.86	0.37	2.84e-6	IgA nephropathy;
PAAD	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.51	0.41	1.51e-7	Mammographic density (dense area);
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg18612461	chr15:75251733	NA	0.59	7.19	0.5	2.72e-11	Breast cancer;
PAAD	cis	rs2016586	0.802	rs5999973	chr22:36115594	G/A	cg26342177	chr22:36113512	APOL5	-0.49	-4.83	-0.37	3.23e-6	Body mass index;
PAAD	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg02421172	chr7:1938701	MAD1L1	0.57	4.27	0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.98	0.37	1.74e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.27	0.51	1.79e-11	Neuroticism;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.61	5.04	0.38	1.33e-6	Birth weight;
PAAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs7582720	1.000	rs74675536	chr2:203673073	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg13206674	chr6:150067644	NUP43	0.6	5.43	0.4	2.19e-7	Lung cancer;
PAAD	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	0.84	5.73	0.42	5.35e-8	Gut microbiota (bacterial taxa);
PAAD	trans	rs1015213	0.609	rs77334030	chr8:52873650	A/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.29e-7	Coronary artery disease;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg11416102	chr8:651193	ERICH1	0.75	4.85	0.37	2.99e-6	IgG glycosylation;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.87	6.43	0.46	1.57e-9	Alzheimer's disease;
PAAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.83	8.64	0.57	7.29e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg25200586	chr1:148000763	NA	-0.61	-6.37	-0.46	2.1e-9	Hip geometry;
PAAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-5.28	-0.39	4.36e-7	Type 2 diabetes;
PAAD	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.39	9.7	0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg16083429	chr3:49237500	CCDC36	0.42	4.6	0.35	8.88e-6	Menarche (age at onset);
PAAD	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.76	8.3	0.56	5.4e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg14926445	chr8:58193284	C8orf71	-0.63	-5.2	-0.39	6.26e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.78	10.14	0.64	8.85e-19	Vitiligo;
PAAD	cis	rs2289328	0.823	rs71472433	chr15:40649609	A/C	cg13931752	chr15:40660718	DISP2	0.59	5.36	0.4	3.02e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs965469	1.000	rs2236098	chr20:3267133	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.84	-0.54	7.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.02	0.5	6.74e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.79	-5.55	-0.41	1.25e-7	Ulcerative colitis;
PAAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.72	9.8	0.62	6.89e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	1.0	9.06	0.59	6.18e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.81	5.34	0.4	3.36e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.49	4.95	0.37	1.94e-6	Menopause (age at onset);
PAAD	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.94	-9.8	-0.62	7.24e-18	Monocyte percentage of white cells;
PAAD	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg08992911	chr2:238395768	MLPH	0.97	6.54	0.47	9e-10	Prostate cancer;
PAAD	cis	rs375066	0.762	rs1073654	chr19:44411420	T/C	cg21496419	chr19:44306685	LYPD5	-0.42	-4.93	-0.37	2.17e-6	Breast cancer;
PAAD	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.5	4.65	0.35	7.24e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg25036284	chr2:26402008	FAM59B	0.64	4.93	0.37	2.09e-6	Gut microbiome composition (summer);
PAAD	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg01097406	chr16:89675127	NA	-0.35	-4.26	-0.33	3.52e-5	Vitiligo;
PAAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs55788414	0.725	rs13339333	chr16:81189028	C/A	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.54	-0.57	1.3e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	7.54	0.52	3.9e-12	Schizophrenia;
PAAD	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg21191810	chr6:118973309	C6orf204	0.48	6.16	0.45	6.36e-9	Electrocardiographic conduction measures;
PAAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1468734	1.000	rs35486581	chr16:5003586	A/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.52	5.38	0.4	2.7e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	4.3	0.33	3.1e-5	Iron status biomarkers;
PAAD	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-10.18	-0.64	6.8e-19	Morning vs. evening chronotype;
PAAD	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	0.95	6.51	0.47	1.04e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg16006841	chr5:176797999	RGS14	0.71	6.83	0.48	1.93e-10	Urate levels in lean individuals;
PAAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg06618935	chr21:46677482	NA	-0.6	-7.15	-0.5	3.5e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.68	6.45	0.46	1.43e-9	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-6.02	-0.44	1.26e-8	Prudent dietary pattern;
PAAD	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-4.77	-0.36	4.24e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.76	9.14	0.6	3.71e-16	Lung cancer;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.69	-0.36	6.11e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg06740227	chr12:86229804	RASSF9	0.55	4.97	0.37	1.75e-6	Major depressive disorder;
PAAD	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.84	9.36	0.6	1.02e-16	Mortality in heart failure;
PAAD	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.66	7.1	0.5	4.45e-11	Coronary artery disease;
PAAD	cis	rs58521262	0.530	rs460681	chr19:23140545	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs11671005	0.611	rs56026876	chr19:59006157	G/C	cg25952890	chr19:58913133	NA	0.71	5.51	0.41	1.52e-7	Mean platelet volume;
PAAD	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.02	-0.49	6.85e-11	Monocyte count;
PAAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg07332563	chr6:291687	DUSP22	-0.61	-6.32	-0.46	2.76e-9	Menopause (age at onset);
PAAD	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg03999872	chr20:62272968	STMN3	-0.73	-6.71	-0.48	3.71e-10	Atopic dermatitis;
PAAD	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg22875332	chr1:76189707	ACADM	-0.48	-4.76	-0.36	4.56e-6	Daytime sleep phenotypes;
PAAD	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.27	-0.39	4.57e-7	Daytime sleep phenotypes;
PAAD	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg00228799	chr9:131580591	ENDOG	0.64	6.4	0.46	1.78e-9	Blood metabolite levels;
PAAD	cis	rs61884328	0.866	rs12575721	chr11:46823681	T/C	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.45	4.58	0.35	9.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9900972	0.918	rs4789942	chr17:76877495	T/C	cg00961940	chr17:76876995	TIMP2	0.57	5.31	0.4	3.84e-7	Obesity-related traits;
PAAD	cis	rs2458413	0.903	rs2669448	chr8:105372324	T/G	cg04554929	chr8:105342491	NA	0.32	5.37	0.4	2.91e-7	Paget's disease;
PAAD	cis	rs73019876	0.901	rs426299	chr19:22229275	G/A	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.26	-0.33	3.6e-5	Height;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3026101	0.624	rs62072673	chr17:5317669	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.92	-7.59	-0.52	3.01e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6142102	0.517	rs6059577	chr20:32527686	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	4.35	0.33	2.51e-5	Skin pigmentation;
PAAD	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg12183467	chr14:104352244	NA	0.34	4.37	0.33	2.29e-5	Blood metabolite levels;
PAAD	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.65	5.05	0.38	1.25e-6	Alzheimer's disease (survival time);
PAAD	cis	rs1105228	0.610	rs2874885	chr6:165702037	C/T	cg20535254	chr6:165714960	C6orf118	0.41	4.28	0.33	3.29e-5	Number of pregnancies;Number of children;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2.03e-5	Life satisfaction;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.28	-0.45	3.42e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.51	-4.96	-0.37	1.85e-6	Cutaneous psoriasis;
PAAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg11367502	chr7:22862612	TOMM7	0.51	4.98	0.37	1.7e-6	Fibrinogen;
PAAD	cis	rs889398	0.560	rs8057620	chr16:69884619	A/T	cg00738113	chr16:70207722	CLEC18C	-0.36	-4.33	-0.33	2.67e-5	Body mass index;
PAAD	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.78e-9	Diastolic blood pressure;
PAAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.24	0.84	1.41e-42	IgG glycosylation;
PAAD	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.42	-4.7	-0.36	5.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06548214	chr20:57270552	NPEPL1	0.58	6.46	0.46	1.33e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10982213	1.000	rs7043417	chr9:117164326	G/C	cg00078025	chr9:117159975	NA	0.58	4.32	0.33	2.76e-5	Interleukin-6 levels;
PAAD	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg22467129	chr15:76604101	ETFA	0.52	4.84	0.37	3.13e-6	Blood metabolite levels;
PAAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.05	-0.38	1.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17293817	0.625	rs10794748	chr10:1421516	A/G	cg02408697	chr10:1416920	ADARB2	-0.52	-4.91	-0.37	2.35e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg09455208	chr3:40491958	NA	0.46	5.93	0.43	1.95e-8	Renal cell carcinoma;
PAAD	cis	rs2033732	0.954	rs1550215	chr8:85093121	A/C	cg05716166	chr8:85095498	RALYL	0.49	4.34	0.33	2.55e-5	Body mass index;
PAAD	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg17308606	chr9:130706144	FAM102A	0.49	4.48	0.34	1.47e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9616064	0.849	rs12168432	chr22:46972080	G/A	cg03318428	chr22:46971703	NA	0.39	4.44	0.34	1.73e-5	Urate levels in obese individuals;
PAAD	cis	rs11966931	0.948	rs9486686	chr6:108089545	T/C	cg10566610	chr6:108093680	SCML4	0.47	4.45	0.34	1.66e-5	Neutrophil percentage of white cells;
PAAD	cis	rs2249694	0.810	rs2987785	chr10:135365003	C/T	cg16964102	chr10:135390573	NA	-0.45	-4.87	-0.37	2.79e-6	Obesity-related traits;
PAAD	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.53	0.61	3.51e-17	Post bronchodilator FEV1;
PAAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs72960926	1.000	rs72958951	chr6:75118214	G/A	cg13435101	chr6:74171350	MTO1	0.82	4.25	0.33	3.73e-5	Metabolite levels (MHPG);
PAAD	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.61	4.85	0.37	3.08e-6	Plateletcrit;
PAAD	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs10155981	0.510	rs4719704	chr7:22588827	T/G	cg05062323	chr7:22590069	NA	-0.84	-4.91	-0.37	2.3e-6	Bilirubin levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg22365834	chr1:186646027	PTGS2	-0.62	-7.24	-0.51	2.07e-11	Energy expenditure (24h);
PAAD	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.42	4.32	0.33	2.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09699651	chr6:150184138	LRP11	0.63	6.89	0.49	1.4e-10	Testicular germ cell tumor;
PAAD	cis	rs735539	0.521	rs2585897	chr13:21398979	A/G	cg27499820	chr13:21296301	IL17D	-0.52	-4.62	-0.35	8.02e-6	Dental caries;
PAAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-9.3	-0.6	1.42e-16	Gut microbiome composition (summer);
PAAD	cis	rs6494488	0.500	rs56076814	chr15:64807784	G/A	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg15017067	chr4:17643749	FAM184B	0.4	4.44	0.34	1.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12661256	chr15:31745916	NA	0.61	6.31	0.46	2.97e-9	Warfarin maintenance dose;
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.98	0.37	1.72e-6	Longevity;
PAAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg13611204	chr9:139324423	INPP5E	-0.56	-4.77	-0.36	4.3e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.95	-5.54	-0.41	1.31e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.649	rs10929685	chr2:10732799	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.73	5.38	0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-4.61	-0.35	8.33e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs12257961	0.675	rs10752364	chr10:15352246	T/A	cg10616319	chr10:15468812	NA	-0.44	-4.25	-0.33	3.74e-5	Selective IgA deficiency;
PAAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg23033748	chr14:75592666	NEK9	0.41	4.94	0.37	2.05e-6	Height;
PAAD	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg02404636	chr22:31891804	SFI1	0.64	5.81	0.43	3.51e-8	Colorectal cancer;
PAAD	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg08315770	chr6:39281885	KCNK17	-0.61	-6.44	-0.46	1.49e-9	Type 2 diabetes;
PAAD	cis	rs3753841	0.832	rs11164604	chr1:103253485	C/T	cg24495344	chr1:103574097	COL11A1	0.37	4.32	0.33	2.85e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6585424	1.000	rs6585424	chr10:81933748	A/G	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.74	-0.36	4.94e-6	Dilated cardiomyopathy;
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg00129232	chr17:37814104	STARD3	0.51	4.39	0.34	2.07e-5	Self-reported allergy;
PAAD	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.44	4.84	0.37	3.11e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.8	9.3	0.6	1.42e-16	Diastolic blood pressure;
PAAD	cis	rs458685	0.636	rs441168	chr21:31189792	T/C	cg24620508	chr21:31310605	GRIK1	-0.49	-4.52	-0.34	1.23e-5	Breast cancer;
PAAD	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-4.84	-0.37	3.14e-6	Menarche (age at onset);
PAAD	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06530960	chr19:49140787	SEC1;DBP	-0.61	-5.17	-0.39	7.38e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg20887711	chr4:1340912	KIAA1530	0.49	4.42	0.34	1.88e-5	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs72960926	1.000	rs11756716	chr6:75097407	T/C	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.59	5.56	0.41	1.16e-7	Schizophrenia;
PAAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.35	-0.4	3.13e-7	Obesity-related traits;
PAAD	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg24220031	chr2:73402428	NA	-0.33	-5.1	-0.38	9.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs16958440	0.581	rs11872531	chr18:44689234	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-4.61	-0.35	8.51e-6	Sitting height ratio;
PAAD	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.38	-0.33	2.18e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.66e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.46	4.34	0.33	2.55e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.46e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11669133	1.000	rs75864794	chr19:11090841	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.7	0.36	5.84e-6	LDL cholesterol;
PAAD	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.05	-0.38	1.24e-6	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg18209359	chr17:80159595	CCDC57	-0.46	-4.55	-0.35	1.09e-5	Life satisfaction;
PAAD	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.97e-16	Cannabis dependence symptom count;
PAAD	cis	rs10901513	0.932	rs34120875	chr10:127667812	T/C	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	1.12	16.55	0.8	7.95e-36	Breast cancer;
PAAD	cis	rs6964492	0.576	rs34331674	chr7:134400835	T/C	cg22430036	chr7:134592620	CALD1	-0.5	-4.44	-0.34	1.7e-5	Tonsillectomy;
PAAD	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.82	8.36	0.56	3.78e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07395648	chr5:131743802	NA	-0.51	-4.58	-0.35	9.43e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg15847926	chr7:2749597	AMZ1	-0.38	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg14851346	chr12:38532713	NA	-0.45	-4.27	-0.33	3.37e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	5.41	0.4	2.44e-7	Response to antipsychotic treatment;
PAAD	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg10820045	chr2:198174542	NA	0.53	5.5	0.41	1.55e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14298577	chr7:100272703	GNB2	0.71	7.5	0.52	5.07e-12	Myopia (pathological);
PAAD	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg09163369	chr1:210001066	C1orf107	0.71	6.75	0.48	2.99e-10	Orofacial clefts;
PAAD	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs6011002	0.745	rs4809331	chr20:62370890	A/G	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs1364705	1.000	rs13269824	chr8:120223763	A/G	cg09273054	chr8:120220131	MAL2	0.44	4.94	0.37	2.08e-6	Hippocampal atrophy;
PAAD	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.82	8.32	0.56	4.6e-14	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs294958	0.806	rs294964	chr5:151562982	T/C	cg04453665	chr5:151504455	NA	-0.42	-4.71	-0.36	5.59e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs9810890	1.000	rs73198869	chr3:128530365	G/A	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.61	4.5	0.34	1.35e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	4.49	0.34	1.39e-5	Educational attainment;
PAAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	7.91	0.54	5e-13	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.12	14.72	0.77	4.82e-31	Primary sclerosing cholangitis;
PAAD	cis	rs412658	0.504	rs17769372	chr19:22114704	T/C	cg23859931	chr19:22123797	NA	-0.45	-4.64	-0.35	7.36e-6	Telomere length;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21724796	chr17:8113904	AURKB	0.64	6.45	0.46	1.41e-9	Obesity-related traits;
PAAD	cis	rs4742903	0.904	rs10121829	chr9:106993996	A/G	cg14250997	chr9:106856677	SMC2	0.46	5.0	0.38	1.59e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg24330906	chr2:85765176	MAT2A	-0.47	-5.0	-0.38	1.58e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs600626	0.755	rs10899107	chr11:75448805	A/T	cg24262691	chr11:75473276	NA	0.47	4.38	0.33	2.2e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.4	4.56	0.35	1.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg23024343	chr7:107201750	COG5	0.55	4.64	0.35	7.5e-6	Osteoarthritis;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26926768	chr12:34528122	NA	-0.38	-4.74	-0.36	4.82e-6	Morning vs. evening chronotype;
PAAD	cis	rs10865541	0.967	rs6755327	chr2:3397281	T/C	cg21040360	chr2:3383326	TTC15	-0.42	-4.55	-0.35	1.11e-5	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17879320	chr4:39460513	RPL9;LIAS	-0.65	-6.93	-0.49	1.12e-10	Smoking initiation;
PAAD	trans	rs2249625	0.739	rs9342920	chr6:72783163	A/G	cg04413069	chr12:9800446	LOC374443	-0.59	-6.47	-0.46	1.24e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg26338869	chr17:61819248	STRADA	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.68	-4.58	-0.35	9.51e-6	Vitiligo;
PAAD	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg23682824	chr7:23144976	KLHL7	0.49	4.37	0.33	2.25e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04167844	chr7:27250204	NA	-0.72	-6.39	-0.46	1.96e-9	Neuroticism;
PAAD	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg02631450	chr22:32366979	NA	1.07	5.76	0.42	4.45e-8	Childhood ear infection;
PAAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	6.16	0.45	6.09e-9	Menopause (age at onset);
PAAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.86	-0.37	2.94e-6	Menarche (age at onset);
PAAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.5	-0.47	1.1e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9944275	0.860	rs35074288	chr15:97214163	C/G	cg23969200	chr15:97326567	SPATA8	0.68	4.4	0.34	2.05e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.63	-8.27	-0.56	6.35e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	5.04e-11	Total body bone mineral density;
PAAD	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-1.05	-11.07	-0.67	2.85e-21	Platelet distribution width;
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6894268	0.793	rs7379689	chr5:178992378	A/C	cg26135573	chr5:179059668	NA	0.74	6.16	0.45	6.29e-9	Eating disorders;
PAAD	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.47	-5.7	-0.42	6.13e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21687365	chr1:149899688	SF3B4	0.62	7.11	0.5	4.18e-11	Monocyte percentage of white cells;
PAAD	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg23024343	chr7:107201750	COG5	0.56	4.61	0.35	8.46e-6	Coronary artery disease;
PAAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg15847926	chr7:2749597	AMZ1	-0.38	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg05627522	chr15:75251581	NA	0.47	5.43	0.4	2.15e-7	Breast cancer;
PAAD	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.39	-5.27	-0.39	4.68e-7	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.73	7.49	0.52	5.32e-12	Alcohol dependence;
PAAD	cis	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.44	6.04	0.44	1.11e-8	Cardiovascular disease risk factors;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs818427	0.896	rs818429	chr5:112220534	T/C	cg07820702	chr5:112228657	REEP5	-0.55	-5.01	-0.38	1.52e-6	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.78e-7	Lung cancer;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg08132940	chr7:1081526	C7orf50	-0.63	-4.49	-0.34	1.39e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2730260	0.537	rs56260213	chr7:158875921	C/T	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	6.87	0.49	1.58e-10	Systemic lupus erythematosus;
PAAD	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-6.59	-0.47	6.72e-10	Lymphocyte counts;
PAAD	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.52	-4.56	-0.35	1.07e-5	Orofacial clefts;
PAAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg19413350	chr8:57351067	NA	-0.5	-4.88	-0.37	2.64e-6	Obesity-related traits;
PAAD	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.64	-5.38	-0.4	2.75e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2415984	0.622	rs2123126	chr14:46926609	C/T	cg14871534	chr14:47121158	RPL10L	-0.51	-5.36	-0.4	3.06e-7	Number of children ever born;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Body mass index;
PAAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.63	7.07	0.5	5.34e-11	Emphysema distribution in smoking;
PAAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.84	8.84	0.58	2.27e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2455601	0.744	rs2568085	chr11:8975748	G/T	cg09997546	chr11:8931473	C11orf17;ST5	0.61	6.96	0.49	9.55e-11	Schizophrenia;
PAAD	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.48	-0.34	1.49e-5	Eosinophil percentage of white cells;
PAAD	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs4841899	0.963	rs4841898	chr9:137424233	C/T	cg21123355	chr9:136844644	VAV2	0.33	4.35	0.33	2.51e-5	Stem cell factor levels;
PAAD	cis	rs728616	0.867	rs56123058	chr10:81811072	G/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.73	-7.98	-0.54	3.31e-13	Dental caries;
PAAD	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.6	-5.66	-0.42	7.29e-8	Lymphocyte counts;
PAAD	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.1	-0.38	9.86e-7	Daytime sleep phenotypes;
PAAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.37	-0.4	2.84e-7	Mood instability;
PAAD	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1499972	0.941	rs62266129	chr3:117590704	G/C	cg07612923	chr3:117604196	NA	1.05	6.74	0.48	3.03e-10	Schizophrenia;
PAAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-6.82	-0.48	2.06e-10	Asthma;
PAAD	cis	rs7929679	0.521	rs11499809	chr11:34790743	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	9.14	0.6	3.76e-16	Parkinson's disease;
PAAD	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18357526	chr6:26021779	HIST1H4A	0.51	4.53	0.34	1.21e-5	Height;
PAAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.66	-6.18	-0.45	5.59e-9	Educational attainment;
PAAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.79	-9.19	-0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.75	-0.48	2.86e-10	IgG glycosylation;
PAAD	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	5.89	0.43	2.43e-8	Monocyte count;
PAAD	cis	rs288342	0.835	rs6716810	chr2:183624597	A/G	cg02625481	chr2:183667124	NA	-0.42	-4.3	-0.33	3.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.49	-4.78	-0.36	4.18e-6	Testicular germ cell tumor;
PAAD	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11072373	chr4:100485070	RG9MTD2;MTTP	0.71	8.12	0.55	1.49e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg15145965	chr22:50218605	BRD1	0.58	4.95	0.37	1.96e-6	Schizophrenia;
PAAD	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.48	5.01	0.38	1.5e-6	Morning vs. evening chronotype;
PAAD	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6679454	1.000	rs12117610	chr1:58363108	T/C	cg17491850	chr1:57888480	DAB1	-0.4	-4.42	-0.34	1.84e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.26e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs112990264	1.000	rs112014010	chr1:213014477	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg12218747	chr21:37451666	NA	-0.45	-4.93	-0.37	2.09e-6	Mitral valve prolapse;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.64	-0.42	7.98e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg02415014	chr8:143852576	LYNX1	0.49	6.01	0.44	1.3e-8	Urinary tract infection frequency;
PAAD	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.65	-5.33	-0.4	3.47e-7	Fibrinogen levels;
PAAD	cis	rs58521262	0.556	rs290586	chr19:23202379	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.49	-4.36	-0.33	2.37e-5	Asthma;
PAAD	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg23387468	chr7:139079360	LUC7L2	-0.36	-4.3	-0.33	3.08e-5	Diisocyanate-induced asthma;
PAAD	cis	rs6466055	0.589	rs6950894	chr7:104652671	G/A	cg04380332	chr7:105027541	SRPK2	0.48	4.58	0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg11062466	chr8:58055876	NA	0.69	4.75	0.36	4.58e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.89	-7.86	-0.54	6.44e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	4.41	0.34	1.94e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.77	7.28	0.51	1.66e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	7.72	0.53	1.46e-12	Post bronchodilator FEV1;
PAAD	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.56	-6.2	-0.45	5.05e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	9.17	0.6	3.14e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs13102973	0.720	rs13137075	chr4:135889366	G/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg09526685	chr4:187126073	CYP4V2	0.75	5.56	0.41	1.16e-7	Activated partial thromboplastin time;
PAAD	cis	rs10916814	0.610	rs10799641	chr1:20897250	G/A	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.48	6.4	0.46	1.87e-9	Diastolic blood pressure;
PAAD	cis	rs4704187	0.687	rs4621537	chr5:74362222	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-1.11	-9.21	-0.6	2.45e-16	Post bronchodilator FEV1;
PAAD	cis	rs427941	0.632	rs201503	chr7:101759595	C/G	cg06246474	chr7:101738831	CUX1	0.43	4.29	0.33	3.21e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.71	5.3	0.39	4e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.52	-5.04	-0.38	1.28e-6	Red blood cell count;
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg01053087	chr8:637909	ERICH1	0.63	4.36	0.33	2.36e-5	IgG glycosylation;
PAAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.09	0.5	4.66e-11	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.48	5.69	0.42	6.31e-8	Vitiligo;
PAAD	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg14829155	chr15:31115871	NA	-0.66	-7.25	-0.51	1.97e-11	Huntington's disease progression;
PAAD	cis	rs7219021	1.000	rs2032843	chr17:46847524	T/A	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg10193763	chr2:225306901	NA	-0.49	-4.33	-0.33	2.67e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg09945482	chr18:12777974	NA	0.58	5.12	0.38	9.13e-7	Inflammatory skin disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16500054	chr5:141258783	PCDH1	-0.66	-7.48	-0.52	5.55e-12	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18357291	chr3:13461086	NUP210	0.64	6.31	0.46	2.94e-9	Obesity-related traits;
PAAD	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.73	7.67	0.53	1.9e-12	Menopause (age at onset);
PAAD	cis	rs12826942	0.876	rs17548889	chr12:42722219	C/G	cg19980929	chr12:42632907	YAF2	0.55	5.01	0.38	1.5e-6	Coronary artery disease;
PAAD	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg12179176	chr11:130786555	SNX19	-0.56	-5.52	-0.41	1.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs501120	0.564	rs11238907	chr10:44687780	T/G	cg09554077	chr10:44749378	NA	0.42	5.35	0.4	3.17e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.13	-0.45	7.27e-9	Height;
PAAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg14092988	chr3:52407081	DNAH1	0.42	5.2	0.39	6.35e-7	Bipolar disorder;
PAAD	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg24687543	chr11:63912206	MACROD1	-0.58	-5.32	-0.4	3.64e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02725872	chr8:58115012	NA	-0.62	-5.29	-0.39	4.27e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs4427176	0.507	rs11785927	chr8:9587740	G/A	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.47	4.36	0.33	2.4e-5	RR interval (heart rate);
PAAD	cis	rs12311304	0.965	rs7977262	chr12:15367769	A/G	cg08258403	chr12:15378311	NA	0.35	4.55	0.35	1.07e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.99	-13.41	-0.74	1.52e-27	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.53	-5.35	-0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs1419980	0.730	rs11054583	chr12:7730355	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg14388049	chr10:71211838	TSPAN15	-0.56	-5.61	-0.41	9.26e-8	Venous thromboembolism;
PAAD	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.26	6.8	0.48	2.2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs11955175	0.717	rs112304996	chr5:40867592	A/T	cg17351974	chr5:40835760	RPL37	0.93	5.08	0.38	1.11e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.5	4.56	0.35	1.04e-5	Renal cell carcinoma;
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg11335335	chr11:637885	DRD4	-0.38	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21162817	chr12:133198653	P2RX2	-0.63	-6.33	-0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	trans	rs901683	1.000	rs34618850	chr10:46087863	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.78	9.5	0.61	4.22e-17	Bone mineral density;
PAAD	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.79	8.38	0.56	3.21e-14	Mean corpuscular volume;
PAAD	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.83	-8.93	-0.59	1.3e-15	Anterior chamber depth;
PAAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.62	-7.54	-0.52	3.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.73	7.39	0.51	8.98e-12	Colorectal cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26116724	chr1:10270521	KIF1B	-0.64	-6.35	-0.46	2.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.23	-0.39	5.51e-7	Reticulocyte count;
PAAD	cis	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.5	5.09	0.38	1.04e-6	Vitiligo;
PAAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	1.23	11.56	0.68	1.42e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.56	6.19	0.45	5.25e-9	Cognitive function;
PAAD	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.24	-0.45	4.17e-9	Psoriasis;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.77	-9.25	-0.6	1.95e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.48	4.83	0.36	3.35e-6	Anterior chamber depth;
PAAD	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14823973	chr15:62516966	NA	-0.44	-4.63	-0.35	7.81e-6	Immature fraction of reticulocytes;
PAAD	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg11874272	chr3:121773564	CD86	-0.44	-4.66	-0.35	6.73e-6	Multiple sclerosis;
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.37	0.4	2.89e-7	Eosinophil percentage of white cells;
PAAD	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-11.62	-0.69	1e-22	Height;
PAAD	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-4.37	-0.33	2.3e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.75e-6	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04177201	chr16:56763905	NUP93	-0.61	-7.45	-0.52	6.51e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.69	-10.11	-0.63	1.05e-18	Huntington's disease progression;
PAAD	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg23093090	chr10:104574429	C10orf26	-0.42	-4.66	-0.35	6.72e-6	Arsenic metabolism;
PAAD	cis	rs16958440	1.000	rs62096464	chr18:44629207	T/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs11807834	0.522	rs10864690	chr1:230237540	A/T	cg09847368	chr1:230250326	GALNT2	0.68	8.23	0.56	7.83e-14	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg07362569	chr17:61921086	SMARCD2	0.42	4.78	0.36	4.04e-6	Height;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg21724239	chr8:58056113	NA	0.72	5.64	0.42	7.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.92	-0.37	2.23e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.49	7.3	0.51	1.48e-11	Mean corpuscular volume;
PAAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.4	-0.46	1.81e-9	Longevity;
PAAD	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.43	-0.46	1.6e-9	Morning vs. evening chronotype;
PAAD	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.66	5.94	0.43	1.83e-8	Mean platelet volume;
PAAD	cis	rs12767760	0.669	rs1107518	chr10:99299860	G/C	cg25247692	chr10:99313390	UBTD1	0.56	5.49	0.41	1.68e-7	Obesity-related traits;
PAAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.59	-8.01	-0.54	2.86e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg26939375	chr7:64535504	NA	0.76	9.19	0.6	2.84e-16	Aortic root size;
PAAD	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	7.79	0.53	9.59e-13	Eotaxin levels;
PAAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg17401720	chr7:158221031	PTPRN2	0.48	5.09	0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.76	7.98	0.54	3.32e-13	Gout;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg26338869	chr17:61819248	STRADA	0.62	6.29	0.45	3.24e-9	Prudent dietary pattern;
PAAD	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-5.46	-0.4	1.89e-7	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-4.7	-0.36	5.74e-6	Menarche (age at onset);
PAAD	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.46	-0.4	1.9e-7	Blood metabolite levels;
PAAD	cis	rs12681963	0.688	rs16876622	chr8:30035636	C/T	cg23406830	chr8:30012838	DCTN6	-0.7	-4.37	-0.33	2.28e-5	Migraine;
PAAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg10356904	chr22:49881777	NA	-0.49	-5.37	-0.4	2.84e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17095355	0.818	rs61881638	chr10:111863396	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.45	-0.34	1.63e-5	Biliary atresia;
PAAD	cis	rs17655565	0.581	rs1791625	chr12:52761679	A/G	cg15701111	chr12:52685334	KRT81	0.48	4.36	0.33	2.41e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.84	10.03	0.63	1.78e-18	Blood metabolite ratios;
PAAD	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.59	5.97	0.44	1.61e-8	Ovarian reserve;
PAAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg03959625	chr15:84868606	LOC388152	-0.49	-5.37	-0.4	2.88e-7	Schizophrenia;
PAAD	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg00262122	chr8:11665843	FDFT1	0.48	4.54	0.35	1.14e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.81	9.61	0.61	2.17e-17	Gout;
PAAD	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg11530693	chr1:120165357	ZNF697	0.64	5.95	0.43	1.74e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21384789	chr15:48497653	SLC12A1	0.61	6.35	0.46	2.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs11892454	0.544	rs7599961	chr2:26006479	A/G	cg25181710	chr2:26045287	ASXL2	0.43	4.99	0.38	1.64e-6	Heschl's gyrus morphology;
PAAD	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	10.6	0.65	5.23e-20	Smoking behavior;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg00738919	chr7:1100172	C7orf50	0.64	4.64	0.35	7.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.49	4.52	0.34	1.23e-5	Neutrophil percentage of white cells;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.47	-7.19	-0.5	2.7e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.93	-0.43	1.99e-8	Menopause (age at onset);
PAAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg07959070	chr22:50026188	C22orf34	-0.37	-4.28	-0.33	3.26e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.47	-0.65	1.18e-19	Multiple sclerosis;
PAAD	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg09491104	chr22:46646882	C22orf40	0.69	5.2	0.39	6.23e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs71636778	0.722	rs12746395	chr1:27168188	G/C	cg12203394	chr1:27248618	NUDC	0.63	4.55	0.35	1.08e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs61759167	1.000	rs7518255	chr1:3086464	G/A	cg22396632	chr1:3079212	PRDM16	-0.55	-5.29	-0.39	4.28e-7	Motion sickness;
PAAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.74	6.06	0.44	1.05e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
PAAD	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.49	4.54	0.35	1.14e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.21	-0.39	5.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.58	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg01868782	chr6:126071099	HEY2	0.43	5.06	0.38	1.2e-6	Brugada syndrome;
PAAD	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.75	6.99	0.49	8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.46e-6	Neutrophil percentage of white cells;
PAAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg01017244	chr2:74357527	NA	0.82	6.88	0.49	1.47e-10	Gestational age at birth (maternal effect);
PAAD	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.55	5.48	0.41	1.73e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg21479132	chr6:26055353	NA	1.0	6.1	0.44	8.29e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.5	0.41	1.6e-7	Depression;
PAAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.39	5.07	0.38	1.16e-6	Colorectal cancer;
PAAD	cis	rs1499972	0.517	rs1456193	chr3:117637697	T/C	cg07612923	chr3:117604196	NA	-0.59	-4.64	-0.35	7.49e-6	Schizophrenia;
PAAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-5.12	-0.38	9.1e-7	Neuroticism;
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.34e-7	Total body bone mineral density;
PAAD	cis	rs3764400	0.567	rs12939334	chr17:46302669	A/G	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg15847926	chr7:2749597	AMZ1	-0.37	-4.46	-0.34	1.61e-5	Height;
PAAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.64	-6.04	-0.44	1.16e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25763956	chr7:916402	C7orf20	-0.81	-7.22	-0.51	2.32e-11	Neuroticism;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.75	6.28	0.45	3.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-8.32	-0.56	4.74e-14	Bladder cancer;
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2120243	0.539	rs1840673	chr3:157117977	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-6.04	-0.44	1.13e-8	Platelet count;
PAAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.67	7.88	0.54	5.88e-13	Alcohol dependence;
PAAD	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg08345082	chr10:99160200	RRP12	-0.31	-4.41	-0.34	1.98e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17209837	1.000	rs66510518	chr7:87111875	C/G	cg00919237	chr7:87102261	ABCB4	-0.77	-5.13	-0.38	8.78e-7	Gallbladder cancer;
PAAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.78	10.33	0.64	2.71e-19	Bone mineral density;
PAAD	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.38	-0.61	8.71e-17	Coronary artery disease;
PAAD	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.66	-7.87	-0.54	6.07e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4841398	0.719	rs74301684	chr8:10463576	G/A	cg27411982	chr8:10470053	RP1L1	0.57	4.34	0.33	2.57e-5	Obesity-related traits;
PAAD	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-7.43	-0.52	7.39e-12	Schizophrenia;
PAAD	cis	rs75757892	0.544	rs116039287	chr6:7315840	A/G	cg02954307	chr6:7269328	NA	0.52	4.54	0.35	1.16e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.85	-10.05	-0.63	1.53e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.65	-7.35	-0.51	1.15e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7765175	0.598	rs2801436	chr6:113654001	A/G	cg19037598	chr6:113666021	NA	-0.42	-4.62	-0.35	7.96e-6	Coronary artery calcification;
PAAD	cis	rs73086581	0.945	rs6037715	chr20:3972166	A/T	cg02187196	chr20:3869020	PANK2	0.59	4.95	0.37	1.95e-6	Response to antidepressants in depression;
PAAD	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.43	-4.25	-0.33	3.67e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.71	-0.36	5.61e-6	Schizophrenia;
PAAD	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.42	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	7.12	0.5	4.1e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.99	11.6	0.69	1.08e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.45	-4.29	-0.33	3.16e-5	Male sexual orientation;
PAAD	cis	rs2835872	0.758	rs1787394	chr21:39036176	C/A	cg06728970	chr21:39037746	KCNJ6	0.53	6.15	0.45	6.6e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.54	5.5	0.41	1.59e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs12432203	1.000	rs9918	chr14:51722690	T/C	cg23942311	chr14:51606299	NA	-0.73	-4.66	-0.35	6.76e-6	Cancer;
PAAD	cis	rs6494488	0.500	rs66500186	chr15:65002594	A/G	cg16425858	chr15:64791681	ZNF609	0.86	4.86	0.37	2.89e-6	Coronary artery disease;
PAAD	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.97	5.87	0.43	2.59e-8	LDL cholesterol;
PAAD	cis	rs10504390	0.519	rs75342066	chr8:66644963	T/G	cg21696208	chr8:66556075	MTFR1	0.94	5.09	0.38	1.06e-6	IgG glycosylation;
PAAD	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	cis	rs500492	0.508	rs2573149	chr16:1073149	G/A	cg10293297	chr16:304604	ITFG3	0.6	4.46	0.34	1.6e-5	Polycystic ovary syndrome;
PAAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	4.88	0.37	2.66e-6	Blood metabolite levels;
PAAD	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.04	0.44	1.11e-8	Schizophrenia;
PAAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.46	-4.61	-0.35	8.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.98	0.37	1.74e-6	Neuroticism;
PAAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.7	0.48	3.76e-10	Total body bone mineral density;
PAAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.61	6.24	0.45	4.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1570155	0.967	rs12209841	chr6:20395936	G/A	cg03881924	chr6:20404342	E2F3	0.44	4.43	0.34	1.77e-5	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03144714	chr12:54426694	HOXC4;HOXC5	0.57	6.59	0.47	6.69e-10	Monocyte percentage of white cells;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg23119463	chr10:134592391	INPP5A	-0.46	-4.66	-0.35	6.82e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg05372495	chr19:1063624	ABCA7	-0.5	-4.37	-0.33	2.27e-5	Alzheimer's disease (late onset);
PAAD	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-5.91	-0.43	2.19e-8	Schizophrenia (age at onset);
PAAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.87	-9.85	-0.62	5.15e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.54	5.61	0.41	9.15e-8	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.87	9.3	0.6	1.42e-16	Corneal astigmatism;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs282587	0.569	rs378432	chr13:113398048	A/C	cg04656015	chr13:113407548	ATP11A	0.54	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6662572	1.000	rs28433203	chr1:46196813	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	4.52	0.34	1.26e-5	Blood protein levels;
PAAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs16958440	0.581	rs12386097	chr18:44673268	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.85	-5.33	-0.4	3.55e-7	Sitting height ratio;
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg04520793	chr17:42248056	ASB16	-0.47	-6.33	-0.46	2.67e-9	Total body bone mineral density;
PAAD	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg24733560	chr20:60626293	TAF4	0.42	5.04	0.38	1.33e-6	Body mass index;
PAAD	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.69	0.36	6.14e-6	Menopause (age at onset);
PAAD	cis	rs6066835	0.867	rs73118616	chr20:47364704	G/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.72	-8.65	-0.57	6.99e-15	Body mass index;
PAAD	cis	rs10450586	0.897	rs28416407	chr11:27308244	G/T	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs10950821	0.770	rs75784515	chr7:20687332	C/T	cg21202529	chr7:20656503	ABCB5	-0.54	-5.02	-0.38	1.4e-6	Response to statin therapy;
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg01299579	chr2:10830716	NOL10	-0.6	-6.11	-0.44	8.01e-9	Prostate cancer;
PAAD	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.19	0.45	5.39e-9	Body mass index;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23463186	chr10:82263737	TSPAN14	0.46	4.46	0.34	1.57e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.04	-0.38	1.3e-6	Mean corpuscular volume;
PAAD	cis	rs7873102	0.702	rs2243881	chr9:37990397	C/T	cg03528946	chr9:38069800	SHB	0.49	4.9	0.37	2.38e-6	Brain structure;
PAAD	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg14092571	chr14:90743983	NA	0.42	4.25	0.33	3.7e-5	Mortality in heart failure;
PAAD	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.78	-4.94	-0.37	2.04e-6	Response to metformin (IC50);
PAAD	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.8e-7	Systemic lupus erythematosus;
PAAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.52	-4.47	-0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs6088813	1.000	rs725908	chr20:33968067	T/C	cg14752227	chr20:34000481	UQCC	-0.5	-4.97	-0.37	1.75e-6	Height;
PAAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg06115741	chr20:33292138	TP53INP2	-0.6	-6.29	-0.45	3.13e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.66	-8.44	-0.56	2.38e-14	Body mass index;
PAAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.98	10.25	0.64	4.57e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3857067	1.000	rs1904094	chr4:95012459	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.42	-0.65	1.58e-19	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.81	7.38	0.51	9.78e-12	Glomerular filtration rate (creatinine);
PAAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.61	5.41	0.4	2.41e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3136739	0.614	rs8178769	chr8:42041443	T/C	cg12054981	chr8:42037387	PLAT	0.74	5.4	0.4	2.48e-7	Plasma plasminogen activator levels;
PAAD	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg00666640	chr1:248458726	OR2T12	0.47	4.86	0.37	2.86e-6	Common traits (Other);
PAAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19268947	chr7:77268833	PTPN12	-0.55	-6.41	-0.46	1.75e-9	Energy expenditure (24h);
PAAD	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs1371614	0.611	rs3843322	chr2:27131849	G/T	cg00617064	chr2:27272375	NA	-0.45	-4.77	-0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg15654264	chr1:150340011	RPRD2	0.51	4.88	0.37	2.7e-6	Migraine;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07558682	chr1:43148835	YBX1	0.65	7.29	0.51	1.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg16417436	chr16:28758564	NA	0.43	4.39	0.34	2.08e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.26	19.58	0.85	2.15e-43	IgG glycosylation;
PAAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg05342682	chr7:94953680	PON1	-0.53	-4.67	-0.35	6.54e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10060875	chr16:3285498	ZNF200	0.63	6.41	0.46	1.74e-9	Obesity-related traits;
PAAD	cis	rs73568641	0.508	rs73570652	chr6:154070563	C/T	cg15658985	chr6:154448740	OPRM1	0.55	4.57	0.35	1.01e-5	Methadone dose in opioid dependence;
PAAD	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16953577	chr4:166034162	TMEM192	-0.58	-6.38	-0.46	2.07e-9	Height;
PAAD	cis	rs6681460	0.898	rs2483704	chr1:67195353	C/T	cg02459107	chr1:67143332	SGIP1	-0.7	-6.52	-0.47	9.77e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.3	0.4	3.98e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.46	-5.78	-0.42	4.13e-8	Crohn's disease;
PAAD	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg03098721	chr1:84464084	TTLL7	0.49	4.6	0.35	8.69e-6	Obesity-related traits;
PAAD	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.63	5.71	0.42	5.89e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs7246865	0.510	rs6512161	chr19:17171582	A/G	cg19418318	chr19:17219073	MYO9B	0.35	5.03	0.38	1.35e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6971211	0.655	rs754469	chr7:155671277	G/A	cg14601210	chr7:155671264	NA	-0.37	-4.25	-0.33	3.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-1.2	-9.88	-0.63	4.47e-18	Obesity-related traits;
PAAD	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-9.29	-0.6	1.49e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs59888335	0.708	rs79314344	chr3:80503064	A/G	cg21735741	chr3:80819488	NA	0.54	4.55	0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg09835421	chr16:68378352	PRMT7	-1.1	-8.13	-0.55	1.41e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg05373962	chr22:49881684	NA	-0.47	-4.56	-0.35	1.05e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.63	-5.14	-0.39	8.19e-7	HIV-1 control;
PAAD	cis	rs16975963	0.644	rs111694872	chr19:38046331	T/C	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg06899799	chr12:56650233	ANKRD52	0.33	4.27	0.33	3.46e-5	Cancer;
PAAD	cis	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg18582342	chr19:11591989	ELAVL3	-0.73	-5.85	-0.43	2.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.53	4.82	0.36	3.52e-6	Schizophrenia;
PAAD	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.57	-5.06	-0.38	1.22e-6	Mean corpuscular volume;
PAAD	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg15211996	chr1:2936768	ACTRT2	0.48	4.86	0.37	2.95e-6	Plateletcrit;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg00024416	chr22:24240387	NA	0.57	5.84	0.43	3.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg14393609	chr7:65229607	NA	-0.51	-4.7	-0.36	5.7e-6	Aortic root size;
PAAD	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.89	-0.54	5.4e-13	Hemoglobin concentration;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg13880726	chr7:1868755	MAD1L1	-0.48	-4.59	-0.35	9.21e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg14092988	chr3:52407081	DNAH1	0.38	4.59	0.35	9.26e-6	Bipolar disorder;
PAAD	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.9	10.79	0.66	1.68e-20	Sudden cardiac arrest;
PAAD	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.9	-12.12	-0.7	4.29e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9810890	1.000	rs73198886	chr3:128546420	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.55	-4.6	-0.35	8.75e-6	Body mass index;
PAAD	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	5.27	0.39	4.65e-7	Mood instability;
PAAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg26174226	chr8:58114915	NA	-0.69	-6.17	-0.45	6.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.69	-6.64	-0.47	5.2400000000000005e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg14789911	chr21:47582049	C21orf56	0.44	4.65	0.35	7.09e-6	Testicular germ cell tumor;
PAAD	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg26116495	chr7:807697	HEATR2	-0.46	-4.29	-0.33	3.14e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16184242	chr5:130600405	CDC42SE2	0.64	7.18	0.5	2.88e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.95	12.02	0.7	8e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg20003494	chr4:90757398	SNCA	-0.44	-4.72	-0.36	5.25e-6	Dementia with Lewy bodies;
PAAD	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg10556349	chr10:835070	NA	0.59	4.89	0.37	2.5e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs76917914	0.820	rs3739670	chr9:100819192	C/T	cg03040243	chr9:100819229	NANS	0.58	4.77	0.36	4.25e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg13047869	chr3:10149882	C3orf24	0.79	5.98	0.44	1.55e-8	Alzheimer's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15808723	chr15:89904748	NA	0.55	6.61	0.47	6.24e-10	Metabolite levels  (X-11787);
PAAD	cis	rs11771526	0.681	rs1868775	chr7:32403793	C/T	cg27511599	chr7:32358540	NA	-0.89	-5.24	-0.39	5.39e-7	Body mass index;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs2252790	1.000	rs1204853	chr6:116577113	A/G	cg26893134	chr6:116381904	FRK	0.27	4.28	0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs72480273	0.583	rs12121292	chr1:161650508	C/T	cg26156167	chr1:161582651	NA	0.59	4.72	0.36	5.38e-6	Birth weight;
PAAD	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.55	-6.05	-0.44	1.07e-8	Blood protein levels;
PAAD	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg03233332	chr7:66118400	NA	-0.4	-4.41	-0.34	1.94e-5	Aortic root size;
PAAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.77	0.66	1.9e-20	Smoking behavior;
PAAD	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.7	-6.14	-0.45	7.04e-9	Triglycerides;
PAAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.5	-4.67	-0.35	6.54e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12943633	0.530	rs75397452	chr17:37807707	T/C	cg22243000	chr17:37813369	STARD3	1.18	5.46	0.4	1.92e-7	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg03989125	chr22:38214979	NA	0.59	5.66	0.42	7.27e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs60154123	1.000	rs4844996	chr1:210476423	C/T	cg23283495	chr1:209979779	IRF6	0.62	5.34	0.4	3.38e-7	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg08501292	chr6:25962987	TRIM38	0.8	4.75	0.36	4.69e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6011674	1.000	rs59784306	chr20:61859596	C/T	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.68	-4.27	-0.33	3.48e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs795484	0.963	rs795475	chr12:118597656	C/G	cg16572268	chr12:118583242	PEBP1	-0.46	-4.43	-0.34	1.77e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg05717871	chr11:638507	DRD4	-0.59	-5.29	-0.39	4.19e-7	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00945038	chr17:61921165	SMARCD2	0.5	6.03	0.44	1.2e-8	Prudent dietary pattern;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.13	15.43	0.78	6.36e-33	Subjective well-being;
PAAD	cis	rs1891275	0.576	rs10881942	chr10:93415020	G/A	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.76	7.86	0.54	6.7e-13	Coronary artery disease;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.99	13.62	0.74	4.17e-28	Menarche (age at onset);
PAAD	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg08917208	chr2:24149416	ATAD2B	0.52	4.58	0.35	9.47e-6	Lymphocyte counts;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.6	4.88	0.37	2.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg15193198	chr20:60906057	LAMA5	-0.49	-4.62	-0.35	8.3e-6	Colorectal cancer;
PAAD	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg00277334	chr10:82204260	NA	-0.65	-6.26	-0.45	3.73e-9	Post bronchodilator FEV1;
PAAD	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg18357526	chr6:26021779	HIST1H4A	0.62	5.37	0.4	2.89e-7	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03151194	chr20:61289939	SLCO4A1	0.55	6.42	0.46	1.64e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.79	6.34	0.46	2.43e-9	Brain cytoarchitecture;
PAAD	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg00922110	chr4:57842668	C4orf14	0.4	4.54	0.35	1.14e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.99e-7	Monocyte percentage of white cells;
PAAD	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	1.09	9.32	0.6	1.3e-16	Red blood cell traits;
PAAD	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.47	-0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs302972	0.826	rs7740534	chr6:25077179	A/C	cg09546929	chr6:25930894	SLC17A2	0.76	4.26	0.33	3.58e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.62	6.76	0.48	2.73e-10	Prostate cancer;
PAAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.43e-7	Inflammatory bowel disease;
PAAD	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg22827986	chr11:48284249	OR4X1	-0.45	-5.45	-0.4	2.01e-7	Migraine - clinic-based;
PAAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg03254818	chr6:169586852	NA	0.41	4.25	0.33	3.77e-5	Pulse pressure;
PAAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6074578	0.541	rs6074167	chr20:165908	T/C	cg16931068	chr20:139680	DEFB127	-0.41	-5.52	-0.41	1.44e-7	Hirschsprung disease;
PAAD	cis	rs743757	0.938	rs6788459	chr3:50520695	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	5.06	0.38	1.2e-6	Diastolic blood pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09747232	chr8:103827049	NA	0.58	6.68	0.48	4.26e-10	Metabolite levels  (X-11787);
PAAD	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg00181669	chr3:44000978	NA	-0.45	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs3112530	0.711	rs1462108	chr5:152652414	C/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.92	5.07	0.38	1.13e-6	Aging (time to event);
PAAD	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.71	-4.32	-0.33	2.79e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.23	0.51	2.14e-11	Lung cancer in ever smokers;
PAAD	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg01620082	chr3:125678407	NA	-1.09	-6.33	-0.46	2.63e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg17810781	chr1:201082982	CACNA1S	0.43	5.15	0.39	7.98e-7	Permanent tooth development;
PAAD	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.81	7.91	0.54	5.01e-13	Post bronchodilator FEV1;
PAAD	cis	rs6908034	0.607	rs79406203	chr6:19816221	T/G	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.49	6.34	0.46	2.53e-9	Schizophrenia;
PAAD	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.15	-0.5	3.46e-11	Neuroticism;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.54	5.14	0.38	8.24e-7	Lung cancer;
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg02841227	chr6:26021843	HIST1H4A	0.45	4.51	0.34	1.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4663969	0.839	rs17862866	chr2:234610912	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.73	-0.36	5.17e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs13102973	0.829	rs13126756	chr4:135900185	G/A	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg18898632	chr2:242989856	NA	-0.71	-5.52	-0.41	1.45e-7	Obesity-related traits;
PAAD	cis	rs4462272	0.557	rs17885645	chr10:101987467	T/C	cg11888571	chr10:102027403	CWF19L1	-0.49	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg26816564	chr1:7831052	VAMP3	0.79	5.9	0.43	2.27e-8	Inflammatory bowel disease;
PAAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg10547527	chr2:198650123	BOLL	-0.74	-5.13	-0.38	8.91e-7	Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg09699651	chr6:150184138	LRP11	0.4	4.26	0.33	3.6e-5	Lung cancer;
PAAD	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	1.22	12.15	0.7	3.73e-24	Post bronchodilator FEV1;
PAAD	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	5.04e-11	Total body bone mineral density;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.45	-6.96	-0.49	9.32e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.62	-5.22	-0.39	5.81e-7	Plateletcrit;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17885579	chr8:59572218	NSMAF	0.63	7.25	0.51	1.98e-11	Myopia (pathological);
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.79	8.22	0.55	8.34e-14	Body mass index;
PAAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg03289416	chr15:75166202	SCAMP2	0.56	5.51	0.41	1.51e-7	Breast cancer;
PAAD	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.51	4.38	0.33	2.17e-5	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-4.81	-0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03388025	chr16:89894329	SPIRE2	0.32	4.29	0.33	3.18e-5	Vitiligo;
PAAD	cis	rs72960926	0.661	rs62437444	chr6:75220536	C/G	cg03266952	chr6:74778945	NA	-1.06	-4.89	-0.37	2.52e-6	Metabolite levels (MHPG);
PAAD	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-4.36	-0.33	2.36e-5	Red blood cell count;
PAAD	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-10.94	-0.66	6.55e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28489187	0.683	rs11161611	chr1:85868679	C/A	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg03938978	chr2:103052716	IL18RAP	0.65	8.2	0.55	9.29e-14	Asthma;
PAAD	cis	rs13011075	0.535	rs56904245	chr2:68638477	T/C	cg06275642	chr2:68546038	CNRIP1	0.34	4.39	0.34	2.08e-5	Mean corpuscular volume;
PAAD	cis	rs4073221	0.654	rs13087192	chr3:18307826	C/G	cg07694806	chr3:18168406	NA	-0.63	-4.49	-0.34	1.43e-5	Parkinson's disease;
PAAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.26e-8	Body mass index;
PAAD	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.87e-5	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19655006	chr2:172750994	SLC25A12	-0.67	-6.83	-0.48	1.92e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.31	-0.33	2.93e-5	Educational attainment (years of education);
PAAD	cis	rs12519773	0.576	rs1496337	chr5:92411293	C/T	cg18783429	chr5:92414398	NA	0.42	6.19	0.45	5.32e-9	Migraine;
PAAD	cis	rs11825685	0.806	rs80051554	chr11:134580634	T/G	cg06603561	chr11:134479413	NA	-0.58	-4.5	-0.34	1.37e-5	IgG glycosylation;
PAAD	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.76	7.69	0.53	1.71e-12	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12776158	0.901	rs61086796	chr10:71216848	T/C	cg12610070	chr10:71211762	TSPAN15	-0.49	-4.63	-0.35	7.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg08562672	chr19:21860753	NA	0.45	4.81	0.36	3.62e-6	Pain;
PAAD	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg23250157	chr14:64679961	SYNE2	0.56	5.67	0.42	6.97e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg17372223	chr3:52568218	NT5DC2	0.56	5.49	0.41	1.65e-7	Bipolar disorder;
PAAD	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-6.53	-0.47	9.47e-10	Menopause (age at onset);
PAAD	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.83e-5	Blood protein levels;
PAAD	cis	rs9488822	0.585	rs569201	chr6:116265861	C/T	cg18764771	chr6:116381957	FRK	-0.26	-4.25	-0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.3e-19	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg07332563	chr6:291687	DUSP22	-0.76	-8.06	-0.55	2.15e-13	Menopause (age at onset);
PAAD	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg21191810	chr6:118973309	C6orf204	-0.52	-5.01	-0.38	1.5e-6	Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	4.38	0.33	2.23e-5	Breast cancer;
PAAD	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27393146	chr18:77495563	CTDP1	0.65	8.0	0.54	2.9e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs74181299	0.806	rs2723063	chr2:65280185	A/G	cg20592124	chr2:65290738	CEP68	0.51	4.81	0.36	3.66e-6	Pulse pressure;
PAAD	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.47	-4.51	-0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-14.37	-0.76	4.09e-30	Height;
PAAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Birth weight;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg07648498	chr16:89883185	FANCA	-0.46	-4.5	-0.34	1.37e-5	Vitiligo;
PAAD	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.9e-5	Total body bone mineral density;
PAAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	7.16	0.5	3.27e-11	Menopause (age at onset);
PAAD	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.29e-8	Alcohol dependence;
PAAD	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma;
PAAD	cis	rs1468333	0.667	rs4835677	chr5:137700251	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.66	8.8	0.58	2.84e-15	Eye color traits;
PAAD	cis	rs4740619	0.565	rs10738424	chr9:16032142	G/A	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs7552393	0.595	rs1830827	chr1:84278911	C/T	cg10977910	chr1:84465055	TTLL7	0.59	5.61	0.41	9.41e-8	Select biomarker traits;
PAAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.82	-9.0	-0.59	8.53e-16	Body mass index;
PAAD	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg05484376	chr2:27715224	FNDC4	-0.46	-4.78	-0.36	4.18e-6	Oral cavity cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21618036	chr4:183621609	ODZ3	0.63	6.63	0.47	5.49e-10	Smoking initiation;
PAAD	cis	rs17152411	1.000	rs11245451	chr10:126661428	C/T	cg07906193	chr10:126599966	NA	0.7	5.57	0.41	1.15e-7	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18068487	chr7:150778340	FASTK;TMUB1	0.51	6.43	0.46	1.53e-9	Myopia (pathological);
PAAD	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.57	-5.99	-0.44	1.44e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Cardiac Troponin-T levels;
PAAD	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs1345301	0.905	rs2310243	chr2:102877560	A/G	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.26	-0.33	3.56e-5	Waist circumference;
PAAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.59	7.58	0.52	3.14e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3806308	1.000	rs3806310	chr1:20142681	A/G	cg13843611	chr1:20143089	RNF186	0.52	5.33	0.4	3.41e-7	Ulcerative colitis;
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg10729496	chr3:10149963	C3orf24	0.66	5.88	0.43	2.55e-8	Alzheimer's disease;
PAAD	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.83	6.86	0.49	1.65e-10	Total cholesterol levels;
PAAD	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09695851	chr17:3907499	NA	0.7	7.08	0.5	4.93e-11	Type 2 diabetes;
PAAD	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg06057569	chr22:50219754	BRD1	0.67	4.99	0.38	1.6e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2020921	0.510	rs11784813	chr8:41979431	A/G	cg17828057	chr8:42037527	PLAT	-0.74	-4.88	-0.37	2.64e-6	Plasma plasminogen activator levels;
PAAD	cis	rs12760731	0.623	rs12239670	chr1:178377761	G/T	cg00404053	chr1:178313656	RASAL2	0.65	5.42	0.4	2.24e-7	Obesity-related traits;
PAAD	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.46	4.89	0.37	2.57e-6	QRS complex (12-leadsum);
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg19761014	chr17:28927070	LRRC37B2	0.95	6.48	0.47	1.22e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.13	0.55	1.42e-13	Lymphocyte counts;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.6	4.43	0.34	1.79e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15443301	chr15:93361322	NA	0.55	6.52	0.47	9.77e-10	Myopia (pathological);
PAAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg10978503	chr1:24200527	CNR2	-0.48	-5.52	-0.41	1.43e-7	Immature fraction of reticulocytes;
PAAD	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.48	-4.57	-0.35	1.02e-5	Uric acid levels;
PAAD	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.23	-9.18	-0.6	2.99e-16	Blood pressure (smoking interaction);
PAAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg15571903	chr15:79123663	NA	0.48	6.25	0.45	4.03e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg03805757	chr16:71968109	PKD1L3	-0.54	-4.78	-0.36	4.02e-6	Post bronchodilator FEV1;
PAAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg23153227	chr6:27725408	NA	0.43	4.29	0.33	3.21e-5	Depression;
PAAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg15676125	chr6:33679581	C6orf125	0.47	4.49	0.34	1.4e-5	Plateletcrit;
PAAD	cis	rs900145	0.859	rs1351525	chr11:13301548	A/T	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.44	4.3	0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs73019876	0.869	rs2359812	chr19:22153495	A/T	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg02631450	chr22:32366979	NA	1.07	5.78	0.42	4.08e-8	Childhood ear infection;
PAAD	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	1.09	14.71	0.77	5.22e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.45	5.03	0.38	1.38e-6	Testicular germ cell tumor;
PAAD	cis	rs11105468	0.701	rs10777219	chr12:90416357	A/C	cg16962463	chr12:89968675	NA	0.45	4.36	0.33	2.4e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-8.51	-0.57	1.57e-14	Vitiligo;
PAAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg19784903	chr17:45786737	TBKBP1	0.45	4.58	0.35	9.42e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.58	-0.47	7.09e-10	Triglycerides;
PAAD	cis	rs7156960	0.965	rs7145598	chr14:76701876	A/G	cg13981132	chr14:76734493	NA	-0.49	-4.61	-0.35	8.52e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.86	0.49	1.63e-10	Schizophrenia;
PAAD	cis	rs7771547	0.755	rs6937430	chr6:36601897	G/C	cg07856975	chr6:36356162	ETV7	0.43	4.77	0.36	4.26e-6	Platelet distribution width;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg06375148	chr1:209958343	C1orf74	0.67	5.62	0.41	8.76e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.51	5.25	0.39	4.95e-7	Longevity;Endometriosis;
PAAD	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.76	-10.16	-0.64	8.07e-19	Bone mineral density;
PAAD	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg02100629	chr10:71892760	AIFM2	0.38	4.62	0.35	8.02e-6	Blood protein levels;
PAAD	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs3787159	0.655	rs505714	chr20:56932558	C/T	cg15032960	chr20:56888536	RAB22A	0.4	4.31	0.33	2.88e-5	Systolic blood pressure;
PAAD	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg24503407	chr1:205819492	PM20D1	0.8	8.83	0.58	2.37e-15	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.88	-0.37	2.62e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11167764	0.623	rs62384602	chr5:141477685	T/G	cg08523384	chr5:141488047	NDFIP1	0.57	4.55	0.35	1.11e-5	Crohn's disease;
PAAD	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg02344993	chr17:57696989	CLTC	0.56	5.07	0.38	1.15e-6	Hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26467471	chr10:676529	DIP2C	-0.68	-7.32	-0.51	1.36e-11	Obesity-related traits;
PAAD	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	4.4	0.34	2.07e-5	Mood instability;
PAAD	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.4	0.46	1.85e-9	Triglyceride levels;
PAAD	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg23254163	chr1:152506842	NA	0.59	6.81	0.48	2.1e-10	Hair morphology;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.93	7.57	0.52	3.28e-12	Alzheimer's disease;
PAAD	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg05144285	chr7:158935647	VIPR2	-0.54	-4.79	-0.36	3.97e-6	Height;
PAAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.49	-0.41	1.62e-7	Blood metabolite levels;
PAAD	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg01388757	chr2:102091195	RFX8	-0.56	-7.11	-0.5	4.17e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-4.43	-0.34	1.77e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03526776	chr6:41159608	TREML2	0.38	4.31	0.33	2.97e-5	Alzheimer's disease (late onset);
PAAD	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg00376283	chr12:123451042	ABCB9	0.69	6.52	0.47	9.77e-10	Platelet count;
PAAD	cis	rs11235843	0.929	rs10898943	chr11:73463755	C/G	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-8.01	-0.54	2.8e-13	Bladder cancer;
PAAD	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.32	-0.56	4.66e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4523957	0.715	rs6503321	chr17:2096580	G/A	cg16513277	chr17:2031491	SMG6	-0.49	-5.07	-0.38	1.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17470531	chr2:55646984	CCDC88A	0.58	6.49	0.47	1.14e-9	Immature fraction of reticulocytes;
PAAD	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.24	-0.39	5.25e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs939584	1.000	rs35628463	chr2:653581	G/A	cg03610516	chr2:642275	NA	-0.6	-5.3	-0.4	3.99e-7	Body mass index;
PAAD	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg17326555	chr1:119535693	NA	-0.4	-4.89	-0.37	2.54e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.89	-4.53	-0.35	1.17e-5	Toenail selenium levels;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.88	-0.49	1.43e-10	Type 2 diabetes;
PAAD	cis	rs9287719	0.649	rs10803725	chr2:10732346	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.61	-6.0	-0.44	1.37e-8	Post bronchodilator FEV1;
PAAD	cis	rs12153243	0.686	rs17342813	chr5:142909383	T/C	cg13907255	chr5:142895549	NA	-0.53	-4.87	-0.37	2.8e-6	Migraine;
PAAD	cis	rs9463078	0.691	rs1852986	chr6:45329489	C/G	cg25276700	chr6:44698697	NA	-0.52	-5.78	-0.42	4.12e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11958404	0.517	rs56344822	chr5:157219957	C/T	cg05962755	chr5:157440814	NA	0.66	4.56	0.35	1.05e-5	IgG glycosylation;
PAAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	5.01	0.38	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6681460	0.546	rs1998716	chr1:67117106	T/A	cg02459107	chr1:67143332	SGIP1	0.5	4.74	0.36	4.79e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.76	8.01	0.54	2.83e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09199072	chr6:116692265	DSE	0.62	6.4	0.46	1.87e-9	Primary biliary cholangitis;
PAAD	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.73	6.32	0.46	2.7e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.91	-0.37	2.33e-6	Type 1 diabetes;
PAAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg15598662	chr11:61582890	MIR1908;FADS1	-0.44	-4.36	-0.33	2.34e-5	Trans fatty acid levels;
PAAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.61	6.3	0.45	3.1e-9	DNA methylation (variation);
PAAD	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.72	-7.42	-0.52	7.63e-12	Response to antipsychotic treatment;
PAAD	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.85e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs7487075	0.619	rs11183479	chr12:46824164	T/C	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.47	4.5	0.34	1.33e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13380717	0.657	rs12928641	chr16:86915098	C/T	cg07769121	chr16:86543519	FOXF1	0.58	4.62	0.35	8.22e-6	Sepsis in extremely premature infants;
PAAD	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.19	-10.26	-0.64	4.38e-19	Vitiligo;
PAAD	cis	rs308971	0.611	rs307598	chr3:12102273	T/C	cg02700894	chr3:12045449	SYN2	0.62	5.27	0.39	4.49e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs600550	0.588	rs10792268	chr11:60102631	A/G	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.67	-5.94	-0.43	1.83e-8	Vitamin D levels;
PAAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.35	0.51	1.14e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4908768	0.501	rs11121186	chr1:8540341	G/A	cg20416874	chr1:8611966	RERE	-0.45	-4.36	-0.33	2.4e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.27	-0.33	3.42e-5	Longevity;Endometriosis;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.55	6.14	0.45	6.96e-9	Cognitive function;
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12949688	0.682	rs1476730	chr17:55838676	G/T	cg12582317	chr17:55822272	NA	-0.41	-4.79	-0.36	3.96e-6	Schizophrenia;
PAAD	cis	rs755249	0.567	rs61783376	chr1:39769000	T/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.4	0.4	2.47e-7	Mean platelet volume;
PAAD	cis	rs17135859	0.624	rs2016167	chr5:113050591	G/T	cg12552261	chr5:112820674	MCC	0.69	4.75	0.36	4.76e-6	F-cell distribution;
PAAD	cis	rs3917254	0.543	rs6752379	chr2:102746705	G/A	cg22835712	chr2:102737379	NA	-0.63	-4.9	-0.37	2.4e-6	Blood protein levels;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg17120908	chr11:65337727	SSSCA1	-1.0	-4.67	-0.35	6.61e-6	Height;
PAAD	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.54	0.35	1.13e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.85	-8.92	-0.59	1.38e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.65	4.58	0.35	9.74e-6	Mean platelet volume;
PAAD	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs375066	0.868	rs448829	chr19:44406321	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.95	0.37	1.92e-6	Breast cancer;
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.63	-6.27	-0.45	3.48e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg00105475	chr2:10696890	NA	0.68	7.59	0.52	2.96e-12	Prostate cancer;
PAAD	cis	rs71636778	0.722	rs12729652	chr1:27046982	G/A	cg12203394	chr1:27248618	NUDC	0.64	4.53	0.34	1.21e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.94	10.63	0.65	4.42e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.583	rs7459675	chr8:33837097	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	5.45	0.4	1.95e-7	Body mass index;
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.87	-10.81	-0.66	1.46e-20	Body mass index;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10309166	chr3:42641984	NKTR	0.57	6.32	0.46	2.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10992471	0.518	rs4743876	chr9:95512216	C/G	cg14631576	chr9:95140430	CENPP	-0.48	-4.47	-0.34	1.49e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs282587	0.569	rs377748	chr13:113405482	C/T	cg19217778	chr13:113420270	ATP11A	-0.54	-4.28	-0.33	3.26e-5	Glycated hemoglobin levels;
PAAD	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.5	-4.76	-0.36	4.49e-6	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.68	-6.38	-0.46	2.07e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.61	-6.43	-0.46	1.58e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9503598	0.605	rs9968900	chr6:3457687	C/T	cg00476032	chr6:3446245	SLC22A23	0.51	5.87	0.43	2.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg01657329	chr11:68192670	LRP5	-0.68	-4.87	-0.37	2.76e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs6466055	0.932	rs2057883	chr7:104929837	C/G	cg04380332	chr7:105027541	SRPK2	0.64	7.03	0.5	6.59e-11	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6554196	0.508	rs2237038	chr4:55525833	C/T	cg24867302	chr4:55534703	KIT	-0.4	-4.27	-0.33	3.41e-5	Monocyte count;
PAAD	cis	rs9876781	0.868	rs9875280	chr3:48428911	A/G	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.43	5.15	0.39	7.83e-7	Total body bone mineral density;
PAAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg10547527	chr2:198650123	BOLL	-0.67	-4.3	-0.33	3.07e-5	Ulcerative colitis;
PAAD	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.96	-7.58	-0.52	3.19e-12	Blood protein levels;
PAAD	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs1863918	0.632	rs10464078	chr5:178471034	A/G	cg21905437	chr5:178450457	ZNF879	-0.46	-4.42	-0.34	1.85e-5	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18099408	chr3:52552593	STAB1	-0.49	-5.16	-0.39	7.7e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg02071572	chr4:1403502	NA	-0.45	-6.07	-0.44	9.95e-9	Obesity-related traits;
PAAD	cis	rs72960926	1.000	rs117827660	chr6:75159847	C/A	cg03266952	chr6:74778945	NA	-1.35	-6.81	-0.48	2.13e-10	Metabolite levels (MHPG);
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg19090574	chr1:205240910	TMCC2	-0.42	-4.75	-0.36	4.69e-6	Red blood cell count;
PAAD	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	7.0	0.49	7.5e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs78761021	0.755	rs55660558	chr17:9793811	C/T	cg26853458	chr17:9805074	RCVRN	0.73	8.49	0.57	1.78e-14	Type 2 diabetes;
PAAD	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-6.23	-0.45	4.32e-9	Diabetic retinopathy;
PAAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.58	6.7	0.48	3.83e-10	Blood metabolite levels;
PAAD	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Monocyte percentage of white cells;
PAAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.49	5.19	0.39	6.63e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06544989	chr22:39130855	UNC84B	0.48	4.75	0.36	4.7e-6	Menopause (age at onset);
PAAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg18200150	chr17:30822561	MYO1D	0.54	6.85	0.49	1.72e-10	Schizophrenia;
PAAD	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	4.56	0.35	1.04e-5	Height;
PAAD	cis	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.32	-0.4	3.57e-7	Mononucleosis;
PAAD	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg14146966	chr2:61757674	XPO1	0.39	4.67	0.35	6.52e-6	Tuberculosis;
PAAD	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	5.8	0.43	3.63e-8	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.68	0.42	6.65e-8	Prudent dietary pattern;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.23	0.45	4.25e-9	Alzheimer's disease;
PAAD	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs1499972	0.938	rs846184	chr3:117749852	C/T	cg07612923	chr3:117604196	NA	-1.05	-6.87	-0.49	1.55e-10	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.71	6.41	0.46	1.7e-9	Mean platelet volume;
PAAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.75	-7.44	-0.52	6.85e-12	Tuberculosis;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg00158530	chr16:69966973	MIR140;WWP2	-0.54	-4.93	-0.37	2.15e-6	Menarche (age at onset);
PAAD	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.4	-4.85	-0.37	2.99e-6	Inflammatory bowel disease;
PAAD	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.58	-5.18	-0.39	6.9e-7	Platelet count;
PAAD	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg05784532	chr1:230284198	GALNT2	0.7	5.4	0.4	2.54e-7	Coronary artery disease;
PAAD	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.63	-8.11	-0.55	1.6e-13	Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.94	4.89	0.37	2.49e-6	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13658921	chr2:136499517	UBXN4	0.63	6.88	0.49	1.48e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.3	-0.46	2.99e-9	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-1.1	-8.16	-0.55	1.18e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.63	8.42	0.56	2.68e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg06569542	chr10:98946673	SLIT1	-0.54	-5.89	-0.43	2.36e-8	Monocyte count;
PAAD	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.94	-0.37	2.02e-6	Retinal vascular caliber;
PAAD	cis	rs2282300	1.000	rs12799529	chr11:30408552	T/C	cg25418670	chr11:30344373	C11orf46	-0.5	-4.44	-0.34	1.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.67	6.31	0.46	2.94e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs8060686	0.841	rs7185308	chr16:67767060	A/G	cg09835421	chr16:68378352	PRMT7	-0.64	-4.42	-0.34	1.85e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.23	0.39	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9633402	0.526	rs10788726	chr1:247997114	T/C	cg00785941	chr1:248100591	OR2L13	0.46	4.27	0.33	3.36e-5	Systemic juvenile idiopathic arthritis;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.57e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs59888335	0.858	rs11711508	chr3:80903746	T/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg15609812	chr20:47281632	PREX1	0.64	4.3	0.33	3.03e-5	Tonometry;
PAAD	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	1.06	7.7	0.53	1.62e-12	Dental caries;
PAAD	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.19	0.55	9.98e-14	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs2016586	0.929	rs8136655	chr22:36111820	G/A	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.47	-0.34	1.51e-5	Neuroticism;
PAAD	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.72	7.49	0.52	5.2e-12	Schizophrenia;
PAAD	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.44	-13.54	-0.74	6.51e-28	Corneal structure;
PAAD	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.51	6.16	0.45	6.27e-9	Sitting height ratio;
PAAD	cis	rs1329189	0.798	rs1855651	chr10:130001569	G/C	cg17972361	chr10:130010134	NA	-0.48	-4.96	-0.37	1.9e-6	Orofacial clefts;
PAAD	cis	rs8105895	0.935	rs10406653	chr19:22238023	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.44	0.52	6.95e-12	HIV-1 control;
PAAD	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.59	6.3	0.46	3.04e-9	Lung cancer;
PAAD	cis	rs6460942	0.908	rs6979046	chr7:12232744	A/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.82	-8.9	-0.59	1.54e-15	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.42	5.27	0.39	4.52e-7	Psoriasis;
PAAD	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.4	-0.34	2.06e-5	Blood metabolite levels;
PAAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.83	8.09	0.55	1.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7260598	0.685	rs114404193	chr19:24063068	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs501120	0.925	rs535949	chr10:44752330	A/C	cg09554077	chr10:44749378	NA	-0.51	-6.72	-0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs67257959	0.708	rs10406406	chr19:17198073	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.8	0.36	3.68e-6	Selective IgA deficiency;
PAAD	cis	rs10037758	0.618	rs1073402	chr5:128285438	C/A	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.53	5.26	0.39	4.76e-7	Mean corpuscular volume;
PAAD	cis	rs55728055	0.661	rs7285893	chr22:32010042	A/G	cg01338084	chr22:32026380	PISD	1.58	9.7	0.62	1.29e-17	Age-related hearing impairment;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08439880	chr3:133502540	NA	-0.52	-5.68	-0.42	6.75e-8	Iron status biomarkers;
PAAD	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg06243866	chr13:111019493	COL4A2	-0.56	-4.96	-0.37	1.9e-6	White matter hyperintensity burden;
PAAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	11.76	0.69	4.07e-23	Bone mineral density;
PAAD	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.56	4.58	0.35	9.69e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs900145	0.814	rs10766065	chr11:13277961	C/T	cg15603424	chr11:13300592	ARNTL	0.49	4.33	0.33	2.75e-5	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.77	5.64	0.42	7.88e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs80346118	0.673	rs2145837	chr20:47425799	T/C	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.63	-4.58	-0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs2252790	0.542	rs11970221	chr6:116634325	T/C	cg18828861	chr6:116576566	TSPYL4	-0.42	-5.02	-0.38	1.4e-6	Fast beta electroencephalogram;
PAAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Body mass index;
PAAD	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.56	5.37	0.4	2.9e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg21605333	chr4:119757512	SEC24D	0.8	5.98	0.44	1.5e-8	Cannabis dependence symptom count;
PAAD	cis	rs3734905	1.000	rs79846353	chr6:169894834	C/T	cg11181693	chr6:169825345	NA	-0.92	-5.73	-0.42	5.29e-8	HIV-1 control;
PAAD	cis	rs3096299	0.730	rs3114895	chr16:89394810	C/T	cg00750074	chr16:89608354	SPG7	-0.56	-5.29	-0.39	4.23e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	8.14	0.55	1.33e-13	Cognitive test performance;
PAAD	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.64	0.47	5.29e-10	Lung cancer in ever smokers;
PAAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.49	-5.14	-0.38	8.3e-7	Platelet distribution width;
PAAD	cis	rs10404342	0.655	rs887954	chr19:57120356	C/T	cg13445251	chr19:56156542	ZNF581	-0.65	-4.34	-0.33	2.58e-5	IgE levels in asthmatics;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg11941060	chr3:133502564	NA	-0.61	-6.28	-0.45	3.32e-9	Iron status biomarkers;
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg13191508	chr8:144600686	ZC3H3	-0.85	-4.47	-0.34	1.5e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.79	-0.48	2.35e-10	Coffee consumption (cups per day);
PAAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10450586	0.932	rs10835156	chr11:27325218	T/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.82	-11.83	-0.69	2.66e-23	Psoriasis;
PAAD	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.72	-0.36	5.37e-6	Resting heart rate;
PAAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.49	5.13	0.38	8.73e-7	Total body bone mineral density;
PAAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg06632027	chr4:90757378	SNCA	-0.52	-4.91	-0.37	2.28e-6	Neuroticism;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg24747557	chr10:131355152	MGMT	-0.43	-4.29	-0.33	3.12e-5	Response to temozolomide;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs7567389	0.638	rs12105051	chr2:127990177	T/G	cg09760422	chr2:128146352	NA	-0.4	-6.28	-0.45	3.4e-9	Self-rated health;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.79	5.38	0.4	2.75e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3809060	0.959	rs3858448	chr11:32451099	T/A	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg17178900	chr1:205818956	PM20D1	-0.5	-4.81	-0.36	3.65e-6	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs13102973	0.646	rs4428339	chr4:135886187	C/T	cg14419869	chr4:135874104	NA	0.43	4.32	0.33	2.83e-5	Subjective well-being;
PAAD	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg21399703	chr1:247681439	NA	0.69	6.64	0.47	5.28e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg17347104	chr14:75034677	LTBP2	-0.48	-4.81	-0.36	3.58e-6	Caffeine consumption;
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.72	-9.04	-0.59	6.63e-16	Educational attainment;
PAAD	cis	rs2290419	0.730	rs117478490	chr11:68944030	T/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg13590414	chr9:128173245	NA	0.47	4.72	0.36	5.32e-6	Resting heart rate;
PAAD	cis	rs6782025	0.837	rs338963	chr3:121022874	T/A	cg16417163	chr3:121280760	NA	-0.47	-4.89	-0.37	2.5e-6	Aging (facial);
PAAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-6.24	-0.45	4.06e-9	Bipolar disorder;
PAAD	cis	rs7081476	0.737	rs12571272	chr10:27508861	A/G	cg20349793	chr10:26911186	NA	0.79	4.37	0.33	2.3e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-5.29	-0.39	4.17e-7	Schizophrenia;
PAAD	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg04877966	chr15:75135169	ULK3	0.5	4.29	0.33	3.18e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.52	-4.77	-0.36	4.26e-6	Life satisfaction;
PAAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg23283495	chr1:209979779	IRF6	0.62	5.73	0.42	5.18e-8	Cleft lip with or without cleft palate;
PAAD	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-6.97	-0.49	9.27e-11	D-dimer levels;
PAAD	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.86	-7.32	-0.51	1.31e-11	Body mass index;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.56	6.28	0.45	3.36e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg23417306	chr2:180868811	CWC22	-0.49	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg20007245	chr22:24372913	LOC391322	-0.69	-7.25	-0.51	1.97e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7009110	0.786	rs13282260	chr8:81273135	T/A	cg21158561	chr8:81178149	NA	0.44	4.78	0.36	4.18e-6	Asthma and hay fever;
PAAD	cis	rs7809615	0.748	rs10215854	chr7:99036920	G/A	cg12290671	chr7:99195819	NA	-0.91	-5.14	-0.38	8.31e-7	Blood metabolite ratios;
PAAD	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg24375607	chr4:120327624	NA	0.42	4.29	0.33	3.15e-5	Diastolic blood pressure;
PAAD	cis	rs3753841	0.584	rs61812156	chr1:103238683	A/T	cg24495344	chr1:103574097	COL11A1	0.38	4.47	0.34	1.5e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-1.04	-14.59	-0.76	1.02e-30	Breast cancer;
PAAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg17724175	chr1:150552817	MCL1	0.41	4.55	0.35	1.07e-5	Melanoma;
PAAD	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.5	5.63	0.42	8.53e-8	Heart rate;
PAAD	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.65	6.0	0.44	1.39e-8	Red blood cell count;
PAAD	cis	rs11563648	0.511	rs11563622	chr7:127057076	T/A	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.42	5.31	0.4	3.82e-7	Colorectal cancer;
PAAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.72	10.29	0.64	3.59e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02196227	chr4:89080292	ABCG2	0.66	7.31	0.51	1.43e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs12445022	0.571	rs4843625	chr16:87576996	G/C	cg10479063	chr12:9360933	PZP	-0.61	-6.48	-0.47	1.18e-9	Small vessel stroke;Systemic juvenile idiopathic arthritis;
PAAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.48	5.05	0.38	1.27e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.45	-4.39	-0.34	2.15e-5	Breast cancer;
PAAD	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs17407555	0.779	rs17475461	chr4:10287677	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.44	-0.34	1.7e-5	Schizophrenia (age at onset);
PAAD	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg18518183	chr2:172544446	DYNC1I2	0.49	4.31	0.33	2.92e-5	Schizophrenia;
PAAD	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-8.08	-0.55	1.82e-13	Parkinson's disease;
PAAD	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs859767	0.812	rs842355	chr2:135344881	G/C	cg12500956	chr2:135428796	TMEM163	0.31	4.48	0.34	1.47e-5	Neuroticism;
PAAD	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06998765	chr14:75389618	RPS6KL1	0.29	4.96	0.37	1.84e-6	Caffeine consumption;
PAAD	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.55	-0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.61	-6.58	-0.47	7.18e-10	Dementia with Lewy bodies;
PAAD	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19828022	chr19:7587439	MCOLN1	-0.78	-7.03	-0.5	6.56e-11	Neuroticism;
PAAD	cis	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg27411982	chr8:10470053	RP1L1	0.53	5.86	0.43	2.79e-8	Retinal vascular caliber;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg10729496	chr3:10149963	C3orf24	0.9	7.83	0.54	7.77e-13	Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.24	0.39	5.21e-7	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27343001	chr19:16739049	MED26	-0.59	-6.65	-0.47	5.05e-10	Body fat percentage;
PAAD	cis	rs7873102	0.654	rs2244006	chr9:37988647	T/C	cg03528946	chr9:38069800	SHB	0.5	5.07	0.38	1.12e-6	Brain structure;
PAAD	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.71	-7.53	-0.52	4.24e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg21994712	chr19:21861136	NA	-0.44	-4.38	-0.33	2.23e-5	Pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13380419	chr17:73267556	MIF4GD	-0.76	-6.51	-0.47	1.05e-9	Neuroticism;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-6.95	-0.49	1.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.41	-4.59	-0.35	9.21e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.6e-7	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17775736	chr3:125635174	LOC100125556	-0.62	-6.31	-0.46	2.88e-9	Smoking initiation;
PAAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.46	-5.32	-0.4	3.58e-7	Height;
PAAD	cis	rs57994353	0.570	rs10870139	chr9:139303269	G/A	cg21253087	chr9:139290292	SNAPC4	0.49	4.33	0.33	2.74e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg00206168	chr11:65308501	LTBP3	0.5	5.25	0.39	5.09e-7	Bone mineral density;
PAAD	cis	rs6141769	0.542	rs28548407	chr20:31301495	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs8074700	0.518	rs4239158	chr17:46699851	A/G	cg11561737	chr17:46796908	NA	-0.41	-4.57	-0.35	1.02e-5	Body mass index in non-asthmatics;
PAAD	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.5	4.86	0.37	2.93e-6	Common traits (Other);
PAAD	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.6	-5.86	-0.43	2.83e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.47	-4.84	-0.37	3.16e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg21892295	chr12:121157589	UNC119B	-0.43	-4.27	-0.33	3.49e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs9549328	0.917	rs4907573	chr13:113648742	C/G	cg17524180	chr13:113633600	MCF2L	-0.49	-5.16	-0.39	7.7e-7	Systolic blood pressure;
PAAD	cis	rs12365397	0.526	rs11607331	chr11:43157244	T/C	cg03447554	chr11:43094025	NA	0.58	6.53	0.47	9.47e-10	Migraine;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg13263323	chr15:86062960	AKAP13	0.61	6.9	0.49	1.28e-10	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10519155	chr20:60757898	GTPBP5	-0.64	-6.55	-0.47	8.59e-10	Smoking initiation;
PAAD	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg19423196	chr10:82049429	MAT1A	0.5	5.13	0.38	8.66e-7	Borderline personality disorder;
PAAD	cis	rs9583531	0.760	rs11843661	chr13:111390990	T/C	cg24331049	chr13:111365604	ING1	-0.74	-5.16	-0.39	7.51e-7	Coronary artery disease;
PAAD	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.72	6.83	0.48	1.94e-10	Recombination rate (males);
PAAD	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.5	5.28	0.39	4.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs12127679	0.614	rs12066849	chr1:244171167	G/A	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.74	9.51	0.61	4.02e-17	Cardiovascular disease risk factors;
PAAD	cis	rs7631605	0.518	rs2276808	chr3:36986992	C/T	cg17445812	chr3:36986805	TRANK1	0.36	5.08	0.38	1.1e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.42	-0.4	2.24e-7	Schizophrenia;
PAAD	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.38	-0.33	2.23e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7713065	0.765	rs10062371	chr5:131778413	G/A	cg14196790	chr5:131705035	SLC22A5	0.44	4.36	0.33	2.36e-5	Lung function (FEV1/FVC);
PAAD	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.07	-0.38	1.16e-6	Reticulocyte count;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg24829409	chr8:58192753	C8orf71	-0.91	-8.1	-0.55	1.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.61	7.2	0.5	2.63e-11	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg03482866	chr13:111040579	COL4A2	0.47	4.53	0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg27490568	chr2:178487706	NA	0.41	4.4	0.34	2.01e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.65	-5.16	-0.39	7.5e-7	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg06740227	chr12:86229804	RASSF9	-0.5	-4.55	-0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs9581857	0.685	rs12585587	chr13:28024694	G/A	cg22138327	chr13:27999177	GTF3A	0.68	4.62	0.35	8.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg08493051	chr2:3487164	NA	-0.75	-6.95	-0.49	1.03e-10	Neurofibrillary tangles;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.96	9.99	0.63	2.23e-18	Corneal astigmatism;
PAAD	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.59	6.63	0.47	5.46e-10	Carotid intima media thickness;
PAAD	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.67	-5.94	-0.43	1.85e-8	Coronary artery disease;
PAAD	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.47	-4.47	-0.34	1.5e-5	Stearic acid (18:0) levels;
PAAD	trans	rs8177376	0.727	rs601985	chr11:126197557	C/T	cg02219016	chr2:44222742	LRPPRC	0.71	6.29	0.45	3.25e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2637266	0.655	rs846595	chr10:78531300	C/T	cg18941641	chr10:78392320	NA	0.37	4.42	0.34	1.86e-5	Pulmonary function;
PAAD	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg10011062	chr15:43941034	CATSPER2	-0.81	-4.62	-0.35	8.01e-6	Lung cancer in ever smokers;
PAAD	cis	rs7923609	0.967	rs2393986	chr10:65320006	A/T	cg01631684	chr10:65280961	REEP3	-0.43	-4.34	-0.33	2.63e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs877529	0.934	rs139425	chr22:39559742	G/C	cg13455509	chr22:39551605	NA	-0.52	-5.03	-0.38	1.36e-6	Multiple myeloma;
PAAD	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.4	-0.4	2.46e-7	Mood instability;
PAAD	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.34	0.46	2.45e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs2980439	0.517	rs17594065	chr8:8105405	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.46	-0.46	1.32e-9	Neuroticism;
PAAD	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.48	-0.47	1.23e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.68	0.53	1.83e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3749237	0.964	rs10049413	chr3:49892896	A/G	cg21659725	chr3:3221576	CRBN	0.74	7.01	0.49	7.32e-11	Resting heart rate;
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg00024416	chr22:24240387	NA	-0.52	-5.55	-0.41	1.27e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7714584	1.000	rs58717741	chr5:150284936	A/G	cg22134413	chr5:150180641	NA	0.94	6.27	0.45	3.62e-9	Crohn's disease;
PAAD	cis	rs35740288	0.742	rs2061818	chr15:86136244	G/A	cg07943548	chr15:86304357	KLHL25	-0.58	-5.94	-0.43	1.84e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.96	-8.53	-0.57	1.36e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.46	-4.61	-0.35	8.52e-6	Colorectal cancer;
PAAD	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.82	7.96	0.54	3.64e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	1.2	15.33	0.78	1.15e-32	Ewing sarcoma;
PAAD	cis	rs9900972	0.918	rs2277700	chr17:76866711	C/T	cg20937029	chr17:76870563	TIMP2	0.51	4.53	0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18621852	chr3:10150065	C3orf24	0.5	4.68	0.35	6.26e-6	Alzheimer's disease;
PAAD	cis	rs727479	0.543	rs6493488	chr15:51513922	G/C	cg21478137	chr15:51532386	CYP19A1	0.44	4.48	0.34	1.47e-5	Estradiol levels;
PAAD	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.16	-0.39	7.51e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.61	5.24	0.39	5.23e-7	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24438779	chr18:158551	USP14	0.69	7.17	0.5	3e-11	Obesity-related traits;
PAAD	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg03983476	chr2:10830698	NOL10	-0.5	-4.88	-0.37	2.68e-6	Prostate cancer;
PAAD	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.82	-0.36	3.4e-6	Morning vs. evening chronotype;
PAAD	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg07679836	chr6:33548423	BAK1	0.31	4.44	0.34	1.74e-5	Platelet count;
PAAD	cis	rs863345	0.967	rs7534319	chr1:158532295	G/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21862992	chr11:68658383	NA	0.47	5.2	0.39	6.47e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.46	4.59	0.35	9.42e-6	Aortic root size;
PAAD	cis	rs300774	1.000	rs400978	chr2:119437	A/G	cg23649280	chr2:140451	NA	-0.52	-4.65	-0.35	7.1e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.6	9.07	0.59	5.75e-16	Diastolic blood pressure;
PAAD	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.66	4.91	0.37	2.34e-6	Hip geometry;
PAAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.46	-4.73	-0.36	5.18e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.84	7.21	0.5	2.48e-11	Recombination rate (females);
PAAD	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.57	5.28	0.39	4.42e-7	Height;
PAAD	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg00750074	chr16:89608354	SPG7	-0.55	-5.13	-0.38	8.83e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg22587600	chr2:46883368	NA	0.35	4.72	0.36	5.4e-6	Height;
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg15193198	chr20:60906057	LAMA5	-0.44	-4.84	-0.37	3.23e-6	Colorectal cancer;
PAAD	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.49	-4.32	-0.33	2.77e-5	Schizophrenia;
PAAD	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28655083	0.500	rs9972728	chr16:77064484	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.43	4.3	0.33	3.05e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg08992911	chr2:238395768	MLPH	-0.68	-6.86	-0.49	1.65e-10	Prostate cancer;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.86	-9.1	-0.59	4.63e-16	Menopause (age at onset);
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.99	0.44	1.43e-8	Lung cancer;
PAAD	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13021479	chr17:8380298	MYH10	0.55	6.58	0.47	7.11e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23158103	chr7:148848205	ZNF398	-0.51	-4.61	-0.35	8.59e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.27	0.56	6.4e-14	Bladder cancer;
PAAD	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg09835421	chr16:68378352	PRMT7	-0.67	-4.41	-0.34	1.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs4704187	0.687	rs9654426	chr5:74466737	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02071572	chr4:1403502	NA	0.35	4.5	0.34	1.34e-5	Obesity-related traits;
PAAD	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.54	5.74	0.42	4.99e-8	Red blood cell count;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.62	7.06	0.5	5.64e-11	Mean corpuscular volume;
PAAD	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.51	5.27	0.39	4.63e-7	Red blood cell count;
PAAD	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.47	-0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	cis	rs617219	0.710	rs10805925	chr5:78539399	A/G	cg24856658	chr5:78533917	JMY	-0.4	-4.48	-0.34	1.49e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.4	4.29	0.33	3.13e-5	Life satisfaction;
PAAD	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.63	6.32	0.46	2.7e-9	Dialysis-related mortality;
PAAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.8	-0.36	3.81e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.72	-0.36	5.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.64	-7.29	-0.51	1.62e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg14343924	chr8:8086146	FLJ10661	0.53	4.48	0.34	1.47e-5	Mood instability;
PAAD	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.64	-6.86	-0.49	1.59e-10	Dementia with Lewy bodies;
PAAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg10589385	chr1:150898437	SETDB1	0.39	4.89	0.37	2.51e-6	Melanoma;
PAAD	cis	rs12476592	0.602	rs262527	chr2:63900292	C/G	cg10828910	chr2:63850056	LOC388955	0.67	5.14	0.38	8.33e-7	Childhood ear infection;
PAAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.85	-8.17	-0.55	1.09e-13	Cognitive function;
PAAD	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg00012203	chr2:219082015	ARPC2	0.6	5.79	0.43	3.82e-8	Colorectal cancer;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg11995313	chr8:8860691	ERI1	0.43	4.3	0.33	3.03e-5	Mood instability;
PAAD	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.57	-6.58	-0.47	7.23e-10	Schizophrenia;
PAAD	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.48	5.03	0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23268417	chr19:36705437	ZNF565;ZNF146	-0.58	-6.52	-0.47	9.96e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg15764593	chr10:829463	NA	-0.71	-6.3	-0.46	3.01e-9	Uric acid levels;
PAAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	6.39	0.46	1.94e-9	Body mass index;
PAAD	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.03e-5	Systolic blood pressure;
PAAD	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12516959	chr21:47718080	NA	-0.44	-4.33	-0.33	2.69e-5	Testicular germ cell tumor;
PAAD	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg15128208	chr22:42549153	NA	0.52	4.59	0.35	9.05e-6	Birth weight;
PAAD	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	5.59	0.41	1.04e-7	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17314961	chr13:113435942	ATP11A	-0.66	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.92	6.26	0.45	3.74e-9	Thyroid stimulating hormone;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.94	11.42	0.68	3.29e-22	Longevity;
PAAD	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg09695851	chr17:3907499	NA	0.84	8.96	0.59	1.12e-15	Type 2 diabetes;
PAAD	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.43	0.4	2.16e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	5.27	0.39	4.59e-7	Mood instability;
PAAD	cis	rs6681460	1.000	rs1536115	chr1:67121001	A/T	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg10591111	chr5:226296	SDHA	-0.73	-5.73	-0.42	5.33e-8	Breast cancer;
PAAD	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg20356878	chr3:121714668	ILDR1	0.48	4.51	0.34	1.27e-5	Cognitive performance;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1692580	0.807	rs4648628	chr1:2203490	C/T	cg21194808	chr1:2205498	SKI	0.45	4.41	0.34	1.97e-5	Coronary artery disease;
PAAD	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs74181299	0.684	rs1228	chr2:65311555	C/T	cg20592124	chr2:65290738	CEP68	-0.47	-4.41	-0.34	1.95e-5	Pulse pressure;
PAAD	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg02743256	chr7:2109353	MAD1L1	-0.58	-4.41	-0.34	1.93e-5	Bipolar disorder;
PAAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg03676636	chr4:99064102	C4orf37	0.35	5.31	0.4	3.82e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg09491104	chr22:46646882	C22orf40	-0.98	-8.45	-0.57	2.16e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.7	-0.66	2.8e-20	Total body bone mineral density;
PAAD	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.65	-4.69	-0.36	6.03e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
PAAD	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.24	0.6	2.02e-16	Bipolar disorder;
PAAD	cis	rs41311933	1.000	rs10514838	chr9:123746796	T/C	cg13567360	chr9:123745713	C5	-0.7	-4.5	-0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.649	rs10188373	chr2:10718802	A/G	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg23759393	chr7:158110405	PTPRN2	0.37	4.48	0.34	1.48e-5	Response to amphetamines;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-7.87	-0.54	6.03e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11828289	0.660	rs77575887	chr11:23174504	T/A	cg20040320	chr11:23191996	NA	-0.8	-5.74	-0.42	4.97e-8	Cancer;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg06636001	chr8:8085503	FLJ10661	0.59	6.13	0.45	7.32e-9	Systolic blood pressure;
PAAD	cis	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs7487075	0.578	rs4768122	chr12:46832334	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg02891314	chr5:179741120	GFPT2	-0.77	-7.74	-0.53	1.29e-12	Height;
PAAD	cis	rs818427	1.000	rs514763	chr5:112215156	C/T	cg07820702	chr5:112228657	REEP5	-0.51	-4.63	-0.35	7.66e-6	Total body bone mineral density;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg14346243	chr4:90757452	SNCA	-0.49	-4.28	-0.33	3.24e-5	Neuroticism;
PAAD	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs4242434	1.000	rs4242434	chr8:22501830	C/A	cg03733263	chr8:22462867	KIAA1967	1.03	12.77	0.72	7.95e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.68	-5.73	-0.42	5.27e-8	Coronary artery disease;
PAAD	cis	rs7092929	0.723	rs7082020	chr10:3535672	T/C	cg14308648	chr10:3568949	NA	0.56	5.46	0.4	1.93e-7	Coronary artery calcification;
PAAD	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.6	-5.71	-0.42	5.77e-8	Platelet count;
PAAD	cis	rs7113874	0.802	rs7118611	chr11:8685685	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-4.52	-0.34	1.25e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18138036	chr10:133769891	PPP2R2D	0.6	7.42	0.52	7.59e-12	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19603390	chr7:7222222	C1GALT1	0.57	6.68	0.48	4.2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg19680485	chr15:31195859	MTMR15	0.43	4.26	0.33	3.53e-5	Huntington's disease progression;
PAAD	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11644478	chr21:40555479	PSMG1	-0.46	-4.57	-0.35	1e-5	Menarche (age at onset);
PAAD	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.53	5.9	0.43	2.31e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26574964	chr11:117049906	SIDT2	0.72	7.2	0.5	2.66e-11	Primary biliary cholangitis;
PAAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.65	7.24	0.51	2.12e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.46	4.5	0.34	1.35e-5	Malaria;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02025083	chr17:56064295	VEZF1	-0.63	-6.52	-0.47	9.65e-10	Lung cancer in ever smokers;
PAAD	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.7	0.36	5.69e-6	Educational attainment;
PAAD	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.6	-6.08	-0.44	9.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10929159	0.928	rs7557044	chr2:236932554	A/G	cg14226755	chr2:236923322	AGAP1	-0.27	-4.64	-0.35	7.51e-6	Parkinson's disease;
PAAD	cis	rs8105895	1.000	rs1849004	chr19:22142455	A/C	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs950881	0.866	rs72823628	chr2:102928617	G/A	cg03938978	chr2:103052716	IL18RAP	0.54	4.39	0.34	2.14e-5	Allergy;
PAAD	cis	rs58521262	0.556	rs289339	chr19:23150899	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs12989701	0.778	rs7583814	chr2:127863029	C/T	cg08168897	chr2:127865431	BIN1	0.7	6.05	0.44	1.08e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11671005	0.656	rs73066226	chr19:59008213	T/C	cg25952890	chr19:58913133	NA	0.65	4.71	0.36	5.43e-6	Mean platelet volume;
PAAD	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.1	-0.5	4.5e-11	Blood pressure (smoking interaction);
PAAD	cis	rs7236492	0.872	rs74569193	chr18:77232698	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-5.95	-0.43	1.8e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8112211	0.689	rs112311840	chr19:38796572	G/A	cg14299480	chr19:38876666	GGN	-0.53	-4.75	-0.36	4.74e-6	Blood protein levels;
PAAD	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.59	5.89	0.43	2.35e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.6	-0.41	9.82e-8	Tonsillectomy;
PAAD	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.64	-6.15	-0.45	6.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg21929781	chr1:2537748	MMEL1	0.54	5.65	0.42	7.85e-8	Ulcerative colitis;
PAAD	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.34	4.3	0.33	3.02e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs7017697	0.507	rs10112790	chr8:19684414	A/T	cg03894339	chr8:19674705	INTS10	-0.57	-4.32	-0.33	2.82e-5	Breast cancer;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4073221	0.520	rs66659472	chr3:18196527	G/A	cg07694806	chr3:18168406	NA	-1.07	-6.22	-0.45	4.65e-9	Parkinson's disease;
PAAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.52	5.58	0.41	1.09e-7	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.65	-0.35	7.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg08079166	chr15:68083412	MAP2K5	0.58	4.44	0.34	1.7e-5	Obesity;
PAAD	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg27565382	chr3:53032988	SFMBT1	0.74	4.46	0.34	1.6e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.67	4.62	0.35	7.99e-6	Mean platelet volume;
PAAD	cis	rs4281086	0.864	rs13280674	chr8:10345960	G/A	cg01072821	chr8:10382165	T-SP1	-0.47	-4.51	-0.34	1.29e-5	Obesity-related traits;
PAAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	6.81	0.48	2.13e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2036402	0.518	rs114188794	chr5:156345992	A/G	cg21915449	chr5:156456672	HAVCR1	-0.47	-4.99	-0.38	1.63e-6	Hypertriglyceridemia;
PAAD	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.53	4.76	0.36	4.5e-6	Testicular germ cell tumor;
PAAD	cis	rs2051773	0.567	rs11024116	chr11:17045886	A/G	cg15378786	chr11:17036137	PLEKHA7	0.51	4.36	0.33	2.42e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.94e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg26571870	chr16:85723150	GINS2	-0.42	-4.72	-0.36	5.25e-6	Platelet distribution width;
PAAD	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg13565585	chr5:132299512	AFF4	0.6	4.36	0.33	2.38e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.73	-4.92	-0.37	2.18e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.67	-7.92	-0.54	4.64e-13	Huntington's disease progression;
PAAD	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.51	-5.0	-0.38	1.6e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.68	8.37	0.56	3.51e-14	Dupuytren's disease;
PAAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.47	-4.33	-0.33	2.7e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03860051	chr10:124768608	IKZF5;ACADSB	0.67	6.74	0.48	3.08e-10	Obesity-related traits;
PAAD	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg04995300	chr3:66848608	NA	0.41	4.27	0.33	3.41e-5	Type 2 diabetes;
PAAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg23346134	chr3:49453900	TCTA	0.42	4.45	0.34	1.68e-5	Menarche (age at onset);
PAAD	cis	rs7487075	0.619	rs2408498	chr12:46796900	G/A	cg09447675	chr12:46877466	NA	-0.48	-4.43	-0.34	1.81e-5	Itch intensity from mosquito bite;
PAAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-8.01	-0.54	2.81e-13	Total body bone mineral density;
PAAD	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.65	-6.86	-0.49	1.61e-10	Corneal astigmatism;
PAAD	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.51	5.62	0.41	8.8e-8	Height;
PAAD	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.54	-4.41	-0.34	1.97e-5	Type 2 diabetes;
PAAD	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.85	10.16	0.64	7.66e-19	Lung cancer;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.68	7.72	0.53	1.41e-12	Height;
PAAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.9	11.04	0.67	3.57e-21	Methadone dose in opioid dependence;
PAAD	cis	rs7688540	0.771	rs11723803	chr4:292369	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.66	0.35	6.98e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs2637266	0.846	rs2637261	chr10:78320593	A/G	cg18941641	chr10:78392320	NA	-0.35	-4.3	-0.33	3.08e-5	Pulmonary function;
PAAD	cis	rs16975963	0.644	rs73033117	chr19:38073146	C/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.72	-7.44	-0.52	7.01e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg11783602	chr8:55087084	NA	-0.64	-7.7	-0.53	1.6e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.86	11.26	0.67	9.12e-22	Vitiligo;
PAAD	cis	rs621942	0.544	rs615887	chr11:85690041	A/G	cg07180834	chr11:85838833	NA	0.47	4.32	0.33	2.83e-5	Tourette syndrome;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.57	5.92	0.43	2.05e-8	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18621852	chr3:10150065	C3orf24	-0.66	-5.79	-0.42	3.99e-8	Alzheimer's disease;
PAAD	cis	rs2051773	0.567	rs4456241	chr11:17043041	G/A	cg15378786	chr11:17036137	PLEKHA7	0.53	4.56	0.35	1.06e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.49	0.34	1.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg16928487	chr17:17741425	SREBF1	0.37	4.98	0.37	1.73e-6	Total body bone mineral density;
PAAD	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg01388757	chr2:102091195	RFX8	-0.54	-6.79	-0.48	2.37e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg00228799	chr9:131580591	ENDOG	0.64	6.43	0.46	1.58e-9	Blood metabolite levels;
PAAD	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.56	-6.04	-0.44	1.16e-8	Pancreatic cancer;
PAAD	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.02	7.22	0.51	2.37e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.74	-8.36	-0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.53	5.3	0.4	3.95e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.49	-0.41	1.62e-7	Prevalent atrial fibrillation;
PAAD	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09597638	chr17:3907349	NA	0.72	7.54	0.52	4.04e-12	Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs73198875	chr3:128540286	C/T	cg19129842	chr3:128565090	NA	-0.88	-5.8	-0.43	3.7e-8	Dental caries;
PAAD	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.08	-0.63	1.31e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-0.48	-4.77	-0.36	4.25e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-5.44	-0.4	2.11e-7	Body mass index;
PAAD	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg17326555	chr1:119535693	NA	-0.46	-5.48	-0.41	1.69e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.49	-5.46	-0.4	1.92e-7	Calcium levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14544631	chr5:150138130	DCTN4	-0.63	-6.7	-0.48	3.88e-10	Smoking initiation;
PAAD	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg01426195	chr3:39028469	NA	0.78	8.8	0.58	2.77e-15	Handedness;
PAAD	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.62	7.04	0.5	6.36e-11	Menopause (age at onset);
PAAD	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.9	9.47	0.61	5.1e-17	Homoarginine levels;
PAAD	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.86	-4.63	-0.35	7.67e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	10.31	0.64	3.2e-19	Platelet count;
PAAD	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.1	6.53	0.47	9.38e-10	Body mass index;
PAAD	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.68	0.35	6.37e-6	Body mass index;
PAAD	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs55692468	0.520	rs62180799	chr2:153302108	G/A	cg24749089	chr2:153322823	FMNL2	-0.27	-4.76	-0.36	4.48e-6	Intraocular pressure;
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12773846	0.568	rs71488613	chr10:126272662	C/T	cg04949429	chr10:126290192	LHPP	0.66	5.74	0.42	4.95e-8	Subcutaneous adipose tissue;
PAAD	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9810890	1.000	rs73198856	chr3:128513001	C/T	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.43	-0.34	1.77e-5	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	1.16	13.08	0.73	1.17e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.65	5.45	0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6494488	0.500	rs72744741	chr15:65050514	T/C	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.63	0.35	7.87e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg20295408	chr7:1910781	MAD1L1	-0.57	-5.61	-0.41	9.39e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.52	5.54	0.41	1.3e-7	Life satisfaction;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg25952890	chr19:58913133	NA	0.67	5.71	0.42	5.73e-8	Mean platelet volume;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	cis	rs10501293	1.000	rs4755698	chr11:43123536	G/T	cg03447554	chr11:43094025	NA	-0.5	-4.96	-0.37	1.86e-6	Cognitive performance;
PAAD	cis	rs564309	0.867	rs3738687	chr1:228565445	C/A	cg01328119	chr1:228783545	DUSP5P	0.71	4.4	0.34	2.03e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs9535307	0.929	rs6561552	chr13:50260905	A/G	cg04663916	chr13:50265991	EBPL	0.6	4.66	0.35	6.89e-6	Obesity-related traits;
PAAD	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg20243544	chr17:37824526	PNMT	-0.52	-4.67	-0.35	6.67e-6	Self-reported allergy;
PAAD	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.43	-5.11	-0.38	9.6e-7	Blood pressure (smoking interaction);
PAAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg21361702	chr7:150065534	REPIN1	0.61	5.25	0.39	5.01e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg06740227	chr12:86229804	RASSF9	-0.49	-4.87	-0.37	2.79e-6	Major depressive disorder;
PAAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.55	5.42	0.4	2.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2882667	0.690	rs311596	chr5:138072082	A/T	cg09476006	chr5:138032270	NA	-0.47	-6.16	-0.45	6.26e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg18209359	chr17:80159595	CCDC57	-0.46	-4.55	-0.35	1.1e-5	Life satisfaction;
PAAD	cis	rs73206853	0.620	rs111354540	chr12:111150302	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	4.36	0.33	2.35e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	5.61	0.41	9.49e-8	Response to antipsychotic treatment;
PAAD	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.24	0.45	4.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.46	-0.34	1.56e-5	Morning vs. evening chronotype;
PAAD	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.42	5.04	0.38	1.32e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs988913	1.000	rs6926997	chr6:54817326	C/G	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03442064	chr6:41515050	FOXP4	0.58	6.47	0.46	1.29e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7202877	0.519	rs3743606	chr16:75335474	C/A	cg03315344	chr16:75512273	CHST6	0.62	5.23	0.39	5.47e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.78	-0.36	4.07e-6	Height;
PAAD	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.91	10.89	0.66	9.19e-21	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg10591111	chr5:226296	SDHA	-0.67	-4.97	-0.37	1.78e-6	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06896857	chr19:49375797	PPP1R15A	0.62	6.61	0.47	6.02e-10	Myopia (pathological);
PAAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg09796270	chr17:17721594	SREBF1	-0.41	-4.41	-0.34	1.91e-5	Total body bone mineral density;
PAAD	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg19640130	chr10:64028056	RTKN2	-0.39	-4.79	-0.36	3.88e-6	Rheumatoid arthritis;
PAAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-8.01	-0.54	2.81e-13	Total body bone mineral density;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.62	7.03	0.5	6.71e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.35	-0.33	2.5e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3790645	0.645	rs3790644	chr1:26884676	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.96	0.37	1.9e-6	Glucose homeostasis traits;
PAAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg09579323	chr1:150459698	TARS2	-0.46	-4.46	-0.34	1.55e-5	Migraine;
PAAD	cis	rs58521262	0.556	rs399132	chr19:23180700	C/A	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg26935685	chr1:15502881	TMEM51	-0.52	-4.31	-0.33	2.94e-5	Systolic blood pressure;
PAAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.83	-0.54	7.88e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11811982	0.793	rs114003530	chr1:227602109	G/A	cg24860534	chr1:227506868	CDC42BPA	0.51	4.69	0.36	6.08e-6	Optic disc area;
PAAD	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg10820045	chr2:198174542	NA	-0.43	-4.41	-0.34	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg14393609	chr7:65229607	NA	0.48	4.58	0.35	9.76e-6	Aortic root size;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg18279126	chr7:2041391	MAD1L1	0.63	6.4	0.46	1.86e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09897416	chr1:149859252	HIST2H2AB;HIST2H2BE	-0.62	-6.31	-0.46	2.84e-9	Myopia (pathological);
PAAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.53	4.46	0.34	1.55e-5	Type 2 diabetes;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg01059385	chr22:42394853	WBP2NL	-0.54	-4.35	-0.33	2.47e-5	Birth weight;
PAAD	cis	rs1448094	0.565	rs11117106	chr12:86320275	C/G	cg06740227	chr12:86229804	RASSF9	0.48	4.31	0.33	2.94e-5	Major depressive disorder;
PAAD	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.75	7.33	0.51	1.25e-11	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12426141	chr15:57210872	TCF12;LOC145783	-0.6	-6.83	-0.48	1.88e-10	Body fat percentage;
PAAD	cis	rs2587695	1.000	rs2587687	chr2:120284152	A/G	cg05839767	chr2:119914248	C1QL2	-0.41	-4.25	-0.33	3.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Lymphocyte counts;
PAAD	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg06060754	chr5:176797920	RGS14	0.74	8.56	0.57	1.16e-14	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.88e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.68	-4.97	-0.37	1.75e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11642254	chr7:156684974	LMBR1	0.57	6.47	0.46	1.3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.99	0.54	3.19e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg22325292	chr17:80708367	FN3K	0.6	4.49	0.34	1.4e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	6.32	0.46	2.69e-9	Personality dimensions;
PAAD	cis	rs72827839	0.841	rs16952265	chr17:46184883	G/A	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-5.78	-0.42	4.08e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg11952622	chr19:58962976	ZNF324B	0.46	4.39	0.34	2.08e-5	Uric acid clearance;
PAAD	cis	rs7127900	1.000	rs6579001	chr11:2232056	A/G	cg25635251	chr11:2234043	NA	0.85	7.58	0.52	3.18e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.9	0.37	2.47e-6	Ovarian reserve;
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.48	-0.57	1.86e-14	Thrombosis;
PAAD	cis	rs72960926	0.661	rs62437422	chr6:75186759	A/G	cg03266952	chr6:74778945	NA	-1.03	-4.9	-0.37	2.46e-6	Metabolite levels (MHPG);
PAAD	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.7	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-13.5	-0.74	8.59e-28	Schizophrenia;
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.63	-6.72	-0.48	3.4e-10	Iron status biomarkers;
PAAD	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg14343924	chr8:8086146	FLJ10661	0.56	5.13	0.38	8.54e-7	Joint mobility (Beighton score);
PAAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.86	0.49	1.65e-10	Rheumatoid arthritis;
PAAD	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	1.08	5.95	0.43	1.76e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	6.83	0.48	1.87e-10	Renal function-related traits (BUN);
PAAD	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.93	9.67	0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-4.44	-0.34	1.74e-5	Morning vs. evening chronotype;
PAAD	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	10.0	0.63	2.13e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7594192	0.778	rs10931816	chr2:199430670	G/A	cg03163783	chr2:200326591	SATB2	-0.36	-4.9	-0.37	2.45e-6	Educational attainment;
PAAD	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.06	0.55	2.05e-13	Homoarginine levels;
PAAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.19	7.49	0.52	5.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11235843	0.929	rs3825003	chr11:73389112	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.41	-0.34	1.93e-5	Lung cancer in ever smokers;
PAAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.68	-0.42	6.74e-8	HDL cholesterol;
PAAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.0	0.44	1.38e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02282317	chr17:35306345	AATF	0.66	6.56	0.47	8.02e-10	Obesity-related traits;
PAAD	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.67	-7.1	-0.5	4.42e-11	Menarche (age at onset);
PAAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg26174226	chr8:58114915	NA	-0.64	-5.33	-0.4	3.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.74	7.05	0.5	5.96e-11	Monocyte count;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-6.83	-0.48	1.88e-10	Lymphocyte counts;
PAAD	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.5	5.78	0.42	4.16e-8	Coronary artery disease;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.66	-7.83	-0.54	7.9e-13	Longevity;Endometriosis;
PAAD	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg18753928	chr3:113234510	CCDC52	-0.44	-4.88	-0.37	2.64e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-1.01	-9.18	-0.6	2.87e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg06569542	chr10:98946673	SLIT1	-0.47	-5.19	-0.39	6.73e-7	Monocyte count;
PAAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.62	6.94	0.49	1.07e-10	Multiple sclerosis;
PAAD	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.77	8.45	0.57	2.23e-14	Heart rate;
PAAD	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg27499820	chr13:21296301	IL17D	0.49	5.1	0.38	9.91e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs58521262	0.556	rs453743	chr19:23121640	G/A	cg22640819	chr19:22990650	NA	-0.29	-4.39	-0.34	2.15e-5	Testicular germ cell tumor;
PAAD	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.52	0.52	4.55e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg01942863	chr7:99769432	GPC2	0.5	4.71	0.36	5.57e-6	Coronary artery disease;
PAAD	cis	rs9463078	0.753	rs636845	chr6:44935341	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.57	-0.41	1.13e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg19774624	chr17:42201019	HDAC5	-0.8	-7.52	-0.52	4.4e-12	Total body bone mineral density;
PAAD	cis	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg09913449	chr8:42400586	C8orf40	-0.43	-4.63	-0.35	7.79e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.62	-5.93	-0.43	1.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs57244997	0.652	rs78477696	chr6:162428316	C/T	cg17173639	chr6:162384350	PARK2	-0.71	-5.32	-0.4	3.67e-7	Mosquito bite size;
PAAD	cis	rs6089829	0.723	rs747128	chr20:61656398	G/A	cg08564027	chr20:61660810	NA	-0.77	-6.96	-0.49	9.49e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.52	-4.78	-0.36	4.17e-6	Height;
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs4909764	1.000	rs4909764	chr8:139255918	A/G	cg16476975	chr7:155164995	NA	-0.92	-6.31	-0.46	2.85e-9	Inflammatory biomarkers;
PAAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg06618935	chr21:46677482	NA	0.54	6.81	0.48	2.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.6	-6.32	-0.46	2.75e-9	Corneal astigmatism;
PAAD	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg24253500	chr15:84953950	NA	0.42	4.4	0.34	2.05e-5	P wave terminal force;
PAAD	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-4.26	-0.33	3.54e-5	Axial length;
PAAD	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg00277334	chr10:82204260	NA	-0.63	-6.73	-0.48	3.31e-10	Post bronchodilator FEV1;
PAAD	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.38	0.33	2.19e-5	Total cholesterol levels;
PAAD	cis	rs4713118	1.000	rs4713118	chr6:27676794	A/G	cg22143856	chr6:28129313	ZNF389	0.48	4.36	0.33	2.38e-5	Parkinson's disease;
PAAD	cis	rs2290402	0.536	rs56253935	chr4:853871	A/T	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.5	-5.02	-0.38	1.45e-6	Type 2 diabetes;
PAAD	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.22	12.02	0.7	7.95e-24	Corneal structure;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.79	-0.43	3.92e-8	Lung cancer;
PAAD	cis	rs1468333	0.667	rs35635987	chr5:137690876	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg07469887	chr10:131262384	NA	0.48	5.93	0.43	1.94e-8	Response to temozolomide;
PAAD	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.43	7.19	0.5	2.69e-11	IgG glycosylation;
PAAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.58	-4.45	-0.34	1.68e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.76	8.29	0.56	5.44e-14	Body mass index;
PAAD	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg03289416	chr15:75166202	SCAMP2	0.52	5.54	0.41	1.29e-7	Breast cancer;
PAAD	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg01388757	chr2:102091195	RFX8	-0.55	-7.07	-0.5	5.2e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg22325292	chr17:80708367	FN3K	-0.65	-4.7	-0.36	5.83e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01557844	chr1:151432001	POGZ	0.61	6.88	0.49	1.43e-10	Monocyte percentage of white cells;
PAAD	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.25	-4.59	-0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.46	-4.75	-0.36	4.7e-6	Blood protein levels;
PAAD	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.54	5.33	0.4	3.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08677398	chr8:58056175	NA	0.61	4.54	0.35	1.16e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg02910952	chr12:132569714	EP400NL	0.58	4.38	0.33	2.23e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.55	-5.58	-0.41	1.09e-7	Ulcerative colitis;
PAAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	4.63	0.35	7.88e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg14926445	chr8:58193284	C8orf71	-0.66	-5.19	-0.39	6.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.25	-0.33	3.68e-5	Height;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18621852	chr3:10150065	C3orf24	-0.65	-5.74	-0.42	4.96e-8	Alzheimer's disease;
PAAD	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.6	-0.47	6.48e-10	Neuroticism;
PAAD	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.39	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12136530	0.593	rs9287046	chr1:19736395	C/G	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.86	-0.37	2.88e-6	Lead levels in blood;
PAAD	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.5	4.57	0.35	1.02e-5	Multiple sclerosis;
PAAD	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.83	10.2	0.64	6.18e-19	Height;
PAAD	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.24	0.6	2.09e-16	Bipolar disorder;
PAAD	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.63	6.23	0.45	4.43e-9	Type 2 diabetes;
PAAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7795096	0.743	rs9648726	chr7:151537433	C/T	cg17008978	chr7:151542804	PRKAG2	0.44	5.16	0.39	7.76e-7	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.67	-5.75	-0.42	4.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.777	rs11765899	chr7:104923002	T/C	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs9549328	0.917	rs4907573	chr13:113648742	C/G	cg20742385	chr13:113633654	MCF2L	-0.44	-4.46	-0.34	1.58e-5	Systolic blood pressure;
PAAD	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.56	-5.04	-0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.44	-4.42	-0.34	1.86e-5	Age of smoking initiation;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.09	0.38	1.05e-6	Urinary tract infection frequency;
PAAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.45	4.5	0.34	1.36e-5	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14007458	chr4:144257692	GAB1	0.63	7.15	0.5	3.34e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08206098	chr4:1750476	NA	0.66	6.71	0.48	3.57e-10	Obesity-related traits;
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.74	-7.77	-0.53	1.06e-12	Blood metabolite levels;
PAAD	cis	rs9503598	0.543	rs4959832	chr6:3435112	A/C	cg00476032	chr6:3446245	SLC22A23	-0.43	-4.46	-0.34	1.59e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs10073892	0.703	rs9327821	chr5:101637995	A/G	cg17280723	chr5:101634495	NA	-0.4	-4.29	-0.33	3.22e-5	Cognitive decline (age-related);
PAAD	cis	rs1011018	0.955	rs1541480	chr7:139465278	G/A	cg03224163	chr7:139420300	HIPK2	-0.62	-4.28	-0.33	3.32e-5	Systolic blood pressure;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.79	0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs8077577	0.895	rs1563371	chr17:18111793	C/T	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg01763666	chr17:80159506	CCDC57	0.45	4.56	0.35	1.04e-5	Life satisfaction;
PAAD	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-6.44	-0.46	1.52e-9	Lymphocyte counts;
PAAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg21191810	chr6:118973309	C6orf204	-0.51	-4.9	-0.37	2.45e-6	Diastolic blood pressure;
PAAD	cis	rs11264213	0.686	rs72661655	chr1:36475401	G/T	cg27506609	chr1:36549197	TEKT2	1.07	5.6	0.41	9.62e-8	Schizophrenia;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.69	-7.82	-0.54	8.02e-13	Vitiligo;
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.58	7.29	0.51	1.55e-11	Hypertriglyceridemia;
PAAD	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs564309	0.681	rs1188482	chr1:228617493	T/G	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg14459158	chr9:96720562	NA	0.35	4.56	0.35	1.04e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06002616	chr8:101225028	SPAG1	0.45	5.2	0.39	6.32e-7	Atrioventricular conduction;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.92	11.07	0.67	2.99e-21	Prudent dietary pattern;
PAAD	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.77	-6.87	-0.49	1.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg24542046	chr7:102782124	NAPEPLD;RPL19P12	0.92	6.31	0.46	2.88e-9	Airflow obstruction;
PAAD	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.78e-5	Cognitive function;
PAAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.42	-0.46	1.63e-9	Mood instability;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg20607798	chr8:58055168	NA	0.64	4.73	0.36	5.08e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg26497354	chr6:109612229	NA	-0.43	-4.33	-0.33	2.72e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg12908607	chr1:44402522	ARTN	-0.42	-4.57	-0.35	9.98e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg09835421	chr16:68378352	PRMT7	-1.01	-6.6	-0.47	6.45e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg23649088	chr2:200775458	C2orf69	0.64	4.92	0.37	2.21e-6	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17601876	0.843	rs28490942	chr15:51559845	G/C	cg21478137	chr15:51532386	CYP19A1	0.42	4.35	0.33	2.47e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg01420254	chr6:26195488	NA	1.0	6.94	0.49	1.08e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2327429	0.858	rs1832181	chr6:134186165	C/G	cg06296503	chr6:134217401	NA	0.48	4.91	0.37	2.37e-6	Coronary artery disease;
PAAD	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg05338066	chr1:7812865	CAMTA1	0.65	4.97	0.37	1.79e-6	Inflammatory bowel disease;
PAAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2249694	1.000	rs2249695	chr10:135352168	T/C	cg16964102	chr10:135390573	NA	-0.45	-4.54	-0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.97	10.96	0.66	5.85e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18364779	chr6:26104403	HIST1H4C	0.44	4.43	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg18898632	chr2:242989856	NA	-0.78	-5.85	-0.43	2.86e-8	Obesity-related traits;
PAAD	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.66	6.33	0.46	2.57e-9	Asthma;
PAAD	cis	rs16975963	0.895	rs8103383	chr19:38327701	A/C	cg25793785	chr19:38281423	NA	0.57	4.74	0.36	4.83e-6	Longevity;
PAAD	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg00262122	chr8:11665843	FDFT1	-0.47	-4.27	-0.33	3.39e-5	Retinal vascular caliber;
PAAD	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.75	7.43	0.52	7.29e-12	Schizophrenia;
PAAD	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg13859433	chr6:33739653	LEMD2	-0.63	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.86	-0.43	2.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg01631408	chr1:248437212	OR2T33	-0.55	-5.15	-0.39	8.11e-7	Common traits (Other);
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg21665744	chr7:39171113	POU6F2	0.33	4.94	0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.49	7.87	0.54	6.02e-13	Mean corpuscular volume;
PAAD	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.46	5.64	0.42	8.01e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.5	5.53	0.41	1.34e-7	Heart rate;
PAAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg13722127	chr7:150037890	RARRES2	0.62	5.98	0.44	1.5e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03647317	chr4:187891568	NA	-0.52	-6.53	-0.47	9.45e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg26752003	chr8:145688521	CYHR1	-0.58	-6.55	-0.47	8.18e-10	Age at first birth;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10819733	chr22:24237672	NA	-0.52	-5.48	-0.41	1.74e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.64	-5.83	-0.43	3.24e-8	Cognitive test performance;
PAAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg16898833	chr6:26189333	HIST1H4D	0.59	4.7	0.36	5.71e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.57	-6.02	-0.44	1.24e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3026101	0.671	rs1806265	chr17:5320044	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.35	0.46	2.35e-9	Body mass index;
PAAD	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg07153921	chr17:41440717	NA	-0.42	-4.43	-0.34	1.78e-5	Menopause (age at onset);
PAAD	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg16898833	chr6:26189333	HIST1H4D	0.68	4.28	0.33	3.26e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.88e-6	Height;
PAAD	cis	rs76419734	0.510	rs961472	chr4:106535062	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	4.56	0.35	1.06e-5	Post bronchodilator FEV1;
PAAD	cis	rs4234284	0.965	rs11915186	chr3:126959331	A/G	cg27326032	chr3:127006922	NA	-0.48	-4.95	-0.37	1.96e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg21770322	chr7:97807741	LMTK2	0.51	5.6	0.41	9.84e-8	Breast cancer;
PAAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.42	-5.27	-0.39	4.56e-7	Ulcerative colitis;
PAAD	cis	rs295140	0.647	rs295132	chr2:201233502	A/G	cg05691004	chr2:201170426	SPATS2L	0.43	4.26	0.33	3.63e-5	QT interval;
PAAD	trans	rs4657482	0.606	rs2241965	chr1:165865694	G/A	cg03151810	chr8:144371745	NA	-0.51	-6.29	-0.45	3.18e-9	Testicular germ cell tumor;
PAAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg25456477	chr12:86230367	RASSF9	0.49	4.31	0.33	2.96e-5	Major depressive disorder;
PAAD	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25043643	chr14:102609274	WDR20	0.56	6.34	0.46	2.46e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7804356	0.871	rs6972378	chr7:26753074	C/T	cg03456212	chr7:26904342	SKAP2	0.54	4.36	0.33	2.36e-5	Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.77	-0.48	2.56e-10	Lung cancer;
PAAD	cis	rs4839542	0.711	rs75308045	chr1:111150195	A/G	cg06215569	chr1:110611465	ALX3	0.25	4.27	0.33	3.37e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.8	-6.2	-0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23158103	chr7:148848205	ZNF398	-0.62	-6.07	-0.44	9.6e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs787274	1.000	rs787296	chr9:115541703	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.97	9.14	0.6	3.83e-16	Psoriasis;
PAAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.7	-7.69	-0.53	1.68e-12	IgG glycosylation;
PAAD	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.58	-5.65	-0.42	7.86e-8	Systolic blood pressure;
PAAD	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.97	11.28	0.68	7.92e-22	Bone mineral density;
PAAD	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.68	0.35	6.27e-6	HDL cholesterol;
PAAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg00944433	chr1:107599041	PRMT6	0.43	5.0	0.38	1.56e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.57	-4.99	-0.38	1.6e-6	Type 2 diabetes;
PAAD	cis	rs876084	0.527	rs7460965	chr8:121164389	C/T	cg06265175	chr8:121136014	COL14A1	0.45	4.29	0.33	3.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.44	4.52	0.34	1.23e-5	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.52	-0.34	1.23e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg23205692	chr1:25664452	TMEM50A	0.48	4.53	0.35	1.17e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs686320	0.748	rs580933	chr11:65196884	C/G	cg16175245	chr11:65246563	NA	-0.47	-4.35	-0.33	2.44e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.58	6.29	0.45	3.21e-9	Obesity-related traits;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg11112914	chr7:18067530	PRPS1L1	-0.62	-6.33	-0.46	2.6e-9	Survival in colon cancer;
PAAD	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg21535247	chr6:8435926	SLC35B3	-0.49	-4.71	-0.36	5.57e-6	Motion sickness;
PAAD	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.75	9.37	0.6	9.62e-17	Bladder cancer;
PAAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.75	-0.48	2.99e-10	Neuroticism;
PAAD	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.79	-7.33	-0.51	1.28e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01616529	chr11:638424	DRD4	-0.62	-5.62	-0.41	9e-8	Systemic lupus erythematosus;
PAAD	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.86	6.83	0.48	1.93e-10	Obesity-related traits;
PAAD	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg08992911	chr2:238395768	MLPH	0.66	5.27	0.39	4.61e-7	Prostate cancer;
PAAD	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg23107878	chr1:152161397	NA	0.49	4.92	0.37	2.21e-6	Inflammatory skin disease;
PAAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg22143856	chr6:28129313	ZNF389	0.65	5.11	0.38	9.57e-7	Depression;
PAAD	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07304068	chr3:47823820	SMARCC1	0.71	7.22	0.51	2.35e-11	Obesity-related traits;
PAAD	cis	rs427941	0.703	rs201456	chr7:101741059	C/G	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.46	4.92	0.37	2.22e-6	Monocyte percentage of white cells;
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg08200582	chr11:442649	ANO9	0.51	4.46	0.34	1.59e-5	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg14515779	chr1:101123966	NA	0.44	5.11	0.38	9.56e-7	Monocyte count;
PAAD	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg20673841	chr7:107026890	COG5	0.48	4.32	0.33	2.79e-5	Coronary artery disease;
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.89	9.89	0.63	4.02e-18	Blood metabolite levels;
PAAD	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.22e-11	Alcohol dependence;
PAAD	cis	rs9463078	0.585	rs1748242	chr6:45163350	T/C	cg25276700	chr6:44698697	NA	-0.45	-5.09	-0.38	1.03e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-4.28	-0.33	3.32e-5	Hemoglobin concentration;
PAAD	cis	rs17401966	0.809	rs12733312	chr1:10237960	T/C	cg15208524	chr1:10270712	KIF1B	0.51	4.71	0.36	5.54e-6	Hepatocellular carcinoma;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.8	0.36	3.79e-6	Vitiligo;
PAAD	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8042680	1.000	rs6496743	chr15:91528358	G/A	cg08919649	chr15:91565780	VPS33B	0.49	4.27	0.33	3.42e-5	Type 2 diabetes;
PAAD	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	1.31	11.06	0.67	3.19e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg01388757	chr2:102091195	RFX8	0.66	8.23	0.56	7.93e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs60154123	0.730	rs12040684	chr1:210472053	C/T	cg21951975	chr1:209979733	IRF6	0.5	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs3736485	0.966	rs12440990	chr15:51902259	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.28	-0.33	3.32e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs61677309	1.000	rs1074457	chr11:118156117	A/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg21589280	chr1:85930151	DDAH1	-0.6	-4.59	-0.35	9.06e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.82e-6	Biliary atresia;
PAAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.33	-4.98	-0.37	1.74e-6	Cystic fibrosis severity;
PAAD	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.52	5.24	0.39	5.28e-7	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00026457	chr1:200116736	NR5A2	-0.67	-6.98	-0.49	8.6e-11	Obesity-related traits;
PAAD	cis	rs7577696	0.962	rs12617289	chr2:32341399	A/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.62	-0.35	8.11e-6	Inflammatory biomarkers;
PAAD	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.74	11.1	0.67	2.47e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.41	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.6	-0.35	8.77e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.68	-7.26	-0.51	1.92e-11	Post bronchodilator FEV1;
PAAD	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs303386	0.520	rs12143634	chr1:99598759	A/G	cg03593336	chr1:99471295	LPPR5	0.52	4.86	0.37	2.93e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.95	12.36	0.71	1.02e-24	Menopause (age at onset);
PAAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs1443512	0.588	rs1838173	chr12:54342822	C/T	cg17410650	chr12:54324560	NA	0.39	4.98	0.37	1.71e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.65	6.26	0.45	3.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	5.1	0.38	9.92e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg03188948	chr7:1209495	NA	0.56	5.74	0.42	4.94e-8	Longevity;Endometriosis;
PAAD	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg19949948	chr17:19361230	NA	-0.43	-4.44	-0.34	1.74e-5	Schizophrenia;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.61	7.74	0.53	1.28e-12	Hypertriglyceridemia;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg00024416	chr22:24240387	NA	-0.57	-6.02	-0.44	1.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg07701084	chr6:150067640	NUP43	0.56	4.84	0.37	3.1e-6	Lung cancer;
PAAD	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg20893579	chr22:38215064	NA	0.54	5.83	0.43	3.22e-8	Glioblastoma;Glioma;
PAAD	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	6.95	0.49	1.01e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg02696790	chr15:75250997	RPP25	0.4	4.53	0.35	1.18e-5	Caffeine consumption;
PAAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg01475735	chr3:40494733	NA	-0.47	-4.36	-0.33	2.42e-5	Renal cell carcinoma;
PAAD	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg16691251	chr5:66510806	NA	-0.78	-9.32	-0.6	1.29e-16	Breast cancer;
PAAD	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-7.2	-0.5	2.61e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.96	8.43	0.56	2.52e-14	Other erythrocyte phenotypes;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-6.26	-0.45	3.77e-9	Life satisfaction;
PAAD	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.95	9.58	0.61	2.59e-17	Corneal astigmatism;
PAAD	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg22138327	chr13:27999177	GTF3A	0.85	5.31	0.4	3.75e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg23985595	chr17:80112537	CCDC57	0.45	5.67	0.42	6.87e-8	Life satisfaction;
PAAD	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.04	0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.57	5.82	0.43	3.4e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs10957961	0.565	rs1426147	chr8:81072183	C/T	cg10609868	chr8:81963379	PAG1	-0.36	-4.32	-0.33	2.79e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.83	5.95	0.43	1.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21097640	chr13:28195548	POLR1D;LNX2	-0.58	-6.41	-0.46	1.71e-9	Energy expenditure (24h);
PAAD	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-4.59	-0.35	9.09e-6	Educational attainment (years of education);
PAAD	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg00614314	chr15:82944287	LOC80154	0.52	5.26	0.39	4.73e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs6076065	0.723	rs6137909	chr20:23344728	A/G	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	7.79e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.71	7.19	0.5	2.8e-11	Lymphocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18337803	chr17:48638187	CACNA1G	0.71	8.39	0.56	3.09e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.12	0.44	7.59e-9	Lung cancer;
PAAD	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg04034577	chr2:241836375	C2orf54	-0.33	-4.95	-0.37	1.94e-6	Urinary metabolites;
PAAD	cis	rs988913	1.000	rs9367600	chr6:54837977	T/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.4	-4.56	-0.35	1.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.36	0.33	2.35e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-5.47	-0.41	1.8e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.49	-4.27	-0.33	3.46e-5	Height;
PAAD	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg12215294	chr3:40350768	EIF1B	-0.47	-4.84	-0.37	3.09e-6	Renal cell carcinoma;
PAAD	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.39	4.4	0.34	2.06e-5	High light scatter reticulocyte count;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9469890	0.591	rs11754773	chr6:34577257	A/G	cg14254433	chr6:34482411	PACSIN1	-0.83	-5.43	-0.4	2.23e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.48	5.7	0.42	5.9e-8	Atrioventricular conduction;
PAAD	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.92	-9.02	-0.59	7.8e-16	Obesity-related traits;
PAAD	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs7291412	0.579	rs11090867	chr22:46454792	T/C	cg05468064	chr22:46423449	NA	0.42	5.08	0.38	1.12e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.5	9.4	0.61	7.93e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.89	11.06	0.67	3.13e-21	Mean corpuscular volume;
PAAD	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg13741927	chr9:139327495	INPP5E	0.44	4.4	0.34	2.02e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.66e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.02	-0.59	7.65e-16	Exhaled nitric oxide output;
PAAD	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg14668889	chr17:73230827	NUP85	0.56	5.21	0.39	5.97e-7	Systemic lupus erythematosus;
PAAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.42	-4.6	-0.35	8.83e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.14	-0.45	6.75e-9	Schizophrenia;
PAAD	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.92	-11.14	-0.67	1.9e-21	Dental caries;
PAAD	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-5.61	-0.41	9.5e-8	Schizophrenia;
PAAD	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.18e-17	Resting heart rate;
PAAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg06740227	chr12:86229804	RASSF9	-0.5	-4.83	-0.36	3.3e-6	Major depressive disorder;
PAAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.47	0.61	5.3e-17	Gut microbiome composition (summer);
PAAD	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.77	7.44	0.52	6.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs9810890	1.000	rs28694035	chr3:128575365	G/A	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg20744362	chr22:50050164	C22orf34	0.63	7.25	0.51	2.02e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.46	4.34	0.33	2.54e-5	Hip circumference;
PAAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.72	7.74	0.53	1.28e-12	Colorectal cancer;
PAAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.54	-6.29	-0.45	3.28e-9	Alzheimer's disease (late onset);
PAAD	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg14917874	chr2:235941519	SH3BP4	0.56	5.54	0.41	1.3e-7	Dialysis-related mortality;
PAAD	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg19257562	chr1:2043853	PRKCZ	-0.4	-4.58	-0.35	9.75e-6	Coronary artery disease;
PAAD	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg25753631	chr6:25732923	NA	0.36	4.48	0.34	1.48e-5	Blood metabolite levels;
PAAD	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.86	11.89	0.69	1.85e-23	Vitiligo;
PAAD	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1419980	0.730	rs11054612	chr12:7733804	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	4.49	0.34	1.39e-5	Educational attainment;
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg18279126	chr7:2041391	MAD1L1	0.59	5.8	0.43	3.79e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2553268	0.958	rs1800389	chr8:30924557	C/T	cg00964221	chr8:30240029	NA	0.51	4.27	0.33	3.38e-5	Exercise treadmill test traits;
PAAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.79	7.14	0.5	3.58e-11	Obesity-related traits;
PAAD	cis	rs2599510	0.811	rs2754523	chr2:32837110	A/G	cg02381751	chr2:32503542	YIPF4	0.5	5.11	0.38	9.45e-7	Interleukin-18 levels;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6782228	0.606	rs2811497	chr3:128363332	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.63	-0.47	5.37e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.57	5.62	0.41	9.03e-8	Osteoporosis;
PAAD	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.14	15.52	0.78	3.76e-33	Schizophrenia;
PAAD	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.55	-5.65	-0.42	7.78e-8	Psoriasis;
PAAD	cis	rs11776272	0.927	rs11135789	chr8:21878607	C/T	cg17168535	chr8:21777572	XPO7	-0.69	-6.9	-0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-9.83	-0.62	5.92e-18	Total body bone mineral density;
PAAD	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs5756391	0.532	rs4820261	chr22:37316949	G/A	cg21209356	chr22:37319042	CSF2RB	0.39	4.75	0.36	4.65e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg15309053	chr8:964076	NA	0.51	5.72	0.42	5.37e-8	Schizophrenia;
PAAD	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg05110241	chr16:68378359	PRMT7	-1.02	-7.47	-0.52	5.83e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19671926	chr4:122722719	EXOSC9	-0.67	-6.15	-0.45	6.57e-9	Type 2 diabetes;
PAAD	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.85	-0.37	3e-6	Kawasaki disease;
PAAD	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.64	5.07	0.38	1.15e-6	Osteoarthritis;
PAAD	cis	rs4523957	0.820	rs216193	chr17:2203453	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.45	0.4	1.98e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.55	6.08	0.44	9.51e-9	Type 2 diabetes;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.94	11.71	0.69	5.5e-23	Menarche (age at onset);
PAAD	cis	rs501120	0.584	rs61857460	chr10:44688877	A/C	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10131879	chr7:8011594	GLCCI1	0.56	6.35	0.46	2.33e-9	Body fat percentage;
PAAD	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.64	4.53	0.34	1.19e-5	Depression;
PAAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.8	-7.61	-0.53	2.66e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.34	-15.46	-0.78	5.24e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.64	4.36	0.33	2.41e-5	Lung cancer in ever smokers;
PAAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.25	0.45	3.99e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg26205652	chr12:48591994	NA	0.85	7.74	0.53	1.26e-12	Longevity (90 years and older);
PAAD	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.5	-5.25	-0.39	5.06e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg15693483	chr7:1102177	C7orf50	0.47	5.15	0.39	7.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.86	9.26	0.6	1.82e-16	Body mass index;
PAAD	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs863345	0.584	rs10908676	chr1:158506163	C/G	cg12129480	chr1:158549410	OR10X1	-0.43	-5.0	-0.38	1.57e-6	Pneumococcal bacteremia;
PAAD	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.51	4.81	0.36	3.57e-6	HDL cholesterol;
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs10450586	0.796	rs10437624	chr11:27307345	C/G	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02761476	chr19:4472180	HDGF2	0.65	7.38	0.51	9.44e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11245990	chr11:68621969	NA	0.37	4.82	0.36	3.46e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.45	-0.4	1.97e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7785730	0.744	rs117742893	chr7:28088993	G/A	cg15506609	chr7:27206073	HOXA9	-0.26	-4.59	-0.35	9.1e-6	Free thyroxine concentration;
PAAD	cis	rs258892	0.841	rs266425	chr5:72132531	T/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs9810890	0.850	rs73198858	chr3:128514061	T/G	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	6.03	0.44	1.17e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.26	0.33	3.61e-5	Alzheimer's disease;
PAAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.65	6.84	0.48	1.85e-10	DNA methylation (variation);
PAAD	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.55	-4.43	-0.34	1.77e-5	Facial morphology (factor 19);
PAAD	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs656900	0.669	rs7178799	chr15:80119323	T/C	cg02196730	chr15:80188777	MTHFS	0.45	4.97	0.37	1.76e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg03605226	chr16:87637261	JPH3	0.4	4.57	0.35	1e-5	Menopause (age at onset);
PAAD	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg23665729	chr3:49977591	RBM6	0.66	4.26	0.33	3.52e-5	Schizophrenia;
PAAD	cis	rs7264396	0.887	rs6060434	chr20:34068382	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs1957429	0.708	rs8019346	chr14:65353011	G/A	cg23373153	chr14:65346875	NA	-1.14	-5.8	-0.43	3.79e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs655641	0.520	rs2508691	chr11:85750671	A/T	cg07180834	chr11:85838833	NA	-0.46	-4.91	-0.37	2.34e-6	Platelet count;
PAAD	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs901683	1.000	rs12771275	chr10:45959652	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg00717180	chr2:96193071	NA	-0.68	-8.15	-0.55	1.22e-13	Coronary artery disease;
PAAD	cis	rs2492906	0.515	rs2637304	chr10:27980562	G/A	cg25523538	chr10:28031957	MKX	0.51	4.35	0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg25952890	chr19:58913133	NA	0.73	5.78	0.42	4.04e-8	Mean platelet volume;
PAAD	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.54	5.12	0.38	9.17e-7	Resting heart rate;
PAAD	cis	rs11997175	0.516	rs6981283	chr8:33619363	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13006833	0.739	rs6434387	chr2:191205969	C/T	cg01027365	chr2:191184571	HIBCH	0.43	4.26	0.33	3.59e-5	Urinary metabolites;
PAAD	cis	rs3981351	0.797	rs34293126	chr10:115465925	G/T	cg24846397	chr10:115438155	CASP7	-0.58	-5.39	-0.4	2.59e-7	Obesity-related traits;
PAAD	cis	rs7092929	0.941	rs575738	chr10:3579283	C/A	cg14308648	chr10:3568949	NA	0.67	5.02	0.38	1.4e-6	Coronary artery calcification;
PAAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.75	-8.63	-0.57	7.7e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg08886695	chr4:3369023	RGS12	0.53	5.26	0.39	4.77e-7	Mean platelet volume;
PAAD	cis	rs2885056	0.891	rs73018643	chr19:10688969	G/C	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.48	4.47	0.34	1.5e-5	HDL cholesterol;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.54	-5.76	-0.42	4.62e-8	Lung cancer;
PAAD	cis	rs8170	0.554	rs60397819	chr19:17451369	G/T	cg04749549	chr19:17459798	NA	-0.5	-5.48	-0.41	1.69e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.05e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	4.97	0.37	1.77e-6	Bone mineral density;
PAAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.44	0.34	1.71e-5	Aortic root size;
PAAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.59	-0.41	1.03e-7	Glomerular filtration rate;
PAAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.44	-5.63	-0.42	8.48e-8	Ulcerative colitis;
PAAD	cis	rs7260329	0.507	rs71358958	chr19:41530883	G/A	cg06653635	chr19:40910092	PRX	-0.63	-4.59	-0.35	9.05e-6	Smoking behavior;
PAAD	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg21238619	chr17:78079768	GAA	-0.57	-5.76	-0.42	4.58e-8	Yeast infection;
PAAD	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.28	-0.33	3.34e-5	Total body bone mineral density;
PAAD	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.73	-7.24	-0.51	2.09e-11	Sum neutrophil eosinophil counts;
PAAD	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.75	-0.48	2.85e-10	Glomerular filtration rate;
PAAD	cis	rs525304	1.000	rs525304	chr11:70506206	A/C	cg13988209	chr11:69683043	NA	-0.39	-4.25	-0.33	3.77e-5	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg27182935	chr16:89790473	ZNF276	-0.68	-4.28	-0.33	3.3e-5	Skin colour saturation;
PAAD	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg22517653	chr1:2918612	NA	0.6	4.96	0.37	1.87e-6	Plateletcrit;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.47	-4.31	-0.33	2.86e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs533581	0.789	rs7404039	chr16:88975954	A/G	cg08698997	chr16:88989212	CBFA2T3	0.49	5.92	0.43	2.11e-8	Social autistic-like traits;
PAAD	cis	rs11264799	0.731	rs6427396	chr1:157690514	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.6	0.41	9.77e-8	IgA nephropathy;
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg05110241	chr16:68378359	PRMT7	-0.74	-5.73	-0.42	5.28e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10885582	0.809	rs11196784	chr10:116305140	A/G	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.12	-0.38	9.21e-7	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20968439	chr14:103298732	TRAF3	-0.71	-7.55	-0.52	3.8e-12	Obesity-related traits;
PAAD	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.6	4.63	0.35	7.68e-6	Information processing speed;
PAAD	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.82	-9.87	-0.62	4.74e-18	Brugada syndrome;
PAAD	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.15	0.5	3.34e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.44	-4.41	-0.34	1.91e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.61	-7.97	-0.54	3.59e-13	Renal cell carcinoma;
PAAD	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.6	5.54	0.41	1.31e-7	Malaria;
PAAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-4.5	-0.34	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	9.51	0.61	4.01e-17	Alzheimer's disease;
PAAD	cis	rs17209837	0.915	rs7805184	chr7:87118601	G/A	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs10267417	0.603	rs10244374	chr7:19863170	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Night sleep phenotypes;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.61e-9	Cognitive function;
PAAD	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg22138327	chr13:27999177	GTF3A	-0.82	-7.06	-0.5	5.65e-11	Body mass index;
PAAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.35	0.33	2.48e-5	Renal cell carcinoma;
PAAD	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg02221750	chr19:17393354	ANKLE1	-0.73	-5.67	-0.42	7.09e-8	Systemic lupus erythematosus;
PAAD	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.69	7.1	0.5	4.51e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12799264	1.000	rs10833203	chr11:19979229	C/T	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218026	chr1:154582156	ADAR	-0.37	-5.47	-0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.41	4.46	0.34	1.58e-5	Aortic root size;
PAAD	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6137287	0.855	rs3748438	chr20:21196089	A/G	cg04219410	chr20:21106687	PLK1S1	-0.4	-4.5	-0.34	1.34e-5	Height;
PAAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg14393609	chr7:65229607	NA	-0.48	-4.58	-0.35	9.76e-6	Aortic root size;
PAAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.08	-11.6	-0.69	1.09e-22	Blood pressure (smoking interaction);
PAAD	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.4	5.38	0.4	2.81e-7	Mean corpuscular volume;
PAAD	cis	rs2882667	0.690	rs825754	chr5:138131889	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16935709	chr3:130745618	NEK11;ASTE1	-0.65	-6.59	-0.47	6.91e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.68	-7.17	-0.5	3.11e-11	DNA methylation (variation);
PAAD	cis	rs28489187	0.660	rs4949900	chr1:85861034	T/G	cg16011679	chr1:85725395	C1orf52	-0.54	-5.16	-0.39	7.53e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.22	8.15	0.55	1.23e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01189475	chr2:152685088	ARL5A	-0.57	-6.35	-0.46	2.31e-9	Smoking initiation;
PAAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg07148914	chr20:33460835	GGT7	0.49	4.88	0.37	2.65e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1198430	0.639	rs1767147	chr1:23770516	A/G	cg27447006	chr1:23763279	ASAP3	0.65	5.0	0.38	1.58e-6	Total cholesterol levels;
PAAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.75	-0.48	3.01e-10	Response to antipsychotic treatment;
PAAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.58	6.36	0.46	2.28e-9	Cardiovascular disease risk factors;
PAAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.48	4.63	0.35	7.65e-6	Height;
PAAD	cis	rs7631605	0.905	rs931721	chr3:37211972	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.56	4.82	0.36	3.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.62	0.35	8.07e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02513392	chr12:112601463	C12orf51	0.83	7.28	0.51	1.67e-11	Neuroticism;
PAAD	cis	rs9815354	0.951	rs17060961	chr3:41763711	A/G	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg04106633	chr4:1044584	NA	-0.54	-4.99	-0.38	1.65e-6	Recombination rate (males);
PAAD	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.27	19.36	0.84	7.03e-43	IgG glycosylation;
PAAD	cis	rs11203032	0.831	rs10887925	chr10:90938902	G/T	cg16672925	chr10:90967113	CH25H	0.72	5.62	0.41	8.85e-8	Heart failure;
PAAD	cis	rs3892630	0.500	rs35170371	chr19:33355081	G/A	cg22980127	chr19:33182716	NUDT19	0.92	7.81	0.54	8.76e-13	Red blood cell traits;
PAAD	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	10.1	0.63	1.14e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16016104	chr18:74073724	ZNF516	-0.55	-5.74	-0.42	4.86e-8	Obesity-related traits;
PAAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.6	5.46	0.4	1.94e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg02917321	chr22:38215204	NA	-0.46	-4.97	-0.37	1.81e-6	Glioblastoma;Glioma;
PAAD	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	4.37	0.33	2.29e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224314	1.000	rs62084079	chr17:65386917	C/T	cg01507342	chr17:65387096	PITPNC1	-0.64	-6.0	-0.44	1.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg08132940	chr7:1081526	C7orf50	-0.58	-4.37	-0.33	2.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73206853	0.841	rs73191825	chr12:110942205	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-4.76	-0.36	4.5e-6	Menarche (age at onset);
PAAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.33	-0.46	2.68e-9	Type 2 diabetes;
PAAD	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg19949948	chr17:19361230	NA	0.46	4.61	0.35	8.54e-6	Schizophrenia;
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	6.47	0.46	1.24e-9	Lung function (FEV1/FVC);
PAAD	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.58	5.27	0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg10223061	chr2:219282414	VIL1	0.41	4.82	0.36	3.47e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.6	5.83	0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs329674	0.556	rs1793681	chr11:133763230	A/C	cg06766960	chr11:133703094	NA	-0.7	-4.41	-0.34	1.95e-5	Bipolar disorder;
PAAD	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.59	-0.47	6.93e-10	Systolic blood pressure;
PAAD	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg01851573	chr8:8652454	MFHAS1	0.54	4.49	0.34	1.38e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg26071806	chr7:100318239	EPO	-0.42	-4.26	-0.33	3.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73196956	chr3:128430834	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg18612461	chr15:75251733	NA	-0.39	-4.46	-0.34	1.6e-5	Systemic lupus erythematosus;
PAAD	cis	rs2816062	0.813	rs2745314	chr1:18902851	T/A	cg18795169	chr1:18902165	NA	-1.08	-19.8	-0.85	6.37e-44	Urate levels in lean individuals;
PAAD	cis	rs79911532	0.515	rs41296488	chr7:75595580	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.81	-4.77	-0.36	4.24e-6	Mononucleosis;
PAAD	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.45	-0.34	1.64e-5	Blood metabolite levels;
PAAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.66	0.62	1.66e-17	Cognitive function;
PAAD	cis	rs80064395	0.850	rs12152276	chr3:196368501	A/G	cg20534585	chr3:196373598	LRRC33	0.77	5.14	0.38	8.45e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.79	7.47	0.52	6.01e-12	Mean platelet volume;
PAAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg16928487	chr17:17741425	SREBF1	-0.36	-4.89	-0.37	2.51e-6	Total body bone mineral density;
PAAD	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19882132	chr14:106167949	NA	-0.56	-4.98	-0.37	1.71e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg07703079	chr11:430292	ANO9	0.79	4.51	0.34	1.3e-5	Body mass index;
PAAD	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.21e-6	Airway imaging phenotypes;
PAAD	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg02459107	chr1:67143332	SGIP1	0.76	7.46	0.52	6.1e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg05721444	chr7:32995514	FKBP9	-0.55	-5.38	-0.4	2.74e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.52	-6.3	-0.45	3.09e-9	Lewy body disease;
PAAD	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg25664220	chr3:72788482	NA	0.68	6.85	0.49	1.71e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	5.15	0.39	7.92e-7	Mean corpuscular volume;
PAAD	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs877529	0.967	rs139405	chr22:39549526	C/A	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.42	4.31	0.33	2.94e-5	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg21479132	chr6:26055353	NA	1.0	6.44	0.46	1.5e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.51	5.45	0.4	2.01e-7	Obesity-related traits;
PAAD	cis	rs8005172	0.750	rs2269315	chr14:88432942	A/G	cg18078958	chr14:88630771	NA	0.47	5.4	0.4	2.51e-7	Parkinson's disease;
PAAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs899997	1.000	rs1814880	chr15:79021140	T/C	cg16602846	chr15:78114278	NA	0.39	4.32	0.33	2.84e-5	Coronary artery disease or large artery stroke;
PAAD	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.76	-7.24	-0.51	2.07e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg10820045	chr2:198174542	NA	-0.49	-4.98	-0.37	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg10356904	chr22:49881777	NA	-0.49	-5.25	-0.39	5.1e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.71	-0.36	5.48e-6	Type 2 diabetes;
PAAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg02841227	chr6:26021843	HIST1H4A	-0.41	-4.27	-0.33	3.39e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs12545912	0.863	rs7015787	chr8:9580712	G/A	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.59	5.26	0.39	4.75e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	5.81	0.43	3.46e-8	Monocyte count;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg10074409	chr1:209979377	IRF6	0.41	5.86	0.43	2.76e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.66	-0.35	6.78e-6	Lung cancer;
PAAD	cis	rs317865	0.737	rs73234642	chr4:16186730	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.67	0.48	4.54e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.6	5.46	0.4	1.91e-7	Breast cancer;
PAAD	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg04996195	chr7:87105398	ABCB4	0.49	4.38	0.33	2.21e-5	Gallbladder cancer;
PAAD	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	4.64	0.35	7.47e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.3	-0.56	5.26e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg21419209	chr3:44054225	NA	-0.55	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2882667	0.659	rs288037	chr5:138208441	A/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.37	0.61	9.43e-17	Diabetic retinopathy;
PAAD	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg21145140	chr5:110409467	TSLP	0.46	4.56	0.35	1.03e-5	Eosinophilic esophagitis;
PAAD	cis	rs863345	0.604	rs1342952	chr1:158464430	C/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.68	7.55	0.52	3.71e-12	Menopause (age at onset);
PAAD	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.83	-0.36	3.27e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg21427119	chr20:30132790	HM13	-0.56	-5.21	-0.39	5.97e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.63	0.62	1.94e-17	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13932606	chr11:47664508	MTCH2	0.66	6.49	0.47	1.15e-9	Obesity-related traits;
PAAD	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9463078	0.605	rs9472407	chr6:44908800	T/C	cg25276700	chr6:44698697	NA	0.41	4.84	0.37	3.11e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2744375	0.600	rs2744362	chr6:7551208	A/C	cg27023638	chr6:7288726	SSR1	-0.41	-4.25	-0.33	3.72e-5	Resting heart rate;
PAAD	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.49	4.96	0.37	1.86e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.98	11.28	0.68	8e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.6	4.74	0.36	4.98e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8067287	0.597	rs4985725	chr17:16863477	T/A	cg26910001	chr17:16838321	NA	0.46	4.44	0.34	1.72e-5	Diabetic kidney disease;
PAAD	cis	rs4704187	0.687	rs4340901	chr5:74404905	C/T	cg03227963	chr5:74354835	NA	0.52	5.14	0.38	8.47e-7	Response to amphetamines;
PAAD	cis	rs12799264	1.000	rs2625307	chr11:19978065	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.67	-0.42	6.96e-8	Longevity;Endometriosis;
PAAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.68	0.62	1.46e-17	Total body bone mineral density;
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg23465465	chr6:26364728	BTN3A2	0.79	4.4	0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg16205897	chr5:131564050	P4HA2	-0.46	-4.92	-0.37	2.26e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.97	-0.49	8.91e-11	Eye color traits;
PAAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg16205897	chr5:131564050	P4HA2	-0.53	-5.92	-0.43	2.06e-8	Blood metabolite levels;
PAAD	cis	rs8053891	0.673	rs11645582	chr16:72029008	T/G	cg16558253	chr16:72132732	DHX38	-0.55	-4.91	-0.37	2.33e-6	Coronary artery disease;
PAAD	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.7	7.34	0.51	1.2e-11	Schizophrenia;
PAAD	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-5.39	-0.4	2.69e-7	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.42	5.33	0.4	3.48e-7	Colorectal cancer;
PAAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.73	-10.23	-0.64	4.99e-19	Nonalcoholic fatty liver disease;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs17407555	1.000	rs73224437	chr4:10329825	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.3	-0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.73	8.35	0.56	4e-14	Lung cancer;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg05313129	chr8:58192883	C8orf71	-0.54	-4.87	-0.37	2.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462846	0.960	rs12194860	chr6:42862934	C/T	cg02353165	chr6:42928485	GNMT	0.59	5.02	0.38	1.4e-6	Blood protein levels;
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg13699009	chr12:122356056	WDR66	0.46	6.78	0.48	2.48e-10	Mean corpuscular volume;
PAAD	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg15654264	chr1:150340011	RPRD2	0.52	5.09	0.38	1.06e-6	Migraine;
PAAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.38	9.77	0.62	8.4e-18	Opioid sensitivity;
PAAD	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-10.37	-0.64	2.22e-19	Ulcerative colitis;
PAAD	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg10434728	chr15:90938212	IQGAP1	-0.44	-4.55	-0.35	1.08e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.73	-7.44	-0.52	6.74e-12	Retinal vascular caliber;
PAAD	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.76	-7.37	-0.51	1.03e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs8060686	0.920	rs56845922	chr16:67770828	T/C	cg05110241	chr16:68378359	PRMT7	-0.96	-5.45	-0.4	1.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg06771106	chr2:113671356	IL1F7	-0.57	-5.73	-0.42	5.11e-8	Pulmonary function;
PAAD	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	5.47	0.41	1.82e-7	Mean platelet volume;
PAAD	cis	rs9535307	0.696	rs9535305	chr13:50290415	A/T	cg04663916	chr13:50265991	EBPL	0.61	4.69	0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg02404636	chr22:31891804	SFI1	0.59	5.24	0.39	5.37e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.51e-5	Coronary artery disease;
PAAD	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-5.52	-0.41	1.41e-7	Prevalent atrial fibrillation;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.86	0.43	2.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg14926445	chr8:58193284	C8orf71	-0.55	-4.41	-0.34	1.94e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.58	-5.32	-0.4	3.72e-7	Corneal structure;
PAAD	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.74	-0.36	4.94e-6	Dilated cardiomyopathy;
PAAD	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg11757124	chr7:157526947	PTPRN2	-0.58	-5.53	-0.41	1.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.68	5.69	0.42	6.27e-8	Common traits (Other);
PAAD	cis	rs7727544	0.545	rs7716474	chr5:131383983	G/C	cg14196790	chr5:131705035	SLC22A5	0.43	4.48	0.34	1.45e-5	Blood metabolite levels;
PAAD	cis	rs3857067	1.000	rs1588382	chr4:95017589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.83	9.17	0.6	3.05e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.92	9.17	0.6	3.19e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.62	-5.08	-0.38	1.07e-6	Monocyte count;
PAAD	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.07	15.12	0.78	4.12e-32	Multiple system atrophy;
PAAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.1	-8.69	-0.58	5.28e-15	Diabetic kidney disease;
PAAD	cis	rs7301826	0.932	rs1007246	chr12:131280130	T/A	cg11011512	chr12:131303247	STX2	0.42	4.39	0.34	2.12e-5	Plasma plasminogen activator levels;
PAAD	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.37	4.55	0.35	1.09e-5	Rheumatoid arthritis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21224834	chr15:32162823	NA	-0.87	-7.85	-0.54	6.77e-13	Neuroticism;
PAAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6604026	0.656	rs2481710	chr1:93337494	T/C	cg17283838	chr1:93427260	FAM69A	-0.63	-5.82	-0.43	3.37e-8	Multiple sclerosis;
PAAD	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	1.09	15.35	0.78	1.02e-32	Breast cancer;
PAAD	trans	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.54e-16	Aortic root size;
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-5.81	-0.43	3.5e-8	Schizophrenia;
PAAD	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.54	4.77	0.36	4.37e-6	Lung cancer;
PAAD	cis	rs1514658	0.903	rs13119545	chr4:119273712	C/G	cg23709618	chr4:119273073	PRSS12	0.31	4.37	0.33	2.31e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg04257695	chr17:30186438	C17orf79	-0.61	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg00035074	chr7:2701567	TTYH3	-0.67	-4.63	-0.35	7.89e-6	Bipolar disorder;
PAAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.6	6.73	0.48	3.2e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.6	6.17	0.45	5.94e-9	Migraine;
PAAD	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.56	5.91	0.43	2.11e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.45	0.46	1.38e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs662064	0.748	rs12375	chr1:10596341	C/T	cg17425144	chr1:10567563	PEX14	-0.39	-4.31	-0.33	2.87e-5	Asthma;
PAAD	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg11271282	chr2:238384023	NA	0.57	4.44	0.34	1.72e-5	Prostate cancer;
PAAD	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.03	-0.5	6.43e-11	Breast cancer;
PAAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	trans	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg00717180	chr2:96193071	NA	-0.61	-6.66	-0.48	4.63e-10	HDL cholesterol;
PAAD	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.78	-0.36	4.16e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.59	5.59	0.41	1.01e-7	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	4.27	0.33	3.43e-5	Personality dimensions;
PAAD	cis	rs3782123	0.514	rs3782119	chr11:206421	T/G	cg25796445	chr11:207425	RIC8A;BET1L	-0.73	-4.49	-0.34	1.43e-5	Glycated hemoglobin levels;Red cell distribution width;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13341441	chr13:44824424	NA	0.63	6.99	0.49	8.15e-11	Smoking initiation;
PAAD	cis	rs13201294	1	rs13201294	chr6:27556141	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.48	4.38	0.33	2.23e-5	Squamous cell lung carcinoma;
PAAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.35	-4.38	-0.33	2.22e-5	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4073221	0.929	rs66479003	chr3:18280276	G/T	cg07694806	chr3:18168406	NA	-0.75	-5.07	-0.38	1.15e-6	Parkinson's disease;
PAAD	cis	rs58521262	0.505	rs457741	chr19:23140579	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.57	4.5	0.34	1.37e-5	Bronchopulmonary dysplasia;
PAAD	trans	rs901683	1.000	rs75820736	chr10:46076236	C/A	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.76	-9.15	-0.6	3.53e-16	Height;
PAAD	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg08885800	chr1:201084119	NA	0.54	4.93	0.37	2.11e-6	Permanent tooth development;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.71	8.97	0.59	1.04e-15	Dupuytren's disease;
PAAD	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	5.04e-11	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Calcium levels;
PAAD	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg24747557	chr10:131355152	MGMT	-0.44	-4.75	-0.36	4.73e-6	Response to temozolomide;
PAAD	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg10453019	chr3:16216215	GALNTL2	0.39	4.35	0.33	2.44e-5	Mean platelet volume;
PAAD	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.27	0.39	4.7e-7	Neuroticism;
PAAD	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.67	-7.03	-0.5	6.36e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	7.78	0.53	1.04e-12	LDL cholesterol;
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	1.09	8.41	0.56	2.76e-14	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.46	-0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7714584	1.000	rs2345001	chr5:150266518	G/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg07395648	chr5:131743802	NA	-0.64	-6.62	-0.47	5.73e-10	Blood metabolite levels;
PAAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg27411982	chr8:10470053	RP1L1	0.46	4.7	0.36	5.81e-6	Retinal vascular caliber;
PAAD	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.61	6.91	0.49	1.24e-10	Height;
PAAD	cis	rs7627468	0.770	rs13326577	chr3:121965246	A/T	cg17240004	chr3:121949083	CASR	0.5	4.76	0.36	4.44e-6	Kidney stones;
PAAD	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.84	-0.37	3.15e-6	Blood pressure;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.48	-4.51	-0.34	1.28e-5	Total body bone mineral density;
PAAD	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg14593290	chr7:50529359	DDC	-0.43	-4.37	-0.33	2.28e-5	Systemic sclerosis;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.09	15.99	0.79	2.19e-34	Chronic sinus infection;
PAAD	cis	rs1351164	1.000	rs10183694	chr2:218279923	T/A	cg15335768	chr2:218268053	DIRC3	-0.49	-5.43	-0.4	2.14e-7	Height;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.33	0.81	8.1e-38	Height;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.73	-7.12	-0.5	3.98e-11	Migraine;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.87	6.93	0.49	1.12e-10	Axial length;
PAAD	cis	rs34375054	0.672	rs2291247	chr12:125618953	C/G	cg06287003	chr12:125626642	AACS	-0.48	-4.76	-0.36	4.53e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg15847926	chr7:2749597	AMZ1	-0.37	-4.34	-0.33	2.54e-5	Height;
PAAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.85	6.74	0.48	3.07e-10	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07509252	chr16:88725730	MVD	0.57	6.87	0.49	1.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg04154034	chr17:28927549	LRRC37B2	0.68	4.33	0.33	2.68e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.52	-6.0	-0.44	1.4e-8	Alcohol dependence;
PAAD	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.52	4.73	0.36	5.03e-6	Total body bone mineral density;
PAAD	cis	rs7188861	0.681	rs12922090	chr16:11415117	C/T	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.6	-0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00280220	chr17:61926910	NA	0.44	4.65	0.35	7.23e-6	Prudent dietary pattern;
PAAD	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg13332499	chr17:408570	NA	0.53	5.69	0.42	6.38e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.6	6.12	0.44	7.46e-9	Type 2 diabetes;
PAAD	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.84	10.3	0.64	3.27e-19	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.37	4.83	0.36	3.35e-6	Calcium levels;
PAAD	trans	rs62179067	0.708	rs62175987	chr2:179876514	A/G	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	6.97	0.49	9.28e-11	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.69	-6.43	-0.46	1.58e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.5	6.39	0.46	1.94e-9	Renal cell carcinoma;
PAAD	cis	rs11811982	0.793	rs78903489	chr1:227485912	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg07648498	chr16:89883185	FANCA	0.49	4.76	0.36	4.43e-6	Vitiligo;
PAAD	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg01064725	chr1:204461714	NA	-0.47	-4.38	-0.33	2.19e-5	Schizophrenia;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.13	15.37	0.78	9.03e-33	Cognitive function;
PAAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg06740227	chr12:86229804	RASSF9	0.54	4.96	0.37	1.83e-6	Major depressive disorder;
PAAD	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs3126085	0.515	rs10788837	chr1:152351487	A/G	cg26876637	chr1:152193138	HRNR	-0.66	-5.03	-0.38	1.38e-6	Atopic dermatitis;
PAAD	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-5.76	-0.42	4.58e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs747650	0.504	rs7112854	chr11:47116823	T/C	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.45	3.07e-9	Acne (severe);
PAAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg26497354	chr6:109612229	NA	0.43	4.49	0.34	1.38e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08962682	chr12:8850939	RIMKLB	-0.67	-6.53	-0.47	9.22e-10	Smoking initiation;
PAAD	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg18551225	chr6:44695536	NA	-0.69	-6.87	-0.49	1.58e-10	Total body bone mineral density;
PAAD	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.89	10.36	0.64	2.27e-19	White blood cell count;
PAAD	cis	rs394563	0.556	rs398159	chr6:149792768	T/C	cg13597629	chr6:149777806	ZC3H12D	-0.44	-4.25	-0.33	3.66e-5	Dupuytren's disease;
PAAD	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.51	-5.32	-0.4	3.67e-7	Breast cancer;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.37	0.4	2.89e-7	Total body bone mineral density;
PAAD	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg06042504	chr8:55087323	NA	-0.64	-6.27	-0.45	3.58e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg10090792	chr1:38198142	EPHA10	-0.41	-4.38	-0.33	2.24e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs75920871	0.640	rs4938357	chr11:117084040	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-5.08	-0.38	1.08e-6	Subjective well-being;
PAAD	cis	rs1419980	0.643	rs11054592	chr12:7731561	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg10534938	chr5:1868639	NA	0.46	6.05	0.44	1.08e-8	Cardiovascular disease risk factors;
PAAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.64	-6.12	-0.44	7.71e-9	Schizophrenia;
PAAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.5	4.53	0.34	1.2e-5	Mood instability;
PAAD	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.71	7.65	0.53	2.1e-12	Menarche (age at onset);
PAAD	cis	rs1891275	0.551	rs7900863	chr10:93425494	T/C	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12350342	chr11:46558181	AMBRA1	0.59	6.29	0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.65e-8	Obesity-related traits;
PAAD	cis	rs7772172	0.549	rs9370916	chr6:16642966	G/A	cg26843612	chr6:16636157	ATXN1	0.39	4.32	0.33	2.86e-5	Educational attainment (years of education);
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Body mass index;
PAAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.69	7.59	0.52	2.95e-12	Melanoma;
PAAD	cis	rs9287604	0.953	rs3888914	chr2:237779996	G/C	cg15065627	chr2:237796583	NA	-0.54	-4.56	-0.35	1.04e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.38	-0.33	2.21e-5	Menopause (age at onset);
PAAD	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	0.95	5.79	0.42	3.98e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs4740619	0.556	rs3008726	chr9:16009266	A/C	cg14451791	chr9:16040625	NA	-0.39	-4.54	-0.35	1.13e-5	Body mass index;
PAAD	cis	rs2290405	0.532	rs11248050	chr4:854409	T/C	cg09237302	chr4:906077	GAK	-0.39	-4.93	-0.37	2.14e-6	Systemic sclerosis;
PAAD	cis	rs59888335	0.964	rs12629692	chr3:80742577	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg19423196	chr10:82049429	MAT1A	0.55	4.43	0.34	1.82e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.85	-10.76	-0.66	1.98e-20	Menopause (age at onset);
PAAD	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg26939375	chr7:64535504	NA	0.79	9.37	0.61	9.2e-17	Aortic root size;
PAAD	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	8.43	0.56	2.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7707921	0.881	rs324910	chr5:81400264	A/C	cg21483461	chr5:81570383	RPS23	-0.53	-4.42	-0.34	1.86e-5	Breast cancer;
PAAD	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.62	0.35	8.07e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19404215	chr3:33155277	CRTAP	-0.62	-6.75	-0.48	2.9e-10	Smoking initiation;
PAAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.9	8.56	0.57	1.17e-14	Eosinophil percentage of granulocytes;
PAAD	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.75	7.53	0.52	4.2e-12	Mosquito bite size;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg26516362	chr5:178986906	RUFY1	-0.54	-6.56	-0.47	7.86e-10	Lung cancer;
PAAD	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs9788682	0.792	rs2869032	chr15:78714561	C/T	cg24631222	chr15:78858424	CHRNA5	-0.71	-5.35	-0.4	3.21e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06544989	chr22:39130855	UNC84B	0.52	5.15	0.39	7.94e-7	Menopause (age at onset);
PAAD	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9659323	0.601	rs12033970	chr1:119640401	C/G	cg26570165	chr1:119541833	NA	-0.51	-5.57	-0.41	1.13e-7	Body mass index;
PAAD	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg26205652	chr12:48591994	NA	0.46	4.4	0.34	2e-5	Plateletcrit;
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.6	6.34	0.46	2.45e-9	Morning vs. evening chronotype;
PAAD	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.52	5.41	0.4	2.39e-7	Red blood cell count;
PAAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg03060546	chr3:49711283	APEH	0.46	4.28	0.33	3.31e-5	Parkinson's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22929018	chr2:207024348	EEF1B2;NDUFS1	-0.62	-7.12	-0.5	4.08e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3812111	0.677	rs1204849	chr6:116525269	C/T	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.3	-0.33	3.02e-5	Age-related macular degeneration;
PAAD	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.68	8.42	0.56	2.68e-14	Dupuytren's disease;
PAAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs288326	0.561	rs79221349	chr2:183751591	T/A	cg09997497	chr2:183902928	NCKAP1	0.88	4.9	0.37	2.41e-6	Blood protein levels;
PAAD	trans	rs901683	1.000	rs71499567	chr10:46083956	G/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.48	-4.58	-0.35	9.63e-6	Height;
PAAD	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.56	-0.35	1.05e-5	Systemic lupus erythematosus;
PAAD	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	10.21	0.64	5.68e-19	Platelet count;
PAAD	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg23024343	chr7:107201750	COG5	0.55	4.56	0.35	1.05e-5	Coronary artery disease;
PAAD	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.89e-10	Monocyte count;
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.0	-0.38	1.54e-6	Longevity;Endometriosis;
PAAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg03983715	chr16:68378420	PRMT7	-0.99	-7.38	-0.51	9.85e-12	Magnesium levels;
PAAD	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.07e-6	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-1.02	-14.27	-0.76	7.6e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6782025	0.914	rs702019	chr3:121239027	G/A	cg16417163	chr3:121280760	NA	-0.47	-4.8	-0.36	3.78e-6	Aging (facial);
PAAD	cis	rs59888335	0.964	rs66767701	chr3:80705055	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.84	9.63	0.62	1.96e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.81	4.35	0.33	2.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.7	6.76	0.48	2.81e-10	Menarche (age at onset);
PAAD	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	5.76	0.42	4.55e-8	Neuroticism;
PAAD	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04937402	chr14:23770452	PPP1R3E	-0.56	-6.47	-0.46	1.27e-9	Body fat percentage;
PAAD	cis	rs3106136	0.681	rs11097420	chr4:95301035	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.52	-0.34	1.21e-5	Capecitabine sensitivity;
PAAD	cis	rs829661	0.947	rs829575	chr2:30680633	G/T	cg12454169	chr2:30669597	LCLAT1	-0.67	-5.09	-0.38	1.04e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg10864074	chr7:100318194	EPO	0.48	4.7	0.36	5.71e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg08999081	chr20:33150536	PIGU	0.61	6.84	0.49	1.78e-10	Height;
PAAD	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.85	10.79	0.66	1.65e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg01444801	chr10:135216882	MTG1	-0.59	-5.33	-0.4	3.42e-7	Systemic lupus erythematosus;
PAAD	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.35	0.33	2.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.73	-0.42	5.35e-8	Total cholesterol levels;
PAAD	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-8.36	-0.56	3.64e-14	Hemoglobin concentration;
PAAD	cis	rs4523957	0.583	rs2760739	chr17:2024217	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg10467557	chr13:21893662	NA	-0.42	-4.56	-0.35	1.06e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4420500	1	rs4420500	chr15:78962964	C/T	cg00540400	chr15:79124168	NA	-0.43	-4.82	-0.36	3.49e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs564309	0.681	rs1150917	chr1:228607395	T/C	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg06883089	chr1:45254480	BEST4	-0.34	-4.26	-0.33	3.61e-5	High light scatter reticulocyte count;
PAAD	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.75	-7.43	-0.52	7.16e-12	White matter hyperintensity burden;
PAAD	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.07	9.42	0.61	7.04e-17	Vitiligo;
PAAD	cis	rs7192380	0.651	rs9788803	chr16:69691995	A/T	cg05250797	chr16:70222502	NA	0.66	5.83	0.43	3.18e-8	Sjögren's syndrome;
PAAD	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.57e-19	Morning vs. evening chronotype;
PAAD	cis	rs4343996	0.905	rs10233166	chr7:3343382	A/G	cg21248987	chr7:3385318	SDK1	0.48	5.28	0.39	4.43e-7	Motion sickness;
PAAD	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.53	4.81	0.36	3.57e-6	Dental caries;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg04352962	chr1:209979756	IRF6	0.53	4.66	0.35	6.99e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs1419980	0.643	rs11054590	chr12:7731490	T/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7487075	0.619	rs9669404	chr12:46798963	A/G	cg09447675	chr12:46877466	NA	0.48	4.35	0.33	2.47e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.26	-0.33	3.55e-5	Retinal vascular caliber;
PAAD	cis	rs2415984	0.579	rs4485263	chr14:46967552	A/G	cg14871534	chr14:47121158	RPL10L	-0.47	-4.89	-0.37	2.49e-6	Number of children ever born;
PAAD	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg17326555	chr1:119535693	NA	-0.35	-4.26	-0.33	3.6e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.7	9.32	0.6	1.28e-16	Hemoglobin concentration;
PAAD	cis	rs282587	0.569	rs409896	chr13:113400338	G/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.78	-0.36	4.16e-6	Glycated hemoglobin levels;
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.63	6.02	0.44	1.26e-8	Cystic fibrosis severity;
PAAD	cis	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.88	-4.83	-0.36	3.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.18	-8.44	-0.56	2.34e-14	Schizophrenia;
PAAD	cis	rs662064	0.748	rs2506896	chr1:10603716	T/C	cg17425144	chr1:10567563	PEX14	-0.42	-4.74	-0.36	4.82e-6	Asthma;
PAAD	cis	rs7922314	0.571	rs61865692	chr10:64728697	A/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.0	0.38	1.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg03098644	chr7:100410630	EPHB4	-0.54	-4.43	-0.34	1.83e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	9.39	0.61	8.19e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.69	7.16	0.5	3.16e-11	Monocyte count;
PAAD	cis	rs10981012	0.504	rs56245878	chr9:114584787	G/A	cg14428669	chr9:114659192	UGCG	-0.59	-4.39	-0.34	2.1e-5	Coronary artery disease;
PAAD	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.73	-7.79	-0.53	9.92e-13	Schizophrenia;
PAAD	cis	rs10214930	0.781	rs759271	chr7:27647113	C/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.65	-6.98	-0.49	8.62e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04906764	chr14:50789510	ATP5S	-0.49	-6.5	-0.47	1.09e-9	Energy expenditure (24h);
PAAD	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg23587288	chr2:27483067	SLC30A3	-0.84	-7.32	-0.51	1.34e-11	Blood metabolite levels;
PAAD	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg04450456	chr4:17643702	FAM184B	0.48	5.21	0.39	6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg00262122	chr8:11665843	FDFT1	-0.64	-5.46	-0.4	1.9e-7	Neuroticism;
PAAD	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.79	-6.77	-0.48	2.57e-10	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg18279126	chr7:2041391	MAD1L1	0.64	6.33	0.46	2.62e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg05872129	chr22:39784769	NA	-0.83	-7.96	-0.54	3.79e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.89	0.58	1.69e-15	Alzheimer's disease;
PAAD	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.63	-6.77	-0.48	2.69e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs61884328	0.733	rs74898661	chr11:47225730	G/A	cg23433285	chr11:47201945	PACSIN3	0.85	4.48	0.34	1.46e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.51	-5.7	-0.42	5.92e-8	Prostate cancer;
PAAD	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.18	8.78	0.58	3.16e-15	Lymphocyte counts;
PAAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg20893579	chr22:38215064	NA	0.52	4.86	0.37	2.9e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg17650747	chr5:1873721	NA	0.44	4.5	0.34	1.36e-5	Cardiovascular disease risk factors;
PAAD	cis	rs35160687	0.712	rs12988844	chr2:86479035	A/G	cg10973622	chr2:86423274	IMMT	-0.44	-4.9	-0.37	2.41e-6	Night sleep phenotypes;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.51	5.64	0.42	7.99e-8	Calcium levels;
PAAD	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.51	-5.2	-0.39	6.26e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11718455	0.548	rs11918413	chr3:43902518	C/A	cg21419209	chr3:44054225	NA	0.57	5.66	0.42	7.26e-8	Coronary artery disease;
PAAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-4.3	-0.33	3.06e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07603881	chr1:21065497	NA	0.59	6.72	0.48	3.39e-10	Smoking initiation;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06753367	chr22:24256600	NA	-0.42	-4.39	-0.34	2.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11172134	0.508	rs7305179	chr12:57576567	G/C	cg01515074	chr12:57585135	LRP1	0.48	4.52	0.34	1.21e-5	Urate levels in overweight individuals;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg15117754	chr3:10150083	C3orf24	0.66	5.55	0.41	1.23e-7	Alzheimer's disease;
PAAD	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg03277515	chr1:153321198	PGLYRP4	0.4	4.65	0.35	7.12e-6	Psoriasis;
PAAD	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.3	-0.46	3.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6688613	0.679	rs12116418	chr1:166944273	T/A	cg07049167	chr1:166818506	POGK	0.47	4.65	0.35	7.25e-6	Refractive astigmatism;
PAAD	cis	rs3091242	0.836	rs35346083	chr1:25788425	C/A	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.83	-0.36	3.27e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg24249390	chr15:90295951	MESP1	-0.52	-5.41	-0.4	2.42e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	10.47	0.65	1.2e-19	Smoking behavior;
PAAD	cis	rs7561149	0.527	rs7592323	chr2:179693338	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.52	4.47	0.34	1.54e-5	QT interval;
PAAD	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	5.94	0.43	1.83e-8	Lung cancer in ever smokers;
PAAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs8067354	0.574	rs9789060	chr17:58018570	A/G	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.59	6.84	0.48	1.84e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs1007738	0.579	rs61896136	chr11:47120299	C/A	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.45	3.07e-9	Bone mineral density (hip);
PAAD	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg24733560	chr20:60626293	TAF4	0.52	6.87	0.49	1.57e-10	Body mass index;
PAAD	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.47	7.59	0.52	2.93e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg08992911	chr2:238395768	MLPH	0.68	6.36	0.46	2.28e-9	Prostate cancer;
PAAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.59	-4.56	-0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.6	-5.34	-0.4	3.38e-7	Renal function-related traits (BUN);
PAAD	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.75	5.45	0.4	2.03e-7	Major depressive disorder;
PAAD	cis	rs9463078	0.585	rs4714847	chr6:45231074	C/T	cg25276700	chr6:44698697	NA	0.45	5.1	0.38	1.01e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06444984	chr1:153651297	NPR1	0.69	7.09	0.5	4.78e-11	Obesity-related traits;
PAAD	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg15117754	chr3:10150083	C3orf24	0.66	5.55	0.41	1.23e-7	Alzheimer's disease;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.55	-5.68	-0.42	6.76e-8	Testicular germ cell tumor;
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs78761021	0.898	rs79593970	chr17:9768261	T/C	cg26853458	chr17:9805074	RCVRN	0.7	8.13	0.55	1.43e-13	Type 2 diabetes;
PAAD	cis	rs731174	0.505	rs6686248	chr1:38192296	A/G	cg06917450	chr1:38156652	C1orf109	-0.51	-4.45	-0.34	1.63e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg14515779	chr1:101123966	NA	-0.4	-4.37	-0.33	2.28e-5	Monocyte count;
PAAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	7.75e-7	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01900832	chr20:50385371	ATP9A	-0.62	-6.64	-0.47	5.2e-10	Smoking initiation;
PAAD	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg25203885	chr2:87302643	LOC285074	-0.81	-5.71	-0.42	5.62e-8	Schizophrenia;
PAAD	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.05	-0.63	1.5e-18	Cognitive function;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg09127314	chr1:152161683	NA	-0.72	-5.04	-0.38	1.29e-6	Atopic dermatitis;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg11859384	chr17:80120422	CCDC57	0.46	4.78	0.36	4.15e-6	Life satisfaction;
PAAD	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.47	6.13	0.45	7.34e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs17534004	1.000	rs12876002	chr13:31467467	A/G	cg00570269	chr13:31480942	C13orf33	0.59	4.42	0.34	1.9e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.6	-6.97	-0.49	8.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg12633918	chr20:23549525	CST9L	-0.45	-4.98	-0.37	1.74e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.96	11.1	0.67	2.41e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs16854884	0.802	rs6786460	chr3:143805895	A/G	cg06585982	chr3:143692056	C3orf58	0.56	5.56	0.41	1.2e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg15309053	chr8:964076	NA	0.54	6.23	0.45	4.31e-9	Schizophrenia;
PAAD	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg15192750	chr16:69999425	NA	0.82	6.19	0.45	5.46e-9	IgE levels;
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-5.8	-0.43	3.65e-8	Lung cancer;
PAAD	cis	rs16975963	0.843	rs75802547	chr19:38393321	C/T	cg25793785	chr19:38281423	NA	0.57	4.66	0.35	6.88e-6	Longevity;
PAAD	trans	rs901683	0.572	rs17157859	chr10:45989409	T/C	cg13065504	chr15:42448234	PLA2G4F	0.83	6.45	0.46	1.43e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.7	-8.11	-0.55	1.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1977876	0.929	rs11119763	chr1:211705734	G/A	cg01575408	chr1:211752895	SLC30A1	0.53	4.39	0.34	2.08e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-5.84	-0.43	3.07e-8	Blood protein levels;
PAAD	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.6	5.6	0.41	9.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8084125	1.000	rs1944560	chr18:74939705	G/T	cg15443732	chr18:74961078	GALR1	0.63	5.51	0.41	1.5e-7	Obesity-related traits;
PAAD	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.75	-8.59	-0.57	9.82e-15	Bipolar disorder;
PAAD	cis	rs8051149	0.625	rs876987	chr16:87882209	A/G	cg01412419	chr16:87856264	NA	0.56	5.02	0.38	1.44e-6	Blood metabolite levels;
PAAD	cis	rs6066825	0.644	rs2869669	chr20:47321449	T/C	cg18078177	chr20:47281410	PREX1	0.43	4.28	0.33	3.31e-5	Colorectal cancer;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-6.6	-0.47	6.44e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.86	-10.96	-0.66	5.66e-21	Aortic root size;
PAAD	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg11764359	chr7:65958608	NA	0.77	5.24	0.39	5.27e-7	Diabetic kidney disease;
PAAD	cis	rs3736485	0.673	rs7170980	chr15:51956056	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.35	-0.33	2.53e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.53	-7.55	-0.52	3.81e-12	Longevity;Endometriosis;
PAAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.65	6.34	0.46	2.43e-9	Initial pursuit acceleration;
PAAD	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs10916814	0.588	rs4571937	chr1:20897033	G/A	cg04087271	chr1:20915334	CDA	0.39	4.84	0.37	3.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18965322	chr2:99735582	TSGA10	0.56	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2882667	0.690	rs288021	chr5:138224283	C/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2839627	0.683	rs11555158	chr21:44337914	A/G	cg03543861	chr21:44258195	NA	0.62	4.6	0.35	8.88e-6	Information processing speed;
PAAD	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg05342945	chr12:48394962	COL2A1	-0.74	-4.73	-0.36	5.17e-6	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23228694	chr20:35089521	DLGAP4	-0.66	-6.54	-0.47	8.73e-10	Smoking initiation;
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.33	5.31	0.4	3.79e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg26850624	chr5:429559	AHRR	0.84	10.67	0.65	3.44e-20	Cystic fibrosis severity;
PAAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.66	6.53	0.47	9.48e-10	Prostate cancer;
PAAD	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	1.0	8.28	0.56	6.03e-14	Initial pursuit acceleration;
PAAD	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-5.83	-0.43	3.19e-8	Cognitive function;
PAAD	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-10.76	-0.66	1.98e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.65	-0.35	7.28e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.59	5.35	0.4	3.22e-7	Schizophrenia;
PAAD	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05049329	chr1:226924846	ITPKB	0.52	6.95	0.49	9.82e-11	Parkinson's disease;
PAAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg20243544	chr17:37824526	PNMT	-0.52	-4.51	-0.34	1.27e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg26528668	chr16:1614120	IFT140	0.5	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.25	-0.6	1.96e-16	Response to antipsychotic treatment;
PAAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.94	11.66	0.69	7.6e-23	Diastolic blood pressure;
PAAD	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg10356904	chr22:49881777	NA	-0.54	-5.02	-0.38	1.42e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.41	-0.34	1.94e-5	Vitiligo;
PAAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.86	-7.64	-0.53	2.29e-12	Coronary artery disease;
PAAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.6	-6.97	-0.49	8.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	1.01	6.17	0.45	5.92e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.97e-7	Monocyte percentage of white cells;
PAAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.77	-0.36	4.23e-6	Daytime sleep phenotypes;
PAAD	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs2834256	0.530	rs7281554	chr21:34928355	C/T	cg14850771	chr21:34775459	IFNGR2	0.42	4.36	0.33	2.38e-5	Red cell distribution width;
PAAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg04522676	chr10:134968826	NA	0.48	4.52	0.34	1.23e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24729792	chr2:113192114	RGPD8;RGPD5	0.57	4.68	0.36	6.18e-6	Yeast infection;
PAAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg24585817	chr7:64895279	NA	-0.48	-4.77	-0.36	4.36e-6	Aortic root size;
PAAD	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg12092346	chr18:77659572	KCNG2	-0.61	-4.26	-0.33	3.53e-5	Opioid sensitivity;
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg19337854	chr7:99768885	GPC2	0.48	4.41	0.34	1.97e-5	Platelet count;
PAAD	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.38	-4.58	-0.35	9.65e-6	Lewy body disease;
PAAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-4.27	-0.33	3.37e-5	Fat distribution (HIV);
PAAD	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.85	6.42	0.46	1.69e-9	Axial length;
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.2	-0.45	5.14e-9	Morning vs. evening chronotype;
PAAD	cis	rs7561149	1.000	rs12992014	chr2:179691285	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.56	5.62	0.41	8.82e-8	QT interval;
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.49	8.01	0.54	2.74e-13	IgG glycosylation;
PAAD	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.49	-7.0	-0.49	7.54e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.64	-6.17	-0.45	5.81e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-5.69	-0.42	6.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg22089800	chr15:90895588	ZNF774	0.59	5.59	0.41	1.03e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg11901034	chr3:128598214	ACAD9	0.53	4.42	0.34	1.88e-5	IgG glycosylation;
PAAD	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.52	-5.25	-0.39	5.15e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.77	9.05	0.59	6.54e-16	Noise-induced hearing loss;
PAAD	cis	rs375066	0.710	rs11881193	chr19:44421516	G/T	cg11993925	chr19:44307056	LYPD5	-0.49	-5.96	-0.44	1.69e-8	Breast cancer;
PAAD	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.58	5.1	0.38	9.97e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-5.23	-0.39	5.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	4.57	0.35	1.01e-5	Axial length;
PAAD	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.61	7.1	0.5	4.36e-11	Iron status biomarkers (transferrin levels);
PAAD	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.72	9.34	0.6	1.15e-16	Weight;
PAAD	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.61	-8.06	-0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.64	8.27	0.56	6.33e-14	Hypertriglyceridemia;
PAAD	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.49	-5.4	-0.4	2.54e-7	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20167471	chr1:16528984	ARHGEF19	0.49	4.87	0.37	2.82e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.54	6.05	0.44	1.06e-8	Longevity;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.63	-7.4	-0.51	8.86e-12	Aortic root size;
PAAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.58	-5.67	-0.42	7.04e-8	Height;
PAAD	cis	rs12760731	0.720	rs1994233	chr1:178269823	C/T	cg00404053	chr1:178313656	RASAL2	-0.64	-4.96	-0.37	1.9e-6	Obesity-related traits;
PAAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.73	-5.75	-0.42	4.8e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg08048268	chr3:133502702	NA	-0.51	-6.37	-0.46	2.08e-9	Iron status biomarkers;
PAAD	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Itch intensity from mosquito bite;
PAAD	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs731174	0.592	rs1010805	chr1:38189142	A/C	cg06917450	chr1:38156652	C1orf109	-0.58	-5.06	-0.38	1.17e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	5.84	0.43	3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs35160687	0.712	rs7568971	chr2:86488040	G/A	cg10973622	chr2:86423274	IMMT	-0.43	-4.65	-0.35	7.2e-6	Night sleep phenotypes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25880573	chr1:24073129	TCEB3	-0.59	-6.83	-0.48	1.91e-10	Monocyte percentage of white cells;
PAAD	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg09835421	chr16:68378352	PRMT7	-0.97	-5.8	-0.43	3.78e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.08	8.16	0.55	1.17e-13	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02737307	chr1:152190020	HRNR	0.57	6.61	0.47	6.02e-10	Smoking initiation;
PAAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-4.71	-0.36	5.62e-6	Colorectal cancer;
PAAD	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.41	5.15	0.39	8e-7	Pulmonary function;
PAAD	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg11650704	chr1:154556575	ADAR	0.39	4.28	0.33	3.34e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs138918	0.772	rs138933	chr22:43565855	C/T	cg00343092	chr22:43547974	TSPO	0.43	4.94	0.37	2.02e-6	Monocyte count;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.46	4.61	0.35	8.35e-6	Longevity;Endometriosis;
PAAD	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg17775713	chr3:133465469	TF	0.5	5.67	0.42	7.06e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg18944383	chr4:111397179	ENPEP	0.77	8.37	0.56	3.46e-14	Coronary artery disease;
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.85	-8.93	-0.59	1.34e-15	Total body bone mineral density;
PAAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.13	0.55	1.43e-13	Schizophrenia;
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.87	-0.37	2.76e-6	Lung cancer;
PAAD	cis	rs12893597	0.704	rs34065247	chr14:76834029	A/C	cg20290672	chr14:76816747	NA	-0.55	-4.74	-0.36	4.87e-6	Maximal oxygen uptake response;
PAAD	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.67	-8.51	-0.57	1.53e-14	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16286776	chr8:141644897	EIF2C2	0.61	6.54	0.47	8.92e-10	Myopia (pathological);
PAAD	cis	rs4740619	0.967	rs10756688	chr9:15660497	T/C	cg14451791	chr9:16040625	NA	-0.38	-4.42	-0.34	1.88e-5	Body mass index;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg14725641	chr11:61582763	MIR1908;FADS1	0.52	4.58	0.35	9.6e-6	Trans fatty acid levels;
PAAD	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	1.29	7.55	0.52	3.71e-12	Corneal curvature;
PAAD	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	cis	rs6066835	0.572	rs11698365	chr20:47259527	C/T	cg18078177	chr20:47281410	PREX1	1.03	5.34	0.4	3.37e-7	Multiple myeloma;
PAAD	cis	rs892961	1.000	rs747147	chr17:75399552	A/G	cg05865280	chr17:75406074	SEPT9	0.7	9.7	0.62	1.26e-17	Airflow obstruction;
PAAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.3e-6	Calcium levels;
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.89	0.58	1.66e-15	Lung cancer;
PAAD	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.44	-4.27	-0.33	3.48e-5	Chronic sinus infection;
PAAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11997175	0.655	rs72630923	chr8:33662404	C/A	ch.8.33884649F	chr8:33765107	NA	0.51	5.55	0.41	1.26e-7	Body mass index;
PAAD	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.66	-0.48	4.6e-10	Triglycerides;
PAAD	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.72	-7.18	-0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs4356203	0.905	rs550667	chr11:17218975	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.4	-0.34	2.07e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.94	12.37	0.71	9.43e-25	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09848324	chr4:56458183	PDCL2	-0.64	-6.51	-0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs758747	0.546	rs740862	chr16:3689678	A/C	cg01678580	chr16:4674018	MGRN1	0.51	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg06287003	chr12:125626642	AACS	-0.52	-5.15	-0.39	8.14e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	5.97e-6	Lung cancer;
PAAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg14092988	chr3:52407081	DNAH1	0.45	5.63	0.42	8.27e-8	Electroencephalogram traits;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18621852	chr3:10150065	C3orf24	0.66	5.97	0.44	1.58e-8	Alzheimer's disease;
PAAD	cis	rs17169634	1.000	rs78417989	chr7:34089919	A/G	cg24927974	chr7:35078269	DPY19L1	-0.63	-5.23	-0.39	5.59e-7	Alzheimer's disease;
PAAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.79	12.41	0.71	7.2e-25	Breast cancer;
PAAD	cis	rs4455778	0.580	rs4276634	chr7:49118612	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.83	-9.92	-0.63	3.37e-18	Personality dimensions;
PAAD	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.57e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.54	-4.52	-0.34	1.24e-5	Heschl's gyrus morphology;
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.81	-6.81	-0.48	2.11e-10	Initial pursuit acceleration;
PAAD	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs4740619	0.682	rs10738422	chr9:15998987	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.56	-0.35	1.03e-5	Body mass index;
PAAD	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg04990556	chr1:26633338	UBXN11	-0.62	-4.48	-0.34	1.45e-5	Obesity-related traits;
PAAD	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.33	-0.4	3.52e-7	Monocyte percentage of white cells;
PAAD	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.25	4.4	0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg00491522	chr10:135256596	NA	0.48	5.01	0.38	1.48e-6	Systemic lupus erythematosus;
PAAD	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.55	-5.16	-0.39	7.5e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21840211	chr17:76802223	USP36	-0.69	-6.99	-0.49	7.97e-11	Obesity-related traits;
PAAD	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-6.44	-0.46	1.51e-9	Schizophrenia;
PAAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg27121462	chr16:89883253	FANCA	0.81	4.83	0.36	3.33e-6	Skin colour saturation;
PAAD	cis	rs8040855	0.627	rs12900012	chr15:85590186	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.71	-0.42	5.65e-8	Lung cancer;
PAAD	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.83e-5	Blood protein levels;
PAAD	trans	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg18187862	chr3:45730750	SACM1L	0.7	6.6	0.47	6.31e-10	Primary sclerosing cholangitis;
PAAD	trans	rs5417	0.610	rs222843	chr17:7145981	T/C	cg15655154	chr3:113604241	GRAMD1C	0.74	7.88	0.54	5.84e-13	Diastolic blood pressure;
PAAD	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs6714788	0.565	rs12712063	chr2:100663281	C/T	cg07810366	chr2:100720526	AFF3	-0.35	-4.38	-0.33	2.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4450131	0.569	rs3824801	chr10:126356840	T/G	cg20435097	chr10:126320824	FAM53B	0.53	5.68	0.42	6.6e-8	White blood cell count (basophil);
PAAD	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.65	-7.03	-0.5	6.42e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs294958	0.777	rs68004240	chr5:151532184	C/T	cg04453665	chr5:151504455	NA	0.47	5.15	0.39	7.89e-7	Periodontitis (PAL4Q3);
PAAD	cis	rs216303	0.630	rs4764533	chr12:6160744	A/G	cg12895370	chr12:6755816	ACRBP	-0.5	-4.4	-0.34	2.06e-5	Low vWF levels;
PAAD	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.04	0.38	1.29e-6	HDL cholesterol;
PAAD	cis	rs288342	0.835	rs6729801	chr2:183584755	G/A	cg02625481	chr2:183667124	NA	-0.42	-4.39	-0.34	2.1e-5	Recurrent major depressive disorder;
PAAD	cis	rs2070677	0.756	rs2987795	chr10:135378656	A/G	cg08390786	chr10:135334061	NA	-0.65	-5.5	-0.41	1.57e-7	Gout;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.44	4.46	0.34	1.56e-5	Obesity-related traits;
PAAD	cis	rs2133450	0.712	rs1546238	chr3:7366551	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6604026	0.656	rs2255717	chr1:93368500	G/T	cg13858687	chr1:93297071	RPL5	-0.48	-4.34	-0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.57	0.35	1.01e-5	Homoarginine levels;
PAAD	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.72	-0.48	3.48e-10	Retinal vascular caliber;
PAAD	cis	rs4144027	0.935	rs8008020	chr14:104355883	T/C	cg08213375	chr14:104286397	PPP1R13B	-0.36	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.24	0.39	5.19e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs501120	1.000	rs915083	chr10:44755406	T/G	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.62e-7	Bipolar disorder;
PAAD	cis	rs4343996	0.542	rs6969267	chr7:3435750	T/C	cg21248987	chr7:3385318	SDK1	0.43	4.5	0.34	1.32e-5	Motion sickness;
PAAD	cis	rs2944591	0.505	rs2675952	chr2:233790522	T/A	cg08000102	chr2:233561755	GIGYF2	-0.47	-4.53	-0.34	1.18e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.46	-4.85	-0.37	3.05e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.79	-5.67	-0.42	6.91e-8	Coronary artery disease;
PAAD	cis	rs4388249	0.687	rs3797692	chr5:109097686	G/A	cg17395555	chr5:108820864	NA	0.31	4.28	0.33	3.29e-5	Schizophrenia;
PAAD	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13560548	chr3:10150139	C3orf24	0.56	5.03	0.38	1.34e-6	Alzheimer's disease;
PAAD	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.77	-0.42	4.3e-8	Gut microbiome composition (summer);
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.45	-6.28	-0.45	3.45e-9	Vitiligo;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.09	0.44	8.88e-9	Height;
PAAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.35	-4.33	-0.33	2.74e-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs10865541	0.545	rs10176868	chr2:3383662	C/T	cg21040360	chr2:3383326	TTC15	0.43	4.76	0.36	4.55e-6	Obesity-related traits;
PAAD	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.58	4.9	0.37	2.42e-6	Response to antidepressants in depression;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg08219700	chr8:58056026	NA	0.66	5.11	0.38	9.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264213	0.901	rs645123	chr1:36458075	T/C	cg27506609	chr1:36549197	TEKT2	1.06	6.31	0.46	2.96e-9	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.62	7.14	0.5	3.66e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	trans	rs901683	1.000	rs12776336	chr10:46063911	G/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7011049	0.908	rs113206545	chr8:53858648	A/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs7631605	0.905	rs4678939	chr3:37187398	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06911519	chr2:28615662	FOSL2	0.62	7.23	0.51	2.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg24110177	chr3:50126178	RBM5	0.68	7.29	0.51	1.61e-11	Menarche (age at onset);
PAAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-9.08	-0.59	5.26e-16	Mortality in heart failure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15127867	chr2:128457218	SFT2D3	-0.66	-6.75	-0.48	2.87e-10	Obesity-related traits;
PAAD	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.53	4.32	0.33	2.81e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	4.93	0.37	2.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg09658497	chr7:2847517	GNA12	-0.4	-4.35	-0.33	2.48e-5	Height;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg23083516	chr15:85180758	SCAND2	0.4	4.44	0.34	1.74e-5	P wave terminal force;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.5	4.94	0.37	2.05e-6	Menarche (age at onset);
PAAD	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.79	-0.42	3.96e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01200585	chr1:228362443	C1orf69	-0.52	-5.81	-0.43	3.5e-8	Diastolic blood pressure;
PAAD	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg05085585	chr16:30420623	ZNF771	0.47	4.55	0.35	1.07e-5	Tonsillectomy;
PAAD	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.51	-5.62	-0.41	8.82e-8	Migraine;
PAAD	cis	rs2016586	0.860	rs5995154	chr22:36102668	A/G	cg26342177	chr22:36113512	APOL5	-0.48	-4.82	-0.36	3.4e-6	Body mass index;
PAAD	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.41	0.71	7.24e-25	Cognitive ability;
PAAD	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg07701084	chr6:150067640	NUP43	-0.53	-4.59	-0.35	9.36e-6	Lung cancer;
PAAD	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	4.6	0.35	8.98e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.76	8.1	0.55	1.7e-13	Coronary artery disease;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg20594519	chr1:145611013	POLR3C;RNF115	0.76	7.49	0.52	5.38e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg13468214	chr4:1046988	NA	-0.52	-4.95	-0.37	1.98e-6	Recombination rate (females);
PAAD	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg00798850	chr10:35625974	CCNY	-0.56	-6.34	-0.46	2.45e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	1.26	15.75	0.79	9.4e-34	Ewing sarcoma;
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	4.28	0.33	3.35e-5	Vitiligo;
PAAD	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg06740227	chr12:86229804	RASSF9	0.55	5.51	0.41	1.49e-7	Major depressive disorder;
PAAD	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg11608241	chr8:8085544	FLJ10661	0.51	4.58	0.35	9.45e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Mosquito bite size;
PAAD	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.38	-0.46	1.99e-9	HDL cholesterol;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.57	-0.35	9.91e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11718455	0.548	rs9824340	chr3:43902170	A/G	cg21419209	chr3:44054225	NA	-0.56	-5.64	-0.42	7.92e-8	Coronary artery disease;
PAAD	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.78	0.42	4.19e-8	Ileal carcinoids;
PAAD	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.71	6.62	0.47	5.75e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg21918786	chr6:109611834	NA	-0.59	-6.69	-0.48	4.01e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.73	5.57	0.41	1.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.692	rs13226540	chr7:104999901	G/A	cg04380332	chr7:105027541	SRPK2	-0.64	-6.92	-0.49	1.21e-10	Schizophrenia;
PAAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.53	4.7	0.36	5.85e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.29	0.39	4.12e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg06157335	chr1:53164003	C1orf163	0.48	4.84	0.37	3.12e-6	Hand grip strength;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs7591351	0.656	rs6709192	chr2:46062213	A/G	cg16240781	chr2:45234379	SIX2	-0.36	-4.27	-0.33	3.44e-5	Pathological gambling;
PAAD	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg20630647	chr19:41531805	NA	0.37	4.37	0.33	2.26e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs6070	0.933	rs2739482	chr19:51394286	C/T	cg11738530	chr19:51047879	LRRC4B	0.42	4.4	0.34	2.03e-5	Prostate-specific antigen levels;Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.37	0.33	2.25e-5	Bipolar disorder;
PAAD	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.22	0.45	4.61e-9	Schizophrenia;
PAAD	cis	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg21546286	chr11:48923668	NA	0.53	5.43	0.4	2.15e-7	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25208863	chr8:110656982	GOLSYN	0.7	8.56	0.57	1.14e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg15956490	chr3:53032818	SFMBT1	0.76	4.65	0.35	7.11e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg24553058	chr2:113831203	IL1F10	-0.73	-8.26	-0.56	6.71e-14	Protein quantitative trait loci;
PAAD	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg00262122	chr8:11665843	FDFT1	0.52	4.97	0.37	1.78e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.79	0.62	7.65e-18	Response to antipsychotic treatment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23714660	chr4:3426363	RGS12	0.56	6.35	0.46	2.34e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.91	12.42	0.71	6.75e-25	Superior crus of antihelix expression;
PAAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.62	0.42	8.68e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7631605	0.935	rs4678945	chr3:37239324	G/C	cg17445812	chr3:36986805	TRANK1	0.35	4.69	0.36	6.09e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.28e-11	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.69	5.13	0.38	8.81e-7	Initial pursuit acceleration;
PAAD	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.62	-5.9	-0.43	2.3e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13253111	0.967	rs7821358	chr8:28060690	A/G	cg26534493	chr8:28060551	NA	0.44	4.91	0.37	2.31e-6	Childhood body mass index;
PAAD	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.65	7.49	0.52	5.13e-12	Testicular germ cell tumor;
PAAD	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18397137	chr19:59055873	TRIM28	-0.64	-6.57	-0.47	7.61e-10	Smoking initiation;
PAAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.21	-0.55	8.67e-14	Height;
PAAD	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.31	0.4	3.83e-7	HDL cholesterol;
PAAD	trans	rs2162440	0.571	rs1427042	chr18:35208228	T/C	cg18355902	chr4:154681128	RNF175	0.75	6.33	0.46	2.56e-9	Telomere length;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25133786	chr1:145096125	SEC22B	-0.66	-6.64	-0.47	5.15e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23767433	chr11:75946703	NA	0.58	6.33	0.46	2.68e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1925576	0.935	rs7904215	chr10:68665358	T/C	cg04444303	chr10:69634106	NA	-0.46	-4.5	-0.34	1.37e-5	Educational attainment (years of education);
PAAD	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.04	-0.38	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18715318	chr22:19420067	HIRA;MRPL40	0.63	7.04	0.5	6.06e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg03037974	chr15:76606532	NA	0.58	6.96	0.49	9.31e-11	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09294077	chr14:66975599	GPHN	0.57	6.63	0.47	5.42e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs3796727	0.583	rs73213402	chr4:8620848	G/A	cg05284713	chr4:8621361	CPZ	-0.43	-4.42	-0.34	1.83e-5	Sporadic neuroblastoma;
PAAD	cis	rs9616064	0.849	rs73181057	chr22:46972152	G/A	cg03318428	chr22:46971703	NA	0.41	4.7	0.36	5.76e-6	Urate levels in obese individuals;
PAAD	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.26	-0.33	3.64e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00083937	chr22:51039805	MAPK8IP2	0.57	6.26	0.45	3.77e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9810890	0.717	rs73210625	chr3:128668246	G/A	cg15676455	chr3:128564943	NA	-0.8	-4.57	-0.35	9.96e-6	Dental caries;
PAAD	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.04	-0.38	1.34e-6	Blood metabolite levels;
PAAD	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.28e-6	Tuberculosis;
PAAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg16727027	chr4:57844010	C4orf14;POLR2B	0.58	6.65	0.47	5e-10	Immature fraction of reticulocytes;
PAAD	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs12681288	0.723	rs11784252	chr8:1027964	T/C	cg04851639	chr8:1020857	NA	-0.65	-7.92	-0.54	4.56e-13	Schizophrenia;
PAAD	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-5.98	-0.44	1.51e-8	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg24220031	chr2:73402428	NA	-0.33	-5.1	-0.38	9.91e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.26	0.6	1.87e-16	Morning vs. evening chronotype;
PAAD	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg03999872	chr20:62272968	STMN3	0.57	5.07	0.38	1.15e-6	Ulcerative colitis;
PAAD	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-4.9	-0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.52	-4.68	-0.35	6.33e-6	Glycated hemoglobin levels;
PAAD	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.47	4.6	0.35	8.82e-6	Recombination measurement;
PAAD	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.91	0.37	2.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.6	5.78	0.42	4.15e-8	Mood instability;
PAAD	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.61	-5.5	-0.41	1.56e-7	Total body bone mineral density (age 0-15);
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	5.92	0.43	2.11e-8	Lung cancer in ever smokers;
PAAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.83	-8.9	-0.59	1.52e-15	Type 2 diabetes;
PAAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.51	-0.34	1.32e-5	Joint mobility (Beighton score);
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.88	-7.23	-0.51	2.19e-11	Initial pursuit acceleration;
PAAD	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg05791153	chr7:19748676	TWISTNB	0.68	5.15	0.39	8.11e-7	Thyroid stimulating hormone;
PAAD	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-5.88	-0.43	2.54e-8	Mood instability;
PAAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs1198430	0.683	rs1077514	chr1:23766233	A/G	cg19827787	chr1:23763612	ASAP3	-0.58	-4.99	-0.37	1.66e-6	Total cholesterol levels;
PAAD	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.15	-0.5	3.43e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg17948913	chr5:572064	NA	0.55	4.32	0.33	2.84e-5	Obesity-related traits;
PAAD	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.56	-0.35	1.03e-5	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg07138768	chr7:917805	C7orf20	0.35	5.41	0.4	2.43e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.84	-8.53	-0.57	1.35e-14	Schizophrenia;
PAAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02421172	chr7:1938701	MAD1L1	0.62	4.51	0.34	1.3e-5	Bipolar disorder;
PAAD	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg26668713	chr11:65405903	SIPA1	-0.41	-4.54	-0.35	1.12e-5	Systemic lupus erythematosus;
PAAD	cis	rs6011674	0.708	rs78017705	chr20:61880073	G/A	cg12207022	chr20:61734930	HAR1A;HAR1B	0.85	4.28	0.33	3.3e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg02135003	chr7:105160482	PUS7	-0.84	-6.75	-0.48	2.97e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.77	-7.96	-0.54	3.67e-13	Neurofibrillary tangles;
PAAD	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.61	0.35	8.35e-6	Schizophrenia;
PAAD	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.44	-4.61	-0.35	8.49e-6	Response to antidepressants in depression;
PAAD	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-5.07	-0.38	1.16e-6	Osteoarthritis;
PAAD	cis	rs950881	0.867	rs10197862	chr2:102966549	A/G	cg03938978	chr2:103052716	IL18RAP	0.54	4.45	0.34	1.63e-5	Allergy;
PAAD	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.58	-0.35	9.58e-6	Bipolar disorder;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs2274459	0.778	rs2281917	chr6:33655728	G/C	cg06253072	chr6:33679850	C6orf125	0.64	5.09	0.38	1.06e-6	Obesity (extreme);
PAAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.22e-10	Blood protein levels;
PAAD	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg21419209	chr3:44054225	NA	-0.73	-7.61	-0.53	2.73e-12	Coronary artery disease;
PAAD	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	4.56	0.35	1.05e-5	Corneal astigmatism;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg05627522	chr15:75251581	NA	0.49	5.85	0.43	2.93e-8	Breast cancer;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.66	0.48	4.69e-10	Height;
PAAD	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg24053715	chr22:38214548	NA	0.5	5.14	0.38	8.42e-7	Glioblastoma;Glioma;
PAAD	cis	rs67257959	0.708	rs1979261	chr19:17193518	C/T	cg19418318	chr19:17219073	MYO9B	-0.31	-4.57	-0.35	1e-5	Selective IgA deficiency;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg07841815	chr7:100318223	EPO	-0.48	-4.54	-0.35	1.12e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.71	7.24	0.51	2.13e-11	Menarche (age at onset);
PAAD	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06771106	chr2:113671356	IL1F7	0.62	6.67	0.48	4.4e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs134594	0.885	rs134596	chr22:29470115	C/T	cg01361351	chr22:29467363	NA	0.39	4.38	0.33	2.2e-5	Birth weight;
PAAD	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-4.32	-0.33	2.77e-5	Coronary artery disease;
PAAD	cis	rs111342015	0.730	rs73736735	chr6:43187526	C/T	cg17076780	chr6:43251928	TTBK1	0.6	4.6	0.35	8.87e-6	Breast cancer;
PAAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg23298862	chr7:158159286	PTPRN2	0.57	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs7688540	0.800	rs10023604	chr4:281038	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	4.59	0.35	9.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.64	0.42	7.9e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6494488	0.500	rs55881719	chr15:64714903	T/G	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	cis	rs17092148	1.000	rs17092148	chr20:33435161	A/C	cg06115741	chr20:33292138	TP53INP2	0.7	4.4	0.34	1.99e-5	Neuroticism;
PAAD	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg14686297	chr22:46650375	NA	-0.46	-4.68	-0.36	6.2e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg17470449	chr10:769945	NA	0.49	4.96	0.37	1.88e-6	Uric acid levels;
PAAD	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06307176	chr5:131281290	NA	-0.53	-4.77	-0.36	4.26e-6	Life satisfaction;
PAAD	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	6.51	0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg00383909	chr3:49044727	WDR6	0.56	4.59	0.35	9.24e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg18827107	chr12:86230957	RASSF9	-0.44	-4.6	-0.35	8.75e-6	Major depressive disorder;
PAAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.66	4.97	0.37	1.82e-6	Breast cancer;
PAAD	cis	rs746265	0.818	rs8037045	chr15:39582337	C/G	cg10099207	chr15:39544144	C15orf54	0.57	4.37	0.33	2.3e-5	PR interval;
PAAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg25837213	chr17:80849375	TBCD	-0.5	-4.52	-0.34	1.21e-5	Breast cancer;
PAAD	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg25364880	chr3:44379878	C3orf23	0.53	5.19	0.39	6.5e-7	Depressive symptoms;
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg23710748	chr7:124431027	NA	-0.58	-7.46	-0.52	6.14e-12	Lewy body disease;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg16606324	chr3:10149918	C3orf24	0.64	4.28	0.33	3.27e-5	Alzheimer's disease;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-4.84	-0.37	3.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.09	8.45	0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg24112000	chr20:60950667	NA	-0.47	-5.41	-0.4	2.42e-7	Pelvic organ prolapse;
PAAD	cis	rs8105895	0.877	rs28822164	chr19:22245108	C/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.42	-0.34	1.9e-5	Ileal carcinoids;
PAAD	cis	rs2899832	0.810	rs8015051	chr14:35784602	T/A	cg09327582	chr14:35236912	BAZ1A	0.58	4.45	0.34	1.67e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23708337	chr7:1209742	NA	0.46	4.84	0.37	3.12e-6	Longevity;Endometriosis;
PAAD	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs10950821	0.519	rs1476484	chr7:20669553	C/G	cg21202529	chr7:20656503	ABCB5	-0.41	-4.25	-0.33	3.72e-5	Response to statin therapy;
PAAD	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.71	0.36	5.48e-6	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.7	-7.59	-0.52	3e-12	Colorectal cancer;
PAAD	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.56	0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.88	-7.03	-0.5	6.39e-11	Schizophrenia;
PAAD	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.68	-8.06	-0.55	2.1e-13	Alcohol dependence;
PAAD	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.6	-5.98	-0.44	1.55e-8	Systolic blood pressure;
PAAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg26816564	chr1:7831052	VAMP3	0.75	5.79	0.43	3.9e-8	Inflammatory bowel disease;
PAAD	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.91	7.16	0.5	3.16e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.67e-7	Life satisfaction;
PAAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.5	4.32	0.33	2.86e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.96	-17.52	-0.82	2.65e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.98	8.61	0.57	8.59e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4919087	0.532	rs7068063	chr10:99083968	C/T	cg25902810	chr10:99078978	FRAT1	-0.57	-5.18	-0.39	6.98e-7	Monocyte count;
PAAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg09835421	chr16:68378352	PRMT7	1.2	8.47	0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.68	0.42	6.59e-8	Schizophrenia;
PAAD	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg08992911	chr2:238395768	MLPH	0.53	5.51	0.41	1.52e-7	Prostate cancer;
PAAD	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.72	-7.68	-0.53	1.85e-12	Blood protein levels;
PAAD	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.35	4.91	0.37	2.3e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg14851346	chr12:38532713	NA	0.49	4.6	0.35	8.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg05585544	chr11:47624801	NA	0.49	5.5	0.41	1.56e-7	Subjective well-being;
PAAD	cis	rs2004318	1.000	rs79707451	chr19:55133252	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg18490616	chr2:88469792	THNSL2	-0.44	-4.27	-0.33	3.49e-5	Response to metformin (IC50);
PAAD	cis	rs4455778	0.580	rs4529410	chr7:49125486	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.43e-5	Lung cancer in never smokers;
PAAD	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.46	4.73	0.36	5.11e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.56	5.11	0.38	9.71e-7	Testicular germ cell tumor;
PAAD	cis	rs4547160	1.000	rs4547160	chr12:63503650	A/C	cg26727693	chr12:63544175	AVPR1A	0.39	4.93	0.37	2.13e-6	Morning vs. evening chronotype;
PAAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.76	-0.48	2.79e-10	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.0	8.82	0.58	2.46e-15	Diabetic kidney disease;
PAAD	cis	rs7715811	1.000	rs6554814	chr5:13774231	T/A	cg09526469	chr5:14277668	TRIO	-0.39	-4.26	-0.33	3.61e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-5.64	-0.42	8.16e-8	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.71	4.71	0.36	5.54e-6	Lung cancer in ever smokers;
PAAD	cis	rs3764400	0.567	rs1452662	chr17:46293310	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg05564831	chr3:52568323	NT5DC2	-0.43	-4.31	-0.33	2.89e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs863345	0.604	rs2317969	chr1:158491753	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.62	4.87	0.37	2.82e-6	Multiple sclerosis;
PAAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.95	8.22	0.55	8.33e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.86	0.37	2.94e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.25	-0.39	4.97e-7	Schizophrenia;
PAAD	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	ch.11.42038R	chr11:967971	AP2A2	0.6	5.82	0.43	3.43e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg10985347	chr2:127963512	CYP27C1	-0.46	-4.28	-0.33	3.26e-5	Protein C levels;
PAAD	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.82	9.65	0.62	1.74e-17	Gout;
PAAD	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.6	5.34	0.4	3.39e-7	Coronary heart disease;
PAAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg14349672	chr11:133703707	NA	-0.56	-6.25	-0.45	4e-9	Childhood ear infection;
PAAD	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.75	-6.8	-0.48	2.25e-10	Blood protein levels;
PAAD	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs30380	1.000	rs30187	chr5:96124330	T/C	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8049634	0.913	rs2098738	chr16:84222593	A/C	cg26466773	chr16:84211947	TAF1C	0.52	4.48	0.34	1.46e-5	Small cell lung carcinoma;
PAAD	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4740619	0.745	rs10810485	chr9:15941175	T/A	cg14451791	chr9:16040625	NA	-0.41	-4.69	-0.36	5.98e-6	Body mass index;
PAAD	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	6.11	0.44	7.85e-9	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg14008862	chr17:28927542	LRRC37B2	0.79	5.57	0.41	1.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6594713	0.921	rs34316732	chr5:112699627	T/C	cg12552261	chr5:112820674	MCC	0.7	5.37	0.4	2.85e-7	Brain cytoarchitecture;
PAAD	cis	rs11807834	0.522	rs10864692	chr1:230240469	G/A	cg09847368	chr1:230250326	GALNT2	-0.67	-8.24	-0.56	7.35e-14	Schizophrenia;
PAAD	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.73	7.15	0.5	3.34e-11	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg09677638	chr11:61582810	MIR1908;FADS1	0.55	4.83	0.37	3.23e-6	Bipolar disorder;
PAAD	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.1	0.5	4.45e-11	Coffee consumption (cups per day);
PAAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.32e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11987576	chr13:52378294	DHRS12	-0.55	-6.48	-0.47	1.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.65e-13	Eye color traits;
PAAD	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.47	4.83	0.37	3.24e-6	IgG glycosylation;
PAAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6107516	0.830	rs4815729	chr20:4670510	C/T	cg02413285	chr20:4668134	PRNP	-0.53	-4.31	-0.33	2.94e-5	Creutzfeldt-Jakob disease (variant);Creutzfeldt-Jakob disease (sporadic);
PAAD	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.61	-5.87	-0.43	2.61e-8	Height;
PAAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg27395922	chr11:50257633	LOC441601	-0.42	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-1.03	-8.28	-0.56	5.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg14926445	chr8:58193284	C8orf71	-0.62	-4.53	-0.35	1.17e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17407555	0.865	rs2241464	chr4:10158961	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-5.53	-0.41	1.33e-7	Schizophrenia (age at onset);
PAAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.4	-6.27	-0.45	3.56e-9	Diastolic blood pressure;
PAAD	cis	rs8077889	0.703	rs231543	chr17:41940360	G/T	cg26893861	chr17:41843967	DUSP3	-0.77	-5.64	-0.42	8.07e-8	Triglycerides;
PAAD	cis	rs9880772	0.602	rs4680843	chr3:27798071	G/A	cg21473142	chr3:27762095	EOMES	0.3	5.01	0.38	1.46e-6	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.53	-5.01	-0.38	1.48e-6	White matter hyperintensity burden;
PAAD	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-4.98	-0.37	1.73e-6	Diastolic blood pressure;
PAAD	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.15e-11	Corneal astigmatism;
PAAD	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.3	-0.33	3.1e-5	Fibrinogen levels;
PAAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.59	5.36	0.4	3.04e-7	Obesity-related traits;
PAAD	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	1.11	12.19	0.7	2.89e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg00750074	chr16:89608354	SPG7	-0.55	-5.13	-0.38	8.83e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg14703610	chr5:56206110	C5orf35	0.6	5.79	0.42	3.94e-8	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.37	-0.33	2.31e-5	Life satisfaction;
PAAD	cis	rs2882667	0.690	rs6873425	chr5:138155245	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.56	-5.48	-0.41	1.7e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.2	0.6	2.58e-16	Platelet count;
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.8	9.18	0.6	2.97e-16	Lung cancer;
PAAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg19640517	chr22:41707109	ZC3H7B	0.52	4.28	0.33	3.35e-5	Vitiligo;
PAAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg25204440	chr1:209979598	IRF6	0.61	4.84	0.37	3.21e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.73	-8.05	-0.55	2.26e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg21584241	chr15:63341463	TPM1	0.7	5.2	0.39	6.3e-7	Orofacial clefts;
PAAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.67	0.42	6.85e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7627468	0.802	rs1354158	chr3:121941750	A/G	cg03198317	chr3:121949109	CASR	0.51	4.59	0.35	9.19e-6	Kidney stones;
PAAD	cis	rs2384550	0.838	rs6489992	chr12:115352769	C/T	cg05726002	chr12:115341178	NA	-0.35	-4.37	-0.33	2.25e-5	Blood pressure;Diastolic blood pressure;
PAAD	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.44	-4.58	-0.35	9.52e-6	Resting heart rate;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26320663	chr1:152161521	NA	0.5	4.94	0.37	2.06e-6	Inflammatory skin disease;
PAAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.71	9.33	0.6	1.19e-16	Eye color traits;
PAAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg08589418	chr20:61993913	CHRNA4	-0.5	-4.32	-0.33	2.86e-5	Atopic dermatitis;
PAAD	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.53	-6.33	-0.46	2.57e-9	Alcohol dependence;
PAAD	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.53	-5.02	-0.38	1.46e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.49	0.34	1.4e-5	Depression;
PAAD	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg10006428	chr1:248814059	OR2T27	0.36	4.35	0.33	2.51e-5	Common traits (Other);
PAAD	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.5	5.02	0.38	1.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.81	7.48	0.52	5.61e-12	Neurofibrillary tangles;
PAAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.9	-0.59	1.54e-15	Body mass index;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	5.08	0.38	1.11e-6	Lymphocyte counts;
PAAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.7	9.77	0.62	8.61e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs6782025	1.000	rs6782025	chr3:121137976	C/T	cg16417163	chr3:121280760	NA	-0.47	-4.85	-0.37	3.02e-6	Aging (facial);
PAAD	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg23684204	chr15:91497937	RCCD1	0.74	5.98	0.44	1.5e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-9.09	-0.59	5.13e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.58	7.63	0.53	2.34e-12	Primary biliary cholangitis;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg13047869	chr3:10149882	C3orf24	0.54	4.75	0.36	4.74e-6	Alzheimer's disease;
PAAD	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35883536	1.000	rs11586051	chr1:101096240	A/T	cg14515779	chr1:101123966	NA	0.53	6.59	0.47	6.89e-10	Monocyte count;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg14182682	chr14:57857589	NAA30	-0.68	-6.73	-0.48	3.34e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg09659197	chr4:152720779	NA	0.47	6.22	0.45	4.5e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg20607287	chr7:12443886	VWDE	-0.6	-4.72	-0.36	5.32e-6	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2120991	0.901	rs9919682	chr12:54293218	G/C	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.29	-0.33	3.15e-5	Biliary atresia;
PAAD	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.17	-9.55	-0.61	3.12e-17	Post bronchodilator FEV1;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.16	0.39	7.53e-7	Electroencephalogram traits;
PAAD	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.7	6.69	0.48	4.06e-10	Cognitive ability;
PAAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.79	-9.88	-0.63	4.23e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.92	11.1	0.67	2.45e-21	Schizophrenia;
PAAD	cis	rs10850408	0.809	rs10850402	chr12:115354123	G/A	cg05726002	chr12:115341178	NA	-0.42	-5.17	-0.39	7.23e-7	Alzheimer's disease;
PAAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg20848291	chr7:100343083	ZAN	-0.76	-6.55	-0.47	8.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg26876637	chr1:152193138	HRNR	-0.83	-6.05	-0.44	1.08e-8	Atopic dermatitis;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04245873	chr15:63796130	USP3	0.41	4.62	0.35	8.19e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2492906	0.564	rs2782339	chr10:28077443	C/A	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.42	7.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg15764593	chr10:829463	NA	-0.77	-6.11	-0.44	7.96e-9	Uric acid levels;
PAAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-6.68	-0.48	4.32e-10	Glomerular filtration rate;
PAAD	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.42	-0.4	2.26e-7	Mood instability;
PAAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg21351543	chr2:191399470	TMEM194B	-0.59	-4.55	-0.35	1.08e-5	Diastolic blood pressure;
PAAD	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	cis	rs2133450	0.745	rs7639597	chr3:7364047	T/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.26	-0.39	4.75e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs2061333	0.724	rs4802208	chr19:44627912	G/C	cg18700516	chr19:44507157	ZNF230	-0.65	-4.89	-0.37	2.53e-6	Alzheimer's disease;
PAAD	cis	rs7092929	0.941	rs668923	chr10:3575664	G/T	cg14308648	chr10:3568949	NA	0.67	5.02	0.38	1.4e-6	Coronary artery calcification;
PAAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.76	-7.15	-0.5	3.35e-11	DNA methylation (variation);
PAAD	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.3	-0.39	4.08e-7	Educational attainment;
PAAD	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.81e-7	White blood cell count;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.72	-0.36	5.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.748	rs3785098	chr16:67993643	T/C	cg09835421	chr16:68378352	PRMT7	-0.73	-5.78	-0.42	4e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.73	8.6	0.57	9.18e-15	Height;
PAAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg16928487	chr17:17741425	SREBF1	-0.31	-4.27	-0.33	3.5e-5	Total body bone mineral density;
PAAD	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-6.13	-0.45	7.32e-9	Hypospadias;
PAAD	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.82e-7	Interstitial lung disease;
PAAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.22	-0.45	4.55e-9	Menarche (age at onset);
PAAD	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.33	4.96	0.37	1.87e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg03605463	chr16:89740564	NA	-0.53	-5.08	-0.38	1.08e-6	Vitiligo;
PAAD	cis	rs10894308	0.543	rs7106928	chr11:130809259	T/G	cg12179176	chr11:130786555	SNX19	0.66	6.13	0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs2320952	0.874	rs34046958	chr17:10489176	A/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg08632701	chr21:37451849	NA	-0.61	-6.36	-0.46	2.28e-9	Mitral valve prolapse;
PAAD	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs2017305	0.915	rs7920	chr10:70744679	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.8	-9.02	-0.59	7.58e-16	Sudden cardiac arrest;
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.65	-0.42	7.6e-8	Lung cancer;
PAAD	cis	rs116175783	0.557	rs2042487	chr2:162150245	C/T	cg08807892	chr2:162101083	NA	-0.69	-4.89	-0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg10985347	chr2:127963512	CYP27C1	0.47	4.32	0.33	2.83e-5	Protein C levels;
PAAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.76	6.63	0.47	5.55e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.92	-11.19	-0.67	1.37e-21	Menopause (age at onset);
PAAD	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-7.76	-0.53	1.15e-12	Menarche (age at onset);
PAAD	cis	rs9646944	0.531	rs17027029	chr2:102990648	G/C	cg03938978	chr2:103052716	IL18RAP	0.51	4.33	0.33	2.66e-5	Blood protein levels;
PAAD	cis	rs3018712	0.616	rs948852	chr11:68450573	G/T	cg23009355	chr11:68451396	GAL	-0.5	-5.52	-0.41	1.46e-7	Total body bone mineral density;
PAAD	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.65	7.23	0.51	2.21e-11	High light scatter reticulocyte count;
PAAD	cis	rs12767760	0.669	rs11189275	chr10:99312538	A/C	cg25247692	chr10:99313390	UBTD1	-0.6	-6.02	-0.44	1.24e-8	Obesity-related traits;
PAAD	cis	rs1075265	0.584	rs11896781	chr2:54324124	G/C	cg04546899	chr2:54196757	PSME4	0.31	4.61	0.35	8.45e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg18402987	chr7:1209562	NA	1.11	5.59	0.41	1.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg21040360	chr2:3383326	TTC15	-0.42	-4.55	-0.35	1.11e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.25	0.45	3.84e-9	Schizophrenia;
PAAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.87	7.86	0.54	6.4e-13	Coronary artery disease;
PAAD	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.42	-0.4	2.3e-7	Schizophrenia;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.64	7.24	0.51	2.11e-11	Mean corpuscular volume;
PAAD	cis	rs1624802	1.000	rs1707934	chr12:130497611	C/T	cg15444478	chr12:130494697	NA	0.35	4.4	0.34	2.02e-5	Obesity-related traits;
PAAD	cis	rs7178572	0.633	rs11855188	chr15:77840714	A/G	cg22256960	chr15:77711686	NA	-0.56	-4.47	-0.34	1.53e-5	Type 2 diabetes;
PAAD	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg14003231	chr6:33640908	ITPR3	0.37	4.74	0.36	4.8e-6	Plateletcrit;
PAAD	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-8.04	-0.55	2.41e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.94	12.25	0.7	1.92e-24	Menopause (age at onset);
PAAD	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	4.7	0.36	5.84e-6	Psychosis and Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02278228	chr7:43313745	HECW1	0.6	6.31	0.46	2.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.58	6.4	0.46	1.86e-9	Testicular germ cell tumor;
PAAD	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg03700679	chr2:178418002	TTC30B	-0.65	-5.22	-0.39	5.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2004318	1.000	rs76189918	chr19:55082868	C/T	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.37	-7.03	-0.5	6.44e-11	Psoriasis vulgaris;
PAAD	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg14146966	chr2:61757674	XPO1	-0.37	-4.66	-0.35	7e-6	Tuberculosis;
PAAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg11859384	chr17:80120422	CCDC57	0.45	4.72	0.36	5.34e-6	Life satisfaction;
PAAD	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.47	4.8	0.36	3.71e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs476633	0.708	rs28547298	chr15:41446951	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.8	-8.37	-0.56	3.45e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.81e-6	Lymphocyte counts;
PAAD	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.55	-4.74	-0.36	4.9e-6	Total body bone mineral density;
PAAD	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg21775007	chr8:11205619	TDH	-0.54	-4.95	-0.37	1.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.48e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	7.6	0.52	2.89e-12	Body mass index (adult);
PAAD	cis	rs7264396	0.887	rs750487	chr20:34066645	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.3	0.33	3.08e-5	Total cholesterol levels;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.14	-0.5	3.62e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.37	-0.4	2.96e-7	Height;
PAAD	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg21479132	chr6:26055353	NA	0.85	5.27	0.39	4.5e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7123876	0.587	rs11600831	chr11:72360220	C/T	cg03713592	chr11:72463424	ARAP1	0.64	4.3	0.33	3e-5	Body mass index;
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.53	-6.67	-0.48	4.39e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.43	-4.89	-0.37	2.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11021305	chr6:36410485	PXT1;KCTD20	0.67	6.98	0.49	8.47e-11	Obesity-related traits;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg20295408	chr7:1910781	MAD1L1	0.56	5.58	0.41	1.08e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs911119	0.913	rs3004139	chr20:23578674	C/T	cg16589663	chr20:23618590	CST3	-0.79	-6.93	-0.49	1.14e-10	Chronic kidney disease;
PAAD	cis	rs7577696	0.785	rs11694630	chr2:32376201	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-4.74	-0.36	4.9e-6	Inflammatory biomarkers;
PAAD	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.62	-5.48	-0.41	1.72e-7	Type 2 diabetes;
PAAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg24253500	chr15:84953950	NA	0.54	6.43	0.46	1.55e-9	Schizophrenia;
PAAD	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg11779900	chr17:80519722	FOXK2	-0.48	-4.97	-0.37	1.77e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.11	-0.38	9.5e-7	Menopause (age at onset);
PAAD	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg13406893	chr12:131568647	GPR133	-0.43	-4.28	-0.33	3.32e-5	Longevity;
PAAD	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06026331	chr20:60912101	LAMA5	0.58	4.82	0.36	3.41e-6	Colorectal cancer;
PAAD	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg19949948	chr17:19361230	NA	-0.43	-4.44	-0.34	1.74e-5	Schizophrenia;
PAAD	cis	rs1595825	0.786	rs1902246	chr2:198492827	C/T	cg10547527	chr2:198650123	BOLL	-0.66	-4.6	-0.35	8.87e-6	Ulcerative colitis;
PAAD	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.31	-0.46	2.86e-9	Neuroticism;
PAAD	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.28	0.6	1.62e-16	Bipolar disorder;
PAAD	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.15	0.45	6.48e-9	Mean platelet volume;
PAAD	cis	rs2882667	0.690	rs3804199	chr5:138162129	T/C	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06850241	chr22:41845214	NA	0.6	5.38	0.4	2.71e-7	Vitiligo;
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23868899	chr8:124553478	FBXO32	0.61	6.47	0.46	1.24e-9	Myopia (pathological);
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg27094323	chr7:1216898	NA	-0.45	-5.19	-0.39	6.61e-7	Longevity;Endometriosis;
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.67e-5	Menopause (age at onset);
PAAD	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.6	6.18	0.45	5.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.26	-19.12	-0.84	2.7e-42	Ulcerative colitis;
PAAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.78	6.99	0.49	8.15e-11	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs864745	0.600	rs849335	chr7:28223990	T/C	cg01883759	chr7:28220576	JAZF1	-0.5	-5.13	-0.38	8.56e-7	Crohn's disease;Type 2 diabetes;
PAAD	cis	rs9503598	0.644	rs9503593	chr6:3430787	T/C	cg00476032	chr6:3446245	SLC22A23	0.48	5.44	0.4	2.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.63	-6.53	-0.47	9.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-5.22	-0.39	5.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg07148914	chr20:33460835	GGT7	0.5	4.93	0.37	2.12e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	4.6	0.35	8.98e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16573663	chr11:67169076	PPP1CA	0.66	6.48	0.47	1.21e-9	Obesity-related traits;
PAAD	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg21017887	chr14:105400489	NA	1.0	13.88	0.75	8.17e-29	Rheumatoid arthritis;
PAAD	cis	rs4761470	0.637	rs11107531	chr12:94801321	C/T	cg05135942	chr12:94854469	CCDC41;LOC144486	0.47	4.25	0.33	3.66e-5	Estradiol plasma levels (breast cancer);
PAAD	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.58	-5.1	-0.38	9.82e-7	Post bronchodilator FEV1;
PAAD	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.67	-5.81	-0.43	3.58e-8	Lung cancer;
PAAD	cis	rs9810890	1.000	rs73198806	chr3:128465094	A/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg14686297	chr22:46650375	NA	-0.46	-4.68	-0.36	6.2e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg13446199	chr8:143762866	PSCA	0.37	4.39	0.34	2.14e-5	Urinary tract infection frequency;
PAAD	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.65	6.94	0.49	1.05e-10	Crohn's disease;
PAAD	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.59	-4.88	-0.37	2.64e-6	Iron status biomarkers;
PAAD	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.47	-5.54	-0.41	1.31e-7	Coronary artery disease;
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01765077	chr12:122356316	WDR66	0.63	7.23	0.51	2.25e-11	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.83	7.13	0.5	3.73e-11	Alzheimer's disease;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg11601000	chr22:42348013	LOC339674	-0.49	-5.9	-0.43	2.22e-8	Intelligence;
PAAD	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	9.86	0.62	4.84e-18	Response to antipsychotic treatment;
PAAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.27	0.6	1.68e-16	Rheumatoid arthritis;
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.69	-0.42	6.49e-8	Lung cancer;
PAAD	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg01620082	chr3:125678407	NA	-1.51	-8.87	-0.58	1.83e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs35160687	0.862	rs13023154	chr2:86516984	A/G	cg10973622	chr2:86423274	IMMT	-0.47	-5.28	-0.39	4.32e-7	Night sleep phenotypes;
PAAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	6.97	0.49	8.85e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs300774	0.925	rs300723	chr2:134131	C/T	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.6	-6.22	-0.45	4.57e-9	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs41311933	0.656	rs72758198	chr9:123820400	G/T	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.73	-0.36	5.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13198984	chr17:80129470	CCDC57	0.41	5.16	0.39	7.69e-7	Life satisfaction;
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.77	8.63	0.57	7.63e-15	Longevity;
PAAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.81	8.42	0.56	2.69e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6893807	0.673	rs35267052	chr5:87949118	T/G	cg02225085	chr5:87975992	LOC645323	-0.82	-4.75	-0.36	4.65e-6	Body mass index;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03236725	chr15:92396240	SLCO3A1	0.58	6.43	0.46	1.56e-9	Metabolite levels  (X-11787);
PAAD	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.86	9.08	0.59	5.33e-16	Body mass index;
PAAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg23684787	chr19:1848742	REXO1	-0.51	-4.29	-0.33	3.16e-5	Bipolar disorder;
PAAD	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg05791153	chr7:19748676	TWISTNB	-0.53	-4.42	-0.34	1.9e-5	Thyroid stimulating hormone;
PAAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.73	8.58	0.57	1.05e-14	Type 2 diabetes;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05665937	chr4:1216051	CTBP1	-0.44	-4.38	-0.33	2.21e-5	Obesity-related traits;
PAAD	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	4.29	0.33	3.15e-5	Thyroid stimulating hormone;
PAAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.27	-0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg14393609	chr7:65229607	NA	-0.66	-7.19	-0.5	2.67e-11	Aortic root size;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg14583973	chr4:3374767	RGS12	0.33	4.71	0.36	5.58e-6	Mean platelet volume;
PAAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-7.83	-0.54	7.96e-13	Triglycerides;
PAAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12165864	chr7:66369176	NA	-0.81	-5.17	-0.39	7.29e-7	Diabetic kidney disease;
PAAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg08885800	chr1:201084119	NA	0.72	7.99	0.54	3.15e-13	Permanent tooth development;
PAAD	cis	rs2072732	0.756	rs77415878	chr1:2954047	C/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg06375148	chr1:209958343	C1orf74	-0.56	-5.66	-0.42	7.41e-8	Monobrow;
PAAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.88	9.67	0.62	1.53e-17	Cognitive function;
PAAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg23465465	chr6:26364728	BTN3A2	0.79	4.43	0.34	1.83e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.44	5.57	0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.92	-7.96	-0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs1075265	0.901	rs7591194	chr2:54313836	A/T	cg04546899	chr2:54196757	PSME4	-0.31	-4.33	-0.33	2.68e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg10864074	chr7:100318194	EPO	-0.48	-4.75	-0.36	4.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.57	6.25	0.45	3.87e-9	Coronary artery disease;
PAAD	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.66	-6.12	-0.44	7.8e-9	Diisocyanate-induced asthma;
PAAD	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.65	-6.31	-0.46	2.85e-9	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4910442	0.564	rs11042162	chr11:9067368	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	4.62	0.35	8.26e-6	Tonsillectomy;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.61	-6.92	-0.49	1.18e-10	Rheumatoid arthritis;
PAAD	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.64	6.79	0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.28	-0.51	1.67e-11	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	4.64	0.35	7.52e-6	Eosinophil percentage of white cells;
PAAD	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.62	6.01	0.44	1.32e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs901683	0.850	rs76294334	chr10:45964279	T/C	cg12869334	chr8:37699360	GPR124	0.97	6.47	0.46	1.29e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.66	0.35	6.85e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg24053715	chr22:38214548	NA	0.57	5.23	0.39	5.65e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.44	4.96	0.37	1.84e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8070740	0.841	rs4790771	chr17:5324966	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.66	0.35	6.78e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.83	-0.48	1.95e-10	Personality dimensions;
PAAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg21929781	chr1:2537748	MMEL1	-0.44	-4.68	-0.36	6.23e-6	Ulcerative colitis;
PAAD	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg22029157	chr1:209979665	IRF6	0.72	6.4	0.46	1.82e-9	Coronary artery disease;
PAAD	cis	rs2153535	0.518	rs9505510	chr6:8657836	G/T	cg07606381	chr6:8435919	SLC35B3	0.44	4.43	0.34	1.83e-5	Motion sickness;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg07685180	chr8:600429	NA	-1.01	-6.35	-0.46	2.33e-9	IgG glycosylation;
PAAD	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg04289385	chr6:36355825	ETV7	0.46	4.59	0.35	9.39e-6	Platelet distribution width;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17101358	chr17:42422688	GRN	-0.76	-6.53	-0.47	9.37e-10	Neuroticism;
PAAD	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.69	-5.58	-0.41	1.07e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-1.11	-10.52	-0.65	8.45e-20	Red blood cell traits;
PAAD	cis	rs4740619	0.688	rs10810484	chr9:15935338	G/A	cg14451791	chr9:16040625	NA	-0.42	-4.77	-0.36	4.23e-6	Body mass index;
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.55e-5	Systolic blood pressure;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.41	-0.34	1.96e-5	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs6500550	1.000	rs6500550	chr16:3746241	A/G	cg01678580	chr16:4674018	MGRN1	-0.48	-4.4	-0.34	2.03e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
PAAD	cis	rs4742903	0.935	rs10991182	chr9:106983578	T/C	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg00181669	chr3:44000978	NA	0.55	5.89	0.43	2.37e-8	Coronary artery disease;
PAAD	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg12315302	chr6:26189340	HIST1H4D	0.86	4.58	0.35	9.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg01763666	chr17:80159506	CCDC57	-0.45	-4.5	-0.34	1.32e-5	Life satisfaction;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg05861140	chr6:150128134	PCMT1	-0.54	-6.3	-0.46	3.01e-9	Lung cancer;
PAAD	cis	rs11618113	0.540	rs11616672	chr13:111178646	A/T	cg11688093	chr13:111178359	RAB20	-0.81	-4.63	-0.35	7.71e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	4.39	0.34	2.15e-5	Longevity;Endometriosis;
PAAD	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg21395723	chr22:39101663	GTPBP1	-0.44	-4.73	-0.36	5.11e-6	Menopause (age at onset);
PAAD	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg09127314	chr1:152161683	NA	0.7	4.92	0.37	2.21e-6	Atopic dermatitis;
PAAD	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.56	-6.31	-0.46	2.85e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.08	-0.38	1.11e-6	Total body bone mineral density;
PAAD	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.54	-0.47	8.85e-10	Neuroticism;
PAAD	cis	rs13144136	0.748	rs4697774	chr4:10670461	A/G	cg10242279	chr4:10666415	CLNK	-0.37	-4.59	-0.35	9.18e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.56	5.22	0.39	5.84e-7	Red blood cell count;
PAAD	cis	rs60617249	0.542	rs1023633	chr7:50931562	A/G	cg15805451	chr7:51135775	COBL	-0.43	-4.61	-0.35	8.32e-6	Major depression and alcohol dependence;
PAAD	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.81	9.77	0.62	8.62e-18	Colorectal cancer;
PAAD	cis	rs3857067	1.000	rs899134	chr4:95019675	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg21546286	chr11:48923668	NA	0.55	5.76	0.42	4.48e-8	HDL cholesterol;
PAAD	cis	rs1198430	0.562	rs7522616	chr1:23794914	A/G	cg27447006	chr1:23763279	ASAP3	0.63	5.54	0.41	1.3e-7	Total cholesterol levels;
PAAD	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.49	0.52	5.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21759430	chr11:134134922	ACAD8	0.6	6.64	0.47	5.17e-10	Smoking initiation;
PAAD	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	7.26	0.51	1.86e-11	Neuroticism;
PAAD	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.0	0.38	1.56e-6	Colorectal cancer;
PAAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.85	7.94	0.54	4.18e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg12163867	chr12:51592794	POU6F1	0.53	4.67	0.35	6.63e-6	Cisplatin-induced ototoxicity;
PAAD	cis	rs35164067	1.000	rs34953890	chr19:10526854	C/A	cg07306197	chr19:9546377	ZNF266	0.59	4.48	0.34	1.46e-5	Inflammatory bowel disease;
PAAD	trans	rs901683	1.000	rs77649955	chr10:46050689	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.64	5.98	0.44	1.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2882667	0.690	rs13174008	chr5:138257909	T/C	cg09476006	chr5:138032270	NA	0.48	6.09	0.44	8.74e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.83	8.6	0.57	9.37e-15	Body mass index;
PAAD	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.56	6.08	0.44	9.24e-9	Menopause (age at onset);
PAAD	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.84	0.37	3.12e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.24	0.51	2.12e-11	IgG glycosylation;
PAAD	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.96e-8	Personality dimensions;
PAAD	cis	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg27449352	chr6:97285386	GPR63	-0.53	-4.87	-0.37	2.81e-6	Body mass index;
PAAD	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.45	-4.53	-0.34	1.21e-5	IgG glycosylation;
PAAD	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	14.79	0.77	3.1e-31	Prudent dietary pattern;
PAAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-5.12	-0.38	8.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg13206674	chr6:150067644	NUP43	0.63	6.55	0.47	8.49e-10	Testicular germ cell tumor;
PAAD	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.68	6.42	0.46	1.63e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg27499820	chr13:21296301	IL17D	0.5	4.77	0.36	4.21e-6	Dental caries;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20869501	chr1:216774677	ESRRG	0.57	6.68	0.48	4.14e-10	Myopia (pathological);
PAAD	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.16	-0.39	7.62e-7	QT interval;
PAAD	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14169450	chr9:139327907	INPP5E	-0.5	-4.84	-0.37	3.21e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg23759393	chr7:158110405	PTPRN2	0.37	4.48	0.34	1.48e-5	Response to amphetamines;
PAAD	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg00666640	chr1:248458726	OR2T12	0.54	4.37	0.33	2.32e-5	Common traits (Other);
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	11.17	0.67	1.54e-21	Platelet count;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	0.99	6.58	0.47	7.12e-10	IgG glycosylation;
PAAD	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg15128208	chr22:42549153	NA	-0.42	-4.25	-0.33	3.72e-5	Cognitive function;
PAAD	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.38	5.21	0.39	6.1e-7	Blood protein levels;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.43	-5.84	-0.43	3.03e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.44	5.12	0.38	9.23e-7	Coronary artery disease;
PAAD	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg12386194	chr3:101231763	SENP7	0.52	5.32	0.4	3.59e-7	Colorectal cancer;
PAAD	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg19131313	chr8:1704013	NA	-0.41	-4.46	-0.34	1.59e-5	Systolic blood pressure;
PAAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.62	6.44	0.46	1.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11087358	chr12:57940980	DCTN2	0.62	6.82	0.48	1.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg17644776	chr2:200775616	C2orf69	-0.64	-5.02	-0.38	1.42e-6	Schizophrenia;
PAAD	cis	rs3747547	0.710	rs16934658	chr9:37950543	C/A	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg06375148	chr1:209958343	C1orf74	0.68	5.63	0.42	8.39e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg18856388	chr5:1875886	NA	0.23	4.25	0.33	3.69e-5	Gut microbiome composition (winter);
PAAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.54	5.8	0.43	3.72e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9491697	0.546	rs719726	chr6:127414801	A/G	cg09503566	chr4:15907489	NA	-0.28	-6.31	-0.46	2.92e-9	Crohn's disease;
PAAD	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.75	-5.31	-0.4	3.83e-7	Lung cancer;
PAAD	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.99	8.64	0.57	7.29e-15	Bipolar disorder;
PAAD	cis	rs3812111	0.525	rs1055814	chr6:116570597	T/C	cg05304507	chr6:116381966	FRK	-0.27	-4.55	-0.35	1.08e-5	Age-related macular degeneration;
PAAD	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.62	6.72	0.48	3.4e-10	High light scatter reticulocyte count;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.51e-6	Lung cancer;
PAAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg20821713	chr7:1055600	C7orf50	-0.39	-4.47	-0.34	1.51e-5	Longevity;Endometriosis;
PAAD	trans	rs3129682	1	rs3129682	chr6:29283672	C/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Blood protein levels;
PAAD	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.63	-0.47	5.52e-10	Neuroticism;
PAAD	cis	rs6921919	0.789	rs1119211	chr6:28309136	C/G	cg23153227	chr6:27725408	NA	-0.5	-4.28	-0.33	3.35e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2033908	0.620	rs10765993	chr11:12849185	C/G	cg25843174	chr11:12811716	TEAD1	-0.35	-4.73	-0.36	5.09e-6	Sitting height ratio;
PAAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4740619	0.875	rs10962142	chr9:15756094	A/G	cg14451791	chr9:16040625	NA	-0.38	-4.58	-0.35	9.48e-6	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06630098	chr19:16683316	SLC35E1	-0.78	-7.14	-0.5	3.59e-11	Neuroticism;
PAAD	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-5.48	-0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.84	0.66	1.25e-20	Tonsillectomy;
PAAD	cis	rs57994353	0.568	rs10747044	chr9:139319129	G/T	cg21253087	chr9:139290292	SNAPC4	0.53	4.73	0.36	5.02e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.28	0.33	3.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg14851346	chr12:38532713	NA	0.5	4.55	0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg26071806	chr7:100318239	EPO	-0.51	-4.94	-0.37	1.99e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-1.33	-10.66	-0.65	3.72e-20	Schizophrenia;
PAAD	cis	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg21479132	chr6:26055353	NA	0.86	4.25	0.33	3.69e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.87	-0.49	1.53e-10	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.46	4.73	0.36	5.17e-6	Body mass index;
PAAD	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-6.17	-0.45	5.8e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.72	0.53	1.42e-12	Prudent dietary pattern;
PAAD	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	5.14	0.38	8.31e-7	Thyroid stimulating hormone;
PAAD	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg01064725	chr1:204461714	NA	-0.52	-4.85	-0.37	2.96e-6	Schizophrenia;
PAAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.78	-7.76	-0.53	1.16e-12	Urate levels in lean individuals;
PAAD	cis	rs800160	0.777	rs2651781	chr11:2345677	G/A	cg09785033	chr11:2336066	TSPAN32	-0.5	-4.29	-0.33	3.2e-5	Bacteremia;
PAAD	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg02986791	chr19:1062178	ABCA7	-0.5	-4.38	-0.33	2.21e-5	Alzheimer's disease (late onset);
PAAD	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.84	6.56	0.47	7.93e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg04160749	chr8:58172571	NA	-0.64	-4.66	-0.35	6.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17848003	chr1:3704513	LRRC47	-0.4	-4.32	-0.33	2.84e-5	Red cell distribution width;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg22535103	chr8:58192502	C8orf71	-1.22	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-6.75	-0.48	2.87e-10	Plateletcrit;Platelet count;
PAAD	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg04450456	chr4:17643702	FAM184B	0.5	5.62	0.41	8.79e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.41	4.81	0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.5	5.02	0.38	1.46e-6	Type 2 diabetes;
PAAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg13468214	chr4:1046988	NA	0.52	4.89	0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg19337854	chr7:99768885	GPC2	-0.39	-4.26	-0.33	3.62e-5	Coronary artery disease;
PAAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.77	-0.36	4.23e-6	Blood metabolite levels;
PAAD	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.04	-0.38	1.31e-6	Bipolar disorder;
PAAD	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.56	0.35	1.03e-5	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.02	0.49	7.02e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.88	-8.18	-0.55	1.06e-13	Exhaled nitric oxide output;
PAAD	trans	rs6490294	0.528	rs57502306	chr12:112290443	G/A	cg08332908	chr17:38465326	RARA	0.77	6.34	0.46	2.53e-9	Mean platelet volume;
PAAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg23346134	chr3:49453900	TCTA	0.41	4.32	0.33	2.82e-5	Menarche (age at onset);
PAAD	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.6	-0.35	9e-6	Neuroticism;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03927896	chr11:124670850	C11orf61	-0.62	-6.67	-0.48	4.45e-10	Smoking initiation;
PAAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.22	0.6	2.29e-16	Parkinson's disease;
PAAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.55	5.38	0.4	2.72e-7	Schizophrenia;
PAAD	cis	rs1478898	0.569	rs2249260	chr8:11388714	T/C	cg00262122	chr8:11665843	FDFT1	-0.54	-4.6	-0.35	9.02e-6	Morning vs. evening chronotype;
PAAD	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg21855830	chr2:127963489	CYP27C1	0.47	4.35	0.33	2.48e-5	Protein C levels;
PAAD	cis	rs3812111	0.608	rs9400888	chr6:116422534	C/T	cg05304507	chr6:116381966	FRK	-0.27	-4.83	-0.36	3.28e-6	Age-related macular degeneration;
PAAD	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg17644776	chr2:200775616	C2orf69	0.55	4.45	0.34	1.68e-5	Schizophrenia;
PAAD	cis	rs61861422	0.516	rs12767762	chr10:134443032	A/G	cg27286337	chr10:134555280	INPP5A	0.67	5.82	0.43	3.31e-8	Primary sclerosing cholangitis;
PAAD	cis	rs72960926	1.000	rs72956942	chr6:75093037	G/A	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.89	-11.05	-0.67	3.24e-21	Coronary artery disease;
PAAD	cis	rs1075265	0.584	rs4671178	chr2:54283493	C/T	cg04546899	chr2:54196757	PSME4	-0.35	-5.12	-0.38	8.93e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.31	-0.51	1.39e-11	Personality dimensions;
PAAD	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs113835537	0.597	rs11227527	chr11:66313026	A/G	cg24851651	chr11:66362959	CCS	0.5	4.71	0.36	5.45e-6	Airway imaging phenotypes;
PAAD	cis	rs743757	1.000	rs2282758	chr3:50477905	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.67	4.53	0.34	1.18e-5	Diastolic blood pressure;
PAAD	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.72	0.36	5.28e-6	Resting heart rate;
PAAD	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg08975724	chr8:8085496	FLJ10661	-0.7	-6.94	-0.49	1.05e-10	Neuroticism;
PAAD	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg20406979	chr6:167373233	NA	0.34	4.55	0.35	1.09e-5	Crohn's disease;
PAAD	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg26695010	chr11:65641043	EFEMP2	0.54	5.0	0.38	1.58e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.24	0.56	7.48e-14	Rheumatoid arthritis;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg13206674	chr6:150067644	NUP43	0.61	6.53	0.47	9.19e-10	Lung cancer;
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.81	10.36	0.64	2.36e-19	Vitiligo;
PAAD	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg24881330	chr22:46731750	TRMU	1.16	5.73	0.42	5.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1198430	0.571	rs1001207	chr1:23749148	G/A	cg27447006	chr1:23763279	ASAP3	0.63	5.7	0.42	5.91e-8	Total cholesterol levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16326819	chr2:118771837	CCDC93	0.56	6.33	0.46	2.63e-9	Monocyte percentage of white cells;
PAAD	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg07884673	chr3:53033167	SFMBT1	0.7	4.48	0.34	1.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.6	0.57	8.94e-15	Menopause (age at onset);
PAAD	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.62	-0.35	8.05e-6	Morning vs. evening chronotype;
PAAD	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.63	-5.1	-0.38	9.81e-7	Cognitive test performance;
PAAD	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg04877966	chr15:75135169	ULK3	0.57	4.89	0.37	2.51e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg23119463	chr10:134592391	INPP5A	-0.51	-4.93	-0.37	2.15e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16640753	chr5:634043	CEP72	-0.65	-6.8	-0.48	2.26e-10	Obesity-related traits;
PAAD	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.46	-5.01	-0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.68	7.42	0.52	7.51e-12	Platelet distribution width;
PAAD	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-6.86	-0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs4880487	0.888	rs35341304	chr10:1252526	T/C	cg03183215	chr10:1252341	ADARB2	-0.48	-4.75	-0.36	4.77e-6	Migraine;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.22	0.7	2.41e-24	Prudent dietary pattern;
PAAD	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg14019146	chr3:50243930	SLC38A3	0.53	4.35	0.33	2.53e-5	Menarche (age at onset);
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.52	-0.34	1.25e-5	Joint mobility (Beighton score);
PAAD	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg23283495	chr1:209979779	IRF6	0.62	5.82	0.43	3.4e-8	Coronary artery disease;
PAAD	cis	rs2718812	1.000	rs2718815	chr3:133398786	A/G	cg08048268	chr3:133502702	NA	0.43	5.24	0.39	5.18e-7	Iron status biomarkers;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.78	-5.12	-0.38	8.96e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.76	7.87	0.54	6.18e-13	Breast cancer;
PAAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	10.85	0.66	1.12e-20	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg09796270	chr17:17721594	SREBF1	-0.41	-4.45	-0.34	1.63e-5	Total body bone mineral density;
PAAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.69	-4.52	-0.34	1.23e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.78	10.14	0.64	8.9e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs16958440	0.867	rs80006910	chr18:44696382	C/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.6	-5.94	-0.43	1.85e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs13144136	0.687	rs6850317	chr4:10664294	T/C	cg10242279	chr4:10666415	CLNK	-0.47	-5.98	-0.44	1.54e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.67	-7.02	-0.49	6.98e-11	Total body bone mineral density;
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg00206168	chr11:65308501	LTBP3	0.86	5.68	0.42	6.58e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.24	0.51	2.07e-11	Morning vs. evening chronotype;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.11	0.44	8.04e-9	Height;
PAAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs6473252	0.584	rs735839	chr8:81808254	C/G	cg08595989	chr8:81827712	NA	-0.32	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs941408	0.964	rs1736195	chr19:2786557	C/T	cg11232448	chr19:2858854	NA	-0.5	-4.95	-0.37	1.94e-6	Total cholesterol levels;
PAAD	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs8037137	0.915	rs77554484	chr15:91509215	C/A	cg23684204	chr15:91497937	RCCD1	0.81	4.95	0.37	1.95e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs2562456	0.833	rs56187954	chr19:21528060	T/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.66	6.47	0.46	1.3e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs58521262	0.519	rs55903018	chr19:22991714	G/C	cg07749055	chr19:23076870	NA	-0.61	-4.57	-0.35	9.86e-6	Testicular germ cell tumor;
PAAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.72	8.89	0.59	1.61e-15	Coronary artery disease;
PAAD	cis	rs12431939	1.000	rs60818073	chr14:51696649	T/C	cg23942311	chr14:51606299	NA	-0.62	-4.83	-0.37	3.24e-6	Cancer;
PAAD	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg10395934	chr14:104002654	TRMT61A	-0.54	-5.75	-0.42	4.75e-8	Body mass index;
PAAD	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.77	8.32	0.56	4.79e-14	Blood metabolite levels;
PAAD	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.5	4.59	0.35	9.41e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.32e-9	Blood metabolite levels;
PAAD	cis	rs4950928	1.000	rs4950928	chr1:203155882	G/C	cg17014757	chr1:203156097	CHI3L1	-0.56	-5.72	-0.42	5.61e-8	YKL-40 levels;
PAAD	cis	rs10450586	0.932	rs10835158	chr11:27331770	A/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs838147	0.844	rs12982115	chr19:49248640	A/G	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.86	-0.49	1.64e-10	Life satisfaction;
PAAD	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	6.48	0.47	1.19e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg23033748	chr14:75592666	NEK9	-0.4	-4.8	-0.36	3.73e-6	Height;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.31	-0.33	2.97e-5	Lung cancer;
PAAD	cis	rs4906172	0.898	rs10135027	chr14:102497772	A/G	cg23904247	chr14:102554826	HSP90AA1	0.41	4.58	0.35	9.56e-6	Menopause (age at onset);
PAAD	cis	rs3818285	0.959	rs35420248	chr10:111643074	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.73	-7.14	-0.5	3.57e-11	Superior crus of antihelix expression;
PAAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.71	7.12	0.5	4.04e-11	Obesity-related traits;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg13264159	chr8:625131	ERICH1	-0.77	-5.25	-0.39	5.15e-7	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.55	5.45	0.4	1.99e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.7	-0.42	5.99e-8	Schizophrenia;
PAAD	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.6	-6.13	-0.45	7.3e-9	Ankylosing spondylitis;
PAAD	cis	rs17162190	0.605	rs9438626	chr1:26775367	G/C	cg17456097	chr1:26900765	RPS6KA1	0.54	4.4	0.34	2.04e-5	Mean corpuscular volume;
PAAD	trans	rs2919917	1.000	rs1466526	chr8:79555474	C/G	cg18585273	chr17:66197086	NA	0.6	6.31	0.46	2.86e-9	Lymphocyte counts;
PAAD	cis	rs943466	1.000	rs755495	chr6:33734128	A/G	cg04704449	chr6:33738291	NA	0.49	4.92	0.37	2.21e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.63	8.89	0.58	1.63e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs11718455	0.503	rs1404481	chr3:44006666	C/T	cg21419209	chr3:44054225	NA	-0.57	-6.36	-0.46	2.19e-9	Coronary artery disease;
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg16479474	chr6:28041457	NA	0.47	4.4	0.34	2.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg17470449	chr10:769945	NA	0.5	5.0	0.38	1.59e-6	Uric acid levels;
PAAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg21856205	chr7:94953877	PON1	-0.52	-4.32	-0.33	2.79e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg08029281	chr1:67600428	NA	0.45	5.47	0.41	1.85e-7	Psoriasis;
PAAD	cis	rs6074578	0.541	rs4813043	chr20:168728	A/T	cg16931068	chr20:139680	DEFB127	-0.41	-5.52	-0.41	1.42e-7	Hirschsprung disease;
PAAD	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02244288	chr16:89573955	SPG7	-0.31	-4.27	-0.33	3.48e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg16591659	chr17:78472290	NA	-0.46	-4.3	-0.33	3.02e-5	Fractional excretion of uric acid;
PAAD	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.84	8.43	0.56	2.46e-14	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23089227	chr13:76112973	COMMD6	-0.68	-7.34	-0.51	1.18e-11	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13614469	chr8:1787467	ARHGEF10	0.59	6.38	0.46	2.03e-9	Smoking initiation;
PAAD	trans	rs2725236	0.520	rs6818927	chr4:88907257	C/T	cg23656380	chr20:60877581	ADRM1	-0.64	-6.62	-0.47	5.81e-10	Caffeine consumption;
PAAD	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.47	-5.03	-0.38	1.35e-6	Age of smoking initiation;
PAAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12599982	chr1:44399894	ARTN	0.42	4.42	0.34	1.83e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg22040403	chr1:23858016	E2F2	0.67	4.45	0.34	1.65e-5	Total cholesterol levels;
PAAD	cis	rs600626	0.636	rs11236515	chr11:75451411	A/G	cg24262691	chr11:75473276	NA	0.81	6.41	0.46	1.74e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.74	7.34	0.51	1.21e-11	Menarche (age at onset);
PAAD	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg16591659	chr17:78472290	NA	-0.47	-4.42	-0.34	1.85e-5	Fractional excretion of uric acid;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-4.8	-0.36	3.84e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg03538708	chr1:25844672	NA	-0.49	-5.01	-0.38	1.52e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7326068	0.610	rs2013546	chr13:21386229	G/A	cg27499820	chr13:21296301	IL17D	0.53	4.8	0.36	3.78e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg19223190	chr17:80058835	NA	-0.52	-5.35	-0.4	3.18e-7	Life satisfaction;
PAAD	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.59	-5.72	-0.42	5.36e-8	Crohn's disease;
PAAD	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.59	-5.43	-0.4	2.21e-7	Total body bone mineral density;
PAAD	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.63	6.34	0.46	2.46e-9	Multiple sclerosis;
PAAD	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	10.62	0.65	4.69e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.35	-0.33	2.5e-5	Height;
PAAD	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.93	10.41	0.64	1.75e-19	Testicular germ cell tumor;
PAAD	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.35	4.51	0.34	1.28e-5	Calcium levels;
PAAD	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg04450456	chr4:17643702	FAM184B	0.5	5.59	0.41	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.66	-7.66	-0.53	2.02e-12	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18935396	chr17:4089136	ANKFY1	-0.69	-7.0	-0.49	7.87e-11	Obesity-related traits;
PAAD	trans	rs9982086	0.557	rs383700	chr21:27298769	A/G	cg04970570	chr5:87990145	NA	0.6	6.35	0.46	2.34e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg02580895	chr19:2754563	NA	-0.57	-4.85	-0.37	3.03e-6	Total cholesterol levels;
PAAD	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs13065560	0.594	rs4364115	chr3:38895359	C/T	cg01426195	chr3:39028469	NA	-0.48	-5.13	-0.38	8.57e-7	Interleukin-18 levels;
PAAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.56	0.65	6.85e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.62	5.07	0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-7.21	-0.5	2.47e-11	Colorectal cancer;
PAAD	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg18477163	chr1:228402036	OBSCN	-0.44	-4.57	-0.35	9.94e-6	Adult asthma;
PAAD	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.6	-6.11	-0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.32	-8.88	-0.58	1.79e-15	Diabetic retinopathy;
PAAD	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg18200150	chr17:30822561	MYO1D	0.8	12.34	0.71	1.09e-24	Schizophrenia;
PAAD	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.7	8.93	0.59	1.27e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02711726	chr17:80685570	FN3KRP	-0.52	-4.73	-0.36	5.12e-6	Glycated hemoglobin levels;
PAAD	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16090375	chr4:170913579	MFAP3L	-0.71	-7.48	-0.52	5.42e-12	Obesity-related traits;
PAAD	cis	rs73419609	1.000	rs73419641	chr15:54729592	A/T	cg11288833	chr15:55489084	RSL24D1	-1.0	-4.34	-0.33	2.57e-5	Post-traumatic stress disorder;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs1371614	0.632	rs6718978	chr2:27161591	G/A	cg00617064	chr2:27272375	NA	-0.41	-4.4	-0.34	2e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.45	-0.4	2.02e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.74	8.32	0.56	4.59e-14	Colorectal cancer;
PAAD	trans	rs901683	1.000	rs71494798	chr10:45998980	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	4.43	0.34	1.79e-5	Hip circumference;
PAAD	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg15956490	chr3:53032818	SFMBT1	0.78	4.37	0.33	2.27e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07400628	chr1:6761934	DNAJC11	0.61	6.78	0.48	2.5e-10	Myopia (pathological);
PAAD	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.84	-9.34	-0.6	1.16e-16	Mortality in heart failure;
PAAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21028142	chr17:79581711	NPLOC4	-0.58	-7.85	-0.54	6.96e-13	Eye color traits;
PAAD	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.71	6.86	0.49	1.67e-10	Platelet count;
PAAD	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs11696501	0.688	rs6073834	chr20:44279989	C/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15168842	chr8:144766844	ZNF707	-0.74	-6.47	-0.46	1.28e-9	Neuroticism;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.35	0.33	2.5e-5	Renal cell carcinoma;
PAAD	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg12092346	chr18:77659572	KCNG2	-0.6	-4.32	-0.33	2.77e-5	Opioid sensitivity;
PAAD	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.47	-5.04	-0.38	1.33e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg26318627	chr11:63887540	MACROD1	-0.44	-4.34	-0.33	2.57e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12906542	0.516	rs16969422	chr15:78326199	T/C	cg23683012	chr15:78369302	TBC1D2B	0.69	5.15	0.39	8.04e-7	Breast cancer;
PAAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.92	-10.09	-0.63	1.21e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg23024343	chr7:107201750	COG5	0.58	4.46	0.34	1.57e-5	Coronary artery disease;
PAAD	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg06713675	chr4:122721982	EXOSC9	0.47	4.59	0.35	9.21e-6	Type 2 diabetes;
PAAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.96e-6	HDL cholesterol;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.85	0.54	6.74e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.9	8.77	0.58	3.38e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg14580859	chr9:123691850	NA	0.41	4.49	0.34	1.39e-5	Rheumatoid arthritis;
PAAD	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-1.1	-11.75	-0.69	4.46e-23	Hip circumference adjusted for BMI;
PAAD	cis	rs2120461	0.517	rs754346	chr1:8433747	T/C	cg23262827	chr1:8395557	SLC45A1	-0.46	-4.29	-0.33	3.13e-5	Bone mineral density;
PAAD	cis	rs4908768	0.501	rs6677736	chr1:8552804	A/T	cg20416874	chr1:8611966	RERE	-0.46	-4.48	-0.34	1.45e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs60617249	0.542	rs7779063	chr7:50933039	A/G	cg15805451	chr7:51135775	COBL	-0.43	-4.61	-0.35	8.32e-6	Major depression and alcohol dependence;
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-4.57	-0.35	1e-5	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02891801	chr12:6472782	SCNN1A	0.68	7.81	0.54	8.91e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg14515779	chr1:101123966	NA	0.39	4.26	0.33	3.54e-5	Monocyte count;
PAAD	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4906332	1.000	rs911549	chr14:103984537	T/C	cg26031613	chr14:104095156	KLC1	0.44	4.35	0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-6.96	-0.49	9.3e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs2645694	0.569	rs11097584	chr4:77836059	C/T	cg10057126	chr4:77819792	ANKRD56	0.69	5.57	0.41	1.14e-7	Emphysema distribution in smoking;
PAAD	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg09659197	chr4:152720779	NA	-0.42	-5.63	-0.42	8.39e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg09339527	chr5:178322752	ZFP2	-0.43	-4.52	-0.34	1.24e-5	Sleep duration;
PAAD	cis	rs12042938	0.935	rs751229	chr1:231768539	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	4.85	0.37	3.09e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs13033859	0.602	rs7605004	chr2:199502	G/T	cg12623918	chr2:306882	NA	0.46	4.53	0.34	1.21e-5	Mitochondrial DNA levels;
PAAD	trans	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.42	0.46	1.62e-9	Calcium levels;
PAAD	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.52	-4.76	-0.36	4.5e-6	Schizophrenia;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.57	-5.17	-0.39	7.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs10267417	0.603	rs4721831	chr7:19876769	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	4.5	0.34	1.32e-5	Night sleep phenotypes;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs75920871	1.000	rs79974099	chr11:116802581	T/A	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	0.86	6.11	0.44	7.9e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.76	-5.28	-0.39	4.34e-7	Red cell distribution width;
PAAD	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26926768	chr12:34528122	NA	0.37	4.58	0.35	9.79e-6	Morning vs. evening chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23372537	chr19:10138480	NA	-0.58	-7.17	-0.5	3.11e-11	Body fat percentage;
PAAD	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	1.05	9.47	0.61	5.24e-17	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16974379	chr10:38146505	ZNF248	0.61	6.93	0.49	1.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs593531	0.614	rs486758	chr11:74058932	C/T	cg15851278	chr11:73669449	DNAJB13	-0.39	-4.62	-0.35	7.98e-6	Neuroticism;
PAAD	cis	rs642743	0.967	rs527154	chr10:105943683	C/G	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.31	0.33	2.9e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-4.68	-0.35	6.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg21951975	chr1:209979733	IRF6	0.5	4.85	0.37	3.07e-6	Coronary artery disease;
PAAD	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg26138144	chr22:38071188	LGALS1	0.44	4.85	0.37	3.04e-6	Fat distribution (HIV);
PAAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-6.71	-0.48	3.54e-10	Personality dimensions;
PAAD	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.72	-7.45	-0.52	6.38e-12	DNA methylation (variation);
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.94	8.38	0.56	3.31e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.41	-5.35	-0.4	3.17e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs73019876	0.869	rs10408274	chr19:22144930	C/T	cg11619707	chr19:22235551	ZNF257	-0.4	-4.4	-0.34	2.04e-5	Testicular germ cell tumor;
PAAD	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.5e-9	Hepatitis;
PAAD	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg23985595	chr17:80112537	CCDC57	0.53	6.89	0.49	1.36e-10	Life satisfaction;
PAAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg19630374	chr17:18023558	MYO15A	0.46	4.94	0.37	2.03e-6	Total body bone mineral density;
PAAD	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.35	-0.33	2.5e-5	Neuroticism;
PAAD	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.23	0.45	4.3e-9	Hip circumference;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.17	-0.39	7.16e-7	Pulmonary function;
PAAD	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg20503657	chr10:835505	NA	0.54	5.67	0.42	7.03e-8	Survival in rectal cancer;
PAAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.51	-5.92	-0.43	2.04e-8	Breast cancer;
PAAD	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg14092571	chr14:90743983	NA	-0.52	-4.99	-0.37	1.67e-6	Mortality in heart failure;
PAAD	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.61	5.4	0.4	2.49e-7	Height;
PAAD	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.66	7.34	0.51	1.21e-11	Corneal astigmatism;
PAAD	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-6.47	-0.46	1.25e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.91	-0.63	3.52e-18	Tonsillectomy;
PAAD	cis	rs9815354	1.000	rs9848754	chr3:41753647	C/T	cg03022575	chr3:42003672	ULK4	0.84	5.85	0.43	2.88e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs9636436	0.635	rs75654459	chr2:49538074	G/A	cg09044294	chr2:50234533	NRXN1	0.43	4.54	0.35	1.16e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6466055	0.720	rs12668097	chr7:104996472	A/G	cg04380332	chr7:105027541	SRPK2	0.65	7.28	0.51	1.67e-11	Schizophrenia;
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.89	9.32	0.6	1.27e-16	Asthma;
PAAD	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.84	7.39	0.51	8.94e-12	Phospholipid levels (plasma);
PAAD	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.92	-0.37	2.27e-6	Recombination measurement;
PAAD	cis	rs76793172	1.000	rs75504740	chr19:46313376	G/A	cg13320842	chr19:46175254	GIPR	0.59	4.49	0.34	1.4e-5	Eosinophil counts;
PAAD	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05625889	chr1:25944100	MAN1C1	0.56	6.4	0.46	1.83e-9	Monocyte percentage of white cells;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.59	6.29	0.45	3.29e-9	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs115391636	chr10:46012045	C/T	cg23720331	chr10:123873670	TACC2	-0.84	-6.63	-0.47	5.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.01	13.83	0.75	1.1e-28	Heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19611418	chr2:131851282	FAM168B	0.65	6.34	0.46	2.52e-9	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.84	7.99	0.54	3.07e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.83	-9.23	-0.6	2.17e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.73	-7.44	-0.52	6.74e-12	Retinal vascular caliber;
PAAD	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs3026101	0.671	rs14231	chr17:5294976	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.53	5.81	0.43	3.53e-8	Obesity-related traits;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.35	-4.31	-0.33	2.86e-5	Pubertal anthropometrics;
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs595018	0.505	rs72916908	chr11:60601423	C/T	cg23904249	chr11:60608951	CCDC86	0.69	4.95	0.37	1.95e-6	Wegener's granulomatosis;
PAAD	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.59	5.64	0.42	8.23e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs61884328	0.789	rs56904688	chr11:46857504	T/C	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg03909863	chr11:638404	DRD4	-0.6	-5.45	-0.4	1.94e-7	Systemic lupus erythematosus;
PAAD	cis	rs12935418	0.672	rs9934957	chr16:81049683	C/T	cg16651780	chr16:81037892	C16orf61	-0.69	-6.5	-0.47	1.09e-9	Mean corpuscular volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27194164	chr19:17666205	GLT25D1	0.57	6.56	0.47	8.04e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg02117656	chr17:79614917	TSPAN10	0.58	6.33	0.46	2.67e-9	Eye color traits;
PAAD	cis	rs4144027	0.791	rs66473563	chr14:104361871	C/T	cg12183467	chr14:104352244	NA	0.35	4.43	0.34	1.77e-5	Blood metabolite levels;
PAAD	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-5.54	-0.41	1.28e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg18833306	chr6:118973337	C6orf204	0.43	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg15556689	chr8:8085844	FLJ10661	-0.72	-7.31	-0.51	1.38e-11	Neuroticism;
PAAD	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.79	-5.34	-0.4	3.4e-7	Coronary artery calcification;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.5	4.97	0.37	1.78e-6	Height;
PAAD	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14019695	chr9:139328340	INPP5E	0.58	4.91	0.37	2.35e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2900174	0.793	rs11054280	chr12:11560012	T/C	cg25373614	chr12:11548019	PRB2	-1.14	-4.62	-0.35	8.03e-6	Survival in pancreatic cancer;Response to gemcitabine in pancreatic cancer;
PAAD	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.71e-14	Dupuytren's disease;
PAAD	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.36	-4.45	-0.34	1.64e-5	Cognitive performance;
PAAD	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg16386425	chr10:429943	DIP2C	-0.4	-4.28	-0.33	3.34e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs730566	0.714	rs2889854	chr3:48268509	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.68	6.48	0.47	1.2e-9	Prion diseases;
PAAD	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.62	5.88	0.43	2.48e-8	Plateletcrit;Platelet count;
PAAD	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs11681884	0.892	rs112189581	chr2:113852913	T/C	cg06156847	chr2:113672199	IL1F7	-0.74	-4.26	-0.33	3.56e-5	Stroke;
PAAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.53e-7	Total body bone mineral density;
PAAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-9.16	-0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs3857067	0.933	rs10023582	chr4:95035811	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-4.27	-0.33	3.46e-5	QT interval;
PAAD	cis	rs57244997	0.725	rs61574422	chr6:162425056	T/C	cg17173639	chr6:162384350	PARK2	-0.68	-5.07	-0.38	1.13e-6	Mosquito bite size;
PAAD	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.66	0.48	4.81e-10	IgG glycosylation;
PAAD	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg10518543	chr12:38710700	ALG10B	-0.46	-4.29	-0.33	3.18e-5	Morning vs. evening chronotype;
PAAD	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg16329197	chr12:53359506	NA	-0.99	-6.23	-0.45	4.35e-9	Prostate cancer;
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.81	0.58	2.6e-15	Lung cancer;
PAAD	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg15585409	chr19:12750806	NA	-0.47	-4.25	-0.33	3.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10565270	chr11:71498202	FAM86C	-0.75	-7.46	-0.52	6.13e-12	Lung cancer in ever smokers;
PAAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs67397200	0.632	rs11666308	chr19:17437744	T/C	cg04749549	chr19:17459798	NA	-0.4	-4.68	-0.35	6.29e-6	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.7	6.14	0.45	7.04e-9	Triglycerides;
PAAD	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	1.07	6.79	0.48	2.42e-10	Skin colour saturation;
PAAD	cis	rs735539	0.521	rs9552278	chr13:21352318	C/T	cg27234864	chr13:21295941	IL17D	0.58	4.63	0.35	7.68e-6	Dental caries;
PAAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.78	-7.8	-0.53	9.19e-13	Coronary artery disease;
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.73	8.55	0.57	1.25e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23675362	chr1:180601130	XPR1	0.75	8.34	0.56	4.14e-14	Obesity-related traits;
PAAD	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.05	0.38	1.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg11874272	chr3:121773564	CD86	-0.42	-4.39	-0.34	2.14e-5	Multiple sclerosis;
PAAD	cis	rs2464469	0.526	rs11071363	chr15:58333961	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.38	-0.33	2.18e-5	Barrett's esophagus  or Esophageal adenocarcinoma;
PAAD	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg16553119	chr1:165599451	MGST3	-0.57	-4.6	-0.35	9e-6	Total ventricular volume;
PAAD	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.72	7.54	0.52	3.9e-12	Schizophrenia;
PAAD	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.52	4.99	0.37	1.66e-6	High light scatter reticulocyte count;
PAAD	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-5.88	-0.43	2.45e-8	Menarche (age at onset);
PAAD	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	5.83	0.43	3.19e-8	Rheumatoid arthritis;
PAAD	cis	rs735539	0.521	rs509099	chr13:21453738	G/A	cg27234864	chr13:21295941	IL17D	0.59	4.81	0.36	3.65e-6	Dental caries;
PAAD	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.63	6.15	0.45	6.62e-9	Bone properties (heel);
PAAD	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.2e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.8	0.53	9.32e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2996428	0.778	rs1891934	chr1:3694796	G/A	cg17443473	chr1:3703550	LRRC47	0.43	4.32	0.33	2.81e-5	Red cell distribution width;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00316677	chr5:151151425	G3BP1	-0.74	-6.31	-0.46	2.84e-9	Neuroticism;
PAAD	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.62	5.86	0.43	2.73e-8	Vitamin D levels;
PAAD	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.81	6.09	0.44	8.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13148126	chr17:8924759	NTN1	0.58	6.39	0.46	1.89e-9	Monocyte percentage of white cells;
PAAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18854424	chr1:2615690	NA	0.43	5.44	0.4	2.11e-7	Ulcerative colitis;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.96	11.8	0.69	3.28e-23	Bone mineral density;
PAAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14639822	chr9:136131484	ABO	0.65	6.56	0.47	8.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs375066	0.935	rs446674	chr19:44421007	G/A	cg08633290	chr19:44405433	NA	-0.55	-5.42	-0.4	2.31e-7	Breast cancer;
PAAD	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21646471	chr2:242523971	THAP4	0.5	4.32	0.33	2.86e-5	Prostate cancer;
PAAD	cis	rs13053817	1.000	rs7290855	chr22:29852474	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.56	-4.88	-0.37	2.67e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.51	-0.47	1.03e-9	Aortic root size;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg00666640	chr1:248458726	OR2T12	0.47	4.92	0.37	2.27e-6	Common traits (Other);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22092082	chr2:191184568	HIBCH	-0.74	-6.48	-0.47	1.2e-9	Neuroticism;
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg11859384	chr17:80120422	CCDC57	-0.47	-4.77	-0.36	4.28e-6	Life satisfaction;
PAAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg00794529	chr3:52445096	PHF7;BAP1	-0.49	-4.39	-0.34	2.1e-5	Height;
PAAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.69	7.16	0.5	3.31e-11	Colorectal cancer;
PAAD	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.35	-0.4	3.13e-7	Obesity-related traits;
PAAD	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	4.98	0.37	1.73e-6	Mean platelet volume;
PAAD	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-6.02	-0.44	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg12126869	chr10:346505	DIP2C	-0.81	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	4.28	0.33	3.34e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs1105228	1.000	rs584013	chr6:165709926	C/T	cg20535254	chr6:165714960	C6orf118	-0.51	-5.06	-0.38	1.19e-6	Number of pregnancies;Number of children;
PAAD	cis	rs6921542	0.861	rs9372987	chr6:131360522	G/T	cg17329834	chr6:131380543	EPB41L2	0.48	4.36	0.33	2.39e-5	Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.53	5.08	0.38	1.07e-6	Motion sickness;
PAAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg01320130	chr1:67600311	NA	0.56	5.81	0.43	3.52e-8	Psoriasis;
PAAD	cis	rs6594713	0.921	rs7725712	chr5:112744642	T/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg13777783	chr17:79615861	NA	0.4	4.28	0.33	3.31e-5	Eye color traits;
PAAD	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.54	-0.35	1.12e-5	Educational attainment (years of education);
PAAD	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2271400	0.556	rs11986852	chr8:56654061	C/G	cg08894788	chr8:56792171	LYN	-0.5	-4.76	-0.36	4.48e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.66	-7.49	-0.52	5.37e-12	Lung cancer;
PAAD	cis	rs6466055	0.720	rs6466057	chr7:104952483	A/G	cg04380332	chr7:105027541	SRPK2	0.65	7.37	0.51	1.04e-11	Schizophrenia;
PAAD	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg13293535	chr8:11597251	GATA4	0.32	4.29	0.33	3.15e-5	Neuroticism;
PAAD	cis	rs1364705	1.000	rs12675172	chr8:120222625	G/A	cg09273054	chr8:120220131	MAL2	0.43	4.77	0.36	4.27e-6	Hippocampal atrophy;
PAAD	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs6011674	0.803	rs6011692	chr20:61867828	G/A	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.75	-4.61	-0.35	8.32e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.75	-7.98	-0.54	3.23e-13	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3213545	0.645	rs2859398	chr12:121479655	T/C	cg02403541	chr12:121454288	C12orf43	0.58	6.21	0.45	4.72e-9	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg14132834	chr19:41945861	ATP5SL	0.52	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.77	-0.36	4.23e-6	Renal cell carcinoma;
PAAD	cis	rs13242816	1.000	rs13226307	chr7:116137485	A/T	cg16553024	chr7:116138462	CAV2	0.72	4.81	0.36	3.63e-6	P wave duration;
PAAD	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-18.17	-0.83	6.2e-40	Exhaled nitric oxide output;
PAAD	cis	rs2814982	0.514	rs76499914	chr6:34469263	C/T	cg17674042	chr6:34482479	PACSIN1	-0.96	-7.32	-0.51	1.33e-11	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.61	6.71	0.48	3.6e-10	Height;
PAAD	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.03	-0.38	1.39e-6	Corneal astigmatism;
PAAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.51	4.76	0.36	4.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg00173435	chr12:106696525	TCP11L2	0.57	5.22	0.39	5.71e-7	Tourette syndrome;
PAAD	cis	rs57786342	0.853	rs72731564	chr14:69280158	C/T	cg03189333	chr14:69283534	NA	-0.61	-4.4	-0.34	1.99e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.71	-0.42	5.83e-8	Schizophrenia;
PAAD	cis	rs672059	1.000	rs3120034	chr1:183167051	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	4.32	0.33	2.81e-5	Hypertriglyceridemia;
PAAD	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-4.67	-0.35	6.44e-6	Educational attainment (years of education);
PAAD	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.78	7.19	0.5	2.78e-11	Obesity-related traits;
PAAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.99	-0.44	1.46e-8	Joint mobility (Beighton score);
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02071572	chr4:1403502	NA	0.35	4.35	0.33	2.5e-5	Longevity;
PAAD	cis	rs4077515	0.743	rs3812571	chr9:139275294	G/C	cg14169450	chr9:139327907	INPP5E	0.57	5.86	0.43	2.71e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.49	-4.78	-0.36	4.09e-6	Obesity-related traits;
PAAD	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.93	7.54	0.52	4e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.89	8.48	0.57	1.81e-14	Response to diuretic therapy;
PAAD	cis	rs6688613	1.000	rs11578336	chr1:166958710	T/G	cg07049167	chr1:166818506	POGK	0.46	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.46	5.05	0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.32	4.76	0.36	4.43e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg10729496	chr3:10149963	C3orf24	0.88	7.25	0.51	1.94e-11	Alzheimer's disease;
PAAD	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	6.17	0.45	6.01e-9	Body mass index;
PAAD	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.88	10.89	0.66	8.96e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.43	5.12	0.38	9e-7	Systemic lupus erythematosus;
PAAD	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-5.19	-0.39	6.72e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.31	0.4	3.8e-7	Diabetic kidney disease;
PAAD	cis	rs77956314	0.901	rs117425351	chr12:117409752	A/G	cg02017074	chr12:117425053	FBXW8	-1.07	-5.1	-0.38	1e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg05110241	chr16:68378359	PRMT7	-0.91	-7.11	-0.5	4.25e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8040855	0.794	rs4843024	chr15:85705900	A/G	cg08123816	chr15:85640762	PDE8A	0.38	4.35	0.33	2.48e-5	Bulimia nervosa;
PAAD	cis	rs10791323	0.604	rs7928888	chr11:133703696	A/C	cg06766960	chr11:133703094	NA	-0.72	-8.09	-0.55	1.76e-13	Childhood ear infection;
PAAD	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg17971929	chr21:40555470	PSMG1	0.7	5.95	0.43	1.75e-8	Cognitive function;
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.73	-8.92	-0.59	1.42e-15	Vitiligo;
PAAD	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	1.06	8.27	0.56	6.09e-14	Menopause (age at onset);
PAAD	cis	rs4144743	1.000	rs67923812	chr17:45326151	T/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.58	5.58	0.41	1.08e-7	Lung cancer;
PAAD	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	1.02	9.23	0.6	2.14e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs10516089	0.504	rs13359217	chr5:171141491	G/T	cg21066063	chr5:171570130	STK10	-0.35	-4.47	-0.34	1.53e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.76	6.95	0.49	9.8e-11	Homoarginine levels;
PAAD	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg24966363	chr8:8932588	NA	-0.37	-4.48	-0.34	1.48e-5	Cervical cancer;
PAAD	cis	rs4455778	0.580	rs4607559	chr7:49121902	G/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.69	-7.82	-0.54	8.07e-13	Heart rate;
PAAD	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.64	6.13	0.45	7.07e-9	Blood metabolite levels;
PAAD	cis	rs2834902	0.633	rs2834899	chr21:36685788	A/G	cg04915566	chr21:36421472	RUNX1	-0.36	-4.66	-0.35	6.9e-6	Corneal curvature;
PAAD	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.56	-0.41	1.17e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg04315214	chr1:2043799	PRKCZ	0.66	9.29	0.6	1.57e-16	Height;
PAAD	cis	rs2282930	0.801	rs2237468	chr7:50734362	A/G	cg07379434	chr7:49814597	VWC2	-0.27	-4.69	-0.36	6.11e-6	Bone mineral density;
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg14515779	chr1:101123966	NA	-0.49	-6.23	-0.45	4.3e-9	Monocyte count;
PAAD	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.66	7.13	0.5	3.7e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.71	7.19	0.5	2.8e-11	Lymphocyte percentage of white cells;
PAAD	cis	rs2562152	0.744	rs216597	chr16:106777	G/C	cg02949481	chr16:131562	MPG	0.75	6.35	0.46	2.36e-9	Glioblastoma;
PAAD	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06850241	chr22:41845214	NA	-0.49	-4.26	-0.33	3.55e-5	Vitiligo;
PAAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.81	-9.35	-0.6	1.09e-16	Ulcerative colitis;
PAAD	cis	rs4740619	0.689	rs12379234	chr9:15932372	G/A	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs13382275	0.632	rs6548283	chr2:941534	A/C	cg21195176	chr2:593345	NA	0.53	4.34	0.33	2.57e-5	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	5.35	0.4	3.14e-7	Height;
PAAD	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg20673841	chr7:107026890	COG5	0.48	4.36	0.33	2.41e-5	Coronary artery disease;
PAAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.94	10.19	0.64	6.77e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.6	6.17	0.45	5.94e-9	Migraine;
PAAD	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.42	0.34	1.89e-5	Eye color traits;
PAAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.7	0.36	5.84e-6	Bipolar disorder;
PAAD	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.88	11.2	0.67	1.32e-21	Prudent dietary pattern;
PAAD	cis	rs6594713	0.679	rs34147627	chr5:112948161	G/A	cg12552261	chr5:112820674	MCC	0.7	4.71	0.36	5.44e-6	Brain cytoarchitecture;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6e-8	Life satisfaction;
PAAD	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.81	6.84	0.49	1.78e-10	Morning vs. evening chronotype;
PAAD	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg00666640	chr1:248458726	OR2T12	0.47	4.75	0.36	4.64e-6	Common traits (Other);
PAAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.14	-0.6	3.79e-16	Mean platelet volume;
PAAD	cis	rs6028335	0.674	rs61213966	chr20:37621906	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.51	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.61	-0.35	8.63e-6	Red blood cell traits;
PAAD	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg03538708	chr1:25844672	NA	-0.51	-5.19	-0.39	6.55e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg09222892	chr1:25734099	RHCE	-0.44	-4.27	-0.33	3.44e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.72	6.34	0.46	2.46e-9	Platelet count;
PAAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.66	-6.63	-0.47	5.44e-10	Uric acid levels;
PAAD	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.7	4.46	0.34	1.61e-5	White matter integrity;
PAAD	cis	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg21546286	chr11:48923668	NA	-0.53	-5.41	-0.4	2.44e-7	HDL cholesterol;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25915536	chr15:67074303	SMAD6	0.63	6.3	0.46	3.03e-9	Lung cancer in ever smokers;
PAAD	cis	rs8014252	0.803	rs74062746	chr14:71024944	A/G	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.87	12.08	0.7	5.47e-24	Vitiligo;
PAAD	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.6	-6.57	-0.47	7.45e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.9	6.46	0.46	1.35e-9	Height;
PAAD	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22162314	chr17:61951766	CSH2	-0.57	-5.95	-0.43	1.79e-8	Height;
PAAD	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9649465	1.000	rs2299982	chr7:123356511	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg22792862	chr14:67827087	EIF2S1;ATP6V1D	0.67	6.31	0.46	2.89e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15172601	chr10:62538042	CDK1;CDC2	0.63	6.66	0.48	4.75e-10	Myopia (pathological);
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.813	rs12700830	chr7:27688859	T/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-7.46	-0.52	6.11e-12	Prostate cancer;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg02463844	chr16:88152170	NA	0.31	5.14	0.39	8.16e-7	Menopause (age at onset);
PAAD	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.37	0.56	3.46e-14	Coffee consumption (cups per day);
PAAD	cis	rs9815354	0.812	rs13084436	chr3:42017537	T/A	cg03022575	chr3:42003672	ULK4	-0.71	-4.98	-0.37	1.68e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs593531	0.571	rs11236087	chr11:74094138	C/T	cg23327896	chr11:73669290	DNAJB13	0.38	5.03	0.38	1.34e-6	Neuroticism;
PAAD	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.56	-5.78	-0.42	4e-8	Metabolic syndrome;
PAAD	cis	rs2295359	0.697	rs11209017	chr1:67666235	A/T	cg08029281	chr1:67600428	NA	0.43	5.05	0.38	1.27e-6	Psoriasis;
PAAD	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.47	-5.6	-0.41	9.84e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg27124370	chr19:33622961	WDR88	0.49	4.54	0.35	1.15e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	1.01	7.62	0.53	2.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs59888335	0.895	rs1474204	chr3:80852741	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs4280164	0.945	rs11158632	chr14:24769663	A/C	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.38	-0.4	2.74e-7	Daytime sleep phenotypes;
PAAD	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.66	-6.08	-0.44	9.11e-9	Blood metabolite levels;
PAAD	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg13332499	chr17:408570	NA	0.64	7.11	0.5	4.27e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16857609	0.600	rs4674179	chr2:218310686	C/A	cg15335768	chr2:218268053	DIRC3	-0.47	-4.79	-0.36	3.9e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg11764359	chr7:65958608	NA	-0.75	-4.96	-0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg11802864	chr11:65308245	LTBP3	0.48	4.84	0.37	3.15e-6	Bone mineral density;
PAAD	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.58	6.08	0.44	9.17e-9	Longevity;
PAAD	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.35	-0.51	1.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg01489256	chr8:11204017	TDH	-0.44	-4.26	-0.33	3.61e-5	Retinal vascular caliber;
PAAD	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.55	5.95	0.43	1.76e-8	Bladder cancer;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08677398	chr8:58056175	NA	0.62	4.63	0.35	7.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.14e-8	Life satisfaction;
PAAD	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg09659197	chr4:152720779	NA	0.5	6.84	0.49	1.81e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3736485	0.934	rs882385	chr15:51882369	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14375640	chr9:131937121	NA	0.66	6.33	0.46	2.67e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.12	-0.38	9.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8067354	0.574	rs7219089	chr17:58032865	C/T	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.62	-0.65	4.77e-20	Late-onset Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs35626777	chr10:46088167	G/C	cg14076390	chr17:34947837	DHRS11	0.92	6.67	0.48	4.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs757081	0.658	rs214069	chr11:17305600	G/A	cg04705435	chr11:17411270	KCNJ11	-0.57	-6.08	-0.44	9.35e-9	Systolic blood pressure;
PAAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.64	5.01	0.38	1.48e-6	Alzheimer's disease (survival time);
PAAD	cis	rs5009270	0.512	rs6977807	chr7:112249863	C/T	cg23628563	chr7:112262597	NA	0.65	5.69	0.42	6.4e-8	Osteoarthritis (hip);
PAAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.29	-0.33	3.1e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.59	-6.61	-0.47	6.18e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.57	6.17	0.45	5.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg02376097	chr19:46275166	DMPK	0.66	8.25	0.56	7.11e-14	Coronary artery disease;
PAAD	cis	rs730532	0.597	rs57847444	chr14:52504950	T/C	cg10149976	chr14:52535953	NID2	-0.66	-5.17	-0.39	7.28e-7	Pulmonary function;
PAAD	cis	rs4792901	0.802	rs2242598	chr17:41610398	C/T	cg05614735	chr17:40936078	WNK4	-0.37	-4.31	-0.33	2.96e-5	Dupuytren's disease;
PAAD	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	4.62	0.35	8.25e-6	Subjective well-being;
PAAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.19	-0.5	2.8e-11	Gut microbiome composition (summer);
PAAD	cis	rs6076065	0.723	rs2253924	chr20:23388020	G/A	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg08132940	chr7:1081526	C7orf50	-0.57	-4.25	-0.33	3.78e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs13102973	0.640	rs11737779	chr4:135831516	C/T	cg14419869	chr4:135874104	NA	0.45	4.58	0.35	9.8200000000000008e-06	Subjective well-being;
PAAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.6	-7.98	-0.54	3.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.29	-0.33	3.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg20913747	chr6:44695427	NA	-0.56	-5.93	-0.43	1.95e-8	Total body bone mineral density;
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg15691649	chr6:25882328	NA	0.51	4.54	0.35	1.12e-5	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00292662	chr22:38071168	LGALS1	0.64	6.77	0.48	2.66e-10	Fat distribution (HIV);
PAAD	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.93e-6	Breast cancer;
PAAD	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.97	12.01	0.7	8.58e-24	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs553086	0.592	rs646146	chr11:56910972	A/G	cg01427848	chr11:56972618	NA	-0.42	-4.28	-0.33	3.31e-5	Fear of severe pain;
PAAD	cis	rs71520386	0.898	rs12536144	chr7:22822509	G/A	cg04907244	chr7:22894795	SNORD93	0.5	4.3	0.33	3e-5	Fibrinogen levels;
PAAD	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.88	6.8	0.48	2.3e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs13396519	1.000	rs13405250	chr2:11039965	G/A	cg04169469	chr2:10588434	ODC1;SNORA80B	-0.7	-4.42	-0.34	1.87e-5	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
PAAD	cis	rs11700980	0.551	rs11701759	chr21:30115571	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs425535	0.757	rs164617	chr4:74796915	A/G	cg01447579	chr4:74847100	PF4	0.66	4.32	0.33	2.86e-5	Blood protein levels;
PAAD	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.84	5.73	0.42	5.35e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.78	8.8	0.58	2.8e-15	Heart rate;
PAAD	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg23188684	chr11:67383651	NA	-0.4	-4.25	-0.33	3.72e-5	Mean corpuscular volume;
PAAD	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg04359828	chr10:32216031	ARHGAP12	0.27	4.28	0.33	3.3e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.85	7.8	0.53	9.18e-13	Response to diuretic therapy;
PAAD	cis	rs308971	0.563	rs307560	chr3:12093405	A/G	cg02700894	chr3:12045449	SYN2	0.62	4.48	0.34	1.46e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.5	2.51e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg05215272	chr17:6899095	ALOX12	0.39	4.39	0.34	2.09e-5	Tonsillectomy;
PAAD	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs17125944	0.686	rs7158114	chr14:53353471	C/G	cg00686598	chr14:53173677	PSMC6	-0.85	-5.25	-0.39	4.97e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.82	-9.87	-0.62	4.71e-18	Brugada syndrome;
PAAD	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg13535736	chr9:111863775	C9orf5	-0.37	-4.71	-0.36	5.55e-6	Menarche (age at onset);
PAAD	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2051773	0.567	rs6486348	chr11:17057774	T/C	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.78	-6.96	-0.49	9.35e-11	Blood pressure (smoking interaction);
PAAD	trans	rs13196614	1.000	rs13198941	chr6:148933523	T/C	cg03938110	chr21:31120485	NCRNA00110;GRIK1	0.68	6.29	0.45	3.14e-9	Migraine;
PAAD	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	-0.95	-5.07	-0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg03651054	chr13:50194643	NA	0.39	5.45	0.4	2.02e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.8	-0.43	3.75e-8	Mood instability;
PAAD	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	1.12	14.73	0.77	4.45e-31	Migraine;
PAAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg23957660	chr17:17878224	LRRC48	0.37	4.32	0.33	2.77e-5	Total body bone mineral density;
PAAD	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg01320130	chr1:67600311	NA	0.56	5.81	0.43	3.52e-8	Psoriasis;
PAAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.63	-0.47	5.64e-10	Mood instability;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.75	6.82	0.48	1.99e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg20913747	chr6:44695427	NA	-0.58	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22817421	chr14:95623838	FLJ45244;DICER1	-0.73	-6.4	-0.46	1.85e-9	Neuroticism;
PAAD	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg20085588	chr10:81316188	SFTPA2	0.4	4.27	0.33	3.41e-5	Post bronchodilator FEV1;
PAAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg09835421	chr16:68378352	PRMT7	-1.14	-8.15	-0.55	1.24e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.84e-19	Tonsillectomy;
PAAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg11214544	chr1:2391121	NA	-0.61	-6.49	-0.47	1.14e-9	Schizophrenia;
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.58	-7.82	-0.54	8.39e-13	Height;
PAAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14169450	chr9:139327907	INPP5E	0.54	4.79	0.36	4.01e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.59	5.34	0.4	3.26e-7	Cleft lip with or without cleft palate;
PAAD	trans	rs901683	0.850	rs12778143	chr10:46063540	T/C	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg02023728	chr11:77925099	USP35	-0.44	-4.45	-0.34	1.68e-5	Alzheimer's disease (survival time);
PAAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs2882667	0.587	rs825674	chr5:138102720	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.98	-0.44	1.56e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.83	9.46	0.61	5.67e-17	Total body bone mineral density;
PAAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24229701	chr12:130821962	PIWIL1	0.41	4.29	0.33	3.21e-5	Menopause (age at onset);
PAAD	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg22189786	chr22:42395067	WBP2NL	0.63	6.12	0.44	7.43e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7816613	0.831	rs7821561	chr8:102702161	G/A	cg20585841	chr8:102729926	NCALD	-0.65	-6.25	-0.45	3.89e-9	Age-related hearing impairment;
PAAD	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.07	10.52	0.65	8.52e-20	Red cell distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13841373	chr1:8484084	RERE	0.63	7.03	0.5	6.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.77	0.36	4.21e-6	Birth weight;
PAAD	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg19680485	chr15:31195859	MTMR15	-0.49	-4.84	-0.37	3.18e-6	Huntington's disease progression;
PAAD	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-6.17	-0.45	5.8e-9	Monocyte percentage of white cells;
PAAD	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	8.07e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14019695	chr9:139328340	INPP5E	0.48	4.49	0.34	1.4e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.47	-5.27	-0.39	4.53e-7	Body mass index;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.6	-6.44	-0.46	1.47e-9	Lymphocyte counts;
PAAD	cis	rs7594192	0.744	rs6736290	chr2:199367709	A/T	cg03163783	chr2:200326591	SATB2	0.33	4.4	0.34	2.02e-5	Educational attainment;
PAAD	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.67	8.76	0.58	3.55e-15	Birth weight;
PAAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.92	5.01	0.38	1.52e-6	Childhood ear infection;
PAAD	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.93	-0.37	2.17e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1468734	0.927	rs4786566	chr16:5001029	A/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.58	-0.35	9.75e-6	Cancer;
PAAD	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.06	-0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs2252790	1.000	rs13214667	chr6:116637440	G/A	cg18764771	chr6:116381957	FRK	0.25	4.35	0.33	2.52e-5	Fast beta electroencephalogram;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07877852	chr6:110012591	AKD1;FIG4	-0.83	-7.21	-0.5	2.47e-11	Neuroticism;
PAAD	cis	rs17209837	1.000	rs7802555	chr7:87130350	A/C	cg00919237	chr7:87102261	ABCB4	-0.74	-4.86	-0.37	2.87e-6	Gallbladder cancer;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22162314	chr17:61951766	CSH2	0.58	5.88	0.43	2.53e-8	Height;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.74	0.66	2.23e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.8	-9.23	-0.6	2.23e-16	Type 2 diabetes;
PAAD	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs9649465	0.967	rs1005567	chr7:123305836	A/T	cg04330084	chr7:123175371	IQUB	0.5	4.66	0.35	6.92e-6	Migraine;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07089783	chr10:31607955	ZEB1;LOC220930	-0.56	-6.45	-0.46	1.41e-9	Body fat percentage;
PAAD	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs2730260	0.537	rs56023468	chr7:158875329	T/C	cg13444538	chr7:158905317	VIPR2	-0.7	-5.21	-0.39	6.16e-7	Myopia (pathological);
PAAD	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg10011062	chr15:43941034	CATSPER2	-0.81	-4.78	-0.36	4.05e-6	Lung cancer in ever smokers;
PAAD	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg10290764	chr8:4849399	CSMD1	0.41	6.9	0.49	1.3e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs375066	0.935	rs417699	chr19:44417575	A/G	cg11993925	chr19:44307056	LYPD5	0.49	6.3	0.45	3.08e-9	Breast cancer;
PAAD	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.85	10.79	0.66	1.62e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9659323	0.670	rs17023223	chr1:119631174	T/C	cg26570165	chr1:119541833	NA	-0.46	-5.03	-0.38	1.38e-6	Body mass index;
PAAD	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.91	-0.63	3.52e-18	Tonsillectomy;
PAAD	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.7	7.56	0.52	3.47e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.4	-8.53	-0.57	1.39e-14	Mean corpuscular volume;
PAAD	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.53	-4.59	-0.35	9.21e-6	Schizophrenia;
PAAD	cis	rs2286503	1.000	rs2286503	chr7:22856606	C/T	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.25e-5	Fibrinogen;
PAAD	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.85	0.37	2.97e-6	Mood instability;
PAAD	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.39	5.59	0.41	1.05e-7	Educational attainment (years of education);
PAAD	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.94	0.37	2.08e-6	Systolic blood pressure;
PAAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.67	-8.21	-0.55	8.63e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.44	-0.56	2.32e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.61	6.76	0.48	2.76e-10	Testicular germ cell tumor;
PAAD	cis	rs9463078	0.715	rs1557143	chr6:44756415	T/C	cg25276700	chr6:44698697	NA	0.52	6.03	0.44	1.19e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9547692	0.793	rs556429	chr13:37487021	C/A	cg01493522	chr13:37497338	NA	-0.61	-5.78	-0.42	4.03e-8	Coronary artery disease;
PAAD	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.62	0.35	8.05e-6	Homocysteine levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19655961	chr11:96123147	CCDC82;JRKL	-0.61	-6.31	-0.46	2.97e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10547527	chr2:198650123	BOLL	0.48	4.34	0.33	2.54e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg01267373	chr18:77410094	NA	0.43	4.75	0.36	4.63e-6	Monocyte count;
PAAD	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs11645898	0.513	rs55741258	chr16:72112480	C/T	cg16579770	chr16:72058938	DHODH	0.48	4.26	0.33	3.6e-5	Blood protein levels;
PAAD	cis	rs9992101	0.547	rs7654754	chr4:77409795	C/T	cg20311846	chr4:77356250	SHROOM3	-0.39	-4.89	-0.37	2.56e-6	Creatinine levels;
PAAD	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.79	9.98	0.63	2.3e-18	Alcohol dependence;
PAAD	cis	rs73206853	0.841	rs60013768	chr12:110576095	A/G	cg12870014	chr12:110450643	ANKRD13A	0.71	4.47	0.34	1.55e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-5.01	-0.38	1.49e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05978187	chr14:69864930	ERH;SLC39A9	0.65	7.6	0.52	2.86e-12	Myopia (pathological);
PAAD	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.53	0.35	1.17e-5	Educational attainment;
PAAD	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.6	5.71	0.42	5.72e-8	Schizophrenia;
PAAD	cis	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.74	4.98	0.37	1.68e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs9463078	0.547	rs1418434	chr6:44748365	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.55	-0.41	1.22e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.57	-6.81	-0.48	2.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg20243544	chr17:37824526	PNMT	0.53	4.57	0.35	9.86e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.8	-0.43	3.67e-8	Colorectal cancer;
PAAD	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.97	0.49	8.99e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22601762	chr1:19526929	UBR4	0.6	6.55	0.47	8.25e-10	Smoking initiation;
PAAD	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg09579323	chr1:150459698	TARS2	0.45	4.46	0.34	1.57e-5	Migraine;
PAAD	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg12568669	chr8:11666485	FDFT1	-0.3	-5.18	-0.39	7.04e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.59	-5.53	-0.41	1.39e-7	Total body bone mineral density;
PAAD	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.78	7.72	0.53	1.43e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.75	-4.81	-0.36	3.65e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.9	0.37	2.41e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.49	-0.41	1.66e-7	Prostate cancer;
PAAD	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-4.26	-0.33	3.56e-5	HDL cholesterol;
PAAD	cis	rs2286503	0.901	rs2286505	chr7:22854840	G/A	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.25e-5	Fibrinogen;
PAAD	cis	rs12936587	0.601	rs8068296	chr17:17554563	A/C	cg04398451	chr17:18023971	MYO15A	0.47	4.35	0.33	2.47e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs13242816	1.000	rs35505552	chr7:116104867	T/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.94	-10.13	-0.63	9.53e-19	Parkinson's disease;
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26850624	chr5:429559	AHRR	-0.8	-9.38	-0.61	8.68e-17	Cystic fibrosis severity;
PAAD	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg07541023	chr7:19748670	TWISTNB	0.53	4.43	0.34	1.77e-5	Thyroid stimulating hormone;
PAAD	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg21226059	chr5:178986404	RUFY1	-0.62	-7.29	-0.51	1.54e-11	Lung cancer;
PAAD	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.69	6.17	0.45	6.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs10274279	0.688	rs7459356	chr7:157398852	G/C	cg26886268	chr7:157387156	PTPRN2	-0.62	-4.68	-0.36	6.2e-6	Myopia (pathological);
PAAD	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.82	-0.43	3.45e-8	Menarche (age at onset);
PAAD	cis	rs939584	0.935	rs7567710	chr2:645372	T/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg27017172	chr16:57497170	POLR2C	-0.6	-6.31	-0.46	2.93e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.62	5.98	0.44	1.53e-8	Acylcarnitine levels;
PAAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	7.44	0.52	6.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00720764	chr2:150444429	MMADHC	-0.69	-6.6	-0.47	6.58e-10	Neuroticism;
PAAD	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.67	-5.81	-0.43	3.58e-8	Lung cancer;
PAAD	cis	rs12550646	0.585	rs74887565	chr8:41681935	T/C	cg12180191	chr8:41686706	ANK1	-0.49	-4.93	-0.37	2.17e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.84	0.54	7.18e-13	Personality dimensions;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.55	5.4	0.4	2.52e-7	Parkinson's disease;
PAAD	cis	rs6066835	0.867	rs8123336	chr20:47361725	C/T	cg18078177	chr20:47281410	PREX1	-0.92	-5.14	-0.38	8.31e-7	Multiple myeloma;
PAAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.77	-9.41	-0.61	7.39e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs11811982	0.793	rs77703354	chr1:227370713	C/T	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.56	5.0	0.38	1.53e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Urinary tract infection frequency;
PAAD	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	1.09	12.42	0.71	6.62e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg27411982	chr8:10470053	RP1L1	-0.48	-5.64	-0.42	8.11e-8	Neuroticism;
PAAD	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.55	4.67	0.35	6.46e-6	QRS duration;
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.75	-8.13	-0.55	1.4e-13	Blood metabolite levels;
PAAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.46	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13065560	0.594	rs7633981	chr3:38889901	A/C	cg01426195	chr3:39028469	NA	-0.57	-5.91	-0.43	2.15e-8	Interleukin-18 levels;
PAAD	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg02264943	chr11:130785842	SNX19	0.4	4.8	0.36	3.69e-6	Schizophrenia;
PAAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.93	-8.57	-0.57	1.09e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-7.79	-0.53	9.97e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.71	8.97	0.59	1.02e-15	Dupuytren's disease;
PAAD	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.73	0.48	3.19e-10	Lung cancer in ever smokers;
PAAD	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs41308713	0.786	rs8116471	chr20:37034694	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.18	5.69	0.42	6.41e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03766516	chr19:3627160	C19orf29	0.55	6.29	0.45	3.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs2882667	0.893	rs7717375	chr5:138291405	A/G	cg09476006	chr5:138032270	NA	0.36	4.48	0.34	1.49e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20462899	chr1:40367831	MYCL1	0.56	6.31	0.46	2.86e-9	Monocyte percentage of white cells;
PAAD	trans	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.53	5.18	0.39	7e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.4	0.64	1.82e-19	Smoking behavior;
PAAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg00758881	chr16:58534681	NDRG4	-0.91	-4.9	-0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs559928	0.692	rs915987	chr11:64027888	G/A	cg05555928	chr11:63887634	MACROD1	-0.61	-4.55	-0.35	1.08e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.92	0.59	1.38e-15	Lung cancer;
PAAD	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14831746	chr12:49961631	MCRS1	0.76	6.91	0.49	1.27e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.42	-0.34	1.89e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.94	8.42	0.56	2.61e-14	Body mass index;
PAAD	cis	rs4692589	0.581	rs62344679	chr4:170963591	G/A	cg19918862	chr4:170955249	NA	0.5	4.44	0.34	1.71e-5	Anxiety disorder;
PAAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-6.75	-0.48	2.92e-10	Menopause (age at onset);
PAAD	cis	rs375066	0.935	rs387689	chr19:44420111	C/T	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.51	6.08	0.44	9.16e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9674544	0.556	rs9890278	chr17:47073949	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.47	-6.14	-0.45	7.02e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.84e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.63	6.92	0.49	1.18e-10	Prostate cancer;
PAAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.49	4.61	0.35	8.64e-6	Renal cell carcinoma;
PAAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Diastolic blood pressure;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg27194152	chr7:157982427	PTPRN2	0.51	5.23	0.39	5.64e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg18180107	chr4:99064573	C4orf37	-0.46	-4.25	-0.33	3.72e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg17105886	chr17:28927953	LRRC37B2	0.86	5.07	0.38	1.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg22040403	chr1:23858016	E2F2	0.67	4.45	0.34	1.65e-5	Total cholesterol levels;
PAAD	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.54	0.35	1.15e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg23033748	chr14:75592666	NEK9	0.4	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.4	-4.54	-0.35	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.6	6.02	0.44	1.28e-8	Monocyte count;
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.62	7.83	0.54	7.72e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg16898833	chr6:26189333	HIST1H4D	0.49	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.85	6.46	0.46	1.36e-9	Type 2 diabetes;
PAAD	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg06569542	chr10:98946673	SLIT1	-0.51	-5.61	-0.41	9.29e-8	Monocyte count;
PAAD	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg22431228	chr1:16359049	CLCNKA	0.42	5.11	0.38	9.53e-7	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs76793172	0.920	rs77799462	chr19:46342500	G/A	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg27211696	chr2:191398769	TMEM194B	0.44	4.32	0.33	2.81e-5	Urinary metabolites;
PAAD	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.67	-4.77	-0.36	4.21e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09082664	chr4:23890701	PPARGC1A	-0.66	-6.76	-0.48	2.74e-10	Smoking initiation;
PAAD	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg11232448	chr19:2858854	NA	-0.48	-4.73	-0.36	5.05e-6	Total cholesterol levels;
PAAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs1507153	0.775	rs12210702	chr6:79369333	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.69	-0.36	6.12e-6	Sjögren's syndrome;
PAAD	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs3736485	0.816	rs882386	chr15:51882273	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.33	-0.33	2.74e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.51	5.69	0.42	6.33e-8	Heart rate;
PAAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.74	-8.33	-0.56	4.29e-14	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.97	8.05	0.55	2.21e-13	Iron status biomarkers;
PAAD	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03332314	chr8:146278003	C8orf33	-0.64	-6.43	-0.46	1.6e-9	Smoking initiation;
PAAD	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.48	-0.34	1.44e-5	Height;
PAAD	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.95	12.16	0.7	3.37e-24	Heart rate;
PAAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg23465465	chr6:26364728	BTN3A2	0.79	4.87	0.37	2.79e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.45	-4.31	-0.33	2.9e-5	Height;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	6.18	0.45	5.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.21	-18.92	-0.84	8.69e-42	Exhaled nitric oxide output;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg07202610	chr7:1142643	C7orf50	-0.63	-4.78	-0.36	4.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.59	6.33	0.46	2.64e-9	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12743169	chr17:40021713	KLHL11	-0.7	-7.4	-0.51	8.5e-12	Smoking initiation;
PAAD	cis	rs7552393	0.636	rs12144970	chr1:84260626	A/G	cg10977910	chr1:84465055	TTLL7	-0.54	-4.89	-0.37	2.49e-6	Select biomarker traits;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg17372657	chr7:1216933	NA	-0.37	-4.85	-0.37	3.05e-6	Longevity;Endometriosis;
PAAD	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg18084798	chr19:33555255	RHPN2	0.45	4.8	0.36	3.72e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.5	5.11	0.38	9.6e-7	Colorectal cancer;
PAAD	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg00277334	chr10:82204260	NA	-0.6	-5.92	-0.43	2.09e-8	Post bronchodilator FEV1;
PAAD	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg14181355	chr19:12984996	MAST1	0.49	4.49	0.34	1.38e-5	Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17769705	chr8:27634001	ESCO2	-0.52	-6.37	-0.46	2.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg22467129	chr15:76604101	ETFA	0.51	4.78	0.36	4.08e-6	Blood metabolite levels;
PAAD	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg09276445	chr13:102106423	ITGBL1	0.42	4.89	0.37	2.54e-6	Obesity-related traits;
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg18402987	chr7:1209562	NA	1.0	5.26	0.39	4.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg24737193	chr18:12778029	NA	0.7	6.01	0.44	1.34e-8	Inflammatory skin disease;
PAAD	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.73	-0.36	5.05e-6	Renal cell carcinoma;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg06873352	chr17:61820015	STRADA	0.88	11.05	0.67	3.26e-21	Prudent dietary pattern;
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg22442454	chr1:209979470	IRF6	0.53	4.75	0.36	4.69e-6	Coronary artery disease;
PAAD	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.98	12.02	0.7	8.09e-24	Multiple myeloma;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg22189786	chr22:42395067	WBP2NL	0.5	5.55	0.41	1.22e-7	Intelligence;
PAAD	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-7.65	-0.53	2.11e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.66	-6.57	-0.47	7.5e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg05973401	chr12:123451056	ABCB9	0.51	4.61	0.35	8.4e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-1.06	-18.93	-0.84	7.91e-42	Urate levels in lean individuals;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.43	4.35	0.33	2.51e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.49	-4.69	-0.36	6.06e-6	Type 2 diabetes;
PAAD	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg08601574	chr20:25228251	PYGB	0.48	4.94	0.37	2.08e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.14	16.33	0.8	2.93e-35	Cognitive function;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.62	6.47	0.46	1.29e-9	Caffeine consumption;
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.59	4.72	0.36	5.34e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.73	8.07	0.55	2e-13	Melanoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17387746	chr19:2950636	NA	0.62	6.89	0.49	1.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs10899021	0.920	rs7122710	chr11:74323175	C/T	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.64	-0.53	2.28e-12	Height;
PAAD	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.37	4.86	0.37	2.84e-6	Mean corpuscular volume;
PAAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.9	9.66	0.62	1.68e-17	Obesity-related traits;
PAAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.53	-5.75	-0.42	4.82e-8	Multiple sclerosis;
PAAD	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.75	-7.94	-0.54	4.22e-13	Prostate cancer;
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.5	5.71	0.42	5.85e-8	Bipolar disorder;
PAAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.77e-11	Eye color traits;
PAAD	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg11657440	chr19:46296263	DMWD	-0.66	-5.72	-0.42	5.53e-8	Coronary artery disease;
PAAD	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.56	-5.81	-0.43	3.53e-8	Hepatitis;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.81	6.09	0.44	8.68e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg10820045	chr2:198174542	NA	-0.47	-4.74	-0.36	4.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2415984	0.783	rs61993307	chr14:46952034	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-4.46	-0.34	1.6e-5	Number of children ever born;
PAAD	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs12767760	0.669	rs12221474	chr10:99332488	A/C	cg25247692	chr10:99313390	UBTD1	0.56	5.28	0.39	4.45e-7	Obesity-related traits;
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg27094323	chr7:1216898	NA	-0.44	-4.9	-0.37	2.47e-6	Longevity;Endometriosis;
PAAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs35740288	0.929	rs11630684	chr15:86306256	C/A	cg07943548	chr15:86304357	KLHL25	-0.6	-5.16	-0.39	7.7e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg14171944	chr9:126323477	DENND1A	0.55	6.42	0.46	1.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs116641256	chr3:128587572	G/A	cg18531004	chr3:128564980	NA	-0.9	-4.41	-0.34	1.94e-5	Dental caries;
PAAD	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.52	-5.31	-0.4	3.77e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21889078	chr8:56675203	TMEM68	-0.65	-7.26	-0.51	1.88e-11	Iris heterochromicity;
PAAD	cis	rs72960926	0.661	rs13219809	chr6:75187547	A/T	cg03266952	chr6:74778945	NA	-1.03	-4.9	-0.37	2.46e-6	Metabolite levels (MHPG);
PAAD	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.65	5.12	0.38	9.07e-7	Mammographic density (dense area);
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.25	0.51	1.98e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9463078	0.739	rs6910749	chr6:44773892	A/G	cg25276700	chr6:44698697	NA	-0.48	-5.46	-0.4	1.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.56	0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg05585544	chr11:47624801	NA	-0.48	-5.35	-0.4	3.16e-7	Subjective well-being;
PAAD	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.47	-4.35	-0.33	2.49e-5	Ulcerative colitis;
PAAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg24849736	chr1:201084428	NA	-0.44	-4.51	-0.34	1.3e-5	Permanent tooth development;
PAAD	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.75	8.69	0.58	5.29e-15	Blood metabolite ratios;
PAAD	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.23	0.6	2.21e-16	Morning vs. evening chronotype;
PAAD	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.48	5.04	0.38	1.33e-6	QRS complex (12-leadsum);
PAAD	cis	rs8077577	0.945	rs8065026	chr17:18046290	A/G	cg16794390	chr17:18148240	FLII	0.59	5.4	0.4	2.53e-7	Obesity-related traits;
PAAD	cis	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	trans	rs34698933	0.719	rs1570375	chr6:11169113	G/C	cg06252564	chr9:970605	NA	-0.43	-6.31	-0.46	2.88e-9	Heschl's gyrus morphology;
PAAD	cis	rs7795096	0.806	rs1109277	chr7:151540959	C/G	cg17008978	chr7:151542804	PRKAG2	-0.4	-4.64	-0.35	7.54e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.16	-0.45	6.37e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg02071572	chr4:1403502	NA	0.36	4.54	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg10932868	chr11:921992	NA	0.45	4.71	0.36	5.43e-6	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg21496419	chr19:44306685	LYPD5	0.39	4.98	0.37	1.7e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg13444538	chr7:158905317	VIPR2	0.46	4.45	0.34	1.65e-5	Facial morphology (factor 20);
PAAD	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.71	-7.34	-0.51	1.18e-11	Colorectal cancer;
PAAD	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.86	-9.83	-0.62	5.99e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg02696790	chr15:75250997	RPP25	-0.39	-4.61	-0.35	8.6e-6	Systemic lupus erythematosus;
PAAD	cis	rs4478858	0.746	rs6703593	chr1:31689284	A/C	cg00250761	chr1:31883323	NA	0.4	4.45	0.34	1.68e-5	Alcohol dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18164362	chr11:49873118	NA	-0.48	-6.69	-0.48	3.95e-10	Myopia (pathological);
PAAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.31e-17	Prostate cancer;
PAAD	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.72	7.11	0.5	4.29e-11	Prostate cancer;
PAAD	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg16419906	chr5:132167176	NA	-0.61	-4.87	-0.37	2.8e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg01262667	chr19:19385393	TM6SF2	0.45	5.04	0.38	1.33e-6	Tonsillectomy;
PAAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.8	-7.22	-0.51	2.31e-11	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25104716	chr18:45936047	NA	-0.63	-6.33	-0.46	2.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.48	-4.48	-0.34	1.48e-5	Educational attainment (years of education);
PAAD	trans	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg15770106	chr1:208133116	NA	-0.66	-6.45	-0.46	1.38e-9	Corneal structure;
PAAD	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg06569542	chr10:98946673	SLIT1	-0.47	-5.19	-0.39	6.73e-7	Monocyte count;
PAAD	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg12568669	chr8:11666485	FDFT1	0.36	4.7	0.36	5.69e-6	Myopia (pathological);
PAAD	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.52	-6.51	-0.47	1.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	1.13	6.36	0.46	2.25e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.88	-9.69	-0.62	1.38e-17	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05597554	chr13:46038994	COG3	-0.73	-6.34	-0.46	2.49e-9	Neuroticism;
PAAD	cis	rs3905706	0.607	rs1937810	chr10:28463950	T/C	cg03576554	chr10:29014846	NA	-0.65	-4.77	-0.36	4.21e-6	Bone mineral density;Bone mineral density (paediatric, skull);
PAAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.52	0.34	1.25e-5	Axial length;
PAAD	cis	rs2073300	0.793	rs36165478	chr20:23457261	C/T	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg20003494	chr4:90757398	SNCA	-0.75	-7.29	-0.51	1.56e-11	Neuroticism;
PAAD	cis	rs8081395	0.651	rs1292067	chr17:57930646	A/C	cg02344993	chr17:57696989	CLTC	-0.49	-4.56	-0.35	1.03e-5	White blood cell count;
PAAD	cis	rs7252505	1.000	rs7252505	chr19:33575064	A/G	cg08321942	chr19:34310625	NA	-0.57	-4.59	-0.35	9.13e-6	Colorectal cancer;
PAAD	cis	rs911119	0.913	rs1158167	chr20:23578189	G/A	cg16589663	chr20:23618590	CST3	-0.79	-6.93	-0.49	1.14e-10	Chronic kidney disease;
PAAD	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-5.42	-0.4	2.32e-7	Mean corpuscular volume;
PAAD	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.66	-8.41	-0.56	2.74e-14	Schizophrenia;
PAAD	cis	rs3730682	1.000	rs3730729	chr18:51804702	A/G	cg00142378	chr18:51793448	NA	0.56	4.31	0.33	2.88e-5	Psoriasis;
PAAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.88e-6	Height;
PAAD	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	6.56	0.47	8.07e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4605213	0.528	rs11868594	chr17:49316992	T/G	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg08222618	chr4:941054	TMEM175	-0.42	-4.72	-0.36	5.37e-6	Systemic sclerosis;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg23958373	chr8:599963	NA	-1.12	-6.79	-0.48	2.39e-10	IgG glycosylation;
PAAD	cis	rs3739998	0.509	rs61841115	chr10:30333025	C/T	cg27036936	chr10:30305021	KIAA1462	-0.4	-4.47	-0.34	1.52e-5	Coronary heart disease;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg06375148	chr1:209958343	C1orf74	0.6	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs9646944	0.501	rs13030642	chr2:103091585	C/A	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs6132905	0.590	rs2092655	chr20:2626050	G/A	cg24848351	chr20:2622020	TMC2	-0.76	-5.54	-0.41	1.31e-7	Mumps;
PAAD	cis	rs2124910	0.717	rs1160392	chr19:52007787	A/G	cg14953197	chr19:52005651	SIGLEC12	0.49	5.24	0.39	5.2e-7	Blood protein levels;
PAAD	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	9.25	0.6	1.94e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg27284194	chr4:1044797	NA	0.49	4.58	0.35	9.69e-6	Obesity-related traits;
PAAD	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.68	0.36	6.23e-6	Neuroticism;
PAAD	cis	rs698813	0.572	rs12712914	chr2:44478649	C/G	cg04920474	chr2:44395004	PPM1B	0.45	4.41	0.34	1.95e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs4594175	0.926	rs12434681	chr14:51595335	A/G	cg23942311	chr14:51606299	NA	0.69	6.59	0.47	6.7e-10	Cancer;
PAAD	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.69	-8.15	-0.55	1.27e-13	Lung cancer;
PAAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg02297831	chr4:17616191	MED28	0.61	6.21	0.45	4.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11997175	0.568	rs4733169	chr8:33581855	T/C	ch.8.33884649F	chr8:33765107	NA	0.53	5.8	0.43	3.75e-8	Body mass index;
PAAD	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.7	0.42	5.96e-8	Restless legs syndrome;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg15831200	chr1:110765724	KCNC4	-0.8	-6.45	-0.46	1.44e-9	Photic sneeze reflex;
PAAD	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs9810890	1.000	rs73198883	chr3:128543187	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.72	0.42	5.42e-8	Total body bone mineral density;
PAAD	cis	rs4845552	0.767	rs16835368	chr1:153468701	C/T	cg15998505	chr1:153479701	NA	-0.5	-4.67	-0.35	6.45e-6	Hippocampal atrophy;
PAAD	cis	rs7517847	0.598	rs10789228	chr1:67687064	C/T	cg22500004	chr1:68516272	DIRAS3	-0.49	-4.91	-0.37	2.3e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-5.06	-0.38	1.21e-6	Testicular germ cell tumor;
PAAD	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-5.78	-0.42	4.05e-8	Fibrinogen levels;
PAAD	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.53	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03159660	chr11:2078197	NA	-0.54	-6.5	-0.47	1.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs7173743	0.525	rs7166501	chr15:79133739	C/T	cg00540400	chr15:79124168	NA	0.44	4.52	0.34	1.24e-5	Coronary artery disease;
PAAD	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg25972092	chr12:117363249	FBXW8	0.81	6.33	0.46	2.6e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg21565972	chr17:80109576	CCDC57	-0.6	-6.97	-0.49	8.88e-11	Life satisfaction;
PAAD	cis	rs8027181	0.740	rs8038247	chr15:73096573	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.53	4.93	0.37	2.1e-6	Triglyceride levels;
PAAD	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.58	5.85	0.43	2.87e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg05299278	chr17:33885742	SLFN14	-0.44	-5.19	-0.39	6.78e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.83	-8.13	-0.55	1.42e-13	Bone mineral density;
PAAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.62	6.18	0.45	5.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.49	4.55	0.35	1.09e-5	Mean platelet volume;
PAAD	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.72	8.71	0.58	4.91e-15	Monocyte percentage of white cells;
PAAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.6	7.62	0.53	2.55e-12	Monobrow;
PAAD	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg02900213	chr11:20385756	HTATIP2	0.47	4.41	0.34	1.95e-5	Pursuit maintenance gain;
PAAD	cis	rs35955747	1.000	rs35955747	chr22:31813058	A/T	cg02404636	chr22:31891804	SFI1	-0.5	-4.54	-0.35	1.14e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.63	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg24747557	chr10:131355152	MGMT	-0.47	-5.04	-0.38	1.31e-6	Response to temozolomide;
PAAD	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-7.83	-0.54	7.7e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.69	7.72	0.53	1.48e-12	Airway imaging phenotypes;
PAAD	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg13012494	chr21:47604986	C21orf56	0.53	5.65	0.42	7.69e-8	Testicular germ cell tumor;
PAAD	cis	rs1419980	0.730	rs11054553	chr12:7727676	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg03318428	chr22:46971703	NA	0.37	4.47	0.34	1.5e-5	Urate levels in obese individuals;
PAAD	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg09796270	chr17:17721594	SREBF1	0.43	4.91	0.37	2.34e-6	Total body bone mineral density;
PAAD	cis	rs1075265	0.547	rs10865279	chr2:54324701	T/C	cg04546899	chr2:54196757	PSME4	0.31	4.61	0.35	8.45e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg19413350	chr8:57351067	NA	-0.49	-4.85	-0.37	3.05e-6	Obesity-related traits;
PAAD	cis	rs642743	0.901	rs674850	chr10:105961427	A/C	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.68	0.35	6.4e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2790216	0.951	rs2590324	chr10:60000951	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.73	-7.38	-0.51	9.8e-12	Neurofibrillary tangles;
PAAD	cis	rs432925	0.625	rs2858003	chr16:342191	A/G	cg06233593	chr16:337645	AXIN1	0.48	5.51	0.41	1.52e-7	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2030114	0.531	rs1072858	chr16:51593364	C/T	cg03758633	chr16:51611768	NA	0.51	4.95	0.37	1.96e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg19784903	chr17:45786737	TBKBP1	-0.62	-6.57	-0.47	7.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.28	-0.39	4.38e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7680126	0.671	rs7663044	chr4:10023939	C/G	cg00071950	chr4:10020882	SLC2A9	0.57	4.59	0.35	9.06e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.47	-4.84	-0.37	3.16e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.56e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.65	5.88	0.43	2.52e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg19630374	chr17:18023558	MYO15A	-0.46	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg03137908	chr10:81447366	LOC650623	-0.39	-4.31	-0.33	2.87e-5	Height;
PAAD	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg17326555	chr1:119535693	NA	-0.43	-5.09	-0.38	1.03e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.48	-4.37	-0.33	2.32e-5	Tuberculosis;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.63	-0.42	8.49e-8	Joint mobility (Beighton score);
PAAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	4.49	0.34	1.41e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6466055	0.777	rs2299319	chr7:104877916	C/T	cg04380332	chr7:105027541	SRPK2	-0.66	-7.42	-0.52	7.81e-12	Schizophrenia;
PAAD	cis	rs4740619	0.836	rs7019430	chr9:15704337	A/G	cg14451791	chr9:16040625	NA	-0.41	-4.59	-0.35	9.18e-6	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14524337	chr9:100459217	XPA	0.56	6.46	0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg10411590	chr13:21900810	NA	0.63	7.05	0.5	5.92e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.73	8.12	0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.42	5.19	0.39	6.55e-7	Corneal astigmatism;
PAAD	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	0.4	4.37	0.33	2.27e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7554547	0.721	rs12092734	chr1:11968406	T/C	cg07603449	chr1:11986842	KIAA2013	-0.38	-6.06	-0.44	1.03e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.79	-7.11	-0.5	4.14e-11	Pancreatic cancer;
PAAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25162946	chr20:33265105	PIGU	0.6	6.67	0.48	4.52e-10	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6942407	0.542	rs1981535	chr7:86747375	A/G	cg02420886	chr7:86849541	C7orf23	0.51	4.3	0.33	3.1e-5	Food allergy;
PAAD	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.47	-0.46	1.29e-9	Hip circumference;
PAAD	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg13565585	chr5:132299512	AFF4	0.52	5.09	0.38	1.03e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-5.43	-0.4	2.2e-7	Rheumatoid arthritis;
PAAD	cis	rs6896969	0.504	rs10472332	chr5:40368373	T/G	cg05240017	chr5:40756081	TTC33	0.5	4.31	0.33	2.94e-5	Multiple sclerosis;
PAAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.4	0.34	2.03e-5	Iron status biomarkers;
PAAD	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg24253500	chr15:84953950	NA	0.41	4.32	0.33	2.8e-5	Schizophrenia;
PAAD	cis	rs2286503	0.839	rs2270107	chr7:22862183	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.86	0.66	1.09e-20	Smoking behavior;
PAAD	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.92	7.26	0.51	1.83e-11	Bipolar disorder;
PAAD	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs1692120	0.545	rs1812458	chr11:61408449	C/T	cg23038520	chr11:61406508	RPLP0P2	-0.54	-5.76	-0.42	4.47e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16447950	chr5:562315	NA	-0.73	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.47	-6.86	-0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10885582	1.000	rs10885582	chr10:116327550	T/C	cg17056676	chr10:116301354	ABLIM1	-0.37	-4.8	-0.36	3.74e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg01851573	chr8:8652454	MFHAS1	0.6	5.08	0.38	1.08e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2992756	0.663	rs2992764	chr1:18804144	A/G	cg14356550	chr1:18808102	KLHDC7A	0.56	6.3	0.46	2.99e-9	Breast cancer;
PAAD	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg26898376	chr11:64110657	CCDC88B	0.46	4.93	0.37	2.12e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.5	5.26	0.39	4.73e-7	Breast cancer;
PAAD	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.66e-6	Educational attainment;
PAAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.7	7.7	0.53	1.66e-12	Bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24111503	chr14:59112900	DACT1	-0.55	-6.52	-0.47	9.81e-10	Monocyte percentage of white cells;
PAAD	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg08390786	chr10:135334061	NA	0.47	4.53	0.34	1.18e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs36054203	chr10:46037861	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7688540	0.800	rs1578898	chr4:228919	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.48	0.34	1.44e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.71	-5.2	-0.39	6.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7577696	0.925	rs12474443	chr2:32337872	G/T	cg02381751	chr2:32503542	YIPF4	-0.41	-4.39	-0.34	2.1e-5	Inflammatory biomarkers;
PAAD	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-7.27	-0.51	1.79e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.61	-4.9	-0.37	2.47e-6	Mammographic density (dense area);
PAAD	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs55863869	0.748	rs3754953	chr2:179618019	A/T	cg02880032	chr2:179629472	TTN	0.65	4.51	0.34	1.29e-5	QT interval;
PAAD	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.67	-0.53	1.96e-12	Total cholesterol levels;
PAAD	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg23216685	chr1:86174607	ZNHIT6	-0.29	-4.28	-0.33	3.23e-5	Urate levels in overweight individuals;
PAAD	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.71	8.14	0.55	1.33e-13	Morning vs. evening chronotype;
PAAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.78	6.85	0.49	1.68e-10	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg25811867	chr2:3488468	NA	0.48	4.95	0.37	1.93e-6	Neurofibrillary tangles;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.42	4.58	0.35	9.67e-6	Obesity-related traits;
PAAD	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.94	-8.27	-0.56	6.39e-14	Alopecia areata;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.3.41099661F	chr3:41124657	NA	-0.72	-6.95	-0.49	1.03e-10	Lung cancer in ever smokers;
PAAD	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.67	-6.54	-0.47	8.74e-10	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg18093559	chr17:18951025	GRAP	0.43	4.5	0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6585424	0.850	rs61860036	chr10:81934859	C/T	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs300774	0.858	rs300736	chr2:168466	C/G	cg21211680	chr2:198530	NA	-0.65	-5.81	-0.43	3.54e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg19760965	chr3:194868843	C3orf21	0.51	4.87	0.37	2.81e-6	Non-small cell lung cancer;
PAAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.12	-0.5	4.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7577696	0.889	rs212731	chr2:32472150	G/A	cg02381751	chr2:32503542	YIPF4	0.43	4.76	0.36	4.53e-6	Inflammatory biomarkers;
PAAD	cis	rs2415984	0.579	rs10140977	chr14:46955156	T/A	cg14871534	chr14:47121158	RPL10L	-0.48	-4.94	-0.37	2.03e-6	Number of children ever born;
PAAD	trans	rs41264869	1.000	rs2242000	chr1:205031769	G/A	cg08840230	chr19:15622718	CYP4F22	0.49	6.41	0.46	1.7e-9	Blood protein levels;
PAAD	cis	rs2936519	0.872	rs2936537	chr8:6641444	A/G	cg22103414	chr8:6638082	NA	-0.41	-4.44	-0.34	1.74e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg00945038	chr17:61921165	SMARCD2	0.46	5.38	0.4	2.79e-7	Prudent dietary pattern;
PAAD	trans	rs2790216	0.951	rs1698384	chr10:59928695	A/G	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00797602	chr14:39901757	FBXO33	0.61	6.96	0.49	9.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.6	0.41	9.88e-8	Tonsillectomy;
PAAD	cis	rs3749237	0.964	rs10049413	chr3:49892896	A/G	cg03060546	chr3:49711283	APEH	0.63	6.28	0.45	3.33e-9	Resting heart rate;
PAAD	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-10.89	-0.66	8.88e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26926768	chr12:34528122	NA	0.37	4.57	0.35	1e-5	Morning vs. evening chronotype;
PAAD	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.73	8.47	0.57	1.92e-14	Total body bone mineral density;
PAAD	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.72	8.7	0.58	5.08e-15	Monocyte percentage of white cells;
PAAD	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.64	7.6	0.52	2.8e-12	Schizophrenia;
PAAD	cis	rs3768617	0.868	rs20561	chr1:183105705	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	6.6	0.47	6.6e-10	Fuchs's corneal dystrophy;
PAAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.74	-7.81	-0.54	8.75e-13	Obesity-related traits;
PAAD	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.92	11.05	0.67	3.24e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.65	-6.33	-0.46	2.63e-9	Visceral fat;
PAAD	trans	rs2725236	0.520	rs12509864	chr4:88909766	C/T	cg23656380	chr20:60877581	ADRM1	0.61	6.3	0.46	2.98e-9	Caffeine consumption;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13438300	chr1:32254265	NA	0.76	6.66	0.48	4.77e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19751406	chr1:203764676	ZC3H11A	-0.73	-6.66	-0.48	4.68e-10	Neuroticism;
PAAD	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.51	8.41	0.56	2.81e-14	Cutaneous nevi;
PAAD	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.83	8.73	0.58	4.37e-15	Blood protein levels;
PAAD	cis	rs4072705	0.586	rs7855380	chr9:127246763	T/C	cg13515842	chr9:127215440	GPR144	-0.4	-4.44	-0.34	1.7e-5	Menarche (age at onset);
PAAD	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg10587741	chr22:38071170	LGALS1	0.43	4.76	0.36	4.5e-6	Fat distribution (HIV);
PAAD	cis	rs4740619	0.619	rs4741561	chr9:16045827	A/G	cg14451791	chr9:16040625	NA	-0.44	-4.99	-0.38	1.65e-6	Body mass index;
PAAD	cis	rs497273	0.530	rs2701185	chr12:121352974	A/G	cg02403541	chr12:121454288	C12orf43	0.41	4.28	0.33	3.33e-5	Systemic lupus erythematosus;
PAAD	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg08109568	chr15:31115862	NA	-0.72	-7.93	-0.54	4.31e-13	Huntington's disease progression;
PAAD	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.77	-7.83	-0.54	7.9e-13	Colorectal adenoma (advanced);
PAAD	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.72	-5.92	-0.43	2.08e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.76	-9.45	-0.61	5.99e-17	Bone mineral density;
PAAD	cis	rs3733418	0.860	rs13124015	chr4:165930282	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.57	-5.17	-0.39	7.38e-7	Obesity-related traits;
PAAD	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.63	-6.36	-0.46	2.23e-9	Blood protein levels;
PAAD	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.65	-6.5	-0.47	1.08e-9	Orofacial clefts;
PAAD	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.38	4.35	0.33	2.54e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg19904058	chr10:135279010	LOC619207	-0.49	-5.78	-0.42	4.06e-8	Systemic lupus erythematosus;
PAAD	trans	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg24657687	chr15:69707291	KIF23	0.66	6.52	0.47	1e-9	HIV-1 control;
PAAD	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg18551225	chr6:44695536	NA	-0.72	-7.39	-0.51	9e-12	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.66	8.22	0.55	8.57e-14	Lipoprotein (a) levels;
PAAD	cis	rs1007738	0.542	rs901747	chr11:47204981	G/C	cg19486271	chr11:47235900	DDB2	-0.63	-5.77	-0.42	4.21e-8	Bone mineral density (hip);
PAAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs6531296	0.915	rs10010927	chr4:34094653	C/G	cg06870266	chr13:43192608	NA	0.7	6.34	0.46	2.55e-9	Thoracic-to-hip circumference ratio;
PAAD	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.96	0.37	1.9e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.67	-0.53	1.97e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg00806126	chr19:22604979	ZNF98	-0.41	-4.95	-0.37	1.97e-6	Pain;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06398481	chr20:35492283	C20orf117	-0.64	-6.47	-0.46	1.26e-9	Smoking initiation;
PAAD	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.6	-0.71	2.22e-25	Primary sclerosing cholangitis;
PAAD	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.69	-8.8	-0.58	2.74e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.47	-5.53	-0.41	1.37e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg02462569	chr6:150064036	NUP43	-0.53	-5.91	-0.43	2.13e-8	Lung cancer;
PAAD	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg23587288	chr2:27483067	SLC30A3	-0.8	-6.57	-0.47	7.55e-10	Blood metabolite levels;
PAAD	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.74	7.51	0.52	4.62e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.42	0.46	1.62e-9	Bladder cancer;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.15	-0.39	7.91e-7	Menarche (age at onset);
PAAD	cis	rs1595825	0.732	rs74885211	chr2:198419911	C/T	cg00982548	chr2:198649783	BOLL	-0.64	-4.27	-0.33	3.42e-5	Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18621852	chr3:10150065	C3orf24	0.68	5.94	0.43	1.89e-8	Alzheimer's disease;
PAAD	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.75	5.41	0.4	2.42e-7	Blood protein levels;
PAAD	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-4.73	-0.36	5.11e-6	Pulmonary function;
PAAD	cis	rs1042026	0.848	rs1039151	chr4:100192782	G/T	cg21548116	chr4:100009993	ADH5	-0.48	-4.25	-0.33	3.78e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.99e-6	Cognitive function;
PAAD	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2637266	0.905	rs10824428	chr10:78346041	G/A	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.46e-6	Pulmonary function;
PAAD	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15974416	chr22:50329893	NA	-0.72	-6.45	-0.46	1.39e-9	Neuroticism;
PAAD	cis	rs62025270	0.632	rs62022919	chr15:86218310	C/A	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.7e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.85e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg09796270	chr17:17721594	SREBF1	0.44	4.6	0.35	8.69e-6	Total body bone mineral density;
PAAD	cis	rs3106136	0.772	rs2865353	chr4:95270878	T/C	cg11021082	chr4:95130006	SMARCAD1	0.59	5.71	0.42	5.7e-8	Capecitabine sensitivity;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11372683	chr5:154237500	CNOT8	0.57	6.35	0.46	2.36e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12963312	chr6:52441723	TRAM2	0.64	6.86	0.49	1.59e-10	Myopia (pathological);
PAAD	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg05791153	chr7:19748676	TWISTNB	0.66	5.05	0.38	1.26e-6	Thyroid stimulating hormone;
PAAD	cis	rs490234	0.841	rs477813	chr9:128416874	C/T	cg14078157	chr9:128172775	NA	0.45	5.24	0.39	5.4e-7	Mean arterial pressure;
PAAD	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13274775	chr6:74078997	OOEP	0.56	6.29	0.45	3.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2882667	0.690	rs160403	chr5:138058482	T/C	cg09476006	chr5:138032270	NA	0.49	6.43	0.46	1.57e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21126163	chr19:49149765	SEC1;CA11	-0.74	-6.34	-0.46	2.53e-9	Neuroticism;
PAAD	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16417436	chr16:28758564	NA	0.47	4.4	0.34	2.06e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs469568	0.543	rs4700789	chr5:178669361	A/G	cg08999896	chr5:178685787	ADAMTS2	0.54	5.63	0.42	8.36e-8	Stroke (pediatric);
PAAD	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.6	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.39	-0.4	2.7e-7	Retinal vascular caliber;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.64	6.74	0.48	3.05e-10	Obesity-related traits;
PAAD	cis	rs16975963	0.644	rs12462505	chr19:38138125	C/G	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.33e-5	Longevity;
PAAD	cis	rs2361763	0.511	rs8053185	chr16:86000092	A/G	cg20368988	chr16:86542943	FOXF1	-0.46	-4.25	-0.33	3.74e-5	Classic bladder exstrophy;Monocyte percentage of white cells;
PAAD	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg22437258	chr11:111473054	SIK2	-0.53	-4.93	-0.37	2.12e-6	Primary sclerosing cholangitis;
PAAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg25649188	chr17:73499917	CASKIN2	0.74	4.81	0.36	3.58e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs11669133	1.000	rs17001073	chr19:11101993	G/A	cg25243385	chr19:11167475	SMARCA4	0.93	4.35	0.33	2.44e-5	LDL cholesterol;
PAAD	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.61	6.76	0.48	2.76e-10	Testicular germ cell tumor;
PAAD	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.84	9.07	0.59	5.76e-16	Corneal astigmatism;
PAAD	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.55e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26770200	chr8:119752914	NA	-0.65	-7.36	-0.51	1.05e-11	Obesity-related traits;
PAAD	cis	rs2072732	0.861	rs2993479	chr1:2967039	A/T	cg22517653	chr1:2918612	NA	-0.61	-4.77	-0.36	4.35e-6	Plateletcrit;
PAAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.07	-0.44	9.6e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.49	-0.34	1.41e-5	Renal cell carcinoma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15123149	chr5:14485252	TRIO	-0.57	-6.48	-0.47	1.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.29	-0.33	3.11e-5	Mean corpuscular volume;
PAAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.51	5.14	0.39	8.2e-7	Platelet count;
PAAD	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-5.99	-0.44	1.49e-8	Congenital heart disease (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26181622	chr13:45011042	TSC22D1	0.63	6.37	0.46	2.15e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14350545	chr9:135820463	TSC1	0.56	6.38	0.46	1.99e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.37	0.4	2.84e-7	Bipolar disorder;
PAAD	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg23758822	chr17:41437982	NA	0.95	12.03	0.7	7.63e-24	Menopause (age at onset);
PAAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg13271783	chr10:134563150	INPP5A	-0.45	-4.81	-0.36	3.53e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13260726	chr2:234763101	HJURP	0.58	6.68	0.48	4.21e-10	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs7195605	chr16:67989523	T/C	cg09835421	chr16:68378352	PRMT7	-0.74	-5.86	-0.43	2.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.61	-6.52	-0.47	9.68e-10	Schizophrenia;
PAAD	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.56	4.79	0.36	3.87e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12165864	chr7:66369176	NA	-0.72	-4.54	-0.35	1.14e-5	Diabetic kidney disease;
PAAD	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.28	-0.39	4.38e-7	QT interval;
PAAD	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.72e-6	Height;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.0	-0.49	7.71e-11	Coffee consumption (cups per day);
PAAD	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.67	7.27	0.51	1.8e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg15847926	chr7:2749597	AMZ1	-0.36	-4.27	-0.33	3.46e-5	Height;
PAAD	cis	rs6893807	0.778	rs13174131	chr5:87959538	T/G	cg02225085	chr5:87975992	LOC645323	-0.69	-5.06	-0.38	1.2e-6	Body mass index;
PAAD	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.3	-0.33	3.08e-5	Schizophrenia;
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.83	-8.91	-0.59	1.49e-15	Total body bone mineral density;
PAAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.39e-7	Monocyte count;
PAAD	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	6.84e-7	Pulmonary function;
PAAD	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg15676125	chr6:33679581	C6orf125	0.49	4.78	0.36	4.11e-6	Plateletcrit;
PAAD	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg01763666	chr17:80159506	CCDC57	-0.45	-4.51	-0.34	1.31e-5	Life satisfaction;
PAAD	cis	rs17309827	0.965	rs13206693	chr6:3433347	T/C	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Crohn's disease;
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg18279126	chr7:2041391	MAD1L1	0.54	5.23	0.39	5.46e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08693754	chr19:8668698	ADAMTS10	-0.67	-6.81	-0.48	2.18e-10	Obesity-related traits;
PAAD	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	4.94	0.37	2.06e-6	Coronary artery disease;
PAAD	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21775007	chr8:11205619	TDH	-0.51	-4.65	-0.35	7.01e-6	Triglycerides;
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg02696790	chr15:75250997	RPP25	0.48	5.69	0.42	6.35e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg12046867	chr14:103022105	NA	-0.63	-4.96	-0.37	1.85e-6	Platelet count;
PAAD	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.5	5.24	0.39	5.3e-7	Resting heart rate;
PAAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-1.3	-10.43	-0.65	1.49e-19	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.99	9.3	0.6	1.47e-16	Psoriasis;
PAAD	cis	rs11105468	0.659	rs7313782	chr12:90537270	G/A	cg16962463	chr12:89968675	NA	0.45	4.65	0.35	7.17e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.28	-0.33	3.24e-5	Renal cell carcinoma;
PAAD	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-5.22	-0.39	5.84e-7	Axial length;
PAAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-0.93	-6.19	-0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs708547	0.766	rs781545	chr4:57732025	A/G	cg00922110	chr4:57842668	C4orf14	0.45	4.48	0.34	1.46e-5	Response to bleomycin (chromatid breaks);
PAAD	trans	rs2247341	0.965	rs11730727	chr4:1738313	T/C	cg21720802	chr11:66232921	PELI3	0.54	6.35	0.46	2.33e-9	Hip circumference adjusted for BMI;Height;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg11766577	chr21:47581405	C21orf56	-0.4	-4.5	-0.34	1.34e-5	Testicular germ cell tumor;
PAAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg00310523	chr12:86230176	RASSF9	0.42	4.46	0.34	1.56e-5	Major depressive disorder;
PAAD	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.58	4.92	0.37	2.23e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.46e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg25809561	chr17:30822961	MYO1D	0.59	6.12	0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.67	8.05	0.55	2.24e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.85e-6	Type 2 diabetes;
PAAD	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.47	0.41	1.79e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10819733	chr22:24237672	NA	-0.61	-6.57	-0.47	7.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19692318	chr6:131384600	EPB41L2	0.66	6.66	0.48	4.72e-10	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.68	-0.35	6.28e-6	Breast cancer;
PAAD	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.95	0.37	1.94e-6	Common traits (Other);
PAAD	cis	rs7264396	0.887	rs4281980	chr20:34096581	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg24829409	chr8:58192753	C8orf71	-0.9	-7.99	-0.54	3.21e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9585327	0.738	rs12018015	chr13:100688671	A/G	cg11288260	chr13:100117058	NA	0.22	4.6	0.35	8.96e-6	Myopia;
PAAD	cis	rs11671005	0.737	rs11673101	chr19:58995053	G/C	cg25952890	chr19:58913133	NA	0.74	5.7	0.42	5.97e-8	Mean platelet volume;
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs1015213	0.609	rs76209356	chr8:52872709	A/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	10.2	0.64	6.2800000000000005e-19	Smoking behavior;
PAAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.61	6.21	0.45	4.84e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	7.51	0.52	4.56e-12	Total body bone mineral density;
PAAD	cis	rs62025270	0.806	rs62025266	chr15:86298448	C/A	cg13263323	chr15:86062960	AKAP13	0.59	5.52	0.41	1.42e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.7	8.49	0.57	1.71e-14	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg05082376	chr22:42548792	NA	0.43	4.44	0.34	1.69e-5	Cognitive function;
PAAD	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg19090574	chr1:205240910	TMCC2	-0.44	-4.76	-0.36	4.48e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg08562672	chr19:21860753	NA	-0.46	-4.93	-0.37	2.12e-6	Pain;
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.62	-5.48	-0.41	1.72e-7	Mean corpuscular volume;
PAAD	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.74	-0.66	2.24e-20	Heart rate;
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.09	-0.38	1.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.97	-7.28	-0.51	1.67e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.68	5.04	0.38	1.3e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.84	6.92	0.49	1.19e-10	Pulmonary function decline;
PAAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.5	5.03	0.38	1.37e-6	Breast cancer;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.63	-6.15	-0.45	6.45e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-10.03	-0.63	1.78e-18	Brugada syndrome;
PAAD	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg23033748	chr14:75592666	NEK9	0.43	5.26	0.39	4.9e-7	Height;
PAAD	cis	rs3104707	0.588	rs2650432	chr16:10069081	A/G	cg06299307	chr16:10133466	GRIN2A	0.61	4.3	0.33	3.05e-5	Subjective well-being;
PAAD	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.59	6.61	0.47	6.05e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4747197	1.000	rs10823849	chr10:73562744	G/A	cg04506911	chr10:72937119	NA	0.4	4.36	0.33	2.35e-5	Progranulin levels;
PAAD	cis	rs6929137	0.666	rs12210699	chr6:151938003	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-4.81	-0.36	3.67e-6	Bone mineral density (spine);
PAAD	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg13736514	chr6:26305472	NA	-0.46	-4.81	-0.36	3.62e-6	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.51	-6.14	-0.45	6.95e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1359582	0.736	rs7913742	chr10:90376864	C/A	cg15661332	chr10:90342814	RNLS	0.55	4.86	0.37	2.95e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs9810890	0.557	rs78115835	chr3:128583226	C/T	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.72	-8.37	-0.56	3.49e-14	Educational attainment;
PAAD	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.65	-6.48	-0.47	1.18e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.88	-0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs62025270	0.688	rs56388190	chr15:86314896	C/G	cg13263323	chr15:86062960	AKAP13	0.55	4.91	0.37	2.31e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs4662592	0.628	rs13005793	chr2:128920741	A/G	cg03222009	chr2:129077232	HS6ST1	-0.5	-4.68	-0.35	6.39e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs17169634	0.557	rs73329157	chr7:34088932	C/T	cg24927974	chr7:35078269	DPY19L1	-0.59	-4.61	-0.35	8.56e-6	Alzheimer's disease;
PAAD	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.34	-0.4	3.29e-7	Atrioventricular conduction;
PAAD	cis	rs56046484	0.956	rs34345801	chr15:85645073	C/G	cg08123816	chr15:85640762	PDE8A	-0.44	-4.66	-0.35	6.72e-6	Testicular germ cell tumor;
PAAD	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg20712883	chr12:51590929	POU6F1	0.44	4.47	0.34	1.5e-5	Cisplatin-induced ototoxicity;
PAAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.89e-7	Schizophrenia;
PAAD	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.37	4.55	0.35	1.09e-5	Corneal astigmatism;
PAAD	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.64	6.37	0.46	2.12e-9	Coronary artery disease;
PAAD	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.64	-7.37	-0.51	1.02e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-4.31	-0.33	2.92e-5	Metabolite levels;
PAAD	cis	rs931127	0.532	rs4930304	chr11:65463447	T/G	cg06492744	chr11:65406254	SIPA1	-0.31	-4.31	-0.33	2.97e-5	Systemic lupus erythematosus;
PAAD	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.38	4.61	0.35	8.33e-6	Sitting height ratio;
PAAD	cis	rs56046484	1.000	rs28718705	chr15:85617810	G/C	cg08123816	chr15:85640762	PDE8A	-0.44	-4.59	-0.35	9.31e-6	Testicular germ cell tumor;
PAAD	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg10395934	chr14:104002654	TRMT61A	0.55	5.51	0.41	1.51e-7	Body mass index;
PAAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.53	4.95	0.37	1.94e-6	Mood instability;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-5.07	-0.38	1.15e-6	Lung cancer;
PAAD	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg27246729	chr12:121163418	ACADS	0.43	4.29	0.33	3.14e-5	Mean corpuscular volume;
PAAD	cis	rs6782025	0.837	rs338986	chr3:121003444	G/A	cg16417163	chr3:121280760	NA	-0.44	-4.58	-0.35	9.43e-6	Aging (facial);
PAAD	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg19486271	chr11:47235900	DDB2	-0.59	-5.92	-0.43	2.09e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg14403583	chr14:105418241	AHNAK2	-0.78	-8.45	-0.57	2.23e-14	Rheumatoid arthritis;
PAAD	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00255919	chr5:131827918	IRF1	0.61	8.41	0.56	2.71e-14	Asthma (sex interaction);
PAAD	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.31	0.64	3.22e-19	Morning vs. evening chronotype;
PAAD	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.39	-0.4	2.66e-7	Joint mobility (Beighton score);
PAAD	cis	rs9659323	0.650	rs12066653	chr1:119482508	C/T	cg17326555	chr1:119535693	NA	-0.35	-4.25	-0.33	3.7e-5	Body mass index;
PAAD	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.94e-7	HDL cholesterol;
PAAD	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.58	6.52	0.47	9.96e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.75	8.0	0.54	2.99e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg06569542	chr10:98946673	SLIT1	0.5	5.06	0.38	1.2e-6	Monocyte count;
PAAD	trans	rs350729	0.649	rs2288639	chr2:53188267	A/G	cg24639469	chr1:4837462	AJAP1	0.66	6.35	0.46	2.41e-9	Bronchodilator response in asthma;
PAAD	cis	rs9815354	0.904	rs4621303	chr3:41839370	T/A	cg03022575	chr3:42003672	ULK4	0.8	5.99	0.44	1.43e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.51	4.83	0.36	3.31e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2555155	0.935	rs10769694	chr11:6520503	T/C	cg11185456	chr11:6592066	DNHD1	0.41	4.37	0.33	2.26e-5	DNA methylation (variation);
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.67	9.83	0.62	5.8e-18	Airflow obstruction;
PAAD	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.51	-0.47	1.05e-9	Neuroticism;
PAAD	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.76	8.0	0.54	3.03e-13	Parkinson's disease;
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.62	6.82	0.48	1.99e-10	Mean corpuscular volume;
PAAD	cis	rs7113874	0.802	rs35319120	chr11:8669694	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.68	-0.36	6.21e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.92	8.49	0.57	1.74e-14	Gut microbiome composition (summer);
PAAD	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	5.54	0.41	1.31e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs2067615	0.521	rs1216002	chr12:107213601	A/T	cg15890332	chr12:107067104	RFX4	0.39	4.35	0.33	2.45e-5	Heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13916967	chr11:16635104	NA	0.7	7.06	0.5	5.7e-11	Obesity-related traits;
PAAD	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.21e-5	Educational attainment (years of education);
PAAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg13606994	chr1:44402422	ARTN	0.48	4.44	0.34	1.72e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs4742903	0.904	rs10820628	chr9:107007188	G/T	cg14250997	chr9:106856677	SMC2	0.43	4.64	0.35	7.62e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs783540	0.846	rs783539	chr15:83254070	A/C	cg00614314	chr15:82944287	LOC80154	0.42	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.65	7.43	0.52	7.2e-12	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.64e-5	Bipolar disorder;
PAAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.93	7.49	0.52	5.24e-12	Initial pursuit acceleration;
PAAD	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.28	12.46	0.71	5.46e-25	Corneal structure;
PAAD	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg15510373	chr7:100224934	TFR2	-0.54	-4.72	-0.36	5.42e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.51	-0.57	1.54e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.47	-0.41	1.79e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.74	9.89	0.63	4.21e-18	Birth weight;
PAAD	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.41	-5.08	-0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	trans	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.46	-0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2147959	0.941	rs7524236	chr1:228630395	C/T	cg02753203	chr1:228287806	NA	0.57	4.79	0.36	3.87e-6	Adult asthma;
PAAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26850624	chr5:429559	AHRR	0.43	5.29	0.39	4.23e-7	Cystic fibrosis severity;
PAAD	cis	rs4668356	1.000	rs6711423	chr2:172012079	A/T	cg13882835	chr2:172017928	TLK1	0.83	4.48	0.34	1.47e-5	Cognitive performance;
PAAD	cis	rs57502260	0.915	rs7106320	chr11:68210118	C/T	cg01657329	chr11:68192670	LRP5	-0.7	-4.92	-0.37	2.23e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg15192750	chr16:69999425	NA	0.71	5.39	0.4	2.67e-7	IgE levels;
PAAD	cis	rs12431939	0.817	rs7153408	chr14:51671492	G/A	cg23942311	chr14:51606299	NA	0.5	4.4	0.34	2.02e-5	Cancer;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg10729496	chr3:10149963	C3orf24	0.65	5.54	0.41	1.27e-7	Alzheimer's disease;
PAAD	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.18	0.39	6.91e-7	Common traits (Other);
PAAD	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg10818794	chr15:86012489	AKAP13	-0.45	-4.82	-0.36	3.42e-6	Coronary artery disease;
PAAD	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.45	6.88	0.49	1.48e-10	Cutaneous nevi;
PAAD	cis	rs2117029	0.553	rs731350	chr12:49524587	G/C	cg05368762	chr12:50135785	TMBIM6	0.45	4.41	0.34	1.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.92	-0.43	2.03e-8	Schizophrenia;
PAAD	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.93	-7.46	-0.52	6.1e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs1977876	0.929	rs60707186	chr1:211707950	T/C	cg01575408	chr1:211752895	SLC30A1	0.54	4.43	0.34	1.78e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.7	6.87	0.49	1.55e-10	Lymphocyte counts;
PAAD	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.53	0.61	3.6e-17	Colorectal cancer;
PAAD	cis	rs59888335	0.964	rs33938207	chr3:80727514	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs11623869	0.695	rs3759579	chr14:103851272	A/G	cg26031613	chr14:104095156	KLC1	-0.62	-6.65	-0.47	4.9e-10	Bone mineral density;
PAAD	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-1.09	-11.42	-0.68	3.36e-22	IgG glycosylation;
PAAD	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg09659197	chr4:152720779	NA	0.46	6.04	0.44	1.14e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11044823	chr5:64858848	CENPK;PPWD1	0.56	6.36	0.46	2.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.72	-7.29	-0.51	1.61e-11	Colorectal cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13830393	chr12:108079615	PWP1	0.59	6.37	0.46	2.17e-9	Myopia (pathological);
PAAD	cis	rs72772787	1.000	rs59203167	chr1:248014245	A/G	cg04028570	chr1:248100427	OR2L13	0.57	4.45	0.34	1.63e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs2882667	0.654	rs6862845	chr5:138273145	A/C	cg09476006	chr5:138032270	NA	0.47	6.01	0.44	1.34e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg14092988	chr3:52407081	DNAH1	0.46	5.41	0.4	2.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.39	0.4	2.58e-7	Life satisfaction;
PAAD	cis	rs2446066	0.872	rs2608302	chr12:53790296	T/G	cg20591337	chr12:53693442	C12orf10	-0.63	-4.4	-0.34	2.05e-5	Red blood cell count;
PAAD	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.46	0.41	1.87e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg06217071	chr17:408420	NA	0.63	5.99	0.44	1.44e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.46	-0.41	1.88e-7	Prostate cancer;
PAAD	cis	rs2236267	0.600	rs993688	chr14:88616722	A/T	cg18078958	chr14:88630771	NA	-0.51	-6.61	-0.47	6.15e-10	Food antigen IgG levels;
PAAD	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.1	14.51	0.76	1.76e-30	Cognitive function;
PAAD	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.62	5.65	0.42	7.86e-8	Fractional excretion of uric acid;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24836822	chr7:150648840	KCNH2	0.6	7.02	0.49	6.75e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9398803	0.698	rs1262550	chr6:127078110	A/C	cg19875578	chr6:126661172	C6orf173	-0.42	-4.35	-0.33	2.5e-5	Male-pattern baldness;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg14003231	chr6:33640908	ITPR3	-0.35	-4.41	-0.34	1.95e-5	Plateletcrit;
PAAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg23018236	chr17:30244563	NA	-0.6	-4.5	-0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg22920501	chr2:26401640	FAM59B	0.98	8.33	0.56	4.41e-14	Gut microbiome composition (summer);
PAAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.38	0.56	3.26e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2236521	0.632	rs35265388	chr20:60894278	C/T	cg22601191	chr20:60968625	CABLES2	0.47	4.39	0.34	2.14e-5	Pelvic organ prolapse;
PAAD	cis	rs2242420	0.920	rs16825746	chr1:21958909	G/A	cg26362272	chr1:22108717	USP48	0.59	4.54	0.35	1.15e-5	Hematological and biochemical traits;
PAAD	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg07164556	chr1:145727247	PDZK1	-0.85	-4.33	-0.33	2.64e-5	Mitochondrial DNA levels;
PAAD	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.61	5.24	0.39	5.35e-7	Common traits (Other);
PAAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg14851346	chr12:38532713	NA	0.49	4.53	0.34	1.2e-5	Morning vs. evening chronotype;
PAAD	cis	rs6542838	0.698	rs7565736	chr2:99464952	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.56	-0.35	1.04e-5	Fear of minor pain;
PAAD	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6137287	0.813	rs13042216	chr20:21222126	C/G	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.39	-0.34	2.1e-5	Height;
PAAD	cis	rs10885582	0.781	rs10787535	chr10:116301436	G/A	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.1	-0.38	1e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg04132472	chr17:19861366	AKAP10	0.45	4.98	0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-4.62	-0.35	8.18e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.79	0.36	3.93e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22780026	chr13:20235870	MPHOSPH8	-0.58	-6.72	-0.48	3.39e-10	Monocyte percentage of white cells;
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Body mass index;
PAAD	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.57	0.35	9.91e-6	Parkinson's disease;
PAAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.66	6.15	0.45	6.4e-9	Blood metabolite levels;
PAAD	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg21479132	chr6:26055353	NA	0.92	5.2	0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.62	-6.47	-0.46	1.27e-9	Height;
PAAD	cis	rs76878669	0.617	rs10896114	chr11:66143797	A/G	cg10685839	chr11:66611485	RCE1	0.47	4.39	0.34	2.15e-5	Educational attainment (years of education);
PAAD	cis	rs939584	0.935	rs11127490	chr2:646110	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	1.07	10.8	0.66	1.58e-20	Orofacial clefts;
PAAD	cis	rs1519814	0.654	rs6469888	chr8:121018175	A/G	cg22335954	chr8:121166405	COL14A1	-0.62	-4.77	-0.36	4.29e-6	Breast cancer;
PAAD	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg15145965	chr22:50218605	BRD1	0.61	5.25	0.39	5.11e-7	Schizophrenia;
PAAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7998202	0.614	rs394369	chr13:113370228	A/G	cg02820901	chr13:113351484	ATP11A	0.7	4.69	0.36	5.95e-6	Glycated hemoglobin levels;
PAAD	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.19	-0.45	5.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.9	-7.92	-0.54	4.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120243	0.539	rs12486427	chr3:157113276	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00292662	chr22:38071168	LGALS1	0.52	5.49	0.41	1.66e-7	Fat distribution (HIV);
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07362569	chr17:61921086	SMARCD2	0.61	7.17	0.5	2.98e-11	Prudent dietary pattern;
PAAD	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.24	-0.56	7.56e-14	Chronic sinus infection;
PAAD	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg15691649	chr6:25882328	NA	-0.49	-4.51	-0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg04607235	chr12:12878440	APOLD1	-1.04	-11.41	-0.68	3.63e-22	Lymphocyte counts;
PAAD	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg09491104	chr22:46646882	C22orf40	-1.01	-6.08	-0.44	9.17e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.71	-0.36	5.55e-6	Neuroticism;
PAAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	4.63	0.35	7.72e-6	Menopause (age at onset);
PAAD	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.42	-6.22	-0.45	4.56e-9	Subjective well-being;
PAAD	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.62	-0.41	9.09e-8	Mood instability;
PAAD	cis	rs11638815	0.581	rs2870965	chr15:83301029	A/G	cg00614314	chr15:82944287	LOC80154	0.44	4.25	0.33	3.67e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs603424	0.551	rs646767	chr10:102084897	A/G	cg10365880	chr10:102089681	PKD2L1	-0.64	-4.35	-0.33	2.45e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg17366294	chr4:99064904	C4orf37	0.59	6.3	0.46	3.02e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6558530	0.666	rs4242539	chr8:1694236	A/G	cg08198773	chr8:1697536	NA	0.46	5.14	0.38	8.48e-7	Systolic blood pressure;
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.96	-0.37	1.9e-6	Tuberculosis;
PAAD	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg12935359	chr14:103987150	CKB	-0.56	-5.84	-0.43	3.07e-8	Body mass index;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12379764	chr21:47803548	PCNT	0.45	4.27	0.33	3.49e-5	Testicular germ cell tumor;
PAAD	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.49	-5.37	-0.4	2.85e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12449964	0.524	rs7225934	chr17:17572544	T/C	cg04398451	chr17:18023971	MYO15A	0.49	4.83	0.36	3.36e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	1.04	9.09	0.59	4.93e-16	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.59	5.28	0.39	4.4e-7	Retinal vascular caliber;
PAAD	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg11783602	chr8:55087084	NA	-0.63	-7.29	-0.51	1.58e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.41	0.4	2.37e-7	Lung cancer in ever smokers;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.67	-7.12	-0.5	4.02e-11	Longevity;Endometriosis;
PAAD	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-5.01	-0.38	1.47e-6	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22390894	chr1:70671645	SFRS11;LRRC40	0.65	6.49	0.47	1.14e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.4	-0.34	2.05e-5	Morning vs. evening chronotype;
PAAD	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.9	0.69	1.7e-23	Corneal structure;
PAAD	cis	rs16975963	0.644	rs73035158	chr19:38141880	C/A	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.33e-5	Longevity;
PAAD	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.87	-9.1	-0.59	4.62e-16	Systemic lupus erythematosus;
PAAD	cis	rs8018808	0.935	rs6574372	chr14:77906295	T/G	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22043652	chr11:1301434	TOLLIP	-0.8	-8.75	-0.58	3.8e-15	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs7224685	0.731	rs35514092	chr17:4183041	G/A	cg11204139	chr17:3907470	NA	0.68	5.65	0.42	7.72e-8	Type 2 diabetes;
PAAD	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.17	16.49	0.8	1.15e-35	Body mass index;
PAAD	cis	rs17681684	0.505	rs62064491	chr17:9803564	G/A	cg26853458	chr17:9805074	RCVRN	0.88	9.74	0.62	1.02e-17	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.87	12.38	0.71	8.73e-25	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.64	7.52	0.52	4.39e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.81	-7.91	-0.54	4.97e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-5.11	-0.38	9.56e-7	Eosinophil percentage of white cells;
PAAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.81	-0.36	3.66e-6	Menarche (age at onset);
PAAD	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs12936587	0.633	rs12951181	chr17:17502453	T/C	cg03641529	chr17:17716218	SREBF1	-0.4	-4.31	-0.33	2.88e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg22153407	chr1:230290089	GALNT2	0.49	4.99	0.37	1.67e-6	Coronary artery disease;
PAAD	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg04450456	chr4:17643702	FAM184B	0.5	5.3	0.39	4.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.95	-11.33	-0.68	5.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg11822372	chr1:151115635	SEMA6C	0.53	4.9	0.37	2.43e-6	Childhood ear infection;
PAAD	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.41	-0.34	1.98e-5	IgG glycosylation;
PAAD	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.16e-8	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg02524346	chr8:600233	NA	-1.07	-7.14	-0.5	3.5e-11	IgG glycosylation;
PAAD	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05049329	chr1:226924846	ITPKB	0.54	7.34	0.51	1.19e-11	Parkinson's disease;
PAAD	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs7580658	0.588	rs2069920	chr2:128179646	T/C	cg21855830	chr2:127963489	CYP27C1	0.46	4.37	0.33	2.31e-5	Protein C levels;
PAAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.69	-0.36	6.01e-6	Body mass index;
PAAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.66	-6.91	-0.49	1.24e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	6.98	0.49	8.54e-11	Blood protein levels;
PAAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.16	16.82	0.81	1.6e-36	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01170758	chr4:1957019	WHSC1	0.65	6.61	0.47	6.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.54	-0.35	1.14e-5	Life satisfaction;
PAAD	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.75	0.36	4.6e-6	Menopause (age at onset);
PAAD	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg09754948	chr16:28834200	ATXN2L	-0.49	-4.44	-0.34	1.73e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs16910800	0.906	rs2449436	chr11:23204720	G/T	cg20040320	chr11:23191996	NA	0.58	4.92	0.37	2.27e-6	Cancer;
PAAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.24	0.39	5.39e-7	Bone mineral density;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.89	-8.1	-0.55	1.64e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs17095355	1.000	rs17126883	chr10:111694696	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.42	-0.34	1.88e-5	Biliary atresia;
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.23	-0.39	5.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.85e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	5.19	0.39	6.7e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs62179067	0.708	rs62175984	chr2:179876164	A/C	cg13380624	chr19:7735426	NA	-0.73	-6.96	-0.49	9.73e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.5	4.81	0.36	3.53e-6	Longevity;
PAAD	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	1.13	10.21	0.64	5.93e-19	Colorectal cancer;
PAAD	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg00086871	chr4:6988644	TBC1D14	1.17	5.31	0.4	3.79e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-5.89	-0.43	2.38e-8	Coronary artery disease;
PAAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg22143856	chr6:28129313	ZNF389	0.51	4.75	0.36	4.74e-6	Parkinson's disease;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.46	4.57	0.35	1.02e-5	Cognitive function;
PAAD	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.47	4.96	0.37	1.89e-6	Breast cancer;
PAAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg24163568	chr5:669837	TPPP	-0.36	-4.26	-0.33	3.51e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs713477	1.000	rs12893000	chr14:55912280	G/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1507153	0.549	rs236861	chr6:79334147	C/T	cg05283184	chr6:79620031	NA	0.36	4.32	0.33	2.76e-5	Sjögren's syndrome;
PAAD	cis	rs412050	0.547	rs17821500	chr22:22152480	T/C	cg17089214	chr22:22089827	YPEL1	0.67	4.53	0.35	1.17e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg23912435	chr1:150601613	ENSA	0.5	4.64	0.35	7.52e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4834770	0.765	rs1511016	chr4:120170355	A/T	cg09307838	chr4:120376055	NA	0.54	5.03	0.38	1.37e-6	Blood protein levels;
PAAD	cis	rs16970672	0.501	rs62079061	chr17:76080670	G/A	cg15618347	chr17:76503643	DNAH17	-0.45	-4.38	-0.33	2.21e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.61	-6.01	-0.44	1.31e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9659323	0.804	rs10923722	chr1:119543486	C/T	cg17326555	chr1:119535693	NA	-0.46	-6.24	-0.45	4.09e-9	Body mass index;
PAAD	cis	rs2070677	0.673	rs3020503	chr10:135381766	C/T	cg08390786	chr10:135334061	NA	-0.65	-5.71	-0.42	5.8e-8	Gout;
PAAD	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	5.68	0.42	6.68e-8	Blood protein levels;
PAAD	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg14345882	chr6:26364793	BTN3A2	0.71	4.26	0.33	3.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4443100	0.958	rs5996455	chr22:23379255	G/A	cg14186256	chr22:23484241	RTDR1	0.52	4.59	0.35	9.31e-6	Serum parathyroid hormone levels;
PAAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg19192590	chr2:178524533	PDE11A	0.42	4.28	0.33	3.32e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3931020	0.720	rs1327090	chr1:75266479	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.56	5.59	0.41	1.05e-7	Resistin levels;
PAAD	cis	rs7084783	0.600	rs11191738	chr10:105345984	A/T	cg00126946	chr10:105363258	SH3PXD2A	-0.44	-4.55	-0.35	1.11e-5	Fear of pain;
PAAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.46	-5.85	-0.43	2.89e-8	Vitiligo;
PAAD	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-4.63	-0.35	7.9e-6	Type 2 diabetes;
PAAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.58	4.69	0.36	6.09e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6088813	1.000	rs4911491	chr20:33947285	C/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs6844506	1.000	rs1776004	chr4:185215460	A/C	cg12654155	chr4:185238627	NA	-0.51	-4.77	-0.36	4.22e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.07	-0.5	5.22e-11	Life satisfaction;
PAAD	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg16766828	chr3:128327626	NA	0.44	5.85	0.43	2.92e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.8	-6.2	-0.45	5.08e-9	Psoriasis;
PAAD	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.92	-0.37	2.23e-6	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04256674	chr7:227662	FAM20C	-0.57	-6.29	-0.45	3.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg22482690	chr17:47019901	SNF8	0.49	5.14	0.38	8.39e-7	Type 2 diabetes;
PAAD	cis	rs9462846	1.000	rs9471941	chr6:42857827	C/T	cg02353165	chr6:42928485	GNMT	-0.61	-4.72	-0.36	5.38e-6	Blood protein levels;
PAAD	cis	rs73206853	0.841	rs74728497	chr12:111020179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	4.52	0.34	1.23e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9918079	0.506	rs10214	chr4:15606431	T/C	cg16509355	chr4:15471240	CC2D2A	0.34	4.33	0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-5.43	-0.4	2.21e-7	Crohn's disease;
PAAD	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.7	-0.72	1.18e-25	Primary sclerosing cholangitis;
PAAD	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg06057569	chr22:50219754	BRD1	0.67	5.06	0.38	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.6	5.38	0.4	2.78e-7	Height;
PAAD	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg08975724	chr8:8085496	FLJ10661	-0.71	-6.83	-0.48	1.88e-10	Mood instability;
PAAD	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.33	12.28	0.71	1.67e-24	Uric acid levels;
PAAD	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.31	12.48	0.71	4.8e-25	Corneal structure;
PAAD	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.6	-5.72	-0.42	5.38e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg01075559	chr1:2537774	MMEL1	0.52	5.46	0.4	1.93e-7	Ulcerative colitis;
PAAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg00262122	chr8:11665843	FDFT1	0.53	4.62	0.35	8.13e-6	Retinal vascular caliber;
PAAD	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.57	-5.93	-0.43	1.92e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg07202610	chr7:1142643	C7orf50	-0.64	-4.85	-0.37	2.97e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg00071950	chr4:10020882	SLC2A9	0.61	5.08	0.38	1.11e-6	Blood metabolite levels;
PAAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs795484	0.633	rs904662	chr12:118581833	C/T	cg16572268	chr12:118583242	PEBP1	0.61	6.2	0.45	5.16e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07167872	chr1:205819463	PM20D1	0.46	4.28	0.33	3.24e-5	Parkinson's disease;
PAAD	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg10208897	chr5:178548229	ADAMTS2	0.52	4.62	0.35	8.25e-6	Pubertal anthropometrics;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.69	7.33	0.51	1.28e-11	Obesity-related traits;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.53	-5.36	-0.4	2.98e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.87	9.83	0.62	5.96e-18	Prudent dietary pattern;
PAAD	cis	rs4547160	0.788	rs12227007	chr12:63484710	G/T	cg26727693	chr12:63544175	AVPR1A	-0.36	-4.37	-0.33	2.29e-5	Morning vs. evening chronotype;
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.48	0.34	1.49e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24110177	chr3:50126178	RBM5	-0.61	-6.86	-0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.78e-6	Lung cancer;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22162314	chr17:61951766	CSH2	-0.57	-5.95	-0.43	1.79e-8	Height;
PAAD	cis	rs2296225	0.722	rs58464781	chr1:21051430	C/A	cg24673385	chr1:21051448	SH2D5	0.49	4.54	0.35	1.13e-5	Eosinophilic esophagitis;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-6.7	-0.48	3.74e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg22338127	chr1:209979572	IRF6	0.53	4.37	0.33	2.3e-5	Coronary artery disease;
PAAD	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.23	-0.51	2.24e-11	Retinal vascular caliber;
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.55	6.16	0.45	6.14e-9	Facial morphology (factor 20);
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.98e-10	Lung cancer;
PAAD	cis	rs4750440	0.706	rs1599413	chr10:14019197	C/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.5	4.66	0.35	6.83e-6	Red blood cell count;
PAAD	cis	rs501916	0.833	rs11629796	chr15:48045248	A/G	cg16110827	chr15:48056943	SEMA6D	-0.49	-4.99	-0.38	1.62e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-5.22	-0.39	5.67e-7	Vitiligo;
PAAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	3.43e-18	Cognitive function;
PAAD	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.52	-5.39	-0.4	2.61e-7	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg00750074	chr16:89608354	SPG7	-0.6	-5.72	-0.42	5.41e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.62	0.41	8.78e-8	Prudent dietary pattern;
PAAD	cis	rs7873102	0.654	rs2265166	chr9:37988829	C/T	cg03528946	chr9:38069800	SHB	0.5	5.07	0.38	1.12e-6	Brain structure;
PAAD	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.78	6.18	0.45	5.55e-9	Neutrophil percentage of white cells;
PAAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.28e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.87	-8.48	-0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1020064	0.636	rs2576750	chr2:105916635	A/T	cg02543470	chr2:105862877	NA	-0.48	-5.32	-0.4	3.62e-7	AIDS;
PAAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs75920871	0.589	rs4938342	chr11:117003420	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-4.92	-0.37	2.19e-6	Subjective well-being;
PAAD	cis	rs10510102	1.000	rs7923678	chr10:123592061	G/A	cg09536375	chr10:123735128	NSMCE4A	-0.38	-4.33	-0.33	2.73e-5	Breast cancer;
PAAD	cis	rs4326844	0.583	rs10506328	chr12:54687232	A/C	cg18321976	chr12:53893000	MAP3K12	0.45	4.29	0.33	3.16e-5	Platelet count;
PAAD	cis	rs1950500	0.585	rs8003339	chr14:24817817	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.51	4.56	0.35	1.03e-5	Height;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.9	11.69	0.69	6.37e-23	Total body bone mineral density;
PAAD	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.81	-7.73	-0.53	1.33e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg21994712	chr19:21861136	NA	-0.45	-4.43	-0.34	1.78e-5	Pain;
PAAD	cis	rs7577696	0.597	rs212751	chr2:32418808	T/A	cg02381751	chr2:32503542	YIPF4	0.49	4.71	0.36	5.44e-6	Inflammatory biomarkers;
PAAD	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs9810890	1.000	rs73198843	chr3:128502514	G/A	cg19129842	chr3:128565090	NA	-0.75	-5.23	-0.39	5.5e-7	Dental caries;
PAAD	cis	rs9652601	0.959	rs7198621	chr16:11167458	C/G	cg04616529	chr16:11181986	CLEC16A	0.47	5.14	0.38	8.38e-7	Systemic lupus erythematosus;
PAAD	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg16756631	chr2:172967274	DLX2	0.46	4.42	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.68	-4.84	-0.37	3.14e-6	LDL cholesterol levels;
PAAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.56	0.47	8.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.78	-6.46	-0.46	1.36e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg01305830	chr4:1604576	NA	-0.48	-4.65	-0.35	7.2e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.74	0.69	4.77e-23	Smoking behavior;
PAAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.97	10.0	0.63	2.09e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg17401720	chr7:158221031	PTPRN2	0.48	5.09	0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg22467129	chr15:76604101	ETFA	0.49	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.31	0.64	3.2e-19	Total body bone mineral density;
PAAD	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61931739	0.507	rs1352393	chr12:33815820	A/G	cg26384229	chr12:38710491	ALG10B	0.62	6.36	0.46	2.29e-9	Morning vs. evening chronotype;
PAAD	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.82	8.37	0.56	3.52e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs8005677	0.770	rs56180741	chr14:23377246	T/C	cg01529538	chr14:23388837	RBM23	0.48	4.8	0.36	3.8e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.59	7.07	0.5	5.31e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.52	-0.34	1.25e-5	Biliary atresia;
PAAD	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg04374321	chr14:90722782	PSMC1	-0.46	-4.29	-0.33	3.21e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.35	-0.33	2.52e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg07159951	chr1:45983175	PRDX1	-0.41	-4.46	-0.34	1.56e-5	High light scatter reticulocyte count;
PAAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.52	7.07	0.5	5.2e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs300774	0.925	rs435919	chr2:128890	T/G	cg21211680	chr2:198530	NA	-0.66	-6.04	-0.44	1.12e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg21226059	chr5:178986404	RUFY1	-0.57	-6.74	-0.48	3.06e-10	Lung cancer;
PAAD	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs1371614	0.588	rs11126784	chr2:27169842	C/A	cg00617064	chr2:27272375	NA	-0.45	-4.63	-0.35	7.8e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg08975724	chr8:8085496	FLJ10661	-0.67	-6.65	-0.47	5e-10	Morning vs. evening chronotype;
PAAD	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.2	0.39	6.47e-7	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg10932868	chr11:921992	NA	-0.5	-5.83	-0.43	3.15e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.66	7.23	0.51	2.17e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs863345	0.967	rs863357	chr1:158544253	C/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs7766436	0.848	rs6903685	chr6:22605813	C/T	cg13666174	chr6:22585274	NA	-0.59	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs5756391	0.568	rs2075940	chr22:37318446	G/A	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg17633681	chr16:88106987	BANP	0.6	6.99	0.49	8.25e-11	Menopause (age at onset);
PAAD	cis	rs12714314	0.830	rs12612812	chr2:1962131	A/C	cg22350835	chr2:1868857	MYT1L	0.46	4.82	0.36	3.48e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg17644776	chr2:200775616	C2orf69	-0.56	-4.58	-0.35	9.51e-6	Schizophrenia;
PAAD	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg07159951	chr1:45983175	PRDX1	0.43	4.72	0.36	5.33e-6	High light scatter reticulocyte count;
PAAD	cis	rs57908212	1	rs57908212	chr19:2161321	T/C	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.15e-6	Red blood cell count;Hemoglobin concentration;Hematocrit;
PAAD	cis	rs9616064	0.778	rs9616050	chr22:46966536	G/A	cg03318428	chr22:46971703	NA	0.41	4.73	0.36	5.04e-6	Urate levels in obese individuals;
PAAD	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.43	-4.52	-0.34	1.25e-5	Height;
PAAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-5.21	-0.39	5.96e-7	Testicular germ cell tumor;
PAAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.09	-8.47	-0.57	1.95e-14	Diabetic kidney disease;
PAAD	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg05579598	chr16:88989069	CBFA2T3	0.52	7.85	0.54	6.76e-13	Social autistic-like traits;
PAAD	cis	rs4740619	0.619	rs943789	chr9:16031951	G/A	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg25886479	chr11:50257625	LOC441601	-0.43	-4.45	-0.34	1.67e-5	Coronary artery disease;
PAAD	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.59	5.26	0.39	4.75e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.74	-6.1	-0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	1.16	6.23	0.45	4.38e-9	Skin colour saturation;
PAAD	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.64	-0.47	5.21e-10	Lung cancer;
PAAD	trans	rs2249625	0.739	rs2496535	chr6:72788647	G/A	cg04413069	chr12:9800446	LOC374443	0.59	6.56	0.47	7.92e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17648537	chr2:86333281	PTCD3;POLR1A	0.72	7.28	0.51	1.7e-11	Obesity-related traits;
PAAD	cis	rs4843185	0.699	rs8571	chr16:85709610	G/A	cg26571870	chr16:85723150	GINS2	-0.48	-5.83	-0.43	3.2e-8	Platelet distribution width;
PAAD	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.87e-5	Dermatomyositis;
PAAD	cis	rs722864	0.665	rs3754747	chr2:173965296	C/T	cg09210666	chr2:173941575	ZAK	0.53	4.51	0.34	1.28e-5	Lung cancer;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg26939375	chr7:64535504	NA	-0.76	-9.14	-0.6	3.8e-16	Calcium levels;
PAAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.36e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23281280	chr6:28129359	ZNF389	-0.7	-5.45	-0.4	2.01e-7	Depression;
PAAD	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg04117972	chr1:227635322	NA	0.59	4.26	0.33	3.57e-5	Major depressive disorder;
PAAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs112990264	1.000	rs111261646	chr1:213020558	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg03983715	chr16:68378420	PRMT7	-0.72	-5.18	-0.39	7.04e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-7.15	-0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs802075	0.676	rs545487	chr6:49772063	G/T	cg20364632	chr6:49636226	NA	0.48	5.38	0.4	2.82e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.7	7.62	0.53	2.47e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs385076	0.562	rs1119292	chr2:32045773	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-4.68	-0.35	6.39e-6	Interleukin-18 levels;
PAAD	cis	rs7737355	0.812	rs171523	chr5:130844946	A/G	cg06307176	chr5:131281290	NA	0.49	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.5	4.65	0.35	7.24e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg03959625	chr15:84868606	LOC388152	0.43	4.46	0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg05294307	chr14:35346193	BAZ1A	-0.51	-4.83	-0.36	3.28e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg05993574	chr11:61129284	CYBASC3;TMEM138	-0.61	-6.44	-0.46	1.46e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg17764715	chr19:33622953	WDR88	0.67	6.47	0.46	1.3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.64	-5.89	-0.43	2.34e-8	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00991659	chr20:61315831	NA	0.63	6.64	0.47	5.15e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4740619	0.557	rs3008729	chr9:16009057	G/T	cg14451791	chr9:16040625	NA	-0.39	-4.54	-0.35	1.13e-5	Body mass index;
PAAD	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.9	5.89	0.43	2.36e-8	Major depressive disorder;
PAAD	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.35	6.34e-6	Vitiligo;
PAAD	cis	rs7766436	0.767	rs13200993	chr6:22612912	C/T	cg13666174	chr6:22585274	NA	-0.47	-4.9	-0.37	2.43e-6	Coronary artery disease;
PAAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.6	-6.24	-0.45	4.11e-9	Body mass index;
PAAD	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.72	8.48	0.57	1.83e-14	Bladder cancer;
PAAD	cis	rs17155006	0.746	rs430628	chr7:107746214	T/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg01631408	chr1:248437212	OR2T33	-0.55	-4.64	-0.35	7.52e-6	Common traits (Other);
PAAD	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg06243866	chr13:111019493	COL4A2	0.58	5.41	0.4	2.37e-7	White matter hyperintensity burden;
PAAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.67	-7.15	-0.5	3.42e-11	DNA methylation (variation);
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg02725872	chr8:58115012	NA	-0.6	-5.2	-0.39	6.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.73	-7.02	-0.49	6.91e-11	Cognitive function;
PAAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.73	-7.43	-0.52	7.2e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs9398803	0.723	rs1022573	chr6:127054914	C/A	cg19875578	chr6:126661172	C6orf173	-0.45	-4.74	-0.36	4.95e-6	Male-pattern baldness;
PAAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-10.9	-0.66	8.44e-21	Heart rate;
PAAD	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg14254433	chr6:34482411	PACSIN1	-1.12	-6.34	-0.46	2.52e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.86	-5.97	-0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.82	-8.15	-0.55	1.23e-13	Vitamin D levels;
PAAD	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.66	6.39	0.46	1.89e-9	Hip circumference;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.8	-6.0	-0.44	1.36e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-4.97	-0.37	1.81e-6	Total body bone mineral density;
PAAD	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.58	-5.9	-0.43	2.22e-8	Coronary artery disease;
PAAD	cis	rs2506028	1.000	rs788261	chr10:43437970	A/G	cg20628663	chr10:43360327	NA	-0.37	-4.4	-0.34	2.03e-5	Blood protein levels;
PAAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg23463467	chr20:60627584	TAF4	0.47	4.96	0.37	1.84e-6	Body mass index;
PAAD	cis	rs3736485	0.934	rs11635216	chr15:51871947	A/G	cg19558802	chr15:51695713	GLDN	0.42	4.29	0.33	3.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.68	4.74	0.36	4.94e-6	Vitiligo;
PAAD	cis	rs11264213	0.818	rs2765012	chr1:36356457	A/G	cg27506609	chr1:36549197	TEKT2	0.73	5.06	0.38	1.21e-6	Schizophrenia;
PAAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-10.0	-0.63	2.11e-18	Bone mineral density;
PAAD	cis	rs6466055	0.661	rs6963661	chr7:104932821	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03881711	chr4:118497266	NA	0.53	6.47	0.46	1.27e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17023223	0.537	rs12086	chr1:119573860	T/C	cg26570165	chr1:119541833	NA	-0.51	-4.38	-0.33	2.24e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.74	6.49	0.47	1.13e-9	Pulmonary function decline;
PAAD	cis	rs56046484	0.871	rs7177110	chr15:85671755	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-4.44	-0.34	1.73e-5	Testicular germ cell tumor;
PAAD	cis	rs12760731	0.565	rs34593395	chr1:178129488	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.38	-4.26	-0.33	3.5e-5	Blood protein levels;
PAAD	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21028142	chr17:79581711	NPLOC4	0.46	5.49	0.41	1.68e-7	Eye color traits;
PAAD	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-5.4	-0.4	2.47e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.91	-7.21	-0.5	2.52e-11	Blood protein levels;
PAAD	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.46	-5.09	-0.38	1.03e-6	Pneumonia;
PAAD	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.49	5.03	0.38	1.37e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6494488	0.500	rs72743002	chr15:65011195	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg10207240	chr12:122356781	WDR66	0.63	6.62	0.47	5.76e-10	Mean corpuscular volume;
PAAD	cis	rs4356203	0.870	rs10832746	chr11:17249953	A/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs11811982	0.793	rs114967166	chr1:227288330	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg08886695	chr4:3369023	RGS12	-0.5	-4.64	-0.35	7.32e-6	Serum sulfate level;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.57	-0.41	1.14e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg06629702	chr1:2706960	NA	-0.36	-4.26	-0.33	3.55e-5	Ulcerative colitis;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg16920238	chr17:80076378	CCDC57	0.46	4.3	0.33	3.05e-5	Life satisfaction;
PAAD	cis	rs11696501	0.843	rs6073774	chr20:44150077	C/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-5.94	-0.43	1.91e-8	Brain structure;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.07	0.44	9.99e-9	Height;
PAAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.79	7.14	0.5	3.58e-11	Obesity-related traits;
PAAD	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.54	6.36	0.46	2.21e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg07291445	chr7:39015928	NA	0.29	4.29	0.33	3.15e-5	IgG glycosylation;
PAAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	1.31	14.28	0.76	6.97e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19757253	chr2:32853039	TTC27	0.59	6.56	0.47	7.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9314614	0.789	rs2951863	chr8:6710502	A/C	cg27319216	chr8:6693540	XKR5	-0.37	-4.98	-0.37	1.68e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.8	-9.0	-0.59	8.46e-16	Height;
PAAD	cis	rs9659323	0.612	rs10923721	chr1:119542187	A/G	cg17326555	chr1:119535693	NA	-0.46	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.58	-0.35	9.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-6.72	-0.48	3.37e-10	Mood instability;
PAAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.49	-4.59	-0.35	9.19e-6	Menarche (age at onset);
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.9	6.93	0.49	1.13e-10	Schizophrenia;
PAAD	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg17595323	chr11:93583763	C11orf90	-0.37	-4.61	-0.35	8.38e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg00944433	chr1:107599041	PRMT6	0.4	4.56	0.35	1.06e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs66731853	0.557	rs576968	chr1:20901246	A/G	cg04087271	chr1:20915334	CDA	-0.51	-6.13	-0.45	7.22e-9	Mean corpuscular volume;
PAAD	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg11993925	chr19:44307056	LYPD5	-0.51	-6.82	-0.48	1.98e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.61	-0.47	6.14e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.55	0.47	8.38e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.8	7.15	0.5	3.4e-11	Exhaled nitric oxide levels;
PAAD	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-14.29	-0.76	6.6e-30	Primary sclerosing cholangitis;
PAAD	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.84	-0.49	1.81e-10	Schizophrenia;
PAAD	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg09579323	chr1:150459698	TARS2	-0.45	-4.25	-0.33	3.67e-5	Migraine;
PAAD	cis	rs2730260	0.800	rs73169216	chr7:158834662	G/A	cg02254261	chr7:158964346	NA	-0.6	-4.58	-0.35	9.72e-6	Myopia (pathological);
PAAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.65	-0.42	7.71e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg02012338	chr4:187126139	CYP4V2	0.71	4.6	0.35	8.87e-6	Blood protein levels;
PAAD	cis	rs7534824	0.625	rs61780327	chr1:101449810	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg20607287	chr7:12443886	VWDE	-0.92	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg26031613	chr14:104095156	KLC1	0.53	5.72	0.42	5.56e-8	Schizophrenia;
PAAD	cis	rs74181299	0.684	rs11126028	chr2:65338150	C/G	cg20592124	chr2:65290738	CEP68	-0.46	-4.3	-0.33	3.07e-5	Pulse pressure;
PAAD	cis	rs28830936	0.966	rs4924580	chr15:42137773	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.54	-6.79	-0.48	2.38e-10	Diastolic blood pressure;
PAAD	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg23254163	chr1:152506842	NA	0.57	6.59	0.47	6.92e-10	Hair morphology;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs7631605	0.870	rs55755638	chr3:37157145	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg07503211	chr7:5402297	TNRC18	-0.61	-6.45	-0.46	1.42e-9	Educational attainment;
PAAD	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	7.44	0.52	6.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.73	-6.89	-0.49	1.41e-10	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.62	-4.52	-0.34	1.23e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.49	7.2	0.5	2.59e-11	Mean corpuscular volume;
PAAD	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.37	-0.61	9.35e-17	Calcium levels;
PAAD	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg07159951	chr1:45983175	PRDX1	0.43	4.72	0.36	5.33e-6	High light scatter reticulocyte count;
PAAD	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.01	-0.38	1.49e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	7.01	0.49	7.26e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7945718	0.621	rs10831887	chr11:12665436	A/C	cg25843174	chr11:12811716	TEAD1	0.31	4.64	0.35	7.44e-6	Educational attainment (years of education);
PAAD	cis	rs6137287	0.813	rs6035811	chr20:21203946	G/C	cg04219410	chr20:21106687	PLK1S1	0.39	4.37	0.33	2.28e-5	Height;
PAAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.72	8.83	0.58	2.35e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.94	8.17	0.55	1.08e-13	Alzheimer's disease;
PAAD	cis	rs1656368	0.726	rs12492884	chr3:158252566	A/G	cg16708174	chr3:158430962	RARRES1	0.52	4.72	0.36	5.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.12	-0.38	9.16e-7	Pulmonary function;
PAAD	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg03367679	chr17:38183553	MED24;SNORD124	0.35	4.71	0.36	5.65e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs1941184	0.759	rs10048228	chr18:29023539	G/A	cg03238162	chr18:29027701	DSG3	0.41	4.74	0.36	4.89e-6	Parkinson's disease (age of onset);
PAAD	cis	rs7084921	0.578	rs12776318	chr10:101868677	T/G	cg04359915	chr10:101825029	CPN1	-0.34	-5.21	-0.39	6.18e-7	Bone mineral density;
PAAD	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg23752985	chr2:85803571	VAMP8	0.56	6.26	0.45	3.77e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs16857609	0.550	rs1351163	chr2:218267992	A/G	cg15335768	chr2:218268053	DIRC3	-0.5	-5.19	-0.39	6.7e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-5.84	-0.43	3.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-4.35	-0.33	2.47e-5	Blood metabolite levels;
PAAD	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.41	-4.87	-0.37	2.83e-6	Mean arterial pressure;
PAAD	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.85	-8.11	-0.55	1.61e-13	Colorectal adenoma (advanced);
PAAD	trans	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg26939375	chr7:64535504	NA	0.72	8.43	0.56	2.44e-14	Aortic root size;
PAAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.48	-4.64	-0.35	7.49e-6	Urate levels in obese individuals;
PAAD	cis	rs4073221	0.789	rs67392505	chr3:18217031	G/C	cg07694806	chr3:18168406	NA	-0.83	-4.96	-0.37	1.86e-6	Parkinson's disease;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs10894604	0.520	rs10894605	chr11:132654027	A/G	cg13055484	chr11:132662455	OPCML	-0.38	-4.36	-0.33	2.38e-5	Waist-hip ratio;
PAAD	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg26876637	chr1:152193138	HRNR	0.85	6.32	0.46	2.75e-9	Atopic dermatitis;
PAAD	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg08501292	chr6:25962987	TRIM38	0.77	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.76	-4.33	-0.33	2.69e-5	Diabetic retinopathy;
PAAD	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.72	4.49	0.34	1.39e-5	IgG glycosylation;
PAAD	cis	rs2133450	1.000	rs12489402	chr3:7346663	C/T	cg19930620	chr3:7340148	GRM7	-0.44	-4.58	-0.35	9.7e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg02711726	chr17:80685570	FN3KRP	-0.68	-6.85	-0.49	1.68e-10	Glycated hemoglobin levels;
PAAD	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.79	-8.84	-0.58	2.2e-15	DNA methylation (variation);
PAAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg21546286	chr11:48923668	NA	-0.47	-4.98	-0.37	1.74e-6	Height;
PAAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09303701	chr2:20190082	WDR35	-0.78	-6.64	-0.47	5.32e-10	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19987840	chr4:123844099	SPATA5;NUDT6	0.69	8.06	0.55	2.05e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9810890	1.000	rs73196999	chr3:128460581	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg03340356	chr1:67600835	NA	-0.52	-6.07	-0.44	9.73e-9	Psoriasis;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.53	-5.56	-0.41	1.16e-7	Iron status biomarkers;
PAAD	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.58	-0.47	7.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.47	-5.15	-0.39	7.81e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7631605	0.905	rs11920928	chr3:37210874	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.56	7.22	0.51	2.37e-11	Longevity;
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.91	0.59	1.46e-15	Lung cancer;
PAAD	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	6.52	0.47	9.57e-10	Lymphocyte counts;
PAAD	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg11995313	chr8:8860691	ERI1	0.49	4.86	0.37	2.91e-6	Joint mobility (Beighton score);
PAAD	cis	rs939584	1.000	rs4854348	chr2:647760	A/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.39	-0.34	2.14e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg00376283	chr12:123451042	ABCB9	0.69	6.59	0.47	6.77e-10	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg10168330	chr8:27262164	PTK2B	0.38	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg10006428	chr1:248814059	OR2T27	0.4	4.72	0.36	5.21e-6	Common traits (Other);
PAAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.52	-4.53	-0.34	1.2e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.83	8.66	0.57	6.53e-15	Calcium levels;
PAAD	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-5.18	-0.39	6.85e-7	Coronary artery disease;
PAAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.44	5.6	0.41	9.73e-8	Crohn's disease;
PAAD	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22674798	chr1:3096360	PRDM16	0.63	9.85	0.62	5.07e-18	Migraine;
PAAD	cis	rs6499129	0.867	rs4360931	chr16:67471926	C/G	cg10189135	chr16:67516162	ATP6V0D1	-0.6	-4.62	-0.35	8.26e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs902774	1.000	rs11831942	chr12:53272113	T/G	cg00800353	chr12:53273449	NA	0.57	4.4	0.34	1.99e-5	Prostate cancer;
PAAD	cis	rs4561483	0.603	rs62038777	chr16:11934176	A/C	cg08843971	chr16:11963173	GSPT1	0.43	4.84	0.37	3.2e-6	Testicular germ cell tumor;
PAAD	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.53	-6.24	-0.45	4.16e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.5	4.93	0.37	2.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs385076	0.527	rs10779914	chr2:32106040	C/A	cg02381751	chr2:32503542	YIPF4	-0.49	-4.68	-0.36	6.21e-6	Interleukin-18 levels;
PAAD	cis	rs75920871	0.800	rs6589595	chr11:116981335	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.8	-0.36	3.78e-6	Subjective well-being;
PAAD	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg02297831	chr4:17616191	MED28	-0.59	-5.58	-0.41	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12042052	0.793	rs12036759	chr1:232925441	A/G	cg02903907	chr1:232941055	KIAA1383	0.85	4.6	0.35	8.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9463078	0.546	rs969211	chr6:45022378	T/C	cg25276700	chr6:44698697	NA	0.45	5.04	0.38	1.31e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs9936833	1.000	rs1532167	chr16:86404204	T/G	cg03554962	chr16:86404423	NA	0.38	4.38	0.33	2.17e-5	Barrett's esophagus;
PAAD	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.72	0.36	5.35e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.3	-0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1443512	1.000	rs1443512	chr12:54342684	A/C	cg25382128	chr12:54346509	NA	-0.6	-6.06	-0.44	1.01e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.86	10.17	0.64	7.34e-19	Blood protein levels;
PAAD	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.63	6.29	0.45	3.25e-9	Type 2 diabetes;
PAAD	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.49	4.62	0.35	7.97e-6	Depression;
PAAD	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.9	6.79	0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23158103	chr7:148848205	ZNF398	-0.53	-4.78	-0.36	4.06e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.41	-5.08	-0.38	1.1e-6	Corneal astigmatism;
PAAD	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.83	9.38	0.61	9.1e-17	Monocyte count;
PAAD	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06251068	chr11:910944	CHID1	-0.67	-6.53	-0.47	9.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2834288	0.500	rs766425	chr21:35334566	G/T	cg22542663	chr21:34915757	GART;SON	0.43	4.35	0.33	2.51e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.91	-6.56	-0.47	8.02e-10	Psoriasis vulgaris;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.89	0.43	2.44e-8	Prudent dietary pattern;
PAAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg19413350	chr8:57351067	NA	-0.48	-4.94	-0.37	2.03e-6	Obesity-related traits;
PAAD	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.85	7.02	0.49	7.06e-11	Obesity-related traits;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg16506815	chr2:162101123	NA	0.67	7.15	0.5	3.39e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.34	-0.51	1.23e-11	Neuroticism;
PAAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg04844267	chr4:1394941	NA	0.53	5.79	0.43	3.91e-8	Obesity-related traits;
PAAD	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg03885332	chr11:832357	CD151	-0.45	-5.24	-0.39	5.27e-7	Mean platelet volume;
PAAD	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.97	8.24	0.56	7.23e-14	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950880	0.710	rs4851011	chr2:103089678	A/G	cg23450938	chr2:102972792	NA	-0.41	-4.35	-0.33	2.52e-5	Serum protein levels (sST2);
PAAD	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1105228	0.918	rs93927	chr6:165714834	A/G	cg20535254	chr6:165714960	C6orf118	-0.5	-4.92	-0.37	2.22e-6	Number of pregnancies;Number of children;
PAAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg01176363	chr20:62369445	LIME1	-0.58	-5.5	-0.41	1.56e-7	Prostate cancer;
PAAD	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.88	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs405795	0.661	rs314413	chr13:89785069	A/G	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Yeast infection;
PAAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.76	6.27	0.45	3.55e-9	Recombination rate (females);
PAAD	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.53	0.34	1.18e-5	Tonsillectomy;
PAAD	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.46	-0.34	1.57e-5	Testicular germ cell tumor;
PAAD	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg08975724	chr8:8085496	FLJ10661	0.79	8.12	0.55	1.5e-13	Schizophrenia;
PAAD	cis	rs7873102	0.654	rs2266012	chr9:37979857	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.67	6.87	0.49	1.56e-10	Blood protein levels;
PAAD	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.38	-4.34	-0.33	2.61e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10769393	chr19:2819754	ZNF554	0.67	7.3	0.51	1.5e-11	Myopia (pathological);
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	7.36	0.51	1.08e-11	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18621852	chr3:10150065	C3orf24	0.66	5.64	0.42	8.03e-8	Alzheimer's disease;
PAAD	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	1.11	12.31	0.71	1.33e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg08132940	chr7:1081526	C7orf50	0.59	4.29	0.33	3.12e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg26174226	chr8:58114915	NA	-0.62	-4.74	-0.36	4.79e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.68	-5.0	-0.38	1.54e-6	Body mass index;
PAAD	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg01631408	chr1:248437212	OR2T33	-0.62	-5.27	-0.39	4.63e-7	Common traits (Other);
PAAD	cis	rs6137287	0.813	rs2424355	chr20:21229391	A/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.39	0.34	2.1e-5	Height;
PAAD	cis	rs1499972	0.941	rs7631320	chr3:117650116	T/C	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg01763666	chr17:80159506	CCDC57	-0.45	-4.55	-0.35	1.09e-5	Life satisfaction;
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.4	5.0	0.38	1.53e-6	Iron status biomarkers;
PAAD	cis	rs7172689	0.908	rs55697022	chr15:81567474	T/G	cg05624577	chr15:81411055	NA	-0.57	-4.32	-0.33	2.77e-5	Inattentive symptoms;
PAAD	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.52	-6.11	-0.44	8.11e-9	Mean arterial pressure;
PAAD	cis	rs41311933	1.000	rs12683026	chr9:123758632	A/G	cg13567360	chr9:123745713	C5	-0.72	-4.59	-0.35	9.12e-6	Coronary artery disease;
PAAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg08677398	chr8:58056175	NA	0.62	4.63	0.35	7.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg19264203	chr11:92714893	MTNR1B	0.4	4.56	0.35	1.06e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.45e-7	Monocyte percentage of white cells;
PAAD	cis	rs7011049	1.000	rs78200075	chr8:53845907	G/A	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs595018	0.505	rs7942904	chr11:60598483	G/A	cg23904249	chr11:60608951	CCDC86	0.7	5.18	0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg06636001	chr8:8085503	FLJ10661	0.6	6.23	0.45	4.3e-9	Joint mobility (Beighton score);
PAAD	cis	rs2798269	0.564	rs1967778	chr13:22164868	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.54	-4.85	-0.37	2.99e-6	PR segment;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.56	5.38	0.4	2.75e-7	Lung cancer;
PAAD	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs12580194	0.593	rs12099665	chr12:55731191	G/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.41	4.43	0.34	1.8e-5	Mean corpuscular volume;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.93	-8.17	-0.55	1.09e-13	Other erythrocyte phenotypes;
PAAD	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs2221894	0.922	rs11136052	chr8:28803075	G/C	cg20212339	chr8:28908912	HMBOX1	0.5	5.31	0.4	3.82e-7	Obesity-related traits;
PAAD	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.45	-4.51	-0.34	1.31e-5	Adiposity;
PAAD	cis	rs354033	0.959	rs735120	chr7:149313811	C/T	cg06920324	chr7:149264011	ZNF767	-0.61	-4.98	-0.37	1.7e-6	Multiple sclerosis;
PAAD	cis	rs4780401	0.933	rs4780396	chr16:11816671	G/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-5.19	-0.39	6.58e-7	Rheumatoid arthritis;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.34	-0.56	4.07e-14	Longevity;Endometriosis;
PAAD	cis	rs9394841	0.573	rs28360509	chr6:41748263	C/T	cg08135965	chr6:41755394	TOMM6	0.51	5.24	0.39	5.32e-7	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg00540400	chr15:79124168	NA	-0.55	-6.59	-0.47	6.82e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.09	0.44	8.74e-9	Lung cancer;
PAAD	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26926768	chr12:34528122	NA	-0.4	-4.88	-0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.38	4.44	0.34	1.73e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.58	-0.41	1.07e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00280220	chr17:61926910	NA	0.46	4.68	0.35	6.36e-6	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.88	5.85	0.43	2.96e-8	Thyroid stimulating hormone;
PAAD	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.65	-5.57	-0.41	1.15e-7	Educational attainment;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.49	5.5	0.41	1.61e-7	QRS complex (12-leadsum);
PAAD	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.84	-7.89	-0.54	5.49e-13	Neurofibrillary tangles;
PAAD	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.81	9.71	0.62	1.25e-17	Gut microbiome composition (winter);
PAAD	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7638995	0.878	rs17005384	chr3:69181552	A/G	cg26574240	chr3:69171822	LMOD3	0.68	4.79	0.36	3.9e-6	Alzheimer's disease (late onset);
PAAD	cis	rs10875746	0.551	rs2054904	chr12:48724354	C/G	cg26205652	chr12:48591994	NA	0.76	7.03	0.5	6.6e-11	Longevity (90 years and older);
PAAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg25614726	chr1:10490058	APITD1	0.37	4.35	0.33	2.45e-5	Prostate cancer;
PAAD	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Intracranial aneurysm;
PAAD	cis	rs2120991	0.967	rs7133456	chr12:54268206	G/A	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.25	-0.33	3.76e-5	Biliary atresia;
PAAD	cis	rs8014252	0.803	rs73282127	chr14:70986413	T/C	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9815354	0.812	rs939561	chr3:42057101	G/A	cg03022575	chr3:42003672	ULK4	-0.73	-5.29	-0.39	4.21e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.44	6.11	0.44	7.83e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4742903	0.935	rs9775540	chr9:106977722	A/G	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg20243544	chr17:37824526	PNMT	0.53	4.6	0.35	8.75e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2835872	0.758	rs1787395	chr21:39036478	A/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.52	-4.8	-0.36	3.68e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg21775007	chr8:11205619	TDH	0.52	4.84	0.37	3.2e-6	Systolic blood pressure;
PAAD	cis	rs988913	1.000	rs6941796	chr6:54837621	A/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg17650747	chr5:1873721	NA	0.44	4.5	0.34	1.36e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg01388757	chr2:102091195	RFX8	-0.55	-7.06	-0.5	5.54e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs96067	0.652	rs274137	chr1:36577945	A/G	cg27506609	chr1:36549197	TEKT2	-0.83	-5.12	-0.38	9.22e-7	Corneal structure;
PAAD	cis	rs35955747	0.838	rs5997887	chr22:31543197	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-4.74	-0.36	4.97e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg04160749	chr8:58172571	NA	-0.71	-4.76	-0.36	4.38e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.25	0.33	3.75e-5	Tonsillectomy;
PAAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.8	-0.43	3.79e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.84e-5	Height;
PAAD	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.76	9.3	0.6	1.44e-16	Alcohol dependence;
PAAD	cis	rs72960926	0.744	rs56004196	chr6:74880673	G/A	cg03266952	chr6:74778945	NA	-1.11	-5.96	-0.44	1.7e-8	Metabolite levels (MHPG);
PAAD	cis	rs2790216	0.950	rs9415552	chr10:60009289	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17471019	chr8:94767003	TMEM67	0.56	6.32	0.46	2.69e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.6	6.82	0.48	1.99e-10	Bladder cancer;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.62	7.66	0.53	1.97e-12	Lung cancer;
PAAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs72828912	0.656	rs2139792	chr6:24094347	C/T	cg27524988	chr6:24583477	KIAA0319	-0.49	-4.38	-0.33	2.19e-5	Squamous cell lung carcinoma;
PAAD	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.65	5.86	0.43	2.83e-8	Mean corpuscular volume;
PAAD	cis	rs600626	0.588	rs72997616	chr11:75474195	C/A	cg24262691	chr11:75473276	NA	0.74	6.1	0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4455778	0.600	rs4478520	chr7:49079788	A/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.62	0.53	2.5e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8005677	0.798	rs4536383	chr14:23410926	T/C	cg01529538	chr14:23388837	RBM23	0.48	4.78	0.36	4.17e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.6	-8.07	-0.55	1.94e-13	Endometriosis;
PAAD	cis	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg25886479	chr11:50257625	LOC441601	-0.44	-4.79	-0.36	3.96e-6	Height;
PAAD	cis	rs1209950	0.901	rs1209953	chr21:40180383	T/A	cg01359822	chr21:40176597	ETS2	0.31	5.08	0.38	1.07e-6	Non-small cell lung cancer (survival);
PAAD	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg02023728	chr11:77925099	USP35	-0.44	-4.47	-0.34	1.51e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	trans	rs9257809	1	rs9257809	chr6:29356331	A/G	cg01620082	chr3:125678407	NA	-1.61	-10.04	-0.63	1.62e-18	Breast cancer;Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma;
PAAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg24253500	chr15:84953950	NA	0.43	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.81	-6.8	-0.48	2.26e-10	Cancer;
PAAD	cis	rs7567389	0.504	rs2069898	chr2:128174227	T/C	cg11380483	chr2:127933992	NA	0.52	4.9	0.37	2.45e-6	Self-rated health;
PAAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22633769	chr20:60982531	CABLES2	0.49	4.71	0.36	5.59e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs7301016	0.846	rs12369751	chr12:63031133	G/C	cg11441379	chr12:63026424	NA	0.89	6.47	0.46	1.26e-9	IgG glycosylation;
PAAD	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.28	0.39	4.45e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.79e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7688540	0.760	rs4510422	chr4:231940	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.4	0.34	2e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs2268241	0.938	rs9808753	chr21:34787312	A/G	cg14850771	chr21:34775459	IFNGR2	0.93	7.3	0.51	1.5e-11	Obesity-related traits;
PAAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg12193833	chr17:30244370	NA	-0.62	-4.75	-0.36	4.69e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25151836	chr18:48346543	MRO	0.51	6.44	0.46	1.52e-9	Monocyte percentage of white cells;
PAAD	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.77	0.53	1.07e-12	Morning vs. evening chronotype;
PAAD	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.28	10.39	0.64	1.9e-19	Uric acid levels;
PAAD	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.35	-0.6	1.1e-16	Depression;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13560548	chr3:10150139	C3orf24	0.62	5.65	0.42	7.74e-8	Alzheimer's disease;
PAAD	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs57024841	0.819	rs11145948	chr9:139857912	C/T	cg00693599	chr9:139836323	FBXW5	-0.48	-4.64	-0.35	7.53e-6	Beta-trace protein levels;
PAAD	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.45	-4.43	-0.34	1.8e-5	Ovarian reserve;
PAAD	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg19846168	chr1:2845268	NA	0.46	4.28	0.33	3.23e-5	Plateletcrit;
PAAD	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg25801113	chr15:45476975	SHF	-0.42	-5.06	-0.38	1.19e-6	Uric acid levels;
PAAD	cis	rs2241685	0.646	rs13016585	chr2:1934252	G/C	cg22511877	chr2:1942942	MYT1L	-0.58	-4.58	-0.35	9.75e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg27490568	chr2:178487706	NA	0.42	4.73	0.36	5.07e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg01798341	chr17:80842262	TBCD	-0.42	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg03233332	chr7:66118400	NA	0.41	4.45	0.34	1.65e-5	Aortic root size;
PAAD	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.78	-5.46	-0.4	1.94e-7	Blood protein levels;
PAAD	cis	rs11753937	0.735	rs572004	chr6:133580411	G/T	cg07327468	chr6:133561765	EYA4	0.39	4.61	0.35	8.55e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6906287	0.573	rs12205899	chr6:118699928	C/G	cg21191810	chr6:118973309	C6orf204	0.44	5.5	0.41	1.58e-7	Electrocardiographic conduction measures;
PAAD	cis	rs9653442	0.900	rs6754937	chr2:100827720	T/G	cg07810366	chr2:100720526	AFF3	-0.37	-4.74	-0.36	4.79e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6494488	0.500	rs72744719	chr15:65018928	T/C	cg16425858	chr15:64791681	ZNF609	1.01	4.73	0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs1032355	0.558	rs7668586	chr4:100536363	C/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.56	-7.1	-0.5	4.39e-11	Educational attainment;
PAAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.75	-8.11	-0.55	1.54e-13	DNA methylation (variation);
PAAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6732160	0.619	rs12105975	chr2:73406049	T/A	cg24220031	chr2:73402428	NA	-0.41	-6.44	-0.46	1.49e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07602571	chr7:77644868	NA	0.55	6.45	0.46	1.41e-9	Smoking initiation;
PAAD	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.55	-4.8	-0.36	3.71e-6	Mean platelet volume;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg15331088	chr8:600555	NA	0.74	4.73	0.36	4.99e-6	IgG glycosylation;
PAAD	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.71	8.48	0.57	1.88e-14	Lewy body disease;
PAAD	cis	rs818427	0.929	rs469663	chr5:112231829	A/G	cg06941702	chr5:112196734	SRP19	0.52	4.76	0.36	4.51e-6	Total body bone mineral density;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.72	-0.48	3.41e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.3	0.39	4.04e-7	Ovarian reserve;
PAAD	cis	rs2147959	0.824	rs10916313	chr1:228625882	C/G	cg18477163	chr1:228402036	OBSCN	-0.44	-4.47	-0.34	1.53e-5	Adult asthma;
PAAD	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg05925327	chr15:68127851	NA	-0.63	-5.74	-0.42	4.88e-8	Restless legs syndrome;
PAAD	cis	rs9992101	0.589	rs7675217	chr4:77413142	G/C	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.43	6.24	0.45	4.12e-9	Information processing speed;
PAAD	cis	rs6804624	0.676	rs2700650	chr3:99158618	A/G	cg02646433	chr3:99218170	NA	0.42	4.31	0.33	2.97e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.65	7.33	0.51	1.25e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07677032	chr17:61819896	STRADA	0.52	5.13	0.38	8.68e-7	Prudent dietary pattern;
PAAD	cis	rs11811982	0.793	rs79766410	chr1:227289103	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.83	-9.57	-0.61	2.78e-17	Superior crus of antihelix expression;
PAAD	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.44	6.9	0.49	1.28e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs16958440	0.581	rs11873880	chr18:44692465	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-4.61	-0.35	8.51e-6	Sitting height ratio;
PAAD	cis	rs9322817	0.583	rs7741733	chr6:105182839	T/C	cg02098413	chr6:105308735	HACE1	-0.45	-5.72	-0.42	5.54e-8	Thyroid stimulating hormone;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17418956	chr7:158672758	WDR60	-0.66	-6.67	-0.48	4.56e-10	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs1497406	0.802	rs7519043	chr1:16500523	C/T	cg20167471	chr1:16528984	ARHGEF19	0.45	4.48	0.34	1.45e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.35	-0.4	3.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.72	7.25	0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg20849893	chr7:64541193	NA	0.53	5.23	0.39	5.45e-7	Calcium levels;
PAAD	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.67	0.53	1.94e-12	HIV-1 control;
PAAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.52	-6.8	-0.48	2.25e-10	Height;
PAAD	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg12310025	chr6:25882481	NA	0.47	4.5	0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-5.94	-0.43	1.9e-8	Menarche (age at onset);
PAAD	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg17347104	chr14:75034677	LTBP2	0.56	4.64	0.35	7.33e-6	Non-small cell lung cancer;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-7.49	-0.52	5.1e-12	Prudent dietary pattern;
PAAD	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.44	4.77	0.36	4.27e-6	HDL cholesterol levels;
PAAD	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26926768	chr12:34528122	NA	0.4	4.93	0.37	2.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.13	15.43	0.78	6.36e-33	Subjective well-being;
PAAD	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg02454025	chr1:11042201	C1orf127	1.26	15.1	0.77	4.64e-32	Ewing sarcoma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01056358	chr6:166858118	RPS6KA2	-0.65	-7.06	-0.5	5.55e-11	Myopia (pathological);
PAAD	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.5	-4.87	-0.37	2.79e-6	Menarche (age at onset);
PAAD	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg12179176	chr11:130786555	SNX19	0.76	7.93	0.54	4.43e-13	Schizophrenia;
PAAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23544223	chr18:12777786	NA	0.75	6.53	0.47	9.38e-10	Inflammatory skin disease;
PAAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg00717180	chr2:96193071	NA	0.57	6.37	0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.67	-6.9	-0.49	1.32e-10	Response to antidepressants and depression;
PAAD	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg24375607	chr4:120327624	NA	0.55	5.25	0.39	5.15e-7	Corneal astigmatism;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.83	9.88	0.63	4.41e-18	Coronary artery disease;
PAAD	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	7.02	0.49	6.83e-11	Monocyte count;
PAAD	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-5.97	-0.44	1.58e-8	Body mass index (adult);
PAAD	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.8	-0.48	2.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.76	0.42	4.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.73	7.94	0.54	4.11e-13	Prostate cancer;
PAAD	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.75	-4.56	-0.35	1.04e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs457162	0.643	rs283063	chr6:118621314	T/G	cg21191810	chr6:118973309	C6orf204	0.71	4.69	0.36	5.93e-6	QT interval;
PAAD	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-5.71	-0.42	5.68e-8	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.87	11.03	0.67	3.67e-21	Prudent dietary pattern;
PAAD	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.74	-7.57	-0.52	3.31e-12	Uric acid clearance;
PAAD	cis	rs17095355	0.901	rs61881586	chr10:111758419	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.43	-0.34	1.8e-5	Biliary atresia;
PAAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg10556349	chr10:835070	NA	0.7	5.49	0.41	1.61e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13939156	chr17:80058883	NA	-0.41	-4.46	-0.34	1.59e-5	Life satisfaction;
PAAD	cis	rs11048434	0.518	rs7311267	chr12:9178678	C/T	cg04548204	chr12:9162872	KLRG1	-0.39	-4.43	-0.34	1.78e-5	Sjögren's syndrome;
PAAD	cis	rs4953404	0.613	rs2346877	chr2:46892958	C/G	cg12784625	chr2:46524557	EPAS1	-0.48	-4.31	-0.33	2.9e-5	Pulse pressure (alcohol consumption interaction);
PAAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.76	7.81	0.54	8.8e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.38	4.34	0.33	2.63e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg02487422	chr3:49467188	NICN1	0.45	4.57	0.35	1.01e-5	Resting heart rate;
PAAD	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs2034650	0.544	rs2289330	chr15:40705105	A/G	cg05276125	chr15:40653601	DISP2	0.45	4.37	0.33	2.3e-5	Interstitial lung disease;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg23788917	chr6:8435910	SLC35B3	-0.54	-5.63	-0.42	8.43e-8	Motion sickness;
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs10155981	0.510	rs28661240	chr7:22594075	G/A	cg05062323	chr7:22590069	NA	-0.92	-5.62	-0.41	8.9e-8	Bilirubin levels;
PAAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.87	8.05	0.55	2.15e-13	Homoarginine levels;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.66	-7.12	-0.5	4.01e-11	Menopause (age at onset);
PAAD	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg26897989	chr16:1907736	C16orf73	0.47	4.77	0.36	4.26e-6	Insulin-like growth factors;
PAAD	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.47	5.12	0.38	9.08e-7	Multiple sclerosis;
PAAD	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.66	-6.6	-0.47	6.49e-10	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg03605226	chr16:87637261	JPH3	0.41	4.58	0.35	9.46e-6	Menopause (age at onset);
PAAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs501120	0.584	rs11238927	chr10:44704112	C/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.14	0.45	6.77e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.76	8.72	0.58	4.64e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.49	5.33	0.4	3.43e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-5.1	-0.38	9.93e-7	Schizophrenia;
PAAD	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg18721089	chr20:30220636	NA	-0.55	-4.37	-0.33	2.3e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs3781663	0.500	rs7931752	chr11:70022846	T/C	cg06393558	chr11:69982916	ANO1	-0.58	-6.02	-0.44	1.28e-8	Survival in rectal cancer;
PAAD	cis	rs7267979	0.649	rs2500406	chr20:25401862	A/C	cg08601574	chr20:25228251	PYGB	-0.58	-5.57	-0.41	1.13e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.02	0.59	7.75e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs35160687	0.644	rs2113615	chr2:86517602	G/A	cg10973622	chr2:86423274	IMMT	-0.45	-4.93	-0.37	2.12e-6	Night sleep phenotypes;
PAAD	cis	rs3018712	0.700	rs2187331	chr11:68446424	C/T	cg02340541	chr11:68451699	GAL	-0.63	-5.22	-0.39	5.69e-7	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21110585	chr12:12510155	LOH12CR1;LOH12CR2	0.64	6.8	0.48	2.24e-10	Myopia (pathological);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07414984	chr11:93517374	MED17	-0.73	-6.43	-0.46	1.57e-9	Neuroticism;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg18538332	chr22:24372958	LOC391322	0.63	5.92	0.43	2.1e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	trans	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg15770106	chr1:208133116	NA	-0.64	-6.42	-0.46	1.68e-9	Corneal structure;
PAAD	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.55	-5.25	-0.39	5e-7	Hypertension (SNP x SNP interaction);
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.7	7.62	0.53	2.48e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs507080	0.771	rs523715	chr11:118574188	G/A	cg08498647	chr11:118550644	TREH	-0.39	-4.42	-0.34	1.83e-5	Serum metabolite levels;
PAAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-5.05	-0.38	1.27e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.74	9.49	0.61	4.52e-17	Cancer;
PAAD	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs2280630	0.529	rs6599010	chr3:39153222	C/T	cg01426195	chr3:39028469	NA	-0.65	-6.89	-0.49	1.42e-10	Verbal declarative memory;
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.11	0.63	1.08e-18	Platelet count;
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.07	0.38	1.15e-6	Body mass index;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.65	4.55	0.35	1.1e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6723226	0.552	rs62136336	chr2:32804106	G/A	cg02381751	chr2:32503542	YIPF4	0.8	8.67	0.58	5.93e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg21546286	chr11:48923668	NA	-0.44	-4.72	-0.36	5.41e-6	HDL cholesterol;
PAAD	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.22e-6	Mortality in heart failure;
PAAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01942863	chr7:99769432	GPC2	0.52	4.26	0.33	3.51e-5	Platelet count;
PAAD	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20617956	chr10:82168530	C10orf58	0.57	6.55	0.47	8.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00791764	chr4:53727839	RASL11B	0.75	4.77	0.36	4.28e-6	Optic nerve measurement (cup area);
PAAD	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg21211680	chr2:198530	NA	0.49	5.41	0.4	2.44e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg04996195	chr7:87105398	ABCB4	0.47	4.32	0.33	2.86e-5	Gallbladder cancer;
PAAD	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.72	8.32	0.56	4.56e-14	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24427944	chr11:113644552	ZW10	-0.76	-6.79	-0.48	2.38e-10	Neuroticism;
PAAD	cis	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg20159608	chr7:32802032	NA	-0.53	-5.23	-0.39	5.55e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3826795	0.569	rs11671360	chr19:46795171	T/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg02631450	chr22:32366979	NA	-1.07	-5.77	-0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.2	-0.39	6.29e-7	Reticulocyte count;
PAAD	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg17646820	chr3:66848679	NA	0.41	4.29	0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.24	13.51	0.74	8.22e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.57	5.56	0.41	1.18e-7	Mortality in heart failure;
PAAD	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1358748	0.522	rs6701962	chr1:67564857	A/T	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg14393609	chr7:65229607	NA	0.68	7.54	0.52	3.93e-12	Aortic root size;
PAAD	cis	rs34226255	0.957	rs12978678	chr19:16428398	C/T	cg26918011	chr19:16634068	CHERP	-0.53	-4.6	-0.35	8.96e-6	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11141652	chr22:24348549	GSTTP1	0.5	4.8	0.36	3.81e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.46	-0.41	1.88e-7	Prostate cancer;
PAAD	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.5	5.11	0.38	9.6e-7	Colorectal cancer;
PAAD	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.89	10.36	0.64	2.27e-19	White blood cell count;
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg10621924	chr7:39171070	POU6F2	0.32	5.02	0.38	1.46e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.91	12.07	0.7	6.12e-24	Body mass index;
PAAD	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg14146966	chr2:61757674	XPO1	0.38	4.81	0.36	3.66e-6	Tuberculosis;
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg10547527	chr2:198650123	BOLL	-0.72	-4.98	-0.37	1.68e-6	Ulcerative colitis;
PAAD	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg16205897	chr5:131564050	P4HA2	-0.41	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.68	6.63	0.47	5.59e-10	Depressive symptoms;
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27436995	chr16:743998	FBXL16	-0.37	-4.47	-0.34	1.54e-5	Height;
PAAD	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.83e-13	Motion sickness;
PAAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg08493051	chr2:3487164	NA	-0.72	-6.97	-0.49	8.8e-11	Neurofibrillary tangles;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.64	-7.75	-0.53	1.19e-12	Menopause (age at onset);
PAAD	cis	rs2290419	0.730	rs74342245	chr11:68938776	G/A	cg17042914	chr11:68898666	NA	-0.76	-4.37	-0.33	2.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.71	0.48	3.71e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg19413350	chr8:57351067	NA	-0.45	-4.27	-0.33	3.44e-5	Obesity-related traits;
PAAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.27	-0.56	6.3e-14	Alcohol dependence;
PAAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12315302	chr6:26189340	HIST1H4D	0.56	4.3	0.33	2.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.49	0.34	1.41e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.97	11.1	0.67	2.47e-21	Parkinson's disease;
PAAD	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg13206674	chr6:150067644	NUP43	-0.55	-4.99	-0.37	1.67e-6	Lung cancer;
PAAD	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg17385448	chr1:15911702	AGMAT	0.38	4.68	0.35	6.27e-6	Systolic blood pressure;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.37e-10	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16516888	chr11:77532772	C11orf67;RSF1	0.61	6.43	0.46	1.58e-9	Pancreatic cancer;
PAAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.64	6.43	0.46	1.54e-9	Monocyte count;
PAAD	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.49	4.63	0.35	7.83e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.69	6.73	0.48	3.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.35	0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.54	-5.51	-0.41	1.48e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6074578	0.679	rs1594918	chr20:143754	C/T	cg16931068	chr20:139680	DEFB127	0.38	5.14	0.39	8.18e-7	Hirschsprung disease;
PAAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	Trans fatty acid levels;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg22338127	chr1:209979572	IRF6	0.53	4.34	0.33	2.55e-5	Coronary artery disease;
PAAD	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg10932868	chr11:921992	NA	0.5	6.06	0.44	1.04e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg20045696	chr14:77926864	AHSA1	0.52	5.15	0.39	7.95e-7	Myeloid white cell count;
PAAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg17987982	chr7:158820591	NA	-0.43	-4.74	-0.36	4.81e-6	Facial morphology (factor 20);
PAAD	trans	rs901683	1.000	rs33997730	chr10:46068113	G/A	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26714410	chr13:45150072	TSC22D1	0.58	6.32	0.46	2.69e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2965280	1.000	rs2965280	chr19:34917700	C/T	cg00878516	chr19:35842853	FFAR1	-0.65	-4.27	-0.33	3.4e-5	Colorectal cancer;
PAAD	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg17514665	chr17:1657533	SERPINF2	0.65	6.03	0.44	1.18e-8	Serum albumin level;
PAAD	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.69	-7.3	-0.51	1.53e-11	Osteoporosis;
PAAD	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg12870014	chr12:110450643	ANKRD13A	0.71	5.02	0.38	1.41e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg10645314	chr2:3704589	ALLC	-0.45	-4.67	-0.35	6.7e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.75	-7.13	-0.5	3.73e-11	Systemic lupus erythematosus;
PAAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg24733560	chr20:60626293	TAF4	0.53	7.03	0.5	6.36e-11	Body mass index;
PAAD	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg14593290	chr7:50529359	DDC	-0.44	-4.38	-0.33	2.24e-5	Body mass index;
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.92e-7	Prostate cancer;
PAAD	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.26	11.9	0.69	1.7e-23	Corneal structure;
PAAD	cis	rs2790216	0.950	rs1698431	chr10:59963146	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg11143131	chr5:131608246	PDLIM4	0.46	4.27	0.33	3.49e-5	Breast cancer;
PAAD	cis	rs9377188	0.843	rs2340801	chr6:149348359	C/G	cg21368479	chr6:149415018	NA	0.43	4.47	0.34	1.52e-5	Cancer;
PAAD	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.47	-0.41	1.83e-7	Response to antipsychotic treatment;
PAAD	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs2880058	0.709	rs10918601	chr1:162037670	C/T	cg22816059	chr5:422114	AHRR	-0.62	-6.49	-0.47	1.12e-9	QT interval;
PAAD	cis	rs6137287	0.813	rs2236128	chr20:21194437	C/T	cg04219410	chr20:21106687	PLK1S1	-0.4	-4.5	-0.34	1.34e-5	Height;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	7.07	0.5	5.3e-11	Renal function-related traits (BUN);
PAAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg21625146	chr5:486483	SLC9A3	0.36	5.31	0.4	3.75e-7	Cystic fibrosis severity;
PAAD	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg05110241	chr16:68378359	PRMT7	-0.69	-5.13	-0.38	8.7e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg20933634	chr6:27740509	NA	0.66	6.29	0.45	3.26e-9	Parkinson's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07301433	chr2:38303999	CYP1B1	0.59	6.53	0.47	9.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-6.05	-0.44	1.06e-8	Total body bone mineral density;
PAAD	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.37	9.33	0.6	1.2e-16	Diabetic retinopathy;
PAAD	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.49	-0.41	1.66e-7	Triglycerides;
PAAD	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939584	1.000	rs13388043	chr2:637597	A/G	cg03610516	chr2:642275	NA	-0.57	-5.26	-0.39	4.91e-7	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13212159	chr17:38075554	GSDMB	-0.65	-6.82	-0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.66	7.28	0.51	1.64e-11	Longevity;Endometriosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18207308	chr7:2018435	MAD1L1	0.68	6.79	0.48	2.33e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.52	-0.34	1.22e-5	Breast cancer;
PAAD	cis	rs73416724	1.000	rs113163694	chr6:43283410	C/T	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7554547	0.622	rs2179110	chr1:11972811	C/T	cg13216073	chr1:12042593	MFN2	0.4	4.25	0.33	3.76e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.77	9.46	0.61	5.51e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02071572	chr4:1403502	NA	0.49	6.34	0.46	2.47e-9	Longevity;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.86	5.59	0.41	1.01e-7	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18391955	chr19:51303514	SNORD88A;C19orf48;SNORD88B	0.63	7.59	0.52	3.01e-12	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25971741	chr6:15343116	JARID2	-0.68	-6.92	-0.49	1.2e-10	Obesity-related traits;
PAAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg00999904	chr2:3704751	ALLC	-0.51	-5.87	-0.43	2.64e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.49	-4.26	-0.33	3.53e-5	Red blood cell traits;
PAAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00692763	chr18:47088373	LIPG	0.62	7.0	0.49	7.81e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.66	-0.35	6.79e-6	Lung cancer;
PAAD	cis	rs656900	0.765	rs599842	chr15:80111891	A/G	cg02196730	chr15:80188777	MTHFS	0.46	4.82	0.36	3.44e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg21205071	chr1:161993677	OLFML2B	0.49	4.51	0.34	1.3e-5	IgG glycosylation;
PAAD	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.38	0.33	2.18e-5	Educational attainment;
PAAD	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.69	6.4	0.46	1.87e-9	Lymphocyte counts;
PAAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg14703610	chr5:56206110	C5orf35	0.56	5.28	0.39	4.4e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg23643435	chr2:38893251	GALM	-0.62	-4.47	-0.34	1.49e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg11057378	chr10:81107060	PPIF	0.46	5.51	0.41	1.49e-7	Height;
PAAD	cis	rs4455778	0.580	rs4357241	chr7:49089468	A/G	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	7.46	0.52	6.1e-12	Neuroticism;
PAAD	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11547950	chr5:77652471	NA	-0.68	-5.93	-0.43	1.94e-8	Triglycerides;
PAAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.47	4.42	0.34	1.83e-5	Morning vs. evening chronotype;
PAAD	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg03315344	chr16:75512273	CHST6	-0.63	-5.31	-0.4	3.86e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.48	4.49	0.34	1.39e-5	Menarche (age at onset);
PAAD	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.75	5.79	0.42	3.96e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22601191	chr20:60968625	CABLES2	0.55	4.97	0.37	1.81e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.79	5.61	0.41	9.54e-8	White matter hyperintensity burden;
PAAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.24	-0.39	5.31e-7	Daytime sleep phenotypes;
PAAD	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs564309	1.000	rs58462432	chr1:228604788	T/C	cg01328119	chr1:228783545	DUSP5P	0.66	4.31	0.33	2.93e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs10078545	0.558	rs56103860	chr5:82133257	G/T	cg20697188	chr5:82360356	TMEM167A;SCARNA18	-0.5	-4.52	-0.34	1.24e-5	Chin dimples;
PAAD	cis	rs422249	0.634	rs174610	chr11:61627833	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.51	0.34	1.29e-5	Trans fatty acid levels;
PAAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg20344442	chr15:51633704	GLDN	0.52	4.85	0.37	3.04e-6	Hormone measurements;
PAAD	cis	rs7594192	0.744	rs6736290	chr2:199367709	A/T	cg01558212	chr2:200327336	NA	0.34	4.37	0.33	2.28e-5	Educational attainment;
PAAD	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.28	-0.33	3.34e-5	Joint mobility (Beighton score);
PAAD	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg14515779	chr1:101123966	NA	0.39	4.4	0.34	2e-5	Monocyte count;
PAAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg06740227	chr12:86229804	RASSF9	0.59	5.84	0.43	3.07e-8	Major depressive disorder;
PAAD	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg00543991	chr22:32367038	NA	1.13	6.91	0.49	1.23e-10	Childhood ear infection;
PAAD	cis	rs3026101	0.697	rs2107152	chr17:5297350	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	trans	rs111756027	0.522	rs72800053	chr16:77279682	C/T	cg17418387	chr1:17761802	RCC2	-0.78	-6.43	-0.46	1.53e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg19930314	chr7:98593876	TRRAP	0.48	4.42	0.34	1.87e-5	Breast cancer;
PAAD	cis	rs4454254	0.666	rs11166943	chr8:141025997	A/G	cg07454640	chr8:140990901	TRAPPC9	0.48	4.91	0.37	2.3e-6	Pulse pressure;
PAAD	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.17	15.03	0.77	7.12e-32	Type 1 diabetes nephropathy;
PAAD	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6028335	0.610	rs3752291	chr20:37570404	G/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.66	-4.94	-0.37	2.08e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13198984	chr17:80129470	CCDC57	-0.4	-4.78	-0.36	4.1e-6	Life satisfaction;
PAAD	cis	rs10186876	0.665	rs6756365	chr2:44135997	A/C	cg26828767	chr2:44457733	PPM1B	0.48	4.6	0.35	8.92e-6	Hand grip strength;
PAAD	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.35	-0.4	3.16e-7	Mean corpuscular volume;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg16590910	chr6:42928470	GNMT	0.5	5.09	0.38	1.06e-6	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg08885800	chr1:201084119	NA	0.51	4.34	0.33	2.63e-5	Permanent tooth development;
PAAD	cis	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg01990334	chr1:42801334	FOXJ3	-0.58	-5.46	-0.41	1.88e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.34	-0.33	2.62e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7551222	0.714	rs2926534	chr1:204464181	C/T	cg01064725	chr1:204461714	NA	0.52	4.28	0.33	3.31e-5	Schizophrenia;
PAAD	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-6.15	-0.45	6.48e-9	Vitamin D levels;
PAAD	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.3	0.64	3.29e-19	Bladder cancer;
PAAD	cis	rs11264799	0.598	rs6662117	chr1:157718835	G/A	cg18268488	chr1:157545234	FCRL4	0.65	5.81	0.43	3.58e-8	IgA nephropathy;
PAAD	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.28e-6	Tuberculosis;
PAAD	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg02869306	chr7:64672164	INTS4L1	-0.42	-4.84	-0.37	3.13e-6	Aortic root size;
PAAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.84	-10.79	-0.66	1.64e-20	Height;
PAAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.48	-4.81	-0.36	3.55e-6	Menopause (age at onset);
PAAD	cis	rs3847687	1.000	rs10848269	chr12:131518622	A/G	cg13406893	chr12:131568647	GPR133	-0.46	-4.56	-0.35	1.04e-5	Longevity;
PAAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.49	5.79	0.43	3.82e-8	Coronary artery disease;
PAAD	cis	rs4141404	0.577	rs2413045	chr22:31665862	A/G	cg22777020	chr22:31556080	RNF185	-0.67	-5.06	-0.38	1.17e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs793571	0.822	rs11858989	chr15:59175228	C/T	cg08898775	chr15:59042684	ADAM10	0.4	4.53	0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.02e-5	Platelet count;
PAAD	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-16.32	-0.8	3.05e-35	Exhaled nitric oxide levels;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg11062466	chr8:58055876	NA	0.69	4.75	0.36	4.75e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00463171	chr13:100741364	PCCA	0.6	6.32	0.46	2.82e-9	Pancreatic cancer;
PAAD	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-8.89	-0.58	1.65e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg16026760	chr19:4791699	FEM1A	-0.61	-6.41	-0.46	1.72e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-5.94	-0.43	1.89e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.08	7.97	0.54	3.48e-13	Left atrial antero-posterior diameter;
PAAD	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.08e-15	Exhaled nitric oxide output;
PAAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.42	-5.42	-0.4	2.33e-7	Ulcerative colitis;
PAAD	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4740619	0.711	rs4740629	chr9:15981633	T/G	cg14451791	chr9:16040625	NA	-0.4	-4.72	-0.36	5.29e-6	Body mass index;
PAAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.89	9.79	0.62	7.47e-18	Cognitive function;
PAAD	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg15696662	chr1:46669221	C1orf190;POMGNT1	-0.46	-5.45	-0.4	2.04e-7	Red blood cell count;Reticulocyte count;
PAAD	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.4	5.09	0.38	1.05e-6	Pulmonary function;
PAAD	cis	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg25886479	chr11:50257625	LOC441601	-0.41	-4.44	-0.34	1.7e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21813546	chr1:182808991	DHX9	0.6	6.69	0.48	3.99e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.74	8.27	0.56	6.4e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg22143856	chr6:28129313	ZNF389	0.6	4.66	0.35	6.96e-6	Parkinson's disease;
PAAD	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-5.0	-0.38	1.54e-6	Self-reported allergy;
PAAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg27499820	chr13:21296301	IL17D	0.52	4.93	0.37	2.12e-6	Dental caries;
PAAD	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg25401027	chr5:176370377	UIMC1	-0.42	-4.25	-0.33	3.7e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16953577	chr4:166034162	TMEM192	0.61	6.88	0.49	1.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.51	5.49	0.41	1.67e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg27129171	chr3:47204927	SETD2	0.6	6.12	0.44	7.67e-9	Birth weight;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.39	0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.82	9.14	0.6	3.64e-16	Mean corpuscular volume;
PAAD	cis	rs10885582	0.839	rs11196794	chr10:116349314	A/G	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.21	-0.39	6.05e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.66	9.16	0.6	3.28e-16	Airflow obstruction;
PAAD	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-15.53	-0.78	3.47e-33	Ulcerative colitis;
PAAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.51	-4.93	-0.37	2.13e-6	Parkinson's disease;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg15117754	chr3:10150083	C3orf24	-0.64	-4.73	-0.36	5.12e-6	Alzheimer's disease;
PAAD	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg21828629	chr1:205913422	SLC26A9	0.41	4.49	0.34	1.39e-5	Cystic fibrosis-related diabetes;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13198984	chr17:80129470	CCDC57	0.45	5.68	0.42	6.58e-8	Life satisfaction;
PAAD	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.75	-8.84	-0.58	2.27e-15	Childhood ear infection;
PAAD	cis	rs7220401	0.542	rs55644350	chr17:27913368	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	4.94	0.37	2.04e-6	Coronary artery disease;
PAAD	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs757081	0.658	rs214075	chr11:17300417	G/T	cg04705435	chr11:17411270	KCNJ11	-0.54	-5.82	-0.43	3.35e-8	Systolic blood pressure;
PAAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg24585817	chr7:64895279	NA	0.37	4.28	0.33	3.33e-5	Calcium levels;
PAAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.93	10.57	0.65	6.51e-20	Parkinson's disease;
PAAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.27	-0.33	3.37e-5	Renal cell carcinoma;
PAAD	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs8179	0.514	rs6954290	chr7:92283098	G/T	cg03496780	chr7:92466842	CDK6	0.47	4.4	0.34	2.01e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.76e-5	Migraine;
PAAD	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.57	-5.35	-0.4	3.14e-7	Primary biliary cholangitis;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.52	0.71	3.66e-25	Platelet count;
PAAD	cis	rs2034650	0.544	rs2289331	chr15:40699940	T/C	cg05276125	chr15:40653601	DISP2	0.45	4.39	0.34	2.15e-5	Interstitial lung disease;
PAAD	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg05373962	chr22:49881684	NA	-0.54	-5.24	-0.39	5.21e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.5	-4.8	-0.36	3.76e-6	Schizophrenia;
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg00035074	chr7:2701567	TTYH3	0.61	4.34	0.33	2.55e-5	Bipolar disorder;
PAAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.59	-0.35	9.31e-6	Alcohol dependence;
PAAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15145965	chr22:50218605	BRD1	0.62	5.38	0.4	2.75e-7	Schizophrenia;
PAAD	cis	rs11696501	0.688	rs6124727	chr20:44325623	T/C	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.4	0.46	1.82e-9	Coffee consumption (cups per day);
PAAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.79	-0.43	3.92e-8	Subjective well-being;
PAAD	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-4.41	-0.34	1.91e-5	Skin colour saturation;
PAAD	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.72	5.19	0.39	6.76e-7	Tuberculosis;
PAAD	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.52	6.44	0.46	1.48e-9	Longevity;Endometriosis;
PAAD	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11811982	0.793	rs74599093	chr1:227447282	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4443100	0.958	rs11090217	chr22:23378505	G/A	cg14186256	chr22:23484241	RTDR1	0.52	4.47	0.34	1.52e-5	Serum parathyroid hormone levels;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg07017636	chr1:165567312	NA	0.64	7.21	0.5	2.47e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg20821713	chr7:1055600	C7orf50	-0.62	-6.38	-0.46	2.07e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg06028605	chr16:24865363	SLC5A11	0.6	6.99	0.49	8.15e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs72960926	0.744	rs3898077	chr6:74959122	G/A	cg03266952	chr6:74778945	NA	-1.14	-6.33	-0.46	2.61e-9	Metabolite levels (MHPG);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22011436	chr11:45310837	NA	-0.55	-6.45	-0.46	1.38e-9	Monocyte percentage of white cells;
PAAD	cis	rs785830	0.811	rs661356	chr9:244457	G/A	cg14500300	chr9:211689	NA	0.41	4.35	0.33	2.45e-5	Platelet distribution width;
PAAD	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.98	6.23	0.45	4.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.78	8.57	0.57	1.11e-14	Caffeine consumption;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.56	-5.67	-0.42	6.98e-8	Parkinson's disease;
PAAD	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-4.46	-0.34	1.57e-5	Mean corpuscular volume;
PAAD	cis	rs35160687	0.901	rs34048420	chr2:86529748	A/G	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs7715811	1.000	rs7715552	chr5:13769959	A/T	cg07548982	chr5:13769939	DNAH5	-0.64	-6.23	-0.45	4.43e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.32	0.64	2.95e-19	Smoking behavior;
PAAD	cis	rs11671653	1.000	rs60755785	chr19:10839494	T/G	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.47	-6.28	-0.45	3.32e-9	Height;
PAAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.98	12.05	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.48	-5.97	-0.44	1.64e-8	Crohn's disease;
PAAD	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.63e-7	Life satisfaction;
PAAD	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg11247378	chr22:39784982	NA	-0.73	-7.66	-0.53	2.01e-12	IgG glycosylation;
PAAD	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.22	-0.39	5.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11051970	1.000	rs11051970	chr12:32537488	G/T	cg24626660	chr12:32551988	NA	0.47	5.43	0.4	2.15e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.56	4.7	0.36	5.91e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.64e-5	Bipolar disorder;
PAAD	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg12639453	chr1:2035780	PRKCZ	-0.53	-5.51	-0.41	1.52e-7	Height;
PAAD	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.32	-0.33	2.81e-5	Height;
PAAD	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.58	-0.35	9.56e-6	Triglycerides;
PAAD	cis	rs1020064	0.636	rs1529975	chr2:105929901	T/C	cg02543470	chr2:105862877	NA	-0.48	-5.28	-0.39	4.36e-7	AIDS;
PAAD	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.19	0.5	2.76e-11	Schizophrenia;
PAAD	cis	rs6500395	0.962	rs55782524	chr16:48557493	A/G	cg04672837	chr16:48644449	N4BP1	0.53	4.89	0.37	2.49e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.55	5.69	0.42	6.32e-8	Pancreatic cancer;
PAAD	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.56	5.34	0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05545111	chr9:6758140	KDM4C	0.61	6.63	0.47	5.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.36	-0.33	2.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg19438565	chr8:143695827	ARC	-0.57	-5.5	-0.41	1.56e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg07202610	chr7:1142643	C7orf50	-0.68	-5.68	-0.42	6.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg19680485	chr15:31195859	MTMR15	-0.43	-4.35	-0.33	2.49e-5	Huntington's disease progression;
PAAD	cis	rs941408	0.963	rs2537854	chr19:2786726	A/C	cg06609049	chr19:2785107	THOP1	0.95	10.86	0.66	1.08e-20	Total cholesterol levels;
PAAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg10006428	chr1:248814059	OR2T27	-0.38	-4.47	-0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg07469887	chr10:131262384	NA	-0.45	-5.32	-0.4	3.67e-7	Response to temozolomide;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08525424	chr20:62439150	NA	-0.62	-6.41	-0.46	1.76e-9	Obesity-related traits;
PAAD	cis	rs55883249	0.505	rs2357157	chr2:9758217	A/G	cg12832956	chr2:9616023	IAH1	-0.51	-5.03	-0.38	1.35e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg00999904	chr2:3704751	ALLC	0.66	7.21	0.5	2.5e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1198430	0.562	rs10917388	chr1:23803138	A/G	cg19827787	chr1:23763612	ASAP3	0.49	4.5	0.34	1.34e-5	Total cholesterol levels;
PAAD	cis	rs11811982	0.793	rs11808843	chr1:227535418	A/T	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.43e-5	Resting heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03625951	chr6:149867442	PPIL4	0.6	6.97	0.49	8.91e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22168489	chr12:122356033	WDR66	0.29	4.6	0.35	8.84e-6	Mean corpuscular volume;
PAAD	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.69	-7.84	-0.54	7.52e-13	Renal function-related traits (BUN);
PAAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.77	7.84	0.54	7.37e-13	Calcium levels;
PAAD	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.43	-0.4	2.17e-7	Retinal vascular caliber;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg13264159	chr8:625131	ERICH1	0.74	4.63	0.35	7.65e-6	IgG glycosylation;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg12193833	chr17:30244370	NA	0.58	4.31	0.33	2.94e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.93	8.31	0.56	5.01e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9649465	1.000	rs7776792	chr7:123335350	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.81	0.36	3.64e-6	Migraine;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.66	-0.53	2.02e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.4	-0.4	2.53e-7	Glomerular filtration rate;
PAAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.41	-4.92	-0.37	2.24e-6	Uric acid levels;
PAAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.64	-6.94	-0.49	1.08e-10	Bone mineral density;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg21565972	chr17:80109576	CCDC57	-0.6	-6.99	-0.49	8.25e-11	Life satisfaction;
PAAD	cis	rs797680	0.786	rs10874772	chr1:93787770	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.42	0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	4.59	0.35	9.09e-6	HIV-1 control;
PAAD	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	0.83	6.62	0.47	5.75e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	4.43	0.34	1.76e-5	Menarche (age at onset);
PAAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.35	0.51	1.11e-11	Menarche (age at onset);
PAAD	cis	rs4742903	0.904	rs7047747	chr9:106939922	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.66	0.35	6.98e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.49	-0.34	1.37e-5	Alzheimer's disease (survival time);
PAAD	cis	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.36	6.61	0.47	6.2e-10	Type 2 diabetes;
PAAD	cis	rs2882667	0.556	rs6873733	chr5:138403317	G/T	cg22797968	chr5:138629998	MATR3	0.43	4.34	0.33	2.54e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.51	4.98	0.37	1.68e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs78132593	0.723	rs34593358	chr1:150686633	A/T	cg13175981	chr1:150552382	MCL1	0.5	4.29	0.33	3.2e-5	High light scatter reticulocyte count;
PAAD	trans	rs17076896	0.520	rs61742516	chr13:19727056	A/G	cg20227530	chr10:79085138	KCNMA1	0.82	6.41	0.46	1.7e-9	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg23112188	chr14:24563095	PCK2	-0.52	-5.52	-0.41	1.4e-7	IgG glycosylation;
PAAD	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.53	5.6	0.41	9.63e-8	Menopause (age at onset);
PAAD	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.44	-6.53	-0.47	9.45e-10	Breast cancer;
PAAD	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg09163369	chr1:210001066	C1orf107	0.65	6.06	0.44	1.03e-8	Orofacial clefts;
PAAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.89	7.19	0.5	2.69e-11	Chronic kidney disease;
PAAD	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.57	-4.37	-0.33	2.31e-5	Resting heart rate;
PAAD	cis	rs7771547	0.589	rs6941918	chr6:36514721	T/G	cg07856975	chr6:36356162	ETV7	0.6	6.82	0.48	2.02e-10	Platelet distribution width;
PAAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg02196655	chr2:10830764	NOL10	0.54	5.59	0.41	1.04e-7	Prostate cancer;
PAAD	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-5.47	-0.41	1.8e-7	Longevity;Endometriosis;
PAAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg00579200	chr11:133705235	NA	-0.47	-5.07	-0.38	1.14e-6	Childhood ear infection;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.64	-6.06	-0.44	1.01e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg07148914	chr20:33460835	GGT7	0.46	4.53	0.35	1.17e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.67	-10.92	-0.66	7.41e-21	Longevity;Endometriosis;
PAAD	cis	rs76793172	0.925	rs111404322	chr19:46360739	C/T	cg13320842	chr19:46175254	GIPR	0.63	4.68	0.35	6.36e-6	Eosinophil counts;
PAAD	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs988712	0.672	rs36029218	chr11:27648371	A/T	cg10635145	chr11:27742435	BDNF	-0.37	-4.44	-0.34	1.7e-5	Obesity;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.14	-0.38	8.46e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.84	-0.49	1.81e-10	Morning vs. evening chronotype;
PAAD	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.6	-0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	cis	rs9469890	0.604	rs76452512	chr6:34504388	G/C	cg17674042	chr6:34482479	PACSIN1	-1.0	-6.81	-0.48	2.12e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs9815354	0.953	rs11717170	chr3:42002811	G/C	cg03022575	chr3:42003672	ULK4	-0.73	-5.29	-0.39	4.18e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8112211	0.554	rs7256575	chr19:38840805	C/T	cg01275006	chr19:38876250	GGN	-1.08	-6.77	-0.48	2.68e-10	Blood protein levels;
PAAD	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.69	-4.93	-0.37	2.13e-6	Type 2 diabetes;
PAAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.07e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.81	0.66	1.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg07362569	chr17:61921086	SMARCD2	0.43	4.76	0.36	4.41e-6	Height;
PAAD	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg27234864	chr13:21295941	IL17D	-0.51	-4.48	-0.34	1.48e-5	Dental caries;
PAAD	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-5.22	-0.39	5.89e-7	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs9398803	0.723	rs853968	chr6:127071753	C/T	cg19875578	chr6:126661172	C6orf173	-0.45	-4.76	-0.36	4.52e-6	Male-pattern baldness;
PAAD	cis	rs354225	0.539	rs6752720	chr2:54962352	G/A	cg01766943	chr2:54829624	SPTBN1	0.54	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.85	10.3	0.64	3.33e-19	Lung cancer;
PAAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg15478930	chr2:27652102	NRBP1	0.48	4.46	0.34	1.57e-5	Total body bone mineral density;
PAAD	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.57	-5.71	-0.42	5.64e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.92	12.25	0.7	2.01e-24	Body mass index;
PAAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.26	-0.39	4.82e-7	Monocyte count;
PAAD	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.42	5.11	0.38	9.6e-7	Systolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08664849	chr16:2546474	TBC1D24	-0.64	-6.95	-0.49	9.81e-11	Smoking initiation;
PAAD	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg08315770	chr6:39281885	KCNK17	-0.61	-6.47	-0.46	1.27e-9	Type 2 diabetes;
PAAD	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg13047869	chr3:10149882	C3orf24	0.56	4.99	0.38	1.61e-6	Alzheimer's disease;
PAAD	cis	rs11892454	0.533	rs7592985	chr2:26100227	A/C	cg25181710	chr2:26045287	ASXL2	0.39	4.4	0.34	2.07e-5	Heschl's gyrus morphology;
PAAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.72	6.54	0.47	8.88e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg07061783	chr6:25882402	NA	0.46	4.53	0.34	1.2e-5	Blood metabolite levels;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg00738919	chr7:1100172	C7orf50	0.68	5.45	0.4	1.95e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.67	7.13	0.5	3.89e-11	Prostate cancer;
PAAD	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.49	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9913156	0.517	rs8069382	chr17:4612874	G/T	cg19197139	chr17:4613644	ARRB2	0.61	6.48	0.47	1.23e-9	Lymphocyte counts;
PAAD	cis	rs12754538	0.961	rs12047377	chr1:8493933	A/T	cg06159269	chr1:8767347	RERE	0.38	4.53	0.34	1.2e-5	Subjective well-being;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7301826	1.000	rs7301826	chr12:131291101	C/T	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	cis	rs721399	0.568	rs35942058	chr8:18274398	G/A	cg18736775	chr8:18248649	NAT2	-0.66	-4.94	-0.37	2e-6	Blood metabolite levels;
PAAD	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg25204440	chr1:209979598	IRF6	0.68	5.81	0.43	3.63e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-4.76	-0.36	4.4e-6	Post bronchodilator FEV1;
PAAD	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	7.39	0.51	9.02e-12	Lymphocyte counts;
PAAD	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.66	6.04	0.44	1.16e-8	Red blood cell count;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg05457628	chr5:178986728	RUFY1	0.58	5.64	0.42	8.22e-8	Lung cancer;
PAAD	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6494488	0.500	rs72742930	chr15:64870344	A/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	1.15	12.72	0.72	1.09e-25	Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10254974	chr17:16342133	NCRNA00188;SNORD49B;SNORD49A	0.61	6.93	0.49	1.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.48	-5.2	-0.39	6.27e-7	Migraine;
PAAD	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg11417675	chr11:73694801	UCP2	0.97	4.34	0.33	2.61e-5	Obesity-related traits;
PAAD	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.67	5.56	0.41	1.17e-7	Obesity (extreme);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23928525	chr17:19266198	B9D1	0.62	7.46	0.52	6.35e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.48	-4.26	-0.33	3.5e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8024058	1.000	rs8024058	chr15:89165031	A/T	cg00367546	chr15:89165046	AEN	0.69	5.94	0.43	1.87e-8	Night sleep phenotypes;
PAAD	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.37	9.39	0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs730532	0.556	rs1497086	chr14:52517190	C/G	cg00766845	chr14:52536022	NID2	-0.6	-4.47	-0.34	1.55e-5	Pulmonary function;
PAAD	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.74	7.31	0.51	1.44e-11	Asthma;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.74	5.55	0.41	1.26e-7	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14548611	chr19:15367059	BRD4	-0.72	-7.44	-0.52	6.95e-12	Obesity-related traits;
PAAD	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.54	5.12	0.38	9.19e-7	Alcohol dependence;
PAAD	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg22827986	chr11:48284249	OR4X1	-0.36	-4.75	-0.36	4.59e-6	Migraine - clinic-based;
PAAD	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.88	-6.82	-0.48	2.01e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg11802864	chr11:65308245	LTBP3	0.43	4.38	0.33	2.19e-5	Bone mineral density;
PAAD	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.54	-8.23	-0.56	7.86e-14	Urinary metabolites;
PAAD	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	cis	rs42648	0.623	rs194505	chr7:89841307	G/A	cg27367526	chr7:89841692	STEAP2	-0.34	-4.66	-0.35	6.72e-6	Homocysteine levels;
PAAD	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg22349387	chr12:9600060	DDX12	-0.4	-4.3	-0.33	3.05e-5	Breast size;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg21565972	chr17:80109576	CCDC57	-0.56	-6.47	-0.46	1.29e-9	Life satisfaction;
PAAD	cis	rs12541635	1.000	rs1896919	chr8:107090357	C/G	cg10147462	chr8:107024639	NA	-0.44	-4.71	-0.36	5.54e-6	Age of smoking initiation;
PAAD	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg06569542	chr10:98946673	SLIT1	-0.46	-5.13	-0.38	8.7e-7	Monocyte count;
PAAD	cis	rs11209002	1.000	rs2863202	chr1:67584335	T/C	cg02640540	chr1:67518911	SLC35D1	0.6	4.32	0.33	2.82e-5	Crohn's disease;
PAAD	cis	rs251130	1.000	rs251130	chr5:110859797	A/G	cg11925263	chr5:110849104	STARD4	-0.36	-4.46	-0.34	1.56e-5	Menarche (age at onset);
PAAD	cis	rs2034088	0.897	rs4968124	chr17:436900	T/C	cg13332499	chr17:408570	NA	0.64	6.87	0.49	1.52e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg01585852	chr22:24235823	MIF	-0.46	-4.87	-0.37	2.76e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg02297831	chr4:17616191	MED28	-0.62	-6.27	-0.45	3.57e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.64	-8.11	-0.55	1.6e-13	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs642743	0.967	rs1147610	chr10:105941167	G/T	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.25	0.33	3.75e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg11843238	chr5:131593191	PDLIM4	0.48	4.5	0.34	1.37e-5	Acylcarnitine levels;
PAAD	cis	rs2120991	0.967	rs10506325	chr12:54261760	A/G	cg25640699	chr12:54070114	ATP5G2	0.43	4.53	0.34	1.19e-5	Biliary atresia;
PAAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.49	-4.76	-0.36	4.39e-6	Pulse pressure;
PAAD	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Coronary artery disease;
PAAD	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.76	7.82	0.54	8.37e-13	Neuroticism;
PAAD	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg22189786	chr22:42395067	WBP2NL	0.57	4.81	0.36	3.59e-6	Birth weight;
PAAD	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs7945718	0.563	rs4525215	chr11:12664830	T/C	cg25843174	chr11:12811716	TEAD1	0.32	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.89	11.11	0.67	2.35e-21	Prudent dietary pattern;
PAAD	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.68	4.99	0.38	1.64e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.94	12.78	0.72	7.52e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.41	-4.98	-0.37	1.7e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.82	0.43	3.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13115616	chr1:17338059	ATP13A2	-0.66	-6.94	-0.49	1.07e-10	Smoking initiation;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.79	9.98	0.63	2.31e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10267417	0.603	rs10273239	chr7:19911524	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	4.85	0.37	3.08e-6	Night sleep phenotypes;
PAAD	cis	rs3996993	0.737	rs9367495	chr6:52648106	G/A	cg20803780	chr6:52668592	GSTA1	-0.36	-4.37	-0.33	2.3e-5	Hemoglobin concentration;
PAAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	1.07	15.02	0.77	7.55e-32	Breast cancer;
PAAD	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	4.29	0.33	3.21e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs58521262	0.530	rs289367	chr19:23114530	A/T	cg22640819	chr19:22990650	NA	-0.28	-4.25	-0.33	3.69e-5	Testicular germ cell tumor;
PAAD	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg21918786	chr6:109611834	NA	-0.4	-4.41	-0.34	1.97e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg00945038	chr17:61921165	SMARCD2	-0.39	-4.76	-0.36	4.38e-6	Prudent dietary pattern;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg00450029	chr8:599525	NA	-0.87	-5.49	-0.41	1.69e-7	IgG glycosylation;
PAAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.49e-8	Menopause (age at onset);
PAAD	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.74	7.39	0.51	9.22e-12	Resting heart rate;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg00450029	chr8:599525	NA	-0.8	-4.62	-0.35	8.25e-6	IgG glycosylation;
PAAD	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg17802220	chr15:77601643	NA	-0.64	-4.78	-0.36	4.09e-6	Risky sexual behaviors (alcohol dependence interaction);
PAAD	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.68	0.62	1.5e-17	Menopause (age at onset);
PAAD	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.56	4.98	0.37	1.71e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.27	-0.33	3.44e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg08992911	chr2:238395768	MLPH	0.58	4.94	0.37	2.01e-6	Prostate cancer;
PAAD	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.98	-12.68	-0.72	1.32e-25	Coronary artery disease;
PAAD	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg22467129	chr15:76604101	ETFA	0.51	4.79	0.36	4e-6	Blood metabolite levels;
PAAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.55	-4.46	-0.34	1.59e-5	Birth weight;
PAAD	cis	rs113779084	0.777	rs12535049	chr7:11936958	A/G	cg15090509	chr7:11872073	THSD7A	0.4	5.13	0.38	8.81e-7	Educational attainment (years of education);
PAAD	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-7.08	-0.5	5.05e-11	Eye color traits;
PAAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6604026	1.000	rs6604026	chr1:93303603	A/G	cg17283838	chr1:93427260	FAM69A	0.52	4.41	0.34	1.98e-5	Multiple sclerosis;
PAAD	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	5.53	0.41	1.39e-7	Monocyte percentage of white cells;
PAAD	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.74	5.51	0.41	1.51e-7	Initial pursuit acceleration;
PAAD	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs11892454	0.515	rs10168718	chr2:26053166	G/A	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.89	-0.37	2.52e-6	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg10729496	chr3:10149963	C3orf24	0.9	7.83	0.54	7.77e-13	Alzheimer's disease;
PAAD	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.24	-0.45	4.14e-9	Alcohol dependence;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs9506514	0.509	rs9509279	chr13:21133719	C/G	cg27499820	chr13:21296301	IL17D	0.43	4.55	0.35	1.09e-5	Coronary artery calcification;
PAAD	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.92e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg08481491	chr3:125900108	ALDH1L1	0.48	5.28	0.39	4.48e-7	Metabolite levels;
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.66	-5.46	-0.41	1.87e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62408225	0.862	rs60066732	chr6:90935383	A/G	cg03795776	chr6:90687632	BACH2	0.47	4.74	0.36	4.84e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg23649088	chr2:200775458	C2orf69	0.64	5.51	0.41	1.53e-7	Schizophrenia;
PAAD	trans	rs7172971	0.688	rs75441807	chr15:42382436	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-5.07	-0.38	1.16e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs939584	1.000	rs7560127	chr2:643315	T/C	cg14515364	chr2:636606	NA	0.48	4.36	0.33	2.36e-5	Body mass index;
PAAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.3	-0.4	3.98e-7	Blood metabolite levels;
PAAD	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.87	-10.39	-0.64	1.9e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09059670	chr5:79552137	SERINC5	-0.75	-7.02	-0.49	6.83e-11	Neuroticism;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg06815965	chr1:205818668	PM20D1	-0.51	-5.57	-0.41	1.11e-7	Monocyte percentage of white cells;
PAAD	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.58	5.75	0.42	4.65e-8	Height;
PAAD	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.98	0.59	9.51e-16	Cognitive test performance;
PAAD	cis	rs859767	0.672	rs10203582	chr2:135362839	C/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.59	-0.35	9.24e-6	Neuroticism;
PAAD	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg02734326	chr4:10020555	SLC2A9	-0.52	-4.88	-0.37	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.72	5.71	0.42	5.8e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.52	-0.41	1.42e-7	Iron status biomarkers;
PAAD	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.28	-0.33	3.32e-5	Total body bone mineral density;
PAAD	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg11251234	chr10:101825055	CPN1	-0.32	-4.74	-0.36	4.92e-6	Bone mineral density;
PAAD	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.49	4.93	0.37	2.17e-6	Corneal astigmatism;
PAAD	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.61	-0.41	9.27e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.34	-0.33	2.54e-5	QT interval;
PAAD	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg18105134	chr13:113819100	PROZ	-1.02	-10.42	-0.65	1.62e-19	Platelet distribution width;
PAAD	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg25686905	chr3:183603175	PARL	-0.32	-4.25	-0.33	3.73e-5	Menopause (age at onset);
PAAD	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Lung cancer in ever smokers;
PAAD	cis	rs9397240	0.841	rs950995	chr6:155621052	T/C	cg06694381	chr6:155569200	TIAM2	-0.47	-4.3	-0.33	2.99e-5	Life satisfaction;
PAAD	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.45	-4.31	-0.33	2.87e-5	Sudden cardiac arrest;
PAAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.64	-0.62	1.84e-17	Lung cancer;
PAAD	cis	rs527409	1.000	rs75643418	chr1:58722304	A/G	cg26345888	chr1:58716257	DAB1	0.64	4.3	0.33	3.01e-5	Kawasaki disease;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-5.23	-0.39	5.55e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.84	0.43	3.07e-8	Prudent dietary pattern;
PAAD	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.65	6.89	0.49	1.41e-10	Testicular germ cell tumor;
PAAD	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.4	-5.1	-0.38	9.95e-7	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.42	-0.34	1.86e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.58	5.7	0.42	6.07e-8	Educational attainment;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.77	-9.19	-0.6	2.78e-16	Cystic fibrosis severity;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.87e-15	Lung cancer;
PAAD	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	1.04	5.4	0.4	2.51e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.5	0.52	5.07e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.74	-5.66	-0.42	7.32e-8	Psoriasis;
PAAD	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.77	9.22	0.6	2.31e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg20535931	chr7:97615658	OCM2	0.75	7.18	0.5	2.92e-11	Photic sneeze reflex;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.55	-5.32	-0.4	3.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.08	0.55	1.83e-13	Lymphocyte counts;
PAAD	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-13.33	-0.73	2.38e-27	Coronary artery disease;
PAAD	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.8	8.83	0.58	2.3e-15	Iron status biomarkers;
PAAD	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs3857067	0.869	rs6837655	chr4:95051742	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-4.92	-0.37	2.18e-6	QT interval;
PAAD	cis	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.37	0.33	2.33e-5	Depression;
PAAD	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1941184	0.526	rs9953370	chr18:29029435	T/C	cg03238162	chr18:29027701	DSG3	0.42	4.81	0.36	3.65e-6	Parkinson's disease (age of onset);
PAAD	cis	rs7771547	0.603	rs9296193	chr6:36601456	C/G	cg07856975	chr6:36356162	ETV7	-0.55	-5.84	-0.43	3.09e-8	Platelet distribution width;
PAAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.78	8.36	0.56	3.6e-14	Prostate cancer;
PAAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg07617317	chr6:118971624	C6orf204	0.56	4.72	0.36	5.38e-6	Diastolic blood pressure;
PAAD	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.85	-7.77	-0.53	1.08e-12	Neurofibrillary tangles;
PAAD	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-6.06	-0.44	1.04e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs66530629	0.917	rs3122053	chr1:25094233	G/T	cg22509179	chr1:25234806	RUNX3	-0.49	-4.58	-0.35	9.76e-6	Plateletcrit;
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs427941	0.869	rs424549	chr7:101804222	G/T	cg06721601	chr7:101762633	CUX1	0.45	4.66	0.35	6.77e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs12304921	0.938	rs73090631	chr12:51336006	T/C	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.33	-0.33	2.7e-5	Type 2 diabetes;
PAAD	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.12	8.03	0.55	2.47e-13	Type 2 diabetes;
PAAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.61	0.41	9.13e-8	Tonsillectomy;
PAAD	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg02056144	chr12:54070517	ATP5G2	-0.48	-5.03	-0.38	1.35e-6	Height;
PAAD	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg05082376	chr22:42548792	NA	-0.47	-4.8	-0.36	3.82e-6	Cognitive function;
PAAD	cis	rs3787159	0.523	rs482956	chr20:56879263	A/G	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs55728055	0.661	rs8139560	chr22:32003798	C/T	cg01338084	chr22:32026380	PISD	1.61	8.57	0.57	1.12e-14	Age-related hearing impairment;
PAAD	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.68	6.96	0.49	9.62e-11	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.68	-0.42	6.53e-8	Lung cancer;
PAAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.87	6.62	0.47	5.75e-10	Alzheimer's disease;
PAAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.56	7.58	0.52	3.22e-12	Renal cell carcinoma;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	7.67	0.53	1.88e-12	Alzheimer's disease;
PAAD	cis	rs727479	0.543	rs6493489	chr15:51514203	C/T	cg21478137	chr15:51532386	CYP19A1	0.49	4.95	0.37	1.93e-6	Estradiol levels;
PAAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.26	0.39	4.84e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.88	6.3	0.46	3.03e-9	Breast cancer;
PAAD	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.54	4.88	0.37	2.61e-6	Anterior chamber depth;
PAAD	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.37	0.46	2.19e-9	Mean platelet volume;
PAAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-9.26	-0.6	1.81e-16	Gut microbiome composition (summer);
PAAD	cis	rs494003	0.553	rs10896045	chr11:65555524	A/G	cg08755490	chr11:65554678	OVOL1	0.51	4.46	0.34	1.59e-5	Systemic lupus erythematosus;
PAAD	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05025164	chr4:1340916	KIAA1530	0.59	5.38	0.4	2.76e-7	Obesity-related traits;
PAAD	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.63	6.97	0.49	9.15e-11	Colorectal cancer;
PAAD	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-5.2	-0.39	6.24e-7	Menopause (age at onset);
PAAD	cis	rs1927702	0.721	rs17353213	chr9:16017055	C/G	cg14451791	chr9:16040625	NA	-0.36	-4.33	-0.33	2.73e-5	Body mass index;
PAAD	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	8.97	0.59	1.01e-15	Menarche (age at onset);
PAAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.78	8.21	0.55	8.79e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.01e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9535307	0.651	rs1198327	chr13:50387759	G/A	cg04663916	chr13:50265991	EBPL	-0.63	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs10508896	chr10:46030643	A/G	cg14076390	chr17:34947837	DHRS11	0.88	6.78	0.48	2.44e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.63	-6.37	-0.46	2.1e-9	Pulse pressure;
PAAD	cis	rs354033	0.837	rs56402950	chr7:149180219	C/T	cg06920324	chr7:149264011	ZNF767	-0.55	-4.72	-0.36	5.23e-6	Multiple sclerosis;
PAAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-5.18	-0.39	6.87e-7	Mean platelet volume;
PAAD	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	trans	rs61931739	0.686	rs708145	chr12:33731580	G/A	cg26384229	chr12:38710491	ALG10B	0.69	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs9888739	1.000	rs11861161	chr16:31329954	T/C	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.52	-4.37	-0.33	2.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-1.0	-10.98	-0.67	5.07e-21	Bone mineral density;
PAAD	cis	rs1318772	0.536	rs13355330	chr5:113001735	C/T	cg12552261	chr5:112820674	MCC	0.48	4.27	0.33	3.49e-5	F-cell distribution;
PAAD	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg06067394	chr11:133789110	IGSF9B	0.37	4.27	0.33	3.47e-5	Parkinson's disease;
PAAD	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11073060	0.569	rs4924127	chr15:34986076	A/T	cg03492641	chr15:34807679	NA	-0.46	-4.4	-0.34	2.03e-5	Hyperopia;
PAAD	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-10.52	-0.65	8.68e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg26554054	chr8:600488	NA	0.94	6.06	0.44	1.03e-8	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11858474	chr10:81107246	PPIF	0.6	6.87	0.49	1.58e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24713789	chr21:45285448	AGPAT3	0.64	6.48	0.47	1.2e-9	Myopia (pathological);
PAAD	trans	rs3130746	1	rs3130746	chr6:29153155	A/G	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Tuberculosis;
PAAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg05373962	chr22:49881684	NA	-0.45	-4.38	-0.33	2.18e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs67257959	0.708	rs10405158	chr19:17195997	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.9	0.37	2.4e-6	Selective IgA deficiency;
PAAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.84	0.37	3.15e-6	Bipolar disorder;
PAAD	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg21775007	chr8:11205619	TDH	-0.46	-4.32	-0.33	2.81e-5	Neuroticism;
PAAD	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.56	-7.39	-0.51	9.05e-12	Migraine;
PAAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.48	-0.34	1.45e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.78	8.06	0.55	2.09e-13	Schizophrenia;
PAAD	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.44	4.4	0.34	2.04e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.33	0.4	3.55e-7	Coronary artery disease;
PAAD	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.52	-4.88	-0.37	2.71e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs73416724	1.000	rs111467122	chr6:43334547	C/T	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.64	-0.57	7.33e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.27e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-4.88	-0.37	2.65e-6	Electrocardiographic conduction measures;
PAAD	cis	rs13424612	0.839	rs6716293	chr2:240923146	T/C	cg01812947	chr2:240904978	NDUFA10	0.53	4.9	0.37	2.38e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.55	5.13	0.38	8.6e-7	Acylcarnitine levels;
PAAD	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.65	7.91	0.54	5.02e-13	Schizophrenia;
PAAD	cis	rs900145	0.773	rs11022755	chr11:13315049	T/C	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.77	7.79	0.53	9.8e-13	Corneal astigmatism;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.97	-0.37	1.76e-6	Triglycerides;
PAAD	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	1.06	12.09	0.7	5.4e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.5	-5.42	-0.4	2.29e-7	Motion sickness;
PAAD	cis	rs9650657	0.769	rs1115866	chr8:10638333	C/T	cg13293535	chr8:11597251	GATA4	0.35	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-4.69	-0.36	6.15e-6	Menarche (age at onset);
PAAD	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.76	9.01	0.59	8.1e-16	Emphysema distribution in smoking;
PAAD	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.25	-0.51	1.93e-11	Psoriasis;
PAAD	cis	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg21546286	chr11:48923668	NA	-0.6	-6.24	-0.45	4.06e-9	HDL cholesterol;
PAAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs28489187	0.706	rs233074	chr1:85809065	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg23024343	chr7:107201750	COG5	0.58	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21191710	chr11:66512979	C11orf80	0.63	6.58	0.47	6.99e-10	Monocyte percentage of white cells;
PAAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.63	-6.48	-0.47	1.2e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.49	4.61	0.35	8.56e-6	Neutrophil percentage of white cells;
PAAD	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg04415270	chr2:102091202	RFX8	0.56	6.93	0.49	1.14e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.61	-4.59	-0.35	9.17e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg12568669	chr8:11666485	FDFT1	0.3	5.17	0.39	7.28e-7	Monocyte count;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-4.25	-0.33	3.66e-5	Height;
PAAD	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.44	0.34	1.69e-5	Menarche (age at onset);
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.81	-6.63	-0.47	5.41e-10	Alzheimer's disease;
PAAD	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg08106661	chr6:34855635	TAF11;ANKS1A	0.59	6.41	0.46	1.77e-9	Positive affect;
PAAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg05562828	chr17:3906858	NA	-0.54	-6.11	-0.44	7.89e-9	Type 2 diabetes;
PAAD	cis	rs8037137	0.915	rs8026714	chr15:91522253	G/A	cg23684204	chr15:91497937	RCCD1	0.71	4.49	0.34	1.38e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.29	-0.6	1.53e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.83	8.91	0.59	1.49e-15	Calcium levels;
PAAD	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.48	4.36	0.33	2.4e-5	Diastolic blood pressure;
PAAD	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.12e-9	Type 2 diabetes;
PAAD	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.6	-6.34	-0.46	2.43e-9	Caffeine consumption;
PAAD	cis	rs4454254	0.830	rs6994517	chr8:141050171	A/G	cg06693505	chr8:141057453	TRAPPC9	-0.33	-4.64	-0.35	7.37e-6	Pulse pressure;
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.9	7.62	0.53	2.53e-12	Initial pursuit acceleration;
PAAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.39	-0.46	1.9e-9	Hip circumference;
PAAD	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.7	-7.76	-0.53	1.14e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	4.06e-10	Total body bone mineral density;
PAAD	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-5.57	-0.41	1.13e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.34	0.33	2.55e-5	Platelet count;
PAAD	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.79e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10267417	0.535	rs10272487	chr7:19862415	A/T	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Night sleep phenotypes;
PAAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.11e-5	Renal cell carcinoma;
PAAD	cis	rs2031532	0.587	rs7317772	chr13:50042797	A/G	cg03651054	chr13:50194643	NA	0.32	4.29	0.33	3.21e-5	Cardiac hypertrophy;
PAAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg26248373	chr2:1572462	NA	-1.07	-8.55	-0.57	1.23e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2579500	0.807	rs4907200	chr2:97320737	T/G	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Body mass index;
PAAD	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg16810054	chr20:33298113	TP53INP2	-0.56	-4.29	-0.33	3.1e-5	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15083677	chr6:164758516	NA	-0.61	-6.46	-0.46	1.33e-9	Obesity-related traits;
PAAD	cis	rs743757	0.878	rs750510	chr3:50546340	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.67	5.03	0.38	1.36e-6	Diastolic blood pressure;
PAAD	cis	rs12760731	0.669	rs10798609	chr1:178431648	C/T	cg00404053	chr1:178313656	RASAL2	0.71	5.53	0.41	1.35e-7	Obesity-related traits;
PAAD	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08757611	chr17:76250500	NA	0.61	6.42	0.46	1.62e-9	Myopia (pathological);
PAAD	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.61	0.35	8.46e-6	Height;
PAAD	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.66	6.98	0.49	8.38e-11	Testicular germ cell tumor;
PAAD	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.89	-9.24	-0.6	2.11e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4841899	1.000	rs4841896	chr9:137424102	G/A	cg21123355	chr9:136844644	VAV2	0.32	4.3	0.33	3.04e-5	Stem cell factor levels;
PAAD	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.58	-0.52	3.15e-12	Morning vs. evening chronotype;
PAAD	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.88	-11.42	-0.68	3.3e-22	Body mass index;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg16031515	chr1:205743344	RAB7L1	-0.4	-4.56	-0.35	1.06e-5	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.68	-0.36	6.2e-6	Body mass index;
PAAD	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.58	0.41	1.06e-7	Educational attainment;
PAAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.56	5.29	0.39	4.28e-7	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.58	0.65	5.97e-20	Bladder cancer;
PAAD	cis	rs9398803	0.713	rs1490384	chr6:126851160	C/T	cg19875578	chr6:126661172	C6orf173	0.44	4.58	0.35	9.55e-6	Male-pattern baldness;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg26071806	chr7:100318239	EPO	-0.48	-4.53	-0.35	1.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg02841227	chr6:26021843	HIST1H4A	0.48	4.7	0.36	5.79e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg00490450	chr3:139108681	COPB2	-0.63	-5.54	-0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	4.99e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.66	6.38	0.46	2.01e-9	Visceral fat;
PAAD	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12476592	0.602	rs7608470	chr2:63691478	T/C	cg10828910	chr2:63850056	LOC388955	0.52	4.46	0.34	1.57e-5	Childhood ear infection;
PAAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.99	-10.27	-0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.53	8.0	0.54	3.01e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.96	12.61	0.72	2.1e-25	Rheumatoid arthritis;
PAAD	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.78	-0.42	4.02e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg14682080	chr5:6737778	POLS	0.42	4.85	0.37	3e-6	Menopause (age at onset);
PAAD	cis	rs990171	0.538	rs11123934	chr2:103115568	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.69	0.53	1.67e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	5.29	0.39	4.24e-7	Homocysteine levels;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg24879335	chr3:133465180	TF	-0.53	-5.7	-0.42	6e-8	Iron status biomarkers;
PAAD	cis	rs282587	0.569	rs399569	chr13:113398464	A/T	cg04656015	chr13:113407548	ATP11A	0.54	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8016982	0.531	rs11621116	chr14:81740763	G/C	cg01989461	chr14:81687754	GTF2A1	0.57	4.3	0.33	3.08e-5	Schizophrenia;
PAAD	cis	rs12754538	0.739	rs6577518	chr1:8748923	T/C	cg06159269	chr1:8767347	RERE	0.39	4.51	0.34	1.3e-5	Subjective well-being;
PAAD	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.68	-7.86	-0.54	6.71e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs54211	0.803	rs137643	chr22:39728032	A/C	cg11247378	chr22:39784982	NA	-0.77	-4.47	-0.34	1.51e-5	Sudden cardiac arrest;
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg00431813	chr7:1051703	C7orf50	-0.35	-4.35	-0.33	2.53e-5	Longevity;Endometriosis;
PAAD	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.53	5.19	0.39	6.72e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs16831128	1.000	rs72997280	chr2:133135959	T/C	cg11467141	chr2:132348705	NA	-0.66	-4.46	-0.34	1.58e-5	Conduct disorder;Conduct disorder (symptom count);
PAAD	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.36	4.37	0.33	2.3e-5	Sitting height ratio;
PAAD	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg03252829	chr6:39282164	KCNK17	-0.55	-5.75	-0.42	4.7e-8	Type 2 diabetes;
PAAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.97	9.94	0.63	3.07e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7705042	0.828	rs11750521	chr5:141500704	T/C	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.92	-0.37	2.21e-6	Asthma;
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.76	-7.27	-0.51	1.73e-11	Systemic lupus erythematosus;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27011620	chr12:94136156	CRADD	0.69	6.38	0.46	2.01e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs73198271	0.515	rs76620708	chr8:8619083	C/T	cg01851573	chr8:8652454	MFHAS1	0.9	6.12	0.44	7.44e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-5.15	-0.39	7.92e-7	Bipolar disorder;
PAAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.65	-0.35	7.19e-6	Alcohol dependence;
PAAD	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.56	-5.29	-0.39	4.21e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.63	7.3	0.51	1.46e-11	Height;
PAAD	cis	rs17213078	0.505	rs3795909	chr2:106754734	A/G	cg15412446	chr2:106886593	NA	0.57	5.64	0.42	7.92e-8	Facial morphology (factor 23);
PAAD	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.56	-0.57	1.14e-14	Depression;
PAAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.53	0.35	1.18e-5	Breast cancer;
PAAD	cis	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg21546286	chr11:48923668	NA	-0.52	-5.4	-0.4	2.52e-7	HDL cholesterol;
PAAD	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg06207120	chr15:45996521	NA	0.3	4.43	0.34	1.78e-5	Waist circumference;Weight;
PAAD	cis	rs245880	0.702	rs245884	chr7:29188475	T/G	cg17163760	chr7:29186267	CPVL	-0.52	-6.21	-0.45	4.76e-9	Warfarin maintenance dose;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.47e-7	Life satisfaction;
PAAD	cis	rs2882667	0.728	rs10068766	chr5:138276784	G/A	cg09476006	chr5:138032270	NA	0.46	5.77	0.42	4.23e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.67	-6.04	-0.44	1.14e-8	Monocyte count;
PAAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg14515779	chr1:101123966	NA	0.49	6.33	0.46	2.57e-9	Monocyte count;
PAAD	cis	rs4523957	0.615	rs59207721	chr17:2070479	C/A	cg16513277	chr17:2031491	SMG6	-0.69	-7.25	-0.51	1.97e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.47	-4.39	-0.34	2.11e-5	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	6.56	0.47	7.83e-10	Lung cancer in ever smokers;
PAAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.69	6.77	0.48	2.67e-10	Tuberculosis;
PAAD	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-7.11	-0.5	4.13e-11	Menarche (age at onset);
PAAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.59	-5.46	-0.4	1.93e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs7823896	0.722	rs66582255	chr8:110289037	G/A	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.31	0.4	3.86e-7	Bipolar disorder;
PAAD	cis	rs10878977	0.542	rs60878854	chr12:69815236	G/A	cg13322954	chr12:69198953	NA	0.68	4.32	0.33	2.79e-5	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.76	-8.35	-0.56	4.03e-14	Schizophrenia;
PAAD	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.69	7.66	0.53	1.99e-12	Colorectal cancer;
PAAD	cis	rs4906332	0.966	rs12885786	chr14:103972503	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-4.67	-0.35	6.5e-6	Coronary artery disease;
PAAD	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg03315344	chr16:75512273	CHST6	0.53	4.6	0.35	8.68e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.46	0.61	5.55e-17	Rheumatoid arthritis;
PAAD	cis	rs4704187	0.687	rs9293643	chr5:74365053	C/T	cg03227963	chr5:74354835	NA	-0.49	-4.81	-0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs367943	0.666	rs6594704	chr5:112692834	A/T	cg12552261	chr5:112820674	MCC	0.64	6.31	0.46	2.89e-9	Type 2 diabetes;
PAAD	cis	rs7567389	0.671	rs72845993	chr2:128108601	T/C	cg11380483	chr2:127933992	NA	0.43	4.29	0.33	3.1e-5	Self-rated health;
PAAD	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.9	11.42	0.68	3.3e-22	Mean corpuscular volume;
PAAD	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.46	4.5	0.34	1.37e-5	Blood pressure;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg07404363	chr5:112197029	SRP19	0.68	6.81	0.48	2.14e-10	Primary biliary cholangitis;
PAAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg10589385	chr1:150898437	SETDB1	-0.38	-4.57	-0.35	9.88e-6	Melanoma;
PAAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.54	5.25	0.39	4.98e-7	Aortic root size;
PAAD	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8040855	0.520	rs11629962	chr15:85530028	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-4.71	-0.36	5.52e-6	Bulimia nervosa;
PAAD	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.48	-0.34	1.48e-5	Resting heart rate;
PAAD	cis	rs1468333	1.000	rs13356202	chr5:137564588	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	cis	rs1371614	0.611	rs877272	chr2:27139888	C/T	cg00617064	chr2:27272375	NA	-0.44	-4.66	-0.35	6.95e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg02023728	chr11:77925099	USP35	0.44	4.63	0.35	7.73e-6	Alzheimer's disease (survival time);
PAAD	cis	rs3951016	0.514	rs283067	chr6:118620030	T/A	cg21191810	chr6:118973309	C6orf204	0.41	5.27	0.39	4.58e-7	Resting heart rate;
PAAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.56	5.25	0.39	5.12e-7	Type 2 diabetes;
PAAD	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.8	8.97	0.59	1.01e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg01765077	chr12:122356316	WDR66	-0.49	-4.79	-0.36	3.98e-6	Mean corpuscular volume;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08181646	chr11:111472771	SIK2	0.65	6.37	0.46	2.11e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-7.24	-0.51	2.11e-11	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.67	5.91	0.43	2.15e-8	Breast cancer;
PAAD	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.89e-8	Ileal carcinoids;
PAAD	cis	rs17407555	0.657	rs10489076	chr4:10270848	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	4.3	0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg24399712	chr22:39784796	NA	-0.62	-5.88	-0.43	2.48e-8	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.44	-0.52	7.07e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-8.89	-0.58	1.63e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs901683	1.000	rs12779198	chr10:46013547	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.49	5.41	0.4	2.35e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg19337854	chr7:99768885	GPC2	0.53	4.94	0.37	2.03e-6	Lung function (FEV1/FVC);
PAAD	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs11208446	0.769	rs12133485	chr1:64876965	T/A	cg25192081	chr1:65308244	JAK1	-0.64	-4.27	-0.33	3.38e-5	Bilirubin levels;
PAAD	cis	rs9815354	1.000	rs9869440	chr3:41763155	G/C	cg03022575	chr3:42003672	ULK4	0.8	5.76	0.42	4.43e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg08198773	chr8:1697536	NA	0.45	5.01	0.38	1.49e-6	Systolic blood pressure;
PAAD	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19427701	chr9:140196790	NRARP	0.59	6.78	0.48	2.49e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	1.09	15.94	0.79	2.96e-34	Menarche (age at onset);
PAAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.71	-6.9	-0.49	1.3e-10	Urate levels in lean individuals;
PAAD	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg10349874	chr16:420996	TMEM8A;MRPL28	0.53	4.49	0.34	1.38e-5	Body mass index;
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg19223190	chr17:80058835	NA	-0.52	-5.31	-0.4	3.78e-7	Life satisfaction;
PAAD	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	6.06	0.44	1.01e-8	Body mass index;
PAAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.82	9.48	0.61	4.84e-17	Huntington's disease progression;
PAAD	cis	rs2075671	0.818	rs10953303	chr7:100365613	G/T	cg03098644	chr7:100410630	EPHB4	0.63	4.63	0.35	7.84e-6	Other erythrocyte phenotypes;
PAAD	cis	rs7192380	0.825	rs3811348	chr16:69782855	C/T	cg05250797	chr16:70222502	NA	-0.52	-4.43	-0.34	1.79e-5	Sjögren's syndrome;
PAAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.73	8.63	0.57	7.61e-15	Huntington's disease progression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00873937	chr10:69991564	ATOH7	0.57	6.52	0.47	1e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.79	-8.69	-0.58	5.44e-15	Corneal astigmatism;
PAAD	cis	rs2885056	0.891	rs12979033	chr19:10691618	G/A	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.74	8.04	0.55	2.33e-13	Lewy body disease;
PAAD	cis	rs11159086	1.000	rs17100588	chr14:74954327	C/A	cg10195687	chr14:74926396	NA	-0.46	-4.88	-0.37	2.66e-6	Advanced glycation end-product levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06370795	chr19:33572183	GPATCH1	-0.76	-6.95	-0.49	1.01e-10	Neuroticism;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	2.85e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.83e-7	Total body bone mineral density;
PAAD	trans	rs1838564	0.850	rs11049275	chr12:28162341	T/A	cg21416529	chr22:49795435	NA	1.2	6.55	0.47	8.43e-10	Breast size;
PAAD	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.34	0.4	3.27e-7	Lung cancer in ever smokers;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.64	0.62	1.91e-17	Lymphocyte counts;
PAAD	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.43	-0.4	2.17e-7	Blood metabolite levels;
PAAD	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2790216	1.000	rs2253192	chr10:59999323	C/T	cg20442379	chr10:60024634	IPMK	0.6	4.6	0.35	8.68e-6	Inflammatory bowel disease;
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg18764771	chr6:116381957	FRK	0.45	7.88	0.54	5.9e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7729723	0.653	rs4835678	chr5:137708434	A/G	cg26069252	chr5:137800343	EGR1	0.46	4.33	0.33	2.66e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs4987094	0.505	rs12292113	chr11:113227790	T/A	cg14632485	chr11:113216820	TTC12	0.53	4.51	0.34	1.31e-5	Schizophrenia;
PAAD	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.35	9.33	0.6	1.22e-16	Diabetic retinopathy;
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	5.42	0.4	2.33e-7	Total body bone mineral density;
PAAD	cis	rs6681460	0.700	rs984409	chr1:67020440	G/A	cg02459107	chr1:67143332	SGIP1	0.6	5.47	0.41	1.82e-7	Presence of antiphospholipid antibodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07024458	chr16:56390600	GNAO1	0.69	8.14	0.55	1.29e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg16434002	chr17:42200994	HDAC5	-0.43	-4.28	-0.33	3.32e-5	Total body bone mineral density;
PAAD	cis	rs2115386	0.717	rs2042902	chr19:7204470	G/A	cg00428638	chr19:7224713	INSR	0.48	5.02	0.38	1.41e-6	Diabetic retinopathy;
PAAD	cis	rs10899021	0.920	rs61901541	chr11:74317985	T/C	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.74	-6.18	-0.45	5.62e-9	Neuroticism;
PAAD	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg04165759	chr1:150448943	RPRD2	0.49	5.01	0.38	1.5e-6	Migraine;
PAAD	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs8077577	0.708	rs7211573	chr17:18131613	T/C	cg16794390	chr17:18148240	FLII	-0.54	-4.6	-0.35	8.94e-6	Obesity-related traits;
PAAD	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21659725	chr3:3221576	CRBN	0.79	9.11	0.59	4.55e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg21782813	chr7:2030301	MAD1L1	0.58	6.03	0.44	1.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.61	6.25	0.45	3.91e-9	Coronary artery disease;
PAAD	cis	rs10189230	0.904	rs1864462	chr2:222343823	G/C	cg14652038	chr2:222343519	EPHA4	0.54	5.89	0.43	2.35e-8	Urate levels in lean individuals;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.18e-6	Prudent dietary pattern;
PAAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg21130718	chr4:1044621	NA	0.78	5.91	0.43	2.21e-8	Recombination rate (females);
PAAD	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg04725166	chr1:7887271	PER3	-0.59	-5.7	-0.42	6.01e-8	Crohn's disease;
PAAD	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg09035930	chr12:129282057	SLC15A4	-0.74	-4.35	-0.33	2.5e-5	Systemic lupus erythematosus;
PAAD	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.57	0.35	1.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs73206853	0.841	rs7963504	chr12:110906880	C/A	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8032158	0.634	rs12898589	chr15:56127733	A/G	cg02198044	chr15:56286336	NEDD4	0.46	4.84	0.37	3.22e-6	Keloid;
PAAD	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg06521852	chr22:38141419	TRIOBP	0.4	4.33	0.33	2.65e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.23	-0.39	5.5e-7	QT interval;
PAAD	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.62	-8.7	-0.58	5.2e-15	Breast cancer;
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg17105886	chr17:28927953	LRRC37B2	0.69	4.46	0.34	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.52	5.29	0.39	4.15e-7	Colorectal cancer;
PAAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg06632027	chr4:90757378	SNCA	-0.53	-4.64	-0.35	7.39e-6	Neuroticism;
PAAD	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs12760731	0.720	rs2862379	chr1:178442906	T/A	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-5.16	-0.39	7.52e-7	Cystic fibrosis severity;
PAAD	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-8.67	-0.58	6e-15	Vitiligo;
PAAD	cis	rs11867934	0.769	rs7208929	chr17:16974408	G/A	cg05552144	chr17:17942551	ATPAF2;C17orf39	-0.56	-4.25	-0.33	3.69e-5	Diabetic retinopathy;
PAAD	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.47	-4.87	-0.37	2.78e-6	Motion sickness;
PAAD	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.35	0.4	3.22e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.49	0.41	1.61e-7	Prudent dietary pattern;
PAAD	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs883565	0.606	rs883349	chr3:39067925	T/C	cg01426195	chr3:39028469	NA	-0.7	-7.8	-0.53	8.94e-13	Handedness;
PAAD	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg27411982	chr8:10470053	RP1L1	-0.5	-5.61	-0.41	9.37e-8	Neuroticism;
PAAD	trans	rs901683	0.867	rs35356752	chr10:45980106	G/A	cg14076390	chr17:34947837	DHRS11	0.92	6.81	0.48	2.18e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1468333	1.000	rs423258	chr5:137475787	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.3	0.45	3.13e-9	Resting heart rate;
PAAD	cis	rs1042026	0.813	rs10032099	chr4:100073025	A/G	cg09112717	chr4:100009950	ADH5	-0.5	-4.4	-0.34	2.03e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.05	-0.38	1.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg14146966	chr2:61757674	XPO1	-0.37	-4.85	-0.37	3.04e-6	Tuberculosis;
PAAD	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg25364880	chr3:44379878	C3orf23	0.59	5.74	0.42	4.91e-8	Depressive symptoms;
PAAD	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13560548	chr3:10150139	C3orf24	0.62	5.65	0.42	7.74e-8	Alzheimer's disease;
PAAD	cis	rs855965	0.527	rs4237505	chr10:119472119	C/G	cg17249170	chr10:119305798	EMX2;EMX2OS	-0.32	-4.29	-0.33	3.2e-5	Ovarian disease with few adhesions;
PAAD	cis	rs9368222	1.000	rs9368222	chr6:20686996	G/T	cg01798595	chr6:21664778	NA	-0.48	-4.53	-0.34	1.2e-5	Acute insulin response;Peak insulin response;Body mass index;
PAAD	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg05338066	chr1:7812865	CAMTA1	0.69	5.15	0.39	7.93e-7	Inflammatory bowel disease;
PAAD	cis	rs2387326	0.767	rs2015726	chr10:129941839	C/T	cg16087940	chr10:129947807	NA	-0.51	-4.25	-0.33	3.74e-5	Select biomarker traits;
PAAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg15192750	chr16:69999425	NA	0.78	6.06	0.44	1.04e-8	IgE levels;
PAAD	cis	rs3809060	0.919	rs5030178	chr11:32448569	A/C	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg02531859	chr7:37888154	TXNDC3	-0.56	-4.51	-0.34	1.29e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.28	-0.51	1.65e-11	Coronary artery disease;
PAAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.41	0.34	1.93e-5	Trans fatty acid levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13522186	chr19:7069483	ZNF557	0.55	6.39	0.46	1.93e-9	Monocyte percentage of white cells;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13870426	chr17:30244630	NA	0.74	6.59	0.47	6.91e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.33	6.84	0.49	1.78e-10	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.46	-4.85	-0.37	2.96e-6	Ulcerative colitis;
PAAD	cis	rs375066	0.967	rs436249	chr19:44399565	C/T	cg11993925	chr19:44307056	LYPD5	0.51	6.54	0.47	8.78e-10	Breast cancer;
PAAD	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.03	-4.67	-0.35	6.44e-6	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
PAAD	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.64	6.16	0.45	6.33e-9	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg19637330	chr1:19110922	NA	-0.65	-5.73	-0.42	5.35e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.94	12.37	0.71	9.36e-25	Prudent dietary pattern;
PAAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs2415984	0.579	rs61993339	chr14:46969266	G/A	cg14871534	chr14:47121158	RPL10L	-0.49	-5.09	-0.38	1.05e-6	Number of children ever born;
PAAD	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.98	-0.44	1.56e-8	Caffeine consumption;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg19223190	chr17:80058835	NA	0.51	5.25	0.39	5.07e-7	Life satisfaction;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg05313129	chr8:58192883	C8orf71	-0.59	-5.55	-0.41	1.24e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.62	7.49	0.52	5.17e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg25809561	chr17:30822961	MYO1D	0.59	6.12	0.44	7.49e-9	Schizophrenia;
PAAD	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.83	9.13	0.59	4.07e-16	Prostate cancer;
PAAD	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	6.85	0.49	1.71e-10	Hip circumference;
PAAD	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.51	-4.93	-0.37	2.13e-6	Metabolic syndrome;
PAAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4e-8	Electroencephalogram traits;
PAAD	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.42	0.65	1.6e-19	Electrocardiographic conduction measures;
PAAD	cis	rs34734847	0.806	rs696340	chr12:121173653	A/T	cg21892295	chr12:121157589	UNC119B	-0.4	-4.76	-0.36	4.4e-6	Mean corpuscular volume;
PAAD	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-5.84	-0.43	3.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg03538708	chr1:25844672	NA	0.53	5.42	0.4	2.32e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-5.83	-0.43	3.2e-8	Neuroticism;
PAAD	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg01966878	chr4:90757139	SNCA	-0.47	-4.43	-0.34	1.79e-5	Dementia with Lewy bodies;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.22e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10815395	chr12:49237807	DDX23	0.63	7.5	0.52	5.01e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs911119	0.955	rs7270413	chr20:23593821	C/G	cg16589663	chr20:23618590	CST3	0.76	6.39	0.46	1.93e-9	Chronic kidney disease;
PAAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg17775713	chr3:133465469	TF	0.5	5.71	0.42	5.86e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg25204440	chr1:209979598	IRF6	0.64	5.58	0.41	1.08e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg18892244	chr7:807596	HEATR2	-0.72	-5.49	-0.41	1.64e-7	Initial pursuit acceleration;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.44	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.42	-4.33	-0.33	2.7e-5	Aortic root size;
PAAD	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.71	6.98	0.49	8.72e-11	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.61	7.93	0.54	4.4e-13	Renal cell carcinoma;
PAAD	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs990171	1.000	rs6713618	chr2:103048437	A/T	cg03938978	chr2:103052716	IL18RAP	0.45	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs2279463	0.667	rs4123902	chr6:160628053	A/T	cg09900253	chr6:160186100	ACAT2	-0.65	-4.29	-0.33	3.13e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg08648136	chr8:956695	NA	0.43	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.6	0.41	9.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-6.59	-0.47	6.83e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.64e-6	Breast cancer;
PAAD	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.1	0.38	9.93e-7	Systemic lupus erythematosus;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05684406	chr22:21386914	SLC7A4	0.58	6.65	0.47	4.89e-10	Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg16578609	chr1:2399051	NA	-0.53	-6.44	-0.46	1.47e-9	Schizophrenia;
PAAD	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.44	5.68	0.42	6.67e-8	Panic disorder;
PAAD	cis	rs9810890	1.000	rs73198856	chr3:128513001	C/T	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs3925075	0.500	rs11641624	chr16:31268985	C/T	cg02846316	chr16:31340340	ITGAM	0.43	5.0	0.38	1.57e-6	IgA nephropathy;
PAAD	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	1.0	8.63	0.57	7.8e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	6.47	0.46	1.29e-9	Lung function (FEV1/FVC);
PAAD	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.58	-5.03	-0.38	1.36e-6	Pursuit maintenance gain;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.64	-5.51	-0.41	1.53e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	1.09	5.19	0.39	6.76e-7	Breast cancer;
PAAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62392365	0.536	rs114354133	chr6:25157902	G/A	cg19882886	chr6:25043046	NA	0.97	4.33	0.33	2.7e-5	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.74	-8.83	-0.58	2.3e-15	Educational attainment;
PAAD	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg05998816	chr21:47859926	PCNT	0.54	4.28	0.33	3.27e-5	Lymphocyte counts;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.35	-0.51	1.16e-11	Diastolic blood pressure;
PAAD	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.53	0.34	1.19e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.44	4.35	0.33	2.49e-5	Trans fatty acid levels;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.64	7.09	0.5	4.77e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.57	-5.2	-0.39	6.35e-7	Diastolic blood pressure;
PAAD	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-1.23	-12.57	-0.71	2.75e-25	Hair shape;
PAAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg10729496	chr3:10149963	C3orf24	0.91	7.77	0.53	1.09e-12	Alzheimer's disease;
PAAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.53	-5.48	-0.41	1.73e-7	White blood cell count;
PAAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.76	0.36	4.53e-6	Menopause (age at onset);
PAAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-6.36	-0.46	2.29e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg08886695	chr4:3369023	RGS12	-0.48	-4.51	-0.34	1.28e-5	Serum sulfate level;
PAAD	cis	rs8067287	1.000	rs4318250	chr17:16817593	A/T	cg26910001	chr17:16838321	NA	-0.73	-5.97	-0.44	1.61e-8	Diabetic kidney disease;
PAAD	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.68	-7.84	-0.54	7.22e-13	Educational attainment;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.85	9.33	0.6	1.23e-16	Prostate cancer;
PAAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs1419980	0.730	rs57677315	chr12:7746232	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs2120243	0.533	rs1392798	chr3:157056287	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.42	-4.35	-0.33	2.49e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs17155006	0.655	rs378641	chr7:107722149	C/T	cg05962710	chr7:107745446	LAMB4	0.45	5.52	0.41	1.45e-7	Pneumococcal bacteremia;
PAAD	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	1.4	9.46	0.61	5.61e-17	Diabetic retinopathy;
PAAD	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg05697835	chr1:2722811	NA	-0.42	-4.77	-0.36	4.36e-6	Ulcerative colitis;
PAAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg04315214	chr1:2043799	PRKCZ	-0.56	-7.24	-0.51	2.09e-11	Height;
PAAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.88	-6.76	-0.48	2.71e-10	Alzheimer's disease;
PAAD	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.49	4.78	0.36	4.02e-6	Airway imaging phenotypes;
PAAD	cis	rs15676	0.783	rs2417128	chr9:131571756	G/A	cg00228799	chr9:131580591	ENDOG	0.65	6.47	0.46	1.28e-9	Blood metabolite levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg10660249	chr9:5833007	ERMP1	0.6	7.15	0.5	3.45e-11	Metabolite levels  (X-11787);
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.7	-0.36	5.84e-6	Lung cancer;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02725872	chr8:58115012	NA	-0.62	-4.99	-0.38	1.63e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2735413	0.837	rs7194946	chr16:78095274	G/A	cg04733911	chr16:78082701	NA	0.55	5.67	0.42	7.1e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs4750440	0.736	rs4748070	chr10:14031388	G/A	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.39	-0.34	2.11e-5	Adiponectin levels;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	6.96	0.49	9.77e-11	Hip circumference;
PAAD	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.31	0.6	1.37e-16	Diabetic retinopathy;
PAAD	cis	rs7081476	0.737	rs4747592	chr10:27498757	T/C	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg15798862	chr7:76129360	DTX2	-0.49	-6.66	-0.48	4.72e-10	Multiple sclerosis;
PAAD	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg09998033	chr7:158218633	PTPRN2	-0.65	-6.29	-0.45	3.18e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg21130718	chr4:1044621	NA	0.5	4.89	0.37	2.56e-6	Recombination rate (males);
PAAD	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.06	0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg04450456	chr4:17643702	FAM184B	0.48	4.91	0.37	2.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg14631576	chr9:95140430	CENPP	-0.47	-4.64	-0.35	7.41e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35110281	0.601	rs7278282	chr21:44981958	T/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.05	-0.38	1.24e-6	Mean corpuscular volume;
PAAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.51	-6.56	-0.47	8.04e-10	Height;
PAAD	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.63	-6.38	-0.46	2e-9	Smoking initiation;
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2882667	0.690	rs700619	chr5:138088749	G/C	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2649	0.542	rs8023506	chr15:63884462	A/G	cg22599514	chr15:63798201	USP3	0.6	5.19	0.39	6.52e-7	Aortic root size;
PAAD	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg10985347	chr2:127963512	CYP27C1	0.49	4.76	0.36	4.55e-6	Protein C levels;
PAAD	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.81	8.21	0.55	8.83e-14	Alzheimer's disease (late onset);
PAAD	cis	rs9876781	1.000	rs3214041	chr3:48454468	C/T	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.32e-5	Longevity;
PAAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.72	9.7	0.62	1.28e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Breast cancer;
PAAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-8.5	-0.57	1.64e-14	Height;
PAAD	cis	rs9815354	1.000	rs1716693	chr3:41985600	C/T	cg03022575	chr3:42003672	ULK4	-0.76	-5.57	-0.41	1.12e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.86	-9.6	-0.61	2.35e-17	Mortality in heart failure;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	7.99	0.54	3.1400000000000003e-13	Prudent dietary pattern;
PAAD	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.42e-17	Longevity (90 years and older);
PAAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	1.28	13.0	0.73	1.9e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs4242434	0.892	rs1809452	chr8:22491397	G/A	cg03733263	chr8:22462867	KIAA1967	1.04	12.79	0.72	6.7e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.07	-0.55	1.97e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.73	7.78	0.53	1.03e-12	Mean corpuscular volume;
PAAD	cis	rs539096	0.602	rs1143702	chr1:44086831	C/T	cg12908607	chr1:44402522	ARTN	-0.4	-4.28	-0.33	3.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg25204440	chr1:209979598	IRF6	0.62	4.96	0.37	1.87e-6	Coronary artery disease;
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.68	-6.26	-0.45	3.83e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00632861	chr13:46626485	ZC3H13	0.55	6.37	0.46	2.17e-9	Immature fraction of reticulocytes;
PAAD	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg27411982	chr8:10470053	RP1L1	0.44	4.48	0.34	1.49e-5	Retinal vascular caliber;
PAAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.72	-0.42	5.39e-8	Mood instability;
PAAD	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.69	6.65	0.47	5.05e-10	Lymphocyte counts;
PAAD	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg14583973	chr4:3374767	RGS12	0.35	5.05	0.38	1.27e-6	Mean platelet volume;
PAAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Tonsillectomy;
PAAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.64	5.59	0.41	1.02e-7	Resistin levels;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01691987	chr17:7789028	CHD3	-0.57	-6.38	-0.46	2.07e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7537660	0.562	rs4417105	chr1:248016487	G/T	cg00785941	chr1:248100591	OR2L13	-0.42	-6.11	-0.44	7.9e-9	Platelet distribution width;
PAAD	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.4	-0.46	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg26875137	chr12:53738046	NA	-0.47	-4.7	-0.36	5.72e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-1.11	-8.21	-0.55	8.68e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs73206853	0.841	rs73191818	chr12:110918721	T/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25876186	chr17:77979405	TBC1D16	-0.59	-6.57	-0.47	7.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.67	-7.75	-0.53	1.23e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.63	-0.42	8.5e-8	Personality dimensions;
PAAD	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.52	5.31	0.4	3.79e-7	Schizophrenia;
PAAD	cis	rs11264213	0.901	rs682686	chr1:36443778	T/A	cg27506609	chr1:36549197	TEKT2	0.74	5.19	0.39	6.56e-7	Schizophrenia;
PAAD	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg00522288	chr12:125625016	AACS	-0.49	-4.99	-0.38	1.61e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.57	-5.49	-0.41	1.67e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg14393609	chr7:65229607	NA	-0.48	-4.66	-0.35	6.78e-6	Aortic root size;
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg22896917	chr6:28093420	ZSCAN16	0.37	4.49	0.34	1.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	0.850	rs76040096	chr10:46094626	C/T	cg11747279	chr17:21096632	NA	0.9	6.5	0.47	1.08e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg02461739	chr17:72860448	FDXR	0.63	7.37	0.51	9.92e-12	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08948225	chr8:27288300	PTK2B	-0.54	-6.69	-0.48	4.09e-10	Obesity-related traits;
PAAD	cis	rs12986413	1.000	rs12983458	chr19:2168612	A/G	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.13e-6	Height;
PAAD	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.47	-0.46	1.27e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.67	0.53	1.9e-12	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11735308	chr3:107941242	IFT57	0.67	6.83	0.48	1.89e-10	Obesity-related traits;
PAAD	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.25	-0.45	3.86e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7382539	1.000	rs7382539	chr6:169668998	G/A	cg16479247	chr6:168716332	DACT2	-0.58	-5.44	-0.4	2.04e-7	Liver disease severity in Alagille syndrome;
PAAD	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg09127314	chr1:152161683	NA	0.68	4.97	0.37	1.77e-6	Atopic dermatitis;
PAAD	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.44	4.72	0.36	5.31e-6	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.27	0.33	3.43e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.86	5.84	0.43	3.11e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs704	0.739	rs733914	chr17:26671196	C/G	cg10342447	chr17:26645325	TMEM97	-0.37	-4.55	-0.35	1.1e-5	Osteoprotegerin levels;
PAAD	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.52	4.93	0.37	2.14e-6	Cognitive function;
PAAD	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.57	5.12	0.38	8.94e-7	RR interval (heart rate);
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.92	7.96	0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.48	4.89	0.37	2.55e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01765077	chr12:122356316	WDR66	-0.67	-7.11	-0.5	4.16e-11	Mean corpuscular volume;
PAAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	1.0	13.93	0.75	5.95e-29	Rheumatoid arthritis;
PAAD	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs282587	0.569	rs401223	chr13:113375721	C/T	cg02820901	chr13:113351484	ATP11A	0.65	4.73	0.36	5.11e-6	Glycated hemoglobin levels;
PAAD	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg23153227	chr6:27725408	NA	0.43	4.5	0.34	1.34e-5	Cardiac Troponin-T levels;
PAAD	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg08886695	chr4:3369023	RGS12	0.53	5.3	0.39	4.08e-7	Mean platelet volume;
PAAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.72	-7.63	-0.53	2.45e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg23860436	chr12:58378763	NA	0.46	4.33	0.33	2.7e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04736112	chr10:118935095	NA	0.56	6.62	0.47	5.91e-10	Myopia (pathological);
PAAD	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.51	-5.02	-0.38	1.41e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.68	-4.93	-0.37	2.14e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27031506	chr7:128379115	CALU	-0.69	-6.63	-0.47	5.63e-10	Lung cancer in ever smokers;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.59	-5.71	-0.42	5.82e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2997447	0.761	rs2783670	chr1:26455182	A/G	cg24519413	chr1:26490540	NA	0.54	4.78	0.36	4.13e-6	QRS complex (12-leadsum);
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg21269045	chr12:125625041	AACS	-0.47	-4.55	-0.35	1.08e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2320952	0.903	rs12452392	chr17:10487258	G/A	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.27e-5	Gut microbiome composition (winter);
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg02440177	chr19:53496695	ZNF702P	-0.67	-7.07	-0.5	5.31e-11	Psoriasis;
PAAD	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.1	-0.38	1.01e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.68	0.53	1.76e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg24220031	chr2:73402428	NA	-0.34	-5.25	-0.39	5.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs258892	0.895	rs13182583	chr5:72051575	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	1.05	6.61	0.47	6.08e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs2834902	0.633	rs2834895	chr21:36682561	A/G	cg04915566	chr21:36421472	RUNX1	-0.33	-4.47	-0.34	1.53e-5	Corneal curvature;
PAAD	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.81	9.09	0.59	4.95e-16	Metabolic syndrome;
PAAD	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.77	-6.37	-0.46	2.09e-9	Pancreatic cancer;
PAAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7264396	0.832	rs224378	chr20:34088764	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22137270	chr8:140841474	TRAPPC9	0.62	6.3	0.46	3.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg21775007	chr8:11205619	TDH	-0.46	-4.27	-0.33	3.48e-5	Triglycerides;
PAAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23281280	chr6:28129359	ZNF389	-0.69	-5.3	-0.39	4.02e-7	Depression;
PAAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg21361702	chr7:150065534	REPIN1	0.59	4.73	0.36	5.13e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7301016	0.948	rs12369985	chr12:62918780	A/G	cg11441379	chr12:63026424	NA	0.84	6.07	0.44	9.66e-9	IgG glycosylation;
PAAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.79	9.07	0.59	5.65e-16	Diastolic blood pressure;
PAAD	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs9395066	0.545	rs10484627	chr6:44884267	A/T	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs4417704	0.551	rs12620108	chr2:241874076	G/A	cg26818257	chr2:241905806	NA	-0.52	-5.53	-0.41	1.39e-7	Joint mobility (Beighton score);
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.75	-6.42	-0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs8014252	0.803	rs58092588	chr14:71028678	T/C	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.22e-10	Life satisfaction;
PAAD	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg20821713	chr7:1055600	C7orf50	-0.38	-4.31	-0.33	2.88e-5	Longevity;Endometriosis;
PAAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1198430	0.714	rs946265	chr1:23775296	T/G	cg19827787	chr1:23763612	ASAP3	0.58	4.79	0.36	4.01e-6	Total cholesterol levels;
PAAD	cis	rs864537	1.000	rs840016	chr1:167408670	C/T	cg09179987	chr1:167433047	CD247	0.42	4.65	0.35	7.22e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg06618935	chr21:46677482	NA	-0.56	-6.45	-0.46	1.43e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.83	-9.27	-0.6	1.68e-16	Prudent dietary pattern;
PAAD	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.3	-0.46	3.12e-9	Triglycerides;
PAAD	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.23	0.51	2.19e-11	Obesity-related traits;
PAAD	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg14132834	chr19:41945861	ATP5SL	0.52	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs1957429	0.520	rs12435626	chr14:65295215	A/G	cg23373153	chr14:65346875	NA	1.12	6.24	0.45	4.12e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.62	8.42	0.56	2.62e-14	Renal cell carcinoma;
PAAD	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.87	0.54	6.33e-13	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.56	7.03	0.5	6.57e-11	Schizophrenia;
PAAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19784903	chr17:45786737	TBKBP1	-0.67	-7.47	-0.52	5.74e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.46	-4.62	-0.35	8.15e-6	Primary biliary cholangitis;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg19337854	chr7:99768885	GPC2	0.55	5.05	0.38	1.23e-6	Platelet count;
PAAD	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.37	-0.33	2.32e-5	Asthma;
PAAD	cis	rs722599	0.501	rs2286912	chr14:75385437	C/T	cg08847533	chr14:75593920	NEK9	-0.58	-5.86	-0.43	2.76e-8	IgG glycosylation;
PAAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.95	-0.37	1.93e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg09184832	chr6:79620586	NA	-0.42	-4.31	-0.33	2.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.56	-5.62	-0.42	8.72e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs8099014	0.861	rs4940705	chr18:56120155	G/A	cg12907477	chr18:56117327	MIR122	0.59	4.65	0.35	7.27e-6	Platelet count;
PAAD	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.13	-0.38	8.79e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09225658	chr9:95709582	FGD3	0.56	6.47	0.46	1.26e-9	Monocyte percentage of white cells;
PAAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-8.48	-0.57	1.87e-14	Huntington's disease progression;
PAAD	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01756814	chr4:111119868	ELOVL6	0.63	6.43	0.46	1.55e-9	Obesity-related traits;
PAAD	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.68	5.0	0.38	1.55e-6	Mean platelet volume;
PAAD	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.85	-6.93	-0.49	1.13e-10	Pulmonary function decline;
PAAD	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.41	-4.76	-0.36	4.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.46	-0.4	1.91e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs55637147	0.521	rs56077100	chr11:57124634	T/A	cg25492363	chr11:57319872	UBE2L6	-0.4	-4.47	-0.34	1.55e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg01815783	chr4:1047043	NA	-0.46	-4.51	-0.34	1.29e-5	Recombination rate (females);
PAAD	cis	rs6460942	0.505	rs62448708	chr7:12328450	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-4.64	-0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.58e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg14926445	chr8:58193284	C8orf71	-0.66	-5.38	-0.4	2.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	4.31	0.33	2.96e-5	Red cell distribution width;
PAAD	cis	rs8181588	1.000	rs2074197	chr11:2825279	C/T	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	0.71	4.94	0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.58	-5.52	-0.41	1.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.55	5.37	0.4	2.84e-7	Itch intensity from mosquito bite;
PAAD	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.73	-8.92	-0.59	1.41e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	13.84	0.75	1.08e-28	Colorectal cancer;
PAAD	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2916733	0.530	rs1867385	chr8:6306024	A/G	cg02465761	chr8:6735510	DEFB1	0.46	4.83	0.36	3.32e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs12760731	0.565	rs34676994	chr1:178054513	A/T	cg00404053	chr1:178313656	RASAL2	0.67	4.59	0.35	9.26e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs7765175	0.598	rs2842818	chr6:113643678	G/T	cg19037598	chr6:113666021	NA	-0.41	-4.53	-0.34	1.2e-5	Coronary artery calcification;
PAAD	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.29	-0.33	3.12e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.21	-0.45	4.8e-9	Schizophrenia;
PAAD	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.98	0.54	3.36e-13	Response to antipsychotic treatment;
PAAD	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-5.06	-0.38	1.21e-6	QT interval;
PAAD	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	4.37	0.33	2.29e-5	Mood instability;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg10544611	chr16:67998164	SLC12A4	-0.59	-4.25	-0.33	3.72e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg16176600	chr6:116381609	FRK	-0.32	-4.75	-0.36	4.73e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg05434287	chr7:2030229	MAD1L1	-0.37	-4.25	-0.33	3.73e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.76	9.1	0.59	4.75e-16	Vitiligo;
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg05861140	chr6:150128134	PCMT1	-0.5	-5.32	-0.4	3.58e-7	Lung cancer;
PAAD	cis	rs2281845	0.560	rs12079819	chr1:201085420	G/A	cg06714761	chr1:201096289	NA	0.38	5.12	0.38	8.99e-7	Permanent tooth development;
PAAD	cis	rs6782025	0.837	rs3914745	chr3:120799666	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.64	6.95	0.49	1.02e-10	IgG glycosylation;
PAAD	cis	rs12044355	0.927	rs61835382	chr1:231833225	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.7	0.36	5.7e-6	Alzheimer's disease;
PAAD	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg24296786	chr1:45957014	TESK2	0.59	6.22	0.45	4.58e-9	High light scatter reticulocyte count;
PAAD	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg05577173	chr5:78908678	PAPD4	-0.62	-6.38	-0.46	2.05e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg17347104	chr14:75034677	LTBP2	0.54	4.46	0.34	1.57e-5	Non-small cell lung cancer;
PAAD	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs3136739	0.614	rs8178749	chr8:42044897	C/T	cg12054981	chr8:42037387	PLAT	0.74	5.4	0.4	2.48e-7	Plasma plasminogen activator levels;
PAAD	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16417436	chr16:28758564	NA	0.43	4.27	0.33	3.37e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7072216	0.922	rs942813	chr10:100153608	A/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.25	-0.33	3.65e-5	Metabolite levels;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg10864074	chr7:100318194	EPO	0.45	5.26	0.39	4.88e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.94	0.37	2.06e-6	Longevity;
PAAD	trans	rs6828577	0.732	rs60711916	chr4:119461284	G/T	cg26518628	chr1:97050305	NA	-0.72	-6.38	-0.46	2.05e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs2120243	0.647	rs1456099	chr3:157146307	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.43	-4.29	-0.33	3.15e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	8.84	0.58	2.18e-15	IgG glycosylation;
PAAD	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.64	4.29	0.33	3.21e-5	Lung cancer in ever smokers;
PAAD	cis	rs9810890	1.000	rs114352136	chr3:128440226	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.49	-5.41	-0.4	2.46e-7	Cognitive function;
PAAD	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg09760422	chr2:128146352	NA	-0.44	-7.59	-0.52	2.96e-12	Protein C levels;
PAAD	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.56	4.75	0.36	4.6e-6	Blood protein levels;
PAAD	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.94	12.4	0.71	7.6e-25	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02071572	chr4:1403502	NA	0.38	4.76	0.36	4.42e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.1	-0.44	8.61e-9	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.63	6.25	0.45	3.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04976999	chr3:42632121	SS18L2	0.6	6.59	0.47	6.77e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2997447	0.761	rs17257093	chr1:26436231	C/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.74	-7.12	-0.5	4.09e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs6723108	0.616	rs6752634	chr2:135407355	G/A	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Type 2 diabetes;
PAAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.47	4.44	0.34	1.71e-5	Multiple sclerosis;
PAAD	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg02415014	chr8:143852576	LYNX1	-0.38	-4.8	-0.36	3.77e-6	Urinary tract infection frequency;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15815730	chr19:52491114	ZNF350	0.64	6.39	0.46	1.96e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg07777115	chr5:623756	CEP72	-0.53	-4.55	-0.35	1.11e-5	Cystic fibrosis severity;
PAAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.58e-7	Bipolar disorder;
PAAD	cis	rs2117029	0.521	rs7953169	chr12:49578172	G/A	cg05368762	chr12:50135785	TMBIM6	0.48	4.8	0.36	3.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.75	8.75	0.58	3.83e-15	Blood metabolite ratios;
PAAD	cis	rs7264396	0.887	rs736032	chr20:34048661	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs7255	0.545	rs9306894	chr2:20878105	A/G	cg07755735	chr2:20870362	GDF7	-0.39	-4.38	-0.33	2.23e-5	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.27	-0.33	3.44e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg00262122	chr8:11665843	FDFT1	-0.55	-4.99	-0.38	1.62e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10835365	chr22:50169858	BRD1	-0.7	-7.05	-0.5	5.71e-11	Obesity-related traits;
PAAD	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.97	-9.15	-0.6	3.55e-16	Tonometry;
PAAD	cis	rs4751006	0.649	rs76125285	chr10:128779647	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.11e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg19847866	chr10:1019161	NA	-0.49	-4.28	-0.33	3.28e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.3e-5	Parkinson's disease;
PAAD	cis	rs860295	0.580	rs10908463	chr1:155286258	C/T	cg02153340	chr1:155202674	NA	-0.52	-4.62	-0.35	7.98e-6	Body mass index;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	4.9	0.37	2.38e-6	Prudent dietary pattern;
PAAD	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs2944755	0.723	rs13274321	chr8:141588206	A/G	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.61	-0.35	8.42e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.79	8.14	0.55	1.33e-13	Alzheimer's disease (late onset);
PAAD	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.63	6.49	0.47	1.16e-9	Crohn's disease;
PAAD	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg24053715	chr22:38214548	NA	-0.55	-5.47	-0.41	1.84e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg00181669	chr3:44000978	NA	-0.42	-4.25	-0.33	3.69e-5	Coronary artery disease;
PAAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg24733560	chr20:60626293	TAF4	-0.48	-5.59	-0.41	1.03e-7	Body mass index;
PAAD	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.65	6.14	0.45	7.04e-9	Corneal astigmatism;
PAAD	cis	rs507080	0.736	rs659564	chr11:118570914	C/A	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs4740619	0.619	rs11788695	chr9:16032323	G/A	cg14451791	chr9:16040625	NA	-0.45	-5.33	-0.4	3.52e-7	Body mass index;
PAAD	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.43	-0.52	7.27e-12	Colorectal cancer;
PAAD	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg05342682	chr7:94953680	PON1	-0.57	-4.83	-0.36	3.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.86	-10.29	-0.64	3.52e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.47	4.83	0.36	3.32e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08219700	chr8:58056026	NA	0.63	4.93	0.37	2.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.36	4.61	0.35	8.48e-6	Calcium levels;
PAAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.65	0.35	7.12e-6	Coronary artery disease;
PAAD	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.53	5.28	0.39	4.4e-7	Resting heart rate;
PAAD	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg14078157	chr9:128172775	NA	-0.53	-6.45	-0.46	1.41e-9	Mean arterial pressure;
PAAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Breast cancer;
PAAD	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg08514558	chr10:81106712	PPIF	0.51	6.18	0.45	5.74e-9	Height;
PAAD	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.14e-10	Cutaneous nevi;
PAAD	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg13786083	chr1:19110734	NA	0.72	6.39	0.46	1.89e-9	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg26690034	chr1:75198963	CRYZ;TYW3	0.53	4.89	0.37	2.57e-6	Resistin levels;
PAAD	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.62	6.65	0.47	5.05e-10	Testicular germ cell tumor;
PAAD	cis	rs3026101	0.671	rs1806222	chr17:5289676	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.83	5.62	0.41	8.8e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.8	8.58	0.57	1.05e-14	Caffeine consumption;
PAAD	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg24330906	chr2:85765176	MAT2A	0.58	5.66	0.42	7.3900000000000007e-08	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7264396	0.887	rs1886696	chr20:34055706	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	4.43	0.34	1.81e-5	Total cholesterol levels;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.7	-7.41	-0.52	8.22e-12	Height;
PAAD	cis	rs6466055	0.574	rs3087867	chr7:105028238	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.79	5.55	0.41	1.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-4.42	-0.34	1.84e-5	Crohn's disease;
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg04520793	chr17:42248056	ASB16	-0.49	-6.67	-0.48	4.55e-10	Total body bone mineral density;
PAAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.14	-0.39	8.14e-7	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs608114	0.623	rs845539	chr6:96364197	G/C	cg03043157	chr6:97010903	FHL5	0.93	4.88	0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.57	5.37	0.4	2.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.43	-0.4	2.2e-7	Body mass index;
PAAD	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-4.68	-0.35	6.36e-6	Neuroticism;
PAAD	cis	rs2072732	0.861	rs12044848	chr1:2960790	C/T	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs75920871	1.000	rs1473325	chr11:116822034	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg21892295	chr12:121157589	UNC119B	-0.41	-4.91	-0.37	2.29e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.74	8.71	0.58	4.77e-15	Lung cancer;
PAAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.93	-16.3	-0.8	3.41e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19238422	chr1:228353246	C1orf69	-0.62	-6.29	-0.45	3.24e-9	Smoking initiation;
PAAD	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	4.37	0.33	2.27e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9826463	0.702	rs55994893	chr3:142304694	G/C	cg20824294	chr3:142316082	PLS1	0.43	4.82	0.36	3.41e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg21518248	chr2:162101506	NA	0.64	6.8	0.48	2.27e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.8e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.55	-0.41	1.23e-7	Monocyte percentage of white cells;
PAAD	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg11204139	chr17:3907470	NA	-0.58	-5.57	-0.41	1.14e-7	Type 2 diabetes;
PAAD	cis	rs13242816	1.000	rs56250718	chr7:116103303	A/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-7.03	-0.5	6.5e-11	Morning vs. evening chronotype;
PAAD	cis	rs735539	0.645	rs9550662	chr13:21141552	C/T	cg27499820	chr13:21296301	IL17D	0.52	4.94	0.37	2.03e-6	Dental caries;
PAAD	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg20913747	chr6:44695427	NA	-0.54	-4.77	-0.36	4.2e-6	Total body bone mineral density;
PAAD	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs939584	0.877	rs13028737	chr2:630782	G/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs2133450	0.545	rs12492204	chr3:7350481	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.07	-0.38	1.17e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.23	17.4	0.82	5.47e-38	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg16342193	chr10:102329863	NA	-0.75	-8.13	-0.55	1.44e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg11250194	chr11:61601937	FADS2	-0.53	-4.76	-0.36	4.49e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.2	0.39	6.32e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	cis	rs77880822	0.562	rs7264468	chr20:1233431	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.48	-5.5	-0.41	1.6e-7	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
PAAD	cis	rs3747547	0.892	rs11789441	chr9:37993303	G/T	cg13774184	chr9:37916125	SHB	-0.6	-4.3	-0.33	2.99e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.74	-0.48	3.02e-10	Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04591732	chr17:79419108	BAHCC1	-0.63	-6.95	-0.49	9.86e-11	Myopia (pathological);
PAAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg10556349	chr10:835070	NA	0.56	4.6	0.35	8.89e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.69	-0.53	1.74e-12	Coronary artery disease;
PAAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.53	-5.19	-0.39	6.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.74	6.45	0.46	1.41e-9	Dilated cardiomyopathy;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02071572	chr4:1403502	NA	0.43	5.86	0.43	2.8e-8	Obesity-related traits;
PAAD	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.59	-6.32	-0.46	2.79e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.4	-0.46	1.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.48	-5.51	-0.41	1.49e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.44	4.8	0.36	3.77e-6	Motion sickness;
PAAD	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.43	-5.08	-0.38	1.1e-6	Uric acid levels;
PAAD	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.69e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2882667	0.654	rs288019	chr5:138191393	A/G	cg09476006	chr5:138032270	NA	-0.44	-5.39	-0.4	2.62e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-4.76	-0.36	4.38e-6	Asthma;
PAAD	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-1.03	-16.95	-0.81	7.42e-37	Urate levels in lean individuals;
PAAD	cis	rs12773846	0.537	rs35637027	chr10:126267685	C/T	cg04949429	chr10:126290192	LHPP	0.66	5.79	0.43	3.83e-8	Subcutaneous adipose tissue;
PAAD	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs2668423	1.000	rs2668423	chr19:1370526	T/G	cg02639931	chr19:1387894	NDUFS7	-0.61	-6.86	-0.49	1.64e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs72827839	0.802	rs1986693	chr17:46026156	A/G	cg23391107	chr17:45924227	SP6	-0.59	-4.93	-0.37	2.14e-6	Ease of getting up in the morning;
PAAD	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.59	0.41	1.02e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs10186876	0.728	rs10205130	chr2:44151572	G/C	cg26828767	chr2:44457733	PPM1B	-0.45	-4.3	-0.33	2.98e-5	Hand grip strength;
PAAD	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg15838173	chr10:75533400	FUT11	-0.48	-4.76	-0.36	4.49e-6	Inflammatory bowel disease;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.63	-6.64	-0.47	5.13e-10	Prostate cancer;
PAAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.53	6.67	0.48	4.48e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1864585	0.520	rs6984391	chr8:10646111	A/G	cg21775007	chr8:11205619	TDH	-0.55	-4.26	-0.33	3.63e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs72960926	0.590	rs72955114	chr6:74753250	C/T	cg03266952	chr6:74778945	NA	-1.23	-7.33	-0.51	1.3e-11	Metabolite levels (MHPG);
PAAD	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.49	0.61	4.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg20673841	chr7:107026890	COG5	-0.48	-4.36	-0.33	2.41e-5	Coronary artery disease;
PAAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.64	-0.57	7.33e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.48	4.94	0.37	2.04e-6	Breast cancer;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.95	-16.1	-0.79	1.17e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16858210	0.607	rs57874587	chr3:183584749	C/T	cg25686905	chr3:183603175	PARL	-0.38	-4.39	-0.34	2.11e-5	Menopause (age at onset);
PAAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.88	9.42	0.61	6.84e-17	Parkinson's disease;
PAAD	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.26e-6	Hepatitis;
PAAD	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.91	-10.95	-0.66	6.09e-21	IgG glycosylation;
PAAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.75	-5.51	-0.41	1.52e-7	Initial pursuit acceleration;
PAAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg05697835	chr1:2722811	NA	-0.41	-4.62	-0.35	8.22e-6	Ulcerative colitis;
PAAD	cis	rs73019876	0.901	rs394457	chr19:22230428	G/T	cg11619707	chr19:22235551	ZNF257	-0.42	-4.49	-0.34	1.39e-5	Testicular germ cell tumor;
PAAD	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.57	5.92	0.43	2.09e-8	Dupuytren's disease;
PAAD	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.89	11.04	0.67	3.45e-21	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.47	5.27	0.39	4.53e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs728616	0.867	rs61859980	chr10:81888694	T/C	cg19423196	chr10:82049429	MAT1A	0.62	4.68	0.35	6.29e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.68	9.14	0.6	3.66e-16	Systolic blood pressure;
PAAD	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-5.4	-0.4	2.48e-7	Calcium levels;
PAAD	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.68	-4.85	-0.37	3.01e-6	LDL cholesterol levels;
PAAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.27	0.45	3.6e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg07679836	chr6:33548423	BAK1	0.31	4.43	0.34	1.78e-5	Platelet count;
PAAD	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.06	-0.5	5.51e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs714031	0.872	rs3788576	chr22:40071894	G/A	cg21377881	chr22:40064566	CACNA1I	-0.47	-4.41	-0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.13	-0.7	4.21e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.54	5.18	0.39	6.98e-7	Endometrial cancer;
PAAD	cis	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg01613454	chr2:70366299	NA	0.41	4.38	0.33	2.19e-5	Obesity-related traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg02397073	chr6:107349626	C6orf203	0.66	6.29	0.45	3.17e-9	Primary biliary cholangitis;
PAAD	cis	rs8105895	0.877	rs7248305	chr19:22250271	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.98	-11.84	-0.69	2.43e-23	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.86	0.54	6.41e-13	Motion sickness;
PAAD	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg26818257	chr2:241905806	NA	0.46	4.85	0.37	3.06e-6	Joint mobility (Beighton score);
PAAD	cis	rs73206853	0.534	rs12302069	chr12:110512359	A/G	cg12870014	chr12:110450643	ANKRD13A	0.84	5.03	0.38	1.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-8.51	-0.57	1.56e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs61759167	1.000	rs61759167	chr1:3091587	C/T	cg22674798	chr1:3096360	PRDM16	0.4	4.66	0.35	6.89e-6	Motion sickness;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.69	-7.9	-0.54	5.24e-13	Prudent dietary pattern;
PAAD	cis	rs6604026	0.656	rs6698233	chr1:93397300	C/T	cg13858687	chr1:93297071	RPL5	0.49	4.5	0.34	1.33e-5	Multiple sclerosis;
PAAD	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	4.61	0.35	8.54e-6	Schizophrenia;
PAAD	cis	rs13424612	0.930	rs12478169	chr2:240951603	C/T	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.66	-0.35	6.98e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg23119463	chr10:134592391	INPP5A	-0.47	-4.72	-0.36	5.4e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.61	5.61	0.41	9.27e-8	Schizophrenia;
PAAD	cis	rs4594175	0.926	rs11157804	chr14:51630340	A/G	cg23942311	chr14:51606299	NA	-0.7	-7.03	-0.5	6.58e-11	Cancer;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.47	-0.46	1.25e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21210496	chr17:71419763	SDK2	-0.8	-8.58	-0.57	1.02e-14	Obesity-related traits;
PAAD	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.78	8.06	0.55	2.06e-13	Morning vs. evening chronotype;
PAAD	trans	rs12714314	0.957	rs2060195	chr2:1955801	A/G	cg17170872	chr1:91487911	ZNF644	-0.76	-6.3	-0.46	3.12e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs1413885	0.934	rs7516118	chr1:65817097	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.96	0.37	1.9e-6	Anticoagulant levels;
PAAD	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg02353165	chr6:42928485	GNMT	0.6	4.81	0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	5.5	0.41	1.6e-7	Neuroticism;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg23018236	chr17:30244563	NA	-0.63	-5.44	-0.4	2.13e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg00982548	chr2:198649783	BOLL	-0.92	-6.35	-0.46	2.4e-9	Ulcerative colitis;
PAAD	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg11204139	chr17:3907470	NA	0.63	5.75	0.42	4.75e-8	Type 2 diabetes;
PAAD	cis	rs9463078	0.565	rs4714845	chr6:45230421	G/A	cg25276700	chr6:44698697	NA	0.45	5.1	0.38	1.01e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7072216	0.687	rs7908310	chr10:100156227	G/A	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-1.06	-14.85	-0.77	2.18e-31	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	7.31	0.51	1.43e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00079375	chr15:79125835	NA	0.43	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.75	-0.36	4.68e-6	Total body bone mineral density;
PAAD	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.22e-7	HDL cholesterol;
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.44	4.66	0.35	6.85e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg00758881	chr16:58534681	NDRG4	-0.84	-4.57	-0.35	9.84e-6	Schizophrenia;
PAAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-1.34	-9.89	-0.63	4.11e-18	Magnesium levels;
PAAD	cis	rs2466035	0.545	rs1021955	chr8:128203973	A/G	cg23179168	chr8:127570165	FAM84B	-0.47	-4.42	-0.34	1.88e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg26031613	chr14:104095156	KLC1	-0.52	-5.47	-0.41	1.84e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.44	-0.46	1.49e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.85	-10.36	-0.64	2.26e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14169450	chr9:139327907	INPP5E	0.57	4.94	0.37	2.02e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs258892	0.843	rs34329209	chr5:72045517	T/C	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06850241	chr22:41845214	NA	0.55	5.05	0.38	1.24e-6	Vitiligo;
PAAD	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg00531865	chr16:30841666	NA	0.6	4.45	0.34	1.68e-5	Dementia with Lewy bodies;
PAAD	cis	rs469568	0.543	rs6601023	chr5:178671774	A/G	cg08999896	chr5:178685787	ADAMTS2	0.55	5.67	0.42	6.82e-8	Stroke (pediatric);
PAAD	cis	rs377457	0.893	rs451871	chr16:85736429	A/G	cg07784872	chr16:85687041	KIAA0182	-0.77	-8.03	-0.55	2.54e-13	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09695851	chr17:3907499	NA	0.68	6.91	0.49	1.23e-10	Type 2 diabetes;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.98	-14.18	-0.75	1.28e-29	Post bronchodilator FEV1;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16188349	chr3:61656617	PTPRG	-0.59	-6.95	-0.49	1.01e-10	Monocyte percentage of white cells;
PAAD	cis	rs7989332	0.925	rs6490585	chr13:21052298	C/T	cg06710890	chr13:21477865	XPO4	0.47	4.49	0.34	1.42e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.54	-4.72	-0.36	5.37e-6	Testicular germ cell tumor;
PAAD	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.36	-0.33	2.37e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-5.02	-0.38	1.43e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs72960926	0.744	rs11752920	chr6:75000195	C/T	cg03266952	chr6:74778945	NA	-1.13	-6.26	-0.45	3.68e-9	Metabolite levels (MHPG);
PAAD	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.79	7.54	0.52	3.88e-12	Platelet distribution width;
PAAD	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.49	4.76	0.36	4.55e-6	Selective IgA deficiency;
PAAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.45	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs7565124	0.909	rs6747473	chr2:20252008	C/G	cg23821541	chr2:20251993	LAPTM4A	0.52	4.54	0.35	1.15e-5	Major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23884421	chr19:5623195	SAFB2;SAFB	0.65	6.3	0.46	3.11e-9	Obesity-related traits;
PAAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.75	-7.66	-0.53	2.03e-12	Monocyte count;
PAAD	cis	rs4321325	0.668	rs56346774	chr2:127932551	G/A	cg11380483	chr2:127933992	NA	0.74	5.34	0.4	3.37e-7	Protein C levels;
PAAD	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.74	-6.55	-0.47	8.2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-6.13	-0.45	7.12e-9	Caffeine consumption;
PAAD	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.79	6.04	0.44	1.14e-8	Mean platelet volume;
PAAD	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.55	5.29	0.39	4.18e-7	Rheumatoid arthritis;
PAAD	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.5	0.47	1.09e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg27005118	chr17:13972210	COX10	-0.53	-7.6	-0.52	2.85e-12	Temperament;
PAAD	cis	rs2290419	0.730	rs75889999	chr11:68942374	T/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.49	4.89	0.37	2.59e-6	Menopause (age at onset);
PAAD	cis	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.05	-0.38	1.27e-6	Blood pressure (smoking interaction);
PAAD	cis	rs16910800	0.953	rs73481423	chr11:23205302	T/C	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.28	0.39	4.3e-7	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.49	4.82	0.36	3.39e-6	Menopause (age at onset);
PAAD	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs11166927	0.904	rs12547230	chr8:140818544	C/T	cg16909799	chr8:140841666	TRAPPC9	0.66	7.79	0.53	9.92e-13	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.88	-0.37	2.67e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-1.12	-10.25	-0.64	4.43e-19	Blood trace element (Zn levels);
PAAD	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	5.92	0.43	2.02e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.84	-9.32	-0.6	1.28e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs17169635	0.765	rs1014832	chr7:134572672	C/T	cg02516134	chr7:134575187	CALD1	0.48	4.43	0.34	1.77e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.75	-12.07	-0.7	6e-24	Body mass index;
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg07291445	chr7:39015928	NA	0.29	4.27	0.33	3.41e-5	IgG glycosylation;
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13047869	chr3:10149882	C3orf24	0.65	4.94	0.37	2.05e-6	Alzheimer's disease;
PAAD	cis	rs2424590	1.000	rs2424590	chr20:23636980	C/T	cg16589663	chr20:23618590	CST3	-0.82	-4.96	-0.37	1.88e-6	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10296688	chr13:52598408	UTP14C;ALG11	-0.78	-8.16	-0.55	1.2e-13	Obesity-related traits;
PAAD	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.78	8.97	0.59	1.04e-15	Heart rate;
PAAD	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-1.06	-18.93	-0.84	7.91e-42	Urate levels in lean individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24858207	chr7:1989993	MAD1L1	-0.65	-6.82	-0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.66	-0.35	7e-6	Lung cancer;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	1.09	15.77	0.79	8.22e-34	Systemic lupus erythematosus;
PAAD	cis	rs9646944	0.531	rs17027029	chr2:102990648	G/C	cg20060108	chr2:102954350	IL1RL1	0.52	4.26	0.33	3.63e-5	Blood protein levels;
PAAD	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26926768	chr12:34528122	NA	0.4	4.86	0.37	2.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.41	-0.46	1.78e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17442961	chr17:78635428	RPTOR	0.54	6.48	0.47	1.18e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	1.13	12.06	0.7	6.54e-24	Post bronchodilator FEV1;
PAAD	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18364779	chr6:26104403	HIST1H4C	0.45	4.53	0.35	1.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.68	-0.35	6.27e-6	Body mass index;
PAAD	cis	rs6908034	0.607	rs75060331	chr6:19812956	C/T	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.09	7.19	0.5	2.71e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.53	4.76	0.36	4.39e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg08514558	chr10:81106712	PPIF	0.51	6.18	0.45	5.74e-9	Height;
PAAD	cis	rs537626	0.767	rs680618	chr11:69316881	T/C	cg08353955	chr11:69289746	NA	-0.71	-5.85	-0.43	2.84e-8	Breast cancer (early onset);
PAAD	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.04	17.52	0.82	2.67e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12220238	0.915	rs11000948	chr10:76031721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.67	-4.35	-0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.92	-9.75	-0.62	9.33e-18	Type 2 diabetes;
PAAD	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	1.05	14.58	0.76	1.09e-30	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg05333889	chr7:157238977	NA	-0.44	-4.73	-0.36	5.17e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg00629941	chr15:75287862	SCAMP5	-0.56	-4.29	-0.33	3.22e-5	Blood trace element (Zn levels);
PAAD	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.83	10.59	0.65	5.55e-20	Breast cancer;
PAAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.93	7.49	0.52	5.24e-12	Initial pursuit acceleration;
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg02475695	chr16:616220	NHLRC4	0.47	5.36	0.4	3.02e-7	Height;
PAAD	cis	rs11159086	0.793	rs28378078	chr14:74954643	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.23	-0.39	5.55e-7	Advanced glycation end-product levels;
PAAD	cis	rs17688076	0.558	rs12446418	chr16:68290200	G/A	cg05110241	chr16:68378359	PRMT7	-1.11	-6.38	-0.46	1.97e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.26	-0.33	3.58e-5	Lung cancer;
PAAD	cis	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg00614314	chr15:82944287	LOC80154	0.49	4.77	0.36	4.37e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	8.04	0.55	2.33e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7873102	0.630	rs60510358	chr9:38001902	C/T	cg03528946	chr9:38069800	SHB	-0.5	-5.04	-0.38	1.28e-6	Brain structure;
PAAD	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg20913747	chr6:44695427	NA	-0.63	-5.92	-0.43	2.04e-8	Total body bone mineral density;
PAAD	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-7.06	-0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.67	6.11	0.44	8.14e-9	Response to metformin (IC50);
PAAD	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-4.46	-0.34	1.58e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.96e-6	Vitiligo;
PAAD	cis	rs6718203	1.000	rs56080318	chr2:60640346	G/T	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
PAAD	cis	rs2928148	0.500	rs12912887	chr15:41257608	G/T	cg18705301	chr15:41695430	NDUFAF1	0.63	5.78	0.42	4.03e-8	Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.77	6.47	0.46	1.29e-9	Nonalcoholic fatty liver disease;
PAAD	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg01181863	chr3:195395398	SDHAP2	0.6	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	cis	rs2790216	1.000	rs2095893	chr10:59969551	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.52	-5.28	-0.39	4.36e-7	Schizophrenia;
PAAD	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs91	0.575	rs2521644	chr7:24427969	C/T	cg13313214	chr7:23749942	STK31	-0.46	-4.73	-0.36	5.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-5.55	-0.41	1.25e-7	Morning vs. evening chronotype;
PAAD	cis	rs9467711	1.000	rs9467713	chr6:26338128	T/C	cg16898833	chr6:26189333	HIST1H4D	0.86	4.74	0.36	4.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg26516362	chr5:178986906	RUFY1	-0.49	-5.74	-0.42	4.87e-8	Lung cancer;
PAAD	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg09654669	chr8:57350985	NA	0.49	4.51	0.34	1.29e-5	Obesity-related traits;
PAAD	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2031532	0.587	rs7991226	chr13:50032293	C/T	cg03651054	chr13:50194643	NA	0.33	4.41	0.34	1.95e-5	Cardiac hypertrophy;
PAAD	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg26818257	chr2:241905806	NA	0.42	4.28	0.33	3.34e-5	Urinary metabolites;
PAAD	cis	rs13242816	1.000	rs56010123	chr7:116173046	C/T	cg16553024	chr7:116138462	CAV2	-0.64	-4.47	-0.34	1.55e-5	P wave duration;
PAAD	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg01631408	chr1:248437212	OR2T33	0.58	5.33	0.4	3.48e-7	Common traits (Other);
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05665937	chr4:1216051	CTBP1	0.4	4.37	0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg23254163	chr1:152506842	NA	-0.59	-6.91	-0.49	1.24e-10	Hair morphology;
PAAD	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.08	0.38	1.07e-6	Prostate cancer;
PAAD	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.73	7.47	0.52	5.95e-12	Cognitive function;
PAAD	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.6	5.86	0.43	2.79e-8	IgG glycosylation;
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.81	-0.48	2.16e-10	Lung cancer;
PAAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.43	-5.28	-0.39	4.48e-7	Blood pressure;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg25204440	chr1:209979598	IRF6	0.56	4.56	0.35	1.04e-5	Coronary artery disease;
PAAD	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8105895	0.935	rs8110289	chr19:22239717	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.85	9.82	0.62	6.43e-18	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs10421328	0.848	rs7253821	chr19:19784891	G/A	cg11584989	chr19:19387371	SF4	0.84	6.35	0.46	2.38e-9	Parental longevity (combined parental age at death);
PAAD	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.64	-0.35	7.57e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg03999872	chr20:62272968	STMN3	-0.61	-5.41	-0.4	2.38e-7	Atopic dermatitis;
PAAD	trans	rs901683	1.000	rs12781506	chr10:46038702	T/C	cg11747279	chr17:21096632	NA	0.78	6.35	0.46	2.41e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs818427	0.858	rs469827	chr5:112242139	C/A	cg06941702	chr5:112196734	SRP19	0.54	5.0	0.38	1.55e-6	Total body bone mineral density;
PAAD	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg00601450	chr5:74908170	NA	-0.46	-4.36	-0.33	2.34e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00771170	chr19:3971184	DAPK3	-0.54	-6.44	-0.46	1.49e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.82	9.94	0.63	2.95e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-1.17	-8.15	-0.55	1.23e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.89	11.13	0.67	1.97e-21	Mean corpuscular volume;
PAAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg13722127	chr7:150037890	RARRES2	0.65	6.29	0.45	3.24e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg19636519	chr7:99541626	NA	0.4	4.48	0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2798269	0.604	rs2798275	chr13:22159035	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.51	-4.72	-0.36	5.31e-6	PR segment;
PAAD	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg16745616	chr19:8428856	ANGPTL4	-0.53	-4.72	-0.36	5.25e-6	HDL cholesterol;
PAAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.25	0.33	3.75e-5	Tonsillectomy;
PAAD	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.55	5.69	0.42	6.28e-8	Crohn's disease;
PAAD	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.46	4.73	0.36	5.13e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg11547950	chr5:77652471	NA	0.91	7.75	0.53	1.24e-12	Triglycerides;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.7	-0.36	5.87e-6	Testicular germ cell tumor;
PAAD	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.73	7.69	0.53	1.73e-12	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs4455778	0.580	rs4524741	chr7:49105138	A/C	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.33e-5	Lung cancer in never smokers;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg20821713	chr7:1055600	C7orf50	-0.41	-4.6	-0.35	8.98e-6	Longevity;Endometriosis;
PAAD	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg12486944	chr17:80159399	CCDC57	-0.51	-4.53	-0.35	1.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.71	-8.35	-0.56	3.86e-14	Facial morphology (factor 20);
PAAD	trans	rs6694672	0.717	rs2151135	chr1:197106604	C/T	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.81	8.72	0.58	4.47e-15	Coronary artery disease;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-4.46	-0.34	1.59e-5	Schizophrenia;
PAAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	12.68	0.72	1.33e-25	Bone mineral density;
PAAD	cis	rs6442522	0.678	rs13085575	chr3:15499330	C/T	cg16303742	chr3:15540471	COLQ	0.46	4.98	0.37	1.69e-6	Uric acid levels;
PAAD	cis	rs7631605	0.905	rs3774338	chr3:37062959	G/T	cg17445812	chr3:36986805	TRANK1	0.34	4.54	0.35	1.14e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg12757816	chr2:10669957	NA	-0.55	-5.85	-0.43	2.87e-8	Prostate cancer;
PAAD	cis	rs6466055	0.589	rs67909511	chr7:104971848	A/G	cg04380332	chr7:105027541	SRPK2	0.5	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg07469887	chr10:131262384	NA	-0.43	-5.03	-0.38	1.34e-6	Response to temozolomide;
PAAD	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.25	-17.63	-0.82	1.4e-38	Ulcerative colitis;
PAAD	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	8.95	0.59	1.17e-15	Lymphocyte counts;
PAAD	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.39	0.46	1.93e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15034692	chr19:44008318	PHLDB3	-0.57	-6.86	-0.49	1.66e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.93	-6.42	-0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.37	-7.01	-0.49	7.17e-11	Mean corpuscular volume;
PAAD	cis	rs11159086	0.793	rs1029702	chr14:74940612	C/T	cg10195687	chr14:74926396	NA	-0.47	-5.35	-0.4	3.18e-7	Advanced glycation end-product levels;
PAAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg10556349	chr10:835070	NA	-0.53	-4.98	-0.37	1.68e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	11.91	0.69	1.64e-23	Platelet count;
PAAD	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.69	6.72	0.48	3.37e-10	Schizophrenia;
PAAD	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs367943	0.672	rs6594712	chr5:112715211	T/G	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.7	-0.48	3.89e-10	Height;
PAAD	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.74e-9	Coffee consumption (cups per day);
PAAD	cis	rs8112449	0.930	rs8112675	chr19:10538719	C/T	cg03722295	chr19:10519375	NA	0.32	4.41	0.34	1.96e-5	Multiple sclerosis;Gastritis;
PAAD	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.51	0.47	1.04e-9	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.86	-7.71	-0.53	1.54e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg11416102	chr8:651193	ERICH1	-0.74	-4.7	-0.36	5.89e-6	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs57709857	0.957	rs72630624	chr8:38240392	C/T	cg16625770	chr8:38300134	FGFR1	-0.47	-4.38	-0.33	2.18e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-5.31	-0.4	3.82e-7	Reticulocyte count;
PAAD	cis	rs7594192	0.744	rs7581634	chr2:199370347	T/A	cg01558212	chr2:200327336	NA	0.35	4.62	0.35	8.1e-6	Educational attainment;
PAAD	cis	rs595018	0.505	rs55653938	chr11:60597831	G/A	cg07588442	chr11:60673866	PRPF19	0.64	4.49	0.34	1.42e-5	Wegener's granulomatosis;
PAAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.72	5.8	0.43	3.77e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg15691649	chr6:25882328	NA	-0.52	-4.67	-0.35	6.48e-6	Blood metabolite levels;
PAAD	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.55	-4.91	-0.37	2.36e-6	Retinal vascular caliber;
PAAD	cis	rs75757892	0.543	rs77223242	chr6:7312680	T/A	cg02954307	chr6:7269328	NA	0.59	4.75	0.36	4.72e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg26072250	chr5:443457	EXOC3;C5orf55	-0.55	-4.85	-0.37	3.08e-6	Fat distribution (HIV);
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.67	0.42	6.82e-8	Prudent dietary pattern;
PAAD	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.14	-0.38	8.46e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.75	0.48	2.86e-10	Lung cancer;
PAAD	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-1.18	-7.43	-0.52	7.22e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg11764359	chr7:65958608	NA	0.79	5.17	0.39	7.11e-7	Diabetic kidney disease;
PAAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.46	4.46	0.34	1.61e-5	Trans fatty acid levels;
PAAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.7	-8.06	-0.55	2.06e-13	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.49	-5.47	-0.41	1.82e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg13206674	chr6:150067644	NUP43	0.61	5.5	0.41	1.56e-7	Lung cancer;
PAAD	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.59	-5.41	-0.4	2.38e-7	Total body bone mineral density;
PAAD	cis	rs4704187	0.640	rs4704188	chr5:74482675	A/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.59	-5.99	-0.44	1.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.51	5.15	0.39	8.02e-7	QT interval;
PAAD	cis	rs9810890	0.764	rs2340465	chr3:128557819	C/G	cg18531004	chr3:128564980	NA	-0.67	-4.36	-0.33	2.37e-5	Dental caries;
PAAD	cis	rs76917914	0.820	rs7846880	chr9:100822940	G/A	cg03040243	chr9:100819229	NANS	0.58	4.69	0.36	5.91e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.65	-7.13	-0.5	3.84e-11	Menarche (age at onset);
PAAD	cis	rs10899021	0.790	rs12296094	chr11:74321700	C/T	cg25880958	chr11:74394337	NA	-0.73	-4.65	-0.35	7.31e-6	Response to metformin (IC50);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05149234	chr11:66024911	KLC2	0.6	6.33	0.46	2.56e-9	Myopia (pathological);
PAAD	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.54	5.63	0.42	8.59e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg05038881	chr1:10490043	APITD1	0.42	4.9	0.37	2.38e-6	Prostate cancer;
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.31	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg00181669	chr3:44000978	NA	-0.52	-5.57	-0.41	1.13e-7	Coronary artery disease;
PAAD	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.13	9.09	0.59	4.94e-16	Left atrial antero-posterior diameter;
PAAD	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.31	-0.46	2.97e-9	Neuroticism;
PAAD	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg05627522	chr15:75251581	NA	-0.51	-6.23	-0.45	4.39e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.75	7.34	0.51	1.2e-11	Methadone dose in opioid dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08049060	chr3:50396974	TMEM115	0.6	6.32	0.46	2.73e-9	Myopia (pathological);
PAAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.78	10.47	0.65	1.19e-19	Sjögren's syndrome;
PAAD	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.55	-6.28	-0.45	3.41e-9	Prostate cancer;
PAAD	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg08926642	chr1:7887455	PER3	0.5	4.52	0.34	1.22e-5	Inflammatory bowel disease;
PAAD	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.79	-0.48	2.35e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg15798862	chr7:76129360	DTX2	-0.49	-6.61	-0.47	6.18e-10	Multiple sclerosis;
PAAD	cis	rs1018697	1.000	rs7080587	chr10:104545274	C/T	cg04362960	chr10:104952993	NT5C2	0.59	5.95	0.43	1.76e-8	Colorectal adenoma (advanced);
PAAD	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg22431228	chr1:16359049	CLCNKA	0.41	5.08	0.38	1.07e-6	Systolic blood pressure;
PAAD	cis	rs12600053	0.687	rs8058664	chr16:84849100	A/G	cg09249803	chr16:84846936	NA	0.52	4.32	0.33	2.84e-5	Asthma (childhood onset);
PAAD	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-1.06	-10.04	-0.63	1.65e-18	IgG glycosylation;
PAAD	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.38	-0.33	2.21e-5	Dupuytren's disease;
PAAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.49	-4.42	-0.34	1.85e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.94	-0.59	1.24e-15	Bone mineral density;
PAAD	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.37	5.34	0.4	3.27e-7	Educational attainment (years of education);
PAAD	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.62	8.27	0.56	6.41e-14	Crohn's disease;
PAAD	cis	rs10849605	0.867	rs10849602	chr12:1062479	A/G	cg22937753	chr12:1022477	RAD52	-0.51	-5.02	-0.38	1.45e-6	Lung cancer;
PAAD	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.16	0.55	1.18e-13	Corneal astigmatism;
PAAD	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	cis	rs17539620	0.808	rs62434162	chr6:154874495	A/C	cg20019720	chr6:154832845	CNKSR3	0.47	6.27	0.45	3.59e-9	Lipoprotein (a) levels;
PAAD	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08704250	chr15:31115839	NA	-0.62	-8.66	-0.57	6.27e-15	Huntington's disease progression;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13901433	chr17:73285524	SLC25A19	-0.58	-6.51	-0.47	1.02e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-4.46	-0.34	1.57e-5	Dementia with Lewy bodies;
PAAD	cis	rs7804356	0.871	rs212848	chr7:26722155	G/T	cg03456212	chr7:26904342	SKAP2	0.55	4.43	0.34	1.83e-5	Type 1 diabetes;
PAAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	9.51	0.61	4.04e-17	Smoking behavior;
PAAD	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.96	0.37	1.83e-6	Vitamin D levels;
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg22875332	chr1:76189707	ACADM	-0.46	-4.68	-0.35	6.3e-6	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15541315	chr11:114309932	REXO2	0.62	6.85	0.49	1.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg10820045	chr2:198174542	NA	0.48	4.86	0.37	2.92e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.17e-7	Ulcerative colitis;
PAAD	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	12.0	0.7	9.02e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg13206674	chr6:150067644	NUP43	0.59	5.42	0.4	2.27e-7	Lung cancer;
PAAD	cis	rs7165102	1.000	rs2456009	chr15:65840082	C/A	cg22900193	chr15:65823441	PTPLAD1	-0.48	-4.45	-0.34	1.64e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.62	-4.81	-0.36	3.56e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	0.94	7.01	0.49	7.24e-11	Prostate cancer;
PAAD	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.97	7.42	0.52	7.72e-12	Eosinophilic esophagitis;
PAAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.6	-0.41	9.79e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.01	-0.38	1.5e-6	Electroencephalogram traits;
PAAD	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.69	7.14	0.5	3.69e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg16147221	chr4:10020634	SLC2A9	0.47	4.34	0.33	2.54e-5	Bone mineral density;
PAAD	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.55	-0.35	1.11e-5	Joint mobility (Beighton score);
PAAD	cis	rs3096490	0.765	rs3096509	chr4:109947312	G/A	cg08760493	chr4:109994039	COL25A1	0.39	4.39	0.34	2.15e-5	Body mass index;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg21724239	chr8:58056113	NA	0.73	5.39	0.4	2.58e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs4144027	0.904	rs10438243	chr14:104345822	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.38	-4.64	-0.35	7.39e-6	Blood metabolite levels;
PAAD	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.48	4.54	0.35	1.13e-5	Height;
PAAD	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.41	-4.5	-0.34	1.37e-5	Mean arterial pressure;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14094449	chr14:60558589	C14orf135	0.7	6.5	0.47	1.07e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg21226059	chr5:178986404	RUFY1	0.58	6.31	0.46	2.89e-9	Lung cancer;
PAAD	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.85	-7.19	-0.5	2.81e-11	Prostate cancer;
PAAD	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg04520793	chr17:42248056	ASB16	0.41	4.68	0.35	6.31e-6	Total body bone mineral density;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg25452165	chr22:42524984	CYP2D6	0.6	5.52	0.41	1.4e-7	Schizophrenia;
PAAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg03303774	chr4:1407052	NA	0.47	5.97	0.44	1.59e-8	Obesity-related traits;
PAAD	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg23254163	chr1:152506842	NA	-0.55	-6.3	-0.46	2.99e-9	Hair morphology;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.82	-9.23	-0.6	2.14e-16	Monocyte percentage of white cells;
PAAD	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg10705379	chr10:99080932	FRAT1	0.44	5.19	0.39	6.56e-7	Monocyte count;
PAAD	cis	rs3812111	0.677	rs1204838	chr6:116515224	C/A	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.31	-0.33	2.9e-5	Age-related macular degeneration;
PAAD	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.48	-4.34	-0.33	2.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg00083937	chr22:51039805	MAPK8IP2	-0.44	-4.64	-0.35	7.49e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs72772787	1.000	rs12096473	chr1:248016894	C/T	cg04028570	chr1:248100427	OR2L13	0.63	4.95	0.37	1.93e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.44e-9	Lung cancer;
PAAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg25833597	chr17:30823145	MYO1D	0.55	5.33	0.4	3.44e-7	Schizophrenia;
PAAD	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	4.36	0.33	2.42e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.48	-4.62	-0.35	8.25e-6	Monocyte count;
PAAD	cis	rs367943	0.604	rs28519541	chr5:113006931	C/G	cg12552261	chr5:112820674	MCC	0.64	6.5	0.47	1.08e-9	Type 2 diabetes;
PAAD	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg23250157	chr14:64679961	SYNE2	0.56	5.62	0.41	8.77e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg02683114	chr2:24398427	C2orf84	0.45	5.22	0.39	5.69e-7	Asthma;
PAAD	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg04607699	chr11:48328132	OR4S1	-0.52	-4.89	-0.37	2.5e-6	Migraine - clinic-based;
PAAD	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.91	-9.33	-0.6	1.21e-16	Asthma;
PAAD	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs11997175	0.574	rs4400340	chr8:33713343	C/T	ch.8.33884649F	chr8:33765107	NA	0.55	5.79	0.43	3.84e-8	Body mass index;
PAAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.44	-0.34	1.73e-5	Iron status biomarkers;
PAAD	cis	rs11129295	0.618	rs17020288	chr3:27801959	A/G	cg21473142	chr3:27762095	EOMES	0.28	4.6	0.35	9.03e-6	Multiple sclerosis;
PAAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.34	0.4	3.36e-7	Menarche (age at onset);
PAAD	cis	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg21546286	chr11:48923668	NA	0.54	5.78	0.42	4.01e-8	HDL cholesterol;
PAAD	cis	rs4722166	0.598	rs4722180	chr7:22805072	A/G	cg05472934	chr7:22766657	IL6	0.65	7.56	0.52	3.52e-12	Lung cancer;
PAAD	cis	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.88	-0.37	2.62e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.51	0.34	1.28e-5	Cognitive function;
PAAD	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.54	4.71	0.36	5.49e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.71	7.1	0.5	4.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.8	-9.95	-0.63	2.82e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27064285	chr15:101503542	LRRK1	-0.52	-6.64	-0.47	5.3e-10	Energy expenditure (24h);
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.39e-9	Lung cancer;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.38	4.44	0.34	1.73e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.61	6.36	0.46	2.2e-9	Lung cancer;
PAAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg20744362	chr22:50050164	C22orf34	0.68	8.41	0.56	2.82e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.21	15.64	0.79	1.84e-33	Type 1 diabetes nephropathy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15924582	chr14:102356845	PPP2R5C	-0.54	-6.3	-0.46	3.04e-9	Monocyte percentage of white cells;
PAAD	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21028142	chr17:79581711	NPLOC4	-0.49	-5.87	-0.43	2.7e-8	Eye color traits;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.6	7.25	0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.41	0.34	1.97e-5	Lung cancer;
PAAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg05110241	chr16:68378359	PRMT7	-0.9	-6.74	-0.48	3.1e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.17	0.5	3.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.43	4.79	0.36	3.91e-6	Refractive error;
PAAD	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-1.43	-8.38	-0.56	3.26e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1879734	0.731	rs11206198	chr1:54165910	C/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.75	7.32	0.51	1.33e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.75	8.08	0.55	1.88e-13	Lung cancer;
PAAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg09796270	chr17:17721594	SREBF1	0.45	4.86	0.37	2.85e-6	Total body bone mineral density;
PAAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.48e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4722672	0.786	rs13243033	chr7:27248373	T/C	cg09871315	chr7:27142682	HOXA2	0.49	4.79	0.36	3.92e-6	Ulcerative colitis;
PAAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg00253185	chr1:247542119	NA	0.54	4.39	0.34	2.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.89	-9.41	-0.61	7.39e-17	Prostate cancer;
PAAD	cis	rs9395066	0.509	rs6922772	chr6:45059584	G/A	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg16362232	chr11:430036	ANO9	0.88	5.35	0.4	3.19e-7	Body mass index;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.13e-6	Testicular germ cell tumor;
PAAD	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg09659197	chr4:152720779	NA	0.35	5.13	0.38	8.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28830936	1.000	rs4924570	chr15:41974660	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.64	-7.63	-0.53	2.46e-12	Diastolic blood pressure;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00149659	chr3:10157352	C3orf10	0.78	5.79	0.43	3.84e-8	Alzheimer's disease;
PAAD	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.53	-5.05	-0.38	1.26e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg13474877	chr9:5450724	CD274	-0.55	-6.29	-0.45	3.25e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.54	5.37	0.4	2.91e-7	Menarche (age at onset);
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.6	-6.07	-0.44	9.67e-9	Acylcarnitine levels;
PAAD	cis	rs10793968	0.681	rs4740364	chr9:133630153	C/T	cg21207741	chr9:134148648	FAM78A	-0.44	-4.25	-0.33	3.72e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg06970076	chr16:1560791	IFT140	0.51	4.56	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg00919237	chr7:87102261	ABCB4	-0.75	-6.16	-0.45	6.2e-9	Gallbladder cancer;
PAAD	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.66	-0.35	6.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.26	-13.75	-0.74	1.87e-28	Hip circumference adjusted for BMI;
PAAD	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.42	4.29	0.33	3.18e-5	Height;
PAAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.09	-0.44	9.03e-9	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg23346134	chr3:49453900	TCTA	0.41	4.35	0.33	2.49e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.66	-6.57	-0.47	7.36e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.5	4.27	0.33	3.48e-5	Height;
PAAD	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	9.59	0.61	2.52e-17	Electrocardiographic conduction measures;
PAAD	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg02404636	chr22:31891804	SFI1	-0.6	-5.42	-0.4	2.28e-7	Colorectal cancer;
PAAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.92	-0.37	2.18e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21683783	chr13:50624746	MIR15A;DLEU2	-0.7	-7.19	-0.5	2.72e-11	Obesity-related traits;
PAAD	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg10818794	chr15:86012489	AKAP13	-0.48	-5.25	-0.39	5.11e-7	Interstitial lung disease;
PAAD	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg18884388	chr7:190334	NA	0.53	4.27	0.33	3.43e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs75920871	1.000	rs4938325	chr11:116898479	G/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs10768122	1.000	rs10768123	chr11:35293162	G/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.3	-0.33	3.07e-5	Vitiligo;
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22442454	chr1:209979470	IRF6	0.53	4.52	0.34	1.21e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg17372223	chr3:52568218	NT5DC2	0.52	5.23	0.39	5.45e-7	Bipolar disorder;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg04775059	chr7:64541387	NA	-0.58	-5.98	-0.44	1.53e-8	Calcium levels;
PAAD	cis	rs13125782	0.526	rs4536926	chr4:7440242	C/A	cg03194122	chr4:7437027	SORCS2;PSAPL1	-0.45	-4.57	-0.35	9.96e-6	Anorexia nervosa;
PAAD	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg14393609	chr7:65229607	NA	0.63	6.83	0.48	1.93e-10	Aortic root size;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg05215272	chr17:6899095	ALOX12	0.4	4.46	0.34	1.58e-5	Tonsillectomy;
PAAD	cis	rs11159086	1.000	rs4899516	chr14:74959528	C/A	cg10195687	chr14:74926396	NA	-0.47	-5.13	-0.38	8.75e-7	Advanced glycation end-product levels;
PAAD	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg21535247	chr6:8435926	SLC35B3	-0.56	-5.47	-0.41	1.79e-7	Motion sickness;
PAAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4742903	0.967	rs10820601	chr9:106861281	G/A	cg14250997	chr9:106856677	SMC2	0.48	5.21	0.39	6.01e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs6009527	1.000	rs2318942	chr22:49573505	G/A	cg12746016	chr22:49560550	NA	0.46	4.71	0.36	5.63e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg19744528	chr7:157553346	PTPRN2	0.4	4.27	0.33	3.46e-5	Body mass index;
PAAD	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.63	-5.95	-0.43	1.77e-8	Coronary artery disease;
PAAD	cis	rs2262909	1.000	rs2262909	chr19:22135270	A/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.61	-0.41	9.3e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9810890	0.850	rs62265295	chr3:128654636	C/T	cg05163071	chr3:108476540	RETNLB	0.87	6.56	0.47	7.91e-10	Dental caries;
PAAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg27478167	chr7:817139	HEATR2	-0.72	-5.64	-0.42	7.95e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-5.84	-0.43	3e-8	Morning vs. evening chronotype;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11190155	chr3:9975447	CRELD1	0.6	6.81	0.48	2.19e-10	Metabolite levels  (X-11787);
PAAD	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.67	-0.77	6.55e-31	Height;
PAAD	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.65	0.57	6.69e-15	Chronic sinus infection;
PAAD	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2004318	1.000	rs6509884	chr19:55080431	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04582541	chr7:148844610	ZNF398	0.62	6.62	0.47	5.84e-10	Myopia (pathological);
PAAD	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-5.75	-0.42	4.81e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10121009	0.592	rs7852335	chr9:35332788	C/T	cg11846315	chr9:35647073	NA	-0.52	-4.69	-0.36	5.99e-6	Parkinson's disease;
PAAD	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	1.0	4.53	0.35	1.17e-5	Economic and political preferences (immigration/crime);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04132851	chr1:85155548	SSX2IP	0.7	8.32	0.56	4.77e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.68	-6.82	-0.48	2.05e-10	Cancer;
PAAD	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg02297831	chr4:17616191	MED28	0.55	4.99	0.38	1.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg22868518	chr11:507468	RNH1	-0.97	-4.95	-0.37	1.95e-6	Body mass index;
PAAD	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg19792802	chr11:65647270	CTSW	0.53	6.91	0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs9283706	0.594	rs1428405	chr5:66327193	A/T	cg11590213	chr5:66331682	MAST4	0.57	4.68	0.35	6.33e-6	Coronary artery disease;
PAAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs6494488	0.500	rs951721	chr15:65044435	C/T	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs7953249	0.791	rs1920792	chr12:121404584	T/C	cg02403541	chr12:121454288	C12orf43	-0.42	-4.51	-0.34	1.28e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs9287719	0.601	rs13427815	chr2:10707985	C/T	cg00105475	chr2:10696890	NA	0.65	6.89	0.49	1.37e-10	Prostate cancer;
PAAD	cis	rs55637147	0.671	rs3781900	chr11:57126838	A/G	cg25492363	chr11:57319872	UBE2L6	-0.39	-4.31	-0.33	2.93e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.5	0.47	1.11e-9	Aortic root size;
PAAD	cis	rs3733418	0.860	rs12647419	chr4:165929153	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.58	-5.34	-0.4	3.33e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12634124	chr2:224809992	WDFY1	-0.57	-6.54	-0.47	8.83e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05765482	chr17:52978194	TOM1L1	0.68	7.74	0.53	1.3e-12	Myopia (pathological);
PAAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-6.28	-0.45	3.41e-9	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.61	0.53	2.69e-12	Prudent dietary pattern;
PAAD	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.74	-7.82	-0.54	8.15e-13	Brugada syndrome;
PAAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs1190596	0.526	rs1190572	chr14:102634589	A/G	cg23289024	chr14:102554846	HSP90AA1	-0.35	-4.32	-0.33	2.82e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	0.96	12.22	0.7	2.41e-24	Heart rate;
PAAD	cis	rs7792596	0.894	rs6948901	chr7:93977748	T/C	cg20814616	chr7:94014465	NA	-0.43	-4.32	-0.33	2.86e-5	Intelligence;
PAAD	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.59	6.84	0.49	1.84e-10	Menopause (age at onset);
PAAD	cis	rs939584	1.000	rs1320337	chr2:649867	A/T	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.58	6.08	0.44	9.31e-9	Pancreatic cancer;
PAAD	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.69	5.87	0.43	2.69e-8	Common traits (Other);
PAAD	cis	rs9287604	1.000	rs2568569	chr2:237796392	A/G	cg15065627	chr2:237796583	NA	-0.54	-4.48	-0.34	1.46e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg16083429	chr3:49237500	CCDC36	-0.43	-4.25	-0.33	3.75e-5	Menarche (age at onset);
PAAD	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.67	-5.83	-0.43	3.25e-8	Lung cancer;
PAAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.07	-0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-4.89	-0.37	2.52e-6	Schizophrenia;
PAAD	cis	rs7833787	0.860	rs6981676	chr8:18679114	A/G	cg17701159	chr8:18705777	PSD3	-0.45	-5.11	-0.38	9.72e-7	Obesity-related traits;
PAAD	cis	rs59888335	0.789	rs13066591	chr3:80899831	T/C	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.43	0.4	2.22e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.11	-0.5	4.12e-11	Life satisfaction;
PAAD	cis	rs743757	0.557	rs2236950	chr3:50420554	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.85	6.55	0.47	8.58e-10	Diastolic blood pressure;
PAAD	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.33	-0.4	3.42e-7	Atrioventricular conduction;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.48	-4.33	-0.33	2.67e-5	Lung cancer;
PAAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.3	-0.46	3.01e-9	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24310461	chr1:220863572	C1orf115	0.61	6.5	0.47	1.09e-9	Myopia (pathological);
PAAD	cis	rs12476592	0.602	rs4671068	chr2:63798333	C/T	cg10828910	chr2:63850056	LOC388955	0.5	4.28	0.33	3.3e-5	Childhood ear infection;
PAAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.27	0.39	4.7e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.72	0.42	5.59e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.55	4.33	0.33	2.74e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.82	0.36	3.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.78	8.94	0.59	1.2e-15	Hemoglobin concentration;
PAAD	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12044355	0.789	rs953244	chr1:231823583	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	5.8	0.43	3.65e-8	Alzheimer's disease;
PAAD	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	8.19	0.55	1e-13	LDL cholesterol;
PAAD	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.48	4.61	0.35	8.55e-6	Depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17543804	chr13:22179073	EFHA1	0.62	6.43	0.46	1.6e-9	Smoking initiation;
PAAD	cis	rs894157	0.563	rs78320715	chr15:90255062	C/T	cg20467658	chr15:89933347	LOC254559	0.79	4.42	0.34	1.9e-5	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15069785	chr12:46361154	SFRS2IP	-0.63	-6.45	-0.46	1.38e-9	Obesity-related traits;
PAAD	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg20636351	chr8:55087400	NA	0.64	6.22	0.45	4.65e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.18e-17	Resting heart rate;
PAAD	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16447950	chr5:562315	NA	-0.67	-5.98	-0.44	1.53e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.51	5.0	0.38	1.59e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16513905	chr5:137879008	ETF1	-0.75	-6.29	-0.45	3.22e-9	Neuroticism;
PAAD	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.56	-5.51	-0.41	1.53e-7	Hypospadias;
PAAD	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.93	0.37	2.13e-6	Myopia (pathological);
PAAD	cis	rs4716602	0.898	rs13243950	chr7:156160996	T/C	cg04090468	chr7:156181990	NA	0.5	4.81	0.36	3.64e-6	Anti-saccade response;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.49	-5.72	-0.42	5.46e-8	Electroencephalogram traits;
PAAD	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.64	-6.22	-0.45	4.55e-9	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.73	-7.92	-0.54	4.64e-13	Sudden cardiac arrest;
PAAD	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg09163369	chr1:210001066	C1orf107	0.52	5.33	0.4	3.43e-7	Orofacial clefts;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg08888203	chr3:10149979	C3orf24	0.83	6.87	0.49	1.57e-10	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09154826	chr1:200635573	DDX59	-0.73	-7.4	-0.51	8.78e-12	Obesity-related traits;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.77	8.53	0.57	1.36e-14	Response to antipsychotic treatment;
PAAD	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg25783544	chr11:47291846	MADD	0.54	4.36	0.33	2.42e-5	HDL cholesterol;
PAAD	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs9463078	0.691	rs4398713	chr6:45003928	C/T	cg25276700	chr6:44698697	NA	0.53	5.88	0.43	2.52e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.76	-8.7	-0.58	5.14e-15	Lung cancer;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.76	0.48	2.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg23752985	chr2:85803571	VAMP8	0.55	6.19	0.45	5.45e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs793571	0.738	rs12595482	chr15:59195679	G/A	cg05156742	chr15:59063176	FAM63B	0.57	4.43	0.34	1.81e-5	Schizophrenia;
PAAD	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg14440974	chr22:39074834	NA	-0.5	-5.95	-0.43	1.77e-8	Menopause (age at onset);
PAAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.8	-9.23	-0.6	2.19e-16	Type 2 diabetes;
PAAD	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.52	5.0	0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs17138114	1.000	rs7747061	chr6:4381445	C/T	cg02635494	chr6:4018361	NA	0.66	4.39	0.34	2.12e-5	Obesity-related traits;
PAAD	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.93	6.19	0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9364554	0.691	rs3918286	chr6:160868668	A/G	cg25313204	chr6:160768801	SLC22A3	0.54	4.87	0.37	2.72e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.09	-0.38	1.03e-6	Glomerular filtration rate;
PAAD	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.73	0.36	5.09e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.78e-10	Life satisfaction;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.73	7.24	0.51	2.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.87	-9.57	-0.61	2.87e-17	Prudent dietary pattern;
PAAD	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.88	9.45	0.61	5.87e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.96	0.37	1.83e-6	Ovarian reserve;
PAAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg14219918	chr9:127249562	NR5A1	0.38	5.09	0.38	1.03e-6	Menarche (age at onset);
PAAD	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-6.26	-0.45	3.79e-9	Body mass index;
PAAD	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.58	5.63	0.42	8.34e-8	Alcohol dependence;
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.09	-0.5	4.74e-11	Longevity;
PAAD	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	6.47	0.46	1.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19451435	chr6:158402916	SYNJ2	0.68	6.65	0.47	4.85e-10	Primary biliary cholangitis;
PAAD	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg00531865	chr16:30841666	NA	-0.51	-4.98	-0.37	1.74e-6	Dementia with Lewy bodies;
PAAD	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14440934	chr16:67450691	ZDHHC1	-0.66	-6.49	-0.47	1.15e-9	Lung cancer in ever smokers;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25820971	chr14:21852127	SUPT16H	-0.59	-7.01	-0.49	7.4e-11	Energy expenditure (24h);
PAAD	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-4.26	-0.33	3.55e-5	Morning vs. evening chronotype;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.81e-6	Lymphocyte counts;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.76	5.41	0.4	2.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg02404636	chr22:31891804	SFI1	0.65	6.09	0.44	9.02e-9	Colorectal cancer;
PAAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.77	-7.3	-0.51	1.51e-11	DNA methylation (variation);
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-6.79	-0.48	2.4e-10	Bipolar disorder;
PAAD	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg08859206	chr1:53392774	SCP2	-0.69	-7.02	-0.49	7e-11	Monocyte count;
PAAD	cis	rs1008375	0.762	rs17499929	chr4:17590671	G/A	cg02297831	chr4:17616191	MED28	0.52	5.22	0.39	5.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.64	-5.56	-0.41	1.18e-7	Obesity-related traits;
PAAD	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs7552393	0.595	rs12116654	chr1:84270215	A/T	cg10977910	chr1:84465055	TTLL7	0.56	5.28	0.39	4.39e-7	Select biomarker traits;
PAAD	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.5e-12	Resting heart rate;
PAAD	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg03989125	chr22:38214979	NA	-0.66	-6.89	-0.49	1.38e-10	Glioblastoma;Glioma;
PAAD	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg05392440	chr1:2478653	NA	-0.5	-5.38	-0.4	2.79e-7	Ulcerative colitis;
PAAD	cis	rs9646944	0.501	rs9807934	chr2:103040182	T/G	cg03938978	chr2:103052716	IL18RAP	0.5	4.28	0.33	3.24e-5	Blood protein levels;
PAAD	cis	rs12913538	0.575	rs35909407	chr15:62890035	A/G	cg09983546	chr15:62884068	NA	0.63	6.29	0.45	3.21e-9	Sleep depth;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09826364	chr7:158789723	NA	-0.4	-5.12	-0.38	9.15e-7	Facial morphology (factor 20);
PAAD	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	1.16	6.23	0.45	4.38e-9	Skin colour saturation;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13560548	chr3:10150139	C3orf24	0.6	5.35	0.4	3.24e-7	Alzheimer's disease;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.93	0.37	2.12e-6	Platelet count;
PAAD	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.88	9.48	0.61	4.77e-17	Corneal astigmatism;
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27297192	chr10:134578999	INPP5A	0.56	5.51	0.41	1.48e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-7.09	-0.5	4.66e-11	Gut microbiome composition (summer);
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18337363	chr3:52569053	NT5DC2	-0.41	-4.4	-0.34	2.01e-5	Bipolar disorder;
PAAD	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06634786	chr22:41940651	POLR3H	-0.57	-4.69	-0.36	5.93e-6	Vitiligo;
PAAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.42	-4.58	-0.35	9.58e-6	Height;
PAAD	cis	rs10929159	0.928	rs1349731	chr2:236924047	C/T	cg14226755	chr2:236923322	AGAP1	-0.29	-4.53	-0.34	1.2e-5	Parkinson's disease;
PAAD	cis	rs4792901	0.802	rs58141510	chr17:41586475	C/T	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg00576331	chr11:65640516	EFEMP2	-0.62	-5.46	-0.4	1.92e-7	DNA methylation (variation);
PAAD	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.73	-0.36	5.16e-6	Prevalent atrial fibrillation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08568385	chr19:9449831	ZNF559	-0.61	-6.33	-0.46	2.58e-9	Obesity-related traits;
PAAD	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.29	-0.39	4.1e-7	Menopause (age at onset);
PAAD	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.15e-11	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg10820045	chr2:198174542	NA	0.51	5.11	0.38	9.36e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02204205	chr7:50861487	GRB10	0.55	6.46	0.46	1.33e-9	Monocyte percentage of white cells;
PAAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs11023332	0.617	rs1451678	chr11:14781621	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-4.3	-0.33	3.09e-5	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg15208524	chr1:10270712	KIF1B	0.52	4.74	0.36	4.95e-6	Hepatocellular carcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11135003	chr1:225998164	EPHX1	0.59	6.69	0.48	3.97e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs13095912	0.925	rs34187723	chr3:185349425	T/C	cg02401761	chr3:185826130	ETV5	0.46	4.29	0.33	3.16e-5	Systolic blood pressure;
PAAD	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs10073892	0.703	rs9327824	chr5:101638168	G/T	cg17280723	chr5:101634495	NA	0.41	4.41	0.34	1.98e-5	Cognitive decline (age-related);
PAAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14180030	chr9:123475675	MEGF9	-0.45	-5.01	-0.38	1.47e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.04	0.59	6.73e-16	Menopause (age at onset);
PAAD	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg05627522	chr15:75251581	NA	0.47	5.77	0.42	4.3e-8	Breast cancer;
PAAD	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-7.16	-0.5	3.15e-11	Idiopathic membranous nephropathy;
PAAD	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg24733560	chr20:60626293	TAF4	0.45	5.5	0.41	1.58e-7	Body mass index;
PAAD	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.49	0.52	5.32e-12	Multiple sclerosis;
PAAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	4.55	0.35	1.07e-5	Menopause (age at onset);
PAAD	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg11995313	chr8:8860691	ERI1	0.48	4.81	0.36	3.68e-6	Joint mobility (Beighton score);
PAAD	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg05555928	chr11:63887634	MACROD1	-0.62	-6.2	-0.45	5.01e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-9.0	-0.59	8.53e-16	Body mass index;
PAAD	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg20636351	chr8:55087400	NA	-0.8	-9.08	-0.59	5.5e-16	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.9e-7	Resting heart rate;
PAAD	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.44e-5	Hepatocellular carcinoma;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg21565972	chr17:80109576	CCDC57	-0.6	-6.86	-0.49	1.65e-10	Life satisfaction;
PAAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.69	0.58	5.48e-15	Schizophrenia;
PAAD	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.57	5.12	0.38	8.93e-7	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg16928487	chr17:17741425	SREBF1	0.34	4.52	0.34	1.23e-5	Total body bone mineral density;
PAAD	cis	rs593531	0.571	rs10793081	chr11:74092403	T/C	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.53	-0.35	1.18e-5	Neuroticism;
PAAD	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.78	5.98	0.44	1.5e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.79	-7.38	-0.51	9.81e-12	Asthma;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs60154123	1.000	rs12138216	chr1:210480361	G/A	cg22029157	chr1:209979665	IRF6	0.71	5.67	0.42	6.99e-8	Coronary artery disease;
PAAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.79	-0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.58	5.64	0.42	7.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09695851	chr17:3907499	NA	0.83	8.59	0.57	9.52e-15	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.48	5.17	0.39	7.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.37	4.73	0.36	5.09e-6	Educational attainment (years of education);
PAAD	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg26850624	chr5:429559	AHRR	-0.51	-4.79	-0.36	3.97e-6	Fat distribution (HIV);
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs11168618	0.740	rs11495433	chr12:48929072	T/C	cg01881778	chr12:48919444	OR8S1	-0.52	-5.61	-0.41	9.12e-8	Adiponectin levels;
PAAD	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.65	6.58	0.47	7.19e-10	White matter hyperintensity burden;
PAAD	cis	rs2952768	0.802	rs2709391	chr2:208506731	A/G	cg22329743	chr2:208688774	PLEKHM3	0.24	4.64	0.35	7.35e-6	Opioid sensitivity;
PAAD	cis	rs2286379	0.596	rs7296521	chr12:1802988	C/T	cg05227549	chr12:1770782	NA	-0.43	-4.98	-0.37	1.71e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.86	-11.15	-0.67	1.74e-21	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11235843	0.929	rs11235882	chr11:73443001	G/A	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs6942227	0.947	rs1986731	chr6:25174070	C/T	cg26336265	chr6:25042955	NA	-0.58	-4.97	-0.37	1.78e-6	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10155981	0.510	rs75613086	chr7:22584526	A/C	cg05062323	chr7:22590069	NA	-0.8	-4.51	-0.34	1.27e-5	Bilirubin levels;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.57	5.44	0.4	2.06e-7	Vitiligo;
PAAD	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg25839482	chr15:75931953	IMP3	0.44	4.29	0.33	3.21e-5	Height;
PAAD	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.53	0.57	1.37e-14	Fuchs's corneal dystrophy;
PAAD	cis	rs9815354	1.000	rs9863915	chr3:41762002	G/A	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.45e-6	Diastolic blood pressure;
PAAD	cis	rs16958440	0.867	rs78547658	chr18:44669852	C/T	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.91	12.89	0.72	3.77e-26	Prostate-specific antigen levels;
PAAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs56046484	0.957	rs35127646	chr15:85601871	G/A	cg08123816	chr15:85640762	PDE8A	-0.44	-4.59	-0.35	9.31e-6	Testicular germ cell tumor;
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.81	10.58	0.65	5.83e-20	Vitiligo;
PAAD	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	7.09	0.5	4.83e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.75	-7.18	-0.5	2.84e-11	Cognitive function;
PAAD	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte percentage of white cells;
PAAD	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.62	-5.88	-0.43	2.53e-8	Corneal astigmatism;
PAAD	cis	rs2251260	0.891	rs1088674	chr14:62006693	C/A	cg23386212	chr14:62041363	NA	0.55	4.4	0.34	2.06e-5	Yeast infection;
PAAD	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.92	-7.96	-0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.02	-0.49	6.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg19257562	chr1:2043853	PRKCZ	-0.41	-4.87	-0.37	2.73e-6	Height;
PAAD	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.5	-0.52	5.07e-12	Chronic sinus infection;
PAAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	4.41	0.34	1.91e-5	Renal cell carcinoma;
PAAD	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.53	-0.35	1.16e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13006833	0.668	rs2136569	chr2:191167414	C/T	cg27211696	chr2:191398769	TMEM194B	-0.49	-4.82	-0.36	3.48e-6	Urinary metabolites;
PAAD	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.78	-5.28	-0.39	4.38e-7	Anti-saccade response;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14381390	chr4:2044056	C4orf48	0.61	6.34	0.46	2.46e-9	Myopia (pathological);
PAAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg27539214	chr16:67997921	SLC12A4	-0.67	-5.14	-0.39	8.15e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg07157834	chr1:205819609	PM20D1	0.53	4.79	0.36	3.87e-6	White blood cell types;
PAAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.26	-0.56	6.45e-14	Eye color traits;
PAAD	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.82	-9.99	-0.63	2.2e-18	Brugada syndrome;
PAAD	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	4.31	0.33	2.93e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-5.04	-0.38	1.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939584	0.627	rs13028310	chr2:632591	T/C	cg03610516	chr2:642275	NA	0.62	5.49	0.41	1.68e-7	Body mass index;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.46	6.22	0.45	4.58e-9	Vitiligo;
PAAD	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs17592366	0.517	rs7156153	chr14:35308074	G/A	cg09327582	chr14:35236912	BAZ1A	0.57	5.38	0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.89	-0.63	4.16e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	1.11	5.95	0.43	1.74e-8	Body mass index;
PAAD	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.39	0.51	9.31e-12	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08744097	chr16:1550264	TELO2	0.57	6.48	0.47	1.23e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg02696790	chr15:75250997	RPP25	0.42	4.92	0.37	2.21e-6	Systemic lupus erythematosus;
PAAD	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg01075559	chr1:2537774	MMEL1	0.47	4.97	0.37	1.8e-6	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11160944	chr17:45570048	NA	-0.61	-6.58	-0.47	7.21e-10	Smoking initiation;
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1256061	0.603	rs915057	chr14:64686207	A/G	cg23250157	chr14:64679961	SYNE2	0.57	5.89	0.43	2.44e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg14926445	chr8:58193284	C8orf71	-0.71	-5.57	-0.41	1.11e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.53	0.68	1.73e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.56	-5.04	-0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs3764400	0.567	rs2229369	chr17:46136133	G/C	cg10706073	chr17:46328419	SKAP1	-1.01	-6.23	-0.45	4.39e-9	Body mass index;
PAAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.63e-6	Personality dimensions;
PAAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg05697835	chr1:2722811	NA	-0.42	-4.7	-0.36	5.86e-6	Ulcerative colitis;
PAAD	cis	rs2241685	1.000	rs2241685	chr2:1925993	C/T	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs17824933	0.778	rs17752099	chr11:60760794	G/C	cg27098804	chr11:60776124	CD6	0.43	4.3	0.33	3e-5	Multiple sclerosis;
PAAD	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.81	-0.62	6.5e-18	Coronary artery disease;
PAAD	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.45	0.4	2.01e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg14346243	chr4:90757452	SNCA	-0.54	-4.93	-0.37	2.13e-6	Neuroticism;
PAAD	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg05555928	chr11:63887634	MACROD1	-0.79	-5.7	-0.42	6.01e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg06671706	chr8:8559999	CLDN23	0.75	7.36	0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs11165354	0.687	rs6660484	chr1:92172608	A/G	cg00730172	chr1:91176405	NA	0.34	4.37	0.33	2.28e-5	Type 2 diabetes;
PAAD	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs76917914	0.735	rs4742716	chr9:100851420	C/T	cg03040243	chr9:100819229	NANS	0.58	4.47	0.34	1.51e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.74	8.77	0.58	3.38e-15	Emphysema distribution in smoking;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg26935685	chr1:15502881	TMEM51	-0.49	-4.27	-0.33	3.4e-5	Systolic blood pressure;
PAAD	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.64	6.71	0.48	3.54e-10	Dementia with Lewy bodies;
PAAD	cis	rs17227506	0.529	rs13263378	chr8:13471193	A/G	cg02718516	chr8:13424094	C8orf48	0.34	4.32	0.33	2.82e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg18265118	chr7:2139243	MAD1L1	0.52	4.25	0.33	3.71e-5	Neuroticism;
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.59	-6.52	-0.47	9.62e-10	Systemic lupus erythematosus;
PAAD	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.66	6.49	0.47	1.12e-9	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.54	0.57	1.29e-14	Platelet count;
PAAD	cis	rs17169635	0.819	rs1869261	chr7:134503247	C/T	cg02516134	chr7:134575187	CALD1	-0.43	-4.47	-0.34	1.5e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs35740288	0.770	rs12907126	chr15:86171357	A/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.54	-0.41	1.33e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.58	-6.68	-0.48	4.31e-10	Aortic root size;
PAAD	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.53	5.79	0.42	3.97e-8	Carotid intima media thickness;
PAAD	cis	rs13011075	0.535	rs8761	chr2:68624260	A/G	cg06275642	chr2:68546038	CNRIP1	-0.32	-4.25	-0.33	3.73e-5	Mean corpuscular volume;
PAAD	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg01620082	chr3:125678407	NA	-1.13	-6.52	-0.47	9.89e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758511	0.573	rs5996074	chr22:42236337	C/T	cg03131358	chr22:42195972	CCDC134	-0.49	-5.15	-0.39	7.82e-7	Birth weight;
PAAD	cis	rs10804591	1.000	rs2625984	chr3:129339101	A/G	cg18548199	chr3:129281892	PLXND1	-0.52	-4.35	-0.33	2.52e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg04738700	chr2:239367308	NA	0.47	5.14	0.39	8.15e-7	Multiple system atrophy;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg08676812	chr11:65308423	LTBP3	1.55	8.0	0.54	2.88e-13	Height;
PAAD	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg20356878	chr3:121714668	ILDR1	0.49	4.74	0.36	4.84e-6	Cognitive performance;
PAAD	cis	rs1789	0.839	rs9997068	chr4:15650990	T/C	cg16509355	chr4:15471240	CC2D2A	-0.33	-4.34	-0.33	2.61e-5	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597480	0.652	rs2044391	chr11:85521829	C/G	cg11817631	chr11:85522609	SYTL2	0.51	5.1	0.38	9.76e-7	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg16898833	chr6:26189333	HIST1H4D	0.78	4.43	0.34	1.76e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs2637266	0.568	rs1907329	chr10:78248191	G/A	cg18941641	chr10:78392320	NA	0.36	4.26	0.33	3.57e-5	Pulmonary function;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg21679674	chr2:128283815	IWS1	0.59	6.32	0.46	2.82e-9	Smoking initiation;
PAAD	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.69	7.22	0.51	2.32e-11	Prostate cancer;
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	cis	rs9399135	0.715	rs7743042	chr6:135419834	A/G	cg24558204	chr6:135376177	HBS1L	0.45	4.38	0.33	2.18e-5	Red blood cell count;
PAAD	cis	rs17125944	0.686	rs3818453	chr14:53326454	C/A	cg00686598	chr14:53173677	PSMC6	-0.95	-5.92	-0.43	2.09e-8	Alzheimer's disease (late onset);
PAAD	cis	rs728616	0.571	rs113030473	chr10:81649031	G/T	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.81	-0.36	3.59e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13144136	0.687	rs61796835	chr4:10656807	C/A	cg10242279	chr4:10666415	CLNK	-0.46	-5.77	-0.42	4.26e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg04450456	chr4:17643702	FAM184B	0.48	4.96	0.37	1.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-10.13	-0.63	9.36e-19	Height;
PAAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-4.59	-0.35	9.14e-6	Mean corpuscular volume;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26549601	chr10:134560360	INPP5A	-0.5	-4.96	-0.37	1.86e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.52	-5.22	-0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.29	-0.39	4.24e-7	Prudent dietary pattern;
PAAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02743256	chr7:2109353	MAD1L1	-0.66	-4.98	-0.37	1.68e-6	Bipolar disorder;
PAAD	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg18551225	chr6:44695536	NA	-0.7	-6.99	-0.49	7.95e-11	Total body bone mineral density;
PAAD	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-1.01	-6.56	-0.47	8.04e-10	Subcortical brain region volumes;Hippocampal volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07981599	chr16:68119049	NFATC3	0.62	6.35	0.46	2.39e-9	Obesity-related traits;
PAAD	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.71	6.98	0.49	8.58e-11	Blood protein levels;
PAAD	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.95	8.8	0.58	2.88e-15	Migraine;
PAAD	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.48	0.41	1.76e-7	Bipolar disorder;
PAAD	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.91	9.88	0.63	4.46e-18	Corneal astigmatism;
PAAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-1.11	-9.57	-0.61	2.92e-17	Blood trace element (Zn levels);
PAAD	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg05785598	chr3:49045655	WDR6	0.42	4.97	0.37	1.76e-6	Parkinson's disease;
PAAD	cis	rs9467711	0.520	rs13211947	chr6:25864818	C/T	cg16898833	chr6:26189333	HIST1H4D	0.96	4.81	0.36	3.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg14593290	chr7:50529359	DDC	0.47	4.51	0.34	1.31e-5	Malaria;
PAAD	cis	rs863345	0.564	rs11264988	chr1:158466912	A/G	cg12129480	chr1:158549410	OR10X1	-0.4	-4.62	-0.35	8.05e-6	Pneumococcal bacteremia;
PAAD	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.77	-7.48	-0.52	5.45e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.82	-0.36	3.41e-6	Recombination measurement;
PAAD	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.56	-6.21	-0.45	4.87e-9	Metabolite levels;
PAAD	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.85	-8.07	-0.55	1.92e-13	Pancreatic cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07594977	chr10:12209668	SEC61A2;NUDT5	-0.55	-6.36	-0.46	2.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs863345	0.604	rs1112915	chr1:158444447	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.9	-0.37	2.48e-6	Pneumococcal bacteremia;
PAAD	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg13207630	chr7:32358064	NA	0.76	4.25	0.33	3.68e-5	Body mass index;
PAAD	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.41	0.51	8.3e-12	Educational attainment;
PAAD	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	0.85	6.64	0.47	5.12e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19183248	chr4:152364959	FAM160A1	0.6	6.4	0.46	1.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.43	-0.34	1.81e-5	Joint mobility (Beighton score);
PAAD	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.41e-5	Hepatocellular carcinoma;
PAAD	cis	rs6604026	0.656	rs2774945	chr1:93346239	T/C	cg17283838	chr1:93427260	FAM69A	-0.61	-5.63	-0.42	8.64e-8	Multiple sclerosis;
PAAD	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg19784903	chr17:45786737	TBKBP1	-0.45	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg14789911	chr21:47582049	C21orf56	0.48	4.99	0.38	1.64e-6	Testicular germ cell tumor;
PAAD	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.53	5.2	0.39	6.26e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.6	-6.19	-0.45	5.21e-9	Monocyte count;
PAAD	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.57	-0.41	1.14e-7	Mean platelet volume;
PAAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.38	4.44	0.34	1.74e-5	Fat distribution (HIV);
PAAD	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.49	-5.21	-0.39	6.11e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg04398451	chr17:18023971	MYO15A	0.73	7.76	0.53	1.13e-12	Total body bone mineral density;
PAAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.68	0.69	6.9e-23	Smoking behavior;
PAAD	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.01	0.59	8.37e-16	Response to antipsychotic treatment;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16262614	chr3:133464971	TF	0.46	5.03	0.38	1.35e-6	Iron status biomarkers;
PAAD	cis	rs2882667	0.690	rs12656942	chr5:138176458	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22256482	chr8:124513308	NA	-0.67	-6.92	-0.49	1.19e-10	Obesity-related traits;
PAAD	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg20312557	chr2:97357134	FER1L5	-0.88	-4.59	-0.35	9.25e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.13e-11	Coronary artery disease;
PAAD	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.35	-0.51	1.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg15595755	chr5:1867978	NA	0.57	6.15	0.45	6.56e-9	Cardiovascular disease risk factors;
PAAD	cis	rs16975963	0.644	rs11665759	chr19:38039675	C/G	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs4621152	0.708	rs2888450	chr2:217866841	T/A	cg21875423	chr2:217559867	IGFBP5	-0.42	-4.26	-0.33	3.61e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.6	-0.35	8.9e-6	Coronary artery disease;
PAAD	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg08198773	chr8:1697536	NA	0.47	5.18	0.39	6.94e-7	Systolic blood pressure;
PAAD	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs35160687	0.623	rs2276625	chr2:86481835	A/G	cg10973622	chr2:86423274	IMMT	0.45	4.92	0.37	2.19e-6	Night sleep phenotypes;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg20933634	chr6:27740509	NA	0.66	6.29	0.45	3.26e-9	Parkinson's disease;
PAAD	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10820045	chr2:198174542	NA	-0.48	-4.94	-0.37	2.03e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg02415014	chr8:143852576	LYNX1	0.38	4.8	0.36	3.77e-6	Urinary tract infection frequency;
PAAD	cis	rs6137287	0.813	rs6082354	chr20:21217976	A/C	cg04219410	chr20:21106687	PLK1S1	0.39	4.39	0.34	2.1e-5	Height;
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.65	5.89	0.43	2.39e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg13468214	chr4:1046988	NA	-0.55	-4.95	-0.37	1.96e-6	Recombination rate (females);
PAAD	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.52	6.02	0.44	1.27e-8	Platelet count;
PAAD	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14550570	chr1:3712988	LRRC47	0.63	7.14	0.5	3.64e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs12760731	0.720	rs12161419	chr1:178379040	A/C	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg09060608	chr5:178986726	RUFY1	0.47	4.55	0.35	1.08e-5	Lung cancer;
PAAD	trans	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.3	0.46	3.03e-9	Calcium levels;
PAAD	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg26031613	chr14:104095156	KLC1	0.51	5.53	0.41	1.38e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs728616	0.614	rs61859189	chr10:82089250	T/C	cg19423196	chr10:82049429	MAT1A	0.45	4.44	0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7853377	0.699	rs9410888	chr9:86465402	G/A	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2036402	0.955	rs6863148	chr5:156406643	G/A	cg21915449	chr5:156456672	HAVCR1	-0.37	-4.25	-0.33	3.65e-5	Hypertriglyceridemia;
PAAD	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.51	-4.84	-0.37	3.11e-6	Mean platelet volume;
PAAD	cis	rs11997175	0.546	rs13282996	chr8:33596397	C/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.61	0.47	6.25e-10	Body mass index;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01218534	chr11:116658528	ZNF259	0.65	7.47	0.52	5.76e-12	Metabolite levels  (X-11787);
PAAD	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-7.65	-0.53	2.11e-12	Cognitive function;
PAAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.56	5.37	0.4	2.9e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs6708331	0.517	rs6743372	chr2:70352640	G/T	cg01613454	chr2:70366299	NA	0.43	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs7631605	0.935	rs2286939	chr3:37062040	T/C	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.35e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18268492	chr10:99185986	PGAM1	0.67	6.91	0.49	1.23e-10	Primary biliary cholangitis;
PAAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.62	-7.44	-0.52	7.03e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs17023223	0.537	rs2361269	chr1:119602215	A/G	cg26570165	chr1:119541833	NA	-0.45	-4.26	-0.33	3.63e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.64	-0.42	8.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg20243544	chr17:37824526	PNMT	0.53	4.67	0.35	6.71e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.27	0.33	3.43e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg05338066	chr1:7812865	CAMTA1	0.62	4.55	0.35	1.11e-5	Inflammatory bowel disease;
PAAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.79	6.91	0.49	1.22e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.68	6.91	0.49	1.21e-10	Resistin levels;
PAAD	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.71	4.48	0.34	1.45e-5	Lung cancer in ever smokers;
PAAD	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.6	-5.91	-0.43	2.22e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.53	5.4	0.4	2.49e-7	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1532557	1.000	rs61827075	chr1:224768817	G/A	cg09988837	chr1:224811939	CNIH3	0.65	4.9	0.37	2.42e-6	Cancer;
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.72	7.86	0.54	6.67e-13	Longevity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15135999	chr3:142297224	ATR	-0.74	-6.4	-0.46	1.84e-9	Neuroticism;
PAAD	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.52	5.46	0.4	1.94e-7	Male-pattern baldness;
PAAD	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg02353165	chr6:42928485	GNMT	0.58	4.48	0.34	1.44e-5	Blood protein levels;
PAAD	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-4.34	-0.33	2.61e-5	QT interval;
PAAD	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.62	6.88	0.49	1.46e-10	Colorectal cancer;
PAAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.39	-0.4	2.62e-7	Alcohol dependence;
PAAD	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg19930314	chr7:98593876	TRRAP	-0.48	-4.53	-0.34	1.19e-5	Breast cancer;
PAAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.54	5.16	0.39	7.49e-7	Aortic root size;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00166722	chr3:10149974	C3orf24	1.1	7.94	0.54	4.21e-13	Alzheimer's disease;
PAAD	cis	rs11811982	0.793	rs11800169	chr1:227452952	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg23715586	chr3:58305044	RPP14	-0.5	-4.29	-0.33	3.19e-5	Platelet count;
PAAD	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23598886	chr18:12777645	NA	-0.76	-6.33	-0.46	2.56e-9	Inflammatory skin disease;
PAAD	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.96	10.67	0.65	3.54e-20	Primary sclerosing cholangitis;
PAAD	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg24699146	chr1:24152579	HMGCL	0.48	5.05	0.38	1.27e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.88	-0.37	2.62e-6	Body mass index;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg09699651	chr6:150184138	LRP11	0.52	5.41	0.4	2.41e-7	Lung cancer;
PAAD	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.38	4.91	0.37	2.32e-6	Calcium levels;
PAAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg08029281	chr1:67600428	NA	0.43	5.11	0.38	9.43e-7	Psoriasis;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.79	5.99	0.44	1.45e-8	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.15e-6	Lung cancer;
PAAD	cis	rs682748	0.810	rs62349987	chr5:17108579	T/C	cg23987134	chr5:17158319	LOC285696	-0.35	-4.37	-0.33	2.26e-5	Hippocampal atrophy;
PAAD	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.88	7.41	0.52	8.21e-12	Diastolic blood pressure;
PAAD	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-4.75	-0.36	4.62e-6	Joint mobility (Beighton score);
PAAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg17366294	chr4:99064904	C4orf37	0.47	5.1	0.38	9.78e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06440287	chr16:21739761	OTOA	-0.61	-6.57	-0.47	7.74e-10	Obesity-related traits;
PAAD	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.31	-0.33	2.97e-5	Lung cancer;
PAAD	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg21130718	chr4:1044621	NA	0.54	4.59	0.35	9.22e-6	Recombination rate (females);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22500102	chr1:207226830	PFKFB2	0.66	6.64	0.47	5.2e-10	Obesity-related traits;
PAAD	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.6	-5.92	-0.43	2.07e-8	Systolic blood pressure;
PAAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg12463550	chr7:65579703	CRCP	0.91	5.85	0.43	2.97e-8	Diabetic kidney disease;
PAAD	cis	rs6835098	0.692	rs10520252	chr4:174070959	T/C	cg08422745	chr4:174089978	GALNT7	-0.58	-5.49	-0.41	1.67e-7	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg12288994	chr5:1860383	NA	0.59	6.95	0.49	9.81e-11	Cardiovascular disease risk factors;
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-4.87	-0.37	2.72e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg13047869	chr3:10149882	C3orf24	-0.59	-5.15	-0.39	7.79e-7	Alzheimer's disease;
PAAD	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.59	-6.03	-0.44	1.2e-8	Monocyte count;
PAAD	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.51	-5.36	-0.4	3.06e-7	Migraine;Coronary artery disease;
PAAD	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg18827107	chr12:86230957	RASSF9	0.4	4.26	0.33	3.52e-5	Major depressive disorder;
PAAD	cis	rs7188861	0.681	rs12598646	chr16:11406519	C/T	cg16532467	chr16:11454386	NA	-0.53	-4.26	-0.33	3.53e-5	HDL cholesterol;
PAAD	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22509189	chr2:225307070	NA	-0.46	-4.54	-0.35	1.14e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.59	-6.58	-0.47	7.26e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9039	0.918	rs12933086	chr16:9225494	A/G	cg08831531	chr16:9218945	NA	-0.58	-5.57	-0.41	1.15e-7	Menopause (age at onset);
PAAD	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.51	-7.12	-0.5	4.09e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg04398451	chr17:18023971	MYO15A	0.74	7.79	0.53	9.67e-13	Total body bone mineral density;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	7.65	0.53	2.14e-12	Height;
PAAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.7	7.36	0.51	1.05e-11	Pulse pressure;
PAAD	cis	rs6782025	0.801	rs2127025	chr3:121148255	A/T	cg16417163	chr3:121280760	NA	-0.48	-4.88	-0.37	2.61e-6	Aging (facial);
PAAD	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.7	-4.79	-0.36	3.85e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499755	0.712	rs31107	chr16:55377574	A/C	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg12215294	chr3:40350768	EIF1B	-0.49	-4.79	-0.36	3.92e-6	Renal cell carcinoma;
PAAD	cis	rs2839627	0.564	rs2839595	chr21:44298966	G/A	cg03543861	chr21:44258195	NA	0.65	4.75	0.36	4.7e-6	Information processing speed;
PAAD	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.64	-0.47	5.28e-10	Triglycerides;
PAAD	cis	rs897984	1.000	rs897984	chr16:30886643	T/C	cg02466173	chr16:30829666	NA	0.59	6.54	0.47	9.02e-10	Dementia with Lewy bodies;
PAAD	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.35	4.83	0.36	3.31e-6	Schizophrenia;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg00738919	chr7:1100172	C7orf50	0.55	4.34	0.33	2.55e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.65	-6.76	-0.48	2.72e-10	Capecitabine sensitivity;
PAAD	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.81	5.69	0.42	6.47e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.63	-6.38	-0.46	1.99e-9	Migraine;
PAAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.58	0.57	1.02e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7594645	1.000	rs115889150	chr2:207597807	A/G	cg25244921	chr15:65342634	OSTBETA	-1.17	-6.4	-0.46	1.81e-9	Episodic memory;
PAAD	cis	rs16975963	0.895	rs8103383	chr19:38327701	A/C	cg08679971	chr19:38281047	NA	0.5	4.79	0.36	3.88e-6	Longevity;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg12193833	chr17:30244370	NA	-0.65	-5.44	-0.4	2.1e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	4.43	0.34	1.8e-5	Schizophrenia;
PAAD	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.76	9.28	0.6	1.61e-16	Alcohol dependence;
PAAD	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-4.6	-0.35	8.77e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	1.19	13.4	0.74	1.55e-27	Hair shape;
PAAD	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.27	-0.51	1.73e-11	Neuroticism;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21625146	chr5:486483	SLC9A3	-0.43	-5.52	-0.41	1.44e-7	Cystic fibrosis severity;
PAAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-5.12	-0.38	9.27e-7	Mood instability;
PAAD	cis	rs11669133	1.000	rs78186498	chr19:11129880	C/T	cg25243385	chr19:11167475	SMARCA4	0.98	4.59	0.35	9.11e-6	LDL cholesterol;
PAAD	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg11965913	chr1:205819406	PM20D1	0.67	5.37	0.4	2.84e-7	Basophil percentage of granulocytes;
PAAD	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.68	-6.98	-0.49	8.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1113500	0.509	rs17020915	chr1:108647006	G/T	cg06207961	chr1:108661230	NA	0.45	4.51	0.34	1.3e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.27	-9.31	-0.6	1.33e-16	Post bronchodilator FEV1;
PAAD	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg04607235	chr12:12878440	APOLD1	-1.04	-11.41	-0.68	3.63e-22	Lymphocyte counts;
PAAD	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.49	5.09	0.38	1.04e-6	Plasma plasminogen activator levels;
PAAD	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-4.61	-0.35	8.63e-6	Red blood cell traits;
PAAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.61	-5.45	-0.4	1.96e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.52	-0.41	1.45e-7	Prostate cancer;
PAAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.63	4.67	0.35	6.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9462846	0.959	rs9462843	chr6:42856499	T/G	cg13397359	chr6:42928475	GNMT	0.62	4.58	0.35	9.52e-6	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24312492	chr1:155532423	ASH1L;LOC645676	0.65	7.3	0.51	1.5e-11	Monocyte percentage of white cells;
PAAD	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.53	-0.35	1.17e-5	Blood protein levels;
PAAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.74	7.14	0.5	3.62e-11	Urate levels in lean individuals;
PAAD	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.17e-6	Type 2 diabetes;
PAAD	cis	rs2885056	0.891	rs116449616	chr19:10689023	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.91	8.22	0.55	8.56e-14	Body mass index;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg02462569	chr6:150064036	NUP43	-0.49	-5.42	-0.4	2.25e-7	Lung cancer;
PAAD	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.54	5.03	0.38	1.35e-6	Airway imaging phenotypes;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-5.55	-0.41	1.26e-7	Electroencephalogram traits;
PAAD	cis	rs4740619	0.619	rs10738426	chr9:16041615	T/C	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.54	5.89	0.43	2.44e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-1.14	-7.71	-0.53	1.53e-12	Pediatric areal bone mineral density (radius);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22944632	chr2:63277684	OTX1	0.62	6.48	0.47	1.2e-9	Myopia (pathological);
PAAD	cis	rs7084783	0.967	rs7067666	chr10:105332452	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.44	4.51	0.34	1.29e-5	Fear of pain;
PAAD	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.55	5.23	0.39	5.64e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.77	8.01	0.55	2.72e-13	Alzheimer's disease (late onset);
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg00149659	chr3:10157352	C3orf10	0.81	6.18	0.45	5.65e-9	Alzheimer's disease;
PAAD	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.18	13.07	0.73	1.21e-26	Post bronchodilator FEV1;
PAAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg25319279	chr11:5960081	NA	-0.61	-6.2	-0.45	5.21e-9	DNA methylation (variation);
PAAD	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.79	-8.73	-0.58	4.16e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7627468	1.000	rs1501892	chr3:121938903	G/A	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs7326068	0.610	rs2314720	chr13:21313373	G/A	cg27234864	chr13:21295941	IL17D	0.59	4.94	0.37	2.04e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16417436	chr16:28758564	NA	0.45	4.3	0.33	3.06e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs66530629	0.917	rs6604979	chr1:25099438	A/C	cg01905478	chr1:25040257	NA	0.47	5.27	0.39	4.67e-7	Plateletcrit;
PAAD	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.49	4.91	0.37	2.32e-6	Obesity-related traits;
PAAD	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	4.56	0.35	1.06e-5	Height;
PAAD	cis	rs11942476	0.619	rs4314272	chr4:21489702	A/G	cg14992154	chr4:20701870	PACRGL	0.62	4.69	0.36	6e-6	IgG glycosylation;
PAAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg03538708	chr1:25844672	NA	-0.49	-5.02	-0.38	1.45e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.47	7.5	0.52	4.93e-12	IgG glycosylation;
PAAD	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg02683114	chr2:24398427	C2orf84	-0.52	-4.99	-0.37	1.66e-6	Asthma;
PAAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.04e-6	Life satisfaction;
PAAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-5.97	-0.44	1.62e-8	Schizophrenia;
PAAD	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.56	7.14	0.5	3.54e-11	Sitting height ratio;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.95	11.93	0.7	1.4e-23	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg06917634	chr15:78832804	PSMA4	-0.46	-4.45	-0.34	1.69e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.86	9.27	0.6	1.7e-16	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs569214	0.515	rs492786	chr8:27520184	G/A	cg04264299	chr8:27491209	SCARA3	0.56	5.46	0.4	1.93e-7	Alzheimer's disease;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.24e-5	Cognitive function;
PAAD	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	1.09	15.25	0.78	1.86e-32	Breast cancer;
PAAD	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.58	-0.47	7.3e-10	Retinal vascular caliber;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-1.05	-13.32	-0.73	2.59e-27	Urate levels;
PAAD	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg01304814	chr3:48885189	PRKAR2A	0.67	4.55	0.35	1.09e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-6.87	-0.49	1.56e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	5.1	0.38	1.02e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg21951975	chr1:209979733	IRF6	-0.56	-5.69	-0.42	6.25e-8	Coronary artery disease;
PAAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.67	-5.14	-0.38	8.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.53	5.38	0.4	2.74e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-10.98	-0.67	5.09e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11669133	1.000	rs17001070	chr19:11086746	T/C	cg25243385	chr19:11167475	SMARCA4	0.99	4.7	0.36	5.84e-6	LDL cholesterol;
PAAD	cis	rs375066	0.762	rs239943	chr19:44374716	A/T	cg21496419	chr19:44306685	LYPD5	0.42	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg15571903	chr15:79123663	NA	-0.4	-4.94	-0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-4.61	-0.35	8.3e-6	Ulcerative colitis;
PAAD	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.8	5.94	0.43	1.85e-8	Height;
PAAD	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg10556349	chr10:835070	NA	0.59	4.81	0.36	3.63e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.77	-7.79	-0.53	9.53e-13	Gut microbiome composition (winter);
PAAD	cis	rs17407555	0.560	rs73229842	chr4:10044524	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.39	-0.4	2.59e-7	Schizophrenia (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14685339	chr14:77787351	POMT2;GSTZ1	0.61	6.79	0.48	2.43e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs59888335	0.823	rs67359752	chr3:80543917	A/C	cg21735741	chr3:80819488	NA	0.59	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	7.74	0.53	1.3e-12	Alzheimer's disease;
PAAD	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.79	7.73	0.53	1.33e-12	Testicular germ cell tumor;
PAAD	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6684514	0.961	rs68170055	chr1:156332331	C/G	cg16558208	chr1:156270281	VHLL	0.48	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs35791980	0.567	rs7790123	chr7:76942644	A/G	cg02756451	chr7:76178720	LOC100133091	0.51	4.38	0.33	2.22e-5	Pursuit maintenance gain;
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	5.61	0.41	9.37e-8	Blood protein levels;
PAAD	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27068297	chr22:50451975	IL17REL	0.44	4.41	0.34	1.93e-5	Ulcerative colitis;
PAAD	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	6.87	0.49	1.58e-10	Educational attainment;
PAAD	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg21977766	chr11:1107580	NA	0.43	4.37	0.33	2.28e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-7.78	-0.53	1.03e-12	Coffee consumption (cups per day);
PAAD	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.59	4.9	0.37	2.41e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.55	-0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs73019876	0.836	rs431474	chr19:22228792	A/G	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.63	-0.42	8.42e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg22496339	chr2:162101262	NA	-0.59	-7.08	-0.5	4.9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.9	-9.37	-0.61	9.57e-17	Bone mineral density;
PAAD	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.36	3.28e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.45	0.4	1.96e-7	Total body bone mineral density;
PAAD	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.58	-0.35	9.42e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg14820908	chr5:178986412	RUFY1	0.49	4.82	0.36	3.47e-6	Lung cancer;
PAAD	cis	rs1419980	0.730	rs7299184	chr12:7729168	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.9	8.01	0.54	2.78e-13	Gut microbiome composition (summer);
PAAD	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.77	7.99	0.54	3.16e-13	Mean corpuscular volume;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.5	0.47	1.07e-9	Height;
PAAD	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.63	-6.33	-0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	10.91	0.66	8.08e-21	Primary sclerosing cholangitis;
PAAD	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg04520793	chr17:42248056	ASB16	0.43	4.83	0.36	3.34e-6	Total body bone mineral density;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg12705353	chr12:122356852	WDR66	0.47	4.92	0.37	2.22e-6	Mean corpuscular volume;
PAAD	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg02297831	chr4:17616191	MED28	0.61	5.93	0.43	1.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg22771759	chr13:24902376	NA	0.48	4.72	0.36	5.34e-6	Obesity-related traits;
PAAD	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9395066	0.527	rs1590864	chr6:44906151	C/A	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg20917491	chr3:195578259	NA	0.52	4.96	0.37	1.9e-6	Pancreatic cancer;
PAAD	cis	rs438465	0.685	rs9371116	chr6:169765884	C/T	cg00289362	chr6:170482788	NA	0.5	4.44	0.34	1.69e-5	Corneal astigmatism;
PAAD	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.56	-7.66	-0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.54	-4.37	-0.33	2.25e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.62	-5.54	-0.41	1.29e-7	Response to antineoplastic agents;
PAAD	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.88	-7.88	-0.54	5.99e-13	Urate levels in lean individuals;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	4.76	0.36	4.47e-6	Educational attainment;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.56	-4.59	-0.35	9.37e-6	Iron status biomarkers;
PAAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.37	0.33	2.25e-5	Mean corpuscular volume;
PAAD	cis	rs498136	0.966	rs872515	chr11:69373025	T/C	cg24388239	chr11:68438018	NA	-0.42	-4.48	-0.34	1.47e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.63	-4.37	-0.33	2.29e-5	Blood protein levels;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg15557168	chr22:42548783	NA	0.41	4.34	0.33	2.55e-5	Intelligence;
PAAD	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg02404636	chr22:31891804	SFI1	0.66	6.15	0.45	6.57e-9	Colorectal cancer;
PAAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.9	0.69	1.67e-23	Smoking behavior;
PAAD	cis	rs1865721	0.848	rs12966327	chr18:73208445	C/T	cg26385618	chr18:73139727	C18orf62	-0.46	-5.34	-0.4	3.39e-7	Intelligence;
PAAD	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg04607699	chr11:48328132	OR4S1	-0.53	-5.11	-0.38	9.54e-7	Migraine - clinic-based;
PAAD	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.83	-0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10450586	0.799	rs1871255	chr11:27277756	A/G	cg10370305	chr11:27303972	NA	0.38	4.53	0.34	1.2e-5	Total body bone mineral density;
PAAD	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.81	-8.86	-0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.57e-5	Breast cancer;
PAAD	cis	rs7688540	0.800	rs28429717	chr4:260173	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	4.83	0.37	3.24e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	trans	rs2982694	0.764	rs2982700	chr6:152286523	G/C	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.1	6.45	0.46	1.39e-9	Body mass index;
PAAD	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.5	-0.61	4.26e-17	Blood trace element (Zn levels);
PAAD	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg12257692	chr3:49977190	RBM6	0.34	4.28	0.33	3.34e-5	Body mass index;
PAAD	cis	rs6466055	0.589	rs7805639	chr7:104987284	C/G	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.52e-6	Schizophrenia;
PAAD	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	7.16	0.5	3.21e-11	Schizophrenia;
PAAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.6	-0.41	9.74e-8	Coronary artery calcification;
PAAD	cis	rs282587	0.569	rs413110	chr13:113413755	A/G	cg02820901	chr13:113351484	ATP11A	0.72	5.63	0.42	8.5e-8	Glycated hemoglobin levels;
PAAD	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.71	8.39	0.56	3.08e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	4.78	0.36	4.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.98	12.41	0.71	7.11e-25	Bone mineral density;
PAAD	trans	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Coronary artery disease;
PAAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.54	4.9	0.37	2.48e-6	Monocyte count;
PAAD	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg02841227	chr6:26021843	HIST1H4A	0.54	5.2	0.39	6.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.27	-0.6	1.73e-16	Mean platelet volume;
PAAD	cis	rs800160	0.720	rs2651791	chr11:2358554	A/G	cg09785033	chr11:2336066	TSPAN32	-0.53	-4.46	-0.34	1.59e-5	Bacteremia;
PAAD	cis	rs2347503	0.510	rs16879344	chr8:32262521	A/G	cg17547296	chr8:32461618	NRG1	0.92	4.71	0.36	5.63e-6	Cognitive function;
PAAD	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.85	-8.68	-0.58	5.77e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20868518	chr1:33593038	NA	0.66	6.45	0.46	1.43e-9	Obesity-related traits;
PAAD	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01311909	chr12:46320890	SFRS2IP	-0.69	-6.34	-0.46	2.53e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21763021	chr20:54967671	AURKA;CSTF1	-0.76	-6.39	-0.46	1.88e-9	Neuroticism;
PAAD	cis	rs7180079	1.000	rs77627789	chr15:64444276	G/C	cg08069370	chr15:64387884	SNX1	-0.77	-4.54	-0.35	1.16e-5	Monocyte count;
PAAD	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg21479132	chr6:26055353	NA	0.9	5.37	0.4	2.88e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg14349672	chr11:133703707	NA	-0.54	-6.09	-0.44	8.89e-9	Childhood ear infection;
PAAD	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.93	-0.37	2.15e-6	Pulmonary function;
PAAD	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg02917321	chr22:38215204	NA	0.45	4.35	0.33	2.53e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs13242816	1.000	rs12672236	chr7:116111369	A/G	cg16553024	chr7:116138462	CAV2	0.68	5.2	0.39	6.33e-7	P wave duration;
PAAD	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.46	5.92	0.43	2.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.89	0.54	5.41e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.93	0.37	2.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.41	8.86e-8	Bipolar disorder;
PAAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg25456477	chr12:86230367	RASSF9	0.48	4.29	0.33	3.21e-5	Major depressive disorder;
PAAD	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.78	-5.89	-0.43	2.42e-8	Initial pursuit acceleration;
PAAD	cis	rs8005677	0.649	rs11629120	chr14:23458457	T/C	cg25600027	chr14:23388339	RBM23	0.49	4.59	0.35	9.11e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.48	6.37	0.46	2.08e-9	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.38	-4.33	-0.33	2.69e-5	Intelligence;
PAAD	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.71	-0.36	5.51e-6	Red cell distribution width;
PAAD	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg01426195	chr3:39028469	NA	0.61	5.97	0.44	1.64e-8	Handedness;
PAAD	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.07	0.44	9.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2790216	1.000	rs1339588	chr10:59998210	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs5756391	0.524	rs2413436	chr22:37312561	A/G	cg21209356	chr22:37319042	CSF2RB	0.35	4.26	0.33	3.6e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg05579598	chr16:88989069	CBFA2T3	0.52	7.83	0.54	7.61e-13	Social autistic-like traits;
PAAD	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg24053715	chr22:38214548	NA	-0.51	-5.3	-0.39	3.99e-7	Glioblastoma;Glioma;
PAAD	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.67	-0.35	6.58e-6	Mean corpuscular volume;
PAAD	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg10820045	chr2:198174542	NA	0.44	4.34	0.33	2.54e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs939584	0.935	rs5017301	chr2:631096	G/A	cg14515364	chr2:636606	NA	0.5	4.59	0.35	9.27e-6	Body mass index;
PAAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.41	0.4	2.44e-7	Major depressive disorder;
PAAD	cis	rs75920871	0.623	rs7946729	chr11:116963180	C/T	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.78	-9.55	-0.61	3.2e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg26816564	chr1:7831052	VAMP3	-0.68	-5.78	-0.42	4.16e-8	Inflammatory bowel disease;
PAAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg08493051	chr2:3487164	NA	-0.69	-6.46	-0.46	1.36e-9	Neurofibrillary tangles;
PAAD	cis	rs727479	0.523	rs8034835	chr15:51512664	A/G	cg21478137	chr15:51532386	CYP19A1	0.44	4.45	0.34	1.63e-5	Estradiol levels;
PAAD	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.57	5.75	0.42	4.76e-8	YKL-40 levels;
PAAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.83e-7	Monocyte count;
PAAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg04672351	chr11:27722889	BDNF	0.59	7.09	0.5	4.76e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.8	5.83	0.43	3.27e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs10821973	0.527	rs7085402	chr10:64020896	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg27539214	chr16:67997921	SLC12A4	0.63	4.67	0.35	6.56e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.92	10.99	0.67	4.82e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs75920871	1.000	rs61905691	chr11:116880703	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.53	4.27	0.33	3.37e-5	HDL cholesterol;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09299307	chr5:86709023	CCNH	0.59	6.39	0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.61	-4.95	-0.37	1.97e-6	Neuroblastoma;
PAAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15110300	chr7:45039670	CCM2	0.61	6.55	0.47	8.38e-10	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09524880	chr19:11560291	PRKCSH	-0.66	-6.88	-0.49	1.5e-10	Obesity-related traits;
PAAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs258892	0.841	rs34665	chr5:72158396	T/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.73	-12.23	-0.7	2.18e-24	Urate levels in overweight individuals;
PAAD	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.75	7.27	0.51	1.73e-11	Corneal astigmatism;
PAAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	4.9	0.37	2.45e-6	Neuroticism;
PAAD	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.76	-7.86	-0.54	6.7e-13	Mosquito bite size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20276874	chr14:90721474	PSMC1	-0.55	-6.32	-0.46	2.82e-9	Obesity-related traits;
PAAD	cis	rs2594989	0.677	rs7631716	chr3:11576689	T/C	cg02835301	chr3:11609216	VGLL4	0.47	4.41	0.34	1.97e-5	Circulating chemerin levels;
PAAD	cis	rs3779195	0.627	rs6967728	chr7:97915637	A/G	cg24562669	chr7:97807699	LMTK2	0.52	4.6	0.35	8.73e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.21	-0.39	5.98e-7	Pulmonary function;
PAAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg09222892	chr1:25734099	RHCE	0.48	4.55	0.35	1.07e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.72	-0.36	5.41e-6	Neuroticism;
PAAD	cis	rs58521262	0.530	rs289353	chr19:23144589	C/T	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs1334894	0.901	rs7768163	chr6:35492740	G/T	cg07213720	chr6:35227408	ZNF76	-0.83	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.63	-6.14	-0.45	6.93e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs2410601	0.503	rs4921984	chr8:18924056	G/T	cg19414122	chr8:18896631	NA	-0.37	-4.35	-0.33	2.52e-5	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-7.08	-0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg10818794	chr15:86012489	AKAP13	-0.52	-5.8	-0.43	3.8e-8	Coronary artery disease;
PAAD	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.73	-8.12	-0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.48	-4.33	-0.33	2.69e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.47	5.02	0.38	1.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9467603	0.800	rs28360585	chr6:25790356	A/T	cg08501292	chr6:25962987	TRIM38	0.79	5.05	0.38	1.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg07689907	chr11:61582574	FADS1	0.47	4.52	0.34	1.24e-5	Trans fatty acid levels;
PAAD	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.72	0.77	4.64e-31	Chronic sinus infection;
PAAD	cis	rs8060686	0.641	rs112556034	chr16:68045724	C/T	cg03983715	chr16:68378420	PRMT7	-0.86	-5.19	-0.39	6.56e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6940638	0.637	rs13217239	chr6:27254967	T/C	cg12292205	chr6:26970375	C6orf41	-0.45	-4.33	-0.33	2.73e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1012068	0.581	rs5753817	chr22:32313727	G/A	cg01338084	chr22:32026380	PISD	0.51	4.26	0.33	3.54e-5	Chronic hepatitis C infection;
PAAD	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg06236206	chr7:66120395	NA	0.54	4.48	0.34	1.43e-5	Diabetic kidney disease;
PAAD	cis	rs9287719	0.601	rs10178751	chr2:10734203	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7656342	0.535	rs13116446	chr4:9859897	C/T	cg16147221	chr4:10020634	SLC2A9	0.44	4.25	0.33	3.74e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs11212737	0.818	rs2624136	chr11:108513720	A/G	cg13462821	chr8:86214814	NA	-0.55	-6.47	-0.46	1.27e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.33	0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.6	-6.06	-0.44	1.01e-8	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13932035	chr19:11266624	SPC24	0.6	6.37	0.46	2.14e-9	Monocyte percentage of white cells;
PAAD	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs3781663	1.000	rs7125020	chr11:70001534	T/C	cg06393558	chr11:69982916	ANO1	-0.45	-4.83	-0.37	3.23e-6	Survival in rectal cancer;
PAAD	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.68	-7.86	-0.54	6.71e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.73	7.95	0.54	3.93e-13	Longevity;
PAAD	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.77	-0.42	4.28e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs17125944	0.686	rs7145242	chr14:53349842	G/A	cg13660082	chr14:53194042	PSMC6	0.73	4.54	0.35	1.16e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.79	0.36	3.92e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg19673125	chr6:150240577	RAET1G	0.43	6.08	0.44	9.23e-9	Testicular germ cell tumor;
PAAD	cis	rs863345	0.901	rs1342956	chr1:158467755	A/G	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.72	0.36	5.36e-6	Blood metabolite levels;
PAAD	cis	rs288342	0.763	rs418474	chr2:183610466	T/A	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.86	-9.26	-0.6	1.81e-16	Calcium levels;
PAAD	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.45	-0.34	1.68e-5	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.56	-5.21	-0.39	6.18e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18357526	chr6:26021779	HIST1H4A	0.68	6.65	0.47	4.9e-10	Blood metabolite levels;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.59	6.25	0.45	3.88e-9	Iron status biomarkers;
PAAD	cis	rs642743	0.595	rs607069	chr10:105991003	T/A	cg10697286	chr10:106209748	CCDC147	0.47	4.34	0.33	2.57e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg11673840	chr17:47092156	IGF2BP1	0.38	4.31	0.33	2.94e-5	Type 2 diabetes;
PAAD	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs4343996	0.719	rs885011	chr7:3484778	T/C	cg21248987	chr7:3385318	SDK1	0.46	4.9	0.37	2.39e-6	Motion sickness;
PAAD	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.53	5.36	0.4	2.96e-7	Resting heart rate;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.76	-8.35	-0.56	3.91e-14	Menopause (age at onset);
PAAD	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.68	6.29	0.45	3.17e-9	Endometrial cancer;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1793004	1.000	rs1793004	chr11:20698929	C/G	cg02027945	chr11:20618230	NA	-0.33	-4.28	-0.33	3.32e-5	Crohn's disease;
PAAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs10887741	0.646	rs4244979	chr10:89425507	A/C	cg13926569	chr10:89418898	PAPSS2	0.5	5.07	0.38	1.14e-6	Exercise (leisure time);
PAAD	cis	rs36715	1.000	rs36710	chr5:127559444	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.58	0.47	7.16e-10	Breast cancer;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg22110888	chr17:80059540	CCDC57	-0.41	-4.25	-0.33	3.65e-5	Life satisfaction;
PAAD	cis	rs2898290	0.532	rs4841566	chr8:11432438	C/G	cg21175976	chr8:11421337	BLK	-0.5	-5.27	-0.39	4.7e-7	Systolic blood pressure;
PAAD	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-5.26	-0.39	4.74e-7	Menarche (age at onset);
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg10729496	chr3:10149963	C3orf24	0.88	7.31	0.51	1.42e-11	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs72960926	0.744	rs9360792	chr6:75128956	G/C	cg03266952	chr6:74778945	NA	-0.85	-4.77	-0.36	4.24e-6	Metabolite levels (MHPG);
PAAD	cis	rs10924309	0.855	rs1807291	chr1:245860210	G/A	cg00036263	chr1:245852353	KIF26B	-0.68	-5.9	-0.43	2.24e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg14851346	chr12:38532713	NA	-0.47	-4.52	-0.34	1.22e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11051970	0.918	rs7309706	chr12:32538208	A/T	cg24626660	chr12:32551988	NA	0.42	4.58	0.35	9.73e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4905014	1.000	rs4905014	chr14:93412031	C/G	cg21097788	chr14:93502930	ITPK1	0.81	4.76	0.36	4.48e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.93	11.59	0.68	1.18e-22	Pulse pressure;
PAAD	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	4.7	0.36	5.78e-6	Blood metabolite levels;
PAAD	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.7	7.52	0.52	4.34e-12	Body mass index;
PAAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg05697835	chr1:2722811	NA	-0.37	-4.28	-0.33	3.33e-5	Ulcerative colitis;
PAAD	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.91	8.35	0.56	4e-14	Obesity-related traits;
PAAD	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-4.26	-0.33	3.63e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.83	-0.58	2.31e-15	Type 2 diabetes;
PAAD	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg13736514	chr6:26305472	NA	-0.59	-6.27	-0.45	3.63e-9	Educational attainment;
PAAD	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.39	4.65	0.35	7.02e-6	Hemoglobin concentration;
PAAD	cis	rs908922	0.923	rs11205010	chr1:152457964	C/T	cg23254163	chr1:152506842	NA	0.57	5.86	0.43	2.76e-8	Hair morphology;
PAAD	cis	rs2147959	0.882	rs4653552	chr1:228628138	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.43	-0.34	1.83e-5	Adult asthma;
PAAD	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg02683114	chr2:24398427	C2orf84	-0.53	-5.19	-0.39	6.52e-7	Asthma;
PAAD	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.52	-0.34	1.22e-5	Systemic lupus erythematosus;
PAAD	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg03004497	chr11:58874207	FAM111B	-0.53	-4.38	-0.33	2.24e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.71	-7.26	-0.51	1.87e-11	Retinal vascular caliber;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg05627522	chr15:75251581	NA	0.59	7.21	0.5	2.45e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg23119463	chr10:134592391	INPP5A	-0.44	-4.51	-0.34	1.26e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg24101359	chr6:42928495	GNMT	0.58	4.72	0.36	5.36e-6	Blood protein levels;
PAAD	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.87	-9.32	-0.6	1.25e-16	Platelet distribution width;
PAAD	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.58	-0.47	7.34e-10	Schizophrenia;
PAAD	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg03367679	chr17:38183553	MED24;SNORD124	0.35	4.74	0.36	4.95e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2274459	1.000	rs34339105	chr6:33723457	G/T	cg06253072	chr6:33679850	C6orf125	0.68	4.85	0.37	3.08e-6	Obesity (extreme);
PAAD	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.58	5.39	0.4	2.61e-7	Malaria;
PAAD	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.86	0.43	2.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.61	0.35	8.63e-6	Electroencephalogram traits;
PAAD	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg07785726	chr13:50159788	RCBTB1	0.58	6.51	0.47	1.05e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg12508331	chr16:3208203	NA	0.47	4.35	0.33	2.49e-5	Body mass index (adult);
PAAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.82	-0.48	2.02e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.57	5.78	0.42	4.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1413885	0.504	rs36067635	chr1:65865574	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	5.02	0.38	1.46e-6	Anticoagulant levels;
PAAD	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.69	8.6	0.57	9.19e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	4.99	0.37	1.66e-6	Axial length;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.7	4.97	0.37	1.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12282928	0.959	rs10769331	chr11:48249779	G/A	cg04721828	chr11:48285200	OR4X1	-0.47	-5.92	-0.43	2.09e-8	Migraine - clinic-based;
PAAD	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg08601574	chr20:25228251	PYGB	-0.64	-6.96	-0.49	9.66e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.54	0.35	1.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	0.935	rs1320330	chr2:622225	T/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.81	-7.53	-0.52	4.1e-12	DNA methylation (variation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21547190	chr19:33793141	CEBPA;LOC80054	0.67	6.59	0.47	6.75e-10	Obesity-related traits;
PAAD	cis	rs67257959	0.708	rs11671858	chr19:17201520	T/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.47	4.61	0.35	8.52e-6	Selective IgA deficiency;
PAAD	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.62	-4.83	-0.36	3.31e-6	Rheumatoid arthritis;
PAAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.54	0.47	8.72e-10	Morning vs. evening chronotype;
PAAD	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11203032	0.901	rs4073283	chr10:90958000	G/C	cg16672925	chr10:90967113	CH25H	0.78	5.98	0.44	1.57e-8	Heart failure;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.6	-7.27	-0.51	1.79e-11	Iron status biomarkers;
PAAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.46	-4.71	-0.36	5.48e-6	Height;
PAAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.72	-8.33	-0.56	4.48e-14	Height;
PAAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.74	0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.48	-4.52	-0.34	1.25e-5	Endometrial cancer;
PAAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.84	8.98	0.59	9.98e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.6	5.47	0.41	1.83e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs6723108	0.603	rs3814354	chr2:135711657	G/A	cg26890182	chr2:135621176	ACMSD	0.3	4.27	0.33	3.4e-5	Type 2 diabetes;
PAAD	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.9	9.71	0.62	1.19e-17	Breast cancer;
PAAD	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg06197492	chr11:2016605	H19	0.53	5.84	0.43	3.07e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs8005172	0.750	rs10142115	chr14:88451251	A/G	cg18078958	chr14:88630771	NA	0.46	5.4	0.4	2.47e-7	Parkinson's disease;
PAAD	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.56	-4.85	-0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23708337	chr7:1209742	NA	0.44	4.62	0.35	7.98e-6	Longevity;Endometriosis;
PAAD	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.66	6.64	0.47	5.16e-10	Coronary artery disease;
PAAD	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Urinary tract infection frequency;
PAAD	trans	rs3130746	1	rs3130746	chr6:29153155	A/G	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Tuberculosis;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.66	0.48	4.6e-10	Lung cancer;
PAAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg23024343	chr7:107201750	COG5	0.54	4.5	0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.2e-14	Bone mineral density;
PAAD	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	6.09	0.44	8.94e-9	Blood protein levels;
PAAD	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg10437265	chr15:77819839	NA	0.41	4.59	0.35	9.07e-6	Type 2 diabetes;
PAAD	cis	rs4704187	0.649	rs1422701	chr5:74510517	T/G	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.86	7.95	0.54	3.92e-13	Response to diuretic therapy;
PAAD	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.76	7.85	0.54	6.77e-13	Breast cancer;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.98	13.14	0.73	7.86e-27	Menarche (age at onset);
PAAD	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.65	6.12	0.44	7.63e-9	Platelet distribution width;
PAAD	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.96	12.15	0.7	3.55e-24	Metabolite levels;
PAAD	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg08562672	chr19:21860753	NA	0.47	4.83	0.36	3.32e-6	Pain;
PAAD	cis	rs758324	0.773	rs10069521	chr5:131174215	A/G	cg06307176	chr5:131281290	NA	0.51	4.46	0.34	1.56e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.86	10.81	0.66	1.47e-20	Prudent dietary pattern;
PAAD	cis	rs4887059	1	rs4887059	chr15:78782095	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-4.46	-0.34	1.6e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.64	6.5	0.47	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26926768	chr12:34528122	NA	0.39	4.64	0.35	7.45e-6	Morning vs. evening chronotype;
PAAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.38	0.33	2.24e-5	Electroencephalogram traits;
PAAD	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.56	5.23	0.39	5.62e-7	Night sleep phenotypes;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg05861140	chr6:150128134	PCMT1	-0.5	-5.25	-0.39	5.04e-7	Lung cancer;
PAAD	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg03989125	chr22:38214979	NA	-0.54	-5.58	-0.41	1.07e-7	Glioblastoma;Glioma;
PAAD	cis	rs58521262	0.585	rs289307	chr19:23166956	C/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.46	-0.34	1.58e-5	Aortic root size;
PAAD	cis	rs6684514	0.922	rs2075166	chr1:156215562	G/A	cg16558208	chr1:156270281	VHLL	0.46	4.34	0.33	2.59e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs3795579	0.517	rs7549807	chr1:204079268	C/T	cg19081101	chr1:203156625	CHI3L1	0.37	4.37	0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.65	-6.58	-0.47	7.05e-10	Liver enzyme levels;
PAAD	cis	rs527409	0.850	rs9436585	chr1:58748004	C/T	cg26345888	chr1:58716257	DAB1	-0.66	-4.45	-0.34	1.62e-5	Kawasaki disease;
PAAD	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.66	6.61	0.47	6.12e-10	Schizophrenia;
PAAD	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg21226059	chr5:178986404	RUFY1	-0.44	-5.07	-0.38	1.16e-6	Lung cancer;
PAAD	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12315302	chr6:26189340	HIST1H4D	0.52	4.37	0.33	2.31e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs300774	1.000	rs300774	chr2:112496	G/T	cg21211680	chr2:198530	NA	0.66	6.11	0.44	8.04e-9	Suicide attempts in bipolar disorder;
PAAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs9660180	0.819	rs4648629	chr1:1695462	C/A	cg13866156	chr1:1669148	SLC35E2	0.73	8.33	0.56	4.43e-14	Body mass index;
PAAD	cis	rs13380717	0.657	rs4335778	chr16:86914742	A/G	cg07769121	chr16:86543519	FOXF1	-0.55	-4.51	-0.34	1.27e-5	Sepsis in extremely premature infants;
PAAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.45	-4.61	-0.35	8.65e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs829661	0.947	rs1252646	chr2:30741913	C/T	cg12454169	chr2:30669597	LCLAT1	-0.64	-5.04	-0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg07648498	chr16:89883185	FANCA	0.45	4.4	0.34	2.04e-5	Vitiligo;
PAAD	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.95	0.37	1.93e-6	Colorectal cancer;
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.6	5.01	0.38	1.5e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg01097406	chr16:89675127	NA	-0.37	-4.34	-0.33	2.59e-5	Vitiligo;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs4908768	0.657	rs3938719	chr1:8804997	A/G	cg00590817	chr1:8272081	NA	-0.37	-4.42	-0.34	1.89e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.84	9.16	0.6	3.26e-16	Colorectal cancer;
PAAD	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg03808351	chr9:123631620	PHF19	0.45	4.88	0.37	2.7e-6	Rheumatoid arthritis;
PAAD	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.79e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4378999	0.660	rs4443210	chr3:51067562	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	4.29	0.33	3.19e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg20673091	chr1:2541236	MMEL1	-0.88	-10.23	-0.64	5.27e-19	Ulcerative colitis;
PAAD	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg20283391	chr11:68216788	NA	0.55	5.28	0.39	4.41e-7	Total body bone mineral density;
PAAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.87	10.45	0.65	1.35e-19	Multiple sclerosis;
PAAD	cis	rs7487075	0.619	rs10785628	chr12:46854676	T/G	cg14671384	chr12:47219920	SLC38A4	0.45	4.44	0.34	1.71e-5	Itch intensity from mosquito bite;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.8	0.62	6.91e-18	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06175825	chr1:55007736	NA	0.71	7.29	0.51	1.6e-11	Myopia (pathological);
PAAD	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13198984	chr17:80129470	CCDC57	-0.4	-4.78	-0.36	4.1e-6	Life satisfaction;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21178979	chr7:1889533	MAD1L1	0.4	4.39	0.34	2.15e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09497020	chr5:893046	TRIP13;BRD9	-0.61	-6.42	-0.46	1.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs728616	0.867	rs1983775	chr10:81663575	G/A	cg19423196	chr10:82049429	MAT1A	0.59	4.32	0.33	2.76e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12935418	0.583	rs1469124	chr16:81029654	C/G	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs2278796	0.918	rs11240326	chr1:204955416	G/A	cg04862289	chr1:204966208	NFASC	0.43	4.33	0.33	2.71e-5	Mean platelet volume;
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.83	9.95	0.63	2.81e-18	Bladder cancer;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs4787491	0.729	rs11150584	chr16:30039678	C/A	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg05861140	chr6:150128134	PCMT1	-0.57	-6.53	-0.47	9.44e-10	Lung cancer;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.7	-0.42	6.12e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.77	-0.36	4.26e-6	Aortic root size;
PAAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-5.27	-0.39	4.66e-7	Type 2 diabetes;
PAAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs9866391	0.607	rs1344672	chr3:141125705	C/G	cg00789793	chr3:141329863	RASA2	-0.42	-4.29	-0.33	3.19e-5	Myopia;
PAAD	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-4.88	-0.37	2.62e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs2120991	1.000	rs11170737	chr12:54279604	A/G	cg23795217	chr12:54812000	ITGA5	-0.34	-4.79	-0.36	3.99e-6	Biliary atresia;
PAAD	cis	rs4130590	0.934	rs7041940	chr9:130109746	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.54	4.96	0.37	1.88e-6	Bipolar disorder;
PAAD	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.25	-0.51	1.93e-11	Psoriasis;
PAAD	cis	rs800160	0.858	rs800117	chr11:2362790	T/C	cg09785033	chr11:2336066	TSPAN32	-0.51	-4.29	-0.33	3.12e-5	Bacteremia;
PAAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.39	-0.56	3.08e-14	Calcium levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13199958	chr6:151663671	AKAP12	-0.61	-6.31	-0.46	2.88e-9	Obesity-related traits;
PAAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	6.86	0.49	1.66e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.69e-5	Coronary artery disease;
PAAD	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.57	4.83	0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs117623576	0.941	rs7070675	chr10:32407269	G/T	cg03047570	chr10:32398778	NA	-0.85	-5.35	-0.4	3.14e-7	Anti-saccade response;
PAAD	trans	rs11794666	1.000	rs116767910	chr9:31656636	T/G	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.43	0.65	1.53e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.53	4.76	0.36	4.39e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.54	-0.47	8.67e-10	Colorectal cancer;
PAAD	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	4.83	0.36	3.34e-6	Mood instability;
PAAD	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.72	7.75	0.53	1.22e-12	Neuroticism;
PAAD	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg21546286	chr11:48923668	NA	0.58	6.09	0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.01	0.38	1.47e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-12.21	-0.7	2.58e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg07075026	chr17:47091521	IGF2BP1	0.44	5.64	0.42	7.92e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.52	5.46	0.4	1.93e-7	Tonsillectomy;
PAAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg26174226	chr8:58114915	NA	-0.57	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.42	-0.34	1.89e-5	Fear of minor pain;
PAAD	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.47	4.61	0.35	8.39e-6	Mean corpuscular volume;
PAAD	cis	rs7619427	0.544	rs9866639	chr3:43990450	G/A	cg12796028	chr3:44040206	NA	-0.54	-4.69	-0.36	6.03e-6	Schizophrenia;
PAAD	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	4.61	0.35	8.57e-6	Menarche (age at onset);
PAAD	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg26437564	chr7:45808727	SEPT13	0.63	4.48	0.34	1.47e-5	Subjective response to lithium treatment in bipolar disorder;
PAAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	1.09	6.05	0.44	1.11e-8	Body mass index;
PAAD	cis	rs527409	0.655	rs666435	chr1:58750078	G/A	cg26345888	chr1:58716257	DAB1	-0.66	-4.45	-0.34	1.62e-5	Kawasaki disease;
PAAD	cis	rs9810890	1.000	rs73196965	chr3:128436709	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs2562456	0.833	rs62110071	chr19:21470903	C/G	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.46	-4.32	-0.33	2.84e-5	Glomerular filtration rate;
PAAD	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12568669	chr8:11666485	FDFT1	-0.3	-4.78	-0.36	4.09e-6	Myopia (pathological);
PAAD	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	7.48	0.52	5.39e-12	Coronary artery disease;
PAAD	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	4.4	0.34	2.03e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	1.18	13.56	0.74	5.96e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.65	-0.47	4.93e-10	Longevity;Endometriosis;
PAAD	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg21040360	chr2:3383326	TTC15	-0.42	-4.34	-0.33	2.62e-5	Obesity-related traits;
PAAD	cis	rs11764590	0.813	rs11768212	chr7:1992582	A/C	cg02743256	chr7:2109353	MAD1L1	-0.71	-5.52	-0.41	1.46e-7	Neuroticism;
PAAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.72	7.35	0.51	1.13e-11	Response to antidepressants and depression;
PAAD	cis	rs1376877	0.519	rs10197623	chr2:204243759	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.57	4.77	0.36	4.37e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.85	0.54	6.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs7582720	1.000	rs72932763	chr2:203678658	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.85	-9.04	-0.59	6.86e-16	Non-obstructive azoospermia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05842890	chr17:4643958	ZMYND15;CXCL16	-0.67	-6.36	-0.46	2.26e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	1.68	9.48	0.61	5.01e-17	Height;
PAAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.83	10.65	0.65	3.79e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15724116	chr17:64781874	PRKCA;MIR634	-0.73	-7.87	-0.54	6.23e-13	Obesity-related traits;
PAAD	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs73206853	0.841	rs56130410	chr12:110824112	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs55986470	0.630	rs67981771	chr2:239402647	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-5.27	-0.39	4.51e-7	Chronotype;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	1.08	7.47	0.52	5.85e-12	IgG glycosylation;
PAAD	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.68	10.48	0.65	1.08e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18297960	chr7:1142765	C7orf50	-0.62	-4.3	-0.33	3.07e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg00522288	chr12:125625016	AACS	-0.55	-5.64	-0.42	8.02e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.87	6.43	0.46	1.57e-9	Alzheimer's disease;
PAAD	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14631576	chr9:95140430	CENPP	-0.44	-4.37	-0.33	2.25e-5	Height;
PAAD	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg24154853	chr7:158122151	PTPRN2	0.7	7.18	0.5	2.9e-11	Calcium levels;
PAAD	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg19486271	chr11:47235900	DDB2	-0.59	-5.84	-0.43	3.01e-8	Acne (severe);
PAAD	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg08824895	chr13:115047677	UPF3A	0.52	4.84	0.37	3.11e-6	Schizophrenia;
PAAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-6.18	-0.45	5.75e-9	Mood instability;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	5.57	0.41	1.11e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg15842884	chr20:5591925	RP5-1022P6.2	0.48	5.13	0.38	8.85e-7	Occipital cortical area (total cortical area interaction);
PAAD	cis	rs6710503	0.574	rs60372293	chr2:24779230	T/G	cg21151432	chr2:25142229	ADCY3	-0.37	-4.3	-0.33	3e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.53	5.23	0.39	5.53e-7	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg21951975	chr1:209979733	IRF6	0.58	5.98	0.44	1.52e-8	Coronary artery disease;
PAAD	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.58	-5.42	-0.4	2.33e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11770404	chr20:60962048	RPS21	-0.78	-6.89	-0.49	1.4e-10	Neuroticism;
PAAD	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.29	0.51	1.56e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.69	-0.36	6.1e-6	Neuroticism;
PAAD	cis	rs10929159	0.928	rs7569558	chr2:236924309	G/A	cg14226755	chr2:236923322	AGAP1	0.28	4.41	0.34	1.98e-5	Parkinson's disease;
PAAD	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg23912435	chr1:150601613	ENSA	0.52	4.93	0.37	2.12e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.63	7.12	0.5	3.99e-11	Bone mineral density;
PAAD	cis	rs2147959	0.824	rs4653969	chr1:228690289	C/G	cg18477163	chr1:228402036	OBSCN	-0.45	-4.35	-0.33	2.44e-5	Adult asthma;
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg07777115	chr5:623756	CEP72	-0.52	-4.52	-0.34	1.23e-5	Cystic fibrosis severity;
PAAD	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-14.63	-0.76	8.45e-31	Primary sclerosing cholangitis;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.95	12.56	0.71	2.86e-25	Menarche (age at onset);
PAAD	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.54	6.69	0.48	4e-10	Atrioventricular conduction;
PAAD	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.44	-6.79	-0.48	2.31e-10	Cutaneous nevi;
PAAD	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg06637938	chr14:75390232	RPS6KL1	0.48	4.71	0.36	5.48e-6	Height;
PAAD	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.69	-7.43	-0.52	7.14e-12	Schizophrenia;
PAAD	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg05025164	chr4:1340916	KIAA1530	0.57	5.64	0.42	8.16e-8	Longevity;
PAAD	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg03513858	chr6:54763001	FAM83B	-0.41	-4.58	-0.35	9.74e-6	Menarche (age at onset);
PAAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06860352	chr19:14142585	IL27RA	0.67	6.64	0.47	5.19e-10	Obesity-related traits;
PAAD	cis	rs76419734	0.558	rs11730080	chr4:106521859	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.43	0.34	1.8e-5	Post bronchodilator FEV1;
PAAD	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg09796270	chr17:17721594	SREBF1	0.44	5.0	0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.59	-6.94	-0.49	1.04e-10	Dementia with Lewy bodies;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.56e-11	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02774070	chr7:66093889	KCTD7	0.71	7.74	0.53	1.32e-12	Myopia (pathological);
PAAD	cis	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.85	-0.43	2.91e-8	HDL cholesterol;
PAAD	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.74	7.21	0.5	2.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg22882665	chr2:45241110	NA	-0.33	-4.41	-0.34	1.96e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs3764400	0.508	rs2240121	chr17:46152322	T/C	cg10706073	chr17:46328419	SKAP1	-1.08	-6.28	-0.45	3.36e-9	Body mass index;
PAAD	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.66e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.74	-8.25	-0.56	7.13e-14	Lung cancer;
PAAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg03989125	chr22:38214979	NA	0.61	5.97	0.44	1.61e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.85	-7.27	-0.51	1.76e-11	Blood pressure (smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20814826	chr17:2206919	SRR;SMG6	0.61	7.05	0.5	5.73e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs258430	0.714	rs10843022	chr12:28057915	C/G	cg23291886	chr4:174440681	NA	-0.35	-6.3	-0.46	3.09e-9	Fast beta electroencephalogram;
PAAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg05110241	chr16:68378359	PRMT7	-1.16	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1042026	0.848	rs3819197	chr4:100200509	C/T	cg09112717	chr4:100009950	ADH5	-0.51	-4.59	-0.35	9.37e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg09127314	chr1:152161683	NA	-0.75	-5.4	-0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.15	0.39	7.94e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg07371521	chr5:154026371	NA	-0.47	-5.8	-0.43	3.8e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.53	-5.73	-0.42	5.34e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12541635	0.677	rs7003520	chr8:107061724	G/A	cg10147462	chr8:107024639	NA	0.45	4.8	0.36	3.73e-6	Age of smoking initiation;
PAAD	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg00129232	chr17:37814104	STARD3	-0.52	-4.39	-0.34	2.14e-5	Self-reported allergy;
PAAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.82	8.9	0.59	1.61e-15	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11490986	chr7:143599184	FAM115A	-0.6	-6.85	-0.49	1.76e-10	Body fat percentage;
PAAD	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.72	7.29	0.51	1.61e-11	Morning vs. evening chronotype;
PAAD	trans	rs12282928	0.700	rs2047815	chr11:48199897	C/T	cg00717180	chr2:96193071	NA	0.67	7.08	0.5	5.09e-11	Migraine - clinic-based;
PAAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.17	-0.39	7.16e-7	Breast cancer;
PAAD	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.5	-0.34	1.33e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.25e-9	Lymphocyte counts;
PAAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg06740227	chr12:86229804	RASSF9	0.59	5.27	0.39	4.66e-7	Major depressive disorder;
PAAD	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	4.53	0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs75920871	0.748	rs61905689	chr11:116869217	C/T	cg04087571	chr11:116723030	SIK3	-0.4	-4.84	-0.37	3.14e-6	Subjective well-being;
PAAD	cis	rs12144094	0.882	rs1441011	chr1:120245374	T/C	cg20995928	chr1:120229863	NA	0.5	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.43	4.3	0.33	2.99e-5	Immature fraction of reticulocytes;
PAAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-6.65	-0.47	5.05e-10	Migraine;Coronary artery disease;
PAAD	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.59	5.99	0.44	1.48e-8	Obesity;
PAAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.76	0.42	4.5e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg14983838	chr19:29218262	NA	0.7	6.11	0.44	7.98e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.92	-9.22	-0.6	2.38e-16	Strep throat;
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg19223190	chr17:80058835	NA	-0.55	-5.6	-0.41	9.67e-8	Life satisfaction;
PAAD	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.96	-0.72	2.42e-26	Primary sclerosing cholangitis;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4144027	0.818	rs881057	chr14:104354258	T/G	cg08213375	chr14:104286397	PPP1R13B	-0.38	-4.52	-0.34	1.26e-5	Blood metabolite levels;
PAAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg24699146	chr1:24152579	HMGCL	0.51	5.37	0.4	2.89e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7224314	0.943	rs6504501	chr17:65367292	T/C	cg01507342	chr17:65387096	PITPNC1	-0.57	-5.24	-0.39	5.19e-7	Diisocyanate-induced asthma;
PAAD	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.6	-0.35	8.7e-6	Recombination measurement;
PAAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.56	6.08	0.44	9.24e-9	Menopause (age at onset);
PAAD	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg18721089	chr20:30220636	NA	-0.59	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg06386533	chr2:46925753	SOCS5	0.55	4.55	0.35	1.09e-5	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19571127	chr19:4867897	PLIN3	0.58	6.52	0.47	9.98e-10	Monocyte percentage of white cells;
PAAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg20821713	chr7:1055600	C7orf50	-0.55	-4.42	-0.34	1.84e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg00536532	chr6:33561449	C6orf227	-0.41	-4.31	-0.33	2.93e-5	Plateletcrit;
PAAD	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.1	0.55	1.67e-13	Asthma (sex interaction);
PAAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.61	-6.25	-0.45	3.87e-9	IgG glycosylation;
PAAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg23283495	chr1:209979779	IRF6	0.8	7.4	0.51	8.82e-12	Coronary artery disease;
PAAD	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.38	4.3	0.33	2.98e-5	Hemoglobin concentration;
PAAD	cis	rs1497828	0.956	rs2646821	chr1:217528236	C/T	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs17169635	0.819	rs1563046	chr7:134498297	A/G	cg02516134	chr7:134575187	CALD1	-0.44	-4.49	-0.34	1.43e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.85	9.9	0.63	3.8e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.87	7.47	0.52	5.93e-12	Neutrophil percentage of white cells;
PAAD	cis	rs4586057	0.868	rs11186336	chr10:92612195	G/C	cg05934333	chr10:93372513	LOC100188947	0.5	4.28	0.33	3.25e-5	Economic and political preferences (time);
PAAD	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.86	0.58	1.96e-15	Motion sickness;
PAAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.81	-5.18	-0.39	7e-7	Tuberculosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25890074	chr13:102067343	NALCN	-0.72	-7.83	-0.54	7.65e-13	Obesity-related traits;
PAAD	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.63	6.13	0.45	7.31e-9	Schizophrenia;
PAAD	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.47	5.58	0.41	1.06e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg24829409	chr8:58192753	C8orf71	-0.7	-5.85	-0.43	2.88e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2997447	0.706	rs1414419	chr1:26430501	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg08254353	chr17:31254670	TMEM98	-0.39	-4.58	-0.35	9.74e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22857025	chr5:266934	NA	-1.19	-10.13	-0.63	9.59e-19	Breast cancer;
PAAD	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg22517653	chr1:2918612	NA	0.62	4.83	0.37	3.24e-6	Plateletcrit;
PAAD	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg16898833	chr6:26189333	HIST1H4D	0.48	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg22089800	chr15:90895588	ZNF774	0.58	5.58	0.41	1.09e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14831266	chr1:33283905	YARS;S100PBP	0.59	6.44	0.46	1.47e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6457821	0.661	rs6905853	chr6:35493369	A/T	cg19040012	chr6:35185397	SCUBE3	0.64	4.27	0.33	3.39e-5	Height;
PAAD	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.51	-6.5	-0.47	1.09e-9	Sitting height ratio;
PAAD	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg06386533	chr2:46925753	SOCS5	0.48	4.3	0.33	3.06e-5	Height;
PAAD	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.3	-0.33	2.99e-5	Blood metabolite levels;
PAAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.96	-11.31	-0.68	6.5600000000000005e-22	Cognitive function;
PAAD	cis	rs2036402	0.704	rs57783907	chr5:156345464	T/G	cg21915449	chr5:156456672	HAVCR1	-0.45	-4.81	-0.36	3.68e-6	Hypertriglyceridemia;
PAAD	cis	rs7084921	0.608	rs11597390	chr10:101861435	A/G	cg04359915	chr10:101825029	CPN1	0.34	5.3	0.39	4.08e-7	Bone mineral density;
PAAD	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.63	6.19	0.45	5.25e-9	Schizophrenia;
PAAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.48	4.28	0.33	3.34e-5	Height;
PAAD	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-6.09	-0.44	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg02573091	chr5:74908125	NA	0.52	4.42	0.34	1.86e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.75	8.19	0.55	1.01e-13	Psoriasis;
PAAD	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg19486271	chr11:47235900	DDB2	0.56	5.69	0.42	6.21e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	6.36	0.46	2.24e-9	Retinal vascular caliber;
PAAD	cis	rs9810890	1.000	rs114329538	chr3:128558387	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg00325661	chr8:49890786	NA	0.57	5.01	0.38	1.51e-6	Sudden cardiac arrest;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg13647721	chr17:30228624	UTP6	0.57	4.37	0.33	2.27e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9322817	0.691	rs2034821	chr6:105219537	C/T	cg02098413	chr6:105308735	HACE1	-0.44	-5.49	-0.41	1.63e-7	Thyroid stimulating hormone;
PAAD	cis	rs9584850	0.794	rs72655609	chr13:99128622	C/G	cg20487152	chr13:99095054	FARP1	0.63	5.54	0.41	1.28e-7	Neuroticism;
PAAD	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	6.57	0.47	7.49e-10	Lung function (FEV1/FVC);
PAAD	cis	rs3812111	0.525	rs1052443	chr6:116568773	A/C	cg18828861	chr6:116576566	TSPYL4	0.46	4.86	0.37	2.92e-6	Age-related macular degeneration;
PAAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.57	-7.77	-0.53	1.11e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1198430	0.925	rs2510072	chr1:23769674	A/G	cg22040403	chr1:23858016	E2F2	0.76	4.82	0.36	3.41e-6	Total cholesterol levels;
PAAD	cis	rs795484	0.889	rs353884	chr12:118663767	T/C	cg16572268	chr12:118583242	PEBP1	-0.46	-4.49	-0.34	1.4e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg13271783	chr10:134563150	INPP5A	0.4	4.27	0.33	3.46e-5	Migraine;
PAAD	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.88	-7.07	-0.5	5.21e-11	Migraine;Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09704049	chr3:38348016	SLC22A14	-0.65	-6.37	-0.46	2.17e-9	Obesity-related traits;
PAAD	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.79	-7.3	-0.51	1.54e-11	Breast cancer;
PAAD	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.96	0.37	1.89e-6	Post bronchodilator FEV1;
PAAD	cis	rs8014252	0.803	rs17108274	chr14:71070401	G/A	cg11204974	chr14:71022665	NA	-0.76	-4.85	-0.37	3.04e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.52	4.54	0.35	1.13e-5	Depressive symptoms;
PAAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg06521852	chr22:38141419	TRIOBP	0.44	4.66	0.35	6.98e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.81	6.09	0.44	8.68e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs7551222	0.634	rs12139477	chr1:204553104	A/C	cg01064725	chr1:204461714	NA	-0.53	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.5	-4.66	-0.35	6.95e-6	Multiple sclerosis;
PAAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.5	-0.41	1.59e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg20302533	chr7:39170763	POU6F2	0.39	6.2	0.45	5.13e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00166722	chr3:10149974	C3orf24	0.73	6.29	0.45	3.19e-9	Alzheimer's disease;
PAAD	cis	rs17095355	0.539	rs12260509	chr10:111920995	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.62	-0.35	8.23e-6	Biliary atresia;
PAAD	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg22601191	chr20:60968625	CABLES2	0.49	4.57	0.35	9.92e-6	Colorectal cancer;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	1.09	8.43	0.56	2.43e-14	IgG glycosylation;
PAAD	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.8	-5.14	-0.38	8.29e-7	Tuberculosis;
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-1.1	-8.27	-0.56	6.41e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg05895507	chr15:77155635	SCAPER	0.41	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.57	4.69	0.36	5.96e-6	Schizophrenia;
PAAD	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.52	5.28	0.39	4.45e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.75	-8.68	-0.58	5.87e-15	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.57	7.19	0.5	2.71e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1075265	0.655	rs13432632	chr2:53940723	G/T	cg04546899	chr2:54196757	PSME4	0.31	4.49	0.34	1.39e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs11853189	0.938	rs16969705	chr15:78593362	A/G	cg22935921	chr15:78556834	DNAJA4	0.77	5.21	0.39	6.04e-7	Red cell distribution width;
PAAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.66	10.07	0.63	1.4e-18	Body mass index;
PAAD	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.55	4.5	0.34	1.36e-5	Heschl's gyrus morphology;
PAAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.45	0.61	5.7e-17	Total body bone mineral density;
PAAD	cis	rs4740619	0.592	rs9407702	chr9:15984545	G/A	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.74	7.15	0.5	3.41e-11	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs508970	0.556	rs612822	chr11:60912840	C/T	cg24692310	chr11:60915630	VPS37C	0.35	4.89	0.37	2.53e-6	Rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13382707	chr1:161015776	USF1	0.58	6.32	0.46	2.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.69	6.64	0.47	5.12e-10	Lymphocyte counts;
PAAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.61	-0.35	8.5e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.62	8.06	0.55	2.03e-13	Rheumatoid arthritis;
PAAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg05110241	chr16:68378359	PRMT7	-0.9	-7.27	-0.51	1.76e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18648122	chr4:105412473	CXXC4	-0.58	-6.82	-0.48	1.99e-10	Body fat percentage;
PAAD	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.51	-4.87	-0.37	2.72e-6	Pancreatic cancer;
PAAD	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.9	7.13	0.5	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg04450456	chr4:17643702	FAM184B	0.47	5.06	0.38	1.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	9.56	0.61	3.04e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11051970	0.559	rs11051944	chr12:32485918	A/T	cg24626660	chr12:32551988	NA	0.42	4.3	0.33	3.03e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs60154123	0.881	rs1774107	chr1:210453923	C/T	cg23283495	chr1:209979779	IRF6	0.64	6.0	0.44	1.42e-8	Coronary artery disease;
PAAD	cis	rs6992820	0.528	rs6991618	chr8:56745631	G/A	cg08894788	chr8:56792171	LYN	-0.5	-4.49	-0.34	1.42e-5	Mean platelet volume;
PAAD	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg09226986	chr6:160852328	SLC22A3	-0.45	-4.33	-0.33	2.66e-5	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05563107	chr19:50528575	VRK3;ZNF473	0.67	7.8	0.53	9.22e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs539096	0.505	rs501861	chr1:44101440	T/A	cg12908607	chr1:44402522	ARTN	-0.41	-4.29	-0.33	3.21e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9913156	0.748	rs7215274	chr17:4561834	A/G	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg11972305	chr2:233791962	NGEF	-0.43	-4.47	-0.34	1.5e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28647808	1.000	rs7031883	chr9:136276519	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.6	-0.47	6.54e-10	Chronic sinus infection;
PAAD	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.12	0.55	1.48e-13	Monocyte percentage of white cells;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.6	7.43	0.52	7.26e-12	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61677309	1.000	rs1599809	chr11:118179200	G/A	cg15548380	chr1:19984784	NBL1	-0.62	-6.43	-0.46	1.57e-9	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.36	-0.33	2.41e-5	Life satisfaction;
PAAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg01320130	chr1:67600311	NA	0.53	5.33	0.4	3.42e-7	Psoriasis;
PAAD	cis	rs6681460	1.000	rs2147777	chr1:67129254	A/T	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.95e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs941024	0.651	rs117587508	chr12:56049545	C/A	cg20737382	chr12:56040096	NA	-0.76	-4.76	-0.36	4.5e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.87	10.53	0.65	8.04e-20	Methadone dose in opioid dependence;
PAAD	cis	rs4790333	0.813	rs2005029	chr17:2255138	G/T	cg02569219	chr17:2266849	SGSM2	-0.6	-5.7	-0.42	6.16e-8	Proinsulin levels;
PAAD	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs2279817	0.863	rs3766311	chr1:17978186	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.75	-6.4	-0.46	1.81e-9	Neuroticism;
PAAD	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg06217245	chr20:33103252	DYNLRB1	0.43	5.17	0.39	7.31e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg17182837	chr8:41585554	ANK1	-0.41	-4.49	-0.34	1.41e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08981282	chr16:2653240	LOC652276	-0.64	-6.59	-0.47	6.68e-10	Lung cancer in ever smokers;
PAAD	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.82	9.97	0.63	2.52e-18	Bladder cancer;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25102872	chr13:64386291	NA	-0.59	-7.11	-0.5	4.27e-11	Energy expenditure (24h);
PAAD	cis	rs1562242	0.500	rs37522	chr5:57576414	T/G	cg25655489	chr5:57484208	NA	0.33	4.29	0.33	3.16e-5	Educational attainment (years of education);
PAAD	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.82	-8.29	-0.56	5.63e-14	Corneal astigmatism;
PAAD	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg01942863	chr7:99769432	GPC2	0.49	4.57	0.35	9.92e-6	Coronary artery disease;
PAAD	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.82e-6	Personality dimensions;
PAAD	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	5.16	0.39	7.75e-7	Neuroticism;
PAAD	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.77	-7.45	-0.52	6.45e-12	Macular telangiectasia type 2;
PAAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg10207240	chr12:122356781	WDR66	-0.48	-4.98	-0.37	1.74e-6	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.73	-8.48	-0.57	1.82e-14	White blood cell count (basophil);
PAAD	cis	rs874426	0.528	rs7928986	chr11:19573108	C/G	cg13922121	chr11:19575262	NAV2	0.39	4.37	0.33	2.28e-5	Attention deficit hyperactivity disorder (time to onset);
PAAD	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.98	11.64	0.69	8.64e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.38	4.57	0.35	9.91e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.74	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.62	-5.17	-0.39	7.17e-7	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18978643	chr13:111165437	NA	-0.67	-6.32	-0.46	2.75e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.69	4.74	0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.7	-5.91	-0.43	2.14e-8	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg04160749	chr8:58172571	NA	-0.65	-4.49	-0.34	1.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-4.57	-0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.55	-5.17	-0.39	7.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2421770	1.000	rs2421770	chr11:35320880	G/C	cg13971030	chr11:35366721	SLC1A2	-0.54	-6.36	-0.46	2.27e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg07701084	chr6:150067640	NUP43	0.55	4.76	0.36	4.56e-6	Lung cancer;
PAAD	cis	rs73568641	0.583	rs73570675	chr6:154077590	T/A	cg15658985	chr6:154448740	OPRM1	0.55	4.57	0.35	1.01e-5	Methadone dose in opioid dependence;
PAAD	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg00543991	chr22:32367038	NA	1.21	7.39	0.51	9e-12	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23416307	chr4:858299	GAK	0.61	7.12	0.5	4.1e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20240601	chr1:11322805	MTOR	0.63	7.06	0.5	5.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg00280220	chr17:61926910	NA	0.46	4.77	0.36	4.24e-6	Prudent dietary pattern;
PAAD	cis	rs4740619	0.557	rs997410	chr9:16040430	A/G	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs17123764	0.710	rs11169118	chr12:50102535	C/T	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1358748	0.522	rs2144656	chr1:67579386	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs303386	0.501	rs4908303	chr1:99583230	C/T	cg03593336	chr1:99471295	LPPR5	-0.56	-5.41	-0.4	2.43e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs9907295	0.748	rs11868785	chr17:34139218	A/G	cg16983627	chr17:34238386	NA	-0.55	-4.48	-0.34	1.44e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.54	-6.33	-0.46	2.63e-9	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27229823	chr2:105858015	GPR45	-0.63	-6.41	-0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.76	-9.13	-0.6	3.92e-16	Blood pressure (smoking interaction);
PAAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.67	-0.35	6.5e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16854884	1.000	rs62269906	chr3:143808812	A/G	cg06585982	chr3:143692056	C3orf58	0.58	5.41	0.4	2.36e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.64	-5.57	-0.41	1.15e-7	Coronary artery disease;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.7	-7.82	-0.54	8.19e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.9	-10.22	-0.64	5.53e-19	Gut microbiome composition (winter);
PAAD	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg02958167	chr6:170151846	TCTE3;C6orf70	-0.71	-7.07	-0.5	5.4e-11	Body mass index;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10467557	chr13:21893662	NA	-0.42	-4.57	-0.35	9.87e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	1.0	6.34	0.46	2.44e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs89107	0.688	rs283087	chr6:118596207	C/T	cg21191810	chr6:118973309	C6orf204	0.44	5.99	0.44	1.47e-8	Cardiac structure and function;
PAAD	cis	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.8	9.04	0.59	6.77e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg01969543	chr11:61895209	INCENP	-0.49	-4.25	-0.33	3.67e-5	Breast cancer;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08677398	chr8:58056175	NA	0.58	4.5	0.34	1.36e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.6	0.61	2.3e-17	Bladder cancer;
PAAD	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg12315302	chr6:26189340	HIST1H4D	0.86	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.46	-4.48	-0.34	1.46e-5	Urinary tract infection frequency;
PAAD	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.47	5.03	0.38	1.37e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs10500871	0.804	rs11606812	chr11:20222719	A/T	cg02956962	chr6:161097311	NA	0.65	6.36	0.46	2.3e-9	Educational attainment;
PAAD	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg13695288	chr21:47294981	PCBP3	0.47	4.68	0.35	6.4e-6	Schizophrenia;
PAAD	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14180030	chr9:123475675	MEGF9	-0.41	-4.63	-0.35	7.79e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.92	-0.37	2.21e-6	Neuroticism;
PAAD	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22633769	chr20:60982531	CABLES2	0.53	4.91	0.37	2.28e-6	Colorectal cancer;
PAAD	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.65	0.35	7.12e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.85	-7.27	-0.51	1.76e-11	Blood pressure (smoking interaction);
PAAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13012494	chr21:47604986	C21orf56	0.48	5.03	0.38	1.35e-6	Testicular germ cell tumor;
PAAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	7.89	0.54	5.68e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.0	11.83	0.69	2.62e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-6.45	-0.46	1.38e-9	Triglycerides;
PAAD	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs11671653	1.000	rs59715646	chr19:10839447	G/A	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs7274811	0.516	rs3213141	chr20:32274380	G/A	cg21523528	chr20:32077966	CBFA2T2	0.62	4.84	0.37	3.12e-6	Height;
PAAD	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.81	7.37	0.51	1.01e-11	Psoriasis;
PAAD	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.55	5.39	0.4	2.62e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08219700	chr8:58056026	NA	0.7	5.28	0.39	4.43e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg03522150	chr11:46969673	C11orf49	0.44	5.27	0.39	4.56e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.79	-0.42	3.96e-8	Androgen levels;
PAAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.72	-0.42	5.42e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-7.89	-0.54	5.62e-13	Chronic sinus infection;
PAAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.57e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6137287	0.924	rs6035808	chr20:21157565	T/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.12	0.59	4.33e-16	Menopause (age at onset);
PAAD	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg03938978	chr2:103052716	IL18RAP	0.63	4.42	0.34	1.86e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06850241	chr22:41845214	NA	-0.54	-5.16	-0.39	7.58e-7	Vitiligo;
PAAD	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.63	6.19	0.45	5.36e-9	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14351634	chr17:7590742	WRAP53;TP53	-0.71	-6.55	-0.47	8.34e-10	Neuroticism;
PAAD	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs3026101	0.671	rs9789012	chr17:5301070	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.45	6.22	0.45	4.67e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19419581	chr17:79482410	NA	0.62	6.96	0.49	9.52e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07936541	chr2:98206095	ANKRD36B	0.64	7.37	0.51	1.02e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg18518183	chr2:172544446	DYNC1I2	0.5	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.9	6.05	0.44	1.07e-8	Diabetic kidney disease;
PAAD	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg11650704	chr1:154556575	ADAR	-0.39	-4.27	-0.33	3.43e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12136530	0.593	rs9287047	chr1:19736534	T/C	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.54	5.41	0.4	2.38e-7	Pulmonary function;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.61	0.53	2.69e-12	Prudent dietary pattern;
PAAD	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg20893579	chr22:38215064	NA	-0.47	-4.7	-0.36	5.86e-6	Glioblastoma;Glioma;
PAAD	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.6	-5.35	-0.4	3.11e-7	Renal function-related traits (BUN);
PAAD	cis	rs1035491	0.715	rs4116460	chr5:63919981	C/T	cg01791865	chr5:63954708	NA	0.52	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Urinary tract infection frequency;
PAAD	cis	rs4479964	1.000	rs4479964	chr6:129971544	A/G	cg12774946	chr6:129966801	ARHGAP18	-0.35	-4.95	-0.37	1.95e-6	Gut microbiome composition (summer);
PAAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.4	0.46	1.83e-9	Personality dimensions;
PAAD	cis	rs4780401	0.703	rs12921129	chr16:11769176	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.9	-0.43	2.27e-8	Rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09755102	chr1:33283495	S100PBP;YARS	0.6	6.69	0.48	4.09e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.03	-12.74	-0.72	9.51e-26	Schizophrenia;
PAAD	cis	rs17407555	0.909	rs73222546	chr4:10244074	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.6	-0.35	8.91e-6	Schizophrenia (age at onset);
PAAD	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.32	-0.33	2.82e-5	Ulcerative colitis;
PAAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.41	-4.88	-0.37	2.63e-6	Height;
PAAD	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-4.54	-0.35	1.14e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.85	8.65	0.57	6.96e-15	Prostate cancer;
PAAD	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg13263323	chr15:86062960	AKAP13	-0.65	-7.41	-0.52	8.22e-12	Interstitial lung disease;
PAAD	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.55	-0.35	1.09e-5	Height;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.39	-5.77	-0.42	4.34e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.52	4.97	0.37	1.81e-6	Mortality in heart failure;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.8	8.27	0.56	6.1e-14	Height;
PAAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.6	-4.8	-0.36	3.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg09695851	chr17:3907499	NA	0.61	6.06	0.44	1.03e-8	Type 2 diabetes;
PAAD	cis	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg22101045	chr11:47927509	NA	0.57	4.29	0.33	3.11e-5	Intraocular pressure;
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.47e-9	Hypospadias;
PAAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.81	-8.29	-0.56	5.56e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.64	-8.08	-0.55	1.83e-13	Body mass index;
PAAD	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-6.63	-0.47	5.41e-10	Blood trace element (Zn levels);
PAAD	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.41	-4.25	-0.33	3.69e-5	Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14461570	chr2:170683907	UBR3	0.64	7.14	0.5	3.7e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg08676812	chr11:65308423	LTBP3	1.55	8.0	0.54	2.88e-13	Height;
PAAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.59	6.26	0.45	3.7e-9	Melanoma;
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.27	-0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg03517284	chr6:25882590	NA	0.52	4.94	0.37	2.02e-6	Blood metabolite levels;
PAAD	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg23024343	chr7:107201750	COG5	0.55	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.72	-6.66	-0.48	4.76e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg19980929	chr12:42632907	YAF2	0.58	6.99	0.49	8.06e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8063160	0.621	rs12925026	chr16:89792856	C/T	cg07984980	chr16:89898383	SPIRE2	0.92	4.91	0.37	2.33e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.79	9.96	0.63	2.62e-18	Vitiligo;
PAAD	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs4756864	0.554	rs7943587	chr11:16814631	G/T	cg19428160	chr11:17761718	KCNC1	-0.51	-4.83	-0.37	3.25e-6	Systolic blood pressure change trajectories;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg08219700	chr8:58056026	NA	0.67	5.19	0.39	6.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs654384	0.507	rs2342505	chr7:4175710	C/T	cg20359426	chr7:4789676	FOXK1	-0.52	-4.73	-0.36	5.17e-6	Positive affect;
PAAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg02023728	chr11:77925099	USP35	0.55	5.9	0.43	2.29e-8	Testicular germ cell tumor;
PAAD	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.41	0.34	1.97e-5	Lung cancer;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.82	9.63	0.62	1.92e-17	Blood metabolite ratios;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-5.82	-0.43	3.39e-8	Longevity;Endometriosis;
PAAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	1.07	5.83	0.43	3.17e-8	Body mass index;
PAAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.76	7.53	0.52	4.14e-12	Tuberculosis;
PAAD	cis	rs71636778	0.722	rs34502618	chr1:27094156	A/G	cg12203394	chr1:27248618	NUDC	0.62	4.39	0.34	2.15e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07648498	chr16:89883185	FANCA	0.7	7.34	0.51	1.23e-11	Vitiligo;
PAAD	cis	rs4427176	0.825	rs4841205	chr8:9583584	T/C	cg03024720	chr8:9765601	NA	0.48	4.61	0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs11811982	0.793	rs11801282	chr1:227402910	G/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg21300403	chr2:198650112	BOLL	0.5	4.43	0.34	1.79e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.38	-0.4	2.7e-7	Glaucoma (primary open-angle);
PAAD	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.51	4.98	0.37	1.72e-6	Longevity;
PAAD	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.16	-0.64	7.76e-19	Response to antipsychotic treatment;
PAAD	cis	rs12519773	0.641	rs4489042	chr5:92428154	G/C	cg18783429	chr5:92414398	NA	0.42	5.96	0.44	1.65e-8	Migraine;
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.6	9.57	0.61	2.91e-17	IgG glycosylation;
PAAD	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg13859433	chr6:33739653	LEMD2	0.67	4.5	0.34	1.32e-5	Schizophrenia;
PAAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.35	0.33	2.49e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15929587	chr14:24701962	GMPR2;NEDD8	-0.75	-6.45	-0.46	1.43e-9	Neuroticism;
PAAD	cis	rs12940923	0.554	rs12600886	chr17:56388683	C/T	cg26072851	chr17:56296444	MKS1	-0.57	-4.9	-0.37	2.46e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs16975963	0.843	rs3848624	chr19:38262816	C/T	cg14218481	chr19:38281219	NA	0.44	4.6	0.35	8.92e-6	Longevity;
PAAD	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.98	11.8	0.69	3.28e-23	Breast cancer;
PAAD	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg06553033	chr12:53270239	NA	0.47	4.65	0.35	7.16e-6	Cancer (pleiotropy);
PAAD	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.05	-0.38	1.22e-6	Pulmonary function;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.48	-0.34	1.48e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.84	0.49	1.79e-10	Chronic sinus infection;
PAAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.08	0.67	2.7e-21	Homoarginine levels;
PAAD	cis	rs7945718	0.591	rs4515952	chr11:12690200	G/A	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.35	0.56	3.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17209837	1.000	rs67721532	chr7:87084403	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-4.96	-0.37	1.85e-6	Gallbladder cancer;
PAAD	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs10242455	0.702	rs73713580	chr7:99241610	C/T	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	cis	rs12311304	0.965	rs17835113	chr12:15369665	G/A	cg08258403	chr12:15378311	NA	0.35	4.41	0.34	1.94e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.6	5.82	0.43	3.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.55	-5.67	-0.42	6.99e-8	Iron status biomarkers;
PAAD	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.45	-4.44	-0.34	1.69e-5	Type 2 diabetes;
PAAD	cis	rs6942407	0.546	rs7810647	chr7:86805961	C/A	cg02420886	chr7:86849541	C7orf23	0.65	5.02	0.38	1.45e-6	Food allergy;
PAAD	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.49	-4.69	-0.36	6.1e-6	Menarche (age at onset);
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.49	5.68	0.42	6.56e-8	Coronary artery disease;
PAAD	cis	rs2859741	0.608	rs480411	chr1:37476077	T/C	cg09363841	chr1:37513479	NA	-0.57	-6.85	-0.49	1.7e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.77	-7.95	-0.54	3.89e-13	Hypertriglyceridemia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27320666	chr6:160885486	NA	-0.5	-6.41	-0.46	1.75e-9	Energy expenditure (24h);
PAAD	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.5	-4.81	-0.36	3.61e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg08493051	chr2:3487164	NA	0.63	5.81	0.43	3.51e-8	Neurofibrillary tangles;
PAAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	6.45	0.46	1.4e-9	Initial pursuit acceleration;
PAAD	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.62	-6.14	-0.45	7.04e-9	Systemic sclerosis;
PAAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.63	-0.35	7.89e-6	Alcohol dependence;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.87e-10	Lymphocyte counts;
PAAD	cis	rs914615	0.552	rs4971089	chr1:155142927	A/G	cg18645493	chr1:154167437	MIR190B	0.46	4.52	0.34	1.25e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-5.62	-0.41	8.87e-8	Monocyte count;
PAAD	cis	rs4140564	0.667	rs10911915	chr1:186698224	A/C	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.17e-10	Lymphocyte counts;
PAAD	cis	rs4720118	0.563	rs117843593	chr7:33205474	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.56	-4.89	-0.37	2.58e-6	Leprosy;
PAAD	cis	rs375066	0.935	rs417699	chr19:44417575	A/G	cg21496419	chr19:44306685	LYPD5	0.36	4.33	0.33	2.66e-5	Breast cancer;
PAAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.58	0.61	2.62e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.69	5.0	0.38	1.56e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg09386050	chr7:809078	HEATR2	-0.67	-7.14	-0.5	3.63e-11	Subjective well-being;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.51	5.35	0.4	3.19e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.63	0.57	7.86e-15	Monocyte percentage of white cells;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.87	-7.28	-0.51	1.69e-11	Initial pursuit acceleration;
PAAD	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.29	-5.48	-0.41	1.77e-7	Urinary metabolites;
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15040075	chr2:232379222	C2orf52	0.66	6.41	0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	4.28	0.33	3.27e-5	Menopause (age at onset);
PAAD	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg12661370	chr5:149340060	SLC26A2	0.64	5.39	0.4	2.65e-7	HIV-1 control;
PAAD	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg06096015	chr1:231504339	EGLN1	-0.68	-9.07	-0.59	5.77e-16	Hemoglobin concentration;
PAAD	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.85	8.8	0.58	2.82e-15	Corneal astigmatism;
PAAD	cis	rs797680	0.820	rs11164879	chr1:93655522	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg06899799	chr12:56650233	ANKRD52	-0.35	-4.61	-0.35	8.45e-6	Cancer;
PAAD	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg19442545	chr10:75533431	FUT11	-0.51	-5.33	-0.4	3.57e-7	Inflammatory bowel disease;
PAAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.55	5.5	0.41	1.61e-7	Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg24253500	chr15:84953950	NA	0.43	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.25	-0.39	4.98e-7	Aortic root size;
PAAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.17	16.69	0.8	3.38e-36	Cognitive function;
PAAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.53	-4.83	-0.36	3.36e-6	Asthma;
PAAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs9467160	1.000	rs9461011	chr6:24440351	C/T	cg16211469	chr6:24423932	MRS2	-0.54	-5.52	-0.41	1.44e-7	Liver enzyme levels;
PAAD	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01200585	chr1:228362443	C1orf69	-0.49	-5.54	-0.41	1.31e-7	Diastolic blood pressure;
PAAD	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg26031613	chr14:104095156	KLC1	-0.55	-5.47	-0.41	1.84e-7	Reticulocyte count;
PAAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.73	7.12	0.5	3.98e-11	Recombination rate (males);
PAAD	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg21890820	chr11:65308645	LTBP3	0.98	7.86	0.54	6.37e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.98	-10.13	-0.63	9.42e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.78	8.4	0.56	2.94e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs113123495	0.609	rs2485275	chr19:5636672	A/T	cg26242866	chr19:5711310	LONP1	1.07	5.27	0.39	4.67e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.65	-5.45	-0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.76	-8.87	-0.58	1.81e-15	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	6.36	0.46	2.28e-9	Myopia (pathological);
PAAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg08562672	chr19:21860753	NA	-0.49	-5.13	-0.38	8.7e-7	Pain;
PAAD	cis	rs3733418	0.799	rs13151735	chr4:165932516	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.56	-5.14	-0.38	8.35e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.15	0.39	8.12e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-8.96	-0.59	1.11e-15	Mean platelet volume;
PAAD	cis	rs8060686	0.920	rs67114979	chr16:67691645	G/T	cg27539214	chr16:67997921	SLC12A4	-0.75	-4.54	-0.35	1.16e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg08999081	chr20:33150536	PIGU	0.49	5.28	0.39	4.3e-7	Height;
PAAD	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.77	-9.19	-0.6	2.83e-16	White blood cell count (basophil);
PAAD	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg16766828	chr3:128327626	NA	-0.48	-6.59	-0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg00988841	chr10:134556463	INPP5A	0.48	4.34	0.33	2.57e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.55	-6.07	-0.44	9.95e-9	IgG glycosylation;
PAAD	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.46	-4.26	-0.33	3.63e-5	Testicular germ cell tumor;
PAAD	cis	rs62025270	0.688	rs7179917	chr15:86265644	G/A	cg13263323	chr15:86062960	AKAP13	0.49	4.39	0.34	2.13e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.74	-0.36	4.95e-6	Asthma;
PAAD	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.77	5.44	0.4	2.08e-7	Migraine;Coronary artery disease;
PAAD	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	5.01	0.38	1.49e-6	Parkinson's disease;
PAAD	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.08	-7.97	-0.54	3.48e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.65	-5.99	-0.44	1.46e-8	Exhaled nitric oxide output;
PAAD	cis	rs7092929	0.883	rs705458	chr10:3611415	C/T	cg14308648	chr10:3568949	NA	-0.67	-4.82	-0.36	3.52e-6	Coronary artery calcification;
PAAD	cis	rs6545883	0.839	rs778764	chr2:61785680	C/T	cg14146966	chr2:61757674	XPO1	0.37	4.46	0.34	1.58e-5	Tuberculosis;
PAAD	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg20821713	chr7:1055600	C7orf50	-0.54	-4.41	-0.34	1.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg14393609	chr7:65229607	NA	0.46	4.68	0.35	6.43e-6	Aortic root size;
PAAD	cis	rs58521262	0.585	rs2081175	chr19:23194463	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.44	-6.53	-0.47	9.45e-10	Breast cancer;
PAAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg10729496	chr3:10149963	C3orf24	0.85	7.05	0.5	5.8e-11	Alzheimer's disease;
PAAD	cis	rs7714584	0.793	rs11955174	chr5:150254391	T/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.98	12.92	0.72	3.08e-26	Menarche (age at onset);
PAAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg02734326	chr4:10020555	SLC2A9	0.49	4.88	0.37	2.61e-6	Bone mineral density;
PAAD	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-5.74	-0.42	5.05e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06668844	chr19:35521630	SCN1B	0.59	6.59	0.47	6.93e-10	Monocyte percentage of white cells;
PAAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.06	-15.16	-0.78	3.21e-32	Multiple system atrophy;
PAAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.09	0.44	8.8e-9	Tonsillectomy;
PAAD	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg23248424	chr5:179741104	GFPT2	0.48	4.37	0.33	2.32e-5	TRAIL levels;
PAAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg03037974	chr15:76606532	NA	0.58	6.97	0.49	8.97e-11	Blood metabolite levels;
PAAD	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.79	-8.94	-0.59	1.2e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs597583	0.951	rs579239	chr11:117425009	T/C	cg27161313	chr11:117392002	DSCAML1	-0.48	-4.46	-0.34	1.62e-5	Putamen volume;
PAAD	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	1.89	10.8	0.66	1.54e-20	Cannabis dependence symptom count;
PAAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09256517	chr2:42396442	EML4	-0.63	-6.34	-0.46	2.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg08057985	chr22:42470123	FAM109B	0.36	4.33	0.33	2.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3809060	0.878	rs66798575	chr11:32451920	T/G	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg23024343	chr7:107201750	COG5	0.56	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.35	-0.46	2.42e-9	Hip circumference;
PAAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.69e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.43	-4.49	-0.34	1.41e-5	Bipolar disorder;
PAAD	cis	rs863345	0.535	rs12068285	chr1:158499632	G/A	cg12129480	chr1:158549410	OR10X1	-0.41	-4.66	-0.35	6.74e-6	Pneumococcal bacteremia;
PAAD	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.43	5.5	0.41	1.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg05785598	chr3:49045655	WDR6	0.42	4.93	0.37	2.12e-6	Parkinson's disease;
PAAD	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg24519413	chr1:26490540	NA	0.49	4.59	0.35	9.24e-6	QRS complex (12-leadsum);
PAAD	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.91	-0.37	2.34e-6	Body mass index;
PAAD	cis	rs288342	0.832	rs13509	chr2:183642878	G/A	cg02625481	chr2:183667124	NA	-0.46	-4.57	-0.35	9.92e-6	Recurrent major depressive disorder;
PAAD	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.82	-5.02	-0.38	1.43e-6	Alzheimer's disease (late onset);
PAAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	4.6	0.35	8.88e-6	Height;
PAAD	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs6921919	0.789	rs17301128	chr6:28308034	C/G	cg23153227	chr6:27725408	NA	0.55	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg23119463	chr10:134592391	INPP5A	-0.47	-4.32	-0.33	2.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs12760731	0.720	rs10913560	chr1:178452629	A/G	cg00404053	chr1:178313656	RASAL2	0.66	4.8	0.36	3.7e-6	Obesity-related traits;
PAAD	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg14343924	chr8:8086146	FLJ10661	0.48	4.33	0.33	2.73e-5	Systolic blood pressure;
PAAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.77	-0.36	4.26e-6	Aortic root size;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-5.0	-0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.69	7.52	0.52	4.54e-12	Prudent dietary pattern;
PAAD	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg23688817	chr7:87105293	ABCB4	0.56	4.66	0.35	6.95e-6	Gallbladder cancer;
PAAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.56	5.18	0.39	6.88e-7	Mood instability;
PAAD	cis	rs2327429	0.858	rs17062991	chr6:134193910	G/A	cg06296503	chr6:134217401	NA	0.48	4.93	0.37	2.16e-6	Coronary artery disease;
PAAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.11	-0.38	9.59e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg07423050	chr13:99094983	FARP1	0.38	4.36	0.33	2.41e-5	Longevity;
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.52e-8	Body mass index;
PAAD	cis	rs6449502	0.702	rs4700398	chr5:60135985	A/G	cg27085488	chr5:60541865	NA	-0.34	-4.25	-0.33	3.71e-5	Mean platelet volume;
PAAD	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.52	-4.76	-0.36	4.57e-6	Mean corpuscular volume;
PAAD	cis	rs72960926	0.744	rs16884624	chr6:74998293	G/C	cg03266952	chr6:74778945	NA	-1.04	-5.94	-0.43	1.91e-8	Metabolite levels (MHPG);
PAAD	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.19	-0.5	2.72e-11	Breast cancer;
PAAD	cis	rs427941	0.632	rs201508	chr7:101764199	T/G	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08893839	chr5:154027129	NA	-0.8	-6.48	-0.47	1.21e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.75	9.61	0.61	2.21e-17	Cardiovascular disease risk factors;
PAAD	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs2281680	1.000	rs2281680	chr14:24033070	C/T	cg11891504	chr14:23425909	HAUS4	0.65	4.58	0.35	9.44e-6	Sudden cardiac arrest;
PAAD	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19671926	chr4:122722719	EXOSC9	0.59	5.72	0.42	5.55e-8	Type 2 diabetes;
PAAD	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg00750074	chr16:89608354	SPG7	0.49	4.66	0.35	6.75e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.22	0.55	8.14e-14	Alzheimer's disease;
PAAD	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02037518	chr11:57283212	SLC43A1	-0.69	-7.44	-0.52	7.1e-12	Smoking initiation;
PAAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	4.99e-6	Coronary artery disease;
PAAD	cis	rs501120	1.000	rs607363	chr10:44761623	A/G	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.08	-0.38	1.09e-6	Interstitial lung disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01683948	chr16:4784196	ANKS3;C16orf71	0.65	7.34	0.51	1.21e-11	Monocyte percentage of white cells;
PAAD	cis	rs11951515	0.508	rs7706431	chr5:43582423	C/T	cg01983248	chr5:43482804	C5orf28	-0.3	-4.29	-0.33	3.14e-5	Metabolite levels  (X-11787);
PAAD	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg16083429	chr3:49237500	CCDC36	0.46	4.39	0.34	2.12e-5	Menarche (age at onset);
PAAD	cis	rs10140922	0.966	rs762010	chr14:35816665	C/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-4.94	-0.37	2e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.54	5.22	0.39	5.66e-7	Essential tremor;
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16083429	chr3:49237500	CCDC36	-0.43	-4.57	-0.35	1.02e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02244288	chr16:89573955	SPG7	-0.33	-4.33	-0.33	2.69e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.42	-5.6	-0.41	9.77e-8	Prostate cancer;
PAAD	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.61	5.24	0.39	5.35e-7	Common traits (Other);
PAAD	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06850241	chr22:41845214	NA	0.58	5.12	0.38	9.16e-7	Vitiligo;
PAAD	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg21823605	chr1:152486609	CRCT1	0.5	6.36	0.46	2.28e-9	Hair morphology;
PAAD	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg08807101	chr21:30365312	RNF160	0.62	5.12	0.38	8.97e-7	Cognitive test performance;
PAAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg18769074	chr3:133464867	TF	-0.46	-5.61	-0.41	9.29e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg10818794	chr15:86012489	AKAP13	-0.46	-5.05	-0.38	1.23e-6	Interstitial lung disease;
PAAD	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.65	5.32	0.4	3.68e-7	Response to antidepressants in depression;
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-4.42	-0.34	1.87e-5	Tonsillectomy;
PAAD	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.52	5.34	0.4	3.3e-7	Interleukin-18 levels;
PAAD	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.67	9.74	0.62	1.04e-17	Airflow obstruction;
PAAD	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs427941	1.000	rs427941	chr7:101882095	C/T	cg06721601	chr7:101762633	CUX1	-0.44	-4.49	-0.34	1.38e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22509189	chr2:225307070	NA	-0.51	-4.97	-0.37	1.82e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg02056144	chr12:54070517	ATP5G2	-0.51	-5.54	-0.41	1.3e-7	Height;
PAAD	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg24262691	chr11:75473276	NA	0.74	6.1	0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10821973	0.527	rs10733771	chr10:63982434	A/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.53	4.97	0.37	1.81e-6	Uric acid clearance;
PAAD	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.71	6.48	0.47	1.19e-9	Platelet count;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06437144	chr17:45973627	SP2	0.55	6.43	0.46	1.54e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.62	6.14	0.45	6.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.7	6.56	0.47	7.93e-10	Uric acid levels;
PAAD	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.72	0.62	1.17e-17	Total body bone mineral density;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.49	6.69	0.48	3.96e-10	Life satisfaction;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.32	-0.33	2.78e-5	Joint mobility (Beighton score);
PAAD	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg21419209	chr3:44054225	NA	-0.73	-7.51	-0.52	4.66e-12	Coronary artery disease;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs11811982	0.793	rs11803919	chr1:227228955	G/A	cg24860534	chr1:227506868	CDC42BPA	0.47	4.65	0.35	7.24e-6	Optic disc area;
PAAD	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg06197492	chr11:2016605	H19	0.52	5.88	0.43	2.53e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg19090574	chr1:205240910	TMCC2	-0.42	-4.53	-0.34	1.18e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.62	-8.26	-0.56	6.75e-14	Renal cell carcinoma;
PAAD	cis	rs13011075	0.535	rs115662925	chr2:68626631	T/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17226575	chr8:90914282	OSGIN2	0.57	6.45	0.46	1.38e-9	Metabolite levels  (X-11787);
PAAD	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.69	-7.5	-0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.59	-7.57	-0.52	3.31e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.56	5.35	0.4	3.13e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-6.36	-0.46	2.23e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.67	6.54	0.47	8.66e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg27234864	chr13:21295941	IL17D	0.61	5.28	0.39	4.48e-7	Dental caries;
PAAD	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.62	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.05e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.4	4.5	0.34	1.35e-5	High light scatter reticulocyte count;
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.24	-0.51	2.12e-11	Longevity;
PAAD	cis	rs10045504	0.502	rs10512692	chr5:38762993	G/A	cg15396434	chr5:38725168	NA	-0.87	-6.17	-0.45	5.9e-9	Night sleep phenotypes;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.75	7.63	0.53	2.34e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.28	-0.51	1.71e-11	Colorectal cancer;
PAAD	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-5.65	-0.42	7.86e-8	Asthma;
PAAD	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg08601574	chr20:25228251	PYGB	0.49	5.0	0.38	1.59e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs59888335	0.964	rs67817674	chr3:80684440	A/T	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09835421	chr16:68378352	PRMT7	-1.19	-8.53	-0.57	1.34e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6741892	0.793	rs13005073	chr2:38903899	C/T	cg05275752	chr2:38892887	GALM	-0.68	-4.25	-0.33	3.73e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.64	-7.85	-0.54	6.95e-13	Schizophrenia;
PAAD	cis	rs3106136	0.564	rs77055143	chr4:95064162	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.85	-0.37	3.05e-6	Capecitabine sensitivity;
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg00450029	chr8:599525	NA	0.79	5.21	0.39	5.92e-7	IgG glycosylation;
PAAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.74	-8.34	-0.56	4.1e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	4.37	0.33	2.26e-5	Schizophrenia;
PAAD	cis	rs9815354	0.638	rs17284933	chr3:42029835	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6700896	0.500	rs11208692	chr1:66107946	A/C	cg04111102	chr1:66153794	NA	0.48	4.55	0.35	1.09e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs6537837	1.000	rs7537507	chr1:110131105	G/A	cg05049280	chr1:110155535	GNAT2	0.44	4.4	0.34	2.05e-5	Major depressive disorder;
PAAD	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.58	-5.16	-0.39	7.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg08219700	chr8:58056026	NA	0.67	5.19	0.39	6.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.71	-0.36	5.54e-6	Height;
PAAD	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.51	4.77	0.36	4.22e-6	Self-reported allergy;
PAAD	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg19486271	chr11:47235900	DDB2	-0.58	-5.87	-0.43	2.61e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs7713065	1.000	rs3857440	chr5:131794069	C/T	cg14196790	chr5:131705035	SLC22A5	-0.53	-5.77	-0.42	4.38e-8	Lung function (FEV1/FVC);
PAAD	cis	rs8133932	0.598	rs753092	chr21:47293521	C/A	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs2290419	0.730	rs79092605	chr11:68943613	A/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.98	15.45	0.78	5.6e-33	Prudent dietary pattern;
PAAD	cis	rs1030877	0.824	rs2576738	chr2:105891644	C/A	cg02079111	chr2:105885981	TGFBRAP1	0.75	7.8	0.53	9.27e-13	Obesity-related traits;
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.69	7.68	0.53	1.84e-12	Mean corpuscular volume;
PAAD	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.48	7.09	0.5	4.81e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg23358612	chr7:1275258	UNCX	-0.42	-4.69	-0.36	6e-6	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
PAAD	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	0.88	5.26	0.39	4.86e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs3096299	0.754	rs3096320	chr16:89403057	C/A	cg00750074	chr16:89608354	SPG7	-0.53	-4.8	-0.36	3.8e-6	Multiple myeloma (IgH translocation);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06659057	chr2:8825907	NA	0.59	6.55	0.47	8.36e-10	Monocyte percentage of white cells;
PAAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.62	6.09	0.44	8.66e-9	Blood protein levels;
PAAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.67	-6.46	-0.46	1.35e-9	Blood metabolite levels;
PAAD	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	1.1	9.83	0.62	5.77e-18	Orofacial clefts;
PAAD	cis	rs6009527	0.963	rs6009532	chr22:49572757	C/G	cg12746016	chr22:49560550	NA	0.49	4.96	0.37	1.83e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs8105895	0.935	rs10407250	chr19:22238151	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.65	0.57	6.71e-15	Menarche (age at onset);
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.04	-0.38	1.33e-6	Vitiligo;
PAAD	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-6.06	-0.44	1.02e-8	Eye color traits;
PAAD	trans	rs11794666	0.872	rs72717577	chr9:31720712	T/C	cg05628366	chr6:35744188	C6orf126	0.95	6.29	0.45	3.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	5.5	0.41	1.54e-7	Mood instability;
PAAD	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg26876637	chr1:152193138	HRNR	-0.83	-6.07	-0.44	9.8e-9	Atopic dermatitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20486294	chr6:143266300	HIVEP2	0.61	6.44	0.46	1.47e-9	Obesity-related traits;
PAAD	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg05085585	chr16:30420623	ZNF771	-0.44	-4.46	-0.34	1.59e-5	Tonsillectomy;
PAAD	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.9	7.19	0.5	2.75e-11	Chronic kidney disease;
PAAD	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.18	0.5	2.92e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg21191810	chr6:118973309	C6orf204	-0.52	-5.08	-0.38	1.1e-6	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21186775	chr2:173941045	ZAK	0.65	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg26149184	chr10:133730230	NA	0.8	7.02	0.49	6.95e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg19337854	chr7:99768885	GPC2	-0.51	-5.24	-0.39	5.37e-7	Coronary artery disease;
PAAD	cis	rs2384207	0.818	rs3815889	chr12:113722758	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.61	5.06	0.38	1.22e-6	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.85	-9.4	-0.61	8.04e-17	Obesity-related traits;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg10025462	chr17:27046956	SNORD42B;RPL23A	-0.61	-6.3	-0.46	3.07e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg12215294	chr3:40350768	EIF1B	0.49	4.73	0.36	5.16e-6	Renal cell carcinoma;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs959260	0.588	rs8079197	chr17:73316679	G/C	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.85	-10.6	-0.65	5.31e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3996993	0.597	rs62412901	chr6:52724949	G/A	cg00536792	chr6:53530503	KLHL31	-0.42	-4.43	-0.34	1.8e-5	Hemoglobin concentration;
PAAD	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-16.22	-0.8	5.75e-35	Schizophrenia;
PAAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.47	5.06	0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.34	-0.46	2.47e-9	Hip circumference;
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.48	5.17	0.39	7.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs73196974	chr3:128449006	A/C	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs80346118	0.673	rs750085	chr20:47415898	T/C	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.59	-4.48	-0.34	1.45e-5	Diastolic blood pressure;
PAAD	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.4	-0.34	1.99e-5	Tuberculosis;
PAAD	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-4.83	-0.36	3.29e-6	Vitiligo;
PAAD	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs12714314	0.830	rs12612812	chr2:1962131	A/C	cg17170872	chr1:91487911	ZNF644	-0.73	-6.4	-0.46	1.83e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg07469887	chr10:131262384	NA	-0.41	-4.65	-0.35	7.19e-6	Response to temozolomide;
PAAD	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg02776659	chr21:47717406	C21orf57	-0.45	-4.82	-0.36	3.46e-6	Testicular germ cell tumor;
PAAD	cis	rs728616	0.681	rs55838345	chr10:82085120	G/C	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs2997447	0.653	rs2802329	chr1:26466189	T/C	cg24519413	chr1:26490540	NA	0.55	4.9	0.37	2.38e-6	QRS complex (12-leadsum);
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.86	0.58	1.98e-15	Bipolar disorder;
PAAD	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.16	0.5	3.29e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12667521	chr19:29218732	NA	0.75	7.05	0.5	5.74e-11	Methadone dose in opioid dependence;
PAAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-5.6	-0.41	9.86e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6028335	0.610	rs28578430	chr20:37542467	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.99	-0.37	1.67e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg19486271	chr11:47235900	DDB2	0.6	6.07	0.44	9.62e-9	Bone mineral density (hip);Bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26907351	chr6:2765585	WRNIP1	0.62	6.57	0.47	7.58e-10	Myopia (pathological);
PAAD	cis	rs12753920	0.816	rs12406749	chr1:92695398	G/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.45	-4.38	-0.34	2.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.72	-0.42	5.56e-8	P wave terminal force;
PAAD	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.66	5.28	0.39	4.49e-7	Prostate cancer;
PAAD	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.57	5.58	0.41	1.09e-7	Asthma;
PAAD	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.5	-4.77	-0.36	4.31e-6	Crohn's disease;
PAAD	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.03	0.38	1.36e-6	Mean platelet volume;
PAAD	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.48	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11245990	chr11:68621969	NA	0.38	4.99	0.37	1.65e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.67	-6.42	-0.46	1.61e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.55	-4.83	-0.37	3.24e-6	Squamous cell lung carcinoma;
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.44	0.4	2.04e-7	Bipolar disorder;
PAAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg13722127	chr7:150037890	RARRES2	0.66	6.94	0.49	1.08e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6694270	1.000	rs12139558	chr1:19121246	G/A	cg26220594	chr1:19110978	NA	-0.64	-5.33	-0.4	3.49e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.81	7.85	0.54	7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs111342015	0.881	rs111492053	chr6:43217239	G/C	cg18683047	chr6:43424751	DLK2	0.78	4.3	0.33	3.04e-5	Breast cancer;
PAAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.7	-8.07	-0.55	1.99e-13	Diastolic blood pressure;
PAAD	cis	rs17155006	0.746	rs370495	chr7:107746246	T/C	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.76	9.41	0.61	7.23e-17	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	10.22	0.64	5.53e-19	Monocyte percentage of white cells;
PAAD	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs11641365	0.651	rs2879902	chr16:88778133	C/A	cg06988897	chr16:88803803	FAM38A	0.44	4.5	0.34	1.33e-5	Autism spectrum disorder-related traits;
PAAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.96	-11.68	-0.69	6.7e-23	Height;
PAAD	trans	rs901683	1.000	rs35049879	chr10:46081744	C/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg19640517	chr22:41707109	ZC3H7B	0.5	4.26	0.33	3.53e-5	Vitiligo;
PAAD	cis	rs7112043	1.000	rs7112043	chr11:34789386	A/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.4	0.34	2.04e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3540	1.000	rs3540	chr15:91045408	G/A	cg22089800	chr15:90895588	ZNF774	0.54	5.12	0.38	9.06e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09275406	chr1:62786082	KANK4	-0.68	-7.24	-0.51	2.11e-11	Obesity-related traits;
PAAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg15448220	chr1:150897856	SETDB1	-0.64	-6.62	-0.47	5.69e-10	Tonsillectomy;
PAAD	cis	rs8049634	0.732	rs2303243	chr16:84230500	A/C	cg00961177	chr16:84213833	TAF1C	-0.43	-4.4	-0.34	2.04e-5	Small cell lung carcinoma;
PAAD	cis	rs3018712	0.553	rs2097042	chr11:68450314	C/T	cg23009355	chr11:68451396	GAL	-0.53	-5.76	-0.42	4.47e-8	Total body bone mineral density;
PAAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	Trans fatty acid levels;
PAAD	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg01851573	chr8:8652454	MFHAS1	-0.51	-5.37	-0.4	2.95e-7	Parkinson's disease;
PAAD	cis	rs1476670	0.683	rs2057967	chr1:44515446	T/C	cg09470012	chr1:44509516	NA	0.48	4.67	0.35	6.66e-6	Eotaxin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05085101	chr17:4890696	CAMTA2	0.62	7.32	0.51	1.38e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg03568305	chr17:38183559	MED24;SNORD124	-0.45	-5.95	-0.43	1.78e-8	Myeloid white cell count;
PAAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.57	-5.38	-0.4	2.72e-7	Monocyte count;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg08835956	chr7:39171034	POU6F2	0.32	5.7	0.42	6.17e-8	IgG glycosylation;
PAAD	cis	rs10186876	0.561	rs10175281	chr2:44195272	G/C	cg09541576	chr2:44873248	C2orf34	0.44	4.33	0.33	2.71e-5	Hand grip strength;
PAAD	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.78	8.87	0.58	1.83e-15	Breast cancer;
PAAD	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.14	17.58	0.82	1.82e-38	Cognitive function;
PAAD	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.11	-0.44	7.88e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.47	-4.27	-0.33	3.41e-5	P wave terminal force;
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.61	-7.21	-0.51	2.4e-11	Vitiligo;
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.77	-0.36	4.2e-6	Lung cancer;
PAAD	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.17	16.85	0.81	1.32e-36	Body mass index;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.82	7.99	0.54	3.08e-13	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.51	-5.03	-0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.43	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.58	5.39	0.4	2.61e-7	Malaria;
PAAD	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.87	0.37	2.83e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.5	5.16	0.39	7.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs59888335	0.858	rs9871898	chr3:80988194	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs16975963	0.843	rs73031215	chr19:38433555	G/A	cg14218481	chr19:38281219	NA	0.48	4.95	0.37	1.93e-6	Longevity;
PAAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs988913	1.000	rs9382402	chr6:54809493	C/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.59	-0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.6	-5.18	-0.39	7.03e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.09e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-4.46	-0.34	1.61e-5	Self-reported allergy;
PAAD	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.48	-4.48	-0.34	1.43e-5	IgG glycosylation;
PAAD	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg06131755	chr6:160182447	ACAT2	0.53	4.61	0.35	8.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7923609	0.740	rs10761784	chr10:65308750	A/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.68	-7.46	-0.52	6.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.29	0.6	1.54e-16	Post bronchodilator FEV1;
PAAD	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.66	7.3	0.51	1.49e-11	Corneal astigmatism;
PAAD	cis	rs12127944	1.000	rs4423077	chr1:205470275	C/T	cg08473693	chr1:205342340	NA	-0.8	-4.95	-0.37	1.96e-6	IgG glycosylation;
PAAD	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.66	-0.79	1.63e-33	Height;
PAAD	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.46	-5.34	-0.4	3.31e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-5.06	-0.38	1.19e-6	Hirschsprung disease;
PAAD	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-10.15	-0.64	8.27e-19	Height;
PAAD	cis	rs1208285	0.836	rs1208281	chr6:134159812	G/A	cg08640361	chr6:134494620	SGK1	-0.44	-4.3	-0.33	3.02e-5	Infantile hypertrophic pyloric stenosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10078703	chr11:35963440	NA	-0.59	-6.36	-0.46	2.2e-9	Myopia (pathological);
PAAD	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.71	9.26	0.6	1.85e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.79	-0.53	9.58e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs61931739	0.613	rs7971612	chr12:33644835	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-6.45	-0.46	1.41e-9	Morning vs. evening chronotype;
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.44	-0.34	1.72e-5	Platelet count;
PAAD	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10886678	chr20:30946050	ASXL1	0.67	6.6	0.47	6.39e-10	Obesity-related traits;
PAAD	cis	rs8054556	0.633	rs12928610	chr16:30016022	C/T	cg06015834	chr16:30021696	DOC2A	-0.41	-4.35	-0.33	2.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.79	-7.09	-0.5	4.71e-11	Blood protein levels;
PAAD	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg09796270	chr17:17721594	SREBF1	-0.44	-4.74	-0.36	4.9e-6	Total body bone mineral density;
PAAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07682378	chr3:150128910	TSC22D2	0.68	8.29	0.56	5.4e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg13660082	chr14:53194042	PSMC6	0.71	4.44	0.34	1.72e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg23465465	chr6:26364728	BTN3A2	0.87	5.01	0.38	1.49e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg15145965	chr22:50218605	BRD1	0.6	5.2	0.39	6.4e-7	Schizophrenia;
PAAD	cis	rs4750440	0.702	rs4750444	chr10:14029068	C/T	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.46	-4.75	-0.36	4.63e-6	Ulcerative colitis;
PAAD	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.58	4.78	0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs6466055	0.661	rs55671517	chr7:104827528	A/G	cg04380332	chr7:105027541	SRPK2	0.51	4.99	0.38	1.6e-6	Schizophrenia;
PAAD	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg05110241	chr16:68378359	PRMT7	-0.69	-5.12	-0.38	9.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg03538708	chr1:25844672	NA	-0.51	-5.24	-0.39	5.19e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.73	-7.37	-0.51	9.92e-12	Uric acid clearance;
PAAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg09002919	chr12:50339186	NA	0.53	4.93	0.37	2.13e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg24154853	chr7:158122151	PTPRN2	0.79	7.37	0.51	1.03e-11	Response to amphetamines;
PAAD	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.57	-0.35	9.83e-6	Mean corpuscular volume;
PAAD	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg09934977	chr17:18586148	ZNF286B	0.44	4.25	0.33	3.77e-5	Educational attainment (years of education);
PAAD	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.67	-6.81	-0.48	2.12e-10	Sleep quality;
PAAD	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.22	5.0	0.38	1.57e-6	Urinary tract infection frequency;
PAAD	cis	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs11009175	0.556	rs11009173	chr10:33292325	A/G	cg00146027	chr10:33299147	NA	0.37	4.65	0.35	7.3e-6	Depression (quantitative trait);
PAAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.69	5.9	0.43	2.33e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.55	4.72	0.36	5.35e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg11062466	chr8:58055876	NA	0.69	5.04	0.38	1.29e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.94	-7.45	-0.52	6.45e-12	Initial pursuit acceleration;
PAAD	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs15676	0.947	rs1572912	chr9:131565554	T/C	cg00228799	chr9:131580591	ENDOG	-0.6	-5.91	-0.43	2.21e-8	Blood metabolite levels;
PAAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.73	7.42	0.52	7.64e-12	Schizophrenia;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.77	-0.42	4.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6804624	0.636	rs2670325	chr3:99169461	G/A	cg02646433	chr3:99218170	NA	0.45	4.52	0.34	1.23e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg07068956	chr7:100330872	ZAN	0.55	5.0	0.38	1.56e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg12935359	chr14:103987150	CKB	-0.55	-5.7	-0.42	5.9e-8	Body mass index;
PAAD	cis	rs2637266	0.905	rs4357630	chr10:78382883	T/G	cg18941641	chr10:78392320	NA	0.39	4.63	0.35	7.65e-6	Pulmonary function;
PAAD	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03605463	chr16:89740564	NA	-0.53	-5.05	-0.38	1.25e-6	Vitiligo;
PAAD	cis	rs2249694	0.620	rs12218790	chr10:135434551	A/C	cg16964102	chr10:135390573	NA	-0.5	-4.54	-0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs1519814	1.000	rs6983133	chr8:121166682	T/G	cg22335954	chr8:121166405	COL14A1	-0.61	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg10395934	chr14:104002654	TRMT61A	0.57	5.8	0.43	3.78e-8	Body mass index;
PAAD	trans	rs901683	1.000	rs34771643	chr10:45970632	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	10.51	0.65	9.34e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.94	-0.49	1.08e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs9535307	1.000	rs9535307	chr13:50291842	A/C	cg03658251	chr13:50265850	EBPL	0.81	5.61	0.41	9.52e-8	Obesity-related traits;
PAAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.34e-15	Emphysema distribution in smoking;
PAAD	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.38	-4.43	-0.34	1.82e-5	Pubertal anthropometrics;
PAAD	cis	rs12912251	0.895	rs35795311	chr15:38998669	C/G	cg01338139	chr15:38987640	C15orf53	-0.48	-4.65	-0.35	7.28e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.99	8.29	0.56	5.53e-14	Inflammatory bowel disease;
PAAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.47	0.46	1.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.92	12.67	0.72	1.43e-25	Prudent dietary pattern;
PAAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.55	6.8	0.48	2.22e-10	Psoriasis;
PAAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs9815354	1.000	rs1716690	chr3:41922102	T/G	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12580194	0.593	rs56677471	chr12:55749967	T/A	cg06899799	chr12:56650233	ANKRD52	0.33	4.36	0.33	2.39e-5	Cancer;
PAAD	cis	rs10450586	0.829	rs6484286	chr11:27301922	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.13e-5	Total body bone mineral density;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.48	-4.75	-0.36	4.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13102973	0.965	rs4640720	chr4:135850050	G/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs72960926	0.744	rs6923498	chr6:74913523	C/T	cg03266952	chr6:74778945	NA	-1.07	-6.35	-0.46	2.41e-9	Metabolite levels (MHPG);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22360317	chr1:236902424	ACTN2	-0.52	-6.33	-0.46	2.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg19223190	chr17:80058835	NA	0.52	5.27	0.39	4.57e-7	Life satisfaction;
PAAD	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.38	5.66	0.42	7.29e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16176834	chr1:26028188	MAN1C1	0.59	6.54	0.47	8.68e-10	Smoking initiation;
PAAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg08132940	chr7:1081526	C7orf50	0.59	4.29	0.33	3.12e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.71	-4.91	-0.37	2.37e-6	Vitiligo;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.93	12.83	0.72	5.53e-26	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10813240	chr12:124422061	CCDC92	0.67	6.92	0.49	1.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27402713	chr2:130831550	POTEF	-0.59	-6.37	-0.46	2.15e-9	Obesity-related traits;
PAAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	5.44	0.4	2.06e-7	Monocyte count;
PAAD	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.55	6.12	0.44	7.52e-9	Mean corpuscular volume;
PAAD	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.45	4.45	0.34	1.63e-5	Adiposity;
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Body mass index;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05281506	chr4:72052869	SLC4A4	0.62	7.07	0.5	5.16e-11	Metabolite levels  (X-11787);
PAAD	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs7190551	0.826	rs187614	chr16:9032877	T/C	cg03441945	chr16:8862653	ABAT	-0.5	-4.26	-0.33	3.51e-5	Platelet distribution width;
PAAD	cis	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg12639453	chr1:2035780	PRKCZ	-0.47	-5.07	-0.38	1.13e-6	Height;
PAAD	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	0.98	6.05	0.44	1.08e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs5756931	0.503	rs2012725	chr22:38536861	C/G	cg25457927	chr22:38595422	NA	-0.44	-6.16	-0.45	6.18e-9	Triglycerides;
PAAD	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs6494488	0.500	rs72741329	chr15:64736091	A/G	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg12046867	chr14:103022105	NA	-0.65	-5.04	-0.38	1.28e-6	Platelet count;
PAAD	cis	rs4704187	0.687	rs6872475	chr5:74419793	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg07943548	chr15:86304357	KLHL25	0.67	5.94	0.43	1.83e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg20129853	chr10:51489980	NA	0.45	4.35	0.33	2.46e-5	Prostate-specific antigen levels;
PAAD	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.57e-7	Bladder cancer;
PAAD	cis	rs3781663	0.929	rs4625490	chr11:70000885	T/G	cg06393558	chr11:69982916	ANO1	-0.45	-4.83	-0.37	3.23e-6	Survival in rectal cancer;
PAAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.85	0.43	2.92e-8	Menopause (age at onset);
PAAD	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg11764359	chr7:65958608	NA	0.47	4.3	0.33	3.01e-5	Corneal structure;
PAAD	cis	rs12475964	0.666	rs13027513	chr2:37382576	T/C	cg22370082	chr2:37384244	EIF2AK2	0.44	4.37	0.33	2.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.57	6.09	0.44	8.74e-9	Lung cancer;
PAAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.64	-0.35	7.53e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7943953	0.580	rs1608211	chr11:59137282	A/G	cg06466547	chr11:59191289	OR5A2	-0.44	-4.26	-0.33	3.54e-5	Odorant perception (&beta-ionone);
PAAD	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14094449	chr14:60558589	C14orf135	-0.6	-6.54	-0.47	9e-10	Myopia (pathological);
PAAD	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg09127314	chr1:152161683	NA	0.68	4.91	0.37	2.28e-6	Atopic dermatitis;
PAAD	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.2	-0.45	5.14e-9	Hypospadias;
PAAD	cis	rs9914578	0.943	rs9904872	chr17:2005241	T/A	cg16513277	chr17:2031491	SMG6	-0.59	-5.35	-0.4	3.23e-7	Body mass index;
PAAD	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg01966878	chr4:90757139	SNCA	0.6	4.55	0.35	1.09e-5	Neuroticism;
PAAD	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg02487422	chr3:49467188	NICN1	0.47	4.67	0.35	6.58e-6	Resting heart rate;
PAAD	trans	rs901683	1.000	rs71496605	chr10:46009818	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.78	0.48	2.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs42648	0.564	rs6465248	chr7:89824740	C/T	cg27367526	chr7:89841692	STEAP2	-0.32	-4.49	-0.34	1.42e-5	Homocysteine levels;
PAAD	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.55	-4.98	-0.37	1.73e-6	HDL cholesterol;
PAAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.48	4.66	0.35	6.73e-6	Pulse pressure;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg04673462	chr1:38461896	NA	-0.49	-6.66	-0.48	4.61e-10	Coronary artery disease;
PAAD	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg25790453	chr13:113633590	MCF2L	-0.38	-4.35	-0.33	2.51e-5	Systolic blood pressure;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs3857067	0.772	rs10018905	chr4:95076767	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.48	-0.41	1.73e-7	QT interval;
PAAD	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs11037575	0.739	rs12277307	chr11:43721672	C/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.57	-6.87	-0.49	1.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg20406979	chr6:167373233	NA	-0.38	-5.24	-0.39	5.29e-7	Crohn's disease;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22442454	chr1:209979470	IRF6	0.6	5.42	0.4	2.29e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.79	9.15	0.6	3.57e-16	Heart rate;
PAAD	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13893634	chr17:48229117	PPP1R9B	-0.54	-5.5	-0.41	1.61e-7	Temporomandibular joint disorder;
PAAD	cis	rs911119	0.837	rs2208289	chr20:23579526	A/G	cg16589663	chr20:23618590	CST3	-0.72	-6.2	-0.45	5.19e-9	Chronic kidney disease;
PAAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg05227288	chr16:32489822	NA	0.61	6.53	0.47	9.28e-10	Blood protein levels;
PAAD	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg14343924	chr8:8086146	FLJ10661	-0.68	-5.99	-0.44	1.44e-8	Mood instability;
PAAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg25801113	chr15:45476975	SHF	0.39	4.72	0.36	5.36e-6	Uric acid levels;
PAAD	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-1.03	-6.83	-0.48	1.95e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg21191810	chr6:118973309	C6orf204	0.47	6.0	0.44	1.37e-8	Electrocardiographic conduction measures;
PAAD	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg00750074	chr16:89608354	SPG7	-0.54	-5.07	-0.38	1.12e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs2252790	0.859	rs1204822	chr6:116563547	A/G	cg18764771	chr6:116381957	FRK	-0.27	-4.63	-0.35	7.93e-6	Fast beta electroencephalogram;
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	1.02	8.47	0.57	1.94e-14	Initial pursuit acceleration;
PAAD	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.5	5.34	0.4	3.35e-7	Asthma or chronic obstructive pulmonary disease;
PAAD	cis	rs76533333	0.646	rs71446626	chr13:113390361	G/A	cg02820901	chr13:113351484	ATP11A	-0.75	-4.56	-0.35	1.04e-5	Red cell distribution width;
PAAD	cis	rs71520386	0.632	rs10224533	chr7:22861141	T/G	cg04907244	chr7:22894795	SNORD93	0.5	5.44	0.4	2.1e-7	Fibrinogen levels;
PAAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.72	-6.53	-0.47	9.18e-10	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs8112211	0.554	rs60082376	chr19:38843512	G/A	cg14299480	chr19:38876666	GGN	-0.57	-4.87	-0.37	2.79e-6	Blood protein levels;
PAAD	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.86	6.81	0.48	2.09e-10	Mean platelet volume;
PAAD	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg21427119	chr20:30132790	HM13	-0.51	-4.66	-0.35	6.78e-6	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg21937377	chr3:194868750	C3orf21	0.46	4.85	0.37	2.97e-6	Non-small cell lung cancer;
PAAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	8.58	0.57	1.03e-14	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.78	7.38	0.51	9.47e-12	Corneal astigmatism;
PAAD	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg18171855	chr10:2543474	NA	-0.69	-6.85	-0.49	1.68e-10	Age-related hearing impairment;
PAAD	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.53	4.86	0.37	2.88e-6	Resting heart rate;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg21479132	chr6:26055353	NA	0.83	4.61	0.35	8.34e-6	Lung cancer in ever smokers;
PAAD	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.51	5.48	0.41	1.72e-7	Asthma or chronic obstructive pulmonary disease;
PAAD	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg15556689	chr8:8085844	FLJ10661	-0.72	-7.25	-0.51	1.98e-11	Neuroticism;
PAAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.59	4.94	0.37	2.05e-6	Schizophrenia;
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.85	-9.62	-0.62	2.09e-17	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg04154034	chr17:28927549	LRRC37B2	0.68	4.33	0.33	2.68e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17294081	chr20:3452173	ATRN	0.61	7.08	0.5	4.91e-11	Metabolite levels  (X-11787);
PAAD	cis	rs3790645	0.645	rs17162190	chr1:26872832	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.91	0.37	2.29e-6	Glucose homeostasis traits;
PAAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	4.54	0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.5	5.9	0.43	2.27e-8	Height;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.36	0.4	2.99e-7	Mean corpuscular volume;
PAAD	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.67	-0.48	4.4e-10	Systolic blood pressure;
PAAD	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.86	-7.41	-0.51	8.34e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.57	5.44	0.4	2.13e-7	Uric acid clearance;
PAAD	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg11802864	chr11:65308245	LTBP3	0.48	4.94	0.37	2.05e-6	Bone mineral density;
PAAD	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg00750074	chr16:89608354	SPG7	-0.46	-4.41	-0.34	1.94e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.64	0.53	2.27e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.13	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.63	6.96	0.49	9.51e-11	Tonsillectomy;
PAAD	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg23093090	chr10:104574429	C10orf26	-0.43	-5.08	-0.38	1.11e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.65	4.55	0.35	1.1e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.61	-6.72	-0.48	3.49e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.49	7.76	0.53	1.17e-12	Neuroticism;
PAAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4281086	0.648	rs7834351	chr8:10378405	A/G	cg01072821	chr8:10382165	T-SP1	-0.46	-4.96	-0.37	1.83e-6	Obesity-related traits;
PAAD	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	4.84	0.37	3.1e-6	Schizophrenia;
PAAD	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg11992317	chr20:44520160	CTSA;NEURL2	0.56	5.78	0.42	4.08e-8	Positive affect;
PAAD	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12292205	chr6:26970375	C6orf41	-0.49	-4.63	-0.35	7.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.66e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2221894	1.000	rs6558085	chr8:28802932	A/G	cg20212339	chr8:28908912	HMBOX1	0.48	4.94	0.37	2.03e-6	Obesity-related traits;
PAAD	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg23461800	chr14:103021989	NA	0.6	4.39	0.34	2.1e-5	Platelet count;
PAAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.56	6.06	0.44	1.02e-8	Facial morphology (factor 20);
PAAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	6.05	0.44	1.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg21130718	chr4:1044621	NA	0.55	4.68	0.35	6.28e-6	Recombination rate (females);
PAAD	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.63	7.53	0.52	4.09e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-8.62	-0.57	8.07e-15	Morning vs. evening chronotype;
PAAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.52	-4.84	-0.37	3.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12776158	0.901	rs61848384	chr10:71215225	T/G	cg12610070	chr10:71211762	TSPAN15	-0.5	-4.98	-0.37	1.67e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.88	-0.72	3.91e-26	Dental caries;
PAAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.67	8.06	0.55	2.04e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs593531	0.513	rs479968	chr11:74038274	C/G	cg15670924	chr11:73669256	DNAJB13	0.47	5.18	0.39	6.98e-7	Neuroticism;
PAAD	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	0.44	4.89	0.37	2.55e-6	Childhood body mass index;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-5.45	-0.4	2.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-1.14	-12.44	-0.71	6.06e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.81	5.89	0.43	2.34e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15805337	chr11:12935897	TEAD1	-0.69	-7.24	-0.51	2.05e-11	Obesity-related traits;
PAAD	cis	rs1722141	0.633	rs2471552	chr7:45977173	C/T	cg13814990	chr7:46016683	NA	0.55	4.34	0.33	2.58e-5	Sitting height ratio;
PAAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.77	-7.92	-0.54	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.51	0.41	1.53e-7	Prudent dietary pattern;
PAAD	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.5	5.11	0.38	9.46e-7	Corneal astigmatism;
PAAD	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	1.11	16.12	0.79	9.92e-35	Systemic lupus erythematosus;
PAAD	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg19980929	chr12:42632907	YAF2	0.62	7.45	0.52	6.38e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs735539	0.645	rs9552250	chr13:21175217	C/G	cg27234864	chr13:21295941	IL17D	0.63	5.48	0.41	1.76e-7	Dental caries;
PAAD	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg03989125	chr22:38214979	NA	-0.66	-6.91	-0.49	1.25e-10	Glioblastoma;Glioma;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	1.01	8.32	0.56	4.68e-14	Initial pursuit acceleration;
PAAD	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.68	0.42	6.55e-8	Ileal carcinoids;
PAAD	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.2	0.5	2.6e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.58	-0.35	9.63e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg27478167	chr7:817139	HEATR2	-0.57	-4.46	-0.34	1.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.45	4.42	0.34	1.88e-5	Dupuytren's disease;
PAAD	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.39	-0.34	2.13e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2797685	0.735	rs56204811	chr1:7895069	A/G	cg00864860	chr1:7907996	UTS2	-0.63	-4.98	-0.37	1.7e-6	Crohn's disease;
PAAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.44	-5.13	-0.38	8.89e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.7	6.6	0.47	6.49e-10	Plateletcrit;Platelet count;
PAAD	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.63	-7.42	-0.52	7.53e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg14515779	chr1:101123966	NA	0.39	4.31	0.33	2.88e-5	Monocyte count;
PAAD	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.67	-7.05	-0.5	5.92e-11	Coronary artery disease;
PAAD	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.712	rs6705366	chr2:86484782	C/T	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2882667	0.690	rs160401	chr5:138061341	C/T	cg09476006	chr5:138032270	NA	-0.47	-6.19	-0.45	5.4e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9650315	0.530	rs68005065	chr8:57090308	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	4.33	0.33	2.69e-5	Height;
PAAD	cis	rs17266958	1.000	rs62572852	chr9:83228428	A/T	cg13911576	chr9:84174038	NA	0.81	4.36	0.33	2.39e-5	Preschool internalizing problems;
PAAD	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg03805757	chr16:71968109	PKD1L3	-0.53	-4.77	-0.36	4.27e-6	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08677398	chr8:58056175	NA	0.68	4.66	0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.4	-0.34	2.06e-5	Mood instability;
PAAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg17366294	chr4:99064904	C4orf37	0.59	6.3	0.46	3.02e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11264213	0.792	rs12562583	chr1:36178868	G/T	cg27506609	chr1:36549197	TEKT2	0.63	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg24721873	chr10:135334122	NA	0.61	4.46	0.34	1.61e-5	Gout;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg01652476	chr7:809048	HEATR2	-0.65	-7.34	-0.51	1.21e-11	Subjective well-being;
PAAD	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.96	7.54	0.52	3.9e-12	Gut microbiome composition (summer);
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00166722	chr3:10149974	C3orf24	1.03	7.82	0.54	8.39e-13	Alzheimer's disease;
PAAD	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.48e-6	High light scatter reticulocyte count;
PAAD	cis	rs16975963	0.644	rs35205379	chr19:38176842	C/T	cg14218481	chr19:38281219	NA	-0.42	-4.45	-0.34	1.64e-5	Longevity;
PAAD	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg14515779	chr1:101123966	NA	0.44	5.1	0.38	1e-6	Monocyte count;
PAAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.62	-0.47	5.81e-10	Aortic root size;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.82	10.64	0.65	4.06e-20	Vitiligo;
PAAD	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.62	-4.85	-0.37	3.09e-6	Dialysis-related mortality;
PAAD	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.99	-0.37	1.66e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.7	-0.48	3.88e-10	Lung cancer;
PAAD	cis	rs501916	0.605	rs17332642	chr15:48080805	G/A	cg16110827	chr15:48056943	SEMA6D	-0.49	-5.27	-0.39	4.65e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.86	-0.37	2.9e-6	Tuberculosis;
PAAD	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs11638815	0.603	rs10162807	chr15:83289181	G/A	cg00614314	chr15:82944287	LOC80154	0.47	4.57	0.35	9.98e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg01866162	chr16:67596514	CTCF	0.57	4.29	0.33	3.23e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs55823223	0.680	rs3744020	chr17:73871773	G/A	cg08125733	chr17:73851984	WBP2	0.96	8.27	0.56	6.35e-14	Psoriasis;
PAAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.16	0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.75	8.36	0.56	3.7e-14	Prostate cancer;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs58521262	0.556	rs452404	chr19:23127435	A/C	cg02350677	chr19:23254381	NA	-0.26	-4.47	-0.34	1.55e-5	Testicular germ cell tumor;
PAAD	trans	rs790110	1.000	rs812047	chr3:122382074	C/G	cg15869492	chr17:36907295	NA	-1.05	-6.52	-0.47	9.94e-10	Acoustic startle blink response;
PAAD	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.72	4.52	0.34	1.24e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	4.43	0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.85	9.98	0.63	2.29e-18	Height;
PAAD	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24391128	chr15:22979826	CYFIP1	0.56	6.7	0.48	3.82e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7714584	1.000	rs2344181	chr5:150262574	T/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.72	8.83	0.58	2.3e-15	Height;
PAAD	cis	rs7631605	0.905	rs58693636	chr3:37102623	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.29e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg01631408	chr1:248437212	OR2T33	-0.63	-5.39	-0.4	2.69e-7	Common traits (Other);
PAAD	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg00262122	chr8:11665843	FDFT1	-0.64	-5.46	-0.4	1.9e-7	Neuroticism;
PAAD	cis	rs3781663	1.000	rs10160719	chr11:70000259	T/C	cg06393558	chr11:69982916	ANO1	-0.44	-4.74	-0.36	4.93e-6	Survival in rectal cancer;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs761746	0.960	rs4820982	chr22:31929480	T/C	cg01338084	chr22:32026380	PISD	-0.49	-4.54	-0.35	1.15e-5	Intelligence;
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02071572	chr4:1403502	NA	0.52	6.84	0.49	1.81e-10	Longevity;
PAAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.76	-0.48	2.83e-10	Type 2 diabetes;
PAAD	cis	rs10768122	1.000	rs3763888	chr11:35307148	T/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2.01e-5	Vitiligo;
PAAD	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg22153463	chr1:85462885	MCOLN2	0.72	5.34	0.4	3.27e-7	Serum sulfate level;
PAAD	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg25457927	chr22:38595422	NA	-0.41	-5.85	-0.43	2.92e-8	Breast cancer;
PAAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2481665	0.742	rs6670849	chr1:62542717	C/T	cg18591186	chr1:62594603	INADL	-0.49	-4.46	-0.34	1.58e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg01305830	chr4:1604576	NA	-0.49	-4.73	-0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.5	-4.49	-0.34	1.41e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9463078	0.585	rs4072928	chr6:45291229	A/G	cg18551225	chr6:44695536	NA	0.42	4.44	0.34	1.74e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg18508148	chr11:34937573	PDHX;APIP	0.51	4.85	0.37	3.08e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	1.0	6.67	0.48	4.47e-10	IgG glycosylation;
PAAD	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16417436	chr16:28758564	NA	0.45	4.64	0.35	7.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.49	4.35	0.33	2.44e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.94	-0.43	1.91e-8	Vitiligo;
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg23978390	chr7:1156363	C7orf50	0.54	4.31	0.33	2.91e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg11764359	chr7:65958608	NA	0.77	5.09	0.38	1.02e-6	Diabetic kidney disease;
PAAD	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.55	4.92	0.37	2.21e-6	Lung cancer;
PAAD	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.81	8.72	0.58	4.46e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4740619	0.619	rs752490	chr9:16032570	C/T	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1507153	0.702	rs7740665	chr6:79353465	C/T	cg05283184	chr6:79620031	NA	-0.38	-4.55	-0.35	1.09e-5	Sjögren's syndrome;
PAAD	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs4787951	0.560	rs3916997	chr16:27345114	A/G	cg08008352	chr16:27322356	NA	0.46	4.65	0.35	7.28e-6	Eosinophil percentage of white cells;
PAAD	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg21395723	chr22:39101663	GTPBP1	0.46	4.59	0.35	9.07e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.58	5.47	0.41	1.79e-7	Type 2 diabetes;
PAAD	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg18833306	chr6:118973337	C6orf204	-0.42	-4.3	-0.33	2.98e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.09	0.59	4.9e-16	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	7.64	0.53	2.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.6	6.25	0.45	3.93e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg15181151	chr6:150070149	PCMT1	0.6	6.74	0.48	3.04e-10	Lung cancer;
PAAD	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.96	0.54	3.68e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg06877860	chr20:55043471	C20orf43	-0.62	-6.59	-0.47	6.77e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs28489187	0.643	rs233054	chr1:85840191	T/G	cg16011679	chr1:85725395	C1orf52	0.55	5.34	0.4	3.4e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.92	-0.37	2.19e-6	Platelet count;
PAAD	cis	rs1355223	0.701	rs745377	chr11:34858413	G/T	cg18508148	chr11:34937573	PDHX;APIP	-0.51	-4.94	-0.37	2.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg03713592	chr11:72463424	ARAP1	0.73	6.5	0.47	1.06e-9	Type 2 diabetes;
PAAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-5.9	-0.43	2.31e-8	Urinary metabolites;
PAAD	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg15181151	chr6:150070149	PCMT1	0.59	6.41	0.46	1.78e-9	Lung cancer;
PAAD	cis	rs6466055	0.501	rs6965384	chr7:104603112	A/G	cg04380332	chr7:105027541	SRPK2	-0.66	-6.89	-0.49	1.39e-10	Schizophrenia;
PAAD	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	cis	rs558003	0.702	rs797475	chr13:51203769	A/G	cg24585282	chr13:51257555	NA	0.67	4.53	0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg00750074	chr16:89608354	SPG7	-0.55	-5.13	-0.38	8.83e-7	Multiple myeloma (IgH translocation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08878360	chr19:19303979	LOC729991-MEF2B;LOC729991;RFXANK	0.63	6.32	0.46	2.81e-9	Obesity-related traits;
PAAD	cis	rs78761021	0.867	rs77902029	chr17:9791780	T/A	cg26853458	chr17:9805074	RCVRN	0.71	8.3	0.56	5.23e-14	Type 2 diabetes;
PAAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.38	-0.34	2.17e-5	Tonsillectomy;
PAAD	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.34	-0.33	2.58e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-5.92	-0.43	2.04e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs501120	0.584	rs11238929	chr10:44708596	T/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.61	-0.35	8.51e-6	Breast cancer;
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-7.72	-0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg26312998	chr6:43337775	ZNF318	0.7	5.79	0.42	3.99e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.76	9.11	0.59	4.36e-16	Brugada syndrome;
PAAD	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.7	7.28	0.51	1.64e-11	Triglyceride levels;
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27436995	chr16:743998	FBXL16	-0.36	-4.26	-0.33	3.52e-5	Height;
PAAD	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	4.83	0.36	3.36e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg04154034	chr17:28927549	LRRC37B2	-0.65	-4.29	-0.33	3.19e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg24633833	chr3:10029261	TMEM111	0.59	4.34	0.33	2.54e-5	Alzheimer's disease;
PAAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-5.23	-0.39	5.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6494488	0.500	rs72742987	chr15:64993757	T/C	cg16425858	chr15:64791681	ZNF609	0.96	4.85	0.37	3.02e-6	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs7247513	0.927	rs34956595	chr19:12702797	A/C	cg01871581	chr19:12707946	ZNF490	-0.9	-11.1	-0.67	2.4e-21	Bipolar disorder;
PAAD	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg16766828	chr3:128327626	NA	-0.46	-6.17	-0.45	5.78e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg14631576	chr9:95140430	CENPP	-0.61	-5.93	-0.43	1.94e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.58	0.57	1.02e-14	Alzheimer's disease;
PAAD	cis	rs528301	0.613	rs4953143	chr2:45124291	C/G	cg15393275	chr2:45165193	NA	0.44	4.6	0.35	8.87e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	4.62	0.35	8.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.57	-5.34	-0.4	3.3e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.49	-4.75	-0.36	4.72e-6	Pancreatic cancer;
PAAD	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.42	-0.34	1.85e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg02135003	chr7:105160482	PUS7	-0.92	-6.7	-0.48	3.84e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.62	5.73	0.42	5.12e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.52	-5.03	-0.38	1.37e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7336332	0.574	rs9512699	chr13:28029896	G/A	cg22138327	chr13:27999177	GTF3A	-0.72	-5.83	-0.43	3.23e-8	Weight;
PAAD	cis	rs56046484	0.913	rs17611290	chr15:85574419	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.56	-6.08	-0.44	9.39e-9	Testicular germ cell tumor;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.38	4.44	0.34	1.76e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4740619	0.689	rs10756724	chr9:15951855	A/T	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg10818794	chr15:86012489	AKAP13	-0.53	-5.87	-0.43	2.69e-8	Coronary artery disease;
PAAD	cis	rs1775715	0.614	rs806808	chr10:32381186	T/C	cg03047570	chr10:32398778	NA	0.41	4.25	0.33	3.75e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs8112211	0.834	rs3843754	chr19:38807184	G/A	cg14299480	chr19:38876666	GGN	-0.52	-6.86	-0.49	1.63e-10	Blood protein levels;
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg12483801	chr4:183727862	NA	0.77	5.67	0.42	6.88e-8	Pediatric autoimmune diseases;
PAAD	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg26935685	chr1:15502881	TMEM51	-0.5	-4.33	-0.33	2.69e-5	Systolic blood pressure;
PAAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-9.76	-0.62	8.82e-18	Schizophrenia;
PAAD	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.97	13.35	0.73	2.09e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.93	8.04	0.55	2.32e-13	Alzheimer's disease;
PAAD	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg05805236	chr11:65401703	PCNXL3	0.49	4.62	0.35	8.21e-6	Breast cancer;
PAAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg08885800	chr1:201084119	NA	0.72	8.01	0.54	2.74e-13	Permanent tooth development;
PAAD	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.55	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.23	19.21	0.84	1.71e-42	IgG glycosylation;
PAAD	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.79	7.87	0.54	6.18e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.86	0.49	1.66e-10	Schizophrenia;
PAAD	cis	rs9815354	1.000	rs6781326	chr3:41777028	T/C	cg03022575	chr3:42003672	ULK4	0.72	5.23	0.39	5.51e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	0.84	6.1	0.44	8.4e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.79	10.05	0.63	1.53e-18	Alcohol dependence;
PAAD	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.41	-0.34	1.93e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg21419209	chr3:44054225	NA	-0.59	-5.86	-0.43	2.75e-8	Coronary artery disease;
PAAD	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg16586182	chr3:47516702	SCAP	-0.43	-4.38	-0.33	2.18e-5	Birth weight;
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950881	0.932	rs72823619	chr2:102924615	C/T	cg20060108	chr2:102954350	IL1RL1	0.59	4.4	0.34	1.99e-5	Allergy;
PAAD	cis	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg14345882	chr6:26364793	BTN3A2	-0.66	-4.51	-0.34	1.29e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.21	0.45	4.75e-9	Coffee consumption (cups per day);
PAAD	cis	rs59191668	0.838	rs8029492	chr15:62820324	A/G	cg12918536	chr15:62891943	NA	0.35	4.64	0.35	7.45e-6	Immature fraction of reticulocytes;
PAAD	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.85e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.77	-0.36	4.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.63	-8.0	-0.54	2.98e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg19761014	chr17:28927070	LRRC37B2	-0.86	-6.05	-0.44	1.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg13271783	chr10:134563150	INPP5A	-0.53	-5.69	-0.42	6.27e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.85	8.59	0.57	9.79e-15	Post bronchodilator FEV1;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg17541715	chr7:1216824	NA	-0.41	-4.44	-0.34	1.69e-5	Longevity;Endometriosis;
PAAD	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg01620082	chr3:125678407	NA	-1.17	-6.98	-0.49	8.75e-11	Urinary tract infection frequency;
PAAD	cis	rs77688320	1.000	rs77688320	chr2:202367589	T/G	cg02738983	chr2:202315807	TRAK2;STRADB	-0.61	-4.38	-0.33	2.17e-5	Breast cancer;
PAAD	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.86	-9.61	-0.61	2.29e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs9463078	0.527	rs2040032	chr6:44743009	C/T	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.83	-6.03	-0.44	1.22e-8	Yeast infection;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg08699206	chr4:1595414	NA	0.52	4.73	0.36	5.03e-6	Obesity-related traits;
PAAD	cis	rs655641	0.539	rs587038	chr11:85689712	A/T	cg07180834	chr11:85838833	NA	-0.44	-4.79	-0.36	3.96e-6	Platelet count;
PAAD	trans	rs738968	0.908	rs5994945	chr22:34881836	G/A	cg02653559	chr3:147112081	ZIC4	-0.57	-6.31	-0.46	2.97e-9	Immune reponse to smallpox (secreted TNF-alpha);
PAAD	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07791476	chr4:8456156	C4orf23	-0.56	-6.75	-0.48	2.98e-10	Immature fraction of reticulocytes;
PAAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg23719950	chr11:63933701	MACROD1	-0.51	-4.37	-0.33	2.28e-5	Platelet count;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.79	-8.94	-0.59	1.24e-15	DNA methylation (variation);
PAAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.1	-0.44	8.36e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	7.81	0.53	8.92e-13	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs904092	0.720	rs1618572	chr4:100195121	C/G	cg12011299	chr4:100065546	ADH4	0.58	5.43	0.4	2.2e-7	Alcohol dependence;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07104230	chr1:120909060	HIST2H2BA	-0.54	-6.47	-0.46	1.3e-9	Energy expenditure (24h);
PAAD	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.9	11.4	0.68	3.77e-22	Dental caries;
PAAD	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.13	0.55	1.42e-13	Alzheimer's disease;
PAAD	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18297960	chr7:1142765	C7orf50	-0.55	-4.32	-0.33	2.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg03954918	chr16:12278468	SNX29	-0.51	-5.15	-0.39	8.06e-7	Testicular germ cell tumor;
PAAD	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.74	7.44	0.52	7.09e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg20243544	chr17:37824526	PNMT	0.53	4.71	0.36	5.65e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.18	0.45	5.66e-9	Rheumatoid arthritis;
PAAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg14847009	chr1:175162515	KIAA0040	-0.32	-5.08	-0.38	1.08e-6	Alcohol dependence;
PAAD	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg01064725	chr1:204461714	NA	0.51	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs7945705	0.902	rs11042088	chr11:8843515	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.74	7.67	0.53	1.95e-12	Hemoglobin concentration;
PAAD	cis	rs8133932	0.554	rs11089028	chr21:47298312	T/C	cg13695288	chr21:47294981	PCBP3	-0.45	-4.45	-0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs894157	0.668	rs8179067	chr15:90211686	T/C	cg20467658	chr15:89933347	LOC254559	0.84	4.39	0.34	2.13e-5	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.93	-0.43	1.99e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.66	6.46	0.46	1.35e-9	Pulse pressure;
PAAD	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg17346650	chr17:80929145	B3GNTL1	0.34	4.51	0.34	1.28e-5	Glycated hemoglobin levels;
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs728616	0.867	rs56365235	chr10:81894739	C/T	cg19423196	chr10:82049429	MAT1A	0.66	5.08	0.38	1.08e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9876781	1.000	rs9864371	chr3:48426766	A/C	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs818427	0.684	rs866006	chr5:112176559	T/G	cg06941702	chr5:112196734	SRP19	-0.52	-4.72	-0.36	5.31e-6	Total body bone mineral density;
PAAD	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg24699146	chr1:24152579	HMGCL	0.54	5.67	0.42	7.13e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg18833306	chr6:118973337	C6orf204	0.43	4.4	0.34	2.02e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.5	0.47	1.06e-9	Schizophrenia;
PAAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg10556349	chr10:835070	NA	0.68	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs877282	0.731	rs67369760	chr10:791583	C/T	cg17470449	chr10:769945	NA	0.76	7.8	0.53	9.42e-13	Uric acid levels;
PAAD	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7975161	0.580	rs10735393	chr12:104680661	G/T	cg25273343	chr12:104657179	TXNRD1	-0.75	-4.38	-0.33	2.22e-5	Toenail selenium levels;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg05313129	chr8:58192883	C8orf71	-0.63	-5.49	-0.41	1.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg07777115	chr5:623756	CEP72	-0.47	-4.34	-0.33	2.64e-5	Cystic fibrosis severity;
PAAD	cis	rs76419734	0.558	rs4326019	chr4:106527381	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.56	0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.61	-5.96	-0.44	1.71e-8	Social autistic-like traits;
PAAD	cis	rs73206853	0.841	rs55754138	chr12:110869335	G/T	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.47	-5.45	-0.4	1.97e-7	Mean arterial pressure;
PAAD	cis	rs12209128	0.893	rs1544090	chr6:47880264	T/C	cg20497205	chr6:47754005	OPN5	-0.36	-4.27	-0.33	3.44e-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg18279126	chr7:2041391	MAD1L1	0.54	5.39	0.4	2.66e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg15674680	chr20:60982522	CABLES2	-0.48	-4.43	-0.34	1.8e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg19418318	chr19:17219073	MYO9B	0.48	5.72	0.42	5.53e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs258892	0.793	rs6452682	chr5:72082390	T/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs7651511	1.000	rs13095168	chr3:141257904	C/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.5	4.94	0.37	2.03e-6	Asthma;
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22442454	chr1:209979470	IRF6	0.59	5.31	0.4	3.74e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.71	6.98	0.49	8.6e-11	Uric acid levels;
PAAD	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg11901034	chr3:128598214	ACAD9	0.52	4.33	0.33	2.74e-5	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10044254	0.813	rs4293917	chr5:15742599	T/C	cg07238450	chr5:15720153	FBXL7	-0.53	-4.46	-0.34	1.58e-5	Asthma (corticosteroid response);
PAAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg21929781	chr1:2537748	MMEL1	0.44	4.7	0.36	5.69e-6	Ulcerative colitis;
PAAD	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-5.87	-0.43	2.63e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11811982	0.793	rs76046364	chr1:227439222	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg08893839	chr5:154027129	NA	0.95	6.55	0.47	8.54e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17130815	chr7:2558891	LFNG	0.6	6.79	0.48	2.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Coronary artery disease;
PAAD	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.4	5.37	0.4	2.84e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.62	-5.33	-0.4	3.44e-7	Mean corpuscular volume;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05434287	chr7:2030229	MAD1L1	0.41	4.46	0.34	1.56e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.58	-8.09	-0.55	1.73e-13	Height;
PAAD	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.96	-7.92	-0.54	4.63e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.41	0.34	1.96e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.37	-0.33	2.33e-5	Neuroticism;
PAAD	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.91	0.43	2.21e-8	Prudent dietary pattern;
PAAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.6	5.75	0.42	4.73e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1797885	0.714	rs299651	chr3:12537955	A/T	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	12.26	0.71	1.89e-24	Body mass index (adult);
PAAD	cis	rs375066	0.868	rs378112	chr19:44421929	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.67	-7.05	-0.5	5.86e-11	Type 2 diabetes;
PAAD	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs2137920	0.685	rs17773323	chr10:50238570	C/T	cg02657375	chr10:50863136	CHAT	0.54	4.32	0.33	2.8e-5	Migraine with aura;
PAAD	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.71	7.53	0.52	4.14e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg24737193	chr18:12778029	NA	0.63	5.58	0.41	1.09e-7	Inflammatory skin disease;
PAAD	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.54	-5.12	-0.38	9.1e-7	Crohn's disease;
PAAD	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg00024989	chr19:17902242	NA	0.42	4.65	0.35	7.26e-6	Tumor biomarkers;
PAAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg20243544	chr17:37824526	PNMT	-0.51	-4.44	-0.34	1.74e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg00431813	chr7:1051703	C7orf50	0.69	4.78	0.36	4.13e-6	Longevity;Endometriosis;
PAAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	0.98	10.87	0.66	1e-20	Gestational age at birth (maternal effect);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26930615	chr7:42971990	MRPL32;PSMA2	0.6	6.77	0.48	2.59e-10	Myopia (pathological);
PAAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg27284194	chr4:1044797	NA	0.51	4.69	0.36	6.01e-6	Obesity-related traits;
PAAD	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.67	7.06	0.5	5.55e-11	Primary sclerosing cholangitis;
PAAD	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs6724465	1.000	rs72967954	chr2:219922569	C/A	cg25908985	chr2:219925065	IHH	0.63	4.28	0.33	3.25e-5	Height;
PAAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.68	-6.6	-0.47	6.6e-10	Total body bone mineral density;
PAAD	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.54	6.69	0.48	4e-10	Atrioventricular conduction;
PAAD	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.3	-0.39	4.06e-7	Vitiligo;
PAAD	cis	rs2274459	0.545	rs12205667	chr6:33611525	G/T	cg06253072	chr6:33679850	C6orf125	0.65	4.76	0.36	4.46e-6	Obesity (extreme);
PAAD	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.75	7.5	0.52	4.92e-12	Corneal astigmatism;
PAAD	cis	rs2373794	0.583	rs374153	chr2:40382712	C/T	cg12449404	chr2:40437698	SLC8A1	-0.55	-4.6	-0.35	8.67e-6	Asthma;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg24747557	chr10:131355152	MGMT	0.47	4.61	0.35	8.61e-6	Response to temozolomide;
PAAD	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg04522676	chr10:134968826	NA	0.45	4.27	0.33	3.42e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.75	8.64	0.57	7.19e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.97	-13.73	-0.74	2.08e-28	Post bronchodilator FEV1;
PAAD	cis	rs9915657	0.660	rs1558748	chr17:70066502	T/C	cg09344028	chr17:70110421	NA	0.54	6.92	0.49	1.17e-10	Thyroid hormone levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03468541	chr14:89029199	ZC3H14	-0.72	-6.45	-0.46	1.38e-9	Neuroticism;
PAAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg11707556	chr5:10655725	ANKRD33B	0.61	6.58	0.47	7.04e-10	Coronary artery disease;
PAAD	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.68	7.24	0.51	2.04e-11	Hematocrit;
PAAD	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23158103	chr7:148848205	ZNF398	-0.59	-5.67	-0.42	6.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.4	4.56	0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg06740227	chr12:86229804	RASSF9	0.5	4.95	0.37	1.91e-6	Major depressive disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08628431	chr5:14506972	TRIO	0.59	6.68	0.48	4.28e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.81	5.13	0.38	8.85e-7	Schizophrenia;
PAAD	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.5	5.9	0.43	2.24e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.61	6.37	0.46	2.08e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7584330	0.518	rs74970394	chr2:238443483	C/T	cg08992911	chr2:238395768	MLPH	0.95	4.43	0.34	1.78e-5	Prostate cancer;
PAAD	cis	rs6142102	0.580	rs761233	chr20:32568886	A/G	cg06115741	chr20:33292138	TP53INP2	0.56	5.02	0.38	1.44e-6	Skin pigmentation;
PAAD	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg03894339	chr8:19674705	INTS10	0.45	4.34	0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs757081	0.658	rs105290	chr11:17292068	T/C	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.73	-0.36	5.19e-6	Systolic blood pressure;
PAAD	cis	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.75	6.4	0.46	1.87e-9	Pulmonary function decline;
PAAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.61	-6.26	-0.45	3.66e-9	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15074876	chr1:110950234	HBXIP	0.6	6.45	0.46	1.43e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06061760	chr3:178970302	KCNMB3	-0.62	-7.25	-0.51	1.99e-11	Monocyte percentage of white cells;
PAAD	cis	rs4280164	0.613	rs11621353	chr14:24736669	G/A	cg07162820	chr14:24837146	NFATC4	0.43	4.82	0.36	3.4e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.52	5.29	0.39	4.15e-7	Colorectal cancer;
PAAD	cis	rs9815354	0.680	rs73073291	chr3:42028004	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12931792	0.875	rs7199462	chr16:30158757	T/G	cg17640201	chr16:30407289	ZNF48	0.58	6.11	0.44	7.87e-9	Tonsillectomy;
PAAD	cis	rs1419980	0.730	rs11054866	chr12:7770533	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg17031739	chr1:67600172	NA	0.44	4.59	0.35	9.33e-6	Psoriasis;
PAAD	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg02743256	chr7:2109353	MAD1L1	-0.56	-4.41	-0.34	1.97e-5	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.71	-0.58	4.82e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.78	6.57	0.47	7.7e-10	Type 2 diabetes;
PAAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.51	-4.28	-0.33	3.33e-5	Height;
PAAD	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.64	-4.8	-0.36	3.78e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35995292	0.926	rs10259755	chr7:38897012	A/C	cg19327137	chr7:38886074	VPS41	0.42	4.34	0.33	2.61e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.48e-14	Renal cell carcinoma;
PAAD	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.17	-0.39	7.34e-7	IgG glycosylation;
PAAD	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.43	4.41	0.34	1.94e-5	Heart rate;
PAAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.69	9.11	0.59	4.52e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg09491104	chr22:46646882	C22orf40	-0.66	-6.12	-0.44	7.5e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.92	6.57	0.47	7.54e-10	Psoriasis vulgaris;
PAAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.92	7.7	0.53	1.6e-12	Cerebrospinal P-tau181p levels;
PAAD	trans	rs12738007	0.967	rs10915233	chr1:29475975	G/A	cg05667379	chr2:115920764	DPP10	0.38	6.44	0.46	1.51e-9	Schizophrenia;
PAAD	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.45	-0.4	2.02e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg04450456	chr4:17643702	FAM184B	-0.47	-4.84	-0.37	3.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-4.44	-0.34	1.7e-5	Prostate cancer;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.1	-0.5	4.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.61	-6.43	-0.46	1.54e-9	Height;
PAAD	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs6466055	0.556	rs12533348	chr7:105024595	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.62	9.77	0.62	8.69e-18	Diastolic blood pressure;
PAAD	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.49	4.74	0.36	4.8e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.79	5.97	0.44	1.57e-8	Mean platelet volume;
PAAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.56	3.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.6	-5.38	-0.4	2.79e-7	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.74	7.88	0.54	5.73e-13	Mosquito bite size;
PAAD	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	5.02	0.38	1.42e-6	Educational attainment;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-5.76	-0.42	4.43e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35740288	0.770	rs35348278	chr15:86200340	G/A	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg09760422	chr2:128146352	NA	-0.38	-6.78	-0.48	2.5e-10	Protein C levels;
PAAD	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.43	4.89	0.37	2.49e-6	Coronary artery disease;
PAAD	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs12612619	0.685	rs4665937	chr2:27241795	A/T	cg00617064	chr2:27272375	NA	0.44	4.66	0.35	6.98e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.55	-5.93	-0.43	2.01e-8	Type 2 diabetes;
PAAD	cis	rs2410601	0.558	rs34747927	chr8:18922851	C/T	cg19414122	chr8:18896631	NA	-0.41	-4.69	-0.36	6.06e-6	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg22029157	chr1:209979665	IRF6	0.72	6.39	0.46	1.95e-9	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19152024	chr3:50374954	RASSF1	0.7	6.74	0.48	3.17e-10	Obesity-related traits;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg11547950	chr5:77652471	NA	0.89	7.37	0.51	9.92e-12	Triglycerides;
PAAD	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.7	-6.79	-0.48	2.39e-10	Platelet distribution width;
PAAD	cis	rs9534288	0.751	rs2806920	chr13:46514506	T/C	cg15192986	chr13:46630673	CPB2	0.6	5.41	0.4	2.45e-7	Blood protein levels;
PAAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg13468214	chr4:1046988	NA	-0.53	-5.73	-0.42	5.34e-8	Recombination rate (males);
PAAD	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.62	5.87	0.43	2.6e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs8113142	0.614	rs2098038	chr19:29192883	A/T	cg04546413	chr19:29218101	NA	0.43	4.41	0.34	1.94e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.64	-6.54	-0.47	8.91e-10	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg23531748	chr20:60969906	CABLES2	0.45	4.52	0.34	1.22e-5	Colorectal cancer;
PAAD	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.5	4.46	0.34	1.56e-5	Multiple sclerosis;
PAAD	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.74	7.87	0.54	6.03e-13	Sjögren's syndrome;
PAAD	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs2275565	0.872	rs7525347	chr1:237022420	T/G	cg17297354	chr1:237056641	MTR	-0.53	-4.74	-0.36	4.95e-6	Homocysteine levels;
PAAD	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg05805236	chr11:65401703	PCNXL3	-0.62	-6.45	-0.46	1.42e-9	Acne (severe);
PAAD	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg23957660	chr17:17878224	LRRC48	-0.38	-4.3	-0.33	3.08e-5	Total body bone mineral density;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg19337854	chr7:99768885	GPC2	0.55	5.05	0.38	1.23e-6	Platelet count;
PAAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg22189786	chr22:42395067	WBP2NL	0.42	4.42	0.34	1.91e-5	Cognitive function;
PAAD	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.17	0.39	7.17e-7	Childhood ear infection;
PAAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.71	8.05	0.55	2.25e-13	Huntington's disease progression;
PAAD	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg14631576	chr9:95140430	CENPP	-0.62	-5.96	-0.44	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12989701	0.877	rs35832505	chr2:127846505	T/C	cg08168897	chr2:127865431	BIN1	0.7	6.15	0.45	6.5e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.93	-0.54	4.47e-13	Blood metabolite levels;
PAAD	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.71	4.74	0.36	4.79e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.47	4.82	0.36	3.5e-6	Red blood cell count;
PAAD	cis	rs2284367	0.941	rs3781709	chr11:34504711	T/C	cg20406267	chr11:34377921	ABTB2	0.41	4.26	0.33	3.58e-5	Blood protein levels;
PAAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs4281086	0.541	rs10094938	chr8:10395326	A/C	cg01072821	chr8:10382165	T-SP1	-0.46	-4.73	-0.36	5.01e-6	Obesity-related traits;
PAAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.43e-6	White blood cell count;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-4.88	-0.37	2.63e-6	Lung cancer;
PAAD	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	7.15	0.5	3.35e-11	Schizophrenia;
PAAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg12807937	chr2:240965920	NDUFA10	0.44	4.49	0.34	1.42e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.9	-0.37	2.43e-6	Height;
PAAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.72	-6.44	-0.46	1.45e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Vitiligo;
PAAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.83	-9.05	-0.59	6.56e-16	Multiple sclerosis;
PAAD	cis	rs939584	0.935	rs6751994	chr2:635866	A/G	cg03610516	chr2:642275	NA	0.56	4.92	0.37	2.25e-6	Body mass index;
PAAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.31	0.56	4.88e-14	Parkinson's disease;
PAAD	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg01422370	chr2:73384389	NA	0.39	5.12	0.38	9.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs72960926	1.000	rs72958945	chr6:75109509	G/C	cg13997649	chr6:74171430	MTO1	0.81	4.5	0.34	1.37e-5	Metabolite levels (MHPG);
PAAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.88	-0.37	2.64e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.26	-0.39	4.8e-7	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.48	4.67	0.35	6.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.9	-0.37	2.41e-6	Height;
PAAD	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.81	9.43	0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg11530693	chr1:120165357	ZNF697	0.61	6.73	0.48	3.27e-10	Systemic lupus erythematosus;
PAAD	cis	rs2278796	0.639	rs6661381	chr1:204971553	A/G	cg17947172	chr1:204966197	NFASC	0.43	4.67	0.35	6.66e-6	Mean platelet volume;
PAAD	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.52	5.94	0.43	1.82e-8	Migraine;
PAAD	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg08992911	chr2:238395768	MLPH	0.85	6.8	0.48	2.3e-10	Prostate cancer;
PAAD	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.48	0.34	1.45e-5	Schizophrenia;
PAAD	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.88	6.65	0.47	4.99e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.63	-6.62	-0.47	5.74e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs367943	0.660	rs9632462	chr5:112697801	T/C	cg12552261	chr5:112820674	MCC	0.65	6.35	0.46	2.41e-9	Type 2 diabetes;
PAAD	cis	rs17774123	0.851	rs11830166	chr12:54287370	A/C	cg26201952	chr12:54446253	HOXC4	-0.49	-4.4	-0.34	2.02e-5	Diastolic blood pressure;
PAAD	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg08619932	chr19:49200058	FUT2	0.61	6.72	0.48	3.47e-10	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.64	-4.93	-0.37	2.1e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.81	7.86	0.54	6.38e-13	Methadone dose in opioid dependence;
PAAD	cis	rs72781680	0.566	rs6713979	chr2:23899876	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	5.78	0.42	4.1e-8	Lymphocyte counts;
PAAD	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.6	7.52	0.52	4.54e-12	Multiple sclerosis;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.72	0.48	3.47e-10	Coffee consumption (cups per day);
PAAD	cis	rs939584	1.000	rs13415094	chr2:653093	T/C	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg00738919	chr7:1100172	C7orf50	0.68	4.76	0.36	4.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg24633833	chr3:10029261	TMEM111	0.58	4.27	0.33	3.5e-5	Alzheimer's disease;
PAAD	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg19723775	chr5:179050963	HNRNPH1	0.48	4.3	0.33	2.98e-5	Lung cancer;
PAAD	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.41	5.04	0.38	1.28e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.86	8.64	0.57	7.18e-15	Cognitive function;
PAAD	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg10434728	chr15:90938212	IQGAP1	0.49	4.96	0.37	1.88e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg26205652	chr12:48591994	NA	0.85	8.27	0.56	6.25e-14	Longevity (90 years and older);
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.84	-0.43	3.06e-8	Tonsillectomy;
PAAD	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.35	-0.4	3.19e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	6.08	0.44	9.46e-9	Lung cancer;
PAAD	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.63	-0.35	7.91e-6	Mood instability;
PAAD	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-4.96	-0.37	1.9e-6	Reticulocyte count;
PAAD	cis	rs9384478	0.850	rs67367007	chr6:156919569	G/A	cg21827153	chr6:157009102	NA	1.05	4.45	0.34	1.64e-5	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6028335	0.610	rs73108592	chr20:37532139	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.65	-0.35	7.01e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.54	5.4	0.4	2.54e-7	Mean corpuscular volume;
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.66	-6.57	-0.47	7.5e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.53	5.59	0.41	1.03e-7	Red blood cell count;
PAAD	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.71	-5.46	-0.41	1.86e-7	Electroencephalogram traits;
PAAD	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg14440974	chr22:39074834	NA	-0.62	-7.0	-0.49	7.88e-11	Menopause (age at onset);
PAAD	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg22532475	chr10:104410764	TRIM8	-0.47	-5.26	-0.39	4.85e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg24642844	chr7:1081250	C7orf50	0.59	4.67	0.35	6.47e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-15.31	-0.78	1.34e-32	Height;
PAAD	trans	rs9392556	0.829	rs853416	chr6:4113047	A/T	cg00616965	chr11:1331217	LOC255512;TOLLIP	0.53	6.37	0.46	2.15e-9	Blood metabolite levels;
PAAD	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	8.07	0.55	1.98e-13	Eotaxin levels;
PAAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.79	0.62	7.63e-18	Chronic sinus infection;
PAAD	cis	rs2124910	1.000	rs2290660	chr19:52031304	C/A	cg12008991	chr19:52034861	SIGLEC6	0.39	5.16	0.39	7.77e-7	Blood protein levels;
PAAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.9	-0.43	2.32e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6076065	0.723	rs2424539	chr20:23384904	C/T	cg11657817	chr20:23433608	CST11	-0.5	-5.05	-0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.72e-15	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08267141	chr4:110354820	SEC24B	0.68	6.69	0.48	3.96e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Breast cancer;
PAAD	cis	rs4455778	0.580	rs7796664	chr7:49117787	C/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9810890	1.000	rs41266497	chr3:128526207	A/G	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.74	0.48	3.06e-10	Atopic dermatitis;
PAAD	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.79	0.58	2.99e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11702148	0.552	rs2834235	chr21:34901423	C/T	cg14850771	chr21:34775459	IFNGR2	-0.44	-4.58	-0.35	9.53e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg02264943	chr11:130785842	SNX19	0.37	4.36	0.33	2.38e-5	Schizophrenia;
PAAD	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.65	-6.75	-0.48	2.99e-10	Primary sclerosing cholangitis;
PAAD	cis	rs8018808	0.935	rs11625365	chr14:77908588	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg14349672	chr11:133703707	NA	-0.53	-6.0	-0.44	1.42e-8	Childhood ear infection;
PAAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.93	-7.29	-0.51	1.6e-11	Initial pursuit acceleration;
PAAD	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.96	-9.16	-0.6	3.27e-16	Body mass index;
PAAD	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.57	4.34	0.33	2.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.6e-13	Rheumatoid arthritis;
PAAD	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.69	-7.9	-0.54	5.24e-13	Prudent dietary pattern;
PAAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg24253500	chr15:84953950	NA	0.41	4.38	0.33	2.22e-5	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.62	-8.24	-0.56	7.25e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs11264213	0.892	rs72659664	chr1:36185467	G/A	cg27506609	chr1:36549197	TEKT2	0.63	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs73416724	0.841	rs75782786	chr6:43320055	C/A	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10450586	0.932	rs10160687	chr11:27337183	T/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.18e-22	Parkinson's disease;
PAAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.72	-7.35	-0.51	1.12e-11	Colorectal cancer;
PAAD	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.84	8.9	0.59	1.6e-15	Corneal astigmatism;
PAAD	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.63	-0.35	7.69e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	7.67	0.53	1.96e-12	Homoarginine levels;
PAAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.62	7.42	0.52	7.81e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.73	-6.04	-0.44	1.13e-8	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01818648	chr8:30515364	GTF2E2	-0.66	-6.55	-0.47	8.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.07	-18.7	-0.83	3.04e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3784262	0.669	rs1063666	chr15:58246602	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.35	-0.4	3.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2221894	0.960	rs10093622	chr8:28862937	G/T	cg20212339	chr8:28908912	HMBOX1	0.51	5.35	0.4	3.23e-7	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.92	9.12	0.59	4.33e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03884976	chr16:577621	SOLH;C16orf10	0.63	6.5	0.47	1.12e-9	Myopia (pathological);
PAAD	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs829661	1.000	rs2609951	chr2:30870614	A/G	cg12454169	chr2:30669597	LCLAT1	0.63	4.69	0.36	6e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.64	5.32	0.4	3.71e-7	Diastolic blood pressure;
PAAD	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.61	6.61	0.47	6.28e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg00262122	chr8:11665843	FDFT1	0.51	4.88	0.37	2.61e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.57	5.62	0.41	8.88e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg21361702	chr7:150065534	REPIN1	0.55	4.67	0.35	6.55e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg01021169	chr22:30184971	ASCC2	-0.46	-4.62	-0.35	8.22e-6	Type 1 diabetes;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.5	-5.37	-0.4	2.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.85	8.85	0.58	2.05e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs17641971	0.645	rs341805	chr8:50034658	T/G	cg00325661	chr8:49890786	NA	0.64	6.46	0.46	1.34e-9	Blood metabolite levels;
PAAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg09796270	chr17:17721594	SREBF1	0.48	5.29	0.39	4.22e-7	Total body bone mineral density;
PAAD	cis	rs2790216	1.000	rs2790169	chr10:60025654	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs59901009	0.577	rs7130610	chr11:10044104	C/G	cg06876053	chr11:9810051	SBF2	-0.33	-4.36	-0.33	2.39e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs8064299	0.536	rs2290038	chr17:72786611	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.95	-9.83	-0.62	5.95e-18	Monocyte count;
PAAD	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-4.55	-0.35	1.08e-5	Mean platelet volume;
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.5	-4.89	-0.37	2.59e-6	Motion sickness;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg26298942	chr17:58603427	APPBP2	0.59	6.41	0.46	1.76e-9	Iris heterochromicity;
PAAD	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg02883595	chr6:39281421	KCNK17	-0.44	-4.26	-0.33	3.57e-5	Type 2 diabetes;
PAAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	4.25	0.33	3.74e-5	Menarche (age at onset);
PAAD	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.57	4.31	0.33	2.97e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs245880	0.740	rs245890	chr7:29190720	T/C	cg17163760	chr7:29186267	CPVL	-0.52	-6.21	-0.45	4.76e-9	Warfarin maintenance dose;
PAAD	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.72	7.14	0.5	3.61e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.92	-7.29	-0.51	1.62e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs990171	0.538	rs6543150	chr2:103113983	C/T	cg03938978	chr2:103052716	IL18RAP	0.42	4.3	0.33	3.07e-5	Lymphocyte counts;
PAAD	cis	rs6466479	0.925	rs10242355	chr7:113762940	G/A	cg03012726	chr7:113722758	NA	-0.45	-4.39	-0.34	2.15e-5	IgG glycosylation;
PAAD	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.78	7.76	0.53	1.18e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs7588746	0.544	rs2163548	chr2:201226862	C/G	cg23649088	chr2:200775458	C2orf69	-0.66	-4.25	-0.33	3.64e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs9810890	1.000	rs73196971	chr3:128443606	G/C	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.49	-0.41	1.66e-7	Glomerular filtration rate;
PAAD	cis	rs881827	0.821	rs1047221	chr21:48003193	A/G	cg14789911	chr21:47582049	C21orf56	-0.49	-4.7	-0.36	5.88e-6	Lymphocyte counts;
PAAD	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.79	-0.36	3.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg08219700	chr8:58056026	NA	0.7	5.59	0.41	1.01e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.61	-6.82	-0.48	2.01e-10	Monocyte count;
PAAD	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg14851346	chr12:38532713	NA	-0.46	-4.44	-0.34	1.7e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.32	-0.46	2.72e-9	Hip circumference;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11464285	chr11:33796225	FBXO3	0.64	7.12	0.5	4.03e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-5.04	-0.38	1.33e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.57	-0.47	7.42e-10	HDL cholesterol;
PAAD	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs863345	0.967	rs12133354	chr1:158526537	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06850241	chr22:41845214	NA	-0.54	-5.16	-0.39	7.58e-7	Vitiligo;
PAAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.35	-4.88	-0.37	2.64e-6	Breast cancer;
PAAD	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.63	6.49	0.47	1.17e-9	Dupuytren's disease;
PAAD	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.63	-5.49	-0.41	1.62e-7	Red blood cell count;
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg15181151	chr6:150070149	PCMT1	0.6	6.54	0.47	8.96e-10	Lung cancer;
PAAD	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.8	6.13	0.45	7.14e-9	Diisocyanate-induced asthma;
PAAD	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.49	5.3	0.4	3.92e-7	Heart rate;
PAAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	0.86	8.21	0.55	9.04e-14	Gestational age at birth (maternal effect);
PAAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs9469890	0.604	rs77587944	chr6:34503644	T/G	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.99	0.49	7.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.75	-7.59	-0.52	3.07e-12	Gout;
PAAD	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.53	4.83	0.37	3.23e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg09417038	chr21:47716443	C21orf57	-0.41	-4.33	-0.33	2.73e-5	Testicular germ cell tumor;
PAAD	cis	rs7267348	0.579	rs6012677	chr20:48103201	T/C	cg03558299	chr20:47662597	CSE1L	-0.63	-4.25	-0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg19949948	chr17:19361230	NA	0.44	4.83	0.36	3.28e-6	Schizophrenia;
PAAD	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.97e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4704187	0.687	rs11957125	chr5:74527639	G/A	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.87	9.34	0.6	1.12e-16	Schizophrenia;
PAAD	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.34	-4.25	-0.33	3.76e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg21211367	chr2:162094118	NA	0.49	4.7	0.36	5.81e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.96	0.37	1.88e-6	Height;
PAAD	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg03233332	chr7:66118400	NA	0.4	4.31	0.33	2.88e-5	Aortic root size;
PAAD	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs8018808	1.000	rs4575469	chr14:77860543	G/A	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg05709478	chr1:6581295	PLEKHG5	0.73	4.7	0.36	5.72e-6	Body mass index;
PAAD	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.82	-0.54	8.14e-13	Neuroticism;
PAAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.65	7.75	0.53	1.24e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16371080	chr4:3309069	NA	0.56	6.34	0.46	2.5e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.61	6.45	0.46	1.39e-9	Bone mineral density;
PAAD	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.45	5.86	0.43	2.81e-8	Cystic fibrosis severity;
PAAD	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs75920871	0.925	rs4936362	chr11:116952200	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.47	4.32	0.33	2.83e-5	Resistin levels;
PAAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.76e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2790457	0.795	rs7903703	chr10:28935149	T/C	cg05705492	chr10:28955341	NA	-0.49	-4.95	-0.37	1.92e-6	Multiple myeloma;
PAAD	cis	rs59888335	0.929	rs34681735	chr3:80807976	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs80130819	0.688	rs4760692	chr12:48587549	T/C	cg26205652	chr12:48591994	NA	0.7	4.83	0.36	3.34e-6	Prostate cancer;
PAAD	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg06131755	chr6:160182447	ACAT2	0.51	4.28	0.33	3.26e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg27182935	chr16:89790473	ZNF276	-0.86	-4.26	-0.33	3.63e-5	Skin colour saturation;
PAAD	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.27e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.58	4.92	0.37	2.23e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.3	0.4	3.97e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg04520793	chr17:42248056	ASB16	-0.43	-5.1	-0.38	9.93e-7	Total body bone mineral density;
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.63	-7.01	-0.49	7.22e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.19	0.45	5.23e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.84	8.01	0.54	2.78e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1930961	1.000	rs6004672	chr22:25881013	T/A	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.31	-0.46	2.83e-9	Mood instability;
PAAD	trans	rs901683	1.000	rs71494802	chr10:46005624	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	5.72	0.42	5.47e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs76533333	0.646	rs71446628	chr13:113393611	C/T	cg02820901	chr13:113351484	ATP11A	-0.79	-4.69	-0.36	5.98e-6	Red cell distribution width;
PAAD	cis	rs78773383	0.505	rs6823497	chr4:39385821	C/A	cg16714752	chr4:39368184	RFC1	-0.5	-5.06	-0.38	1.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs9463078	0.764	rs3799971	chr6:44819319	G/C	cg25276700	chr6:44698697	NA	-0.46	-5.24	-0.39	5.22e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs2139634	0.965	rs2037391	chr3:46539523	G/A	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.57	0.35	1e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-8.84	-0.58	2.22e-15	Prostate cancer;
PAAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg06115741	chr20:33292138	TP53INP2	-0.44	-4.26	-0.33	3.55e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.46	-4.73	-0.36	5.11e-6	Dementia with Lewy bodies;
PAAD	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg04265051	chr11:68079686	LRP5	-0.36	-4.41	-0.34	1.96e-5	Mean corpuscular volume;
PAAD	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-9.1	-0.59	4.66e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7360412	1.000	rs7360412	chr20:2800801	G/T	cg18164281	chr20:2797721	LOC100288797	-0.54	-5.1	-0.38	9.82e-7	White matter integrity;
PAAD	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.64	-0.42	8.14e-8	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg19442545	chr10:75533431	FUT11	-0.43	-4.36	-0.33	2.41e-5	Inflammatory bowel disease;
PAAD	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg07395648	chr5:131743802	NA	0.5	4.26	0.33	3.5e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.91	-4.78	-0.36	4.05e-6	Childhood ear infection;
PAAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.89	-7.68	-0.53	1.84e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg10818794	chr15:86012489	AKAP13	-0.58	-4.92	-0.37	2.22e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.26e-6	Neuroticism;
PAAD	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.82	-5.84	-0.43	3.04e-8	Coronary artery disease;
PAAD	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.69	5.06	0.38	1.22e-6	Type 2 diabetes;
PAAD	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg08079166	chr15:68083412	MAP2K5	0.65	5.14	0.39	8.16e-7	Restless legs syndrome;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23708337	chr7:1209742	NA	0.64	4.46	0.34	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.65	-5.8	-0.43	3.69e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.88	0.37	2.69e-6	Iron status biomarkers;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6988985	0.560	rs7826809	chr8:143925609	C/T	cg10324643	chr8:143916377	GML	0.42	4.52	0.34	1.26e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.64	6.67	0.48	4.4e-10	Multiple sclerosis;
PAAD	cis	rs12935418	0.616	rs7184568	chr16:80964848	G/C	cg16651780	chr16:81037892	C16orf61	0.59	4.89	0.37	2.57e-6	Mean corpuscular volume;
PAAD	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg25008857	chr14:105974488	NA	0.39	4.26	0.33	3.62e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs1572438	0.760	rs7766707	chr6:869501	C/T	cg13447295	chr6:887704	NA	-0.54	-5.3	-0.39	4e-7	Aging;
PAAD	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg11657817	chr20:23433608	CST11	0.41	4.52	0.34	1.23e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.64	6.72	0.48	3.44e-10	Schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16925659	chr1:31192151	MATN1	0.58	6.32	0.46	2.69e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg09237302	chr4:906077	GAK	-0.43	-4.49	-0.34	1.43e-5	Type 2 diabetes;
PAAD	cis	rs1499972	0.582	rs7427670	chr3:117884913	C/A	cg07612923	chr3:117604196	NA	-0.83	-5.32	-0.4	3.64e-7	Schizophrenia;
PAAD	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.36	0.6	9.84e-17	Diabetic retinopathy;
PAAD	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.74	9.5	0.61	4.43e-17	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-1.01	-11.39	-0.68	3.96e-22	Cancer (pleiotropy);
PAAD	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18085070	chr1:109825730	PSRC1	0.65	6.35	0.46	2.33e-9	Obesity-related traits;
PAAD	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg23033748	chr14:75592666	NEK9	-0.41	-5.09	-0.38	1.06e-6	Height;
PAAD	cis	rs7594192	0.701	rs6727763	chr2:199371236	A/G	cg07835424	chr2:200327334	NA	0.35	4.28	0.33	3.28e-5	Educational attainment;
PAAD	cis	rs8005172	0.750	rs2245387	chr14:88454691	C/T	cg18078958	chr14:88630771	NA	0.48	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.56	5.22	0.39	5.78e-7	Coronary artery disease;
PAAD	cis	rs13088645	0.621	rs6767595	chr3:134146845	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.54	5.19	0.39	6.7e-7	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg21823605	chr1:152486609	CRCT1	0.49	6.15	0.45	6.54e-9	Hair morphology;
PAAD	cis	rs2594989	0.943	rs9878389	chr3:11457099	T/G	cg01796438	chr3:11312864	ATG7	-0.56	-4.36	-0.33	2.35e-5	Circulating chemerin levels;
PAAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.95	5.88	0.43	2.53e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25726224	chr4:2402046	ZFYVE28	0.64	6.94	0.49	1.06e-10	Smoking initiation;
PAAD	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.49	4.7	0.36	5.74e-6	Corneal structure;
PAAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.65	-0.57	6.99e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4908768	0.594	rs11121228	chr1:8830642	T/C	cg00590817	chr1:8272081	NA	-0.36	-4.37	-0.33	2.27e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7219021	0.926	rs7208848	chr17:46855295	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg25972092	chr12:117363249	FBXW8	0.83	6.4	0.46	1.83e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	trans	rs6991952	0.663	rs7004286	chr8:25732001	G/T	cg22376929	chr19:2478127	GADD45B	-0.55	-6.42	-0.46	1.65e-9	Inguinal hernia;
PAAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.86	0.37	2.85e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg21351543	chr2:191399470	TMEM194B	-0.57	-4.39	-0.34	2.12e-5	Diastolic blood pressure;
PAAD	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.65	5.19	0.39	6.57e-7	Prostate cancer;
PAAD	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.86	-0.54	6.7e-13	Neuroticism;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.36	-0.4	3.08e-7	Testicular germ cell tumor;
PAAD	cis	rs7187994	0.848	rs35019923	chr16:84782214	A/C	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs10861342	0.579	rs77585712	chr12:105482251	T/C	cg23923672	chr12:105501055	KIAA1033	0.78	4.62	0.35	8.11e-6	IgG glycosylation;
PAAD	cis	rs3112530	1.000	rs1462126	chr5:152638353	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.94	-5.25	-0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg08835956	chr7:39171034	POU6F2	0.3	5.03	0.38	1.38e-6	IgG glycosylation;
PAAD	cis	rs300774	0.925	rs365967	chr2:123233	G/A	cg21211680	chr2:198530	NA	-0.64	-5.84	-0.43	3e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.92	0.37	2.23e-6	Menopause (age at onset);
PAAD	cis	rs757081	0.613	rs11024151	chr11:17105730	T/G	cg15432903	chr11:17409602	KCNJ11	-0.61	-6.21	-0.45	4.76e-9	Systolic blood pressure;
PAAD	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	7.18	0.5	2.82e-11	Schizophrenia;
PAAD	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg11288833	chr15:55489084	RSL24D1	0.56	4.62	0.35	8.07e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg12315302	chr6:26189340	HIST1H4D	0.86	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs13242816	1.000	rs3807988	chr7:116180735	A/C	cg16553024	chr7:116138462	CAV2	-0.64	-4.47	-0.34	1.55e-5	P wave duration;
PAAD	cis	rs12453682	0.568	rs3794712	chr17:37791487	A/C	cg20243544	chr17:37824526	PNMT	0.59	4.7	0.36	5.8e-6	Mean corpuscular hemoglobin;Red blood cell count;
PAAD	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.61	6.62	0.47	5.81e-10	High light scatter reticulocyte count;
PAAD	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06850241	chr22:41845214	NA	-0.59	-5.43	-0.4	2.22e-7	Vitiligo;
PAAD	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.0	14.06	0.75	2.69e-29	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg03999872	chr20:62272968	STMN3	-0.76	-7.06	-0.5	5.47e-11	Atopic dermatitis;
PAAD	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.22	21.94	0.87	5.7e-49	Myeloid white cell count;
PAAD	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg10437265	chr15:77819839	NA	-0.37	-4.29	-0.33	3.22e-5	Type 2 diabetes;
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.47	-4.42	-0.34	1.9e-5	Breast cancer;
PAAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12799264	1.000	rs2449499	chr11:19976582	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.67	-0.35	6.67e-6	Recombination measurement;
PAAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9535307	0.929	rs3851162	chr13:50354150	T/G	cg03658251	chr13:50265850	EBPL	0.81	5.49	0.41	1.68e-7	Obesity-related traits;
PAAD	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs1018697	0.966	rs1953930	chr10:104549461	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.17	0.45	5.83e-9	Colorectal adenoma (advanced);
PAAD	cis	rs9430161	0.611	rs72644044	chr1:11034347	C/G	cg11949866	chr1:10754891	CASZ1	0.53	4.32	0.33	2.75e-5	Ewing sarcoma;
PAAD	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.62	6.65	0.47	4.88e-10	Menarche (age at onset);
PAAD	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-5.31	-0.4	3.74e-7	Lung cancer in ever smokers;
PAAD	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07630564	chr3:128445061	RAB7A	0.57	6.49	0.47	1.12e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg13660082	chr14:53194042	PSMC6	0.71	4.48	0.34	1.43e-5	Alzheimer's disease (late onset);
PAAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg06671706	chr8:8559999	CLDN23	0.75	7.36	0.51	1.09e-11	Obesity-related traits;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg14393609	chr7:65229607	NA	-0.64	-6.68	-0.48	4.16e-10	Calcium levels;
PAAD	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	8.94e-7	Motion sickness;
PAAD	cis	rs1569175	0.522	rs1396972	chr2:200867028	C/T	cg23649088	chr2:200775458	C2orf69	0.8	4.58	0.35	9.7e-6	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.51	-6.68	-0.48	4.23e-10	Life satisfaction;
PAAD	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.83	0.43	3.18e-8	Obesity-related traits;
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs12986413	0.934	rs6510645	chr19:2158398	T/C	cg09261902	chr19:2140048	AP3D1	0.5	4.85	0.37	2.99e-6	Height;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg04160749	chr8:58172571	NA	-0.75	-4.87	-0.37	2.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.47	-0.34	1.51e-5	Joint mobility (Beighton score);
PAAD	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.37	9.57	0.61	2.92e-17	Diabetic retinopathy;
PAAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg21856205	chr7:94953877	PON1	0.51	4.28	0.33	3.35e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.32	-0.4	3.7e-7	Alcohol dependence;
PAAD	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.89	-0.66	8.74e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg01683948	chr16:4784196	ANKS3;C16orf71	-0.51	-4.5	-0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	5.27	0.39	4.58e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg06207120	chr15:45996521	NA	-0.3	-4.44	-0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.09	0.38	1.03e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg26014689	chr19:7917955	EVI5L	-0.63	-6.22	-0.45	4.58e-9	Menarche (age at onset);
PAAD	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg05731713	chr7:157510257	PTPRN2	0.55	5.82	0.43	3.39e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.55	-5.45	-0.4	1.96e-7	Capecitabine sensitivity;
PAAD	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06998765	chr14:75389618	RPS6KL1	0.28	4.98	0.37	1.69e-6	Caffeine consumption;
PAAD	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.63	4.63	0.35	7.69e-6	Alzheimer's disease (survival time);
PAAD	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.68	5.75	0.42	4.7e-8	Educational attainment;
PAAD	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.63	5.61	0.41	9.41e-8	Lung cancer;
PAAD	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.23	-0.51	2.22e-11	Breast cancer;
PAAD	cis	rs6604026	0.656	rs2774956	chr1:93364726	A/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.71	8.93	0.59	1.32e-15	Dupuytren's disease;
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.23e-14	Colorectal cancer;
PAAD	cis	rs7594192	0.736	rs1378402	chr2:199421578	G/C	cg03163783	chr2:200326591	SATB2	0.32	4.53	0.34	1.2e-5	Educational attainment;
PAAD	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	6.84e-7	Pulmonary function;
PAAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.75	8.79	0.58	2.93e-15	Emphysema distribution in smoking;
PAAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.51	-5.21	-0.39	6.13e-7	Coronary artery disease;
PAAD	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs17681684	0.565	rs12150149	chr17:9764039	A/C	cg26853458	chr17:9805074	RCVRN	-0.73	-7.66	-0.53	1.99e-12	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11669133	1.000	rs45471592	chr19:11107085	G/A	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.95	-0.37	1.91e-6	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-7.81	-0.54	8.59e-13	Body mass index;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs6429082	0.744	rs903347	chr1:235586613	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.52	-5.27	-0.39	4.63e-7	Adiposity;
PAAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg03676636	chr4:99064102	C4orf37	0.25	4.3	0.33	3.03e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7300001	0.504	rs12318462	chr12:110504717	C/A	cg12870014	chr12:110450643	ANKRD13A	1.0	5.66	0.42	7.34e-8	Headache;
PAAD	cis	rs76917914	0.820	rs55978131	chr9:100813404	G/A	cg21225548	chr9:100864335	TRIM14	-0.55	-5.96	-0.44	1.71e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.84	-10.89	-0.66	9.17e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg23018236	chr17:30244563	NA	-0.6	-4.5	-0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.9	8.42	0.56	2.64e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.69	8.11	0.55	1.58e-13	Multiple sclerosis;
PAAD	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	5.78	0.42	4.16e-8	Adiposity;
PAAD	cis	rs939584	1.000	rs4452188	chr2:648810	A/G	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	ch.11.42038R	chr11:967971	AP2A2	0.62	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6681460	0.932	rs665319	chr1:67175488	A/G	cg02459107	chr1:67143332	SGIP1	0.7	6.49	0.47	1.12e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-4.61	-0.35	8.4e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9462027	0.527	rs11755393	chr6:34824636	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.35	-0.4	3.11e-7	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03612258	chr19:8070121	ELAVL1	0.65	7.85	0.54	6.78e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.92	-0.54	4.77e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.32	-0.33	2.83e-5	Type 2 diabetes;
PAAD	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.11	-0.38	9.33e-7	Schizophrenia;
PAAD	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.68	5.74	0.42	4.87e-8	Menarche (age at onset);
PAAD	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.04	-0.38	1.3e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg17445618	chr1:19577962	KIAA0090;MRTO4	-0.53	-5.14	-0.38	8.48e-7	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19522332	chr3:178866004	PIK3CA	0.6	7.07	0.5	5.29e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.85	5.47	0.41	1.78e-7	Body mass index;
PAAD	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.37	10.26	0.64	4.36e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.81	9.73	0.62	1.05e-17	Bladder cancer;
PAAD	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-6.39	-0.46	1.92e-9	Monocyte percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24432051	chr3:50606741	HEMK1	-0.74	-6.57	-0.47	7.47e-10	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26273962	chr10:97321188	SORBS1	-0.78	-6.89	-0.49	1.41e-10	Neuroticism;
PAAD	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.54	5.15	0.39	7.99e-7	Mortality in heart failure;
PAAD	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg19131313	chr8:1704013	NA	-0.43	-4.53	-0.34	1.2e-5	Systolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23968551	chr4:40818214	APBB2	0.62	6.32	0.46	2.79e-9	Smoking initiation;
PAAD	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg18721089	chr20:30220636	NA	-0.6	-4.93	-0.37	2.17e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs488248	0.540	rs17514479	chr13:106596215	T/A	cg03898952	chr13:107069935	NA	0.75	4.58	0.35	9.5e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.44	0.34	1.69e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs6828577	0.695	rs62324878	chr4:119455605	G/A	cg26518628	chr1:97050305	NA	-0.71	-6.31	-0.46	2.87e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.2	-0.39	6.33e-7	Aortic root size;
PAAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.67	0.42	7.01e-8	Tonsillectomy;
PAAD	cis	rs9660180	0.819	rs4648629	chr1:1695462	C/A	cg23982607	chr1:1823379	GNB1	0.65	7.03	0.5	6.67e-11	Body mass index;
PAAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02071572	chr4:1403502	NA	-0.44	-5.92	-0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs863345	0.625	rs10489833	chr1:158490451	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.33	-0.4	3.48e-7	Systolic blood pressure;
PAAD	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27164771	chr11:19138675	ZDHHC13	0.61	6.93	0.49	1.14e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs61677309	1.000	rs61390396	chr11:118156718	C/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg02631450	chr22:32366979	NA	1.02	5.56	0.41	1.19e-7	Childhood ear infection;
PAAD	cis	rs6987853	0.563	rs10958723	chr8:42448188	T/C	cg09913449	chr8:42400586	C8orf40	0.51	5.82	0.43	3.38e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg00129232	chr17:37814104	STARD3	-0.52	-4.39	-0.34	2.14e-5	Self-reported allergy;
PAAD	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.5	-4.89	-0.37	2.49e-6	Facial morphology (factor 20);
PAAD	cis	rs1419980	0.730	rs7974405	chr12:7739219	C/T	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04166115	chr12:125671104	NA	0.62	7.06	0.5	5.7e-11	Myopia (pathological);
PAAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.72e-6	Oral cavity cancer;
PAAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg18230493	chr5:56204884	C5orf35	-0.57	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs16975963	0.793	rs1807157	chr19:38465523	G/T	cg14218481	chr19:38281219	NA	0.49	5.04	0.38	1.29e-6	Longevity;
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.46	0.46	1.31e-9	Lung cancer;
PAAD	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.59	-5.1	-0.38	1e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.5	-0.52	4.82e-12	Colorectal cancer;
PAAD	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs354225	0.584	rs10206143	chr2:54817453	A/T	cg01766943	chr2:54829624	SPTBN1	0.53	5.03	0.38	1.39e-6	Schizophrenia;
PAAD	cis	rs11807834	0.522	rs7549029	chr1:230253406	G/A	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.9	7.81	0.54	8.75e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.19	0.39	6.58e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg14329783	chr7:75779857	NA	0.79	4.63	0.35	7.64e-6	Mononucleosis;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg02462569	chr6:150064036	NUP43	-0.51	-5.81	-0.43	3.46e-8	Lung cancer;
PAAD	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	4.4	0.34	2.06e-5	Neutrophil percentage of white cells;
PAAD	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.55	-5.12	-0.38	9.13e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7551345	0.853	rs6425724	chr1:31728856	G/A	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.48	4.39	0.34	2.15e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.38e-5	Longevity (90 years and older);
PAAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.14	0.5	3.54e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	5.23	0.39	5.4e-7	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08734194	chr17:3527458	SHPK	-0.62	-6.72	-0.48	3.46e-10	Obesity-related traits;
PAAD	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg17840343	chr10:93683703	BTAF1	0.94	6.79	0.48	2.43e-10	Lung function (FEV1/FVC);
PAAD	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs9659323	0.700	rs10923746	chr1:119616278	A/G	cg17326555	chr1:119535693	NA	-0.38	-5.23	-0.39	5.45e-7	Body mass index;
PAAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs1198430	0.636	rs2156087	chr1:23743581	C/G	cg27447006	chr1:23763279	ASAP3	-0.69	-6.21	-0.45	4.81e-9	Total cholesterol levels;
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.64	6.15	0.45	6.5e-9	Blood metabolite levels;
PAAD	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.75	11.54	0.68	1.58e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg03303774	chr4:1407052	NA	0.37	4.37	0.33	2.32e-5	Obesity-related traits;
PAAD	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg07541023	chr7:19748670	TWISTNB	0.54	4.68	0.36	6.2e-6	Thyroid stimulating hormone;
PAAD	cis	rs990171	1.000	rs1420106	chr2:103035044	C/T	cg03938978	chr2:103052716	IL18RAP	-0.44	-4.31	-0.33	2.89e-5	Lymphocyte counts;
PAAD	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.73	6.85	0.49	1.73e-10	Asthma;
PAAD	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.9	10.76	0.66	1.94e-20	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.57	6.34	0.46	2.5e-9	Metabolite levels  (X-11787);
PAAD	cis	rs847851	0.917	rs6912327	chr6:34764922	T/C	cg13196216	chr6:34231128	NA	-0.64	-4.65	-0.35	7.07e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.66	6.17	0.45	5.85e-9	Subjective well-being;
PAAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs300774	1.000	rs378456	chr2:119346	C/G	cg23649280	chr2:140451	NA	-0.5	-4.72	-0.36	5.29e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs643506	0.874	rs634983	chr11:111747427	C/T	cg09085632	chr11:111637200	PPP2R1B	0.53	4.45	0.34	1.66e-5	Breast cancer;
PAAD	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg00531865	chr16:30841666	NA	-0.62	-5.39	-0.4	2.67e-7	Multiple myeloma;
PAAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.57	-5.37	-0.4	2.84e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.76	4.75	0.36	4.65e-6	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg15117754	chr3:10150083	C3orf24	0.76	6.26	0.45	3.75e-9	Alzheimer's disease;
PAAD	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08228715	chr17:79895357	PYCR1	0.69	7.98	0.54	3.39e-13	Myopia (pathological);
PAAD	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg07154921	chr7:157260426	NA	0.44	4.25	0.33	3.71e-5	Body mass index;
PAAD	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg00071950	chr4:10020882	SLC2A9	-0.66	-6.22	-0.45	4.58e-9	Schizophrenia (age at onset);
PAAD	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-8.98	-0.59	9.51e-16	Colorectal cancer;
PAAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.87	10.06	0.63	1.49e-18	Ulcerative colitis;
PAAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg01489032	chr8:143877656	NA	-0.4	-4.56	-0.35	1.05e-5	Urinary tract infection frequency;
PAAD	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg00277334	chr10:82204260	NA	-0.76	-8.9	-0.59	1.55e-15	Post bronchodilator FEV1;
PAAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.29	-0.33	3.19e-5	Renal cell carcinoma;
PAAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg24733560	chr20:60626293	TAF4	0.44	5.37	0.4	2.92e-7	Body mass index;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14824382	chr8:144680115	EEF1D;TIGD5	0.66	6.51	0.47	1.01e-9	Primary biliary cholangitis;
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg16898833	chr6:26189333	HIST1H4D	0.56	4.32	0.33	2.84e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.63	6.52	0.47	9.75e-10	Testicular germ cell tumor;
PAAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.93	7.83	0.54	7.54e-13	Alzheimer's disease;
PAAD	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.3	0.45	3.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.7	7.58	0.52	3.16e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs367943	0.698	rs12719164	chr5:112960802	A/C	cg12552261	chr5:112820674	MCC	0.53	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs11203032	0.831	rs11203027	chr10:90956290	T/A	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00289084	chr20:3828030	MAVS	0.62	7.35	0.51	1.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg13160058	chr8:26243215	BNIP3L	0.4	4.9	0.37	2.42e-6	Height;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg18279126	chr7:2041391	MAD1L1	-0.6	-6.15	-0.45	6.69e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.81	-0.48	2.16e-10	Aortic root size;
PAAD	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg03522150	chr11:46969673	C11orf49	0.43	5.19	0.39	6.72e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.27e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-4.45	-0.34	1.65e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs4448343	1.000	rs16909919	chr9:98265780	A/G	cg13428213	chr9:98267529	PTCH1	-0.45	-4.25	-0.33	3.69e-5	Height;
PAAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg25204440	chr1:209979598	IRF6	0.67	5.61	0.41	9.43e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.82	9.49	0.61	4.53e-17	Breast cancer;
PAAD	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg18939081	chr1:31884902	SERINC2	-0.49	-5.71	-0.42	5.78e-8	Alcohol dependence;
PAAD	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12992689	chr12:121015354	RNF10	0.61	6.31	0.46	2.87e-9	Smoking initiation;
PAAD	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.31e-16	Asthma;
PAAD	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.69	7.72	0.53	1.45e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.67	-0.42	6.87e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.64	7.34	0.51	1.18e-11	Mosquito bite size;
PAAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.91	9.81	0.62	6.48e-18	Breast cancer;
PAAD	cis	rs730532	0.556	rs2173145	chr14:52518485	T/C	cg16066272	chr14:52535949	NID2	0.56	4.26	0.33	3.55e-5	Pulmonary function;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.66	7.12	0.5	3.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg00988841	chr10:134556463	INPP5A	0.47	4.43	0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.98	-5.2	-0.39	6.24e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06529459	chr11:67397595	NUDT8	0.56	6.3	0.46	2.98e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.76	-6.9	-0.49	1.3100000000000001e-10	Response to metformin (IC50);
PAAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.8	-0.36	3.69e-6	Menarche (age at onset);
PAAD	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg08992911	chr2:238395768	MLPH	0.66	6.46	0.46	1.36e-9	Prostate cancer;
PAAD	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	1.14	12.34	0.71	1.13e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	0.94	11.32	0.68	6.13e-22	Testicular germ cell tumor;
PAAD	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs4343996	0.870	rs4722708	chr7:3382563	A/T	cg21248987	chr7:3385318	SDK1	-0.48	-5.3	-0.39	4e-7	Motion sickness;
PAAD	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.58	0.35	9.46e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs112990264	0.881	rs77064501	chr1:213022132	G/T	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg03983476	chr2:10830698	NOL10	0.45	4.34	0.33	2.55e-5	Prostate cancer;
PAAD	cis	rs6782025	1.000	rs502643	chr3:121245041	G/A	cg16417163	chr3:121280760	NA	-0.47	-4.8	-0.36	3.78e-6	Aging (facial);
PAAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg23950597	chr19:37808831	NA	-0.76	-5.46	-0.4	1.9e-7	Coronary artery calcification;
PAAD	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.52	6.34	0.46	2.53e-9	Endometriosis;
PAAD	cis	rs2180233	0.753	rs12732380	chr1:30676733	C/T	cg06703062	chr1:31191648	MATN1	-0.53	-4.7	-0.36	5.77e-6	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.72	0.58	4.57e-15	Personality dimensions;
PAAD	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.68	6.32	0.46	2.72e-9	Platelet count;
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg15674680	chr20:60982522	CABLES2	0.55	4.93	0.37	2.18e-6	Colorectal cancer;
PAAD	cis	rs9309711	0.961	rs4296457	chr2:3470595	G/A	cg10845886	chr2:3471009	TTC15	-0.9	-8.33	-0.56	4.39e-14	Neurofibrillary tangles;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.89	9.7	0.62	1.31e-17	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00310044	chr1:45826423	TESK2	0.59	6.49	0.47	1.17e-9	Smoking initiation;
PAAD	cis	rs1075265	0.783	rs698858	chr2:54170470	C/G	cg04546899	chr2:54196757	PSME4	0.33	4.96	0.37	1.83e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.36	-4.97	-0.37	1.8e-6	Schizophrenia;
PAAD	cis	rs6804624	0.654	rs2246020	chr3:99180244	T/G	cg02646433	chr3:99218170	NA	0.44	4.41	0.34	1.97e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.98	13.23	0.73	4.45e-27	Menarche (age at onset);
PAAD	cis	rs7567389	0.568	rs7568070	chr2:127953054	A/C	cg09760422	chr2:128146352	NA	0.48	7.23	0.51	2.19e-11	Self-rated health;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg10729496	chr3:10149963	C3orf24	0.82	6.93	0.49	1.14e-10	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.93e-6	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03676636	chr4:99064102	C4orf37	0.33	6.02	0.44	1.24e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13198984	chr17:80129470	CCDC57	0.4	4.97	0.37	1.77e-6	Life satisfaction;
PAAD	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg08648136	chr8:956695	NA	0.44	4.64	0.35	7.62e-6	Schizophrenia;
PAAD	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.44	6.8	0.48	2.27e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg01631684	chr10:65280961	REEP3	-0.46	-4.66	-0.35	6.86e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	1.02	10.99	0.67	4.73e-21	Ulcerative colitis;
PAAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	1.27	11.98	0.7	1.04e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg21466736	chr12:48725269	NA	0.54	5.11	0.38	9.55e-7	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs2371030	0.659	rs13427306	chr2:211560510	A/G	cg21186888	chr2:210674232	UNC80	-0.65	-4.51	-0.34	1.29e-5	Non-small cell lung cancer;
PAAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.97	12.41	0.71	7.1e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg12700464	chr11:78128424	GAB2	0.59	4.45	0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs12136530	0.577	rs12066114	chr1:19792527	A/G	cg12763668	chr1:19687257	CAPZB	0.49	4.46	0.34	1.61e-5	Lead levels in blood;
PAAD	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.71	-7.44	-0.52	7.02e-12	Monocyte count;
PAAD	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	5.78	0.42	4.16e-8	Testicular germ cell tumor;
PAAD	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.19	-0.39	6.58e-7	Electroencephalogram traits;
PAAD	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.47	4.42	0.34	1.84e-5	Optic cup area;
PAAD	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.57	-0.41	1.1e-7	Crohn's disease;
PAAD	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.55	5.47	0.41	1.85e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.01e-5	Migraine;
PAAD	cis	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg14279842	chr14:50159788	KLHDC1	-0.52	-4.38	-0.33	2.19e-5	Subjective well-being;
PAAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg04106633	chr4:1044584	NA	0.53	4.96	0.37	1.85e-6	Recombination rate (males);
PAAD	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.8	-9.02	-0.59	7.58e-16	Sudden cardiac arrest;
PAAD	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.61	5.0	0.38	1.56e-6	Response to antidepressants in depression;
PAAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.51	-0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg01800442	chr17:74086473	EXOC7	0.53	4.25	0.33	3.67e-5	Psoriasis;
PAAD	cis	rs113779084	0.711	rs13229356	chr7:11987379	T/C	cg15090509	chr7:11872073	THSD7A	0.43	5.12	0.38	9.1e-7	Educational attainment (years of education);
PAAD	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.68	-7.84	-0.54	7.4e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg00806126	chr19:22604979	ZNF98	0.42	5.57	0.41	1.13e-7	Pain;
PAAD	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.91	5.5	0.41	1.57e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.45	-0.4	2.02e-7	Bladder cancer;
PAAD	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.65	-7.57	-0.52	3.3e-12	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg23254163	chr1:152506842	NA	-0.59	-6.98	-0.49	8.34e-11	Hair morphology;
PAAD	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs16958440	0.867	rs117060920	chr18:44709035	G/A	cg17192377	chr18:44677553	HDHD2	1.06	5.6	0.41	9.74e-8	Sitting height ratio;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs73568641	0.583	rs73570612	chr6:154060947	A/G	cg15658985	chr6:154448740	OPRM1	0.56	4.72	0.36	5.33e-6	Methadone dose in opioid dependence;
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg18612461	chr15:75251733	NA	-0.59	-7.16	-0.5	3.22e-11	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.78	8.66	0.57	6.42e-15	Lung cancer;
PAAD	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg23587288	chr2:27483067	SLC30A3	-0.68	-6.05	-0.44	1.08e-8	Blood metabolite levels;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.71	-0.42	5.86e-8	Tonsillectomy;
PAAD	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg00277334	chr10:82204260	NA	-0.59	-5.95	-0.43	1.75e-8	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-11.31	-0.68	6.79e-22	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.45	5.23	0.39	5.5e-7	Inattentive symptoms;
PAAD	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs12780845	0.931	rs34665628	chr10:17252296	G/A	cg00857480	chr10:17188594	TRDMT1	0.35	4.41	0.34	1.96e-5	Homocysteine levels;
PAAD	cis	rs59888335	0.862	rs2164645	chr3:80643245	C/T	cg21735741	chr3:80819488	NA	0.58	5.04	0.38	1.33e-6	Schizophrenia;
PAAD	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg07828340	chr4:882639	GAK	0.77	6.11	0.44	7.91e-9	Parkinson's disease;
PAAD	cis	rs28489187	0.683	rs2892888	chr1:85866147	A/G	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs16958440	0.867	rs12326221	chr18:44682893	G/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7705042	1.000	rs7705042	chr5:141492419	C/A	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.26	-0.39	4.89e-7	Asthma;
PAAD	cis	rs9296095	0.554	rs12214883	chr6:33513968	A/G	cg14003231	chr6:33640908	ITPR3	0.43	5.68	0.42	6.54e-8	Platelet count;
PAAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg23283495	chr1:209979779	IRF6	0.8	7.07	0.5	5.39e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg20673841	chr7:107026890	COG5	0.48	4.31	0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg18518183	chr2:172544446	DYNC1I2	0.5	4.47	0.34	1.53e-5	Schizophrenia;
PAAD	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.65	6.66	0.48	4.83e-10	Joint mobility (Beighton score);
PAAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg07153921	chr17:41440717	NA	-0.42	-4.42	-0.34	1.85e-5	Menopause (age at onset);
PAAD	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.13	15.91	0.79	3.56e-34	Schizophrenia;
PAAD	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.51	-4.42	-0.34	1.85e-5	Acne (severe);
PAAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.82	-8.85	-0.58	2.1e-15	Obesity-related traits;
PAAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.59	0.35	9.3e-6	Parkinson's disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18965322	chr2:99735582	TSGA10	-0.68	-6.36	-0.46	2.23e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.7	-8.31	-0.56	5.07e-14	Huntington's disease progression;
PAAD	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.8	8.06	0.55	2.13e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg14440974	chr22:39074834	NA	-0.51	-6.1	-0.44	8.56e-9	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.82	10.07	0.63	1.39e-18	Gut microbiome composition (winter);
PAAD	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg14700524	chr10:3282231	NA	0.31	4.39	0.34	2.07e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.71	-7.32	-0.51	1.38e-11	Platelet count;
PAAD	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg10395934	chr14:104002654	TRMT61A	0.56	5.72	0.42	5.48e-8	Body mass index;
PAAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.21	4.93	0.37	2.15e-6	Urinary tract infection frequency;
PAAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	4.44	0.34	1.74e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.62	6.47	0.46	1.24e-9	Menopause (age at onset);
PAAD	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg12568669	chr8:11666485	FDFT1	0.26	4.39	0.34	2.08e-5	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22983827	chr6:793567	NA	-0.73	-7.21	-0.5	2.39e-11	Obesity-related traits;
PAAD	cis	rs8014252	0.711	rs59044667	chr14:71043704	A/G	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.57	5.34	0.4	3.33e-7	Resting heart rate;
PAAD	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	7.84	0.54	7.21e-13	Mean platelet volume;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs2882667	0.658	rs10076442	chr5:138276779	T/C	cg09476006	chr5:138032270	NA	0.46	5.84	0.43	3.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.77	-0.36	4.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg04450456	chr4:17643702	FAM184B	0.53	5.78	0.42	4.16e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13319406	0.546	rs6801014	chr3:189832834	T/C	cg03343083	chr3:189718843	LEPREL1	-0.82	-5.59	-0.41	1.04e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.42	-4.33	-0.33	2.7e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2131877	0.701	rs57357728	chr3:194832106	G/A	cg16306870	chr3:194868790	C3orf21	0.5	4.83	0.37	3.24e-6	Non-small cell lung cancer;
PAAD	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.04	0.44	1.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1413885	0.526	rs6588144	chr1:65858088	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-4.28	-0.33	3.33e-5	Anticoagulant levels;
PAAD	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.5	-5.06	-0.38	1.21e-6	Daytime sleep phenotypes;
PAAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.68	-0.35	6.37e-6	Total body bone mineral density;
PAAD	cis	rs9398803	0.698	rs853979	chr6:127057941	A/T	cg19875578	chr6:126661172	C6orf173	-0.42	-4.33	-0.33	2.7e-5	Male-pattern baldness;
PAAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.8	-9.96	-0.63	2.71e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.56	-0.52	3.53e-12	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs2131877	0.913	rs1874099	chr3:194848766	G/T	cg19760965	chr3:194868843	C3orf21	0.44	4.59	0.35	9.33e-6	Non-small cell lung cancer;
PAAD	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.45	-0.61	5.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg13814708	chr10:81144099	ZCCHC24	-0.4	-4.43	-0.34	1.79e-5	Height;
PAAD	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.83	-0.48	1.93e-10	Retinal vascular caliber;
PAAD	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg20607287	chr7:12443886	VWDE	-0.66	-5.22	-0.39	5.87e-7	Coronary artery disease;
PAAD	cis	rs72960926	0.744	rs6926572	chr6:75044118	A/G	cg03266952	chr6:74778945	NA	-1.01	-5.74	-0.42	4.98e-8	Metabolite levels (MHPG);
PAAD	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-7.59	-0.52	2.96e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg16434002	chr17:42200994	HDAC5	0.64	5.68	0.42	6.59e-8	Total body bone mineral density;
PAAD	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.85	-10.09	-0.63	1.21e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.6	5.42	0.4	2.29e-7	Mean platelet volume;
PAAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs3736485	0.966	rs8042289	chr15:51899884	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.66e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs988913	0.957	rs1910350	chr6:54852462	C/A	cg03513858	chr6:54763001	FAM83B	-0.43	-4.66	-0.35	6.83e-6	Menarche (age at onset);
PAAD	cis	rs1499972	0.590	rs62264777	chr3:117653515	G/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14307304	chr9:97221786	HIATL1	-0.7	-7.32	-0.51	1.36e-11	Obesity-related traits;
PAAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.51	-4.8	-0.36	3.78e-6	Menarche (age at onset);
PAAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.64	-6.22	-0.45	4.55e-9	Colorectal cancer;
PAAD	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg06637938	chr14:75390232	RPS6KL1	0.48	4.71	0.36	5.56e-6	Height;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg07747251	chr5:1868357	NA	0.58	6.45	0.46	1.38e-9	Cardiovascular disease risk factors;
PAAD	cis	rs2790216	1.000	rs2790230	chr10:59989772	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.85	-5.92	-0.43	2.03e-8	Coronary artery disease;
PAAD	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.69	-7.62	-0.53	2.59e-12	Eosinophil percentage of white cells;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18337363	chr3:52569053	NT5DC2	0.41	4.42	0.34	1.89e-5	Bipolar disorder;
PAAD	cis	rs375066	0.901	rs368316	chr19:44431894	C/A	cg21496419	chr19:44306685	LYPD5	0.4	4.86	0.37	2.88e-6	Breast cancer;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07176514	chr1:185126191	C1orf25;C1orf26	0.59	6.46	0.46	1.32e-9	Pancreatic cancer;
PAAD	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16386425	chr10:429943	DIP2C	-0.48	-4.56	-0.35	1.06e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.61	-5.99	-0.44	1.43e-8	Fibrinogen levels;
PAAD	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg02023728	chr11:77925099	USP35	-0.44	-4.54	-0.35	1.14e-5	Alzheimer's disease (survival time);
PAAD	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.8	9.49	0.61	4.66e-17	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-10.47	-0.65	1.18e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9815354	1.000	rs1025646	chr3:41754422	A/T	cg03022575	chr3:42003672	ULK4	0.84	6.09	0.44	8.73e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg09491104	chr22:46646882	C22orf40	-0.82	-5.54	-0.41	1.32e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.61	5.53	0.41	1.38e-7	Height;
PAAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.44	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg17987982	chr7:158820591	NA	-0.42	-4.79	-0.36	3.87e-6	Facial morphology (factor 20);
PAAD	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.79e-7	Mammographic density (dense area);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25489746	chr17:7232870	NEURL4	-0.65	-7.05	-0.5	5.88e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg21496419	chr19:44306685	LYPD5	-0.4	-5.08	-0.38	1.08e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.65	6.64	0.47	5.13e-10	Testicular germ cell tumor;
PAAD	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.74	7.13	0.5	3.88e-11	Breast cancer;
PAAD	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs939584	0.935	rs13387939	chr2:637498	C/A	cg03610516	chr2:642275	NA	0.6	5.41	0.4	2.44e-7	Body mass index;
PAAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.39	-0.56	3.1e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4731207	0.564	rs13234634	chr7:124676033	G/A	cg14311320	chr7:124405732	GPR37	-0.42	-4.34	-0.33	2.55e-5	Cutaneous malignant melanoma;
PAAD	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs7627468	0.770	rs7635354	chr3:121966638	C/A	cg17240004	chr3:121949083	CASR	0.5	4.77	0.36	4.33e-6	Kidney stones;
PAAD	cis	rs41311933	0.803	rs10985112	chr9:123731408	A/G	cg21241889	chr9:123690658	TRAF1	0.74	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7487075	0.619	rs12822345	chr12:46834677	G/C	cg09447675	chr12:46877466	NA	-0.47	-4.3	-0.33	3.09e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10905065	0.766	rs11598374	chr10:5826986	T/C	cg11519256	chr10:5708881	ASB13	-0.52	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg08029281	chr1:67600428	NA	0.43	5.21	0.39	5.95e-7	Psoriasis;
PAAD	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.48	4.33	0.33	2.73e-5	Morning vs. evening chronotype;
PAAD	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02985541	chr2:219472218	PLCD4	-0.32	-4.79	-0.36	3.99e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.79	7.07	0.5	5.18e-11	Obesity-related traits;
PAAD	cis	rs4704187	0.687	rs10214239	chr5:74357475	G/A	cg03227963	chr5:74354835	NA	0.48	4.7	0.36	5.78e-6	Response to amphetamines;
PAAD	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.62	6.37	0.46	2.13e-9	Vitiligo;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14082959	chr9:11618283	NA	0.59	7.13	0.5	3.74e-11	Body fat percentage;
PAAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.73	0.53	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10850408	0.922	rs4331155	chr12:115377676	G/T	cg05726002	chr12:115341178	NA	-0.4	-4.68	-0.35	6.4e-6	Alzheimer's disease;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.91	12.34	0.71	1.09e-24	Prudent dietary pattern;
PAAD	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg22601191	chr20:60968625	CABLES2	-0.6	-5.72	-0.42	5.4e-8	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16879222	chr17:41176744	RND2	-0.84	-7.35	-0.51	1.13e-11	Neuroticism;
PAAD	cis	rs7236492	0.810	rs9957497	chr18:77227217	A/G	cg15644404	chr18:77186268	NFATC1	-0.86	-6.15	-0.45	6.69e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7932354	0.583	rs7101374	chr11:46824241	G/A	cg19486271	chr11:47235900	DDB2	-0.63	-6.25	-0.45	3.96e-9	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs6689305	0.674	rs1416235	chr1:100214578	G/A	cg22872634	chr1:100462710	SLC35A3	-0.5	-4.36	-0.33	2.39e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg25401027	chr5:176370377	UIMC1	0.56	5.55	0.41	1.24e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.63	6.46	0.46	1.31e-9	Blood protein levels;
PAAD	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.81	8.36	0.56	3.73e-14	Schizophrenia;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.63	-7.89	-0.54	5.46e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs2131877	0.506	rs62290318	chr3:194825342	G/A	cg19760965	chr3:194868843	C3orf21	0.48	4.53	0.34	1.19e-5	Non-small cell lung cancer;
PAAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.56	5.84	0.43	3.05e-8	Schizophrenia;
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.61e-16	Aortic root size;
PAAD	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13939156	chr17:80058883	NA	-0.42	-4.58	-0.35	9.63e-6	Life satisfaction;
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs4727443	0.866	rs6963345	chr7:99618606	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.61	0.35	8.59e-6	Interstitial lung disease;
PAAD	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.57	-7.39	-0.51	9.07e-12	Longevity;
PAAD	cis	rs72960926	0.744	rs11759133	chr6:74932518	A/G	cg03266952	chr6:74778945	NA	-1.1	-6.4	-0.46	1.79e-9	Metabolite levels (MHPG);
PAAD	cis	rs4478858	0.655	rs6696341	chr1:31782052	A/G	cg00250761	chr1:31883323	NA	-0.49	-5.72	-0.42	5.54e-8	Alcohol dependence;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.5	5.76	0.42	4.48e-8	Coronary artery disease;
PAAD	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.83	-8.43	-0.56	2.46e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs10203711	0.509	rs72996355	chr2:239591620	A/C	cg03761885	chr2:238707879	RBM44	0.49	4.79	0.36	3.93e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg26174226	chr8:58114915	NA	-0.56	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.39	-4.76	-0.36	4.42e-6	Blood metabolite levels;
PAAD	cis	rs4906332	0.782	rs12880224	chr14:104006414	C/G	cg19000871	chr14:103996768	TRMT61A	-0.58	-6.15	-0.45	6.5e-9	Coronary artery disease;
PAAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06627801	chr4:1975624	WHSC1;SCARNA22	0.72	8.89	0.58	1.65e-15	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.56	-5.81	-0.43	3.52e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.92	-10.16	-0.64	7.71e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.49	-4.83	-0.36	3.32e-6	Menarche (age at onset);
PAAD	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-8.33	-0.56	4.39e-14	Morning vs. evening chronotype;
PAAD	cis	rs1977584	0.725	rs7903148	chr10:45403471	A/G	cg04218760	chr10:45406644	TMEM72	0.37	4.79	0.36	3.85e-6	Selective IgA deficiency;
PAAD	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg02527881	chr3:46936655	PTH1R	-0.82	-12.49	-0.71	4.54e-25	Birth weight;
PAAD	cis	rs10792830	0.706	rs563773	chr11:85673270	C/T	cg07180834	chr11:85838833	NA	-0.46	-5.15	-0.39	7.83e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg14583973	chr4:3374767	RGS12	0.38	5.75	0.42	4.78e-8	Parental longevity (mother's age at death);
PAAD	cis	rs7534824	0.543	rs60978318	chr1:101400413	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs501120	1.000	rs605445	chr10:44756779	C/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.74	-0.36	4.95e-6	Asthma (childhood onset);
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	5.72	0.42	5.52e-8	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg05562828	chr17:3906858	NA	-0.56	-6.33	-0.46	2.57e-9	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.66	7.41	0.52	8.2e-12	Airway imaging phenotypes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17679864	chr3:40498818	RPL14	0.58	6.58	0.47	7.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.56	5.42	0.4	2.32e-7	Breast cancer;
PAAD	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.62	-7.1	-0.5	4.56e-11	Atrial fibrillation;
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.82	0.58	2.53e-15	Lung cancer;
PAAD	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg02264943	chr11:130785842	SNX19	0.36	4.31	0.33	2.98e-5	Schizophrenia;
PAAD	cis	rs7142002	0.881	rs3783362	chr14:102345752	G/A	cg16201061	chr14:102358090	PPP2R5C	1.0	4.79	0.36	3.87e-6	Autism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06184463	chr3:11888509	C3orf31	0.62	6.9	0.49	1.3100000000000001e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	trans	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg26939375	chr7:64535504	NA	0.73	8.93	0.59	1.28e-15	Aortic root size;
PAAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.49	-5.78	-0.42	4.01e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26926768	chr12:34528122	NA	0.38	4.71	0.36	5.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg01059385	chr22:42394853	WBP2NL	0.43	4.39	0.34	2.14e-5	Cognitive function;
PAAD	cis	rs2555155	1.000	rs2555154	chr11:6524556	C/T	cg11185456	chr11:6592066	DNHD1	0.41	4.3	0.33	3.04e-5	DNA methylation (variation);
PAAD	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg07943548	chr15:86304357	KLHL25	-0.75	-6.12	-0.44	7.61e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.88	10.19	0.64	6.61e-19	Tuberculosis;
PAAD	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.94	13.02	0.73	1.69e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.89	-10.71	-0.66	2.64e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.89	-8.91	-0.59	1.51e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.42	5.16	0.39	7.63e-7	Sitting height ratio;
PAAD	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19891022	chr5:14388565	TRIO	-0.7	-7.27	-0.51	1.75e-11	Obesity-related traits;
PAAD	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.64	6.49	0.47	1.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg03945807	chr20:60948434	NA	0.44	4.44	0.34	1.69e-5	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21618036	chr4:183621609	ODZ3	-0.63	-6.55	-0.47	8.35e-10	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.54	-0.35	1.14e-5	Migraine;
PAAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.47	5.72	0.42	5.37e-8	Vitiligo;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg22029157	chr1:209979665	IRF6	0.78	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs1499972	0.887	rs73163707	chr3:117536135	A/T	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.47	5.85	0.43	2.98e-8	Crohn's disease;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.65	5.23	0.39	5.5e-7	Alzheimer's disease;
PAAD	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.65	5.89	0.43	2.39e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20615379	chr1:3827578	LOC100133612	0.64	7.48	0.52	5.5e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1371614	0.635	rs4665923	chr2:27138911	C/T	cg00617064	chr2:27272375	NA	-0.46	-4.8	-0.36	3.71e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg19784903	chr17:45786737	TBKBP1	0.55	5.84	0.43	3.12e-8	Multiple sclerosis or amyotrophic lateral sclerosis;
PAAD	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	6.3	0.46	3.05e-9	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17125944	0.615	rs7146915	chr14:53316039	C/T	cg00686598	chr14:53173677	PSMC6	-0.9	-5.7	-0.42	5.99e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24929613	chr19:37064166	ZNF529	-0.64	-6.62	-0.47	5.9e-10	Smoking initiation;
PAAD	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.78	-6.28	-0.45	3.38e-9	Coronary artery disease;
PAAD	cis	rs802075	0.967	rs635895	chr6:49658348	C/T	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg26850624	chr5:429559	AHRR	-0.71	-8.65	-0.57	6.99e-15	Cystic fibrosis severity;
PAAD	cis	rs17209837	1.000	rs17209837	chr7:87124822	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs2279817	0.780	rs1124447	chr1:18007598	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg25790453	chr13:113633590	MCF2L	-0.38	-4.45	-0.34	1.64e-5	Systolic blood pressure;
PAAD	cis	rs4352251	0.543	rs935065	chr2:101899130	T/C	cg01660407	chr2:101008576	CHST10	-0.53	-4.26	-0.33	3.63e-5	Adiponectin levels (BMI-adjusted);Adiponectin levels;
PAAD	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10793968	0.748	rs2789763	chr9:133634666	A/G	cg01474677	chr9:133586259	NA	-0.59	-4.45	-0.34	1.67e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg18279126	chr7:2041391	MAD1L1	0.55	5.4	0.4	2.5e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.15	-0.5	3.45e-11	Colorectal cancer;
PAAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.96	12.46	0.71	5.28e-25	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.63	8.91	0.59	1.43e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.02	0.38	1.44e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg00631329	chr6:26305371	NA	-0.42	-4.34	-0.33	2.63e-5	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20707008	chr6:160210612	MRPL18;TCP1	0.7	8.12	0.55	1.47e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3748682	0.808	rs12728438	chr1:38349400	G/A	cg12658694	chr1:38397304	INPP5B	0.48	4.46	0.34	1.55e-5	Hypothyroidism;
PAAD	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.07	13.71	0.74	2.39e-28	Testicular germ cell tumor;
PAAD	cis	rs96067	0.652	rs274764	chr1:36574912	T/C	cg27506609	chr1:36549197	TEKT2	-0.83	-5.0	-0.38	1.55e-6	Corneal structure;
PAAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.45	5.02	0.38	1.42e-6	Schizophrenia;
PAAD	cis	rs6142102	0.961	rs4911144	chr20:32614371	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs6782228	0.527	rs2811491	chr3:128353950	C/A	cg16766828	chr3:128327626	NA	-0.48	-6.47	-0.46	1.29e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7251275	0.744	rs34163641	chr19:44118191	G/A	cg17121205	chr19:44009353	PHLDB3	0.4	4.88	0.37	2.63e-6	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs4908768	0.639	rs4908512	chr1:8830366	A/T	cg25722041	chr1:8623473	RERE	0.5	4.29	0.33	3.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs13201294	1	rs13201294	chr6:27556141	A/T	cg20933634	chr6:27740509	NA	0.72	4.34	0.33	2.55e-5	Squamous cell lung carcinoma;
PAAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.17	-0.39	7.16e-7	Breast cancer;
PAAD	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.06	13.39	0.74	1.73e-27	Testicular germ cell tumor;
PAAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.75	-8.55	-0.57	1.26e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1144333	0.655	rs17097681	chr1:76376926	C/T	cg22875332	chr1:76189707	ACADM	0.75	4.59	0.35	9.22e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.53	-4.96	-0.37	1.84e-6	P wave terminal force;
PAAD	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.67	-6.87	-0.49	1.54e-10	Sudden cardiac arrest;
PAAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	1.06	15.11	0.77	4.5e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg14019146	chr3:50243930	SLC38A3	-0.45	-4.51	-0.34	1.29e-5	Body mass index;
PAAD	cis	rs16975963	0.793	rs59616348	chr19:38447753	G/A	cg08679971	chr19:38281047	NA	0.53	5.14	0.38	8.37e-7	Longevity;
PAAD	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.87	-0.49	1.51e-10	Lung cancer;
PAAD	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.4	-0.34	2.05e-5	Resting heart rate;
PAAD	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2051773	0.567	rs12794156	chr11:17063005	G/C	cg15084286	chr11:17036142	PLEKHA7	0.54	4.58	0.35	9.75e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs11771526	0.681	rs6956350	chr7:32403428	C/A	cg27511599	chr7:32358540	NA	0.9	4.88	0.37	2.62e-6	Body mass index;
PAAD	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.07	0.7	5.93e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg09915433	chr19:53449742	NA	-0.8	-11.9	-0.69	1.75e-23	Psoriasis;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.48	5.21	0.39	6.14e-7	Electroencephalogram traits;
PAAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.83	8.1	0.55	1.65e-13	Post bronchodilator FEV1;
PAAD	cis	rs7873102	0.654	rs7043495	chr9:37961922	C/T	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	5.55	0.41	1.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs899997	1.000	rs12907207	chr15:79031290	G/A	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.93	12.27	0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.72	6.77	0.48	2.67e-10	Monocyte count;
PAAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.78	0.36	4.14e-6	Depression;
PAAD	cis	rs11892454	0.515	rs11888036	chr2:26063775	C/T	cg03373490	chr2:26702396	OTOF	-0.52	-4.47	-0.34	1.5e-5	Heschl's gyrus morphology;
PAAD	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.61	-0.35	8.35e-6	Testicular germ cell tumor;
PAAD	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.78	7.19	0.5	2.78e-11	Obesity-related traits;
PAAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.78	9.96	0.63	2.72e-18	Bone mineral density;
PAAD	cis	rs933688	0.556	rs4916855	chr5:90596345	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.75	-6.09	-0.44	9e-9	Smoking behavior;
PAAD	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.64	6.91	0.49	1.25e-10	Longevity;
PAAD	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.88	-10.91	-0.66	7.68e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08550205	chr17:45786854	TBKBP1	-0.4	-4.52	-0.34	1.22e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.72	8.68	0.58	5.74e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.4e-9	IgG glycosylation;
PAAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.34	-0.46	2.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.65	6.2	0.45	4.99e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg04851639	chr8:1020857	NA	-0.58	-6.94	-0.49	1.04e-10	Schizophrenia;
PAAD	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.93	-6.61	-0.47	6.12e-10	Body mass index;
PAAD	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.76	-0.42	4.55e-8	QT interval;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg05110241	chr16:68378359	PRMT7	-1.13	-8.44	-0.56	2.35e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs28472312	0.832	rs62037422	chr16:28963012	T/C	cg16576597	chr16:28551801	NUPR1	-0.47	-4.63	-0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	1.12	17.33	0.81	7.85e-38	Menarche (age at onset);
PAAD	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.47	-7.76	-0.53	1.14e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.66	-0.42	7.33e-8	Cystic fibrosis severity;
PAAD	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.27	0.67	8.75e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.38	0.4	2.82e-7	Prudent dietary pattern;
PAAD	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg00262122	chr8:11665843	FDFT1	-0.59	-5.17	-0.39	7.25e-7	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.41	4.27	0.33	3.39e-5	Breast cancer;
PAAD	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.5	4.49	0.34	1.4e-5	Corneal astigmatism;
PAAD	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg26685658	chr5:74633012	HMGCR	-0.51	-4.27	-0.33	3.48e-5	Age-related disease endophenotypes;
PAAD	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	trans	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg01620082	chr3:125678407	NA	-1.09	-6.3	-0.46	3.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.730	rs12030512	chr1:210466886	A/G	cg22029157	chr1:209979665	IRF6	0.7	6.13	0.45	7.36e-9	Coronary artery disease;
PAAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg01798341	chr17:80842262	TBCD	0.45	4.78	0.36	4.07e-6	Breast cancer;
PAAD	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.21	0.45	4.73e-9	Coronary artery disease;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg26939375	chr7:64535504	NA	0.76	9.15	0.6	3.49e-16	Aortic root size;
PAAD	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.89	-12.94	-0.72	2.72e-26	Dental caries;
PAAD	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg27124370	chr19:33622961	WDR88	0.62	5.77	0.42	4.24e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	9.21	0.6	2.53e-16	Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13384867	chr19:39663807	PAK4	-0.58	-6.32	-0.46	2.73e-9	Monocyte percentage of white cells;
PAAD	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.52	-0.47	9.94e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg17456097	chr1:26900765	RPS6KA1	0.52	4.32	0.33	2.85e-5	Glucose homeostasis traits;
PAAD	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg03252829	chr6:39282164	KCNK17	-0.55	-5.83	-0.43	3.26e-8	Type 2 diabetes;
PAAD	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg06102954	chr21:42741788	MX2	0.47	4.71	0.36	5.47e-6	Melanoma;
PAAD	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg14703610	chr5:56206110	C5orf35	-0.6	-5.65	-0.42	7.59e-8	Coronary artery disease;
PAAD	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.46	-0.52	6.31e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9549260	0.609	rs9315781	chr13:41264053	T/C	cg21288729	chr13:41239152	FOXO1	0.55	4.47	0.34	1.55e-5	Red blood cell count;
PAAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.77	-8.34	-0.56	4.11e-14	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.55	-5.37	-0.4	2.95e-7	Prudent dietary pattern;
PAAD	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg05341575	chr12:125625032	AACS	-0.53	-4.89	-0.37	2.57e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.49	0.52	5.12e-12	Alzheimer's disease;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.55	5.68	0.42	6.76e-8	Testicular germ cell tumor;
PAAD	cis	rs5756391	0.546	rs4820262	chr22:37317109	T/C	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	4.46	0.34	1.56e-5	Neutrophil percentage of white cells;
PAAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-5.92	-0.43	2.03e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg26597838	chr10:835615	NA	0.52	5.65	0.42	7.6e-8	Survival in rectal cancer;
PAAD	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Magnesium levels;
PAAD	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07094693	chr2:119876466	NA	0.56	6.52	0.47	9.68e-10	Smoking initiation;
PAAD	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.88	0.37	2.6e-6	Blood metabolite levels;
PAAD	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg01766943	chr2:54829624	SPTBN1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.58	-6.3	-0.46	2.98e-9	Calcium levels;
PAAD	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-8.05	-0.55	2.27e-13	Bladder cancer;
PAAD	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.97	8.93	0.59	1.31e-15	Resting heart rate;
PAAD	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-6.65	-0.47	4.96e-10	Blood pressure (smoking interaction);
PAAD	trans	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg00717180	chr2:96193071	NA	0.62	6.61	0.47	6.2e-10	Migraine - clinic-based;
PAAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-4.55	-0.35	1.1e-5	Inflammatory bowel disease;
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs72636617	0.867	rs58459780	chr13:95063962	G/A	cg07907493	chr13:95480448	NA	0.65	4.35	0.33	2.48e-5	Pelvic organ prolapse;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-0.63	-4.77	-0.36	4.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.9	0.69	1.67e-23	Smoking behavior;
PAAD	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs501120	0.584	rs677465	chr10:44732917	G/A	cg09554077	chr10:44749378	NA	0.46	5.36	0.4	3e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.78	10.14	0.64	8.85e-19	Vitiligo;
PAAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.7	-8.9	-0.59	1.54e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2004318	1.000	rs10407009	chr19:55117374	C/T	cg03320607	chr19:54800032	LILRA3	-0.94	-5.57	-0.41	1.15e-7	Blood protein levels;
PAAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-4.34	-0.33	2.64e-5	Vitiligo;
PAAD	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg01620082	chr3:125678407	NA	-1.14	-7.5	-0.52	5.03e-12	Depression;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg21698718	chr17:80085957	CCDC57	0.46	5.21	0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.07	-0.38	1.12e-6	Retinal vascular caliber;
PAAD	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg05555928	chr11:63887634	MACROD1	0.61	4.81	0.36	3.58e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg09835421	chr16:68378352	PRMT7	-0.95	-5.75	-0.42	4.79e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.59	5.64	0.42	8.14e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18883852	chr13:45965548	LOC100190939	-0.69	-6.91	-0.49	1.27e-10	Obesity-related traits;
PAAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg14349672	chr11:133703707	NA	-0.57	-6.71	-0.48	3.54e-10	Childhood ear infection;
PAAD	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.62	-5.76	-0.42	4.42e-8	Multiple myeloma;
PAAD	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13775575	chr19:48018329	NAPA	0.66	7.8	0.53	9.09e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg10935138	chr17:73851978	WBP2	0.81	7.13	0.5	3.8e-11	Psoriasis;
PAAD	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.47	-4.78	-0.36	4.12e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs656319	0.729	rs471480	chr8:9812462	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.77	-0.48	2.59e-10	Myopia (pathological);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22481606	chr17:56429567	SUPT4H1	0.7	8.36	0.56	3.75e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.53	4.95	0.37	1.96e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.51	5.45	0.4	2.01e-7	Obesity-related traits;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.4	9.8	0.62	7.13e-18	Diabetic retinopathy;
PAAD	cis	rs682748	0.846	rs13178413	chr5:17151456	G/A	cg23987134	chr5:17158319	LOC285696	-0.36	-4.45	-0.34	1.66e-5	Hippocampal atrophy;
PAAD	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg25401027	chr5:176370377	UIMC1	0.56	5.54	0.41	1.29e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07904983	chr20:17511988	BFSP1	0.69	6.81	0.48	2.17e-10	Obesity-related traits;
PAAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.83	-8.84	-0.58	2.2e-15	DNA methylation (variation);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06270147	chr10:73078971	SLC29A3	-0.54	-6.87	-0.49	1.51e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg24519413	chr1:26490540	NA	0.52	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg17201900	chr20:34330562	RBM39	0.62	4.34	0.33	2.64e-5	Total cholesterol levels;
PAAD	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg01631408	chr1:248437212	OR2T33	-0.6	-5.6	-0.41	9.77e-8	Common traits (Other);
PAAD	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.57	5.59	0.41	1.03e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.84	-0.43	3.02e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg06375148	chr1:209958343	C1orf74	0.68	5.01	0.38	1.51e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.69	-6.86	-0.49	1.63e-10	Pubertal anthropometrics;
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.61	-5.1	-0.38	9.92e-7	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg01422370	chr2:73384389	NA	0.43	5.34	0.4	3.32e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.85	-9.86	-0.62	5.01e-18	Ulcerative colitis;
PAAD	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg10871876	chr19:53194124	ZNF83	0.65	5.85	0.43	2.97e-8	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.59	0.47	6.65e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1519814	0.915	rs6992410	chr8:121113566	T/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.44	-0.4	2.09e-7	Breast cancer;
PAAD	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.91	-9.71	-0.62	1.22e-17	Pulse pressure;
PAAD	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.16	0.5	3.18e-11	Lymphocyte counts;
PAAD	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.54	-4.93	-0.37	2.14e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.67	0.53	1.9e-12	Menarche (age at onset);
PAAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.04	0.55	2.39e-13	Menopause (age at onset);
PAAD	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Diabetic kidney disease;
PAAD	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg10395934	chr14:104002654	TRMT61A	0.56	5.73	0.42	5.35e-8	Body mass index;
PAAD	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg23995914	chr4:10459228	ZNF518B	-0.36	-4.37	-0.33	2.27e-5	Schizophrenia (age at onset);
PAAD	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.97	14.28	0.76	7.04e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg21918786	chr6:109611834	NA	-0.44	-4.82	-0.36	3.43e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.44	4.37	0.33	2.31e-5	Crohn's disease;
PAAD	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.04	-0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg03959625	chr15:84868606	LOC388152	-0.41	-4.26	-0.33	3.52e-5	P wave terminal force;
PAAD	cis	rs1468333	1.000	rs7729926	chr5:137514641	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.29	0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-4.27	-0.33	3.48e-5	Bipolar disorder;
PAAD	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs9549328	0.796	rs7993665	chr13:113651132	T/C	cg20742385	chr13:113633654	MCF2L	-0.43	-4.35	-0.33	2.53e-5	Systolic blood pressure;
PAAD	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.84	-9.18	-0.6	2.99e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.88	0.58	1.81e-15	Lung cancer;
PAAD	cis	rs655601	0.558	rs11544558	chr5:180235737	C/A	cg13724780	chr5:180237085	MGAT1	1.1	5.86	0.43	2.78e-8	Quantitative traits;
PAAD	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.64	-0.35	7.56e-6	Type 1 diabetes;
PAAD	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-4.89	-0.37	2.57e-6	Pancreatic cancer;
PAAD	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.91	-7.81	-0.54	8.68e-13	Obesity-related traits;
PAAD	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-4.53	-0.34	1.2e-5	Fear of minor pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02165978	chr17:56296710	MKS1	-0.71	-6.34	-0.46	2.5e-9	Neuroticism;
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.93	7.44	0.52	7.02e-12	Initial pursuit acceleration;
PAAD	cis	rs10754283	0.967	rs10801764	chr1:90121751	T/G	cg21401794	chr1:90099060	LRRC8C	0.59	5.61	0.41	9.34e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs11129295	0.618	rs9814971	chr3:27802163	A/T	cg21473142	chr3:27762095	EOMES	0.29	4.88	0.37	2.68e-6	Multiple sclerosis;
PAAD	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.34	5.4	0.4	2.5e-7	Alzheimer's disease (late onset);
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg25173405	chr17:45401733	C17orf57	-0.51	-4.9	-0.37	2.46e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.56	0.57	1.19e-14	Prudent dietary pattern;
PAAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg01075559	chr1:2537774	MMEL1	-0.53	-5.56	-0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.55	6.06	0.44	1.04e-8	Menopause (age at onset);
PAAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg03959625	chr15:84868606	LOC388152	0.52	5.73	0.42	5.24e-8	Schizophrenia;
PAAD	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg02487422	chr3:49467188	NICN1	0.47	4.71	0.36	5.52e-6	Resting heart rate;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.11	-0.38	9.47e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg08132940	chr7:1081526	C7orf50	0.6	4.56	0.35	1.07e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg16926213	chr1:1841314	NA	0.38	4.58	0.35	9.79e-6	Body mass index;
PAAD	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.78	8.06	0.55	2.06e-13	Morning vs. evening chronotype;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.44	-0.46	1.5e-9	Coffee consumption (cups per day);
PAAD	cis	rs17601876	0.843	rs12901187	chr15:51549537	G/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.36	0.33	2.42e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg19257562	chr1:2043853	PRKCZ	0.41	4.68	0.35	6.28e-6	Height;
PAAD	cis	rs761746	0.579	rs5998121	chr22:32172367	T/C	cg01338084	chr22:32026380	PISD	0.59	5.04	0.38	1.31e-6	Intelligence;
PAAD	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.28	0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.89	9.44	0.61	6.23e-17	Testicular germ cell tumor;
PAAD	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26286098	chr13:31905755	B3GALTL	0.58	6.32	0.46	2.73e-9	Smoking initiation;
PAAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.26	-0.45	3.78e-9	Breast cancer;
PAAD	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.81	6.07	0.44	9.87e-9	Height;
PAAD	trans	rs901683	1.000	rs9422651	chr10:46047456	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4950322	0.553	rs12093870	chr1:146852536	A/C	cg22381352	chr1:146742008	CHD1L	-0.4	-4.26	-0.33	3.54e-5	Protein quantitative trait loci;
PAAD	trans	rs901683	1.000	rs35183191	chr10:46080617	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg02696790	chr15:75250997	RPP25	0.44	5.23	0.39	5.43e-7	Caffeine consumption;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.51	-0.52	4.81e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs12893597	0.715	rs71429953	chr14:76819480	C/T	cg20290672	chr14:76816747	NA	-0.57	-5.06	-0.38	1.18e-6	Maximal oxygen uptake response;
PAAD	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.66	0.35	6.78e-6	Menopause (age at onset);
PAAD	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg06131755	chr6:160182447	ACAT2	0.57	5.06	0.38	1.18e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-13.39	-0.74	1.72e-27	Primary sclerosing cholangitis;
PAAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.87	6.11	0.44	8.01e-9	Initial pursuit acceleration;
PAAD	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.05	-0.38	1.23e-6	Retinal vascular caliber;
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs56011263	0.512	rs12502944	chr4:736054	G/A	cg17689763	chr4:710664	PCGF3	-0.58	-5.73	-0.42	5.27e-8	White blood cell count;
PAAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs7260598	0.539	rs115825618	chr19:24065018	G/T	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg05313129	chr8:58192883	C8orf71	-0.65	-5.14	-0.38	8.24e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11159086	0.793	rs3784035	chr14:74948924	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.14	-0.38	8.25e-7	Advanced glycation end-product levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03468541	chr14:89029199	ZC3H14	-0.61	-6.41	-0.46	1.72e-9	Smoking initiation;
PAAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.48	-4.8	-0.36	3.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.86	11.08	0.67	2.83e-21	Body mass index;
PAAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.75	-8.01	-0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.27	-0.39	4.59e-7	Corneal astigmatism;
PAAD	trans	rs1015213	0.609	rs78364597	chr8:52873399	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.41	-5.67	-0.42	7.1e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg21194808	chr1:2205498	SKI	0.43	4.32	0.33	2.83e-5	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	6.75	0.48	2.93e-10	Height;
PAAD	cis	rs7833787	1.000	rs7002237	chr8:18704514	A/G	cg17701159	chr8:18705777	PSD3	0.43	5.13	0.38	8.73e-7	Obesity-related traits;
PAAD	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg24747557	chr10:131355152	MGMT	-0.43	-4.73	-0.36	5.14e-6	Response to temozolomide;
PAAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	trans	rs9467711	0.651	rs55912630	chr6:25866935	T/C	cg01620082	chr3:125678407	NA	-1.41	-7.8	-0.53	9.33e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.23	-0.39	5.43e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.08	0.55	1.82e-13	Lymphocyte counts;
PAAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg03286735	chr4:906491	GAK	-0.37	-5.12	-0.38	9.31e-7	Systemic sclerosis;
PAAD	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.96	-0.44	1.68e-8	Morning vs. evening chronotype;
PAAD	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs4343996	0.967	rs10268249	chr7:3347074	C/T	cg21248987	chr7:3385318	SDK1	0.47	5.2	0.39	6.32e-7	Motion sickness;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg18769074	chr3:133464867	TF	0.41	4.68	0.36	6.2e-6	Iron status biomarkers;
PAAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.13	-0.63	9.53e-19	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	6.06	0.44	1e-8	Prudent dietary pattern;
PAAD	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg07636037	chr3:49044803	WDR6	-0.56	-4.42	-0.34	1.84e-5	Menarche (age at onset);
PAAD	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg15798862	chr7:76129360	DTX2	-0.52	-6.87	-0.49	1.57e-10	Multiple sclerosis;
PAAD	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.18e-10	Initial pursuit acceleration;
PAAD	cis	rs4740619	0.569	rs3008728	chr9:16009099	G/C	cg14451791	chr9:16040625	NA	-0.39	-4.54	-0.35	1.13e-5	Body mass index;
PAAD	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	4.4	0.34	2.03e-5	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23003881	chr5:173043929	BOD1	-0.68	-6.6	-0.47	6.33e-10	Lung cancer in ever smokers;
PAAD	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.53	6.13	0.45	7.11e-9	Mean corpuscular volume;
PAAD	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.82	-5.84	-0.43	3.12e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs6430585	0.592	rs2016636	chr2:136058820	G/A	cg07169764	chr2:136633963	MCM6	0.72	6.77	0.48	2.58e-10	Corneal structure;
PAAD	cis	rs7873102	0.702	rs10814639	chr9:38009663	A/G	cg03528946	chr9:38069800	SHB	-0.53	-5.4	-0.4	2.47e-7	Brain structure;
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.73	-7.75	-0.53	1.24e-12	Blood metabolite levels;
PAAD	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4737010	0.644	rs552904	chr8:41610114	C/T	cg17182837	chr8:41585554	ANK1	0.48	4.7	0.36	5.72e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	5.21	0.39	6e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg14851346	chr12:38532713	NA	0.49	4.56	0.35	1.07e-5	Morning vs. evening chronotype;
PAAD	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.45	4.99	0.37	1.66e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7561149	0.902	rs6733291	chr2:179649871	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.47	4.72	0.36	5.39e-6	QT interval;
PAAD	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.87e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.6	-5.3	-0.4	3.93e-7	Cognitive test performance;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.47e-7	Total body bone mineral density;
PAAD	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.47	4.83	0.36	3.35e-6	Age of smoking initiation;
PAAD	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg25753631	chr6:25732923	NA	-0.49	-5.56	-0.41	1.2e-7	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs73196964	chr3:128436391	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.99	8.76	0.58	3.6e-15	Bipolar disorder;
PAAD	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.45	4.53	0.34	1.2e-5	Age of smoking initiation;
PAAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg01320130	chr1:67600311	NA	-0.52	-5.52	-0.41	1.46e-7	Psoriasis;
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg04575393	chr19:53496094	ZNF702P	-0.51	-5.52	-0.41	1.43e-7	Psoriasis;
PAAD	cis	rs9583531	0.714	rs79483970	chr13:111342298	G/A	cg24331049	chr13:111365604	ING1	-0.87	-4.63	-0.35	7.71e-6	Coronary artery disease;
PAAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.48	4.65	0.35	7.22e-6	Pulse pressure;
PAAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.51	0.57	1.54e-14	Menopause (age at onset);
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02071572	chr4:1403502	NA	-0.48	-6.29	-0.45	3.28e-9	Longevity;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.64	6.58	0.47	7.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg08125733	chr17:73851984	WBP2	0.96	8.4	0.56	2.98e-14	Psoriasis;
PAAD	cis	rs13401104	0.587	rs62190974	chr2:237145263	C/T	cg02367144	chr2:237146137	ASB18	0.43	5.45	0.4	1.99e-7	Educational attainment;
PAAD	cis	rs859767	0.501	rs71348712	chr2:135391590	T/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.48	-0.34	1.46e-5	Neuroticism;
PAAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.09e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg08523384	chr5:141488047	NDFIP1	-0.51	-4.93	-0.37	2.13e-6	Asthma;
PAAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.59	-7.08	-0.5	5e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12935418	0.672	rs6564814	chr16:81050172	A/G	cg16651780	chr16:81037892	C16orf61	0.67	6.21	0.45	4.89e-9	Mean corpuscular volume;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21548788	chr4:77997565	CCNI	0.58	6.77	0.48	2.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.82	9.3	0.6	1.44e-16	Total body bone mineral density;
PAAD	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg00262122	chr8:11665843	FDFT1	-0.55	-4.84	-0.37	3.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.86	-0.54	6.65e-13	Neuroticism;
PAAD	cis	rs2275565	0.872	rs10925261	chr1:237053186	C/T	cg17297354	chr1:237056641	MTR	-0.55	-4.88	-0.37	2.63e-6	Homocysteine levels;
PAAD	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.59	-4.34	-0.33	2.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28489187	0.706	rs233060	chr1:85798943	C/T	cg16011679	chr1:85725395	C1orf52	0.52	4.88	0.37	2.71e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs16975963	0.744	rs11672724	chr19:38457488	C/T	cg14218481	chr19:38281219	NA	0.49	5.09	0.38	1.04e-6	Longevity;
PAAD	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.88	10.68	0.65	3.26e-20	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg14926445	chr8:58193284	C8orf71	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.5	5.1	0.38	9.78e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-5.51	-0.41	1.51e-7	Cystic fibrosis severity;
PAAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.99	-9.11	-0.59	4.38e-16	Gut microbiome composition (summer);
PAAD	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.46	-4.41	-0.34	1.95e-5	Menarche (age at onset);
PAAD	trans	rs901683	1.000	rs35183191	chr10:46080617	C/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs969930	0.526	rs4738043	chr8:70775307	T/A	cg03719092	chr8:70744881	SLCO5A1	-0.4	-4.71	-0.36	5.62e-6	Lower body strength;
PAAD	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.84e-19	Tonsillectomy;
PAAD	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.74	-5.81	-0.43	3.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg16928487	chr17:17741425	SREBF1	0.37	4.83	0.37	3.25e-6	Total body bone mineral density;
PAAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-4.43	-0.34	1.82e-5	Blood metabolite levels;
PAAD	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.51	-4.93	-0.37	2.1e-6	Longevity;
PAAD	cis	rs3736485	0.673	rs7171884	chr15:51955733	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.35	-0.33	2.53e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.44	4.36	0.33	2.42e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs501120	0.584	rs61857484	chr10:44719215	C/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-4.28	-0.33	3.31e-5	Diabetic retinopathy;
PAAD	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.73	-0.36	4.98e-6	Renal cell carcinoma;
PAAD	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg07587117	chr16:2239488	CASKIN1	-0.45	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.57	5.0	0.38	1.57e-6	Mean platelet volume;
PAAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg14343924	chr8:8086146	FLJ10661	0.5	4.72	0.36	5.28e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.36	-0.33	2.35e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.61	-5.78	-0.42	4e-8	Obesity-related traits;
PAAD	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.67	6.33	0.46	2.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.11	0.63	1.08e-18	Platelet count;
PAAD	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg02683114	chr2:24398427	C2orf84	0.62	6.83	0.48	1.89e-10	Asthma;
PAAD	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.98	11.64	0.69	8.64e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11563648	0.553	rs6467118	chr7:126958741	C/A	cg21885361	chr7:127911034	NA	-0.4	-4.28	-0.33	3.3e-5	Resting heart rate;
PAAD	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg25730555	chr22:47059586	GRAMD4	0.46	4.73	0.36	4.98e-6	Urate levels in obese individuals;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs6460942	0.597	rs6944517	chr7:12515283	C/T	cg06484146	chr7:12443880	VWDE	-0.84	-5.26	-0.39	4.89e-7	Coronary artery disease;
PAAD	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg03315344	chr16:75512273	CHST6	-0.63	-5.35	-0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.59	-6.28	-0.45	3.45e-9	Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-4.79	-0.36	3.89e-6	Schizophrenia;
PAAD	cis	rs9503598	0.502	rs17309827	chr6:3433318	A/C	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.9e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09364756	chr6:160148626	WTAP	0.52	6.6	0.47	6.38e-10	Primary biliary cholangitis;
PAAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs6495122	0.658	rs12909307	chr15:75061929	A/G	cg14664628	chr15:75095509	CSK	-0.72	-6.55	-0.47	8.5e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg20913747	chr6:44695427	NA	-0.7	-7.01	-0.49	7.21e-11	Total body bone mineral density;
PAAD	cis	rs7172971	0.688	rs7162019	chr15:42385617	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.5	-5.81	-0.43	3.53e-8	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19276012	chr2:219861030	NA	0.62	6.74	0.48	3.17e-10	Myopia (pathological);
PAAD	cis	rs1865721	0.804	rs4510115	chr18:73209635	G/A	cg26385618	chr18:73139727	C18orf62	-0.46	-5.34	-0.4	3.39e-7	Intelligence;
PAAD	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg17771515	chr6:154831774	CNKSR3	0.61	4.34	0.33	2.59e-5	Lipoprotein (a) levels;
PAAD	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.54	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.57	6.05	0.44	1.07e-8	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg11783356	chr20:44313418	WFDC10B	-0.74	-6.64	-0.47	5.2e-10	Brain structure;
PAAD	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.6	0.47	6.42e-10	Total body bone mineral density;
PAAD	cis	rs4795519	0.701	rs12450905	chr17:22187673	G/A	cg22648282	chr17:21454238	C17orf51	-0.55	-5.24	-0.39	5.32e-7	Chronic myeloid leukemia;
PAAD	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	1.08	9.81	0.62	6.83e-18	Corneal structure;
PAAD	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.51	0.34	1.31e-5	Educational attainment;
PAAD	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.54	5.9	0.43	2.25e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.59	8.46	0.57	2.03e-14	Thyroid hormone levels;
PAAD	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.63	5.66	0.42	7.47e-8	Dilated cardiomyopathy;
PAAD	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg23034840	chr1:205782522	SLC41A1	-0.85	-6.37	-0.46	2.16e-9	Prostate-specific antigen levels;
PAAD	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07975834	chr1:112282151	C1orf183	0.58	6.42	0.46	1.67e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.95	14.02	0.75	3.41e-29	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.61	5.87	0.43	2.65e-8	Subjective well-being;
PAAD	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg20893579	chr22:38215064	NA	-0.56	-6.01	-0.44	1.33e-8	Glioblastoma;Glioma;
PAAD	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg27205649	chr11:78285834	NARS2	0.62	4.44	0.34	1.72e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18728316	chr6:157241162	ARID1B	-0.64	-6.66	-0.48	4.6e-10	Obesity-related traits;
PAAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.21	-0.39	6.17e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.93	10.63	0.65	4.4e-20	Colorectal adenoma (advanced);
PAAD	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.61	-6.19	-0.45	5.31e-9	Testicular germ cell tumor;
PAAD	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07677032	chr17:61819896	STRADA	0.62	5.89	0.43	2.36e-8	Prudent dietary pattern;
PAAD	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.68	-5.62	-0.41	8.79e-8	Bone mineral density;
PAAD	cis	rs7011049	1.000	rs72643576	chr8:53845016	A/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.61	-7.01	-0.49	7.25e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs216303	0.722	rs216296	chr12:6154670	A/G	cg12895370	chr12:6755816	ACRBP	-0.52	-4.43	-0.34	1.81e-5	Low vWF levels;
PAAD	cis	rs6494488	0.500	rs112226132	chr15:64911475	A/G	cg16425858	chr15:64791681	ZNF609	0.95	4.53	0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322817	0.691	rs12203954	chr6:105295647	C/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.35	-0.4	3.23e-7	Number of children ever born;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08920249	chr1:209405771	NA	-0.66	-6.94	-0.49	1.04e-10	Obesity-related traits;
PAAD	trans	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.28	0.56	5.95e-14	Educational attainment;
PAAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.55	-0.47	8.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg14709524	chr16:89940631	TCF25	0.9	4.61	0.35	8.43e-6	Skin colour saturation;
PAAD	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg08835956	chr7:39171034	POU6F2	0.32	5.7	0.42	6.17e-8	IgG glycosylation;
PAAD	cis	rs747650	0.504	rs10838646	chr11:47036794	G/C	cg19486271	chr11:47235900	DDB2	-0.68	-6.26	-0.45	3.73e-9	Acne (severe);
PAAD	cis	rs9810890	1.000	rs115394279	chr3:128493714	C/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.29e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.9	7.44	0.52	6.93e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.25	0.45	3.94e-9	Lung cancer in ever smokers;
PAAD	cis	rs4605213	0.528	rs9912882	chr17:49271342	C/T	cg25022915	chr17:49243257	NME2;NME1-NME2	0.36	4.62	0.35	8.25e-6	Height;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg04106633	chr4:1044584	NA	-0.51	-4.77	-0.36	4.19e-6	Recombination rate (males);
PAAD	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.49	4.7	0.36	5.78e-6	Type 2 diabetes;
PAAD	cis	rs7551345	0.671	rs71646317	chr1:31846775	C/T	cg17086398	chr1:31896392	SERINC2	-0.66	-4.57	-0.35	9.83e-6	Schizophrenia;
PAAD	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	1.02	12.53	0.71	3.48e-25	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg15181151	chr6:150070149	PCMT1	0.59	6.47	0.46	1.25e-9	Lung cancer;
PAAD	cis	rs10274279	0.688	rs7459356	chr7:157398852	G/C	cg09270525	chr7:157391030	PTPRN2	0.6	4.52	0.34	1.25e-5	Myopia (pathological);
PAAD	cis	rs1358748	0.555	rs2815340	chr1:67533623	G/C	cg02640540	chr1:67518911	SLC35D1	0.66	4.41	0.34	1.92e-5	Tuberculosis;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-4.68	-0.35	6.28e-6	Systemic lupus erythematosus;
PAAD	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.59	-5.59	-0.41	1.01e-7	Neuroticism;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg09060608	chr5:178986726	RUFY1	-0.65	-7.01	-0.49	7.48e-11	Lung cancer;
PAAD	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg11464842	chr2:97427975	CNNM4	0.63	4.39	0.34	2.1e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg09473613	chr1:24152604	HMGCL	0.54	5.74	0.42	5.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.76	7.56	0.52	3.58e-12	Tonsillectomy;
PAAD	cis	rs73086581	1.000	rs6037708	chr20:3961253	C/G	cg02187196	chr20:3869020	PANK2	0.58	4.89	0.37	2.52e-6	Response to antidepressants in depression;
PAAD	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.39	0.34	2.08e-5	Bipolar disorder;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04122329	chr1:89149714	PKN2	0.72	6.81	0.48	2.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10949834	0.824	rs3801461	chr7:73536368	C/G	cg07137043	chr7:73588983	EIF4H	-0.67	-5.05	-0.38	1.26e-6	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg09760422	chr2:128146352	NA	-0.35	-5.89	-0.43	2.37e-8	Protein C levels;
PAAD	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-7.62	-0.53	2.58e-12	Colorectal cancer;
PAAD	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.58	7.07	0.5	5.34e-11	Multiple sclerosis;
PAAD	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg09184832	chr6:79620586	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	1e-10	Axial length;
PAAD	cis	rs959260	1.000	rs2385264	chr17:73364992	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-5.33	-0.4	3.47e-7	Sitting height ratio;
PAAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23021241	chr1:44679211	DMAP1	-0.74	-6.81	-0.48	2.09e-10	Neuroticism;
PAAD	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.73	-7.59	-0.52	3.06e-12	Magnesium levels;
PAAD	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.63	6.14	0.45	6.98e-9	Schizophrenia;
PAAD	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	1.02	8.52	0.57	1.49e-14	Vitiligo;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	5.95	0.43	1.78e-8	Schizophrenia;
PAAD	cis	rs516243	0.660	rs521513	chr1:10740444	T/A	cg02903756	chr1:10750680	CASZ1	-0.43	-4.67	-0.35	6.7e-6	Migraine - clinic-based;
PAAD	cis	rs11250714	0.845	rs11250702	chr10:1691116	C/T	cg10435618	chr10:838112	NA	0.49	4.62	0.35	8.24e-6	Gut microbiome composition (summer);
PAAD	cis	rs9810890	1.000	rs73207976	chr3:128569020	C/T	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.56	5.26	0.39	4.71e-7	Corneal astigmatism;
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg23708337	chr7:1209742	NA	0.67	5.29	0.39	4.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.25	-0.33	3.72e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.83	8.11	0.55	1.59e-13	Post bronchodilator FEV1;
PAAD	cis	rs41419946	1.000	rs74118603	chr1:165406711	T/A	cg24428232	chr1:166124419	MIR921;FAM78B	0.81	4.42	0.34	1.9e-5	Gut microbiome composition (winter);
PAAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.36	16.94	0.81	7.81e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.78	9.17	0.6	3.16e-16	Blood metabolite ratios;
PAAD	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.74	5.97	0.44	1.61e-8	Alzheimer's disease;
PAAD	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.82	-8.82	-0.58	2.44e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2637266	0.597	rs846622	chr10:78543005	G/A	cg18941641	chr10:78392320	NA	0.36	4.35	0.33	2.53e-5	Pulmonary function;
PAAD	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg18989491	chr10:6185502	PFKFB3	-0.46	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs425535	0.824	rs189511	chr4:74828639	T/C	cg01447579	chr4:74847100	PF4	0.67	4.25	0.33	3.75e-5	Blood protein levels;
PAAD	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01113040	chr17:42440939	FAM171A2	0.57	6.69	0.48	4e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.68	6.8	0.48	2.28e-10	Prostate cancer;
PAAD	cis	rs73019876	0.901	rs436194	chr19:22228527	A/G	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs6460942	0.597	rs4721107	chr7:12535105	T/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-4.75	-0.36	4.73e-6	Asthma;
PAAD	cis	rs11669133	0.655	rs117801813	chr19:11055104	A/G	cg25243385	chr19:11167475	SMARCA4	0.99	4.55	0.35	1.08e-5	LDL cholesterol;
PAAD	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.55	-5.17	-0.39	7.22e-7	Coronary artery disease;
PAAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs11583200	0.709	rs12758298	chr1:50484613	C/A	cg09846084	chr1:50888024	DMRTA2	0.43	4.34	0.33	2.58e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.78	-9.13	-0.59	4.07e-16	DNA methylation (variation);
PAAD	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4668356	0.730	rs7604392	chr2:171911986	T/C	cg13882835	chr2:172017928	TLK1	0.92	5.37	0.4	2.83e-7	Cognitive performance;
PAAD	cis	rs1532557	1.000	rs1499291	chr1:224763790	G/A	cg09988837	chr1:224811939	CNIH3	0.62	4.54	0.35	1.15e-5	Cancer;
PAAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	8.18	0.55	1.05e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg05627522	chr15:75251581	NA	0.53	6.21	0.45	4.8e-9	Caffeine consumption;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg21698718	chr17:80085957	CCDC57	0.46	5.16	0.39	7.5e-7	Life satisfaction;
PAAD	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.55	0.61	3.11e-17	Bladder cancer;
PAAD	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.65	6.66	0.48	4.7e-10	Colorectal cancer;
PAAD	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.76	8.74	0.58	3.94e-15	Heart rate;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.66	0.57	6.49e-15	Alzheimer's disease;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.54	0.47	8.79e-10	Coronary artery disease;
PAAD	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg12756303	chr2:74692479	MOGS	-0.5	-4.49	-0.34	1.39e-5	Metabolite levels;
PAAD	cis	rs8051149	0.793	rs34831152	chr16:87870607	A/G	cg01412419	chr16:87856264	NA	0.72	6.22	0.45	4.63e-9	Blood metabolite levels;
PAAD	cis	rs134594	0.806	rs134664	chr22:29494148	T/C	cg01361351	chr22:29467363	NA	-0.38	-4.33	-0.33	2.65e-5	Birth weight;
PAAD	cis	rs9659323	0.730	rs10923720	chr1:119541879	T/C	cg17326555	chr1:119535693	NA	-0.46	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg04522676	chr10:134968826	NA	-0.47	-4.44	-0.34	1.71e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.48	-7.74	-0.53	1.28e-12	Cutaneous nevi;
PAAD	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs364477	0.818	rs279886	chr9:979585	G/T	cg13952963	chr9:998547	NA	0.57	4.71	0.36	5.49e-6	Major depressive disorder;
PAAD	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.59	6.72	0.48	3.39e-10	Schizophrenia;
PAAD	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.88	-10.65	-0.65	3.96e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00746864	chr17:65373877	PITPNC1	0.67	6.91	0.49	1.24e-10	Obesity-related traits;
PAAD	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg07469887	chr10:131262384	NA	-0.41	-4.64	-0.35	7.37e-6	Response to temozolomide;
PAAD	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg08992911	chr2:238395768	MLPH	0.62	5.7	0.42	6e-8	Prostate cancer;
PAAD	cis	rs11203032	0.831	rs11203024	chr10:90955239	G/T	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg19052272	chr2:3704530	ALLC	-0.57	-6.6	-0.47	6.43e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg21496419	chr19:44306685	LYPD5	0.39	4.99	0.38	1.61e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6594535	0.922	rs3797737	chr5:111090124	C/G	cg06838283	chr5:111090142	C5orf13	0.51	4.57	0.35	9.89e-6	Chickenpox;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06019718	chr3:186288436	TBCCD1;DNAJB11	-0.56	-6.33	-0.46	2.67e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1144333	0.655	rs76175698	chr1:76454792	C/T	cg22875332	chr1:76189707	ACADM	0.76	4.46	0.34	1.59e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10512697	0.655	rs35209468	chr5:3473582	C/T	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16434002	chr17:42200994	HDAC5	-0.55	-5.68	-0.42	6.8e-8	Total body bone mineral density;
PAAD	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.7	0.36	5.76e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs3206736	0.548	rs328937	chr7:35049131	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12961656	chr3:193853443	HES1	-0.75	-7.4	-0.51	8.56e-12	Lung cancer in ever smokers;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.44	5.08	0.38	1.08e-6	Tonsillectomy;
PAAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg05082376	chr22:42548792	NA	0.51	5.61	0.41	9.47e-8	Cognitive function;
PAAD	cis	rs7765175	0.698	rs9320440	chr6:113667184	A/C	cg19037598	chr6:113666021	NA	-0.41	-4.4	-0.34	2.06e-5	Coronary artery calcification;
PAAD	cis	rs6669119	0.651	rs79435445	chr1:19105023	C/T	cg26220594	chr1:19110978	NA	0.85	5.09	0.38	1.02e-6	Percentage gas trapping;
PAAD	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.84	-0.49	1.81e-10	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12255698	chr17:1953305	MIR132	0.59	6.38	0.46	2.07e-9	Myopia (pathological);
PAAD	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg07061783	chr6:25882402	NA	0.45	4.32	0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg22903657	chr4:1355424	KIAA1530	0.42	4.48	0.34	1.46e-5	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-4.28	-0.33	3.3e-5	Renal cell carcinoma;
PAAD	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3126085	0.515	rs9633409	chr1:152362329	G/T	cg26876637	chr1:152193138	HRNR	-0.59	-4.3	-0.33	3.04e-5	Atopic dermatitis;
PAAD	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.89	-7.25	-0.51	1.97e-11	Blood protein levels;
PAAD	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.26	-0.39	4.85e-7	Common traits (Other);
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21016266	chr12:122356598	WDR66	0.58	6.97	0.49	9.06e-11	Mean corpuscular volume;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.52	-5.16	-0.39	7.76e-7	Iron status biomarkers;
PAAD	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	6.96	0.49	9.47e-11	Systemic lupus erythematosus;
PAAD	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.59	-5.31	-0.4	3.78e-7	White blood cell count;
PAAD	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	1.08	15.07	0.77	5.83e-32	Breast cancer;
PAAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.3e-22	Coronary artery disease;
PAAD	cis	rs755249	0.567	rs4660208	chr1:39722214	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg08886695	chr4:3369023	RGS12	-0.48	-4.73	-0.36	5.03e-6	Serum sulfate level;
PAAD	cis	rs4727443	0.682	rs6962405	chr7:99557217	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.46	4.62	0.35	8.23e-6	Interstitial lung disease;
PAAD	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.48	6.7	0.48	3.77e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2229238	0.868	rs73023348	chr1:154513418	G/A	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.63	-6.93	-0.49	1.12e-10	Colorectal cancer;
PAAD	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg13207630	chr7:32358064	NA	0.88	4.59	0.35	9.15e-6	Body mass index;
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.79	9.78	0.62	8.14e-18	Lymphocyte counts;
PAAD	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg02404636	chr22:31891804	SFI1	-0.61	-5.48	-0.41	1.71e-7	Colorectal cancer;
PAAD	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.47	-4.93	-0.37	2.13e-6	Platelet count;
PAAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-5.19	-0.39	6.49e-7	Mood instability;
PAAD	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.77	-0.36	4.34e-6	Systemic lupus erythematosus;
PAAD	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-4.39	-0.34	2.14e-5	Self-reported allergy;
PAAD	cis	rs3169166	0.521	rs62007839	chr15:78570875	G/A	cg09214398	chr15:78556534	DNAJA4	0.31	5.31	0.4	3.82e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26951706	chr15:82575848	FAM154B	-0.65	-6.82	-0.48	2e-10	Obesity-related traits;
PAAD	cis	rs256277	0.657	rs255923	chr5:111380052	G/T	cg17919331	chr5:112312406	DCP2	0.52	4.3	0.33	3.07e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13754251	chr22:43583855	TTLL12	-0.77	-7.12	-0.5	3.92e-11	Neuroticism;
PAAD	cis	rs11867934	0.813	rs2349646	chr17:17017170	G/T	cg05552144	chr17:17942551	ATPAF2;C17orf39	-0.57	-4.41	-0.34	1.91e-5	Diabetic retinopathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06555155	chr6:158981441	TMEM181	0.62	6.4	0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.58	-7.94	-0.54	4.1e-13	Rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18238366	chr20:34542436	SCAND1	0.61	6.87	0.49	1.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg10150615	chr22:24372951	LOC391322	0.53	4.38	0.33	2.19e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs507080	0.922	rs592280	chr11:118553218	T/C	cg08498647	chr11:118550644	TREH	-0.37	-4.33	-0.33	2.73e-5	Serum metabolite levels;
PAAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg12564285	chr5:131593104	PDLIM4	0.48	4.91	0.37	2.33e-6	Blood metabolite levels;
PAAD	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.17	-0.6	3.12e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg05082376	chr22:42548792	NA	-0.45	-4.38	-0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.58	4.3	0.33	3.04e-5	Alzheimer's disease (survival time);
PAAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg06207120	chr15:45996521	NA	0.31	4.61	0.35	8.53e-6	Waist circumference;Weight;
PAAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.65	6.36	0.46	2.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.75	-6.04	-0.44	1.12e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.48	4.92	0.37	2.26e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.75	6.89	0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.2	0.6	2.57e-16	Hemoglobin concentration;
PAAD	cis	rs7627468	0.770	rs3863977	chr3:121964262	T/C	cg17240004	chr3:121949083	CASR	0.5	4.77	0.36	4.33e-6	Kidney stones;
PAAD	cis	rs642743	0.967	rs687557	chr10:105989509	T/A	cg03775802	chr10:105978702	MIR609;C10orf79	0.33	4.63	0.35	7.67e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg24531977	chr5:56204891	C5orf35	-0.51	-4.68	-0.35	6.28e-6	Coronary artery disease;
PAAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg18944383	chr4:111397179	ENPEP	0.63	7.07	0.5	5.24e-11	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.57	7.59	0.52	2.96e-12	Renal cell carcinoma;
PAAD	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg24112000	chr20:60950667	NA	-0.7	-8.8	-0.58	2.77e-15	Colorectal cancer;
PAAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg14356550	chr1:18808102	KLHDC7A	-0.59	-6.65	-0.47	4.98e-10	Breast cancer;
PAAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.55	-5.18	-0.39	7.09e-7	Obesity-related traits;
PAAD	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.5	4.56	0.35	1.05e-5	Breast cancer;
PAAD	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg11764359	chr7:65958608	NA	-0.74	-4.85	-0.37	2.97e-6	Diabetic kidney disease;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01585852	chr22:24235823	MIF	-0.47	-5.07	-0.38	1.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg05585544	chr11:47624801	NA	-0.47	-5.26	-0.39	4.91e-7	Subjective well-being;
PAAD	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs258892	0.895	rs155433	chr5:72139664	G/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1190596	0.525	rs10133613	chr14:102736183	T/C	cg23904247	chr14:102554826	HSP90AA1	0.43	4.87	0.37	2.82e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.08	13.61	0.74	4.37e-28	Subjective well-being;
PAAD	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.67	-0.58	6.12e-15	Exhaled nitric oxide output;
PAAD	cis	rs910187	0.624	rs6063077	chr20:45787261	C/T	cg27589058	chr20:45804311	EYA2	-0.42	-4.34	-0.33	2.62e-5	Migraine;
PAAD	cis	rs9677476	0.909	rs7573577	chr2:232104079	C/T	cg07929768	chr2:232055508	NA	0.38	4.3	0.33	2.99e-5	Food antigen IgG levels;
PAAD	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.53	-0.52	4.28e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8133932	0.701	rs7279887	chr21:47301148	T/C	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs17155006	0.655	rs448742	chr7:107733993	C/T	cg05962710	chr7:107745446	LAMB4	0.46	5.75	0.42	4.67e-8	Pneumococcal bacteremia;
PAAD	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.39	0.56	3.05e-14	Rheumatoid arthritis;
PAAD	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg16006841	chr5:176797999	RGS14	0.8	9.3	0.6	1.47e-16	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs17641971	0.965	rs341815	chr8:49978424	A/C	cg00325661	chr8:49890786	NA	0.48	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	6.14	0.45	6.86e-9	Menopause (age at onset);
PAAD	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg20003494	chr4:90757398	SNCA	-0.41	-4.53	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.58	-6.04	-0.44	1.16e-8	Lung cancer;
PAAD	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.77	-7.33	-0.51	1.28e-11	DNA methylation (variation);
PAAD	cis	rs317865	0.737	rs73234668	chr4:16240306	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.53	0.47	9.28e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.65	0.47	5.06e-10	Multiple sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13458596	chr1:150208665	ANP32E	0.68	6.74	0.48	3.02e-10	Obesity-related traits;
PAAD	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg13540341	chr19:49222985	MAMSTR	0.41	4.51	0.34	1.3e-5	Dietary macronutrient intake;
PAAD	cis	rs3774830	0.748	rs17367445	chr4:5464903	C/T	cg26943120	chr4:5472116	STK32B	0.34	4.29	0.33	3.2e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs72960926	0.590	rs72952344	chr6:74800914	G/C	cg03266952	chr6:74778945	NA	-1.24	-6.95	-0.49	9.81e-11	Metabolite levels (MHPG);
PAAD	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.57	5.04	0.38	1.31e-6	Life satisfaction;
PAAD	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	trans	rs901683	0.702	rs34019727	chr10:45987751	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.59	6.91	0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg19980929	chr12:42632907	YAF2	0.54	6.24	0.45	4.11e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs17407555	0.633	rs10022367	chr4:10277093	C/A	cg11266682	chr4:10021025	SLC2A9	0.42	4.28	0.33	3.24e-5	Schizophrenia (age at onset);
PAAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2131877	0.830	rs62285221	chr3:194875140	A/G	cg24618514	chr3:194868507	C3orf21	0.49	4.41	0.34	1.93e-5	Non-small cell lung cancer;
PAAD	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.48	-4.57	-0.35	1.02e-5	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14085606	chr9:130454671	STXBP1	0.59	6.97	0.49	9.13e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7219021	1.000	rs7219021	chr17:46840541	A/C	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.36	-0.33	2.41e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-5.99	-0.44	1.46e-8	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04287289	chr16:89883240	FANCA	0.75	4.31	0.33	2.94e-5	Skin colour saturation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04856841	chr1:156308275	CCT3;C1orf182	0.59	6.84	0.49	1.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.44	4.49	0.34	1.39e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.94	-9.8	-0.62	6.88e-18	Cognitive function;
PAAD	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-5.59	-0.41	1.01e-7	Vitiligo;
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg26071806	chr7:100318239	EPO	-0.47	-4.63	-0.35	7.9e-6	Other erythrocyte phenotypes;
PAAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg05785598	chr3:49045655	WDR6	0.4	4.76	0.36	4.52e-6	Parkinson's disease;
PAAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.7	7.43	0.52	7.15e-12	Calcium levels;
PAAD	cis	rs4740619	0.587	rs10756740	chr9:16037723	T/C	cg14451791	chr9:16040625	NA	-0.45	-5.11	-0.38	9.33e-7	Body mass index;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.45	4.28	0.33	3.32e-5	Heart rate;
PAAD	cis	rs300774	1.000	rs167282	chr2:117174	A/G	cg23649280	chr2:140451	NA	-0.5	-4.72	-0.36	5.29e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg10871876	chr19:53194124	ZNF83	0.62	5.47	0.41	1.81e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.37	-0.4	2.85e-7	Bladder cancer;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg21698718	chr17:80085957	CCDC57	0.45	5.26	0.39	4.8e-7	Life satisfaction;
PAAD	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09065629	chr16:1709722	CRAMP1L	0.47	4.82	0.36	3.46e-6	Coronary artery disease;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.85	11.36	0.68	4.94e-22	Vitiligo;
PAAD	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg05187965	chr10:45406764	TMEM72	-0.38	-5.28	-0.39	4.49e-7	Mean corpuscular volume;
PAAD	cis	rs3981351	0.797	rs12777332	chr10:115458936	A/G	cg24846397	chr10:115438155	CASP7	-0.56	-5.12	-0.38	8.98e-7	Obesity-related traits;
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.59	-0.57	9.92e-15	Body mass index;
PAAD	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.56	-0.47	8.07e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.14	-0.38	8.22e-7	Schizophrenia;
PAAD	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg00922110	chr4:57842668	C4orf14	0.42	4.81	0.36	3.65e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg10820045	chr2:198174542	NA	-0.46	-4.67	-0.35	6.54e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1499972	0.504	rs1499978	chr3:117778292	C/T	cg07612923	chr3:117604196	NA	-0.71	-5.05	-0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.63	6.12	0.44	7.48e-9	Platelet distribution width;
PAAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.41	0.52	8e-12	Menopause (age at onset);
PAAD	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.87	-8.71	-0.58	4.86e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.98	12.01	0.7	8.44e-24	Multiple system atrophy;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg07527105	chr16:88053339	BANP	-0.49	-4.88	-0.37	2.68e-6	Menopause (age at onset);
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.82	9.44	0.61	6.19e-17	Mean platelet volume;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg06815965	chr1:205818668	PM20D1	0.55	5.97	0.44	1.64e-8	Menarche (age at onset);
PAAD	cis	rs12311304	0.965	rs73065457	chr12:15366321	C/T	cg08258403	chr12:15378311	NA	0.36	4.57	0.35	9.96e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.8	8.63	0.57	7.67e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.661	rs12537196	chr7:104922624	A/G	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16176834	chr1:26028188	MAN1C1	-0.61	-6.64	-0.47	5.33e-10	Obesity-related traits;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23298160	chr5:137514800	BRD8;KIF20A	0.67	6.31	0.46	2.89e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg26174226	chr8:58114915	NA	-0.57	-4.34	-0.33	2.56e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.38	-4.83	-0.36	3.34e-6	Red cell distribution width;
PAAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.15	-14.1	-0.75	2.17e-29	Ulcerative colitis;
PAAD	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.2	-0.5	2.65e-11	Total cholesterol levels;
PAAD	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg27490568	chr2:178487706	NA	0.44	4.73	0.36	5.19e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg13786083	chr1:19110734	NA	0.52	4.25	0.33	3.69e-5	Percentage gas trapping;
PAAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.54	-4.38	-0.33	2.23e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.92e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2718812	1.000	rs2953740	chr3:133406351	T/C	cg08048268	chr3:133502702	NA	0.43	5.24	0.39	5.21e-7	Iron status biomarkers;
PAAD	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg08992911	chr2:238395768	MLPH	0.63	5.9	0.43	2.32e-8	Prostate cancer;
PAAD	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.77	6.2	0.45	5.12e-9	Schizophrenia;
PAAD	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs35160687	0.644	rs17738058	chr2:86513203	G/C	cg10973622	chr2:86423274	IMMT	-0.45	-4.93	-0.37	2.12e-6	Night sleep phenotypes;
PAAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.89	-8.99	-0.59	9.4e-16	Asthma;
PAAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.61	-7.35	-0.51	1.12e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7998202	0.667	rs282577	chr13:113358838	G/A	cg02820901	chr13:113351484	ATP11A	0.73	4.78	0.36	4.14e-6	Glycated hemoglobin levels;
PAAD	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.38	-0.51	9.81e-12	Neuroticism;
PAAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg22134325	chr11:66188745	NPAS4	0.41	5.14	0.39	8.18e-7	Airway imaging phenotypes;
PAAD	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg21523528	chr20:32077966	CBFA2T2	0.53	4.37	0.33	2.32e-5	Height;
PAAD	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	5.27	0.39	4.57e-7	Height;
PAAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.19	-0.5	2.8e-11	Gut microbiome composition (summer);
PAAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg25753631	chr6:25732923	NA	-0.46	-5.23	-0.39	5.48e-7	Iron status biomarkers;
PAAD	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg07810366	chr2:100720526	AFF3	-0.35	-4.46	-0.34	1.59e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.28	-8.88	-0.58	1.73e-15	Diabetic retinopathy;
PAAD	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.67	5.51	0.41	1.47e-7	Prostate cancer;
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg22654517	chr2:96458247	NA	0.38	4.51	0.34	1.29e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.38	4.92	0.37	2.24e-6	Calcium levels;
PAAD	cis	rs12799264	1.000	rs1808914	chr11:19977234	A/T	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.77	6.18	0.45	5.74e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg03605226	chr16:87637261	JPH3	0.39	4.32	0.33	2.78e-5	Menopause (age at onset);
PAAD	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.44	5.56	0.41	1.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg13606994	chr1:44402422	ARTN	-0.43	-4.66	-0.35	6.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.35	-5.57	-0.41	1.11e-7	Urate levels in overweight individuals;
PAAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg01075559	chr1:2537774	MMEL1	0.53	5.52	0.41	1.41e-7	Ulcerative colitis;
PAAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.6	-6.97	-0.49	9.03e-11	Rheumatoid arthritis;
PAAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.43	5.05	0.38	1.27e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07182965	chr18:71815169	FBXO15;C18orf55	0.58	6.44	0.46	1.52e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs59888335	0.830	rs35730471	chr3:80526005	T/G	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg18944383	chr4:111397179	ENPEP	0.76	7.8	0.53	9.24e-13	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20465933	chr4:152376761	FAM160A1	-0.64	-6.58	-0.47	7.2e-10	Obesity-related traits;
PAAD	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs988913	1.000	rs9349741	chr6:54841709	G/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.81	-0.36	3.62e-6	Menarche (age at onset);
PAAD	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.56	5.37	0.4	2.94e-7	Platelet count;
PAAD	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg17347104	chr14:75034677	LTBP2	-0.53	-4.56	-0.35	1.03e-5	Non-small cell lung cancer;
PAAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.73	-0.36	5.1e-6	Mean corpuscular volume;
PAAD	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg03233332	chr7:66118400	NA	0.39	4.25	0.33	3.64e-5	Aortic root size;
PAAD	trans	rs17181550	0.502	rs2079542	chr17:70274439	A/G	cg03164275	chr2:219826805	CDK5R2	0.38	6.36	0.46	2.25e-9	Lung adenocarcinoma;Lung cancer;
PAAD	cis	rs4443100	0.916	rs2330335	chr22:23382362	G/A	cg14186256	chr22:23484241	RTDR1	0.52	4.59	0.35	9.31e-6	Serum parathyroid hormone levels;
PAAD	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-5.16	-0.39	7.49e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg10556349	chr10:835070	NA	0.6	4.97	0.37	1.77e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.41	-5.23	-0.39	5.53e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg11166453	chr1:247681781	NA	0.58	7.0	0.49	7.89e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg20007245	chr22:24372913	LOC391322	-0.64	-5.9	-0.43	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24716125	chr3:46933808	PTH1R	0.57	6.76	0.48	2.8e-10	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.51	7.2	0.5	2.53e-11	Homoarginine levels;
PAAD	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.92	7.49	0.52	5.38e-12	Bipolar disorder;
PAAD	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.43	-0.34	1.77e-5	Height;
PAAD	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg27119904	chr13:114814333	RASA3	0.43	4.55	0.35	1.11e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs73416724	0.610	rs111981370	chr6:43255380	G/T	cg00507679	chr6:43251876	TTBK1	0.65	5.16	0.39	7.75e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg01815783	chr4:1047043	NA	-0.48	-4.6	-0.35	8.77e-6	Recombination rate (females);
PAAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg05562828	chr17:3906858	NA	0.59	6.34	0.46	2.48e-9	Type 2 diabetes;
PAAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg05535760	chr7:792225	HEATR2	1.02	8.17	0.55	1.13e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12450239	0.778	rs12940455	chr17:77441124	C/T	cg09567646	chr17:76962761	NA	-0.49	-4.65	-0.35	7.26e-6	Body mass index;
PAAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Coronary artery disease;
PAAD	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.89	-7.34	-0.51	1.23e-11	Obesity-related traits;
PAAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg05110241	chr16:68378359	PRMT7	-0.91	-7.3	-0.51	1.5e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.64	-0.35	7.56e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.77	7.44	0.52	6.91e-12	Asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08493356	chr3:196668755	NCBP2;LOC152217	-0.7	-6.4	-0.46	1.79e-9	Neuroticism;
PAAD	cis	rs9463078	0.774	rs6458441	chr6:45327401	G/T	cg25276700	chr6:44698697	NA	0.46	5.26	0.39	4.81e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg25613170	chr17:45772523	TBKBP1	0.79	6.44	0.46	1.45e-9	Atopic dermatitis;
PAAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg05554000	chr7:158905015	VIPR2	-0.56	-4.35	-0.33	2.5e-5	Facial morphology (factor 20);
PAAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.42	4.41	0.34	1.94e-5	Psoriasis;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.28	0.51	1.65e-11	Lung function (FEV1/FVC);
PAAD	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.48	-0.34	1.45e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.69	-0.42	6.32e-8	Resting heart rate;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25344845	chr8:103263981	NA	0.64	6.55	0.47	8.59e-10	Smoking initiation;
PAAD	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg02415014	chr8:143852576	LYNX1	0.49	6.06	0.44	1.01e-8	Urinary tract infection frequency;
PAAD	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg18490616	chr2:88469792	THNSL2	-0.44	-4.28	-0.33	3.35e-5	Response to metformin (IC50);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25356261	chr21:38639833	DSCR3	0.66	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.37	12.27	0.71	1.77e-24	Uric acid levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11843090	chr12:110433832	GIT2	-0.78	-7.0	-0.49	7.81e-11	Neuroticism;
PAAD	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.73	-8.48	-0.57	1.81e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg23788917	chr6:8435910	SLC35B3	-0.67	-7.29	-0.51	1.58e-11	Motion sickness;
PAAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26068169	chr12:123717786	C12orf65	0.62	6.51	0.47	1.02e-9	Pancreatic cancer;
PAAD	cis	rs72960926	0.744	rs11752717	chr6:74954435	G/A	cg03266952	chr6:74778945	NA	-1.2	-6.59	-0.47	6.77e-10	Metabolite levels (MHPG);
PAAD	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.38	-0.33	2.21e-5	Depression;
PAAD	cis	rs1529711	0.568	rs11880504	chr19:10957733	A/G	cg18582342	chr19:11591989	ELAVL3	-0.57	-4.87	-0.37	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17169634	0.557	rs17169636	chr7:34094687	G/T	cg24927974	chr7:35078269	DPY19L1	0.64	4.81	0.36	3.62e-6	Alzheimer's disease;
PAAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg05725404	chr16:58534157	NDRG4	-0.74	-4.72	-0.36	5.31e-6	Schizophrenia;
PAAD	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.44	-5.9	-0.43	2.27e-8	White blood cell count;
PAAD	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.42	-5.24	-0.39	5.39e-7	Colorectal cancer;
PAAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09247346	chr2:219081710	ARPC2	-0.69	-6.66	-0.48	4.7e-10	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.13	0.38	8.57e-7	Life satisfaction;
PAAD	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.9	-0.49	1.35e-10	Neuroticism;
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-5.86	-0.43	2.76e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.51	-5.11	-0.38	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.26	-0.51	1.89e-11	Total cholesterol levels;
PAAD	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.51	6.11	0.44	8.19e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg22601191	chr20:60968625	CABLES2	0.55	5.5	0.41	1.56e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.42	4.37	0.33	2.29e-5	Obesity-related traits;
PAAD	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs11718455	0.538	rs1524887	chr3:44016371	C/T	cg08738300	chr3:44038990	NA	0.41	4.39	0.34	2.14e-5	Coronary artery disease;
PAAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.43	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	5e-20	Heart rate;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.49	0.52	5.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17525856	chr2:47596787	EPCAM	-0.63	-6.45	-0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-4.79	-0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.79	6.26	0.45	3.78e-9	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.68	6.92	0.49	1.15e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.58	7.35	0.51	1.15e-11	Hypertriglyceridemia;
PAAD	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg07606381	chr6:8435919	SLC35B3	-0.51	-5.76	-0.42	4.51e-8	Motion sickness;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23361579	chr13:114087964	ADPRHL1	0.53	6.39	0.46	1.95e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19784903	chr17:45786737	TBKBP1	0.57	6.28	0.45	3.32e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs600626	0.588	rs10160802	chr11:75457950	A/C	cg24262691	chr11:75473276	NA	0.75	6.1	0.44	8.31e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg02683114	chr2:24398427	C2orf84	-0.46	-4.81	-0.36	3.57e-6	Sjögren's syndrome;
PAAD	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.65	6.69	0.48	4.01e-10	Menarche (age at onset);
PAAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg17507749	chr15:85114479	UBE2QP1	0.7	7.08	0.5	5e-11	Schizophrenia;
PAAD	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.05	-0.38	1.24e-6	Lung cancer in ever smokers;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21107197	chr14:51027861	ATL1	-0.53	-6.62	-0.47	5.72e-10	Body fat percentage;
PAAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg26727032	chr16:67993705	SLC12A4	0.71	5.04	0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.68	-6.7	-0.48	3.75e-10	Blood metabolite levels;
PAAD	cis	rs2070677	0.756	rs2987795	chr10:135378656	A/G	cg20169779	chr10:135381914	SYCE1	0.76	7.17	0.5	2.99e-11	Gout;
PAAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19346786	chr7:2764209	NA	-0.38	-5.09	-0.38	1.03e-6	Height;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg15660573	chr17:549704	VPS53	-0.76	-7.67	-0.53	1.94e-12	Prostate cancer;
PAAD	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22482690	chr17:47019901	SNF8	-0.43	-4.51	-0.34	1.27e-5	Type 2 diabetes;
PAAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Lymphocyte counts;
PAAD	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.48	0.34	1.44e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg02353165	chr6:42928485	GNMT	0.57	4.84	0.37	3.15e-6	Blood protein levels;
PAAD	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06677660	chr19:49140777	SEC1;DBP	0.75	5.9	0.43	2.29e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs10121009	0.635	rs579461	chr9:35298717	C/A	cg11846315	chr9:35647073	NA	-0.49	-4.37	-0.33	2.33e-5	Parkinson's disease;
PAAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg14703610	chr5:56206110	C5orf35	-0.55	-5.07	-0.38	1.14e-6	Initial pursuit acceleration;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06009330	chr2:70485380	PCYOX1	-0.54	-6.5	-0.47	1.08e-9	Body fat percentage;
PAAD	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.94	-10.15	-0.64	8.22e-19	Parkinson's disease;
PAAD	cis	rs2077654	0.556	rs4756888	chr11:17442658	T/C	cg25308976	chr11:17434268	ABCC8	0.69	4.95	0.37	1.95e-6	Gout;
PAAD	cis	rs11997175	0.562	rs72630962	chr8:33761447	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	5.44	0.4	2.1e-7	Body mass index;
PAAD	cis	rs7671266	0.616	rs4320137	chr4:10072969	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.26	0.33	3.64e-5	Cardiovascular disease risk factors;
PAAD	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26534614	chr2:232826398	DIS3L2	-0.63	-6.4	-0.46	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.46	0.71	5.18e-25	Cognitive ability;
PAAD	cis	rs8014252	0.803	rs61388426	chr14:71045002	G/A	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.49	5.5	0.41	1.54e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.1	0.55	1.67e-13	Height;
PAAD	cis	rs9923856	0.519	rs2867168	chr16:11123789	G/T	cg04616529	chr16:11181986	CLEC16A	0.37	4.31	0.33	2.94e-5	Atopic dermatitis;Adult asthma;
PAAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.75	8.28	0.56	5.97e-14	Longevity;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23117592	chr2:210674163	UNC80	0.56	7.11	0.5	4.26e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.92	7.08	0.5	5.07e-11	Gut microbiome composition (summer);
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24147428	chr11:65409760	SIPA1	-0.49	-5.19	-0.39	6.78e-7	Blood pressure (age interaction);
PAAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.27	-7.09	-0.5	4.71e-11	Body mass index;
PAAD	cis	rs2296225	0.556	rs7552264	chr1:21087927	G/A	cg24673385	chr1:21051448	SH2D5	0.47	4.31	0.33	2.96e-5	Eosinophilic esophagitis;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg26513180	chr16:89883248	FANCA	0.93	12.39	0.71	8.38e-25	Schizophrenia;
PAAD	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg01796438	chr3:11312864	ATG7	-0.67	-5.13	-0.38	8.85e-7	Circulating chemerin levels;
PAAD	cis	rs1135642	0.841	rs116423554	chr4:77875899	C/T	cg03477792	chr4:77819574	ANKRD56	0.68	4.35	0.33	2.45e-5	Food addiction;
PAAD	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg25558440	chr8:11882962	NA	-0.44	-4.27	-0.33	3.41e-5	Neuroticism;
PAAD	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.39	4.39	0.34	2.08e-5	IgG glycosylation;
PAAD	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.64	-7.58	-0.52	3.11e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs3760982	0.776	rs56103707	chr19:44304188	G/A	cg21496419	chr19:44306685	LYPD5	-0.38	-4.56	-0.35	1.03e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg07648498	chr16:89883185	FANCA	0.46	4.49	0.34	1.42e-5	Vitiligo;
PAAD	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	0.99	6.6	0.47	6.34e-10	Sexual dysfunction (female);
PAAD	cis	rs1879734	0.731	rs10888805	chr1:54160571	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.48	-5.52	-0.41	1.4e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-5.45	-0.4	1.98e-7	Cognitive test performance;
PAAD	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg09654669	chr8:57350985	NA	-0.48	-4.35	-0.33	2.48e-5	Obesity-related traits;
PAAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.79e-9	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg09945482	chr18:12777974	NA	0.61	5.38	0.4	2.74e-7	Inflammatory skin disease;
PAAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.59	6.71	0.48	3.6e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.61	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.63	7.61	0.53	2.71e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.97	0.49	8.99e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.92e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.63	-7.66	-0.53	1.99e-12	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.51	4.93	0.37	2.17e-6	Rheumatoid arthritis;
PAAD	cis	rs57244997	0.725	rs7738080	chr6:162413377	A/G	cg17173639	chr6:162384350	PARK2	-0.59	-4.43	-0.34	1.78e-5	Mosquito bite size;
PAAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.53	-5.22	-0.39	5.7e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16854630	chr12:127348285	NA	-0.58	-6.46	-0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.85	10.66	0.65	3.62e-20	Mean corpuscular volume;
PAAD	cis	rs1692580	0.807	rs4648627	chr1:2200404	C/T	cg21194808	chr1:2205498	SKI	0.44	4.34	0.33	2.54e-5	Coronary artery disease;
PAAD	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.93	-9.92	-0.63	3.32e-18	Blood metabolite levels;
PAAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs3784262	0.527	rs4646557	chr15:58354697	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.61	-0.41	9.21e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.61	5.59	0.41	1.04e-7	Obesity-related traits;
PAAD	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-1.31	-10.53	-0.65	8.42e-20	Schizophrenia;
PAAD	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.55	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	cis	rs761746	0.614	rs5994427	chr22:32132576	C/T	cg01338084	chr22:32026380	PISD	0.61	5.39	0.4	2.62e-7	Intelligence;
PAAD	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.52	-4.57	-0.35	1.02e-5	Lymphocyte counts;
PAAD	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg00864171	chr11:67383662	NA	-0.5	-5.33	-0.4	3.54e-7	Mean corpuscular volume;
PAAD	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg06287003	chr12:125626642	AACS	-0.46	-4.48	-0.34	1.44e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.7	-6.86	-0.49	1.66e-10	Uric acid levels;
PAAD	cis	rs56046484	0.956	rs17540501	chr15:85638101	C/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	cis	rs1468734	0.929	rs759197	chr16:5006076	C/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.52	-4.33	-0.33	2.74e-5	Cancer;
PAAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.1	-8.78	-0.58	3.25e-15	Gout;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg16031515	chr1:205743344	RAB7L1	-0.39	-4.53	-0.34	1.19e-5	Menarche (age at onset);
PAAD	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.6	7.08	0.5	5e-11	Monocyte count;
PAAD	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.48	4.62	0.35	7.99e-6	Acylcarnitine levels;
PAAD	cis	rs3736485	0.873	rs12442725	chr15:51874412	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.61	-7.14	-0.5	3.66e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg03060546	chr3:49711283	APEH	-0.51	-4.41	-0.34	1.92e-5	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.51	5.02	0.38	1.43e-6	Malaria;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12112073	chr3:16926338	PLCL2	-0.68	-6.76	-0.48	2.76e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.59	4.48	0.34	1.47e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs716804	0.740	rs56063978	chr11:10256941	A/G	cg06875754	chr11:10328428	ADM	-0.33	-4.25	-0.33	3.75e-5	Neuroticism;
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.68	0.58	5.62e-15	Menopause (age at onset);
PAAD	cis	rs1529711	0.636	rs56753835	chr19:10929150	G/C	cg18582342	chr19:11591989	ELAVL3	-0.66	-5.35	-0.4	3.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.22	-0.45	4.61e-9	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.61	0.57	8.85e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg18898632	chr2:242989856	NA	-0.63	-4.62	-0.35	8.26e-6	Obesity-related traits;
PAAD	cis	rs1046491	0.522	rs4130177	chr18:9174711	G/T	cg14213543	chr18:9102531	NDUFV2	1.04	5.01	0.38	1.52e-6	Scarlet fever;
PAAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.77	4.6	0.35	8.84e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4448343	0.963	rs28457763	chr9:98260514	G/A	cg13428213	chr9:98267529	PTCH1	0.45	4.25	0.33	3.78e-5	Height;
PAAD	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.81	0.36	3.61e-6	Schizophrenia;
PAAD	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg27478167	chr7:817139	HEATR2	-0.72	-5.65	-0.42	7.77e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg25886479	chr11:50257625	LOC441601	0.45	4.56	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.74	-5.12	-0.38	9.2e-7	Lung cancer;
PAAD	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg15123519	chr2:136567270	LCT	0.37	4.5	0.34	1.37e-5	Mosquito bite size;
PAAD	cis	rs6834538	0.965	rs4834294	chr4:113529020	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.49	4.4	0.34	2.03e-5	Free thyroxine concentration;
PAAD	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.57	-5.77	-0.42	4.41e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs9422653	chr10:46048918	A/G	cg23720331	chr10:123873670	TACC2	0.83	6.45	0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19090549	chr1:85355904	LPAR3	0.59	6.5	0.47	1.11e-9	Smoking initiation;
PAAD	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	9.44	0.61	6.28e-17	Ulcerative colitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24643801	chr12:120315015	CIT	-0.73	-6.38	-0.46	2.01e-9	Neuroticism;
PAAD	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg20283391	chr11:68216788	NA	-0.54	-5.18	-0.39	6.98e-7	Total body bone mineral density;
PAAD	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg22517653	chr1:2918612	NA	-0.61	-5.07	-0.38	1.14e-6	Plateletcrit;
PAAD	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.46	-5.17	-0.39	7.16e-7	Testicular germ cell tumor;
PAAD	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg09491104	chr22:46646882	C22orf40	-1.01	-6.08	-0.44	9.17e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6908034	0.505	rs77880623	chr6:19819454	T/C	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg25364880	chr3:44379878	C3orf23	0.67	5.29	0.39	4.11e-7	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.6	6.7	0.48	3.77e-10	Carotid intima media thickness;
PAAD	cis	rs367943	0.666	rs10064031	chr5:112970924	C/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.88	-0.49	1.46e-10	Neuroticism;
PAAD	trans	rs901683	1.000	rs34163035	chr10:46080719	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-5.15	-0.39	7.82e-7	Bladder cancer;
PAAD	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs10949834	0.824	rs13236108	chr7:73521113	A/G	cg07137043	chr7:73588983	EIF4H	-0.59	-4.44	-0.34	1.75e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg00290607	chr11:67383545	NA	0.45	4.38	0.33	2.21e-5	Mean corpuscular volume;
PAAD	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.89	0.66	8.74e-21	Bladder cancer;
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.98	0.37	1.72e-6	Body mass index;
PAAD	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs8044995	0.563	rs79543001	chr16:68387341	C/T	cg05110241	chr16:68378359	PRMT7	-1.34	-8.86	-0.58	2.03e-15	Schizophrenia;
PAAD	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg02795151	chr17:7402630	POLR2A	0.59	5.39	0.4	2.61e-7	Androgen levels;
PAAD	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.77	6.11	0.44	7.97e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg14393609	chr7:65229607	NA	-0.65	-6.97	-0.49	9.2e-11	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16773799	chr2:10092403	GRHL1	0.62	7.56	0.52	3.45e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.7	-0.36	5.7e-6	Diastolic blood pressure;
PAAD	cis	rs11590090	1.000	rs12733192	chr1:113310418	C/T	cg25707805	chr1:113285387	NA	0.33	4.5	0.34	1.36e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.18	-0.39	7.08e-7	Dental caries;
PAAD	cis	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg21546286	chr11:48923668	NA	-0.56	-5.89	-0.43	2.44e-8	HDL cholesterol;
PAAD	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.48	6.88	0.49	1.47e-10	Schizophrenia;
PAAD	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.74	7.97	0.54	3.54e-13	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08402873	chr20:10653164	JAG1	0.6	6.97	0.49	8.97e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23025395	chr11:18127696	SAAL1	0.56	6.37	0.46	2.13e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2133450	0.712	rs1546237	chr3:7366674	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2279817	0.863	rs34820073	chr1:18010535	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.54	5.18	0.39	7.08e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26433838	chr3:160167749	TRIM59	0.55	6.36	0.46	2.22e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7792596	0.565	rs10487252	chr7:93981089	C/T	cg20814616	chr7:94014465	NA	0.62	5.96	0.44	1.71e-8	Intelligence;
PAAD	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg13160058	chr8:26243215	BNIP3L	-0.35	-4.36	-0.33	2.42e-5	Height;
PAAD	cis	rs75920871	1.000	rs61905680	chr11:116836031	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.82	9.95	0.63	2.86e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	1.11	16.56	0.8	7.51e-36	Breast cancer;
PAAD	cis	rs7172677	0.960	rs11072526	chr15:75432517	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.85	-0.37	2.99e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.64	0.42	8.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg06917634	chr15:78832804	PSMA4	-0.85	-9.64	-0.62	1.86e-17	Sudden cardiac arrest;
PAAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg25276700	chr6:44698697	NA	0.45	4.36	0.33	2.42e-5	Total body bone mineral density;
PAAD	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.53	0.61	3.53e-17	Post bronchodilator FEV1;
PAAD	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.69	7.7	0.53	1.66e-12	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg23920097	chr1:209922102	NA	-0.5	-4.64	-0.35	7.46e-6	Red blood cell count;
PAAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.85	-9.64	-0.62	1.8e-17	Cancer (pleiotropy);
PAAD	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.72	7.84	0.54	7.21e-13	Colorectal cancer;
PAAD	cis	rs11718455	1.000	rs1012410	chr3:44053516	G/C	cg21419209	chr3:44054225	NA	-0.74	-7.7	-0.53	1.63e-12	Coronary artery disease;
PAAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	5.21	0.39	6.19e-7	Mood instability;
PAAD	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.51	5.53	0.41	1.35e-7	Testicular germ cell tumor;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21862992	chr11:68658383	NA	0.42	4.56	0.35	1.06e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4906332	0.966	rs4906331	chr14:103971374	C/T	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.42	-0.4	2.3e-7	Coronary artery disease;
PAAD	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.51	0.41	1.53e-7	Coronary heart disease;
PAAD	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00029397	chr12:57940957	DCTN2	0.64	7.24	0.51	2.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9857275	0.788	rs35225290	chr3:141130835	C/T	cg00789793	chr3:141329863	RASA2	0.49	4.29	0.33	3.16e-5	Prion diseases;
PAAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18989661	chr2:231585649	CAB39	-0.61	-6.41	-0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg04844267	chr4:1394941	NA	0.43	4.79	0.36	3.93e-6	Obesity-related traits;
PAAD	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.87	8.0	0.54	2.95e-13	Response to diuretic therapy;
PAAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs727479	0.502	rs7167936	chr15:51499545	A/G	cg21478137	chr15:51532386	CYP19A1	0.47	4.67	0.35	6.53e-6	Estradiol levels;
PAAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg05896902	chr15:45671018	LOC145663;GATM	0.53	4.58	0.35	9.46e-6	Homoarginine levels;
PAAD	cis	rs4455778	0.538	rs6965822	chr7:49123931	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs17095355	0.901	rs28365866	chr10:111767214	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.31	-0.33	2.97e-5	Biliary atresia;
PAAD	cis	rs375066	0.762	rs17656688	chr19:44425077	T/C	cg11993925	chr19:44307056	LYPD5	-0.48	-5.71	-0.42	5.84e-8	Breast cancer;
PAAD	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24209723	chr18:12913133	NA	0.55	6.39	0.46	1.96e-9	Pancreatic cancer;
PAAD	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.33	4.7	0.36	5.83e-6	Migraine;
PAAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09653758	chr16:19883256	GPRC5B	0.6	6.98	0.49	8.39e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9652601	0.719	rs2867880	chr16:11231857	C/T	cg04616529	chr16:11181986	CLEC16A	0.42	4.49	0.34	1.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12165864	chr7:66369176	NA	0.79	5.2	0.39	6.28e-7	Diabetic kidney disease;
PAAD	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg15047889	chr8:124780837	FAM91A1	-0.69	-5.39	-0.4	2.63e-7	Pancreatic cancer;
PAAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.69	-0.42	6.31e-8	Ulcerative colitis;
PAAD	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.86	-9.2	-0.6	2.68e-16	Morning vs. evening chronotype;
PAAD	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.01	-0.54	2.76e-13	Brugada syndrome;
PAAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18867708	chr6:26865862	GUSBL1	0.44	4.35	0.33	2.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.44	5.37	0.4	2.93e-7	Height;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.5	-4.83	-0.36	3.26e-6	Obesity-related traits;
PAAD	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.42	4.43	0.34	1.79e-5	Coronary artery disease;
PAAD	cis	rs4478858	0.611	rs1007012	chr1:31710068	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.85	-0.43	2.87e-8	Alcohol dependence;
PAAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-5.59	-0.41	1.02e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-1.07	-14.87	-0.77	1.97e-31	Breast cancer;
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.67	7.29	0.51	1.59e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg10856724	chr12:34555212	NA	-0.42	-4.44	-0.34	1.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.58	0.61	2.63e-17	Menarche (age at onset);
PAAD	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.72	0.66	2.57e-20	Prudent dietary pattern;
PAAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg12623918	chr2:306882	NA	0.48	5.03	0.38	1.35e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg10556349	chr10:835070	NA	0.55	4.96	0.37	1.86e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.64	-5.6	-0.41	9.91e-8	Coronary artery disease;
PAAD	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg06386533	chr2:46925753	SOCS5	0.55	4.62	0.35	8.18e-6	Height;
PAAD	cis	rs282587	0.569	rs419334	chr13:113415346	G/A	cg19217778	chr13:113420270	ATP11A	-0.56	-4.49	-0.34	1.42e-5	Glycated hemoglobin levels;
PAAD	cis	rs787274	1.000	rs4304397	chr9:115598154	C/T	cg13803584	chr9:115635662	SNX30	0.79	4.67	0.35	6.47e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2019216	0.605	rs2341280	chr17:21981326	T/C	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.23	0.56	7.98e-14	Prudent dietary pattern;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs4739066	0.579	rs4739028	chr8:63862646	C/A	cg25248160	chr8:63776642	NKAIN3	0.74	4.77	0.36	4.27e-6	Myocardial infarction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15429179	chr11:130013355	APLP2	-0.67	-6.65	-0.47	4.96e-10	Obesity-related traits;
PAAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.9	9.41	0.61	7.31e-17	Blood metabolite levels;
PAAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.45	-0.34	1.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg02876276	chr17:77834299	NA	0.63	4.33	0.33	2.71e-5	Electroencephalogram traits;
PAAD	cis	rs4455778	0.580	rs4551289	chr7:49112437	G/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.48e-5	Lung cancer in never smokers;
PAAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg06569542	chr10:98946673	SLIT1	-0.51	-5.7	-0.42	6.05e-8	Monocyte count;
PAAD	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.29	11.24	0.67	1.02e-21	Uric acid levels;
PAAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs9472414	0.510	rs609643	chr6:44705303	A/G	cg20913747	chr6:44695427	NA	-0.55	-5.79	-0.42	3.95e-8	Height;
PAAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.97	-13.92	-0.75	6.51e-29	Post bronchodilator FEV1;
PAAD	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs8105895	0.935	rs62111039	chr19:22287336	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07234876	chr8:600039	NA	1.08	7.14	0.5	3.69e-11	IgG glycosylation;
PAAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.51	4.35	0.33	2.51e-5	Depression;
PAAD	cis	rs7487075	0.619	rs67249026	chr12:46835768	T/C	cg09447675	chr12:46877466	NA	-0.47	-4.3	-0.33	3.09e-5	Itch intensity from mosquito bite;
PAAD	cis	rs4073221	0.654	rs13071665	chr3:18308095	T/C	cg07694806	chr3:18168406	NA	-0.62	-4.59	-0.35	9.18e-6	Parkinson's disease;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.56	-6.54	-0.47	8.87e-10	Lung cancer;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07677032	chr17:61819896	STRADA	0.55	5.45	0.4	1.96e-7	Prudent dietary pattern;
PAAD	cis	rs7627468	0.955	rs11717321	chr3:121936278	T/C	cg17240004	chr3:121949083	CASR	0.51	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.63	-5.33	-0.4	3.47e-7	Neuroticism;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.7	0.48	3.83e-10	Lung cancer;
PAAD	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.58	6.1	0.44	8.59e-9	Hepatitis;
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.92	0.7	1.5e-23	Platelet count;
PAAD	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg18551225	chr6:44695536	NA	-0.75	-7.53	-0.52	4.28e-12	Total body bone mineral density;
PAAD	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.48	-0.34	1.46e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.3	0.6	1.47e-16	Lymphocyte counts;
PAAD	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.7	8.9	0.59	1.59e-15	Asthma;
PAAD	cis	rs2414856	0.510	rs77109323	chr15:64704941	G/A	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.61e-6	Pulse pressure;Systolic blood pressure;
PAAD	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.8	9.33	0.6	1.23e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.62	-6.7	-0.48	3.74e-10	Colorectal cancer;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	1.07	15.42	0.78	6.67e-33	Menarche (age at onset);
PAAD	cis	rs10916814	0.588	rs10799640	chr1:20896411	T/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	4.87	0.37	2.83e-6	Lung function (FEV1/FVC);
PAAD	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg24241305	chr13:114826075	RASA3	-0.56	-4.47	-0.34	1.55e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.8e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22151608	chr7:128175779	NA	0.6	6.5	0.47	1.11e-9	Smoking initiation;
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.62	6.64	0.47	5.11e-10	Testicular germ cell tumor;
PAAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.34	-0.33	2.59e-5	Cystic fibrosis severity;
PAAD	cis	rs1035491	0.753	rs9291816	chr5:63932508	C/T	cg01791865	chr5:63954708	NA	0.46	4.68	0.36	6.21e-6	Body mass index;
PAAD	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.57	5.13	0.38	8.73e-7	Common traits (Other);
PAAD	cis	rs7715811	0.956	rs5023693	chr5:13767129	T/C	cg07548982	chr5:13769939	DNAH5	-0.65	-6.26	-0.45	3.7e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.87	7.62	0.53	2.6e-12	Alzheimer's disease;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg26554054	chr8:600488	NA	-0.95	-6.7	-0.48	3.74e-10	IgG glycosylation;
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.59	-5.5	-0.41	1.54e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01620082	chr3:125678407	NA	-0.99	-6.63	-0.47	5.38e-10	Depression;
PAAD	cis	rs6496932	0.755	rs4842875	chr15:85889244	C/A	cg19183879	chr15:85880815	NA	-0.54	-4.82	-0.36	3.42e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs8112211	0.689	rs8106900	chr19:38821041	G/T	cg14299480	chr19:38876666	GGN	-0.62	-6.01	-0.44	1.3e-8	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg00922110	chr4:57842668	C4orf14	0.42	4.81	0.36	3.65e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs722208	0.565	rs2982705	chr6:152347858	C/G	cg24322333	chr6:151646584	AKAP12	0.44	4.4	0.34	1.99e-5	Developmental language disorder;
PAAD	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.62	5.83	0.43	3.27e-8	Refractive astigmatism;
PAAD	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.39	-0.51	9.18e-12	Body mass index;
PAAD	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg02683114	chr2:24398427	C2orf84	-0.51	-4.88	-0.37	2.61e-6	Asthma;
PAAD	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	0.54	6.09	0.44	8.87e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.07	8.64	0.57	7.05e-15	Corneal structure;
PAAD	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	7.13	0.5	3.75e-11	Hip circumference;
PAAD	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.56e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg17771515	chr6:154831774	CNKSR3	0.63	4.52	0.34	1.22e-5	Lipoprotein (a) levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19846447	chr2:48814721	STON1;STON1-GTF2A1L	-0.62	-6.74	-0.48	3.07e-10	Obesity-related traits;
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.7e-6	Cognitive function;
PAAD	cis	rs16975963	0.639	rs112997435	chr19:38204631	C/T	cg14218481	chr19:38281219	NA	0.41	4.4	0.34	2.03e-5	Longevity;
PAAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg12215294	chr3:40350768	EIF1B	-0.44	-4.54	-0.35	1.12e-5	Renal cell carcinoma;
PAAD	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.63	-6.18	-0.45	5.55e-9	Obesity-related traits;
PAAD	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1997066	0.831	rs78534344	chr10:106825600	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.45	0.34	1.68e-5	Diabetic kidney disease;
PAAD	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	7.06	0.5	5.51e-11	Schizophrenia;
PAAD	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	6.97	0.49	8.83e-11	Eosinophil percentage of white cells;
PAAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.85	10.76	0.66	1.98e-20	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03004497	chr11:58874207	FAM111B	0.57	6.29	0.45	3.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg18357526	chr6:26021779	HIST1H4A	0.5	4.31	0.33	2.88e-5	Height;
PAAD	cis	rs2221894	0.960	rs1487970	chr8:28889166	A/G	cg20212339	chr8:28908912	HMBOX1	-0.52	-5.5	-0.41	1.55e-7	Obesity-related traits;
PAAD	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.65	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.49	-4.8	-0.36	3.84e-6	Inflammatory bowel disease;
PAAD	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.45	4.28	0.33	3.31e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.64	-6.18	-0.45	5.7e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.85	-7.76	-0.53	1.18e-12	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.48	-6.03	-0.44	1.17e-8	Schizophrenia;
PAAD	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.95	-8.65	-0.57	6.86e-15	IgG glycosylation;
PAAD	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg20406979	chr6:167373233	NA	0.32	4.38	0.33	2.21e-5	Crohn's disease;
PAAD	cis	rs11264799	0.731	rs2873404	chr1:157687237	A/G	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg00334542	chr7:100209784	MOSPD3	-0.68	-5.15	-0.39	7.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs863345	0.584	rs11265018	chr1:158506409	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg26695010	chr11:65641043	EFEMP2	-0.48	-4.65	-0.35	7.16e-6	Eosinophil percentage of white cells;
PAAD	cis	rs9650657	0.738	rs11250078	chr8:10666581	G/A	cg00262122	chr8:11665843	FDFT1	-0.51	-4.76	-0.36	4.5e-6	Neuroticism;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	6.0	0.44	1.4e-8	Prudent dietary pattern;
PAAD	cis	rs6681460	1.000	rs6670378	chr1:67126585	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.95e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg06138931	chr13:21896616	NA	0.75	5.58	0.41	1.05e-7	White matter hyperintensity burden;
PAAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.52	-0.34	1.22e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3206736	0.548	rs73110562	chr7:35069923	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.49	-4.63	-0.35	7.71e-6	Diastolic blood pressure;
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16262614	chr3:133464971	TF	0.48	5.24	0.39	5.34e-7	Iron status biomarkers;
PAAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg00576331	chr11:65640516	EFEMP2	-0.5	-5.02	-0.38	1.43e-6	Eosinophil percentage of white cells;
PAAD	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.78	7.12	0.5	4.06e-11	Obesity-related traits;
PAAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg07703079	chr11:430292	ANO9	0.92	5.0	0.38	1.6e-6	Body mass index;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2017305	0.915	rs117811919	chr10:70737716	A/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.63	0.35	7.77e-6	Personality dimensions;
PAAD	cis	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg15465823	chr12:48382534	COL2A1	-0.45	-4.49	-0.34	1.4e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6987853	0.661	rs4641053	chr8:42352161	G/A	cg09913449	chr8:42400586	C8orf40	-0.47	-5.03	-0.38	1.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.77	-8.41	-0.56	2.82e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs417013	0.668	rs201519	chr7:101770505	G/A	cg06246474	chr7:101738831	CUX1	0.44	4.3	0.33	3.04e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg14345882	chr6:26364793	BTN3A2	-0.67	-4.55	-0.35	1.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs332507	0.789	rs13064861	chr3:124352236	A/G	cg05980111	chr3:124395277	KALRN	0.44	4.4	0.34	2.06e-5	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11588637	chr6:164393860	NA	-0.58	-6.62	-0.47	5.94e-10	Obesity-related traits;
PAAD	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.49	4.76	0.36	4.55e-6	Morning vs. evening chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25087352	chr3:24213704	THRB	0.64	6.94	0.49	1.07e-10	Smoking initiation;
PAAD	cis	rs151997	0.671	rs27907	chr5:50193797	C/G	cg06027927	chr5:50259733	NA	0.66	6.62	0.47	5.8e-10	Callous-unemotional behaviour;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.52	5.07	0.38	1.14e-6	Lung cancer;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	6.51	0.47	1.03e-9	Lymphocyte counts;
PAAD	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg14440974	chr22:39074834	NA	-0.55	-6.78	-0.48	2.5e-10	Menopause (age at onset);
PAAD	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.61	7.09	0.5	4.78e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6908034	0.660	rs111509549	chr6:19798370	A/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.86	7.33	0.51	1.25e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.44	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.96	-0.37	1.88e-6	Mean corpuscular volume;
PAAD	cis	rs3106136	0.678	rs7691132	chr4:95285372	T/G	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.82	-0.43	3.37e-8	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	4.69	0.36	6.08e-6	Cognitive ability;
PAAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-8.15	-0.55	1.27e-13	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17106462	chr19:48956129	GRWD1	0.67	6.76	0.48	2.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.13	0.45	7.25e-9	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06851336	chr10:104678166	CNNM2	0.61	7.11	0.5	4.14e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs6028335	0.877	rs16987800	chr20:37748570	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	0.52	4.28	0.33	3.28e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs4417704	0.501	rs13015336	chr2:241900706	T/C	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.69e-7	Joint mobility (Beighton score);
PAAD	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg25809561	chr17:30822961	MYO1D	0.69	7.57	0.52	3.39e-12	Schizophrenia;
PAAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.79	-8.76	-0.58	3.52e-15	Aortic root size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13620921	chr11:3400587	ZNF195	-0.53	-6.33	-0.46	2.67e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.66	-6.49	-0.47	1.12e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7646881	0.812	rs9864589	chr3:158430706	A/G	cg19483011	chr3:158453295	NA	-0.68	-5.77	-0.42	4.23e-8	Tetralogy of Fallot;
PAAD	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg11266682	chr4:10021025	SLC2A9	-0.64	-5.74	-0.42	5.09e-8	Schizophrenia (age at onset);
PAAD	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg11995313	chr8:8860691	ERI1	0.51	5.3	0.39	4.02e-7	Joint mobility (Beighton score);
PAAD	cis	rs12148477	1.000	rs12148477	chr15:51653119	A/G	cg25905881	chr15:51634250	GLDN	0.42	4.47	0.34	1.52e-5	Follicule stimulating hormone;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08572315	chr2:85133831	NA	0.61	6.59	0.47	6.85e-10	Pancreatic cancer;
PAAD	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.53	5.48	0.41	1.74e-7	Male-pattern baldness;
PAAD	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.84e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg23417306	chr2:180868811	CWC22	-0.5	-4.6	-0.35	8.87e-6	Schizophrenia;
PAAD	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.6	-6.19	-0.45	5.35e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.55	-4.94	-0.37	2e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs4547160	0.962	rs12229749	chr12:63503447	C/T	cg26727693	chr12:63544175	AVPR1A	-0.37	-4.53	-0.34	1.21e-5	Morning vs. evening chronotype;
PAAD	cis	rs5417	0.775	rs367181	chr17:7160524	A/C	cg13768953	chr17:7114967	DLG4	0.43	5.38	0.4	2.79e-7	Diastolic blood pressure;
PAAD	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.11	0.55	1.61e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg01244601	chr4:120671846	NA	-0.5	-4.28	-0.33	3.23e-5	Corneal astigmatism;
PAAD	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.29e-8	Alcohol dependence;
PAAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg03303774	chr4:1407052	NA	0.48	6.09	0.44	8.79e-9	Obesity-related traits;
PAAD	cis	rs59888335	0.895	rs13086426	chr3:80839513	C/A	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs12304921	1.000	rs73090629	chr12:51335777	T/G	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.42	-0.34	1.85e-5	Type 2 diabetes;
PAAD	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.34	-4.33	-0.33	2.72e-5	Colorectal cancer;
PAAD	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg15192750	chr16:69999425	NA	0.81	6.34	0.46	2.5e-9	IgE levels;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg00334542	chr7:100209784	MOSPD3	-0.75	-5.59	-0.41	1.04e-7	Other erythrocyte phenotypes;
PAAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.7	-7.34	-0.51	1.2e-11	Colorectal cancer;
PAAD	cis	rs34043524	1.000	rs55890464	chr4:117999735	T/G	cg14562394	chr4:117851367	NA	0.82	4.35	0.33	2.48e-5	Lateral ventricle volume in trauma-exposed individuals;
PAAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.54	-5.85	-0.43	2.95e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.16	0.5	3.18e-11	Lymphocyte counts;
PAAD	cis	rs11825064	0.673	rs11602494	chr11:134463311	C/T	cg02089395	chr11:134479357	NA	-0.73	-4.51	-0.34	1.28e-5	Seasonality;
PAAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24729792	chr2:113192114	RGPD8;RGPD5	0.57	4.53	0.34	1.18e-5	Yeast infection;
PAAD	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.91e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.79	-9.51	-0.61	4.19e-17	White blood cell count (basophil);
PAAD	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	4.49	0.34	1.38e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.64	5.24	0.39	5.33e-7	Schizophrenia;
PAAD	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg19784903	chr17:45786737	TBKBP1	-0.44	-4.35	-0.33	2.5e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.08	-11.6	-0.69	1.09e-22	Blood pressure (smoking interaction);
PAAD	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg22903471	chr2:27725779	GCKR	0.39	4.29	0.33	3.2e-5	Total body bone mineral density;
PAAD	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.62	6.87	0.49	1.53e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.73	0.36	5.09e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs1620921	0.505	rs2115869	chr6:161207892	C/T	cg01280913	chr6:161186852	NA	-0.46	-5.12	-0.38	9.17e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg14393609	chr7:65229607	NA	-0.47	-4.78	-0.36	4.05e-6	Aortic root size;
PAAD	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19671926	chr4:122722719	EXOSC9	-0.54	-4.95	-0.37	1.93e-6	Type 2 diabetes;
PAAD	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg22705602	chr4:152727874	NA	-0.47	-4.75	-0.36	4.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7631605	0.623	rs4535177	chr3:36977460	A/G	cg10333520	chr3:36987040	TRANK1	0.35	4.64	0.35	7.52e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.89	-13.56	-0.74	5.86e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10547527	chr2:198650123	BOLL	0.49	4.37	0.33	2.25e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg07841815	chr7:100318223	EPO	-0.5	-4.82	-0.36	3.44e-6	Other erythrocyte phenotypes;
PAAD	trans	rs9372498	1.000	rs1690664	chr6:118611428	A/G	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.1	-0.44	8.33e-9	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.51	6.34	0.46	2.49e-9	Vitiligo;
PAAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.96	6.9	0.49	1.32e-10	Gut microbiome composition (summer);
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	1.2	9.04	0.59	6.66e-16	IgG glycosylation;
PAAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18319916	chr18:54305957	TXNL1	0.66	7.42	0.52	7.56e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9361491	0.578	rs2145688	chr6:79460217	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6129846	1.000	rs1010304	chr20:40101647	A/G	cg23060191	chr20:39666765	PRO0628;TOP1	-0.75	-4.43	-0.34	1.78e-5	Verbal declarative memory;
PAAD	cis	rs9715521	0.718	rs62301190	chr4:59842351	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.5	4.87	0.37	2.78e-6	Cancer;
PAAD	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.82	-6.68	-0.48	4.26e-10	Putamen volume;
PAAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg16205897	chr5:131564050	P4HA2	-0.43	-4.49	-0.34	1.38e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs2274459	1.000	rs12211490	chr6:33725528	G/T	cg06253072	chr6:33679850	C6orf125	0.67	4.78	0.36	4.17e-6	Obesity (extreme);
PAAD	cis	rs2415984	0.579	rs2642103	chr14:46963280	C/T	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.43	-4.97	-0.37	1.76e-6	Testicular germ cell tumor;
PAAD	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-8.1	-0.55	1.65e-13	Prudent dietary pattern;
PAAD	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs72960926	0.590	rs117275111	chr6:74750921	G/A	cg03266952	chr6:74778945	NA	-1.13	-7.22	-0.51	2.28e-11	Metabolite levels (MHPG);
PAAD	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.18e-17	Resting heart rate;
PAAD	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg12011299	chr4:100065546	ADH4	0.99	15.81	0.79	6.63e-34	Alcohol dependence;
PAAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.62	6.55	0.47	8.24e-10	Longevity;
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg09873201	chr16:3507582	NAT15	-0.53	-5.03	-0.38	1.38e-6	Tuberculosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03066081	chr17:77784036	NA	0.56	6.29	0.45	3.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.74	7.58	0.52	3.21e-12	Prostate cancer;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg24879335	chr3:133465180	TF	0.55	5.92	0.43	2.08e-8	Iron status biomarkers;
PAAD	cis	rs78761021	0.829	rs62066057	chr17:9784047	A/G	cg26853458	chr17:9805074	RCVRN	0.71	8.04	0.55	2.28e-13	Type 2 diabetes;
PAAD	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	8.72	0.58	4.44e-15	Exhaled nitric oxide output;
PAAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs6694672	0.850	rs1576880	chr1:196992511	C/T	cg26994526	chr18:47719735	MYO5B	-0.81	-6.38	-0.46	2.04e-9	Asthma;
PAAD	cis	rs9913156	0.748	rs72835626	chr17:4560326	C/A	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-5.07	-0.38	1.16e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg03676636	chr4:99064102	C4orf37	-0.25	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs59888335	0.862	rs13073306	chr3:80614158	G/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg11410649	chr1:24122853	GALE	0.63	4.28	0.33	3.26e-5	Psoriasis vulgaris;
PAAD	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg03115019	chr17:80708279	FN3K	0.53	4.85	0.37	3.05e-6	Glycated hemoglobin levels;
PAAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.91	12.29	0.71	1.55e-24	Menopause (age at onset);
PAAD	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.28	-0.39	4.49e-7	Neuroticism;
PAAD	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.52	4.41	0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.39	-4.36	-0.33	2.37e-5	Prostate cancer;
PAAD	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg24296786	chr1:45957014	TESK2	0.66	7.35	0.51	1.16e-11	High light scatter reticulocyte count;
PAAD	cis	rs939584	0.935	rs6731872	chr2:624205	T/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.5	4.9	0.37	2.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03576123	chr11:487126	PTDSS2	-1.19	-5.36	-0.4	3.05e-7	Body mass index;
PAAD	cis	rs375066	0.935	rs403137	chr19:44427626	A/G	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.87	-0.37	2.77e-6	Migraine;
PAAD	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.19	0.64	6.71e-19	Bladder cancer;
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.49	5.12	0.38	9.19e-7	Obesity-related traits;
PAAD	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.25	-0.33	3.7e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg03233332	chr7:66118400	NA	-0.42	-4.66	-0.35	6.88e-6	Aortic root size;
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.82	9.64	0.62	1.91e-17	Bladder cancer;
PAAD	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.61e-8	Height;
PAAD	cis	rs1372356	0.725	rs2896074	chr14:88555444	G/C	cg18078958	chr14:88630771	NA	0.49	6.24	0.45	4.1e-9	Food antigen IgG levels;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg16606324	chr3:10149918	C3orf24	0.81	6.31	0.46	2.95e-9	Alzheimer's disease;
PAAD	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg06492744	chr11:65406254	SIPA1	0.52	4.77	0.36	4.2e-6	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.46	-4.8	-0.36	3.84e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7251275	0.625	rs304720	chr19:44109856	C/G	cg17121205	chr19:44009353	PHLDB3	0.35	4.48	0.34	1.45e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs758324	0.648	rs152126	chr5:131383667	A/C	cg06307176	chr5:131281290	NA	-0.57	-4.68	-0.35	6.39e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg05925327	chr15:68127851	NA	-0.57	-5.11	-0.38	9.59e-7	Restless legs syndrome;
PAAD	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg00543991	chr22:32367038	NA	1.06	6.96	0.49	9.36e-11	Childhood ear infection;
PAAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.93	10.57	0.65	6.51e-20	Parkinson's disease;
PAAD	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-9.52	-0.61	3.95e-17	Selective IgA deficiency;
PAAD	cis	rs28472312	0.862	rs11150623	chr16:28881001	G/T	cg16576597	chr16:28551801	NUPR1	0.49	5.01	0.38	1.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.36	-0.33	2.35e-5	Renal cell carcinoma;
PAAD	cis	rs1699337	1.000	rs1596667	chr3:12403119	G/T	cg00923996	chr3:13322657	NA	0.42	4.32	0.33	2.76e-5	Cholesterol, total;
PAAD	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.14e-6	Testicular germ cell tumor;
PAAD	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-4.81	-0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg15660573	chr17:549704	VPS53	-0.6	-5.6	-0.41	1e-7	Prostate cancer;
PAAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.84	7.56	0.52	3.58e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.79	-0.36	3.94e-6	Personality dimensions;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.81	5.89	0.43	2.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9907295	0.591	rs2291299	chr17:34191406	T/C	cg19411729	chr17:34207663	CCL5	-0.55	-4.93	-0.37	2.13e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg07636037	chr3:49044803	WDR6	0.6	4.53	0.34	1.2e-5	Menarche (age at onset);
PAAD	cis	rs6981523	0.532	rs1987190	chr8:11053514	T/A	cg21775007	chr8:11205619	TDH	-0.49	-4.26	-0.33	3.56e-5	Neuroticism;
PAAD	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg08824895	chr13:115047677	UPF3A	0.52	4.86	0.37	2.94e-6	Schizophrenia;
PAAD	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.22e-6	Mortality in heart failure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10783584	chr11:3686892	CHRNA10	-0.68	-7.04	-0.5	6.15e-11	Obesity-related traits;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.61	-6.23	-0.45	4.44e-9	Blood metabolite levels;
PAAD	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.64	5.84	0.43	3e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	7.4	0.51	8.5e-12	IgG glycosylation;
PAAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg03983715	chr16:68378420	PRMT7	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg17945004	chr17:58984873	BCAS3	-0.64	-6.6	-0.47	6.37e-10	Alcohol dependence;
PAAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.27	-7.06	-0.5	5.6e-11	Body mass index;
PAAD	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg04370829	chr17:406249	NA	-0.56	-5.46	-0.4	1.9e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.58	5.36	0.4	3.04e-7	Self-reported allergy;
PAAD	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg10705379	chr10:99080932	FRAT1	-0.43	-5.03	-0.38	1.36e-6	Monocyte count;
PAAD	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg12700319	chr1:8272199	NA	0.39	4.25	0.33	3.72e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.67	4.56	0.35	1.06e-5	Lung cancer in ever smokers;
PAAD	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.85	-4.65	-0.35	7.26e-6	Toenail selenium levels;
PAAD	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.49	6.69	0.48	3.96e-10	Life satisfaction;
PAAD	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs9903692	0.505	rs208005	chr17:46239985	A/G	cg24322968	chr17:46507895	SKAP1	-0.87	-5.28	-0.39	4.39e-7	Pulse pressure;
PAAD	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs10924309	0.737	rs1122736	chr1:245852695	A/G	cg00036263	chr1:245852353	KIF26B	-0.63	-5.95	-0.43	1.75e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01422452	chr2:241526768	CAPN10	-0.73	-6.31	-0.46	2.9e-9	Neuroticism;
PAAD	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.03	6.92	0.49	1.21e-10	Body mass index;
PAAD	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.71	-7.53	-0.52	4.17e-12	Cognitive test performance;
PAAD	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.59	6.87	0.49	1.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg13482628	chr17:19912719	NA	-0.53	-4.94	-0.37	2.04e-6	Schizophrenia;
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg14416269	chr4:6271139	WFS1	0.66	8.9	0.59	1.54e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.78	9.58	0.61	2.71e-17	Breast cancer;
PAAD	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	0.92	6.5	0.47	1.08e-9	Pulse pressure;
PAAD	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.54	-5.4	-0.4	2.54e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18652453	chr5:68665041	TAF9;RAD17	0.61	6.83	0.48	1.94e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.52	-5.59	-0.41	1.03e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg23531748	chr20:60969906	CABLES2	0.47	4.56	0.35	1.06e-5	Colorectal cancer;
PAAD	cis	rs11711311	0.712	rs6764048	chr3:113332859	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.51	-5.14	-0.39	8.21e-7	IgG glycosylation;
PAAD	cis	rs761746	0.579	rs131253	chr22:32130682	C/G	cg01338084	chr22:32026380	PISD	0.61	5.44	0.4	2.05e-7	Intelligence;
PAAD	cis	rs6604026	0.656	rs11164836	chr1:93381415	C/T	cg17283838	chr1:93427260	FAM69A	0.63	5.81	0.43	3.59e-8	Multiple sclerosis;
PAAD	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg14906510	chr12:7781169	NA	0.6	4.34	0.33	2.61e-5	HDL cholesterol levels;
PAAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg22258538	chr11:14403163	NA	0.33	4.31	0.33	2.91e-5	Mitochondrial DNA levels;
PAAD	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.09	0.5	4.61e-11	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.1	-8.52	-0.57	1.5e-14	Diabetic kidney disease;
PAAD	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg05791153	chr7:19748676	TWISTNB	-0.59	-5.17	-0.39	7.24e-7	Thyroid stimulating hormone;
PAAD	cis	rs13102973	0.867	rs4543187	chr4:135906850	G/A	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg08436684	chr16:88034427	BANP	-0.49	-4.34	-0.33	2.59e-5	Menopause (age at onset);
PAAD	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.49e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-5.26	-0.39	4.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.582	rs8182201	chr16:68091150	T/G	cg05110241	chr16:68378359	PRMT7	-0.77	-6.2	-0.45	5.06e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.31	-0.6	1.38e-16	Height;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.97	-9.43	-0.61	6.69e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7173419	0.628	rs3884517	chr15:28214759	C/T	cg20906524	chr15:28200668	OCA2	-0.46	-5.28	-0.39	4.34e-7	Eye color;
PAAD	cis	rs16976116	0.901	rs8031949	chr15:55492724	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13560548	chr3:10150139	C3orf24	0.58	5.24	0.39	5.18e-7	Alzheimer's disease;
PAAD	cis	rs16958440	1.000	rs62096474	chr18:44647504	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg00228799	chr9:131580591	ENDOG	0.62	5.92	0.43	2.07e-8	Blood metabolite levels;
PAAD	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.33	6.11	0.44	8.05e-9	Type 2 diabetes;
PAAD	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-6.25	-0.45	3.91e-9	Total cholesterol levels;
PAAD	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs877529	1.000	rs139396	chr22:39538485	G/T	cg18708252	chr22:39545030	CBX7	-0.44	-4.27	-0.33	3.39e-5	Multiple myeloma;
PAAD	cis	rs3126085	0.560	rs3818831	chr1:152331240	G/A	cg26876637	chr1:152193138	HRNR	-0.7	-5.26	-0.39	4.88e-7	Atopic dermatitis;
PAAD	cis	rs12760731	0.565	rs16828608	chr1:178129899	C/T	cg00404053	chr1:178313656	RASAL2	0.65	5.24	0.39	5.29e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.77	9.74	0.62	9.87e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	5.96	0.43	1.73e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11696501	0.947	rs11696176	chr20:44115425	G/C	cg11783356	chr20:44313418	WFDC10B	-0.63	-5.38	-0.4	2.74e-7	Brain structure;
PAAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.75	-6.99	-0.49	8.16e-11	Cognitive ability;
PAAD	cis	rs72960926	1.000	rs72959000	chr6:75134312	A/T	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.72	4.27	0.33	3.44e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs11191193	0.967	rs11191156	chr10:103702763	C/T	cg11685391	chr10:103594334	KCNIP2	0.32	4.33	0.33	2.73e-5	Educational attainment;
PAAD	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.76	0.48	2.75e-10	Eye color traits;
PAAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.81	-8.3	-0.56	5.13e-14	Vitiligo;
PAAD	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg13647721	chr17:30228624	UTP6	0.6	4.44	0.34	1.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg00579200	chr11:133705235	NA	-0.46	-4.98	-0.37	1.7e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.74	-8.61	-0.57	8.54e-15	Lung cancer;
PAAD	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.58	5.38	0.4	2.71e-7	Self-reported allergy;
PAAD	cis	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg11783602	chr8:55087084	NA	-0.64	-7.73	-0.53	1.35e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.55	5.01	0.38	1.52e-6	Multiple sclerosis;
PAAD	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.96	14.21	0.76	1.08e-29	Dental caries;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.89	9.55	0.61	3.26e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs7853377	0.680	rs796004	chr9:86594798	C/T	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15305564	chr11:121322637	SORL1	0.69	7.38	0.51	9.52e-12	Myopia (pathological);
PAAD	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg01305830	chr4:1604576	NA	-0.48	-4.65	-0.35	7.23e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.66	-0.42	7.29e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6442522	0.768	rs3821638	chr3:15511044	A/G	cg16303742	chr3:15540471	COLQ	0.42	4.49	0.34	1.41e-5	Uric acid levels;
PAAD	cis	rs10214930	0.651	rs4722728	chr7:27694288	C/T	cg22168087	chr7:27702803	HIBADH	-0.49	-4.51	-0.34	1.27e-5	Hypospadias;
PAAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.64	-0.42	8.15e-8	Post bronchodilator FEV1;
PAAD	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.89	8.21	0.55	9e-14	Coronary artery disease;
PAAD	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07454192	chr8:74888262	TMEM70	0.62	6.72	0.48	3.51e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.51	5.24	0.39	5.29e-7	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23034014	chr3:115485166	NA	-0.62	-6.34	-0.46	2.48e-9	Obesity-related traits;
PAAD	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg06138931	chr13:21896616	NA	-0.61	-4.28	-0.33	3.3e-5	White matter hyperintensity burden;
PAAD	cis	rs4740619	0.592	rs2017943	chr9:16005919	A/T	cg14451791	chr9:16040625	NA	0.39	4.54	0.35	1.13e-5	Body mass index;
PAAD	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg03700679	chr2:178418002	TTC30B	0.52	4.28	0.33	3.24e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-14.13	-0.75	1.75e-29	Height;
PAAD	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg02743256	chr7:2109353	MAD1L1	-0.65	-4.92	-0.37	2.26e-6	Bipolar disorder;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.01e-5	Systemic lupus erythematosus;
PAAD	cis	rs6679454	1.000	rs6679454	chr1:58367236	A/G	cg17491850	chr1:57888480	DAB1	-0.41	-4.63	-0.35	7.87e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21028142	chr17:79581711	NPLOC4	0.51	5.94	0.43	1.88e-8	Eye color traits;
PAAD	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-5.24	-0.39	5.34e-7	Monocyte percentage of white cells;
PAAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg20582800	chr6:43612764	RSPH9	-0.56	-4.47	-0.34	1.54e-5	Blood protein levels;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.45	-4.93	-0.37	2.09e-6	Testicular germ cell tumor;
PAAD	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.47e-14	Dupuytren's disease;
PAAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02450064	chr17:40260053	DHX58	-0.37	-4.34	-0.33	2.59e-5	Fibrinogen levels;
PAAD	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Diabetic kidney disease;
PAAD	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.21	-0.39	6.03e-7	Pulmonary function;
PAAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg21130718	chr4:1044621	NA	-0.48	-4.64	-0.35	7.42e-6	Recombination rate (males);
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg23298862	chr7:158159286	PTPRN2	0.57	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.1	-6.91	-0.49	1.28e-10	Body mass index;
PAAD	trans	rs901683	1.000	rs71496624	chr10:46085949	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg07148914	chr20:33460835	GGT7	0.49	4.68	0.35	6.38e-6	Coronary artery disease;
PAAD	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.95	-9.17	-0.6	3.07e-16	Monocyte percentage of white cells;
PAAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg20639618	chr4:183729073	NA	0.67	5.33	0.4	3.53e-7	Pediatric autoimmune diseases;
PAAD	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.96	-0.54	3.7e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.85	8.38	0.56	3.35e-14	Vitamin D levels;
PAAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11207081	chr8:145000968	PLEC1	-0.62	-7.2	-0.5	2.66e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg14789911	chr21:47582049	C21orf56	0.51	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs965469	0.779	rs6051710	chr20:3264661	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs13102973	0.899	rs13104662	chr4:135904615	C/T	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs9361491	0.608	rs1180825	chr6:79433850	G/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg17294928	chr15:75287854	SCAMP5	0.44	4.4	0.34	2.06e-5	Caffeine consumption;
PAAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.68	7.17	0.5	3.03e-11	Platelet distribution width;
PAAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.36	0.51	1.07e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg03989125	chr22:38214979	NA	-0.53	-5.49	-0.41	1.63e-7	Glioblastoma;Glioma;
PAAD	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.82	-0.36	3.42e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.29	-0.33	3.21e-5	Total body bone mineral density;
PAAD	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs9815354	0.556	rs116717051	chr3:42027411	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11811982	0.793	rs76897971	chr1:227328388	G/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.87	7.13	0.5	3.82e-11	Alzheimer's disease;
PAAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.73	8.07	0.55	2e-13	Melanoma;
PAAD	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg05392440	chr1:2478653	NA	0.56	6.27	0.45	3.56e-9	Ulcerative colitis;
PAAD	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg09491104	chr22:46646882	C22orf40	-0.81	-4.88	-0.37	2.63e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00671759	chr17:79479205	ACTG1	-0.67	-6.48	-0.47	1.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.62	6.65	0.47	4.99e-10	Glomerular filtration rate;
PAAD	cis	rs12304921	1.000	rs224454	chr12:51393116	C/T	cg18059802	chr12:51347058	HIGD1C	-0.71	-5.58	-0.41	1.08e-7	Type 2 diabetes;
PAAD	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.8	9.08	0.59	5.26e-16	Superior crus of antihelix expression;
PAAD	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.53	-5.02	-0.38	1.43e-6	Schizophrenia;
PAAD	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg08501292	chr6:25962987	TRIM38	0.91	4.94	0.37	2.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7168353	0.519	rs11074140	chr15:93635244	C/G	cg12595281	chr15:93633172	RGMA	-0.4	-5.27	-0.39	4.65e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.24	-0.39	5.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06753367	chr22:24256600	NA	0.42	4.43	0.34	1.82e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg17674042	chr6:34482479	PACSIN1	-1.24	-7.08	-0.5	4.95e-11	Cholesterol, total;Total cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04852413	chr12:2986358	FOXM1;C12orf32	-0.64	-6.51	-0.47	1.03e-9	Smoking initiation;
PAAD	cis	rs73019876	0.803	rs10419899	chr19:22157302	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg00806126	chr19:22604979	ZNF98	-0.39	-4.79	-0.36	3.95e-6	Pain;
PAAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-4.89	-0.37	2.49e-6	Coronary artery disease;
PAAD	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	7.2	0.5	2.6e-11	Lung cancer in ever smokers;
PAAD	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.61	5.35	0.4	3.16e-7	Lymphocyte counts;
PAAD	cis	rs71403859	0.685	rs12927044	chr16:71930105	C/A	cg08717414	chr16:71523259	ZNF19	-1.05	-5.85	-0.43	2.87e-8	Post bronchodilator FEV1;
PAAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg19413350	chr8:57351067	NA	-0.46	-4.58	-0.35	9.8e-6	Obesity-related traits;
PAAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.62	-6.06	-0.44	1.04e-8	Narcolepsy;
PAAD	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.12	0.63	1.03e-18	Chronic sinus infection;
PAAD	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg18538332	chr22:24372958	LOC391322	0.55	4.5	0.34	1.34e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10949319	chr10:105154064	MIR1307;USMG5	0.5	6.44	0.46	1.48e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.51	-0.34	1.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5742933	0.817	rs2033870	chr2:190603830	A/G	cg04003228	chr2:190539410	ANKAR	0.51	4.27	0.33	3.48e-5	Ferritin levels;
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.65	0.47	4.9e-10	Blood metabolite levels;
PAAD	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg15212455	chr7:39170539	POU6F2	-0.45	-6.39	-0.46	1.9e-9	IgG glycosylation;
PAAD	cis	rs28647808	1.000	rs28756699	chr9:136273527	G/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs4740619	0.619	rs12379466	chr9:16028394	A/G	cg14451791	chr9:16040625	NA	-0.45	-5.26	-0.39	4.8e-7	Body mass index;
PAAD	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.935	rs384329	chr19:44423981	A/G	cg21496419	chr19:44306685	LYPD5	0.37	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.49	-4.36	-0.33	2.4e-5	Systemic lupus erythematosus;
PAAD	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-4.25	-0.33	3.73e-5	Type 2 diabetes;
PAAD	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.42	0.46	1.62e-9	Bladder cancer;
PAAD	cis	rs787274	0.681	rs4978506	chr9:115600162	C/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.69	5.23	0.39	5.65e-7	Initial pursuit acceleration;
PAAD	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-7.0	-0.49	7.72e-11	Colorectal cancer;
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg02475695	chr16:616220	NHLRC4	0.48	5.63	0.42	8.39e-8	Height;
PAAD	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.8e-6	Personality dimensions;
PAAD	cis	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.51e-5	Dental caries;
PAAD	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-8.45	-0.57	2.23e-14	Mortality in heart failure;
PAAD	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.62	-5.35	-0.4	3.15e-7	Resistin levels;
PAAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.54	-5.23	-0.39	5.52e-7	Mean platelet volume;
PAAD	cis	rs7542091	0.518	rs6675416	chr1:210061006	A/G	cg23283495	chr1:209979779	IRF6	-0.5	-5.9	-0.43	2.28e-8	Monobrow;
PAAD	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg05156742	chr15:59063176	FAM63B	0.78	8.08	0.55	1.86e-13	Schizophrenia;
PAAD	trans	rs2309322	0.622	rs2309323	chr4:181247941	T/A	cg24124977	chr17:78010277	CCDC40;TBC1D16	0.77	6.3	0.46	3.08e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.47e-6	Cognitive function;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg17971929	chr21:40555470	PSMG1	0.81	7.82	0.54	8.15e-13	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17408923	chr2:109335769	RANBP2	0.55	6.29	0.45	3.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.76	0.66	1.98e-20	Menopause (age at onset);
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg19673125	chr6:150240577	RAET1G	0.45	6.28	0.45	3.31e-9	Testicular germ cell tumor;
PAAD	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.95	9.45	0.61	5.69e-17	Resting heart rate;
PAAD	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.41	-0.4	2.42e-7	Mood instability;
PAAD	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.56	-5.7	-0.42	6.14e-8	Hepatitis;
PAAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg15017067	chr4:17643749	FAM184B	0.39	4.37	0.33	2.3e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg00786201	chr11:61583134	MIR1908;FADS1	0.47	4.45	0.34	1.64e-5	Trans fatty acid levels;
PAAD	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.66	5.88	0.43	2.45e-8	Mean corpuscular volume;
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.55	-5.6	-0.41	9.97e-8	Iron status biomarkers;
PAAD	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.87	11.14	0.67	1.94e-21	Body mass index;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.62	7.1	0.5	4.36e-11	Heart rate;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07648498	chr16:89883185	FANCA	-0.68	-7.28	-0.51	1.67e-11	Vitiligo;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.88	10.64	0.65	4.25e-20	Menarche (age at onset);
PAAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.6	-5.54	-0.41	1.31e-7	Acylcarnitine levels;
PAAD	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.19	0.45	5.28e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg27411982	chr8:10470053	RP1L1	0.49	5.02	0.38	1.46e-6	Retinal vascular caliber;
PAAD	cis	rs7633770	0.643	rs59048074	chr3:46689155	C/T	cg11219411	chr3:46661640	NA	-0.53	-6.01	-0.44	1.32e-8	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05412045	chr2:3337680	TSSC1	0.57	6.7	0.48	3.89e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3826795	0.569	rs7254961	chr19:46795884	C/T	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.73	6.74	0.48	3.14e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg00277334	chr10:82204260	NA	-0.76	-8.9	-0.59	1.55e-15	Post bronchodilator FEV1;
PAAD	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.52	4.85	0.37	3.08e-6	Height;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06799790	chr17:61951754	CSH2	-0.47	-4.81	-0.36	3.62e-6	Height;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg00738919	chr7:1100172	C7orf50	0.6	4.83	0.36	3.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg27394845	chr17:28928406	LRRC37B2	0.67	4.59	0.35	9.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4660214	0.671	rs17491275	chr1:39672545	T/G	cg14018543	chr1:39659967	MACF1	-0.56	-4.47	-0.34	1.53e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4690686	0.731	rs11941845	chr4:177276526	G/A	cg17059388	chr4:177262070	NA	0.55	5.44	0.4	2.05e-7	Essential tremor;
PAAD	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.75	7.5	0.52	4.92e-12	Corneal astigmatism;
PAAD	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.64	6.44	0.46	1.5e-9	Primary sclerosing cholangitis;
PAAD	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-6.48	-0.47	1.22e-9	Exhaled nitric oxide output;
PAAD	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg08355456	chr11:67383691	NA	0.43	4.28	0.33	3.24e-5	Mean corpuscular volume;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07362569	chr17:61921086	SMARCD2	0.6	7.3	0.51	1.51e-11	Prudent dietary pattern;
PAAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg09695851	chr17:3907499	NA	0.8	8.0	0.54	2.93e-13	Type 2 diabetes;
PAAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.63	-5.48	-0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07234876	chr8:600039	NA	-1.07	-6.98	-0.49	8.57e-11	IgG glycosylation;
PAAD	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58521262	0.519	rs10500220	chr19:23008102	C/T	cg07749055	chr19:23076870	NA	0.59	4.58	0.35	9.58e-6	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg27494647	chr7:150038898	RARRES2	0.46	4.8	0.36	3.82e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg05925327	chr15:68127851	NA	-0.56	-5.05	-0.38	1.26e-6	Restless legs syndrome;
PAAD	cis	rs7811528	0.527	rs7787450	chr7:2707709	A/G	cg11411865	chr7:2701802	TTYH3	0.5	4.42	0.34	1.86e-5	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.68	0.65	3.19e-20	Homoarginine levels;
PAAD	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg12633918	chr20:23549525	CST9L	-0.45	-4.98	-0.37	1.74e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.13	0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-11.0	-0.67	4.48e-21	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14470479	chr9:34339403	NUDT2	0.63	6.38	0.46	2.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg07150166	chr2:30669952	LCLAT1	0.69	5.13	0.38	8.53e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.85	-0.43	2.89e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.76	-0.36	4.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.51	-0.47	1.02e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs12304921	0.549	rs11169689	chr12:51443561	C/G	cg18059802	chr12:51347058	HIGD1C	-0.58	-4.66	-0.35	6.86e-6	Type 2 diabetes;
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02102829	chr10:126849762	CTBP2	0.62	7.18	0.5	2.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.6	7.08	0.5	4.93e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.1e-6	Parkinson's disease;
PAAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.53	5.21	0.39	5.94e-7	Sleep duration;
PAAD	trans	rs11794666	0.929	rs75584793	chr9:31730947	C/G	cg05628366	chr6:35744188	C6orf126	1.03	6.5	0.47	1.11e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs728616	0.558	rs55803802	chr10:81752664	A/G	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.78	-0.36	4.14e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.11	0.38	9.72e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6963495	0.510	rs73192157	chr7:105225862	A/T	cg02135003	chr7:105160482	PUS7	-0.59	-4.29	-0.33	3.14e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg05805236	chr11:65401703	PCNXL3	0.41	4.38	0.33	2.21e-5	Acne (severe);
PAAD	cis	rs78761021	0.720	rs874174	chr17:9798619	C/T	cg26853458	chr17:9805074	RCVRN	-0.72	-8.26	-0.56	6.78e-14	Type 2 diabetes;
PAAD	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg12486944	chr17:80159399	CCDC57	0.52	4.62	0.35	8.18e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.69	-6.23	-0.45	4.31e-9	Type 2 diabetes;
PAAD	cis	rs30380	0.632	rs26491	chr5:96134113	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.15	-0.39	8.12e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4713675	0.510	rs943470	chr6:33654591	G/C	cg15676125	chr6:33679581	C6orf125	0.43	4.28	0.33	3.3e-5	Plateletcrit;
PAAD	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg04990556	chr1:26633338	UBXN11	0.7	5.14	0.39	8.16e-7	Obesity-related traits;
PAAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg05110241	chr16:68378359	PRMT7	-1.33	-9.56	-0.61	3.08e-17	Schizophrenia;
PAAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.86	7.65	0.53	2.08e-12	Recombination rate (females);
PAAD	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.69	-7.09	-0.5	4.85e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.68	6.54	0.47	8.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.21	0.55	8.91e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27241907	chr3:23244637	UBE2E2	0.65	6.54	0.47	8.89e-10	Obesity-related traits;
PAAD	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs6137287	0.793	rs3762194	chr20:21126723	A/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.43	0.34	1.76e-5	Height;
PAAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.59	-4.37	-0.33	2.29e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13396519	1.000	rs13396519	chr2:11040146	T/C	cg04169469	chr2:10588434	ODC1;SNORA80B	-0.71	-4.41	-0.34	1.94e-5	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg01448562	chr3:133502909	NA	-0.61	-6.18	-0.45	5.63e-9	Iron status biomarkers;
PAAD	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.47	-7.15	-0.5	3.4e-11	Cutaneous nevi;
PAAD	cis	rs9522267	0.966	rs9515443	chr13:112197387	T/C	cg10483660	chr13:112241077	NA	-0.48	-5.06	-0.38	1.18e-6	Hepatitis;
PAAD	cis	rs7264396	0.887	rs6060442	chr20:34093757	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs17123764	0.710	rs1574326	chr12:50090543	A/G	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.7	5.84	0.43	3.05e-8	Pulmonary function decline;
PAAD	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	8.2	0.55	9.32e-14	Neuroticism;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.23	-0.39	5.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1499972	0.938	rs817509	chr3:117750861	A/G	cg07612923	chr3:117604196	NA	-1.05	-6.88	-0.49	1.43e-10	Schizophrenia;
PAAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg22800045	chr5:56110881	MAP3K1	0.65	5.23	0.39	5.57e-7	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02836830	chr20:3767452	CENPB	0.59	6.89	0.49	1.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.48	4.38	0.33	2.17e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	4.86	0.37	2.85e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.41	0.46	1.71e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.51	4.76	0.36	4.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.58	-5.77	-0.42	4.31e-8	Obesity-related traits;
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Body mass index;
PAAD	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.7	0.36	5.78e-6	Blood metabolite levels;
PAAD	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.4	-4.8	-0.36	3.74e-6	Electrocardiographic conduction measures;
PAAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg04106633	chr4:1044584	NA	0.54	5.04	0.38	1.33e-6	Recombination rate (males);
PAAD	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	7.66	0.53	1.98e-12	Bipolar disorder;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.28	0.33	3.31e-5	Menopause (age at onset);
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg18612461	chr15:75251733	NA	0.69	8.91	0.59	1.49e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07391610	chr1:211432754	RCOR3	-0.65	-6.99	-0.49	8.09e-11	Smoking initiation;
PAAD	cis	rs7771547	0.589	rs6941918	chr6:36514721	T/G	cg04289385	chr6:36355825	ETV7	0.45	4.45	0.34	1.63e-5	Platelet distribution width;
PAAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.53e-5	Aortic root size;
PAAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.44	5.18	0.39	6.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.72	-7.57	-0.52	3.42e-12	Multiple myeloma (IgH translocation);
PAAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg03037974	chr15:76606532	NA	-0.38	-4.35	-0.33	2.44e-5	Blood metabolite levels;
PAAD	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg09075268	chr16:1270372	CACNA1H	0.5	4.84	0.37	3.17e-6	Blood protein levels;
PAAD	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.42	-0.34	1.89e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.56	4.36	0.33	2.42e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg19131313	chr8:1704013	NA	-0.41	-4.46	-0.34	1.59e-5	Systolic blood pressure;
PAAD	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.57	4.37	0.33	2.32e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12620999	1.000	rs13004252	chr2:238035408	C/A	cg23555395	chr2:238036564	NA	-0.44	-4.91	-0.37	2.36e-6	Systemic lupus erythematosus;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14826516	chr22:50639351	SELO	0.66	7.09	0.5	4.67e-11	Myopia (pathological);
PAAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	9.27	0.6	1.68e-16	Personality dimensions;
PAAD	cis	rs2421770	0.594	rs7115246	chr11:35286478	A/G	cg13971030	chr11:35366721	SLC1A2	-0.43	-5.29	-0.39	4.27e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.62	0.57	8.14e-15	Bipolar disorder;
PAAD	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg06697600	chr4:7070879	GRPEL1	0.88	4.45	0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg19223190	chr17:80058835	NA	0.52	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs7260329	0.713	rs4803414	chr19:41486082	T/C	cg06653635	chr19:40910092	PRX	-0.49	-4.36	-0.33	2.34e-5	Smoking behavior;
PAAD	cis	rs2562456	0.641	rs62107468	chr19:21489979	A/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.83	-9.15	-0.6	3.49e-16	Prostate cancer;
PAAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg06112835	chr11:68658793	MRPL21	-0.49	-5.28	-0.39	4.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs642743	0.967	rs593151	chr10:105935979	A/G	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.26	0.33	3.54e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.51	-4.36	-0.33	2.38e-5	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.03	7.84	0.54	7.22e-13	Diabetic kidney disease;
PAAD	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.66	-6.6	-0.47	6.45e-10	Pubertal anthropometrics;
PAAD	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg08619932	chr19:49200058	FUT2	0.58	6.5	0.47	1.06e-9	Dietary macronutrient intake;
PAAD	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg17524180	chr13:113633600	MCF2L	-0.52	-5.68	-0.42	6.79e-8	Systolic blood pressure;
PAAD	cis	rs3812111	0.774	rs509002	chr6:116423299	T/C	cg18764771	chr6:116381957	FRK	-0.27	-4.64	-0.35	7.57e-6	Age-related macular degeneration;
PAAD	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.76	9.23	0.6	2.17e-16	Monocyte percentage of white cells;
PAAD	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-4.48	-0.34	1.49e-5	Rheumatoid arthritis;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-8.25	-0.56	7.18e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs939584	1.000	rs7559018	chr2:645203	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.05	0.44	1.06e-8	Lung cancer;
PAAD	cis	rs834811	0.583	rs73168818	chr7:135878903	G/A	cg01726295	chr7:135938950	NA	0.4	4.35	0.33	2.49e-5	Post-traumatic stress disorder;
PAAD	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-0.93	-4.29	-0.33	3.21e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg14440974	chr22:39074834	NA	-0.55	-6.62	-0.47	5.93e-10	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.47	4.73	0.36	5.12e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-1.2	-5.45	-0.4	1.98e-7	Pediatric areal bone mineral density (radius);
PAAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs4843747	0.749	rs8053309	chr16:88044980	G/A	cg06915872	chr16:87998081	BANP	0.47	4.28	0.33	3.34e-5	Menopause (age at onset);
PAAD	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	7.92	0.54	4.66e-13	Mean platelet volume;
PAAD	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.28	0.45	3.46e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.43	6.51	0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.9	9.67	0.62	1.57e-17	Blood metabolite levels;
PAAD	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.77	4.29	0.33	3.14e-5	Coronary artery disease;
PAAD	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.57	-4.96	-0.37	1.84e-6	Total ventricular volume;
PAAD	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg14146966	chr2:61757674	XPO1	0.41	4.92	0.37	2.21e-6	Tuberculosis;
PAAD	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg17764715	chr19:33622953	WDR88	0.67	6.47	0.46	1.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12799172	0.572	rs2741826	chr11:6845273	A/G	cg23386594	chr11:6866523	OR10A5	0.41	4.26	0.33	3.59e-5	Periodontal disease-related phenotypes;
PAAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.97	0.49	8.8e-11	Rheumatoid arthritis;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-7.59	-0.52	3.06e-12	Systemic lupus erythematosus;
PAAD	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21643547	chr1:205240462	TMCC2	-0.4	-4.49	-0.34	1.4e-5	Red blood cell count;
PAAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.23	-0.45	4.36e-9	Glomerular filtration rate;
PAAD	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.12e-5	Blood pressure (smoking interaction);
PAAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-8.64	-0.57	7.28e-15	Calcium levels;
PAAD	cis	rs3026445	0.962	rs10774599	chr12:110697448	T/G	cg19752449	chr12:109915316	UBE3B;KCTD10	-0.49	-4.39	-0.34	2.14e-5	QT interval;
PAAD	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.88	9.57	0.61	2.83e-17	Anterior chamber depth;
PAAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.25	7.89	0.54	5.38e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10500715	0.676	rs6483860	chr11:9993887	G/T	cg06875754	chr11:10328428	ADM	-0.32	-4.38	-0.33	2.24e-5	Pancreatic cancer;
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.41e-12	Aortic root size;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.92	-7.15	-0.5	3.44e-11	Alzheimer's disease;
PAAD	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-1.06	-11.71	-0.69	5.56e-23	Blood pressure (smoking interaction);
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.53	-5.31	-0.4	3.82e-7	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Myopia (pathological);
PAAD	cis	rs300774	1.000	rs300773	chr2:115035	C/T	cg23649280	chr2:140451	NA	-0.49	-4.58	-0.35	9.8200000000000008e-06	Suicide attempts in bipolar disorder;
PAAD	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg06627628	chr2:24431161	ITSN2	0.55	5.46	0.4	1.93e-7	Sjögren's syndrome;
PAAD	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.78	-0.48	2.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4655582	0.510	rs12022410	chr1:66153933	A/G	cg04111102	chr1:66153794	NA	0.43	4.57	0.35	1.01e-5	Fibrinogen levels;
PAAD	cis	rs4906172	1.000	rs1678033	chr14:102435852	G/A	cg23289024	chr14:102554846	HSP90AA1	0.4	4.42	0.34	1.85e-5	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.74	-8.35	-0.56	3.94e-14	Childhood ear infection;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.54	0.35	1.16e-5	Electroencephalogram traits;
PAAD	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.72	-6.76	-0.48	2.73e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg25811766	chr13:21894605	NA	0.75	5.46	0.41	1.87e-7	White matter hyperintensity burden;
PAAD	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.38e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.38	8.84e-7	Platelet count;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	4.89	0.37	2.59e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7823896	0.722	rs16879302	chr8:110333207	T/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.11	0.44	7.89e-9	Height;
PAAD	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.38	7.39	0.51	9.08e-12	Skin colour saturation;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.39e-6	Type 2 diabetes;
PAAD	cis	rs2147959	0.824	rs10916313	chr1:228625882	C/G	cg00655913	chr1:228633920	NA	0.53	4.79	0.36	3.93e-6	Adult asthma;
PAAD	trans	rs61677309	1.000	rs56785719	chr11:118176623	C/G	cg15548380	chr1:19984784	NBL1	-0.63	-6.51	-0.47	1.03e-9	Lung cancer in ever smokers;
PAAD	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg12215294	chr3:40350768	EIF1B	0.45	4.69	0.36	6.07e-6	Renal cell carcinoma;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26418147	chr1:205743515	RAB7L1	-0.42	-4.8	-0.36	3.69e-6	Menarche (age at onset);
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18404041	chr3:52824283	ITIH1	0.56	6.43	0.46	1.58e-9	Electroencephalogram traits;
PAAD	cis	rs17407555	1.000	rs17407324	chr4:10273043	A/C	cg00071950	chr4:10020882	SLC2A9	0.63	5.74	0.42	5.04e-8	Schizophrenia (age at onset);
PAAD	cis	rs1160297	0.517	rs1451462	chr2:53123412	C/T	cg07782112	chr2:53107842	NA	-0.37	-4.54	-0.35	1.15e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs818427	1.000	rs2545167	chr5:112213071	G/T	cg06941702	chr5:112196734	SRP19	-0.47	-4.4	-0.34	2.07e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08119082	chr22:50608521	PANX2	0.64	6.51	0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs7567389	0.719	rs6744237	chr2:128004045	C/G	cg09760422	chr2:128146352	NA	-0.39	-5.94	-0.43	1.9e-8	Self-rated health;
PAAD	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	5.38	0.4	2.82e-7	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg17326555	chr1:119535693	NA	-0.44	-5.12	-0.38	9.02e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.62	-6.02	-0.44	1.25e-8	Systolic blood pressure;
PAAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg09835421	chr16:68378352	PRMT7	-0.85	-6.89	-0.49	1.42e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.55	-6.01	-0.44	1.33e-8	Hepatitis;
PAAD	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg18477163	chr1:228402036	OBSCN	0.56	7.08	0.5	5.1e-11	Diastolic blood pressure;
PAAD	cis	rs58521262	0.585	rs440580	chr19:23121679	T/C	cg03433597	chr19:22806448	NA	-0.25	-4.48	-0.34	1.45e-5	Testicular germ cell tumor;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	6.66	0.48	4.8e-10	Lung function (FEV1/FVC);
PAAD	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg04607235	chr12:12878440	APOLD1	-1.04	-11.39	-0.68	4.1e-22	Lymphocyte counts;
PAAD	trans	rs4455778	0.579	rs10265045	chr7:49131824	G/T	cg15743358	chr6:28303923	ZNF323	0.58	6.32	0.46	2.7e-9	Lung cancer in never smokers;
PAAD	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg26816564	chr1:7831052	VAMP3	0.75	5.75	0.42	4.86e-8	Inflammatory bowel disease;
PAAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs10121009	0.610	rs10814227	chr9:35330608	C/T	cg11846315	chr9:35647073	NA	-0.49	-4.67	-0.35	6.66e-6	Parkinson's disease;
PAAD	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.14	-0.38	8.26e-7	Myopia (pathological);
PAAD	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg09127314	chr1:152161683	NA	-0.61	-4.26	-0.33	3.53e-5	Atopic dermatitis;
PAAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg02734326	chr4:10020555	SLC2A9	0.5	4.99	0.38	1.63e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.9	7.13	0.5	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.48	-5.24	-0.39	5.23e-7	Coronary artery disease;
PAAD	cis	rs1144333	0.655	rs12405994	chr1:76435420	A/T	cg22875332	chr1:76189707	ACADM	0.76	4.45	0.34	1.62e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2286379	0.716	rs7978783	chr12:1858719	G/A	cg05227549	chr12:1770782	NA	0.43	4.97	0.37	1.81e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.38	0.51	9.49e-12	Menarche (age at onset);
PAAD	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg11764359	chr7:65958608	NA	-0.77	-5.0	-0.38	1.56e-6	Diabetic kidney disease;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg14393609	chr7:65229607	NA	0.67	7.42	0.52	7.82e-12	Calcium levels;
PAAD	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg15956490	chr3:53032818	SFMBT1	0.83	4.81	0.36	3.53e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-4.34	-0.33	2.62e-5	IFN-related cytopenia;
PAAD	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.19	-0.39	6.58e-7	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg08219700	chr8:58056026	NA	0.7	5.62	0.41	8.83e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg02421172	chr7:1938701	MAD1L1	0.63	4.93	0.37	2.17e-6	Bipolar disorder;
PAAD	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg10072921	chr12:121022843	NA	-0.44	-5.29	-0.39	4.12e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	6.09	0.44	8.98e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs10888329	0.741	rs6587438	chr1:248355881	G/C	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Autism spectrum disorder;
PAAD	cis	rs8105895	0.932	rs60548522	chr19:22214874	G/A	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg10729496	chr3:10149963	C3orf24	0.95	8.06	0.55	2.12e-13	Alzheimer's disease;
PAAD	cis	rs10073892	0.703	rs62372213	chr5:101639236	T/G	cg17280723	chr5:101634495	NA	0.41	4.38	0.34	2.16e-5	Cognitive decline (age-related);
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6494488	0.500	rs72742926	chr15:64864461	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.32	0.46	2.73e-9	Morning vs. evening chronotype;
PAAD	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-5.39	-0.4	2.6e-7	Colorectal cancer;
PAAD	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	1.02	12.35	0.71	1.03e-24	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs804280	0.703	rs745379	chr8:11615695	A/G	cg12395012	chr8:11607386	GATA4	0.71	8.27	0.56	6.2e-14	Myopia (pathological);
PAAD	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg00700412	chr12:58011837	NA	0.44	4.8	0.36	3.7e-6	Multiple sclerosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03941040	chr10:60145128	TFAM	-0.74	-6.61	-0.47	6.02e-10	Neuroticism;
PAAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg15193198	chr20:60906057	LAMA5	-0.52	-5.57	-0.41	1.13e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4740619	0.689	rs10810509	chr9:15955666	C/T	cg14451791	chr9:16040625	NA	-0.45	-5.16	-0.39	7.48e-7	Body mass index;
PAAD	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.54	4.39	0.34	2.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.45	5.95	0.43	1.8e-8	Ulcerative colitis;
PAAD	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.42	-4.62	-0.35	8.17e-6	Mean arterial pressure;
PAAD	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.75	-0.36	4.62e-6	Tuberculosis;
PAAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.57	-6.17	-0.45	6.02e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs4660214	0.671	rs72637904	chr1:39668682	C/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.47	-0.34	1.53e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.53	-5.98	-0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.69	6.47	0.46	1.25e-9	Lymphocyte counts;
PAAD	cis	rs6499755	0.932	rs1370386	chr16:55340167	G/C	cg02859129	chr16:55357253	IRX6	0.33	4.42	0.34	1.9e-5	Hypospadias;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.61	7.22	0.51	2.29e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-6.07	-0.44	9.6e-9	Schizophrenia;
PAAD	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.23	-16.94	-0.81	8.11e-37	IgG glycosylation;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.5	5.53	0.41	1.33e-7	Calcium levels;
PAAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.01e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs5756391	0.568	rs11705504	chr22:37317493	G/A	cg21209356	chr22:37319042	CSF2RB	0.4	4.84	0.37	3.09e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs1400816	0.718	rs7579509	chr2:172819161	A/G	cg21590967	chr2:120517099	PTPN4	-0.86	-6.32	-0.46	2.81e-9	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.5	-0.78	4.21e-33	Height;
PAAD	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.48	-4.39	-0.34	2.14e-5	Asthma;
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs4704187	0.687	rs67065524	chr5:74534309	A/G	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.6	0.41	9.93e-8	Bipolar disorder;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-7.1	-0.5	4.36e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.35	0.33	2.46e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02788857	chr8:22132959	PIWIL2	0.54	7.09	0.5	4.82e-11	Hypertriglyceridemia;
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg10978503	chr1:24200527	CNR2	0.51	6.06	0.44	1.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs12304921	0.745	rs7397054	chr12:51431740	G/C	cg18059802	chr12:51347058	HIGD1C	-0.73	-5.69	-0.42	6.31e-8	Type 2 diabetes;
PAAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg06026331	chr20:60912101	LAMA5	0.47	4.3	0.33	3.02e-5	Colorectal cancer;
PAAD	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.8	9.48	0.61	4.89e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.98e-19	Response to antipsychotic treatment;
PAAD	trans	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08418111	chr11:18433745	LDHC	0.63	6.53	0.47	9.27e-10	Calcium levels;
PAAD	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	1.08	9.07	0.59	5.73e-16	Corneal structure;
PAAD	cis	rs6700896	0.966	rs1938485	chr1:66082084	A/G	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.64e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.59	7.13	0.5	3.88e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-6.02	-0.44	1.26e-8	QT interval;
PAAD	cis	rs3764400	0.567	rs2325784	chr17:46212309	A/G	cg24322968	chr17:46507895	SKAP1	-0.85	-5.27	-0.39	4.5e-7	Body mass index;
PAAD	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg01028140	chr2:1542097	TPO	-1.03	-9.36	-0.6	1.03e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.56	-6.94	-0.49	1.07e-10	Monobrow;
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.5	0.47	1.1e-9	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7551345	0.901	rs12755701	chr1:31832313	C/T	cg17086398	chr1:31896392	SERINC2	-0.54	-4.56	-0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13102973	0.899	rs4643872	chr4:135901432	A/G	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.66e-5	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg02462569	chr6:150064036	NUP43	-0.48	-5.16	-0.39	7.72e-7	Lung cancer;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	1.04	8.29	0.56	5.4e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2834188	0.924	rs2007849	chr21:34681116	G/A	cg04842828	chr21:34696676	IFNAR1	0.49	4.63	0.35	7.89e-6	Narcolepsy;
PAAD	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg18892244	chr7:807596	HEATR2	-0.7	-5.28	-0.39	4.34e-7	Initial pursuit acceleration;
PAAD	cis	rs1075265	0.656	rs2542574	chr2:54047432	G/A	cg04546899	chr2:54196757	PSME4	0.31	4.59	0.35	9.14e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-4.92	-0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs7818688	0.697	rs11780130	chr8:95976083	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs8060686	0.668	rs255048	chr16:68012849	C/T	cg03983715	chr16:68378420	PRMT7	-0.9	-5.49	-0.41	1.65e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7631605	0.905	rs9814918	chr3:37121613	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23898175	chr11:118796425	NA	-0.73	-8.04	-0.55	2.34e-13	Smoking initiation;
PAAD	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg18281939	chr5:77783895	LHFPL2	0.49	5.58	0.41	1.08e-7	Triglycerides;
PAAD	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.75	-8.18	-0.55	1.08e-13	Type 2 diabetes;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.69	-7.91	-0.54	5.06e-13	Educational attainment;
PAAD	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg08886695	chr4:3369023	RGS12	-0.5	-4.64	-0.35	7.48e-6	Serum sulfate level;
PAAD	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs258892	1.000	rs187731	chr5:72289671	G/T	cg21869765	chr5:72125136	TNPO1	0.69	4.84	0.37	3.1e-6	Small cell lung carcinoma;
PAAD	cis	rs7101378	0.577	rs1912234	chr11:108898314	T/C	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18621852	chr3:10150065	C3orf24	0.69	5.73	0.42	5.26e-8	Alzheimer's disease;
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1075232	0.655	rs77987193	chr15:31588258	C/G	cg06530883	chr15:30699977	NA	0.99	4.26	0.33	3.56e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.56	5.58	0.41	1.07e-7	Body mass index;
PAAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.83	0.66	1.26e-20	Homoarginine levels;
PAAD	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.52	5.45	0.4	1.99e-7	Male-pattern baldness;
PAAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.61	-7.27	-0.51	1.8e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-5.33	-0.4	3.55e-7	Gut microbiome composition (summer);
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.78	12.54	0.71	3.3e-25	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	5.2	0.39	6.24e-7	Longevity;
PAAD	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.59	-0.41	1.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs939584	0.935	rs13391851	chr2:642467	A/G	cg03610516	chr2:642275	NA	0.6	5.4	0.4	2.52e-7	Body mass index;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.93	11.76	0.69	4.16e-23	Menarche (age at onset);
PAAD	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.65	7.4	0.51	8.79e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.67	0.42	7.12e-8	Ileal carcinoids;
PAAD	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.88	-8.75	-0.58	3.89e-15	Obesity;Body mass index;
PAAD	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.79	9.95	0.63	2.8e-18	Cancer;
PAAD	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.61	6.35	0.46	2.31e-9	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.59	-0.41	1.03e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg23958373	chr8:599963	NA	1.16	8.34	0.56	4.13e-14	IgG glycosylation;
PAAD	cis	rs3736757	1.000	rs3736757	chr1:184677464	G/A	cg05045817	chr1:184633523	NA	0.44	4.73	0.36	5.19e-6	Obesity-related traits;
PAAD	cis	rs4704187	0.687	rs2335136	chr5:74407994	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.5	0.34	1.36e-5	Breast cancer;
PAAD	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-4.95	-0.37	1.97e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	6.23	0.45	4.34e-9	Schizophrenia;
PAAD	cis	rs11696501	0.739	rs6073843	chr20:44293956	G/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs8077577	0.747	rs62072507	chr17:18172335	G/A	cg16794390	chr17:18148240	FLII	0.52	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.5	5.1	0.38	9.93e-7	Longevity;Endometriosis;
PAAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg01305830	chr4:1604576	NA	0.52	4.85	0.37	3.09e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.71	7.72	0.53	1.46e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.83	6.13	0.45	7.35e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg20742385	chr13:113633654	MCF2L	-0.43	-4.33	-0.33	2.71e-5	Systolic blood pressure;
PAAD	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.79	-0.75	1.47e-28	Primary sclerosing cholangitis;
PAAD	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg17099306	chr13:50123645	RCBTB1	-0.46	-4.7	-0.36	5.72e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg13918804	chr1:2043761	PRKCZ	0.4	5.4	0.4	2.49e-7	Height;
PAAD	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.51	6.18	0.45	5.57e-9	Sitting height ratio;
PAAD	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg14196790	chr5:131705035	SLC22A5	0.43	4.71	0.36	5.65e-6	Breast cancer;
PAAD	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg17401720	chr7:158221031	PTPRN2	0.42	4.8	0.36	3.76e-6	Obesity-related traits;
PAAD	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.86	-8.67	-0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs600550	0.588	rs10431136	chr11:60074313	A/T	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.94	9.98	0.63	2.37e-18	Height;
PAAD	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.5	-5.02	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.51	-5.87	-0.43	2.6e-8	Migraine;
PAAD	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg04034577	chr2:241836375	C2orf54	-0.34	-5.15	-0.39	7.79e-7	Urinary metabolites;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg21565972	chr17:80109576	CCDC57	-0.56	-6.54	-0.47	8.74e-10	Life satisfaction;
PAAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.48	-5.27	-0.39	4.62e-7	Monocyte count;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg16898833	chr6:26189333	HIST1H4D	0.56	4.32	0.33	2.84e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg14329783	chr7:75779857	NA	0.78	4.59	0.35	9.4e-6	Mononucleosis;
PAAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg16322792	chr1:120165303	ZNF697	0.54	7.33	0.51	1.3e-11	Systemic lupus erythematosus;
PAAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg16083429	chr3:49237500	CCDC36	-0.43	-4.56	-0.35	1.06e-5	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21647170	chr7:56119546	CCT6A;PSPH	0.63	7.16	0.5	3.28e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.58	-7.05	-0.5	5.79e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	2.02e-13	Melanoma;
PAAD	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.64	-0.42	8.15e-8	Lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07257042	chr17:40428882	STAT5B	-0.74	-6.37	-0.46	2.08e-9	Neuroticism;
PAAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs9810890	1.000	rs9862012	chr3:128572219	C/T	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs7385804	0.895	rs4729597	chr7:100221849	C/T	cg16850897	chr7:100343110	ZAN	0.44	4.29	0.33	3.14e-5	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2644899	0.593	rs3733828	chr19:41310609	A/G	cg10585486	chr19:41304133	EGLN2	-0.49	-4.83	-0.36	3.29e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg03303774	chr4:1407052	NA	0.33	4.26	0.33	3.64e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs12761573	chr10:46079517	A/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1274963	0.601	rs811970	chr3:39196552	A/G	cg23654821	chr3:39188656	CSRNP1	-0.4	-4.44	-0.34	1.74e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.75	8.37	0.56	3.46e-14	Prostate cancer;
PAAD	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	7.34	0.51	1.19e-11	Schizophrenia;
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3743102	0.591	rs79849356	chr15:83402305	T/C	cg00614314	chr15:82944287	LOC80154	-0.66	-4.35	-0.33	2.51e-5	Colorectal adenoma (advanced);
PAAD	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.47e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg14393609	chr7:65229607	NA	-0.45	-4.48	-0.34	1.47e-5	Aortic root size;
PAAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg01966878	chr4:90757139	SNCA	-0.61	-4.75	-0.36	4.59e-6	Neuroticism;
PAAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.18	11.92	0.7	1.54e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg02462569	chr6:150064036	NUP43	-0.41	-4.43	-0.34	1.82e-5	Testicular germ cell tumor;
PAAD	cis	rs12999616	0.817	rs62157581	chr2:98327502	G/T	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.83	-5.9	-0.43	2.31e-8	Response to treatment for acute lymphoblastic leukemia;
PAAD	trans	rs10500871	1.000	rs10500871	chr11:20215756	C/T	cg02956962	chr6:161097311	NA	0.6	6.38	0.46	2.01e-9	Educational attainment;
PAAD	cis	rs6908034	0.607	rs77386860	chr6:19814755	A/C	cg02682789	chr6:19804855	NA	0.82	4.76	0.36	4.49e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg08885800	chr1:201084119	NA	0.5	4.45	0.34	1.62e-5	Permanent tooth development;
PAAD	trans	rs901683	1.000	rs34670342	chr10:46066162	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg00495681	chr13:53174319	NA	0.47	4.69	0.36	5.98e-6	Lewy body disease;
PAAD	cis	rs2790216	1.000	rs1867572	chr10:60038940	C/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg14146966	chr2:61757674	XPO1	0.44	5.41	0.4	2.45e-7	Tuberculosis;
PAAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.94	-11.22	-0.67	1.19e-21	IgG glycosylation;
PAAD	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.78	8.85	0.58	2.11e-15	Response to antipsychotic treatment;
PAAD	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4908768	0.501	rs6577494	chr1:8576925	C/T	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Menarche (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19475930	chr12:120907604	DYNLL1;SFRS9	0.62	6.37	0.46	2.14e-9	Myopia (pathological);
PAAD	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.7	9.24	0.6	2.05e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.11	-0.38	9.63e-7	Monocyte count;
PAAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.97	11.08	0.67	2.73e-21	Parkinson's disease;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg10207240	chr12:122356781	WDR66	0.52	5.55	0.41	1.26e-7	Mean corpuscular volume;
PAAD	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs16895831	0.519	rs16895863	chr6:42571346	A/T	cg10605015	chr6:42532144	UBR2	-0.66	-5.0	-0.38	1.56e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.66	7.03	0.5	6.5e-11	Aortic root size;
PAAD	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.93	8.04	0.55	2.3e-13	IgG glycosylation;
PAAD	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.94	-11.37	-0.68	4.46e-22	Height;
PAAD	cis	rs2637030	0.559	rs372135	chr5:52944948	T/C	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg02795151	chr17:7402630	POLR2A	-0.65	-5.8	-0.43	3.74e-8	Androgen levels;
PAAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg05425664	chr17:57184151	TRIM37	-0.53	-4.57	-0.35	1.02e-5	Testicular germ cell tumor;
PAAD	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg19904058	chr10:135279010	LOC619207	-0.47	-5.7	-0.42	6e-8	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	0.44	5.05	0.38	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg02917321	chr22:38215204	NA	0.48	4.6	0.35	8.77e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.66	6.81	0.48	2.15e-10	Height;
PAAD	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.85	-9.77	-0.62	8.7e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26926768	chr12:34528122	NA	0.39	4.79	0.36	3.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs11694441	0.618	rs55752124	chr2:119570624	G/A	cg14634534	chr2:119616825	NA	-0.43	-4.72	-0.36	5.37e-6	Monobrow;
PAAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.86	-9.28	-0.6	1.62e-16	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.67	0.65	3.45e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs427941	0.667	rs34247954	chr7:101740993	C/T	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.96	8.97	0.59	1.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Birth weight;
PAAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14169450	chr9:139327907	INPP5E	0.76	9.22	0.6	2.3e-16	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg10547527	chr2:198650123	BOLL	-0.75	-5.22	-0.39	5.73e-7	Ulcerative colitis;
PAAD	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	0.81	6.41	0.46	1.77e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs732765	0.734	rs11844127	chr14:75139936	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.48	-0.34	1.44e-5	Non-small cell lung cancer;
PAAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.61	4.53	0.34	1.2e-5	Breast cancer;
PAAD	cis	rs11811982	0.793	rs75767425	chr1:227577520	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs732765	0.657	rs67520590	chr14:75235457	C/T	cg17347104	chr14:75034677	LTBP2	0.56	4.29	0.33	3.1e-5	Non-small cell lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14264380	chr17:79651103	ARL16;HGS	0.57	6.7	0.48	3.87e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.49	-4.44	-0.34	1.73e-5	Tuberculosis;
PAAD	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08439880	chr3:133502540	NA	-0.5	-5.34	-0.4	3.38e-7	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.93	13.5	0.74	8.3e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs4838594	0.563	rs9794032	chr10:49681286	A/G	cg17291251	chr10:49678358	ARHGAP22	0.47	4.41	0.34	1.97e-5	Daytime sleep phenotypes;
PAAD	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg01515732	chr14:76012927	BATF	-0.54	-4.34	-0.33	2.6e-5	Non-small cell lung cancer;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.23	-0.39	5.41e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs939584	0.709	rs115342375	chr2:605176	T/A	cg03610516	chr2:642275	NA	0.58	4.89	0.37	2.58e-6	Body mass index;
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.53	4.93	0.37	2.09e-6	Prostate-specific antigen levels;
PAAD	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs10821973	0.527	rs4979777	chr10:63981896	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.47	-0.34	1.52e-5	Hypothyroidism;
PAAD	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.15	0.45	6.6e-9	Breast cancer;
PAAD	cis	rs114540395	0.858	rs77209663	chr10:103300166	G/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.32	-0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.02	-0.38	1.42e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	11.7	0.69	5.85e-23	Platelet count;
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.58	0.47	7e-10	Lung function (FEV1/FVC);
PAAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.46	4.84	0.37	3.2e-6	Personality dimensions;
PAAD	cis	rs3857067	0.550	rs1600086	chr4:95001695	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.61	7.22	0.51	2.3e-11	Mean corpuscular volume;
PAAD	cis	rs12541635	0.739	rs10955412	chr8:107075592	T/C	cg10147462	chr8:107024639	NA	-0.47	-4.91	-0.37	2.33e-6	Age of smoking initiation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21790657	chr18:77675478	PQLC1	0.57	6.86	0.49	1.67e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.69	5.78	0.42	4.07e-8	Prostate cancer;
PAAD	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.75	8.35	0.56	3.91e-14	N-glycan levels;
PAAD	cis	rs10741210	0.795	rs10764937	chr10:131986722	C/T	cg15459887	chr10:131993170	NA	0.48	4.79	0.36	3.95e-6	Alcohol dependence;
PAAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg23346134	chr3:49453900	TCTA	0.44	4.37	0.33	2.29e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg08992911	chr2:238395768	MLPH	0.59	5.16	0.39	7.54e-7	Prostate cancer;
PAAD	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg09659197	chr4:152720779	NA	0.46	6.14	0.45	6.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.54	5.91	0.43	2.17e-8	Testicular germ cell tumor;
PAAD	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.33	-0.4	3.41e-7	Common traits (Other);
PAAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Tonsillectomy;
PAAD	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-5.85	-0.43	2.86e-8	Homocysteine levels;
PAAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.57	-5.45	-0.4	1.96e-7	Breast size;
PAAD	cis	rs66530629	0.958	rs4024244	chr1:25050228	G/A	cg22509179	chr1:25234806	RUNX3	0.49	4.35	0.33	2.5e-5	Plateletcrit;
PAAD	cis	rs28489187	0.706	rs4949890	chr1:85830632	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg08088566	chr11:430123	ANO9	-0.77	-4.94	-0.37	2e-6	Body mass index;
PAAD	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs78472555	0.661	rs78202235	chr15:100222791	G/A	cg18869061	chr15:100272053	LYSMD4	-0.51	-4.32	-0.33	2.79e-5	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.42	6.21	0.45	4.82e-9	Subjective well-being;
PAAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.86	9.69	0.62	1.4e-17	Total body bone mineral density;
PAAD	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.79	0.36	3.93e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs78761021	0.867	rs8077150	chr17:9788769	C/T	cg26853458	chr17:9805074	RCVRN	0.71	8.24	0.56	7.24e-14	Type 2 diabetes;
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-5.17	-0.39	7.12e-7	Cystic fibrosis severity;
PAAD	trans	rs12406019	0.548	rs7524877	chr1:78615645	A/G	cg20826526	chr3:156266748	SSR3	-0.66	-6.5	-0.47	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs933688	0.556	rs4916855	chr5:90596345	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.69	-5.38	-0.4	2.82e-7	Smoking behavior;
PAAD	cis	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-5.29	-0.39	4.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.77	7.72	0.53	1.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs2790216	1.000	rs2790168	chr10:60025448	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.62	-7.6	-0.52	2.85e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1075265	0.704	rs805410	chr2:54120497	G/T	cg04546899	chr2:54196757	PSME4	0.31	4.59	0.35	9.27e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.51	-5.03	-0.38	1.35e-6	Coronary artery disease;
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	5.02	0.38	1.45e-6	Vitiligo;
PAAD	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg09324608	chr17:30823087	MYO1D	0.46	4.65	0.35	7.04e-6	Schizophrenia;
PAAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg06375148	chr1:209958343	C1orf74	0.44	4.43	0.34	1.82e-5	Monobrow;
PAAD	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.66	8.61	0.57	8.62e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs3782123	0.514	rs11246009	chr11:223733	T/A	cg25796445	chr11:207425	RIC8A;BET1L	-0.83	-5.31	-0.4	3.78e-7	Glycated hemoglobin levels;Red cell distribution width;
PAAD	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.63	5.9	0.43	2.28e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.82	-0.43	3.42e-8	Mood instability;
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.48	5.83	0.43	3.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13446404	chr3:46640523	NA	0.59	6.42	0.46	1.65e-9	Smoking initiation;
PAAD	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg16040993	chr19:53496440	ZNF702P	-0.46	-4.61	-0.35	8.53e-6	Psoriasis;
PAAD	cis	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg13821571	chr21:34406537	NA	-0.48	-4.65	-0.35	7.13e-6	Gastritis;
PAAD	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.58	8.03	0.55	2.5e-13	Asthma (sex interaction);
PAAD	cis	rs329674	0.556	rs55807834	chr11:133769957	T/C	cg06766960	chr11:133703094	NA	-0.69	-4.31	-0.33	2.91e-5	Bipolar disorder;
PAAD	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs9525927	0.521	rs4942298	chr13:44798622	G/A	cg19190762	chr13:44806055	NA	0.39	4.27	0.33	3.37e-5	Dupuytren's disease;
PAAD	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.69	6.71	0.48	3.71e-10	Coronary artery disease;
PAAD	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs747650	0.504	rs7127741	chr11:47074479	T/C	cg19486271	chr11:47235900	DDB2	-0.68	-6.29	-0.45	3.26e-9	Acne (severe);
PAAD	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.17	16.85	0.81	1.32e-36	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17087759	chr2:220094168	ANKZF1;ATG9A	-0.68	-6.71	-0.48	3.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13278911	chr3:39222419	NA	-0.64	-6.66	-0.48	4.69e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg04450456	chr4:17643702	FAM184B	0.48	5.27	0.39	4.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20487152	chr13:99095054	FARP1	0.47	4.56	0.35	1.04e-5	Longevity;
PAAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.78	-6.71	-0.48	3.65e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.76	8.92	0.59	1.38e-15	Blood metabolite ratios;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg26071806	chr7:100318239	EPO	-0.51	-5.06	-0.38	1.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2004318	1.000	rs2555685	chr19:55067465	C/T	cg03320607	chr19:54800032	LILRA3	1.01	5.82	0.43	3.44e-8	Blood protein levels;
PAAD	cis	rs73058052	0.597	rs11083979	chr19:50096144	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.59	-5.13	-0.38	8.75e-7	Fibrinogen levels;
PAAD	cis	rs704	0.752	rs6505079	chr17:26718177	T/A	cg10342447	chr17:26645325	TMEM97	-0.35	-4.31	-0.33	2.96e-5	Osteoprotegerin levels;
PAAD	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	9.34	0.6	1.11e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7715811	1.000	rs12153762	chr5:13778890	A/G	cg09526469	chr5:14277668	TRIO	-0.4	-4.32	-0.33	2.77e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs11159086	0.793	rs8021664	chr14:74943295	T/C	cg10195687	chr14:74926396	NA	-0.47	-5.27	-0.39	4.54e-7	Advanced glycation end-product levels;
PAAD	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.87	0.54	6.33e-13	Response to antipsychotic treatment;
PAAD	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.41	5.04	0.38	1.31e-6	Joint mobility (Beighton score);
PAAD	cis	rs939584	1.000	rs12463617	chr2:629244	A/C	cg03610516	chr2:642275	NA	0.62	5.55	0.41	1.25e-7	Body mass index;
PAAD	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg01620082	chr3:125678407	NA	-1.56	-9.55	-0.61	3.14e-17	Depression;
PAAD	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.49	0.68	2.2e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.18	-0.39	7.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.77	-8.55	-0.57	1.21e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.54	5.78	0.42	4.17e-8	Menopause (age at onset);
PAAD	cis	rs12780845	0.931	rs2884038	chr10:17252158	T/C	cg00857480	chr10:17188594	TRDMT1	0.34	4.3	0.33	3.09e-5	Homocysteine levels;
PAAD	cis	rs11009175	0.556	rs7072034	chr10:33298617	A/G	cg00146027	chr10:33299147	NA	-0.39	-4.79	-0.36	3.94e-6	Depression (quantitative trait);
PAAD	cis	rs12949688	0.601	rs11079327	chr17:55837375	C/T	cg12582317	chr17:55822272	NA	0.45	5.27	0.39	4.7e-7	Schizophrenia;
PAAD	cis	rs17665859	1.000	rs17665859	chr8:445601	T/C	cg17960703	chr8:356704	FBXO25	0.9	4.37	0.33	2.29e-5	Bilirubin levels;
PAAD	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg01064725	chr1:204461714	NA	-0.47	-4.51	-0.34	1.29e-5	Schizophrenia;
PAAD	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	10.8	0.66	1.58e-20	Total body bone mineral density;
PAAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02725872	chr8:58115012	NA	-0.54	-4.41	-0.34	1.98e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs11048434	0.518	rs17730331	chr12:9178432	A/G	cg04548204	chr12:9162872	KLRG1	0.39	4.38	0.33	2.23e-5	Sjögren's syndrome;
PAAD	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.57	7.01	0.49	7.44e-11	Crohn's disease;
PAAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-4.96	-0.37	1.83e-6	Longevity;
PAAD	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg03989125	chr22:38214979	NA	-0.52	-4.9	-0.37	2.42e-6	Glioblastoma;Glioma;
PAAD	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-4.28	-0.33	3.27e-5	Retinal vascular caliber;
PAAD	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg07954423	chr9:130741881	FAM102A	-0.55	-5.24	-0.39	5.19e-7	Glaucoma (primary angle closure);
PAAD	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-6.43	-0.46	1.57e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.66	8.24	0.56	7.44e-14	Schizophrenia;
PAAD	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.58	5.96	0.44	1.71e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg17385448	chr1:15911702	AGMAT	0.34	4.28	0.33	3.34e-5	Systolic blood pressure;
PAAD	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.45	-0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	cis	rs28489187	0.683	rs6657817	chr1:85874614	C/T	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs797680	1.000	rs797680	chr1:93716974	G/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.39	-0.34	2.08e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg01426195	chr3:39028469	NA	0.73	6.74	0.48	3.04e-10	Handedness;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.6	5.72	0.42	5.51e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	trans	rs320203	0.662	rs1165879	chr9:104810553	C/A	cg27499259	chr13:28400924	NA	0.98	6.38	0.46	1.99e-9	Mucinous ovarian carcinoma;
PAAD	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-5.08	-0.38	1.08e-6	Body mass index;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.7	5.46	0.4	1.92e-7	Alzheimer's disease;
PAAD	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.17	0.73	6.56e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg18612461	chr15:75251733	NA	-0.56	-7.02	-0.49	7.05e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs17681684	0.541	rs17810219	chr17:9764998	A/G	cg26853458	chr17:9805074	RCVRN	0.73	7.73	0.53	1.36e-12	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs10950821	0.959	rs7777864	chr7:20663684	G/C	cg21202529	chr7:20656503	ABCB5	-0.47	-4.41	-0.34	1.92e-5	Response to statin therapy;
PAAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.8	9.07	0.59	5.77e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24229701	chr12:130821962	PIWIL1	-0.42	-4.34	-0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg01796438	chr3:11312864	ATG7	-0.56	-4.39	-0.34	2.15e-5	Circulating chemerin levels;
PAAD	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg12935359	chr14:103987150	CKB	-0.73	-8.45	-0.57	2.18e-14	Body mass index;
PAAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.83	7.24	0.51	2.04e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.86	8.95	0.59	1.16e-15	Prostate cancer;
PAAD	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.74	5.54	0.41	1.29e-7	Mean platelet volume;
PAAD	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.59	0.35	9.07e-6	Self-reported allergy;
PAAD	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.86	6.57	0.47	7.58e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.36e-7	Protein quantitative trait loci;
PAAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg11707556	chr5:10655725	ANKRD33B	0.63	6.86	0.49	1.6e-10	Coronary artery disease;
PAAD	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg19025524	chr12:109796872	NA	-0.56	-4.42	-0.34	1.9e-5	Neuroticism;
PAAD	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.02	0.38	1.42e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.58	-5.51	-0.41	1.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg25886479	chr11:50257625	LOC441601	-0.43	-4.72	-0.36	5.27e-6	Height;
PAAD	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00540400	chr15:79124168	NA	0.59	6.62	0.47	5.8e-10	Coronary artery disease;
PAAD	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-4.38	-0.33	2.2e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15008879	chr10:22292810	DNAJC1	0.57	6.34	0.46	2.43e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.43	-4.72	-0.36	5.23e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	0.7	4.25	0.33	3.65e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4889855	1.000	rs4889855	chr17:78513280	G/A	cg16591659	chr17:78472290	NA	-0.65	-5.36	-0.4	3.04e-7	Fractional excretion of uric acid;
PAAD	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.49	4.26	0.33	3.51e-5	Homoarginine levels;
PAAD	cis	rs3796727	0.690	rs4696863	chr4:8614729	T/C	cg05284713	chr4:8621361	CPZ	-0.44	-4.36	-0.33	2.42e-5	Sporadic neuroblastoma;
PAAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg15510373	chr7:100224934	TFR2	-0.53	-4.3	-0.33	3.02e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.6	6.02	0.44	1.23e-8	Triglyceride levels;
PAAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg05627522	chr15:75251581	NA	0.56	6.51	0.47	1.04e-9	Breast cancer;
PAAD	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-5.04	-0.38	1.28e-6	Testicular germ cell tumor;
PAAD	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.29	0.39	4.17e-7	Bipolar disorder;
PAAD	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.69	6.95	0.49	9.83e-11	Body mass index;
PAAD	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-5.57	-0.41	1.13e-7	Bladder cancer;
PAAD	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg05528293	chr18:74961138	GALR1	0.55	5.13	0.38	8.8e-7	Obesity-related traits;
PAAD	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-5.12	-0.38	9.26e-7	Body mass index;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg14684375	chr19:45540895	SFRS16;RELB	0.57	6.49	0.47	1.17e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.08	-11.29	-0.68	7.68e-22	Blood pressure (smoking interaction);
PAAD	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	5.96	0.44	1.69e-8	Schizophrenia;
PAAD	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.73	7.49	0.52	5.36e-12	Schizophrenia;
PAAD	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.37	0.4	2.86e-7	Urate levels in lean individuals;
PAAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg00431813	chr7:1051703	C7orf50	0.72	4.49	0.34	1.4e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.39e-9	Lung cancer;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.767	rs56282178	chr7:27698592	C/A	cg22168087	chr7:27702803	HIBADH	-0.49	-4.42	-0.34	1.85e-5	Hypospadias;
PAAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.56	6.2	0.45	5.11e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg09017928	chr7:158110068	PTPRN2	0.45	4.43	0.34	1.81e-5	Calcium levels;
PAAD	cis	rs1879734	0.815	rs1780391	chr1:54177708	C/G	cg14659662	chr1:54151053	GLIS1	0.38	6.26	0.45	3.71e-9	Mitral valve prolapse;
PAAD	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg08601574	chr20:25228251	PYGB	0.62	6.85	0.49	1.75e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.26e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-5.07	-0.38	1.12e-6	Menarche (age at onset);
PAAD	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg11498726	chr8:26250323	BNIP3L	-0.54	-5.06	-0.38	1.17e-6	Red cell distribution width;
PAAD	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg02353165	chr6:42928485	GNMT	0.59	5.03	0.38	1.36e-6	Blood protein levels;
PAAD	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.57	6.49	0.47	1.16e-9	Mean corpuscular volume;
PAAD	cis	rs35740288	0.770	rs1382538	chr15:86165896	G/C	cg07943548	chr15:86304357	KLHL25	-0.53	-4.41	-0.34	1.91e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.58	-0.35	9.8e-6	Bipolar disorder;
PAAD	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs4795519	0.592	rs34035904	chr17:22170381	T/C	cg22648282	chr17:21454238	C17orf51	-0.5	-5.05	-0.38	1.26e-6	Chronic myeloid leukemia;
PAAD	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.52	-0.41	1.45e-7	Monocyte percentage of white cells;
PAAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg03999872	chr20:62272968	STMN3	0.48	4.37	0.33	2.31e-5	Prostate cancer;
PAAD	cis	rs8018808	0.935	rs4899655	chr14:77898077	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs354033	0.837	rs6971236	chr7:149184850	A/C	cg06920324	chr7:149264011	ZNF767	0.58	4.99	0.38	1.61e-6	Multiple sclerosis;
PAAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg03808351	chr9:123631620	PHF19	0.45	4.87	0.37	2.76e-6	Rheumatoid arthritis;
PAAD	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs78472555	0.789	rs2603229	chr15:100263499	T/C	cg23669855	chr15:100272142	LYSMD4	0.63	5.25	0.39	4.97e-7	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs75757892	0.500	rs2714357	chr6:7225995	G/T	cg15365232	chr6:7261319	NA	0.39	4.6	0.35	8.99e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg01763666	chr17:80159506	CCDC57	0.43	4.37	0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg11764359	chr7:65958608	NA	0.8	5.51	0.41	1.51e-7	Diabetic kidney disease;
PAAD	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg03983715	chr16:68378420	PRMT7	-0.96	-6.81	-0.48	2.1e-10	Schizophrenia;
PAAD	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg24881330	chr22:46731750	TRMU	1.17	5.77	0.42	4.24e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.6	0.35	8.75e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-8.46	-0.57	2.13e-14	Response to antipsychotic treatment;
PAAD	cis	rs1569175	1.000	rs17591301	chr2:200854215	A/G	cg23649088	chr2:200775458	C2orf69	-0.78	-4.37	-0.33	2.3e-5	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs829661	1.000	rs829673	chr2:30711784	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.89	0.37	2.51e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.82	9.93	0.63	3.16e-18	Bladder cancer;
PAAD	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.63	6.64	0.47	5.2400000000000005e-10	Testicular germ cell tumor;
PAAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.45	6.05	0.44	1.1e-8	Ulcerative colitis;
PAAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	4.82	0.36	3.39e-6	Height;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg19500098	chr13:21900506	NA	0.54	5.38	0.4	2.74e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.09	-0.5	4.82e-11	Systemic lupus erythematosus;
PAAD	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13560548	chr3:10150139	C3orf24	0.62	5.65	0.42	7.74e-8	Alzheimer's disease;
PAAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.2	0.5	2.56e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.57	6.03	0.44	1.21e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg21253087	chr9:139290292	SNAPC4	0.49	4.31	0.33	2.96e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.52	4.7	0.36	5.77e-6	Mean platelet volume;
PAAD	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.73	-5.03	-0.38	1.37e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg05110241	chr16:68378359	PRMT7	-0.66	-4.88	-0.37	2.61e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9395066	0.527	rs12524069	chr6:44897973	C/A	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.41	1.1e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.17	9.81	0.62	6.67e-18	Uric acid levels;
PAAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15145965	chr22:50218605	BRD1	-0.59	-5.12	-0.38	9.33e-7	Schizophrenia;
PAAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.1	0.44	8.55e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg01953289	chr20:60874239	NA	0.69	5.16	0.39	7.71e-7	Obesity-related traits;
PAAD	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg09127314	chr1:152161683	NA	-0.71	-4.91	-0.37	2.3e-6	Atopic dermatitis;
PAAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-6.09	-0.44	8.73e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.78	-5.91	-0.43	2.13e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.49e-11	Total cholesterol levels;
PAAD	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.38	4.73	0.36	5.12e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07781247	chr5:93954443	ANKRD32;C5orf36	0.61	6.88	0.49	1.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.34	-0.46	2.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg17372657	chr7:1216933	NA	-0.38	-4.84	-0.37	3.17e-6	Longevity;Endometriosis;
PAAD	cis	rs55955238	0.605	rs10048172	chr17:35282364	C/T	cg13677415	chr17:35291900	NA	-0.32	-4.38	-0.34	2.17e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.36	0.46	2.26e-9	Morning vs. evening chronotype;
PAAD	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg04415270	chr2:102091202	RFX8	0.7	8.99	0.59	9.24e-16	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.08	-0.63	1.31e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7623687	0.892	rs73074830	chr3:49577017	A/C	cg19401529	chr3:49056140	DALRD3	0.87	5.72	0.42	5.58e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.23	-0.39	5.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg08436684	chr16:88034427	BANP	-0.57	-4.8	-0.36	3.8e-6	Menopause (age at onset);
PAAD	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.67	0.42	7.14e-8	Body mass index;
PAAD	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.47	5.36	0.4	3.08e-7	Blood pressure (smoking interaction);
PAAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.89	0.63	4.07e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11018357	chr17:7788298	CHD3	0.68	7.33	0.51	1.26e-11	Obesity-related traits;
PAAD	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18292763	chr14:62581650	NA	-0.64	-6.86	-0.49	1.61e-10	Obesity-related traits;
PAAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.67	-0.53	1.89e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	4.7	0.36	5.88e-6	Height;
PAAD	cis	rs2229238	0.911	rs4639752	chr1:154508974	T/A	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs8105895	1.000	rs6511313	chr19:22215905	C/T	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9398803	0.661	rs9375449	chr6:126963807	T/C	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs10090774	0.965	rs6578146	chr8:141965867	C/A	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg00383909	chr3:49044727	WDR6	-0.43	-4.42	-0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.57	6.11	0.44	8.08e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs16854884	0.770	rs1530478	chr3:143819553	C/T	cg06585982	chr3:143692056	C3orf58	0.48	4.7	0.36	5.75e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg18370025	chr7:2749541	AMZ1	-0.4	-4.83	-0.36	3.32e-6	Height;
PAAD	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs28655083	0.529	rs589002	chr16:77104044	T/C	cg06128999	chr16:77247126	NA	-0.42	-5.14	-0.38	8.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs988913	0.581	rs2174115	chr6:54857779	G/A	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg11459648	chr5:138714337	SLC23A1	-0.64	-5.87	-0.43	2.6e-8	Schizophrenia;
PAAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.09e-13	Diastolic blood pressure;
PAAD	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs300774	0.925	rs300779	chr2:111486	G/A	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.33	-0.4	3.45e-7	Aortic root size;
PAAD	cis	rs12935418	0.672	rs12446810	chr16:81042974	T/C	cg16651780	chr16:81037892	C16orf61	0.65	6.08	0.44	9.11e-9	Mean corpuscular volume;
PAAD	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.19	0.67	1.36e-21	Total body bone mineral density;
PAAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.72	6.34	0.46	2.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-8.3	-0.56	5.4e-14	Body mass index;
PAAD	cis	rs7532866	0.885	rs7520137	chr1:26731035	T/G	cg17456097	chr1:26900765	RPS6KA1	-0.53	-4.51	-0.34	1.28e-5	Height;
PAAD	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.72	0.48	3.37e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.56	-0.35	1.05e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.74	7.51	0.52	4.7e-12	Prostate cancer;
PAAD	cis	rs6604026	0.656	rs2774956	chr1:93364726	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs2445762	0.518	rs12441073	chr15:51644472	T/C	cg20344442	chr15:51633704	GLDN	0.46	4.64	0.35	7.36e-6	Hormone measurements;
PAAD	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.32e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7792596	0.539	rs71562851	chr7:94011557	C/T	cg20814616	chr7:94014465	NA	-0.57	-4.28	-0.33	3.25e-5	Intelligence;
PAAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs9398803	0.723	rs853982	chr6:127046121	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.46	-0.34	1.56e-5	Male-pattern baldness;
PAAD	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.84	-0.49	1.83e-10	Triglycerides;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2834188	1.000	rs2409488	chr21:34688914	A/C	cg04842828	chr21:34696676	IFNAR1	0.46	4.41	0.34	1.92e-5	Narcolepsy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23260004	chr1:161736072	ATF6	0.58	6.39	0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg06484146	chr7:12443880	VWDE	-0.58	-4.89	-0.37	2.52e-6	Coronary artery disease;
PAAD	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.19	0.6	2.82e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg07545535	chr7:76256818	POMZP3;LOC100133091	0.89	6.37	0.46	2.15e-9	Lung function (FEV1/FVC);
PAAD	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.45	-5.04	-0.38	1.33e-6	Post-traumatic stress disorder;
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.13	0.55	1.37e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg09796270	chr17:17721594	SREBF1	0.45	4.8	0.36	3.8e-6	Total body bone mineral density;
PAAD	cis	rs802075	1.000	rs802072	chr6:49656000	G/A	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs2518049	0.539	rs1937924	chr10:5158682	G/C	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs2033711	0.936	rs3794968	chr19:58986799	G/C	cg26874164	chr19:58962979	ZNF324B	0.47	4.37	0.33	2.27e-5	Uric acid clearance;
PAAD	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.84	-8.73	-0.58	4.34e-15	Systemic lupus erythematosus;
PAAD	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.41	4.98	0.37	1.71e-6	Electrocardiographic conduction measures;
PAAD	cis	rs790123	0.541	rs4678205	chr3:122393829	C/T	cg15604389	chr3:122379662	NA	-0.55	-4.61	-0.35	8.39e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.79	-8.61	-0.57	8.8e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs757081	0.514	rs214087	chr11:17298365	G/C	cg04705435	chr11:17411270	KCNJ11	-0.51	-5.35	-0.4	3.2e-7	Systolic blood pressure;
PAAD	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.95	-14.07	-0.75	2.5e-29	Dental caries;
PAAD	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.82	-6.38	-0.46	2.01e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.65	-5.92	-0.43	2.07e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.27	-0.39	4.52e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13242816	1.000	rs62468978	chr7:116127099	A/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.01	-0.38	1.48e-6	P wave duration;
PAAD	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.28	-0.64	3.87e-19	Bladder cancer;
PAAD	cis	rs58521262	0.556	rs2935437	chr19:23196456	A/C	cg02350677	chr19:23254381	NA	0.26	4.45	0.34	1.64e-5	Testicular germ cell tumor;
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg15193198	chr20:60906057	LAMA5	0.64	7.62	0.53	2.5e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg15847926	chr7:2749597	AMZ1	-0.42	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2637266	0.875	rs115333453	chr10:78369011	G/A	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.65e-5	Pulmonary function;
PAAD	cis	rs1950357	0.589	rs2144317	chr14:37211957	C/T	cg14479910	chr14:36975263	SFTA3	0.33	4.61	0.35	8.47e-6	Lobe attachment (rater scored);Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3736485	0.966	rs12102203	chr15:51791559	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.26	-0.33	3.63e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8025118	0.583	rs12903363	chr15:79551676	A/T	cg24739098	chr15:79297159	RASGRF1	0.38	4.27	0.33	3.48e-5	Cognitive function;
PAAD	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	4.84	0.37	3.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg19438565	chr8:143695827	ARC	-0.57	-5.57	-0.41	1.12e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg08835956	chr7:39171034	POU6F2	0.27	4.52	0.34	1.23e-5	IgG glycosylation;
PAAD	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-5.15	-0.39	8.04e-7	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.29	0.39	4.25e-7	Red blood cell count;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg27565382	chr3:53032988	SFMBT1	0.72	4.3	0.33	3.06e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.82	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.5	5.47	0.41	1.81e-7	Major depressive disorder;
PAAD	cis	rs2526932	0.967	rs2803959	chr14:73080618	T/C	cg13588403	chr14:73209128	DPF3	0.45	5.62	0.41	8.98e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg20435097	chr10:126320824	FAM53B	-0.48	-4.64	-0.35	7.58e-6	Cocaine dependence;
PAAD	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg11995313	chr8:8860691	ERI1	0.51	5.14	0.38	8.39e-7	Joint mobility (Beighton score);
PAAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.03	0.38	1.36e-6	Childhood ear infection;
PAAD	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-5.41	-0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg23033748	chr14:75592666	NEK9	0.4	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg05890377	chr2:74357713	NA	0.77	7.53	0.52	4.18e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-6.03	-0.44	1.2e-8	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22633941	chr12:113796271	PLBD2	-0.72	-7.73	-0.53	1.34e-12	Smoking initiation;
PAAD	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.4	0.4	2.49e-7	Heart rate;
PAAD	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.4	-0.34	2e-5	Triglycerides;
PAAD	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11890956	chr21:40555474	PSMG1	-0.55	-5.63	-0.42	8.35e-8	Menarche (age at onset);
PAAD	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg15737290	chr11:93063684	CCDC67	0.66	5.66	0.42	7.24e-8	Pulmonary function decline;
PAAD	cis	rs2092319	0.649	rs1971442	chr1:26031014	G/T	cg02327719	chr1:26185386	C1orf135	-0.83	-4.49	-0.34	1.37e-5	Nose morphology;
PAAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg19052272	chr2:3704530	ALLC	-0.59	-6.7	-0.48	3.74e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.51	-6.93	-0.49	1.13e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22482690	chr17:47019901	SNF8	-0.49	-5.26	-0.39	4.9e-7	Type 2 diabetes;
PAAD	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs577948	0.770	rs488062	chr11:122050913	A/G	cg10262710	chr11:122074011	LOC399959	0.47	5.28	0.39	4.46e-7	Myopia (pathological);
PAAD	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.35	0.56	4.02e-14	Hypertriglyceridemia;
PAAD	cis	rs10905065	0.931	rs2497	chr10:5807608	A/G	cg11519256	chr10:5708881	ASB13	-0.53	-4.51	-0.34	1.3e-5	Menopause (age at onset);
PAAD	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.26	0.39	4.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4740619	0.905	rs10962099	chr9:15611443	A/G	cg14451791	chr9:16040625	NA	-0.37	-4.25	-0.33	3.67e-5	Body mass index;
PAAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.5	4.56	0.35	1.03e-5	IgG glycosylation;
PAAD	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.65	-6.08	-0.44	9.31e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8070740	0.786	rs12761	chr17:5326145	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.74	0.36	4.84e-6	Menopause (age at onset);
PAAD	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs13380717	0.657	rs12928641	chr16:86915098	C/T	cg16630791	chr16:86543538	FOXF1	0.54	4.34	0.33	2.55e-5	Sepsis in extremely premature infants;
PAAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.41	-4.48	-0.34	1.44e-5	Aortic root size;
PAAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.44	-5.14	-0.38	8.32e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg23752985	chr2:85803571	VAMP8	-0.54	-6.19	-0.45	5.45e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Cannabis dependence symptom count;
PAAD	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs11167764	0.945	rs891985	chr5:141466066	C/G	cg23435118	chr5:141488016	NDFIP1	-0.52	-5.05	-0.38	1.23e-6	Crohn's disease;
PAAD	cis	rs2415984	0.579	rs2415999	chr14:46966224	T/C	cg14871534	chr14:47121158	RPL10L	-0.47	-4.89	-0.37	2.49e-6	Number of children ever born;
PAAD	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.66e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs757978	0.777	rs35533015	chr2:242191689	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-4.72	-0.36	5.34e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg03959625	chr15:84868606	LOC388152	0.43	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.23	0.39	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg12927641	chr6:109611667	NA	-0.45	-4.68	-0.35	6.39e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs258892	0.895	rs13170247	chr5:72069684	A/G	cg21869765	chr5:72125136	TNPO1	-0.79	-5.28	-0.39	4.39e-7	Small cell lung carcinoma;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.61	4.52	0.34	1.23e-5	Neuroblastoma;
PAAD	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.48	5.44	0.4	2.13e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs16975963	0.644	rs112666969	chr19:38047645	G/A	cg14218481	chr19:38281219	NA	0.42	4.51	0.34	1.28e-5	Longevity;
PAAD	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.56	-5.41	-0.4	2.46e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.95	0.59	1.16e-15	Menopause (age at onset);
PAAD	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	1.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Body mass index;
PAAD	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg02404636	chr22:31891804	SFI1	0.61	5.51	0.41	1.47e-7	Colorectal cancer;
PAAD	cis	rs30380	1.000	rs27529	chr5:96126308	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.42	4.47	0.34	1.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg27631724	chr1:11040367	C1orf127	0.52	6.38	0.46	1.99e-9	Ewing sarcoma;
PAAD	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.55	-0.41	1.25e-7	Response to antipsychotic treatment;
PAAD	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.27	19.88	0.85	4.06e-44	IgG glycosylation;
PAAD	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs859767	0.741	rs35599954	chr2:135392481	T/C	cg12500956	chr2:135428796	TMEM163	-0.32	-4.58	-0.35	9.71e-6	Neuroticism;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.85	7.22	0.51	2.39e-11	Alzheimer's disease;
PAAD	cis	rs741702	0.928	rs10451496	chr19:13017876	C/T	cg15585409	chr19:12750806	NA	0.48	4.37	0.33	2.25e-5	Red blood cell traits;
PAAD	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.48	-6.53	-0.47	9.29e-10	Panic disorder;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08449448	chr8:58056501	NA	0.51	4.7	0.36	5.82e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.57e-7	Bladder cancer;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg22815214	chr1:201083145	CACNA1S	0.67	6.98	0.49	8.38e-11	Permanent tooth development;
PAAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9815354	1.000	rs9869282	chr3:41756064	A/G	cg03022575	chr3:42003672	ULK4	0.77	5.55	0.41	1.25e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.08	0.59	5.52e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs16882447	0.641	rs6871446	chr5:53496587	T/C	cg06461071	chr5:53490839	ARL15	0.45	4.65	0.35	7.08e-6	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.55	-5.34	-0.4	3.27e-7	Testicular germ cell tumor;
PAAD	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg01942863	chr7:99769432	GPC2	0.5	4.71	0.36	5.57e-6	Coronary artery disease;
PAAD	trans	rs2309322	0.622	rs2309319	chr4:181239313	C/T	cg24124977	chr17:78010277	CCDC40;TBC1D16	-0.79	-6.29	-0.45	3.18e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4845552	0.717	rs6672390	chr1:153466704	G/T	cg15998505	chr1:153479701	NA	0.48	4.32	0.33	2.85e-5	Hippocampal atrophy;
PAAD	trans	rs687432	0.688	rs12788387	chr11:57893347	A/C	cg16052390	chr3:100428147	TFG	-0.6	-6.3	-0.46	3.05e-9	Parkinson's disease;
PAAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg10864074	chr7:100318194	EPO	-0.46	-4.36	-0.33	2.37e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11809207	0.719	rs4659415	chr1:26580790	C/T	cg00147160	chr1:26503991	CNKSR1	0.44	4.71	0.36	5.56e-6	Height;
PAAD	cis	rs17266958	1.000	rs62574467	chr9:83249264	T/C	cg13911576	chr9:84174038	NA	0.8	4.26	0.33	3.63e-5	Preschool internalizing problems;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.54	5.33	0.4	3.41e-7	Testicular germ cell tumor;
PAAD	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.07	0.63	1.4e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.59	-0.41	1.05e-7	Total body bone mineral density;
PAAD	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg02574844	chr11:5959923	NA	-0.56	-5.69	-0.42	6.27e-8	DNA methylation (variation);
PAAD	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-4.81	-0.36	3.55e-6	Bipolar disorder;
PAAD	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.69	5.74	0.42	4.93e-8	Common traits (Other);
PAAD	cis	rs12476592	0.571	rs68183503	chr2:63802888	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.09	8.53	0.57	1.37e-14	Vitiligo;
PAAD	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.27	19.35	0.84	7.73e-43	IgG glycosylation;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.63	-5.79	-0.43	3.85e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.73	-7.91	-0.54	5.06e-13	Facial morphology (factor 20);
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.17	-0.39	7.26e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.78	9.31	0.6	1.37e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.63	-6.24	-0.45	4.16e-9	Iron status biomarkers;
PAAD	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.73	6.44	0.46	1.5e-9	Breast cancer;
PAAD	cis	rs7011049	1.000	rs72648410	chr8:53859225	G/A	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23933339	chr15:57731055	CGNL1	0.55	6.58	0.47	7.19e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.75	-0.53	1.24e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.22	17.17	0.81	2.1e-37	Schizophrenia;
PAAD	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	4.74	0.36	4.87e-6	Skin pigmentation;
PAAD	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.62	4.38	0.33	2.2e-5	Depression;
PAAD	cis	rs7692976	0.503	rs11569100	chr4:110921374	T/C	cg06981781	chr4:110842888	EGF	-0.41	-4.6	-0.35	8.73e-6	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs12935418	0.583	rs2549841	chr16:81023572	C/T	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.54	5.12	0.38	9.24e-7	Schizophrenia;
PAAD	cis	rs76419734	0.558	rs59936741	chr4:106518916	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	4.39	0.34	2.07e-5	Post bronchodilator FEV1;
PAAD	cis	rs41311933	1.000	rs41311867	chr9:123753600	G/T	cg13567360	chr9:123745713	C5	-0.73	-4.63	-0.35	7.63e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.64	4.33	0.33	2.73e-5	Vitiligo;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.08	-0.44	9.13e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.75	-0.53	1.2e-12	HDL cholesterol;
PAAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg21130718	chr4:1044621	NA	0.57	4.81	0.36	3.53e-6	Recombination rate (females);
PAAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.59	6.32	0.46	2.72e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-4.95	-0.37	1.96e-6	Blood metabolite levels;
PAAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4917300	0.606	rs4917291	chr8:143115093	A/G	cg26003909	chr8:143102224	NA	-0.32	-4.54	-0.35	1.15e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.56	4.7	0.36	5.91e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs17407555	0.683	rs4697999	chr4:10274934	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	4.63	0.35	7.66e-6	Schizophrenia (age at onset);
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.5	4.89	0.37	2.56e-6	Glycated hemoglobin levels;
PAAD	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg16898833	chr6:26189333	HIST1H4D	0.86	4.8	0.36	3.74e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10929159	0.964	rs11692136	chr2:236936377	A/G	cg14226755	chr2:236923322	AGAP1	0.29	4.71	0.36	5.63e-6	Parkinson's disease;
PAAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg25833597	chr17:30823145	MYO1D	0.48	4.63	0.35	7.93e-6	Schizophrenia;
PAAD	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.21	0.6	2.47e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.54	-5.76	-0.42	4.57e-8	Testicular germ cell tumor;
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-4.42	-0.34	1.84e-5	Schizophrenia;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.67	-5.75	-0.42	4.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.41	-0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16841119	chr11:65743851	SART1	0.68	7.34	0.51	1.18e-11	Smoking initiation;
PAAD	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg09659197	chr4:152720779	NA	0.46	6.1	0.44	8.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.57	5.89	0.43	2.34e-8	Anxiety disorder;
PAAD	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg08886695	chr4:3369023	RGS12	-0.5	-4.83	-0.36	3.33e-6	Mean platelet volume;
PAAD	cis	rs3809060	0.959	rs2301250	chr11:32458219	C/T	cg27259320	chr11:32460587	WIT1	0.34	4.42	0.34	1.9e-5	Inguinal hernia;
PAAD	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2790216	1.000	rs2440849	chr10:60002164	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg02462569	chr6:150064036	NUP43	-0.44	-4.87	-0.37	2.81e-6	Lung cancer;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.98	-0.44	1.54e-8	Cystic fibrosis severity;
PAAD	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.65	-6.22	-0.45	4.6e-9	Cognitive function;
PAAD	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.75	-7.15	-0.5	3.32e-11	Retinal vascular caliber;
PAAD	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.75	-0.36	4.7e-6	Dilated cardiomyopathy;
PAAD	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg07395648	chr5:131743802	NA	-0.57	-5.11	-0.38	9.57e-7	Breast cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23002008	chr8:17600575	MTUS1	-0.66	-6.29	-0.45	3.15e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.79	9.04	0.59	6.98e-16	Lung cancer;
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	4.64	0.35	7.36e-6	Lymphocyte counts;
PAAD	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.61	0.35	8.55e-6	Schizophrenia;
PAAD	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg08992911	chr2:238395768	MLPH	0.61	5.33	0.4	3.5e-7	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18271581	chr22:34047559	LARGE	-0.62	-6.44	-0.46	1.48e-9	Obesity-related traits;
PAAD	cis	rs2790216	1.000	rs2653504	chr10:59964042	C/T	cg20442379	chr10:60024634	IPMK	-0.57	-4.32	-0.33	2.77e-5	Inflammatory bowel disease;
PAAD	cis	rs7873102	0.580	rs4637937	chr9:37965816	T/C	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs35855737	0.779	rs35557878	chr3:65573858	G/A	cg07071417	chr3:65365250	MAGI1	-0.67	-4.42	-0.34	1.88e-5	Neuroticism;
PAAD	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs3026101	0.671	rs55662604	chr17:5297457	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg14926445	chr8:58193284	C8orf71	-0.72	-5.85	-0.43	2.91e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.81	-8.92	-0.59	1.38e-15	Prostate cancer;
PAAD	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg14092571	chr14:90743983	NA	-0.52	-5.02	-0.38	1.41e-6	Mortality in heart failure;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg15181151	chr6:150070149	PCMT1	0.56	6.04	0.44	1.12e-8	Lung cancer;
PAAD	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg18183817	chr3:13665008	FBLN2	-0.38	-4.26	-0.33	3.53e-5	QRS complex (12-leadsum);
PAAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-9.37	-0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs7180079	1.000	rs62021590	chr15:64521349	A/T	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.83	8.95	0.59	1.15e-15	Prudent dietary pattern;
PAAD	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.17e-5	Life satisfaction;
PAAD	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.48	-4.35	-0.33	2.5e-5	Tuberculosis;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.32	-0.33	2.8e-5	Height;
PAAD	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs7584330	0.554	rs3751106	chr2:238428418	G/A	cg08992911	chr2:238395768	MLPH	0.59	5.15	0.39	7.92e-7	Prostate cancer;
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg02555727	chr12:129281546	SLC15A4	0.44	4.62	0.35	8.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-8.42	-0.56	2.6e-14	Colorectal cancer;
PAAD	cis	rs4936891	0.599	rs729775	chr11:123910401	C/A	cg22125253	chr11:123886957	OR10G4	-0.43	-4.54	-0.35	1.16e-5	Male fertility;
PAAD	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs2882667	0.658	rs311592	chr5:138070195	T/C	cg09476006	chr5:138032270	NA	0.47	6.16	0.45	6.26e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.38	-0.33	2.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg27411982	chr8:10470053	RP1L1	-0.48	-5.35	-0.4	3.16e-7	Systolic blood pressure;
PAAD	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg03959625	chr15:84868606	LOC388152	-0.5	-4.82	-0.36	3.42e-6	P wave terminal force;
PAAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.65	0.35	7.12e-6	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.74	0.62	1e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg17514665	chr17:1657533	SERPINF2	0.65	6.03	0.44	1.18e-8	Serum albumin level;
PAAD	cis	rs4455778	0.500	rs10224270	chr7:49041354	T/C	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg25456477	chr12:86230367	RASSF9	0.49	4.42	0.34	1.87e-5	Major depressive disorder;
PAAD	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.83	7.74	0.53	1.31e-12	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.51	4.75	0.36	4.67e-6	Height;
PAAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.38	-0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.89	6.35	0.46	2.4e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.72	7.88	0.54	5.79e-13	Schizophrenia;
PAAD	cis	rs5752326	0.510	rs739291	chr22:26877539	C/T	cg21431832	chr22:26875652	HPS4	-0.61	-4.32	-0.33	2.81e-5	Ischemic stroke;
PAAD	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg26384229	chr12:38710491	ALG10B	0.7	7.26	0.51	1.87e-11	Morning vs. evening chronotype;
PAAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg01852476	chr1:2232063	SKI	-0.27	-4.41	-0.34	1.94e-5	Ulcerative colitis;
PAAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg06873352	chr17:61820015	STRADA	-0.56	-5.84	-0.43	3.13e-8	Height;
PAAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg26939375	chr7:64535504	NA	-0.72	-8.14	-0.55	1.36e-13	Calcium levels;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.75	0.58	3.89e-15	Alzheimer's disease;
PAAD	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.52	-5.21	-0.39	5.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14022322	chr14:104206702	PPP1R13B	0.59	6.56	0.47	7.85e-10	Body fat percentage;
PAAD	cis	rs4713118	0.500	rs9461434	chr6:28102465	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.42	4.31	0.33	2.9e-5	Parkinson's disease;
PAAD	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.46	-7.48	-0.52	5.62e-12	Mean corpuscular volume;
PAAD	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg12017631	chr7:1980892	MAD1L1	-0.45	-4.25	-0.33	3.67e-5	Neuroticism;
PAAD	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg11764359	chr7:65958608	NA	0.49	5.06	0.38	1.21e-6	Aortic root size;
PAAD	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.63	-5.41	-0.4	2.4e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.72	7.06	0.5	5.6e-11	White matter hyperintensity burden;
PAAD	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs2997447	0.739	rs60141220	chr1:26395741	G/A	cg24519413	chr1:26490540	NA	0.51	4.89	0.37	2.56e-6	QRS complex (12-leadsum);
PAAD	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.04	0.44	1.13e-8	Colorectal cancer;
PAAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-4.42	-0.34	1.86e-5	Height;
PAAD	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.77	7.85	0.54	6.86e-13	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	5.49	0.41	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.64	-8.21	-0.55	9.01e-14	Body mass index;
PAAD	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.6	0.57	9.26e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.84	-9.95	-0.63	2.86e-18	Monocyte percentage of white cells;
PAAD	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.54	-0.41	1.32e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10121009	0.635	rs7855761	chr9:35333127	C/A	cg11846315	chr9:35647073	NA	-0.5	-4.55	-0.35	1.09e-5	Parkinson's disease;
PAAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.6	0.35	8.89e-6	Breast cancer;
PAAD	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.55	5.49	0.41	1.67e-7	Temperament;
PAAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	6.17	0.45	6e-9	Initial pursuit acceleration;
PAAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.32e-10	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08656222	chr5:180688266	TRIM52	0.61	6.64	0.47	5.15e-10	Myopia (pathological);
PAAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.8	-4.71	-0.36	5.48e-6	Skin colour saturation;
PAAD	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10991814	1.000	rs77983835	chr9:93956086	C/T	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.38	-0.4	2.75e-7	Vitamin D levels;
PAAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.73	8.7	0.58	4.99e-15	Total body bone mineral density;
PAAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.55	5.95	0.43	1.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7301016	0.802	rs73139054	chr12:62842227	T/C	cg11441379	chr12:63026424	NA	0.83	5.7	0.42	5.92e-8	IgG glycosylation;
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.79	0.58	2.98e-15	Lung cancer;
PAAD	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.23	-15.48	-0.78	4.67e-33	Ulcerative colitis;
PAAD	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.32	0.68	6.15e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15186042	chr10:81965490	ANXA11	-0.48	-4.42	-0.34	1.83e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg10547527	chr2:198650123	BOLL	-0.73	-5.03	-0.38	1.34e-6	Ulcerative colitis;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.84e-19	Coronary artery disease;
PAAD	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.53	-6.33	-0.46	2.59e-9	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.65	8.14	0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1930961	1.000	rs6004675	chr22:25889385	A/C	cg07493324	chr22:26857165	HPS4	0.73	4.43	0.34	1.79e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs740474	0.569	rs9324851	chr5:140884527	A/G	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.51	6.28	0.45	3.45e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7561273	0.717	rs35933493	chr2:24264991	C/G	cg04809136	chr2:24300158	SF3B14	-0.47	-5.19	-0.39	6.63e-7	Quantitative traits;
PAAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.86	-0.49	1.63e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.51	-0.34	1.31e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg01798341	chr17:80842262	TBCD	0.43	4.57	0.35	9.84e-6	Breast cancer;
PAAD	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06850241	chr22:41845214	NA	-0.64	-5.7	-0.42	5.92e-8	Vitiligo;
PAAD	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg03615921	chr16:89375284	ANKRD11	-0.69	-4.44	-0.34	1.75e-5	Joint mobility (Beighton score);
PAAD	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	4.18e-17	IgG glycosylation;
PAAD	cis	rs7678296	0.764	rs1426408	chr4:37183131	G/C	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.47	4.67	0.35	6.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-4.33	-0.33	2.73e-5	Neuroticism;
PAAD	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs67981189	0.529	rs2810097	chr14:71434114	C/T	cg15910301	chr14:71632612	NA	-0.39	-4.31	-0.33	2.89e-5	Schizophrenia;
PAAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	6.78	0.48	2.56e-10	Coronary artery disease;
PAAD	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.4	-8.64	-0.57	7.15e-15	Mean corpuscular volume;
PAAD	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.68	6.55	0.47	8.51e-10	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	cis	rs1419980	0.730	rs73256880	chr12:7740176	A/C	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.69	8.26	0.56	6.55e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23666278	chr2:171785822	GORASP2	0.58	6.86	0.49	1.63e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg26939375	chr7:64535504	NA	-0.76	-9.17	-0.6	3.06e-16	Aortic root size;
PAAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	1.1	12.23	0.7	2.25e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.29	-0.45	3.14e-9	Bone mineral density;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19231082	chr3:119217133	C3orf1	0.55	6.6	0.47	6.59e-10	Immature fraction of reticulocytes;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs7651511	1.000	rs7651511	chr3:141231932	G/A	cg25967872	chr3:141205623	RASA2	0.48	4.36	0.33	2.41e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs4908768	0.501	rs7530745	chr1:8557691	A/C	cg20416874	chr1:8611966	RERE	-0.47	-4.44	-0.34	1.73e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.54	-5.08	-0.38	1.1e-6	Blood metabolite levels;
PAAD	cis	rs6010044	0.551	rs35205773	chr22:51089716	C/G	cg00083937	chr22:51039805	MAPK8IP2	0.55	4.3	0.33	3.03e-5	Fibrinogen levels;Fibrinogen;
PAAD	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.85	-7.27	-0.51	1.76e-11	Blood pressure (smoking interaction);
PAAD	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Mean corpuscular volume;
PAAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-4.5	-0.34	1.35e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.67	7.55	0.52	3.84e-12	Resting heart rate;
PAAD	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg21479132	chr6:26055353	NA	0.76	4.96	0.37	1.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9646944	0.501	rs10176820	chr2:103054420	T/C	cg03938978	chr2:103052716	IL18RAP	0.53	4.56	0.35	1.03e-5	Blood protein levels;
PAAD	cis	rs2439831	0.681	rs884704	chr15:43691150	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	6.06	0.44	1.05e-8	Lung cancer in ever smokers;
PAAD	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.57	-6.51	-0.47	1.03e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs3812111	0.506	rs17582201	chr6:116567048	T/C	cg05304507	chr6:116381966	FRK	-0.26	-4.53	-0.35	1.16e-5	Age-related macular degeneration;
PAAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.29	0.39	4.18e-7	Aortic root size;
PAAD	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.46	-6.28	-0.45	3.41e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.64	6.12	0.44	7.48e-9	Blood metabolite levels;
PAAD	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.69	7.56	0.52	3.49e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15447669	chr2:234160727	ATG16L1	0.64	7.39	0.51	8.93e-12	Metabolite levels  (X-11787);
PAAD	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.83	9.13	0.6	3.88e-16	Height;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.24	0.56	7.43e-14	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07478893	chr8:106406412	ZFPM2	0.54	6.39	0.46	1.92e-9	Myopia (pathological);
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.92	7.66	0.53	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66530629	0.834	rs11249171	chr1:25073571	A/C	cg22509179	chr1:25234806	RUNX3	-0.5	-4.55	-0.35	1.09e-5	Plateletcrit;
PAAD	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.53	0.41	1.38e-7	Total body bone mineral density;
PAAD	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.49	4.59	0.35	9.29e-6	Inflammatory skin disease;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18099408	chr3:52552593	STAB1	-0.51	-5.79	-0.43	3.92e-8	Electroencephalogram traits;
PAAD	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	4.7	0.36	5.68e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Androgen levels;
PAAD	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.59	5.53	0.41	1.34e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.02	-0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.5	-0.57	1.64e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9815354	0.638	rs73075241	chr3:42058045	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.15	0.45	6.49e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03376183	chr17:61699771	MAP3K3	-0.67	-6.43	-0.46	1.53e-9	Lung cancer in ever smokers;
PAAD	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg09226986	chr6:160852328	SLC22A3	-0.45	-4.26	-0.33	3.51e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.49	0.47	1.15e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15380115	chr2:133430560	LYPD1;NCKAP5	0.6	6.5	0.47	1.08e-9	Smoking initiation;
PAAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg03808351	chr9:123631620	PHF19	0.43	4.62	0.35	8.25e-6	Rheumatoid arthritis;
PAAD	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg11459648	chr5:138714337	SLC23A1	-0.63	-5.8	-0.43	3.69e-8	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.66	5.38	0.4	2.82e-7	Obesity (extreme);
PAAD	cis	rs6088813	1.000	rs4911496	chr20:33972053	A/G	cg14752227	chr20:34000481	UQCC	0.52	5.2	0.39	6.47e-7	Height;
PAAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.75	8.6	0.57	9.19e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg24296786	chr1:45957014	TESK2	0.66	7.35	0.51	1.16e-11	High light scatter reticulocyte count;
PAAD	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.25	19.14	0.84	2.55e-42	IgG glycosylation;
PAAD	cis	rs16944613	0.510	rs17180057	chr15:91155834	G/A	cg15547629	chr15:90437138	AP3S2	-0.5	-4.28	-0.33	3.28e-5	Colorectal cancer;
PAAD	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.48	5.1	0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.66	-4.82	-0.36	3.43e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.2	-12.45	-0.71	5.74e-25	Platelet count;
PAAD	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.82	-0.54	8.1e-13	Colorectal cancer;
PAAD	cis	rs3106136	0.678	rs61056400	chr4:95282376	C/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.71	7.69	0.53	1.72e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7168592	1.000	rs56132489	chr15:101734162	C/T	cg24254196	chr15:101719523	CHSY1	-0.65	-4.64	-0.35	7.4e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.86	10.84	0.66	1.22e-20	Height;
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.63	6.59	0.47	6.9e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.16e-8	Vitiligo;
PAAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg03538708	chr1:25844672	NA	-0.51	-5.29	-0.39	4.13e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg22162314	chr17:61951766	CSH2	0.53	5.24	0.39	5.35e-7	Height;
PAAD	cis	rs16975963	0.644	rs35205379	chr19:38176842	C/T	cg08679971	chr19:38281047	NA	-0.47	-4.6	-0.35	8.98e-6	Longevity;
PAAD	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg12560992	chr17:57184187	TRIM37	0.62	4.81	0.36	3.67e-6	Vitamin D levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12912258	chr5:131630175	SLC22A4	0.56	6.39	0.46	1.91e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg16810054	chr20:33298113	TP53INP2	0.59	4.62	0.35	8.17e-6	Neuroticism;
PAAD	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg27411982	chr8:10470053	RP1L1	0.47	5.13	0.38	8.88e-7	Retinal vascular caliber;
PAAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg03676636	chr4:99064102	C4orf37	-0.26	-4.45	-0.34	1.66e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.23	0.6	2.16e-16	Colorectal cancer;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Resting heart rate;
PAAD	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.9	6.37	0.46	2.15e-9	Pulse pressure;
PAAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.69	7.09	0.5	4.85e-11	Morning vs. evening chronotype;
PAAD	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.75	-8.01	-0.54	2.84e-13	Migraine;Coronary artery disease;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.93	-0.37	2.15e-6	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.49	-6.06	-0.44	1.05e-8	Lung cancer;
PAAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg13468214	chr4:1046988	NA	-0.57	-5.36	-0.4	2.98e-7	Recombination rate (females);
PAAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-1.37	-11.0	-0.67	4.65e-21	Schizophrenia;
PAAD	trans	rs4290173	0.526	rs981404	chr10:52705663	T/A	cg20234910	chr13:105238499	NA	0.59	6.56	0.47	8.07e-10	Narcolepsy with cataplexy;
PAAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.45	5.59	0.41	1.05e-7	Childhood ear infection;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.91	0.37	2.36e-6	Platelet count;
PAAD	cis	rs35740288	0.770	rs11632750	chr15:86215614	A/C	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.46	-4.41	-0.34	1.95e-5	Menarche (age at onset);
PAAD	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg25620797	chr2:55921863	PNPT1	-0.51	-4.84	-0.37	3.19e-6	Metabolic syndrome;
PAAD	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08109568	chr15:31115862	NA	-0.72	-8.22	-0.55	8.52e-14	Huntington's disease progression;
PAAD	cis	rs11955175	1.000	rs11953977	chr5:40674690	G/C	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9913156	0.748	rs7217849	chr17:4562165	G/C	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.35e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.88	11.2	0.67	1.31e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.56	5.58	0.41	1.06e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs9469890	0.604	rs78871484	chr6:34503677	T/C	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg00262122	chr8:11665843	FDFT1	-0.56	-5.14	-0.39	8.15e-7	Neuroticism;
PAAD	cis	rs9814567	0.574	rs4974488	chr3:134168137	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.52	-0.41	1.4e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg17775713	chr3:133465469	TF	0.48	5.45	0.4	2.04e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs2882667	0.728	rs10068786	chr5:138276944	C/T	cg09476006	chr5:138032270	NA	0.42	5.14	0.38	8.33e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13198984	chr17:80129470	CCDC57	0.44	5.43	0.4	2.18e-7	Life satisfaction;
PAAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.68	5.42	0.4	2.27e-7	Plateletcrit;
PAAD	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.86	6.64	0.47	5.22e-10	Axial length;
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg03983476	chr2:10830698	NOL10	-0.59	-5.85	-0.43	2.89e-8	Prostate cancer;
PAAD	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg23912435	chr1:150601613	ENSA	-0.5	-4.53	-0.34	1.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-7.39	-0.51	9.1e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.46	4.76	0.36	4.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.47	-5.32	-0.4	3.64e-7	Longevity;Endometriosis;
PAAD	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.61	-5.76	-0.42	4.62e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs71636778	0.631	rs71636788	chr1:27186485	T/C	cg12203394	chr1:27248618	NUDC	0.63	4.49	0.34	1.37e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.64	-6.36	-0.46	2.2e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg09876464	chr15:85330779	ZNF592	0.44	4.37	0.33	2.28e-5	P wave terminal force;
PAAD	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.28	-0.51	1.64e-11	Chronic sinus infection;
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.89	-8.19	-0.55	9.74e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.64	-0.42	8.16e-8	Psoriasis;
PAAD	cis	rs1190596	0.732	rs7156564	chr14:102558588	A/G	cg23904247	chr14:102554826	HSP90AA1	-0.5	-5.48	-0.41	1.69e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10490626	0.710	rs34206258	chr2:118624964	T/C	cg19263433	chr2:118618151	NA	-0.74	-4.92	-0.37	2.23e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg14515779	chr1:101123966	NA	-0.42	-4.43	-0.34	1.81e-5	Breast cancer;
PAAD	cis	rs7631605	0.623	rs13421	chr3:36985879	T/C	cg17445812	chr3:36986805	TRANK1	0.31	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg13047869	chr3:10149882	C3orf24	0.85	7.38	0.51	9.65e-12	Alzheimer's disease;
PAAD	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.7e-13	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2718812	1.000	rs2718813	chr3:133399212	A/G	cg11941060	chr3:133502564	NA	0.47	4.98	0.37	1.73e-6	Iron status biomarkers;
PAAD	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.53	5.65	0.42	7.63e-8	Fibrinogen levels;
PAAD	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.5	0.61	4.23e-17	Cognitive test performance;
PAAD	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.67	-5.91	-0.43	2.15e-8	Serum sulfate level;
PAAD	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg12935359	chr14:103987150	CKB	-0.72	-8.27	-0.56	6.14e-14	Body mass index;
PAAD	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.86	-6.56	-0.47	7.94e-10	Coronary artery calcification;
PAAD	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg00738919	chr7:1100172	C7orf50	0.67	5.18	0.39	7.09e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62229266	0.659	rs2835258	chr21:37424365	G/A	cg08632701	chr21:37451849	NA	-0.63	-6.91	-0.49	1.27e-10	Mitral valve prolapse;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.88	5.83	0.43	3.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13560548	chr3:10150139	C3orf24	0.56	5.04	0.38	1.28e-6	Alzheimer's disease;
PAAD	cis	rs2899832	0.714	rs10131625	chr14:35760888	T/G	cg09327582	chr14:35236912	BAZ1A	0.6	4.68	0.35	6.26e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg03983715	chr16:68378420	PRMT7	-0.95	-6.73	-0.48	3.23e-10	Schizophrenia;
PAAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.62	5.94	0.43	1.9e-8	Monocyte count;
PAAD	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.56	5.54	0.41	1.28e-7	Breast cancer;
PAAD	cis	rs4750440	0.706	rs4748065	chr10:14019876	G/T	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.44e-13	Eotaxin levels;
PAAD	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6688613	1.000	rs7533688	chr1:166944123	G/A	cg07049167	chr1:166818506	POGK	0.48	4.79	0.36	3.92e-6	Refractive astigmatism;
PAAD	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg14515779	chr1:101123966	NA	-0.52	-6.58	-0.47	7.35e-10	Monocyte count;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg12288994	chr5:1860383	NA	0.76	9.71	0.62	1.21e-17	Cardiovascular disease risk factors;
PAAD	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.58	5.93	0.43	1.92e-8	Systolic blood pressure;
PAAD	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.8	5.53	0.41	1.35e-7	Anti-saccade response;
PAAD	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.49	5.15	0.39	8.14e-7	Mean corpuscular volume;
PAAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.97	12.81	0.72	6.2e-26	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs9462846	1.000	rs2395939	chr6:42851396	G/A	cg13397359	chr6:42928475	GNMT	0.62	4.58	0.35	9.52e-6	Blood protein levels;
PAAD	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg00262122	chr8:11665843	FDFT1	0.5	4.35	0.33	2.44e-5	Retinal vascular caliber;
PAAD	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	6.66	0.48	4.81e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.41e-7	Monocyte percentage of white cells;
PAAD	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.74	4.52	0.34	1.24e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs600550	0.588	rs11230239	chr11:60072149	C/T	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.06	-0.38	1.2e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.51	5.28	0.39	4.34e-7	Daytime sleep phenotypes;
PAAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg27121462	chr16:89883253	FANCA	0.48	5.03	0.38	1.34e-6	Vitiligo;
PAAD	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.67	-6.55	-0.47	8.38e-10	Pubertal anthropometrics;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg19223190	chr17:80058835	NA	0.52	5.39	0.4	2.67e-7	Life satisfaction;
PAAD	cis	rs10497721	1.000	rs58354071	chr2:192938431	T/C	cg22795891	chr2:192543908	OBFC2A	-0.58	-4.45	-0.34	1.64e-5	Diabetes (incident);
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg21285383	chr16:89894308	SPIRE2	0.35	4.51	0.34	1.28e-5	Schizophrenia;
PAAD	cis	rs11615916	0.790	rs17659468	chr12:62670296	A/G	cg11441379	chr12:63026424	NA	0.69	4.57	0.35	1.02e-5	Pulmonary function decline;
PAAD	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	6.63	0.47	5.54e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs77741769	0.571	rs11065324	chr12:121346795	C/G	cg02419362	chr12:121203948	SPPL3	-0.56	-6.36	-0.46	2.24e-9	Mean corpuscular volume;
PAAD	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs9815354	1.000	rs1716676	chr3:41903208	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.75	-6.37	-0.46	2.15e-9	Blood protein levels;
PAAD	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.58	-6.23	-0.45	4.47e-9	Pelvic organ prolapse;
PAAD	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg14926445	chr8:58193284	C8orf71	0.64	4.82	0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg12568669	chr8:11666485	FDFT1	0.27	4.4	0.34	2.05e-5	Neuroticism;
PAAD	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.75	8.71	0.58	4.93e-15	Lung function (FVC);
PAAD	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.89	0.37	2.54e-6	Ovarian reserve;
PAAD	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.43	4.78	0.36	4.15e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.45	4.34	0.33	2.54e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs7925523	0.891	rs17156244	chr11:61482395	T/G	cg12472022	chr11:61462803	DAGLA	0.59	4.6	0.35	8.83e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.49	4.93	0.37	2.09e-6	Height;
PAAD	cis	rs4727443	0.736	rs11761882	chr7:99581469	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.86	0.37	2.94e-6	Interstitial lung disease;
PAAD	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg08856118	chr10:27389908	ANKRD26	-0.4	-4.3	-0.33	3e-5	Breast cancer;
PAAD	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.21	0.45	4.75e-9	Lung cancer in ever smokers;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg27121462	chr16:89883253	FANCA	-0.9	-4.65	-0.35	7.16e-6	Skin colour saturation;
PAAD	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg16419906	chr5:132167176	NA	-0.56	-4.68	-0.35	6.4e-6	Apolipoprotein A-IV levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20274790	chr1:157111560	NA	-0.55	-6.38	-0.46	1.99e-9	Monocyte percentage of white cells;
PAAD	cis	rs11811982	0.793	rs75714085	chr1:227325816	C/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg03871329	chr12:110338662	TCHP	-0.5	-4.34	-0.33	2.62e-5	Neuroticism;
PAAD	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg08079166	chr15:68083412	MAP2K5	0.61	5.73	0.42	5.24e-8	Restless legs syndrome;
PAAD	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg26393015	chr7:128809301	NA	-0.56	-4.3	-0.33	3.05e-5	White matter hyperintensity burden;
PAAD	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs10991814	0.841	rs79219699	chr9:94028898	C/T	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.08	0.73	1.17e-26	Platelet count;
PAAD	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.09	-0.59	4.97e-16	Prostate cancer;
PAAD	cis	rs3764400	0.567	rs67345313	chr17:46302201	T/C	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg05895507	chr15:77155635	SCAPER	-0.39	-4.29	-0.33	3.11e-5	Blood metabolite levels;
PAAD	cis	rs13111989	1.000	rs871927	chr4:177548580	A/G	cg11287292	chr4:178277261	NEIL3	0.53	4.33	0.33	2.71e-5	HIV-1 viral setpoint;
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.75	-8.55	-0.57	1.22e-14	Age at first birth;
PAAD	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg05313129	chr8:58192883	C8orf71	-0.61	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs59888335	0.798	rs1877920	chr3:80506695	T/C	cg21735741	chr3:80819488	NA	0.59	5.15	0.39	7.84e-7	Schizophrenia;
PAAD	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg10820045	chr2:198174542	NA	0.48	4.88	0.37	2.66e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg21929781	chr1:2537748	MMEL1	-0.44	-4.69	-0.36	6.05e-6	Ulcerative colitis;
PAAD	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg11783602	chr8:55087084	NA	-0.48	-5.02	-0.38	1.41e-6	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6594713	0.642	rs13171630	chr5:112837037	C/T	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.16	15.17	0.78	3.09e-32	Type 1 diabetes nephropathy;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21636432	chr6:35887842	SRPK1	0.58	6.31	0.46	2.92e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg21130718	chr4:1044621	NA	0.54	4.6	0.35	8.76e-6	Recombination rate (females);
PAAD	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	5.34	0.4	3.32e-7	Depressive symptoms;
PAAD	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.61	-8.05	-0.55	2.28e-13	Lewy body disease;
PAAD	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg12757816	chr2:10669957	NA	-0.44	-4.51	-0.34	1.3e-5	Prostate cancer;
PAAD	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.62	-5.66	-0.42	7.44e-8	Mean corpuscular volume;
PAAD	cis	rs1957429	0.522	rs57319601	chr14:65415743	C/T	cg23373153	chr14:65346875	NA	-1.22	-5.87	-0.43	2.64e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.67	-0.42	7.08e-8	Longevity;Endometriosis;
PAAD	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.82	-10.08	-0.63	1.28e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5756391	0.606	rs5756408	chr22:37317848	T/C	cg16356956	chr22:37317934	CSF2RB	0.42	4.91	0.37	2.31e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.62	6.0	0.44	1.42e-8	Total body bone mineral density;
PAAD	cis	rs2221894	0.922	rs4732890	chr8:28751381	C/T	cg20212339	chr8:28908912	HMBOX1	0.49	5.14	0.38	8.38e-7	Obesity-related traits;
PAAD	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26306683	chr17:18585705	ZNF286B	0.54	5.47	0.41	1.82e-7	Educational attainment (years of education);
PAAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs329648	0.571	rs10894761	chr11:133772854	G/A	cg12362517	chr11:133800685	IGSF9B	0.61	6.56	0.47	7.78e-10	Parkinson's disease;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg01359822	chr21:40176597	ETS2	0.31	5.02	0.38	1.44e-6	Non-small cell lung cancer (survival);
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.53	0.57	1.38e-14	Lung cancer;
PAAD	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18261571	chr7:94921347	PPP1R9A	0.69	6.31	0.46	2.91e-9	Neuroticism;
PAAD	cis	rs7577696	0.962	rs7608127	chr2:32279923	C/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.59	-0.35	9.27e-6	Inflammatory biomarkers;
PAAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	1.02	11.87	0.69	2.08e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-7.85	-0.54	6.91e-13	Systemic lupus erythematosus;
PAAD	cis	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.78	-0.36	4.13e-6	Triglycerides;
PAAD	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.65	-6.44	-0.46	1.45e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.49	-5.44	-0.4	2.06e-7	Psychosis in Alzheimer's disease;
PAAD	trans	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg19414122	chr8:18896631	NA	0.5	6.31	0.46	2.97e-9	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	7.85	0.54	7e-13	Schizophrenia;
PAAD	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22633769	chr20:60982531	CABLES2	0.51	4.57	0.35	1.01e-5	Colorectal cancer;
PAAD	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Height;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.68	-8.69	-0.58	5.25e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.45	-4.51	-0.34	1.29e-5	Schizophrenia;
PAAD	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Breast cancer;
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.73	-11.54	-0.68	1.59e-22	Body mass index;
PAAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10890917	chr17:296572	FAM101B	-0.74	-7.55	-0.52	3.72e-12	Obesity-related traits;
PAAD	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.65	-0.35	7.03e-6	Breast cancer;
PAAD	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.83	0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26332535	chr17:78803184	RPTOR	-0.68	-7.13	-0.5	3.75e-11	Obesity-related traits;
PAAD	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.12	-0.44	7.79e-9	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs58521262	0.530	rs289346	chr19:23148000	T/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg07841815	chr7:100318223	EPO	0.44	4.85	0.37	3.07e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg19337854	chr7:99768885	GPC2	0.48	4.4	0.34	2.07e-5	Platelet count;
PAAD	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.9	-0.43	2.22e-8	Height;
PAAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.48	-4.41	-0.34	1.92e-5	Response to antidepressants and depression;
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.67	7.65	0.53	2.19e-12	Vitiligo;
PAAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.11	0.38	9.59e-7	Rheumatoid arthritis;
PAAD	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-1.08	-11.12	-0.67	2.1e-21	Platelet distribution width;
PAAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.85	-0.37	3.08e-6	Parkinson's disease;
PAAD	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.66	0.65	3.7e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13198984	chr17:80129470	CCDC57	0.42	5.27	0.39	4.62e-7	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	4.57	0.35	1.01e-5	Coronary artery disease;
PAAD	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.77	-9.19	-0.6	2.83e-16	White blood cell count (basophil);
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg08439880	chr3:133502540	NA	-0.44	-4.84	-0.37	3.17e-6	Iron status biomarkers;
PAAD	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg05484376	chr2:27715224	FNDC4	-0.46	-4.84	-0.37	3.22e-6	Oral cavity cancer;
PAAD	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.69	-7.51	-0.52	4.65e-12	Multiple sclerosis;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg05025164	chr4:1340916	KIAA1530	0.52	4.95	0.37	1.98e-6	Obesity-related traits;
PAAD	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.45	-4.65	-0.35	7.24e-6	Response to antidepressants in depression;
PAAD	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs988913	0.957	rs10485136	chr6:54756495	A/G	cg03513858	chr6:54763001	FAM83B	0.41	4.53	0.34	1.18e-5	Menarche (age at onset);
PAAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.65	5.69	0.42	6.42e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.32	4.94	0.37	2.06e-6	Alcohol dependence;
PAAD	cis	rs333332	0.504	rs72962889	chr3:124329748	A/G	cg01436551	chr3:125037763	ZNF148	0.72	5.19	0.39	6.52e-7	Heschl's gyrus morphology;
PAAD	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.44	0.56	2.37e-14	Corneal astigmatism;
PAAD	cis	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg20159608	chr7:32802032	NA	-0.52	-5.17	-0.39	7.3e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17676354	chr5:179224836	MGAT4B	0.65	7.73	0.53	1.34e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg15017067	chr4:17643749	FAM184B	0.45	5.38	0.4	2.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.57	5.37	0.4	2.94e-7	Type 2 diabetes;
PAAD	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	11.47	0.68	2.5e-22	Bone mineral density;
PAAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2051773	0.510	rs11024131	chr11:17056440	C/G	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.89	-9.29	-0.6	1.49e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.92	11.37	0.68	4.5e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg07599136	chr5:415885	AHRR	0.66	4.89	0.37	2.49e-6	Fat distribution (HIV);
PAAD	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg03098721	chr1:84464084	TTLL7	0.48	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg13918804	chr1:2043761	PRKCZ	-0.34	-4.5	-0.34	1.34e-5	Height;
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg05132306	chr1:1846340	CALML6	-0.43	-5.05	-0.38	1.24e-6	Body mass index;
PAAD	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05923103	chr1:51701583	RNF11	0.73	9.01	0.59	8.26e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg10534938	chr5:1868639	NA	0.49	6.38	0.46	2.02e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.6	5.3	0.39	3.99e-7	Height;
PAAD	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.78	-0.36	4.03e-6	Daytime sleep phenotypes;
PAAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.03	-0.59	7.05e-16	Caffeine consumption;
PAAD	cis	rs6988985	0.647	rs28558934	chr8:143986555	T/C	cg10324643	chr8:143916377	GML	0.42	4.87	0.37	2.75e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg23346134	chr3:49453900	TCTA	0.45	4.9	0.37	2.48e-6	Menarche (age at onset);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg02053340	chr20:49348184	PARD6B	-0.65	-6.39	-0.46	1.92e-9	Body mass index;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg22437258	chr11:111473054	SIK2	-0.63	-6.17	-0.45	5.89e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.53	-5.88	-0.43	2.51e-8	Facial morphology (factor 20);
PAAD	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg10208897	chr5:178548229	ADAMTS2	-0.51	-4.5	-0.34	1.35e-5	Pubertal anthropometrics;
PAAD	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-0.88	-9.3	-0.6	1.47e-16	Educational attainment;
PAAD	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg08390786	chr10:135334061	NA	-0.48	-4.52	-0.34	1.26e-5	Obesity-related traits;
PAAD	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg08558340	chr7:100472263	SRRT	0.52	4.6	0.35	8.71e-6	Resting heart rate;
PAAD	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg22517653	chr1:2918612	NA	-0.59	-4.86	-0.37	2.93e-6	Plateletcrit;
PAAD	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.45	-4.65	-0.35	7.31e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs939584	1.000	rs7560127	chr2:643315	T/C	cg03610516	chr2:642275	NA	0.61	5.53	0.41	1.37e-7	Body mass index;
PAAD	cis	rs16958440	1.000	rs60422392	chr18:44621473	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11245990	chr11:68621969	NA	0.4	5.19	0.39	6.58e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.53	4.69	0.36	5.96e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	trans	rs61677309	0.964	rs60652614	chr11:118168543	G/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg08648136	chr8:956695	NA	0.43	4.46	0.34	1.61e-5	Schizophrenia;
PAAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.73	6.69	0.48	4.02e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs7639513	0.545	rs9874557	chr3:12720967	A/G	cg23032965	chr3:12705835	RAF1	0.89	7.75	0.53	1.2e-12	Itch intensity from mosquito bite;
PAAD	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg18357526	chr6:26021779	HIST1H4A	0.61	4.87	0.37	2.77e-6	Homocysteine levels;
PAAD	cis	rs870825	0.655	rs6845058	chr4:185653696	G/A	cg04058563	chr4:185651563	MLF1IP	-0.88	-6.4	-0.46	1.78e-9	Blood protein levels;
PAAD	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.62	-5.48	-0.41	1.73e-7	Diastolic blood pressure;
PAAD	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.25	-0.45	3.84e-9	Alcohol dependence;
PAAD	cis	rs375066	0.901	rs451945	chr19:44408753	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.56	4.92	0.37	2.22e-6	Life satisfaction;
PAAD	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.36	7.97	0.54	3.53e-13	Corneal curvature;
PAAD	cis	rs9467603	0.800	rs1892252	chr6:25772639	C/G	cg08501292	chr6:25962987	TRIM38	-0.69	-4.65	-0.35	7.09e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.46	5.75	0.42	4.64e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg05373962	chr22:49881684	NA	-0.48	-4.79	-0.36	3.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02476533	chr19:48283760	SEPW1	0.69	7.52	0.52	4.45e-12	Smoking initiation;
PAAD	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.53	5.8	0.43	3.79e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg21130718	chr4:1044621	NA	0.54	4.6	0.35	8.76e-6	Recombination rate (females);
PAAD	cis	rs35000415	0.938	rs17339836	chr7:128681062	C/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	7.33	0.51	1.28e-11	Lymphocyte counts;
PAAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.51	-4.49	-0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.47	4.82	0.36	3.4e-6	Major depressive disorder;
PAAD	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23158103	chr7:148848205	ZNF398	-0.59	-5.77	-0.42	4.34e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1997066	0.831	rs73344334	chr10:106829818	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs77106637	0.585	rs10898870	chr11:72456218	A/C	cg04827223	chr11:72435913	ARAP1	-0.52	-5.51	-0.41	1.52e-7	Type 2 diabetes;
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.79	5.55	0.41	1.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.22e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.51	5.7	0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.48	-4.41	-0.34	1.95e-5	Red blood cell count;
PAAD	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.65	-0.35	7.19e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8054556	0.539	rs12596543	chr16:30029135	A/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.7e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.56	4.98	0.37	1.71e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.73	7.67	0.53	1.96e-12	Prostate cancer;
PAAD	cis	rs11009175	0.615	rs6481820	chr10:33299937	C/T	cg00146027	chr10:33299147	NA	-0.4	-4.87	-0.37	2.81e-6	Depression (quantitative trait);
PAAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg15571903	chr15:79123663	NA	-0.44	-5.5	-0.41	1.56e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.09	-0.5	4.81e-11	Chronic sinus infection;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.34	-0.33	2.59e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs727479	0.502	rs28757202	chr15:51503881	T/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.46	0.34	1.61e-5	Estradiol levels;
PAAD	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs73086581	1.000	rs73086597	chr20:3983571	G/A	cg02187196	chr20:3869020	PANK2	0.61	5.21	0.39	6.13e-7	Response to antidepressants in depression;
PAAD	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs931127	0.554	rs11227261	chr11:65462843	C/G	cg26668713	chr11:65405903	SIPA1	0.41	4.59	0.35	9.15e-6	Systemic lupus erythematosus;
PAAD	cis	rs939584	0.932	rs1320336	chr2:650012	G/A	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	6.5	0.47	1.1e-9	Type 2 diabetes;
PAAD	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;
PAAD	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg04165759	chr1:150448943	RPRD2	0.5	5.17	0.39	7.4e-7	Migraine;
PAAD	cis	rs10899021	1.000	rs11236193	chr11:74368307	T/C	cg25880958	chr11:74394337	NA	-0.88	-5.65	-0.42	7.87e-8	Response to metformin (IC50);
PAAD	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg10518543	chr12:38710700	ALG10B	-0.46	-4.51	-0.34	1.32e-5	Morning vs. evening chronotype;
PAAD	cis	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg21546286	chr11:48923668	NA	0.57	5.96	0.44	1.68e-8	HDL cholesterol;
PAAD	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.9	0.37	2.41e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.8	7.14	0.5	3.57e-11	Recombination rate (females);
PAAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24070123	chr6:34665156	C6orf106	0.52	6.34	0.46	2.46e-9	Immature fraction of reticulocytes;
PAAD	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6686889	1	rs6686889	chr1:25030470	C/T	cg01905478	chr1:25040257	NA	0.54	5.72	0.42	5.5e-8	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.64	-7.73	-0.53	1.36e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.49	-5.6	-0.41	9.75e-8	Blood pressure (age interaction);
PAAD	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg15571903	chr15:79123663	NA	0.39	4.75	0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs72829446	1.000	rs28362665	chr17:7460758	G/A	cg17267493	chr17:7460485	TNFSF12;TNFSF13;TNFSF12-TNFSF13	0.6	4.27	0.33	3.36e-5	Androgen levels;
PAAD	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg22089800	chr15:90895588	ZNF774	-0.58	-5.54	-0.41	1.28e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg24519413	chr1:26490540	NA	0.5	4.63	0.35	7.8e-6	Height;
PAAD	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.44	6.82	0.48	2.01e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.83	7.34	0.51	1.23e-11	Alzheimer's disease;
PAAD	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg21479132	chr6:26055353	NA	-0.93	-5.22	-0.39	5.7e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.64	-6.97	-0.49	9.17e-11	Menarche (age at onset);
PAAD	cis	rs7678555	0.540	rs7659369	chr4:120843004	C/T	cg09307838	chr4:120376055	NA	0.47	4.54	0.35	1.15e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.5	-7.22	-0.51	2.31e-11	Diastolic blood pressure;
PAAD	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg21823605	chr1:152486609	CRCT1	0.5	6.23	0.45	4.35e-9	Hair morphology;
PAAD	cis	rs9972944	0.676	rs8067129	chr17:63762984	C/T	cg07283582	chr17:63770753	CCDC46	-0.57	-6.65	-0.47	5.06e-10	Total body bone mineral density;
PAAD	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.57	5.06	0.38	1.18e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.68	7.46	0.52	6.08e-12	Mean platelet volume;
PAAD	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg15309053	chr8:964076	NA	0.56	6.36	0.46	2.21e-9	Schizophrenia;
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg20917491	chr3:195578259	NA	0.49	4.85	0.37	3e-6	Pancreatic cancer;
PAAD	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.71	8.39	0.56	3.16e-14	Lung cancer;
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Body mass index;
PAAD	cis	rs7217780	0.569	rs7226363	chr17:15234895	C/T	cg20358362	chr17:14248304	HS3ST3B1	-0.54	-4.62	-0.35	8.17e-6	Preterm birth (maternal effect);
PAAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-12.71	-0.72	1.14e-25	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73198872	chr3:128537683	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.52	-0.41	1.43e-7	Dental caries;
PAAD	cis	rs4450131	0.522	rs3781460	chr10:126342919	A/G	cg20435097	chr10:126320824	FAM53B	-0.47	-4.71	-0.36	5.63e-6	White blood cell count (basophil);
PAAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg10935138	chr17:73851978	WBP2	0.89	7.58	0.52	3.24e-12	Psoriasis;
PAAD	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.43	-4.71	-0.36	5.58e-6	Post-traumatic stress disorder;
PAAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-5.13	-0.38	8.71e-7	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06864046	chr12:89746505	DUSP6	0.63	6.9	0.49	1.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.63	7.38	0.51	9.39e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-11.72	-0.69	5.33e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7714584	1.000	rs17727568	chr5:150244688	A/G	cg22134413	chr5:150180641	NA	1.04	6.6	0.47	6.45e-10	Crohn's disease;
PAAD	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.71	7.29	0.51	1.55e-11	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.97	-0.44	1.6e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9810890	1.000	rs73198846	chr3:128505472	A/C	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.32	0.81	8.35e-38	Height;
PAAD	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg00599163	chr2:162100495	NA	-0.36	-4.39	-0.34	2.11e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	1.04	9.79	0.62	7.47e-18	Orofacial clefts;
PAAD	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-1.01	-9.61	-0.61	2.17e-17	Alcohol dependence;Nicotine use;
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.61	6.84	0.48	1.85e-10	Vitiligo;
PAAD	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.43	-4.89	-0.37	2.53e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg22029157	chr1:209979665	IRF6	0.72	6.4	0.46	1.82e-9	Coronary artery disease;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.92	-0.37	2.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.77	5.4	0.4	2.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18349281	chr19:4944398	UHRF1	-0.56	-6.37	-0.46	2.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg16766828	chr3:128327626	NA	-0.48	-6.59	-0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs10276303	0.516	rs2705612	chr7:3619763	A/C	cg24872851	chr7:4265468	SDK1	0.46	4.7	0.36	5.83e-6	Dupuytren's disease;
PAAD	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.72	-6.65	-0.47	4.94e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.28	0.68	7.81e-22	Platelet count;
PAAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg05555928	chr11:63887634	MACROD1	-0.64	-4.85	-0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.86	9.17	0.6	3.18e-16	Prudent dietary pattern;
PAAD	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-6.25	-0.45	4.03e-9	Lymphocyte counts;
PAAD	cis	rs7646881	0.812	rs6788069	chr3:158459459	C/T	cg19483011	chr3:158453295	NA	0.66	5.16	0.39	7.57e-7	Tetralogy of Fallot;
PAAD	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	6.86	0.49	1.65e-10	Multiple sclerosis;
PAAD	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.21	0.67	1.23e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg22800045	chr5:56110881	MAP3K1	0.7	5.77	0.42	4.27e-8	Coronary artery disease;
PAAD	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg16606324	chr3:10149918	C3orf24	0.61	4.67	0.35	6.58e-6	Alzheimer's disease;
PAAD	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.84	8.33	0.56	4.44e-14	Response to hepatitis C treatment;
PAAD	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg04398451	chr17:18023971	MYO15A	0.75	7.94	0.54	4.11e-13	Total body bone mineral density;
PAAD	cis	rs16975963	0.843	rs7254809	chr19:38365695	A/G	cg14218481	chr19:38281219	NA	0.43	4.49	0.34	1.42e-5	Longevity;
PAAD	cis	rs4605213	0.528	rs8076039	chr17:49323807	T/A	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.15	-0.55	1.26e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26921846	chr21:30671131	BACH1	-0.59	-6.94	-0.49	1.06e-10	Body fat percentage;
PAAD	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.59	5.55	0.41	1.23e-7	Height;
PAAD	cis	rs2290416	0.892	rs2278898	chr8:144691512	G/C	cg16316162	chr8:144660157	NAPRT1	0.91	4.46	0.34	1.58e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.908	rs117753937	chr22:32595919	C/T	cg02631450	chr22:32366979	NA	1.0	4.67	0.35	6.71e-6	Childhood ear infection;
PAAD	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.61	5.4	0.4	2.5e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs75920871	1.000	rs10892044	chr11:116766899	C/T	cg04087571	chr11:116723030	SIK3	0.41	4.3	0.33	3.01e-5	Subjective well-being;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg05313129	chr8:58192883	C8orf71	-0.67	-5.68	-0.42	6.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.83	-7.05	-0.5	5.72e-11	Gut microbiome composition (summer);
PAAD	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.29e-12	Bone mineral density;
PAAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg16205897	chr5:131564050	P4HA2	-0.46	-4.94	-0.37	2.07e-6	Blood metabolite levels;
PAAD	cis	rs8102137	0.706	rs17599450	chr19:30328753	C/T	cg27475126	chr19:30303651	CCNE1	-0.5	-5.06	-0.38	1.18e-6	Bladder cancer;
PAAD	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.81	10.39	0.64	1.88e-19	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.37	0.51	9.94e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg03128945	chr5:622914	CEP72	-0.5	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.69	-5.61	-0.41	9.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.73	-7.36	-0.51	1.1e-11	Colorectal cancer;
PAAD	cis	rs6142102	0.961	rs6088361	chr20:32557326	G/A	cg06217245	chr20:33103252	DYNLRB1	0.44	4.31	0.33	2.96e-5	Skin pigmentation;
PAAD	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-7.07	-0.5	5.37e-11	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg04154034	chr17:28927549	LRRC37B2	0.62	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg10150615	chr22:24372951	LOC391322	-0.62	-4.58	-0.35	9.62e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg14092988	chr3:52407081	DNAH1	-0.43	-5.46	-0.41	1.88e-7	Bipolar disorder;
PAAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	6.62	0.47	5.77e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.45	-6.82	-0.48	1.98e-10	Breast cancer;
PAAD	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs4455778	0.538	rs4288325	chr7:49130239	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.56	5.37	0.4	2.9e-7	Osteoporosis;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	9.81	0.62	6.77e-18	Smoking behavior;
PAAD	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.85	10.27	0.64	4.06e-19	Body mass index;
PAAD	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.31e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg21698718	chr17:80085957	CCDC57	-0.44	-4.86	-0.37	2.91e-6	Life satisfaction;
PAAD	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14769373	chr6:40998127	UNC5CL	0.54	4.81	0.36	3.65e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg17524265	chr8:144659883	NAPRT1	0.98	7.82	0.54	8.32e-13	Attention deficit hyperactivity disorder;
PAAD	cis	rs1113500	0.548	rs3853497	chr1:108657184	C/T	cg06207961	chr1:108661230	NA	0.45	4.51	0.34	1.3e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.51	5.51	0.41	1.51e-7	Testicular germ cell tumor;
PAAD	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg13207630	chr7:32358064	NA	0.76	4.25	0.33	3.68e-5	Body mass index;
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.97	0.37	1.77e-6	Vitiligo;
PAAD	cis	rs3857067	0.836	rs6815207	chr4:95051894	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-4.92	-0.37	2.18e-6	QT interval;
PAAD	cis	rs8112211	0.816	rs80248244	chr19:38841714	A/C	cg01275006	chr19:38876250	GGN	-0.64	-4.81	-0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg21995147	chr19:1064017	ABCA7	-0.58	-5.12	-0.38	9.26e-7	Alzheimer's disease (late onset);
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.75	-7.02	-0.5	6.75e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs73416724	1.000	rs79009481	chr6:43343239	T/C	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs15676	0.783	rs7858732	chr9:131563540	A/G	cg00228799	chr9:131580591	ENDOG	-0.62	-5.77	-0.42	4.24e-8	Blood metabolite levels;
PAAD	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.47	4.58	0.35	9.56e-6	Crohn's disease;
PAAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.78	-0.36	4.11e-6	Parkinson's disease;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg19264203	chr11:92714893	MTNR1B	0.42	4.85	0.37	2.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.78	-0.48	2.53e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02850689	chr1:2391347	NA	-0.41	-4.4	-0.34	2.03e-5	Schizophrenia;
PAAD	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.76	-9.61	-0.61	2.16e-17	Educational attainment;
PAAD	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.68	7.27	0.51	1.72e-11	Economic and political preferences (feminism/equality);
PAAD	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.54	5.31	0.4	3.76e-7	Corneal astigmatism;
PAAD	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.75	5.35	0.4	3.23e-7	Schizophrenia;
PAAD	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.54	-6.98	-0.49	8.58e-11	Primary biliary cholangitis;
PAAD	cis	rs990171	0.506	rs9284725	chr2:102744854	C/A	cg22835712	chr2:102737379	NA	0.54	5.46	0.4	1.93e-7	Lymphocyte counts;
PAAD	cis	rs2421770	0.532	rs2273688	chr11:35338743	C/T	cg13971030	chr11:35366721	SLC1A2	0.55	5.22	0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg16576597	chr16:28551801	NUPR1	0.66	7.06	0.5	5.42e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg11494091	chr17:61959527	GH2	-0.57	-5.94	-0.43	1.87e-8	Height;
PAAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg18850127	chr7:39170497	POU6F2	0.54	7.19	0.5	2.76e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.59	5.53	0.41	1.39e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs12311304	0.965	rs7973089	chr12:15360454	A/G	cg08258403	chr12:15378311	NA	0.37	4.67	0.35	6.68e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.72	-0.42	5.44e-8	Schizophrenia;
PAAD	cis	rs10186876	0.503	rs6737767	chr2:44150511	C/G	cg09541576	chr2:44873248	C2orf34	-0.46	-4.28	-0.33	3.33e-5	Hand grip strength;
PAAD	cis	rs2299116	0.889	rs1468446	chr7:28796788	G/A	cg06647007	chr7:28747836	CREB5	-0.48	-4.55	-0.35	1.08e-5	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs1421334	0.715	rs11776713	chr8:30861607	T/C	cg00964221	chr8:30240029	NA	0.43	4.35	0.33	2.45e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14013457	chr9:27530602	MOBKL2B	-0.63	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs6681460	0.966	rs9659879	chr1:67121434	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs7627468	0.770	rs1463891	chr3:121970131	A/G	cg17240004	chr3:121949083	CASR	0.5	4.76	0.36	4.48e-6	Kidney stones;
PAAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs829661	0.793	rs829564	chr2:30694846	C/T	cg12454169	chr2:30669597	LCLAT1	0.64	4.4	0.34	2.03e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.24	0.39	5.37e-7	Birth weight;
PAAD	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg24241305	chr13:114826075	RASA3	-0.58	-4.79	-0.36	3.88e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.81	8.42	0.56	2.69e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.5	-4.43	-0.34	1.8e-5	Prion diseases;
PAAD	cis	rs77106637	0.585	rs67260737	chr11:72458196	A/G	cg04827223	chr11:72435913	ARAP1	-0.52	-5.5	-0.41	1.58e-7	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13404331	chr5:37638144	WDR70	-0.63	-6.33	-0.46	2.64e-9	Obesity-related traits;
PAAD	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-5.17	-0.39	7.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.49	-0.41	1.62e-7	Blood metabolite levels;
PAAD	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg14825688	chr5:132208181	LEAP2	-0.59	-4.37	-0.33	2.26e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.55	8.69	0.58	5.36e-15	IgG glycosylation;
PAAD	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.98	11.99	0.7	9.75e-24	Bone mineral density;
PAAD	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.68e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.638	rs56008529	chr3:42026755	A/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3951016	0.501	rs6911599	chr6:119009913	C/T	cg26247263	chr6:118972830	C6orf204	0.44	4.57	0.35	1e-5	Resting heart rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14986314	chr10:32345441	KIF5B	0.66	7.1	0.5	4.39e-11	Myopia (pathological);
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.56	0.35	1.03e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10411262	0.935	rs2871987	chr19:47175528	A/G	cg13467550	chr19:47212573	PRKD2	0.51	5.27	0.39	4.67e-7	Tonsillectomy;
PAAD	cis	rs12432203	1.000	rs72622423	chr14:51726108	A/T	cg23942311	chr14:51606299	NA	-0.74	-4.79	-0.36	3.89e-6	Cancer;
PAAD	cis	rs3026101	0.671	rs3026129	chr17:5295371	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.56	-5.03	-0.38	1.35e-6	Glycated hemoglobin levels;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.17	-0.45	5.9e-9	Lung cancer;
PAAD	cis	rs12042938	0.622	rs12030517	chr1:231808385	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.55	0.35	1.1e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg16509142	chr19:1026757	CNN2	-0.65	-6.67	-0.48	4.56e-10	Primary biliary cholangitis;
PAAD	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg17644776	chr2:200775616	C2orf69	0.67	6.19	0.45	5.26e-9	Schizophrenia;
PAAD	cis	rs9462027	0.606	rs7768759	chr6:34795685	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.27	-0.39	4.5e-7	Systemic lupus erythematosus;
PAAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg04705435	chr11:17411270	KCNJ11	0.59	6.13	0.45	7.35e-9	Type 2 diabetes;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg15660573	chr17:549704	VPS53	0.79	8.4	0.56	2.86e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.71	7.5	0.52	4.9e-12	Morning vs. evening chronotype;
PAAD	cis	rs716804	0.654	rs7102016	chr11:10127309	C/T	cg06875754	chr11:10328428	ADM	-0.34	-4.26	-0.33	3.52e-5	Neuroticism;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.65	-0.42	7.58e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.91	-6.47	-0.46	1.29e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg27411982	chr8:10470053	RP1L1	0.42	4.25	0.33	3.68e-5	Retinal vascular caliber;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.62	7.93	0.54	4.38e-13	Hypertriglyceridemia;
PAAD	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.13e-18	Vitiligo;
PAAD	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.5	-4.72	-0.36	5.39e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg11833968	chr6:79620685	NA	0.42	4.3	0.33	3.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06112835	chr11:68658793	MRPL21	0.61	5.97	0.44	1.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-7.28	-0.51	1.66e-11	Urate levels in overweight individuals;
PAAD	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-10.12	-0.63	9.95e-19	Height;
PAAD	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.64	6.61	0.47	6.15e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-1.2	-9.97	-0.63	2.48e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.77	-0.48	2.57e-10	Post bronchodilator FEV1;
PAAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.9	-0.37	2.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14841628	chr1:16258280	SPEN	-0.63	-6.32	-0.46	2.71e-9	Obesity-related traits;
PAAD	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-1.43	-10.55	-0.65	7.32e-20	Schizophrenia;
PAAD	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg00179576	chr16:74483694	GLG1	-0.42	-4.6	-0.35	8.76e-6	Testicular germ cell tumor;
PAAD	cis	rs1499972	0.618	rs73168386	chr3:117644339	T/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.56	-5.39	-0.4	2.65e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	4.61	0.35	8.32e-6	HDL cholesterol;
PAAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg09873201	chr16:3507582	NAT15	-0.57	-5.33	-0.4	3.54e-7	Tuberculosis;
PAAD	cis	rs113123495	0.609	rs2485278	chr19:5645204	A/G	cg26242866	chr19:5711310	LONP1	1.07	5.27	0.39	4.7e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs10887741	1.000	rs12761361	chr10:89427203	G/C	cg13926569	chr10:89418898	PAPSS2	0.46	4.7	0.36	5.76e-6	Exercise (leisure time);
PAAD	cis	rs6141769	0.542	rs28523897	chr20:31301248	C/T	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.57	4.9	0.37	2.44e-6	RR interval (heart rate);
PAAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-6.56	-0.47	7.75e-10	Body mass index;
PAAD	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.52	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.62	0.57	7.96e-15	Bipolar disorder;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg16590910	chr6:42928470	GNMT	0.51	5.21	0.39	6.08e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	4.8	0.36	3.81e-6	Height;
PAAD	cis	rs2235573	0.662	rs6000991	chr22:38460484	T/C	cg20893579	chr22:38215064	NA	-0.47	-4.7	-0.36	5.86e-6	Glioblastoma;Glioma;
PAAD	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.69	4.9	0.37	2.44e-6	Inflammatory bowel disease;
PAAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg03676636	chr4:99064102	C4orf37	0.26	4.5	0.34	1.37e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9322817	0.607	rs7772567	chr6:105155782	C/A	cg02098413	chr6:105308735	HACE1	-0.42	-5.26	-0.39	4.78e-7	Thyroid stimulating hormone;
PAAD	cis	rs9463078	0.834	rs7770401	chr6:45320500	A/G	cg25276700	chr6:44698697	NA	0.47	5.54	0.41	1.28e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg20673841	chr7:107026890	COG5	0.51	4.3	0.33	3e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1903068	0.785	rs10020668	chr4:55996903	C/T	cg09978860	chr4:56023921	NA	0.4	4.37	0.33	2.31e-5	Endometriosis;
PAAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.83	8.9	0.59	1.58e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-1.12	-11.93	-0.7	1.46e-23	Blood pressure (smoking interaction);
PAAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.59	5.57	0.41	1.11e-7	Schizophrenia;
PAAD	cis	rs9488822	0.612	rs13209599	chr6:116247394	A/G	cg18764771	chr6:116381957	FRK	0.28	4.37	0.33	2.29e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg26695010	chr11:65641043	EFEMP2	-0.63	-5.57	-0.41	1.15e-7	DNA methylation (variation);
PAAD	cis	rs11055008	0.868	rs10845602	chr12:12825237	A/G	cg20525461	chr12:12867724	NA	0.45	4.42	0.34	1.88e-5	Pulse pressure;
PAAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg10018233	chr7:150070692	REPIN1	0.61	6.49	0.47	1.15e-9	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18120975	chr6:151313327	MTHFD1L	-0.69	-6.97	-0.49	8.88e-11	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.78	-0.36	4.12e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.6	8.07	0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs148696809	1	rs148696809	chr6:28934352	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg15181151	chr6:150070149	PCMT1	0.6	6.53	0.47	9.18e-10	Lung cancer;
PAAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.59	-0.41	1.04e-7	Monocyte count;
PAAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.08	0.44	9.34e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg13722127	chr7:150037890	RARRES2	0.55	5.55	0.41	1.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg17644776	chr2:200775616	C2orf69	-0.68	-6.25	-0.45	3.91e-9	Schizophrenia;
PAAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.62	0.57	8.1e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs9652601	0.691	rs3893660	chr16:11193930	A/G	cg04616529	chr16:11181986	CLEC16A	0.36	4.41	0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg25364880	chr3:44379878	C3orf23	0.59	5.77	0.42	4.22e-8	Depressive symptoms;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27628854	chr8:121823482	SNTB1	-0.63	-6.67	-0.48	4.43e-10	Smoking initiation;
PAAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg03340356	chr1:67600835	NA	0.55	6.23	0.45	4.44e-9	Psoriasis;
PAAD	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.54	-5.67	-0.42	7.14e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs62179067	0.708	rs12467652	chr2:179913593	C/T	cg13380624	chr19:7735426	NA	-0.73	-6.96	-0.49	9.73e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg18279126	chr7:2041391	MAD1L1	0.6	5.77	0.42	4.4e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.45	7.04	0.5	6.17e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7809615	0.892	rs58964157	chr7:99034055	G/A	cg12290671	chr7:99195819	NA	-0.95	-5.29	-0.39	4.19e-7	Blood metabolite ratios;
PAAD	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.18	0.6	2.91e-16	Colorectal cancer;
PAAD	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg18323236	chr1:24743029	NIPAL3	0.44	4.78	0.36	4.16e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs73416724	1.000	rs77538445	chr6:43285773	A/C	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.58	-0.35	9.73e-6	Rheumatoid arthritis;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26240353	chr12:96429271	LTA4H	-0.6	-7.18	-0.5	2.86e-11	Body fat percentage;
PAAD	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.75	-9.09	-0.59	5.1e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.47	4.85	0.37	3.08e-6	Longevity;Endometriosis;
PAAD	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.59	-5.18	-0.39	6.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg01064725	chr1:204461714	NA	-0.52	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs28655083	0.529	rs285018	chr16:77099065	G/A	cg06128999	chr16:77247126	NA	-0.39	-4.68	-0.35	6.28e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs78761021	0.867	rs7222664	chr17:9785283	G/C	cg26853458	chr17:9805074	RCVRN	0.66	7.59	0.52	2.92e-12	Type 2 diabetes;
PAAD	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.35	11.59	0.69	1.14e-22	Corneal structure;
PAAD	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg12549451	chr6:135224345	NA	0.42	4.35	0.33	2.5e-5	Red blood cell count;
PAAD	cis	rs8040855	0.627	rs62019482	chr15:85615027	A/C	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg13918804	chr1:2043761	PRKCZ	0.42	5.69	0.42	6.26e-8	Height;
PAAD	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg17401720	chr7:158221031	PTPRN2	0.42	4.57	0.35	9.89e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.6	6.11	0.44	7.95e-9	Calcium levels;
PAAD	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg02725872	chr8:58115012	NA	-0.6	-4.93	-0.37	2.09e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg26174226	chr8:58114915	NA	-0.56	-4.25	-0.33	3.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8064299	0.503	rs62084914	chr17:72773110	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.53	4.69	0.36	6.06e-6	Monocyte count;
PAAD	cis	rs4908768	0.501	rs12046643	chr1:8547866	A/C	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	trans	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg25214090	chr10:38739885	LOC399744	-0.65	-7.24	-0.51	2.05e-11	Diastolic blood pressure;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.57	-4.47	-0.34	1.49e-5	Alzheimer's disease;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg07220939	chr11:64358617	SLC22A12	-0.45	-4.73	-0.36	5.07e-6	Urate levels in obese individuals;
PAAD	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.36	-0.4	3.08e-7	Daytime sleep phenotypes;
PAAD	cis	rs17655565	0.537	rs1732276	chr12:52761469	A/C	cg15701111	chr12:52685334	KRT81	0.48	4.31	0.33	2.94e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.53	5.63	0.42	8.49e-8	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.58	-5.71	-0.42	5.75e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9815354	1.000	rs1717006	chr3:41940448	A/C	cg03022575	chr3:42003672	ULK4	0.78	5.66	0.42	7.49e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.92	-8.12	-0.55	1.52e-13	Gut microbiome composition (summer);
PAAD	cis	rs11608355	0.538	rs12228876	chr12:109796799	C/A	cg19025524	chr12:109796872	NA	-0.59	-6.21	-0.45	4.94e-9	Neuroticism;
PAAD	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06156847	chr2:113672199	IL1F7	-0.57	-6.16	-0.45	6.17e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11245990	chr11:68621969	NA	0.43	5.6	0.41	9.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg01475735	chr3:40494733	NA	0.46	4.25	0.33	3.74e-5	Renal cell carcinoma;
PAAD	cis	rs9361491	0.608	rs9350769	chr6:79444561	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	6.88	0.49	1.48e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs933688	0.556	rs4916855	chr5:90596345	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.69	-5.38	-0.4	2.77e-7	Smoking behavior;
PAAD	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg11143131	chr5:131608246	PDLIM4	0.47	4.39	0.34	2.11e-5	Breast cancer;
PAAD	cis	rs2124910	0.636	rs3829658	chr19:52000672	G/A	cg14953197	chr19:52005651	SIGLEC12	0.52	5.02	0.38	1.41e-6	Blood protein levels;
PAAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg10645314	chr2:3704589	ALLC	-0.49	-5.03	-0.38	1.39e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	1.25	10.71	0.66	2.72e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg25011627	chr2:152042657	NA	0.59	6.59	0.47	6.91e-10	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00756215	chr1:55230057	PARS2	0.58	6.35	0.46	2.34e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	9.38	0.61	9.15e-17	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.69	9.83	0.62	6.02e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.89	-0.49	1.35e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2051773	0.510	rs11024131	chr11:17056440	C/G	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.54	-7.62	-0.53	2.51e-12	Homoarginine levels;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20553930	chr7:120590671	ING3	0.59	6.57	0.47	7.66e-10	Immature fraction of reticulocytes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17915139	chr4:74904765	CXCL3	0.62	6.97	0.49	9.05e-11	Metabolite levels  (X-11787);
PAAD	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.37	-0.46	2.11e-9	Capecitabine sensitivity;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg21929781	chr1:2537748	MMEL1	-0.54	-5.7	-0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs4759375	0.585	rs28898283	chr12:123854766	G/C	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs4889855	0.556	rs4890040	chr17:78518408	G/A	cg16591659	chr17:78472290	NA	0.53	5.17	0.39	7.13e-7	Fractional excretion of uric acid;
PAAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.59	-7.86	-0.54	6.59e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18621852	chr3:10150065	C3orf24	0.56	4.43	0.34	1.81e-5	Alzheimer's disease;
PAAD	cis	rs4704187	0.624	rs35719345	chr5:74551962	T/C	cg03227963	chr5:74354835	NA	0.48	4.69	0.36	5.92e-6	Response to amphetamines;
PAAD	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg21479132	chr6:26055353	NA	0.98	5.48	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	4.78	0.36	4.18e-6	Mean platelet volume;
PAAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.62	6.18	0.45	5.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7131987	0.675	rs2194515	chr12:29550383	T/C	cg09582351	chr12:29534625	ERGIC2	0.34	4.95	0.37	1.97e-6	QT interval;
PAAD	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs742132	0.520	rs4140641	chr6:25635400	C/T	cg12310025	chr6:25882481	NA	0.65	4.37	0.33	2.26e-5	Uric acid levels;
PAAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-4.81	-0.36	3.56e-6	Schizophrenia (age at onset);
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg02071572	chr4:1403502	NA	-0.43	-5.51	-0.41	1.52e-7	Obesity-related traits;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.85	6.86	0.49	1.67e-10	Lung function (FEV1/FVC);
PAAD	cis	rs7071247	1.000	rs7071247	chr10:105257786	G/T	cg06423925	chr10:105883847	C10orf78	0.59	4.49	0.34	1.41e-5	Platelet aggregation;
PAAD	cis	rs11958404	0.517	rs17680818	chr5:157248548	T/A	cg05962755	chr5:157440814	NA	0.66	4.56	0.35	1.05e-5	IgG glycosylation;
PAAD	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.53	6.23	0.45	4.38e-9	Mean corpuscular volume;
PAAD	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs7591163	1.000	rs2396499	chr2:228724368	C/T	cg22994281	chr2:228029448	COL4A3;COL4A4	-0.48	-4.86	-0.37	2.86e-6	Blood pressure;
PAAD	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16385703	chr16:71323358	FTSJD1	-0.71	-6.58	-0.47	7.22e-10	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25049295	chr2:131116527	PTPN18	0.64	7.86	0.54	6.68e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13821490	chr7:100798061	AP1S1	0.65	7.64	0.53	2.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg18279126	chr7:2041391	MAD1L1	0.61	6.25	0.45	3.97e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg25401027	chr5:176370377	UIMC1	0.47	4.78	0.36	4.15e-6	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12980830	chr11:12798726	TEAD1	-0.57	-7.17	-0.5	3.12e-11	Monocyte percentage of white cells;
PAAD	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg26695010	chr11:65641043	EFEMP2	-0.49	-4.87	-0.37	2.77e-6	Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg00700412	chr12:58011837	NA	0.4	4.35	0.33	2.53e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg11843238	chr5:131593191	PDLIM4	0.5	4.65	0.35	7.25e-6	Acylcarnitine levels;
PAAD	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.53	-6.34	-0.46	2.54e-9	Alcohol dependence;
PAAD	cis	rs804280	0.544	rs804276	chr8:11625008	G/A	cg12568669	chr8:11666485	FDFT1	-0.25	-4.39	-0.34	2.1e-5	Myopia (pathological);
PAAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.68	-6.55	-0.47	8.19e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.55	6.41	0.46	1.71e-9	Multiple system atrophy;
PAAD	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg07148914	chr20:33460835	GGT7	-0.45	-4.32	-0.33	2.82e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4867766	0.585	rs6878032	chr5:173950070	A/G	cg20434911	chr5:173954559	NA	0.63	5.62	0.41	8.92e-8	Stroke;
PAAD	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.98	6.98	0.49	8.46e-11	Breast cancer (early onset);
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23281280	chr6:28129359	ZNF389	0.52	4.26	0.33	3.58e-5	Parkinson's disease;
PAAD	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-4.32	-0.33	2.83e-5	IFN-related cytopenia;
PAAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.52	-7.6	-0.52	2.81e-12	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18491775	chr10:76586186	MYST4	0.57	6.32	0.46	2.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.49	4.39	0.34	2.07e-5	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.82	6.1	0.44	8.29e-9	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.88	10.9	0.66	8.34e-21	Prudent dietary pattern;
PAAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.68e-5	Parkinson's disease;
PAAD	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.32	6.0	0.44	1.41e-8	Type 2 diabetes;
PAAD	cis	rs9715521	0.815	rs7441547	chr4:59838120	A/G	cg11281224	chr4:60001000	NA	-0.59	-5.59	-0.41	1.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2252790	0.542	rs11970221	chr6:116634325	T/C	cg23214565	chr6:116600728	DSE;TSPYL1	-0.48	-5.09	-0.38	1.07e-6	Fast beta electroencephalogram;
PAAD	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.84	9.93	0.63	3.26e-18	Blood metabolite ratios;
PAAD	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25256661	chr17:7137939	DVL2	-0.79	-7.99	-0.54	3.15e-13	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9900972	0.877	rs8064344	chr17:76876974	C/T	cg20937029	chr17:76870563	TIMP2	0.59	5.24	0.39	5.32e-7	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00597055	chr15:41523239	CHP;EXD1	-0.71	-7.72	-0.53	1.43e-12	Smoking initiation;
PAAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.52	5.8	0.43	3.7e-8	Major depressive disorder;
PAAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.79	-6.93	-0.49	1.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.87	7.13	0.5	3.75e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9430161	0.611	rs12565727	chr1:11033082	A/G	cg27631724	chr1:11040367	C1orf127	0.56	7.09	0.5	4.68e-11	Ewing sarcoma;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.13	-0.73	8.47e-27	Height;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	1.03	8.36	0.56	3.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.58e-5	Prostate cancer;
PAAD	cis	rs3764618	1.000	rs2287754	chr19:49496494	C/T	cg12515942	chr19:49552529	CGB8	-0.71	-4.31	-0.33	2.97e-5	Follicule stimulating hormone;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20840634	chr4:69434475	UGT2B15;UGT2B17	-0.61	-6.73	-0.48	3.26e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.64	-8.38	-0.56	3.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.87e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.66	-8.87	-0.58	1.82e-15	Asthma (sex interaction);
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs1499972	0.504	rs2865303	chr3:117792986	G/C	cg07612923	chr3:117604196	NA	-0.73	-5.27	-0.39	4.6e-7	Schizophrenia;
PAAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.66	-8.9	-0.59	1.54e-15	Eye color traits;
PAAD	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg10729496	chr3:10149963	C3orf24	0.8	6.65	0.47	4.91e-10	Alzheimer's disease;
PAAD	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.48	6.07	0.44	9.61e-9	Crohn's disease;
PAAD	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg02389323	chr16:88786976	FAM38A	0.95	6.24	0.45	4.12e-9	Plateletcrit;
PAAD	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.6	5.49	0.41	1.68e-7	YKL-40 levels;
PAAD	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.55	-6.8	-0.48	2.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg05484376	chr2:27715224	FNDC4	0.45	4.44	0.34	1.7e-5	Oral cavity cancer;
PAAD	cis	rs1555895	0.599	rs4881535	chr10:847769	G/A	cg26597838	chr10:835615	NA	0.51	5.49	0.41	1.63e-7	Survival in rectal cancer;
PAAD	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	IgG glycosylation;
PAAD	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.71	4.99	0.38	1.65e-6	HDL cholesterol levels;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs11700980	0.551	rs56263139	chr21:30109451	A/G	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg16506815	chr2:162101123	NA	-0.57	-5.2	-0.39	6.42e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.2	-0.39	6.22e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg19257562	chr1:2043853	PRKCZ	-0.41	-4.87	-0.37	2.73e-6	Height;
PAAD	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg26394196	chr10:1453818	ADARB2	-0.58	-6.54	-0.47	8.85e-10	Radiation response;
PAAD	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.38	-4.29	-0.33	3.13e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9810890	1.000	rs74961584	chr3:128567032	T/C	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.95	-9.9	-0.63	3.88e-18	Blood pressure (smoking interaction);
PAAD	cis	rs17683430	0.614	rs2006253	chr22:32530256	A/C	cg02631450	chr22:32366979	NA	0.76	5.23	0.39	5.62e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16452756	chr5:172483361	C5orf41	-0.65	-6.4	-0.46	1.79e-9	Smoking initiation;
PAAD	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg26338869	chr17:61819248	STRADA	0.47	4.52	0.34	1.25e-5	Height;
PAAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg21518248	chr2:162101506	NA	-0.6	-6.11	-0.44	8.16e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg20937029	chr17:76870563	TIMP2	0.58	5.16	0.39	7.62e-7	Obesity-related traits;
PAAD	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs35000415	0.938	rs10488631	chr7:128594183	T/C	cg19972273	chr7:128594194	NA	0.97	5.64	0.42	7.88e-8	Systemic lupus erythematosus;
PAAD	cis	rs4218	0.619	rs10851643	chr15:59395184	A/C	cg25595834	chr15:59156878	NA	0.44	4.36	0.33	2.38e-5	Social communication problems;
PAAD	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg10437265	chr15:77819839	NA	0.37	4.34	0.33	2.57e-5	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.5	-4.85	-0.37	3.07e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.43	4.56	0.35	1.02e-5	Longevity;Endometriosis;
PAAD	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg17524180	chr13:113633600	MCF2L	-0.49	-5.09	-0.38	1.05e-6	Systolic blood pressure;
PAAD	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.71	-6.74	-0.48	3.03e-10	Gout;
PAAD	cis	rs9677476	0.909	rs60240472	chr2:232131217	A/G	cg07929768	chr2:232055508	NA	0.4	4.38	0.34	2.16e-5	Food antigen IgG levels;
PAAD	cis	rs7127900	0.904	rs11043132	chr11:2232624	T/C	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.55	-5.49	-0.41	1.63e-7	QT interval;
PAAD	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.54	5.58	0.41	1.07e-7	Number of children ever born;
PAAD	cis	rs1109501	0.770	rs34877483	chr4:71418769	T/C	cg25553522	chr4:71388589	AMTN	0.54	4.54	0.35	1.15e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.53	5.41	0.4	2.44e-7	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.92	-10.56	-0.65	6.77e-20	Prudent dietary pattern;
PAAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.54	-5.34	-0.4	3.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg07943548	chr15:86304357	KLHL25	-0.78	-6.3	-0.45	3.11e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.59	-7.06	-0.5	5.45e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs990171	1.000	rs2270297	chr2:102992675	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.49	0.34	1.38e-5	Lymphocyte counts;
PAAD	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	4.32	0.33	2.85e-5	Uric acid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02473376	chr12:125573329	AACS	-0.67	-7.14	-0.5	3.57e-11	Obesity-related traits;
PAAD	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.75	-8.61	-0.57	8.76e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.69	6.83	0.48	1.88e-10	Blood metabolite levels;
PAAD	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.81	-7.67	-0.53	1.89e-12	Body mass index;
PAAD	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg10705379	chr10:99080932	FRAT1	0.44	5.09	0.38	1.02e-6	Monocyte count;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.77	9.0	0.59	8.67e-16	Lung cancer;
PAAD	cis	rs3812762	0.783	rs34524863	chr11:8777408	T/C	cg11156914	chr11:8892616	ST5	0.52	4.55	0.35	1.1e-5	Hypospadias;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.67	-0.42	7.15e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.54	-4.78	-0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.68	6.99	0.49	8.09e-11	Heart rate;
PAAD	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.64	-7.64	-0.53	2.23e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.46	0.34	1.58e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.64	6.89	0.49	1.4e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.58	5.06	0.38	1.21e-6	Obesity-related traits;
PAAD	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-5.73	-0.42	5.34e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4481887	0.508	rs4916115	chr1:248383316	T/G	cg01631408	chr1:248437212	OR2T33	-0.52	-4.65	-0.35	7.29e-6	Common traits (Other);
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2455826	0.544	rs2455842	chr3:15764428	C/G	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg00181669	chr3:44000978	NA	0.55	5.77	0.42	4.24e-8	Coronary artery disease;
PAAD	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.37	-0.46	2.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-6.79	-0.48	2.32e-10	Chronic sinus infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04737207	chr4:140222858	NAA15	0.64	7.22	0.51	2.29e-11	Monocyte percentage of white cells;
PAAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg26354017	chr1:205819088	PM20D1	-0.47	-4.33	-0.33	2.64e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.78	5.54	0.41	1.27e-7	Major depressive disorder;
PAAD	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.54	-6.49	-0.47	1.16e-9	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2526932	0.625	rs2526905	chr14:73049783	C/T	cg13588403	chr14:73209128	DPF3	-0.41	-5.48	-0.41	1.72e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	4.84	0.37	3.14e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10887741	0.646	rs11202502	chr10:89437933	C/T	cg13926569	chr10:89418898	PAPSS2	0.45	4.46	0.34	1.61e-5	Exercise (leisure time);
PAAD	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-7.23	-0.51	2.17e-11	Body mass index;
PAAD	cis	rs1419980	0.730	rs9634123	chr12:7734179	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.58	-5.41	-0.4	2.41e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.5	4.99	0.37	1.66e-6	Height;
PAAD	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-1.34	-10.72	-0.66	2.52e-20	Obesity-related traits;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg07336987	chr11:625147	MUPCDH	-0.38	-4.73	-0.36	5.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.6	5.47	0.41	1.8e-7	Red blood cell count;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.83	8.96	0.59	1.12e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs7326068	0.524	rs2497484	chr13:21199265	C/T	cg27499820	chr13:21296301	IL17D	-0.49	-4.98	-0.37	1.71e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs9361491	0.608	rs9350773	chr6:79456705	A/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7326068	0.524	rs2497484	chr13:21199265	C/T	cg27234864	chr13:21295941	IL17D	-0.5	-4.56	-0.35	1.05e-5	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.79	-0.48	2.35e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs12304921	1.000	rs67654320	chr12:51356459	A/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02359409	chr6:42947317	PEX6	-0.43	-4.34	-0.33	2.56e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10924309	0.880	rs12141908	chr1:245857829	C/A	cg00036263	chr1:245852353	KIF26B	-0.74	-6.27	-0.45	3.5e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	5.68	0.42	6.8e-8	Systemic lupus erythematosus;
PAAD	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.36	3.63e-6	Coronary artery disease;
PAAD	cis	rs3996993	0.621	rs60120296	chr6:52732547	G/T	cg00536792	chr6:53530503	KLHL31	-0.41	-4.47	-0.34	1.54e-5	Hemoglobin concentration;
PAAD	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.8	4.48	0.34	1.45e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg23127183	chr11:57508653	C11orf31	-0.52	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.67	0.62	1.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.4	-0.46	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-7.53	-0.52	4.15e-12	Longevity;Endometriosis;
PAAD	cis	rs528301	0.613	rs4143310	chr2:45124563	C/A	cg15393275	chr2:45165193	NA	-0.45	-4.76	-0.36	4.51e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.88	-11.25	-0.67	9.52e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg15226751	chr1:10001911	LZIC	0.38	4.28	0.33	3.24e-5	Hepatocellular carcinoma;
PAAD	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-4.87	-0.37	2.83e-6	Coronary artery disease;
PAAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-5.91	-0.43	2.22e-8	Tonsillectomy;
PAAD	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.59	-0.35	9.4e-6	Resting heart rate;
PAAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg14393609	chr7:65229607	NA	-0.48	-4.65	-0.35	7.05e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.66	-6.19	-0.45	5.26e-9	Platelet count;
PAAD	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.67	-7.15	-0.5	3.36e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09940138	chr22:47456901	TBC1D22A	-0.74	-7.35	-0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs4787491	0.704	rs66467443	chr16:30050494	G/A	cg06015834	chr16:30021696	DOC2A	-0.41	-4.3	-0.33	2.99e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7172677	1.000	rs7172677	chr15:75424593	G/T	cg10253484	chr15:75165896	SCAMP2	0.49	4.64	0.35	7.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg17810781	chr1:201082982	CACNA1S	0.46	5.38	0.4	2.77e-7	Permanent tooth development;
PAAD	cis	rs4751006	0.543	rs61875506	chr10:128778438	A/G	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.11e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.762	rs239938	chr19:44390305	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.16	-0.39	7.61e-7	Breast cancer;
PAAD	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.53	-5.47	-0.41	1.81e-7	Height;
PAAD	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs743757	0.938	rs6787890	chr3:50520128	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	5.07	0.38	1.14e-6	Diastolic blood pressure;
PAAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	6.98	0.49	8.38e-11	Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	cis	rs2521634	0.938	rs17149217	chr7:24358090	G/A	cg15037663	chr7:24797835	DFNA5	-0.47	-4.34	-0.33	2.64e-5	Periodontitis;
PAAD	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26926768	chr12:34528122	NA	0.37	4.51	0.34	1.31e-5	Morning vs. evening chronotype;
PAAD	cis	rs6782228	0.606	rs6775270	chr3:128403498	A/G	cg16766828	chr3:128327626	NA	-0.46	-6.23	-0.45	4.33e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.58	6.97	0.49	9.07e-11	Multiple sclerosis;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg19500098	chr13:21900506	NA	0.57	5.83	0.43	3.26e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg21479132	chr6:26055353	NA	0.99	6.01	0.44	1.31e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.45	-5.51	-0.41	1.53e-7	Body mass index in non-asthmatics;
PAAD	cis	rs9310709	0.517	rs616006	chr3:23037791	T/C	cg00327796	chr3:23032191	NA	-0.49	-4.71	-0.36	5.44e-6	Chronic kidney disease and serum creatinine levels;
PAAD	cis	rs11112613	0.609	rs7350593	chr12:106038119	C/T	cg03607813	chr12:105948248	NA	0.79	5.78	0.42	4.08e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.56	-5.23	-0.39	5.51e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.76	-9.19	-0.6	2.78e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg05721444	chr7:32995514	FKBP9	-0.52	-5.18	-0.39	7.01e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.52	-0.34	1.24e-5	Educational attainment (years of education);
PAAD	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg09526685	chr4:187126073	CYP4V2	0.74	5.6	0.41	9.87e-8	Blood protein levels;
PAAD	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg21479132	chr6:26055353	NA	0.98	5.48	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2421770	0.560	rs7114936	chr11:35374075	A/G	cg13971030	chr11:35366721	SLC1A2	-0.53	-5.15	-0.39	7.84e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg20129853	chr10:51489980	NA	-0.44	-4.39	-0.34	2.07e-5	Prostate-specific antigen levels;
PAAD	cis	rs4740619	0.967	rs4741528	chr9:15655978	C/T	cg14451791	chr9:16040625	NA	0.37	4.32	0.33	2.78e-5	Body mass index;
PAAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.59	7.02	0.49	6.85e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.81	-8.79	-0.58	3.03e-15	Lung cancer;
PAAD	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.57	0.41	1.12e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg11204139	chr17:3907470	NA	0.68	6.76	0.48	2.79e-10	Type 2 diabetes;
PAAD	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg18643199	chr10:82363313	SH2D4B	-0.62	-4.96	-0.37	1.87e-6	Post bronchodilator FEV1;
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.58	-0.47	7.07e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.85	-9.83	-0.62	5.86e-18	Iron status biomarkers;
PAAD	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg07220939	chr11:64358617	SLC22A12	-0.41	-4.42	-0.34	1.87e-5	Urate levels in obese individuals;
PAAD	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.36	-0.33	2.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs990171	0.687	rs6742381	chr2:103125466	T/C	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.37	-4.77	-0.36	4.23e-6	Prostate cancer;
PAAD	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.41	-0.4	2.38e-7	Pulmonary function;
PAAD	cis	rs932287	0.651	rs1111010	chr11:9049935	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	4.27	0.33	3.48e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.65	-0.35	7.26e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.56	5.92	0.43	2.02e-8	Monobrow;
PAAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	1.1	10.23	0.64	5.09e-19	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.87	10.04	0.63	1.66e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02779429	chr16:88753010	MGC23284;SNAI3	0.57	6.77	0.48	2.69e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg19442545	chr10:75533431	FUT11	0.42	4.31	0.33	2.97e-5	Inflammatory bowel disease;
PAAD	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg06784991	chr1:53308768	ZYG11A	0.27	4.25	0.33	3.66e-5	Monocyte count;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26549601	chr10:134560360	INPP5A	-0.49	-4.78	-0.36	4.18e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26378065	chr17:18585709	ZNF286B	-0.58	-4.48	-0.34	1.48e-5	Pancreatic cancer;
PAAD	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-4.81	-0.36	3.55e-6	Rheumatoid arthritis;
PAAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg23205692	chr1:25664452	TMEM50A	0.51	4.88	0.37	2.62e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.29e-6	Rheumatoid arthritis;
PAAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg18809830	chr7:99032528	PTCD1	-1.04	-4.56	-0.35	1.06e-5	Blood metabolite levels;
PAAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.69	0.36	6.04e-6	Bipolar disorder;
PAAD	cis	rs1642645	0.831	rs4660212	chr1:42496399	C/T	cg01990334	chr1:42801334	FOXJ3	0.59	5.4	0.4	2.47e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.69	-0.42	6.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4073221	0.789	rs13092771	chr3:18213426	C/T	cg07694806	chr3:18168406	NA	-0.77	-4.84	-0.37	3.14e-6	Parkinson's disease;
PAAD	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.78	-6.02	-0.44	1.23e-8	Iron status biomarkers;
PAAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-5.35	-0.4	3.13e-7	Rheumatoid arthritis;
PAAD	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.76	8.63	0.57	7.52e-15	Lung cancer;
PAAD	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.78	-8.85	-0.58	2.04e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.03	-13.37	-0.74	1.91e-27	Schizophrenia;
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.61e-8	Prostate cancer;
PAAD	cis	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Breast cancer;
PAAD	cis	rs7866181	0.848	rs2183702	chr9:117978829	T/C	cg13910071	chr9:117023199	COL27A1	-0.43	-4.48	-0.34	1.47e-5	Dupuytren's disease;
PAAD	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg27411982	chr8:10470053	RP1L1	0.46	4.81	0.36	3.57e-6	Retinal vascular caliber;
PAAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.36	6.23e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.95	0.81	7.51e-37	Prudent dietary pattern;
PAAD	cis	rs600550	0.588	rs2304935	chr11:60102384	C/T	cg05040360	chr11:60102449	MS4A6E	0.43	5.05	0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.61	-5.05	-0.38	1.22e-6	IgG glycosylation;
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.64	-0.42	8.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	12.26	0.71	1.87e-24	Platelet count;
PAAD	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.77	-6.94	-0.49	1.05e-10	Body mass index;
PAAD	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs73416724	0.544	rs79306700	chr6:43234901	T/C	cg17076780	chr6:43251928	TTBK1	0.63	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-11.29	-0.68	7.36e-22	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.91	9.63	0.62	2.01e-17	Blood metabolite levels;
PAAD	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.75	8.85	0.58	2.14e-15	Blood metabolite ratios;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7101378	0.538	rs7942258	chr11:108899569	T/C	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.61	5.24	0.39	5.19e-7	Coronary artery disease;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.58	0.35	9.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs728616	0.867	rs61859977	chr10:81883689	A/T	cg19423196	chr10:82049429	MAT1A	0.63	4.73	0.36	5.18e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.63	6.1	0.44	8.44e-9	Mosquito bite size;
PAAD	cis	rs58521262	0.519	rs11673536	chr19:22902590	A/T	cg07749055	chr19:23076870	NA	0.57	4.28	0.33	3.29e-5	Testicular germ cell tumor;
PAAD	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.6	4.42	0.34	1.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2080501	0.601	rs3803665	chr16:49672520	A/G	cg27618369	chr16:49636483	ZNF423	0.52	5.26	0.39	4.72e-7	IgG glycosylation;
PAAD	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.69	7.56	0.52	3.54e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17023223	0.537	rs2361273	chr1:119603700	A/T	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4740619	0.689	rs1590750	chr9:15953422	G/C	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg23024343	chr7:107201750	COG5	0.57	4.72	0.36	5.31e-6	Coronary artery disease;
PAAD	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-5.57	-0.41	1.11e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.7	-7.94	-0.54	4.08e-13	White blood cell count (basophil);
PAAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg06217071	chr17:408420	NA	-0.6	-6.55	-0.47	8.26e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9715521	0.645	rs6551791	chr4:59845586	G/A	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg01046593	chr21:45079544	HSF2BP;RRP1B	0.94	6.59	0.47	6.69e-10	Lung function (FEV1/FVC);
PAAD	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg11439826	chr17:76250004	NA	-0.46	-4.74	-0.36	4.95e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.23	-0.39	5.42e-7	Educational attainment;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg16606324	chr3:10149918	C3orf24	0.58	4.54	0.35	1.15e-5	Alzheimer's disease;
PAAD	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg08390786	chr10:135334061	NA	-0.61	-5.15	-0.39	7.79e-7	Gout;
PAAD	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	1.22	9.79	0.62	7.44e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04027446	chr6:74230918	EEF1A1	0.6	6.67	0.48	4.39e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg05313129	chr8:58192883	C8orf71	-0.44	-4.26	-0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.54	-5.86	-0.43	2.83e-8	Total body bone mineral density;
PAAD	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.81	-7.8	-0.53	8.94e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.79	7.38	0.51	9.52e-12	Blood protein levels;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.39	4.3	0.33	3.03e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg07099767	chr17:78039528	CCDC40	0.53	4.55	0.35	1.1e-5	Yeast infection;
PAAD	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs59888335	0.858	rs7652113	chr3:80987990	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.82	0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.89	11.99	0.7	9.75e-24	Prudent dietary pattern;
PAAD	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.31e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-5.39	-0.4	2.62e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg22143856	chr6:28129313	ZNF389	0.6	4.64	0.35	7.49e-6	Parkinson's disease;
PAAD	cis	rs62247992	0.546	rs9840881	chr3:43167735	A/G	cg12239580	chr3:43073058	FAM198A	-0.5	-4.96	-0.37	1.88e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.71	7.23	0.51	2.23e-11	Caffeine consumption;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.29	0.33	3.11e-5	Mean corpuscular volume;
PAAD	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.85	-9.69	-0.62	1.38e-17	Superior crus of antihelix expression;
PAAD	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs728616	0.717	rs17098169	chr10:81816134	C/T	cg05935833	chr10:81318306	SFTPA2	0.64	4.92	0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.63	-7.43	-0.52	7.2e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg24253500	chr15:84953950	NA	-0.41	-4.36	-0.33	2.34e-5	P wave terminal force;
PAAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	1.28	13.0	0.73	1.9e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.56	-0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24993688	chr2:170550885	C2orf77;PHOSPHO2;KLHL23	0.62	6.97	0.49	9.03e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.81	6.24	0.45	4.18e-9	Pulmonary function decline;
PAAD	cis	rs16910800	0.953	rs7126961	chr11:23204237	C/T	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs2046867	0.529	rs62249900	chr3:72951863	T/C	cg25664220	chr3:72788482	NA	-0.49	-5.24	-0.39	5.29e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs7162310	0.906	rs11858705	chr15:63570340	T/A	cg25165958	chr15:64126091	HERC1	0.55	4.47	0.34	1.54e-5	Myopia;
PAAD	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.42	-4.33	-0.33	2.7e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg19567339	chr10:100142640	NA	0.51	5.07	0.38	1.15e-6	Metabolite levels;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20047447	chr15:44084326	SERF2	-0.49	-4.65	-0.35	7.02e-6	Lung cancer in ever smokers;
PAAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg21361702	chr7:150065534	REPIN1	0.59	4.94	0.37	2.08e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg10621924	chr7:39171070	POU6F2	0.31	4.76	0.36	4.56e-6	IgG glycosylation;
PAAD	cis	rs4679121	0.643	rs113384423	chr3:126145060	C/A	cg05485589	chr3:126194908	ZXDC	-0.99	-4.77	-0.36	4.26e-6	Pursuit maintenance gain;
PAAD	cis	rs7765175	0.698	rs9488155	chr6:113664985	T/C	cg19037598	chr6:113666021	NA	-0.44	-4.63	-0.35	7.87e-6	Coronary artery calcification;
PAAD	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg20129853	chr10:51489980	NA	0.5	4.75	0.36	4.62e-6	Prostate-specific antigen levels;
PAAD	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs4455778	0.561	rs10243463	chr7:49081185	T/G	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs73419609	1.000	rs73419647	chr15:54734351	C/G	cg11288833	chr15:55489084	RSL24D1	-0.98	-4.29	-0.33	3.22e-5	Post-traumatic stress disorder;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg21724239	chr8:58056113	NA	0.71	5.35	0.4	3.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-6.5	-0.47	1.12e-9	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs58521262	0.530	rs381403	chr19:23126236	C/T	cg03433597	chr19:22806448	NA	-0.23	-4.27	-0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.71	7.13	0.5	3.7e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.68e-6	Oral cavity cancer;
PAAD	cis	rs2797685	0.786	rs72632093	chr1:7897988	G/A	cg00546117	chr1:8445545	RERE	-0.53	-4.78	-0.36	4.19e-6	Crohn's disease;
PAAD	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.53	-5.15	-0.39	8.1e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.58	-6.19	-0.45	5.25e-9	Blood metabolite levels;
PAAD	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.61	4.4	0.34	2.02e-5	Inhibitory control;
PAAD	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.24	0.64	4.87e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.57	7.82	0.54	8.13e-13	Electrocardiographic conduction measures;
PAAD	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg18833306	chr6:118973337	C6orf204	-0.53	-5.86	-0.43	2.84e-8	Electrocardiographic conduction measures;
PAAD	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-4.69	-0.36	6.05e-6	Schizophrenia;
PAAD	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.89	-10.38	-0.64	2.09e-19	Coronary artery disease;
PAAD	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg02869306	chr7:64672164	INTS4L1	0.41	4.75	0.36	4.59e-6	Aortic root size;
PAAD	cis	rs73206853	0.640	rs2098140	chr12:110726081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.29	0.33	3.18e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	7.02e-7	Alzheimer's disease;
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-4.33	-0.33	2.74e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.65	6.61	0.47	6.05e-10	Dupuytren's disease;
PAAD	cis	rs2688419	0.509	rs115374	chr3:23048377	A/G	cg00327796	chr3:23032191	NA	-0.46	-4.57	-0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.73	6.31	0.46	2.83e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14380609	chr1:22264166	HSPG2	0.59	6.83	0.48	1.94e-10	Monocyte percentage of white cells;
PAAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.81	6.33	0.46	2.56e-9	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18621852	chr3:10150065	C3orf24	0.69	6.22	0.45	4.57e-9	Alzheimer's disease;
PAAD	cis	rs1011018	0.955	rs4726525	chr7:139468472	T/C	cg03224163	chr7:139420300	HIPK2	-0.62	-4.28	-0.33	3.32e-5	Systolic blood pressure;
PAAD	cis	rs11825685	0.790	rs74733798	chr11:134538378	A/G	cg02089395	chr11:134479357	NA	-0.78	-5.46	-0.41	1.87e-7	IgG glycosylation;
PAAD	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06850241	chr22:41845214	NA	-0.56	-5.32	-0.4	3.7e-7	Vitiligo;
PAAD	trans	rs901683	1.000	rs79490183	chr10:46080241	C/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3857067	0.901	rs965807	chr4:95045567	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.59	-0.35	9.23e-6	QT interval;
PAAD	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.46	4.99	0.38	1.64e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.36	0.4	2.97e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg18551225	chr6:44695536	NA	-0.58	-5.18	-0.39	6.86e-7	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg23461800	chr14:103021989	NA	-0.59	-4.88	-0.37	2.68e-6	Platelet count;
PAAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg21496419	chr19:44306685	LYPD5	0.44	5.43	0.4	2.15e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	6.73	0.48	3.24e-10	Mean platelet volume;
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg10621924	chr7:39171070	POU6F2	0.25	4.3	0.33	3.04e-5	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04310316	chr7:131241713	PODXL	-0.62	-6.44	-0.46	1.49e-9	Smoking initiation;
PAAD	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	1.13	6.15	0.45	6.6e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.99	8.32	0.56	4.81e-14	Neutrophil percentage of white cells;
PAAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.38	0.33	2.19e-5	Menopause (age at onset);
PAAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01756814	chr4:111119868	ELOVL6	-0.62	-6.47	-0.46	1.25e-9	Smoking initiation;
PAAD	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg20628663	chr10:43360327	NA	0.62	4.32	0.33	2.84e-5	Blood protein levels;
PAAD	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg16898833	chr6:26189333	HIST1H4D	0.52	4.53	0.35	1.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.5	0.34	1.33e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.65	4.9	0.37	2.48e-6	Exhaled nitric oxide output;
PAAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.24	-9.8	-0.62	7.2e-18	Breast cancer;
PAAD	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.43	0.46	1.54e-9	Lung cancer in ever smokers;
PAAD	cis	rs12799264	0.915	rs2707085	chr11:19974879	T/C	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-6.19	-0.45	5.43e-9	Ileal carcinoids;
PAAD	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.46	-0.34	1.56e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10915437	0.516	rs4233260	chr1:4197987	A/G	cg27165836	chr1:4193882	NA	0.47	4.65	0.35	7.19e-6	Migraine - clinic-based;
PAAD	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-4.58	-0.35	9.8e-6	Systemic lupus erythematosus;
PAAD	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.72	5.13	0.38	8.75e-7	Diisocyanate-induced asthma;
PAAD	cis	rs3736485	0.966	rs28428679	chr15:51913040	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7833787	0.965	rs7830045	chr8:18700282	A/C	cg17701159	chr8:18705777	PSD3	-0.45	-5.32	-0.4	3.62e-7	Obesity-related traits;
PAAD	cis	rs370915	0.578	rs2375939	chr4:187783726	G/A	cg12892747	chr4:187813459	NA	-0.45	-4.55	-0.35	1.09e-5	Gout;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.54	4.89	0.37	2.5e-6	RR interval (heart rate);
PAAD	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.47	-4.36	-0.33	2.37e-5	Tuberculosis;
PAAD	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.76	7.58	0.52	3.14e-12	Callous-unemotional behaviour;
PAAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.9	6.84	0.49	1.81e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.62	-6.63	-0.47	5.64e-10	Schizophrenia;
PAAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.43	0.34	1.8e-5	Tonsillectomy;
PAAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27068297	chr22:50451975	IL17REL	-0.49	-5.01	-0.38	1.49e-6	Ulcerative colitis;
PAAD	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.34	0.33	2.6e-5	Bipolar disorder;
PAAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.7	6.74	0.48	3.01e-10	Parkinson's disease;
PAAD	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.46	4.48	0.34	1.47e-5	Dupuytren's disease;
PAAD	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs868943	0.582	rs12209747	chr6:116452561	A/G	cg18764771	chr6:116381957	FRK	0.26	4.25	0.33	3.78e-5	Total cholesterol levels;
PAAD	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13870426	chr17:30244630	NA	-0.69	-6.34	-0.46	2.47e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg16685388	chr1:42384056	HIVEP3	0.38	4.25	0.33	3.69e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg27478167	chr7:817139	HEATR2	-0.62	-4.91	-0.37	2.35e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.67	-7.36	-0.51	1.06e-11	Menarche (age at onset);
PAAD	cis	rs704	0.764	rs3093692	chr17:26670627	G/A	cg10342447	chr17:26645325	TMEM97	-0.37	-4.55	-0.35	1.1e-5	Osteoprotegerin levels;
PAAD	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.07	6.81	0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg19223190	chr17:80058835	NA	-0.54	-5.72	-0.42	5.47e-8	Life satisfaction;
PAAD	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.77	-8.8	-0.58	2.76e-15	Total body bone mineral density;
PAAD	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg12072164	chr19:44306565	LYPD5	-0.45	-4.82	-0.36	3.39e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg01942863	chr7:99769432	GPC2	-0.44	-4.26	-0.33	3.62e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg11941060	chr3:133502564	NA	-0.63	-6.46	-0.46	1.31e-9	Iron status biomarkers;
PAAD	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg14003231	chr6:33640908	ITPR3	0.37	4.73	0.36	5.19e-6	Height;
PAAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.71	6.9	0.49	1.32e-10	Breast cancer;
PAAD	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg07061783	chr6:25882402	NA	-0.53	-5.3	-0.39	4.09e-7	Blood metabolite levels;
PAAD	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	1.02	16.68	0.8	3.58e-36	Height;
PAAD	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.93	5.14	0.38	8.3e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg00738919	chr7:1100172	C7orf50	0.68	5.06	0.38	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.51	0.34	1.29e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.89	-8.94	-0.59	1.24e-15	Asthma;
PAAD	cis	rs8032158	1.000	rs8032158	chr15:56194877	T/C	cg02198044	chr15:56286336	NEDD4	-0.52	-5.39	-0.4	2.69e-7	Keloid;
PAAD	cis	rs7224685	0.689	rs67831913	chr17:4184856	T/C	cg09597638	chr17:3907349	NA	0.66	5.62	0.41	8.83e-8	Type 2 diabetes;
PAAD	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.04	0.5	6.07e-11	Coffee consumption (cups per day);
PAAD	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	7.82	0.54	8.2e-13	Response to antipsychotic treatment;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg13264159	chr8:625131	ERICH1	0.64	4.4	0.34	2e-5	IgG glycosylation;
PAAD	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.34	4.35	0.33	2.46e-5	Dupuytren's disease;
PAAD	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08219700	chr8:58056026	NA	0.73	5.82	0.43	3.33e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.23	0.51	2.22e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-5.59	-0.41	1.01e-7	Coronary artery disease;
PAAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.5	-5.86	-0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg12564285	chr5:131593104	PDLIM4	0.48	4.91	0.37	2.33e-6	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16024904	chr19:17905718	B3GNT3	0.44	4.35	0.33	2.45e-5	Tumor biomarkers;
PAAD	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	1.27	7.44	0.52	6.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs3806308	0.966	rs3820328	chr1:20142447	A/G	cg13843611	chr1:20143089	RNF186	0.52	5.33	0.4	3.41e-7	Ulcerative colitis;
PAAD	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg05627522	chr15:75251581	NA	-0.42	-4.44	-0.34	1.7e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.08	0.38	1.07e-6	Bone mineral density;
PAAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.9	-0.49	1.33e-10	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg03676636	chr4:99064102	C4orf37	-0.27	-4.99	-0.38	1.64e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.93e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2275731	0.686	rs10904753	chr10:16541341	C/A	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.35	-4.79	-0.36	3.89e-6	Sitting height ratio;
PAAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.74	-8.38	-0.56	3.26e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg11143131	chr5:131608246	PDLIM4	0.51	5.16	0.39	7.7e-7	Blood metabolite levels;
PAAD	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.74	7.9	0.54	5.18e-13	Menopause (age at onset);
PAAD	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.5	-4.92	-0.37	2.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	1.0	10.12	0.63	1.03e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg14146966	chr2:61757674	XPO1	-0.4	-4.99	-0.38	1.63e-6	Tuberculosis;
PAAD	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg19847866	chr10:1019161	NA	-0.69	-6.85	-0.49	1.75e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.06	0.44	1.04e-8	Coffee consumption (cups per day);
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.28	-0.33	3.28e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6024905	0.935	rs6069759	chr20:36957619	T/C	cg07053727	chr20:36965646	BPI	0.46	4.87	0.37	2.77e-6	Bipolar disorder and schizophrenia;
PAAD	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.94	13.06	0.73	1.32e-26	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg20744362	chr22:50050164	C22orf34	0.66	7.6	0.52	2.9e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg21395723	chr22:39101663	GTPBP1	0.49	5.01	0.38	1.48e-6	Menopause (age at onset);
PAAD	cis	rs761746	0.960	rs3818134	chr22:31926725	C/T	cg01338084	chr22:32026380	PISD	-0.47	-4.36	-0.33	2.41e-5	Intelligence;
PAAD	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs2456568	0.808	rs7127351	chr11:93683768	C/T	cg19264203	chr11:92714893	MTNR1B	-0.4	-4.59	-0.35	9.38e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.0	14.39	0.76	3.48e-30	Heart rate;
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.89	12.16	0.7	3.36e-24	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24360773	chr3:23987459	NR1D2	-0.7	-7.44	-0.52	6.93e-12	Smoking initiation;
PAAD	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg24330906	chr2:85765176	MAT2A	0.44	4.46	0.34	1.6e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.48	4.91	0.37	2.32e-6	Total body bone mineral density;
PAAD	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg00277334	chr10:82204260	NA	-0.57	-6.05	-0.44	1.1e-8	Post bronchodilator FEV1;
PAAD	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-10.34	-0.64	2.66e-19	Height;
PAAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.79	-0.36	4e-6	Alcohol dependence;
PAAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Coronary artery disease;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.11	-0.38	9.66e-7	Prudent dietary pattern;
PAAD	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.74	8.53	0.57	1.38e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.63	-6.06	-0.44	1.04e-8	Aortic root size;
PAAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg03303774	chr4:1407052	NA	0.48	6.02	0.44	1.27e-8	Obesity-related traits;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg17774058	chr20:6748719	BMP2	0.52	6.56	0.47	7.85e-10	Response to antipsychotic treatment;
PAAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg21132104	chr15:45694354	SPATA5L1	0.48	4.61	0.35	8.42e-6	Glomerular filtration rate;
PAAD	cis	rs3736485	0.934	rs8036904	chr15:51861438	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs216303	0.570	rs216339	chr12:6149284	T/C	cg12895370	chr12:6755816	ACRBP	-0.58	-4.48	-0.34	1.44e-5	Low vWF levels;
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.81	-0.43	3.59e-8	Bipolar disorder;
PAAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.6e-9	Childhood ear infection;
PAAD	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg06217245	chr20:33103252	DYNLRB1	0.41	4.59	0.35	9.19e-6	Height;
PAAD	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.47	-5.43	-0.4	2.19e-7	Intelligence;
PAAD	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.92	11.72	0.69	5.35e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg07617317	chr6:118971624	C6orf204	0.54	4.56	0.35	1.04e-5	Diastolic blood pressure;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg14582546	chr20:61427684	C20orf20	-0.65	-6.46	-0.46	1.36e-9	Dental caries;
PAAD	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs16958440	0.867	rs79078752	chr18:44667462	A/G	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.6	6.12	0.44	7.46e-9	Ovarian reserve;
PAAD	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs6806253	0.524	rs34584352	chr3:128238629	T/C	cg06796779	chr3:128204927	GATA2	-0.33	-4.25	-0.33	3.77e-5	Pit-and-Fissure caries;
PAAD	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.63	5.97	0.44	1.6e-8	Mean corpuscular volume;
PAAD	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.86e-7	Bladder cancer;
PAAD	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.55	5.39	0.4	2.67e-7	Mortality in heart failure;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.86	6.58	0.47	7e-10	Axial length;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23075101	chr2:215674522	BARD1	0.57	6.59	0.47	6.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg23920097	chr1:209922102	NA	-0.49	-4.39	-0.34	2.11e-5	Red blood cell count;
PAAD	cis	rs863345	0.604	rs1578762	chr1:158497440	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.58	4.27	0.33	3.38e-5	Schizophrenia;
PAAD	trans	rs9409082	0.798	rs62576745	chr9:108918175	G/T	cg07010948	chr13:79181613	NA	-0.34	-6.31	-0.46	2.86e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	10.84	0.66	1.23e-20	Monocyte count;
PAAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg18892244	chr7:807596	HEATR2	-0.7	-5.28	-0.39	4.34e-7	Initial pursuit acceleration;
PAAD	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg06565975	chr8:143823917	SLURP1	-0.26	-5.44	-0.4	2.13e-7	Urinary tract infection frequency;
PAAD	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg03098721	chr1:84464084	TTLL7	-0.47	-4.31	-0.33	2.89e-5	Obesity-related traits;
PAAD	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs58521262	0.556	rs289337	chr19:23151790	A/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg09659197	chr4:152720779	NA	0.39	5.08	0.38	1.08e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.56	-6.31	-0.46	2.9e-9	Educational attainment;
PAAD	cis	rs3784262	0.740	rs33960206	chr15:58288731	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-5.78	-0.42	4.12e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg00428638	chr19:7224713	INSR	0.51	5.59	0.41	1e-7	Hypothyroidism;
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg21665744	chr7:39171113	POU6F2	0.34	5.73	0.42	5.2e-8	IgG glycosylation;
PAAD	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.99	14.21	0.76	1.07e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.64	-0.35	7.54e-6	Renal cell carcinoma;
PAAD	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg08897044	chr19:12950850	MAST1	-0.36	-4.64	-0.35	7.5e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg02462569	chr6:150064036	NUP43	0.49	5.48	0.41	1.71e-7	Lung cancer;
PAAD	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	8.01	0.54	2.74e-13	Eotaxin levels;
PAAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg19847866	chr10:1019161	NA	0.73	7.31	0.51	1.38e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.61	-5.35	-0.4	3.21e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.64	-7.41	-0.52	8.23e-12	Breast cancer;
PAAD	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.69	9.82	0.62	6.25e-18	Breast size;
PAAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs4417704	0.551	rs6754171	chr2:241896013	G/C	cg26818257	chr2:241905806	NA	0.49	5.02	0.38	1.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.75	7.0	0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg24829409	chr8:58192753	C8orf71	-0.9	-7.99	-0.54	3.21e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.56	5.62	0.41	8.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.6	6.19	0.45	5.46e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.74	0.42	4.97e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.81	-7.22	-0.51	2.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6687840	0.544	rs12734524	chr1:159451069	T/G	cg13968061	chr1:159557257	APCS	-0.46	-4.58	-0.35	9.66e-6	Chemerin levels;
PAAD	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg12559170	chr11:5275217	HBG2	0.48	4.75	0.36	4.67e-6	Hemoglobin levels;
PAAD	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.31	0.46	2.92e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.8	6.88	0.49	1.5e-10	Inflammatory skin disease;
PAAD	trans	rs1442089	1.000	rs7236483	chr18:51113479	C/A	cg24118715	chr10:70232072	DNA2	0.73	6.44	0.46	1.48e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg10820045	chr2:198174542	NA	-0.46	-4.63	-0.35	7.72e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.5	5.96	0.43	1.73e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.91	0.66	7.73e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.72	-0.36	5.33e-6	Height;
PAAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.53	5.36	0.4	3.1e-7	Platelet count;
PAAD	cis	rs11825064	0.562	rs80265266	chr11:134509727	A/G	cg02089395	chr11:134479357	NA	-0.93	-5.96	-0.44	1.68e-8	Seasonality;
PAAD	trans	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg01957732	chr6:133561716	EYA4	-0.94	-7.25	-0.51	1.95e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14019695	chr9:139328340	INPP5E	0.61	6.41	0.46	1.77e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs13396519	1.000	rs13387419	chr2:11038833	A/G	cg04169469	chr2:10588434	ODC1;SNORA80B	-0.7	-4.42	-0.34	1.87e-5	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
PAAD	cis	rs7960581	0.722	rs35070158	chr12:99193496	G/A	cg17109042	chr12:99139387	ANKS1B	-0.71	-4.65	-0.35	7.24e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1678542	1.000	rs1284464	chr12:57964617	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.12	0.38	8.95e-7	Rheumatoid arthritis;
PAAD	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.71	4.94	0.37	2.02e-6	Vitiligo;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.79	5.53	0.41	1.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	6.83	0.48	1.89e-10	Schizophrenia;
PAAD	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.54	0.61	3.39e-17	Electrocardiographic conduction measures;
PAAD	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg03098721	chr1:84464084	TTLL7	0.46	4.44	0.34	1.75e-5	Obesity-related traits;
PAAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.5	4.89	0.37	2.54e-6	Morning vs. evening chronotype;
PAAD	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs6499244	0.529	rs7200005	chr16:69929137	G/A	cg05250797	chr16:70222502	NA	0.52	4.69	0.36	5.98e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg14008862	chr17:28927542	LRRC37B2	0.73	5.13	0.38	8.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.26	0.45	3.68e-9	Hip circumference;
PAAD	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.71	5.76	0.42	4.51e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs42648	0.564	rs39284	chr7:89791981	T/C	cg27367526	chr7:89841692	STEAP2	-0.34	-4.76	-0.36	4.55e-6	Homocysteine levels;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg11416102	chr8:651193	ERICH1	0.94	5.9	0.43	2.3e-8	IgG glycosylation;
PAAD	cis	rs863345	0.967	rs2873588	chr1:158467615	T/A	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg26898376	chr11:64110657	CCDC88B	0.55	4.51	0.34	1.27e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs3136441	1.000	rs78500566	chr11:46769788	A/C	cg19486271	chr11:47235900	DDB2	0.65	5.09	0.38	1.05e-6	HDL cholesterol;
PAAD	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.13	-7.01	-0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6804624	0.654	rs2700654	chr3:99169981	C/T	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.71	0.42	5.73e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	6.78	0.48	2.56e-10	Coronary artery disease;
PAAD	cis	rs2635047	0.615	rs1512238	chr18:44748467	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.34	0.33	2.57e-5	Educational attainment;
PAAD	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg04289385	chr6:36355825	ETV7	-0.45	-4.79	-0.36	3.85e-6	Platelet distribution width;
PAAD	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.54	5.72	0.42	5.47e-8	Red blood cell count;
PAAD	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	9.66	0.62	1.68e-17	Cognitive test performance;
PAAD	cis	rs11871801	1.000	rs12937756	chr17:40576813	C/A	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.98e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg23346134	chr3:49453900	TCTA	0.43	4.68	0.36	6.19e-6	Menarche (age at onset);
PAAD	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg04520793	chr17:42248056	ASB16	0.44	5.17	0.39	7.35e-7	Total body bone mineral density;
PAAD	cis	rs16868941	0.534	rs1111909	chr8:103054583	C/T	cg26831001	chr8:102092959	NA	0.48	4.49	0.34	1.38e-5	Coffee consumption;
PAAD	trans	rs1633735	1.000	rs1700575	chr5:8544037	A/T	cg00071051	chr6:44222845	SLC35B2	0.63	6.41	0.46	1.71e-9	Verbal declarative memory;
PAAD	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.06	0.38	1.21e-6	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.23	-0.39	5.64e-7	Personality dimensions;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-8.15	-0.55	1.24e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.71	-5.63	-0.42	8.58e-8	Tuberculosis;
PAAD	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.66	7.85	0.54	6.96e-13	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg08501292	chr6:25962987	TRIM38	0.55	4.3	0.33	3.01e-5	Homocysteine levels;
PAAD	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.87	8.46	0.57	2.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg17366294	chr4:99064904	C4orf37	-0.56	-6.1	-0.44	8.39e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.24	-0.39	5.26e-7	Mean corpuscular volume;
PAAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.98	-7.23	-0.51	2.19e-11	Opioid sensitivity;
PAAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg19784903	chr17:45786737	TBKBP1	-0.43	-4.27	-0.33	3.48e-5	Multiple sclerosis;Ankylosing spondylitis;
PAAD	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.33	-0.4	3.44e-7	Corneal astigmatism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15111708	chr5:154146853	LARP1	0.59	6.49	0.47	1.15e-9	Smoking initiation;
PAAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg22189786	chr22:42395067	WBP2NL	0.67	5.71	0.42	5.64e-8	Birth weight;
PAAD	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.59	-0.41	1.04e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.61	4.55	0.35	1.11e-5	Neuroblastoma;
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.63	8.18	0.55	1.05e-13	Hypertriglyceridemia;
PAAD	cis	rs1436294	0.757	rs616849	chr4:20199470	G/A	cg18206137	chr4:20811042	KCNIP4	-0.45	-4.28	-0.33	3.23e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.38	-0.4	2.73e-7	Height;
PAAD	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.53	-5.01	-0.38	1.48e-6	Vitiligo;
PAAD	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg19898043	chr22:18121309	BCL2L13	0.72	6.93	0.49	1.1e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs9463078	0.838	rs9395066	chr6:45095163	A/C	cg25276700	chr6:44698697	NA	-0.48	-5.56	-0.41	1.2e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs427941	1.000	rs449806	chr7:101875641	C/T	cg06721601	chr7:101762633	CUX1	-0.44	-4.49	-0.34	1.38e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs72843506	0.656	rs111249650	chr17:19911830	A/T	cg05625806	chr17:19284432	MAPK7	0.69	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.62	6.85	0.49	1.69e-10	Lung cancer;
PAAD	cis	rs7180079	1.000	rs4238425	chr15:64671193	C/A	cg18210365	chr15:65066710	RBPMS2	0.65	4.93	0.37	2.14e-6	Monocyte count;
PAAD	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.1	-11.79	-0.69	3.5e-23	Blood pressure (smoking interaction);
PAAD	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg01796438	chr3:11312864	ATG7	-0.62	-4.9	-0.37	2.4e-6	Circulating chemerin levels;
PAAD	cis	rs7326068	0.610	rs2314719	chr13:21313282	G/A	cg27234864	chr13:21295941	IL17D	0.59	4.94	0.37	2.04e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10864907	0.837	rs11123153	chr2:113707114	G/A	cg06156847	chr2:113672199	IL1F7	-0.42	-4.34	-0.33	2.62e-5	Pulmonary function;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	5.16	0.39	7.53e-7	Tonsillectomy;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg06287003	chr12:125626642	AACS	-0.47	-4.48	-0.34	1.43e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg19413350	chr8:57351067	NA	-0.47	-4.43	-0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.81	-8.68	-0.58	5.85e-15	Paraoxonase activity;
PAAD	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.47	4.82	0.36	3.5e-6	Systemic lupus erythematosus;
PAAD	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg17380795	chr3:122379686	NA	0.49	5.05	0.38	1.26e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	4.37	0.33	2.26e-5	Thyroid stimulating hormone;
PAAD	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	6.98	0.49	8.6e-11	Homoarginine levels;
PAAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.59	4.82	0.36	3.41e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.45	4.3	0.33	3.08e-5	Breast cancer;
PAAD	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.11	-0.38	9.6e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.9	10.95	0.66	6.15e-21	Menarche (age at onset);
PAAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.6	0.47	6.42e-10	Total body bone mineral density;
PAAD	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg01620082	chr3:125678407	NA	-1.48	-8.65	-0.57	6.92e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.84	7.39	0.51	8.94e-12	Phospholipid levels (plasma);
PAAD	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.28	-0.56	6.06e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07167872	chr1:205819463	PM20D1	0.5	4.74	0.36	4.98e-6	Parkinson's disease;
PAAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.22	-0.39	5.68e-7	Myopia (pathological);
PAAD	cis	rs10991814	0.920	rs75136602	chr9:93969277	G/A	cg14446406	chr9:93919335	NA	0.59	4.53	0.34	1.19e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.69	-0.42	6.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.34	0.56	4.22e-14	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.65	7.88	0.54	5.96e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.05	0.38	1.26e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.39	-0.34	2.15e-5	Joint mobility (Beighton score);
PAAD	cis	rs8070740	0.503	rs10792	chr17:5288179	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.46	-0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg20503657	chr10:835505	NA	0.53	5.58	0.41	1.06e-7	Survival in rectal cancer;
PAAD	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09107932	chr16:84853583	CRISPLD2	0.58	6.36	0.46	2.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.1e-9	Morning vs. evening chronotype;
PAAD	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.45	-4.27	-0.33	3.4e-5	Symmetrical dimethylarginine levels;
PAAD	cis	rs7009516	0.669	rs12674766	chr8:24241732	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.75	-0.42	4.74e-8	Hair greying;
PAAD	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.82	-6.55	-0.47	8.32e-10	Brain cytoarchitecture;
PAAD	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.64	6.57	0.47	7.71e-10	Primary sclerosing cholangitis;
PAAD	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.73	7.99	0.54	3.16e-13	Morning vs. evening chronotype;
PAAD	cis	rs4899554	0.640	rs72719914	chr14:75708305	G/A	cg18117039	chr14:75741733	NA	0.41	4.71	0.36	5.65e-6	Inflammatory bowel disease;
PAAD	cis	rs990171	0.955	rs3817465	chr2:103039584	A/T	cg03938978	chr2:103052716	IL18RAP	0.43	4.29	0.33	3.17e-5	Lymphocyte counts;
PAAD	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.74	-8.33	-0.56	4.42e-14	Lung cancer;
PAAD	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg03161606	chr19:29218774	NA	0.7	6.66	0.48	4.8e-10	Methadone dose in opioid dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04180125	chr19:3557666	C19orf28	0.61	6.33	0.46	2.59e-9	Myopia (pathological);
PAAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg10356904	chr22:49881777	NA	-0.51	-4.86	-0.37	2.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg08501292	chr6:25962987	TRIM38	0.79	5.06	0.38	1.22e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs528301	0.833	rs567047	chr2:45139093	A/G	cg15393275	chr2:45165193	NA	-0.52	-5.64	-0.42	8.16e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.88	8.12	0.55	1.45e-13	Response to diuretic therapy;
PAAD	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23871388	chr19:56609854	ZNF787	-0.63	-7.26	-0.51	1.87e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg14146966	chr2:61757674	XPO1	0.44	5.41	0.4	2.45e-7	Tuberculosis;
PAAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.77	-8.89	-0.58	1.63e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg03538708	chr1:25844672	NA	0.53	5.42	0.4	2.32e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.54e-5	Total body bone mineral density;
PAAD	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg24375607	chr4:120327624	NA	0.57	5.46	0.4	1.9e-7	Corneal astigmatism;
PAAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.84	6.71	0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.92	7.74	0.53	1.31e-12	Psoriasis;
PAAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs732765	0.734	rs12323361	chr14:75171706	T/C	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-5.4	-0.4	2.48e-7	Schizophrenia;
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.72	7.66	0.53	1.99e-12	Longevity;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg24565620	chr2:194026	NA	0.55	4.39	0.34	2.08e-5	Blood protein levels;
PAAD	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	7.05e-7	Tuberculosis;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.66	8.54	0.57	1.28e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg26174226	chr8:58114915	NA	-0.59	-4.43	-0.34	1.79e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg05457628	chr5:178986728	RUFY1	-0.54	-5.48	-0.41	1.7e-7	Lung cancer;
PAAD	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.26	0.64	4.16e-19	Prudent dietary pattern;
PAAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.53	4.88	0.37	2.7e-6	Schizophrenia;
PAAD	cis	rs1075265	0.870	rs7569214	chr2:54216186	G/A	cg04546899	chr2:54196757	PSME4	0.38	5.62	0.41	8.94e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.58	-0.41	1.07e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.58	5.26	0.39	4.89e-7	Schizophrenia;
PAAD	cis	rs66530629	0.874	rs6667299	chr1:25158500	T/C	cg01905478	chr1:25040257	NA	-0.48	-5.27	-0.39	4.66e-7	Plateletcrit;
PAAD	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg27211696	chr2:191398769	TMEM194B	0.44	4.34	0.33	2.55e-5	Urinary metabolites;
PAAD	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	1.08	14.51	0.76	1.71e-30	Headache;
PAAD	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.85	0.54	6.92e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.6	0.52	2.85e-12	Morning vs. evening chronotype;
PAAD	cis	rs1371614	0.588	rs10181727	chr2:27171245	C/T	cg07507200	chr2:27712693	IFT172	0.48	4.34	0.33	2.55e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04016957	chr4:1044486	NA	0.54	5.98	0.44	1.53e-8	Recombination rate (males);
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.6	0.41	9.94e-8	Prudent dietary pattern;
PAAD	cis	rs1075265	0.633	rs4671190	chr2:54312741	T/C	cg04546899	chr2:54196757	PSME4	0.33	4.72	0.36	5.37e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg25558440	chr8:11882962	NA	-0.45	-4.3	-0.33	3.08e-5	Triglycerides;
PAAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.59	-5.65	-0.42	7.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	10.01	0.63	1.98e-18	Smoking behavior;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg25382128	chr12:54346509	NA	-0.48	-4.84	-0.37	3.13e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.42	-0.34	1.85e-5	Caffeine consumption;
PAAD	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg26816564	chr1:7831052	VAMP3	0.6	5.0	0.38	1.59e-6	Inflammatory bowel disease;
PAAD	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg06617341	chr2:177005611	NA	-0.48	-4.33	-0.33	2.69e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg03676636	chr4:99064102	C4orf37	0.34	4.83	0.36	3.31e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10937913	0.782	rs9683949	chr4:2744480	C/T	cg00231918	chr4:2819393	SH3BP2	-0.38	-4.27	-0.33	3.49e-5	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.59	-7.86	-0.54	6.55e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.5e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	1.01	6.28	0.45	3.46e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07228441	chr8:681215	ERICH1	0.57	6.62	0.47	5.72e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-11.12	-0.67	2.11e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg22029157	chr1:209979665	IRF6	0.73	6.96	0.49	9.72e-11	Coronary artery disease;
PAAD	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg00277334	chr10:82204260	NA	-0.58	-5.98	-0.44	1.56e-8	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.2	15.4	0.78	7.58e-33	IgG glycosylation;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg22601191	chr20:60968625	CABLES2	-0.56	-5.31	-0.4	3.79e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs62179067	0.708	rs62176021	chr2:179909130	C/G	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.94e-7	Red blood cell count;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg22307297	chr20:60903441	LAMA5	-0.45	-4.26	-0.33	3.62e-5	Colorectal cancer;
PAAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.42	-0.34	1.85e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg16578609	chr1:2399051	NA	-0.42	-4.32	-0.33	2.79e-5	Non-obstructive azoospermia;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg07218578	chr22:31556156	RNF185	0.64	6.76	0.48	2.79e-10	Iris heterochromicity;
PAAD	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.73	-0.36	5.13e-6	Height;
PAAD	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.5	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.11e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs28489187	0.683	rs1498373	chr1:85790633	G/A	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	cis	rs2936519	1.000	rs2978921	chr8:6640803	A/G	cg22103414	chr8:6638082	NA	-0.4	-4.27	-0.33	3.44e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs11563648	0.553	rs6979232	chr7:127016217	T/A	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs17125944	0.686	rs2357947	chr14:53345378	C/T	cg00686598	chr14:53173677	PSMC6	-0.96	-6.22	-0.45	4.53e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg09197432	chr4:183729176	NA	0.62	5.35	0.4	3.18e-7	Pediatric autoimmune diseases;
PAAD	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.62	-5.32	-0.4	3.64e-7	Corneal structure;
PAAD	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.6	-6.51	-0.47	1.03e-9	Pancreatic cancer;
PAAD	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	4.58	0.35	9.64e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08219700	chr8:58056026	NA	0.68	5.21	0.39	6.08e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2902440	0.502	rs58621044	chr1:67664840	G/C	cg03340356	chr1:67600835	NA	0.43	4.71	0.36	5.66e-6	Crohn's disease;
PAAD	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.4	-5.88	-0.43	2.55e-8	Educational attainment (years of education);
PAAD	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.92	-8.51	-0.57	1.5e-14	Chronic sinus infection;
PAAD	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.56	-5.29	-0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	cis	rs863345	0.604	rs7525362	chr1:158493890	G/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.56	6.86	0.49	1.63e-10	Monobrow;
PAAD	cis	rs2061333	0.894	rs10853771	chr19:44629448	C/T	cg23489630	chr19:44645078	ZNF234	-0.57	-4.3	-0.33	3.06e-5	Alzheimer's disease;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.85	10.27	0.64	4.12e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.81	7.22	0.51	2.29e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.82	4.41	0.34	1.97e-5	Childhood ear infection;
PAAD	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.72	7.74	0.53	1.27e-12	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg05313129	chr8:58192883	C8orf71	-0.67	-5.68	-0.42	6.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-11.29	-0.68	7.68e-22	Height;
PAAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.76	8.79	0.58	3.01e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg05805236	chr11:65401703	PCNXL3	-0.63	-6.62	-0.47	5.77e-10	Acne (severe);
PAAD	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4919087	0.620	rs1253427	chr10:98981092	G/A	cg25902810	chr10:99078978	FRAT1	-0.54	-4.68	-0.36	6.21e-6	Monocyte count;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg23708337	chr7:1209742	NA	0.7	5.38	0.4	2.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.93	7.12	0.5	3.93e-11	Inflammatory bowel disease;
PAAD	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-5.82	-0.43	3.33e-8	Blood protein levels;
PAAD	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg03948781	chr1:205179583	DSTYK	0.48	4.47	0.34	1.51e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	10.48	0.65	1.14e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs375066	0.935	rs365556	chr19:44408199	A/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg22143856	chr6:28129313	ZNF389	0.63	4.9	0.37	2.39e-6	Depression;
PAAD	cis	rs501120	0.584	rs11238937	chr10:44719816	T/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2286503	0.966	rs6949233	chr7:22858191	T/G	cg04907244	chr7:22894795	SNORD93	-0.43	-5.31	-0.4	3.84e-7	Fibrinogen;
PAAD	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg26205652	chr12:48591994	NA	0.83	7.51	0.52	4.73e-12	Longevity (90 years and older);
PAAD	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.39	-0.51	9e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.5	-4.87	-0.37	2.83e-6	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.31e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.57	6.26	0.45	3.67e-9	Mean corpuscular volume;
PAAD	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg07154921	chr7:157260426	NA	0.44	4.35	0.33	2.5e-5	Body mass index;
PAAD	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.06	0.63	1.43e-18	Bladder cancer;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.57	-5.61	-0.41	9.15e-8	Crohn's disease;
PAAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.64	-6.9	-0.49	1.28e-10	Schizophrenia;
PAAD	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.77	-6.53	-0.47	9.08e-10	Vitiligo;
PAAD	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg07671805	chr5:74907694	NA	0.56	4.34	0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.75	9.23	0.6	2.14e-16	Alcohol dependence;
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.85	13.36	0.73	2.08e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.73	-9.16	-0.6	3.25e-16	Educational attainment;
PAAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.65	-6.36	-0.46	2.26e-9	Body mass index;
PAAD	cis	rs3106136	0.681	rs11097423	chr4:95303161	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg12908607	chr1:44402522	ARTN	-0.42	-4.64	-0.35	7.53e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg10356904	chr22:49881777	NA	-0.49	-4.94	-0.37	2.04e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg10395934	chr14:104002654	TRMT61A	0.48	4.65	0.35	7.18e-6	Body mass index;
PAAD	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-4.33	-0.33	2.71e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	8.14	0.55	1.3e-13	Prudent dietary pattern;
PAAD	cis	rs728616	0.867	rs41298231	chr10:81682461	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.77	-0.36	4.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs761746	0.542	rs7290856	chr22:32230916	G/A	cg01338084	chr22:32026380	PISD	0.54	4.8	0.36	3.72e-6	Intelligence;
PAAD	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.5	4.72	0.36	5.22e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.77	6.75	0.48	2.92e-10	Breast cancer;
PAAD	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg16964102	chr10:135390573	NA	0.42	4.54	0.35	1.14e-5	Obesity-related traits;
PAAD	cis	rs1018697	0.761	rs7904281	chr10:104544836	A/G	cg14489801	chr10:103603810	KCNIP2	-0.3	-4.35	-0.33	2.46e-5	Colorectal adenoma (advanced);
PAAD	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg04450456	chr4:17643702	FAM184B	0.53	5.74	0.42	5.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.57	-5.64	-0.42	8.25e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.86	-12.0	-0.7	9.14e-24	Cystic fibrosis severity;
PAAD	cis	rs17209837	1.000	rs59616301	chr7:87118407	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	5.36	0.4	3.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg11949866	chr1:10754891	CASZ1	0.52	4.32	0.33	2.76e-5	Ewing sarcoma;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.74	9.02	0.59	7.64e-16	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19034510	chr7:44058724	POLR2J4	-0.64	-6.66	-0.48	4.74e-10	Smoking initiation;
PAAD	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg23283495	chr1:209979779	IRF6	0.77	7.06	0.5	5.58e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg10589385	chr1:150898437	SETDB1	0.39	4.89	0.37	2.51e-6	Melanoma;
PAAD	cis	rs1419980	0.730	rs11054699	chr12:7744539	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg12935359	chr14:103987150	CKB	-0.63	-7.11	-0.5	4.16e-11	Body mass index;
PAAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs8040855	0.627	rs4980357	chr15:85608109	G/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs73019876	0.901	rs430614	chr19:22233034	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	1.99e-5	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19880899	chr2:64067976	UGP2	0.63	6.41	0.46	1.71e-9	Obesity-related traits;
PAAD	cis	rs727479	0.543	rs6493489	chr15:51514203	C/T	cg18154567	chr15:51464013	NA	-0.41	-4.26	-0.33	3.56e-5	Estradiol levels;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs6494488	0.500	rs72741385	chr15:64809311	A/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs258892	0.842	rs11956081	chr5:72020287	T/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs3135063	0.847	rs1138690	chr4:3291401	G/T	cg01612440	chr4:3296283	NA	0.47	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs7932354	0.583	rs10742784	chr11:46899282	G/A	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.86	-11.09	-0.67	2.67e-21	Prudent dietary pattern;
PAAD	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	12.18	0.7	3.06e-24	Birth weight;
PAAD	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.89	10.71	0.66	2.78e-20	Coronary artery disease;
PAAD	cis	rs1800795	0.530	rs62449494	chr7:22758035	A/G	cg05472934	chr7:22766657	IL6	0.56	5.93	0.43	1.94e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.66	7.0	0.49	7.72e-11	Blood protein levels;
PAAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg18769074	chr3:133464867	TF	0.42	4.95	0.37	1.99e-6	Iron status biomarkers (transferrin levels);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08770590	chr10:112064742	SMNDC1	-0.64	-8.09	-0.55	1.73e-13	Body fat percentage;
PAAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg10591111	chr5:226296	SDHA	-0.67	-4.73	-0.36	5.2e-6	Breast cancer;
PAAD	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg19760965	chr3:194868843	C3orf21	0.45	4.69	0.36	5.95e-6	Non-small cell lung cancer;
PAAD	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg04087571	chr11:116723030	SIK3	-0.37	-5.46	-0.4	1.91e-7	Subjective well-being;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg20302533	chr7:39170763	POU6F2	0.5	6.95	0.49	1.03e-10	IgG glycosylation;
PAAD	cis	rs73019876	0.502	rs7251108	chr19:22250689	G/C	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.57	7.15	0.5	3.47e-11	Schizophrenia;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg24213567	chr19:53496664	ZNF702P	-0.41	-4.3	-0.33	3.08e-5	Psoriasis;
PAAD	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg05791153	chr7:19748676	TWISTNB	0.65	4.99	0.38	1.6e-6	Thyroid stimulating hormone;
PAAD	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.81	6.86	0.49	1.61e-10	Morning vs. evening chronotype;
PAAD	cis	rs7714584	1.000	rs4958424	chr5:150225036	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00982548	chr2:198649783	BOLL	-0.79	-5.77	-0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.89	-0.49	1.37e-10	Menopause (age at onset);
PAAD	cis	rs3764400	0.567	rs208012	chr17:46258017	G/A	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg00647317	chr7:50633725	DDC	0.47	4.92	0.37	2.21e-6	Systemic sclerosis;
PAAD	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.84	9.36	0.6	1.01e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.86	7.48	0.52	5.54e-12	Alzheimer's disease;
PAAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.05	13.76	0.74	1.72e-28	Body mass index;
PAAD	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.11	0.38	9.52e-7	Lung cancer in ever smokers;
PAAD	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg08648136	chr8:956695	NA	0.51	5.45	0.4	2.02e-7	Schizophrenia;
PAAD	cis	rs4792901	0.802	rs28636996	chr17:41572786	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.95e-5	Dupuytren's disease;
PAAD	cis	rs2235642	0.582	rs11643891	chr16:1565540	C/T	cg06970076	chr16:1560791	IFT140	0.56	5.01	0.38	1.47e-6	Coronary artery disease;
PAAD	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19671926	chr4:122722719	EXOSC9	-0.57	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg23196781	chr12:27117782	FGFR1OP2	-0.56	-6.53	-0.47	9.44e-10	Energy expenditure (24h);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02025656	chr7:668612	PRKAR1B	0.6	7.29	0.51	1.57e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11105468	1.000	rs7975788	chr12:90273927	T/G	cg16962463	chr12:89968675	NA	0.44	4.31	0.33	2.94e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.49	4.39	0.34	2.12e-5	Homoarginine levels;
PAAD	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.27	0.33	3.46e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.72	5.2	0.39	6.23e-7	Plateletcrit;
PAAD	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.38	5.37	0.4	2.89e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12097340	chr4:103244130	SLC39A8	-0.61	-6.29	-0.45	3.14e-9	Obesity-related traits;
PAAD	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00730794	chr14:24617010	PSME2;RNF31	-0.78	-6.68	-0.48	4.13e-10	Neuroticism;
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.86	-0.49	1.63e-10	Blood metabolite levels;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.53	6.69	0.48	3.99e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg24642844	chr7:1081250	C7orf50	-0.83	-4.98	-0.37	1.67e-6	Longevity;Endometriosis;
PAAD	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.55	5.92	0.43	2.09e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9815354	0.951	rs12492599	chr3:42005734	C/A	cg03022575	chr3:42003672	ULK4	-0.74	-5.43	-0.4	2.14e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg15017067	chr4:17643749	FAM184B	0.4	4.53	0.35	1.17e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg23417306	chr2:180868811	CWC22	-0.5	-4.6	-0.35	8.87e-6	Schizophrenia;
PAAD	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg19197139	chr17:4613644	ARRB2	0.86	8.97	0.59	1.02e-15	Lymphocyte counts;
PAAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.76	-9.58	-0.61	2.74e-17	Bone mineral density;
PAAD	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.59	-5.53	-0.41	1.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13606994	chr1:44402422	ARTN	-0.48	-4.78	-0.36	4.13e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg05110241	chr16:68378359	PRMT7	-0.68	-5.25	-0.39	5.13e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg25382128	chr12:54346509	NA	-0.59	-5.95	-0.43	1.8e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.45	4.84	0.37	3.22e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.45	-4.37	-0.33	2.33e-5	Height;
PAAD	cis	rs6466055	0.636	rs7796945	chr7:104838050	G/A	cg04380332	chr7:105027541	SRPK2	0.51	4.99	0.38	1.6e-6	Schizophrenia;
PAAD	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	4.51	0.34	1.27e-5	IgG glycosylation;
PAAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.89	-0.37	2.55e-6	Vitiligo;
PAAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg06565975	chr8:143823917	SLURP1	-0.22	-4.66	-0.35	6.74e-6	Urinary tract infection frequency;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.57	5.63	0.42	8.59e-8	Parkinson's disease;
PAAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs11892454	0.515	rs2176180	chr2:26030368	C/T	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg14008862	chr17:28927542	LRRC37B2	0.79	4.86	0.37	2.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs375066	0.935	rs397913	chr19:44398940	C/T	cg08633290	chr19:44405433	NA	0.54	5.3	0.4	3.92e-7	Breast cancer;
PAAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg00579200	chr11:133705235	NA	-0.5	-5.75	-0.42	4.7e-8	Childhood ear infection;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.75	8.68	0.58	5.7e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg13606994	chr1:44402422	ARTN	0.42	4.54	0.35	1.14e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8077577	0.945	rs62073649	chr17:18080522	T/C	cg16794390	chr17:18148240	FLII	0.58	4.83	0.37	3.25e-6	Obesity-related traits;
PAAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.59	-6.12	-0.44	7.71e-9	Monocyte count;
PAAD	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.81	9.26	0.6	1.85e-16	Heart rate;
PAAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg01815783	chr4:1047043	NA	-0.41	-4.43	-0.34	1.82e-5	Recombination rate (males);
PAAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs10044254	0.703	rs55983626	chr5:15734242	A/T	cg07238450	chr5:15720153	FBXL7	-0.52	-4.36	-0.33	2.39e-5	Asthma (corticosteroid response);
PAAD	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.92	-0.37	2.27e-6	Mean corpuscular volume;
PAAD	cis	rs17023223	0.537	rs61808892	chr1:119599207	C/T	cg26570165	chr1:119541833	NA	-0.45	-4.26	-0.33	3.63e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.69	-7.35	-0.51	1.13e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg11812906	chr14:75593930	NEK9	-0.51	-4.96	-0.37	1.88e-6	Caffeine consumption;
PAAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg01939980	chr4:1354348	KIAA1530	0.44	4.33	0.33	2.64e-5	Longevity;
PAAD	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13047869	chr3:10149882	C3orf24	0.78	6.38	0.46	2.04e-9	Alzheimer's disease;
PAAD	cis	rs6681460	0.674	rs2121051	chr1:67017177	G/A	cg02459107	chr1:67143332	SGIP1	0.58	5.06	0.38	1.19e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Electroencephalogram traits;
PAAD	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.46	-4.41	-0.34	1.95e-5	Menarche (age at onset);
PAAD	cis	rs7192380	0.651	rs61460899	chr16:69682780	T/A	cg05250797	chr16:70222502	NA	0.64	5.61	0.41	9.33e-8	Sjögren's syndrome;
PAAD	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.73	7.77	0.53	1.09e-12	Schizophrenia;
PAAD	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.63	5.61	0.41	9.41e-8	Lung cancer;
PAAD	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg25811867	chr2:3488468	NA	0.47	4.41	0.34	1.95e-5	Neurofibrillary tangles;
PAAD	cis	rs4740619	0.689	rs10810508	chr9:15955566	C/T	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.75	-7.76	-0.53	1.16e-12	Prostate cancer;
PAAD	cis	rs7071247	0.915	rs12252305	chr10:105279335	G/A	cg14553436	chr10:104822996	CNNM2	0.65	4.77	0.36	4.26e-6	Platelet aggregation;
PAAD	trans	rs1376303	0.778	rs4723220	chr7:32954032	A/G	cg19007141	chr4:140808552	MAML3	-0.59	-6.49	-0.47	1.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.18	-0.5	2.9e-11	Personality dimensions;
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.34	4.85	0.37	3.07e-6	Asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17742617	chr12:63039927	PPM1H	-0.61	-6.3	-0.46	2.98e-9	Obesity-related traits;
PAAD	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.49	5.01	0.38	1.47e-6	Male-pattern baldness;
PAAD	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg22827986	chr11:48284249	OR4X1	-0.41	-5.04	-0.38	1.31e-6	Migraine - clinic-based;
PAAD	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg20790798	chr5:1857306	NA	-0.41	-4.39	-0.34	2.09e-5	Cardiovascular disease risk factors;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13939156	chr17:80058883	NA	0.45	5.11	0.38	9.57e-7	Life satisfaction;
PAAD	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01630567	chr9:26892919	C9orf82	0.62	7.02	0.49	6.96e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg00792783	chr2:198669748	PLCL1	-0.48	-4.28	-0.33	3.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs834811	0.623	rs1097151	chr7:135883871	A/G	cg01726295	chr7:135938950	NA	-0.4	-4.29	-0.33	3.13e-5	Post-traumatic stress disorder;
PAAD	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg12508331	chr16:3208203	NA	0.48	4.4	0.34	2.02e-5	Body mass index (adult);
PAAD	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.57	6.52	0.47	9.79e-10	Total body bone mineral density;
PAAD	cis	rs7714584	1.000	rs1896709	chr5:150245032	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.49	0.41	1.62e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.45	0.4	2.03e-7	Type 2 diabetes;
PAAD	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg20761395	chr17:511517	VPS53	0.69	7.82	0.54	8.35e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2290405	0.532	rs11248050	chr4:854409	T/C	cg04824913	chr4:887549	GAK	0.76	7.96	0.54	3.71e-13	Systemic sclerosis;
PAAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.78	7.06	0.5	5.68e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs4234284	1.000	rs6767820	chr3:126976217	G/C	cg27326032	chr3:127006922	NA	-0.45	-4.54	-0.35	1.12e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg22601191	chr20:60968625	CABLES2	0.57	5.76	0.42	4.57e-8	Colorectal cancer;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03605463	chr16:89740564	NA	0.52	4.79	0.36	4.01e-6	Vitiligo;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.08	13.61	0.74	4.37e-28	Subjective well-being;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.88	-7.59	-0.52	2.98e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg00166722	chr3:10149974	C3orf24	0.69	6.22	0.45	4.62e-9	Alzheimer's disease;
PAAD	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs939584	1.000	rs7571967	chr2:646839	T/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs10421328	0.848	rs867616	chr19:19757682	C/T	cg11584989	chr19:19387371	SF4	0.88	6.75	0.48	3e-10	Parental longevity (combined parental age at death);
PAAD	cis	rs28493229	0.737	rs2288450	chr19:41209177	C/T	cg11601297	chr19:41224147	ITPKC;ADCK4	0.41	4.35	0.33	2.51e-5	Kawasaki disease;
PAAD	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.0	9.23	0.6	2.14e-16	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs1371614	0.632	rs6759548	chr2:27161060	A/G	cg00617064	chr2:27272375	NA	-0.41	-4.37	-0.33	2.29e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs438465	1.000	rs433756	chr6:169813309	T/C	cg11181693	chr6:169825345	NA	-0.57	-4.38	-0.34	2.16e-5	Corneal astigmatism;
PAAD	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.78	0.42	4.09e-8	Response to antipsychotic treatment;
PAAD	cis	rs34043524	1.000	rs6853063	chr4:117993647	A/C	cg14562394	chr4:117851367	NA	0.82	4.35	0.33	2.48e-5	Lateral ventricle volume in trauma-exposed individuals;
PAAD	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.66	-6.61	-0.47	6.14e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.52	-5.16	-0.39	7.59e-7	Mortality in heart failure;
PAAD	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.52	-5.01	-0.38	1.46e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2013441	0.606	rs12942179	chr17:19999781	G/A	cg25070565	chr17:20044324	CYTSB	-0.47	-4.9	-0.37	2.4e-6	Obesity-related traits;
PAAD	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.3	-0.33	2.99e-5	IgG glycosylation;
PAAD	cis	rs7707921	0.881	rs73136782	chr5:81443520	T/G	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs6908034	0.660	rs6918235	chr6:19788427	A/T	cg02682789	chr6:19804855	NA	0.8	4.47	0.34	1.54e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg21546286	chr11:48923668	NA	-0.47	-4.98	-0.37	1.74e-6	Height;
PAAD	cis	rs11696501	0.694	rs6130870	chr20:44263263	T/C	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.67	4.57	0.35	9.87e-6	IgG glycosylation;
PAAD	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	1.000	rs1052501	chr3:41925398	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.85	-0.43	2.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.5	5.17	0.39	7.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.85	6.42	0.46	1.69e-9	Axial length;
PAAD	cis	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs17401966	0.597	rs2180185	chr1:10246129	C/G	cg15226751	chr1:10001911	LZIC	0.4	4.43	0.34	1.79e-5	Hepatocellular carcinoma;
PAAD	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.5	-0.34	1.34e-5	Triglycerides;
PAAD	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg16898833	chr6:26189333	HIST1H4D	0.77	4.4	0.34	2.06e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.61	5.69	0.42	6.29e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.67	-7.68	-0.53	1.84e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.87	-10.51	-0.65	9.01e-20	Sudden cardiac arrest;
PAAD	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.78	-8.47	-0.57	2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.7	-6.7	-0.48	3.77e-10	Body mass index;
PAAD	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.51	-5.75	-0.42	4.76e-8	Personality dimensions;
PAAD	trans	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2213920	0.619	rs2188047	chr9:118256660	G/C	cg13918206	chr9:118159781	DEC1	0.93	5.99	0.44	1.45e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08905358	chr2:109065694	GCC2	0.68	6.7	0.48	3.86e-10	Obesity-related traits;
PAAD	cis	rs3857067	0.629	rs2865342	chr4:95099609	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.61	-6.09	-0.44	8.73e-9	QT interval;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05357674	chr10:88963437	NA	0.71	7.21	0.5	2.52e-11	Obesity-related traits;
PAAD	cis	rs7896691	1.000	rs7896691	chr10:3155173	C/T	cg15228268	chr10:3146741	PFKP	-0.81	-4.99	-0.37	1.66e-6	Disc degeneration (lumbar);
PAAD	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Mosquito bite size;
PAAD	cis	rs7534824	0.625	rs17525507	chr1:101430504	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs939584	1.000	rs4854346	chr2:638918	A/C	cg14515364	chr2:636606	NA	0.47	4.28	0.33	3.26e-5	Body mass index;
PAAD	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.5	0.71	4.04e-25	Breast cancer;
PAAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.51	0.41	1.5e-7	Depression;
PAAD	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.67	4.7	0.36	5.9e-6	HDL cholesterol levels;
PAAD	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.76	-8.04	-0.55	2.29e-13	Schizophrenia;
PAAD	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.31	0.56	5.07e-14	Alzheimer's disease (late onset);
PAAD	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.03	-0.44	1.17e-8	Morning vs. evening chronotype;
PAAD	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg23119463	chr10:134592391	INPP5A	-0.5	-4.7	-0.36	5.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg02580895	chr19:2754563	NA	-0.51	-4.45	-0.34	1.64e-5	Total cholesterol levels;
PAAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	5.57	0.41	1.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.49	4.59	0.35	9.4e-6	Red blood cell count;
PAAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15557168	chr22:42548783	NA	-0.58	-5.81	-0.43	3.58e-8	Cognitive function;
PAAD	cis	rs662064	0.748	rs2480777	chr1:10597551	C/T	cg17425144	chr1:10567563	PEX14	-0.39	-4.31	-0.33	2.87e-5	Asthma;
PAAD	cis	rs78707713	0.841	rs76628955	chr10:71208625	C/T	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	cis	rs73019876	0.869	rs8103163	chr19:22174752	A/C	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.67	7.05	0.5	5.75e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	1.15	5.48	0.41	1.71e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.66	-5.46	-0.4	1.91e-7	Common traits (Other);
PAAD	cis	rs7168592	1.000	rs62019723	chr15:101739721	C/T	cg24254196	chr15:101719523	CHSY1	-0.65	-4.58	-0.35	9.44e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg03983715	chr16:68378420	PRMT7	-0.94	-7.13	-0.5	3.83e-11	Schizophrenia;
PAAD	cis	rs73086581	0.786	rs6037705	chr20:3952830	G/C	cg02187196	chr20:3869020	PANK2	0.58	4.89	0.37	2.52e-6	Response to antidepressants in depression;
PAAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.76	8.15	0.55	1.26e-13	DNA methylation (variation);
PAAD	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg14458575	chr2:238380390	NA	0.63	5.23	0.39	5.43e-7	Prostate cancer;
PAAD	cis	rs10885582	0.781	rs10159857	chr10:116294870	C/A	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.6	-6.1	-0.44	8.21e-9	Glioblastoma;
PAAD	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.73	7.43	0.52	7.28e-12	Superior crus of antihelix expression;
PAAD	cis	rs2249296	0.504	rs7548881	chr1:86795817	G/A	cg17424433	chr1:86913263	CLCA2	0.45	4.34	0.33	2.63e-5	Crohn's disease-related phenotypes;
PAAD	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-6.1	-0.44	8.49e-9	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.7	4.97	0.37	1.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.72	6.9	0.49	1.35e-10	Obesity-related traits;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.59	5.57	0.41	1.13e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg01114163	chr5:1856713	NA	-0.42	-4.4	-0.34	1.99e-5	Cardiovascular disease risk factors;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14640736	chr13:39612797	NHLRC3;C13orf23	-0.63	-6.32	-0.46	2.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg01200585	chr1:228362443	C1orf69	0.62	5.51	0.41	1.53e-7	Coronary artery disease;
PAAD	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21646471	chr2:242523971	THAP4	0.68	5.04	0.38	1.31e-6	Prostate cancer;
PAAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs4704187	0.687	rs4295370	chr5:74528858	G/T	cg03227963	chr5:74354835	NA	0.49	4.75	0.36	4.75e-6	Response to amphetamines;
PAAD	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	4.61	0.35	8.53e-6	Lung cancer in ever smokers;
PAAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg15017067	chr4:17643749	FAM184B	0.39	4.3	0.33	3.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg10191248	chr10:134441085	INPP5A	-0.45	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	7.06	0.5	5.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4692589	0.581	rs6817357	chr4:170962516	A/G	cg19918862	chr4:170955249	NA	0.5	4.44	0.34	1.71e-5	Anxiety disorder;
PAAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg14345882	chr6:26364793	BTN3A2	0.38	4.38	0.33	2.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	6.7	0.48	3.75e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg00614314	chr15:82944287	LOC80154	0.5	5.04	0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.28	0.33	3.35e-5	Red blood cell count;
PAAD	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg19592336	chr6:28129416	ZNF389	0.62	4.4	0.34	2.05e-5	Parkinson's disease;
PAAD	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-1.01	-8.75	-0.58	3.72e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.45e-5	Resting heart rate;
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.7	-4.96	-0.37	1.87e-6	Type 2 diabetes;
PAAD	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.43	4.83	0.36	3.27e-6	Breast cancer;
PAAD	cis	rs7264396	0.887	rs11698935	chr20:34075015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.65	-0.42	7.51e-8	Total cholesterol levels;
PAAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	6.2	0.45	5.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg27494647	chr7:150038898	RARRES2	-0.43	-4.81	-0.36	3.63e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02071572	chr4:1403502	NA	0.42	5.76	0.42	4.46e-8	Obesity-related traits;
PAAD	cis	rs6089829	0.692	rs62197304	chr20:61656064	C/T	cg03213289	chr20:61660250	NA	-0.48	-6.27	-0.45	3.59e-9	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07877517	chr5:55488249	ANKRD55	0.54	6.59	0.47	6.87e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.44	0.46	1.5e-9	Triglycerides;
PAAD	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2936519	0.722	rs2978929	chr8:6638295	T/C	cg22103414	chr8:6638082	NA	-0.41	-4.31	-0.33	2.91e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.28	-0.6	1.64e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.49	-5.23	-0.39	5.56e-7	Testicular germ cell tumor;
PAAD	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg07384165	chr1:10488281	NA	-0.47	-5.0	-0.38	1.55e-6	Breast size;
PAAD	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.74	0.48	3.12e-10	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg13722127	chr7:150037890	RARRES2	0.52	5.41	0.4	2.42e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5756391	0.568	rs11705450	chr22:37317529	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg10556349	chr10:835070	NA	0.57	4.75	0.36	4.62e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.44	6.34	0.46	2.44e-9	Oropharynx cancer;
PAAD	cis	rs11958404	0.929	rs72816508	chr5:157356031	G/T	cg05962755	chr5:157440814	NA	1.0	6.3	0.45	3.13e-9	IgG glycosylation;
PAAD	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg06287003	chr12:125626642	AACS	-0.46	-4.48	-0.34	1.44e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25446329	chr10:21802824	C10orf140	-0.45	-4.78	-0.36	4.18e-6	Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27098574	chr16:75285489	BCAR1	0.59	6.47	0.46	1.3e-9	Myopia (pathological);
PAAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg24879335	chr3:133465180	TF	0.59	6.58	0.47	7.04e-10	Iron status biomarkers;
PAAD	cis	rs469568	0.562	rs11741099	chr5:178664463	A/G	cg08999896	chr5:178685787	ADAMTS2	0.55	5.83	0.43	3.2e-8	Stroke (pediatric);
PAAD	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.54	-6.99	-0.49	8.26e-11	Menopause (age at onset);
PAAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.25	-0.33	3.74e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.32e-14	Hemoglobin concentration;
PAAD	cis	rs4740619	0.525	rs7032457	chr9:15826730	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.3	-0.33	3.04e-5	Body mass index;
PAAD	cis	rs7561149	0.966	rs12471428	chr2:179687519	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.57	-5.72	-0.42	5.39e-8	QT interval;
PAAD	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs7202877	0.610	rs10871307	chr16:75335114	G/T	cg03315344	chr16:75512273	CHST6	0.62	5.23	0.39	5.47e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.51	-6.15	-0.45	6.39e-9	Iron status biomarkers;
PAAD	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-5.03	-0.38	1.4e-6	Mean platelet volume;
PAAD	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.71	-6.14	-0.45	6.9e-9	Schizophrenia;
PAAD	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg08099141	chr12:7053170	C12orf57	0.43	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg10395934	chr14:104002654	TRMT61A	0.49	4.73	0.36	5.07e-6	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23672291	chr13:45694820	GTF2F2	-0.8	-6.88	-0.49	1.47e-10	Neuroticism;
PAAD	cis	rs9304742	0.850	rs9304741	chr19:53451228	T/C	cg02440177	chr19:53496695	ZNF702P	-0.53	-5.53	-0.41	1.35e-7	Psoriasis;
PAAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.78	10.39	0.64	1.9e-19	Coronary artery disease;
PAAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-8.23	-0.56	7.95e-14	Bone mineral density;
PAAD	cis	rs8014252	0.803	rs59233924	chr14:71050660	A/G	cg11204974	chr14:71022665	NA	-0.76	-4.94	-0.37	2.07e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs16910800	1.000	rs1384473	chr11:23194943	T/C	cg20040320	chr11:23191996	NA	0.54	4.66	0.35	6.75e-6	Cancer;
PAAD	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg16950941	chr11:66035639	RAB1B	0.55	4.62	0.35	8.06e-6	Electroencephalogram traits;
PAAD	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs28830936	0.535	rs2289743	chr15:41860698	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.45	-4.92	-0.37	2.25e-6	Diastolic blood pressure;
PAAD	cis	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs863345	0.604	rs10908653	chr1:158455353	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.78	-6.1	-0.44	8.58e-9	Type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24155025	chr17:78803179	RPTOR	0.63	6.39	0.46	1.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg17737388	chr1:85724454	C1orf52	0.5	4.34	0.33	2.63e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.53	6.52	0.47	9.99e-10	Sitting height ratio;
PAAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-7.23	-0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs9659323	0.623	rs12091291	chr1:119478828	A/G	cg17326555	chr1:119535693	NA	0.36	4.49	0.34	1.38e-5	Body mass index;
PAAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.13	0.45	7.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1413885	0.502	rs7545397	chr1:65856282	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.74	0.36	4.89e-6	Anticoagulant levels;
PAAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg15847926	chr7:2749597	AMZ1	-0.41	-4.92	-0.37	2.18e-6	Height;
PAAD	cis	rs6496667	0.600	rs28674812	chr15:91077809	G/T	cg22089800	chr15:90895588	ZNF774	0.63	4.88	0.37	2.66e-6	Rheumatoid arthritis;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg04156016	chr5:1868137	NA	0.49	4.93	0.37	2.09e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.39	-4.42	-0.34	1.89e-5	Tonsillectomy;
PAAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.54	-0.57	1.26e-14	Body mass index;
PAAD	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24549020	chr5:56110836	MAP3K1	0.49	4.29	0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.91	0.43	2.17e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11694119	chr1:145611008	POLR3C;RNF115	0.64	7.07	0.5	5.22e-11	Monocyte percentage of white cells;
PAAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.43	-0.4	2.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg08853572	chr16:1843915	IGFALS	-0.26	-4.42	-0.34	1.89e-5	Blood metabolite levels;
PAAD	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.57	-4.98	-0.37	1.69e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.6	0.35	8.81e-6	Electroencephalogram traits;
PAAD	cis	rs7688540	0.511	rs11731623	chr4:201010	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs73416724	1.000	rs74690967	chr6:43370915	C/T	cg17076780	chr6:43251928	TTBK1	0.59	4.65	0.35	7.19e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.92	-0.37	2.23e-6	Body mass index;
PAAD	cis	rs13424612	0.896	rs12466838	chr2:240893427	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.86	-0.37	2.86e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	1.01	8.31	0.56	4.84e-14	Initial pursuit acceleration;
PAAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.73	6.57	0.47	7.71e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-6.47	-0.46	1.25e-9	Bone mineral density;
PAAD	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.93	-0.43	1.97e-8	Coronary artery calcification;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg20744362	chr22:50050164	C22orf34	0.59	7.58	0.52	3.14e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.43e-7	Type 2 diabetes;
PAAD	cis	rs72960926	0.744	rs72964203	chr6:74858552	T/C	cg03266952	chr6:74778945	NA	-1.08	-6.87	-0.49	1.56e-10	Metabolite levels (MHPG);
PAAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.66	0.53	2.07e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	9.45	0.61	5.9e-17	Bone mineral density;
PAAD	cis	rs1862626	0.506	rs11957122	chr5:56048827	C/T	cg14703610	chr5:56206110	C5orf35	0.51	4.72	0.36	5.35e-6	Cancer (pleiotropy);
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg18281939	chr5:77783895	LHFPL2	-0.47	-5.51	-0.41	1.51e-7	Triglycerides;
PAAD	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.48	4.96	0.37	1.87e-6	Body mass index;
PAAD	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs12913538	0.862	rs1550053	chr15:62890532	G/C	cg09983546	chr15:62884068	NA	0.64	7.31	0.51	1.38e-11	Sleep depth;
PAAD	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10815272	chr5:49962509	PARP8	0.63	6.36	0.46	2.2e-9	Obesity-related traits;
PAAD	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.59	5.93	0.43	1.98e-8	Blood metabolite levels;
PAAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg06618935	chr21:46677482	NA	-0.6	-7.84	-0.54	7.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg08807101	chr21:30365312	RNF160	0.61	6.31	0.46	2.83e-9	Dental caries;
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-8.97	-0.59	1.01e-15	Total body bone mineral density;
PAAD	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg10239410	chr1:235292449	SNORA14B;TOMM20	0.42	4.44	0.34	1.75e-5	Adiposity;
PAAD	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.97	9.51	0.61	4.02e-17	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10214930	0.767	rs10081339	chr7:27698594	G/T	cg22168087	chr7:27702803	HIBADH	-0.49	-4.42	-0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.71	7.24	0.51	2.12e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.97	-8.93	-0.59	1.29e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg25566285	chr7:158114605	PTPRN2	0.85	8.84	0.58	2.2e-15	Calcium levels;
PAAD	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14169450	chr9:139327907	INPP5E	0.57	5.68	0.42	6.68e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8053891	0.507	rs12919469	chr16:72028612	A/G	cg01557791	chr16:72042693	DHODH	-0.46	-4.28	-0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs71636778	0.509	rs17162311	chr1:27174966	C/T	cg12733254	chr1:26682999	NA	-0.62	-4.42	-0.34	1.87e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09597638	chr17:3907349	NA	0.65	7.05	0.5	5.8200000000000003e-11	Type 2 diabetes;
PAAD	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.71	7.04	0.5	6.17e-11	Lymphocyte counts;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs3136441	1.000	rs2306028	chr11:46900659	G/T	cg19486271	chr11:47235900	DDB2	0.63	4.83	0.36	3.31e-6	HDL cholesterol;
PAAD	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.58	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10214930	0.671	rs6948460	chr7:27690238	T/A	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.42	5.19	0.39	6.73e-7	Corneal astigmatism;
PAAD	cis	rs728616	0.867	rs7906286	chr10:81834035	T/C	cg05935833	chr10:81318306	SFTPA2	-0.6	-4.67	-0.35	6.56e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg19192590	chr2:178524533	PDE11A	0.4	4.56	0.35	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7127900	0.583	rs67186729	chr11:2233549	T/C	cg25635251	chr11:2234043	NA	0.8	7.71	0.53	1.57e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg00999904	chr2:3704751	ALLC	-0.81	-8.08	-0.55	1.91e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg21994712	chr19:21861136	NA	-0.47	-4.28	-0.33	3.33e-5	Pain;
PAAD	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs12432203	1.000	rs12432203	chr14:51710861	A/G	cg23942311	chr14:51606299	NA	-0.73	-4.66	-0.35	6.76e-6	Cancer;
PAAD	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.45	-4.36	-0.33	2.35e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg10820045	chr2:198174542	NA	0.45	4.53	0.35	1.17e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg22143856	chr6:28129313	ZNF389	0.51	4.75	0.36	4.74e-6	Parkinson's disease;
PAAD	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.51	-0.41	1.48e-7	Adiposity;
PAAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.58	-6.19	-0.45	5.3e-9	Blood metabolite levels;
PAAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg05484376	chr2:27715224	FNDC4	0.51	5.08	0.38	1.08e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.63	6.09	0.44	8.94e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs354033	1.000	rs354031	chr7:149285921	A/G	cg06920324	chr7:149264011	ZNF767	-0.61	-5.08	-0.38	1.08e-6	Multiple sclerosis;
PAAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs2031532	0.819	rs7981627	chr13:50094187	G/T	cg08779649	chr13:50194554	NA	0.35	4.46	0.34	1.62e-5	Cardiac hypertrophy;
PAAD	cis	rs17291845	0.519	rs12920164	chr16:55278457	C/G	cg09919735	chr16:54545884	NA	-0.74	-4.57	-0.35	9.89e-6	Information processing speed;
PAAD	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22902161	chr4:94683967	GRID2	-0.59	-6.5	-0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs72827839	0.615	rs72827864	chr17:46492878	C/T	cg23391107	chr17:45924227	SP6	0.5	4.78	0.36	4.17e-6	Ease of getting up in the morning;
PAAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-5.86	-0.43	2.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.24e-22	Parkinson's disease;
PAAD	cis	rs12257961	0.525	rs2883023	chr10:15372931	C/T	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.02	-0.38	1.44e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg02734326	chr4:10020555	SLC2A9	0.45	4.75	0.36	4.74e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20136959	chr13:49821950	CDADC1	0.65	7.16	0.5	3.16e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs4786125	0.581	rs1967404	chr16:6921483	G/A	cg03623568	chr16:6915990	A2BP1	-0.43	-4.3	-0.33	2.98e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs2286503	0.901	rs10950922	chr7:22854006	C/T	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.25e-5	Fibrinogen;
PAAD	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-4.74	-0.36	4.97e-6	Dental caries;
PAAD	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg09659197	chr4:152720779	NA	0.36	5.41	0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6137287	0.722	rs1007226	chr20:21103987	A/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.82	0.36	3.45e-6	Height;
PAAD	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg17517138	chr11:73019481	ARHGEF17	0.96	4.91	0.37	2.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00437399	chr15:40886176	CASC5	-0.7	-7.94	-0.54	4.15e-13	Smoking initiation;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07399312	chr1:156470683	MEF2D	-0.58	-6.5	-0.47	1.09e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg08222618	chr4:941054	TMEM175	0.8	10.54	0.65	7.89e-20	Sjögren's syndrome;
PAAD	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg15192750	chr16:69999425	NA	0.76	5.99	0.44	1.48e-8	IgE levels;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg07982082	chr11:65414261	SIPA1	-0.47	-4.28	-0.33	3.3e-5	Blood pressure (age interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20085812	chr3:39149038	GORASP1;TTC21A	0.62	6.34	0.46	2.52e-9	Myopia (pathological);
PAAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg23912435	chr1:150601613	ENSA	0.5	4.6	0.35	8.74e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.82	-8.9	-0.59	1.58e-15	Body mass index;
PAAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.58	0.68	1.24e-22	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.96	-7.95	-0.54	3.96e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg22674798	chr1:3096360	PRDM16	-0.64	-9.75	-0.62	9.55e-18	Migraine;
PAAD	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.07	-0.38	1.17e-6	Platelet count;
PAAD	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg01191920	chr7:158217561	PTPRN2	-0.77	-7.7	-0.53	1.66e-12	Obesity-related traits;
PAAD	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.71	7.1	0.5	4.53e-11	Coronary artery disease;
PAAD	cis	rs9630089	0.513	rs12571098	chr10:99095208	A/G	cg10705379	chr10:99080932	FRAT1	-0.44	-5.02	-0.38	1.42e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12580194	0.593	rs12099808	chr12:55731178	T/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs7873102	0.654	rs7036483	chr9:37972165	A/G	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.72	-8.29	-0.56	5.51e-14	Height;
PAAD	cis	rs7577696	0.525	rs11124272	chr2:32142520	A/C	cg02381751	chr2:32503542	YIPF4	0.53	5.09	0.38	1.04e-6	Inflammatory biomarkers;
PAAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.64	-6.04	-0.44	1.16e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.583	rs8068508	chr17:2047624	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.45	5.71	0.42	5.8e-8	Panic disorder;
PAAD	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.75	6.46	0.46	1.32e-9	Pulmonary function decline;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.82	6.47	0.46	1.3e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg11814155	chr7:99998594	ZCWPW1	0.52	4.3	0.33	3.07e-5	Platelet count;
PAAD	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg15654264	chr1:150340011	RPRD2	-0.49	-4.75	-0.36	4.68e-6	Migraine;
PAAD	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.37	0.33	2.25e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg23009452	chr2:25264872	EFR3B	0.64	6.51	0.47	1.03e-9	Iris heterochromicity;
PAAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	7.67	0.53	1.88e-12	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs548987	0.529	rs1165165	chr6:25862466	C/T	cg18357526	chr6:26021779	HIST1H4A	0.59	4.74	0.36	4.78e-6	Homocysteine levels;
PAAD	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.79	-5.04	-0.38	1.32e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.34	-0.33	2.61e-5	Joint mobility (Beighton score);
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.73	-7.27	-0.51	1.8e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17328794	chr8:144922745	NRBP2	0.6	6.79	0.48	2.35e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21749275	chr4:110460898	SEC24B	0.58	6.72	0.48	3.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.77	9.67	0.62	1.54e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	7.93	0.54	4.41e-13	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.61	-6.37	-0.46	2.13e-9	Blood protein levels;
PAAD	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.31	-0.4	3.9e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg05392440	chr1:2478653	NA	0.55	6.14	0.45	6.86e-9	Ulcerative colitis;
PAAD	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.64	6.65	0.47	4.91e-10	Menarche (age at onset);
PAAD	cis	rs13070279	0.655	rs11718929	chr3:71792688	G/A	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg08992911	chr2:238395768	MLPH	0.74	5.68	0.42	6.62e-8	Prostate cancer;
PAAD	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.01	-0.44	1.33e-8	Bipolar disorder;
PAAD	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.77	8.21	0.55	8.71e-14	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06287708	chr2:179345168	MIR548N;PLEKHA3	0.71	7.59	0.52	3.02e-12	Obesity-related traits;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.52	5.11	0.38	9.63e-7	Resistin levels;
PAAD	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.84	7.47	0.52	5.79e-12	Obesity;Body mass index;
PAAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.19	0.5	2.69e-11	Eosinophil percentage of white cells;
PAAD	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.5	7.3	0.51	1.48e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1656368	0.726	rs12491598	chr3:158263154	C/A	cg16708174	chr3:158430962	RARRES1	0.56	5.14	0.38	8.52e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.57	-5.62	-0.42	8.71e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg10547527	chr2:198650123	BOLL	0.49	4.31	0.33	2.98e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg12870014	chr12:110450643	ANKRD13A	0.71	5.09	0.38	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg18612461	chr15:75251733	NA	-0.4	-4.39	-0.34	2.09e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.6	-6.33	-0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.76	5.45	0.4	2.03e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.55	-5.69	-0.42	6.49e-8	Daytime sleep phenotypes;
PAAD	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.54	-0.52	3.96e-12	Hemoglobin concentration;
PAAD	cis	rs9918079	0.542	rs7688984	chr4:15657253	G/T	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.37	-0.33	2.3e-5	Obesity-related traits;
PAAD	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg01064725	chr1:204461714	NA	-0.52	-4.85	-0.37	2.96e-6	Schizophrenia;
PAAD	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.74	-6.31	-0.46	2.84e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.65	-0.42	7.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs2790216	0.951	rs1769021	chr10:59929127	C/T	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs863345	0.604	rs7544134	chr1:158475421	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-5.04	-0.38	1.32e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.78	0.42	4.09e-8	Response to antipsychotic treatment;
PAAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-7.91	-0.54	4.79e-13	Diastolic blood pressure;
PAAD	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs4455778	0.580	rs6583509	chr7:49122419	A/G	cg26309511	chr7:48887640	NA	-0.38	-4.67	-0.35	6.63e-6	Lung cancer in never smokers;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.89	-15.17	-0.78	3.1e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.6	5.4	0.4	2.5e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs7176527	0.500	rs895571	chr15:85117153	A/C	cg03959625	chr15:84868606	LOC388152	-0.51	-4.67	-0.35	6.44e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg01362358	chr17:58117360	NA	0.39	4.43	0.34	1.76e-5	Hemoglobin concentration;
PAAD	cis	rs1499972	0.941	rs817506	chr3:117679394	A/G	cg07612923	chr3:117604196	NA	-1.08	-7.2	-0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.19	0.39	6.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.49	-4.97	-0.37	1.81e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6499129	0.558	rs13334205	chr16:67581883	A/G	cg05110241	chr16:68378359	PRMT7	-0.78	-5.21	-0.39	6.08e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.46	0.34	1.6e-5	Asthma;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.7	6.76	0.48	2.82e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1642645	0.793	rs4083557	chr1:42478177	C/T	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6735179	0.565	rs6726887	chr2:1749257	A/G	cg08534653	chr2:1747700	PXDN	0.24	4.28	0.33	3.29e-5	Response to antipsychotic treatment;
PAAD	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.93	5.79	0.43	3.9e-8	Major depressive disorder;
PAAD	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.72	0.36	5.34e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg08917208	chr2:24149416	ATAD2B	0.49	4.3	0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg09835421	chr16:68378352	PRMT7	-1.17	-8.36	-0.56	3.71e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.59	4.46	0.34	1.61e-5	Crohn's disease;
PAAD	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg01657329	chr11:68192670	LRP5	-0.68	-4.75	-0.36	4.61e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg19847866	chr10:1019161	NA	-0.54	-4.36	-0.33	2.38e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.95	-7.83	-0.54	7.83e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs965604	1.000	rs8042260	chr15:78774374	A/G	cg18825076	chr15:78729989	IREB2	-0.46	-4.47	-0.34	1.5e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.58	6.03	0.44	1.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.73	-7.8	-0.53	9.19e-13	Body mass index;
PAAD	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.8	-6.04	-0.44	1.12e-8	Coronary artery disease;
PAAD	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14019695	chr9:139328340	INPP5E	0.58	5.03	0.38	1.34e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs61677309	1.000	rs894677	chr11:118172535	C/T	cg15548380	chr1:19984784	NBL1	-0.64	-6.53	-0.47	9.25e-10	Lung cancer in ever smokers;
PAAD	cis	rs864537	1.000	rs840015	chr1:167409114	G/A	cg09179987	chr1:167433047	CD247	0.43	4.83	0.36	3.37e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg09179987	chr1:167433047	CD247	0.5	5.8	0.43	3.66e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.68	-6.57	-0.47	7.44e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg16973527	chr15:70767570	NA	0.4	6.36	0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6076065	0.723	rs761726	chr20:23401481	G/C	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.18	-0.39	6.91e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs11871801	1.000	rs34610643	chr17:40574388	A/C	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.54	6.04	0.44	1.15e-8	Testicular germ cell tumor;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.52	5.05	0.38	1.23e-6	Parkinson's disease;
PAAD	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.54	-0.35	1.14e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.74	-8.5	-0.57	1.68e-14	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg08439880	chr3:133502540	NA	-0.47	-5.27	-0.39	4.59e-7	Iron status biomarkers;
PAAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg09509183	chr1:209979624	IRF6	-0.37	-4.42	-0.34	1.87e-5	Monobrow;
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg19337854	chr7:99768885	GPC2	0.46	4.27	0.33	3.5e-5	Platelet count;
PAAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Aortic root size;
PAAD	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs10851411	0.559	rs79044457	chr15:42895208	G/T	cg21293051	chr15:42870591	STARD9	0.61	4.77	0.36	4.2e-6	Glucose homeostasis traits;
PAAD	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.77	7.96	0.54	3.62e-13	Body mass index;
PAAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22847251	chr19:17378248	C19orf62	0.63	7.3	0.51	1.46e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.86	10.99	0.67	4.89e-21	Height;
PAAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg25753631	chr6:25732923	NA	-0.49	-5.45	-0.4	1.96e-7	Iron status biomarkers;
PAAD	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.74	7.37	0.51	1.01e-11	Retinal vascular caliber;
PAAD	cis	rs59888335	1.000	rs12632613	chr3:80672682	T/G	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.74	-7.65	-0.53	2.1e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs501120	0.584	rs1746042	chr10:44731897	C/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs12681288	0.821	rs12547181	chr8:1035601	C/T	cg04851639	chr8:1020857	NA	-0.65	-7.84	-0.54	7.45e-13	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg27205649	chr11:78285834	NARS2	-0.59	-4.49	-0.34	1.37e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.64	9.14	0.6	3.65e-16	IgG glycosylation;
PAAD	cis	rs6594713	0.531	rs13362189	chr5:112940706	A/G	cg12552261	chr5:112820674	MCC	0.83	6.59	0.47	6.79e-10	Brain cytoarchitecture;
PAAD	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs80346118	0.673	rs16994152	chr20:47426126	T/G	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.63	-4.66	-0.35	6.97e-6	Diastolic blood pressure;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00166722	chr3:10149974	C3orf24	0.95	8.33	0.56	4.51e-14	Alzheimer's disease;
PAAD	cis	rs1667255	0.830	rs7235277	chr18:29176873	G/C	cg18808318	chr18:29669225	NA	0.48	4.55	0.35	1.09e-5	Retinol levels;
PAAD	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg10547527	chr2:198650123	BOLL	-0.62	-4.45	-0.34	1.66e-5	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945705	0.935	rs2251536	chr11:8853177	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.05	0.5	5.73e-11	Hemoglobin concentration;
PAAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.66	9.17	0.6	3.04e-16	Height;
PAAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.33	-0.46	2.68e-9	Type 2 diabetes;
PAAD	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.56	-6.01	-0.44	1.3e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2286379	0.777	rs7294668	chr12:1878535	C/T	cg05227549	chr12:1770782	NA	0.41	4.86	0.37	2.95e-6	Blood pressure (smoking interaction);
PAAD	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.95	0.37	1.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2274459	0.841	rs12205398	chr6:33701543	C/T	cg06253072	chr6:33679850	C6orf125	0.62	4.88	0.37	2.7e-6	Obesity (extreme);
PAAD	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	7.06	0.5	5.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg24253500	chr15:84953950	NA	0.42	4.35	0.33	2.48e-5	Schizophrenia;
PAAD	cis	rs8077577	0.789	rs11078411	chr17:18088094	C/T	cg16794390	chr17:18148240	FLII	0.57	4.71	0.36	5.61e-6	Obesity-related traits;
PAAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.72	6.61	0.47	6.16e-10	Menarche (age at onset);
PAAD	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	5.96	0.44	1.66e-8	Lung cancer in ever smokers;
PAAD	cis	rs16852403	0.861	rs11583320	chr1:178042145	T/C	cg00404053	chr1:178313656	RASAL2	0.42	4.32	0.33	2.76e-5	Childhood ear infection;
PAAD	cis	rs77880822	0.562	rs79088681	chr20:1210827	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg22875332	chr1:76189707	ACADM	-0.51	-5.05	-0.38	1.27e-6	Daytime sleep phenotypes;
PAAD	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-8.45	-0.57	2.18e-14	Vitiligo;
PAAD	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg18084798	chr19:33555255	RHPN2	0.46	4.69	0.36	6.1e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	1.49	9.69	0.62	1.36e-17	Age-related hearing impairment;
PAAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-5.48	-0.41	1.69e-7	Mean corpuscular volume;
PAAD	trans	rs80195177	1.000	rs80195177	chr7:37637238	G/A	cg02150354	chr5:92914202	FLJ42709	-0.68	-6.91	-0.49	1.25e-10	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs8070740	0.836	rs4444392	chr17:5324588	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	4.64	0.35	7.36e-6	Menopause (age at onset);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.6	4.34	0.33	2.56e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs73198271	0.729	rs67000451	chr8:8605083	A/G	cg01851573	chr8:8652454	MFHAS1	0.57	4.51	0.34	1.28e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg10556349	chr10:835070	NA	0.57	4.96	0.37	1.9e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs747650	0.504	rs11601798	chr11:47158392	A/G	cg19486271	chr11:47235900	DDB2	0.67	6.24	0.45	4.05e-9	Acne (severe);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03228054	chr9:19049082	RRAGA	0.6	6.45	0.46	1.38e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs77633900	0.772	rs166933	chr15:76736265	G/A	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs11807834	0.522	rs7519536	chr1:230233864	G/C	cg00566187	chr1:230250356	GALNT2	-0.61	-6.49	-0.47	1.13e-9	Schizophrenia;
PAAD	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg05709478	chr1:6581295	PLEKHG5	0.72	4.55	0.35	1.11e-5	Body mass index;
PAAD	cis	rs11264799	0.520	rs849828	chr1:157545047	A/G	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg22138327	chr13:27999177	GTF3A	0.85	5.28	0.39	4.32e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.97	11.8	0.69	3.23e-23	Bone mineral density;
PAAD	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.98	-0.44	1.52e-8	Adiposity;
PAAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17407555	0.789	rs12648610	chr4:10114812	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-5.99	-0.44	1.47e-8	Schizophrenia (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13910484	chr9:80851062	CEP78	0.55	6.44	0.46	1.52e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.09	-0.38	1.06e-6	Bipolar disorder;
PAAD	cis	rs9487051	0.621	rs351721	chr6:109551109	G/T	cg21918786	chr6:109611834	NA	-0.41	-4.28	-0.33	3.28e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs787274	0.764	rs787287	chr9:115534245	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.88	-8.22	-0.55	8.37e-14	Breast cancer;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg15117754	chr3:10150083	C3orf24	0.68	5.84	0.43	3.04e-8	Alzheimer's disease;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.88	-12.78	-0.72	7.31e-26	Cystic fibrosis severity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02181369	chr6:83877953	DOPEY1	0.56	6.38	0.46	2.01e-9	Smoking initiation;
PAAD	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg14343924	chr8:8086146	FLJ10661	0.55	4.98	0.37	1.74e-6	Joint mobility (Beighton score);
PAAD	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.63e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs62055045	1.000	rs62055047	chr16:71401027	C/T	cg02517497	chr16:71572050	CHST4	0.59	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs6466055	0.661	rs12535043	chr7:104831655	G/C	cg04380332	chr7:105027541	SRPK2	0.49	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.46	5.57	0.41	1.14e-7	Permanent tooth development;
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.73	8.28	0.56	5.8e-14	Lung cancer;
PAAD	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs73058052	0.530	rs10421333	chr19:50086080	A/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.52	-4.45	-0.34	1.67e-5	Fibrinogen levels;
PAAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.52	-6.55	-0.47	8.28e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	6.28	0.45	3.46e-9	Lung cancer in ever smokers;
PAAD	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	4.54	0.35	1.16e-5	Systolic blood pressure;
PAAD	cis	rs507080	0.524	rs524409	chr11:118574311	C/T	cg08498647	chr11:118550644	TREH	-0.42	-5.21	-0.39	6.01e-7	Serum metabolite levels;
PAAD	cis	rs12600304	0.709	rs11646277	chr16:58017529	A/T	cg08699646	chr16:58019359	TEPP	0.39	4.51	0.34	1.3e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.63	-6.66	-0.48	4.81e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs3779195	0.585	rs56694862	chr7:97897120	G/T	cg24562669	chr7:97807699	LMTK2	-0.54	-4.43	-0.34	1.8e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg16898833	chr6:26189333	HIST1H4D	0.66	4.89	0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	11.95	0.7	1.3e-23	Platelet count;
PAAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.7	0.36	5.69e-6	Homoarginine levels;
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg08200582	chr11:442649	ANO9	0.56	4.75	0.36	4.71e-6	Systemic lupus erythematosus;
PAAD	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg27499820	chr13:21296301	IL17D	0.5	4.74	0.36	4.78e-6	Dental caries;
PAAD	cis	rs1903068	0.819	rs17711320	chr4:56000053	A/C	cg09978860	chr4:56023921	NA	0.41	4.45	0.34	1.67e-5	Endometriosis;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.43	-4.3	-0.33	3.01e-5	Platelet distribution width;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.48	4.92	0.37	2.23e-6	Body mass index;
PAAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.87	5.5	0.41	1.6e-7	Diabetic kidney disease;
PAAD	cis	rs3106136	0.678	rs7670194	chr4:95281078	G/A	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg11247378	chr22:39784982	NA	0.63	5.45	0.4	1.99e-7	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg20913747	chr6:44695427	NA	0.71	6.97	0.49	9.2e-11	Total body bone mineral density;
PAAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg13722127	chr7:150037890	RARRES2	0.61	6.07	0.44	9.68e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.58	-7.43	-0.52	7.22e-12	Lewy body disease;
PAAD	cis	rs3007168	1.000	rs3007079	chr14:51613517	A/G	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs6545977	1.000	rs6545977	chr2:63301164	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-4.25	-0.33	3.64e-5	Prostate cancer;
PAAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs11718455	0.573	rs4682701	chr3:43905870	G/A	cg00181669	chr3:44000978	NA	0.54	5.7	0.42	6.06e-8	Coronary artery disease;
PAAD	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg11657817	chr20:23433608	CST11	-0.49	-5.04	-0.38	1.33e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25650185	chr19:21324782	ZNF431	-0.5	-4.43	-0.34	1.79e-5	Pain;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.52	0.34	1.24e-5	Electroencephalogram traits;
PAAD	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.43	-6.29	-0.45	3.22e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11002227	chr3:155588016	GMPS	0.63	6.35	0.46	2.35e-9	Obesity-related traits;
PAAD	cis	rs8067287	0.749	rs62065426	chr17:16831506	G/C	cg26910001	chr17:16838321	NA	-0.68	-6.09	-0.44	8.7e-9	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs4740619	0.901	rs10810435	chr9:15719658	T/G	cg14451791	chr9:16040625	NA	-0.4	-4.61	-0.35	8.35e-6	Body mass index;
PAAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	5.07	0.38	1.14e-6	Menarche (age at onset);
PAAD	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	4.62	0.35	8.14e-6	Menarche (age at onset);
PAAD	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg21775007	chr8:11205619	TDH	-0.46	-4.35	-0.33	2.5e-5	Systolic blood pressure;
PAAD	cis	rs11669133	1.000	rs11669656	chr19:11097385	G/A	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.42	-4.62	-0.35	8.3e-6	Blood metabolite levels;
PAAD	cis	rs9896052	0.573	rs61059062	chr17:73443863	A/T	cg25649188	chr17:73499917	CASKIN2	0.61	4.58	0.35	9.67e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg07595035	chr13:111291582	CARKD	0.8	4.97	0.37	1.76e-6	Coronary artery disease;
PAAD	cis	rs2492906	0.515	rs2492912	chr10:27981573	A/G	cg25523538	chr10:28031957	MKX	-0.51	-4.35	-0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.5	4.96	0.37	1.83e-6	QT interval;
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.65	-7.52	-0.52	4.37e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.75	0.42	4.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg01028140	chr2:1542097	TPO	-1.02	-8.95	-0.59	1.18e-15	IgG glycosylation;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.77	-8.31	-0.56	4.87e-14	Menopause (age at onset);
PAAD	cis	rs3996993	0.527	rs2144698	chr6:52623807	T/G	cg00536792	chr6:53530503	KLHL31	0.48	4.81	0.36	3.55e-6	Hemoglobin concentration;
PAAD	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.33	-0.4	3.47e-7	Atrioventricular conduction;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.99	0.44	1.46e-8	Prudent dietary pattern;
PAAD	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg00262122	chr8:11665843	FDFT1	0.45	4.34	0.33	2.54e-5	Retinal vascular caliber;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23009387	chr5:135468634	SMAD5;SMAD5OS	0.61	6.44	0.46	1.46e-9	Myopia (pathological);
PAAD	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.54	5.74	0.42	4.87e-8	Schizophrenia;
PAAD	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.87	11.76	0.69	4.18e-23	Height;
PAAD	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-6.9	-0.49	1.33e-10	Migraine;Coronary artery disease;
PAAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.77	8.29	0.56	5.44e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.91	-0.37	2.36e-6	Neuroticism;
PAAD	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.57	-0.35	1.01e-5	Joint mobility (Beighton score);
PAAD	cis	rs17155006	0.664	rs1735499	chr7:107738882	G/A	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.67	8.71	0.58	4.82e-15	Hemoglobin concentration;
PAAD	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.61	-7.08	-0.5	4.86e-11	Schizophrenia;
PAAD	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.63	-5.07	-0.38	1.15e-6	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.99	0.38	1.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.67	5.37	0.4	2.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.4	-0.56	2.89e-14	Longevity;Endometriosis;
PAAD	cis	rs6102074	0.967	rs11698990	chr20:39271008	T/G	cg22477343	chr20:39312069	NA	0.3	4.26	0.33	3.62e-5	White blood cell count;
PAAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.6	-5.26	-0.39	4.84e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.53	-5.28	-0.39	4.36e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.99	8.78	0.58	3.19e-15	Bipolar disorder;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg09471204	chr22:42347991	LOC339674	0.34	4.52	0.34	1.23e-5	Cognitive function;
PAAD	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg19784903	chr17:45786737	TBKBP1	0.58	6.44	0.46	1.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17539620	0.507	rs6927301	chr6:154872080	G/T	cg20019720	chr6:154832845	CNKSR3	-0.41	-5.93	-0.43	1.93e-8	Lipoprotein (a) levels;
PAAD	cis	rs6688613	1.000	rs12569084	chr1:166943352	T/C	cg07049167	chr1:166818506	POGK	0.48	4.79	0.36	3.92e-6	Refractive astigmatism;
PAAD	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8121916	1.000	rs6109397	chr20:12401534	C/T	cg16404259	chr20:12988931	SPTLC3	0.42	4.28	0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.87	10.09	0.63	1.18e-18	Ulcerative colitis;
PAAD	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-7.28	-0.51	1.63e-11	Vitiligo;
PAAD	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg09237302	chr4:906077	GAK	-0.43	-4.41	-0.34	1.99e-5	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.94	0.59	1.22e-15	Lung cancer;
PAAD	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs2296225	0.778	rs2001454	chr1:21032619	G/A	cg13843611	chr1:20143089	RNF186	-0.55	-4.46	-0.34	1.57e-5	Eosinophilic esophagitis;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg21698718	chr17:80085957	CCDC57	-0.44	-5.04	-0.38	1.34e-6	Life satisfaction;
PAAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.1e-8	Electroencephalogram traits;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.53	-6.38	-0.46	2.04e-9	Lewy body disease;
PAAD	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.37	-0.33	2.33e-5	Joint mobility (Beighton score);
PAAD	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg25650185	chr19:21324782	ZNF431	-0.49	-4.49	-0.34	1.4e-5	Pain;
PAAD	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.66	4.96	0.37	1.87e-6	Obesity-related traits;
PAAD	cis	rs375066	0.935	rs397913	chr19:44398940	C/T	cg11993925	chr19:44307056	LYPD5	-0.49	-6.22	-0.45	4.48e-9	Breast cancer;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs1816752	1.000	rs9511272	chr13:25020633	A/G	cg22771759	chr13:24902376	NA	0.46	4.41	0.34	1.98e-5	Obesity-related traits;
PAAD	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.63	-5.96	-0.44	1.7e-8	Total body bone mineral density;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.67	0.58	6.06e-15	Menopause (age at onset);
PAAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.84	7.46	0.52	6.18e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.71	-7.96	-0.54	3.68e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs6089829	0.747	rs57767914	chr20:61659108	C/G	cg08564027	chr20:61660810	NA	-0.82	-7.59	-0.52	2.98e-12	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7577696	0.886	rs6737500	chr2:32263087	C/T	cg02381751	chr2:32503542	YIPF4	-0.45	-4.78	-0.36	4.08e-6	Inflammatory biomarkers;
PAAD	cis	rs2712184	0.756	rs2541393	chr2:217651230	G/C	cg05032264	chr2:217675019	NA	-0.55	-6.13	-0.45	7.15e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18302933	chr2:88491318	NA	-0.44	-5.21	-0.39	5.95e-7	Response to metformin (IC50);
PAAD	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.66	6.98	0.49	8.38e-11	Testicular germ cell tumor;
PAAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.74	-0.42	5.05e-8	Schizophrenia;
PAAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.6	-0.35	8.71e-6	Parkinson's disease;
PAAD	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.35e-10	Monocyte count;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.07	-0.59	5.65e-16	Height;
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg12436631	chr1:155007014	DCST1;DCST2	-0.5	-6.35	-0.46	2.39e-9	Prostate cancer;
PAAD	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg27411982	chr8:10470053	RP1L1	0.48	5.22	0.39	5.84e-7	Retinal vascular caliber;
PAAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	0.8	7.23	0.51	2.22e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2404602	0.669	rs12911987	chr15:76953256	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-4.85	-0.37	2.97e-6	Blood metabolite levels;
PAAD	cis	rs7487075	0.619	rs7489242	chr12:46828631	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.58	0.35	9.73e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	4.38	0.34	2.16e-5	Menarche (age at onset);
PAAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.49	-4.75	-0.36	4.6e-6	Migraine;
PAAD	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.54	4.98	0.37	1.73e-6	Renal cell carcinoma;
PAAD	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg14129931	chr18:74513950	NA	0.7	6.13	0.45	7.11e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
PAAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.79	9.32	0.6	1.29e-16	Eye color traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21735491	chr11:66749665	NA	0.64	6.89	0.49	1.36e-10	Myopia (pathological);
PAAD	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg01329690	chr21:38580129	DSCR9	0.32	4.3	0.33	3.06e-5	Eye color traits;
PAAD	cis	rs1468333	0.567	rs2277067	chr5:137775273	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	4.82	0.36	3.51e-6	Resting heart rate;
PAAD	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.67	-0.42	7.12e-8	Menopause (age at onset);
PAAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.92	-8.03	-0.55	2.47e-13	Gut microbiome composition (summer);
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg07061783	chr6:25882402	NA	0.69	6.98	0.49	8.44e-11	Blood metabolite levels;
PAAD	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.46	-0.4	1.92e-7	Schizophrenia;
PAAD	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg16386425	chr10:429943	DIP2C	-0.49	-5.1	-0.38	9.87e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.43	-4.87	-0.37	2.74e-6	Metabolite levels;
PAAD	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg27490568	chr2:178487706	NA	0.43	4.69	0.36	6.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.3	0.39	4.06e-7	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg23034840	chr1:205782522	SLC41A1	0.62	6.16	0.45	6.1e-9	Menarche (age at onset);
PAAD	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg19423196	chr10:82049429	MAT1A	0.53	4.94	0.37	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.36	4.37	0.33	2.25e-5	Pulmonary function;
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.54	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.84	10.33	0.64	2.71e-19	Height;
PAAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.7	-0.36	5.68e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.94	-0.43	1.85e-8	Adiposity;
PAAD	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	1.19	8.77	0.58	3.46e-15	Lymphocyte counts;
PAAD	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.17	19.03	0.84	4.7e-42	Multiple myeloma;
PAAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-7.41	-0.52	8.23e-12	Systemic lupus erythematosus;
PAAD	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg09839279	chr12:125627357	AACS	-0.47	-4.47	-0.34	1.49e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg08027265	chr7:2291960	NA	-0.43	-4.3	-0.33	3.03e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg22153407	chr1:230290089	GALNT2	0.47	4.5	0.34	1.32e-5	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04635366	chr4:120548589	PDE5A	-0.62	-6.38	-0.46	1.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.74	-9.03	-0.59	7.08e-16	Body mass index;
PAAD	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg20744362	chr22:50050164	C22orf34	0.69	7.74	0.53	1.3e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.86	9.56	0.61	2.94e-17	Prudent dietary pattern;
PAAD	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.86	8.0	0.54	2.91e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7246865	0.531	rs8103913	chr19:17166229	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.69	0.42	6.35e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.67	-7.62	-0.53	2.55e-12	Huntington's disease progression;
PAAD	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg09491104	chr22:46646882	C22orf40	-0.91	-5.77	-0.42	4.26e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6782025	0.837	rs1688680	chr3:120760810	A/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs6782025	0.837	rs1523508	chr3:120719564	C/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.4	-0.61	7.97e-17	Pancreatic cancer;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs89107	0.603	rs387945	chr6:118613313	G/A	cg18833306	chr6:118973337	C6orf204	0.49	5.71	0.42	5.79e-8	Cardiac structure and function;
PAAD	cis	rs8121916	1.000	rs6078561	chr20:12400804	C/T	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.68	7.96	0.54	3.65e-13	Height;
PAAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.17	16.8	0.81	1.75e-36	Cognitive function;
PAAD	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg03989125	chr22:38214979	NA	-0.56	-5.53	-0.41	1.34e-7	Glioblastoma;Glioma;
PAAD	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg22467129	chr15:76604101	ETFA	0.53	5.02	0.38	1.4e-6	Blood metabolite levels;
PAAD	cis	rs7084921	0.809	rs12415923	chr10:101797945	C/T	cg04359915	chr10:101825029	CPN1	-0.39	-5.41	-0.4	2.44e-7	Bone mineral density;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg14169450	chr9:139327907	INPP5E	0.54	4.84	0.37	3.14e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.34	5.01	0.38	1.48e-6	IgG glycosylation;
PAAD	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.5	-6.23	-0.45	4.46e-9	Lewy body disease;
PAAD	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.62	-6.85	-0.49	1.74e-10	Neuroticism;
PAAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs501120	0.584	rs11238912	chr10:44695909	T/C	cg09554077	chr10:44749378	NA	0.45	5.33	0.4	3.43e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg09980403	chr19:12975529	MAST1	0.29	4.77	0.36	4.36e-6	Mean corpuscular volume;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.9	-11.77	-0.69	3.8e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.64	-6.34	-0.46	2.54e-9	Coronary artery disease;
PAAD	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.68	0.42	6.8e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg21890820	chr11:65308645	LTBP3	0.66	7.95	0.54	3.85e-13	Bone mineral density;
PAAD	cis	rs2124910	0.808	rs7259990	chr19:52035703	C/T	cg12008991	chr19:52034861	SIGLEC6	0.35	4.45	0.34	1.62e-5	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07240877	chr1:238649445	LOC339535	-0.56	-6.34	-0.46	2.48e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.8	-9.01	-0.59	8.03e-16	Height;
PAAD	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.64	-5.57	-0.41	1.11e-7	Lung cancer;
PAAD	cis	rs2241047	0.526	rs738034	chr22:17594915	A/G	cg24435209	chr22:17640972	CECR5;CECR4	-0.3	-4.54	-0.35	1.14e-5	Blood protein levels;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.77	0.48	2.59e-10	Height;
PAAD	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12482904	0.578	rs9981624	chr21:43825722	G/C	cg23042151	chr21:43824109	UBASH3A	-0.46	-5.8	-0.43	3.79e-8	Vitiligo;
PAAD	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.97	8.09	0.55	1.77e-13	Neutrophil percentage of white cells;
PAAD	cis	rs2885056	0.891	rs73016784	chr19:10688785	C/T	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-1.12	-4.68	-0.35	6.28e-6	Asthma (childhood onset);
PAAD	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.75	-0.53	1.2e-12	HDL cholesterol;
PAAD	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	1.84	10.22	0.64	5.31e-19	Cannabis dependence symptom count;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.78	5.02	0.38	1.44e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-7.23	-0.51	2.19e-11	Initial pursuit acceleration;
PAAD	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.55	6.3	0.45	3.11e-9	Mean corpuscular volume;
PAAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.79	-7.59	-0.52	2.98e-12	Schizophrenia;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.58	6.46	0.46	1.36e-9	Mean corpuscular volume;
PAAD	cis	rs9896052	0.649	rs6501801	chr17:73447030	A/G	cg25649188	chr17:73499917	CASKIN2	-0.63	-5.83	-0.43	3.28e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14416316	chr13:111145583	COL4A2	0.59	6.44	0.46	1.45e-9	Myopia (pathological);
PAAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg24053715	chr22:38214548	NA	-0.52	-5.03	-0.38	1.36e-6	Glioblastoma;Glioma;
PAAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg15485101	chr11:133734466	NA	0.43	4.55	0.35	1.07e-5	Parkinson's disease;
PAAD	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.89	11.58	0.68	1.21e-22	Body mass index;
PAAD	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-5.48	-0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs761746	0.614	rs8141214	chr22:32196181	G/T	cg01338084	chr22:32026380	PISD	0.58	4.99	0.38	1.63e-6	Intelligence;
PAAD	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg23534315	chr17:78082725	GAA	0.51	4.75	0.36	4.68e-6	Yeast infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12294403	chr11:67250360	AIP	0.66	7.67	0.53	1.89e-12	Monocyte percentage of white cells;
PAAD	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.41	0.34	1.98e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.52	-0.78	3.84e-33	Height;
PAAD	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.5	5.54	0.41	1.32e-7	Schizophrenia;
PAAD	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.69	-7.6	-0.52	2.82e-12	Calcium levels;
PAAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.51	-0.41	1.47e-7	Lung cancer;
PAAD	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.24e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg14329783	chr7:75779857	NA	0.79	4.63	0.35	7.64e-6	Mononucleosis;
PAAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	1.09	8.72	0.58	4.42e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-6.29	-0.45	3.2e-9	Lymphocyte counts;
PAAD	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.51	-4.52	-0.34	1.25e-5	Lung cancer;
PAAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.39e-6	Height;
PAAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg25204440	chr1:209979598	IRF6	0.63	5.28	0.39	4.47e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.16	-0.39	7.48e-7	Recombination measurement;
PAAD	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.81	-0.48	2.11e-10	Neuroticism;
PAAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg02056144	chr12:54070517	ATP5G2	-0.51	-5.54	-0.41	1.3e-7	Height;
PAAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-5.87	-0.43	2.68e-8	Monocyte count;
PAAD	cis	rs35160687	0.901	rs12622200	chr2:86498595	A/G	cg10973622	chr2:86423274	IMMT	-0.42	-4.84	-0.37	3.1e-6	Night sleep phenotypes;
PAAD	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2004318	1.000	rs79612392	chr19:55134730	T/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-4.91	-0.37	2.32e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg27490568	chr2:178487706	NA	0.78	7.41	0.52	8.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	0.98	7.92	0.54	4.79e-13	Vitiligo;
PAAD	cis	rs12438356	0.556	rs12905214	chr15:69625270	A/G	cg02375503	chr15:69591110	PAQR5	0.52	4.32	0.33	2.85e-5	CTACK levels;
PAAD	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.53	5.19	0.39	6.77e-7	White matter hyperintensity burden;
PAAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-6.08	-0.44	9.24e-9	Breast cancer;
PAAD	cis	rs7762544	0.690	rs668036	chr6:41362578	G/A	cg18315060	chr6:41374532	NA	0.48	4.39	0.34	2.13e-5	Periodontitis;
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.41	-0.34	1.95e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs755249	0.567	rs61779275	chr1:39820310	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs10861342	1.000	rs11112398	chr12:105572967	A/G	cg11421182	chr20:36153479	BLCAP	-0.56	-6.72	-0.48	3.35e-10	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11264213	0.901	rs72661644	chr1:36453894	G/A	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.45e-9	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg18209359	chr17:80159595	CCDC57	-0.46	-4.61	-0.35	8.55e-6	Life satisfaction;
PAAD	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.61	5.23	0.39	5.51e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.61	-0.41	9.17e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.98	10.12	0.63	1.03e-18	Platelet distribution width;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg00101154	chr16:420108	MRPL28	-0.86	-9.37	-0.61	9.29e-17	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs901683	0.850	rs74914325	chr10:46097648	A/C	cg12869334	chr8:37699360	GPR124	0.96	6.46	0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	4.27	0.33	3.37e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	5.63	0.42	8.59e-8	Cognitive test performance;
PAAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg01075559	chr1:2537774	MMEL1	-0.54	-5.66	-0.42	7.5e-8	Ulcerative colitis;
PAAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.53	4.72	0.36	5.22e-6	Tonsillectomy;
PAAD	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg26703956	chr19:39260304	NA	-0.42	-5.29	-0.39	4.17e-7	Heart rate;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.81	6.68	0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09807452	chr4:140099025	NA	0.62	7.14	0.5	3.61e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.29	0.39	4.26e-7	Coronary heart disease;
PAAD	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs6009527	0.963	rs6009532	chr22:49572757	C/G	cg12986453	chr22:49137906	FAM19A5	0.44	4.33	0.33	2.71e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-6.19	-0.45	5.29e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2342371	0.756	rs12637868	chr3:196106754	G/A	cg09821211	chr3:195954098	OSTalpha	0.64	6.01	0.44	1.34e-8	Fat distribution (HIV);
PAAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.78	-6.76	-0.48	2.83e-10	Blood pressure (smoking interaction);
PAAD	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.13	-0.5	3.87e-11	Morning vs. evening chronotype;
PAAD	cis	rs4455778	0.580	rs7803736	chr7:49125011	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.1	-0.55	1.71e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24336123	chr20:34286939	ROMO1;NFS1	0.61	6.41	0.46	1.71e-9	Myopia (pathological);
PAAD	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.22	-0.39	5.88e-7	Monocyte count;
PAAD	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg23024775	chr7:97920730	BRI3	0.4	4.25	0.33	3.7e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3818638	0.501	rs4679	chr9:124914613	C/T	cg14107457	chr9:124889836	NA	-0.42	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02725872	chr8:58115012	NA	-0.63	-4.98	-0.37	1.73e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.69	4.75	0.36	4.73e-6	Vitiligo;
PAAD	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.84	0.43	3.08e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg09127314	chr1:152161683	NA	0.69	4.85	0.37	3.05e-6	Atopic dermatitis;
PAAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg05110241	chr16:68378359	PRMT7	-0.73	-5.75	-0.42	4.85e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.78	-0.36	4.05e-6	Eotaxin levels;
PAAD	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	4.69	0.36	6.16e-6	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14139814	chr7:83378795	NA	-0.6	-6.37	-0.46	2.15e-9	Obesity-related traits;
PAAD	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.93	10.81	0.66	1.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs785830	0.600	rs618810	chr9:242529	T/A	cg17093826	chr7:138458720	ATP6V0A4	0.51	6.42	0.46	1.62e-9	Platelet distribution width;
PAAD	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg09473613	chr1:24152604	HMGCL	0.54	5.74	0.42	5.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.56	4.61	0.35	8.41e-6	Response to antidepressants in depression;
PAAD	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	6.27	0.45	3.54e-9	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.73	0.42	5.15e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10901513	0.900	rs2138276	chr10:127671865	C/T	cg22975853	chr10:127789788	ADAM12	0.41	4.42	0.34	1.85e-5	Visceral fat;
PAAD	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.71	-8.02	-0.55	2.62e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7567389	0.583	rs11683427	chr2:127956543	A/G	cg09760422	chr2:128146352	NA	0.48	7.19	0.5	2.76e-11	Self-rated health;
PAAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.52	5.9	0.43	2.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1358748	0.522	rs1830513	chr1:67575549	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.68	9.14	0.6	3.75e-16	Hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07161071	chr7:128578164	IRF5	0.57	6.41	0.46	1.75e-9	Myopia (pathological);
PAAD	cis	rs1468333	1.000	rs7735635	chr5:137508336	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.59	-6.25	-0.45	3.95e-9	Resting heart rate;
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.42	4.54	0.35	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2952768	1.000	rs2709394	chr2:208491975	G/C	cg22329743	chr2:208688774	PLEKHM3	0.23	4.48	0.34	1.45e-5	Opioid sensitivity;
PAAD	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.74	7.53	0.52	4.26e-12	Schizophrenia;
PAAD	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.75	-5.34	-0.4	3.32e-7	Caffeine consumption;
PAAD	cis	rs7119038	0.818	rs10892279	chr11:118611781	G/A	cg19308663	chr11:118741387	NA	0.53	4.32	0.33	2.75e-5	Sjögren's syndrome;
PAAD	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs8083432	0.935	rs72887758	chr18:22709098	G/A	cg13981356	chr18:22006370	IMPACT	0.6	4.69	0.36	6.04e-6	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.86	-0.54	6.72e-13	Hemoglobin concentration;
PAAD	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.94	0.37	2.02e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg00310523	chr12:86230176	RASSF9	0.42	4.44	0.34	1.75e-5	Major depressive disorder;
PAAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.54	4.67	0.35	6.57e-6	Red blood cell count;
PAAD	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.11	0.38	9.55e-7	Vitamin D levels;
PAAD	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.48	4.44	0.34	1.74e-5	Response to antidepressants and depression;
PAAD	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	4.7	0.36	5.68e-6	Neuroticism;
PAAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.68	0.36	6.23e-6	Lung cancer;
PAAD	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-4.3	-0.33	3.04e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg25364880	chr3:44379878	C3orf23	-0.58	-5.25	-0.39	5.08e-7	Depressive symptoms;
PAAD	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	7.17	0.5	3.04e-11	Educational attainment;
PAAD	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.25	-0.45	3.86e-9	Longevity;Endometriosis;
PAAD	cis	rs13053817	1.000	rs13340033	chr22:29846339	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.55	-4.99	-0.37	1.65e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg11266682	chr4:10021025	SLC2A9	0.53	4.25	0.33	3.66e-5	Blood metabolite levels;
PAAD	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14169450	chr9:139327907	INPP5E	0.62	5.58	0.41	1.07e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	1.11	17.15	0.81	2.24e-37	Menarche (age at onset);
PAAD	cis	rs804280	0.544	rs804270	chr8:11627621	G/C	cg12395012	chr8:11607386	GATA4	-0.69	-8.82	-0.58	2.55e-15	Myopia (pathological);
PAAD	cis	rs11615916	0.790	rs17717265	chr12:62765577	T/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.85	10.49	0.65	1.03e-19	Height;
PAAD	cis	rs2882667	0.964	rs12108892	chr5:138299630	G/A	cg09476006	chr5:138032270	NA	0.36	4.52	0.34	1.23e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.79	8.31	0.56	4.82e-14	Blood protein levels;
PAAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg09835421	chr16:68378352	PRMT7	-0.97	-5.8	-0.43	3.78e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.47e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs375066	0.901	rs368316	chr19:44431894	C/A	cg11993925	chr19:44307056	LYPD5	0.51	6.45	0.46	1.39e-9	Breast cancer;
PAAD	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg24069376	chr3:38537580	EXOG	0.34	4.25	0.33	3.72e-5	Electrocardiographic conduction measures;
PAAD	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.89	10.18	0.64	7.16e-19	Height;
PAAD	cis	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg11619707	chr19:22235551	ZNF257	-0.58	-5.7	-0.42	5.93e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-7.29	-0.51	1.58e-11	Rheumatoid arthritis;
PAAD	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg12639453	chr1:2035780	PRKCZ	0.54	5.79	0.43	3.93e-8	Height;
PAAD	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-6.76	-0.48	2.73e-10	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.59	5.82	0.43	3.36e-8	Type 2 diabetes;
PAAD	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg18833306	chr6:118973337	C6orf204	0.42	4.44	0.34	1.75e-5	Electrocardiographic conduction measures;
PAAD	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.5	4.9	0.37	2.41e-6	Lung cancer;
PAAD	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.47	-0.52	5.93e-12	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.58	5.14	0.38	8.23e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.62	-6.7	-0.48	3.91e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg09242541	chr1:10490025	APITD1	0.37	4.33	0.33	2.69e-5	Asthma;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs507080	0.922	rs514143	chr11:118558449	G/A	cg08498647	chr11:118550644	TREH	-0.37	-4.27	-0.33	3.49e-5	Serum metabolite levels;
PAAD	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.56	5.14	0.38	8.44e-7	Type 2 diabetes;
PAAD	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25833597	chr17:30823145	MYO1D	0.48	4.69	0.36	6.14e-6	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.99	13.23	0.73	4.49e-27	Menopause (age at onset);
PAAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg09876464	chr15:85330779	ZNF592	0.42	4.39	0.34	2.08e-5	P wave terminal force;
PAAD	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.77	0.48	2.69e-10	Leprosy;
PAAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg01851573	chr8:8652454	MFHAS1	-0.49	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.67	6.46	0.46	1.35e-9	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.12	0.38	9.22e-7	Alzheimer's disease;
PAAD	cis	rs4965869	0.866	rs11856811	chr15:101976322	A/G	cg12371147	chr15:101978424	PCSK6	-0.51	-4.51	-0.34	1.27e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.2	0.6	2.59e-16	Morning vs. evening chronotype;
PAAD	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg23957660	chr17:17878224	LRRC48	0.38	4.3	0.33	3.08e-5	Total body bone mineral density;
PAAD	cis	rs9361491	0.677	rs9352630	chr6:79462192	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.71	-5.16	-0.39	7.68e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	6.87	0.49	1.56e-10	Educational attainment;
PAAD	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg01267373	chr18:77410094	NA	0.43	4.69	0.36	6.08e-6	Monocyte count;
PAAD	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02653313	chr3:49131667	QRICH1	0.58	6.75	0.48	3e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs405795	1.000	rs192871	chr13:89790372	G/A	cg27422345	chr7:1715242	NA	-0.99	-6.7	-0.48	3.73e-10	Yeast infection;
PAAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.63	-6.71	-0.48	3.58e-10	Schizophrenia;
PAAD	cis	rs2031532	0.565	rs1543513	chr13:50034684	C/A	cg03651054	chr13:50194643	NA	0.33	4.41	0.34	1.98e-5	Cardiac hypertrophy;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.77e-7	Life satisfaction;
PAAD	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg15192750	chr16:69999425	NA	0.79	6.18	0.45	5.58e-9	IgE levels;
PAAD	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg04515608	chr11:48129067	PTPRJ	-0.39	-4.74	-0.36	4.87e-6	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs375066	0.935	rs425221	chr19:44418544	C/T	cg11993925	chr19:44307056	LYPD5	-0.52	-6.65	-0.47	4.84e-10	Breast cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12525736	chr1:228269915	ARF1	0.6	6.84	0.49	1.86e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.84	-6.42	-0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.56	-0.35	1.05e-5	Obesity-related traits;
PAAD	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.24	0.51	2.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg17385448	chr1:15911702	AGMAT	0.35	4.36	0.33	2.36e-5	Systolic blood pressure;
PAAD	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.55	4.39	0.34	2.1e-5	IFN-related cytopenia;
PAAD	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.57	-0.35	9.98e-6	Resting heart rate;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02050181	chr1:52344849	NRD1	0.72	6.9	0.49	1.29e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.71	6.11	0.44	8.15e-9	Obesity-related traits;
PAAD	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg07469887	chr10:131262384	NA	0.4	4.45	0.34	1.67e-5	Response to temozolomide;
PAAD	cis	rs2657888	0.598	rs2657909	chr12:56895503	T/C	cg23002907	chr12:56915593	RBMS2	0.44	4.28	0.33	3.3e-5	Adiponectin levels;
PAAD	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.83	-0.37	3.24e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18791136	chr2:201237307	SPATS2L	-0.75	-7.68	-0.53	1.78e-12	Obesity-related traits;
PAAD	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg24553058	chr2:113831203	IL1F10	0.42	4.66	0.35	6.8e-6	Inflammatory biomarkers;
PAAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg13918804	chr1:2043761	PRKCZ	-0.36	-4.71	-0.36	5.57e-6	Height;
PAAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.47	-4.82	-0.36	3.49e-6	Menarche (age at onset);
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs2327429	0.858	rs13218281	chr6:134193714	T/G	cg06296503	chr6:134217401	NA	0.48	4.93	0.37	2.16e-6	Coronary artery disease;
PAAD	cis	rs621942	0.635	rs61905902	chr11:85858129	G/T	cg07180834	chr11:85838833	NA	-0.45	-4.71	-0.36	5.45e-6	Tourette syndrome;
PAAD	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	12.17	0.7	3.18e-24	Post bronchodilator FEV1;
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg04089426	chr11:65307791	LTBP3	0.71	4.47	0.34	1.52e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.74	8.11	0.55	1.61e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs9322817	0.653	rs2400051	chr6:105169478	A/C	cg02098413	chr6:105308735	HACE1	-0.41	-5.15	-0.39	8.01e-7	Thyroid stimulating hormone;
PAAD	cis	rs62025270	0.688	rs17576534	chr15:86285740	C/T	cg13263323	chr15:86062960	AKAP13	0.49	4.32	0.33	2.75e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.28	0.39	4.41e-7	Prostate cancer;
PAAD	cis	rs4708431	0.540	rs12527674	chr6:168492582	A/G	cg09211372	chr6:168490623	NA	-0.41	-4.48	-0.34	1.45e-5	Attention deficit hyperactivity disorder (combined symptoms);
PAAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.78	12.52	0.71	3.6e-25	Breast cancer;
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	1.0	10.88	0.66	9.3e-21	Homoarginine levels;
PAAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.51	-0.78	4.05e-33	Schizophrenia;
PAAD	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.72	8.87	0.58	1.82e-15	Obesity (extreme);
PAAD	trans	rs901683	0.850	rs79529960	chr10:46045315	C/T	cg11747279	chr17:21096632	NA	0.88	6.71	0.48	3.53e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.6	-8.25	-0.56	7.04e-14	Huntington's disease progression;
PAAD	cis	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs10988449	1.000	rs10988449	chr9:132370360	C/T	cg18327994	chr9:132372705	NA	-0.59	-4.36	-0.33	2.41e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.56	0.65	6.74e-20	Platelet count;
PAAD	cis	rs5753037	0.809	rs2057882	chr22:30217827	A/T	cg01021169	chr22:30184971	ASCC2	-0.44	-4.52	-0.34	1.23e-5	Type 1 diabetes;
PAAD	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-0.97	-4.71	-0.36	5.44e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg18612461	chr15:75251733	NA	0.39	4.38	0.33	2.24e-5	Systemic lupus erythematosus;
PAAD	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.99	12.3	0.71	1.39e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.63	5.81	0.43	3.5e-8	Obesity-related traits;
PAAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs1468734	1.000	rs1468734	chr16:5001304	G/A	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.58	-0.35	9.75e-6	Cancer;
PAAD	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.79	8.3	0.56	5.2e-14	Coronary artery disease;
PAAD	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.26	0.51	1.84e-11	Body mass index (adult);
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.88	-12.78	-0.72	7.31e-26	Cystic fibrosis severity;
PAAD	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.83	10.11	0.63	1.06e-18	Bladder cancer;
PAAD	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.87	-0.37	2.77e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Blood protein levels;
PAAD	cis	rs6597981	0.543	rs3901233	chr11:749452	T/A	cg17739936	chr11:789930	CEND1	-0.69	-6.7	-0.48	3.89e-10	Breast cancer;
PAAD	cis	rs17624523	0.892	rs17624303	chr2:105148418	C/T	cg25549459	chr2:105471252	POU3F3	-0.38	-5.11	-0.38	9.67e-7	Response to taxane treatment (docetaxel);
PAAD	cis	rs1018836	0.505	rs7015030	chr8:91460331	T/C	cg16814680	chr8:91681699	NA	-0.73	-7.02	-0.49	6.96e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	0.54	6.07	0.44	9.8e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.57	5.9	0.43	2.25e-8	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	5.1	0.38	1.02e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.59	-5.18	-0.39	6.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.5	5.41	0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.49	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg05627522	chr15:75251581	NA	0.49	5.66	0.42	7.47e-8	Breast cancer;
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.89	10.77	0.66	1.88e-20	Ulcerative colitis;
PAAD	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg01798341	chr17:80842262	TBCD	-0.39	-4.41	-0.34	1.98e-5	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.76	8.88	0.58	1.77e-15	Lung cancer;
PAAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs3736485	0.934	rs28393906	chr15:51867605	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7631605	0.905	rs6773752	chr3:37225837	C/T	cg17445812	chr3:36986805	TRANK1	0.33	4.47	0.34	1.54e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg05562828	chr17:3906858	NA	0.48	5.09	0.38	1.03e-6	Type 2 diabetes;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.78	8.8	0.58	2.82e-15	Lung cancer;
PAAD	cis	rs12780845	1.000	rs67505314	chr10:17240134	A/G	cg00857480	chr10:17188594	TRDMT1	0.35	4.38	0.33	2.19e-5	Homocysteine levels;
PAAD	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg08917208	chr2:24149416	ATAD2B	0.5	4.5	0.34	1.32e-5	Asthma;
PAAD	cis	rs17106184	0.786	rs72900944	chr1:51126914	C/T	cg07174182	chr1:51127561	FAF1	-0.82	-4.25	-0.33	3.73e-5	Type 2 diabetes;
PAAD	cis	rs138918	1.000	rs113515	chr22:43556922	C/G	cg00343092	chr22:43547974	TSPO	0.47	5.55	0.41	1.25e-7	Monocyte count;
PAAD	cis	rs7119038	0.509	rs10892260	chr11:118583525	A/C	cg08498647	chr11:118550644	TREH	0.41	4.48	0.34	1.45e-5	Sjögren's syndrome;
PAAD	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg25620797	chr2:55921863	PNPT1	-0.52	-5.09	-0.38	1.03e-6	Metabolic syndrome;
PAAD	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg26027780	chr6:27100370	HIST1H2AG;HIST1H2BJ	0.49	4.31	0.33	2.96e-5	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-4.65	-0.35	7.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg24733560	chr20:60626293	TAF4	0.46	5.69	0.42	6.42e-8	Body mass index;
PAAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.78	0.58	3.22e-15	Eye color traits;
PAAD	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-4.58	-0.35	9.77e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg11143131	chr5:131608246	PDLIM4	0.5	4.98	0.37	1.69e-6	Blood metabolite levels;
PAAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.45	5.86	0.43	2.81e-8	Cystic fibrosis severity;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg11266682	chr4:10021025	SLC2A9	0.53	4.35	0.33	2.48e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-1.03	-14.16	-0.75	1.43e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.77	7.66	0.53	2e-12	Asthma;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6688613	1.000	rs6688613	chr1:166951869	A/G	cg07049167	chr1:166818506	POGK	-0.45	-4.41	-0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs1075232	1.000	rs72722847	chr15:31682346	C/T	cg01030201	chr15:31746330	NA	-1.09	-4.45	-0.34	1.67e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg25200586	chr1:148000763	NA	-0.6	-6.33	-0.46	2.64e-9	Hip geometry;
PAAD	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg01388757	chr2:102091195	RFX8	-0.56	-7.21	-0.5	2.47e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	5.79	0.43	3.91e-8	Lung cancer in ever smokers;
PAAD	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11828289	0.660	rs75816907	chr11:23175126	G/A	cg20040320	chr11:23191996	NA	-0.8	-5.74	-0.42	4.97e-8	Cancer;
PAAD	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg00035074	chr7:2701567	TTYH3	0.57	4.36	0.33	2.42e-5	Bipolar disorder;
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.16	-14.81	-0.77	2.71e-31	Type 1 diabetes nephropathy;
PAAD	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.37	4.53	0.34	1.2e-5	Mosquito bite size;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2817937	1.000	rs2357972	chr6:121098311	C/T	cg22125214	chr7:135612081	LUZP6;MTPN	-1.11	-6.66	-0.48	4.63e-10	Primary tooth development (number of teeth);
PAAD	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.79	-8.62	-0.57	8.34e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.72	7.23	0.51	2.22e-11	Lung cancer;
PAAD	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg20900008	chr2:392811	NA	-0.56	-4.4	-0.34	2.06e-5	Blood protein levels;
PAAD	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg09796270	chr17:17721594	SREBF1	0.43	4.85	0.37	2.97e-6	Total body bone mineral density;
PAAD	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs282587	0.569	rs373653	chr13:113406699	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.6e-6	Glycated hemoglobin levels;
PAAD	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.53	0.41	1.36e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.81	9.12	0.59	4.22e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg06392426	chr19:10676186	KRI1	0.6	5.92	0.43	2.03e-8	Red cell distribution width;
PAAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.55	-0.52	3.8e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-1.05	-14.31	-0.76	5.69e-30	Breast cancer;
PAAD	cis	rs6494488	0.500	rs112190405	chr15:64766025	G/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs2790216	1.000	rs2590339	chr10:60012231	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14437442	chr4:185140328	ENPP6	-0.69	-7.84	-0.54	7.16e-13	Obesity-related traits;
PAAD	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg05484376	chr2:27715224	FNDC4	-0.43	-4.31	-0.33	2.96e-5	Oral cavity cancer;
PAAD	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.76	-0.48	2.81e-10	Exhaled nitric oxide output;
PAAD	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg00543991	chr22:32367038	NA	1.15	7.02	0.49	6.78e-11	Childhood ear infection;
PAAD	cis	rs2562456	0.754	rs62109228	chr19:21536931	G/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.39	0.68	4.07e-22	Smoking behavior;
PAAD	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs8014252	0.803	rs8012025	chr14:71012205	T/C	cg11204974	chr14:71022665	NA	-0.69	-4.52	-0.34	1.24e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg13476313	chr9:127244764	NR5A1	-0.32	-5.18	-0.39	6.97e-7	Menarche (age at onset);
PAAD	cis	rs28647808	1.000	rs35348753	chr9:136270070	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg13798912	chr7:905769	UNC84A	0.58	4.45	0.34	1.67e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg19700328	chr14:106028568	NA	-0.64	-6.18	-0.45	5.55e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-4.97	-0.37	1.75e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.2	0.64	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.54	0.57	1.31e-14	Rheumatoid arthritis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17683031	chr3:183165430	NA	-0.6	-6.99	-0.49	8.19e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.98	-0.44	1.54e-8	Cystic fibrosis severity;
PAAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.43	0.56	2.51e-14	Homoarginine levels;
PAAD	cis	rs13242816	1.000	rs62468973	chr7:116125834	G/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.01	-0.38	1.48e-6	P wave duration;
PAAD	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg20003494	chr4:90757398	SNCA	-0.41	-4.53	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.83	-5.84	-0.43	3.04e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg04879861	chr1:47134311	ATPAF1	0.57	4.47	0.34	1.54e-5	Monobrow;
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.86	-0.37	2.92e-6	Coronary artery disease;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.57	5.89	0.43	2.44e-8	Longevity;Endometriosis;
PAAD	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2555155	0.935	rs2555158	chr11:6520164	T/A	cg24637308	chr11:6592297	DNHD1	0.48	4.96	0.37	1.88e-6	DNA methylation (variation);
PAAD	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg18404041	chr3:52824283	ITIH1	-0.41	-4.27	-0.33	3.37e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs202065757	1	rs202065757	chr6:28766359	C/CAT	cg06606381	chr12:133084897	FBRSL1	-1.41	-9.31	-0.6	1.38e-16	Tuberculosis;
PAAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.77	-0.36	4.27e-6	Menarche (age at onset);
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.79	5.89	0.43	2.4e-8	Initial pursuit acceleration;
PAAD	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg20129853	chr10:51489980	NA	-0.47	-4.55	-0.35	1.07e-5	Prostate-specific antigen levels;
PAAD	cis	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.4	-0.4	2.49e-7	Mononucleosis;
PAAD	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.45	-4.71	-0.36	5.51e-6	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.57	-5.97	-0.44	1.61e-8	White matter hyperintensity burden;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01171360	chr6:293285	DUSP22	-0.65	-6.71	-0.48	3.7e-10	Menopause (age at onset);
PAAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03605463	chr16:89740564	NA	-0.47	-4.51	-0.34	1.3e-5	Vitiligo;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg25155006	chr6:37138205	PIM1	0.51	4.55	0.35	1.09e-5	QRS duration;
PAAD	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg21062780	chr6:887772	NA	-0.59	-5.66	-0.42	7.36e-8	Aging;
PAAD	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.94	9.93	0.63	3.22e-18	Cognitive function;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg18833306	chr6:118973337	C6orf204	0.41	4.33	0.33	2.67e-5	Electrocardiographic conduction measures;
PAAD	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.39	0.4	2.6e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg18209359	chr17:80159595	CCDC57	0.44	4.56	0.35	1.05e-5	Life satisfaction;
PAAD	cis	rs7572733	0.504	rs72928581	chr2:198866620	G/A	cg10820045	chr2:198174542	NA	0.45	4.58	0.35	9.61e-6	Dermatomyositis;
PAAD	cis	rs7224685	0.731	rs35514092	chr17:4183041	G/A	cg05562828	chr17:3906858	NA	0.51	4.71	0.36	5.62e-6	Type 2 diabetes;
PAAD	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs61931739	0.649	rs12424056	chr12:33714314	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-5.89	-0.43	2.42e-8	Monocyte count;
PAAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.64	6.44	0.46	1.52e-9	Monocyte count;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.6	-0.47	6.34e-10	Obesity-related traits;
PAAD	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.3e-5	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs114098136	chr1:227235510	A/G	cg24860534	chr1:227506868	CDC42BPA	0.5	4.75	0.36	4.71e-6	Optic disc area;
PAAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.92	-8.12	-0.55	1.52e-13	Gut microbiome composition (summer);
PAAD	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma;
PAAD	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg24623649	chr8:11872141	NA	-0.45	-4.36	-0.33	2.43e-5	Monocyte count;
PAAD	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	1.06	7.55	0.52	3.81e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg20673841	chr7:107026890	COG5	0.51	4.32	0.33	2.85e-5	Coronary artery disease;
PAAD	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg00922110	chr4:57842668	C4orf14	0.46	4.58	0.35	9.64e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12615435	0.536	rs34090087	chr2:200636212	C/A	cg23649088	chr2:200775458	C2orf69	0.79	4.33	0.33	2.72e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);
PAAD	cis	rs4742903	0.875	rs10991141	chr9:106938280	T/C	cg14250997	chr9:106856677	SMC2	0.44	4.66	0.35	6.98e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg04117972	chr1:227635322	NA	0.76	4.84	0.37	3.2e-6	Major depressive disorder;
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.87e-15	Lung cancer;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.03	-0.5	6.65e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg23119463	chr10:134592391	INPP5A	-0.46	-4.67	-0.35	6.59e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10788264	0.504	rs10749451	chr10:124028040	C/T	cg09507567	chr10:124027408	NA	0.41	4.87	0.37	2.76e-6	Total body bone mineral density;
PAAD	cis	rs10795433	1.000	rs10795433	chr10:16969923	A/C	cg00939682	chr10:16933505	CUBN	0.59	5.09	0.38	1.06e-6	Urinary albumin-to-creatinine ratio;Microalbuminuria;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg01966878	chr4:90757139	SNCA	0.61	4.75	0.36	4.59e-6	Neuroticism;
PAAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg05785598	chr3:49045655	WDR6	0.42	4.9	0.37	2.44e-6	Parkinson's disease;
PAAD	cis	rs11252926	0.800	rs12763675	chr10:744591	C/T	cg03684893	chr10:554711	DIP2C	0.48	4.65	0.35	7.15e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18122406	chr2:203130903	NOP58	0.56	6.97	0.49	9.27e-11	Monocyte percentage of white cells;
PAAD	cis	rs2300603	0.879	rs28465205	chr14:76011853	T/C	cg01624173	chr14:75981868	NA	0.56	5.82	0.43	3.45e-8	Multiple sclerosis;
PAAD	cis	rs6850606	0.577	rs13142149	chr4:42867461	C/T	cg24533989	chr4:42659536	ATP8A1	-0.5	-4.32	-0.33	2.81e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.61	5.55	0.41	1.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.85	10.07	0.63	1.41e-18	Selective IgA deficiency;
PAAD	cis	rs9398803	0.651	rs4895813	chr6:126975786	G/T	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs1274963	0.601	rs2063634	chr3:39196452	A/G	cg02254461	chr3:39195904	CSRNP1	-0.59	-5.11	-0.38	9.61e-7	Chronic lymphocytic leukemia;
PAAD	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg19949948	chr17:19361230	NA	0.44	4.69	0.36	5.98e-6	Schizophrenia;
PAAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09802426	chr7:140396638	LOC100134713;NDUFB2	-0.81	-7.11	-0.5	4.26e-11	Neuroticism;
PAAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg08371190	chr1:87598514	LOC339524	-0.44	-5.73	-0.42	5.27e-8	Smoking behavior;
PAAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg22800045	chr5:56110881	MAP3K1	-0.57	-5.05	-0.38	1.27e-6	Initial pursuit acceleration;
PAAD	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.46	-5.4	-0.4	2.53e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs654384	0.507	rs2342505	chr7:4175710	C/T	cg27574739	chr7:4176374	SDK1	-0.5	-4.78	-0.36	4.04e-6	Positive affect;
PAAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg14092988	chr3:52407081	DNAH1	0.45	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg18892244	chr7:807596	HEATR2	-0.72	-5.44	-0.4	2.04e-7	Initial pursuit acceleration;
PAAD	cis	rs17023223	0.537	rs2645300	chr1:119603067	C/A	cg26570165	chr1:119541833	NA	-0.45	-4.26	-0.33	3.63e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.73	0.58	4.16e-15	Lung cancer;
PAAD	cis	rs6496932	0.635	rs28559998	chr15:85903836	G/A	cg19183879	chr15:85880815	NA	-0.5	-4.71	-0.36	5.6e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	6.17	0.45	6.03e-9	Lung cancer in ever smokers;
PAAD	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.48	-5.56	-0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.78	0.42	4.04e-8	Prostate cancer;
PAAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.53	-0.34	1.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-7.4	-0.51	8.57e-12	Hemoglobin concentration;
PAAD	cis	rs6011002	0.590	rs1298721	chr20:62352319	T/C	cg01176363	chr20:62369445	LIME1	-0.92	-4.28	-0.33	3.28e-5	Dental caries;
PAAD	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	8.04e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg12641515	chr19:46296257	DMWD	0.45	4.33	0.33	2.72e-5	Coronary artery disease;
PAAD	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.9	-7.16	-0.5	3.26e-11	Orofacial clefts;
PAAD	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.78	-8.41	-0.56	2.75e-14	Superior crus of antihelix expression;
PAAD	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.11	13.63	0.74	3.74e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.65	6.21	0.45	4.72e-9	Coronary artery disease;
PAAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.61	-6.85	-0.49	1.76e-10	Urate levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09828226	chr1:1500093	SSU72	-0.7	-7.61	-0.53	2.64e-12	Obesity-related traits;
PAAD	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.63	-7.19	-0.5	2.74e-11	Menarche (age at onset);
PAAD	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs965469	0.779	rs2236088	chr20:3256342	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.49	-5.42	-0.4	2.26e-7	Bipolar disorder;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.56	-5.31	-0.4	3.88e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4427176	0.660	rs59004915	chr8:9580496	C/T	cg03024720	chr8:9765601	NA	-0.48	-4.61	-0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs4281086	0.932	rs7838089	chr8:10346651	C/T	cg01072821	chr8:10382165	T-SP1	-0.46	-4.45	-0.34	1.63e-5	Obesity-related traits;
PAAD	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.93	-9.67	-0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.79	5.53	0.41	1.37e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02221684	chr16:57220272	FAM192A;RSPRY1	0.68	7.16	0.5	3.25e-11	Myopia (pathological);
PAAD	cis	rs73072330	0.555	rs77580994	chr3:47935727	T/C	cg09665691	chr3:47563885	NA	1.45	6.32	0.46	2.7e-9	Stem cell growth factor beta levels;
PAAD	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg09074113	chr2:20870087	GDF7	-0.37	-4.35	-0.33	2.47e-5	Abdominal aortic aneurysm;
PAAD	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs12304921	0.935	rs4768948	chr12:51365168	C/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.39	-0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg21823605	chr1:152486609	CRCT1	0.53	5.9	0.43	2.32e-8	Hair morphology;
PAAD	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs7929679	0.551	rs906902	chr11:34780278	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.39	-0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.38	0.34	2.16e-5	Tonsillectomy;
PAAD	cis	rs136211	0.929	rs1883273	chr22:36769685	A/G	cg11153328	chr22:36877737	TXN2	0.49	4.57	0.35	1.01e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3112530	0.901	rs2262711	chr5:152713775	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg00750074	chr16:89608354	SPG7	-0.6	-5.76	-0.42	4.59e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs9401295	0.641	rs6915773	chr6:98287329	G/A	cg00987395	chr6:98934664	NA	0.38	4.57	0.35	1.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.32	-0.33	2.76e-5	Mood instability;
PAAD	cis	rs72827839	0.846	rs41280120	chr17:46114692	C/G	cg23391107	chr17:45924227	SP6	0.6	5.24	0.39	5.33e-7	Ease of getting up in the morning;
PAAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	6.08	0.44	9.26e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.91	-6.12	-0.44	7.73e-9	Systolic blood pressure;
PAAD	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.56	4.71	0.36	5.59e-6	Menopause (age at onset);
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.01e-6	Lung cancer;
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-5.12	-0.38	9.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg05528293	chr18:74961138	GALR1	0.57	5.31	0.4	3.9e-7	Obesity-related traits;
PAAD	cis	rs9659323	0.650	rs61528304	chr1:119463599	A/G	cg17326555	chr1:119535693	NA	-0.35	-4.27	-0.33	3.49e-5	Body mass index;
PAAD	cis	rs9810890	1.000	rs9810890	chr3:128652553	C/T	cg15676455	chr3:128564943	NA	-0.68	-4.46	-0.34	1.59e-5	Dental caries;
PAAD	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.37	4.66	0.35	6.87e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	trans	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.48	-0.47	1.22e-9	Mean corpuscular volume;
PAAD	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs13196614	0.648	rs9498072	chr6:148940673	A/G	cg04930982	chr6:149202328	UST	-0.5	-4.51	-0.34	1.3e-5	Migraine;
PAAD	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	4.62	0.35	8.25e-6	Aortic root size;
PAAD	cis	rs11168618	0.846	rs11168592	chr12:48865079	C/T	cg01881778	chr12:48919444	OR8S1	-0.49	-4.92	-0.37	2.19e-6	Adiponectin levels;
PAAD	cis	rs6066835	0.614	rs2224504	chr20:47400304	T/C	cg18078177	chr20:47281410	PREX1	-0.85	-4.43	-0.34	1.76e-5	Multiple myeloma;
PAAD	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.57	-4.79	-0.36	4.01e-6	Total body bone mineral density;
PAAD	cis	rs950169	0.690	rs12901166	chr15:84699113	G/A	cg24253500	chr15:84953950	NA	0.58	6.31	0.46	2.84e-9	Schizophrenia;
PAAD	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.86	-9.28	-0.6	1.61e-16	Parkinson's disease;
PAAD	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-4.64	-0.35	7.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.7	-7.7	-0.53	1.58e-12	Mean corpuscular volume;
PAAD	cis	rs4879913	0.801	rs7047802	chr9:35591601	G/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.45	-4.38	-0.33	2.2e-5	Electroencephalogram traits;
PAAD	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.5	5.21	0.39	6.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.63	6.44	0.46	1.49e-9	Crohn's disease;
PAAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.98	7.06	0.5	5.71e-11	Plateletcrit;
PAAD	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg09945482	chr18:12777974	NA	0.61	5.28	0.39	4.35e-7	Inflammatory skin disease;
PAAD	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18578119	chr4:1236638	CTBP1	0.55	6.67	0.48	4.41e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.55	-6.2	-0.45	5.06e-9	Colorectal cancer;
PAAD	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.94	-7.68	-0.53	1.8e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg10985347	chr2:127963512	CYP27C1	0.46	4.27	0.33	3.41e-5	Protein C levels;
PAAD	cis	rs8014252	0.803	rs60120955	chr14:71061733	A/C	cg11204974	chr14:71022665	NA	-0.73	-4.85	-0.37	3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.39	-4.34	-0.33	2.64e-5	Lung cancer;
PAAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs3540	0.538	rs2074585	chr15:91009484	G/A	cg22089800	chr15:90895588	ZNF774	0.7	7.36	0.51	1.06e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.35	-0.33	2.46e-5	Lewy body disease;
PAAD	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.44	5.6	0.41	9.73e-8	Crohn's disease;
PAAD	cis	rs2120991	0.935	rs2165901	chr12:54270780	T/C	cg25640699	chr12:54070114	ATP5G2	-0.46	-4.69	-0.36	6.1e-6	Biliary atresia;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg04287289	chr16:89883240	FANCA	0.91	4.64	0.35	7.45e-6	Skin colour saturation;
PAAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.64	-6.08	-0.44	9.18e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg06207120	chr15:45996521	NA	0.31	4.47	0.34	1.54e-5	Waist circumference;Weight;
PAAD	cis	rs300774	0.925	rs300715	chr2:137962	A/G	cg23649280	chr2:140451	NA	-0.47	-4.46	-0.34	1.61e-5	Suicide attempts in bipolar disorder;
PAAD	trans	rs17150703	0.722	rs510591	chr8:9786355	A/G	cg23209606	chr1:8515930	RERE	0.68	6.32	0.46	2.8e-9	Obesity (early onset extreme);
PAAD	cis	rs58521262	0.556	rs289298	chr19:23175945	G/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	6.95	0.49	9.88e-11	Coronary artery disease;
PAAD	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.7	-0.36	5.91e-6	Menopause (age at onset);
PAAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.93	-0.37	2.16e-6	Mean corpuscular volume;
PAAD	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg22517653	chr1:2918612	NA	-0.64	-5.14	-0.38	8.27e-7	Plateletcrit;
PAAD	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg23752985	chr2:85803571	VAMP8	0.6	6.4	0.46	1.82e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.51	-0.47	1.01e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.03e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.81	-9.49	-0.61	4.67e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.08	-0.44	9.5e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg20933634	chr6:27740509	NA	0.44	4.25	0.33	3.76e-5	Parkinson's disease;
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.27	0.39	4.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg27490568	chr2:178487706	NA	0.42	4.5	0.34	1.35e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg09796270	chr17:17721594	SREBF1	0.43	4.91	0.37	2.33e-6	Total body bone mineral density;
PAAD	cis	rs7631605	0.875	rs2110194	chr3:37097087	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.29e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg05228244	chr10:1102351	WDR37	0.92	4.58	0.35	9.74e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	9.98	0.63	2.36e-18	Cognitive test performance;
PAAD	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17376030	chr22:41985996	PMM1	-0.61	-4.44	-0.34	1.74e-5	Vitiligo;
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg22963979	chr7:1858916	MAD1L1	0.77	9.06	0.59	5.87e-16	Bipolar disorder and schizophrenia;
PAAD	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.72	-6.65	-0.47	4.99e-10	Primary sclerosing cholangitis;
PAAD	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.07	5.19	0.39	6.52e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs863345	0.604	rs12133794	chr1:158506697	C/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.96	-0.37	1.87e-6	Pneumococcal bacteremia;
PAAD	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg12310025	chr6:25882481	NA	0.44	4.38	0.33	2.21e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17401966	0.898	rs12122107	chr1:10251449	C/T	cg15208524	chr1:10270712	KIF1B	0.51	4.77	0.36	4.33e-6	Hepatocellular carcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23489587	chr5:177303156	LOC728554	0.69	8.13	0.55	1.38e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg26248373	chr2:1572462	NA	-1.09	-8.37	-0.56	3.51e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg14784428	chr8:11660061	FDFT1	-0.48	-4.25	-0.33	3.7e-5	Triglycerides;
PAAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1075265	0.584	rs1559037	chr2:54278585	C/G	cg04546899	chr2:54196757	PSME4	0.37	5.45	0.4	2.04e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	5.59	0.41	1.02e-7	Eosinophil percentage of white cells;
PAAD	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs3733346	0.510	rs6815138	chr4:941290	A/C	cg20814179	chr4:940893	TMEM175	0.68	8.18	0.55	1.06e-13	Sjögren's syndrome;
PAAD	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.53	0.57	1.34e-14	Personality dimensions;
PAAD	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg20814179	chr4:940893	TMEM175	0.75	9.1	0.59	4.8e-16	Sjögren's syndrome;
PAAD	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.63	5.95	0.43	1.79e-8	Breast cancer;
PAAD	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg17333051	chr19:2783644	SGTA	0.46	5.03	0.38	1.35e-6	Total cholesterol levels;
PAAD	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.56	-5.15	-0.39	8.06e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.64	6.17	0.45	6.03e-9	Primary sclerosing cholangitis;
PAAD	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.79	-9.18	-0.6	2.92e-16	Huntington's disease progression;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.95	0.54	3.95e-13	Prudent dietary pattern;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17354807	chr6:44280781	AARS2	-0.7	-6.96	-0.49	9.53e-11	Lung cancer in ever smokers;
PAAD	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.57	-0.41	1.12e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg04520793	chr17:42248056	ASB16	0.39	4.46	0.34	1.61e-5	Total body bone mineral density;
PAAD	cis	rs73198271	0.729	rs66564323	chr8:8604996	G/A	cg01851573	chr8:8652454	MFHAS1	0.57	4.51	0.34	1.28e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.72	-7.16	-0.5	3.22e-11	Retinal vascular caliber;
PAAD	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-4.92	-0.37	2.25e-6	Common traits (Other);
PAAD	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.59	5.5	0.41	1.55e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25650185	chr19:21324782	ZNF431	-0.49	-4.49	-0.34	1.4e-5	Pain;
PAAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.13	-7.38	-0.51	9.77e-12	Plateletcrit;
PAAD	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-4.32	-0.33	2.78e-5	Metabolite levels;
PAAD	cis	rs13380717	0.657	rs12928641	chr16:86915098	C/T	cg00721125	chr16:87417448	FBXO31	0.53	4.36	0.33	2.42e-5	Sepsis in extremely premature infants;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20750606	chr13:21714611	SAP18	0.6	6.3	0.46	3.04e-9	Myopia (pathological);
PAAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.84	0.37	3.12e-6	Schizophrenia;
PAAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg21361702	chr7:150065534	REPIN1	0.58	4.65	0.35	7.24e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg06784991	chr1:53308768	ZYG11A	0.29	4.42	0.34	1.86e-5	Monocyte count;
PAAD	cis	rs3026101	0.671	rs2871203	chr17:5298490	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.87	-10.67	-0.65	3.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.74	-8.7	-0.58	5.07e-15	Type 2 diabetes;
PAAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.6	5.53	0.41	1.34e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17021463	0.673	rs35898424	chr4:95289278	A/G	cg11021082	chr4:95130006	SMARCAD1	0.57	5.82	0.43	3.3e-8	Testicular germ cell tumor;
PAAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg02841227	chr6:26021843	HIST1H4A	0.51	5.29	0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg01796438	chr3:11312864	ATG7	-0.63	-4.94	-0.37	2.06e-6	Circulating chemerin levels;
PAAD	cis	rs59888335	0.858	rs12635288	chr3:80927313	T/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.34	-0.4	3.37e-7	Fear of minor pain;
PAAD	cis	rs7765175	0.598	rs2130849	chr6:113624121	T/C	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.24	-0.39	5.33e-7	Menopause (age at onset);
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg21698718	chr17:80085957	CCDC57	0.45	5.11	0.38	9.46e-7	Life satisfaction;
PAAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.48	5.41	0.4	2.4e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg00531865	chr16:30841666	NA	-0.52	-5.01	-0.38	1.5e-6	Dementia with Lewy bodies;
PAAD	cis	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg18898632	chr2:242989856	NA	-0.63	-4.76	-0.36	4.53e-6	Obesity-related traits;
PAAD	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.77	7.81	0.54	8.73e-13	Alzheimer's disease (late onset);
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg03351412	chr1:154909251	PMVK	0.73	7.38	0.51	9.88e-12	Prostate cancer;
PAAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.59	6.46	0.46	1.35e-9	Eye color traits;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg15433604	chr19:18942513	UPF1	0.6	7.04	0.5	6.04e-11	Immature fraction of reticulocytes;
PAAD	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.67	5.66	0.42	7.38e-8	HIV-1 control;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11608897	chr2:85766394	MAT2A	-0.65	-6.71	-0.48	3.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs61863408	0.557	rs1676719	chr10:127843169	T/C	cg03862225	chr10:126850454	CTBP2	-0.47	-4.31	-0.33	2.94e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.45	0.34	1.63e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs7301016	0.948	rs11174498	chr12:62865345	T/C	cg11441379	chr12:63026424	NA	0.85	6.11	0.44	8.06e-9	IgG glycosylation;
PAAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21761045	chr8:87354805	WWP1	0.64	6.35	0.46	2.36e-9	Obesity-related traits;
PAAD	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-7.93	-0.54	4.35e-13	Dental caries;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.51	5.26	0.39	4.82e-7	Obesity-related traits;
PAAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.67	-7.61	-0.53	2.73e-12	Renal function-related traits (BUN);
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.89	-0.54	5.44e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3771514	0.543	rs67894625	chr2:70688381	C/G	cg18150120	chr2:71134936	VAX2	-0.38	-4.55	-0.35	1.09e-5	Obesity-related traits;
PAAD	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.87	10.99	0.67	4.7e-21	Menarche (age at onset);
PAAD	cis	rs75920871	0.858	rs78857232	chr11:116727465	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.8	-4.51	-0.34	1.31e-5	Subjective well-being;
PAAD	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg00450029	chr8:599525	NA	0.82	5.24	0.39	5.38e-7	IgG glycosylation;
PAAD	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.66	-10.46	-0.65	1.28e-19	Diastolic blood pressure;
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.56	4.74	0.36	4.87e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.84	-0.43	3.04e-8	Pulmonary function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15136568	chr1:154938439	SHC1	-0.66	-6.52	-0.47	9.63e-10	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02362970	chr6:136871947	MAP7	0.6	6.74	0.48	3.03e-10	Myopia (pathological);
PAAD	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16262614	chr3:133464971	TF	-0.48	-5.26	-0.39	4.85e-7	Iron status biomarkers;
PAAD	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.26	-6.89	-0.49	1.42e-10	Body mass index;
PAAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg10932868	chr11:921992	NA	0.44	4.8	0.36	3.79e-6	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs11671653	1.000	rs76291634	chr19:10836545	T/C	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs6494488	0.500	rs7181953	chr15:64924516	A/G	cg16425858	chr15:64791681	ZNF609	0.89	4.77	0.36	4.24e-6	Coronary artery disease;
PAAD	cis	rs12410462	0.636	rs2819515	chr1:227632125	G/A	cg23173402	chr1:227635558	NA	-0.55	-4.56	-0.35	1.06e-5	Major depressive disorder;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs4740619	0.967	rs10810428	chr9:15689759	C/G	cg14451791	chr9:16040625	NA	-0.38	-4.42	-0.34	1.9e-5	Body mass index;
PAAD	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.54	-6.08	-0.44	9.43e-9	HDL cholesterol levels;
PAAD	cis	rs859767	0.812	rs842360	chr2:135347885	T/C	cg12500956	chr2:135428796	TMEM163	0.31	4.47	0.34	1.53e-5	Neuroticism;
PAAD	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.51	-4.9	-0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg25251562	chr2:3704773	ALLC	-0.56	-6.49	-0.47	1.12e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.69	-6.85	-0.49	1.74e-10	Lung cancer;
PAAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.63	-7.0	-0.49	7.49e-11	Monocyte count;
PAAD	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.6	-6.31	-0.46	2.95e-9	Body mass index;
PAAD	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.49	5.13	0.38	8.84e-7	Plasma plasminogen activator levels;
PAAD	cis	rs7627468	1.000	rs3845917	chr3:121935826	G/A	cg17240004	chr3:121949083	CASR	0.51	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs2120991	0.967	rs10876512	chr12:54277756	G/A	cg25640699	chr12:54070114	ATP5G2	-0.42	-4.48	-0.34	1.44e-5	Biliary atresia;
PAAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.7	6.06	0.44	1.03e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.27	-0.39	4.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.62	5.32	0.4	3.64e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.59	-4.94	-0.37	2.03e-6	Coronary artery disease;
PAAD	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.6	4.42	0.34	1.89e-5	Pulse pressure;
PAAD	cis	rs72960926	1.000	rs16884731	chr6:75064418	A/G	cg13435101	chr6:74171350	MTO1	0.85	4.5	0.34	1.35e-5	Metabolite levels (MHPG);
PAAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs11807834	0.522	rs754265	chr1:230249435	A/G	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg25173405	chr17:45401733	C17orf57	0.49	5.07	0.38	1.13e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs80282103	0.717	rs74117685	chr10:1100410	A/G	cg05228244	chr10:1102351	WDR37	0.92	4.29	0.33	3.17e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg01631408	chr1:248437212	OR2T33	-0.57	-5.22	-0.39	5.66e-7	Common traits (Other);
PAAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg18551225	chr6:44695536	NA	-0.6	-5.74	-0.42	4.96e-8	Total body bone mineral density;
PAAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.75	9.94	0.63	2.99e-18	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24069935	chr14:74226554	C14orf43	-0.66	-6.43	-0.46	1.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg27121462	chr16:89883253	FANCA	0.46	4.81	0.36	3.62e-6	Vitiligo;
PAAD	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.61	5.93	0.43	1.99e-8	Rheumatoid arthritis;
PAAD	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg16898833	chr6:26189333	HIST1H4D	0.87	4.7	0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.87	-9.99	-0.63	2.17e-18	Cancer (pleiotropy);
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18621852	chr3:10150065	C3orf24	0.52	4.99	0.38	1.63e-6	Alzheimer's disease;
PAAD	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	0.81	6.11	0.44	7.82e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2004318	1.000	rs75393417	chr19:55070614	C/T	cg03320607	chr19:54800032	LILRA3	-1.11	-6.1	-0.44	8.24e-9	Blood protein levels;
PAAD	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.48	4.46	0.34	1.61e-5	Personality dimensions;
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.83	-0.54	7.77e-13	Initial pursuit acceleration;
PAAD	cis	rs925946	0.565	rs11030088	chr11:27646247	G/A	cg01418645	chr11:27679469	BDNF;BDNFOS	-0.52	-4.37	-0.33	2.25e-5	Body mass index;Weight;
PAAD	cis	rs11696501	1.000	rs11696501	chr20:44124523	A/G	cg11783356	chr20:44313418	WFDC10B	-0.58	-5.32	-0.4	3.73e-7	Brain structure;
PAAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.38	8.84e-7	Platelet count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12784625	chr2:46524557	EPAS1	-0.68	-6.72	-0.48	3.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg01800442	chr17:74086473	EXOC7	0.54	4.31	0.33	2.89e-5	Psoriasis;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.33	0.68	5.91e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.78	-0.36	4.02e-6	Resting heart rate;
PAAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.78	-8.04	-0.55	2.4e-13	Body mass index;
PAAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27602786	chr16:30934666	NCRNA00095;FBXL19	0.6	6.33	0.46	2.67e-9	Monocyte percentage of white cells;
PAAD	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.77e-14	Dupuytren's disease;
PAAD	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.53	0.47	9.4e-10	Coffee consumption (cups per day);
PAAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs10214930	0.697	rs5009225	chr7:27616785	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg26552733	chr10:5542941	CALML5	0.78	4.68	0.35	6.28e-6	Major depressive disorder;
PAAD	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg10729496	chr3:10149963	C3orf24	0.67	5.95	0.43	1.76e-8	Alzheimer's disease;
PAAD	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.51	6.02	0.44	1.28e-8	Migraine;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17331738	chr1:156647236	NES	0.6	6.66	0.48	4.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.61	6.02	0.44	1.29e-8	Depressive symptoms;
PAAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg11812906	chr14:75593930	NEK9	0.44	4.25	0.33	3.7e-5	IgG glycosylation;
PAAD	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.56	-6.06	-0.44	1.05e-8	Rheumatoid arthritis;
PAAD	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg10556349	chr10:835070	NA	0.59	4.87	0.37	2.82e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg01475377	chr6:109611718	NA	-0.41	-4.48	-0.34	1.44e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9942416	0.533	rs4704235	chr5:75024380	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.52	4.44	0.34	1.69e-5	Age-related disease endophenotypes;
PAAD	cis	rs9341808	0.529	rs9350851	chr6:81059188	A/G	cg08355045	chr6:80787529	NA	0.4	4.9	0.37	2.42e-6	Sitting height ratio;
PAAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg06521852	chr22:38141419	TRIOBP	0.44	4.35	0.33	2.47e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6688613	1.000	rs17551703	chr1:166957879	T/C	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11455018	chr16:30709778	SRCAP	0.61	6.95	0.49	9.91e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.45	4.36	0.33	2.35e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.15	-0.39	7.97e-7	Pulmonary function;
PAAD	cis	rs11700980	0.551	rs60360679	chr21:30118752	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	5.75	0.42	4.76e-8	Prostate-specific antigen levels;
PAAD	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg20790798	chr5:1857306	NA	-0.53	-6.02	-0.44	1.25e-8	Cardiovascular disease risk factors;
PAAD	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.96	-10.97	-0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.77	7.59	0.52	2.92e-12	Sudden cardiac arrest;
PAAD	cis	rs6076065	1.000	rs2424547	chr20:23392690	A/G	cg11657817	chr20:23433608	CST11	0.41	4.49	0.34	1.38e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs13102973	0.899	rs4546304	chr4:135902382	G/A	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-5.16	-0.39	7.46e-7	Eye color traits;
PAAD	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.84	7.1	0.5	4.39e-11	Neutrophil percentage of white cells;
PAAD	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.71	-7.11	-0.5	4.33e-11	Retinal vascular caliber;
PAAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg10356904	chr22:49881777	NA	-0.48	-4.77	-0.36	4.34e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.59	-6.48	-0.46	1.24e-9	Coronary artery disease;
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08322205	chr5:139127283	NA	-0.64	-6.71	-0.48	3.54e-10	Smoking initiation;
PAAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.46	0.46	1.35e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg06307176	chr5:131281290	NA	0.49	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg06782351	chr1:3566715	WDR8	-0.79	-6.46	-0.46	1.33e-9	Atopic dermatitis;
PAAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.13	-9.06	-0.59	6.05e-16	Diabetic kidney disease;
PAAD	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.76	7.87	0.54	6.18e-13	Breast cancer;
PAAD	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.63	7.06	0.5	5.48e-11	Menarche (age at onset);
PAAD	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg15123519	chr2:136567270	LCT	-0.39	-4.68	-0.35	6.31e-6	Mosquito bite size;
PAAD	cis	rs11811982	0.793	rs115655458	chr1:227465458	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs4740619	0.716	rs10810510	chr9:15958991	A/G	cg14451791	chr9:16040625	NA	-0.41	-4.6	-0.35	8.98e-6	Body mass index;
PAAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.28	0.33	3.29e-5	Parkinson's disease;
PAAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.38	-0.51	9.62e-12	Colorectal cancer;
PAAD	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14169450	chr9:139327907	INPP5E	0.65	6.11	0.44	8.05e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.94	-0.43	1.88e-8	Total cholesterol levels;
PAAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.61	-5.33	-0.4	3.5e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.82	9.79	0.62	7.29e-18	Bladder cancer;
PAAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg03983715	chr16:68378420	PRMT7	-0.94	-7.07	-0.5	5.18e-11	Schizophrenia;
PAAD	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg04176122	chr11:118779835	BCL9L	-0.45	-4.49	-0.34	1.37e-5	Sjögren's syndrome;
PAAD	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24146714	chr8:129073877	PVT1	-0.51	-6.49	-0.47	1.15e-9	Monocyte percentage of white cells;
PAAD	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg17326555	chr1:119535693	NA	-0.35	-4.37	-0.33	2.24e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	1.01	14.2	0.76	1.16e-29	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg14008862	chr17:28927542	LRRC37B2	0.86	6.21	0.45	4.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.68	10.01	0.63	1.96e-18	Huntington's disease progression;
PAAD	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.7	6.56	0.47	7.93e-10	Uric acid levels;
PAAD	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-5.54	-0.41	1.29e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs755249	0.567	rs16826093	chr1:39815143	T/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg23985595	chr17:80112537	CCDC57	0.51	6.84	0.49	1.83e-10	Life satisfaction;
PAAD	cis	rs116248771	0.739	rs12639329	chr3:158347145	T/C	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs4742903	0.967	rs3739737	chr9:106858192	A/G	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.77	7.99	0.54	3.08e-13	Alzheimer's disease (late onset);
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg13264159	chr8:625131	ERICH1	-0.75	-5.08	-0.38	1.1e-6	IgG glycosylation;
PAAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.68	8.34	0.56	4.23e-14	Bone mineral density;
PAAD	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.53	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs6142102	0.961	rs2235597	chr20:32665614	G/T	cg06115741	chr20:33292138	TP53INP2	0.53	4.35	0.33	2.51e-5	Skin pigmentation;
PAAD	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg08390786	chr10:135334061	NA	-0.65	-5.46	-0.41	1.88e-7	Gout;
PAAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.87	-7.64	-0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.8	6.85	0.49	1.75e-10	Other erythrocyte phenotypes;
PAAD	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.52	4.88	0.37	2.65e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.84	-8.12	-0.55	1.53e-13	Body mass index;
PAAD	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.5	5.05	0.38	1.26e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg05228244	chr10:1102351	WDR37	0.87	4.43	0.34	1.81e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9657904	0.826	rs7637327	chr3:105599169	A/G	cg16975614	chr3:105601834	NA	-0.46	-4.62	-0.35	7.98e-6	Multiple sclerosis;
PAAD	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.5	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.91	-10.84	-0.66	1.19e-20	IgG glycosylation;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-6.79	-0.48	2.38e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	9.16	0.6	3.27e-16	Smoking behavior;
PAAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-1.34	-10.77	-0.66	1.8899999999999998e-20	Schizophrenia;
PAAD	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-1.13	-15.31	-0.78	1.29e-32	Total cholesterol levels;
PAAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.59	-7.33	-0.51	1.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.69	6.66	0.48	4.74e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08262764	chr14:57735278	MUDENG;EXOC5	0.71	6.31	0.46	2.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.72	-0.62	1.14e-17	Response to antipsychotic treatment;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.56	-0.35	1.05e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.67	6.67	0.48	4.51e-10	Pancreatic cancer;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	8.4	0.56	2.99e-14	Educational attainment;
PAAD	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg08648136	chr8:956695	NA	0.46	4.92	0.37	2.26e-6	Schizophrenia;
PAAD	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.73	-0.36	5.13e-6	Height;
PAAD	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23272098	chr11:77185129	PAK1	0.74	8.48	0.57	1.9e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6980507	0.524	rs4568607	chr8:42364354	T/C	cg09913449	chr8:42400586	C8orf40	-0.52	-5.99	-0.44	1.46e-8	Glycated hemoglobin levels;
PAAD	cis	rs375066	0.935	rs368089	chr19:44399084	A/G	cg08633290	chr19:44405433	NA	-0.59	-5.93	-0.43	1.99e-8	Breast cancer;
PAAD	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.94	0.49	1.09e-10	Exhaled nitric oxide levels;
PAAD	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg20893579	chr22:38215064	NA	0.49	4.61	0.35	8.39e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg19978312	chr5:179634688	RASGEF1C	0.43	4.37	0.33	2.26e-5	LDL cholesterol;
PAAD	cis	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15145965	chr22:50218605	BRD1	0.62	5.44	0.4	2.06e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17342064	chr17:8013457	ALOXE3	0.65	6.83	0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9913156	0.841	rs4522461	chr17:4621773	T/G	cg00122941	chr17:4613640	ARRB2	-0.86	-8.54	-0.57	1.32e-14	Lymphocyte counts;
PAAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs911555	0.713	rs1107070	chr14:103970508	G/T	cg12935359	chr14:103987150	CKB	0.63	6.48	0.47	1.2e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg19429281	chr19:53496738	ZNF702P	-0.54	-5.67	-0.42	6.91e-8	Psoriasis;
PAAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.16	-0.39	7.67e-7	High light scatter reticulocyte count;
PAAD	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.81	10.33	0.64	2.78e-19	Breast cancer;
PAAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg27284194	chr4:1044797	NA	0.5	4.77	0.36	4.28e-6	Obesity-related traits;
PAAD	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17401966	0.597	rs6667639	chr1:10246471	C/A	cg15226751	chr1:10001911	LZIC	0.41	4.47	0.34	1.51e-5	Hepatocellular carcinoma;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs901683	1.000	rs35183751	chr10:46081358	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.66	-0.42	7.16e-8	Primary biliary cholangitis;
PAAD	cis	rs12304921	1.000	rs2269685	chr12:51417671	G/C	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.45	-0.34	1.64e-5	Type 2 diabetes;
PAAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.84	-0.37	3.22e-6	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11248182	chr5:138774785	DNAJC18	-0.64	-6.63	-0.47	5.4e-10	Smoking initiation;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27565366	chr1:28198926	C1orf38	0.7	7.38	0.51	9.53e-12	Obesity-related traits;
PAAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16491274	chr1:16678832	FBXO42	0.62	6.68	0.48	4.24e-10	Myopia (pathological);
PAAD	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg14851346	chr12:38532713	NA	0.43	4.25	0.33	3.69e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs6256	0.860	rs74932445	chr11:13500645	G/A	cg11976911	chr11:13509032	NA	-0.68	-5.26	-0.39	4.76e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-1.12	-9.16	-0.6	3.36e-16	Developmental language disorder (linguistic errors);
PAAD	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18329349	chr7:116164847	CAV1	-0.65	-7.92	-0.54	4.53e-13	Body fat percentage;
PAAD	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.5	5.18	0.39	6.9e-7	Red blood cell count;
PAAD	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs11650494	0.710	rs76305536	chr17:47488913	G/A	cg08112188	chr17:47440006	ZNF652	1.7	7.73	0.53	1.33e-12	Prostate cancer;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg15212455	chr7:39170539	POU6F2	0.49	6.91	0.49	1.22e-10	IgG glycosylation;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg04160749	chr8:58172571	NA	-0.71	-4.73	-0.36	5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs66530629	0.874	rs4648878	chr1:25164113	A/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.64	-0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.47	-4.4	-0.34	2.06e-5	Neutrophil percentage of white cells;
PAAD	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.84	8.74	0.58	3.91e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg23250157	chr14:64679961	SYNE2	0.5	5.25	0.39	5.02e-7	Atrial fibrillation;
PAAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03469617	chr2:74699267	MRPL53	-0.8	-7.51	-0.52	4.77e-12	Neuroticism;
PAAD	cis	rs714515	0.569	rs2032528	chr1:172452087	A/G	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg20636351	chr8:55087400	NA	-0.74	-7.52	-0.52	4.53e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12438356	0.881	rs11855522	chr15:69578638	C/T	cg02375503	chr15:69591110	PAQR5	-0.67	-4.58	-0.35	9.75e-6	CTACK levels;
PAAD	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.97	0.44	1.59e-8	Coffee consumption (cups per day);
PAAD	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	6.43	0.46	1.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg04862289	chr1:204966208	NFASC	0.48	4.83	0.37	3.23e-6	Mean platelet volume;
PAAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg21253087	chr9:139290292	SNAPC4	-0.42	-4.34	-0.33	2.57e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.71	-8.17	-0.55	1.12e-13	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg08132940	chr7:1081526	C7orf50	0.6	4.48	0.34	1.43e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg11271282	chr2:238384023	NA	0.49	4.54	0.35	1.13e-5	Prostate cancer;
PAAD	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.32e-5	Skin colour saturation;
PAAD	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	6.66	0.48	4.64e-10	Response to antipsychotic treatment;
PAAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.31	-0.33	2.9e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg25833597	chr17:30823145	MYO1D	0.51	5.01	0.38	1.5e-6	Schizophrenia;
PAAD	cis	rs12760731	0.720	rs12026110	chr1:178410984	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg02056144	chr12:54070517	ATP5G2	-0.5	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.4e-5	Parkinson's disease;
PAAD	cis	rs3745672	0.590	rs75275742	chr19:12168397	G/A	cg11321965	chr19:12780562	MORG1;C19orf56	-1.02	-4.64	-0.35	7.55e-6	Multiple sclerosis;
PAAD	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.57	6.37	0.46	2.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-4.92	-0.37	2.27e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.48	4.67	0.35	6.7e-6	Cancer;
PAAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-4.33	-0.33	2.68e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg03959625	chr15:84868606	LOC388152	-0.44	-4.59	-0.35	9.19e-6	P wave terminal force;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25075644	chr18:56338565	MALT1	0.63	6.34	0.46	2.51e-9	Obesity-related traits;
PAAD	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.97e-6	Triglycerides;
PAAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.71	-8.85	-0.58	2.08e-15	Bone mineral density;
PAAD	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.43	-0.4	2.16e-7	Mood instability;
PAAD	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg21775007	chr8:11205619	TDH	-0.52	-4.84	-0.37	3.18e-6	Retinal vascular caliber;
PAAD	cis	rs9888739	1.000	rs9888879	chr16:31310372	C/T	cg02256631	chr16:31342952	ITGAM	0.57	4.58	0.35	9.51e-6	Systemic lupus erythematosus;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07588109	chr1:156024479	ROBLD3;UBQLN4	0.58	6.36	0.46	2.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.84	-10.35	-0.64	2.53e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-4.37	-0.33	2.32e-5	Breast cancer;
PAAD	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.84	-0.49	1.8e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3136739	0.614	rs11778382	chr8:42013295	A/G	cg17828057	chr8:42037527	PLAT	0.68	4.63	0.35	7.76e-6	Plasma plasminogen activator levels;
PAAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00280220	chr17:61926910	NA	-0.45	-4.72	-0.36	5.32e-6	Prudent dietary pattern;
PAAD	cis	rs6558530	0.666	rs4242538	chr8:1694010	G/C	cg08198773	chr8:1697536	NA	0.46	5.14	0.38	8.48e-7	Systolic blood pressure;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01634057	chr4:123843788	NUDT6;SPATA5	-0.56	-6.35	-0.46	2.37e-9	Body fat percentage;
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-0.74	-5.01	-0.38	1.49e-6	IgG glycosylation;
PAAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.35	4.47	0.34	1.52e-5	Colorectal cancer;
PAAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.76	8.74	0.58	3.94e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1468333	1.000	rs17171770	chr5:137514815	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.95e-9	Resting heart rate;
PAAD	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg06713675	chr4:122721982	EXOSC9	0.46	4.46	0.34	1.56e-5	Type 2 diabetes;
PAAD	cis	rs9463078	0.585	rs12205274	chr6:45245026	G/A	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg07636037	chr3:49044803	WDR6	-0.81	-6.31	-0.46	2.95e-9	Menarche (age at onset);
PAAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg18551225	chr6:44695536	NA	-0.67	-7.16	-0.5	3.15e-11	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	-0.94	-5.05	-0.38	1.25e-6	Childhood ear infection;
PAAD	cis	rs3826795	0.530	rs117992292	chr19:46797295	A/G	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs6074578	0.679	rs6055460	chr20:139362	G/A	cg16931068	chr20:139680	DEFB127	-0.38	-5.25	-0.39	4.97e-7	Hirschsprung disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23410386	chr6:56637189	DST	-0.73	-7.93	-0.54	4.4e-13	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.68	-7.37	-0.51	1.04e-11	Body mass index;
PAAD	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs6439924	0.527	rs10212231	chr3:140176233	C/G	cg22717015	chr3:140951447	ACPL2	-0.52	-4.45	-0.34	1.63e-5	Hodgkin's lymphoma;
PAAD	trans	rs10500871	1.000	rs12806043	chr11:20217343	C/T	cg02956962	chr6:161097311	NA	0.6	6.31	0.46	2.89e-9	Educational attainment;
PAAD	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.63	-4.48	-0.34	1.47e-5	Smoking behavior;
PAAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-5.41	-0.4	2.35e-7	Monocyte count;
PAAD	cis	rs2017305	0.915	rs77571334	chr10:70777773	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.08	-11.56	-0.68	1.45e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs818427	0.896	rs458451	chr5:112224331	T/C	cg07820702	chr5:112228657	REEP5	-0.52	-4.67	-0.35	6.53e-6	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22874560	chr6:37225361	TMEM217;TBC1D22B	0.58	6.63	0.47	5.47e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.89	10.0	0.63	2.13e-18	Breast cancer;
PAAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.56	4.89	0.37	2.58e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.45	0.46	1.42e-9	Lung cancer;
PAAD	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg10090792	chr1:38198142	EPHA10	-0.44	-4.54	-0.35	1.14e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs910873	0.505	rs6087607	chr20:33197489	A/G	cg16810054	chr20:33298113	TP53INP2	-0.57	-4.28	-0.33	3.28e-5	Melanoma;
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg10925829	chr20:60860984	OSBPL2	-0.42	-4.39	-0.34	2.08e-5	Colorectal cancer;
PAAD	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.76	6.22	0.45	4.67e-9	Monocyte percentage of white cells;
PAAD	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg08008475	chr13:27977779	NA	0.43	4.27	0.33	3.46e-5	Weight;
PAAD	cis	rs2544527	0.819	rs2693019	chr2:15922288	T/C	cg26669897	chr2:15909070	NA	0.46	4.57	0.35	9.93e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.67e-5	Life satisfaction;
PAAD	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.9	11.6	0.69	1.11e-22	Body mass index;
PAAD	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.83	-0.36	3.31e-6	Aortic root size;
PAAD	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-6.03	-0.44	1.19e-8	Resting heart rate;
PAAD	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.51	5.02	0.38	1.43e-6	Malaria;
PAAD	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.78	7.66	0.53	2.03e-12	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg15309053	chr8:964076	NA	0.41	4.35	0.33	2.45e-5	Schizophrenia;
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg01942863	chr7:99769432	GPC2	-0.47	-4.49	-0.34	1.38e-5	Coronary artery disease;
PAAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.52	6.0	0.44	1.37e-8	Major depressive disorder;
PAAD	cis	rs73416724	1.000	rs41281798	chr6:43325787	C/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6594713	0.604	rs1922679	chr5:112637754	A/G	cg12552261	chr5:112820674	MCC	-0.63	-4.51	-0.34	1.3e-5	Brain cytoarchitecture;
PAAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06799790	chr17:61951754	CSH2	-0.46	-4.74	-0.36	4.93e-6	Height;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg22601191	chr20:60968625	CABLES2	0.48	4.6	0.35	8.93e-6	Pelvic organ prolapse;
PAAD	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg21724239	chr8:58056113	NA	0.67	5.09	0.38	1.04e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.93	11.29	0.68	7.32e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs859767	0.709	rs1516990	chr2:135369630	C/G	cg12500956	chr2:135428796	TMEM163	-0.3	-4.4	-0.34	2.03e-5	Neuroticism;
PAAD	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	7.78	0.53	1.03e-12	Coronary artery disease;
PAAD	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg16579770	chr16:72058938	DHODH	0.38	4.46	0.34	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg11410649	chr1:24122853	GALE	-0.57	-4.25	-0.33	3.71e-5	Psoriasis vulgaris;
PAAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.72	8.01	0.54	2.74e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9395066	0.509	rs11967188	chr6:44956925	C/T	cg25276700	chr6:44698697	NA	0.49	5.64	0.42	7.91e-8	Height;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	7.96e-7	Myeloid white cell count;
PAAD	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.4	4.83	0.36	3.3e-6	Thyroid stimulating hormone;
PAAD	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17507749	chr15:85114479	UBE2QP1	0.59	5.88	0.43	2.56e-8	Schizophrenia;
PAAD	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs13024765	0.527	rs76434727	chr2:225182400	A/G	cg22455342	chr2:225449267	CUL3	0.49	4.59	0.35	9.06e-6	Platelet-derived growth factor BB levels;
PAAD	cis	rs959260	0.858	rs2053156	chr17:73378440	G/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs7752195	0.555	rs6909365	chr6:25191427	G/A	cg26336265	chr6:25042955	NA	0.71	4.81	0.36	3.61e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.4e-8	Coronary artery disease;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12016809	chr21:47604291	C21orf56	0.46	4.56	0.35	1.05e-5	Testicular germ cell tumor;
PAAD	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.56	-5.61	-0.41	9.21e-8	QT interval;
PAAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg05110241	chr16:68378359	PRMT7	-0.97	-5.87	-0.43	2.69e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg16850897	chr7:100343110	ZAN	-0.58	-4.84	-0.37	3.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7998202	0.614	rs668967	chr13:113369948	G/A	cg19217778	chr13:113420270	ATP11A	0.6	4.31	0.33	2.89e-5	Glycated hemoglobin levels;
PAAD	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs1569175	1.000	rs3094761	chr2:200934490	T/G	cg23649088	chr2:200775458	C2orf69	-0.78	-4.39	-0.34	2.07e-5	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.1	0.38	1e-6	Body mass index;
PAAD	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs17155006	0.691	rs409815	chr7:107745443	A/G	cg05962710	chr7:107745446	LAMB4	0.57	7.68	0.53	1.86e-12	Pneumococcal bacteremia;
PAAD	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-6.67	-0.48	4.35e-10	Body mass index (adult);
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg25547332	chr5:131281432	NA	-0.56	-4.39	-0.34	2.09e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.52	-5.03	-0.38	1.35e-6	Motion sickness;
PAAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg05373962	chr22:49881684	NA	-0.55	-5.04	-0.38	1.31e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg06217071	chr17:408420	NA	0.65	7.05	0.5	5.76e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.61	-7.81	-0.54	8.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg06697600	chr4:7070879	GRPEL1	0.94	5.8	0.43	3.65e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.66	-7.26	-0.51	1.91e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg09699651	chr6:150184138	LRP11	0.4	4.27	0.33	3.47e-5	Lung cancer;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg12143784	chr7:64541923	NA	-0.33	-4.27	-0.33	3.5e-5	Calcium levels;
PAAD	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.62	-5.58	-0.41	1.08e-7	Tonsillectomy;
PAAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg13859433	chr6:33739653	LEMD2	0.67	4.45	0.34	1.62e-5	Schizophrenia;
PAAD	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg09796270	chr17:17721594	SREBF1	-0.47	-5.24	-0.39	5.32e-7	Total body bone mineral density;
PAAD	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.08	-0.63	1.31e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs8005172	0.676	rs400777	chr14:88404706	G/A	cg18078958	chr14:88630771	NA	-0.45	-5.5	-0.41	1.57e-7	Parkinson's disease;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10819733	chr22:24237672	NA	0.46	4.55	0.35	1.07e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs1497828	1.000	rs2646823	chr1:217537011	C/A	cg04411442	chr1:217543379	NA	-0.47	-4.56	-0.35	1.04e-5	Dialysis-related mortality;
PAAD	trans	rs901683	1.000	rs17157852	chr10:45967801	C/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.78	-0.36	4.16e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	5.69	0.42	6.26e-8	Blood protein levels;
PAAD	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.7	0.42	5.96e-8	Restless legs syndrome;
PAAD	cis	rs12304921	0.748	rs73090630	chr12:51335813	G/A	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.11	-0.38	9.62e-7	Type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg18279126	chr7:2041391	MAD1L1	0.59	5.6	0.41	9.75e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg16606324	chr3:10149918	C3orf24	0.75	5.96	0.44	1.68e-8	Alzheimer's disease;
PAAD	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-6.94	-0.49	1.05e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1942	0.813	rs8032846	chr15:41605653	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-7.06	-0.5	5.47e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg12560992	chr17:57184187	TRIM37	0.65	4.98	0.37	1.67e-6	Vitamin D levels;
PAAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg23947450	chr7:900037	UNC84A	-0.51	-4.26	-0.33	3.52e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.49	-4.28	-0.33	3.25e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.4	-0.46	1.79e-9	Menarche (age at onset);
PAAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-7.73	-0.53	1.38e-12	Colorectal cancer;
PAAD	cis	rs2790216	0.760	rs11006091	chr10:60005296	A/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-5.16	-0.39	7.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4704187	0.649	rs58999738	chr5:74545798	A/G	cg03227963	chr5:74354835	NA	0.48	4.69	0.36	5.92e-6	Response to amphetamines;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24425342	chr19:3114929	GNA11	-0.57	-6.29	-0.45	3.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg21300403	chr2:198650112	BOLL	-0.49	-4.4	-0.34	2.06e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10214930	0.697	rs6947731	chr7:27638695	C/A	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11078597	0.636	rs4790821	chr17:1654048	A/G	cg18436246	chr17:1640651	WDR81	0.82	7.2	0.5	2.55e-11	Serum albumin level;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12997796	0.503	rs4366909	chr2:87021001	G/A	cg25203885	chr2:87302643	LOC285074	-0.69	-4.61	-0.35	8.49e-6	Schizophrenia;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg12143784	chr7:64541923	NA	0.43	5.63	0.42	8.57e-8	Calcium levels;
PAAD	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.93	12.43	0.71	6.37e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.91	-8.95	-0.59	1.15e-15	Asthma;
PAAD	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg16341495	chr8:142228727	SLC45A4	-0.51	-4.85	-0.37	3e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2790216	1.000	rs2153283	chr10:59972299	C/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs10988449	0.830	rs10988448	chr9:132368645	C/A	cg18327994	chr9:132372705	NA	-0.6	-4.25	-0.33	3.67e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.5	-0.34	1.35e-5	Testicular germ cell tumor;
PAAD	cis	rs4455778	0.519	rs6583488	chr7:49039939	A/G	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	8.46	0.57	2.1e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg03885332	chr11:832357	CD151	-0.45	-5.34	-0.4	3.33e-7	Mean platelet volume;
PAAD	cis	rs1594829	0.655	rs111283523	chr8:26143503	C/T	cg13160058	chr8:26243215	BNIP3L	0.48	4.28	0.33	3.35e-5	Height;
PAAD	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.41	13.79	0.75	1.47e-28	Corneal structure;
PAAD	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg24253500	chr15:84953950	NA	0.41	4.32	0.33	2.8e-5	Schizophrenia;
PAAD	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg07703079	chr11:430292	ANO9	0.79	4.4	0.34	1.99e-5	Body mass index;
PAAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.76	-8.75	-0.58	3.87e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg09366796	chr5:75012313	C5orf37	0.49	4.45	0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10267417	0.657	rs6963367	chr7:19857873	A/C	cg05791153	chr7:19748676	TWISTNB	0.79	5.02	0.38	1.44e-6	Night sleep phenotypes;
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7246760	1.000	rs28802413	chr19:9901617	T/C	cg16876255	chr19:9731953	ZNF561	0.95	4.56	0.35	1.06e-5	Pursuit maintenance gain;
PAAD	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.46	-4.36	-0.33	2.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs600550	0.588	rs11230248	chr11:60085893	T/C	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-5.06	-0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11245990	chr11:68621969	NA	0.4	5.36	0.4	2.96e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.41e-7	Monocyte percentage of white cells;
PAAD	cis	rs9595066	0.627	rs9562536	chr13:44731588	G/A	cg04068111	chr13:44716778	NA	-0.54	-6.0	-0.44	1.4e-8	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-1.03	-11.66	-0.69	7.66e-23	Cancer (pleiotropy);
PAAD	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.69	6.64	0.47	5.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	1.02	8.47	0.57	1.94e-14	Initial pursuit acceleration;
PAAD	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.66	6.74	0.48	3.02e-10	Menarche (age at onset);
PAAD	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	5.65	0.42	7.76e-8	Lung cancer in ever smokers;
PAAD	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.56	-5.33	-0.4	3.46e-7	Systemic sclerosis;
PAAD	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.48	-0.34	1.44e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	1.17	7.92	0.54	4.7e-13	Obesity (early onset extreme);
PAAD	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.58	-0.35	9.67e-6	Type 2 diabetes;
PAAD	cis	rs7251275	0.625	rs304719	chr19:44108635	G/A	cg17121205	chr19:44009353	PHLDB3	-0.34	-4.36	-0.33	2.43e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs9398803	0.678	rs9372841	chr6:126898541	A/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.58	0.35	9.46e-6	Homoarginine levels;
PAAD	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg09491104	chr22:46646882	C22orf40	-0.71	-4.27	-0.33	3.47e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.43	0.61	6.71e-17	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07907998	chr16:27561398	GTF3C1;KIAA0556	0.68	6.75	0.48	2.87e-10	Obesity-related traits;
PAAD	cis	rs58521262	0.519	rs11085543	chr19:22957112	C/A	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.29e-5	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13012494	chr21:47604986	C21orf56	0.47	4.96	0.37	1.83e-6	Testicular germ cell tumor;
PAAD	cis	rs9659323	0.650	rs10802064	chr1:119458137	A/G	cg17326555	chr1:119535693	NA	-0.35	-4.25	-0.33	3.76e-5	Body mass index;
PAAD	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.59	5.79	0.42	3.94e-8	Sudden cardiac arrest;
PAAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg10494973	chr17:80897199	TBCD	-0.53	-4.96	-0.37	1.85e-6	Breast cancer;
PAAD	trans	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg00938859	chr5:1591904	SDHAP3	0.88	6.31	0.46	2.96e-9	Breast cancer;
PAAD	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.44	5.24	0.39	5.24e-7	Body mass index;
PAAD	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.46	0.71	5.2e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg05874882	chr4:1763078	NA	-0.36	-4.73	-0.36	5.09e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9880406	0.599	rs10934767	chr3:126032949	C/G	cg11830761	chr3:126007485	NA	-0.58	-5.28	-0.39	4.49e-7	Macular telangiectasia type 2;
PAAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg14703610	chr5:56206110	C5orf35	0.63	6.1	0.44	8.46e-9	Coronary artery disease;
PAAD	cis	rs10214930	0.697	rs1980329	chr7:27630300	T/A	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg07202610	chr7:1142643	C7orf50	-0.64	-5.54	-0.41	1.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.85	9.88	0.63	4.3e-18	Menarche (age at onset);
PAAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.21	15.37	0.78	9.29e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.4	5.37	0.4	2.84e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg17541715	chr7:1216824	NA	-0.56	-6.73	-0.48	3.26e-10	Longevity;Endometriosis;
PAAD	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg00310523	chr12:86230176	RASSF9	0.49	5.56	0.41	1.17e-7	Major depressive disorder;
PAAD	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.49	5.51	0.41	1.47e-7	Platelet count;
PAAD	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg05697835	chr1:2722811	NA	-0.43	-4.79	-0.36	4e-6	Multiple sclerosis;
PAAD	cis	rs2120991	0.901	rs6580966	chr12:54260941	T/C	cg25640699	chr12:54070114	ATP5G2	-0.41	-4.25	-0.33	3.72e-5	Biliary atresia;
PAAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.95	-0.37	1.91e-6	Eosinophil percentage of white cells;
PAAD	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg14784868	chr12:69753453	YEATS4	0.53	4.47	0.34	1.51e-5	Response to diuretic therapy;
PAAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg02951883	chr7:2050386	MAD1L1	0.59	5.2	0.39	6.46e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.15	0.5	3.41e-11	Hemoglobin concentration;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08677398	chr8:58056175	NA	0.73	4.89	0.37	2.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6663390	0.510	rs2267896	chr1:208080972	C/T	cg00387621	chr1:208086895	NA	-0.75	-4.41	-0.34	1.94e-5	Facial morphology (factor 18);
PAAD	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg08758996	chr17:66097529	LOC651250	-0.52	-4.83	-0.36	3.36e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg10395934	chr14:104002654	TRMT61A	0.53	5.06	0.38	1.18e-6	Body mass index;
PAAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.51	0.47	1.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.46	4.79	0.36	4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.57	-0.35	1.01e-5	Height;
PAAD	cis	rs12773846	0.537	rs58077952	chr10:126273432	A/G	cg04949429	chr10:126290192	LHPP	0.66	5.68	0.42	6.57e-8	Subcutaneous adipose tissue;
PAAD	cis	rs245880	0.740	rs245889	chr7:29190626	C/T	cg17163760	chr7:29186267	CPVL	-0.51	-6.02	-0.44	1.27e-8	Warfarin maintenance dose;
PAAD	cis	rs227425	0.686	rs1471243	chr14:70469120	A/G	cg15823642	chr14:70516416	SLC8A3	-0.42	-4.64	-0.35	7.44e-6	Bone mineral density;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg07682378	chr3:150128910	TSC22D2	0.62	7.32	0.51	1.35e-11	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.47	7.43	0.52	7.43e-12	Neuroticism;
PAAD	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg06671706	chr8:8559999	CLDN23	0.69	6.52	0.47	9.61e-10	Obesity-related traits;
PAAD	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.52	-6.43	-0.46	1.54e-9	Lewy body disease;
PAAD	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19671926	chr4:122722719	EXOSC9	0.52	5.11	0.38	9.59e-7	Type 2 diabetes;
PAAD	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.68	7.71	0.53	1.51e-12	N-glycan levels;
PAAD	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.56	-6.02	-0.44	1.27e-8	IgG glycosylation;
PAAD	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	1.04	7.41	0.52	8.17e-12	Alzheimer's disease;
PAAD	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs4073221	0.585	rs13093950	chr3:18325997	C/T	cg07694806	chr3:18168406	NA	-0.62	-4.56	-0.35	1.04e-5	Parkinson's disease;
PAAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.81	7.52	0.52	4.4e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs501916	1.000	rs3743276	chr15:48055119	C/T	cg16110827	chr15:48056943	SEMA6D	0.4	4.27	0.33	3.42e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.05	-0.44	1.11e-8	Lymphocyte counts;
PAAD	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.31	0.33	2.87e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg23688817	chr7:87105293	ABCB4	0.56	4.66	0.35	6.95e-6	Gallbladder cancer;
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.21	0.55	8.86e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.82	9.91	0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg01759136	chr6:27242945	NA	0.42	4.57	0.35	9.89e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01513714	chr14:99738164	BCL11B	0.65	6.3	0.46	3.05e-9	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg05341575	chr12:125625032	AACS	-0.47	-4.38	-0.33	2.23e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.73	5.38	0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.85	9.85	0.62	5.13e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg26174226	chr8:58114915	NA	-0.69	-4.72	-0.36	5.37e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.09	0.44	8.63e-9	Height;
PAAD	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg19257562	chr1:2043853	PRKCZ	-0.4	-4.58	-0.35	9.75e-6	Coronary artery disease;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.62	5.14	0.38	8.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg20129853	chr10:51489980	NA	0.42	4.28	0.33	3.29e-5	Prostate-specific antigen levels;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg00450029	chr8:599525	NA	0.91	6.2	0.45	5.13e-9	IgG glycosylation;
PAAD	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.56	5.3	0.4	3.97e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg25753631	chr6:25732923	NA	-0.41	-4.47	-0.34	1.51e-5	Iron status biomarkers;
PAAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.66	-7.58	-0.52	3.2e-12	Huntington's disease progression;
PAAD	cis	rs9815354	1.000	rs17061431	chr3:41792655	T/C	cg03022575	chr3:42003672	ULK4	0.64	4.5	0.34	1.37e-5	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22168489	chr12:122356033	WDR66	-0.3	-4.4	-0.34	2.03e-5	Mean corpuscular volume;
PAAD	cis	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9039	1.000	rs56193985	chr16:9207199	C/A	cg08831531	chr16:9218945	NA	-0.54	-5.53	-0.41	1.38e-7	Menopause (age at onset);
PAAD	cis	rs7727544	0.548	rs2069614	chr5:131407601	T/C	cg16205897	chr5:131564050	P4HA2	-0.44	-4.75	-0.36	4.76e-6	Blood metabolite levels;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.51	5.65	0.42	7.74e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg18505879	chr18:60382658	PHLPP1	0.57	6.29	0.45	3.29e-9	Iris heterochromicity;
PAAD	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg12568669	chr8:11666485	FDFT1	0.27	4.36	0.33	2.41e-5	Neuroticism;
PAAD	cis	rs7567389	0.677	rs6757492	chr2:127995332	G/A	cg11380483	chr2:127933992	NA	-0.47	-4.67	-0.35	6.63e-6	Self-rated health;
PAAD	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs2562456	0.833	rs2358993	chr19:21558169	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.67	6.75	0.48	2.94e-10	Systolic blood pressure;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-1.01	-16.82	-0.81	1.58e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.86	10.66	0.65	3.7e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg23083516	chr15:85180758	SCAND2	0.38	4.26	0.33	3.55e-5	P wave terminal force;
PAAD	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.52	-5.91	-0.43	2.15e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.98	6.84	0.49	1.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.42	5.23	0.39	5.61e-7	Sitting height ratio;
PAAD	cis	rs1109501	0.734	rs4146576	chr4:71407385	A/G	cg25553522	chr4:71388589	AMTN	0.53	4.51	0.34	1.29e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.58	-4.61	-0.35	8.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17318866	1.000	rs3734220	chr6:3832574	G/T	cg11393995	chr6:2842359	SERPINB1	0.47	4.27	0.33	3.47e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.8	8.58	0.57	1.05e-14	Caffeine consumption;
PAAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	8.96	0.59	1.11e-15	Personality dimensions;
PAAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.36	0.33	2.43e-5	IgG glycosylation;
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg03605463	chr16:89740564	NA	0.45	4.25	0.33	3.68e-5	Vitiligo;
PAAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.87	-10.86	-0.66	1.06e-20	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.79	8.66	0.57	6.3e-15	Lung cancer;
PAAD	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	1.04	13.92	0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg21194808	chr1:2205498	SKI	0.43	4.32	0.33	2.83e-5	Coronary artery disease;
PAAD	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg09017928	chr7:158110068	PTPRN2	0.55	4.75	0.36	4.63e-6	Response to amphetamines;
PAAD	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	1.01	11.86	0.69	2.24e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs73086581	1.000	rs56324992	chr20:3978153	C/A	cg02187196	chr20:3869020	PANK2	0.58	5.05	0.38	1.24e-6	Response to antidepressants in depression;
PAAD	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg12437481	chr16:420112	MRPL28	-0.85	-8.66	-0.57	6.32e-15	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9463078	0.900	rs1555681	chr6:45086367	A/G	cg25276700	chr6:44698697	NA	-0.49	-5.64	-0.42	8.18e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg21130718	chr4:1044621	NA	0.56	4.81	0.36	3.53e-6	Recombination rate (females);
PAAD	cis	rs6496932	0.802	rs2063442	chr15:85858044	T/C	cg19183879	chr15:85880815	NA	0.52	4.78	0.36	4.07e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.79	0.62	7.63e-18	Chronic sinus infection;
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.48e-6	Lung cancer;
PAAD	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg00181669	chr3:44000978	NA	-0.45	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs12760731	0.565	rs12040475	chr1:178185651	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs818427	0.593	rs67293732	chr5:112217964	G/C	cg06941702	chr5:112196734	SRP19	0.55	5.32	0.4	3.57e-7	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21219744	chr4:44680344	GUF1	0.63	7.0	0.49	7.81e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08299755	chr10:99496695	ZFYVE27	0.63	6.78	0.48	2.51e-10	Myopia (pathological);
PAAD	cis	rs10267417	0.603	rs10248506	chr7:19905674	T/A	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs7101378	0.577	rs2136534	chr11:108900066	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.97	0.44	1.58e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg02820901	chr13:113351484	ATP11A	0.72	4.65	0.35	7.09e-6	Glycated hemoglobin levels;
PAAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg10210715	chr6:160221411	PNLDC1	-0.46	-4.39	-0.34	2.14e-5	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg21284376	chr1:72748601	NEGR1	0.54	6.44	0.46	1.47e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg22143856	chr6:28129313	ZNF389	0.6	4.66	0.35	6.96e-6	Parkinson's disease;
PAAD	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7551345	0.901	rs35282110	chr1:31831178	T/G	cg17086398	chr1:31896392	SERINC2	-0.54	-4.75	-0.36	4.6e-6	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.73	0.62	1.09e-17	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01587190	chr19:45874071	ERCC2	0.68	8.05	0.55	2.26e-13	Monocyte percentage of white cells;
PAAD	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.51	-5.39	-0.4	2.69e-7	Colorectal cancer;
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.6	4.91	0.37	2.36e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs71520386	0.530	rs10256628	chr7:22883259	G/C	cg04907244	chr7:22894795	SNORD93	0.54	5.79	0.43	3.92e-8	Fibrinogen levels;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18621852	chr3:10150065	C3orf24	0.52	4.94	0.37	2.02e-6	Alzheimer's disease;
PAAD	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.83	6.76	0.48	2.76e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7809615	0.748	rs10808112	chr7:99070988	C/T	cg12290671	chr7:99195819	NA	-0.89	-5.1	-0.38	1.01e-6	Blood metabolite ratios;
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg08835956	chr7:39171034	POU6F2	0.32	4.93	0.37	2.15e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.79	-5.92	-0.43	2.08e-8	Initial pursuit acceleration;
PAAD	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.49	4.62	0.35	8.25e-6	Menarche (age at onset);
PAAD	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg21130718	chr4:1044621	NA	0.5	4.84	0.37	3.18e-6	Recombination rate (males);
PAAD	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.39	4.88	0.37	2.68e-6	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.7	8.09	0.55	1.75e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.55	5.88	0.43	2.47e-8	Calcium levels;
PAAD	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.75	9.23	0.6	2.14e-16	Alcohol dependence;
PAAD	cis	rs11020478	0.681	rs2186685	chr11:93420322	C/G	cg10523193	chr11:93463762	SNORA25	0.43	4.51	0.34	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs11828289	0.660	rs17306384	chr11:23189320	T/C	cg20040320	chr11:23191996	NA	-0.78	-5.55	-0.41	1.27e-7	Cancer;
PAAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg24733560	chr20:60626293	TAF4	0.43	5.18	0.39	7e-7	Body mass index;
PAAD	cis	rs6976053	0.935	rs3847063	chr7:100498475	C/T	cg22425096	chr7:100417404	EPHB4	-0.5	-4.33	-0.33	2.73e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.67	6.21	0.45	4.82e-9	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg00490450	chr3:139108681	COPB2	-0.66	-5.84	-0.43	3.03e-8	Obesity-related traits;
PAAD	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg20356878	chr3:121714668	ILDR1	0.48	4.58	0.35	9.72e-6	Cognitive performance;
PAAD	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg04289385	chr6:36355825	ETV7	0.49	4.96	0.37	1.88e-6	Platelet distribution width;
PAAD	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.46	5.24	0.39	5.34e-7	Bipolar disorder;
PAAD	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs8105895	0.935	rs4257328	chr19:22240090	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs6494488	0.500	rs11854894	chr15:65020245	G/C	cg16425858	chr15:64791681	ZNF609	0.97	4.55	0.35	1.08e-5	Coronary artery disease;
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Electroencephalogram traits;
PAAD	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg21479132	chr6:26055353	NA	0.9	5.37	0.4	2.88e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.88	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4455778	0.543	rs4357242	chr7:49067599	T/C	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.34e-5	Lung cancer in never smokers;
PAAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.72	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.91	9.72	0.62	1.11e-17	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23662487	chr3:50654958	MAPKAPK3	0.65	6.36	0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.65	6.52	0.47	9.71e-10	Height;
PAAD	cis	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Lung cancer in ever smokers;
PAAD	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg16342193	chr10:102329863	NA	-0.75	-8.14	-0.55	1.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.5	2.45e-11	Schizophrenia;
PAAD	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg14146966	chr2:61757674	XPO1	0.42	5.22	0.39	5.7e-7	Tuberculosis;
PAAD	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.85	-8.95	-0.59	1.16e-15	Multiple sclerosis;
PAAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-7.41	-0.51	8.34e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.66	-6.84	-0.49	1.81e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2011503	0.509	rs76347963	chr19:19780145	C/T	cg11584989	chr19:19387371	SF4	0.86	6.41	0.46	1.74e-9	Bipolar disorder;
PAAD	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg01966878	chr4:90757139	SNCA	0.48	4.47	0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.65	7.54	0.52	3.98e-12	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs7915414	0.802	rs12762067	chr10:96398333	T/C	cg00735080	chr21:47285121	PCBP3	0.51	6.4	0.46	1.84e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg21300403	chr2:198650112	BOLL	-0.49	-4.32	-0.33	2.77e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.69	9.9	0.63	3.86e-18	Pursuit maintenance gain;
PAAD	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Lymphocyte counts;
PAAD	cis	rs73416724	1.000	rs41281796	chr6:43323917	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.21	0.5	2.49e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg13266496	chr6:110720918	DDO	-0.47	-4.95	-0.37	1.91e-6	Platelet distribution width;
PAAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.79	-8.0	-0.54	2.98e-13	Neurofibrillary tangles;
PAAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.79	12.42	0.71	7.02e-25	Breast cancer;
PAAD	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg14036092	chr11:66035641	RAB1B	0.65	5.52	0.41	1.42e-7	Gout;
PAAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00982548	chr2:198649783	BOLL	-0.79	-5.77	-0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-4.29	-0.33	3.17e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2421770	0.827	rs7130385	chr11:35270761	C/T	cg13971030	chr11:35366721	SLC1A2	-0.46	-5.51	-0.41	1.47e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs10929159	0.928	rs2123511	chr2:236923187	C/T	cg14226755	chr2:236923322	AGAP1	0.29	4.55	0.35	1.08e-5	Parkinson's disease;
PAAD	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.83	10.44	0.65	1.46e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg08501292	chr6:25962987	TRIM38	1.0	5.87	0.43	2.59e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10450586	0.932	rs11029932	chr11:27328254	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.51	-4.42	-0.34	1.85e-5	Multiple sclerosis;
PAAD	cis	rs2109514	1.000	rs6466579	chr7:116151155	T/C	cg19719915	chr7:115928094	NA	-0.45	-4.3	-0.33	3.06e-5	Prevalent atrial fibrillation;
PAAD	cis	rs2944755	0.686	rs11997913	chr8:141588660	C/G	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.59	-0.35	9.07e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	4.4	0.34	2.04e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.61	-0.47	6.13e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg05643964	chr20:62369504	LIME1	0.48	4.52	0.34	1.25e-5	Prostate cancer;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.53	-5.26	-0.39	4.87e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6942407	0.696	rs6465103	chr7:86862068	A/G	cg02420886	chr7:86849541	C7orf23	0.57	4.5	0.34	1.34e-5	Food allergy;
PAAD	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.12	-0.5	4.03e-11	Blood pressure (smoking interaction);
PAAD	cis	rs4774899	0.583	rs10459625	chr15:57622926	C/T	cg14026238	chr15:57616123	NA	0.39	5.05	0.38	1.26e-6	Urinary tract infection frequency;
PAAD	cis	rs73384572	0.541	rs12416644	chr10:130859405	C/T	cg27413539	chr10:131576096	NA	-0.68	-4.39	-0.34	2.1e-5	Neuroticism;
PAAD	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.64	-5.4	-0.4	2.47e-7	Menarche (age at onset);
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg21226059	chr5:178986404	RUFY1	0.56	6.24	0.45	4.05e-9	Lung cancer;
PAAD	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.6	-8.14	-0.55	1.36e-13	Renal cell carcinoma;
PAAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs3007168	0.904	rs12884159	chr14:51661855	G/C	cg23942311	chr14:51606299	NA	0.58	4.36	0.33	2.35e-5	Cancer;
PAAD	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	5.0	0.38	1.55e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.55	-6.19	-0.45	5.29e-9	Calcium levels;
PAAD	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.44	4.34	0.33	2.57e-5	Chronic sinus infection;
PAAD	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs1499972	0.941	rs1093464	chr3:117726256	C/T	cg07612923	chr3:117604196	NA	-1.02	-6.94	-0.49	1.07e-10	Schizophrenia;
PAAD	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.47	0.41	1.79e-7	Bipolar disorder;
PAAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	4.99	0.38	1.61e-6	Bone mineral density;
PAAD	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg26205652	chr12:48591994	NA	0.98	9.89	0.63	4.05e-18	Longevity (90 years and older);
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg01075559	chr1:2537774	MMEL1	-0.54	-5.7	-0.42	5.96e-8	Ulcerative colitis;
PAAD	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg22437258	chr11:111473054	SIK2	0.56	5.3	0.39	4.05e-7	Primary sclerosing cholangitis;
PAAD	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.01	14.25	0.76	8.45e-30	Heart rate;
PAAD	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.51	4.88	0.37	2.71e-6	Pancreatic cancer;
PAAD	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg20913747	chr6:44695427	NA	-0.68	-6.73	-0.48	3.32e-10	Total body bone mineral density;
PAAD	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg16589663	chr20:23618590	CST3	0.79	6.8	0.48	2.27e-10	Chronic kidney disease;
PAAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg24154853	chr7:158122151	PTPRN2	0.71	7.35	0.51	1.16e-11	Calcium levels;
PAAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg05861140	chr6:150128134	PCMT1	-0.54	-6.22	-0.45	4.52e-9	Lung cancer;
PAAD	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.64	5.99	0.44	1.43e-8	Height;
PAAD	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs910187	0.571	rs3746489	chr20:45801716	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.39	-0.4	2.63e-7	Migraine;
PAAD	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.49	0.61	4.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg10556349	chr10:835070	NA	0.57	4.77	0.36	4.23e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg24642844	chr7:1081250	C7orf50	-0.89	-4.82	-0.36	3.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.71	-0.42	5.79e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.73	6.92	0.49	1.2e-10	Blood metabolite levels;
PAAD	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.61	6.42	0.46	1.67e-9	Schizophrenia;
PAAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.72	-8.44	-0.56	2.33e-14	Diastolic blood pressure;
PAAD	cis	rs4742903	0.935	rs4587392	chr9:106972508	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.68	0.36	6.19e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.81	9.37	0.61	9.54e-17	Sudden cardiac arrest;
PAAD	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-7.28	-0.51	1.71e-11	Red cell distribution width;
PAAD	cis	rs2031532	0.569	rs7326345	chr13:50067443	G/A	cg08779649	chr13:50194554	NA	0.36	4.88	0.37	2.68e-6	Cardiac hypertrophy;
PAAD	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg04398451	chr17:18023971	MYO15A	-0.82	-9.2	-0.6	2.69e-16	Total body bone mineral density;
PAAD	cis	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg03938978	chr2:103052716	IL18RAP	-0.45	-4.55	-0.35	1.11e-5	Blood protein levels;
PAAD	cis	rs308971	0.656	rs307578	chr3:12084158	A/G	cg15873301	chr3:12045459	SYN2	0.63	5.2	0.39	6.21e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.61	0.35	8.62e-6	Personality dimensions;
PAAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.38	4.57	0.35	9.91e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.51	5.29	0.39	4.18e-7	Testicular germ cell tumor;
PAAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg15226275	chr6:116381976	FRK	0.3	5.58	0.41	1.07e-7	Total cholesterol levels;
PAAD	cis	rs13102973	0.674	rs11730572	chr4:135885397	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	4.38	0.33	2.23e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs13006833	0.694	rs291448	chr2:191177216	T/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs16858210	0.874	rs55666767	chr3:183573235	C/T	cg03417191	chr3:183542750	MAP6D1	-0.54	-4.46	-0.34	1.57e-5	Menopause (age at onset);
PAAD	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.41	0.52	8.17e-12	Response to antipsychotic treatment;
PAAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19346786	chr7:2764209	NA	-0.39	-5.29	-0.39	4.14e-7	Height;
PAAD	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs11203032	0.831	rs10887929	chr10:90948864	T/C	cg16672925	chr10:90967113	CH25H	0.72	5.59	0.41	1e-7	Heart failure;
PAAD	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16386425	chr10:429943	DIP2C	0.49	4.62	0.35	8.23e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07685180	chr8:600429	NA	-0.9	-5.48	-0.41	1.73e-7	IgG glycosylation;
PAAD	cis	rs6076065	0.823	rs743021	chr20:23401707	C/T	cg11657817	chr20:23433608	CST11	-0.48	-5.24	-0.39	5.22e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-4.66	-0.35	6.82e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs3026101	0.671	rs8081481	chr17:5282763	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	5.34	0.4	3.34e-7	Body mass index;
PAAD	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.53	4.83	0.37	3.24e-6	Platelet count;
PAAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.6	-5.58	-0.41	1.06e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg03676636	chr4:99064102	C4orf37	0.32	5.36	0.4	2.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.58	-5.59	-0.41	1.02e-7	Red cell distribution width;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02071572	chr4:1403502	NA	-0.48	-6.06	-0.44	1.04e-8	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg05085585	chr16:30420623	ZNF771	-0.43	-4.42	-0.34	1.84e-5	Tonsillectomy;
PAAD	cis	rs11250098	0.583	rs36030755	chr8:10816771	G/C	cg01489256	chr8:11204017	TDH	0.49	5.0	0.38	1.57e-6	Morning vs. evening chronotype;
PAAD	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg09226986	chr6:160852328	SLC22A3	-0.45	-4.33	-0.33	2.74e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1497828	0.956	rs2646817	chr1:217525251	T/G	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs1468734	0.927	rs4786565	chr16:5000945	C/T	cg06510647	chr16:5006106	NA	0.56	4.96	0.37	1.9e-6	Cancer;
PAAD	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg21855830	chr2:127963489	CYP27C1	0.44	4.25	0.33	3.72e-5	Protein C levels;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13939156	chr17:80058883	NA	0.39	4.28	0.33	3.31e-5	Life satisfaction;
PAAD	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.73	5.14	0.38	8.39e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02044337	chr19:50270616	AP2A1	0.66	6.38	0.46	2.01e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.76	-8.75	-0.58	3.8e-15	Handedness;
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	9.84e-7	Lung cancer;
PAAD	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.61	-5.83	-0.43	3.14e-8	Subjective well-being;
PAAD	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	4.85	0.37	2.99e-6	Mood instability;
PAAD	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs3826795	0.569	rs73059726	chr19:46797194	G/A	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg08992911	chr2:238395768	MLPH	0.69	6.95	0.49	1.03e-10	Prostate cancer;
PAAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.59	-8.01	-0.54	2.84e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.96	-13.7	-0.74	2.42e-28	Dental caries;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07234876	chr8:600039	NA	1.03	7.74	0.53	1.26e-12	IgG glycosylation;
PAAD	cis	rs629922	0.671	rs513039	chr11:114037158	G/A	cg25009965	chr11:114031120	ZBTB16	0.5	4.45	0.34	1.66e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs2790216	0.950	rs2440851	chr10:60011818	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-7.3	-0.51	1.48e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.73	-7.71	-0.53	1.51e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22442454	chr1:209979470	IRF6	-0.57	-5.11	-0.38	9.48e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.46	0.52	6.34e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg08648136	chr8:956695	NA	0.42	4.62	0.35	7.98e-6	Schizophrenia;
PAAD	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg25952890	chr19:58913133	NA	0.67	5.21	0.39	6.04e-7	Mean platelet volume;
PAAD	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.75	6.51	0.47	1.04e-9	Dilated cardiomyopathy;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	9.0	0.59	8.38e-16	Lymphocyte counts;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.67	-6.61	-0.47	6.14e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.17e-6	Schizophrenia;
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.49	4.6	0.35	8.88e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg03060546	chr3:49711283	APEH	-0.58	-4.28	-0.33	3.28e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.31	-0.33	2.97e-5	Ileal carcinoids;
PAAD	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.49	5.48	0.41	1.69e-7	Prevalent atrial fibrillation;
PAAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs3996993	0.809	rs2397112	chr6:52684333	A/G	cg20803780	chr6:52668592	GSTA1	0.34	4.25	0.33	3.75e-5	Hemoglobin concentration;
PAAD	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.47	-4.6	-0.35	8.94e-6	Birth weight;
PAAD	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.52	-4.53	-0.34	1.19e-5	Red blood cell traits;
PAAD	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.65	-7.03	-0.5	6.41e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs1639906	0.560	rs1639915	chr7:2258084	C/G	cg18772858	chr7:2296703	SNX8	-0.46	-4.26	-0.33	3.59e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg07511668	chr11:68622177	NA	0.38	4.3	0.33	2.99e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	1.11	6.56	0.47	8.07e-10	Body mass index;
PAAD	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.7	-7.32	-0.51	1.32e-11	Body mass index;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.68	0.48	4.17e-10	Life satisfaction;
PAAD	cis	rs6137287	0.883	rs6047310	chr20:21201708	C/A	cg04219410	chr20:21106687	PLK1S1	0.43	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Calcium levels;
PAAD	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs28472312	0.723	rs11150675	chr16:28980531	G/A	cg16576597	chr16:28551801	NUPR1	-0.46	-4.76	-0.36	4.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg21565972	chr17:80109576	CCDC57	0.59	6.97	0.49	8.86e-11	Life satisfaction;
PAAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg00049323	chr5:472564	LOC25845	0.38	4.48	0.34	1.44e-5	Cystic fibrosis severity;
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.53	5.6	0.41	9.73e-8	Bladder cancer;
PAAD	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.37	-0.33	2.25e-5	Height;
PAAD	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.75	5.57	0.41	1.14e-7	Vitiligo;
PAAD	cis	rs10207060	0.500	rs4365487	chr2:240706803	T/C	cg07506560	chr2:240697449	NA	0.55	5.76	0.42	4.62e-8	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.4	-0.56	3.02e-14	Aortic root size;
PAAD	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.51	0.34	1.32e-5	Height;
PAAD	cis	rs4740619	0.619	rs1410455	chr9:16042277	A/G	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.52	-5.66	-0.42	7.31e-8	Major depressive disorder;
PAAD	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg27455613	chr17:80820699	TBCD	-0.5	-4.98	-0.37	1.7e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	4.83	0.36	3.29e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.74	-5.66	-0.42	7.25e-8	Mean platelet volume;
PAAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.46	-0.41	1.88e-7	Glomerular filtration rate;
PAAD	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	1.1	14.42	0.76	3.06e-30	Total cholesterol levels;
PAAD	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	10.99	0.67	4.87e-21	Menopause (age at onset);
PAAD	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.36	-4.99	-0.38	1.6e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg07784872	chr16:85687041	KIAA0182	-0.58	-5.36	-0.4	2.99e-7	Platelet distribution width;
PAAD	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg05250797	chr16:70222502	NA	0.83	6.25	0.45	4e-9	IgE levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16529639	chr3:32726786	CNOT10	0.58	6.43	0.46	1.55e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg15890332	chr12:107067104	RFX4	0.41	4.35	0.33	2.53e-5	Total body bone mineral density;
PAAD	cis	rs1555895	0.599	rs4881535	chr10:847769	G/A	cg20503657	chr10:835505	NA	0.51	5.33	0.4	3.5e-7	Survival in rectal cancer;
PAAD	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	0.82	6.37	0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.64	6.47	0.46	1.29e-9	Blood metabolite levels;
PAAD	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.46	-4.71	-0.36	5.44e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4919087	0.590	rs1253397	chr10:99045556	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21963583	chr11:68658836	MRPL21	0.41	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05608716	chr16:3096484	MMP25	-0.84	-7.37	-0.51	1.03e-11	Neuroticism;
PAAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.17	17.29	0.81	1.03e-37	Cognitive function;
PAAD	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-8.05	-0.55	2.24e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg05425664	chr17:57184151	TRIM37	0.57	4.86	0.37	2.9e-6	Testicular germ cell tumor;
PAAD	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.31	-0.33	2.92e-5	Lewy body disease;
PAAD	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg15654264	chr1:150340011	RPRD2	-0.51	-4.95	-0.37	1.91e-6	Migraine;
PAAD	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs787274	1.000	rs4979154	chr9:115555031	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.39	0.68	4.07e-22	Smoking behavior;
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.67	7.32	0.51	1.34e-11	Vitiligo;
PAAD	cis	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs72960926	1.000	rs2171709	chr6:75100810	A/T	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.4	0.56	3.02e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.73	7.34	0.51	1.18e-11	Tonsillectomy;
PAAD	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.47	-7.59	-0.52	2.96e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	1.0	12.43	0.71	6.55e-25	Breast cancer;
PAAD	cis	rs11887277	0.718	rs12992179	chr2:27031271	C/T	cg12368169	chr2:27073192	DPYSL5	-0.4	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs258892	0.895	rs2338790	chr5:72055184	A/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg13175981	chr1:150552382	MCL1	0.74	7.23	0.51	2.15e-11	Tonsillectomy;
PAAD	cis	rs9535307	0.719	rs1570353	chr13:50385967	G/T	cg04663916	chr13:50265991	EBPL	-0.57	-4.31	-0.33	2.94e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.61	7.21	0.51	2.4e-11	Lung cancer;
PAAD	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs863345	0.564	rs11265014	chr1:158503221	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs909002	0.887	rs10914463	chr1:32132063	C/T	cg13919466	chr1:32135498	COL16A1	-0.41	-4.74	-0.36	4.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-9.12	-0.59	4.14e-16	Total body bone mineral density;
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg06697600	chr4:7070879	GRPEL1	0.79	5.22	0.39	5.79e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.46	-4.97	-0.37	1.75e-6	Type 2 diabetes;
PAAD	cis	rs1667255	0.830	rs1667239	chr18:29156721	G/A	cg18808318	chr18:29669225	NA	0.51	4.91	0.37	2.37e-6	Retinol levels;
PAAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.19	0.5	2.67e-11	Yeast infection;
PAAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg19767477	chr5:127420684	SLC12A2	-0.58	-4.7	-0.36	5.7e-6	Ileal carcinoids;
PAAD	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.52	5.44	0.4	2.13e-7	Daytime sleep phenotypes;
PAAD	cis	rs2242420	0.920	rs10917028	chr1:21963854	C/T	cg26362272	chr1:22108717	USP48	0.56	4.41	0.34	1.91e-5	Hematological and biochemical traits;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.13	9.78	0.62	7.85e-18	Vitiligo;
PAAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	1.1	11.26	0.67	8.92e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.41	-6.05	-0.44	1.08e-8	Neuroticism;
PAAD	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.6	5.8	0.43	3.7e-8	Body mass index;
PAAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg27494647	chr7:150038898	RARRES2	0.45	4.91	0.37	2.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06815965	chr1:205818668	PM20D1	0.71	8.12	0.55	1.47e-13	Menarche (age at onset);
PAAD	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.62e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.5	4.3	0.33	3.06e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs608114	0.623	rs126837	chr6:96364585	A/T	cg03043157	chr6:97010903	FHL5	0.84	4.44	0.34	1.72e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.45	4.3	0.33	3.1e-5	Renal cell carcinoma;
PAAD	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.7	6.83	0.48	1.92e-10	Schizophrenia;
PAAD	cis	rs2790216	1.000	rs2790214	chr10:60013404	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.56	5.35	0.4	3.17e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.3	0.51	1.47e-11	Rheumatoid arthritis;
PAAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.27	19.03	0.84	4.68e-42	IgG glycosylation;
PAAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.68	-6.67	-0.48	4.47e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-1.03	-10.94	-0.66	6.54e-21	Platelet distribution width;
PAAD	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg21361702	chr7:150065534	REPIN1	0.54	4.35	0.33	2.52e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	7.09	0.5	4.75e-11	Birth weight;
PAAD	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg08856118	chr10:27389908	ANKRD26	-0.4	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.41	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.49	6.49	0.47	1.14e-9	Renal cell carcinoma;
PAAD	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.59e-16	Morning vs. evening chronotype;
PAAD	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.24	10.68	0.65	3.29e-20	Uric acid levels;
PAAD	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.44	-4.72	-0.36	5.33e-6	Platelet count;
PAAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-4.81	-0.36	3.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg03030879	chr14:75389066	RPS6KL1	0.62	6.59	0.47	6.76e-10	Caffeine consumption;
PAAD	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.4	4.59	0.35	9.39e-6	Metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10354845	chr8:30013713	DCTN6	-0.66	-7.14	-0.5	3.6e-11	Smoking initiation;
PAAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.24e-8	Life satisfaction;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07851189	chr5:178053231	CLK4	-0.67	-6.59	-0.47	6.93e-10	Lung cancer in ever smokers;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.52	-4.93	-0.37	2.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	7.62	0.53	2.47e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3781663	1.000	rs3781663	chr11:69999252	C/T	cg06393558	chr11:69982916	ANO1	-0.44	-4.82	-0.36	3.41e-6	Survival in rectal cancer;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.84	7.16	0.5	3.28e-11	Alzheimer's disease;
PAAD	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg10223061	chr2:219282414	VIL1	0.41	4.81	0.36	3.65e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	7.93	0.54	4.39e-13	Mean platelet volume;
PAAD	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg09323728	chr8:95962352	TP53INP1	0.41	4.35	0.33	2.45e-5	Type 2 diabetes;
PAAD	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.55	5.24	0.39	5.18e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.58	-0.41	1.09e-7	Triglycerides;
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.99	0.37	1.66e-6	Joint mobility (Beighton score);
PAAD	cis	rs56114371	0.530	rs2056923	chr6:27689939	T/C	cg20933634	chr6:27740509	NA	0.68	5.76	0.42	4.47e-8	Breast cancer;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.41	-0.4	2.45e-7	Response to antipsychotic treatment;
PAAD	cis	rs58521262	0.530	rs289352	chr19:23145270	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg10729496	chr3:10149963	C3orf24	0.88	7.22	0.51	2.36e-11	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg03517284	chr6:25882590	NA	0.49	4.61	0.35	8.38e-6	Blood metabolite levels;
PAAD	cis	rs853679	0.567	rs7740429	chr6:28399246	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.31	-0.33	2.9e-5	Depression;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs758324	0.812	rs4280859	chr5:131246941	A/T	cg06307176	chr5:131281290	NA	-0.53	-4.61	-0.35	8.43e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10804591	0.848	rs6782700	chr3:129309147	G/C	cg18548199	chr3:129281892	PLXND1	0.52	4.55	0.35	1.11e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7465272	0.735	rs28420666	chr8:143695825	C/G	cg19438565	chr8:143695827	ARC	0.63	5.78	0.42	4.08e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs261360	0.666	rs6053067	chr20:5044402	C/T	cg19239041	chr20:4795444	RASSF2	0.4	4.26	0.33	3.62e-5	Hair morphology;
PAAD	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg06569542	chr10:98946673	SLIT1	0.44	4.5	0.34	1.34e-5	Monocyte count;
PAAD	cis	rs3996993	0.714	rs2608630	chr6:52625913	T/A	cg00536792	chr6:53530503	KLHL31	0.47	4.95	0.37	1.94e-6	Hemoglobin concentration;
PAAD	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-9.82	-0.62	6.31e-18	Height;
PAAD	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.74	0.58	3.97e-15	Cognitive test performance;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg04160749	chr8:58172571	NA	-0.71	-4.77	-0.36	4.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg08562672	chr19:21860753	NA	0.43	4.55	0.35	1.07e-5	Pain;
PAAD	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg20607287	chr7:12443886	VWDE	-0.62	-4.93	-0.37	2.14e-6	Coronary artery disease;
PAAD	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.62	4.92	0.37	2.19e-6	HIV-1 control;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.6	5.97	0.44	1.58e-8	Monocyte count;
PAAD	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.78	-0.48	2.52e-10	Total cholesterol levels;
PAAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.43	-4.5	-0.34	1.36e-5	Breast cancer;
PAAD	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.73	6.86	0.49	1.66e-10	Neuroticism;
PAAD	cis	rs9810890	1.000	rs73196978	chr3:128450228	C/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.73	-4.82	-0.36	3.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg18370025	chr7:2749541	AMZ1	-0.4	-4.82	-0.36	3.48e-6	Height;
PAAD	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.65	-4.93	-0.37	2.11e-6	Post bronchodilator FEV1;
PAAD	cis	rs7246760	1.000	rs28441975	chr19:9897631	C/A	cg16876255	chr19:9731953	ZNF561	0.95	4.56	0.35	1.06e-5	Pursuit maintenance gain;
PAAD	cis	rs4294134	0.608	rs35229763	chr7:135246305	A/G	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.63	7.62	0.53	2.57e-12	IgG glycosylation;
PAAD	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.84	10.3	0.64	3.32e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7631605	0.905	rs6781146	chr3:37068257	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7250872	0.606	rs4453627	chr19:1829860	T/C	cg10370574	chr19:1840461	REXO1	-0.5	-4.59	-0.35	9.25e-6	Bipolar disorder;
PAAD	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.6e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.52	5.28	0.39	4.46e-7	Schizophrenia;
PAAD	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg26585981	chr11:48327164	OR4S1	-0.49	-4.34	-0.33	2.62e-5	Migraine - clinic-based;
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.71	-5.47	-0.41	1.85e-7	Initial pursuit acceleration;
PAAD	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.71	5.05	0.38	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs2834188	0.924	rs2040107	chr21:34675962	C/G	cg04842828	chr21:34696676	IFNAR1	-0.47	-4.58	-0.35	9.79e-6	Narcolepsy;
PAAD	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.56	-5.03	-0.38	1.36e-6	Breast cancer;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.76	8.82	0.58	2.52e-15	Lung cancer;
PAAD	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg16898833	chr6:26189333	HIST1H4D	0.9	4.88	0.37	2.69e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.84	10.25	0.64	4.65e-19	Menopause (age at onset);
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg07061783	chr6:25882402	NA	-0.53	-5.21	-0.39	6.02e-7	Blood metabolite levels;
PAAD	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4704187	0.687	rs1363577	chr5:74463185	T/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs10769945	0.572	rs217206	chr11:1974542	G/A	cg23202291	chr11:1979235	NA	-0.46	-4.28	-0.33	3.31e-5	DNA methylation (variation);
PAAD	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	5.0	0.38	1.56e-6	Cognitive ability;
PAAD	cis	rs2882667	0.690	rs1725335	chr5:138081230	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.92	-0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.74	-6.62	-0.47	5.79e-10	Triglycerides;
PAAD	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg13722127	chr7:150037890	RARRES2	0.6	5.75	0.42	4.82e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg00579200	chr11:133705235	NA	0.45	4.88	0.37	2.65e-6	Childhood ear infection;
PAAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs1334894	0.818	rs72899794	chr6:35515234	G/A	cg07213720	chr6:35227408	ZNF76	-0.78	-4.25	-0.33	3.73e-5	Coronary artery disease;
PAAD	cis	rs2242420	0.790	rs10917029	chr1:21964134	C/T	cg26362272	chr1:22108717	USP48	0.53	4.31	0.33	2.93e-5	Hematological and biochemical traits;
PAAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.34	-0.33	2.63e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06766273	chr11:62521983	ZBTB3	0.63	7.08	0.5	4.98e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12304921	1.000	rs73090647	chr12:51345465	G/C	cg04427360	chr12:51347099	HIGD1C	-0.68	-5.22	-0.39	5.78e-7	Type 2 diabetes;
PAAD	cis	rs7326068	0.595	rs2477164	chr13:21402388	A/C	cg27234864	chr13:21295941	IL17D	0.59	4.8	0.36	3.73e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg21589280	chr1:85930151	DDAH1	-0.58	-4.38	-0.33	2.21e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1879734	1.000	rs2141080	chr1:54138489	C/T	cg14659662	chr1:54151053	GLIS1	-0.37	-5.51	-0.41	1.49e-7	Mitral valve prolapse;
PAAD	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14895029	chr7:2775587	GNA12	-0.46	-4.68	-0.36	6.2e-6	Height;
PAAD	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.84	8.34	0.56	4.09e-14	Vitamin D levels;
PAAD	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg14515779	chr1:101123966	NA	0.42	4.49	0.34	1.37e-5	Monocyte count;
PAAD	cis	rs6546550	0.901	rs12475412	chr2:70167197	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-5.68	-0.42	6.57e-8	Prevalent atrial fibrillation;
PAAD	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.13	-0.38	8.65e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.59	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.79	7.41	0.52	7.97e-12	Mean platelet volume;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2730260	0.500	rs73169244	chr7:158887293	T/C	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.73	8.12	0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs9810890	1.000	rs41266497	chr3:128526207	A/G	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.96	8.19	0.55	1.02e-13	IgG glycosylation;
PAAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1;
PAAD	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	trans	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg26939375	chr7:64535504	NA	0.72	8.42	0.56	2.57e-14	Aortic root size;
PAAD	cis	rs71636778	0.631	rs77402838	chr1:27197733	T/A	cg12203394	chr1:27248618	NUDC	0.64	4.57	0.35	9.9e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11105468	0.845	rs10858941	chr12:90375142	C/T	cg16962463	chr12:89968675	NA	-0.42	-4.26	-0.33	3.55e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-4.41	-0.34	1.91e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.41	-4.68	-0.36	6.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg15117754	chr3:10150083	C3orf24	0.74	6.52	0.47	9.87e-10	Alzheimer's disease;
PAAD	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.42	0.4	2.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.37	5.0	0.38	1.53e-6	Blood protein levels;
PAAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.51	4.61	0.35	8.44e-6	Height;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	1.01	14.34	0.76	4.82e-30	Menarche (age at onset);
PAAD	cis	rs11997175	0.603	rs6468199	chr8:33738770	A/C	ch.8.33884649F	chr8:33765107	NA	0.59	6.0	0.44	1.38e-8	Body mass index;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18402987	chr7:1209562	NA	0.53	5.39	0.4	2.59e-7	Longevity;Endometriosis;
PAAD	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.95	6.14	0.45	6.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10821973	0.527	rs7078397	chr10:63984649	C/T	cg09941381	chr10:64027924	RTKN2	-0.41	-4.33	-0.33	2.69e-5	Hypothyroidism;
PAAD	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg23254163	chr1:152506842	NA	0.6	7.02	0.49	6.81e-11	Hair morphology;
PAAD	cis	rs13323323	1.000	rs13323323	chr3:44333324	G/T	cg25364880	chr3:44379878	C3orf23	0.69	5.67	0.42	7.08e-8	IgG glycosylation;
PAAD	cis	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.5	0.34	1.32e-5	Depression;
PAAD	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.68e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg16596103	chr2:233749413	NGEF	0.42	4.39	0.34	2.12e-5	Schizophrenia;
PAAD	cis	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg27411982	chr8:10470053	RP1L1	0.44	4.6	0.35	8.8e-6	Retinal vascular caliber;
PAAD	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.52	5.37	0.4	2.87e-7	Red blood cell count;
PAAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-8.42	-0.56	2.61e-14	Coronary artery disease;
PAAD	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs1075232	1.000	rs12439239	chr15:31651718	G/A	cg06530883	chr15:30699977	NA	1.04	4.62	0.35	8.08e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.58	5.24	0.39	5.22e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.81	0.43	3.55e-8	Dupuytren's disease;
PAAD	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg09165964	chr15:75287851	SCAMP5	1.09	12.44	0.71	6.05e-25	Blood trace element (Zn levels);
PAAD	trans	rs2309322	0.702	rs6813993	chr4:181243155	A/G	cg24124977	chr17:78010277	CCDC40;TBC1D16	0.79	6.49	0.47	1.17e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.27	0.33	3.46e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3787159	0.523	rs560866	chr20:56923288	A/G	cg15032960	chr20:56888536	RAB22A	-0.42	-4.42	-0.34	1.89e-5	Systolic blood pressure;
PAAD	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.67	-6.35	-0.46	2.38e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25915131	chr11:67070756	SSH3	-0.63	-6.31	-0.46	2.9e-9	Smoking initiation;
PAAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg16083429	chr3:49237500	CCDC36	-0.44	-4.63	-0.35	7.81e-6	Parkinson's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13716933	chr12:57472580	TMEM194A	0.51	6.33	0.46	2.68e-9	Monocyte percentage of white cells;
PAAD	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.51	-4.79	-0.36	3.99e-6	Multiple myeloma;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.94	8.38	0.56	3.31e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20921751	chr2:48604775	FOXN2	-0.51	-6.58	-0.47	7.03e-10	Energy expenditure (24h);
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-9.08	-0.59	5.43e-16	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10767703	chr3:186524559	RFC4	0.65	6.59	0.47	6.64e-10	Obesity-related traits;
PAAD	cis	rs802075	0.905	rs1025347	chr6:49652977	G/A	cg20364632	chr6:49636226	NA	-0.44	-5.1	-0.38	9.85e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.6	5.12	0.38	9.15e-7	Common traits (Other);
PAAD	cis	rs7243821	1.000	rs56955176	chr18:52642427	G/T	cg16669619	chr18:52630472	NA	-0.44	-4.48	-0.34	1.48e-5	Chin dimples;
PAAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.07e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6604026	0.698	rs10874744	chr1:93306317	G/A	cg13858687	chr1:93297071	RPL5	-0.46	-4.29	-0.33	3.16e-5	Multiple sclerosis;
PAAD	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg20578329	chr17:80767326	TBCD	0.79	4.85	0.37	3.08e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.57	6.09	0.44	8.74e-9	Lung cancer;
PAAD	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.43	4.4	0.34	2.07e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg00945038	chr17:61921165	SMARCD2	0.46	5.44	0.4	2.13e-7	Prudent dietary pattern;
PAAD	trans	rs4471226	1.000	rs13376505	chr1:176422326	G/A	cg01325552	chr4:187025420	NA	0.88	6.77	0.48	2.57e-10	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.57	0.52	3.42e-12	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18450294	chr17:423235	VPS53	0.65	8.0	0.54	2.99e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg02297831	chr4:17616191	MED28	-0.61	-5.93	-0.43	1.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11997175	0.598	rs4599769	chr8:33601425	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	6.52	0.47	1e-9	Body mass index;
PAAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.5	5.02	0.38	1.4e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.88	10.37	0.64	2.13e-19	Ulcerative colitis;
PAAD	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.89	10.63	0.65	4.39e-20	Type 2 diabetes;
PAAD	cis	rs2061333	0.500	rs8113750	chr19:44608789	C/T	cg20607764	chr19:44506953	ZNF230	-0.72	-4.88	-0.37	2.63e-6	Alzheimer's disease;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.47	6.02	0.44	1.23e-8	Longevity;Endometriosis;
PAAD	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg09592244	chr17:37024020	NA	0.41	4.33	0.33	2.68e-5	Height;
PAAD	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.08	0.5	4.98e-11	Body mass index;
PAAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	1.12	16.58	0.8	6.46e-36	Breast cancer;
PAAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.75	8.56	0.57	1.18e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.8	0.36	3.8e-6	Mood instability;
PAAD	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.54	5.09	0.38	1.03e-6	Mortality in heart failure;
PAAD	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs2627282	0.569	rs12541136	chr8:2761343	A/T	cg21769514	chr8:2743697	NA	0.5	4.91	0.37	2.28e-6	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.43	4.86	0.37	2.87e-6	Dietary macronutrient intake;
PAAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg04063615	chr12:132293388	NA	0.46	4.88	0.37	2.7e-6	Migraine;
PAAD	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.56	-0.57	1.17e-14	Thrombosis;
PAAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.6e-6	Childhood ear infection;
PAAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-5.07	-0.38	1.13e-6	Diastolic blood pressure;
PAAD	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.52	-5.31	-0.4	3.86e-7	Height;
PAAD	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.62	-0.35	8.29e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16901402	chr2:96348691	NA	0.56	6.32	0.46	2.8e-9	Metabolite levels  (X-11787);
PAAD	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.49	4.45	0.34	1.68e-5	Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00933542	chr6:150070202	PCMT1	0.57	6.07	0.44	9.81e-9	Lung cancer;
PAAD	cis	rs72843506	0.520	rs78178505	chr17:19887723	A/G	cg05625806	chr17:19284432	MAPK7	0.67	4.36	0.33	2.39e-5	Schizophrenia;
PAAD	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-5.31	-0.4	3.74e-7	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01366085	chr8:103668528	KLF10	0.65	7.54	0.52	3.91e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.74	7.33	0.51	1.24e-11	Total body bone mineral density;
PAAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.65	0.42	7.77e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.46	4.3	0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.68	-6.63	-0.47	5.43e-10	Blood metabolite levels;
PAAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.49	4.87	0.37	2.73e-6	Trans fatty acid levels;
PAAD	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.43	-4.93	-0.37	2.13e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	4.68	0.35	6.42e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.64	7.62	0.53	2.6e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.91	0.43	2.21e-8	Prudent dietary pattern;
PAAD	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.62e-17	White blood cell count (basophil);
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.75	5.57	0.41	1.14e-7	Initial pursuit acceleration;
PAAD	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.3	-0.33	2.98e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg10856724	chr12:34555212	NA	-0.41	-4.33	-0.33	2.67e-5	Morning vs. evening chronotype;
PAAD	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.37	-5.78	-0.42	4.15e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.97	9.92	0.63	3.49e-18	Post bronchodilator FEV1;
PAAD	cis	rs58521262	0.519	rs11669040	chr19:22993844	C/T	cg07749055	chr19:23076870	NA	-0.61	-4.6	-0.35	8.98e-6	Testicular germ cell tumor;
PAAD	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.4	-0.51	8.39e-12	Total cholesterol levels;
PAAD	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg01422370	chr2:73384389	NA	0.44	5.63	0.42	8.53e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09841884	chr4:16504379	LDB2	-0.57	-6.46	-0.46	1.33e-9	Monocyte percentage of white cells;
PAAD	cis	rs877529	0.967	rs139385	chr22:39530132	C/A	cg18708252	chr22:39545030	CBX7	-0.46	-4.53	-0.34	1.2e-5	Multiple myeloma;
PAAD	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.0	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs9815354	1.000	rs11923562	chr3:41760331	G/T	cg03022575	chr3:42003672	ULK4	0.84	6.06	0.44	1.02e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg21546286	chr11:48923668	NA	0.55	5.8	0.43	3.75e-8	HDL cholesterol;
PAAD	cis	rs17155006	0.655	rs426812	chr7:107728512	T/C	cg05962710	chr7:107745446	LAMB4	-0.45	-5.52	-0.41	1.42e-7	Pneumococcal bacteremia;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg26338869	chr17:61819248	STRADA	0.8	8.49	0.57	1.7e-14	Prudent dietary pattern;
PAAD	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs7567389	0.677	rs61422716	chr2:128087651	C/T	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	5.1	0.38	1e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.63	-5.41	-0.4	2.4e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.82	9.17	0.6	3.05e-16	Coronary artery disease;
PAAD	cis	rs10214930	0.813	rs7806415	chr7:27673537	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.85	7.77	0.53	1.08e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.62	7.45	0.52	6.48e-12	Lung cancer;
PAAD	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.88	-0.37	2.7e-6	Height;
PAAD	cis	rs939584	1.000	rs11127486	chr2:632101	C/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs1364705	1.000	rs1364705	chr8:120224806	C/T	cg09273054	chr8:120220131	MAL2	-0.45	-5.25	-0.39	5e-7	Hippocampal atrophy;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.42	-0.34	1.85e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.5	-4.52	-0.34	1.24e-5	Triglycerides;
PAAD	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.69	0.36	5.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.62	-5.92	-0.43	2.1e-8	Subjective well-being;
PAAD	cis	rs251130	0.540	rs251133	chr5:110859246	A/G	cg11925263	chr5:110849104	STARD4	-0.4	-4.48	-0.34	1.46e-5	Menarche (age at onset);
PAAD	trans	rs901683	0.850	rs78999882	chr10:46076813	A/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2252790	0.859	rs1204810	chr6:116551638	C/A	cg26893134	chr6:116381904	FRK	-0.28	-4.5	-0.34	1.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs13102973	0.867	rs4429776	chr4:135883394	G/T	cg14419869	chr4:135874104	NA	0.44	4.49	0.34	1.37e-5	Subjective well-being;
PAAD	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.01	-0.38	1.5e-6	Coronary artery disease;
PAAD	cis	rs597583	0.755	rs562422	chr11:117428278	G/A	cg27161313	chr11:117392002	DSCAML1	-0.65	-5.53	-0.41	1.4e-7	Putamen volume;
PAAD	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs4668356	0.730	rs16859137	chr2:171912604	T/C	cg13882835	chr2:172017928	TLK1	0.92	5.37	0.4	2.83e-7	Cognitive performance;
PAAD	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.77	6.99	0.49	8.21e-11	Obesity-related traits;
PAAD	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.96	-10.14	-0.64	8.79e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2900174	1.000	rs7312028	chr12:11561039	A/T	cg25373614	chr12:11548019	PRB2	-1.14	-4.62	-0.35	8.03e-6	Survival in pancreatic cancer;Response to gemcitabine in pancreatic cancer;
PAAD	cis	rs11159086	1.000	rs17100451	chr14:74942913	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.11	-0.38	9.74e-7	Advanced glycation end-product levels;
PAAD	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg08917208	chr2:24149416	ATAD2B	0.53	4.62	0.35	8.21e-6	Lymphocyte counts;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.08	10.18	0.64	7.14e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg26939375	chr7:64535504	NA	-0.75	-8.37	-0.56	3.45e-14	Aortic root size;
PAAD	cis	rs1499972	0.527	rs62263507	chr3:117946498	G/A	cg07612923	chr3:117604196	NA	0.68	4.45	0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.8	7.54	0.52	3.93e-12	Asthma;
PAAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.49	-4.7	-0.36	5.88e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.34	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18402987	chr7:1209562	NA	0.53	5.39	0.4	2.59e-7	Longevity;Endometriosis;
PAAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.64	4.29	0.33	3.11e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.69	-4.57	-0.35	9.93e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.99	8.59	0.57	9.79e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9810890	0.702	rs73207972	chr3:128568186	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.55	-4.75	-0.36	4.69e-6	Schizophrenia;
PAAD	cis	rs6804624	0.636	rs2700656	chr3:99157832	A/G	cg02646433	chr3:99218170	NA	0.42	4.31	0.33	2.97e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.09e-13	Diastolic blood pressure;
PAAD	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.61	-5.34	-0.4	3.4e-7	Corneal astigmatism;
PAAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.84e-9	Blood metabolite levels;
PAAD	cis	rs2017305	0.915	rs75496049	chr10:70777549	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg11802864	chr11:65308245	LTBP3	0.48	4.89	0.37	2.52e-6	Bone mineral density;
PAAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.45	4.85	0.37	3.08e-6	Aortic root size;
PAAD	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.72	-4.58	-0.35	9.61e-6	White matter integrity;
PAAD	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg05309399	chr4:106552544	FLJ20184	-0.58	-4.79	-0.36	4e-6	Post bronchodilator FEV1;
PAAD	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.88	7.94	0.54	4.14e-13	Itch intensity from mosquito bite;
PAAD	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg21546286	chr11:48923668	NA	-0.58	-5.87	-0.43	2.58e-8	HDL cholesterol;
PAAD	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg15211996	chr1:2936768	ACTRT2	0.5	4.9	0.37	2.47e-6	Plateletcrit;
PAAD	cis	rs9913156	0.748	rs55869432	chr17:4562901	A/G	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.59	-0.35	9.41e-6	Eosinophil percentage of white cells;
PAAD	cis	rs9488822	0.585	rs550480	chr6:116264354	C/A	cg18764771	chr6:116381957	FRK	-0.26	-4.25	-0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23881601	chr1:156698494	C1orf66;ISG20L2	0.69	7.07	0.5	5.3e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs7129556	0.859	rs11605638	chr11:77239334	C/T	cg24456632	chr11:77314957	AQP11	-0.57	-4.68	-0.36	6.2e-6	Weight loss (gastric bypass surgery);
PAAD	cis	rs2412208	0.527	rs4436414	chr1:7120915	G/A	cg20434152	chr1:7120926	CAMTA1	-0.55	-6.35	-0.46	2.35e-9	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs16958440	0.521	rs62095426	chr18:44585481	C/T	cg17192377	chr18:44677553	HDHD2	0.88	5.44	0.4	2.08e-7	Sitting height ratio;
PAAD	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.02	0.63	1.88e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.64	-0.42	8.06e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.85	-6.46	-0.46	1.37e-9	Coronary artery calcification;
PAAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	1.01	11.07	0.67	2.86e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.46	-0.4	1.92e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg23947450	chr7:900037	UNC84A	-0.53	-4.49	-0.34	1.42e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg00400743	chr4:148603008	PRMT10	-0.68	-4.27	-0.33	3.47e-5	Pulse pressure;
PAAD	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg04520793	chr17:42248056	ASB16	0.41	4.78	0.36	4.11e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00319157	chr22:47052970	GRAMD4	0.63	6.88	0.49	1.45e-10	Obesity-related traits;
PAAD	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs927833	0.502	rs1535203	chr20:21819249	G/A	cg08156066	chr20:21695334	PAX1	0.59	4.32	0.33	2.83e-5	facial morphology traits (multivariate analysis);middle facial morphology traits (quantitative measurement);
PAAD	cis	rs6963495	0.615	rs1728645	chr7:105205115	A/G	cg02135003	chr7:105160482	PUS7	-0.58	-4.85	-0.37	2.98e-6	Bipolar disorder (body mass index interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20900676	chr11:72810918	FCHSD2	0.52	6.34	0.46	2.52e-9	Body fat percentage;
PAAD	cis	rs2685295	0.546	rs12145884	chr1:237901815	G/T	cg13968398	chr1:236958353	MTR	0.55	4.28	0.33	3.28e-5	Bipolar disorder and eating disorder;
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg09677638	chr11:61582810	MIR1908;FADS1	0.52	4.41	0.34	1.93e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.71	0.36	5.51e-6	Breast cancer;
PAAD	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.3	-0.39	4.02e-7	Bipolar disorder;
PAAD	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.76	-8.86	-0.58	1.92e-15	White blood cell count (basophil);
PAAD	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.92	5.12	0.38	9.01e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18766754	chr10:38299406	ZNF33A	-0.62	-7.46	-0.52	6.35e-12	Body fat percentage;
PAAD	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.22	-9.87	-0.63	4.54e-18	Breast cancer;
PAAD	cis	rs7804356	0.871	rs727450	chr7:26787642	G/A	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.8	-8.52	-0.57	1.44e-14	Tuberculosis;
PAAD	cis	rs12042938	0.505	rs6541275	chr1:231752942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-4.57	-0.35	1.02e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.47	7.27	0.51	1.81e-11	Information processing speed;
PAAD	trans	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg26939375	chr7:64535504	NA	0.75	9.02	0.59	7.72e-16	Aortic root size;
PAAD	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg21823605	chr1:152486609	CRCT1	0.54	5.91	0.43	2.13e-8	Hair morphology;
PAAD	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg04844267	chr4:1394941	NA	0.51	5.52	0.41	1.43e-7	Obesity-related traits;
PAAD	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.07	-0.55	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg27234864	chr13:21295941	IL17D	-0.53	-4.66	-0.35	6.94e-6	Dental caries;
PAAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg06569542	chr10:98946673	SLIT1	-0.51	-5.76	-0.42	4.61e-8	Monocyte count;
PAAD	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg27449745	chr7:23145252	KLHL7	-0.59	-5.13	-0.38	8.82e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.7	0.36	5.79e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg02725872	chr8:58115012	NA	-0.57	-4.75	-0.36	4.69e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.51	5.14	0.38	8.42e-7	Testicular germ cell tumor;
PAAD	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.7	0.58	5.1e-15	Coffee consumption (cups per day);
PAAD	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.63	-0.42	8.51e-8	Subjective well-being;
PAAD	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg13695288	chr21:47294981	PCBP3	-0.48	-4.76	-0.36	4.57e-6	Schizophrenia;
PAAD	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7074356	0.704	rs1417220	chr10:82168154	G/A	cg19423196	chr10:82049429	MAT1A	0.47	4.9	0.37	2.39e-6	Borderline personality disorder;
PAAD	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.76e-8	Eye color traits;
PAAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27436995	chr16:743998	FBXL16	-0.37	-4.42	-0.34	1.84e-5	Height;
PAAD	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.29e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs2882667	0.690	rs160399	chr5:138063241	A/G	cg09476006	chr5:138032270	NA	0.47	6.07	0.44	9.64e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	4.52	0.34	1.21e-5	Height;
PAAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19346786	chr7:2764209	NA	-0.38	-5.21	-0.39	5.94e-7	Height;
PAAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.47	-4.68	-0.35	6.32e-6	Mortality in heart failure;
PAAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.44e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	1.0	9.72	0.62	1.13e-17	Psoriasis;
PAAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs8014252	0.803	rs58777530	chr14:71001222	C/T	cg11204974	chr14:71022665	NA	-0.7	-4.57	-0.35	1e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05547152	chr16:11343312	NA	0.62	7.44	0.52	6.96e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.51	-4.88	-0.37	2.67e-6	Neutrophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23438505	chr17:78489298	NA	0.55	6.77	0.48	2.66e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.57e-6	Bipolar disorder;
PAAD	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs62238980	0.901	rs117397604	chr22:32580840	C/A	cg00543991	chr22:32367038	NA	1.14	6.24	0.45	4.09e-9	Childhood ear infection;
PAAD	cis	rs6585424	1.000	rs12411386	chr10:81926231	T/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-5.63	-0.42	8.58e-8	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10317778	chr4:6890977	NA	-0.66	-6.8	-0.48	2.29e-10	Obesity-related traits;
PAAD	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.72	-7.33	-0.51	1.29e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs72843506	0.656	rs58313980	chr17:19940050	A/G	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.28	-0.39	4.41e-7	Neuroticism;
PAAD	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg02573091	chr5:74908125	NA	-0.55	-4.6	-0.35	8.68e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.77	8.91	0.59	1.48e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	trans	rs4427176	0.507	rs7016561	chr8:9580493	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs8040855	0.627	rs12904238	chr15:85639841	A/T	cg08123816	chr15:85640762	PDE8A	-0.43	-5.11	-0.38	9.75e-7	Bulimia nervosa;
PAAD	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg04721828	chr11:48285200	OR4X1	-0.47	-5.77	-0.42	4.24e-8	Migraine - clinic-based;
PAAD	cis	rs17407555	0.657	rs12505144	chr4:10270919	G/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.21	0.39	6.17e-7	Schizophrenia (age at onset);
PAAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.53	0.41	1.39e-7	Body mass index;
PAAD	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.84	9.52	0.61	3.86e-17	Schizophrenia;
PAAD	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	1.15	17.62	0.82	1.48e-38	Multiple myeloma;
PAAD	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.44e-9	HDL cholesterol;
PAAD	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs11871801	0.560	rs8068844	chr17:40571284	T/C	cg09776463	chr17:40836087	CNTNAP1	-0.55	-5.08	-0.38	1.07e-6	Crohn's disease;
PAAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.56	0.35	1.06e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6547631	0.622	rs1437744	chr2:85925084	G/A	cg24620635	chr2:85921963	GNLY	0.42	5.55	0.41	1.23e-7	Blood protein levels;
PAAD	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg05835009	chr4:710272	PCGF3	0.71	6.31	0.46	2.9e-9	White blood cell count;
PAAD	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg10011062	chr15:43941034	CATSPER2	0.82	5.03	0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.71	0.66	2.64e-20	Smoking behavior;
PAAD	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.17	0.55	1.13e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs540425	0.572	rs217372	chr7:44612753	T/C	cg14633139	chr7:44645728	OGDH	0.44	4.4	0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs17824933	0.943	rs11230562	chr11:60776186	C/T	cg27098804	chr11:60776124	CD6	0.45	4.38	0.33	2.21e-5	Multiple sclerosis;
PAAD	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.48	-4.9	-0.37	2.43e-6	Coronary artery disease;
PAAD	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.53	-0.41	1.39e-7	Atrioventricular conduction;
PAAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.69	-0.53	1.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg06484146	chr7:12443880	VWDE	0.79	4.97	0.37	1.75e-6	Coronary artery disease;
PAAD	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg21191810	chr6:118973309	C6orf204	0.49	6.19	0.45	5.3300000000000004e-09	Electrocardiographic conduction measures;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.29	0.64	3.55e-19	Menopause (age at onset);
PAAD	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg09659197	chr4:152720779	NA	0.4	4.98	0.37	1.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.58	5.74	0.42	4.92e-8	Systolic blood pressure;
PAAD	cis	rs1014246	0.826	rs11197802	chr10:118472000	T/A	cg14471191	chr10:117818509	GFRA1	0.38	4.37	0.33	2.28e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs8081395	0.836	rs2063353	chr17:57889192	T/G	cg02344993	chr17:57696989	CLTC	-0.43	-4.27	-0.33	3.47e-5	White blood cell count;
PAAD	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg10631289	chr15:39006617	NA	-0.58	-5.36	-0.4	2.99e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg22338127	chr1:209979572	IRF6	0.54	4.36	0.33	2.4e-5	Coronary artery disease;
PAAD	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.98	-12.68	-0.72	1.32e-25	Coronary artery disease;
PAAD	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.67	6.49	0.47	1.16e-9	IgG glycosylation;
PAAD	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg11601000	chr22:42348013	LOC339674	-0.45	-4.96	-0.37	1.88e-6	Cognitive function;
PAAD	cis	rs55692468	0.606	rs1878632	chr2:153323158	A/C	cg04681845	chr2:153283485	FMNL2	-0.45	-5.54	-0.41	1.28e-7	Intraocular pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16857335	chr19:47633940	SAE1	0.69	7.36	0.51	1.08e-11	Myopia (pathological);
PAAD	cis	rs950037	0.593	rs10493818	chr1:89333557	C/T	cg13109106	chr1:89333529	GTF2B	0.5	4.84	0.37	3.15e-6	Coronary artery disease;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-4.48	-0.34	1.46e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.97e-15	Prostate cancer;
PAAD	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.32	-0.33	2.78e-5	Height;
PAAD	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.56	5.87	0.43	2.63e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs3857067	0.550	rs66638531	chr4:95002595	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs1692120	0.545	rs7930946	chr11:61407838	C/A	cg23038520	chr11:61406508	RPLP0P2	0.51	5.31	0.4	3.78e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs308971	0.563	rs453131	chr3:12140953	C/G	cg15873301	chr3:12045459	SYN2	0.63	4.51	0.34	1.27e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg25686905	chr3:183603175	PARL	-0.33	-4.35	-0.33	2.5e-5	Menopause (age at onset);
PAAD	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg02631450	chr22:32366979	NA	0.96	5.61	0.41	9.26e-8	Childhood ear infection;
PAAD	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-1.02	-8.38	-0.56	3.39e-14	Inflammatory bowel disease;
PAAD	cis	rs9810890	1.000	rs115356727	chr3:128558380	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04004882	chr2:215674386	BARD1	-0.62	-5.07	-0.38	1.12e-6	Neuroblastoma;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27603082	chr10:134405566	INPP5A	0.41	4.29	0.33	3.12e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.94	-7.76	-0.53	1.16e-12	Dupuytren's disease;
PAAD	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.98	8.26	0.56	6.74e-14	Triglycerides;
PAAD	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.43e-9	Skin colour saturation;
PAAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.77	7.35	0.51	1.14e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.74	-0.42	5.09e-8	Schizophrenia;
PAAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7765175	0.674	rs9400614	chr6:113680516	C/T	cg19037598	chr6:113666021	NA	-0.44	-4.79	-0.36	3.85e-6	Coronary artery calcification;
PAAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.7	-5.48	-0.41	1.73e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs1529711	0.500	rs115016167	chr19:10917799	A/G	cg18582342	chr19:11591989	ELAVL3	-0.6	-5.1	-0.38	1.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.44	-5.66	-0.42	7.38e-8	Ulcerative colitis;
PAAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.02e-6	Diastolic blood pressure;
PAAD	cis	rs10851478	0.515	rs12439429	chr15:49734634	C/T	cg08060515	chr15:49448048	GALK2;COPS2	-0.46	-4.44	-0.34	1.74e-5	Oral cavity cancer;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08450091	chr3:82857215	NA	0.61	6.33	0.46	2.58e-9	Warfarin maintenance dose;
PAAD	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.42	-4.73	-0.36	5.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12078820	chr2:184125555	NA	-0.65	-6.38	-0.46	2.08e-9	Obesity-related traits;
PAAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.7	7.29	0.51	1.6e-11	Calcium levels;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg10729496	chr3:10149963	C3orf24	0.89	6.69	0.48	4.11e-10	Alzheimer's disease;
PAAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	1.13	13.02	0.73	1.67e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.59	6.25	0.45	3.84e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg15193198	chr20:60906057	LAMA5	-0.47	-5.22	-0.39	5.73e-7	Colorectal cancer;
PAAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.73	-5.79	-0.43	3.86e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg00206168	chr11:65308501	LTBP3	0.49	4.99	0.38	1.65e-6	Bone mineral density;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.56	7.11	0.5	4.31e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg21565972	chr17:80109576	CCDC57	0.49	5.26	0.39	4.86e-7	Life satisfaction;
PAAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.92	-8.3	-0.56	5.38e-14	Gut microbiome composition (summer);
PAAD	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.71	8.42	0.56	2.56e-14	Bladder cancer;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.38	4.44	0.34	1.73e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7172971	0.565	rs17748132	chr15:42386002	C/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5762534	0.770	rs130413	chr22:28488105	A/C	cg08599437	chr22:28033286	NA	0.48	5.0	0.38	1.59e-6	Menopause (age at onset);
PAAD	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-9.41	-0.61	7.54e-17	Vitiligo;
PAAD	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9463078	0.691	rs9381373	chr6:45175908	T/C	cg25276700	chr6:44698697	NA	-0.52	-5.72	-0.42	5.39e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.19	8.13	0.55	1.41e-13	Lung cancer in ever smokers;
PAAD	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg17366294	chr4:99064904	C4orf37	-0.46	-5.02	-0.38	1.45e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg01304814	chr3:48885189	PRKAR2A	1.05	5.88	0.43	2.51e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.23	0.51	2.21e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7762544	0.756	rs606347	chr6:41362677	A/G	cg18315060	chr6:41374532	NA	0.61	4.74	0.36	4.88e-6	Periodontitis;
PAAD	cis	rs1925576	0.935	rs4745920	chr10:68656788	A/T	cg04444303	chr10:69634106	NA	-0.44	-4.41	-0.34	1.97e-5	Educational attainment (years of education);
PAAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Calcium levels;
PAAD	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21646471	chr2:242523971	THAP4	-0.65	-5.03	-0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.52	4.41	0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.5	-0.34	1.32e-5	Personality dimensions;
PAAD	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg00012203	chr2:219082015	ARPC2	-0.58	-5.84	-0.43	3.13e-8	Colorectal cancer;
PAAD	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg09509183	chr1:209979624	IRF6	0.51	4.78	0.36	4.14e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.54	5.33	0.4	3.52e-7	Menopause (age at onset);
PAAD	cis	rs492146	0.935	rs405729	chr6:52842781	T/C	cg24393602	chr6:52860404	GSTA4	-0.44	-4.29	-0.33	3.13e-5	Epilepsy (remission after treatment);
PAAD	cis	rs2020921	0.510	rs12545129	chr8:41981118	G/T	cg12054981	chr8:42037387	PLAT	0.79	5.37	0.4	2.89e-7	Plasma plasminogen activator levels;
PAAD	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.37	4.88	0.37	2.71e-6	Schizophrenia;
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg11335335	chr11:637885	DRD4	-0.37	-4.82	-0.36	3.48e-6	Systemic lupus erythematosus;
PAAD	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg01851573	chr8:8652454	MFHAS1	0.57	4.97	0.37	1.76e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18253516	chr20:62612348	SAMD10;PRPF6	0.6	6.31	0.46	2.97e-9	Myopia (pathological);
PAAD	cis	rs319204	1.000	rs319196	chr5:146267038	C/T	cg13983063	chr5:146258615	PPP2R2B	0.37	4.28	0.33	3.3e-5	Schizophrenia;
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.53	-6.69	-0.48	3.99e-10	Abdominal aortic aneurysm;
PAAD	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.78	7.77	0.53	1.08e-12	Corneal astigmatism;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg27121462	chr16:89883253	FANCA	-0.46	-4.96	-0.37	1.85e-6	Vitiligo;
PAAD	cis	rs17002988	0.539	rs10023697	chr4:79080010	C/T	cg07442568	chr4:78980533	FRAS1	0.56	4.67	0.35	6.54e-6	Uric acid levels;
PAAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.53	-0.35	1.17e-5	Breast cancer;
PAAD	cis	rs72681920	0.881	rs7692974	chr4:100051161	C/A	cg12011299	chr4:100065546	ADH4	-0.72	-4.44	-0.34	1.72e-5	Alcohol dependence;
PAAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.1e-6	Type 2 diabetes;
PAAD	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg14709524	chr16:89940631	TCF25	0.99	4.63	0.35	7.84e-6	Skin colour saturation;
PAAD	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.68	-0.48	4.24e-10	Neuroticism;
PAAD	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-4.79	-0.36	3.92e-6	Menarche (age at onset);
PAAD	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg26876637	chr1:152193138	HRNR	-0.83	-5.96	-0.44	1.65e-8	Atopic dermatitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02628050	chr2:70418124	C2orf42	0.65	6.54	0.47	8.62e-10	Obesity-related traits;
PAAD	cis	rs58521262	0.530	rs460681	chr19:23140545	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg22325292	chr17:80708367	FN3K	0.63	4.26	0.33	3.59e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs730570	1.000	rs10141733	chr14:101142651	A/G	cg15541609	chr14:100705844	YY1	0.64	4.57	0.35	1.01e-5	Type 2 diabetes;
PAAD	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.97	-13.45	-0.74	1.19e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg14219918	chr9:127249562	NR5A1	-0.37	-5.0	-0.38	1.54e-6	Menarche (age at onset);
PAAD	cis	rs6499755	0.712	rs31114	chr16:55380055	C/T	cg02859129	chr16:55357253	IRX6	0.33	4.58	0.35	9.57e-6	Hypospadias;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.49	4.82	0.36	3.52e-6	Pulmonary function;
PAAD	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-7.42	-0.52	7.67e-12	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20695238	chr15:68499752	CLN6;CALML4	0.62	6.34	0.46	2.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg12215294	chr3:40350768	EIF1B	-0.44	-4.28	-0.33	3.34e-5	Renal cell carcinoma;
PAAD	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg10223061	chr2:219282414	VIL1	0.37	4.35	0.33	2.47e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.14	-0.5	3.54e-11	Blood pressure (smoking interaction);
PAAD	cis	rs10037758	0.643	rs6890670	chr5:128283017	C/A	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.55	5.16	0.39	7.67e-7	Resting heart rate;
PAAD	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.53	0.68	1.73e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.72	8.54	0.57	1.33e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2555155	1.000	rs11040899	chr11:6520015	A/C	cg11185456	chr11:6592066	DNHD1	-0.43	-4.61	-0.35	8.63e-6	DNA methylation (variation);
PAAD	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.66	6.31	0.46	2.91e-9	Platelet count;
PAAD	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6604026	0.630	rs2391177	chr1:93353943	G/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.54	4.93	0.37	2.13e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs12431939	0.546	rs4424815	chr14:51714360	C/A	cg23942311	chr14:51606299	NA	0.51	4.67	0.35	6.52e-6	Cancer;
PAAD	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4654748	0.741	rs1106357	chr1:21817085	C/T	cg21906605	chr1:21766650	NBPF3	0.51	4.91	0.37	2.3e-6	Folate pathway vitamin levels;
PAAD	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.33	-0.33	2.7e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs179429	0.645	rs179435	chr11:2553703	A/G	cg22366698	chr11:3400543	ZNF195	-0.56	-4.62	-0.35	8.28e-6	Platelet aggregation;
PAAD	cis	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20713333	chr4:100484892	RG9MTD2;MTTP	-0.58	-6.72	-0.48	3.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.52	-0.47	9.98e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.64	7.42	0.52	7.7e-12	Bone mineral density;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07784012	chr12:76466892	NAP1L1	-0.5	-6.42	-0.46	1.64e-9	Energy expenditure (24h);
PAAD	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-5.7	-0.42	5.92e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.73	-0.36	5e-6	Type 2 diabetes;
PAAD	cis	rs2017305	1.000	rs2017305	chr10:70712062	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.5	4.62	0.35	7.98e-6	Renal cell carcinoma;
PAAD	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.55	-0.41	1.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.59	5.43	0.4	2.15e-7	Coronary artery disease;
PAAD	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg22153407	chr1:230290089	GALNT2	0.46	4.57	0.35	9.97e-6	Coronary artery disease;
PAAD	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs858239	0.931	rs9690941	chr7:23281753	C/T	cg27449745	chr7:23145252	KLHL7	-0.55	-4.73	-0.36	4.99e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.47	4.92	0.37	2.26e-6	Longevity;Endometriosis;
PAAD	cis	rs802075	0.905	rs2396917	chr6:49635987	G/A	cg20364632	chr6:49636226	NA	-0.52	-6.0	-0.44	1.4e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.75	7.43	0.52	7.16e-12	White matter hyperintensity burden;
PAAD	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg11288833	chr15:55489084	RSL24D1	0.58	4.77	0.36	4.21e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11411865	chr7:2701802	TTYH3	0.61	4.39	0.34	2.11e-5	Bipolar disorder;
PAAD	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.49	-0.34	1.43e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14032070	chr9:115098991	NA	-0.5	-6.3	-0.46	2.99e-9	Energy expenditure (24h);
PAAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23281280	chr6:28129359	ZNF389	0.7	5.49	0.41	1.67e-7	Parkinson's disease;
PAAD	trans	rs62179067	0.708	rs62175995	chr2:179907478	C/T	cg13380624	chr19:7735426	NA	-0.74	-7.09	-0.5	4.64e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg22143635	chr11:980567	AP2A2	-0.52	-5.56	-0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg17796960	chr10:135278976	LOC619207	-0.39	-4.35	-0.33	2.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs7089973	0.668	rs11196962	chr10:116646827	A/C	cg23260525	chr10:116636907	FAM160B1	0.42	6.25	0.45	3.92e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.22	7.15	0.5	3.35e-11	Lung cancer in ever smokers;
PAAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.7	-0.36	5.72e-6	Life satisfaction;
PAAD	cis	rs8112211	0.731	rs73041302	chr19:38819098	A/G	cg14299480	chr19:38876666	GGN	-0.62	-6.01	-0.44	1.3e-8	Blood protein levels;
PAAD	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg14146966	chr2:61757674	XPO1	0.36	4.38	0.33	2.22e-5	Tuberculosis;
PAAD	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.46	5.09	0.38	1.05e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6e-8	Life satisfaction;
PAAD	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs9467603	0.925	rs6910549	chr6:25780811	A/G	cg23465465	chr6:26364728	BTN3A2	-0.71	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs900145	0.953	rs1384029	chr11:13293019	T/C	cg15603424	chr11:13300592	ARNTL	0.53	4.74	0.36	4.81e-6	Menarche (age at onset);
PAAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.62	-6.37	-0.46	2.11e-9	Monocyte count;
PAAD	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg01426195	chr3:39028469	NA	-0.77	-8.52	-0.57	1.46e-14	Handedness;
PAAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs2421770	1.000	rs3847609	chr11:35321749	C/T	cg13971030	chr11:35366721	SLC1A2	0.52	6.34	0.46	2.55e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs9857275	0.788	rs9858603	chr3:141095949	A/G	cg00789793	chr3:141329863	RASA2	0.49	4.32	0.33	2.78e-5	Prion diseases;
PAAD	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01490772	chr12:7282593	CLSTN3;RBP5	0.63	6.84	0.49	1.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.4	-0.34	2.03e-5	Breast cancer;
PAAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg23465465	chr6:26364728	BTN3A2	-0.7	-4.34	-0.33	2.61e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.52	5.54	0.41	1.28e-7	Total body bone mineral density;
PAAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.76	0.36	4.43e-6	Breast cancer;
PAAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.92	-8.52	-0.57	1.44e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg24733560	chr20:60626293	TAF4	0.53	6.61	0.47	6.21e-10	Body mass index;
PAAD	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs2147959	0.883	rs10916314	chr1:228633332	A/T	cg00655913	chr1:228633920	NA	0.47	4.35	0.33	2.49e-5	Adult asthma;
PAAD	cis	rs30380	0.632	rs149189	chr5:96137804	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.22	-0.39	5.87e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.38	0.33	2.22e-5	Electroencephalogram traits;
PAAD	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.59	0.35	9.32e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.63	-7.19	-0.5	2.74e-11	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.27e-5	Menopause (age at onset);
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg22868518	chr11:507468	RNH1	-0.9	-4.75	-0.36	4.61e-6	Body mass index;
PAAD	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-4.61	-0.35	8.45e-6	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.74	-7.83	-0.54	7.93e-13	Triglyceride levels;
PAAD	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.65	4.44	0.34	1.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.47	4.47	0.34	1.55e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
PAAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.86	9.23	0.6	2.24e-16	Cognitive function;
PAAD	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg01388757	chr2:102091195	RFX8	-0.66	-8.33	-0.56	4.44e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	0.99	6.11	0.44	7.9e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-6.63	-0.47	5.64e-10	Bipolar disorder;
PAAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg02640540	chr1:67518911	SLC35D1	-0.61	-4.83	-0.37	3.24e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.49	5.19	0.39	6.74e-7	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs11828289	0.660	rs79043125	chr11:23203646	T/A	cg20040320	chr11:23191996	NA	-0.77	-5.48	-0.41	1.75e-7	Cancer;
PAAD	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg02683114	chr2:24398427	C2orf84	-0.58	-6.2	-0.45	5.02e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9677476	0.909	rs10181602	chr2:232121642	G/C	cg07929768	chr2:232055508	NA	0.38	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs3206736	0.548	rs329243	chr7:35059716	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.6	-0.35	8.84e-6	Diastolic blood pressure;
PAAD	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.48	-4.96	-0.37	1.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.92	11.39	0.68	4.01e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13981034	chr14:21860709	SNORD9;CHD8	-0.66	-6.68	-0.48	4.31e-10	Obesity-related traits;
PAAD	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24915620	chr6:128903377	NA	-0.58	-6.75	-0.48	2.94e-10	Obesity-related traits;
PAAD	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.43	-4.59	-0.35	9.19e-6	Prostate cancer;
PAAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-4.74	-0.36	4.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.35	-0.33	2.48e-5	Childhood ear infection;
PAAD	cis	rs12620999	0.591	rs7597414	chr2:237957754	G/T	cg23555395	chr2:238036564	NA	0.46	5.02	0.38	1.43e-6	Systemic lupus erythematosus;
PAAD	cis	rs73198271	0.603	rs570364	chr8:8593638	G/T	cg01851573	chr8:8652454	MFHAS1	0.5	4.35	0.33	2.48e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.68	7.02	0.49	7.08e-11	Morning vs. evening chronotype;
PAAD	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.53	0.34	1.18e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.38	-0.34	2.16e-5	Tuberculosis;
PAAD	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.77	7.85	0.54	6.83e-13	Retinal vascular caliber;
PAAD	cis	rs7537660	0.704	rs4925741	chr1:248007696	A/G	cg00785941	chr1:248100591	OR2L13	-0.4	-4.81	-0.36	3.66e-6	Platelet distribution width;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.48	-0.47	1.21e-9	Bipolar disorder;
PAAD	cis	rs6782025	0.837	rs13319262	chr3:120889263	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg03676636	chr4:99064102	C4orf37	0.3	5.2	0.39	6.34e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.47	-5.54	-0.41	1.31e-7	Coronary artery disease;
PAAD	cis	rs9990220	0.586	rs9755930	chr3:112022870	A/G	cg01411366	chr3:112012867	SLC9A10	-0.3	-4.79	-0.36	3.92e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.64	5.18	0.39	6.83e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg18944383	chr4:111397179	ENPEP	0.65	7.18	0.5	2.82e-11	Coronary artery disease;
PAAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.65	-5.7	-0.42	6.01e-8	Coronary artery disease;
PAAD	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs7624766	0.714	rs7640348	chr3:160515470	A/G	cg22637730	chr3:160473554	PPM1L	0.54	4.92	0.37	2.21e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg08132940	chr7:1081526	C7orf50	-0.66	-4.74	-0.36	4.88e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.71	7.96	0.54	3.76e-13	Colorectal cancer;
PAAD	cis	rs4073221	0.654	rs34591568	chr3:18288424	C/T	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.69	-4.74	-0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.94	0.49	1.04e-10	Coffee consumption (cups per day);
PAAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.65	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06839820	chr22:43485161	TTLL1	0.58	6.43	0.46	1.6e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24468199	chr11:65410028	SIPA1	-0.51	-4.51	-0.34	1.27e-5	Blood pressure (age interaction);
PAAD	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.18	0.5	2.82e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg21918786	chr6:109611834	NA	-0.4	-4.41	-0.34	1.97e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01254234	chr15:44580517	CASC4	-0.5	-4.48	-0.34	1.44e-5	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-7.05	-0.5	5.79e-11	Asthma;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.58	-5.64	-0.42	7.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.09	-0.44	8.84e-9	Height;
PAAD	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.92	-0.37	2.19e-6	Self-reported allergy;
PAAD	cis	rs10186876	0.797	rs4953037	chr2:44149442	C/T	cg09541576	chr2:44873248	C2orf34	0.48	5.08	0.38	1.12e-6	Hand grip strength;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.82	9.58	0.61	2.74e-17	Age at first birth;
PAAD	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	5.87	0.43	2.69e-8	Blood metabolite levels;
PAAD	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.63	7.71	0.53	1.5e-12	Lung cancer;
PAAD	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.5	-5.21	-0.39	6.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2769264	0.649	rs9436029	chr1:151367378	C/T	cg18801370	chr1:151430492	POGZ	-0.87	-4.63	-0.35	7.87e-6	Blood trace element (Cu levels);
PAAD	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.7	6.61	0.47	6.25e-10	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.42	0.46	1.69e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg02917321	chr22:38215204	NA	-0.45	-4.82	-0.36	3.52e-6	Glioblastoma;Glioma;
PAAD	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg26554054	chr8:600488	NA	0.98	7.17	0.5	3.1e-11	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.96	-12.55	-0.71	3.07e-25	Height;
PAAD	cis	rs469568	0.556	rs462815	chr5:178687913	A/G	cg01624164	chr5:179498943	RNF130	-0.48	-4.36	-0.33	2.43e-5	Stroke (pediatric);
PAAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10556349	chr10:835070	NA	0.67	5.56	0.41	1.17e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	5.23	0.39	5.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs12450239	0.700	rs35693727	chr17:77438248	A/G	cg09567646	chr17:76962761	NA	-0.47	-4.42	-0.34	1.87e-5	Body mass index;
PAAD	cis	rs2387326	0.868	rs769005	chr10:129920241	C/T	cg16087940	chr10:129947807	NA	-0.53	-4.53	-0.34	1.2e-5	Select biomarker traits;
PAAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26850624	chr5:429559	AHRR	0.47	5.85	0.43	2.88e-8	Cystic fibrosis severity;
PAAD	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg10820045	chr2:198174542	NA	0.44	4.42	0.34	1.91e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6669119	0.651	rs79435445	chr1:19105023	C/T	cg13786083	chr1:19110734	NA	0.71	4.31	0.33	2.93e-5	Percentage gas trapping;
PAAD	cis	rs7705042	0.865	rs12653866	chr5:141489921	C/T	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.25	-0.39	5.02e-7	Asthma;
PAAD	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.62	4.85	0.37	2.99e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs1499972	0.941	rs56148567	chr3:117540528	A/G	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.75	6.7	0.48	3.84e-10	Schizophrenia;
PAAD	cis	rs9913156	0.748	rs72835635	chr17:4563127	A/G	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs12714314	0.635	rs1432541	chr2:1962153	A/G	cg22350835	chr2:1868857	MYT1L	0.49	4.95	0.37	1.98e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg23463467	chr20:60627584	TAF4	0.39	4.32	0.33	2.85e-5	Body mass index;
PAAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	8.25	0.56	7.15e-14	Platelet count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22482014	chr5:1087095	SLC12A7	0.61	7.3	0.51	1.51e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg17633681	chr16:88106987	BANP	0.65	8.21	0.55	8.92e-14	Menopause (age at onset);
PAAD	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.42e-5	Calcium levels;
PAAD	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg12940439	chr1:67600707	NA	0.54	6.1	0.44	8.45e-9	Psoriasis;
PAAD	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.48	-4.78	-0.36	4.16e-6	Hirschsprung disease;
PAAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs4740619	0.619	rs10962260	chr9:16039883	T/G	cg14451791	chr9:16040625	NA	-0.46	-5.17	-0.39	7.24e-7	Body mass index;
PAAD	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.79	-9.06	-0.59	6.15e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs527409	1.000	rs11207180	chr1:58722598	T/C	cg26345888	chr1:58716257	DAB1	0.64	4.3	0.33	3.01e-5	Kawasaki disease;
PAAD	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.76	7.28	0.51	1.68e-11	Obesity-related traits;
PAAD	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg26596419	chr16:1591503	IFT140;TMEM204	0.44	4.28	0.33	3.26e-5	Coronary artery disease;
PAAD	cis	rs861020	0.582	rs6675890	chr1:210022893	G/C	cg05527609	chr1:210001259	C1orf107	1.02	9.45	0.61	5.85e-17	Orofacial clefts;
PAAD	cis	rs7766436	0.648	rs2876643	chr6:22591525	C/A	cg13666174	chr6:22585274	NA	-0.51	-5.45	-0.4	1.99e-7	Coronary artery disease;
PAAD	trans	rs9860250	0.891	rs9844950	chr3:100689310	T/C	cg07896438	chr2:214053162	NA	0.79	6.3	0.46	3.09e-9	Optic disc area;
PAAD	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg02680254	chr11:34378975	ABTB2	0.46	4.3	0.33	3e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.65	-7.28	-0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.98	7.77	0.53	1.09e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.59	4.82	0.36	3.42e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.6	6.56	0.47	8.03e-10	Melanoma;
PAAD	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg23860436	chr12:58378763	NA	0.46	4.3	0.33	2.98e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.93	8.36	0.56	3.66e-14	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08802409	chr3:50649298	CISH	0.65	7.08	0.5	4.91e-11	Myopia (pathological);
PAAD	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg07204747	chr5:141030761	FCHSD1	0.47	4.27	0.33	3.44e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	19.36	0.84	7.03e-43	IgG glycosylation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18008467	chr2:236586710	AGAP1	-0.55	-6.43	-0.46	1.6e-9	Monocyte percentage of white cells;
PAAD	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7264396	0.887	rs2236159	chr20:34102189	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg12310025	chr6:25882481	NA	0.49	4.5	0.34	1.37e-5	Iron status biomarkers;
PAAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg00717180	chr2:96193071	NA	-0.65	-7.85	-0.54	6.83e-13	Height;
PAAD	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.48	-4.83	-0.36	3.34e-6	Common traits (Other);
PAAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg23281280	chr6:28129359	ZNF389	0.6	4.69	0.36	6.13e-6	Parkinson's disease;
PAAD	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.77	-6.72	-0.48	3.51e-10	Blood metabolite levels;
PAAD	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs4668356	1.000	rs1035839	chr2:171809485	C/T	cg13882835	chr2:172017928	TLK1	-0.83	-4.25	-0.33	3.78e-5	Cognitive performance;
PAAD	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg13468214	chr4:1046988	NA	-0.52	-4.96	-0.37	1.9e-6	Recombination rate (females);
PAAD	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg01970496	chr2:177005398	NA	-0.51	-4.26	-0.33	3.53e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	trans	rs11794666	0.929	rs72717558	chr9:31710994	G/A	cg05628366	chr6:35744188	C6orf126	1.12	7.15	0.5	3.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.03	-0.63	1.73e-18	Morning vs. evening chronotype;
PAAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-5.51	-0.41	1.5e-7	Longevity;Endometriosis;
PAAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg26897989	chr16:1907736	C16orf73	0.46	4.76	0.36	4.38e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs494459	0.756	rs570806	chr11:118657311	C/A	cg08498647	chr11:118550644	TREH	-0.35	-4.28	-0.33	3.35e-5	Height;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21155852	chr7:2048760	MAD1L1	-0.41	-4.25	-0.33	3.72e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11264799	0.594	rs74229860	chr1:157788361	G/C	cg18268488	chr1:157545234	FCRL4	0.57	5.03	0.38	1.36e-6	IgA nephropathy;
PAAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.77	6.72	0.48	3.4e-10	Cognitive function;
PAAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.11	-0.38	9.49e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg04160749	chr8:58172571	NA	-0.68	-4.9	-0.37	2.44e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.19e-8	Menopause (age at onset);
PAAD	cis	rs12136530	0.593	rs12404362	chr1:19739958	A/G	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.59	-6.94	-0.49	1.04e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.99	10.91	0.66	7.77e-21	Multiple myeloma;
PAAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.64	5.8	0.43	3.77e-8	Blood metabolite levels;
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg06883089	chr1:45254480	BEST4	0.36	4.63	0.35	7.94e-6	High light scatter reticulocyte count;
PAAD	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg14631576	chr9:95140430	CENPP	-0.43	-4.29	-0.33	3.12e-5	Height;
PAAD	cis	rs9467160	0.953	rs13205577	chr6:24448648	A/T	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.75e-7	Liver enzyme levels;
PAAD	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26926768	chr12:34528122	NA	0.39	4.59	0.35	9.39e-6	Morning vs. evening chronotype;
PAAD	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg02683114	chr2:24398427	C2orf84	0.57	6.16	0.45	6.17e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3026101	0.671	rs12603639	chr17:5320808	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	6.27	0.45	3.51e-9	Body mass index;
PAAD	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg02917321	chr22:38215204	NA	0.43	4.69	0.36	6.05e-6	Glioblastoma;Glioma;
PAAD	cis	rs3951016	0.514	rs283067	chr6:118620030	T/A	cg18833306	chr6:118973337	C6orf204	0.51	5.8	0.43	3.72e-8	Resting heart rate;
PAAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.56	7.36	0.51	1.1e-11	Renal cell carcinoma;
PAAD	cis	rs13065560	0.594	rs9858516	chr3:38891548	C/T	cg01426195	chr3:39028469	NA	-0.57	-5.91	-0.43	2.15e-8	Interleukin-18 levels;
PAAD	cis	rs4867766	0.789	rs17781920	chr5:173955939	G/A	cg20434911	chr5:173954559	NA	-0.66	-6.7	-0.48	3.82e-10	Stroke;
PAAD	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-5.04	-0.38	1.28e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.0	0.63	2.11e-18	Prudent dietary pattern;
PAAD	cis	rs6987853	0.636	rs6988165	chr8:42351176	C/G	cg09913449	chr8:42400586	C8orf40	-0.47	-5.01	-0.38	1.5e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg15123519	chr2:136567270	LCT	0.36	4.38	0.33	2.19e-5	Mosquito bite size;
PAAD	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg22830091	chr7:75961684	YWHAG	-0.43	-4.51	-0.34	1.27e-5	Multiple sclerosis;
PAAD	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.78	-8.24	-0.56	7.24e-14	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12394377	chr1:24514218	IL28RA	0.61	7.06	0.5	5.65e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.07	-0.44	9.98e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13369981	chr7:100027501	MEPCE;ZCWPW1	0.64	6.35	0.46	2.31e-9	Smoking initiation;
PAAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg04450456	chr4:17643702	FAM184B	0.52	5.87	0.43	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg23860436	chr12:58378763	NA	0.5	4.86	0.37	2.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12136530	0.593	rs4911990	chr1:19731873	A/C	cg03321592	chr1:19991676	HTR6	0.51	4.52	0.34	1.22e-5	Lead levels in blood;
PAAD	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg10518543	chr12:38710700	ALG10B	-0.52	-5.02	-0.38	1.42e-6	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05976119	chr12:56615697	RNF41	0.62	7.51	0.52	4.82e-12	Monocyte percentage of white cells;
PAAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	1.01	13.37	0.74	1.9e-27	Gestational age at birth (maternal effect);
PAAD	cis	rs11112613	0.609	rs4991814	chr12:106046709	G/A	cg03607813	chr12:105948248	NA	0.78	5.62	0.41	8.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	4.52	0.34	1.22e-5	Thyroid stimulating hormone;
PAAD	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.46	-5.24	-0.39	5.36e-7	Mean arterial pressure;
PAAD	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg11262906	chr1:85462892	MCOLN2	0.59	4.57	0.35	1e-5	Serum sulfate level;
PAAD	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.59	5.37	0.4	2.85e-7	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.33	0.46	2.62e-9	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.24	0.8	5e-35	Prudent dietary pattern;
PAAD	trans	rs901683	1.000	rs12761573	chr10:46079517	A/C	cg14076390	chr17:34947837	DHRS11	0.92	6.67	0.48	4.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg12560992	chr17:57184187	TRIM37	0.65	4.76	0.36	4.44e-6	Vitamin D levels;
PAAD	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.66	-4.64	-0.35	7.42e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9810890	1.000	rs6795293	chr3:128592669	C/T	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.58	6.83	0.48	1.92e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs59888335	0.862	rs13080256	chr3:80567748	A/T	cg21735741	chr3:80819488	NA	0.61	5.27	0.39	4.54e-7	Schizophrenia;
PAAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg21351543	chr2:191399470	TMEM194B	-0.58	-4.44	-0.34	1.69e-5	Diastolic blood pressure;
PAAD	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.82	5.33	0.4	3.41e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg07703079	chr11:430292	ANO9	0.92	5.78	0.42	4.2e-8	Body mass index;
PAAD	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.32	-0.51	1.34e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg00655913	chr1:228633920	NA	-0.51	-4.67	-0.35	6.51e-6	Adult asthma;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.64	-6.81	-0.48	2.14e-10	Ankylosing spondylitis;
PAAD	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.47	-0.41	1.85e-7	Total body bone mineral density;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.8	-0.48	2.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.51	4.97	0.37	1.75e-6	Menarche (age at onset);
PAAD	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg12395012	chr8:11607386	GATA4	0.41	4.29	0.33	3.18e-5	Triglycerides;
PAAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.75	-8.67	-0.58	5.95e-15	Prostate cancer;
PAAD	cis	rs2031532	0.544	rs3764089	chr13:50063238	C/T	cg08779649	chr13:50194554	NA	0.36	4.88	0.37	2.68e-6	Cardiac hypertrophy;
PAAD	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.65	6.06	0.44	1.04e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg12645284	chr15:79092878	ADAMTS7	0.5	4.37	0.33	2.31e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.24	0.45	4.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.28e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.51	4.28	0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg23708337	chr7:1209742	NA	0.67	5.05	0.38	1.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.59	6.27	0.45	3.53e-9	Longevity;
PAAD	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.69	-7.4	-0.51	8.77e-12	Neuroticism;
PAAD	cis	rs2764208	0.576	rs6906500	chr6:34692585	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.41	4.41	0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	trans	rs901683	0.850	rs112392416	chr10:46070466	C/T	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.76	8.0	0.54	3.03e-13	Itch intensity from mosquito bite;
PAAD	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.6	0.35	8.69e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.16	-0.39	7.68e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11671653	1.000	rs8113457	chr19:10832225	T/G	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs12900413	0.840	rs28700196	chr15:90297238	G/T	cg24249390	chr15:90295951	MESP1	-0.44	-4.25	-0.33	3.68e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.58	5.63	0.42	8.34e-8	Alcohol dependence;
PAAD	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09324608	chr17:30823087	MYO1D	-0.56	-5.67	-0.42	6.97e-8	Schizophrenia;
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg23298862	chr7:158159286	PTPRN2	0.56	4.72	0.36	5.41e-6	Response to amphetamines;
PAAD	cis	rs75920871	0.925	rs4938333	chr11:116930888	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.58	6.81	0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.6	5.83	0.43	3.24e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.58	-4.32	-0.33	2.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg19636519	chr7:99541626	NA	0.38	4.3	0.33	3.06e-5	Coronary artery disease;
PAAD	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg04995300	chr3:66848608	NA	0.43	4.57	0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs212524	0.623	rs212534	chr1:21590754	C/T	cg23992472	chr1:21503364	EIF4G3	-0.44	-4.48	-0.34	1.46e-5	Height;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.67	7.37	0.51	1e-11	Mean corpuscular volume;
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg01262667	chr19:19385393	TM6SF2	-0.43	-4.78	-0.36	4.06e-6	Tonsillectomy;
PAAD	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.44	-5.11	-0.38	9.55e-7	Itch intensity from mosquito bite;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs6785206	0.614	rs35732133	chr3:128476978	A/C	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs950880	0.645	rs11679889	chr2:102941009	G/A	cg23450938	chr2:102972792	NA	0.41	4.55	0.35	1.08e-5	Serum protein levels (sST2);
PAAD	cis	rs7326068	0.647	rs2818978	chr13:21319537	C/G	cg27234864	chr13:21295941	IL17D	0.59	4.94	0.37	2.04e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.8	6.22	0.45	4.61e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg25124228	chr12:125621409	AACS	-0.63	-6.11	-0.44	8.16e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	5.75	0.42	4.77e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg14703610	chr5:56206110	C5orf35	-0.56	-5.23	-0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg04330084	chr7:123175371	IQUB	-0.52	-4.54	-0.35	1.15e-5	Plateletcrit;Platelet count;
PAAD	cis	rs1656368	0.726	rs73154331	chr3:158258662	A/G	cg16708174	chr3:158430962	RARRES1	0.56	5.14	0.38	8.52e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.8	-5.12	-0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09424554	chr8:22445599	PDLIM2	0.67	6.69	0.48	4.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13253111	0.624	rs1979330	chr8:28096051	T/A	cg26534493	chr8:28060551	NA	0.41	4.57	0.35	9.91e-6	Childhood body mass index;
PAAD	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.74	-0.48	3.02e-10	Capecitabine sensitivity;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	4.25	0.33	3.67e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg19680485	chr15:31195859	MTMR15	-0.51	-5.04	-0.38	1.33e-6	Huntington's disease progression;
PAAD	cis	rs11807834	0.522	rs10864687	chr1:230237142	C/T	cg09847368	chr1:230250326	GALNT2	-0.67	-8.06	-0.55	2.1e-13	Schizophrenia;
PAAD	cis	rs7259965	0.804	rs2054675	chr19:41495755	T/C	cg20630647	chr19:41531805	NA	0.47	4.26	0.33	3.54e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.73	-6.62	-0.47	5.76e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1983170	0.668	rs77687738	chr1:92016191	C/G	cg07011357	chr1:92949813	GFI1	-0.53	-4.32	-0.33	2.76e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.84e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg00738919	chr7:1100172	C7orf50	0.71	5.03	0.38	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.96	-9.99	-0.63	2.24e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.93	11.62	0.69	9.88e-23	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.52	-6.67	-0.48	4.38e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg13264159	chr8:625131	ERICH1	-0.75	-4.99	-0.37	1.66e-6	IgG glycosylation;
PAAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.66	-7.39	-0.51	9.18e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	6.0	0.44	1.38e-8	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg18888403	chr1:24152774	HMGCL	0.4	4.53	0.35	1.17e-5	Immature fraction of reticulocytes;
PAAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.42	-4.78	-0.36	4.07e-6	Height;
PAAD	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg12623918	chr2:306882	NA	0.46	4.79	0.36	3.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.44	5.64	0.42	8.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	1.97e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4746818	0.579	rs79229724	chr10:70953872	C/T	cg11621586	chr10:70884670	VPS26A	-1.17	-5.85	-0.43	2.92e-8	Left atrial antero-posterior diameter;
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg03289416	chr15:75166202	SCAMP2	0.53	5.6	0.41	9.74e-8	Breast cancer;
PAAD	cis	rs9652601	0.691	rs9939397	chr16:11209764	A/G	cg04616529	chr16:11181986	CLEC16A	0.36	4.4	0.34	2e-5	Systemic lupus erythematosus;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.0	-0.44	1.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.48	5.28	0.39	4.34e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg12826209	chr6:26865740	GUSBL1	0.74	4.33	0.33	2.74e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.66	-7.34	-0.51	1.2e-11	Neuroticism;
PAAD	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	4.99	0.38	1.61e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.72	5.92	0.43	2.09e-8	Common traits (Other);
PAAD	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.74	-6.18	-0.45	5.68e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg18209359	chr17:80159595	CCDC57	0.44	4.44	0.34	1.69e-5	Life satisfaction;
PAAD	cis	rs6499755	0.712	rs31105	chr16:55375723	C/T	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg18281939	chr5:77783895	LHFPL2	0.5	5.66	0.42	7.26e-8	Triglycerides;
PAAD	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.99	11.37	0.68	4.72e-22	Multiple myeloma;
PAAD	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg04156016	chr5:1868137	NA	0.43	4.37	0.33	2.26e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.37	4.35	0.33	2.52e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4795519	0.569	rs2176132	chr17:22185887	T/C	cg22648282	chr17:21454238	C17orf51	-0.5	-4.62	-0.35	8.1e-6	Chronic myeloid leukemia;
PAAD	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.15	8.55	0.57	1.22e-14	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13316171	chr2:187351035	ZC3H15	0.67	6.79	0.48	2.4e-10	Obesity-related traits;
PAAD	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-4.44	-0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.53	5.02	0.38	1.41e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs501120	0.810	rs535176	chr10:44747059	C/T	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22213235	chr4:748946	PCGF3	0.56	6.69	0.48	4.04e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.45	-4.82	-0.36	3.46e-6	Major depressive disorder;
PAAD	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	trans	rs7172971	0.688	rs7165460	chr15:42382873	A/G	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.67	0.42	6.9e-8	Coronary artery disease;
PAAD	cis	rs7534824	0.625	rs61780287	chr1:101382744	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-4.73	-0.36	5.16e-6	Joint mobility (Beighton score);
PAAD	cis	rs10768122	0.933	rs3794103	chr11:35291714	G/A	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.29	-0.33	3.13e-5	Vitiligo;
PAAD	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	7.93	0.54	4.48e-13	Caffeine consumption;
PAAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg15847926	chr7:2749597	AMZ1	-0.38	-4.82	-0.36	3.43e-6	Height;
PAAD	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs3736485	0.934	rs4775956	chr15:51882638	G/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.84	6.78	0.48	2.55e-10	Chronic kidney disease;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg02555727	chr12:129281546	SLC15A4	0.44	4.71	0.36	5.47e-6	Systemic lupus erythematosus;
PAAD	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	9.02e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00933542	chr6:150070202	PCMT1	0.58	5.95	0.43	1.76e-8	Lung cancer;
PAAD	cis	rs2133450	0.712	rs13090234	chr3:7365244	T/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.24	-0.39	5.2e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg19264203	chr11:92714893	MTNR1B	0.42	4.78	0.36	4.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2882667	0.690	rs9327829	chr5:138261671	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.75	-0.42	4.7e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-5.37	-0.4	2.91e-7	Body mass index;
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.65	-7.71	-0.53	1.49e-12	Longevity;Endometriosis;
PAAD	cis	rs911119	0.955	rs8115417	chr20:23605223	T/A	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.68	7.17	0.5	3.03e-11	Body mass index;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-5.11	-0.38	9.46e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg00522288	chr12:125625016	AACS	-0.43	-4.32	-0.33	2.85e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg00990874	chr7:1149470	C7orf50	-0.49	-4.29	-0.33	3.23e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.48	5.35	0.4	3.22e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.4	4.81	0.36	3.55e-6	Hemoglobin concentration;
PAAD	trans	rs901683	0.572	rs17157859	chr10:45989409	T/C	cg11747279	chr17:21096632	NA	0.91	6.76	0.48	2.77e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7187994	0.848	rs60566983	chr16:84774799	A/G	cg07647771	chr16:84786436	USP10	-0.35	-4.28	-0.33	3.24e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg12463550	chr7:65579703	CRCP	0.87	5.57	0.41	1.12e-7	Diabetic kidney disease;
PAAD	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06753367	chr22:24256600	NA	-0.46	-4.87	-0.37	2.77e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	10.15	0.64	8.16e-19	Bone mineral density;
PAAD	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg10072921	chr12:121022843	NA	-0.4	-4.78	-0.36	4.13e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.6	-6.24	-0.45	4.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.58	5.7	0.42	6.04e-8	Blood metabolite levels;
PAAD	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg19949948	chr17:19361230	NA	0.43	4.67	0.35	6.56e-6	Schizophrenia;
PAAD	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.6	5.51	0.41	1.48e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.71	0.48	3.56e-10	Height;
PAAD	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg01612440	chr4:3296283	NA	0.45	4.45	0.34	1.63e-5	Serum sulfate level;
PAAD	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.53	-0.41	1.34e-7	Intelligence;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.16	-0.39	7.45e-7	Mood instability;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.58	0.57	1.02e-14	Alzheimer's disease;
PAAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.5	0.34	1.33e-5	Tonsillectomy;
PAAD	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	1.1	15.47	0.78	5.13e-33	Breast cancer;
PAAD	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.5	5.22	0.39	5.87e-7	Type 2 diabetes;
PAAD	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg26935685	chr1:15502881	TMEM51	-0.55	-4.89	-0.37	2.59e-6	Systolic blood pressure;
PAAD	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg18402987	chr7:1209562	NA	1.1	5.53	0.41	1.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.78	-8.2	-0.55	9.49e-14	Neurofibrillary tangles;
PAAD	cis	rs300774	0.925	rs397911	chr2:147317	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.66	6.24	0.45	4.14e-9	Obesity-related traits;
PAAD	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg01244601	chr4:120671846	NA	-0.5	-4.37	-0.33	2.3e-5	Corneal astigmatism;
PAAD	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.38	4.7	0.36	5.68e-6	Sitting height ratio;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.58	4.95	0.37	1.93e-6	Response to diuretic therapy;
PAAD	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.58	-6.02	-0.44	1.25e-8	Type 2 diabetes;
PAAD	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.7	7.12	0.5	3.96e-11	Morning vs. evening chronotype;
PAAD	cis	rs57994353	0.600	rs4400499	chr9:139305041	C/T	cg14169450	chr9:139327907	INPP5E	0.52	4.32	0.33	2.82e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.6	6.1	0.44	8.37e-9	Multiple sclerosis;
PAAD	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Vitiligo;
PAAD	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.74	8.04	0.55	2.33e-13	Lewy body disease;
PAAD	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.41	0.4	2.45e-7	Red blood cell count;
PAAD	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.73	-10.2	-0.64	6.24e-19	Late-onset Alzheimer's disease;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg10729496	chr3:10149963	C3orf24	0.9	6.62	0.47	5.69e-10	Alzheimer's disease;
PAAD	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg19264203	chr11:92714893	MTNR1B	0.41	4.64	0.35	7.35e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.46	-0.4	1.91e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg14092988	chr3:52407081	DNAH1	0.45	5.73	0.42	5.23e-8	Bipolar disorder;
PAAD	cis	rs797680	0.856	rs6682670	chr1:93649732	A/G	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.04	-0.55	2.35e-13	Coronary artery disease;
PAAD	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-1.11	-7.56	-0.52	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs3736485	0.966	rs7176044	chr15:51895343	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.86e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs10821973	0.527	rs4266956	chr10:64026108	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.41	-0.34	1.95e-5	Hypothyroidism;
PAAD	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg05110241	chr16:68378359	PRMT7	-0.95	-7.52	-0.52	4.45e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-1.16	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs7168353	0.519	rs7162381	chr15:93636440	T/G	cg12595281	chr15:93633172	RGMA	0.39	5.06	0.38	1.21e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.65	-5.71	-0.42	5.66e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.68	6.44	0.46	1.52e-9	Platelet count;
PAAD	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.6	-5.78	-0.42	4.16e-8	Adiposity;
PAAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg24130564	chr14:104152367	KLC1	-0.56	-5.44	-0.4	2.13e-7	Reticulocyte count;
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9549328	0.796	rs7993665	chr13:113651132	T/C	cg25790453	chr13:113633590	MCF2L	-0.38	-4.49	-0.34	1.37e-5	Systolic blood pressure;
PAAD	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg18939081	chr1:31884902	SERINC2	0.47	5.24	0.39	5.36e-7	Alcohol dependence;
PAAD	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg03808351	chr9:123631620	PHF19	0.45	4.86	0.37	2.85e-6	Rheumatoid arthritis;
PAAD	cis	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg21401794	chr1:90099060	LRRC8C	0.52	4.89	0.37	2.52e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2964802	0.505	rs11133627	chr5:10830474	T/G	cg14521931	chr5:10832172	NA	-0.47	-4.91	-0.37	2.31e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg23283495	chr1:209979779	IRF6	-0.5	-6.12	-0.44	7.58e-9	Monobrow;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.49e-10	Platelet count;
PAAD	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	6.62	0.47	5.7e-10	Body mass index (adult);
PAAD	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg18064842	chr5:14874549	NA	-0.45	-4.37	-0.33	2.29e-5	Blood metabolite levels;
PAAD	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg18944383	chr4:111397179	ENPEP	0.65	7.19	0.5	2.75e-11	Coronary artery disease;
PAAD	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.66	6.04	0.44	1.15e-8	Platelet count;
PAAD	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.59	4.68	0.35	6.29e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.7	6.0	0.44	1.36e-8	Height;
PAAD	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg25828445	chr12:7781288	NA	0.77	5.48	0.41	1.7e-7	HDL cholesterol levels;
PAAD	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg03568305	chr17:38183559	MED24;SNORD124	-0.44	-5.91	-0.43	2.19e-8	White blood cell count;
PAAD	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg08603382	chr10:743973	NA	-0.45	-4.26	-0.33	3.52e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.82	0.48	2.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg06521331	chr12:34319734	NA	-0.44	-4.58	-0.35	9.52e-6	Resting heart rate;
PAAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg07617317	chr6:118971624	C6orf204	0.57	4.75	0.36	4.72e-6	Diastolic blood pressure;
PAAD	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.61	-6.15	-0.45	6.51e-9	Post bronchodilator FEV1;
PAAD	cis	rs787274	0.867	rs1711747	chr9:115452286	T/C	cg13803584	chr9:115635662	SNX30	0.79	4.71	0.36	5.45e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.61	-6.87	-0.49	1.55e-10	Sense of smell;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.62e-7	Bipolar disorder;
PAAD	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18297960	chr7:1142765	C7orf50	-0.54	-4.25	-0.33	3.73e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05320259	chr20:25370897	ABHD12	0.58	6.39	0.46	1.93e-9	Metabolite levels  (X-11787);
PAAD	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.98	13.71	0.74	2.27e-28	Heart rate;
PAAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	1.33	6.91	0.49	1.27e-10	Prostate cancer;
PAAD	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg08345082	chr10:99160200	RRP12	-0.32	-4.32	-0.33	2.75e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg00576331	chr11:65640516	EFEMP2	0.6	5.31	0.4	3.8e-7	DNA methylation (variation);
PAAD	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg14851346	chr12:38532713	NA	0.46	4.52	0.34	1.24e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.59	0.35	9.12e-6	Refractive astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16293817	chr20:55101347	GCNT7	-0.64	-7.04	-0.5	6.03e-11	Obesity-related traits;
PAAD	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.85	-0.43	2.87e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.83	8.73	0.58	4.16e-15	Prostate cancer;
PAAD	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg06618935	chr21:46677482	NA	-0.59	-7.36	-0.51	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.51	-5.14	-0.38	8.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg07617317	chr6:118971624	C6orf204	-0.54	-4.51	-0.34	1.3e-5	Diastolic blood pressure;
PAAD	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.95	-8.84	-0.58	2.19e-15	Body mass index;
PAAD	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.48	-5.22	-0.39	5.87e-7	Ulcerative colitis;
PAAD	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.92	7.99	0.54	3.07e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.67	-5.48	-0.41	1.74e-7	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4719841	0.651	rs7789194	chr7:25992510	T/C	cg24254488	chr7:25991654	NA	-0.31	-4.42	-0.34	1.88e-5	Triglyceride levels;
PAAD	cis	rs6604026	0.740	rs6700585	chr1:93364156	T/G	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	8.65	0.57	6.88e-15	Cognitive test performance;
PAAD	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg00543991	chr22:32367038	NA	1.22	7.4	0.51	8.55e-12	Childhood ear infection;
PAAD	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.61	-5.99	-0.44	1.43e-8	Fibrinogen levels;
PAAD	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.75	9.65	0.62	1.76e-17	Obesity (extreme);
PAAD	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg22185043	chr18:12947723	SEH1L	0.63	6.39	0.46	1.95e-9	Primary biliary cholangitis;
PAAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14895029	chr7:2775587	GNA12	-0.43	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs2662368	0.542	rs10942833	chr5:77122846	C/T	cg02570643	chr5:77531473	AP3B1	-0.43	-4.58	-0.35	9.44e-6	Platelet distribution width;
PAAD	cis	rs12220238	1.000	rs79952914	chr10:75907464	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.78	4.28	0.33	3.26e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.63	4.28	0.33	3.27e-5	Vitiligo;
PAAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.86	9.91	0.63	3.71e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	4.9e-14	Prudent dietary pattern;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06348038	chr1:207038460	IL20	-0.61	-7.12	-0.5	4.04e-11	Body fat percentage;
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg07511668	chr11:68622177	NA	0.39	4.33	0.33	2.67e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.81	8.71	0.58	4.78e-15	Corneal astigmatism;
PAAD	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg19254793	chr6:44695348	NA	-0.47	-4.45	-0.34	1.65e-5	Total body bone mineral density;
PAAD	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.62	5.91	0.43	2.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg11088901	chr6:166572345	T	-0.49	-4.45	-0.34	1.62e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13094219	chr2:46926190	SOCS5	0.64	6.6	0.47	6.46e-10	Obesity-related traits;
PAAD	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs11264799	0.817	rs58517866	chr1:157669580	T/A	cg18268488	chr1:157545234	FCRL4	0.57	5.33	0.4	3.51e-7	IgA nephropathy;
PAAD	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	1.97e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	5.23	0.39	5.44e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg23461800	chr14:103021989	NA	-0.59	-4.88	-0.37	2.68e-6	Platelet count;
PAAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.81	-8.42	-0.56	2.63e-14	Body mass index;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg15117754	chr3:10150083	C3orf24	0.75	6.74	0.48	3.09e-10	Alzheimer's disease;
PAAD	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.86	-0.49	1.64e-10	Type 2 diabetes;
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.65	6.89	0.49	1.41e-10	Testicular germ cell tumor;
PAAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.51	6.2	0.45	5.07e-9	Monobrow;
PAAD	cis	rs7705042	0.897	rs249681	chr5:141538017	G/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-4.49	-0.34	1.38e-5	Asthma;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg20007245	chr22:24372913	LOC391322	-0.81	-8.34	-0.56	4.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs35164067	1.000	rs11085730	chr19:10497976	G/A	cg07306197	chr19:9546377	ZNF266	0.57	4.33	0.33	2.66e-5	Inflammatory bowel disease;
PAAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	trans	rs3905000	1.000	rs7043581	chr9:107649984	A/G	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs1957429	1.000	rs1957431	chr14:65353187	A/G	cg23373153	chr14:65346875	NA	1.02	7.15	0.5	3.49e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.52	-5.28	-0.39	4.38e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6976053	0.868	rs7783457	chr7:100471595	A/G	cg22425096	chr7:100417404	EPHB4	0.51	4.44	0.34	1.69e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.47	4.34	0.33	2.61e-5	White matter hyperintensity burden;
PAAD	cis	rs863345	0.604	rs6669271	chr1:158471999	A/G	cg12129480	chr1:158549410	OR10X1	-0.38	-4.42	-0.34	1.85e-5	Pneumococcal bacteremia;
PAAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.69	8.09	0.55	1.73e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02581909	chr20:56964033	VAPB	-0.57	-6.47	-0.46	1.3e-9	Body fat percentage;
PAAD	cis	rs17407555	0.821	rs73222526	chr4:10203917	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.19	-0.39	6.62e-7	Schizophrenia (age at onset);
PAAD	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14180030	chr9:123475675	MEGF9	-0.4	-4.38	-0.33	2.22e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3018712	0.522	rs11228322	chr11:68445688	T/C	cg02340541	chr11:68451699	GAL	-0.46	-4.61	-0.35	8.62e-6	Total body bone mineral density;
PAAD	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Morning vs. evening chronotype;
PAAD	cis	rs4740619	0.661	rs769151	chr9:15947240	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.04	-0.38	1.28e-6	Body mass index;
PAAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg22143856	chr6:28129313	ZNF389	0.65	5.11	0.38	9.57e-7	Depression;
PAAD	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.69	-0.42	6.44e-8	Mean corpuscular volume;
PAAD	cis	rs7631605	0.905	rs9869432	chr3:37196601	A/G	cg17445812	chr3:36986805	TRANK1	0.33	4.44	0.34	1.7e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs557074	0.861	rs9379077	chr6:7167170	C/T	cg01785233	chr6:7260807	NA	-0.53	-4.63	-0.35	7.82e-6	Monocyte count;
PAAD	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg09659197	chr4:152720779	NA	0.41	5.85	0.43	2.91e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg04851639	chr8:1020857	NA	-0.62	-7.76	-0.53	1.15e-12	Schizophrenia;
PAAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.41	0.34	1.91e-5	Personality dimensions;
PAAD	cis	rs1497828	0.956	rs2646803	chr1:217522466	A/G	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.55	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs7246865	0.510	rs6512161	chr19:17171582	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.72	0.42	5.37e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.78	7.88	0.54	5.69e-13	Total body bone mineral density;
PAAD	cis	rs2296225	0.722	rs6668854	chr1:21045508	C/A	cg13843611	chr1:20143089	RNF186	-0.55	-4.28	-0.33	3.36e-5	Eosinophilic esophagitis;
PAAD	cis	rs16975963	0.843	rs73025630	chr19:38351284	G/A	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg08898775	chr15:59042684	ADAM10	0.45	5.88	0.43	2.57e-8	Schizophrenia;
PAAD	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.46	-0.34	1.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg14343924	chr8:8086146	FLJ10661	0.57	5.3	0.4	3.96e-7	Mood instability;
PAAD	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.6	-6.27	-0.45	3.61e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.73	6.68	0.48	4.16e-10	Obesity-related traits;
PAAD	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.62	6.77	0.48	2.6200000000000003e-10	Leprosy;
PAAD	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.57	-4.32	-0.33	2.86e-5	Prostate cancer;
PAAD	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.23	-14.72	-0.77	4.7e-31	Ulcerative colitis;
PAAD	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg20487152	chr13:99095054	FARP1	0.56	4.79	0.36	3.86e-6	Neuroticism;
PAAD	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.61	-5.96	-0.44	1.67e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg17347104	chr14:75034677	LTBP2	-0.49	-4.84	-0.37	3.21e-6	Caffeine consumption;
PAAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03934478	chr11:495069	RNH1	1.06	5.35	0.4	3.24e-7	Body mass index;
PAAD	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg06217071	chr17:408420	NA	0.64	7.05	0.5	5.94e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg19767477	chr5:127420684	SLC12A2	-0.6	-4.86	-0.37	2.94e-6	Ileal carcinoids;
PAAD	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg04055981	chr11:115044050	NA	-0.44	-4.68	-0.36	6.21e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.1e-7	Schizophrenia;
PAAD	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.49	4.39	0.34	2.13e-5	Anterior chamber depth;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg22764044	chr5:178986830	RUFY1	-0.57	-6.14	-0.45	6.87e-9	Lung cancer;
PAAD	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg03700679	chr2:178418002	TTC30B	-0.57	-4.54	-0.35	1.13e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11825685	0.806	rs11826073	chr11:134579241	G/A	cg06603561	chr11:134479413	NA	-0.6	-4.64	-0.35	7.51e-6	IgG glycosylation;
PAAD	cis	rs498136	0.871	rs1586344	chr11:69376710	T/A	cg24388239	chr11:68438018	NA	-0.42	-4.45	-0.34	1.64e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg14393609	chr7:65229607	NA	-0.67	-7.35	-0.51	1.11e-11	Aortic root size;
PAAD	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg11822372	chr1:151115635	SEMA6C	0.55	5.15	0.39	8.07e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.3	-0.51	1.51e-11	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.47	-4.82	-0.36	3.38e-6	Motion sickness;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26320663	chr1:152161521	NA	0.5	4.94	0.37	2.06e-6	Inflammatory skin disease;
PAAD	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.46	-0.34	1.61e-5	Educational attainment;
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.45	4.84	0.37	3.15e-6	Yeast infection;
PAAD	cis	rs6466055	0.661	rs2299328	chr7:104905588	A/T	cg04380332	chr7:105027541	SRPK2	0.52	5.15	0.39	8.12e-7	Schizophrenia;
PAAD	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.25	-8.55	-0.57	1.21e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg00629941	chr15:75287862	SCAMP5	-0.57	-4.33	-0.33	2.67e-5	Blood trace element (Zn levels);
PAAD	cis	rs939584	1.000	rs7576635	chr2:625057	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg26875137	chr12:53738046	NA	-0.48	-4.72	-0.36	5.31e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.52	5.41	0.4	2.43e-7	Number of children ever born;
PAAD	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs10956805	0.544	rs2657197	chr8:92531120	C/T	cg00865390	chr8:91713322	NA	-0.39	-4.42	-0.34	1.85e-5	Subjective well-being (multi-trait analysis);Depressive symptoms (multi-trait analysis);
PAAD	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.55	-5.17	-0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.21	6.46	0.46	1.37e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.32	0.33	2.76e-5	Educational attainment (years of education);
PAAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.65	6.87	0.49	1.53e-10	Crohn's disease;
PAAD	cis	rs10875746	0.729	rs1990028	chr12:48408013	A/G	cg26205652	chr12:48591994	NA	0.78	7.63	0.53	2.41e-12	Longevity (90 years and older);
PAAD	cis	rs6066825	0.532	rs6012506	chr20:47285637	A/G	cg18078177	chr20:47281410	PREX1	0.49	4.72	0.36	5.41e-6	Colorectal cancer;
PAAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.11	-8.47	-0.57	1.99e-14	Diabetic kidney disease;
PAAD	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.73	-0.42	5.2100000000000003e-08	Glomerular filtration rate (creatinine);
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14159672	chr1:205819179	PM20D1	0.52	4.94	0.37	2.04e-6	Prostate-specific antigen levels;
PAAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg03303774	chr4:1407052	NA	0.48	6.09	0.44	8.79e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.82	-0.36	3.48e-6	Life satisfaction;
PAAD	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg22815214	chr1:201083145	CACNA1S	-0.56	-4.82	-0.36	3.43e-6	Permanent tooth development;
PAAD	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	1.11	7.91	0.54	5.06e-13	Mitochondrial DNA levels;
PAAD	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg14092988	chr3:52407081	DNAH1	0.58	7.32	0.51	1.37e-11	Bipolar disorder;
PAAD	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg01426195	chr3:39028469	NA	-0.74	-8.5	-0.57	1.68e-14	Handedness;
PAAD	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.49	-5.31	-0.4	3.82e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs35123781	0.502	rs355157	chr5:138993415	T/C	cg26929925	chr5:138714136	SLC23A1	-0.52	-4.85	-0.37	3.09e-6	Schizophrenia;
PAAD	trans	rs62179067	1.000	rs62175448	chr2:179990206	C/T	cg23458843	chr12:58136445	AGAP2	0.96	6.38	0.46	2.06e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.57	-5.2	-0.39	6.35e-7	Diastolic blood pressure;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.5	-7.01	-0.49	7.23e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19623624	chr10:135278901	LOC619207	-0.42	-4.41	-0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11748319	chr10:5708674	ASB13	0.62	6.54	0.47	8.89e-10	Myopia (pathological);
PAAD	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.42e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	4.35	0.33	2.48e-5	Height;
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.64	4.97	0.37	1.81e-6	Initial pursuit acceleration;
PAAD	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.45	-0.34	1.64e-5	Joint mobility (Beighton score);
PAAD	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.64	-0.35	7.4e-6	Lung cancer in ever smokers;
PAAD	cis	rs494459	0.838	rs567680	chr11:118608532	C/G	cg08498647	chr11:118550644	TREH	-0.39	-4.92	-0.37	2.27e-6	Height;
PAAD	trans	rs111756027	0.679	rs72800078	chr16:77308600	G/A	cg21624833	chr8:49111711	NA	0.99	6.29	0.45	3.27e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg01388757	chr2:102091195	RFX8	-0.65	-8.24	-0.56	7.3e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.5	-0.41	1.54e-7	Blood metabolite levels;
PAAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.81	6.98	0.49	8.49e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.95	-16.15	-0.79	8.67e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.19e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13198984	chr17:80129470	CCDC57	-0.43	-5.47	-0.41	1.82e-7	Life satisfaction;
PAAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg03030879	chr14:75389066	RPS6KL1	0.41	4.26	0.33	3.63e-5	Height;
PAAD	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg01868782	chr6:126071099	HEY2	-0.45	-5.38	-0.4	2.72e-7	Brugada syndrome;
PAAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23262073	chr20:60523788	NA	-0.44	-4.42	-0.34	1.9e-5	Body mass index;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.85	9.74	0.62	9.86e-18	Iron status biomarkers;
PAAD	cis	rs6504340	0.739	rs872760	chr17:46668951	A/G	cg14263884	chr17:46048822	CDK5RAP3	0.59	4.26	0.33	3.56e-5	Primary tooth development (number of teeth);
PAAD	cis	rs16895831	0.519	rs12210135	chr6:42570156	G/T	cg10605015	chr6:42532144	UBR2	-0.66	-5.0	-0.38	1.59e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.61	4.6	0.35	8.77e-6	Fat distribution (HIV);
PAAD	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	1.03	14.7	0.77	5.27e-31	Metabolite levels;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.48	7.63	0.53	2.37e-12	IgG glycosylation;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	6.24	0.45	4.07e-9	Lung function (FEV1/FVC);
PAAD	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.96	14.21	0.76	1.08e-29	Dental caries;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.65	-6.95	-0.49	9.86e-11	Coronary artery disease;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg19626725	chr5:178986131	RUFY1	0.53	5.61	0.41	9.47e-8	Lung cancer;
PAAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg16766828	chr3:128327626	NA	0.47	6.27	0.45	3.57e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg23093090	chr10:104574429	C10orf26	-0.46	-5.01	-0.38	1.48e-6	Arsenic metabolism;
PAAD	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.44	6.88	0.49	1.48e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.92	-7.7	-0.53	1.59e-12	Bipolar disorder;
PAAD	cis	rs939584	0.825	rs4423631	chr2:648758	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg00024416	chr22:24240387	NA	-0.47	-4.65	-0.35	7.02e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.88	10.69	0.66	2.98e-20	Menopause (age at onset);
PAAD	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg00982548	chr2:198649783	BOLL	-0.78	-5.54	-0.41	1.31e-7	Ulcerative colitis;
PAAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs258892	0.895	rs7702660	chr5:72044687	A/G	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.61	4.44	0.34	1.69e-5	Depression;
PAAD	cis	rs7084783	1.000	rs7084783	chr10:105324170	C/T	cg00126946	chr10:105363258	SH3PXD2A	-0.43	-4.35	-0.33	2.51e-5	Fear of pain;
PAAD	cis	rs4455778	0.580	rs6583508	chr7:49122331	C/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg13263323	chr15:86062960	AKAP13	-0.6	-6.9	-0.49	1.28e-10	Interstitial lung disease;
PAAD	cis	rs12760731	0.565	rs11585355	chr1:178181219	T/G	cg00404053	chr1:178313656	RASAL2	0.7	5.09	0.38	1.03e-6	Obesity-related traits;
PAAD	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-5.63	-0.42	8.59e-8	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.86	5.66	0.42	7.48e-8	Diabetic kidney disease;
PAAD	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs17407555	0.683	rs6823180	chr4:10275831	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.16	0.39	7.59e-7	Schizophrenia (age at onset);
PAAD	cis	rs864537	1.000	rs840015	chr1:167409114	G/A	cg22356347	chr1:167427500	CD247	-0.43	-4.45	-0.34	1.66e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg11494091	chr17:61959527	GH2	0.52	4.4	0.34	1.99e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.46	-4.42	-0.34	1.86e-5	Retinal vascular caliber;
PAAD	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-4.52	-0.34	1.24e-5	Breast cancer;
PAAD	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.91	-0.37	2.34e-6	Asthma;
PAAD	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.79	-8.37	-0.56	3.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05229649	chr10:102765404	LZTS2	0.57	6.69	0.48	4.13e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11105468	0.659	rs11105519	chr12:90544888	A/C	cg16962463	chr12:89968675	NA	0.45	4.78	0.36	4.09e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	1.2	8.82	0.58	2.45e-15	IgG glycosylation;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-5.49	-0.41	1.62e-7	Total body bone mineral density;
PAAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.41	-4.53	-0.34	1.21e-5	Lung cancer;
PAAD	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg13535736	chr9:111863775	C9orf5	-0.36	-4.56	-0.35	1.05e-5	Menarche (age at onset);
PAAD	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.71	-9.48	-0.61	5.02e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg09324608	chr17:30823087	MYO1D	0.47	4.61	0.35	8.43e-6	Schizophrenia;
PAAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg11764359	chr7:65958608	NA	0.78	5.22	0.39	5.82e-7	Diabetic kidney disease;
PAAD	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.59	-5.56	-0.41	1.18e-7	Height;
PAAD	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07147218	chr11:65769464	EIF1AD;BANF1	0.61	6.95	0.49	1.03e-10	Metabolite levels  (X-11787);
PAAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg00579200	chr11:133705235	NA	0.45	5.03	0.38	1.39e-6	Childhood ear infection;
PAAD	cis	rs6076065	0.723	rs7269627	chr20:23362727	A/T	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23213016	chr3:152880098	RAP2B	-0.62	-6.3	-0.46	3.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.11	0.5	4.29e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09657256	chr17:42153683	G6PC3	-0.58	-6.55	-0.47	8.39e-10	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	6.77	0.48	2.6200000000000003e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.93	-0.49	1.13e-10	Eye color traits;
PAAD	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.63	9.11	0.59	4.42e-16	Breast cancer;
PAAD	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.41	5.07	0.38	1.13e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-5.8	-0.43	3.71e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11264213	0.551	rs172081	chr1:36497498	T/G	cg27506609	chr1:36549197	TEKT2	1.13	6.83	0.48	1.96e-10	Schizophrenia;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.6	6.53	0.47	9.52e-10	Menarche (age at onset);
PAAD	trans	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg05993574	chr11:61129284	CYBASC3;TMEM138	0.62	6.33	0.46	2.58e-9	IgG glycosylation;
PAAD	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.69	6.84	0.48	1.85e-10	Uric acid levels;
PAAD	cis	rs41311933	1.000	rs41311897	chr9:123745816	T/C	cg13567360	chr9:123745713	C5	-0.72	-4.53	-0.34	1.21e-5	Coronary artery disease;
PAAD	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.84	-9.44	-0.61	6.12e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2274459	0.591	rs10947427	chr6:33644253	A/G	cg06253072	chr6:33679850	C6orf125	-0.62	-4.86	-0.37	2.92e-6	Obesity (extreme);
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-1.0	-8.15	-0.55	1.26e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2627282	0.569	rs73179541	chr8:2766017	C/A	cg21769514	chr8:2743697	NA	0.52	5.05	0.38	1.26e-6	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.87	-10.74	-0.66	2.25e-20	Aortic root size;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	4.59	0.35	9.18e-6	Eosinophil percentage of white cells;
PAAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.53	-5.87	-0.43	2.67e-8	Bipolar disorder;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.96	6.96	0.49	9.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.82	8.13	0.55	1.36e-13	Breast cancer;
PAAD	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs6693295	0.536	rs12132151	chr1:246229264	C/T	cg11798871	chr1:246315928	SMYD3	-0.77	-5.57	-0.41	1.11e-7	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.55	4.52	0.34	1.22e-5	Dementia with Lewy bodies;
PAAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12463550	chr7:65579703	CRCP	0.96	5.94	0.43	1.89e-8	Diabetic kidney disease;
PAAD	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-5.04	-0.38	1.31e-6	Neuroticism;
PAAD	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.45	4.4	0.34	2.01e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg26031613	chr14:104095156	KLC1	0.8	8.28	0.56	6e-14	Body mass index;
PAAD	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg03268063	chr7:1337281	NA	-0.5	-4.27	-0.33	3.48e-5	Neuroticism;
PAAD	cis	rs10821973	0.527	rs5006763	chr10:63977673	C/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.3	-0.33	3.06e-5	Hypothyroidism;
PAAD	cis	rs12615435	1.000	rs71424235	chr2:200639507	A/G	cg23649088	chr2:200775458	C2orf69	0.79	4.3	0.33	3.02e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs);
PAAD	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.26	0.56	6.56e-14	Height;
PAAD	cis	rs2518564	0.541	rs2852723	chr1:159073725	G/A	cg11003133	chr1:159046391	AIM2	0.63	4.28	0.33	3.34e-5	White blood cell count;
PAAD	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg17192377	chr18:44677553	HDHD2	0.62	4.37	0.33	2.28e-5	Sitting height ratio;
PAAD	cis	rs10465746	0.570	rs12402130	chr1:84479838	G/A	cg10977910	chr1:84465055	TTLL7	0.48	4.35	0.33	2.52e-5	Obesity-related traits;
PAAD	cis	rs2133450	0.712	rs17697952	chr3:7368066	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.23	-0.39	5.54e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.89	-11.44	-0.68	3.05e-22	Total body bone mineral density;
PAAD	cis	rs11690462	0.534	rs7571808	chr2:26572068	G/T	cg13255216	chr2:26625047	C2orf39	-0.44	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16497277	chr3:49208875	KLHDC8B	0.59	5.55	0.41	1.24e-7	Menarche (age at onset);
PAAD	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg18612461	chr15:75251733	NA	0.61	7.7	0.53	1.66e-12	Breast cancer;
PAAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2290419	0.730	rs57096576	chr11:68946781	C/T	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg24565620	chr2:194026	NA	-0.69	-5.28	-0.39	4.4e-7	Blood protein levels;
PAAD	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.45	-4.99	-0.38	1.64e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg00750074	chr16:89608354	SPG7	-0.5	-4.87	-0.37	2.81e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg19828298	chr1:3713105	LRRC47	0.56	6.34	0.46	2.46e-9	Metabolite levels  (X-11787);
PAAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg18230493	chr5:56204884	C5orf35	-0.57	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg17252645	chr8:143867129	LY6D	0.51	4.84	0.37	3.1e-6	Urinary tract infection frequency;
PAAD	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.2	6.92	0.49	1.18e-10	Type 2 diabetes nephropathy;
PAAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg07703079	chr11:430292	ANO9	0.77	4.36	0.33	2.4e-5	Body mass index;
PAAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.78	7.41	0.52	8.24e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.74	-7.27	-0.51	1.78e-11	DNA methylation (variation);
PAAD	cis	rs754423	0.600	rs754424	chr14:52527188	T/G	cg00766845	chr14:52536022	NID2	-0.54	-4.39	-0.34	2.13e-5	Craniofacial microsomia;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg04154034	chr17:28927549	LRRC37B2	0.64	4.28	0.33	3.25e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.46	0.34	1.6e-5	Educational attainment (years of education);
PAAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.71	6.03	0.44	1.18e-8	Inflammatory skin disease;
PAAD	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.85	10.3	0.64	3.33e-19	Lung cancer;
PAAD	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg05895507	chr15:77155635	SCAPER	-0.39	-4.52	-0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs3779195	0.858	rs3779196	chr7:97990106	T/C	cg24562669	chr7:97807699	LMTK2	0.51	4.86	0.37	2.91e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.53	-5.84	-0.43	3.03e-8	Testicular germ cell tumor;
PAAD	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.38e-5	Life satisfaction;
PAAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18621852	chr3:10150065	C3orf24	0.63	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.43	4.4	0.34	2.02e-5	Age of smoking initiation;
PAAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg01075559	chr1:2537774	MMEL1	0.52	5.44	0.4	2.13e-7	Ulcerative colitis;
PAAD	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg08736918	chr1:9241615	NA	-0.46	-4.4	-0.34	2.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.06	-0.38	1.2e-6	Common traits (Other);
PAAD	trans	rs901683	1.000	rs9422440	chr10:46045125	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.88	-0.37	2.71e-6	Menarche (age at onset);
PAAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.68	-5.72	-0.42	5.57e-8	Blood protein levels;
PAAD	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.55	5.76	0.42	4.62e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs6804624	0.654	rs6440606	chr3:99153006	T/G	cg02646433	chr3:99218170	NA	0.42	4.31	0.33	2.89e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg09168692	chr1:7887560	PER3	-0.43	-4.44	-0.34	1.7e-5	Inflammatory bowel disease;
PAAD	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg17842918	chr13:113540400	ATP11A	-0.42	-4.67	-0.35	6.54e-6	Interstitial lung disease;
PAAD	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.0	7.33	0.51	1.26e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.63e-6	Renal cell carcinoma;
PAAD	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.82	-9.22	-0.6	2.35e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg25790453	chr13:113633590	MCF2L	-0.4	-4.75	-0.36	4.66e-6	Systolic blood pressure;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg22189786	chr22:42395067	WBP2NL	-0.46	-5.09	-0.38	1.04e-6	Cognitive function;
PAAD	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg02745156	chr12:32552066	NA	0.42	4.36	0.33	2.34e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg00564555	chr16:1970112	NA	-0.38	-4.25	-0.33	3.64e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.62	7.16	0.5	3.15e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg13332499	chr17:408570	NA	0.73	9.14	0.6	3.78e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg20917491	chr3:195578259	NA	0.53	5.06	0.38	1.19e-6	Pancreatic cancer;
PAAD	cis	rs5015933	0.801	rs6478703	chr9:128141348	A/G	cg14078157	chr9:128172775	NA	0.39	4.47	0.34	1.55e-5	Body mass index;
PAAD	cis	rs17407555	0.710	rs10489072	chr4:10273244	T/C	cg00071950	chr4:10020882	SLC2A9	0.43	4.44	0.34	1.74e-5	Schizophrenia (age at onset);
PAAD	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.26	-0.33	3.57e-5	QT interval;
PAAD	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.36	-5.1	-0.38	9.88e-7	Educational attainment (years of education);
PAAD	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.67	5.89	0.43	2.39e-8	Common traits (Other);
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264213	0.686	rs625306	chr1:36454016	T/C	cg27506609	chr1:36549197	TEKT2	0.73	5.2	0.39	6.3e-7	Schizophrenia;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.74	-0.53	1.33e-12	Initial pursuit acceleration;
PAAD	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg09582351	chr12:29534625	ERGIC2	0.32	4.49	0.34	1.43e-5	QT interval;
PAAD	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.23	-0.39	5.49e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg23923672	chr12:105501055	KIAA1033	-0.7	-4.39	-0.34	2.12e-5	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18397137	chr19:59055873	TRIM28	0.72	7.51	0.52	4.59e-12	Obesity-related traits;
PAAD	cis	rs4883201	0.536	rs7974486	chr12:9131964	A/G	cg15384867	chr12:8995808	A2ML1	-0.54	-4.32	-0.33	2.76e-5	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs17209837	0.607	rs7789645	chr7:87122603	G/C	cg23688817	chr7:87105293	ABCB4	0.52	4.39	0.34	2.12e-5	Gallbladder cancer;
PAAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.96	11.94	0.7	1.35e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs9341808	0.587	rs3805859	chr6:81048946	C/A	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.74e-8	Life satisfaction;
PAAD	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.87	8.44	0.57	2.26e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.67	4.38	0.34	2.16e-5	Systolic blood pressure;
PAAD	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg09168692	chr1:7887560	PER3	-0.48	-4.76	-0.36	4.53e-6	Inflammatory bowel disease;
PAAD	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.57	0.52	3.41e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg04520793	chr17:42248056	ASB16	0.43	5.12	0.38	9.13e-7	Total body bone mineral density;
PAAD	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-1.23	-9.82	-0.62	6.33e-18	Post bronchodilator FEV1;
PAAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg10434728	chr15:90938212	IQGAP1	0.42	4.42	0.34	1.89e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.6	6.5	0.47	1.08e-9	Colorectal cancer;
PAAD	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg07810366	chr2:100720526	AFF3	0.35	4.26	0.33	3.62e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg09340386	chr2:1605954	NA	-0.63	-4.36	-0.33	2.43e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.76	9.44	0.61	6.36e-17	Lymphocyte counts;
PAAD	cis	rs35955747	0.902	rs5997938	chr22:31676992	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.99	14.76	0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs2268667	0.597	rs1403954	chr1:85940157	C/T	cg11648968	chr1:85931116	DDAH1	0.47	4.95	0.37	1.94e-6	Asymmetrical dimethylarginine levels;
PAAD	cis	rs9535307	0.719	rs1198319	chr13:50376858	T/C	cg03658251	chr13:50265850	EBPL	-0.82	-5.62	-0.42	8.68e-8	Obesity-related traits;
PAAD	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg02196655	chr2:10830764	NOL10	0.57	6.17	0.45	5.93e-9	Prostate cancer;
PAAD	cis	rs10512697	0.655	rs13170915	chr5:3511974	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.06	-0.38	1.2e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.39	-4.33	-0.33	2.66e-5	Prostate cancer;
PAAD	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13573980	chr1:223963249	CAPN2	0.66	6.55	0.47	8.49e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs990171	0.687	rs9989749	chr2:103123642	G/A	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg08975724	chr8:8085496	FLJ10661	0.47	4.81	0.36	3.67e-6	Joint mobility (Beighton score);
PAAD	cis	rs35110281	0.667	rs8133276	chr21:45126629	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-5.83	-0.43	3.22e-8	Mean corpuscular volume;
PAAD	cis	rs6076065	0.723	rs7988	chr20:23352685	C/A	cg11657817	chr20:23433608	CST11	0.5	5.26	0.39	4.74e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.92	-10.76	-0.66	1.98e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg06565975	chr8:143823917	SLURP1	-0.22	-5.02	-0.38	1.45e-6	Urinary tract infection frequency;
PAAD	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.58	5.06	0.38	1.19e-6	Interleukin-17 levels;
PAAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.45	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	9.34	0.6	1.15e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs7631605	0.905	rs3172297	chr3:37032370	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17215036	chr3:48129188	MAP4	0.63	6.73	0.48	3.21e-10	Myopia (pathological);
PAAD	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg04165759	chr1:150448943	RPRD2	-0.52	-5.34	-0.4	3.38e-7	Migraine;
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.17	-0.5	3.06e-11	Hemoglobin concentration;
PAAD	cis	rs834811	0.871	rs834819	chr7:135895281	G/A	cg01726295	chr7:135938950	NA	0.43	4.63	0.35	7.76e-6	Post-traumatic stress disorder;
PAAD	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.89	0.58	1.66e-15	Airflow obstruction;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00662400	chr16:88510783	NA	0.57	6.42	0.46	1.67e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05576016	chr12:12966271	DDX47	-0.73	-6.49	-0.47	1.18e-9	Neuroticism;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg00700412	chr12:58011837	NA	0.45	4.79	0.36	3.84e-6	Multiple sclerosis;
PAAD	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.74	-8.83	-0.58	2.4e-15	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13303377	chr17:78640245	RPTOR	-0.69	-7.49	-0.52	5.22e-12	Obesity-related traits;
PAAD	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.35	-4.52	-0.34	1.22e-5	Schizophrenia;
PAAD	cis	rs9810890	0.850	rs73198871	chr3:128537238	C/T	cg18531004	chr3:128564980	NA	-0.87	-5.01	-0.38	1.5e-6	Dental caries;
PAAD	cis	rs1451882	0.719	rs12541746	chr8:1052693	C/T	cg07395941	chr8:1078200	NA	0.62	4.62	0.35	8.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4711350	0.834	rs9461905	chr6:33721933	T/C	cg13859433	chr6:33739653	LEMD2	-0.59	-4.31	-0.33	2.96e-5	Schizophrenia;
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.9	-12.34	-0.71	1.11e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg00784671	chr22:46762841	CELSR1	-0.81	-4.43	-0.34	1.8e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.67	4.78	0.36	4.14e-6	Depression;
PAAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.33	-0.46	2.68e-9	Longevity;
PAAD	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.77	8.21	0.55	8.71e-14	Corneal astigmatism;
PAAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.75	8.42	0.56	2.62e-14	Longevity;
PAAD	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.33	0.4	3.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs655601	0.643	rs112702671	chr5:180220930	C/T	cg13724780	chr5:180237085	MGAT1	1.08	5.25	0.39	5.11e-7	Quantitative traits;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27558006	chr16:19563474	CP110	-0.68	-6.5	-0.47	1.08e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.36	0.33	2.41e-5	Bipolar disorder;
PAAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs728616	0.510	rs35671072	chr10:82172255	A/G	cg19423196	chr10:82049429	MAT1A	0.51	4.8	0.36	3.82e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.47	6.0	0.44	1.38e-8	Renal cell carcinoma;
PAAD	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.97	7.25	0.51	1.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08439880	chr3:133502540	NA	-0.5	-5.53	-0.41	1.37e-7	Iron status biomarkers;
PAAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	1.31	14.28	0.76	6.97e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs804280	0.544	rs804276	chr8:11625008	G/A	cg00405596	chr8:11794950	NA	0.44	4.87	0.37	2.74e-6	Myopia (pathological);
PAAD	cis	rs662064	0.748	rs2506889	chr1:10596022	C/T	cg17425144	chr1:10567563	PEX14	-0.39	-4.31	-0.33	2.87e-5	Asthma;
PAAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.69	-8.46	-0.57	2.09e-14	Bone mineral density;
PAAD	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg09127314	chr1:152161683	NA	0.75	5.43	0.4	2.16e-7	Atopic dermatitis;
PAAD	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.61	4.46	0.34	1.57e-5	Exhaled nitric oxide output;
PAAD	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs73195822	0.881	rs73194022	chr12:111137628	A/G	cg12870014	chr12:110450643	ANKRD13A	0.98	5.25	0.39	5.13e-7	Itch intensity from mosquito bite;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg15181151	chr6:150070149	PCMT1	-0.54	-5.82	-0.43	3.32e-8	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19680388	chr11:134118306	THYN1	-0.67	-6.88	-0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs16975963	0.793	rs73034929	chr19:38456697	T/C	cg14218481	chr19:38281219	NA	0.49	5.09	0.38	1.04e-6	Longevity;
PAAD	cis	rs4908768	0.657	rs4908778	chr1:8804888	C/G	cg25722041	chr1:8623473	RERE	0.53	4.57	0.35	9.92e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg14458575	chr2:238380390	NA	0.46	4.28	0.33	3.32e-5	Prostate cancer;
PAAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-7.79	-0.53	9.7e-13	Type 2 diabetes;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.67	-0.42	6.98e-8	Gut microbiome composition (summer);
PAAD	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.93	-0.37	2.17e-6	QT interval;
PAAD	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.09	-0.38	1.02e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7873102	0.654	rs3922775	chr9:37959397	C/T	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	7.96e-8	Brain structure;
PAAD	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15557168	chr22:42548783	NA	-0.5	-5.11	-0.38	9.4e-7	Cognitive function;
PAAD	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	7.98	0.54	3.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.69	-6.76	-0.48	2.84e-10	Callous-unemotional behaviour;
PAAD	cis	rs7567389	0.600	rs11691088	chr2:128131853	A/G	cg11380483	chr2:127933992	NA	0.49	4.73	0.36	5.12e-6	Self-rated health;
PAAD	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-5.72	-0.42	5.61e-8	Morning vs. evening chronotype;
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.59	-0.57	9.92e-15	Body mass index;
PAAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.61	0.35	8.51e-6	Height;
PAAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.76	-8.46	-0.57	2.11e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.81	9.84	0.62	5.62e-18	Blood metabolite ratios;
PAAD	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.48	-4.37	-0.33	2.32e-5	Red blood cell count;
PAAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Gut microbiome composition (summer);
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.5	5.31	0.4	3.81e-7	Electroencephalogram traits;
PAAD	cis	rs7830933	0.955	rs10101061	chr8:23593300	T/A	cg04349084	chr8:23602677	NA	0.41	4.41	0.34	1.95e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.7	8.94	0.59	1.22e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs11159086	0.793	rs12432412	chr14:74940997	T/C	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.58	-8.01	-0.54	2.73e-13	Height;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.24	0.56	7.52e-14	Alzheimer's disease;
PAAD	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.48	-7.74	-0.53	1.29e-12	Urinary metabolites;
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.34	-0.46	2.52e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.59	5.59	0.41	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.74	-0.58	4.04e-15	Schizophrenia;
PAAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.51	5.55	0.41	1.25e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg03983715	chr16:68378420	PRMT7	-0.88	-6.5	-0.47	1.1e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs60154123	0.730	rs58366398	chr1:210471924	G/A	cg21951975	chr1:209979733	IRF6	0.5	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.76	-14.47	-0.76	2.24e-30	Longevity;Endometriosis;
PAAD	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-1.0	-8.61	-0.57	8.86e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.1	-0.44	8.62e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg21479132	chr6:26055353	NA	1.0	6.44	0.46	1.5e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.89	10.47	0.65	1.2e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.62	-0.35	8.15e-6	Mood instability;
PAAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg24053715	chr22:38214548	NA	0.61	6.05	0.44	1.09e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg14146966	chr2:61757674	XPO1	-0.35	-4.46	-0.34	1.58e-5	Tuberculosis;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.65	-7.28	-0.51	1.71e-11	Iron status biomarkers;
PAAD	trans	rs901683	1.000	rs71494790	chr10:45972611	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs1850744	0.702	rs11724183	chr4:9609894	A/G	cg08077071	chr2:157176106	NA	0.92	6.33	0.46	2.65e-9	Economic and political preferences;
PAAD	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-4.86	-0.37	2.94e-6	Height;
PAAD	trans	rs1326986	0.826	rs7071564	chr10:20042199	G/T	cg04724540	chr1:166916762	ILDR2	-1.04	-6.4	-0.46	1.84e-9	Ankylosing spondylitis;
PAAD	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.18	8.84	0.58	2.2e-15	Lymphocyte counts;
PAAD	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg06569542	chr10:98946673	SLIT1	-0.52	-5.85	-0.43	2.92e-8	Monocyte count;
PAAD	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.85	6.4	0.46	1.79e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.7	7.71	0.53	1.51e-12	Cisplatin-induced ototoxicity;
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-4.56	-0.35	1.03e-5	Testicular germ cell tumor;
PAAD	cis	rs8067545	0.512	rs34726000	chr17:19887821	G/T	cg04132472	chr17:19861366	AKAP10	0.43	4.32	0.33	2.85e-5	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.73	0.42	5.34e-8	Testicular germ cell tumor;
PAAD	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.26	0.56	6.72e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.41	-4.49	-0.34	1.39e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.24e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg00280220	chr17:61926910	NA	0.43	4.63	0.35	7.88e-6	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.77	8.05	0.55	2.22e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg11335335	chr11:637885	DRD4	-0.31	-4.43	-0.34	1.76e-5	Systemic lupus erythematosus;
PAAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12599982	chr1:44399894	ARTN	0.44	4.8	0.36	3.79e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg09945482	chr18:12777974	NA	-0.63	-5.44	-0.4	2.07e-7	Inflammatory skin disease;
PAAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.53	0.65	7.94e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs300774	0.925	rs300722	chr2:134249	A/C	cg23649280	chr2:140451	NA	-0.45	-4.38	-0.33	2.22e-5	Suicide attempts in bipolar disorder;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20850055	chr8:101718959	PABPC1	-0.77	-7.22	-0.51	2.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg01059385	chr22:42394853	WBP2NL	-0.45	-4.34	-0.33	2.6e-5	Cognitive function;
PAAD	cis	rs6674176	0.611	rs12737898	chr1:44407401	C/G	cg12908607	chr1:44402522	ARTN	-0.62	-4.26	-0.33	3.55e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2637266	0.756	rs846631	chr10:78536928	T/G	cg18941641	chr10:78392320	NA	0.38	4.6	0.35	9.02e-6	Pulmonary function;
PAAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.52	-5.35	-0.4	3.11e-7	Blood protein levels;
PAAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06217245	chr20:33103252	DYNLRB1	0.4	4.83	0.36	3.35e-6	Coronary artery disease;
PAAD	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11651753	0.636	rs4793731	chr17:46033693	G/A	cg24458315	chr17:46148407	CBX1	0.42	4.44	0.34	1.75e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg14926445	chr8:58193284	C8orf71	-0.59	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4774830	0.744	rs10438326	chr15:56158075	A/G	cg24530489	chr15:56299380	NA	1.09	4.65	0.35	7.16e-6	Delta-5 desaturase activity;
PAAD	trans	rs17054480	0.614	rs60387764	chr4:169618014	A/G	cg18174542	chr22:41956861	CSDC2	0.8	6.44	0.46	1.48e-9	Advanced glycation end-product levels;
PAAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.5	-4.93	-0.37	2.16e-6	Daytime sleep phenotypes;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13560548	chr3:10150139	C3orf24	0.58	5.13	0.38	8.74e-7	Alzheimer's disease;
PAAD	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.74	6.74	0.48	3.09e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01730684	chr13:114145160	DCUN1D2;TMCO3	0.58	6.51	0.47	1.03e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.47	4.37	0.33	2.33e-5	Breast cancer;
PAAD	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.59	5.36	0.4	3.04e-7	Obesity-related traits;
PAAD	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Dermatomyositis;
PAAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.85	8.18	0.55	1.05e-13	Cognitive function;
PAAD	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg19507638	chr5:93509721	C5orf36	-0.65	-4.31	-0.33	2.91e-5	Diabetic retinopathy;
PAAD	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg15211996	chr1:2936768	ACTRT2	0.46	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.25	-0.39	4.98e-7	Aortic root size;
PAAD	cis	rs593531	0.571	rs10898981	chr11:74092465	A/C	cg23327896	chr11:73669290	DNAJB13	-0.34	-4.3	-0.33	3.01e-5	Neuroticism;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.63	6.2	0.45	4.98e-9	Lung cancer;
PAAD	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg17076780	chr6:43251928	TTBK1	0.58	4.59	0.35	9.27e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs2163761	1.000	rs2163761	chr5:168211254	C/T	cg21233722	chr5:169064660	DOCK2	-0.27	-4.3	-0.33	3.1e-5	Gut microbiota (functional units);
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg20007245	chr22:24372913	LOC391322	-0.8	-8.41	-0.56	2.78e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg15017067	chr4:17643749	FAM184B	0.43	4.96	0.37	1.88e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6782025	1.000	rs7609781	chr3:121132817	A/C	cg16417163	chr3:121280760	NA	-0.49	-5.03	-0.38	1.34e-6	Aging (facial);
PAAD	cis	rs8121916	0.954	rs8119584	chr20:12403570	T/C	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg23605961	chr7:751331	PRKAR1B	0.31	4.94	0.37	2.04e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs11615916	0.790	rs17659938	chr12:62711409	T/C	cg11441379	chr12:63026424	NA	0.64	4.33	0.33	2.72e-5	Pulmonary function decline;
PAAD	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.62	-0.41	8.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.36	-0.4	3.08e-7	Testicular germ cell tumor;
PAAD	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.87	-8.98	-0.59	9.98e-16	QRS duration;
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.33e-10	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.93	12.27	0.71	1.74e-24	Prudent dietary pattern;
PAAD	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg05555928	chr11:63887634	MACROD1	0.48	5.35	0.4	3.16e-7	Platelet count;
PAAD	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.69	-6.78	-0.48	2.48e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg19680485	chr15:31195859	MTMR15	-0.45	-4.34	-0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.61	-4.94	-0.37	2.06e-6	Platelet count;
PAAD	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.66	4.31	0.33	2.9e-5	Lung cancer;
PAAD	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs1507153	0.847	rs9341741	chr6:79426838	G/A	cg05283184	chr6:79620031	NA	-0.42	-5.22	-0.39	5.89e-7	Sjögren's syndrome;
PAAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.49	0.41	1.65e-7	Obesity-related traits;
PAAD	cis	rs11613048	0.897	rs12423411	chr12:30327801	C/G	cg03476860	chr12:30948794	NA	-0.35	-4.3	-0.33	3.1e-5	Major depressive disorder;
PAAD	cis	rs7107174	0.636	rs11237451	chr11:78025459	G/A	cg02023728	chr11:77925099	USP35	-0.43	-4.77	-0.36	4.27e-6	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03073402	chr19:42927676	LIPE	-0.7	-6.37	-0.46	2.08e-9	Neuroticism;
PAAD	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.52	4.98	0.37	1.68e-6	Mortality in heart failure;
PAAD	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.82	-6.11	-0.44	7.94e-9	Coronary artery calcification;
PAAD	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.38	-0.33	2.23e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg11673840	chr17:47092156	IGF2BP1	0.4	4.68	0.35	6.26e-6	Type 2 diabetes;
PAAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.17	0.55	1.13e-13	Schizophrenia;
PAAD	cis	rs3764400	0.517	rs7224461	chr17:46203430	C/G	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs7264396	0.832	rs224416	chr20:34138406	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.29	-0.39	4.2e-7	Total cholesterol levels;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.51	5.19	0.39	6.63e-7	Lymphocyte counts;
PAAD	cis	rs6032067	0.683	rs13042431	chr20:43781253	A/G	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg13785189	chr17:73150884	HN1	-0.74	-6.29	-0.45	3.2e-9	Anxiety disorder;
PAAD	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg09659197	chr4:152720779	NA	0.43	5.29	0.39	4.28e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs785830	0.558	rs549707	chr9:259575	G/A	cg17093826	chr7:138458720	ATP6V0A4	0.5	6.45	0.46	1.39e-9	Platelet distribution width;
PAAD	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.43	-0.34	1.81e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.91	-9.07	-0.59	5.77e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08677398	chr8:58056175	NA	0.58	4.25	0.33	3.76e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.83	-10.06	-0.63	1.48e-18	Blood metabolite ratios;
PAAD	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs6604026	0.644	rs12069727	chr1:93399060	A/C	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.55	-0.41	1.21e-7	Bipolar disorder;
PAAD	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.79	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.53	5.79	0.42	3.99e-8	Testicular germ cell tumor;
PAAD	cis	rs1031261	0.749	rs17012044	chr2:32881702	A/G	cg26820922	chr2:32503023	YIPF4	-0.71	-4.37	-0.33	2.27e-5	Hippocampal atrophy;
PAAD	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg06917634	chr15:78832804	PSMA4	0.45	4.34	0.33	2.64e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.86	0.66	1.09e-20	Smoking behavior;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.83	0.43	3.2e-8	Menopause (age at onset);
PAAD	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg26174226	chr8:58114915	NA	-0.67	-5.42	-0.4	2.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.05	0.55	2.27e-13	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.11	-0.67	2.35e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-4.75	-0.36	4.57e-6	Joint mobility (Beighton score);
PAAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.91	0.54	4.79e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9646944	0.501	rs10197310	chr2:103020030	A/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.25	-0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07157834	chr1:205819609	PM20D1	-0.51	-4.89	-0.37	2.52e-6	Parkinson's disease;
PAAD	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.5	-5.66	-0.42	7.37e-8	Obesity-related traits;
PAAD	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg00522288	chr12:125625016	AACS	-0.51	-5.16	-0.39	7.58e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.91	-11.34	-0.68	5.53e-22	Prudent dietary pattern;
PAAD	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6e-9	Subjective well-being;
PAAD	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs28472312	0.685	rs4788111	chr16:28980693	T/G	cg16576597	chr16:28551801	NUPR1	-0.46	-4.76	-0.36	4.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.87	10.96	0.66	5.68e-21	Prudent dietary pattern;
PAAD	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.86e-8	Subjective well-being;
PAAD	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.69e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs227833	1.000	rs227835	chr6:44682316	A/G	cg18551225	chr6:44695536	NA	0.49	4.94	0.37	2.01e-6	Monobrow;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg03983715	chr16:68378420	PRMT7	-0.7	-5.19	-0.39	6.57e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20494108	chr6:42981763	MEA1;KLHDC3	0.65	6.35	0.46	2.33e-9	Obesity-related traits;
PAAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.31	-0.33	2.92e-5	Height;
PAAD	cis	rs1893592	0.559	rs34217522	chr21:43868647	C/T	cg13826749	chr21:43867568	UBASH3A	-0.45	-5.24	-0.39	5.23e-7	Primary sclerosing cholangitis;Rheumatoid arthritis;
PAAD	cis	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg05299278	chr17:33885742	SLFN14	0.43	5.08	0.38	1.08e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg04877966	chr15:75135169	ULK3	0.54	4.57	0.35	9.99e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1420338	0.933	rs10228731	chr7:34150782	G/T	cg01275685	chr7:34179230	BMPER	-0.54	-5.11	-0.38	9.73e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.51	4.34	0.33	2.61e-5	Height;
PAAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.75	-8.18	-0.55	1.08e-13	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.4	-0.34	2.03e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03790075	chr10:102732171	SEMA4G	0.55	6.5	0.47	1.09e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg25204440	chr1:209979598	IRF6	0.53	4.34	0.33	2.55e-5	Coronary artery disease;
PAAD	cis	rs1015362	0.540	rs2050209	chr20:32485536	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.49	-4.3	-0.33	3.05e-5	Skin sensitivity to sun;Red vs. non-red hair color;Burning and freckling;Freckles;
PAAD	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	6.85	0.49	1.7e-10	Response to antipsychotic treatment;
PAAD	cis	rs7594192	0.701	rs6727763	chr2:199371236	A/G	cg01558212	chr2:200327336	NA	0.35	4.57	0.35	9.95e-6	Educational attainment;
PAAD	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.34	-4.71	-0.36	5.55e-6	Pulse pressure;
PAAD	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	4.87	0.37	2.83e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-5.62	-0.41	8.84e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-5.3	-0.39	4.01e-7	Axial length;
PAAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.08	-0.38	1.11e-6	Myopia (pathological);
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.6	-0.35	8.91e-6	Aortic root size;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg04352962	chr1:209979756	IRF6	0.54	4.87	0.37	2.78e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg17644776	chr2:200775616	C2orf69	-0.7	-5.37	-0.4	2.92e-7	Schizophrenia;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg12639453	chr1:2035780	PRKCZ	0.51	4.88	0.37	2.67e-6	Height;
PAAD	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	1.26	13.06	0.73	1.29e-26	Post bronchodilator FEV1;
PAAD	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg09876464	chr15:85330779	ZNF592	0.44	4.39	0.34	2.09e-5	P wave terminal force;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07494646	chr22:37415349	MPST;TST	-0.55	-6.4	-0.46	1.85e-9	Body fat percentage;
PAAD	cis	rs4417704	0.551	rs4334491	chr2:241892478	G/A	cg26818257	chr2:241905806	NA	0.51	5.32	0.4	3.72e-7	Joint mobility (Beighton score);
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.71	5.72	0.42	5.39e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
PAAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	8.31	0.56	4.83e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs1499972	0.941	rs62266065	chr3:117547059	C/T	cg07612923	chr3:117604196	NA	0.96	6.67	0.48	4.52e-10	Schizophrenia;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg13253694	chr11:60609608	CCDC86	0.61	6.46	0.46	1.34e-9	Iris heterochromicity;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.8	8.97	0.59	1.01e-15	Aortic root size;
PAAD	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.42	6.26	0.45	3.79e-9	Information processing speed;
PAAD	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.27	-0.51	1.72e-11	Monocyte count;
PAAD	cis	rs2278796	0.697	rs11240323	chr1:204952737	T/C	cg09852221	chr1:205912646	SLC26A9	-0.39	-4.37	-0.33	2.29e-5	Mean platelet volume;
PAAD	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg05872129	chr22:39784769	NA	-0.63	-5.61	-0.41	9.23e-8	IgG glycosylation;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.82	9.36	0.6	1e-16	Prudent dietary pattern;
PAAD	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.58	6.15	0.45	6.41e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg14983838	chr19:29218262	NA	0.7	6.11	0.44	7.98e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.28	0.33	3.31e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs901683	1.000	rs12773463	chr10:46003631	A/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.05	0.55	2.26e-13	Lung cancer;
PAAD	cis	rs6715793	0.869	rs58786532	chr2:33406050	C/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.74	-5.8	-0.43	3.69e-8	Orofacial clefts;
PAAD	cis	rs7786877	0.723	rs62482237	chr7:100213476	A/G	cg26071806	chr7:100318239	EPO	-0.45	-4.3	-0.33	3.09e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-8.71	-0.58	4.81e-15	Blood trace element (Zn levels);
PAAD	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.71	-5.14	-0.38	8.49e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10450586	0.932	rs7950335	chr11:27322503	A/G	cg10370305	chr11:27303972	NA	-0.37	-4.6	-0.35	8.77e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14597492	chr8:125487571	RNF139	0.66	6.35	0.46	2.35e-9	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.79	-4.44	-0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.53	-0.47	9.53e-10	Life satisfaction;
PAAD	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.43	0.52	7.27e-12	Menarche (age at onset);
PAAD	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.42	-6.24	-0.45	4.23e-9	Subjective well-being;
PAAD	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.91	-6.2	-0.45	4.96e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs56046484	0.956	rs34054841	chr15:85601346	C/G	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.66	-0.35	6.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.69	-0.42	6.31e-8	Ulcerative colitis;
PAAD	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg10934807	chr2:113191815	RGPD8;RGPD5	0.97	7.42	0.52	7.58e-12	Yeast infection;
PAAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.5	0.52	4.9e-12	Morning vs. evening chronotype;
PAAD	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.85	10.4	0.64	1.79e-19	Tonsillectomy;
PAAD	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.52	-4.42	-0.34	1.89e-5	Neuroticism;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg09659197	chr4:152720779	NA	-0.46	-6.15	-0.45	6.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7487075	0.656	rs3936214	chr12:46825812	T/C	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.54	-4.52	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs11892454	0.645	rs10184492	chr2:25950511	C/G	cg25181710	chr2:26045287	ASXL2	0.4	4.53	0.35	1.16e-5	Heschl's gyrus morphology;
PAAD	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.81	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.65	6.33	0.46	2.59e-9	Blood metabolite levels;
PAAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	4.46	0.34	1.57e-5	Eosinophil percentage of white cells;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.63	0.35	7.72e-6	Breast cancer;
PAAD	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg12463550	chr7:65579703	CRCP	-0.82	-5.2	-0.39	6.38e-7	Diabetic kidney disease;
PAAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg13722127	chr7:150037890	RARRES2	0.62	6.59	0.47	6.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.32	0.33	2.81e-5	Lung cancer;
PAAD	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg24110177	chr3:50126178	RBM5	-0.54	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	1.01	6.8	0.48	2.22e-10	Thyroid stimulating hormone;
PAAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.63	6.34	0.46	2.46e-9	Multiple sclerosis;
PAAD	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.39	0.34	2.09e-5	Educational attainment (years of education);
PAAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.25	0.56	7.1e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.83e-13	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-4.73	-0.36	5.12e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg14440974	chr22:39074834	NA	-0.57	-6.62	-0.47	5.68e-10	Menopause (age at onset);
PAAD	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg25452165	chr22:42524984	CYP2D6	0.53	4.84	0.37	3.18e-6	Schizophrenia;
PAAD	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.88	5.69	0.42	6.47e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10981012	0.504	rs10981092	chr9:114584031	A/G	cg14428669	chr9:114659192	UGCG	0.59	4.53	0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs863345	0.967	rs12081915	chr1:158533224	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.97e-6	Pneumococcal bacteremia;
PAAD	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-4.27	-0.33	3.43e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.71	-7.56	-0.52	3.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6704644	0.656	rs11681704	chr2:234338402	G/A	cg27141176	chr2:235272562	NA	-0.68	-4.26	-0.33	3.58e-5	Bilirubin levels;
PAAD	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.55	4.39	0.34	2.1e-5	Neutrophil percentage of white cells;
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.6	-5.98	-0.44	1.55e-8	Itch intensity from mosquito bite;
PAAD	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	4.48	0.34	1.48e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.97	-10.48	-0.65	1.15e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.89	0.37	2.5e-6	Lung cancer in ever smokers;
PAAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.7	5.77	0.42	4.41e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.83	-10.13	-0.63	9.39e-19	DNA methylation (variation);
PAAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.13	15.48	0.78	4.8e-33	Cognitive function;
PAAD	cis	rs2455826	0.544	rs2455844	chr3:15767846	C/T	cg13420985	chr3:16524424	RFTN1	-0.46	-4.36	-0.33	2.37e-5	Inflammatory skin disease;
PAAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg18279126	chr7:2041391	MAD1L1	0.55	5.57	0.41	1.14e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg06671706	chr8:8559999	CLDN23	0.72	7.3	0.51	1.49e-11	Obesity-related traits;
PAAD	cis	rs9311474	0.775	rs164640	chr3:52247314	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.15	-0.39	8.03e-7	Electroencephalogram traits;
PAAD	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs8181588	1.000	rs11602964	chr11:2825871	C/T	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	0.7	4.9	0.37	2.48e-6	Type 2 diabetes;
PAAD	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.57	-0.52	3.31e-12	Blood metabolite levels;
PAAD	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.74	0.58	3.99e-15	Lung cancer;
PAAD	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg16898833	chr6:26189333	HIST1H4D	0.67	4.91	0.37	2.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.88	0.63	4.22e-18	Platelet count;
PAAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.95	12.27	0.71	1.74e-24	Menopause (age at onset);
PAAD	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.53	-4.73	-0.36	5.02e-6	Schizophrenia;
PAAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.29	0.6	1.49e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs1879734	0.636	rs1526910	chr1:54182174	G/A	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.52	-5.75	-0.42	4.82e-8	Mean corpuscular volume;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg19337854	chr7:99768885	GPC2	0.46	4.28	0.33	3.32e-5	Platelet count;
PAAD	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.85	9.9	0.63	3.8e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09065880	chr20:55966446	RBM38	-0.59	-6.45	-0.46	1.41e-9	Smoking initiation;
PAAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06544989	chr22:39130855	UNC84B	0.52	5.47	0.41	1.84e-7	Menopause (age at onset);
PAAD	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.59	4.87	0.37	2.77e-6	Metabolite levels;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.34	0.46	2.46e-9	Alzheimer's disease;
PAAD	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.44	4.9	0.37	2.39e-6	Testicular germ cell tumor;
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04002758	chr16:28303471	SBK1	0.6	6.74	0.48	3.1e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26908755	chr19:8373137	CD320	0.73	7.15	0.5	3.47e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.62	-6.05	-0.44	1.07e-8	Multiple sclerosis;
PAAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.72	7.31	0.51	1.42e-11	Permanent tooth development;
PAAD	cis	rs7246865	0.510	rs8103578	chr19:17171227	C/T	cg19418318	chr19:17219073	MYO9B	0.35	5.01	0.38	1.5e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.59	7.97	0.54	3.56e-13	Hypertriglyceridemia;
PAAD	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg02527881	chr3:46936655	PTH1R	-0.46	-5.57	-0.41	1.14e-7	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.52	-0.47	9.93e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.49	4.67	0.35	6.71e-6	Airway imaging phenotypes;
PAAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.58	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg15117754	chr3:10150083	C3orf24	0.78	6.95	0.49	9.92e-11	Alzheimer's disease;
PAAD	cis	rs16933812	0.510	rs7850976	chr9:36988851	C/T	cg13738729	chr9:36989127	PAX5	-0.53	-7.65	-0.53	2.14e-12	Obesity-related traits;
PAAD	cis	rs7678296	0.649	rs6831699	chr4:37237387	A/G	cg18431856	chr4:37245254	KIAA1239	0.78	4.5	0.34	1.34e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg26571870	chr16:85723150	GINS2	-0.42	-4.58	-0.35	9.62e-6	Platelet distribution width;
PAAD	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs4272720	0.855	rs61848153	chr10:50230127	A/C	cg07637213	chr10:50820604	CHAT;SLC18A3	0.4	4.31	0.33	2.96e-5	Platelet count;Plateletcrit;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	-0.61	-5.74	-0.42	4.95e-8	Resistin levels;
PAAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6715793	0.901	rs726429	chr2:33404662	A/G	cg26672287	chr2:33391915	LTBP1	-0.42	-4.9	-0.37	2.4e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg01631408	chr1:248437212	OR2T33	-0.53	-4.91	-0.37	2.29e-6	Common traits (Other);
PAAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.54	-7.27	-0.51	1.78e-11	Renal cell carcinoma;
PAAD	cis	rs17123764	0.710	rs59849800	chr12:50116773	C/T	cg14846292	chr12:49726500	C1QL4	-0.67	-4.33	-0.33	2.69e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12753920	0.775	rs2128648	chr1:92674474	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.47	-4.44	-0.34	1.75e-5	Systemic lupus erythematosus;
PAAD	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg15440763	chr7:158190612	PTPRN2	0.44	4.45	0.34	1.63e-5	Obesity-related traits;
PAAD	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.42	-4.63	-0.35	7.89e-6	Mean platelet volume;
PAAD	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.66	0.48	4.81e-10	IgG glycosylation;
PAAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs6782025	0.837	rs1688677	chr3:120758285	A/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.36	-0.46	2.29e-9	Menopause (age at onset);
PAAD	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg10820045	chr2:198174542	NA	-0.44	-4.45	-0.34	1.65e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg23033748	chr14:75592666	NEK9	-0.42	-5.17	-0.39	7.22e-7	Height;
PAAD	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg14631576	chr9:95140430	CENPP	-0.53	-5.31	-0.4	3.86e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.54	5.94	0.43	1.9e-8	Urate levels in lean individuals;
PAAD	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.64	-5.65	-0.42	7.52e-8	Coronary artery disease;
PAAD	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.85	-7.1	-0.5	4.48e-11	Body mass index;
PAAD	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.39	-4.95	-0.37	1.98e-6	Prostate cancer;
PAAD	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg23033748	chr14:75592666	NEK9	-0.46	-5.39	-0.4	2.59e-7	Height;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4343996	0.967	rs10224769	chr7:3347166	A/T	cg21248987	chr7:3385318	SDK1	0.47	5.17	0.39	7.36e-7	Motion sickness;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27311414	chr1:161147232	B4GALT3	0.65	7.56	0.52	3.49e-12	Monocyte percentage of white cells;
PAAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg21709803	chr11:61594965	FADS2	-0.54	-4.41	-0.34	1.94e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.26	-0.39	4.71e-7	Joint mobility (Beighton score);
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.21	-0.45	4.95e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.8	9.81	0.62	6.56e-18	Breast cancer;
PAAD	cis	rs73388146	0.772	rs4712888	chr6:25147518	C/T	cg26336265	chr6:25042955	NA	-0.99	-6.01	-0.44	1.3e-8	Schizophrenia;
PAAD	cis	rs8049634	0.732	rs11149631	chr16:84228770	G/C	cg26466773	chr16:84211947	TAF1C	0.57	5.27	0.39	4.64e-7	Small cell lung carcinoma;
PAAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12178287	chr19:17631836	PGLS	0.6	7.42	0.52	7.91e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg14349672	chr11:133703707	NA	0.47	5.16	0.39	7.7e-7	Childhood ear infection;
PAAD	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg09237515	chr14:105715926	BTBD6;BRF1	0.53	4.84	0.37	3.16e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.65	6.92	0.49	1.17e-10	Testicular germ cell tumor;
PAAD	cis	rs4740619	0.809	rs7855235	chr9:15709741	T/C	cg14451791	chr9:16040625	NA	-0.4	-4.62	-0.35	8.29e-6	Body mass index;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.67	8.71	0.58	4.78e-15	Lymphocyte counts;
PAAD	cis	rs12997796	1.000	rs12997796	chr2:86974318	A/G	cg25203885	chr2:87302643	LOC285074	-0.76	-5.26	-0.39	4.75e-7	Schizophrenia;
PAAD	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.53	-0.41	1.35e-7	Bladder cancer;
PAAD	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg16606324	chr3:10149918	C3orf24	0.54	4.63	0.35	7.74e-6	Alzheimer's disease;
PAAD	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.84	7.65	0.53	2.14e-12	Menarche (age at onset);
PAAD	cis	rs288342	0.832	rs288283	chr2:183642628	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.69	-0.36	6.16e-6	Recurrent major depressive disorder;
PAAD	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg18551225	chr6:44695536	NA	-0.7	-6.96	-0.49	9.42e-11	Total body bone mineral density;
PAAD	cis	rs2244613	0.507	rs7205803	chr16:55794849	C/T	cg27396498	chr16:55794478	CES4	0.62	4.37	0.33	2.26e-5	Response to dabigatran etexilate treatment;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg08677398	chr8:58056175	NA	0.6	4.32	0.33	2.83e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-11.82	-0.69	2.75e-23	Height;
PAAD	cis	rs2117029	0.587	rs1865157	chr12:49522786	C/A	cg05368762	chr12:50135785	TMBIM6	0.43	4.26	0.33	3.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.67	5.34	0.4	3.34e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	7.62	0.53	2.59e-12	Eotaxin levels;
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.88	-0.43	2.57e-8	Mood instability;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs3753841	0.563	rs62995062	chr1:103238682	C/A	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03676636	chr4:99064102	C4orf37	0.34	5.79	0.42	3.95e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg02734326	chr4:10020555	SLC2A9	0.5	5.09	0.38	1.06e-6	Bone mineral density;
PAAD	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	7.32	0.51	1.37e-11	Hemoglobin concentration;
PAAD	trans	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg01620082	chr3:125678407	NA	1.13	6.52	0.47	9.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.42	-4.83	-0.36	3.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs2033908	0.620	rs1992335	chr11:12851717	A/C	cg25843174	chr11:12811716	TEAD1	-0.35	-4.83	-0.36	3.31e-6	Sitting height ratio;
PAAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg20243544	chr17:37824526	PNMT	0.52	4.37	0.33	2.26e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs12432203	1.000	rs12431427	chr14:51734282	C/T	cg23942311	chr14:51606299	NA	0.69	4.72	0.36	5.22e-6	Cancer;
PAAD	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg21466736	chr12:48725269	NA	0.52	4.87	0.37	2.79e-6	Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15922045	chr3:130278187	COL6A6	-0.6	-7.66	-0.53	2.06e-12	Obesity-related traits;
PAAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.47	5.68	0.42	6.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg19744528	chr7:157553346	PTPRN2	0.4	4.27	0.33	3.46e-5	Body mass index;
PAAD	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.32	6.08	0.44	9.19e-9	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07362569	chr17:61921086	SMARCD2	0.66	8.14	0.55	1.34e-13	Prudent dietary pattern;
PAAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.66	6.86	0.49	1.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg02100629	chr10:71892760	AIFM2	-0.37	-4.33	-0.33	2.74e-5	Blood protein levels;
PAAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg27411982	chr8:10470053	RP1L1	0.48	5.06	0.38	1.21e-6	Retinal vascular caliber;
PAAD	cis	rs7617773	0.823	rs9839447	chr3:48194667	T/C	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.42e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-5.71	-0.42	5.81e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1419980	0.730	rs7965947	chr12:7755908	G/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.35	-0.33	2.5e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4662750	0.828	rs2248519	chr2:128377833	C/G	cg09760422	chr2:128146352	NA	0.31	4.57	0.35	1.01e-5	Renal cell carcinoma;
PAAD	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-4.95	-0.37	1.91e-6	Rheumatoid arthritis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08416054	chr7:43967515	UBE2D4	0.55	6.55	0.47	8.54e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.81	-6.08	-0.44	9.48e-9	Atopic dermatitis;
PAAD	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.38	0.56	3.36e-14	Bipolar disorder;
PAAD	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.83	-0.48	1.88e-10	Atrioventricular conduction;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.86	-0.37	2.92e-6	Height;
PAAD	cis	rs3764563	0.935	rs646816	chr19:15695101	T/G	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.55	5.14	0.38	8.42e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs8077577	0.895	rs16960996	chr17:18110559	A/G	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg15145296	chr3:125709740	NA	-0.65	-4.87	-0.37	2.83e-6	Blood pressure (smoking interaction);
PAAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.44	-0.34	1.7e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.68	-6.69	-0.48	3.93e-10	Retinal vascular caliber;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-1.05	-13.57	-0.74	5.38e-28	Urate levels;
PAAD	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-4.43	-0.34	1.79e-5	Menarche (age at onset);
PAAD	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg20092376	chr4:56023423	NA	-0.5	-5.42	-0.4	2.29e-7	Endometriosis;
PAAD	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.4	0.46	1.85e-9	Triglyceride levels;
PAAD	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.41	5.03	0.38	1.35e-6	Pulmonary function;
PAAD	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.6	-0.47	6.54e-10	Chronic sinus infection;
PAAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.48	0.47	1.21e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg11494091	chr17:61959527	GH2	0.53	4.26	0.33	3.51e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs35164067	1.000	rs73923215	chr19:10514842	A/C	cg24189696	chr19:10585866	NA	0.41	4.59	0.35	9.4e-6	Inflammatory bowel disease;
PAAD	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	4.7	0.36	5.79e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg04374321	chr14:90722782	PSMC1	-0.52	-4.37	-0.33	2.28e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg01059385	chr22:42394853	WBP2NL	-0.46	-4.32	-0.33	2.82e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs36715	1.000	rs36715	chr5:127562880	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	4.33	0.33	2.67e-5	Breast cancer;
PAAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.84	11.61	0.69	1.03e-22	Emphysema distribution in smoking;
PAAD	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg04160749	chr8:58172571	NA	-0.6	-4.38	-0.33	2.22e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg27539214	chr16:67997921	SLC12A4	-0.62	-4.7	-0.36	5.87e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.9	9.49	0.61	4.69e-17	Testicular germ cell tumor;
PAAD	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.89	-9.02	-0.59	7.84e-16	Asthma;
PAAD	cis	rs425535	0.824	rs352013	chr4:74810423	T/C	cg01447579	chr4:74847100	PF4	0.67	4.34	0.33	2.56e-5	Blood protein levels;
PAAD	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7873102	0.654	rs2243782	chr9:37990693	C/T	cg03528946	chr9:38069800	SHB	0.5	5.07	0.38	1.12e-6	Brain structure;
PAAD	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	1.04	6.49	0.47	1.14e-9	Major depressive disorder;
PAAD	cis	rs2548003	0.541	rs1160444	chr5:28763652	G/A	cg22863700	chr5:28928346	NA	0.56	5.45	0.4	1.99e-7	Hip geometry;
PAAD	cis	rs7567389	0.502	rs2069919	chr2:128179553	G/A	cg11380483	chr2:127933992	NA	0.51	4.84	0.37	3.19e-6	Self-rated health;
PAAD	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.64	-0.35	7.56e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs755249	0.567	rs66531516	chr1:39629062	G/A	cg14018543	chr1:39659967	MACF1	-0.51	-4.35	-0.33	2.44e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs758324	0.812	rs30159	chr5:131306535	T/C	cg06307176	chr5:131281290	NA	-0.57	-4.74	-0.36	4.94e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.12	0.59	4.23e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.61	-6.55	-0.47	8.33e-10	Coronary artery disease;
PAAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.85	11.59	0.69	1.15e-22	Metabolite levels;
PAAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.85	-9.21	-0.6	2.47e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.62	5.08	0.38	1.1e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg07841815	chr7:100318223	EPO	0.5	4.68	0.35	6.34e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19882132	chr14:106167949	NA	-0.55	-4.91	-0.37	2.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.49e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.69	-6.68	-0.48	4.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.53	5.5	0.41	1.6e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12084869	chr19:31210560	NA	0.61	6.74	0.48	3.15e-10	Myopia (pathological);
PAAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.56	7.4	0.51	8.75e-12	Huntington's disease progression;
PAAD	cis	rs7512552	0.803	rs59898460	chr1:150493004	T/C	cg15654264	chr1:150340011	RPRD2	0.74	7.45	0.52	6.66e-12	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.85	0.43	2.91e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.71	-7.04	-0.5	6.04e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.68	0.35	6.42e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.62	7.29	0.51	1.56e-11	HDL cholesterol;
PAAD	cis	rs4427176	0.765	rs13275314	chr8:9584925	A/G	cg03024720	chr8:9765601	NA	0.48	4.61	0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.47	-0.34	1.49e-5	Glomerular filtration rate;
PAAD	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.9e-6	Lung cancer;
PAAD	cis	rs728616	0.681	rs34816332	chr10:81907967	G/A	cg19423196	chr10:82049429	MAT1A	0.46	4.32	0.33	2.79e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.97	-10.11	-0.63	1.05e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.56	-4.37	-0.33	2.31e-5	Depression;
PAAD	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg11779900	chr17:80519722	FOXK2	-0.49	-5.15	-0.39	7.97e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19610267	chr10:92913472	NUDT9P1	0.55	6.29	0.45	3.26e-9	Body fat percentage;
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.59	6.46	0.46	1.36e-9	Menopause (age at onset);
PAAD	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13030586	chr4:186347098	UFSP2	0.66	7.59	0.52	2.94e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg04055107	chr11:65626734	MUS81;CFL1	0.46	4.6	0.35	8.73e-6	Eosinophil percentage of white cells;
PAAD	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.74	8.02	0.55	2.64e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg17736920	chr1:242011382	EXO1	0.54	5.31	0.4	3.77e-7	Menopause (age at onset);
PAAD	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.78	6.09	0.44	8.85e-9	IgE levels;
PAAD	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9463078	0.585	rs964452	chr6:45128742	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08084218	chr2:20850887	HS1BP3	0.64	6.97	0.49	9.14e-11	Myopia (pathological);
PAAD	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg23250157	chr14:64679961	SYNE2	0.46	4.72	0.36	5.32e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14895029	chr7:2775587	GNA12	-0.49	-4.91	-0.37	2.34e-6	Height;
PAAD	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.46	0.34	1.59e-5	Lung cancer;
PAAD	cis	rs10875746	0.669	rs10875770	chr12:48600520	A/G	cg26205652	chr12:48591994	NA	0.72	6.69	0.48	3.92e-10	Longevity (90 years and older);
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00166722	chr3:10149974	C3orf24	0.87	7.61	0.53	2.66e-12	Alzheimer's disease;
PAAD	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.41	0.34	1.98e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.45	0.34	1.65e-5	Depression;
PAAD	trans	rs901683	0.850	rs76491632	chr10:45966598	T/C	cg11747279	chr17:21096632	NA	0.92	6.79	0.48	2.37e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg13198984	chr17:80129470	CCDC57	0.44	5.45	0.4	1.94e-7	Life satisfaction;
PAAD	cis	rs593531	0.550	rs592644	chr11:74053547	C/T	cg15851278	chr11:73669449	DNAJB13	-0.38	-4.52	-0.34	1.22e-5	Neuroticism;
PAAD	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	4.81	0.36	3.62e-6	Systolic blood pressure;
PAAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.09e-13	Diastolic blood pressure;
PAAD	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.46	5.39	0.4	2.68e-7	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.73	-8.65	-0.57	6.81e-15	Height;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.39	0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.64	-4.64	-0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6715793	0.901	rs12617948	chr2:33403734	A/G	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.44	-4.31	-0.33	2.87e-5	Mean platelet volume;
PAAD	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.88	-9.19	-0.6	2.71e-16	Obesity-related traits;
PAAD	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.53	4.95	0.37	1.93e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs35000415	0.872	rs2070197	chr7:128589000	T/C	cg19972273	chr7:128594194	NA	0.99	5.73	0.42	5.35e-8	Systemic lupus erythematosus;
PAAD	cis	rs2457480	0.733	rs1545845	chr10:44679802	A/C	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;
PAAD	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.64	-6.19	-0.45	5.47e-9	Mosquito bite size;
PAAD	trans	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg19694781	chr19:47549865	TMEM160	-0.58	-6.59	-0.47	6.65e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.87	7.04	0.5	6.27e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs258892	0.895	rs2338793	chr5:72073172	T/G	cg21869765	chr5:72125136	TNPO1	-0.8	-5.38	-0.4	2.79e-7	Small cell lung carcinoma;
PAAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.42	-5.28	-0.39	4.43e-7	Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15740054	chr19:41221099	ADCK4	0.57	6.39	0.46	1.92e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11811982	0.655	rs78384568	chr1:227448375	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.18	-0.5	2.89e-11	Hemoglobin concentration;
PAAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg22189786	chr22:42395067	WBP2NL	-0.63	-4.94	-0.37	2.06e-6	Birth weight;
PAAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.84	7.5	0.52	5.07e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs7651511	1.000	rs9289634	chr3:141251655	A/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7765004	0.961	rs9374426	chr6:114074366	A/G	cg13100190	chr6:114053961	NA	0.35	4.32	0.33	2.84e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.72	7.69	0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs2916733	0.607	rs2920669	chr8:6313933	G/C	cg02465761	chr8:6735510	DEFB1	0.47	4.53	0.35	1.18e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg02071572	chr4:1403502	NA	0.44	5.93	0.43	1.95e-8	Obesity-related traits;
PAAD	cis	rs900145	0.953	rs4757137	chr11:13291827	G/T	cg15603424	chr11:13300592	ARNTL	-0.54	-4.62	-0.35	8.04e-6	Menarche (age at onset);
PAAD	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg15628303	chr1:26608928	UBXN11	0.71	7.06	0.5	5.6e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.81	5.91	0.43	2.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.44	4.52	0.34	1.23e-5	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1329189	0.954	rs7083120	chr10:129994262	A/G	cg17972361	chr10:130010134	NA	-0.46	-4.79	-0.36	3.99e-6	Orofacial clefts;
PAAD	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg05283184	chr6:79620031	NA	-0.45	-5.35	-0.4	3.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.62	-5.98	-0.44	1.52e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.85	9.33	0.6	1.23e-16	Prostate cancer;
PAAD	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg07202610	chr7:1142643	C7orf50	-0.6	-4.55	-0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19346786	chr7:2764209	NA	-0.39	-4.73	-0.36	5.11e-6	Plateletcrit;
PAAD	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.62	6.9	0.49	1.29e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg02841227	chr6:26021843	HIST1H4A	0.48	4.64	0.35	7.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-4.96	-0.37	1.84e-6	Common traits (Other);
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13198984	chr17:80129470	CCDC57	-0.39	-4.61	-0.35	8.45e-6	Life satisfaction;
PAAD	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs2077654	0.822	rs7939973	chr11:17433291	G/T	cg25308976	chr11:17434268	ABCC8	0.92	6.22	0.45	4.51e-9	Gout;
PAAD	cis	rs735539	0.593	rs4463942	chr13:21367434	C/T	cg27234864	chr13:21295941	IL17D	0.61	5.31	0.4	3.88e-7	Dental caries;
PAAD	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg24296786	chr1:45957014	TESK2	0.52	4.85	0.37	3.05e-6	Homocysteine levels;
PAAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg18944383	chr4:111397179	ENPEP	0.73	8.09	0.55	1.78e-13	Coronary artery disease;
PAAD	trans	rs9467603	0.548	rs34991172	chr6:25480328	T/G	cg01620082	chr3:125678407	NA	-1.3	-6.57	-0.47	7.49e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-1.01	-8.32	-0.56	4.56e-14	Initial pursuit acceleration;
PAAD	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg23024343	chr7:107201750	COG5	0.58	4.9	0.37	2.39e-6	Coronary artery disease;
PAAD	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.06e-8	Platelet count;
PAAD	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.51	4.54	0.35	1.14e-5	Anterior chamber depth;
PAAD	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg06784991	chr1:53308768	ZYG11A	0.29	4.54	0.35	1.15e-5	Monocyte count;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23227945	chr10:104154202	NFKB2	-0.79	-7.25	-0.51	1.94e-11	Neuroticism;
PAAD	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.46	4.71	0.36	5.57e-6	Breast cancer;
PAAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.15	-8.62	-0.57	7.92e-15	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.01e-9	Life satisfaction;
PAAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.77	-7.94	-0.54	4.17e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2882667	0.537	rs6887866	chr5:138437696	T/C	cg22797968	chr5:138629998	MATR3	0.47	4.74	0.36	4.95e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg10820045	chr2:198174542	NA	0.44	4.25	0.33	3.75e-5	Intracranial aneurysm;
PAAD	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg18209359	chr17:80159595	CCDC57	0.46	4.61	0.35	8.63e-6	Life satisfaction;
PAAD	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg09659197	chr4:152720779	NA	0.33	4.77	0.36	4.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.59	-5.53	-0.41	1.39e-7	Total body bone mineral density;
PAAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.58	4.82	0.36	3.42e-6	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2282930	0.836	rs2237472	chr7:50741502	C/T	cg07379434	chr7:49814597	VWC2	0.25	4.39	0.34	2.15e-5	Bone mineral density;
PAAD	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.53	5.15	0.39	7.91e-7	Height;
PAAD	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.39	-0.56	3.08e-14	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.65	-7.39	-0.51	9.25e-12	Personality dimensions;
PAAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.17	16.72	0.8	2.8e-36	Cognitive function;
PAAD	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg20130138	chr11:64956067	CAPN1	-0.58	-4.34	-0.33	2.57e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.9	-0.43	2.28e-8	QT interval;
PAAD	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-5.98	-0.44	1.5e-8	Platelet count;
PAAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs73206853	0.563	rs73194040	chr12:111181106	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	4.6	0.35	8.75e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.77	-0.36	4.3e-6	Testicular germ cell tumor;
PAAD	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg10072921	chr12:121022843	NA	0.37	4.93	0.37	2.15e-6	High light scatter reticulocyte count;
PAAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.58	-6.19	-0.45	5.37e-9	Total body bone mineral density;
PAAD	cis	rs2657888	0.628	rs7314242	chr12:56876372	C/A	cg23002907	chr12:56915593	RBMS2	-0.44	-4.42	-0.34	1.86e-5	Adiponectin levels;
PAAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.74	-6.36	-0.46	2.2e-9	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26281728	chr15:85923949	AKAP13	0.65	6.72	0.48	3.41e-10	Myopia (pathological);
PAAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.6200000000000003e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg20169779	chr10:135381914	SYCE1	-0.44	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs7187994	0.614	rs2291649	chr16:84800907	G/A	cg07647771	chr16:84786436	USP10	-0.35	-4.26	-0.33	3.62e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.27	16.22	0.8	5.63e-35	Schizophrenia;
PAAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.91	-11.54	-0.68	1.6400000000000001e-22	Coronary artery disease;
PAAD	cis	rs8067287	0.546	rs62065425	chr17:16828711	C/T	cg26910001	chr17:16838321	NA	-0.68	-6.09	-0.44	8.7e-9	Diabetic kidney disease;
PAAD	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	1.000	rs2132818	chr19:23182380	C/T	cg22640819	chr19:22990650	NA	-0.36	-4.4	-0.34	2.06e-5	Testicular germ cell tumor;
PAAD	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.68	7.41	0.52	7.96e-12	Body mass index;
PAAD	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.62	4.76	0.36	4.39e-6	Body mass index;
PAAD	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.76e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.64	6.83	0.48	1.94e-10	Crohn's disease;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23848647	chr2:42588967	COX7A2L	0.58	6.57	0.47	7.57e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7584330	0.554	rs74003110	chr2:238448188	C/T	cg11271282	chr2:238384023	NA	0.59	4.59	0.35	9.1e-6	Prostate cancer;
PAAD	cis	rs7264396	0.832	rs224349	chr20:34045392	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-6.08	-0.44	9.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.32e-13	Prostate cancer;
PAAD	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.77	6.18	0.45	5.53e-9	Height;
PAAD	cis	rs9285223	0.709	rs9317097	chr13:23170374	C/T	cg14669226	chr13:22249362	FGF9	-0.65	-4.42	-0.34	1.84e-5	Idiopathic osteonecrosis of the femoral head;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23459997	chr3:9932426	JAGN1	0.72	6.6	0.47	6.34e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	1.11	9.4	0.61	7.77e-17	Vitiligo;
PAAD	cis	rs11958404	1.000	rs72816528	chr5:157410949	G/A	cg05962755	chr5:157440814	NA	0.91	7.93	0.54	4.41e-13	IgG glycosylation;
PAAD	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.59	4.69	0.36	5.97e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.23	-0.45	4.27e-9	Coffee consumption (cups per day);
PAAD	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.52	4.34	0.33	2.56e-5	Coronary artery disease;
PAAD	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.88	8.13	0.55	1.42e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.45	-0.65	1.32e-19	Heart rate;
PAAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg00206168	chr11:65308501	LTBP3	0.52	5.4	0.4	2.5e-7	Bone mineral density;
PAAD	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.7	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs73416724	0.688	rs76514175	chr6:43347125	A/G	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg19486271	chr11:47235900	DDB2	-0.59	-5.92	-0.43	2.09e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg11494091	chr17:61959527	GH2	0.9	11.06	0.67	3.21e-21	Prudent dietary pattern;
PAAD	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg27234864	chr13:21295941	IL17D	0.53	4.64	0.35	7.32e-6	Dental caries;
PAAD	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg23254163	chr1:152506842	NA	0.5	4.85	0.37	3.08e-6	Hair morphology;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg08888203	chr3:10149979	C3orf24	-0.71	-6.38	-0.46	2.03e-9	Alzheimer's disease;
PAAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.91	9.47	0.61	5.25e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19346786	chr7:2764209	NA	-0.39	-5.42	-0.4	2.24e-7	Height;
PAAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.46	0.34	1.57e-5	Depression;
PAAD	trans	rs901683	1.000	rs71494786	chr10:45970117	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg16386425	chr10:429943	DIP2C	0.46	4.27	0.33	3.38e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.44	-4.67	-0.35	6.71e-6	HDL cholesterol;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.8	-6.53	-0.47	9.46e-10	Alzheimer's disease;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg14780883	chr15:25466402	SNORD115-15;SNORD115-21;HBII-52-28	0.65	6.67	0.48	4.55e-10	Blood protein levels;
PAAD	cis	rs2718812	0.935	rs1867502	chr3:133410625	C/A	cg12372414	chr3:134319805	KY	-0.41	-4.51	-0.34	1.27e-5	Iron status biomarkers;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06307176	chr5:131281290	NA	-0.52	-4.74	-0.36	4.96e-6	Life satisfaction;
PAAD	cis	rs10890920	0.587	rs10890932	chr11:108894922	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	QT interval (drug interaction);
PAAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg00035074	chr7:2701567	TTYH3	0.65	4.43	0.34	1.78e-5	Bipolar disorder;
PAAD	cis	rs9535307	0.584	rs73194445	chr13:50406547	T/C	cg03658251	chr13:50265850	EBPL	-0.8	-4.98	-0.37	1.68e-6	Obesity-related traits;
PAAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs4417704	0.551	rs4675789	chr2:241875481	A/G	cg26818257	chr2:241905806	NA	-0.47	-4.96	-0.37	1.85e-6	Joint mobility (Beighton score);
PAAD	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg02795151	chr17:7402630	POLR2A	-0.61	-5.8	-0.43	3.69e-8	Androgen levels;
PAAD	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.64	-0.35	7.33e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.79	-5.34	-0.4	3.4e-7	Coronary artery calcification;
PAAD	cis	rs75757892	0.544	rs9328414	chr6:7317630	A/G	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.47	-4.8	-0.36	3.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.2e-18	Electrocardiographic conduction measures;
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.66e-7	Blood metabolite levels;
PAAD	cis	rs2735413	0.875	rs12924402	chr16:78083477	C/G	cg04733911	chr16:78082701	NA	-0.55	-5.82	-0.43	3.3e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg23912435	chr1:150601613	ENSA	0.51	4.79	0.36	3.99e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-4.27	-0.33	3.45e-5	Monocyte count;
PAAD	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.92	9.02	0.59	7.76e-16	Nonalcoholic fatty liver disease;
PAAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.93	0.59	1.33e-15	Lung cancer;
PAAD	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.66	7.43	0.52	7.12e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08516262	chr3:101292886	PCNP	0.71	7.28	0.51	1.65e-11	Obesity-related traits;
PAAD	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.69	7.05	0.5	5.83e-11	Platelet count;
PAAD	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg17644776	chr2:200775616	C2orf69	-0.68	-5.88	-0.43	2.56e-8	Schizophrenia;
PAAD	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.72	7.47	0.52	6.01e-12	Retinal vascular caliber;
PAAD	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.72	6.75	0.48	2.97e-10	Total body bone mineral density;
PAAD	cis	rs1572438	0.839	rs6597297	chr6:864484	C/T	cg13447295	chr6:887704	NA	0.47	4.67	0.35	6.69e-6	Aging;
PAAD	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs5771040	0.521	rs4824155	chr22:50913543	A/C	cg03450049	chr22:50913555	SBF1	0.56	4.78	0.36	4.16e-6	IgG glycosylation;
PAAD	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg09163369	chr1:210001066	C1orf107	0.67	6.34	0.46	2.55e-9	Orofacial clefts;
PAAD	cis	rs8105895	0.935	rs9653142	chr19:22249596	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.08	0.38	1.11e-6	Vitamin D levels;
PAAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg27490568	chr2:178487706	NA	0.41	4.4	0.34	2.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6074578	0.679	rs1434789	chr20:137900	T/G	cg16931068	chr20:139680	DEFB127	0.36	4.92	0.37	2.24e-6	Hirschsprung disease;
PAAD	cis	rs1075265	0.840	rs10084355	chr2:54248848	G/A	cg04546899	chr2:54196757	PSME4	0.38	5.65	0.42	7.81e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.59	4.87	0.37	2.81e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.93	-0.54	4.44e-13	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23655816	chr2:162164767	PSMD14	-0.67	-6.77	-0.48	2.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs9815354	0.857	rs13087502	chr3:42015110	A/G	cg03022575	chr3:42003672	ULK4	0.73	5.27	0.39	4.58e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.93	8.07	0.55	1.99e-13	Gut microbiome composition (summer);
PAAD	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-4.71	-0.36	5.44e-6	Mean corpuscular volume;
PAAD	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.55e-5	Menopause (age at onset);
PAAD	cis	rs77880822	0.562	rs75601744	chr20:1251431	G/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg05895507	chr15:77155635	SCAPER	0.42	4.71	0.36	5.62e-6	Blood metabolite levels;
PAAD	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-5.01	-0.38	1.48e-6	Glycated hemoglobin levels;
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg13866156	chr1:1669148	SLC35E2	-0.79	-9.06	-0.59	6.16e-16	Body mass index;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.57	5.71	0.42	5.88e-8	Prostate cancer;
PAAD	cis	rs12042938	0.507	rs1765775	chr1:231731446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.74	-0.48	3.12e-10	Neuranatomic and neurocognitive phenotypes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14210634	chr1:25870291	LDLRAP1	0.61	6.99	0.49	8.14e-11	Monocyte percentage of white cells;
PAAD	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs877529	1.000	rs877529	chr22:39542292	G/A	cg18708252	chr22:39545030	CBX7	-0.44	-4.25	-0.33	3.73e-5	Multiple myeloma;
PAAD	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.69	-6.62	-0.47	5.8e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg22029157	chr1:209979665	IRF6	0.71	6.65	0.47	5.09e-10	Coronary artery disease;
PAAD	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.91	-9.85	-0.62	5.3e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4448343	0.963	rs3758302	chr9:98272630	G/C	cg13428213	chr9:98267529	PTCH1	0.46	4.38	0.33	2.2e-5	Height;
PAAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg14346243	chr4:90757452	SNCA	-0.52	-4.55	-0.35	1.1e-5	Neuroticism;
PAAD	cis	rs593531	0.513	rs7947911	chr11:74023751	G/A	cg15670924	chr11:73669256	DNAJB13	0.45	4.89	0.37	2.55e-6	Neuroticism;
PAAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.62	5.71	0.42	5.79e-8	Corneal astigmatism;
PAAD	cis	rs1075265	0.935	rs6545384	chr2:54301064	A/T	cg04546899	chr2:54196757	PSME4	0.31	4.37	0.33	2.29e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.57	-5.77	-0.42	4.24e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.13e-13	Dupuytren's disease;
PAAD	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg25025879	chr12:53359317	NA	-0.89	-5.57	-0.41	1.11e-7	Prostate cancer;
PAAD	cis	rs5769765	0.720	rs9628127	chr22:50166092	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.65	-5.39	-0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.34	4.39	0.34	2.12e-5	Schizophrenia;
PAAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.89	0.37	2.49e-6	Menopause (age at onset);
PAAD	cis	rs58521262	0.530	rs462713	chr19:23140705	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.04	-0.38	1.28e-6	Systemic lupus erythematosus;
PAAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg23033748	chr14:75592666	NEK9	0.42	5.05	0.38	1.23e-6	Height;
PAAD	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg21479132	chr6:26055353	NA	0.81	4.5	0.34	1.32e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.83	-8.43	-0.56	2.47e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs16958440	0.867	rs75481537	chr18:44719946	C/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs1075265	0.633	rs7564912	chr2:54222185	A/G	cg04546899	chr2:54196757	PSME4	0.31	4.69	0.36	6.13e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.62	-5.72	-0.42	5.4e-8	Multiple myeloma;
PAAD	cis	rs11158559	0.865	rs17102073	chr14:65242577	C/T	cg22797773	chr14:65239943	SPTB	-0.53	-4.35	-0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.58	-5.18	-0.39	7.03e-7	Iron status biomarkers;
PAAD	cis	rs76866386	0.892	rs3923912	chr2:44057570	A/C	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.31	-0.4	3.74e-7	Cholesterol, total;
PAAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.41	-4.53	-0.34	1.21e-5	Lung cancer;
PAAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.76	-8.63	-0.57	7.69e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.61	5.35	0.4	3.21e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg02683114	chr2:24398427	C2orf84	0.61	6.9	0.49	1.33e-10	Asthma;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.87	10.53	0.65	8.04e-20	Methadone dose in opioid dependence;
PAAD	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.4	4.35	0.33	2.51e-5	Monocyte count;
PAAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	trans	rs901683	0.702	rs34176769	chr10:46071027	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.47	6.02	0.44	1.27e-8	Electrocardiographic conduction measures;
PAAD	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.48	4.43	0.34	1.82e-5	Lewy body disease;
PAAD	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg17143192	chr8:8559678	CLDN23	0.57	5.3	0.39	4.04e-7	Obesity-related traits;
PAAD	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.53	5.74	0.42	5.01e-8	Mitral valve prolapse;
PAAD	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.5	4.55	0.35	1.1e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs6466055	0.661	rs67154126	chr7:104934281	A/G	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg21175976	chr8:11421337	BLK	-0.38	-4.31	-0.33	2.92e-5	Triglycerides;
PAAD	cis	rs11825685	0.836	rs56327979	chr11:134588757	A/T	cg02089395	chr11:134479357	NA	-0.66	-4.73	-0.36	5.19e-6	IgG glycosylation;
PAAD	cis	rs2031532	0.587	rs7317772	chr13:50042797	A/G	cg08779649	chr13:50194554	NA	0.35	4.76	0.36	4.45e-6	Cardiac hypertrophy;
PAAD	cis	rs7119167	0.813	rs7101831	chr11:73106690	T/C	cg17517138	chr11:73019481	ARHGEF17	0.59	4.25	0.33	3.68e-5	Blood protein levels;
PAAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.59	-5.46	-0.4	1.94e-7	Breast cancer;Mosquito bite size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06505107	chr7:1177883	C7orf50	-0.58	-7.08	-0.5	4.96e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.55	5.16	0.39	7.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07395648	chr5:131743802	NA	0.5	4.51	0.34	1.29e-5	Breast cancer;Mosquito bite size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10444080	chr1:3773652	DFFB;KIAA0562	-0.74	-6.36	-0.46	2.27e-9	Neuroticism;
PAAD	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.54	8.26	0.56	6.69e-14	Urinary metabolites;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.78e-5	Life satisfaction;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.34	0.33	2.63e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.6	6.6	0.47	6.5e-10	Melanoma;
PAAD	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg08698997	chr16:88989212	CBFA2T3	0.47	5.62	0.41	9.08e-8	Social autistic-like traits;
PAAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	5.76	0.42	4.44e-8	Educational attainment (years of education);
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.46	-0.34	1.62e-5	Tonsillectomy;
PAAD	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.97	-0.37	1.82e-6	Neuroticism;
PAAD	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.75	7.32	0.51	1.36e-11	Schizophrenia;
PAAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.65	-6.92	-0.49	1.18e-10	Childhood ear infection;
PAAD	cis	rs1642645	0.957	rs7550497	chr1:42505510	C/T	cg01990334	chr1:42801334	FOXJ3	0.58	5.43	0.4	2.23e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs1997066	0.831	rs73340295	chr10:106814619	C/A	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26068169	chr12:123717786	C12orf65	0.68	6.86	0.49	1.65e-10	Obesity-related traits;
PAAD	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.51	-5.43	-0.4	2.22e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg00262122	chr8:11665843	FDFT1	-0.51	-4.5	-0.34	1.36e-5	Neuroticism;
PAAD	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.61	4.82	0.36	3.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.99	0.37	1.66e-6	Menarche (age at onset);
PAAD	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs527409	1.000	rs528375	chr1:58725888	C/T	cg26345888	chr1:58716257	DAB1	0.64	4.3	0.33	3.01e-5	Kawasaki disease;
PAAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.3	0.68	7.09e-22	Menopause (age at onset);
PAAD	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.12e-6	Pulmonary function;
PAAD	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg06028605	chr16:24865363	SLC5A11	0.36	4.76	0.36	4.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs793571	0.784	rs12915713	chr15:59107862	T/A	cg05156742	chr15:59063176	FAM63B	0.6	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.83	9.94	0.63	2.98e-18	Coronary artery disease;
PAAD	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.64	-5.13	-0.38	8.54e-7	Vitiligo;
PAAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.56	0.35	1.04e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.77	6.74	0.48	3.03e-10	Dupuytren's disease;
PAAD	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-1.01	-14.4	-0.76	3.4e-30	Heart rate;
PAAD	cis	rs113779084	0.632	rs9648142	chr7:11939228	A/G	cg15090509	chr7:11872073	THSD7A	0.38	4.93	0.37	2.12e-6	Educational attainment (years of education);
PAAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg19000871	chr14:103996768	TRMT61A	-0.48	-4.98	-0.37	1.71e-6	Reticulocyte count;
PAAD	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg05250797	chr16:70222502	NA	0.79	5.85	0.43	2.88e-8	IgE levels;
PAAD	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg10518543	chr12:38710700	ALG10B	-0.47	-4.38	-0.33	2.24e-5	Morning vs. evening chronotype;
PAAD	cis	rs17094222	0.898	rs17113301	chr10:102396758	C/A	cg23779240	chr10:102438217	NA	-0.4	-4.42	-0.34	1.84e-5	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Bladder cancer;
PAAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.66	7.35	0.51	1.12e-11	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7291412	0.579	rs11090867	chr22:46454792	T/C	cg09693106	chr22:46449821	C22orf26;LOC150381	0.42	4.32	0.33	2.81e-5	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.68	7.1	0.5	4.48e-11	Colorectal cancer;
PAAD	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3e-7	Heart rate;
PAAD	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03923535	chr7:1197113	ZFAND2A	0.47	4.95	0.37	1.99e-6	Longevity;Endometriosis;
PAAD	cis	rs6466055	0.589	rs12534212	chr7:104641241	C/G	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs4742903	0.935	rs7872034	chr9:106896809	G/A	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4751058	0.526	rs10764841	chr10:130856829	A/C	cg09559163	chr10:130298860	NA	-0.4	-4.54	-0.35	1.13e-5	Vitamin D levels;
PAAD	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs950169	0.920	rs34672825	chr15:84703470	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.2	0.5	2.64e-11	Schizophrenia;
PAAD	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.55	4.26	0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.17	-0.45	5.9e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7873102	0.654	rs7044060	chr9:37956271	G/A	cg03528946	chr9:38069800	SHB	0.56	5.62	0.41	8.86e-8	Brain structure;
PAAD	cis	rs950880	0.710	rs3771172	chr2:102985812	C/T	cg23450938	chr2:102972792	NA	0.45	4.59	0.35	9.03e-6	Serum protein levels (sST2);
PAAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.63	-0.47	5.59e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.65	-7.04	-0.5	6.09e-11	Leprosy;
PAAD	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.6	-5.85	-0.43	2.9e-8	Post bronchodilator FEV1;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	6.55	0.47	8.59e-10	Total body bone mineral density;
PAAD	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.67	6.3	0.46	3.04e-9	Lymphocyte counts;
PAAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg03989125	chr22:38214979	NA	0.54	4.68	0.35	6.36e-6	Fat distribution (HIV);
PAAD	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.7	7.62	0.53	2.48e-12	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12292205	chr6:26970375	C6orf41	-0.52	-4.88	-0.37	2.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.44	4.51	0.34	1.31e-5	Longevity;Endometriosis;
PAAD	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	7.02	0.49	7.02e-11	Educational attainment;
PAAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.96	6.46	0.46	1.36e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg03538708	chr1:25844672	NA	-0.5	-5.05	-0.38	1.22e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.5	-5.84	-0.43	3.06e-8	Intelligence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25669900	chr5:133861733	PHF15	0.61	6.29	0.45	3.18e-9	Myopia (pathological);
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.92	7.98	0.54	3.25e-13	Alzheimer's disease;
PAAD	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.51	-4.67	-0.35	6.67e-6	Monocyte count;
PAAD	cis	rs7187994	0.848	rs34327141	chr16:84776991	C/T	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.62	5.72	0.42	5.45e-8	Mean corpuscular volume;
PAAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg24110177	chr3:50126178	RBM5	-0.71	-6.5	-0.47	1.08e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.65	-7.36	-0.51	1.06e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-4.53	-0.34	1.18e-5	Daytime sleep phenotypes;
PAAD	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.62	-0.35	8.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1797885	0.714	rs299662	chr3:12556507	T/A	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9435732	0.697	rs9435671	chr1:17339939	T/C	cg12442246	chr1:17004764	NA	0.52	4.81	0.36	3.55e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	7.8	0.53	9.12e-13	Menarche (age at onset);
PAAD	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg14515779	chr1:101123966	NA	0.53	6.72	0.48	3.39e-10	Monocyte count;
PAAD	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.67	-6.34	-0.46	2.52e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13606994	chr1:44402422	ARTN	-0.56	-5.52	-0.41	1.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg23018236	chr17:30244563	NA	0.64	4.94	0.37	2.07e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.22	-0.51	2.36e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.82	5.33	0.4	3.41e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	6.44	0.46	1.47e-9	Response to bleomycin (chromatid breaks);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21060784	chr13:99460097	DOCK9	-0.64	-6.86	-0.49	1.62e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.96	10.98	0.67	5.06e-21	Parkinson's disease;
PAAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.99	9.87	0.63	4.53e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	trans	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg14171944	chr9:126323477	DENND1A	0.54	6.32	0.46	2.79e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg05484376	chr2:27715224	FNDC4	0.47	4.66	0.35	6.99e-6	Total body bone mineral density;
PAAD	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.94	7.41	0.52	8.05e-12	Lymphocyte counts;
PAAD	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	6.53	0.47	9.33e-10	Body mass index;
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.77	5.72	0.42	5.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.91	-7.47	-0.52	5.91e-12	Orofacial clefts;
PAAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.95	12.26	0.71	1.89e-24	Pulse pressure;
PAAD	cis	rs6594713	0.533	rs67589221	chr5:112980860	G/T	cg12552261	chr5:112820674	MCC	0.71	4.42	0.34	1.84e-5	Brain cytoarchitecture;
PAAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg07153921	chr17:41440717	NA	-0.4	-4.32	-0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.72	-7.23	-0.51	2.16e-11	Urate levels in lean individuals;
PAAD	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs10991814	0.920	rs10512211	chr9:94104260	C/G	cg14446406	chr9:93919335	NA	0.54	4.54	0.35	1.15e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.51	5.98	0.44	1.53e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7631605	0.905	rs9836891	chr3:37148882	C/G	cg17445812	chr3:36986805	TRANK1	0.35	4.68	0.35	6.28e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26930615	chr7:42971990	MRPL32;PSMA2	0.55	6.46	0.46	1.36e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.53	-4.92	-0.37	2.24e-6	Red blood cell count;
PAAD	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.58	5.86	0.43	2.71e-8	Menopause (age at onset);
PAAD	cis	rs1499972	0.887	rs6799997	chr3:117520297	A/C	cg07612923	chr3:117604196	NA	1.06	7.0	0.49	7.85e-11	Schizophrenia;
PAAD	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	1.02	12.59	0.71	2.38e-25	Breast cancer;
PAAD	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg20406979	chr6:167373233	NA	0.33	4.43	0.34	1.76e-5	Crohn's disease;
PAAD	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24933247	chr19:19729558	PBX4	0.69	7.45	0.52	6.44e-12	Obesity-related traits;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.12	7.93	0.54	4.35e-13	Type 2 diabetes;
PAAD	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.62	6.68	0.48	4.31e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs4740619	0.682	rs10810514	chr9:16011896	C/G	cg14451791	chr9:16040625	NA	-0.4	-4.57	-0.35	1.02e-5	Body mass index;
PAAD	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.79	-6.24	-0.45	4.22e-9	Schizophrenia;
PAAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.63	7.07	0.5	5.3e-11	Emphysema distribution in smoking;
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.49	0.41	1.61e-7	Alzheimer's disease;
PAAD	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg00631329	chr6:26305371	NA	-0.49	-4.94	-0.37	2.07e-6	Educational attainment;
PAAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.5	-4.65	-0.35	7.16e-6	Breast cancer;
PAAD	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	14.4	0.76	3.43e-30	Testicular germ cell tumor;
PAAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7009516	0.647	rs12676485	chr8:24209891	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.42	-5.12	-0.38	8.97e-7	Hair greying;
PAAD	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.36	0.46	2.2e-9	Cognitive test performance;
PAAD	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg07636037	chr3:49044803	WDR6	-0.57	-4.51	-0.34	1.29e-5	Menarche (age at onset);
PAAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg22800045	chr5:56110881	MAP3K1	0.61	4.9	0.37	2.41e-6	Coronary artery disease;
PAAD	trans	rs1326986	0.702	rs12357731	chr10:20014781	G/A	cg04724540	chr1:166916762	ILDR2	-0.98	-6.55	-0.47	8.35e-10	Ankylosing spondylitis;
PAAD	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg25364880	chr3:44379878	C3orf23	0.57	5.13	0.38	8.62e-7	Depressive symptoms;
PAAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.78	4.62	0.35	8.24e-6	Body mass index;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg08235057	chr22:21057110	TMEM191A	0.55	6.3	0.46	3.08e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.71	-7.55	-0.52	3.81e-12	Response to antipsychotic treatment;
PAAD	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg16205897	chr5:131564050	P4HA2	0.42	4.65	0.35	7.03e-6	Breast cancer;
PAAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-9.79	-0.62	7.53e-18	Cognitive function;
PAAD	cis	rs72827839	0.802	rs16953382	chr17:46252906	C/T	cg23391107	chr17:45924227	SP6	0.62	5.31	0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs4450131	0.522	rs3781455	chr10:126347688	T/C	cg20435097	chr10:126320824	FAM53B	0.53	5.36	0.4	3e-7	White blood cell count (basophil);
PAAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.21	-0.39	6.12e-7	Monocyte count;
PAAD	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.63	5.86	0.43	2.76e-8	Red blood cell count;
PAAD	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.86	5.73	0.42	5.31e-8	Total cholesterol levels;
PAAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg18944383	chr4:111397179	ENPEP	-0.7	-8.2	-0.55	9.35e-14	Coronary artery disease;
PAAD	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs11828289	0.660	rs79067807	chr11:23228262	T/C	cg20040320	chr11:23191996	NA	-0.77	-5.48	-0.41	1.75e-7	Cancer;
PAAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.51	4.49	0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.61	6.33	0.46	2.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7082209	0.591	rs56179443	chr10:44816730	T/C	cg13191911	chr10:44806660	NA	-0.94	-4.31	-0.33	2.88e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.07	-8.59	-0.57	9.76e-15	Diabetic kidney disease;
PAAD	cis	rs2882667	0.690	rs288023	chr5:138224048	A/G	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs58653258	0.730	rs883278	chr1:234990504	C/T	cg03518729	chr1:235147744	NA	0.46	4.44	0.34	1.72e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4743820	0.590	rs10991785	chr9:93917111	C/T	cg14446406	chr9:93919335	NA	0.5	6.03	0.44	1.21e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-1.0	-6.98	-0.49	8.66e-11	Breast cancer (early onset);
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs2858942	0.575	rs2858011	chr16:247938	C/T	cg08400316	chr16:204221	HBZ	0.43	4.9	0.37	2.41e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg00601450	chr5:74908170	NA	-0.51	-5.06	-0.38	1.2e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
PAAD	cis	rs9287719	0.649	rs10803724	chr2:10732323	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg13047869	chr3:10149882	C3orf24	0.7	5.88	0.43	2.48e-8	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg11859384	chr17:80120422	CCDC57	-0.55	-5.82	-0.43	3.29e-8	Life satisfaction;
PAAD	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.86	-9.08	-0.59	5.24e-16	Body mass index;
PAAD	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.44	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09826364	chr7:158789723	NA	-0.37	-4.69	-0.36	5.95e-6	Facial morphology (factor 20);
PAAD	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.56	0.35	1.04e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.24	19.05	0.84	4.01e-42	Triglycerides;
PAAD	cis	rs16958440	0.867	rs10083937	chr18:44695602	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs17655565	0.581	rs7294465	chr12:52766001	C/G	cg22980804	chr12:52818037	KRT75	0.49	4.35	0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs7251275	0.625	rs304723	chr19:44102338	C/T	cg17121205	chr19:44009353	PHLDB3	0.35	4.4	0.34	2.02e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg08048268	chr3:133502702	NA	-0.52	-6.09	-0.44	8.64e-9	Iron status biomarkers;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg05313129	chr8:58192883	C8orf71	-0.68	-6.15	-0.45	6.65e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg03392386	chr11:133800800	IGSF9B	0.59	5.72	0.42	5.43e-8	Parkinson's disease;
PAAD	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.52	4.75	0.36	4.71e-6	Dental caries;
PAAD	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.6	-5.56	-0.41	1.18e-7	White matter hyperintensity burden;
PAAD	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.9	0.37	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs9462027	0.628	rs9469894	chr6:34774725	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.45	4.74	0.36	4.79e-6	Menopause (age at onset);
PAAD	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.28	-0.33	3.26e-5	Neuroticism;
PAAD	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs4253772	0.575	rs75097576	chr22:46763233	G/A	cg09491104	chr22:46646882	C22orf40	-1.03	-5.94	-0.43	1.84e-8	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg12395012	chr8:11607386	GATA4	0.41	4.25	0.33	3.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs2051773	0.567	rs11024116	chr11:17045886	A/G	cg15084286	chr11:17036142	PLEKHA7	0.55	4.88	0.37	2.67e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.63	-8.31	-0.56	4.93e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-6.25	-0.45	3.88e-9	Mitochondrial DNA levels;
PAAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.68	6.41	0.46	1.72e-9	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09800235	chr12:133250183	POLE	-0.7	-7.15	-0.5	3.36e-11	Obesity-related traits;
PAAD	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.62	5.68	0.42	6.7e-8	Alcohol dependence (age at onset);
PAAD	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg07469887	chr10:131262384	NA	-0.38	-4.27	-0.33	3.46e-5	Response to temozolomide;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.48	5.18	0.39	6.97e-7	Longevity;Endometriosis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21705063	chr6:108279337	SEC63	-0.73	-7.14	-0.5	3.7e-11	Lung cancer in ever smokers;
PAAD	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg00717180	chr2:96193071	NA	-0.6	-6.94	-0.49	1.04e-10	Height;
PAAD	cis	rs7301016	1.000	rs11614022	chr12:62891329	A/G	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs988913	0.647	rs3125287	chr6:54843606	A/C	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.15	0.39	8.05e-7	Total body bone mineral density;
PAAD	trans	rs34112283	0.568	rs34587631	chr2:144220173	G/A	cg10530280	chr1:167759869	MPZL1	-0.68	-6.68	-0.48	4.34e-10	Neuroticism;
PAAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.08	-0.38	1.1e-6	HDL cholesterol;
PAAD	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.69	-5.09	-0.38	1.03e-6	Hand grip strength;
PAAD	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg02404636	chr22:31891804	SFI1	0.63	6.06	0.44	1.01e-8	Colorectal cancer;
PAAD	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.94	9.81	0.62	6.47e-18	Cognitive function;
PAAD	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg01868782	chr6:126071099	HEY2	0.46	5.44	0.4	2.07e-7	Brugada syndrome;
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg17105886	chr17:28927953	LRRC37B2	0.67	4.47	0.34	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.66	6.92	0.49	1.19e-10	Schizophrenia;
PAAD	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg15676125	chr6:33679581	C6orf125	0.45	4.29	0.33	3.19e-5	Plateletcrit;
PAAD	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg25204440	chr1:209979598	IRF6	0.62	5.43	0.4	2.16e-7	Coronary artery disease;
PAAD	cis	rs939584	1.000	rs6711012	chr2:624034	C/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.53	4.7	0.36	5.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg01214346	chr17:406501	NA	-0.45	-4.62	-0.35	8e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01616529	chr11:638424	DRD4	-0.62	-5.82	-0.43	3.39e-8	Systemic lupus erythematosus;
PAAD	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg07162820	chr14:24837146	NFATC4	0.34	4.52	0.34	1.22e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg07308232	chr7:1071921	C7orf50	-0.44	-4.41	-0.34	1.91e-5	Longevity;Endometriosis;
PAAD	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.44	-6.53	-0.47	9.45e-10	Breast cancer;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs4462272	0.605	rs7079072	chr10:102008169	C/G	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.25e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg10351095	chr21:47802916	PCNT	0.5	4.88	0.37	2.65e-6	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg26597838	chr10:835615	NA	1.17	11.83	0.69	2.63e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2342371	0.715	rs9846106	chr3:196126539	G/A	cg08209042	chr3:196295218	WDR53;FBXO45	-0.58	-4.64	-0.35	7.38e-6	Fat distribution (HIV);
PAAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg23018236	chr17:30244563	NA	-0.61	-5.0	-0.38	1.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9921192	1.000	rs251736	chr16:4318455	A/G	cg07945448	chr16:4304224	NA	0.44	4.25	0.33	3.7e-5	Prostate-specific antigen levels;
PAAD	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg15145965	chr22:50218605	BRD1	0.56	4.59	0.35	9.08e-6	Schizophrenia;
PAAD	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.57	4.88	0.37	2.64e-6	Response to diuretic therapy;
PAAD	cis	rs3764563	0.825	rs682745	chr19:15701102	A/G	cg04981492	chr19:15218713	SYDE1	-0.45	-4.31	-0.33	2.94e-5	Inflammatory biomarkers;
PAAD	cis	rs1499972	0.564	rs62264773	chr3:117647875	G/A	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg20302533	chr7:39170763	POU6F2	0.45	6.92	0.49	1.17e-10	IgG glycosylation;
PAAD	cis	rs7250872	0.568	rs10405979	chr19:1840267	A/G	cg10370574	chr19:1840461	REXO1	-0.49	-4.58	-0.35	9.6e-6	Bipolar disorder;
PAAD	cis	rs9912789	0.518	rs62075318	chr17:79182778	T/C	cg14413466	chr17:79170920	AZI1	0.44	6.0	0.44	1.42e-8	Frontotemporal dementia;
PAAD	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.82	-6.7	-0.48	3.82e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.01e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.54	5.62	0.41	9.04e-8	Red blood cell count;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg10785373	chr7:4456119	NA	-0.77	-5.57	-0.41	1.15e-7	Borderline personality disorder;
PAAD	cis	rs2193412	0.502	rs58519896	chr2:51155839	C/A	cg27112565	chr2:51259552	NRXN1	-0.26	-4.28	-0.33	3.27e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg01329690	chr21:38580129	DSCR9	0.34	4.81	0.36	3.58e-6	Eye color traits;
PAAD	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs55788414	0.725	rs55634380	chr16:81188793	T/G	cg06400318	chr16:81190750	PKD1L2	-1.13	-8.27	-0.56	6.22e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg02297831	chr4:17616191	MED28	-0.61	-5.85	-0.43	2.98e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg06265175	chr8:121136014	COL14A1	0.47	4.53	0.34	1.18e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.34	0.33	2.56e-5	Schizophrenia;
PAAD	cis	rs2241685	0.646	rs1432539	chr2:1919847	C/T	cg22511877	chr2:1942942	MYT1L	0.54	4.26	0.33	3.54e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs2063714	1.000	rs2063714	chr6:157195980	C/G	cg23222435	chr6:157204239	ARID1B	-0.44	-4.33	-0.33	2.73e-5	Sitting height ratio;
PAAD	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.8	-9.18	-0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.81	8.36	0.56	3.81e-14	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg05025164	chr4:1340916	KIAA1530	0.58	4.33	0.33	2.65e-5	Systolic blood pressure;
PAAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs59104589	0.521	rs62190404	chr2:242401422	C/T	cg19488206	chr2:242435732	STK25	0.48	4.7	0.36	5.91e-6	Fibrinogen levels;
PAAD	cis	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg21546286	chr11:48923668	NA	-0.46	-4.91	-0.37	2.29e-6	Height;
PAAD	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg20312557	chr2:97357134	FER1L5	-0.85	-4.4	-0.34	2.01e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs10214930	0.671	rs2391449	chr7:27685146	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg10729496	chr3:10149963	C3orf24	0.84	6.74	0.48	3.14e-10	Alzheimer's disease;
PAAD	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.57	5.06	0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9361491	0.578	rs1180827	chr6:79434628	G/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11700980	0.551	rs58732433	chr21:30109534	C/T	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.94	11.43	0.68	3.16e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11051970	0.918	rs7309115	chr12:32541241	A/G	cg24626660	chr12:32551988	NA	0.42	4.59	0.35	9.36e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg22134325	chr11:66188745	NPAS4	0.32	4.71	0.36	5.64e-6	Airway imaging phenotypes;
PAAD	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs77741769	0.857	rs2004910	chr12:121374727	A/G	cg02403541	chr12:121454288	C12orf43	0.48	4.96	0.37	1.88e-6	Mean corpuscular volume;
PAAD	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.48	5.06	0.38	1.21e-6	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.8	10.65	0.65	3.98e-20	Cancer;
PAAD	cis	rs35160687	0.798	rs6547674	chr2:86552919	G/T	cg10973622	chr2:86423274	IMMT	-0.43	-4.57	-0.35	1e-5	Night sleep phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16737422	chr16:56642500	MT2A	-0.71	-6.36	-0.46	2.22e-9	Neuroticism;
PAAD	trans	rs12738007	0.717	rs4654328	chr1:29230345	C/T	cg05072552	chr11:65623512	CFL1	0.59	6.38	0.46	2.07e-9	Schizophrenia;
PAAD	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg02071572	chr4:1403502	NA	0.38	4.49	0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-6.37	-0.46	2.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.45	4.41	0.34	1.98e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16867321	1.000	rs10185265	chr2:181438860	G/C	cg23363182	chr2:181467187	NA	-0.52	-4.64	-0.35	7.55e-6	Obesity;
PAAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.44	4.96	0.37	1.84e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06850241	chr22:41845214	NA	0.57	5.03	0.38	1.38e-6	Vitiligo;
PAAD	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-10.63	-0.65	4.31e-20	Headache;
PAAD	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Height;
PAAD	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg02917321	chr22:38215204	NA	-0.45	-4.85	-0.37	3.01e-6	Glioblastoma;Glioma;
PAAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg23887609	chr12:130822674	PIWIL1	0.62	6.07	0.44	9.87e-9	Menopause (age at onset);
PAAD	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg22906224	chr7:99728672	NA	-0.65	-5.68	-0.42	6.75e-8	Coronary artery disease;
PAAD	cis	rs3126085	0.515	rs6671146	chr1:152354472	C/T	cg26876637	chr1:152193138	HRNR	-0.63	-4.6	-0.35	8.75e-6	Atopic dermatitis;
PAAD	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg08992911	chr2:238395768	MLPH	0.73	5.63	0.42	8.55e-8	Prostate cancer;
PAAD	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.87	6.82	0.48	2.07e-10	Prostate cancer;
PAAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.99	9.83	0.62	5.99e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs16867321	1.000	rs16867321	chr2:181362379	C/T	cg23363182	chr2:181467187	NA	-0.48	-4.29	-0.33	3.23e-5	Obesity;
PAAD	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.72	-7.26	-0.51	1.89e-11	Mosquito bite size;
PAAD	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg14393609	chr7:65229607	NA	0.5	4.34	0.33	2.57e-5	Aortic root size;
PAAD	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-5.31	-0.4	3.86e-7	Vitiligo;
PAAD	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg09597638	chr17:3907349	NA	-0.72	-7.77	-0.53	1.08e-12	Type 2 diabetes;
PAAD	cis	rs7766436	0.727	rs6908574	chr6:22610165	T/C	cg13666174	chr6:22585274	NA	-0.47	-4.88	-0.37	2.69e-6	Coronary artery disease;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg11335335	chr11:637885	DRD4	-0.37	-5.19	-0.39	6.74e-7	Systemic lupus erythematosus;
PAAD	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.61	-5.3	-0.4	3.92e-7	Schizophrenia;
PAAD	cis	rs11696501	0.694	rs1487325	chr20:44258989	A/G	cg11783356	chr20:44313418	WFDC10B	0.73	6.58	0.47	7.34e-10	Brain structure;
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs488248	0.507	rs78969061	chr13:106595652	A/T	cg03898952	chr13:107069935	NA	0.74	4.59	0.35	9.11e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.68	-5.15	-0.39	8.06e-7	Type 2 diabetes;
PAAD	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.39	-0.34	2.13e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.64	-5.57	-0.41	1.15e-7	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.11	0.5	4.29e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs17023223	0.537	rs12072768	chr1:119593918	A/G	cg17326555	chr1:119535693	NA	-0.43	-5.32	-0.4	3.7e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.29e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.87	0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11563648	0.517	rs10255062	chr7:127024057	T/C	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg03417191	chr3:183542750	MAP6D1	-0.58	-5.09	-0.38	1.03e-6	Menopause (age at onset);
PAAD	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.43	4.37	0.33	2.26e-5	Height;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg08088566	chr11:430123	ANO9	0.85	5.39	0.4	2.7e-7	Body mass index;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20377999	chr15:62538159	NA	0.46	4.87	0.37	2.83e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.09	0.63	1.22e-18	Bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00610583	chr4:74735056	CXCL1	-0.68	-7.34	-0.51	1.23e-11	Smoking initiation;
PAAD	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.87	6.89	0.49	1.38e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Testicular germ cell tumor;
PAAD	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-4.59	-0.35	9.19e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg24879335	chr3:133465180	TF	-0.61	-7.19	-0.5	2.68e-11	Iron status biomarkers (transferrin levels);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18226478	chr1:166845693	TADA1	-0.67	-6.72	-0.48	3.41e-10	Lung cancer in ever smokers;
PAAD	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg01489032	chr8:143877656	NA	0.42	4.42	0.34	1.87e-5	Urinary tract infection frequency;
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	2.99e-5	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.78	-8.33	-0.56	4.41e-14	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16654771	chr6:159239474	EZR	-0.57	-6.7	-0.48	3.74e-10	Body fat percentage;
PAAD	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.82	-0.36	3.48e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.37	4.62	0.35	8.21e-6	Height;
PAAD	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.91	0.37	2.35e-6	High light scatter reticulocyte count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23151374	chr4:164415611	C4orf43	0.63	6.97	0.49	8.81e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.53	-4.86	-0.37	2.87e-6	Height;
PAAD	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg01631408	chr1:248437212	OR2T33	0.59	5.44	0.4	2.08e-7	Common traits (Other);
PAAD	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.09	0.38	1.02e-6	Childhood ear infection;
PAAD	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.5e-12	Resting heart rate;
PAAD	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs1997066	0.831	rs73340277	chr10:106809239	T/C	cg17321814	chr10:106440892	SORCS3	0.64	4.42	0.34	1.87e-5	Diabetic kidney disease;
PAAD	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.49	4.78	0.36	4.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.5	4.42	0.34	1.85e-5	Acne (severe);
PAAD	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg07384165	chr1:10488281	NA	-0.45	-4.79	-0.36	3.94e-6	Breast size;
PAAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg05785598	chr3:49045655	WDR6	0.43	5.2	0.39	6.24e-7	Parkinson's disease;
PAAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg16434002	chr17:42200994	HDAC5	-0.51	-5.41	-0.4	2.4e-7	Bone mineral density (hip);Bone mineral density;
PAAD	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.96	11.22	0.67	1.13e-21	Total cholesterol levels;
PAAD	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.45	-5.06	-0.38	1.22e-6	Inflammatory bowel disease;
PAAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.53	-4.44	-0.34	1.75e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.43	4.68	0.35	6.38e-6	HDL cholesterol levels;
PAAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg02725872	chr8:58115012	NA	-0.61	-4.91	-0.37	2.32e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.97	13.03	0.73	1.56e-26	Menopause (age at onset);
PAAD	trans	rs34416917	0.500	rs114875036	chr5:36426671	C/A	cg10008757	chr10:8097183	GATA3	-0.95	-6.51	-0.47	1.01e-9	Borderline personality disorder;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg25312966	chr22:24408316	CABIN1	-0.61	-6.69	-0.48	3.94e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg23920097	chr1:209922102	NA	-0.52	-4.9	-0.37	2.41e-6	Red blood cell count;
PAAD	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg17764715	chr19:33622953	WDR88	0.68	6.34	0.46	2.5e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.54	4.6	0.35	8.87e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15192986	chr13:46630673	CPB2	-0.51	-4.8	-0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.84e-8	Personality dimensions;
PAAD	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	9.71	0.62	1.19e-17	Ulcerative colitis;
PAAD	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.63	-5.7	-0.42	5.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	6.11	0.44	8.1e-9	Multiple sclerosis;
PAAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg12639453	chr1:2035780	PRKCZ	0.52	5.49	0.41	1.66e-7	Height;
PAAD	cis	rs80346118	0.636	rs6012533	chr20:47416665	T/A	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.59	-4.38	-0.33	2.19e-5	Diastolic blood pressure;
PAAD	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.78	-0.42	4.02e-8	Coronary artery disease;
PAAD	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg23109721	chr2:106886537	NA	-0.67	-5.94	-0.43	1.86e-8	Facial morphology (factor 23);
PAAD	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.67	10.07	0.63	1.33e-18	Huntington's disease progression;
PAAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg14393609	chr7:65229607	NA	-0.59	-6.25	-0.45	3.91e-9	Aortic root size;
PAAD	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06771106	chr2:113671356	IL1F7	-0.62	-6.74	-0.48	3.05e-10	Pulmonary function;
PAAD	cis	rs16854884	1.000	rs17668478	chr3:143794370	G/A	cg06585982	chr3:143692056	C3orf58	0.59	5.57	0.41	1.11e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-1.04	-8.33	-0.56	4.43e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.67	5.81	0.43	3.53e-8	Inflammatory skin disease;
PAAD	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg01585852	chr22:24235823	MIF	0.47	4.88	0.37	2.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19434433	chr17:44849214	WNT3	0.62	6.53	0.47	9.44e-10	Myopia (pathological);
PAAD	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23654844	chr1:153643515	ILF2	-0.79	-8.34	-0.56	4.06e-14	Lung cancer in ever smokers;
PAAD	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12940923	0.507	rs12944679	chr17:56372280	C/T	cg14843216	chr17:56064736	VEZF1	-0.51	-4.3	-0.33	3.09e-5	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22396632	chr1:3079212	PRDM16	0.41	4.34	0.33	2.56e-5	Migraine;
PAAD	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.54	5.91	0.43	2.17e-8	Testicular germ cell tumor;
PAAD	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg23947450	chr7:900037	UNC84A	-0.56	-4.54	-0.35	1.16e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg16176600	chr6:116381609	FRK	-0.31	-4.53	-0.34	1.21e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg14146966	chr2:61757674	XPO1	0.37	4.69	0.36	5.93e-6	Tuberculosis;
PAAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.52	0.47	9.58e-10	Lung cancer;
PAAD	cis	rs6594713	0.605	rs66540465	chr5:112840706	G/A	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg14346243	chr4:90757452	SNCA	-0.51	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.42	-0.4	2.27e-7	Response to antipsychotic treatment;
PAAD	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg19039313	chr2:136634366	MCM6	-0.51	-4.33	-0.33	2.74e-5	Corneal structure;
PAAD	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21862992	chr11:68658383	NA	0.41	4.49	0.34	1.41e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs17655565	0.588	rs12426932	chr12:52727876	A/G	cg22980804	chr12:52818037	KRT75	-0.53	-4.56	-0.35	1.07e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg24555670	chr8:18244502	NA	0.59	5.56	0.41	1.19e-7	Blood metabolite levels;
PAAD	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg01064725	chr1:204461714	NA	-0.51	-4.66	-0.35	6.91e-6	Schizophrenia;
PAAD	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.72	6.98	0.49	8.62e-11	Hip circumference;
PAAD	trans	rs7172971	0.592	rs78171718	chr15:42386342	C/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-5.94	-0.43	1.89e-8	Longevity;
PAAD	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.75	8.16	0.55	1.18e-13	Superior crus of antihelix expression;
PAAD	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.51	-0.47	1.03e-9	Chronic sinus infection;
PAAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.83	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg14393609	chr7:65229607	NA	0.64	6.82	0.48	2.02e-10	Calcium levels;
PAAD	cis	rs12779790	0.556	rs17565905	chr10:12239944	C/T	cg10286056	chr10:12940470	CCDC3	0.5	4.34	0.33	2.57e-5	Type 2 diabetes;
PAAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02244288	chr16:89573955	SPG7	-0.3	-4.25	-0.33	3.72e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg10820045	chr2:198174542	NA	-0.49	-4.98	-0.37	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09436681	chr12:124497105	ZNF664	-0.63	-6.42	-0.46	1.62e-9	Obesity-related traits;
PAAD	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.15	-0.39	7.83e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs4621152	0.775	rs17777330	chr2:217891692	A/G	cg21875423	chr2:217559867	IGFBP5	-0.45	-4.48	-0.34	1.44e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2036402	0.704	rs60573342	chr5:156345439	C/G	cg21915449	chr5:156456672	HAVCR1	-0.43	-4.68	-0.35	6.39e-6	Hypertriglyceridemia;
PAAD	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg14458575	chr2:238380390	NA	0.55	6.22	0.45	4.62e-9	Prostate cancer;
PAAD	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3760982	0.520	rs425578	chr19:44302256	A/T	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs17601876	0.814	rs8038715	chr15:51561120	T/A	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg07689907	chr11:61582574	FADS1	0.56	5.0	0.38	1.59e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.87	6.54	0.47	8.72e-10	Axial length;
PAAD	cis	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.55	-5.34	-0.4	3.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.77	-0.42	4.3e-8	Gut microbiome composition (summer);
PAAD	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.22	-17.43	-0.82	4.37e-38	Triglycerides;
PAAD	cis	rs1997066	0.831	rs80041068	chr10:106821846	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg27490568	chr2:178487706	NA	0.45	4.85	0.37	3.08e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg01304814	chr3:48885189	PRKAR2A	0.97	5.4	0.4	2.5e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.8	-8.93	-0.59	1.3e-15	Iron status biomarkers;
PAAD	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg21775007	chr8:11205619	TDH	-0.57	-4.93	-0.37	2.12e-6	Neuroticism;
PAAD	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.63	-0.35	7.69e-6	Prevalent atrial fibrillation;
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07343612	chr16:622815	PIGQ	-0.81	-9.03	-0.59	7.4e-16	Height;
PAAD	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg20893579	chr22:38215064	NA	0.53	4.91	0.37	2.34e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11958404	0.546	rs6556332	chr5:157433684	A/G	cg05962755	chr5:157440814	NA	0.55	5.37	0.4	2.85e-7	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22792063	chr14:23067579	ABHD4	0.66	6.93	0.49	1.1e-10	Obesity-related traits;
PAAD	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.55	-5.32	-0.4	3.7e-7	Multiple sclerosis;
PAAD	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.43	4.79	0.36	4e-6	Refractive error;
PAAD	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.84	8.61	0.57	8.73e-15	Height;
PAAD	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg22517653	chr1:2918612	NA	0.66	5.23	0.39	5.42e-7	Plateletcrit;
PAAD	cis	rs3739998	0.686	rs2505084	chr10:30335520	C/T	cg27036936	chr10:30305021	KIAA1462	0.39	4.53	0.35	1.17e-5	Coronary heart disease;
PAAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg14416269	chr4:6271139	WFS1	0.7	7.71	0.53	1.51e-12	Cisplatin-induced ototoxicity;
PAAD	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.91	-9.85	-0.62	5.3e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6494488	0.500	rs72742982	chr15:64977055	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.38	0.33	2.18e-5	Coronary artery disease;
PAAD	cis	rs12040273	0.908	rs1555291	chr1:230207475	A/G	cg22077894	chr1:229730133	TAF5L	0.65	4.47	0.34	1.5e-5	Carotid intima media thickness;
PAAD	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg10705379	chr10:99080932	FRAT1	-0.4	-4.39	-0.34	2.08e-5	Monocyte count;
PAAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.57	-6.48	-0.47	1.22e-9	Prostate cancer;
PAAD	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.99	14.06	0.75	2.68e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs332507	0.750	rs3755680	chr3:124356460	A/G	cg05980111	chr3:124395277	KALRN	0.48	4.48	0.34	1.48e-5	Plateletcrit;
PAAD	cis	rs829661	0.762	rs829680	chr2:30709088	G/T	cg12454169	chr2:30669597	LCLAT1	0.64	4.89	0.37	2.51e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.04e-5	Life satisfaction;
PAAD	cis	rs58521262	0.685	rs289291	chr19:23177889	T/C	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs4343996	0.692	rs10258501	chr7:3460355	A/C	cg21248987	chr7:3385318	SDK1	0.5	5.46	0.4	1.91e-7	Motion sickness;
PAAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.98e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg00455402	chr19:21769736	NA	-0.48	-4.3	-0.33	3.06e-5	Pain;
PAAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.71	7.02	0.49	7.06e-11	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg22143856	chr6:28129313	ZNF389	0.59	4.69	0.36	5.99e-6	Depression;
PAAD	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.75e-9	Hip circumference;
PAAD	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	5.12	0.38	9.02e-7	Mean platelet volume;
PAAD	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25053232	chr7:2394393	EIF3B	0.65	6.31	0.46	2.88e-9	Obesity-related traits;
PAAD	cis	rs7688540	0.511	rs11735723	chr4:199637	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.61	4.91	0.37	2.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs863345	0.604	rs12041350	chr1:158482048	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-5.0	-0.38	1.59e-6	Pneumococcal bacteremia;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs73206853	0.688	rs60971459	chr12:110702051	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.35e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17508320	chr5:86180476	NA	-0.62	-6.84	-0.49	1.82e-10	Obesity-related traits;
PAAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.78	6.73	0.48	3.25e-10	Response to amphetamines;
PAAD	cis	rs9649465	0.967	rs10269196	chr7:123321073	G/T	cg04330084	chr7:123175371	IQUB	-0.52	-4.9	-0.37	2.4e-6	Migraine;
PAAD	cis	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.46	4.34	0.33	2.57e-5	Endometrial cancer;
PAAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.92	-10.78	-0.66	1.78e-20	Cognitive function;
PAAD	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg15309053	chr8:964076	NA	0.61	7.08	0.5	4.9e-11	Schizophrenia;
PAAD	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs9810890	1.000	rs114352136	chr3:128440226	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg17541715	chr7:1216824	NA	-0.55	-6.37	-0.46	2.17e-9	Longevity;Endometriosis;
PAAD	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.44	4.32	0.33	2.86e-5	Breast cancer;
PAAD	cis	rs859767	0.812	rs842358	chr2:135345109	C/T	cg12500956	chr2:135428796	TMEM163	0.35	5.08	0.38	1.08e-6	Neuroticism;
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	1.06	8.64	0.57	7.44e-15	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.42	5.67	0.42	7.01e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs9463078	0.585	rs12208924	chr6:45342051	C/T	cg18551225	chr6:44695536	NA	-0.41	-4.3	-0.33	2.99e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06634786	chr22:41940651	POLR3H	0.66	4.74	0.36	4.77e-6	Vitiligo;
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21862992	chr11:68658383	NA	0.44	4.66	0.35	6.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg16558253	chr16:72132732	DHX38	-0.45	-5.12	-0.38	9.17e-7	Fibrinogen levels;
PAAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.48	-5.31	-0.4	3.74e-7	Major depressive disorder;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01200585	chr1:228362443	C1orf69	0.54	5.95	0.43	1.79e-8	Diastolic blood pressure;
PAAD	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-8.39	-0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.49	-4.36	-0.33	2.39e-5	Metabolite levels;
PAAD	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg16386425	chr10:429943	DIP2C	0.52	5.07	0.38	1.13e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg03983715	chr16:68378420	PRMT7	-0.94	-7.1	-0.5	4.46e-11	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.72	7.72	0.53	1.47e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg02196655	chr2:10830764	NOL10	-0.57	-5.82	-0.43	3.4e-8	Prostate cancer;
PAAD	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.83	-6.29	-0.45	3.18e-9	Coronary artery calcification;
PAAD	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.63	7.12	0.5	4e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.76	8.51	0.57	1.58e-14	Lewy body disease;
PAAD	cis	rs7624766	0.555	rs1378654	chr3:160527151	C/T	cg22637730	chr3:160473554	PPM1L	0.51	4.38	0.34	2.16e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg04165759	chr1:150448943	RPRD2	0.5	5.17	0.39	7.4e-7	Migraine;
PAAD	cis	rs12913538	0.513	rs12441930	chr15:62889367	C/G	cg09983546	chr15:62884068	NA	0.63	6.33	0.46	2.65e-9	Sleep depth;
PAAD	cis	rs4455778	0.580	rs34005483	chr7:49094307	A/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg05484376	chr2:27715224	FNDC4	0.49	5.01	0.38	1.5e-6	Total body bone mineral density;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg04775059	chr7:64541387	NA	0.59	6.19	0.45	5.39e-9	Calcium levels;
PAAD	cis	rs11718455	0.573	rs4682701	chr3:43905870	G/A	cg21419209	chr3:44054225	NA	0.57	5.59	0.41	1.02e-7	Coronary artery disease;
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg21665744	chr7:39171113	POU6F2	-0.35	-5.98	-0.44	1.53e-8	IgG glycosylation;
PAAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.78	9.69	0.62	1.4e-17	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.75	7.33	0.51	1.3e-11	Post bronchodilator FEV1;
PAAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.77	-8.7	-0.58	5.03e-15	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.43	4.3	0.33	2.99e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.47e-10	Lung cancer;
PAAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.78	-0.36	4.18e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg13010199	chr12:38710504	ALG10B	-0.45	-4.25	-0.33	3.71e-5	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg06740227	chr12:86229804	RASSF9	0.49	4.68	0.36	6.2e-6	Major depressive disorder;
PAAD	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.65	-0.42	7.59e-8	Reticulocyte count;
PAAD	cis	rs11696501	0.688	rs1487310	chr20:44308789	A/G	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.65	-5.19	-0.39	6.64e-7	IgG glycosylation;
PAAD	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23260799	chr11:451101	PTDSS2	0.6	6.66	0.48	4.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2659703	0.749	rs2713611	chr3:128171536	G/A	cg24680163	chr3:127842675	RUVBL1	0.51	4.39	0.34	2.1e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.85	5.53	0.41	1.37e-7	Systolic blood pressure;
PAAD	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.76	-0.36	4.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Educational attainment;
PAAD	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.49	4.55	0.35	1.07e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-1.02	-9.31	-0.6	1.33e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.94	0.37	2.06e-6	Ovarian reserve;
PAAD	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.67	-7.41	-0.52	8.05e-12	Systemic lupus erythematosus;
PAAD	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg18093559	chr17:18951025	GRAP	0.47	4.78	0.36	4.06e-6	Schizophrenia;
PAAD	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg14343924	chr8:8086146	FLJ10661	-0.56	-5.03	-0.38	1.34e-6	Joint mobility (Beighton score);
PAAD	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg08992911	chr2:238395768	MLPH	0.54	4.83	0.36	3.29e-6	Prostate cancer;
PAAD	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.4	5.01	0.38	1.5e-6	Pulmonary function;
PAAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.5	0.34	1.33e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.87	9.65	0.62	1.8e-17	Cognitive function;
PAAD	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.72	8.12	0.55	1.48e-13	Prostate cancer;
PAAD	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.71	8.3	0.56	5.18e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs1075265	0.901	rs9808326	chr2:54343108	G/C	cg04546899	chr2:54196757	PSME4	0.33	4.63	0.35	7.77e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.78	0.36	4.12e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	4.53	0.34	1.18e-5	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg09796270	chr17:17721594	SREBF1	0.47	5.0	0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg21784768	chr11:537496	LRRC56	0.83	4.32	0.33	2.77e-5	Body mass index;
PAAD	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg20487152	chr13:99095054	FARP1	-0.48	-4.74	-0.36	4.98e-6	Longevity;
PAAD	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.73	-0.36	5.12e-6	HDL cholesterol;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	6.0	0.44	1.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.71	5.24	0.39	5.17e-7	Initial pursuit acceleration;
PAAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg04844267	chr4:1394941	NA	0.44	5.0	0.38	1.59e-6	Longevity;
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.8	10.13	0.63	9.32e-19	Vitiligo;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.48	4.49	0.34	1.42e-5	Airway imaging phenotypes;
PAAD	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.87	10.28	0.64	3.84e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg05650719	chr12:132293520	NA	0.47	4.84	0.37	3.12e-6	Migraine;
PAAD	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.57	-5.12	-0.38	9.22e-7	Breast cancer;
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.03	0.55	2.5e-13	Menopause (age at onset);
PAAD	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Subjective well-being;
PAAD	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-6.47	-0.46	1.25e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.63e-6	Renal cell carcinoma;
PAAD	cis	rs6912958	0.703	rs4365903	chr6:88282653	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.76	-0.36	4.54e-6	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg21977766	chr11:1107580	NA	0.46	4.61	0.35	8.41e-6	Alzheimer's disease (late onset);
PAAD	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg02404636	chr22:31891804	SFI1	-0.54	-5.01	-0.38	1.53e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.75	9.23	0.6	2.17e-16	Bladder cancer;
PAAD	cis	rs6800768	0.633	rs60706278	chr3:24101424	T/A	cg10674438	chr3:24145617	LOC152024	-0.47	-4.34	-0.33	2.54e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-4.39	-0.34	2.09e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg04025307	chr7:1156635	C7orf50	0.68	5.01	0.38	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.86	11.23	0.67	1.09e-21	Heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24659538	chr1:160222618	DCAF8	-0.64	-6.61	-0.47	6.13e-10	Obesity-related traits;
PAAD	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg23018236	chr17:30244563	NA	-0.54	-5.13	-0.38	8.66e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	1.09	12.09	0.7	5.24e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-6.63	-0.47	5.66e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00982548	chr2:198649783	BOLL	-0.84	-5.85	-0.43	2.9e-8	Ulcerative colitis;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.67	-0.48	4.52e-10	Initial pursuit acceleration;
PAAD	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.98	-15.31	-0.78	1.3e-32	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06175036	chr4:846732	GAK	0.62	7.23	0.51	2.16e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2885056	0.891	rs12978787	chr19:10691557	G/A	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	cis	rs12935418	0.583	rs2167889	chr16:81021472	G/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.34e-8	Mean corpuscular volume;
PAAD	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.59	-5.33	-0.4	3.41e-7	Post bronchodilator FEV1;
PAAD	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.42	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.82	-0.36	3.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.92	7.21	0.5	2.5e-11	Iron status biomarkers;
PAAD	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg03060546	chr3:49711283	APEH	0.67	6.66	0.48	4.69e-10	Red cell distribution width;
PAAD	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg10495392	chr1:46806563	NSUN4	-0.54	-5.42	-0.4	2.3e-7	Menopause (age at onset);
PAAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.49e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.1	-0.38	9.84e-7	Common traits (Other);
PAAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.56	5.29	0.39	4.23e-7	Type 2 diabetes;
PAAD	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.13	-13.79	-0.75	1.44e-28	Colorectal cancer;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.06e-8	Life satisfaction;
PAAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12936587	0.633	rs12941217	chr17:17503206	G/A	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.36	-0.33	2.4e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg19486271	chr11:47235900	DDB2	-0.59	-5.83	-0.43	3.18e-8	Acne (severe);
PAAD	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.26	-7.26	-0.51	1.85e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs11615916	0.722	rs7133047	chr12:62673088	T/C	cg11441379	chr12:63026424	NA	0.69	4.56	0.35	1.06e-5	Pulmonary function decline;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07012231	chr7:47384322	TNS3	0.57	6.53	0.47	9.27e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3785309	0.519	rs111739409	chr16:283955	T/G	cg27201940	chr16:1219628	CACNA1H	0.86	4.66	0.35	6.97e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.97	-0.44	1.6e-8	Menarche (age at onset);
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg14851346	chr12:38532713	NA	0.49	4.52	0.34	1.25e-5	Morning vs. evening chronotype;
PAAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.45	-4.69	-0.36	6.02e-6	Blood protein levels;
PAAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.58	-6.44	-0.46	1.45e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs564309	0.867	rs35711644	chr1:228556403	C/T	cg01328119	chr1:228783545	DUSP5P	0.71	4.43	0.34	1.81e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.7	-6.85	-0.49	1.73e-10	Anterior chamber depth;
PAAD	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg22134325	chr11:66188745	NPAS4	0.29	4.3	0.33	2.99e-5	Airway imaging phenotypes;
PAAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.35	-0.68	5.25e-22	Height;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.89	0.37	2.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.53	5.38	0.4	2.71e-7	Schizophrenia;
PAAD	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg06026331	chr20:60912101	LAMA5	-0.6	-5.56	-0.41	1.17e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs654950	0.875	rs2759248	chr1:41990795	T/C	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.65	-0.42	7.68e-8	Airway imaging phenotypes;
PAAD	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.5	7.33	0.51	1.27e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs863345	0.967	rs863346	chr1:158535911	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.97e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.51	-4.29	-0.33	3.21e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14169450	chr9:139327907	INPP5E	0.57	4.94	0.37	2.02e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	4.92	0.37	2.27e-6	Yeast infection;
PAAD	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Cognitive function;
PAAD	cis	rs6460942	0.597	rs17448913	chr7:12533984	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.48	5.18	0.39	6.9e-7	Electroencephalogram traits;
PAAD	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg04546413	chr19:29218101	NA	0.71	5.93	0.43	1.94e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs686320	0.588	rs11602839	chr11:65177439	G/A	cg16175245	chr11:65246563	NA	0.48	4.31	0.33	2.9e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg18833306	chr6:118973337	C6orf204	0.56	4.65	0.35	7.13e-6	Diastolic blood pressure;
PAAD	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.61	4.95	0.37	1.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs58749629	1.000	rs3827066	chr20:44586023	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.7	-4.81	-0.36	3.55e-6	Abdominal aortic aneurysm;
PAAD	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.46	6.19	0.45	5.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg14393609	chr7:65229607	NA	0.64	6.8	0.48	2.25e-10	Aortic root size;
PAAD	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.53	-5.03	-0.38	1.39e-6	Glycated hemoglobin levels;
PAAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.42	0.34	1.88e-5	Personality dimensions;
PAAD	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-8.15	-0.55	1.25e-13	Alcohol dependence;
PAAD	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-4.66	-0.35	6.72e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg22437258	chr11:111473054	SIK2	-0.53	-4.93	-0.37	2.12e-6	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg04194840	chr16:58545502	NDRG4	0.72	4.39	0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.56	8.19	0.55	1.01e-13	Diastolic blood pressure;
PAAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg12705353	chr12:122356852	WDR66	0.51	5.16	0.39	7.58e-7	Mean corpuscular volume;
PAAD	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg16083429	chr3:49237500	CCDC36	0.45	4.35	0.33	2.46e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg02841227	chr6:26021843	HIST1H4A	-0.42	-4.3	-0.33	3.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.6	7.0	0.49	7.81e-11	Dupuytren's disease;
PAAD	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs939584	1.000	rs1320337	chr2:649867	A/T	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-6.81	-0.48	2.11e-10	Asthma;
PAAD	cis	rs7651511	1.000	rs3806647	chr3:141205563	G/A	cg25967872	chr3:141205623	RASA2	0.51	4.53	0.35	1.16e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.61	6.42	0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14180030	chr9:123475675	MEGF9	-0.46	-5.12	-0.38	9.14e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4742903	0.935	rs10116938	chr9:106977255	T/G	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg07148914	chr20:33460835	GGT7	-0.57	-5.63	-0.42	8.27e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.5	4.9	0.37	2.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg13722127	chr7:150037890	RARRES2	0.69	6.91	0.49	1.26e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg02462569	chr6:150064036	NUP43	-0.43	-4.62	-0.35	8.22e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.56	-0.35	1.05e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs16975963	0.843	rs17249047	chr19:38336563	A/G	cg25793785	chr19:38281423	NA	0.6	4.95	0.37	1.91e-6	Longevity;
PAAD	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg14500798	chr7:98100126	NA	0.43	4.56	0.35	1.03e-5	Breast cancer;
PAAD	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.7	-0.42	6.17e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2880058	0.709	rs12568518	chr1:162036570	A/C	cg22816059	chr5:422114	AHRR	-0.63	-6.31	-0.46	2.94e-9	QT interval;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13198984	chr17:80129470	CCDC57	0.42	5.17	0.39	7.26e-7	Life satisfaction;
PAAD	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.53	-0.47	9.4e-10	Aortic root size;
PAAD	cis	rs75920871	0.688	rs55703909	chr11:116984866	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.85	-4.27	-0.33	3.45e-5	Subjective well-being;
PAAD	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg12395012	chr8:11607386	GATA4	-0.42	-4.71	-0.36	5.57e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs73001065	0.786	rs72999033	chr19:19366632	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	4.56	0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	7.62	0.53	2.47e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23158103	chr7:148848205	ZNF398	-0.6	-5.58	-0.41	1.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs73019876	0.869	rs2522092	chr19:22126992	G/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-11.5	-0.68	2.06e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs7715811	1.000	rs2173980	chr5:13767116	A/T	cg07548982	chr5:13769939	DNAH5	-0.65	-6.26	-0.45	3.7e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06360820	chr2:242988706	NA	-1.18	-9.84	-0.62	5.4e-18	Obesity-related traits;
PAAD	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.81	-0.79	6.49e-34	Schizophrenia;
PAAD	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs17507216	0.591	rs7163848	chr15:83398315	C/T	cg03180980	chr15:83240633	CPEB1	0.55	4.28	0.33	3.24e-5	Excessive daytime sleepiness;
PAAD	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.75	-5.53	-0.41	1.33e-7	Coronary artery calcification;
PAAD	cis	rs11078597	0.731	rs4989024	chr17:1639719	A/G	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.4e-8	Serum albumin level;
PAAD	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.15	0.39	8.03e-7	Cognitive test performance;
PAAD	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.47	-0.41	1.83e-7	Response to antipsychotic treatment;
PAAD	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.49	-0.34	1.43e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg08648136	chr8:956695	NA	0.42	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs7084783	0.538	rs3781367	chr10:105337294	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.47	4.73	0.36	4.98e-6	Fear of pain;
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg20849893	chr7:64541193	NA	0.48	4.76	0.36	4.54e-6	Calcium levels;
PAAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.61	-5.92	-0.43	2.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.66	-0.35	6.98e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6132905	0.590	rs17228085	chr20:2607429	C/T	cg24848351	chr20:2622020	TMC2	0.59	4.48	0.34	1.48e-5	Mumps;
PAAD	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.51	-5.53	-0.41	1.33e-7	Migraine - clinic-based;
PAAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.34	0.33	2.57e-5	IgG glycosylation;
PAAD	cis	rs818427	0.684	rs501250	chr5:112155793	C/G	cg07820702	chr5:112228657	REEP5	0.53	4.58	0.35	9.81e-6	Total body bone mineral density;
PAAD	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.79	-0.62	7.39e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.85	10.76	0.66	1.93e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07362569	chr17:61921086	SMARCD2	0.45	5.26	0.39	4.71e-7	Prudent dietary pattern;
PAAD	cis	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg01489032	chr8:143877656	NA	-0.4	-4.52	-0.34	1.23e-5	Urinary tract infection frequency;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.66	0.35	6.96e-6	Height;
PAAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	10.79	0.66	1.61e-20	Total body bone mineral density;
PAAD	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-4.76	-0.36	4.41e-6	Blood metabolite levels;
PAAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.41	5.34	0.4	3.38e-7	Alcohol dependence;
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02071572	chr4:1403502	NA	0.52	6.84	0.49	1.81e-10	Longevity;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07685180	chr8:600429	NA	0.95	6.34	0.46	2.47e-9	IgG glycosylation;
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs11168618	0.567	rs7314569	chr12:48816981	G/T	cg01881778	chr12:48919444	OR8S1	-0.45	-4.53	-0.35	1.18e-5	Adiponectin levels;
PAAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg17775713	chr3:133465469	TF	0.49	5.57	0.41	1.11e-7	Iron status biomarkers (transferrin levels);
PAAD	trans	rs2982694	0.558	rs2982692	chr6:152285632	T/C	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs10885582	0.781	rs11196783	chr10:116304133	T/A	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.18	-0.39	7.1e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-5.98	-0.44	1.52e-8	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6446731	1.000	rs6446731	chr4:3284751	G/A	cg08886695	chr4:3369023	RGS12	-0.56	-5.08	-0.38	1.09e-6	Mean platelet volume;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.78	-4.86	-0.37	2.93e-6	Mononucleosis;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.59	7.53	0.52	4.24e-12	Diastolic blood pressure;
PAAD	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.55	0.41	1.24e-7	Coronary artery disease;
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.58	-0.57	1.04e-14	Body mass index;
PAAD	cis	rs11665867	0.648	rs2604910	chr19:41297254	C/T	cg08367223	chr19:41255304	C19orf54;SNRPA	0.48	4.43	0.34	1.77e-5	Hematocrit;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg03267160	chr19:30433556	C19orf2	0.68	6.54	0.47	8.92e-10	Primary biliary cholangitis;
PAAD	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.55	4.97	0.37	1.82e-6	Blood metabolite levels;
PAAD	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg16766828	chr3:128327626	NA	-0.46	-6.17	-0.45	5.78e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg09579323	chr1:150459698	TARS2	0.45	4.26	0.33	3.51e-5	Migraine;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14693961	chr19:42388097	ARHGEF1	-0.64	-6.29	-0.45	3.24e-9	Smoking initiation;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg19660806	chr8:588740	NA	-0.63	-4.41	-0.34	1.91e-5	IgG glycosylation;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.63	-5.55	-0.41	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.72	-7.93	-0.54	4.44e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg02883503	chr16:75423900	CFDP1	-0.42	-4.27	-0.33	3.5e-5	Dupuytren's disease;
PAAD	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00024722	chr15:32163260	NA	0.59	6.62	0.47	5.7e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7598759	0.712	rs6735961	chr2:232334414	T/C	cg10034588	chr2:232392055	NMUR1	-0.37	-4.39	-0.34	2.11e-5	Noise-induced hearing loss;
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.6	4.91	0.37	2.36e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.64e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.54	-0.47	8.61e-10	Chronic sinus infection;
PAAD	cis	rs621942	0.898	rs7926460	chr11:85840322	T/C	cg07180834	chr11:85838833	NA	-0.52	-5.02	-0.38	1.46e-6	Tourette syndrome;
PAAD	cis	rs7853377	0.800	rs696825	chr9:86583076	C/T	cg03531853	chr9:86535572	KIF27	0.41	4.41	0.34	1.97e-5	Height;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg22601191	chr20:60968625	CABLES2	0.45	4.35	0.33	2.47e-5	Pelvic organ prolapse;
PAAD	cis	rs58521262	0.556	rs188343	chr19:23186197	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg19197139	chr17:4613644	ARRB2	0.86	8.93	0.59	1.32e-15	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg03983715	chr16:68378420	PRMT7	-0.73	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.83	10.47	0.65	1.2e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17376030	chr22:41985996	PMM1	-0.63	-4.4	-0.34	2.04e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.42e-8	Height;
PAAD	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.68	7.55	0.52	3.71e-12	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.14e-15	Prostate cancer;
PAAD	cis	rs12760731	0.641	rs12038910	chr1:178444907	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs10943724	0.679	rs546848	chr6:81228418	A/G	cg19323245	chr6:80716898	TTK	0.45	4.71	0.36	5.55e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11825685	0.579	rs3016429	chr11:134548918	A/G	cg06603561	chr11:134479413	NA	0.57	4.95	0.37	1.96e-6	IgG glycosylation;
PAAD	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-6.01	-0.44	1.33e-8	Primary biliary cholangitis;
PAAD	cis	rs76917914	0.820	rs58427887	chr9:100820671	C/T	cg21225548	chr9:100864335	TRIM14	-0.55	-5.8	-0.43	3.72e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-5.24	-0.39	5.23e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg16583315	chr14:65563665	MAX	-0.41	-4.36	-0.33	2.42e-5	Obesity-related traits;
PAAD	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.66	6.21	0.45	4.74e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03331258	chr1:45205518	KIF2C	0.67	6.64	0.47	5.2400000000000005e-10	Obesity-related traits;
PAAD	cis	rs787274	1.000	rs1539338	chr9:115586187	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18364779	chr6:26104403	HIST1H4C	0.52	5.18	0.39	7.03e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10899021	0.790	rs12280434	chr11:74332827	C/T	cg25880958	chr11:74394337	NA	-0.73	-4.65	-0.35	7.31e-6	Response to metformin (IC50);
PAAD	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg03959625	chr15:84868606	LOC388152	0.41	4.28	0.33	3.31e-5	Schizophrenia;
PAAD	cis	rs2120243	0.539	rs7629293	chr3:157114462	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs1550582	0.547	rs6991998	chr8:135580221	C/A	cg17885191	chr8:135476712	NA	0.54	4.44	0.34	1.72e-5	Educational attainment;
PAAD	cis	rs4690686	0.653	rs6553948	chr4:177288328	A/T	cg17059388	chr4:177262070	NA	0.51	4.87	0.37	2.82e-6	Essential tremor;
PAAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.8	8.23	0.56	7.76e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs4704187	0.687	rs6879894	chr5:74498164	C/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-5.35	-0.4	3.15e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.55	-0.41	1.23e-7	Atrioventricular conduction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12366960	chr10:23122421	NA	-0.63	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Dermatomyositis;
PAAD	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.57	-0.35	9.91e-6	Lung cancer;
PAAD	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.84	-9.16	-0.6	3.26e-16	Colorectal cancer;
PAAD	cis	rs72960926	1.000	rs72960912	chr6:75144719	C/T	cg13435101	chr6:74171350	MTO1	0.93	4.67	0.35	6.5e-6	Metabolite levels (MHPG);
PAAD	cis	rs2594989	0.943	rs2606737	chr3:11398654	A/G	cg01796438	chr3:11312864	ATG7	-0.62	-4.83	-0.36	3.34e-6	Circulating chemerin levels;
PAAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg04705435	chr11:17411270	KCNJ11	0.59	6.2	0.45	4.96e-9	Type 2 diabetes;
PAAD	cis	rs6604026	0.656	rs2811590	chr1:93367166	C/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.51	0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.78	10.77	0.66	1.91e-20	Cannabis dependence symptom count;
PAAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg21300403	chr2:198650112	BOLL	-0.65	-4.36	-0.33	2.36e-5	Ulcerative colitis;
PAAD	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-0.94	-6.87	-0.49	1.57e-10	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04701106	chr11:118955609	HMBS	0.59	6.58	0.47	7e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg20891283	chr12:69753455	YEATS4	0.69	4.7	0.36	5.82e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.14	-0.45	6.72e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.61	-4.61	-0.35	8.57e-6	Initial pursuit acceleration;
PAAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.62	5.99	0.44	1.48e-8	Blood metabolite levels;
PAAD	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	cis	rs6076065	0.723	rs2424531	chr20:23372754	C/T	cg11657817	chr20:23433608	CST11	-0.48	-4.68	-0.36	6.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12153243	0.714	rs17402447	chr5:142916732	G/T	cg13907255	chr5:142895549	NA	0.53	4.96	0.37	1.83e-6	Migraine;
PAAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.49	5.31	0.4	3.85e-7	Schizophrenia;
PAAD	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.84	-7.15	-0.5	3.43e-11	Blood pressure (smoking interaction);
PAAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Coronary artery disease;
PAAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.46	-5.54	-0.41	1.29e-7	Height;
PAAD	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg26174226	chr8:58114915	NA	-0.61	-5.09	-0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10750165	0.716	rs11606569	chr11:119654208	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.57	5.67	0.42	6.95e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1499972	0.941	rs62263116	chr3:117622719	T/G	cg07612923	chr3:117604196	NA	1.06	7.27	0.51	1.76e-11	Schizophrenia;
PAAD	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg08676812	chr11:65308423	LTBP3	0.82	5.59	0.41	1.04e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	1.05	17.29	0.81	1.02e-37	Height;
PAAD	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.73	-8.19	-0.55	9.98e-14	Airway imaging phenotypes;
PAAD	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.79	0.36	3.94e-6	Lung cancer in ever smokers;
PAAD	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.56e-5	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg02841227	chr6:26021843	HIST1H4A	0.51	5.0	0.38	1.59e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.66	-7.64	-0.53	2.26e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs4588572	0.561	rs12697887	chr5:77804729	A/G	cg18281939	chr5:77783895	LHFPL2	0.43	4.94	0.37	2.03e-6	Triglycerides;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.67	5.98	0.44	1.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg24733560	chr20:60626293	TAF4	0.53	6.69	0.48	4.01e-10	Body mass index;
PAAD	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.79	8.68	0.58	5.7e-15	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.47	0.34	1.55e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.43	4.36	0.33	2.38e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.85	11.77	0.69	3.75e-23	Bone mineral density;
PAAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.97	-0.37	1.82e-6	Neuroticism;
PAAD	cis	rs496547	0.686	rs2508916	chr11:118654651	G/C	cg19308663	chr11:118741387	NA	-0.46	-4.33	-0.33	2.71e-5	Hip minimal joint space width;
PAAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.84	9.39	0.61	8.45e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs7619427	0.507	rs7616472	chr3:44016039	G/A	cg16646616	chr3:44040527	NA	-0.57	-4.67	-0.35	6.48e-6	Schizophrenia;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-4.67	-0.35	6.44e-6	Educational attainment (years of education);
PAAD	cis	rs16975963	0.843	rs75802547	chr19:38393321	C/T	cg08679971	chr19:38281047	NA	0.56	5.36	0.4	3.07e-7	Longevity;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg14239635	chr6:116892067	RWDD1	-0.58	-6.81	-0.48	2.12e-10	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00767846	chr2:170655407	SSB	-0.61	-6.29	-0.45	3.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg12908607	chr1:44402522	ARTN	-0.42	-4.64	-0.35	7.53e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs4740619	0.933	rs6474955	chr9:15715526	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.14e-5	Body mass index;
PAAD	cis	rs1359582	0.556	rs701825	chr10:90417547	G/A	cg15661332	chr10:90342814	RNLS	0.55	4.84	0.37	3.19e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs895470	1.000	rs895470	chr12:118146742	A/G	cg11944746	chr12:117457846	FBXW8	0.43	4.41	0.34	1.97e-5	Gut microbiome composition (winter);
PAAD	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg00898013	chr13:113819073	PROZ	-0.76	-6.03	-0.44	1.21e-8	Platelet distribution width;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs375066	0.935	rs406968	chr19:44418343	C/T	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg12092346	chr18:77659572	KCNG2	-0.66	-4.75	-0.36	4.75e-6	Opioid sensitivity;
PAAD	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs1468333	1.000	rs62381795	chr5:137577870	G/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.44	0.46	1.5e-9	Resting heart rate;
PAAD	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg08390786	chr10:135334061	NA	0.6	5.11	0.38	9.41e-7	Gout;
PAAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.44	-0.34	1.72e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.73	0.48	3.18e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg20607287	chr7:12443886	VWDE	-0.75	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg22143856	chr6:28129313	ZNF389	-0.68	-5.38	-0.4	2.82e-7	Depression;
PAAD	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.75	-9.13	-0.6	4.03e-16	Heart rate;
PAAD	cis	rs332507	0.789	rs11928787	chr3:124408149	C/T	cg05980111	chr3:124395277	KALRN	0.46	4.59	0.35	9.04e-6	Plateletcrit;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.5	-4.42	-0.34	1.84e-5	Testicular germ cell tumor;
PAAD	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.45	-4.4	-0.34	2.02e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.69	6.66	0.48	4.74e-10	Subjective well-being;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.61	-8.34	-0.56	4.2e-14	Longevity;Endometriosis;
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.53	-5.11	-0.38	9.44e-7	Squamous cell lung carcinoma;
PAAD	cis	rs8133932	0.654	rs407651	chr21:47350587	C/T	cg11214348	chr21:47283868	PCBP3	-0.5	-4.51	-0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.62	4.93	0.37	2.11e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.61	0.47	6.09e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg15017067	chr4:17643749	FAM184B	-0.37	-4.3	-0.33	3.06e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11809230	0.541	rs7515624	chr1:70116541	A/T	cg01791338	chr1:70606906	NA	-0.75	-5.05	-0.38	1.23e-6	Cannabis use (initiation);
PAAD	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.76	0.36	4.5e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.8	7.55	0.52	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.82	7.47	0.52	5.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg18279126	chr7:2041391	MAD1L1	0.55	5.46	0.4	1.91e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs12989701	0.877	rs35860453	chr2:127866047	C/T	cg00091827	chr2:127863656	BIN1	0.59	4.32	0.33	2.78e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2562456	0.754	rs62109227	chr19:21536930	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs1075265	0.744	rs2909460	chr2:54194748	A/G	cg04546899	chr2:54196757	PSME4	0.37	5.67	0.42	7.08e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs16958440	0.867	rs79420880	chr18:44663687	C/T	cg17192377	chr18:44677553	HDHD2	0.95	5.13	0.38	8.64e-7	Sitting height ratio;
PAAD	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-4.61	-0.35	8.53e-6	Blood protein levels;
PAAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.71	8.18	0.55	1.04e-13	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg15798862	chr7:76129360	DTX2	-0.37	-4.41	-0.34	1.95e-5	Eotaxin levels;
PAAD	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.61	-0.35	8.57e-6	Mean corpuscular volume;
PAAD	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.74	7.25	0.51	1.94e-11	Response to diuretic therapy;
PAAD	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	4.32	0.33	2.8e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg17644776	chr2:200775616	C2orf69	-0.45	-4.28	-0.33	3.3e-5	QT interval;
PAAD	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg06492744	chr11:65406254	SIPA1	-0.37	-4.33	-0.33	2.68e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.44	0.34	1.72e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg05697835	chr1:2722811	NA	0.42	4.68	0.36	6.21e-6	Ulcerative colitis;
PAAD	cis	rs72960926	0.744	rs11756283	chr6:74901380	T/C	cg03266952	chr6:74778945	NA	-1.18	-6.6	-0.47	6.43e-10	Metabolite levels (MHPG);
PAAD	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.7	-8.02	-0.55	2.61e-13	Alcohol dependence;
PAAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg09796270	chr17:17721594	SREBF1	-0.46	-5.11	-0.38	9.65e-7	Total body bone mineral density;
PAAD	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.61	-4.47	-0.34	1.49e-5	Prostate cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20929922	chr5:43484725	C5orf28	-0.63	-7.1	-0.5	4.52e-11	Body fat percentage;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg14345882	chr6:26364793	BTN3A2	0.71	4.26	0.33	3.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.62	-6.69	-0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.94	0.54	4.18e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg22189786	chr22:42395067	WBP2NL	0.64	5.46	0.4	1.9e-7	Birth weight;
PAAD	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.89	-7.83	-0.54	7.67e-13	Body mass index;
PAAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-5.88	-0.43	2.52e-8	Total body bone mineral density;
PAAD	cis	rs11637339	0.660	rs4965238	chr15:99996562	A/G	cg03300787	chr15:100533202	ADAMTS17	-0.42	-4.28	-0.33	3.25e-5	Cervical cancer;
PAAD	cis	rs11250714	0.845	rs4880891	chr10:1681672	G/A	cg10435618	chr10:838112	NA	-0.5	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.26	-0.39	4.73e-7	Schizophrenia;
PAAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.95	-0.37	1.94e-6	Type 2 diabetes;
PAAD	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.15	-0.86	3.84e-47	Myeloid white cell count;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg23605961	chr7:751331	PRKAR1B	0.3	4.73	0.36	5.18e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.94	10.21	0.64	5.81e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.81	6.14	0.45	6.83e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12582317	chr17:55822272	NA	0.71	8.7	0.58	5.07e-15	Schizophrenia;
PAAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.36	0.56	3.66e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9346353	0.737	rs7758405	chr6:70445684	A/T	cg03001484	chr6:70507230	LMBRD1	-0.3	-4.36	-0.33	2.35e-5	Sleep duration;
PAAD	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs2916733	0.548	rs1373306	chr8:6307322	A/C	cg01691696	chr8:6734962	DEFB1	0.56	4.53	0.35	1.16e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.56	5.17	0.39	7.3e-7	Schizophrenia;
PAAD	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg22875332	chr1:76189707	ACADM	-0.49	-4.79	-0.36	3.87e-6	Daytime sleep phenotypes;
PAAD	cis	rs10821973	0.527	rs4979777	chr10:63981896	C/T	cg19640130	chr10:64028056	RTKN2	-0.41	-4.3	-0.33	3.06e-5	Hypothyroidism;
PAAD	cis	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg21546286	chr11:48923668	NA	-0.45	-4.78	-0.36	4.02e-6	Coronary artery disease;
PAAD	cis	rs687432	0.688	rs12788387	chr11:57893347	A/C	cg25169875	chr11:58347178	ZFP91;ZFP91-CNTF	-0.41	-4.48	-0.34	1.47e-5	Parkinson's disease;
PAAD	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.78	-7.56	-0.52	3.55e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg02404636	chr22:31891804	SFI1	-0.61	-5.48	-0.41	1.69e-7	Colorectal cancer;
PAAD	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg03340356	chr1:67600835	NA	0.56	6.49	0.47	1.17e-9	Psoriasis;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.96	7.03	0.5	6.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg01852476	chr1:2232063	SKI	-0.27	-4.41	-0.34	1.93e-5	Ulcerative colitis;
PAAD	cis	rs12304921	0.688	rs79111258	chr12:51361878	G/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.31	-0.33	2.91e-5	Type 2 diabetes;
PAAD	cis	rs6076065	0.676	rs1419005	chr20:23336432	G/T	cg11657817	chr20:23433608	CST11	-0.48	-4.96	-0.37	1.85e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	0.44	4.99	0.38	1.65e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.52	5.46	0.4	1.92e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.58	-0.47	7.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	8.29	0.56	5.62e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2882667	0.690	rs13181762	chr5:138250106	G/A	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-5.07	-0.38	1.14e-6	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs17824933	0.836	rs2074233	chr11:60785464	G/A	cg27098804	chr11:60776124	CD6	0.44	4.35	0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.53	5.48	0.41	1.76e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.93	-6.46	-0.46	1.31e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1371614	0.611	rs4665920	chr2:27128834	G/A	cg00617064	chr2:27272375	NA	0.46	4.76	0.36	4.52e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs716804	0.608	rs7944706	chr11:10331311	A/G	cg06875754	chr11:10328428	ADM	-0.35	-4.59	-0.35	9.29e-6	Neuroticism;
PAAD	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.49	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg21951975	chr1:209979733	IRF6	-0.57	-5.08	-0.38	1.1e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2412488	1.000	rs2412488	chr4:54330867	A/G	cg19408398	chr4:54243328	FIP1L1	-0.5	-4.35	-0.33	2.5e-5	DNA methylation (variation);
PAAD	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12463550	chr7:65579703	CRCP	0.84	5.39	0.4	2.66e-7	Diabetic kidney disease;
PAAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.92	11.5	0.68	2.06e-22	Menopause (age at onset);
PAAD	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg01620082	chr3:125678407	NA	-1.5	-9.19	-0.6	2.78e-16	Depression;
PAAD	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.37	2.51e-6	Morning vs. evening chronotype;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24360513	chr1:249120106	SH3BP5L	0.54	6.44	0.46	1.51e-9	Immature fraction of reticulocytes;
PAAD	cis	rs13102973	0.640	rs6833827	chr4:135839731	T/C	cg14419869	chr4:135874104	NA	0.45	4.56	0.35	1.04e-5	Subjective well-being;
PAAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg20913747	chr6:44695427	NA	-0.69	-7.02	-0.5	6.76e-11	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7685785	1	rs7685785	chr4:78440425	C/T	cg08400124	chr4:77507102	SHROOM3	0.66	4.6	0.35	8.88e-6	Tonsillectomy;
PAAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.44	-5.86	-0.43	2.81e-8	Ulcerative colitis;
PAAD	cis	rs17152411	0.625	rs10751611	chr10:126658893	A/G	cg04726013	chr10:126223236	LHPP	-0.31	-4.54	-0.35	1.13e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27278084	chr20:45868110	ZMYND8	-0.69	-6.89	-0.49	1.36e-10	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.49	0.34	1.38e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9810890	1.000	rs73198827	chr3:128489521	G/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18621852	chr3:10150065	C3orf24	0.62	5.4	0.4	2.5e-7	Alzheimer's disease;
PAAD	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg09876464	chr15:85330779	ZNF592	0.44	4.35	0.33	2.52e-5	P wave terminal force;
PAAD	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg08992911	chr2:238395768	MLPH	0.67	6.58	0.47	7.11e-10	Prostate cancer;
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.68	-7.27	-0.51	1.74e-11	Iron status biomarkers;
PAAD	cis	rs847851	1.000	rs4646949	chr6:34845449	A/C	cg13196216	chr6:34231128	NA	-0.54	-4.3	-0.33	3.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.75	-7.69	-0.53	1.69e-12	Blood metabolite levels;
PAAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.55	5.45	0.4	1.99e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg13468214	chr4:1046988	NA	-0.56	-6.07	-0.44	9.73e-9	Recombination rate (males);
PAAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08766850	chr12:32112438	C12orf35	0.68	6.73	0.48	3.21e-10	Obesity-related traits;
PAAD	cis	rs7705042	0.865	rs4912622	chr5:141490587	A/G	cg08523384	chr5:141488047	NDFIP1	0.55	5.25	0.39	5.02e-7	Asthma;
PAAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.92	9.12	0.59	4.33e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.39	4.34	0.33	2.58e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.01	-0.38	1.52e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg17401720	chr7:158221031	PTPRN2	0.41	4.45	0.34	1.64e-5	Obesity-related traits;
PAAD	cis	rs4356203	0.905	rs511119	chr11:17215117	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.7	7.56	0.52	3.57e-12	Blood protein levels;
PAAD	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-5.12	-0.38	8.98e-7	Vitiligo;
PAAD	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs17209837	1.000	rs4148808	chr7:87105795	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-5.23	-0.39	5.52e-7	Gallbladder cancer;
PAAD	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg01601518	chr4:2404284	ZFYVE28	-0.49	-5.06	-0.38	1.2e-6	Cognitive function;
PAAD	cis	rs367943	0.712	rs26968	chr5:112742429	A/G	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.72	8.92	0.59	1.38e-15	IgG glycosylation;
PAAD	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.62	-6.68	-0.48	4.32e-10	Neuroticism;
PAAD	cis	rs11825685	0.790	rs56657264	chr11:134543459	C/T	cg06603561	chr11:134479413	NA	-0.9	-6.28	-0.45	3.45e-9	IgG glycosylation;
PAAD	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg05585544	chr11:47624801	NA	-0.48	-5.29	-0.39	4.24e-7	Subjective well-being;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.56	-6.51	-0.47	1.05e-9	Aortic root size;
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs10450586	0.932	rs10082679	chr11:27320658	A/T	cg10370305	chr11:27303972	NA	0.37	4.56	0.35	1.07e-5	Total body bone mineral density;
PAAD	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.72	0.48	3.43e-10	Schizophrenia;
PAAD	cis	rs1075232	0.579	rs58156651	chr15:31749067	C/A	cg01030201	chr15:31746330	NA	-1.11	-4.72	-0.36	5.2e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.77	-8.37	-0.56	3.56e-14	Coronary artery disease;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.9	9.68	0.62	1.46e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs950881	0.932	rs13408661	chr2:102955082	G/A	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg16558253	chr16:72132732	DHX38	-0.6	-5.03	-0.38	1.37e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg16766828	chr3:128327626	NA	-0.46	-6.04	-0.44	1.13e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	trans	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg00626422	chr7:22894849	SNORD93	-0.54	-6.38	-0.46	2.04e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg27057461	chr7:158136379	PTPRN2	-0.47	-4.3	-0.33	3.06e-5	Response to amphetamines;
PAAD	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg08917208	chr2:24149416	ATAD2B	0.51	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.84	10.33	0.64	2.87e-19	Height;
PAAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg17372223	chr3:52568218	NT5DC2	-0.53	-5.2	-0.39	6.46e-7	Bipolar disorder;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.45	-5.51	-0.41	1.47e-7	Iron status biomarkers;
PAAD	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs793571	0.915	rs2270664	chr15:59181985	G/A	cg05156742	chr15:59063176	FAM63B	-0.59	-5.03	-0.38	1.36e-6	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.65	6.23	0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.71	0.48	3.67e-10	Coffee consumption (cups per day);
PAAD	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	4.95	0.37	1.96e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.72	0.48	3.36e-10	Morning vs. evening chronotype;
PAAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.76	6.84	0.49	1.79e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2446066	0.872	rs10876451	chr12:53813424	A/C	cg23431730	chr12:53887070	MAP3K12	-0.62	-4.28	-0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.48	-4.53	-0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg10589385	chr1:150898437	SETDB1	0.35	4.4	0.34	2.02e-5	Melanoma;
PAAD	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.45	5.03	0.38	1.34e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs10875595	0.836	rs56756237	chr5:140678342	T/C	cg24830062	chr5:140700576	TAF7	-0.53	-4.42	-0.34	1.89e-5	Pulmonary function decline;
PAAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg03225093	chr5:2008713	NA	-0.35	-4.29	-0.33	3.21e-5	Lung cancer;
PAAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.15	-0.45	6.65e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	6.08	0.44	9.15e-9	Platelet count;
PAAD	cis	rs4594175	0.892	rs10135768	chr14:51671017	G/T	cg23942311	chr14:51606299	NA	0.62	5.97	0.44	1.61e-8	Cancer;
PAAD	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.65	6.95	0.49	9.99e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg23281280	chr6:28129359	ZNF389	0.52	4.79	0.36	4e-6	Parkinson's disease;
PAAD	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.61	-6.08	-0.44	9.33e-9	Itch intensity from mosquito bite;
PAAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg05697835	chr1:2722811	NA	-0.42	-4.75	-0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.86	0.43	2.8e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.7	0.66	2.9e-20	Smoking behavior;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16582344	chr1:228270207	ARF1	0.65	6.95	0.49	1.02e-10	Myopia (pathological);
PAAD	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.39	12.82	0.72	5.83e-26	Corneal structure;
PAAD	cis	rs2882667	0.690	rs9327831	chr5:138272286	A/C	cg09476006	chr5:138032270	NA	0.47	5.94	0.43	1.91e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.99	9.5	0.61	4.42e-17	Monocyte percentage of white cells;
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.53	0.41	1.38e-7	Immature fraction of reticulocytes;
PAAD	cis	rs807669	0.935	rs712963	chr22:19156543	A/G	cg02655711	chr22:19163373	SLC25A1	0.78	9.04	0.59	6.84e-16	Metabolite levels;
PAAD	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.59	5.32	0.4	3.64e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs59901009	0.577	rs2896514	chr11:10027901	T/C	cg06876053	chr11:9810051	SBF2	-0.34	-4.45	-0.34	1.63e-5	Hematocrit;Hemoglobin concentration;
PAAD	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18621852	chr3:10150065	C3orf24	0.54	5.15	0.39	7.87e-7	Alzheimer's disease;
PAAD	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg26248373	chr2:1572462	NA	-1.1	-8.52	-0.57	1.44e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.25	-0.6	1.96e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	1.03	8.04	0.55	2.29e-13	Menopause (age at onset);
PAAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.96	0.37	1.9e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.53	-5.88	-0.43	2.51e-8	Facial morphology (factor 20);
PAAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.59	-5.46	-0.41	1.86e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17441377	chr17:3906640	NA	0.53	6.29	0.45	3.19e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19623624	chr10:135278901	LOC619207	-0.43	-4.5	-0.34	1.36e-5	Systemic lupus erythematosus;
PAAD	cis	rs2730260	0.736	rs7784586	chr7:158836379	T/C	cg13444538	chr7:158905317	VIPR2	-0.66	-5.0	-0.38	1.58e-6	Myopia (pathological);
PAAD	cis	rs6715793	0.755	rs6728094	chr2:33392911	G/A	cg26672287	chr2:33391915	LTBP1	-0.44	-4.88	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	cis	rs10501293	0.956	rs11037235	chr11:43100381	G/C	cg03447554	chr11:43094025	NA	-0.51	-5.09	-0.38	1.04e-6	Cognitive performance;
PAAD	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg01388757	chr2:102091195	RFX8	-0.54	-6.89	-0.49	1.42e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6710503	0.547	rs2304892	chr2:24714923	C/T	cg21151432	chr2:25142229	ADCY3	-0.4	-4.88	-0.37	2.68e-6	Lung cancer in ever smokers;Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10746341	chr17:63096940	NA	-0.68	-6.94	-0.49	1.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg03983715	chr16:68378420	PRMT7	-0.89	-6.36	-0.46	2.28e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4740619	0.967	rs35146544	chr9:15693225	C/G	cg14451791	chr9:16040625	NA	-0.41	-4.81	-0.36	3.54e-6	Body mass index;
PAAD	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.68	7.1	0.5	4.51e-11	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23281280	chr6:28129359	ZNF389	-0.69	-5.32	-0.4	3.58e-7	Depression;
PAAD	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.86	0.37	2.86e-6	Testicular germ cell tumor;
PAAD	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.2	10.33	0.64	2.79e-19	Uric acid levels;
PAAD	cis	rs590121	0.876	rs681390	chr11:75274630	T/C	cg26104986	chr11:75275303	SERPINH1	-0.43	-4.59	-0.35	9.09e-6	Coronary artery disease;
PAAD	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.43	4.34	0.33	2.57e-5	Depression;
PAAD	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.82	-9.8	-0.62	6.93e-18	Brugada syndrome;
PAAD	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.75	7.89	0.54	5.48e-13	Blood metabolite levels;
PAAD	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg23281280	chr6:28129359	ZNF389	0.51	4.55	0.35	1.11e-5	Parkinson's disease;
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs340025	0.523	rs58113229	chr15:60918046	C/A	cg00200653	chr15:60883225	RORA	0.48	4.29	0.33	3.14e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73568641	0.669	rs73568685	chr6:154049469	A/G	cg15658985	chr6:154448740	OPRM1	0.55	4.5	0.34	1.36e-5	Methadone dose in opioid dependence;
PAAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.39	-0.56	3.08e-14	Calcium levels;
PAAD	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg08514558	chr10:81106712	PPIF	0.49	5.91	0.43	2.11e-8	Height;
PAAD	cis	rs78472555	0.865	rs12185079	chr15:100271253	C/T	cg23669855	chr15:100272142	LYSMD4	-0.64	-4.93	-0.37	2.16e-6	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.78	-8.23	-0.56	7.87e-14	Prostate cancer;
PAAD	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs498136	0.966	rs657432	chr11:69364461	T/G	cg24388239	chr11:68438018	NA	-0.43	-4.38	-0.33	2.22e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.52	6.47	0.46	1.25e-9	Longevity;Endometriosis;
PAAD	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.83	8.32	0.56	4.56e-14	Corneal astigmatism;
PAAD	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg26618903	chr10:100175079	PYROXD2	-0.49	-5.22	-0.39	5.81e-7	Metabolite levels;
PAAD	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg05768032	chr16:30646687	NA	0.52	4.97	0.37	1.77e-6	Multiple myeloma;
PAAD	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.76	8.62	0.57	8.03e-15	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.3	-0.51	1.47e-11	Longevity;
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg16596103	chr2:233749413	NGEF	0.43	4.42	0.34	1.84e-5	Schizophrenia;
PAAD	cis	rs6601327	0.550	rs4422774	chr8:9522011	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.62	-0.35	8.06e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg17775713	chr3:133465469	TF	-0.38	-4.31	-0.33	2.94e-5	Iron status biomarkers (transferrin levels);
PAAD	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.36	-0.4	3.08e-7	Daytime sleep phenotypes;
PAAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.73	-7.66	-0.53	2.08e-12	Neurofibrillary tangles;
PAAD	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.84	-9.27	-0.6	1.7e-16	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg21929781	chr1:2537748	MMEL1	0.44	4.68	0.35	6.29e-6	Ulcerative colitis;
PAAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5e-7	Life satisfaction;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.02	-0.55	2.7e-13	Blood metabolite levels;
PAAD	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.38	9.43	0.61	6.68e-17	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15552239	chr22:36623087	APOL2	0.62	6.32	0.46	2.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg16205897	chr5:131564050	P4HA2	-0.43	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg21238619	chr17:78079768	GAA	-0.54	-6.13	-0.45	7.3e-9	Yeast infection;
PAAD	cis	rs7714584	1.000	rs11167520	chr5:150265639	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.59	-6.2	-0.45	5.13e-9	Lung function (FVC);
PAAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.63	-8.29	-0.56	5.69e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg00666640	chr1:248458726	OR2T12	0.53	5.2	0.39	6.45e-7	Common traits (Other);
PAAD	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00292662	chr22:38071168	LGALS1	0.54	5.64	0.42	7.91e-8	Fat distribution (HIV);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02581963	chr10:102133317	C10orf75	0.6	6.56	0.47	7.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg07648498	chr16:89883185	FANCA	0.53	5.24	0.39	5.37e-7	Vitiligo;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-7.05	-0.5	5.81e-11	Neuroticism;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg18135555	chr8:22132992	PIWIL2	0.57	8.57	0.57	1.1e-14	Hypertriglyceridemia;
PAAD	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg26205652	chr12:48591994	NA	0.98	9.89	0.63	4.05e-18	Longevity (90 years and older);
PAAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg15017067	chr4:17643749	FAM184B	-0.41	-4.43	-0.34	1.79e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg09017928	chr7:158110068	PTPRN2	-0.44	-4.26	-0.33	3.64e-5	Calcium levels;
PAAD	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.98	-0.49	8.48e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.71	6.75	0.48	2.91e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs3747547	0.892	rs3747545	chr9:37916164	C/T	cg13774184	chr9:37916125	SHB	-0.64	-4.5	-0.34	1.36e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.94	-7.94	-0.54	4.05e-13	Initial pursuit acceleration;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg25487775	chr2:162093969	NA	0.76	8.71	0.58	4.67e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.75	-7.9	-0.54	5.15e-13	Facial morphology (factor 20);
PAAD	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.65	-5.65	-0.42	7.82e-8	Schizophrenia;
PAAD	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg10518543	chr12:38710700	ALG10B	-0.45	-4.41	-0.34	1.95e-5	Morning vs. evening chronotype;
PAAD	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg15309053	chr8:964076	NA	0.46	5.12	0.38	9.15e-7	Schizophrenia;
PAAD	cis	rs17539620	0.624	rs58469593	chr6:154850105	G/A	cg20019720	chr6:154832845	CNKSR3	0.64	7.33	0.51	1.26e-11	Lipoprotein (a) levels;
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.51	-0.47	1.03e-9	Blood metabolite levels;
PAAD	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05910615	chr19:36248877	HSPB6;C19orf55	0.56	6.63	0.47	5.53e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg03264133	chr6:25882463	NA	0.44	4.37	0.33	2.31e-5	Schizophrenia;
PAAD	cis	rs8103278	0.507	rs62111759	chr19:46296230	A/T	cg02376097	chr19:46275166	DMPK	0.66	7.94	0.54	4.18e-13	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2594989	0.943	rs4684780	chr3:11478960	C/T	cg01796438	chr3:11312864	ATG7	-0.58	-4.5	-0.34	1.34e-5	Circulating chemerin levels;
PAAD	cis	rs1144333	0.850	rs1146651	chr1:76273594	C/A	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-4.73	-0.36	5.13e-6	Crohn's disease;
PAAD	cis	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg21546286	chr11:48923668	NA	-0.46	-4.77	-0.36	4.31e-6	Height;
PAAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	1.03	12.84	0.72	4.99e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg21929781	chr1:2537748	MMEL1	0.44	4.7	0.36	5.69e-6	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04085025	chr7:30029442	SCRN1	-0.67	-6.78	-0.48	2.55e-10	Smoking initiation;
PAAD	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.49	0.57	1.77e-14	Bipolar disorder;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.61	6.83	0.48	1.9e-10	Systemic lupus erythematosus;
PAAD	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.64	-6.48	-0.47	1.2e-9	Blood protein levels;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-4.94	-0.37	2.06e-6	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.85	-9.27	-0.6	1.67e-16	Prostate cancer;
PAAD	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.5	-5.14	-0.39	8.21e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.08	-11.45	-0.68	2.86e-22	Blood pressure (smoking interaction);
PAAD	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05347473	chr6:146136440	FBXO30	0.52	5.05	0.38	1.24e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-4.46	-0.34	1.6e-5	Resting heart rate;
PAAD	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.67	7.72	0.53	1.44e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.65	6.71	0.48	3.54e-10	Electroencephalogram traits;
PAAD	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.0	11.91	0.69	1.65e-23	Schizophrenia;
PAAD	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.54	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.47	4.67	0.35	6.7e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.87	8.87	0.58	1.86e-15	Testicular germ cell tumor;
PAAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.57	-5.51	-0.41	1.53e-7	Obesity-related traits;
PAAD	cis	rs7771547	0.723	rs7741888	chr6:36552304	T/C	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16632644	chr7:32908251	KBTBD2	0.72	6.45	0.46	1.38e-9	Neuroticism;
PAAD	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.69	4.89	0.37	2.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg15117754	chr3:10150083	C3orf24	0.81	7.11	0.5	4.14e-11	Alzheimer's disease;
PAAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg05234568	chr11:5960015	NA	0.57	6.27	0.45	3.49e-9	DNA methylation (variation);
PAAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg16584676	chr17:46985605	UBE2Z	0.56	5.62	0.41	8.73e-8	Type 2 diabetes;
PAAD	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.63	6.37	0.46	2.16e-9	Mood instability;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.84	8.98	0.59	9.57e-16	Osteoporosis;
PAAD	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg25364880	chr3:44379878	C3orf23	0.67	5.29	0.39	4.11e-7	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22292462	chr13:45799592	GTF2F2	-0.62	-6.32	-0.46	2.75e-9	Obesity-related traits;
PAAD	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.57	5.03	0.38	1.38e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.53	6.97	0.49	8.81e-11	Ewing sarcoma;
PAAD	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.83	9.29	0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08219700	chr8:58056026	NA	0.7	5.62	0.41	8.83e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.72	7.43	0.52	7.48e-12	Corneal astigmatism;
PAAD	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg05373962	chr22:49881684	NA	-0.54	-5.15	-0.39	7.89e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7742824	1.000	rs73429745	chr6:44101422	C/T	cg21657043	chr6:44035552	NA	0.5	5.12	0.38	8.94e-7	Major depressive disorder;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2051773	0.567	rs12293395	chr11:17047661	C/G	cg15084286	chr11:17036142	PLEKHA7	-0.56	-5.02	-0.38	1.45e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs863345	0.625	rs6663286	chr1:158473725	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-5.04	-0.38	1.32e-6	Pneumococcal bacteremia;
PAAD	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.61	5.42	0.4	2.33e-7	Height;
PAAD	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg01631408	chr1:248437212	OR2T33	-0.57	-5.27	-0.39	4.68e-7	Common traits (Other);
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg21724239	chr8:58056113	NA	0.67	5.29	0.39	4.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.29e-8	Subjective well-being;
PAAD	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.86	9.52	0.61	3.74e-17	Mortality in heart failure;
PAAD	cis	rs939584	1.000	rs6748821	chr2:629601	A/G	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.54	6.87	0.49	1.57e-10	Ewing sarcoma;
PAAD	cis	rs7577696	0.962	rs13024004	chr2:32282362	A/G	cg02381751	chr2:32503542	YIPF4	-0.41	-4.45	-0.34	1.64e-5	Inflammatory biomarkers;
PAAD	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10342447	chr17:26645325	TMEM97	-0.46	-6.03	-0.44	1.17e-8	Osteoprotegerin levels;
PAAD	cis	rs2422052	0.519	rs11123458	chr2:118633602	A/G	cg22545206	chr2:118617499	NA	0.49	4.8	0.36	3.77e-6	Mosquito bite size;
PAAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.44	-0.34	1.72e-5	Initial pursuit acceleration;
PAAD	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.46	-5.01	-0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.81	-7.71	-0.53	1.56e-12	IgG glycosylation;
PAAD	cis	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg00883854	chr14:50053110	RPS29	0.58	5.02	0.38	1.44e-6	Subjective well-being;
PAAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg19875578	chr6:126661172	C6orf173	0.43	4.5	0.34	1.32e-5	Male-pattern baldness;
PAAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg00717180	chr2:96193071	NA	0.59	6.48	0.47	1.18e-9	HDL cholesterol;
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.65	6.49	0.47	1.16e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.43	-4.98	-0.37	1.74e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.64	-6.85	-0.49	1.76e-10	Calcium levels;
PAAD	cis	rs7213347	0.780	rs7209564	chr17:2168233	C/T	cg15816464	chr17:2026533	SMG6	0.5	5.45	0.4	1.97e-7	Total body bone mineral density;
PAAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.8	9.05	0.59	6.53e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg07944420	chr16:89185293	ACSF3	0.48	4.53	0.34	1.2e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg26174226	chr8:58114915	NA	-0.6	-4.39	-0.34	2.13e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg12705353	chr12:122356852	WDR66	0.5	5.08	0.38	1.11e-6	Mean corpuscular volume;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg07313626	chr1:247681931	NA	0.5	5.26	0.39	4.87e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg19630374	chr17:18023558	MYO15A	-0.45	-4.87	-0.37	2.78e-6	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg17105886	chr17:28927953	LRRC37B2	0.76	4.86	0.37	2.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26690034	chr1:75198963	CRYZ;TYW3	-0.56	-5.07	-0.38	1.13e-6	Resistin levels;
PAAD	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.64	-5.59	-0.41	1.02e-7	Resistin levels;
PAAD	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	6.78	0.48	2.54e-10	Cognitive ability;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.12	0.38	9.02e-7	Multiple sclerosis;
PAAD	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.16	-9.99	-0.63	2.2e-18	Vitiligo;
PAAD	trans	rs901683	1.000	rs34937315	chr10:45970717	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.67	-6.83	-0.48	1.89e-10	Body mass index;
PAAD	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.85	-0.54	7.03e-13	Mosquito bite size;
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg04369109	chr6:150039330	LATS1	-0.44	-4.3	-0.33	3.1e-5	Lung cancer;
PAAD	cis	rs7808424	0.651	rs10487362	chr7:116929065	G/A	cg00307073	chr7:116502428	CAPZA2	0.68	4.27	0.33	3.36e-5	Coronary heart disease;
PAAD	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs7684253	0.526	rs34112167	chr4:57719549	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-4.28	-0.33	3.34e-5	Migraine;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.49	4.28	0.33	3.29e-5	IgG glycosylation;
PAAD	cis	rs6585424	0.929	rs12256429	chr10:81938632	A/G	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg23202291	chr11:1979235	NA	-0.52	-5.04	-0.38	1.31e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14019695	chr9:139328340	INPP5E	0.58	4.97	0.37	1.78e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.67	6.99	0.49	8.29e-11	Platelet distribution width;
PAAD	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.98	0.37	1.74e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.64	-8.31	-0.56	4.85e-14	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25890074	chr13:102067343	NALCN	0.62	6.49	0.47	1.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs79911532	0.515	rs41296488	chr7:75595580	C/T	cg14329783	chr7:75779857	NA	0.81	4.5	0.34	1.33e-5	Mononucleosis;
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6700896	0.500	rs11208690	chr1:66092349	A/G	cg04111102	chr1:66153794	NA	0.48	4.31	0.33	2.87e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.69	-6.21	-0.45	4.73e-9	Diabetic retinopathy;
PAAD	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.6	-7.55	-0.52	3.81e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg23947450	chr7:900037	UNC84A	-0.57	-4.69	-0.36	6.14e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.89	8.71	0.58	4.7e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg10518543	chr12:38710700	ALG10B	0.51	4.91	0.37	2.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.93	-11.34	-0.68	5.68e-22	Menarche (age at onset);
PAAD	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.69	-8.23	-0.56	7.77e-14	Colorectal cancer;
PAAD	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.53	-5.38	-0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.47	-4.68	-0.35	6.35e-6	Blood metabolite levels;
PAAD	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.16	-0.5	3.16e-11	Psoriasis;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.85	-13.08	-0.73	1.16e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg15192750	chr16:69999425	NA	0.77	5.95	0.43	1.76e-8	IgE levels;
PAAD	cis	rs1656368	0.726	rs6788907	chr3:158212823	G/A	cg16708174	chr3:158430962	RARRES1	0.59	5.34	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	1.01	12.54	0.71	3.22e-25	Breast cancer;
PAAD	cis	rs6681460	0.546	rs10889648	chr1:67168182	T/C	cg02459107	chr1:67143332	SGIP1	0.61	5.85	0.43	2.89e-8	Presence of antiphospholipid antibodies;
PAAD	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg17845761	chr1:175162550	KIAA0040	-0.33	-4.93	-0.37	2.17e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9581857	0.547	rs1235848	chr13:28111559	G/T	cg22138327	chr13:27999177	GTF3A	-0.68	-4.77	-0.36	4.22e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg02297831	chr4:17616191	MED28	-0.61	-5.94	-0.43	1.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.63	5.64	0.42	7.88e-8	Crohn's disease;
PAAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	10.93	0.66	7.16e-21	Menopause (age at onset);
PAAD	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.53	-5.39	-0.4	2.67e-7	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.85	9.66	0.62	1.64e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg03989125	chr22:38214979	NA	0.63	5.9	0.43	2.33e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs593531	0.592	rs3168173	chr11:74042787	A/G	cg15851278	chr11:73669449	DNAJB13	-0.41	-4.98	-0.37	1.69e-6	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22268271	chr22:39548261	CBX7	0.62	7.28	0.51	1.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-4.47	-0.34	1.5e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2286503	0.809	rs4719716	chr7:22861369	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.78	-6.25	-0.45	3.96e-9	Coronary artery disease;
PAAD	cis	rs375066	0.935	rs439665	chr19:44414467	G/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.42	-0.52	7.7e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.86	9.84	0.62	5.47e-18	Prudent dietary pattern;
PAAD	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.68	7.65	0.53	2.18e-12	Platelet distribution width;
PAAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.19	0.6	2.86e-16	Parkinson's disease;
PAAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8102137	1.000	rs17513613	chr19:30286822	T/C	cg27475126	chr19:30303651	CCNE1	-0.45	-4.88	-0.37	2.64e-6	Bladder cancer;
PAAD	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Aortic root size;
PAAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg06915872	chr16:87998081	BANP	0.5	4.62	0.35	8.26e-6	Menopause (age at onset);
PAAD	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.61	-5.33	-0.4	3.52e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3206736	0.548	rs1186721	chr7:34974602	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs17407555	0.657	rs12505222	chr4:10271136	G/T	cg00071950	chr4:10020882	SLC2A9	0.47	5.08	0.38	1.08e-6	Schizophrenia (age at onset);
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7577696	0.539	rs13010405	chr2:32338204	A/T	cg02381751	chr2:32503542	YIPF4	-0.49	-4.66	-0.35	6.93e-6	Inflammatory biomarkers;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg10729496	chr3:10149963	C3orf24	-0.66	-5.91	-0.43	2.13e-8	Alzheimer's disease;
PAAD	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg14413466	chr17:79170920	AZI1	-0.36	-4.3	-0.33	3.05e-5	Frontotemporal dementia;
PAAD	cis	rs11105468	0.922	rs7960337	chr12:90277578	T/C	cg16962463	chr12:89968675	NA	0.44	4.31	0.33	2.94e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg27094323	chr7:1216898	NA	-0.4	-4.69	-0.36	5.99e-6	Longevity;Endometriosis;
PAAD	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.09	10.26	0.64	4.32e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.54	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs282587	0.542	rs914021	chr13:113375548	T/C	cg02820901	chr13:113351484	ATP11A	0.64	4.67	0.35	6.45e-6	Glycated hemoglobin levels;
PAAD	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.81	0.48	2.13e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.48	-0.41	1.72e-7	Type 2 diabetes;
PAAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.61	5.86	0.43	2.75e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.62	-0.35	8.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg20761395	chr17:511517	VPS53	-0.58	-6.27	-0.45	3.55e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.44	6.82	0.48	2.01e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09695851	chr17:3907499	NA	-0.68	-6.91	-0.49	1.22e-10	Type 2 diabetes;
PAAD	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg22601191	chr20:60968625	CABLES2	-0.56	-5.44	-0.4	2.11e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.79	8.18	0.55	1.05e-13	Body mass index;
PAAD	cis	rs9918079	0.560	rs7438356	chr4:15624770	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.83	-0.43	3.27e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.48	-5.43	-0.4	2.15e-7	Testicular germ cell tumor;
PAAD	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.55	-0.47	8.44e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg13722127	chr7:150037890	RARRES2	0.65	6.24	0.45	4.06e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7904985	0.793	rs11201996	chr10:88120263	T/C	cg07322936	chr10:88137208	NA	-0.54	-4.91	-0.37	2.33e-6	Barrett's esophagus;
PAAD	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.84	10.22	0.64	5.51e-19	Lung cancer;
PAAD	cis	rs11756438	0.505	rs9481850	chr6:119022953	C/A	cg21191810	chr6:118973309	C6orf204	0.39	4.49	0.34	1.42e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.13e-7	Obesity-related traits;
PAAD	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.97	0.37	1.76e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg02297831	chr4:17616191	MED28	0.58	5.64	0.42	8.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.45	6.21	0.45	4.82e-9	Vitiligo;
PAAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs72960926	0.744	rs1817735	chr6:74980974	T/C	cg03266952	chr6:74778945	NA	-1.2	-6.6	-0.47	6.3e-10	Metabolite levels (MHPG);
PAAD	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs4780401	1.000	rs4780401	chr16:11839326	G/T	cg01061890	chr16:11836724	TXNDC11	-0.52	-4.81	-0.36	3.6e-6	Rheumatoid arthritis;
PAAD	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.67	-6.64	-0.47	5.29e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.74	-7.86	-0.54	6.46e-13	Handedness;
PAAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs73568641	0.583	rs73572674	chr6:154098476	A/G	cg15658985	chr6:154448740	OPRM1	0.53	4.42	0.34	1.86e-5	Methadone dose in opioid dependence;
PAAD	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12963246	chr6:28129442	ZNF389	0.63	4.42	0.34	1.9e-5	Depression;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.61	4.96	0.37	1.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.62	-7.39	-0.51	9.28e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg14078157	chr9:128172775	NA	-0.53	-6.38	-0.46	1.99e-9	Mean arterial pressure;
PAAD	cis	rs12612619	0.704	rs6714547	chr2:27321206	T/G	cg00617064	chr2:27272375	NA	-0.49	-4.82	-0.36	3.47e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg22134325	chr11:66188745	NPAS4	0.29	4.62	0.35	8.28e-6	Airway imaging phenotypes;
PAAD	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.6	-6.22	-0.45	4.64e-9	Educational attainment (years of education);
PAAD	trans	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg05993574	chr11:61129284	CYBASC3;TMEM138	0.62	6.33	0.46	2.58e-9	IgG glycosylation;
PAAD	cis	rs1035491	0.715	rs10055308	chr5:63923911	G/A	cg01791865	chr5:63954708	NA	0.52	5.58	0.41	1.09e-7	Body mass index;
PAAD	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.61	-0.35	8.59e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00881440	chr7:2595255	C7orf27	0.63	6.64	0.47	5.35e-10	Myopia (pathological);
PAAD	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.91e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg04374321	chr14:90722782	PSMC1	0.52	4.26	0.33	3.61e-5	Longevity;
PAAD	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.48	-0.34	1.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.79	12.6	0.71	2.25e-25	Breast cancer;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs7631605	0.870	rs9846039	chr3:37125699	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.83	5.46	0.4	1.93e-7	Yeast infection;
PAAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg19192590	chr2:178524533	PDE11A	0.38	4.39	0.34	2.08e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12999616	0.817	rs17695937	chr2:98327875	A/G	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.86	-10.5	-0.65	1.01e-19	Body mass index;
PAAD	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg10223061	chr2:219282414	VIL1	0.36	4.36	0.33	2.43e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg02264943	chr11:130785842	SNX19	0.36	4.28	0.33	3.35e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-1.06	-8.53	-0.57	1.34e-14	Developmental language disorder (linguistic errors);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg27614445	chr3:179041226	ZNF639	0.64	7.45	0.52	6.62e-12	Immature fraction of reticulocytes;
PAAD	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.32	0.33	2.81e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20203792	chr4:20701925	PACRGL	0.67	7.73	0.53	1.37e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9896052	0.580	rs6416847	chr17:73468434	G/A	cg25649188	chr17:73499917	CASKIN2	0.6	4.62	0.35	8.2e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.95	10.58	0.65	6.15e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.54	4.82	0.36	3.38e-6	Lymphocyte counts;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07167872	chr1:205819463	PM20D1	0.45	4.26	0.33	3.64e-5	Parkinson's disease;
PAAD	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26926768	chr12:34528122	NA	0.4	4.87	0.37	2.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs6784615	0.744	rs353545	chr3:52267580	G/C	cg27565382	chr3:53032988	SFMBT1	-1.06	-4.69	-0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.02e-6	Lung cancer;
PAAD	cis	rs62025270	0.632	rs17636096	chr15:86218734	C/G	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.7e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.42	0.34	1.88e-5	HDL cholesterol;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07203258	chr10:70660989	DDX50	0.57	6.38	0.46	2e-9	Monocyte percentage of white cells;
PAAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.86	8.13	0.55	1.37e-13	Methadone dose in opioid dependence;
PAAD	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.82	8.56	0.57	1.14e-14	Uric acid levels;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.64	6.73	0.48	3.25e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.92	-12.34	-0.71	1.11e-24	Ulcerative colitis;
PAAD	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg02404636	chr22:31891804	SFI1	0.64	5.88	0.43	2.57e-8	Colorectal cancer;
PAAD	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs56346965	0.967	rs11900804	chr2:191533767	T/C	cg27211696	chr2:191398769	TMEM194B	-0.49	-4.3	-0.33	3.04e-5	Bone mineral density (Ward's triangle area);
PAAD	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	7.96e-9	Lung cancer;
PAAD	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.45	-0.34	1.62e-5	Blood metabolite levels;
PAAD	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	7.29	0.51	1.56e-11	Lymphocyte counts;
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg23173402	chr1:227635558	NA	0.64	4.3	0.33	3.01e-5	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00926874	chr1:226309722	NA	0.58	6.35	0.46	2.37e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg13263323	chr15:86062960	AKAP13	-0.61	-6.9	-0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.85	-8.85	-0.58	2.04e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg01426195	chr3:39028469	NA	0.64	6.4	0.46	1.8e-9	Handedness;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.95	12.31	0.71	1.38e-24	Menopause (age at onset);
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg07061783	chr6:25882402	NA	0.53	5.04	0.38	1.28e-6	Blood metabolite levels;
PAAD	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.26e-18	Vitiligo;
PAAD	trans	rs9372498	1.000	rs3904613	chr6:118586487	T/C	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs4427176	0.765	rs7001044	chr8:9600181	G/A	cg03024720	chr8:9765601	NA	0.47	4.52	0.34	1.26e-5	Mosquito bite size;
PAAD	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.03	0.38	1.34e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg23188684	chr11:67383651	NA	-0.42	-4.31	-0.33	2.95e-5	Mean corpuscular volume;
PAAD	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.89	7.17	0.5	3.07e-11	Chronic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26110562	chr2:236877461	AGAP1	0.6	6.59	0.47	6.93e-10	Smoking initiation;
PAAD	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg18078177	chr20:47281410	PREX1	0.9	6.17	0.45	6.03e-9	Tonometry;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	2e-13	Alzheimer's disease;
PAAD	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg17739936	chr11:789930	CEND1	-0.58	-5.73	-0.42	5.27e-8	Breast cancer;
PAAD	cis	rs4662592	0.554	rs35615728	chr2:128903862	G/T	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg13263323	chr15:86062960	AKAP13	-0.61	-6.9	-0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-4.65	-0.35	7.05e-6	Mean corpuscular volume;
PAAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg21698718	chr17:80085957	CCDC57	0.45	5.11	0.38	9.34e-7	Life satisfaction;
PAAD	cis	rs742132	0.520	rs4712950	chr6:25657590	A/G	cg03517284	chr6:25882590	NA	0.65	4.3	0.33	2.99e-5	Uric acid levels;
PAAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg03983715	chr16:68378420	PRMT7	-0.98	-6.91	-0.49	1.22e-10	Magnesium levels;
PAAD	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	10.25	0.64	4.5e-19	Response to antipsychotic treatment;
PAAD	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg03233332	chr7:66118400	NA	0.41	4.42	0.34	1.9e-5	Aortic root size;
PAAD	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.62	4.94	0.37	2e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07116851	chr12:58146173	CDK4	0.63	6.92	0.49	1.17e-10	Myopia (pathological);
PAAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.6e-8	Height;
PAAD	cis	rs7129556	0.815	rs11607715	chr11:77238859	T/C	cg24456632	chr11:77314957	AQP11	-0.57	-4.7	-0.36	5.76e-6	Weight loss (gastric bypass surgery);
PAAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.5	0.41	1.56e-7	Menarche (age at onset);
PAAD	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg00922110	chr4:57842668	C4orf14	0.42	4.35	0.33	2.46e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	4.94	0.37	2.01e-6	Yeast infection;
PAAD	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6681460	0.898	rs536527	chr1:67193793	A/C	cg02459107	chr1:67143332	SGIP1	0.69	6.54	0.47	8.91e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.24e-8	Life satisfaction;
PAAD	cis	rs727479	0.502	rs12591172	chr15:51503727	G/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.49	0.34	1.38e-5	Estradiol levels;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	5.28	0.39	4.36e-7	Axial length;
PAAD	cis	rs258892	0.895	rs10065972	chr5:72044091	A/G	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg06131755	chr6:160182447	ACAT2	0.53	4.61	0.35	8.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs17162190	0.590	rs6669111	chr1:26828182	A/G	cg17456097	chr1:26900765	RPS6KA1	0.59	4.79	0.36	3.88e-6	Mean corpuscular volume;
PAAD	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg20936604	chr3:58311152	NA	-0.77	-4.39	-0.34	2.15e-5	Cholesterol, total;
PAAD	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.57	7.13	0.5	3.77e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs362296	0.550	rs3135064	chr4:3285389	T/C	cg08886695	chr4:3369023	RGS12	-0.49	-4.44	-0.34	1.75e-5	Parental longevity (mother's age at death);
PAAD	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-8.28	-0.56	5.73e-14	Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.23	-0.39	5.47e-7	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg07068956	chr7:100330872	ZAN	-0.72	-5.66	-0.42	7.37e-8	Other erythrocyte phenotypes;
PAAD	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	4.35	0.33	2.46e-5	Height;
PAAD	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg08779649	chr13:50194554	NA	0.46	6.24	0.45	4.19e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.63	-7.25	-0.51	1.97e-11	Bone mineral density;
PAAD	cis	rs7631605	0.905	rs3774335	chr3:37072627	A/C	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg14703610	chr5:56206110	C5orf35	0.62	5.8	0.43	3.72e-8	Coronary artery disease;
PAAD	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg09389931	chr14:103748217	NA	-0.4	-4.27	-0.33	3.37e-5	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs12799264	1.000	rs2585779	chr11:19976230	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs11811982	0.793	rs115767103	chr1:227510306	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.26	0.45	3.75e-9	Hip circumference;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg08213375	chr14:104286397	PPP1R13B	0.48	6.44	0.46	1.52e-9	Schizophrenia;
PAAD	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.83	-0.36	3.35e-6	Body mass index;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.53	-5.2	-0.39	6.21e-7	Testicular germ cell tumor;
PAAD	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.79	7.26	0.51	1.84e-11	Gout;
PAAD	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg00277334	chr10:82204260	NA	-0.61	-5.63	-0.42	8.35e-8	Post bronchodilator FEV1;
PAAD	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg01090926	chr14:75137805	KIAA0317	0.54	4.84	0.37	3.17e-6	Non-small cell lung cancer;
PAAD	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-4.53	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg21929781	chr1:2537748	MMEL1	-0.48	-5.11	-0.38	9.41e-7	Ulcerative colitis;
PAAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	5.01	0.38	1.48e-6	Bone mineral density;
PAAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg14664628	chr15:75095509	CSK	0.46	4.31	0.33	2.9e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg05304507	chr6:116381966	FRK	0.43	8.3	0.56	5.11e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.36	-4.87	-0.37	2.8e-6	Schizophrenia;
PAAD	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.85	-10.68	-0.65	3.28e-20	Aortic root size;
PAAD	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.54e-10	Eye color traits;
PAAD	cis	rs2147959	0.825	rs12746910	chr1:228658133	G/A	cg02753203	chr1:228287806	NA	0.57	4.55	0.35	1.08e-5	Adult asthma;
PAAD	cis	rs3026101	0.671	rs11868032	chr17:5283617	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.44	0.4	2.05e-7	Body mass index;
PAAD	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	1.06	10.67	0.65	3.52e-20	Post bronchodilator FEV1;
PAAD	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00806126	chr19:22604979	ZNF98	-0.41	-5.19	-0.39	6.52e-7	Pain;
PAAD	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20583141	chr14:88461098	GALC	0.66	6.85	0.49	1.7e-10	Smoking initiation;
PAAD	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg03162506	chr22:38580953	NA	-0.39	-4.36	-0.33	2.41e-5	Cutaneous nevi;
PAAD	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-6.94	-0.49	1.05e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.29	0.56	5.49e-14	Alzheimer's disease;
PAAD	cis	rs8084125	1.000	rs62102949	chr18:74939594	A/T	cg05528293	chr18:74961138	GALR1	0.63	5.1	0.38	9.76e-7	Obesity-related traits;
PAAD	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.61	4.51	0.34	1.31e-5	Schizophrenia;
PAAD	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	5.7	0.42	6.01e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.39	0.34	2.07e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.6	4.69	0.36	6.01e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.54	-5.34	-0.4	3.32e-7	Educational attainment (years of education);
PAAD	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.59	-0.35	9.22e-6	Prevalent atrial fibrillation;
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg17105886	chr17:28927953	LRRC37B2	0.69	4.63	0.35	7.79e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg06618935	chr21:46677482	NA	-0.54	-6.7	-0.48	3.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11871801	1.000	rs78594996	chr17:40570109	A/G	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.78	-0.36	4.09e-6	Crohn's disease;
PAAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.9	-8.6	-0.57	9.04e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg07701084	chr6:150067640	NUP43	0.58	5.02	0.38	1.42e-6	Lung cancer;
PAAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg08676812	chr11:65308423	LTBP3	0.43	4.31	0.33	2.96e-5	Bone mineral density;
PAAD	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.74	6.86	0.49	1.6e-10	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-5.07	-0.38	1.13e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.52	-0.41	1.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.34e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.37	-4.66	-0.35	6.72e-6	Menarche (age at onset);
PAAD	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.84	9.08	0.59	5.23e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs59918340	0.738	rs7017848	chr8:142222374	A/G	cg23750338	chr8:142222470	SLC45A4	0.58	7.0	0.49	7.82e-11	Immature fraction of reticulocytes;
PAAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.82	-9.83	-0.62	5.75e-18	Prostate cancer;
PAAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg06375148	chr1:209958343	C1orf74	0.58	4.27	0.33	3.44e-5	Cleft lip with or without cleft palate;
PAAD	trans	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.78	-0.42	4.19e-8	Colorectal cancer;
PAAD	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.73	-7.45	-0.52	6.42e-12	Cognitive function;
PAAD	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg22467129	chr15:76604101	ETFA	0.56	5.26	0.39	4.78e-7	Blood metabolite levels;
PAAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs2286379	0.806	rs7974422	chr12:1885262	A/G	cg05227549	chr12:1770782	NA	-0.41	-4.65	-0.35	7.19e-6	Blood pressure (smoking interaction);
PAAD	cis	rs8179	0.645	rs10264916	chr7:92286376	A/G	cg03496780	chr7:92466842	CDK6	0.49	4.7	0.36	5.9e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg25902810	chr10:99078978	FRAT1	-0.6	-5.44	-0.4	2.08e-7	Monocyte count;
PAAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.58	4.71	0.36	5.64e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg07362569	chr17:61921086	SMARCD2	0.44	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-5.39	-0.4	2.61e-7	Tonsillectomy;
PAAD	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26853093	chr19:17448469	GTPBP3	0.65	7.21	0.5	2.52e-11	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5e-7	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	8.02	0.55	2.59e-13	Prudent dietary pattern;
PAAD	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg20936604	chr3:58311152	NA	-0.79	-4.27	-0.33	3.4e-5	Cholesterol, total;
PAAD	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.72	7.58	0.52	3.1e-12	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.68	0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs11037575	0.739	rs11037565	chr11:43708752	A/G	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-5.39	-0.4	2.6e-7	Psoriasis;
PAAD	cis	rs4761702	0.524	rs12581099	chr12:93727496	A/C	cg09688127	chr12:93770794	NUDT4;NUDT4P1	0.37	4.52	0.34	1.24e-5	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.38	8.26e-7	Serum sulfate level;
PAAD	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs151997	0.571	rs13340385	chr5:50318847	T/G	cg06027927	chr5:50259733	NA	0.73	6.29	0.45	3.18e-9	Callous-unemotional behaviour;
PAAD	cis	rs757081	0.514	rs214087	chr11:17298365	G/C	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.74	-0.42	4.91e-8	Systolic blood pressure;
PAAD	cis	rs11811982	0.793	rs114038031	chr1:227459144	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg04520793	chr17:42248056	ASB16	0.4	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg10616300	chr11:66138557	SLC29A2	0.33	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.3	-0.39	4.01e-7	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.9	-0.43	2.31e-8	Lung cancer;
PAAD	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg12639453	chr1:2035780	PRKCZ	0.5	4.69	0.36	5.99e-6	Height;
PAAD	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21643547	chr1:205240462	TMCC2	0.38	4.28	0.33	3.31e-5	Red blood cell count;
PAAD	cis	rs2797160	0.904	rs1777198	chr6:126007416	C/T	cg05901451	chr6:126070800	HEY2	0.48	4.53	0.35	1.17e-5	Endometrial cancer;
PAAD	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.68	-6.7	-0.48	3.75e-10	White matter hyperintensity burden;
PAAD	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.83	-4.76	-0.36	4.41e-6	Toenail selenium levels;
PAAD	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg06217245	chr20:33103252	DYNLRB1	0.46	5.28	0.39	4.3e-7	Height;
PAAD	cis	rs4907240	0.922	rs4907246	chr2:97326286	T/C	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.56	-0.35	1.05e-5	Event-related brain oscillations;
PAAD	cis	rs914615	0.552	rs4421576	chr1:155142210	A/G	cg20311333	chr1:155197753	GBAP1	0.43	4.26	0.33	3.56e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs2061333	0.724	rs4802208	chr19:44627912	G/C	cg23489630	chr19:44645078	ZNF234	-0.58	-4.38	-0.33	2.19e-5	Alzheimer's disease;
PAAD	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs10776612	0.565	rs11101356	chr10:49723133	A/G	cg08348173	chr10:49687869	ARHGAP22	-0.4	-4.27	-0.33	3.43e-5	Conduct disorder;
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-1.2	-11.28	-0.68	7.81e-22	Developmental language disorder (linguistic errors);
PAAD	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.95	0.49	9.8e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-7.9	-0.54	5.24e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.15	0.7	3.65e-24	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4908768	0.579	rs56280806	chr1:8875542	G/A	cg12700319	chr1:8272199	NA	-0.38	-4.25	-0.33	3.72e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2944755	0.723	rs13274041	chr8:141587915	T/C	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.61	-0.35	8.42e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.49	-4.55	-0.35	1.11e-5	Tuberculosis;
PAAD	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.85e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg24747557	chr10:131355152	MGMT	0.52	5.43	0.4	2.24e-7	Response to temozolomide;
PAAD	cis	rs3206736	0.548	rs1649221	chr7:34987758	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-6.6	-0.47	6.44e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10929159	0.928	rs2317303	chr2:236921702	A/G	cg14226755	chr2:236923322	AGAP1	0.29	4.66	0.35	6.97e-6	Parkinson's disease;
PAAD	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg02527881	chr3:46936655	PTH1R	0.38	4.4	0.34	1.99e-5	Colorectal cancer;
PAAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs35955747	0.869	rs131213	chr22:31753849	C/T	cg02404636	chr22:31891804	SFI1	0.57	5.75	0.42	4.73e-8	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-5.48	-0.41	1.72e-7	Resistin levels;
PAAD	cis	rs778371	0.749	rs2592120	chr2:233793664	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.1	-0.44	8.26e-9	Schizophrenia;
PAAD	cis	rs73206853	0.841	rs7297096	chr12:110798322	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg10864074	chr7:100318194	EPO	-0.48	-4.72	-0.36	5.4e-6	Other erythrocyte phenotypes;
PAAD	cis	rs4455778	0.580	rs35333419	chr7:49120543	A/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11853189	0.938	rs2277551	chr15:78580481	G/A	cg22935921	chr15:78556834	DNAJA4	0.78	5.36	0.4	3.03e-7	Red cell distribution width;
PAAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-8.65	-0.57	6.94e-15	Coronary artery disease;
PAAD	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.82	-8.74	-0.58	4.04e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Calcium levels;
PAAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg00206168	chr11:65308501	LTBP3	-0.51	-5.3	-0.4	3.96e-7	Bone mineral density;
PAAD	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.65	-6.07	-0.44	9.96e-9	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.93	-9.78	-0.62	7.78e-18	Urate levels in obese individuals;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.93	-0.43	1.97e-8	Schizophrenia;
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00339695	chr16:24857497	SLC5A11	0.46	4.3	0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.25	10.47	0.65	1.18e-19	Corneal structure;
PAAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg05082376	chr22:42548792	NA	-0.55	-5.69	-0.42	6.45e-8	Cognitive function;
PAAD	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	5.28	0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs367943	0.608	rs2972662	chr5:112990330	C/T	cg12552261	chr5:112820674	MCC	-0.56	-6.02	-0.44	1.23e-8	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.96	10.59	0.65	5.62e-20	Primary sclerosing cholangitis;
PAAD	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-1.0	-14.15	-0.75	1.55e-29	Heart rate;
PAAD	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg00071950	chr4:10020882	SLC2A9	0.53	4.51	0.34	1.28e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.94	0.37	2.02e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.72	7.15	0.5	3.39e-11	Sudden cardiac arrest;
PAAD	cis	rs16958440	0.867	rs78585258	chr18:44677729	T/A	cg17192377	chr18:44677553	HDHD2	1.05	5.58	0.41	1.1e-7	Sitting height ratio;
PAAD	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.89	7.15	0.5	3.37e-11	Chronic kidney disease;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.73	6.77	0.48	2.68e-10	Asthma;
PAAD	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.71	-5.82	-0.43	3.34e-8	Non-small cell lung cancer;
PAAD	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg07384165	chr1:10488281	NA	-0.47	-4.93	-0.37	2.12e-6	Breast size;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.72	5.08	0.38	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.69	5.76	0.42	4.43e-8	Common traits (Other);
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	cis	rs4662592	0.590	rs28372711	chr2:128848652	C/G	cg03222009	chr2:129077232	HS6ST1	-0.47	-4.52	-0.34	1.21e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs4321325	1.000	rs4321325	chr2:127950997	C/T	cg09760422	chr2:128146352	NA	0.42	5.5	0.41	1.6e-7	Protein C levels;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	6.86e-11	Life satisfaction;
PAAD	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg07395648	chr5:131743802	NA	0.51	4.28	0.33	3.26e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.64	-0.35	7.33e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.99	10.7	0.66	2.86e-20	Corneal astigmatism;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.57	-5.27	-0.39	4.54e-7	Obesity-related traits;
PAAD	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	5.36	0.4	3.06e-7	Height;
PAAD	cis	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg16928487	chr17:17741425	SREBF1	-0.34	-4.65	-0.35	7.16e-6	Total body bone mineral density;
PAAD	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.6	-5.99	-0.44	1.47e-8	Height;
PAAD	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.62	5.67	0.42	6.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.76	-0.48	2.85e-10	Retinal vascular caliber;
PAAD	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg17385448	chr1:15911702	AGMAT	0.36	4.42	0.34	1.86e-5	Systolic blood pressure;
PAAD	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.64	-0.35	7.62e-6	Total body bone mineral density;
PAAD	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg24747557	chr10:131355152	MGMT	0.44	4.44	0.34	1.69e-5	Response to temozolomide;
PAAD	cis	rs4938573	0.526	rs11216973	chr11:118587001	T/C	cg04176122	chr11:118779835	BCL9L	0.39	4.36	0.33	2.42e-5	Follicular lymphoma;
PAAD	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg24053715	chr22:38214548	NA	0.63	5.8	0.43	3.7e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.79	6.49	0.47	1.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg13549667	chr19:18284397	IFI30	0.46	4.3	0.33	2.98e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08884368	chr17:49244154	NME2;NME1-NME2	0.58	6.29	0.45	3.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811528	0.656	rs7782028	chr7:2706478	T/C	cg11411865	chr7:2701802	TTYH3	0.51	4.35	0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-5.88	-0.43	2.46e-8	Bipolar disorder;
PAAD	cis	rs8025118	0.583	rs7168501	chr15:79557833	T/G	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.45	-0.34	1.66e-5	Cognitive function;
PAAD	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.44	6.0	0.44	1.38e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs3925075	0.531	rs4075052	chr16:31348233	G/T	cg02846316	chr16:31340340	ITGAM	-0.47	-5.4	-0.4	2.54e-7	IgA nephropathy;
PAAD	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.57	5.58	0.41	1.09e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.09	0.55	1.76e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs34112283	0.561	rs35648233	chr2:144223391	T/C	cg10530280	chr1:167759869	MPZL1	-0.67	-6.74	-0.48	3.13e-10	Neuroticism;
PAAD	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg15956490	chr3:53032818	SFMBT1	0.82	4.81	0.36	3.58e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs2894802	0.564	rs55999189	chr6:52652329	C/A	cg00536792	chr6:53530503	KLHL31	-0.42	-4.48	-0.34	1.49e-5	Platelet count;Plateletcrit;
PAAD	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.9	7.19	0.5	2.75e-11	Chronic kidney disease;
PAAD	cis	rs9810890	0.850	rs1466572	chr3:128543415	T/A	cg15676455	chr3:128564943	NA	-0.86	-4.8	-0.36	3.78e-6	Dental caries;
PAAD	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.91	-0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-6.42	-0.46	1.66e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg24747557	chr10:131355152	MGMT	0.57	5.52	0.41	1.41e-7	Response to temozolomide;
PAAD	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg21132104	chr15:45694354	SPATA5L1	0.84	7.59	0.52	2.96e-12	Homoarginine levels;
PAAD	cis	rs4757319	0.515	rs4757316	chr11:15432094	A/G	cg03245590	chr11:15329459	NA	0.43	5.19	0.39	6.66e-7	Breast cancer;
PAAD	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs8018808	1.000	rs2193595	chr14:77845121	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg20893579	chr22:38215064	NA	-0.56	-6.04	-0.44	1.12e-8	Glioblastoma;Glioma;
PAAD	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.53	-0.41	1.36e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.65	8.17	0.55	1.11e-13	Prostate cancer;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.66	-4.61	-0.35	8.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.77	7.99	0.54	3.08e-13	Alzheimer's disease (late onset);
PAAD	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.76	9.07	0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs10988802	0.516	rs10819953	chr9:98398956	C/T	cg14323293	chr9:98280076	PTCH1	0.54	4.42	0.34	1.9e-5	Chemerin levels;
PAAD	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg08824895	chr13:115047677	UPF3A	-0.46	-4.43	-0.34	1.8e-5	Schizophrenia;
PAAD	cis	rs9653442	0.900	rs1160544	chr2:100832218	A/C	cg07810366	chr2:100720526	AFF3	-0.38	-4.8	-0.36	3.82e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.53	-9.18	-0.6	2.95e-16	Cutaneous nevi;
PAAD	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.77	-7.96	-0.54	3.66e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	1.02	8.85	0.58	2.06e-15	Vitiligo;
PAAD	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.38	4.81	0.36	3.62e-6	Sitting height ratio;
PAAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-4.63	-0.35	7.92e-6	Menopause (age at onset);
PAAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23158103	chr7:148848205	ZNF398	-0.59	-5.74	-0.42	4.97e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2562456	0.793	rs62110424	chr19:21599637	A/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.9	0.37	2.39e-6	Schizophrenia;
PAAD	cis	rs1371614	0.552	rs35538505	chr2:27126027	G/T	cg00617064	chr2:27272375	NA	0.45	4.53	0.35	1.17e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs4662592	0.553	rs7605179	chr2:128843513	G/A	cg17144508	chr2:128283727	IWS1	-0.55	-4.33	-0.33	2.64e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.89	5.85	0.43	2.85e-8	Major depressive disorder;
PAAD	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg26014689	chr19:7917955	EVI5L	-0.5	-5.01	-0.38	1.53e-6	Menarche (age at onset);
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.3e-6	Height;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26726542	chr13:20702031	NA	-0.63	-7.45	-0.52	6.55e-12	Energy expenditure (24h);
PAAD	cis	rs9463078	0.625	rs7742360	chr6:44998692	C/G	cg25276700	chr6:44698697	NA	-0.53	-6.08	-0.44	9.24e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg14440974	chr22:39074834	NA	-0.54	-6.44	-0.46	1.52e-9	Menopause (age at onset);
PAAD	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.86	0.62	4.78e-18	Smoking behavior;
PAAD	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.4	5.02	0.38	1.43e-6	Corneal astigmatism;
PAAD	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4757319	0.515	rs10832402	chr11:15334036	C/T	cg03245590	chr11:15329459	NA	-0.45	-5.38	-0.4	2.79e-7	Breast cancer;
PAAD	cis	rs593531	0.504	rs4944041	chr11:74029859	C/T	cg15851278	chr11:73669449	DNAJB13	0.39	4.96	0.37	1.9e-6	Neuroticism;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.68	7.47	0.52	5.85e-12	Morning vs. evening chronotype;
PAAD	cis	rs939584	0.877	rs6749087	chr2:629818	A/T	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs6137287	0.668	rs6047256	chr20:21095964	C/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.76	0.36	4.54e-6	Height;
PAAD	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24029028	chr14:59295237	NA	0.55	6.44	0.46	1.48e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18646088	chr12:69139829	SLC35E3	0.64	6.85	0.49	1.71e-10	Myopia (pathological);
PAAD	cis	rs7172971	0.506	rs116953180	chr15:42384290	T/C	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.67	5.56	0.41	1.16e-7	Crohn's disease;
PAAD	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.6	-0.41	9.79e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.69	4.91	0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs5756391	0.523	rs2049908	chr22:37311089	A/G	cg21209356	chr22:37319042	CSF2RB	0.37	4.56	0.35	1.05e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.52	-4.46	-0.34	1.59e-5	Facial morphology (factor 19);
PAAD	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.65	-6.35	-0.46	2.4e-9	Uric acid levels;
PAAD	cis	rs1113500	0.548	rs11185269	chr1:108647636	T/C	cg06207961	chr1:108661230	NA	0.45	4.51	0.34	1.3e-5	Growth-regulated protein alpha levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02714192	chr18:77201972	NFATC1	0.55	7.09	0.5	4.63e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.48	-4.77	-0.36	4.35e-6	Corneal structure;
PAAD	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.47	-0.34	1.5e-5	Neuroticism;
PAAD	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.64	7.05	0.5	6.01e-11	Smoking initiation;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg26554054	chr8:600488	NA	-1.07	-6.95	-0.49	9.99e-11	IgG glycosylation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07818096	chr15:55700549	CCPG1	-0.72	-6.34	-0.46	2.43e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18932008	chr1:85426586	MCOLN2	-0.61	-6.45	-0.46	1.39e-9	Obesity-related traits;
PAAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.91	-10.15	-0.64	8.29e-19	Cancer (pleiotropy);
PAAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.88	10.37	0.64	2.13e-19	Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15451272	chr1:25071355	CLIC4	0.56	6.52	0.47	9.91e-10	Monocyte percentage of white cells;
PAAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg00579200	chr11:133705235	NA	-0.47	-5.0	-0.38	1.54e-6	Childhood ear infection;
PAAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg27494647	chr7:150038898	RARRES2	0.46	4.99	0.38	1.62e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.62	8.18	0.55	1.07e-13	Renal cell carcinoma;
PAAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.44	-4.39	-0.34	2.09e-5	Menarche (age at onset);
PAAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs11807834	0.522	rs4582798	chr1:230239628	C/T	cg00566187	chr1:230250356	GALNT2	-0.64	-6.81	-0.48	2.16e-10	Schizophrenia;
PAAD	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.63	8.03	0.55	2.46e-13	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.82	5.34	0.4	3.38e-7	Systolic blood pressure;
PAAD	cis	rs10861342	1.000	rs34705618	chr12:105518611	C/G	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-1.19	-13.25	-0.73	3.91e-27	Hair shape;
PAAD	cis	rs2882667	0.690	rs3749664	chr5:138271421	T/C	cg09476006	chr5:138032270	NA	0.44	5.33	0.4	3.41e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6429082	0.522	rs6687021	chr1:235558804	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.61	-6.21	-0.45	4.82e-9	Adiposity;
PAAD	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.57	0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.64	-6.68	-0.48	4.23e-10	Body mass index;
PAAD	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	1.08	6.77	0.48	2.68e-10	Skin colour saturation;
PAAD	cis	rs593531	0.513	rs479968	chr11:74038274	C/G	cg15851278	chr11:73669449	DNAJB13	0.4	5.13	0.38	8.82e-7	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12035585	chr17:40761707	FAM134C;TUBG1	0.7	6.89	0.49	1.38e-10	Obesity-related traits;
PAAD	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg13798912	chr7:905769	UNC84A	0.59	4.49	0.34	1.42e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.67	-6.95	-0.49	9.84e-11	Corneal astigmatism;
PAAD	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.02	0.38	1.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7577696	1.000	rs7577696	chr2:32278782	A/G	cg02381751	chr2:32503542	YIPF4	-0.41	-4.39	-0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21545522	chr1:205238299	TMCC2	0.48	4.38	0.33	2.17e-5	Red blood cell count;
PAAD	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.02	-0.75	3.37e-29	Primary sclerosing cholangitis;
PAAD	trans	rs901683	0.850	rs17157890	chr10:46020652	T/C	cg11747279	chr17:21096632	NA	0.88	6.67	0.48	4.45e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.54	-6.52	-0.47	9.74e-10	Lewy body disease;
PAAD	cis	rs13242816	1.000	rs34228114	chr7:116106986	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02725872	chr8:58115012	NA	-0.82	-5.79	-0.43	3.83e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.88	10.22	0.64	5.53e-19	Adiposity;
PAAD	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.65	-0.47	4.98e-10	Glomerular filtration rate;
PAAD	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.54	5.06	0.38	1.19e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs55728055	0.661	rs16989760	chr22:31951808	A/G	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs4740619	0.933	rs7859788	chr9:15710606	A/T	cg14451791	chr9:16040625	NA	-0.4	-4.59	-0.35	9.08e-6	Body mass index;
PAAD	cis	rs8040855	0.627	rs12909130	chr15:85590501	T/C	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-5.0	-0.38	1.58e-6	Body mass index;
PAAD	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.52	5.87	0.43	2.6e-8	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg27394845	chr17:28928406	LRRC37B2	0.62	4.4	0.34	2.05e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11203032	0.831	rs11203018	chr10:90948783	T/C	cg16672925	chr10:90967113	CH25H	0.72	5.59	0.41	1e-7	Heart failure;
PAAD	cis	rs4906332	0.933	rs4906330	chr14:103971202	T/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.42	-0.4	2.3e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.7	-6.72	-0.48	3.42e-10	Recombination rate (males);
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.36	-4.63	-0.35	7.81e-6	Abdominal aortic aneurysm;
PAAD	cis	rs3781458	0.803	rs11245321	chr10:126323279	C/T	cg20435097	chr10:126320824	FAM53B	0.51	5.47	0.41	1.81e-7	Male-pattern baldness;
PAAD	cis	rs3764400	0.567	rs8079616	chr17:46213488	C/T	cg10706073	chr17:46328419	SKAP1	1.05	6.3	0.46	3e-9	Body mass index;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.96	-11.81	-0.69	2.92e-23	Menarche (age at onset);
PAAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg20933634	chr6:27740509	NA	0.68	6.42	0.46	1.63e-9	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15025362	chr3:186256331	CRYGS	-0.65	-6.59	-0.47	6.71e-10	Obesity-related traits;
PAAD	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.91	-0.49	1.26e-10	Psoriasis;
PAAD	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg18898632	chr2:242989856	NA	-0.81	-6.41	-0.46	1.77e-9	Obesity-related traits;
PAAD	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-0.97	-6.38	-0.46	2.03e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg21419209	chr3:44054225	NA	-0.75	-7.72	-0.53	1.46e-12	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.02	0.38	1.43e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.63	-0.57	7.59e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs1642645	0.606	rs638734	chr1:42460581	G/A	cg01990334	chr1:42801334	FOXJ3	-0.65	-5.7	-0.42	5.99e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.88	9.78	0.62	7.91e-18	Prudent dietary pattern;
PAAD	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.83	0.66	1.27e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	5.28	0.39	4.32e-7	Blood metabolite levels;
PAAD	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg00105475	chr2:10696890	NA	0.73	7.88	0.54	5.86e-13	Prostate cancer;
PAAD	cis	rs4234284	1.000	rs11925520	chr3:126949354	C/T	cg27326032	chr3:127006922	NA	0.48	4.95	0.37	1.96e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg25456477	chr12:86230367	RASSF9	0.48	4.32	0.33	2.82e-5	Major depressive disorder;
PAAD	trans	rs901683	1.000	rs71496608	chr10:46017132	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.51	-0.47	1.05e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6718203	0.818	rs55990324	chr2:60704743	G/T	cg10480506	chr2:60280451	NA	0.67	4.63	0.35	7.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-4.31	-0.33	2.88e-5	Morning vs. evening chronotype;
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.58	5.9	0.43	2.33e-8	Menarche (age at onset);
PAAD	trans	rs13196614	1.000	rs35708663	chr6:148946347	G/C	cg01596495	chr11:57317706	SMTNL1	-0.72	-6.46	-0.46	1.36e-9	Migraine;
PAAD	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.8	9.9	0.63	3.83e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.55	5.81	0.43	3.55e-8	Dupuytren's disease;
PAAD	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.92	-5.79	-0.42	3.99e-8	Lung cancer in ever smokers;
PAAD	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.95	6.6	0.47	6.61e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.67	-6.49	-0.47	1.15e-9	Callous-unemotional behaviour;
PAAD	cis	rs6537837	1.000	rs7371	chr1:110135308	G/A	cg05049280	chr1:110155535	GNAT2	0.45	4.49	0.34	1.38e-5	Major depressive disorder;
PAAD	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.44	-5.3	-0.4	3.93e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs13092825	1.000	rs74803054	chr3:113281370	A/T	cg18753928	chr3:113234510	CCDC52	-0.46	-4.42	-0.34	1.88e-5	Dental caries;
PAAD	trans	rs901683	1.000	rs35034867	chr10:46039565	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.62	6.67	0.48	4.37e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-4.42	-0.34	1.85e-5	Rheumatoid arthritis;
PAAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.28	-0.39	4.35e-7	Electroencephalogram traits;
PAAD	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	ch.8.33884649F	chr8:33765107	NA	-0.53	-5.9	-0.43	2.22e-8	Body mass index;
PAAD	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.72	-6.95	-0.49	9.98e-11	Alcohol dependence;
PAAD	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.17	16.49	0.8	1.15e-35	Body mass index;
PAAD	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.06	9.89	0.63	4e-18	Red blood cell traits;
PAAD	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.45	4.71	0.36	5.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-4.81	-0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.09	0.44	8.88e-9	Height;
PAAD	cis	rs2415984	0.622	rs1955262	chr14:46940639	A/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.37e-7	Number of children ever born;
PAAD	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.47	4.45	0.34	1.62e-5	Renal cell carcinoma;
PAAD	cis	rs6466055	0.616	rs113860003	chr7:104991190	A/G	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg04520793	chr17:42248056	ASB16	-0.46	-6.16	-0.45	6.31e-9	Total body bone mineral density;
PAAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg27532560	chr4:187881888	NA	-0.54	-6.56	-0.47	7.88e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9535307	0.522	rs3851166	chr13:50409236	G/T	cg04663916	chr13:50265991	EBPL	-0.67	-4.85	-0.37	2.97e-6	Obesity-related traits;
PAAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.45	0.65	1.35e-19	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.54	5.7	0.42	5.96e-8	Menopause (age at onset);
PAAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.61	6.54	0.47	8.68e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg19493303	chr19:41414353	NA	0.55	5.69	0.42	6.38e-8	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
PAAD	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.37	0.33	2.33e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.49	-4.8	-0.36	3.71e-6	Mean corpuscular volume;
PAAD	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg00531865	chr16:30841666	NA	-0.51	-4.98	-0.37	1.74e-6	Dementia with Lewy bodies;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02673636	chr1:109647056	NA	-0.73	-7.64	-0.53	2.24e-12	Smoking initiation;
PAAD	cis	rs600626	0.636	rs11236514	chr11:75451343	A/C	cg24262691	chr11:75473276	NA	-0.75	-5.88	-0.43	2.46e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.61	-5.26	-0.39	4.74e-7	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14071524	chr9:10615205	NA	-0.55	-6.31	-0.46	2.95e-9	Obesity-related traits;
PAAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00982548	chr2:198649783	BOLL	-0.83	-5.87	-0.43	2.67e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1561176	0.783	rs1124175	chr7:155015124	A/C	cg08570118	chr7:155025533	NA	0.62	5.6	0.41	9.63e-8	Personality dimensions;
PAAD	cis	rs10901513	0.900	rs2366345	chr10:127671790	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.47	0.34	1.52e-5	Visceral fat;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.51e-7	Life satisfaction;
PAAD	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.56	4.92	0.37	2.22e-6	Life satisfaction;
PAAD	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.42	4.61	0.35	8.38e-6	HDL cholesterol levels;
PAAD	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6700896	0.966	rs4655557	chr1:66080787	T/C	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.64e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg26497354	chr6:109612229	NA	0.45	4.88	0.37	2.69e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs8020912	0.504	rs3759577	chr14:103850963	C/T	cg12935359	chr14:103987150	CKB	0.64	5.87	0.43	2.59e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.67	5.25	0.39	4.93e-7	Alzheimer's disease;
PAAD	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.52	-5.35	-0.4	3.25e-7	Migraine;
PAAD	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg09760422	chr2:128146352	NA	-0.36	-6.28	-0.45	3.36e-9	Protein C levels;
PAAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg16576597	chr16:28551801	NUPR1	-0.71	-7.39	-0.51	9.04e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.03	0.38	1.34e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-4.78	-0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	5e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.54	0.35	1.12e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs12936587	0.601	rs7212538	chr17:17554587	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-5.33	-0.4	3.46e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg16329197	chr12:53359506	NA	-0.92	-10.59	-0.65	5.63e-20	Cancer (pleiotropy);
PAAD	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.11	0.44	8.09e-9	Rheumatoid arthritis;
PAAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.42	5.02	0.38	1.4e-6	Psoriasis;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.63	-6.25	-0.45	3.87e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35084382	1.000	rs2431663	chr5:172196711	A/C	cg19801141	chr5:172198162	DUSP1	1.19	6.2	0.45	5.06e-9	Optic cup area;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.61	6.58	0.47	7.01e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.39	0.71	8.03e-25	Cognitive ability;
PAAD	cis	rs939584	1.000	rs6717005	chr2:621910	A/C	cg14515364	chr2:636606	NA	0.48	4.34	0.33	2.63e-5	Body mass index;
PAAD	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg03277515	chr1:153321198	PGLYRP4	0.43	5.14	0.38	8.32e-7	Psoriasis;
PAAD	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	5.35	0.4	3.14e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1883415	0.750	rs2076317	chr6:24490147	A/G	cg20631270	chr6:24437470	GPLD1	0.46	4.26	0.33	3.55e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.77	-6.84	-0.49	1.78e-10	Exhaled nitric oxide output;
PAAD	cis	rs2882667	0.690	rs288012	chr5:138196273	C/T	cg09476006	chr5:138032270	NA	-0.47	-5.98	-0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2526932	0.623	rs2803956	chr14:73079464	C/T	cg13588403	chr14:73209128	DPF3	-0.36	-4.26	-0.33	3.52e-5	C-reactive protein and white blood cell count;
PAAD	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.47	-4.36	-0.33	2.37e-5	Endometrial cancer;
PAAD	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg11783602	chr8:55087084	NA	-0.6	-6.76	-0.48	2.79e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.66	-5.29	-0.39	4.2e-7	Schizophrenia;
PAAD	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.48	-0.57	1.86e-14	Mean corpuscular volume;
PAAD	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs1042026	0.848	rs12650681	chr4:100186978	T/A	cg21548116	chr4:100009993	ADH5	-0.49	-4.29	-0.33	3.21e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.67	5.34	0.4	3.34e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.69	7.31	0.51	1.41e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.87	-8.63	-0.57	7.82e-15	Hip circumference adjusted for BMI;
PAAD	trans	rs10500871	0.835	rs11602566	chr11:20222140	G/A	cg02956962	chr6:161097311	NA	0.66	6.42	0.46	1.65e-9	Educational attainment;
PAAD	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-1.12	-12.13	-0.7	4.21e-24	Blood pressure (smoking interaction);
PAAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.83	7.35	0.51	1.13e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs1957429	0.520	rs72625633	chr14:65284303	A/G	cg23373153	chr14:65346875	NA	-1.04	-5.3	-0.4	3.94e-7	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-4.65	-0.35	7.18e-6	Retinal vascular caliber;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	0.95	13.54	0.74	6.6e-28	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.34	4.48	0.34	1.46e-5	Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.49	-4.34	-0.33	2.57e-5	Multiple sclerosis;
PAAD	cis	rs7084783	0.538	rs1077016	chr10:105333242	T/C	cg09754828	chr10:105363329	SH3PXD2A	0.45	4.29	0.33	3.21e-5	Fear of pain;
PAAD	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-6.29	-0.45	3.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs72829446	0.505	rs72842824	chr17:7352910	G/A	cg02795151	chr17:7402630	POLR2A	0.6	5.24	0.39	5.27e-7	Androgen levels;
PAAD	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.28	-0.51	1.66e-11	Morning vs. evening chronotype;
PAAD	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.63	-0.42	8.56e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.75	7.43	0.52	7.41e-12	Asthma;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19680388	chr11:134118306	THYN1	0.68	7.18	0.5	2.9e-11	Smoking initiation;
PAAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	trans	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs78761021	0.617	rs756224	chr17:9768941	A/G	cg26853458	chr17:9805074	RCVRN	0.47	5.55	0.41	1.21e-7	Type 2 diabetes;
PAAD	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.62	5.82	0.43	3.45e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.5	5.17	0.39	7.25e-7	Fibrinogen levels;
PAAD	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.5	2.62e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.46	5.38	0.4	2.77e-7	Coronary artery disease;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg27588902	chr6:42928151	GNMT	-0.41	-4.38	-0.34	2.16e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg25649188	chr17:73499917	CASKIN2	0.63	5.83	0.43	3.22e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg18551225	chr6:44695536	NA	-0.67	-6.76	-0.48	2.71e-10	Total body bone mineral density;
PAAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg26174226	chr8:58114915	NA	-0.61	-4.88	-0.37	2.63e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg20003494	chr4:90757398	SNCA	0.65	5.87	0.43	2.62e-8	Neuroticism;
PAAD	cis	rs757978	1.000	rs11681497	chr2:242344333	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-4.9	-0.37	2.44e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs10512697	0.655	rs35451111	chr5:3466737	A/G	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.39	-0.4	2.66e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.71	-7.25	-0.51	2.01e-11	Alcohol dependence;
PAAD	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.06	0.44	1.04e-8	Personality dimensions;
PAAD	cis	rs16958440	0.867	rs75287977	chr18:44686823	G/A	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-6.77	-0.48	2.57e-10	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs258892	0.895	rs16901102	chr5:72048749	C/T	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs3112530	1.000	rs159972	chr5:152732406	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg14311320	chr7:124405732	GPR37	-0.45	-4.48	-0.34	1.48e-5	Lewy body disease;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18621852	chr3:10150065	C3orf24	0.62	5.46	0.4	1.92e-7	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.82	-0.43	3.45e-8	IgG glycosylation;
PAAD	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.47	-0.34	1.5e-5	Reticulocyte count;
PAAD	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.39	-0.4	2.66e-7	Joint mobility (Beighton score);
PAAD	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.53	5.15	0.39	7.89e-7	Alcohol dependence;
PAAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-6.82	-0.48	2.01e-10	Body mass index;
PAAD	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg12568669	chr8:11666485	FDFT1	0.32	5.44	0.4	2.07e-7	Monocyte count;
PAAD	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs9913156	0.517	rs8069382	chr17:4612874	G/T	cg00122941	chr17:4613640	ARRB2	0.66	7.05	0.5	5.92e-11	Lymphocyte counts;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.71	6.92	0.49	1.15e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg21775007	chr8:11205619	TDH	-0.48	-4.54	-0.35	1.13e-5	Systolic blood pressure;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09700085	chr3:45838028	SLC6A20	0.56	6.35	0.46	2.34e-9	Immature fraction of reticulocytes;
PAAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00982548	chr2:198649783	BOLL	-0.84	-5.85	-0.43	2.9e-8	Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg21130718	chr4:1044621	NA	0.51	4.5	0.34	1.35e-5	Recombination rate (females);
PAAD	cis	rs2415984	0.505	rs1389607	chr14:46957922	T/C	cg14871534	chr14:47121158	RPL10L	0.5	4.92	0.37	2.27e-6	Number of children ever born;
PAAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg03989125	chr22:38214979	NA	0.61	5.64	0.42	8.26e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs901683	1.000	rs35670420	chr10:46088052	T/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.59	6.47	0.46	1.29e-9	Lung cancer;
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.5	4.27	0.33	3.5e-5	Sudden cardiac arrest;
PAAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg01815783	chr4:1047043	NA	-0.45	-4.32	-0.33	2.78e-5	Recombination rate (females);
PAAD	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg08601574	chr20:25228251	PYGB	0.48	4.93	0.37	2.16e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg20169779	chr10:135381914	SYCE1	-0.59	-6.0	-0.44	1.37e-8	Gout;
PAAD	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.84	-9.94	-0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg18279126	chr7:2041391	MAD1L1	0.57	5.69	0.42	6.42e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs5757949	0.553	rs5750968	chr22:40978118	C/G	cg14701072	chr22:41075428	MCHR1	-0.44	-4.31	-0.33	2.92e-5	Height;
PAAD	cis	rs2173063	0.892	rs78494750	chr15:93139569	T/C	cg05917748	chr15:93139515	NA	0.71	4.5	0.34	1.35e-5	Subcutaneous adipose tissue;
PAAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg17372223	chr3:52568218	NT5DC2	0.49	4.78	0.36	4.1e-6	Bipolar disorder;
PAAD	cis	rs818427	0.896	rs712663	chr5:112223594	T/C	cg07820702	chr5:112228657	REEP5	-0.56	-5.1	-0.38	1.01e-6	Total body bone mineral density;
PAAD	cis	rs28489187	0.597	rs506082	chr1:85899215	A/C	cg16011679	chr1:85725395	C1orf52	-0.5	-4.64	-0.35	7.54e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.21e-6	Skin colour saturation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20898305	chr2:3215160	TSSC1	0.55	6.37	0.46	2.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.98	12.41	0.71	7.11e-25	Bone mineral density;
PAAD	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Intracranial aneurysm;
PAAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	4.92	0.37	2.27e-6	Yeast infection;
PAAD	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.93	-6.97	-0.49	9.13e-11	Monocyte percentage of white cells;
PAAD	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg24053715	chr22:38214548	NA	-0.62	-6.57	-0.47	7.71e-10	Glioblastoma;Glioma;
PAAD	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.76	-8.2	-0.55	9.38e-14	Blood metabolite levels;
PAAD	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.91e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-4.56	-0.35	1.06e-5	Vitiligo;
PAAD	cis	rs6942407	0.696	rs4400318	chr7:86860524	A/C	cg02420886	chr7:86849541	C7orf23	0.58	4.57	0.35	1.01e-5	Food allergy;
PAAD	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-8.84	-0.58	2.19e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.19e-7	Red blood cell count;
PAAD	cis	rs12325245	0.536	rs71389028	chr16:58663260	G/A	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs2882667	0.591	rs56322405	chr5:138173382	C/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.45e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.59	-5.19	-0.39	6.69e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-5.65	-0.42	7.68e-8	Response to antipsychotic treatment;
PAAD	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.51	-0.52	4.68e-12	Neuroticism;
PAAD	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg04717802	chr22:42394638	WBP2NL	0.42	4.61	0.35	8.59e-6	Intelligence;
PAAD	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	5.01	0.38	1.48e-6	Educational attainment;
PAAD	cis	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg00806245	chr18:76673096	NA	-0.8	-5.65	-0.42	7.87e-8	Obesity-related traits;
PAAD	cis	rs9287719	0.649	rs7589694	chr2:10700874	T/C	cg00105475	chr2:10696890	NA	0.63	6.64	0.47	5.2400000000000005e-10	Prostate cancer;
PAAD	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg23555395	chr2:238036564	NA	0.46	5.18	0.39	7.09e-7	Systemic lupus erythematosus;
PAAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs7714584	1.000	rs7709388	chr5:150246539	C/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg21546286	chr11:48923668	NA	-0.46	-4.91	-0.37	2.36e-6	Coronary artery disease;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg10351095	chr21:47802916	PCNT	0.48	4.79	0.36	3.92e-6	Testicular germ cell tumor;
PAAD	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.16	-0.55	1.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.97	0.44	1.59e-8	Coffee consumption (cups per day);
PAAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.36	0.33	2.36e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.52	5.52	0.41	1.45e-7	Longevity;Endometriosis;
PAAD	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg19197139	chr17:4613644	ARRB2	0.88	8.69	0.58	5.4e-15	Lymphocyte counts;
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg08048268	chr3:133502702	NA	-0.48	-5.93	-0.43	1.98e-8	Iron status biomarkers;
PAAD	cis	rs2072732	0.861	rs41334845	chr1:2950370	A/C	cg15211996	chr1:2936768	ACTRT2	-0.47	-4.4	-0.34	2.05e-5	Plateletcrit;
PAAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.38e-12	Height;
PAAD	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg15557168	chr22:42548783	NA	-0.44	-4.49	-0.34	1.37e-5	Cognitive function;
PAAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.43	-4.83	-0.36	3.27e-6	Height;
PAAD	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.52	-4.73	-0.36	5.12e-6	Red blood cell traits;
PAAD	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.52	-0.34	1.24e-5	Myopia (pathological);
PAAD	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg04415270	chr2:102091202	RFX8	-0.56	-7.26	-0.51	1.82e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	7.26	0.51	1.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4455778	0.580	rs7777309	chr7:49085524	C/T	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.62	-0.35	8.17e-6	Neuroticism;
PAAD	trans	rs11794666	0.799	rs17273598	chr9:31734616	C/T	cg05628366	chr6:35744188	C6orf126	0.95	6.7	0.48	3.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg15443732	chr18:74961078	GALR1	0.6	5.54	0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.74	-6.79	-0.48	2.39e-10	Total body bone mineral density;
PAAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.4	1.93e-7	Personality dimensions;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-4.67	-0.35	6.53e-6	Height;
PAAD	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.47	0.41	1.8e-7	Bipolar disorder;
PAAD	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21815047	chr1:156182617	PMF1	0.57	6.34	0.46	2.44e-9	Monocyte percentage of white cells;
PAAD	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.39	4.92	0.37	2.26e-6	Pulmonary function;
PAAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-5.99	-0.44	1.48e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg11441379	chr12:63026424	NA	0.85	6.3	0.45	3.13e-9	IgG glycosylation;
PAAD	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-4.9	-0.37	2.47e-6	Height;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.09	10.17	0.64	7.3e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7640424	0.649	rs35876429	chr3:107928557	C/T	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg08219700	chr8:58056026	NA	0.72	5.29	0.39	4.29e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.62	5.5	0.41	1.57e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08078772	chr17:66244589	AMZ2	0.63	7.04	0.5	6.31e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg27394845	chr17:28928406	LRRC37B2	0.67	4.59	0.35	9.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9650657	0.740	rs7002282	chr8:10666993	A/G	cg00262122	chr8:11665843	FDFT1	-0.47	-4.42	-0.34	1.9e-5	Neuroticism;
PAAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14132460	chr6:79943592	HMGN3	0.67	7.28	0.51	1.7e-11	Myopia (pathological);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.67	0.72	1.46e-25	Prudent dietary pattern;
PAAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.74	6.83	0.48	1.95e-10	Obesity-related traits;
PAAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg13722127	chr7:150037890	RARRES2	-0.57	-5.89	-0.43	2.37e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12165864	chr7:66369176	NA	-0.84	-5.55	-0.41	1.22e-7	Diabetic kidney disease;
PAAD	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg11143131	chr5:131608246	PDLIM4	0.5	5.09	0.38	1.02e-6	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg19223190	chr17:80058835	NA	0.53	5.57	0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.71	-7.12	-0.5	3.98e-11	Visceral fat;
PAAD	cis	rs17155006	0.746	rs420753	chr7:107746253	A/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	7.5	0.52	4.87e-12	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19014323	chr10:43902618	HNRNPF	0.66	6.49	0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg10591111	chr5:226296	SDHA	-0.75	-5.79	-0.42	3.97e-8	Breast cancer;
PAAD	cis	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.61	-7.35	-0.51	1.16e-11	Inflammatory skin disease;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09597638	chr17:3907349	NA	-0.71	-7.64	-0.53	2.3e-12	Type 2 diabetes;
PAAD	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg12870014	chr12:110450643	ANKRD13A	0.6	4.26	0.33	3.54e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-1.03	-14.13	-0.75	1.78e-29	Breast cancer;
PAAD	cis	rs1977584	0.725	rs17507956	chr10:45401394	C/T	cg04218760	chr10:45406644	TMEM72	0.36	4.48	0.34	1.46e-5	Selective IgA deficiency;
PAAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Aortic root size;
PAAD	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.47	-5.91	-0.43	2.16e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.88	-4.96	-0.37	1.87e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	trans	rs6923462	0.735	rs4371882	chr6:7793169	A/G	cg02318454	chr8:143961141	CYP11B1	0.67	6.46	0.46	1.36e-9	Lung function (forced vital capacity);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26710055	chr3:15468825	EAF1;METTL6	0.67	7.28	0.51	1.64e-11	Obesity-related traits;
PAAD	cis	rs7301016	0.948	rs11174537	chr12:62929827	G/C	cg19781863	chr12:62918364	MON2	0.74	4.36	0.33	2.36e-5	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.697	rs6974932	chr7:27696830	A/C	cg22168087	chr7:27702803	HIBADH	-0.47	-4.48	-0.34	1.44e-5	Hypospadias;
PAAD	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg05481257	chr2:20870211	GDF7	0.4	5.6	0.41	9.96e-8	Abdominal aortic aneurysm;
PAAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.89	-0.49	1.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.9	-10.53	-0.65	8e-20	Refractive error;
PAAD	cis	rs9815354	1.000	rs6599175	chr3:41786009	C/T	cg03022575	chr3:42003672	ULK4	-0.7	-5.18	-0.39	6.92e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg06484146	chr7:12443880	VWDE	-0.61	-4.99	-0.38	1.61e-6	Coronary artery disease;
PAAD	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.03	10.8	0.66	1.59e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs593531	0.571	rs11236088	chr11:74094343	A/G	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.65	-0.35	7.25e-6	Neuroticism;
PAAD	cis	rs6718203	0.818	rs115610086	chr2:60646489	T/C	cg10480506	chr2:60280451	NA	0.79	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
PAAD	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	cg07049167	chr1:166818506	POGK	0.66	6.39	0.46	1.96e-9	Refractive astigmatism;
PAAD	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-10.71	-0.66	2.78e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.62	-0.35	8.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs9462846	1.000	rs9471941	chr6:42857827	C/T	cg13397359	chr6:42928475	GNMT	-0.62	-4.58	-0.35	9.52e-6	Blood protein levels;
PAAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.51	-6.71	-0.48	3.58e-10	Height;
PAAD	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.66	6.48	0.47	1.19e-9	Height;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg27094323	chr7:1216898	NA	-0.49	-5.89	-0.43	2.38e-8	Longevity;Endometriosis;
PAAD	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg22437258	chr11:111473054	SIK2	-0.62	-6.06	-0.44	1.05e-8	Primary sclerosing cholangitis;
PAAD	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.57	5.27	0.39	4.56e-7	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs4979778	chr10:63981919	G/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	5.73	0.42	5.16e-8	Height;
PAAD	cis	rs7714584	1.000	rs60134818	chr5:150261043	A/G	cg22134413	chr5:150180641	NA	0.69	5.02	0.38	1.42e-6	Crohn's disease;
PAAD	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	4.47	0.34	1.53e-5	IgG glycosylation;
PAAD	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.99	6.96	0.49	9.35e-11	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13965224	chr4:1218386	CTBP1	0.61	6.53	0.47	9.18e-10	Smoking initiation;
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.89	-0.37	2.5e-6	Lung cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14286274	chr1:211555998	C1orf97	0.64	7.25	0.51	1.92e-11	Myopia (pathological);
PAAD	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.77	7.11	0.5	4.21e-11	Mean platelet volume;
PAAD	cis	rs818427	0.927	rs153546	chr5:112238039	A/C	cg06941702	chr5:112196734	SRP19	0.47	4.39	0.34	2.11e-5	Total body bone mineral density;
PAAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-7.48	-0.52	5.6e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.45	-0.34	1.63e-5	Type 2 diabetes;
PAAD	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.12	0.38	8.96e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-7.43	-0.52	7.34e-12	Blood pressure (smoking interaction);
PAAD	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg12165864	chr7:66369176	NA	-0.54	-4.28	-0.33	3.3e-5	Corneal structure;
PAAD	cis	rs9462027	1.000	rs6457792	chr6:34764443	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.93	0.63	3.18e-18	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10679147	chr20:60877989	ADRM1	0.66	6.38	0.46	1.99e-9	Obesity-related traits;
PAAD	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.48	-0.34	1.47e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.58	-5.53	-0.41	1.35e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg24519413	chr1:26490540	NA	0.46	5.94	0.43	1.91e-8	Height;
PAAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg01489256	chr8:11204017	TDH	-0.45	-4.51	-0.34	1.26e-5	Retinal vascular caliber;
PAAD	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.7	7.27	0.51	1.8e-11	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.02	0.38	1.46e-6	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg26818257	chr2:241905806	NA	0.47	4.9	0.37	2.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.2	-0.39	6.2e-7	Menopause (age at onset);
PAAD	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.98	6.26	0.45	3.65e-9	Major depressive disorder;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	1.01	7.61	0.53	2.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6132905	0.590	rs74370935	chr20:2625458	G/C	cg24848351	chr20:2622020	TMC2	-0.76	-5.51	-0.41	1.49e-7	Mumps;
PAAD	cis	rs17407555	0.955	rs56099802	chr4:10179379	C/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.6	-0.35	8.79e-6	Schizophrenia (age at onset);
PAAD	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	0.56	6.26	0.45	3.81e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7619427	0.544	rs9848662	chr3:43962778	T/C	cg12796028	chr3:44040206	NA	-0.54	-4.72	-0.36	5.28e-6	Schizophrenia;
PAAD	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg18898632	chr2:242989856	NA	-0.71	-5.29	-0.39	4.27e-7	Obesity-related traits;
PAAD	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.56e-11	Triglycerides;
PAAD	cis	rs375066	0.935	rs424729	chr19:44422802	G/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs12935418	0.583	rs1469125	chr16:81029768	G/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.71	6.72	0.48	3.35e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.13	-0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs728616	0.510	rs12768957	chr10:82187293	G/A	cg19423196	chr10:82049429	MAT1A	0.49	4.4	0.34	2.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg26816564	chr1:7831052	VAMP3	-0.61	-5.25	-0.39	4.97e-7	Inflammatory bowel disease;
PAAD	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.82	9.01	0.59	8.17e-16	Mortality in heart failure;
PAAD	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.68	-0.35	6.4e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg00988841	chr10:134556463	INPP5A	0.49	4.54	0.35	1.12e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg10556349	chr10:835070	NA	0.59	4.89	0.37	2.5e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.81	-5.69	-0.42	6.23e-8	Vitiligo;
PAAD	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg09179987	chr1:167433047	CD247	0.49	5.82	0.43	3.32e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.64	6.46	0.46	1.34e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6076065	0.723	rs2224074	chr20:23360171	G/C	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	7.79e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.51	5.65	0.42	7.57e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs787274	1.000	rs787272	chr9:115549547	C/T	cg13803584	chr9:115635662	SNX30	0.84	5.76	0.42	4.55e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.54	-0.35	1.11e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.51	5.33	0.4	3.41e-7	Diastolic blood pressure;
PAAD	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg27565382	chr3:53032988	SFMBT1	0.75	4.5	0.34	1.34e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs11992162	0.591	rs56001613	chr8:11809480	G/C	cg12568669	chr8:11666485	FDFT1	0.31	5.15	0.39	8.09e-7	Monocyte count;
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.98	10.53	0.65	8.4e-20	Blood metabolite levels;
PAAD	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-8.42	-0.56	2.58e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg20283391	chr11:68216788	NA	-0.53	-5.05	-0.38	1.24e-6	Total body bone mineral density;
PAAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.8	-8.1	-0.55	1.62e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs899997	1.000	rs11852909	chr15:79030499	C/T	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6782025	0.837	rs6775508	chr3:120865481	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.59	-0.47	6.71e-10	Life satisfaction;
PAAD	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.88	10.84	0.66	1.19e-20	Schizophrenia;
PAAD	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-7.45	-0.52	6.64e-12	Exhaled nitric oxide output;
PAAD	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.65	6.53	0.47	9.36e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg06740227	chr12:86229804	RASSF9	0.49	4.34	0.33	2.6e-5	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23602684	chr14:24584099	DCAF11	0.64	6.44	0.46	1.45e-9	Myopia (pathological);
PAAD	cis	rs12449964	0.524	rs897457	chr17:17572987	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-5.26	-0.39	4.92e-7	Coronary artery disease or ischemic stroke;
PAAD	cis	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg14023874	chr1:168698975	DPT	-0.5	-5.22	-0.39	5.67e-7	Coronary artery disease;
PAAD	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.55	-5.28	-0.39	4.47e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02112609	chr16:85589949	NA	0.57	6.46	0.46	1.31e-9	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.63e-6	Alzheimer's disease;
PAAD	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.66	6.43	0.46	1.55e-9	Corneal astigmatism;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-11.16	-0.67	1.7e-21	Longevity;Endometriosis;
PAAD	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg15942720	chr14:51706980	TMX1	-0.5	-4.36	-0.33	2.43e-5	Cancer;
PAAD	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg00753924	chr9:137298813	RXRA	0.5	5.52	0.41	1.41e-7	Intelligence;
PAAD	cis	rs12767760	0.669	rs12219064	chr10:99332223	C/G	cg25247692	chr10:99313390	UBTD1	0.53	4.91	0.37	2.3e-6	Obesity-related traits;
PAAD	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg24053715	chr22:38214548	NA	-0.57	-5.81	-0.43	3.5e-8	Glioblastoma;Glioma;
PAAD	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.62	-6.67	-0.48	4.43e-10	Type 2 diabetes;
PAAD	cis	rs600550	0.618	rs1443250	chr11:60102790	G/A	cg05040360	chr11:60102449	MS4A6E	0.41	4.67	0.35	6.69e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.13	0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7853377	0.800	rs796003	chr9:86595801	G/T	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.24	0.56	7.33e-14	Lung cancer;
PAAD	trans	rs901683	1.000	rs17157919	chr10:46044092	A/C	cg23720331	chr10:123873670	TACC2	0.83	6.45	0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.49	6.53	0.47	9.15e-10	Schizophrenia;
PAAD	cis	rs6494488	0.500	rs28731170	chr15:64757099	G/T	cg16425858	chr15:64791681	ZNF609	0.86	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg05338066	chr1:7812865	CAMTA1	0.55	4.54	0.35	1.15e-5	Inflammatory bowel disease;
PAAD	cis	rs727479	0.502	rs28757200	chr15:51504061	C/T	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.52e-5	Estradiol levels;
PAAD	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.63	6.49	0.47	1.16e-9	Crohn's disease;
PAAD	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.84	-0.58	2.25e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9595066	0.627	rs2246432	chr13:44756784	G/C	cg04068111	chr13:44716778	NA	0.38	4.31	0.33	2.9e-5	Schizophrenia;
PAAD	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.85	-8.12	-0.55	1.46e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1144333	0.655	rs1417402	chr1:76437196	C/T	cg22875332	chr1:76189707	ACADM	0.75	4.49	0.34	1.39e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.6	-6.18	-0.45	5.66e-9	Neuroticism;
PAAD	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.4	-5.79	-0.43	3.92e-8	Subjective well-being;
PAAD	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.53	13.24	0.73	4.14e-27	Atopic dermatitis;
PAAD	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-6.81	-0.48	2.11e-10	Asthma;
PAAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg06375148	chr1:209958343	C1orf74	0.67	4.98	0.37	1.73e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.57	4.76	0.36	4.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.89	10.95	0.66	5.99e-21	Dental caries;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.93	0.43	1.95e-8	Prudent dietary pattern;
PAAD	cis	rs6894268	0.751	rs28410430	chr5:179022113	G/A	cg26135573	chr5:179059668	NA	0.5	4.29	0.33	3.2e-5	Eating disorders;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg15117754	chr3:10150083	C3orf24	0.67	5.6	0.41	9.66e-8	Alzheimer's disease;
PAAD	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg01426195	chr3:39028469	NA	-0.67	-6.8	-0.48	2.25e-10	Handedness;
PAAD	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg03948781	chr1:205179583	DSTYK	0.48	4.48	0.34	1.46e-5	Red blood cell count;
PAAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.75	0.42	4.84e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.77	9.25	0.6	1.94e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.62	5.47	0.41	1.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.56	5.46	0.41	1.88e-7	Platelet count;
PAAD	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.04	-0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.51	-4.82	-0.36	3.46e-6	Multiple sclerosis;
PAAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.85	9.81	0.62	6.5e-18	Tuberculosis;
PAAD	cis	rs4979906	1.000	rs11002243	chr10:79446083	A/G	cg07817648	chr10:79422355	NA	-0.58	-5.14	-0.38	8.23e-7	Mortality in heart failure;
PAAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.8	-7.87	-0.54	6.1e-13	DNA methylation (variation);
PAAD	cis	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg18582342	chr19:11591989	ELAVL3	-0.67	-5.55	-0.41	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	1.12	18.58	0.83	5.98e-41	Colorectal adenoma (advanced);
PAAD	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.85	10.32	0.64	2.88e-19	Dental caries;
PAAD	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg23004174	chr6:74404879	CD109	0.52	5.38	0.4	2.73e-7	Blood protein levels;Calcium levels;
PAAD	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg18551225	chr6:44695536	NA	-0.69	-7.07	-0.5	5.4e-11	Total body bone mineral density;
PAAD	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	1.01	13.3	0.73	3.02e-27	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs11671653	1.000	rs11671653	chr19:10838486	A/G	cg16667279	chr19:11591998	ELAVL3	0.52	4.3	0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg07541023	chr7:19748670	TWISTNB	0.6	4.41	0.34	1.91e-5	Thyroid stimulating hormone;
PAAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.3	-0.33	3.02e-5	Mood instability;
PAAD	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.72	6.9	0.49	1.3100000000000001e-10	Platelet count;
PAAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg14092988	chr3:52407081	DNAH1	-0.41	-5.17	-0.39	7.28e-7	Bipolar disorder;
PAAD	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.39	0.34	2.12e-5	Height;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs4834770	0.717	rs1022146	chr4:120236103	A/G	cg09307838	chr4:120376055	NA	0.59	5.76	0.42	4.57e-8	Blood protein levels;
PAAD	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.49	5.02	0.38	1.46e-6	Corneal astigmatism;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.64	6.8	0.48	2.3e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-1.12	-10.69	-0.65	3.12e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	7.24	0.51	2.05e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	5.18	0.39	7.09e-7	Height;
PAAD	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.54	0.57	1.28e-14	Homoarginine levels;
PAAD	cis	rs9674544	0.556	rs9890278	chr17:47073949	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.6	-7.66	-0.53	2.07e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.16	0.39	7.72e-7	Prostate cancer;
PAAD	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.88e-8	HIV-1 control;
PAAD	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.8	-0.53	9.28e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs908922	0.961	rs574749	chr1:152460672	T/G	cg23254163	chr1:152506842	NA	0.51	4.94	0.37	2e-6	Hair morphology;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg19223190	chr17:80058835	NA	0.51	5.21	0.39	6.01e-7	Life satisfaction;
PAAD	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.56	-7.05	-0.5	5.8e-11	Atrioventricular conduction;
PAAD	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs62045849	0.546	rs71395385	chr16:89196279	A/G	cg27661460	chr16:88844969	FAM38A	0.76	4.34	0.33	2.62e-5	Red blood cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21772997	chr5:55407615	ANKRD55	-0.67	-6.93	-0.49	1.11e-10	Obesity-related traits;
PAAD	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.55	-5.71	-0.42	5.76e-8	Testicular germ cell tumor;
PAAD	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06002616	chr8:101225028	SPAG1	-0.46	-5.33	-0.4	3.42e-7	Atrioventricular conduction;
PAAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg04257695	chr17:30186438	C17orf79	-0.61	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.4	-5.43	-0.4	2.15e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	5.12	0.38	8.95e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs73384572	0.541	rs12413141	chr10:130857201	G/A	cg27413539	chr10:131576096	NA	-0.7	-4.68	-0.35	6.44e-6	Neuroticism;
PAAD	cis	rs1421334	0.647	rs4733067	chr8:30856943	A/G	cg00964221	chr8:30240029	NA	0.47	4.41	0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Bone mineral density;
PAAD	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.29	-0.33	3.23e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.49	0.34	1.41e-5	Lung cancer in ever smokers;
PAAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.67	6.78	0.48	2.46e-10	Coronary artery disease;
PAAD	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.72	8.17	0.55	1.1e-13	Bladder cancer;
PAAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs114431655	chr3:128459173	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14155388	chr9:92087586	SEMA4D	-0.67	-6.62	-0.47	5.92e-10	Obesity-related traits;
PAAD	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.91	-0.54	4.8e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.67	6.7	0.48	3.91e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.45	0.4	1.95e-7	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.77	6.42	0.46	1.62e-9	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.83	9.17	0.6	3.16e-16	Mortality in heart failure;
PAAD	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.49	-4.38	-0.33	2.21e-5	Asthma;
PAAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg00431813	chr7:1051703	C7orf50	0.74	4.54	0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg24565620	chr2:194026	NA	0.63	4.95	0.37	1.96e-6	Blood protein levels;
PAAD	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg03252829	chr6:39282164	KCNK17	-0.5	-5.1	-0.38	9.82e-7	Type 2 diabetes;
PAAD	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.28	-13.96	-0.75	5.09e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.14e-8	Lung cancer;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg26174226	chr8:58114915	NA	-0.63	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00982548	chr2:198649783	BOLL	-0.79	-5.77	-0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-5.66	-0.42	7.22e-8	Crohn's disease;
PAAD	cis	rs300774	1.000	rs378456	chr2:119346	C/G	cg21211680	chr2:198530	NA	-0.57	-5.31	-0.4	3.85e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-5.77	-0.42	4.33e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.77	8.87	0.58	1.9e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs2531992	0.702	rs1045475	chr16:4015316	A/G	cg05927578	chr16:4029543	ADCY9	0.71	6.13	0.44	7.38e-9	Waist circumference;
PAAD	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.55	-4.99	-0.38	1.62e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.17e-9	Body mass index;
PAAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.68	-4.93	-0.37	2.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2835872	0.758	rs1709817	chr21:39036349	T/A	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.66	-10.02	-0.63	1.87e-18	Asthma (sex interaction);
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.59	8.95	0.59	1.18e-15	Hypertriglyceridemia;
PAAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.65	-0.57	6.99e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-4.37	-0.33	2.32e-5	Mean corpuscular volume;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.8	8.72	0.58	4.5e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg24397884	chr7:158709396	WDR60	0.95	10.05	0.63	1.57e-18	Height;
PAAD	cis	rs6540	0.744	rs879872	chr11:256714	C/T	cg20282913	chr11:252683	PSMD13	-1.1	-4.57	-0.35	1.02e-5	Endometriosis;
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg05132306	chr1:1846340	CALML6	-0.42	-4.97	-0.37	1.8e-6	Body mass index;
PAAD	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg00531865	chr16:30841666	NA	-0.53	-4.89	-0.37	2.51e-6	Dementia with Lewy bodies;
PAAD	cis	rs12760731	0.623	rs10913536	chr1:178315257	G/A	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.53	-6.88	-0.49	1.44e-10	Childhood ear infection;
PAAD	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.9	-0.49	1.34e-10	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.48	-0.34	1.46e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.56	-5.9	-0.43	2.23e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.69	7.2	0.5	2.53e-11	Bipolar disorder;
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.63	6.72	0.48	3.4e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.5	-5.46	-0.4	1.91e-7	Coronary artery disease;
PAAD	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg03934865	chr2:198174659	NA	-0.46	-4.56	-0.35	1.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.75	-7.41	-0.52	8.05e-12	Blood metabolite levels;
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-5.68	-0.42	6.6e-8	Prostate cancer;
PAAD	cis	rs72772090	0.614	rs10447215	chr5:96056373	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-6.32	-0.46	2.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1126510	0.897	rs11083840	chr19:47119910	A/C	cg07844738	chr19:47129343	PTGIR	0.46	5.54	0.41	1.28e-7	Ulcerative colitis;
PAAD	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.97e-6	Triglycerides;
PAAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06026331	chr20:60912101	LAMA5	0.56	4.59	0.35	9.35e-6	Colorectal cancer;
PAAD	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.89	8.2	0.55	9.59e-14	Itch intensity from mosquito bite;
PAAD	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.34	7.57	0.52	3.27e-12	Psoriasis vulgaris;
PAAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.72	0.58	4.57e-15	Personality dimensions;
PAAD	cis	rs9913156	0.841	rs34230287	chr17:4613630	C/T	cg23387401	chr17:4582204	PELP1	0.48	4.63	0.35	7.69e-6	Lymphocyte counts;
PAAD	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.45	4.86	0.37	2.95e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-6.71	-0.48	3.7e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09597638	chr17:3907349	NA	-0.71	-7.58	-0.52	3.21e-12	Type 2 diabetes;
PAAD	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg08975724	chr8:8085496	FLJ10661	-0.69	-6.85	-0.49	1.71e-10	Neuroticism;
PAAD	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.78	-0.58	3.21e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14079492	chr11:3692562	CHRNA10	0.58	6.56	0.47	7.83e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-4.76	-0.36	4.47e-6	Schizophrenia;
PAAD	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.13	0.38	8.67e-7	HIV-1 control;
PAAD	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.46	-4.87	-0.37	2.83e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.61	5.65	0.42	7.74e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.34	0.56	4.26e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.16	-0.6	3.33e-16	Mean platelet volume;
PAAD	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.81	-8.95	-0.59	1.16e-15	Height;
PAAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.02	-11.53	-0.68	1.66e-22	Homoarginine levels;
PAAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs367943	0.576	rs2972673	chr5:112980671	C/T	cg12552261	chr5:112820674	MCC	-0.58	-5.98	-0.44	1.53e-8	Type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg22153463	chr1:85462885	MCOLN2	0.72	5.53	0.41	1.34e-7	Serum sulfate level;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.86	-0.43	2.81e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.9	11.16	0.67	1.7e-21	Prudent dietary pattern;
PAAD	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.35	-4.33	-0.33	2.68e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25085719	chr6:4889428	CDYL	-0.52	-6.31	-0.46	2.95e-9	Monocyte percentage of white cells;
PAAD	cis	rs4737010	0.630	rs569451	chr8:41623001	G/A	cg17182837	chr8:41585554	ANK1	0.49	4.55	0.35	1.07e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.51	5.63	0.42	8.66e-8	Major depressive disorder;
PAAD	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6942407	0.546	rs2190424	chr7:86841971	T/C	cg02420886	chr7:86849541	C7orf23	0.69	5.34	0.4	3.26e-7	Food allergy;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.73	-0.42	5.12e-8	Prudent dietary pattern;
PAAD	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.43	-0.4	2.2e-7	Common traits (Other);
PAAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.48	-4.68	-0.35	6.31e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.99	4.87	0.37	2.77e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-6.8	-0.48	2.25e-10	Blood pressure (smoking interaction);
PAAD	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26926768	chr12:34528122	NA	0.39	4.68	0.35	6.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	1.1	8.2	0.55	9.25e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.77	-9.25	-0.6	1.95e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.22	0.39	5.91e-7	Lung cancer in ever smokers;
PAAD	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg01966878	chr4:90757139	SNCA	-0.6	-4.6	-0.35	8.92e-6	Neuroticism;
PAAD	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg15017067	chr4:17643749	FAM184B	0.4	4.61	0.35	8.39e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4751006	0.543	rs9794806	chr10:128770868	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.92	-0.49	1.16e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3760982	0.776	rs56103707	chr19:44304188	G/A	cg11993925	chr19:44307056	LYPD5	-0.51	-6.4	-0.46	1.81e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg22663859	chr13:21900854	NA	0.56	6.16	0.45	6.33e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg03909863	chr11:638404	DRD4	-0.57	-5.25	-0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.51	0.41	1.5e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27114661	chr2:242255285	SEPT2;HDLBP	0.58	6.3	0.46	3.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.46	4.87	0.37	2.78e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-5.26	-0.39	4.88e-7	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg15472797	chr10:135243109	NA	-0.43	-4.43	-0.34	1.78e-5	Systemic lupus erythematosus;
PAAD	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg00262122	chr8:11665843	FDFT1	0.53	4.62	0.35	8.07e-6	Neuroticism;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	7.78	0.53	1.02e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg01489032	chr8:143877656	NA	-0.48	-5.06	-0.38	1.2e-6	Urinary tract infection frequency;
PAAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.07	-0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.59	-6.67	-0.48	4.53e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.35	0.4	3.15e-7	Monocyte percentage of white cells;
PAAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg09835421	chr16:68378352	PRMT7	-0.85	-6.89	-0.49	1.42e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.01	-0.54	2.75e-13	Brugada syndrome;
PAAD	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.6	-4.92	-0.37	2.19e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg09941381	chr10:64027924	RTKN2	-0.37	-4.49	-0.34	1.43e-5	Rheumatoid arthritis;
PAAD	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs2301888	1.000	rs2240335	chr1:17674537	G/T	cg01790353	chr1:17674483	PADI4	0.43	5.1	0.38	9.99e-7	Rheumatoid arthritis;
PAAD	cis	rs6088813	1.000	rs6088820	chr20:33987298	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.61	-6.51	-0.47	1.06e-9	Monocyte count;
PAAD	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26378065	chr17:18585709	ZNF286B	0.56	5.49	0.41	1.64e-7	Educational attainment (years of education);
PAAD	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg15841412	chr13:111365552	ING1	0.52	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.54	-4.37	-0.33	2.33e-5	Diastolic blood pressure;
PAAD	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.76	6.69	0.48	4.11e-10	Morning vs. evening chronotype;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23606286	chr1:145470592	ANKRD34A;POLR3GL	0.58	6.74	0.48	3.1e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.3	0.39	4.05e-7	Body mass index;
PAAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.08	-0.77	5.26e-32	Height;
PAAD	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg14664628	chr15:75095509	CSK	0.51	4.85	0.37	3.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09658438	chr12:56693554	CS	0.62	6.35	0.46	2.33e-9	Myopia (pathological);
PAAD	cis	rs12304921	0.935	rs67646958	chr12:51354625	G/A	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.4e-7	Red blood cell count;
PAAD	cis	rs7255436	0.898	rs7252574	chr19:8441779	C/T	cg10174797	chr19:8464628	RAB11B	0.57	5.43	0.4	2.14e-7	HDL cholesterol;
PAAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.4	-5.48	-0.41	1.73e-7	Abdominal aortic aneurysm;
PAAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.95	-7.72	-0.53	1.46e-12	Initial pursuit acceleration;
PAAD	cis	rs7264396	0.887	rs224392	chr20:34107956	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.98	-0.44	1.51e-8	Total cholesterol levels;
PAAD	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.55	6.12	0.44	7.46e-9	Mean corpuscular volume;
PAAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.87	0.37	2.82e-6	Height;
PAAD	cis	rs2555155	0.870	rs2723644	chr11:6543017	T/C	cg11185456	chr11:6592066	DNHD1	0.43	4.54	0.35	1.12e-5	DNA methylation (variation);
PAAD	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg24519413	chr1:26490540	NA	0.48	4.44	0.34	1.72e-5	QRS complex (12-leadsum);
PAAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.08	-0.38	1.08e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.95	-7.31	-0.51	1.44e-11	Multiple sclerosis;
PAAD	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-9.73	-0.62	1.1e-17	Total body bone mineral density;
PAAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg15847926	chr7:2749597	AMZ1	0.41	5.04	0.38	1.28e-6	Height;
PAAD	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg21181453	chr9:130700954	DPM2	-0.41	-4.69	-0.36	6.1e-6	Glaucoma (primary angle closure);
PAAD	cis	rs6142102	0.961	rs6059651	chr20:32645052	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.39	-0.34	2.11e-5	Blood metabolite levels;
PAAD	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.49	-0.34	1.42e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs6681460	0.932	rs618093	chr1:67178428	T/G	cg02459107	chr1:67143332	SGIP1	0.7	6.49	0.47	1.12e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.47	4.98	0.37	1.68e-6	Longevity;Endometriosis;
PAAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19636519	chr7:99541626	NA	0.41	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.95	9.53	0.61	3.64e-17	Response to antineoplastic agents;
PAAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.54	-4.98	-0.37	1.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.43	-0.56	2.41e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs245880	0.740	rs245888	chr7:29190414	C/T	cg17163760	chr7:29186267	CPVL	-0.49	-5.84	-0.43	3.07e-8	Warfarin maintenance dose;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07216258	chr3:101568851	NFKBIZ	-0.6	-6.86	-0.49	1.67e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg14440974	chr22:39074834	NA	-0.54	-6.5	-0.47	1.1e-9	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.54e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9810890	1.000	rs73198887	chr3:128546426	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg00700412	chr12:58011837	NA	0.41	4.42	0.34	1.87e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs11168618	0.904	rs10875829	chr12:48927197	A/C	cg01881778	chr12:48919444	OR8S1	-0.48	-4.89	-0.37	2.57e-6	Adiponectin levels;
PAAD	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg21977766	chr11:1107580	NA	0.43	4.37	0.33	2.28e-5	Alzheimer's disease (late onset);
PAAD	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg24747557	chr10:131355152	MGMT	-0.47	-4.92	-0.37	2.18e-6	Response to temozolomide;
PAAD	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg18190219	chr22:46762943	CELSR1	-0.8	-4.46	-0.34	1.59e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.01e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12949688	1.000	rs7211686	chr17:55816300	T/C	cg12582317	chr17:55822272	NA	0.69	8.71	0.58	4.7e-15	Schizophrenia;
PAAD	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.6	6.3	0.46	3.01e-9	Lewy body disease;
PAAD	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.49	-5.43	-0.4	2.24e-7	Menarche (age at onset);
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.5	4.99	0.38	1.64e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.63	5.46	0.41	1.86e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg20744362	chr22:50050164	C22orf34	0.58	7.47	0.52	6e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-5.15	-0.39	7.93e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg00919237	chr7:87102261	ABCB4	-0.75	-6.15	-0.45	6.69e-9	Gallbladder cancer;
PAAD	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg20085588	chr10:81316188	SFTPA2	0.39	4.26	0.33	3.55e-5	Post bronchodilator FEV1;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg15693483	chr7:1102177	C7orf50	0.4	4.63	0.35	7.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg25358565	chr5:93447407	FAM172A	1.4	9.55	0.61	3.27e-17	Diabetic retinopathy;
PAAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23978390	chr7:1156363	C7orf50	0.54	5.22	0.39	5.91e-7	Longevity;Endometriosis;
PAAD	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.25	-0.33	3.68e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.4e-6	Diastolic blood pressure;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg15557168	chr22:42548783	NA	0.41	4.44	0.34	1.7e-5	Intelligence;
PAAD	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs300774	0.925	rs300713	chr2:138363	A/G	cg21211680	chr2:198530	NA	-0.6	-5.65	-0.42	7.53e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg18721089	chr20:30220636	NA	-0.59	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6028335	0.610	rs6028191	chr20:37529043	T/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.64	-4.84	-0.37	3.11e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs2645694	0.569	rs11097584	chr4:77836059	C/T	cg18351406	chr4:77819688	ANKRD56	0.67	5.32	0.4	3.66e-7	Emphysema distribution in smoking;
PAAD	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg08886695	chr4:3369023	RGS12	-0.52	-4.9	-0.37	2.41e-6	Serum sulfate level;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01516881	chr6:292596	DUSP22	-0.74	-7.31	-0.51	1.43e-11	Menopause (age at onset);
PAAD	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.57	4.88	0.37	2.64e-6	Response to diuretic therapy;
PAAD	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.38	0.4	2.79e-7	Prudent dietary pattern;
PAAD	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-6.18	-0.45	5.51e-9	Gallbladder cancer;
PAAD	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.95	0.54	3.93e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs925946	0.666	rs11030107	chr11:27694835	A/G	cg01418645	chr11:27679469	BDNF;BDNFOS	-0.52	-4.56	-0.35	1.03e-5	Body mass index;Weight;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.51	-5.16	-0.39	7.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-4.52	-0.34	1.24e-5	Tonsillectomy;
PAAD	cis	rs10768122	0.705	rs11033073	chr11:35353944	C/T	cg13971030	chr11:35366721	SLC1A2	-0.41	-4.84	-0.37	3.09e-6	Vitiligo;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.54	-0.57	1.31e-14	Longevity;Endometriosis;
PAAD	cis	rs847851	1.000	rs1535001	chr6:34927280	A/G	cg13196216	chr6:34231128	NA	-0.61	-5.02	-0.38	1.44e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	7.51	0.52	4.65e-12	Coronary artery disease;
PAAD	cis	rs8056742	1.000	rs8056742	chr16:85092748	C/T	cg16399368	chr16:85517462	NA	-0.51	-4.49	-0.34	1.43e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs77633900	0.772	rs284884	chr15:76828289	A/G	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-4.83	-0.36	3.29e-6	Daytime sleep phenotypes;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.72	0.77	4.64e-31	Chronic sinus infection;
PAAD	cis	rs6782025	0.837	rs114055119	chr3:120803908	T/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.8	-0.36	3.84e-6	Lung cancer;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13012494	chr21:47604986	C21orf56	0.5	5.28	0.39	4.32e-7	Testicular germ cell tumor;
PAAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.61	4.39	0.34	2.1e-5	Depression;
PAAD	cis	rs3130844	1	rs3130844	chr6:28916594	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Urinary tract infection frequency;
PAAD	cis	rs2526932	0.625	rs17118212	chr14:73061755	A/G	cg13588403	chr14:73209128	DPF3	-0.41	-5.5	-0.41	1.56e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs9472414	0.680	rs9463040	chr6:44752286	C/T	cg20913747	chr6:44695427	NA	0.46	4.38	0.33	2.23e-5	Height;
PAAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.8	-7.61	-0.53	2.66e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg20887711	chr4:1340912	KIAA1530	0.67	6.87	0.49	1.58e-10	Longevity;
PAAD	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg16586182	chr3:47516702	SCAP	0.65	7.22	0.51	2.34e-11	Colorectal cancer;
PAAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg09659197	chr4:152720779	NA	-0.47	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	11.6	0.69	1.13e-22	Menopause (age at onset);
PAAD	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg22338127	chr1:209979572	IRF6	-0.54	-4.45	-0.34	1.62e-5	Coronary artery disease;
PAAD	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg12568669	chr8:11666485	FDFT1	-0.26	-4.41	-0.34	1.92e-5	Neuroticism;
PAAD	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg23465465	chr6:26364728	BTN3A2	0.7	4.43	0.34	1.82e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg12288994	chr5:1860383	NA	0.59	6.92	0.49	1.17e-10	Cardiovascular disease risk factors;
PAAD	cis	rs593531	0.571	rs35170680	chr11:74085420	T/G	cg15851278	chr11:73669449	DNAJB13	-0.37	-4.41	-0.34	1.92e-5	Neuroticism;
PAAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.74	-9.88	-0.63	4.3e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-4.7	-0.36	5.75e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.51	4.91	0.37	2.32e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.72	-7.23	-0.51	2.16e-11	Urate levels in lean individuals;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	1.0	8.98	0.59	9.92e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4903604	0.581	rs4903607	chr14:78038462	G/A	cg18872420	chr14:78023429	SPTLC2	0.42	4.29	0.33	3.11e-5	Gut microbiome composition (winter);
PAAD	cis	rs863345	0.584	rs1117125	chr1:158509396	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.22e-17	Electrocardiographic conduction measures;
PAAD	cis	rs5753037	0.809	rs5752964	chr22:30208608	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.63	-0.35	7.78e-6	Type 1 diabetes;
PAAD	cis	rs4548095	1	rs4548095	chr7:100226665	C/T	cg16850897	chr7:100343110	ZAN	0.44	4.29	0.33	3.14e-5	Plateletcrit;
PAAD	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.7	-7.69	-0.53	1.73e-12	Alcohol dependence;
PAAD	cis	rs258892	0.895	rs35317818	chr5:72073502	G/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg03732007	chr1:2071316	PRKCZ	-0.43	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs7567389	0.719	rs4150499	chr2:128028792	T/C	cg09760422	chr2:128146352	NA	-0.38	-5.91	-0.43	2.12e-8	Self-rated health;
PAAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.53	4.31	0.33	2.86e-5	Mean platelet volume;
PAAD	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.58	5.76	0.42	4.45e-8	Lymphocyte counts;
PAAD	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg16417436	chr16:28758564	NA	0.48	4.42	0.34	1.86e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17308151	chr11:8703888	RPL27A	0.58	6.58	0.47	7.15e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.02e-9	Life satisfaction;
PAAD	cis	rs2562456	0.833	rs2650776	chr19:21613397	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.46	-0.34	1.55e-5	Pain;
PAAD	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.59	5.33	0.4	3.42e-7	Putamen volume;
PAAD	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg23649088	chr2:200775458	C2orf69	-0.71	-5.81	-0.43	3.56e-8	Schizophrenia;
PAAD	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2286503	0.901	rs10950922	chr7:22854006	C/T	cg04907244	chr7:22894795	SNORD93	-0.43	-5.33	-0.4	3.51e-7	Fibrinogen;
PAAD	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.76	0.36	4.43e-6	Anticoagulant levels;
PAAD	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.65	6.64	0.47	5.31e-10	Uric acid levels;
PAAD	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.08	0.38	1.09e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12780845	1.000	rs35630951	chr10:17215649	A/G	cg00857480	chr10:17188594	TRDMT1	0.37	4.65	0.35	7.14e-6	Homocysteine levels;
PAAD	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.67	-4.7	-0.36	5.9e-6	HDL cholesterol levels;
PAAD	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg09659197	chr4:152720779	NA	0.4	5.25	0.39	4.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-5.13	-0.38	8.86e-7	Diastolic blood pressure;
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg05434287	chr7:2030229	MAD1L1	0.43	4.8	0.36	3.78e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg24881330	chr22:46731750	TRMU	1.09	4.97	0.37	1.77e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.1	-0.55	1.7e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs16854884	0.710	rs1867607	chr3:143809274	T/C	cg06585982	chr3:143692056	C3orf58	0.58	5.48	0.41	1.76e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs787274	1.000	rs787291	chr9:115507904	A/T	cg13803584	chr9:115635662	SNX30	0.8	4.41	0.34	1.96e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8067287	0.762	rs11650981	chr17:16824038	A/G	cg26910001	chr17:16838321	NA	-0.68	-6.1	-0.44	8.35e-9	Diabetic kidney disease;
PAAD	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.46	0.34	1.56e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9857275	0.527	rs1863870	chr3:141190538	G/A	cg25967872	chr3:141205623	RASA2	0.5	4.42	0.34	1.9e-5	Prion diseases;
PAAD	cis	rs9394169	0.613	rs7774682	chr6:33722644	C/T	cg25922239	chr6:33757077	LEMD2	0.47	4.36	0.33	2.38e-5	Essential tremor;
PAAD	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.93	10.93	0.66	6.81e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10899021	1.000	rs61900635	chr11:74359010	C/G	cg25880958	chr11:74394337	NA	-0.86	-5.58	-0.41	1.08e-7	Response to metformin (IC50);
PAAD	cis	rs11048434	0.518	rs1805707	chr12:9181706	T/C	cg04548204	chr12:9162872	KLRG1	0.4	4.45	0.34	1.67e-5	Sjögren's syndrome;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07648498	chr16:89883185	FANCA	0.62	6.33	0.46	2.63e-9	Vitiligo;
PAAD	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.74	-7.94	-0.54	4.15e-13	Blood metabolite levels;
PAAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.71	7.92	0.54	4.68e-13	Melanoma;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.84	6.83	0.48	1.92e-10	Alzheimer's disease;
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-5.33	-0.4	3.56e-7	Bipolar disorder;
PAAD	cis	rs62392365	0.536	rs303020	chr6:25137516	C/G	cg26336265	chr6:25042955	NA	0.85	5.01	0.38	1.52e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.61	5.61	0.41	9.2e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg24747557	chr10:131355152	MGMT	-0.42	-4.34	-0.33	2.59e-5	Response to temozolomide;
PAAD	cis	rs16975963	0.843	rs60731897	chr19:38269259	C/A	cg25793785	chr19:38281423	NA	0.57	4.75	0.36	4.69e-6	Longevity;
PAAD	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg10920065	chr6:169824652	NA	-0.48	-4.7	-0.36	5.77e-6	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03923535	chr7:1197113	ZFAND2A	0.45	4.64	0.35	7.46e-6	Longevity;Endometriosis;
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.24	0.45	4.19e-9	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-5.84	-0.43	3e-8	Morning vs. evening chronotype;
PAAD	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs11009175	0.725	rs10827170	chr10:33290343	C/G	cg00146027	chr10:33299147	NA	0.4	4.41	0.34	1.94e-5	Depression (quantitative trait);
PAAD	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.51	-5.95	-0.43	1.74e-8	Mean arterial pressure;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg23033748	chr14:75592666	NEK9	-0.43	-5.46	-0.4	1.92e-7	Height;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-5.51	-0.41	1.53e-7	Personality dimensions;
PAAD	cis	rs2019216	0.500	rs12946184	chr17:21944675	A/C	cg22648282	chr17:21454238	C17orf51	-0.51	-4.59	-0.35	9.35e-6	Pelvic organ prolapse;
PAAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg18765565	chr5:669397	TPPP	0.44	4.78	0.36	4.18e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10214930	0.697	rs4722719	chr7:27614922	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs965469	1.000	rs2236106	chr20:3278410	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs7619427	0.544	rs9848662	chr3:43962778	T/C	cg16646616	chr3:44040527	NA	-0.56	-4.54	-0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs9361491	0.608	rs7744731	chr6:79454471	G/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.15	-0.39	7.88e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.75e-6	Mortality in heart failure;
PAAD	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.95	-6.57	-0.47	7.71e-10	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg01631408	chr1:248437212	OR2T33	-0.56	-5.08	-0.38	1.11e-6	Common traits (Other);
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.87	-9.61	-0.61	2.28e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg19784903	chr17:45786737	TBKBP1	0.55	5.92	0.43	2.07e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg03894339	chr8:19674705	INTS10	-0.46	-4.4	-0.34	2.04e-5	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05445914	chr16:30134068	MAPK3	0.58	6.66	0.48	4.67e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.37	-0.4	2.95e-7	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15001673	chr7:155436868	RBM33	0.6	6.8	0.48	2.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6499766	0.518	rs11076104	chr16:55554737	C/T	cg00427604	chr16:55542751	LPCAT2	0.37	4.28	0.33	3.34e-5	Thyroid hormone levels;
PAAD	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg00325661	chr8:49890786	NA	0.52	4.52	0.34	1.24e-5	Sudden cardiac arrest;
PAAD	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs1011018	0.955	rs7782128	chr7:139441661	C/T	cg03224163	chr7:139420300	HIPK2	0.61	4.36	0.33	2.34e-5	Systolic blood pressure;
PAAD	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-13.98	-0.75	4.56e-29	Schizophrenia;
PAAD	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.67	-0.42	6.83e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs939584	1.000	rs6744646	chr2:628504	A/G	cg14515364	chr2:636606	NA	0.47	4.35	0.33	2.5e-5	Body mass index;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg23034840	chr1:205782522	SLC41A1	0.49	4.44	0.34	1.71e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.44	-4.44	-0.34	1.72e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg13722127	chr7:150037890	RARRES2	-0.55	-5.95	-0.43	1.79e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5752326	0.558	rs6005059	chr22:26879297	C/G	cg27087377	chr22:26875563	HPS4	0.69	4.44	0.34	1.73e-5	Ischemic stroke;
PAAD	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1864585	0.520	rs17776946	chr8:10682674	A/C	cg21775007	chr8:11205619	TDH	-0.59	-4.59	-0.35	9.38e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.87	0.37	2.8e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18679886	chr7:107531975	DLD	0.6	6.67	0.48	4.54e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.93	0.37	2.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3867498	0.943	rs61994671	chr15:25071618	A/T	cg08194505	chr15:25684383	UBE3A	-0.68	-4.75	-0.36	4.7e-6	Pulmonary function;
PAAD	cis	rs2562456	0.834	rs13346641	chr19:21592283	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.31	-0.33	2.92e-5	Pain;
PAAD	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.52	-4.67	-0.35	6.7e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12612619	0.732	rs2053385	chr2:27231145	G/A	cg00617064	chr2:27272375	NA	-0.48	-5.12	-0.38	8.92e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Height;
PAAD	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg24555670	chr8:18244502	NA	0.53	4.48	0.34	1.48e-5	Blood metabolite levels;
PAAD	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.49	5.24	0.39	5.16e-7	Total body bone mineral density;
PAAD	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg00717180	chr2:96193071	NA	-0.62	-6.89	-0.49	1.38e-10	HDL cholesterol;
PAAD	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.28	0.45	3.3e-9	Skin colour saturation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15627628	chr11:992652	AP2A2	0.56	6.66	0.48	4.77e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg00540400	chr15:79124168	NA	-0.55	-6.59	-0.47	6.65e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	trans	rs901683	1.000	rs12766550	chr10:46011355	C/G	cg23720331	chr10:123873670	TACC2	-0.87	-6.63	-0.47	5.48e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7809950	0.559	rs2248465	chr7:107303628	C/T	cg23024343	chr7:107201750	COG5	0.88	10.49	0.65	1.04e-19	Coronary artery disease;
PAAD	cis	rs7923609	0.756	rs7080386	chr10:65048306	C/A	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.34	-0.33	2.58e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.8	-7.13	-0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-4.79	-0.36	3.92e-6	Coronary artery disease;
PAAD	cis	rs17095355	1.000	rs7904096	chr10:111755319	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.81	-0.36	3.64e-6	Biliary atresia;
PAAD	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.02	0.38	1.44e-6	Breast cancer;
PAAD	cis	rs900145	0.863	rs61882122	chr11:13299895	A/G	cg15603424	chr11:13300592	ARNTL	0.52	4.61	0.35	8.39e-6	Menarche (age at onset);
PAAD	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg08648136	chr8:956695	NA	0.45	4.96	0.37	1.88e-6	Schizophrenia;
PAAD	cis	rs1144	0.537	rs2470938	chr7:104581402	C/A	cg04380332	chr7:105027541	SRPK2	-0.64	-6.71	-0.48	3.55e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.81	10.04	0.63	1.65e-18	Methadone dose in opioid dependence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24397040	chr21:45138847	PDXK	-0.75	-6.72	-0.48	3.35e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03676636	chr4:99064102	C4orf37	0.32	5.97	0.44	1.58e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.84	10.22	0.64	5.53e-19	Body mass index;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg07202610	chr7:1142643	C7orf50	-0.69	-5.4	-0.4	2.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1823874	0.720	rs2003037	chr15:100361962	G/T	cg16400843	chr15:100339927	C15orf51	0.4	5.13	0.38	8.81e-7	IgG glycosylation;
PAAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.59	-0.35	9.31e-6	Alcohol dependence;
PAAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg04106633	chr4:1044584	NA	0.7	5.92	0.43	2.01e-8	Recombination rate (females);
PAAD	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.51	4.82	0.36	3.46e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.07	-19.5	-0.85	3.28e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.45	5.96	0.43	1.73e-8	Childhood ear infection;
PAAD	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.49	-4.71	-0.36	5.45e-6	Inflammatory biomarkers;
PAAD	cis	rs3136739	0.681	rs78427883	chr8:41991348	A/T	cg17828057	chr8:42037527	PLAT	0.66	4.46	0.34	1.56e-5	Plasma plasminogen activator levels;
PAAD	cis	rs488248	0.574	rs7330156	chr13:106587857	T/C	cg03898952	chr13:107069935	NA	0.7	4.45	0.34	1.66e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-5.02	-0.38	1.42e-6	Asthma;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	1.13	8.57	0.57	1.09e-14	IgG glycosylation;
PAAD	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg07159951	chr1:45983175	PRDX1	-0.47	-4.29	-0.33	3.12e-5	Platelet count;
PAAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.43	0.34	1.78e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs3935740	0.649	rs8031046	chr15:81625028	C/T	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.12	-12.21	-0.7	2.56e-24	Blood pressure (smoking interaction);
PAAD	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.09	-0.38	1.06e-6	Subjective well-being;
PAAD	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg20406979	chr6:167373233	NA	0.35	4.71	0.36	5.62e-6	Crohn's disease;
PAAD	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.82	-8.84	-0.58	2.2e-15	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.49	5.02	0.38	1.46e-6	Corneal astigmatism;
PAAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg15847926	chr7:2749597	AMZ1	-0.41	-4.73	-0.36	5.02e-6	Height;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	7.62	0.53	2.58e-12	Coffee consumption (cups per day);
PAAD	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.84	9.23	0.6	2.2e-16	Schizophrenia;
PAAD	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg07246713	chr20:62722933	OPRL1	-0.49	-5.64	-0.42	7.89e-8	Pulse pressure;Mean corpuscular volume;
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg06287003	chr12:125626642	AACS	-0.51	-4.91	-0.37	2.35e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02071572	chr4:1403502	NA	-0.48	-6.1	-0.44	8.51e-9	Obesity-related traits;
PAAD	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	10.49	0.65	1.03e-19	Cognitive test performance;
PAAD	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.42	-4.88	-0.37	2.68e-6	Coronary artery disease;
PAAD	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-4.59	-0.35	9.21e-6	Schizophrenia;
PAAD	cis	rs11235843	0.853	rs66556722	chr11:73403039	A/G	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.3e-8	Alzheimer's disease;
PAAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16417436	chr16:28758564	NA	0.48	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13560548	chr3:10150139	C3orf24	0.54	4.96	0.37	1.88e-6	Alzheimer's disease;
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg08284496	chr17:37894027	GRB7	0.25	4.26	0.33	3.59e-5	Asthma;
PAAD	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	1.84	10.22	0.64	5.31e-19	Cannabis dependence symptom count;
PAAD	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.78	-9.0	-0.59	8.58e-16	Age at first birth;
PAAD	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.51	-4.8	-0.36	3.83e-6	Multiple sclerosis;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg26174226	chr8:58114915	NA	-0.56	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-4.96	-0.37	1.84e-6	Bipolar disorder;
PAAD	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Vitiligo;
PAAD	cis	rs10795130	0.568	rs10904181	chr10:4138459	A/T	cg08594816	chr10:3248399	NA	-0.71	-4.31	-0.33	2.9e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg21361702	chr7:150065534	REPIN1	0.58	5.23	0.39	5.53e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs818427	0.820	rs712666	chr5:112227939	T/C	cg06941702	chr5:112196734	SRP19	0.51	4.75	0.36	4.67e-6	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.54	-0.41	1.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.74	6.06	0.44	1.01e-8	HDL cholesterol;
PAAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	6.38	0.46	2.05e-9	Initial pursuit acceleration;
PAAD	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16484811	chr12:58149022	MARCH9	0.61	6.87	0.49	1.53e-10	Monocyte percentage of white cells;
PAAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.83	-8.84	-0.58	2.25e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg23346134	chr3:49453900	TCTA	0.41	4.29	0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg01503450	chr10:980765	NA	-0.52	-4.35	-0.33	2.44e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs4356203	0.905	rs594034	chr11:17222380	G/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.39	-0.34	2.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs59888335	0.964	rs13062910	chr3:80725118	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs1507153	0.775	rs9343780	chr6:79355335	T/C	cg05283184	chr6:79620031	NA	-0.38	-4.54	-0.35	1.14e-5	Sjögren's syndrome;
PAAD	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg20356878	chr3:121714668	ILDR1	0.49	4.74	0.36	4.84e-6	Cognitive performance;
PAAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19569208	chr2:105654888	MRPS9	0.73	6.88	0.49	1.44e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg09998033	chr7:158218633	PTPRN2	-0.77	-7.99	-0.54	3.15e-13	Obesity-related traits;
PAAD	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	1.03	13.01	0.73	1.8e-26	Breast cancer;
PAAD	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	5.42	0.4	2.3e-7	Blood metabolite levels;
PAAD	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.54	-4.43	-0.34	1.76e-5	Cocaine dependence;
PAAD	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.79	8.58	0.57	1e-14	Schizophrenia;
PAAD	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7771547	0.821	rs10947613	chr6:36572340	G/A	cg07856975	chr6:36356162	ETV7	0.43	4.57	0.35	9.97e-6	Platelet distribution width;
PAAD	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.78	0.36	4.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.95	9.21	0.6	2.48e-16	Psoriasis;
PAAD	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-6.04	-0.44	1.13e-8	Platelet count;
PAAD	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-13.99	-0.75	4.26e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.56	0.57	1.18e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs1329189	1.000	rs1952471	chr10:129998001	A/G	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.58e-6	Orofacial clefts;
PAAD	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.7	-8.13	-0.55	1.39e-13	Schizophrenia;
PAAD	trans	rs10810935	0.608	rs16936350	chr9:18129414	A/G	cg01356653	chr12:50135491	TMBIM6	-0.79	-6.43	-0.46	1.61e-9	Alcohol dependence (age at onset);
PAAD	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19882132	chr14:106167949	NA	-0.55	-4.88	-0.37	2.69e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23978513	chr4:39979310	PDS5A	-0.61	-6.42	-0.46	1.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg15117754	chr3:10150083	C3orf24	0.7	5.94	0.43	1.9e-8	Alzheimer's disease;
PAAD	cis	rs1692120	0.545	rs962371	chr11:61408285	T/G	cg23038520	chr11:61406508	RPLP0P2	0.51	5.31	0.4	3.78e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.4	-4.46	-0.34	1.59e-5	Pneumonia;
PAAD	cis	rs1619661	0.591	rs605414	chr10:44744110	C/T	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	QT interval (ambient particulate matter interaction);
PAAD	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg11657440	chr19:46296263	DMWD	-0.66	-5.06	-0.38	1.22e-6	Eosinophil counts;
PAAD	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	6.76	0.48	2.76e-10	Blood protein levels;
PAAD	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg17178900	chr1:205818956	PM20D1	0.55	4.28	0.33	3.3e-5	Prostate-specific antigen levels;
PAAD	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.81	-0.43	3.46e-8	Retinal vascular caliber;
PAAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	10.61	0.65	4.97e-20	Menopause (age at onset);
PAAD	cis	rs89107	0.651	rs447193	chr6:118607662	G/A	cg18833306	chr6:118973337	C6orf204	0.48	5.41	0.4	2.42e-7	Cardiac structure and function;
PAAD	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.77	-6.84	-0.49	1.78e-10	Exhaled nitric oxide output;
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.6	5.84	0.43	3.12e-8	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.53	-0.34	1.2e-5	Renal cell carcinoma;
PAAD	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg20045696	chr14:77926864	AHSA1	-0.53	-5.28	-0.39	4.45e-7	Myeloid white cell count;
PAAD	cis	rs1468333	0.565	rs4507481	chr5:137573073	G/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	5.16	0.39	7.71e-7	Resting heart rate;
PAAD	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg22153407	chr1:230290089	GALNT2	0.47	4.66	0.35	6.75e-6	Coronary artery disease;
PAAD	cis	rs72960926	1.000	rs55813969	chr6:75099746	C/T	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg17372223	chr3:52568218	NT5DC2	0.47	4.26	0.33	3.5e-5	Bipolar disorder;
PAAD	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.47	4.73	0.36	5.12e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg12623918	chr2:306882	NA	-0.59	-4.39	-0.34	2.14e-5	Blood protein levels;
PAAD	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.68	-0.35	6.4e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg13611204	chr9:139324423	INPP5E	-0.57	-4.87	-0.37	2.82e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9467160	1.000	rs9467166	chr6:24444435	G/A	cg16211469	chr6:24423932	MRS2	0.55	5.13	0.38	8.74e-7	Liver enzyme levels;
PAAD	cis	rs2839627	0.638	rs8133179	chr21:44272327	G/A	cg03543861	chr21:44258195	NA	0.58	4.34	0.33	2.59e-5	Information processing speed;
PAAD	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.1	-0.38	9.93e-7	Systemic lupus erythematosus;
PAAD	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg15226275	chr6:116381976	FRK	0.41	7.5	0.52	4.85e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-4.26	-0.33	3.51e-5	Coronary artery disease;
PAAD	cis	rs3736485	0.873	rs12101920	chr15:51820909	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.21e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.75	6.75	0.48	2.97e-10	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg21132104	chr15:45694354	SPATA5L1	0.52	5.1	0.38	9.81e-7	Glomerular filtration rate;
PAAD	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.54	-4.91	-0.37	2.35e-6	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.6	7.27	0.51	1.75e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.46	4.59	0.35	9.23e-6	Aortic root size;
PAAD	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.6	5.21	0.39	6.2e-7	QRS duration;
PAAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.85	11.78	0.69	3.7e-23	Emphysema distribution in smoking;
PAAD	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.67	-6.07	-0.44	9.78e-9	Response to antineoplastic agents;
PAAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8044868	0.530	rs7185840	chr16:72102112	A/G	cg16579770	chr16:72058938	DHODH	0.41	4.61	0.35	8.31e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.43e-6	White blood cell count;
PAAD	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-5.17	-0.39	7.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.43	0.34	1.78e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg25823085	chr7:87105416	ABCB4	0.46	4.36	0.33	2.41e-5	Gallbladder cancer;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22442454	chr1:209979470	IRF6	0.59	5.34	0.4	3.3e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg25664220	chr3:72788482	NA	-0.49	-5.23	-0.39	5.57e-7	Motion sickness;
PAAD	cis	rs329648	0.553	rs10791337	chr11:133765127	A/C	cg18057887	chr11:133800913	IGSF9B	-0.61	-6.8	-0.48	2.27e-10	Parkinson's disease;
PAAD	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Body mass index;
PAAD	cis	rs7246865	0.510	rs1130222	chr19:17170885	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.6	0.41	9.66e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	4.3	0.33	3.03e-5	Self-reported allergy;
PAAD	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg09376583	chr16:88111425	NA	-0.5	-4.38	-0.33	2.19e-5	Menopause (age at onset);
PAAD	cis	rs78761021	0.898	rs62066051	chr17:9780360	C/G	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs4908768	0.556	rs11121230	chr1:8834706	C/T	cg00590817	chr1:8272081	NA	-0.38	-4.65	-0.35	7.05e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.63	-7.47	-0.52	5.89e-12	Aortic root size;
PAAD	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.84	-6.82	-0.48	2.05e-10	Putamen volume;
PAAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.55	-6.08	-0.44	9.48e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7737355	0.773	rs3756291	chr5:130926822	T/C	cg06307176	chr5:131281290	NA	0.51	4.35	0.33	2.53e-5	Life satisfaction;
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg02725872	chr8:58115012	NA	-0.61	-4.91	-0.37	2.32e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.62	6.4	0.46	1.82e-9	Adiponectin levels;
PAAD	cis	rs6442522	0.644	rs6442528	chr3:15505224	C/G	cg16303742	chr3:15540471	COLQ	0.47	5.0	0.38	1.6e-6	Uric acid levels;
PAAD	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-1.11	-8.26	-0.56	6.79e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22104487	chr8:42010424	AP3M2	0.62	6.86	0.49	1.67e-10	Monocyte percentage of white cells;
PAAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.04	-14.83	-0.77	2.43e-31	Multiple system atrophy;
PAAD	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg15017067	chr4:17643749	FAM184B	0.39	4.36	0.33	2.34e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.69	0.42	6.44e-8	Bipolar disorder;
PAAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.35	0.4	3.2e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.78	7.59	0.52	2.92e-12	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg08501292	chr6:25962987	TRIM38	1.0	5.58	0.41	1.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	9.85	0.62	5.11e-18	Monocyte percentage of white cells;
PAAD	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-5.65	-0.42	7.54e-8	Colorectal cancer;
PAAD	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.79	8.6	0.57	9.21e-15	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12165864	chr7:66369176	NA	-0.75	-4.8	-0.36	3.75e-6	Diabetic kidney disease;
PAAD	cis	rs72901758	0.768	rs11655421	chr17:76251518	T/A	cg11439826	chr17:76250004	NA	0.46	4.57	0.35	1.01e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.81	6.51	0.47	1.02e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9677476	0.657	rs13418346	chr2:232132374	A/G	cg07929768	chr2:232055508	NA	-0.38	-4.67	-0.35	6.67e-6	Food antigen IgG levels;
PAAD	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg21775007	chr8:11205619	TDH	-0.57	-5.01	-0.38	1.51e-6	Neuroticism;
PAAD	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.71	-0.53	1.53e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6604026	0.656	rs12074608	chr1:93411781	T/C	cg13858687	chr1:93297071	RPL5	0.47	4.36	0.33	2.35e-5	Multiple sclerosis;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.47	5.4	0.4	2.48e-7	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-4.9	-0.37	2.4e-6	Lung cancer;
PAAD	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.59	6.93	0.49	1.09e-10	Mean corpuscular volume;
PAAD	cis	rs11051970	0.918	rs325417	chr12:32574217	A/G	cg24626660	chr12:32551988	NA	0.4	4.46	0.34	1.61e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.28e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.17	-0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.69	6.16	0.45	6.31e-9	Blood trace element (Zn levels);
PAAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	11.13	0.67	1.99e-21	Tonsillectomy;
PAAD	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.4	-5.04	-0.38	1.28e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs35740288	0.770	rs11631386	chr15:86191995	A/G	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs113779084	0.728	rs67823574	chr7:11949278	C/T	cg15090509	chr7:11872073	THSD7A	0.39	4.88	0.37	2.71e-6	Educational attainment (years of education);
PAAD	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg08992911	chr2:238395768	MLPH	0.6	5.13	0.38	8.82e-7	Prostate cancer;
PAAD	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.73	-0.36	5.1e-6	Parkinson's disease;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg04518342	chr5:131593106	PDLIM4	0.53	5.05	0.38	1.23e-6	Acylcarnitine levels;
PAAD	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.72	8.32	0.56	4.61e-14	Age-related hearing impairment;
PAAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.83	9.21	0.6	2.47e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11076805	0.529	rs446395	chr16:4154536	C/A	cg01959050	chr16:4170088	NA	0.55	5.37	0.4	2.9e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-10.52	-0.65	8.64e-20	Primary sclerosing cholangitis;
PAAD	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00142150	chr22:38071001	LGALS1	0.7	7.74	0.53	1.29e-12	Fat distribution (HIV);
PAAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs7149242	0.771	rs8012970	chr14:101168491	T/C	cg10189261	chr14:101176105	NA	0.33	4.26	0.33	3.59e-5	Platelet count;
PAAD	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg16898833	chr6:26189333	HIST1H4D	0.83	4.53	0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.89	7.95	0.54	3.9e-13	Diastolic blood pressure;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs80130819	0.515	rs1793956	chr12:48392914	C/G	cg05342945	chr12:48394962	COL2A1	-0.72	-4.7	-0.36	5.81e-6	Prostate cancer;
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg18764771	chr6:116381957	FRK	0.45	7.88	0.54	5.9e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.59	6.75	0.48	2.95e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg00750074	chr16:89608354	SPG7	-0.62	-6.47	-0.46	1.28e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs6011674	1.000	rs6011691	chr20:61867454	A/G	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.75	-4.55	-0.35	1.08e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg06217071	chr17:408420	NA	0.65	7.05	0.5	5.76e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg01815783	chr4:1047043	NA	-0.47	-4.43	-0.34	1.76e-5	Recombination rate (females);
PAAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.35	-0.33	2.47e-5	Obesity-related traits;
PAAD	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.74	0.48	3.01e-10	Neuroticism;
PAAD	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06869415	chr14:35183946	CFL2	0.63	6.64	0.47	5.15e-10	Myopia (pathological);
PAAD	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.22e-7	HDL cholesterol;
PAAD	trans	rs9409082	0.798	rs71494583	chr9:108922126	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.34	-0.46	2.5e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs56011263	0.532	rs6845891	chr4:744233	T/C	cg17689763	chr4:710664	PCGF3	-0.59	-5.8	-0.43	3.68e-8	White blood cell count;
PAAD	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.27	0.51	1.73e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg03989125	chr22:38214979	NA	0.62	5.88	0.43	2.45e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg26174226	chr8:58114915	NA	-0.67	-4.78	-0.36	4.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.39	-0.51	9.35e-12	Total body bone mineral density;
PAAD	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.71	-7.04	-0.5	6.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.73	7.98	0.54	3.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.8	-6.95	-0.49	1e-10	Diastolic blood pressure;
PAAD	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg21366198	chr4:185655624	MLF1IP	0.55	4.92	0.37	2.26e-6	Kawasaki disease;
PAAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.65	0.35	7.29e-6	Calcium levels;
PAAD	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.43	4.27	0.33	3.39e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg23024343	chr7:107201750	COG5	0.52	4.39	0.34	2.14e-5	Coronary artery disease;
PAAD	cis	rs7715806	0.517	rs34340	chr5:74932099	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.51	0.34	1.29e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.85	-6.3	-0.46	3.05e-9	Prostate-specific antigen levels;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.39e-10	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	7.33	0.51	1.27e-11	Lymphocyte counts;
PAAD	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.21	0.73	5.09e-27	Platelet count;
PAAD	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.53	6.86	0.49	1.62e-10	Childhood ear infection;
PAAD	cis	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg11088901	chr6:166572345	T	-0.48	-4.43	-0.34	1.76e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12282928	0.917	rs1503175	chr11:48269192	A/G	cg22827986	chr11:48284249	OR4X1	-0.41	-5.2	-0.39	6.28e-7	Migraine - clinic-based;
PAAD	cis	rs2120243	0.510	rs7623173	chr3:157119949	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg16584676	chr17:46985605	UBE2Z	-0.64	-6.54	-0.47	8.97e-10	Type 2 diabetes;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.75	9.46	0.61	5.36e-17	Vitiligo;
PAAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg03983476	chr2:10830698	NOL10	-0.62	-6.3	-0.46	3.02e-9	Prostate cancer;
PAAD	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg12757816	chr2:10669957	NA	0.45	4.67	0.35	6.67e-6	Prostate cancer;
PAAD	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.89	11.11	0.67	2.25e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg14851346	chr12:38532713	NA	0.5	4.57	0.35	9.98e-6	Heart rate;
PAAD	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.56	5.98	0.44	1.54e-8	Monocyte percentage of white cells;
PAAD	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg13010199	chr12:38710504	ALG10B	0.57	4.67	0.35	6.56e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.62	4.94	0.37	2e-6	Behavioural disinhibition (generation interaction);
PAAD	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.43	-4.81	-0.36	3.61e-6	Dietary macronutrient intake;
PAAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs2834288	0.500	rs2834305	chr21:35327624	T/C	cg22542663	chr21:34915757	GART;SON	0.44	4.35	0.33	2.46e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	0.93	6.19	0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg04415270	chr2:102091202	RFX8	-0.51	-6.35	-0.46	2.4e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg15017067	chr4:17643749	FAM184B	0.42	4.65	0.35	7.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1497828	0.956	rs2646832	chr1:217544979	A/G	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20707764	chr2:42796178	MTA3	-0.7	-7.64	-0.53	2.32e-12	Smoking initiation;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.07	13.26	0.73	3.69e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.3	0.39	4.04e-7	Ovarian reserve;
PAAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg06740227	chr12:86229804	RASSF9	0.59	5.19	0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.71	0.58	4.92e-15	Lung cancer;
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.71	-8.0	-0.54	3.03e-13	Blood trace element (Cu levels);
PAAD	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.56	-4.7	-0.36	5.75e-6	Testicular germ cell tumor;
PAAD	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.67	-7.49	-0.52	5.35e-12	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18743305	chr3:108115132	MYH15	-0.6	-6.34	-0.46	2.44e-9	Obesity-related traits;
PAAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.47	4.38	0.34	2.17e-5	Height;
PAAD	cis	rs7187994	0.790	rs16974508	chr16:84781075	G/A	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.25	-0.39	5e-7	Tonsillectomy;
PAAD	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.78	-9.25	-0.6	1.93e-16	Height;
PAAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-1.04	-17.48	-0.82	3.42e-38	Height;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.7	-5.86	-0.43	2.84e-8	Coronary artery disease;
PAAD	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs3784262	0.740	rs4646600	chr15:58295616	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.51	-5.88	-0.43	2.53e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.47	-5.07	-0.38	1.16e-6	Motion sickness;
PAAD	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7766436	0.767	rs6909574	chr6:22606773	A/G	cg13666174	chr6:22585274	NA	-0.54	-5.84	-0.43	3.09e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg08888203	chr3:10149979	C3orf24	0.68	6.21	0.45	4.87e-9	Alzheimer's disease;
PAAD	cis	rs6594713	0.757	rs13154300	chr5:112719356	T/C	cg12552261	chr5:112820674	MCC	0.6	4.35	0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-6.31	-0.46	2.93e-9	Coronary artery disease;
PAAD	cis	rs73058052	0.597	rs7251877	chr19:50097547	A/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.6	-5.15	-0.39	7.84e-7	Fibrinogen levels;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.16	17.57	0.82	1.93e-38	Prudent dietary pattern;
PAAD	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.56	-5.24	-0.39	5.24e-7	Retinal vascular caliber;
PAAD	cis	rs4921915	0.526	rs13277738	chr8:18241507	C/T	cg18736775	chr8:18248649	NAT2	-0.65	-4.51	-0.34	1.27e-5	Iron status biomarkers (transferrin levels);
PAAD	cis	rs3743102	0.519	rs76496098	chr15:83229141	T/C	cg00614314	chr15:82944287	LOC80154	-0.73	-5.22	-0.39	5.79e-7	Colorectal adenoma (advanced);
PAAD	cis	rs4759375	0.667	rs10773010	chr12:123823685	G/A	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg02023728	chr11:77925099	USP35	-0.43	-4.46	-0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.6	6.5	0.47	1.11e-9	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.68	7.69	0.53	1.7e-12	Schizophrenia;
PAAD	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-8.57	-0.57	1.06e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12780845	0.931	rs7089849	chr10:17249487	C/A	cg00857480	chr10:17188594	TRDMT1	0.35	4.41	0.34	1.96e-5	Homocysteine levels;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs1497828	1.000	rs2810770	chr1:217563574	A/G	cg04411442	chr1:217543379	NA	-0.49	-4.89	-0.37	2.55e-6	Dialysis-related mortality;
PAAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-9.18	-0.6	2.98e-16	Colorectal cancer;
PAAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.63	6.19	0.45	5.3300000000000004e-09	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs66530629	1.000	rs1316829	chr1:25051225	C/T	cg01905478	chr1:25040257	NA	0.54	5.85	0.43	2.84e-8	Plateletcrit;
PAAD	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.76	-0.36	4.55e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg16447950	chr5:562315	NA	-0.51	-4.8	-0.36	3.71e-6	Obesity-related traits;
PAAD	cis	rs16975963	0.793	rs1807157	chr19:38465523	G/T	cg08679971	chr19:38281047	NA	0.55	5.24	0.39	5.4e-7	Longevity;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.51	-5.03	-0.38	1.34e-6	Testicular germ cell tumor;
PAAD	cis	rs8067354	0.958	rs2333563	chr17:57839568	A/G	cg02344993	chr17:57696989	CLTC	0.54	4.96	0.37	1.86e-6	Hemoglobin concentration;
PAAD	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg05250797	chr16:70222502	NA	0.84	6.5	0.47	1.06e-9	IgE levels;
PAAD	cis	rs11159086	0.793	rs1860108	chr14:74945265	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.27	-0.39	4.54e-7	Advanced glycation end-product levels;
PAAD	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg22705602	chr4:152727874	NA	-0.51	-5.49	-0.41	1.65e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	1.000	rs2440847	chr10:59996176	A/G	cg20442379	chr10:60024634	IPMK	-0.59	-4.51	-0.34	1.28e-5	Inflammatory bowel disease;
PAAD	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.51	5.1	0.38	9.91e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-6.19	-0.45	5.29e-9	Schizophrenia;
PAAD	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27511599	chr7:32358540	NA	0.86	4.91	0.37	2.34e-6	Body mass index;
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg08316009	chr16:89165765	ACSF3	-0.87	-4.53	-0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg16926213	chr1:1841314	NA	0.38	4.63	0.35	7.89e-6	Body mass index;
PAAD	cis	rs7719624	0.756	rs13188659	chr5:135396468	T/A	cg16684184	chr5:135415129	NA	0.39	4.91	0.37	2.34e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.98	-0.37	1.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.88	6.65	0.47	4.99e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-11.12	-0.67	2.12e-21	Height;
PAAD	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11825685	0.607	rs3016420	chr11:134551259	A/G	cg06603561	chr11:134479413	NA	0.61	5.07	0.38	1.12e-6	IgG glycosylation;
PAAD	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.35	-0.51	1.12e-11	Neuroticism;
PAAD	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.58	5.81	0.43	3.59e-8	Fibrinogen levels;
PAAD	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.73	7.37	0.51	1.01e-11	Colorectal cancer;
PAAD	cis	rs7591163	1.000	rs1039665	chr2:228717392	A/G	cg22994281	chr2:228029448	COL4A3;COL4A4	0.44	4.43	0.34	1.77e-5	Blood pressure;
PAAD	cis	rs11191270	1.000	rs11191270	chr10:104124605	C/T	cg15320455	chr10:103880129	LDB1	0.55	4.68	0.36	6.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.64	5.31	0.4	3.77e-7	Prostate cancer;
PAAD	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.13	-0.38	8.62e-7	Neuroticism;
PAAD	cis	rs7084921	0.526	rs12783181	chr10:101775157	G/A	cg04359915	chr10:101825029	CPN1	-0.33	-5.05	-0.38	1.28e-6	Bone mineral density;
PAAD	cis	rs877282	0.682	rs2265092	chr10:780293	C/T	cg17470449	chr10:769945	NA	-0.58	-6.37	-0.46	2.13e-9	Uric acid levels;
PAAD	cis	rs11037575	0.715	rs11037572	chr11:43724168	G/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2e-5	Neuroblastoma;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg01765077	chr12:122356316	WDR66	0.64	6.59	0.47	6.97e-10	Mean platelet volume;
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05665937	chr4:1216051	CTBP1	0.44	4.71	0.36	5.57e-6	Obesity-related traits;
PAAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs6025261	0.761	rs6099360	chr20:55511902	C/T	cg11868041	chr20:55503363	NA	-0.43	-4.8	-0.36	3.8e-6	Verbal memory performance (delayed recall level);
PAAD	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4074493	1.000	rs4460622	chr1:231173033	C/T	cg22172038	chr1:231176991	FAM89A	0.51	4.8	0.36	3.84e-6	Carotid plaque burden (smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16787365	chr14:77499911	NA	0.66	6.45	0.46	1.44e-9	Obesity-related traits;
PAAD	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.7	6.1	0.44	8.32e-9	Radiation response;
PAAD	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg20913747	chr6:44695427	NA	-0.66	-6.61	-0.47	6.19e-10	Total body bone mineral density;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26418147	chr1:205743515	RAB7L1	-0.43	-4.88	-0.37	2.66e-6	Menarche (age at onset);
PAAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19784903	chr17:45786737	TBKBP1	0.58	6.21	0.45	4.79e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs258892	0.895	rs13156244	chr5:72032166	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs669446	0.561	rs530201	chr1:44102257	T/C	cg12908607	chr1:44402522	ARTN	-0.41	-4.29	-0.33	3.19e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	trans	rs901683	1.000	rs76469200	chr10:46080033	C/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.53	-0.57	1.38e-14	Body mass index;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.16	-0.7	3.51e-24	Longevity;Endometriosis;
PAAD	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.09	-0.38	1.06e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.528	rs12524323	chr6:45303853	C/A	cg18551225	chr6:44695536	NA	-0.43	-4.49	-0.34	1.41e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27578458	chr19:7968585	MAP2K7	0.68	6.84	0.49	1.82e-10	Obesity-related traits;
PAAD	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Breast cancer;
PAAD	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.91	-5.95	-0.43	1.76e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs5742933	0.725	rs1132360	chr2:190526224	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-4.31	-0.33	2.87e-5	Ferritin levels;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21862992	chr11:68658383	NA	0.41	4.54	0.35	1.15e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.36	4.26	0.33	3.62e-5	Schizophrenia;
PAAD	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.31	-5.96	-0.44	1.67e-8	Type 2 diabetes;
PAAD	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg09760422	chr2:128146352	NA	-0.51	-9.08	-0.59	5.23e-16	Self-rated health;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs655641	0.520	rs606505	chr11:85682817	A/G	cg07180834	chr11:85838833	NA	-0.45	-5.02	-0.38	1.44e-6	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27298830	chr3:31977309	OSBPL10	-0.61	-6.29	-0.45	3.28e-9	Obesity-related traits;
PAAD	cis	rs950881	0.932	rs3771175	chr2:102960210	A/T	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.45	-0.34	1.63e-5	Allergy;
PAAD	cis	rs2662368	0.542	rs352559	chr5:77108747	G/C	cg02570643	chr5:77531473	AP3B1	-0.42	-4.53	-0.34	1.18e-5	Platelet distribution width;
PAAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.39	4.38	0.34	2.16e-5	High light scatter reticulocyte count;
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.67	6.73	0.48	3.31e-10	Blood metabolite levels;
PAAD	cis	rs4523957	0.891	rs216200	chr17:2199846	C/T	cg16513277	chr17:2031491	SMG6	0.51	5.19	0.39	6.69e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.94	6.0	0.44	1.39e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.68	-6.06	-0.44	1.03e-8	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07058639	chr14:24711602	TINF2	0.56	6.37	0.46	2.1e-9	Monocyte percentage of white cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13872326	chr17:27901067	GIT1	0.53	6.7	0.48	3.84e-10	Body fat percentage;
PAAD	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg04315214	chr1:2043799	PRKCZ	-0.46	-5.44	-0.4	2.13e-7	Coronary artery disease;
PAAD	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg08601574	chr20:25228251	PYGB	0.6	6.51	0.47	1.02e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.75	-7.97	-0.54	3.46e-13	DNA methylation (variation);
PAAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg02683114	chr2:24398427	C2orf84	-0.56	-5.26	-0.39	4.83e-7	Asthma;
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.82	-6.83	-0.48	1.96e-10	Type 2 diabetes;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg25753631	chr6:25732923	NA	-0.48	-5.85	-0.43	2.91e-8	Iron status biomarkers;
PAAD	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09065629	chr16:1709722	CRAMP1L	0.99	6.23	0.45	4.4e-9	Snoring;
PAAD	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg18721089	chr20:30220636	NA	0.59	4.52	0.34	1.25e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.71	-0.36	5.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg09237302	chr4:906077	GAK	-0.43	-4.53	-0.34	1.21e-5	Type 2 diabetes;
PAAD	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.38	13.01	0.73	1.8e-26	Corneal structure;
PAAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg00310523	chr12:86230176	RASSF9	0.38	4.32	0.33	2.79e-5	Major depressive disorder;
PAAD	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg13206674	chr6:150067644	NUP43	0.57	5.22	0.39	5.86e-7	Testicular germ cell tumor;
PAAD	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.89	9.72	0.62	1.13e-17	Anterior chamber depth;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg07362569	chr17:61921086	SMARCD2	0.43	4.96	0.37	1.88e-6	Height;
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.59	-6.6	-0.47	6.56e-10	Mean corpuscular volume;
PAAD	cis	rs9810890	0.850	rs73198871	chr3:128537238	C/T	cg19129842	chr3:128565090	NA	-0.87	-5.52	-0.41	1.43e-7	Dental caries;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24132527	chr5:140019269	TMCO6	0.61	7.27	0.51	1.8e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00232805	chr2:97779565	ANKRD36	0.66	7.52	0.52	4.41e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35955747	0.601	rs5749302	chr22:31950618	C/T	cg02404636	chr22:31891804	SFI1	0.56	5.48	0.41	1.77e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs694739	0.861	rs479552	chr11:64110683	G/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.54	0.47	8.82e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-5.8	-0.43	3.66e-8	Personality dimensions;
PAAD	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg08897044	chr19:12950850	MAST1	0.34	4.32	0.33	2.81e-5	Mean corpuscular volume;
PAAD	cis	rs3736485	0.934	rs1902592	chr15:51881980	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg22325292	chr17:80708367	FN3K	0.61	4.33	0.33	2.74e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.93	12.47	0.71	5.15e-25	Methadone dose in opioid dependence;
PAAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.8	8.56	0.57	1.17e-14	Selective IgA deficiency;
PAAD	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2627282	0.541	rs10503185	chr8:2760178	A/G	cg21769514	chr8:2743697	NA	-0.46	-4.51	-0.34	1.28e-5	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00262122	chr8:11665843	FDFT1	0.48	4.57	0.35	9.86e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.31	-0.4	3.88e-7	Daytime sleep phenotypes;
PAAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg09796270	chr17:17721594	SREBF1	-0.48	-5.28	-0.39	4.4e-7	Total body bone mineral density;
PAAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg02440177	chr19:53496695	ZNF702P	-0.55	-5.45	-0.4	1.95e-7	Psoriasis;
PAAD	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.46	-0.34	1.6e-5	Coronary artery disease;
PAAD	cis	rs12286929	0.679	rs11601041	chr11:115083348	A/G	cg04055981	chr11:115044050	NA	0.5	5.01	0.38	1.49e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.82	5.38	0.4	2.81e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs501120	0.584	rs11238889	chr10:44668724	G/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs58521262	0.789	rs55925020	chr19:23067580	G/A	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.27	-0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-4.81	-0.36	3.6e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8077577	0.562	rs8081042	chr17:18199067	C/G	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs2481665	0.709	rs6674784	chr1:62529094	T/A	cg18591186	chr1:62594603	INADL	-0.5	-4.52	-0.34	1.24e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg23254163	chr1:152506842	NA	0.51	5.56	0.41	1.21e-7	Hair morphology;
PAAD	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.33	-0.33	2.72e-5	Renal cell carcinoma;
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21016266	chr12:122356598	WDR66	0.6	6.47	0.46	1.3e-9	Mean corpuscular volume;
PAAD	cis	rs2610025	0.662	rs2610035	chr8:57445348	G/A	cg25937216	chr8:58172855	NA	0.48	4.55	0.35	1.09e-5	Suicide in bipolar disorder;
PAAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.5	-5.58	-0.41	1.08e-7	Coronary artery disease;
PAAD	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.43	0.74	1.35e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg12092346	chr18:77659572	KCNG2	-0.56	-4.35	-0.33	2.47e-5	Opioid sensitivity;
PAAD	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.88	10.52	0.65	8.81e-20	Monocyte count;
PAAD	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg13206674	chr6:150067644	NUP43	0.55	5.22	0.39	5.74e-7	Lung cancer;
PAAD	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.49	5.77	0.42	4.25e-8	Systemic lupus erythematosus;
PAAD	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.48	5.1	0.38	9.79e-7	Red blood cell count;Reticulocyte count;
PAAD	cis	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg25886479	chr11:50257625	LOC441601	-0.4	-4.28	-0.33	3.32e-5	Coronary artery disease;
PAAD	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg01305830	chr4:1604576	NA	-0.48	-4.65	-0.35	7.23e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.51	4.81	0.36	3.66e-6	Menarche (age at onset);
PAAD	cis	rs10957961	0.586	rs12543481	chr8:81067366	A/G	cg10609868	chr8:81963379	PAG1	-0.37	-4.49	-0.34	1.42e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	4.7	0.36	5.87e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg04554929	chr8:105342491	NA	-0.42	-6.99	-0.49	8.28e-11	Paget's disease;
PAAD	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.59	6.12	0.44	7.43e-9	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.62	-5.91	-0.43	2.2e-8	Total body bone mineral density;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.68	-0.35	6.39e-6	Bipolar disorder;
PAAD	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.6	-5.56	-0.41	1.17e-7	Cognitive function;
PAAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg03188948	chr7:1209495	NA	1.11	5.54	0.41	1.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs12413624	0.791	rs880964	chr10:120282397	A/G	cg20624923	chr10:120355427	PRLHR	0.2	4.41	0.34	1.97e-5	Pancreatic cancer;
PAAD	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.45	5.26	0.39	4.75e-7	Systemic lupus erythematosus;
PAAD	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs73206853	0.620	rs55845219	chr12:111164875	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.4	0.34	2.03e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.67	5.57	0.41	1.12e-7	Obesity (extreme);
PAAD	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.76	-7.93	-0.54	4.31e-13	Gut microbiome composition (winter);
PAAD	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22857025	chr5:266934	NA	-0.89	-4.33	-0.33	2.73e-5	Breast cancer;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.9	0.63	3.82e-18	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26510428	chr2:3471345	TTC15	-0.64	-6.3	-0.46	2.98e-9	Obesity-related traits;
PAAD	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.6	-6.49	-0.47	1.17e-9	Calcium levels;
PAAD	cis	rs10979	0.669	rs9484764	chr6:143867336	G/T	cg25407410	chr6:143891975	LOC285740	-0.47	-4.27	-0.33	3.41e-5	Hypospadias;
PAAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	1.17	12.11	0.7	4.8e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.89	-0.37	2.59e-6	Life satisfaction;
PAAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.61	5.45	0.4	2e-7	Coronary heart disease;
PAAD	cis	rs89107	0.688	rs283088	chr6:118592191	T/C	cg21191810	chr6:118973309	C6orf204	0.45	6.2	0.45	5.12e-9	Cardiac structure and function;
PAAD	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg13263323	chr15:86062960	AKAP13	-0.62	-7.16	-0.5	3.27e-11	Interstitial lung disease;
PAAD	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.43	-0.4	2.22e-7	Height;
PAAD	cis	rs8105895	0.736	rs2359835	chr19:22242690	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs728616	1.000	rs728616	chr10:81847914	G/T	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.54	-0.35	1.15e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24312321	chr15:80430079	ZFAND6	-0.62	-6.38	-0.46	1.97e-9	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24547755	chr1:150980980	FAM63A;PRUNE	-0.77	-6.54	-0.47	8.67e-10	Neuroticism;
PAAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6995541	0.744	rs10109416	chr8:10684755	C/G	cg14855657	chr8:10587604	SOX7	0.46	4.29	0.33	3.19e-5	Triglyceride levels;
PAAD	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-4.81	-0.36	3.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-1.11	-7.87	-0.54	6.16e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg05347473	chr6:146136440	FBXO30	0.57	5.53	0.41	1.35e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	9.27e-7	Motion sickness;
PAAD	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.72	-7.72	-0.53	1.45e-12	Morning vs. evening chronotype;
PAAD	cis	rs11051970	0.614	rs2728684	chr12:32575665	C/A	cg24626660	chr12:32551988	NA	0.39	4.39	0.34	2.13e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-1.3	-10.05	-0.63	1.55e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.47	4.28	0.33	3.26e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.54	4.52	0.34	1.25e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00142150	chr22:38071001	LGALS1	0.53	4.62	0.35	8.15e-6	Fat distribution (HIV);
PAAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs3112530	0.901	rs2615170	chr5:152716081	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.71	-6.55	-0.47	8.4e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg05373962	chr22:49881684	NA	-0.55	-5.23	-0.39	5.63e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.06	-0.55	2.13e-13	Prostate cancer;
PAAD	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg14709524	chr16:89940631	TCF25	0.9	4.61	0.35	8.43e-6	Skin colour saturation;
PAAD	cis	rs2290405	0.591	rs7687129	chr4:939883	T/C	cg04824913	chr4:887549	GAK	0.73	7.43	0.52	7.35e-12	Systemic sclerosis;
PAAD	cis	rs10838687	0.606	rs4494268	chr11:47038220	A/G	cg19486271	chr11:47235900	DDB2	-0.57	-4.39	-0.34	2.09e-5	Proinsulin levels;
PAAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6604026	0.656	rs11577636	chr1:93402849	T/C	cg13858687	chr1:93297071	RPL5	0.47	4.28	0.33	3.28e-5	Multiple sclerosis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg16311803	chr12:88178298	NA	-0.64	-6.32	-0.46	2.7e-9	Primary biliary cholangitis;
PAAD	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.13	6.24	0.45	4.22e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	1.02	8.65	0.57	6.67e-15	Triglycerides;
PAAD	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05360402	chr5:110848191	STARD4	0.62	6.73	0.48	3.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2034088	0.930	rs9907540	chr17:448042	A/G	cg06217071	chr17:408420	NA	0.77	8.61	0.57	8.38e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7941600	0.581	rs11042273	chr11:9322132	T/G	cg19415743	chr11:9336845	TMEM41B	0.96	5.89	0.43	2.44e-8	Coronary artery disease;
PAAD	cis	rs9308433	0.798	rs10157166	chr1:214484950	C/T	cg06198575	chr1:214491504	SMYD2	0.48	4.72	0.36	5.32e-6	IgG glycosylation;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.7	7.28	0.51	1.63e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6501435	0.840	rs9899737	chr17:69082786	A/C	cg00193521	chr17:68133597	NA	-0.43	-4.41	-0.34	1.92e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.62	5.96	0.44	1.69e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg05643964	chr20:62369504	LIME1	-0.49	-4.73	-0.36	4.98e-6	Prostate cancer;
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg04844267	chr4:1394941	NA	0.45	5.12	0.38	9.01e-7	Longevity;
PAAD	cis	rs4679121	0.554	rs16837488	chr3:126166762	T/C	cg05485589	chr3:126194908	ZXDC	-0.92	-4.56	-0.35	1.03e-5	Pursuit maintenance gain;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12698834	chr17:18128735	LLGL1	0.58	6.65	0.47	4.95e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg19592336	chr6:28129416	ZNF389	0.61	4.33	0.33	2.72e-5	Depression;
PAAD	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.62	-4.83	-0.36	3.31e-6	Rheumatoid arthritis;
PAAD	cis	rs7487075	0.567	rs7486580	chr12:46828348	C/A	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	1.02	6.4	0.46	1.85e-9	Alzheimer's disease;
PAAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.98	9.97	0.63	2.54e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs6445525	0.935	rs6806075	chr3:66000650	G/T	cg06109867	chr3:66002991	MAGI1	-0.47	-4.74	-0.36	4.8e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg18898632	chr2:242989856	NA	-0.83	-6.67	-0.48	4.51e-10	Obesity-related traits;
PAAD	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-5.33	-0.4	3.49e-7	Daytime sleep phenotypes;
PAAD	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.65	6.35	0.46	2.41e-9	Type 2 diabetes;
PAAD	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg21918786	chr6:109611834	NA	-0.45	-4.92	-0.37	2.23e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.9	15.24	0.78	2e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61403071	0.826	rs7203324	chr16:86701426	C/G	cg01953615	chr16:87102366	NA	0.91	4.25	0.33	3.71e-5	Coronary artery disease;
PAAD	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.2	-0.8	6.44e-35	Height;
PAAD	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.81	8.64	0.57	7.41e-15	Height;
PAAD	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg12081754	chr8:22256438	SLC39A14	0.66	7.5	0.52	4.95e-12	Verbal declarative memory;
PAAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.68	-6.55	-0.47	8.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg03808351	chr9:123631620	PHF19	0.45	4.87	0.37	2.76e-6	Rheumatoid arthritis;
PAAD	cis	rs1816752	0.679	rs7999480	chr13:24972003	A/T	cg02811702	chr13:24901961	NA	-0.53	-5.46	-0.41	1.86e-7	Obesity-related traits;
PAAD	cis	rs2085601	0.542	rs1513807	chr4:89961290	C/A	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs3787159	0.655	rs1883799	chr20:56936747	C/T	cg15032960	chr20:56888536	RAB22A	0.4	4.26	0.33	3.5e-5	Systolic blood pressure;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.21	-0.39	6e-7	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24441121	chr2:98262430	COX5B	0.63	6.52	0.47	9.86e-10	Pancreatic cancer;
PAAD	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26306683	chr17:18585705	ZNF286B	0.51	5.06	0.38	1.2e-6	Educational attainment (years of education);
PAAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg21951975	chr1:209979733	IRF6	0.55	5.41	0.4	2.35e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg08994789	chr17:28903642	LRRC37B2	0.55	4.46	0.34	1.6e-5	Body mass index;
PAAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.66	-6.6	-0.47	6.58e-10	Menopause (age at onset);
PAAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.6	5.65	0.42	7.7e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.65	6.12	0.44	7.7e-9	Obesity-related traits;
PAAD	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.92	7.29	0.51	1.55e-11	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg17633681	chr16:88106987	BANP	-0.55	-6.74	-0.48	3.17e-10	Menopause (age at onset);
PAAD	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg14196790	chr5:131705035	SLC22A5	0.44	4.7	0.36	5.7e-6	Blood metabolite levels;
PAAD	cis	rs7833787	1.000	rs12546946	chr8:18703078	C/G	cg17701159	chr8:18705777	PSD3	-0.46	-5.39	-0.4	2.63e-7	Obesity-related traits;
PAAD	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.74	8.32	0.56	4.59e-14	Colorectal cancer;
PAAD	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.87	11.4	0.68	3.77e-22	Subjective well-being (multi-trait analysis);
PAAD	cis	rs7551345	0.853	rs7536471	chr1:31873142	A/T	cg17086398	chr1:31896392	SERINC2	-0.59	-4.85	-0.37	3.04e-6	Schizophrenia;
PAAD	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg02264943	chr11:130785842	SNX19	0.37	4.47	0.34	1.51e-5	Schizophrenia;
PAAD	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg05791153	chr7:19748676	TWISTNB	0.53	4.32	0.33	2.78e-5	Thyroid stimulating hormone;
PAAD	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg23281280	chr6:28129359	ZNF389	0.61	4.71	0.36	5.51e-6	Parkinson's disease;
PAAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg07617317	chr6:118971624	C6orf204	0.55	4.63	0.35	7.64e-6	Renal cell carcinoma;
PAAD	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-4.57	-0.35	9.91e-6	Mean platelet volume;
PAAD	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.42	6.12	0.44	7.45e-9	Migraine;
PAAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.68	-7.45	-0.52	6.57e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-7.31	-0.51	1.45e-11	Coffee consumption (cups per day);
PAAD	cis	rs17162190	0.698	rs12094989	chr1:26848386	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.6	-4.93	-0.37	2.1e-6	Mean corpuscular volume;
PAAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg01503450	chr10:980765	NA	-0.52	-4.66	-0.35	6.9e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg26597838	chr10:835615	NA	-0.39	-4.28	-0.33	3.31e-5	Survival in rectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13564702	chr6:160220519	PNLDC1	-0.58	-6.37	-0.46	2.13e-9	Obesity-related traits;
PAAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.48	-4.31	-0.33	2.86e-5	P wave terminal force;
PAAD	cis	rs2236918	0.710	rs1626057	chr1:242038136	G/C	cg17736920	chr1:242011382	EXO1	0.54	5.31	0.4	3.77e-7	Menopause (age at onset);
PAAD	cis	rs71636778	0.722	rs116491347	chr1:27172684	C/T	cg12203394	chr1:27248618	NUDC	0.64	4.62	0.35	8.05e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.61	5.55	0.41	1.23e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.76	8.98	0.59	9.98e-16	Morning vs. evening chronotype;
PAAD	cis	rs9907295	0.636	rs4796107	chr17:34102775	G/A	cg13376404	chr17:34077293	GAS2L2	0.66	4.26	0.33	3.57e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg04369109	chr6:150039330	LATS1	0.47	4.62	0.35	8.04e-6	Lung cancer;
PAAD	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.71	6.47	0.46	1.28e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.48	6.2	0.45	5.04e-9	Height;
PAAD	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.54	-4.75	-0.36	4.61e-6	Total body bone mineral density;
PAAD	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.94	-0.37	2.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.46	4.35	0.33	2.5e-5	Trans fatty acid levels;
PAAD	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg24110177	chr3:50126178	RBM5	-0.58	-5.64	-0.42	8.2e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg13918804	chr1:2043761	PRKCZ	-0.34	-4.4	-0.34	2.04e-5	Height;
PAAD	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.33	0.64	2.76e-19	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.49	0.41	1.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7631605	0.935	rs9861967	chr3:37158798	C/T	cg17445812	chr3:36986805	TRANK1	0.32	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07677032	chr17:61819896	STRADA	0.62	5.89	0.43	2.36e-8	Prudent dietary pattern;
PAAD	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg08027265	chr7:2291960	NA	-0.52	-5.25	-0.39	5.01e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.53	5.63	0.42	8.49e-8	Testicular germ cell tumor;
PAAD	cis	rs11405769	1	rs11405769	chr2:63658293	A/AT	cg10828910	chr2:63850056	LOC388955	0.5	4.35	0.33	2.49e-5	Childhood ear infection;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.45	0.57	2.22e-14	Alzheimer's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26557005	chr13:96086249	CLDN10	-0.53	-6.38	-0.46	2.04e-9	Energy expenditure (24h);
PAAD	cis	rs13102973	0.720	rs7668824	chr4:135884707	A/T	cg14419869	chr4:135874104	NA	0.44	4.37	0.33	2.26e-5	Subjective well-being;
PAAD	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs7224685	0.815	rs8070159	chr17:4073447	A/G	cg09597638	chr17:3907349	NA	0.56	5.38	0.4	2.82e-7	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg02683114	chr2:24398427	C2orf84	-0.54	-5.04	-0.38	1.31e-6	Asthma;
PAAD	trans	rs901683	1.000	rs71494799	chr10:46002856	T/C	cg14076390	chr17:34947837	DHRS11	0.92	6.81	0.48	2.15e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg10729496	chr3:10149963	C3orf24	0.88	7.24	0.51	2.08e-11	Alzheimer's disease;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.66	-7.18	-0.5	2.94e-11	Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.7e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg01631408	chr1:248437212	OR2T33	-0.55	-5.0	-0.38	1.54e-6	Common traits (Other);
PAAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.59e-5	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.49	5.56	0.41	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg18944383	chr4:111397179	ENPEP	0.77	8.37	0.56	3.46e-14	Coronary artery disease;
PAAD	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.62	6.68	0.48	4.22e-10	Neuroticism;
PAAD	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.68	7.53	0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.29	0.56	5.72e-14	Alzheimer's disease;
PAAD	cis	rs858239	0.863	rs466225	chr7:23332403	G/T	cg27449745	chr7:23145252	KLHL7	-0.57	-4.9	-0.37	2.39e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.73	-7.0	-0.49	7.69e-11	Platelet count;
PAAD	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.9	-7.42	-0.52	7.86e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.38	-0.33	2.23e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.49	-0.41	1.68e-7	Life satisfaction;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.61	-6.73	-0.48	3.22e-10	Lung cancer;
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.6	-9.5	-0.61	4.22e-17	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08919224	chr12:9569744	NA	-0.54	-5.0	-0.38	1.57e-6	IgG glycosylation;
PAAD	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.84	-0.37	3.12e-6	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.68	-0.35	6.27e-6	Lung cancer;
PAAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg00758881	chr16:58534681	NDRG4	-0.88	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg10207240	chr12:122356781	WDR66	0.56	5.91	0.43	2.19e-8	Mean corpuscular volume;
PAAD	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03629577	chr8:146228461	ZNF252;C8orf77	0.66	6.97	0.49	8.95e-11	Myopia (pathological);
PAAD	cis	rs4800452	0.778	rs35699973	chr18:20726731	G/A	cg26136497	chr18:20735537	CABLES1	-0.46	-4.32	-0.33	2.8e-5	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06233122	chr8:74888597	TMEM70	0.64	7.08	0.5	4.93e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.67	0.35	6.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	6.46	0.46	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14159672	chr1:205819179	PM20D1	0.53	5.17	0.39	7.21e-7	Parkinson's disease;
PAAD	cis	rs16975963	0.644	rs73031309	chr19:38031984	C/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.6	-5.86	-0.43	2.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg04389838	chr3:44770851	ZNF501	-0.57	-5.09	-0.38	1.04e-6	Depressive symptoms;
PAAD	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg01631408	chr1:248437212	OR2T33	-0.6	-5.57	-0.41	1.15e-7	Common traits (Other);
PAAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.85	-10.55	-0.65	7.35e-20	Body mass index;
PAAD	cis	rs12091966	1.000	rs12091966	chr1:231243211	A/G	cg26538035	chr1:231178722	NA	-0.49	-4.6	-0.35	8.75e-6	Interleukin-4 levels;
PAAD	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.18	-0.39	6.82e-7	Schizophrenia;
PAAD	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg00024416	chr22:24240387	NA	-0.52	-5.68	-0.42	6.67e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04071446	chr10:115933849	C10orf118	0.62	6.79	0.48	2.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.49	4.27	0.33	3.37e-5	Lymphocyte counts;
PAAD	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.11	-0.38	9.38e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg23033748	chr14:75592666	NEK9	-0.42	-5.21	-0.39	6.19e-7	Height;
PAAD	cis	rs7326068	0.595	rs9552284	chr13:21378344	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.66	0.35	6.75e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9888739	1.000	rs6565227	chr16:31328991	A/T	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.43	6.34	0.46	2.44e-9	Information processing speed;
PAAD	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs1816752	0.524	rs1965154	chr13:25072200	T/C	cg01628528	chr13:24882594	C1QTNF9	0.56	5.27	0.39	4.63e-7	Obesity-related traits;
PAAD	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg22771759	chr13:24902376	NA	0.43	4.27	0.33	3.43e-5	Obesity-related traits;
PAAD	cis	rs72960926	1.000	rs11756290	chr6:75093529	A/G	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs4740619	0.689	rs9969685	chr9:15956278	A/G	cg14451791	chr9:16040625	NA	-0.44	-5.02	-0.38	1.45e-6	Body mass index;
PAAD	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.6	-6.24	-0.45	4.15e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg03948781	chr1:205179583	DSTYK	0.49	4.53	0.34	1.2e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.74	-0.36	4.86e-6	Self-reported allergy;
PAAD	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-4.58	-0.35	9.52e-6	Schizophrenia;
PAAD	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.42	5.25	0.39	5.04e-7	Colorectal cancer;
PAAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.7	8.88	0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	10.77	0.66	1.86e-20	Smoking behavior;
PAAD	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06085890	chr1:156024343	ROBLD3;UBQLN4	-0.71	-7.88	-0.54	5.74e-13	Smoking initiation;
PAAD	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.86	8.1	0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.55	5.62	0.41	8.82e-8	Menopause (age at onset);
PAAD	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.62	0.57	8.09e-15	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg25837213	chr17:80849375	TBCD	-0.46	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs2229238	0.911	rs4379670	chr1:154439865	T/A	cg21262032	chr1:154437693	IL6R	0.44	4.57	0.35	1.01e-5	Coronary heart disease;
PAAD	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg11411865	chr7:2701802	TTYH3	0.63	4.47	0.34	1.52e-5	Bipolar disorder;
PAAD	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg08632701	chr21:37451849	NA	-0.59	-6.15	-0.45	6.47e-9	Mitral valve prolapse;
PAAD	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs2858942	0.780	rs2858014	chr16:248357	T/C	cg08400316	chr16:204221	HBZ	0.51	5.6	0.41	9.71e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg17644776	chr2:200775616	C2orf69	-0.65	-5.08	-0.38	1.08e-6	Schizophrenia;
PAAD	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17376030	chr22:41985996	PMM1	-0.68	-4.69	-0.36	6.04e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg09324608	chr17:30823087	MYO1D	0.48	4.83	0.36	3.32e-6	Schizophrenia;
PAAD	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg17294928	chr15:75287854	SCAMP5	0.44	4.5	0.34	1.33e-5	Caffeine consumption;
PAAD	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.56	0.47	7.81e-10	Platelet count;
PAAD	cis	rs3177980	0.560	rs11589247	chr1:169882910	C/T	cg18229820	chr1:169693534	SELE	0.51	4.51	0.34	1.31e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.71e-10	Life satisfaction;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg00035636	chr13:21900591	NA	0.63	6.9	0.49	1.34e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01534707	chr3:57130436	IL17RD	-0.56	-6.87	-0.49	1.53e-10	Monocyte percentage of white cells;
PAAD	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.19	0.64	6.71e-19	Bladder cancer;
PAAD	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.75	8.72	0.58	4.49e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs67257959	0.708	rs10412843	chr19:17198287	A/G	cg19418318	chr19:17219073	MYO9B	0.31	4.42	0.34	1.9e-5	Selective IgA deficiency;
PAAD	cis	rs2279817	0.735	rs75044419	chr1:18008241	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs12304921	0.935	rs17125116	chr12:51343976	C/G	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.52	-0.34	1.25e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4919087	0.715	rs793524	chr10:99024572	A/G	cg25902810	chr10:99078978	FRAT1	-0.63	-5.58	-0.41	1.09e-7	Monocyte count;
PAAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.47	-4.56	-0.35	1.04e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20301680	chr1:54786494	SSBP3	0.61	6.69	0.48	4.05e-10	Myopia (pathological);
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22442454	chr1:209979470	IRF6	0.58	5.18	0.39	6.83e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6074578	0.648	rs16995685	chr20:139576	G/T	cg16931068	chr20:139680	DEFB127	0.37	4.95	0.37	1.91e-6	Hirschsprung disease;
PAAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg14349672	chr11:133703707	NA	-0.51	-5.85	-0.43	2.97e-8	Childhood ear infection;
PAAD	cis	rs28655083	0.529	rs1847161	chr16:77097796	C/G	cg06128999	chr16:77247126	NA	-0.42	-5.14	-0.38	8.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.79	0.36	3.92e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg06296503	chr6:134217401	NA	-0.55	-5.68	-0.42	6.79e-8	Coronary artery disease;
PAAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-5.77	-0.42	4.31e-8	Mood instability;
PAAD	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	5.17	0.39	7.27e-7	Iron status biomarkers;
PAAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.6	-6.96	-0.49	9.43e-11	Psoriasis;
PAAD	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	10.52	0.65	8.53e-20	Colorectal cancer;
PAAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.51	5.25	0.39	5.02e-7	Corneal astigmatism;
PAAD	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.4	0.34	2.03e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2299116	0.785	rs4719950	chr7:28792966	A/T	cg06647007	chr7:28747836	CREB5	-0.51	-5.0	-0.38	1.53e-6	Serum thyroid-stimulating hormone levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08089031	chr6:139456240	HECA	0.59	6.92	0.49	1.2e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg05805236	chr11:65401703	PCNXL3	-0.42	-4.43	-0.34	1.77e-5	Acne (severe);
PAAD	cis	rs354033	0.959	rs4727082	chr7:149228110	C/T	cg06920324	chr7:149264011	ZNF767	-0.61	-5.08	-0.38	1.11e-6	Multiple sclerosis;
PAAD	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10186876	0.541	rs12712901	chr2:44189338	G/A	cg09541576	chr2:44873248	C2orf34	0.44	4.46	0.34	1.56e-5	Hand grip strength;
PAAD	cis	rs6076065	0.723	rs2249943	chr20:23378098	A/G	cg11657817	chr20:23433608	CST11	0.51	5.06	0.38	1.2e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.32	-0.33	2.77e-5	Caffeine consumption;
PAAD	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-14.26	-0.76	7.93e-30	Headache;
PAAD	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23322531	chr2:8821658	ID2	-0.59	-6.34	-0.46	2.42e-9	Smoking initiation;
PAAD	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg18099408	chr3:52552593	STAB1	0.43	4.77	0.36	4.36e-6	Electroencephalogram traits;
PAAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg10591111	chr5:226296	SDHA	-0.71	-5.48	-0.41	1.75e-7	Breast cancer;
PAAD	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.31e-6	Type 2 diabetes;
PAAD	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg12486944	chr17:80159399	CCDC57	0.53	4.69	0.36	6.05e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.72	-4.58	-0.35	9.61e-6	White matter integrity;
PAAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.56	0.35	1.06e-5	Eosinophil percentage of white cells;
PAAD	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.46	-4.58	-0.35	9.68e-6	Schizophrenia;
PAAD	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.34	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs11129295	0.618	rs11711117	chr3:27809342	A/G	cg21473142	chr3:27762095	EOMES	0.27	4.47	0.34	1.54e-5	Multiple sclerosis;
PAAD	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13981329	chr14:24025037	THTPA	-0.77	-6.64	-0.47	5.17e-10	Neuroticism;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.66	6.65	0.47	5.04e-10	Height;
PAAD	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.45	-4.76	-0.36	4.54e-6	Dementia with Lewy bodies;
PAAD	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.7	-9.1	-0.59	4.73e-16	Myopia (pathological);
PAAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg17380795	chr3:122379686	NA	0.54	5.68	0.42	6.56e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg02737268	chr20:3780182	CDC25B	0.43	4.51	0.34	1.3e-5	Bipolar disorder;
PAAD	cis	rs4478147	0.506	rs17417758	chr4:87307398	G/C	cg10685359	chr4:87814065	C4orf36	-0.52	-5.36	-0.4	2.98e-7	Migraine - clinic-based;
PAAD	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.93	-10.92	-0.66	7.43e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3781663	1.000	rs10751195	chr11:70001976	A/G	cg06393558	chr11:69982916	ANO1	-0.45	-4.83	-0.37	3.23e-6	Survival in rectal cancer;
PAAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg04450456	chr4:17643702	FAM184B	0.47	5.01	0.38	1.5e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10924309	0.889	rs10802246	chr1:245858493	T/G	cg00036263	chr1:245852353	KIF26B	-0.69	-6.12	-0.44	7.74e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.6	5.3	0.4	3.97e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg09659197	chr4:152720779	NA	0.39	5.03	0.38	1.35e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg09835421	chr16:68378352	PRMT7	-0.99	-7.3	-0.51	1.49e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-4.99	-0.38	1.62e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2302729	0.932	rs10848683	chr12:2791130	C/T	cg19945202	chr12:2788847	CACNA1C	-0.69	-6.22	-0.45	4.5e-9	Sleep quality;
PAAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg15443732	chr18:74961078	GALR1	0.61	5.62	0.41	8.96e-8	Obesity-related traits;
PAAD	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.9	10.96	0.66	5.81e-21	Ulcerative colitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11065634	chr14:99736978	BCL11B	0.59	6.49	0.47	1.17e-9	Myopia (pathological);
PAAD	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13426544	chr11:65729012	SART1	-0.6	-7.4	-0.51	8.59e-12	Body fat percentage;
PAAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.68	-0.35	6.31e-6	Recombination rate (females);
PAAD	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.55	6.2	0.45	5.15e-9	Cognitive function;
PAAD	cis	rs6681460	1.000	rs10889634	chr1:67065911	A/G	cg02459107	chr1:67143332	SGIP1	-0.75	-7.65	-0.53	2.2e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg17401720	chr7:158221031	PTPRN2	0.42	4.8	0.36	3.76e-6	Obesity-related traits;
PAAD	cis	rs6074578	0.679	rs6077246	chr20:136454	T/C	cg16931068	chr20:139680	DEFB127	0.38	4.99	0.38	1.62e-6	Hirschsprung disease;
PAAD	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg21483461	chr5:81570383	RPS23	0.53	4.91	0.37	2.32e-6	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14878150	chr12:101673760	UTP20	0.6	6.52	0.47	9.67e-10	Monocyte percentage of white cells;
PAAD	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-1.09	-11.2	-0.67	1.32e-21	Platelet distribution width;
PAAD	cis	rs524281	0.729	rs12790034	chr11:65785739	T/C	cg16950941	chr11:66035639	RAB1B	0.58	4.26	0.33	3.5e-5	Electroencephalogram traits;
PAAD	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.55	-5.67	-0.42	7.04e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg03959625	chr15:84868606	LOC388152	-0.45	-4.75	-0.36	4.61e-6	P wave terminal force;
PAAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.47	-5.11	-0.38	9.4e-7	Facial morphology (factor 20);
PAAD	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.74	-7.7	-0.53	1.59e-12	Type 2 diabetes;
PAAD	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.74	6.9	0.49	1.3100000000000001e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.51	0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13012494	chr21:47604986	C21orf56	0.48	5.04	0.38	1.31e-6	Testicular germ cell tumor;
PAAD	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.44	-5.18	-0.39	6.84e-7	Mean arterial pressure;
PAAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.47	-4.46	-0.34	1.56e-5	Monocyte count;
PAAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.44e-5	Blood metabolite levels;
PAAD	cis	rs12714314	1.000	rs12714314	chr2:1943617	C/T	cg22350835	chr2:1868857	MYT1L	0.51	5.04	0.38	1.29e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg00599163	chr2:162100495	NA	0.52	7.43	0.52	7.17e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00610583	chr4:74735056	CXCL1	0.71	7.6	0.52	2.77e-12	Obesity-related traits;
PAAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	trans	rs12282928	0.700	rs10838817	chr11:48200265	G/A	cg00717180	chr2:96193071	NA	-0.64	-6.78	-0.48	2.5e-10	Migraine - clinic-based;
PAAD	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.05	5.36	0.4	2.98e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs13053817	1.000	rs78186489	chr22:29845703	C/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.56	-5.0	-0.38	1.56e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg09835421	chr16:68378352	PRMT7	-1.09	-7.89	-0.54	5.54e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	0.94	6.96	0.49	9.55e-11	Prostate cancer;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.54	5.24	0.39	5.17e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.52	-4.8	-0.36	3.77e-6	Schizophrenia;
PAAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.56	0.47	8.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs829661	0.947	rs829654	chr2:30714717	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	5.79	0.42	3.94e-8	Lung cancer in ever smokers;
PAAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23161317	chr6:28129485	ZNF389	-0.55	-4.26	-0.33	3.51e-5	Depression;
PAAD	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	6.14	0.45	6.84e-9	LDL cholesterol;
PAAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.55	-5.24	-0.39	5.18e-7	Monocyte count;
PAAD	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.73	-0.48	3.18e-10	Body mass index;
PAAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg05697835	chr1:2722811	NA	0.43	4.82	0.36	3.39e-6	Ulcerative colitis;
PAAD	cis	rs714515	0.609	rs4916262	chr1:172450528	A/C	cg13446689	chr1:172328377	DNM3	-0.44	-5.32	-0.4	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.22e-6	Menopause (age at onset);
PAAD	cis	rs8113142	0.573	rs8103836	chr19:29006711	C/T	cg12756686	chr19:29218302	NA	0.74	5.43	0.4	2.19e-7	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.79	-6.96	-0.49	9.73e-11	Blood protein levels;
PAAD	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg21918786	chr6:109611834	NA	-0.55	-5.91	-0.43	2.12e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2997447	0.761	rs61776585	chr1:26438498	G/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.82	4.97	0.37	1.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg19130645	chr7:65235666	NA	0.43	4.53	0.34	1.18e-5	Calcium levels;
PAAD	cis	rs59888335	0.858	rs67523161	chr3:80929158	C/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Aortic root size;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.61	-6.97	-0.49	9.05e-11	Bipolar disorder;
PAAD	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs7083	0.716	rs574603	chr11:117177741	C/T	cg26034313	chr11:117110208	RNF214	0.35	4.42	0.34	1.87e-5	Blood protein levels;
PAAD	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg23534315	chr17:78082725	GAA	0.49	4.44	0.34	1.74e-5	Yeast infection;
PAAD	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.4	4.93	0.37	2.14e-6	Colorectal cancer;
PAAD	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg10820045	chr2:198174542	NA	0.54	5.4	0.4	2.53e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8042680	0.522	rs1867225	chr15:91563829	A/G	cg08919649	chr15:91565780	VPS33B	0.51	4.64	0.35	7.59e-6	Type 2 diabetes;
PAAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg26174226	chr8:58114915	NA	-0.64	-5.33	-0.4	3.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.62	-6.91	-0.49	1.27e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.47	-11.1	-0.67	2.46e-21	Atopic dermatitis;
PAAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.48	4.77	0.36	4.31e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4073221	0.789	rs4333081	chr3:18245616	C/T	cg07694806	chr3:18168406	NA	-0.78	-4.98	-0.37	1.71e-6	Parkinson's disease;
PAAD	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg24687543	chr11:63912206	MACROD1	0.53	4.68	0.36	6.24e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.7	6.92	0.49	1.21e-10	Platelet count;
PAAD	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.49	-5.29	-0.39	4.12e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg24220031	chr2:73402428	NA	-0.44	-6.77	-0.48	2.67e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7853377	0.689	rs7853254	chr9:86552049	C/T	cg03531853	chr9:86535572	KIF27	0.41	4.35	0.33	2.45e-5	Height;
PAAD	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.8	8.04	0.55	2.41e-13	Testicular germ cell tumor;
PAAD	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.53	-0.47	9.46e-10	Body mass index;
PAAD	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.83	8.86	0.58	1.99e-15	Prostate cancer;
PAAD	cis	rs863345	0.967	rs11265023	chr1:158513048	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.99	-0.38	1.65e-6	Pneumococcal bacteremia;
PAAD	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-5.12	-0.38	9.13e-7	Coronary artery disease;
PAAD	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg05925327	chr15:68127851	NA	-0.56	-5.05	-0.38	1.26e-6	Restless legs syndrome;
PAAD	cis	rs7662987	1.000	rs28730591	chr4:100003747	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-4.25	-0.33	3.73e-5	Smoking initiation;
PAAD	cis	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.74	-6.53	-0.47	9.55e-10	Type 2 diabetes;
PAAD	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.43	-4.59	-0.35	9.19e-6	Prostate cancer;
PAAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg09835421	chr16:68378352	PRMT7	-1.22	-8.79	-0.58	3.04e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10512697	0.655	rs35573920	chr5:3486281	C/T	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs7746199	0.736	rs13217620	chr6:27653120	C/T	cg06606381	chr12:133084897	FBRSL1	-1.39	-8.05	-0.55	2.18e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg02527881	chr3:46936655	PTH1R	0.37	4.26	0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.57	-6.35	-0.46	2.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.64	6.88	0.49	1.5e-10	N-glycan levels;
PAAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.49	-0.41	1.66e-7	Monocyte count;
PAAD	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.89	-10.69	-0.66	2.99e-20	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.48	5.85	0.43	2.94e-8	Height;
PAAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg06521852	chr22:38141419	TRIOBP	0.43	4.46	0.34	1.61e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.54	-5.65	-0.42	7.51e-8	Height;
PAAD	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.89e-5	Height;
PAAD	cis	rs8060686	0.920	rs72556537	chr16:67691477	A/T	cg05110241	chr16:68378359	PRMT7	-1.1	-5.44	-0.4	2.07e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.05e-5	Blood metabolite levels;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg07202610	chr7:1142643	C7orf50	-0.76	-5.24	-0.39	5.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.64	-4.34	-0.33	2.6e-5	Vitiligo;
PAAD	cis	rs73416724	1.000	rs78014492	chr6:43289599	C/T	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg26394196	chr10:1453818	ADARB2	-0.58	-6.6	-0.47	6.38e-10	Radiation response;
PAAD	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg26027780	chr6:27100370	HIST1H2AG;HIST1H2BJ	0.51	4.27	0.33	3.42e-5	Educational attainment;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg23119463	chr10:134592391	INPP5A	-0.47	-4.42	-0.34	1.89e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.59	-6.67	-0.48	4.52e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.55	5.93	0.43	1.96e-8	Mean corpuscular volume;
PAAD	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg00181669	chr3:44000978	NA	-0.57	-5.81	-0.43	3.48e-8	Coronary artery disease;
PAAD	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.49	-4.89	-0.37	2.59e-6	Immature fraction of reticulocytes;
PAAD	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.41	4.44	0.34	1.75e-5	Schizophrenia;
PAAD	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.72	-0.36	5.21e-6	Migraine;
PAAD	cis	rs6426558	0.681	rs10495274	chr1:227175253	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.84	-8.84	-0.58	2.17e-15	Neutrophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.86	7.21	0.5	2.47e-11	Pulmonary function decline;
PAAD	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs7619427	0.544	rs9872382	chr3:44021964	C/A	cg12796028	chr3:44040206	NA	-0.56	-4.77	-0.36	4.22e-6	Schizophrenia;
PAAD	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.38	4.71	0.36	5.66e-6	Sitting height ratio;
PAAD	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-1.13	-7.95	-0.54	3.98e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg09526469	chr5:14277668	TRIO	-0.4	-4.25	-0.33	3.67e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs4604234	0.573	rs11961361	chr6:81004557	C/G	cg23115158	chr6:80341412	SH3BGRL2	-1.08	-4.25	-0.33	3.72e-5	Cancer;
PAAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.75	-7.24	-0.51	2.13e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17774305	chr12:50505649	C12orf62	0.61	6.74	0.48	3.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg15352829	chr14:105391018	PLD4	-0.57	-7.74	-0.53	1.31e-12	Systemic lupus erythematosus;
PAAD	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.98	5.71	0.42	5.84e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.72	5.78	0.42	4.13e-8	Mean platelet volume;
PAAD	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.59	6.87	0.49	1.56e-10	HDL cholesterol levels;
PAAD	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.96	13.14	0.73	7.89e-27	Heart rate;
PAAD	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11825685	0.848	rs4936244	chr11:134581403	A/C	cg06603561	chr11:134479413	NA	-0.66	-5.09	-0.38	1.05e-6	IgG glycosylation;
PAAD	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-6.68	-0.48	4.26e-10	Schizophrenia (age at onset);
PAAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.67	7.84	0.54	7.27e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs12935418	0.616	rs9921448	chr16:81009490	A/G	cg16651780	chr16:81037892	C16orf61	0.65	6.03	0.44	1.22e-8	Mean corpuscular volume;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-6.4	-0.46	1.79e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg05132306	chr1:1846340	CALML6	-0.41	-4.89	-0.37	2.51e-6	Body mass index;
PAAD	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg27411982	chr8:10470053	RP1L1	-0.47	-5.11	-0.38	9.4e-7	Neuroticism;
PAAD	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.64	-0.47	5.32e-10	Blood pressure (smoking interaction);
PAAD	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.6	4.46	0.34	1.56e-5	Exhaled nitric oxide output;
PAAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.58	4.38	0.33	2.21e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg05110241	chr16:68378359	PRMT7	1.19	8.11	0.55	1.5700000000000001e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg03989125	chr22:38214979	NA	0.61	5.65	0.42	7.82e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02359409	chr6:42947317	PEX6	-0.5	-5.07	-0.38	1.12e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg04044120	chr11:73668757	DNAJB13	0.58	4.37	0.33	2.33e-5	Hand grip strength;
PAAD	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.14	-0.6	3.66e-16	Alzheimer's disease (late onset);
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg15193198	chr20:60906057	LAMA5	-0.55	-5.4	-0.4	2.54e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.65e-7	Monocyte count;
PAAD	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.77	-0.36	4.2e-6	Breast cancer;
PAAD	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.69	7.33	0.51	1.26e-11	Body mass index;
PAAD	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.7	-6.28	-0.45	3.45e-9	Blood trace element (Zn levels);
PAAD	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.78	5.63	0.42	8.44e-8	Pulse pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24616138	chr10:126850126	CTBP2	0.59	6.6	0.47	6.58e-10	Monocyte percentage of white cells;
PAAD	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	6.92	0.49	1.17e-10	Lung cancer in ever smokers;
PAAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg05342682	chr7:94953680	PON1	-0.53	-4.59	-0.35	9.28e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg17366294	chr4:99064904	C4orf37	0.47	5.26	0.39	4.86e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18337363	chr3:52569053	NT5DC2	0.46	5.25	0.39	5.12e-7	Electroencephalogram traits;
PAAD	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	cis	rs732765	0.689	rs8019690	chr14:75135142	A/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-4.26	-0.33	3.61e-5	Systemic lupus erythematosus;
PAAD	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.67	-5.33	-0.4	3.43e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.87	11.26	0.67	9.04e-22	Subjective well-being (multi-trait analysis);
PAAD	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg27449745	chr7:23145252	KLHL7	0.56	5.13	0.38	8.76e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg19223190	chr17:80058835	NA	0.54	5.53	0.41	1.38e-7	Life satisfaction;
PAAD	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg23298862	chr7:158159286	PTPRN2	-0.47	-4.43	-0.34	1.8e-5	Calcium levels;
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs427941	0.517	rs201530	chr7:101777382	A/G	cg06246474	chr7:101738831	CUX1	0.44	4.3	0.33	3e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg15448220	chr1:150897856	SETDB1	0.61	6.83	0.48	1.94e-10	Tonsillectomy;
PAAD	cis	rs5751901	0.614	rs6519519	chr22:24991863	C/T	cg08808123	chr22:24999002	GGT1	-0.43	-4.43	-0.34	1.82e-5	Protein quantitative trait loci;
PAAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg26031613	chr14:104095156	KLC1	-0.57	-5.85	-0.43	2.94e-8	Reticulocyte count;
PAAD	cis	rs75757892	0.544	rs79106361	chr6:7317463	G/C	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	trans	rs405795	1.000	rs2774176	chr13:89781937	C/T	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Yeast infection;
PAAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.55	6.31	0.46	2.87e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg18512352	chr11:47633146	NA	0.42	6.23	0.45	4.34e-9	Subjective well-being;
PAAD	cis	rs3925075	0.531	rs7206295	chr16:31336519	T/C	cg02846316	chr16:31340340	ITGAM	0.46	5.28	0.39	4.31e-7	IgA nephropathy;
PAAD	cis	rs9581857	0.546	rs9581837	chr13:27965764	G/T	cg22138327	chr13:27999177	GTF3A	0.87	5.42	0.4	2.3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27331225	chr3:193852938	HES1	-0.8	-6.85	-0.49	1.7e-10	Neuroticism;
PAAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.51	5.02	0.38	1.41e-6	Morning vs. evening chronotype;
PAAD	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg14906510	chr12:7781169	NA	-0.6	-4.34	-0.33	2.61e-5	HDL cholesterol levels;
PAAD	cis	rs2131877	0.830	rs952586	chr3:194842322	G/A	cg19760965	chr3:194868843	C3orf21	0.47	4.73	0.36	5.04e-6	Non-small cell lung cancer;
PAAD	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.52	-5.09	-0.38	1.02e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.56	5.1	0.38	9.87e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.61	4.95	0.37	1.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.4	0.64	1.77e-19	Smoking behavior;
PAAD	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.91	5.79	0.42	3.97e-8	Blood protein levels;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.91	7.76	0.53	1.15e-12	Alzheimer's disease;
PAAD	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg09127314	chr1:152161683	NA	-0.67	-4.87	-0.37	2.74e-6	Atopic dermatitis;
PAAD	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs11113894	0.901	rs17040591	chr12:108860695	A/T	cg06834313	chr12:108851556	NA	-0.68	-4.34	-0.33	2.6e-5	Obesity-related traits;
PAAD	cis	rs7224737	1.000	rs8072215	chr17:40271970	A/G	cg02228675	chr17:40259724	DHX58	-0.47	-5.77	-0.42	4.39e-8	Fibrinogen levels;
PAAD	trans	rs901683	0.850	rs77876088	chr10:46094121	T/C	cg13065504	chr15:42448234	PLA2G4F	0.85	6.7	0.48	3.81e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4953404	0.613	rs930853	chr2:46898849	A/G	cg12784625	chr2:46524557	EPAS1	-0.49	-4.4	-0.34	2.05e-5	Pulse pressure (alcohol consumption interaction);
PAAD	trans	rs34112283	0.592	rs13004149	chr2:144252485	C/T	cg10530280	chr1:167759869	MPZL1	-0.65	-6.41	-0.46	1.7e-9	Neuroticism;
PAAD	cis	rs970548	0.643	rs12765320	chr10:45930805	A/G	cg15590007	chr10:45870220	ALOX5	0.45	4.87	0.37	2.79e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg21565972	chr17:80109576	CCDC57	0.59	6.93	0.49	1.15e-10	Life satisfaction;
PAAD	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg18612461	chr15:75251733	NA	-0.39	-4.29	-0.33	3.23e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.27	0.39	4.6e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg00601450	chr5:74908170	NA	0.48	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.63	0.35	7.72e-6	Breast cancer;
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.95	6.45	0.46	1.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs75804782	0.522	rs7561954	chr2:239318280	G/A	cg18131467	chr2:239335373	ASB1	-0.65	-4.67	-0.35	6.48e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.35	-0.4	3.21e-7	Myeloid white cell count;
PAAD	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	trans	rs894157	0.563	rs72752568	chr15:90253828	C/T	cg05600044	chr1:222721340	HHIPL2	0.98	6.41	0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs1045902	0.967	rs1469530	chr2:73464948	C/T	cg24220031	chr2:73402428	NA	-0.43	-6.36	-0.46	2.25e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg03733263	chr8:22462867	KIAA1967	-0.93	-11.07	-0.67	2.91e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs901683	1.000	rs34771643	chr10:45970632	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.7	6.27	0.45	3.6e-9	Menarche (age at onset);
PAAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.63	4.71	0.36	5.5e-6	Breast cancer;
PAAD	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg08648136	chr8:956695	NA	0.44	4.82	0.36	3.41e-6	Schizophrenia;
PAAD	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.31	5.58	0.41	1.05e-7	Type 2 diabetes;
PAAD	cis	rs4523957	0.928	rs216198	chr17:2201735	C/T	cg16513277	chr17:2031491	SMG6	0.54	5.64	0.42	7.9e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.66	6.69	0.48	3.99e-10	Schizophrenia;
PAAD	cis	rs2790216	1.000	rs2440856	chr10:60030789	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-5.44	-0.4	2.07e-7	Educational attainment;
PAAD	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.83	6.69	0.48	4.01e-10	Psoriasis;
PAAD	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg16928487	chr17:17741425	SREBF1	-0.36	-4.88	-0.37	2.6e-6	Total body bone mineral density;
PAAD	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	6.36	0.46	2.29e-9	Cognitive test performance;
PAAD	cis	rs9287604	1.000	rs1098866	chr2:237791541	C/T	cg15065627	chr2:237796583	NA	0.53	4.4	0.34	2.01e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs2371030	1.000	rs2193618	chr2:211573464	A/G	cg18417063	chr2:211583084	NA	-0.46	-4.65	-0.35	7.28e-6	Non-small cell lung cancer;
PAAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.53	4.97	0.37	1.8e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.48	4.4	0.34	2.05e-5	Depression;
PAAD	cis	rs735539	0.555	rs3000678	chr13:21302058	G/A	cg27234864	chr13:21295941	IL17D	0.58	4.82	0.36	3.4e-6	Dental caries;
PAAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.69	-5.03	-0.38	1.35e-6	Type 2 diabetes;
PAAD	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs3771514	0.543	rs13408582	chr2:70688866	C/G	cg18150120	chr2:71134936	VAX2	-0.39	-4.69	-0.36	6.01e-6	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.9	8.85	0.58	2.1e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg14829155	chr15:31115871	NA	-0.63	-6.52	-0.47	9.95e-10	Huntington's disease progression;
PAAD	cis	rs9467603	0.800	rs28360585	chr6:25790356	A/T	cg21479132	chr6:26055353	NA	0.78	5.14	0.38	8.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg01304814	chr3:48885189	PRKAR2A	0.64	4.35	0.33	2.53e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.27	-0.45	3.59e-9	Height;
PAAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.53	5.21	0.39	6.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17162190	0.643	rs6656196	chr1:26758773	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.63	0.35	7.8e-6	Mean corpuscular volume;
PAAD	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg01884057	chr2:25150051	NA	-0.38	-4.63	-0.35	7.79e-6	Body mass index in non-asthmatics;
PAAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	1.23	11.56	0.68	1.42e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg12517394	chr11:61582795	MIR1908;FADS1	-0.46	-4.62	-0.35	7.98e-6	Trans fatty acid levels;
PAAD	cis	rs12760731	0.720	rs10913542	chr1:178348568	A/G	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs5746492	0.539	rs5747385	chr22:18352679	C/T	cg06148736	chr22:18985691	NA	-0.38	-4.41	-0.34	1.94e-5	Eotaxin levels;
PAAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2481665	0.709	rs2476187	chr1:62528738	T/C	cg18591186	chr1:62594603	INADL	-0.54	-5.21	-0.39	6.19e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg26501369	chr6:133561814	EYA4	-0.9	-6.63	-0.47	5.62e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.69	6.85	0.49	1.68e-10	Mood instability;
PAAD	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg04787325	chr16:19179251	SYT17	0.61	5.04	0.38	1.32e-6	Parkinson's disease;
PAAD	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg20406979	chr6:167373233	NA	0.37	4.81	0.36	3.68e-6	Crohn's disease;
PAAD	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg09839279	chr12:125627357	AACS	-0.5	-4.91	-0.37	2.32e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg21351543	chr2:191399470	TMEM194B	-0.64	-4.87	-0.37	2.76e-6	Diastolic blood pressure;
PAAD	cis	rs9652601	0.920	rs12923098	chr16:11177053	T/C	cg04616529	chr16:11181986	CLEC16A	0.46	5.01	0.38	1.49e-6	Systemic lupus erythematosus;
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs10140922	0.607	rs2415274	chr14:35651467	A/G	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.36	-0.33	2.43e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-5.28	-0.39	4.46e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg02056144	chr12:54070517	ATP5G2	-0.51	-5.54	-0.41	1.3e-7	Height;
PAAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.2	0.45	5.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg20848291	chr7:100343083	ZAN	-0.79	-6.63	-0.47	5.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg02230254	chr11:65586170	NA	-0.32	-4.79	-0.36	3.88e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg14458575	chr2:238380390	NA	0.55	6.18	0.45	5.51e-9	Prostate cancer;
PAAD	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.83	9.88	0.63	4.34e-18	Coronary artery disease;
PAAD	cis	rs3784262	0.528	rs4646589	chr15:58303165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.39	4.53	0.34	1.21e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23220623	chr17:79819037	P4HB	0.57	6.47	0.46	1.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg09876464	chr15:85330779	ZNF592	0.43	4.33	0.33	2.71e-5	P wave terminal force;
PAAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.61	0.35	8.61e-6	Melanoma;
PAAD	cis	rs7127900	0.950	rs6579003	chr11:2232310	A/C	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg11367502	chr7:22862612	TOMM7	0.53	5.39	0.4	2.66e-7	Fibrinogen;
PAAD	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg16512390	chr1:228756714	NA	0.59	4.79	0.36	3.88e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12997796	0.503	rs3020728	chr2:87013771	A/C	cg25203885	chr2:87302643	LOC285074	-0.86	-5.77	-0.42	4.33e-8	Schizophrenia;
PAAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.58	0.35	9.67e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg16434002	chr17:42200994	HDAC5	0.57	5.17	0.39	7.15e-7	Total body bone mineral density;
PAAD	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg03417191	chr3:183542750	MAP6D1	0.63	5.59	0.41	1.02e-7	Menopause (age at onset);
PAAD	cis	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.05	-0.38	1.27e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-1.07	-14.71	-0.77	4.95e-31	Multiple myeloma;
PAAD	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg15440763	chr7:158190612	PTPRN2	0.48	4.8	0.36	3.8e-6	Obesity-related traits;
PAAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.09	14.34	0.76	4.91e-30	Cognitive function;
PAAD	cis	rs17152411	0.652	rs10794190	chr10:126603231	G/A	cg07081759	chr10:126330905	FAM53B	-0.39	-4.26	-0.33	3.52e-5	Height;
PAAD	cis	rs11825685	0.579	rs3017996	chr11:134541247	C/T	cg06603561	chr11:134479413	NA	-0.56	-4.88	-0.37	2.63e-6	IgG glycosylation;
PAAD	cis	rs4479964	0.817	rs9375648	chr6:129974114	T/C	cg12774946	chr6:129966801	ARHGAP18	0.31	4.4	0.34	2.03e-5	Gut microbiome composition (summer);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26495758	chr8:21999587	REEP4	-0.73	-6.35	-0.46	2.39e-9	Neuroticism;
PAAD	cis	rs1018697	1.000	rs4919678	chr10:104554363	C/G	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.8	7.61	0.53	2.75e-12	Vitamin D levels;
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg20639618	chr4:183729073	NA	0.68	5.35	0.4	3.18e-7	Pediatric autoimmune diseases;
PAAD	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.38	-0.4	2.7e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.71	5.85	0.43	2.92e-8	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg04160749	chr8:58172571	NA	0.7	4.96	0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.556	rs289323	chr19:23157215	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.97	6.18	0.45	5.49e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg12215294	chr3:40350768	EIF1B	0.49	4.95	0.37	1.95e-6	Renal cell carcinoma;
PAAD	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.43	-5.66	-0.42	7.36e-8	Congenital heart disease (maternal effect);
PAAD	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg14500267	chr11:67383377	NA	0.43	4.32	0.33	2.85e-5	Mean corpuscular volume;
PAAD	cis	rs6766510	1.000	rs3856807	chr3:12527600	G/T	cg07775309	chr3:12595852	NA	-0.69	-4.38	-0.33	2.19e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4748857	0.782	rs1319250	chr10:23529098	C/T	cg18853376	chr10:23633759	C10orf67	0.56	4.99	0.38	1.61e-6	Systemic lupus erythematosus;
PAAD	cis	rs17401966	0.593	rs11121523	chr1:10214442	T/A	cg15208524	chr1:10270712	KIF1B	0.51	4.72	0.36	5.34e-6	Hepatocellular carcinoma;
PAAD	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg02683114	chr2:24398427	C2orf84	-0.61	-6.55	-0.47	8.4e-10	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.56	-4.88	-0.37	2.64e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9287604	1.000	rs1344760	chr2:237775494	A/G	cg15065627	chr2:237796583	NA	0.52	4.33	0.33	2.7e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs501120	0.810	rs498810	chr10:44740776	A/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-6.41	-0.46	1.7e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg03115019	chr17:80708279	FN3K	0.66	7.15	0.5	3.44e-11	Glycated hemoglobin levels;
PAAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.53	4.38	0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.96	0.54	3.68e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	4.85	0.37	3.02e-6	Bone mineral density;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22162314	chr17:61951766	CSH2	-0.6	-6.2	-0.45	5.05e-9	Height;
PAAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.51	4.46	0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4865169	0.595	rs9998008	chr4:57766052	A/G	cg24291500	chr4:57773398	REST	0.42	4.81	0.36	3.64e-6	Breast cancer;
PAAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.11	0.38	9.34e-7	Coronary artery disease;
PAAD	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.66	-7.42	-0.52	7.86e-12	Platelet distribution width;
PAAD	cis	rs9506514	0.509	rs9506515	chr13:21132009	T/G	cg27499820	chr13:21296301	IL17D	-0.43	-4.49	-0.34	1.4e-5	Coronary artery calcification;
PAAD	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.58	5.47	0.41	1.79e-7	Type 2 diabetes;
PAAD	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.62	-0.53	2.51e-12	Hemoglobin concentration;
PAAD	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg14515779	chr1:101123966	NA	-0.52	-6.59	-0.47	6.75e-10	Monocyte count;
PAAD	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.46	4.49	0.34	1.43e-5	Breast cancer;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg25287198	chr4:183728479	NA	0.85	6.96	0.49	9.79e-11	Pediatric autoimmune diseases;
PAAD	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg04450456	chr4:17643702	FAM184B	0.52	5.77	0.42	4.21e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg12310025	chr6:25882481	NA	0.44	4.38	0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs1642645	0.793	rs4660211	chr1:42484294	T/C	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16573901	chr1:38061607	GNL2	0.7	7.52	0.52	4.33e-12	Myopia (pathological);
PAAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg13332499	chr17:408570	NA	0.56	6.12	0.44	7.44e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.73	6.36	0.46	2.22e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1620921	0.505	rs13196324	chr6:161201842	A/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs11807834	0.522	rs10864688	chr1:230237167	C/T	cg00566187	chr1:230250356	GALNT2	-0.63	-6.6	-0.47	6.62e-10	Schizophrenia;
PAAD	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.53	5.61	0.41	9.38e-8	Height;
PAAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.52	0.52	4.54e-12	Eosinophil percentage of white cells;
PAAD	cis	rs7551345	0.853	rs33917597	chr1:31774503	C/T	cg17086398	chr1:31896392	SERINC2	0.49	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22893405	chr7:6198604	USP42	-0.65	-6.52	-0.47	9.55e-10	Obesity-related traits;
PAAD	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.74	5.79	0.43	3.87e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11129295	0.618	rs17020287	chr3:27801879	G/A	cg21473142	chr3:27762095	EOMES	0.28	4.66	0.35	6.99e-6	Multiple sclerosis;
PAAD	cis	rs7727544	0.617	rs3843503	chr5:131466629	T/A	cg16205897	chr5:131564050	P4HA2	-0.48	-5.08	-0.38	1.08e-6	Blood metabolite levels;
PAAD	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.59	5.2	0.39	6.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11875119	chr22:31003147	TCN2	0.55	6.31	0.46	2.96e-9	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.58	5.62	0.42	8.69e-8	Monocyte count;
PAAD	cis	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.8	-5.05	-0.38	1.25e-6	Mononucleosis;
PAAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.35	0.33	2.52e-5	Cancer;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.73	-12.23	-0.7	2.17e-24	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs2882667	0.690	rs2016720	chr5:138264058	C/T	cg09476006	chr5:138032270	NA	0.47	5.8	0.43	3.63e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.7	5.69	0.42	6.35e-8	Vitiligo;
PAAD	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	6.76	0.48	2.8e-10	Blood protein levels;
PAAD	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg20913747	chr6:44695427	NA	-0.71	-7.19	-0.5	2.8e-11	Total body bone mineral density;
PAAD	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.55	5.46	0.41	1.86e-7	Platelet count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20474699	chr14:102976161	ANKRD9	-0.72	-7.79	-0.53	1e-12	Smoking initiation;
PAAD	cis	rs35110281	0.667	rs8133276	chr21:45126629	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.51	-0.34	1.29e-5	Mean corpuscular volume;
PAAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.57	6.29	0.45	3.28e-9	Blood metabolite levels;
PAAD	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.39	13.24	0.73	4.26e-27	Corneal structure;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg07061783	chr6:25882402	NA	-0.53	-5.21	-0.39	6.02e-7	Blood metabolite levels;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12820191	chr3:186524311	RFC4	0.48	4.78	0.36	4.13e-6	Myopia (pathological);
PAAD	cis	rs2016586	0.929	rs5999961	chr22:36105275	A/C	cg26342177	chr22:36113512	APOL5	-0.49	-4.93	-0.37	2.14e-6	Body mass index;
PAAD	cis	rs73416724	1.000	rs17209400	chr6:43328062	A/G	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg14926445	chr8:58193284	C8orf71	-0.66	-5.48	-0.41	1.72e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1497828	0.956	rs2810774	chr1:217540771	A/G	cg04411442	chr1:217543379	NA	-0.5	-4.88	-0.37	2.68e-6	Dialysis-related mortality;
PAAD	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.5	5.65	0.42	7.53e-8	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
PAAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg21130718	chr4:1044621	NA	0.53	4.57	0.35	1.02e-5	Recombination rate (females);
PAAD	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.45	4.26	0.33	3.56e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-5.02	-0.38	1.43e-6	Diastolic blood pressure;
PAAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	5.04	0.38	1.32e-6	Bone mineral density;
PAAD	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg25342568	chr4:1768564	NA	-0.33	-4.41	-0.34	1.98e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4742903	0.904	rs28658011	chr9:107006925	G/A	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.96e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.7	-7.87	-0.54	6.29e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.73	-8.22	-0.55	8.18e-14	Dental caries;
PAAD	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.63	-0.42	8.49e-8	Total cholesterol levels;
PAAD	cis	rs728616	0.867	rs2152548	chr10:81802667	G/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.13	-0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.79e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.84	6.44	0.46	1.47e-9	Axial length;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12141179	chr2:172016663	TLK1	-0.64	-6.31	-0.46	2.83e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.76	8.8	0.58	2.77e-15	Blood metabolite ratios;
PAAD	cis	rs6449957	0.801	rs6449953	chr5:67456530	A/G	cg23036683	chr5:67512108	NA	0.49	4.51	0.34	1.27e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03115019	chr17:80708279	FN3K	0.51	4.61	0.35	8.6e-6	Glycated hemoglobin levels;
PAAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	5.5	0.41	1.58e-7	Monocyte percentage of white cells;
PAAD	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.68	7.73	0.53	1.34e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.83	-0.36	3.26e-6	Life satisfaction;
PAAD	cis	rs965469	0.779	rs6037515	chr20:3233091	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.41	-0.34	1.92e-5	IFN-related cytopenia;
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg12757816	chr2:10669957	NA	-0.54	-5.79	-0.43	3.82e-8	Prostate cancer;
PAAD	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.82e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	4.66	0.35	6.86e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-5.66	-0.42	7.26e-8	Mean corpuscular volume;
PAAD	cis	rs3857067	0.550	rs7685853	chr4:95028183	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.18	-0.39	6.92e-7	QT interval;
PAAD	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.55	4.99	0.38	1.61e-6	Type 2 diabetes;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26419957	chr12:122252518	SETD1B	-0.65	-6.48	-0.47	1.23e-9	Primary biliary cholangitis;
PAAD	cis	rs13256369	0.737	rs34194904	chr8:8554553	C/T	cg18904891	chr8:8559673	CLDN23	0.64	5.65	0.42	7.75e-8	Obesity-related traits;
PAAD	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.85	10.0	0.63	2.04e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4974559	0.739	rs60722337	chr4:1320542	C/G	cg02980000	chr4:1222292	CTBP1	0.8	5.74	0.42	4.96e-8	Systolic blood pressure;
PAAD	cis	rs111342015	0.881	rs111492053	chr6:43217239	G/C	cg17076780	chr6:43251928	TTBK1	0.72	4.43	0.34	1.82e-5	Breast cancer;
PAAD	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.84	10.06	0.63	1.42e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2790216	1.000	rs2590371	chr10:60054487	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.57	5.26	0.39	4.83e-7	Schizophrenia;
PAAD	cis	rs28489187	0.706	rs3768227	chr1:85804087	A/G	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg21145140	chr5:110409467	TSLP	0.44	4.26	0.33	3.54e-5	Eosinophilic esophagitis;
PAAD	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs300774	0.748	rs409657	chr2:129009	C/T	cg21211680	chr2:198530	NA	-0.6	-5.69	-0.42	6.45e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.33	-0.4	3.55e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.84	10.1	0.63	1.13e-18	Menopause (age at onset);
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg00988841	chr10:134556463	INPP5A	0.51	4.72	0.36	5.36e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.62	8.12	0.55	1.48e-13	Renal cell carcinoma;
PAAD	cis	rs2567519	1.000	rs2714017	chr17:70788741	C/T	cg26978064	chr17:70461791	NA	0.28	4.48	0.34	1.44e-5	Smoking initiation;
PAAD	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.78	7.2	0.5	2.59e-11	Corneal astigmatism;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-5.72	-0.42	5.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.88	6.86	0.49	1.61e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs2834188	0.557	rs7283095	chr21:34687500	C/G	cg04842828	chr21:34696676	IFNAR1	0.48	5.08	0.38	1.1e-6	Narcolepsy;
PAAD	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.63	-5.48	-0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs9333029	0.524	rs1126743	chr1:47395973	G/A	cg08644498	chr1:46502608	NA	-0.47	-4.36	-0.33	2.41e-5	Blood metabolite levels;
PAAD	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07741184	chr6:167504864	NA	-0.36	-4.76	-0.36	4.48e-6	Primary biliary cholangitis;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.74	0.42	4.89e-8	Lung cancer;
PAAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.7	-0.36	5.69e-6	Endometrial cancer;
PAAD	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg03948781	chr1:205179583	DSTYK	0.49	4.53	0.34	1.2e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15926342	chr5:171881757	SH3PXD2B	0.64	7.46	0.52	6.15e-12	Monocyte percentage of white cells;
PAAD	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.42	4.37	0.33	2.28e-5	Menopause (age at onset);
PAAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.7	5.29	0.39	4.27e-7	Fat distribution (HIV);
PAAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.57	7.44	0.52	6.96e-12	Schizophrenia;
PAAD	cis	rs3112530	0.901	rs304863	chr5:152719988	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.56	-4.55	-0.35	1.11e-5	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.98	0.44	1.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.56	5.55	0.41	1.26e-7	Cognitive function;
PAAD	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02357389	chr12:82752162	CCDC59;C12orf26	0.7	6.36	0.46	2.22e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20893717	chr7:100318190	EPO	-0.46	-4.34	-0.33	2.64e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.45	0.4	1.99e-7	Lung cancer;
PAAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.41	0.4	2.43e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs773506	0.628	rs4743820	chr9:93928416	C/T	cg14446406	chr9:93919335	NA	-0.41	-5.52	-0.41	1.42e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs7932354	0.583	rs7934421	chr11:46852753	T/A	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9039	0.513	rs9937906	chr16:9203871	A/G	cg08831531	chr16:9218945	NA	-0.45	-5.22	-0.39	5.71e-7	Menopause (age at onset);
PAAD	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg07777115	chr5:623756	CEP72	-0.52	-4.52	-0.34	1.23e-5	Cystic fibrosis severity;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.49	-6.05	-0.44	1.08e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg25686905	chr3:183603175	PARL	-0.32	-4.26	-0.33	3.52e-5	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.53	6.18	0.45	5.51e-9	Skin aging (microtopography measurement);
PAAD	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg13332499	chr17:408570	NA	0.57	6.16	0.45	6.12e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg02398342	chr17:80708632	TBCD;FN3K	0.71	5.07	0.38	1.15e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs2061333	0.557	rs10420143	chr19:44608082	A/G	cg20607764	chr19:44506953	ZNF230	-0.73	-4.84	-0.37	3.21e-6	Alzheimer's disease;
PAAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	8.71	0.58	4.76e-15	Systolic blood pressure;
PAAD	cis	rs13242816	0.881	rs12672038	chr7:116187106	G/A	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs17253792	0.511	rs76781598	chr14:55998379	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-5.27	-0.39	4.71e-7	Putamen volume;
PAAD	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg03315344	chr16:75512273	CHST6	0.63	5.35	0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.52	5.19	0.39	6.57e-7	Schizophrenia;
PAAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.06	0.38	1.18e-6	Menarche (age at onset);
PAAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.79	-9.14	-0.6	3.76e-16	DNA methylation (variation);
PAAD	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.72	7.09	0.5	4.82e-11	Neuroticism;
PAAD	cis	rs9810890	1.000	rs73198815	chr3:128473832	C/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs2180233	0.683	rs6659140	chr1:30676063	T/G	cg06703062	chr1:31191648	MATN1	-0.5	-4.46	-0.34	1.55e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs868036	0.681	rs745213	chr15:68060389	T/G	cg08079166	chr15:68083412	MAP2K5	-0.61	-4.51	-0.34	1.27e-5	Restless legs syndrome;
PAAD	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg20333904	chr2:240724165	NA	-0.41	-4.5	-0.34	1.33e-5	Obesity-related traits;
PAAD	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.92	-0.63	3.35e-18	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs375066	0.935	rs429027	chr19:44395489	G/A	cg21496419	chr19:44306685	LYPD5	0.44	5.27	0.39	4.69e-7	Breast cancer;
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.59	6.42	0.46	1.65e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg23283495	chr1:209979779	IRF6	0.66	6.4	0.46	1.78e-9	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	trans	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs688181	0.568	rs661983	chr6:158100698	T/C	cg17310882	chr6:158066609	ZDHHC14	0.35	4.29	0.33	3.11e-5	Platelet distribution width;
PAAD	cis	rs4740619	0.647	rs4741545	chr9:15830506	T/G	cg14451791	chr9:16040625	NA	-0.38	-4.49	-0.34	1.41e-5	Body mass index;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg04539111	chr16:67997858	SLC12A4	-0.58	-4.26	-0.33	3.63e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8181588	1.000	rs8181588	chr11:2831541	A/G	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	0.73	5.49	0.41	1.67e-7	Type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg21775007	chr8:11205619	TDH	0.79	7.84	0.54	7.48e-13	Retinal vascular caliber;
PAAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.68	4.84	0.37	3.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4455778	0.538	rs9642332	chr7:49113177	T/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.66	5.56	0.41	1.18e-7	Pubertal anthropometrics;
PAAD	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.3e-6	Myopia (pathological);
PAAD	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.29	0.51	1.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	6.23	0.45	4.4e-9	Systolic blood pressure;
PAAD	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.92	7.28	0.51	1.72e-11	Iron status biomarkers;
PAAD	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.56	-5.44	-0.4	2.08e-7	Blood protein levels;
PAAD	cis	rs9826463	0.757	rs73240310	chr3:142240459	T/C	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11811982	0.793	rs41270147	chr1:227406908	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.44	4.32	0.33	2.86e-5	Red blood cell count;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19171120	chr6:47682172	GPR115	-0.66	-6.61	-0.47	6.22e-10	Obesity-related traits;
PAAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg06632027	chr4:90757378	SNCA	-0.52	-4.91	-0.37	2.28e-6	Neuroticism;
PAAD	cis	rs9880406	0.876	rs1399712	chr3:126048439	C/T	cg13708016	chr3:126007563	NA	-0.44	-4.36	-0.33	2.34e-5	Macular telangiectasia type 2;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg17541715	chr7:1216824	NA	-0.39	-4.3	-0.33	2.98e-5	Longevity;Endometriosis;
PAAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.59	0.61	2.54e-17	Electrocardiographic conduction measures;
PAAD	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	ch.11.42038R	chr11:967971	AP2A2	0.62	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs2092319	0.649	rs2744771	chr1:26060101	T/C	cg02327719	chr1:26185386	C1orf135	-0.9	-5.11	-0.38	9.67e-7	Nose morphology;
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.75	-11.92	-0.69	1.55e-23	Body mass index;
PAAD	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.73	-9.56	-0.61	3.04e-17	Breast cancer;
PAAD	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.81	9.41	0.61	7.59e-17	Breast cancer;
PAAD	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg02118564	chr11:1241341	NA	0.3	4.36	0.33	2.35e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs11230563	0.501	rs599856	chr11:60818176	G/A	cg10158843	chr11:60776172	CD6	-0.47	-4.56	-0.35	1.05e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.45	5.66	0.42	7.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7809615	0.901	rs10273424	chr7:99196073	T/A	cg12290671	chr7:99195819	NA	-0.93	-5.26	-0.39	4.91e-7	Blood metabolite ratios;
PAAD	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.01	0.44	1.34e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.16	16.62	0.8	5.11e-36	Cognitive function;
PAAD	cis	rs35955747	1.000	rs35955747	chr22:31813058	A/T	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.51	-0.34	1.27e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.1	-0.44	8.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.92	5.81	0.43	3.49e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.52	-4.77	-0.36	4.22e-6	Liver enzyme levels;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs10943724	0.704	rs2874882	chr6:81270576	T/A	cg19323245	chr6:80716898	TTK	-0.42	-4.49	-0.34	1.38e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg27211696	chr2:191398769	TMEM194B	0.46	4.53	0.35	1.17e-5	Urinary metabolites;
PAAD	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg23283495	chr1:209979779	IRF6	-0.63	-6.01	-0.44	1.33e-8	Coronary artery disease;
PAAD	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.93	-6.15	-0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg11494123	chr11:66726233	PC	0.63	7.16	0.5	3.15e-11	Smoking initiation;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg04777881	chr12:27677019	PPFIBP1	-0.6	-6.84	-0.49	1.83e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.41	4.36	0.33	2.37e-5	QRS complex (12-leadsum);
PAAD	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.45	-7.14	-0.5	3.65e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	1.23	15.54	0.78	3.4e-33	Ewing sarcoma;
PAAD	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg21433313	chr16:3507492	NAT15	0.92	7.46	0.52	6.22e-12	Tuberculosis;
PAAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.58	-6.06	-0.44	1.01e-8	Cognitive function;
PAAD	cis	rs1334894	1.000	rs12527329	chr6:35610751	A/T	cg07213720	chr6:35227408	ZNF76	-0.89	-4.85	-0.37	3.01e-6	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455826	0.544	rs2470517	chr3:15759360	T/A	cg13420985	chr3:16524424	RFTN1	-0.45	-4.3	-0.33	3.05e-5	Inflammatory skin disease;
PAAD	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-4.43	-0.34	1.76e-5	Diastolic blood pressure;
PAAD	cis	rs10821973	0.527	rs7092870	chr10:63971272	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-4.27	-0.33	3.4e-5	Hypothyroidism;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11825064	0.562	rs77914414	chr11:134513571	G/A	cg02089395	chr11:134479357	NA	-0.91	-5.89	-0.43	2.35e-8	Seasonality;
PAAD	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.58	0.41	1.09e-7	Alcohol dependence;
PAAD	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-9.01	-0.59	8.11e-16	Heart rate;
PAAD	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.53	4.82	0.36	3.5e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs216026	0.638	rs12312322	chr12:2771806	A/G	cg19945202	chr12:2788847	CACNA1C	-0.63	-4.89	-0.37	2.49e-6	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.4	4.8	0.36	3.7e-6	Intraocular pressure;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.76	5.46	0.4	1.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.51	-5.17	-0.39	7.41e-7	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg26384229	chr12:38710491	ALG10B	0.71	7.26	0.51	1.83e-11	Morning vs. evening chronotype;
PAAD	cis	rs4409675	0.913	rs4908375	chr1:28251898	T/A	cg23691781	chr1:28212827	C1orf38	-0.41	-4.94	-0.37	2.08e-6	Corneal astigmatism;
PAAD	cis	rs7771547	0.642	rs1003250	chr6:36437412	A/G	cg07856975	chr6:36356162	ETV7	-0.5	-5.75	-0.42	4.72e-8	Platelet distribution width;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.68	-5.57	-0.41	1.11e-7	Resting heart rate;
PAAD	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg11214544	chr1:2391121	NA	-0.85	-8.99	-0.59	9.24e-16	Non-obstructive azoospermia;
PAAD	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-6.01	-0.44	1.3e-8	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs17169635	0.579	rs10954474	chr7:134567368	G/A	cg02516134	chr7:134575187	CALD1	-0.45	-4.33	-0.33	2.74e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	trans	rs9409082	0.715	rs34571426	chr9:108956449	T/A	cg07010948	chr13:79181613	NA	-0.34	-6.46	-0.46	1.34e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.8	6.1	0.44	8.61e-9	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06079273	chr8:97247865	UQCRB	0.62	6.97	0.49	9e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6032067	0.538	rs6017489	chr20:43731932	C/T	cg10761708	chr20:43804764	PI3	0.5	4.26	0.33	3.61e-5	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06975592	chr1:165796857	UCK2	0.62	7.32	0.51	1.36e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.53	4.94	0.37	2.07e-6	Red blood cell count;
PAAD	cis	rs2882667	0.690	rs288010	chr5:138200029	A/C	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg10820045	chr2:198174542	NA	-0.5	-5.13	-0.38	8.64e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.86	0.43	2.75e-8	Prudent dietary pattern;
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.51	4.52	0.34	1.25e-5	Lung cancer;
PAAD	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-8.05	-0.55	2.18e-13	Systemic lupus erythematosus;
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.68	-6.63	-0.47	5.43e-10	Blood metabolite levels;
PAAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.87	9.26	0.6	1.84e-16	Cognitive function;
PAAD	cis	rs282587	0.542	rs282565	chr13:113373490	C/T	cg02820901	chr13:113351484	ATP11A	0.65	4.73	0.36	5.11e-6	Glycated hemoglobin levels;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13047869	chr3:10149882	C3orf24	0.89	7.32	0.51	1.34e-11	Alzheimer's disease;
PAAD	trans	rs9345521	1.000	rs12530332	chr6:65506838	G/A	cg26414000	chr1:85721327	C1orf52	0.52	6.35	0.46	2.39e-9	Iris color (a* coordinate);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26389465	chr11:112097071	PTS	-0.7	-6.41	-0.46	1.73e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7219021	1.000	rs11657371	chr17:46843873	T/C	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.78	6.34	0.46	2.53e-9	Monocyte percentage of white cells;
PAAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs490234	0.841	rs829311	chr9:128394623	C/T	cg14078157	chr9:128172775	NA	-0.43	-4.8	-0.36	3.83e-6	Mean arterial pressure;
PAAD	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.71	4.79	0.36	3.87e-6	Major depressive disorder;
PAAD	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg08099141	chr12:7053170	C12orf57	0.44	4.49	0.34	1.41e-5	IgG glycosylation;
PAAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	6.3	0.46	3.06e-9	Mood instability;
PAAD	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg25233709	chr10:116636983	FAM160B1	0.42	5.33	0.4	3.51e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.54	-4.75	-0.36	4.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.37	0.51	1.04e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.61	-4.47	-0.34	1.49e-5	Prostate cancer;
PAAD	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.58	-6.16	-0.45	6.34e-9	Mean corpuscular volume;
PAAD	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg01620082	chr3:125678407	NA	-1.61	-9.7	-0.62	1.29e-17	Urinary tract infection frequency;
PAAD	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs4740619	0.617	rs7873925	chr9:16027483	C/T	cg14451791	chr9:16040625	NA	-0.46	-5.27	-0.39	4.68e-7	Body mass index;
PAAD	cis	rs11892454	0.515	rs10185886	chr2:26077947	G/T	cg03373490	chr2:26702396	OTOF	-0.5	-4.32	-0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.65	4.58	0.35	9.59e-6	Platelet count;
PAAD	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.99	-0.49	8.18e-11	Hip circumference;
PAAD	cis	rs3136441	1.000	rs4076557	chr11:46764649	C/T	cg19486271	chr11:47235900	DDB2	0.64	4.88	0.37	2.69e-6	HDL cholesterol;
PAAD	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg22482690	chr17:47019901	SNF8	0.5	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg03808351	chr9:123631620	PHF19	0.46	5.01	0.38	1.51e-6	Rheumatoid arthritis;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg16590910	chr6:42928470	GNMT	0.5	5.09	0.38	1.06e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21862992	chr11:68658383	NA	0.41	4.66	0.35	7e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03576123	chr11:487126	PTDSS2	-1.2	-6.04	-0.44	1.15e-8	Body mass index;
PAAD	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-10.04	-0.63	1.68e-18	Response to antipsychotic treatment;
PAAD	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg15128208	chr22:42549153	NA	0.49	4.49	0.34	1.41e-5	Birth weight;
PAAD	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-0.94	-4.62	-0.35	8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	1.07	8.37	0.56	3.59e-14	Inflammatory bowel disease;
PAAD	cis	rs9463078	0.715	rs7738526	chr6:45168417	C/A	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.85	8.85	0.58	2.05e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.09	-0.59	4.97e-16	Prostate cancer;
PAAD	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.57	-6.17	-0.45	5.83e-9	Pelvic organ prolapse;
PAAD	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10647644	chr5:118788352	HSD17B4	0.7	7.7	0.53	1.63e-12	Myopia (pathological);
PAAD	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg22134325	chr11:66188745	NPAS4	0.41	5.2	0.39	6.26e-7	Airway imaging phenotypes;
PAAD	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.68	-7.48	-0.52	5.51e-12	Cotinine glucuronidation;
PAAD	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.36	-0.51	1.05e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.56	-4.85	-0.37	3.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8112211	0.681	rs59898212	chr19:38826656	G/C	cg14299480	chr19:38876666	GGN	-0.58	-7.3	-0.51	1.46e-11	Blood protein levels;
PAAD	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	6.06	0.44	1.01e-8	Body mass index;
PAAD	cis	rs6604026	0.656	rs17380908	chr1:93402551	C/T	cg13858687	chr1:93297071	RPL5	0.48	4.27	0.33	3.47e-5	Multiple sclerosis;
PAAD	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg19792802	chr11:65647270	CTSW	0.45	5.74	0.42	4.87e-8	Inflammatory bowel disease;
PAAD	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	1.01	8.16	0.55	1.21e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs2131877	0.830	rs1874104	chr3:194845226	A/C	cg16306870	chr3:194868790	C3orf21	-0.51	-5.03	-0.38	1.35e-6	Non-small cell lung cancer;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.94	12.58	0.71	2.51e-25	Menarche (age at onset);
PAAD	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.98	10.26	0.64	4.4e-19	Post bronchodilator FEV1;
PAAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.65	0.35	7.18e-6	Blood metabolite levels;
PAAD	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs2744375	0.600	rs2744374	chr6:7554609	A/C	cg27023638	chr6:7288726	SSR1	0.4	4.3	0.33	3.03e-5	Resting heart rate;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.52	-5.63	-0.42	8.35e-8	Life satisfaction;
PAAD	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.67	-5.96	-0.44	1.7e-8	Mean corpuscular volume;
PAAD	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg06883089	chr1:45254480	BEST4	-0.34	-4.26	-0.33	3.61e-5	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1697938	0.590	rs1901165	chr5:40950576	G/A	cg17351974	chr5:40835760	RPL37	0.41	4.26	0.33	3.52e-5	Multiple system atrophy;
PAAD	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.67	-5.25	-0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.59	5.92	0.43	2.02e-8	Systolic blood pressure;
PAAD	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.88	-0.54	5.81e-13	Neuroticism;
PAAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-4.28	-0.33	3.35e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs12773263	chr10:45984346	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs425535	0.757	rs13117734	chr4:74787503	T/C	cg01447579	chr4:74847100	PF4	0.62	4.26	0.33	3.63e-5	Blood protein levels;
PAAD	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs6191	0.901	rs33383	chr5:142709986	C/T	cg08845721	chr5:142780693	NR3C1	-0.4	-4.41	-0.34	1.93e-5	Night sleep phenotypes;
PAAD	cis	rs4722404	0.560	rs6975818	chr7:3115520	C/G	cg19214707	chr7:3157722	NA	-0.5	-4.71	-0.36	5.43e-6	Atopic dermatitis;
PAAD	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.5	-4.63	-0.35	7.73e-6	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Bladder cancer;
PAAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.42	0.56	2.63e-14	Alzheimer's disease;
PAAD	cis	rs3087591	0.659	rs8065496	chr17:29720140	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	4.36	0.33	2.37e-5	Hip circumference;
PAAD	cis	rs4450131	0.522	rs3781463	chr10:126337190	C/T	cg20435097	chr10:126320824	FAM53B	0.5	5.02	0.38	1.44e-6	White blood cell count (basophil);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12100965	chr1:1623803	CDK11B;LOC728661	-0.61	-6.67	-0.48	4.36e-10	Smoking initiation;
PAAD	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg09366796	chr5:75012313	C5orf37	0.5	4.52	0.34	1.23e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.78	7.09	0.5	4.78e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs757081	0.648	rs12276859	chr11:17276965	C/T	cg04705435	chr11:17411270	KCNJ11	-0.54	-5.38	-0.4	2.81e-7	Systolic blood pressure;
PAAD	cis	rs4740619	0.618	rs10738421	chr9:15975380	T/A	cg14451791	chr9:16040625	NA	-0.39	-4.52	-0.34	1.23e-5	Body mass index;
PAAD	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.44	4.46	0.34	1.59e-5	Age of smoking initiation;
PAAD	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1075265	0.568	rs3095756	chr2:54049469	G/A	cg04546899	chr2:54196757	PSME4	0.3	4.4	0.34	1.99e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.74	-0.36	4.77e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs17824933	0.943	rs11230566	chr11:60780007	G/A	cg16817237	chr11:60793675	NA	0.53	6.32	0.46	2.76e-9	Multiple sclerosis;
PAAD	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg04181038	chr4:183730758	NA	0.5	4.57	0.35	9.89e-6	Pediatric autoimmune diseases;
PAAD	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg19197139	chr17:4613644	ARRB2	0.84	8.69	0.58	5.49e-15	Lymphocyte counts;
PAAD	trans	rs12545912	0.866	rs4626604	chr8:9588112	T/G	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs12127679	0.614	rs76810521	chr1:244172513	C/A	cg03519879	chr14:74227499	C14orf43	0.87	6.65	0.47	4.99e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11892454	0.515	rs10208202	chr2:26053576	T/C	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.62	6.08	0.44	9.32e-9	Refractive astigmatism;
PAAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs3026101	0.723	rs1806247	chr17:5310409	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.41	-0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	0.78	5.28	0.39	4.36e-7	Body mass index;
PAAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.62	-7.16	-0.5	3.18e-11	Huntington's disease progression;
PAAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.68	0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01283332	chr5:1856932	NA	-0.47	-4.96	-0.37	1.83e-6	Cardiovascular disease risk factors;
PAAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.27e-5	Renal cell carcinoma;
PAAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg26497354	chr6:109612229	NA	-0.39	-4.29	-0.33	3.1e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.77	6.61	0.47	6.09e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs4908768	0.501	rs6702060	chr1:8607024	G/A	cg20416874	chr1:8611966	RERE	-0.46	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg17105886	chr17:28927953	LRRC37B2	0.76	4.86	0.37	2.95e-6	Body mass index;
PAAD	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.51	-5.43	-0.4	2.16e-7	Motion sickness;
PAAD	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.87	10.83	0.66	1.31e-20	Lung cancer;
PAAD	cis	rs17539620	0.808	rs6904264	chr6:154878380	C/G	cg20019720	chr6:154832845	CNKSR3	-0.42	-5.71	-0.42	5.76e-8	Lipoprotein (a) levels;
PAAD	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.7	-6.68	-0.48	4.17e-10	Schizophrenia;
PAAD	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg22349387	chr12:9600060	DDX12	-0.41	-4.53	-0.34	1.2e-5	Breast size;
PAAD	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg16691251	chr5:66510806	NA	0.73	7.8	0.53	9.41e-13	Breast cancer;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.68	-8.55	-0.57	1.26e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11235843	0.929	rs68128239	chr11:73420592	G/A	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg11380483	chr2:127933992	NA	-0.5	-5.17	-0.39	7.11e-7	Self-rated health;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14028892	chr1:184943191	FAM129A	-0.73	-6.63	-0.47	5.6e-10	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.59	-0.41	1.03e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.74	-0.36	4.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg14792160	chr1:152758632	LCE1E	-0.37	-4.38	-0.33	2.18e-5	Vitamin D levels;
PAAD	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs4740619	0.630	rs2987024	chr9:15986795	A/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs12304921	0.748	rs17125258	chr12:51445679	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.76	-0.36	4.47e-6	Type 2 diabetes;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg07336987	chr11:625147	MUPCDH	-0.38	-4.73	-0.36	5.13e-6	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08646051	chr12:26205524	RASSF8	-0.62	-6.67	-0.48	4.48e-10	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.71	0.36	5.46e-6	Bipolar disorder;
PAAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.57	6.85	0.49	1.71e-10	Diastolic blood pressure;
PAAD	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg05083358	chr7:2394359	EIF3B	-0.71	-5.31	-0.4	3.75e-7	Multiple sclerosis;
PAAD	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	4.74	0.36	4.8e-6	Lung cancer;
PAAD	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.83	9.4	0.61	7.77e-17	Total body bone mineral density;
PAAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.63	4.69	0.36	5.98e-6	Fat distribution (HIV);
PAAD	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.59	6.89	0.49	1.39e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg05627522	chr15:75251581	NA	-0.39	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs11997175	0.625	rs7460540	chr8:33597907	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	6.39	0.46	1.9e-9	Body mass index;
PAAD	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.34	-0.33	2.55e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg19500098	chr13:21900506	NA	0.57	5.98	0.44	1.53e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.89	11.58	0.68	1.21e-22	Body mass index;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs71636778	0.524	rs78614739	chr1:27174180	C/T	cg12203394	chr1:27248618	NUDC	0.63	4.55	0.35	1.08e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26151477	chr10:81181818	ZCCHC24	0.48	4.84	0.37	3.2e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.83	8.88	0.58	1.75e-15	Tuberculosis;
PAAD	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.4	-4.4	-0.34	2.05e-5	Mean arterial pressure;
PAAD	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg19734201	chr4:39699603	UBE2K	-0.46	-5.07	-0.38	1.13e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.97	11.58	0.68	1.27e-22	Breast cancer;
PAAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg23109721	chr2:106886537	NA	-0.71	-6.39	-0.46	1.93e-9	Facial morphology (factor 23);
PAAD	cis	rs28489187	0.706	rs233095	chr1:85824816	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs8040855	0.826	rs6496771	chr15:85705328	A/G	cg08123816	chr15:85640762	PDE8A	0.38	4.35	0.33	2.48e-5	Bulimia nervosa;
PAAD	cis	rs959260	1.000	rs9909076	chr17:73384809	G/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs7646881	0.812	rs75267618	chr3:158443816	T/C	cg19483011	chr3:158453295	NA	-0.68	-5.73	-0.42	5.13e-8	Tetralogy of Fallot;
PAAD	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-4.32	-0.33	2.84e-5	Eosinophil percentage of white cells;
PAAD	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.15	8.29	0.56	5.54e-14	Lymphocyte counts;
PAAD	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.76	8.94	0.59	1.23e-15	Eosinophil percentage of white cells;
PAAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg16205897	chr5:131564050	P4HA2	-0.51	-5.58	-0.41	1.05e-7	Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.1	-0.38	9.86e-7	Monocyte count;
PAAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.55	6.02	0.44	1.27e-8	Major depressive disorder;
PAAD	cis	rs863345	0.604	rs4313395	chr1:158505135	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg18084798	chr19:33555255	RHPN2	-0.46	-4.73	-0.36	5.14e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-11.57	-0.68	1.33e-22	Height;
PAAD	cis	rs4417704	0.526	rs4130554	chr2:241881642	G/A	cg26818257	chr2:241905806	NA	0.47	4.63	0.35	7.76e-6	Joint mobility (Beighton score);
PAAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg03037974	chr15:76606532	NA	0.38	4.33	0.33	2.68e-5	Blood metabolite levels;
PAAD	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.4	-0.34	1.99e-5	Height;
PAAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.54	-4.85	-0.37	3.07e-6	Schizophrenia;
PAAD	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	7.76	0.53	1.18e-12	Multiple sclerosis;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg09579323	chr1:150459698	TARS2	-0.45	-4.25	-0.33	3.67e-5	Migraine;
PAAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.53	-6.1	-0.44	8.58e-9	Systemic lupus erythematosus;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.24e-17	Lymphocyte counts;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26549601	chr10:134560360	INPP5A	-0.49	-4.74	-0.36	4.93e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05134232	chr1:109968980	PSMA5	-0.63	-6.38	-0.46	1.98e-9	Smoking initiation;
PAAD	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.35	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg06217245	chr20:33103252	DYNLRB1	0.42	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg08898775	chr15:59042684	ADAM10	0.41	5.36	0.4	3.07e-7	Asperger disorder;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg06771106	chr2:113671356	IL1F7	-0.57	-5.73	-0.42	5.11e-8	Pulmonary function;
PAAD	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.51	-5.2	-0.39	6.42e-7	Menarche (age at onset);
PAAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.46	4.36	0.33	2.37e-5	Coronary artery disease;
PAAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.6	-6.18	-0.45	5.71e-9	Tonsillectomy;
PAAD	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-1.25	-9.28	-0.6	1.63e-16	Blood pressure (smoking interaction);
PAAD	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs11807834	0.522	rs11122314	chr1:230236011	C/T	cg00566187	chr1:230250356	GALNT2	-0.61	-6.49	-0.47	1.13e-9	Schizophrenia;
PAAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg20503657	chr10:835505	NA	0.43	4.51	0.34	1.29e-5	Survival in rectal cancer;
PAAD	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.83	-8.47	-0.57	1.93e-14	Educational attainment;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.69	-5.37	-0.4	2.86e-7	Initial pursuit acceleration;
PAAD	cis	rs62264129	0.500	rs11923402	chr3:112050148	G/T	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.76e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00166722	chr3:10149974	C3orf24	0.9	6.74	0.48	3.04e-10	Alzheimer's disease;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg24846343	chr22:24311635	DDTL	0.57	5.51	0.41	1.5e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01283332	chr5:1856932	NA	-0.45	-4.75	-0.36	4.61e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.69	10.49	0.65	1.07e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.63	6.31	0.46	2.93e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.96	8.4	0.56	2.99e-14	Alzheimer's disease;
PAAD	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg03999872	chr20:62272968	STMN3	0.67	5.74	0.42	4.99e-8	Atopic dermatitis;
PAAD	cis	rs7671266	0.532	rs7349721	chr4:10042562	A/T	cg00071950	chr4:10020882	SLC2A9	0.56	5.05	0.38	1.27e-6	Cardiovascular disease risk factors;
PAAD	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	5.46	0.4	1.9e-7	Caffeine consumption;
PAAD	cis	rs251130	0.872	rs152220	chr5:110853126	A/C	cg11925263	chr5:110849104	STARD4	0.37	4.58	0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs4722404	0.592	rs6461820	chr7:3118246	T/C	cg19214707	chr7:3157722	NA	-0.5	-4.77	-0.36	4.31e-6	Atopic dermatitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09644451	chr10:103578372	MGEA5	-0.77	-6.75	-0.48	2.86e-10	Neuroticism;
PAAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.67	-0.42	7.03e-8	Tonsillectomy;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.83	0.62	5.96e-18	Prudent dietary pattern;
PAAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	8.26	0.56	6.55e-14	Bone mineral density;
PAAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg27539214	chr16:67997921	SLC12A4	-0.69	-5.51	-0.41	1.5e-7	HDL cholesterol;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg15117754	chr3:10150083	C3orf24	0.8	7.0	0.49	7.76e-11	Alzheimer's disease;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.47	-0.34	1.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-1.24	-9.14	-0.6	3.67e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.52	-4.97	-0.37	1.76e-6	Daytime sleep phenotypes;
PAAD	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.4	0.34	2e-5	Neuroticism;
PAAD	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.51	5.1	0.38	9.84e-7	Interleukin-18 levels;
PAAD	cis	rs7582720	0.945	rs72932707	chr2:203639395	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.05	7.3	0.51	1.52e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs59104589	0.617	rs62186409	chr2:242235710	C/A	cg04488487	chr2:242709673	NA	0.58	4.43	0.34	1.81e-5	Fibrinogen levels;
PAAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.72	-8.11	-0.55	1.61e-13	Schizophrenia;
PAAD	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.81	-11.5	-0.68	2.03e-22	Colorectal cancer;
PAAD	cis	rs3753841	0.801	rs2376259	chr1:103318973	T/G	cg24495344	chr1:103574097	COL11A1	0.39	4.49	0.34	1.39e-5	Glaucoma (primary angle closure);
PAAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg16680214	chr1:154839983	KCNN3	0.4	4.61	0.35	8.35e-6	Schizophrenia;
PAAD	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg06392426	chr19:10676186	KRI1	0.6	5.24	0.39	5.24e-7	Red cell distribution width;
PAAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.9	10.11	0.63	1.07e-18	Total cholesterol levels;
PAAD	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-5.43	-0.4	2.18e-7	Mood instability;
PAAD	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.9	4.89	0.37	2.56e-6	Childhood ear infection;
PAAD	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg01759136	chr6:27242945	NA	-0.4	-4.36	-0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg23024343	chr7:107201750	COG5	0.57	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.6	6.43	0.46	1.56e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.84	-5.83	-0.43	3.27e-8	Night sleep phenotypes;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.88	11.39	0.68	4.04e-22	Menarche (age at onset);
PAAD	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.76	7.87	0.54	6.18e-13	Breast cancer;
PAAD	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.53	-5.2	-0.39	6.46e-7	Mortality in heart failure;
PAAD	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23018091	chr1:32758168	HDAC1	-0.72	-7.32	-0.51	1.36e-11	Lung cancer in ever smokers;
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.7	6.94	0.49	1.04e-10	Prostate cancer;
PAAD	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01373369	chr2:27600323	ZNF513	0.66	8.22	0.55	8.13e-14	Smoking initiation;
PAAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.85	0.43	2.92e-8	Menopause (age at onset);
PAAD	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.69	-4.91	-0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg12432903	chr7:1882776	MAD1L1	0.65	4.25	0.33	3.72e-5	Bipolar disorder;
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.59	6.01	0.44	1.3e-8	Motion sickness;
PAAD	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg05585544	chr11:47624801	NA	-0.48	-5.36	-0.4	3.06e-7	Subjective well-being;
PAAD	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.45	4.26	0.33	3.53e-5	Schizophrenia;
PAAD	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.93e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1018697	1.000	rs2150928	chr10:104550985	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.81e-5	Colorectal adenoma (advanced);
PAAD	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs78472555	0.865	rs12185079	chr15:100271253	C/T	cg18869061	chr15:100272053	LYSMD4	-0.75	-5.84	-0.43	3.03e-8	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.6	0.47	6.45e-10	Schizophrenia;
PAAD	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.96	14.21	0.76	1.08e-29	Dental caries;
PAAD	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs4918918	0.868	rs4918916	chr10:97118537	C/T	cg03417182	chr10:97121241	SORBS1	-0.46	-4.25	-0.33	3.75e-5	Suicide risk;
PAAD	cis	rs528301	0.766	rs473098	chr2:45139779	C/T	cg15393275	chr2:45165193	NA	-0.49	-5.39	-0.4	2.6e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.93	6.87	0.49	1.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.65	6.98	0.49	8.55e-11	Morning vs. evening chronotype;
PAAD	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.43	4.48	0.34	1.43e-5	Menopause (age at onset);
PAAD	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.46	-0.52	6.31e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6964492	0.576	rs13240724	chr7:134418136	T/C	cg22430036	chr7:134592620	CALD1	-0.49	-4.5	-0.34	1.36e-5	Tonsillectomy;
PAAD	cis	rs7873102	0.654	rs7038759	chr9:37958729	T/C	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	7.96e-8	Brain structure;
PAAD	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-6.11	-0.44	7.82e-9	Hypospadias;
PAAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg01320130	chr1:67600311	NA	-0.53	-5.86	-0.43	2.78e-8	Psoriasis;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	5.98	0.44	1.5e-8	Platelet count;
PAAD	cis	rs10915437	0.515	rs4408122	chr1:4197418	A/G	cg27165836	chr1:4193882	NA	-0.47	-4.74	-0.36	4.82e-6	Migraine - clinic-based;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11955175	1.000	rs2228058	chr5:40681254	C/T	cg17351974	chr5:40835760	RPL37	0.77	4.52	0.34	1.23e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg20295408	chr7:1910781	MAD1L1	0.62	6.24	0.45	4.18e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2073300	1.000	rs6114135	chr20:23456746	C/A	cg12062639	chr20:23401060	NAPB	0.87	4.84	0.37	3.15e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9395066	0.545	rs3799977	chr6:44837356	G/T	cg25276700	chr6:44698697	NA	-0.48	-5.59	-0.41	1.01e-7	Height;
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg05697835	chr1:2722811	NA	0.4	4.5	0.34	1.32e-5	Multiple sclerosis;
PAAD	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11690462	0.591	rs6546910	chr2:26544524	C/G	cg13255216	chr2:26625047	C2orf39	0.43	4.35	0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg12384639	chr17:618140	VPS53	0.49	4.39	0.34	2.16e-5	Prostate cancer;
PAAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg02635607	chr3:119396309	COX17	0.79	6.36	0.46	2.23e-9	Morning vs. evening chronotype;
PAAD	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.52	-4.8	-0.36	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg07089783	chr10:31607955	ZEB1;LOC220930	0.67	7.03	0.5	6.5500000000000006e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.54	4.88	0.37	2.62e-6	Type 2 diabetes;
PAAD	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.15	0.39	8e-7	HIV-1 control;
PAAD	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.53	5.34	0.4	3.28e-7	Resting heart rate;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs375066	0.868	rs370190	chr19:44424254	A/T	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.72	7.54	0.52	3.87e-12	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.83	-8.88	-0.58	1.75e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.76	0.36	4.56e-6	Bipolar disorder;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.51	4.54	0.35	1.13e-5	Testicular germ cell tumor;
PAAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	5.08	0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs56046484	0.956	rs35204319	chr15:85650477	C/T	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg07061783	chr6:25882402	NA	0.69	6.98	0.49	8.44e-11	Blood metabolite levels;
PAAD	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg13647721	chr17:30228624	UTP6	-0.65	-4.58	-0.35	9.55e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.962	rs2272088	chr3:52456973	A/G	cg17372223	chr3:52568218	NT5DC2	0.47	4.28	0.33	3.23e-5	Bipolar disorder;
PAAD	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.65	-5.68	-0.42	6.81e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.76	-8.58	-0.57	1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8005172	0.750	rs12878241	chr14:88489630	A/G	cg18078958	chr14:88630771	NA	0.5	5.89	0.43	2.34e-8	Parkinson's disease;
PAAD	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs89107	0.576	rs117344633	chr6:118837268	T/C	cg21191810	chr6:118973309	C6orf204	0.39	4.55	0.35	1.08e-5	Cardiac structure and function;
PAAD	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.63	4.57	0.35	9.99e-6	Neutrophil percentage of white cells;
PAAD	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.66	5.76	0.42	4.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg18850127	chr7:39170497	POU6F2	0.54	7.16	0.5	3.31e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs288342	0.832	rs288299	chr2:183657289	C/T	cg02625481	chr2:183667124	NA	-0.47	-4.85	-0.37	3.06e-6	Recurrent major depressive disorder;
PAAD	cis	rs113779084	0.632	rs2355756	chr7:11937215	A/T	cg15090509	chr7:11872073	THSD7A	-0.37	-4.66	-0.35	6.86e-6	Educational attainment (years of education);
PAAD	trans	rs6991952	0.663	rs4416827	chr8:25731580	A/G	cg22376929	chr19:2478127	GADD45B	0.55	6.31	0.46	2.89e-9	Inguinal hernia;
PAAD	cis	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-4.51	-0.34	1.28e-5	Systemic lupus erythematosus;
PAAD	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	1.11	12.19	0.7	2.89e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg27182935	chr16:89790473	ZNF276	-0.69	-4.37	-0.33	2.28e-5	Skin colour saturation;
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg19744528	chr7:157553346	PTPRN2	0.39	4.25	0.33	3.78e-5	Body mass index;
PAAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-1.05	-13.7	-0.74	2.56e-28	Headache;
PAAD	cis	rs597480	0.864	rs493078	chr11:85483310	T/C	cg11817631	chr11:85522609	SYTL2	-0.45	-4.31	-0.33	2.92e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs7714584	1.000	rs4560537	chr5:150262586	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.63	-0.42	8.39e-8	Iron status biomarkers;
PAAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.97	10.38	0.64	2.1e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.63	-0.47	5.49e-10	Mood instability;
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg03094675	chr11:5960213	NA	-0.47	-4.39	-0.34	2.1e-5	DNA methylation (variation);
PAAD	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.64	5.7	0.42	6.12e-8	Corneal astigmatism;
PAAD	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg18551225	chr6:44695536	NA	-0.68	-6.76	-0.48	2.75e-10	Total body bone mineral density;
PAAD	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg24519413	chr1:26490540	NA	0.51	4.98	0.37	1.69e-6	Height;
PAAD	cis	rs12461016	1	rs12461016	chr19:17161687	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.76	0.36	4.56e-6	Diastolic blood pressure;
PAAD	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.43e-7	Inflammatory bowel disease;
PAAD	cis	rs11811982	0.655	rs11805662	chr1:227238540	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.36	-0.51	1.08e-11	Chronic sinus infection;
PAAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14895029	chr7:2775587	GNA12	-0.48	-4.77	-0.36	4.27e-6	Height;
PAAD	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.87	6.92	0.49	1.21e-10	Type 2 diabetes;
PAAD	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg00228799	chr9:131580591	ENDOG	0.64	6.37	0.46	2.11e-9	Blood metabolite levels;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg01059385	chr22:42394853	WBP2NL	-0.43	-4.64	-0.35	7.47e-6	Cognitive function;
PAAD	cis	rs17407555	0.909	rs60318661	chr4:10245247	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.53	-0.34	1.2e-5	Schizophrenia (age at onset);
PAAD	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg12432526	chr17:79354702	NA	0.44	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.34	-0.33	2.57e-5	Post bronchodilator FEV1;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.55	-5.68	-0.42	6.76e-8	Testicular germ cell tumor;
PAAD	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.62	-7.37	-0.51	1.04e-11	HDL cholesterol;
PAAD	cis	rs1198430	0.925	rs2811975	chr1:23801081	A/T	cg22040403	chr1:23858016	E2F2	0.82	5.07	0.38	1.13e-6	Total cholesterol levels;
PAAD	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg15331088	chr8:600555	NA	0.7	4.57	0.35	1e-5	IgG glycosylation;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg18279126	chr7:2041391	MAD1L1	0.6	6.09	0.44	8.74e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs62408225	1.000	rs2875584	chr6:90950628	C/T	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.48	5.33	0.4	3.56e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs5417	0.775	rs367181	chr17:7160524	A/C	cg25256661	chr17:7137939	DVL2	-0.79	-8.11	-0.55	1.56e-13	Diastolic blood pressure;
PAAD	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg01059385	chr22:42394853	WBP2NL	0.52	4.34	0.33	2.64e-5	Birth weight;
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Electroencephalogram traits;
PAAD	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg19000871	chr14:103996768	TRMT61A	-0.48	-4.98	-0.37	1.74e-6	Reticulocyte count;
PAAD	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg15145965	chr22:50218605	BRD1	-0.53	-4.44	-0.34	1.76e-5	Schizophrenia;
PAAD	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg26695010	chr11:65641043	EFEMP2	-0.64	-5.63	-0.42	8.29e-8	Breast cancer;
PAAD	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.79	-0.53	9.56e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	4.32	0.33	2.8e-5	Height;
PAAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.64	5.08	0.38	1.08e-6	Osteoarthritis;
PAAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-4.32	-0.33	2.78e-5	Total body bone mineral density;
PAAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-5.47	-0.41	1.78e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg00431813	chr7:1051703	C7orf50	0.71	4.76	0.36	4.45e-6	Longevity;Endometriosis;
PAAD	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg05562828	chr17:3906858	NA	0.59	6.26	0.45	3.65e-9	Type 2 diabetes;
PAAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.42	-0.34	1.83e-5	Height;
PAAD	cis	rs11618113	0.634	rs11619620	chr13:111198636	A/G	cg11688093	chr13:111178359	RAB20	-0.77	-4.73	-0.36	5.03e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.6	-0.41	9.68e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.78	0.42	4.03e-8	Eosinophil percentage of white cells;
PAAD	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg19423196	chr10:82049429	MAT1A	0.53	4.94	0.37	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.91	-7.72	-0.53	1.47e-12	Gut microbiome composition (summer);
PAAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg13918804	chr1:2043761	PRKCZ	0.42	5.61	0.41	9.29e-8	Height;
PAAD	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.55	-0.35	1.07e-5	Blood metabolite levels;
PAAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	7.98	0.54	3.35e-13	Parkinson's disease;
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.55	4.96	0.37	1.85e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg09127314	chr1:152161683	NA	-0.68	-4.49	-0.34	1.39e-5	Atopic dermatitis;
PAAD	cis	rs12760731	0.623	rs11584977	chr1:178387283	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.42	0.4	2.24e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.1	10.34	0.64	2.61e-19	Cognitive test performance;
PAAD	cis	rs4130590	1.000	rs4130590	chr9:130107964	C/T	cg13736810	chr9:130213283	LRSAM1;RPL12	-0.54	-4.95	-0.37	1.91e-6	Bipolar disorder;
PAAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.89	9.77	0.62	8.61e-18	Height;
PAAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.91	-0.37	2.33e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs713477	0.524	rs7149317	chr14:55902542	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.26	-0.33	3.55e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg21605333	chr4:119757512	SEC24D	1.44	8.41	0.56	2.8e-14	Cannabis dependence symptom count;
PAAD	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.48	4.46	0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.62	4.94	0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg25837213	chr17:80849375	TBCD	-0.48	-4.37	-0.33	2.29e-5	Breast cancer;
PAAD	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.55e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs11811982	0.793	rs116732179	chr1:227526671	A/G	cg24860534	chr1:227506868	CDC42BPA	0.53	5.09	0.38	1.04e-6	Optic disc area;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg06740227	chr12:86229804	RASSF9	0.6	5.86	0.43	2.72e-8	Major depressive disorder;
PAAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg19640130	chr10:64028056	RTKN2	-0.37	-4.53	-0.34	1.21e-5	Rheumatoid arthritis;
PAAD	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.5	2.47e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.92	-11.05	-0.67	3.36e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg11204139	chr17:3907470	NA	0.61	6.25	0.45	3.87e-9	Type 2 diabetes;
PAAD	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.66	-7.6	-0.52	2.8e-12	Mosquito bite size;
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.56	6.02	0.44	1.24e-8	Fibrinogen levels;
PAAD	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.76	6.16	0.45	6.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg11812906	chr14:75593930	NEK9	-0.45	-4.4	-0.34	2.01e-5	Neuroticism;
PAAD	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.86	6.69	0.48	4e-10	Prostate cancer;
PAAD	cis	rs438465	0.580	rs12174595	chr6:169771178	C/A	cg00289362	chr6:170482788	NA	0.55	4.79	0.36	4e-6	Corneal astigmatism;
PAAD	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg04254540	chr16:71951199	KIAA0174	0.44	4.35	0.33	2.48e-5	Fibrinogen levels;
PAAD	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.75	-9.15	-0.6	3.57e-16	Motion sickness;
PAAD	cis	rs1334894	0.901	rs1977655	chr6:35521702	G/A	cg07213720	chr6:35227408	ZNF76	-0.82	-4.49	-0.34	1.4e-5	Coronary artery disease;
PAAD	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.26	0.45	3.68e-9	Hip circumference;
PAAD	cis	rs72634501	0.540	rs16826036	chr1:39757799	G/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	HDL cholesterol;
PAAD	cis	rs732765	0.734	rs12323899	chr14:75117513	T/C	cg17347104	chr14:75034677	LTBP2	0.64	5.46	0.4	1.9e-7	Non-small cell lung cancer;
PAAD	cis	rs61123157	0.929	rs9372118	chr6:106601355	A/C	cg09187505	chr6:106434429	NA	0.41	4.84	0.37	3.19e-6	Monobrow;Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-5.55	-0.41	1.24e-7	Coronary artery disease;
PAAD	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs8005172	0.628	rs1837849	chr14:88520292	A/T	cg18078958	chr14:88630771	NA	0.35	4.38	0.33	2.18e-5	Parkinson's disease;
PAAD	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg24253500	chr15:84953950	NA	-0.41	-4.42	-0.34	1.89e-5	P wave terminal force;
PAAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.48	-4.4	-0.34	2.03e-5	Monocyte count;
PAAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.29	-0.33	3.11e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.57	-0.57	1.07e-14	Body mass index;
PAAD	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.83	-10.02	-0.63	1.81e-18	Coronary artery disease;
PAAD	cis	rs12913538	0.855	rs11071677	chr15:62896909	T/A	cg09983546	chr15:62884068	NA	0.73	8.13	0.55	1.4e-13	Sleep depth;
PAAD	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.99	6.58	0.47	7.08e-10	Parkinson's disease;
PAAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-4.62	-0.35	8.18e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11779988	0.543	rs379066	chr8:17881835	T/C	cg08627089	chr8:17753878	FGL1	-0.48	-4.5	-0.34	1.32e-5	Breast cancer;
PAAD	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.63	6.41	0.46	1.77e-9	Ease of getting up in the morning;
PAAD	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.69	-0.53	1.74e-12	Coronary artery disease;
PAAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg20744362	chr22:50050164	C22orf34	0.67	8.15	0.55	1.28e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.51	5.24	0.39	5.22e-7	Monocyte count;
PAAD	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.63	-6.63	-0.47	5.59e-10	Body mass index;
PAAD	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.35	4.33	0.33	2.66e-5	Sitting height ratio;
PAAD	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.56	-0.47	8.05e-10	Colorectal cancer;
PAAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.57	5.3	0.39	4.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28655083	0.636	rs1485793	chr16:77101836	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.57	-4.96	-0.37	1.87e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg11783602	chr8:55087084	NA	-0.67	-7.71	-0.53	1.55e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.79	9.05	0.59	6.58e-16	Blood metabolite ratios;
PAAD	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg20805835	chr1:248005719	OR11L1	0.51	4.51	0.34	1.31e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.43	-5.24	-0.39	5.21e-7	Iron status biomarkers;
PAAD	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.38	-0.4	2.8e-7	Mood instability;
PAAD	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg02353165	chr6:42928485	GNMT	-0.57	-4.91	-0.37	2.31e-6	Blood protein levels;
PAAD	cis	rs59918340	0.738	rs3739241	chr8:142221361	C/G	cg23750338	chr8:142222470	SLC45A4	0.58	6.89	0.49	1.4e-10	Immature fraction of reticulocytes;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg21108841	chr4:24914750	CCDC149	-0.54	-4.48	-0.34	1.48e-5	Heschl's gyrus morphology;
PAAD	cis	rs4455778	0.580	rs4467894	chr7:49116541	G/T	cg26309511	chr7:48887640	NA	-0.37	-4.48	-0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg26014466	chr7:809109	HEATR2	0.58	4.45	0.34	1.63e-5	Initial pursuit acceleration;
PAAD	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg02527881	chr3:46936655	PTH1R	0.37	4.31	0.33	2.96e-5	Colorectal cancer;
PAAD	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.62	-5.51	-0.41	1.48e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1355223	0.573	rs1597961	chr11:34727114	A/T	cg11622362	chr11:34938112	PDHX;APIP	0.44	4.44	0.34	1.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg08807892	chr2:162101083	NA	0.71	7.63	0.53	2.35e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg01953289	chr20:60874239	NA	0.7	5.32	0.4	3.65e-7	Obesity-related traits;
PAAD	cis	rs7766436	0.621	rs2294822	chr6:22596815	C/T	cg13666174	chr6:22585274	NA	0.48	5.8	0.43	3.71e-8	Coronary artery disease;
PAAD	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg20243544	chr17:37824526	PNMT	-0.52	-4.52	-0.34	1.22e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg02135003	chr7:105160482	PUS7	-0.7	-5.57	-0.41	1.12e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	14.24	0.76	8.95e-30	Colorectal cancer;
PAAD	cis	rs2229238	0.911	rs11490956	chr1:154487258	G/T	cg21262032	chr1:154437693	IL6R	-0.45	-4.77	-0.36	4.32e-6	Coronary heart disease;
PAAD	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12667521	chr19:29218732	NA	0.66	5.6	0.41	9.65e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs1996152	0.543	rs11650701	chr17:72386274	G/A	cg23221732	chr17:72383708	NA	-0.68	-5.67	-0.42	6.9e-8	Interleukin-12p70 levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17891715	chr19:50529185	VRK3;ZNF473	-0.55	-6.37	-0.46	2.14e-9	Energy expenditure (24h);
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.16	0.39	7.51e-7	Electroencephalogram traits;
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.63	8.14	0.55	1.33e-13	Renal cell carcinoma;
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.58	5.51	0.41	1.5e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs56046484	0.956	rs34919315	chr15:85631906	C/A	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg26174226	chr8:58114915	NA	-0.64	-4.83	-0.36	3.35e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27452451	chr7:56119366	PSPH;CCT6A	0.64	6.29	0.45	3.26e-9	Smoking initiation;
PAAD	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.78	8.13	0.55	1.37e-13	Gout;
PAAD	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.43	4.3	0.33	3.04e-5	Ulcerative colitis;
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.9	0.63	3.89e-18	Smoking behavior;
PAAD	cis	rs3126085	0.560	rs941935	chr1:152339488	A/G	cg26876637	chr1:152193138	HRNR	-0.68	-5.15	-0.39	8.05e-7	Atopic dermatitis;
PAAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-1.0	-12.1	-0.7	5.03e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-4.85	-0.37	3.01e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.74	-7.76	-0.53	1.14e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9409082	0.677	rs2222133	chr9:108917072	T/C	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.48	4.98	0.37	1.71e-6	Testicular germ cell tumor;
PAAD	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-5.99	-0.44	1.49e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg09877947	chr5:131593287	PDLIM4	0.58	5.4	0.4	2.56e-7	Acylcarnitine levels;
PAAD	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.81	8.97	0.59	1.02e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27436995	chr16:743998	FBXL16	-0.37	-4.48	-0.34	1.47e-5	Height;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.28	0.39	4.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs793571	0.744	rs11630265	chr15:59159826	C/T	cg05156742	chr15:59063176	FAM63B	-0.66	-6.19	-0.45	5.37e-9	Schizophrenia;
PAAD	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.38	-5.11	-0.38	9.65e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05927802	chr8:110346885	ENY2;NUDCD1	0.65	6.83	0.48	1.95e-10	Myopia (pathological);
PAAD	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg03517284	chr6:25882590	NA	0.53	5.16	0.39	7.67e-7	Blood metabolite levels;
PAAD	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg23920097	chr1:209922102	NA	-0.44	-4.34	-0.33	2.61e-5	Red blood cell count;
PAAD	cis	rs329674	0.556	rs73028354	chr11:133728578	G/A	cg06766960	chr11:133703094	NA	-0.76	-4.69	-0.36	5.94e-6	Bipolar disorder;
PAAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs2085601	0.542	rs28498689	chr4:89972316	T/C	cg17769793	chr4:89976368	FAM13A	-0.44	-5.5	-0.41	1.6e-7	Hair greying;
PAAD	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.47	6.07	0.44	9.62e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.74	8.67	0.58	5.89e-15	Height;
PAAD	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.86	10.46	0.65	1.24e-19	Coronary artery disease;
PAAD	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.82	-9.13	-0.6	4.01e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.63	-0.42	8.42e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.21	0.5	2.44e-11	Obesity-related traits;
PAAD	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01250699	chr8:22225185	SLC39A14	0.7	8.15	0.55	1.24e-13	Metabolite levels  (X-11787);
PAAD	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.81	-5.75	-0.42	4.81e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2371030	0.965	rs4672590	chr2:211575322	G/C	cg18417063	chr2:211583084	NA	-0.45	-4.36	-0.33	2.39e-5	Non-small cell lung cancer;
PAAD	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.85	-0.37	3.07e-6	Height;
PAAD	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.65	6.18	0.45	5.75e-9	Corneal astigmatism;
PAAD	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.72	-5.1	-0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4795519	0.634	rs12942556	chr17:22193626	C/T	cg22648282	chr17:21454238	C17orf51	-0.53	-4.71	-0.36	5.43e-6	Chronic myeloid leukemia;
PAAD	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg24253500	chr15:84953950	NA	0.41	4.29	0.33	3.15e-5	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02072885	chr3:182880477	LAMP3	0.57	6.66	0.48	4.72e-10	Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.68	7.43	0.52	7.23e-12	Personality dimensions;
PAAD	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03713592	chr11:72463424	ARAP1	0.62	5.57	0.41	1.1e-7	Body mass index;
PAAD	cis	rs1075265	0.704	rs805405	chr2:54118151	A/G	cg04546899	chr2:54196757	PSME4	0.29	4.25	0.33	3.74e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.39e-10	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs9463078	0.691	rs1041332	chr6:45012811	A/T	cg25276700	chr6:44698697	NA	0.49	5.39	0.4	2.64e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16417436	chr16:28758564	NA	0.45	4.64	0.35	7.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg16602846	chr15:78114278	NA	0.41	4.49	0.34	1.38e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg05585544	chr11:47624801	NA	-0.49	-5.5	-0.41	1.56e-7	Subjective well-being;
PAAD	cis	rs7537052	0.669	rs6686192	chr1:36642991	C/T	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.46	-0.4	1.92e-7	Schizophrenia;
PAAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs9535307	0.518	rs73194439	chr13:50403217	G/C	cg03658251	chr13:50265850	EBPL	-0.74	-4.77	-0.36	4.3e-6	Obesity-related traits;
PAAD	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg08501292	chr6:25962987	TRIM38	0.84	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg15676125	chr6:33679581	C6orf125	0.45	4.28	0.33	3.24e-5	Plateletcrit;
PAAD	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg06958567	chr18:52495541	RAB27B	0.88	6.33	0.46	2.63e-9	Myocardial infarction;
PAAD	cis	rs7487075	0.619	rs4768709	chr12:46805765	A/G	cg14671384	chr12:47219920	SLC38A4	0.44	4.31	0.33	2.88e-5	Itch intensity from mosquito bite;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.72	-0.36	5.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.73	-8.29	-0.56	5.59e-14	White blood cell count (basophil);
PAAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.25	0.39	5.14e-7	Bone mineral density;
PAAD	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg06042504	chr8:55087323	NA	0.7	7.23	0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs16975963	0.793	rs73041034	chr19:38286272	G/A	cg25793785	chr19:38281423	NA	0.57	4.75	0.36	4.69e-6	Longevity;
PAAD	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg00255135	chr8:143090366	NA	0.43	4.3	0.33	3.04e-5	Schizophrenia;
PAAD	cis	rs2249694	0.878	rs2480257	chr10:135352509	T/A	cg20169779	chr10:135381914	SYCE1	0.46	4.53	0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg18531004	chr3:128564980	NA	-0.89	-5.02	-0.38	1.43e-6	Dental caries;
PAAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.54	-5.84	-0.43	3.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.38	0.4	2.75e-7	HDL cholesterol;
PAAD	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10844884	chr10:45498904	ZNF22	-0.68	-6.98	-0.49	8.52e-11	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00760200	chr1:115053833	TRIM33	0.73	7.76	0.53	1.13e-12	Myopia (pathological);
PAAD	cis	rs7771547	0.855	rs1406945	chr6:36562441	C/G	cg07856975	chr6:36356162	ETV7	0.46	5.18	0.39	6.86e-7	Platelet distribution width;
PAAD	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.8	7.3	0.51	1.53e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg00359181	chr2:38893519	GALM	-0.6	-4.49	-0.34	1.38e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.43	5.63	0.42	8.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11669133	1.000	rs77604063	chr19:11129339	T/C	cg25243385	chr19:11167475	SMARCA4	0.98	4.59	0.35	9.11e-6	LDL cholesterol;
PAAD	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg11232448	chr19:2858854	NA	-0.52	-5.18	-0.39	6.99e-7	Total cholesterol levels;
PAAD	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg18904891	chr8:8559673	CLDN23	0.71	6.54	0.47	8.66e-10	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.04	-17.1	-0.81	3.12e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.3e-19	Bone mineral density;
PAAD	cis	rs1730008	0.865	rs827118	chr3:158038442	A/G	cg01557547	chr3:157823089	SHOX2	0.41	4.27	0.33	3.48e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.79	6.04	0.44	1.14e-8	Mean platelet volume;
PAAD	cis	rs10768122	1.000	rs7105690	chr11:35296772	C/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.44	-0.34	1.73e-5	Vitiligo;
PAAD	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.97	13.7	0.74	2.43e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1043763	0.826	rs4132932	chr12:122605923	C/T	cg26218692	chr12:122497826	BCL7A	-0.59	-5.62	-0.41	9.06e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.84	-6.85	-0.49	1.75e-10	Psoriasis;
PAAD	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-6.48	-0.47	1.2e-9	Body mass index;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.84e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.7	10.71	0.66	2.77e-20	Breast cancer;
PAAD	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.78	7.04	0.5	6.35e-11	Inhibitory control;
PAAD	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	1.11	16.12	0.79	9.92e-35	Systemic lupus erythematosus;
PAAD	cis	rs2997447	0.846	rs3008234	chr1:26405458	A/G	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs776905	0.598	rs561241	chr13:113760034	T/C	cg09069900	chr13:113776964	F10	-0.61	-4.93	-0.37	2.13e-6	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.69	6.94	0.49	1.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.63	6.58	0.47	7.11e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.42	5.17	0.39	7.41e-7	Systolic blood pressure;
PAAD	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.48	-4.5	-0.34	1.34e-5	Triglycerides;
PAAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg20821713	chr7:1055600	C7orf50	-0.55	-4.74	-0.36	4.97e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.57	-7.06	-0.5	5.69e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2051773	0.567	rs11024116	chr11:17045886	A/G	cg15432903	chr11:17409602	KCNJ11	-0.53	-4.75	-0.36	4.58e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.87	6.64	0.47	5.11e-10	Alzheimer's disease;
PAAD	cis	rs78761021	0.617	rs905022	chr17:9788181	G/A	cg26853458	chr17:9805074	RCVRN	0.43	4.94	0.37	2.05e-6	Type 2 diabetes;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.68	-6.51	-0.47	1.02e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg07841815	chr7:100318223	EPO	-0.51	-4.87	-0.37	2.82e-6	Other erythrocyte phenotypes;
PAAD	cis	rs1559473	0.621	rs2395842	chr2:222896641	T/C	cg15825116	chr2:223169586	CCDC140	-0.31	-4.26	-0.33	3.64e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.76	-8.06	-0.55	2.14e-13	Menarche (age at onset);
PAAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.92	-0.37	2.27e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.63	-7.12	-0.5	3.92e-11	Schizophrenia;
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.26	-0.45	3.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.68	-7.51	-0.52	4.71e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.78	8.37	0.56	3.47e-14	Height;
PAAD	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.64	7.28	0.51	1.64e-11	Height;
PAAD	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg25319279	chr11:5960081	NA	0.76	7.72	0.53	1.47e-12	DNA methylation (variation);
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.66	-7.21	-0.5	2.42e-11	Menopause (age at onset);
PAAD	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs6684428	0.706	rs12058087	chr1:56319257	C/G	cg11651538	chr1:56320950	NA	-0.53	-4.63	-0.35	7.87e-6	Airflow obstruction;
PAAD	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg14433983	chr11:636460	DRD4	-0.46	-4.74	-0.36	4.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.64	-5.61	-0.41	9.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg04827223	chr11:72435913	ARAP1	0.42	4.66	0.35	6.73e-6	Body mass index;
PAAD	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.56	-5.39	-0.4	2.69e-7	Obesity-related traits;
PAAD	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg21253087	chr9:139290292	SNAPC4	0.43	4.41	0.34	1.98e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg20917491	chr3:195578259	NA	0.49	4.85	0.37	3e-6	Pancreatic cancer;
PAAD	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg00792783	chr2:198669748	PLCL1	-0.48	-4.28	-0.33	3.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23568552	chr17:73105988	ARMC7	0.6	6.77	0.48	2.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.84	0.58	2.27e-15	Alzheimer's disease;
PAAD	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26306683	chr17:18585705	ZNF286B	0.59	5.95	0.43	1.74e-8	Educational attainment (years of education);
PAAD	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs1620921	0.505	rs9456588	chr6:161212564	C/G	cg01280913	chr6:161186852	NA	-0.42	-4.69	-0.36	5.99e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.73	-0.48	3.34e-10	Systolic blood pressure;
PAAD	cis	rs1997066	0.748	rs111274492	chr10:106820441	A/T	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs7123876	0.541	rs61895574	chr11:72347988	A/T	cg03713592	chr11:72463424	ARAP1	0.7	4.29	0.33	3.11e-5	Body mass index;
PAAD	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.75	6.15	0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs7251275	0.660	rs2240633	chr19:44128437	C/T	cg17121205	chr19:44009353	PHLDB3	-0.34	-4.3	-0.33	3.01e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.47	6.11	0.44	8.08e-9	Huntington's disease progression;
PAAD	cis	rs11615916	0.790	rs11614922	chr12:62658288	T/C	cg11441379	chr12:63026424	NA	0.64	4.41	0.34	1.98e-5	Pulmonary function decline;
PAAD	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.03	0.63	1.71e-18	Cognitive test performance;
PAAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs4666360	1.000	rs10196396	chr2:20337035	C/T	cg23291376	chr2:20336282	NA	0.41	4.61	0.35	8.58e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.81	0.36	3.56e-6	Major depressive disorder;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.71	5.85	0.43	2.85e-8	Alzheimer's disease;
PAAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.95	-8.08	-0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.41	-0.4	2.41e-7	HDL cholesterol;
PAAD	cis	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.61	-4.29	-0.33	3.14e-5	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.71e-8	Life satisfaction;
PAAD	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-5.08	-0.38	1.09e-6	Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg18084798	chr19:33555255	RHPN2	0.47	5.06	0.38	1.21e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2055729	0.500	rs1396186	chr8:9875204	T/C	cg21625330	chr8:9911636	MSRA	-0.58	-4.74	-0.36	4.87e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.47	4.82	0.36	3.4e-6	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg22705602	chr4:152727874	NA	-0.48	-5.19	-0.39	6.51e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.75	6.67	0.48	4.49e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.66	4.88	0.37	2.69e-6	Exhaled nitric oxide output;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.53	-0.41	1.36e-7	Myopia (pathological);
PAAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.43	4.32	0.33	2.79e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.46	-7.01	-0.49	7.24e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.92	9.75	0.62	9.33e-18	Cognitive function;
PAAD	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.71	4.62	0.35	8.28e-6	Major depressive disorder;
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg13722127	chr7:150037890	RARRES2	0.56	5.49	0.41	1.64e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg27499820	chr13:21296301	IL17D	0.52	4.96	0.37	1.84e-6	Dental caries;
PAAD	cis	rs7646881	0.812	rs113166116	chr3:158460256	C/T	cg19483011	chr3:158453295	NA	-0.59	-4.8	-0.36	3.8e-6	Tetralogy of Fallot;
PAAD	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.7	7.49	0.52	5.29e-12	Triglyceride levels;
PAAD	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.69	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.72	-8.24	-0.56	7.24e-14	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs17641971	0.645	rs186891	chr8:50038758	T/C	cg00325661	chr8:49890786	NA	0.64	6.47	0.46	1.29e-9	Blood metabolite levels;
PAAD	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.25	10.43	0.65	1.55e-19	Corneal structure;
PAAD	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.8	-0.36	3.8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.85	-7.18	-0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.62	5.8	0.43	3.76e-8	Height;
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02071572	chr4:1403502	NA	-0.47	-6.19	-0.45	5.3e-9	Longevity;
PAAD	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.92	-0.43	2.03e-8	Coronary artery disease;
PAAD	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-7.02	-0.49	6.96e-11	Total cholesterol levels;
PAAD	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.58	5.39	0.4	2.68e-7	Height;
PAAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.01	0.38	1.48e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.49	0.41	1.67e-7	Electroencephalogram traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00241998	chr4:40058606	N4BP2;LOC344967	0.6	6.83	0.48	1.88e-10	Monocyte percentage of white cells;
PAAD	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.66	-7.02	-0.49	6.88e-11	Blood protein levels;
PAAD	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.47	-4.53	-0.34	1.2e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.84	-0.37	3.21e-6	Body mass index;
PAAD	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.75	-7.99	-0.54	3.09e-13	Gout;
PAAD	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.99	-10.56	-0.65	6.96e-20	Blood pressure (smoking interaction);
PAAD	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.54	4.73	0.36	5.19e-6	Corneal astigmatism;
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.51	4.83	0.36	3.37e-6	Bipolar disorder;
PAAD	cis	rs2668423	1.000	rs2526136	chr19:1368398	A/G	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.59	-0.47	6.66e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs9810890	1.000	rs13434201	chr3:128609255	T/A	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs8044995	0.929	rs3743739	chr16:68293320	T/C	cg09835421	chr16:68378352	PRMT7	-0.96	-7.41	-0.52	8.2e-12	Schizophrenia;
PAAD	cis	rs35000415	0.873	rs62478615	chr7:128684316	G/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26850624	chr5:429559	AHRR	-0.79	-8.27	-0.56	6.12e-14	Cystic fibrosis severity;
PAAD	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.49	5.46	0.4	1.92e-7	Testicular germ cell tumor;
PAAD	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg09659197	chr4:152720779	NA	0.4	5.04	0.38	1.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9913156	0.748	rs55986729	chr17:4560499	G/T	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23158103	chr7:148848205	ZNF398	-0.64	-6.41	-0.46	1.69e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.84	7.01	0.49	7.27e-11	Lymphocyte counts;
PAAD	cis	rs3736485	0.966	rs7177471	chr15:51911232	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.38	-0.33	2.24e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs17032980	0.910	rs7575826	chr2:67309631	G/A	cg06994420	chr2:66672553	MEIS1	-0.51	-4.51	-0.34	1.3e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg15309053	chr8:964076	NA	0.61	7.08	0.5	4.9e-11	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs11825685	0.708	rs73044092	chr11:134546621	G/A	cg06603561	chr11:134479413	NA	-0.7	-5.15	-0.39	7.92e-7	IgG glycosylation;
PAAD	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg19254793	chr6:44695348	NA	-0.41	-4.5	-0.34	1.36e-5	Total body bone mineral density;
PAAD	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg23244877	chr17:73518230	TSEN54	0.73	7.0	0.49	7.63e-11	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.65	7.87	0.54	6.09e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-6.01	-0.44	1.33e-8	Total body bone mineral density;
PAAD	cis	rs10450586	0.829	rs7105320	chr11:27306168	A/G	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10819733	chr22:24237672	NA	-0.6	-6.69	-0.48	3.98e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg12568669	chr8:11666485	FDFT1	0.3	5.01	0.38	1.52e-6	Myopia (pathological);
PAAD	cis	rs427941	0.703	rs201447	chr7:101738384	C/A	cg06246474	chr7:101738831	CUX1	0.45	4.64	0.35	7.48e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.48	-5.59	-0.41	1.05e-7	High light scatter reticulocyte count;
PAAD	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.47	-4.26	-0.33	3.58e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.5	-7.21	-0.51	2.4e-11	Diastolic blood pressure;
PAAD	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.83	0.48	1.94e-10	Cognitive test performance;
PAAD	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.76	-0.53	1.15e-12	Hemoglobin concentration;
PAAD	cis	rs72634501	0.542	rs2134472	chr1:39603214	T/G	cg11070191	chr1:39582205	MACF1	0.49	4.47	0.34	1.54e-5	HDL cholesterol;
PAAD	cis	rs12432203	1.000	rs72622436	chr14:51735443	A/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.41	-0.34	1.94e-5	Coronary artery disease;
PAAD	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg04398451	chr17:18023971	MYO15A	0.74	7.79	0.53	1e-12	Total body bone mineral density;
PAAD	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.23	-0.39	5.51e-7	Reticulocyte count;
PAAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg13271783	chr10:134563150	INPP5A	-0.55	-5.81	-0.43	3.61e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.38	-0.33	2.18e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg09168692	chr1:7887560	PER3	0.52	4.97	0.37	1.75e-6	Inflammatory bowel disease;
PAAD	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.48	4.56	0.35	1.04e-5	RR interval (heart rate);
PAAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.51	0.65	9.45e-20	Total body bone mineral density;
PAAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-4.85	-0.37	3e-6	Body mass index;
PAAD	cis	rs56011263	0.532	rs55990625	chr4:736485	C/T	cg14024328	chr4:719362	PCGF3	-0.53	-5.07	-0.38	1.13e-6	White blood cell count;
PAAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.91	-5.99	-0.44	1.46e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.27	-0.39	4.62e-7	Glomerular filtration rate;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-5.0	-0.38	1.58e-6	Body mass index;
PAAD	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Educational attainment;
PAAD	cis	rs3169166	0.500	rs3813575	chr15:78560742	C/T	cg09214398	chr15:78556534	DNAJA4	0.29	5.02	0.38	1.46e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-4.97	-0.37	1.76e-6	Hirschsprung disease;
PAAD	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.83	-10.56	-0.65	6.84e-20	Breast cancer;
PAAD	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.5	4.77	0.36	4.3e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs11264213	0.901	rs7542179	chr1:36461122	A/G	cg27506609	chr1:36549197	TEKT2	-0.72	-5.18	-0.39	6.9e-7	Schizophrenia;
PAAD	cis	rs282587	0.502	rs408476	chr13:113400056	A/C	cg04656015	chr13:113407548	ATP11A	0.54	4.31	0.33	2.88e-5	Glycated hemoglobin levels;
PAAD	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.2	0.55	9.51e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9810890	1.000	rs73196959	chr3:128431919	A/G	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.58	5.79	0.43	3.91e-8	Body mass index;
PAAD	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg27236539	chr20:62289627	RTEL1	0.57	4.64	0.35	7.38e-6	Atopic dermatitis;
PAAD	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.74	-7.33	-0.51	1.28e-11	White matter hyperintensity burden;
PAAD	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.74	8.84	0.58	2.29e-15	Dental caries;
PAAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.8	0.48	2.2e-10	Mood instability;
PAAD	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.46	-4.37	-0.33	2.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4727012	1	rs4727012	chr7:148740493	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.8	-5.13	-0.38	8.63e-7	Colorectal or endometrial cancer;
PAAD	cis	rs829880	0.558	rs249820	chr12:98897473	A/G	cg25150519	chr12:98850993	NA	0.71	6.71	0.48	3.69e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg07841815	chr7:100318223	EPO	-0.48	-4.39	-0.34	2.11e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg14343924	chr8:8086146	FLJ10661	0.56	4.92	0.37	2.21e-6	Mood instability;
PAAD	cis	rs494459	0.838	rs12796102	chr11:118662028	C/T	cg08498647	chr11:118550644	TREH	-0.35	-4.28	-0.33	3.35e-5	Height;
PAAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg16083429	chr3:49237500	CCDC36	-0.42	-4.49	-0.34	1.42e-5	Parkinson's disease;
PAAD	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05085101	chr17:4890696	CAMTA2	0.64	7.12	0.5	4.03e-11	Myopia (pathological);
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.77	5.59	0.41	1e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09826364	chr7:158789723	NA	-0.45	-5.67	-0.42	7.03e-8	Facial morphology (factor 20);
PAAD	cis	rs12307997	0.558	rs11055277	chr12:7852052	C/T	cg26645069	chr12:6861493	MLF2	0.52	4.29	0.33	3.16e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.85	10.32	0.64	2.99e-19	Methadone dose in opioid dependence;
PAAD	cis	rs35740288	0.731	rs11634651	chr15:86093926	A/C	cg07943548	chr15:86304357	KLHL25	-0.61	-5.37	-0.4	2.87e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs12612619	0.579	rs6722906	chr2:27080035	C/A	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.38	-0.33	2.22e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.71	6.53	0.47	9.34e-10	Monocyte count;
PAAD	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23158103	chr7:148848205	ZNF398	-0.57	-5.24	-0.39	5.3e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07930192	chr7:1003750	NA	0.38	4.7	0.36	5.85e-6	Longevity;Endometriosis;
PAAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	4.97	0.37	1.75e-6	Menarche (age at onset);
PAAD	cis	rs863345	0.604	rs12044283	chr1:158463833	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.9	-0.37	2.39e-6	Pneumococcal bacteremia;
PAAD	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.1	-0.55	1.71e-13	Brugada syndrome;
PAAD	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.85	-6.13	-0.45	7.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.73	-0.42	5.15e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.58	-7.19	-0.5	2.78e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.6	7.05	0.5	5.78e-11	Aortic root size;
PAAD	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.65	-0.53	2.12e-12	Coffee consumption (cups per day);
PAAD	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg13786083	chr1:19110734	NA	-0.72	-6.21	-0.45	4.89e-9	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.29e-5	Rheumatoid arthritis;
PAAD	cis	rs258892	0.841	rs266427	chr5:72130751	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.74	-8.25	-0.56	7.03e-14	Airway imaging phenotypes;
PAAD	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.55	5.39	0.4	2.59e-7	Menopause (age at onset);
PAAD	cis	rs863345	0.564	rs34701257	chr1:158480955	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-5.08	-0.38	1.1e-6	Pneumococcal bacteremia;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.62	5.99	0.44	1.44e-8	Prudent dietary pattern;
PAAD	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.55	-6.43	-0.46	1.58e-9	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg08847533	chr14:75593920	NEK9	0.46	4.51	0.34	1.27e-5	IgG glycosylation;
PAAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg15017067	chr4:17643749	FAM184B	0.44	5.15	0.39	8.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg03037974	chr15:76606532	NA	0.51	5.56	0.41	1.21e-7	Blood metabolite levels;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg06074448	chr4:187884817	NA	-0.66	-8.26	-0.56	6.63e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg00988841	chr10:134556463	INPP5A	0.47	4.43	0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4234798	0.933	rs7678751	chr4:7219035	A/G	cg18431297	chr4:7219810	SORCS2	0.42	5.13	0.38	8.82e-7	Insulin-like growth factors;
PAAD	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.29	0.51	1.56e-11	Neuroticism;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1499972	0.941	rs62264766	chr3:117641227	A/G	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg10208897	chr5:178548229	ADAMTS2	0.49	4.43	0.34	1.79e-5	Pubertal anthropometrics;
PAAD	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.61	7.4	0.51	8.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2143950	0.512	rs79000843	chr14:35510900	C/A	cg14523979	chr14:35838413	NA	-0.49	-4.3	-0.33	2.99e-5	Atopic dermatitis;
PAAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	7.01	0.49	7.43e-11	Mood instability;
PAAD	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg15211996	chr1:2936768	ACTRT2	0.47	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg15192750	chr16:69999425	NA	0.71	5.49	0.41	1.67e-7	IgE levels;
PAAD	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg04851639	chr8:1020857	NA	-0.66	-8.38	-0.56	3.39e-14	Schizophrenia;
PAAD	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg19904058	chr10:135279010	LOC619207	0.47	5.65	0.42	7.57e-8	Systemic lupus erythematosus;
PAAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg20805835	chr1:248005719	OR11L1	0.47	4.28	0.33	3.34e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.78	-0.48	2.44e-10	Blood pressure (smoking interaction);
PAAD	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.55	6.56	0.47	7.94e-10	Multiple sclerosis;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg05552183	chr6:42928497	GNMT	0.78	8.76	0.58	3.6e-15	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.4	0.4	2.54e-7	Bipolar disorder;
PAAD	cis	rs9652601	0.843	rs7204643	chr16:11167603	C/T	cg04616529	chr16:11181986	CLEC16A	-0.48	-5.22	-0.39	5.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.63	-0.35	7.75e-6	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-6.4	-0.46	1.79e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg19423196	chr10:82049429	MAT1A	0.49	4.73	0.36	5.1e-6	Borderline personality disorder;
PAAD	cis	rs508970	0.595	rs668323	chr11:60905748	G/C	cg24692310	chr11:60915630	VPS37C	0.33	4.46	0.34	1.6e-5	Rheumatoid arthritis;
PAAD	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.9	0.37	2.48e-6	Major depressive disorder;
PAAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg21351543	chr2:191399470	TMEM194B	0.6	4.62	0.35	7.99e-6	Diastolic blood pressure;
PAAD	cis	rs7818688	0.697	rs77805255	chr8:95983566	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4280164	0.887	rs2748543	chr14:24778674	C/A	cg07162820	chr14:24837146	NFATC4	0.39	4.5	0.34	1.34e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19089337	chr2:121103360	INHBB	0.64	6.54	0.47	8.88e-10	Obesity-related traits;
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.45	5.28	0.39	4.46e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.81e-7	Bipolar disorder;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.4	13.75	0.74	1.83e-28	Corneal structure;
PAAD	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.69	-6.3	-0.45	3.1e-9	Vitamin D levels;
PAAD	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.83	7.28	0.51	1.66e-11	Menopause (age at onset);
PAAD	cis	rs11168618	0.875	rs11168606	chr12:48892689	G/T	cg01881778	chr12:48919444	OR8S1	-0.47	-4.68	-0.36	6.24e-6	Adiponectin levels;
PAAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg26014466	chr7:809109	HEATR2	-0.57	-4.32	-0.33	2.8e-5	Initial pursuit acceleration;
PAAD	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.48	-4.46	-0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.67	-0.42	7.12e-8	Crohn's disease;
PAAD	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg12673499	chr10:104412063	TRIM8	-0.36	-4.26	-0.33	3.62e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.5	4.86	0.37	2.84e-6	Migraine;
PAAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg07959070	chr22:50026188	C22orf34	-0.38	-4.41	-0.34	1.94e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	5.53	0.41	1.36e-7	Height;
PAAD	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-1.09	-7.54	-0.52	3.94e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-5.84	-0.43	2.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg25972092	chr12:117363249	FBXW8	0.83	6.42	0.46	1.67e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.56	5.2	0.39	6.21e-7	Breast cancer;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.9	6.92	0.49	1.17e-10	Alzheimer's disease;
PAAD	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg14500798	chr7:98100126	NA	-0.42	-4.48	-0.34	1.44e-5	Breast cancer;
PAAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg16576597	chr16:28551801	NUPR1	-0.71	-7.33	-0.51	1.28e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.51	-4.61	-0.35	8.63e-6	Red blood cell traits;
PAAD	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs62025270	1.000	rs62025270	chr15:86300198	G/A	cg13263323	chr15:86062960	AKAP13	0.62	5.83	0.43	3.16e-8	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09695851	chr17:3907499	NA	-0.66	-6.82	-0.48	1.99e-10	Type 2 diabetes;
PAAD	trans	rs111756027	0.522	rs72800051	chr16:77277233	G/A	cg17418387	chr1:17761802	RCC2	-0.79	-6.39	-0.46	1.93e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.71	6.33	0.46	2.55e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.66	0.69	7.84e-23	Platelet count;
PAAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.84	10.19	0.64	6.42e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs16975963	0.843	rs73029180	chr19:38420406	C/T	cg08679971	chr19:38281047	NA	0.56	5.36	0.4	3.07e-7	Longevity;
PAAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg01866162	chr16:67596514	CTCF	0.58	4.45	0.34	1.65e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg13918804	chr1:2043761	PRKCZ	0.42	5.6	0.41	9.79e-8	Height;
PAAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.5	-4.91	-0.37	2.31e-6	Mean platelet volume;
PAAD	cis	rs435746	1.000	rs435746	chr16:77916191	A/T	cg03119442	chr16:78466546	WWOX	-0.49	-4.49	-0.34	1.41e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg09491104	chr22:46646882	C22orf40	-0.71	-4.25	-0.33	3.75e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.8	-7.61	-0.53	2.66e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15418297	chr8:12294676	FAM86B2	0.58	6.63	0.47	5.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.46	5.78	0.42	4.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.63	6.67	0.48	4.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg19784903	chr17:45786737	TBKBP1	0.53	5.66	0.42	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs73019876	0.869	rs2079062	chr19:22125212	T/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg10547527	chr2:198650123	BOLL	-0.64	-4.41	-0.34	1.98e-5	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.89	11.33	0.68	5.94e-22	Menopause (age at onset);
PAAD	cis	rs3125734	0.633	rs1835862	chr10:64056068	G/A	cg09941381	chr10:64027924	RTKN2	-0.38	-4.51	-0.34	1.27e-5	Rheumatoid arthritis;
PAAD	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.58	5.33	0.4	3.45e-7	Breast cancer;
PAAD	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.86	-0.37	2.9e-6	Mood instability;
PAAD	cis	rs10924309	0.889	rs884987	chr1:245860076	G/C	cg00036263	chr1:245852353	KIF26B	-0.69	-6.01	-0.44	1.29e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg00990874	chr7:1149470	C7orf50	-0.55	-4.76	-0.36	4.45e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.65	5.23	0.39	5.5e-7	Alzheimer's disease;
PAAD	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.72	-7.51	-0.52	4.8e-12	Cognitive function;
PAAD	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-4.92	-0.37	2.2e-6	Oropharynx cancer;
PAAD	cis	rs3779195	0.585	rs56694862	chr7:97897120	G/T	cg21770322	chr7:97807741	LMTK2	-0.55	-4.39	-0.34	2.12e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg19882132	chr14:106167949	NA	-0.56	-4.88	-0.37	2.61e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs16975963	0.843	rs11083442	chr19:38427528	C/A	cg14218481	chr19:38281219	NA	0.48	5.01	0.38	1.49e-6	Longevity;
PAAD	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.65	6.46	0.46	1.34e-9	Coronary artery disease;
PAAD	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.33	-0.33	2.69e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs7819412	0.618	rs13276836	chr8:10981003	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.61	-0.47	6.03e-10	Triglycerides;
PAAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.46	4.49	0.34	1.39e-5	Trans fatty acid levels;
PAAD	cis	rs35791980	0.567	rs2272316	chr7:76942959	G/A	cg02756451	chr7:76178720	LOC100133091	0.51	4.28	0.33	3.24e-5	Pursuit maintenance gain;
PAAD	cis	rs10186876	0.767	rs9309111	chr2:44165733	C/G	cg09541576	chr2:44873248	C2orf34	-0.43	-4.39	-0.34	2.07e-5	Hand grip strength;
PAAD	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg05425664	chr17:57184151	TRIM37	-0.51	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg00717180	chr2:96193071	NA	-0.62	-6.89	-0.49	1.38e-10	HDL cholesterol;
PAAD	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-6.84	-0.49	1.78e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	0.91	4.33	0.33	2.67e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs742132	0.520	rs113164182	chr6:25633829	A/C	cg12310025	chr6:25882481	NA	0.65	4.37	0.33	2.26e-5	Uric acid levels;
PAAD	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.74	7.75	0.53	1.23e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.71	4.79	0.36	3.87e-6	Major depressive disorder;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24441121	chr2:98262430	COX5B	0.71	6.96	0.49	9.28e-11	Obesity-related traits;
PAAD	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.51	4.75	0.36	4.59e-6	Menopause (age at onset);
PAAD	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg11288833	chr15:55489084	RSL24D1	0.56	4.62	0.35	8.07e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	7.92e-8	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.24	0.39	5.38e-7	Prudent dietary pattern;
PAAD	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.62	-0.41	8.96e-8	Bipolar disorder;
PAAD	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	Fibrinogen levels;
PAAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06850241	chr22:41845214	NA	-0.56	-5.31	-0.4	3.75e-7	Vitiligo;
PAAD	cis	rs741702	0.928	rs2009222	chr19:13034543	T/C	cg15585409	chr19:12750806	NA	-0.47	-4.27	-0.33	3.44e-5	Red blood cell traits;
PAAD	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1419980	0.730	rs11533528	chr12:7764616	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.7	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.3	0.45	3.09e-9	Personality dimensions;
PAAD	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.55	5.43	0.4	2.16e-7	Schizophrenia;
PAAD	cis	rs782107	0.898	rs3847704	chr12:58801594	A/G	cg22842717	chr12:57939823	DCTN2	-0.44	-4.44	-0.34	1.7e-5	Interleukin-12p70 levels;
PAAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.62	-6.02	-0.44	1.27e-8	Breast cancer;
PAAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-4.93	-0.37	2.11e-6	Neurofibrillary tangles;
PAAD	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg19630374	chr17:18023558	MYO15A	-0.4	-4.3	-0.33	3.07e-5	Total body bone mineral density;
PAAD	cis	rs1152591	0.601	rs3866738	chr14:64614770	G/C	cg23250157	chr14:64679961	SYNE2	0.57	6.07	0.44	9.87e-9	Atrial fibrillation;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10819733	chr22:24237672	NA	-0.54	-5.68	-0.42	6.51e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.45	4.53	0.35	1.17e-5	Airway imaging phenotypes;
PAAD	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.5	-4.81	-0.36	3.61e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4343996	0.715	rs4722827	chr7:3500379	G/C	cg21248987	chr7:3385318	SDK1	0.49	5.27	0.39	4.65e-7	Motion sickness;
PAAD	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs6733011	0.500	rs6542837	chr2:99444701	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	4.97	0.37	1.8e-6	Bipolar disorder;
PAAD	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg08079166	chr15:68083412	MAP2K5	0.62	4.91	0.37	2.31e-6	Restless legs syndrome;
PAAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10795710	chr1:16693622	C1orf144	0.6	6.44	0.46	1.48e-9	Monocyte percentage of white cells;
PAAD	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.94	5.6	0.41	9.77e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg00129232	chr17:37814104	STARD3	-0.6	-4.43	-0.34	1.76e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.93e-11	Eye color traits;
PAAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.73	0.58	4.16e-15	Menopause (age at onset);
PAAD	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-9.61	-0.61	2.22e-17	Body mass index;
PAAD	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg15193198	chr20:60906057	LAMA5	0.59	6.68	0.48	4.27e-10	Colorectal cancer;
PAAD	cis	rs8077059	1.000	rs8077059	chr17:55823552	C/T	cg12582317	chr17:55822272	NA	0.46	4.46	0.34	1.58e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg00629941	chr15:75287862	SCAMP5	0.58	4.49	0.34	1.43e-5	Blood trace element (Zn levels);
PAAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.83	0.43	3.23e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7260329	0.590	rs11671108	chr19:41481973	A/C	cg22249281	chr19:41082756	SHKBP1	-0.57	-4.26	-0.33	3.53e-5	Smoking behavior;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27394817	chr17:78848679	RPTOR	-0.65	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg01851573	chr8:8652454	MFHAS1	-0.49	-4.4	-0.34	1.99e-5	Obesity-related traits;
PAAD	cis	rs7074356	0.688	rs7898568	chr10:82183531	G/A	cg19423196	chr10:82049429	MAT1A	0.45	4.74	0.36	4.79e-6	Borderline personality disorder;
PAAD	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg09978860	chr4:56023921	NA	0.39	4.35	0.33	2.45e-5	Endometriosis;
PAAD	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4448343	0.727	rs28591501	chr9:98278644	C/A	cg13428213	chr9:98267529	PTCH1	0.47	4.42	0.34	1.87e-5	Height;
PAAD	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.45	9.98	0.63	2.4e-18	Prostate cancer;
PAAD	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	7.83	0.54	7.88e-13	Morning vs. evening chronotype;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14655858	chr8:37978472	ASH2L	-0.69	-6.73	-0.48	3.27e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.69	-0.62	1.38e-17	Height;
PAAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.38	-4.55	-0.35	1.08e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.38	9.73	0.62	1.1e-17	Opioid sensitivity;
PAAD	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.45	5.26	0.39	4.91e-7	Age at first birth;
PAAD	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg00049323	chr5:472564	LOC25845	-0.49	-4.36	-0.33	2.35e-5	Cystic fibrosis severity;
PAAD	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg25382128	chr12:54346509	NA	-0.46	-4.62	-0.35	8.18e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.59	-5.65	-0.42	7.55e-8	Rheumatoid arthritis;
PAAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg14440974	chr22:39074834	NA	0.54	6.53	0.47	9.2e-10	Menopause (age at onset);
PAAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg13266496	chr6:110720918	DDO	-0.46	-4.87	-0.37	2.78e-6	Platelet distribution width;
PAAD	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.4	-0.51	8.47e-12	Diastolic blood pressure;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.48	4.52	0.34	1.24e-5	Resistin levels;
PAAD	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.74	-0.42	5.09e-8	Schizophrenia;
PAAD	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.86	8.77	0.58	3.44e-15	Uric acid levels;
PAAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.79	6.51	0.47	1.05e-9	Monocyte percentage of white cells;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17270843	chr10:99079074	FRAT1	0.54	6.82	0.48	2.06e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07707227	chr5:54469532	MIR449C;CDC20B	0.57	6.68	0.48	4.31e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg20641545	chr12:89984390	ATP2B1	-0.51	-6.31	-0.46	2.94e-9	Cancer;
PAAD	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg15017067	chr4:17643749	FAM184B	0.43	4.72	0.36	5.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg02421172	chr7:1938701	MAD1L1	0.59	4.64	0.35	7.49e-6	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg27447006	chr1:23763279	ASAP3	0.64	4.91	0.37	2.3e-6	Total cholesterol levels;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.76	-5.94	-0.43	1.9e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg18357526	chr6:26021779	HIST1H4A	0.67	6.79	0.48	2.4e-10	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27309155	chr11:1300211	TOLLIP	0.63	7.41	0.52	7.97e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.84	-0.43	3.12e-8	Schizophrenia (age at onset);
PAAD	cis	rs1198430	0.568	rs1119439	chr1:23828904	A/T	cg22040403	chr1:23858016	E2F2	0.81	5.79	0.42	3.96e-8	Total cholesterol levels;
PAAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.59	-6.12	-0.44	7.71e-9	Monocyte count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13055374	chr1:54872983	SSBP3	-0.67	-7.08	-0.5	4.87e-11	Smoking initiation;
PAAD	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.4	-0.34	2.07e-5	Crohn's disease;
PAAD	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.16	-0.5	3.16e-11	Diastolic blood pressure;
PAAD	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-0.67	-6.89	-0.49	1.42e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.48	-4.41	-0.34	1.94e-5	Triglycerides;
PAAD	cis	rs10073892	0.830	rs10072122	chr5:101587931	G/A	cg17280723	chr5:101634495	NA	0.42	4.37	0.33	2.31e-5	Cognitive decline (age-related);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg04653776	chr20:32399093	CHMP4B	0.67	6.74	0.48	3.05e-10	Primary biliary cholangitis;
PAAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.63	5.21	0.39	6.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg10705379	chr10:99080932	FRAT1	0.38	4.59	0.35	9.25e-6	Monocyte percentage of white cells;
PAAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.53	-5.06	-0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs12908161	1.000	rs3803403	chr15:85383145	C/G	cg17507749	chr15:85114479	UBE2QP1	0.65	6.21	0.45	4.93e-9	Schizophrenia;
PAAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg01388757	chr2:102091195	RFX8	-0.53	-6.65	-0.47	5.03e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg27411982	chr8:10470053	RP1L1	0.5	5.55	0.41	1.25e-7	Neuroticism;
PAAD	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs2456568	0.808	rs12792941	chr11:93685640	G/C	cg19264203	chr11:92714893	MTNR1B	-0.4	-4.67	-0.35	6.56e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg25902810	chr10:99078978	FRAT1	-0.52	-4.64	-0.35	7.42e-6	Monocyte count;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07930192	chr7:1003750	NA	0.39	4.83	0.36	3.3e-6	Longevity;Endometriosis;
PAAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.64	-5.57	-0.41	1.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	1.05	15.05	0.77	6.41e-32	Menarche (age at onset);
PAAD	cis	rs508970	0.519	rs642712	chr11:60921448	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.06	0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs818427	0.826	rs153565	chr5:112250376	A/T	cg06941702	chr5:112196734	SRP19	0.5	4.36	0.33	2.35e-5	Total body bone mineral density;
PAAD	cis	rs4234284	1.000	rs4679354	chr3:126947703	G/A	cg27326032	chr3:127006922	NA	-0.46	-4.69	-0.36	6.05e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.56	5.98	0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.74	6.78	0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs9815354	1.000	rs9830064	chr3:41881801	T/C	cg03022575	chr3:42003672	ULK4	0.77	5.62	0.41	8.98e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg20731937	chr12:48336164	NA	0.52	4.37	0.33	2.28e-5	Longevity (90 years and older);
PAAD	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.73	8.56	0.57	1.19e-14	Colorectal cancer;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.94	11.66	0.69	7.78e-23	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04204118	chr10:4194429	NA	-0.67	-6.8	-0.48	2.26e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09736950	chr15:62938334	MGC15885;TLN2	-0.65	-6.66	-0.48	4.74e-10	Obesity-related traits;
PAAD	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs925642	0.700	rs11727497	chr4:187669842	C/G	cg20274950	chr4:187647402	NA	0.37	4.3	0.33	3.01e-5	Obesity;
PAAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.97	-0.54	3.57e-13	Neuroticism;
PAAD	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs10044254	0.614	rs13358928	chr5:15737539	G/T	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.49	-0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.77	-6.33	-0.46	2.63e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.47	5.91	0.43	2.17e-8	Crohn's disease;
PAAD	cis	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs7072216	0.687	rs10786416	chr10:100153600	G/T	cg19567339	chr10:100142640	NA	0.44	4.61	0.35	8.53e-6	Metabolite levels;
PAAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.57	-4.55	-0.35	1.08e-5	QRS complex (12-leadsum);
PAAD	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg02487422	chr3:49467188	NICN1	0.45	4.6	0.35	9e-6	Resting heart rate;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg13699009	chr12:122356056	WDR66	0.47	7.0	0.49	7.53e-11	Mean corpuscular volume;
PAAD	cis	rs8027181	0.682	rs4777546	chr15:73104435	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.51	-4.92	-0.37	2.23e-6	Triglyceride levels;
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.6	9.04	0.59	6.69e-16	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg21565972	chr17:80109576	CCDC57	0.59	6.93	0.49	1.15e-10	Life satisfaction;
PAAD	cis	rs757110	0.524	rs214095	chr11:17293462	T/A	cg04705435	chr11:17411270	KCNJ11	-0.56	-6.0	-0.44	1.38e-8	Type 2 diabetes;
PAAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs950037	0.710	rs10922492	chr1:89304059	T/A	cg13109106	chr1:89333529	GTF2B	0.47	4.57	0.35	1e-5	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs375066	0.935	rs371875	chr19:44393257	A/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.32	0.6	1.24e-16	Total body bone mineral density;
PAAD	trans	rs9372498	1.000	rs10499086	chr6:118567764	G/C	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.0	-0.54	2.98e-13	Diastolic blood pressure;
PAAD	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg17366294	chr4:99064904	C4orf37	0.55	5.81	0.43	3.51e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.7	6.65	0.47	4.91e-10	Asthma;
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.86	10.08	0.63	1.3e-18	Longevity;
PAAD	cis	rs2077654	0.556	rs4148624	chr11:17444024	A/G	cg25308976	chr11:17434268	ABCC8	0.67	4.84	0.37	3.14e-6	Gout;
PAAD	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg11439826	chr17:76250004	NA	0.48	4.93	0.37	2.18e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.8	7.92	0.54	4.65e-13	Response to antineoplastic agents;
PAAD	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.43	-6.47	-0.46	1.26e-9	Breast cancer;
PAAD	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.63	8.91	0.59	1.43e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4321325	0.733	rs78593261	chr2:127947044	G/A	cg11380483	chr2:127933992	NA	0.71	5.3	0.39	4.05e-7	Protein C levels;
PAAD	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.6	6.15	0.45	6.59e-9	Testicular germ cell tumor;
PAAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-5.97	-0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.34	0.51	1.22e-11	Lung cancer in ever smokers;
PAAD	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13705251	chr19:8509791	HNRNPM	0.58	6.8	0.48	2.24e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.7	5.73	0.42	5.13e-8	Exhaled nitric oxide output;
PAAD	cis	rs76866386	0.892	rs72875462	chr2:44079310	C/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.76	-4.73	-0.36	5.14e-6	Cholesterol, total;
PAAD	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.76	-6.88	-0.49	1.46e-10	Blood protein levels;
PAAD	cis	rs9815354	1.000	rs1716688	chr3:41926546	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.85	-0.43	2.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg02071572	chr4:1403502	NA	0.38	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg10864074	chr7:100318194	EPO	-0.46	-4.47	-0.34	1.54e-5	Other erythrocyte phenotypes;
PAAD	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.45	0.4	1.99e-7	Lung cancer;
PAAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.81	0.36	3.61e-6	Coronary artery disease;
PAAD	cis	rs30380	0.688	rs27524	chr5:96101944	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.51	5.27	0.39	4.57e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg26149184	chr10:133730230	NA	0.8	7.02	0.49	6.95e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1497828	0.869	rs2646838	chr1:217552687	C/G	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs7772486	0.875	rs2777482	chr6:146320341	A/C	cg23711669	chr6:146136114	FBXO30	0.65	7.35	0.51	1.13e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7707921	0.881	rs74906189	chr5:81261923	A/G	cg21483461	chr5:81570383	RPS23	-0.56	-4.69	-0.36	6.09e-6	Breast cancer;
PAAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg09017928	chr7:158110068	PTPRN2	0.45	4.42	0.34	1.89e-5	Calcium levels;
PAAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg10818794	chr15:86012489	AKAP13	0.46	4.93	0.37	2.12e-6	Coronary artery disease;
PAAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg26497354	chr6:109612229	NA	-0.46	-4.57	-0.35	9.87e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6088813	0.922	rs4911493	chr20:33960799	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg18944383	chr4:111397179	ENPEP	0.65	7.57	0.52	3.39e-12	Coronary artery disease;
PAAD	cis	rs58521262	0.519	rs11672160	chr19:22932550	T/G	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg05082376	chr22:42548792	NA	-0.5	-5.52	-0.41	1.46e-7	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07240554	chr1:152009457	S100A11	0.68	7.1	0.5	4.38e-11	Obesity-related traits;
PAAD	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.44	5.2	0.39	6.42e-7	Uric acid levels;
PAAD	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs17681684	0.565	rs12150182	chr17:9764757	C/T	cg26853458	chr17:9805074	RCVRN	0.74	7.96	0.54	3.61e-13	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs7615952	0.611	rs114419739	chr3:125722490	C/T	cg05084668	chr3:125655381	ALG1L	-1.01	-8.35	-0.56	3.86e-14	Blood pressure (smoking interaction);
PAAD	cis	rs17021463	0.673	rs12507134	chr4:95283980	C/A	cg11021082	chr4:95130006	SMARCAD1	0.57	5.82	0.43	3.3e-8	Testicular germ cell tumor;
PAAD	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.75	7.17	0.5	3.12e-11	Height;
PAAD	cis	rs1620921	0.505	rs9456586	chr6:161207643	G/A	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg11812906	chr14:75593930	NEK9	-0.45	-4.4	-0.34	2.01e-5	Neuroticism;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs6466055	0.576	rs1011468	chr7:104613791	G/A	cg04380332	chr7:105027541	SRPK2	-0.48	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.75	-7.66	-0.53	2.03e-12	Monocyte count;
PAAD	cis	rs863345	1.000	rs863352	chr1:158539006	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg10494973	chr17:80897199	TBCD	-0.57	-4.7	-0.36	5.8e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg00738919	chr7:1100172	C7orf50	0.7	5.0	0.38	1.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg03225093	chr5:2008713	NA	0.35	4.35	0.33	2.45e-5	Lung cancer;
PAAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-6.65	-0.47	5.1e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.17	0.55	1.09e-13	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.52	-5.1	-0.38	1e-6	Motion sickness;
PAAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.87	9.26	0.6	1.84e-16	Cognitive function;
PAAD	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg22134325	chr11:66188745	NPAS4	0.29	4.7	0.36	5.82e-6	Airway imaging phenotypes;
PAAD	cis	rs9677476	0.818	rs28678038	chr2:232063997	A/T	cg07929768	chr2:232055508	NA	0.39	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs752010	0.545	rs6600379	chr1:42053497	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	5.13	0.38	8.55e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg08992911	chr2:238395768	MLPH	0.7	5.53	0.41	1.39e-7	Prostate cancer;
PAAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.5	6.55	0.47	8.22e-10	Schizophrenia;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.47	5.11	0.38	9.7e-7	Motion sickness;
PAAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.84	8.37	0.56	3.57e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22164177	chr12:117013718	MAP1LC3B2	-0.59	-6.46	-0.46	1.35e-9	Smoking initiation;
PAAD	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.57	-6.41	-0.46	1.7e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02071572	chr4:1403502	NA	0.38	4.9	0.37	2.45e-6	Longevity;
PAAD	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21646471	chr2:242523971	THAP4	0.64	5.02	0.38	1.45e-6	Prostate cancer;
PAAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-4.39	-0.34	2.14e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7213347	0.780	rs7209564	chr17:2168233	C/T	cg02569219	chr17:2266849	SGSM2	-0.52	-4.39	-0.34	2.11e-5	Total body bone mineral density;
PAAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg18370025	chr7:2749541	AMZ1	-0.42	-5.07	-0.38	1.16e-6	Height;
PAAD	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.65	-6.45	-0.46	1.43e-9	Depressive symptoms;
PAAD	cis	rs60733400	0.509	rs56814247	chr1:2622489	A/G	cg05697835	chr1:2722811	NA	-0.42	-4.6	-0.35	9e-6	Multiple sclerosis;
PAAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg08493051	chr2:3487164	NA	-0.75	-7.22	-0.51	2.32e-11	Neurofibrillary tangles;
PAAD	cis	rs3736485	0.934	rs4143721	chr15:51866781	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6466055	0.777	rs10487150	chr7:104797450	A/C	cg04380332	chr7:105027541	SRPK2	-0.64	-7.14	-0.5	3.56e-11	Schizophrenia;
PAAD	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.73	0.36	5.18e-6	Obesity-related traits;
PAAD	cis	rs747650	0.504	rs7945558	chr11:46957808	G/A	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.06	0.38	1.18e-6	Blood protein levels;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.85	6.37	0.46	2.12e-9	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.81	8.83	0.58	2.31e-15	Mortality in heart failure;
PAAD	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg03938978	chr2:103052716	IL18RAP	0.51	5.18	0.39	6.86e-7	Blood protein levels;
PAAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-8.58	-0.57	1.04e-14	Mean platelet volume;
PAAD	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-4.41	-0.34	1.94e-5	Metabolite levels;
PAAD	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.4	5.44	0.4	2.09e-7	Oropharynx cancer;
PAAD	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg20092376	chr4:56023423	NA	0.47	4.82	0.36	3.46e-6	Endometriosis;
PAAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg09835421	chr16:68378352	PRMT7	-1.31	-9.43	-0.61	6.47e-17	Schizophrenia;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.53	4.35	0.33	2.46e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg02776659	chr21:47717406	C21orf57	0.42	4.39	0.34	2.12e-5	Testicular germ cell tumor;
PAAD	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.68	5.75	0.42	4.77e-8	Exhaled nitric oxide output;
PAAD	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg02475695	chr16:616220	NHLRC4	0.47	5.43	0.4	2.2e-7	Height;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.35	0.33	2.46e-5	Bipolar disorder;
PAAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.62	-0.35	8.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.84	-13.03	-0.73	1.59e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4144743	1.000	rs11871251	chr17:45331427	G/A	cg18085866	chr17:45331354	ITGB3	-0.89	-7.35	-0.51	1.13e-11	Body mass index;
PAAD	cis	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg15590007	chr10:45870220	ALOX5	0.54	5.17	0.39	7.2e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg01620082	chr3:125678407	NA	-0.92	-6.64	-0.47	5.21e-10	Depression;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	6.99	0.49	8e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7582720	1.000	rs72932727	chr2:203649501	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.47	0.52	5.81e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.35e-5	Testicular germ cell tumor;
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg14008862	chr17:28927542	LRRC37B2	-0.68	-5.0	-0.38	1.54e-6	Body mass index;
PAAD	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg27236539	chr20:62289627	RTEL1	0.58	4.68	0.36	6.2e-6	Atopic dermatitis;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg09699651	chr6:150184138	LRP11	0.52	5.37	0.4	2.93e-7	Lung cancer;
PAAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.45	0.34	1.63e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.6	-6.97	-0.49	8.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-4.27	-0.33	3.49e-5	Testicular germ cell tumor;
PAAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.49	8.01	0.54	2.74e-13	IgG glycosylation;
PAAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg09324608	chr17:30823087	MYO1D	0.48	4.83	0.36	3.32e-6	Schizophrenia;
PAAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs16857609	0.564	rs1478581	chr2:218292652	C/T	cg15335768	chr2:218268053	DIRC3	-0.49	-5.09	-0.38	1.05e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.51	0.34	1.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.61	-0.41	9.45e-8	Schizophrenia;
PAAD	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg02487422	chr3:49467188	NICN1	0.48	4.88	0.37	2.62e-6	Resting heart rate;
PAAD	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.86	10.94	0.66	6.39e-21	Body mass index;
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg15691649	chr6:25882328	NA	0.51	4.59	0.35	9.34e-6	Blood metabolite levels;
PAAD	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg27094323	chr7:1216898	NA	-0.47	-5.42	-0.4	2.34e-7	Longevity;Endometriosis;
PAAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg11518657	chr1:67396239	MIER1	-0.68	-5.11	-0.38	9.43e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.65	7.98	0.54	3.31e-13	Inflammatory bowel disease;
PAAD	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.71	6.53	0.47	9.1e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs501120	0.810	rs684666	chr10:44745847	T/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.59	-6.2	-0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07777599	chr8:81487959	NA	-0.66	-6.86	-0.49	1.59e-10	Obesity-related traits;
PAAD	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.66	-7.01	-0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.62	5.89	0.43	2.36e-8	Blood metabolite levels;
PAAD	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.39	0.34	2.11e-5	Hepatocellular carcinoma;
PAAD	cis	rs6782025	0.716	rs583955	chr3:120713325	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.43	4.3	0.33	3.05e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.88	9.36	0.6	9.87e-17	Corneal astigmatism;
PAAD	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.68	6.21	0.45	4.84e-9	Blood metabolite levels;
PAAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-6.15	-0.45	6.69e-9	Blood metabolite levels;
PAAD	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Height;
PAAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.71	7.92	0.54	4.62e-13	Cisplatin-induced ototoxicity;
PAAD	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.49	4.89	0.37	2.55e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.71	8.14	0.55	1.32e-13	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.32	6.04	0.44	1.13e-8	Skin colour saturation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15847614	chr17:6348019	FAM64A	0.5	6.32	0.46	2.8e-9	Monocyte percentage of white cells;
PAAD	cis	rs876084	0.505	rs12680859	chr8:121118968	A/G	cg06265175	chr8:121136014	COL14A1	0.48	4.66	0.35	6.95e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg12123941	chr10:130493103	NA	-0.41	-4.28	-0.33	3.31e-5	Vitamin D levels;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.81	-6.65	-0.47	5.01e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13198984	chr17:80129470	CCDC57	-0.43	-5.47	-0.41	1.82e-7	Life satisfaction;
PAAD	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg23920097	chr1:209922102	NA	-0.49	-4.46	-0.34	1.6e-5	Red blood cell count;
PAAD	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.66	-7.28	-0.51	1.67e-11	Schizophrenia;
PAAD	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.15	-13.64	-0.74	3.68e-28	Type 1 diabetes nephropathy;
PAAD	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.77	-6.39	-0.46	1.89e-9	Blood trace element (Cu levels);
PAAD	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.64	6.51	0.47	1.02e-9	Blood protein levels;
PAAD	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg23024343	chr7:107201750	COG5	-0.55	-4.58	-0.35	9.51e-6	Coronary artery disease;
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.62	5.72	0.42	5.37e-8	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18633736	chr12:120639105	RPLP0	-0.56	-6.31	-0.46	2.83e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.48	-4.68	-0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs73416724	0.614	rs78882866	chr6:43263473	T/G	cg26312998	chr6:43337775	ZNF318	0.63	4.38	0.33	2.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3736485	0.934	rs17609812	chr15:51879260	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs735539	0.521	rs7997062	chr13:21368822	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.65	0.35	7.22e-6	Dental caries;
PAAD	cis	rs950880	0.710	rs55927292	chr2:102964861	C/T	cg03938978	chr2:103052716	IL18RAP	-0.39	-4.37	-0.33	2.3e-5	Serum protein levels (sST2);
PAAD	cis	rs1934953	0.503	rs1200313	chr10:96722059	C/A	cg09036531	chr10:96991505	NA	-0.55	-5.21	-0.39	6.1e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs12779281	chr10:45977447	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.9e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	cis	rs3733418	0.799	rs35680343	chr4:165953134	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.52	-4.9	-0.37	2.48e-6	Obesity-related traits;
PAAD	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-1.01	-7.74	-0.53	1.31e-12	Blood protein levels;
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.7	-5.82	-0.43	3.45e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.74	8.47	0.57	2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs75920871	0.925	rs61903399	chr11:116942475	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6723226	0.750	rs762019	chr2:32688601	A/C	cg02381751	chr2:32503542	YIPF4	0.69	7.72	0.53	1.43e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	4.48	0.34	1.46e-5	Systolic blood pressure;
PAAD	cis	rs8112211	0.599	rs2887262	chr19:38831311	A/G	cg14299480	chr19:38876666	GGN	-0.51	-4.45	-0.34	1.64e-5	Blood protein levels;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg16300553	chr8:8131077	NA	0.36	4.26	0.33	3.63e-5	Mood instability;
PAAD	cis	rs17135859	0.672	rs35039050	chr5:113016563	C/T	cg12552261	chr5:112820674	MCC	0.73	4.37	0.33	2.27e-5	F-cell distribution;
PAAD	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.9	8.76	0.58	3.67e-15	Exhaled nitric oxide output;
PAAD	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.7	-7.16	-0.5	3.2e-11	Primary sclerosing cholangitis;
PAAD	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.63	0.47	5.45e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg19429281	chr19:53496738	ZNF702P	-0.48	-4.92	-0.37	2.23e-6	Psoriasis;
PAAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.8	-0.36	3.69e-6	Life satisfaction;
PAAD	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.36	-5.08	-0.38	1.07e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.82	9.54	0.61	3.49e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg07148914	chr20:33460835	GGT7	0.48	4.79	0.36	3.94e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.68	7.02	0.49	6.81e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg21665744	chr7:39171113	POU6F2	0.34	5.61	0.41	9.27e-8	IgG glycosylation;
PAAD	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-8.39	-0.56	3.08e-14	Morning vs. evening chronotype;
PAAD	cis	rs375066	0.868	rs370190	chr19:44424254	A/T	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	6.55	0.47	8.59e-10	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20705251	chr17:7382278	ZBTB4	0.59	6.78	0.48	2.49e-10	Myopia (pathological);
PAAD	cis	rs4713118	0.500	rs9461434	chr6:28102465	A/C	cg23281280	chr6:28129359	ZNF389	0.68	4.95	0.37	1.99e-6	Parkinson's disease;
PAAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.12	0.67	2.13e-21	Menopause (age at onset);
PAAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.91	-10.96	-0.66	5.88e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg11843238	chr5:131593191	PDLIM4	-0.48	-4.47	-0.34	1.51e-5	Acylcarnitine levels;
PAAD	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.64	9.17	0.6	3.09e-16	IgG glycosylation;
PAAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-6.77	-0.48	2.6200000000000003e-10	Migraine;Coronary artery disease;
PAAD	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.68	-7.34	-0.51	1.22e-11	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg03948781	chr1:205179583	DSTYK	0.45	4.28	0.33	3.26e-5	Red blood cell count;
PAAD	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs17023223	0.537	rs2645300	chr1:119603067	C/A	cg17326555	chr1:119535693	NA	-0.43	-5.32	-0.4	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.82	9.81	0.62	6.73e-18	Blood metabolite ratios;
PAAD	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg23435118	chr5:141488016	NDFIP1	-0.57	-5.54	-0.41	1.32e-7	Crohn's disease;
PAAD	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs818427	0.964	rs456313	chr5:112224952	G/C	cg07820702	chr5:112228657	REEP5	-0.5	-4.56	-0.35	1.05e-5	Total body bone mineral density;
PAAD	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.58	-0.35	9.67e-6	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.98	0.54	3.36e-13	Response to antipsychotic treatment;
PAAD	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg09179987	chr1:167433047	CD247	0.51	5.93	0.43	1.99e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.59	-5.75	-0.42	4.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.62	-4.78	-0.36	4.04e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.83	9.42	0.61	7.18e-17	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02999463	chr8:37707322	BRF2	0.59	6.51	0.47	1.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.66	7.3	0.51	1.47e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg04844267	chr4:1394941	NA	0.53	5.79	0.43	3.91e-8	Obesity-related traits;
PAAD	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-5.12	-0.38	9.06e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg00531865	chr16:30841666	NA	-0.52	-5.09	-0.38	1.03e-6	Dementia with Lewy bodies;
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.43	-0.56	2.41e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-7.32	-0.51	1.36e-11	Neuroticism;
PAAD	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.99	-10.27	-0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	5.11	0.38	9.64e-7	Mood instability;
PAAD	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg02404636	chr22:31891804	SFI1	-0.56	-5.04	-0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.73	8.17	0.55	1.09e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-1.08	-7.77	-0.53	1.09e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.44e-7	Life satisfaction;
PAAD	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.18	-8.15	-0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg02841227	chr6:26021843	HIST1H4A	0.49	4.91	0.37	2.31e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-7.28	-0.51	1.71e-11	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.76	-6.31	-0.46	2.88e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.71	7.62	0.53	2.49e-12	Platelet distribution width;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs2814982	0.605	rs73405697	chr6:34470396	T/C	cg14254433	chr6:34482411	PACSIN1	-1.1	-6.29	-0.45	3.18e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.97	11.71	0.69	5.69e-23	Bone mineral density;
PAAD	trans	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.92	9.87	0.62	4.63e-18	Cleft lip with or without cleft palate;
PAAD	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09747230	chr5:43613142	NNT	-0.72	-7.41	-0.52	8e-12	Obesity-related traits;
PAAD	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg26876637	chr1:152193138	HRNR	0.87	6.52	0.47	9.63e-10	Atopic dermatitis;
PAAD	cis	rs6694270	0.529	rs12565650	chr1:19108355	G/A	cg19637330	chr1:19110922	NA	-0.65	-5.27	-0.39	4.63e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs13177180	0.671	rs10043094	chr5:114919459	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.48	-5.09	-0.38	1.03e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.27e-26	Breast cancer;
PAAD	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.53	0.57	1.38e-14	Morning vs. evening chronotype;
PAAD	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	4.29	0.33	3.17e-5	Menarche (age at onset);
PAAD	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Resting heart rate;
PAAD	cis	rs61884328	0.852	rs61884324	chr11:46762817	G/A	cg23433285	chr11:47201945	PACSIN3	0.84	4.31	0.33	2.89e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.65	5.38	0.4	2.79e-7	Prostate cancer;
PAAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.82	-6.83	-0.48	1.96e-10	Initial pursuit acceleration;
PAAD	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-6.09	-0.44	8.65e-9	Metabolite levels;
PAAD	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs965604	1.000	rs965604	chr15:78789223	G/A	cg18825076	chr15:78729989	IREB2	-0.47	-4.56	-0.35	1.04e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.82	-0.43	3.34e-8	Prostate cancer;
PAAD	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg11619707	chr19:22235551	ZNF257	0.58	5.77	0.42	4.26e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs593531	0.614	rs10736795	chr11:74039546	A/G	cg15670924	chr11:73669256	DNAJB13	-0.45	-4.55	-0.35	1.08e-5	Neuroticism;
PAAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.51	6.21	0.45	4.92e-9	Longevity;Endometriosis;
PAAD	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.47	-5.26	-0.39	4.85e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.47	5.01	0.38	1.47e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7009516	0.819	rs11986557	chr8:24221339	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.47	-5.63	-0.42	8.45e-8	Hair greying;
PAAD	trans	rs901683	0.702	rs113478021	chr10:46063563	C/T	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.69	6.74	0.48	3.15e-10	Coronary artery disease;
PAAD	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg16964102	chr10:135390573	NA	-0.42	-4.49	-0.34	1.39e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.77	-0.42	4.27e-8	Life satisfaction;
PAAD	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg08562672	chr19:21860753	NA	-0.47	-4.95	-0.37	1.96e-6	Pain;
PAAD	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14342823	chr17:10584091	SCO1	0.67	7.05	0.5	5.94e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	11.29	0.68	7.75e-22	IgG glycosylation;
PAAD	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.6	5.84	0.43	3e-8	Eye color traits;
PAAD	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg17718321	chr1:152188247	HRNR	0.51	4.96	0.37	1.85e-6	Inflammatory skin disease;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07685180	chr8:600429	NA	0.81	5.16	0.39	7.57e-7	IgG glycosylation;
PAAD	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.66	-0.35	6.95e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs77633900	0.772	rs2957612	chr15:76703688	C/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs790123	0.579	rs9875934	chr3:122396599	A/C	cg15604389	chr3:122379662	NA	0.55	5.0	0.38	1.55e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs73019876	0.869	rs11085504	chr19:22148582	A/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.28	-0.33	3.32e-5	Testicular germ cell tumor;
PAAD	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	0.555	rs2818987	chr13:21304911	C/T	cg27234864	chr13:21295941	IL17D	0.58	4.96	0.37	1.88e-6	Dental caries;
PAAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3738772	1.000	rs527277	chr1:110046093	G/A	cg08704217	chr1:110036942	CYB561D1	0.5	4.68	0.35	6.31e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.8	9.78	0.62	8.15e-18	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.55	5.45	0.4	2.01e-7	Prudent dietary pattern;
PAAD	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.78	6.78	0.48	2.51e-10	Blood pressure (smoking interaction);
PAAD	cis	rs904092	0.671	rs10002894	chr4:100141240	G/A	cg12011299	chr4:100065546	ADH4	-0.48	-4.44	-0.34	1.76e-5	Alcohol dependence;
PAAD	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs1816752	0.716	rs9553289	chr13:24974778	T/A	cg02811702	chr13:24901961	NA	-0.46	-4.69	-0.36	6e-6	Obesity-related traits;
PAAD	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	1.13	14.47	0.76	2.2e-30	Migraine;
PAAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	0.97	10.08	0.63	1.3e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg09760422	chr2:128146352	NA	0.4	6.04	0.44	1.15e-8	Self-rated health;
PAAD	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	7.63	0.53	2.43e-12	Eotaxin levels;
PAAD	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.37	-0.46	2.09e-9	Mood instability;
PAAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg23346134	chr3:49453900	TCTA	-0.46	-4.96	-0.37	1.9e-6	Menarche (age at onset);
PAAD	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.43	-0.34	1.78e-5	IgG glycosylation;
PAAD	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.4	-0.34	1.99e-5	Height;
PAAD	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.66	0.35	6.89e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg07883600	chr3:53528162	CACNA1D	-0.43	-4.61	-0.35	8.56e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.75	-7.43	-0.52	7.16e-12	White matter hyperintensity burden;
PAAD	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg25722041	chr1:8623473	RERE	0.52	4.54	0.35	1.12e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20419410	chr7:155089803	INSIG1	0.63	6.58	0.47	7.07e-10	Myopia (pathological);
PAAD	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.05e-15	Exhaled nitric oxide output;
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07157834	chr1:205819609	PM20D1	0.53	5.14	0.38	8.32e-7	Parkinson's disease;
PAAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.48e-14	Renal cell carcinoma;
PAAD	cis	rs12799264	1.000	rs4757866	chr11:19979083	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.33	-0.4	3.44e-7	Mean platelet volume;
PAAD	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06850241	chr22:41845214	NA	-0.45	-4.31	-0.33	2.88e-5	Vitiligo;
PAAD	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.39	-5.27	-0.39	4.68e-7	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.45	4.61	0.35	8.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg08088566	chr11:430123	ANO9	0.85	5.39	0.4	2.7e-7	Body mass index;
PAAD	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg14686297	chr22:46650375	NA	-0.45	-4.42	-0.34	1.86e-5	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.78	-0.48	2.55e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.37	-0.33	2.25e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.84	-8.77	-0.58	3.4e-15	Total body bone mineral density;
PAAD	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs66530629	0.917	rs4648879	chr1:25175246	A/G	cg01905478	chr1:25040257	NA	-0.51	-5.68	-0.42	6.68e-8	Plateletcrit;
PAAD	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg18357526	chr6:26021779	HIST1H4A	0.51	4.56	0.35	1.06e-5	Height;
PAAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.84	9.67	0.62	1.57e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.81	9.76	0.62	8.82e-18	Coronary artery disease;
PAAD	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.76	5.61	0.41	9.46e-8	Initial pursuit acceleration;
PAAD	cis	rs4523957	0.757	rs216199	chr17:2200871	C/T	cg16513277	chr17:2031491	SMG6	0.53	5.64	0.42	8.14e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.68	-0.42	6.59e-8	Coronary artery disease;
PAAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg03037974	chr15:76606532	NA	0.51	5.56	0.41	1.21e-7	Blood metabolite levels;
PAAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.81	-0.43	3.59e-8	Gut microbiome composition (summer);
PAAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26253258	chr20:60697513	LSM14B	-0.61	-7.51	-0.52	4.78e-12	Body fat percentage;
PAAD	cis	rs6681460	0.966	rs4655506	chr1:67150811	C/T	cg02459107	chr1:67143332	SGIP1	0.75	7.57	0.52	3.34e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg09017928	chr7:158110068	PTPRN2	0.45	4.54	0.35	1.12e-5	Calcium levels;
PAAD	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18621852	chr3:10150065	C3orf24	0.64	5.51	0.41	1.5e-7	Alzheimer's disease;
PAAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.61	5.21	0.39	5.94e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.89	-10.37	-0.64	2.23e-19	Coronary artery disease;
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.5	7.18	0.5	2.9100000000000002e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7896691	0.925	rs56221890	chr10:3151824	G/A	cg15228268	chr10:3146741	PFKP	0.9	4.75	0.36	4.72e-6	Disc degeneration (lumbar);
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg22442454	chr1:209979470	IRF6	0.51	4.5	0.34	1.37e-5	Coronary artery disease;
PAAD	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.42	-6.17	-0.45	6.06e-9	Migraine;
PAAD	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs7224685	0.689	rs67831913	chr17:4184856	T/C	cg09695851	chr17:3907499	NA	0.64	5.38	0.4	2.82e-7	Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg06740227	chr12:86229804	RASSF9	-0.5	-4.95	-0.37	1.91e-6	Major depressive disorder;
PAAD	cis	rs7624766	0.743	rs959960	chr3:160469056	T/C	cg22637730	chr3:160473554	PPM1L	0.55	4.9	0.37	2.42e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.88	10.37	0.64	2.18e-19	Ulcerative colitis;
PAAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg07181952	chr1:1239999	ACAP3	0.42	4.43	0.34	1.77e-5	Height;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg10729496	chr3:10149963	C3orf24	0.9	7.56	0.52	3.56e-12	Alzheimer's disease;
PAAD	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.07	0.55	1.93e-13	Dupuytren's disease;
PAAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.58	6.56	0.47	8.07e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.51	4.75	0.36	4.64e-6	Hepatocellular carcinoma;
PAAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg01800442	chr17:74086473	EXOC7	0.54	4.33	0.33	2.68e-5	Psoriasis;
PAAD	cis	rs9361491	0.608	rs7747874	chr6:79437394	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6782025	0.837	rs1688683	chr3:120766444	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1198872	0.892	rs10427170	chr2:10902170	C/T	cg07921008	chr2:10924176	ATP6V1C2;PDIA6	-0.44	-4.26	-0.33	3.62e-5	Cardiac Troponin-T levels;
PAAD	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	4.41	0.34	1.91e-5	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-5.67	-0.42	7e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.82	8.96	0.59	1.08e-15	Tuberculosis;
PAAD	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.59	4.75	0.36	4.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.04	-0.63	1.64e-18	Coronary artery disease;
PAAD	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-4.94	-0.37	2.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.95	8.23	0.56	7.88e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.91	5.35	0.4	3.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg18240062	chr17:79603768	NPLOC4	0.57	5.58	0.41	1.09e-7	Myopia;
PAAD	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.98	-8.86	-0.58	1.93e-15	IgG glycosylation;
PAAD	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	1.17	12.94	0.72	2.77e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.4	4.26	0.33	3.5e-5	Cystic fibrosis severity;
PAAD	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.57	5.76	0.42	4.57e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.04e-7	Bipolar disorder;
PAAD	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.08	-0.55	1.89e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs818427	0.896	rs460832	chr5:112225148	G/A	cg07820702	chr5:112228657	REEP5	-0.52	-4.67	-0.35	6.53e-6	Total body bone mineral density;
PAAD	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg05250797	chr16:70222502	NA	0.69	5.24	0.39	5.28e-7	IgE levels;
PAAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.58	8.13	0.55	1.39e-13	Thyroid hormone levels;
PAAD	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg22532475	chr10:104410764	TRIM8	-0.39	-4.6	-0.35	8.93e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.56	6.51	0.47	1.02e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.32	4.94	0.37	2.06e-6	Diastolic blood pressure;
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg07068956	chr7:100330872	ZAN	-0.69	-5.39	-0.4	2.66e-7	Other erythrocyte phenotypes;
PAAD	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	5.02	0.38	1.44e-6	Ovarian reserve;
PAAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.75	-6.07	-0.44	9.77e-9	Blood protein levels;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-5.21	-0.39	5.92e-7	Lymphocyte counts;
PAAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-6.06	-0.44	1.04e-8	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.83	5.69	0.42	6.24e-8	Diabetic kidney disease;
PAAD	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.68	6.39	0.46	1.9e-9	Lymphocyte counts;
PAAD	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.81	8.9	0.59	1.55e-15	Mortality in heart failure;
PAAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg19052272	chr2:3704530	ALLC	-0.57	-6.76	-0.48	2.78e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10029851	0.645	rs1436504	chr4:109625184	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	-0.48	-4.53	-0.34	1.18e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.79	-0.36	3.93e-6	Educational attainment;
PAAD	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.64	6.45	0.46	1.42e-9	Schizophrenia;
PAAD	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.54	4.33	0.33	2.74e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.87	-0.49	1.59e-10	Atrioventricular conduction;
PAAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg14092988	chr3:52407081	DNAH1	0.44	5.47	0.41	1.77e-7	Bipolar disorder;
PAAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.55	-5.27	-0.39	4.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6142102	0.517	rs8119076	chr20:32525715	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	4.42	0.34	1.89e-5	Skin pigmentation;
PAAD	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg03684893	chr10:554711	DIP2C	0.53	5.07	0.38	1.13e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.73e-6	Coronary artery disease;
PAAD	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.68	7.27	0.51	1.81e-11	Metabolic syndrome;
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.66	6.16	0.45	6.2e-9	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg00450029	chr8:599525	NA	0.8	5.03	0.38	1.38e-6	IgG glycosylation;
PAAD	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2252790	0.859	rs2858848	chr6:116679275	A/G	cg18764771	chr6:116381957	FRK	-0.27	-4.37	-0.33	2.32e-5	Fast beta electroencephalogram;
PAAD	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.79	6.39	0.46	1.97e-9	Neutrophil percentage of white cells;
PAAD	cis	rs1334894	1.000	rs747411	chr6:35586373	G/A	cg07213720	chr6:35227408	ZNF76	-0.87	-4.85	-0.37	3.03e-6	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18440188	chr14:50999316	MAP4K5;ATL1	-0.74	-6.51	-0.47	1.06e-9	Neuroticism;
PAAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg18200150	chr17:30822561	MYO1D	0.57	7.1	0.5	4.51e-11	Schizophrenia;
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.76	4.31	0.33	2.93e-5	Coronary artery disease;
PAAD	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg01329690	chr21:38580129	DSCR9	0.32	4.26	0.33	3.55e-5	Eye color traits;
PAAD	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.86	-11.51	-0.68	1.91e-22	Height;
PAAD	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg23254163	chr1:152506842	NA	0.5	4.97	0.37	1.82e-6	Hair morphology;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg00431813	chr7:1051703	C7orf50	0.75	4.8	0.36	3.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg12935359	chr14:103987150	CKB	0.61	6.46	0.46	1.35e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg22153463	chr1:85462885	MCOLN2	0.64	5.04	0.38	1.33e-6	Serum sulfate level;
PAAD	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.77	0.36	4.35e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg12623918	chr2:306882	NA	0.46	4.8	0.36	3.7e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.23	-0.6	2.19e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.56	-0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25809561	chr17:30822961	MYO1D	0.57	6.14	0.45	6.76e-9	Schizophrenia;
PAAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.99	-10.1	-0.63	1.17e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.62	-5.71	-0.42	5.82e-8	Lung cancer;
PAAD	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.8	-0.43	3.7e-8	Total cholesterol levels;
PAAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.67	5.81	0.43	3.53e-8	Inflammatory skin disease;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg14926445	chr8:58193284	C8orf71	-0.56	-4.51	-0.34	1.29e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg24849736	chr1:201084428	NA	0.44	4.38	0.33	2.2e-5	Permanent tooth development;
PAAD	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.44	-0.52	6.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg01388757	chr2:102091195	RFX8	-0.64	-8.19	-0.55	9.9e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6804624	0.636	rs2670335	chr3:99161297	C/T	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.72e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg00280220	chr17:61926910	NA	0.42	4.5	0.34	1.33e-5	Prudent dietary pattern;
PAAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg15847926	chr7:2749597	AMZ1	0.41	4.87	0.37	2.83e-6	Height;
PAAD	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg22325292	chr17:80708367	FN3K	-0.66	-4.49	-0.34	1.39e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.28	0.33	3.33e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09256448	chr16:638327	NA	0.42	4.39	0.34	2.09e-5	Height;
PAAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.61	4.81	0.36	3.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-4.57	-0.35	9.86e-6	Diastolic blood pressure;
PAAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs7236492	0.935	rs77865749	chr18:77216756	G/A	cg15644404	chr18:77186268	NFATC1	-0.88	-6.13	-0.45	7.12e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.58	-5.98	-0.44	1.51e-8	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72827839	0.779	rs59386258	chr17:46499918	T/C	cg23391107	chr17:45924227	SP6	0.5	4.78	0.36	4.17e-6	Ease of getting up in the morning;
PAAD	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg01868782	chr6:126071099	HEY2	0.43	4.88	0.37	2.64e-6	High light scatter reticulocyte count;
PAAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.76	-8.03	-0.55	2.47e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.83	7.09	0.5	4.62e-11	Brain cytoarchitecture;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg16589663	chr20:23618590	CST3	0.75	6.5	0.47	1.08e-9	Chronic kidney disease;
PAAD	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-5.02	-0.38	1.45e-6	Pancreatic cancer;
PAAD	cis	rs939584	0.935	rs7579427	chr2:631183	C/A	cg03610516	chr2:642275	NA	0.59	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.55	-0.57	1.2e-14	Type 2 diabetes;
PAAD	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.51	-0.41	1.51e-7	Colorectal cancer;
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg25124228	chr12:125621409	AACS	-0.68	-6.61	-0.47	6.14e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.92	-11.77	-0.69	3.75e-23	Coronary artery disease;
PAAD	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.72e-5	Self-reported allergy;
PAAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.31	13.64	0.74	3.56e-28	Eosinophil percentage of granulocytes;
PAAD	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.74	7.39	0.51	9.22e-12	Resting heart rate;
PAAD	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00339695	chr16:24857497	SLC5A11	0.46	4.3	0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.37	9.4	0.61	7.67e-17	Diabetic retinopathy;
PAAD	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.25	-0.33	3.65e-5	Educational attainment (years of education);
PAAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs58521262	0.556	rs289339	chr19:23150899	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.94	-8.14	-0.55	1.3e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13870426	chr17:30244630	NA	-0.78	-7.63	-0.53	2.46e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.89	-15.18	-0.78	2.93e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.49	-0.61	4.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.61	-7.81	-0.53	8.93e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.55	4.49	0.34	1.39e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.16	-0.45	6.28e-9	Schizophrenia;
PAAD	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg18477163	chr1:228402036	OBSCN	-0.53	-6.96	-0.49	9.65e-11	Parkinson's disease;
PAAD	cis	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.95	-6.1	-0.44	8.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.66	7.34	0.51	1.23e-11	Tonsillectomy;
PAAD	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg13207630	chr7:32358064	NA	0.97	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg24562669	chr7:97807699	LMTK2	-0.45	-5.13	-0.38	8.72e-7	Breast cancer;
PAAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.29	0.39	4.29e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.09	0.5	4.77e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg03676636	chr4:99064102	C4orf37	0.25	4.26	0.33	3.6e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg08992911	chr2:238395768	MLPH	0.52	5.25	0.39	4.94e-7	Prostate cancer;
PAAD	trans	rs10767455	1.000	rs16914608	chr11:25794091	C/T	cg11239016	chr16:90085722	DBNDD1	0.61	6.44	0.46	1.5e-9	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-4.57	-0.35	1.01e-5	Metabolite levels;
PAAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.72	8.0	0.54	3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	0.95	6.76	0.48	2.81e-10	Pulse pressure;
PAAD	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.62	5.65	0.42	7.74e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.69	9.97	0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.87	10.82	0.66	1.41e-20	Lung cancer;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15025362	chr3:186256331	CRYGS	0.5	5.24	0.39	5.33e-7	Myopia (pathological);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17514098	chr12:125302114	SCARB1	0.58	6.63	0.47	5.46e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.64	0.8	4.72e-36	Prudent dietary pattern;
PAAD	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.12	-0.38	9.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.67	6.18	0.45	5.51e-9	Coronary artery disease;
PAAD	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg06375148	chr1:209958343	C1orf74	0.66	4.83	0.36	3.31e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg14393609	chr7:65229607	NA	-0.47	-4.52	-0.34	1.25e-5	Aortic root size;
PAAD	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.36	4.6	0.35	8.94e-6	Calcium levels;
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.43	-6.2	-0.45	5.04e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.89	10.22	0.64	5.5e-19	Sudden cardiac arrest;
PAAD	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.01	0.49	7.17e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.56	-0.41	1.18e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg09873201	chr16:3507582	NAT15	0.59	5.53	0.41	1.38e-7	Tuberculosis;
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs4972755	0.696	rs7579257	chr2:176221858	A/G	cg10142566	chr2:175645413	NA	-0.5	-4.35	-0.33	2.45e-5	Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs1879734	0.689	rs11206191	chr1:54158102	A/G	cg14659662	chr1:54151053	GLIS1	0.44	5.8	0.43	3.74e-8	Mitral valve prolapse;
PAAD	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.53	5.69	0.42	6.45e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg03948781	chr1:205179583	DSTYK	0.48	4.47	0.34	1.52e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12220238	0.822	rs2395087	chr10:76082637	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg13160058	chr8:26243215	BNIP3L	-0.38	-4.63	-0.35	7.71e-6	Red cell distribution width;
PAAD	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg27205649	chr11:78285834	NARS2	-0.62	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs16857609	0.564	rs12624106	chr2:218290445	A/G	cg15335768	chr2:218268053	DIRC3	-0.49	-5.09	-0.38	1.05e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.56	-5.98	-0.44	1.52e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.91e-7	Red blood cell count;
PAAD	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs901683	1.000	rs71496611	chr10:46021732	G/A	cg06308084	chr22:50493570	TTLL8	0.84	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs367943	0.698	rs4336355	chr5:113000368	C/T	cg12552261	chr5:112820674	MCC	0.62	6.71	0.48	3.65e-10	Type 2 diabetes;
PAAD	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg17830980	chr10:43048298	ZNF37B	0.67	7.77	0.53	1.07e-12	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.53	5.08	0.38	1.07e-6	Motion sickness;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.64	5.97	0.44	1.63e-8	Blood metabolite levels;
PAAD	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs2017305	0.834	rs12266901	chr10:70783522	T/C	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.54	-0.41	1.31e-7	Depression (quantitative trait);
PAAD	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.78e-10	Plateletcrit;Platelet count;
PAAD	cis	rs6681460	1.000	rs6689864	chr1:67068112	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.74	0.53	1.28e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs9398803	0.687	rs1538956	chr6:126964026	G/T	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.8	9.84	0.62	5.42e-18	Metabolic syndrome;
PAAD	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg03948781	chr1:205179583	DSTYK	0.47	4.7	0.36	5.68e-6	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
PAAD	cis	rs501120	0.925	rs494045	chr10:44773498	C/T	cg09554077	chr10:44749378	NA	0.43	5.3	0.39	4.03e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.65	-5.03	-0.38	1.37e-6	Vitiligo;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.34e-13	Alzheimer's disease;
PAAD	cis	rs2034088	0.897	rs4968124	chr17:436900	T/C	cg20761395	chr17:511517	VPS53	0.48	4.69	0.36	5.93e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16905586	chr3:49761211	GMPPB	0.7	7.94	0.54	4.12e-13	Myopia (pathological);
PAAD	cis	rs9815354	0.597	rs112912733	chr3:42054910	C/A	cg03022575	chr3:42003672	ULK4	0.88	4.73	0.36	5.03e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10899021	0.704	rs11236177	chr11:74339067	T/C	cg25880958	chr11:74394337	NA	-0.76	-4.79	-0.36	3.9e-6	Response to metformin (IC50);
PAAD	cis	rs10774547	0.965	rs11065109	chr12:120863914	T/C	cg10072921	chr12:121022843	NA	-0.35	-4.25	-0.33	3.65e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
PAAD	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg09127314	chr1:152161683	NA	0.68	4.91	0.37	2.28e-6	Atopic dermatitis;
PAAD	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg23688817	chr7:87105293	ABCB4	0.55	4.53	0.35	1.17e-5	Gallbladder cancer;
PAAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.65	-6.15	-0.45	6.45e-9	Tuberculosis;
PAAD	cis	rs10793968	0.688	rs4740366	chr9:133630622	C/T	cg01474677	chr9:133586259	NA	0.6	4.56	0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.23e-5	Life satisfaction;
PAAD	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.5	-5.59	-0.41	1.02e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2302729	0.515	rs10161158	chr12:2768972	T/A	cg19945202	chr12:2788847	CACNA1C	-0.72	-7.16	-0.5	3.19e-11	Sleep quality;
PAAD	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.23	0.6	2.21e-16	Morning vs. evening chronotype;
PAAD	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14019695	chr9:139328340	INPP5E	0.62	6.68	0.48	4.24e-10	Monocyte percentage of white cells;
PAAD	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.44	-0.46	1.5e-9	Hip circumference;
PAAD	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.73	-8.94	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.98	6.68	0.48	4.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8032158	1.000	rs2288344	chr15:56122347	T/G	cg02198044	chr15:56286336	NEDD4	-0.52	-5.48	-0.41	1.77e-7	Keloid;
PAAD	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg05627522	chr15:75251581	NA	-0.4	-4.39	-0.34	2.14e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7631605	0.875	rs7616105	chr3:37229522	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.49e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.99e-7	Monocyte percentage of white cells;
PAAD	cis	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg14545590	chr8:40388592	ZMAT4	-0.46	-5.14	-0.38	8.3e-7	Parkinson's disease (motor and cognition);
PAAD	cis	rs939584	1.000	rs6751993	chr2:635864	A/G	cg14515364	chr2:636606	NA	0.48	4.31	0.33	2.88e-5	Body mass index;
PAAD	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.69	7.61	0.53	2.66e-12	Cognitive function;
PAAD	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg12907477	chr18:56117327	MIR122	0.61	4.77	0.36	4.3e-6	Platelet count;
PAAD	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.58	4.78	0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs17152411	0.625	rs10751611	chr10:126658893	A/G	cg07081759	chr10:126330905	FAM53B	-0.39	-4.28	-0.33	3.34e-5	Height;
PAAD	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg16342193	chr10:102329863	NA	-0.82	-8.99	-0.59	9.15e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.71	5.8	0.43	3.7e-8	Methadone dose in opioid dependence;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.75	8.3	0.56	5.17e-14	Lung cancer;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg05096259	chr3:69101575	TMF1	-0.68	-6.92	-0.49	1.19e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg14416269	chr4:6271139	WFS1	0.68	6.46	0.46	1.37e-9	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.89	6.34	0.46	2.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg00450029	chr8:599525	NA	-0.81	-5.63	-0.42	8.35e-8	IgG glycosylation;
PAAD	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg02743256	chr7:2109353	MAD1L1	-0.66	-5.2	-0.39	6.3e-7	Bipolar disorder;
PAAD	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.77	8.1	0.55	1.65e-13	Uric acid levels;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.8	9.18	0.6	2.97e-16	Lung cancer;
PAAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.55	5.13	0.38	8.57e-7	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	1.04	12.75	0.72	8.8e-26	Primary sclerosing cholangitis;
PAAD	trans	rs12127679	0.614	rs12118536	chr1:244168955	T/C	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.86	-9.04	-0.59	6.72e-16	Menopause (age at onset);
PAAD	cis	rs5756391	0.782	rs735562	chr22:37296946	C/G	cg16356956	chr22:37317934	CSF2RB	0.36	4.51	0.34	1.27e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.62	5.82	0.43	3.34e-8	Height;
PAAD	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.74	-0.36	4.84e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7925523	1.000	rs7925523	chr11:61442492	G/A	cg12472022	chr11:61462803	DAGLA	0.66	5.63	0.42	8.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	Cognitive function;
PAAD	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.68	5.57	0.41	1.15e-7	Putamen volume;
PAAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg09324608	chr17:30823087	MYO1D	0.61	6.5	0.47	1.07e-9	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.73	0.72	1.01e-25	Prudent dietary pattern;
PAAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-4.73	-0.36	5.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs377457	0.856	rs11117268	chr16:85738269	A/T	cg07784872	chr16:85687041	KIAA0182	-0.74	-7.64	-0.53	2.22e-12	Type 2 diabetes;
PAAD	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg12395012	chr8:11607386	GATA4	-0.61	-6.56	-0.47	7.83e-10	Myopia (pathological);
PAAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.37	0.4	2.84e-7	Bipolar disorder;
PAAD	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.64	7.72	0.53	1.45e-12	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-1.04	-14.59	-0.76	1.02e-30	Breast cancer;
PAAD	cis	rs12044355	0.929	rs12045248	chr1:231850748	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	5.11	0.38	9.4e-7	Alzheimer's disease;
PAAD	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.9	-11.35	-0.68	5.05e-22	Dental caries;
PAAD	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.47	-8.04	-0.55	2.3e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg20821713	chr7:1055600	C7orf50	-0.38	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg07959490	chr17:80112427	CCDC57	-0.38	-4.54	-0.35	1.15e-5	Life satisfaction;
PAAD	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-6.41	-0.46	1.74e-9	Intraocular pressure;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.61	5.6	0.41	9.89e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.34	4.52	0.34	1.23e-5	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg02196655	chr2:10830764	NOL10	0.63	6.89	0.49	1.39e-10	Prostate cancer;
PAAD	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.4	0.56	2.9e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.83	4.83	0.36	3.32e-6	Toenail selenium levels;
PAAD	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.83	6.22	0.45	4.68e-9	HDL cholesterol;
PAAD	cis	rs329648	0.571	rs10894761	chr11:133772854	G/A	cg03392386	chr11:133800800	IGSF9B	0.55	6.19	0.45	5.36e-9	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01624937	chr1:43997446	PTPRF	-0.77	-6.32	-0.46	2.79e-9	Neuroticism;
PAAD	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-5.76	-0.42	4.49e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg02734326	chr4:10020555	SLC2A9	0.46	4.75	0.36	4.74e-6	Bone mineral density;
PAAD	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg01028140	chr2:1542097	TPO	-1.08	-7.78	-0.53	1.04e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06799790	chr17:61951754	CSH2	-0.44	-4.62	-0.35	8.15e-6	Height;
PAAD	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg16850897	chr7:100343110	ZAN	-0.6	-4.93	-0.37	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg00376283	chr12:123451042	ABCB9	0.69	6.46	0.46	1.36e-9	Platelet count;
PAAD	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	6.75	0.48	2.97e-10	Educational attainment;
PAAD	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.35	0.51	1.16e-11	Schizophrenia;
PAAD	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.98e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg12092346	chr18:77659572	KCNG2	-0.66	-4.75	-0.36	4.75e-6	Opioid sensitivity;
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.71	-5.38	-0.4	2.8e-7	Initial pursuit acceleration;
PAAD	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.85	-11.22	-0.67	1.15e-21	Height;
PAAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.46e-22	Emphysema distribution in smoking;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10578696	chr1:65532742	NA	-0.64	-6.65	-0.47	5.09e-10	Smoking initiation;
PAAD	cis	rs7631605	0.875	rs11709376	chr3:37116808	C/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	6.1e-7	Tonsillectomy;
PAAD	cis	rs11853189	1.000	rs11856774	chr15:78566039	A/G	cg22935921	chr15:78556834	DNAJA4	0.78	5.36	0.4	3.03e-7	Red cell distribution width;
PAAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs16975963	0.604	rs17305326	chr19:38119547	T/C	cg14218481	chr19:38281219	NA	0.41	4.4	0.34	2.03e-5	Longevity;
PAAD	cis	rs7243821	1.000	rs7226871	chr18:52645561	T/A	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.54	5.27	0.39	4.62e-7	IgG glycosylation;
PAAD	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.68	-5.91	-0.43	2.13e-8	Blood protein levels;
PAAD	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg07803811	chr1:43423981	SLC2A1	-0.47	-4.49	-0.34	1.42e-5	Red cell distribution width;
PAAD	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg00522288	chr12:125625016	AACS	-0.54	-5.6	-0.41	9.82e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg20636351	chr8:55087400	NA	-0.74	-7.52	-0.52	4.53e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.35	-0.33	2.47e-5	Daytime sleep phenotypes;
PAAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs6142102	0.602	rs6141435	chr20:32551279	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs5417	0.627	rs62059170	chr17:7155056	T/C	cg14438174	chr17:7137923	DVL2	-0.46	-4.34	-0.33	2.54e-5	Diastolic blood pressure;
PAAD	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.64	-0.8	4.76e-36	Height;
PAAD	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4930103	0.564	rs1618613	chr11:1969888	G/A	cg23202291	chr11:1979235	NA	-0.48	-4.7	-0.36	5.78e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.4	0.4	2.47e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-8.34	-0.56	4.22e-14	Coronary artery disease;
PAAD	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg01236616	chr12:121019343	POP5	0.46	4.29	0.33	3.18e-5	High light scatter reticulocyte count;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.51	0.57	1.51e-14	Dupuytren's disease;
PAAD	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.67	-6.98	-0.49	8.41e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7009516	0.819	rs11997686	chr8:24221608	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.46	-5.6	-0.41	9.77e-8	Hair greying;
PAAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18364779	chr6:26104403	HIST1H4C	0.52	5.18	0.39	7.03e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.04	19.13	0.84	2.69e-42	Birth weight;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.57	6.48	0.47	1.23e-9	Lymphocyte counts;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-1.37	-11.0	-0.67	4.65e-21	Schizophrenia;
PAAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.38	-0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.79	7.68	0.53	1.84e-12	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.75	5.95	0.43	1.74e-8	Height;
PAAD	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-5.34	-0.4	3.37e-7	Coronary artery disease;
PAAD	cis	rs11264799	0.765	rs10489676	chr1:157619889	A/G	cg18268488	chr1:157545234	FCRL4	0.42	4.67	0.35	6.48e-6	IgA nephropathy;
PAAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg11421182	chr20:36153479	BLCAP	-0.53	-6.29	-0.45	3.15e-9	IgG glycosylation;
PAAD	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	6.49	0.47	1.15e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09751810	chr7:128323245	FAM71F2	0.69	7.66	0.53	2.04e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-5.84	-0.43	3.07e-8	Blood protein levels;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.81	-0.43	3.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11020478	0.663	rs11529070	chr11:93443628	C/A	cg10523193	chr11:93463762	SNORA25	0.43	4.49	0.34	1.4e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.68	-0.48	4.16e-10	Mood instability;
PAAD	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-1.19	-9.98	-0.63	2.39e-18	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05796909	chr17:7465070	SENP3	0.62	7.34	0.51	1.21e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs7713065	0.840	rs11748326	chr5:131799959	C/T	cg14196790	chr5:131705035	SLC22A5	-0.53	-5.11	-0.38	9.71e-7	Lung function (FEV1/FVC);
PAAD	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.85	-7.86	-0.54	6.59e-13	Exhaled nitric oxide output;
PAAD	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	5.44	0.4	2.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-5.4	-0.4	2.54e-7	Daytime sleep phenotypes;
PAAD	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.66	-6.24	-0.45	4.08e-9	Subjective well-being;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.43	4.34	0.33	2.61e-5	Red blood cell count;
PAAD	cis	rs62264129	0.500	rs4682400	chr3:112045215	T/C	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.75e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2964802	0.505	rs7447014	chr5:10814212	T/C	cg14521931	chr5:10832172	NA	-0.47	-4.83	-0.36	3.28e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07480762	chr3:155422145	PLCH1	0.68	7.01	0.49	7.29e-11	Smoking initiation;
PAAD	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.71	-5.78	-0.42	4.03e-8	Blood protein levels;
PAAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.92	7.96	0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg12623918	chr2:306882	NA	-0.6	-4.58	-0.35	9.79e-6	Blood protein levels;
PAAD	cis	rs4704187	0.687	rs7709707	chr5:74363575	T/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.55	4.99	0.38	1.6e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6066835	0.867	rs6095280	chr20:47365072	C/G	cg18078177	chr20:47281410	PREX1	0.93	4.44	0.34	1.72e-5	Multiple myeloma;
PAAD	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs8032158	1.000	rs12232351	chr15:56140995	T/A	cg02198044	chr15:56286336	NEDD4	-0.5	-5.23	-0.39	5.44e-7	Keloid;
PAAD	cis	rs9815354	0.951	rs1716679	chr3:41905339	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3126085	0.825	rs116321073	chr1:152240413	A/T	cg09127314	chr1:152161683	NA	0.69	4.87	0.37	2.81e-6	Atopic dermatitis;
PAAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.32	-0.33	2.77e-5	Aortic root size;
PAAD	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.96	0.37	1.91e-6	Lung cancer in ever smokers;
PAAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg14393609	chr7:65229607	NA	-0.48	-4.86	-0.37	2.93e-6	Aortic root size;
PAAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg23957660	chr17:17878224	LRRC48	-0.38	-4.3	-0.33	3.04e-5	Total body bone mineral density;
PAAD	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.54	0.57	1.3e-14	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg26174226	chr8:58114915	NA	-0.64	-5.33	-0.4	3.52e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.22e-7	Alzheimer's disease (late onset);
PAAD	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-10.68	-0.65	3.25e-20	Ulcerative colitis;
PAAD	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg00536532	chr6:33561449	C6orf227	-0.44	-4.64	-0.35	7.62e-6	Plateletcrit;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18405786	chr19:18746985	KLHL26	0.62	7.56	0.52	3.64e-12	Metabolite levels  (X-11787);
PAAD	cis	rs9287719	0.601	rs759401	chr2:10709922	G/A	cg00105475	chr2:10696890	NA	0.65	6.89	0.49	1.37e-10	Prostate cancer;
PAAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs2004318	1.000	rs10403091	chr19:55120237	G/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.74	-0.42	4.96e-8	Blood protein levels;
PAAD	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.88	9.37	0.61	9.43e-17	Breast cancer;
PAAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg05835009	chr4:710272	PCGF3	0.71	6.31	0.46	2.9e-9	White blood cell count;
PAAD	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.73	5.82	0.43	3.34e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.99	7.76	0.53	1.17e-12	LDL cholesterol;
PAAD	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg09582351	chr12:29534625	ERGIC2	0.32	4.4	0.34	2.05e-5	QT interval;
PAAD	cis	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13560548	chr3:10150139	C3orf24	0.55	4.91	0.37	2.31e-6	Alzheimer's disease;
PAAD	cis	rs8005677	0.851	rs8010804	chr14:23396480	T/G	cg01529538	chr14:23388837	RBM23	0.62	6.05	0.44	1.09e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs10821973	0.505	rs2130778	chr10:63995535	A/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.67	7.44	0.52	6.93e-12	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12477012	chr1:46049214	NASP	0.66	7.36	0.51	1.06e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	5.08	0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-7.57	-0.52	3.39e-12	Morning vs. evening chronotype;
PAAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg23442198	chr4:187126114	CYP4V2	0.66	4.69	0.36	6.04e-6	Activated partial thromboplastin time;
PAAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg05697835	chr1:2722811	NA	0.42	4.68	0.36	6.21e-6	Ulcerative colitis;
PAAD	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.23	-0.39	5.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg27395922	chr11:50257633	LOC441601	0.42	4.54	0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-5.82	-0.43	3.31e-8	Mean corpuscular volume;
PAAD	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg00601450	chr5:74908170	NA	-0.41	-4.32	-0.33	2.81e-5	Age-related disease endophenotypes;
PAAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.37	-5.76	-0.42	4.54e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.82	-7.8	-0.53	9.43e-13	Body mass index;
PAAD	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26897989	chr16:1907736	C16orf73	-0.53	-4.52	-0.34	1.22e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.83	8.76	0.58	3.58e-15	Itch intensity from mosquito bite;
PAAD	cis	rs4919087	0.748	rs11189131	chr10:99085835	G/A	cg25902810	chr10:99078978	FRAT1	-0.57	-5.38	-0.4	2.73e-7	Monocyte count;
PAAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.71	-0.36	5.66e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.83	-7.98	-0.54	3.38e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.53	5.14	0.38	8.39e-7	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs11051970	0.885	rs7309692	chr12:32538180	A/G	cg02745156	chr12:32552066	NA	0.39	4.28	0.33	3.31e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg13444538	chr7:158905317	VIPR2	0.53	4.99	0.38	1.65e-6	Facial morphology (factor 20);
PAAD	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.57	5.34	0.4	3.33e-7	Resting heart rate;
PAAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg15436174	chr10:43711423	RASGEF1A	0.62	5.81	0.43	3.63e-8	Hirschsprung disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26143326	chr5:218493	SDHA;CCDC127	0.67	7.27	0.51	1.75e-11	Myopia (pathological);
PAAD	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.78	-7.38	-0.51	9.82e-12	Asthma;
PAAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.75	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs3779195	0.524	rs76976120	chr7:97894172	C/G	cg24562669	chr7:97807699	LMTK2	-0.55	-4.58	-0.35	9.69e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.79	7.37	0.51	1.02e-11	Large artery stroke;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18337363	chr3:52569053	NT5DC2	-0.42	-4.62	-0.35	8.09e-6	Electroencephalogram traits;
PAAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	1.17	11.88	0.69	1.91e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs12304921	0.683	rs55987825	chr12:51443387	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.75	-0.36	4.74e-6	Type 2 diabetes;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.6e-7	Systemic lupus erythematosus;
PAAD	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg15847926	chr7:2749597	AMZ1	-0.37	-4.53	-0.34	1.2e-5	Height;
PAAD	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg00982548	chr2:198649783	BOLL	0.73	5.21	0.39	6.09e-7	Ulcerative colitis;
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg19761014	chr17:28927070	LRRC37B2	0.74	5.16	0.39	7.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20553930	chr7:120590671	ING3	-0.6	-6.37	-0.46	2.18e-9	Myopia (pathological);
PAAD	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	0.7	4.35	0.33	2.49e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6496044	0.507	rs62022863	chr15:86162053	C/G	cg10818794	chr15:86012489	AKAP13	0.44	4.61	0.35	8.33e-6	Interstitial lung disease;
PAAD	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.67	-5.98	-0.44	1.53e-8	Blood trace element (Zn levels);
PAAD	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg05562828	chr17:3906858	NA	0.61	6.76	0.48	2.73e-10	Type 2 diabetes;
PAAD	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg19026207	chr17:26645466	TMEM97	0.42	4.36	0.33	2.37e-5	Blood protein levels;
PAAD	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.7	7.23	0.51	2.2e-11	Tourette syndrome;
PAAD	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-8.49	-0.57	1.71e-14	Hemoglobin concentration;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.72	7.36	0.51	1.06e-11	Menarche (age at onset);
PAAD	cis	rs2882667	0.654	rs884470	chr5:138155925	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17169635	0.765	rs1015350	chr7:134575255	C/T	cg02516134	chr7:134575187	CALD1	0.48	4.37	0.33	2.25e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.45	0.4	1.99e-7	Lung cancer;
PAAD	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-0.99	-11.79	-0.69	3.31e-23	Dilated cardiomyopathy;
PAAD	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.31	0.33	2.94e-5	Longevity;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.79	5.65	0.42	7.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368222	1.000	rs7766070	chr6:20686573	C/A	cg01798595	chr6:21664778	NA	-0.46	-4.31	-0.33	2.88e-5	Acute insulin response;Peak insulin response;Body mass index;
PAAD	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs3112530	1.000	rs3101130	chr5:152639495	C/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	4.81	0.36	3.64e-6	Educational attainment;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-1.2	-9.93	-0.63	3.18e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs6028335	0.610	rs72623594	chr20:37576255	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.89	-0.37	2.59e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs6715793	0.901	rs1065324	chr2:33412077	G/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13939156	chr17:80058883	NA	-0.41	-4.38	-0.34	2.17e-5	Life satisfaction;
PAAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.43	-0.71	6.41e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13987042	chr11:74660265	XRRA1;SPCS2	-0.6	-7.04	-0.5	6.08e-11	Body fat percentage;
PAAD	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.89	9.05	0.59	6.24e-16	Response to antineoplastic agents;
PAAD	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg04257695	chr17:30186438	C17orf79	0.62	5.09	0.38	1.05e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg23464041	chr6:33663938	ITPR3	0.47	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg14346243	chr4:90757452	SNCA	0.51	4.38	0.33	2.21e-5	Neuroticism;
PAAD	cis	rs508970	0.556	rs615968	chr11:60913556	C/G	cg24692310	chr11:60915630	VPS37C	0.34	4.8	0.36	3.69e-6	Rheumatoid arthritis;
PAAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.87	10.09	0.63	1.18e-18	Ulcerative colitis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08573270	chr6:170041713	WDR27	0.67	7.22	0.51	2.28e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg14583973	chr4:3374767	RGS12	0.38	5.76	0.42	4.45e-8	Serum sulfate level;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.63	-0.42	8.48e-8	Lung cancer;
PAAD	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg05935833	chr10:81318306	SFTPA2	-0.52	-4.27	-0.33	3.48e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.83	-9.53	-0.61	3.64e-17	Height;
PAAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	6.51	0.47	1.01e-9	Menarche (age at onset);
PAAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs11628318	0.853	rs4906224	chr14:103025040	C/T	cg23461800	chr14:103021989	NA	-0.68	-5.3	-0.4	3.93e-7	Platelet count;
PAAD	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.29	0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12282928	0.959	rs713325	chr11:48285301	A/G	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.74	-7.39	-0.51	8.94e-12	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.49	-4.83	-0.36	3.34e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-5.66	-0.42	7.21e-8	Schizophrenia;
PAAD	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.89	5.8	0.43	3.69e-8	LDL cholesterol;
PAAD	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.8	8.0	0.54	2.91e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.99	6.7	0.48	3.75e-10	Prostate cancer;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.86	6.95	0.49	1.03e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.95	-11.38	-0.68	4.38e-22	Height;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.79	-8.06	-0.55	2.1e-13	Prostate cancer;
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.54e-10	Lung cancer;
PAAD	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14201224	chr9:133454820	LOC100272217;FUBP3	0.58	6.52	0.47	9.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg01075559	chr1:2537774	MMEL1	0.54	5.56	0.41	1.2e-7	Ulcerative colitis;
PAAD	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg04087571	chr11:116723030	SIK3	-0.34	-4.47	-0.34	1.54e-5	Subjective well-being;
PAAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg01422370	chr2:73384389	NA	0.38	5.03	0.38	1.36e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06103301	chr3:23987730	NR1D2	0.56	6.36	0.46	2.19e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Cannabis dependence symptom count;
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.67	7.05	0.5	5.75e-11	Longevity;
PAAD	cis	rs7631605	0.905	rs1558529	chr3:37093064	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10875595	0.836	rs3749780	chr5:140682757	C/T	cg24830062	chr5:140700576	TAF7	-0.52	-4.31	-0.33	2.92e-5	Pulmonary function decline;
PAAD	cis	rs877529	1.000	rs139401	chr22:39546074	C/G	cg18708252	chr22:39545030	CBX7	-0.44	-4.25	-0.33	3.73e-5	Multiple myeloma;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.53	5.54	0.41	1.32e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.51	5.01	0.38	1.46e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.47	6.0	0.44	1.38e-8	Renal cell carcinoma;
PAAD	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg16342193	chr10:102329863	NA	-0.76	-8.38	-0.56	3.37e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg01620082	chr3:125678407	NA	-1.41	-7.82	-0.54	8.25e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.72	0.42	5.46e-8	Prudent dietary pattern;
PAAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg26695010	chr11:65641043	EFEMP2	-0.44	-4.27	-0.33	3.46e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.53	-0.41	1.38e-7	Crohn's disease;
PAAD	cis	rs12780845	1.000	rs7084476	chr10:17211383	T/C	cg00857480	chr10:17188594	TRDMT1	0.34	4.45	0.34	1.67e-5	Homocysteine levels;
PAAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	8.87	0.58	1.88e-15	Total body bone mineral density;
PAAD	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.94	8.26	0.56	6.68e-14	Bipolar disorder;
PAAD	cis	rs1891275	0.551	rs2421623	chr10:93414457	T/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg03808351	chr9:123631620	PHF19	-0.41	-4.47	-0.34	1.5e-5	Rheumatoid arthritis;
PAAD	cis	rs9638182	0.848	rs62466318	chr7:73042085	C/T	cg07467649	chr7:72856462	BAZ1B	0.52	4.68	0.36	6.24e-6	Triglycerides;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	cis	rs6137287	0.855	rs6113163	chr20:21187960	A/G	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.46	-0.34	1.6e-5	Height;
PAAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.87	-9.65	-0.62	1.73e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7487075	0.578	rs4768716	chr12:46831158	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs2274459	0.722	rs2296328	chr6:33651277	C/T	cg06253072	chr6:33679850	C6orf125	0.64	5.07	0.38	1.12e-6	Obesity (extreme);
PAAD	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.45	-0.4	2.02e-7	Atrioventricular conduction;
PAAD	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.42	4.59	0.35	9.29e-6	Platelet count;
PAAD	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	4.32	0.33	2.76e-5	Height;
PAAD	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19671926	chr4:122722719	EXOSC9	-0.56	-4.98	-0.37	1.68e-6	Type 2 diabetes;
PAAD	cis	rs12997796	0.503	rs34492196	chr2:87021758	T/C	cg25203885	chr2:87302643	LOC285074	-0.7	-4.62	-0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.08	-0.38	1.08e-6	Obesity-related traits;
PAAD	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.6	-4.86	-0.37	2.84e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.18e-7	Eye color traits;
PAAD	cis	rs7534824	0.625	rs17448356	chr1:101345093	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	4.65	0.35	7.29e-6	Refractive astigmatism;
PAAD	cis	rs13102973	0.867	rs4521398	chr4:135906934	T/G	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.82	8.91	0.59	1.45e-15	Aortic root size;
PAAD	cis	rs7598759	0.966	rs6754426	chr2:232322779	G/A	cg10034588	chr2:232392055	NMUR1	-0.37	-4.34	-0.33	2.61e-5	Noise-induced hearing loss;
PAAD	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.05	13.22	0.73	4.79e-27	Schizophrenia;
PAAD	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.35	-0.4	3.18e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	5.93	0.43	1.96e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs977987	0.868	rs10871313	chr16:75507094	C/T	cg03315344	chr16:75512273	CHST6	0.67	8.03	0.55	2.51e-13	Dupuytren's disease;
PAAD	cis	rs6074578	0.541	rs6086589	chr20:146995	A/T	cg16931068	chr20:139680	DEFB127	-0.4	-5.52	-0.41	1.41e-7	Hirschsprung disease;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg25403298	chr7:129251373	NRF1	-0.58	-6.33	-0.46	2.56e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10822097	chr17:17480829	PEMT	-0.52	-6.32	-0.46	2.69e-9	Monocyte percentage of white cells;
PAAD	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.66	-4.97	-0.37	1.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.51	-5.15	-0.39	8.09e-7	Prostate cancer;
PAAD	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.58	5.56	0.41	1.16e-7	Mood instability;
PAAD	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.88	-0.43	2.57e-8	Tonsillectomy;
PAAD	cis	rs2031532	0.917	rs6561529	chr13:50074756	A/C	cg08779649	chr13:50194554	NA	0.35	4.29	0.33	3.22e-5	Cardiac hypertrophy;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	6.26	0.45	3.71e-9	Ileal carcinoids;
PAAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	7.74	0.53	1.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-7.57	-0.52	3.31e-12	Coronary artery disease;
PAAD	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg23947450	chr7:900037	UNC84A	-0.55	-4.47	-0.34	1.51e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-5.38	-0.4	2.72e-7	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.03	0.44	1.2e-8	Platelet count;
PAAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.83	0.36	3.28e-6	Breast cancer;
PAAD	cis	rs642743	0.967	rs678292	chr10:105957561	G/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.71	0.36	5.46e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.22	-0.39	5.77e-7	Pulmonary function;
PAAD	cis	rs6599192	1	rs6599192	chr3:41992408	G/A	cg03022575	chr3:42003672	ULK4	-0.75	-5.4	-0.4	2.47e-7	Multiple myeloma;
PAAD	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg20312557	chr2:97357134	FER1L5	0.78	4.41	0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.27	0.39	4.57e-7	Educational attainment;
PAAD	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg27373749	chr11:63775612	MACROD1	0.43	4.88	0.37	2.69e-6	Pulse pressure;
PAAD	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2882667	1.000	rs2882667	chr5:138314106	C/T	cg04439458	chr5:138467593	SIL1	-0.43	-4.44	-0.34	1.72e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg02440177	chr19:53496695	ZNF702P	-0.56	-5.83	-0.43	3.27e-8	Psoriasis;
PAAD	cis	rs12145833	0.596	rs10737887	chr1:243424146	T/C	cg02356786	chr1:243265016	LOC731275	-0.85	-5.48	-0.41	1.76e-7	Obesity (early onset extreme);
PAAD	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.05	-0.38	1.28e-6	Total body bone mineral density;
PAAD	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.72	-5.88	-0.43	2.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.66	7.2	0.5	2.55e-11	Testicular germ cell tumor;
PAAD	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs10850408	0.848	rs7964325	chr12:115368787	G/C	cg05726002	chr12:115341178	NA	-0.41	-4.85	-0.37	3.04e-6	Alzheimer's disease;
PAAD	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg24519413	chr1:26490540	NA	0.52	4.81	0.36	3.57e-6	Height;
PAAD	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.53	-0.34	1.19e-5	Colorectal cancer;
PAAD	cis	rs58521262	0.585	rs1676465	chr19:23189968	C/T	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.54e-5	Testicular germ cell tumor;
PAAD	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.74e-9	Coffee consumption (cups per day);
PAAD	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.35	6.57	0.47	7.4e-10	Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg06637938	chr14:75390232	RPS6KL1	0.48	4.7	0.36	5.89e-6	Height;
PAAD	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg12963246	chr6:28129442	ZNF389	0.56	4.29	0.33	3.23e-5	Depression;
PAAD	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.96	-11.41	-0.68	3.62e-22	Refractive error;
PAAD	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg14515779	chr1:101123966	NA	-0.55	-6.18	-0.45	5.63e-9	Monocyte count;
PAAD	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.54	5.48	0.41	1.7e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-4.57	-0.35	9.88e-6	Schizophrenia;
PAAD	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg09357268	chr20:43379437	KCNK15	0.45	4.64	0.35	7.34e-6	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.68	-7.11	-0.5	4.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.03e-6	Type 2 diabetes;
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.41	-4.44	-0.34	1.7e-5	Non-obstructive azoospermia;
PAAD	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.99	8.25	0.56	6.88e-14	Dupuytren's disease;
PAAD	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-5.88	-0.43	2.53e-8	Testicular germ cell tumor;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs988712	0.881	rs4923456	chr11:27609127	C/T	cg10635145	chr11:27742435	BDNF	0.35	4.26	0.33	3.53e-5	Obesity;
PAAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.32	0.33	2.83e-5	Menarche (age at onset);
PAAD	cis	rs2420915	0.630	rs2243609	chr10:122874348	A/C	cg04170468	chr10:122610882	WDR11	-0.54	-4.28	-0.33	3.34e-5	Fibrinogen levels;
PAAD	cis	rs10121009	0.587	rs10738942	chr9:35439202	C/T	cg11846315	chr9:35647073	NA	-0.49	-4.33	-0.33	2.71e-5	Parkinson's disease;
PAAD	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.6	-0.57	9.17e-15	Coffee consumption (cups per day);
PAAD	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg13877915	chr19:58951672	ZNF132	0.55	5.06	0.38	1.18e-6	Uric acid clearance;
PAAD	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.59	6.49	0.47	1.15e-9	Testicular germ cell tumor;
PAAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23158103	chr7:148848205	ZNF398	-0.48	-4.27	-0.33	3.45e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.61	5.96	0.44	1.69e-8	Subjective well-being;
PAAD	cis	rs9506514	0.722	rs11147813	chr13:21258558	T/C	cg27234864	chr13:21295941	IL17D	0.44	4.41	0.34	1.95e-5	Coronary artery calcification;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.11	-0.5	4.17e-11	Longevity;Endometriosis;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.65	6.96	0.49	9.43e-11	Mean corpuscular volume;
PAAD	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg10395934	chr14:104002654	TRMT61A	0.49	4.81	0.36	3.56e-6	Body mass index;
PAAD	cis	rs7189233	0.956	rs62048478	chr16:53429180	C/T	cg00221382	chr16:54322308	NA	-0.29	-4.58	-0.35	9.65e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.87	-9.14	-0.6	3.72e-16	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10611863	chr8:22722817	PEBP4	0.56	6.29	0.45	3.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg09952232	chr10:1438024	ADARB2	0.46	4.52	0.34	1.26e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7567389	0.677	rs10496661	chr2:128090144	G/T	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.6	5.85	0.43	2.97e-8	Type 2 diabetes;
PAAD	cis	rs11051970	0.918	rs1055876	chr12:32536200	C/T	cg02745156	chr12:32552066	NA	0.47	4.77	0.36	4.35e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.74e-7	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.96	-13.63	-0.74	3.91e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.47	8.42	0.56	2.6e-14	Multiple system atrophy;
PAAD	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg03999872	chr20:62272968	STMN3	-0.75	-6.92	-0.49	1.17e-10	Atopic dermatitis;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.68	-0.35	6.27e-6	Life satisfaction;
PAAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.94	-12.58	-0.71	2.46e-25	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.33	-0.33	2.68e-5	Migraine - clinic-based;
PAAD	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.6	6.27	0.45	3.62e-9	Lewy body disease;
PAAD	cis	rs54211	0.572	rs79290	chr22:39685832	G/A	cg02038168	chr22:39784481	NA	-0.64	-4.33	-0.33	2.68e-5	Sudden cardiac arrest;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7082209	1.000	rs7082209	chr10:44814336	C/T	cg13191911	chr10:44806660	NA	0.88	5.13	0.38	8.76e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg12215294	chr3:40350768	EIF1B	0.47	4.67	0.35	6.66e-6	Renal cell carcinoma;
PAAD	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.2	0.6	2.65e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs5756391	0.782	rs6000476	chr22:37300410	A/G	cg16356956	chr22:37317934	CSF2RB	0.38	4.72	0.36	5.37e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20662616	chr2:30454643	LBH	0.54	6.29	0.45	3.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3981351	0.797	rs61866462	chr10:115464690	C/T	cg24846397	chr10:115438155	CASP7	-0.58	-5.46	-0.41	1.86e-7	Obesity-related traits;
PAAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.84	9.77	0.62	8.31e-18	Schizophrenia;
PAAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg25837213	chr17:80849375	TBCD	0.55	4.36	0.33	2.4e-5	Breast cancer;
PAAD	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.71	7.4	0.51	8.76e-12	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs4742903	0.935	rs10739885	chr9:106912892	G/A	cg14250997	chr9:106856677	SMC2	0.49	5.31	0.4	3.8e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26418147	chr1:205743515	RAB7L1	-0.41	-4.68	-0.36	6.22e-6	Menarche (age at onset);
PAAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg12486944	chr17:80159399	CCDC57	-0.51	-4.52	-0.34	1.21e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs4388249	0.659	rs10065099	chr5:109177378	C/T	cg17395555	chr5:108820864	NA	0.31	4.35	0.33	2.51e-5	Schizophrenia;
PAAD	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs6923462	0.935	rs66908775	chr6:7795032	G/A	cg20969151	chr6:7787925	BMP6	-0.54	-4.33	-0.33	2.7e-5	Lung function (forced vital capacity);
PAAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	1.0	9.97	0.63	2.46e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12304921	1.000	rs12304921	chr12:51357542	C/T	cg18059802	chr12:51347058	HIGD1C	0.7	5.79	0.43	3.93e-8	Type 2 diabetes;
PAAD	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg16339924	chr4:17578868	LAP3	-0.57	-4.97	-0.37	1.81e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.57	-0.41	1.15e-7	Schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg12204423	chr4:129732568	PHF17	-0.53	-6.49	-0.47	1.12e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg09998033	chr7:158218633	PTPRN2	-0.77	-8.17	-0.55	1.13e-13	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.53	0.34	1.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.52	-5.01	-0.38	1.47e-6	Hypospadias;
PAAD	cis	rs13242816	1.000	rs55833477	chr7:116110375	C/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.52	4.97	0.37	1.8e-6	Night sleep phenotypes;
PAAD	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.77	8.78	0.58	3.13e-15	Morning vs. evening chronotype;
PAAD	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg20636351	chr8:55087400	NA	-0.8	-9.08	-0.59	5.5e-16	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13131339	chr17:37879267	ERBB2	-0.61	-6.49	-0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.44	5.6	0.41	9.77e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg02580895	chr19:2754563	NA	-0.51	-4.45	-0.34	1.64e-5	Total cholesterol levels;
PAAD	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.79	-8.18	-0.55	1.05e-13	Heart rate;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg04482110	chr17:41364121	TMEM106A	0.41	4.7	0.36	5.85e-6	Menopause (age at onset);
PAAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.57	-5.3	-0.4	3.97e-7	Obesity-related traits;
PAAD	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.72	7.42	0.52	7.53e-12	Uric acid levels;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.62	5.22	0.39	5.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.92	11.36	0.68	4.76e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.6	-5.91	-0.43	2.15e-8	Coronary artery disease;
PAAD	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg00181669	chr3:44000978	NA	0.43	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs8040855	0.657	rs6496733	chr15:85673176	G/T	cg08123816	chr15:85640762	PDE8A	0.43	5.17	0.39	7.4e-7	Bulimia nervosa;
PAAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs11958404	1.000	rs72816529	chr5:157411454	G/C	cg05962755	chr5:157440814	NA	1.1	8.23	0.55	8.09e-14	IgG glycosylation;
PAAD	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07402062	chr16:89894098	SPIRE2	0.37	4.65	0.35	7.28e-6	Vitiligo;
PAAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.74	-10.17	-0.64	7.5e-19	Iron status biomarkers;
PAAD	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	0.85	6.64	0.47	5.12e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.72	-4.89	-0.37	2.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.17	0.5	3e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.64	6.86	0.49	1.59e-10	Leprosy;
PAAD	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.62	7.27	0.51	1.75e-11	HDL cholesterol levels;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.85	-13.06	-0.73	1.33e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs73526541	0.541	rs12544013	chr8:1071033	T/C	cg20458277	chr8:1053508	NA	0.56	4.27	0.33	3.41e-5	Verbal memory performance (immediate recall change);
PAAD	cis	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.73	-0.36	5.02e-6	Neuroticism;
PAAD	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg03959625	chr15:84868606	LOC388152	0.47	5.13	0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.69	-7.42	-0.52	7.86e-12	Platelet distribution width;
PAAD	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19623624	chr10:135278901	LOC619207	-0.43	-4.5	-0.34	1.34e-5	Systemic lupus erythematosus;
PAAD	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg09455208	chr3:40491958	NA	0.46	5.97	0.44	1.58e-8	Renal cell carcinoma;
PAAD	cis	rs6076065	0.723	rs16985308	chr20:23359780	A/T	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg19980771	chr6:110798022	SLC22A16	0.33	4.26	0.33	3.51e-5	Blood metabolite levels;
PAAD	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.56	2.93e-14	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.79	-4.86	-0.37	2.86e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.51	-0.41	1.51e-7	Alcohol dependence;
PAAD	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.74	0.48	3.13e-10	Morning vs. evening chronotype;
PAAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.51	-5.74	-0.42	5.06e-8	Testicular germ cell tumor;
PAAD	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.07	0.63	1.39e-18	Monocyte percentage of white cells;
PAAD	cis	rs10276381	0.685	rs56398224	chr7:28205748	A/AT	cg23620719	chr7:28220237	JAZF1	0.79	4.61	0.35	8.36e-6	Crohn's disease;
PAAD	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg09701102	chr11:67373083	NDUFV1	-0.42	-4.29	-0.33	3.13e-5	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.29	0.45	3.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1891275	0.576	rs7900117	chr10:93417287	A/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	4.52	0.34	1.22e-5	Hypertriglyceridemia;
PAAD	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-1.07	-7.08	-0.5	4.95e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg12463550	chr7:65579703	CRCP	0.85	5.38	0.4	2.76e-7	Diabetic kidney disease;
PAAD	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg14583973	chr4:3374767	RGS12	-0.36	-5.45	-0.4	2.02e-7	Mean platelet volume;
PAAD	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs6782228	1.000	rs34890930	chr3:128329223	T/C	cg15607142	chr3:128420513	NA	-0.39	-4.27	-0.33	3.41e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.43	-0.34	1.81e-5	Joint mobility (Beighton score);
PAAD	cis	rs9810890	1.000	rs114261227	chr3:128469760	A/C	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs113779084	0.593	rs4275120	chr7:11925433	T/C	cg15090509	chr7:11872073	THSD7A	0.39	5.13	0.38	8.6e-7	Educational attainment (years of education);
PAAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg21130718	chr4:1044621	NA	-0.59	-5.28	-0.39	4.41e-7	Recombination rate (females);
PAAD	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg09399716	chr2:46890238	NA	-0.52	-4.32	-0.33	2.8e-5	Height;
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.6	-0.47	6.34e-10	Obesity-related traits;
PAAD	cis	rs62045849	0.546	rs12933826	chr16:89165984	T/C	cg03605463	chr16:89740564	NA	1.08	5.19	0.39	6.7e-7	Red blood cell count;
PAAD	cis	rs593531	0.592	rs598869	chr11:74046975	C/T	cg15670924	chr11:73669256	DNAJB13	-0.4	-4.28	-0.33	3.33e-5	Neuroticism;
PAAD	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.72	9.42	0.61	7.01e-17	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg11608241	chr8:8085544	FLJ10661	0.47	4.38	0.34	2.17e-5	Neuroticism;
PAAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg21890820	chr11:65308645	LTBP3	0.63	7.4	0.51	8.77e-12	Bone mineral density;
PAAD	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.68	7.68	0.53	1.83e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg23465465	chr6:26364728	BTN3A2	0.78	4.34	0.33	2.58e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg06565975	chr8:143823917	SLURP1	-0.24	-5.36	-0.4	3.04e-7	Urinary tract infection frequency;
PAAD	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.15	-0.6	3.61e-16	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27567206	chr4:7787983	AFAP1	0.57	6.99	0.49	8.07e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg20607287	chr7:12443886	VWDE	-0.63	-5.76	-0.42	4.59e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg10729496	chr3:10149963	C3orf24	0.89	7.88	0.54	5.99e-13	Alzheimer's disease;
PAAD	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.52	5.06	0.38	1.18e-6	Type 2 diabetes;
PAAD	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.84	8.18	0.55	1.06e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.87	-10.74	-0.66	2.25e-20	Aortic root size;
PAAD	cis	rs1371614	0.566	rs11887401	chr2:27181112	G/T	cg00617064	chr2:27272375	NA	-0.46	-4.94	-0.37	2.02e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs501120	1.000	rs573141	chr10:44758587	G/A	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26440355	chr15:52043657	TMOD2;LYSMD2	-0.7	-7.39	-0.51	9e-12	Smoking initiation;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.57	6.87	0.49	1.56e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6494488	0.500	rs72742941	chr15:64888931	A/C	cg16425858	chr15:64791681	ZNF609	0.95	4.53	0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs7873102	0.702	rs10973638	chr9:38005435	T/C	cg03528946	chr9:38069800	SHB	-0.53	-5.38	-0.4	2.81e-7	Brain structure;
PAAD	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg12310025	chr6:25882481	NA	-0.43	-4.26	-0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs6466055	0.661	rs56132497	chr7:104933707	G/C	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs3996993	0.737	rs2608659	chr6:52647660	T/G	cg00536792	chr6:53530503	KLHL31	0.4	4.29	0.33	3.13e-5	Hemoglobin concentration;
PAAD	cis	rs8067287	0.635	rs4343329	chr17:16840889	C/G	cg26910001	chr17:16838321	NA	0.49	4.66	0.35	6.77e-6	Diabetic kidney disease;
PAAD	cis	rs943466	1.000	rs4711346	chr6:33730996	C/G	cg04704449	chr6:33738291	NA	-0.47	-4.72	-0.36	5.35e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs11681884	0.786	rs1992763	chr2:113810736	T/A	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-5.62	-0.41	9.03e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.48	4.46	0.34	1.59e-5	Response to antidepressants and depression;
PAAD	cis	rs1516489	0.881	rs116124112	chr3:191508582	A/G	cg14855367	chr3:191048308	UTS2D;CCDC50	0.49	4.3	0.33	3.07e-5	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15153412	chr8:121823462	SNTB1	-0.69	-7.37	-0.51	9.91e-12	Smoking initiation;
PAAD	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg20917491	chr3:195578259	NA	-0.43	-4.28	-0.33	3.32e-5	Pancreatic cancer;
PAAD	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.31	-0.33	2.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.41	-0.34	1.96e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.48	4.81	0.36	3.54e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.59	6.91	0.49	1.22e-10	Iron status biomarkers;
PAAD	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.27	0.33	3.37e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.83	0.36	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg03303774	chr4:1407052	NA	0.36	4.47	0.34	1.55e-5	Obesity-related traits;
PAAD	cis	rs8060686	0.668	rs255048	chr16:68012849	C/T	cg05110241	chr16:68378359	PRMT7	-1.06	-6.06	-0.44	1.05e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs501120	0.584	rs11238935	chr10:44714402	C/T	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs75920871	1.000	rs7950213	chr11:116868654	C/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.49	-0.34	1.4e-5	Prevalent atrial fibrillation;
PAAD	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg02781088	chr2:113192302	RGPD8;RGPD5	0.85	5.79	0.42	3.98e-8	Yeast infection;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.37	-4.48	-0.34	1.43e-5	Electrocardiographic conduction measures;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03495059	chr16:30913719	CTF1	0.6	6.98	0.49	8.77e-11	Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08559361	chr10:119134981	PDZD8	0.69	7.28	0.51	1.67e-11	Myopia (pathological);
PAAD	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.37	0.33	2.3e-5	Height;
PAAD	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.93	-7.66	-0.53	2.06e-12	Alopecia areata;
PAAD	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.46	4.25	0.33	3.78e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6684428	0.706	rs10493185	chr1:56321789	A/G	cg11651538	chr1:56320950	NA	-0.5	-4.35	-0.33	2.46e-5	Airflow obstruction;
PAAD	cis	rs4141404	0.781	rs4820945	chr22:31549155	T/C	cg02404636	chr22:31891804	SFI1	-0.53	-4.48	-0.34	1.46e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg25837213	chr17:80849375	TBCD	-0.49	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.69	7.17	0.5	3.14e-11	Type 2 diabetes;
PAAD	cis	rs10450586	0.932	rs10835154	chr11:27315356	G/A	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg02275930	chr1:2372054	NA	-0.41	-4.44	-0.34	1.7e-5	Non-obstructive azoospermia;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg17868515	chr10:100992068	HPSE2	-0.39	-4.48	-0.34	1.49e-5	Metabolite levels;
PAAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg12639453	chr1:2035780	PRKCZ	-0.62	-6.69	-0.48	3.97e-10	Height;
PAAD	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.85	-6.57	-0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg20913747	chr6:44695427	NA	-0.56	-5.18	-0.39	6.85e-7	Total body bone mineral density;
PAAD	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg14388049	chr10:71211838	TSPAN15	-0.49	-5.18	-0.39	6.91e-7	Venous thromboembolism;
PAAD	cis	rs1419980	0.730	rs7970227	chr12:7738052	C/A	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs73019876	0.502	rs3752163	chr19:22256396	G/A	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16262614	chr3:133464971	TF	0.49	5.55	0.41	1.24e-7	Iron status biomarkers;
PAAD	cis	rs61542988	0.535	rs10807813	chr7:22829961	C/T	cg11367502	chr7:22862612	TOMM7	0.6	5.69	0.42	6.36e-8	Fibrinogen levels;
PAAD	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.51	5.12	0.38	9.02e-7	Glycated hemoglobin levels;
PAAD	cis	rs367943	0.665	rs13180704	chr5:112969261	A/T	cg12552261	chr5:112820674	MCC	-0.48	-4.89	-0.37	2.49e-6	Type 2 diabetes;
PAAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg14440974	chr22:39074834	NA	-0.57	-6.49	-0.47	1.16e-9	Menopause (age at onset);
PAAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg15017067	chr4:17643749	FAM184B	0.4	4.63	0.35	7.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.67	-4.96	-0.37	1.9e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.41	-0.46	1.74e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg21395723	chr22:39101663	GTPBP1	-0.44	-4.65	-0.35	7.06e-6	Menopause (age at onset);
PAAD	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.73	0.36	5.05e-6	Axial length;
PAAD	cis	rs11250714	0.845	rs7901958	chr10:1693504	C/T	cg10435618	chr10:838112	NA	-0.49	-4.6	-0.35	8.86e-6	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.78	10.02	0.63	1.85e-18	Vitiligo;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.66	-6.19	-0.45	5.29e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	trans	rs7915414	0.901	rs1998590	chr10:96408005	T/C	cg00735080	chr21:47285121	PCBP3	0.51	6.4	0.46	1.84e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs6604026	0.656	rs11577636	chr1:93402849	T/C	cg17283838	chr1:93427260	FAM69A	0.61	5.71	0.42	5.64e-8	Multiple sclerosis;
PAAD	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.73	4.61	0.35	8.6e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.72	-7.74	-0.53	1.31e-12	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.72	-9.13	-0.6	3.87e-16	Motion sickness;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Body mass index;
PAAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-6.46	-0.46	1.36e-9	Body mass index;
PAAD	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.15	-0.55	1.26e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.48	-0.34	1.49e-5	Inflammatory bowel disease;
PAAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.43	-0.34	1.8e-5	Renal cell carcinoma;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.16	0.39	7.51e-7	Electroencephalogram traits;
PAAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.74	8.36	0.56	3.67e-14	Birth weight;
PAAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.7	9.24	0.6	2.05e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.62	-4.85	-0.37	2.98e-6	Smoking behavior;
PAAD	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-1.26	-7.72	-0.53	1.47e-12	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20193839	chr8:61834501	NA	0.57	6.43	0.46	1.6e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.28	0.45	3.36e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	1.13	13.02	0.73	1.67e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs9467603	1.000	rs13201341	chr6:25822661	C/T	cg16898833	chr6:26189333	HIST1H4D	0.97	4.83	0.36	3.3e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18285309	chr1:40157229	HPCAL4	-0.77	-6.4	-0.46	1.87e-9	Neuroticism;
PAAD	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.09	16.35	0.8	2.66e-35	Height;
PAAD	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.6	-7.14	-0.5	3.54e-11	Systolic blood pressure;
PAAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26850624	chr5:429559	AHRR	0.47	5.85	0.43	2.88e-8	Cystic fibrosis severity;
PAAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.91	-10.29	-0.64	3.51e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08872933	chr1:155231766	SCAMP3	0.66	6.41	0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7534824	0.625	rs61780286	chr1:101359898	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.58	0.35	9.48e-6	Refractive astigmatism;
PAAD	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.33	-0.4	3.41e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.19	-0.39	6.77e-7	Diastolic blood pressure;
PAAD	cis	rs847851	1.000	rs4646926	chr6:34852253	G/T	cg13196216	chr6:34231128	NA	-0.6	-4.92	-0.37	2.22e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.64	6.62	0.47	5.75e-10	Colorectal cancer;
PAAD	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.49	5.45	0.4	2.01e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	5.65	0.42	7.76e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs59888335	0.929	rs35789707	chr3:80857654	G/A	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.34	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.7	6.52	0.47	9.81e-10	Diabetic retinopathy;
PAAD	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg25809561	chr17:30822961	MYO1D	0.55	5.64	0.42	7.91e-8	Schizophrenia;
PAAD	cis	rs12130219	0.588	rs2282302	chr1:152329369	C/G	cg26879891	chr1:152191343	HRNR	0.51	4.42	0.34	1.86e-5	Inflammatory skin disease;
PAAD	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg26876637	chr1:152193138	HRNR	-0.8	-5.32	-0.4	3.6e-7	Atopic dermatitis;
PAAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.85	8.38	0.56	3.35e-14	Vitamin D levels;
PAAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.36	-5.26	-0.39	4.91e-7	Educational attainment (years of education);
PAAD	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.78	-10.3	-0.64	3.34e-19	Coronary artery disease;
PAAD	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.19	0.45	5.3300000000000004e-09	Aortic root size;
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg27094323	chr7:1216898	NA	-0.45	-5.29	-0.39	4.14e-7	Longevity;Endometriosis;
PAAD	cis	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Body mass index;
PAAD	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.65	0.47	4.92e-10	Triglycerides;
PAAD	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg09163369	chr1:210001066	C1orf107	0.5	5.28	0.39	4.32e-7	Orofacial clefts;
PAAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.82	-0.36	3.46e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg11232448	chr19:2858854	NA	-0.49	-4.81	-0.36	3.62e-6	Total cholesterol levels;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	trans	rs137891020	1	rs137891020	chr10:96420339	G/T	cg00735080	chr21:47285121	PCBP3	0.51	6.4	0.46	1.84e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg24565620	chr2:194026	NA	0.55	4.53	0.34	1.18e-5	Blood protein levels;
PAAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.6	7.01	0.49	7.37e-11	Immature fraction of reticulocytes;
PAAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.28	0.39	4.31e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.49	-7.57	-0.52	3.28e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22162314	chr17:61951766	CSH2	-0.61	-6.29	-0.45	3.15e-9	Height;
PAAD	cis	rs12282928	1.000	rs7952009	chr11:48286845	A/G	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	4.63	0.35	7.89e-6	Tonsillectomy;
PAAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg23283495	chr1:209979779	IRF6	0.66	5.99	0.44	1.42e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00292662	chr22:38071168	LGALS1	0.64	6.77	0.48	2.66e-10	Fat distribution (HIV);
PAAD	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg22830091	chr7:75961684	YWHAG	-0.43	-4.57	-0.35	1.01e-5	Multiple sclerosis;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.85	9.39	0.61	8.3e-17	Tuberculosis;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg19445457	chr11:5799446	OR52N5	-0.52	-4.65	-0.35	7.09e-6	DNA methylation (variation);
PAAD	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.29e-8	Alcohol dependence;
PAAD	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg08198773	chr8:1697536	NA	0.42	4.63	0.35	7.78e-6	Systolic blood pressure;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.83	-0.58	2.38e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.15	-0.45	6.54e-9	Body mass index;
PAAD	cis	rs1668873	0.562	rs10157145	chr1:205261963	T/C	cg03948781	chr1:205179583	DSTYK	-0.48	-4.9	-0.37	2.39e-6	Mean platelet volume;
PAAD	cis	rs1371614	0.610	rs2384511	chr2:27152735	G/A	cg00617064	chr2:27272375	NA	-0.42	-4.45	-0.34	1.62e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1499972	0.941	rs6769144	chr3:117624517	C/T	cg07612923	chr3:117604196	NA	1.06	7.25	0.51	1.99e-11	Schizophrenia;
PAAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.65	-7.77	-0.53	1.07e-12	Huntington's disease progression;
PAAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.51	-4.47	-0.34	1.5e-5	Tonsillectomy;
PAAD	cis	rs1152591	0.505	rs968257	chr14:64680285	T/C	cg23250157	chr14:64679961	SYNE2	0.44	4.51	0.34	1.27e-5	Atrial fibrillation;
PAAD	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	6.13	0.45	7.18e-9	Mean corpuscular hemoglobin;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14200859	chr9:129695196	RALGPS1	-0.58	-6.82	-0.48	1.99e-10	Monocyte percentage of white cells;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12746706	chr6:169276508	NA	0.57	6.57	0.47	7.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg09399716	chr2:46890238	NA	-0.73	-6.02	-0.44	1.25e-8	Height;
PAAD	cis	rs9581857	0.579	rs75024088	chr13:27970105	G/T	cg22138327	chr13:27999177	GTF3A	0.88	5.55	0.41	1.27e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg09839279	chr12:125627357	AACS	-0.43	-4.35	-0.33	2.47e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg23117778	chr20:1206693	RAD21L1	1.02	12.48	0.71	4.57e-25	Multiple sclerosis;
PAAD	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.49	4.52	0.34	1.21e-5	Height;
PAAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg24253500	chr15:84953950	NA	0.55	6.41	0.46	1.77e-9	Schizophrenia;
PAAD	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg17182837	chr8:41585554	ANK1	-0.44	-4.73	-0.36	5.08e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	4.98	0.37	1.74e-6	Neuroticism;
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	5.89	0.43	2.45e-8	Cognitive test performance;
PAAD	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.75	5.62	0.41	8.97e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.47	-5.34	-0.4	3.38e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-8.65	-0.57	6.7e-15	Body mass index;
PAAD	cis	rs7674212	0.531	rs4699048	chr4:103926727	A/G	cg16532752	chr4:104119610	CENPE	-0.47	-4.25	-0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg10932868	chr11:921992	NA	0.44	4.71	0.36	5.62e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2712184	0.875	rs2541381	chr2:217683836	G/T	cg05032264	chr2:217675019	NA	-0.56	-6.16	-0.45	6.35e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.83	9.54	0.61	3.32e-17	DNA methylation (variation);
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-5.77	-0.42	4.3e-8	Gut microbiome composition (summer);
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs8070740	0.617	rs9908179	chr17:5323631	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.69	0.42	6.23e-8	Menopause (age at onset);
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg22963979	chr7:1858916	MAD1L1	-0.66	-6.96	-0.49	9.47e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs2885056	0.843	rs2360745	chr19:10693836	G/T	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.61	6.42	0.46	1.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg02683114	chr2:24398427	C2orf84	-0.57	-5.85	-0.43	2.93e-8	Asthma;
PAAD	cis	rs4454254	0.589	rs883612	chr8:141076133	C/G	cg07454640	chr8:140990901	TRAPPC9	0.51	4.83	0.36	3.3e-6	Pulse pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17913255	chr3:195595244	TNK2	0.62	7.25	0.51	2.03e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.75	5.7	0.42	5.97e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.89	-0.37	2.57e-6	Life satisfaction;
PAAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.02	0.49	7.02e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.48	-0.41	1.77e-7	Blood metabolite levels;
PAAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.59	-6.36	-0.46	2.26e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.585	rs1797147	chr6:45162159	T/C	cg18551225	chr6:44695536	NA	0.43	4.47	0.34	1.49e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs74544699	1.000	rs353028	chr4:74777223	C/T	cg05509609	chr4:74847829	PF4	1.14	4.4	0.34	2.04e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.26	-0.45	3.66e-9	Neuroticism;
PAAD	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.95	9.51	0.61	3.98e-17	Corneal astigmatism;
PAAD	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.79	6.12	0.44	7.44e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg02600875	chr7:8008949	GLCCI1	0.61	6.34	0.46	2.44e-9	Primary biliary cholangitis;
PAAD	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.73	6.19	0.45	5.3e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.31	-0.33	2.87e-5	Platelet count;
PAAD	cis	rs2798269	0.604	rs9552438	chr13:22067809	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.58	-5.59	-0.41	1.02e-7	PR segment;
PAAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs469727	0.533	rs2909958	chr5:112167941	C/G	cg06941702	chr5:112196734	SRP19	-0.53	-4.98	-0.37	1.7e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	9.43	0.61	6.58e-17	Menarche (age at onset);
PAAD	cis	rs3764400	0.508	rs978263	chr17:46180664	A/G	cg10706073	chr17:46328419	SKAP1	1.08	6.38	0.46	2.02e-9	Body mass index;
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.5	4.96	0.37	1.84e-6	Height;
PAAD	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.6	5.71	0.42	5.84e-8	Platelet count;
PAAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.82	-8.01	-0.54	2.77e-13	Breast cancer;
PAAD	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	4.94	0.37	2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg20744362	chr22:50050164	C22orf34	0.68	8.41	0.56	2.82e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2274459	1.000	rs3806107	chr6:33767413	C/T	cg06253072	chr6:33679850	C6orf125	0.64	4.62	0.35	8.16e-6	Obesity (extreme);
PAAD	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg25382128	chr12:54346509	NA	-0.45	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.23	0.45	4.28e-9	Lung cancer;
PAAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.99	-0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs55728055	0.661	rs73160611	chr22:31803487	A/G	cg01338084	chr22:32026380	PISD	1.4	7.05	0.5	5.87e-11	Age-related hearing impairment;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08199273	chr10:131934535	GLRX3	-0.55	-6.38	-0.46	1.98e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.92	-10.49	-0.65	1.06e-19	Prostate cancer;
PAAD	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.63	6.82	0.48	1.99e-10	Colorectal cancer;
PAAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg27490568	chr2:178487706	NA	-0.41	-4.35	-0.33	2.5e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.87	-11.15	-0.67	1.8e-21	Dental caries;
PAAD	cis	rs6066835	1.000	rs6066832	chr20:47354132	C/A	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.69	-0.42	6.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.59	7.15	0.5	3.37e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00982548	chr2:198649783	BOLL	0.63	4.29	0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14725215	chr17:4607647	PELP1	0.64	6.5	0.47	1.06e-9	Obesity-related traits;
PAAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.49	4.53	0.34	1.18e-5	Renal cell carcinoma;
PAAD	cis	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg22637538	chr17:7348327	CHRNB1	0.48	5.39	0.4	2.59e-7	Height;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg12705353	chr12:122356852	WDR66	0.47	4.87	0.37	2.83e-6	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	7.43	0.52	7.11e-12	Alzheimer's disease;
PAAD	cis	rs13102973	0.682	rs7691622	chr4:135889689	T/C	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs11700980	0.551	rs2832044	chr21:30116713	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12568669	chr8:11666485	FDFT1	-0.27	-4.6	-0.35	8.74e-6	Myopia (pathological);
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg00933542	chr6:150070202	PCMT1	0.53	5.62	0.41	9.06e-8	Lung cancer;
PAAD	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20555564	chr14:77924342	C14orf133;AHSA1	-0.7	-6.68	-0.48	4.28e-10	Lung cancer in ever smokers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03258011	chr17:54857409	NA	0.61	6.86	0.49	1.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.17	-0.39	7.3e-7	Common traits (Other);
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs72960926	0.744	rs3846756	chr6:75061918	A/T	cg13435101	chr6:74171350	MTO1	0.92	4.86	0.37	2.84e-6	Metabolite levels (MHPG);
PAAD	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.62	-0.47	5.66e-10	Schizophrenia;
PAAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.47	-6.28	-0.45	3.32e-9	Height;
PAAD	cis	rs4748857	1.000	rs4633356	chr10:23548027	T/C	cg18853376	chr10:23633759	C10orf67	0.51	4.47	0.34	1.52e-5	Systemic lupus erythematosus;
PAAD	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-4.47	-0.34	1.5e-5	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26195366	chr10:102242535	WNT8B	-0.56	-6.34	-0.46	2.5e-9	Body fat percentage;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	10.17	0.64	7.28e-19	Tonsillectomy;
PAAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.62	7.05	0.5	5.95e-11	Schizophrenia;
PAAD	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg16405210	chr4:1374714	KIAA1530	0.5	5.26	0.39	4.72e-7	Obesity-related traits;
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg22338127	chr1:209979572	IRF6	0.51	4.26	0.33	3.58e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg05313129	chr8:58192883	C8orf71	-0.63	-5.34	-0.4	3.29e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.73	7.24	0.51	2.14e-11	Corneal astigmatism;
PAAD	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg00944433	chr1:107599041	PRMT6	0.41	4.63	0.35	7.67e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.89	-8.38	-0.56	3.38e-14	Breast cancer;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05273006	chr15:62534197	NA	0.41	4.3	0.33	3.01e-5	Immature fraction of reticulocytes;
PAAD	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.47	-5.27	-0.39	4.64e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-5.86	-0.43	2.73e-8	Gut microbiome composition (summer);
PAAD	cis	rs7631605	0.875	rs9823120	chr3:37199050	A/G	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.15	-0.39	7.98e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.68	0.42	6.59e-8	Schizophrenia;
PAAD	cis	rs4343996	0.967	rs6958390	chr7:3353005	T/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.14	-0.38	8.24e-7	Motion sickness;
PAAD	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs1413885	1.000	rs1334880	chr1:65818481	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-4.95	-0.37	1.98e-6	Anticoagulant levels;
PAAD	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs1144	0.537	rs2430486	chr7:104584410	C/T	cg04380332	chr7:105027541	SRPK2	-0.65	-6.93	-0.49	1.1e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs859767	0.679	rs4954158	chr2:135426618	T/C	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs2019216	0.538	rs2341278	chr17:21994959	G/A	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.5e-5	Pelvic organ prolapse;
PAAD	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.92	7.6	0.52	2.81e-12	Alzheimer's disease;
PAAD	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg05784532	chr1:230284198	GALNT2	0.69	5.78	0.42	4.13e-8	Coronary artery disease;
PAAD	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg13263323	chr15:86062960	AKAP13	-0.62	-7.17	-0.5	3.13e-11	Interstitial lung disease;
PAAD	cis	rs7713065	0.840	rs10069798	chr5:131788421	T/A	cg14196790	chr5:131705035	SLC22A5	-0.52	-4.99	-0.38	1.61e-6	Lung function (FEV1/FVC);
PAAD	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.65	7.07	0.5	5.18e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.68	-4.62	-0.35	8.19e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-4.97	-0.37	1.78e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12304921	1.000	rs67420027	chr12:51349847	T/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-4.57	-0.35	9.88e-6	Longevity;Endometriosis;
PAAD	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.9	-9.5	-0.61	4.42e-17	Inhibitory control;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.72	0.36	5.29e-6	Height;
PAAD	cis	rs7618915	0.962	rs13094687	chr3:52450043	A/G	cg14092988	chr3:52407081	DNAH1	0.61	7.63	0.53	2.39e-12	Bipolar disorder;
PAAD	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg10381502	chr11:71823885	C11orf51	0.93	4.55	0.35	1.08e-5	Severe influenza A (H1N1) infection;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.2	-0.55	9.49e-14	Coffee consumption (cups per day);
PAAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.4	0.46	1.83e-9	Personality dimensions;
PAAD	cis	rs6076065	0.676	rs6076059	chr20:23336261	C/T	cg11657817	chr20:23433608	CST11	0.5	5.13	0.38	8.77e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg24254488	chr7:25991654	NA	0.31	4.52	0.34	1.22e-5	Triglyceride levels;
PAAD	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg02820901	chr13:113351484	ATP11A	-0.67	-5.2	-0.39	6.46e-7	Glycated hemoglobin levels;
PAAD	cis	rs9652601	0.677	rs35732840	chr16:11228355	T/G	cg04616529	chr16:11181986	CLEC16A	0.42	4.54	0.35	1.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.85	7.07	0.5	5.13e-11	Brain cytoarchitecture;
PAAD	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	5e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.48	-5.0	-0.38	1.55e-6	Testicular germ cell tumor;
PAAD	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs7640424	0.649	rs17233248	chr3:107899513	T/C	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-10.25	-0.64	4.49e-19	Height;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.42	4.58	0.35	9.67e-6	Obesity-related traits;
PAAD	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg24565620	chr2:194026	NA	-0.63	-5.3	-0.39	4.09e-7	Blood protein levels;
PAAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.65	-6.9	-0.49	1.3e-10	Bone mineral density;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12963246	chr6:28129442	ZNF389	-0.66	-4.86	-0.37	2.91e-6	Depression;
PAAD	cis	rs12900413	0.687	rs28428808	chr15:90315516	C/T	cg24249390	chr15:90295951	MESP1	-0.52	-5.62	-0.41	8.89e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9942416	0.533	rs12109251	chr5:75024240	C/A	cg07025548	chr5:74632477	HMGCR	-0.57	-4.36	-0.33	2.36e-5	Age-related disease endophenotypes;
PAAD	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.56	5.23	0.39	5.62e-7	Night sleep phenotypes;
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	cis	rs258892	0.895	rs4540158	chr5:72038224	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.86	9.94	0.63	2.97e-18	White blood cell count;
PAAD	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.81	10.03	0.63	1.76e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.43	-4.89	-0.37	2.5e-6	Inattentive symptoms;
PAAD	cis	rs9395066	0.545	rs12525009	chr6:44875843	C/T	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.54	5.63	0.42	8.36e-8	Body mass index;
PAAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg01966878	chr4:90757139	SNCA	-0.66	-5.2	-0.39	6.27e-7	Neuroticism;
PAAD	cis	rs959260	1.000	rs4789193	chr17:73404796	A/T	cg20590849	chr17:73267439	MIF4GD	0.53	4.3	0.33	3.07e-5	Systemic lupus erythematosus;
PAAD	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.98	-12.93	-0.72	2.85e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.58	-5.05	-0.38	1.24e-6	Type 2 diabetes;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.47	5.46	0.4	1.94e-7	Cystic fibrosis severity;
PAAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.81	8.5	0.57	1.66e-14	Selective IgA deficiency;
PAAD	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg10589385	chr1:150898437	SETDB1	0.42	5.08	0.38	1.11e-6	Tonsillectomy;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.69	7.49	0.52	5.31e-12	Aortic root size;
PAAD	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.53	4.3	0.33	3e-5	Response to antidepressants in depression;
PAAD	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	trans	rs901683	1.000	rs36074276	chr10:46055741	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.55	7.78	0.53	1.04e-12	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.67	0.72	1.43e-25	Prudent dietary pattern;
PAAD	cis	rs7624766	0.508	rs9833075	chr3:160527846	T/G	cg22637730	chr3:160473554	PPM1L	0.51	4.38	0.34	2.16e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.676	rs11964178	chr6:109562035	A/G	cg21918786	chr6:109611834	NA	-0.41	-4.36	-0.33	2.4e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02687055	chr2:24232865	MFSD2B	0.57	6.47	0.46	1.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg11218175	chr11:495084	RNH1	0.77	4.44	0.34	1.69e-5	Body mass index;
PAAD	cis	rs2456568	0.808	rs2511398	chr11:93684809	A/G	cg19264203	chr11:92714893	MTNR1B	0.43	4.86	0.37	2.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg07159951	chr1:45983175	PRDX1	0.42	4.64	0.35	7.38e-6	High light scatter reticulocyte count;
PAAD	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.87	-9.14	-0.6	3.72e-16	Body mass index;
PAAD	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.7	6.94	0.49	1.06e-10	Lymphocyte counts;
PAAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg17775713	chr3:133465469	TF	0.49	5.57	0.41	1.15e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg07068956	chr7:100330872	ZAN	-0.6	-4.63	-0.35	7.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.23	12.64	0.72	1.79e-25	Post bronchodilator FEV1;
PAAD	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23622325	chr17:34901867	GGNBP2	0.58	6.46	0.46	1.35e-9	Triglycerides;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13468249	chr17:7154818	DULLARD;C17orf81	0.54	6.67	0.48	4.45e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9646944	0.501	rs12991737	chr2:103018128	T/A	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.53	4.98	0.37	1.68e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.49	4.83	0.36	3.28e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs8105895	0.799	rs62112922	chr19:22228340	C/T	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg08676812	chr11:65308423	LTBP3	0.87	5.66	0.42	7.29e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg08975724	chr8:8085496	FLJ10661	0.76	7.47	0.52	5.88e-12	Mood instability;
PAAD	cis	rs794728	0.522	rs7709651	chr5:173862015	T/C	cg20434911	chr5:173954559	NA	-0.46	-4.3	-0.33	3.02e-5	Depressive symptoms (SSRI exposure interaction);
PAAD	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02556042	chr12:117471086	NA	0.49	5.0	0.38	1.54e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.45	-4.39	-0.34	2.07e-5	Height;
PAAD	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-1.03	-6.98	-0.49	8.47e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg10290764	chr8:4849399	CSMD1	-0.39	-6.47	-0.46	1.27e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.57	5.99	0.44	1.47e-8	Coronary artery disease;
PAAD	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.8	-8.96	-0.59	1.11e-15	Mean platelet volume;
PAAD	cis	rs1891275	0.551	rs2421629	chr10:93423775	T/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.46	-0.4	1.9e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg09127314	chr1:152161683	NA	-0.71	-4.95	-0.37	1.94e-6	Atopic dermatitis;
PAAD	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.56	-5.24	-0.39	5.34e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04080353	chr10:126849780	CTBP2	0.64	6.39	0.46	1.97e-9	Obesity-related traits;
PAAD	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.7e-8	Daytime sleep phenotypes;
PAAD	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.39	0.61	8.49e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2882667	0.690	rs13172507	chr5:138243098	G/A	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.48	-5.08	-0.38	1.09e-6	Bipolar disorder;
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg21929781	chr1:2537748	MMEL1	-0.53	-5.6	-0.41	9.66e-8	Ulcerative colitis;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.47	5.46	0.4	1.94e-7	Cystic fibrosis severity;
PAAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs6494488	0.500	rs72742910	chr15:64841834	G/A	cg16425858	chr15:64791681	ZNF609	1.0	4.68	0.35	6.26e-6	Coronary artery disease;
PAAD	cis	rs8112211	0.648	rs79381523	chr19:38816976	T/C	cg14299480	chr19:38876666	GGN	-0.48	-4.33	-0.33	2.72e-5	Blood protein levels;
PAAD	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.47	-5.36	-0.4	2.98e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg05085585	chr16:30420623	ZNF771	0.45	4.49	0.34	1.38e-5	Tonsillectomy;
PAAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-5.24	-0.39	5.21e-7	Personality dimensions;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.76	-7.8	-0.53	9.2e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.68	6.42	0.46	1.64e-9	Lymphocyte counts;
PAAD	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.57	-0.61	2.78e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.6	5.04	0.38	1.3e-6	Cystic fibrosis severity;
PAAD	cis	rs2274459	1.000	rs35646598	chr6:33717416	T/C	cg06253072	chr6:33679850	C6orf125	0.67	4.7	0.36	5.7e-6	Obesity (extreme);
PAAD	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.84	8.4	0.56	2.93e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.43	4.39	0.34	2.14e-5	Longevity;Endometriosis;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg00717180	chr2:96193071	NA	-0.62	-7.48	-0.52	5.45e-12	Height;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.86	-6.36	-0.46	2.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	0.98	8.72	0.58	4.65e-15	Psoriasis;
PAAD	cis	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.69	7.37	0.51	1.01e-11	Lung cancer;
PAAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.8	-8.14	-0.55	1.32e-13	Coronary artery disease;
PAAD	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg18833306	chr6:118973337	C6orf204	0.52	5.81	0.43	3.57e-8	Electrocardiographic conduction measures;
PAAD	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	7.61	0.53	2.7e-12	Menopause (age at onset);
PAAD	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.59	-5.87	-0.43	2.64e-8	Monocyte count;
PAAD	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.56	-6.33	-0.46	2.58e-9	Leprosy;
PAAD	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs863345	0.604	rs2023632	chr1:158459034	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg23920097	chr1:209922102	NA	0.48	4.27	0.33	3.44e-5	Red blood cell count;
PAAD	cis	rs1198430	0.759	rs1198427	chr1:23752898	G/C	cg19827787	chr1:23763612	ASAP3	0.55	4.68	0.36	6.2e-6	Total cholesterol levels;
PAAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02725872	chr8:58115012	NA	-0.66	-5.65	-0.42	7.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs16975963	0.843	rs11672163	chr19:38373856	G/A	cg08679971	chr19:38281047	NA	0.5	4.84	0.37	3.22e-6	Longevity;
PAAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.67	8.09	0.55	1.81e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs787274	1.000	rs786961	chr9:115471346	T/C	cg13803584	chr9:115635662	SNX30	0.78	4.37	0.33	2.31e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.69	7.11	0.5	4.18e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs12127679	0.614	rs10927100	chr1:244171029	C/T	cg03519879	chr14:74227499	C14orf43	-0.87	-6.78	-0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg10556349	chr10:835070	NA	0.69	5.18	0.39	6.95e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg19949948	chr17:19361230	NA	0.44	4.61	0.35	8.45e-6	Schizophrenia;
PAAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg11802864	chr11:65308245	LTBP3	0.46	4.64	0.35	7.61e-6	Bone mineral density;
PAAD	cis	rs16975963	0.793	rs59616348	chr19:38447753	G/A	cg14218481	chr19:38281219	NA	0.47	4.91	0.37	2.32e-6	Longevity;
PAAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.48	-5.28	-0.39	4.4e-7	Platelet distribution width;
PAAD	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.52	-6.43	-0.46	1.54e-9	Lewy body disease;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg26236440	chr2:113341947	CHCHD5	-0.65	-6.62	-0.47	5.94e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-9.08	-0.59	5.3e-16	Dental caries;
PAAD	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21646471	chr2:242523971	THAP4	0.6	4.73	0.36	5.13e-6	Prostate cancer;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg20821713	chr7:1055600	C7orf50	-0.38	-4.34	-0.33	2.6e-5	Longevity;Endometriosis;
PAAD	cis	rs367943	0.556	rs7709820	chr5:112991327	G/A	cg12552261	chr5:112820674	MCC	0.57	6.09	0.44	8.97e-9	Type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Diabetic kidney disease;
PAAD	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.55	5.53	0.41	1.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.5	5.26	0.39	4.87e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.62	6.15	0.45	6.58e-9	Narcolepsy;
PAAD	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs7567389	0.504	rs1568278	chr2:128190195	G/A	cg09760422	chr2:128146352	NA	0.39	5.73	0.42	5.23e-8	Self-rated health;
PAAD	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07701084	chr6:150067640	NUP43	0.6	6.07	0.44	9.56e-9	Testicular germ cell tumor;
PAAD	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.7	6.41	0.46	1.78e-9	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs901683	1.000	rs17157836	chr10:45963586	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16063666	chr7:86974833	TP53TG1;CROT	0.7	7.2	0.5	2.58e-11	Obesity-related traits;
PAAD	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg08558340	chr7:100472263	SRRT	0.51	4.51	0.34	1.27e-5	Resting heart rate;
PAAD	cis	rs758324	0.947	rs11242098	chr5:131206837	T/G	cg06307176	chr5:131281290	NA	0.54	4.62	0.35	8.22e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2659703	0.694	rs2713612	chr3:128171539	C/T	cg24680163	chr3:127842675	RUVBL1	0.51	4.39	0.34	2.1e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12982440	chr20:36661586	RPRD1B;KIAA0406	0.57	6.29	0.45	3.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg19792802	chr11:65647270	CTSW	0.59	7.21	0.51	2.4e-11	Crohn's disease;
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.67	6.73	0.48	3.21e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.42	-0.4	2.27e-7	Prostate cancer;
PAAD	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.9	-0.37	2.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg22771759	chr13:24902376	NA	0.43	4.29	0.33	3.21e-5	Obesity-related traits;
PAAD	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg12140854	chr5:148520817	ABLIM3	-0.4	-4.3	-0.33	3.01e-5	Breast cancer;
PAAD	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.35e-13	Coronary artery disease;
PAAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.57	5.21	0.39	5.98e-7	IgG glycosylation;
PAAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.84	0.37	3.13e-6	Blood metabolite levels;
PAAD	cis	rs17023223	0.537	rs2765534	chr1:119597792	A/C	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.39e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12435494	chr20:61493322	TCFL5	0.54	6.44	0.46	1.52e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.38	-0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.8	7.66	0.53	2.08e-12	Neuroticism;
PAAD	cis	rs17601876	0.814	rs3889391	chr15:51558422	G/A	cg21478137	chr15:51532386	CYP19A1	0.48	4.75	0.36	4.69e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22999066	chr14:71867244	NA	-0.62	-6.59	-0.47	6.65e-10	Obesity-related traits;
PAAD	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg20936604	chr3:58311152	NA	-0.86	-5.12	-0.38	9.07e-7	Cholesterol, total;
PAAD	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.72	-7.49	-0.52	5.15e-12	Body mass index;
PAAD	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.42	-0.34	1.87e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.61	-5.47	-0.41	1.82e-7	Type 2 diabetes;
PAAD	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg21419209	chr3:44054225	NA	-0.64	-6.54	-0.47	8.89e-10	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15757507	chr22:19554171	LOC150185	0.57	6.83	0.48	1.96e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg05585544	chr11:47624801	NA	0.46	5.09	0.38	1.05e-6	Subjective well-being;
PAAD	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg15145296	chr3:125709740	NA	-0.64	-4.84	-0.37	3.22e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg24220031	chr2:73402428	NA	-0.32	-4.81	-0.36	3.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.68	-6.81	-0.48	2.15e-10	Obesity-related traits;
PAAD	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg15956490	chr3:53032818	SFMBT1	0.73	4.42	0.34	1.84e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-4.55	-0.35	1.08e-5	Menarche (age at onset);
PAAD	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.71	7.79	0.53	9.91e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.9	9.66	0.62	1.68e-17	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.68	7.23	0.51	2.23e-11	Colorectal cancer;
PAAD	cis	rs4450131	1.000	rs10901799	chr10:126348274	A/G	cg20435097	chr10:126320824	FAM53B	-0.48	-5.41	-0.4	2.41e-7	White blood cell count (basophil);
PAAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg27494647	chr7:150038898	RARRES2	0.43	4.63	0.35	7.72e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.66	-5.46	-0.41	1.87e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.65	-0.42	7.67e-8	P wave terminal force;
PAAD	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.55	5.08	0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.47	-5.57	-0.41	1.11e-7	Inflammatory bowel disease;
PAAD	cis	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg20630943	chr20:44563219	PCIF1	0.49	4.58	0.35	9.57e-6	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
PAAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg05373962	chr22:49881684	NA	-0.46	-4.45	-0.34	1.64e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.22	0.6	2.26e-16	Post bronchodilator FEV1;
PAAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.66e-5	Aortic root size;
PAAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.41	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1274963	0.601	rs811970	chr3:39196552	A/G	cg02254461	chr3:39195904	CSRNP1	-0.55	-4.76	-0.36	4.51e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.55	5.56	0.41	1.15e-7	Menopause (age at onset);
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg09509183	chr1:209979624	IRF6	0.56	5.13	0.38	8.6e-7	Cleft lip with or without cleft palate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02380278	chr5:71756236	ZNF366	-0.58	-6.3	-0.46	3.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.96	8.61	0.57	8.65e-15	Triglycerides;
PAAD	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg08648136	chr8:956695	NA	0.42	4.41	0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs2017305	0.749	rs7071782	chr10:70790763	G/C	cg25290552	chr10:70751067	KIAA1279	-0.87	-5.4	-0.4	2.54e-7	Depression (quantitative trait);
PAAD	cis	rs2733310	1.000	rs2703595	chr15:57490290	A/G	cg13626582	chr15:57592083	LOC283663	-0.36	-4.26	-0.33	3.6e-5	Mean platelet volume;
PAAD	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs859767	0.704	rs7570717	chr2:135361035	C/T	cg12500956	chr2:135428796	TMEM163	-0.31	-4.59	-0.35	9.24e-6	Neuroticism;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.97	-0.72	2.28e-26	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg21698718	chr17:80085957	CCDC57	0.41	4.44	0.34	1.74e-5	Life satisfaction;
PAAD	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg01426195	chr3:39028469	NA	-0.55	-5.7	-0.42	6.02e-8	Interleukin-18 levels;
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.52	-5.62	-0.41	9.09e-8	Life satisfaction;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.34e-6	Lung cancer;
PAAD	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.39	-5.81	-0.43	3.48e-8	Educational attainment (years of education);
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg07786776	chr17:40250289	NA	0.37	4.48	0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.45	-0.4	2e-7	Prevalent atrial fibrillation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11769841	chr22:38795061	LOC400927	0.66	7.82	0.54	8.43e-13	Myopia (pathological);
PAAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-8.49	-0.57	1.73e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.84	7.44	0.52	6.79e-12	Schizophrenia;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	trans	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.67	-0.48	4.39e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4321143	0.595	rs7165153	chr15:96147390	C/T	cg12279294	chr15:96877300	NR2F2	-0.38	-4.4	-0.34	2.05e-5	Conduct disorder (maternal expressed emotions interaction);
PAAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.96	-0.59	1.12e-15	Bone mineral density;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	4.62	0.35	8.25e-6	Educational attainment;
PAAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.39	-0.34	2.12e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg15590007	chr10:45870220	ALOX5	0.49	5.25	0.39	5e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.48	-4.31	-0.33	2.88e-5	Tuberculosis;
PAAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.68	0.58	5.77e-15	Bipolar disorder;
PAAD	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.53	0.57	1.42e-14	Caffeine consumption;
PAAD	cis	rs12044355	0.827	rs1572899	chr1:231825490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	6.12	0.44	7.46e-9	Alzheimer's disease;
PAAD	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg20487152	chr13:99095054	FARP1	0.46	4.8	0.36	3.73e-6	Longevity;
PAAD	cis	rs7941600	0.708	rs4627080	chr11:9336349	G/T	cg19415743	chr11:9336845	TMEM41B	-0.94	-5.9	-0.43	2.29e-8	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs12098973	0.591	rs76722130	chr11:131799553	C/T	cg13055484	chr11:132662455	OPCML	0.52	4.38	0.34	2.16e-5	Cardiac Troponin-T levels;
PAAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.39	-0.34	2.12e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg01028140	chr2:1542097	TPO	-1.04	-8.99	-0.59	9.23e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.92	-11.19	-0.67	1.4e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.06	-0.38	1.22e-6	Breast cancer;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.28	0.51	1.64e-11	Longevity;Endometriosis;
PAAD	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.74	-0.42	5.04e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg07701084	chr6:150067640	NUP43	0.59	5.07	0.38	1.17e-6	Lung cancer;
PAAD	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs12153243	0.714	rs72804744	chr5:142917084	G/C	cg13907255	chr5:142895549	NA	-0.53	-4.91	-0.37	2.34e-6	Migraine;
PAAD	cis	rs9581857	0.579	rs76614377	chr13:27974251	A/T	cg22138327	chr13:27999177	GTF3A	0.87	5.52	0.41	1.44e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4148087	0.858	rs28435557	chr21:43634623	A/G	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.62	-6.32	-0.46	2.76e-9	Obesity;
PAAD	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.85	6.17	0.45	5.83e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6137287	0.668	rs6047255	chr20:21095936	A/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.72	0.36	5.37e-6	Height;
PAAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.58	-5.94	-0.43	1.9e-8	Longevity;Endometriosis;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.96	12.79	0.72	6.8e-26	Menopause (age at onset);
PAAD	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.7	7.37	0.51	1.02e-11	Colorectal cancer;
PAAD	cis	rs151997	0.830	rs27282	chr5:50198970	G/A	cg06027927	chr5:50259733	NA	0.66	6.62	0.47	5.8e-10	Callous-unemotional behaviour;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.69	-6.83	-0.48	1.88e-10	Blood metabolite levels;
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg18569988	chr3:195679450	NA	0.42	4.32	0.33	2.85e-5	Pancreatic cancer;
PAAD	cis	rs2885056	0.891	rs2304160	chr19:10692129	G/A	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg04520793	chr17:42248056	ASB16	-0.41	-4.9	-0.37	2.39e-6	Total body bone mineral density;
PAAD	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs2213920	1.000	rs9299227	chr9:118263508	A/G	cg13918206	chr9:118159781	DEC1	0.77	5.29	0.39	4.16e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9361491	0.608	rs4706066	chr6:79459777	T/C	cg05283184	chr6:79620031	NA	-0.38	-4.64	-0.35	7.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.585	rs1284965	chr6:45176911	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.28	-0.39	4.47e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs215088	0.879	rs129116	chr16:16066040	G/A	cg08996506	chr16:16070868	ABCC1	0.35	4.29	0.33	3.11e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg10973622	chr2:86423274	IMMT	0.49	5.68	0.42	6.65e-8	Night sleep phenotypes;
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09640425	chr7:158790006	NA	-0.5	-5.58	-0.41	1.09e-7	Facial morphology (factor 20);
PAAD	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	1.11	10.58	0.65	5.89e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.29	5.47	0.41	1.78e-7	Urinary metabolites;
PAAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.64	7.29	0.51	1.56e-11	Emphysema distribution in smoking;
PAAD	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.71	0.36	5.54e-6	Breast cancer;
PAAD	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7598759	0.679	rs10202701	chr2:232328681	C/T	cg10034588	chr2:232392055	NMUR1	0.37	4.3	0.33	3.02e-5	Noise-induced hearing loss;
PAAD	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs7620363	0.859	rs7609671	chr3:34092931	A/G	cg02064073	chr3:33155252	CRTAP	-0.51	-4.41	-0.34	1.95e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs6804624	0.676	rs2951497	chr3:99166634	A/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.56	-5.87	-0.43	2.64e-8	Hepatitis;
PAAD	cis	rs7172677	0.961	rs62027287	chr15:75429721	A/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.72	-0.36	5.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.37	5.01	0.38	1.5e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13871588	chr6:42981948	MEA1;KLHDC3	0.65	6.89	0.49	1.39e-10	Myopia (pathological);
PAAD	cis	rs1345301	0.518	rs12468355	chr2:102861250	T/G	cg03938978	chr2:103052716	IL18RAP	-0.42	-4.57	-0.35	9.92e-6	Waist circumference;
PAAD	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg12647257	chr2:47043387	NA	0.46	4.57	0.35	1.01e-5	Height;
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg26516362	chr5:178986906	RUFY1	0.41	4.54	0.35	1.13e-5	Lung cancer;
PAAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.91	-10.89	-0.66	9.12e-21	Pulse pressure;
PAAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg11989407	chr2:239091683	ILKAP	0.45	4.27	0.33	3.4e-5	Multiple system atrophy;
PAAD	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-1.23	-10.3	-0.64	3.34e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.66	-0.35	6.95e-6	Rheumatoid arthritis;
PAAD	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.14	0.45	6.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg25452165	chr22:42524984	CYP2D6	0.6	5.51	0.41	1.5e-7	Schizophrenia;
PAAD	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.56	5.1	0.38	9.98e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.34	0.6	1.14e-16	Colorectal cancer;
PAAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22442454	chr1:209979470	IRF6	0.54	4.44	0.34	1.72e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs643506	0.845	rs762550	chr11:111783100	T/C	cg09085632	chr11:111637200	PPP2R1B	0.56	4.62	0.35	8.21e-6	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23334298	chr4:78692537	CNOT6L	-0.68	-7.38	-0.51	9.7e-12	Obesity-related traits;
PAAD	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.6	-4.36	-0.33	2.38e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg00368415	chr1:151584398	SNX27	0.42	4.3	0.33	3.1e-5	Melanoma;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs1529711	0.636	rs34464972	chr19:10969134	G/A	cg16667279	chr19:11591998	ELAVL3	-0.61	-4.72	-0.36	5.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs713477	0.505	rs8019080	chr14:55891372	C/T	cg13175173	chr14:55914753	NA	-0.36	-4.77	-0.36	4.25e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6715793	0.901	rs12611549	chr2:33403583	G/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg27234864	chr13:21295941	IL17D	-0.62	-5.43	-0.4	2.2e-7	Dental caries;
PAAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12599982	chr1:44399894	ARTN	0.44	4.72	0.36	5.22e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.76	5.85	0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.5	5.3	0.4	3.97e-7	Menopause (age at onset);
PAAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.57	5.8	0.43	3.79e-8	Childhood ear infection;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.6e-5	Platelet count;
PAAD	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg16794390	chr17:18148240	FLII	0.6	4.94	0.37	2.04e-6	Obesity-related traits;
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg03199926	chr20:60860733	OSBPL2	-0.35	-4.26	-0.33	3.52e-5	Colorectal cancer;
PAAD	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg24747557	chr10:131355152	MGMT	-0.46	-4.94	-0.37	2.01e-6	Response to temozolomide;
PAAD	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg21479132	chr6:26055353	NA	0.94	5.52	0.41	1.4e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	1.07	12.86	0.72	4.58e-26	Breast cancer;
PAAD	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.85	6.43	0.46	1.54e-9	Alzheimer's disease;
PAAD	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.76e-5	Migraine;
PAAD	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3126085	0.932	rs11587676	chr1:152159961	C/T	cg26876637	chr1:152193138	HRNR	-0.82	-6.02	-0.44	1.26e-8	Atopic dermatitis;
PAAD	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.83	7.49	0.52	5.27e-12	Multiple myeloma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27572240	chr22:41682267	RANGAP1	0.69	7.14	0.5	3.5e-11	Obesity-related traits;
PAAD	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.75	11.0	0.67	4.41e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.36	0.33	2.37e-5	Lung cancer;
PAAD	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg23815491	chr16:72088622	HP	0.4	4.36	0.33	2.37e-5	Fibrinogen levels;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg07873178	chr11:65307616	LTBP3	0.99	4.62	0.35	8.04e-6	Height;
PAAD	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26200001	chr6:56955042	ZNF451	0.63	7.16	0.5	3.24e-11	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.19	-0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs10991814	0.920	rs16907297	chr9:94008934	T/C	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.6	5.53	0.41	1.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.62	6.27	0.45	3.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1499972	0.941	rs62264774	chr3:117647906	C/G	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-5.66	-0.42	7.45e-8	Coronary artery disease;
PAAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg22143856	chr6:28129313	ZNF389	0.51	4.75	0.36	4.74e-6	Parkinson's disease;
PAAD	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	4.34	0.33	2.55e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.62	6.83	0.48	1.89e-10	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27529569	chr19:2977348	TLE6	0.62	7.0	0.49	7.69e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.41	-0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.17e-5	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.39	5.53	0.41	1.38e-7	Neuroticism;
PAAD	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.75	8.19	0.55	1.01e-13	Psoriasis;
PAAD	cis	rs11031096	0.933	rs725519	chr11:4128486	A/G	cg18678763	chr11:4115507	RRM1	0.42	4.35	0.33	2.44e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs728616	0.681	rs17677908	chr10:82049603	A/G	cg19423196	chr10:82049429	MAT1A	0.5	4.92	0.37	2.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg05393297	chr12:53359155	NA	-0.93	-10.06	-0.63	1.44e-18	Prostate cancer;
PAAD	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.8	4.85	0.37	3.02e-6	Obesity-related traits;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.28e-10	HDL cholesterol;
PAAD	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.67	-6.74	-0.48	3.06e-10	Alcohol dependence;
PAAD	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.97	8.32	0.56	4.8e-14	Blood protein levels;
PAAD	cis	rs3131082	1	rs3131082	chr6:28983274	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.51	0.34	1.32e-5	Tuberculosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25543170	chr8:94535210	NA	0.61	6.35	0.46	2.4e-9	Smoking initiation;
PAAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01200585	chr1:228362443	C1orf69	-0.49	-5.53	-0.41	1.35e-7	Diastolic blood pressure;
PAAD	cis	rs11892454	0.544	rs7571093	chr2:25992894	C/G	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	4.61	0.35	8.3e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.59	5.88	0.43	2.47e-8	Parkinson's disease;
PAAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg14393609	chr7:65229607	NA	0.47	4.92	0.37	2.26e-6	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08450256	chr7:100487572	UFSP1	0.61	7.14	0.5	3.55e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg18209359	chr17:80159595	CCDC57	-0.46	-4.71	-0.36	5.65e-6	Life satisfaction;
PAAD	cis	rs2229238	0.774	rs4509570	chr1:154436384	G/C	cg21262032	chr1:154437693	IL6R	0.39	4.29	0.33	3.19e-5	Coronary heart disease;
PAAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	1.16	12.17	0.7	3.13e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs941024	0.651	rs73117228	chr12:56039076	G/C	cg20737382	chr12:56040096	NA	-0.73	-4.73	-0.36	5.02e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-4.98	-0.37	1.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg00310523	chr12:86230176	RASSF9	-0.47	-5.19	-0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs300774	1.000	rs300802	chr2:104762	G/A	cg23649280	chr2:140451	NA	-0.52	-5.0	-0.38	1.57e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg24565620	chr2:194026	NA	-0.52	-4.26	-0.33	3.51e-5	Blood protein levels;
PAAD	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.06	15.24	0.78	2.04e-32	Chronic sinus infection;
PAAD	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	5.58	0.41	1.1e-7	Blood metabolite levels;
PAAD	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.36	-0.46	2.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27297192	chr10:134578999	INPP5A	0.62	5.52	0.41	1.45e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.5	4.63	0.35	7.9e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.37	0.33	2.32e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.66	-6.63	-0.47	5.47e-10	Uric acid levels;
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg17986701	chr20:44574422	PCIF1	0.57	5.8	0.43	3.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-1.03	-13.44	-0.74	1.27e-27	Refractive error;
PAAD	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04271782	chr7:104654707	MLL5;LOC100216545	-0.7	-6.34	-0.46	2.54e-9	Neuroticism;
PAAD	cis	rs2249694	0.620	rs9418990	chr10:135337966	C/T	cg20169779	chr10:135381914	SYCE1	0.55	5.38	0.4	2.82e-7	Obesity-related traits;
PAAD	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg08526024	chr16:1796832	MAPK8IP3	-0.77	-4.25	-0.33	3.69e-5	Snoring;
PAAD	cis	rs9346353	0.645	rs2445962	chr6:70403085	G/A	cg03001484	chr6:70507230	LMBRD1	0.31	4.34	0.33	2.55e-5	Sleep duration;
PAAD	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.55	4.92	0.37	2.21e-6	Lung cancer;
PAAD	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.6	5.16	0.39	7.56e-7	Response to diuretic therapy;
PAAD	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg10985347	chr2:127963512	CYP27C1	0.5	5.0	0.38	1.55e-6	Protein C levels;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.5	-5.62	-0.41	8.88e-8	Age at first birth;
PAAD	cis	rs867371	1.000	rs867371	chr15:82438346	A/T	cg00614314	chr15:82944287	LOC80154	-0.45	-4.32	-0.33	2.78e-5	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.93	-15.45	-0.78	5.58e-33	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13576061	chr5:55291172	IL6ST	0.71	6.54	0.47	8.84e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg02743256	chr7:2109353	MAD1L1	-0.66	-5.56	-0.41	1.19e-7	Neuroticism;
PAAD	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg27605358	chr2:226265475	KIAA1486	-0.41	-4.3	-0.33	3.07e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg03538708	chr1:25844672	NA	-0.53	-5.36	-0.4	3.07e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.55	6.25	0.45	3.84e-9	Mean corpuscular volume;
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-6.08	-0.44	9.51e-9	Prostate cancer;
PAAD	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.56	5.21	0.39	5.93e-7	Red blood cell count;
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.58	-0.47	7.23e-10	Lung cancer;
PAAD	cis	rs1329189	1.000	rs1360788	chr10:130006499	G/T	cg17972361	chr10:130010134	NA	-0.48	-4.89	-0.37	2.52e-6	Orofacial clefts;
PAAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs773506	0.602	rs10761110	chr9:93929884	A/G	cg14446406	chr9:93919335	NA	-0.43	-5.87	-0.43	2.64e-8	Type 2 diabetes nephropathy;
PAAD	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.51	-0.41	1.5e-7	Neuroticism;
PAAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.52	5.75	0.42	4.84e-8	Heart rate;
PAAD	trans	rs1422110	0.641	rs12514639	chr5:85523929	C/T	cg01787110	chr1:109008453	NBPF6	-0.82	-8.04	-0.55	2.33e-13	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg26929247	chr19:58907184	NA	-0.39	-4.27	-0.33	3.37e-5	Uric acid clearance;
PAAD	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg06627628	chr2:24431161	ITSN2	-0.58	-5.62	-0.41	9.08e-8	Sjögren's syndrome;
PAAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-1.01	-14.24	-0.76	8.98e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19671926	chr4:122722719	EXOSC9	-0.66	-6.41	-0.46	1.71e-9	Type 2 diabetes;
PAAD	cis	rs10850408	0.922	rs10850407	chr12:115378037	T/G	cg05726002	chr12:115341178	NA	-0.4	-4.65	-0.35	7.2e-6	Alzheimer's disease;
PAAD	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg27490568	chr2:178487706	NA	0.42	4.65	0.35	7.29e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg05150608	chr14:102990211	NA	0.4	4.68	0.36	6.18e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.61	-6.1	-0.44	8.53e-9	Systemic sclerosis;
PAAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18621852	chr3:10150065	C3orf24	0.68	6.05	0.44	1.07e-8	Alzheimer's disease;
PAAD	cis	rs303386	0.501	rs6698436	chr1:99588903	A/G	cg03593336	chr1:99471295	LPPR5	-0.55	-5.42	-0.4	2.34e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.74	-7.72	-0.53	1.46e-12	Cognitive function;
PAAD	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.41	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.5	4.3	0.33	3.07e-5	Triglycerides;
PAAD	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs9815354	1.000	rs2371623	chr3:41761083	T/C	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs4382726	0.525	rs2135817	chr1:209421109	A/T	cg14042241	chr19:1474872	C19orf25	0.54	6.46	0.46	1.33e-9	Response to amphetamines;
PAAD	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg03315344	chr16:75512273	CHST6	-0.62	-5.19	-0.39	6.59e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.57e-6	Bipolar disorder;
PAAD	cis	rs35740288	0.822	rs34734963	chr15:86217644	C/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.25	-0.39	5e-7	Tonsillectomy;
PAAD	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-5.14	-0.38	8.51e-7	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03667862	chr12:8123463	NA	0.73	7.41	0.52	8.27e-12	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.27	0.45	3.54e-9	Height;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10966500	chr12:110338339	TCHP	0.65	6.37	0.46	2.14e-9	Myopia (pathological);
PAAD	cis	rs2290419	0.730	rs116683298	chr11:68943571	G/A	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.91	-0.43	2.14e-8	Menarche (age at onset);
PAAD	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-7.12	-0.5	4.03e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg05895507	chr15:77155635	SCAPER	-0.42	-4.42	-0.34	1.86e-5	Blood metabolite levels;
PAAD	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg08992911	chr2:238395768	MLPH	0.63	5.08	0.38	1.11e-6	Prostate cancer;
PAAD	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.54	4.66	0.35	6.76e-6	Cocaine dependence;
PAAD	cis	rs12476592	0.571	rs6546005	chr2:63672071	G/A	cg10828910	chr2:63850056	LOC388955	0.52	4.49	0.34	1.42e-5	Childhood ear infection;
PAAD	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg14440974	chr22:39074834	NA	0.52	6.12	0.44	7.57e-9	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04824914	chr11:6704797	MRPL17	-0.54	-6.3	-0.46	2.99e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg25319279	chr11:5960081	NA	0.65	6.09	0.44	8.83e-9	DNA methylation (variation);
PAAD	cis	rs2882667	0.690	rs10044401	chr5:138237557	A/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.3	-0.33	3.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.83	10.48	0.65	1.08e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9309711	0.961	rs6739269	chr2:3470995	C/T	cg10845886	chr2:3471009	TTC15	-0.95	-9.32	-0.6	1.31e-16	Neurofibrillary tangles;
PAAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg01059385	chr22:42394853	WBP2NL	0.58	4.72	0.36	5.21e-6	Birth weight;
PAAD	cis	rs198426	0.506	rs11230766	chr11:61426582	A/T	cg23038520	chr11:61406508	RPLP0P2	-0.49	-5.62	-0.41	8.74e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
PAAD	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.56	0.61	3.07e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg20917491	chr3:195578259	NA	0.52	4.94	0.37	2.07e-6	Pancreatic cancer;
PAAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.69	7.1	0.5	4.53e-11	Monocyte count;
PAAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs35160687	0.901	rs6713456	chr2:86507653	T/A	cg10973622	chr2:86423274	IMMT	0.41	4.76	0.36	4.54e-6	Night sleep phenotypes;
PAAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs2286379	0.745	rs4765843	chr12:1868726	C/T	cg05227549	chr12:1770782	NA	-0.4	-4.71	-0.36	5.55e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg08992911	chr2:238395768	MLPH	0.47	4.85	0.37	3.03e-6	Prostate cancer;
PAAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.81	-9.38	-0.61	8.87e-17	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16293131	chr17:79885702	LOC92659;MAFG	0.61	7.42	0.52	7.85e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.22	0.55	8.4e-14	Alzheimer's disease;
PAAD	cis	rs6531209	0.748	rs4666368	chr2:20347806	A/G	cg03801179	chr2:20212423	MATN3	-0.54	-4.47	-0.34	1.53e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs11942476	0.619	rs4482750	chr4:21489698	T/C	cg14992154	chr4:20701870	PACRGL	0.62	4.69	0.36	6e-6	IgG glycosylation;
PAAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.77	8.98	0.59	9.87e-16	Emphysema distribution in smoking;
PAAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.99	-11.76	-0.69	4.17e-23	Cognitive function;
PAAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.59	0.61	2.49e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.49	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs860295	0.580	rs2297480	chr1:155279482	T/G	cg02153340	chr1:155202674	NA	-0.52	-4.68	-0.35	6.3e-6	Body mass index;
PAAD	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.51	5.58	0.41	1.08e-7	Major depressive disorder;
PAAD	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.56	4.87	0.37	2.81e-6	Common traits (Other);
PAAD	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	4.45	0.34	1.62e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1015291	0.599	rs2694980	chr12:20010909	A/G	cg25401612	chr12:20009446	NA	-0.54	-5.33	-0.4	3.53e-7	Diastolic blood pressure;
PAAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04108612	chr1:26324550	PAFAH2	0.65	6.83	0.48	1.87e-10	Obesity-related traits;
PAAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.62	6.41	0.46	1.72e-9	Monocyte count;
PAAD	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.3	-0.4	3.97e-7	Common traits (Other);
PAAD	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.69	-0.42	6.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-11.15	-0.67	1.77e-21	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11558328	chr11:46722331	ARHGAP1;ZNF408	-0.7	-6.65	-0.47	4.96e-10	Neuroticism;
PAAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.45	4.5	0.34	1.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.76	-0.42	4.43e-8	Common traits (Other);
PAAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.77	7.35	0.51	1.14e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs73206853	0.620	rs112599609	chr12:111147643	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	4.45	0.34	1.66e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs783540	1.000	rs1259180	chr15:83244680	T/C	cg00614314	chr15:82944287	LOC80154	0.44	4.52	0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-5.06	-0.38	1.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg19192590	chr2:178524533	PDE11A	0.41	4.74	0.36	4.79e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.57	5.46	0.4	1.94e-7	Menopause (age at onset);
PAAD	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.6	-6.39	-0.46	1.89e-9	Calcium levels;
PAAD	cis	rs501916	0.605	rs2118917	chr15:48078992	C/T	cg16110827	chr15:48056943	SEMA6D	-0.49	-5.27	-0.39	4.65e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17820247	chr12:6579852	VAMP1	0.43	6.63	0.47	5.53e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg17076780	chr6:43251928	TTBK1	0.54	4.38	0.34	2.16e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.86	10.79	0.66	1.63e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	trans	rs1326986	0.826	rs11011239	chr10:20004471	A/G	cg04724540	chr1:166916762	ILDR2	-1.04	-6.46	-0.46	1.33e-9	Ankylosing spondylitis;
PAAD	cis	rs58141407	1	rs58141407	chr8:21791772	C/T	cg25597362	chr8:21767310	DOK2	-0.44	-4.36	-0.33	2.36e-5	Red blood cell count;Mean corpuscular volume;
PAAD	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.64	-0.35	7.42e-6	Joint mobility (Beighton score);
PAAD	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg18721089	chr20:30220636	NA	-0.62	-5.12	-0.38	9.14e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-4.67	-0.35	6.49e-6	Testicular germ cell tumor;
PAAD	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	5.61	0.41	9.44e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg11645453	chr3:52864694	ITIH4	-0.3	-4.4	-0.34	2.04e-5	Height;
PAAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.11	-0.44	8.17e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg12310025	chr6:25882481	NA	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs59888335	0.929	rs35675228	chr3:80884867	T/A	cg21735741	chr3:80819488	NA	0.55	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15454598	chr10:81852004	C10orf57	-0.65	-6.95	-0.49	1.01e-10	Obesity-related traits;
PAAD	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.71	-6.92	-0.49	1.16e-10	White matter hyperintensity burden;
PAAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.79	6.95	0.49	9.91e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs12773846	0.522	rs12772807	chr10:126238915	T/A	cg04949429	chr10:126290192	LHPP	0.66	5.5	0.41	1.57e-7	Subcutaneous adipose tissue;
PAAD	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg16586182	chr3:47516702	SCAP	-0.69	-7.86	-0.54	6.68e-13	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18061656	chr11:74699908	NEU3	-0.79	-6.72	-0.48	3.38e-10	Neuroticism;
PAAD	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.34	0.4	3.27e-7	Lung cancer in ever smokers;
PAAD	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	1e-10	Axial length;
PAAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.49	-0.57	1.78e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.62	-6.15	-0.45	6.42e-9	Post bronchodilator FEV1;
PAAD	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.67	5.19	0.39	6.53e-7	Alzheimer's disease (survival time);
PAAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.5	-4.42	-0.34	1.86e-5	Coronary artery disease;
PAAD	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.4	-4.51	-0.34	1.3e-5	IgG glycosylation;
PAAD	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.5	-5.13	-0.38	8.55e-7	Type 2 diabetes;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00282704	chr10:21786410	MIR1915;C10orf114	0.44	4.62	0.35	8.1e-6	Monocyte percentage of white cells;
PAAD	cis	rs864537	0.691	rs9662048	chr1:167412947	A/T	cg22356347	chr1:167427500	CD247	0.44	5.02	0.38	1.45e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg10168330	chr8:27262164	PTK2B	0.38	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6519955	0.691	rs9627447	chr22:46423928	G/C	cg05468064	chr22:46423449	NA	0.53	6.38	0.46	2.07e-9	Dupuytren's disease;
PAAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg13468214	chr4:1046988	NA	0.52	4.9	0.37	2.45e-6	Recombination rate (females);
PAAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.95	-9.18	-0.6	2.94e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.59	-6.11	-0.44	7.91e-9	Response to antidepressants and depression;
PAAD	cis	rs939421	0.521	rs3827494	chr3:46602231	A/G	cg23009419	chr3:46618597	LRRC2;TDGF1	0.33	4.82	0.36	3.47e-6	Blood protein levels;
PAAD	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.53	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg07148914	chr20:33460835	GGT7	0.48	4.76	0.36	4.51e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.43	4.7	0.36	5.66e-6	HDL cholesterol levels;
PAAD	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-1.04	-9.41	-0.61	7.64e-17	Uric acid levels;
PAAD	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg26818257	chr2:241905806	NA	0.46	4.86	0.37	2.92e-6	Joint mobility (Beighton score);
PAAD	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.68	7.46	0.52	6.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.91	12.29	0.71	1.55e-24	Menopause (age at onset);
PAAD	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-8.3	-0.56	5.4e-14	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11114063	chr6:147524085	STXBP5	-0.76	-6.6	-0.47	6.41e-10	Neuroticism;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.77	8.55	0.57	1.23e-14	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs564309	0.764	rs12089997	chr1:228527186	T/A	cg01328119	chr1:228783545	DUSP5P	0.71	4.41	0.34	1.98e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.95	0.63	2.77e-18	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19205136	chr13:102170398	ITGBL1	-0.65	-6.57	-0.47	7.51e-10	Obesity-related traits;
PAAD	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19904058	chr10:135279010	LOC619207	-0.61	-7.42	-0.52	7.61e-12	Systemic lupus erythematosus;
PAAD	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg24851651	chr11:66362959	CCS	-0.54	-5.06	-0.38	1.2e-6	Airway imaging phenotypes;
PAAD	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg27494647	chr7:150038898	RARRES2	0.41	4.42	0.34	1.86e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg16926213	chr1:1841314	NA	0.37	4.48	0.34	1.46e-5	Body mass index;
PAAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.76	-0.36	4.56e-6	Breast cancer;
PAAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.54	6.16	0.45	6.13e-9	Prostate cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25713793	chr10:33590732	NRP1	-0.55	-6.41	-0.46	1.77e-9	Monocyte percentage of white cells;
PAAD	cis	rs2834188	0.889	rs8134026	chr21:34671098	T/A	cg04842828	chr21:34696676	IFNAR1	0.49	4.67	0.35	6.63e-6	Narcolepsy;
PAAD	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08494713	chr6:99872804	SFRS18	-0.64	-6.63	-0.47	5.49e-10	Neuroticism;
PAAD	cis	rs9652601	0.649	rs767448	chr16:11204221	A/G	cg04616529	chr16:11181986	CLEC16A	0.37	4.52	0.34	1.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.49	-4.47	-0.34	1.54e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.48	-4.7	-0.36	5.7e-6	Vitiligo;
PAAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.77e-6	Recombination rate (females);
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.6	4.41	0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.9	12.03	0.7	7.53e-24	Prudent dietary pattern;
PAAD	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg16584676	chr17:46985605	UBE2Z	-0.51	-5.02	-0.38	1.44e-6	Type 2 diabetes;
PAAD	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.31	-4.34	-0.33	2.54e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8112909	0.843	rs10406475	chr19:46414293	A/C	cg11657440	chr19:46296263	DMWD	0.61	4.38	0.34	2.17e-5	Interferon gamma-induced protein 10 levels;
PAAD	cis	rs3136739	0.614	rs8178895	chr8:42032379	A/G	cg17828057	chr8:42037527	PLAT	0.63	4.25	0.33	3.66e-5	Plasma plasminogen activator levels;
PAAD	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg02049472	chr2:177466316	MIR1246	-0.41	-4.38	-0.33	2.22e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7631605	0.623	rs9857252	chr3:36985232	C/A	cg10333520	chr3:36987040	TRANK1	0.33	4.43	0.34	1.81e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.83	-8.99	-0.59	9.04e-16	Urate levels in obese individuals;
PAAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.86	9.69	0.62	1.36e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9992101	0.547	rs2137154	chr4:77411501	C/G	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13560548	chr3:10150139	C3orf24	0.64	5.57	0.41	1.1e-7	Alzheimer's disease;
PAAD	cis	rs12304921	0.683	rs17125401	chr12:51514352	A/G	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.51	-0.41	1.52e-7	Type 2 diabetes;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg02462569	chr6:150064036	NUP43	-0.56	-6.24	-0.45	4.25e-9	Lung cancer;
PAAD	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg09163369	chr1:210001066	C1orf107	0.69	6.58	0.47	7.09e-10	Orofacial clefts;
PAAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg15017067	chr4:17643749	FAM184B	0.43	5.12	0.38	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg05299278	chr17:33885742	SLFN14	-0.42	-5.02	-0.38	1.45e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg18964960	chr10:1102726	WDR37	0.85	4.62	0.35	8.05e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg18769074	chr3:133464867	TF	0.42	4.9	0.37	2.4e-6	Iron status biomarkers;
PAAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.78	-9.09	-0.59	5.06e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.59	-5.82	-0.43	3.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.56	5.03	0.38	1.36e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06963648	chr14:23340939	LRP10	0.59	6.51	0.47	1.01e-9	Monocyte percentage of white cells;
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.69	6.73	0.48	3.31e-10	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg16342193	chr10:102329863	NA	-0.75	-8.2	-0.55	9.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1144333	0.655	rs17097867	chr1:76471614	C/T	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs4740619	0.647	rs9792412	chr9:16025889	C/T	cg14451791	chr9:16040625	NA	-0.46	-5.28	-0.39	4.4e-7	Body mass index;
PAAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23544223	chr18:12777786	NA	-0.73	-6.24	-0.45	4.22e-9	Inflammatory skin disease;
PAAD	cis	rs9815354	0.830	rs1624519	chr3:41984800	G/A	cg03022575	chr3:42003672	ULK4	-0.77	-5.48	-0.41	1.76e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6735179	0.601	rs114382205	chr2:1747539	G/A	cg08534653	chr2:1747700	PXDN	0.24	4.32	0.33	2.84e-5	Response to antipsychotic treatment;
PAAD	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg18612461	chr15:75251733	NA	0.43	4.52	0.34	1.25e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.59	-6.06	-0.44	1e-8	Lung function (FVC);
PAAD	cis	rs3112530	0.901	rs1824311	chr5:152649413	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg24747557	chr10:131355152	MGMT	-0.51	-5.24	-0.39	5.35e-7	Response to temozolomide;
PAAD	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.36	-0.6	9.97e-17	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11615916	0.790	rs73135294	chr12:62698735	C/A	cg11441379	chr12:63026424	NA	0.65	4.41	0.34	1.93e-5	Pulmonary function decline;
PAAD	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg14459158	chr9:96720562	NA	-0.36	-4.69	-0.36	5.99e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19352808	chr19:6737754	GPR108	0.54	6.48	0.47	1.18e-9	Monocyte percentage of white cells;
PAAD	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.8	10.46	0.65	1.22e-19	Iron status biomarkers (transferrin levels);
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.78	-9.8	-0.62	7.2e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.48	-5.11	-0.38	9.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs1413885	0.549	rs7545720	chr1:65856443	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.76	0.36	4.43e-6	Anticoagulant levels;
PAAD	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.57	-5.32	-0.4	3.58e-7	Daytime sleep phenotypes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08284876	chr5:91970207	NA	0.62	6.83	0.48	1.91e-10	Smoking initiation;
PAAD	cis	rs11892454	0.533	rs10193672	chr2:26104264	C/G	cg03373490	chr2:26702396	OTOF	0.52	4.34	0.33	2.57e-5	Heschl's gyrus morphology;
PAAD	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.32	-4.29	-0.33	3.11e-5	Dupuytren's disease;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.31	0.4	3.85e-7	Personality dimensions;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-1.03	-8.41	-0.56	2.75e-14	Corneal structure;
PAAD	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg27411982	chr8:10470053	RP1L1	-0.51	-5.42	-0.4	2.31e-7	Triglycerides;
PAAD	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg27478167	chr7:817139	HEATR2	0.7	5.36	0.4	3.05e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg02462569	chr6:150064036	NUP43	-0.49	-5.42	-0.4	2.25e-7	Lung cancer;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00166722	chr3:10149974	C3orf24	0.97	7.98	0.54	3.38e-13	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.79	9.07	0.59	5.72e-16	Lung cancer;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	1.11	16.94	0.81	7.81e-37	Menarche (age at onset);
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.03	-0.55	2.45e-13	Prostate cancer;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.78	-9.56	-0.61	2.97e-17	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs755249	0.567	rs6668369	chr1:39848347	C/G	cg14018543	chr1:39659967	MACF1	-0.57	-4.78	-0.36	4.13e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6669119	0.877	rs76369903	chr1:19112568	A/T	cg19637330	chr1:19110922	NA	0.83	5.13	0.38	8.63e-7	Percentage gas trapping;
PAAD	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg02344993	chr17:57696989	CLTC	0.58	5.34	0.4	3.3e-7	Hemoglobin concentration;
PAAD	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg14146966	chr2:61757674	XPO1	0.37	4.38	0.33	2.18e-5	Tuberculosis;
PAAD	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.69	8.86	0.58	1.94e-15	Educational attainment;
PAAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.51e-9	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00489408	chr16:29910669	SEZ6L2;ASPHD1	0.58	6.68	0.48	4.15e-10	Myopia (pathological);
PAAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	1.15	13.51	0.74	8.21e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.73	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.6	-5.56	-0.41	1.19e-7	Breast cancer;
PAAD	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.98	-0.54	3.38e-13	Schizophrenia;
PAAD	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7101378	0.577	rs4370904	chr11:108894516	G/A	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-4.99	-0.38	1.63e-6	IgG glycosylation;
PAAD	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.89	10.82	0.66	1.39e-20	Metabolic syndrome;
PAAD	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.4	13.67	0.74	3.06e-28	Corneal structure;
PAAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-5.8	-0.43	3.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.4	0.34	2e-5	Neuroticism;
PAAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.88e-9	Tonsillectomy;
PAAD	cis	rs6547631	0.622	rs4832185	chr2:85928814	T/A	cg24620635	chr2:85921963	GNLY	0.4	5.39	0.4	2.69e-7	Blood protein levels;
PAAD	cis	rs73206853	0.841	rs17792048	chr12:110866543	C/A	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.68	-0.36	6.21e-6	Height;
PAAD	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg03350042	chr15:40733177	BAHD1	-0.71	-6.56	-0.47	8.01e-10	Blood protein levels;
PAAD	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.47	-5.93	-0.43	1.94e-8	Crohn's disease;
PAAD	cis	rs9788721	0.806	rs72738704	chr15:78719832	G/C	cg06917634	chr15:78832804	PSMA4	-0.44	-4.29	-0.33	3.19e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg14154082	chr13:112174009	NA	0.35	4.29	0.33	3.21e-5	Menarche (age at onset);
PAAD	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.43	-4.75	-0.36	4.61e-6	Pneumonia;
PAAD	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density (age over 60);Total body bone mineral density;
PAAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	10.78	0.66	1.75e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.57	0.52	3.42e-12	Multiple sclerosis;
PAAD	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-6.48	-0.47	1.21e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.61	6.54	0.47	8.89e-10	Menarche (age at onset);
PAAD	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg10072921	chr12:121022843	NA	-0.34	-4.53	-0.34	1.2e-5	High light scatter reticulocyte count;
PAAD	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.82	8.39	0.56	3.12e-14	Response to diuretic therapy;
PAAD	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg05110241	chr16:68378359	PRMT7	-0.88	-7.16	-0.5	3.24e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.8	-0.36	3.82e-6	Menopause (age at onset);
PAAD	cis	rs6466055	0.553	rs10263499	chr7:104671659	T/G	cg04380332	chr7:105027541	SRPK2	-0.49	-4.59	-0.35	9.35e-6	Schizophrenia;
PAAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.97	-6.78	-0.48	2.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs728616	0.614	rs61859191	chr10:82091027	T/C	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18357526	chr6:26021779	HIST1H4A	0.53	4.64	0.35	7.61e-6	Height;
PAAD	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg20129853	chr10:51489980	NA	-0.47	-4.69	-0.36	6.06e-6	Prostate-specific antigen levels;
PAAD	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	1.02	6.7	0.48	3.8e-10	Fat distribution (HIV);
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg16606324	chr3:10149918	C3orf24	-0.56	-4.69	-0.36	5.91e-6	Alzheimer's disease;
PAAD	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.16	0.5	3.22e-11	Hemoglobin concentration;
PAAD	cis	rs4843185	0.764	rs12149210	chr16:85700481	G/A	cg26571870	chr16:85723150	GINS2	-0.44	-5.03	-0.38	1.37e-6	Platelet distribution width;
PAAD	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.61	-5.42	-0.4	2.29e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg07168214	chr17:7380112	ZBTB4	0.65	5.84	0.43	3.01e-8	Androgen levels;
PAAD	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.53	-8.1	-0.55	1.68e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg08614441	chr13:113633676	MCF2L	-0.43	-4.32	-0.33	2.76e-5	Systolic blood pressure;
PAAD	cis	rs10916814	0.632	rs12409100	chr1:20903207	G/A	cg04087271	chr1:20915334	CDA	0.37	4.49	0.34	1.37e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.31	0.56	4.85e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.62	6.07	0.44	9.64e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.920	rs76841123	chr16:67683564	C/G	cg05110241	chr16:68378359	PRMT7	-0.98	-5.02	-0.38	1.46e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.79	-8.77	-0.58	3.39e-15	Longevity;
PAAD	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06850241	chr22:41845214	NA	-0.49	-4.26	-0.33	3.55e-5	Vitiligo;
PAAD	cis	rs4795519	0.553	rs1814029	chr17:22214259	C/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.39	-0.4	2.63e-7	Chronic myeloid leukemia;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10819733	chr22:24237672	NA	-0.62	-6.92	-0.49	1.2e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.47	0.61	5.19e-17	Bipolar disorder;
PAAD	cis	rs2252790	0.895	rs1204833	chr6:116572828	A/G	cg26893134	chr6:116381904	FRK	-0.29	-4.65	-0.35	7.15e-6	Fast beta electroencephalogram;
PAAD	cis	rs6137287	0.668	rs6047258	chr20:21098277	A/C	cg04219410	chr20:21106687	PLK1S1	0.38	4.5	0.34	1.36e-5	Height;
PAAD	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs12304921	0.683	rs17125401	chr12:51514352	A/G	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.72	-0.36	5.41e-6	Type 2 diabetes;
PAAD	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.33	0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Aortic root size;
PAAD	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.43	-0.34	1.8e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs829661	0.947	rs829660	chr2:30726765	A/C	cg12454169	chr2:30669597	LCLAT1	0.66	4.49	0.34	1.41e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs35740288	0.688	rs12904047	chr15:86212866	A/G	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg03959625	chr15:84868606	LOC388152	0.49	5.37	0.4	2.96e-7	Schizophrenia;
PAAD	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.34	-0.56	4.22e-14	Hemoglobin concentration;
PAAD	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9435732	1.000	rs9435732	chr1:17308158	C/T	cg22045253	chr1:17337346	ATP13A2	0.45	4.49	0.34	1.4e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg00262122	chr8:11665843	FDFT1	0.5	4.41	0.34	1.94e-5	Retinal vascular caliber;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg20295408	chr7:1910781	MAD1L1	0.55	5.49	0.41	1.68e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.68	7.4	0.51	8.58e-12	Blood metabolite levels;
PAAD	cis	rs243505	0.632	rs887571	chr7:148505253	G/A	cg09806900	chr7:148480153	CUL1	0.49	4.59	0.35	9.13e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg10729496	chr3:10149963	C3orf24	0.85	6.87	0.49	1.58e-10	Alzheimer's disease;
PAAD	cis	rs6594713	0.602	rs33992630	chr5:112903169	G/A	cg12552261	chr5:112820674	MCC	0.83	6.47	0.46	1.27e-9	Brain cytoarchitecture;
PAAD	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.75	-8.33	-0.56	4.32e-14	Breast cancer;
PAAD	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02725872	chr8:58115012	NA	-0.6	-5.22	-0.39	5.89e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.7	-0.48	3.87e-10	Total cholesterol levels;
PAAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.6e-5	Renal cell carcinoma;
PAAD	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.63	6.26	0.45	3.67e-9	Eosinophil percentage of white cells;
PAAD	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-7.16	-0.5	3.2e-11	Axial length;
PAAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg25833597	chr17:30823145	MYO1D	0.56	5.14	0.39	8.21e-7	Schizophrenia;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.85	-6.73	-0.48	3.26e-10	Migraine;Coronary artery disease;
PAAD	cis	rs3743832	0.520	rs8045589	chr16:9210373	A/T	cg08831531	chr16:9218945	NA	0.46	5.12	0.38	9.22e-7	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25075015	chr11:40138552	LRRC4C	-0.54	-6.79	-0.48	2.33e-10	Energy expenditure (24h);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21742872	chr21:43373869	C2CD2	0.6	7.3	0.51	1.48e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11764359	chr7:65958608	NA	-0.54	-5.01	-0.38	1.47e-6	Aortic root size;
PAAD	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg20813462	chr7:2646259	IQCE	-0.65	-4.67	-0.35	6.5e-6	Urate levels in lean individuals;
PAAD	cis	rs6686423	0.511	rs3908731	chr1:157387117	A/T	cg24251193	chr1:156676542	CRABP2	-0.45	-4.27	-0.33	3.45e-5	Renal sinus fat;
PAAD	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-5.78	-0.42	4.15e-8	Prudent dietary pattern;
PAAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs943072	0.915	rs2396087	chr6:43796058	C/T	cg06892548	chr6:43243945	TTBK1	0.63	4.58	0.35	9.72e-6	Ulcerative colitis;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs2271400	0.556	rs11986856	chr8:56654112	C/T	cg08894788	chr8:56792171	LYN	-0.52	-4.98	-0.37	1.69e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs11828289	0.714	rs1384478	chr11:23243582	T/C	cg20040320	chr11:23191996	NA	0.75	5.07	0.38	1.12e-6	Cancer;
PAAD	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.47	-4.78	-0.36	4.16e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	6.62	0.47	5.78e-10	Glomerular filtration rate;
PAAD	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-9.42	-0.61	6.95e-17	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.79	9.84	0.62	5.49e-18	Height;
PAAD	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.07	9.37	0.61	9.33e-17	Vitiligo;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.61	-6.49	-0.47	1.14e-9	Lymphocyte counts;
PAAD	cis	rs6681460	0.625	rs2872079	chr1:67130071	G/A	cg02459107	chr1:67143332	SGIP1	0.56	5.4	0.4	2.46e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg21399703	chr1:247681439	NA	0.71	6.9	0.49	1.3e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	6.68	0.48	4.2e-10	Response to antipsychotic treatment;
PAAD	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.93	-5.94	-0.43	1.86e-8	Alzheimer's disease (late onset);
PAAD	cis	rs76419734	0.558	rs11730825	chr4:106527568	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.56	0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg10351095	chr21:47802916	PCNT	-0.49	-4.84	-0.37	3.1e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-0.93	-8.94	-0.59	1.23e-15	Exhaled nitric oxide output;
PAAD	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg07679836	chr6:33548423	BAK1	0.31	4.36	0.33	2.35e-5	Platelet count;
PAAD	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.85	6.55	0.47	8.25e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.66	6.53	0.47	9.27e-10	Gastritis;
PAAD	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg16342193	chr10:102329863	NA	-0.82	-8.92	-0.59	1.42e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.65	8.63	0.57	7.56e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.55	0.47	8.37e-10	Body mass index;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.77	8.42	0.56	2.61e-14	Lung cancer;
PAAD	cis	rs1797885	0.763	rs796291	chr3:12521571	G/A	cg07775309	chr3:12595852	NA	0.41	4.4	0.34	2.03e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7651511	1.000	rs9840697	chr3:141210749	C/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.76	-6.78	-0.48	2.44e-10	Blood pressure (smoking interaction);
PAAD	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.52	4.86	0.37	2.87e-6	Educational attainment;
PAAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	1.25	7.74	0.53	1.32e-12	Skin colour saturation;
PAAD	cis	rs11264799	0.594	rs72710035	chr1:157787859	A/G	cg18268488	chr1:157545234	FCRL4	0.57	5.03	0.38	1.36e-6	IgA nephropathy;
PAAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg25554036	chr4:6271136	WFS1	0.73	10.13	0.63	9.28e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.82	6.43	0.46	1.6e-9	Alzheimer's disease;
PAAD	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.35	-0.51	1.14e-11	Cognitive function;
PAAD	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3026101	0.578	rs11209	chr17:5289580	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.49	-5.31	-0.4	3.84e-7	Body mass index;
PAAD	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg00262122	chr8:11665843	FDFT1	-0.51	-4.46	-0.34	1.57e-5	Neuroticism;
PAAD	cis	rs12304921	0.626	rs73105025	chr12:51508406	A/G	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.45	-0.4	2e-7	Type 2 diabetes;
PAAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.59	0.57	9.44e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05155371	chr1:11994697	PLOD1	0.74	7.78	0.53	1.06e-12	Obesity-related traits;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17171448	chr3:113415262	KIAA2018	-0.67	-6.75	-0.48	2.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13884470	chr9:86595151	HNRNPK;RMI1	0.67	7.15	0.5	3.46e-11	Primary biliary cholangitis;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.68	6.94	0.49	1.09e-10	Menarche (age at onset);
PAAD	cis	rs7255	0.538	rs10193919	chr2:20880833	C/T	cg09074113	chr2:20870087	GDF7	-0.41	-4.61	-0.35	8.61e-6	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg19337854	chr7:99768885	GPC2	-0.45	-4.83	-0.36	3.33e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.85	-0.62	5.33e-18	Coronary artery disease;
PAAD	cis	rs4454254	0.589	rs883612	chr8:141076133	C/G	cg05910124	chr8:141057427	TRAPPC9	-0.31	-4.44	-0.34	1.74e-5	Pulse pressure;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs3096299	0.584	rs3114889	chr16:89415505	T/C	cg04143805	chr16:89395205	ANKRD11	-0.37	-4.6	-0.35	8.81e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2147959	0.941	rs4653960	chr1:228631719	T/C	cg00655913	chr1:228633920	NA	0.48	4.49	0.34	1.39e-5	Adult asthma;
PAAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.67e-6	Menopause (age at onset);
PAAD	cis	rs7873102	0.702	rs7851957	chr9:37976667	G/A	cg03528946	chr9:38069800	SHB	0.56	5.72	0.42	5.39e-8	Brain structure;
PAAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.86	-9.39	-0.61	8.5e-17	Post bronchodilator FEV1;
PAAD	cis	rs4605213	0.528	rs11868199	chr17:49311334	T/C	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.45	-4.91	-0.37	2.32e-6	Prevalent atrial fibrillation;
PAAD	cis	rs6129846	0.881	rs6065362	chr20:40108567	C/T	cg23060191	chr20:39666765	PRO0628;TOP1	-0.76	-4.48	-0.34	1.44e-5	Verbal declarative memory;
PAAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg10729496	chr3:10149963	C3orf24	0.89	7.17	0.5	3.03e-11	Alzheimer's disease;
PAAD	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.82e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg24069376	chr3:38537580	EXOG	-0.35	-4.42	-0.34	1.89e-5	Electrocardiographic conduction measures;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	0.44	4.25	0.33	3.69e-5	Trans fatty acid levels;
PAAD	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.68	6.49	0.47	1.15e-9	Platelet count;
PAAD	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg11802864	chr11:65308245	LTBP3	-0.76	-5.42	-0.4	2.27e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg22189786	chr22:42395067	WBP2NL	0.54	4.48	0.34	1.43e-5	Birth weight;
PAAD	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg21584241	chr15:63341463	TPM1	0.66	4.8	0.36	3.69e-6	Orofacial clefts;
PAAD	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.19	-0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.41	-0.56	2.79e-14	Urate levels in overweight individuals;
PAAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs11113894	0.901	rs59728581	chr12:108861658	T/C	cg06834313	chr12:108851556	NA	-0.68	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs9646944	0.501	rs1403552	chr2:103088777	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.52	-4.59	-0.35	9.37e-6	Total body bone mineral density;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.36	-0.33	2.39e-5	Lung cancer;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg26071806	chr7:100318239	EPO	0.37	4.25	0.33	3.66e-5	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-7.59	-0.52	2.96e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg04854917	chr10:131378330	MGMT	-0.46	-4.77	-0.36	4.2e-6	Vitamin D levels;
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.34	-4.5	-0.34	1.35e-5	Age at first birth;
PAAD	cis	rs73206853	0.841	rs73191816	chr12:110918564	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.78e-10	Plateletcrit;Platelet count;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.67	7.15	0.5	3.48e-11	Obesity-related traits;
PAAD	cis	rs5756391	0.546	rs5750338	chr22:37316125	G/A	cg21209356	chr22:37319042	CSF2RB	0.39	4.78	0.36	4.03e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08668909	chr2:183903412	NCKAP1	0.6	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Morning vs. evening chronotype;
PAAD	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg00181669	chr3:44000978	NA	-0.46	-4.53	-0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg21145140	chr5:110409467	TSLP	0.49	4.7	0.36	5.81e-6	Eosinophilic esophagitis;
PAAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	4.3	0.33	3.04e-5	Menarche (age at onset);
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.5	5.8	0.43	3.75e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3812111	0.545	rs1931895	chr6:116572971	C/G	cg26893134	chr6:116381904	FRK	-0.29	-4.31	-0.33	2.91e-5	Age-related macular degeneration;
PAAD	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.46	-7.8	-0.53	9.03e-13	Mean corpuscular volume;
PAAD	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.6	-0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg04851639	chr8:1020857	NA	-0.65	-7.91	-0.54	4.96e-13	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg11764359	chr7:65958608	NA	0.75	4.66	0.35	6.83e-6	Diabetic kidney disease;
PAAD	cis	rs7534824	0.582	rs61780297	chr1:101400855	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	1.12	18.58	0.83	5.98e-41	Colorectal adenoma (advanced);
PAAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	12.1	0.7	5.03e-24	Smoking behavior;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.08	14.86	0.77	2.03e-31	Height;
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg08355456	chr11:67383691	NA	0.49	4.9	0.37	2.47e-6	Mean corpuscular volume;
PAAD	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.59	-5.79	-0.42	3.95e-8	Heschl's gyrus morphology;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg18700516	chr19:44507157	ZNF230	0.47	4.4	0.34	2.01e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg12486944	chr17:80159399	CCDC57	0.53	4.69	0.36	6.05e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg20582800	chr6:43612764	RSPH9	-0.56	-4.44	-0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.42	-0.61	7.2e-17	Mortality in heart failure;
PAAD	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-4.47	-0.34	1.53e-5	Mean corpuscular volume;
PAAD	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg18612461	chr15:75251733	NA	-0.56	-6.98	-0.49	8.36e-11	Caffeine consumption;
PAAD	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.62	6.76	0.48	2.73e-10	Mean platelet volume;
PAAD	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg17644776	chr2:200775616	C2orf69	-0.65	-5.16	-0.39	7.61e-7	Schizophrenia;
PAAD	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.86	-9.6	-0.61	2.35e-17	Mortality in heart failure;
PAAD	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg08875078	chr22:50639485	SELO	0.48	4.42	0.34	1.89e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-5.84	-0.43	3e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.81	9.81	0.62	6.59e-18	Height;
PAAD	cis	rs4740619	0.869	rs1341732	chr9:15901875	A/G	cg14451791	chr9:16040625	NA	-0.4	-4.49	-0.34	1.43e-5	Body mass index;
PAAD	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	1.04	13.92	0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17376030	chr22:41985996	PMM1	-0.63	-4.49	-0.34	1.4e-5	Vitiligo;
PAAD	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg00262122	chr8:11665843	FDFT1	-0.49	-4.31	-0.33	2.89e-5	Retinal vascular caliber;
PAAD	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07777115	chr5:623756	CEP72	0.67	4.36	0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.53	5.58	0.41	1.09e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.81	6.18	0.45	5.7e-9	Alzheimer's disease;
PAAD	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08219700	chr8:58056026	NA	0.67	5.15	0.39	7.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.86	-0.43	2.79e-8	Coronary artery disease;
PAAD	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.51	7.35	0.51	1.11e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg03983715	chr16:68378420	PRMT7	-0.85	-6.26	-0.45	3.67e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.68	6.5	0.47	1.07e-9	Blood metabolite levels;
PAAD	cis	rs4074493	1.000	rs11122198	chr1:231171139	G/A	cg22172038	chr1:231176991	FAM89A	0.51	4.77	0.36	4.24e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs735539	0.555	rs2818987	chr13:21304911	C/T	cg27499820	chr13:21296301	IL17D	0.54	5.12	0.38	9.02e-7	Dental caries;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.24	-0.39	5.38e-7	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.74	8.27	0.56	6.42e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs375066	0.868	rs448829	chr19:44406321	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.46	0.46	1.31e-9	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17567317	chr22:38349719	POLR2F;C22orf23	0.61	6.8	0.48	2.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	4.75	0.36	4.74e-6	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.56	-6.95	-0.49	9.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.83	-5.9	-0.43	2.26e-8	Gallbladder cancer;
PAAD	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.5	4.8	0.36	3.8e-6	Airway imaging phenotypes;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.35	4.49	0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.59	6.46	0.46	1.33e-9	Mean corpuscular volume;
PAAD	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	0.93	6.34	0.46	2.47e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg07469887	chr10:131262384	NA	-0.44	-5.15	-0.39	8.08e-7	Response to temozolomide;
PAAD	cis	rs743757	0.697	rs754298	chr3:50548895	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.59	-4.29	-0.33	3.2e-5	Diastolic blood pressure;
PAAD	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg22875332	chr1:76189707	ACADM	-0.5	-5.02	-0.38	1.42e-6	Daytime sleep phenotypes;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.55	-5.13	-0.38	8.75e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.39	-0.4	2.67e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.53	-0.35	1.17e-5	Asthma;
PAAD	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.8	-0.58	2.74e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7874142	0.714	rs10776907	chr9:137692739	T/G	cg13803559	chr9:137684506	COL5A1	0.4	4.4	0.34	2.03e-5	Longevity;
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg26939375	chr7:64535504	NA	-0.65	-7.25	-0.51	1.98e-11	Calcium levels;
PAAD	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.36	0.51	1.09e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13870426	chr17:30244630	NA	0.57	5.6	0.41	9.95e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.94	11.69	0.69	6.21e-23	Bone mineral density;
PAAD	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	7.19	0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg05562828	chr17:3906858	NA	0.51	5.12	0.38	9.24e-7	Type 2 diabetes;
PAAD	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.86	10.94	0.66	6.39e-21	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13509954	chr10:30638275	MTPAP	-0.71	-6.35	-0.46	2.32e-9	Neuroticism;
PAAD	cis	rs11825685	0.790	rs74733798	chr11:134538378	A/G	cg06603561	chr11:134479413	NA	-0.9	-6.28	-0.45	3.45e-9	IgG glycosylation;
PAAD	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.1	-11.07	-0.67	2.89e-21	Blood pressure (smoking interaction);
PAAD	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg19949948	chr17:19361230	NA	-0.43	-4.44	-0.34	1.74e-5	Schizophrenia;
PAAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.78	-10.48	-0.65	1.08e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20700152	chr12:56618241	OBFC2B	0.62	6.75	0.48	2.85e-10	Monocyte percentage of white cells;
PAAD	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.71	7.52	0.52	4.46e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg21191810	chr6:118973309	C6orf204	0.48	6.68	0.48	4.33e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg26554054	chr8:600488	NA	0.87	5.73	0.42	5.15e-8	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7534824	0.625	rs2391574	chr1:101373298	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.64	6.72	0.48	3.35e-10	Colorectal cancer;
PAAD	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.89	10.22	0.64	5.35e-19	Breast cancer;
PAAD	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7631605	0.875	rs4678935	chr3:37119835	A/C	cg17445812	chr3:36986805	TRANK1	0.35	4.63	0.35	7.93e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14530801	chr4:4544016	STX18	0.71	6.41	0.46	1.72e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.34	-0.33	2.62e-5	Caffeine consumption;
PAAD	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg06131755	chr6:160182447	ACAT2	0.54	4.82	0.36	3.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs13242816	0.881	rs35037267	chr7:116117587	A/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.83	10.48	0.65	1.08e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs62025270	0.688	rs55851385	chr15:86268631	C/G	cg13263323	chr15:86062960	AKAP13	0.5	4.39	0.34	2.08e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.97	10.57	0.65	6.21e-20	Parkinson's disease;
PAAD	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.85	0.49	1.76e-10	Exhaled nitric oxide levels;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09799789	chr1:245836746	KIF26B	-0.74	-7.51	-0.52	4.75e-12	Obesity-related traits;
PAAD	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-6.23	-0.45	4.32e-9	Hippocampal volume;
PAAD	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10342447	chr17:26645325	TMEM97	-0.42	-5.7	-0.42	6.05e-8	Osteoprotegerin levels;
PAAD	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.9	5.93	0.43	2.01e-8	LDL cholesterol;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12315302	chr6:26189340	HIST1H4D	0.55	4.43	0.34	1.79e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.98	8.42	0.56	2.57e-14	Gut microbiome composition (summer);
PAAD	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.85	0.37	3.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9361491	0.657	rs9359344	chr6:79461033	G/A	cg05283184	chr6:79620031	NA	-0.36	-4.43	-0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950881	0.932	rs3771175	chr2:102960210	A/T	cg20060108	chr2:102954350	IL1RL1	-0.59	-4.64	-0.35	7.5e-6	Allergy;
PAAD	cis	rs1042026	0.772	rs6813962	chr4:100088005	C/T	cg09112717	chr4:100009950	ADH5	-0.5	-4.41	-0.34	1.91e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs72772787	1.000	rs74152845	chr1:248013317	T/G	cg03748376	chr1:248100585	OR2L13	0.52	4.25	0.33	3.78e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs78761021	0.898	rs9674498	chr17:9777841	T/G	cg26853458	chr17:9805074	RCVRN	0.7	8.26	0.56	6.64e-14	Type 2 diabetes;
PAAD	cis	rs6141769	0.542	rs2064933	chr20:31314625	A/G	cg13636640	chr20:31349939	DNMT3B	-0.49	-4.64	-0.35	7.32e-6	Subjective well-being;
PAAD	cis	rs800160	0.777	rs962902	chr11:2352225	T/C	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.54	-0.35	1.13e-5	Bacteremia;
PAAD	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.57	5.16	0.39	7.56e-7	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs11700980	0.551	rs56066604	chr21:30116217	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.64	6.29	0.45	3.14e-9	Type 2 diabetes;
PAAD	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3996993	0.737	rs9370149	chr6:52643606	C/G	cg20803780	chr6:52668592	GSTA1	-0.36	-4.37	-0.33	2.3e-5	Hemoglobin concentration;
PAAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09835421	chr16:68378352	PRMT7	-1.18	-8.67	-0.58	6.19e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs793571	0.518	rs12906705	chr15:58955036	C/T	cg05156742	chr15:59063176	FAM63B	0.61	4.37	0.33	2.31e-5	Schizophrenia;
PAAD	cis	rs9876781	1.000	rs9812647	chr3:48448914	C/G	cg24898236	chr3:49228699	LOC646498	-0.42	-4.62	-0.35	7.99e-6	Longevity;
PAAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-1.02	-13.99	-0.75	4.1e-29	Breast cancer;
PAAD	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.91	-6.23	-0.45	4.36e-9	Major depressive disorder;
PAAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.67	7.9	0.54	5.17e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02985541	chr2:219472218	PLCD4	-0.31	-4.66	-0.35	6.92e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg12661370	chr5:149340060	SLC26A2	0.66	5.52	0.41	1.4e-7	HIV-1 control;
PAAD	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.64	5.57	0.41	1.12e-7	Obesity-related traits;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.88	-10.75	-0.66	2.11e-20	Ulcerative colitis;
PAAD	cis	rs2242420	0.920	rs72876070	chr1:21965486	C/T	cg04297819	chr1:22260125	HSPG2	0.48	4.26	0.33	3.5e-5	Hematological and biochemical traits;
PAAD	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.85	4.64	0.35	7.52e-6	Childhood ear infection;
PAAD	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.75	6.02	0.44	1.23e-8	Schizophrenia;
PAAD	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12780845	1.000	rs11813099	chr10:17183451	G/A	cg00857480	chr10:17188594	TRDMT1	0.39	4.95	0.37	1.97e-6	Homocysteine levels;
PAAD	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg09112717	chr4:100009950	ADH5	0.42	4.26	0.33	3.51e-5	Alcohol dependence;
PAAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	cis	rs4704187	0.687	rs58067979	chr5:74523555	C/T	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.87	0.37	2.73e-6	Cognitive function;
PAAD	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.77	7.47	0.52	5.85e-12	Testicular germ cell tumor;
PAAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-6.12	-0.44	7.72e-9	Schizophrenia;
PAAD	cis	rs3136441	1.000	rs4752947	chr11:46901156	A/T	cg19486271	chr11:47235900	DDB2	0.63	4.83	0.36	3.31e-6	HDL cholesterol;
PAAD	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs72960926	0.744	rs72957983	chr6:74968228	A/G	cg03266952	chr6:74778945	NA	-1.1	-6.33	-0.46	2.67e-9	Metabolite levels (MHPG);
PAAD	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.51	-4.52	-0.34	1.22e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.71	4.92	0.37	2.19e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.65	-7.06	-0.5	5.46e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.63e-7	Life satisfaction;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.39	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.72	-6.88	-0.49	1.44e-10	Platelet distribution width;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg00450029	chr8:599525	NA	0.81	5.37	0.4	2.91e-7	IgG glycosylation;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.29	-5.59	-0.41	1.04e-7	Urinary metabolites;
PAAD	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	8.26	0.56	6.44e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.43	4.43	0.34	1.82e-5	Red cell distribution width;
PAAD	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg10064339	chr11:73693792	UCP2	1.31	5.98	0.44	1.52e-8	Obesity-related traits;
PAAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg07648498	chr16:89883185	FANCA	0.53	4.91	0.37	2.3e-6	Vitiligo;
PAAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.53	-0.52	4.1e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs11669133	1.000	rs117913601	chr19:11119335	G/T	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.85	10.27	0.64	4.06e-19	Body mass index;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.59	5.62	0.41	8.94e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3812111	0.774	rs509002	chr6:116423299	T/C	cg05304507	chr6:116381966	FRK	-0.28	-5.21	-0.39	6.07e-7	Age-related macular degeneration;
PAAD	cis	rs6734238	0.666	rs6738377	chr2:113850902	C/G	cg06156847	chr2:113672199	IL1F7	-0.43	-4.31	-0.33	2.96e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.76	-7.88	-0.54	5.88e-13	Menopause (age at onset);
PAAD	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg00262122	chr8:11665843	FDFT1	-0.53	-4.53	-0.35	1.17e-5	Systolic blood pressure;
PAAD	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg02421172	chr7:1938701	MAD1L1	0.57	4.27	0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg08493265	chr3:195539297	MUC4	0.58	4.42	0.34	1.84e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.38	0.4	2.74e-7	Mean platelet volume;
PAAD	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7551222	0.614	rs7519417	chr1:204449952	T/C	cg01064725	chr1:204461714	NA	-0.52	-4.73	-0.36	5.05e-6	Schizophrenia;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.66	6.43	0.46	1.58e-9	Tuberculosis;
PAAD	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.68	7.33	0.51	1.25e-11	Longevity;
PAAD	cis	rs9463078	0.585	rs718112	chr6:44859451	T/G	cg25276700	chr6:44698697	NA	0.41	4.84	0.37	3.11e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.04	0.59	6.96e-16	Parkinson's disease;
PAAD	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.12e-6	Coronary artery disease;
PAAD	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.22	0.67	1.13e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs9815354	0.951	rs7626217	chr3:41842415	A/G	cg03022575	chr3:42003672	ULK4	0.81	6.13	0.45	7.34e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg16928487	chr17:17741425	SREBF1	0.34	4.47	0.34	1.51e-5	Total body bone mineral density;
PAAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg14343924	chr8:8086146	FLJ10661	0.55	4.77	0.36	4.22e-6	Mood instability;
PAAD	cis	rs713477	1.000	rs10782426	chr14:55890702	G/A	cg23573665	chr14:55907122	TBPL2	-0.33	-4.53	-0.34	1.21e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg06521852	chr22:38141419	TRIOBP	0.44	4.65	0.35	7.03e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg16040993	chr19:53496440	ZNF702P	-0.49	-4.83	-0.36	3.29e-6	Psoriasis;
PAAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.72	-7.86	-0.54	6.41e-13	Brain structure;
PAAD	cis	rs10493340	1.000	rs11589445	chr1:63608134	C/A	cg08634298	chr1:64337861	ROR1	-0.46	-4.5	-0.34	1.33e-5	Blood pressure;
PAAD	cis	rs7873102	0.654	rs2244322	chr9:37986109	T/G	cg03528946	chr9:38069800	SHB	0.52	5.21	0.39	6.01e-7	Brain structure;
PAAD	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.26	-0.39	4.82e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.94	8.68	0.58	5.69e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.94	14.06	0.75	2.65e-29	Age at first birth;
PAAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.53	-5.19	-0.39	6.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.57	-6.11	-0.44	8.02e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.85	7.47	0.52	6.01e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.8	7.87	0.54	6.36e-13	Corneal astigmatism;
PAAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.59	-7.97	-0.54	3.53e-13	Eye color traits;
PAAD	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg02910952	chr12:132569714	EP400NL	0.56	4.27	0.33	3.49e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.32	4.43	0.34	1.77e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs1879734	0.636	rs17109178	chr1:54173551	C/G	cg14659662	chr1:54151053	GLIS1	-0.39	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.9	-10.57	-0.65	6.46e-20	Total body bone mineral density;
PAAD	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.84	0.37	3.18e-6	Lung cancer;
PAAD	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	6.56	0.47	8.02e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.56	5.93	0.43	1.95e-8	Lung cancer;
PAAD	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg12568669	chr8:11666485	FDFT1	-0.3	-5.16	-0.39	7.57e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.42	0.34	1.87e-5	Lipoprotein (a) levels;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-4.37	-0.33	2.33e-5	Height;
PAAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-4.73	-0.36	5.16e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1569175	0.655	rs281792	chr2:200850378	C/T	cg23649088	chr2:200775458	C2orf69	-0.94	-4.82	-0.36	3.51e-6	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs11669133	1.000	rs76557781	chr19:11097822	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs990171	0.538	rs7593935	chr2:103118128	G/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg08390786	chr10:135334061	NA	0.58	4.85	0.37	2.98e-6	Gout;
PAAD	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg21518248	chr2:162101506	NA	0.47	4.76	0.36	4.43e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.84	9.63	0.62	1.93e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.47	5.24	0.39	5.39e-7	Anti-saccade response;
PAAD	trans	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	4.45	0.34	1.67e-5	Mood instability;
PAAD	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-1.11	-8.26	-0.56	6.79e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11807834	0.522	rs7519536	chr1:230233864	G/C	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.49e-13	Schizophrenia;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10094210	chr1:52733843	ZFYVE9	0.73	7.29	0.51	1.58e-11	Neuroticism;
PAAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs61861422	0.543	rs34309159	chr10:134419166	C/T	cg24416232	chr10:134405482	INPP5A	-0.46	-4.7	-0.36	5.68e-6	Primary sclerosing cholangitis;
PAAD	cis	rs2904967	0.636	rs184734	chr11:64982203	T/C	cg11802864	chr11:65308245	LTBP3	-0.5	-4.49	-0.34	1.4e-5	Mean corpuscular volume;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.74	-7.52	-0.52	4.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1419980	0.730	rs11533526	chr12:7750484	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.49	5.41	0.4	2.43e-7	Urate levels in lean individuals;
PAAD	cis	rs35160687	0.644	rs11687392	chr2:86502663	A/G	cg10973622	chr2:86423274	IMMT	-0.45	-4.98	-0.37	1.7e-6	Night sleep phenotypes;
PAAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.38	0.4	2.81e-7	Rheumatoid arthritis;
PAAD	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.69	5.81	0.43	3.61e-8	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.55	0.52	3.79e-12	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07332178	chr7:43798019	BLVRA	0.63	7.34	0.51	1.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10789285	0.650	rs4265389	chr1:69693244	G/A	cg04447890	chr1:68697988	GPR177	-0.54	-4.37	-0.33	2.29e-5	Psoriasis;
PAAD	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.86	-9.66	-0.62	1.6e-17	Obesity-related traits;
PAAD	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg13926569	chr10:89418898	PAPSS2	0.73	7.39	0.51	9.27e-12	Magnesium levels;
PAAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05949524	chr17:77812992	CBX4	-0.69	-6.98	-0.49	8.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	0.76	5.89	0.43	2.45e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Renal cell carcinoma;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg25801113	chr15:45476975	SHF	-0.41	-4.75	-0.36	4.6e-6	Uric acid levels;
PAAD	cis	rs10214930	0.813	rs7779990	chr7:27671899	T/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.5	0.52	4.84e-12	Body mass index;
PAAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg12215294	chr3:40350768	EIF1B	0.49	4.77	0.36	4.29e-6	Renal cell carcinoma;
PAAD	cis	rs58521262	0.615	rs2088374	chr19:23212562	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.58	6.43	0.46	1.59e-9	Cardiovascular disease risk factors;
PAAD	cis	rs6011674	1.000	rs45469101	chr20:61875007	C/T	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.8	-4.7	-0.36	5.77e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.66	6.32	0.46	2.76e-9	Hip circumference;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13560548	chr3:10150139	C3orf24	0.64	5.66	0.42	7.21e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg21724239	chr8:58056113	NA	0.67	5.41	0.4	2.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.69	-0.36	6.07e-6	Type 2 diabetes;
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg23298862	chr7:158159286	PTPRN2	-0.58	-4.98	-0.37	1.68e-6	Response to amphetamines;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.09	0.59	5.02e-16	Lymphocyte counts;
PAAD	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.52	-4.7	-0.36	5.77e-6	Total body bone mineral density;
PAAD	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04513197	chr1:100504319	HIAT1	0.66	7.51	0.52	4.56e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-5.14	-0.38	8.22e-7	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3106136	0.843	rs6840479	chr4:95275842	A/G	cg11021082	chr4:95130006	SMARCAD1	0.58	5.31	0.4	3.83e-7	Capecitabine sensitivity;
PAAD	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23708337	chr7:1209742	NA	0.5	5.56	0.41	1.21e-7	Longevity;Endometriosis;
PAAD	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.44	-4.28	-0.33	3.25e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.56	0.41	1.16e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.78	-8.72	-0.58	4.58e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9463078	0.525	rs9395058	chr6:44984069	T/A	cg25276700	chr6:44698697	NA	-0.55	-6.35	-0.46	2.34e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg08029281	chr1:67600428	NA	0.45	5.2	0.39	6.47e-7	Psoriasis;
PAAD	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.75	-5.75	-0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05665937	chr4:1216051	CTBP1	0.4	4.37	0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg20295408	chr7:1910781	MAD1L1	0.5	4.66	0.35	6.97e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.62	-0.41	9.01e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.3	-5.68	-0.42	6.7e-8	Type 2 diabetes;
PAAD	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.69	8.85	0.58	2.1e-15	Asthma (sex interaction);
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs294958	0.806	rs294952	chr5:151551733	G/A	cg04453665	chr5:151504455	NA	-0.45	-5.09	-0.38	1.05e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg17105886	chr17:28927953	LRRC37B2	0.76	4.86	0.37	2.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg01815783	chr4:1047043	NA	0.43	4.63	0.35	7.72e-6	Recombination rate (males);
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.74	8.42	0.56	2.69e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs61542988	0.606	rs4722185	chr7:22832711	G/A	cg11367502	chr7:22862612	TOMM7	0.61	5.59	0.41	1.04e-7	Fibrinogen levels;
PAAD	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.77	-7.5	-0.52	4.93e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.67	6.88	0.49	1.43e-10	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.81	-0.48	2.14e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg15770106	chr1:208133116	NA	-0.63	-6.33	-0.46	2.65e-9	Corneal structure;
PAAD	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.58	6.22	0.45	4.51e-9	Subjective well-being;
PAAD	cis	rs17331151	0.585	rs36012032	chr3:52814709	C/A	cg27565382	chr3:53032988	SFMBT1	0.94	4.56	0.35	1.07e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.53	-5.81	-0.43	3.58e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs990171	0.538	rs12712153	chr2:103111761	C/T	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.27	-0.39	4.58e-7	Lymphocyte counts;
PAAD	cis	rs17021463	0.673	rs17377118	chr4:95285622	G/A	cg11021082	chr4:95130006	SMARCAD1	0.57	5.82	0.43	3.3e-8	Testicular germ cell tumor;
PAAD	cis	rs1227969	0.964	rs1227968	chr10:71263403	G/A	cg12610070	chr10:71211762	TSPAN15	-0.3	-4.38	-0.33	2.17e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs9467603	1.000	rs6902211	chr6:25767437	G/A	cg23465465	chr6:26364728	BTN3A2	-0.79	-4.73	-0.36	4.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.35	-0.33	2.5e-5	Systolic blood pressure;
PAAD	cis	rs151997	0.508	rs9292165	chr5:50272619	T/C	cg06027927	chr5:50259733	NA	0.62	5.51	0.41	1.47e-7	Callous-unemotional behaviour;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.54	5.35	0.4	3.13e-7	Resistin levels;
PAAD	trans	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg15770106	chr1:208133116	NA	-0.64	-6.31	-0.46	2.88e-9	Corneal structure;
PAAD	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.69	6.94	0.49	1.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4073221	0.546	rs13069372	chr3:18234144	A/C	cg07694806	chr3:18168406	NA	-0.63	-4.6	-0.35	8.94e-6	Parkinson's disease;
PAAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg00536532	chr6:33561449	C6orf227	-0.41	-4.29	-0.33	3.1e-5	Plateletcrit;
PAAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.5	4.33	0.33	2.72e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14848469	chr12:132045286	NA	-0.7	-7.18	-0.5	2.9e-11	Obesity-related traits;
PAAD	cis	rs10501293	1.000	rs2862694	chr11:43064753	C/T	cg03447554	chr11:43094025	NA	0.52	5.16	0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14936460	chr18:74175592	ZNF516	-0.69	-7.29	-0.51	1.6e-11	Obesity-related traits;
PAAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg12908607	chr1:44402522	ARTN	-0.7	-6.39	-0.46	1.92e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg02683114	chr2:24398427	C2orf84	0.56	5.84	0.43	3.06e-8	Asthma;
PAAD	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg08886695	chr4:3369023	RGS12	-0.5	-4.83	-0.36	3.33e-6	Mean platelet volume;
PAAD	cis	rs7534824	0.625	rs61780331	chr1:101480610	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.4e-5	Parkinson's disease;
PAAD	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.1	-0.77	4.66e-32	Height;
PAAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.6	6.32	0.46	2.77e-9	Childhood ear infection;
PAAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.48	-4.82	-0.36	3.42e-6	Body mass index;
PAAD	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.87	9.36	0.6	9.85e-17	Anterior chamber depth;
PAAD	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg12310025	chr6:25882481	NA	0.44	4.32	0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg08886695	chr4:3369023	RGS12	-0.48	-4.58	-0.35	9.78e-6	Mean platelet volume;
PAAD	cis	rs800160	0.720	rs2651782	chr11:2345842	A/G	cg09785033	chr11:2336066	TSPAN32	-0.52	-4.33	-0.33	2.7e-5	Bacteremia;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9815354	0.951	rs6794211	chr3:41751324	A/T	cg03022575	chr3:42003672	ULK4	0.87	6.29	0.45	3.2e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg05895507	chr15:77155635	SCAPER	-0.38	-4.76	-0.36	4.42e-6	Blood metabolite levels;
PAAD	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21643547	chr1:205240462	TMCC2	0.38	4.29	0.33	3.13e-5	Red blood cell count;
PAAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg14851346	chr12:38532713	NA	0.49	4.54	0.35	1.12e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-4.85	-0.37	3e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.5	4.75	0.36	4.67e-6	HDL cholesterol;
PAAD	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg02404636	chr22:31891804	SFI1	0.64	6.18	0.45	5.53e-9	Colorectal cancer;
PAAD	cis	rs600626	0.891	rs498936	chr11:75454878	T/A	cg24262691	chr11:75473276	NA	0.53	4.97	0.37	1.8e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.43	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg08779649	chr13:50194554	NA	-0.39	-4.88	-0.37	2.71e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.16	-0.39	7.69e-7	Body mass index;
PAAD	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.3	0.4	3.92e-7	Bipolar disorder;
PAAD	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg10631289	chr15:39006617	NA	0.45	4.35	0.33	2.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9646944	0.501	rs10181785	chr2:103025274	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg15211996	chr1:2936768	ACTRT2	0.47	4.65	0.35	7.03e-6	Plateletcrit;
PAAD	cis	rs9581857	0.546	rs9579082	chr13:27965763	C/T	cg22138327	chr13:27999177	GTF3A	0.87	5.42	0.4	2.3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	9.96	0.63	2.63e-18	Smoking behavior;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.65	6.26	0.45	3.82e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17407555	0.955	rs11734209	chr4:10170371	T/A	cg23995914	chr4:10459228	ZNF518B	-0.34	-4.26	-0.33	3.63e-5	Schizophrenia (age at onset);
PAAD	cis	rs8040855	0.520	rs67613323	chr15:85529772	T/C	cg08123816	chr15:85640762	PDE8A	-0.44	-4.71	-0.36	5.52e-6	Bulimia nervosa;
PAAD	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg09222892	chr1:25734099	RHCE	-0.45	-4.41	-0.34	1.94e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.7	7.68	0.53	1.76e-12	Cisplatin-induced ototoxicity;
PAAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.64	-6.06	-0.44	1.01e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.59	7.4	0.51	8.44e-12	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16600119	chr3:129033604	NA	0.55	6.4	0.46	1.81e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.48	7.16	0.5	3.2e-11	Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg16386425	chr10:429943	DIP2C	-0.4	-4.26	-0.33	3.63e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs10754283	0.967	rs4658308	chr1:90122931	C/G	cg21401794	chr1:90099060	LRRC8C	0.59	5.55	0.41	1.23e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg19630374	chr17:18023558	MYO15A	0.45	4.87	0.37	2.78e-6	Total body bone mineral density;
PAAD	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.51	-5.15	-0.39	7.9e-7	Subjective well-being;
PAAD	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.62	6.05	0.44	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.67	-0.42	6.84e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg27478167	chr7:817139	HEATR2	-0.64	-4.97	-0.37	1.79e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.3	0.51	1.47e-11	Multiple sclerosis;
PAAD	cis	rs939584	1.000	rs939583	chr2:622531	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.49	0.34	1.41e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs4843747	0.762	rs4843294	chr16:88035356	G/T	cg06915872	chr16:87998081	BANP	0.49	4.61	0.35	8.66e-6	Menopause (age at onset);
PAAD	cis	rs12044355	0.927	rs11585959	chr1:231833718	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-4.79	-0.36	3.88e-6	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20795428	chr22:39715674	SNORD43;RPL3	0.64	7.2	0.5	2.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.51	-4.71	-0.36	5.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs72960926	0.744	rs3897895	chr6:74917550	C/T	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22168489	chr12:122356033	WDR66	-0.3	-4.4	-0.34	2.03e-5	Mean corpuscular volume;
PAAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg06740227	chr12:86229804	RASSF9	0.52	4.62	0.35	8.08e-6	Major depressive disorder;
PAAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	8.01	0.54	2.75e-13	Bone mineral density;
PAAD	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.94	8.68	0.58	5.58e-15	Schizophrenia;
PAAD	cis	rs2171564	0.791	rs9826586	chr3:112441312	C/T	cg18194305	chr3:113160637	WDR52	0.4	4.25	0.33	3.69e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg20850873	chr3:10149803	C3orf24	0.56	4.42	0.34	1.84e-5	Alzheimer's disease;
PAAD	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.26	-0.33	3.53e-5	Educational attainment;
PAAD	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg27490568	chr2:178487706	NA	0.44	4.87	0.37	2.83e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.64	0.53	2.26e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.61	6.34	0.46	2.47e-9	Testicular germ cell tumor;
PAAD	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.42	-5.04	-0.38	1.33e-6	Blood pressure (smoking interaction);
PAAD	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.59	-5.81	-0.43	3.47e-8	Body mass index;
PAAD	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.27	0.33	3.37e-5	HDL cholesterol;
PAAD	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.87	0.43	2.65e-8	Ileal carcinoids;
PAAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.67e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-5.06	-0.38	1.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.86	-6.65	-0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.6	-5.6	-0.41	9.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.86	-8.99	-0.59	9.28e-16	Corneal astigmatism;
PAAD	cis	rs8014252	0.803	rs74712571	chr14:70986751	C/G	cg11204974	chr14:71022665	NA	-0.77	-5.04	-0.38	1.3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.72	0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.74	-7.56	-0.52	3.61e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	trans	rs901683	0.850	rs79319916	chr10:46073980	C/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.26	0.33	3.64e-5	Renal cell carcinoma;
PAAD	cis	rs9876781	1.000	rs7636782	chr3:48421387	G/T	cg24898236	chr3:49228699	LOC646498	0.38	4.27	0.33	3.42e-5	Longevity;
PAAD	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.62	8.07	0.55	1.94e-13	Crohn's disease;
PAAD	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg19980929	chr12:42632907	YAF2	-0.57	-6.6	-0.47	6.42e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg25204440	chr1:209979598	IRF6	0.66	5.63	0.42	8.64e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.43	0.46	1.52e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.81	-0.36	3.54e-6	Platelet count;
PAAD	cis	rs7577696	0.962	rs6758024	chr2:32294486	G/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.83e-6	Inflammatory biomarkers;
PAAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-4.44	-0.34	1.72e-5	Height;
PAAD	cis	rs375066	0.762	rs239939	chr19:44387967	A/T	cg08633290	chr19:44405433	NA	-0.54	-5.16	-0.39	7.61e-7	Breast cancer;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg16606324	chr3:10149918	C3orf24	0.52	4.44	0.34	1.73e-5	Alzheimer's disease;
PAAD	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07016325	chr14:96968745	PAPOLA	-0.64	-7.87	-0.54	6.02e-13	Body fat percentage;
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.75	-0.48	2.85e-10	Life satisfaction;
PAAD	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	0.98	7.92	0.54	4.79e-13	Vitiligo;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs438465	0.947	rs400607	chr6:169808409	C/T	cg11181693	chr6:169825345	NA	-0.56	-4.33	-0.33	2.74e-5	Corneal astigmatism;
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.73	5.38	0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg10820045	chr2:198174542	NA	-0.43	-4.32	-0.33	2.85e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.51	-5.13	-0.38	8.77e-7	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10210959	chr5:112257975	REEP5	0.59	6.55	0.47	8.36e-10	Myopia (pathological);
PAAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.57	-5.61	-0.41	9.54e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg09796270	chr17:17721594	SREBF1	0.45	4.86	0.37	2.85e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg02376097	chr19:46275166	DMPK	0.66	8.19	0.55	9.95e-14	Coronary artery disease;
PAAD	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.03	-0.38	1.34e-6	Daytime sleep phenotypes;
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.73	7.52	0.52	4.34e-12	Height;
PAAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs6921542	0.861	rs9375796	chr6:131340998	C/T	cg17329834	chr6:131380543	EPB41L2	-0.5	-4.51	-0.34	1.3e-5	Mean corpuscular volume;
PAAD	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg08029281	chr1:67600428	NA	0.45	5.2	0.39	6.47e-7	Psoriasis;
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-7.6	-0.52	2.89e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg09509183	chr1:209979624	IRF6	0.54	5.28	0.39	4.44e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-7.35	-0.51	1.15e-11	Bipolar disorder;
PAAD	cis	rs72960926	1.000	rs16884731	chr6:75064418	A/G	cg03266952	chr6:74778945	NA	-1.07	-5.76	-0.42	4.45e-8	Metabolite levels (MHPG);
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.93	8.01	0.54	2.84e-13	Alzheimer's disease;
PAAD	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.49	-4.31	-0.33	2.98e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg00280220	chr17:61926910	NA	0.42	4.3	0.33	3.01e-5	Prudent dietary pattern;
PAAD	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.94	7.99	0.54	3.09e-13	Dupuytren's disease;
PAAD	cis	rs113835537	0.877	rs2229455	chr11:66328055	A/G	cg22134325	chr11:66188745	NPAS4	0.39	4.87	0.37	2.75e-6	Airway imaging phenotypes;
PAAD	cis	rs71520386	0.632	rs10254365	chr7:22864754	A/T	cg04907244	chr7:22894795	SNORD93	0.5	5.43	0.4	2.17e-7	Fibrinogen levels;
PAAD	cis	rs4764487	0.760	rs2268009	chr12:6340388	A/G	cg08284733	chr12:6341482	CD9	0.39	4.33	0.33	2.64e-5	Mean platelet volume;
PAAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.86	10.77	0.66	1.86e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.93	9.82	0.62	6.41e-18	Testicular germ cell tumor;
PAAD	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg14345882	chr6:26364793	BTN3A2	0.67	4.43	0.34	1.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs58521262	0.585	rs463879	chr19:23130983	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg24747557	chr10:131355152	MGMT	-0.48	-5.2	-0.39	6.31e-7	Response to temozolomide;
PAAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.46	4.65	0.35	7.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg05110241	chr16:68378359	PRMT7	-0.91	-7.3	-0.51	1.5e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.23	12.42	0.71	6.67e-25	Corneal structure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25241845	chr20:44519697	NEURL2;CTSA	0.62	6.96	0.49	9.45e-11	Myopia (pathological);
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg24699146	chr1:24152579	HMGCL	0.54	5.7	0.42	6.02e-8	Immature fraction of reticulocytes;
PAAD	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.02	-0.38	1.42e-6	Height;
PAAD	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03676636	chr4:99064102	C4orf37	-0.33	-6.13	-0.45	7.26e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-7.41	-0.52	8.29e-12	Asthma;
PAAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.82	-8.91	-0.59	1.48e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.46	-5.4	-0.4	2.53e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs6024905	0.783	rs6069757	chr20:36956516	G/A	cg07053727	chr20:36965646	BPI	0.49	5.19	0.39	6.58e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14752139	chr8:7328654	DEFB104B;DEFB104A	0.56	6.57	0.47	7.43e-10	Smoking initiation;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg16590910	chr6:42928470	GNMT	-0.47	-4.76	-0.36	4.39e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01662117	chr14:38065435	FOXA1	0.6	6.55	0.47	8.48e-10	Pancreatic cancer;
PAAD	cis	rs1345301	0.518	rs1558623	chr2:102862402	T/A	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.46	-0.34	1.57e-5	Waist circumference;
PAAD	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.7	7.28	0.51	1.7e-11	Platelet distribution width;
PAAD	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Acylcarnitine levels;
PAAD	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-5.99	-0.44	1.45e-8	Lung cancer;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg04111992	chr7:158790115	NA	-0.53	-5.15	-0.39	8.05e-7	Facial morphology (factor 20);
PAAD	cis	rs6748734	0.779	rs11680800	chr2:241793977	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-7.64	-0.53	2.24e-12	Urinary metabolites;
PAAD	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-10.74	-0.66	2.24e-20	Heart rate;
PAAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.74	8.5	0.57	1.66e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg08648136	chr8:956695	NA	0.41	4.35	0.33	2.46e-5	Schizophrenia;
PAAD	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg18833306	chr6:118973337	C6orf204	0.53	5.9	0.43	2.32e-8	Electrocardiographic conduction measures;
PAAD	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.15	-0.39	7.88e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.3	-0.33	3.02e-5	Prostate cancer;
PAAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04622620	chr7:127032509	ZNF800	0.66	6.76	0.48	2.83e-10	Obesity-related traits;
PAAD	cis	rs962856	0.521	rs668175	chr2:67664187	C/G	cg09028215	chr2:67624308	ETAA1	-0.51	-4.31	-0.33	2.93e-5	Pancreatic cancer;
PAAD	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg22189786	chr22:42395067	WBP2NL	0.62	5.98	0.44	1.54e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.49	-4.46	-0.34	1.59e-5	Systemic sclerosis;
PAAD	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.67	0.35	6.55e-6	Plateletcrit;
PAAD	cis	rs1656368	0.726	rs16829104	chr3:158258420	G/A	cg16708174	chr3:158430962	RARRES1	0.53	4.83	0.37	3.23e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.47	4.36	0.33	2.37e-5	Urate levels;
PAAD	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	15.63	0.79	1.98e-33	Schizophrenia;
PAAD	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg25809561	chr17:30822961	MYO1D	0.47	4.77	0.36	4.3e-6	Schizophrenia;
PAAD	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.79	9.17	0.6	3.09e-16	Diastolic blood pressure;
PAAD	cis	rs959260	1.000	rs8081927	chr17:73379085	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.69	-5.09	-0.38	1.03e-6	Hand grip strength;
PAAD	trans	rs901683	1.000	rs17157832	chr10:45961761	T/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-5.26	-0.39	4.88e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.37	-0.33	2.32e-5	Ileal carcinoids;
PAAD	cis	rs12612619	0.732	rs4665366	chr2:27212596	G/A	cg00617064	chr2:27272375	NA	0.5	5.23	0.39	5.45e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.64	6.16	0.45	6.13e-9	Schizophrenia;
PAAD	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.46	4.45	0.34	1.64e-5	Alcohol consumption (transferrin glycosylation);
PAAD	trans	rs901683	1.000	rs12766764	chr10:46079513	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg09491104	chr22:46646882	C22orf40	-0.74	-4.64	-0.35	7.57e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.68	6.44	0.46	1.52e-9	Plateletcrit;Platelet count;
PAAD	cis	rs427941	0.632	rs382228	chr7:101786064	A/C	cg06246474	chr7:101738831	CUX1	0.43	4.26	0.33	3.59e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.87e-7	Bladder cancer;
PAAD	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg01064725	chr1:204461714	NA	-0.48	-4.41	-0.34	1.95e-5	Schizophrenia;
PAAD	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg14631576	chr9:95140430	CENPP	-0.62	-5.96	-0.44	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9816226	0.591	rs75135487	chr3:185805294	C/G	cg00760338	chr3:185826511	ETV5	-0.72	-5.55	-0.41	1.26e-7	Obesity;Body mass index;
PAAD	trans	rs10767971	1.000	rs10767972	chr11:32896419	C/T	cg03700492	chr17:73874623	TRIM47	0.62	6.47	0.46	1.25e-9	Parkinson's disease (age of onset);
PAAD	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.73	0.48	3.18e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	7.82	0.54	8.2e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg09695851	chr17:3907499	NA	0.84	8.98	0.59	9.6e-16	Type 2 diabetes;
PAAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.46	6.05	0.44	1.08e-8	Childhood ear infection;
PAAD	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05347473	chr6:146136440	FBXO30	0.48	4.52	0.34	1.26e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4455778	0.543	rs7808690	chr7:49065751	A/C	cg26309511	chr7:48887640	NA	0.38	4.59	0.35	9.35e-6	Lung cancer in never smokers;
PAAD	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.09	-0.5	4.66e-11	Parkinson's disease;
PAAD	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg24220031	chr2:73402428	NA	-0.34	-4.86	-0.37	2.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.44	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07362569	chr17:61921086	SMARCD2	0.61	7.17	0.5	2.98e-11	Prudent dietary pattern;
PAAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg13770153	chr20:60521292	NA	-0.46	-4.37	-0.33	2.33e-5	Body mass index;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.76	9.17	0.6	3.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6762	0.748	rs28677123	chr11:840604	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.54	-0.41	1.3e-7	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01825986	chr20:47804552	STAU1	0.59	6.94	0.49	1.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.47	0.61	5.26e-17	Platelet count;
PAAD	cis	rs3018712	0.590	rs4930601	chr11:68497371	T/C	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.5	4.95	0.37	1.99e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.7	6.94	0.49	1.04e-10	Prostate cancer;
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	6.98	0.49	8.49e-11	Alzheimer's disease;
PAAD	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg22654517	chr2:96458247	NA	0.38	4.51	0.34	1.29e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.27	-0.67	8.44e-22	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.75	-4.68	-0.36	6.23e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2526932	0.598	rs9671285	chr14:73062831	G/A	cg13588403	chr14:73209128	DPF3	-0.4	-5.44	-0.4	2.08e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-8.69	-0.58	5.54e-15	Body mass index;
PAAD	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.56	-0.35	1.05e-5	Joint mobility (Beighton score);
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg00976097	chr5:421733	AHRR	-0.5	-4.82	-0.36	3.47e-6	Cystic fibrosis severity;
PAAD	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs457162	0.588	rs281870	chr6:118572150	A/C	cg21191810	chr6:118973309	C6orf204	0.73	4.92	0.37	2.24e-6	QT interval;
PAAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg16586182	chr3:47516702	SCAP	0.53	5.21	0.39	6.08e-7	Birth weight;
PAAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg18612461	chr15:75251733	NA	0.57	6.47	0.46	1.25e-9	Breast cancer;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.7	-7.93	-0.54	4.48e-13	Iron status biomarkers;
PAAD	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg00262122	chr8:11665843	FDFT1	-0.62	-5.31	-0.4	3.87e-7	Neuroticism;
PAAD	cis	rs11669133	1.000	rs76483582	chr19:11139656	C/G	cg25243385	chr19:11167475	SMARCA4	0.98	4.58	0.35	9.81e-6	LDL cholesterol;
PAAD	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.76	-6.88	-0.49	1.46e-10	Inhibitory control;
PAAD	cis	rs6880778	0.505	rs11952844	chr5:40384295	G/C	cg05240017	chr5:40756081	TTC33	0.55	4.73	0.36	4.99e-6	Inflammatory bowel disease;
PAAD	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.76	8.73	0.58	4.14e-15	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg13444538	chr7:158905317	VIPR2	0.52	4.91	0.37	2.3e-6	Facial morphology (factor 20);
PAAD	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.67	-0.42	7.12e-8	Coronary artery calcification;
PAAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	1.09	6.05	0.44	1.09e-8	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17407668	chr17:38375510	WIPF2	0.6	6.66	0.48	4.65e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg21855830	chr2:127963489	CYP27C1	-0.46	-4.31	-0.33	2.9e-5	Protein C levels;
PAAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.99	12.93	0.72	2.94e-26	Gestational age at birth (maternal effect);
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Body mass index;
PAAD	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.65	6.97	0.49	9.08e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.42	-0.34	1.85e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs758324	0.716	rs27348	chr5:131407139	A/T	cg06307176	chr5:131281290	NA	-0.51	-4.64	-0.35	7.51e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg14829360	chr17:73884958	NA	-0.61	-5.82	-0.43	3.42e-8	Psoriasis;
PAAD	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg19264203	chr11:92714893	MTNR1B	0.4	4.56	0.35	1.06e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg05228244	chr10:1102351	WDR37	0.9	4.27	0.33	3.39e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.69	10.66	0.65	3.76e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.33	0.33	2.66e-5	Height;
PAAD	cis	rs9866391	0.537	rs6807935	chr3:141114293	A/G	cg00789793	chr3:141329863	RASA2	0.49	4.25	0.33	3.76e-5	Myopia;
PAAD	cis	rs91	0.624	rs9638820	chr7:24462817	G/A	cg13313214	chr7:23749942	STK31	0.45	4.34	0.33	2.54e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13683516	chr12:56618066	OBFC2B	0.59	6.43	0.46	1.55e-9	Myopia (pathological);
PAAD	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.36	0.4	3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6782025	0.837	rs470502	chr3:120643524	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.64	-5.94	-0.43	1.86e-8	Multiple myeloma;
PAAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.53	-5.2	-0.39	6.33e-7	Aortic root size;
PAAD	cis	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg20159608	chr7:32802032	NA	-0.59	-6.05	-0.44	1.1e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-5.51	-0.41	1.5e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.97	0.63	2.55e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg08676812	chr11:65308423	LTBP3	0.81	5.46	0.4	1.93e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.68	-6.63	-0.47	5.65e-10	Pubertal anthropometrics;
PAAD	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.56	5.6	0.41	9.73e-8	Systolic blood pressure;
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.69	7.68	0.53	1.84e-12	Mean corpuscular volume;
PAAD	cis	rs1572438	1.000	rs9379167	chr6:866372	C/T	cg21062780	chr6:887772	NA	-0.48	-4.71	-0.36	5.45e-6	Aging;
PAAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.45e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.36	0.4	2.97e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10924309	0.737	rs1538957	chr1:245855639	A/G	cg00036263	chr1:245852353	KIF26B	-0.65	-6.24	-0.45	4.24e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs2564921	0.513	rs12638195	chr3:52876639	G/A	cg00794529	chr3:52445096	PHF7;BAP1	-0.54	-4.6	-0.35	8.76e-6	Height;
PAAD	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.72	8.51	0.57	1.55e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs10256972	0.680	rs7784708	chr7:1003049	A/G	cg07930192	chr7:1003750	NA	0.6	7.85	0.54	6.87e-13	Longevity;Endometriosis;
PAAD	cis	rs114540395	0.777	rs114076639	chr10:103333323	G/A	cg21381511	chr10:104264849	SUFU	-0.93	-4.54	-0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.91	-0.49	1.26e-10	Blood metabolite levels;
PAAD	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg10985347	chr2:127963512	CYP27C1	0.47	4.71	0.36	5.62e-6	Protein C levels;
PAAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.41	-4.25	-0.33	3.74e-5	Inflammatory skin disease;
PAAD	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.15	-13.72	-0.74	2.2e-28	Type 1 diabetes nephropathy;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.82	-10.0	-0.63	2.05e-18	Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg07636037	chr3:49044803	WDR6	0.6	4.67	0.35	6.47e-6	Menarche (age at onset);
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.82e-9	Lung cancer;
PAAD	cis	rs7360412	0.649	rs6037419	chr20:2800208	G/A	cg18164281	chr20:2797721	LOC100288797	0.53	4.65	0.35	7.16e-6	White matter integrity;
PAAD	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg21269045	chr12:125625041	AACS	-0.45	-4.25	-0.33	3.65e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg15145965	chr22:50218605	BRD1	-0.71	-4.37	-0.33	2.25e-5	Schizophrenia;
PAAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-5.66	-0.42	7.43e-8	Monocyte count;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.95	12.68	0.72	1.39e-25	Menarche (age at onset);
PAAD	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg00700412	chr12:58011837	NA	0.48	5.2	0.39	6.42e-7	Multiple sclerosis;
PAAD	cis	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04916103	chr17:4270032	UBE2G1	-0.48	-4.49	-0.34	1.42e-5	Myopia (pathological);
PAAD	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.1	-0.38	9.95e-7	Cervical cancer;
PAAD	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.24	0.51	2.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.34	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.51	4.68	0.36	6.23e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7727544	0.604	rs2069803	chr5:131400433	T/C	cg16205897	chr5:131564050	P4HA2	-0.46	-4.93	-0.37	2.13e-6	Blood metabolite levels;
PAAD	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg06207120	chr15:45996521	NA	0.3	4.43	0.34	1.78e-5	Waist circumference;Weight;
PAAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9392556	0.829	rs853416	chr6:4113047	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.41	-4.53	-0.34	1.18e-5	Blood metabolite levels;
PAAD	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg21130718	chr4:1044621	NA	0.57	4.81	0.36	3.53e-6	Recombination rate (females);
PAAD	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.89	10.97	0.66	5.41e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg27478167	chr7:817139	HEATR2	0.7	5.34	0.4	3.31e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.51	5.53	0.41	1.34e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06799790	chr17:61951754	CSH2	-0.45	-4.66	-0.35	6.73e-6	Height;
PAAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg06740227	chr12:86229804	RASSF9	0.53	5.2	0.39	6.45e-7	Major depressive disorder;
PAAD	cis	rs360071	0.528	rs360097	chr1:226065755	C/A	cg11967457	chr1:226128626	LEFTY2	0.52	4.91	0.37	2.35e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg01942863	chr7:99769432	GPC2	0.51	4.76	0.36	4.42e-6	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00625939	chr4:189028032	NA	-0.53	-6.42	-0.46	1.65e-9	Smoking initiation;
PAAD	cis	rs593531	0.531	rs662393	chr11:74086308	T/G	cg15851278	chr11:73669449	DNAJB13	-0.37	-4.36	-0.33	2.38e-5	Neuroticism;
PAAD	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg15309053	chr8:964076	NA	0.43	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.7	-6.86	-0.49	1.61e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg09017928	chr7:158110068	PTPRN2	-0.48	-4.94	-0.37	2.04e-6	Calcium levels;
PAAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.83	-8.54	-0.57	1.27e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.65	-6.94	-0.49	1.08e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg24829409	chr8:58192753	C8orf71	-0.86	-8.1	-0.55	1.65e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-4.65	-0.35	7.21e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	trans	rs9345521	0.967	rs2132278	chr6:65495320	G/T	cg26414000	chr1:85721327	C1orf52	-0.54	-6.6	-0.47	6.51e-10	Iris color (a* coordinate);
PAAD	cis	rs2594989	0.887	rs7643330	chr3:11442093	A/G	cg01796438	chr3:11312864	ATG7	-0.57	-4.43	-0.34	1.83e-5	Circulating chemerin levels;
PAAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	5.32	0.4	3.62e-7	Coronary artery disease;
PAAD	cis	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.59	-0.41	1.03e-7	HDL cholesterol;
PAAD	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg00717180	chr2:96193071	NA	-0.63	-7.66	-0.53	2e-12	HDL cholesterol;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.7	6.76	0.48	2.82e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09597638	chr17:3907349	NA	0.72	8.08	0.55	1.89e-13	Type 2 diabetes;
PAAD	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-1.0	-9.61	-0.61	2.17e-17	Corneal structure;
PAAD	cis	rs9473924	0.913	rs2206271	chr6:50786008	T/A	cg24161652	chr6:50813859	TFAP2B	0.3	4.35	0.33	2.45e-5	Body mass index;
PAAD	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.51	-4.88	-0.37	2.62e-6	Psoriasis;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg14926445	chr8:58193284	C8orf71	-0.58	-4.27	-0.33	3.41e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.35	0.56	4e-14	Prudent dietary pattern;
PAAD	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.7	6.95	0.49	1e-10	Lymphocyte counts;
PAAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.56	6.0	0.44	1.36e-8	Menopause (age at onset);
PAAD	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.92	-6.8	-0.48	2.23e-10	Opioid sensitivity;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.91	7.06	0.5	5.62e-11	Alzheimer's disease;
PAAD	cis	rs66478310	0.793	rs11113814	chr12:108712258	C/T	cg04872675	chr12:108983234	NA	0.89	5.74	0.42	5.08e-8	Plasma clusterin levels;
PAAD	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.65	-7.01	-0.49	7.46e-11	Dilated cardiomyopathy;
PAAD	cis	rs668210	0.793	rs615646	chr11:65777544	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.57	4.75	0.36	4.62e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-5.91	-0.43	2.15e-8	Obesity (extreme);
PAAD	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.84	-8.51	-0.57	1.58e-14	Multiple sclerosis;
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.61	-0.41	9.33e-8	Iron status biomarkers;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07295248	chr9:79074560	GCNT1	0.58	6.37	0.46	2.13e-9	Monocyte percentage of white cells;
PAAD	cis	rs700651	0.675	rs1371665	chr2:198942568	C/T	cg10820045	chr2:198174542	NA	0.47	4.38	0.34	2.17e-5	Intracranial aneurysm;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.82e-6	Lymphocyte counts;
PAAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	cis	rs12431939	0.947	rs115193312	chr14:51592571	C/A	cg23942311	chr14:51606299	NA	-0.7	-5.57	-0.41	1.12e-7	Cancer;
PAAD	trans	rs901683	1.000	rs35916836	chr10:46082516	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg04450456	chr4:17643702	FAM184B	0.47	5.1	0.38	9.94e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.01e-5	Systemic lupus erythematosus;
PAAD	cis	rs12431939	0.598	rs10873047	chr14:51727239	G/T	cg23942311	chr14:51606299	NA	0.58	5.32	0.4	3.57e-7	Cancer;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.39	5.33	0.4	3.48e-7	Schizophrenia;
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg15691649	chr6:25882328	NA	0.51	4.63	0.35	7.81e-6	Blood metabolite levels;
PAAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg10589385	chr1:150898437	SETDB1	-0.38	-4.86	-0.37	2.9e-6	Melanoma;
PAAD	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.63	9.71	0.62	1.21e-17	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.91	0.37	2.34e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-7.22	-0.51	2.33e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg03517284	chr6:25882590	NA	-0.55	-4.58	-0.35	9.78e-6	Iron status biomarkers;
PAAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.56	0.57	1.16e-14	Homoarginine levels;
PAAD	cis	rs77831929	0.739	rs2634073	chr4:111665783	T/C	cg18064927	chr4:111531975	NA	-0.48	-4.36	-0.33	2.41e-5	Atrial fibrillation;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26418147	chr1:205743515	RAB7L1	-0.47	-5.65	-0.42	7.76e-8	Menarche (age at onset);
PAAD	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg18898632	chr2:242989856	NA	-0.79	-6.23	-0.45	4.45e-9	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.64	6.48	0.47	1.2e-9	Blood metabolite levels;
PAAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.75	-7.11	-0.5	4.24e-11	Pancreatic cancer;
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.8	8.83	0.58	2.37e-15	Coronary artery disease;
PAAD	cis	rs4668356	0.881	rs73017268	chr2:172034644	T/C	cg13882835	chr2:172017928	TLK1	0.93	4.53	0.34	1.19e-5	Cognitive performance;
PAAD	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg16205897	chr5:131564050	P4HA2	-0.5	-5.41	-0.4	2.42e-7	Blood metabolite levels;
PAAD	cis	rs1075232	0.826	rs12437800	chr15:31671432	A/G	cg15751117	chr15:30700112	NA	0.87	4.44	0.34	1.75e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.56	-4.99	-0.38	1.64e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9535307	0.696	rs9535305	chr13:50290415	A/T	cg03658251	chr13:50265850	EBPL	0.81	5.61	0.41	9.52e-8	Obesity-related traits;
PAAD	cis	rs8102137	1.000	rs17513752	chr19:30290811	C/T	cg27475126	chr19:30303651	CCNE1	0.45	5.01	0.38	1.47e-6	Bladder cancer;
PAAD	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.69	8.05	0.55	2.26e-13	Eye color traits;
PAAD	cis	rs6693295	0.729	rs2185074	chr1:246213781	T/G	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.45	-0.34	1.66e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg01763666	chr17:80159506	CCDC57	0.45	4.62	0.35	8.27e-6	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.13e-6	Life satisfaction;
PAAD	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	11.33	0.68	5.88e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs116248771	0.739	rs4680455	chr3:158384883	C/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg16898833	chr6:26189333	HIST1H4D	0.86	5.73	0.42	5.25e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10547527	chr2:198650123	BOLL	0.49	4.4	0.34	2.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2790216	1.000	rs2105220	chr10:59969064	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.93	-8.17	-0.55	1.14e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg19438565	chr8:143695827	ARC	-0.56	-5.44	-0.4	2.08e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs59888335	0.929	rs11706383	chr3:80872773	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.36	4.34	0.33	2.61e-5	Pulmonary function;
PAAD	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.37	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.76	6.36	0.46	2.3e-9	Alzheimer's disease;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18337363	chr3:52569053	NT5DC2	0.42	4.4	0.34	2e-5	Bipolar disorder;
PAAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.59	6.58	0.47	7.3e-10	Emphysema distribution in smoking;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.55	5.59	0.41	1.03e-7	Acylcarnitine levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14783646	chr7:4800873	FOXK1	0.63	7.67	0.53	1.86e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.44	-4.49	-0.34	1.43e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.8	8.25	0.56	7.15e-14	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.4	0.4	2.54e-7	Bipolar disorder;
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.69	6.83	0.48	1.88e-10	Blood metabolite levels;
PAAD	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
PAAD	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-5.52	-0.41	1.46e-7	Blood metabolite levels;
PAAD	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg02376097	chr19:46275166	DMPK	-0.58	-5.71	-0.42	5.86e-8	Coronary artery disease;
PAAD	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg10978503	chr1:24200527	CNR2	-0.39	-4.44	-0.34	1.74e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg06632027	chr4:90757378	SNCA	-0.5	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg16342193	chr10:102329863	NA	-0.79	-8.75	-0.58	3.74e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.66	8.43	0.56	2.46e-14	Hemoglobin concentration;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg18769074	chr3:133464867	TF	-0.42	-4.87	-0.37	2.76e-6	Iron status biomarkers;
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg14393609	chr7:65229607	NA	0.7	7.72	0.53	1.45e-12	Aortic root size;
PAAD	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.99	7.79	0.53	9.67e-13	LDL cholesterol;
PAAD	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-6.57	-0.47	7.46e-10	Coronary artery disease;
PAAD	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	4.75	0.36	4.59e-6	Colorectal cancer;
PAAD	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg00206168	chr11:65308501	LTBP3	0.53	5.36	0.4	3e-7	Bone mineral density;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg07636037	chr3:49044803	WDR6	0.57	4.56	0.35	1.03e-5	Menarche (age at onset);
PAAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Calcium levels;
PAAD	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.37	0.4	2.88e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.82	-9.1	-0.59	4.75e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg00431813	chr7:1051703	C7orf50	0.56	4.64	0.35	7.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.46	5.97	0.44	1.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.72	-5.7	-0.42	5.96e-8	Coronary artery disease;
PAAD	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	6.05	0.44	1.08e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07990511	chr6:36853609	C6orf89	0.57	6.3	0.46	3.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg00262122	chr8:11665843	FDFT1	-0.47	-4.29	-0.33	3.17e-5	Systolic blood pressure;
PAAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.43	-4.8	-0.36	3.75e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs557074	0.821	rs9406002	chr6:7181735	A/G	cg01785233	chr6:7260807	NA	0.52	4.32	0.33	2.82e-5	Monocyte count;
PAAD	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.88	4.76	0.36	4.4e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.7	7.39	0.51	9.16e-12	Colorectal cancer;
PAAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.66	4.86	0.37	2.96e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.55	-5.26	-0.39	4.73e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.66	-6.38	-0.46	2.01e-9	Lung cancer;
PAAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.69	6.72	0.48	3.41e-10	Tuberculosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01708711	chr7:75959031	YWHAG	0.64	7.56	0.52	3.49e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg07469887	chr10:131262384	NA	0.47	5.88	0.43	2.49e-8	Response to temozolomide;
PAAD	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-6.45	-0.46	1.39e-9	Body mass index;
PAAD	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.96	-10.63	-0.65	4.43e-20	Homoarginine levels;
PAAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-5.03	-0.38	1.34e-6	Height;
PAAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-4.27	-0.33	3.38e-5	Asthma;
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg23254163	chr1:152506842	NA	0.59	6.83	0.48	1.95e-10	Hair morphology;
PAAD	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.67	4.8	0.36	3.7e-6	Neuroticism;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.04	-12.54	-0.71	3.3e-25	Height;
PAAD	cis	rs9314614	0.872	rs2977792	chr8:6711508	G/C	cg27319216	chr8:6693540	XKR5	-0.37	-4.95	-0.37	1.96e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14119001	chr9:139324193	INPP5E	-0.61	-5.53	-0.41	1.36e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1903068	0.853	rs17773240	chr4:55999781	T/C	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.69e-5	Endometriosis;
PAAD	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-4.57	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.62	5.14	0.38	8.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6494488	0.500	rs55978417	chr15:64817369	A/C	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.64	-0.35	7.57e-6	Toenail selenium levels;
PAAD	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.6	-0.41	9.96e-8	Corneal astigmatism;
PAAD	cis	rs4690686	0.500	rs3921993	chr4:177263284	A/G	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.36e-6	Asthma;
PAAD	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg19176072	chr10:135083742	ADAM8	0.95	4.59	0.35	9.22e-6	Lifespan;
PAAD	cis	rs7824557	0.736	rs6601578	chr8:11136604	A/G	cg21775007	chr8:11205619	TDH	-0.61	-5.47	-0.41	1.81e-7	Retinal vascular caliber;
PAAD	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.7	-5.91	-0.43	2.13e-8	Common traits (Other);
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg08677398	chr8:58056175	NA	0.61	4.34	0.33	2.57e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg08992911	chr2:238395768	MLPH	0.68	5.67	0.42	7.09e-8	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg27532560	chr4:187881888	NA	-0.55	-6.72	-0.48	3.39e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs501120	0.657	rs1704222	chr10:44710465	T/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs56050415	0.951	rs1318175	chr15:58586129	C/T	cg02704931	chr15:57998412	GCOM1;GRINL1A	0.58	4.26	0.33	3.51e-5	Metabolite levels (lipoprotein measures);
PAAD	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.58	4.73	0.36	5.05e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.85	6.42	0.46	1.69e-9	Axial length;
PAAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg19636519	chr7:99541626	NA	0.41	4.58	0.35	9.53e-6	Coronary artery disease;
PAAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.76	8.61	0.57	8.61e-15	Age-related hearing impairment;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.8e-5	Cognitive function;
PAAD	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg23815491	chr16:72088622	HP	0.4	4.36	0.33	2.37e-5	Fibrinogen levels;
PAAD	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg15841412	chr13:111365552	ING1	-0.53	-4.39	-0.34	2.08e-5	Coronary artery disease;
PAAD	cis	rs4819143	0.517	rs442953	chr21:47374343	G/A	cg13695288	chr21:47294981	PCBP3	0.53	4.61	0.35	8.43e-6	Insulin resistance/response;
PAAD	trans	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg26151163	chr2:239079168	ILKAP	1.0	6.29	0.45	3.29e-9	Major depressive disorder;
PAAD	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg00522288	chr12:125625016	AACS	-0.56	-6.19	-0.45	5.32e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.3	-0.33	3.06e-5	Blood protein levels;
PAAD	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.49	-4.52	-0.34	1.25e-5	Tuberculosis;
PAAD	cis	rs10465746	0.935	rs1871925	chr1:84464468	C/G	cg10977910	chr1:84465055	TTLL7	0.61	5.58	0.41	1.06e-7	Obesity-related traits;
PAAD	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.43e-8	QRS complex (12-leadsum);
PAAD	cis	rs2882667	0.686	rs62381196	chr5:138176689	C/T	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2834902	0.605	rs28436268	chr21:36681625	A/C	cg04915566	chr21:36421472	RUNX1	-0.33	-4.47	-0.34	1.53e-5	Corneal curvature;
PAAD	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.86	-6.42	-0.46	1.64e-9	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10720867	chr6:155537595	TIAM2	-0.63	-6.57	-0.47	7.36e-10	Obesity-related traits;
PAAD	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-10.92	-0.66	7.63e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	1.06	8.59	0.57	9.49e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.76	-8.61	-0.57	8.49e-15	Childhood ear infection;
PAAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.59	-0.41	1.01e-7	Height;
PAAD	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-6.76	-0.48	2.78e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg08558340	chr7:100472263	SRRT	0.48	4.48	0.34	1.49e-5	Resting heart rate;
PAAD	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.52	-4.62	-0.35	8.29e-6	Total body bone mineral density;
PAAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.78	8.97	0.59	1.02e-15	Schizophrenia;
PAAD	cis	rs28493229	1.000	rs28493229	chr19:41224204	G/C	cg21869046	chr19:41225005	ITPKC	0.65	6.64	0.47	5.26e-10	Kawasaki disease;
PAAD	cis	rs58521262	0.585	rs289290	chr19:23178873	C/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs10450586	0.863	rs10437622	chr11:27307178	C/T	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	6.54	0.47	9.05e-10	Mood instability;
PAAD	cis	rs9857275	0.527	rs13098300	chr3:141179516	T/C	cg25967872	chr3:141205623	RASA2	0.51	4.4	0.34	2.01e-5	Prion diseases;
PAAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-4.79	-0.36	3.9e-6	Dementia with Lewy bodies;
PAAD	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg22532475	chr10:104410764	TRIM8	-0.37	-4.49	-0.34	1.4e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg02781088	chr2:113192302	RGPD8;RGPD5	0.91	6.74	0.48	3.15e-10	Yeast infection;
PAAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs2019216	0.605	rs11868258	chr17:21995777	C/T	cg05591447	chr17:21909280	FLJ36000	-0.33	-4.39	-0.34	2.12e-5	Pelvic organ prolapse;
PAAD	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg09659197	chr4:152720779	NA	-0.37	-5.38	-0.4	2.78e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.57	-6.55	-0.47	8.31e-10	Monocyte count;
PAAD	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg10253484	chr15:75165896	SCAMP2	-0.65	-6.05	-0.44	1.08e-8	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00152838	chr16:24741724	TNRC6A	-0.52	-4.39	-0.34	2.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.76	8.83	0.58	2.37e-15	Blood metabolite ratios;
PAAD	cis	rs6594713	0.851	rs6594706	chr5:112693267	T/C	cg12552261	chr5:112820674	MCC	0.64	5.15	0.39	7.93e-7	Brain cytoarchitecture;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.46	3.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.87	8.15	0.55	1.25e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.75	0.36	4.66e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06002616	chr8:101225028	SPAG1	-0.46	-5.33	-0.4	3.42e-7	Atrioventricular conduction;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg23112188	chr14:24563095	PCK2	-0.5	-5.54	-0.41	1.31e-7	IgG glycosylation;
PAAD	cis	rs8063160	0.622	rs34659644	chr16:89796017	G/A	cg07984980	chr16:89898383	SPIRE2	0.92	4.99	0.38	1.63e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs4478858	0.775	rs6685868	chr1:31706956	C/T	cg00250761	chr1:31883323	NA	-0.51	-5.85	-0.43	2.87e-8	Alcohol dependence;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.67	-6.41	-0.46	1.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.75	8.64	0.57	7.19e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs3764618	1.000	rs112256404	chr19:49505313	G/T	cg12515942	chr19:49552529	CGB8	-0.72	-4.3	-0.33	3.06e-5	Follicule stimulating hormone;
PAAD	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs7301016	1.000	rs10877855	chr12:62870510	C/G	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs6011002	0.590	rs1291212	chr20:62340115	C/G	cg01176363	chr20:62369445	LIME1	-0.92	-4.31	-0.33	2.87e-5	Dental caries;
PAAD	trans	rs901683	0.850	rs113722818	chr10:46093208	G/A	cg13065504	chr15:42448234	PLA2G4F	0.8	6.54	0.47	8.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg14703610	chr5:56206110	C5orf35	-0.55	-5.21	-0.39	6.15e-7	Initial pursuit acceleration;
PAAD	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs7623687	0.786	rs34759087	chr3:49162284	C/T	cg19401529	chr3:49056140	DALRD3	1.04	6.53	0.47	9.4e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.53	-4.85	-0.37	3.06e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg15145965	chr22:50218605	BRD1	0.6	5.2	0.39	6.4e-7	Schizophrenia;
PAAD	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.36	0.51	1.07e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.51	5.04	0.38	1.32e-6	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.57	-4.72	-0.36	5.36e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg22089800	chr15:90895588	ZNF774	0.54	5.06	0.38	1.21e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7873102	0.654	rs55773241	chr9:38008732	G/A	cg03528946	chr9:38069800	SHB	-0.5	-4.97	-0.37	1.77e-6	Brain structure;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg17380795	chr3:122379686	NA	0.47	4.76	0.36	4.38e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.87	11.34	0.68	5.57e-22	Subjective well-being (multi-trait analysis);
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.9	-14.5	-0.76	1.88e-30	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.64	7.06	0.5	5.5e-11	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.26	-0.33	3.59e-5	Renal cell carcinoma;
PAAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	6.58	0.47	7.24e-10	Educational attainment;
PAAD	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg12218747	chr21:37451666	NA	-0.52	-5.47	-0.41	1.85e-7	Mitral valve prolapse;
PAAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg07251872	chr6:41169918	TREML2	-0.45	-4.28	-0.33	3.28e-5	Alzheimer's disease (late onset);
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg17372223	chr3:52568218	NT5DC2	0.48	4.74	0.36	4.86e-6	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	0.81	8.76	0.58	3.61e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg02734326	chr4:10020555	SLC2A9	0.48	4.84	0.37	3.18e-6	Bone mineral density;
PAAD	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	10.92	0.66	7.39e-21	Electrocardiographic conduction measures;
PAAD	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26926768	chr12:34528122	NA	0.38	4.63	0.35	7.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-5.25	-0.39	5.09e-7	Morning vs. evening chronotype;
PAAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.75	-0.36	4.74e-6	Parkinson's disease;
PAAD	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg10977910	chr1:84465055	TTLL7	0.49	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20887711	chr4:1340912	KIAA1530	0.75	8.2	0.55	9.51e-14	Longevity;
PAAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg12215294	chr3:40350768	EIF1B	-0.49	-4.88	-0.37	2.66e-6	Renal cell carcinoma;
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg25037394	chr1:24152592	HMGCL	0.41	4.48	0.34	1.49e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.74	-5.87	-0.43	2.64e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.95	-6.15	-0.45	6.43e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.97	-9.91	-0.63	3.57e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.92	7.39	0.51	9.36e-12	Initial pursuit acceleration;
PAAD	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.43	4.27	0.33	3.41e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.68	-0.42	6.54e-8	Resting heart rate;
PAAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.72	-6.98	-0.49	8.76e-11	DNA methylation (variation);
PAAD	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.57	0.41	1.14e-7	Ileal carcinoids;
PAAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.78	7.29	0.51	1.6e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.58	-0.35	9.63e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.32	0.33	2.76e-5	Height;
PAAD	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.88	-0.43	2.47e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12776158	0.901	rs57805780	chr10:71216455	A/C	cg12610070	chr10:71211762	TSPAN15	-0.51	-5.0	-0.38	1.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.51	5.89	0.43	2.36e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.56	5.12	0.38	9.29e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs60154123	0.730	rs58366398	chr1:210471924	G/A	cg23283495	chr1:209979779	IRF6	0.63	5.5	0.41	1.56e-7	Coronary artery disease;
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	6.05	0.44	1.1e-8	Renal function-related traits (BUN);
PAAD	cis	rs10792830	0.706	rs484154	chr11:85705476	A/T	cg07180834	chr11:85838833	NA	0.48	5.4	0.4	2.53e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2057884	0.503	rs2385558	chr7:105019603	A/T	cg04380332	chr7:105027541	SRPK2	0.48	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.71	5.88	0.43	2.51e-8	Schizophrenia;
PAAD	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.88	-7.45	-0.52	6.63e-12	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.66	5.94	0.43	1.85e-8	Platelet count;
PAAD	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.58	-6.59	-0.47	6.89e-10	Platelet distribution width;
PAAD	cis	rs4716602	0.827	rs10270019	chr7:156158973	T/C	cg04090468	chr7:156181990	NA	0.5	4.82	0.36	3.42e-6	Anti-saccade response;
PAAD	cis	rs939584	0.877	rs6752470	chr2:629694	T/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg27411982	chr8:10470053	RP1L1	0.43	4.33	0.33	2.68e-5	Retinal vascular caliber;
PAAD	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.52	-5.02	-0.38	1.44e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.62	7.21	0.5	2.47e-11	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14625594	chr9:129291374	NA	-0.72	-7.84	-0.54	7.45e-13	Obesity-related traits;
PAAD	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.31e-6	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-7.51	-0.52	4.6e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.15e-10	Atrioventricular conduction;
PAAD	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.95	-14.53	-0.76	1.54e-30	Height;
PAAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.8	8.05	0.55	2.28e-13	Blood protein levels;
PAAD	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.29	-0.51	1.59e-11	Retinal vascular caliber;
PAAD	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.52	6.15	0.45	6.61e-9	Total body bone mineral density;
PAAD	cis	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-5.17	-0.39	7.14e-7	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs54211	0.803	rs137643	chr22:39728032	A/C	cg24399712	chr22:39784796	NA	-0.77	-4.35	-0.33	2.47e-5	Sudden cardiac arrest;
PAAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg06609049	chr19:2785107	THOP1	0.9	10.09	0.63	1.24e-18	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs10073892	0.784	rs10052669	chr5:101622966	G/A	cg17280723	chr5:101634495	NA	0.4	4.29	0.33	3.11e-5	Cognitive decline (age-related);
PAAD	cis	rs4073221	0.860	rs13060052	chr3:18257585	C/A	cg07694806	chr3:18168406	NA	-0.76	-5.04	-0.38	1.28e-6	Parkinson's disease;
PAAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-5.42	-0.4	2.33e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.4	-4.94	-0.37	2.01e-6	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02760007	chr6:43139670	SRF	0.64	6.65	0.47	5.04e-10	Myopia (pathological);
PAAD	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-5.65	-0.42	7.71e-8	Blood protein levels;
PAAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.68	-0.48	4.14e-10	Bone mineral density;
PAAD	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg18279126	chr7:2041391	MAD1L1	0.54	5.5	0.41	1.54e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg08619932	chr19:49200058	FUT2	0.57	6.3	0.45	3.08e-9	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg12639453	chr1:2035780	PRKCZ	-0.54	-5.68	-0.42	6.61e-8	Height;
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.53	0.41	1.34e-7	Platelet count;
PAAD	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.48	-4.76	-0.36	4.56e-6	Diastolic blood pressure;
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg26169700	chr22:42538906	CYP2D7P1	-0.55	-4.28	-0.33	3.34e-5	Birth weight;
PAAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.78	0.48	2.45e-10	Total body bone mineral density;
PAAD	cis	rs78540526	0.500	rs657686	chr11:69332670	A/G	cg08353955	chr11:69289746	NA	-1.04	-6.13	-0.45	7.29e-9	Breast cancer;
PAAD	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06002616	chr8:101225028	SPAG1	0.46	5.38	0.4	2.74e-7	Atrioventricular conduction;
PAAD	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	1.04	12.65	0.72	1.64e-25	Breast cancer;
PAAD	cis	rs3784262	0.669	rs1061278	chr15:58246029	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.31	-0.4	3.82e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.29	0.6	1.49e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	7.67	0.53	1.88e-12	Alzheimer's disease;
PAAD	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22509189	chr2:225307070	NA	-0.48	-4.43	-0.34	1.8e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg08601574	chr20:25228251	PYGB	0.48	4.94	0.37	2.08e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.61	5.57	0.41	1.11e-7	Red blood cell count;
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13560548	chr3:10150139	C3orf24	0.63	5.67	0.42	7.05e-8	Alzheimer's disease;
PAAD	cis	rs4740619	0.592	rs3008714	chr9:16015859	C/A	cg14451791	chr9:16040625	NA	-0.37	-4.26	-0.33	3.56e-5	Body mass index;
PAAD	cis	rs6922632	0.764	rs55905647	chr6:24117170	C/T	cg26194775	chr6:24126114	NRSN1	-0.59	-4.59	-0.35	9.12e-6	Information processing speed;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.51	-5.16	-0.39	7.52e-7	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.43	5.64	0.42	7.97e-8	Calcium levels;
PAAD	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-5.91	-0.43	2.15e-8	Crohn's disease;
PAAD	cis	rs10861661	0.963	rs10778511	chr12:107225331	A/T	cg15890332	chr12:107067104	RFX4	0.51	5.17	0.39	7.41e-7	Triglyceride levels;
PAAD	cis	rs10982256	0.904	rs4527950	chr9:117267472	G/T	cg12877860	chr9:117266580	DFNB31	0.47	4.91	0.37	2.33e-6	Bipolar disorder;
PAAD	cis	rs17123764	0.605	rs7956181	chr12:50056339	T/C	cg14846292	chr12:49726500	C1QL4	-0.74	-4.85	-0.37	3.02e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20457193	chr1:32645180	TXLNA	0.67	7.47	0.52	5.84e-12	Myopia (pathological);
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.39	-0.56	3.08e-14	Morning vs. evening chronotype;
PAAD	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.38	-4.28	-0.33	3.23e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.71	7.29	0.51	1.6e-11	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01622965	chr7:98476371	TRRAP	0.59	6.64	0.47	5.2400000000000005e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.71	7.06	0.5	5.45e-11	Age-related hearing impairment;
PAAD	cis	rs10887741	0.646	rs10218939	chr10:89436853	A/G	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.52	-4.47	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.63e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs72827839	1.000	rs72827876	chr17:46523974	A/G	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs7631605	0.935	rs6550448	chr3:37108896	T/A	cg17445812	chr3:36986805	TRANK1	0.32	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09026224	chr5:172484103	C5orf41	0.63	7.01	0.49	7.42e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58521262	0.585	rs12978716	chr19:23216456	C/T	cg03433597	chr19:22806448	NA	0.24	4.31	0.33	2.93e-5	Testicular germ cell tumor;
PAAD	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.48	5.87	0.43	2.58e-8	Systemic lupus erythematosus;
PAAD	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs728616	0.867	rs41302709	chr10:81807278	G/A	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.99	-0.38	1.6e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg10587741	chr22:38071170	LGALS1	0.44	4.83	0.36	3.27e-6	Fat distribution (HIV);
PAAD	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.48	4.79	0.36	3.97e-6	Airway imaging phenotypes;
PAAD	cis	rs2835872	0.758	rs1787399	chr21:39037883	A/G	cg06728970	chr21:39037746	KCNJ6	0.53	6.09	0.44	8.77e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg02344993	chr17:57696989	CLTC	0.62	5.2	0.39	6.47e-7	Hemoglobin concentration;
PAAD	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.61	0.57	8.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.72	-0.48	3.4e-10	Response to antipsychotic treatment;
PAAD	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs113862353	chr10:46068586	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.88	-8.31	-0.56	5.06e-14	Post bronchodilator FEV1;
PAAD	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg08601574	chr20:25228251	PYGB	0.6	6.58	0.47	7.06e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg19413350	chr8:57351067	NA	-0.6	-6.3	-0.45	3.1e-9	Obesity-related traits;
PAAD	cis	rs9435732	1.000	rs2076600	chr1:17337391	G/A	cg12442246	chr1:17004764	NA	0.51	4.34	0.33	2.62e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.58	-0.35	9.8e-6	Testicular germ cell tumor;
PAAD	cis	rs13053817	1.000	rs13055707	chr22:29851172	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.56	-4.88	-0.37	2.67e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg00579200	chr11:133705235	NA	-0.46	-5.04	-0.38	1.32e-6	Childhood ear infection;
PAAD	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.66	-6.58	-0.47	7.32e-10	Pulse pressure;
PAAD	cis	rs10450586	0.799	rs11029901	chr11:27287108	A/G	cg10370305	chr11:27303972	NA	0.36	4.28	0.33	3.31e-5	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.6	-0.47	6.3e-10	Lung cancer;
PAAD	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.69	-6.95	-0.49	9.81e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.45	4.59	0.35	9.09e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.29	-0.39	4.16e-7	Daytime sleep phenotypes;
PAAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	9.24	0.6	2.11e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.69	7.74	0.53	1.3e-12	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.41	0.34	1.93e-5	Asthma;
PAAD	cis	rs6011674	1.000	rs41282998	chr20:61875513	A/G	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.74	-4.42	-0.34	1.89e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.58	-6.93	-0.49	1.1e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs950880	0.710	rs12470867	chr2:102926366	G/A	cg23450938	chr2:102972792	NA	0.42	4.57	0.35	1.02e-5	Serum protein levels (sST2);
PAAD	cis	rs7727544	0.617	rs3843503	chr5:131466629	T/A	cg14196790	chr5:131705035	SLC22A5	0.47	4.98	0.37	1.67e-6	Blood metabolite levels;
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.54	5.22	0.39	5.82e-7	Menarche (age at onset);
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.81	10.58	0.65	5.83e-20	Vitiligo;
PAAD	cis	rs12257961	0.675	rs7086171	chr10:15348034	C/T	cg10616319	chr10:15468812	NA	-0.44	-4.25	-0.33	3.74e-5	Selective IgA deficiency;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.52	4.65	0.35	7.16e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg11783602	chr8:55087084	NA	-0.65	-7.77	-0.53	1.11e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg13722127	chr7:150037890	RARRES2	0.57	5.89	0.43	2.44e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.37	-0.33	2.32e-5	Coronary artery disease;
PAAD	cis	rs6987853	0.563	rs2923414	chr8:42455509	G/A	cg09913449	chr8:42400586	C8orf40	0.48	5.38	0.4	2.71e-7	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09194750	chr11:34937341	PDHX;APIP	-0.73	-6.36	-0.46	2.3e-9	Neuroticism;
PAAD	cis	rs6774280	0.656	rs7649851	chr3:6280410	T/G	cg18469270	chr3:5468035	NA	0.54	4.27	0.33	3.45e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2017305	0.915	rs17471932	chr10:70751024	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.0	-0.38	1.57e-6	Depression (quantitative trait);
PAAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.59	-0.35	9.41e-6	Breast cancer;
PAAD	cis	rs10958369	0.934	rs11781325	chr8:54412679	A/G	cg12485204	chr8:54507357	NA	0.53	5.38	0.4	2.7e-7	Response to antineoplastic agents;
PAAD	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	4.46	0.34	1.6e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22465824	chr12:123746176	CDK2AP1	-0.55	-6.57	-0.47	7.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs2340727	0.668	rs10800032	chr1:161794336	T/C	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs11807834	0.522	rs3811489	chr1:230239259	T/C	cg00566187	chr1:230250356	GALNT2	-0.64	-6.79	-0.48	2.38e-10	Schizophrenia;
PAAD	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.64	-0.35	7.32e-6	Ulcerative colitis;
PAAD	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.66	-0.35	6.98e-6	Total body bone mineral density;
PAAD	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.66	-8.34	-0.56	4.07e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.43	-4.68	-0.35	6.31e-6	Platelet count;
PAAD	cis	rs66530629	0.874	rs6692599	chr1:25094714	T/C	cg22509179	chr1:25234806	RUNX3	-0.49	-4.54	-0.35	1.16e-5	Plateletcrit;
PAAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.83	10.27	0.64	3.95e-19	Menopause (age at onset);
PAAD	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg26876637	chr1:152193138	HRNR	-0.81	-6.08	-0.44	9.48e-9	Atopic dermatitis;
PAAD	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	6.3	0.45	3.08e-9	Blood protein levels;
PAAD	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.83	6.62	0.47	5.95e-10	Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.64	0.42	8.24e-8	Lung cancer in ever smokers;
PAAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.98	-10.3	-0.64	3.39e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12410462	0.591	rs72748074	chr1:227763286	G/A	cg23173402	chr1:227635558	NA	0.55	4.34	0.33	2.62e-5	Major depressive disorder;
PAAD	cis	rs427941	0.703	rs201446	chr7:101738323	C/G	cg06246474	chr7:101738831	CUX1	0.45	4.64	0.35	7.48e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.05	-0.44	1.1e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20227714	chr4:12539883	NA	-0.66	-7.17	-0.5	3.05e-11	Obesity-related traits;
PAAD	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.07	-0.5	5.32e-11	Protein C levels;
PAAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.35	-0.33	2.49e-5	Menarche (age at onset);
PAAD	trans	rs3935740	0.649	rs7174400	chr15:81629438	G/C	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.6	4.42	0.34	1.85e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.48	-4.72	-0.36	5.28e-6	Body mass index;
PAAD	trans	rs11794666	0.929	rs11793102	chr9:31787837	C/T	cg05628366	chr6:35744188	C6orf126	1.11	7.4	0.51	8.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg26220594	chr1:19110978	NA	-0.65	-5.66	-0.42	7.29e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg01765077	chr12:122356316	WDR66	-0.61	-6.29	-0.45	3.13e-9	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7191439	0.584	rs11076698	chr16:88752693	T/G	cg02389323	chr16:88786976	FAM38A	0.9	4.97	0.37	1.82e-6	Plateletcrit;
PAAD	cis	rs608114	0.510	rs602916	chr6:96363319	A/G	cg03043157	chr6:97010903	FHL5	0.93	4.88	0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	8.06e-9	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs6762644	0.507	rs9809576	chr3:4765211	A/T	cg11584376	chr3:4789075	ITPR1	-0.39	-4.34	-0.33	2.62e-5	Breast cancer;
PAAD	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.4	-0.68	3.75e-22	Chronic sinus infection;
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.83	-8.89	-0.58	1.68e-15	Prostate cancer;
PAAD	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	1.07	8.52	0.57	1.45e-14	Inflammatory bowel disease;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.94	11.26	0.67	8.94e-22	Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs72744722	chr15:65020453	C/A	cg16425858	chr15:64791681	ZNF609	1.01	4.73	0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs8070740	0.786	rs980407	chr17:5338818	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.59	0.35	9.38e-6	Menopause (age at onset);
PAAD	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	1.0	9.59	0.61	2.52e-17	Corneal structure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16050878	chr6:144508685	STX11	-0.71	-7.03	-0.5	6.7e-11	Obesity-related traits;
PAAD	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs669446	0.558	rs6429631	chr1:44113441	T/C	cg12908607	chr1:44402522	ARTN	-0.41	-4.37	-0.33	2.26e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg11416102	chr8:651193	ERICH1	-0.88	-5.4	-0.4	2.5e-7	IgG glycosylation;
PAAD	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-8.43	-0.56	2.42e-14	Alcohol dependence;
PAAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg06453172	chr10:134556979	INPP5A	0.45	4.28	0.33	3.35e-5	Migraine;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.78	-6.75	-0.48	2.92e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	7.58	0.52	3.16e-12	Eotaxin levels;
PAAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs1075265	0.749	rs805379	chr2:54092984	C/T	cg04546899	chr2:54196757	PSME4	0.3	4.58	0.35	9.59e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg03805757	chr16:71968109	PKD1L3	-0.59	-5.34	-0.4	3.38e-7	Post bronchodilator FEV1;
PAAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg23602478	chr1:26503979	CNKSR1	0.33	4.47	0.34	1.53e-5	Height;
PAAD	cis	rs7713065	0.765	rs6867325	chr5:131784005	A/G	cg14196790	chr5:131705035	SLC22A5	0.46	4.42	0.34	1.89e-5	Lung function (FEV1/FVC);
PAAD	cis	rs8049603	0.646	rs57860557	chr16:23189937	T/C	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.3	-0.33	3.01e-5	Multiple sclerosis;
PAAD	cis	rs1400816	0.850	rs6714214	chr2:172851990	T/C	cg23624723	chr2:173292262	ITGA6	-0.76	-4.38	-0.33	2.2e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.51	4.53	0.34	1.21e-5	Coronary artery disease;
PAAD	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-5.65	-0.42	7.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.7	-6.31	-0.46	2.9e-9	Diabetic retinopathy;
PAAD	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-1.17	-16.55	-0.8	7.76e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04004754	chr3:18466481	SATB1	0.75	6.84	0.49	1.84e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	8.05	0.55	2.16e-13	LDL cholesterol;
PAAD	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.57	-6.41	-0.46	1.7e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs62435770	0.615	rs833681	chr6:169506837	C/T	cg15038512	chr6:170123185	PHF10	0.49	4.33	0.33	2.66e-5	Loneliness;
PAAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.53	6.61	0.47	6.02e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg19784903	chr17:45786737	TBKBP1	-0.65	-6.9	-0.49	1.3100000000000001e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg22601191	chr20:60968625	CABLES2	0.49	4.77	0.36	4.2e-6	Colorectal cancer;
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.21	0.5	2.51e-11	Systemic lupus erythematosus;
PAAD	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.53	5.96	0.44	1.71e-8	Heart rate;
PAAD	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.83	11.29	0.68	7.46e-22	Metabolite levels;
PAAD	cis	rs12986413	1.000	rs12986413	chr19:2170954	A/T	cg09261902	chr19:2140048	AP3D1	-0.48	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs9810890	1.000	rs73196979	chr3:128450276	T/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg14254433	chr6:34482411	PACSIN1	-1.14	-6.41	-0.46	1.76e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs427941	0.967	rs6970036	chr7:101841824	A/G	cg06721601	chr7:101762633	CUX1	0.43	4.52	0.34	1.25e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27456951	chr17:37351756	CACNB1	-0.65	-6.44	-0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.49	-5.33	-0.4	3.51e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg25364880	chr3:44379878	C3orf23	0.58	5.4	0.4	2.55e-7	Depressive symptoms;
PAAD	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22633769	chr20:60982531	CABLES2	0.5	4.66	0.35	6.92e-6	Colorectal cancer;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg14926445	chr8:58193284	C8orf71	-0.62	-4.72	-0.36	5.3e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg03808351	chr9:123631620	PHF19	0.41	4.31	0.33	2.97e-5	Rheumatoid arthritis;
PAAD	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.49	0.47	1.13e-9	Menarche (age at onset);
PAAD	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.66	6.43	0.46	1.55e-9	Corneal astigmatism;
PAAD	cis	rs4073221	0.520	rs13065273	chr3:18194852	T/C	cg07694806	chr3:18168406	NA	-0.98	-6.19	-0.45	5.28e-9	Parkinson's disease;
PAAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.2	0.45	5.21e-9	Lung cancer;
PAAD	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.58	4.32	0.33	2.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg15192750	chr16:69999425	NA	0.77	5.93	0.43	1.94e-8	IgE levels;
PAAD	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.87	0.37	2.81e-6	Testicular germ cell tumor;
PAAD	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.67	6.43	0.46	1.56e-9	Type 2 diabetes;
PAAD	cis	rs34734847	0.648	rs575437	chr12:121173431	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-4.75	-0.36	4.68e-6	Mean corpuscular volume;
PAAD	cis	rs4662750	0.536	rs4662744	chr2:128350965	C/T	cg09760422	chr2:128146352	NA	0.34	5.06	0.38	1.22e-6	Renal cell carcinoma;
PAAD	cis	rs4343996	0.640	rs1546743	chr7:3456218	A/G	cg21248987	chr7:3385318	SDK1	0.5	5.35	0.4	3.11e-7	Motion sickness;
PAAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.77e-11	Eye color traits;
PAAD	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg06131755	chr6:160182447	ACAT2	0.54	4.82	0.36	3.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg08501292	chr6:25962987	TRIM38	0.86	5.23	0.39	5.54e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10821973	0.558	rs6479799	chr10:64023166	A/G	cg09941381	chr10:64027924	RTKN2	-0.38	-4.28	-0.33	3.31e-5	Hypothyroidism;
PAAD	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.85	6.48	0.46	1.24e-9	Gut microbiome composition (summer);
PAAD	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.96	-8.01	-0.54	2.71e-13	Dupuytren's disease;
PAAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.55	5.26	0.39	4.85e-7	Height;
PAAD	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg03959625	chr15:84868606	LOC388152	-0.43	-4.55	-0.35	1.11e-5	P wave terminal force;
PAAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.81	9.29	0.6	1.57e-16	Methadone dose in opioid dependence;
PAAD	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs780142	0.855	rs8040228	chr15:62836083	G/A	cg12918536	chr15:62891943	NA	0.34	4.27	0.33	3.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs11051970	0.559	rs4931012	chr12:32481904	A/G	cg24626660	chr12:32551988	NA	0.43	4.31	0.33	2.87e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.77	-6.18	-0.45	5.49e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.93	-0.37	2.11e-6	Neuroticism;
PAAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg23506979	chr15:79090958	ADAMTS7	0.25	4.3	0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg04257695	chr17:30186438	C17orf79	-0.63	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.5	-4.85	-0.37	3.05e-6	Inflammatory biomarkers;
PAAD	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.66	0.42	7.17e-8	Restless legs syndrome;
PAAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.13e-6	Motion sickness;
PAAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.42	5.3	0.4	3.92e-7	Ulcerative colitis;
PAAD	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.06	-0.5	5.43e-11	Neuroticism;
PAAD	cis	rs12776158	0.901	rs59145567	chr10:71217065	G/T	cg12610070	chr10:71211762	TSPAN15	-0.49	-4.63	-0.35	7.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.92	7.21	0.5	2.5e-11	Iron status biomarkers;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3747547	1.000	rs17418324	chr9:37921712	G/A	cg13774184	chr9:37916125	SHB	-0.65	-4.55	-0.35	1.11e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs863345	0.808	rs7517316	chr1:158469914	A/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.71	-0.36	5.47e-6	Pneumococcal bacteremia;
PAAD	cis	rs3996993	0.809	rs4535545	chr6:52694033	C/T	cg20803780	chr6:52668592	GSTA1	-0.35	-4.49	-0.34	1.39e-5	Hemoglobin concentration;
PAAD	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs1270639	0.673	rs1263566	chr7:157455933	T/C	cg13357408	chr7:157437802	PTPRN2	0.71	6.01	0.44	1.35e-8	Colorectal cancer;
PAAD	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg19630374	chr17:18023558	MYO15A	-0.56	-6.08	-0.44	9.08e-9	Total body bone mineral density;
PAAD	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-4.31	-0.33	2.92e-5	Metabolite levels;
PAAD	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg14631576	chr9:95140430	CENPP	-0.49	-4.91	-0.37	2.38e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.77	5.77	0.42	4.36e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Breast cancer;
PAAD	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg01620082	chr3:125678407	NA	-1.47	-8.17	-0.55	1.09e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg04896959	chr15:78267971	NA	-0.6	-4.56	-0.35	1.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.15	16.83	0.81	1.54e-36	Cognitive function;
PAAD	cis	rs9715521	0.645	rs11932542	chr4:59842999	A/G	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.71	-6.97	-0.49	8.94e-11	Retinal vascular caliber;
PAAD	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.72	6.18	0.45	5.57e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs12775527	chr10:46024990	G/A	cg06308084	chr22:50493570	TTLL8	0.84	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.95	6.06	0.44	1.02e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	13.84	0.75	1.07e-28	Body mass index (adult);
PAAD	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.59	-6.15	-0.45	6.51e-9	Hypospadias;
PAAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.55	-4.67	-0.35	6.61e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28655083	0.529	rs285027	chr16:77100932	A/G	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg27615366	chr5:131592974	PDLIM4	0.41	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.99	9.32	0.6	1.29e-16	Mosquito bite size;
PAAD	cis	rs787274	1.000	rs4549852	chr9:115584223	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1800469	1.000	rs2241715	chr19:41856886	A/C	cg08477640	chr19:41863820	B9D2	0.67	7.03	0.5	6.44e-11	Colorectal cancer;
PAAD	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs60154123	0.881	rs116161686	chr1:210473622	G/A	cg25204440	chr1:209979598	IRF6	0.65	4.91	0.37	2.3e-6	Coronary artery disease;
PAAD	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.61	-6.14	-0.45	6.84e-9	Hemoglobin concentration;
PAAD	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.56	5.92	0.43	2.09e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs950881	0.866	rs72823628	chr2:102928617	G/A	cg20060108	chr2:102954350	IL1RL1	0.61	4.78	0.36	4.17e-6	Allergy;
PAAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.48	5.35	0.4	3.21e-7	Major depressive disorder;
PAAD	cis	rs818427	0.684	rs41115	chr5:112175770	G/A	cg06941702	chr5:112196734	SRP19	-0.52	-4.72	-0.36	5.31e-6	Total body bone mineral density;
PAAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg06565975	chr8:143823917	SLURP1	-0.22	-4.66	-0.35	6.74e-6	Urinary tract infection frequency;
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26549601	chr10:134560360	INPP5A	-0.44	-4.43	-0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.99	0.44	1.46e-8	Prudent dietary pattern;
PAAD	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.43	-6.43	-0.46	1.59e-9	Subjective well-being;
PAAD	cis	rs13034020	0.522	rs13005116	chr2:61241567	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	4.76	0.36	4.53e-6	Menarche (age at onset);
PAAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.7	8.76	0.58	3.64e-15	Cancer;
PAAD	cis	rs10982213	1.000	rs10982193	chr9:117152302	G/A	cg00078025	chr9:117159975	NA	0.61	4.39	0.34	2.09e-5	Interleukin-6 levels;
PAAD	cis	rs10899021	0.920	rs7112384	chr11:74348205	T/G	cg25880958	chr11:74394337	NA	-0.82	-5.19	-0.39	6.6e-7	Response to metformin (IC50);
PAAD	cis	rs4141404	0.701	rs5753483	chr22:31549581	A/G	cg02404636	chr22:31891804	SFI1	-0.53	-4.48	-0.34	1.46e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg27449745	chr7:23145252	KLHL7	0.6	5.29	0.39	4.22e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.09	8.69	0.58	5.25e-15	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.39	5.86	0.43	2.84e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.83	7.85	0.54	6.94e-13	Corneal astigmatism;
PAAD	cis	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg11271282	chr2:238384023	NA	0.52	4.85	0.37	3.04e-6	Prostate cancer;
PAAD	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.2e-20	Electrocardiographic conduction measures;
PAAD	cis	rs73206853	0.841	rs11065631	chr12:110778383	A/G	cg12870014	chr12:110450643	ANKRD13A	0.73	4.72	0.36	5.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17447014	chr15:52821424	MYO5A	-0.65	-6.59	-0.47	6.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Alcohol dependence;
PAAD	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	cis	rs6142102	0.886	rs6142098	chr20:32688294	A/C	cg06115741	chr20:33292138	TP53INP2	0.57	4.79	0.36	3.95e-6	Skin pigmentation;
PAAD	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	4.79	0.36	4e-6	Schizophrenia;
PAAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.49	-4.27	-0.33	3.41e-5	Vitiligo;
PAAD	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg22601191	chr20:60968625	CABLES2	0.49	4.73	0.36	5.1e-6	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg03732007	chr1:2071316	PRKCZ	0.53	5.79	0.42	3.96e-8	Height;
PAAD	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.81	7.8	0.53	9.41e-13	Corneal astigmatism;
PAAD	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg23024343	chr7:107201750	COG5	0.58	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg26703956	chr19:39260304	NA	-0.47	-5.51	-0.41	1.52e-7	Heart rate;
PAAD	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg07856975	chr6:36356162	ETV7	0.46	5.24	0.39	5.38e-7	Platelet distribution width;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09976282	chr15:31357238	TRPM1;MIR211	0.67	7.09	0.5	4.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.79	7.95	0.54	3.82e-13	Uric acid levels;
PAAD	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.38	0.56	3.26e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg24330906	chr2:85765176	MAT2A	0.58	5.62	0.42	8.69e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	4.79	0.36	3.86e-6	Total body bone mineral density;
PAAD	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.84	10.2	0.64	6.29e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6715793	0.869	rs60000782	chr2:33421791	A/G	cg26672287	chr2:33391915	LTBP1	-0.42	-4.87	-0.37	2.74e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs60733400	0.509	rs56814247	chr1:2622489	A/G	cg01075559	chr1:2537774	MMEL1	-0.51	-5.27	-0.39	4.62e-7	Multiple sclerosis;
PAAD	cis	rs6494488	0.500	rs72742968	chr15:64919920	A/T	cg16425858	chr15:64791681	ZNF609	0.95	4.53	0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.49	-5.06	-0.38	1.18e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.49	-4.81	-0.36	3.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg20913747	chr6:44695427	NA	0.57	5.27	0.39	4.55e-7	Total body bone mineral density;
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg21665744	chr7:39171113	POU6F2	-0.33	-4.94	-0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.66	6.36	0.46	2.21e-9	Blood metabolite levels;
PAAD	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg05250797	chr16:70222502	NA	0.82	6.14	0.45	6.73e-9	IgE levels;
PAAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg05484376	chr2:27715224	FNDC4	0.48	4.72	0.36	5.22e-6	Total body bone mineral density;
PAAD	cis	rs12760731	0.720	rs10913535	chr1:178302914	C/A	cg00404053	chr1:178313656	RASAL2	0.68	4.86	0.37	2.86e-6	Obesity-related traits;
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.61	-0.35	8.61e-6	Testicular germ cell tumor;
PAAD	cis	rs17169635	0.836	rs3800739	chr7:134538147	A/G	cg02516134	chr7:134575187	CALD1	0.49	4.8	0.36	3.82e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	0.99	6.12	0.44	7.66e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.58	-5.77	-0.42	4.3e-8	Height;
PAAD	trans	rs9409082	0.798	rs7047281	chr9:108918634	C/A	cg07010948	chr13:79181613	NA	-0.34	-6.34	-0.46	2.42e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.48	6.13	0.45	7.12e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs859767	0.704	rs7558554	chr2:135357203	C/G	cg12500956	chr2:135428796	TMEM163	0.32	4.39	0.34	2.13e-5	Neuroticism;
PAAD	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.18	19.19	0.84	1.9e-42	Platelet distribution width;
PAAD	cis	rs7707921	1.000	rs7707921	chr5:81538046	T/A	cg21483461	chr5:81570383	RPS23	0.54	4.55	0.35	1.11e-5	Breast cancer;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.28	-0.51	1.7e-11	Longevity;
PAAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg11764359	chr7:65958608	NA	0.79	5.22	0.39	5.91e-7	Diabetic kidney disease;
PAAD	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.91	-5.03	-0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.75	7.88	0.54	5.75e-13	Gout;
PAAD	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.68	-6.39	-0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs12042107	0.656	rs1342780	chr1:91198676	A/C	cg13456504	chr1:91191583	NA	0.4	4.43	0.34	1.77e-5	Educational attainment;
PAAD	cis	rs7705042	0.865	rs6580225	chr5:141489381	G/C	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.25	-0.39	5.02e-7	Asthma;
PAAD	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.65	6.85	0.49	1.7e-10	Platelet distribution width;
PAAD	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.15	-0.39	7.95e-7	Fear of minor pain;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.91	-15.27	-0.78	1.67e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg23460851	chr4:1604456	NA	-0.41	-4.3	-0.33	3.07e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.57	5.45	0.4	2.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.617	rs9381365	chr6:45077975	G/A	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs2562456	0.833	rs11880624	chr19:21523830	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.54	-6.56	-0.47	7.82e-10	Mean corpuscular volume;
PAAD	trans	rs901683	0.850	rs75402959	chr10:46092807	C/G	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.07e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg08999081	chr20:33150536	PIGU	0.52	5.6	0.41	9.89e-8	Height;
PAAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.88	-0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.6	5.36	0.4	2.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-4.46	-0.34	1.61e-5	Self-reported allergy;
PAAD	cis	rs12153243	0.714	rs17341992	chr5:142893637	T/C	cg13907255	chr5:142895549	NA	-0.49	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.68	-6.34	-0.46	2.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.08e-7	Tonsillectomy;
PAAD	cis	rs412658	0.523	rs440597	chr19:22096519	T/C	cg07498013	chr19:22123504	NA	-0.41	-4.39	-0.34	2.12e-5	Telomere length;
PAAD	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	5.47	0.41	1.84e-7	LDL cholesterol;
PAAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg14983838	chr19:29218262	NA	-0.69	-6.15	-0.45	6.56e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2916733	0.887	rs2515582	chr8:6321814	G/C	cg01691696	chr8:6734962	DEFB1	-0.57	-4.43	-0.34	1.81e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.45	6.18	0.45	5.65e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7631605	0.905	rs4647215	chr3:37041320	C/A	cg17445812	chr3:36986805	TRANK1	0.34	4.59	0.35	9.18e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.71	-5.76	-0.42	4.48e-8	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg06219351	chr7:158114137	PTPRN2	-0.82	-7.51	-0.52	4.66e-12	Response to amphetamines;
PAAD	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg20406979	chr6:167373233	NA	-0.37	-4.97	-0.37	1.78e-6	Crohn's disease;
PAAD	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.59	4.5	0.34	1.37e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs62130978	0.509	rs243372	chr19:4432973	G/A	cg21934504	chr19:4445085	UBXN6	0.6	5.65	0.42	7.62e-8	Red cell distribution width;
PAAD	cis	rs10044254	0.614	rs4273604	chr5:15732604	A/C	cg07238450	chr5:15720153	FBXL7	-0.54	-5.07	-0.38	1.15e-6	Asthma (corticosteroid response);
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.79	0.48	2.33e-10	Bladder cancer;
PAAD	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg19192590	chr2:178524533	PDE11A	0.4	4.51	0.34	1.31e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.7	7.33	0.51	1.24e-11	Alcohol dependence;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg03167980	chr7:73021497	MLXIPL	-0.65	-6.33	-0.46	2.62e-9	Dental caries;
PAAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg03983715	chr16:68378420	PRMT7	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4716602	0.898	rs10249494	chr7:156159448	G/T	cg04090468	chr7:156181990	NA	0.5	4.78	0.36	4.15e-6	Anti-saccade response;
PAAD	cis	rs4727443	0.769	rs2283017	chr7:99574758	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.48	4.92	0.37	2.25e-6	Interstitial lung disease;
PAAD	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.83	10.59	0.65	5.61e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2235573	0.685	rs4384887	chr22:38447365	T/C	cg03989125	chr22:38214979	NA	-0.53	-5.49	-0.41	1.61e-7	Glioblastoma;Glioma;
PAAD	cis	rs6191	1.000	rs6191	chr5:142658156	C/A	cg08845721	chr5:142780693	NR3C1	0.39	4.3	0.33	3.04e-5	Night sleep phenotypes;
PAAD	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	0.8	6.31	0.46	2.97e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.62	4.81	0.36	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.44	6.99	0.49	8.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13732677	chr9:101017931	TBC1D2	-0.57	-6.37	-0.46	2.11e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.63	5.44	0.4	2.1e-7	Plateletcrit;
PAAD	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.56	5.98	0.44	1.5e-8	Eye color traits;
PAAD	cis	rs6009527	1.000	rs2873853	chr22:49573628	G/A	cg12746016	chr22:49560550	NA	0.47	4.93	0.37	2.15e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg05110241	chr16:68378359	PRMT7	-0.99	-5.88	-0.43	2.54e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21545522	chr1:205238299	TMCC2	0.47	4.26	0.33	3.51e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119038	0.818	rs4938572	chr11:118740931	C/T	cg04176122	chr11:118779835	BCL9L	-0.45	-4.55	-0.35	1.07e-5	Sjögren's syndrome;
PAAD	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg01444801	chr10:135216882	MTG1	-0.59	-5.2	-0.39	6.25e-7	Systemic lupus erythematosus;
PAAD	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	-0.46	-4.49	-0.34	1.43e-5	Lung cancer;
PAAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg07148914	chr20:33460835	GGT7	0.49	4.88	0.37	2.65e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.53	-8.49	-0.57	1.69e-14	Atopic dermatitis;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.73	6.3	0.45	3.11e-9	Alzheimer's disease;
PAAD	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	4.88	0.37	2.66e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.77	6.61	0.47	6.16e-10	Recombination rate (females);
PAAD	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.71	9.28	0.6	1.65e-16	Coronary artery disease;
PAAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.86	-0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs2046867	0.818	rs7620212	chr3:72778610	C/T	cg25664220	chr3:72788482	NA	-0.71	-7.22	-0.51	2.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg25886479	chr11:50257625	LOC441601	-0.41	-4.34	-0.33	2.61e-5	Coronary artery disease;
PAAD	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg02487422	chr3:49467188	NICN1	0.46	4.73	0.36	5.06e-6	Resting heart rate;
PAAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.69	7.1	0.5	4.42e-11	Morning vs. evening chronotype;
PAAD	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg11204139	chr17:3907470	NA	0.68	6.78	0.48	2.47e-10	Type 2 diabetes;
PAAD	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.66	0.48	4.81e-10	IgG glycosylation;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.74	7.45	0.52	6.43e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.63	-5.61	-0.41	9.41e-8	Lung cancer;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2284378	0.515	rs6059579	chr20:32527865	C/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.48	0.34	1.48e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.43	-4.98	-0.37	1.74e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.67	-5.15	-0.39	7.83e-7	Vitiligo;
PAAD	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg06766960	chr11:133703094	NA	-0.56	-5.71	-0.42	5.66e-8	Childhood ear infection;
PAAD	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg04877966	chr15:75135169	ULK3	0.55	4.65	0.35	7.07e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg21130718	chr4:1044621	NA	0.56	4.76	0.36	4.46e-6	Recombination rate (females);
PAAD	cis	rs2415984	0.558	rs754960	chr14:46962969	C/T	cg14871534	chr14:47121158	RPL10L	0.45	4.68	0.36	6.25e-6	Number of children ever born;
PAAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg06521852	chr22:38141419	TRIOBP	0.42	4.26	0.33	3.61e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg03999872	chr20:62272968	STMN3	0.59	5.29	0.39	4.15e-7	Atopic dermatitis;
PAAD	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.45	-0.34	1.67e-5	Breast cancer;
PAAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.74	-6.68	-0.48	4.21e-10	Systemic lupus erythematosus;
PAAD	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.75	8.85	0.58	2.14e-15	Blood metabolite ratios;
PAAD	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg02415014	chr8:143852576	LYNX1	0.44	5.87	0.43	2.65e-8	Urinary tract infection frequency;
PAAD	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.51	5.48	0.41	1.72e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg09471204	chr22:42347991	LOC339674	-0.33	-4.26	-0.33	3.6e-5	Cognitive function;
PAAD	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.61	5.99	0.44	1.46e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.09	-0.38	1.03e-6	High light scatter reticulocyte count;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-7.91	-0.54	4.82e-13	Hemoglobin concentration;
PAAD	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	0.89	8.41	0.56	2.8e-14	Breast cancer;
PAAD	cis	rs11615916	0.790	rs17660575	chr12:62751388	A/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs35785195	0.633	rs1035774	chr12:114230856	G/C	cg23469448	chr12:114232746	NA	0.58	4.51	0.34	1.27e-5	Daytime sleep phenotypes;
PAAD	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.69	7.53	0.52	4.29e-12	Schizophrenia;
PAAD	cis	rs11250714	0.845	rs4880899	chr10:1692433	G/T	cg10435618	chr10:838112	NA	-0.49	-4.63	-0.35	7.88e-6	Gut microbiome composition (summer);
PAAD	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.84	8.31	0.56	5.08e-14	Vitamin D levels;
PAAD	cis	rs1045902	0.583	rs36106493	chr2:73442339	C/T	cg24220031	chr2:73402428	NA	-0.4	-5.62	-0.41	8.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.11	-0.44	8.15e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg26338869	chr17:61819248	STRADA	0.5	4.69	0.36	6.05e-6	Height;
PAAD	cis	rs7998202	0.667	rs282569	chr13:113371507	T/C	cg19217778	chr13:113420270	ATP11A	0.6	4.3	0.33	3.08e-5	Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14156121	chr10:33948478	NA	-0.72	-7.39	-0.51	9.24e-12	Obesity-related traits;
PAAD	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12292205	chr6:26970375	C6orf41	-0.48	-4.52	-0.34	1.25e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.61	4.89	0.37	2.6e-6	Information processing speed;
PAAD	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg21775007	chr8:11205619	TDH	0.54	4.98	0.37	1.67e-6	Neuroticism;
PAAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01739569	chr14:31091426	SCFD1	-0.57	-6.64	-0.47	5.19e-10	Body fat percentage;
PAAD	cis	rs28374715	0.629	rs2118740	chr15:41577232	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.76	-0.74	1.75e-28	Ulcerative colitis;
PAAD	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.89	10.78	0.66	1.73e-20	Tonsillectomy;
PAAD	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.46	-7.19	-0.5	2.76e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1043763	0.826	rs9668430	chr12:122623595	A/G	cg26218692	chr12:122497826	BCL7A	-0.58	-5.51	-0.41	1.48e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-4.51	-0.34	1.29e-5	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26119529	chr3:62111228	ID2B;PTPRG	-0.54	-6.41	-0.46	1.69e-9	Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.44	5.69	0.42	6.36e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7551222	0.680	rs2125855	chr1:204546947	T/C	cg01064725	chr1:204461714	NA	-0.56	-4.79	-0.36	4.01e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24478926	chr11:69237550	NA	-0.66	-6.57	-0.47	7.63e-10	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg23018236	chr17:30244563	NA	-0.62	-4.67	-0.35	6.44e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.37	-0.4	2.95e-7	Height;
PAAD	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.6	6.82	0.48	2.02e-10	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg09695851	chr17:3907499	NA	-0.47	-4.37	-0.33	2.26e-5	Type 2 diabetes;
PAAD	cis	rs4740619	0.619	rs10810527	chr9:16043350	C/G	cg14451791	chr9:16040625	NA	0.45	5.13	0.38	8.55e-7	Body mass index;
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg01097406	chr16:89675127	NA	-0.37	-4.38	-0.34	2.17e-5	Vitiligo;
PAAD	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg15733309	chr7:157513707	PTPRN2	0.63	7.92	0.54	4.69e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	1.07	14.87	0.77	1.86e-31	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.9	-10.25	-0.64	4.64e-19	Prudent dietary pattern;
PAAD	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.96	8.41	0.56	2.82e-14	Bipolar disorder;
PAAD	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.33	-0.51	1.26e-11	Heart rate;
PAAD	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2735413	1.000	rs2735413	chr16:78053643	A/T	cg04733911	chr16:78082701	NA	-0.52	-4.88	-0.37	2.7e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs58521262	0.585	rs1645766	chr19:23209241	C/A	cg03433597	chr19:22806448	NA	0.24	4.26	0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-1.04	-14.62	-0.76	8.81e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12614442	chr1:147142665	ACP6	-0.73	-6.56	-0.47	7.78e-10	Neuroticism;
PAAD	cis	rs2221894	0.922	rs2323134	chr8:28839922	G/C	cg20212339	chr8:28908912	HMBOX1	0.5	5.21	0.39	6.08e-7	Obesity-related traits;
PAAD	cis	rs2070433	0.851	rs8129793	chr21:47925719	T/C	cg12379764	chr21:47803548	PCNT	0.54	4.77	0.36	4.37e-6	Lymphocyte counts;
PAAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	10.47	0.65	1.2e-19	Smoking behavior;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.8	-5.67	-0.42	6.9e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg16590910	chr6:42928470	GNMT	0.48	4.82	0.36	3.45e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg00262122	chr8:11665843	FDFT1	0.51	4.49	0.34	1.37e-5	Neuroticism;
PAAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg03037974	chr15:76606532	NA	0.53	6.25	0.45	3.96e-9	Blood metabolite levels;
PAAD	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg15193198	chr20:60906057	LAMA5	-0.5	-5.5	-0.41	1.6e-7	Colorectal cancer;
PAAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.53	-5.41	-0.4	2.45e-7	Immature fraction of reticulocytes;
PAAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.77	-6.97	-0.49	9.04e-11	Psoriasis;
PAAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.71	10.75	0.66	2.13e-20	Schizophrenia;
PAAD	cis	rs600550	0.588	rs61900468	chr11:60079555	C/T	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg06145435	chr7:1022769	CYP2W1	0.32	4.3	0.33	3.07e-5	Longevity;Endometriosis;
PAAD	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	4.56	0.35	1.03e-5	Mood instability;
PAAD	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg02415014	chr8:143852576	LYNX1	0.39	4.75	0.36	4.7e-6	Urinary tract infection frequency;
PAAD	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-6.5	-0.47	1.07e-9	Neuroticism;
PAAD	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-4.61	-0.35	8.58e-6	Tuberculosis;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg03909863	chr11:638404	DRD4	-0.57	-5.25	-0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	cis	rs1519814	0.696	rs7386139	chr8:121027419	C/T	cg22335954	chr8:121166405	COL14A1	-0.62	-4.75	-0.36	4.7e-6	Breast cancer;
PAAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.46	5.97	0.44	1.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.58	-5.72	-0.42	5.62e-8	Crohn's disease;
PAAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	9.68	0.62	1.5e-17	Personality dimensions;
PAAD	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs735539	0.521	rs2031353	chr13:21380474	C/A	cg27499820	chr13:21296301	IL17D	0.53	4.8	0.36	3.78e-6	Dental caries;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg00988841	chr10:134556463	INPP5A	0.52	4.79	0.36	3.93e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg18809830	chr7:99032528	PTCD1	-1.11	-4.89	-0.37	2.52e-6	Blood metabolite levels;
PAAD	cis	rs4453791	0.696	rs35330920	chr3:38956328	T/G	cg02254461	chr3:39195904	CSRNP1	0.58	5.09	0.38	1.03e-6	Social communication problems;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.47	5.46	0.4	1.94e-7	Cystic fibrosis severity;
PAAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.47e-6	Cognitive function;
PAAD	cis	rs3026101	0.624	rs1058383	chr17:5288203	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.53	0.41	1.33e-7	Body mass index;
PAAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.79	8.28	0.56	5.92e-14	Tuberculosis;
PAAD	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg11441379	chr12:63026424	NA	0.85	6.13	0.45	7.19e-9	IgG glycosylation;
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.84	9.12	0.59	4.29e-16	Corneal astigmatism;
PAAD	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.82	5.88	0.43	2.56e-8	Iron status biomarkers;
PAAD	cis	rs2278796	1.000	rs3892249	chr1:204947489	C/G	cg04862289	chr1:204966208	NFASC	0.45	4.58	0.35	9.53e-6	Mean platelet volume;
PAAD	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.84	0.43	3.04e-8	Lung disease severity in cystic fibrosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10996014	chr3:49449848	RHOA;TCTA	0.6	6.76	0.48	2.76e-10	Monocyte percentage of white cells;
PAAD	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.42	6.21	0.45	4.82e-9	Subjective well-being;
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg07061783	chr6:25882402	NA	-0.49	-5.06	-0.38	1.17e-6	Blood metabolite levels;
PAAD	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.64	5.87	0.43	2.63e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.91	12.04	0.7	7.27e-24	Prudent dietary pattern;
PAAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.72	6.77	0.48	2.67e-10	Monocyte count;
PAAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.75	6.96	0.49	9.36e-11	Coronary artery disease;
PAAD	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18337363	chr3:52569053	NT5DC2	-0.46	-4.85	-0.37	3.07e-6	Electroencephalogram traits;
PAAD	cis	rs7577696	0.597	rs11691939	chr2:32339561	A/G	cg02381751	chr2:32503542	YIPF4	0.49	4.79	0.36	4.01e-6	Inflammatory biomarkers;
PAAD	cis	rs2013441	0.613	rs12451841	chr17:20004875	G/A	cg13482628	chr17:19912719	NA	0.49	4.73	0.36	5.06e-6	Obesity-related traits;
PAAD	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.78e-5	Neuroticism;
PAAD	cis	rs1656368	0.553	rs12631704	chr3:158177751	A/G	cg16708174	chr3:158430962	RARRES1	0.56	4.65	0.35	7.29e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg02743256	chr7:2109353	MAD1L1	-0.72	-5.95	-0.43	1.8e-8	Bipolar disorder;
PAAD	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.56	4.54	0.35	1.14e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.53	6.48	0.47	1.22e-9	Psoriasis;
PAAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs3026101	0.624	rs55970234	chr17:5316765	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	6.02	0.44	1.28e-8	Body mass index;
PAAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.68	-8.61	-0.57	8.86e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	1.27	7.44	0.52	6.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs3753841	0.801	rs10782910	chr1:103317086	C/T	cg24495344	chr1:103574097	COL11A1	0.39	4.47	0.34	1.53e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.8	0.48	2.3e-10	Menarche (age at onset);
PAAD	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg16359550	chr11:109292809	C11orf87	0.22	4.46	0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs10916814	0.546	rs1890006	chr1:20898841	G/T	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4073221	0.520	rs1108439	chr3:18201319	A/G	cg07694806	chr3:18168406	NA	-0.91	-5.57	-0.41	1.11e-7	Parkinson's disease;
PAAD	cis	rs1329189	0.911	rs10764763	chr10:129998231	A/G	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.58e-6	Orofacial clefts;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.83	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg04482110	chr17:41364121	TMEM106A	0.4	4.61	0.35	8.51e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.03	-0.44	1.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.46	-0.41	1.87e-7	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14164252	chr22:51066919	ARSA	0.59	7.13	0.5	3.71e-11	Monocyte percentage of white cells;
PAAD	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.08	-0.44	9.5e-9	Bipolar disorder;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.64	7.19	0.5	2.69e-11	Vitiligo;
PAAD	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg19090574	chr1:205240910	TMCC2	0.4	4.27	0.33	3.46e-5	Red blood cell count;
PAAD	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.08	-0.38	1.08e-6	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14936158	chr2:178482258	TTC30A	-0.64	-6.58	-0.47	7.02e-10	Obesity-related traits;
PAAD	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg08992911	chr2:238395768	MLPH	0.91	6.48	0.47	1.18e-9	Prostate cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07754138	chr22:46973496	NA	-0.55	-6.36	-0.46	2.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.5	5.48	0.41	1.77e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg08501292	chr6:25962987	TRIM38	-0.9	-4.91	-0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13100165	1.000	rs12498092	chr3:73275538	C/T	cg07385778	chr3:72320634	NA	0.3	4.73	0.36	5.12e-6	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7551345	0.853	rs6425726	chr1:31742629	T/A	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs77651228	chr10:46056129	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.19	0.6	2.74e-16	Parkinson's disease;
PAAD	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.39	-0.34	2.11e-5	Life satisfaction;
PAAD	cis	rs6460942	0.749	rs79221452	chr7:12202897	T/C	cg06484146	chr7:12443880	VWDE	-0.7	-4.39	-0.34	2.12e-5	Coronary artery disease;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-5.88	-0.43	2.49e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg02169279	chr8:22733261	PEBP4	-0.48	-4.3	-0.33	3.01e-5	Waist-hip ratio;
PAAD	trans	rs12401457	0.748	rs16833108	chr1:236179042	G/T	cg17253517	chr5:93447700	FAM172A	0.82	6.29	0.45	3.19e-9	Urate levels in overweight individuals;
PAAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.41	-4.89	-0.37	2.54e-6	Psoriasis;
PAAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.63	-7.49	-0.52	5.21e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs77741769	0.571	rs11065284	chr12:121266621	G/A	cg02419362	chr12:121203948	SPPL3	0.54	5.98	0.44	1.51e-8	Mean corpuscular volume;
PAAD	cis	rs258892	0.895	rs266430	chr5:72125176	A/G	cg21869765	chr5:72125136	TNPO1	-0.8	-5.32	-0.4	3.63e-7	Small cell lung carcinoma;
PAAD	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-7.46	-0.52	6.27e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs354033	0.918	rs67256453	chr7:149314756	T/C	cg06920324	chr7:149264011	ZNF767	-0.6	-4.94	-0.37	2.07e-6	Multiple sclerosis;
PAAD	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.87	9.84	0.62	5.37e-18	Gout;
PAAD	cis	rs58521262	0.649	rs464598	chr19:23131067	A/C	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs1620921	0.505	rs4708882	chr6:161203182	C/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06915872	chr16:87998081	BANP	0.48	4.41	0.34	1.93e-5	Menopause (age at onset);
PAAD	cis	rs2051773	0.567	rs12288579	chr11:17039910	G/A	cg15432903	chr11:17409602	KCNJ11	-0.51	-4.6	-0.35	8.89e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.67	-5.75	-0.42	4.63e-8	Total ventricular volume;
PAAD	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.99	-0.38	1.61e-6	Pulmonary function;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13939156	chr17:80058883	NA	-0.41	-4.37	-0.33	2.33e-5	Life satisfaction;
PAAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg03983715	chr16:68378420	PRMT7	-0.91	-6.44	-0.46	1.49e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8084125	1.000	rs62102949	chr18:74939594	A/T	cg15443732	chr18:74961078	GALR1	0.61	4.74	0.36	4.85e-6	Obesity-related traits;
PAAD	cis	rs62025270	0.688	rs17575870	chr15:86257157	C/T	cg13263323	chr15:86062960	AKAP13	0.48	4.38	0.33	2.21e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg15660573	chr17:549704	VPS53	-0.6	-5.61	-0.41	9.44e-8	Prostate cancer;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-6.59	-0.47	6.72e-10	Lymphocyte counts;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg09835421	chr16:68378352	PRMT7	-0.79	-6.49	-0.47	1.12e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs7624766	0.594	rs1839017	chr3:160577670	A/G	cg22637730	chr3:160473554	PPM1L	-0.53	-4.6	-0.35	8.72e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.6	-4.51	-0.34	1.27e-5	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg13821571	chr21:34406537	NA	-0.46	-4.37	-0.33	2.26e-5	Gastritis;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs11761408	0.585	rs9986967	chr7:5258493	C/A	cg02820836	chr7:4652842	NA	-0.72	-4.35	-0.33	2.52e-5	Mean corpuscular volume;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.63	-7.17	-0.5	2.98e-11	Renal function-related traits (BUN);
PAAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	0.44	4.34	0.33	2.58e-5	Daytime sleep phenotypes;
PAAD	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	5.99	0.44	1.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09376238	chr14:96830058	ATG2B	0.63	7.3	0.51	1.5e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.54	6.21	0.45	4.73e-9	Monocyte count;
PAAD	cis	rs807669	0.869	rs807672	chr22:19157819	C/G	cg02655711	chr22:19163373	SLC25A1	0.82	10.41	0.64	1.76e-19	Metabolite levels;
PAAD	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg15654264	chr1:150340011	RPRD2	0.49	4.8	0.36	3.79e-6	Migraine;
PAAD	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.62	0.47	5.94e-10	Educational attainment;
PAAD	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg24053715	chr22:38214548	NA	-0.52	-5.31	-0.4	3.83e-7	Glioblastoma;Glioma;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18930143	chr12:8185050	FOXJ2	0.59	7.03	0.5	6.57e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.47	-0.52	5.77e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.55	-5.08	-0.38	1.11e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02071572	chr4:1403502	NA	-0.46	-5.82	-0.43	3.42e-8	Longevity;
PAAD	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.71	10.05	0.63	1.58e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.78	7.24	0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs4751058	0.607	rs4750732	chr10:130864640	C/T	cg27413539	chr10:131576096	NA	-0.58	-5.55	-0.41	1.26e-7	Vitamin D levels;
PAAD	cis	rs77880822	0.562	rs79601154	chr20:1233065	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	4.61	0.35	8.54e-6	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18853435	chr2:219263149	CTDSP1	-0.58	-6.31	-0.46	2.92e-9	Smoking initiation;
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.5	-4.8	-0.36	3.82e-6	Longevity;
PAAD	cis	rs2421770	0.532	rs4756216	chr11:35366112	G/A	cg13971030	chr11:35366721	SLC1A2	-0.56	-5.37	-0.4	2.83e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	1.08	15.19	0.78	2.77e-32	Breast cancer;
PAAD	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.93	-7.35	-0.51	1.12e-11	Initial pursuit acceleration;
PAAD	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9652601	0.779	rs7186106	chr16:11210831	G/A	cg04616529	chr16:11181986	CLEC16A	0.41	4.7	0.36	5.7e-6	Systemic lupus erythematosus;
PAAD	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.77	8.02	0.55	2.63e-13	Schizophrenia;
PAAD	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.83	-9.34	-0.6	1.12e-16	Coronary artery disease;
PAAD	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.84	9.72	0.62	1.15e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg13722127	chr7:150037890	RARRES2	0.52	5.27	0.39	4.63e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg03910582	chr17:19030146	GRAPL	-0.48	-4.48	-0.34	1.48e-5	Schizophrenia;
PAAD	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.52	4.84	0.37	3.21e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg06864796	chr17:48072833	DLX3	-0.65	-6.55	-0.47	8.41e-10	Dental caries;
PAAD	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.02	-0.38	1.42e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg18654377	chr3:49208889	KLHDC8B	0.46	4.27	0.33	3.46e-5	Menarche (age at onset);
PAAD	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.79	7.99	0.54	3.2e-13	Coronary artery disease;
PAAD	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.29	-0.33	3.21e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg22027985	chr11:4115532	RRM1	-0.46	-4.42	-0.34	1.88e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg25418670	chr11:30344373	C11orf46	0.65	6.28	0.45	3.42e-9	Morning vs. evening chronotype;
PAAD	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg22153407	chr1:230290089	GALNT2	0.49	5.0	0.38	1.55e-6	Coronary artery disease;
PAAD	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13198984	chr17:80129470	CCDC57	-0.43	-5.36	-0.4	3e-7	Life satisfaction;
PAAD	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg15654264	chr1:150340011	RPRD2	0.46	4.39	0.34	2.1e-5	Migraine;
PAAD	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.56	4.81	0.36	3.68e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg20607287	chr7:12443886	VWDE	-0.6	-4.87	-0.37	2.77e-6	Coronary artery disease;
PAAD	cis	rs12681963	0.614	rs2341178	chr8:30098195	C/T	cg23406830	chr8:30012838	DCTN6	-0.72	-4.47	-0.34	1.49e-5	Migraine;
PAAD	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.6	6.3	0.46	2.99e-9	Lewy body disease;
PAAD	cis	rs9810890	1.000	rs73198840	chr3:128502194	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg13870426	chr17:30244630	NA	0.75	6.31	0.46	2.86e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.08	-0.55	1.88e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-1.07	-7.55	-0.52	3.75e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6723108	0.603	rs3769023	chr2:135713703	G/A	cg26890182	chr2:135621176	ACMSD	0.3	4.27	0.33	3.41e-5	Type 2 diabetes;
PAAD	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.55	5.85	0.43	2.93e-8	Mean corpuscular volume;
PAAD	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.92	5.84	0.43	3e-8	Eosinophilic esophagitis;
PAAD	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg11262906	chr1:85462892	MCOLN2	-0.59	-4.58	-0.35	9.74e-6	Serum sulfate level;
PAAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73198874	chr3:128538514	A/T	cg19129842	chr3:128565090	NA	-0.87	-5.52	-0.41	1.43e-7	Dental caries;
PAAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Calcium levels;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg23947450	chr7:900037	UNC84A	-0.55	-4.48	-0.34	1.44e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1625975	0.681	rs4746090	chr10:73395483	C/T	cg26005973	chr10:72643678	PCBD1	0.73	5.05	0.38	1.23e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg22437258	chr11:111473054	SIK2	0.67	6.71	0.48	3.62e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.58	-7.21	-0.51	2.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg04106633	chr4:1044584	NA	0.66	5.46	0.4	1.9e-7	Recombination rate (females);
PAAD	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg12215294	chr3:40350768	EIF1B	0.48	4.79	0.36	3.95e-6	Renal cell carcinoma;
PAAD	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	4.9	0.37	2.41e-6	Prostate cancer;
PAAD	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-5.31	-0.4	3.81e-7	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12684684	chr2:219082027	ARPC2	0.73	7.87	0.54	6.34e-13	Obesity-related traits;
PAAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg15847926	chr7:2749597	AMZ1	-0.38	-4.82	-0.36	3.43e-6	Height;
PAAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	cis	rs12282928	1.000	rs10769343	chr11:48321098	G/A	cg22827986	chr11:48284249	OR4X1	0.41	5.22	0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg04518342	chr5:131593106	PDLIM4	0.47	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.82	-7.95	-0.54	3.89e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg09127314	chr1:152161683	NA	0.68	4.97	0.37	1.82e-6	Atopic dermatitis;
PAAD	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	-0.48	-5.33	-0.4	3.49e-7	Childhood body mass index;
PAAD	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	1.01	5.65	0.42	7.67e-8	Parkinson's disease;
PAAD	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.95	-9.79	-0.62	7.38e-18	Hair shape;
PAAD	cis	rs10214930	0.671	rs12534603	chr7:27652653	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.5	0.34	1.37e-5	Hypospadias;
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13198984	chr17:80129470	CCDC57	-0.36	-4.36	-0.33	2.4e-5	Life satisfaction;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg26856871	chr21:45363775	AGPAT3	0.58	6.67	0.48	4.39e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.45	-4.79	-0.36	3.87e-6	Coronary artery disease;
PAAD	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg05717871	chr11:638507	DRD4	-0.57	-5.47	-0.41	1.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs2882667	0.652	rs700622	chr5:138098551	T/C	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg18279126	chr7:2041391	MAD1L1	0.6	5.91	0.43	2.17e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs740474	0.533	rs3844598	chr5:140992235	A/G	cg15949553	chr5:141879669	NA	0.28	4.56	0.35	1.05e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.79	-7.86	-0.54	6.6e-13	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06500355	chr6:111804104	REV3L	-0.68	-6.67	-0.48	4.45e-10	Obesity-related traits;
PAAD	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg20159608	chr7:32802032	NA	-0.59	-5.99	-0.44	1.45e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27503015	chr2:162270453	NA	-0.59	-6.67	-0.48	4.55e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.6	4.47	0.34	1.5e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg05110241	chr16:68378359	PRMT7	-0.97	-7.47	-0.52	6.01e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.58	5.85	0.43	2.94e-8	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.27	-7.77	-0.53	1.09e-12	Body mass index;
PAAD	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg18612461	chr15:75251733	NA	-0.39	-4.29	-0.33	3.23e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	5.51	0.41	1.49e-7	Mood instability;
PAAD	cis	rs35995292	0.927	rs2190666	chr7:38919395	C/T	cg19327137	chr7:38886074	VPS41	0.49	4.89	0.37	2.54e-6	Subjective well-being (multi-trait analysis);
PAAD	cis	rs9367125	0.700	rs9381120	chr6:41996607	A/T	cg12151296	chr6:42013349	CCND3	-0.59	-4.46	-0.34	1.59e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.5	5.58	0.41	1.07e-7	Coronary artery disease;
PAAD	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.36	4.3	0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg21782813	chr7:2030301	MAD1L1	0.51	5.31	0.4	3.9e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	5.86	0.43	2.75e-8	Lung cancer;
PAAD	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.87	-8.21	-0.55	8.98e-14	Neurofibrillary tangles;
PAAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg14847009	chr1:175162515	KIAA0040	0.33	5.26	0.39	4.72e-7	Alcohol dependence;
PAAD	cis	rs2765041	1	rs2765041	chr14:103991478	T/A	cg09389931	chr14:103748217	NA	0.4	4.25	0.33	3.77e-5	High light scatter reticulocyte count;
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.42	-0.52	7.73e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg24053715	chr22:38214548	NA	-0.62	-6.57	-0.47	7.71e-10	Glioblastoma;Glioma;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.7	4.97	0.37	1.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.64	9.64	0.62	1.83e-17	Body mass index;
PAAD	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24110177	chr3:50126178	RBM5	-0.59	-6.54	-0.47	8.65e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12780845	0.928	rs11813029	chr10:17244915	T/C	cg00857480	chr10:17188594	TRDMT1	0.35	4.35	0.33	2.52e-5	Homocysteine levels;
PAAD	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.25	0.56	6.93e-14	Hypertriglyceridemia;
PAAD	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg17524180	chr13:113633600	MCF2L	-0.48	-5.18	-0.39	6.95e-7	Systolic blood pressure;
PAAD	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg00280220	chr17:61926910	NA	0.43	4.61	0.35	8.41e-6	Prudent dietary pattern;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13560548	chr3:10150139	C3orf24	0.49	4.27	0.33	3.38e-5	Alzheimer's disease;
PAAD	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.37	-5.56	-0.41	1.18e-7	Educational attainment (years of education);
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg06350203	chr17:34062219	RASL10B	0.5	4.47	0.34	1.54e-5	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs6466055	0.777	rs917114	chr7:104907507	C/T	cg04380332	chr7:105027541	SRPK2	0.66	7.44	0.52	6.87e-12	Schizophrenia;
PAAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.16	-0.39	7.46e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9333029	0.524	rs4660978	chr1:47396298	G/C	cg08644498	chr1:46502608	NA	-0.47	-4.36	-0.33	2.41e-5	Blood metabolite levels;
PAAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.75	-0.53	1.21e-12	HDL cholesterol;
PAAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg04106633	chr4:1044584	NA	0.64	5.4	0.4	2.52e-7	Recombination rate (females);
PAAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.25e-27	Height;
PAAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.63	4.63	0.35	7.85e-6	Alzheimer's disease (survival time);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17786216	chr6:142468191	VTA1	-0.54	-6.46	-0.46	1.34e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.74	-4.3	-0.33	3.04e-5	Left atrial antero-posterior diameter;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.86	10.36	0.64	2.32e-19	Prudent dietary pattern;
PAAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg03983715	chr16:68378420	PRMT7	-0.55	-4.25	-0.33	3.78e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg08999081	chr20:33150536	PIGU	0.61	6.74	0.48	3.06e-10	Height;
PAAD	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.46	-4.25	-0.33	3.65e-5	Vitiligo;
PAAD	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22509189	chr2:225307070	NA	-0.46	-4.56	-0.35	1.02e-5	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg15054260	chr8:90769710	RIPK2	0.59	6.53	0.47	9.46e-10	Thyroid cancer;
PAAD	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg21605333	chr4:119757512	SEC24D	2.0	10.54	0.65	7.83e-20	Cannabis dependence symptom count;
PAAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.57	-6.52	-0.47	9.89e-10	Aortic root size;
PAAD	cis	rs2229238	0.911	rs7526293	chr1:154444209	T/C	cg21262032	chr1:154437693	IL6R	0.46	4.77	0.36	4.37e-6	Coronary heart disease;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg02776659	chr21:47717406	C21orf57	0.45	4.93	0.37	2.16e-6	Testicular germ cell tumor;
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.98	0.44	1.5e-8	Body mass index;
PAAD	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-4.5	-0.34	1.37e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Educational attainment;
PAAD	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.81	9.05	0.59	6.4e-16	Type 2 diabetes;
PAAD	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-1.19	-10.34	-0.64	2.58e-19	Height;
PAAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.93	10.51	0.65	9.29e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg10253484	chr15:75165896	SCAMP2	-0.54	-4.44	-0.34	1.69e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.82	-8.27	-0.56	6.1e-14	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs67257959	0.739	rs10416982	chr19:17202933	C/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.47	4.61	0.35	8.52e-6	Selective IgA deficiency;
PAAD	trans	rs901683	1.000	rs35626777	chr10:46088167	G/C	cg06308084	chr22:50493570	TTLL8	0.88	6.47	0.46	1.28e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg20312557	chr2:97357134	FER1L5	-0.82	-4.38	-0.33	2.17e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.86	-5.28	-0.39	4.3e-7	Cholesterol, total;
PAAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.74	6.83	0.48	1.95e-10	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg14393609	chr7:65229607	NA	-0.48	-4.63	-0.35	7.79e-6	Aortic root size;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.44e-7	Life satisfaction;
PAAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19346786	chr7:2764209	NA	-0.35	-4.6	-0.35	9.02e-6	Height;
PAAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg09017928	chr7:158110068	PTPRN2	0.45	4.42	0.34	1.89e-5	Calcium levels;
PAAD	cis	rs12476592	0.602	rs262487	chr2:63880517	G/T	cg10828910	chr2:63850056	LOC388955	-0.51	-4.36	-0.33	2.34e-5	Childhood ear infection;
PAAD	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.97	10.39	0.64	1.92e-19	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.75	7.77	0.53	1.1e-12	Height;
PAAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.5	5.39	0.4	2.67e-7	Height;
PAAD	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.82	-9.22	-0.6	2.32e-16	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg04738700	chr2:239367308	NA	0.46	5.01	0.38	1.51e-6	Multiple system atrophy;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.4	0.4	2.47e-7	Prudent dietary pattern;
PAAD	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.74	-8.79	-0.58	2.94e-15	Body mass index;
PAAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.72	0.36	5.2e-6	Dental caries;
PAAD	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg25457927	chr22:38595422	NA	0.49	7.66	0.53	2.07e-12	Cutaneous nevi;
PAAD	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-1.05	-14.77	-0.77	3.53e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11997175	0.625	rs7018213	chr8:33625770	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	6.25	0.45	3.94e-9	Body mass index;
PAAD	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.89	-7.54	-0.52	3.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.45	-4.28	-0.33	3.33e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.65	8.42	0.56	2.64e-14	Hypertriglyceridemia;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg13870426	chr17:30244630	NA	-0.72	-6.33	-0.46	2.65e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs9810890	1.000	rs73207974	chr3:128568455	T/C	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.52	-7.3	-0.51	1.51e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs58521262	0.556	rs289334	chr19:23152964	C/T	cg02350677	chr19:23254381	NA	0.26	4.43	0.34	1.78e-5	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs950037	0.710	rs6671230	chr1:89255039	C/T	cg13109106	chr1:89333529	GTF2B	-0.47	-4.54	-0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.45	0.34	1.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.74	-5.12	-0.38	9.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg21253087	chr9:139290292	SNAPC4	0.43	4.39	0.34	2.15e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.75	8.64	0.57	7.19e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.91	11.47	0.68	2.53e-22	Methadone dose in opioid dependence;
PAAD	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	6.98	0.49	8.47e-11	Educational attainment;
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.08	-0.38	1.08e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07325041	chr3:17783979	TBC1D5	0.58	6.31	0.46	2.97e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg26394196	chr10:1453818	ADARB2	0.58	6.59	0.47	6.96e-10	Radiation response;
PAAD	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	1.06	14.37	0.76	3.99e-30	Metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08018789	chr16:90039187	AFG3L1;CENPBD1	-0.61	-6.99	-0.49	8.08e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21501234	chr15:64683155	TRIP4	0.6	6.32	0.46	2.73e-9	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26082320	chr14:23240781	OXA1L	-0.63	-6.54	-0.47	8.7e-10	Obesity-related traits;
PAAD	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg04165759	chr1:150448943	RPRD2	0.52	5.45	0.4	2.04e-7	Migraine;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg02462569	chr6:150064036	NUP43	0.47	5.3	0.39	4.01e-7	Lung cancer;
PAAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11771526	0.681	rs6956350	chr7:32403428	C/A	cg13207630	chr7:32358064	NA	0.89	4.47	0.34	1.54e-5	Body mass index;
PAAD	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.53	0.41	1.35e-7	Ileal carcinoids;
PAAD	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	11.18	0.67	1.52e-21	Monocyte count;
PAAD	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-5.91	-0.43	2.18e-8	Blood protein levels;
PAAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.76	7.79	0.53	9.5e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.68	7.3	0.51	1.46e-11	Blood protein levels;
PAAD	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.64	-0.35	7.42e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.14	-0.45	6.92e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17162190	0.698	rs3816539	chr1:26786627	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.7	0.36	5.71e-6	Mean corpuscular volume;
PAAD	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.13	-0.38	8.53e-7	Neuroticism;
PAAD	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.69	5.76	0.42	4.43e-8	Common traits (Other);
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.9	-7.57	-0.52	3.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	9.67	0.62	1.52e-17	Monocyte percentage of white cells;
PAAD	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.8	8.03	0.55	2.49e-13	Retinal vascular caliber;
PAAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs4338575	0.785	rs12426561	chr12:77721709	A/G	cg08610361	chr12:77459885	E2F7	0.5	4.35	0.33	2.47e-5	Methadone dose in opioid dependence;
PAAD	cis	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.7	7.16	0.5	3.3e-11	Response to antidepressants and depression;
PAAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.28	0.51	1.7e-11	Hip circumference adjusted for BMI;
PAAD	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-6.32	-0.46	2.79e-9	Colorectal cancer;
PAAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.8	5.84	0.43	3.13e-8	Ulcerative colitis;
PAAD	cis	rs2790216	1.000	rs2790222	chr10:59995438	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.75e-5	Morning vs. evening chronotype;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.57	7.22	0.51	2.36e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16718920	chr1:21113643	HP1BP3	0.65	6.59	0.47	6.83e-10	Myopia (pathological);
PAAD	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg03684893	chr10:554711	DIP2C	0.57	5.79	0.43	3.86e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.62	-5.69	-0.42	6.41e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg26247942	chr15:43984922	CKMT1A	0.36	4.35	0.33	2.51e-5	Schizophrenia;
PAAD	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.44	-4.46	-0.34	1.57e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.39	0.34	2.15e-5	Total body bone mineral density;
PAAD	cis	rs28655083	0.785	rs7404856	chr16:77130339	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	4.25	0.33	3.72e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.94	-8.44	-0.56	2.33e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs11825685	0.836	rs77575039	chr11:134578532	C/T	cg06603561	chr11:134479413	NA	-0.64	-4.26	-0.33	3.64e-5	IgG glycosylation;
PAAD	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg24253500	chr15:84953950	NA	0.56	6.3	0.46	3e-9	Schizophrenia;
PAAD	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg08898775	chr15:59042684	ADAM10	0.41	5.39	0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg00149659	chr3:10157352	C3orf10	1.11	8.15	0.55	1.22e-13	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg20003494	chr4:90757398	SNCA	0.4	4.53	0.35	1.16e-5	Dementia with Lewy bodies;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18855426	chr11:20631935	SLC6A5	-0.59	-6.81	-0.48	2.11e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6785206	0.504	rs34992870	chr3:128503052	A/G	cg19205850	chr3:128446370	RAB7A	0.67	5.15	0.39	7.95e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.78	-9.49	-0.61	4.68e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg27129171	chr3:47204927	SETD2	0.73	8.01	0.54	2.77e-13	Birth weight;
PAAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg09796270	chr17:17721594	SREBF1	0.43	4.64	0.35	7.42e-6	Total body bone mineral density;
PAAD	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.58	-4.98	-0.37	1.71e-6	Type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.57	5.51	0.41	1.5e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg14458575	chr2:238380390	NA	0.62	5.45	0.4	2.03e-7	Prostate cancer;
PAAD	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.92	-0.49	1.19e-10	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05665937	chr4:1216051	CTBP1	-0.46	-4.81	-0.36	3.67e-6	Obesity-related traits;
PAAD	cis	rs17776563	0.959	rs11857151	chr15:89112877	C/G	cg27664085	chr15:89157815	NA	0.32	4.28	0.33	3.25e-5	Thyroid hormone levels;
PAAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs13065560	0.593	rs9818630	chr3:38930307	T/G	cg01426195	chr3:39028469	NA	-0.58	-5.92	-0.43	2.06e-8	Interleukin-18 levels;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg14349672	chr11:133703707	NA	-0.56	-6.26	-0.45	3.83e-9	Childhood ear infection;
PAAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.73	8.61	0.57	8.4e-15	Emphysema distribution in smoking;
PAAD	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg00647317	chr7:50633725	DDC	0.47	4.92	0.37	2.21e-6	Systemic sclerosis;
PAAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.74	-7.58	-0.52	3.24e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg12458913	chr13:53173898	NA	0.56	5.45	0.4	1.99e-7	Lewy body disease;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	17.3	0.81	9.45e-38	Prudent dietary pattern;
PAAD	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.13	-0.38	8.61e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg00431813	chr7:1051703	C7orf50	0.75	4.54	0.35	1.15e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.53	-5.53	-0.41	1.34e-7	Lung cancer;
PAAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-5.47	-0.41	1.83e-7	Electroencephalogram traits;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.61	6.69	0.48	3.94e-10	Height;
PAAD	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.99	-12.82	-0.72	5.62e-26	Coronary artery disease;
PAAD	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-7.64	-0.53	2.21e-12	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.52	5.38	0.4	2.75e-7	Hemoglobin concentration;
PAAD	cis	rs7132746	0.553	rs61928890	chr12:86185637	A/T	cg18827107	chr12:86230957	RASSF9	-0.49	-4.71	-0.36	5.55e-6	Lewy body disease;
PAAD	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.39	5.83	0.43	3.24e-8	Educational attainment (years of education);
PAAD	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.43	10.08	0.63	1.26e-18	Opioid sensitivity;
PAAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Androgen levels;
PAAD	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.79	8.24	0.56	7.39e-14	Selective IgA deficiency;
PAAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg27539214	chr16:67997921	SLC12A4	-0.62	-4.95	-0.37	1.96e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg19254793	chr6:44695348	NA	-0.46	-4.38	-0.33	2.22e-5	Total body bone mineral density;
PAAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.29	0.6	1.49e-16	Gut microbiome composition (summer);
PAAD	cis	rs10214930	0.813	rs961725	chr7:27658070	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.48	-0.34	1.46e-5	Neuroticism;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg07202610	chr7:1142643	C7orf50	-0.76	-5.38	-0.4	2.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.3	0.33	3.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8077577	0.945	rs34474249	chr17:18074525	T/C	cg16794390	chr17:18148240	FLII	0.58	4.88	0.37	2.68e-6	Obesity-related traits;
PAAD	cis	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-15.33	-0.78	1.14e-32	Height;
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.48	2.25e-10	Blood metabolite levels;
PAAD	cis	rs7534824	0.543	rs72734254	chr1:101382039	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs11671653	0.688	rs11671888	chr19:10838381	C/T	cg16667279	chr19:11591998	ELAVL3	-0.73	-4.7	-0.36	5.75e-6	LDL cholesterol;
PAAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg09835421	chr16:68378352	PRMT7	-0.67	-5.2	-0.39	6.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9815354	1.000	rs1716683	chr3:41923074	A/G	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7714584	1.000	rs2115069	chr5:150252365	G/A	cg22134413	chr5:150180641	NA	0.78	5.48	0.41	1.7e-7	Crohn's disease;
PAAD	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg14346243	chr4:90757452	SNCA	0.5	4.39	0.34	2.14e-5	Neuroticism;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.54	-4.26	-0.33	3.62e-5	Coronary artery disease;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg05717871	chr11:638507	DRD4	-0.58	-5.49	-0.41	1.62e-7	Systemic lupus erythematosus;
PAAD	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.9	5.83	0.43	3.17e-8	Prostate cancer;
PAAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.43	0.4	2.23e-7	Personality dimensions;
PAAD	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.25	0.33	3.78e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26856583	chr16:87425887	MAP1LC3B;FBXO31	0.59	6.41	0.46	1.78e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.9	11.03	0.67	3.75e-21	Dental caries;
PAAD	cis	rs7567389	0.677	rs6757492	chr2:127995332	G/A	cg09760422	chr2:128146352	NA	-0.4	-6.26	-0.45	3.83e-9	Self-rated health;
PAAD	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.5	0.47	1.09e-9	Mean platelet volume;
PAAD	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	10.39	0.64	1.95e-19	Testicular germ cell tumor;
PAAD	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.71	7.99	0.54	3.18e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg15847926	chr7:2749597	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-6.25	-0.45	3.86e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3931020	0.745	rs1969111	chr1:75263485	A/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.57	-5.7	-0.42	6.11e-8	Resistin levels;
PAAD	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.69	7.43	0.52	7.25e-12	Triglyceride levels;
PAAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.84	8.53	0.57	1.34e-14	Blood protein levels;
PAAD	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.9	9.71	0.62	1.19e-17	Breast cancer;
PAAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.14	6.98	0.49	8.43e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs15676	0.947	rs3115874	chr9:131579338	G/C	cg00228799	chr9:131580591	ENDOG	0.65	6.49	0.47	1.15e-9	Blood metabolite levels;
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.6	-6.09	-0.44	8.9e-9	Blood metabolite levels;
PAAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs35000415	0.938	rs34725944	chr7:128641653	T/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs11811982	0.744	rs116035891	chr1:227618836	G/A	cg06057666	chr1:227327429	CDC42BPA	0.74	4.66	0.35	6.89e-6	Optic disc area;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.92	-12.36	-0.71	1.01e-24	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.44	5.14	0.38	8.39e-7	Coronary artery disease;
PAAD	cis	rs216303	0.642	rs216314	chr12:6136580	T/C	cg12895370	chr12:6755816	ACRBP	-0.59	-4.62	-0.35	8.03e-6	Low vWF levels;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg01868782	chr6:126071099	HEY2	0.46	5.48	0.41	1.77e-7	Brugada syndrome;
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.06	-17.86	-0.82	3.68e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.76	-7.0	-0.49	7.7e-11	Body mass index;
PAAD	cis	rs1468333	1.000	rs4835671	chr5:137511801	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.16	0.45	6.19e-9	Resting heart rate;
PAAD	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.5	-0.41	1.58e-7	Height;
PAAD	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg13332499	chr17:408570	NA	0.64	7.11	0.5	4.27e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2834902	0.605	rs13048915	chr21:36683519	C/A	cg04915566	chr21:36421472	RUNX1	-0.33	-4.47	-0.34	1.53e-5	Corneal curvature;
PAAD	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.36	-4.42	-0.34	1.88e-5	Schizophrenia;
PAAD	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.37	4.56	0.35	1.02e-5	Corneal astigmatism;
PAAD	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg16342193	chr10:102329863	NA	0.74	8.25	0.56	7.15e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg03808351	chr9:123631620	PHF19	0.47	5.14	0.38	8.43e-7	Rheumatoid arthritis;
PAAD	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs7072216	0.687	rs10883087	chr10:100156990	T/A	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg11764359	chr7:65958608	NA	0.51	4.67	0.35	6.62e-6	Corneal structure;
PAAD	cis	rs12576326	1.000	rs35403813	chr11:44980322	G/A	cg07619142	chr11:44971049	TP53I11	-0.55	-5.15	-0.39	7.99e-7	Resting heart rate;
PAAD	cis	rs990171	1.000	rs1035127	chr2:103019919	C/T	cg03938978	chr2:103052716	IL18RAP	-0.43	-4.29	-0.33	3.17e-5	Lymphocyte counts;
PAAD	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg22437258	chr11:111473054	SIK2	-0.65	-6.38	-0.46	2.02e-9	Primary sclerosing cholangitis;
PAAD	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-4.81	-0.36	3.65e-6	Height;
PAAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg00257455	chr1:65530538	NA	-0.4	-4.36	-0.33	2.43e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.08	0.59	5.46e-16	Menopause (age at onset);
PAAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg04844267	chr4:1394941	NA	0.45	5.0	0.38	1.54e-6	Longevity;
PAAD	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.3	8.51	0.57	1.56e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	1.1	12.03	0.7	7.56e-24	Gut microbiota (bacterial taxa);
PAAD	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.83	0.48	1.92e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg09835421	chr16:68378352	PRMT7	-0.89	-6.9	-0.49	1.33e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04916103	chr17:4270032	UBE2G1	-0.58	-6.64	-0.47	5.35e-10	Body fat percentage;
PAAD	cis	rs6604026	0.656	rs11164844	chr1:93416650	C/A	cg13858687	chr1:93297071	RPL5	0.46	4.26	0.33	3.52e-5	Multiple sclerosis;
PAAD	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2077654	0.556	rs2299638	chr11:17443587	A/G	cg25308976	chr11:17434268	ABCC8	-0.7	-5.0	-0.38	1.56e-6	Gout;
PAAD	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-1.06	-9.79	-0.62	7.39e-18	Prostate cancer;
PAAD	cis	rs507080	0.885	rs7926959	chr11:118559866	T/C	cg08498647	chr11:118550644	TREH	-0.37	-4.27	-0.33	3.49e-5	Serum metabolite levels;
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg05042697	chr2:10830656	NOL10	0.43	4.25	0.33	3.71e-5	Prostate cancer;
PAAD	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.41	4.58	0.35	9.46e-6	Height;
PAAD	cis	rs16975963	0.843	rs1056405	chr19:38313021	T/C	cg08679971	chr19:38281047	NA	0.54	5.09	0.38	1.04e-6	Longevity;
PAAD	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.54	-0.35	1.13e-5	Iron status biomarkers;
PAAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.55	5.2	0.39	6.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg26939375	chr7:64535504	NA	0.76	9.17	0.6	3.06e-16	Aortic root size;
PAAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg18370025	chr7:2749541	AMZ1	-0.38	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs10425465	0.548	rs33840	chr19:34010289	T/C	cg02272751	chr19:33882848	PEPD	-0.36	-4.42	-0.34	1.88e-5	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.49	5.14	0.38	8.33e-7	Lung cancer;
PAAD	trans	rs12714314	0.914	rs12986730	chr2:1959401	G/A	cg17170872	chr1:91487911	ZNF644	-0.73	-6.4	-0.46	1.83e-9	Type 2 diabetes (age of onset);
PAAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg18944383	chr4:111397179	ENPEP	0.65	7.57	0.52	3.39e-12	Coronary artery disease;
PAAD	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.4	-0.46	1.83e-9	Neuroticism;
PAAD	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg24562669	chr7:97807699	LMTK2	-0.72	-10.74	-0.66	2.31e-20	Breast cancer;
PAAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.91	-7.82	-0.54	8.14e-13	Gut microbiome composition (summer);
PAAD	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-4.69	-0.36	6.05e-6	Schizophrenia;
PAAD	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.41	0.65	1.69e-19	Electrocardiographic conduction measures;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00166722	chr3:10149974	C3orf24	0.94	7.96	0.54	3.77e-13	Alzheimer's disease;
PAAD	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.98	10.92	0.66	7.29e-21	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg00147160	chr1:26503991	CNKSR1	0.41	4.73	0.36	4.99e-6	QRS complex (12-leadsum);
PAAD	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.85	9.52	0.61	3.87e-17	Mortality in heart failure;
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	1.01	8.31	0.56	4.84e-14	Initial pursuit acceleration;
PAAD	cis	rs7487075	0.619	rs4768718	chr12:46834336	G/C	cg09447675	chr12:46877466	NA	-0.47	-4.3	-0.33	3.09e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1144333	0.655	rs17097695	chr1:76387258	A/C	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg03733263	chr8:22462867	KIAA1967	-0.81	-9.51	-0.61	4.07e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.63	5.16	0.39	7.61e-7	Pulse pressure;
PAAD	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.65	9.89	0.63	3.99e-18	Migraine;
PAAD	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.49	5.04	0.38	1.29e-6	Bladder cancer;
PAAD	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.35	4.36	0.33	2.38e-5	Body mass index in non-asthmatics;
PAAD	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs11264213	0.591	rs538638	chr1:36534644	G/T	cg27506609	chr1:36549197	TEKT2	-0.83	-6.12	-0.44	7.56e-9	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26926768	chr12:34528122	NA	0.37	4.58	0.35	9.79e-6	Morning vs. evening chronotype;
PAAD	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg14440974	chr22:39074834	NA	-0.56	-6.7	-0.48	3.86e-10	Menopause (age at onset);
PAAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.97	0.59	1.06e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg19254793	chr6:44695348	NA	0.47	4.42	0.34	1.85e-5	Total body bone mineral density;
PAAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg00536532	chr6:33561449	C6orf227	-0.42	-4.38	-0.33	2.2e-5	Plateletcrit;
PAAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs10861342	0.892	rs11112378	chr12:105514033	A/G	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg15117754	chr3:10150083	C3orf24	0.75	6.73	0.48	3.25e-10	Alzheimer's disease;
PAAD	trans	rs2249625	0.679	rs9342924	chr6:72823754	G/A	cg04413069	chr12:9800446	LOC374443	-0.59	-6.54	-0.47	8.69e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs8040855	0.627	rs11634975	chr15:85606478	T/C	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00373665	chr1:234735703	NA	0.57	6.41	0.46	1.75e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-15.03	-0.77	7.28e-32	Height;
PAAD	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.54	-5.21	-0.39	5.93e-7	Dialysis-related mortality;
PAAD	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg27499820	chr13:21296301	IL17D	-0.52	-5.14	-0.38	8.39e-7	Dental caries;
PAAD	cis	rs8112211	0.731	rs8101488	chr19:38825094	A/G	cg14299480	chr19:38876666	GGN	-0.58	-5.75	-0.42	4.86e-8	Blood protein levels;
PAAD	cis	rs732765	0.657	rs10139082	chr14:75223338	C/A	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg09491104	chr22:46646882	C22orf40	-0.94	-6.05	-0.44	1.07e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.52	-5.09	-0.38	1.04e-6	Motion sickness;
PAAD	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.63	-6.51	-0.47	1.02e-9	Height;
PAAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.31	-0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg10011062	chr15:43941034	CATSPER2	0.72	4.57	0.35	9.95e-6	Lung cancer in ever smokers;
PAAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05454323	chr22:42978119	RRP7B	-0.6	-6.55	-0.47	8.25e-10	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01996304	chr16:31085596	ZNF668;ZNF646	0.66	6.7	0.48	3.74e-10	Obesity-related traits;
PAAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	1.16	10.49	0.65	1.06e-19	Eosinophil percentage of granulocytes;
PAAD	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg04450456	chr4:17643702	FAM184B	-0.47	-4.86	-0.37	2.95e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.83	9.95	0.63	2.76e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg00576331	chr11:65640516	EFEMP2	-0.49	-4.9	-0.37	2.46e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6585424	1.000	rs34100029	chr10:81923598	C/G	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs13092825	0.857	rs17325304	chr3:113303278	G/A	cg18753928	chr3:113234510	CCDC52	-0.46	-4.43	-0.34	1.77e-5	Dental caries;
PAAD	cis	rs58521262	0.556	rs388507	chr19:23122614	C/A	cg03433597	chr19:22806448	NA	-0.24	-4.4	-0.34	2.07e-5	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.21	-0.5	2.49e-11	Response to antipsychotic treatment;
PAAD	cis	rs2790457	0.958	rs2807754	chr10:28887192	C/T	cg05705492	chr10:28955341	NA	-0.43	-4.3	-0.33	3.06e-5	Multiple myeloma;
PAAD	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.66	7.35	0.51	1.13e-11	Carotid intima media thickness;
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.82	6.1	0.44	8.29e-9	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22532997	chr6:25279002	LRRC16A	0.6	6.6	0.47	6.59e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg22437258	chr11:111473054	SIK2	0.63	6.17	0.45	5.89e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.24	-0.39	5.37e-7	Daytime sleep phenotypes;
PAAD	trans	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg03188948	chr7:1209495	NA	1.07	5.41	0.4	2.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939584	1.000	rs6749375	chr2:636017	C/T	cg14515364	chr2:636606	NA	0.5	4.61	0.35	8.56e-6	Body mass index;
PAAD	cis	rs6540	1.000	rs12274855	chr11:262234	C/T	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs3925075	0.500	rs7193943	chr16:31271063	C/T	cg02846316	chr16:31340340	ITGAM	0.48	5.62	0.41	9.07e-8	IgA nephropathy;
PAAD	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.58	0.52	3.2e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	5.95	0.43	1.79e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg02725872	chr8:58115012	NA	-0.6	-5.16	-0.39	7.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-5.44	-0.4	2.08e-7	Coronary artery disease;
PAAD	cis	rs11212260	0.678	rs11212204	chr11:107267630	G/T	cg25435332	chr11:107328525	CWF19L2	1.33	6.43	0.46	1.53e-9	IgG glycosylation;
PAAD	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22442454	chr1:209979470	IRF6	0.61	5.74	0.42	4.96e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg00701064	chr4:6280414	WFS1	0.78	5.97	0.44	1.62e-8	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs17095355	0.901	rs11194947	chr10:111763731	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.31	-0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg21546286	chr11:48923668	NA	-0.57	-5.93	-0.43	1.98e-8	HDL cholesterol;
PAAD	cis	rs427941	0.703	rs201442	chr7:101737627	C/T	cg06246474	chr7:101738831	CUX1	-0.44	-4.58	-0.35	9.65e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.39e-8	Height;
PAAD	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.57	6.49	0.47	1.16e-9	Mean corpuscular volume;
PAAD	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.77	-5.88	-0.43	2.5e-8	Mean platelet volume;
PAAD	cis	rs12935418	0.583	rs2549836	chr16:81023081	T/C	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.32e-8	Mean corpuscular volume;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg11941060	chr3:133502564	NA	-0.61	-6.27	-0.45	3.56e-9	Iron status biomarkers;
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg08994789	chr17:28903642	LRRC37B2	0.61	4.65	0.35	7.12e-6	Body mass index;
PAAD	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs6499755	0.768	rs31097	chr16:55368635	A/G	cg02859129	chr16:55357253	IRX6	-0.37	-5.16	-0.39	7.5e-7	Hypospadias;
PAAD	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.9	10.77	0.66	1.9e-20	Tonsillectomy;
PAAD	cis	rs16958440	0.867	rs12326465	chr18:44678645	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.39	0.4	2.59e-7	Sitting height ratio;
PAAD	cis	rs6907629	0.776	rs1999375	chr6:167576698	A/C	cg18761763	chr6:168424818	KIF25	0.29	4.25	0.33	3.73e-5	Asthma (childhood onset);
PAAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.75	9.32	0.6	1.3e-16	Bone mineral density;
PAAD	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg25150519	chr12:98850993	NA	0.54	5.48	0.41	1.75e-7	Colorectal adenoma (advanced);
PAAD	cis	rs12760731	0.623	rs2295019	chr1:178451732	A/G	cg00404053	chr1:178313656	RASAL2	0.59	4.37	0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg06636001	chr8:8085503	FLJ10661	-0.81	-8.21	-0.55	9.04e-14	Triglycerides;
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.24	0.45	4.23e-9	Lung cancer;
PAAD	cis	rs6499755	0.712	rs31088	chr16:55363336	A/C	cg02859129	chr16:55357253	IRX6	0.36	5.0	0.38	1.56e-6	Hypospadias;
PAAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.77	-7.92	-0.54	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2286379	0.777	rs2286384	chr12:1891043	G/C	cg05227549	chr12:1770782	NA	0.44	5.22	0.39	5.77e-7	Blood pressure (smoking interaction);
PAAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.44	5.49	0.41	1.68e-7	Psoriasis;
PAAD	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.74	-0.36	4.95e-6	Resting heart rate;
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.66	6.54	0.47	9e-10	Blood metabolite levels;
PAAD	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg01839639	chr16:202542	HBZ	0.31	4.87	0.37	2.79e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs72960926	0.744	rs1552568	chr6:75035349	G/T	cg03266952	chr6:74778945	NA	-0.83	-5.13	-0.38	8.82e-7	Metabolite levels (MHPG);
PAAD	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.7	-6.85	-0.49	1.73e-10	Platelet distribution width;
PAAD	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19671926	chr4:122722719	EXOSC9	0.51	4.99	0.38	1.64e-6	Type 2 diabetes;
PAAD	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.48	-4.39	-0.34	2.14e-5	Asthma;
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.37	5.02	0.38	1.44e-6	Age at first birth;
PAAD	cis	rs7098414	0.530	rs12220655	chr10:82219066	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	8.58	0.57	1.03e-14	Post bronchodilator FEV1;
PAAD	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.63	6.23	0.45	4.36e-9	Coronary artery disease;
PAAD	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg22827986	chr11:48284249	OR4X1	-0.36	-4.75	-0.36	4.59e-6	Migraine - clinic-based;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg16920238	chr17:80076378	CCDC57	0.45	4.28	0.33	3.33e-5	Life satisfaction;
PAAD	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg16898833	chr6:26189333	HIST1H4D	0.92	5.15	0.39	8.05e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.23	-0.51	2.25e-11	Heart rate;
PAAD	cis	rs60154123	1.000	rs4844996	chr1:210476423	C/T	cg21951975	chr1:209979733	IRF6	0.5	4.44	0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.64	8.5	0.57	1.62e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4073221	0.789	rs13078687	chr3:18223442	C/T	cg07694806	chr3:18168406	NA	-0.83	-5.23	-0.39	5.65e-7	Parkinson's disease;
PAAD	cis	rs9810890	1.000	rs73198892	chr3:128559117	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05491587	chr18:77659695	KCNG2	-0.44	-4.25	-0.33	3.74e-5	Schizophrenia;
PAAD	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.56	5.31	0.4	3.8e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10836716	chr7:73868151	GTF2IRD1	0.63	6.35	0.46	2.37e-9	Obesity-related traits;
PAAD	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	4.67	0.35	6.59e-6	Depressive symptoms;
PAAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.22	-0.39	5.9e-7	Mean corpuscular volume;
PAAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.1	-0.55	1.63e-13	Mean corpuscular volume;
PAAD	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.84	-10.68	-0.65	3.2e-20	Menopause (age at onset);
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.67	-0.35	6.5e-6	Obesity-related traits;
PAAD	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.71	8.35	0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.6	-4.84	-0.37	3.17e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.93	6.15	0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.84	6.12	0.44	7.7e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg02573091	chr5:74908125	NA	0.51	4.5	0.34	1.32e-5	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs7937840	0.559	rs2000957	chr11:61877744	A/G	cg01969543	chr11:61895209	INCENP	-0.49	-4.29	-0.33	3.11e-5	Breast cancer;
PAAD	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.55	5.3	0.39	4.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7193541	0.550	rs76881401	chr16:74634309	G/A	cg01733217	chr16:74700730	RFWD3	0.76	6.65	0.47	5.08e-10	Multiple myeloma;
PAAD	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.75	0.36	4.63e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Colorectal cancer;
PAAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	5.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg12568669	chr8:11666485	FDFT1	0.26	4.34	0.33	2.54e-5	Neuroticism;
PAAD	cis	rs17407555	0.683	rs4698000	chr4:10277467	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-4.9	-0.37	2.46e-6	Schizophrenia (age at onset);
PAAD	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-4.29	-0.33	3.23e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg25797454	chr6:150327115	RAET1K	0.29	4.54	0.35	1.15e-5	Alopecia areata;
PAAD	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.96	-8.69	-0.58	5.54e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4523957	0.583	rs2760741	chr17:2020443	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.91	9.83	0.62	5.95e-18	Corneal astigmatism;
PAAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.75	6.91	0.49	1.27e-10	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.54	-0.47	8.67e-10	Eye color traits;
PAAD	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-4.79	-0.36	3.88e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.67	-6.83	-0.48	1.93e-10	Blood metabolite levels;
PAAD	cis	rs6545883	0.860	rs6545848	chr2:61461183	G/T	cg14146966	chr2:61757674	XPO1	-0.4	-4.99	-0.38	1.63e-6	Tuberculosis;
PAAD	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10915437	0.531	rs4233259	chr1:4197842	G/A	cg27165836	chr1:4193882	NA	0.52	5.36	0.4	3.01e-7	Migraine - clinic-based;
PAAD	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.6	0.41	1e-7	Coronary artery disease;
PAAD	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg15654264	chr1:150340011	RPRD2	0.51	4.92	0.37	2.26e-6	Migraine;
PAAD	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.63	-5.33	-0.4	3.47e-7	Neuroticism;
PAAD	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg15660573	chr17:549704	VPS53	-0.78	-7.62	-0.53	2.6e-12	Prostate cancer;
PAAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7113874	0.802	rs11042029	chr11:8688125	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.68	-0.35	6.39e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs797680	0.822	rs1057257	chr1:93621483	A/G	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.47	-0.34	1.51e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs17713676	0.558	rs16949364	chr16:79074986	A/G	cg05696950	chr2:8715754	NA	-0.85	-6.53	-0.47	9.27e-10	Response to amphetamines;
PAAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg03037974	chr15:76606532	NA	0.5	5.74	0.42	4.94e-8	Blood metabolite levels;
PAAD	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.89	10.69	0.65	3.14e-20	Resting heart rate;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1512829	0.578	rs1828639	chr11:9906879	T/C	cg06876053	chr11:9810051	SBF2	-0.4	-4.62	-0.35	8.09e-6	Lung adenocarcinoma;
PAAD	cis	rs1468734	1.000	rs35555573	chr16:5003581	G/A	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.73	5.5	0.41	1.55e-7	Initial pursuit acceleration;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg06915872	chr16:87998081	BANP	0.46	4.45	0.34	1.63e-5	Menopause (age at onset);
PAAD	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	14.63	0.76	8.45e-31	Primary sclerosing cholangitis;
PAAD	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.79	-9.81	-0.62	6.8e-18	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.63e-5	Coronary artery disease;
PAAD	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg14515779	chr1:101123966	NA	-0.41	-4.47	-0.34	1.5e-5	Monocyte count;
PAAD	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg17333051	chr19:2783644	SGTA	-0.43	-4.71	-0.36	5.47e-6	Total cholesterol levels;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.64	5.97	0.44	1.62e-8	Obesity-related traits;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.5	5.05	0.38	1.25e-6	Height;
PAAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg26898376	chr11:64110657	CCDC88B	0.45	4.77	0.36	4.23e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.77	-6.96	-0.49	9.38e-11	Schizophrenia;
PAAD	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.58	7.85	0.54	6.83e-13	Asthma (sex interaction);
PAAD	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg10183150	chr4:120222239	C4orf3	-0.41	-5.67	-0.42	7.14e-8	Corneal astigmatism;
PAAD	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg03989125	chr22:38214979	NA	-0.55	-5.49	-0.41	1.62e-7	Glioblastoma;Glioma;
PAAD	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.62	5.53	0.41	1.39e-7	Mean corpuscular volume;
PAAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg11989407	chr2:239091683	ILKAP	0.45	4.27	0.33	3.4e-5	Multiple system atrophy;
PAAD	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.43	4.44	0.34	1.69e-5	Longevity;
PAAD	cis	rs72960926	0.661	rs72969239	chr6:75066475	A/G	cg03266952	chr6:74778945	NA	-1.02	-5.51	-0.41	1.47e-7	Metabolite levels (MHPG);
PAAD	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.4	4.42	0.34	1.85e-5	Calcium levels;
PAAD	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.66	5.27	0.39	4.57e-7	Response to antidepressants in depression;
PAAD	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg14169450	chr9:139327907	INPP5E	0.52	4.43	0.34	1.78e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-1.05	-11.31	-0.68	6.71e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs2286379	0.749	rs4766417	chr12:1898650	G/A	cg05227549	chr12:1770782	NA	-0.43	-4.89	-0.37	2.53e-6	Blood pressure (smoking interaction);
PAAD	cis	rs59888335	1.000	rs11708247	chr3:80674048	C/G	cg21735741	chr3:80819488	NA	-0.57	-5.13	-0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs73198271	0.628	rs11777742	chr8:8589858	C/T	cg01851573	chr8:8652454	MFHAS1	0.62	4.67	0.35	6.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.53	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg24053715	chr22:38214548	NA	0.64	5.98	0.44	1.55e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-7.99	-0.54	3.19e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.6	5.6	0.41	9.86e-8	Height;
PAAD	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.11	-0.38	9.5e-7	Menopause (age at onset);
PAAD	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.06e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg11764359	chr7:65958608	NA	0.79	5.25	0.39	5.03e-7	Diabetic kidney disease;
PAAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.26	0.39	4.87e-7	Bone mineral density;
PAAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13126279	chr21:47581558	C21orf56	-0.4	-4.44	-0.34	1.7e-5	Testicular germ cell tumor;
PAAD	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-4.46	-0.34	1.56e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6594713	0.533	rs7709362	chr5:112990998	G/C	cg12552261	chr5:112820674	MCC	0.69	4.44	0.34	1.73e-5	Brain cytoarchitecture;
PAAD	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg02459107	chr1:67143332	SGIP1	0.78	7.54	0.52	3.92e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.87	7.77	0.53	1.11e-12	Migraine;Coronary artery disease;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.54	-0.41	1.28e-7	Longevity;Endometriosis;
PAAD	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg17644776	chr2:200775616	C2orf69	0.54	4.44	0.34	1.75e-5	Schizophrenia;
PAAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg00750074	chr16:89608354	SPG7	-0.6	-5.76	-0.42	4.59e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg22349387	chr12:9600060	DDX12	-0.41	-4.3	-0.33	3e-5	Breast size;
PAAD	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.5	-0.34	1.33e-5	Joint mobility (Beighton score);
PAAD	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg27411982	chr8:10470053	RP1L1	-0.48	-5.12	-0.38	9.27e-7	Retinal vascular caliber;
PAAD	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.55	0.47	8.37e-10	Body mass index;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12682931	chr6:90119710	RRAGD	0.46	4.97	0.37	1.81e-6	Vitiligo;Type 1 diabetes;
PAAD	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg05579598	chr16:88989069	CBFA2T3	0.64	9.91	0.63	3.6e-18	Social autistic-like traits;
PAAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg03648155	chr10:81106771	PPIF	0.37	4.25	0.33	3.78e-5	Height;
PAAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.81	9.89	0.63	3.98e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-7.62	-0.53	2.48e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg00071950	chr4:10020882	SLC2A9	0.51	5.01	0.38	1.5e-6	Cardiovascular disease risk factors;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23708337	chr7:1209742	NA	0.43	4.51	0.34	1.3e-5	Longevity;Endometriosis;
PAAD	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.62	5.68	0.42	6.53e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7873102	0.702	rs2243762	chr9:37991170	C/T	cg03528946	chr9:38069800	SHB	0.52	5.21	0.39	6.15e-7	Brain structure;
PAAD	cis	rs2594989	0.748	rs9653970	chr3:11412754	A/G	cg01796438	chr3:11312864	ATG7	-0.62	-5.18	-0.39	7.07e-7	Circulating chemerin levels;
PAAD	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.2	17.61	0.82	1.61e-38	Ulcerative colitis;
PAAD	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.87	-8.48	-0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21175976	chr8:11421337	BLK	-0.42	-4.57	-0.35	1.01e-5	Triglycerides;
PAAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg02841227	chr6:26021843	HIST1H4A	0.48	4.87	0.37	2.72e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg01008267	chr22:47515249	TBC1D22A	0.71	6.86	0.49	1.62e-10	Cancer;
PAAD	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.82	0.36	3.51e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs59698941	0.825	rs4705974	chr5:132198942	C/T	cg14825688	chr5:132208181	LEAP2	-0.66	-4.89	-0.37	2.59e-6	Apolipoprotein A-IV levels;
PAAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.45	-0.4	2.02e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.88e-8	HIV-1 control;
PAAD	cis	rs501916	0.714	rs11854427	chr15:48047421	G/A	cg16110827	chr15:48056943	SEMA6D	-0.49	-4.62	-0.35	8.15e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.53	-5.48	-0.41	1.73e-7	White blood cell count;
PAAD	cis	rs2153535	0.518	rs9393054	chr6:8647442	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	4.25	0.33	3.74e-5	Motion sickness;
PAAD	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.42	4.92	0.37	2.24e-6	Total body bone mineral density;
PAAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.74	7.43	0.52	7.3e-12	Uric acid levels;
PAAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs12257961	0.549	rs1949435	chr10:15373670	G/T	cg10616319	chr10:15468812	NA	-0.47	-4.47	-0.34	1.55e-5	Selective IgA deficiency;
PAAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg03340356	chr1:67600835	NA	0.53	6.1	0.44	8.57e-9	Psoriasis;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg17646418	chr6:166911767	RPS6KA2	-0.62	-6.34	-0.46	2.47e-9	Survival in colon cancer;
PAAD	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.51	-0.41	1.49e-7	Vitamin D levels;
PAAD	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.16	-0.5	3.3e-11	Schizophrenia;
PAAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.49	4.69	0.36	6.08e-6	Aortic root size;
PAAD	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	7.6	0.52	2.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.14	-0.45	6.72e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.84	-0.49	1.81e-10	Morning vs. evening chronotype;
PAAD	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.64e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.57	-6.91	-0.49	1.22e-10	Blood pressure (smoking interaction);
PAAD	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs27434	0.583	rs34761	chr5:96153624	C/T	cg16492584	chr5:96139282	ERAP1	-0.53	-5.15	-0.39	8.02e-7	Ankylosing spondylitis;
PAAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22947322	chr17:47091978	IGF2BP1	0.38	4.44	0.34	1.75e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg26174226	chr8:58114915	NA	-0.56	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg24642844	chr7:1081250	C7orf50	0.55	4.41	0.34	1.91e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6908034	0.607	rs12529148	chr6:19806797	G/C	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs55794721	0.672	rs78103988	chr1:25747655	C/T	cg23205692	chr1:25664452	TMEM50A	0.49	4.65	0.35	7.15e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg07883600	chr3:53528162	CACNA1D	-0.43	-4.61	-0.35	8.56e-6	Body mass index;
PAAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.38	4.81	0.36	3.62e-6	Sitting height ratio;
PAAD	cis	rs10991814	1.000	rs76953614	chr9:93985979	G/C	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs11867129	0.908	rs13332514	chr16:2367336	G/A	cg05196366	chr16:3239155	NA	-0.47	-4.36	-0.33	2.39e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg10437265	chr15:77819839	NA	0.38	4.34	0.33	2.6e-5	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02904838	chr3:187871519	LPP	0.64	6.82	0.48	2.03e-10	Myopia (pathological);
PAAD	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.74	-0.36	4.97e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.46	-4.41	-0.34	1.93e-5	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg14345882	chr6:26364793	BTN3A2	0.83	5.97	0.44	1.62e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06002616	chr8:101225028	SPAG1	-0.45	-5.24	-0.39	5.25e-7	Atrioventricular conduction;
PAAD	cis	rs5009270	0.553	rs11771324	chr7:112207795	T/C	cg23628563	chr7:112262597	NA	0.57	4.82	0.36	3.5e-6	Osteoarthritis (hip);
PAAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.66	-6.4	-0.46	1.79e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs735539	0.555	rs2762990	chr13:21371427	T/C	cg27499820	chr13:21296301	IL17D	0.54	5.14	0.39	8.17e-7	Dental caries;
PAAD	cis	rs10888501	1.000	rs10888501	chr1:152537954	C/T	cg25202261	chr1:151668357	SNX27	-0.43	-4.28	-0.33	3.32e-5	Response to antipsychotic treatment;
PAAD	cis	rs8025118	0.583	rs12906934	chr15:79542881	C/A	cg24739098	chr15:79297159	RASGRF1	-0.4	-4.46	-0.34	1.58e-5	Cognitive function;
PAAD	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.07	-0.44	9.66e-9	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.48	-4.32	-0.33	2.75e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	4.5	0.34	1.36e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.69	-6.73	-0.48	3.18e-10	Initial pursuit acceleration;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03604417	chr9:135116708	NTNG2	-0.67	-6.6	-0.47	6.55e-10	Lung cancer in ever smokers;
PAAD	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.63	0.53	2.36e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.49	-4.35	-0.33	2.48e-5	Mean corpuscular volume;
PAAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.5	0.34	1.36e-5	Electroencephalogram traits;
PAAD	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.63	-7.16	-0.5	3.16e-11	Aortic root size;
PAAD	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg02415014	chr8:143852576	LYNX1	-0.52	-6.3	-0.46	3.02e-9	Urinary tract infection frequency;
PAAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs6694270	1.000	rs6694270	chr1:19120377	A/G	cg26220594	chr1:19110978	NA	-0.61	-5.05	-0.38	1.22e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.86	0.49	1.66e-10	Height;
PAAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	5.89	0.43	2.42e-8	Mood instability;
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg26513180	chr16:89883248	FANCA	0.65	7.56	0.52	3.6e-12	Vitiligo;
PAAD	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.47	-4.97	-0.37	1.75e-6	Yeast infection;
PAAD	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21659725	chr3:3221576	CRBN	-0.67	-6.62	-0.47	5.72e-10	Menarche (age at onset);
PAAD	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.45	-0.34	1.64e-5	Blood metabolite levels;
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.54	7.13	0.5	3.9e-11	Prostate cancer;
PAAD	cis	rs7301016	1.000	rs10877857	chr12:62872211	C/T	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.76	7.86	0.54	6.7e-13	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.88	0.54	5.8e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21963583	chr11:68658836	MRPL21	-0.39	-4.47	-0.34	1.54e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.67	-0.42	6.94e-8	Schizophrenia;
PAAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg22916017	chr11:64110731	CCDC88B	0.38	4.45	0.34	1.65e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg11335335	chr11:637885	DRD4	-0.31	-4.43	-0.34	1.76e-5	Systemic lupus erythematosus;
PAAD	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.49	-0.34	1.42e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-7.94	-0.54	4.19e-13	Parkinson's disease;
PAAD	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.614	rs2641439	chr17:2017561	C/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs950169	0.690	rs12901166	chr15:84699113	G/A	cg03959625	chr15:84868606	LOC388152	0.47	4.75	0.36	4.65e-6	Schizophrenia;
PAAD	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.5	-0.61	4.26e-17	Blood trace element (Zn levels);
PAAD	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg15604389	chr3:122379662	NA	0.59	6.55	0.47	8.3e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg01529538	chr14:23388837	RBM23	0.48	4.8	0.36	3.8e-6	Cognitive ability (multi-trait analysis);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg09741240	chr6:3000097	NQO2	-0.61	-6.63	-0.47	5.6e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3126085	1.000	rs11588170	chr1:152286032	C/T	cg26876637	chr1:152193138	HRNR	-0.8	-5.43	-0.4	2.19e-7	Atopic dermatitis;
PAAD	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs28655083	0.826	rs2134335	chr16:77079272	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-4.85	-0.37	3.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg14019146	chr3:50243930	SLC38A3	0.42	4.32	0.33	2.82e-5	Menarche (age at onset);
PAAD	cis	rs73086581	1.000	rs73086588	chr20:3982224	A/T	cg02187196	chr20:3869020	PANK2	0.61	5.21	0.39	6.13e-7	Response to antidepressants in depression;
PAAD	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.46	0.71	5.4e-25	Chronic sinus infection;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10266483	0.562	rs10949887	chr7:63752080	C/T	cg24201672	chr7:64023550	ZNF680	-0.56	-4.4	-0.34	1.99e-5	Response to statin therapy;
PAAD	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg16898833	chr6:26189333	HIST1H4D	0.63	4.99	0.38	1.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg26354017	chr1:205819088	PM20D1	0.63	6.22	0.45	4.51e-9	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.8	0.53	9.01e-13	Coronary artery disease;
PAAD	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.47	-4.6	-0.35	8.93e-6	Mean platelet volume;
PAAD	cis	rs1903068	0.853	rs10012701	chr4:56002776	A/G	cg20092376	chr4:56023423	NA	0.41	4.27	0.33	3.48e-5	Endometriosis;
PAAD	cis	rs212524	0.967	rs212526	chr1:21584941	C/T	cg23992472	chr1:21503364	EIF4G3	-0.43	-4.37	-0.33	2.28e-5	Height;
PAAD	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.63	-5.7	-0.42	5.91e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20824237	chr3:99979579	TBC1D23	0.63	7.14	0.5	3.68e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.79	-9.51	-0.61	4.19e-17	White blood cell count (basophil);
PAAD	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.63	-6.49	-0.47	1.15e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.51	-4.97	-0.37	1.81e-6	Facial morphology (factor 20);
PAAD	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.9	-0.43	2.29e-8	QT interval;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.88	-0.43	2.5e-8	Mood instability;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg20007245	chr22:24372913	LOC391322	-0.66	-6.92	-0.49	1.18e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17592366	0.517	rs4982219	chr14:35286483	A/T	cg09327582	chr14:35236912	BAZ1A	0.57	5.38	0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs721399	0.539	rs7460653	chr8:18266983	G/C	cg18736775	chr8:18248649	NAT2	-0.61	-4.66	-0.35	6.9e-6	Blood metabolite levels;
PAAD	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12908607	chr1:44402522	ARTN	-0.43	-4.76	-0.36	4.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13424612	0.864	rs4854071	chr2:240885050	C/T	cg01812947	chr2:240904978	NDUFA10	0.6	5.48	0.41	1.76e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.56	-5.34	-0.4	3.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.87	9.97	0.63	2.44e-18	Blood protein levels;
PAAD	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs1561288	0.731	rs7596747	chr2:25350321	G/T	cg02492873	chr2:25193821	DNAJC27	0.49	4.28	0.33	3.3e-5	Body mass index;
PAAD	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.74	0.82	7.26e-39	Height;
PAAD	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.88	-12.67	-0.72	1.44e-25	Height;
PAAD	cis	rs10090774	0.830	rs2369409	chr8:141989870	A/G	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg05341575	chr12:125625032	AACS	-0.53	-4.95	-0.37	1.91e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.01	-0.38	1.49e-6	Mood instability;
PAAD	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg03733263	chr8:22462867	KIAA1967	-0.79	-9.3	-0.6	1.41e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.63	-0.47	5.52e-10	Brain structure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19756622	chr19:54233120	MIR518A1;MIR518E	-0.59	-6.65	-0.47	5.02e-10	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25388168	chr10:43904408	HNRNPF	0.7	7.26	0.51	1.83e-11	Myopia (pathological);
PAAD	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.29	-0.51	1.56e-11	Systolic blood pressure;
PAAD	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg21770322	chr7:97807741	LMTK2	0.51	7.04	0.5	6.18e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.45	5.57	0.41	1.14e-7	Panic disorder;
PAAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg25319279	chr11:5960081	NA	-0.61	-5.77	-0.42	4.4e-8	DNA methylation (variation);
PAAD	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	9.57	0.61	2.87e-17	Ulcerative colitis;
PAAD	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	6.38	0.46	2e-9	Mean platelet volume;
PAAD	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.73	8.25	0.56	7.05e-14	N-glycan levels;
PAAD	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.38	-5.47	-0.41	1.81e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg05627522	chr15:75251581	NA	0.5	5.98	0.44	1.57e-8	Caffeine consumption;
PAAD	cis	rs3784262	0.528	rs4646588	chr15:58304313	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	4.5	0.34	1.33e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs7594192	0.744	rs12621458	chr2:199365595	C/G	cg07835424	chr2:200327334	NA	0.37	4.65	0.35	7.13e-6	Educational attainment;
PAAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.48	-4.48	-0.34	1.45e-5	Vitiligo;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg22029157	chr1:209979665	IRF6	-0.7	-6.74	-0.48	3.1e-10	Coronary artery disease;
PAAD	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-5.03	-0.38	1.38e-6	Life satisfaction;
PAAD	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-6.43	-0.46	1.56e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg10729496	chr3:10149963	C3orf24	0.78	6.13	0.44	7.4e-9	Alzheimer's disease;
PAAD	cis	rs1557351	1.000	rs12605291	chr18:54749223	C/T	cg00016439	chr18:55018650	ST8SIA3	0.48	4.29	0.33	3.19e-5	Multiple sclerosis (age of onset);
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.15	-0.5	3.45e-11	Life satisfaction;
PAAD	cis	rs9616064	0.744	rs9616058	chr22:46974203	G/A	cg03318428	chr22:46971703	NA	0.39	4.43	0.34	1.79e-5	Urate levels in obese individuals;
PAAD	cis	rs743757	0.938	rs4688719	chr3:50508213	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.73	5.04	0.38	1.29e-6	Diastolic blood pressure;
PAAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs2594989	1.000	rs2606742	chr3:11391717	G/A	cg01796438	chr3:11312864	ATG7	-0.66	-5.26	-0.39	4.91e-7	Circulating chemerin levels;
PAAD	cis	rs9715521	0.778	rs7681689	chr4:59840103	C/T	cg11281224	chr4:60001000	NA	-0.56	-5.33	-0.4	3.44e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.78e-18	Cognitive function;
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6060960	0.537	rs6089119	chr20:30514161	T/G	cg13852791	chr20:30311386	BCL2L1	0.63	4.54	0.35	1.14e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7631605	0.518	rs6776697	chr3:36985664	C/T	cg17445812	chr3:36986805	TRANK1	0.36	5.08	0.38	1.1e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg02696790	chr15:75250997	RPP25	0.36	4.37	0.33	2.33e-5	Breast cancer;
PAAD	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	6.56	0.47	8.02e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.71	-0.36	5.48e-6	Height;
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg05861140	chr6:150128134	PCMT1	-0.55	-6.41	-0.46	1.69e-9	Lung cancer;
PAAD	cis	rs6466055	0.589	rs17342493	chr7:105010684	G/A	cg04380332	chr7:105027541	SRPK2	0.52	5.17	0.39	7.43e-7	Schizophrenia;
PAAD	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg12935359	chr14:103987150	CKB	-0.58	-6.09	-0.44	8.8e-9	Body mass index;
PAAD	cis	rs7614311	1.000	rs2637983	chr3:63821632	G/A	cg22134162	chr3:63841271	THOC7	-0.5	-4.37	-0.33	2.33e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs17301329	0.964	rs11783652	chr8:54858494	A/G	cg06042504	chr8:55087323	NA	0.43	4.33	0.33	2.65e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs9876781	1.000	rs6796491	chr3:48430465	T/G	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.49	-0.61	4.57e-17	Tonsillectomy;
PAAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04287289	chr16:89883240	FANCA	0.91	4.53	0.34	1.19e-5	Skin colour saturation;
PAAD	cis	rs6062788	0.524	rs6122362	chr20:61701245	C/T	cg20652954	chr20:61716293	NA	-0.43	-5.88	-0.43	2.52e-8	Body mass index;
PAAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.53	-4.27	-0.33	3.49e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg06740227	chr12:86229804	RASSF9	-0.55	-4.95	-0.37	1.94e-6	Major depressive disorder;
PAAD	cis	rs1519814	0.702	rs7846263	chr8:121039036	C/T	cg22335954	chr8:121166405	COL14A1	-0.66	-5.16	-0.39	7.5e-7	Breast cancer;
PAAD	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.23	0.51	2.24e-11	Educational attainment;
PAAD	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.66	-0.65	3.61e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.77	9.05	0.59	6.3e-16	Blood metabolite ratios;
PAAD	cis	rs2275565	0.872	rs3768136	chr1:237027453	T/A	cg17297354	chr1:237056641	MTR	-0.53	-4.74	-0.36	4.95e-6	Homocysteine levels;
PAAD	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.57	-4.78	-0.36	4.11e-6	Atopic dermatitis;
PAAD	cis	rs630539	0.793	rs4270219	chr17:40773348	A/G	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg12082871	chr5:141017675	RELL2;HDAC3	-0.61	-6.5	-0.47	1.08e-9	Survival in colon cancer;
PAAD	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.81	0.54	8.7e-13	Lung cancer in ever smokers;
PAAD	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs6828577	0.643	rs10031658	chr4:119440766	C/T	cg26518628	chr1:97050305	NA	-0.73	-6.65	-0.47	4.86e-10	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.77e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.47	-5.17	-0.39	7.25e-7	Testicular germ cell tumor;
PAAD	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-4.99	-0.37	1.67e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.68	-5.01	-0.38	1.48e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4974559	0.744	rs10024529	chr4:1363886	G/A	cg02980000	chr4:1222292	CTBP1	0.84	5.34	0.4	3.26e-7	Systolic blood pressure;
PAAD	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg17644776	chr2:200775616	C2orf69	0.53	4.35	0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs9361491	0.608	rs7768125	chr6:79446389	G/A	cg05283184	chr6:79620031	NA	-0.38	-4.52	-0.34	1.25e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.56	4.42	0.34	1.9e-5	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21034903	chr2:172544336	DYNC1I2	-0.59	-6.31	-0.46	2.85e-9	Smoking initiation;
PAAD	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg24555670	chr8:18244502	NA	0.55	4.27	0.33	3.41e-5	Blood metabolite levels;
PAAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.54	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.62	-8.26	-0.56	6.75e-14	Renal cell carcinoma;
PAAD	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06850241	chr22:41845214	NA	-0.53	-4.34	-0.33	2.6e-5	Vitiligo;
PAAD	cis	rs73198271	0.515	rs78790772	chr8:8634367	A/G	cg01851573	chr8:8652454	MFHAS1	0.81	5.47	0.41	1.85e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04155289	chr7:94953770	PON1	0.51	4.27	0.33	3.44e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.68	6.99	0.49	8.18e-11	Lung cancer;
PAAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.36	4.93	0.37	2.11e-6	Height;
PAAD	cis	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs7264396	0.887	rs2236161	chr20:34101631	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs5009270	0.512	rs1024412	chr7:112247758	A/G	cg25550468	chr7:112262557	NA	0.5	4.55	0.35	1.09e-5	Osteoarthritis (hip);
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.79	5.53	0.41	1.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	6.89	0.49	1.37e-10	Response to antipsychotic treatment;
PAAD	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg10578991	chr7:12443926	VWDE	-0.5	-4.38	-0.33	2.17e-5	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.46	-0.46	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg23688817	chr7:87105293	ABCB4	0.52	4.39	0.34	2.12e-5	Gallbladder cancer;
PAAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.6	6.09	0.44	8.81e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.49	4.67	0.35	6.5e-6	HDL cholesterol;
PAAD	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg23587288	chr2:27483067	SLC30A3	0.69	6.53	0.47	9.34e-10	Blood metabolite levels;
PAAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22482690	chr17:47019901	SNF8	0.49	5.25	0.39	5.01e-7	Type 2 diabetes;
PAAD	cis	rs4704187	0.649	rs7717415	chr5:74558893	A/G	cg03227963	chr5:74354835	NA	0.45	4.46	0.34	1.58e-5	Response to amphetamines;
PAAD	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9646944	0.501	rs17027246	chr2:103080055	C/G	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.41e-8	Coronary artery disease;
PAAD	cis	rs17824933	0.767	rs2074223	chr11:60774578	G/C	cg16817237	chr11:60793675	NA	0.52	6.76	0.48	2.71e-10	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17840164	chr10:104262570	SUFU;ACTR1A	0.59	6.5	0.47	1.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg10137597	chr8:22132714	PIWIL2	0.5	5.89	0.43	2.41e-8	Hypertriglyceridemia;
PAAD	cis	rs2851391	0.501	rs732672	chr21:44464034	G/C	cg19312314	chr21:44473962	CBS	-0.44	-4.26	-0.33	3.52e-5	Homocysteine levels;Obesity-related traits;Blood metabolite levels;
PAAD	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.67	7.01	0.49	7.34e-11	Platelet distribution width;
PAAD	cis	rs4759375	0.667	rs28660661	chr12:123848455	C/A	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.52	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs35955747	0.838	rs5997887	chr22:31543197	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.35	-4.28	-0.33	3.28e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10214930	0.697	rs13242248	chr7:27682871	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18057185	chr3:48342999	NME6	0.67	6.63	0.47	5.64e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7517847	0.598	rs10789228	chr1:67687064	C/T	cg16314899	chr1:68516101	DIRAS3	-0.47	-4.66	-0.35	6.97e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.82	-6.63	-0.47	5.55e-10	Blood protein levels;
PAAD	cis	rs1542829	0.634	rs819079	chr3:130178066	A/C	cg03541853	chr3:129408948	TMCC1	-0.77	-5.0	-0.38	1.57e-6	Body mass index;
PAAD	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	1.03	13.13	0.73	8.58e-27	Breast cancer;
PAAD	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg14146966	chr2:61757674	XPO1	0.4	4.92	0.37	2.24e-6	Tuberculosis;
PAAD	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.52	4.78	0.36	4.06e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Gut microbiome composition (summer);
PAAD	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg05998816	chr21:47859926	PCNT	0.54	4.29	0.33	3.18e-5	Lymphocyte counts;
PAAD	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.48	4.62	0.35	8.13e-6	Mean corpuscular volume;
PAAD	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.67	7.09	0.5	4.71e-11	Dupuytren's disease;
PAAD	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	5.1	0.38	9.93e-7	Joint mobility (Beighton score);
PAAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.6	-7.41	-0.52	8.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-1.04	-11.26	-0.67	9.28e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg20243544	chr17:37824526	PNMT	0.7	6.64	0.47	5.2400000000000005e-10	Asthma;
PAAD	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg22587600	chr2:46883368	NA	0.34	4.6	0.35	8.98e-6	Height;
PAAD	trans	rs901683	1.000	rs17157836	chr10:45963586	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.57	5.95	0.43	1.79e-8	Body mass index;
PAAD	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2251260	0.685	rs2246609	chr14:62007872	G/A	cg23386212	chr14:62041363	NA	0.56	4.48	0.34	1.44e-5	Yeast infection;
PAAD	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.99	-0.49	8.28e-11	Triglycerides;
PAAD	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg25952890	chr19:58913133	NA	0.67	5.7	0.42	5.94e-8	Mean platelet volume;
PAAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.51	5.4	0.4	2.49e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.43	4.38	0.33	2.22e-5	Height;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.68	4.66	0.35	6.92e-6	Major depressive disorder;
PAAD	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg00990874	chr7:1149470	C7orf50	-0.55	-5.1	-0.38	1e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs57244997	0.725	rs58957516	chr6:162427889	C/A	cg17173639	chr6:162384350	PARK2	-0.62	-4.67	-0.35	6.5e-6	Mosquito bite size;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg26071806	chr7:100318239	EPO	-0.49	-4.84	-0.37	3.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg10495392	chr1:46806563	NSUN4	0.58	5.78	0.42	4.19e-8	Menopause (age at onset);
PAAD	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.87	0.58	1.88e-15	Motion sickness;
PAAD	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11235843	0.516	rs666839	chr11:73346041	A/G	cg15851278	chr11:73669449	DNAJB13	-0.49	-4.81	-0.36	3.59e-6	Hand grip strength;
PAAD	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.8	0.48	2.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.58	-5.0	-0.38	1.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg07153921	chr17:41440717	NA	-0.4	-4.25	-0.33	3.7e-5	Menopause (age at onset);
PAAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.66	6.91	0.49	1.23e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	6.62	0.47	5.78e-10	Body mass index;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.66	-0.42	7.27e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs72843506	0.656	rs8073875	chr17:19939059	A/G	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	5.92e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.33	-0.33	2.75e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-1.09	-16.27	-0.8	4.21e-35	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.77	-0.42	4.27e-8	Life satisfaction;
PAAD	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.35	-0.4	3.19e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.43	-4.33	-0.33	2.69e-5	Calcium levels;
PAAD	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.56	6.8	0.48	2.23e-10	Monobrow;
PAAD	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg08888203	chr3:10149979	C3orf24	0.77	5.73	0.42	5.2100000000000003e-08	Alzheimer's disease;
PAAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07395075	chr16:56642428	MT2A	-0.62	-6.69	-0.48	4.02e-10	Smoking initiation;
PAAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.72	7.77	0.53	1.12e-12	Melanoma;
PAAD	cis	rs796364	0.570	rs35733345	chr2:200647533	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-5.56	-0.41	1.16e-7	Schizophrenia;
PAAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg21395723	chr22:39101663	GTPBP1	0.44	4.49	0.34	1.4e-5	Menopause (age at onset);
PAAD	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.66e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs932287	0.545	rs7941341	chr11:9038925	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.61	-5.68	-0.42	6.6e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	cis	rs11971779	0.650	rs4732380	chr7:139126859	C/T	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.7	-11.08	-0.67	2.71e-21	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25495844	chr22:45560678	NUP50	0.69	7.2	0.5	2.62e-11	Obesity-related traits;
PAAD	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.36	-4.25	-0.33	3.72e-5	Colorectal cancer;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.59	-5.18	-0.39	6.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.9	-11.05	-0.67	3.38e-21	Dental caries;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.82e-9	Height;
PAAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.6	6.28	0.45	3.37e-9	Body mass index;
PAAD	cis	rs36093844	0.898	rs12361800	chr11:85565864	G/A	cg25872744	chr11:85566296	CCDC83	-0.6	-4.7	-0.36	5.81e-6	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.7	-5.78	-0.42	4.19e-8	Neuroticism;
PAAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.35	0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs7180079	1.000	rs77627789	chr15:64444276	G/C	cg26157579	chr15:65137040	PLEKHO2	-0.51	-4.89	-0.37	2.58e-6	Monocyte count;
PAAD	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.59	-6.15	-0.45	6.69e-9	Blood metabolite levels;
PAAD	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.17e-8	Height;
PAAD	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.81	6.06	0.44	1.05e-8	Diisocyanate-induced asthma;
PAAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00147160	chr1:26503991	CNKSR1	0.43	6.78	0.48	2.46e-10	Height;
PAAD	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs58521262	0.556	rs2645878	chr19:23210946	G/A	cg02350677	chr19:23254381	NA	0.26	4.61	0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs11811982	0.793	rs78587644	chr1:227251572	G/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.75	7.92	0.54	4.63e-13	Schizophrenia;
PAAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.22e-10	Blood protein levels;
PAAD	cis	rs11668609	0.515	rs73525894	chr19:24070778	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.77	-8.81	-0.58	2.59e-15	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08219700	chr8:58056026	NA	0.7	5.62	0.41	8.83e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.46	-4.27	-0.33	3.44e-5	Urate levels;
PAAD	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-5.21	-0.39	6.11e-7	P wave terminal force;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	8.47	0.57	1.96e-14	Lymphocyte counts;
PAAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.46	0.41	1.88e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4427176	0.765	rs11249943	chr8:9607863	A/C	cg03024720	chr8:9765601	NA	-0.47	-4.46	-0.34	1.61e-5	Mosquito bite size;
PAAD	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs7260329	0.713	rs8100458	chr19:41500213	T/C	cg06653635	chr19:40910092	PRX	-0.45	-4.26	-0.33	3.59e-5	Smoking behavior;
PAAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.6	5.67	0.42	7.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.63	0.65	4.49e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg19792802	chr11:65647270	CTSW	0.37	4.63	0.35	7.75e-6	DNA methylation (variation);
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	1.67	10.52	0.65	8.94e-20	Height;
PAAD	cis	rs3774830	0.714	rs7688517	chr4:5466392	A/C	cg26943120	chr4:5472116	STK32B	0.38	4.74	0.36	4.89e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6460942	0.659	rs13247370	chr7:12514632	T/C	cg06484146	chr7:12443880	VWDE	-0.84	-5.16	-0.39	7.6e-7	Coronary artery disease;
PAAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs5009270	0.597	rs10225077	chr7:112159448	G/A	cg23628563	chr7:112262597	NA	0.56	4.95	0.37	1.94e-6	Osteoarthritis (hip);
PAAD	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	7.3	0.51	1.53e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.96	-0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03404566	chr17:6899310	ALOX12	0.44	4.61	0.35	8.39e-6	Tonsillectomy;
PAAD	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg04087571	chr11:116723030	SIK3	-0.35	-4.55	-0.35	1.11e-5	Subjective well-being;
PAAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg00181669	chr3:44000978	NA	-0.42	-4.25	-0.33	3.73e-5	Coronary artery disease;
PAAD	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.33	0.64	2.82e-19	Cognitive test performance;
PAAD	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.39	-0.34	2.15e-5	Bipolar disorder;
PAAD	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.25	-0.39	5.02e-7	Schizophrenia;
PAAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.39	-5.08	-0.38	1.09e-6	Colorectal cancer;
PAAD	cis	rs4294134	0.608	rs35357843	chr7:135245068	T/C	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-5.2	-0.39	6.32e-7	Vitiligo;
PAAD	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.75	-8.86	-0.58	1.93e-15	Lung function (FVC);
PAAD	cis	rs1656368	0.655	rs10936145	chr3:158193136	A/G	cg16708174	chr3:158430962	RARRES1	0.62	5.52	0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.48	4.39	0.34	2.1e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2120243	0.539	rs4679793	chr3:157122661	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	-0.42	-4.5	-0.34	1.33e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.76	8.41	0.56	2.83e-14	Iron status biomarkers;
PAAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg00253185	chr1:247542119	NA	0.54	4.39	0.34	2.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.63	6.16	0.45	6.29e-9	Uric acid clearance;
PAAD	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.47e-9	Hypospadias;
PAAD	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.73	0.53	1.34e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg24296786	chr1:45957014	TESK2	0.54	5.12	0.38	9.32e-7	Homocysteine levels;
PAAD	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	1.14	6.98	0.49	8.43e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.91	-10.2	-0.64	6.22e-19	Obesity-related traits;
PAAD	cis	rs7833787	0.827	rs12544633	chr8:18678302	C/T	cg17701159	chr8:18705777	PSD3	-0.46	-5.17	-0.39	7.35e-7	Obesity-related traits;
PAAD	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.78	-9.04	-0.59	6.64e-16	Hemoglobin concentration;
PAAD	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg13859433	chr6:33739653	LEMD2	0.58	4.62	0.35	8.03e-6	Schizophrenia;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg09471204	chr22:42347991	LOC339674	0.34	4.49	0.34	1.39e-5	Cognitive function;
PAAD	cis	rs818427	0.593	rs3317	chr5:112212151	G/A	cg06941702	chr5:112196734	SRP19	-0.53	-5.05	-0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.49	-4.25	-0.33	3.66e-5	Blood pressure (smoking interaction);
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg15181151	chr6:150070149	PCMT1	0.59	6.41	0.46	1.78e-9	Lung cancer;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.74	0.42	4.9e-8	Prudent dietary pattern;
PAAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18404041	chr3:52824283	ITIH1	0.42	4.49	0.34	1.4e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg14440974	chr22:39074834	NA	-0.53	-6.48	-0.47	1.2e-9	Menopause (age at onset);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03578886	chr8:94928855	PDP1	0.58	6.4	0.46	1.82e-9	Immature fraction of reticulocytes;
PAAD	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.25e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-5.23	-0.39	5.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.56	5.37	0.4	2.84e-7	Coronary artery disease;
PAAD	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9577481	1.000	rs9577481	chr13:113860900	C/T	cg05907821	chr13:114074394	NA	0.49	4.51	0.34	1.28e-5	Blood protein levels;
PAAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.46	4.87	0.37	2.75e-6	Longevity;Endometriosis;
PAAD	trans	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.74e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.79	8.71	0.58	4.73e-15	Colorectal cancer;
PAAD	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.57	5.76	0.42	4.51e-8	Longevity;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.52	6.69	0.48	4.04e-10	Prostate cancer;
PAAD	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	7.63	0.53	2.43e-12	Eotaxin levels;
PAAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg18357526	chr6:26021779	HIST1H4A	0.55	5.01	0.38	1.48e-6	Mosquito bite size;
PAAD	cis	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.17	9.06	0.59	6.07e-16	Mitochondrial DNA levels;
PAAD	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.5	2.62e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs258892	0.895	rs2338789	chr5:72038481	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.3	-0.33	3.08e-5	Educational attainment;
PAAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.13e-7	Electroencephalogram traits;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.65	-9.72	-0.62	1.16e-17	Longevity;Endometriosis;
PAAD	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	10.75	0.66	2.05e-20	Primary sclerosing cholangitis;
PAAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg00901687	chr17:48585270	MYCBPAP	0.62	6.24	0.45	4.14e-9	Visceral fat;
PAAD	cis	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.68	0.58	5.8e-15	Platelet count;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.67	-6.3	-0.45	3.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.84	-0.54	7.29e-13	Triglycerides;
PAAD	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg02380750	chr20:61661411	NA	-0.38	-4.47	-0.34	1.52e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.55	-4.39	-0.34	2.1e-5	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21156006	chr9:129455121	LMX1B	0.64	7.36	0.51	1.08e-11	Smoking initiation;
PAAD	cis	rs859767	0.741	rs11682346	chr2:135388261	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.44	-0.34	1.73e-5	Neuroticism;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs728616	0.867	rs2152550	chr10:81818509	G/A	cg05935833	chr10:81318306	SFTPA2	-0.6	-4.73	-0.36	5.1e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.65	6.94	0.49	1.05e-10	Crohn's disease;
PAAD	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.67	-0.42	7.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs8105895	0.935	rs10405673	chr19:22244890	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.68	5.68	0.42	6.73e-8	Response to antidepressants in depression;
PAAD	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-4.27	-0.33	3.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg22189786	chr22:42395067	WBP2NL	0.59	5.75	0.42	4.85e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.83	-9.88	-0.63	4.43e-18	Breast cancer;
PAAD	cis	rs11113894	1.000	rs11113889	chr12:108835544	A/C	cg06834313	chr12:108851556	NA	-0.75	-4.35	-0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg15123519	chr2:136567270	LCT	-0.36	-4.47	-0.34	1.52e-5	Mosquito bite size;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg05627522	chr15:75251581	NA	-0.52	-6.31	-0.46	2.95e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.41	4.44	0.34	1.71e-5	Height;
PAAD	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.81	7.58	0.52	3.2e-12	Colorectal cancer;
PAAD	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-1.03	-8.08	-0.55	1.89e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.89	0.54	5.62e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg21784768	chr11:537496	LRRC56	-0.85	-4.28	-0.33	3.29e-5	Body mass index;
PAAD	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.42	-4.49	-0.34	1.4e-5	Menarche (age at onset);
PAAD	cis	rs11696501	0.694	rs6124722	chr20:44263264	G/A	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.53	-5.39	-0.4	2.62e-7	Squamous cell lung carcinoma;
PAAD	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.8	-6.74	-0.48	3.06e-10	Gut microbiome composition (summer);
PAAD	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.58	-0.47	7.33e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.56	7.67	0.53	1.88e-12	Electrocardiographic conduction measures;
PAAD	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg12310025	chr6:25882481	NA	0.43	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.1	-0.38	9.81e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.39	-4.33	-0.33	2.66e-5	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.78	0.62	8.02e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	1.14	12.12	0.7	4.32e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.62	-5.9	-0.43	2.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.76	4.7	0.36	5.86e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-4.86	-0.37	2.84e-6	Mean corpuscular volume;
PAAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14343924	chr8:8086146	FLJ10661	0.5	4.64	0.35	7.53e-6	Mood instability;
PAAD	cis	rs5022636	0.594	rs11204791	chr1:151240542	C/G	cg10963543	chr1:151226935	PSMD4	0.46	4.26	0.33	3.51e-5	Gut microbiota (functional units);
PAAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg00184732	chr15:51633821	GLDN	0.47	4.7	0.36	5.77e-6	Hormone measurements;
PAAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg02917321	chr22:38215204	NA	0.44	4.41	0.34	1.97e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1692580	0.807	rs4648627	chr1:2200404	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.84	-0.37	3.12e-6	Coronary artery disease;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26418147	chr1:205743515	RAB7L1	-0.5	-5.98	-0.44	1.5e-8	Menarche (age at onset);
PAAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.43	4.39	0.34	2.1e-5	Atrioventricular conduction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02087416	chr1:200182788	FAM58B	0.57	6.49	0.47	1.17e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg05338066	chr1:7812865	CAMTA1	0.66	4.89	0.37	2.5e-6	Inflammatory bowel disease;
PAAD	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.58	4.33	0.33	2.74e-5	Fat distribution (HIV);
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26418147	chr1:205743515	RAB7L1	-0.5	-5.98	-0.44	1.53e-8	Menarche (age at onset);
PAAD	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.58	-5.67	-0.42	7.02e-8	Itch intensity from mosquito bite;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg17541715	chr7:1216824	NA	-0.38	-4.26	-0.33	3.53e-5	Longevity;Endometriosis;
PAAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-5.84	-0.43	3.04e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg27449745	chr7:23145252	KLHL7	-0.51	-4.47	-0.34	1.52e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg07689907	chr11:61582574	FADS1	0.46	4.58	0.35	9.8e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg04160749	chr8:58172571	NA	-0.63	-4.53	-0.34	1.18e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	6.25	0.45	4.02e-9	Renal function-related traits (BUN);
PAAD	cis	rs8077577	0.895	rs10048161	chr17:18082796	C/G	cg16794390	chr17:18148240	FLII	0.6	4.97	0.37	1.8e-6	Obesity-related traits;
PAAD	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.43	0.34	1.81e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	4.69	0.36	6.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg02631450	chr22:32366979	NA	1.07	5.76	0.42	4.45e-8	Childhood ear infection;
PAAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs727479	0.543	rs3759811	chr15:51529265	A/G	cg21478137	chr15:51532386	CYP19A1	0.53	5.19	0.39	6.74e-7	Estradiol levels;
PAAD	cis	rs3106136	0.807	rs6851128	chr4:95259455	A/G	cg11021082	chr4:95130006	SMARCAD1	0.62	6.01	0.44	1.33e-8	Capecitabine sensitivity;
PAAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.58	-5.33	-0.4	3.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.57	6.72	0.48	3.45e-10	Total body bone mineral density;
PAAD	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs6963495	0.872	rs116979167	chr7:105222451	C/A	cg02135003	chr7:105160482	PUS7	-0.86	-5.69	-0.42	6.26e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg14583973	chr4:3374767	RGS12	-0.36	-5.44	-0.4	2.13e-7	Mean platelet volume;
PAAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.35	0.56	4.04e-14	Menopause (age at onset);
PAAD	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.49	-6.93	-0.49	1.12e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.22	0.55	8.55e-14	Morning vs. evening chronotype;
PAAD	cis	rs6466055	0.553	rs10228174	chr7:104691505	C/T	cg04380332	chr7:105027541	SRPK2	-0.51	-4.98	-0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs2275565	0.872	rs58213669	chr1:237037881	A/T	cg17297354	chr1:237056641	MTR	-0.53	-4.75	-0.36	4.6e-6	Homocysteine levels;
PAAD	cis	rs80346118	0.673	rs6019433	chr20:47422568	G/A	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.6	-4.47	-0.34	1.49e-5	Diastolic blood pressure;
PAAD	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.41	-0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.38	0.46	2.07e-9	Hip circumference;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07300030	chr2:165698022	COBLL1	-0.58	-6.36	-0.46	2.24e-9	Myopia (pathological);
PAAD	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.77	6.35	0.46	2.35e-9	Glioblastoma;
PAAD	cis	rs8105895	0.733	rs62110979	chr19:22245152	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg20243544	chr17:37824526	PNMT	0.56	5.13	0.38	8.85e-7	Self-reported allergy;
PAAD	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.92	-11.07	-0.67	2.93e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg24296786	chr1:45957014	TESK2	0.49	4.49	0.34	1.39e-5	Homocysteine levels;
PAAD	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12935418	0.583	rs2970085	chr16:81028447	T/C	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.54	0.57	1.28e-14	Homoarginine levels;
PAAD	cis	rs11942476	0.619	rs4456944	chr4:21489567	C/G	cg14992154	chr4:20701870	PACRGL	0.59	4.51	0.34	1.29e-5	IgG glycosylation;
PAAD	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.64	6.77	0.48	2.58e-10	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00166722	chr3:10149974	C3orf24	0.86	6.31	0.46	2.84e-9	Alzheimer's disease;
PAAD	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.8	9.7	0.62	1.33e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	8.43	0.56	2.47e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1499972	0.618	rs61384494	chr3:117640660	C/T	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27007178	chr17:4634690	MED11	-0.73	-6.71	-0.48	3.69e-10	Neuroticism;
PAAD	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.88	-0.49	1.43e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg01612440	chr4:3296283	NA	0.47	4.53	0.34	1.19e-5	Serum sulfate level;
PAAD	cis	rs12136530	0.593	rs12403329	chr1:19735793	G/C	cg03321592	chr1:19991676	HTR6	0.5	4.32	0.33	2.84e-5	Lead levels in blood;
PAAD	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg00491522	chr10:135256596	NA	0.79	4.58	0.35	9.61e-6	Lifespan;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08731084	chr12:44229880	TMEM117	0.7	6.4	0.46	1.86e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.42	-0.46	1.63e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs17741873	0.720	rs16931023	chr10:75683793	G/A	cg01368488	chr10:75493387	NA	-0.52	-4.28	-0.33	3.34e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg18209359	chr17:80159595	CCDC57	-0.46	-4.71	-0.36	5.65e-6	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.41	0.46	1.73e-9	Lung cancer in ever smokers;
PAAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.0	0.38	1.55e-6	Common traits (Other);
PAAD	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg20893579	chr22:38215064	NA	0.51	5.34	0.4	3.33e-7	Glioblastoma;Glioma;
PAAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.94	8.08	0.55	1.82e-13	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.8	9.26	0.6	1.88e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-4.81	-0.36	3.6e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.79	9.27	0.6	1.75e-16	Heart rate;
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.9	-0.43	2.24e-8	Lung cancer;
PAAD	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.67	6.98	0.49	8.37e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-1.0	-7.56	-0.52	3.46e-12	Blood protein levels;
PAAD	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	1.57	9.63	0.62	2.03e-17	Age-related hearing impairment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27457698	chr16:28565225	CCDC101	0.57	6.34	0.46	2.51e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg02696790	chr15:75250997	RPP25	-0.4	-4.83	-0.36	3.36e-6	Systemic lupus erythematosus;
PAAD	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.57	6.45	0.46	1.38e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.92	-7.91	-0.54	4.97e-13	Dupuytren's disease;
PAAD	cis	rs12949688	0.601	rs4793573	chr17:55834533	C/T	cg12582317	chr17:55822272	NA	0.46	5.7	0.42	6.1e-8	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.52e-5	Iron status biomarkers;
PAAD	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg09796270	chr17:17721594	SREBF1	0.44	5.08	0.38	1.07e-6	Total body bone mineral density;
PAAD	cis	rs9616064	0.849	rs28521630	chr22:46971620	C/T	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.54	-0.35	1.14e-5	Urate levels in obese individuals;
PAAD	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.97	-7.78	-0.53	1.01e-12	Blood protein levels;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg18612461	chr15:75251733	NA	0.59	7.16	0.5	3.22e-11	Breast cancer;
PAAD	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg01798341	chr17:80842262	TBCD	0.42	4.65	0.35	7.17e-6	Breast cancer;
PAAD	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10267417	0.603	rs10273376	chr7:19911647	T/A	cg05791153	chr7:19748676	TWISTNB	0.68	4.85	0.37	3.08e-6	Night sleep phenotypes;
PAAD	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.93	0.37	2.16e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-1.07	-10.19	-0.64	6.59e-19	Orofacial clefts;
PAAD	cis	rs9815354	0.627	rs73073268	chr3:42021403	C/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs7129556	0.954	rs11823651	chr11:77253879	G/A	cg24456632	chr11:77314957	AQP11	-0.49	-4.29	-0.33	3.11e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.44	0.46	1.5e-9	Schizophrenia;
PAAD	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.34	-0.33	2.56e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.87	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs6728302	0.557	rs111524519	chr2:233271763	C/A	cg10242318	chr2:233385248	NA	-0.74	-4.32	-0.33	2.82e-5	Height;
PAAD	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg17372657	chr7:1216933	NA	-0.37	-4.72	-0.36	5.29e-6	Longevity;Endometriosis;
PAAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.49	-4.71	-0.36	5.63e-6	Facial morphology (factor 20);
PAAD	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.55	-5.06	-0.38	1.2e-6	Primary sclerosing cholangitis;
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg26939375	chr7:64535504	NA	0.76	9.19	0.6	2.84e-16	Calcium levels;
PAAD	cis	rs2131877	0.871	rs28569214	chr3:194871488	A/G	cg21937377	chr3:194868750	C3orf21	0.44	4.72	0.36	5.24e-6	Non-small cell lung cancer;
PAAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.8	8.32	0.56	4.78e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.49	5.75	0.42	4.8e-8	Height;
PAAD	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.82	0.43	3.4e-8	Menopause (age at onset);
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg18279126	chr7:2041391	MAD1L1	0.56	5.61	0.41	9.26e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg20761395	chr17:511517	VPS53	0.48	4.69	0.36	6.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.58	5.47	0.41	1.79e-7	Type 2 diabetes;
PAAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg02841227	chr6:26021843	HIST1H4A	0.46	4.56	0.35	1.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.87	9.24	0.6	2.03e-16	Height;
PAAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg02297831	chr4:17616191	MED28	0.58	5.34	0.4	3.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.57	6.52	0.47	9.62e-10	Schizophrenia;
PAAD	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.82	-9.16	-0.6	3.33e-16	Body mass index;
PAAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.47	7.54	0.52	3.96e-12	IgG glycosylation;
PAAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg09796270	chr17:17721594	SREBF1	-0.5	-5.49	-0.41	1.65e-7	Total body bone mineral density;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg01097406	chr16:89675127	NA	0.36	4.31	0.33	2.88e-5	Vitiligo;
PAAD	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg02640540	chr1:67518911	SLC35D1	-0.52	-4.55	-0.35	1.08e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.77	-9.06	-0.59	5.93e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg19041857	chr6:27730383	NA	-0.42	-4.98	-0.37	1.7e-6	Parkinson's disease;
PAAD	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.4	4.38	0.33	2.18e-5	Mean platelet volume;
PAAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.78	-7.41	-0.52	8.12e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11811982	0.793	rs115229735	chr1:227556337	T/C	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-4.9	-0.37	2.39e-6	Height;
PAAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs5753037	0.653	rs131271	chr22:30151582	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.97	-0.54	3.59e-13	Blood metabolite levels;
PAAD	cis	rs42648	0.564	rs11563340	chr7:89809579	A/G	cg27367526	chr7:89841692	STEAP2	-0.34	-4.76	-0.36	4.52e-6	Homocysteine levels;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.77	6.2	0.45	5.08e-9	Alzheimer's disease;
PAAD	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg21775007	chr8:11205619	TDH	-0.46	-4.35	-0.33	2.5e-5	Systolic blood pressure;
PAAD	cis	rs4740619	0.630	rs2987021	chr9:15986042	A/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs4740619	0.711	rs10756731	chr9:15975600	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.55	-0.35	1.1e-5	Body mass index;
PAAD	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	1.2	10.03	0.63	1.73e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs61884328	0.866	rs17790156	chr11:46905318	A/T	cg23433285	chr11:47201945	PACSIN3	0.78	4.49	0.34	1.43e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.39	-4.34	-0.33	2.6e-5	Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14834741	chr10:120810245	EIF3A	-0.63	-6.73	-0.48	3.34e-10	Obesity-related traits;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15681981	chr17:42833328	NA	0.65	6.71	0.48	3.55e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg20243544	chr17:37824526	PNMT	0.49	4.32	0.33	2.85e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16761131	chr22:38142377	TRIOBP	0.61	6.59	0.47	6.85e-10	Myopia (pathological);
PAAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg14440974	chr22:39074834	NA	0.56	6.6	0.47	6.3e-10	Menopause (age at onset);
PAAD	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.71	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs4332037	0.715	rs57234495	chr7:1906466	G/A	cg02421172	chr7:1938701	MAD1L1	0.58	4.3	0.33	3e-5	Bipolar disorder;
PAAD	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg26031613	chr14:104095156	KLC1	-0.52	-5.53	-0.41	1.38e-7	Schizophrenia;
PAAD	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.69	4.85	0.37	3.08e-6	Hip geometry;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg13126279	chr21:47581558	C21orf56	-0.39	-4.26	-0.33	3.51e-5	Testicular germ cell tumor;
PAAD	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.95	11.38	0.68	4.34e-22	Primary sclerosing cholangitis;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg13444538	chr7:158905317	VIPR2	0.56	5.19	0.39	6.51e-7	Facial morphology (factor 20);
PAAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14180030	chr9:123475675	MEGF9	-0.4	-4.54	-0.35	1.12e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2834256	0.527	rs9983905	chr21:34866858	C/T	cg14850771	chr21:34775459	IFNGR2	0.43	4.53	0.35	1.18e-5	Red cell distribution width;
PAAD	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg08648136	chr8:956695	NA	0.49	5.13	0.38	8.72e-7	Schizophrenia;
PAAD	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.77	0.48	2.59e-10	Height;
PAAD	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg20744362	chr22:50050164	C22orf34	0.59	7.48	0.52	5.69e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.65	6.98	0.49	8.51e-11	Longevity;
PAAD	cis	rs16866061	0.517	rs56337305	chr2:225475560	T/C	cg12698349	chr2:225449008	CUL3	0.6	6.45	0.46	1.38e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs7818688	0.697	rs74633235	chr8:95981476	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.43e-7	Daytime sleep phenotypes;
PAAD	cis	rs1198430	0.599	rs946269	chr1:23769359	T/C	cg27447006	chr1:23763279	ASAP3	0.65	5.0	0.38	1.58e-6	Total cholesterol levels;
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs2455601	0.786	rs2568068	chr11:8977830	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.59	-6.79	-0.48	2.42e-10	Schizophrenia;
PAAD	cis	rs1395	0.778	rs62128743	chr2:27390169	A/G	cg23587288	chr2:27483067	SLC30A3	-0.87	-7.5	-0.52	4.82e-12	Blood metabolite levels;
PAAD	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.52	-4.87	-0.37	2.72e-6	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs12136530	0.593	rs12121242	chr1:19740609	G/C	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.6	6.53	0.47	9.1e-10	Colorectal cancer;
PAAD	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.15e-10	HDL cholesterol;
PAAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.74	-8.23	-0.56	7.68e-14	DNA methylation (variation);
PAAD	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.55	-4.99	-0.38	1.61e-6	White blood cell count (neutrophil);
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs10901513	0.932	rs11244745	chr10:127668431	A/G	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2072732	0.731	rs10909862	chr1:2936815	G/A	cg22517653	chr1:2918612	NA	0.63	4.97	0.37	1.78e-6	Plateletcrit;
PAAD	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.5	5.03	0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.34	4.25	0.33	3.76e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-11.15	-0.67	1.84e-21	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02009256	chr12:56882326	GLS2	0.58	6.63	0.47	5.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg08079166	chr15:68083412	MAP2K5	0.68	5.33	0.4	3.53e-7	Restless legs syndrome;
PAAD	cis	rs7765175	0.598	rs6568777	chr6:113608616	G/A	cg19037598	chr6:113666021	NA	-0.41	-4.38	-0.33	2.22e-5	Coronary artery calcification;
PAAD	cis	rs11264799	0.603	rs2208753	chr1:157584301	A/C	cg18268488	chr1:157545234	FCRL4	0.47	5.6	0.41	9.78e-8	IgA nephropathy;
PAAD	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.59	-4.78	-0.36	4.16e-6	Post bronchodilator FEV1;
PAAD	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.48	5.09	0.38	1.02e-6	Ulcerative colitis;
PAAD	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg10290764	chr8:4849399	CSMD1	-0.39	-6.56	-0.47	7.79e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.5	-5.07	-0.38	1.16e-6	Rheumatoid arthritis;
PAAD	cis	rs16958440	1.000	rs4609941	chr18:44645491	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11702778	chr19:48185277	GLTSCR1	-0.64	-7.18	-0.5	2.97e-11	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.52	-6.35	-0.46	2.31e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-5.49	-0.41	1.68e-7	Schizophrenia;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.97	13.55	0.74	6.15e-28	Menarche (age at onset);
PAAD	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.65	-7.29	-0.51	1.6e-11	Heart rate;
PAAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-6.25	-0.45	3.91e-9	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-4.29	-0.33	3.11e-5	Coronary artery disease;
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg25886479	chr11:50257625	LOC441601	0.42	4.63	0.35	7.89e-6	Coronary artery disease;
PAAD	cis	rs12893597	0.715	rs34486942	chr14:76831530	G/A	cg20290672	chr14:76816747	NA	-0.58	-4.97	-0.37	1.76e-6	Maximal oxygen uptake response;
PAAD	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.42	-4.53	-0.34	1.19e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg05895507	chr15:77155635	SCAPER	0.37	4.61	0.35	8.35e-6	Blood metabolite levels;
PAAD	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.61	6.21	0.45	4.86e-9	Response to antipsychotic treatment;
PAAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.95	-5.92	-0.43	2.09e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg21565972	chr17:80109576	CCDC57	0.58	6.74	0.48	3.15e-10	Life satisfaction;
PAAD	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04590956	chr2:70057467	GMCL1	0.62	7.02	0.49	6.8e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.52	6.02	0.44	1.25e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6088813	0.663	rs2425056	chr20:33909245	G/A	cg14752227	chr20:34000481	UQCC	0.47	4.31	0.33	2.98e-5	Height;
PAAD	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.54	-4.92	-0.37	2.2e-6	Life satisfaction;
PAAD	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.83	6.89	0.49	1.42e-10	Pulmonary function decline;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11137483	chr3:42695852	ZBTB47	0.72	8.78	0.58	3.14e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	5.73	0.42	5.23e-8	Schizophrenia;
PAAD	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.41	4.28	0.33	3.3e-5	Sense of smell;
PAAD	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.58	5.74	0.42	4.93e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg11494091	chr17:61959527	GH2	-0.93	-12.13	-0.7	4.18e-24	Prudent dietary pattern;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.96	10.94	0.66	6.65e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs72960926	0.744	rs952120	chr6:74917250	T/G	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.75	-0.36	4.7e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6074578	0.541	rs6040343	chr20:169995	C/T	cg16931068	chr20:139680	DEFB127	0.41	5.49	0.41	1.63e-7	Hirschsprung disease;
PAAD	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.58e-13	Eotaxin levels;
PAAD	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.5	-4.45	-0.34	1.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.67	-8.06	-0.55	2.08e-13	Huntington's disease progression;
PAAD	cis	rs9581857	0.579	rs118061689	chr13:27974499	A/T	cg22138327	chr13:27999177	GTF3A	0.88	5.57	0.41	1.11e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg06569542	chr10:98946673	SLIT1	-0.52	-5.84	-0.43	3.01e-8	Monocyte count;
PAAD	cis	rs288342	0.832	rs288305	chr2:183652328	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.75	-0.36	4.74e-6	Recurrent major depressive disorder;
PAAD	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg01064725	chr1:204461714	NA	-0.51	-4.91	-0.37	2.38e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg12647257	chr2:47043387	NA	-0.44	-4.29	-0.33	3.12e-5	Height;
PAAD	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.5e-5	Life satisfaction;
PAAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.3	8.51	0.57	1.56e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs597480	0.857	rs520500	chr11:85451938	A/C	cg11817631	chr11:85522609	SYTL2	-0.49	-4.34	-0.33	2.59e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs7326068	0.610	rs2818985	chr13:21314209	G/T	cg27499820	chr13:21296301	IL17D	0.57	5.34	0.4	3.39e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.34	0.33	2.54e-5	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5753037	0.586	rs140120	chr22:30138548	T/C	cg01021169	chr22:30184971	ASCC2	-0.46	-4.79	-0.36	3.86e-6	Type 1 diabetes;
PAAD	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.56	-5.29	-0.39	4.28e-7	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09959495	chr2:237029385	AGAP1	-0.66	-6.63	-0.47	5.65e-10	Obesity-related traits;
PAAD	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6558530	0.965	rs6558535	chr8:1710632	T/C	cg19131313	chr8:1704013	NA	-0.43	-4.8	-0.36	3.81e-6	Systolic blood pressure;
PAAD	cis	rs12586317	0.642	rs7156944	chr14:35790467	T/G	cg16230307	chr14:35515116	FAM177A1	0.49	4.82	0.36	3.4e-6	Psoriasis;
PAAD	cis	rs2120243	0.539	rs35218020	chr3:157115416	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs10886094	0.881	rs10886091	chr10:119270791	T/C	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg14711859	chr11:8959438	ASCL3	0.48	5.61	0.41	9.22e-8	Hematocrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17365335	chr7:99123938	ZKSCAN5	-0.66	-6.56	-0.47	8.15e-10	Obesity-related traits;
PAAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	0.58	4.25	0.33	3.73e-5	Fat distribution (HIV);
PAAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.48	-0.41	1.69e-7	Subjective well-being;
PAAD	cis	rs10037758	0.569	rs4068744	chr5:128273337	T/A	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4294134	0.608	rs11760746	chr7:135244015	G/A	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.68	7.31	0.51	1.4e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg27411982	chr8:10470053	RP1L1	-0.43	-4.33	-0.33	2.66e-5	Retinal vascular caliber;
PAAD	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg08917208	chr2:24149416	ATAD2B	-0.51	-4.61	-0.35	8.5e-6	Asthma;
PAAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.72	-10.56	-0.65	6.76e-20	Birth weight;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.57	-0.35	1e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg09324608	chr17:30823087	MYO1D	0.47	4.67	0.35	6.44e-6	Schizophrenia;
PAAD	cis	rs2479724	0.776	rs12523672	chr6:41749692	T/G	cg17623882	chr6:41773611	USP49	0.44	4.74	0.36	4.98e-6	Menarche (age at onset);
PAAD	cis	rs787274	1.000	rs4979155	chr9:115560134	G/A	cg13803584	chr9:115635662	SNX30	-0.8	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.45	4.86	0.37	2.96e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-4.39	-0.34	2.08e-5	Longevity;Endometriosis;
PAAD	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15644404	chr18:77186268	NFATC1	-0.89	-5.17	-0.39	7.41e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg21479132	chr6:26055353	NA	1.0	6.13	0.45	7.2e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-11.63	-0.69	9.36e-23	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6460942	0.597	rs35589221	chr7:12535841	T/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-0.43	-4.33	-0.33	2.65e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-5.79	-0.42	3.95e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-4.5	-0.34	1.37e-5	Educational attainment;
PAAD	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.51	-0.34	1.28e-5	Height;
PAAD	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.72	9.11	0.59	4.43e-16	Asthma;
PAAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.56	5.11	0.38	9.72e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg07648498	chr16:89883185	FANCA	-0.51	-4.84	-0.37	3.13e-6	Vitiligo;
PAAD	cis	rs2137920	0.685	rs12782892	chr10:50241938	C/T	cg02657375	chr10:50863136	CHAT	0.57	4.6	0.35	8.84e-6	Migraine with aura;
PAAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	9.91	0.63	3.72e-18	Platelet count;
PAAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.45	8.08	0.55	1.87e-13	Multiple system atrophy;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.76	9.08	0.59	5.31e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.19e-6	Systolic blood pressure;
PAAD	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.69	-0.36	5.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.56	5.67	0.42	6.95e-8	Eosinophil percentage of white cells;
PAAD	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg02696790	chr15:75250997	RPP25	-0.43	-5.26	-0.39	4.72e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.68	-0.53	1.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.68e-13	Motion sickness;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.26	0.39	4.75e-7	Life satisfaction;
PAAD	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-4.32	-0.33	2.78e-5	Toenail selenium levels;
PAAD	cis	rs2579500	0.768	rs11676886	chr2:97249011	A/G	cg09304357	chr2:97220596	NA	-0.47	-5.05	-0.38	1.25e-6	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-9.22	-0.6	2.34e-16	Vitiligo;
PAAD	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-4.44	-0.34	1.69e-5	Red blood cell count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09561351	chr12:42876655	PRICKLE1	0.61	7.14	0.5	3.7e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg04330084	chr7:123175371	IQUB	0.51	4.29	0.33	3.14e-5	Plateletcrit;Platelet count;
PAAD	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg27511599	chr7:32358540	NA	0.73	4.45	0.34	1.62e-5	Body mass index;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.87	-10.9	-0.66	8.54e-21	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg17830980	chr10:43048298	ZNF37B	0.68	7.89	0.54	5.43e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.27	12.09	0.7	5.37e-24	Corneal structure;
PAAD	cis	rs6681460	0.932	rs603750	chr1:67177488	A/G	cg02459107	chr1:67143332	SGIP1	0.68	6.29	0.45	3.15e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs7577696	0.626	rs212754	chr2:32421628	A/G	cg02381751	chr2:32503542	YIPF4	0.49	4.68	0.35	6.4e-6	Inflammatory biomarkers;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.58	4.3	0.33	3.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.87	6.32	0.46	2.78e-9	Lymphocyte counts;
PAAD	cis	rs12801636	0.512	rs7119750	chr11:65422591	C/T	cg06492744	chr11:65406254	SIPA1	0.49	4.36	0.33	2.37e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-10.66	-0.65	3.62e-20	Height;
PAAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg12215294	chr3:40350768	EIF1B	0.46	4.46	0.34	1.58e-5	Renal cell carcinoma;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.44	0.61	6.21e-17	Parkinson's disease;
PAAD	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.81	0.36	3.55e-6	Red blood cell count;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg00738919	chr7:1100172	C7orf50	0.53	4.42	0.34	1.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg09177884	chr7:1199841	ZFAND2A	-0.68	-5.3	-0.39	4.05e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.77	0.48	2.69e-10	Leprosy;
PAAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.52	0.34	1.24e-5	Melanoma;
PAAD	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.69	7.1	0.5	4.59e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-7.24	-0.51	2.06e-11	Morning vs. evening chronotype;
PAAD	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.54	5.34	0.4	3.31e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg09344028	chr17:70110421	NA	0.56	7.16	0.5	3.17e-11	Thyroid hormone levels;
PAAD	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	6.08	0.44	9.24e-9	LDL cholesterol;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.0	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	10.25	0.64	4.43e-19	Smoking behavior;
PAAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	4.57	0.35	9.95e-6	Breast cancer;
PAAD	cis	rs2120243	0.508	rs1456106	chr3:157123456	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.52	5.04	0.38	1.33e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.56	0.35	1.06e-5	Obesity-related traits;
PAAD	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg01191920	chr7:158217561	PTPRN2	-0.77	-7.7	-0.53	1.66e-12	Obesity-related traits;
PAAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05025164	chr4:1340916	KIAA1530	0.6	5.81	0.43	3.62e-8	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.51	-0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs151997	0.569	rs62367393	chr5:50270360	C/A	cg06027927	chr5:50259733	NA	0.62	5.61	0.41	9.3e-8	Callous-unemotional behaviour;
PAAD	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.07	0.38	1.13e-6	Morning vs. evening chronotype;
PAAD	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19500393	chr10:372993	DIP2C	0.54	6.65	0.47	4.98e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.5	-0.34	1.34e-5	Mood instability;
PAAD	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.51	5.78	0.42	4.13e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.74	-0.36	4.82e-6	Mean corpuscular volume;
PAAD	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.75	0.42	4.65e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg09579323	chr1:150459698	TARS2	-0.46	-4.39	-0.34	2.12e-5	Migraine;
PAAD	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.55	-5.39	-0.4	2.65e-7	Adiposity;
PAAD	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-7.81	-0.54	8.76e-13	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.94	7.45	0.52	6.61e-12	Initial pursuit acceleration;
PAAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.43	4.76	0.36	4.4e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01947301	chr1:205718900	NUCKS1	-0.67	-7.95	-0.54	3.87e-13	Body fat percentage;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-7.45	-0.52	6.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg23346134	chr3:49453900	TCTA	0.46	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00675838	chr6:97285024	GPR63	0.63	6.77	0.48	2.69e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.65	4.9	0.37	2.39e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg10729496	chr3:10149963	C3orf24	0.91	7.49	0.52	5.2e-12	Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02296145	chr16:1840711	IGFALS	0.66	6.52	0.47	9.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.66	6.8	0.48	2.24e-10	Renal function-related traits (BUN);
PAAD	cis	rs988913	1.000	rs7764641	chr6:54835469	A/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.63	-0.35	7.84e-6	Menarche (age at onset);
PAAD	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg08029281	chr1:67600428	NA	0.42	4.94	0.37	2.02e-6	Psoriasis;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.68	-8.81	-0.58	2.63e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	1.18	6.26	0.45	3.66e-9	Inflammatory biomarkers;
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg11498726	chr8:26250323	BNIP3L	-0.57	-5.52	-0.41	1.45e-7	Red cell distribution width;
PAAD	cis	rs939584	1.000	rs6734363	chr2:635200	G/A	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs16852403	0.583	rs6670912	chr1:178082410	C/T	cg00404053	chr1:178313656	RASAL2	0.48	4.51	0.34	1.3e-5	Childhood ear infection;
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg02869306	chr7:64672164	INTS4L1	0.41	4.81	0.36	3.59e-6	Calcium levels;
PAAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.41	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg11764359	chr7:65958608	NA	0.76	5.07	0.38	1.12e-6	Gout;
PAAD	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	6.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg06217245	chr20:33103252	DYNLRB1	0.41	4.54	0.35	1.16e-5	Height;
PAAD	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.85	-9.68	-0.62	1.48e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4148087	1.000	rs9981390	chr21:43634081	G/A	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.96	-7.51	-0.52	4.75e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08677398	chr8:58056175	NA	0.59	4.39	0.34	2.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11107903	0.892	rs2033089	chr12:95443532	A/C	cg19510484	chr12:95868044	METAP2	0.9	4.31	0.33	2.86e-5	Coronary artery disease;
PAAD	cis	rs77880822	0.562	rs79787658	chr20:1253252	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.66	5.75	0.42	4.77e-8	Common traits (Other);
PAAD	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg10006428	chr1:248814059	OR2T27	0.4	4.72	0.36	5.21e-6	Common traits (Other);
PAAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.19	-0.45	5.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-5.82	-0.43	3.33e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.35	4.47	0.34	1.52e-5	Educational attainment (years of education);
PAAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.48e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.49	-4.6	-0.35	8.91e-6	P wave terminal force;
PAAD	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs66696671	0.649	rs67414890	chr10:121381843	T/C	cg13975098	chr10:121303635	RGS10	0.36	4.46	0.34	1.6e-5	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
PAAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg02574844	chr11:5959923	NA	-0.76	-7.24	-0.51	2.1e-11	DNA methylation (variation);
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg15208524	chr1:10270712	KIF1B	0.44	4.47	0.34	1.51e-5	Hepatocellular carcinoma;
PAAD	cis	rs9810890	1.000	rs73198852	chr3:128508858	A/C	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg05861140	chr6:150128134	PCMT1	-0.51	-5.37	-0.4	2.95e-7	Lung cancer;
PAAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.73	11.29	0.68	7.57e-22	Breast cancer;
PAAD	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg08345082	chr10:99160200	RRP12	0.3	4.43	0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.48	-4.44	-0.34	1.74e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	4.93	0.37	2.12e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.21	-0.39	5.99e-7	Life satisfaction;
PAAD	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.73	0.58	4.25e-15	Corneal astigmatism;
PAAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.52	-4.98	-0.37	1.68e-6	Glomerular filtration rate;
PAAD	cis	rs797680	0.753	rs11164881	chr1:93658989	C/A	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg20744362	chr22:50050164	C22orf34	0.64	7.42	0.52	7.79e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.71	5.36	0.4	3.09e-7	Vitiligo;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.94	-0.37	2.02e-6	Schizophrenia;
PAAD	cis	rs1997066	0.831	rs10466175	chr10:106776357	A/G	cg17321814	chr10:106440892	SORCS3	0.61	4.29	0.33	3.22e-5	Diabetic kidney disease;
PAAD	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg08601574	chr20:25228251	PYGB	0.66	7.33	0.51	1.29e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.91	4.73	0.36	5.1e-6	Plasma clusterin levels;
PAAD	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg19630374	chr17:18023558	MYO15A	-0.56	-5.93	-0.43	1.99e-8	Total body bone mineral density;
PAAD	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg21951975	chr1:209979733	IRF6	0.53	5.11	0.38	9.47e-7	Coronary artery disease;
PAAD	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.8	-9.0	-0.59	8.44e-16	Idiopathic membranous nephropathy;
PAAD	cis	rs11686241	1.000	rs13410848	chr2:217290643	G/C	cg15830940	chr2:217278069	SMARCAL1	0.44	4.32	0.33	2.86e-5	Cancer;
PAAD	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg19192590	chr2:178524533	PDE11A	0.42	4.27	0.33	3.45e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg03060546	chr3:49711283	APEH	0.47	4.3	0.33	3.02e-5	Parkinson's disease;
PAAD	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.53	5.05	0.38	1.24e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	4.35	0.33	2.44e-5	Height;
PAAD	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg25809561	chr17:30822961	MYO1D	0.67	6.87	0.49	1.55e-10	Schizophrenia;
PAAD	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12900413	0.562	rs12898229	chr15:90295960	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.67	-0.42	7.08e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15458585	chr2:170221103	NA	-0.56	-6.32	-0.46	2.7e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.68	0.53	1.8e-12	Eotaxin levels;
PAAD	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-1.06	-10.55	-0.65	7.03e-20	Platelet distribution width;
PAAD	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.23	0.56	7.95e-14	Dupuytren's disease;
PAAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-5.78	-0.42	4.19e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg23788917	chr6:8435910	SLC35B3	-0.67	-7.29	-0.51	1.58e-11	Motion sickness;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.96	8.51	0.57	1.52e-14	Alzheimer's disease;
PAAD	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.64	6.12	0.44	7.79e-9	Corneal astigmatism;
PAAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.69	8.16	0.55	1.16e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10155981	0.510	rs28579868	chr7:22593997	T/C	cg05062323	chr7:22590069	NA	-0.92	-5.62	-0.41	8.9e-8	Bilirubin levels;
PAAD	cis	rs2834256	0.543	rs8134847	chr21:35020161	C/T	cg14850771	chr21:34775459	IFNGR2	0.44	4.52	0.34	1.26e-5	Red cell distribution width;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg13264159	chr8:625131	ERICH1	-0.75	-5.06	-0.38	1.22e-6	IgG glycosylation;
PAAD	cis	rs2302729	0.929	rs7136355	chr12:2783476	T/C	cg19945202	chr12:2788847	CACNA1C	-0.71	-6.62	-0.47	5.89e-10	Sleep quality;
PAAD	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.56	-5.67	-0.42	6.91e-8	Multiple myeloma;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs7823896	0.790	rs72682635	chr8:110269615	C/G	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs73086581	1.000	rs34640283	chr20:3989576	T/A	cg02187196	chr20:3869020	PANK2	0.55	4.5	0.34	1.32e-5	Response to antidepressants in depression;
PAAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.52	5.21	0.39	6.18e-7	Longevity;
PAAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.24	-0.45	4.13e-9	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.82	9.7	0.62	1.27e-17	Menopause (age at onset);
PAAD	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.0	-0.38	1.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.32	-0.33	2.83e-5	Schizophrenia;
PAAD	cis	rs1891275	0.516	rs10881943	chr10:93415130	G/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.64	5.66	0.42	7.32e-8	Lung cancer;
PAAD	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs4908768	0.657	rs6693466	chr1:8817938	C/T	cg25722041	chr1:8623473	RERE	0.52	4.42	0.34	1.88e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21865762	chr12:52060551	SCN8A	0.52	6.38	0.46	2.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg18833306	chr6:118973337	C6orf204	-0.54	-4.45	-0.34	1.62e-5	Diastolic blood pressure;
PAAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg04106633	chr4:1044584	NA	0.64	5.36	0.4	2.99e-7	Recombination rate (females);
PAAD	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.71	0.48	3.54e-10	Response to antipsychotic treatment;
PAAD	trans	rs901683	1.000	rs34793991	chr10:46080590	A/C	cg14076390	chr17:34947837	DHRS11	0.92	6.67	0.48	4.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg27411982	chr8:10470053	RP1L1	-0.48	-4.81	-0.36	3.59e-6	Neuroticism;
PAAD	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg06740227	chr12:86229804	RASSF9	-0.55	-5.27	-0.39	4.57e-7	Major depressive disorder;
PAAD	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.09	-0.38	1.06e-6	Subjective well-being;
PAAD	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.63	-4.56	-0.35	1.06e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.35e-17	Resting heart rate;
PAAD	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg00543991	chr22:32367038	NA	1.06	6.97	0.49	8.81e-11	Childhood ear infection;
PAAD	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.31	-0.33	2.94e-5	Alzheimer's disease (survival time);
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-4.96	-0.37	1.84e-6	Bipolar disorder;
PAAD	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.79	7.79	0.53	1e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs863345	0.967	rs7520063	chr1:158470198	T/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.54	5.64	0.42	7.93e-8	Longevity;Endometriosis;
PAAD	cis	rs11637339	0.561	rs4965508	chr15:100007155	T/C	cg03300787	chr15:100533202	ADAMTS17	-0.43	-4.43	-0.34	1.81e-5	Cervical cancer;
PAAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.56	4.64	0.35	7.59e-6	Dementia with Lewy bodies;
PAAD	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg04482110	chr17:41364121	TMEM106A	0.39	4.48	0.34	1.44e-5	Menopause (age at onset);
PAAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05904194	chr2:85132663	TMSB10	0.69	7.25	0.51	1.95e-11	Myopia (pathological);
PAAD	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs7925523	0.891	rs731842	chr11:61480191	T/C	cg12472022	chr11:61462803	DAGLA	0.54	4.31	0.33	2.87e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.56	5.35	0.4	3.19e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg02421172	chr7:1938701	MAD1L1	0.57	4.27	0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs9687846	0.877	rs13173241	chr5:55861359	G/A	cg15001016	chr5:55860904	NA	-0.47	-4.53	-0.34	1.18e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-11.63	-0.69	9.28e-23	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;
PAAD	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.53	0.47	9.23e-10	Lung cancer;
PAAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09826364	chr7:158789723	NA	0.35	4.48	0.34	1.48e-5	Facial morphology (factor 20);
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg25452165	chr22:42524984	CYP2D6	-0.58	-5.3	-0.39	4.01e-7	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21269893	chr17:41322169	NBR1	0.7	7.64	0.53	2.25e-12	Myopia (pathological);
PAAD	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg00922110	chr4:57842668	C4orf14	-0.44	-4.47	-0.34	1.51e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.03	-0.44	1.21e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-4.69	-0.36	6.02e-6	Blood protein levels;
PAAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg04705435	chr11:17411270	KCNJ11	0.62	6.46	0.46	1.35e-9	Type 2 diabetes;
PAAD	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg06217245	chr20:33103252	DYNLRB1	0.39	4.38	0.34	2.17e-5	Height;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.59	-5.56	-0.41	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.78	-7.9	-0.54	5.28e-13	Coronary artery disease;
PAAD	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg07099767	chr17:78039528	CCDC40	-0.5	-4.85	-0.37	3.04e-6	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.49	-0.47	1.12e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.11	-0.38	9.74e-7	Daytime sleep phenotypes;
PAAD	cis	rs2004318	1.000	rs10424040	chr19:55119692	T/C	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg07371521	chr5:154026371	NA	0.63	7.15	0.5	3.37e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.93	6.87	0.49	1.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2410601	0.644	rs4579570	chr8:18926977	A/C	cg19414122	chr8:18896631	NA	0.37	4.37	0.33	2.28e-5	Urinary albumin excretion rate in type 1 diabetes;
PAAD	trans	rs12744757	1	rs12744757	chr1:11906821	C/T	cg09422450	chr16:79623618	NA	0.72	6.4	0.46	1.83e-9	Systolic blood pressure;
PAAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg23346134	chr3:49453900	TCTA	0.46	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.45	-5.84	-0.43	3.08e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16639922	chr3:9975056	IL17RC;CRELD1	-0.69	-6.8	-0.48	2.25e-10	Smoking initiation;
PAAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg14349672	chr11:133703707	NA	-0.46	-4.94	-0.37	2.08e-6	Childhood ear infection;
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.56	-6.14	-0.45	7.02e-9	Testicular germ cell tumor;
PAAD	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.55	-4.77	-0.36	4.23e-6	Parkinson's disease;
PAAD	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-4.36	-0.33	2.34e-5	Blood protein levels;
PAAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.6	-6.65	-0.47	4.98e-10	Tonsillectomy;
PAAD	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.27	0.33	3.41e-5	Lung cancer;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.67	0.35	6.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.65	6.2	0.45	5.03e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.99	0.38	1.61e-6	Breast cancer;
PAAD	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg06565975	chr8:143823917	SLURP1	-0.2	-4.53	-0.34	1.2e-5	Urinary tract infection frequency;
PAAD	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-6.53	-0.47	9.48e-10	Cognitive function;
PAAD	trans	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg26939375	chr7:64535504	NA	-0.72	-8.5	-0.57	1.62e-14	Aortic root size;
PAAD	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.87	-8.38	-0.56	3.39e-14	Bone mineral density;
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg02487422	chr3:49467188	NICN1	-0.43	-4.37	-0.33	2.3e-5	Menarche (age at onset);
PAAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.75	0.42	4.77e-8	Personality dimensions;
PAAD	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg07469887	chr10:131262384	NA	-0.44	-5.11	-0.38	9.61e-7	Response to temozolomide;
PAAD	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg03808351	chr9:123631620	PHF19	0.46	5.04	0.38	1.28e-6	Rheumatoid arthritis;
PAAD	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-5.13	-0.38	8.78e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08219700	chr8:58056026	NA	0.67	5.38	0.4	2.71e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.36	-4.97	-0.37	1.82e-6	QT interval;
PAAD	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.69	6.68	0.48	4.34e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.03	-0.44	1.18e-8	Menarche (age at onset);
PAAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.49	-5.82	-0.43	3.29e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg12658694	chr1:38397304	INPP5B	-0.81	-9.39	-0.61	8.33e-17	Coronary artery disease;
PAAD	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.82	6.65	0.47	5.07e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.86	7.42	0.52	7.91e-12	Recombination rate (females);
PAAD	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.57	-6.12	-0.44	7.49e-9	Coronary artery disease;
PAAD	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.66	6.68	0.48	4.32e-10	Smoking initiation;
PAAD	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg25364880	chr3:44379878	C3orf23	-0.59	-5.44	-0.4	2.06e-7	Depressive symptoms;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.74	-8.06	-0.55	2.12e-13	Menopause (age at onset);
PAAD	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.61	-5.47	-0.41	1.82e-7	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.74	8.21	0.55	8.76e-14	Lung cancer;
PAAD	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.83	4.7	0.36	5.73e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.89	12.55	0.71	3.02e-25	Vitiligo;
PAAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.43	-0.52	7.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.63	8.06	0.55	2.04e-13	Body mass index;
PAAD	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.56	5.43	0.4	2.15e-7	Schizophrenia;
PAAD	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.53	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg05082376	chr22:42548792	NA	-0.53	-5.27	-0.39	4.68e-7	Schizophrenia;
PAAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2274459	1.000	rs34460651	chr6:33731312	C/A	cg06253072	chr6:33679850	C6orf125	0.64	4.32	0.33	2.82e-5	Obesity (extreme);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04768764	chr17:78389020	FLJ35220;LOC100294362	0.6	6.31	0.46	2.88e-9	Myopia (pathological);
PAAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg05712903	chr5:178977398	RUFY1	0.6	4.65	0.35	7.04e-6	Lung cancer;
PAAD	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.97	-13.87	-0.75	8.87e-29	Height;
PAAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.36	0.33	2.43e-5	Breast cancer;
PAAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-8.65	-0.57	6.94e-15	Coronary artery disease;
PAAD	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.53	-4.66	-0.35	6.86e-6	RR interval (heart rate);
PAAD	cis	rs1007738	0.507	rs7940240	chr11:47203068	T/C	cg19486271	chr11:47235900	DDB2	-0.61	-5.7	-0.42	5.95e-8	Bone mineral density (hip);
PAAD	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	7.03	0.5	6.6e-11	IgG glycosylation;
PAAD	cis	rs11037575	0.715	rs12294768	chr11:43732463	T/C	cg24662154	chr11:44118094	EXT2	-0.43	-4.34	-0.33	2.55e-5	Neuroblastoma;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs16895831	0.519	rs4379287	chr6:42592486	T/C	cg10605015	chr6:42532144	UBR2	0.66	5.0	0.38	1.59e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.53	5.16	0.39	7.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00405825	chr7:139474807	HIPK2	-0.57	-6.41	-0.46	1.71e-9	Monocyte percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14029169	chr20:23619778	CST3	0.64	6.66	0.48	4.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.61	4.89	0.37	2.53e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg18612461	chr15:75251733	NA	0.58	7.28	0.51	1.65e-11	Breast cancer;
PAAD	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.61	4.62	0.35	8.14e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.64	7.11	0.5	4.32e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg03315344	chr16:75512273	CHST6	0.63	5.29	0.39	4.17e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.47	-0.41	1.85e-7	Bladder cancer;
PAAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19149410	chr17:48474869	LRRC59	-0.71	-6.33	-0.46	2.67e-9	Neuroticism;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg27499820	chr13:21296301	IL17D	-0.47	-4.71	-0.36	5.65e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg14055004	chr2:241860995	NA	0.29	4.53	0.34	1.2e-5	Joint mobility (Beighton score);
PAAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7737355	0.812	rs8180462	chr5:130907189	A/G	cg25547332	chr5:131281432	NA	0.52	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	5.77	0.42	4.37e-8	LDL cholesterol;
PAAD	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs901683	1.000	rs71499565	chr10:45977715	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.24	-0.51	2.07e-11	Personality dimensions;
PAAD	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-6.19	-0.45	5.37e-9	Rheumatoid arthritis;
PAAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.55	0.35	1.07e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.71	10.22	0.64	5.47e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14874893	chr19:50225303	NA	-0.65	-6.58	-0.47	7.35e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06832331	chr3:125635186	LOC100125556	0.63	6.42	0.46	1.68e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg04844267	chr4:1394941	NA	0.52	5.64	0.42	8e-8	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4443100	0.837	rs6003490	chr22:23388447	G/A	cg14186256	chr22:23484241	RTDR1	0.55	4.76	0.36	4.53e-6	Serum parathyroid hormone levels;
PAAD	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.55	4.73	0.36	5.12e-6	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs6694672	0.510	rs1412638	chr1:196995638	T/C	cg26994526	chr18:47719735	MYO5B	-0.8	-6.43	-0.46	1.55e-9	Asthma;
PAAD	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	1.01	13.45	0.74	1.15e-27	Heart rate;
PAAD	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.61	-5.23	-0.39	5.65e-7	Response to diuretic therapy;
PAAD	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.59	5.06	0.38	1.22e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs1678618	0.585	rs1245522	chr10:73786141	C/G	cg20897136	chr10:74034667	DDIT4	0.37	4.31	0.33	2.94e-5	Smoking behavior;
PAAD	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.11	0.55	1.61e-13	Morning vs. evening chronotype;
PAAD	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	1.25	10.27	0.64	3.96e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	1.03	6.86	0.49	1.62e-10	IgG glycosylation;
PAAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.68	-6.74	-0.48	3.11e-10	Multiple sclerosis;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.53	0.57	1.38e-14	Lung cancer;
PAAD	trans	rs2925663	0.929	rs4237028	chr8:59212742	C/T	cg03568859	chr2:97405048	LMAN2L	0.64	6.55	0.47	8.31e-10	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	6.09	0.44	8.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg25256661	chr17:7137939	DVL2	-0.87	-9.62	-0.62	2.08e-17	Diastolic blood pressure;
PAAD	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.86	-10.08	-0.63	1.28e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg11897209	chr6:86302888	SNX14	-0.44	-4.28	-0.33	3.27e-5	Response to antipsychotic treatment;
PAAD	cis	rs1891275	0.576	rs4933216	chr10:93419582	C/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.53	-0.41	1.38e-7	Personality dimensions;
PAAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg05874882	chr4:1763078	NA	-0.39	-5.5	-0.41	1.6e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg17372223	chr3:52568218	NT5DC2	0.47	4.54	0.35	1.16e-5	Bipolar disorder;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21171335	chr12:122356390	WDR66	-0.48	-4.77	-0.36	4.28e-6	Mean corpuscular volume;
PAAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.72	0.42	5.51e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.45	-5.61	-0.41	9.3e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12780845	0.931	rs35016603	chr10:17250261	C/G	cg00857480	chr10:17188594	TRDMT1	0.35	4.41	0.34	1.96e-5	Homocysteine levels;
PAAD	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg25972092	chr12:117363249	FBXW8	0.82	6.36	0.46	2.24e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.56	5.71	0.42	5.73e-8	Hemoglobin levels;
PAAD	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.56	-6.07	-0.44	9.64e-9	Educational attainment;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.85	-9.48	-0.61	4.79e-17	Prudent dietary pattern;
PAAD	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.83	-9.55	-0.61	3.2e-17	Lung cancer;
PAAD	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.48	5.45	0.4	1.97e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.58	-4.54	-0.35	1.14e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2790216	0.950	rs2486491	chr10:59970391	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.38	-0.33	2.22e-5	Height;
PAAD	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.53e-8	Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs74961584	chr3:128567032	T/C	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg10589385	chr1:150898437	SETDB1	-0.38	-4.65	-0.35	7.16e-6	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08307766	chr12:70637393	CNOT2	0.65	6.58	0.47	7.14e-10	Obesity-related traits;
PAAD	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.73	7.4	0.51	8.65e-12	Obesity-related traits;
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg22601191	chr20:60968625	CABLES2	0.65	5.27	0.39	4.52e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs332507	0.601	rs7653534	chr3:124358041	T/C	cg05980111	chr3:124395277	KALRN	0.4	4.26	0.33	3.62e-5	Plateletcrit;
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.43	-0.34	1.81e-5	Recombination measurement;
PAAD	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg07157834	chr1:205819609	PM20D1	0.58	4.62	0.35	8.2e-6	Parkinson's disease;
PAAD	cis	rs258892	0.842	rs34956	chr5:72203696	T/C	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.54	5.13	0.38	8.72e-7	Mortality in heart failure;
PAAD	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg27398640	chr15:77910606	LINGO1	0.45	4.26	0.33	3.5e-5	Type 2 diabetes;
PAAD	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.55	-4.98	-0.37	1.7e-6	Menopause (age at onset);
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.45	0.71	5.6e-25	Platelet count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18344811	chr7:822633	HEATR2	0.63	7.25	0.51	1.95e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.3	0.33	2.99e-5	Bipolar disorder;
PAAD	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-4.31	-0.33	2.89e-5	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.62	-0.42	8.7e-8	Subjective well-being;
PAAD	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.5	0.52	4.84e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg19920283	chr7:105172520	RINT1	0.7	4.28	0.33	3.3e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.57	5.38	0.4	2.81e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg09324608	chr17:30823087	MYO1D	0.47	4.71	0.36	5.53e-6	Schizophrenia;
PAAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.49	0.41	1.68e-7	HDL cholesterol;
PAAD	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg12384639	chr17:618140	VPS53	0.46	4.26	0.33	3.53e-5	Prostate cancer;
PAAD	cis	rs2668423	1.000	rs2526140	chr19:1374450	G/C	cg02639931	chr19:1387894	NDUFS7	-0.57	-6.39	-0.46	1.89e-9	Nonalcoholic fatty liver disease;
PAAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg19930314	chr7:98593876	TRRAP	-0.5	-4.67	-0.35	6.58e-6	Breast cancer;
PAAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.1	-8.45	-0.57	2.14e-14	Diabetic kidney disease;
PAAD	cis	rs11168618	0.740	rs7307588	chr12:48923232	A/G	cg01881778	chr12:48919444	OR8S1	-0.52	-5.65	-0.42	7.69e-8	Adiponectin levels;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.58	6.34	0.46	2.52e-9	Cardiovascular disease risk factors;
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09256448	chr16:638327	NA	0.42	4.33	0.33	2.65e-5	Height;
PAAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.93	-8.73	-0.58	4.15e-15	Asthma;
PAAD	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.79	-0.36	3.9e-6	Blood metabolite levels;
PAAD	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.36	0.46	2.27e-9	Body mass index;
PAAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.13	0.55	1.37e-13	Schizophrenia;
PAAD	cis	rs1950500	0.509	rs12895424	chr14:24823186	G/T	cg22990158	chr14:24802150	ADCY4	-0.46	-4.87	-0.37	2.81e-6	Height;
PAAD	cis	rs4343996	0.902	rs4349886	chr7:3370038	C/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.22	-0.39	5.7e-7	Motion sickness;
PAAD	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.93	0.66	7.06e-21	Chronic sinus infection;
PAAD	cis	rs54211	0.572	rs137626	chr22:39716271	A/G	cg11247378	chr22:39784982	NA	-0.72	-5.45	-0.4	2.03e-7	Sudden cardiac arrest;
PAAD	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs4356203	0.905	rs11024158	chr11:17125168	G/A	cg15432903	chr11:17409602	KCNJ11	0.43	4.45	0.34	1.67e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg27565382	chr3:53032988	SFMBT1	0.77	4.38	0.33	2.19e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg20090143	chr19:45452003	APOC2	0.4	4.89	0.37	2.52e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27574168	chr18:54318782	WDR7	0.57	6.35	0.46	2.42e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-6.13	-0.44	7.39e-9	Monocyte percentage of white cells;
PAAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	4.99	0.38	1.62e-6	Menarche (age at onset);
PAAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg24053715	chr22:38214548	NA	-0.51	-5.19	-0.39	6.73e-7	Glioblastoma;Glioma;
PAAD	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.32	0.46	2.79e-9	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.629	rs708146	chr12:33731808	C/G	cg26384229	chr12:38710491	ALG10B	0.69	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.61	0.35	8.46e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.69	7.55	0.52	3.83e-12	Longevity;
PAAD	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg13722127	chr7:150037890	RARRES2	0.69	6.91	0.49	1.26e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg14003231	chr6:33640908	ITPR3	0.36	4.69	0.36	5.96e-6	Plateletcrit;
PAAD	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs2555155	0.806	rs10839573	chr11:6551339	C/T	cg24637308	chr11:6592297	DNHD1	0.47	4.91	0.37	2.28e-6	DNA methylation (variation);
PAAD	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-5.12	-0.38	8.98e-7	Vitiligo;
PAAD	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	cis	rs41311933	0.710	rs2300929	chr9:123716840	T/C	cg21241889	chr9:123690658	TRAF1	-0.68	-4.32	-0.33	2.75e-5	Coronary artery disease;
PAAD	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.73	-8.56	-0.57	1.18e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7976059	1.000	rs7315236	chr12:52251933	C/T	cg13698196	chr12:52257893	NA	0.55	6.47	0.46	1.27e-9	Urate levels;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg15693483	chr7:1102177	C7orf50	0.4	4.61	0.35	8.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.63	6.24	0.45	4.24e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.84	0.54	7.49e-13	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg04482110	chr17:41364121	TMEM106A	0.42	4.76	0.36	4.53e-6	Menopause (age at onset);
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.71	0.66	2.76e-20	Cognitive ability;
PAAD	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.67	-7.95	-0.54	3.99e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.43	-4.3	-0.33	3.08e-5	Testicular germ cell tumor;
PAAD	cis	rs10943724	0.704	rs10943719	chr6:81274158	A/C	cg19323245	chr6:80716898	TTK	-0.44	-4.58	-0.35	9.79e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.14	-0.38	8.25e-7	Prudent dietary pattern;
PAAD	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg04374321	chr14:90722782	PSMC1	0.5	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg08390786	chr10:135334061	NA	-0.47	-4.35	-0.33	2.44e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.72	7.43	0.52	7.36e-12	Lung cancer;
PAAD	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.61	0.47	6.17e-10	Primary sclerosing cholangitis;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.46	4.93	0.37	2.14e-6	Longevity;Endometriosis;
PAAD	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.88	0.37	2.7e-6	Personality dimensions;
PAAD	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.34	0.6	1.14e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.44	0.46	1.46e-9	Lung cancer;
PAAD	cis	rs72827839	0.947	rs72827814	chr17:46366960	A/G	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg23241863	chr10:102295624	HIF1AN	0.49	4.31	0.33	2.95e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg09659197	chr4:152720779	NA	0.4	4.98	0.37	1.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.55	5.04	0.38	1.31e-6	Resting heart rate;
PAAD	cis	rs4218	0.532	rs17236369	chr15:59313855	A/G	cg25595834	chr15:59156878	NA	0.41	4.28	0.33	3.32e-5	Social communication problems;
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs9463078	0.585	rs1285013	chr6:45165208	C/A	cg18551225	chr6:44695536	NA	-0.4	-4.27	-0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs970548	0.779	rs11239532	chr10:45964505	C/T	cg15590007	chr10:45870220	ALOX5	0.46	4.81	0.36	3.6e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs761746	0.739	rs140081	chr22:32112461	T/C	cg01338084	chr22:32026380	PISD	0.63	5.33	0.4	3.5e-7	Intelligence;
PAAD	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	0.52	4.7	0.36	5.69e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.67	-0.35	6.64e-6	Platelet count;
PAAD	cis	rs1619661	0.505	rs10793525	chr10:44683833	C/A	cg09554077	chr10:44749378	NA	0.32	4.76	0.36	4.39e-6	QT interval (ambient particulate matter interaction);
PAAD	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg20090143	chr19:45452003	APOC2	0.38	4.64	0.35	7.51e-6	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-1.27	-10.06	-0.63	1.46e-18	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	trans	rs12127679	0.688	rs12071930	chr1:244161928	C/T	cg03519879	chr14:74227499	C14orf43	0.89	6.97	0.49	9.21e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg15309053	chr8:964076	NA	0.46	5.19	0.39	6.53e-7	Schizophrenia;
PAAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.1	-0.38	9.84e-7	Ulcerative colitis;
PAAD	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.83	9.35	0.6	1.05e-16	Metabolic syndrome;
PAAD	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg12362517	chr11:133800685	IGSF9B	0.53	5.18	0.39	6.87e-7	Hand grip strength;
PAAD	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg02683114	chr2:24398427	C2orf84	-0.59	-6.28	-0.45	3.43e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.55	-0.41	1.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06757925	chr1:70671216	LRRC40;SFRS11	0.59	6.32	0.46	2.71e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6460942	0.908	rs6956500	chr7:12232120	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.42	-5.13	-0.38	8.81e-7	Body mass index in non-asthmatics;
PAAD	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.38	-0.33	2.18e-5	Educational attainment;
PAAD	cis	rs9361491	0.608	rs7743640	chr6:79454075	A/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06217245	chr20:33103252	DYNLRB1	0.4	4.83	0.36	3.35e-6	Coronary artery disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14119263	chr10:5708327	ASB13	0.66	6.48	0.47	1.21e-9	Primary biliary cholangitis;
PAAD	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.6	-0.35	8.89e-6	Joint mobility (Beighton score);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22082780	chr1:68452167	NA	0.59	6.36	0.46	2.23e-9	Smoking initiation;
PAAD	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-1.14	-9.8	-0.62	6.92e-18	Blood trace element (Zn levels);
PAAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.58	-7.23	-0.51	2.17e-11	Multiple system atrophy;
PAAD	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.73	-7.3	-0.51	1.48e-11	Colorectal cancer;
PAAD	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg14393609	chr7:65229607	NA	-0.64	-7.03	-0.5	6.4e-11	Aortic root size;
PAAD	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.81	8.43	0.56	2.41e-14	Response to antineoplastic agents;
PAAD	cis	rs6558530	0.579	rs6558528	chr8:1703063	C/T	cg05577437	chr8:1586825	DLGAP2	0.38	4.26	0.33	3.53e-5	Systolic blood pressure;
PAAD	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-10.1	-0.63	1.14e-18	Vitiligo;
PAAD	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.6	4.6	0.35	8.85e-6	Exhaled nitric oxide output;
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.74	-0.36	4.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg14146966	chr2:61757674	XPO1	0.38	4.63	0.35	7.72e-6	Tuberculosis;
PAAD	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	5.0	0.38	1.54e-6	Asthma;
PAAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg11633118	chr16:1823531	EME2;MRPS34	0.62	6.56	0.47	7.83e-10	Iris heterochromicity;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg23958373	chr8:599963	NA	-1.13	-7.32	-0.51	1.37e-11	IgG glycosylation;
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.95	0.43	1.78e-8	Lung cancer;
PAAD	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs6906287	0.573	rs6928210	chr6:118699394	C/G	cg21191810	chr6:118973309	C6orf204	0.44	5.5	0.41	1.58e-7	Electrocardiographic conduction measures;
PAAD	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.89	-0.58	1.65e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.75	8.82	0.58	2.53e-15	Lewy body disease;
PAAD	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg16205897	chr5:131564050	P4HA2	-0.42	-4.67	-0.35	6.64e-6	Breast cancer;
PAAD	cis	rs6782228	0.651	rs9289332	chr3:128387884	C/G	cg16766828	chr3:128327626	NA	-0.46	-6.1	-0.44	8.4e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg18084798	chr19:33555255	RHPN2	-0.46	-4.73	-0.36	5.14e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14335408	chr9:1995528	NA	-0.5	-6.3	-0.46	3.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.09e-5	Renal cell carcinoma;
PAAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg09945482	chr18:12777974	NA	0.6	5.38	0.4	2.79e-7	Inflammatory skin disease;
PAAD	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg09873201	chr16:3507582	NAT15	0.56	5.09	0.38	1.06e-6	Tuberculosis;
PAAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.58	5.89	0.43	2.35e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.75	8.18	0.55	1.08e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6088813	1.000	rs4911180	chr20:33972948	G/A	cg14752227	chr20:34000481	UQCC	-0.55	-5.55	-0.41	1.23e-7	Height;
PAAD	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-5.09	-0.38	1.04e-6	Chronic sinus infection;
PAAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.78	0.58	3.24e-15	Menopause (age at onset);
PAAD	cis	rs10090774	0.965	rs7461251	chr8:141721788	A/G	cg02508881	chr8:142216119	NA	-0.43	-4.74	-0.36	4.93e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18543035	chr10:8374526	NA	0.61	6.93	0.49	1.1e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg11946769	chr3:48343235	NME6	-0.52	-4.96	-0.37	1.87e-6	Educational attainment (years of education);
PAAD	cis	rs7647973	0.583	rs55935606	chr3:49565505	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-1.0	-9.66	-0.62	1.69e-17	Menarche (age at onset);
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.37	4.48	0.34	1.43e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8077577	0.895	rs16960986	chr17:18108562	A/G	cg16794390	chr17:18148240	FLII	-0.56	-4.47	-0.34	1.49e-5	Obesity-related traits;
PAAD	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.04	-0.55	2.35e-13	Response to antipsychotic treatment;
PAAD	cis	rs1499972	0.941	rs62264819	chr3:117671941	T/C	cg07612923	chr3:117604196	NA	1.08	7.2	0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.5e-8	Triglycerides;
PAAD	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.92	9.52	0.61	3.85e-17	Alcohol dependence;
PAAD	cis	rs11825064	0.562	rs73596977	chr11:134512290	C/T	cg02089395	chr11:134479357	NA	-0.88	-5.71	-0.42	5.78e-8	Seasonality;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs990171	1.000	rs2058622	chr2:102985424	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs1723838	1.000	rs2886812	chr11:73605159	T/G	cg26954736	chr11:73693896	UCP2	1.09	4.75	0.36	4.64e-6	Obesity-related traits;
PAAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg08029281	chr1:67600428	NA	0.47	5.82	0.43	3.37e-8	Psoriasis;
PAAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg21395723	chr22:39101663	GTPBP1	0.44	4.75	0.36	4.74e-6	Menopause (age at onset);
PAAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.69	8.73	0.58	4.25e-15	Eye color traits;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg20295408	chr7:1910781	MAD1L1	0.57	5.73	0.42	5.23e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.42	0.46	1.64e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.59	5.44	0.4	2.06e-7	Monocyte count;
PAAD	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg04165759	chr1:150448943	RPRD2	0.53	5.51	0.41	1.47e-7	Migraine;
PAAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg10591111	chr5:226296	SDHA	-0.65	-4.54	-0.35	1.14e-5	Breast cancer;
PAAD	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.69	-0.62	1.38e-17	Height;
PAAD	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.48	-4.76	-0.36	4.39e-6	Bipolar disorder;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.57	5.68	0.42	6.59e-8	Platelet count;
PAAD	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.1	-0.38	1.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.75	-11.93	-0.7	1.4e-23	Body mass index;
PAAD	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.82	0.43	3.45e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs597480	0.824	rs1481700	chr11:85508077	A/T	cg11817631	chr11:85522609	SYTL2	0.45	4.45	0.34	1.67e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-6.58	-0.47	7.13e-10	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03075736	chr3:52444632	PHF7;BAP1	-0.8	-7.41	-0.52	8.24e-12	Neuroticism;
PAAD	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg22771759	chr13:24902376	NA	0.45	4.44	0.34	1.75e-5	Obesity-related traits;
PAAD	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.49	4.28	0.33	3.25e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.61	0.57	8.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.73	-8.39	-0.56	3.15e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2137920	0.685	rs12769016	chr10:50239997	C/G	cg02657375	chr10:50863136	CHAT	0.54	4.39	0.34	2.15e-5	Migraine with aura;
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.47	5.46	0.4	1.94e-7	Cystic fibrosis severity;
PAAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.57	0.35	1.02e-5	Height;
PAAD	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg15181151	chr6:150070149	PCMT1	0.53	5.8	0.43	3.69e-8	Lung cancer;
PAAD	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.22	-0.39	5.72e-7	Neuroticism;
PAAD	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs4739066	0.579	rs4739028	chr8:63862646	C/A	cg20602954	chr8:63776762	NKAIN3	0.79	5.11	0.38	9.49e-7	Myocardial infarction;
PAAD	cis	rs1519814	0.956	rs6469900	chr8:121117378	C/T	cg22335954	chr8:121166405	COL14A1	-0.63	-5.47	-0.41	1.82e-7	Breast cancer;
PAAD	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.8	6.38	0.46	1.98e-9	Neutrophil percentage of white cells;
PAAD	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg25547332	chr5:131281432	NA	-0.56	-4.46	-0.34	1.59e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg05110241	chr16:68378359	PRMT7	-1.3	-9.01	-0.59	8.33e-16	Schizophrenia;
PAAD	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.56	-7.55	-0.52	3.82e-12	Urate levels in overweight individuals;
PAAD	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg12560992	chr17:57184187	TRIM37	0.53	4.7	0.36	5.88e-6	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12313886	chr10:134596214	INPP5A	-0.57	-6.59	-0.47	6.64e-10	Monocyte percentage of white cells;
PAAD	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	4.79	0.36	3.99e-6	Asthma;
PAAD	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.62	5.64	0.42	8.16e-8	Obesity-related traits;
PAAD	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg10547527	chr2:198650123	BOLL	0.63	4.33	0.33	2.65e-5	Ulcerative colitis;
PAAD	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.93	-6.55	-0.47	8.2e-10	Body mass index;
PAAD	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-5.49	-0.41	1.63e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg14092988	chr3:52407081	DNAH1	-0.45	-5.63	-0.42	8.46e-8	Electroencephalogram traits;
PAAD	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.48	0.8	1.17e-35	Prudent dietary pattern;
PAAD	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.1	0.44	8.51e-9	Schizophrenia;
PAAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.79	10.18	0.64	7.16e-19	Bone mineral density;
PAAD	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	8.86	0.58	1.98e-15	Bipolar disorder;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.83	9.46	0.61	5.43e-17	Caffeine consumption;
PAAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg08994789	chr17:28903642	LRRC37B2	0.55	4.64	0.35	7.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03595538	chr19:5720731	TMEM146;LONP1	0.66	7.84	0.54	7.15e-13	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.94	10.19	0.64	6.77e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	1.07	8.89	0.58	1.66e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.88	0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	1.000	rs2790159	chr10:60018794	C/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg02462569	chr6:150064036	NUP43	-0.51	-5.79	-0.43	3.92e-8	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07227926	chr12:104609526	TXNRD1	0.61	6.72	0.48	3.42e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15127705	chr10:31006017	NA	-0.67	-6.68	-0.48	4.26e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.99e-9	Lung cancer;
PAAD	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11264799	0.817	rs78605162	chr1:157665680	T/C	cg18268488	chr1:157545234	FCRL4	0.57	5.22	0.39	5.73e-7	IgA nephropathy;
PAAD	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.76	-7.92	-0.54	4.65e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg16928487	chr17:17741425	SREBF1	0.34	4.56	0.35	1.06e-5	Total body bone mineral density;
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.27	0.39	4.62e-7	Prostate cancer;
PAAD	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.16	16.7	0.8	3.33e-36	Exhaled nitric oxide output;
PAAD	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.61	-0.35	8.46e-6	Colorectal cancer;
PAAD	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs3026101	0.671	rs3026134	chr17:5309690	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.68	6.56	0.47	8e-10	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15781957	chr10:106098186	NA	0.69	6.81	0.48	2.17e-10	Obesity-related traits;
PAAD	cis	rs904092	0.638	rs6830685	chr4:100143184	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-4.68	-0.36	6.21e-6	Alcohol dependence;
PAAD	cis	rs6024905	0.595	rs2022499	chr20:36966531	G/T	cg07053727	chr20:36965646	BPI	0.55	6.3	0.46	3.05e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-6.48	-0.47	1.21e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.42	-0.34	1.89e-5	Fear of minor pain;
PAAD	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg26248373	chr2:1572462	NA	-1.09	-8.96	-0.59	1.07e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg22134325	chr11:66188745	NPAS4	0.42	5.23	0.39	5.46e-7	Airway imaging phenotypes;
PAAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.13	0.63	9.33e-19	Cognitive test performance;
PAAD	cis	rs66530629	0.958	rs1002707	chr1:25051102	C/T	cg22509179	chr1:25234806	RUNX3	0.51	4.55	0.35	1.08e-5	Plateletcrit;
PAAD	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg13722127	chr7:150037890	RARRES2	0.61	6.35	0.46	2.33e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-5.13	-0.38	8.86e-7	Diastolic blood pressure;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.76	10.53	0.65	8.34e-20	Iron status biomarkers;
PAAD	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-4.63	-0.35	7.93e-6	Height;
PAAD	cis	rs2457480	0.850	rs11238902	chr10:44681091	C/T	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;
PAAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-9.6	-0.61	2.35e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	1.12	16.24	0.8	4.91e-35	Total body bone mineral density;
PAAD	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-7.46	-0.52	6.18e-12	Hemoglobin concentration;
PAAD	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02853781	chr1:19229053	ALDH4A1	0.61	6.41	0.46	1.72e-9	Myopia (pathological);
PAAD	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.95	-0.37	1.93e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18916488	chr2:45244898	NA	-0.62	-6.83	-0.48	1.94e-10	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.62	5.01	0.38	1.52e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2275731	0.723	rs11254030	chr10:16541701	G/C	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg03938978	chr2:103052716	IL18RAP	0.67	8.45	0.57	2.23e-14	Asthma;
PAAD	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.05	0.38	1.24e-6	Mood instability;
PAAD	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg12369402	chr1:90227771	NA	-0.46	-4.57	-0.35	1.01e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7119038	0.615	rs10892274	chr11:118605463	C/T	cg04176122	chr11:118779835	BCL9L	0.4	4.52	0.34	1.24e-5	Sjögren's syndrome;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16097069	chr5:178552097	ADAMTS2	-0.71	-6.41	-0.46	1.73e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.43	4.75	0.36	4.69e-6	Menarche (age at onset);
PAAD	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.63	-6.41	-0.46	1.71e-9	Monocyte count;
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg25204440	chr1:209979598	IRF6	0.71	6.59	0.47	6.71e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs17209837	0.915	rs12672720	chr7:87126438	A/G	cg00919237	chr7:87102261	ABCB4	-0.76	-5.01	-0.38	1.47e-6	Gallbladder cancer;
PAAD	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	0.92	10.79	0.66	1.69e-20	Testicular germ cell tumor;
PAAD	cis	rs56046484	0.956	rs34889576	chr15:85664676	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.15	-0.39	7.93e-7	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12638728	chr2:113012287	ZC3H8	0.65	6.33	0.46	2.64e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.26e-6	Lung cancer;
PAAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.37	-0.33	2.28e-5	Vitiligo;
PAAD	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg18338521	chr10:69995036	NA	-0.35	-4.5	-0.34	1.33e-5	Optic disc area;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.61	0.57	8.54e-15	Lung cancer;
PAAD	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.37	4.25	0.33	3.75e-5	High light scatter reticulocyte count;
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.61	6.4	0.46	1.81e-9	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16080015	chr7:5085479	RBAK	0.67	6.9	0.49	1.33e-10	Myopia (pathological);
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2235642	0.525	rs2667688	chr16:1561446	A/G	cg06970076	chr16:1560791	IFT140	0.67	6.01	0.44	1.3e-8	Coronary artery disease;
PAAD	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg01620082	chr3:125678407	NA	1.06	6.7	0.48	3.81e-10	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12859382	chr3:52445103	PHF7;BAP1	0.62	6.86	0.49	1.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.19	-0.39	6.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs137887	1.000	rs137891	chr22:50466543	G/A	cg23116504	chr22:50470537	TTLL8	-0.51	-5.28	-0.39	4.37e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg21253087	chr9:139290292	SNAPC4	0.5	4.52	0.34	1.25e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.66	0.57	6.42e-15	Lung cancer;
PAAD	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg11608241	chr8:8085544	FLJ10661	-0.53	-4.31	-0.33	2.87e-5	Cervical cancer;
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.85	-10.32	-0.64	2.88e-19	Body mass index;
PAAD	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.79	8.31	0.56	4.82e-14	Blood protein levels;
PAAD	cis	rs8112211	0.731	rs3745951	chr19:38817486	A/G	cg01275006	chr19:38876250	GGN	-0.67	-4.37	-0.33	2.25e-5	Blood protein levels;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18923906	chr10:82225771	TSPAN14	0.41	5.34	0.4	3.3e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Cardiac Troponin-T levels;
PAAD	cis	rs4740619	0.661	rs10810494	chr9:15947462	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.04	-0.38	1.28e-6	Body mass index;
PAAD	cis	rs12949688	0.682	rs1476729	chr17:55838708	C/T	cg12582317	chr17:55822272	NA	-0.4	-4.68	-0.35	6.4e-6	Schizophrenia;
PAAD	cis	rs863345	0.604	rs879635	chr1:158462908	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.92	-0.37	2.25e-6	Pneumococcal bacteremia;
PAAD	cis	rs2013441	1.000	rs2703782	chr17:20144799	A/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.78	-9.4	-0.61	7.98e-17	Height;
PAAD	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg26752003	chr8:145688521	CYHR1	-0.56	-6.45	-0.46	1.42e-9	Age at first birth;
PAAD	cis	rs11644601	1	rs11644601	chr16:15172118	T/C	cg07549590	chr16:15018862	NA	-0.46	-4.8	-0.36	3.78e-6	Metabolite levels (lipid measures);
PAAD	cis	rs7922314	0.571	rs61865695	chr10:64732512	A/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.68	-4.73	-0.36	5.19e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.0	0.59	8.54e-16	Motion sickness;
PAAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	1.02	6.56	0.47	8.07e-10	Prostate cancer;
PAAD	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.59e-21	Breast cancer;
PAAD	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	5.94e-20	Electrocardiographic conduction measures;
PAAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.63	-0.47	5.62e-10	Blood pressure (smoking interaction);
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg15693483	chr7:1102177	C7orf50	0.37	4.47	0.34	1.5e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg08992911	chr2:238395768	MLPH	0.73	5.55	0.41	1.24e-7	Prostate cancer;
PAAD	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg12935359	chr14:103987150	CKB	-0.63	-6.67	-0.48	4.49e-10	Body mass index;
PAAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	0.850	rs71515355	chr10:45985356	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6141769	0.866	rs1407256	chr20:31213647	A/G	cg13636640	chr20:31349939	DNMT3B	0.57	4.71	0.36	5.5e-6	Subjective well-being;
PAAD	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.6	-5.66	-0.42	7.29e-8	Lymphocyte counts;
PAAD	cis	rs11168618	0.626	rs11609074	chr12:48819335	C/A	cg01881778	chr12:48919444	OR8S1	-0.45	-4.54	-0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.16	0.55	1.18e-13	Height;
PAAD	cis	rs7071247	0.915	rs12252305	chr10:105279335	G/A	cg06423925	chr10:105883847	C10orf78	0.58	4.63	0.35	7.69e-6	Platelet aggregation;
PAAD	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Corneal structure;
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.42	4.43	0.34	1.77e-5	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11708963	chr19:4639510	TNFAIP8L1	0.61	6.96	0.49	9.52e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs728616	0.614	rs61859198	chr10:82114628	C/A	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg12163867	chr12:51592794	POU6F1	-0.65	-6.7	-0.48	3.78e-10	Cisplatin-induced ototoxicity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27319723	chr8:12617083	NA	-0.59	-6.29	-0.45	3.23e-9	Obesity-related traits;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg03268063	chr7:1337281	NA	-0.51	-4.43	-0.34	1.78e-5	Neuroticism;
PAAD	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.55	-5.27	-0.39	4.61e-7	Systemic sclerosis;
PAAD	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	4.79	0.36	3.94e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.27	-0.33	3.38e-5	Eotaxin levels;
PAAD	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg12549451	chr6:135224345	NA	0.48	4.98	0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2735413	0.914	rs2707604	chr16:78054853	A/G	cg04733911	chr16:78082701	NA	-0.52	-4.86	-0.37	2.91e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-9.55	-0.61	3.26e-17	Personality dimensions;
PAAD	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs1015291	0.799	rs10841379	chr12:19992303	A/G	cg25401612	chr12:20009446	NA	-0.51	-5.1	-0.38	1e-6	Diastolic blood pressure;
PAAD	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.63	-4.7	-0.36	5.82e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg00945038	chr17:61921165	SMARCD2	0.43	5.01	0.38	1.5e-6	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.7	-0.36	5.79e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.54	-0.41	1.32e-7	Blood protein levels;
PAAD	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg19510604	chr15:74901076	CLK3	-0.51	-4.25	-0.33	3.76e-5	Blood trace element (Zn levels);
PAAD	cis	rs818427	0.508	rs569940	chr5:112167821	C/T	cg06941702	chr5:112196734	SRP19	-0.52	-4.89	-0.37	2.52e-6	Total body bone mineral density;
PAAD	cis	rs4073221	0.789	rs13080765	chr3:18211326	A/G	cg07694806	chr3:18168406	NA	0.84	5.11	0.38	9.66e-7	Parkinson's disease;
PAAD	cis	rs6800768	0.633	rs57903454	chr3:24092407	A/T	cg10674438	chr3:24145617	LOC152024	-0.47	-4.35	-0.33	2.46e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6594713	0.679	rs71577448	chr5:112768874	C/T	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.61	5.56	0.41	1.2e-7	Retinal vascular caliber;
PAAD	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.78	8.99	0.59	8.96e-16	Heart rate;
PAAD	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.5	5.03	0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg26174226	chr8:58114915	NA	-0.62	-5.14	-0.38	8.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.52	-0.57	1.46e-14	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg25837213	chr17:80849375	TBCD	-0.5	-4.52	-0.34	1.21e-5	Breast cancer;
PAAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg01320130	chr1:67600311	NA	0.43	4.42	0.34	1.86e-5	Crohn's disease;
PAAD	cis	rs11105468	0.695	rs11105498	chr12:90448872	T/C	cg16962463	chr12:89968675	NA	0.45	4.74	0.36	4.89e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg16423265	chr20:60697137	LSM14B	0.6	6.33	0.46	2.67e-9	Iris heterochromicity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22366698	chr11:3400543	ZNF195	-0.69	-7.65	-0.53	2.18e-12	Smoking initiation;
PAAD	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.23	-0.39	5.57e-7	Blood metabolite levels;
PAAD	cis	rs4455778	0.561	rs6975663	chr7:49122743	G/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.29	-0.39	4.17e-7	IgG glycosylation;
PAAD	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.1	0.44	8.44e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15128208	chr22:42549153	NA	-0.49	-4.93	-0.37	2.13e-6	Cognitive function;
PAAD	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg01557791	chr16:72042693	DHODH	-0.66	-6.34	-0.46	2.46e-9	Fibrinogen levels;
PAAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.49	-4.75	-0.36	4.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.29	-0.33	3.11e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	1.02	8.06	0.55	2.05e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.48	5.1	0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.48	-4.31	-0.33	2.86e-5	P wave terminal force;
PAAD	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.75	-0.36	4.73e-6	Joint mobility (Beighton score);
PAAD	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg09659197	chr4:152720779	NA	0.4	5.25	0.39	4.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.5e-5	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07247970	chr1:150293881	PRPF3	-0.81	-7.5	-0.52	4.84e-12	Neuroticism;
PAAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg23719950	chr11:63933701	MACROD1	-0.49	-4.25	-0.33	3.75e-5	Platelet count;
PAAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.54	5.12	0.38	9.15e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.68	7.31	0.51	1.43e-11	Body mass index;
PAAD	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg06096015	chr1:231504339	EGLN1	0.67	8.72	0.58	4.63e-15	Hemoglobin concentration;
PAAD	cis	rs11785693	0.789	rs11776268	chr8:4985852	C/T	cg26367366	chr8:4980734	NA	-0.58	-4.38	-0.33	2.18e-5	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg02587129	chr20:34042870	CEP250	0.73	4.88	0.37	2.66e-6	Height;
PAAD	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.89	5.06	0.38	1.19e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4679904	0.920	rs1920643	chr3:160313263	T/C	cg20378687	chr3:160281681	KPNA4	-0.36	-4.31	-0.33	2.97e-5	Primary biliary cholangitis;
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.45	-0.34	1.68e-5	Primary biliary cholangitis;
PAAD	cis	rs2882667	0.690	rs288011	chr5:138199939	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22359535	chr19:59087367	MGC2752	0.63	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.56	5.34	0.4	3.26e-7	Corneal astigmatism;
PAAD	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.68	-7.73	-0.53	1.35e-12	Motion sickness;
PAAD	cis	rs488248	0.574	rs7999524	chr13:106590549	G/T	cg03898952	chr13:107069935	NA	0.76	4.74	0.36	4.79e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07231102	chr3:19988460	RAB5A	0.63	6.3	0.46	3.05e-9	Obesity-related traits;
PAAD	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.64	-0.47	5.32e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7101378	0.577	rs2136532	chr11:108900150	A/G	cg10976287	chr11:108093109	ATM;NPAT	-0.51	-5.27	-0.39	4.63e-7	IgG glycosylation;
PAAD	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Colorectal cancer;
PAAD	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg01305830	chr4:1604576	NA	-0.44	-4.35	-0.33	2.45e-5	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs747650	0.504	rs2087215	chr11:47144542	A/C	cg19486271	chr11:47235900	DDB2	0.66	6.04	0.44	1.15e-8	Acne (severe);
PAAD	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg03684893	chr10:554711	DIP2C	0.49	5.31	0.4	3.84e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs4588572	0.561	rs7727592	chr5:77804547	G/A	cg11547950	chr5:77652471	NA	-0.77	-6.48	-0.47	1.21e-9	Triglycerides;
PAAD	cis	rs4646404	0.664	rs9908984	chr17:17424499	G/C	cg07083043	chr17:17397972	RASD1	-0.4	-4.31	-0.33	2.92e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
PAAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs501120	0.564	rs7917089	chr10:44688587	G/A	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg02869306	chr7:64672164	INTS4L1	0.41	4.83	0.36	3.31e-6	Aortic root size;
PAAD	trans	rs11212737	0.765	rs2624133	chr11:108511963	A/G	cg13462821	chr8:86214814	NA	0.55	6.29	0.45	3.25e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg02795151	chr17:7402630	POLR2A	0.58	5.34	0.4	3.35e-7	Androgen levels;
PAAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.88	-8.5	-0.57	1.6e-14	DNA methylation (variation);
PAAD	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.51	1.64e-11	Response to antipsychotic treatment;
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg07153921	chr17:41440717	NA	-0.43	-4.45	-0.34	1.63e-5	Menopause (age at onset);
PAAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.59	6.05	0.44	1.09e-8	Multiple sclerosis;
PAAD	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg16386425	chr10:429943	DIP2C	0.58	5.71	0.42	5.65e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg22800045	chr5:56110881	MAP3K1	0.53	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs71520386	0.579	rs4394299	chr7:22865382	A/C	cg04907244	chr7:22894795	SNORD93	0.47	5.18	0.39	6.91e-7	Fibrinogen levels;
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.08e-7	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18368502	chr17:77758580	CBX2	-0.61	-6.74	-0.48	3.12e-10	Obesity-related traits;
PAAD	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-6.05	-0.44	1.08e-8	Schizophrenia;
PAAD	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs9472414	0.510	rs227845	chr6:44695338	C/A	cg20913747	chr6:44695427	NA	0.6	6.2	0.45	5.16e-9	Height;
PAAD	cis	rs12612619	0.704	rs3769139	chr2:27315714	C/T	cg00617064	chr2:27272375	NA	-0.52	-5.37	-0.4	2.91e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17088814	chr2:12856702	TRIB2	0.67	6.48	0.47	1.18e-9	Myopia (pathological);
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.63	-7.82	-0.54	8.21e-13	Lung cancer;
PAAD	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.55	5.81	0.43	3.55e-8	Dupuytren's disease;
PAAD	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.68	-0.42	6.57e-8	Mood instability;
PAAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.78	6.99	0.49	8.15e-11	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-5.39	-0.4	2.63e-7	Diastolic blood pressure;
PAAD	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.52	6.81	0.48	2.13e-10	Longevity;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.73	0.72	9.76e-26	Platelet count;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.61	7.44	0.52	6.74e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.59	-5.27	-0.39	4.54e-7	Platelet count;
PAAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs10421328	0.848	rs10423449	chr19:19755946	G/A	cg11584989	chr19:19387371	SF4	0.89	6.76	0.48	2.82e-10	Parental longevity (combined parental age at death);
PAAD	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05357209	chr7:872208	UNC84A	0.39	4.8	0.36	3.73e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs2790216	1.000	rs2590364	chr10:60038406	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs354033	0.837	rs6945729	chr7:149195972	A/T	cg06920324	chr7:149264011	ZNF767	-0.59	-4.95	-0.37	1.96e-6	Multiple sclerosis;
PAAD	cis	rs258892	0.793	rs10062154	chr5:72021534	C/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg05895507	chr15:77155635	SCAPER	0.39	4.35	0.33	2.51e-5	Blood metabolite levels;
PAAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.01	-0.49	7.19e-11	Gut microbiome composition (summer);
PAAD	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.58	-5.49	-0.41	1.66e-7	Neuroticism;
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg04154034	chr17:28927549	LRRC37B2	0.8	4.74	0.36	4.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.29	-7.71	-0.53	1.57e-12	Body mass index;
PAAD	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.56	5.28	0.39	4.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8077577	0.895	rs11078412	chr17:18100618	C/T	cg16794390	chr17:18148240	FLII	-0.57	-4.75	-0.36	4.71e-6	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14019695	chr9:139328340	INPP5E	0.48	4.48	0.34	1.45e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2051773	0.567	rs4255517	chr11:17043209	C/G	cg15084286	chr11:17036142	PLEKHA7	0.56	5.03	0.38	1.37e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.34	8.13	0.55	1.43e-13	Skin colour saturation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19602139	chr3:49690254	BSN	-0.58	-6.39	-0.46	1.97e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.45	4.84	0.37	3.22e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	2.04e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-4.49	-0.34	1.42e-5	Total body bone mineral density;
PAAD	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.59	-0.47	6.88e-10	Retinal vascular caliber;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs58521262	0.556	rs158695	chr19:23203571	C/T	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.62e-5	Platelet count;
PAAD	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg18512352	chr11:47633146	NA	-0.4	-5.79	-0.43	3.92e-8	Subjective well-being;
PAAD	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs621942	0.950	rs545213	chr11:85737129	T/C	cg07180834	chr11:85838833	NA	-0.46	-4.34	-0.33	2.55e-5	Tourette syndrome;
PAAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.59	-6.99	-0.49	8.11e-11	Breast cancer;
PAAD	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.59	5.11	0.38	9.67e-7	Obesity-related traits;
PAAD	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.5	4.6	0.35	9.02e-6	Triglycerides;
PAAD	cis	rs9866391	0.607	rs6440006	chr3:141142691	G/A	cg00789793	chr3:141329863	RASA2	0.42	4.31	0.33	2.95e-5	Myopia;
PAAD	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.8	9.45	0.61	5.76e-17	Mean corpuscular volume;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14430111	chr11:64879374	TM7SF2	-0.62	-6.34	-0.46	2.52e-9	Warfarin maintenance dose;
PAAD	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg05555928	chr11:63887634	MACROD1	0.69	5.63	0.42	8.59e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg07959070	chr22:50026188	C22orf34	-0.36	-4.36	-0.33	2.39e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	4.87	0.37	2.72e-6	Coronary artery disease;
PAAD	cis	rs9287719	0.624	rs10199635	chr2:10726640	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.87	-12.06	-0.7	6.34e-24	Birth weight;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg14583973	chr4:3374767	RGS12	-0.36	-5.45	-0.4	1.97e-7	Mean platelet volume;
PAAD	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg08632701	chr21:37451849	NA	-0.53	-5.52	-0.41	1.45e-7	Mitral valve prolapse;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.67	4.77	0.36	4.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs490234	0.966	rs1250737	chr9:128428813	G/A	cg14078157	chr9:128172775	NA	0.4	4.43	0.34	1.8e-5	Mean arterial pressure;
PAAD	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.93	-0.37	2.1e-6	High light scatter reticulocyte count;
PAAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.8	8.65	0.57	6.93e-15	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.45	5.21	0.39	5.94e-7	Inattentive symptoms;
PAAD	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.92	10.88	0.66	9.32e-21	Sudden cardiac arrest;
PAAD	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.35	-0.64	2.51e-19	Response to antipsychotic treatment;
PAAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg19257562	chr1:2043853	PRKCZ	0.49	6.02	0.44	1.23e-8	Height;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.72	-5.45	-0.4	1.97e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg20243544	chr17:37824526	PNMT	0.53	4.67	0.35	6.71e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg07362569	chr17:61921086	SMARCD2	0.43	4.79	0.36	3.98e-6	Height;
PAAD	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.69	7.94	0.54	4.19e-13	Colorectal cancer;
PAAD	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.45	-4.74	-0.36	4.95e-6	Response to antidepressants in depression;
PAAD	cis	rs9462846	1.000	rs2894484	chr6:42851497	A/G	cg13397359	chr6:42928475	GNMT	0.6	4.45	0.34	1.65e-5	Blood protein levels;
PAAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.85	-9.41	-0.61	7.47e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.88	-10.92	-0.66	7.42e-21	Monocyte percentage of white cells;
PAAD	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1371614	0.632	rs1992311	chr2:27159341	G/A	cg00617064	chr2:27272375	NA	-0.43	-4.51	-0.34	1.27e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg08999081	chr20:33150536	PIGU	0.51	5.44	0.4	2.11e-7	Height;
PAAD	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.02	-0.38	1.44e-6	Triglycerides;
PAAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg13468214	chr4:1046988	NA	-0.55	-5.18	-0.39	7.05e-7	Recombination rate (females);
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.86	11.38	0.68	4.41e-22	Vitiligo;
PAAD	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.41	-0.34	1.94e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20850055	chr8:101718959	PABPC1	-0.6	-7.1	-0.5	4.38e-11	Energy expenditure (24h);
PAAD	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.95	12.27	0.71	1.74e-24	Menopause (age at onset);
PAAD	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.42	-6.26	-0.45	3.79e-9	Information processing speed;
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.73	0.42	5.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4834770	1.000	rs4336213	chr4:120236469	G/T	cg09307838	chr4:120376055	NA	0.56	5.3	0.39	4.06e-7	Blood protein levels;
PAAD	trans	rs61677309	1.000	rs55899310	chr11:118158702	T/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	5.15	0.39	8.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12153243	0.714	rs3901620	chr5:142911019	C/A	cg13907255	chr5:142895549	NA	-0.53	-4.87	-0.37	2.8e-6	Migraine;
PAAD	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg09340386	chr2:1605954	NA	-0.62	-4.29	-0.33	3.13e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.67	-5.99	-0.44	1.48e-8	Mean platelet volume;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-6.89	-0.49	1.37e-10	Bipolar disorder;
PAAD	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg14711859	chr11:8959438	ASCL3	0.49	5.88	0.43	2.47e-8	Hematocrit;
PAAD	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-1.18	-10.03	-0.63	1.78e-18	Obesity-related traits;
PAAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg15145965	chr22:50218605	BRD1	0.6	5.44	0.4	2.1e-7	Schizophrenia;
PAAD	cis	rs76917914	0.820	rs7046514	chr9:100815088	C/T	cg03040243	chr9:100819229	NANS	0.61	4.82	0.36	3.5e-6	Immature fraction of reticulocytes;
PAAD	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.38	-0.33	2.2e-5	Plateletcrit;
PAAD	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-7.6	-0.52	2.86e-12	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg20893579	chr22:38215064	NA	0.49	4.85	0.37	3.08e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.45	4.76	0.36	4.4e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.93	11.02	0.67	4.07e-21	White blood cell count;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	0.41	4.58	0.35	9.72e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg17551891	chr7:1960795	MAD1L1	-0.51	-4.63	-0.35	7.66e-6	Neuroticism;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg03208016	chr1:180124071	QSOX1	0.88	6.32	0.46	2.77e-9	Lung function (FEV1/FVC);
PAAD	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18424538	chr4:6717981	CNO	0.62	7.16	0.5	3.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.69	7.02	0.49	6.82e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.41	13.34	0.73	2.31e-27	Corneal structure;
PAAD	cis	rs9992101	0.547	rs13146163	chr4:77412091	G/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.53	-4.79	-0.36	3.89e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06622737	chr1:171750501	METTL13	0.67	7.96	0.54	3.68e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.56	5.3	0.39	4.01e-7	Total body bone mineral density;
PAAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.28	-0.45	3.42e-9	IgG glycosylation;
PAAD	cis	rs4880487	0.888	rs72760998	chr10:1251203	T/C	cg03183215	chr10:1252341	ADARB2	-0.48	-4.65	-0.35	7.31e-6	Migraine;
PAAD	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs2790216	1.000	rs2590359	chr10:60021247	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.55	0.57	1.2e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg10547527	chr2:198650123	BOLL	-0.75	-5.22	-0.39	5.73e-7	Ulcerative colitis;
PAAD	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08164617	chr7:95401856	DYNC1I1	-0.64	-6.93	-0.49	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7929679	0.551	rs10466455	chr11:34780936	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.39	-0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs56011263	0.532	rs6845891	chr4:744233	T/C	cg14024328	chr4:719362	PCGF3	-0.54	-5.13	-0.38	8.87e-7	White blood cell count;
PAAD	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.47	-4.39	-0.34	2.07e-5	HDL cholesterol;
PAAD	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.75	-8.27	-0.56	6.23e-14	Inflammatory bowel disease;
PAAD	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg00181669	chr3:44000978	NA	0.45	4.47	0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.07	-0.44	9.95e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.95	-12.79	-0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.51	4.65	0.35	7.25e-6	Airway imaging phenotypes;
PAAD	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.77	-7.83	-0.54	7.86e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs253959	0.503	rs712565	chr5:115605198	A/C	cg05931423	chr5:115697214	NA	0.43	4.29	0.33	3.17e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.35	-4.58	-0.35	9.52e-6	Dupuytren's disease;
PAAD	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg06899799	chr12:56650233	ANKRD52	0.33	4.31	0.33	2.94e-5	Cancer;
PAAD	cis	rs7945718	0.621	rs6485992	chr11:12697359	C/T	cg25843174	chr11:12811716	TEAD1	0.31	4.57	0.35	9.96e-6	Educational attainment (years of education);
PAAD	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.94	-0.63	2.94e-18	Depression;
PAAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.58	-5.82	-0.43	3.4e-8	Height;
PAAD	cis	rs89107	0.688	rs281861	chr6:118579357	T/G	cg18833306	chr6:118973337	C6orf204	0.49	5.75	0.42	4.68e-8	Cardiac structure and function;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.56	4.28	0.33	3.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4704187	0.595	rs7717337	chr5:74377001	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.69	-7.31	-0.51	1.4e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.62	6.17	0.45	6.03e-9	Coronary artery disease;
PAAD	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.6	-7.03	-0.5	6.53e-11	Aortic root size;
PAAD	cis	rs6800768	0.633	rs59374114	chr3:24112202	G/T	cg10674438	chr3:24145617	LOC152024	-0.47	-4.4	-0.34	2.05e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.72	5.9	0.43	2.32e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.62	5.49	0.41	1.61e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg25722041	chr1:8623473	RERE	0.52	4.58	0.35	9.78e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.8	6.13	0.45	7.16e-9	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg08888203	chr3:10149979	C3orf24	0.87	6.52	0.47	9.84e-10	Alzheimer's disease;
PAAD	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg13647721	chr17:30228624	UTP6	-0.65	-4.58	-0.35	9.55e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg20850873	chr3:10149803	C3orf24	0.53	4.26	0.33	3.59e-5	Alzheimer's disease;
PAAD	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.59	5.92	0.43	2.09e-8	Systolic blood pressure;
PAAD	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg12623918	chr2:306882	NA	0.45	4.65	0.35	7.3e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3749237	1.000	rs13316065	chr3:49884913	C/T	cg02487422	chr3:49467188	NICN1	0.5	4.83	0.36	3.29e-6	Resting heart rate;
PAAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.51	-0.41	1.52e-7	Height;
PAAD	cis	rs3736485	0.966	rs11070856	chr15:51853817	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.31	0.4	3.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.11	8.6	0.57	9.37e-15	Vitiligo;
PAAD	trans	rs901683	1.000	rs12766764	chr10:46079513	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg09597638	chr17:3907349	NA	0.49	4.97	0.37	1.82e-6	Type 2 diabetes;
PAAD	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.61	4.87	0.37	2.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-5.04	-0.38	1.31e-6	Neuroticism;
PAAD	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg10168330	chr8:27262164	PTK2B	0.36	4.28	0.33	3.24e-5	Neuroticism;
PAAD	cis	rs909814	0.509	rs10917178	chr1:22555288	T/G	cg07090424	chr1:22535491	NA	-0.46	-5.12	-0.38	9.3e-7	IgG glycosylation;Testosterone levels;
PAAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.67	7.28	0.51	1.67e-11	Personality dimensions;
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg10729496	chr3:10149963	C3orf24	0.63	5.46	0.4	1.89e-7	Alzheimer's disease;
PAAD	cis	rs11892454	0.544	rs7591614	chr2:26003068	C/T	cg25181710	chr2:26045287	ASXL2	0.45	4.9	0.37	2.39e-6	Heschl's gyrus morphology;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg07202610	chr7:1142643	C7orf50	-0.67	-5.55	-0.41	1.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg18265118	chr7:2139243	MAD1L1	0.52	4.34	0.33	2.6e-5	Neuroticism;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg14391382	chr7:866102	UNC84A	0.46	4.3	0.33	3.1e-5	Subjective well-being;
PAAD	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.88	6.53	0.47	9.33e-10	Left atrial antero-posterior diameter;
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.33	4.4	0.34	2.03e-5	Age at first birth;
PAAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.54	5.42	0.4	2.34e-7	Platelet count;
PAAD	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	1.11	6.57	0.47	7.49e-10	Body mass index;
PAAD	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.6	6.53	0.47	9.1e-10	Colorectal cancer;
PAAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.7	-6.0	-0.44	1.39e-8	Body mass index;
PAAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26081025	chr14:92570361	ATXN3	0.6	6.64	0.47	5.19e-10	Smoking initiation;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.17e-5	Life satisfaction;
PAAD	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.94	4.82	0.36	3.43e-6	Breast cancer;
PAAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	0.81	7.29	0.51	1.58e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.65	-6.46	-0.46	1.33e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-6.28	-0.45	3.39e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.24	-0.45	4.25e-9	Type 2 diabetes;
PAAD	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15644404	chr18:77186268	NFATC1	-0.91	-6.15	-0.45	6.67e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09597638	chr17:3907349	NA	0.66	6.39	0.46	1.95e-9	Type 2 diabetes;
PAAD	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.72	-5.84	-0.43	3.07e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs357618	0.965	rs187180	chr5:150847995	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.14	-11.84	-0.69	2.42e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg14458575	chr2:238380390	NA	0.56	4.8	0.36	3.76e-6	Prostate cancer;
PAAD	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.77	8.26	0.56	6.56e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs370915	0.507	rs6835018	chr4:187794328	C/A	cg12892747	chr4:187813459	NA	-0.43	-4.26	-0.33	3.6e-5	Gout;
PAAD	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00982548	chr2:198649783	BOLL	-0.67	-4.81	-0.36	3.59e-6	Ulcerative colitis;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg08677398	chr8:58056175	NA	0.62	4.63	0.35	7.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg02887458	chr19:19495540	GATAD2A	0.49	4.69	0.36	6.14e-6	Bipolar disorder;
PAAD	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-5.68	-0.42	6.51e-8	Mean platelet volume;
PAAD	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg07701084	chr6:150067640	NUP43	-0.53	-4.7	-0.36	5.9e-6	Lung cancer;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.1	-0.5	4.53e-11	Longevity;Endometriosis;
PAAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg17143192	chr8:8559678	CLDN23	0.7	6.49	0.47	1.12e-9	Obesity-related traits;
PAAD	cis	rs6466055	0.661	rs3801279	chr7:104904868	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs2997447	0.802	rs75786059	chr1:26449327	A/G	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.69e-6	QRS complex (12-leadsum);
PAAD	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-5.56	-0.41	1.21e-7	Blood protein levels;
PAAD	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs959260	0.925	rs9747801	chr17:73396572	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg14019146	chr3:50243930	SLC38A3	-0.45	-4.49	-0.34	1.4e-5	Menarche (age at onset);
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.54	6.68	0.48	4.21e-10	Crohn's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21255605	chr3:14989131	NR2C2	-0.59	-6.35	-0.46	2.36e-9	Myopia (pathological);
PAAD	cis	rs2286503	1.000	rs2286498	chr7:22857504	C/T	cg11367502	chr7:22862612	TOMM7	-0.43	-4.28	-0.33	3.34e-5	Fibrinogen;
PAAD	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.52	4.79	0.36	3.89e-6	Schizophrenia;
PAAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg02734326	chr4:10020555	SLC2A9	-0.5	-4.81	-0.36	3.6e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs75920871	1.000	rs61905706	chr11:116883777	G/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs9914578	1.000	rs4061660	chr17:2004377	C/T	cg16513277	chr17:2031491	SMG6	-0.57	-5.32	-0.4	3.66e-7	Body mass index;
PAAD	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-6.19	-0.45	5.45e-9	Longevity;
PAAD	cis	rs10971721	0.822	rs12377078	chr9:33934821	A/C	cg01558151	chr9:34048101	UBAP2	0.68	5.07	0.38	1.12e-6	Body mass index;
PAAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.73	-7.88	-0.54	5.85e-13	Aortic root size;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg26668828	chr6:292823	DUSP22	-0.83	-8.76	-0.58	3.6e-15	Menopause (age at onset);
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13198984	chr17:80129470	CCDC57	-0.41	-5.03	-0.38	1.37e-6	Life satisfaction;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.92	-0.59	1.37e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.99	-14.03	-0.75	3.28e-29	Rheumatoid arthritis;
PAAD	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg22875332	chr1:76189707	ACADM	-0.5	-4.97	-0.37	1.79e-6	Daytime sleep phenotypes;
PAAD	cis	rs12304921	0.748	rs17125375	chr12:51499719	T/C	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.87	-0.37	2.76e-6	Type 2 diabetes;
PAAD	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg21823605	chr1:152486609	CRCT1	0.52	6.58	0.47	7e-10	Hair morphology;
PAAD	trans	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg17830980	chr10:43048298	ZNF37B	0.69	8.08	0.55	1.84e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.47	-0.41	1.84e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg10920065	chr6:169824652	NA	-0.47	-4.67	-0.35	6.7e-6	Obesity-related traits;
PAAD	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	6.81	0.48	2.11e-10	Neuroticism;
PAAD	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.89	7.07	0.5	5.26e-11	Chronic kidney disease;
PAAD	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg05418105	chr22:50981406	NA	-0.49	-4.44	-0.34	1.69e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.48	6.09	0.44	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	cis	rs2637266	0.596	rs2637247	chr10:78273160	A/C	cg18941641	chr10:78392320	NA	0.37	4.49	0.34	1.39e-5	Pulmonary function;
PAAD	cis	rs2997447	0.723	rs2259849	chr1:26474251	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.87e-6	QRS complex (12-leadsum);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15084499	chr1:227505916	CDC42BPA	0.44	6.45	0.46	1.43e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17128730	chr22:38577679	PLA2G6	-0.68	-6.54	-0.47	8.85e-10	Lung cancer in ever smokers;
PAAD	cis	rs929596	0.564	rs2602364	chr2:234524229	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs12776158	0.901	rs57677741	chr10:71217131	G/A	cg12610070	chr10:71211762	TSPAN15	-0.49	-4.63	-0.35	7.85e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg15792487	chr17:7348316	CHRNB1	-0.39	-4.4	-0.34	2.01e-5	Height;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg04160749	chr8:58172571	NA	-0.76	-5.24	-0.39	5.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg03910582	chr17:19030146	GRAPL	-0.47	-4.34	-0.33	2.64e-5	Schizophrenia;
PAAD	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.48	4.64	0.35	7.44e-6	Airway imaging phenotypes;
PAAD	cis	rs2885056	0.599	rs73018654	chr19:10689518	G/A	cg04833646	chr19:10679720	CDKN2D	1.02	10.09	0.63	1.22e-18	Red cell distribution width;
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.62	-0.35	8e-6	Testicular germ cell tumor;
PAAD	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg05555928	chr11:63887634	MACROD1	-0.64	-4.86	-0.37	2.86e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs11676676	1.000	rs11692935	chr2:109770890	A/G	cg23046629	chr2:109745841	LOC100287216;SH3RF3	0.54	4.46	0.34	1.59e-5	Pediatric bone mineral density (spine);
PAAD	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.39	4.45	0.34	1.66e-5	High light scatter reticulocyte count;
PAAD	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.09e-15	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs71496622	chr10:46081588	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.85	-9.17	-0.6	3.09e-16	Schizophrenia;
PAAD	cis	rs2882667	0.690	rs288038	chr5:138207533	G/A	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	4.36	0.33	2.37e-5	Platelet count;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1355223	0.557	rs7936076	chr11:34724672	C/T	cg11622362	chr11:34938112	PDHX;APIP	0.44	4.44	0.34	1.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3131085	1	rs3131085	chr6:29044701	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Blood protein levels;
PAAD	cis	rs4740619	0.689	rs2225182	chr9:15953575	C/A	cg14451791	chr9:16040625	NA	-0.42	-4.84	-0.37	3.2e-6	Body mass index;
PAAD	cis	rs5753037	0.665	rs1961926	chr22:30223813	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.41	-0.34	1.98e-5	Type 1 diabetes;
PAAD	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs251130	0.540	rs251133	chr5:110859246	A/G	cg16397176	chr5:110899314	NA	0.5	4.35	0.33	2.51e-5	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.57	-0.35	1.02e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.81	0.36	3.68e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.64	-0.62	1.84e-17	Lung cancer;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg26554054	chr8:600488	NA	1.0	7.59	0.52	3.05e-12	IgG glycosylation;
PAAD	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08749122	chr1:150459996	TARS2	0.6	6.72	0.48	3.39e-10	Metabolite levels  (X-11787);
PAAD	cis	rs735539	0.521	rs2763000	chr13:21449692	C/G	cg27234864	chr13:21295941	IL17D	0.59	4.81	0.36	3.65e-6	Dental caries;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-6.17	-0.45	5.91e-9	Lung cancer;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg13264159	chr8:625131	ERICH1	-0.78	-4.96	-0.37	1.91e-6	IgG glycosylation;
PAAD	cis	rs117623576	1.000	rs117623576	chr10:32387808	C/T	cg03047570	chr10:32398778	NA	-0.86	-5.4	-0.4	2.51e-7	Anti-saccade response;
PAAD	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg14830002	chr1:247616686	OR2B11	-0.64	-5.18	-0.39	6.87e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs818427	0.896	rs458451	chr5:112224331	T/C	cg06941702	chr5:112196734	SRP19	0.48	4.37	0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.64	6.52	0.47	9.8e-10	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	9.32	0.6	1.29e-16	Exhaled nitric oxide output;
PAAD	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.7	6.81	0.48	2.15e-10	Coronary artery disease;
PAAD	cis	rs7945718	0.621	rs10831894	chr11:12680733	G/A	cg25843174	chr11:12811716	TEAD1	0.31	4.57	0.35	9.91e-6	Educational attainment (years of education);
PAAD	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	4.78	0.36	4.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.8	-6.78	-0.48	2.43e-10	Gut microbiome composition (summer);
PAAD	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.58	5.61	0.41	9.28e-8	Blood protein levels;
PAAD	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.69	6.59	0.47	6.78e-10	Recombination rate (males);
PAAD	cis	rs4234284	0.965	rs2003228	chr3:126971748	C/T	cg27326032	chr3:127006922	NA	-0.47	-4.79	-0.36	3.92e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs35955747	0.902	rs5997929	chr22:31664032	C/T	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg18569988	chr3:195679450	NA	0.42	4.26	0.33	3.57e-5	Pancreatic cancer;
PAAD	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.59	5.29	0.39	4.26e-7	Coronary heart disease;
PAAD	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.63	0.35	7.78e-6	Height;
PAAD	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg14388049	chr10:71211838	TSPAN15	-0.55	-5.61	-0.41	9.28e-8	Venous thromboembolism;
PAAD	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.82	-12.59	-0.71	2.43e-25	Endometriosis;
PAAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg11941060	chr3:133502564	NA	-0.57	-6.05	-0.44	1.09e-8	Iron status biomarkers;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23620433	chr14:58894395	KIAA0586;TIMM9	0.66	6.42	0.46	1.66e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13554667	chr10:62538283	CDK1;CDC2	0.63	6.43	0.46	1.57e-9	Primary biliary cholangitis;
PAAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg22143856	chr6:28129313	ZNF389	-0.69	-5.53	-0.41	1.36e-7	Depression;
PAAD	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg08501292	chr6:25962987	TRIM38	0.44	4.33	0.33	2.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19856749	chr10:124316636	NA	0.58	6.98	0.49	8.52e-11	Body fat percentage;
PAAD	cis	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg20159608	chr7:32802032	NA	-0.52	-5.67	-0.42	6.9e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.58	6.08	0.44	9.31e-9	Pancreatic cancer;
PAAD	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg18436246	chr17:1640651	WDR81	0.86	7.97	0.54	3.5e-13	Serum albumin level;
PAAD	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg04851639	chr8:1020857	NA	-0.58	-6.88	-0.49	1.47e-10	Schizophrenia;
PAAD	cis	rs9907295	0.636	rs76259166	chr17:34114972	G/A	cg13376404	chr17:34077293	GAS2L2	0.65	4.27	0.33	3.38e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.58	4.69	0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs797680	0.681	rs4847406	chr1:93758450	C/T	cg04535902	chr1:92947332	GFI1	0.44	4.47	0.34	1.54e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs28595532	0.720	rs72670222	chr4:119300095	A/T	cg21605333	chr4:119757512	SEC24D	1.42	7.51	0.52	4.74e-12	Cannabis dependence symptom count;
PAAD	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg19254793	chr6:44695348	NA	-0.45	-4.37	-0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.75	0.48	2.91e-10	Schizophrenia;
PAAD	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.59	-6.43	-0.46	1.53e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02475777	chr4:1388615	CRIPAK	0.54	5.16	0.39	7.71e-7	Longevity;
PAAD	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-6.47	-0.46	1.3e-9	Extrinsic epigenetic age acceleration;
PAAD	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.46	-0.46	1.33e-9	HDL cholesterol;
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.8	8.49	0.57	1.74e-14	Tuberculosis;
PAAD	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-6.0	-0.44	1.42e-8	Schizophrenia (age at onset);
PAAD	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.95	-10.04	-0.63	1.65e-18	Asthma;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.36	-0.4	3.08e-7	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.89	-9.99	-0.63	2.27e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.72	7.73	0.53	1.4e-12	Morning vs. evening chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23276598	chr2:8826235	NA	-0.57	-6.38	-0.46	2.06e-9	Body fat percentage;
PAAD	cis	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg07059403	chr6:170151533	C6orf70;TCTE3	-0.5	-5.11	-0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg11204139	chr17:3907470	NA	0.63	6.11	0.44	8.07e-9	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.64	7.27	0.51	1.78e-11	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.21	-0.45	4.91e-9	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12136530	0.593	rs4911989	chr1:19727743	C/G	cg25104613	chr1:20649108	VWA5B1	0.44	4.88	0.37	2.61e-6	Lead levels in blood;
PAAD	cis	rs6700896	0.900	rs4459081	chr1:66164327	G/C	cg04111102	chr1:66153794	NA	-0.44	-5.01	-0.38	1.52e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.66	-0.53	2.02e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	0.85	6.71	0.48	3.67e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg16928487	chr17:17741425	SREBF1	0.33	4.48	0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs113123495	0.623	rs2485256	chr19:5694349	G/A	cg26242866	chr19:5711310	LONP1	0.96	4.61	0.35	8.51e-6	Obsessive-compulsive symptoms;
PAAD	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.71	7.41	0.52	8.19e-12	Body mass index;
PAAD	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	7.02	0.49	6.88e-11	Coffee consumption (cups per day);
PAAD	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg25952890	chr19:58913133	NA	0.67	5.67	0.42	6.85e-8	Mean platelet volume;
PAAD	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.51	-4.54	-0.35	1.16e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg27494647	chr7:150038898	RARRES2	0.42	4.25	0.33	3.74e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-7.98	-0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-1.09	-7.31	-0.51	1.45e-11	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.94	7.69	0.53	1.69e-12	IgG glycosylation;
PAAD	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.92	9.15	0.6	3.46e-16	Orofacial clefts;
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.66	-5.41	-0.4	2.39e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	6.48	0.47	1.23e-9	Mood instability;
PAAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23634193	chr7:636230	PRKAR1B	0.57	6.78	0.48	2.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.49	-4.86	-0.37	2.93e-6	Type 2 diabetes;
PAAD	cis	rs902774	0.938	rs73108457	chr12:53277367	A/G	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.66	-5.91	-0.43	2.15e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs6604026	0.656	rs6694051	chr1:93392760	A/G	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.5	4.92	0.37	2.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.77	0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.9	0.49	1.3e-10	Mood instability;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg11196182	chr7:1989412	MAD1L1	0.42	4.56	0.35	1.06e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg04450456	chr4:17643702	FAM184B	-0.48	-4.83	-0.36	3.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.73	-0.36	5.12e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs34020101	1	rs34020101	chr2:103051474	TA/T	cg05295703	chr2:102895712	NA	-0.44	-4.69	-0.36	6.09e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs12138061	0.906	rs61785503	chr1:50458443	C/T	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.67	-0.35	6.46e-6	Schizophrenia;
PAAD	cis	rs6499755	0.712	rs31085	chr16:55362502	G/A	cg02859129	chr16:55357253	IRX6	0.35	4.88	0.37	2.69e-6	Hypospadias;
PAAD	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	9.9e-7	Lung cancer;
PAAD	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.46	0.41	1.87e-7	Obesity-related traits;
PAAD	cis	rs1499972	0.941	rs55689237	chr3:117554899	C/G	cg07612923	chr3:117604196	NA	1.05	6.8	0.48	2.25e-10	Schizophrenia;
PAAD	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.48	6.47	0.46	1.28e-9	Panic disorder;
PAAD	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg21823605	chr1:152486609	CRCT1	0.49	6.28	0.45	3.43e-9	Hair morphology;
PAAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg18809830	chr7:99032528	PTCD1	-1.15	-4.92	-0.37	2.2e-6	Blood metabolite levels;
PAAD	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.97	6.83	0.48	1.89e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22633769	chr20:60982531	CABLES2	0.51	4.57	0.35	1.01e-5	Colorectal cancer;
PAAD	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.65	0.42	7.72e-8	Life satisfaction;
PAAD	cis	rs58521262	0.519	rs12609007	chr19:23007675	A/C	cg07749055	chr19:23076870	NA	-0.61	-4.63	-0.35	7.81e-6	Testicular germ cell tumor;
PAAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.74	-0.42	4.93e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.89	0.43	2.36e-8	Ileal carcinoids;
PAAD	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.8	7.61	0.53	2.69e-12	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.54	-6.59	-0.47	6.65e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13624320	chr5:134734938	H2AFY	0.64	6.37	0.46	2.16e-9	Obesity-related traits;
PAAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg11707556	chr5:10655725	ANKRD33B	0.65	7.18	0.5	2.85e-11	Coronary artery disease;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.48	-4.8	-0.36	3.77e-6	Vitiligo;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.89	0.54	5.52e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg18589874	chr11:47608310	FAM180B	-0.43	-4.3	-0.33	3.04e-5	Subjective well-being;
PAAD	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.6	0.47	6.3e-10	Lung cancer in ever smokers;
PAAD	cis	rs71520386	0.607	rs28617621	chr7:22857682	A/G	cg04907244	chr7:22894795	SNORD93	0.5	5.49	0.41	1.67e-7	Fibrinogen levels;
PAAD	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg22089800	chr15:90895588	ZNF774	0.59	5.72	0.42	5.55e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg11657440	chr19:46296263	DMWD	-0.63	-5.46	-0.4	1.91e-7	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.57	0.35	9.93e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.38	-0.56	3.4e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.53	5.11	0.38	9.73e-7	Prudent dietary pattern;
PAAD	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.87	-9.63	-0.62	2e-17	Tonsillectomy;
PAAD	trans	rs12545912	0.908	rs6983762	chr8:9581400	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.9	-0.37	2.45e-6	Diabetic retinopathy;
PAAD	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.55	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.64	-0.42	8.06e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7259965	0.755	rs3745274	chr19:41512841	G/T	cg27089200	chr19:41531976	NA	0.48	4.27	0.33	3.43e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	5.41	0.4	2.42e-7	Cognitive test performance;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-6.97	-0.49	8.82e-11	Initial pursuit acceleration;
PAAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.93	10.57	0.65	6.51e-20	Parkinson's disease;
PAAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.73	7.42	0.52	7.74e-12	Calcium levels;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg15693483	chr7:1102177	C7orf50	0.45	4.97	0.37	1.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.54	5.97	0.44	1.58e-8	Lung cancer;
PAAD	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg18944383	chr4:111397179	ENPEP	0.76	7.83	0.54	7.74e-13	Coronary artery disease;
PAAD	trans	rs4678145	0.901	rs17843797	chr3:124453022	T/G	cg03983498	chr1:55107291	C1orf175	1.06	6.63	0.47	5.58e-10	Coronary artery disease;
PAAD	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.51	4.51	0.34	1.29e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.1	-10.54	-0.65	7.64e-20	Cognitive test performance;
PAAD	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.87	-10.24	-0.64	4.75e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.97	-9.84	-0.62	5.47e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs6687430	0.532	rs17035305	chr1:10616505	C/A	cg17425144	chr1:10567563	PEX14	-0.42	-4.62	-0.35	8.24e-6	Hand grip strength;
PAAD	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.49	-5.07	-0.38	1.16e-6	Pancreatic cancer;
PAAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg21929781	chr1:2537748	MMEL1	0.51	5.35	0.4	3.11e-7	Ulcerative colitis;
PAAD	cis	rs6466055	0.661	rs17707878	chr7:104913228	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg25319279	chr11:5960081	NA	-0.6	-5.76	-0.42	4.51e-8	DNA methylation (variation);
PAAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.03e-9	Monobrow;
PAAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.65	5.28	0.39	4.46e-7	Gut microbiome composition (summer);
PAAD	cis	rs422249	0.634	rs174609	chr11:61627811	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.48	0.34	1.46e-5	Trans fatty acid levels;
PAAD	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg14019146	chr3:50243930	SLC38A3	0.47	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.62	-0.35	8.09e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg02887458	chr19:19495540	GATAD2A	0.55	5.13	0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.62	-0.35	8.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.6	7.41	0.52	8.21e-12	Multiple system atrophy;
PAAD	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg25204440	chr1:209979598	IRF6	-0.62	-5.39	-0.4	2.6e-7	Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.6	-5.04	-0.38	1.33e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs62064224	1.000	rs62064224	chr17:30635115	G/A	cg09324608	chr17:30823087	MYO1D	0.44	4.47	0.34	1.53e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23037274	chr19:7968594	MAP2K7	0.58	6.35	0.46	2.34e-9	Monocyte percentage of white cells;
PAAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.69	-8.92	-0.59	1.42e-15	Birth weight;
PAAD	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-8.87	-0.58	1.83e-15	Chronic sinus infection;
PAAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.6	-7.29	-0.51	1.58e-11	Birth weight;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.58	0.52	3.21e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.74	-6.44	-0.46	1.47e-9	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.87	9.83	0.62	5.96e-18	Prudent dietary pattern;
PAAD	cis	rs12773846	0.537	rs35716728	chr10:126273660	T/G	cg04949429	chr10:126290192	LHPP	0.66	5.72	0.42	5.58e-8	Subcutaneous adipose tissue;
PAAD	cis	rs55728055	0.661	rs60324934	chr22:31875654	A/G	cg01338084	chr22:32026380	PISD	1.4	7.24	0.51	2.05e-11	Age-related hearing impairment;
PAAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.44	-4.34	-0.33	2.56e-5	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs367943	0.666	rs6594705	chr5:112692851	T/G	cg12552261	chr5:112820674	MCC	0.65	6.36	0.46	2.2e-9	Type 2 diabetes;
PAAD	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.51	-0.34	1.28e-5	Height;
PAAD	cis	rs8067354	0.540	rs1051424	chr17:58024324	A/G	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.53	-0.41	1.38e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg14346243	chr4:90757452	SNCA	-0.55	-4.86	-0.37	2.86e-6	Neuroticism;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.42	-4.35	-0.33	2.46e-5	Longevity;Endometriosis;
PAAD	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.8	-9.3	-0.6	1.43e-16	Dental caries;
PAAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.69	-5.07	-0.38	1.15e-6	Vitiligo;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9469913	0.867	rs9469895	chr6:34777401	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs8105895	0.935	rs28857211	chr19:22243104	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.7e-5	Pulmonary function;
PAAD	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs901683	1.000	rs12774690	chr10:45989745	G/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.49	-0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.55	6.0	0.44	1.41e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.71	5.72	0.42	5.55e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	trans	rs901683	1.000	rs34285816	chr10:45976851	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.55	-6.93	-0.49	1.12e-10	Hypertriglyceridemia;
PAAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.88	0.63	4.46e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17347593	chr7:155577749	NA	-0.7	-7.3	-0.51	1.54e-11	Obesity-related traits;
PAAD	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg03948781	chr1:205179583	DSTYK	0.49	4.53	0.34	1.2e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg14906510	chr12:7781169	NA	0.65	4.66	0.35	6.98e-6	HDL cholesterol levels;
PAAD	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg01620082	chr3:125678407	NA	-1.07	-7.25	-0.51	1.95e-11	Depression;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.66	-6.22	-0.45	4.68e-9	Urate levels;
PAAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg00999904	chr2:3704751	ALLC	-0.44	-4.92	-0.37	2.22e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.65	6.44	0.46	1.45e-9	Height;
PAAD	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.45	-0.52	6.46e-12	Neuroticism;
PAAD	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00864171	chr11:67383662	NA	0.54	5.63	0.42	8.64e-8	Mean corpuscular volume;
PAAD	cis	rs2446066	0.872	rs114075368	chr12:53801744	T/G	cg20591337	chr12:53693442	C12orf10	-0.64	-4.51	-0.34	1.31e-5	Red blood cell count;
PAAD	cis	rs3736485	0.868	rs8034197	chr15:51922506	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.18e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7608623	1.000	rs2113423	chr2:23942287	C/T	cg08917208	chr2:24149416	ATAD2B	-0.44	-4.34	-0.33	2.63e-5	Obesity-related traits;
PAAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg11601000	chr22:42348013	LOC339674	-0.4	-4.5	-0.34	1.32e-5	Cognitive function;
PAAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg23281280	chr6:28129359	ZNF389	0.52	4.4	0.34	2.05e-5	Breast cancer;
PAAD	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-4.95	-0.37	1.92e-6	Body mass index;
PAAD	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.42e-11	Eye color traits;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.62	-6.05	-0.44	1.1e-8	Height;
PAAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.13e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs16858210	0.647	rs12107414	chr3:183574548	G/C	cg03417191	chr3:183542750	MAP6D1	-0.63	-4.8	-0.36	3.69e-6	Menopause (age at onset);
PAAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.26	-0.51	1.89e-11	Leprosy;
PAAD	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7011192	0.793	rs10086770	chr8:10510511	A/G	cg25377605	chr8:10513717	RP1L1	0.69	4.59	0.35	9.22e-6	Suicide;
PAAD	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.62	-4.41	-0.34	1.94e-5	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.56	5.13	0.38	8.61e-7	Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19212674	chr4:71571625	RUFY3	0.63	7.14	0.5	3.58e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg21253087	chr9:139290292	SNAPC4	0.47	4.29	0.33	3.14e-5	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.49	4.83	0.36	3.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26876637	chr1:152193138	HRNR	0.78	5.91	0.43	2.19e-8	Atopic dermatitis;
PAAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg22143856	chr6:28129313	ZNF389	-0.48	-4.56	-0.35	1.04e-5	Parkinson's disease;
PAAD	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg20259534	chr15:40453036	BUB1B	0.75	5.8	0.43	3.71e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	1.14	6.98	0.49	8.43e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1697938	0.590	rs2455312	chr5:40946648	C/T	cg17351974	chr5:40835760	RPL37	0.39	4.3	0.33	3.01e-5	Multiple system atrophy;
PAAD	cis	rs965469	0.779	rs2236103	chr20:3276821	A/G	cg25506879	chr20:3388711	C20orf194	0.51	4.4	0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg05342682	chr7:94953680	PON1	-0.53	-4.63	-0.35	7.92e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.98	12.88	0.72	3.94e-26	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12292947	chr7:47343625	TNS3	0.59	6.57	0.47	7.7e-10	Body fat percentage;
PAAD	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.43	0.61	6.54e-17	Electrocardiographic conduction measures;
PAAD	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.5	-0.47	1.06e-9	HDL cholesterol;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.48	-5.25	-0.39	5.12e-7	Eosinophil percentage of white cells;
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.08	-0.38	1.07e-6	Total body bone mineral density;
PAAD	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg00825309	chr19:58991885	ZNF446	-0.78	-7.94	-0.54	4.1e-13	Uric acid clearance;
PAAD	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.44	0.46	1.52e-9	Blood protein levels;
PAAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg14703610	chr5:56206110	C5orf35	0.56	5.23	0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4321325	0.733	rs78238478	chr2:127936306	G/A	cg11380483	chr2:127933992	NA	0.72	5.26	0.39	4.87e-7	Protein C levels;
PAAD	cis	rs7873102	0.654	rs3935097	chr9:37977559	C/A	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	4.87	0.37	2.77e-6	Homocysteine levels;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.62	7.04	0.5	6.24e-11	Schizophrenia;
PAAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.84	-0.66	1.2e-20	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	7.62	0.53	2.49e-12	Alzheimer's disease;
PAAD	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.69	7.23	0.51	2.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.49	5.4	0.4	2.49e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.71	-7.44	-0.52	6.83e-12	Type 2 diabetes;
PAAD	cis	rs1997066	0.831	rs73340206	chr10:106801028	T/C	cg17321814	chr10:106440892	SORCS3	0.64	4.29	0.33	3.16e-5	Diabetic kidney disease;
PAAD	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.64	6.45	0.46	1.42e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg11416102	chr8:651193	ERICH1	0.91	5.41	0.4	2.43e-7	IgG glycosylation;
PAAD	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.51	-4.56	-0.35	1.03e-5	Smoking behavior;
PAAD	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.85	-7.02	-0.5	6.75e-11	Alzheimer's disease;
PAAD	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.14	5.58	0.41	1.07e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.21	-0.55	9.03e-14	Urinary metabolites;
PAAD	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.37	-13.09	-0.73	1.06e-26	Corneal structure;
PAAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-4.33	-0.33	2.69e-5	Bipolar disorder;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg11062466	chr8:58055876	NA	0.67	4.84	0.37	3.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs9463078	0.838	rs9381359	chr6:44990625	A/G	cg25276700	chr6:44698697	NA	-0.5	-5.8	-0.43	3.68e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.61	-8.6	-0.57	9.37e-15	Huntington's disease progression;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg17178900	chr1:205818956	PM20D1	0.44	4.41	0.34	1.94e-5	Parkinson's disease;
PAAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.49	4.67	0.35	6.65e-6	Renal cell carcinoma;
PAAD	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs73019876	0.869	rs1987975	chr19:22158299	C/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs1497828	1.000	rs2815237	chr1:217543239	T/C	cg04411442	chr1:217543379	NA	0.47	4.53	0.34	1.19e-5	Dialysis-related mortality;
PAAD	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.74	6.36	0.46	2.25e-9	Menarche (age at onset);
PAAD	cis	rs3857067	0.509	rs61069704	chr4:95091856	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.69	-6.21	-0.45	4.82e-9	QT interval;
PAAD	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.62	-7.09	-0.5	4.6e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.92	0.43	2.04e-8	Prudent dietary pattern;
PAAD	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.62	-6.94	-0.49	1.08e-10	Smoking initiation;
PAAD	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs12989701	0.877	rs34854727	chr2:127855392	C/T	cg08168897	chr2:127865431	BIN1	0.71	6.11	0.44	7.8e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs901683	1.000	rs79752400	chr10:46072088	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs375066	0.967	rs417400	chr19:44410846	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.55	5.63	0.42	8.33e-8	Mortality in heart failure;
PAAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg26513180	chr16:89883248	FANCA	-0.44	-4.53	-0.34	1.19e-5	Vitiligo;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.71	7.02	0.49	7.04e-11	Renal function-related traits (BUN);
PAAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7873102	0.630	rs10973624	chr9:37964730	T/C	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg05697835	chr1:2722811	NA	0.42	4.75	0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg09579323	chr1:150459698	TARS2	-0.45	-4.27	-0.33	3.42e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg00758881	chr16:58534681	NDRG4	-0.93	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.42	4.73	0.36	5.16e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11154715	chr12:52292226	NA	-0.58	-6.33	-0.46	2.68e-9	Obesity-related traits;
PAAD	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg19787841	chr12:53845606	PCBP2	0.42	4.25	0.33	3.78e-5	Height;
PAAD	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.86	-10.96	-0.66	5.66e-21	Aortic root size;
PAAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.75	6.67	0.48	4.49e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg26850624	chr5:429559	AHRR	-1.02	-4.76	-0.36	4.4e-6	Breast cancer;
PAAD	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.5e-7	Restless legs syndrome;
PAAD	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.44	-5.61	-0.41	9.18e-8	Panic disorder;
PAAD	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Subjective well-being;
PAAD	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16417436	chr16:28758564	NA	0.45	4.36	0.33	2.42e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg21130718	chr4:1044621	NA	0.47	4.55	0.35	1.07e-5	Recombination rate (males);
PAAD	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.59e-21	Breast cancer;
PAAD	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19087650	chr15:34152971	RYR3	-0.59	-6.3	-0.46	3.01e-9	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	2e-13	Alzheimer's disease;
PAAD	cis	rs10924309	0.597	rs12143468	chr1:245854465	C/T	cg00036263	chr1:245852353	KIF26B	-0.63	-6.12	-0.44	7.67e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.77	8.84	0.58	2.18e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.8	8.25	0.56	7.04e-14	HIV-1 control;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27383562	chr6:155584850	TFB1M;CLDN20	-0.63	-6.69	-0.48	4.02e-10	Obesity-related traits;
PAAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-4.46	-0.34	1.58e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2835872	0.709	rs1709819	chr21:39036115	A/C	cg06728970	chr21:39037746	KCNJ6	0.51	5.74	0.42	4.95e-8	Electroencephalographic traits in alcoholism;
PAAD	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.85	10.75	0.66	2.11e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.93	8.35	0.56	4.02e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg01214346	chr17:406501	NA	-0.5	-4.88	-0.37	2.66e-6	Prostate cancer;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg19337854	chr7:99768885	GPC2	-0.41	-4.4	-0.34	2.05e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.71	0.36	5.47e-6	Axial length;
PAAD	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.66	-4.8	-0.36	3.8e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.46	-0.8	1.35e-35	Height;
PAAD	cis	rs2555155	0.935	rs61151131	chr11:6521391	C/T	cg11185456	chr11:6592066	DNHD1	0.43	4.62	0.35	8.29e-6	DNA methylation (variation);
PAAD	cis	rs11650175	0.835	rs11655131	chr17:63761581	G/A	cg07283582	chr17:63770753	CCDC46	0.38	4.27	0.33	3.48e-5	Chin dimples;
PAAD	trans	rs901683	1.000	rs34566829	chr10:45973598	G/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.52	-0.34	1.23e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.48	0.57	1.8e-14	Prudent dietary pattern;
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg25204440	chr1:209979598	IRF6	0.63	5.53	0.41	1.36e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs340029	0.828	rs184638	chr15:60911462	G/A	cg00200653	chr15:60883225	RORA	0.55	5.0	0.38	1.6e-6	C-reactive protein levels;
PAAD	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.75	-7.43	-0.52	7.38e-12	Mosquito bite size;
PAAD	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg27490568	chr2:178487706	NA	0.43	4.61	0.35	8.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19636519	chr7:99541626	NA	0.41	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.55	5.29	0.39	4.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg19626725	chr5:178986131	RUFY1	0.52	5.44	0.4	2.04e-7	Lung cancer;
PAAD	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.74	7.13	0.5	3.9e-11	Breast cancer;
PAAD	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	Neutrophil count;
PAAD	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg18281939	chr5:77783895	LHFPL2	0.5	5.63	0.42	8.36e-8	Triglycerides;
PAAD	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.25e-6	Type 2 diabetes;
PAAD	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-8.28	-0.56	5.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.69	-0.36	5.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4295623	0.507	rs2256241	chr8:11494657	C/T	cg12395012	chr8:11607386	GATA4	0.39	4.54	0.35	1.12e-5	Morning vs. evening chronotype;
PAAD	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg24692254	chr21:30365293	RNF160	0.57	4.83	0.36	3.27e-6	Cognitive test performance;
PAAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg13468214	chr4:1046988	NA	0.51	4.9	0.37	2.43e-6	Recombination rate (females);
PAAD	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.41	-4.9	-0.37	2.45e-6	Uric acid levels;
PAAD	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.48	-0.34	1.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs347685	0.600	rs6440058	chr3:141755343	A/G	cg00217306	chr3:141681567	TFDP2	0.64	4.55	0.35	1.07e-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.48	4.88	0.37	2.64e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-5.2	-0.39	6.48e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg22325292	chr17:80708367	FN3K	0.6	4.25	0.33	3.64e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.15	0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs13380717	0.517	rs9932721	chr16:86924246	A/G	cg03834411	chr16:87682036	JPH3	-0.42	-4.35	-0.33	2.44e-5	Sepsis in extremely premature infants;
PAAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.22	-0.39	5.88e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.61	0.35	8.34e-6	Height;
PAAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24838063	chr12:130822603	PIWIL1	-0.6	-6.2	-0.45	5.15e-9	Menopause (age at onset);
PAAD	cis	rs8067287	0.597	rs4985735	chr17:16866164	C/T	cg26910001	chr17:16838321	NA	0.47	4.61	0.35	8.43e-6	Diabetic kidney disease;
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.83	7.46	0.52	6.07e-12	Pulse pressure;
PAAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs863345	0.604	rs1578761	chr1:158497572	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-4.86	-0.37	2.96e-6	Daytime sleep phenotypes;
PAAD	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	0.98	6.02	0.44	1.24e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-4.7	-0.36	5.8e-6	Height;
PAAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-4.34	-0.33	2.56e-5	Resting heart rate;
PAAD	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.39	4.79	0.36	3.96e-6	Sitting height ratio;
PAAD	cis	rs2637266	0.655	rs7902535	chr10:78460889	C/T	cg18941641	chr10:78392320	NA	0.36	4.34	0.33	2.56e-5	Pulmonary function;
PAAD	cis	rs2252790	0.965	rs13209267	chr6:116635819	A/C	cg18764771	chr6:116381957	FRK	0.25	4.33	0.33	2.75e-5	Fast beta electroencephalogram;
PAAD	cis	rs6782025	0.837	rs618133	chr3:120742962	C/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.37	0.33	2.33e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2235573	0.685	rs4384887	chr22:38447365	T/C	cg24053715	chr22:38214548	NA	-0.51	-5.28	-0.39	4.43e-7	Glioblastoma;Glioma;
PAAD	cis	rs4743820	0.503	rs10820834	chr9:93917440	C/T	cg14446406	chr9:93919335	NA	-0.37	-5.06	-0.38	1.22e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg14926445	chr8:58193284	C8orf71	-0.72	-5.74	-0.42	5.08e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18684905	chr19:1822532	REXO1	0.57	6.64	0.47	5.31e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.61	-5.74	-0.42	4.98e-8	Glaucoma (primary open-angle);
PAAD	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.87	10.15	0.64	8.62e-19	Coronary artery disease;
PAAD	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg21225548	chr9:100864335	TRIM14	-0.55	-5.86	-0.43	2.82e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	0.99	6.6	0.47	6.34e-10	Sexual dysfunction (female);
PAAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg19163074	chr7:65112434	INTS4L2	0.48	4.47	0.34	1.53e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.76	0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-8.32	-0.56	4.73e-14	Response to antipsychotic treatment;
PAAD	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg21827317	chr3:136751795	NA	0.5	5.32	0.4	3.69e-7	Gestational age at birth (child effect);
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.64	6.62	0.47	5.77e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.89	7.63	0.53	2.42e-12	Bipolar disorder;
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg07061783	chr6:25882402	NA	0.5	4.72	0.36	5.35e-6	Blood metabolite levels;
PAAD	cis	rs11825064	0.673	rs11602494	chr11:134463311	C/T	cg06603561	chr11:134479413	NA	-1.05	-6.8	-0.48	2.27e-10	Seasonality;
PAAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	0.85	7.21	0.5	2.46e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.28	-0.56	5.89e-14	Hemoglobin concentration;
PAAD	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-5.67	-0.42	7.13e-8	Vitiligo;
PAAD	trans	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg08566640	chr11:64091735	NA	-0.62	-7.48	-0.52	5.53e-12	Height;
PAAD	cis	rs728616	0.867	rs41297151	chr10:81807167	A/T	cg05935833	chr10:81318306	SFTPA2	-0.64	-5.0	-0.38	1.54e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10512697	0.655	rs13161526	chr5:3497620	G/A	cg19473799	chr5:3511975	NA	-1.03	-4.74	-0.36	4.97e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg08742575	chr21:47604166	C21orf56	0.43	4.29	0.33	3.22e-5	Testicular germ cell tumor;
PAAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg16928487	chr17:17741425	SREBF1	-0.34	-4.63	-0.35	7.75e-6	Total body bone mineral density;
PAAD	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg08562672	chr19:21860753	NA	-0.48	-5.12	-0.38	8.94e-7	Pain;
PAAD	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.36	-4.58	-0.35	9.61e-6	Body mass index in non-asthmatics;
PAAD	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.42	-4.83	-0.37	3.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.89	10.67	0.65	3.39e-20	Prudent dietary pattern;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.7	-0.36	5.91e-6	Menopause (age at onset);
PAAD	cis	rs4455778	0.557	rs4289754	chr7:49116730	C/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.14	-0.38	8.26e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-7.67	-0.53	1.89e-12	Menarche (age at onset);
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.94	0.54	4.14e-13	Prudent dietary pattern;
PAAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.86	8.68	0.58	5.75e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.82	-6.25	-0.45	3.85e-9	Coronary artery calcification;
PAAD	cis	rs56133113	0.710	rs17131839	chr11:72830496	C/T	cg25124030	chr11:73498278	MRPL48	-0.49	-4.46	-0.34	1.57e-5	Mean platelet volume;
PAAD	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs899997	1.000	rs2219939	chr15:79029723	G/A	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	4.3	0.33	3.07e-5	Tonsillectomy;
PAAD	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg23752985	chr2:85803571	VAMP8	0.57	6.55	0.47	8.42e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg12573674	chr2:1569213	NA	-0.68	-5.31	-0.4	3.77e-7	IgG glycosylation;
PAAD	cis	rs9604529	0.643	rs75680340	chr13:114639291	C/T	cg13259177	chr13:114761607	RASA3	-0.75	-4.83	-0.36	3.33e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6976053	1.000	rs6976053	chr7:100512119	C/T	cg22425096	chr7:100417404	EPHB4	0.51	4.38	0.34	2.16e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg15193198	chr20:60906057	LAMA5	0.55	6.25	0.45	3.99e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg26660305	chr17:73571056	LLGL2	0.57	6.6	0.47	6.49e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.41	4.65	0.35	7.13e-6	Fat distribution (HIV);
PAAD	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg23260525	chr10:116636907	FAM160B1	-0.37	-4.88	-0.37	2.66e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg12386194	chr3:101231763	SENP7	0.52	5.29	0.39	4.15e-7	Colorectal cancer;
PAAD	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.62	0.47	5.9e-10	Coffee consumption (cups per day);
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg23119463	chr10:134592391	INPP5A	-0.5	-4.7	-0.36	5.71e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.58	-6.21	-0.45	4.76e-9	Schizophrenia;
PAAD	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.51	5.07	0.38	1.13e-6	Common traits (Other);
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.56	-0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg18402987	chr7:1209562	NA	0.97	5.01	0.38	1.52e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07344583	chr15:89456631	MFGE8	0.58	6.73	0.48	3.18e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11997175	0.625	rs11777333	chr8:33596470	C/A	ch.8.33884649F	chr8:33765107	NA	0.58	6.39	0.46	1.9e-9	Body mass index;
PAAD	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg06917450	chr1:38156652	C1orf109	-0.49	-4.3	-0.33	3.07e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg02475695	chr16:616220	NHLRC4	0.49	5.67	0.42	7.01e-8	Height;
PAAD	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	10.96	0.66	5.75e-21	Smoking behavior;
PAAD	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	8.11	0.55	1.59e-13	Homoarginine levels;
PAAD	trans	rs901683	1.000	rs34138033	chr10:46046512	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs58521262	0.519	rs12459461	chr19:22997083	A/G	cg07749055	chr19:23076870	NA	-0.59	-4.64	-0.35	7.36e-6	Testicular germ cell tumor;
PAAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.84	10.37	0.64	2.14e-19	Menopause (age at onset);
PAAD	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.63	-5.0	-0.38	1.54e-6	HIV-1 control;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg02811702	chr13:24901961	NA	0.52	5.54	0.41	1.31e-7	Obesity-related traits;
PAAD	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.58	-5.24	-0.39	5.31e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs732505	0.717	rs3213651	chr19:5593771	A/G	cg26242866	chr19:5711310	LONP1	1.05	5.76	0.42	4.49e-8	vWF and FVIII levels;
PAAD	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg06138931	chr13:21896616	NA	-0.64	-4.33	-0.33	2.67e-5	White matter hyperintensity burden;
PAAD	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.8	8.02	0.55	2.7e-13	Testicular germ cell tumor;
PAAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg05643964	chr20:62369504	LIME1	-0.53	-4.84	-0.37	3.16e-6	Prostate cancer;
PAAD	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.51	5.38	0.4	2.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2996428	0.778	rs1891934	chr1:3694796	G/A	cg17848003	chr1:3704513	LRRC47	0.41	4.45	0.34	1.69e-5	Red cell distribution width;
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	1.17	9.71	0.62	1.25e-17	Initial pursuit acceleration;
PAAD	cis	rs10214930	0.671	rs28416309	chr7:27633742	T/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs7945718	0.621	rs7931934	chr11:12679245	T/G	cg25843174	chr11:12811716	TEAD1	0.31	4.5	0.34	1.32e-5	Educational attainment (years of education);
PAAD	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.71	-0.48	3.54e-10	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22740703	chr7:150755251	CDK5;SLC4A2	0.64	7.4	0.51	8.45e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs3125734	0.710	rs10821967	chr10:63941939	A/G	cg09941381	chr10:64027924	RTKN2	-0.37	-4.5	-0.34	1.32e-5	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg01763666	chr17:80159506	CCDC57	-0.42	-4.3	-0.33	3e-5	Life satisfaction;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.61	-5.62	-0.41	9.03e-8	Menarche (age at onset);
PAAD	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.44	-4.88	-0.37	2.61e-6	Mean arterial pressure;
PAAD	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg21798802	chr22:38057573	PDXP	0.48	5.2	0.39	6.22e-7	Fat distribution (HIV);
PAAD	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.62e-17	White blood cell count (basophil);
PAAD	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	trans	rs9345521	0.967	rs1603247	chr6:65488770	A/G	cg26414000	chr1:85721327	C1orf52	0.53	6.63	0.47	5.47e-10	Iris color (a* coordinate);
PAAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.56	-6.9	-0.49	1.3100000000000001e-10	Multiple system atrophy;
PAAD	cis	rs6088813	0.922	rs6088800	chr20:33934437	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.64	4.72	0.36	5.26e-6	Bipolar disorder;
PAAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.84	-7.36	-0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.34	0.56	4.14e-14	Homoarginine levels;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg02524346	chr8:600233	NA	-1.05	-6.51	-0.47	1.04e-9	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26155676	chr13:111904424	ARHGEF7	-0.63	-6.53	-0.47	9.54e-10	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.89	6.42	0.46	1.66e-9	Alzheimer's disease;
PAAD	cis	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg05084668	chr3:125655381	ALG1L	-0.53	-5.44	-0.4	2.1e-7	Blood pressure (smoking interaction);
PAAD	cis	rs2221894	0.959	rs28679662	chr8:28890787	A/C	cg20212339	chr8:28908912	HMBOX1	-0.49	-5.13	-0.38	8.59e-7	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.7	-9.46	-0.61	5.49e-17	Hemoglobin concentration;
PAAD	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.4	0.4	2.56e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9677476	0.863	rs12478335	chr2:232064967	C/A	cg07929768	chr2:232055508	NA	0.39	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs8103278	1.000	rs7250497	chr19:46358425	A/G	cg02376097	chr19:46275166	DMPK	-0.61	-6.17	-0.45	5.98e-9	Coronary artery disease;
PAAD	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-0.9	-8.93	-0.59	1.29e-15	Exhaled nitric oxide output;
PAAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.4	0.4	2.53e-7	Rheumatoid arthritis;
PAAD	cis	rs1950500	0.509	rs12879087	chr14:24826900	A/T	cg22990158	chr14:24802150	ADCY4	-0.49	-5.19	-0.39	6.5e-7	Height;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.8	5.73	0.42	5.13e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg16083429	chr3:49237500	CCDC36	0.44	4.25	0.33	3.72e-5	Menarche (age at onset);
PAAD	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.63	4.63	0.35	7.69e-6	Alzheimer's disease (survival time);
PAAD	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.43	-4.34	-0.33	2.56e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06439982	chr16:2802372	SRRM2;LOC100128788	0.64	7.33	0.51	1.29e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.68e-7	Life satisfaction;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg15193198	chr20:60906057	LAMA5	0.49	4.67	0.35	6.61e-6	Colorectal cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20584474	chr6:1515696	NA	0.66	7.3	0.51	1.5e-11	Smoking initiation;
PAAD	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.86	-11.51	-0.68	1.91e-22	Height;
PAAD	cis	rs12304921	0.745	rs4768876	chr12:51432055	T/C	cg18059802	chr12:51347058	HIGD1C	-0.73	-5.68	-0.42	6.79e-8	Type 2 diabetes;
PAAD	trans	rs1146751	0.674	rs1248802	chr3:84937009	A/G	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.76	9.9	0.63	3.74e-18	Height;
PAAD	trans	rs901683	1.000	rs71494799	chr10:46002856	T/C	cg11747279	chr17:21096632	NA	0.81	6.41	0.46	1.69e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10750165	0.716	rs11217501	chr11:119652686	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.79	8.63	0.57	7.46e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs35955747	0.869	rs131219	chr22:31760250	T/C	cg07969918	chr22:31682909	PIK3IP1	0.38	4.97	0.37	1.78e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22795569	chr2:64371175	PELI1	-0.64	-6.41	-0.46	1.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg23346134	chr3:49453900	TCTA	0.46	4.93	0.37	2.15e-6	Menarche (age at onset);
PAAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.5	-5.32	-0.4	3.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2242420	0.920	rs16825734	chr1:21956199	C/A	cg26362272	chr1:22108717	USP48	0.58	4.51	0.34	1.28e-5	Hematological and biochemical traits;
PAAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.61	-8.61	-0.57	8.52e-15	Huntington's disease progression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08418508	chr5:159830462	SLU7	0.58	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.16	12.83	0.72	5.5e-26	Post bronchodilator FEV1;
PAAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.75	-7.51	-0.52	4.71e-12	Cognitive function;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26479971	chr2:29096504	NA	0.54	6.55	0.47	8.51e-10	Smoking initiation;
PAAD	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.79	9.41	0.61	7.23e-17	Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	0.79	7.21	0.5	2.47e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs375066	0.551	rs349032	chr19:44317360	A/G	cg11993925	chr19:44307056	LYPD5	0.42	4.65	0.35	7.04e-6	Breast cancer;
PAAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg24737193	chr18:12778029	NA	-0.67	-5.69	-0.42	6.19e-8	Inflammatory skin disease;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg10137597	chr8:22132714	PIWIL2	0.51	6.14	0.45	6.79e-9	Hypertriglyceridemia;
PAAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-8.68	-0.58	5.66e-15	Total body bone mineral density;
PAAD	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.62	0.57	8.14e-15	Bipolar disorder;
PAAD	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg10395934	chr14:104002654	TRMT61A	0.48	4.68	0.35	6.37e-6	Body mass index;
PAAD	trans	rs6694672	1.000	rs857026	chr1:197012194	T/C	cg26994526	chr18:47719735	MYO5B	-0.8	-6.68	-0.48	4.14e-10	Asthma;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg17644776	chr2:200775616	C2orf69	-0.64	-5.05	-0.38	1.23e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg00149659	chr3:10157352	C3orf10	0.77	5.74	0.42	4.91e-8	Alzheimer's disease;
PAAD	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.44	0.4	2.06e-7	Height;
PAAD	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.73e-11	Asthma;
PAAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.83	-9.18	-0.6	3.01e-16	Aortic root size;
PAAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.45	-4.68	-0.35	6.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg03999872	chr20:62272968	STMN3	-0.73	-6.71	-0.48	3.71e-10	Atopic dermatitis;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg19626725	chr5:178986131	RUFY1	0.51	5.51	0.41	1.48e-7	Lung cancer;
PAAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	6.04	0.44	1.12e-8	Menopause (age at onset);
PAAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.36	16.94	0.81	7.81e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs28489187	0.706	rs18582	chr1:85794819	A/G	cg16011679	chr1:85725395	C1orf52	0.51	4.8	0.36	3.84e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs13070279	0.582	rs67109126	chr3:71799808	C/T	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.46	5.41	0.4	2.46e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18621852	chr3:10150065	C3orf24	0.82	6.03	0.44	1.22e-8	Alzheimer's disease;
PAAD	cis	rs13242816	1.000	rs2188243	chr7:116109293	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.1	-0.44	8.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.62	6.22	0.45	4.6e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.62	-0.35	8.29e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.79	-9.29	-0.6	1.53e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg08132940	chr7:1081526	C7orf50	0.6	4.42	0.34	1.89e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.81	-8.8	-0.58	2.76e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.08	-0.44	9.23e-9	Systolic blood pressure;
PAAD	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	0.89	6.9	0.49	1.34e-10	Prostate cancer;
PAAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.73	0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14060898	chr9:97939026	FANCC	0.45	4.31	0.33	2.95e-5	Neuroticism;
PAAD	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.55	-0.47	8.18e-10	Triglycerides;
PAAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg23465465	chr6:26364728	BTN3A2	0.85	5.12	0.38	9.01e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs11168618	0.740	rs4409884	chr12:48927541	A/G	cg01881778	chr12:48919444	OR8S1	-0.51	-5.57	-0.41	1.15e-7	Adiponectin levels;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs747650	0.504	rs4752815	chr11:46978698	G/A	cg19486271	chr11:47235900	DDB2	-0.64	-6.11	-0.44	7.9e-9	Acne (severe);
PAAD	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.55	-6.78	-0.48	2.54e-10	Educational attainment;
PAAD	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.53	5.91	0.43	2.15e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg22800045	chr5:56110881	MAP3K1	0.61	4.74	0.36	4.81e-6	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg22227354	chr20:1206682	RAD21L1	0.54	5.32	0.4	3.58e-7	Multiple sclerosis;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.58	7.31	0.51	1.39e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	1.07	15.25	0.78	1.87e-32	Metabolite levels;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12935418	0.583	rs2970086	chr16:81028440	T/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.08	-0.44	9.25e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.32e-7	Protein quantitative trait loci;
PAAD	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.61	5.87	0.43	2.64e-8	Red cell distribution width;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.77	-0.53	1.09e-12	Body mass index;
PAAD	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs12913538	0.641	rs12591920	chr15:62902495	A/C	cg09983546	chr15:62884068	NA	-0.69	-7.25	-0.51	2.01e-11	Sleep depth;
PAAD	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg08648136	chr8:956695	NA	0.43	4.49	0.34	1.42e-5	Schizophrenia;
PAAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.8	-0.43	3.7e-8	IgG glycosylation;
PAAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg14440974	chr22:39074834	NA	-0.55	-6.61	-0.47	6.2e-10	Menopause (age at onset);
PAAD	cis	rs1499972	0.527	rs73173738	chr3:117946535	T/C	cg07612923	chr3:117604196	NA	0.69	4.38	0.33	2.18e-5	Schizophrenia;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	8.38	0.56	3.35e-14	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20547155	chr2:121554882	GLI2	-0.56	-6.4	-0.46	1.79e-9	Obesity-related traits;
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18099408	chr3:52552593	STAB1	0.45	5.02	0.38	1.43e-6	Bipolar disorder;
PAAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg05785598	chr3:49045655	WDR6	0.41	4.85	0.37	3.04e-6	Parkinson's disease;
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg12143784	chr7:64541923	NA	-0.33	-4.27	-0.33	3.5e-5	Calcium levels;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg10729496	chr3:10149963	C3orf24	-0.83	-6.69	-0.48	4.05e-10	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03068646	chr9:97136929	HIATL1	0.58	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.85	-0.37	3.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.06e-5	Tuberculosis;
PAAD	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-5.28	-0.39	4.3e-7	Vitiligo;
PAAD	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg20913747	chr6:44695427	NA	-0.71	-6.86	-0.49	1.64e-10	Total body bone mineral density;
PAAD	cis	rs7923609	0.875	rs10740118	chr10:65101207	C/G	cg08743896	chr10:65200160	JMJD1C	0.43	4.32	0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.52	-5.06	-0.38	1.17e-6	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23398323	chr19:49122587	RPL18;SPHK2	0.58	6.82	0.48	1.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.94	-9.57	-0.61	2.83e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.75	-4.72	-0.36	5.37e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg03268063	chr7:1337281	NA	-0.51	-4.43	-0.34	1.78e-5	Neuroticism;
PAAD	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.86	-0.37	2.94e-6	Mean corpuscular volume;
PAAD	trans	rs901683	0.702	rs113478021	chr10:46063563	C/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.77	0.53	1.09e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg01244601	chr4:120671846	NA	-0.51	-4.3	-0.33	3.01e-5	Corneal astigmatism;
PAAD	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.73	7.58	0.52	3.09e-12	Uric acid clearance;
PAAD	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.29	-0.45	3.13e-9	Hip circumference;
PAAD	cis	rs2120243	0.539	rs1456108	chr3:157119054	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.66	7.59	0.52	2.99e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.61	-6.78	-0.48	2.48e-10	Type 2 diabetes;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.8	5.65	0.42	7.54e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7326068	0.610	rs2477165	chr13:21445435	A/G	cg27499820	chr13:21296301	IL17D	0.53	5.04	0.38	1.32e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.22	0.55	8.29e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.69	-0.36	5.95e-6	Triglycerides;
PAAD	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg21130718	chr4:1044621	NA	0.48	4.71	0.36	5.61e-6	Recombination rate (males);
PAAD	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs617219	0.889	rs1915705	chr5:78436189	C/T	cg24856658	chr5:78533917	JMY	-0.39	-4.26	-0.33	3.59e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.85e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs4764124	0.652	rs6488712	chr12:14939332	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.55	6.31	0.46	2.91e-9	Pubertal anthropometrics;
PAAD	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.64	-5.69	-0.42	6.35e-8	Breast size;
PAAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg11250194	chr11:61601937	FADS2	-0.52	-4.71	-0.36	5.56e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs863345	0.967	rs4477267	chr1:158470644	C/T	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg03538708	chr1:25844672	NA	-0.5	-5.16	-0.39	7.45e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg08999081	chr20:33150536	PIGU	0.5	4.38	0.34	2.16e-5	Protein C levels;
PAAD	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg09211372	chr6:168490623	NA	-0.46	-4.86	-0.37	2.94e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs508970	0.556	rs10897139	chr11:60893631	C/G	cg24692310	chr11:60915630	VPS37C	0.32	4.38	0.33	2.2e-5	Rheumatoid arthritis;
PAAD	cis	rs12144094	0.832	rs6683122	chr1:120242179	G/T	cg20995928	chr1:120229863	NA	0.51	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs1443512	0.588	rs1975473	chr12:54334625	G/A	cg17410650	chr12:54324560	NA	-0.39	-5.03	-0.38	1.35e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs9916302	0.560	rs3764353	chr17:37790781	T/C	cg07936489	chr17:37558343	FBXL20	-0.63	-5.4	-0.4	2.49e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-1.11	-9.06	-0.59	6.13e-16	Blood trace element (Zn levels);
PAAD	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg27499820	chr13:21296301	IL17D	0.51	5.04	0.38	1.3e-6	Dental caries;
PAAD	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-4.73	-0.36	5.15e-6	Total body bone mineral density;
PAAD	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.7	8.03	0.55	2.5e-13	Colorectal cancer;
PAAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.72	-0.36	5.4e-6	Obesity-related traits;
PAAD	cis	rs6547631	0.844	rs13012309	chr2:85907924	G/A	cg24620635	chr2:85921963	GNLY	0.34	4.3	0.33	2.99e-5	Blood protein levels;
PAAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.32	-0.33	2.85e-5	Tonsillectomy;
PAAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg07527105	chr16:88053339	BANP	-0.42	-4.35	-0.33	2.53e-5	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs7577696	0.752	rs212721	chr2:32466029	A/G	cg02381751	chr2:32503542	YIPF4	0.41	4.36	0.33	2.36e-5	Inflammatory biomarkers;
PAAD	cis	rs2421770	0.532	rs7130967	chr11:35374008	A/G	cg13971030	chr11:35366721	SLC1A2	-0.54	-5.25	-0.39	5.08e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg10856724	chr12:34555212	NA	0.43	4.45	0.34	1.63e-5	Morning vs. evening chronotype;
PAAD	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.4	5.0	0.38	1.57e-6	Blood protein levels;
PAAD	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08048268	chr3:133502702	NA	-0.52	-6.4	-0.46	1.83e-9	Iron status biomarkers;
PAAD	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.54	5.04	0.38	1.29e-6	Total body bone mineral density;
PAAD	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.4	0.61	7.85e-17	Bladder cancer;
PAAD	cis	rs11696501	0.694	rs2272961	chr20:44259549	A/G	cg11783356	chr20:44313418	WFDC10B	0.73	6.63	0.47	5.52e-10	Brain structure;
PAAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.78e-7	Body mass index;
PAAD	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.89e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.72	-7.41	-0.51	8.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7180079	1.000	rs55700118	chr15:64529455	G/T	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-5.18	-0.39	6.93e-7	Daytime sleep phenotypes;
PAAD	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.86	-10.23	-0.64	5.2e-19	Tonsillectomy;
PAAD	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-7.03	-0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg00262122	chr8:11665843	FDFT1	0.56	5.05	0.38	1.27e-6	Morning vs. evening chronotype;
PAAD	cis	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.72	0.48	3.36e-10	Resting heart rate;
PAAD	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9463078	0.546	rs1284973	chr6:45078163	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4605213	0.528	rs12602155	chr17:49313772	A/C	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.83	-0.36	3.37e-6	Educational attainment (years of education);
PAAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg06632027	chr4:90757378	SNCA	-0.53	-4.68	-0.35	6.33e-6	Neuroticism;
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11411865	chr7:2701802	TTYH3	0.59	4.37	0.33	2.28e-5	Bipolar disorder;
PAAD	cis	rs758324	0.773	rs13174385	chr5:131160187	T/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg14393609	chr7:65229607	NA	0.68	7.37	0.51	1.02e-11	Aortic root size;
PAAD	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.54	5.62	0.41	8.95e-8	Type 2 diabetes;
PAAD	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.61	-7.6	-0.52	2.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg15654264	chr1:150340011	RPRD2	0.51	4.92	0.37	2.26e-6	Migraine;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.55	5.9	0.43	2.22e-8	Renal function-related traits (BUN);
PAAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.79	-9.85	-0.62	5.2e-18	Bone mineral density;
PAAD	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.56	6.73	0.48	3.26e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg11062466	chr8:58055876	NA	0.68	5.11	0.38	9.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1400816	0.850	rs6707142	chr2:172854198	C/A	cg23624723	chr2:173292262	ITGA6	-0.76	-4.38	-0.33	2.2e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.62	6.79	0.48	2.35e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-4.28	-0.33	3.34e-5	Multiple sclerosis;
PAAD	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.78	-0.42	4.19e-8	Colorectal cancer;
PAAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg07153921	chr17:41440717	NA	-0.42	-4.44	-0.34	1.69e-5	Menopause (age at onset);
PAAD	cis	rs6580110	0.793	rs6868098	chr5:154080958	G/A	cg05212464	chr5:154071076	NA	0.48	5.03	0.38	1.35e-6	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs7714584	1.000	rs114244137	chr5:150264753	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	1.27	7.51	0.52	4.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg12193833	chr17:30244370	NA	-0.61	-4.84	-0.37	3.23e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.93	-8.28	-0.56	5.74e-14	Breast cancer;
PAAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg22601191	chr20:60968625	CABLES2	-0.59	-5.71	-0.42	5.76e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.48	4.75	0.36	4.67e-6	Hepatocellular carcinoma;
PAAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.6	7.01	0.49	7.28e-11	Immature fraction of reticulocytes;
PAAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.67	-7.47	-0.52	5.72e-12	Renal function-related traits (BUN);
PAAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	5.18	0.39	6.97e-7	Joint mobility (Beighton score);
PAAD	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.75	-9.55	-0.61	3.17e-17	Coronary artery disease;
PAAD	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23158103	chr7:148848205	ZNF398	-0.59	-5.28	-0.39	4.41e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.51	-0.34	1.3e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs400736	0.896	rs225126	chr1:8090615	A/G	cg25007680	chr1:8021821	PARK7	0.69	6.7	0.48	3.81e-10	Response to antidepressants and depression;
PAAD	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg06236206	chr7:66120395	NA	-0.51	-4.4	-0.34	2.04e-5	Diabetic kidney disease;
PAAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.3	-0.33	3.02e-5	Mood instability;
PAAD	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg24375607	chr4:120327624	NA	0.51	5.21	0.39	6.02e-7	Corneal astigmatism;
PAAD	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg00522288	chr12:125625016	AACS	-0.51	-5.16	-0.39	7.58e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.87	8.28	0.56	5.89e-14	Methadone dose in opioid dependence;
PAAD	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.92e-6	Type 2 diabetes;
PAAD	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs72960926	0.744	rs72950548	chr6:74907794	T/C	cg03266952	chr6:74778945	NA	-1.15	-6.52	-0.47	9.89e-10	Metabolite levels (MHPG);
PAAD	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.86	8.6	0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg26939375	chr7:64535504	NA	0.76	9.19	0.6	2.84e-16	Calcium levels;
PAAD	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	4.93e-16	Motion sickness;
PAAD	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.76	8.85	0.58	2.15e-15	Mean corpuscular volume;
PAAD	cis	rs778371	0.749	rs778345	chr2:233799633	A/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.81	-0.43	3.48e-8	Schizophrenia;
PAAD	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-5.56	-0.41	1.21e-7	Crohn's disease;
PAAD	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-5.66	-0.42	7.15e-8	QRS duration;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.99	-0.38	1.63e-6	Obesity-related traits;
PAAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23281280	chr6:28129359	ZNF389	0.62	4.85	0.37	3.05e-6	Parkinson's disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26847029	chr10:101989492	CHUK	-0.69	-6.73	-0.48	3.18e-10	Lung cancer in ever smokers;
PAAD	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.71	4.26	0.33	3.6e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.56	6.54	0.47	8.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs55728055	0.661	rs7285091	chr22:31996363	A/G	cg01338084	chr22:32026380	PISD	1.61	8.57	0.57	1.12e-14	Age-related hearing impairment;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.59	-0.35	9.25e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.71	-0.53	1.54e-12	Sense of smell;
PAAD	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg08898775	chr15:59042684	ADAM10	0.41	5.36	0.4	3.04e-7	Schizophrenia;
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg15640734	chr5:494837	SLC9A3	-0.47	-4.84	-0.37	3.23e-6	Cystic fibrosis severity;
PAAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.09e-5	Breast cancer;
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg08807892	chr2:162101083	NA	0.6	6.39	0.46	1.9e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs4711336	1.000	rs2296740	chr6:33659536	A/G	cg00536532	chr6:33561449	C6orf227	-0.44	-4.61	-0.35	8.38e-6	Height;
PAAD	cis	rs9810890	1.000	rs73198824	chr3:128486699	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4372836	0.543	rs11686412	chr2:28992405	A/G	cg09009506	chr2:28216851	BRE	0.41	4.37	0.33	2.28e-5	Body mass index;
PAAD	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg23127183	chr11:57508653	C11orf31	-0.52	-4.41	-0.34	1.98e-5	Schizophrenia;
PAAD	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	1.0	9.72	0.62	1.13e-17	Psoriasis;
PAAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.77	-8.11	-0.55	1.58e-13	Cognitive function;
PAAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7932354	0.583	rs7940578	chr11:46812227	A/G	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg09998033	chr7:158218633	PTPRN2	0.76	9.05	0.59	6.46e-16	Obesity-related traits;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg05082376	chr22:42548792	NA	0.51	5.6	0.41	9.98e-8	Cognitive function;
PAAD	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.58	6.71	0.48	3.66e-10	Aortic root size;
PAAD	trans	rs901683	0.850	rs76395348	chr10:46082064	T/C	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	8.09e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs28647808	1.000	rs35179461	chr9:136270293	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.83	-7.91	-0.54	4.82e-13	Dilated cardiomyopathy;
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg03909863	chr11:638404	DRD4	-0.6	-5.45	-0.4	1.94e-7	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.94	-0.49	1.04e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs9567406	0.702	rs2875550	chr13:44870615	A/G	cg08635097	chr13:44833857	NA	-0.54	-4.25	-0.33	3.68e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.53	4.66	0.35	6.9e-6	Lymphocyte counts;
PAAD	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.53	-4.97	-0.37	1.76e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.73	7.15	0.5	3.34e-11	Corneal astigmatism;
PAAD	cis	rs35740288	0.857	rs11632034	chr15:86284072	C/T	cg07943548	chr15:86304357	KLHL25	-0.53	-4.51	-0.34	1.27e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs490234	0.586	rs3122934	chr9:128154100	C/G	cg14078157	chr9:128172775	NA	0.53	6.05	0.44	1.08e-8	Mean arterial pressure;
PAAD	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	1.11	16.12	0.79	9.92e-35	Systemic lupus erythematosus;
PAAD	cis	rs5756391	0.546	rs9607392	chr22:37315592	C/T	cg16356956	chr22:37317934	CSF2RB	0.38	4.71	0.36	5.64e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Electroencephalogram traits;
PAAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.77	-9.26	-0.6	1.79e-16	Height;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.61	6.58	0.47	7.3e-10	Lung cancer;
PAAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.69	-8.3	-0.56	5.34e-14	Emphysema distribution in smoking;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01114163	chr5:1856713	NA	-0.41	-4.37	-0.33	2.32e-5	Cardiovascular disease risk factors;
PAAD	cis	rs17601876	0.778	rs11632926	chr15:51564226	G/A	cg21478137	chr15:51532386	CYP19A1	0.42	4.28	0.33	3.27e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg16589663	chr20:23618590	CST3	-0.79	-6.85	-0.49	1.75e-10	Chronic kidney disease;
PAAD	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.52	-4.75	-0.36	4.64e-6	Neuroticism;
PAAD	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.58	-0.35	9.64e-6	Alcohol dependence;
PAAD	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs11078597	0.697	rs3976	chr17:1653091	G/A	cg17514665	chr17:1657533	SERPINF2	0.72	6.66	0.48	4.78e-10	Serum albumin level;
PAAD	cis	rs7551345	0.853	rs6683793	chr1:31864450	G/A	cg17086398	chr1:31896392	SERINC2	-0.52	-4.58	-0.35	9.53e-6	Schizophrenia;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg07784872	chr16:85687041	KIAA0182	0.52	4.3	0.33	3.06e-5	Platelet distribution width;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg00932156	chr14:69618982	DCAF5	0.72	7.17	0.5	3.1e-11	Primary biliary cholangitis;
PAAD	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.89	-5.71	-0.42	5.82e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg26818257	chr2:241905806	NA	0.42	4.28	0.33	3.34e-5	Urinary metabolites;
PAAD	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.43	-4.81	-0.36	3.57e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs13242816	1.000	rs34325296	chr7:116122409	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.45	4.95	0.37	1.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.51	-5.52	-0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23145622	chr1:206859650	MAPKAPK2	0.7	8.08	0.55	1.87e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11250714	0.961	rs7078890	chr10:1706306	G/C	cg10435618	chr10:838112	NA	-0.47	-4.3	-0.33	3.06e-5	Gut microbiome composition (summer);
PAAD	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2562456	0.876	rs2359144	chr19:21590636	C/T	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs4668356	1.000	rs73017249	chr2:172018995	C/T	cg13882835	chr2:172017928	TLK1	0.85	4.41	0.34	1.93e-5	Cognitive performance;
PAAD	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.79	9.31	0.6	1.37e-16	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24011228	chr18:11908772	MPPE1	0.63	6.57	0.47	7.53e-10	Obesity-related traits;
PAAD	cis	rs17608059	0.611	rs62052300	chr17:13916799	G/A	cg11395062	chr17:14139857	CDRT15	0.53	5.4	0.4	2.54e-7	Temperament;
PAAD	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.51	4.57	0.35	9.88e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.5	0.34	1.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.44	4.91	0.37	2.36e-6	Alzheimer's disease (late onset);
PAAD	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12979813	1.000	rs3810307	chr19:11332570	T/A	cg08405405	chr19:11485325	C19orf39	-0.61	-4.46	-0.34	1.61e-5	HDL cholesterol;
PAAD	cis	rs11051970	0.918	rs6488050	chr12:32532499	A/T	cg24626660	chr12:32551988	NA	0.41	4.48	0.34	1.45e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg24565620	chr2:194026	NA	0.58	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs4862562	1.000	rs67910991	chr4:186601293	T/C	cg21367866	chr4:187563992	FAT1	0.84	4.3	0.33	3.01e-5	Cytokine-stimulated IL-6 production;Cytokine and corticosteroid-stimulated IL-6 production;
PAAD	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg20913747	chr6:44695427	NA	-0.65	-6.48	-0.47	1.18e-9	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg22495480	chr3:40350820	EIF1B	0.45	4.36	0.33	2.39e-5	Renal cell carcinoma;
PAAD	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg24739098	chr15:79297159	RASGRF1	0.36	4.58	0.35	9.58e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.85	5.43	0.4	2.18e-7	Diabetic kidney disease;
PAAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.64	5.66	0.42	7.34e-8	Menarche (age at onset);
PAAD	cis	rs11159086	1.000	rs11159087	chr14:74971374	C/T	cg10195687	chr14:74926396	NA	-0.42	-4.44	-0.34	1.72e-5	Advanced glycation end-product levels;
PAAD	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.83	0.62	5.93e-18	Post bronchodilator FEV1;
PAAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12050497	chr2:14773274	FAM84A	-0.63	-7.19	-0.5	2.8e-11	Body fat percentage;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.54	-7.34	-0.51	1.23e-11	Longevity;Endometriosis;
PAAD	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.1	-0.38	9.81e-7	Monocyte percentage of white cells;
PAAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.93	10.06	0.63	1.49e-18	Cognitive function;
PAAD	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.41	-0.34	1.98e-5	Asthma;
PAAD	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg02297831	chr4:17616191	MED28	-0.59	-5.57	-0.41	1.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.65	0.35	7.12e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27313690	chr10:21634014	NA	-0.42	-4.45	-0.34	1.63e-5	Monocyte percentage of white cells;
PAAD	cis	rs12282928	0.700	rs2047815	chr11:48199897	C/T	cg04607699	chr11:48328132	OR4S1	0.52	4.91	0.37	2.38e-6	Migraine - clinic-based;
PAAD	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg12473912	chr3:136751656	NA	0.4	4.46	0.34	1.59e-5	Gestational age at birth (child effect);
PAAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs9463078	0.774	rs7451423	chr6:45241343	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.37	-0.4	2.85e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg21698718	chr17:80085957	CCDC57	0.44	4.94	0.37	2.02e-6	Life satisfaction;
PAAD	cis	rs8077577	0.747	rs3817992	chr17:18194011	C/A	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs73206853	0.764	rs56179460	chr12:111125774	C/G	cg12870014	chr12:110450643	ANKRD13A	0.71	4.44	0.34	1.74e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs28785552	0.554	rs11084182	chr19:53213411	A/G	cg10871876	chr19:53194124	ZNF83	0.5	4.51	0.34	1.28e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg09281539	chr20:20693126	RALGAPA2	-0.81	-7.4	-0.51	8.55e-12	Blood protein levels;
PAAD	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs55794721	0.611	rs74937936	chr1:25747646	G/A	cg23205692	chr1:25664452	TMEM50A	0.49	4.68	0.36	6.23e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-0.48	-4.54	-0.35	1.12e-5	Bipolar disorder;
PAAD	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.43	4.3	0.33	3.07e-5	Lung cancer;
PAAD	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-1.02	-9.25	-0.6	1.96e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.59	-5.57	-0.41	1.13e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs6011674	0.901	rs56783811	chr20:61860505	A/G	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.74	-4.55	-0.35	1.09e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.65	6.44	0.46	1.45e-9	Multiple sclerosis;
PAAD	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs71520386	0.632	rs10279864	chr7:22863824	C/G	cg04907244	chr7:22894795	SNORD93	0.5	5.43	0.4	2.17e-7	Fibrinogen levels;
PAAD	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Vitiligo;
PAAD	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.91	7.07	0.5	5.4e-11	Total cholesterol levels;
PAAD	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	1.0	7.59	0.52	2.93e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25511286	chr10:27793050	RAB18	0.63	6.55	0.47	8.21e-10	Myopia (pathological);
PAAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.33	0.33	2.64e-5	Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.81	6.8	0.48	2.28e-10	Alzheimer's disease;
PAAD	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.48	4.27	0.33	3.4e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg26939375	chr7:64535504	NA	-0.51	-4.41	-0.34	1.95e-5	Aortic root size;
PAAD	cis	rs1329189	1.000	rs6482667	chr10:129994888	T/C	cg17972361	chr10:130010134	NA	-0.46	-4.73	-0.36	5.02e-6	Orofacial clefts;
PAAD	cis	rs8070740	0.786	rs34878464	chr17:5327251	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.45	0.34	1.62e-5	Menopause (age at onset);
PAAD	cis	rs28489187	0.706	rs12124170	chr1:85811182	A/G	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.65	-0.42	7.73e-8	Joint mobility (Beighton score);
PAAD	cis	rs2712184	0.875	rs35925637	chr2:217676628	T/A	cg05032264	chr2:217675019	NA	0.6	6.53	0.47	9.09e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg25783544	chr11:47291846	MADD	0.55	4.49	0.34	1.42e-5	HDL cholesterol;
PAAD	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg27449745	chr7:23145252	KLHL7	-0.59	-5.34	-0.4	3.35e-7	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg12965426	chr2:131863715	PLEKHB2	0.7	7.05	0.5	5.77e-11	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11807834	0.522	rs10864692	chr1:230240469	G/A	cg00566187	chr1:230250356	GALNT2	-0.64	-6.81	-0.48	2.16e-10	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs72827839	0.846	rs76950846	chr17:46102153	G/A	cg23391107	chr17:45924227	SP6	0.63	5.39	0.4	2.68e-7	Ease of getting up in the morning;
PAAD	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg07636037	chr3:49044803	WDR6	0.6	5.47	0.41	1.78e-7	Red cell distribution width;
PAAD	cis	rs4742903	0.584	rs10217250	chr9:106911633	A/T	cg14250997	chr9:106856677	SMC2	0.5	5.41	0.4	2.42e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6681460	0.576	rs1338200	chr1:66992197	C/A	cg02459107	chr1:67143332	SGIP1	0.57	5.01	0.38	1.47e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.57	5.62	0.41	8.89e-8	Educational attainment;
PAAD	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.69	-6.97	-0.49	9.1e-11	Triglycerides;
PAAD	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg14343924	chr8:8086146	FLJ10661	-0.57	-5.18	-0.39	6.79e-7	Joint mobility (Beighton score);
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04717802	chr22:42394638	WBP2NL	-0.42	-4.51	-0.34	1.27e-5	Cognitive function;
PAAD	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg02016764	chr4:38805732	TLR1	-0.55	-4.31	-0.33	2.89e-5	Breast cancer;
PAAD	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.5	-0.47	1.07e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs308971	0.563	rs217049	chr3:12060917	C/T	cg02700894	chr3:12045449	SYN2	0.62	4.5	0.34	1.34e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs8005172	0.663	rs1372356	chr14:88515949	G/A	cg18078958	chr14:88630771	NA	0.35	4.38	0.33	2.18e-5	Parkinson's disease;
PAAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.72	-8.15	-0.55	1.26e-13	Diastolic blood pressure;
PAAD	cis	rs62209635	0.500	rs6088295	chr20:32344656	G/A	cg00997172	chr20:32399000	CHMP4B	-0.79	-4.27	-0.33	3.44e-5	Loneliness;
PAAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-6.03	-0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs2327429	0.519	rs4895388	chr6:134150561	G/A	cg06296503	chr6:134217401	NA	0.43	4.46	0.34	1.58e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.6	-6.81	-0.48	2.17e-10	Lung cancer;
PAAD	cis	rs13102973	0.640	rs10434069	chr4:135840778	G/A	cg14419869	chr4:135874104	NA	0.45	4.56	0.35	1.04e-5	Subjective well-being;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06404838	chr11:117015391	PAFAH1B2	0.62	6.77	0.48	2.6200000000000003e-10	Monocyte percentage of white cells;
PAAD	cis	rs71386933	0.509	rs34400689	chr16:72003454	T/G	cg08717414	chr16:71523259	ZNF19	-0.73	-4.27	-0.33	3.43e-5	Post bronchodilator FEV1;
PAAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg16147221	chr4:10020634	SLC2A9	0.5	4.58	0.35	9.79e-6	Bone mineral density;
PAAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.67	5.66	0.42	7.23e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-1.09	-9.19	-0.6	2.8e-16	Obesity-related traits;
PAAD	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.31	-0.46	2.86e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.2	12.33	0.71	1.17e-24	Corneal structure;
PAAD	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.92	-6.75	-0.48	2.87e-10	Opioid sensitivity;
PAAD	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg01620082	chr3:125678407	NA	-1.44	-8.04	-0.55	2.32e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs3020418	0.964	rs2982708	chr6:152356220	T/C	cg09520904	chr11:69462943	CCND1	-0.54	-6.62	-0.47	5.7e-10	Height;
PAAD	cis	rs13070279	0.582	rs34586454	chr3:71799897	C/G	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs12096438	1.000	rs4603124	chr1:25893243	G/A	cg06359931	chr1:25893405	LDLRAP1	0.36	4.27	0.33	3.47e-5	Platelet count;Mean platelet volume;
PAAD	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.0	6.77	0.48	2.63e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg16479474	chr6:28041457	NA	0.45	4.48	0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7922314	0.571	rs16917988	chr10:64735314	T/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04113920	chr6:56911540	KIAA1586	0.63	6.38	0.46	2e-9	Obesity-related traits;
PAAD	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg19223190	chr17:80058835	NA	0.51	5.27	0.39	4.61e-7	Life satisfaction;
PAAD	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.6	-6.13	-0.45	7.15e-9	Motion sickness;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13585032	chr7:148788766	ZNF786	0.61	6.93	0.49	1.15e-10	Metabolite levels  (X-11787);
PAAD	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	5.38	0.4	2.79e-7	Myopia (pathological);
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.72	0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg23920097	chr1:209922102	NA	-0.49	-4.37	-0.33	2.33e-5	Red blood cell count;
PAAD	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.56	5.5	0.41	1.54e-7	Mean corpuscular volume;
PAAD	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.32	-0.33	2.86e-5	Height;
PAAD	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg26752888	chr8:11627280	NEIL2	1.14	9.96	0.63	2.71e-18	Alcohol dependence;Nicotine use;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	9.96	0.63	2.69e-18	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg13821571	chr21:34406537	NA	-0.46	-4.49	-0.34	1.4e-5	Gastritis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19756253	chr3:128118221	EEFSEC	0.55	6.38	0.46	2.04e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.72	-7.14	-0.5	3.67e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg13918804	chr1:2043761	PRKCZ	0.35	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.95	-0.37	1.96e-6	Type 2 diabetes;
PAAD	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-7.9	-0.54	5.21e-13	Response to antipsychotic treatment;
PAAD	cis	rs61884328	0.733	rs61897855	chr11:47231040	C/T	cg23433285	chr11:47201945	PACSIN3	0.85	4.48	0.34	1.46e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.78	4.71	0.36	5.51e-6	Obesity-related traits;
PAAD	trans	rs3733631	0.696	rs7672658	chr4:104631530	G/A	cg11176159	chr1:28213800	NA	-0.49	-6.43	-0.46	1.54e-9	Menarche (age at onset);
PAAD	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	6.63	0.47	5.56e-10	Lung cancer in ever smokers;
PAAD	cis	rs728616	0.717	rs12412999	chr10:82008141	C/T	cg05935833	chr10:81318306	SFTPA2	-0.63	-4.5	-0.34	1.32e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg20060108	chr2:102954350	IL1RL1	-0.47	-4.52	-0.34	1.23e-5	Blood protein levels;
PAAD	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.86	8.77	0.58	3.44e-15	Uric acid levels;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.52	4.74	0.36	4.82e-6	Dental caries;
PAAD	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.92	-11.1	-0.67	2.49e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.84	7.39	0.51	8.94e-12	Phospholipid levels (plasma);
PAAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg27449745	chr7:23145252	KLHL7	0.56	4.91	0.37	2.38e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7149242	0.771	rs8012970	chr14:101168491	T/C	cg15986276	chr14:101176310	NA	0.34	4.94	0.37	2.02e-6	Platelet count;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg24879335	chr3:133465180	TF	0.6	6.87	0.49	1.56e-10	Iron status biomarkers;
PAAD	cis	rs73206853	0.841	rs56379265	chr12:110956370	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.69	0.36	5.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.56	5.78	0.42	4.04e-8	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.48	-0.34	1.44e-5	Aortic root size;
PAAD	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	5.27	0.39	4.58e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg19413350	chr8:57351067	NA	-0.45	-4.27	-0.33	3.44e-5	Obesity-related traits;
PAAD	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg14154651	chr8:95652577	ESRP1	-0.48	-4.65	-0.35	7.19e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7925523	0.891	rs59200224	chr11:61450137	A/G	cg12472022	chr11:61462803	DAGLA	0.68	5.6	0.41	9.78e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.53	5.66	0.42	7.19e-8	Height;
PAAD	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.25	-0.33	3.72e-5	Recombination measurement;
PAAD	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.48	4.94	0.37	2.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg05895507	chr15:77155635	SCAPER	-0.41	-4.55	-0.35	1.07e-5	Blood metabolite levels;
PAAD	cis	rs6460942	0.908	rs74801929	chr7:12232715	C/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.96	6.46	0.46	1.36e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2017305	0.915	rs76652065	chr10:70772168	T/A	cg25290552	chr10:70751067	KIAA1279	-0.9	-4.92	-0.37	2.22e-6	Depression (quantitative trait);
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264213	0.901	rs665521	chr1:36445837	T/C	cg27506609	chr1:36549197	TEKT2	0.74	5.19	0.39	6.56e-7	Schizophrenia;
PAAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19337854	chr7:99768885	GPC2	-0.45	-4.79	-0.36	3.98e-6	Coronary artery disease;
PAAD	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.88	10.93	0.66	6.97e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.57	6.95	0.49	9.94e-11	Lung cancer;
PAAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-5.87	-0.43	2.66e-8	Body mass index;
PAAD	cis	rs939584	0.935	rs7561556	chr2:638560	T/C	cg03610516	chr2:642275	NA	0.6	5.39	0.4	2.69e-7	Body mass index;
PAAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.67	5.86	0.43	2.72e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.9	8.82	0.58	2.47e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg05110241	chr16:68378359	PRMT7	-0.92	-7.09	-0.5	4.68e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg12757816	chr2:10669957	NA	-0.51	-5.24	-0.39	5.39e-7	Prostate cancer;
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg10207240	chr12:122356781	WDR66	0.53	5.63	0.42	8.42e-8	Mean corpuscular volume;
PAAD	cis	rs9976767	0.932	rs3746924	chr21:43826391	T/C	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.59	-0.35	9.04e-6	Type 1 diabetes;
PAAD	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.51	4.53	0.34	1.19e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4743820	0.651	rs10733738	chr9:93929352	G/A	cg14446406	chr9:93919335	NA	-0.51	-5.94	-0.43	1.86e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg11235426	chr6:292522	DUSP22	-0.75	-7.86	-0.54	6.49e-13	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.72	9.67	0.62	1.52e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs1883415	0.534	rs2760143	chr6:24479472	C/T	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.61	6.4	0.46	1.84e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg06629702	chr1:2706960	NA	0.36	4.28	0.33	3.25e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg24220031	chr2:73402428	NA	-0.34	-5.25	-0.39	5.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19904058	chr10:135279010	LOC619207	-0.49	-5.89	-0.43	2.36e-8	Systemic lupus erythematosus;
PAAD	cis	rs375066	0.935	rs423765	chr19:44416199	C/T	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs1723838	0.826	rs1670560	chr11:73600167	G/A	cg26954736	chr11:73693896	UCP2	1.03	4.58	0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs138918	1.000	rs47341	chr22:43560763	C/T	cg08909806	chr22:43548696	TSPO	0.51	5.0	0.38	1.55e-6	Monocyte count;
PAAD	cis	rs12304921	0.935	rs79534240	chr12:51354696	C/T	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs12304921	1.000	rs56402416	chr12:51357791	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.97	-0.37	1.79e-6	Type 2 diabetes;
PAAD	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg10818794	chr15:86012489	AKAP13	0.43	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.83	-0.36	3.33e-6	Red cell distribution width;
PAAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.96	9.23	0.6	2.15e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg26816564	chr1:7831052	VAMP3	0.67	5.34	0.4	3.4e-7	Inflammatory bowel disease;
PAAD	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg18357526	chr6:26021779	HIST1H4A	0.62	4.92	0.37	2.19e-6	Homocysteine levels;
PAAD	cis	rs501120	0.657	rs589655	chr10:44745315	C/G	cg09554077	chr10:44749378	NA	0.4	4.32	0.33	2.79e-5	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.8	9.17	0.6	3.17e-16	Heart rate;
PAAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.67	7.99	0.54	3.09e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.51	5.23	0.39	5.65e-7	Inflammatory bowel disease;
PAAD	cis	rs4388249	0.687	rs10059767	chr5:109100750	T/G	cg17395555	chr5:108820864	NA	0.32	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.85	11.54	0.68	1.65e-22	Metabolite levels;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6732160	0.564	rs1430346	chr2:73367245	T/C	cg01422370	chr2:73384389	NA	0.46	5.69	0.42	6.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs5753037	0.653	rs131286	chr22:30158351	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.66	-6.79	-0.48	2.34e-10	Non-obstructive azoospermia;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.48	5.08	0.38	1.08e-6	Life satisfaction;
PAAD	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.52	5.71	0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.68	5.61	0.41	9.16e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg26893134	chr6:116381904	FRK	0.31	5.04	0.38	1.3e-6	Total cholesterol levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23897255	chr11:747301	TALDO1	-0.73	-6.36	-0.46	2.21e-9	Neuroticism;
PAAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg14196790	chr5:131705035	SLC22A5	0.49	5.16	0.39	7.78e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-5.94	-0.43	1.85e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs3206736	0.548	rs10278195	chr7:35064459	G/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.54	-0.35	1.12e-5	Diastolic blood pressure;
PAAD	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-6.42	-0.46	1.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.53	7.15	0.5	3.39e-11	Life satisfaction;
PAAD	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.4	-4.96	-0.37	1.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs8077577	0.671	rs6502641	chr17:18132979	A/G	cg16794390	chr17:18148240	FLII	-0.51	-4.42	-0.34	1.91e-5	Obesity-related traits;
PAAD	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14671526	chr3:37035200	MLH1;EPM2AIP1	0.56	6.3	0.46	3.09e-9	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.47	5.33	0.4	3.57e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg18370025	chr7:2749541	AMZ1	-0.36	-4.46	-0.34	1.59e-5	Height;
PAAD	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg14703610	chr5:56206110	C5orf35	0.61	5.45	0.4	1.96e-7	Breast cancer;Breast cancer (early onset);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01476569	chr16:81069244	ATMIN	-0.55	-6.47	-0.46	1.28e-9	Body fat percentage;
PAAD	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	7.29	0.51	1.56e-11	Lymphocyte counts;
PAAD	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg17325771	chr7:75508891	RHBDD2	0.31	4.39	0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.66	7.49	0.52	5.2e-12	Dupuytren's disease;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.29	-0.33	3.11e-5	Lung cancer;
PAAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14867121	chr4:146297077	NA	-0.53	-6.39	-0.46	1.94e-9	Obesity-related traits;
PAAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.65	-6.76	-0.48	2.73e-10	Body mass index;
PAAD	cis	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	5.3	0.4	3.92e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs469727	0.600	rs149192	chr5:112252066	C/T	cg06941702	chr5:112196734	SRP19	0.51	4.88	0.37	2.69e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs3826795	0.569	rs11671319	chr19:46795067	T/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.21e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	7.07e-8	Urinary metabolites;
PAAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.79	-0.36	4e-6	Life satisfaction;
PAAD	trans	rs6030712	0.948	rs1744776	chr20:35726051	C/T	cg12612947	chr3:25706262	TOP2B	0.79	6.52	0.47	9.69e-10	Height;
PAAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.14	-14.09	-0.75	2.29e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07387570	chr22:46663686	TTC38	0.59	6.48	0.47	1.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg15211996	chr1:2936768	ACTRT2	0.46	4.76	0.36	4.44e-6	Plateletcrit;
PAAD	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.02	-0.38	1.44e-6	Cervical cancer;
PAAD	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg05925327	chr15:68127851	NA	-0.64	-5.81	-0.43	3.49e-8	Restless legs syndrome;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg02428538	chr16:24856791	SLC5A11	-0.63	-4.66	-0.35	7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.72e-15	Dupuytren's disease;
PAAD	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	7.95	0.54	3.94e-13	Electrocardiographic conduction measures;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.47	-7.19	-0.5	2.7e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.73	5.33	0.4	3.53e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg27478167	chr7:817139	HEATR2	0.71	5.46	0.41	1.86e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.98	-0.37	1.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg17372657	chr7:1216933	NA	-0.39	-5.11	-0.38	9.56e-7	Longevity;Endometriosis;
PAAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg07952391	chr2:88470173	THNSL2	-0.49	-4.71	-0.36	5.48e-6	Response to metformin (IC50);
PAAD	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg20731937	chr12:48336164	NA	0.52	4.41	0.34	1.95e-5	Longevity (90 years and older);
PAAD	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg03513858	chr6:54763001	FAM83B	0.42	4.59	0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg14349672	chr11:133703707	NA	-0.57	-6.55	-0.47	8.6e-10	Childhood ear infection;
PAAD	cis	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg13821571	chr21:34406537	NA	-0.49	-4.74	-0.36	4.92e-6	Gastritis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16008457	chr7:6865886	C7orf28B	0.66	7.72	0.53	1.47e-12	Monocyte percentage of white cells;
PAAD	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg21937377	chr3:194868750	C3orf21	0.46	4.9	0.37	2.42e-6	Non-small cell lung cancer;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg18279126	chr7:2041391	MAD1L1	0.53	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs55728055	0.661	rs16989682	chr22:31900224	A/G	cg01338084	chr22:32026380	PISD	-1.43	-7.75	-0.53	1.25e-12	Age-related hearing impairment;
PAAD	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg27565382	chr3:53032988	SFMBT1	0.72	4.31	0.33	2.96e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.21	0.51	2.41e-11	Multiple sclerosis;
PAAD	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs1539053	0.966	rs12755476	chr1:58098949	C/T	cg00026909	chr1:58089001	DAB1	-0.7	-8.01	-0.54	2.76e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03676636	chr4:99064102	C4orf37	0.31	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4657482	0.640	rs10918304	chr1:165864687	T/A	cg03151810	chr8:144371745	NA	-0.51	-6.29	-0.45	3.18e-9	Testicular germ cell tumor;
PAAD	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.66	7.23	0.51	2.23e-11	Testicular germ cell tumor;
PAAD	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg04398451	chr17:18023971	MYO15A	0.77	8.58	0.57	1e-14	Total body bone mineral density;
PAAD	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.78	-6.68	-0.48	4.15e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11614333	1.000	rs58120888	chr12:15048281	C/G	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg01304814	chr3:48885189	PRKAR2A	0.67	4.55	0.35	1.09e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg01075559	chr1:2537774	MMEL1	-0.47	-4.99	-0.38	1.63e-6	Ulcerative colitis;
PAAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.96	10.03	0.63	1.72e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.57	-0.35	9.99e-6	Asthma;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.32	-4.91	-0.37	2.28e-6	Longevity;Endometriosis;
PAAD	cis	rs111544199	1	rs111544199	chr19:50091221	GT/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.6	-5.15	-0.39	8.03e-7	Red blood cell count;
PAAD	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.7	-6.6	-0.47	6.42e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg19413350	chr8:57351067	NA	-0.55	-5.55	-0.41	1.26e-7	Obesity-related traits;
PAAD	cis	rs6676180	1.000	rs6676180	chr1:119783223	A/T	cg05756136	chr1:119680316	WARS2	-0.43	-4.29	-0.33	3.21e-5	Monobrow;
PAAD	cis	rs7771547	0.603	rs7344	chr6:36570366	A/G	cg02952361	chr6:36355661	ETV7	0.48	4.31	0.33	2.89e-5	Platelet distribution width;
PAAD	cis	rs11650175	0.778	rs2024274	chr17:63768955	G/A	cg07283582	chr17:63770753	CCDC46	0.38	4.36	0.33	2.4e-5	Chin dimples;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.07	0.44	9.7e-9	Lymphocyte counts;
PAAD	cis	rs10256972	0.680	rs7784708	chr7:1003049	A/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.27	-0.33	3.42e-5	Longevity;Endometriosis;
PAAD	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg01620082	chr3:125678407	NA	-1.17	-6.98	-0.49	8.75e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.54	4.62	0.35	8.15e-6	Height;
PAAD	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg25079218	chr10:134836799	NA	-0.43	-4.39	-0.34	2.13e-5	Gout;
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.55	-6.3	-0.46	3.03e-9	Mean corpuscular volume;
PAAD	cis	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00982548	chr2:198649783	BOLL	-0.8	-5.67	-0.42	7.04e-8	Ulcerative colitis;
PAAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	6.9	0.49	1.32e-10	Type 2 diabetes;
PAAD	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.59	-0.47	6.85e-10	Morning vs. evening chronotype;
PAAD	cis	rs60617249	0.542	rs6593251	chr7:50929535	T/C	cg15805451	chr7:51135775	COBL	-0.42	-4.43	-0.34	1.82e-5	Major depression and alcohol dependence;
PAAD	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.5	6.34	0.46	2.47e-9	Childhood ear infection;
PAAD	cis	rs12541635	0.934	rs60482457	chr8:106970504	A/G	cg10147462	chr8:107024639	NA	0.41	4.32	0.33	2.83e-5	Age of smoking initiation;
PAAD	cis	rs4148087	1.000	rs4148092	chr21:43635162	T/C	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg20517616	chr2:26468218	HADHA;HADHB	-0.59	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg01657329	chr11:68192670	LRP5	-0.67	-4.8	-0.36	3.73e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg01448562	chr3:133502909	NA	-0.48	-4.89	-0.37	2.49e-6	Iron status biomarkers;
PAAD	cis	rs6681460	0.932	rs523132	chr1:67174440	A/G	cg02459107	chr1:67143332	SGIP1	-0.69	-6.69	-0.48	4.06e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.72	-8.14	-0.55	1.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02556042	chr12:117471086	NA	-0.48	-4.88	-0.37	2.68e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg13468214	chr4:1046988	NA	-0.51	-5.51	-0.41	1.5e-7	Recombination rate (males);
PAAD	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.36	-4.37	-0.33	2.31e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	0.850	rs115721474	chr3:128430370	G/A	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg00543991	chr22:32367038	NA	1.04	6.92	0.49	1.19e-10	Childhood ear infection;
PAAD	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.78	-7.13	-0.5	3.86e-11	Homoarginine levels;
PAAD	cis	rs7326068	0.610	rs4769128	chr13:21322682	A/G	cg27234864	chr13:21295941	IL17D	-0.58	-4.87	-0.37	2.78e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	5.2	0.39	6.21e-7	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-7.09	-0.5	4.66e-11	Parkinson's disease;
PAAD	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.47	4.83	0.36	3.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2882667	0.598	rs10078179	chr5:138256099	G/C	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-4.3	-0.33	3.05e-5	Breast cancer;
PAAD	cis	rs59888335	0.858	rs1878761	chr3:80987374	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.85	-0.37	3.02e-6	Recombination rate (females);
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.61	0.41	9.23e-8	Total body bone mineral density;
PAAD	cis	rs7094131	0.530	rs7087066	chr10:22873207	T/C	cg19500236	chr10:22911537	PIP4K2A	0.44	4.71	0.36	5.52e-6	Obesity-related traits;
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20460709	chr12:125553676	AACS	0.56	6.37	0.46	2.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2730260	0.537	rs55683317	chr7:158878599	C/T	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.78	7.63	0.53	2.42e-12	Retinal vascular caliber;
PAAD	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg22143856	chr6:28129313	ZNF389	0.53	4.93	0.37	2.17e-6	Parkinson's disease;
PAAD	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21659725	chr3:3221576	CRBN	0.76	7.99	0.54	3.13e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.52	-6.34	-0.46	2.48e-9	Lung cancer;
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.89	8.53	0.57	1.41e-14	Bone mineral density;
PAAD	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.47	0.41	1.8e-7	Ileal carcinoids;
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14180030	chr9:123475675	MEGF9	-0.42	-5.03	-0.38	1.36e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-4.38	-0.34	2.16e-5	Menarche (age at onset);
PAAD	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.78	8.22	0.55	8.47e-14	Aortic root size;
PAAD	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.5	0.57	1.6e-14	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.71	7.62	0.53	2.52e-12	Cognitive test performance;
PAAD	cis	rs6066835	1.000	rs2223684	chr20:47354880	A/C	cg18078177	chr20:47281410	PREX1	1.01	5.42	0.4	2.3e-7	Multiple myeloma;
PAAD	cis	rs7932354	0.583	rs964551	chr11:46897995	G/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.46	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.63	-0.35	7.87e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6076065	0.723	rs2424548	chr20:23394456	A/C	cg11657817	chr20:23433608	CST11	0.49	5.0	0.38	1.54e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg10167378	chr1:228756711	NA	0.54	4.27	0.33	3.46e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg11530693	chr1:120165357	ZNF697	0.61	6.73	0.48	3.27e-10	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.11e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg20917491	chr3:195578259	NA	0.53	5.06	0.38	1.19e-6	Pancreatic cancer;
PAAD	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.65	6.56	0.47	7.77e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg14709524	chr16:89940631	TCF25	1.0	4.67	0.35	6.69e-6	Skin colour saturation;
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.72	-7.42	-0.52	7.6e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs933688	0.652	rs4916856	chr5:90596403	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.69	-5.38	-0.4	2.77e-7	Smoking behavior;
PAAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg19500098	chr13:21900506	NA	0.57	5.83	0.43	3.26e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16260274	chr17:35849812	DUSP14	0.63	6.42	0.46	1.63e-9	Obesity-related traits;
PAAD	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg00071950	chr4:10020882	SLC2A9	-0.66	-6.3	-0.45	3.06e-9	Schizophrenia (age at onset);
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg18279126	chr7:2041391	MAD1L1	0.61	6.19	0.45	5.45e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07648498	chr16:89883185	FANCA	0.7	7.3	0.51	1.47e-11	Vitiligo;
PAAD	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	4.28	0.33	3.33e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg07469887	chr10:131262384	NA	-0.42	-4.88	-0.37	2.68e-6	Response to temozolomide;
PAAD	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg20607287	chr7:12443886	VWDE	-0.63	-5.01	-0.38	1.48e-6	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05660315	chr16:30543920	ZNF747	0.63	7.47	0.52	5.72e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.54	5.52	0.41	1.43e-7	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs7224685	0.689	rs67831913	chr17:4184856	T/C	cg05562828	chr17:3906858	NA	0.52	4.84	0.37	3.22e-6	Type 2 diabetes;
PAAD	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.64	4.51	0.34	1.29e-5	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18984809	chr17:973184	ABR	-0.66	-6.52	-0.47	9.57e-10	Obesity-related traits;
PAAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.71	6.87	0.49	1.57e-10	Parkinson's disease;
PAAD	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg09760422	chr2:128146352	NA	-0.51	-9.02	-0.59	7.76e-16	Self-rated health;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13336335	chr8:42751664	RNF170;HOOK3	0.62	7.25	0.51	2.02e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg08677398	chr8:58056175	NA	0.61	4.34	0.33	2.57e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg21231944	chr12:82153410	PPFIA2	0.52	4.35	0.33	2.46e-5	Resting heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23743543	chr13:31839589	B3GALTL	-0.65	-6.39	-0.46	1.89e-9	Obesity-related traits;
PAAD	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00540400	chr15:79124168	NA	0.58	6.72	0.48	3.43e-10	Coronary artery disease;
PAAD	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.99	-0.38	1.62e-6	High light scatter reticulocyte count;
PAAD	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.52	5.58	0.41	1.1e-7	Schizophrenia;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	9.0	0.59	8.43e-16	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.25	-0.39	5.07e-7	Diabetic kidney disease;
PAAD	cis	rs988913	1.000	rs9382408	chr6:54836984	A/G	cg03513858	chr6:54763001	FAM83B	-0.43	-4.73	-0.36	5.08e-6	Menarche (age at onset);
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg26850624	chr5:429559	AHRR	-0.83	-11.55	-0.68	1.5e-22	Cystic fibrosis severity;
PAAD	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs12365397	0.552	rs7122200	chr11:43163328	C/G	cg03447554	chr11:43094025	NA	0.58	6.33	0.46	2.56e-9	Migraine;
PAAD	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.79	-7.27	-0.51	1.77e-11	Body mass index;
PAAD	cis	rs3764400	0.567	rs8071199	chr17:46195335	A/T	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs829661	0.947	rs4952147	chr2:30776270	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	5.05	0.38	1.28e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.82	8.66	0.57	6.37e-15	Systemic sclerosis;
PAAD	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg13206674	chr6:150067644	NUP43	-0.55	-4.99	-0.37	1.67e-6	Lung cancer;
PAAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.1	-0.44	8.43e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.84	-5.16	-0.39	7.69e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.51	-0.61	3.98e-17	Colorectal cancer;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.13	0.45	7.11e-9	Height;
PAAD	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.55	5.29	0.39	4.1e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.56	-5.33	-0.4	3.56e-7	Strep throat;
PAAD	cis	rs3857067	1.000	rs12502725	chr4:94999873	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-4.29	-0.33	3.23e-5	QT interval;
PAAD	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg18612461	chr15:75251733	NA	-0.39	-4.61	-0.35	8.33e-6	Systemic lupus erythematosus;
PAAD	cis	rs5742933	0.817	rs1233297	chr2:190694175	C/T	cg04003228	chr2:190539410	ANKAR	0.55	4.6	0.35	8.85e-6	Ferritin levels;
PAAD	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.12	-6.85	-0.49	1.73e-10	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00539624	chr5:10899335	NA	-0.73	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg20744362	chr22:50050164	C22orf34	0.61	7.41	0.52	7.98e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs682748	0.810	rs6893113	chr5:17112370	A/G	cg23987134	chr5:17158319	LOC285696	-0.37	-4.63	-0.35	7.9e-6	Hippocampal atrophy;
PAAD	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg00717180	chr2:96193071	NA	-0.66	-8.15	-0.55	1.27e-13	Height;
PAAD	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8084125	1.000	rs72978662	chr18:74951872	G/A	cg05528293	chr18:74961138	GALR1	0.61	5.02	0.38	1.4e-6	Obesity-related traits;
PAAD	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.78	-0.36	4.18e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.45	-6.86	-0.49	1.64e-10	Subjective well-being;
PAAD	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs11264799	0.817	rs17727309	chr1:157679783	A/G	cg18268488	chr1:157545234	FCRL4	0.58	5.2	0.39	6.4e-7	IgA nephropathy;
PAAD	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.72e-5	QRS complex (12-leadsum);
PAAD	cis	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.68	-0.36	6.18e-6	Eotaxin levels;
PAAD	cis	rs7646881	0.812	rs7624161	chr3:158459914	C/G	cg19483011	chr3:158453295	NA	-0.59	-4.8	-0.36	3.8e-6	Tetralogy of Fallot;
PAAD	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.64	4.7	0.36	5.82e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1056053	0.514	rs3127332	chr6:166573438	G/A	cg11088901	chr6:166572345	T	-0.48	-4.38	-0.33	2.23e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs10056811	0.556	rs57441318	chr5:74379675	T/A	cg00601450	chr5:74908170	NA	0.48	4.83	0.36	3.33e-6	Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs72744751	chr15:65064657	C/T	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.63	4.89	0.37	2.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg05250797	chr16:70222502	NA	0.84	6.38	0.46	1.99e-9	IgE levels;
PAAD	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg14820908	chr5:178986412	RUFY1	-0.43	-4.56	-0.35	1.06e-5	Lung cancer;
PAAD	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.57	5.4	0.4	2.52e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg11288833	chr15:55489084	RSL24D1	0.58	4.82	0.36	3.43e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	1.22	8.7	0.58	5.08e-15	IgG glycosylation;
PAAD	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.42	4.61	0.35	8.3e-6	Aortic root size;
PAAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-4.29	-0.33	3.13e-5	Renal cell carcinoma;
PAAD	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs9657904	0.774	rs4894950	chr3:105507929	T/C	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.78e-6	Multiple sclerosis;
PAAD	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.43	5.21	0.39	6.09e-7	Systemic lupus erythematosus;
PAAD	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.57	6.46	0.46	1.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	5.77	0.42	4.37e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.42	4.57	0.35	1.01e-5	Platelet count;
PAAD	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg03999872	chr20:62272968	STMN3	-0.76	-7.11	-0.5	4.15e-11	Atopic dermatitis;
PAAD	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.47	-5.07	-0.38	1.15e-6	Educational attainment;
PAAD	cis	rs9467160	0.834	rs7766620	chr6:24455543	G/C	cg16211469	chr6:24423932	MRS2	0.48	4.44	0.34	1.71e-5	Liver enzyme levels;
PAAD	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg00614314	chr15:82944287	LOC80154	0.5	5.04	0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17973407	chr1:9969906	CTNNBIP1	0.57	6.52	0.47	9.75e-10	Monocyte percentage of white cells;
PAAD	cis	rs3790455	0.610	rs1171554	chr1:156474119	G/A	cg14087168	chr1:156450669	MEF2D	-0.42	-4.74	-0.36	4.92e-6	Migraine;
PAAD	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.87	9.13	0.6	3.87e-16	Schizophrenia;
PAAD	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-5.92	-0.43	2.1e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9916302	0.560	rs3764353	chr17:37790781	T/C	cg00129232	chr17:37814104	STARD3	-0.77	-6.61	-0.47	6.22e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg23920097	chr1:209922102	NA	-0.48	-4.38	-0.34	2.16e-5	Red blood cell count;
PAAD	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.94	-11.52	-0.68	1.81e-22	Longevity;
PAAD	cis	rs7631605	0.518	rs11706926	chr3:36978647	A/G	cg17445812	chr3:36986805	TRANK1	0.36	5.15	0.39	7.87e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg05717871	chr11:638507	DRD4	-0.6	-5.4	-0.4	2.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg22963979	chr7:1858916	MAD1L1	-0.57	-5.69	-0.42	6.37e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs12304921	0.810	rs73090660	chr12:51355161	A/G	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.19	-0.39	6.74e-7	Type 2 diabetes;
PAAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.57	-0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.81	5.97	0.44	1.6e-8	Vitiligo;
PAAD	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.2	-0.45	5.02e-9	Schizophrenia;
PAAD	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.82	7.75	0.53	1.25e-12	Corneal astigmatism;
PAAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.88	0.49	1.47e-10	Total body bone mineral density;
PAAD	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.48	-0.34	1.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.8	7.55	0.52	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs507080	0.733	rs7108144	chr11:118569694	G/A	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.77	5.41	0.4	2.4e-7	Phospholipid levels (plasma);
PAAD	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.83	-0.37	3.24e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg02580895	chr19:2754563	NA	-0.51	-4.44	-0.34	1.71e-5	Total cholesterol levels;
PAAD	cis	rs7618915	0.962	rs13094687	chr3:52450043	A/G	cg17372223	chr3:52568218	NT5DC2	0.47	4.28	0.33	3.23e-5	Bipolar disorder;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	6.96	0.49	9.47e-11	Systemic lupus erythematosus;
PAAD	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.48	-0.34	1.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg25790453	chr13:113633590	MCF2L	-0.38	-4.51	-0.34	1.29e-5	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05560165	chr5:133450315	TCF7	0.61	6.35	0.46	2.38e-9	Myopia (pathological);
PAAD	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.85	-0.43	2.92e-8	Rheumatoid arthritis;
PAAD	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03676636	chr4:99064102	C4orf37	0.33	6.11	0.44	8.04e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs1012068	0.920	rs5994443	chr22:32275353	A/G	cg01338084	chr22:32026380	PISD	0.58	5.33	0.4	3.5e-7	Chronic hepatitis C infection;
PAAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.79	8.65	0.57	6.99e-15	Aortic root size;
PAAD	cis	rs4372836	0.543	rs6747852	chr2:29009840	A/T	cg09009506	chr2:28216851	BRE	0.43	4.73	0.36	5.13e-6	Body mass index;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.86	-5.54	-0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-4.54	-0.35	1.12e-5	Monocyte percentage of white cells;
PAAD	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.9	9.48	0.61	4.88e-17	Breast cancer;
PAAD	cis	rs7554547	0.630	rs4845889	chr1:11971345	T/C	cg07603449	chr1:11986842	KIAA2013	-0.37	-5.66	-0.42	7.19e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg12215294	chr3:40350768	EIF1B	0.49	5.01	0.38	1.51e-6	Renal cell carcinoma;
PAAD	trans	rs9467711	0.520	rs13211947	chr6:25864818	C/T	cg01620082	chr3:125678407	NA	-1.41	-7.8	-0.53	9.33e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.8	-0.43	3.75e-8	Mood instability;
PAAD	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09695851	chr17:3907499	NA	0.68	6.85	0.49	1.75e-10	Type 2 diabetes;
PAAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.48	-0.41	1.76e-7	Mood instability;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.62	6.75	0.48	2.98e-10	Mean corpuscular volume;
PAAD	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.59	-5.65	-0.42	7.55e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12138061	1.000	rs12118183	chr1:50537618	C/T	cg09846084	chr1:50888024	DMRTA2	-0.53	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.48	5.38	0.4	2.79e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg20090690	chr10:134436459	INPP5A	0.51	4.32	0.33	2.75e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.09	0.5	4.81e-11	IgG glycosylation;
PAAD	cis	rs9463078	0.774	rs9296457	chr6:45264687	A/G	cg25276700	chr6:44698697	NA	-0.47	-5.44	-0.4	2.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg00035074	chr7:2701567	TTYH3	0.65	4.44	0.34	1.74e-5	Bipolar disorder;
PAAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.83	8.09	0.55	1.72e-13	Post bronchodilator FEV1;
PAAD	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.62	-6.54	-0.47	8.97e-10	Brugada syndrome;
PAAD	cis	rs6784615	0.744	rs9855470	chr3:52493275	C/T	cg27565382	chr3:53032988	SFMBT1	1.01	4.75	0.36	4.65e-6	Waist-hip ratio;
PAAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.59	-6.22	-0.45	4.53e-9	Body mass index;
PAAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.01	-0.38	1.5e-6	Coronary artery disease;
PAAD	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg08614441	chr13:113633676	MCF2L	-0.43	-4.25	-0.33	3.78e-5	Systolic blood pressure;
PAAD	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.59	-0.41	1.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs3743832	0.966	rs12708776	chr16:9183770	A/G	cg08831531	chr16:9218945	NA	-0.44	-4.61	-0.35	8.48e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.65	6.35	0.46	2.32e-9	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.54	4.72	0.36	5.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.7	7.1	0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs741677	0.963	rs9907102	chr17:464832	C/T	cg13332499	chr17:408570	NA	0.55	6.07	0.44	9.83e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs59888335	0.825	rs9825376	chr3:81002155	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.94	-5.93	-0.43	1.95e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.51	-0.47	1.03e-9	Schizophrenia;
PAAD	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs595018	0.505	rs56401304	chr11:60595396	T/G	cg07588442	chr11:60673866	PRPF19	0.64	4.46	0.34	1.59e-5	Wegener's granulomatosis;
PAAD	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.26	-0.33	3.6e-5	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07107441	chr3:10157155	C3orf10	0.67	6.71	0.48	3.67e-10	Obesity-related traits;
PAAD	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg03609598	chr5:56110824	MAP3K1	-0.52	-4.37	-0.33	2.32e-5	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18076559	chr10:90639992	STAMBPL1	-0.77	-6.58	-0.47	7.08e-10	Neuroticism;
PAAD	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg27511599	chr7:32358540	NA	0.75	4.44	0.34	1.73e-5	Body mass index;
PAAD	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg26220594	chr1:19110978	NA	0.58	4.54	0.35	1.13e-5	Percentage gas trapping;
PAAD	cis	rs375066	0.762	rs12610287	chr19:44400663	T/C	cg21496419	chr19:44306685	LYPD5	-0.42	-4.93	-0.37	2.17e-6	Breast cancer;
PAAD	cis	rs357618	0.931	rs394736	chr5:150847509	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.76	-8.17	-0.55	1.13e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg17052926	chr7:915758	C7orf20	-0.47	-4.78	-0.36	4.17e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.43	4.45	0.34	1.68e-5	Plateletcrit;
PAAD	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.71	-0.66	2.64e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.36	3.66e-6	Type 2 diabetes;
PAAD	cis	rs17655565	0.553	rs1945287	chr12:52733218	C/G	cg22980804	chr12:52818037	KRT75	-0.49	-4.43	-0.34	1.76e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg26022315	chr17:47021804	SNF8	0.44	4.56	0.35	1.04e-5	Type 2 diabetes;
PAAD	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.93	0.54	4.33e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.54	5.21	0.39	6.1e-7	Aortic root size;
PAAD	cis	rs3136739	0.614	rs8178893	chr8:42033913	C/T	cg17828057	chr8:42037527	PLAT	-0.7	-4.84	-0.37	3.19e-6	Plasma plasminogen activator levels;
PAAD	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs8005677	0.828	rs4981451	chr14:23410281	T/C	cg01529538	chr14:23388837	RBM23	0.48	4.78	0.36	4.17e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg14631576	chr9:95140430	CENPP	-0.54	-5.17	-0.39	7.3e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.95	13.34	0.73	2.32e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg21037935	chr19:58911965	NA	0.52	4.5	0.34	1.33e-5	Mean platelet volume;
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	5.07	0.38	1.17e-6	Total body bone mineral density;
PAAD	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.51	-4.36	-0.33	2.43e-5	Cocaine dependence;
PAAD	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs863345	0.608	rs11265013	chr1:158499625	G/A	cg12129480	chr1:158549410	OR10X1	-0.41	-4.66	-0.35	6.74e-6	Pneumococcal bacteremia;
PAAD	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.19	-0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs867371	1.000	rs867370	chr15:82438262	T/A	cg00614314	chr15:82944287	LOC80154	-0.45	-4.32	-0.33	2.78e-5	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg27494647	chr7:150038898	RARRES2	0.43	4.34	0.33	2.58e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.44	0.46	1.47e-9	IgG glycosylation;
PAAD	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.5	-4.86	-0.37	2.84e-6	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.73	-7.7	-0.53	1.62e-12	Aortic root size;
PAAD	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.6	-5.01	-0.38	1.5e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.88	8.38	0.56	3.25e-14	Methadone dose in opioid dependence;
PAAD	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.83	-8.78	-0.58	3.11e-15	Body mass index;
PAAD	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg20607287	chr7:12443886	VWDE	-0.7	-6.33	-0.46	2.61e-9	Coronary artery disease;
PAAD	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-4.39	-0.34	2.13e-5	Diastolic blood pressure;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg14092988	chr3:52407081	DNAH1	0.44	5.43	0.4	2.14e-7	Bipolar disorder;
PAAD	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.53	-5.98	-0.44	1.5e-8	Blood pressure (smoking interaction);
PAAD	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.78	5.73	0.42	5.29e-8	Pulse pressure;
PAAD	cis	rs2283228	0.737	rs7480855	chr11:2836085	C/T	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	-0.61	-4.45	-0.34	1.65e-5	Type 2 diabetes;
PAAD	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.63	-0.35	7.76e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.93	10.08	0.63	1.3e-18	Testicular germ cell tumor;
PAAD	cis	rs2252790	1.000	rs10456906	chr6:116621035	C/A	cg18764771	chr6:116381957	FRK	0.26	4.41	0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.46	-0.4	1.89e-7	Fear of minor pain;
PAAD	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg22496339	chr2:162101262	NA	-0.49	-4.74	-0.36	4.97e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.4	5.41	0.4	2.38e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.7	-7.23	-0.51	2.2e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.93	10.06	0.63	1.49e-18	Cognitive function;
PAAD	cis	rs4704187	0.687	rs6888707	chr5:74442920	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.77	8.99	0.59	9.42e-16	Lung cancer;
PAAD	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg20761395	chr17:511517	VPS53	-0.69	-7.77	-0.53	1.07e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.83	8.9	0.59	1.59e-15	Prostate cancer;
PAAD	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.57	-4.66	-0.35	6.74e-6	Facial morphology (factor 19);
PAAD	cis	rs17789174	0.594	rs12597072	chr16:85070377	C/T	cg10013998	chr16:85120012	KIAA0513	0.55	4.81	0.36	3.55e-6	Dysphagia;
PAAD	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.52	4.55	0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg05861140	chr6:150128134	PCMT1	0.46	4.83	0.36	3.37e-6	Lung cancer;
PAAD	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg09462578	chr12:12878428	APOLD1	-0.89	-8.96	-0.59	1.09e-15	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg09835421	chr16:68378352	PRMT7	-1.14	-8.42	-0.56	2.64e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg10820045	chr2:198174542	NA	-0.44	-4.39	-0.34	2.11e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	-0.65	-4.3	-0.33	3.03e-5	Atrial fibrillation;
PAAD	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.61	-6.33	-0.46	2.65e-9	Menopause (age at onset);
PAAD	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.33	-0.33	2.65e-5	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14180030	chr9:123475675	MEGF9	-0.45	-5.02	-0.38	1.45e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg08677398	chr8:58056175	NA	0.6	4.32	0.33	2.83e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg16362232	chr11:430036	ANO9	0.84	5.21	0.39	6.16e-7	Body mass index;
PAAD	cis	rs28595532	0.765	rs114082534	chr4:119734184	G/A	cg21605333	chr4:119757512	SEC24D	1.93	10.16	0.64	7.93e-19	Cannabis dependence symptom count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13784769	chr2:134318278	NCKAP5	0.59	6.8	0.48	2.24e-10	Smoking initiation;
PAAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg00623015	chr16:89177293	ACSF3	-0.83	-4.32	-0.33	2.77e-5	Red blood cell count;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.43	-0.4	2.24e-7	Lung cancer;
PAAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg10587741	chr22:38071170	LGALS1	0.61	6.83	0.48	1.92e-10	Fat distribution (HIV);
PAAD	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.55	-6.06	-0.44	1.04e-8	Menopause (age at onset);
PAAD	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.73	8.63	0.57	7.85e-15	Hand grip strength;
PAAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.97	-13.25	-0.73	3.92e-27	Height;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-7.51	-0.52	4.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs3736485	0.966	rs8042840	chr15:51908498	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.64	4.29	0.33	3.21e-5	Lung cancer in ever smokers;
PAAD	cis	rs4704187	0.687	rs6885887	chr5:74497842	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25560831	chr4:152666626	PET112L	-0.53	-6.47	-0.46	1.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	trans	rs790110	1.000	rs790110	chr3:122384020	T/G	cg15869492	chr17:36907295	NA	-1.05	-6.52	-0.47	9.94e-10	Acoustic startle blink response;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.72	8.39	0.56	3.08e-14	Height;
PAAD	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg14181355	chr19:12984996	MAST1	0.45	4.47	0.34	1.5e-5	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs2273156	0.500	rs17103104	chr14:35690978	C/G	cg14523979	chr14:35838413	NA	-0.69	-4.92	-0.37	2.21e-6	Immunoglobulin light chain (AL) amyloidosis;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.81	6.03	0.44	1.21e-8	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	trans	rs9409082	0.677	rs10978430	chr9:108916009	C/T	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	11.29	0.68	7.72e-22	Menopause (age at onset);
PAAD	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.5	5.38	0.4	2.82e-7	Carotid intima media thickness;
PAAD	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.88e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.56	5.22	0.39	5.88e-7	Hirschsprung disease;
PAAD	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.43	-0.4	2.15e-7	Retinal vascular caliber;
PAAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg10547527	chr2:198650123	BOLL	0.73	4.97	0.37	1.8e-6	Ulcerative colitis;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.55	-5.56	-0.41	1.16e-7	Obesity-related traits;
PAAD	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.49	9.65	0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-5.45	-0.4	1.97e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	5.79	0.43	3.92e-8	Total cholesterol levels;
PAAD	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.82	0.58	2.48e-15	Coffee consumption (cups per day);
PAAD	cis	rs17539620	0.808	rs57833052	chr6:154877112	C/T	cg20019720	chr6:154832845	CNKSR3	0.46	6.08	0.44	9.26e-9	Lipoprotein (a) levels;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs3734905	0.908	rs16888175	chr6:169977419	C/T	cg11181693	chr6:169825345	NA	-0.87	-5.52	-0.41	1.41e-7	HIV-1 control;
PAAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg13902645	chr11:5959945	NA	0.6	6.17	0.45	5.84e-9	DNA methylation (variation);
PAAD	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.37	-4.48	-0.34	1.46e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs6594713	0.837	rs13187823	chr5:112722164	C/G	cg12552261	chr5:112820674	MCC	0.6	4.35	0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.68	-7.18	-0.5	2.84e-11	Morning vs. evening chronotype;
PAAD	cis	rs7534824	0.543	rs61780295	chr1:101400264	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg05805236	chr11:65401703	PCNXL3	-0.62	-6.43	-0.46	1.58e-9	Acne (severe);
PAAD	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.7	-6.88	-0.49	1.47e-10	Retinal vascular caliber;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13012494	chr21:47604986	C21orf56	0.47	4.95	0.37	1.99e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.89	7.7	0.53	1.57e-12	Alzheimer's disease;
PAAD	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.5	4.62	0.35	8.07e-6	Hepatocellular carcinoma;
PAAD	cis	rs448720	0.811	rs4776382	chr15:68179651	C/T	cg05925327	chr15:68127851	NA	-0.41	-4.54	-0.35	1.13e-5	Cognitive performance;
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg09127314	chr1:152161683	NA	0.7	5.08	0.38	1.11e-6	Atopic dermatitis;
PAAD	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.54	-5.04	-0.38	1.29e-6	Neurofibrillary tangles;
PAAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.46e-12	Recombination rate (females);
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg10621924	chr7:39171070	POU6F2	0.26	4.36	0.33	2.36e-5	IgG glycosylation;
PAAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg13722127	chr7:150037890	RARRES2	0.55	5.55	0.41	1.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.71	6.92	0.49	1.16e-10	Anterior chamber depth;
PAAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.8	-0.48	2.27e-10	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17128996	chr17:76921031	TIMP2	0.7	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-6.31	-0.46	2.86e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.55	-0.35	1.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.34	6.41	0.46	1.77e-9	Type 2 diabetes;
PAAD	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.5	5.36	0.4	3.02e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.65	7.38	0.51	9.6e-12	Verbal declarative memory;
PAAD	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg10356904	chr22:49881777	NA	-0.52	-5.4	-0.4	2.55e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg19337854	chr7:99768885	GPC2	0.52	4.75	0.36	4.74e-6	Platelet count;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg27405086	chr16:29826859	C16orf53;PRRT2	-0.57	-6.57	-0.47	7.42e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	1.08	12.56	0.71	2.95e-25	Breast cancer;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg00431813	chr7:1051703	C7orf50	0.51	4.43	0.34	1.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8179	0.620	rs73232029	chr7:92287283	G/C	cg03496780	chr7:92466842	CDK6	0.51	4.84	0.37	3.14e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs41271473	0.539	rs763519	chr1:228892855	A/G	cg16512390	chr1:228756714	NA	-0.54	-4.38	-0.33	2.17e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.66	5.48	0.41	1.74e-7	Schizophrenia;
PAAD	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg27411982	chr8:10470053	RP1L1	-0.53	-5.85	-0.43	2.97e-8	Retinal vascular caliber;
PAAD	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-5.97	-0.44	1.6e-8	Mean corpuscular volume;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26418147	chr1:205743515	RAB7L1	-0.46	-5.31	-0.4	3.91e-7	Menarche (age at onset);
PAAD	cis	rs58521262	0.556	rs289318	chr19:23159486	T/C	cg02350677	chr19:23254381	NA	0.26	4.61	0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6782025	0.837	rs1191309	chr3:120897697	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1032355	0.558	rs1491246	chr4:100534482	A/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.69	0.58	5.53e-15	Chronic sinus infection;
PAAD	cis	rs11958404	0.615	rs10053795	chr5:157449185	T/C	cg05962755	chr5:157440814	NA	0.58	5.53	0.41	1.39e-7	IgG glycosylation;
PAAD	cis	rs11650175	0.634	rs1833349	chr17:63778788	G/A	cg07283582	chr17:63770753	CCDC46	0.37	4.25	0.33	3.71e-5	Chin dimples;
PAAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.56	-5.57	-0.41	1.13e-7	Childhood ear infection;
PAAD	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg16339924	chr4:17578868	LAP3	0.69	6.94	0.49	1.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4523957	0.928	rs375245	chr17:2199754	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.93e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.5	5.64	0.42	8.23e-8	QRS complex (12-leadsum);
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg07362569	chr17:61921086	SMARCD2	0.43	4.96	0.37	1.88e-6	Height;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.37	-0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4704187	0.687	rs1363578	chr5:74510341	C/T	cg03227963	chr5:74354835	NA	0.52	5.0	0.38	1.59e-6	Response to amphetamines;
PAAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.35	-0.33	2.49e-5	Menarche (age at onset);
PAAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg03959625	chr15:84868606	LOC388152	0.5	5.36	0.4	3.09e-7	Schizophrenia;
PAAD	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg02230254	chr11:65586170	NA	-0.36	-5.43	-0.4	2.19e-7	Eosinophil percentage of white cells;
PAAD	cis	rs2882667	0.690	rs6596455	chr5:138167105	T/C	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs12766550	chr10:46011355	C/G	cg14076390	chr17:34947837	DHRS11	0.91	6.74	0.48	3.08e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg07150166	chr2:30669952	LCLAT1	0.74	5.85	0.43	2.93e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg23920097	chr1:209922102	NA	-0.49	-4.46	-0.34	1.6e-5	Red blood cell count;
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6942407	0.592	rs739711	chr7:86746741	G/C	cg14887563	chr7:86849180	C7orf23	0.49	4.27	0.33	3.45e-5	Food allergy;
PAAD	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-5.74	-0.42	4.87e-8	Response to antipsychotic treatment;
PAAD	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.42	0.46	1.66e-9	Lung cancer in ever smokers;
PAAD	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg08999081	chr20:33150536	PIGU	0.5	4.41	0.34	1.95e-5	Protein C levels;
PAAD	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.75	4.57	0.35	1e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.68	-6.24	-0.45	4.07e-9	Response to antineoplastic agents;
PAAD	cis	rs9287719	0.614	rs10929679	chr2:10723108	C/T	cg00105475	chr2:10696890	NA	0.62	6.52	0.47	9.94e-10	Prostate cancer;
PAAD	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.13	-14.06	-0.75	2.79e-29	Schizophrenia;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-1.17	-11.11	-0.67	2.22e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.88	9.36	0.6	9.87e-17	Corneal astigmatism;
PAAD	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.82e-11	Interstitial lung disease;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg27109030	chr19:2702898	GNG7	-0.67	-6.33	-0.46	2.65e-9	Blood protein levels;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	5.76	0.42	4.59e-8	Renal function-related traits (BUN);
PAAD	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg18939081	chr1:31884902	SERINC2	0.48	5.4	0.4	2.55e-7	Alcohol dependence;
PAAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs12681963	0.688	rs7004806	chr8:30054518	A/G	cg23406830	chr8:30012838	DCTN6	-0.7	-4.34	-0.33	2.57e-5	Migraine;
PAAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.68	-0.35	6.43e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12956009	0.559	rs1893787	chr18:44856030	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.95	-0.37	1.94e-6	Educational attainment (years of education);
PAAD	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.68	0.65	3.19e-20	Homoarginine levels;
PAAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg23947450	chr7:900037	UNC84A	-0.55	-4.5	-0.34	1.32e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10763059	chr7:77165728	PTPN12	0.52	6.34	0.46	2.53e-9	Monocyte percentage of white cells;
PAAD	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.7	5.74	0.42	4.9e-8	Blood protein levels;
PAAD	cis	rs2133450	0.724	rs1858060	chr3:7361224	C/T	cg19930620	chr3:7340148	GRM7	-0.43	-4.53	-0.34	1.2e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg17366294	chr4:99064904	C4orf37	-0.47	-5.12	-0.38	9.09e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg05805236	chr11:65401703	PCNXL3	-0.62	-6.62	-0.47	5.73e-10	Acne (severe);
PAAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.77	-8.66	-0.57	6.46e-15	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27297192	chr10:134578999	INPP5A	0.61	5.42	0.4	2.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs61861422	0.516	rs11814062	chr10:134439823	C/T	cg09421083	chr10:134358535	INPP5A	-0.53	-4.82	-0.36	3.49e-6	Primary sclerosing cholangitis;
PAAD	cis	rs732765	0.646	rs4508370	chr14:75115887	G/A	cg17347104	chr14:75034677	LTBP2	0.63	5.15	0.39	7.82e-7	Non-small cell lung cancer;
PAAD	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.58	6.01	0.44	1.34e-8	Breast cancer;
PAAD	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg04398451	chr17:18023971	MYO15A	-0.82	-9.2	-0.6	2.69e-16	Total body bone mineral density;
PAAD	cis	rs11945232	1.000	rs13113575	chr4:88327224	G/A	cg23841344	chr4:88312519	HSD17B11	-0.63	-5.61	-0.41	9.34e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg24375607	chr4:120327624	NA	0.55	5.03	0.38	1.36e-6	Corneal astigmatism;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.69	-0.48	4.11e-10	Lung cancer;
PAAD	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7176527	0.519	rs12148368	chr15:85106505	C/G	cg03959625	chr15:84868606	LOC388152	-0.5	-4.68	-0.35	6.28e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	7.46	0.52	6.14e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.82	6.34	0.46	2.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.61	5.56	0.41	1.19e-7	Self-reported allergy;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.93	12.83	0.72	5.53e-26	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs16895831	0.519	rs4714614	chr6:42592183	A/G	cg10605015	chr6:42532144	UBR2	-0.66	-5.0	-0.38	1.59e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.23e-5	Life satisfaction;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.54	-6.52	-0.47	9.57e-10	Iron status biomarkers;
PAAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.57	6.39	0.46	1.94e-9	Type 2 diabetes;
PAAD	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg20356878	chr3:121714668	ILDR1	0.51	4.88	0.37	2.71e-6	Cognitive performance;
PAAD	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.77e-11	Asthma;
PAAD	cis	rs72960926	1.000	rs72956942	chr6:75093037	G/A	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs8112211	0.911	rs60071299	chr19:38850246	G/A	cg14299480	chr19:38876666	GGN	-0.61	-7.68	-0.53	1.83e-12	Blood protein levels;
PAAD	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	5.28	0.39	4.3e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7173743	0.507	rs6495341	chr15:79133026	C/T	cg00540400	chr15:79124168	NA	0.45	4.65	0.35	7.05e-6	Coronary artery disease;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs992157	0.730	rs2382828	chr2:219184492	A/G	cg00012203	chr2:219082015	ARPC2	0.6	5.77	0.42	4.39e-8	Colorectal cancer;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.75	8.81	0.58	2.59e-15	Height;
PAAD	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	8.0	0.54	3.01e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.72e-11	Obesity-related traits;
PAAD	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs8060686	0.641	rs77996485	chr16:68137420	C/G	cg05110241	chr16:68378359	PRMT7	-1.08	-6.19	-0.45	5.3e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15813570	chr14:64854563	MTHFD1	0.6	6.58	0.47	7.13e-10	Response to antipsychotic treatment;
PAAD	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg07220939	chr11:64358617	SLC22A12	-0.46	-4.8	-0.36	3.84e-6	Urate levels in obese individuals;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.78	-5.65	-0.42	7.86e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.88e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg15145965	chr22:50218605	BRD1	0.6	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs6445967	1.000	rs1913716	chr3:58308331	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12846938	chr19:14640140	MIR639;TECR	0.58	6.47	0.46	1.3e-9	Monocyte percentage of white cells;
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7752195	0.643	rs77482156	chr6:25199853	T/C	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	Cognitive function;
PAAD	cis	rs7804356	0.651	rs73061889	chr7:26799874	A/C	cg03456212	chr7:26904342	SKAP2	-0.57	-4.86	-0.37	2.95e-6	Type 1 diabetes;
PAAD	cis	rs4740619	0.509	rs78873905	chr9:15633070	T/G	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.15e-5	Body mass index;
PAAD	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2271400	0.556	rs13254789	chr8:56742981	T/C	cg08894788	chr8:56792171	LYN	-0.54	-5.02	-0.38	1.43e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16262614	chr3:133464971	TF	0.46	5.03	0.38	1.35e-6	Iron status biomarkers;
PAAD	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg05759166	chr8:10452896	NA	-0.38	-4.28	-0.33	3.36e-5	Triglycerides;
PAAD	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.57	4.97	0.37	1.79e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.46	-4.6	-0.35	8.83e-6	Schizophrenia;
PAAD	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.26	-0.45	3.81e-9	Migraine - clinic-based;
PAAD	cis	rs16958440	0.867	rs59217333	chr18:44694844	A/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-4.54	-0.35	1.15e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7219021	1.000	rs57185954	chr17:46844961	T/C	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.54	-0.35	1.15e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg14146966	chr2:61757674	XPO1	0.41	5.18	0.39	6.8e-7	Tuberculosis;
PAAD	cis	rs925946	0.640	rs56133711	chr11:27723334	G/A	cg01418645	chr11:27679469	BDNF;BDNFOS	-0.52	-4.59	-0.35	9.1e-6	Body mass index;Weight;
PAAD	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg18281939	chr5:77783895	LHFPL2	-0.52	-6.7	-0.48	3.9e-10	Triglycerides;
PAAD	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg01503450	chr10:980765	NA	-0.53	-4.33	-0.33	2.68e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg00262122	chr8:11665843	FDFT1	-0.54	-5.01	-0.38	1.51e-6	Morning vs. evening chronotype;
PAAD	trans	rs901683	0.850	rs112392416	chr10:46070466	C/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs258892	0.895	rs9293443	chr5:72055622	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.59	0.61	2.51e-17	Cognitive test performance;
PAAD	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	7.3	0.51	1.48e-11	Body mass index (adult);
PAAD	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.83	-0.48	1.94e-10	Systolic blood pressure;
PAAD	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg09873201	chr16:3507582	NAT15	0.59	5.6	0.41	9.62e-8	Tuberculosis;
PAAD	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.58	-6.11	-0.44	7.81e-9	Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.44	4.35	0.33	2.5e-5	Obesity-related traits;
PAAD	cis	rs300774	0.858	rs423038	chr2:129486	A/C	cg23649280	chr2:140451	NA	-0.47	-4.53	-0.34	1.18e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.08	6.46	0.46	1.36e-9	Body mass index;
PAAD	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs733175	0.855	rs10006397	chr4:10036140	C/A	cg00071950	chr4:10020882	SLC2A9	0.59	5.2	0.39	6.47e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.23	-0.45	4.28e-9	Longevity;Endometriosis;
PAAD	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-6.95	-0.49	1.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.67	-7.44	-0.52	6.77e-12	Motion sickness;
PAAD	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg26205652	chr12:48591994	NA	0.77	6.97	0.49	9.25e-11	Longevity (90 years and older);
PAAD	cis	rs6782228	0.606	rs6439135	chr3:128358633	G/A	cg16766828	chr3:128327626	NA	-0.49	-6.62	-0.47	5.81e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	1.08	14.4	0.76	3.43e-30	Testicular germ cell tumor;
PAAD	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.42	5.09	0.38	1.04e-6	Coronary artery disease;
PAAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.61	7.36	0.51	1.09e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.78	-8.03	-0.55	2.43e-13	Body mass index;
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.62	6.33	0.46	2.66e-9	Lung cancer;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02464098	chr8:26240309	BNIP3L	0.65	6.92	0.49	1.19e-10	Myopia (pathological);
PAAD	cis	rs346785	0.965	rs443970	chr17:74303370	G/A	cg22761670	chr17:74268201	NA	-0.43	-4.35	-0.33	2.45e-5	White matter hyperintensities in ischemic stroke;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06597239	chr19:1651539	TCF3	0.59	6.78	0.48	2.49e-10	Monocyte percentage of white cells;
PAAD	cis	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13939156	chr17:80058883	NA	-0.42	-4.57	-0.35	1.02e-5	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg11196182	chr7:1989412	MAD1L1	0.42	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.72	10.96	0.66	5.66e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.5	5.21	0.39	5.96e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8084125	1.000	rs62105169	chr18:74945193	A/G	cg15443732	chr18:74961078	GALR1	0.72	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs863345	0.604	rs4276920	chr1:158504972	G/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.98	-0.37	1.7e-6	Pneumococcal bacteremia;
PAAD	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.71	-8.6	-0.57	8.97e-15	Body mass index;
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.73	6.96	0.49	9.57e-11	Asthma;
PAAD	cis	rs6801605	0.743	rs4687751	chr3:53883910	C/T	cg15798837	chr3:54122146	NA	0.33	4.38	0.33	2.23e-5	Blood protein levels;
PAAD	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-4.6	-0.35	8.8e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg21130718	chr4:1044621	NA	-0.56	-4.82	-0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.04	-0.44	1.12e-8	Lymphocyte counts;
PAAD	cis	rs12760731	0.623	rs1985761	chr1:178438645	A/G	cg00404053	chr1:178313656	RASAL2	0.63	5.44	0.4	2.12e-7	Obesity-related traits;
PAAD	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg21466736	chr12:48725269	NA	0.51	4.8	0.36	3.84e-6	Glycated hemoglobin levels;
PAAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.95	-10.95	-0.66	6.16e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs621942	0.687	rs67008419	chr11:85803459	C/T	cg07180834	chr11:85838833	NA	-0.46	-4.79	-0.36	4e-6	Tourette syndrome;
PAAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg04844267	chr4:1394941	NA	0.53	5.85	0.43	2.91e-8	Obesity-related traits;
PAAD	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs8081395	0.801	rs2665405	chr17:57875292	G/A	cg02344993	chr17:57696989	CLTC	-0.47	-4.68	-0.36	6.21e-6	White blood cell count;
PAAD	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg14583973	chr4:3374767	RGS12	0.43	6.52	0.47	9.96e-10	Serum sulfate level;
PAAD	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.48	-4.81	-0.36	3.64e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16452756	chr5:172483361	C5orf41	-0.64	-6.29	-0.45	3.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.51	-4.5	-0.34	1.35e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	7.44	0.52	6.98e-12	Lymphocyte counts;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg03542721	chr8:22926253	TNFRSF10B	-0.72	-6.29	-0.45	3.2e-9	Blood protein levels;
PAAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.74	6.92	0.49	1.16e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs13102973	0.965	rs13103954	chr4:135844189	A/G	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.83	-0.36	3.25e-6	Red cell distribution width;
PAAD	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg00522288	chr12:125625016	AACS	-0.42	-4.5	-0.34	1.36e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg02135003	chr7:105160482	PUS7	-0.92	-6.7	-0.48	3.84e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6466055	0.637	rs1144	chr7:104756355	T/C	cg04380332	chr7:105027541	SRPK2	-0.57	-6.45	-0.46	1.44e-9	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg07153921	chr17:41440717	NA	-0.42	-4.42	-0.34	1.87e-5	Menopause (age at onset);
PAAD	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.13e-13	Dupuytren's disease;
PAAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	cis	rs9687846	0.877	rs11743303	chr5:55859952	A/G	cg15001016	chr5:55860904	NA	-0.46	-4.52	-0.34	1.22e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.61	9.41	0.61	7.62e-17	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs17162190	0.698	rs4970514	chr1:26846195	C/T	cg17456097	chr1:26900765	RPS6KA1	0.59	4.79	0.36	3.88e-6	Mean corpuscular volume;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg07703079	chr11:430292	ANO9	0.91	5.71	0.42	5.67e-8	Body mass index;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg02841227	chr6:26021843	HIST1H4A	0.51	4.96	0.37	1.9e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg01329690	chr21:38580129	DSCR9	0.33	4.44	0.34	1.73e-5	Eye color traits;
PAAD	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.25	0.64	4.43e-19	White blood cell count;
PAAD	cis	rs58521262	0.585	rs1066015	chr19:23189388	C/A	cg02350677	chr19:23254381	NA	0.26	4.51	0.34	1.3e-5	Testicular germ cell tumor;
PAAD	cis	rs258892	1.000	rs27952	chr5:72316437	G/A	cg21869765	chr5:72125136	TNPO1	-0.63	-4.42	-0.34	1.9e-5	Small cell lung carcinoma;
PAAD	cis	rs338389	0.516	rs6416484	chr15:68312776	T/C	cg09788352	chr15:68522666	CLN6	0.36	4.48	0.34	1.45e-5	Survival in rectal cancer;
PAAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.23	-0.39	5.58e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs2131877	0.956	rs955825	chr3:194870922	T/C	cg16306870	chr3:194868790	C3orf21	0.42	4.49	0.34	1.4e-5	Non-small cell lung cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15212354	chr10:422330	DIP2C	0.59	6.9	0.49	1.28e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg02683114	chr2:24398427	C2orf84	0.57	5.84	0.43	3.02e-8	Asthma;
PAAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.31	-0.46	2.87e-9	Longevity;
PAAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01200585	chr1:228362443	C1orf69	-0.44	-4.96	-0.37	1.86e-6	Diastolic blood pressure;
PAAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg09839279	chr12:125627357	AACS	-0.5	-4.81	-0.36	3.57e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.56	-5.81	-0.43	3.47e-8	Pancreatic cancer;
PAAD	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	9.26	0.6	1.86e-16	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.86	-0.37	2.84e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.0	-0.44	1.36e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.54	-0.35	1.14e-5	Tonsillectomy;
PAAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.24	0.39	5.24e-7	Ovarian reserve;
PAAD	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg11630242	chr17:19881632	AKAP10	-0.47	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs4906332	0.966	rs4906331	chr14:103971374	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-4.57	-0.35	9.85e-6	Coronary artery disease;
PAAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.92	9.69	0.62	1.39e-17	Blood metabolite levels;
PAAD	cis	rs863345	0.604	rs2873595	chr1:158508382	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg25452165	chr22:42524984	CYP2D6	0.52	4.7	0.36	5.8e-6	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg21546286	chr11:48923668	NA	-0.58	-6.08	-0.44	9.44e-9	HDL cholesterol;
PAAD	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.34	-0.33	2.62e-5	Alcohol dependence;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg20607798	chr8:58055168	NA	0.63	4.43	0.34	1.78e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.79	8.14	0.55	1.31e-13	DNA methylation (variation);
PAAD	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.71	-0.48	3.61e-10	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg00280220	chr17:61926910	NA	0.43	4.46	0.34	1.56e-5	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18076360	chr19:44515398	ZNF230	-0.58	-6.5	-0.47	1.11e-9	Monocyte percentage of white cells;
PAAD	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.76	7.87	0.54	6.12e-13	Sudden cardiac arrest;
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.61	-5.61	-0.41	9.24e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.86	-10.16	-0.64	7.98e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs507080	0.733	rs552079	chr11:118573022	T/C	cg08498647	chr11:118550644	TREH	-0.39	-4.46	-0.34	1.55e-5	Serum metabolite levels;
PAAD	cis	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.7e-6	Reticulocyte count;
PAAD	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.76	9.98	0.63	2.35e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.73	-0.36	5.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs375066	0.901	rs376457	chr19:44412757	C/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.43	0.56	2.49e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.56	5.42	0.4	2.33e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8053891	0.673	rs11645540	chr16:72028930	T/G	cg16558253	chr16:72132732	DHX38	-0.5	-4.53	-0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	1.0	15.88	0.79	4.28e-34	Height;
PAAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.74	7.57	0.52	3.3e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7897654	0.571	rs12764049	chr10:104634956	A/G	cg15744005	chr10:104629667	AS3MT	-0.5	-4.68	-0.36	6.24e-6	Schizophrenia;
PAAD	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.54	-5.22	-0.39	5.68e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12016809	chr21:47604291	C21orf56	0.44	4.35	0.33	2.48e-5	Testicular germ cell tumor;
PAAD	cis	rs508970	0.540	rs495377	chr11:60916005	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.51	0.34	1.27e-5	Rheumatoid arthritis;
PAAD	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.04e-6	Resting heart rate;
PAAD	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-4.96	-0.37	1.88e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.37	-4.76	-0.36	4.46e-6	Prostate cancer;
PAAD	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.62	5.27	0.39	4.51e-7	Common traits (Other);
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.77	8.99	0.59	9.42e-16	Lung cancer;
PAAD	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.75	-7.78	-0.53	1.04e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg15436174	chr10:43711423	RASGEF1A	0.57	5.28	0.39	4.35e-7	Hirschsprung disease;
PAAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.43	5.08	0.38	1.1e-6	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07476944	chr4:39978140	PDS5A	0.71	7.29	0.51	1.57e-11	Obesity-related traits;
PAAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.62	-5.72	-0.42	5.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.8	9.14	0.6	3.8e-16	Lung cancer;
PAAD	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-7.85	-0.54	6.81e-13	Coffee consumption (cups per day);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg18144296	chr6:144385771	PLAGL1	0.88	6.47	0.46	1.26e-9	Lung function (FEV1/FVC);
PAAD	cis	rs2421770	0.532	rs7127824	chr11:35373851	A/G	cg13971030	chr11:35366721	SLC1A2	-0.54	-5.28	-0.39	4.45e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.54	-4.63	-0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs2036402	0.911	rs6555760	chr5:156365366	T/A	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.19e-5	Hypertriglyceridemia;
PAAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.5	-6.18	-0.45	5.61e-9	Schizophrenia;
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.46	-0.46	1.32e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.36	4.82	0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.49	-0.41	1.68e-7	Total body bone mineral density;
PAAD	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg10495392	chr1:46806563	NSUN4	-0.58	-5.78	-0.42	4.19e-8	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17025142	chr5:99871651	FAM174A	-0.64	-6.47	-0.46	1.3e-9	Smoking initiation;
PAAD	cis	rs6466055	0.720	rs13239067	chr7:105011629	T/A	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.67	-4.85	-0.37	3.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8099014	0.906	rs4940696	chr18:56106596	C/T	cg12907477	chr18:56117327	MIR122	-0.59	-4.54	-0.35	1.15e-5	Platelet count;
PAAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg17401720	chr7:158221031	PTPRN2	0.48	5.09	0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg01970496	chr2:177005398	NA	-0.51	-4.26	-0.33	3.53e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	1.0	8.44	0.56	2.32e-14	Blood protein levels;
PAAD	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.57	6.09	0.44	9.01e-9	Lung cancer;
PAAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg01966878	chr4:90757139	SNCA	-0.6	-4.7	-0.36	5.88e-6	Neuroticism;
PAAD	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.37	0.4	2.86e-7	Urate levels in lean individuals;
PAAD	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.43	5.42	0.4	2.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.9	13.01	0.73	1.71e-26	Bone mineral density;
PAAD	cis	rs111342015	0.764	rs75187159	chr6:43188173	A/G	cg17076780	chr6:43251928	TTBK1	0.63	4.48	0.34	1.46e-5	Breast cancer;
PAAD	cis	rs35084382	1.000	rs114015958	chr5:172194282	G/C	cg19801141	chr5:172198162	DUSP1	1.42	6.6	0.47	6.48e-10	Optic cup area;
PAAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs901683	1.000	rs12764485	chr10:46002587	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs17032980	0.956	rs13397289	chr2:67321213	T/C	cg06994420	chr2:66672553	MEIS1	-0.5	-4.47	-0.34	1.53e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6785206	0.554	rs4384970	chr3:128446412	G/T	cg19205850	chr3:128446370	RAB7A	-0.74	-5.59	-0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05208423	chr11:13689596	FAR1	0.64	6.34	0.46	2.49e-9	Obesity-related traits;
PAAD	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg14711859	chr11:8959438	ASCL3	-0.48	-5.44	-0.4	2.09e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg23815491	chr16:72088622	HP	0.4	4.31	0.33	2.86e-5	Fibrinogen levels;
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	1.0	8.28	0.56	6.03e-14	Initial pursuit acceleration;
PAAD	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.35	0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06799790	chr17:61951754	CSH2	-0.46	-4.74	-0.36	4.87e-6	Height;
PAAD	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	5.27	0.39	4.55e-7	Menopause (age at onset);
PAAD	cis	rs1667255	0.830	rs1791200	chr18:29187573	C/T	cg18808318	chr18:29669225	NA	0.46	4.36	0.33	2.43e-5	Retinol levels;
PAAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.32	0.6	1.25e-16	Parkinson's disease;
PAAD	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg24747557	chr10:131355152	MGMT	0.57	5.52	0.41	1.44e-7	Response to temozolomide;
PAAD	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.31	0.51	1.46e-11	Body mass index;
PAAD	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.53	-4.47	-0.34	1.53e-5	Aortic root size;
PAAD	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.71	-7.25	-0.51	2.01e-11	Height;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11700980	0.551	rs2832010	chr21:30110378	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-1.14	-12.44	-0.71	6.06e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg15145965	chr22:50218605	BRD1	0.59	4.57	0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs787274	1.000	rs2796028	chr9:115528755	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.28	-0.45	3.39e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.27e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg08897044	chr19:12950850	MAST1	-0.36	-4.64	-0.35	7.5e-6	Mean corpuscular volume;
PAAD	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.96	-0.37	1.9e-6	Tuberculosis;
PAAD	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.46	4.33	0.33	2.74e-5	Hip circumference;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.12	0.38	8.94e-7	Alzheimer's disease;
PAAD	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02359409	chr6:42947317	PEX6	-0.52	-5.37	-0.4	2.87e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12541635	0.966	rs12544362	chr8:106976344	A/C	cg10147462	chr8:107024639	NA	0.45	4.6	0.35	8.91e-6	Age of smoking initiation;
PAAD	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.48	4.54	0.35	1.14e-5	Educational attainment (years of education);
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18621852	chr3:10150065	C3orf24	0.71	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.83	6.14	0.45	6.96e-9	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20189682	chr2:240112315	HDAC4	-0.65	-6.64	-0.47	5.19e-10	Obesity-related traits;
PAAD	cis	rs1468333	0.724	rs10054835	chr5:137618772	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.54	5.55	0.41	1.23e-7	Resting heart rate;
PAAD	cis	rs11715604	1	rs11715604	chr3:136589549	A/T	cg15507776	chr3:136538369	TMEM22	-0.71	-5.25	-0.39	5.07e-7	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.84	-10.66	-0.65	3.62e-20	Height;
PAAD	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.21	0.45	4.71e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.82	-0.36	3.38e-6	Breast cancer;
PAAD	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs116248771	0.739	rs7617983	chr3:158323716	T/A	cg16708174	chr3:158430962	RARRES1	0.73	5.4	0.4	2.51e-7	diarrhoeal disease at age 2;
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-1.01	-7.9	-0.54	5.28e-13	Initial pursuit acceleration;
PAAD	cis	rs72960926	0.744	rs79176890	chr6:75162791	C/A	cg03266952	chr6:74778945	NA	-1.28	-6.46	-0.46	1.36e-9	Metabolite levels (MHPG);
PAAD	trans	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg01305830	chr4:1604576	NA	-0.46	-4.55	-0.35	1.1e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg11062466	chr8:58055876	NA	0.68	4.79	0.36	3.97e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg17541715	chr7:1216824	NA	-0.4	-4.36	-0.33	2.43e-5	Longevity;Endometriosis;
PAAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg03030879	chr14:75389066	RPS6KL1	0.41	4.27	0.33	3.41e-5	Height;
PAAD	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.42	-0.34	1.87e-5	Coronary artery disease;
PAAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs7923609	0.846	rs7073753	chr10:65062820	C/T	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg26248373	chr2:1572462	NA	-1.06	-9.15	-0.6	3.58e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.22	-0.64	5.32e-19	Response to antipsychotic treatment;
PAAD	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.82	-9.67	-0.62	1.55e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.56	5.43	0.4	2.21e-7	Mood instability;
PAAD	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs59888335	0.830	rs66826901	chr3:80630085	G/A	cg21735741	chr3:80819488	NA	0.58	5.01	0.38	1.46e-6	Schizophrenia;
PAAD	cis	rs2835872	0.733	rs1787393	chr21:39035934	G/A	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	trans	rs12979813	1.000	rs12979813	chr19:11342703	C/T	cg03333546	chr19:13263065	IER2	0.87	6.46	0.46	1.32e-9	HDL cholesterol;
PAAD	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.44	-4.9	-0.37	2.46e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1008126	0.600	rs2528871	chr7:103135470	A/C	cg04218035	chr7:103086829	SLC26A5	0.33	4.63	0.35	7.91e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.58	-4.35	-0.33	2.47e-5	Carotid intima media thickness;
PAAD	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.13	0.38	8.78e-7	HIV-1 control;
PAAD	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg22189786	chr22:42395067	WBP2NL	0.47	5.29	0.39	4.21e-7	Intelligence;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg08538288	chr12:98909445	TMPO;LOC100128191	0.64	6.95	0.49	1.03e-10	Iris heterochromicity;
PAAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.69	8.73	0.58	4.25e-15	Eye color traits;
PAAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.91	10.63	0.65	4.52e-20	Myeloid white cell count;
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg26752003	chr8:145688521	CYHR1	-0.57	-6.34	-0.46	2.48e-9	Age at first birth;
PAAD	cis	rs1468734	0.927	rs4786566	chr16:5001029	A/G	cg06510647	chr16:5006106	NA	0.55	4.98	0.37	1.74e-6	Cancer;
PAAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	5.03	0.38	1.39e-6	Schizophrenia;
PAAD	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg10434728	chr15:90938212	IQGAP1	-0.49	-4.97	-0.37	1.81e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.55	-5.48	-0.41	1.7e-7	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg24213567	chr19:53496664	ZNF702P	-0.48	-5.04	-0.38	1.32e-6	Psoriasis;
PAAD	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-5.12	-0.38	9.31e-7	Schizophrenia;
PAAD	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.55	6.3	0.45	3.09e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-6.36	-0.46	2.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg10820045	chr2:198174542	NA	0.51	5.26	0.39	4.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs11037575	1.000	rs10838152	chr11:43709386	C/T	cg24662154	chr11:44118094	EXT2	0.42	4.29	0.33	3.12e-5	Neuroblastoma;
PAAD	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.46	-0.46	1.36e-9	Monocyte count;
PAAD	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg21483461	chr5:81570383	RPS23	-0.49	-4.72	-0.36	5.42e-6	Breast cancer;
PAAD	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs3779195	0.591	rs77968419	chr7:97866480	G/A	cg21770322	chr7:97807741	LMTK2	-0.55	-4.59	-0.35	9.16e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.54	5.08	0.38	1.07e-6	Crohn's disease;
PAAD	trans	rs62209635	0.500	rs6088295	chr20:32344656	G/A	cg04370807	chr17:29248951	ADAP2	-1.11	-6.65	-0.47	5.05e-10	Loneliness;
PAAD	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-1.03	-11.28	-0.68	7.86e-22	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.49	4.26	0.33	3.61e-5	Resistin levels;
PAAD	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.54	8.27	0.56	6.21e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.63	5.9	0.43	2.24e-8	Large artery stroke;
PAAD	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.89	10.69	0.65	3.14e-20	Resting heart rate;
PAAD	cis	rs9398803	0.651	rs979197	chr6:127075696	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-4.35	-0.33	2.5e-5	Male-pattern baldness;
PAAD	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg10932868	chr11:921992	NA	0.48	5.69	0.42	6.28e-8	Alzheimer's disease (late onset);
PAAD	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.95	8.49	0.57	1.71e-14	Exhaled nitric oxide output;
PAAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14214425	chr12:130623165	NA	-0.6	-6.3	-0.46	3.07e-9	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00306905	chr10:121356070	TIAL1	-0.56	-6.5	-0.47	1.06e-9	Body fat percentage;
PAAD	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg00922110	chr4:57842668	C4orf14	-0.44	-4.32	-0.33	2.78e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs1941184	0.759	rs724481	chr18:29024566	A/G	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg15017067	chr4:17643749	FAM184B	-0.47	-5.62	-0.41	8.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	2.99e-5	Breast cancer;
PAAD	cis	rs9584850	0.834	rs4294654	chr13:99119607	G/A	cg20487152	chr13:99095054	FARP1	0.63	5.76	0.42	4.53e-8	Neuroticism;
PAAD	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.98	8.18	0.55	1.07e-13	Neutrophil percentage of white cells;
PAAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg13379983	chr2:198649727	BOLL	-0.56	-4.28	-0.33	3.28e-5	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.36	0.56	3.61e-14	Prudent dietary pattern;
PAAD	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg00522288	chr12:125625016	AACS	-0.43	-4.46	-0.34	1.57e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.46	-4.9	-0.37	2.41e-6	Age at first birth;
PAAD	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.43	0.34	1.82e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.01e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs12541635	1.000	rs7817197	chr8:107089633	T/G	cg10147462	chr8:107024639	NA	-0.44	-4.71	-0.36	5.54e-6	Age of smoking initiation;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg19223190	chr17:80058835	NA	-0.52	-5.39	-0.4	2.69e-7	Life satisfaction;
PAAD	cis	rs7925523	0.891	rs4963243	chr11:61494327	G/A	cg12472022	chr11:61462803	DAGLA	0.64	4.69	0.36	6.12e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.36	-0.33	2.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.12	14.18	0.75	1.32e-29	Schizophrenia;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12588763	chr5:139555533	C5orf32	-0.67	-6.8	-0.48	2.23e-10	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	1.19	9.56	0.61	3.05e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.81	-10.17	-0.64	7.36e-19	Hemoglobin concentration;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17735131	chr7:86849176	C7orf23	0.59	6.39	0.46	1.96e-9	Primary biliary cholangitis;
PAAD	cis	rs9815354	0.909	rs11717540	chr3:41932938	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.83	-0.43	3.27e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.52	4.78	0.36	4.07e-6	Educational attainment;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	7.2	0.5	2.66e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.31	-0.51	1.44e-11	Colorectal cancer;
PAAD	cis	rs4704187	0.663	rs6897274	chr5:74426103	T/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.72	-0.42	5.54e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs7631605	0.905	rs11720064	chr3:37101519	G/T	cg17445812	chr3:36986805	TRANK1	0.36	4.85	0.37	3.02e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.46	5.27	0.39	4.62e-7	Electroencephalogram traits;
PAAD	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg14631576	chr9:95140430	CENPP	-0.46	-4.54	-0.35	1.13e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	6.09e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.58	-4.65	-0.35	7.27e-6	Personality dimensions;
PAAD	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg27511599	chr7:32358540	NA	0.73	4.45	0.34	1.62e-5	Body mass index;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg07929768	chr2:232055508	NA	0.39	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs4450131	0.569	rs7917674	chr10:126340267	C/A	cg20435097	chr10:126320824	FAM53B	-0.54	-5.81	-0.43	3.54e-8	White blood cell count (basophil);
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.62	5.96	0.44	1.68e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.53	-5.0	-0.38	1.57e-6	Triglycerides;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.05	-0.38	1.28e-6	Longevity;Endometriosis;
PAAD	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.57	5.36	0.4	3.07e-7	Corneal astigmatism;
PAAD	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.97	13.72	0.74	2.17e-28	Heart rate;
PAAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg14393609	chr7:65229607	NA	-0.46	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs7894051	0.557	rs56305006	chr10:135107948	G/A	cg24905316	chr10:135186343	ECHS1	0.77	4.59	0.35	9.41e-6	Lifespan;
PAAD	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	5.49	0.41	1.67e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg27565382	chr3:53032988	SFMBT1	0.78	4.51	0.34	1.28e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.26	-0.33	3.64e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10821973	0.550	rs10761614	chr10:63975930	C/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.61	7.75	0.53	1.19e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55883249	1.000	rs17453752	chr2:9766171	C/T	cg23886495	chr2:9695866	ADAM17	-0.55	-4.78	-0.36	4.12e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.79	7.92	0.54	4.7e-13	Retinal vascular caliber;
PAAD	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.68e-7	Coronary heart disease;
PAAD	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.67	6.79	0.48	2.32e-10	Response to antidepressants and depression;
PAAD	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.67	-8.37	-0.56	3.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.16	0.5	3.14e-11	Colorectal cancer;
PAAD	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg00717180	chr2:96193071	NA	0.59	6.66	0.48	4.64e-10	HDL cholesterol;
PAAD	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg00750074	chr16:89608354	SPG7	-0.67	-7.04	-0.5	6.08e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.52	5.49	0.41	1.64e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.68	0.58	5.55e-15	Exhaled nitric oxide output;
PAAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.07	-15.4	-0.78	7.91e-33	Multiple system atrophy;
PAAD	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.56	5.85	0.43	2.97e-8	White matter hyperintensity burden;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.65	6.43	0.46	1.59e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg20731937	chr12:48336164	NA	0.52	4.35	0.33	2.46e-5	Longevity (90 years and older);
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.86	7.4	0.51	8.57e-12	Obesity-related traits;
PAAD	cis	rs28595532	0.640	rs28649792	chr4:119366463	A/C	cg21605333	chr4:119757512	SEC24D	1.15	7.26	0.51	1.82e-11	Cannabis dependence symptom count;
PAAD	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.53	-0.34	1.2e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.66	0.62	1.65e-17	Prudent dietary pattern;
PAAD	cis	rs3784262	0.565	rs4646605	chr15:58287912	C/A	cg12031962	chr15:58353849	ALDH1A2	0.39	4.59	0.35	9.11e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	7.6	0.52	2.81e-12	Mean platelet volume;
PAAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.6	6.74	0.48	3.02e-10	Tonsillectomy;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-5.22	-0.39	5.92e-7	Monocyte count;
PAAD	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	5.7	0.42	6.08e-8	Ileal carcinoids;
PAAD	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg10985347	chr2:127963512	CYP27C1	0.49	4.76	0.36	4.55e-6	Protein C levels;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.17	0.55	1.13e-13	Alzheimer's disease;
PAAD	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.6	-0.78	2.24e-33	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27554648	chr1:9780397	PIK3CD	-0.66	-6.95	-0.49	1e-10	Obesity-related traits;
PAAD	cis	rs7627468	1.000	rs7629603	chr3:121950065	T/C	cg17240004	chr3:121949083	CASR	0.53	4.63	0.35	7.72e-6	Kidney stones;
PAAD	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	1.1	8.76	0.58	3.66e-15	Iron status biomarkers;
PAAD	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.73e-14	Triglycerides;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs6681460	0.549	rs7547866	chr1:67031924	A/G	cg02459107	chr1:67143332	SGIP1	0.66	7.09	0.5	4.82e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22898145	chr2:162096490	NA	-0.59	-6.36	-0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.61	4.84	0.37	3.15e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7260329	0.670	rs1872122	chr19:41497997	C/T	cg23925301	chr19:41220945	ADCK4	-0.48	-4.27	-0.33	3.36e-5	Smoking behavior;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	4.59	0.35	9.1e-6	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.43	0.34	1.81e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.62	-0.41	9.09e-8	Life satisfaction;
PAAD	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg12573674	chr2:1569213	NA	-0.71	-5.42	-0.4	2.31e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-5.37	-0.4	2.95e-7	Fibrinogen levels;
PAAD	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.39	-0.46	1.93e-9	Brain structure;
PAAD	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg24881330	chr22:46731750	TRMU	1.08	5.71	0.42	5.9e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg13263323	chr15:86062960	AKAP13	-0.62	-7.16	-0.5	3.27e-11	Interstitial lung disease;
PAAD	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.93	8.04	0.55	2.3e-13	IgG glycosylation;
PAAD	cis	rs1865760	0.541	rs1436309	chr6:25970109	T/A	cg18357526	chr6:26021779	HIST1H4A	0.54	4.65	0.35	7.12e-6	Height;
PAAD	trans	rs901683	1.000	rs12772485	chr10:46011421	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.78	0.48	2.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.47	4.88	0.37	2.62e-6	Longevity;
PAAD	cis	rs10214930	0.697	rs10807841	chr7:27619751	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.83	6.98	0.49	8.68e-11	Alzheimer's disease;
PAAD	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.7	0.36	5.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.66	5.12	0.38	9.04e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg15997130	chr1:24165203	NA	-0.53	-5.37	-0.4	2.92e-7	Immature fraction of reticulocytes;
PAAD	cis	rs10512697	0.655	rs35450818	chr5:3491486	T/C	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-6.12	-0.44	7.65e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg08732750	chr1:87598351	LOC339524	-0.27	-4.29	-0.33	3.13e-5	Smoking behavior;
PAAD	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.68	9.11	0.59	4.58e-16	Lipoprotein (a) levels;
PAAD	cis	rs72843506	0.656	rs57040439	chr17:19939835	C/G	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-4.94	-0.37	2.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12425451	0.544	rs28623776	chr12:3147631	C/T	cg05389053	chr12:3131226	TEAD4	-0.62	-5.28	-0.39	4.31e-7	Narcolepsy with cataplexy;
PAAD	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-5.49	-0.41	1.62e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.3	-7.23	-0.51	2.24e-11	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18201871	chr12:119582189	SRRM4	-0.59	-6.4	-0.46	1.79e-9	Obesity-related traits;
PAAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-4.45	-0.34	1.62e-5	Platelet count;
PAAD	cis	rs7582720	1.000	rs6705330	chr2:203662197	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.51	0.52	4.72e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.2	-0.45	5.14e-9	Hypospadias;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23087877	chr10:22022646	MLLT10	-0.4	-4.38	-0.33	2.23e-5	Monocyte percentage of white cells;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.45	4.91	0.37	2.36e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.64	7.98	0.54	3.23e-13	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs3796727	0.721	rs4696868	chr4:8618920	T/G	cg05284713	chr4:8621361	CPZ	-0.43	-4.32	-0.33	2.81e-5	Sporadic neuroblastoma;
PAAD	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01153342	chr14:74254319	C14orf43	0.65	7.43	0.52	7.16e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6681460	0.549	rs7547857	chr1:67031890	A/G	cg02459107	chr1:67143332	SGIP1	0.62	6.66	0.48	4.68e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.78	8.31	0.56	5.03e-14	Sudden cardiac arrest;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs965652	0.624	rs2627231	chr6:134374673	G/A	cg06764333	chr6:133564466	EYA4	0.43	4.31	0.33	2.95e-5	Coronary artery disease;
PAAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.83e-7	Monocyte count;
PAAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.78	7.75	0.53	1.25e-12	Retinal vascular caliber;
PAAD	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.15	-0.6	3.59e-16	Mean platelet volume;
PAAD	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.7	6.48	0.47	1.18e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.26	0.39	4.79e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.53	4.55	0.35	1.09e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg11802864	chr11:65308245	LTBP3	-0.44	-4.42	-0.34	1.88e-5	Bone mineral density;
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	6.24	0.45	4.12e-9	Systemic lupus erythematosus;
PAAD	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.71	5.38	0.4	2.74e-7	Vitiligo;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg18404041	chr3:52824283	ITIH1	-0.47	-4.52	-0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs593531	0.571	rs3862799	chr11:74050262	C/A	cg15851278	chr11:73669449	DNAJB13	-0.38	-4.52	-0.34	1.22e-5	Neuroticism;
PAAD	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs10981012	0.504	rs7045809	chr9:114577770	T/C	cg14428669	chr9:114659192	UGCG	-0.59	-4.47	-0.34	1.51e-5	Coronary artery disease;
PAAD	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg00522288	chr12:125625016	AACS	-0.43	-4.34	-0.33	2.64e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03760483	chr17:6899297	ALOX12	0.43	4.49	0.34	1.39e-5	Tonsillectomy;
PAAD	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.62	5.43	0.4	2.22e-7	Response to diuretic therapy;
PAAD	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg19978312	chr5:179634688	RASGEF1C	0.43	4.32	0.33	2.81e-5	LDL cholesterol;
PAAD	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.56	5.01	0.38	1.51e-6	Type 2 diabetes;
PAAD	cis	rs12935418	0.523	rs1469126	chr16:81029889	G/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg16576597	chr16:28551801	NUPR1	-0.64	-6.56	-0.47	7.8e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4740619	0.901	rs6474953	chr9:15714456	A/C	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.15e-5	Body mass index;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg03999872	chr20:62272968	STMN3	-0.73	-6.71	-0.48	3.71e-10	Atopic dermatitis;
PAAD	cis	rs7713065	0.758	rs7703152	chr5:131783213	C/T	cg14196790	chr5:131705035	SLC22A5	0.46	4.42	0.34	1.89e-5	Lung function (FEV1/FVC);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26364899	chr3:12329070	PPARG	0.61	6.41	0.46	1.73e-9	Obesity-related traits;
PAAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg03094675	chr11:5960213	NA	0.51	4.55	0.35	1.1e-5	DNA methylation (variation);
PAAD	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	4.51	0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	6.3	0.45	3.07e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg16606324	chr3:10149918	C3orf24	0.68	5.75	0.42	4.81e-8	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12906188	chr1:163041702	RGS4	0.6	6.45	0.46	1.4e-9	Monocyte percentage of white cells;
PAAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs6787172	0.667	rs7617165	chr3:158192203	G/A	cg16708174	chr3:158430962	RARRES1	0.43	4.58	0.35	9.64e-6	Subjective well-being;
PAAD	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.34	-0.4	3.32e-7	Chronic sinus infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26545167	chr5:106606747	NA	-0.65	-6.66	-0.48	4.68e-10	Obesity-related traits;
PAAD	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16549711	chr1:208041887	NA	-0.72	-6.59	-0.47	6.64e-10	Neuroticism;
PAAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs595018	0.505	rs11230501	chr11:60598075	G/T	cg23904249	chr11:60608951	CCDC86	0.7	5.18	0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg06553033	chr12:53270239	NA	0.47	4.65	0.35	7.16e-6	Cancer (pleiotropy);
PAAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg05373962	chr22:49881684	NA	-0.51	-4.91	-0.37	2.33e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.55	-5.48	-0.41	1.73e-7	High light scatter reticulocyte count;
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.12e-13	Prostate cancer;
PAAD	cis	rs9815354	0.680	rs73073292	chr3:42028023	C/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9535307	0.929	rs1581745	chr13:50330957	T/C	cg04663916	chr13:50265991	EBPL	0.59	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.5	5.13	0.38	8.61e-7	Longevity;Endometriosis;
PAAD	cis	rs13102973	0.720	rs13137300	chr4:135889460	G/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs1682825	0.547	rs17028925	chr3:10777632	A/G	cg03414471	chr3:11600889	VGLL4	0.5	4.36	0.33	2.41e-5	Economic and political preferences (feminism/equality);
PAAD	cis	rs8060686	0.582	rs8182201	chr16:68091150	T/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.58	-0.41	1.07e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23021076	chr3:64201741	PRICKLE2	-0.55	-6.33	-0.46	2.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg10645314	chr2:3704589	ALLC	-0.55	-5.76	-0.42	4.43e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs757081	0.636	rs664382	chr11:17206519	A/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.83	-0.43	3.16e-8	Systolic blood pressure;
PAAD	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-5.97	-0.44	1.6e-8	Schizophrenia;
PAAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg01299579	chr2:10830716	NOL10	0.56	5.97	0.44	1.61e-8	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg02462569	chr6:150064036	NUP43	-0.48	-5.19	-0.39	6.52e-7	Lung cancer;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs282587	0.569	rs378491	chr13:113398408	C/A	cg02820901	chr13:113351484	ATP11A	-0.65	-4.96	-0.37	1.89e-6	Glycated hemoglobin levels;
PAAD	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.18	8.84	0.58	2.2e-15	Lymphocyte counts;
PAAD	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-1.21	-12.67	-0.72	1.45e-25	Hair shape;
PAAD	cis	rs4834770	1.000	rs4834771	chr4:120242772	C/A	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs3764400	0.567	rs12600980	chr17:46187141	C/T	cg10706073	chr17:46328419	SKAP1	1.08	6.38	0.46	2.02e-9	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18736831	chr11:66036005	RAB1B	-0.79	-6.86	-0.49	1.64e-10	Neuroticism;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg15117754	chr3:10150083	C3orf24	-0.67	-5.58	-0.41	1.07e-7	Alzheimer's disease;
PAAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14895029	chr7:2775587	GNA12	-0.43	-4.45	-0.34	1.66e-5	Height;
PAAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg01852476	chr1:2232063	SKI	-0.27	-4.41	-0.34	1.92e-5	Ulcerative colitis;
PAAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.75	9.53	0.61	3.62e-17	Bone mineral density;
PAAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-4.47	-0.34	1.54e-5	Blood metabolite levels;
PAAD	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.73	-0.42	5.35e-8	Total cholesterol levels;
PAAD	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.33	-0.4	3.49e-7	Daytime sleep phenotypes;
PAAD	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Height;
PAAD	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg20913747	chr6:44695427	NA	-0.67	-6.73	-0.48	3.23e-10	Total body bone mineral density;
PAAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg12193833	chr17:30244370	NA	-0.62	-4.75	-0.36	4.64e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.9	6.37	0.46	2.15e-9	Pulse pressure;
PAAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg24053715	chr22:38214548	NA	0.56	5.47	0.41	1.81e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.66	6.22	0.45	4.69e-9	Parkinson's disease;
PAAD	cis	rs7243821	1.000	rs11661644	chr18:52642849	C/T	cg16669619	chr18:52630472	NA	-0.47	-5.0	-0.38	1.56e-6	Chin dimples;
PAAD	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg02795151	chr17:7402630	POLR2A	0.62	5.81	0.43	3.6e-8	Androgen levels;
PAAD	cis	rs16958440	1.000	rs12326600	chr18:44596497	C/T	cg17192377	chr18:44677553	HDHD2	0.9	5.56	0.41	1.18e-7	Sitting height ratio;
PAAD	cis	rs941898	0.781	rs12435526	chr14:100581743	G/C	cg26002632	chr14:100625216	DEGS2	-0.36	-4.89	-0.37	2.58e-6	White matter hyperintensity burden;
PAAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.86	6.39	0.46	1.97e-9	Tuberculosis;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	1.0	6.95	0.49	9.84e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.8	7.15	0.5	3.4e-11	Exhaled nitric oxide levels;
PAAD	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.6	4.36	0.33	2.38e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.43	-6.7	-0.48	3.89e-10	Mean corpuscular volume;
PAAD	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.66e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6499755	0.932	rs9302665	chr16:55340567	C/G	cg02859129	chr16:55357253	IRX6	-0.33	-4.42	-0.34	1.9e-5	Hypospadias;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07077080	chr8:30585289	GSR	-0.61	-7.54	-0.52	3.94e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.51	5.14	0.38	8.37e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-7.3	-0.51	1.52e-11	Heart rate;
PAAD	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.51	6.5	0.47	1.09e-9	Sitting height ratio;
PAAD	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.96	-10.74	-0.66	2.19e-20	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22252469	chr13:33702794	STARD13	-0.64	-6.48	-0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs12979813	1.000	rs12979813	chr19:11342703	C/T	cg08405405	chr19:11485325	C19orf39	0.6	4.46	0.34	1.6e-5	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25565820	chr12:8932036	NA	-0.64	-6.65	-0.47	5.05e-10	Obesity-related traits;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04176437	chr19:18747727	KLHL26	0.56	6.44	0.46	1.49e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12986413	1.000	rs4807208	chr19:2170205	A/C	cg09261902	chr19:2140048	AP3D1	0.5	4.8	0.36	3.82e-6	Height;
PAAD	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.57	4.7	0.36	5.84e-6	Alzheimer's disease (cognitive decline);
PAAD	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg03517284	chr6:25882590	NA	0.44	4.32	0.33	2.77e-5	Blood metabolite levels;
PAAD	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.25	0.51	1.94e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.06e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1451882	0.698	rs1376786	chr8:1061074	A/G	cg07395941	chr8:1078200	NA	-0.64	-5.15	-0.39	7.86e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7537660	0.636	rs10749635	chr1:248014615	C/T	cg03748376	chr1:248100585	OR2L13	0.45	4.66	0.35	6.95e-6	Platelet distribution width;
PAAD	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.55	-5.26	-0.39	4.74e-7	Monocyte count;
PAAD	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15557168	chr22:42548783	NA	-0.44	-4.49	-0.34	1.39e-5	Cognitive function;
PAAD	cis	rs9646944	0.578	rs13418548	chr2:102917239	C/T	cg20060108	chr2:102954350	IL1RL1	0.59	4.43	0.34	1.77e-5	Blood protein levels;
PAAD	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg24747557	chr10:131355152	MGMT	-0.43	-4.33	-0.33	2.72e-5	Response to temozolomide;
PAAD	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg12610070	chr10:71211762	TSPAN15	-0.61	-8.75	-0.58	3.83e-15	Venous thromboembolism;
PAAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.65	6.79	0.48	2.39e-10	Multiple sclerosis;
PAAD	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg22134325	chr11:66188745	NPAS4	0.29	4.66	0.35	6.92e-6	Airway imaging phenotypes;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.7	8.47	0.57	1.97e-14	Dupuytren's disease;
PAAD	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.71	-6.39	-0.46	1.94e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7742824	1.000	rs66629131	chr6:44101468	C/G	cg21657043	chr6:44035552	NA	0.5	5.12	0.38	8.94e-7	Major depressive disorder;
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg05717871	chr11:638507	DRD4	-0.59	-4.99	-0.38	1.61e-6	Systemic lupus erythematosus;
PAAD	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.69	-5.58	-0.41	1.06e-7	Type 2 diabetes;
PAAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg22143856	chr6:28129313	ZNF389	0.63	4.9	0.37	2.42e-6	Parkinson's disease;
PAAD	cis	rs9447004	0.865	rs6924739	chr6:74445387	C/T	cg23004174	chr6:74404879	CD109	0.43	4.41	0.34	1.97e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.81	-7.71	-0.53	1.49e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs16975963	0.644	rs75499934	chr19:38113043	C/A	cg08679971	chr19:38281047	NA	0.47	4.59	0.35	9.24e-6	Longevity;
PAAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg25204440	chr1:209979598	IRF6	0.58	4.6	0.35	8.67e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs148696809	1	rs148696809	chr6:28934352	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Blood metabolite levels;
PAAD	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.67	4.52	0.34	1.22e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg26528668	chr16:1614120	IFT140	0.55	5.15	0.39	7.84e-7	Coronary artery disease;
PAAD	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg21095983	chr6:86352623	SYNCRIP	0.65	6.58	0.47	7.02e-10	Smooth-surface caries;
PAAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14895029	chr7:2775587	GNA12	-0.47	-4.65	-0.35	7.07e-6	Height;
PAAD	cis	rs35955747	0.633	rs1916	chr22:31892121	C/G	cg02404636	chr22:31891804	SFI1	0.49	4.9	0.37	2.43e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9857275	0.788	rs9822327	chr3:141096755	C/T	cg00789793	chr3:141329863	RASA2	0.49	4.31	0.33	2.88e-5	Prion diseases;
PAAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.89e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg00590817	chr1:8272081	NA	0.39	4.65	0.35	7.22e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11825064	0.720	rs7128710	chr11:134497143	G/A	cg02089395	chr11:134479357	NA	-0.85	-5.67	-0.42	6.93e-8	Seasonality;
PAAD	cis	rs73019876	0.901	rs1849001	chr19:22130763	C/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	2.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7084921	0.579	rs2862947	chr10:101863817	C/G	cg11251234	chr10:101825055	CPN1	-0.33	-4.87	-0.37	2.78e-6	Bone mineral density;
PAAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.6	6.49	0.47	1.15e-9	Lung cancer;
PAAD	cis	rs1561176	0.783	rs1124175	chr7:155015124	A/C	cg25063631	chr7:155025500	NA	0.63	5.34	0.4	3.33e-7	Personality dimensions;
PAAD	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.57	5.38	0.4	2.74e-7	Epilepsy (remission after treatment);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14849071	chr1:226070470	TMEM63A	0.65	6.65	0.47	5.08e-10	Obesity-related traits;
PAAD	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.18	0.45	5.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2562456	0.793	rs3853838	chr19:21601994	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.51	-5.45	-0.4	2.01e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.51	0.52	4.65e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs13034020	0.522	rs35217978	chr2:61246548	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.92	-0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg02527881	chr3:46936655	PTH1R	0.37	4.31	0.33	2.96e-5	Colorectal cancer;
PAAD	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg12870014	chr12:110450643	ANKRD13A	0.73	4.72	0.36	5.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.72	-0.42	5.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg16110827	chr15:48056943	SEMA6D	-0.49	-4.75	-0.36	4.74e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.44	-4.68	-0.35	6.4e-6	Electroencephalogram traits;
PAAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.78e-7	Body mass index;
PAAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.77	-9.11	-0.59	4.35e-16	Height;
PAAD	cis	rs7084783	0.519	rs4917395	chr10:105351382	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.45	4.48	0.34	1.43e-5	Fear of pain;
PAAD	trans	rs61931739	0.511	rs116844963	chr12:33648783	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-6.47	-0.46	1.3e-9	Morning vs. evening chronotype;
PAAD	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-9.04	-0.59	6.8e-16	Idiopathic membranous nephropathy;
PAAD	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg00531865	chr16:30841666	NA	0.52	4.94	0.37	2.02e-6	Dementia with Lewy bodies;
PAAD	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.74	-7.56	-0.52	3.61e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.86	-9.73	-0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.73	7.32	0.51	1.34e-11	HIV-1 control;
PAAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.97	-0.37	1.82e-6	Personality dimensions;
PAAD	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg02135003	chr7:105160482	PUS7	-0.67	-6.04	-0.44	1.13e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.5	4.34	0.33	2.6e-5	Serum parathyroid hormone levels;
PAAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs4517514	0.509	rs12417652	chr11:89905239	T/G	cg05041596	chr11:89867385	NAALAD2	0.66	4.83	0.36	3.31e-6	Trans fatty acid levels;
PAAD	cis	rs6496932	1.000	rs12917495	chr15:85829561	G/A	cg19183879	chr15:85880815	NA	0.52	4.47	0.34	1.53e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.24	0.6	2.02e-16	Bipolar disorder;
PAAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg25767906	chr1:53392781	SCP2	-0.53	-5.12	-0.38	9.31e-7	Monocyte count;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10819733	chr22:24237672	NA	-0.55	-5.81	-0.43	3.63e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg08179530	chr6:36648295	CDKN1A	0.59	4.49	0.34	1.41e-5	QRS duration;
PAAD	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.56	-5.92	-0.43	2.06e-8	Pelvic organ prolapse;
PAAD	cis	rs12773846	0.587	rs61549547	chr10:126251223	A/G	cg04949429	chr10:126290192	LHPP	0.52	4.46	0.34	1.56e-5	Subcutaneous adipose tissue;
PAAD	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.76	-4.29	-0.33	3.19e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.72	-6.0	-0.44	1.39e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.46	-0.4	1.93e-7	HDL cholesterol;
PAAD	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg27411982	chr8:10470053	RP1L1	-0.48	-5.25	-0.39	5.14e-7	Neuroticism;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.76	-6.63	-0.47	5.55e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-9.71	-0.62	1.21e-17	Body mass index;
PAAD	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.76	-6.91	-0.49	1.27e-10	Body mass index;
PAAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.52	5.45	0.4	1.95e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17761864	0.634	rs7221132	chr17:2065438	G/T	cg16513277	chr17:2031491	SMG6	0.45	4.5	0.34	1.37e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.69	7.52	0.52	4.33e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.87	-8.22	-0.55	8.13e-14	Dilated cardiomyopathy;
PAAD	cis	rs76866386	0.892	rs77725792	chr2:44058201	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.31	-0.4	3.74e-7	Cholesterol, total;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00884794	chr14:23565044	C14orf119;ACIN1	0.75	7.03	0.5	6.62e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6466055	0.748	rs1204080	chr7:104988848	A/G	cg04380332	chr7:105027541	SRPK2	0.65	7.44	0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.9e-6	Lung cancer;
PAAD	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	6.47	0.46	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.51	-5.56	-0.41	1.17e-7	Prostate cancer;
PAAD	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.52	6.27	0.45	3.52e-9	Sitting height ratio;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.01	0.54	2.77e-13	Lymphocyte counts;
PAAD	cis	rs28489187	0.617	rs233061	chr1:85799282	G/A	cg16011679	chr1:85725395	C1orf52	0.5	4.65	0.35	7.01e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11811982	0.793	rs7530155	chr1:227410186	C/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03573702	chr19:44669354	ZNF226	0.58	6.76	0.48	2.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19671926	chr4:122722719	EXOSC9	-0.57	-5.12	-0.38	9.11e-7	Type 2 diabetes;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.94	-9.32	-0.6	1.26e-16	Obesity-related traits;
PAAD	cis	rs9581857	0.547	rs9581876	chr13:28101113	T/C	cg22138327	chr13:27999177	GTF3A	0.85	5.44	0.4	2.05e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.56	5.63	0.42	8.45e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg22027985	chr11:4115532	RRM1	-0.49	-4.42	-0.34	1.88e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.24	-0.39	5.18e-7	Neuroticism;
PAAD	cis	rs7180079	1.000	rs6494477	chr15:64667334	T/C	cg18210365	chr15:65066710	RBPMS2	0.65	4.93	0.37	2.14e-6	Monocyte count;
PAAD	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.9	4.89	0.37	2.56e-6	Childhood ear infection;
PAAD	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26556395	chr1:155252359	HCN3	-0.64	-6.36	-0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3777722	0.688	rs2757045	chr6:167350963	C/T	cg01837879	chr6:166900442	RPS6KA2	0.64	4.52	0.34	1.26e-5	Spontaneous preterm birth (preterm birth);
PAAD	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg26597838	chr10:835615	NA	0.47	5.06	0.38	1.18e-6	Survival in rectal cancer;
PAAD	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-7.07	-0.5	5.26e-11	Urate levels in overweight individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20526654	chr3:72495865	RYBP	0.7	7.14	0.5	3.54e-11	Obesity-related traits;
PAAD	cis	rs7729447	0.813	rs7715779	chr5:32690199	T/G	cg16267343	chr5:32710456	NPR3	0.44	4.33	0.33	2.69e-5	Blood pressure;
PAAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg01970496	chr2:177005398	NA	-0.51	-4.26	-0.33	3.53e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.21e-10	Tonsillectomy;
PAAD	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.49	-6.09	-0.44	8.95e-9	Menopause (age at onset);
PAAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.52	-0.34	1.22e-5	Renal cell carcinoma;
PAAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.37	0.46	2.09e-9	Menarche (age at onset);
PAAD	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.87	8.7	0.58	5.2e-15	Response to hepatitis C treatment;
PAAD	cis	rs9810890	1.000	rs73198815	chr3:128473832	C/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.56	-5.59	-0.41	1.04e-7	Coronary artery disease;
PAAD	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.94	8.14	0.55	1.3e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg01304814	chr3:48885189	PRKAR2A	0.91	5.23	0.39	5.64e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00035249	chr1:228270481	ARF1	0.65	7.23	0.51	2.23e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.5	5.43	0.4	2.23e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9810890	1.000	rs73196959	chr3:128431919	A/G	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.23e-27	Height;
PAAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.75	-0.42	4.79e-8	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg02462569	chr6:150064036	NUP43	-0.48	-5.31	-0.4	3.84e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.83	7.37	0.51	1.05e-11	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.24	0.39	5.38e-7	Prudent dietary pattern;
PAAD	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg16691251	chr5:66510806	NA	0.69	7.33	0.51	1.28e-11	Breast cancer;
PAAD	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	6.54	0.47	9.04e-10	Schizophrenia;
PAAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.63	0.57	7.64e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8112211	0.648	rs111958719	chr19:38808533	T/C	cg01275006	chr19:38876250	GGN	-0.89	-5.71	-0.42	5.68e-8	Blood protein levels;
PAAD	cis	rs899997	0.906	rs72625802	chr15:78992811	G/A	cg04896959	chr15:78267971	NA	-0.59	-5.28	-0.39	4.46e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19346786	chr7:2764209	NA	-0.39	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.91	11.58	0.68	1.27e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg10518543	chr12:38710700	ALG10B	-0.48	-4.37	-0.33	2.31e-5	Morning vs. evening chronotype;
PAAD	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-5.11	-0.38	9.4e-7	Pubertal anthropometrics;
PAAD	cis	rs6923462	0.935	rs6924424	chr6:7801611	T/G	cg20969151	chr6:7787925	BMP6	-0.57	-4.39	-0.34	2.1e-5	Lung function (forced vital capacity);
PAAD	cis	rs7213347	0.581	rs11657636	chr17:2053920	C/T	cg15816464	chr17:2026533	SMG6	0.53	5.94	0.43	1.9e-8	Total body bone mineral density;
PAAD	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs655641	0.520	rs536841	chr11:85787824	A/G	cg07180834	chr11:85838833	NA	0.46	4.64	0.35	7.52e-6	Platelet count;
PAAD	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.69	7.16	0.5	3.16e-11	Monocyte count;
PAAD	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.74	-7.87	-0.54	6.23e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg26174226	chr8:58114915	NA	-0.62	-5.14	-0.38	8.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs216026	0.689	rs216051	chr12:2766899	C/A	cg19945202	chr12:2788847	CACNA1C	0.6	4.62	0.35	8.07e-6	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	6.0	0.44	1.38e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.54	5.84	0.43	3.11e-8	Schizophrenia;
PAAD	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.43	-4.63	-0.35	7.94e-6	Blood metabolite levels;
PAAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.54	5.08	0.38	1.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg04810063	chr16:88703634	IL17C	-0.51	-4.53	-0.34	1.21e-5	Menopause (age at onset);
PAAD	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.06	-6.13	-0.45	7.13e-9	Lung cancer in ever smokers;
PAAD	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.24e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17981091	chr3:127770706	SEC61A1	-0.78	-6.76	-0.48	2.75e-10	Neuroticism;
PAAD	trans	rs7172971	0.565	rs113336192	chr15:42383254	T/C	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.75	-0.42	4.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07482373	chr22:50689843	HDAC10	0.58	6.47	0.46	1.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg22029157	chr1:209979665	IRF6	0.72	6.95	0.49	9.81e-11	Coronary artery disease;
PAAD	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs12286929	0.617	rs12800807	chr11:115101353	T/C	cg04055981	chr11:115044050	NA	0.48	4.85	0.37	3.01e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	10.07	0.63	1.37e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.81	6.33	0.46	2.58e-9	Weight;
PAAD	cis	rs12472274	0.941	rs36066920	chr2:239074480	T/G	cg17459225	chr2:239074497	NA	0.85	7.12	0.5	3.99e-11	Phospholipid levels (plasma);
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.9	7.73	0.53	1.35e-12	Alzheimer's disease;
PAAD	cis	rs6137287	0.924	rs6035792	chr20:21138989	G/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs12257961	0.579	rs10737095	chr10:15382547	C/G	cg10616319	chr10:15468812	NA	-0.46	-4.43	-0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.94	-9.88	-0.63	4.43e-18	Blood metabolite levels;
PAAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg01815783	chr4:1047043	NA	-0.45	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg08619932	chr19:49200058	FUT2	-0.58	-6.54	-0.47	8.74e-10	Dietary macronutrient intake;
PAAD	cis	rs72634258	0.945	rs3766606	chr1:8022197	G/T	cg00042356	chr1:8021962	PARK7	0.73	5.09	0.38	1.03e-6	Inflammatory bowel disease;
PAAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.89	7.0	0.49	7.69e-11	Tuberculosis;
PAAD	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.37	0.56	3.44e-14	Lung cancer;
PAAD	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.6	6.45	0.46	1.39e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg04359915	chr10:101825029	CPN1	0.35	5.27	0.39	4.68e-7	Bone mineral density;
PAAD	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.7	6.01	0.44	1.34e-8	Diabetic retinopathy;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.644	rs9309635	chr2:86499402	G/T	cg10973622	chr2:86423274	IMMT	0.45	4.93	0.37	2.12e-6	Night sleep phenotypes;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.9	9.63	0.62	2e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg20811857	chr17:78079795	GAA	-0.48	-4.66	-0.35	6.78e-6	Yeast infection;
PAAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.57	5.51	0.41	1.5e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.17	0.39	7.19e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.87	10.19	0.64	6.65e-19	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.67	-7.79	-0.53	9.69e-13	Motion sickness;
PAAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6782228	0.509	rs2811495	chr3:128359957	A/G	cg16766828	chr3:128327626	NA	-0.49	-6.62	-0.47	5.81e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.73	9.37	0.61	9.52e-17	Cancer;
PAAD	trans	rs901683	1.000	rs36053776	chr10:46088145	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg05234568	chr11:5960015	NA	-0.59	-6.52	-0.47	9.57e-10	DNA methylation (variation);
PAAD	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.53	5.34	0.4	3.28e-7	Resting heart rate;
PAAD	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	10.26	0.64	4.38e-19	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.46	5.99	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10207428	chr6:114663972	NA	0.53	6.51	0.47	1.04e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.47	5.75	0.42	4.81e-8	Crohn's disease;
PAAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg26497354	chr6:109612229	NA	-0.45	-4.53	-0.34	1.19e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.67e-8	Life satisfaction;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.71	-6.73	-0.48	3.31e-10	Monocyte count;
PAAD	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg00531865	chr16:30841666	NA	0.5	4.64	0.35	7.42e-6	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03045721	chr17:5095237	ZNF594	0.58	6.74	0.48	3.15e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21434563	chr6:161413126	MAP3K4	0.74	7.75	0.53	1.21e-12	Obesity-related traits;
PAAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.59	-0.35	9.3e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg15117754	chr3:10150083	C3orf24	0.61	5.15	0.39	7.98e-7	Alzheimer's disease;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.67	6.66	0.48	4.79e-10	Menarche (age at onset);
PAAD	cis	rs258892	0.895	rs36040109	chr5:72050659	A/G	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg27205649	chr11:78285834	NARS2	-0.62	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	5.1	0.38	1.01e-6	Schizophrenia;
PAAD	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	5.57	0.41	1.12e-7	Educational attainment;
PAAD	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.49	5.19	0.39	6.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.29	0.33	3.12e-5	IgG glycosylation;
PAAD	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.23	0.51	2.19e-11	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	trans	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	4.75	0.36	4.63e-6	Bipolar disorder;
PAAD	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg23283495	chr1:209979779	IRF6	0.66	6.43	0.46	1.56e-9	Coronary artery disease;
PAAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg13859433	chr6:33739653	LEMD2	-0.65	-5.09	-0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.55	0.57	1.2e-14	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24149806	chr17:7308003	C17orf61	0.73	7.51	0.52	4.8e-12	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.88	7.52	0.52	4.55e-12	Alzheimer's disease;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg04113056	chr14:64010798	PPP2R5E	-0.66	-6.69	-0.48	3.96e-10	Body mass index;
PAAD	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg03805757	chr16:71968109	PKD1L3	-0.59	-4.61	-0.35	8.53e-6	Blood protein levels;
PAAD	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.72	6.94	0.49	1.07e-10	Schizophrenia;
PAAD	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.81	-0.43	3.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.87	-10.34	-0.64	2.7e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg05484376	chr2:27715224	FNDC4	-0.45	-4.7	-0.36	5.81e-6	Oral cavity cancer;
PAAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg01176363	chr20:62369445	LIME1	-0.58	-5.52	-0.41	1.46e-7	Prostate cancer;
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg07061783	chr6:25882402	NA	-0.53	-5.02	-0.38	1.45e-6	Blood metabolite levels;
PAAD	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg01304814	chr3:48885189	PRKAR2A	0.96	5.03	0.38	1.37e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.73	-0.42	5.22e-8	Colorectal cancer;
PAAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.99	-0.37	1.66e-6	Height;
PAAD	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.48	-0.34	1.43e-5	Ileal carcinoids;
PAAD	cis	rs4774830	0.744	rs1912401	chr15:56161609	A/G	cg24530489	chr15:56299380	NA	-1.09	-4.69	-0.36	6e-6	Delta-5 desaturase activity;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.57e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.94	13.96	0.75	4.87e-29	Age-related hearing impairment;
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg01759136	chr6:27242945	NA	0.39	4.25	0.33	3.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.09	-0.44	8.66e-9	Longevity;Endometriosis;
PAAD	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	1.18	9.49	0.61	4.47e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2342371	0.599	rs7618690	chr3:196146039	T/C	cg08209042	chr3:196295218	WDR53;FBXO45	-0.57	-4.56	-0.35	1.02e-5	Fat distribution (HIV);
PAAD	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.65	-7.07	-0.5	5.29e-11	Capecitabine sensitivity;
PAAD	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	1.11	17.73	0.82	7.61e-39	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.65e-5	Life satisfaction;
PAAD	cis	rs28647808	1.000	rs28504382	chr9:136275674	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.39	-4.76	-0.36	4.42e-6	Blood metabolite levels;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg26338869	chr17:61819248	STRADA	0.5	4.82	0.36	3.52e-6	Height;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	7.63	0.53	2.37e-12	Height;
PAAD	cis	rs11997175	0.715	rs7012923	chr8:33630937	A/C	ch.8.33884649F	chr8:33765107	NA	0.55	6.16	0.45	6.09e-9	Body mass index;
PAAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.56	6.86	0.49	1.63e-10	Monobrow;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg04160749	chr8:58172571	NA	-0.75	-4.87	-0.37	2.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.61	6.33	0.46	2.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2652834	1.000	rs2652816	chr15:63403368	C/T	cg05507819	chr15:63340323	TPM1	0.77	4.95	0.37	1.95e-6	HDL cholesterol;
PAAD	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.55	-5.5	-0.41	1.58e-7	Longevity;Endometriosis;
PAAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg23463467	chr20:60627584	TAF4	0.46	4.95	0.37	1.98e-6	Body mass index;
PAAD	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	IgG glycosylation;
PAAD	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19671926	chr4:122722719	EXOSC9	-0.56	-4.98	-0.37	1.68e-6	Type 2 diabetes;
PAAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07648498	chr16:89883185	FANCA	0.69	7.12	0.5	4.01e-11	Vitiligo;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs7631605	0.905	rs72866099	chr3:37259646	C/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.46e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.67	6.57	0.47	7.41e-10	Blood metabolite levels;
PAAD	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.45	-6.42	-0.46	1.63e-9	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs28655083	0.509	rs679263	chr16:77103829	T/C	cg06128999	chr16:77247126	NA	-0.42	-5.14	-0.38	8.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.41e-21	Ulcerative colitis;
PAAD	cis	rs863345	0.504	rs857707	chr1:158564383	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs11696501	0.688	rs6073854	chr20:44309605	A/G	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.47	5.05	0.38	1.25e-6	Lung cancer;
PAAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.71	0.42	5.69e-8	Prostate cancer;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs9810890	1.000	rs73207974	chr3:128568455	T/C	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg21918786	chr6:109611834	NA	0.51	5.55	0.41	1.24e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-5.09	-0.38	1.03e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3112530	1.000	rs160172	chr5:152735785	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.66	-0.35	6.98e-6	Bone mineral density;
PAAD	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	5.68	0.42	6.65e-8	Testicular germ cell tumor;
PAAD	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.46	-4.46	-0.34	1.61e-5	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg02459107	chr1:67143332	SGIP1	0.76	7.47	0.52	5.82e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs5742933	0.779	rs114408326	chr2:190581396	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.69	5.39	0.4	2.64e-7	Blood protein levels;
PAAD	cis	rs2033908	0.589	rs4757060	chr11:12842990	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-4.71	-0.36	5.58e-6	Sitting height ratio;
PAAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.81	-8.02	-0.55	2.68e-13	Schizophrenia;
PAAD	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.37	-4.84	-0.37	3.23e-6	Primary biliary cholangitis;
PAAD	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.26	-0.39	4.79e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs258892	0.947	rs266443	chr5:72180377	C/T	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs4751058	0.526	rs10764841	chr10:130856829	A/C	cg27413539	chr10:131576096	NA	-0.57	-5.61	-0.41	9.22e-8	Vitamin D levels;
PAAD	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg07929629	chr2:241523174	NA	0.68	6.06	0.44	1.03e-8	Bipolar disorder;
PAAD	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.68	-0.48	4.28e-10	Retinal vascular caliber;
PAAD	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.84	-8.78	-0.58	3.19e-15	Body mass index;
PAAD	cis	rs12042938	0.505	rs9661331	chr1:231752306	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-4.7	-0.36	5.81e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.93e-7	Red blood cell count;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg16590910	chr6:42928470	GNMT	0.55	5.54	0.41	1.29e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.53	4.9	0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-1.06	-9.53	-0.61	3.6e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg04165759	chr1:150448943	RPRD2	0.51	5.23	0.39	5.44e-7	Migraine;
PAAD	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg15117754	chr3:10150083	C3orf24	0.75	6.52	0.47	9.9e-10	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-6.75	-0.48	2.98e-10	Breast cancer;
PAAD	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs12799264	1.000	rs894552	chr11:19977539	C/T	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs4764124	0.646	rs2075268	chr12:14956476	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.56	6.52	0.47	9.67e-10	Pubertal anthropometrics;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12528349	chr7:28070030	JAZF1	0.63	7.23	0.51	2.15e-11	Smoking initiation;
PAAD	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg20295408	chr7:1910781	MAD1L1	-0.56	-5.17	-0.39	7.35e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg21698718	chr17:80085957	CCDC57	-0.44	-5.02	-0.38	1.42e-6	Life satisfaction;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg18370025	chr7:2749541	AMZ1	-0.4	-4.72	-0.36	5.25e-6	Height;
PAAD	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.66	-6.56	-0.47	8.04e-10	Cognitive test performance;
PAAD	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.12	-7.34	-0.51	1.18e-11	Plateletcrit;
PAAD	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs757081	0.669	rs542274	chr11:17207433	C/T	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.71	-0.42	5.66e-8	Systolic blood pressure;
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.67	6.88	0.49	1.48e-10	Mean corpuscular volume;
PAAD	cis	rs10771511	1	rs10771511	chr12:29437217	T/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-4.36	-0.33	2.42e-5	Platelet distribution width;
PAAD	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.48	-0.41	1.75e-7	Schizophrenia;
PAAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg04106633	chr4:1044584	NA	0.64	5.4	0.4	2.52e-7	Recombination rate (females);
PAAD	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.54	-4.9	-0.37	2.46e-6	Glycated hemoglobin levels;
PAAD	cis	rs16975963	0.793	rs73034946	chr19:38460493	T/C	cg14218481	chr19:38281219	NA	0.49	5.04	0.38	1.29e-6	Longevity;
PAAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg13256891	chr4:100009986	ADH5	0.42	4.25	0.33	3.78e-5	Alcohol dependence;
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg17775713	chr3:133465469	TF	0.49	5.54	0.41	1.28e-7	Iron status biomarkers;
PAAD	cis	rs11129295	0.585	rs9868208	chr3:27810888	C/T	cg21473142	chr3:27762095	EOMES	0.27	4.49	0.34	1.4e-5	Multiple sclerosis;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.6	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.67	7.34	0.51	1.21e-11	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13939156	chr17:80058883	NA	0.4	4.29	0.33	3.13e-5	Life satisfaction;
PAAD	cis	rs76917914	0.820	rs4743158	chr9:100821275	T/C	cg03040243	chr9:100819229	NANS	0.59	4.72	0.36	5.32e-6	Immature fraction of reticulocytes;
PAAD	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.29	7.42	0.52	7.89e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs4290173	0.765	rs34376384	chr10:52655506	C/T	cg19653951	chr10:51748232	AGAP6	0.72	4.49	0.34	1.39e-5	Narcolepsy with cataplexy;
PAAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.85	0.49	1.76e-10	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.67	-4.78	-0.36	4.13e-6	Depression;
PAAD	cis	rs400736	0.576	rs10864328	chr1:8164456	G/C	cg25007680	chr1:8021821	PARK7	-0.48	-4.5	-0.34	1.32e-5	Response to antidepressants and depression;
PAAD	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.75	-0.48	2.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23120652	chr10:90639919	STAMBPL1	-0.58	-6.62	-0.47	5.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.98	-0.44	1.56e-8	Schizophrenia;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg00049323	chr5:472564	LOC25845	-0.46	-4.74	-0.36	4.93e-6	Cystic fibrosis severity;
PAAD	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.81	-5.67	-0.42	7.11e-8	Systolic blood pressure;
PAAD	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2415984	0.579	rs61993338	chr14:46969142	T/C	cg14871534	chr14:47121158	RPL10L	-0.49	-5.09	-0.38	1.05e-6	Number of children ever born;
PAAD	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08048268	chr3:133502702	NA	-0.49	-5.77	-0.42	4.28e-8	Iron status biomarkers;
PAAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.82	-8.23	-0.56	7.74e-14	Cisplatin-induced ototoxicity;
PAAD	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.14	0.45	6.71e-9	Electrocardiographic conduction measures;
PAAD	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg02580895	chr19:2754563	NA	-0.51	-4.45	-0.34	1.67e-5	Total cholesterol levels;
PAAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg07725925	chr16:89976287	TCF25	0.72	4.32	0.33	2.84e-5	Skin colour saturation;
PAAD	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg16342193	chr10:102329863	NA	-0.77	-8.43	-0.56	2.41e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg20302533	chr7:39170763	POU6F2	-0.35	-5.0	-0.38	1.56e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-8.09	-0.55	1.79e-13	Prostate cancer;
PAAD	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg23018236	chr17:30244563	NA	-0.52	-4.31	-0.33	2.9e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.45	4.92	0.37	2.27e-6	Life satisfaction;
PAAD	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.0	-0.44	1.37e-8	Menarche (age at onset);
PAAD	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg19423196	chr10:82049429	MAT1A	0.5	5.13	0.38	8.66e-7	Borderline personality disorder;
PAAD	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg02555727	chr12:129281546	SLC15A4	0.49	5.21	0.39	6.16e-7	Systemic lupus erythematosus;
PAAD	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg07841815	chr7:100318223	EPO	-0.48	-4.39	-0.34	2.11e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.5	4.9	0.37	2.38e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1656368	0.726	rs4680444	chr3:158260514	A/G	cg16708174	chr3:158430962	RARRES1	0.56	5.14	0.38	8.52e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	5.1	0.38	1.02e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.9	-10.61	-0.65	4.98e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.49	-5.4	-0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.64	7.06	0.5	5.66e-11	Cognitive function;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.51	4.43	0.34	1.81e-5	Height;
PAAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg11764359	chr7:65958608	NA	-0.77	-5.12	-0.38	9.09e-7	Diabetic kidney disease;
PAAD	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	0.8	7.32	0.51	1.32e-11	Response to hepatitis C treatment;
PAAD	cis	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg08501292	chr6:25962987	TRIM38	0.93	4.49	0.34	1.37e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12696666	chr3:156877901	CCNL1	0.69	7.03	0.5	6.49e-11	Obesity-related traits;
PAAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18490616	chr2:88469792	THNSL2	-0.45	-4.3	-0.33	2.99e-5	Response to metformin (IC50);
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.41	-0.4	2.36e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg13918804	chr1:2043761	PRKCZ	0.43	5.87	0.43	2.59e-8	Height;
PAAD	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg07506560	chr2:240697449	NA	0.6	6.22	0.45	4.52e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.556	rs289334	chr19:23152964	C/T	cg22640819	chr19:22990650	NA	0.28	4.31	0.33	2.95e-5	Testicular germ cell tumor;
PAAD	cis	rs639012	0.667	rs1237999	chr11:85815030	G/A	cg07180834	chr11:85838833	NA	-0.5	-5.64	-0.42	8.22e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg12705353	chr12:122356852	WDR66	-0.46	-4.75	-0.36	4.71e-6	Mean corpuscular volume;
PAAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01033360	chr19:3381432	NFIC	-0.64	-6.57	-0.47	7.41e-10	Obesity-related traits;
PAAD	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.95	-9.09	-0.59	4.98e-16	Blood protein levels;
PAAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg19980929	chr12:42632907	YAF2	0.52	5.98	0.44	1.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.53	0.41	1.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.45	0.46	1.43e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	1.23	11.42	0.68	3.38e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.73	0.62	1.07e-17	Lymphocyte counts;
PAAD	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.4	-0.34	1.99e-5	Height;
PAAD	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.46	-4.4	-0.34	2.06e-5	Inflammatory bowel disease;
PAAD	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.73	-0.42	5.3e-8	Coronary artery disease;
PAAD	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04733989	chr22:42467013	NAGA	0.46	4.72	0.36	5.28e-6	Cognitive function;
PAAD	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.68	6.56	0.47	8.04e-10	Plateletcrit;Platelet count;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.61	-7.41	-0.52	8.18e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4513299	0.540	rs13000279	chr2:115018653	G/A	cg12978357	chr2:114426529	NA	-0.46	-4.43	-0.34	1.83e-5	Inflammatory biomarkers;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.55	6.15	0.45	6.56e-9	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.84e-19	Glomerular filtration rate (creatinine);
PAAD	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg06713675	chr4:122721982	EXOSC9	0.47	4.6	0.35	8.72e-6	Type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg21130718	chr4:1044621	NA	-0.57	-4.81	-0.36	3.53e-6	Recombination rate (females);
PAAD	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.88	-0.58	1.75e-15	Exhaled nitric oxide output;
PAAD	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.46	-5.49	-0.41	1.68e-7	Body mass index;
PAAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.52	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.83	-7.75	-0.53	1.25e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg11619707	chr19:22235551	ZNF257	-0.54	-5.38	-0.4	2.73e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.08	15.6	0.78	2.3e-33	Multiple system atrophy;
PAAD	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg22437258	chr11:111473054	SIK2	-0.52	-4.98	-0.37	1.7e-6	Primary sclerosing cholangitis;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg20302533	chr7:39170763	POU6F2	0.5	7.0	0.49	7.65e-11	IgG glycosylation;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13400003	chr1:111683051	DRAM2;CEPT1	0.54	6.58	0.47	7.24e-10	Immature fraction of reticulocytes;
PAAD	cis	rs9687846	0.877	rs3936510	chr5:55860866	G/T	cg15001016	chr5:55860904	NA	-0.47	-4.53	-0.34	1.18e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.7	-9.37	-0.61	9.31e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.5e-6	Cognitive function;
PAAD	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.78	8.31	0.56	4.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs13191038	1	rs13191038	chr6:28482917	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.33	0.33	2.68e-5	Urinary tract infection frequency;
PAAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg25452165	chr22:42524984	CYP2D6	0.52	4.61	0.35	8.46e-6	Schizophrenia;
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9649465	0.905	rs3757504	chr7:123391750	C/T	cg04330084	chr7:123175371	IQUB	-0.49	-4.62	-0.35	8.05e-6	Migraine;
PAAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.66	-0.35	6.79e-6	Height;
PAAD	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs11203032	0.831	rs11203028	chr10:90956550	C/T	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13986860	chr13:31338421	ALOX5AP	-0.65	-6.38	-0.46	2e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08219700	chr8:58056026	NA	0.68	5.28	0.39	4.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.54	5.24	0.39	5.2e-7	Lung cancer;
PAAD	cis	rs61863818	0.533	rs2275580	chr10:99125949	C/T	cg10705379	chr10:99080932	FRAT1	-0.39	-4.69	-0.36	6.05e-6	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26926768	chr12:34528122	NA	0.37	4.32	0.33	2.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs73198271	1.000	rs73198272	chr8:8606808	A/C	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	7.06	0.5	5.63e-11	Response to antipsychotic treatment;
PAAD	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg10645314	chr2:3704589	ALLC	0.74	7.53	0.52	4.21e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24026388	chr12:48099519	RPAP3	0.61	7.01	0.49	7.4e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.53	4.92	0.37	2.26e-6	Airway imaging phenotypes;
PAAD	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg08562672	chr19:21860753	NA	0.42	4.28	0.33	3.33e-5	Pain;
PAAD	cis	rs7251275	0.625	rs427115	chr19:44098197	A/G	cg17121205	chr19:44009353	PHLDB3	-0.39	-4.94	-0.37	2e-6	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-6.27	-0.45	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg08705958	chr13:113497324	ATP11A	0.5	6.54	0.47	8.72e-10	Coronary artery disease;
PAAD	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.9	0.37	2.43e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg26950739	chr16:89183275	ACSF3	0.78	5.27	0.39	4.56e-7	Red blood cell count;
PAAD	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.83	4.92	0.37	2.19e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.64	-5.67	-0.42	6.93e-8	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.57	-6.43	-0.46	1.59e-9	Lung cancer;
PAAD	cis	rs11113894	0.901	rs11113898	chr12:108851656	C/T	cg06834313	chr12:108851556	NA	-0.77	-4.31	-0.33	2.92e-5	Obesity-related traits;
PAAD	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.47	-4.43	-0.34	1.81e-5	Tonsillectomy;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg18279126	chr7:2041391	MAD1L1	0.56	5.61	0.41	9.26e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg00450029	chr8:599525	NA	-0.87	-5.58	-0.41	1.06e-7	IgG glycosylation;
PAAD	cis	rs2252790	0.930	rs1204860	chr6:116588606	G/A	cg18764771	chr6:116381957	FRK	-0.27	-4.48	-0.34	1.45e-5	Fast beta electroencephalogram;
PAAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.73	-7.15	-0.5	3.4e-11	Paraoxonase activity;
PAAD	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.61	-5.83	-0.43	3.14e-8	Subjective well-being;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg03808351	chr9:123631620	PHF19	0.45	4.88	0.37	2.65e-6	Rheumatoid arthritis;
PAAD	cis	rs11264799	0.639	rs1016849	chr1:157764964	C/T	cg18268488	chr1:157545234	FCRL4	0.56	4.95	0.37	1.96e-6	IgA nephropathy;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01114163	chr5:1856713	NA	-0.42	-4.43	-0.34	1.78e-5	Cardiovascular disease risk factors;
PAAD	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.53	-5.97	-0.44	1.62e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg21951975	chr1:209979733	IRF6	0.61	5.52	0.41	1.41e-7	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg08439880	chr3:133502540	NA	0.41	4.33	0.33	2.74e-5	Iron status biomarkers;
PAAD	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg11266682	chr4:10021025	SLC2A9	0.51	4.39	0.34	2.14e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03668495	chr12:53473478	SPRYD3	0.62	7.06	0.5	5.45e-11	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.62	-7.64	-0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14180030	chr9:123475675	MEGF9	-0.4	-4.47	-0.34	1.5e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.54	-5.87	-0.43	2.63e-8	Monocyte percentage of white cells;
PAAD	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg15128208	chr22:42549153	NA	0.52	4.33	0.33	2.66e-5	Birth weight;
PAAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg09835421	chr16:68378352	PRMT7	-1.07	-7.74	-0.53	1.3e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs950037	0.710	rs786911	chr1:89265248	T/C	cg13109106	chr1:89333529	GTF2B	-0.45	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.52e-7	Recalcitrant atopic dermatitis;
PAAD	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.95	11.38	0.68	4.34e-22	Primary sclerosing cholangitis;
PAAD	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.52	4.61	0.35	8.65e-6	Acylcarnitine levels;
PAAD	cis	rs496300	0.691	rs535024	chr21:44794374	A/G	cg25526717	chr21:45719687	PFKL	0.46	4.3	0.33	3.02e-5	Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14680303	chr17:29059049	SUZ12P	0.63	6.5	0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.66	6.48	0.47	1.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-7.38	-0.51	9.4e-12	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.69	6.89	0.49	1.4e-10	Coronary artery disease;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.41	0.82	5.02e-38	Prudent dietary pattern;
PAAD	cis	rs3736485	0.966	rs7173880	chr15:51785433	C/A	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.25	4.27	0.33	3.39e-5	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.52	6.63	0.47	5.66e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs950027	0.967	rs3120975	chr15:45745125	T/C	cg14582100	chr15:45693742	SPATA5L1	0.33	4.34	0.33	2.61e-5	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4509693	0.882	rs7911997	chr10:102492380	A/G	cg24179445	chr10:102496915	NA	0.53	5.6	0.41	9.57e-8	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.65	6.97	0.49	9.28e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3112530	1.000	rs186183	chr5:152723560	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.75	6.16	0.45	6.16e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.67	6.11	0.44	7.87e-9	Platelet count;
PAAD	cis	rs7833787	0.770	rs4921966	chr8:18698418	G/T	cg17701159	chr8:18705777	PSD3	-0.4	-4.62	-0.35	8.05e-6	Obesity-related traits;
PAAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.61	5.85	0.43	2.95e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs900145	0.823	rs4757140	chr11:13300540	G/T	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.89	-0.43	2.36e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg16606324	chr3:10149918	C3orf24	0.64	4.87	0.37	2.83e-6	Alzheimer's disease;
PAAD	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-7.97	-0.54	3.57e-13	Coffee consumption (cups per day);
PAAD	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.69	6.65	0.47	5.04e-10	Bone mineral density (hip);Bone mineral density (spine);
PAAD	cis	rs818427	0.896	rs455412	chr5:112224389	G/T	cg07820702	chr5:112228657	REEP5	-0.52	-4.67	-0.35	6.53e-6	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15607277	chr11:1312923	TOLLIP	0.56	6.79	0.48	2.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg04721828	chr11:48285200	OR4X1	-0.47	-5.77	-0.42	4.24e-8	Migraine - clinic-based;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.47	0.41	1.79e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.03	-0.44	1.21e-8	Schizophrenia;
PAAD	cis	rs11172134	0.508	rs7398426	chr12:57576370	A/C	cg01515074	chr12:57585135	LRP1	0.48	4.52	0.34	1.21e-5	Urate levels in overweight individuals;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.44	0.61	6.15e-17	Platelet count;
PAAD	cis	rs2885056	0.891	rs1821281	chr19:10692860	C/T	cg04833646	chr19:10679720	CDKN2D	0.94	9.15	0.6	3.53e-16	Red cell distribution width;
PAAD	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg00277334	chr10:82204260	NA	-0.54	-5.61	-0.41	9.34e-8	Post bronchodilator FEV1;
PAAD	cis	rs13102973	0.965	rs11731021	chr4:135850391	G/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16325394	chr5:422633	AHRR	0.64	6.44	0.46	1.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.33	0.46	2.64e-9	Morning vs. evening chronotype;
PAAD	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.71	7.62	0.53	2.48e-12	Menarche (age at onset);
PAAD	cis	rs1799810	0.899	rs7599210	chr2:128164177	G/A	cg09760422	chr2:128146352	NA	0.52	9.49	0.61	4.61e-17	Self-rated health;
PAAD	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg03934865	chr2:198174659	NA	-0.45	-4.37	-0.33	2.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.47	4.86	0.37	2.89e-6	Longevity;Endometriosis;
PAAD	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.62	8.24	0.56	7.25e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00864171	chr11:67383662	NA	0.52	5.26	0.39	4.76e-7	Mean corpuscular volume;
PAAD	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	10.67	0.65	3.54e-20	Primary sclerosing cholangitis;
PAAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.08	-0.38	1.09e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.76	-4.35	-0.33	2.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.35e-10	Monocyte count;
PAAD	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg08523384	chr5:141488047	NDFIP1	-0.63	-5.83	-0.43	3.16e-8	Crohn's disease;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.93	-7.23	-0.51	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.46	0.46	1.31e-9	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.47	6.94	0.49	1.06e-10	Information processing speed;
PAAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.68	-6.95	-0.49	1.03e-10	Schizophrenia;
PAAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg17366294	chr4:99064904	C4orf37	-0.49	-5.3	-0.4	3.94e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg23216685	chr1:86174607	ZNHIT6	-0.31	-4.62	-0.35	7.98e-6	Urate levels in overweight individuals;
PAAD	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-5.45	-0.4	1.96e-7	Coffee consumption (cups per day);
PAAD	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-1.03	-12.18	-0.7	3.05e-24	Breast cancer;
PAAD	cis	rs57244997	0.725	rs7742640	chr6:162413624	T/C	cg17173639	chr6:162384350	PARK2	-0.6	-4.48	-0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.95	9.43	0.61	6.53e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg11619707	chr19:22235551	ZNF257	-0.58	-5.82	-0.43	3.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.65	-7.45	-0.52	6.44e-12	Alcohol dependence;
PAAD	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.5	4.94	0.37	2.06e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg08501292	chr6:25962987	TRIM38	0.83	4.65	0.35	7.31e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.74	-6.38	-0.46	2.04e-9	Diastolic blood pressure;
PAAD	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.64	-5.33	-0.4	3.42e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs734999	0.967	rs10910089	chr1:2498618	G/T	cg20673091	chr1:2541236	MMEL1	0.71	7.6	0.52	2.86e-12	Ulcerative colitis;
PAAD	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.72	8.0	0.54	2.9e-13	Mood instability;
PAAD	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	1.09	12.42	0.71	6.62e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.69	9.23	0.6	2.24e-16	Hemoglobin concentration;
PAAD	cis	rs6256	1.000	rs78828031	chr11:13574150	T/A	cg11976911	chr11:13509032	NA	-0.65	-5.06	-0.38	1.22e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs7631605	0.875	rs56180213	chr3:37109633	C/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg20582800	chr6:43612764	RSPH9	-0.56	-4.47	-0.34	1.54e-5	Blood protein levels;
PAAD	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.46	4.72	0.36	5.26e-6	Corneal astigmatism;
PAAD	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg04554929	chr8:105342491	NA	0.43	7.19	0.5	2.8e-11	Paget's disease;
PAAD	cis	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg19987611	chr2:102090791	RFX8	0.66	5.47	0.41	1.81e-7	Blood protein levels;
PAAD	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.54	5.51	0.41	1.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28489187	0.558	rs6576763	chr1:85859376	T/C	cg16011679	chr1:85725395	C1orf52	-0.51	-4.83	-0.36	3.33e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.55	-5.67	-0.42	6.99e-8	Iron status biomarkers;
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg11673840	chr17:47092156	IGF2BP1	-0.57	-7.5	-0.52	4.95e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg04989185	chr8:9790928	NA	-0.36	-4.37	-0.33	2.32e-5	Recombination measurement;
PAAD	cis	rs2790216	1.000	rs1199095	chr10:59950760	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21735344	chr14:102553260	HSP90AA1	0.62	7.39	0.51	9.16e-12	Metabolite levels  (X-11787);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21066448	chr20:60961605	RPS21	0.69	6.81	0.48	2.13e-10	Obesity-related traits;
PAAD	cis	rs12311304	1.000	rs1479405	chr12:15387519	C/T	cg08258403	chr12:15378311	NA	0.37	4.69	0.36	6.08e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs72627123	1.000	rs59363432	chr14:74397545	T/C	cg19860245	chr14:74300557	NA	-0.74	-5.4	-0.4	2.55e-7	Morning vs. evening chronotype;
PAAD	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.39	-0.34	2.07e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.84	0.49	1.78e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.46	-4.83	-0.36	3.29e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.74	7.43	0.52	7.51e-12	Corneal astigmatism;
PAAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12304921	1.000	rs12318464	chr12:51357346	G/A	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs1865721	0.728	rs67357037	chr18:73219024	G/T	cg26385618	chr18:73139727	C18orf62	-0.45	-5.25	-0.39	4.98e-7	Intelligence;
PAAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg15571903	chr15:79123663	NA	0.39	4.79	0.36	3.91e-6	Coronary artery disease;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01765077	chr12:122356316	WDR66	0.59	6.76	0.48	2.71e-10	Mean corpuscular volume;
PAAD	cis	rs72960926	0.744	rs11755740	chr6:74934131	C/T	cg03266952	chr6:74778945	NA	-1.11	-6.27	-0.45	3.47e-9	Metabolite levels (MHPG);
PAAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19784903	chr17:45786737	TBKBP1	0.52	5.56	0.41	1.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4321325	0.733	rs111245735	chr2:127942522	A/C	cg11380483	chr2:127933992	NA	0.7	5.19	0.39	6.75e-7	Protein C levels;
PAAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07395648	chr5:131743802	NA	0.5	4.54	0.35	1.14e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.5	-5.43	-0.4	2.15e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-10.1	-0.63	1.14e-18	Vitiligo;
PAAD	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.72	7.19	0.5	2.76e-11	Schizophrenia;
PAAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.85e-10	Glomerular filtration rate;
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg21625146	chr5:486483	SLC9A3	-0.42	-5.23	-0.39	5.5e-7	Cystic fibrosis severity;
PAAD	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.66	6.8	0.48	2.22e-10	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg09796270	chr17:17721594	SREBF1	0.43	5.03	0.38	1.37e-6	Total body bone mineral density;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-4.37	-0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03670153	chr3:184079754	CLCN2;POLR2H	0.63	7.21	0.5	2.49e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62025270	0.632	rs62022915	chr15:86213596	G/A	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.7e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.38	-4.81	-0.36	3.63e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.93	0.59	1.33e-15	Lung cancer;
PAAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.38	-0.4	2.75e-7	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19933343	chr17:71241372	C17orf80	-0.54	-6.62	-0.47	5.68e-10	Monocyte percentage of white cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07265985	chr2:220432066	OBSL1	0.58	6.61	0.47	6.03e-10	Body fat percentage;
PAAD	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.92	12.25	0.7	2.01e-24	Body mass index;
PAAD	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg22153407	chr1:230290089	GALNT2	0.5	5.19	0.39	6.61e-7	Coronary artery disease;
PAAD	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg24375607	chr4:120327624	NA	0.53	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs6137287	0.889	rs4813413	chr20:21133072	A/C	cg04219410	chr20:21106687	PLK1S1	0.38	4.39	0.34	2.14e-5	Height;
PAAD	cis	rs2229238	0.823	rs61275241	chr1:154504887	T/G	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs9810890	1.000	rs73207974	chr3:128568455	T/C	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs71496607	chr10:46010316	C/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.62	-0.47	5.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01091698	chr22:43089915	A4GALT	-0.74	-7.82	-0.54	8.24e-13	Obesity-related traits;
PAAD	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.8	-7.39	-0.51	8.88e-12	Neurofibrillary tangles;
PAAD	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	8.55	0.57	1.24e-14	Electrocardiographic conduction measures;
PAAD	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.89	11.11	0.67	2.35e-21	Prudent dietary pattern;
PAAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg14343924	chr8:8086146	FLJ10661	0.56	4.92	0.37	2.21e-6	Mood instability;
PAAD	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg15128208	chr22:42549153	NA	-0.43	-4.27	-0.33	3.41e-5	Cognitive function;
PAAD	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.42	-4.35	-0.33	2.46e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs10392	0.850	rs73110606	chr20:37537178	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.64	-4.81	-0.36	3.66e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.86	9.7	0.62	1.33e-17	Metabolic syndrome;
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73019876	0.869	rs4574045	chr19:22171880	C/T	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs10267417	0.603	rs4593428	chr7:19864061	T/A	cg05791153	chr7:19748676	TWISTNB	0.74	5.0	0.38	1.55e-6	Night sleep phenotypes;
PAAD	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.99	11.66	0.69	7.52e-23	Breast cancer;
PAAD	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg19401529	chr3:49056140	DALRD3	0.52	4.37	0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.35e-19	Bone mineral density;
PAAD	cis	rs2302729	0.625	rs10848693	chr12:2833013	A/T	cg19945202	chr12:2788847	CACNA1C	0.59	4.64	0.35	7.32e-6	Sleep quality;
PAAD	cis	rs2249694	0.520	rs7095996	chr10:135328948	G/A	cg20169779	chr10:135381914	SYCE1	-0.54	-4.38	-0.33	2.2e-5	Obesity-related traits;
PAAD	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg07929629	chr2:241523174	NA	0.63	5.34	0.4	3.29e-7	Bipolar disorder;
PAAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg10645314	chr2:3704589	ALLC	-0.55	-5.76	-0.42	4.43e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-1.06	-7.55	-0.52	3.73e-12	IgG glycosylation;
PAAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.51	5.22	0.39	5.73e-7	Menopause (age at onset);
PAAD	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.68	-7.33	-0.51	1.25e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	0.9	5.46	0.4	1.91e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg05927578	chr16:4029543	ADCY9	0.68	5.63	0.42	8.27e-8	Waist circumference;
PAAD	trans	rs9409082	0.627	rs28498727	chr9:108933214	A/G	cg07010948	chr13:79181613	NA	-0.35	-6.72	-0.48	3.38e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.92	10.5	0.65	9.94e-20	Total cholesterol levels;
PAAD	trans	rs11794666	0.929	rs72719215	chr9:31774127	G/A	cg05628366	chr6:35744188	C6orf126	1.16	7.73	0.53	1.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg27494647	chr7:150038898	RARRES2	0.42	4.27	0.33	3.38e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.79	8.85	0.58	2.07e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	1.06	13.46	0.74	1.09e-27	Breast cancer;
PAAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.78	-0.36	4.09e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.59	8.17	0.55	1.14e-13	Primary biliary cholangitis;
PAAD	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.26	-0.33	3.52e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg00277334	chr10:82204260	NA	-0.55	-5.59	-0.41	1.01e-7	Post bronchodilator FEV1;
PAAD	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg10006428	chr1:248814059	OR2T27	0.42	4.93	0.37	2.14e-6	Common traits (Other);
PAAD	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10508264	0.623	rs2171302	chr10:3815292	A/G	cg05513583	chr10:3829456	NA	0.41	4.26	0.33	3.51e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg15117754	chr3:10150083	C3orf24	0.67	5.6	0.41	9.66e-8	Alzheimer's disease;
PAAD	cis	rs10958605	0.761	rs2980820	chr8:40028438	A/G	cg14545590	chr8:40388592	ZMAT4	0.42	4.59	0.35	9.12e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg25204440	chr1:209979598	IRF6	-0.55	-4.83	-0.36	3.37e-6	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03387256	chr10:90750898	FAS;ACTA2	0.62	6.86	0.49	1.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.79	-7.38	-0.51	9.81e-12	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.71	-7.82	-0.54	8.36e-13	Age at first birth;
PAAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg27417659	chr7:98567827	TRRAP	-0.47	-4.41	-0.34	1.92e-5	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.01	-0.49	7.34e-11	Gut microbiome composition (summer);
PAAD	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.56	-5.95	-0.43	1.74e-8	Body mass index;
PAAD	trans	rs901683	1.000	rs71496622	chr10:46081588	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1419980	0.730	rs7134366	chr12:7737315	G/A	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9715521	0.646	rs6819464	chr4:59841935	T/C	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.84	-0.54	7.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.44	4.5	0.34	1.35e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12292205	chr6:26970375	C6orf41	-0.54	-5.44	-0.4	2.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.56	5.54	0.41	1.28e-7	Breast cancer;
PAAD	cis	rs73416724	0.544	rs111739263	chr6:43243151	G/T	cg17076780	chr6:43251928	TTBK1	0.7	5.79	0.43	3.82e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg14686297	chr22:46650375	NA	-0.48	-4.89	-0.37	2.55e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-8.66	-0.57	6.49e-15	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05010219	chr10:134210111	PWWP2B	0.58	6.64	0.47	5.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs42648	0.564	rs7777651	chr7:89822344	G/A	cg27367526	chr7:89841692	STEAP2	-0.32	-4.49	-0.34	1.42e-5	Homocysteine levels;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.59e-8	Height;
PAAD	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.71	-6.74	-0.48	3.04e-10	Neuroticism;
PAAD	cis	rs7534824	0.625	rs17449022	chr1:101442367	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.8	8.54	0.57	1.32e-14	Calcium levels;
PAAD	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.53	5.4	0.4	2.51e-7	Resting heart rate;
PAAD	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.8	-9.18	-0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.76	-0.48	2.75e-10	Depression;
PAAD	cis	rs7707921	0.881	rs57621982	chr5:81406770	C/T	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.29	0.6	1.53e-16	Total body bone mineral density;
PAAD	cis	rs8105895	0.935	rs10411275	chr19:22259469	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.67	6.4	0.46	1.83e-9	Subjective well-being;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	5.96	0.44	1.7e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19337854	chr7:99768885	GPC2	-0.45	-4.79	-0.36	3.98e-6	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.77	7.27	0.51	1.81e-11	Corneal astigmatism;
PAAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg04398451	chr17:18023971	MYO15A	0.75	7.96	0.54	3.69e-13	Total body bone mineral density;
PAAD	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.7	6.02	0.44	1.26e-8	Interstitial lung disease;
PAAD	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg17771515	chr6:154831774	CNKSR3	0.62	4.33	0.33	2.72e-5	Lipoprotein (a) levels;
PAAD	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.48	4.51	0.34	1.28e-5	Alcohol and nicotine co-dependence;
PAAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.68	-6.41	-0.46	1.69e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.48	-4.69	-0.36	6.12e-6	Breast cancer;
PAAD	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.64	-5.95	-0.43	1.8e-8	Cognitive test performance;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.29	0.39	4.27e-7	IgG glycosylation;
PAAD	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs2120243	0.539	rs4640512	chr3:157120066	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs282587	0.502	rs375741	chr13:113397794	G/C	cg04656015	chr13:113407548	ATP11A	0.54	4.32	0.33	2.85e-5	Glycated hemoglobin levels;
PAAD	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg10072921	chr12:121022843	NA	-0.38	-5.01	-0.38	1.47e-6	High light scatter reticulocyte count;
PAAD	cis	rs1499972	0.887	rs1499970	chr3:117692767	G/A	cg07612923	chr3:117604196	NA	-1.09	-7.27	-0.51	1.8e-11	Schizophrenia;
PAAD	trans	rs901683	1.000	rs34516867	chr10:46081737	T/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.61	-5.51	-0.41	1.53e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.58	-0.35	9.8e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.46	4.48	0.34	1.47e-5	Response to statin therapy;
PAAD	cis	rs7551345	0.853	rs12139997	chr1:31837089	T/C	cg17086398	chr1:31896392	SERINC2	-0.54	-4.56	-0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.3e-6	Height;
PAAD	cis	rs10450586	0.932	rs10742175	chr11:27333897	G/C	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs509477	0.851	rs1941751	chr18:32577017	G/A	cg23791764	chr18:32556832	MAPRE2	-0.6	-5.03	-0.38	1.36e-6	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs7264396	0.887	rs750487	chr20:34066645	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.8	-0.43	3.7e-8	Total cholesterol levels;
PAAD	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.63	-8.06	-0.55	2.05e-13	Breast cancer;
PAAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.36	-0.4	3.01e-7	Mood instability;
PAAD	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.89	0.43	2.35e-8	Eosinophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.48e-14	Renal cell carcinoma;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg17105886	chr17:28927953	LRRC37B2	0.77	5.01	0.38	1.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06186877	chr10:88198874	WAPAL	-0.67	-7.22	-0.51	2.29e-11	Obesity-related traits;
PAAD	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.54	4.39	0.34	2.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.46	5.02	0.38	1.42e-6	Diastolic blood pressure;
PAAD	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg13535736	chr9:111863775	C9orf5	-0.36	-4.45	-0.34	1.66e-5	Menarche (age at onset);
PAAD	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg27094323	chr7:1216898	NA	-0.53	-5.97	-0.44	1.63e-8	Longevity;Endometriosis;
PAAD	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.94	-8.27	-0.56	6.39e-14	Strep throat;
PAAD	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-6.25	-0.45	3.84e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	1.04	6.49	0.47	1.14e-9	Major depressive disorder;
PAAD	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs988913	0.581	rs1108888	chr6:54857288	C/T	cg03513858	chr6:54763001	FAM83B	0.42	4.72	0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg25319279	chr11:5960081	NA	-0.53	-5.62	-0.42	8.68e-8	DNA methylation (variation);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12846938	chr19:14640140	MIR639;TECR	-0.64	-6.59	-0.47	6.94e-10	Smoking initiation;
PAAD	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.93	0.49	1.13e-10	Systolic blood pressure;
PAAD	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.68e-5	Total body bone mineral density;
PAAD	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.62	6.48	0.47	1.18e-9	Resting heart rate;
PAAD	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-0.66	-6.99	-0.49	8.33e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	10.72	0.66	2.48e-20	Menopause (age at onset);
PAAD	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs7577599	0.618	rs6746082	chr2:25659244	G/T	cg23192403	chr2:25781496	DTNB	0.27	4.45	0.34	1.64e-5	Multiple myeloma (IgH translocation);Multiple myeloma;
PAAD	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs72772090	0.539	rs56395748	chr5:96176893	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.69	-0.48	4.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9677476	0.657	rs11897387	chr2:232122576	T/C	cg07929768	chr2:232055508	NA	0.38	4.69	0.36	6.04e-6	Food antigen IgG levels;
PAAD	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.53	5.61	0.41	9.38e-8	Height;
PAAD	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg22875332	chr1:76189707	ACADM	-0.47	-4.73	-0.36	5.1e-6	Daytime sleep phenotypes;
PAAD	cis	rs7804356	0.822	rs6971397	chr7:26782564	C/T	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.95	0.43	1.79e-8	Prudent dietary pattern;
PAAD	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg16434002	chr17:42200994	HDAC5	0.64	5.98	0.44	1.57e-8	Total body bone mineral density;
PAAD	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	1.03	5.25	0.39	4.98e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs6466055	0.661	rs67180946	chr7:104828926	T/A	cg04380332	chr7:105027541	SRPK2	0.51	4.99	0.38	1.6e-6	Schizophrenia;
PAAD	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-7.98	-0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs842828	0.605	rs3769464	chr2:201216280	C/T	cg26842802	chr2:202125212	CASP8	-0.79	-4.72	-0.36	5.21e-6	Urate levels in lean individuals;
PAAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs950881	0.932	rs10179458	chr2:102934974	C/T	cg20060108	chr2:102954350	IL1RL1	0.59	4.62	0.35	8.24e-6	Allergy;
PAAD	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.57	6.1	0.44	8.57e-9	Bladder cancer;
PAAD	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg09658497	chr7:2847517	GNA12	-0.45	-4.53	-0.34	1.18e-5	Height;
PAAD	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.78	7.38	0.51	9.47e-12	Corneal astigmatism;
PAAD	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.31	0.46	2.84e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.55	5.54	0.41	1.31e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.44	-5.15	-0.39	8.12e-7	Colorectal cancer;
PAAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.93	-5.9	-0.43	2.31e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9662662	1	rs9662662	chr1:159519143	C/T	cg13968061	chr1:159557257	APCS	-0.41	-4.28	-0.33	3.23e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.81	-5.18	-0.39	6.95e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.82	-0.43	3.37e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	4.47	0.34	1.49e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01263691	chr6:52535928	TMEM14A	0.62	7.05	0.5	5.9e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13560548	chr3:10150139	C3orf24	0.63	5.71	0.42	5.79e-8	Alzheimer's disease;
PAAD	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg24220031	chr2:73402428	NA	-0.43	-6.73	-0.48	3.27e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	8.32	0.56	4.74e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs17125944	0.615	rs4901301	chr14:53306485	C/T	cg00686598	chr14:53173677	PSMC6	-0.9	-5.61	-0.41	9.21e-8	Alzheimer's disease (late onset);
PAAD	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.68	-8.31	-0.56	5e-14	Rheumatoid arthritis;
PAAD	cis	rs2004318	1.000	rs78192819	chr19:55080918	G/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.86	7.17	0.5	3.03e-11	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18337826	chr14:77495180	C14orf4	-0.84	-7.61	-0.53	2.69e-12	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24011030	chr20:37679017	NA	0.62	6.88	0.49	1.45e-10	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.79	-0.36	3.89e-6	Longevity;Endometriosis;
PAAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg10356904	chr22:49881777	NA	-0.47	-4.55	-0.35	1.07e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-1.14	-7.96	-0.54	3.76e-13	IgG glycosylation;
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg27094323	chr7:1216898	NA	-0.4	-4.44	-0.34	1.72e-5	Longevity;Endometriosis;
PAAD	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.52	4.8	0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg12639453	chr1:2035780	PRKCZ	-0.61	-6.49	-0.47	1.14e-9	Height;
PAAD	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	1.14	11.44	0.68	2.9e-22	Corneal structure;
PAAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	7.07	0.5	5.26e-11	Schizophrenia;
PAAD	cis	rs12286929	0.661	rs7947402	chr11:115088420	T/C	cg04055981	chr11:115044050	NA	0.47	4.59	0.35	9.39e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4268898	0.828	rs2702121	chr2:24610392	C/A	cg02683114	chr2:24398427	C2orf84	0.58	5.96	0.44	1.72e-8	Asthma;
PAAD	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg04265051	chr11:68079686	LRP5	-0.37	-4.62	-0.35	8.25e-6	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.47	0.71	5.05e-25	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.06	-0.5	5.42e-11	Vitiligo;
PAAD	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.59	-6.01	-0.44	1.32e-8	Glioblastoma;
PAAD	cis	rs798766	0.903	rs811316	chr4:1689377	T/C	cg01305830	chr4:1604576	NA	-0.46	-4.42	-0.34	1.83e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.72	-7.2	-0.5	2.57e-11	Retinal vascular caliber;
PAAD	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.79e-7	Blood metabolite levels;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg11843238	chr5:131593191	PDLIM4	0.5	4.65	0.35	7.25e-6	Acylcarnitine levels;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-1.3	-12.63	-0.72	1.88e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.94	9.94	0.63	2.94e-18	Alcohol dependence;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22296756	chr2:240305369	HDAC4	0.56	6.44	0.46	1.48e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg03060546	chr3:49711283	APEH	0.53	4.59	0.35	9.08e-6	Menarche (age at onset);
PAAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.52	5.45	0.4	2.03e-7	Menopause (age at onset);
PAAD	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	cis	rs7537660	1.000	rs7537660	chr1:248006764	C/T	cg08944170	chr1:248100614	OR2L13	-0.47	-4.28	-0.33	3.27e-5	Platelet distribution width;
PAAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	1.01	10.63	0.65	4.54e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.93	0.59	1.28e-15	Motion sickness;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10644772	chr12:123237461	DENR	-0.72	-7.27	-0.51	1.72e-11	Smoking initiation;
PAAD	cis	rs72960926	1.000	rs72958996	chr6:75131378	A/G	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg19637330	chr1:19110922	NA	0.64	5.38	0.4	2.76e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.58	5.46	0.41	1.87e-7	Schizophrenia;
PAAD	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.49	4.43	0.34	1.81e-5	Sudden cardiac arrest;
PAAD	cis	rs829661	0.947	rs829646	chr2:30719326	T/C	cg12454169	chr2:30669597	LCLAT1	0.64	4.86	0.37	2.87e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.54	-5.37	-0.4	2.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs9657904	0.865	rs12636287	chr3:105598424	C/T	cg16975614	chr3:105601834	NA	-0.46	-4.62	-0.35	7.98e-6	Multiple sclerosis;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.02e-20	Prudent dietary pattern;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs10804591	1.000	rs4688808	chr3:129339003	A/G	cg18548199	chr3:129281892	PLXND1	0.54	4.6	0.35	8.67e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	0.97	5.6	0.41	9.64e-8	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
PAAD	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01250320	chr2:18742004	RDH14	0.7	6.31	0.46	2.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.81	-9.12	-0.59	4.16e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.48	4.33	0.33	2.75e-5	Joint mobility (Beighton score);
PAAD	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg24466277	chr1:23519622	HTR1D	-0.56	-5.19	-0.39	6.78e-7	Height;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg04258457	chr17:62207789	ERN1	0.62	6.98	0.49	8.51e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7127900	0.950	rs7395734	chr11:2231694	C/T	cg25635251	chr11:2234043	NA	0.85	7.58	0.52	3.18e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg00857998	chr1:205179979	DSTYK	0.52	5.23	0.39	5.58e-7	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
PAAD	cis	rs2594989	0.733	rs2616538	chr3:11581076	G/T	cg02835301	chr3:11609216	VGLL4	-0.47	-4.43	-0.34	1.81e-5	Circulating chemerin levels;
PAAD	cis	rs939584	0.935	rs6735049	chr2:630569	T/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-1.06	-9.91	-0.63	3.69e-18	Colorectal cancer;
PAAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.82	-0.43	3.43e-8	Prostate cancer;
PAAD	cis	rs6604026	0.656	rs2811596	chr1:93341223	A/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11102324	chr15:49658865	C15orf33	0.61	7.11	0.5	4.21e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9650657	0.705	rs4321967	chr8:10641407	C/T	cg21775007	chr8:11205619	TDH	-0.48	-4.38	-0.33	2.22e-5	Neuroticism;
PAAD	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-1.14	-5.87	-0.43	2.6e-8	Inflammatory biomarkers;
PAAD	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg14703610	chr5:56206110	C5orf35	0.62	5.51	0.41	1.48e-7	Coronary artery disease;
PAAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.92	0.49	1.16e-10	Menarche (age at onset);
PAAD	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	0.79	5.34	0.4	3.28e-7	Body mass index;
PAAD	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg02466173	chr16:30829666	NA	0.56	4.58	0.35	9.78e-6	Dementia with Lewy bodies;
PAAD	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.77	-0.36	4.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs758324	0.812	rs13170176	chr5:131138736	G/C	cg06307176	chr5:131281290	NA	0.52	4.58	0.35	9.72e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg02135003	chr7:105160482	PUS7	-0.72	-5.92	-0.43	2.04e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1539053	1.000	rs1539053	chr1:58099707	A/G	cg20292791	chr1:58089357	DAB1	-0.54	-5.28	-0.39	4.3e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs10829156	1.000	rs10829157	chr10:18951463	G/A	cg03282336	chr10:18947857	ARL5B	-0.56	-4.27	-0.33	3.38e-5	Sudden cardiac arrest;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg15117754	chr3:10150083	C3orf24	0.75	6.74	0.48	3.09e-10	Alzheimer's disease;
PAAD	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg01851573	chr8:8652454	MFHAS1	-0.39	-4.29	-0.33	3.2e-5	Joint mobility (Beighton score);
PAAD	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.68	-0.35	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg12215294	chr3:40350768	EIF1B	0.43	4.38	0.33	2.2e-5	Renal cell carcinoma;
PAAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.4	4.5	0.34	1.35e-5	High light scatter reticulocyte count;
PAAD	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.78	8.85	0.58	2.07e-15	Morning vs. evening chronotype;
PAAD	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1371614	0.635	rs34803465	chr2:27138285	G/A	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13826154	chr19:45754942	MARK4	0.43	4.26	0.33	3.55e-5	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.74	7.57	0.52	3.3e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08408316	chr13:39612443	NHLRC3;C13orf23	0.59	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg16579770	chr16:72058938	DHODH	0.39	4.54	0.35	1.15e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25244628	chr11:65381814	MAP3K11	-0.75	-6.66	-0.48	4.75e-10	Neuroticism;
PAAD	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.6	-5.79	-0.43	3.85e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.5	-0.47	1.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs5771225	0.505	rs5771111	chr22:50695946	C/G	cg08875078	chr22:50639485	SELO	0.5	4.3	0.33	3.09e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs6445967	1.000	rs7640866	chr3:58288362	A/G	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-6.93	-0.49	1.13e-10	Coronary artery disease;
PAAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.23	-0.39	5.43e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2072732	0.656	rs113272167	chr1:2954051	C/T	cg22517653	chr1:2918612	NA	-0.61	-4.88	-0.37	2.6e-6	Plateletcrit;
PAAD	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	1.09	6.83	0.48	1.88e-10	Skin colour saturation;
PAAD	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg01334972	chr11:72463230	ARAP1	0.55	4.25	0.33	3.72e-5	Type 2 diabetes;
PAAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg17810781	chr1:201082982	CACNA1S	0.46	5.53	0.41	1.38e-7	Permanent tooth development;
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg15247247	chr7:4802535	FOXK1	-0.92	-4.66	-0.35	6.87e-6	Borderline personality disorder;
PAAD	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.61	5.8	0.43	3.75e-8	Macular telangiectasia type 2;
PAAD	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-9.96	-0.63	2.73e-18	Height;
PAAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.47	4.87	0.37	2.81e-6	Major depressive disorder;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03501777	chr10:45869613	ALOX5	0.57	6.38	0.46	2.02e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	6.63	0.47	5.39e-10	Schizophrenia;
PAAD	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg00806126	chr19:22604979	ZNF98	-0.4	-5.15	-0.39	8.07e-7	Pain;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	trans	rs889956	0.729	rs12612912	chr2:57210018	A/G	cg20058506	chr2:72013035	NA	0.55	7.21	0.5	2.52e-11	Educational attainment;
PAAD	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg05228244	chr10:1102351	WDR37	-0.88	-4.38	-0.33	2.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg25790453	chr13:113633590	MCF2L	-0.4	-4.75	-0.36	4.66e-6	Systolic blood pressure;
PAAD	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.46	5.97	0.44	1.62e-8	Renal cell carcinoma;
PAAD	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.81	-0.79	6.49e-34	Schizophrenia;
PAAD	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.73	-6.71	-0.48	3.63e-10	Primary sclerosing cholangitis;
PAAD	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg10183150	chr4:120222239	C4orf3	-0.37	-5.2	-0.39	6.47e-7	Corneal astigmatism;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg01262667	chr19:19385393	TM6SF2	0.46	5.2	0.39	6.23e-7	Tonsillectomy;
PAAD	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7264396	0.887	rs2236165	chr20:34096725	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg06375148	chr1:209958343	C1orf74	0.65	5.05	0.38	1.24e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07362569	chr17:61921086	SMARCD2	0.61	7.63	0.53	2.34e-12	Prudent dietary pattern;
PAAD	cis	rs12935418	0.616	rs62054239	chr16:81000184	G/T	cg16651780	chr16:81037892	C16orf61	0.57	4.69	0.36	5.99e-6	Mean corpuscular volume;
PAAD	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14933899	chr2:242041835	MTERFD2	-0.68	-6.96	-0.49	9.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs732765	0.734	rs35461658	chr14:75207264	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12754538	0.922	rs12045438	chr1:8485904	T/C	cg06159269	chr1:8767347	RERE	0.38	4.6	0.35	8.84e-6	Subjective well-being;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.49	-0.52	5.32e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg08898775	chr15:59042684	ADAM10	0.38	4.95	0.37	1.91e-6	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg14515779	chr1:101123966	NA	0.39	4.31	0.33	2.88e-5	Monocyte count;
PAAD	cis	rs17135859	0.904	rs66580212	chr5:113002078	A/G	cg12552261	chr5:112820674	MCC	0.69	4.55	0.35	1.08e-5	F-cell distribution;
PAAD	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.73	8.2	0.55	9.14e-14	Schizophrenia;
PAAD	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.47	4.58	0.35	9.64e-6	Lewy body disease;
PAAD	cis	rs909341	0.909	rs2253829	chr20:62373079	G/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.59	-4.98	-0.37	1.7e-6	Atopic dermatitis;
PAAD	cis	rs6466055	0.720	rs1204058	chr7:104958129	T/G	cg04380332	chr7:105027541	SRPK2	0.64	7.33	0.51	1.3e-11	Schizophrenia;
PAAD	cis	rs35160687	0.712	rs11691807	chr2:86483021	C/T	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13560548	chr3:10150139	C3orf24	0.6	5.48	0.41	1.74e-7	Alzheimer's disease;
PAAD	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg04415270	chr2:102091202	RFX8	-0.67	-8.51	-0.57	1.59e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	0.91	10.26	0.64	4.33e-19	Schizophrenia;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.46	4.71	0.36	5.65e-6	Eosinophil percentage of white cells;
PAAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs6782025	0.752	rs1683982	chr3:120664459	T/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22601191	chr20:60968625	CABLES2	0.64	5.47	0.41	1.78e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.85	-10.3	-0.64	3.31e-19	Monocyte percentage of white cells;
PAAD	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18898632	chr2:242989856	NA	-0.83	-6.69	-0.48	4.09e-10	Obesity-related traits;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22703791	chr19:1479558	C19orf25	0.56	6.41	0.46	1.73e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg24747557	chr10:131355152	MGMT	-0.48	-5.09	-0.38	1.03e-6	Response to temozolomide;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22162314	chr17:61951766	CSH2	0.52	5.2	0.39	6.27e-7	Height;
PAAD	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg20913747	chr6:44695427	NA	-0.72	-7.25	-0.51	1.93e-11	Total body bone mineral density;
PAAD	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.88	10.19	0.64	6.69e-19	Body mass index;
PAAD	cis	rs8070740	0.841	rs2189337	chr17:5326178	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.74	0.36	4.84e-6	Menopause (age at onset);
PAAD	cis	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg05084668	chr3:125655381	ALG1L	-0.54	-5.58	-0.41	1.09e-7	Blood pressure (smoking interaction);
PAAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg23752985	chr2:85803571	VAMP8	-0.58	-6.29	-0.45	3.17e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.94	8.1	0.55	1.66e-13	Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg16342193	chr10:102329863	NA	0.75	8.25	0.56	6.82e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.83	9.21	0.6	2.47e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03123822	chr22:24199866	SLC2A11	0.64	6.44	0.46	1.49e-9	Myopia (pathological);
PAAD	cis	rs12153243	0.714	rs6894302	chr5:142913502	G/A	cg13907255	chr5:142895549	NA	-0.53	-4.87	-0.37	2.8e-6	Migraine;
PAAD	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.73	-6.02	-0.44	1.27e-8	Inhibitory control;
PAAD	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.69	6.77	0.48	2.6e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.85	0.43	2.92e-8	Menopause (age at onset);
PAAD	cis	rs8112211	0.648	rs79590641	chr19:38807541	T/C	cg14299480	chr19:38876666	GGN	-0.54	-4.68	-0.35	6.36e-6	Blood protein levels;
PAAD	cis	rs10793968	0.748	rs7045615	chr9:133605586	A/C	cg01474677	chr9:133586259	NA	-0.56	-4.41	-0.34	1.97e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	8.16e-9	Lung cancer;
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.77	-0.36	4.24e-6	Testicular germ cell tumor;
PAAD	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.88	8.05	0.55	2.2e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg08917208	chr2:24149416	ATAD2B	0.74	5.81	0.43	3.52e-8	Lymphocyte counts;
PAAD	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.62	-6.3	-0.46	3.02e-9	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
PAAD	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.12	0.5	4.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.45	-5.12	-0.38	9.1e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg12757816	chr2:10669957	NA	-0.54	-5.65	-0.42	7.87e-8	Prostate cancer;
PAAD	cis	rs4908768	0.501	rs6577499	chr1:8612104	C/G	cg20416874	chr1:8611966	RERE	0.46	4.43	0.34	1.8e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.48	4.75	0.36	4.72e-6	Menarche (age at onset);
PAAD	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg02683114	chr2:24398427	C2orf84	0.46	4.84	0.37	3.23e-6	Sjögren's syndrome;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2050203	0.534	rs7274643	chr20:24428237	G/A	cg16485975	chr20:25065418	NA	-0.65	-5.12	-0.38	9.26e-7	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
PAAD	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.53	4.76	0.36	4.47e-6	Corneal astigmatism;
PAAD	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg15128208	chr22:42549153	NA	0.49	4.46	0.34	1.56e-5	Birth weight;
PAAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg18888403	chr1:24152774	HMGCL	-0.38	-4.28	-0.33	3.31e-5	Immature fraction of reticulocytes;
PAAD	cis	rs13006833	0.668	rs2664252	chr2:191148347	G/A	cg27211696	chr2:191398769	TMEM194B	0.45	4.54	0.35	1.12e-5	Urinary metabolites;
PAAD	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7301826	0.651	rs12820597	chr12:131280185	T/C	cg11011512	chr12:131303247	STX2	-0.44	-4.5	-0.34	1.34e-5	Plasma plasminogen activator levels;
PAAD	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg10183150	chr4:120222239	C4orf3	-0.35	-4.27	-0.33	3.47e-5	Corneal astigmatism;
PAAD	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs3905706	0.607	rs1937810	chr10:28463950	T/C	cg07483709	chr10:29439573	NA	-0.6	-4.62	-0.35	7.97e-6	Bone mineral density;Bone mineral density (paediatric, skull);
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09256448	chr16:638327	NA	0.42	4.36	0.33	2.37e-5	Height;
PAAD	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg22896917	chr6:28093420	ZSCAN16	-0.36	-4.45	-0.34	1.67e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg12935359	chr14:103987150	CKB	-0.57	-5.98	-0.44	1.54e-8	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13044475	chr13:52976653	THSD1	0.61	6.86	0.49	1.66e-10	Smoking initiation;
PAAD	cis	rs7688540	0.800	rs9328737	chr4:245965	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.7	0.36	5.88e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.63	5.85	0.43	2.92e-8	Type 1 diabetes nephropathy;
PAAD	trans	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg02917381	chr15:37393188	MEIS2	0.64	6.43	0.46	1.6e-9	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
PAAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg08918797	chr8:141566221	EIF2C2	-0.42	-4.33	-0.33	2.65e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.1	-15.13	-0.78	3.9e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs375066	0.935	rs450308	chr19:44422358	C/A	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	trans	rs498136	0.966	rs3903268	chr11:69383988	A/C	cg26613586	chr1:16847289	NA	-0.56	-6.3	-0.46	3.01e-9	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.31	-0.51	1.43e-11	Heart rate;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.79	5.53	0.41	1.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.66	0.48	4.76e-10	Aortic root size;
PAAD	cis	rs4356203	0.870	rs214921	chr11:17237461	C/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs117623576	0.887	rs211411	chr10:32394992	T/C	cg03047570	chr10:32398778	NA	0.79	5.44	0.4	2.09e-7	Anti-saccade response;
PAAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.47	0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.75	-0.42	4.73e-8	Subjective well-being;
PAAD	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg02225085	chr5:87975992	LOC645323	-0.64	-4.64	-0.35	7.31e-6	Body mass index;
PAAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.22e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.71	7.78	0.53	1.01e-12	Corneal astigmatism;
PAAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Depression;
PAAD	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.71	8.06	0.55	2.12e-13	Corneal astigmatism;
PAAD	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.51	-6.57	-0.47	7.57e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg00431813	chr7:1051703	C7orf50	0.49	4.32	0.33	2.77e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.52	-4.3	-0.33	3.04e-5	Gut microbiome composition (summer);
PAAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.91	-11.71	-0.69	5.44e-23	Menopause (age at onset);
PAAD	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg26318627	chr11:63887540	MACROD1	-0.44	-4.34	-0.33	2.57e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.64	-5.83	-0.43	3.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.77	-7.58	-0.52	3.18e-12	Mosquito bite size;
PAAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg19673125	chr6:150240577	RAET1G	0.32	4.32	0.33	2.86e-5	Lung cancer;
PAAD	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.72	-6.67	-0.48	4.56e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06761793	chr1:1550770	MIB2	0.62	6.48	0.47	1.24e-9	Myopia (pathological);
PAAD	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg22532475	chr10:104410764	TRIM8	-0.41	-4.69	-0.36	5.97e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg04844267	chr4:1394941	NA	0.52	5.64	0.42	8e-8	Obesity-related traits;
PAAD	trans	rs12738007	1.000	rs12738007	chr1:29521705	C/T	cg05667379	chr2:115920764	DPP10	0.38	6.3	0.46	3.11e-9	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.43	-4.42	-0.34	1.89e-5	Systemic lupus erythematosus;
PAAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg15145965	chr22:50218605	BRD1	0.57	5.08	0.38	1.1e-6	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.66	7.3	0.51	1.52e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00350441	chr16:57220262	FAM192A;RSPRY1	0.55	6.29	0.45	3.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg14893161	chr1:205819251	PM20D1	0.61	5.95	0.43	1.76e-8	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg15145965	chr22:50218605	BRD1	0.56	4.6	0.35	8.77e-6	Schizophrenia;
PAAD	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.75	8.74	0.58	4.07e-15	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg00522288	chr12:125625016	AACS	-0.42	-4.5	-0.34	1.36e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.17	-0.39	7.23e-7	Mortality in heart failure;
PAAD	cis	rs1190596	0.578	rs35601191	chr14:102742826	T/A	cg23904247	chr14:102554826	HSP90AA1	0.44	5.05	0.38	1.27e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg14349672	chr11:133703707	NA	-0.55	-6.37	-0.46	2.18e-9	Childhood ear infection;
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.71	7.66	0.53	1.98e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	cis	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs2085601	0.518	rs1060693	chr4:89944687	A/C	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs8016947	0.583	rs12879818	chr14:35830938	G/A	cg03549618	chr14:35838977	NA	0.45	4.78	0.36	4.07e-6	Psoriasis;
PAAD	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-4.57	-0.35	9.85e-6	Circulating chemerin levels;
PAAD	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.44	-4.28	-0.33	3.29e-5	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs35585999	chr10:46070159	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6142102	0.961	rs2235596	chr20:32684309	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.58	-0.35	9.46e-6	Skin pigmentation;
PAAD	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg24253500	chr15:84953950	NA	0.41	4.3	0.33	3e-5	Schizophrenia;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01616529	chr11:638424	DRD4	-0.62	-6.02	-0.44	1.28e-8	Systemic lupus erythematosus;
PAAD	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg12082025	chr19:1064218	ABCA7	-0.74	-7.02	-0.49	6.9e-11	Alzheimer's disease (late onset);
PAAD	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.71	9.16	0.6	3.31e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.7	-7.76	-0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7481584	0.924	rs16925010	chr11:3013996	C/T	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.39	4.25	0.33	3.78e-5	Calcium levels;
PAAD	cis	rs10792830	0.640	rs572979	chr11:85803276	C/T	cg07180834	chr11:85838833	NA	-0.56	-6.62	-0.47	5.89e-10	Psychosis and Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.48	-0.34	1.46e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.95	6.22	0.45	4.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2637266	0.783	rs846642	chr10:78522318	A/G	cg18941641	chr10:78392320	NA	-0.38	-4.53	-0.34	1.2e-5	Pulmonary function;
PAAD	cis	rs7202877	0.561	rs7202083	chr16:75383727	G/T	cg03315344	chr16:75512273	CHST6	0.64	4.58	0.35	9.42e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.47	5.07	0.38	1.13e-6	Heart rate;
PAAD	cis	rs66530629	0.874	rs10903104	chr1:25136713	A/G	cg01905478	chr1:25040257	NA	-0.48	-5.31	-0.4	3.81e-7	Plateletcrit;
PAAD	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.66	-0.62	1.62e-17	Blood trace element (Zn levels);
PAAD	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg02951883	chr7:2050386	MAD1L1	0.54	4.99	0.38	1.62e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg23283495	chr1:209979779	IRF6	-0.59	-5.53	-0.41	1.33e-7	Coronary artery disease;
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg07936489	chr17:37558343	FBXL20	-0.54	-4.93	-0.37	2.12e-6	Asthma;
PAAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.29e-5	Renal cell carcinoma;
PAAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.47	4.81	0.36	3.66e-6	Ulcerative colitis;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.73	-0.36	5.07e-6	Alcohol dependence;
PAAD	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.7	7.65	0.53	2.2e-12	Uric acid levels;
PAAD	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	1.06	14.9	0.77	1.56e-31	Body mass index (adult);
PAAD	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg17551891	chr7:1960795	MAD1L1	-0.51	-4.71	-0.36	5.55e-6	Neuroticism;
PAAD	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg06637938	chr14:75390232	RPS6KL1	0.45	4.37	0.33	2.31e-5	Height;
PAAD	cis	rs1497828	0.956	rs2810782	chr1:217544443	C/G	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs35000415	0.745	rs117944677	chr7:128698185	A/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs17601876	0.545	rs17523270	chr15:51538280	A/C	cg21478137	chr15:51532386	CYP19A1	-0.49	-4.99	-0.38	1.64e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.44	4.64	0.35	7.43e-6	Calcium levels;
PAAD	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.49	4.6	0.35	8.85e-6	Breast cancer;
PAAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs990171	0.538	rs6728288	chr2:103117268	A/T	cg13897122	chr2:103039542	IL18RAP	-0.45	-4.99	-0.38	1.62e-6	Lymphocyte counts;
PAAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.79	-7.8	-0.53	9.22e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15636799	chr7:72936614	BAZ1B	-0.55	-6.57	-0.47	7.48e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6088813	0.961	rs2425063	chr20:33924273	C/A	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs6976053	0.935	rs12669120	chr7:100476110	T/C	cg22425096	chr7:100417404	EPHB4	0.5	4.31	0.33	2.91e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25105842	chr2:224831785	MRPL44	0.54	6.34	0.46	2.42e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.67	7.43	0.52	7.27e-12	Resting heart rate;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg06169041	chr4:166306860	MIR578;CPE	0.67	6.42	0.46	1.62e-9	Photic sneeze reflex;
PAAD	cis	rs9322817	0.691	rs7769270	chr6:105230729	C/A	cg02098413	chr6:105308735	HACE1	-0.44	-5.48	-0.41	1.7e-7	Thyroid stimulating hormone;
PAAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg06632027	chr4:90757378	SNCA	-0.51	-4.51	-0.34	1.26e-5	Neuroticism;
PAAD	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.42	-0.34	1.87e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6922632	1.000	rs6922632	chr6:24107093	C/A	cg26194775	chr6:24126114	NRSN1	-0.75	-5.7	-0.42	6.15e-8	Information processing speed;
PAAD	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17114847	chr11:47736795	AGBL2	0.6	6.85	0.49	1.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.94	0.37	2.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.92	8.31	0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1950500	0.617	rs10362	chr14:24846961	G/T	cg07162820	chr14:24837146	NFATC4	0.4	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.86e-9	Bladder cancer;
PAAD	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.77	9.2	0.6	2.55e-16	Breast cancer;
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-4.61	-0.35	8.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.24e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.44	-4.89	-0.37	2.58e-6	Testicular germ cell tumor;
PAAD	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.59	5.75	0.42	4.71e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4819852	0.723	rs2238790	chr22:19983014	G/A	cg07821417	chr22:19972146	ARVCF	-0.48	-5.08	-0.38	1.07e-6	Pulse pressure;
PAAD	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg27411982	chr8:10470053	RP1L1	0.44	4.9	0.37	2.42e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.4	-5.14	-0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.49	-4.58	-0.35	9.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6867032	0.917	rs4975719	chr5:2010162	C/T	cg26168224	chr5:2018326	NA	1.13	14.78	0.77	3.38e-31	Gut microbiome composition (winter);
PAAD	cis	rs11203032	1.000	rs11203030	chr10:90964286	A/G	cg16672925	chr10:90967113	CH25H	0.75	6.01	0.44	1.29e-8	Heart failure;
PAAD	cis	rs3784262	0.765	rs11631127	chr15:58270009	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.52	-5.9	-0.43	2.25e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27174420	chr16:15820903	MYH11	0.42	4.61	0.35	8.34e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg27449745	chr7:23145252	KLHL7	0.49	4.33	0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.16	-0.5	3.17e-11	Neuroticism;
PAAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg03538708	chr1:25844672	NA	-0.51	-5.29	-0.39	4.13e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg05925327	chr15:68127851	NA	0.55	5.08	0.38	1.1e-6	Motion sickness;
PAAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-6.73	-0.48	3.25e-10	Hemoglobin concentration;
PAAD	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.73	-7.3	-0.51	1.52e-11	Mosquito bite size;
PAAD	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.98e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09630589	chr15:52861038	ARPP19	0.61	6.78	0.48	2.5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.24	-0.45	4.21e-9	Lung cancer;
PAAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg04287289	chr16:89883240	FANCA	0.87	4.31	0.33	2.97e-5	Skin colour saturation;
PAAD	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.17	-0.39	7.12e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.48	5.07	0.38	1.15e-6	Major depressive disorder;
PAAD	cis	rs58521262	0.505	rs289348	chr19:23147440	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg05577437	chr8:1586825	DLGAP2	0.39	4.42	0.34	1.89e-5	Systolic blood pressure;
PAAD	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.49e-11	Total cholesterol levels;
PAAD	cis	rs9462027	0.628	rs1543558	chr6:34784371	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.05	-0.5	5.76e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg07700843	chr1:2391317	NA	-0.69	-7.1	-0.5	4.52e-11	Non-obstructive azoospermia;
PAAD	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.66	-0.35	6.83e-6	Diastolic blood pressure;
PAAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.72	0.53	1.49e-12	Personality dimensions;
PAAD	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.47	-4.27	-0.33	3.38e-5	P wave terminal force;
PAAD	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.81	-5.68	-0.42	6.71e-8	HDL cholesterol levels;
PAAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs9462027	0.540	rs9366863	chr6:34688946	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.4	0.4	2.51e-7	Systemic lupus erythematosus;
PAAD	cis	rs4722672	0.786	rs7812039	chr7:27248891	C/G	cg09871315	chr7:27142682	HOXA2	0.49	4.76	0.36	4.41e-6	Ulcerative colitis;
PAAD	cis	rs2415984	0.579	rs11157506	chr14:46976197	T/C	cg14871534	chr14:47121158	RPL10L	-0.49	-5.13	-0.38	8.71e-7	Number of children ever born;
PAAD	cis	rs11264799	0.765	rs12125713	chr1:157636657	A/G	cg18268488	chr1:157545234	FCRL4	0.42	4.52	0.34	1.25e-5	IgA nephropathy;
PAAD	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.79	-6.35	-0.46	2.41e-9	Alzheimer's disease;
PAAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.74	-9.03	-0.59	7.35e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-6.16	-0.45	6.12e-9	Personality dimensions;
PAAD	cis	rs113779084	0.663	rs34562449	chr7:11994774	C/T	cg15090509	chr7:11872073	THSD7A	0.43	5.13	0.38	8.74e-7	Educational attainment (years of education);
PAAD	cis	rs1359582	0.836	rs1359581	chr10:90360515	A/G	cg15661332	chr10:90342814	RNLS	0.57	5.05	0.38	1.23e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg08886695	chr4:3369023	RGS12	0.53	5.26	0.39	4.89e-7	Mean platelet volume;
PAAD	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.97	-0.66	5.49e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2e-5	Menarche (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01146539	chr5:134688623	H2AFY	-0.51	-6.31	-0.46	2.86e-9	Monocyte percentage of white cells;
PAAD	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.13	-0.6	3.9e-16	Type 2 diabetes;
PAAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-7.4	-0.51	8.69e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg26816564	chr1:7831052	VAMP3	0.6	5.0	0.38	1.59e-6	Inflammatory bowel disease;
PAAD	cis	rs7577696	0.525	rs10153876	chr2:32011477	T/C	cg02381751	chr2:32503542	YIPF4	-0.46	-4.3	-0.33	3.01e-5	Inflammatory biomarkers;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	7.48	0.52	5.67e-12	Mood instability;
PAAD	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg01214346	chr17:406501	NA	0.45	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-4.31	-0.33	2.95e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3112530	0.818	rs1381540	chr5:152647990	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs727479	0.502	rs10046	chr15:51502986	G/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.48	0.34	1.47e-5	Estradiol levels;
PAAD	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.82	4.95	0.37	1.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.47	4.57	0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.65	7.02	0.49	6.96e-11	Menarche (age at onset);
PAAD	cis	rs11825685	0.836	rs56100135	chr11:134588756	G/T	cg02089395	chr11:134479357	NA	-0.66	-4.73	-0.36	5.19e-6	IgG glycosylation;
PAAD	cis	rs9323205	1.000	rs9323205	chr14:51586467	A/G	cg23942311	chr14:51606299	NA	-0.49	-4.51	-0.34	1.3e-5	Cancer;
PAAD	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.57	0.35	1.02e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.79	-7.95	-0.54	3.94e-13	Itch intensity from mosquito bite;
PAAD	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg08219700	chr8:58056026	NA	0.72	5.69	0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	1.22	7.2	0.5	2.59e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.97	6.25	0.45	3.98e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6700896	0.522	rs4655583	chr1:66155407	C/A	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs59406912	1	rs59406912	chr13:28843763	CTT/C	cg14731225	chr13:28717375	PAN3	-0.78	-4.46	-0.34	1.58e-5	Hepcidin/transferrin saturation ratio;
PAAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.42	-0.4	2.33e-7	Schizophrenia;
PAAD	cis	rs7011049	1.000	rs72648407	chr8:53857144	C/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	1.03	8.02	0.55	2.62e-13	Vitiligo;
PAAD	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.96	12.01	0.7	8.95e-24	Bone mineral density;
PAAD	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg05579598	chr16:88989069	CBFA2T3	0.65	10.04	0.63	1.67e-18	Social autistic-like traits;
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.48	4.72	0.36	5.41e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs3015497	0.646	rs3015494	chr14:51115157	C/T	cg26011998	chr14:51135199	SAV1	-0.46	-4.32	-0.33	2.75e-5	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07880431	chr15:31508106	NA	0.65	7.5	0.52	4.86e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1372356	0.780	rs11159839	chr14:88552409	A/G	cg18078958	chr14:88630771	NA	0.49	6.2	0.45	5.2e-9	Food antigen IgG levels;
PAAD	cis	rs2814331	0.713	rs58805809	chr10:88073044	G/C	cg08962038	chr10:88022859	GRID1	0.59	4.44	0.34	1.71e-5	Balding;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.73	0.48	3.25e-10	Height;
PAAD	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.46	-4.49	-0.34	1.4e-5	Breast cancer;
PAAD	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs4965869	0.866	rs11856843	chr15:101976244	T/C	cg12371147	chr15:101978424	PCSK6	-0.5	-4.45	-0.34	1.65e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.46	5.57	0.41	1.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.67	-8.68	-0.58	5.63e-15	Birth weight;
PAAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.47	4.53	0.34	1.2e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.49	-0.34	1.4e-5	Mean platelet volume;
PAAD	cis	rs735539	0.521	rs2818998	chr13:21369911	T/C	cg27234864	chr13:21295941	IL17D	0.6	5.11	0.38	9.46e-7	Dental caries;
PAAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.63	6.12	0.44	7.63e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.5	-0.34	1.32e-5	Triglycerides;
PAAD	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.93	-0.43	1.99e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.74	6.42	0.46	1.62e-9	Type 2 diabetes;
PAAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.73	7.65	0.53	2.16e-12	Morning vs. evening chronotype;
PAAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg10518543	chr12:38710700	ALG10B	0.52	4.92	0.37	2.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.6	-4.27	-0.33	3.43e-5	Vitiligo;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.77	5.66	0.42	7.2e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04577441	chr4:100870687	LOC256880;H2AFZ	-0.65	-7.28	-0.51	1.63e-11	Smoking initiation;
PAAD	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg10705379	chr10:99080932	FRAT1	0.44	5.2	0.39	6.31e-7	Monocyte count;
PAAD	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg25811867	chr2:3488468	NA	0.43	4.3	0.33	3.04e-5	Neurofibrillary tangles;
PAAD	cis	rs7583236	0.500	rs7601899	chr2:70335973	C/G	cg19638749	chr2:70312615	NA	1.09	7.65	0.53	2.17e-12	Obesity-related traits;
PAAD	cis	rs7818688	0.545	rs11786429	chr8:95831345	C/T	cg16049864	chr8:95962084	TP53INP1	0.54	4.27	0.33	3.45e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs11811982	0.655	rs115344261	chr1:227420111	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.66	4.75	0.36	4.65e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.48	-5.11	-0.38	9.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	0.87	10.17	0.64	7.29e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.62	0.47	5.95e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8053891	0.756	rs28629271	chr16:72003732	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-5.04	-0.38	1.32e-6	Coronary artery disease;
PAAD	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg10395934	chr14:104002654	TRMT61A	0.56	5.72	0.42	5.49e-8	Body mass index;
PAAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg21951975	chr1:209979733	IRF6	-0.59	-5.4	-0.4	2.53e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.9	12.57	0.71	2.66e-25	Bone mineral density;
PAAD	cis	rs10450586	0.863	rs11029931	chr11:27325542	T/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg01631408	chr1:248437212	OR2T33	-0.6	-5.28	-0.39	4.41e-7	Common traits (Other);
PAAD	cis	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs939584	0.935	rs7571957	chr2:646803	T/C	cg14515364	chr2:636606	NA	0.48	4.36	0.33	2.36e-5	Body mass index;
PAAD	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22857025	chr5:266934	NA	-1.21	-9.76	-0.62	9.03e-18	Breast cancer;
PAAD	cis	rs6782228	0.527	rs7426806	chr3:128412930	G/A	cg16766828	chr3:128327626	NA	-0.47	-6.29	-0.45	3.2e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.63	6.85	0.49	1.74e-10	Multiple sclerosis;
PAAD	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs6842047	0.563	rs1593	chr4:187195551	T/A	cg09526685	chr4:187126073	CYP4V2	0.71	5.51	0.41	1.49e-7	Blood protein levels;
PAAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg17644776	chr2:200775616	C2orf69	-0.69	-5.15	-0.39	8.08e-7	Schizophrenia;
PAAD	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-8.5	-0.57	1.61e-14	Morning vs. evening chronotype;
PAAD	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	6.24	0.45	4.19e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.59	-5.65	-0.42	7.72e-8	Paraoxonase activity;
PAAD	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg26338869	chr17:61819248	STRADA	0.49	4.78	0.36	4.09e-6	Height;
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.49	-5.1	-0.38	9.76e-7	Lung cancer;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	5.52	0.41	1.42e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.04	0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg22903657	chr4:1355424	KIAA1530	0.43	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs4936891	0.599	rs2076941	chr11:123893286	A/G	cg22125253	chr11:123886957	OR10G4	0.45	4.52	0.34	1.25e-5	Male fertility;
PAAD	cis	rs748404	0.578	rs2244746	chr15:43695083	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.55	0.41	1.25e-7	Lung cancer;
PAAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.81	8.3	0.56	5.13e-14	Vitiligo;
PAAD	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg12046867	chr14:103022105	NA	0.64	4.76	0.36	4.42e-6	Platelet count;
PAAD	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.26	-0.33	3.63e-5	Resting heart rate;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.91	7.84	0.54	7.48e-13	Alzheimer's disease;
PAAD	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.47	-4.29	-0.33	3.19e-5	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.64	6.06	0.44	1.01e-8	Aortic root size;
PAAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.54	-4.51	-0.34	1.31e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2271001	0.910	rs3802797	chr11:19182288	T/C	cg00161556	chr11:19138045	ZDHHC13	0.52	5.55	0.41	1.24e-7	Gut microbiome composition (winter);
PAAD	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg03522150	chr11:46969673	C11orf49	0.44	5.27	0.39	4.56e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.73	-0.36	5.08e-6	Educational attainment (years of education);
PAAD	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.6	5.26	0.39	4.78e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg20913747	chr6:44695427	NA	-0.65	-6.46	-0.46	1.31e-9	Total body bone mineral density;
PAAD	cis	rs59901009	0.517	rs2403261	chr11:10021791	T/C	cg06876053	chr11:9810051	SBF2	-0.34	-4.5	-0.34	1.34e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.53	5.3	0.39	4.05e-7	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.18	10.18	0.64	6.86e-19	Vitiligo;
PAAD	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.95	-0.37	1.93e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg14349672	chr11:133703707	NA	-0.58	-6.81	-0.48	2.11e-10	Childhood ear infection;
PAAD	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.79	-6.95	-0.49	1.02e-10	Systemic lupus erythematosus;
PAAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.64	-0.35	7.58e-6	Fractional excretion of uric acid;
PAAD	cis	rs216303	1.000	rs216302	chr12:6158022	G/A	cg12895370	chr12:6755816	ACRBP	-0.49	-4.26	-0.33	3.52e-5	Low vWF levels;
PAAD	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.52	5.45	0.4	1.96e-7	Red blood cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11930768	chr3:9975464	CRELD1	0.58	6.58	0.47	7.23e-10	Monocyte percentage of white cells;
PAAD	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs377457	0.503	rs929865	chr16:85703627	T/G	cg02758499	chr16:85682440	KIAA0182	0.39	5.09	0.38	1.03e-6	Type 2 diabetes;
PAAD	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.67	5.67	0.42	7.06e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg15061591	chr7:98625706	SMURF1	-0.5	-4.69	-0.36	6.05e-6	Breast cancer;
PAAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.0	11.08	0.67	2.7e-21	Homoarginine levels;
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg07061783	chr6:25882402	NA	0.53	5.12	0.38	9.28e-7	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.57	-5.24	-0.39	5.18e-7	Blood pressure;
PAAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg19680485	chr15:31195859	MTMR15	-0.48	-4.93	-0.37	2.1e-6	Huntington's disease progression;
PAAD	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.96	-13.15	-0.73	7.47e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11588062	0.660	rs12738055	chr1:46701222	T/A	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.53	4.97	0.37	1.75e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.4	4.79	0.36	3.85e-6	Uric acid levels;
PAAD	cis	rs2031532	0.587	rs9535247	chr13:50030265	C/G	cg03651054	chr13:50194643	NA	0.34	4.56	0.35	1.04e-5	Cardiac hypertrophy;
PAAD	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.5	0.34	1.36e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2479106	0.963	rs10986093	chr9:126494022	T/C	cg16191174	chr9:126692580	DENND1A	0.49	4.46	0.34	1.61e-5	Polycystic ovary syndrome;
PAAD	cis	rs2576037	0.863	rs8097455	chr18:44593122	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	5.3	0.39	4.05e-7	Personality dimensions;
PAAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg13918804	chr1:2043761	PRKCZ	0.42	5.44	0.4	2.09e-7	Height;
PAAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg21351543	chr2:191399470	TMEM194B	-0.55	-4.27	-0.33	3.46e-5	Diastolic blood pressure;
PAAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.56	5.42	0.4	2.27e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg12639453	chr1:2035780	PRKCZ	-0.6	-6.47	-0.46	1.24e-9	Height;
PAAD	cis	rs7567389	0.719	rs4662713	chr2:127994103	C/T	cg09760422	chr2:128146352	NA	-0.38	-5.86	-0.43	2.81e-8	Self-rated health;
PAAD	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.51	-0.47	1.04e-9	Plateletcrit;Platelet count;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg00717180	chr2:96193071	NA	0.59	6.49	0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.5	-0.41	1.6e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	1.03	11.09	0.67	2.6e-21	Multiple myeloma;
PAAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.61	4.81	0.36	3.53e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.68	10.55	0.65	7.29e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-4.27	-0.33	3.44e-5	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs3136739	0.614	rs77758638	chr8:42014917	C/T	cg17828057	chr8:42037527	PLAT	0.68	4.63	0.35	7.76e-6	Plasma plasminogen activator levels;
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg15212455	chr7:39170539	POU6F2	0.41	5.54	0.41	1.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.71	-5.93	-0.43	1.92e-8	Fibrinogen levels;
PAAD	cis	rs2289328	0.943	rs3803359	chr15:40662748	A/G	cg13931752	chr15:40660718	DISP2	-0.54	-5.02	-0.38	1.4e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-5.14	-0.38	8.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.34	-0.33	2.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8170	0.603	rs4808621	chr19:17414267	C/T	cg01047959	chr19:17666446	GLT25D1	0.51	4.68	0.36	6.21e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg25547332	chr5:131281432	NA	-0.55	-4.29	-0.33	3.12e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg12257692	chr3:49977190	RBM6	0.34	4.28	0.33	3.34e-5	Body mass index;
PAAD	cis	rs6907629	1.000	rs6907629	chr6:167569519	A/G	cg07560741	chr6:167734054	NA	-0.29	-4.28	-0.33	3.34e-5	Asthma (childhood onset);
PAAD	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg21194808	chr1:2205498	SKI	0.43	4.29	0.33	3.2e-5	Coronary artery disease;
PAAD	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	7.79	0.53	9.9e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg08198773	chr8:1697536	NA	0.46	5.14	0.38	8.48e-7	Systolic blood pressure;
PAAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg09945482	chr18:12777974	NA	0.61	5.52	0.41	1.43e-7	Inflammatory skin disease;
PAAD	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.66	-6.71	-0.48	3.7e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.27	-0.33	3.42e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg09017928	chr7:158110068	PTPRN2	0.59	5.3	0.4	3.98e-7	Response to amphetamines;
PAAD	cis	rs7009516	0.819	rs12682329	chr8:24220798	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-5.08	-0.38	1.08e-6	Hair greying;
PAAD	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg18551225	chr6:44695536	NA	-0.75	-7.58	-0.52	3.1e-12	Total body bone mineral density;
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.48	4.47	0.34	1.5e-5	Total body bone mineral density;
PAAD	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.53	0.52	4.11e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg15841412	chr13:111365552	ING1	-0.57	-4.64	-0.35	7.52e-6	Coronary artery disease;
PAAD	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20651456	chr8:179287	RPL23AP53	-0.59	-6.3	-0.46	2.99e-9	Myopia (pathological);
PAAD	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.8	-0.66	1.51e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg00614314	chr15:82944287	LOC80154	0.53	5.36	0.4	3.03e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7631605	0.905	rs1468712	chr3:37106013	C/T	cg17445812	chr3:36986805	TRANK1	-0.35	-4.68	-0.35	6.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1012068	0.686	rs4820996	chr22:32324030	A/G	cg01338084	chr22:32026380	PISD	0.54	4.84	0.37	3.2e-6	Chronic hepatitis C infection;
PAAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.62	5.7	0.42	5.95e-8	Facial morphology (factor 20);
PAAD	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.5	-0.34	1.34e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs75920871	0.688	rs61905679	chr11:116834787	C/T	cg04087571	chr11:116723030	SIK3	-0.45	-4.66	-0.35	6.9e-6	Subjective well-being;
PAAD	cis	rs787274	0.867	rs4978507	chr9:115609376	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-4.54	-0.35	1.14e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg00945038	chr17:61921165	SMARCD2	-0.43	-5.05	-0.38	1.25e-6	Prudent dietary pattern;
PAAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7937127	0.640	rs12792780	chr11:43526907	T/C	cg16963683	chr11:44087684	ACCS	-0.68	-4.27	-0.33	3.44e-5	Fibrinogen levels;
PAAD	cis	rs2131877	0.701	rs61231387	chr3:194832120	G/T	cg21937377	chr3:194868750	C3orf21	0.49	4.77	0.36	4.3e-6	Non-small cell lung cancer;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.66	-6.31	-0.46	2.96e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12136530	0.593	rs12404362	chr1:19739958	A/G	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.49	-4.44	-0.34	1.73e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-5.61	-0.41	9.47e-8	Blood protein levels;
PAAD	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg22830091	chr7:75961684	YWHAG	-0.45	-4.71	-0.36	5.64e-6	Multiple sclerosis;
PAAD	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.65	-7.19	-0.5	2.79e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg10587741	chr22:38071170	LGALS1	0.44	4.83	0.36	3.27e-6	Fat distribution (HIV);
PAAD	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg08501292	chr6:25962987	TRIM38	-0.8	-4.5	-0.34	1.33e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09056223	chr8:145627023	CPSF1;MIR1234	-0.65	-6.69	-0.48	4.04e-10	Obesity-related traits;
PAAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.55	5.2	0.39	6.4e-7	Type 2 diabetes;
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.26	0.33	3.55e-5	Bipolar disorder;
PAAD	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-5.34	-0.4	3.38e-7	Blood protein levels;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.53	5.52	0.41	1.44e-7	Longevity;Endometriosis;
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.75	-11.92	-0.69	1.55e-23	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15984612	chr8:145514624	BOP1;HSF1	0.69	7.71	0.53	1.5e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.62	6.18	0.45	5.76e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.76	-8.12	-0.55	1.5e-13	Mean corpuscular volume;
PAAD	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg23587288	chr2:27483067	SLC30A3	-0.74	-5.94	-0.43	1.91e-8	Blood metabolite levels;
PAAD	cis	rs12467847	1.000	rs12467847	chr2:113691404	A/G	cg06816558	chr2:113912567	NA	-0.5	-4.64	-0.35	7.34e-6	Response to amphetamines;
PAAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg23281280	chr6:28129359	ZNF389	0.64	4.53	0.34	1.2e-5	Depression;
PAAD	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.85	-0.58	2.07e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7624766	0.743	rs6805905	chr3:160496362	G/A	cg22637730	chr3:160473554	PPM1L	0.55	5.04	0.38	1.28e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs469727	0.513	rs566419	chr5:112185513	A/C	cg06941702	chr5:112196734	SRP19	-0.51	-4.78	-0.36	4.04e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.65	9.18	0.6	3e-16	Schizophrenia;
PAAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.77	-6.71	-0.48	3.62e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1329189	1.000	rs1329189	chr10:129998372	T/C	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.58e-6	Orofacial clefts;
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.3	-0.39	3.99e-7	Tonsillectomy;
PAAD	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.45	-5.11	-0.38	9.63e-7	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.95	9.52	0.61	3.79e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3131085	1	rs3131085	chr6:29044701	G/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Blood protein levels;
PAAD	cis	rs17407555	0.657	rs16895675	chr4:10272055	A/G	cg00071950	chr4:10020882	SLC2A9	0.42	4.38	0.33	2.18e-5	Schizophrenia (age at onset);
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.73	8.48	0.57	1.86e-14	Height;
PAAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg23024343	chr7:107201750	COG5	-0.55	-4.62	-0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.67	-7.1	-0.5	4.42e-11	Menarche (age at onset);
PAAD	cis	rs1561176	0.830	rs11773280	chr7:154994990	G/A	cg08570118	chr7:155025533	NA	-0.51	-4.93	-0.37	2.15e-6	Personality dimensions;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs62179067	0.708	rs61397643	chr2:179914640	G/A	cg13380624	chr19:7735426	NA	-0.73	-6.96	-0.49	9.73e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.25	7.89	0.54	5.38e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.94	-0.43	1.86e-8	Schizophrenia;
PAAD	cis	rs746265	0.818	rs6492868	chr15:39575219	G/A	cg10099207	chr15:39544144	C15orf54	0.56	4.28	0.33	3.23e-5	PR interval;
PAAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg26513180	chr16:89883248	FANCA	0.44	4.43	0.34	1.82e-5	Vitiligo;
PAAD	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.74	6.76	0.48	2.78e-10	Crohn's disease;
PAAD	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.39	-4.59	-0.35	9.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg06558623	chr16:89946397	TCF25	0.97	6.17	0.45	5.79e-9	Skin colour saturation;
PAAD	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.92	8.07	0.55	2e-13	IgG glycosylation;
PAAD	cis	rs9549260	0.609	rs9315780	chr13:41263960	C/T	cg21288729	chr13:41239152	FOXO1	0.55	4.47	0.34	1.55e-5	Red blood cell count;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg26354017	chr1:205819088	PM20D1	0.84	9.49	0.61	4.67e-17	Monocyte percentage of white cells;
PAAD	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg11949866	chr1:10754891	CASZ1	0.54	4.37	0.33	2.29e-5	Ewing sarcoma;
PAAD	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg15654264	chr1:150340011	RPRD2	0.53	5.09	0.38	1.04e-6	Migraine;
PAAD	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.5	4.94	0.37	2.03e-6	Asthma;
PAAD	cis	rs7853377	0.546	rs7869321	chr9:86520782	C/T	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs62400317	0.859	rs12205905	chr6:45178498	T/C	cg18551225	chr6:44695536	NA	-0.68	-6.76	-0.48	2.83e-10	Total body bone mineral density;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg16590910	chr6:42928470	GNMT	0.5	5.21	0.39	6.19e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg26174226	chr8:58114915	NA	-0.63	-5.07	-0.38	1.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.51	5.78	0.42	4.13e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.62	-5.83	-0.43	3.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg14191688	chr11:70257035	CTTN	0.56	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.39e-10	Life satisfaction;
PAAD	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg00071950	chr4:10020882	SLC2A9	0.46	4.26	0.33	3.6e-5	Blood metabolite levels;
PAAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.94	8.22	0.55	8.29e-14	Triglycerides;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.6	0.41	9.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.69	5.23	0.39	5.65e-7	Initial pursuit acceleration;
PAAD	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	8.1	0.55	1.64e-13	Monocyte percentage of white cells;
PAAD	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.29	-0.33	3.14e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.34	-4.55	-0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.66	5.2	0.39	6.36e-7	Plateletcrit;
PAAD	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.39	-4.73	-0.36	5.03e-6	Schizophrenia;
PAAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg27478167	chr7:817139	HEATR2	-0.64	-4.97	-0.37	1.75e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	1.14	15.86	0.79	4.98e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg11619707	chr19:22235551	ZNF257	-0.58	-5.58	-0.41	1.07e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.27	-0.39	4.52e-7	Triglycerides;
PAAD	cis	rs818427	0.896	rs455412	chr5:112224389	G/T	cg06941702	chr5:112196734	SRP19	0.48	4.37	0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.92	7.26	0.51	1.89e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.15	-0.39	8.03e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.95	-7.33	-0.51	1.25e-11	Monocyte percentage of white cells;
PAAD	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg04257695	chr17:30186438	C17orf79	-0.52	-4.28	-0.33	3.28e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.74	7.11	0.5	4.24e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	11.15	0.67	1.81e-21	Tonsillectomy;
PAAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	6.35	0.46	2.39e-9	Leprosy;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2061333	0.557	rs10413195	chr19:44634903	A/G	cg20607764	chr19:44506953	ZNF230	-0.78	-5.4	-0.4	2.51e-7	Alzheimer's disease;
PAAD	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	0.8	5.53	0.41	1.39e-7	Body mass index;
PAAD	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs78761021	0.755	rs17681812	chr17:9794540	C/T	cg26853458	chr17:9805074	RCVRN	0.73	8.65	0.57	6.9e-15	Type 2 diabetes;
PAAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.49	-4.46	-0.34	1.56e-5	Monocyte count;
PAAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs654950	0.792	rs625448	chr1:41988541	A/T	cg06885757	chr1:42089581	HIVEP3	0.51	5.77	0.42	4.29e-8	Airway imaging phenotypes;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.48	-4.97	-0.37	1.75e-6	Monocyte count;
PAAD	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.87	-9.65	-0.62	1.79e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.6	-6.45	-0.46	1.43e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.97	11.96	0.7	1.18e-23	Longevity;
PAAD	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-1.1	-7.16	-0.5	3.2e-11	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	7.27	0.51	1.81e-11	Menarche (age at onset);
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg11601000	chr22:42348013	LOC339674	-0.44	-4.36	-0.33	2.35e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11963883	chr10:70715832	DDX21	-0.75	-6.38	-0.46	2.05e-9	Neuroticism;
PAAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	4.43	0.34	1.77e-5	Menopause (age at onset);
PAAD	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.45	-0.4	1.95e-7	Common traits (Other);
PAAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.77	7.38	0.51	9.61e-12	Cognitive function;
PAAD	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11260013	0.874	rs12979200	chr19:7758303	A/G	cg04764898	chr19:7562249	C19orf45	0.41	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6976053	0.935	rs314376	chr7:100457356	A/G	cg22425096	chr7:100417404	EPHB4	0.51	4.44	0.34	1.69e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs11811982	0.793	rs77599485	chr1:227352195	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.13	-11.57	-0.68	1.32e-22	Blood pressure (smoking interaction);
PAAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg27494647	chr7:150038898	RARRES2	0.42	4.28	0.33	3.25e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg14063182	chr7:4682116	NA	-0.67	-6.49	-0.47	1.17e-9	Dental caries;
PAAD	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.65	7.51	0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.6	5.81	0.43	3.59e-8	Coronary artery disease;
PAAD	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg00750074	chr16:89608354	SPG7	-0.5	-4.76	-0.36	4.52e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs11563648	0.535	rs1419395	chr7:126992598	T/C	cg13381984	chr7:127881344	LEP	-0.29	-4.32	-0.33	2.77e-5	Resting heart rate;
PAAD	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs2290402	0.536	rs7684266	chr4:856609	T/C	cg09237302	chr4:906077	GAK	-0.42	-4.4	-0.34	2.04e-5	Type 2 diabetes;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg07559730	chr19:53497048	ZNF702P	-0.53	-5.83	-0.43	3.16e-8	Psoriasis;
PAAD	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg13859433	chr6:33739653	LEMD2	0.66	4.85	0.37	3.04e-6	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.05	-12.39	-0.71	8.27e-25	Colorectal cancer;
PAAD	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg14851346	chr12:38532713	NA	0.43	4.25	0.33	3.69e-5	Bladder cancer;
PAAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg04106633	chr4:1044584	NA	0.71	5.93	0.43	1.93e-8	Recombination rate (females);
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg24733560	chr20:60626293	TAF4	0.51	6.52	0.47	9.57e-10	Body mass index;
PAAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg06671706	chr8:8559999	CLDN23	0.76	7.5	0.52	5.08e-12	Obesity-related traits;
PAAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.47	-4.74	-0.36	4.96e-6	Tonsillectomy;
PAAD	cis	rs2279463	0.667	rs3119304	chr6:160628557	T/C	cg09900253	chr6:160186100	ACAT2	-0.65	-4.29	-0.33	3.13e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
PAAD	cis	rs17162190	0.698	rs4659442	chr1:26823580	T/G	cg17456097	chr1:26900765	RPS6KA1	0.6	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15556689	chr8:8085844	FLJ10661	0.49	4.61	0.35	8.45e-6	Neuroticism;
PAAD	cis	rs755249	0.567	rs2036464	chr1:39688242	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.43	6.66	0.48	4.72e-10	Height;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.34	-0.33	2.54e-5	Platelet count;
PAAD	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg02917321	chr22:38215204	NA	-0.43	-4.6	-0.35	8.8e-6	Glioblastoma;Glioma;
PAAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.41	4.46	0.34	1.56e-5	Height;
PAAD	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg14631576	chr9:95140430	CENPP	-0.43	-4.29	-0.33	3.12e-5	Height;
PAAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	1.03	9.23	0.6	2.18e-16	Neutrophil percentage of white cells;
PAAD	cis	rs6545883	0.894	rs2694634	chr2:61551435	T/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.83	-0.36	3.26e-6	Tuberculosis;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs988913	0.957	rs9475068	chr6:54791581	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-8.81	-0.58	2.59e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.93	5.83	0.43	3.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.65	7.49	0.52	5.2e-12	High light scatter reticulocyte count;
PAAD	cis	rs30380	0.587	rs30185	chr5:96125465	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-5.2	-0.39	6.25e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg05895507	chr15:77155635	SCAPER	-0.4	-4.26	-0.33	3.51e-5	Blood metabolite levels;
PAAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-17.46	-0.82	3.85e-38	Height;
PAAD	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.39	-8.08	-0.55	1.89e-13	Mean corpuscular volume;
PAAD	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg06307176	chr5:131281290	NA	0.5	4.38	0.33	2.17e-5	Life satisfaction;
PAAD	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07648498	chr16:89883185	FANCA	0.7	7.41	0.52	8.18e-12	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14852238	chr1:28562670	ATPIF1	0.56	6.41	0.46	1.72e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.62	-6.3	-0.45	3.13e-9	Urate levels in lean individuals;
PAAD	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.56	7.22	0.51	2.31e-11	Schizophrenia;
PAAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg25173405	chr17:45401733	C17orf57	0.49	5.07	0.38	1.13e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.69	-6.87	-0.49	1.57e-10	Lung cancer;
PAAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg22800045	chr5:56110881	MAP3K1	0.61	4.9	0.37	2.41e-6	Coronary artery disease;
PAAD	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.88	10.25	0.64	4.65e-19	Coronary artery disease;
PAAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.49	4.26	0.33	3.52e-5	Height;
PAAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.94	0.66	6.71e-21	Smoking behavior;
PAAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.52	5.34	0.4	3.35e-7	Schizophrenia;
PAAD	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg21205071	chr1:161993677	OLFML2B	0.49	4.46	0.34	1.61e-5	IgG glycosylation;
PAAD	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.67	-0.53	1.97e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs6074578	0.679	rs6086171	chr20:136374	G/A	cg16931068	chr20:139680	DEFB127	0.38	4.99	0.38	1.62e-6	Hirschsprung disease;
PAAD	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.68	4.94	0.37	2.05e-6	Hip geometry;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.94	-8.69	-0.58	5.51e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs227833	1.000	rs227830	chr6:44680555	G/C	cg20913747	chr6:44695427	NA	0.57	5.96	0.44	1.68e-8	Monobrow;
PAAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg08917208	chr2:24149416	ATAD2B	0.51	4.5	0.34	1.34e-5	Asthma;
PAAD	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.54	-4.63	-0.35	7.85e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg09325174	chr14:50154983	POLE2	-0.71	-6.38	-0.46	2.06e-9	Blood protein levels;
PAAD	cis	rs2790216	1.000	rs2251039	chr10:60028894	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21649569	chr21:40752157	WRB	0.63	6.4	0.46	1.79e-9	Iris heterochromicity;
PAAD	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	6.02	0.44	1.24e-8	Mean platelet volume;
PAAD	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.36	-0.71	9.7e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg05555928	chr11:63887634	MACROD1	-0.44	-4.91	-0.37	2.37e-6	Platelet count;
PAAD	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.41	5.0	0.38	1.54e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg00786201	chr11:61583134	MIR1908;FADS1	0.47	4.45	0.34	1.68e-5	Trans fatty acid levels;
PAAD	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.39	-5.45	-0.4	1.96e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.86	6.17	0.45	5.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.69	-7.53	-0.52	4.11e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.45	-5.05	-0.38	1.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.56	5.54	0.41	1.31e-7	Obesity-related traits;
PAAD	cis	rs1042026	0.813	rs6818077	chr4:100100999	A/G	cg09112717	chr4:100009950	ADH5	-0.5	-4.41	-0.34	1.91e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00142150	chr22:38071001	LGALS1	-0.8	-8.99	-0.59	9.16e-16	Fat distribution (HIV);
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-5.73	-0.42	5.3e-8	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.87	9.68	0.62	1.43e-17	Cognitive function;
PAAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg06714761	chr1:201096289	NA	0.31	4.78	0.36	4.11e-6	Permanent tooth development;
PAAD	cis	rs2412208	0.795	rs4074964	chr1:7105079	A/G	cg26570804	chr1:6352357	ACOT7	0.49	4.28	0.33	3.35e-5	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg14393609	chr7:65229607	NA	0.63	6.72	0.48	3.41e-10	Aortic root size;
PAAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.77	10.11	0.63	1.05e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4740619	0.661	rs10810482	chr9:15931395	C/A	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.06	0.55	2.07e-13	Morning vs. evening chronotype;
PAAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg25319279	chr11:5960081	NA	-0.66	-6.21	-0.45	4.79e-9	DNA methylation (variation);
PAAD	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg12317470	chr15:67143691	NA	0.76	4.45	0.34	1.67e-5	Lung cancer (smoking interaction);
PAAD	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.47	4.96	0.37	1.85e-6	Eye color traits;
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.68	-0.35	6.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7246657	0.507	rs8107654	chr19:37453534	C/T	cg23950597	chr19:37808831	NA	-0.74	-4.66	-0.35	6.85e-6	Coronary artery calcification;
PAAD	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg20592124	chr2:65290738	CEP68	-0.46	-4.35	-0.33	2.5e-5	Pulse pressure;
PAAD	trans	rs12899618	0.850	rs28656084	chr15:71687396	C/T	cg22163535	chr18:6411387	L3MBTL4	-0.7	-6.31	-0.46	2.87e-9	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs1519814	0.654	rs2139438	chr8:121007717	T/C	cg22335954	chr8:121166405	COL14A1	-0.65	-5.0	-0.38	1.59e-6	Breast cancer;
PAAD	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.42	-0.34	1.87e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26222229	chr6:36842844	PPIL1	-0.58	-6.52	-0.47	9.86e-10	Body fat percentage;
PAAD	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.63	0.47	5.46e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg07741184	chr6:167504864	NA	0.38	4.8	0.36	3.74e-6	Primary biliary cholangitis;
PAAD	cis	rs7631605	0.905	rs3774326	chr3:37099566	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg11766577	chr21:47581405	C21orf56	-0.4	-4.44	-0.34	1.73e-5	Testicular germ cell tumor;
PAAD	trans	rs2982694	0.681	rs2982691	chr6:152285596	T/C	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.59	6.72	0.48	3.47e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11871801	0.718	rs34967087	chr17:40576816	A/C	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg09945482	chr18:12777974	NA	-0.63	-5.47	-0.41	1.85e-7	Inflammatory skin disease;
PAAD	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	5.58	0.41	1.08e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg13332499	chr17:408570	NA	-0.49	-4.64	-0.35	7.36e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg05373962	chr22:49881684	NA	-0.53	-5.12	-0.38	9.11e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs9409082	0.715	rs34898409	chr9:108941284	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.43	-0.46	1.54e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2120243	0.539	rs6441128	chr3:157121258	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.89	0.43	2.36e-8	Ileal carcinoids;
PAAD	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.48	-4.28	-0.33	3.35e-5	Obesity-related traits;
PAAD	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.83	9.73	0.62	1.05e-17	Menopause (age at onset);
PAAD	cis	rs4388249	0.687	rs2301016	chr5:109143602	C/T	cg17395555	chr5:108820864	NA	0.33	4.61	0.35	8.44e-6	Schizophrenia;
PAAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02507604	chr12:133417259	CHFR	0.6	7.48	0.52	5.56e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7873102	0.654	rs2244481	chr9:37984731	C/G	cg03528946	chr9:38069800	SHB	0.52	5.21	0.39	6.01e-7	Brain structure;
PAAD	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.63	-5.77	-0.42	4.23e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.78	-8.96	-0.59	1.08e-15	Total body bone mineral density;
PAAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg14583973	chr4:3374767	RGS12	0.42	6.5	0.47	1.08e-9	Serum sulfate level;
PAAD	cis	rs4879913	0.801	rs10758314	chr9:35594724	G/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.45	-4.38	-0.33	2.2e-5	Electroencephalogram traits;
PAAD	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06476606	chr10:91061728	IFIT2	0.61	6.76	0.48	2.71e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03909863	chr11:638404	DRD4	-0.67	-5.63	-0.42	8.27e-8	Systemic lupus erythematosus;
PAAD	cis	rs3747869	0.596	rs3747865	chr10:73527676	A/G	cg07131093	chr10:72648379	PCBD1	-0.66	-4.31	-0.33	2.88e-5	White blood cell count;Myeloid white cell count;
PAAD	cis	rs6066825	0.627	rs6012497	chr20:47228591	C/T	cg18078177	chr20:47281410	PREX1	0.49	4.64	0.35	7.41e-6	Colorectal cancer;
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.0	-0.59	8.44e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg02734326	chr4:10020555	SLC2A9	-0.51	-4.94	-0.37	2e-6	Bone mineral density;
PAAD	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-7.11	-0.5	4.2e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg19254793	chr6:44695348	NA	-0.47	-4.47	-0.34	1.5e-5	Total body bone mineral density;
PAAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.64	8.56	0.57	1.15e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.85	0.43	2.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910873	0.505	rs6059969	chr20:33245284	T/C	cg16810054	chr20:33298113	TP53INP2	-0.56	-4.27	-0.33	3.45e-5	Melanoma;
PAAD	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.62	-0.35	8.18e-6	Resting heart rate;
PAAD	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg09211372	chr6:168490623	NA	-0.45	-4.8	-0.36	3.79e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.32	0.6	1.25e-16	Parkinson's disease;
PAAD	cis	rs939317	0.635	rs843371	chr3:183994536	A/G	cg09405238	chr3:183994500	ECE2	0.5	4.58	0.35	9.47e-6	Menarche (age at onset);
PAAD	cis	rs2274459	0.778	rs2296737	chr6:33656416	G/A	cg06253072	chr6:33679850	C6orf125	0.63	4.96	0.37	1.83e-6	Obesity (extreme);
PAAD	cis	rs8113142	0.573	rs8103836	chr19:29006711	C/T	cg04546413	chr19:29218101	NA	0.7	5.03	0.38	1.34e-6	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg09835421	chr16:68378352	PRMT7	-0.74	-5.97	-0.44	1.61e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg10396713	chr8:602097	NA	0.68	4.88	0.37	2.66e-6	IgG glycosylation;
PAAD	cis	rs3018712	0.584	rs3136540	chr11:68456410	T/C	cg23009355	chr11:68451396	GAL	-0.46	-4.52	-0.34	1.25e-5	Total body bone mineral density;
PAAD	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg14146966	chr2:61757674	XPO1	0.39	4.87	0.37	2.75e-6	Tuberculosis;
PAAD	cis	rs1497828	0.956	rs2815245	chr1:217559982	A/G	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.75	-11.92	-0.7	1.53e-23	Body mass index;
PAAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg04450456	chr4:17643702	FAM184B	0.5	5.3	0.39	4.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.16	-0.39	7.61e-7	Menarche (age at onset);
PAAD	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.33	4.79	0.36	3.89e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg21361702	chr7:150065534	REPIN1	0.54	4.35	0.33	2.52e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.6	-5.66	-0.42	7.29e-8	Lymphocyte counts;
PAAD	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg06740227	chr12:86229804	RASSF9	-0.49	-4.9	-0.37	2.48e-6	Major depressive disorder;
PAAD	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg13535736	chr9:111863775	C9orf5	-0.36	-4.45	-0.34	1.66e-5	Menarche (age at onset);
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.81	-4.98	-0.37	1.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7651511	1.000	rs34342794	chr3:141209101	C/T	cg25967872	chr3:141205623	RASA2	0.5	4.5	0.34	1.34e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	4.88	0.37	2.63e-6	Schizophrenia;
PAAD	cis	rs13177180	0.590	rs10075869	chr5:114956959	A/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-4.81	-0.36	3.63e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg19640130	chr10:64028056	RTKN2	-0.36	-4.32	-0.33	2.82e-5	Rheumatoid arthritis;
PAAD	cis	rs2004318	1.000	rs74388709	chr19:55138597	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs13125782	0.564	rs4234805	chr4:7441323	A/G	cg03194122	chr4:7437027	SORCS2;PSAPL1	0.42	4.4	0.34	2.01e-5	Anorexia nervosa;
PAAD	cis	rs1912528	0.745	rs6852749	chr4:140864455	C/T	cg11128457	chr4:140864437	MAML3	-0.32	-4.31	-0.33	2.91e-5	Educational attainment (years of education);
PAAD	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg00255135	chr8:143090366	NA	-0.42	-4.28	-0.33	3.27e-5	Schizophrenia;
PAAD	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.67	7.68	0.53	1.81e-12	Hand grip strength;
PAAD	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.75	-5.37	-0.4	2.86e-7	Major depressive disorder;
PAAD	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.14	5.41	0.4	2.45e-7	Asthma (childhood onset);
PAAD	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.63	6.47	0.46	1.29e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg15956490	chr3:53032818	SFMBT1	0.74	4.29	0.33	3.19e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22788252	chr4:143050435	INPP4B	0.54	6.33	0.46	2.66e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg12573674	chr2:1569213	NA	-0.69	-4.87	-0.37	2.83e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.27	0.33	3.37e-5	Parkinson's disease;
PAAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.46	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg27094323	chr7:1216898	NA	-0.5	-5.82	-0.43	3.45e-8	Longevity;Endometriosis;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.27	0.39	4.53e-7	Prudent dietary pattern;
PAAD	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.67	-6.54	-0.47	9.05e-10	Pubertal anthropometrics;
PAAD	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.67	-7.27	-0.51	1.73e-11	Menarche (age at onset);
PAAD	cis	rs10037758	0.618	rs7730908	chr5:128283646	C/T	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	11.22	0.67	1.15e-21	Primary sclerosing cholangitis;
PAAD	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.84	7.99	0.54	3.07e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10267417	0.603	rs10950762	chr7:19912203	A/G	cg05791153	chr7:19748676	TWISTNB	0.64	4.42	0.34	1.85e-5	Night sleep phenotypes;
PAAD	cis	rs501120	0.657	rs10899998	chr10:44688524	G/C	cg09554077	chr10:44749378	NA	0.47	5.78	0.42	4.05e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.43	0.46	1.59e-9	Educational attainment;
PAAD	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.64	-0.35	7.62e-6	Total body bone mineral density;
PAAD	cis	rs1555895	0.576	rs4881536	chr10:848058	A/G	cg20503657	chr10:835505	NA	0.48	4.96	0.37	1.87e-6	Survival in rectal cancer;
PAAD	cis	rs2790457	0.958	rs2772431	chr10:28890160	C/T	cg05705492	chr10:28955341	NA	-0.43	-4.3	-0.33	3.06e-5	Multiple myeloma;
PAAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-5.22	-0.39	5.76e-7	Neuroticism;
PAAD	cis	rs2340727	1.000	rs2340727	chr1:161946727	C/T	cg27519958	chr1:161735129	ATF6	0.59	4.65	0.35	7.15e-6	White blood cell count;Hematology traits;
PAAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg21351543	chr2:191399470	TMEM194B	0.58	4.47	0.34	1.55e-5	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.52	4.89	0.37	2.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.8	6.1	0.44	8.24e-9	Gut microbiome composition (summer);
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg12923728	chr3:195709715	SDHAP1	-0.8	-5.87	-0.43	2.67e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.71	-7.26	-0.51	1.87e-11	Retinal vascular caliber;
PAAD	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-1.02	-9.97	-0.63	2.47e-18	Corneal structure;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.36	-0.51	1.08e-11	Mood instability;
PAAD	trans	rs901683	1.000	rs71494788	chr10:45972325	C/G	cg11747279	chr17:21096632	NA	0.81	6.4	0.46	1.81e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.67	8.15	0.55	1.22e-13	Dupuytren's disease;
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Body mass index;
PAAD	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg04705435	chr11:17411270	KCNJ11	0.49	4.58	0.35	9.74e-6	Body mass index;Social communication problems;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.29	0.64	3.55e-19	Menopause (age at onset);
PAAD	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg11752832	chr7:134001865	SLC35B4	0.68	6.18	0.45	5.51e-9	Mean platelet volume;
PAAD	cis	rs3736485	0.934	rs28648597	chr15:51856066	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs7168592	1.000	rs28576902	chr15:101725618	A/C	cg24254196	chr15:101719523	CHSY1	0.63	4.39	0.34	2.15e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.68	5.7	0.42	6.15e-8	Menarche (age at onset);
PAAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg17848003	chr1:3704513	LRRC47	0.41	4.49	0.34	1.39e-5	Red cell distribution width;
PAAD	cis	rs77741769	0.700	rs7980311	chr12:121355860	C/T	cg02403541	chr12:121454288	C12orf43	0.4	4.26	0.33	3.56e-5	Mean corpuscular volume;
PAAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.71	6.78	0.48	2.43e-10	Asthma;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.08	-0.38	1.11e-6	Subjective well-being;
PAAD	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg02404636	chr22:31891804	SFI1	0.63	6.08	0.44	9.34e-9	Colorectal cancer;
PAAD	cis	rs12986413	1.000	rs12459350	chr19:2176586	A/G	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.12e-6	Height;
PAAD	cis	rs13102973	0.640	rs13151892	chr4:135831375	G/A	cg14419869	chr4:135874104	NA	0.45	4.59	0.35	9.1e-6	Subjective well-being;
PAAD	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs1198430	0.562	rs10799795	chr1:23773998	C/A	cg27447006	chr1:23763279	ASAP3	0.69	6.06	0.44	1e-8	Total cholesterol levels;
PAAD	cis	rs16975963	0.793	rs56672492	chr19:38448231	T/C	cg14218481	chr19:38281219	NA	0.47	4.91	0.37	2.32e-6	Longevity;
PAAD	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs7960581	0.585	rs35018642	chr12:99169169	C/G	cg17109042	chr12:99139387	ANKS1B	-0.65	-4.39	-0.34	2.1e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	5.68	0.42	6.58e-8	Iron status biomarkers;
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg22764044	chr5:178986830	RUFY1	0.47	4.75	0.36	4.7e-6	Lung cancer;
PAAD	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.76	7.55	0.52	3.82e-12	Retinal vascular caliber;
PAAD	cis	rs1413885	0.526	rs9728544	chr1:65847105	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.71	0.36	5.56e-6	Anticoagulant levels;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg22162314	chr17:61951766	CSH2	-0.56	-5.61	-0.41	9.18e-8	Height;
PAAD	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg08079166	chr15:68083412	MAP2K5	0.68	5.31	0.4	3.77e-7	Restless legs syndrome;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg00035636	chr13:21900591	NA	0.6	6.09	0.44	8.87e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.63	7.12	0.5	4e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs9462846	1.000	rs2894484	chr6:42851497	A/G	cg02353165	chr6:42928485	GNMT	0.58	4.5	0.34	1.37e-5	Blood protein levels;
PAAD	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.69	-0.36	6.02e-6	Menopause (age at onset);
PAAD	cis	rs10861342	0.892	rs2044307	chr12:105531171	G/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.39	0.34	2.14e-5	IgG glycosylation;
PAAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-4.67	-0.35	6.67e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2249694	0.537	rs4838687	chr10:135295396	C/T	cg20169779	chr10:135381914	SYCE1	0.53	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09810961	chr10:1850372	NA	-0.61	-6.41	-0.46	1.74e-9	Obesity-related traits;
PAAD	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg13722127	chr7:150037890	RARRES2	0.55	5.57	0.41	1.11e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.83	-6.01	-0.44	1.33e-8	Coronary artery disease;
PAAD	cis	rs758324	0.773	rs4540167	chr5:131163022	G/A	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.11	0.38	9.43e-7	Lung cancer;
PAAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.34	4.3	0.33	3.04e-5	Colorectal cancer;
PAAD	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.4	-0.34	2.06e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg09017928	chr7:158110068	PTPRN2	0.59	5.3	0.4	3.98e-7	Response to amphetamines;
PAAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs16852403	0.548	rs316280	chr1:178158085	C/T	cg00404053	chr1:178313656	RASAL2	0.41	4.28	0.33	3.23e-5	Childhood ear infection;
PAAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg15017067	chr4:17643749	FAM184B	-0.4	-4.46	-0.34	1.61e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.77e-11	Eye color traits;
PAAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.58	-6.91	-0.49	1.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs367943	0.608	rs2914170	chr5:112982616	C/T	cg12552261	chr5:112820674	MCC	-0.58	-5.98	-0.44	1.53e-8	Type 2 diabetes;
PAAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.14	0.7	3.82e-24	Smoking behavior;
PAAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg07689907	chr11:61582574	FADS1	-0.45	-4.44	-0.34	1.72e-5	Trans fatty acid levels;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20481151	chr12:117457813	FBXW8	-0.67	-6.51	-0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg09640425	chr7:158790006	NA	-0.41	-4.56	-0.35	1.03e-5	Facial morphology (factor 20);
PAAD	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg23024343	chr7:107201750	COG5	0.62	4.74	0.36	4.84e-6	Coronary artery disease;
PAAD	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.29	-0.6	1.53e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.49	5.36	0.4	3.07e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.08	-11.29	-0.68	7.68e-22	Blood pressure (smoking interaction);
PAAD	cis	rs6700896	0.500	rs10889573	chr1:66129256	C/T	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.96	-11.15	-0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs881827	0.962	rs12483634	chr21:47992401	G/A	cg11766577	chr21:47581405	C21orf56	-0.44	-4.65	-0.35	7.13e-6	Lymphocyte counts;
PAAD	cis	rs375066	0.935	rs428505	chr19:44428911	G/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg16653408	chr22:42313569	NA	-0.4	-4.37	-0.33	2.26e-5	Cognitive function;
PAAD	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.36	-0.4	3.04e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs8112211	0.731	rs4386247	chr19:38821474	A/G	cg14299480	chr19:38876666	GGN	-0.62	-6.07	-0.44	9.63e-9	Blood protein levels;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg26174226	chr8:58114915	NA	-0.69	-4.72	-0.36	5.37e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg14388049	chr10:71211838	TSPAN15	-0.58	-5.72	-0.42	5.48e-8	Venous thromboembolism;
PAAD	cis	rs950880	0.710	rs3732129	chr2:102957532	T/C	cg23450938	chr2:102972792	NA	0.45	4.8	0.36	3.78e-6	Serum protein levels (sST2);
PAAD	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg09659197	chr4:152720779	NA	0.39	5.03	0.38	1.35e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.15	0.55	1.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.65	-6.95	-0.49	1.02e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-4.82	-0.36	3.5e-6	Psoriasis;
PAAD	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.44	5.23	0.39	5.49e-7	Systemic lupus erythematosus;
PAAD	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	0.76	5.86	0.43	2.75e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs2786865	0.609	rs2744779	chr1:26014410	C/T	cg12446045	chr1:25857419	NA	-0.43	-4.32	-0.33	2.86e-5	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-1.03	-14.09	-0.75	2.24e-29	Breast cancer;
PAAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg07148914	chr20:33460835	GGT7	0.5	4.86	0.37	2.93e-6	Coronary artery disease;
PAAD	cis	rs10207060	0.500	rs11884577	chr2:240702216	C/G	cg07506560	chr2:240697449	NA	0.55	5.76	0.42	4.62e-8	Obesity-related traits;
PAAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02034447	chr16:89574710	SPG7	0.5	4.65	0.35	7.09e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.88	7.41	0.52	8.21e-12	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs34897497	chr10:46024677	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21014972	chr2:241380248	GPC1	0.62	6.65	0.47	5.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.29	-0.39	4.17e-7	Monocyte count;
PAAD	cis	rs452036	0.736	rs3729829	chr14:23885887	C/T	cg23613857	chr14:23356614	REM2	0.37	4.27	0.33	3.48e-5	Resting heart rate;P wave duration;
PAAD	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg27565382	chr3:53032988	SFMBT1	0.78	4.52	0.34	1.24e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.44	-8.39	-0.56	3.1e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.51	6.02	0.44	1.24e-8	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.68	-6.88	-0.49	1.5e-10	Height;
PAAD	cis	rs17032980	0.866	rs6546280	chr2:67314661	C/T	cg06994420	chr2:66672553	MEIS1	-0.5	-4.47	-0.34	1.53e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs67257959	0.708	rs13343952	chr19:17197064	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.9	0.37	2.4e-6	Selective IgA deficiency;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14523394	chr9:18777683	ADAMTSL1	-0.7	-6.55	-0.47	8.56e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11674713	chr2:10588468	ODC1;SNORA80B	-0.76	-6.65	-0.47	4.94e-10	Neuroticism;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.73	-6.87	-0.49	1.51e-10	Paraoxonase activity;
PAAD	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.4	-4.92	-0.37	2.27e-6	Red cell distribution width;
PAAD	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.33	-9.17	-0.6	3.18e-16	Atopic dermatitis;
PAAD	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs7534824	0.625	rs17610202	chr1:101429724	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05191435	chr6:7987870	MGC26597	-0.64	-6.37	-0.46	2.14e-9	Smoking initiation;
PAAD	cis	rs7792596	1.000	rs6952539	chr7:93994003	A/G	cg20814616	chr7:94014465	NA	-0.44	-4.55	-0.35	1.09e-5	Intelligence;
PAAD	cis	rs9876781	1.000	rs28824259	chr3:48425675	T/C	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.93	11.62	0.69	1e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.77	-7.83	-0.54	7.86e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg19636519	chr7:99541626	NA	0.4	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs2718812	1.000	rs2718811	chr3:133399738	T/A	cg08048268	chr3:133502702	NA	0.42	5.05	0.38	1.24e-6	Iron status biomarkers;
PAAD	cis	rs11235843	0.929	rs4944856	chr11:73405396	G/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	trans	rs3905000	1.000	rs7027196	chr9:107649606	C/T	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs54211	0.831	rs137649	chr22:39730700	T/C	cg11247378	chr22:39784982	NA	-0.77	-4.47	-0.34	1.51e-5	Sudden cardiac arrest;
PAAD	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.53	-5.47	-0.41	1.77e-7	Height;
PAAD	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg19336497	chr11:14380999	RRAS2	-0.48	-5.27	-0.39	4.7e-7	Vitamin D levels;
PAAD	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.61	-0.41	9.27e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10750165	0.644	rs10892452	chr11:119630385	T/C	cg24085502	chr11:119066850	CCDC153	-0.33	-4.29	-0.33	3.22e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs1042026	0.848	rs975833	chr4:100201739	G/C	cg09112717	chr4:100009950	ADH5	-0.51	-4.59	-0.35	9.37e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.33	0.33	2.73e-5	Personality dimensions;
PAAD	cis	rs7301016	0.846	rs7296573	chr12:63033041	A/C	cg11441379	chr12:63026424	NA	0.89	6.47	0.46	1.26e-9	IgG glycosylation;
PAAD	cis	rs4740619	0.967	rs4741523	chr9:15634244	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.41	-0.34	1.98e-5	Body mass index;
PAAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.45	5.76	0.42	4.52e-8	Childhood ear infection;
PAAD	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg18898632	chr2:242989856	NA	-0.83	-6.2	-0.45	5.01e-9	Obesity-related traits;
PAAD	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.75	8.63	0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Bladder cancer;
PAAD	cis	rs7705042	0.828	rs1036209	chr5:141498632	T/A	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.18	-0.39	7.07e-7	Asthma;
PAAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-4.97	-0.37	1.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-5.09	-0.38	1.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8067354	0.958	rs2777889	chr17:57848006	A/G	cg02344993	chr17:57696989	CLTC	0.54	4.96	0.37	1.86e-6	Hemoglobin concentration;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg15181151	chr6:150070149	PCMT1	0.57	6.14	0.45	6.88e-9	Lung cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07149862	chr1:185286441	IVNS1ABP	-0.68	-6.45	-0.46	1.38e-9	Lung cancer in ever smokers;
PAAD	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.87	8.75	0.58	3.81e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.82	-6.07	-0.44	9.8e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg02027945	chr11:20618230	NA	0.33	4.65	0.35	7.19e-6	Pursuit maintenance gain;
PAAD	cis	rs4795519	0.769	rs7210668	chr17:22168795	A/G	cg22648282	chr17:21454238	C17orf51	-0.55	-5.48	-0.41	1.7e-7	Chronic myeloid leukemia;
PAAD	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.83	-0.36	3.28e-6	Hirschsprung disease;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.36	0.46	2.21e-9	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23158103	chr7:148848205	ZNF398	-0.6	-5.9	-0.43	2.3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.34e-14	Lung cancer;
PAAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12760731	0.623	rs61520802	chr1:178428494	G/A	cg00404053	chr1:178313656	RASAL2	0.64	5.46	0.41	1.89e-7	Obesity-related traits;
PAAD	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.48	4.26	0.33	3.54e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg13175173	chr14:55914753	NA	-0.32	-4.28	-0.33	3.34e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs258892	0.895	rs9293442	chr5:72055595	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7567389	0.719	rs4150404	chr2:128050000	A/G	cg09760422	chr2:128146352	NA	-0.38	-5.87	-0.43	2.7e-8	Self-rated health;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.78	6.09	0.44	8.93e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg14343924	chr8:8086146	FLJ10661	0.48	4.61	0.35	8.61e-6	Joint mobility (Beighton score);
PAAD	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-9.95	-0.63	2.76e-18	Electrocardiographic conduction measures;
PAAD	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2229238	0.868	rs41308419	chr1:154507197	T/C	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.52	-0.41	1.46e-7	Tonsillectomy;
PAAD	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.8	-6.98	-0.49	8.72e-11	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.9	11.16	0.67	1.67e-21	Dental caries;
PAAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg03233332	chr7:66118400	NA	-0.41	-4.35	-0.33	2.52e-5	Aortic root size;
PAAD	cis	rs1870584	0.522	rs4791486	chr17:11908542	A/T	cg18951537	chr17:11950516	MAP2K4	-0.48	-4.46	-0.34	1.61e-5	Response to amphetamines;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.79	0.62	7.68e-18	Platelet count;
PAAD	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21984481	chr17:79567631	NPLOC4	-0.63	-7.7	-0.53	1.62e-12	Eye color traits;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg21269045	chr12:125625041	AACS	-0.48	-4.67	-0.35	6.58e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.71	7.04	0.5	6.08e-11	Mosquito bite size;
PAAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs4141404	0.604	rs2103853	chr22:31855475	T/C	cg02404636	chr22:31891804	SFI1	0.59	5.74	0.42	4.97e-8	Paclitaxel-induced neuropathy;
PAAD	trans	rs111756027	0.522	rs72800054	chr16:77280379	A/G	cg17418387	chr1:17761802	RCC2	-0.78	-6.43	-0.46	1.53e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.65	7.35	0.51	1.13e-11	Body mass index;
PAAD	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg25208724	chr1:156163844	SLC25A44	0.51	4.42	0.34	1.9e-5	Ischemic stroke;
PAAD	cis	rs2885056	0.891	rs73018656	chr19:10689797	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.44	4.46	0.34	1.59e-5	Age of smoking initiation;
PAAD	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.49	-0.41	1.63e-7	Monocyte percentage of white cells;
PAAD	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.66	-7.64	-0.53	2.26e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.21e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg15764593	chr10:829463	NA	-0.82	-4.54	-0.35	1.13e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.62	0.41	8.84e-8	Tonsillectomy;
PAAD	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.5	5.28	0.39	4.29e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-14.46	-0.76	2.36e-30	Primary sclerosing cholangitis;
PAAD	cis	rs4378999	0.660	rs6800279	chr3:51086691	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.55	-4.31	-0.33	2.9e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs16970672	0.501	rs4789525	chr17:76050776	T/C	cg15618347	chr17:76503643	DNAH17	-0.45	-4.72	-0.36	5.35e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg15181151	chr6:150070149	PCMT1	0.57	5.79	0.42	3.98e-8	Lung cancer;
PAAD	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.52	-10.08	-0.63	1.3e-18	Alzheimer's disease (late onset);
PAAD	cis	rs6594713	0.604	rs1922678	chr5:112637874	G/C	cg12552261	chr5:112820674	MCC	0.67	4.79	0.36	3.9e-6	Brain cytoarchitecture;
PAAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.68e-5	Skin colour saturation;
PAAD	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.43	-4.26	-0.33	3.57e-5	Ulcerative colitis;
PAAD	cis	rs72627123	0.737	rs2240632	chr14:74371166	T/C	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.88	10.69	0.66	2.98e-20	Menopause (age at onset);
PAAD	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg12633918	chr20:23549525	CST9L	-0.42	-4.63	-0.35	7.63e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.52	-4.75	-0.36	4.65e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.1	-0.5	4.59e-11	Aortic root size;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg10616300	chr11:66138557	SLC29A2	0.34	4.72	0.36	5.42e-6	Educational attainment (years of education);
PAAD	cis	rs7929679	0.551	rs10836302	chr11:34791897	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04633058	chr17:48474099	LRRC59	0.61	7.09	0.5	4.69e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.72	-8.78	-0.58	3.24e-15	Cystic fibrosis severity;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.71	-7.6	-0.52	2.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.11	0.63	1.06e-18	Bone mineral density;
PAAD	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.69	6.8	0.48	2.25e-10	Platelet distribution width;
PAAD	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6e-9	Subjective well-being;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.07	-0.77	5.6199999999999995e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06850241	chr22:41845214	NA	0.57	5.03	0.38	1.38e-6	Vitiligo;
PAAD	cis	rs10916814	0.632	rs4655224	chr1:20902195	A/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg14092988	chr3:52407081	DNAH1	0.54	6.91	0.49	1.22e-10	Bipolar disorder;
PAAD	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.94	10.34	0.64	2.58e-19	Breast cancer;
PAAD	cis	rs9322817	0.617	rs9391242	chr6:105231257	G/A	cg02098413	chr6:105308735	HACE1	-0.44	-5.49	-0.41	1.68e-7	Thyroid stimulating hormone;
PAAD	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.46	-7.01	-0.49	7.45e-11	Cutaneous nevi;
PAAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg22857025	chr5:266934	NA	-1.09	-4.44	-0.34	1.74e-5	Breast cancer;
PAAD	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.34	1.34e-5	Bladder cancer;
PAAD	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.6	0.52	2.76e-12	Multiple sclerosis;
PAAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.24	10.39	0.64	1.98e-19	Breast cancer;
PAAD	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg18551225	chr6:44695536	NA	-0.7	-7.08	-0.5	4.89e-11	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.62	0.57	8.17e-15	Morning vs. evening chronotype;
PAAD	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.6	5.27	0.39	4.56e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02978262	chr7:32582769	AVL9	-0.58	-6.29	-0.45	3.28e-9	Obesity-related traits;
PAAD	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	9.78	0.62	7.76e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.33	-0.33	2.68e-5	Height;
PAAD	trans	rs901683	1.000	rs17157887	chr10:46020348	G/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs900145	0.859	rs4603287	chr11:13301335	T/G	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.8	-0.36	3.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	1.0	10.96	0.66	5.86e-21	Homoarginine levels;
PAAD	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.51	0.34	1.31e-5	Oral cavity cancer;
PAAD	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.72	-6.25	-0.45	3.97e-9	Diabetic retinopathy;
PAAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.51	-4.41	-0.34	1.98e-5	Self-reported allergy;
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.97	-0.44	1.59e-8	Cystic fibrosis severity;
PAAD	trans	rs3935740	0.649	rs28613351	chr15:81619926	G/T	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs7074356	0.688	rs7898558	chr10:82183505	G/T	cg19423196	chr10:82049429	MAT1A	0.44	4.71	0.36	5.55e-6	Borderline personality disorder;
PAAD	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg06209491	chr1:40138402	NT5C1A	-0.65	-6.26	-0.45	3.73e-9	Amyotrophic lateral sclerosis;
PAAD	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.62	0.53	2.53e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.49	4.52	0.34	1.21e-5	Neutrophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg11764359	chr7:65958608	NA	-0.68	-5.05	-0.38	1.22e-6	Diabetic kidney disease;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.56	5.46	0.4	1.91e-7	Resistin levels;
PAAD	cis	rs61863818	0.521	rs7923907	chr10:99143499	C/T	cg10705379	chr10:99080932	FRAT1	-0.42	-5.17	-0.39	7.26e-7	Monocyte percentage of white cells;
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.51	8.7	0.58	4.97e-15	IgG glycosylation;
PAAD	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.84	10.49	0.65	1.06e-19	Menopause (age at onset);
PAAD	cis	rs9815354	0.857	rs6798152	chr3:42023558	A/T	cg03022575	chr3:42003672	ULK4	0.78	5.47	0.41	1.81e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.82	-5.55	-0.41	1.23e-7	Red cell distribution width;
PAAD	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.68	-7.26	-0.51	1.91e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs8105895	0.935	rs4542784	chr19:22239751	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs13053817	1.000	rs73405097	chr22:29855836	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.99	-0.37	1.66e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg07153921	chr17:41440717	NA	-0.4	-4.26	-0.33	3.52e-5	Menopause (age at onset);
PAAD	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14169450	chr9:139327907	INPP5E	0.5	4.82	0.36	3.49e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	1.03e-18	Response to antipsychotic treatment;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26549601	chr10:134560360	INPP5A	-0.5	-5.03	-0.38	1.39e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.91	11.86	0.69	2.22e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	1.21	11.75	0.69	4.23e-23	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10684940	chr20:2640876	IDH3B	-0.74	-7.7	-0.53	1.62e-12	Obesity-related traits;
PAAD	cis	rs13070279	0.786	rs3796224	chr3:71823582	A/G	cg03457142	chr3:71804859	EIF4E3	0.52	4.32	0.33	2.8e-5	Monocyte count;
PAAD	cis	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg25327839	chr11:73308997	FAM168A	-0.51	-4.46	-0.34	1.59e-5	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16063666	chr7:86974833	TP53TG1;CROT	0.57	6.41	0.46	1.73e-9	Monocyte percentage of white cells;
PAAD	trans	rs6474412	0.581	rs892413	chr8:42614378	A/C	cg07164722	chr1:247587378	NLRP3	-0.59	-6.53	-0.47	9.48e-10	Smoking behavior;
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg19337854	chr7:99768885	GPC2	0.52	4.84	0.37	3.23e-6	Lung function (FEV1/FVC);
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	5.35	0.4	3.18e-7	Obesity-related traits;
PAAD	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.15	-0.39	7.82e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23476955	chr19:16308634	AP1M1	0.6	6.44	0.46	1.51e-9	Myopia (pathological);
PAAD	cis	rs3206736	0.548	rs328940	chr7:35050364	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.72	-7.58	-0.52	3.26e-12	Menarche (age at onset);
PAAD	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.33	0.4	3.42e-7	Male-pattern baldness;
PAAD	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.94	7.64	0.53	2.32e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg21546286	chr11:48923668	NA	-0.52	-5.27	-0.39	4.52e-7	HDL cholesterol;
PAAD	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs17152411	1.000	rs1065301	chr10:126616038	A/G	cg07906193	chr10:126599966	NA	0.72	5.64	0.42	8.19e-8	Height;
PAAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs4975616	0.686	rs40182	chr5:1350397	G/A	cg26209169	chr5:1316264	NA	0.37	4.26	0.33	3.61e-5	Lung cancer;
PAAD	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.48	-6.04	-0.44	1.11e-8	Menopause (age at onset);
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg15782153	chr7:917662	C7orf20	0.52	6.46	0.46	1.32e-9	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg00071950	chr4:10020882	SLC2A9	-0.67	-5.59	-0.41	1.02e-7	Schizophrenia (age at onset);
PAAD	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg15660573	chr17:549704	VPS53	-0.76	-7.67	-0.53	1.94e-12	Prostate cancer;
PAAD	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.77	-0.36	4.35e-6	Smoking behavior;
PAAD	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.56	-6.36	-0.46	2.22e-9	Blood metabolite levels;
PAAD	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.74	8.23	0.56	8.08e-14	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg06138931	chr13:21896616	NA	-0.65	-4.41	-0.34	1.98e-5	White matter hyperintensity burden;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg05627522	chr15:75251581	NA	0.5	5.96	0.43	1.73e-8	Breast cancer;
PAAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-6.49	-0.47	1.15e-9	Monocyte count;
PAAD	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.2	9.63	0.62	2.02e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.39e-10	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	9.51	0.61	4.07e-17	Platelet count;
PAAD	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg11380483	chr2:127933992	NA	-0.47	-4.88	-0.37	2.64e-6	Self-rated health;
PAAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg19847866	chr10:1019161	NA	-0.6	-4.64	-0.35	7.32e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg10515948	chr2:242674491	D2HGDH	0.63	6.29	0.45	3.26e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg06671706	chr8:8559999	CLDN23	0.68	6.85	0.49	1.75e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17309003	chr14:77335130	C14orf166B	-0.64	-6.81	-0.48	2.12e-10	Obesity-related traits;
PAAD	cis	rs3857067	0.578	rs2865340	chr4:95099606	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-6.09	-0.44	8.73e-9	QT interval;
PAAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs9585327	1.000	rs9585327	chr13:100689354	G/A	cg11288260	chr13:100117058	NA	0.22	4.32	0.33	2.82e-5	Myopia;
PAAD	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg23665729	chr3:49977591	RBM6	0.6	4.34	0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs943466	1.000	rs943461	chr6:33769409	C/G	cg04704449	chr6:33738291	NA	-0.48	-4.88	-0.37	2.7e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs501120	0.810	rs510785	chr10:44749990	C/A	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg11608241	chr8:8085544	FLJ10661	-0.51	-4.29	-0.33	3.13e-5	Cervical cancer;
PAAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg13722127	chr7:150037890	RARRES2	0.61	6.0	0.44	1.38e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.43	-4.84	-0.37	3.2e-6	Blood pressure (smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11337261	chr6:3118923	BPHL	0.61	7.04	0.5	6.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.75	-4.91	-0.37	2.37e-6	Lung cancer;
PAAD	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.48	4.96	0.37	1.84e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27425459	chr2:105697589	MRPS9	-0.73	-7.45	-0.52	6.39e-12	Obesity-related traits;
PAAD	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	7.33	0.51	1.3e-11	Migraine;Coronary artery disease;
PAAD	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg26031613	chr14:104095156	KLC1	0.47	5.22	0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs4722404	0.620	rs6978200	chr7:3118835	A/G	cg19214707	chr7:3157722	NA	-0.46	-4.54	-0.35	1.13e-5	Atopic dermatitis;
PAAD	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.63	6.05	0.44	1.07e-8	White matter hyperintensity burden;
PAAD	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.44e-6	Type 2 diabetes;
PAAD	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.52	5.08	0.38	1.11e-6	Mood instability;
PAAD	cis	rs12431939	0.671	rs2999384	chr14:51650328	G/T	cg23942311	chr14:51606299	NA	0.57	4.9	0.37	2.43e-6	Cancer;
PAAD	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.89	-10.74	-0.66	2.3e-20	Tonsillectomy;
PAAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.73	-6.95	-0.49	1.01e-10	Monocyte count;
PAAD	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.61	-0.41	9.15e-8	Bladder cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01112927	chr2:71357293	MCEE;MPHOSPH10	-0.65	-7.82	-0.54	8.01e-13	Body fat percentage;
PAAD	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.97	-8.42	-0.56	2.63e-14	Dilated cardiomyopathy;
PAAD	cis	rs2662368	0.542	rs173282	chr5:77104610	C/T	cg02570643	chr5:77531473	AP3B1	-0.42	-4.53	-0.34	1.18e-5	Platelet distribution width;
PAAD	cis	rs6142102	0.602	rs4911396	chr20:32579945	C/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.93	0.37	2.18e-6	Skin pigmentation;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg15693483	chr7:1102177	C7orf50	0.42	4.89	0.37	2.59e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg10818794	chr15:86012489	AKAP13	-0.58	-4.9	-0.37	2.42e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-5.57	-0.41	1.15e-7	Coronary artery disease;
PAAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.63	7.18	0.5	2.84e-11	High light scatter reticulocyte count;
PAAD	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.52	-0.34	1.25e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23158103	chr7:148848205	ZNF398	-0.6	-5.86	-0.43	2.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg05697835	chr1:2722811	NA	0.39	4.28	0.33	3.29e-5	Ulcerative colitis;
PAAD	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.47	-4.87	-0.37	2.76e-6	Motion sickness;
PAAD	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.86	10.96	0.66	5.73e-21	Body mass index;
PAAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.8	8.49	0.57	1.78e-14	Calcium levels;
PAAD	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg00490450	chr3:139108681	COPB2	-0.66	-6.0	-0.44	1.37e-8	Obesity-related traits;
PAAD	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.89	0.37	2.59e-6	Height;
PAAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.77	8.39	0.56	3.2e-14	Blood metabolite levels;
PAAD	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	5.47	0.41	1.84e-7	LDL cholesterol;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.76	0.36	4.46e-6	Electroencephalogram traits;
PAAD	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg13259177	chr13:114761607	RASA3	-0.87	-7.23	-0.51	2.23e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs7168592	1.000	rs4489986	chr15:101731838	A/G	cg24254196	chr15:101719523	CHSY1	-0.66	-4.69	-0.36	6.02e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-4.7	-0.36	5.84e-6	Axial length;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.65	0.35	7.04e-6	Red cell distribution width;
PAAD	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg16898833	chr6:26189333	HIST1H4D	0.93	5.29	0.39	4.2e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.71	-5.38	-0.4	2.8e-7	Initial pursuit acceleration;
PAAD	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.55	-5.4	-0.4	2.48e-7	Mean corpuscular volume;
PAAD	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.27	-0.51	1.77e-11	Coronary artery disease;
PAAD	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21028142	chr17:79581711	NPLOC4	0.48	5.58	0.41	1.09e-7	Eye color traits;
PAAD	cis	rs66530629	0.797	rs12758422	chr1:25078061	T/C	cg01905478	chr1:25040257	NA	-0.47	-5.12	-0.38	8.99e-7	Plateletcrit;
PAAD	cis	rs743757	1.000	rs4688720	chr3:50497035	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.67	4.53	0.34	1.18e-5	Diastolic blood pressure;
PAAD	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.53	-0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18057185	chr3:48342999	NME6	-0.66	-6.66	-0.48	4.62e-10	Smoking initiation;
PAAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.93	8.16	0.55	1.18e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.67	4.9	0.37	2.48e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg25124228	chr12:125621409	AACS	-0.63	-5.91	-0.43	2.14e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg26312998	chr6:43337775	ZNF318	0.67	5.34	0.4	3.25e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13939156	chr17:80058883	NA	0.42	4.57	0.35	9.92e-6	Life satisfaction;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21740204	chr9:72873544	SMC5	0.71	6.57	0.47	7.36e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.78	6.92	0.49	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.64	6.16	0.45	6.27e-9	Bone properties (heel);
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg12757816	chr2:10669957	NA	0.56	6.06	0.44	1.04e-8	Prostate cancer;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15553612	chr1:119520934	TBX15	0.63	6.44	0.46	1.49e-9	Smoking initiation;
PAAD	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg00129232	chr17:37814104	STARD3	-0.67	-4.67	-0.35	6.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11168618	0.509	rs2705127	chr12:48883012	T/C	cg01881778	chr12:48919444	OR8S1	0.45	4.54	0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg21699342	chr2:239360505	ASB1	0.53	6.39	0.46	1.94e-9	Multiple system atrophy;
PAAD	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg07967677	chr1:161008977	TSTD1	0.5	4.41	0.34	1.96e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	0.54	5.8	0.43	3.76e-8	Hypothyroidism;
PAAD	cis	rs1572438	0.929	rs9406073	chr6:854451	T/C	cg21062780	chr6:887772	NA	-0.46	-4.33	-0.33	2.68e-5	Aging;
PAAD	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg05425664	chr17:57184151	TRIM37	0.64	6.06	0.44	1.01e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.68	-7.32	-0.51	1.33e-11	Lung cancer;
PAAD	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.49	5.42	0.4	2.32e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.61	6.12	0.44	7.57e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg21280719	chr6:42927975	GNMT	-0.43	-6.26	-0.45	3.69e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.54	6.93	0.49	1.1e-10	Alcohol dependence;
PAAD	cis	rs757081	0.507	rs10832727	chr11:17065289	A/G	cg15084286	chr11:17036142	PLEKHA7	0.53	4.81	0.36	3.59e-6	Systolic blood pressure;
PAAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.44	4.59	0.35	9.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs367943	0.665	rs6889298	chr5:112965011	C/T	cg12552261	chr5:112820674	MCC	0.49	4.94	0.37	2.07e-6	Type 2 diabetes;
PAAD	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.86	8.77	0.58	3.44e-15	Uric acid levels;
PAAD	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.38	-0.4	2.74e-7	Subjective well-being;
PAAD	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.42	5.3	0.39	4.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	6.68	0.48	4.22e-10	Menarche (age at onset);
PAAD	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.34	0.51	1.2e-11	Response to antipsychotic treatment;
PAAD	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg17595323	chr11:93583763	C11orf90	0.34	4.25	0.33	3.71e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.98	0.54	3.39e-13	Corneal astigmatism;
PAAD	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.82	-9.3	-0.6	1.46e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.84	-0.54	7.48e-13	Colorectal cancer;
PAAD	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.81	-8.76	-0.58	3.65e-15	Prostate cancer;
PAAD	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.11	0.5	4.19e-11	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.63	0.42	8.4e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.96	0.37	1.86e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs783540	1.000	rs783540	chr15:83254708	C/T	cg00614314	chr15:82944287	LOC80154	-0.44	-4.48	-0.34	1.47e-5	Schizophrenia;
PAAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg18005901	chr6:33739558	LEMD2	-0.57	-4.56	-0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs9876781	1.000	rs13071337	chr3:48438189	A/G	cg24898236	chr3:49228699	LOC646498	0.4	4.36	0.33	2.43e-5	Longevity;
PAAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.84	7.51	0.52	4.59e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs9600832	0.574	rs9565317	chr13:36049080	T/G	cg20704442	chr13:36052768	MIR548F5;NBEA	0.31	4.28	0.33	3.25e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	4.97	0.37	1.77e-6	Depressive symptoms;
PAAD	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-4.96	-0.37	1.9e-6	Reticulocyte count;
PAAD	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	6.32	0.46	2.81e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.67	-0.42	6.98e-8	Mean corpuscular volume;
PAAD	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg10253484	chr15:75165896	SCAMP2	0.51	4.73	0.36	5.15e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs6867913	0.533	rs252152	chr5:141445774	A/G	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.66	-0.35	6.99e-6	Asthma;
PAAD	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg00786952	chr1:21763130	NA	0.54	5.41	0.4	2.43e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.37	-4.84	-0.37	3.22e-6	Primary biliary cholangitis;
PAAD	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.42	-0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.51	5.75	0.42	4.84e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.54	5.18	0.39	6.88e-7	Tonsillectomy;
PAAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs8077577	0.747	rs12451698	chr17:18237116	A/G	cg16794390	chr17:18148240	FLII	0.5	4.3	0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg24154853	chr7:158122151	PTPRN2	0.81	7.5	0.52	4.89e-12	Response to amphetamines;
PAAD	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs1371614	0.611	rs3845685	chr2:27130332	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.03e-7	Life satisfaction;
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.36	-4.43	-0.34	1.76e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.64	-0.53	2.21e-12	Hemoglobin concentration;
PAAD	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs9283706	0.623	rs1159201	chr5:66311339	C/T	cg11590213	chr5:66331682	MAST4	-0.54	-4.63	-0.35	7.79e-6	Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-8.34	-0.56	4.17e-14	Gut microbiome composition (summer);
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs11264213	0.786	rs72659698	chr1:36314688	G/A	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	5.61	0.41	9.28e-8	Mood instability;
PAAD	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.58	-5.64	-0.42	8.09e-8	Rheumatoid arthritis;
PAAD	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.22	-0.39	5.7e-7	Reticulocyte count;
PAAD	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.48	4.43	0.34	1.8e-5	Endometrial cancer;
PAAD	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg09168692	chr1:7887560	PER3	-0.43	-4.44	-0.34	1.7e-5	Inflammatory bowel disease;
PAAD	cis	rs58521262	0.556	rs289321	chr19:23157281	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.1e-12	Colorectal cancer;
PAAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.49	4.97	0.37	1.81e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6782025	1.000	rs3732404	chr3:121134991	A/G	cg16417163	chr3:121280760	NA	-0.48	-4.88	-0.37	2.61e-6	Aging (facial);
PAAD	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12292205	chr6:26970375	C6orf41	-0.48	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7567389	0.677	rs4662720	chr2:128076607	T/C	cg11380483	chr2:127933992	NA	-0.48	-4.69	-0.36	6.01e-6	Self-rated health;
PAAD	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg15507776	chr3:136538369	TMEM22	0.47	4.64	0.35	7.61e-6	Neuroticism;
PAAD	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg13057898	chr1:3703894	LRRC47	0.42	4.27	0.33	3.47e-5	Red cell distribution width;
PAAD	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.23e-14	Colorectal cancer;
PAAD	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.01	11.84	0.69	2.45e-23	Breast cancer;
PAAD	cis	rs12431939	1.000	rs67628731	chr14:51662708	C/G	cg23942311	chr14:51606299	NA	-0.6	-4.86	-0.37	2.93e-6	Cancer;
PAAD	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.57	5.41	0.4	2.44e-7	Bone properties (heel);
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg15478930	chr2:27652102	NRBP1	0.49	4.44	0.34	1.71e-5	Total body bone mineral density;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.81	9.27	0.6	1.69e-16	Methadone dose in opioid dependence;
PAAD	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg08514558	chr10:81106712	PPIF	0.5	6.0	0.44	1.36e-8	Height;
PAAD	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.77	-8.54	-0.57	1.33e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72772090	1.000	rs72772090	chr5:96036311	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.3	-0.45	3.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.54e-6	Plateletcrit;
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.77	-8.12	-0.55	1.52e-13	Prostate cancer;
PAAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg09127314	chr1:152161683	NA	-0.73	-5.01	-0.38	1.5e-6	Atopic dermatitis;
PAAD	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-4.83	-0.36	3.36e-6	Menarche (age at onset);
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01616529	chr11:638424	DRD4	-0.63	-5.64	-0.42	8.11e-8	Systemic lupus erythematosus;
PAAD	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	1.3	10.84	0.66	1.18e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14094449	chr14:60558589	C14orf135	0.55	6.44	0.46	1.47e-9	Energy expenditure (24h);
PAAD	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	1.21	8.75	0.58	3.9e-15	IgG glycosylation;
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-7.76	-0.53	1.17e-12	Prostate cancer;
PAAD	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	7.18	0.5	2.85e-11	Body mass index (adult);
PAAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg04450456	chr4:17643702	FAM184B	-0.48	-4.89	-0.37	2.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs4698934	0.660	rs17035436	chr4:106227373	T/C	cg27505036	chr16:1497467	CLCN7	0.88	6.34	0.46	2.53e-9	Melanoma;
PAAD	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg24747557	chr10:131355152	MGMT	0.52	5.37	0.4	2.91e-7	Response to temozolomide;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.83	-8.81	-0.58	2.71e-15	DNA methylation (variation);
PAAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg21951975	chr1:209979733	IRF6	0.41	5.15	0.39	8e-7	Monobrow;
PAAD	cis	rs6496667	0.609	rs7183707	chr15:90883733	G/T	cg22089800	chr15:90895588	ZNF774	0.62	5.39	0.4	2.59e-7	Rheumatoid arthritis;
PAAD	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	trans	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg13253945	chr7:84569394	NA	-0.65	-6.31	-0.46	2.84e-9	Survival in colon cancer;
PAAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.7	10.77	0.66	1.87e-20	Schizophrenia;
PAAD	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.98	-12.71	-0.72	1.1e-25	Coronary artery disease;
PAAD	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	1.04	7.28	0.51	1.67e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00982548	chr2:198649783	BOLL	-0.8	-5.8	-0.43	3.74e-8	Ulcerative colitis;
PAAD	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.65	7.2	0.5	2.64e-11	Corneal astigmatism;
PAAD	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.42	-0.52	7.8e-12	Eosinophil percentage of white cells;
PAAD	cis	rs17155006	0.691	rs413412	chr7:107745399	A/G	cg05962710	chr7:107745446	LAMB4	-0.58	-7.8	-0.53	9.39e-13	Pneumococcal bacteremia;
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.62	7.71	0.53	1.56e-12	Hypertriglyceridemia;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.69	-7.72	-0.53	1.44e-12	Lung cancer;
PAAD	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.94	4.78	0.36	4.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07677032	chr17:61819896	STRADA	-0.56	-5.63	-0.42	8.56e-8	Prudent dietary pattern;
PAAD	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.68	4.89	0.37	2.55e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.89	10.21	0.64	5.93e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13939156	chr17:80058883	NA	-0.41	-4.35	-0.33	2.5e-5	Life satisfaction;
PAAD	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.5	-5.36	-0.4	3e-7	Retinal vascular caliber;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	8.47	0.57	1.96e-14	Lymphocyte counts;
PAAD	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg20913747	chr6:44695427	NA	-0.68	-6.81	-0.48	2.15e-10	Total body bone mineral density;
PAAD	cis	rs7236492	0.935	rs11659416	chr18:77226973	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.67	-7.43	-0.52	7.22e-12	Type 2 diabetes;
PAAD	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.76	7.44	0.52	6.81e-12	Total body bone mineral density;
PAAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.16	0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.55	4.69	0.36	5.97e-6	Lymphocyte counts;
PAAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.66	-6.99	-0.49	7.91e-11	Obesity-related traits;
PAAD	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.8	7.45	0.52	6.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.58	-4.8	-0.36	3.83e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.7	7.9	0.54	5.09e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.51	-4.48	-0.34	1.45e-5	Pursuit maintenance gain;
PAAD	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.62	-0.47	5.72e-10	Triglycerides;
PAAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg14983838	chr19:29218262	NA	0.72	6.22	0.45	4.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.51	-4.57	-0.35	9.88e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.98	-8.19	-0.55	9.95e-14	Neutrophil percentage of white cells;
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.72	-5.46	-0.4	1.92e-7	Type 2 diabetes;
PAAD	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.56	-5.49	-0.41	1.68e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.21	-0.39	5.93e-7	Lung cancer;
PAAD	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.73	5.65	0.42	7.66e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.58	6.06	0.44	1.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg04717802	chr22:42394638	WBP2NL	0.53	4.49	0.34	1.41e-5	Birth weight;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.49	-0.34	1.43e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.49	-0.34	1.38e-5	Height;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.81	5.34	0.4	3.36e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs988913	0.671	rs4712083	chr6:54853670	C/A	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.96	12.31	0.71	1.35e-24	Menopause (age at onset);
PAAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg15847926	chr7:2749597	AMZ1	-0.38	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg11764359	chr7:65958608	NA	-0.79	-5.29	-0.39	4.24e-7	Diabetic kidney disease;
PAAD	cis	rs12935418	0.583	rs7186230	chr16:80964620	A/G	cg16651780	chr16:81037892	C16orf61	0.59	4.92	0.37	2.22e-6	Mean corpuscular volume;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg25287198	chr4:183728479	NA	0.9	7.82	0.54	8.09e-13	Pediatric autoimmune diseases;
PAAD	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg21584241	chr15:63341463	TPM1	0.67	4.9	0.37	2.38e-6	Orofacial clefts;
PAAD	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.29	-5.6	-0.41	9.92e-8	Urinary metabolites;
PAAD	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg08079166	chr15:68083412	MAP2K5	-0.54	-4.99	-0.38	1.61e-6	Restless legs syndrome;
PAAD	cis	rs3106136	0.681	rs6847590	chr4:95311787	C/T	cg11021082	chr4:95130006	SMARCAD1	0.54	5.01	0.38	1.53e-6	Capecitabine sensitivity;
PAAD	cis	rs1539053	1.000	rs1539053	chr1:58099707	A/G	cg00026909	chr1:58089001	DAB1	-0.69	-7.99	-0.54	3.11e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.18	0.81	1.89e-37	Prudent dietary pattern;
PAAD	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9426935	0.681	rs9427318	chr1:153980904	T/G	cg05848175	chr1:153330257	S100A9	0.35	4.25	0.33	3.77e-5	Lentiform nucleus volume;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.74	0.82	7.26e-39	Height;
PAAD	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.45	-4.35	-0.33	2.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.78	-5.21	-0.39	6.19e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7627468	1.000	rs9814524	chr3:121932534	A/G	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg19847866	chr10:1019161	NA	-0.57	-4.61	-0.35	8.39e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs798766	1.000	rs798744	chr4:1714684	C/A	cg05874882	chr4:1763078	NA	-0.38	-5.3	-0.4	3.93e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg02683114	chr2:24398427	C2orf84	-0.46	-4.82	-0.36	3.4e-6	Sjögren's syndrome;
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.45	4.78	0.36	4.18e-6	Mean corpuscular volume;
PAAD	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.81	-8.68	-0.58	5.56e-15	Mortality in heart failure;
PAAD	cis	rs4919087	0.748	rs793517	chr10:98987522	A/G	cg06569542	chr10:98946673	SLIT1	0.49	4.89	0.37	2.52e-6	Monocyte count;
PAAD	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.61	-5.4	-0.4	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6499755	0.677	rs31092	chr16:55363835	C/A	cg02859129	chr16:55357253	IRX6	0.35	4.89	0.37	2.55e-6	Hypospadias;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.21	0.45	4.94e-9	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.63	5.47	0.41	1.79e-7	Red blood cell count;
PAAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-6.92	-0.49	1.17e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.53	5.24	0.39	5.23e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.16	17.02	0.81	4.89e-37	Cognitive function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10372701	chr3:142546496	PCOLCE2	0.58	7.07	0.5	5.17e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-1.37	-11.0	-0.67	4.65e-21	Schizophrenia;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.35	-0.4	3.23e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg24220031	chr2:73402428	NA	-0.3	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-16.33	-0.8	2.99e-35	Exhaled nitric oxide output;
PAAD	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.22	-0.45	4.64e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg22508957	chr16:3507546	NAT15	0.82	6.27	0.45	3.62e-9	Tuberculosis;
PAAD	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-1.01	-7.75	-0.53	1.2e-12	Blood protein levels;
PAAD	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.2	0.6	2.65e-16	Parkinson's disease;
PAAD	trans	rs12744757	1	rs12744757	chr1:11906821	C/T	cg03943081	chr10:133110646	TCERG1L	0.68	6.55	0.47	8.52e-10	Systolic blood pressure;
PAAD	cis	rs10078	0.660	rs11746538	chr5:427466	A/C	cg08916839	chr5:415575	AHRR	0.6	4.48	0.34	1.45e-5	Fat distribution (HIV);
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.11	-0.38	9.66e-7	Prudent dietary pattern;
PAAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.62	-5.41	-0.4	2.42e-7	Mean corpuscular volume;
PAAD	cis	rs7646881	0.767	rs58152433	chr3:158456640	A/G	cg19483011	chr3:158453295	NA	-0.65	-5.25	-0.39	5.01e-7	Tetralogy of Fallot;
PAAD	trans	rs901683	1.000	rs71496603	chr10:46005649	A/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4594175	0.962	rs72688734	chr14:51634618	T/C	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.58	5.44	0.4	2.09e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06799790	chr17:61951754	CSH2	-0.46	-4.74	-0.36	4.93e-6	Height;
PAAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.99	-0.38	1.6e-6	Blood pressure;
PAAD	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	10.62	0.65	4.56e-20	Smoking behavior;
PAAD	cis	rs73206853	0.688	rs7314248	chr12:110559173	G/A	cg12870014	chr12:110450643	ANKRD13A	0.72	4.73	0.36	5.09e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-5.5	-0.41	1.58e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	LDL cholesterol;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.46	-0.57	2.06e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg05338066	chr1:7812865	CAMTA1	0.54	4.48	0.34	1.48e-5	Inflammatory bowel disease;
PAAD	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.3	-0.39	4.01e-7	Life satisfaction;
PAAD	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg10934807	chr2:113191815	RGPD8;RGPD5	0.9	6.1	0.44	8.27e-9	Yeast infection;
PAAD	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-4.81	-0.36	3.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.78	0.36	4.18e-6	Hepatocellular carcinoma;
PAAD	cis	rs4704187	0.687	rs6862740	chr5:74405749	A/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-5.28	-0.39	4.33e-7	Lymphocyte counts;
PAAD	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg06585982	chr3:143692056	C3orf58	0.58	5.63	0.42	8.66e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.95	0.54	4.01e-13	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21574404	chr19:33792714	CEBPA;LOC80054	0.59	6.33	0.46	2.61e-9	Monocyte percentage of white cells;
PAAD	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs728616	0.867	rs61859022	chr10:81860799	G/A	cg05935833	chr10:81318306	SFTPA2	-0.58	-4.38	-0.33	2.24e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.94	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.34	-0.46	2.44e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.84	-0.49	1.81e-10	Morning vs. evening chronotype;
PAAD	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.79	8.47	0.57	1.96e-14	Mean corpuscular volume;
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.7	7.62	0.53	2.47e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs30380	0.632	rs26497	chr5:96138767	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.1	-0.38	1.01e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.85	7.17	0.5	3.02e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg08562672	chr19:21860753	NA	0.48	4.92	0.37	2.25e-6	Pain;
PAAD	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs10949834	1.000	rs11770302	chr7:73485252	G/C	cg07137043	chr7:73588983	EIF4H	-0.58	-4.27	-0.33	3.49e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg24699146	chr1:24152579	HMGCL	0.54	5.7	0.42	6.05e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7873102	0.631	rs7044501	chr9:37947601	T/C	cg03528946	chr9:38069800	SHB	0.55	5.55	0.41	1.23e-7	Brain structure;
PAAD	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg05083358	chr7:2394359	EIF3B	-0.71	-5.18	-0.39	6.96e-7	Multiple sclerosis;
PAAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.86	-8.1	-0.55	1.65e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg04896959	chr15:78267971	NA	0.64	6.24	0.45	4.18e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.38e-5	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.66e-11	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg23985595	chr17:80112537	CCDC57	-0.49	-6.49	-0.47	1.14e-9	Life satisfaction;
PAAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09597638	chr17:3907349	NA	-0.71	-7.58	-0.52	3.21e-12	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27007426	chr8:87354751	WWP1	0.69	7.47	0.52	5.89e-12	Myopia (pathological);
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.79	-8.67	-0.58	5.96e-15	Menopause (age at onset);
PAAD	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.47	-4.56	-0.35	1.04e-5	Menarche (age at onset);
PAAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.92	9.54	0.61	3.48e-17	Cognitive function;
PAAD	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.73	-9.16	-0.6	3.34e-16	Educational attainment;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.65	5.07	0.38	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-4.96	-0.37	1.87e-6	Common traits (Other);
PAAD	cis	rs762407	0.519	rs4819311	chr21:45189717	G/T	cg11815682	chr21:44486381	CBS	-0.53	-5.28	-0.39	4.36e-7	Systolic blood pressure change trajectories;
PAAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.02	0.59	7.54e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2252790	0.859	rs1204824	chr6:116563825	T/C	cg18764771	chr6:116381957	FRK	-0.27	-4.63	-0.35	7.93e-6	Fast beta electroencephalogram;
PAAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs608114	0.623	rs59195392	chr6:96359041	C/T	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.47	-11.1	-0.67	2.46e-21	Atopic dermatitis;
PAAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.11	0.59	4.6e-16	Menopause (age at onset);
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg16898833	chr6:26189333	HIST1H4D	0.63	4.99	0.38	1.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.16	0.45	6.21e-9	Major depressive disorder;
PAAD	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.52	0.41	1.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.46	5.06	0.38	1.2e-6	Age of smoking initiation;
PAAD	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6604026	0.656	rs10493863	chr1:93399694	T/C	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-5.18	-0.39	6.94e-7	Ulcerative colitis;
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.72	-5.46	-0.4	1.92e-7	Initial pursuit acceleration;
PAAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22601191	chr20:60968625	CABLES2	0.49	4.33	0.33	2.75e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs28647808	1.000	rs4962142	chr9:136274883	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg14515779	chr1:101123966	NA	-0.48	-6.17	-0.45	5.94e-9	Monocyte count;
PAAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg18827107	chr12:86230957	RASSF9	0.41	4.37	0.33	2.3e-5	Major depressive disorder;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18621852	chr3:10150065	C3orf24	0.56	5.18	0.39	6.79e-7	Alzheimer's disease;
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs2882667	0.659	rs10056014	chr5:138256018	T/A	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.17e-10	Lymphocyte counts;
PAAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.83	9.82	0.62	6.25e-18	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	5.99e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	1.18	12.92	0.72	3.14e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.41	0.34	1.98e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs6669119	1.000	rs6669544	chr1:19109036	C/G	cg26220594	chr1:19110978	NA	-0.7	-4.46	-0.34	1.58e-5	Percentage gas trapping;
PAAD	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.44	5.09	0.38	1.07e-6	Coronary artery disease;
PAAD	cis	rs3917254	0.543	rs11123911	chr2:102761538	C/T	cg22835712	chr2:102737379	NA	-0.53	-4.48	-0.34	1.47e-5	Blood protein levels;
PAAD	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.62	5.71	0.42	5.82e-8	Lung cancer;
PAAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.94	8.41	0.56	2.85e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-4.88	-0.37	2.64e-6	Vitiligo;
PAAD	cis	rs116248771	0.739	rs73156489	chr3:158414026	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.7	6.53	0.47	9.43e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg24330906	chr2:85765176	MAT2A	0.41	4.27	0.33	3.39e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.81	8.31	0.56	4.87e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.65	4.89	0.37	2.58e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg14003231	chr6:33640908	ITPR3	-0.38	-4.86	-0.37	2.92e-6	Plateletcrit;
PAAD	cis	rs4294134	0.608	rs11766433	chr7:135243056	A/G	cg04619859	chr7:134855396	C7orf49	0.54	4.25	0.33	3.74e-5	Paget's disease;
PAAD	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.66	-7.08	-0.5	4.89e-11	Aortic root size;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.58	-6.37	-0.46	2.09e-9	Cognitive function;
PAAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg14343924	chr8:8086146	FLJ10661	-0.57	-5.15	-0.39	7.96e-7	Mood instability;
PAAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06797938	chr17:1466136	PITPNA	0.65	7.56	0.52	3.59e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	1.1	8.4	0.56	2.88e-14	Iron status biomarkers;
PAAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.71	5.38	0.4	2.74e-7	Vitiligo;
PAAD	cis	rs28489187	0.730	rs12121675	chr1:85798484	A/G	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.66	-6.12	-0.44	7.8e-9	Diisocyanate-induced asthma;
PAAD	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.77	9.27	0.6	1.7e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs621942	0.665	rs2374702	chr11:85852269	C/G	cg07180834	chr11:85838833	NA	-0.52	-5.36	-0.4	3.08e-7	Tourette syndrome;
PAAD	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.51	-5.53	-0.41	1.33e-7	Migraine;
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.15	0.55	1.28e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	7.98	0.54	3.39e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.85	-9.69	-0.62	1.39e-17	Iron status biomarkers;
PAAD	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.72	-7.51	-0.52	4.67e-12	Menarche (age at onset);
PAAD	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.69	0.48	4.04e-10	Morning vs. evening chronotype;
PAAD	cis	rs76525880	0.538	rs7405452	chr17:46674670	A/G	cg06593406	chr17:46696139	NA	-0.79	-4.57	-0.35	1e-5	Colorectal or endometrial cancer;
PAAD	cis	rs2555155	0.806	rs10839573	chr11:6551339	C/T	cg11185456	chr11:6592066	DNHD1	0.44	4.63	0.35	7.66e-6	DNA methylation (variation);
PAAD	cis	rs2006771	0.647	rs138280	chr22:32131610	T/C	cg02404636	chr22:31891804	SFI1	-0.47	-4.82	-0.36	3.52e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.86	7.58	0.52	3.08e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17968077	chr19:18314992	RAB3A	0.56	6.42	0.46	1.67e-9	Metabolite levels  (X-11787);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04976746	chr1:211751127	SLC30A1	0.7	7.09	0.5	4.77e-11	Obesity-related traits;
PAAD	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg20246863	chr2:73402720	NA	-0.4	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17123010	chr1:94375328	GCLM	0.55	6.3	0.46	3.04e-9	Monocyte percentage of white cells;
PAAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	trans	rs12738007	0.717	rs4654328	chr1:29230345	C/T	cg27546195	chr1:220446041	RAB3GAP2	0.7	6.38	0.46	2e-9	Schizophrenia;
PAAD	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.7	4.89	0.37	2.52e-6	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg00543991	chr22:32367038	NA	1.24	7.84	0.54	7.48e-13	Childhood ear infection;
PAAD	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.4e-6	Depressive symptoms;
PAAD	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.6	-8.1	-0.55	1.64e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.87	9.68	0.62	1.43e-17	Cognitive function;
PAAD	cis	rs308971	0.611	rs387152	chr3:12076032	G/C	cg15873301	chr3:12045459	SYN2	0.64	5.36	0.4	3.06e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg07099767	chr17:78039528	CCDC40	-0.49	-4.62	-0.35	8.11e-6	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs337161	0.654	rs3795536	chr1:220935977	G/A	cg09023136	chr1:220959637	MOSC1	-0.6	-4.49	-0.34	1.42e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.95	-6.89	-0.49	1.38e-10	Initial pursuit acceleration;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg12215294	chr3:40350768	EIF1B	0.46	4.47	0.34	1.54e-5	Renal cell carcinoma;
PAAD	cis	rs3787159	0.547	rs536844	chr20:56892077	A/G	cg15032960	chr20:56888536	RAB22A	-0.41	-4.38	-0.33	2.2e-5	Systolic blood pressure;
PAAD	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg16174234	chr19:33463305	C19orf40;CCDC123	-0.51	-4.43	-0.34	1.81e-5	Red blood cell traits;
PAAD	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.64	6.56	0.47	7.91e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24293976	chr12:111843567	SH2B3	0.58	6.64	0.47	5.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs78761021	0.867	rs17810412	chr17:9788279	C/T	cg26853458	chr17:9805074	RCVRN	0.69	8.0	0.54	2.91e-13	Type 2 diabetes;
PAAD	cis	rs12752838	0.730	rs6661010	chr1:8910542	C/T	cg24027679	chr1:9086621	SLC2A7	0.37	4.37	0.33	2.33e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.23e-9	Height;
PAAD	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.86	0.49	1.64e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.46	-4.96	-0.37	1.84e-6	Calcium levels;
PAAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg05110241	chr16:68378359	PRMT7	-1.02	-7.47	-0.52	5.83e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg25554036	chr4:6271136	WFS1	0.73	7.18	0.5	2.83e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22509189	chr2:225307070	NA	-0.43	-4.26	-0.33	3.53e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	cis	rs7267348	0.579	rs6090988	chr20:48097481	A/G	cg03558299	chr20:47662597	CSE1L	-0.63	-4.35	-0.33	2.48e-5	Schizophrenia;
PAAD	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.58	6.03	0.44	1.18e-8	High light scatter reticulocyte count;
PAAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.83	0.48	1.89e-10	Personality dimensions;
PAAD	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs939584	0.935	rs12623218	chr2:632146	A/T	cg03610516	chr2:642275	NA	0.54	4.72	0.36	5.31e-6	Body mass index;
PAAD	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.8	-9.95	-0.63	2.82e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.56	6.03	0.44	1.2e-8	Menopause (age at onset);
PAAD	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg02986791	chr19:1062178	ABCA7	-0.5	-4.36	-0.33	2.36e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2406342	0.511	rs10469087	chr18:74575538	A/C	cg16472389	chr18:74514291	NA	0.48	5.28	0.39	4.44e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
PAAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg23719950	chr11:63933701	MACROD1	-0.49	-4.26	-0.33	3.62e-5	Platelet count;
PAAD	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg16205897	chr5:131564050	P4HA2	-0.42	-4.56	-0.35	1.05e-5	Breast cancer;
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.48	-0.34	1.45e-5	Lung cancer;
PAAD	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg08316699	chr6:150357289	NA	0.39	4.34	0.33	2.62e-5	Alopecia areata;
PAAD	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-5.97	-0.44	1.6e-8	Diabetic retinopathy;
PAAD	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.52	5.12	0.38	9.25e-7	Mean corpuscular volume;
PAAD	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg06569542	chr10:98946673	SLIT1	-0.47	-4.88	-0.37	2.66e-6	Monocyte count;
PAAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-4.87	-0.37	2.83e-6	Osteoarthritis;
PAAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg20933634	chr6:27740509	NA	0.76	7.04	0.5	6.25e-11	Breast cancer;
PAAD	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.62	5.59	0.41	1.03e-7	Obesity-related traits;
PAAD	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.8	6.21	0.45	4.94e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.77	7.35	0.51	1.14e-11	Cleft lip with or without cleft palate;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17728851	chr19:12893288	NA	-0.73	-7.0	-0.49	7.67e-11	Lung cancer in ever smokers;
PAAD	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.45	4.4	0.34	2.01e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Calcium levels;
PAAD	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	7.34	0.51	1.2e-11	Eotaxin levels;
PAAD	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg24733560	chr20:60626293	TAF4	-0.53	-7.01	-0.49	7.32e-11	Body mass index;
PAAD	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06108461	chr20:60628389	TAF4	-0.8	-8.05	-0.55	2.25e-13	Body mass index;
PAAD	cis	rs73388146	1.000	rs73388146	chr6:25170668	G/A	cg19882886	chr6:25043046	NA	1.09	4.92	0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.45	0.34	1.67e-5	Menarche (age at onset);
PAAD	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg07648498	chr16:89883185	FANCA	0.49	4.73	0.36	5.09e-6	Vitiligo;
PAAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12667521	chr19:29218732	NA	0.61	5.39	0.4	2.61e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs939584	1.000	rs4854343	chr2:638107	G/A	cg14515364	chr2:636606	NA	0.47	4.28	0.33	3.26e-5	Body mass index;
PAAD	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.51	5.02	0.38	1.42e-6	Brain structure;
PAAD	cis	rs3753841	0.832	rs12133652	chr1:103335136	A/G	cg24495344	chr1:103574097	COL11A1	0.4	4.66	0.35	6.97e-6	Glaucoma (primary angle closure);
PAAD	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg14078157	chr9:128172775	NA	-0.64	-7.64	-0.53	2.25e-12	Resting heart rate;
PAAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.71	-0.82	8.76e-39	Height;
PAAD	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.73	10.16	0.64	7.76e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08219700	chr8:58056026	NA	0.67	5.04	0.38	1.33e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg13565585	chr5:132299512	AFF4	0.51	4.98	0.37	1.71e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-8.04	-0.55	2.38e-13	Homoarginine levels;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	7.18	0.5	2.82e-11	Renal function-related traits (BUN);
PAAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.82	-10.34	-0.64	2.65e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.76	4.75	0.36	4.65e-6	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	1.09	15.17	0.78	3.11e-32	Breast cancer;
PAAD	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.44	6.29	0.45	3.16e-9	Information processing speed;
PAAD	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.32	0.56	4.58e-14	Rheumatoid arthritis;
PAAD	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.54	4.7	0.36	5.77e-6	Lymphocyte counts;
PAAD	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.56	-5.52	-0.41	1.43e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg16590910	chr6:42928470	GNMT	0.5	4.99	0.37	1.66e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.69	-8.21	-0.55	9.05e-14	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.64	6.41	0.46	1.77e-9	Blood protein levels;
PAAD	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs375066	0.869	rs379785	chr19:44428101	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg08599294	chr13:96329351	DNAJC3	0.6	6.4	0.46	1.87e-9	Primary biliary cholangitis;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg14709524	chr16:89940631	TCF25	0.69	4.41	0.34	1.92e-5	Skin colour saturation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06154408	chr2:228336240	AGFG1	-0.57	-6.7	-0.48	3.87e-10	Monocyte percentage of white cells;
PAAD	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-0.93	-6.28	-0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12935418	0.583	rs2316923	chr16:81024821	C/G	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.72	6.23	0.45	4.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg07202610	chr7:1142643	C7orf50	-0.72	-5.46	-0.4	1.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2275565	0.872	rs10925257	chr1:237046160	A/G	cg17297354	chr1:237056641	MTR	-0.51	-4.51	-0.34	1.28e-5	Homocysteine levels;
PAAD	cis	rs7591163	1.000	rs6738964	chr2:228739135	G/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.44	4.42	0.34	1.84e-5	Blood pressure;
PAAD	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.53	0.34	1.19e-5	Educational attainment;
PAAD	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-4.5	-0.34	1.35e-5	QRS complex (12-leadsum);
PAAD	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.31	-0.4	3.88e-7	Asthma;
PAAD	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.83	-6.84	-0.49	1.79e-10	Diastolic blood pressure;
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.77	0.58	3.36e-15	Lung cancer;
PAAD	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg11993925	chr19:44307056	LYPD5	0.5	6.66	0.48	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01255747	chr13:108870449	ABHD13;LIG4	0.58	6.51	0.47	1.05e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.53	-0.47	9.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.43	4.79	0.36	3.96e-6	Testicular germ cell tumor;
PAAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.19	0.5	2.8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg21775007	chr8:11205619	TDH	0.82	8.12	0.55	1.48e-13	Retinal vascular caliber;
PAAD	cis	rs12760731	0.565	rs12030488	chr1:178094751	A/C	cg00404053	chr1:178313656	RASAL2	-0.6	-4.55	-0.35	1.08e-5	Obesity-related traits;
PAAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.75	6.73	0.48	3.33e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09080091	chr5:56191109	MAP3K1	-0.56	-6.74	-0.48	3.16e-10	Energy expenditure (24h);
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg21918786	chr6:109611834	NA	-0.46	-4.94	-0.37	2e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg05925327	chr15:68127851	NA	-0.58	-5.3	-0.4	3.93e-7	Restless legs syndrome;
PAAD	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg00031303	chr3:195681400	NA	0.8	7.81	0.53	8.91e-13	Pancreatic cancer;
PAAD	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg09163369	chr1:210001066	C1orf107	0.51	5.34	0.4	3.33e-7	Orofacial clefts;
PAAD	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-5.64	-0.42	8.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs16975963	0.843	rs17249047	chr19:38336563	A/G	cg08679971	chr19:38281047	NA	0.51	4.85	0.37	3.04e-6	Longevity;
PAAD	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg07162820	chr14:24837146	NFATC4	0.35	4.64	0.35	7.45e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg24618514	chr3:194868507	C3orf21	0.48	4.54	0.35	1.15e-5	Non-small cell lung cancer;
PAAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.56	5.9	0.43	2.26e-8	Cognitive function;
PAAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg16928487	chr17:17741425	SREBF1	-0.32	-4.42	-0.34	1.83e-5	Total body bone mineral density;
PAAD	cis	rs6785206	0.554	rs35439439	chr3:128475293	A/G	cg19205850	chr3:128446370	RAB7A	0.67	5.15	0.39	7.95e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg22875332	chr1:76189707	ACADM	-0.49	-4.79	-0.36	3.87e-6	Daytime sleep phenotypes;
PAAD	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg01236616	chr12:121019343	POP5	-0.45	-4.26	-0.33	3.58e-5	High light scatter reticulocyte count;
PAAD	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.93	8.78	0.58	3.22e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.49	5.08	0.38	1.08e-6	Lung cancer;
PAAD	cis	rs35000415	0.938	rs17340351	chr7:128708797	T/A	cg19972273	chr7:128594194	NA	0.94	5.4	0.4	2.47e-7	Systemic lupus erythematosus;
PAAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg06714761	chr1:201096289	NA	0.31	4.78	0.36	4.11e-6	Permanent tooth development;
PAAD	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.42	4.84	0.37	3.16e-6	Refractive error;
PAAD	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.25	0.45	4.04e-9	Personality dimensions;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17302062	chr18:3451564	TGIF1	-0.72	-6.29	-0.45	3.29e-9	Neuroticism;
PAAD	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.82	6.33	0.46	2.65e-9	Crohn's disease;
PAAD	cis	rs375066	0.762	rs62114648	chr19:44414816	T/C	cg21496419	chr19:44306685	LYPD5	-0.42	-4.93	-0.37	2.17e-6	Breast cancer;
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg04013166	chr16:89971882	TCF25	0.65	4.41	0.34	1.98e-5	Skin colour saturation;
PAAD	cis	rs2952768	1.000	rs2248062	chr2:208495051	A/T	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.72	8.91	0.59	1.48e-15	Dupuytren's disease;
PAAD	cis	rs73019876	0.868	rs2262908	chr19:22134800	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.5	-0.34	1.37e-5	Testicular germ cell tumor;
PAAD	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg09955084	chr16:413813	NA	0.3	4.53	0.34	1.21e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.58	6.21	0.45	4.85e-9	Schizophrenia;
PAAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.74	0.36	4.92e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg15017067	chr4:17643749	FAM184B	0.41	4.68	0.35	6.32e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.45	4.66	0.35	6.88e-6	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.49	5.27	0.39	4.62e-7	Diastolic blood pressure;
PAAD	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	4.51	0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27298559	chr17:57785523	PTRH2;TMEM49	0.55	6.29	0.45	3.23e-9	Metabolite levels  (X-11787);
PAAD	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-9.99	-0.63	2.25e-18	Chronic sinus infection;
PAAD	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs6466055	0.748	rs9640686	chr7:104867330	T/G	cg04380332	chr7:105027541	SRPK2	0.65	7.24	0.51	2.1e-11	Schizophrenia;
PAAD	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.73	7.69	0.53	1.74e-12	Blood protein levels;
PAAD	cis	rs2637030	0.559	rs187659	chr5:52916018	G/A	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	1.13	5.07	0.38	1.14e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs59888335	0.858	rs4856314	chr3:81004771	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.6	4.74	0.36	4.98e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs17169634	1.000	rs75741278	chr7:34084841	C/G	cg24927974	chr7:35078269	DPY19L1	-0.63	-5.23	-0.39	5.59e-7	Alzheimer's disease;
PAAD	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.87	-9.65	-0.62	1.79e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.55	-4.65	-0.35	7.12e-6	Obesity-related traits;
PAAD	cis	rs2645424	0.604	rs9644756	chr8:11715100	A/T	cg21281001	chr8:11725306	CTSB	0.51	4.44	0.34	1.74e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs4795519	0.588	rs2203492	chr17:22233279	C/G	cg22648282	chr17:21454238	C17orf51	-0.5	-5.2	-0.39	6.26e-7	Chronic myeloid leukemia;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3106136	0.678	rs11944992	chr4:95298176	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.5	4.48	0.34	1.44e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg10589385	chr1:150898437	SETDB1	0.39	4.76	0.36	4.48e-6	Melanoma;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.51	-0.52	4.56e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.85	-9.14	-0.6	3.64e-16	DNA methylation (variation);
PAAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.5	6.25	0.45	3.99e-9	Longevity;Endometriosis;
PAAD	cis	rs1997066	0.831	rs112529567	chr10:106820695	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.32	0.46	2.7e-9	Hip circumference;
PAAD	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.36	4.73	0.36	5.07e-6	Schizophrenia;
PAAD	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.91	-0.54	4.91e-13	Neuroticism;
PAAD	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10574483	chr12:107380858	MTERFD3	-0.55	-6.56	-0.47	7.85e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.25	-0.33	3.66e-5	Lewy body disease;
PAAD	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.48	4.3	0.33	3.04e-5	HDL cholesterol;
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.74	-0.36	4.96e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.52	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs3736485	0.966	rs11070859	chr15:51890802	C/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg05643964	chr20:62369504	LIME1	-0.5	-4.61	-0.35	8.44e-6	Prostate cancer;
PAAD	cis	rs7752195	0.643	rs115949281	chr6:25240214	G/A	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg17105886	chr17:28927953	LRRC37B2	0.74	4.84	0.37	3.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg19784903	chr17:45786737	TBKBP1	0.45	4.4	0.34	2.02e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.49	-0.34	1.42e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.86	-9.11	-0.59	4.42e-16	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17758439	chr6:99849304	SFRS18	0.55	6.42	0.46	1.63e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11650494	0.570	rs9901650	chr17:47513127	A/G	cg08112188	chr17:47440006	ZNF652	1.27	6.24	0.45	4.18e-9	Prostate cancer;
PAAD	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg09597638	chr17:3907349	NA	0.9	10.12	0.63	1.01e-18	Type 2 diabetes;
PAAD	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-1.07	-7.48	-0.52	5.52e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs35955747	0.902	rs739427	chr22:31659101	C/G	cg02404636	chr22:31891804	SFI1	0.5	5.03	0.38	1.36e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4523957	0.928	rs441750	chr17:2190767	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg09835421	chr16:68378352	PRMT7	-1.34	-9.89	-0.63	4.11e-18	Schizophrenia;
PAAD	cis	rs7631605	0.809	rs10849	chr3:37095070	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.47	0.34	1.55e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.53	-0.34	1.19e-5	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17868920	chr2:158485541	ACVR1C	-0.62	-6.29	-0.45	3.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg26338869	chr17:61819248	STRADA	-0.47	-4.32	-0.33	2.77e-5	Height;
PAAD	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.57	-4.99	-0.38	1.61e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.44	6.36	0.46	2.26e-9	Mean corpuscular volume;
PAAD	cis	rs943466	0.956	rs11758463	chr6:33762625	A/G	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-6.81	-0.48	2.09e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.49	4.68	0.35	6.41e-6	Resistin levels;
PAAD	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.43	6.51	0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.63	6.63	0.47	5.66e-10	Mood instability;
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.83	-0.36	3.31e-6	Aortic root size;
PAAD	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	1.07	11.95	0.7	1.29e-23	Gut microbiota (bacterial taxa);
PAAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg07153921	chr17:41440717	NA	0.4	4.32	0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg27490568	chr2:178487706	NA	0.42	4.52	0.34	1.21e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11245990	chr11:68621969	NA	0.4	5.36	0.4	2.96e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.54	8.37	0.56	3.41e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.8	0.48	2.27e-10	Longevity;Endometriosis;
PAAD	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.61	-7.2	-0.5	2.58e-11	Systolic blood pressure;
PAAD	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.55	5.5	0.41	1.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20701841	chr20:23420121	CSTL1	-0.69	-6.47	-0.46	1.3e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.36	-0.33	2.34e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.53	-0.41	1.36e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg19792802	chr11:65647270	CTSW	-0.44	-5.82	-0.43	3.33e-8	DNA methylation (variation);
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.94	0.7	1.34e-23	Platelet count;
PAAD	cis	rs859767	0.741	rs883964	chr2:135436200	G/C	cg12500956	chr2:135428796	TMEM163	-0.31	-4.32	-0.33	2.83e-5	Neuroticism;
PAAD	cis	rs12760731	0.623	rs2300300	chr1:178419387	G/C	cg00404053	chr1:178313656	RASAL2	0.68	5.57	0.41	1.12e-7	Obesity-related traits;
PAAD	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg03098721	chr1:84464084	TTLL7	0.48	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.66	-4.29	-0.33	3.17e-5	Obesity-related traits;
PAAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.93	0.37	2.16e-6	Breast cancer;
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.93	0.49	1.13e-10	Menarche (age at onset);
PAAD	cis	rs3737883	1.000	rs3737883	chr1:203034906	C/T	cg03900565	chr1:203031815	PPFIA4	-0.34	-5.58	-0.41	1.07e-7	Early onset atrial fibrillation;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03605463	chr16:89740564	NA	-0.54	-5.17	-0.39	7.22e-7	Vitiligo;
PAAD	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg13207630	chr7:32358064	NA	0.97	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs73206853	0.841	rs73191829	chr12:110948906	A/G	cg12870014	chr12:110450643	ANKRD13A	0.86	4.66	0.35	6.94e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs73206853	0.563	rs73194032	chr12:111162182	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.88	-5.8	-0.43	3.75e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.9	-12.05	-0.7	6.73e-24	Menopause (age at onset);
PAAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.12e-15	Personality dimensions;
PAAD	cis	rs735539	0.521	rs693814	chr13:21422910	A/T	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	cis	rs9463078	0.528	rs1284992	chr6:45071144	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	trans	rs901683	1.000	rs901682	chr10:45965861	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs13242816	0.881	rs17138706	chr7:116109019	A/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9283706	0.608	rs1991492	chr5:66328309	A/G	cg11590213	chr5:66331682	MAST4	0.57	4.67	0.35	6.64e-6	Coronary artery disease;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.8	-8.16	-0.55	1.17e-13	Menopause (age at onset);
PAAD	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.74	6.46	0.46	1.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.87	0.37	2.72e-6	Height;
PAAD	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg02404636	chr22:31891804	SFI1	0.64	6.17	0.45	5.91e-9	Colorectal cancer;
PAAD	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-12.3	-0.71	1.39e-24	Primary sclerosing cholangitis;
PAAD	cis	rs112990264	0.892	rs73079887	chr1:212894391	A/G	cg01785514	chr1:212988523	TATDN3	1.22	8.28	0.56	6.04e-14	Itch intensity from mosquito bite;
PAAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12612619	0.621	rs4665943	chr2:27295885	C/T	cg00617064	chr2:27272375	NA	0.48	4.79	0.36	3.85e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg03030879	chr14:75389066	RPS6KL1	0.42	4.38	0.33	2.21e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08135327	chr2:134877962	NA	0.68	7.28	0.51	1.67e-11	Myopia (pathological);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26039092	chr1:231473538	EXOC8;C1orf124	-0.63	-6.34	-0.46	2.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.63	-6.19	-0.45	5.34e-9	Multiple sclerosis;
PAAD	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.33	-0.33	2.66e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.77	-5.68	-0.42	6.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	1.09	15.44	0.78	5.9e-33	Caffeine consumption;
PAAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg12705353	chr12:122356852	WDR66	0.46	4.87	0.37	2.79e-6	Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.14	0.6	3.69e-16	Menopause (age at onset);
PAAD	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg06606381	chr12:133084897	FBRSL1	0.96	6.81	0.48	2.13e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	1.14	14.69	0.77	5.74e-31	Migraine;
PAAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03761210	chr20:32251509	NECAB3;C20orf144	0.6	6.55	0.47	8.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.63	6.06	0.44	1.03e-8	Itch intensity from mosquito bite;
PAAD	cis	rs527409	1.000	rs635459	chr1:58747747	T/C	cg26345888	chr1:58716257	DAB1	-0.66	-4.48	-0.34	1.46e-5	Kawasaki disease;
PAAD	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-6.42	-0.46	1.69e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22747897	chr4:1005994	FGFRL1	-0.63	-7.03	-0.5	6.49e-11	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15276500	chr20:60879007	ADRM1	0.57	6.29	0.45	3.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.51	-4.86	-0.37	2.88e-6	Menarche (age at onset);
PAAD	cis	rs2278796	0.693	rs2794859	chr1:204967256	A/G	cg04862289	chr1:204966208	NFASC	0.49	5.03	0.38	1.4e-6	Mean platelet volume;
PAAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.97	-5.2	-0.39	6.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.37	-0.46	2.09e-9	Mood instability;
PAAD	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.19	0.5	2.73e-11	Body mass index;
PAAD	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg01942863	chr7:99769432	GPC2	0.5	4.71	0.36	5.57e-6	Coronary artery disease;
PAAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg04330084	chr7:123175371	IQUB	-0.53	-4.31	-0.33	2.97e-5	Plateletcrit;Platelet count;
PAAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	4.84	0.37	3.1e-6	Bipolar disorder;
PAAD	cis	rs58521262	0.556	rs380541	chr19:23118931	C/T	cg03433597	chr19:22806448	NA	-0.24	-4.42	-0.34	1.87e-5	Testicular germ cell tumor;
PAAD	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg23024343	chr7:107201750	COG5	0.55	4.64	0.35	7.5e-6	Osteoarthritis;
PAAD	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.929	rs153550	chr5:112234957	C/T	cg06941702	chr5:112196734	SRP19	0.52	4.78	0.36	4.11e-6	Total body bone mineral density;
PAAD	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.84	9.95	0.63	2.8e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg14146966	chr2:61757674	XPO1	-0.4	-4.99	-0.38	1.63e-6	Tuberculosis;
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg08284496	chr17:37894027	GRB7	0.25	4.35	0.33	2.5e-5	Asthma;
PAAD	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	4.76	0.36	4.38e-6	Thyroid stimulating hormone;
PAAD	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-5.52	-0.41	1.4e-7	Dilated cardiomyopathy;
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.85e-5	Skin colour saturation;
PAAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg27478167	chr7:817139	HEATR2	-0.59	-4.7	-0.36	5.69e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg26695010	chr11:65641043	EFEMP2	-0.64	-5.72	-0.42	5.62e-8	DNA methylation (variation);
PAAD	cis	rs8025118	0.583	rs7168501	chr15:79557833	T/G	cg11862246	chr15:78730200	IREB2	-0.55	-4.75	-0.36	4.71e-6	Cognitive function;
PAAD	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.87	15.36	0.78	9.87e-33	Obesity-related traits;
PAAD	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.51	-6.0	-0.44	1.38e-8	Mean arterial pressure;
PAAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.88	7.65	0.53	2.1e-12	Gut microbiome composition (summer);
PAAD	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.51	-6.04	-0.44	1.12e-8	Mean arterial pressure;
PAAD	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.83	0.36	3.3e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.66	-0.72	1.52e-25	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.77	-0.42	4.35e-8	Life satisfaction;
PAAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg08029281	chr1:67600428	NA	0.43	5.13	0.38	8.58e-7	Psoriasis;
PAAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06850241	chr22:41845214	NA	0.61	5.42	0.4	2.34e-7	Vitiligo;
PAAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.4	-0.34	2.04e-5	Skin colour saturation;
PAAD	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg06212747	chr3:49208901	KLHDC8B	0.62	4.87	0.37	2.74e-6	Menarche (age at onset);
PAAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg00071950	chr4:10020882	SLC2A9	0.51	4.48	0.34	1.46e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.54	4.35	0.33	2.51e-5	HDL cholesterol;
PAAD	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.55	-5.24	-0.39	5.33e-7	Coronary artery disease;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg11766577	chr21:47581405	C21orf56	0.38	4.38	0.33	2.21e-5	Testicular germ cell tumor;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg16205897	chr5:131564050	P4HA2	-0.55	-6.01	-0.44	1.31e-8	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg01097406	chr16:89675127	NA	0.36	4.52	0.34	1.21e-5	Vitiligo;
PAAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	6.26	0.45	3.72e-9	Personality dimensions;
PAAD	cis	rs35740288	0.787	rs35250181	chr15:86242662	T/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.45	-0.4	1.95e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg21775007	chr8:11205619	TDH	-0.53	-4.87	-0.37	2.73e-6	Neuroticism;
PAAD	cis	rs8060686	0.920	rs73591955	chr16:67782568	G/T	cg05110241	chr16:68378359	PRMT7	-0.89	-5.08	-0.38	1.08e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-9.23	-0.6	2.22e-16	Body mass index;
PAAD	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7246657	0.524	rs35080624	chr19:37456582	C/T	cg23950597	chr19:37808831	NA	-0.73	-4.6	-0.35	8.71e-6	Coronary artery calcification;
PAAD	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg02493740	chr2:85810744	VAMP5	-0.43	-4.79	-0.36	3.86e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.59	0.35	9.09e-6	Axial length;
PAAD	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs2275731	1.000	rs1411875	chr10:16527890	C/G	cg04254609	chr10:16479192	PTER	-0.5	-4.91	-0.37	2.29e-6	Bone fracture in osteoporosis;
PAAD	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg10168330	chr8:27262164	PTK2B	0.37	4.31	0.33	2.92e-5	Neuroticism;
PAAD	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg20487152	chr13:99095054	FARP1	0.56	4.79	0.36	3.86e-6	Neuroticism;
PAAD	cis	rs3736485	0.966	rs12101730	chr15:51800733	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-4.26	-0.33	3.52e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.61	7.1	0.5	4.38e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs12760731	0.720	rs12021983	chr1:178323800	C/T	cg00404053	chr1:178313656	RASAL2	0.74	5.77	0.42	4.3e-8	Obesity-related traits;
PAAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.61	0.35	8.48e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-8.08	-0.55	1.82e-13	Parkinson's disease;
PAAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.69	8.95	0.59	1.17e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	6.0	0.44	1.4e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg04362095	chr11:63592001	C11orf84	-0.5	-4.44	-0.34	1.75e-5	Platelet count;
PAAD	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs790123	0.541	rs9853835	chr3:122390153	T/C	cg15604389	chr3:122379662	NA	0.54	4.35	0.33	2.48e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.66	5.89	0.43	2.4e-8	Response to diuretic therapy;
PAAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.66	7.02	0.49	7.07e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.46	4.5	0.34	1.35e-5	Malaria;
PAAD	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9381107	0.505	rs9369420	chr6:9486467	A/G	cg14735645	chr6:9486422	NA	0.57	4.81	0.36	3.54e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.85	-10.5	-0.65	9.89e-20	Body mass index;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.85	10.19	0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg09945482	chr18:12777974	NA	0.6	5.38	0.4	2.79e-7	Inflammatory skin disease;
PAAD	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.63	6.29	0.45	3.16e-9	Testicular germ cell tumor;
PAAD	cis	rs6445967	0.966	rs35955376	chr3:58297779	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.33	0.33	2.71e-5	Platelet count;
PAAD	cis	rs6596100	0.538	rs10491280	chr5:132196383	G/T	cg14825688	chr5:132208181	LEAP2	0.66	4.89	0.37	2.59e-6	Breast cancer;
PAAD	cis	rs2004318	1.000	rs73614626	chr19:55139399	T/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.85	6.55	0.47	8.57e-10	Diisocyanate-induced asthma;
PAAD	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.41	-0.46	1.75e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.52	-5.08	-0.38	1.08e-6	Glomerular filtration rate;
PAAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.85	10.19	0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.64e-6	Breast cancer;
PAAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.48	-5.23	-0.39	5.45e-7	Breast cancer;Mosquito bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12704673	chr3:119395842	COX17	0.57	6.29	0.45	3.29e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07432643	chr22:50247581	ZBED4	0.68	6.53	0.47	9.09e-10	Myopia (pathological);
PAAD	cis	rs12044355	0.827	rs11583715	chr1:231829039	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.23	-0.39	5.53e-7	Alzheimer's disease;
PAAD	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.98	8.22	0.55	8.53e-14	Neutrophil percentage of white cells;
PAAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.64	-6.57	-0.47	7.74e-10	Obesity-related traits;
PAAD	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.59	-5.41	-0.4	2.4e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24869393	chr10:99566418	NA	-0.67	-7.29	-0.51	1.58e-11	Obesity-related traits;
PAAD	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs17401966	0.577	rs1556915	chr1:10242654	A/G	cg15226751	chr1:10001911	LZIC	0.4	4.44	0.34	1.75e-5	Hepatocellular carcinoma;
PAAD	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-5.95	-0.43	1.82e-8	Coronary heart disease;
PAAD	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	6.39	0.46	1.94e-9	Body mass index;
PAAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Diastolic blood pressure;
PAAD	cis	rs6893807	0.778	rs13173305	chr5:87945377	A/G	cg02225085	chr5:87975992	LOC645323	-0.69	-4.93	-0.37	2.11e-6	Body mass index;
PAAD	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.28	-0.51	1.71e-11	Colorectal cancer;
PAAD	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.43	-4.35	-0.33	2.5e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	9.85	0.62	5.2e-18	Tonsillectomy;
PAAD	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg20019720	chr6:154832845	CNKSR3	0.64	7.56	0.52	3.53e-12	Lipoprotein (a) levels;
PAAD	cis	rs76419734	0.614	rs17035936	chr4:106525864	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.45	0.34	1.62e-5	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.42	4.3	0.33	3.07e-5	Coronary artery disease;
PAAD	cis	rs144736172	1	rs144736172	chr2:31968142	A/T	cg02381751	chr2:32503542	YIPF4	0.43	4.5	0.34	1.33e-5	Interleukin-18 levels;
PAAD	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.5	-0.34	1.37e-5	Personality dimensions;
PAAD	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.56	5.92	0.43	2.03e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.91	-6.48	-0.47	1.23e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.6	-5.66	-0.42	7.43e-8	Monocyte count;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22261030	chr17:56084860	SFRS1	0.61	6.29	0.45	3.17e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.73	-9.08	-0.59	5.35e-16	Dental caries;
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.68	7.77	0.53	1.1e-12	Body mass index;
PAAD	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.64	5.7	0.42	6.13e-8	Corneal astigmatism;
PAAD	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.67	0.35	6.65e-6	Body mass index;
PAAD	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-4.26	-0.33	3.57e-5	Putamen volume;
PAAD	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.24e-6	Asthma;
PAAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.58	4.41	0.34	1.98e-5	Fat distribution (HIV);
PAAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.59	5.21	0.39	6.16e-7	Coronary artery disease;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.76	-8.02	-0.55	2.7e-13	Blood metabolite levels;
PAAD	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.74e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.82	0.36	3.5e-6	Major depressive disorder;
PAAD	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg23417306	chr2:180868811	CWC22	0.48	4.49	0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg13320842	chr19:46175254	GIPR	-0.58	-5.2	-0.39	6.42e-7	Eosinophil counts;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg20007245	chr22:24372913	LOC391322	-0.68	-7.15	-0.5	3.36e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg04267008	chr7:1944627	MAD1L1	0.76	7.91	0.54	4.93e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs75920871	0.623	rs57582454	chr11:116961892	G/A	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.34e-9	Lung cancer;
PAAD	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg16591659	chr17:78472290	NA	0.5	4.79	0.36	3.92e-6	Fractional excretion of uric acid;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg06207120	chr15:45996521	NA	0.31	4.61	0.35	8.53e-6	Waist circumference;Weight;
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg02869306	chr7:64672164	INTS4L1	0.5	6.06	0.44	1.03e-8	Calcium levels;
PAAD	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	10.46	0.65	1.25e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9287719	0.625	rs12473787	chr2:10717194	G/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.71	-7.01	-0.49	7.22e-11	Prostate cancer;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.58	-5.99	-0.44	1.47e-8	Testicular germ cell tumor;
PAAD	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.42	6.21	0.45	4.82e-9	Subjective well-being;
PAAD	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-4.34	-0.33	2.6e-5	Coronary artery disease;
PAAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg11143131	chr5:131608246	PDLIM4	-0.46	-4.7	-0.36	5.89e-6	Blood metabolite levels;
PAAD	cis	rs12523822	0.957	rs7752829	chr6:154958230	T/G	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs4455778	0.538	rs7786675	chr7:49123150	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg06145435	chr7:1022769	CYP2W1	0.37	4.27	0.33	3.44e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs642743	0.967	rs678292	chr10:105957561	G/A	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.3	0.33	3.03e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6782228	1.000	rs6801509	chr3:128364269	C/T	cg15607142	chr3:128420513	NA	-0.43	-4.6	-0.35	9.01e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.78	8.72	0.58	4.44e-15	Type 2 diabetes;
PAAD	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.35	-0.6	1.09e-16	Venous thromboembolism;
PAAD	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg14393609	chr7:65229607	NA	-0.54	-4.5	-0.34	1.36e-5	Aortic root size;
PAAD	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg13444538	chr7:158905317	VIPR2	-0.7	-5.29	-0.39	4.16e-7	Facial morphology (factor 20);
PAAD	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.59	7.02	0.49	6.89e-11	Aortic root size;
PAAD	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.18	-0.39	6.92e-7	High light scatter reticulocyte count;
PAAD	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06634786	chr22:41940651	POLR3H	0.72	5.8	0.43	3.66e-8	Vitiligo;
PAAD	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.61	-0.35	8.42e-6	Prevalent atrial fibrillation;
PAAD	cis	rs800160	0.777	rs2651779	chr11:2344270	G/A	cg09785033	chr11:2336066	TSPAN32	-0.5	-4.32	-0.33	2.83e-5	Bacteremia;
PAAD	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.26	-0.39	4.76e-7	Mean corpuscular volume;
PAAD	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	1.16	12.78	0.72	7.43e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.16	-0.39	7.61e-7	Triglycerides;
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.85	-5.77	-0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11676855	1.000	rs6710499	chr2:235898590	A/G	cg14917874	chr2:235941519	SH3BP4	0.56	5.4	0.4	2.53e-7	Dialysis-related mortality;
PAAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg08514558	chr10:81106712	PPIF	0.5	6.04	0.44	1.16e-8	Height;
PAAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg09835421	chr16:68378352	PRMT7	1.07	8.07	0.55	1.95e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.54	4.27	0.33	3.36e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg01868782	chr6:126071099	HEY2	-0.45	-5.47	-0.41	1.82e-7	Brugada syndrome;
PAAD	cis	rs9810890	1.000	rs73196989	chr3:128454638	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.78	-7.15	-0.5	3.43e-11	Vitamin D levels;
PAAD	cis	rs2061333	0.842	rs8099869	chr19:44623376	C/T	cg18700516	chr19:44507157	ZNF230	-0.69	-5.14	-0.38	8.5e-7	Alzheimer's disease;
PAAD	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg22089800	chr15:90895588	ZNF774	0.59	5.13	0.38	8.69e-7	Rheumatoid arthritis;
PAAD	trans	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg16973527	chr15:70767570	NA	-0.4	-6.36	-0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.75	8.72	0.58	4.49e-15	Colorectal cancer;
PAAD	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg14132834	chr19:41945861	ATP5SL	-0.52	-5.03	-0.38	1.35e-6	Height;
PAAD	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.08	0.5	4.89e-11	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.88	0.58	1.77e-15	Lung cancer;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.49	5.31	0.4	3.74e-7	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	6.83	0.48	1.93e-10	Platelet count;
PAAD	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.55	-0.41	1.26e-7	Atrioventricular conduction;
PAAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.07	0.5	5.18e-11	Rheumatoid arthritis;
PAAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg03367679	chr17:38183553	MED24;SNORD124	0.3	4.25	0.33	3.7e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.73	-7.37	-0.51	1.04e-11	Itch intensity from mosquito bite;
PAAD	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.74	9.05	0.59	6.5e-16	Methadone dose in opioid dependence;
PAAD	trans	rs11794666	0.872	rs71512749	chr9:31631825	T/G	cg05628366	chr6:35744188	C6orf126	1.05	6.39	0.46	1.88e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs509477	0.887	rs657018	chr18:32558960	C/T	cg23791764	chr18:32556832	MAPRE2	0.6	4.91	0.37	2.36e-6	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01940439	chr12:132252573	SFRS8	0.57	6.73	0.48	3.18e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs17095355	0.605	rs41291880	chr10:111635785	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.45	-0.34	1.68e-5	Biliary atresia;
PAAD	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg02743256	chr7:2109353	MAD1L1	-0.58	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3.09e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs492146	0.935	rs316139	chr6:52846372	G/T	cg24393602	chr6:52860404	GSTA4	-0.44	-4.29	-0.33	3.18e-5	Epilepsy (remission after treatment);
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg11047111	chr1:10490344	APITD1	-0.43	-4.37	-0.33	2.31e-5	Prostate cancer;
PAAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.62	5.14	0.38	8.36e-7	Menarche (age at onset);
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.75	-12.74	-0.72	9.51e-26	Longevity;Endometriosis;
PAAD	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.65	6.47	0.46	1.25e-9	Corneal astigmatism;
PAAD	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs13006833	0.668	rs291458	chr2:191181481	A/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs2137920	0.685	rs12783657	chr10:50242015	A/T	cg02657375	chr10:50863136	CHAT	0.57	4.6	0.35	8.84e-6	Migraine with aura;
PAAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.85	9.55	0.61	3.21e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12935418	0.616	rs2602453	chr16:81027963	C/T	cg16651780	chr16:81037892	C16orf61	-0.63	-5.88	-0.43	2.46e-8	Mean corpuscular volume;
PAAD	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.66	5.38	0.4	2.73e-7	Mammographic density (dense area);
PAAD	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.63	-6.65	-0.47	4.96e-10	Brugada syndrome;
PAAD	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.84	-0.69	2.55e-23	Cognitive function;
PAAD	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg13191508	chr8:144600686	ZC3H3	-1.02	-5.44	-0.4	2.13e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs7713065	0.765	rs4643947	chr5:131780781	A/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.36	0.33	2.36e-5	Lung function (FEV1/FVC);
PAAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.82	6.99	0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs59888335	0.894	rs4352348	chr3:80901362	G/A	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.91	-0.37	2.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	1.11	8.74	0.58	4.05e-15	Iron status biomarkers;
PAAD	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg14181355	chr19:12984996	MAST1	-0.47	-4.34	-0.33	2.62e-5	Mean corpuscular volume;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13198984	chr17:80129470	CCDC57	-0.4	-4.78	-0.36	4.09e-6	Life satisfaction;
PAAD	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.73	5.39	0.4	2.6e-7	Vitiligo;
PAAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.61	6.71	0.48	3.54e-10	Coronary artery disease;
PAAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.4	-0.46	1.85e-9	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg24848339	chr3:12840334	CAND2	-0.49	-5.63	-0.42	8.44e-8	QRS complex (12-leadsum);
PAAD	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg12639453	chr1:2035780	PRKCZ	0.5	4.66	0.35	6.99e-6	Height;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.94	8.17	0.55	1.08e-13	Alzheimer's disease;
PAAD	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4740619	0.967	rs7036172	chr9:15653593	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.49	-0.34	1.38e-5	Body mass index;
PAAD	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.95	0.54	3.95e-13	Prudent dietary pattern;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.59	5.9	0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg16964102	chr10:135390573	NA	0.43	4.61	0.35	8.37e-6	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20887711	chr4:1340912	KIAA1530	0.46	4.61	0.35	8.46e-6	Obesity-related traits;
PAAD	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-9.95	-0.63	2.76e-18	Electrocardiographic conduction measures;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg19337854	chr7:99768885	GPC2	0.52	4.91	0.37	2.36e-6	Platelet count;
PAAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg09835421	chr16:68378352	PRMT7	-1.1	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg00717180	chr2:96193071	NA	0.59	6.46	0.46	1.32e-9	HDL cholesterol;
PAAD	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.53	-5.5	-0.41	1.57e-7	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12750378	chr2:88991122	RPIA	0.62	6.87	0.49	1.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6494488	0.500	rs78659827	chr15:64721927	G/T	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	cis	rs11811982	0.793	rs116628261	chr1:227555669	A/G	cg24860534	chr1:227506868	CDC42BPA	0.55	5.28	0.39	4.37e-7	Optic disc area;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg09376583	chr16:88111425	NA	-0.51	-4.4	-0.34	2.04e-5	Menopause (age at onset);
PAAD	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.7	-7.07	-0.5	5.22e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	10.44	0.65	1.42e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs732765	0.734	rs12895862	chr14:75126566	T/C	cg17347104	chr14:75034677	LTBP2	0.63	5.43	0.4	2.2e-7	Non-small cell lung cancer;
PAAD	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg00601450	chr5:74908170	NA	0.53	5.04	0.38	1.29e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.58	5.1	0.38	1e-6	Lymphocyte counts;
PAAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.57	5.04	0.38	1.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs877529	0.625	rs139390	chr22:39532853	A/G	cg18708252	chr22:39545030	CBX7	-0.67	-7.07	-0.5	5.2e-11	Multiple myeloma;
PAAD	cis	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg27395922	chr11:50257633	LOC441601	-0.46	-4.7	-0.36	5.78e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17162190	0.698	rs4659444	chr1:26825116	C/T	cg17456097	chr1:26900765	RPS6KA1	0.57	4.57	0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg00035636	chr13:21900591	NA	0.63	6.83	0.48	1.93e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20180092	chr3:39425780	SLC25A38	-0.66	-6.87	-0.49	1.54e-10	Smoking initiation;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.65	-7.34	-0.51	1.22e-11	Prudent dietary pattern;
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg12143784	chr7:64541923	NA	0.33	4.26	0.33	3.51e-5	Aortic root size;
PAAD	cis	rs2997447	0.846	rs61775417	chr1:26393347	C/G	cg24519413	chr1:26490540	NA	0.51	4.76	0.36	4.39e-6	QRS complex (12-leadsum);
PAAD	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.56	-4.85	-0.37	3.06e-6	Schizophrenia;
PAAD	cis	rs9341808	0.530	rs3805876	chr6:81031539	C/A	cg08355045	chr6:80787529	NA	0.44	5.44	0.4	2.07e-7	Sitting height ratio;
PAAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13639157	chr9:131419648	WDR34	-0.6	-6.34	-0.46	2.52e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.84	0.58	2.18e-15	Menopause (age at onset);
PAAD	cis	rs7771547	0.574	rs9368943	chr6:36566575	C/T	cg07856975	chr6:36356162	ETV7	0.54	5.77	0.42	4.38e-8	Platelet distribution width;
PAAD	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.36	-0.4	3.03e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.37	0.51	9.94e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.66	-7.3	-0.51	1.49e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.76	-6.64	-0.47	5.32e-10	Blood pressure (smoking interaction);
PAAD	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4757319	0.554	rs11023520	chr11:15332935	A/G	cg03245590	chr11:15329459	NA	-0.45	-5.55	-0.41	1.26e-7	Breast cancer;
PAAD	cis	rs11264799	0.520	rs2779159	chr1:157550357	C/T	cg18268488	chr1:157545234	FCRL4	0.56	6.39	0.46	1.89e-9	IgA nephropathy;
PAAD	cis	rs2131877	0.830	rs62290344	chr3:194849620	T/C	cg16306870	chr3:194868790	C3orf21	0.48	4.32	0.33	2.84e-5	Non-small cell lung cancer;
PAAD	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg12395012	chr8:11607386	GATA4	0.42	4.41	0.34	1.96e-5	Neuroticism;
PAAD	cis	rs77633900	0.772	rs157769	chr15:76834397	G/A	cg21673338	chr15:77095150	SCAPER	-0.86	-4.52	-0.34	1.24e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg20003494	chr4:90757398	SNCA	-0.75	-7.28	-0.51	1.64e-11	Neuroticism;
PAAD	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26926768	chr12:34528122	NA	0.37	4.28	0.33	3.35e-5	Morning vs. evening chronotype;
PAAD	cis	rs1345301	1.000	rs1345301	chr2:102875587	A/G	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.34	-0.33	2.57e-5	Waist circumference;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.28	-0.39	4.31e-7	Mononucleosis;
PAAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.74	-8.35	-0.56	3.87e-14	Renal function-related traits (BUN);
PAAD	cis	rs75920871	0.858	rs11216168	chr11:116741553	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.82	-4.55	-0.35	1.08e-5	Subjective well-being;
PAAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg27182935	chr16:89790473	ZNF276	-0.73	-4.47	-0.34	1.52e-5	Skin colour saturation;
PAAD	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09065629	chr16:1709722	CRAMP1L	-0.44	-4.65	-0.35	7.31e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04136290	chr17:80477136	FOXK2	0.65	6.59	0.47	6.84e-10	Obesity-related traits;
PAAD	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.25	-0.33	3.66e-5	Coronary artery disease;
PAAD	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.69	-7.31	-0.51	1.43e-11	Dental caries;
PAAD	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.34	-0.33	2.62e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-15.53	-0.78	3.47e-33	Ulcerative colitis;
PAAD	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg03309721	chr19:2236316	PLEKHJ1;SF3A2	-0.57	-4.46	-0.34	1.58e-5	Bipolar disorder;
PAAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.45	7.73	0.53	1.33e-12	Multiple system atrophy;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.63	4.9	0.37	2.38e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs6844506	0.898	rs4862359	chr4:185234037	T/G	cg12654155	chr4:185238627	NA	-0.48	-4.89	-0.37	2.49e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs7823896	0.722	rs16879277	chr8:110302993	C/G	cg02458499	chr8:110280928	NUDCD1	-0.74	-4.82	-0.36	3.47e-6	Myopia (pathological);
PAAD	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.8	6.68	0.48	4.2e-10	Neutrophil percentage of white cells;
PAAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs11016883	0.875	rs4751111	chr10:131502995	C/T	cg14312783	chr10:131504572	MGMT	0.45	4.5	0.34	1.33e-5	Waist-to-hip circumference ratio (ever vs never smoking interaction);
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.78	8.11	0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.7	7.19	0.5	2.69e-11	Menarche (age at onset);
PAAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs2242663	0.558	rs11227485	chr11:66215423	C/T	cg16756854	chr11:66116455	B3GNT1	-0.37	-4.61	-0.35	8.39e-6	Bipolar disorder;
PAAD	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.17	-17.8	-0.82	5.12e-39	Exhaled nitric oxide output;
PAAD	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg12870014	chr12:110450643	ANKRD13A	0.71	5.12	0.38	9.03e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.5	-0.34	1.36e-5	Mood instability;
PAAD	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24873593	chr5:139944080	APBB3;SLC35A4	0.63	6.35	0.46	2.36e-9	Obesity-related traits;
PAAD	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.15	0.5	3.39e-11	Eye color traits;
PAAD	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.5	-4.83	-0.37	3.23e-6	Vitiligo;
PAAD	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs375066	1.000	rs375066	chr19:44423570	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs17032980	0.910	rs7575826	chr2:67309631	G/A	cg02551743	chr2:66673428	MEIS1	-0.5	-4.49	-0.34	1.39e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.52	-5.03	-0.38	1.38e-6	Migraine;
PAAD	cis	rs8105895	0.935	rs7252550	chr19:22246017	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.89	-0.37	2.53e-6	Tuberculosis;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.75	-8.42	-0.56	2.65e-14	Colorectal cancer;
PAAD	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.87	10.09	0.63	1.19e-18	Ulcerative colitis;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.82	10.15	0.64	8.36e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.54	-0.52	3.95e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.47	-0.34	1.53e-5	Height;
PAAD	cis	rs66530629	0.874	rs6604978	chr1:25090446	C/G	cg01905478	chr1:25040257	NA	-0.46	-5.02	-0.38	1.46e-6	Plateletcrit;
PAAD	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	13.97	0.75	4.83e-29	Schizophrenia;
PAAD	cis	rs4917300	0.605	rs4917279	chr8:143095690	C/T	cg26003909	chr8:143102224	NA	-0.35	-5.77	-0.42	4.24e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.72	6.77	0.48	2.58e-10	Methadone dose in opioid dependence;
PAAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.11	10.64	0.65	4.09e-20	Orofacial clefts;
PAAD	cis	rs10750165	0.716	rs10892459	chr11:119653883	C/G	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.53	4.76	0.36	4.39e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg01966878	chr4:90757139	SNCA	-0.61	-4.75	-0.36	4.59e-6	Neuroticism;
PAAD	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.76e-10	Plateletcrit;Platelet count;
PAAD	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.62	6.2	0.45	5.17e-9	Monocyte count;
PAAD	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.83	0.36	3.3e-6	Schizophrenia;
PAAD	cis	rs4720118	0.660	rs2006387	chr7:33214278	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.48	-4.26	-0.33	3.53e-5	Leprosy;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22995486	chr5:75592299	SV2C	-0.63	-6.99	-0.49	8.15e-11	Obesity-related traits;
PAAD	cis	rs7567389	0.677	rs72848604	chr2:128120118	G/C	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs1035491	0.715	rs7706303	chr5:63919136	A/G	cg01791865	chr5:63954708	NA	0.51	5.44	0.4	2.06e-7	Body mass index;
PAAD	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg27478167	chr7:817139	HEATR2	0.69	5.29	0.39	4.24e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg12908607	chr1:44402522	ARTN	-0.43	-4.65	-0.35	7.05e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg23346134	chr3:49453900	TCTA	-0.46	-4.88	-0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	4.96	0.37	1.85e-6	Schizophrenia;
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.54	5.31	0.4	3.84e-7	Parkinson's disease;
PAAD	cis	rs7678555	0.540	rs991867	chr4:120864689	T/C	cg09307838	chr4:120376055	NA	0.47	4.35	0.33	2.52e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.65	-0.53	2.11e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.97	-10.61	-0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.84	8.4	0.56	2.93e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.5	-4.37	-0.33	2.28e-5	Coronary artery disease;
PAAD	cis	rs904092	1.000	rs904092	chr4:100214164	A/G	cg12011299	chr4:100065546	ADH4	-0.57	-4.69	-0.36	6.09e-6	Alcohol dependence;
PAAD	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.74	0.42	5.09e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075232	1.000	rs56396205	chr15:31678385	G/A	cg01030201	chr15:31746330	NA	-1.09	-4.45	-0.34	1.67e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.8	-6.65	-0.47	4.93e-10	Pancreatic cancer;
PAAD	cis	rs10450586	0.863	rs7115024	chr11:27301437	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.13e-5	Total body bone mineral density;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.64	7.24	0.51	2.11e-11	Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg12215294	chr3:40350768	EIF1B	0.46	4.49	0.34	1.38e-5	Renal cell carcinoma;
PAAD	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.45	-4.65	-0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-8.59	-0.57	9.88e-15	Blood trace element (Zn levels);
PAAD	cis	rs7187994	0.848	rs16974527	chr16:84782822	C/T	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09579959	chr1:228327934	GUK1	0.65	6.69	0.48	3.97e-10	Myopia (pathological);
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg04520793	chr17:42248056	ASB16	-0.41	-4.61	-0.35	8.57e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	5.76	0.42	4.52e-8	Height;
PAAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.6	-0.52	2.87e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.54	5.78	0.42	4.17e-8	Menopause (age at onset);
PAAD	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg23260525	chr10:116636907	FAM160B1	0.38	5.4	0.4	2.52e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg19192590	chr2:178524533	PDE11A	0.39	4.43	0.34	1.78e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg10090792	chr1:38198142	EPHA10	-0.43	-4.53	-0.34	1.21e-5	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.27	9.03	0.59	7.08e-16	Blood pressure (smoking interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14707898	chr6:41888549	MED20;BYSL	-0.7	-6.96	-0.49	9.66e-11	Neuroticism;
PAAD	cis	rs4588572	0.561	rs12697887	chr5:77804729	A/G	cg11547950	chr5:77652471	NA	-0.77	-6.48	-0.47	1.21e-9	Triglycerides;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg01181863	chr3:195395398	SDHAP2	-0.61	-4.3	-0.33	3.06e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	6.7	0.48	3.74e-10	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.46	-0.34	1.58e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6662572	0.806	rs56067046	chr1:46044314	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	4.41	0.34	1.97e-5	Blood protein levels;
PAAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg21782813	chr7:2030301	MAD1L1	0.56	5.95	0.43	1.81e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.96	11.8	0.69	3.28e-23	Bone mineral density;
PAAD	cis	rs17407555	0.683	rs6833142	chr4:10275982	A/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.16	0.39	7.59e-7	Schizophrenia (age at onset);
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg21929781	chr1:2537748	MMEL1	0.48	5.08	0.38	1.1e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg06375148	chr1:209958343	C1orf74	0.69	5.77	0.42	4.38e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-4.39	-0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg17974515	chr1:2252516	NA	0.61	6.13	0.45	7.25e-9	Coronary artery disease;
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.77	-5.72	-0.42	5.59e-8	Initial pursuit acceleration;
PAAD	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-10.99	-0.67	4.73e-21	Ulcerative colitis;
PAAD	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.73	0.48	3.2e-10	Coffee consumption (cups per day);
PAAD	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.42	5.19	0.39	6.73e-7	Thyroid stimulating hormone;
PAAD	cis	rs62264129	0.525	rs62278769	chr3:112027201	C/T	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.9	-0.37	2.4e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs1075265	0.901	rs1118618	chr2:54326470	T/C	cg04546899	chr2:54196757	PSME4	0.32	4.42	0.34	1.83e-5	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.55	-0.47	8.27e-10	HDL cholesterol;
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.97	-6.78	-0.48	2.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2085601	0.542	rs1398947	chr4:89963824	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg11232448	chr19:2858854	NA	-0.48	-4.72	-0.36	5.25e-6	Total cholesterol levels;
PAAD	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.39	0.34	2.08e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.91	12.05	0.7	6.76e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.48	4.42	0.34	1.9e-5	Retinal vascular caliber;
PAAD	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg16928487	chr17:17741425	SREBF1	0.37	5.01	0.38	1.49e-6	Total body bone mineral density;
PAAD	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	4.54	0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-6.85	-0.49	1.75e-10	Lymphocyte counts;
PAAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.93	-0.49	1.11e-10	Gut microbiome composition (summer);
PAAD	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.58	-0.35	9.77e-6	Testicular germ cell tumor;
PAAD	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg15309053	chr8:964076	NA	0.42	4.63	0.35	7.78e-6	Schizophrenia;
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.78	-9.87	-0.63	4.5e-18	Prudent dietary pattern;
PAAD	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg12568669	chr8:11666485	FDFT1	-0.29	-4.55	-0.35	1.08e-5	Monocyte count;
PAAD	cis	rs795484	0.890	rs811247	chr12:118622836	G/T	cg16572268	chr12:118583242	PEBP1	-0.46	-4.54	-0.35	1.12e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.68	4.61	0.35	8.5e-6	Inflammatory bowel disease;
PAAD	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.58	5.93	0.43	1.98e-8	Coronary artery disease;
PAAD	cis	rs593531	0.571	rs6592557	chr11:74086642	T/C	cg15851278	chr11:73669449	DNAJB13	-0.37	-4.41	-0.34	1.92e-5	Neuroticism;
PAAD	cis	rs838147	0.873	rs28400014	chr19:49250657	C/G	cg13540341	chr19:49222985	MAMSTR	0.38	4.46	0.34	1.6e-5	Dietary macronutrient intake;
PAAD	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs965469	1.000	rs6051737	chr20:3296992	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03129643	chr1:37940147	ZC3H12A	-0.71	-7.92	-0.54	4.69e-13	Smoking initiation;
PAAD	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	1.11	14.49	0.76	1.93e-30	Migraine;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs600550	0.551	rs12792791	chr11:60082497	G/A	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.04	-0.38	1.29e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg16083429	chr3:49237500	CCDC36	-0.43	-4.56	-0.35	1.06e-5	Parkinson's disease;
PAAD	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.62e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.4	-0.34	2.04e-5	Longevity;Endometriosis;
PAAD	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.55	-5.39	-0.4	2.66e-7	Motion sickness;
PAAD	cis	rs17209837	1.000	rs7802783	chr7:87130397	A/G	cg00919237	chr7:87102261	ABCB4	0.66	4.27	0.33	3.38e-5	Gallbladder cancer;
PAAD	cis	rs75757892	0.544	rs9505140	chr6:7318354	C/T	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.69	-6.61	-0.47	6.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6499755	0.965	rs9932163	chr16:55350683	C/A	cg02859129	chr16:55357253	IRX6	0.34	4.61	0.35	8.45e-6	Hypospadias;
PAAD	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.8	-9.13	-0.6	3.87e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.57	4.86	0.37	2.9e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.76	-7.18	-0.5	2.95e-11	Obesity-related traits;
PAAD	trans	rs6686842	0.965	rs1472570	chr1:41714084	G/T	cg04009860	chr15:101853297	PCSK6	0.59	6.41	0.46	1.73e-9	Height;
PAAD	cis	rs17741873	0.614	rs74617374	chr10:75690059	G/T	cg01368488	chr10:75493387	NA	-0.55	-4.55	-0.35	1.08e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg22681709	chr2:178499509	PDE11A	-0.5	-6.02	-0.44	1.28e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg26554054	chr8:600488	NA	-0.86	-5.64	-0.42	8.16e-8	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.63	8.18	0.55	1.08e-13	Renal cell carcinoma;
PAAD	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.63	5.48	0.41	1.7e-7	Diastolic blood pressure;
PAAD	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg05805236	chr11:65401703	PCNXL3	-0.45	-5.18	-0.39	7.07e-7	Systemic lupus erythematosus;
PAAD	cis	rs2131877	0.830	rs59910866	chr3:194876243	C/T	cg24618514	chr3:194868507	C3orf21	0.49	4.41	0.34	1.94e-5	Non-small cell lung cancer;
PAAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg18302933	chr2:88491318	NA	-0.42	-5.02	-0.38	1.43e-6	Response to metformin (IC50);
PAAD	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.48	-0.34	1.45e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs77880822	0.562	rs76914781	chr20:1249081	C/T	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.94	-0.49	1.09e-10	Morning vs. evening chronotype;
PAAD	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.35e-5	Coronary artery disease;
PAAD	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg14664628	chr15:75095509	CSK	-0.67	-6.81	-0.48	2.13e-10	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg04719120	chr6:96025338	MANEA	0.52	4.27	0.33	3.48e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-7.51	-0.52	4.58e-12	D-dimer levels;
PAAD	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.05	-13.58	-0.74	5.29e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.54	4.41	0.34	1.93e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.35	0.46	2.41e-9	Height;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.87	-0.37	2.78e-6	Life satisfaction;
PAAD	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	1.18	7.97	0.54	3.49e-13	Obesity (early onset extreme);
PAAD	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-7.17	-0.5	3.11e-11	Idiopathic membranous nephropathy;
PAAD	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.46	4.7	0.36	5.86e-6	Hirschsprung disease;
PAAD	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.97	7.99	0.54	3.13e-13	Eosinophilic esophagitis;
PAAD	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg13397359	chr6:42928475	GNMT	0.68	5.54	0.41	1.28e-7	Blood protein levels;
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09826364	chr7:158789723	NA	-0.39	-4.93	-0.37	2.13e-6	Facial morphology (factor 20);
PAAD	cis	rs6984449	0.516	rs4921645	chr8:19303736	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.42	-5.23	-0.39	5.46e-7	Educational attainment;
PAAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2242420	0.920	rs16825749	chr1:21958918	A/G	cg04297819	chr1:22260125	HSPG2	0.48	4.27	0.33	3.48e-5	Hematological and biochemical traits;
PAAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.59	4.94	0.37	2.03e-6	Coronary artery disease;
PAAD	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg19413350	chr8:57351067	NA	0.51	5.19	0.39	6.65e-7	Obesity-related traits;
PAAD	cis	rs761746	0.614	rs2108108	chr22:32181937	G/A	cg01338084	chr22:32026380	PISD	0.59	5.04	0.38	1.33e-6	Intelligence;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.9	10.6	0.65	5.43e-20	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.55	-4.59	-0.35	9.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg17366294	chr4:99064904	C4orf37	0.52	5.65	0.42	7.81e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg05697835	chr1:2722811	NA	0.41	4.58	0.35	9.66e-6	Ulcerative colitis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15031763	chr19:49631660	PPFIA3	0.59	7.03	0.5	6.68e-11	Metabolite levels  (X-11787);
PAAD	cis	rs7301016	0.894	rs11174487	chr12:62849999	T/C	cg11441379	chr12:63026424	NA	0.84	5.91	0.43	2.16e-8	IgG glycosylation;
PAAD	cis	rs5009270	0.513	rs11768435	chr7:112219017	C/T	cg23628563	chr7:112262597	NA	0.57	5.51	0.41	1.53e-7	Osteoarthritis (hip);
PAAD	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.47	-0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.56	-5.63	-0.42	8.63e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7731390	0.764	rs75817769	chr5:131707365	A/G	cg07395648	chr5:131743802	NA	-0.7	-4.47	-0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.63	6.09	0.44	8.94e-9	Bone properties (heel);
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg25251562	chr2:3704773	ALLC	-0.68	-6.7	-0.48	3.73e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.45	-4.48	-0.34	1.45e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.78	0.36	4.12e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.41	5.2	0.39	6.38e-7	Electrocardiographic conduction measures;
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16262614	chr3:133464971	TF	0.47	5.04	0.38	1.32e-6	Iron status biomarkers;
PAAD	cis	rs1018697	1.000	rs7909612	chr10:104561456	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.47	-5.25	-0.39	5.12e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	6.17	0.45	5.86e-9	Lung cancer;
PAAD	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.55	5.77	0.42	4.38e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg09237302	chr4:906077	GAK	-0.43	-4.44	-0.34	1.72e-5	Type 2 diabetes;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.04	6.67	0.48	4.47e-10	Fat distribution (HIV);
PAAD	cis	rs6132905	0.548	rs77557811	chr20:2610648	G/A	cg24848351	chr20:2622020	TMC2	-0.64	-4.46	-0.34	1.61e-5	Mumps;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs2279817	0.908	rs3766310	chr1:17977642	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.8	-7.0	-0.49	7.5e-11	Neuroticism;
PAAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.94	12.47	0.71	5.12e-25	Menopause (age at onset);
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.72	7.26	0.51	1.9e-11	Renal function-related traits (BUN);
PAAD	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg03315344	chr16:75512273	CHST6	0.63	7.08	0.5	4.99e-11	Dupuytren's disease;
PAAD	cis	rs9463078	0.510	rs4714832	chr6:44978183	T/C	cg25276700	chr6:44698697	NA	0.49	5.61	0.41	9.29e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09428537	chr16:90039076	AFG3L1;CENPBD1	-0.79	-7.03	-0.5	6.49e-11	Neuroticism;
PAAD	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.9	10.4	0.64	1.78e-19	Parkinson's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04656757	chr16:81663359	CMIP	0.56	6.36	0.46	2.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg05338066	chr1:7812865	CAMTA1	0.53	4.36	0.33	2.35e-5	Inflammatory bowel disease;
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg03806693	chr22:41940476	POLR3H	-0.91	-6.4	-0.46	1.8e-9	Vitiligo;
PAAD	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	5.07	0.38	1.14e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.0	0.63	2.11e-18	Prudent dietary pattern;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20260663	chr12:56211576	ORMDL2;SARNP	-0.76	-6.45	-0.46	1.39e-9	Neuroticism;
PAAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-6.78	-0.48	2.52e-10	Bipolar disorder;
PAAD	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.55	5.07	0.38	1.12e-6	Monocyte count;
PAAD	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.81	-0.36	3.57e-6	Initial pursuit acceleration;
PAAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.8	7.69	0.53	1.75e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03734229	chr1:41236997	NFYC	-0.65	-6.74	-0.48	3.01e-10	Obesity-related traits;
PAAD	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.4	-0.34	2.03e-5	Testicular germ cell tumor;
PAAD	cis	rs1642645	0.872	rs3856258	chr1:42473397	A/G	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.48	-0.41	1.69e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00808730	chr14:93215038	LGMN	-0.57	-6.4	-0.46	1.84e-9	Body fat percentage;
PAAD	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg05874882	chr4:1763078	NA	0.37	4.81	0.36	3.67e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.12	16.07	0.79	1.38e-34	Schizophrenia;
PAAD	cis	rs12145833	1.000	rs76473275	chr1:243460555	T/C	cg02356786	chr1:243265016	LOC731275	0.68	4.66	0.35	6.74e-6	Obesity (early onset extreme);
PAAD	cis	rs6681460	0.899	rs499263	chr1:67179937	T/C	cg02459107	chr1:67143332	SGIP1	0.7	6.5	0.47	1.11e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs761746	0.846	rs2295251	chr22:32013265	C/T	cg01338084	chr22:32026380	PISD	-0.54	-4.7	-0.36	5.68e-6	Intelligence;
PAAD	cis	rs4343996	0.692	rs34148253	chr7:3454978	A/G	cg21248987	chr7:3385318	SDK1	0.47	5.06	0.38	1.21e-6	Motion sickness;
PAAD	cis	rs282587	0.569	rs409896	chr13:113400338	G/T	cg19217778	chr13:113420270	ATP11A	-0.58	-4.49	-0.34	1.39e-5	Glycated hemoglobin levels;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg15117754	chr3:10150083	C3orf24	0.65	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.22	-0.39	5.67e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246657	0.525	rs1667351	chr19:37478027	A/T	cg23950597	chr19:37808831	NA	-0.7	-5.09	-0.38	1.02e-6	Coronary artery calcification;
PAAD	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.67	8.01	0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7246657	0.943	rs4802136	chr19:37849811	T/A	cg23950597	chr19:37808831	NA	-0.76	-5.66	-0.42	7.27e-8	Coronary artery calcification;
PAAD	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg22663859	chr13:21900854	NA	0.56	5.83	0.43	3.16e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.58	-5.24	-0.39	5.4e-7	P wave terminal force;
PAAD	cis	rs11723436	0.543	rs4411968	chr4:120830916	G/A	cg09307838	chr4:120376055	NA	0.47	4.52	0.34	1.24e-5	Coronary artery disease;
PAAD	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg03959625	chr15:84868606	LOC388152	0.49	5.32	0.4	3.67e-7	Schizophrenia;
PAAD	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.55	-0.47	8.31e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs5753037	0.838	rs1076135	chr22:30238317	A/T	cg01021169	chr22:30184971	ASCC2	-0.44	-4.62	-0.35	8.18e-6	Type 1 diabetes;
PAAD	cis	rs13424612	0.930	rs4149545	chr2:240942818	G/T	cg12807937	chr2:240965920	NDUFA10	-0.48	-4.79	-0.36	3.98e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs988913	1.000	rs6902245	chr6:54813006	C/A	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.38	-0.64	2.09e-19	Cognitive function;
PAAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.74	-7.06	-0.5	5.7e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.06	0.5	5.57e-11	Schizophrenia;
PAAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14296220	chr9:32431791	ACO1	-0.73	-7.44	-0.52	7.08e-12	Obesity-related traits;
PAAD	cis	rs6494488	0.500	rs16948187	chr15:64988982	C/T	cg03840511	chr15:64649139	CSNK1G1	0.8	4.84	0.37	3.13e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.92	-0.37	2.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.63	-6.2	-0.45	5.15e-9	Blood metabolite levels;
PAAD	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg15192750	chr16:69999425	NA	0.73	5.65	0.42	7.86e-8	IgE levels;
PAAD	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.16	-0.5	3.3e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg23649088	chr2:200775458	C2orf69	-0.51	-4.8	-0.36	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs4742903	0.935	rs1450681	chr9:106932435	A/G	cg14250997	chr9:106856677	SMC2	0.46	4.94	0.37	2.06e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg22827986	chr11:48284249	OR4X1	0.41	4.98	0.37	1.72e-6	Migraine - clinic-based;
PAAD	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.5	5.86	0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs10849004	1.000	rs10849003	chr12:4292738	G/T	cg03803796	chr12:3575061	NA	0.55	4.46	0.34	1.6e-5	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.7	-7.68	-0.53	1.81e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.54	0.52	4.01e-12	Prudent dietary pattern;
PAAD	cis	rs60154123	0.730	rs12034871	chr1:210475701	T/C	cg25204440	chr1:209979598	IRF6	0.62	5.13	0.38	8.55e-7	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	4.63	0.35	7.76e-6	HIV-1 control;
PAAD	cis	rs12681288	0.821	rs2701944	chr8:1034525	T/A	cg04851639	chr8:1020857	NA	-0.67	-8.28	-0.56	5.98e-14	Schizophrenia;
PAAD	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.54	6.05	0.44	1.08e-8	Mean corpuscular volume;
PAAD	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.25	-0.45	3.87e-9	Mood instability;
PAAD	cis	rs2885056	0.843	rs1821279	chr19:10693008	G/C	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg11764359	chr7:65958608	NA	-0.75	-4.96	-0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8105895	0.935	rs6511314	chr19:22236395	A/C	cg20662725	chr19:22235022	ZNF257	0.54	4.29	0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs73719811	1.000	rs17143495	chr7:121203602	T/G	cg22032706	chr7:120498729	TSPAN12	0.67	4.41	0.34	1.98e-5	Total body bone mineral density;
PAAD	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.89	7.9	0.54	5.31e-13	Monocyte percentage of white cells;
PAAD	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.51	-0.34	1.27e-5	Neuroticism;
PAAD	cis	rs2652834	1.000	rs2729782	chr15:63403354	G/C	cg05507819	chr15:63340323	TPM1	0.77	4.95	0.37	1.95e-6	HDL cholesterol;
PAAD	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16988970	chr17:42248062	ASB16	-0.38	-5.45	-0.4	1.96e-7	Total body bone mineral density;
PAAD	cis	rs1345301	1.000	rs10200410	chr2:102870871	G/A	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.33	-0.33	2.72e-5	Waist circumference;
PAAD	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.47	4.93	0.37	2.09e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06815965	chr1:205818668	PM20D1	0.69	7.73	0.53	1.34e-12	Menarche (age at onset);
PAAD	cis	rs10924309	0.882	rs10924306	chr1:245857065	G/A	cg00036263	chr1:245852353	KIF26B	-0.64	-5.34	-0.4	3.38e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg02997394	chr19:33096574	ANKRD27	0.39	4.26	0.33	3.51e-5	Schizophrenia;
PAAD	cis	rs4343996	0.902	rs9969270	chr7:3368974	C/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.13	-0.38	8.67e-7	Motion sickness;
PAAD	cis	rs1519814	0.740	rs7845541	chr8:121044393	G/C	cg22335954	chr8:121166405	COL14A1	-0.63	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg26554054	chr8:600488	NA	0.9	5.85	0.43	2.88e-8	IgG glycosylation;
PAAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs10905065	0.793	rs10508296	chr10:5864500	C/A	cg11519256	chr10:5708881	ASB13	0.53	4.77	0.36	4.2e-6	Menopause (age at onset);
PAAD	cis	rs863345	0.901	rs10752625	chr1:158468626	G/A	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.6	-4.4	-0.34	2.04e-5	Multiple sclerosis;
PAAD	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg02027945	chr11:20618230	NA	0.32	4.59	0.35	9.04e-6	Pursuit maintenance gain;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	9.69	0.62	1.37e-17	Platelet count;
PAAD	cis	rs9361491	0.608	rs7451373	chr6:79464171	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7923609	0.818	rs10822159	chr10:65096250	C/T	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.95	7.4	0.51	8.84e-12	Migraine;Coronary artery disease;
PAAD	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs12311304	1.000	rs12300553	chr12:15381210	C/T	cg08258403	chr12:15378311	NA	0.35	4.38	0.33	2.22e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg03006477	chr6:74432658	CD109	0.43	4.31	0.33	2.94e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.81	7.15	0.5	3.48e-11	Psoriasis;
PAAD	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	6.05	0.44	1.06e-8	Body mass index;
PAAD	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg06057569	chr22:50219754	BRD1	0.68	5.05	0.38	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs75920871	0.858	rs7950501	chr11:116963965	C/T	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg20821713	chr7:1055600	C7orf50	-0.56	-4.57	-0.35	9.93e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	4.29	0.33	3.17e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs16910800	1.000	rs11027021	chr11:23183529	C/T	cg20040320	chr11:23191996	NA	0.59	5.26	0.39	4.89e-7	Cancer;
PAAD	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.62	4.98	0.37	1.69e-6	Coronary artery disease;
PAAD	cis	rs6499129	1.000	rs9922624	chr16:67478976	C/T	cg10189135	chr16:67516162	ATP6V0D1	-0.56	-4.29	-0.33	3.14e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08219700	chr8:58056026	NA	0.7	5.28	0.39	4.43e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7326068	0.610	rs3924006	chr13:21331779	T/A	cg27234864	chr13:21295941	IL17D	0.57	4.71	0.36	5.43e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.58	-5.62	-0.42	8.72e-8	Reticulocyte count;
PAAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-4.26	-0.33	3.5e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg14458575	chr2:238380390	NA	0.48	4.38	0.33	2.22e-5	Prostate cancer;
PAAD	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg12568669	chr8:11666485	FDFT1	-0.3	-5.27	-0.39	4.57e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs654384	0.830	rs8180800	chr7:4161793	T/C	cg27574739	chr7:4176374	SDK1	0.45	4.45	0.34	1.64e-5	Positive affect;
PAAD	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.3	8.43	0.56	2.47e-14	Opioid sensitivity;
PAAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.08	10.61	0.65	4.9e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg05315796	chr3:52349193	DNAH1	0.43	4.81	0.36	3.56e-6	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15473325	chr12:133137087	FBRSL1	0.65	7.43	0.52	7.26e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg02820901	chr13:113351484	ATP11A	0.69	4.57	0.35	9.97e-6	Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12963246	chr6:28129442	ZNF389	0.6	4.34	0.33	2.56e-5	Parkinson's disease;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.58	-5.86	-0.43	2.72e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6834538	1.000	rs6834538	chr4:113544152	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.53	0.35	1.17e-5	Free thyroxine concentration;
PAAD	cis	rs7873102	0.617	rs2266014	chr9:37980435	T/A	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2414856	0.504	rs67465716	chr15:64960614	T/C	cg16425858	chr15:64791681	ZNF609	0.93	4.93	0.37	2.11e-6	Pulse pressure;Systolic blood pressure;
PAAD	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11547950	chr5:77652471	NA	-0.47	-4.63	-0.35	7.88e-6	Hippocampal atrophy;
PAAD	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.99	7.46	0.52	6.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg00262122	chr8:11665843	FDFT1	0.47	4.39	0.34	2.1e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18337363	chr3:52569053	NT5DC2	0.44	4.47	0.34	1.49e-5	Electroencephalogram traits;
PAAD	cis	rs12912251	0.895	rs35795311	chr15:38998669	C/G	cg10631289	chr15:39006617	NA	0.46	4.43	0.34	1.76e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-1.01	-13.65	-0.74	3.36e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg03959625	chr15:84868606	LOC388152	0.43	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.94	6.02	0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.42	5.15	0.39	7.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.44	4.28	0.33	3.26e-5	Alzheimer's disease (late onset);
PAAD	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.68	7.17	0.5	3.03e-11	Platelet distribution width;
PAAD	cis	rs1334894	1.000	rs72921231	chr6:35589637	T/C	cg07213720	chr6:35227408	ZNF76	-0.88	-4.89	-0.37	2.59e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.61	6.09	0.44	8.77e-9	Essential tremor;
PAAD	trans	rs62179067	0.708	rs17362972	chr2:179909467	C/T	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20516256	chr14:70232567	SFRS5	-0.63	-6.51	-0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	7.16	0.5	3.21e-11	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg08112188	chr17:47440006	ZNF652	1.28	6.45	0.46	1.41e-9	Prostate cancer;
PAAD	cis	rs12144049	0.672	rs10736384	chr1:152439495	C/T	cg25605289	chr1:151974222	NA	-0.33	-4.33	-0.33	2.65e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	5.64	0.42	8.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg24147428	chr11:65409760	SIPA1	-0.35	-4.42	-0.34	1.88e-5	Urate levels;
PAAD	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.42	4.49	0.34	1.4e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.77	8.85	0.58	2.15e-15	White blood cell count (basophil);
PAAD	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg11779900	chr17:80519722	FOXK2	-0.49	-5.05	-0.38	1.23e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Breast cancer;
PAAD	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-6.15	-0.45	6.51e-9	Hypospadias;
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.68	7.45	0.52	6.51e-12	Longevity;
PAAD	cis	rs11159840	0.510	rs7156574	chr14:88541941	A/G	cg18078958	chr14:88630771	NA	-0.39	-4.3	-0.33	3.1e-5	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-5.41	-0.4	2.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.92	9.83	0.62	5.85e-18	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264799	0.603	rs12134075	chr1:157586516	C/T	cg18268488	chr1:157545234	FCRL4	0.45	5.4	0.4	2.55e-7	IgA nephropathy;
PAAD	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.86	-11.22	-0.67	1.17e-21	Heart rate;
PAAD	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.7	-6.32	-0.46	2.8e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg00086871	chr4:6988644	TBC1D14	1.07	4.73	0.36	5.04e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4953404	0.613	rs10180473	chr2:46904168	A/G	cg12784625	chr2:46524557	EPAS1	-0.48	-4.32	-0.33	2.82e-5	Pulse pressure (alcohol consumption interaction);
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12483801	chr4:183727862	NA	0.74	5.64	0.42	8.2e-8	Pediatric autoimmune diseases;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-16.57	-0.8	7.11e-36	Prudent dietary pattern;
PAAD	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg21951975	chr1:209979733	IRF6	0.53	4.93	0.37	2.09e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.11e-9	Life satisfaction;
PAAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14895029	chr7:2775587	GNA12	-0.48	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.56	8.47	0.57	1.92e-14	Hypertriglyceridemia;
PAAD	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg23254163	chr1:152506842	NA	-0.56	-6.13	-0.44	7.4e-9	Hair morphology;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10991303	chr3:142608051	PCOLCE2	0.7	7.2	0.5	2.54e-11	Obesity-related traits;
PAAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs78761021	0.867	rs7219033	chr17:9787958	G/A	cg26853458	chr17:9805074	RCVRN	0.69	7.97	0.54	3.41e-13	Type 2 diabetes;
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.64	-7.04	-0.5	6.16e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.85	-10.05	-0.63	1.53e-18	Idiopathic membranous nephropathy;
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.53	5.36	0.4	3.02e-7	Lung cancer;
PAAD	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	4.34	0.33	2.61e-5	Mood instability;
PAAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.73	-6.95	-0.49	1e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.5	4.9	0.37	2.44e-6	Testicular germ cell tumor;
PAAD	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-4.28	-0.33	3.28e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.52	-5.4	-0.4	2.56e-7	Height;
PAAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.73	-0.36	4.99e-6	Bipolar disorder;
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.64	9.17	0.6	3.09e-16	IgG glycosylation;
PAAD	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg24585817	chr7:64895279	NA	-0.48	-4.75	-0.36	4.63e-6	Aortic root size;
PAAD	cis	rs773506	0.628	rs10733739	chr9:93929515	C/T	cg14446406	chr9:93919335	NA	-0.41	-5.52	-0.41	1.42e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.58	-5.18	-0.39	6.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.77e-6	Recombination rate (females);
PAAD	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.55	7.37	0.51	1.05e-11	Primary biliary cholangitis;
PAAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg26497354	chr6:109612229	NA	-0.44	-4.7	-0.36	5.71e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg09491104	chr22:46646882	C22orf40	-0.87	-5.15	-0.39	8.13e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.83	8.76	0.58	3.58e-15	Itch intensity from mosquito bite;
PAAD	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.93	-7.46	-0.52	6.1e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.74	-8.3	-0.56	5.28e-14	Prostate cancer;
PAAD	cis	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.77	7.45	0.52	6.72e-12	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.87e-7	Personality dimensions;
PAAD	cis	rs990171	1.000	rs6753717	chr2:102993161	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.49	0.34	1.38e-5	Lymphocyte counts;
PAAD	cis	rs76917914	0.820	rs12554583	chr9:100812569	A/G	cg03040243	chr9:100819229	NANS	0.59	4.91	0.37	2.34e-6	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.91	12.34	0.71	1.09e-24	Prudent dietary pattern;
PAAD	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.48	5.12	0.38	9.19e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	trans	rs55692468	0.570	rs12623070	chr2:153318339	T/C	cg16346555	chr2:69374392	ANTXR1	0.56	6.3	0.46	3.1e-9	Intraocular pressure;
PAAD	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.53	-5.57	-0.41	1.15e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.84	0.37	3.22e-6	Oropharynx cancer;
PAAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.94	12.21	0.7	2.58e-24	Menopause (age at onset);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.63	-0.35	7.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	5.41	0.4	2.4e-7	Iron status biomarkers;
PAAD	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.6	5.42	0.4	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg05313129	chr8:58192883	C8orf71	-0.67	-5.68	-0.42	6.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.52e-6	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg03037974	chr15:76606532	NA	-0.55	-6.7	-0.48	3.72e-10	Blood metabolite levels;
PAAD	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs951266	0.505	rs11072785	chr15:78968229	C/T	cg00540400	chr15:79124168	NA	-0.45	-5.08	-0.38	1.1e-6	Post bronchodilator FEV1/FVC ratio in COPD;Pre bronchodilator FEV1;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.66	-0.35	6.95e-6	Rheumatoid arthritis;
PAAD	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.49	-0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg05697835	chr1:2722811	NA	-0.37	-4.28	-0.33	3.28e-5	Ulcerative colitis;
PAAD	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.64	6.11	0.44	7.96e-9	Asthma;
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.55	-5.69	-0.42	6.34e-8	Tonsillectomy;
PAAD	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6500550	0.599	rs73505446	chr16:3694206	A/G	cg01678580	chr16:4674018	MGRN1	0.48	4.54	0.35	1.14e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
PAAD	cis	rs9377188	0.644	rs6931675	chr6:149385168	C/T	cg21368479	chr6:149415018	NA	0.4	4.39	0.34	2.07e-5	Cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16515820	chr3:114866447	ZBTB20	0.64	7.08	0.5	4.88e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.45e-7	Crohn's disease;
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.64	-6.08	-0.44	9.43e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.14	5.59	0.41	1.01e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg04287289	chr16:89883240	FANCA	0.78	4.44	0.34	1.71e-5	Skin colour saturation;
PAAD	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg15654264	chr1:150340011	RPRD2	0.5	4.81	0.36	3.67e-6	Migraine;
PAAD	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.77	7.27	0.51	1.73e-11	Corneal astigmatism;
PAAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg06632027	chr4:90757378	SNCA	-0.51	-4.51	-0.34	1.26e-5	Neuroticism;
PAAD	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-7.48	-0.52	5.55e-12	Heart rate;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.89e-5	Bipolar disorder;
PAAD	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg03989125	chr22:38214979	NA	0.65	6.79	0.48	2.34e-10	Glioblastoma;Glioma;
PAAD	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.55	-6.08	-0.44	9.48e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.53	5.77	0.42	4.34e-8	Heart rate;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19626725	chr5:178986131	RUFY1	-0.53	-5.53	-0.41	1.34e-7	Lung cancer;
PAAD	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg20607287	chr7:12443886	VWDE	-0.6	-4.72	-0.36	5.32e-6	Coronary artery disease;
PAAD	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg14700524	chr10:3282231	NA	-0.32	-4.3	-0.33	3.06e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08142058	chr14:61695425	NA	-0.68	-6.98	-0.49	8.68e-11	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.86	-6.21	-0.45	4.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs300774	1.000	rs146562	chr2:119663	T/G	cg21211680	chr2:198530	NA	-0.62	-5.48	-0.41	1.74e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs12940923	0.554	rs12953025	chr17:56369569	T/C	cg14843216	chr17:56064736	VEZF1	-0.51	-4.3	-0.33	3.09e-5	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17152411	1.000	rs11245432	chr10:126616861	G/A	cg10830905	chr10:126481798	METTL10	0.72	4.51	0.34	1.29e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25069742	chr17:78965448	CHMP6	0.66	6.77	0.48	2.63e-10	Obesity-related traits;
PAAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2.06e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg22963979	chr7:1858916	MAD1L1	-0.72	-8.34	-0.56	4.07e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.62	-8.01	-0.54	2.79e-13	Menarche (age at onset);
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs876084	0.510	rs10096137	chr8:121101910	A/G	cg06265175	chr8:121136014	COL14A1	0.47	4.46	0.34	1.61e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg17541715	chr7:1216824	NA	-0.55	-6.2	-0.45	5.1e-9	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16050165	chr17:72428292	GPRC5C	0.74	7.45	0.52	6.41e-12	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.57	5.45	0.4	1.98e-7	Breast cancer;
PAAD	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.45	-0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg23019889	chr1:146544044	NA	0.37	4.41	0.34	1.97e-5	HIV-1 control;
PAAD	cis	rs1042026	0.848	rs12650681	chr4:100186978	T/A	cg09112717	chr4:100009950	ADH5	-0.52	-4.69	-0.36	6.01e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26378065	chr17:18585709	ZNF286B	0.54	5.41	0.4	2.39e-7	Educational attainment (years of education);
PAAD	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs340029	0.760	rs1657792	chr15:60923429	A/G	cg00200653	chr15:60883225	RORA	0.55	4.86	0.37	2.84e-6	C-reactive protein levels;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg10729496	chr3:10149963	C3orf24	0.89	7.49	0.52	5.24e-12	Alzheimer's disease;
PAAD	cis	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg00262122	chr8:11665843	FDFT1	-0.48	-4.43	-0.34	1.82e-5	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23986219	chr16:88061594	BANP	0.7	7.12	0.5	3.96e-11	Obesity-related traits;
PAAD	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.83	-6.84	-0.49	1.79e-10	Diastolic blood pressure;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg00024416	chr22:24240387	NA	-0.49	-4.93	-0.37	2.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.14	16.54	0.8	8.23e-36	Cognitive function;
PAAD	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-4.3	-0.33	3e-5	Skin colour saturation;
PAAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.43	4.43	0.34	1.82e-5	Red cell distribution width;
PAAD	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.44	5.78	0.42	4.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs375066	0.935	rs421512	chr19:44415580	A/T	cg08633290	chr19:44405433	NA	-0.57	-5.5	-0.41	1.54e-7	Breast cancer;
PAAD	cis	rs501120	0.564	rs2246891	chr10:44680591	A/G	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18621852	chr3:10150065	C3orf24	0.67	5.84	0.43	3.09e-8	Alzheimer's disease;
PAAD	cis	rs7250872	0.550	rs12985849	chr19:1848628	A/G	cg10370574	chr19:1840461	REXO1	-0.5	-4.75	-0.36	4.62e-6	Bipolar disorder;
PAAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.87	-7.62	-0.53	2.47e-12	HIV-1 control;
PAAD	cis	rs7651190	1	rs7651190	chr3:41765955	A/G	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.9	0.63	3.82e-18	Platelet count;
PAAD	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	6.18	0.45	5.75e-9	Personality dimensions;
PAAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	5.1	0.38	9.95e-7	Rheumatoid arthritis;
PAAD	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg05895507	chr15:77155635	SCAPER	-0.36	-4.39	-0.34	2.14e-5	Blood metabolite levels;
PAAD	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.42	5.18	0.39	6.87e-7	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs8005677	0.828	rs8016027	chr14:23420153	T/C	cg01529538	chr14:23388837	RBM23	0.48	4.79	0.36	3.89e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs76866386	1.000	rs76866386	chr2:44075483	T/C	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.8	-5.13	-0.38	8.66e-7	Cholesterol, total;
PAAD	cis	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.73	-0.36	5.09e-6	Neuroticism;
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.46	4.59	0.35	9.08e-6	Trans fatty acid levels;
PAAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg10154010	chr16:2326080	ABCA3	0.53	4.52	0.34	1.24e-5	Coronary artery disease;
PAAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.92	-11.19	-0.67	1.39e-21	Schizophrenia;
PAAD	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.54	-5.23	-0.39	5.44e-7	Plateletcrit;Mean corpuscular volume;
PAAD	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	11.04	0.67	3.53e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.43	0.34	1.79e-5	Bipolar disorder;
PAAD	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.91	11.9	0.69	1.74e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	0.95	6.73	0.48	3.32e-10	Prostate cancer;
PAAD	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg05805236	chr11:65401703	PCNXL3	0.41	4.38	0.33	2.21e-5	Acne (severe);
PAAD	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-6.91	-0.49	1.23e-10	Colorectal cancer;
PAAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.97	-14.88	-0.77	1.81e-31	Post bronchodilator FEV1;
PAAD	cis	rs11168618	0.904	rs12371700	chr12:48919213	G/T	cg01881778	chr12:48919444	OR8S1	0.47	4.77	0.36	4.32e-6	Adiponectin levels;
PAAD	cis	rs9646944	0.501	rs3732127	chr2:103013750	G/C	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.65	6.32	0.46	2.75e-9	Asperger disorder;
PAAD	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.79	8.78	0.58	3.24e-15	Type 2 diabetes;
PAAD	cis	rs9913156	0.894	rs28365158	chr17:4620928	T/C	cg00122941	chr17:4613640	ARRB2	0.86	8.54	0.57	1.32e-14	Lymphocyte counts;
PAAD	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg23587288	chr2:27483067	SLC30A3	0.69	6.49	0.47	1.13e-9	Blood metabolite levels;
PAAD	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.15	-0.39	7.81e-7	High light scatter reticulocyte count;
PAAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.77	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.49	5.36	0.4	3.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs61759167	0.954	rs28594467	chr1:3097051	C/T	cg22674798	chr1:3096360	PRDM16	0.4	4.65	0.35	7.29e-6	Motion sickness;
PAAD	trans	rs1882538	0.504	rs6951416	chr7:133092278	A/G	cg14171944	chr9:126323477	DENND1A	0.55	6.57	0.47	7.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.8e-7	Interstitial lung disease;
PAAD	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.73e-14	Triglycerides;
PAAD	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg19767477	chr5:127420684	SLC12A2	-0.58	-4.69	-0.36	6.11e-6	Ileal carcinoids;
PAAD	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg09796270	chr17:17721594	SREBF1	0.43	4.74	0.36	4.89e-6	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg20283391	chr11:68216788	NA	0.53	5.08	0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.62	-6.25	-0.45	3.9e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.82	7.9	0.54	5.24e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14741685	chr6:74098812	NA	-0.76	-6.52	-0.47	1e-9	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02057148	chr17:4699427	PSMB6	0.57	6.31	0.46	2.91e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg22467129	chr15:76604101	ETFA	0.5	4.72	0.36	5.4e-6	Blood metabolite levels;
PAAD	cis	rs9287719	0.649	rs9973456	chr2:10718130	C/T	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg23024343	chr7:107201750	COG5	0.57	4.8	0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg06026331	chr20:60912101	LAMA5	-0.6	-5.6	-0.41	9.92e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg05754148	chr16:3507555	NAT15	0.66	4.89	0.37	2.55e-6	Tuberculosis;
PAAD	cis	rs13336428	0.663	rs3751883	chr16:1524604	C/T	cg08008072	chr16:1524255	CLCN7	-0.76	-8.94	-0.59	1.22e-15	Bone mineral density;
PAAD	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.7	9.06	0.59	6.1e-16	Asthma;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg26071806	chr7:100318239	EPO	-0.49	-4.89	-0.37	2.55e-6	Other erythrocyte phenotypes;
PAAD	cis	rs1864585	0.520	rs77559025	chr8:10692761	C/A	cg21775007	chr8:11205619	TDH	-0.58	-4.28	-0.33	3.28e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.8	8.23	0.56	7.99e-14	Corneal astigmatism;
PAAD	cis	rs1572438	0.931	rs13215634	chr6:866545	C/T	cg13447295	chr6:887704	NA	0.57	5.67	0.42	6.88e-8	Aging;
PAAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs2133450	0.679	rs28578967	chr3:7365088	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.24	-0.39	5.2e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-5.95	-0.43	1.81e-8	Bipolar disorder;
PAAD	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs73086581	0.947	rs11906612	chr20:3903634	C/T	cg02187196	chr20:3869020	PANK2	0.59	4.74	0.36	4.85e-6	Response to antidepressants in depression;
PAAD	cis	rs939584	1.000	rs10190313	chr2:647577	A/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg15798862	chr7:76129360	DTX2	-0.42	-5.33	-0.4	3.42e-7	Multiple sclerosis;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-7.83	-0.54	7.67e-13	Body mass index;
PAAD	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.62	5.64	0.42	8.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7945718	0.591	rs10831892	chr11:12676272	T/A	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.08e-5	Educational attainment (years of education);
PAAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.47	4.63	0.35	7.66e-6	Migraine;
PAAD	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg10820045	chr2:198174542	NA	0.46	4.64	0.35	7.55e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.74	0.42	4.92e-8	Eosinophil percentage of white cells;
PAAD	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg03098721	chr1:84464084	TTLL7	0.47	4.37	0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5751901	0.614	rs6519520	chr22:24991895	A/G	cg15363607	chr22:24998974	GGT1	-0.47	-4.74	-0.36	4.93e-6	Protein quantitative trait loci;
PAAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.71	-6.31	-0.46	2.87e-9	Breast cancer;
PAAD	cis	rs11048434	0.518	rs35176717	chr12:9177766	A/G	cg04548204	chr12:9162872	KLRG1	0.39	4.38	0.33	2.23e-5	Sjögren's syndrome;
PAAD	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg00504896	chr12:9437009	LOC642846	-0.46	-4.28	-0.33	3.28e-5	Breast size;
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.69	-6.86	-0.49	1.63e-10	Blood metabolite levels;
PAAD	cis	rs1419980	0.730	rs11054576	chr12:7729949	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.48	8.53	0.57	1.41e-14	Multiple system atrophy;
PAAD	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg24747557	chr10:131355152	MGMT	-0.45	-4.93	-0.37	2.15e-6	Response to temozolomide;
PAAD	cis	rs6800768	0.550	rs6794905	chr3:23885328	C/T	cg10674438	chr3:24145617	LOC152024	0.47	4.33	0.33	2.72e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg00531865	chr16:30841666	NA	-0.45	-4.45	-0.34	1.68e-5	Triglycerides;
PAAD	cis	rs4740619	0.967	rs4741529	chr9:15656259	G/C	cg14451791	chr9:16040625	NA	-0.39	-4.54	-0.35	1.13e-5	Body mass index;
PAAD	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg26205652	chr12:48591994	NA	0.77	7.0	0.49	7.49e-11	Longevity (90 years and older);
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	4.98	0.37	1.69e-6	Bipolar disorder;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00933542	chr6:150070202	PCMT1	0.54	5.74	0.42	5.05e-8	Lung cancer;
PAAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg11941060	chr3:133502564	NA	0.53	5.32	0.4	3.62e-7	Iron status biomarkers;
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21211367	chr2:162094118	NA	0.48	4.78	0.36	4.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12365397	0.677	rs12785997	chr11:43141663	G/A	cg03447554	chr11:43094025	NA	0.56	5.65	0.42	7.59e-8	Migraine;
PAAD	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.2	-0.39	6.3e-7	Bipolar disorder;
PAAD	cis	rs7577696	0.962	rs212679	chr2:32431107	C/A	cg02381751	chr2:32503542	YIPF4	0.44	4.61	0.35	8.6e-6	Inflammatory biomarkers;
PAAD	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.8	8.87	0.58	1.91e-15	IgG glycosylation;
PAAD	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.08	0.55	1.84e-13	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09935461	chr17:76802152	USP36	-0.65	-6.58	-0.47	7.32e-10	Obesity-related traits;
PAAD	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.51	-4.79	-0.36	3.95e-6	Red blood cell count;
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg16434002	chr17:42200994	HDAC5	0.69	6.78	0.48	2.48e-10	Total body bone mineral density;
PAAD	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02934500	chr4:142557404	IL15	-0.73	-6.55	-0.47	8.52e-10	Neuroticism;
PAAD	cis	rs61759167	0.955	rs2075968	chr1:3081241	C/T	cg22674798	chr1:3096360	PRDM16	0.38	4.42	0.34	1.85e-5	Motion sickness;
PAAD	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg02966332	chr20:62369605	LIME1	-0.49	-4.58	-0.35	9.78e-6	Prostate cancer;
PAAD	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-10.05	-0.63	1.55e-18	Primary sclerosing cholangitis;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.5	5.0	0.38	1.59e-6	Height;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs2279817	0.863	rs13375585	chr1:18016657	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.78	-0.42	4.02e-8	Neuroticism;
PAAD	cis	rs80346118	0.673	rs7360629	chr20:47417172	G/A	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.6	-4.42	-0.34	1.89e-5	Diastolic blood pressure;
PAAD	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.66	-4.29	-0.33	3.17e-5	Obesity-related traits;
PAAD	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.65	-4.74	-0.36	4.88e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.52	-5.38	-0.4	2.77e-7	Monocyte count;
PAAD	cis	rs1015291	0.708	rs1565591	chr12:19997707	A/G	cg25401612	chr12:20009446	NA	-0.57	-5.58	-0.41	1.08e-7	Diastolic blood pressure;
PAAD	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg13512537	chr8:22265999	SLC39A14	-0.42	-4.33	-0.33	2.69e-5	Verbal declarative memory;
PAAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg13468214	chr4:1046988	NA	-0.56	-6.07	-0.44	9.73e-9	Recombination rate (males);
PAAD	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg26876637	chr1:152193138	HRNR	-0.85	-6.34	-0.46	2.43e-9	Atopic dermatitis;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20887711	chr4:1340912	KIAA1530	0.47	4.63	0.35	7.91e-6	Obesity-related traits;
PAAD	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.51e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1015291	0.708	rs941237	chr12:20004790	A/T	cg25401612	chr12:20009446	NA	-0.55	-5.49	-0.41	1.67e-7	Diastolic blood pressure;
PAAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg14983838	chr19:29218262	NA	0.7	6.11	0.44	7.98e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.73	8.34	0.56	4.1e-14	Height;
PAAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs75920871	0.588	rs6589580	chr11:116819873	G/A	cg04087571	chr11:116723030	SIK3	-0.36	-4.52	-0.34	1.25e-5	Subjective well-being;
PAAD	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.64	-7.89	-0.54	5.55e-13	Schizophrenia;
PAAD	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04731861	chr2:219085781	ARPC2	0.37	4.38	0.34	2.16e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg09835421	chr16:68378352	PRMT7	-1.14	-8.41	-0.56	2.71e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.99	11.58	0.68	1.24e-22	Breast cancer;
PAAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg13611204	chr9:139324423	INPP5E	-0.56	-4.77	-0.36	4.3e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	10.94	0.66	6.36e-21	Monocyte count;
PAAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.58	-5.32	-0.4	3.62e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-4.89	-0.37	2.5e-6	Height;
PAAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg14329783	chr7:75779857	NA	0.79	4.71	0.36	5.46e-6	Mononucleosis;
PAAD	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-1.05	-14.82	-0.77	2.62e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.78	8.1	0.55	1.66e-13	Alzheimer's disease (late onset);
PAAD	cis	rs9487051	0.724	rs11751953	chr6:109635986	G/A	cg26497354	chr6:109612229	NA	-0.43	-4.31	-0.33	2.89e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.88	10.93	0.66	6.97e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg03538708	chr1:25844672	NA	0.48	4.9	0.37	2.46e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs4740619	0.803	rs6474931	chr9:15617677	G/T	cg14451791	chr9:16040625	NA	-0.38	-4.35	-0.33	2.48e-5	Body mass index;
PAAD	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.7	7.7	0.53	1.63e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.43	4.37	0.33	2.27e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs7259965	0.839	rs7250745	chr19:41503460	C/T	cg20630647	chr19:41531805	NA	0.46	4.34	0.33	2.56e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17227506	0.704	rs13280049	chr8:13460257	A/G	cg02718516	chr8:13424094	C8orf48	-0.32	-4.26	-0.33	3.59e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg03538708	chr1:25844672	NA	-0.52	-5.39	-0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.4	-4.85	-0.37	2.99e-6	Inflammatory bowel disease;
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13012494	chr21:47604986	C21orf56	0.47	4.95	0.37	1.99e-6	Testicular germ cell tumor;
PAAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.74	7.43	0.52	7.36e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.66	8.2	0.55	9.24e-14	Lipoprotein (a) levels;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.88	-11.39	-0.68	3.96e-22	Prudent dietary pattern;
PAAD	cis	rs2857891	1.000	rs2638090	chr11:6955142	A/G	cg04053776	chr11:6947353	ZNF215	0.49	4.29	0.33	3.15e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs7752195	0.556	rs940404	chr6:25343444	T/A	cg26336265	chr6:25042955	NA	0.87	4.86	0.37	2.88e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg24699146	chr1:24152579	HMGCL	0.51	5.35	0.4	3.25e-7	Immature fraction of reticulocytes;
PAAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.74	-8.34	-0.56	4.1e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.927	rs193527	chr5:112250198	C/T	cg06941702	chr5:112196734	SRP19	0.49	4.55	0.35	1.11e-5	Total body bone mineral density;
PAAD	cis	rs422249	0.634	rs174617	chr11:61629166	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.52	0.34	1.26e-5	Trans fatty acid levels;
PAAD	cis	rs11669133	1.000	rs11667377	chr19:11076192	A/G	cg25243385	chr19:11167475	SMARCA4	0.99	4.7	0.36	5.84e-6	LDL cholesterol;
PAAD	cis	rs4605213	0.528	rs11653126	chr17:49334706	C/T	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.37	-4.67	-0.35	6.44e-6	Height;
PAAD	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs6681460	0.674	rs7543607	chr1:67012592	G/T	cg02459107	chr1:67143332	SGIP1	0.57	5.05	0.38	1.24e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg02683114	chr2:24398427	C2orf84	-0.46	-4.83	-0.36	3.33e-6	Sjögren's syndrome;
PAAD	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.06	-0.5	5.42e-11	Response to antipsychotic treatment;
PAAD	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg01448562	chr3:133502909	NA	0.45	4.41	0.34	1.91e-5	Iron status biomarkers;
PAAD	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.48	-0.47	1.22e-9	Hip circumference;
PAAD	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg12623918	chr2:306882	NA	0.6	4.45	0.34	1.63e-5	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	8.49	0.57	1.69e-14	Personality dimensions;
PAAD	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-6.5	-0.47	1.06e-9	Morning vs. evening chronotype;
PAAD	cis	rs7168592	1.000	rs12593277	chr15:101730860	C/T	cg24254196	chr15:101719523	CHSY1	-0.66	-4.69	-0.36	6.02e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg05721444	chr7:32995514	FKBP9	-0.56	-5.38	-0.4	2.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg17724175	chr1:150552817	MCL1	-0.4	-4.56	-0.35	1.03e-5	Melanoma;
PAAD	cis	rs6142102	0.651	rs1015361	chr20:32738686	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.44	-4.45	-0.34	1.67e-5	Skin pigmentation;
PAAD	cis	rs12282928	0.917	rs7942804	chr11:48297076	C/A	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07677032	chr17:61819896	STRADA	-0.54	-5.49	-0.41	1.67e-7	Prudent dietary pattern;
PAAD	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.3	-0.51	1.5e-11	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-4.68	-0.36	6.23e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.61	-5.25	-0.39	4.99e-7	Schizophrenia;
PAAD	cis	rs59918340	0.738	rs3739238	chr8:142222445	T/C	cg16341495	chr8:142228727	SLC45A4	-0.55	-5.33	-0.4	3.53e-7	Immature fraction of reticulocytes;
PAAD	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.73	0.48	3.2e-10	Schizophrenia;
PAAD	cis	rs56133113	0.710	rs78861246	chr11:72689732	G/C	cg25124030	chr11:73498278	MRPL48	0.49	4.46	0.34	1.57e-5	Mean platelet volume;
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg15691649	chr6:25882328	NA	-0.46	-4.29	-0.33	3.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs6604026	0.656	rs6604030	chr1:93398336	A/G	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-5.75	-0.42	4.84e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01283332	chr5:1856932	NA	-0.47	-4.92	-0.37	2.19e-6	Cardiovascular disease risk factors;
PAAD	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg24881330	chr22:46731750	TRMU	1.11	5.32	0.4	3.71e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg24130564	chr14:104152367	KLC1	0.46	4.73	0.36	5.07e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-7.59	-0.52	2.94e-12	Body mass index;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07685180	chr8:600429	NA	0.93	6.67	0.48	4.37e-10	IgG glycosylation;
PAAD	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	1.01	6.42	0.46	1.62e-9	Exhaled nitric oxide output;
PAAD	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg03948781	chr1:205179583	DSTYK	0.47	4.36	0.33	2.39e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.6	-0.47	6.48e-10	Neuroticism;
PAAD	cis	rs7092929	0.574	rs7074352	chr10:3538749	G/T	cg14308648	chr10:3568949	NA	0.63	6.26	0.45	3.82e-9	Coronary artery calcification;
PAAD	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg14703610	chr5:56206110	C5orf35	0.61	5.56	0.41	1.21e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs1497828	0.956	rs2815223	chr1:217527843	C/A	cg04411442	chr1:217543379	NA	-0.48	-4.69	-0.36	6.12e-6	Dialysis-related mortality;
PAAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg22189786	chr22:42395067	WBP2NL	0.4	4.31	0.33	2.96e-5	Cognitive function;
PAAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg19413350	chr8:57351067	NA	-0.55	-5.64	-0.42	8.2e-8	Obesity-related traits;
PAAD	cis	rs13242816	1.000	rs2191499	chr7:116138599	C/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg13207630	chr7:32358064	NA	-0.82	-4.44	-0.34	1.7e-5	Body mass index;
PAAD	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.51	-6.79	-0.48	2.36e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.15	0.45	6.43e-9	Rheumatoid arthritis;
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.51	-4.96	-0.37	1.84e-6	Hypertension (SNP x SNP interaction);
PAAD	cis	rs8077577	0.895	rs62073615	chr17:18080329	T/A	cg16794390	chr17:18148240	FLII	0.53	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.63	-6.28	-0.45	3.35e-9	Post bronchodilator FEV1;
PAAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.62	-0.35	8.25e-6	Aortic root size;
PAAD	cis	rs4908768	0.501	rs7527389	chr1:8556545	A/G	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16878641	chr16:1821720	NME3	0.63	7.0	0.49	7.7e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2031532	0.569	rs6561526	chr13:50066524	G/A	cg08779649	chr13:50194554	NA	0.36	4.88	0.37	2.68e-6	Cardiac hypertrophy;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.35	0.33	2.46e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-4.51	-0.34	1.26e-5	Coronary artery disease;
PAAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.58	7.91	0.54	5.02e-13	Renal cell carcinoma;
PAAD	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg10168330	chr8:27262164	PTK2B	0.39	4.58	0.35	9.59e-6	Neuroticism;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg15117754	chr3:10150083	C3orf24	0.68	5.87	0.43	2.63e-8	Alzheimer's disease;
PAAD	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg09537434	chr19:41945824	ATP5SL	-0.56	-5.24	-0.39	5.38e-7	Colorectal cancer;
PAAD	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg08648136	chr8:956695	NA	0.47	5.08	0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19603075	chr15:89010536	MRPS11;MRPL46	0.59	6.4	0.46	1.79e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	4.31	0.33	2.89e-5	Total cholesterol levels;
PAAD	cis	rs11951515	0.508	rs6860493	chr5:43602713	T/C	cg01983248	chr5:43482804	C5orf28	-0.31	-4.41	-0.34	1.91e-5	Metabolite levels  (X-11787);
PAAD	cis	rs17401966	0.965	rs61784572	chr1:10259917	C/T	cg15208524	chr1:10270712	KIF1B	0.51	4.59	0.35	9.11e-6	Hepatocellular carcinoma;
PAAD	cis	rs17592366	0.517	rs1967722	chr14:35285274	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	5.38	0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg20744362	chr22:50050164	C22orf34	0.67	8.15	0.55	1.28e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.61	-0.35	8.49e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs8049603	0.812	rs4073291	chr16:23195993	G/T	cg16484020	chr16:23217411	SCNN1G	0.49	4.35	0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs863345	0.967	rs863347	chr1:158536008	C/G	cg12129480	chr1:158549410	OR10X1	0.44	4.81	0.36	3.53e-6	Pneumococcal bacteremia;
PAAD	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg07384165	chr1:10488281	NA	-0.45	-4.79	-0.36	3.94e-6	Breast size;
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.68	-8.88	-0.58	1.71e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg07469887	chr10:131262384	NA	-0.44	-5.11	-0.38	9.47e-7	Response to temozolomide;
PAAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg09509183	chr1:209979624	IRF6	0.55	5.34	0.4	3.34e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs10887741	0.646	rs11202501	chr10:89437208	C/T	cg13926569	chr10:89418898	PAPSS2	0.47	4.64	0.35	7.34e-6	Exercise (leisure time);
PAAD	cis	rs6011002	0.745	rs2261092	chr20:62353933	A/G	cg01176363	chr20:62369445	LIME1	-0.92	-4.28	-0.33	3.28e-5	Dental caries;
PAAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg18005901	chr6:33739558	LEMD2	-0.59	-4.72	-0.36	5.25e-6	Schizophrenia;
PAAD	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.7	8.42	0.56	2.64e-14	Alcohol dependence;
PAAD	cis	rs7651511	1.000	rs9865971	chr3:141237859	A/G	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg22903657	chr4:1355424	KIAA1530	0.44	4.75	0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.61	-0.35	8.39e-6	Alcohol dependence;
PAAD	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.78e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs735539	0.521	rs7336905	chr13:21447278	T/C	cg27234864	chr13:21295941	IL17D	0.59	4.81	0.36	3.65e-6	Dental caries;
PAAD	cis	rs7236492	0.872	rs74949301	chr18:77229409	C/G	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4698775	0.889	rs1008327	chr4:110565877	C/T	cg05791136	chr4:110223969	COL25A1	-0.33	-4.29	-0.33	3.12e-5	Age-related macular degeneration;
PAAD	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.67	7.13	0.5	3.76e-11	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs5742933	0.857	rs893784	chr2:190536283	C/T	cg04003228	chr2:190539410	ANKAR	0.52	4.28	0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.55	5.62	0.42	8.69e-8	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.23e-5	Life satisfaction;
PAAD	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg23684787	chr19:1848742	REXO1	-0.53	-4.4	-0.34	2.01e-5	Bipolar disorder;
PAAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	5.75	0.42	4.68e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg21929781	chr1:2537748	MMEL1	0.53	5.62	0.41	8.92e-8	Ulcerative colitis;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg23581698	chr14:81686396	GTF2A1	-0.62	-7.12	-0.5	4.06e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13242816	1.000	rs36004201	chr7:116126310	C/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.01	-0.38	1.48e-6	P wave duration;
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg07061783	chr6:25882402	NA	0.5	4.72	0.36	5.35e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.97	-0.37	1.77e-6	Lung cancer;
PAAD	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg19438565	chr8:143695827	ARC	-0.55	-5.45	-0.4	1.99e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.08	0.55	1.85e-13	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg05585544	chr11:47624801	NA	-0.49	-5.48	-0.41	1.69e-7	Subjective well-being;
PAAD	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.32	-0.4	3.67e-7	Height;
PAAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.55	-5.75	-0.42	4.7e-8	Red blood cell count;
PAAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	3.01e-7	Migraine;
PAAD	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg11057378	chr10:81107060	PPIF	0.52	6.13	0.45	7.07e-9	Height;
PAAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.68	7.1	0.5	4.4e-11	Pulse pressure;
PAAD	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.45	-4.29	-0.33	3.16e-5	Renal cell carcinoma;
PAAD	cis	rs2279817	0.743	rs3766309	chr1:17977378	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-6.07	-0.44	9.85e-9	Neuroticism;
PAAD	cis	rs9535307	0.929	rs6561560	chr13:50339507	A/T	cg04663916	chr13:50265991	EBPL	-0.62	-4.35	-0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs2548003	0.565	rs2554894	chr5:28762951	A/G	cg22863700	chr5:28928346	NA	0.56	5.45	0.4	1.99e-7	Hip geometry;
PAAD	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg01388757	chr2:102091195	RFX8	-0.55	-6.9	-0.49	1.33e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.52	-5.0	-0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.75	9.63	0.62	1.93e-17	Cardiovascular disease risk factors;
PAAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.9	-8.48	-0.57	1.88e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10556349	chr10:835070	NA	0.67	5.2	0.39	6.22e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs10274279	0.614	rs12540318	chr7:157398102	C/T	cg09270525	chr7:157391030	PTPRN2	0.71	5.29	0.39	4.25e-7	Myopia (pathological);
PAAD	cis	rs58653258	0.667	rs966121	chr1:234982074	A/T	cg03518729	chr1:235147744	NA	-0.45	-4.34	-0.33	2.55e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.91	11.61	0.69	1.03e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7551222	0.614	rs4951385	chr1:204454165	C/T	cg01064725	chr1:204461714	NA	-0.54	-4.82	-0.36	3.52e-6	Schizophrenia;
PAAD	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg25364880	chr3:44379878	C3orf23	0.59	5.43	0.4	2.17e-7	Depressive symptoms;
PAAD	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg03732007	chr1:2071316	PRKCZ	-0.45	-4.8	-0.36	3.81e-6	Height;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.65	0.47	5.02e-10	Bladder cancer;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.54	-5.36	-0.4	3.08e-7	IgG glycosylation;
PAAD	cis	rs9469913	0.551	rs9469864	chr6:34739932	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16988970	chr17:42248062	ASB16	-0.35	-4.65	-0.35	7.3e-6	Total body bone mineral density;
PAAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.72	9.21	0.6	2.54e-16	Coronary artery disease;
PAAD	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg21951975	chr1:209979733	IRF6	0.5	4.85	0.37	3.07e-6	Coronary artery disease;
PAAD	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.44	4.28	0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.82	10.55	0.65	7.09e-20	Vitiligo;
PAAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg02012338	chr4:187126139	CYP4V2	0.66	4.44	0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.86	5.84	0.43	3.11e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9810890	1.000	rs73198820	chr3:128476794	G/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	trans	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.59	-0.47	6.81e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06850241	chr22:41845214	NA	0.53	4.86	0.37	2.9e-6	Vitiligo;
PAAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.47	4.59	0.35	9.1e-6	Longevity;
PAAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-17.44	-0.82	4.09e-38	Height;
PAAD	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.26e-9	Personality dimensions;
PAAD	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg01304814	chr3:48885189	PRKAR2A	0.97	5.59	0.41	1e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg25377605	chr8:10513717	RP1L1	0.65	5.01	0.38	1.48e-6	Suicide;
PAAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg16576597	chr16:28551801	NUPR1	-0.57	-5.79	-0.42	3.97e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.66	0.42	7.38e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8014252	0.803	rs7157618	chr14:71010166	C/T	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg10864074	chr7:100318194	EPO	0.43	4.98	0.37	1.74e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg01874867	chr7:94954059	PON1	0.54	4.34	0.33	2.64e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs2257129	1.000	rs6585699	chr10:122921660	A/G	cg03717442	chr2:45172201	SIX3	-1.25	-6.29	-0.45	3.18e-9	Coronary artery disease;Body mass index;
PAAD	cis	rs6137287	0.924	rs8120293	chr20:21168395	C/T	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.66	-0.35	6.93e-6	Height;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.7	-5.8	-0.43	3.64e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6929137	0.666	rs66585063	chr6:151952645	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-4.28	-0.33	3.34e-5	Bone mineral density (spine);
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-5.11	-0.38	9.67e-7	Height;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg08994789	chr17:28903642	LRRC37B2	0.62	5.12	0.38	9.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.84e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22583711	chr7:154795321	PAXIP1;LOC202781	0.7	7.79	0.53	9.66e-13	Myopia (pathological);
PAAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.64	-0.35	7.47e-6	Aortic root size;
PAAD	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.6	5.15	0.39	8.03e-7	Neutrophil percentage of white cells;
PAAD	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12038521	chr19:2111714	AP3D1	-0.61	-6.43	-0.46	1.6e-9	Triglycerides;
PAAD	trans	rs901683	1.000	rs75820736	chr10:46076236	C/A	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16014699	chr19:33352871	SLC7A9	0.65	6.91	0.49	1.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg14349672	chr11:133703707	NA	-0.47	-5.01	-0.38	1.48e-6	Childhood ear infection;
PAAD	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg07469887	chr10:131262384	NA	-0.46	-5.72	-0.42	5.43e-8	Response to temozolomide;
PAAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg13798780	chr7:105162888	PUS7	0.61	4.34	0.33	2.61e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg16606324	chr3:10149918	C3orf24	-0.53	-4.53	-0.34	1.2e-5	Alzheimer's disease;
PAAD	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg12473912	chr3:136751656	NA	0.39	4.36	0.33	2.4e-5	Neuroticism;Schizophrenia;
PAAD	cis	rs13326165	0.585	rs11710014	chr3:52359972	C/T	cg08438690	chr3:52279403	PPM1M	-0.44	-4.39	-0.34	2.12e-5	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.55	0.35	1.08e-5	Obesity-related traits;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.59	-8.6	-0.57	9.13e-15	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10073892	0.703	rs59934563	chr5:101634575	T/C	cg17280723	chr5:101634495	NA	0.4	4.27	0.33	3.48e-5	Cognitive decline (age-related);
PAAD	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.56	5.98	0.44	1.52e-8	Coronary artery disease;
PAAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.74	-0.48	3.16e-10	Aortic root size;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00166722	chr3:10149974	C3orf24	0.69	6.29	0.45	3.24e-9	Alzheimer's disease;
PAAD	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	1.04	6.33	0.46	2.66e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	1.17	5.73	0.42	5.1e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs16895831	0.549	rs12209281	chr6:42615451	G/A	cg10605015	chr6:42532144	UBR2	-0.62	-4.68	-0.35	6.28e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs375066	0.967	rs376328	chr19:44407487	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	trans	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.25	-0.56	7.02e-14	Inflammatory bowel disease;
PAAD	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.92	-7.91	-0.54	4.81e-13	Triglycerides;
PAAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs1034435	0.505	rs5768690	chr22:48902117	G/A	cg05992904	chr22:48892994	FAM19A5	-0.62	-6.99	-0.49	7.94e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	11.2	0.67	1.34e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.72	7.09	0.5	4.79e-11	Tonsillectomy;
PAAD	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg00490450	chr3:139108681	COPB2	0.68	6.16	0.45	6.29e-9	Obesity-related traits;
PAAD	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg07622451	chr1:3079886	PRDM16	0.41	4.93	0.37	2.12e-6	Migraine;
PAAD	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg01412419	chr16:87856264	NA	0.74	6.34	0.46	2.51e-9	Blood metabolite levels;
PAAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.9	0.49	1.32e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.95	0.54	3.95e-13	Prudent dietary pattern;
PAAD	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg00806126	chr19:22604979	ZNF98	0.41	5.29	0.39	4.2e-7	Pain;
PAAD	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-1.06	-7.49	-0.52	5.14e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg22029157	chr1:209979665	IRF6	-0.73	-6.81	-0.48	2.14e-10	Coronary artery disease;
PAAD	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.87	0.37	2.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.71	7.35	0.51	1.17e-11	Mood instability;
PAAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.66	6.85	0.49	1.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg18508148	chr11:34937573	PDHX;APIP	0.54	5.33	0.4	3.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.36	-0.87	1.29e-47	Myeloid white cell count;
PAAD	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg12568669	chr8:11666485	FDFT1	0.3	4.94	0.37	2.07e-6	Retinal vascular caliber;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18182039	chr12:93165808	PLEKHG7	-0.6	-7.1	-0.5	4.39e-11	Energy expenditure (24h);
PAAD	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg12661370	chr5:149340060	SLC26A2	0.65	5.53	0.41	1.36e-7	HIV-1 control;
PAAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.53	0.57	1.37e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.54	8.2	0.55	9.48e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.58	6.8	0.48	2.22e-10	Calcium levels;
PAAD	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.63	4.58	0.35	9.6e-6	Neuroticism;
PAAD	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.54	5.8	0.43	3.67e-8	Obesity-related traits;
PAAD	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.71	-7.08	-0.5	5.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.71	7.27	0.51	1.78e-11	Schizophrenia;
PAAD	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.74	-8.55	-0.57	1.25e-14	Heart rate;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10359940	chr2:183580906	DNAJC10	-0.64	-6.61	-0.47	6.13e-10	Warfarin maintenance dose;
PAAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.58e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.62	-5.11	-0.38	9.47e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg09659197	chr4:152720779	NA	-0.48	-6.57	-0.47	7.51e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6804624	0.676	rs4532167	chr3:99156492	G/T	cg02646433	chr3:99218170	NA	0.41	4.25	0.33	3.67e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg25432232	chr19:57742423	AURKC	0.43	4.37	0.33	2.25e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	0.51	5.46	0.41	1.88e-7	Hypothyroidism;
PAAD	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs10512697	0.655	rs35928407	chr5:3503392	G/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.83	5.77	0.42	4.36e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg13429435	chr10:81271195	EIF5AL1	-0.4	-4.39	-0.34	2.1e-5	Sarcoidosis;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.78	8.77	0.58	3.32e-15	Prostate cancer;
PAAD	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.63	-6.72	-0.48	3.39e-10	Brugada syndrome;
PAAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.89	0.63	4.18e-18	Cognitive function;
PAAD	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.16	16.6	0.8	5.87e-36	Cognitive function;
PAAD	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg09796270	chr17:17721594	SREBF1	0.45	4.67	0.35	6.62e-6	Total body bone mineral density;
PAAD	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg23463467	chr20:60627584	TAF4	0.46	4.92	0.37	2.18e-6	Body mass index;
PAAD	trans	rs901683	1.000	rs77651228	chr10:46056129	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19844325	chr19:18314808	RAB3A	0.69	7.62	0.53	2.55e-12	Myopia (pathological);
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.84	-0.43	3.09e-8	Tonsillectomy;
PAAD	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.08	-0.44	9.51e-9	Fibrinogen levels;
PAAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.41	9.51	0.61	4.1e-17	Atopic dermatitis;
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg07061783	chr6:25882402	NA	-0.49	-4.68	-0.35	6.37e-6	Blood metabolite levels;
PAAD	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.97	-0.37	1.81e-6	Mean corpuscular volume;
PAAD	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.81	9.15	0.6	3.44e-16	Birth weight;
PAAD	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.43	-5.03	-0.38	1.38e-6	Urinary metabolites (H-NMR features);
PAAD	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.55	-5.34	-0.4	3.28e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs4481887	0.597	rs2185358	chr1:248585259	T/A	cg00666640	chr1:248458726	OR2T12	0.59	4.89	0.37	2.52e-6	Common traits (Other);
PAAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.52	-0.34	1.25e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1023500	1.000	rs1023497	chr22:42340508	C/G	cg04733989	chr22:42467013	NAGA	-0.67	-5.23	-0.39	5.42e-7	Schizophrenia;
PAAD	cis	rs4740619	0.688	rs4741550	chr9:15937847	G/A	cg14451791	chr9:16040625	NA	-0.42	-4.84	-0.37	3.18e-6	Body mass index;
PAAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg24739098	chr15:79297159	RASGRF1	0.34	4.34	0.33	2.61e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs858239	1.000	rs199347	chr7:23293746	A/G	cg27449745	chr7:23145252	KLHL7	-0.61	-5.46	-0.41	1.87e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10256972	0.593	rs7799483	chr7:1003102	G/A	cg07930192	chr7:1003750	NA	0.58	7.45	0.52	6.44e-12	Longevity;Endometriosis;
PAAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	trans	rs228916	0.748	rs228934	chr22:37516015	C/T	cg14326991	chr6:46889760	GPR116	0.6	6.37	0.46	2.12e-9	Iron status biomarkers (iron levels);
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg08886695	chr4:3369023	RGS12	-0.48	-4.58	-0.35	9.78e-6	Mean platelet volume;
PAAD	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.98	8.63	0.57	7.52e-15	Bipolar disorder;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	cis	rs4605213	0.686	rs8076111	chr17:49302782	C/G	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.37	-4.41	-0.34	1.93e-5	Height;
PAAD	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.67	-7.56	-0.52	3.52e-12	Systemic lupus erythematosus;
PAAD	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.59	5.64	0.42	8.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3206736	0.548	rs328904	chr7:35021176	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs7567389	0.568	rs7568070	chr2:127953054	A/C	cg11380483	chr2:127933992	NA	0.54	5.08	0.38	1.07e-6	Self-rated health;
PAAD	cis	rs6750047	0.573	rs162328	chr2:38318688	G/A	cg19753864	chr2:38320028	NA	0.44	4.94	0.37	2.02e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09065629	chr16:1709722	CRAMP1L	0.44	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.84	-6.82	-0.48	1.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07725658	chr4:71705655	GRSF1	0.66	6.44	0.46	1.46e-9	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.78	-0.36	4.18e-6	Lung cancer in ever smokers;
PAAD	cis	rs8016982	0.662	rs8014406	chr14:81657760	A/C	cg01989461	chr14:81687754	GTF2A1	0.56	4.43	0.34	1.81e-5	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09188016	chr12:64798414	XPOT	0.6	6.3	0.46	2.99e-9	Myopia (pathological);
PAAD	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.75	-0.42	4.76e-8	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18253516	chr20:62612348	SAMD10;PRPF6	0.61	6.93	0.49	1.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.65	0.35	7.04e-6	Menopause (age at onset);
PAAD	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg11584989	chr19:19387371	SF4	-0.77	-6.48	-0.47	1.23e-9	Bipolar disorder;
PAAD	cis	rs9372498	0.536	rs62424195	chr6:118812108	T/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.51	-0.34	1.27e-5	Diastolic blood pressure;
PAAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.77	0.66	1.9e-20	Smoking behavior;
PAAD	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.65	6.93	0.49	1.11e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg00717180	chr2:96193071	NA	0.6	6.68	0.48	4.13e-10	HDL cholesterol;
PAAD	cis	rs2004318	1.000	rs80051736	chr19:55078160	C/G	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs1075265	0.626	rs805412	chr2:54120820	G/A	cg04546899	chr2:54196757	PSME4	0.32	4.8	0.36	3.74e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19915020	chr1:10490985	APITD1	0.59	6.74	0.48	3.08e-10	Monocyte percentage of white cells;
PAAD	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.5e-12	Resting heart rate;
PAAD	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.4	-0.4	2.57e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.86	8.0	0.54	2.99e-13	Homoarginine levels;
PAAD	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.4	0.34	2e-5	Oral cavity cancer;
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg09035930	chr12:129282057	SLC15A4	1.12	15.89	0.79	3.97e-34	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12799537	chr12:56207909	SARNP	-0.62	-6.42	-0.46	1.63e-9	Obesity-related traits;
PAAD	cis	rs4919087	0.748	rs11189131	chr10:99085835	G/A	cg06569542	chr10:98946673	SLIT1	0.48	5.11	0.38	9.73e-7	Monocyte count;
PAAD	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg16342193	chr10:102329863	NA	-0.86	-8.95	-0.59	1.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg10437265	chr15:77819839	NA	-0.39	-4.52	-0.34	1.26e-5	Type 2 diabetes;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.78	5.63	0.42	8.44e-8	Pulse pressure;
PAAD	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-5.76	-0.42	4.6e-8	Fear of minor pain;
PAAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.4	-4.36	-0.33	2.38e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs4499344	0.881	rs35447302	chr19:33068499	G/A	cg22980127	chr19:33182716	NUDT19	0.48	4.45	0.34	1.66e-5	Mean platelet volume;
PAAD	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.49	-4.31	-0.33	2.93e-5	P wave terminal force;
PAAD	cis	rs635808	0.520	rs656938	chr6:167172048	C/T	cg05573767	chr6:167171394	RPS6KA2	0.4	4.28	0.33	3.32e-5	Dental caries;
PAAD	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg10705379	chr10:99080932	FRAT1	0.45	5.14	0.39	8.15e-7	Monocyte count;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08677398	chr8:58056175	NA	0.71	4.93	0.37	2.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg13897122	chr2:103039542	IL18RAP	0.38	4.72	0.36	5.42e-6	Asthma;
PAAD	cis	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.43	4.26	0.33	3.57e-5	Depression;
PAAD	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.62	0.47	5.74e-10	High light scatter reticulocyte count;
PAAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2717559	0.541	rs11774054	chr8:143881976	T/C	cg02415014	chr8:143852576	LYNX1	0.4	5.38	0.4	2.82e-7	Urinary tract infection frequency;
PAAD	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.73	5.85	0.43	2.96e-8	Menopause (age at onset);
PAAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.14e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21646471	chr2:242523971	THAP4	0.66	5.31	0.4	3.89e-7	Prostate cancer;
PAAD	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.45	-0.4	2e-7	Prevalent atrial fibrillation;
PAAD	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06360820	chr2:242988706	NA	-1.24	-10.76	-0.66	2.03e-20	Obesity-related traits;
PAAD	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21016266	chr12:122356598	WDR66	-0.63	-7.01	-0.49	7.35e-11	Mean corpuscular volume;
PAAD	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	4.32	0.33	2.82e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg26695010	chr11:65641043	EFEMP2	0.57	5.03	0.38	1.34e-6	DNA methylation (variation);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09007600	chr2:202508229	ALS2CR4	-0.56	-6.47	-0.46	1.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.77	-6.76	-0.48	2.84e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.56	-4.95	-0.37	1.98e-6	Obesity-related traits;
PAAD	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.38	0.33	2.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg21546286	chr11:48923668	NA	0.53	5.4	0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg02734326	chr4:10020555	SLC2A9	-0.52	-4.4	-0.34	2.04e-5	Schizophrenia (age at onset);
PAAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg21231944	chr12:82153410	PPFIA2	-0.54	-4.63	-0.35	7.72e-6	Resting heart rate;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg15555727	chr8:144692268	PYCRL	0.56	6.48	0.47	1.19e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.51	4.97	0.37	1.81e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs939584	1.000	rs13393304	chr2:637830	A/G	cg14515364	chr2:636606	NA	0.47	4.38	0.33	2.24e-5	Body mass index;
PAAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.65	-6.57	-0.47	7.7e-10	Primary sclerosing cholangitis;
PAAD	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.68	-6.98	-0.49	8.5e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23766305	chr17:27507501	MYO18A	0.66	6.47	0.46	1.24e-9	Myopia (pathological);
PAAD	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.4	4.25	0.33	3.74e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.13	0.38	8.63e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.92	11.97	0.7	1.08e-23	Mean corpuscular volume;
PAAD	cis	rs1018697	1.000	rs10786710	chr10:104548739	C/T	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.85e-5	Colorectal adenoma (advanced);
PAAD	cis	rs7172971	0.745	rs78767619	chr15:42346467	G/A	cg07013680	chr15:42186124	SPTBN5	0.57	4.62	0.35	8.24e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg27511599	chr7:32358540	NA	0.77	4.67	0.35	6.56e-6	Body mass index;
PAAD	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.89	0.37	2.59e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.51	5.13	0.38	8.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs59888335	0.862	rs12637081	chr3:80567749	G/T	cg21735741	chr3:80819488	NA	0.61	5.27	0.39	4.54e-7	Schizophrenia;
PAAD	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.13	0.5	3.87e-11	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.78	-4.34	-0.33	2.61e-5	Coronary artery disease;
PAAD	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.67	6.71	0.48	3.53e-10	Caffeine consumption;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg22868518	chr11:507468	RNH1	-0.94	-4.71	-0.36	5.55e-6	Body mass index;
PAAD	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.45	0.4	2.03e-7	Type 2 diabetes;
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.83	8.13	0.55	1.38e-13	Cleft lip with or without cleft palate;
PAAD	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.64	-6.89	-0.49	1.4e-10	Iron status biomarkers;
PAAD	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg22143856	chr6:28129313	ZNF389	-0.68	-5.63	-0.42	8.37e-8	Depression;
PAAD	cis	rs901683	0.850	rs17157890	chr10:46020652	T/C	cg16908948	chr10:45500256	ZNF22	0.79	4.27	0.33	3.44e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg02780029	chr10:43622663	RET	-0.43	-4.34	-0.33	2.64e-5	Hirschsprung disease;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.72	0.36	5.26e-6	Depressive symptoms;
PAAD	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg12310025	chr6:25882481	NA	-0.43	-4.26	-0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25632853	chr15:73088954	NA	0.4	4.52	0.34	1.24e-5	Triglyceride levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06887471	chr7:149157803	ZNF777	0.62	6.57	0.47	7.43e-10	Myopia (pathological);
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg19429281	chr19:53496738	ZNF702P	-0.54	-5.79	-0.43	3.85e-8	Psoriasis;
PAAD	cis	rs112990264	1.000	rs79759998	chr1:213021342	T/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.79	9.3	0.6	1.42e-16	Colorectal cancer;
PAAD	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.98	12.41	0.71	7.11e-25	Bone mineral density;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.59	6.41	0.46	1.7e-9	Cardiovascular disease risk factors;
PAAD	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-5.75	-0.42	4.84e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.96e-9	Prostate cancer;
PAAD	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.54	4.37	0.33	2.33e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.61	-4.34	-0.33	2.6e-5	Vitiligo;
PAAD	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.65	6.81	0.48	2.12e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs134594	0.885	rs134657	chr22:29490497	G/A	cg01361351	chr22:29467363	NA	-0.39	-4.35	-0.33	2.51e-5	Birth weight;
PAAD	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.72e-5	Self-reported allergy;
PAAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg09796270	chr17:17721594	SREBF1	0.39	4.31	0.33	2.96e-5	Total body bone mineral density;
PAAD	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.65	-8.05	-0.55	2.24e-13	Coronary artery disease;
PAAD	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.81	-7.8	-0.53	9.41e-13	Corneal astigmatism;
PAAD	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs16975963	0.793	rs73034929	chr19:38456697	T/C	cg25793785	chr19:38281423	NA	0.58	4.74	0.36	4.95e-6	Longevity;
PAAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-6.39	-0.46	1.94e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.4	-5.14	-0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.58	7.38	0.51	9.75e-12	Hypertriglyceridemia;
PAAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	4.82	0.36	3.41e-6	Schizophrenia;
PAAD	cis	rs375066	0.592	rs349050	chr19:44301425	G/A	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer;
PAAD	cis	rs1816752	1.000	rs9511272	chr13:25020633	A/G	cg02811702	chr13:24901961	NA	0.58	6.14	0.45	6.8e-9	Obesity-related traits;
PAAD	cis	rs9462846	1.000	rs1150797	chr6:42841231	G/A	cg13397359	chr6:42928475	GNMT	0.62	4.58	0.35	9.52e-6	Blood protein levels;
PAAD	cis	rs11037575	0.739	rs4288745	chr11:43731451	G/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.34	-0.33	2.55e-5	Neuroblastoma;
PAAD	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg18736775	chr8:18248649	NAT2	-0.74	-6.55	-0.47	8.24e-10	Blood metabolite levels;
PAAD	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2414095	0.527	rs10519297	chr15:51541660	C/T	cg21478137	chr15:51532386	CYP19A1	0.53	5.41	0.4	2.44e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.23	20.81	0.86	2.45e-46	Testicular germ cell tumor;
PAAD	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg10356904	chr22:49881777	NA	-0.51	-4.75	-0.36	4.66e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.53	4.77	0.36	4.29e-6	Optic cup area;
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg09473613	chr1:24152604	HMGCL	0.55	5.76	0.42	4.51e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-9.1	-0.59	4.66e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg19784903	chr17:45786737	TBKBP1	-0.66	-7.05	-0.5	5.88e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.81	-10.16	-0.64	7.7e-19	Height;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg23985595	chr17:80112537	CCDC57	0.44	5.51	0.41	1.52e-7	Life satisfaction;
PAAD	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	5.18	0.39	6.82e-7	Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg07153921	chr17:41440717	NA	-0.42	-4.38	-0.33	2.23e-5	Menopause (age at onset);
PAAD	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.95	-9.6	-0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.44	6.29	0.45	3.16e-9	Information processing speed;
PAAD	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.62	0.53	2.5e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4538187	0.855	rs11125981	chr2:63911761	G/A	cg08613950	chr2:64719184	NA	0.66	4.42	0.34	1.9e-5	Systolic blood pressure;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.58	-5.92	-0.43	2.02e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg01388757	chr2:102091195	RFX8	0.66	8.23	0.56	7.93e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.47	4.38	0.33	2.18e-5	Resting heart rate;
PAAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.93	10.61	0.65	5.12e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg00750074	chr16:89608354	SPG7	0.61	5.78	0.42	4.06e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.76	5.84	0.43	3e-8	HDL cholesterol;
PAAD	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg09066997	chr16:75300724	BCAR1	0.59	4.38	0.33	2.2e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.69	6.54	0.47	9.06e-10	Initial pursuit acceleration;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.75	6.56	0.47	7.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.5	-4.61	-0.35	8.52e-6	Free thyroxine concentration;
PAAD	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg00579200	chr11:133705235	NA	-0.43	-4.77	-0.36	4.25e-6	Childhood ear infection;
PAAD	cis	rs1468734	1.000	rs1468734	chr16:5001304	G/A	cg06510647	chr16:5006106	NA	0.55	4.98	0.37	1.74e-6	Cancer;
PAAD	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-9.7	-0.62	1.29e-17	Body mass index;
PAAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	0.96	10.03	0.63	1.72e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.52	-5.04	-0.38	1.31e-6	Cancer;
PAAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-4.75	-0.36	4.59e-6	Neuroticism;
PAAD	cis	rs215088	0.692	rs215056	chr16:16075660	G/A	cg08996506	chr16:16070868	ABCC1	0.36	4.29	0.33	3.21e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.56	0.41	1.16e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg15017067	chr4:17643749	FAM184B	0.43	4.88	0.37	2.71e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg10934807	chr2:113191815	RGPD8;RGPD5	-0.88	-6.65	-0.47	4.95e-10	Yeast infection;
PAAD	cis	rs2092319	0.536	rs2742942	chr1:26067461	G/A	cg02327719	chr1:26185386	C1orf135	-0.85	-4.9	-0.37	2.39e-6	Nose morphology;
PAAD	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg02696790	chr15:75250997	RPP25	-0.41	-4.97	-0.37	1.77e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs8105895	1.000	rs8100042	chr19:22127841	T/A	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.64	-0.42	8.16e-8	Psoriasis;
PAAD	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg14191688	chr11:70257035	CTTN	0.56	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09037867	chr11:75283280	SERPINH1	-0.63	-6.54	-0.47	8.72e-10	Obesity-related traits;
PAAD	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-8.33	-0.56	4.39e-14	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs11794666	0.872	rs17181915	chr9:31722951	A/G	cg05628366	chr6:35744188	C6orf126	0.95	6.29	0.45	3.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.38	4.7	0.36	5.75e-6	Corneal astigmatism;
PAAD	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.62	-0.41	8.96e-8	Fear of minor pain;
PAAD	cis	rs10982256	0.805	rs10759714	chr9:117267591	C/T	cg12877860	chr9:117266580	DFNB31	0.47	4.91	0.37	2.33e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.76	7.19	0.5	2.74e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.45	4.63	0.35	7.84e-6	Dementia with Lewy bodies;
PAAD	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19671926	chr4:122722719	EXOSC9	-0.56	-5.11	-0.38	9.58e-7	Type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12616683	chr3:127323572	MCM2	0.65	7.83	0.54	7.91e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	9.73	0.62	1.1e-17	Smoking behavior;
PAAD	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.41	-6.03	-0.44	1.19e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.5	-0.47	1.1e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg05299278	chr17:33885742	SLFN14	0.42	5.04	0.38	1.32e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11264799	0.520	rs849816	chr1:157542074	A/C	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.42	-4.99	-0.38	1.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	6.29	0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	cis	rs4742903	0.904	rs2417487	chr9:106887581	A/G	cg14250997	chr9:106856677	SMC2	0.46	4.88	0.37	2.69e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg00086871	chr4:6988644	TBC1D14	1.11	5.15	0.39	7.94e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.74	6.32	0.46	2.82e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58521262	0.516	rs1842018	chr19:23095233	A/G	cg03433597	chr19:22806448	NA	-0.25	-4.48	-0.34	1.45e-5	Testicular germ cell tumor;
PAAD	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.46	-0.8	1.35e-35	Height;
PAAD	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs818427	0.927	rs461424	chr5:112229903	G/A	cg06941702	chr5:112196734	SRP19	0.48	4.61	0.35	8.64e-6	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22573456	chr3:12525702	TSEN2	0.63	6.34	0.46	2.52e-9	Obesity-related traits;
PAAD	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10070431	chr2:232322438	NCL;SNORD20	-0.65	-6.62	-0.47	5.85e-10	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg23465465	chr6:26364728	BTN3A2	0.82	5.0	0.38	1.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.68	6.34	0.46	2.48e-9	Uric acid levels;
PAAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.95	10.47	0.65	1.16e-19	Diastolic blood pressure;
PAAD	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.82	-9.92	-0.63	3.36e-18	QT interval;
PAAD	cis	rs10992471	0.580	rs7869521	chr9:95411059	G/T	cg14631576	chr9:95140430	CENPP	-0.5	-4.77	-0.36	4.19e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-6.07	-0.44	9.65e-9	Hyperactive-impulsive symptoms;
PAAD	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.83	-5.98	-0.44	1.55e-8	Coronary artery calcification;
PAAD	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.65	7.2	0.5	2.65e-11	High light scatter reticulocyte count;
PAAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.7	-8.45	-0.57	2.23e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.69	5.65	0.42	7.67e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.8	8.23	0.56	7.76e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2131877	0.701	rs61231387	chr3:194832120	G/T	cg19760965	chr3:194868843	C3orf21	0.5	4.84	0.37	3.1e-6	Non-small cell lung cancer;
PAAD	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs2718812	1.000	rs2953740	chr3:133406351	T/C	cg08439880	chr3:133502540	NA	0.42	4.66	0.35	6.8e-6	Iron status biomarkers;
PAAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg03538708	chr1:25844672	NA	-0.49	-5.05	-0.38	1.24e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs16858210	0.607	rs60244260	chr3:183570734	G/A	cg25686905	chr3:183603175	PARL	-0.39	-4.46	-0.34	1.58e-5	Menopause (age at onset);
PAAD	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg25952890	chr19:58913133	NA	0.68	5.69	0.42	6.29e-8	Mean platelet volume;
PAAD	cis	rs4073221	0.929	rs67878364	chr3:18281446	T/C	cg07694806	chr3:18168406	NA	-0.75	-5.07	-0.38	1.15e-6	Parkinson's disease;
PAAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.61	-6.27	-0.45	3.63e-9	Eosinophil percentage of white cells;
PAAD	cis	rs9810890	1.000	rs114431655	chr3:128459173	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.77	8.69	0.58	5.3e-15	Total body bone mineral density;
PAAD	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.55	5.72	0.42	5.44e-8	Ulcerative colitis;
PAAD	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.67	0.53	1.89e-12	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg07181952	chr1:1239999	ACAP3	-0.45	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.62	0.41	8.91e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg08514558	chr10:81106712	PPIF	0.49	5.91	0.43	2.11e-8	Height;
PAAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.47	-0.34	1.55e-5	Arsenic metabolism;
PAAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.18	-0.39	6.99e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	8.77	0.58	3.41e-15	Platelet count;
PAAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg13722127	chr7:150037890	RARRES2	0.54	5.29	0.39	4.23e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.97	-13.28	-0.73	3.26e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58653258	0.667	rs2459149	chr1:234983043	G/T	cg03518729	chr1:235147744	NA	0.46	4.4	0.34	1.99e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4343996	0.506	rs10274978	chr7:3433777	T/C	cg21248987	chr7:3385318	SDK1	0.41	4.29	0.33	3.2e-5	Motion sickness;
PAAD	cis	rs12410462	0.591	rs59149651	chr1:227877251	T/C	cg23173402	chr1:227635558	NA	0.54	4.28	0.33	3.34e-5	Major depressive disorder;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg01759136	chr6:27242945	NA	0.4	4.35	0.33	2.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2899832	0.866	rs73239074	chr14:35750092	A/T	cg09327582	chr14:35236912	BAZ1A	0.58	4.65	0.35	7.07e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-5.01	-0.38	1.49e-6	Blood metabolite levels;
PAAD	cis	rs3771514	0.543	rs12713698	chr2:70666178	G/A	cg18150120	chr2:71134936	VAX2	-0.4	-4.73	-0.36	5.18e-6	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23077498	chr10:76801843	DUPD1	0.61	6.44	0.46	1.45e-9	Smoking initiation;
PAAD	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.74	8.57	0.57	1.09e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs17331151	0.505	rs79979130	chr3:52551010	C/T	cg27565382	chr3:53032988	SFMBT1	1.0	5.05	0.38	1.24e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-1.3	-8.29	-0.56	5.59e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.69	7.55	0.52	3.83e-12	Longevity;
PAAD	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-4.66	-0.35	6.77e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3779195	0.524	rs80195155	chr7:97878153	G/A	cg24562669	chr7:97807699	LMTK2	-0.53	-4.54	-0.35	1.15e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.41	-4.82	-0.36	3.52e-6	Mean arterial pressure;
PAAD	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.54	4.38	0.33	2.18e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.52	-0.41	1.43e-7	White blood cell count;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05665937	chr4:1216051	CTBP1	0.44	4.7	0.36	5.84e-6	Obesity-related traits;
PAAD	cis	rs7246760	1.000	rs10419915	chr19:9890957	G/A	cg16876255	chr19:9731953	ZNF561	0.94	4.46	0.34	1.6e-5	Pursuit maintenance gain;
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg01359822	chr21:40176597	ETS2	0.3	5.11	0.38	9.74e-7	Non-small cell lung cancer (survival);
PAAD	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg04824913	chr4:887549	GAK	0.61	4.82	0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.64	6.43	0.46	1.53e-9	Menopause (age at onset);
PAAD	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13870426	chr17:30244630	NA	-0.58	-5.67	-0.42	6.88e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00290607	chr11:67383545	NA	-0.56	-5.38	-0.4	2.78e-7	Mean corpuscular volume;
PAAD	cis	rs2415984	0.622	rs61993296	chr14:46934216	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.37e-7	Number of children ever born;
PAAD	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	5.53	0.41	1.35e-7	Systemic lupus erythematosus;
PAAD	cis	rs6594713	0.642	rs6871934	chr5:112787828	T/C	cg12552261	chr5:112820674	MCC	0.74	5.3	0.4	3.95e-7	Brain cytoarchitecture;
PAAD	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg06637938	chr14:75390232	RPS6KL1	0.46	4.51	0.34	1.3e-5	Height;
PAAD	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.78	0.69	3.65e-23	Smoking behavior;
PAAD	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12963246	chr6:28129442	ZNF389	0.56	4.47	0.34	1.5e-5	Parkinson's disease;
PAAD	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg05250797	chr16:70222502	NA	0.86	6.58	0.47	7.16e-10	IgE levels;
PAAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.45	-6.27	-0.45	3.59e-9	Height;
PAAD	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.78	5.01	0.38	1.48e-6	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02247183	chr16:4664062	FAM100A	0.65	6.65	0.47	4.96e-10	Obesity-related traits;
PAAD	cis	rs2153535	0.518	rs9392232	chr6:8636444	C/G	cg07606381	chr6:8435919	SLC35B3	0.44	4.38	0.33	2.21e-5	Motion sickness;
PAAD	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.91	-0.43	2.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg14092988	chr3:52407081	DNAH1	0.54	6.91	0.49	1.22e-10	Bipolar disorder;
PAAD	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	1.05	6.62	0.47	5.75e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg16083429	chr3:49237500	CCDC36	0.44	4.29	0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.65	8.45	0.57	2.19e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.12e-7	Prostate cancer;
PAAD	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.45	5.38	0.4	2.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg22827986	chr11:48284249	OR4X1	-0.37	-4.78	-0.36	4.09e-6	Migraine - clinic-based;
PAAD	cis	rs11992162	0.506	rs55948474	chr8:11809662	A/G	cg12568669	chr8:11666485	FDFT1	0.31	5.16	0.39	7.78e-7	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25876406	chr19:33864478	CEBPG	0.65	7.86	0.54	6.44e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.85	10.11	0.63	1.09e-18	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23846145	chr4:103266423	SLC39A8	0.63	6.46	0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.68	-6.18	-0.45	5.67e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs42648	0.564	rs17867585	chr7:89819174	C/T	cg27367526	chr7:89841692	STEAP2	-0.32	-4.49	-0.34	1.42e-5	Homocysteine levels;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.86	6.58	0.47	7.16e-10	Alzheimer's disease;
PAAD	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00236302	chr12:69004867	RAP1B	0.54	6.59	0.47	6.85e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.79	8.45	0.57	2.21e-14	Mean corpuscular volume;
PAAD	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.8	-6.12	-0.44	7.45e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.66	0.57	6.37e-15	Alzheimer's disease;
PAAD	cis	rs3026101	0.671	rs72634032	chr17:5303437	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.48e-6	Lung cancer;
PAAD	cis	rs15676	0.947	rs2293966	chr9:131591832	G/A	cg00228799	chr9:131580591	ENDOG	0.62	5.91	0.43	2.2e-8	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-1.08	-15.07	-0.77	5.83e-32	Breast cancer;
PAAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs939584	0.866	rs13387090	chr2:650974	G/T	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg01064725	chr1:204461714	NA	-0.5	-4.61	-0.35	8.61e-6	Schizophrenia;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16262614	chr3:133464971	TF	0.41	4.31	0.33	2.95e-5	Iron status biomarkers;
PAAD	cis	rs2017305	0.764	rs2487710	chr10:70782126	C/A	cg25290552	chr10:70751067	KIAA1279	-0.85	-5.47	-0.41	1.79e-7	Depression (quantitative trait);
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02071572	chr4:1403502	NA	0.41	5.72	0.42	5.5e-8	Obesity-related traits;
PAAD	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.72	-7.2	-0.5	2.57e-11	Retinal vascular caliber;
PAAD	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg09760422	chr2:128146352	NA	-0.44	-7.61	-0.53	2.73e-12	Protein C levels;
PAAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs62408225	0.894	rs4707609	chr6:90946479	T/C	cg03795776	chr6:90687632	BACH2	0.44	4.49	0.34	1.38e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.98	6.53	0.47	9.33e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1144333	0.655	rs7418941	chr1:76436020	A/G	cg22875332	chr1:76189707	ACADM	0.76	4.45	0.34	1.62e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.71	-0.42	5.65e-8	Lung cancer;
PAAD	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.23	-0.51	2.26e-11	Neuroticism;
PAAD	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.67	-0.53	1.97e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.97	11.45	0.68	2.82e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10819733	chr22:24237672	NA	-0.57	-6.3	-0.45	3.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.36	-0.4	3.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	4.79	0.36	3.99e-6	Asthma;
PAAD	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.67	6.55	0.47	8.28e-10	Coronary artery disease;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.65	4.51	0.34	1.3e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9463078	0.585	rs4352679	chr6:45239658	G/A	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.42	4.84	0.37	3.16e-6	Refractive error;
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.43	-6.34	-0.46	2.47e-9	Breast cancer;
PAAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00982548	chr2:198649783	BOLL	-0.79	-5.54	-0.41	1.32e-7	Ulcerative colitis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05270572	chr2:119981334	STEAP3	-0.67	-6.43	-0.46	1.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.97	-0.72	2.28e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.72	-7.29	-0.51	1.55e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg09226986	chr6:160852328	SLC22A3	-0.46	-4.36	-0.33	2.35e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.56	-5.4	-0.4	2.48e-7	Systemic sclerosis;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg02440177	chr19:53496695	ZNF702P	-0.63	-6.56	-0.47	8.03e-10	Psoriasis;
PAAD	cis	rs57709857	0.957	rs1906672	chr8:38130025	G/A	cg16625770	chr8:38300134	FGFR1	-0.48	-4.38	-0.33	2.18e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.48	0.41	1.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4843185	0.733	rs1049868	chr16:85706633	A/G	cg07784872	chr16:85687041	KIAA0182	0.5	4.27	0.33	3.43e-5	Platelet distribution width;
PAAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg13611204	chr9:139324423	INPP5E	0.57	4.86	0.37	2.87e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.52	4.92	0.37	2.21e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg27490568	chr2:178487706	NA	0.42	4.44	0.34	1.7e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.47	6.09	0.44	9.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.3	-0.39	4e-7	Common traits (Other);
PAAD	cis	rs6142102	0.961	rs761235	chr20:32534408	A/G	cg08999081	chr20:33150536	PIGU	0.46	4.26	0.33	3.56e-5	Skin pigmentation;
PAAD	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs448720	0.811	rs1996120	chr15:68181534	G/A	cg05925327	chr15:68127851	NA	-0.39	-4.46	-0.34	1.61e-5	Cognitive performance;
PAAD	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.45	-4.82	-0.36	3.52e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg16950941	chr11:66035639	RAB1B	0.62	5.33	0.4	3.51e-7	Electroencephalogram traits;
PAAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Aortic root size;
PAAD	cis	rs6076065	1.000	rs2424547	chr20:23392690	A/G	cg12633918	chr20:23549525	CST9L	-0.4	-4.43	-0.34	1.78e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.51	-4.65	-0.35	7.26e-6	Life satisfaction;
PAAD	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	6.86e-8	Urinary metabolites;
PAAD	cis	rs939584	1.000	rs11127488	chr2:646061	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs16975963	0.843	rs3848624	chr19:38262816	C/T	cg08679971	chr19:38281047	NA	0.51	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs939584	1.000	rs6731348	chr2:630339	A/C	cg14515364	chr2:636606	NA	0.53	4.8	0.36	3.7e-6	Body mass index;
PAAD	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.82	5.33	0.4	3.41e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.74	4.65	0.35	7.06e-6	Coronary artery disease;
PAAD	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg19401529	chr3:49056140	DALRD3	1.02	7.02	0.49	6.78e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.7	4.78	0.36	4.04e-6	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs9361491	0.610	rs4706731	chr6:79468298	C/T	cg05283184	chr6:79620031	NA	-0.41	-4.89	-0.37	2.59e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.4	-0.46	1.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.54	5.04	0.38	1.33e-6	Resting heart rate;
PAAD	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.85	-9.54	-0.61	3.49e-17	Iron status biomarkers;
PAAD	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.68	6.75	0.48	2.87e-10	Uric acid levels;
PAAD	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.81	-8.73	-0.58	4.31e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.6	-5.58	-0.41	1.08e-7	Primary biliary cholangitis;
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.28	-0.51	1.71e-11	Longevity;
PAAD	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.82	-10.22	-0.64	5.5e-19	Height;
PAAD	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-4.6	-0.35	9e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.65	6.2	0.45	5.03e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs595018	0.505	rs7942904	chr11:60598483	G/A	cg07588442	chr11:60673866	PRPF19	0.65	4.56	0.35	1.04e-5	Wegener's granulomatosis;
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	6.77	0.48	2.68e-10	Lung function (FEV1/FVC);
PAAD	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.58	5.72	0.42	5.52e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.84	10.52	0.65	8.7e-20	Menopause (age at onset);
PAAD	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	7.98	0.54	3.39e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.49	-0.34	1.4e-5	Prevalent atrial fibrillation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01051642	chr1:2517410	C1orf93	-0.78	-6.64	-0.47	5.17e-10	Neuroticism;
PAAD	cis	rs59888335	0.862	rs7626516	chr3:80618446	C/T	cg21735741	chr3:80819488	NA	0.56	4.83	0.36	3.3e-6	Schizophrenia;
PAAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg03989125	chr22:38214979	NA	0.63	6.07	0.44	9.64e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.72	7.4	0.51	8.72e-12	Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00919585	chr3:51975770	PARP3;RRP9	-0.59	-6.47	-0.46	1.27e-9	Body fat percentage;
PAAD	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.35	6.5	0.47	1.11e-9	Type 2 diabetes;
PAAD	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10267417	0.535	rs6946403	chr7:19861549	C/T	cg05791153	chr7:19748676	TWISTNB	0.84	5.45	0.4	1.97e-7	Night sleep phenotypes;
PAAD	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	7.86	0.54	6.6e-13	Schizophrenia;
PAAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.56	-0.35	1.05e-5	Obesity-related traits;
PAAD	cis	rs6723226	0.610	rs458628	chr2:32515398	G/A	cg02381751	chr2:32503542	YIPF4	0.85	9.71	0.62	1.22e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg16964102	chr10:135390573	NA	-0.43	-4.45	-0.34	1.68e-5	Obesity-related traits;
PAAD	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.21	-0.39	6.02e-7	Inflammatory bowel disease;
PAAD	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg21584241	chr15:63341463	TPM1	0.67	4.9	0.37	2.38e-6	Orofacial clefts;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.81	9.37	0.61	9.46e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.23	0.45	4.3e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4750440	0.585	rs10508470	chr10:14021822	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.28	-0.33	3.28e-5	Adiponectin levels;
PAAD	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg09760422	chr2:128146352	NA	-0.44	-7.55	-0.52	3.72e-12	Protein C levels;
PAAD	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.15	0.55	1.28e-13	Monocyte percentage of white cells;
PAAD	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.47	5.74	0.42	4.86e-8	Colorectal cancer;
PAAD	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg18099408	chr3:52552593	STAB1	-0.5	-5.71	-0.42	5.63e-8	Electroencephalogram traits;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs9346353	0.737	rs9360406	chr6:70503608	A/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.12	-8.81	-0.58	2.73e-15	Vitiligo;
PAAD	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg20503657	chr10:835505	NA	0.49	5.06	0.38	1.18e-6	Survival in rectal cancer;
PAAD	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg25364880	chr3:44379878	C3orf23	0.59	5.37	0.4	2.88e-7	Depressive symptoms;
PAAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.96	10.9	0.66	8.14e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.81	9.01	0.59	8.12e-16	Metabolic syndrome;
PAAD	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg17960426	chr8:142067321	NA	-0.6	-5.29	-0.39	4.21e-7	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg01176363	chr20:62369445	LIME1	-0.59	-5.69	-0.42	6.41e-8	Prostate cancer;
PAAD	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06307176	chr5:131281290	NA	-0.51	-4.68	-0.35	6.4e-6	Life satisfaction;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.56	-6.08	-0.44	9.39e-9	Testicular germ cell tumor;
PAAD	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg11952622	chr19:58962976	ZNF324B	0.45	4.39	0.34	2.1e-5	Uric acid clearance;
PAAD	cis	rs6844506	0.898	rs12506922	chr4:185234505	A/C	cg12654155	chr4:185238627	NA	0.49	5.17	0.39	7.26e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg16850897	chr7:100343110	ZAN	-0.77	-6.34	-0.46	2.52e-9	Other erythrocyte phenotypes;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.42	4.28	0.33	3.32e-5	Eosinophil percentage of white cells;
PAAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.96	-9.11	-0.59	4.44e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.61	-0.41	9.1e-8	Schizophrenia (age at onset);
PAAD	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.44	5.28	0.39	4.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg21416968	chr1:44441199	ATP6V0B	0.66	6.53	0.47	9.32e-10	Primary biliary cholangitis;
PAAD	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-5.22	-0.39	5.77e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7547997	0.615	rs12038925	chr1:158319449	G/A	cg26014409	chr1:158324471	CD1E	0.37	4.56	0.35	1.04e-5	QRS duration;
PAAD	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14829155	chr15:31115871	NA	-0.68	-7.57	-0.52	3.27e-12	Huntington's disease progression;
PAAD	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg19510604	chr15:74901076	CLK3	0.52	4.29	0.33	3.22e-5	Blood trace element (Zn levels);
PAAD	cis	rs12935418	0.552	rs2549847	chr16:81024222	T/G	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16659407	chr8:98653091	NA	0.63	6.78	0.48	2.54e-10	Smoking initiation;
PAAD	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.75	8.85	0.58	2.06e-15	Morning vs. evening chronotype;
PAAD	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg02415014	chr8:143852576	LYNX1	0.5	6.2	0.45	4.97e-9	Urinary tract infection frequency;
PAAD	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs8102137	0.962	rs58989684	chr19:30299796	A/T	cg27475126	chr19:30303651	CCNE1	-0.45	-5.04	-0.38	1.28e-6	Bladder cancer;
PAAD	cis	rs2952768	0.686	rs7569963	chr2:208473184	G/A	cg22329743	chr2:208688774	PLEKHM3	0.26	4.5	0.34	1.35e-5	Opioid sensitivity;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg07068956	chr7:100330872	ZAN	-0.69	-5.26	-0.39	4.9e-7	Other erythrocyte phenotypes;
PAAD	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs6499255	0.953	rs3811349	chr16:69791266	T/G	cg05250797	chr16:70222502	NA	0.77	5.87	0.43	2.62e-8	IgE levels;
PAAD	cis	rs3857067	0.530	rs28811282	chr4:95003642	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs4668356	1.000	rs56134465	chr2:172005756	A/C	cg13882835	chr2:172017928	TLK1	0.8	4.38	0.33	2.24e-5	Cognitive performance;
PAAD	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-0.66	-6.94	-0.49	1.09e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.77	9.06	0.59	6.2e-16	Heart rate;
PAAD	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21545522	chr1:205238299	TMCC2	0.47	4.32	0.33	2.81e-5	Red blood cell count;
PAAD	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg09835421	chr16:68378352	PRMT7	-0.6	-4.58	-0.35	9.52e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.58	-5.41	-0.4	2.41e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19636519	chr7:99541626	NA	0.41	4.63	0.35	7.82e-6	Coronary artery disease;
PAAD	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.07	13.7	0.74	2.43e-28	Testicular germ cell tumor;
PAAD	cis	rs7627468	0.913	rs4678187	chr3:121946376	T/C	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	trans	rs4678145	1.000	rs62265615	chr3:124447572	A/T	cg03983498	chr1:55107291	C1orf175	1.06	6.63	0.47	5.58e-10	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg06606381	chr12:133084897	FBRSL1	-1.38	-8.57	-0.57	1.09e-14	Depression;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg21226059	chr5:178986404	RUFY1	0.56	6.24	0.45	4.05e-9	Lung cancer;
PAAD	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg15309053	chr8:964076	NA	0.5	5.62	0.41	8.88e-8	Schizophrenia;
PAAD	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.39	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.89	7.07	0.5	5.26e-11	Chronic kidney disease;
PAAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.92	10.78	0.66	1.73e-20	Total body bone mineral density;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03605463	chr16:89740564	NA	0.53	5.16	0.39	7.74e-7	Vitiligo;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.65	7.57	0.52	3.44e-12	Mean corpuscular volume;
PAAD	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg09835421	chr16:68378352	PRMT7	-0.74	-4.69	-0.36	5.98e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.01	-0.38	1.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.44e-9	Alzheimer's disease (late onset);
PAAD	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg00576331	chr11:65640516	EFEMP2	-0.47	-4.4	-0.34	1.99e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg17178900	chr1:205818956	PM20D1	0.53	5.53	0.41	1.34e-7	Prostate cancer;
PAAD	cis	rs3764400	0.508	rs74412170	chr17:46117509	C/G	cg24322968	chr17:46507895	SKAP1	0.87	5.31	0.4	3.78e-7	Body mass index;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.59	-5.54	-0.41	1.28e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15309264	chr2:58274034	VRK2	0.58	6.43	0.46	1.53e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg03808351	chr9:123631620	PHF19	0.45	4.99	0.37	1.66e-6	Rheumatoid arthritis;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12524338	chr4:183729343	NA	0.61	4.72	0.36	5.33e-6	Pediatric autoimmune diseases;
PAAD	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	7.57	0.52	3.29e-12	Eotaxin levels;
PAAD	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg03162506	chr22:38580953	NA	-0.38	-4.44	-0.34	1.75e-5	Cutaneous nevi;
PAAD	cis	rs7567389	0.677	rs72845991	chr2:128107907	A/G	cg09760422	chr2:128146352	NA	0.38	5.96	0.44	1.65e-8	Self-rated health;
PAAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.64	6.45	0.46	1.42e-9	Hemoglobin concentration;
PAAD	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.62	-6.89	-0.49	1.37e-10	Birth weight;
PAAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg12215294	chr3:40350768	EIF1B	-0.48	-4.76	-0.36	4.42e-6	Renal cell carcinoma;
PAAD	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg21775007	chr8:11205619	TDH	0.48	4.33	0.33	2.74e-5	Neuroticism;
PAAD	cis	rs1160297	0.530	rs4672152	chr2:53224276	C/A	cg07782112	chr2:53107842	NA	-0.39	-4.62	-0.35	8e-6	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs12136530	0.593	rs2314145	chr1:19736843	C/G	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.77	4.51	0.34	1.31e-5	Response to cognitive-behavioural therapy in anxiety disorder;
PAAD	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.88	7.01	0.49	7.44e-11	Prostate cancer;
PAAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13560548	chr3:10150139	C3orf24	0.63	5.51	0.41	1.53e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03923535	chr7:1197113	ZFAND2A	0.43	4.25	0.33	3.77e-5	Longevity;Endometriosis;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.6	-6.09	-0.44	8.93e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg15192750	chr16:69999425	NA	0.74	5.77	0.42	4.4e-8	IgE levels;
PAAD	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg07725925	chr16:89976287	TCF25	0.68	4.42	0.34	1.83e-5	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg25452165	chr22:42524984	CYP2D6	0.59	5.59	0.41	1.02e-7	Schizophrenia;
PAAD	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs138918	0.771	rs138934	chr22:43566924	A/C	cg00343092	chr22:43547974	TSPO	0.42	4.77	0.36	4.26e-6	Monocyte count;
PAAD	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.33	0.46	2.65e-9	Hip circumference;
PAAD	cis	rs1329189	0.798	rs7068678	chr10:130007313	A/G	cg17972361	chr10:130010134	NA	0.48	5.02	0.38	1.4e-6	Orofacial clefts;
PAAD	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	1.02	9.06	0.59	5.89e-16	Neutrophil percentage of white cells;
PAAD	cis	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs73019876	0.805	rs1849003	chr19:22142261	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19623624	chr10:135278901	LOC619207	-0.54	-5.48	-0.41	1.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.9	-0.43	2.27e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg09324608	chr17:30823087	MYO1D	0.54	5.61	0.41	9.17e-8	Schizophrenia;
PAAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg21929781	chr1:2537748	MMEL1	0.51	5.31	0.4	3.78e-7	Ulcerative colitis;
PAAD	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.69	-8.31	-0.56	4.91e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Diastolic blood pressure;
PAAD	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.87	10.22	0.64	5.53e-19	Resting heart rate;
PAAD	cis	rs617219	0.710	rs2591386	chr5:78561373	C/T	cg24856658	chr5:78533917	JMY	-0.39	-4.25	-0.33	3.74e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg01097406	chr16:89675127	NA	-0.35	-4.27	-0.33	3.43e-5	Vitiligo;
PAAD	cis	rs16958440	1.000	rs2289130	chr18:44626630	T/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs802075	1.000	rs360560	chr6:49659634	C/A	cg20364632	chr6:49636226	NA	-0.52	-6.03	-0.44	1.21e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.92	-7.99	-0.54	3.07e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.89	-11.64	-0.69	8.82e-23	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.49	-0.61	4.57e-17	Tonsillectomy;
PAAD	cis	rs12042052	1.000	rs6669303	chr1:232912728	G/A	cg02903907	chr1:232941055	KIAA1383	0.82	4.56	0.35	1.03e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-1.49	-9.65	-0.62	1.77e-17	Age-related hearing impairment;
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.82	8.75	0.58	3.89e-15	Prostate cancer;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg27234864	chr13:21295941	IL17D	0.52	4.5	0.34	1.32e-5	Dental caries;
PAAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.8	10.34	0.64	2.68e-19	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6708413	0.520	rs6543151	chr2:103114041	A/G	cg13897122	chr2:103039542	IL18RAP	-0.48	-5.31	-0.4	3.91e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.43	0.46	1.59e-9	Educational attainment;
PAAD	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg03700679	chr2:178418002	TTC30B	-0.57	-4.56	-0.35	1.06e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.66	6.34	0.46	2.5e-9	Mosquito bite size;
PAAD	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.86	-9.49	-0.61	4.61e-17	Systemic sclerosis;
PAAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10526556	chr10:13391149	SEPHS1	-0.73	-6.48	-0.47	1.21e-9	Neuroticism;
PAAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.6	-0.41	9.79e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.38	-0.46	2.06e-9	Bipolar disorder;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9903692	0.505	rs208005	chr17:46239985	A/G	cg10706073	chr17:46328419	SKAP1	1.07	6.34	0.46	2.45e-9	Pulse pressure;
PAAD	cis	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs1620921	0.505	rs4708878	chr6:161203026	A/G	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.48	-4.61	-0.35	8.32e-6	Height;
PAAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.98	-0.54	3.31e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	4.54	0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg12568669	chr8:11666485	FDFT1	-0.31	-5.24	-0.39	5.37e-7	Monocyte count;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07157834	chr1:205819609	PM20D1	-0.6	-5.94	-0.43	1.87e-8	Parkinson's disease;
PAAD	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.47	-0.34	1.51e-5	Joint mobility (Beighton score);
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.74	0.36	4.85e-6	Cognitive function;
PAAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg14440974	chr22:39074834	NA	-0.6	-7.39	-0.51	8.9e-12	Menopause (age at onset);
PAAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.69	8.09	0.55	1.73e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg16926213	chr1:1841314	NA	0.38	4.56	0.35	1.04e-5	Body mass index;
PAAD	cis	rs12286929	0.699	rs1048932	chr11:115044850	C/A	cg04055981	chr11:115044050	NA	-0.45	-4.85	-0.37	3.03e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17983724	chr7:72298804	TYW1B;SBDSP	0.6	6.35	0.46	2.35e-9	Myopia (pathological);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26291195	chr7:98610531	TRRAP	-0.59	-6.48	-0.47	1.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.53	5.27	0.39	4.52e-7	Pulmonary function;
PAAD	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06850241	chr22:41845214	NA	0.5	4.78	0.36	4.19e-6	Vitiligo;
PAAD	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.52	-0.34	1.21e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg14324370	chr2:177042789	NA	0.32	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs73019876	0.836	rs10401697	chr19:22167001	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs1499972	0.887	rs817504	chr3:117678862	A/C	cg07612923	chr3:117604196	NA	-1.08	-7.2	-0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.73	6.44	0.46	1.45e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.89	11.4	0.68	3.7e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg23995914	chr4:10459228	ZNF518B	-0.38	-4.51	-0.34	1.28e-5	Schizophrenia (age at onset);
PAAD	cis	rs7577696	0.962	rs13000753	chr2:32282297	T/C	cg02381751	chr2:32503542	YIPF4	-0.41	-4.45	-0.34	1.64e-5	Inflammatory biomarkers;
PAAD	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.66	8.44	0.57	2.27e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.48	-0.34	1.43e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.901	rs117397604	chr22:32580840	C/A	cg02631450	chr22:32366979	NA	1.02	4.96	0.37	1.87e-6	Childhood ear infection;
PAAD	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.48	4.93	0.37	2.09e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09060823	chr12:56862504	SPRYD4	0.6	6.69	0.48	3.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-5.0	-0.38	1.56e-6	Mean platelet volume;
PAAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.17	0.6	3.06e-16	Cognitive function;
PAAD	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.86	9.56	0.61	2.99e-17	Multiple sclerosis;
PAAD	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg15017067	chr4:17643749	FAM184B	0.47	5.17	0.39	7.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2790216	1.000	rs1867571	chr10:60038850	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.85	8.46	0.57	2.08e-14	Cognitive function;
PAAD	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg21775007	chr8:11205619	TDH	-0.56	-4.98	-0.37	1.71e-6	Retinal vascular caliber;
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.7	7.66	0.53	2.06e-12	Aortic root size;
PAAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.76	8.09	0.55	1.75e-13	Childhood ear infection;
PAAD	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg01304814	chr3:48885189	PRKAR2A	0.98	5.09	0.38	1.04e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg26003909	chr8:143102224	NA	-0.38	-6.36	-0.46	2.22e-9	Amyotrophic lateral sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18936471	chr4:99186446	RAP1GDS1	0.62	7.39	0.51	9.28e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25353064	chr10:96991431	NA	0.58	6.95	0.49	9.99e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18621852	chr3:10150065	C3orf24	-0.53	-4.95	-0.37	1.93e-6	Alzheimer's disease;
PAAD	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg05294307	chr14:35346193	BAZ1A	-0.66	-5.32	-0.4	3.62e-7	Psoriasis;
PAAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg15847926	chr7:2749597	AMZ1	-0.38	-4.59	-0.35	9.13e-6	Height;
PAAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.97	8.75	0.58	3.72e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5753037	0.653	rs131272	chr22:30153655	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg01493522	chr13:37497338	NA	-0.61	-5.87	-0.43	2.64e-8	Coronary artery disease;
PAAD	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-7.78	-0.53	1.02e-12	Total body bone mineral density;
PAAD	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg19792802	chr11:65647270	CTSW	-0.43	-5.74	-0.42	5.08e-8	DNA methylation (variation);
PAAD	cis	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg11619707	chr19:22235551	ZNF257	0.59	5.89	0.43	2.34e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17824933	0.943	rs11230566	chr11:60780007	G/A	cg27098804	chr11:60776124	CD6	0.44	4.33	0.33	2.71e-5	Multiple sclerosis;
PAAD	cis	rs12042052	0.590	rs12048236	chr1:232942251	A/G	cg02191044	chr1:232940990	KIAA1383	0.83	4.32	0.33	2.76e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.3	-9.75	-0.62	9.46e-18	Breast cancer;
PAAD	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.73	-8.09	-0.55	1.73e-13	Airway imaging phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18788891	chr5:70883072	MCCC2	0.71	7.26	0.51	1.85e-11	Obesity-related traits;
PAAD	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.41	-0.4	2.35e-7	Crohn's disease;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.23	-0.39	5.48e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg02869306	chr7:64672164	INTS4L1	0.4	4.6	0.35	8.91e-6	Aortic root size;
PAAD	cis	rs1499972	0.529	rs1353911	chr3:117777904	A/G	cg07612923	chr3:117604196	NA	-0.7	-4.94	-0.37	2.07e-6	Schizophrenia;
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.72e-7	Alzheimer's disease;
PAAD	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.51	-4.9	-0.37	2.42e-6	Menopause (age at onset);
PAAD	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.38	-0.33	2.21e-5	Depression;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.45	5.48	0.41	1.74e-7	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs17021463	0.673	rs17565759	chr4:95280763	C/T	cg11021082	chr4:95130006	SMARCAD1	0.57	5.74	0.42	4.88e-8	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.76e-7	Lung cancer;
PAAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-5.2	-0.39	6.28e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.35	6.43	0.46	1.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.68	-6.53	-0.47	9.07e-10	QRS duration;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-5.33	-0.4	3.42e-7	Lymphocyte counts;
PAAD	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.81	-9.45	-0.61	5.87e-17	DNA methylation (variation);
PAAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.78	-9.49	-0.61	4.68e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.35	0.4	3.15e-7	Multiple sclerosis;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg17346650	chr17:80929145	B3GNTL1	0.43	5.17	0.39	7.19e-7	Glycated hemoglobin levels;
PAAD	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Androgen levels;
PAAD	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.66	6.84	0.49	1.83e-10	Testicular germ cell tumor;
PAAD	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg05925327	chr15:68127851	NA	-0.58	-5.3	-0.4	3.93e-7	Restless legs syndrome;
PAAD	cis	rs13177180	0.705	rs13153908	chr5:114937416	T/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.46	-4.78	-0.36	4.14e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs7301016	0.947	rs10877864	chr12:62893199	T/C	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg09796270	chr17:17721594	SREBF1	-0.44	-4.98	-0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg20503657	chr10:835505	NA	0.82	5.68	0.42	6.53e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-5.9	-0.43	2.24e-8	Prostate cancer;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg23958373	chr8:599963	NA	-1.13	-7.22	-0.51	2.31e-11	IgG glycosylation;
PAAD	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.61	-6.09	-0.44	9.01e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs10267417	0.603	rs10228558	chr7:19911915	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	4.85	0.37	3.08e-6	Night sleep phenotypes;
PAAD	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.78	-9.1	-0.59	4.7e-16	Hemoglobin concentration;
PAAD	cis	rs73206853	0.841	rs4131852	chr12:110812657	C/G	cg12870014	chr12:110450643	ANKRD13A	0.67	4.55	0.35	1.07e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.69	6.4	0.46	1.87e-9	Lymphocyte counts;
PAAD	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21742872	chr21:43373869	C2CD2	0.58	6.48	0.47	1.24e-9	Myopia (pathological);
PAAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg20893579	chr22:38215064	NA	0.5	4.74	0.36	4.94e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg11833968	chr6:79620685	NA	0.41	4.31	0.33	2.95e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.73	0.36	4.99e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7853377	0.739	rs296884	chr9:86582923	G/T	cg03531853	chr9:86535572	KIF27	0.41	4.41	0.34	1.97e-5	Height;
PAAD	cis	rs9815354	0.680	rs57945879	chr3:42038842	C/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.65	7.03	0.5	6.65e-11	Iron status biomarkers;
PAAD	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.52	5.0	0.38	1.54e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.54	-5.67	-0.42	6.9e-8	Airway imaging phenotypes;
PAAD	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg08648136	chr8:956695	NA	0.46	4.92	0.37	2.26e-6	Schizophrenia;
PAAD	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.58	5.72	0.42	5.6e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.95	7.23	0.51	2.22e-11	Alzheimer's disease;
PAAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.61	6.24	0.45	4.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.44	-0.56	2.38e-14	Body mass index;
PAAD	cis	rs2271001	1.000	rs7129326	chr11:19147327	C/T	cg00161556	chr11:19138045	ZDHHC13	0.49	5.38	0.4	2.82e-7	Gut microbiome composition (winter);
PAAD	cis	rs11083840	0.535	rs10424552	chr19:47143779	A/T	cg07844738	chr19:47129343	PTGIR	0.41	4.8	0.36	3.72e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.67	5.73	0.42	5.11e-8	Breast cancer;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.57	-6.65	-0.47	5.05e-10	Orofacial clefts;
PAAD	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.78	-8.17	-0.55	1.13e-13	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18680346	chr10:116391764	ABLIM1	-0.75	-6.47	-0.46	1.29e-9	Neuroticism;
PAAD	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.41	-6.17	-0.45	6.02e-9	Subjective well-being;
PAAD	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26926768	chr12:34528122	NA	0.36	4.53	0.34	1.19e-5	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.62	6.53	0.47	9.32e-10	Bone mineral density;
PAAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	4.76	0.36	4.47e-6	Menarche (age at onset);
PAAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg18209359	chr17:80159595	CCDC57	0.43	4.3	0.33	3.02e-5	Life satisfaction;
PAAD	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg08079166	chr15:68083412	MAP2K5	0.55	5.05	0.38	1.25e-6	Restless legs syndrome;
PAAD	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-4.71	-0.36	5.52e-6	Daytime sleep phenotypes;
PAAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg14092988	chr3:52407081	DNAH1	0.45	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.46	-4.78	-0.36	4.02e-6	Corneal astigmatism;
PAAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.29	-0.39	4.17e-7	IgG glycosylation;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-6.82	-0.48	2.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg25050447	chr17:78165522	CARD14	0.37	4.51	0.34	1.28e-5	Yeast infection;
PAAD	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.14	-0.64	9.12e-19	Response to antipsychotic treatment;
PAAD	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.52	-4.84	-0.37	3.21e-6	Height;
PAAD	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg15117754	chr3:10150083	C3orf24	0.61	5.1	0.38	9.8e-7	Alzheimer's disease;
PAAD	cis	rs72960926	0.744	rs16884519	chr6:74967946	C/T	cg03266952	chr6:74778945	NA	1.1	6.47	0.46	1.26e-9	Metabolite levels (MHPG);
PAAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs939584	0.877	rs6548240	chr2:636929	C/A	cg14515364	chr2:636606	NA	0.49	4.67	0.35	6.55e-6	Body mass index;
PAAD	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg20503657	chr10:835505	NA	0.5	5.15	0.39	7.85e-7	Survival in rectal cancer;
PAAD	cis	rs3743102	0.591	rs12148608	chr15:83382102	A/G	cg00614314	chr15:82944287	LOC80154	0.76	5.05	0.38	1.23e-6	Colorectal adenoma (advanced);
PAAD	cis	rs6076065	0.644	rs2424535	chr20:23381196	T/C	cg11657817	chr20:23433608	CST11	0.47	4.91	0.37	2.37e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs78761021	0.755	rs17681788	chr17:9794415	C/T	cg26853458	chr17:9805074	RCVRN	0.73	8.58	0.57	1.06e-14	Type 2 diabetes;
PAAD	cis	rs2916733	0.530	rs2254903	chr8:6289421	C/T	cg01691696	chr8:6734962	DEFB1	-0.53	-4.58	-0.35	9.49e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.7	8.69	0.58	5.52e-15	Dupuytren's disease;
PAAD	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.43	-0.74	1.32e-27	Height;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg06375148	chr1:209958343	C1orf74	0.57	4.88	0.37	2.71e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg10494973	chr17:80897199	TBCD	-0.51	-4.68	-0.35	6.39e-6	Breast cancer;
PAAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.64	-6.75	-0.48	2.93e-10	Coronary artery disease;
PAAD	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg11380483	chr2:127933992	NA	0.49	4.73	0.36	5.12e-6	Self-rated health;
PAAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.82	10.32	0.64	2.97e-19	Height;
PAAD	cis	rs4253772	0.626	rs9627428	chr22:46765823	G/C	cg24881330	chr22:46731750	TRMU	1.16	5.71	0.42	5.72e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.32e-8	Alzheimer's disease;
PAAD	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.61	6.54	0.47	8.8e-10	Obesity-related traits;
PAAD	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	1.08	8.72	0.58	4.63e-15	Inflammatory bowel disease;
PAAD	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07685180	chr8:600429	NA	-0.9	-5.42	-0.4	2.28e-7	IgG glycosylation;
PAAD	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.46	-5.25	-0.39	5.11e-7	Cognitive function;
PAAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.51e-21	Ulcerative colitis;
PAAD	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.53	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg19401529	chr3:49056140	DALRD3	0.51	4.26	0.33	3.56e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.53	-0.57	1.38e-14	Body mass index;
PAAD	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg16964102	chr10:135390573	NA	0.43	4.37	0.33	2.28e-5	Gout;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23025703	chr14:90769433	C14orf102	0.6	6.64	0.47	5.26e-10	Smoking initiation;
PAAD	cis	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg11619707	chr19:22235551	ZNF257	0.58	5.77	0.42	4.26e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.92	-8.62	-0.57	8.29e-15	Asthma;
PAAD	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07362569	chr17:61921086	SMARCD2	-0.47	-5.63	-0.42	8.29e-8	Prudent dietary pattern;
PAAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg17724175	chr1:150552817	MCL1	0.41	4.55	0.35	1.07e-5	Melanoma;
PAAD	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg11416102	chr8:651193	ERICH1	-0.87	-4.96	-0.37	1.84e-6	IgG glycosylation;
PAAD	cis	rs564309	0.510	rs1188478	chr1:228614692	C/T	cg13099616	chr1:227751251	ZNF678	0.67	4.47	0.34	1.53e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.37	0.61	9.4e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26926768	chr12:34528122	NA	0.4	4.93	0.37	2.15e-6	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01149259	chr3:47021396	NBEAL2	0.63	7.11	0.5	4.3e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs6141769	0.542	rs28542091	chr20:31301402	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg06740227	chr12:86229804	RASSF9	0.6	5.33	0.4	3.46e-7	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18313110	chr3:139108398	COPB2	0.67	7.53	0.52	4.17e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-0.82	-5.67	-0.42	7.01e-8	Breast cancer;
PAAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.99e-10	Bipolar disorder;
PAAD	cis	rs13102973	0.931	rs13103718	chr4:135843990	C/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.66	7.14	0.5	3.63e-11	Blood protein levels;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.6	5.81	0.43	3.47e-8	Acylcarnitine levels;
PAAD	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg17401720	chr7:158221031	PTPRN2	-0.44	-5.11	-0.38	9.66e-7	Obesity-related traits;
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg14092988	chr3:52407081	DNAH1	0.44	5.21	0.39	5.99e-7	Cognitive function;
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg17105886	chr17:28927953	LRRC37B2	0.88	5.32	0.4	3.62e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	5.28	0.39	4.46e-7	Neuroticism;
PAAD	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4509693	0.882	rs7900763	chr10:102492559	A/C	cg24179445	chr10:102496915	NA	0.41	4.42	0.34	1.87e-5	Alzheimer's disease;
PAAD	cis	rs4742903	0.935	rs6479225	chr9:106940330	T/C	cg14250997	chr9:106856677	SMC2	0.44	4.66	0.35	6.98e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs3790455	0.585	rs3790460	chr1:156465029	C/G	cg14087168	chr1:156450669	MEF2D	-0.4	-4.36	-0.33	2.38e-5	Migraine;
PAAD	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg26205652	chr12:48591994	NA	0.74	6.87	0.49	1.55e-10	Longevity (90 years and older);
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg21178979	chr7:1889533	MAD1L1	0.4	4.43	0.34	1.76e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.65	0.42	7.73e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2885056	0.891	rs115850646	chr19:10689027	A/G	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs1075232	0.826	rs12437800	chr15:31671432	A/G	cg06530883	chr15:30699977	NA	0.95	4.28	0.33	3.27e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs427941	0.655	rs201472	chr7:101744428	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.41	0.34	1.92e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg19192590	chr2:178524533	PDE11A	0.43	5.14	0.38	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.8	-6.83	-0.48	1.96e-10	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs273573	0.621	rs10767884	chr11:30990568	A/G	cg21705394	chr11:30344510	C11orf46	0.45	4.3	0.33	3.1e-5	Total body bone mineral density;
PAAD	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-8.32	-0.56	4.7e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs2221894	0.553	rs62502805	chr8:28832095	C/T	cg20212339	chr8:28908912	HMBOX1	0.44	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg05528293	chr18:74961138	GALR1	0.57	5.19	0.39	6.53e-7	Obesity-related traits;
PAAD	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	4.98	0.37	1.73e-6	Mean platelet volume;
PAAD	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.91	9.55	0.61	3.21e-17	Testicular germ cell tumor;
PAAD	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg10705379	chr10:99080932	FRAT1	0.37	4.34	0.33	2.62e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-1.12	-6.04	-0.44	1.13e-8	Inflammatory biomarkers;
PAAD	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.52	-0.34	1.21e-5	Height;
PAAD	cis	rs79387448	0.745	rs7576324	chr2:103142994	G/A	cg09003973	chr2:102972529	NA	0.73	4.52	0.34	1.26e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.9	10.95	0.66	6.04e-21	Metabolic syndrome;
PAAD	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs6430491	0.544	rs1683543	chr2:134811073	G/T	cg18984282	chr2:134326172	NCKAP5	0.4	4.49	0.34	1.38e-5	Schizophrenia;
PAAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg01503450	chr10:980765	NA	-0.52	-4.83	-0.37	3.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11718455	0.503	rs1554654	chr3:44044344	C/T	cg21419209	chr3:44054225	NA	-0.6	-6.84	-0.48	1.85e-10	Coronary artery disease;
PAAD	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.39	-5.0	-0.38	1.55e-6	Prostate cancer;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.83	-0.54	7.86e-13	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.17	-0.5	3.04e-11	Neuroticism;
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.77	-0.42	4.36e-8	Testicular germ cell tumor;
PAAD	cis	rs3018712	0.700	rs2513295	chr11:68447893	C/T	cg23009355	chr11:68451396	GAL	-0.54	-4.76	-0.36	4.49e-6	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.79	-5.92	-0.43	2.03e-8	Alzheimer's disease;
PAAD	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs7301826	0.580	rs61938969	chr12:131316070	A/G	cg11011512	chr12:131303247	STX2	-0.42	-4.3	-0.33	3.08e-5	Plasma plasminogen activator levels;
PAAD	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7823896	0.722	rs72682688	chr8:110326395	A/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg15211996	chr1:2936768	ACTRT2	0.47	4.87	0.37	2.82e-6	Plateletcrit;
PAAD	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.61	6.33	0.46	2.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.18	0.5	2.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.76	-0.36	4.5e-6	Menarche (age at onset);
PAAD	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs2992756	0.663	rs2992763	chr1:18804386	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.4	-0.46	1.8e-9	Breast cancer;
PAAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.79	9.17	0.6	3.09e-16	Diastolic blood pressure;
PAAD	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24841475	chr12:77424228	E2F7	-0.54	-6.37	-0.46	2.15e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg01620082	chr3:125678407	NA	0.88	6.31	0.46	2.87e-9	Depression;
PAAD	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg20243544	chr17:37824526	PNMT	-0.52	-4.57	-0.35	1.02e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.65	7.39	0.51	9.34e-12	Atrial fibrillation;
PAAD	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg03938978	chr2:103052716	IL18RAP	-0.51	-5.19	-0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.6	-6.58	-0.47	6.98e-10	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.85	-0.49	1.71e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2092319	0.649	rs2744778	chr1:26013252	A/G	cg02327719	chr1:26185386	C1orf135	-0.79	-4.71	-0.36	5.62e-6	Nose morphology;
PAAD	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2446066	0.872	rs2608302	chr12:53790296	T/G	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.78	-9.28	-0.6	1.67e-16	Colorectal cancer;
PAAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.41	5.72	0.42	5.61e-8	Vitiligo;
PAAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg19592336	chr6:28129416	ZNF389	-0.6	-4.31	-0.33	2.96e-5	Depression;
PAAD	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.44	4.52	0.34	1.24e-5	Plateletcrit;
PAAD	cis	rs10804591	0.606	rs2625998	chr3:129303744	G/A	cg18548199	chr3:129281892	PLXND1	-0.56	-4.87	-0.37	2.77e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12476592	0.516	rs6546002	chr2:63593829	A/C	cg10828910	chr2:63850056	LOC388955	0.5	4.32	0.33	2.79e-5	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.86	7.24	0.51	2.05e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-4.78	-0.36	4.03e-6	Glycated hemoglobin levels;
PAAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.53	5.27	0.39	4.69e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-8.6	-0.57	9.17e-15	Coffee consumption (cups per day);
PAAD	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg03392386	chr11:133800800	IGSF9B	0.47	4.74	0.36	4.85e-6	Parkinson's disease;
PAAD	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.77	8.64	0.57	7.4e-15	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27533872	chr1:109235055	PRPF38B	0.68	6.94	0.49	1.04e-10	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg12218747	chr21:37451666	NA	-0.55	-5.92	-0.43	2.02e-8	Mitral valve prolapse;
PAAD	cis	rs13168506	0.538	rs12515040	chr5:135441559	A/G	cg16684184	chr5:135415129	NA	-0.36	-4.8	-0.36	3.71e-6	Stroke;
PAAD	cis	rs16831128	1.000	rs72997278	chr2:133132817	T/C	cg11467141	chr2:132348705	NA	-0.66	-4.46	-0.34	1.58e-5	Conduct disorder;Conduct disorder (symptom count);
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.82	11.01	0.67	4.25e-21	Emphysema distribution in smoking;
PAAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg27398640	chr15:77910606	LINGO1	0.48	4.7	0.36	5.88e-6	Type 2 diabetes;
PAAD	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg27094323	chr7:1216898	NA	-0.42	-4.51	-0.34	1.3e-5	Longevity;Endometriosis;
PAAD	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg08601574	chr20:25228251	PYGB	-0.53	-5.66	-0.42	7.26e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.03	0.44	1.19e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.94	10.26	0.64	4.24e-19	Breast cancer;
PAAD	cis	rs10450586	0.932	rs10835152	chr11:27311217	T/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	0.8	7.29	0.51	1.58e-11	Response to hepatitis C treatment;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01942863	chr7:99769432	GPC2	0.52	4.26	0.33	3.51e-5	Platelet count;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.84	-6.82	-0.48	1.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.69	6.93	0.49	1.14e-10	Neuroticism;
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg07068956	chr7:100330872	ZAN	-0.71	-5.37	-0.4	2.95e-7	Other erythrocyte phenotypes;
PAAD	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs89107	0.934	rs281868	chr6:118574061	A/G	cg21191810	chr6:118973309	C6orf204	-0.41	-5.29	-0.39	4.14e-7	Cardiac structure and function;
PAAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.11e-20	Menopause (age at onset);
PAAD	cis	rs939584	0.799	rs2867105	chr2:601905	A/C	cg03610516	chr2:642275	NA	0.57	4.86	0.37	2.86e-6	Body mass index;
PAAD	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg13798912	chr7:905769	UNC84A	0.57	4.35	0.33	2.53e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	5.17	0.39	7.21e-7	Mood instability;
PAAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg01942863	chr7:99769432	GPC2	-0.44	-4.26	-0.33	3.64e-5	Coronary artery disease;
PAAD	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.94	4.78	0.36	4.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.68	-0.48	4.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg03983715	chr16:68378420	PRMT7	-0.95	-7.14	-0.5	3.61e-11	Schizophrenia;
PAAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg25276700	chr6:44698697	NA	0.44	4.27	0.33	3.43e-5	Total body bone mineral density;
PAAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.46	4.56	0.35	1.05e-5	Mean corpuscular volume;
PAAD	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg19636519	chr7:99541626	NA	-0.47	-5.04	-0.38	1.29e-6	Coronary artery disease;
PAAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02733842	chr7:1102375	C7orf50	-0.67	-5.25	-0.39	4.99e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg23024343	chr7:107201750	COG5	0.56	4.64	0.35	7.38e-6	Coronary artery disease;
PAAD	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg24053715	chr22:38214548	NA	-0.58	-5.92	-0.43	2.08e-8	Glioblastoma;Glioma;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.66	-6.16	-0.45	6.29e-9	Blood metabolite levels;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg19337854	chr7:99768885	GPC2	0.44	4.48	0.34	1.46e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.66	-4.97	-0.37	1.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.06	-0.5	5.59e-11	Menarche (age at onset);
PAAD	cis	rs13053817	1.000	rs12484859	chr22:29844884	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.54	-4.82	-0.36	3.43e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2120991	0.967	rs10876512	chr12:54277756	G/A	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.25	-0.33	3.76e-5	Biliary atresia;
PAAD	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.26	0.39	4.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2302729	0.625	rs1592573	chr12:2831556	A/T	cg19945202	chr12:2788847	CACNA1C	-0.54	-4.31	-0.33	2.95e-5	Sleep quality;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287604	1.000	rs30105	chr2:237794545	A/G	cg15065627	chr2:237796583	NA	0.53	4.34	0.33	2.55e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	trans	rs3905000	1.000	rs3847303	chr9:107648652	C/T	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	1.57	8.95	0.59	1.18e-15	Cannabis dependence symptom count;
PAAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.94	10.05	0.63	1.56e-18	Cognitive function;
PAAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg22875332	chr1:76189707	ACADM	-0.49	-4.94	-0.37	2e-6	Daytime sleep phenotypes;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.95	-8.59	-0.57	9.67e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.85	-9.45	-0.61	5.93e-17	Prostate cancer;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.77	5.15	0.39	7.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.56	-5.32	-0.4	3.65e-7	Total body bone mineral density;
PAAD	cis	rs7113874	0.802	rs11042025	chr11:8675475	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	4.64	0.35	7.54e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6547631	0.622	rs61191323	chr2:85928631	G/A	cg24620635	chr2:85921963	GNLY	0.4	5.39	0.4	2.69e-7	Blood protein levels;
PAAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-6.57	-0.47	7.63e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.82	-5.63	-0.42	8.66e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.51	4.98	0.37	1.74e-6	Fractional excretion of uric acid;
PAAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs8077577	0.945	rs11871039	chr17:18078904	C/G	cg16794390	chr17:18148240	FLII	0.58	4.67	0.35	6.64e-6	Obesity-related traits;
PAAD	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21175976	chr8:11421337	BLK	-0.42	-4.52	-0.34	1.24e-5	Triglycerides;
PAAD	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.31	-4.44	-0.34	1.76e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.56	-5.6	-0.41	9.66e-8	IgG glycosylation;
PAAD	cis	rs740160	0.614	rs9969217	chr7:98891438	C/T	cg15059474	chr7:97990184	BAIAP2L1	-0.5	-4.34	-0.33	2.61e-5	Dehydroepiandrosterone sulphate levels;
PAAD	cis	rs11105468	0.530	rs61924662	chr12:90485617	G/A	cg16962463	chr12:89968675	NA	0.41	4.72	0.36	5.27e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18530251	chr8:22409574	SORBS3	-0.62	-6.47	-0.46	1.28e-9	Smoking initiation;
PAAD	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.8	9.06	0.59	6.13e-16	Breast cancer;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.37	-0.4	2.83e-7	Cognitive function;
PAAD	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.71	-6.55	-0.47	8.39e-10	Diabetic retinopathy;
PAAD	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg00459043	chr17:30771460	PSMD11	-0.55	-4.52	-0.34	1.26e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.0	-0.59	8.45e-16	Prostate cancer;
PAAD	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.5	5.48	0.41	1.77e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.49	-0.47	1.16e-9	Schizophrenia;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.66	7.46	0.52	6.19e-12	Menarche (age at onset);
PAAD	cis	rs140410685	1	rs140410685	chr1:66118329	GCCT/G	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.07e-5	Age at voice drop;
PAAD	cis	rs2679053	0.534	rs7118770	chr11:43722181	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.25	-0.33	3.7e-5	Coronary artery disease;
PAAD	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	1.12	8.58	0.57	1.02e-14	Mitochondrial DNA levels;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg26398333	chr1:153895721	GATAD2B	0.57	6.47	0.46	1.24e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg08992911	chr2:238395768	MLPH	0.73	5.42	0.4	2.3e-7	Prostate cancer;
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg00105475	chr2:10696890	NA	0.75	8.37	0.56	3.46e-14	Prostate cancer;
PAAD	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.1	9.78	0.62	8.11e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg24179445	chr10:102496915	NA	0.53	5.58	0.41	1.09e-7	Alzheimer's disease;
PAAD	cis	rs7191439	0.589	rs12709104	chr16:88757940	G/A	cg02389323	chr16:88786976	FAM38A	0.74	4.27	0.33	3.45e-5	Plateletcrit;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.75	0.36	4.59e-6	Height;
PAAD	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.8	-6.78	-0.48	2.5e-10	Alzheimer's disease;
PAAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.51	-0.47	1.06e-9	Aortic root size;
PAAD	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.51	-5.0	-0.38	1.59e-6	Menarche (age at onset);
PAAD	cis	rs6460942	0.749	rs79221452	chr7:12202897	T/C	cg20607287	chr7:12443886	VWDE	-0.68	-4.59	-0.35	9.3e-6	Coronary artery disease;
PAAD	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg27236539	chr20:62289627	RTEL1	-0.56	-4.58	-0.35	9.67e-6	Atopic dermatitis;
PAAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs7631605	0.905	rs7649344	chr3:37006396	C/T	cg17445812	chr3:36986805	TRANK1	-0.34	-4.63	-0.35	7.87e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01585852	chr22:24235823	MIF	0.47	5.07	0.38	1.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11250714	0.922	rs4880903	chr10:1695419	G/A	cg10435618	chr10:838112	NA	-0.49	-4.57	-0.35	1.01e-5	Gut microbiome composition (summer);
PAAD	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.74	-8.46	-0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10907941	chr6:13574842	SIRT5	-0.54	-6.41	-0.46	1.71e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs427941	0.632	rs201475	chr7:101745883	G/T	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.14	0.64	8.75e-19	Bladder cancer;
PAAD	cis	rs4919087	0.590	rs7915926	chr10:99054052	C/T	cg10374248	chr10:99083645	NA	0.5	4.47	0.34	1.55e-5	Monocyte count;
PAAD	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg04165759	chr1:150448943	RPRD2	0.49	5.01	0.38	1.5e-6	Migraine;
PAAD	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.98e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.39	-4.34	-0.33	2.57e-5	Prostate cancer;
PAAD	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.35e-13	Coronary artery disease;
PAAD	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.92	11.18	0.67	1.44e-21	Schizophrenia;
PAAD	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.4	-4.74	-0.36	4.78e-6	Blood protein levels;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.71	-7.21	-0.5	2.43e-11	DNA methylation (variation);
PAAD	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.46	5.27	0.39	4.66e-7	HIV-1 susceptibility;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.47e-6	Cognitive function;
PAAD	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-7.57	-0.52	3.27e-12	Migraine;Coronary artery disease;
PAAD	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	7.13	0.5	3.7e-11	Colorectal cancer;
PAAD	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-6.91	-0.49	1.26e-10	Platelet count;
PAAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	9.2	0.6	2.62e-16	Height;
PAAD	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-10.32	-0.64	2.96e-19	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.65	7.02	0.49	6.96e-11	Menarche (age at onset);
PAAD	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.15	15.96	0.79	2.7e-34	Exhaled nitric oxide output;
PAAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.66	6.77	0.48	2.61e-10	Permanent tooth development;
PAAD	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg17308606	chr9:130706144	FAM102A	-0.48	-4.54	-0.35	1.13e-5	Glaucoma (primary angle closure);
PAAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00290607	chr11:67383545	NA	-0.57	-5.61	-0.41	9.45e-8	Mean corpuscular volume;
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.59	7.21	0.5	2.52e-11	Monobrow;
PAAD	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg02961798	chr16:67687392	RLTPR	-0.39	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg13918804	chr1:2043761	PRKCZ	0.43	5.91	0.43	2.21e-8	Height;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg07454742	chr17:42254645	ASB16;C17orf65	-0.4	-4.33	-0.33	2.68e-5	Total body bone mineral density;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.52	-5.37	-0.4	2.88e-7	Testicular germ cell tumor;
PAAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-4.67	-0.35	6.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.85	9.34	0.6	1.12e-16	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.88	-0.43	2.48e-8	Mood instability;
PAAD	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.47	-4.83	-0.36	3.28e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	7.13	0.5	3.7e-11	Colorectal cancer;
PAAD	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg09659197	chr4:152720779	NA	0.36	5.28	0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.87	7.49	0.52	5.26e-12	Recombination rate (females);
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs7136716	0.541	rs12296276	chr12:7773839	G/A	cg25757697	chr12:8220002	C3AR1	-0.86	-4.37	-0.33	2.32e-5	Hematological and biochemical traits;
PAAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg19630374	chr17:18023558	MYO15A	-0.55	-5.93	-0.43	1.93e-8	Total body bone mineral density;
PAAD	cis	rs721399	0.719	rs4646257	chr8:18262546	A/G	cg18736775	chr8:18248649	NAT2	0.7	6.29	0.45	3.21e-9	Blood metabolite levels;
PAAD	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-10.19	-0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg09796270	chr17:17721594	SREBF1	-0.51	-5.63	-0.42	8.29e-8	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg04315214	chr1:2043799	PRKCZ	-0.47	-5.67	-0.42	7.11e-8	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.57	0.41	1.14e-7	Personality dimensions;
PAAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg10547527	chr2:198650123	BOLL	-0.73	-5.1	-0.38	1e-6	Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12773217	chr14:74040239	ACOT2	-0.5	-6.33	-0.46	2.63e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.47	-0.41	1.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.57	-6.78	-0.48	2.49e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-7.52	-0.52	4.34e-12	Menarche (age at onset);
PAAD	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.49	-4.91	-0.37	2.32e-6	Motion sickness;
PAAD	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs32793	0.590	rs161547	chr5:32077328	A/G	cg21579912	chr5:32710815	NPR3	-0.54	-4.61	-0.35	8.47e-6	Myocardial infarction;
PAAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg14343924	chr8:8086146	FLJ10661	0.54	4.92	0.37	2.18e-6	Mood instability;
PAAD	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.66	-8.28	-0.56	5.74e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-5.03	-0.38	1.39e-6	Type 2 diabetes;
PAAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg05313129	chr8:58192883	C8orf71	-0.44	-4.26	-0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg26205652	chr12:48591994	NA	0.76	6.94	0.49	1.04e-10	Longevity (90 years and older);
PAAD	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4704187	0.687	rs4361493	chr5:74405097	A/G	cg03227963	chr5:74354835	NA	0.52	5.14	0.38	8.47e-7	Response to amphetamines;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg12705353	chr12:122356852	WDR66	0.46	4.87	0.37	2.79e-6	Mean corpuscular volume;
PAAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.85	-0.49	1.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg20913747	chr6:44695427	NA	-0.63	-7.15	-0.5	3.46e-11	Total body bone mineral density;
PAAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Gut microbiome composition (summer);
PAAD	cis	rs246395	1.000	rs246395	chr5:149499672	C/T	cg01948229	chr5:150138087	DCTN4	-0.5	-4.54	-0.35	1.15e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6466055	0.777	rs3779210	chr7:104828098	C/T	cg04380332	chr7:105027541	SRPK2	-0.64	-7.21	-0.5	2.51e-11	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06145909	chr2:70351425	LOC100133985	-0.71	-6.37	-0.46	2.15e-9	Neuroticism;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg17650747	chr5:1873721	NA	0.43	4.39	0.34	2.1e-5	Cardiovascular disease risk factors;
PAAD	cis	rs8037137	0.915	rs60290423	chr15:91529452	T/C	cg23684204	chr15:91497937	RCCD1	0.74	4.66	0.35	6.85e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs57786342	0.851	rs2164627	chr14:69268010	C/G	cg03189333	chr14:69283534	NA	-0.62	-4.44	-0.34	1.73e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12550646	0.625	rs1549064	chr8:41684488	A/C	cg12180191	chr8:41686706	ANK1	-0.46	-4.8	-0.36	3.81e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.72	4.83	0.36	3.28e-6	Lung cancer in ever smokers;
PAAD	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.87	7.42	0.52	7.65e-12	Gastritis;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.9	-7.55	-0.52	3.82e-12	Alzheimer's disease;
PAAD	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg05528293	chr18:74961138	GALR1	0.56	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06089497	chr3:42696574	ZBTB47	0.64	6.29	0.45	3.2e-9	Obesity-related traits;
PAAD	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg27182923	chr3:123129387	ADCY5	0.62	4.43	0.34	1.79e-5	LDL cholesterol levels;
PAAD	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg13515842	chr9:127215440	GPR144	0.44	4.76	0.36	4.41e-6	Menarche (age at onset);
PAAD	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.59	5.89	0.43	2.33e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.74	7.54	0.52	4e-12	Tonsillectomy;
PAAD	trans	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg20379984	chr12:95415152	NR2C1	-0.54	-6.54	-0.47	8.91e-10	Cancer;
PAAD	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.58	-0.35	9.77e-6	Testicular germ cell tumor;
PAAD	cis	rs72960926	0.744	rs11758445	chr6:74979953	T/A	cg03266952	chr6:74778945	NA	-1.2	-6.6	-0.47	6.3e-10	Metabolite levels (MHPG);
PAAD	cis	rs8025118	0.583	rs7166813	chr15:79549205	C/T	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.27	-0.33	3.36e-5	Cognitive function;
PAAD	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg10168330	chr8:27262164	PTK2B	0.36	4.28	0.33	3.24e-5	Neuroticism;
PAAD	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg14346243	chr4:90757452	SNCA	-0.46	-4.28	-0.33	3.36e-5	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04027446	chr6:74230918	EEF1A1	0.69	7.48	0.52	5.63e-12	Myopia (pathological);
PAAD	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg16898833	chr6:26189333	HIST1H4D	0.48	4.33	0.33	2.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg02743256	chr7:2109353	MAD1L1	-0.54	-4.26	-0.33	3.6e-5	Bipolar disorder;
PAAD	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg24675658	chr1:53192096	ZYG11B	-0.51	-4.85	-0.37	3.08e-6	Monocyte count;
PAAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg01503450	chr10:980765	NA	-0.56	-4.92	-0.37	2.27e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs16857609	0.564	rs13425215	chr2:218288580	A/G	cg15335768	chr2:218268053	DIRC3	-0.48	-5.09	-0.38	1.03e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.25	-0.45	3.84e-9	Alcohol dependence;
PAAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg10494973	chr17:80897199	TBCD	0.53	4.31	0.33	2.93e-5	Breast cancer;
PAAD	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg12183467	chr14:104352244	NA	-0.42	-4.78	-0.36	4.16e-6	Bipolar disorder;
PAAD	cis	rs1075265	0.597	rs10490471	chr2:53996583	G/C	cg04546899	chr2:54196757	PSME4	0.3	4.27	0.33	3.41e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs7260598	0.539	rs11665842	chr19:24094648	C/T	cg09235885	chr19:23456588	NA	-0.63	-4.31	-0.33	2.97e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.12	-0.38	9.03e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9815354	1.000	rs7631057	chr3:41817951	C/T	cg03022575	chr3:42003672	ULK4	0.81	6.09	0.44	8.9e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.83	10.13	0.63	9.25e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs10261878	0.826	rs11970922	chr7:26013689	C/T	cg01322214	chr7:25219198	C7orf31	1.03	4.29	0.33	3.2e-5	Body mass index;
PAAD	cis	rs4668356	0.687	rs73017289	chr2:172048823	G/A	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs990171	1.000	rs11694658	chr2:103045020	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.8e-5	Lymphocyte counts;
PAAD	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.34	-4.55	-0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs6084875	0.733	rs6052854	chr20:4742399	A/G	cg05143360	chr20:4741328	NA	0.48	4.38	0.33	2.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26876637	chr1:152193138	HRNR	-0.85	-6.69	-0.48	4e-10	Atopic dermatitis;
PAAD	cis	rs1329189	1.000	rs10764764	chr10:130003737	C/T	cg17972361	chr10:130010134	NA	-0.48	-4.89	-0.37	2.49e-6	Orofacial clefts;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.59	-0.35	9.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.74	0.48	3.09e-10	Obesity-related traits;
PAAD	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.32	-0.33	2.78e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.67	5.96	0.44	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs10512697	0.655	rs58175286	chr5:3495842	G/C	cg19473799	chr5:3511975	NA	-1.06	-4.65	-0.35	7.02e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.61	-8.78	-0.58	3.23e-15	Huntington's disease progression;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.73	0.42	5.15e-8	Alzheimer's disease;
PAAD	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.4	-0.34	2.02e-5	Metabolite levels;
PAAD	cis	rs7766436	0.922	rs11753523	chr6:22602094	G/A	cg13666174	chr6:22585274	NA	-0.56	-5.37	-0.4	2.89e-7	Coronary artery disease;
PAAD	cis	rs2882667	0.690	rs288016	chr5:138194988	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.65	-0.42	7.55e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.62	-0.47	5.77e-10	Systolic blood pressure;
PAAD	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg05299278	chr17:33885742	SLFN14	-0.44	-5.2	-0.39	6.43e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg00086871	chr4:6988644	TBC1D14	1.17	5.31	0.4	3.79e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.52	-4.97	-0.37	1.76e-6	Daytime sleep phenotypes;
PAAD	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.58	-6.42	-0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs727479	0.545	rs10851499	chr15:51537127	G/C	cg21478137	chr15:51532386	CYP19A1	0.63	7.23	0.51	2.22e-11	Estradiol levels;
PAAD	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg11247378	chr22:39784982	NA	-0.69	-7.05	-0.5	5.91e-11	IgG glycosylation;
PAAD	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.6	-5.44	-0.4	2.05e-7	Multiple myeloma;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05296608	chr10:134537282	INPP5A	0.63	6.51	0.47	1.05e-9	Warfarin maintenance dose;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.66	7.44	0.52	7.03e-12	Iron status biomarkers;
PAAD	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg19000871	chr14:103996768	TRMT61A	-0.48	-4.98	-0.37	1.74e-6	Reticulocyte count;
PAAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.93	-8.82	-0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.38	0.34	2.16e-5	Multiple sclerosis;
PAAD	cis	rs1419980	0.730	rs11054896	chr12:7774131	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-5.99	-0.44	1.44e-8	Coronary artery disease;
PAAD	cis	rs17095355	0.636	rs3862007	chr10:111762935	G/C	cg00817464	chr10:111662876	XPNPEP1	0.68	4.98	0.37	1.73e-6	Biliary atresia;
PAAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11157016	chr6:157528657	ARID1B	-0.65	-6.87	-0.49	1.56e-10	Obesity-related traits;
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.75	-11.92	-0.7	1.53e-23	Body mass index;
PAAD	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg14196790	chr5:131705035	SLC22A5	0.57	6.4	0.46	1.79e-9	Blood metabolite levels;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg21698718	chr17:80085957	CCDC57	0.47	5.36	0.4	3.09e-7	Life satisfaction;
PAAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.68	9.9	0.63	3.82e-18	Height;
PAAD	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg00976097	chr5:421733	AHRR	-0.63	-5.62	-0.41	8.87e-8	Cystic fibrosis severity;
PAAD	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.9	-8.76	-0.58	3.67e-15	Exhaled nitric oxide output;
PAAD	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg04607699	chr11:48328132	OR4S1	0.52	4.91	0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.91	8.89	0.59	1.61e-15	Exhaled nitric oxide output;
PAAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.87	10.19	0.64	6.65e-19	Coronary artery disease;
PAAD	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg20302533	chr7:39170763	POU6F2	0.35	5.03	0.38	1.38e-6	IgG glycosylation;
PAAD	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs10949834	0.540	rs810552	chr7:73489298	A/G	cg07137043	chr7:73588983	EIF4H	0.46	4.31	0.33	2.95e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.85	10.27	0.64	4.13e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.52	5.07	0.38	1.12e-6	High light scatter reticulocyte count;
PAAD	cis	rs3736485	0.934	rs28695624	chr15:51874928	A/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02326328	chr3:183967536	ALG3;ECE2	0.66	6.66	0.48	4.63e-10	Obesity-related traits;
PAAD	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-6.35	-0.46	2.37e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	9.88e-6	Educational attainment (years of education);
PAAD	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.71	-0.36	5.59e-6	Blood pressure;
PAAD	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.84	-10.37	-0.64	2.2e-19	Dental caries;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00628130	chr8:95908808	CCNE2	-0.59	-7.07	-0.5	5.18e-11	Body fat percentage;
PAAD	cis	rs7714584	1.000	rs76872831	chr5:150171559	A/G	cg22134413	chr5:150180641	NA	0.95	6.45	0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs8070740	0.898	rs4578712	chr17:5324431	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.75	0.36	4.6e-6	Menopause (age at onset);
PAAD	cis	rs6785206	0.554	rs3772158	chr3:128516142	A/C	cg19205850	chr3:128446370	RAB7A	0.67	5.15	0.39	7.95e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg05333889	chr7:157238977	NA	-0.43	-4.52	-0.34	1.24e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	cis	rs4908768	0.555	rs55939938	chr1:8863664	A/T	cg00590817	chr1:8272081	NA	-0.39	-4.8	-0.36	3.78e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.52	-5.55	-0.41	1.23e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg06792262	chr3:44622596	ZNF167	-0.4	-4.3	-0.33	3.07e-5	Depressive symptoms;
PAAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.65	-5.85	-0.43	2.9e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs7640424	0.649	rs13094403	chr3:107930210	G/T	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.5	4.56	0.35	1.04e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs901683	1.000	rs33997730	chr10:46068113	G/A	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg24737193	chr18:12778029	NA	0.63	5.58	0.41	1.09e-7	Inflammatory skin disease;
PAAD	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg02376097	chr19:46275166	DMPK	-0.59	-5.83	-0.43	3.26e-8	Coronary artery disease;
PAAD	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.48	0.57	1.79e-14	Menarche (age at onset);
PAAD	cis	rs2120243	0.874	rs9868133	chr3:157151461	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	5.6	0.41	9.96e-8	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25809561	chr17:30822961	MYO1D	-0.55	-5.7	-0.42	6.11e-8	Schizophrenia;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg07313626	chr1:247681931	NA	0.51	5.64	0.42	8.16e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4746818	0.643	rs2855020	chr10:70856510	C/T	cg11621586	chr10:70884670	VPS26A	0.84	6.52	0.47	9.69e-10	Left atrial antero-posterior diameter;
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.93	15.34	0.78	1.11e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.51	4.69	0.36	6.12e-6	Dental caries;
PAAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.44	-4.27	-0.33	3.48e-5	Chronic sinus infection;
PAAD	trans	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.35	-0.46	2.33e-9	Mean corpuscular volume;
PAAD	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg24634471	chr8:143751801	JRK	-0.49	-4.58	-0.35	9.71e-6	Urinary tract infection frequency;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.97	9.89	0.63	4.21e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7101378	0.577	rs2136533	chr11:108900072	G/A	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs6782025	0.837	rs1523507	chr3:120719950	C/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.77	8.86	0.58	2.01e-15	Type 2 diabetes;
PAAD	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg17470449	chr10:769945	NA	0.51	4.79	0.36	3.85e-6	Uric acid levels;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg04844267	chr4:1394941	NA	0.52	5.53	0.41	1.33e-7	Obesity-related traits;
PAAD	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.86	-0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg12310025	chr6:25882481	NA	0.45	4.45	0.34	1.64e-5	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.47	0.61	5.23e-17	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-16.83	-0.81	1.55e-36	Prudent dietary pattern;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.8	-8.26	-0.56	6.54e-14	Menopause (age at onset);
PAAD	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.7	7.69	0.53	1.72e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.79	-8.4	-0.56	2.99e-14	Prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07152487	chr11:14665355	PDE3B;PSMA1	-0.78	-6.87	-0.49	1.55e-10	Neuroticism;
PAAD	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.25	0.6	1.95e-16	Total body bone mineral density;
PAAD	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.16e-5	Breast cancer;
PAAD	cis	rs12096438	1.000	rs12096438	chr1:25889422	C/T	cg06359931	chr1:25893405	LDLRAP1	-0.36	-4.33	-0.33	2.72e-5	Platelet count;Mean platelet volume;
PAAD	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.79	8.12	0.55	1.5e-13	Retinal vascular caliber;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg26174226	chr8:58114915	NA	-0.56	-4.41	-0.34	1.97e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.94	6.63	0.47	5.52e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.92	-0.37	2.25e-6	Body mass index;
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg07153921	chr17:41440717	NA	-0.41	-4.3	-0.33	3.05e-5	Menopause (age at onset);
PAAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.51	4.83	0.36	3.31e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.75	5.68	0.42	6.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.79	-0.48	2.35e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg19630374	chr17:18023558	MYO15A	-0.45	-4.82	-0.36	3.5e-6	Total body bone mineral density;
PAAD	cis	rs2627282	0.569	rs13281773	chr8:2766018	A/T	cg21769514	chr8:2743697	NA	0.52	5.05	0.38	1.26e-6	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.45	-0.34	1.66e-5	Sarcoidosis;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.98	13.02	0.73	1.63e-26	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg03959625	chr15:84868606	LOC388152	-0.41	-4.39	-0.34	2.12e-5	P wave terminal force;
PAAD	cis	rs8050755	0.649	rs45477195	chr16:2115481	C/T	cg04515572	chr16:2107413	TSC2	-1.12	-7.1	-0.5	4.38e-11	Major depressive disorder;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.08e-11	Life satisfaction;
PAAD	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	5.38	0.4	2.73e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs62179067	0.708	rs12474600	chr2:179884886	G/A	cg13380624	chr19:7735426	NA	-0.73	-6.96	-0.49	9.73e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.73	-4.84	-0.37	3.16e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.45	5.83	0.43	3.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.8	-6.65	-0.47	4.93e-10	Pancreatic cancer;
PAAD	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.78e-6	Migraine;
PAAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.23	0.51	2.21e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.51	-0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.59e-8	Height;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg17372657	chr7:1216933	NA	-0.34	-4.27	-0.33	3.37e-5	Longevity;Endometriosis;
PAAD	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg26929925	chr5:138714136	SLC23A1	0.55	5.29	0.39	4.23e-7	Esophageal squamous cell carcinoma;
PAAD	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.36	4.76	0.36	4.5e-6	Mean corpuscular volume;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07677032	chr17:61819896	STRADA	-0.51	-5.02	-0.38	1.4e-6	Prudent dietary pattern;
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	4.62	0.35	7.96e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9462846	0.853	rs7747505	chr6:42839062	A/G	cg13397359	chr6:42928475	GNMT	0.56	4.67	0.35	6.49e-6	Blood protein levels;
PAAD	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.77	-0.36	4.34e-6	Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.58	-4.64	-0.35	7.48e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22590775	chr19:49891494	CCDC155	0.67	5.38	0.4	2.79e-7	Multiple sclerosis;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.89	-7.29	-0.51	1.57e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.95	-7.44	-0.52	6.96e-12	Multiple sclerosis;
PAAD	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg04844267	chr4:1394941	NA	-0.4	-4.58	-0.35	9.55e-6	Obesity-related traits;
PAAD	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.44	0.46	1.48e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg13468214	chr4:1046988	NA	-0.5	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.03	-0.55	2.48e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20350165	chr7:140405191	NDUFB2	0.56	6.4	0.46	1.81e-9	Body fat percentage;
PAAD	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.35	9.45	0.61	5.97e-17	Diabetic retinopathy;
PAAD	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg02023728	chr11:77925099	USP35	0.44	4.54	0.35	1.14e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00166722	chr3:10149974	C3orf24	0.83	7.0	0.49	7.85e-11	Alzheimer's disease;
PAAD	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg09667013	chr22:42394590	WBP2NL	0.52	5.1	0.38	9.87e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.5	5.51	0.41	1.48e-7	Menarche (age at onset);
PAAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.71	5.85	0.43	2.85e-8	Schizophrenia;
PAAD	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.6	5.85	0.43	2.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	1.36	7.1	0.5	4.51e-11	Skin colour saturation;
PAAD	cis	rs501120	1.000	rs518594	chr10:44757107	T/C	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6466055	0.669	rs2299304	chr7:104771857	T/C	cg04380332	chr7:105027541	SRPK2	-0.62	-7.01	-0.49	7.35e-11	Schizophrenia;
PAAD	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg12661370	chr5:149340060	SLC26A2	0.64	5.52	0.41	1.4e-7	HIV-1 control;
PAAD	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg26816564	chr1:7831052	VAMP3	-0.61	-4.88	-0.37	2.62e-6	Inflammatory bowel disease;
PAAD	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-4.85	-0.37	2.99e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.44	-0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs77956314	0.711	rs4767492	chr12:117436861	C/T	cg02017074	chr12:117425053	FBXW8	1.04	5.43	0.4	2.17e-7	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs501120	0.866	rs607609	chr10:44750209	T/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11264213	0.901	rs10796876	chr1:36424985	A/G	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12795368	chr11:57103544	SSRP1	0.61	6.77	0.48	2.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.72	10.96	0.66	5.66e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.45	-4.73	-0.36	5.18e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.33	0.33	2.7e-5	Tonsillectomy;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.94	0.37	2.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6137287	0.781	rs6035788	chr20:21121739	C/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.43	0.34	1.77e-5	Height;
PAAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.67	6.65	0.47	4.93e-10	Schizophrenia;
PAAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.96	8.63	0.57	7.65e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs375066	0.592	rs349050	chr19:44301425	G/A	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer;
PAAD	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-6.21	-0.45	4.94e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27068297	chr22:50451975	IL17REL	0.43	4.26	0.33	3.5e-5	Ulcerative colitis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10243591	chr14:21656260	NA	0.54	6.61	0.47	5.98e-10	Body fat percentage;
PAAD	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.45	-0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27537692	chr8:8836977	NA	0.57	6.42	0.46	1.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.09	13.41	0.74	1.44e-27	Colorectal cancer;
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1419980	0.558	rs11054595	chr12:7731726	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.42	-4.59	-0.35	9.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.69	7.2	0.5	2.57e-11	Osteoporosis;
PAAD	trans	rs3131082	1	rs3131082	chr6:28983274	G/C	cg06606381	chr12:133084897	FBRSL1	-1.45	-9.47	-0.61	5.32e-17	Tuberculosis;
PAAD	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	7.68	0.53	1.83e-12	Inflammatory bowel disease;
PAAD	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.79	0.53	9.57e-13	Morning vs. evening chronotype;
PAAD	cis	rs593531	0.504	rs4944041	chr11:74029859	C/T	cg23327896	chr11:73669290	DNAJB13	0.33	4.44	0.34	1.73e-5	Neuroticism;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.5	-4.27	-0.33	3.41e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.47	-0.34	1.49e-5	Glomerular filtration rate;
PAAD	cis	rs72960926	0.744	rs1931272	chr6:74950681	C/T	cg03266952	chr6:74778945	NA	-1.2	-6.59	-0.47	6.77e-10	Metabolite levels (MHPG);
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg07777115	chr5:623756	CEP72	-0.5	-4.45	-0.34	1.68e-5	Cystic fibrosis severity;
PAAD	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Blood protein levels;
PAAD	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-4.99	-0.38	1.6e-6	Height;
PAAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18181496	chr7:107642539	LAMB1	0.43	4.33	0.33	2.74e-5	Ulcerative colitis;
PAAD	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg06569542	chr10:98946673	SLIT1	-0.53	-5.86	-0.43	2.84e-8	Monocyte count;
PAAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06629337	chr2:208424151	CREB1	-0.57	-6.84	-0.49	1.8e-10	Monocyte percentage of white cells;
PAAD	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.72e-6	Height;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.31	5.96	0.44	1.66e-8	Skin colour saturation;
PAAD	cis	rs4740619	0.689	rs10738419	chr9:15956824	C/G	cg14451791	chr9:16040625	NA	-0.4	-4.73	-0.36	5.11e-6	Body mass index;
PAAD	cis	rs9815354	0.680	rs73073301	chr3:42028777	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26224664	chr14:101693935	NA	-0.66	-7.46	-0.52	6.23e-12	Body mass index (alcohol intake interaction);
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.56	-4.89	-0.37	2.58e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg11949866	chr1:10754891	CASZ1	0.5	4.32	0.33	2.79e-5	Ewing sarcoma;
PAAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg15181151	chr6:150070149	PCMT1	0.53	5.75	0.42	4.8e-8	Lung cancer;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg03825332	chr11:128760497	KCNJ5	0.58	6.38	0.46	2.01e-9	Iris heterochromicity;
PAAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg24733560	chr20:60626293	TAF4	0.53	7.01	0.49	7.32e-11	Body mass index;
PAAD	cis	rs7714584	1.000	rs10463310	chr5:150260905	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg04520793	chr17:42248056	ASB16	-0.47	-6.43	-0.46	1.52e-9	Total body bone mineral density;
PAAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	1.16	9.63	0.62	2.01e-17	Initial pursuit acceleration;
PAAD	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.69	4.3	0.33	3e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.57	5.56	0.41	1.19e-7	Systemic lupus erythematosus;
PAAD	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.62	-7.2	-0.5	2.66e-11	Height;
PAAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.7	-8.06	-0.55	2.06e-13	Diastolic blood pressure;
PAAD	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg04721828	chr11:48285200	OR4X1	0.46	5.94	0.43	1.83e-8	Migraine - clinic-based;
PAAD	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs4704187	0.663	rs4704189	chr5:74487375	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs6137287	0.924	rs6082339	chr20:21152742	G/A	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.38	9.43	0.61	6.68e-17	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg03315344	chr16:75512273	CHST6	-0.58	-4.81	-0.36	3.55e-6	Advanced age-related macular degeneration;
PAAD	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg15595755	chr5:1867978	NA	0.45	4.54	0.35	1.15e-5	Cardiovascular disease risk factors;
PAAD	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.79	-8.16	-0.55	1.17e-13	Cognitive function;
PAAD	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg12486944	chr17:80159399	CCDC57	0.5	4.46	0.34	1.61e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg17724175	chr1:150552817	MCL1	-0.51	-5.76	-0.42	4.47e-8	Tonsillectomy;
PAAD	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.8	-8.89	-0.58	1.65e-15	Prostate cancer;
PAAD	cis	rs4605213	0.528	rs17574887	chr17:49332744	G/A	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.37	-4.67	-0.35	6.51e-6	Height;
PAAD	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg02997394	chr19:33096574	ANKRD27	-0.44	-4.85	-0.37	3e-6	Schizophrenia;
PAAD	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg16964102	chr10:135390573	NA	0.43	4.61	0.35	8.37e-6	Obesity-related traits;
PAAD	cis	rs73416724	1.000	rs76649578	chr6:43388024	A/G	cg26312998	chr6:43337775	ZNF318	0.69	5.76	0.42	4.59e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg01631408	chr1:248437212	OR2T33	0.6	5.52	0.41	1.45e-7	Common traits (Other);
PAAD	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.5	-8.74	-0.58	3.95e-15	Atopic dermatitis;
PAAD	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.46	5.99	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11677203	1.000	rs12990104	chr2:12564429	G/A	cg01444004	chr2:11726968	GREB1	0.45	4.26	0.33	3.61e-5	Electroencephalogram traits;
PAAD	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.6	5.8	0.43	3.68e-8	Schizophrenia;
PAAD	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.86	-0.43	2.78e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.92	0.37	2.2e-6	Birth weight;
PAAD	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.76	5.85	0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.61	4.55	0.35	1.11e-5	Neuroblastoma;
PAAD	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-6.31	-0.46	2.93e-9	Testicular germ cell tumor;
PAAD	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg17401720	chr7:158221031	PTPRN2	0.46	4.84	0.37	3.18e-6	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg18850127	chr7:39170497	POU6F2	-0.43	-5.87	-0.43	2.65e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg21823605	chr1:152486609	CRCT1	0.52	6.58	0.47	6.99e-10	Hair morphology;
PAAD	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09065629	chr16:1709722	CRAMP1L	0.48	5.24	0.39	5.27e-7	Coronary artery disease;
PAAD	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.74	-8.8	-0.58	2.79e-15	Body mass index;
PAAD	cis	rs4455778	0.600	rs4282517	chr7:49115450	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.52	-5.09	-0.38	1.06e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.51	-4.79	-0.36	3.91e-6	Endometrial cancer;
PAAD	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.5	-5.62	-0.41	8.78e-8	Educational attainment;
PAAD	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.47	5.19	0.39	6.69e-7	Heart rate;
PAAD	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs1006703	0.544	rs8068362	chr17:3838757	T/C	cg06463185	chr17:3833770	ATP2A3	-0.87	-7.14	-0.5	3.55e-11	Glucose homeostasis traits;
PAAD	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20651681	chr7:50861418	GRB10	-0.56	-6.47	-0.46	1.3e-9	Body fat percentage;
PAAD	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-8.61	-0.57	8.52e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.4	-5.94	-0.43	1.89e-8	Subjective well-being;
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg24699146	chr1:24152579	HMGCL	0.54	5.76	0.42	4.47e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.56	5.88	0.43	2.57e-8	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs12344124	0.516	rs28495522	chr9:116851682	C/A	cg14124261	chr9:116262291	RGS3	0.46	4.25	0.33	3.65e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.62	6.36	0.46	2.19e-9	Hemoglobin concentration;
PAAD	cis	rs62283056	1.000	rs62283056	chr4:6276630	G/C	cg14416269	chr4:6271139	WFS1	-0.46	-4.33	-0.33	2.66e-5	Cisplatin-induced ototoxicity;
PAAD	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.45	4.62	0.35	7.98e-6	Resting heart rate;
PAAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.31	0.68	6.51e-22	Menopause (age at onset);
PAAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.69	-0.53	1.69e-12	Height;
PAAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.96	-12.55	-0.71	3.07e-25	Height;
PAAD	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs9715521	0.775	rs11931812	chr4:59844473	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.58	0.47	7.27e-10	Schizophrenia;
PAAD	cis	rs12956009	0.518	rs4458096	chr18:44819555	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	4.37	0.33	2.3e-5	Educational attainment (years of education);
PAAD	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.58	5.95	0.43	1.78e-8	Blood protein levels;
PAAD	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg14851346	chr12:38532713	NA	-0.46	-4.36	-0.33	2.43e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg07298985	chr8:22133076	PIWIL2	0.41	4.36	0.33	2.4e-5	Hypertriglyceridemia;
PAAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.13	-0.38	8.73e-7	Initial pursuit acceleration;
PAAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.79	-8.26	-0.56	6.47e-14	Menarche (age at onset);
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg17480646	chr11:65405466	SIPA1	0.9	4.28	0.33	3.25e-5	Height;
PAAD	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.74	-0.36	4.86e-6	Hirschsprung disease;
PAAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-1.13	-12.43	-0.71	6.56e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg20007245	chr22:24372913	LOC391322	0.67	6.58	0.47	7.08e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.44	-0.34	1.72e-5	Systolic blood pressure;
PAAD	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-4.74	-0.36	4.8e-6	Lung cancer;
PAAD	cis	rs2271001	0.508	rs1546329	chr11:19137947	C/A	cg00161556	chr11:19138045	ZDHHC13	0.48	5.23	0.39	5.5e-7	Gut microbiome composition (winter);
PAAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.61	5.84	0.43	3.09e-8	Colorectal cancer;
PAAD	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.967	rs8104290	chr19:44367338	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.78	-0.42	4.15e-8	Breast cancer;
PAAD	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.88	-10.15	-0.64	8.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.65	9.17	0.6	3.13e-16	Height;
PAAD	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.86	10.2	0.64	6.14e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.64	-7.67	-0.53	1.88e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs17152411	0.625	rs12265337	chr10:126618620	G/A	cg07081759	chr10:126330905	FAM53B	-0.4	-4.34	-0.33	2.58e-5	Height;
PAAD	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs2425143	0.908	rs6060605	chr20:34378132	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.28	-0.33	3.28e-5	Blood protein levels;
PAAD	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.54	-4.39	-0.34	2.08e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13006833	0.668	rs2582735	chr2:191143798	T/C	cg27211696	chr2:191398769	TMEM194B	0.45	4.41	0.34	1.95e-5	Urinary metabolites;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs6066835	1.000	rs3746819	chr20:47307934	A/G	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6689305	0.510	rs953019	chr1:100188316	C/T	cg20263826	chr1:100176425	MIR548D1;FRRS1	-0.47	-4.77	-0.36	4.23e-6	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.77	0.53	1.09e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.8	8.6	0.57	9.22e-15	Blood metabolite levels;
PAAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.48	-6.02	-0.44	1.24e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09695851	chr17:3907499	NA	0.56	5.0	0.38	1.58e-6	Type 2 diabetes;
PAAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.11e-17	Rheumatoid arthritis;
PAAD	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg09998033	chr7:158218633	PTPRN2	0.77	8.8	0.58	2.75e-15	Obesity-related traits;
PAAD	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-13.97	-0.75	4.57e-29	Height;
PAAD	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-4.62	-0.35	8.27e-6	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg05110241	chr16:68378359	PRMT7	-1.15	-8.16	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs790123	0.842	rs2650957	chr3:122396097	C/G	cg15604389	chr3:122379662	NA	0.57	6.09	0.44	8.86e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.44	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs2147959	0.883	rs7529055	chr1:228636824	T/G	cg02753203	chr1:228287806	NA	-0.58	-4.64	-0.35	7.51e-6	Adult asthma;
PAAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.7	0.48	3.84e-10	Rheumatoid arthritis;
PAAD	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.84e-15	Coffee consumption (cups per day);
PAAD	cis	rs2211560	0.736	rs12754586	chr1:61286896	A/G	cg00575674	chr1:61314297	NA	-0.51	-4.61	-0.35	8.49e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs686320	0.748	rs580933	chr11:65196884	C/G	cg21890820	chr11:65308645	LTBP3	-0.84	-5.45	-0.4	1.97e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.45e-8	Triglycerides;
PAAD	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10991814	1.000	rs2387099	chr9:93985824	A/G	cg14446406	chr9:93919335	NA	0.5	4.38	0.33	2.21e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs6782025	0.837	rs1699966	chr3:121016031	T/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs4234798	0.500	rs34694340	chr4:7221424	A/C	cg18431297	chr4:7219810	SORCS2	0.46	6.29	0.45	3.25e-9	Insulin-like growth factors;
PAAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg13918804	chr1:2043761	PRKCZ	0.4	5.4	0.4	2.57e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00443788	chr10:1072690	C10orf110;IDI2	-0.61	-6.43	-0.46	1.59e-9	Obesity-related traits;
PAAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-6.1	-0.44	8.44e-9	Monocyte count;
PAAD	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-1.09	-15.29	-0.78	1.48e-32	Breast cancer;
PAAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs12304921	1.000	rs12304878	chr12:51353851	C/T	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs7631605	0.686	rs6550443	chr3:36999582	A/T	cg10333520	chr3:36987040	TRANK1	0.36	4.72	0.36	5.34e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg19752551	chr11:57585705	CTNND1	-0.53	-4.6	-0.35	8.86e-6	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.46	4.5	0.34	1.33e-5	Renal cell carcinoma;
PAAD	cis	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6137287	0.924	rs6047273	chr20:21134799	A/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.45	0.34	1.64e-5	Height;
PAAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.64	6.61	0.47	6e-10	Schizophrenia;
PAAD	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.53e-14	Dupuytren's disease;
PAAD	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.65	-5.98	-0.44	1.52e-8	Multiple myeloma;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg23958373	chr8:599963	NA	-1.19	-8.03	-0.55	2.45e-13	IgG glycosylation;
PAAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.3	-0.4	3.98e-7	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.75	8.22	0.55	8.21e-14	Prostate cancer;
PAAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.51	5.27	0.39	4.7e-7	Corneal astigmatism;
PAAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.86	-0.49	1.64e-10	Testicular germ cell tumor;
PAAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg23887609	chr12:130822674	PIWIL1	0.61	6.02	0.44	1.28e-8	Menopause (age at onset);
PAAD	cis	rs7646881	1.000	rs7646987	chr3:158453442	A/G	cg19483011	chr3:158453295	NA	0.68	5.87	0.43	2.68e-8	Tetralogy of Fallot;
PAAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.89	-0.43	2.36e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg26071806	chr7:100318239	EPO	-0.42	-4.26	-0.33	3.56e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg19847866	chr10:1019161	NA	-0.58	-4.48	-0.34	1.43e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs2278796	0.724	rs2794860	chr1:204968392	A/G	cg04862289	chr1:204966208	NFASC	0.48	4.97	0.37	1.77e-6	Mean platelet volume;
PAAD	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.42	4.81	0.36	3.55e-6	Breast cancer;
PAAD	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.58	6.31	0.46	2.89e-9	Mean corpuscular volume;
PAAD	cis	rs17407555	0.657	rs56346932	chr4:10377032	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.33	-0.33	2.74e-5	Schizophrenia (age at onset);
PAAD	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg13870426	chr17:30244630	NA	0.76	6.26	0.45	3.78e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs12989701	0.877	rs71414738	chr2:127876242	C/T	cg08168897	chr2:127865431	BIN1	0.69	5.9	0.43	2.23e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.28e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15145965	chr22:50218605	BRD1	0.56	4.77	0.36	4.25e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.58	0.41	1.08e-7	Prudent dietary pattern;
PAAD	cis	rs13102973	0.965	rs4469136	chr4:135850051	C/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.76	-0.36	4.51e-6	Eosinophil percentage of white cells;
PAAD	cis	rs375066	0.935	rs426534	chr19:44412583	T/G	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.44	-4.89	-0.37	2.5e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Total body bone mineral density;
PAAD	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg09796270	chr17:17721594	SREBF1	-0.49	-5.55	-0.41	1.27e-7	Total body bone mineral density;
PAAD	cis	rs6689305	0.545	rs9729152	chr1:100241763	C/T	cg22872634	chr1:100462710	SLC35A3	-0.45	-4.35	-0.33	2.52e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Myopia (pathological);
PAAD	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.49	4.61	0.35	8.62e-6	Educational attainment;
PAAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.7	10.23	0.64	5.25e-19	Schizophrenia;
PAAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.85	9.39	0.61	8.51e-17	IgG glycosylation;
PAAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.98e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-5.94	-0.43	1.9e-8	Menarche (age at onset);
PAAD	cis	rs7631605	0.518	rs6777094	chr3:36976926	A/T	cg10333520	chr3:36987040	TRANK1	-0.36	-4.94	-0.37	2e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg19131313	chr8:1704013	NA	-0.38	-4.33	-0.33	2.7e-5	Systolic blood pressure;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.1	-0.5	4.53e-11	Longevity;Endometriosis;
PAAD	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg27588902	chr6:42928151	GNMT	-0.51	-5.77	-0.42	4.35e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18357526	chr6:26021779	HIST1H4A	0.51	4.53	0.34	1.21e-5	Height;
PAAD	cis	rs7180079	1.000	rs7180079	chr15:64629873	A/G	cg18210365	chr15:65066710	RBPMS2	0.65	4.95	0.37	1.91e-6	Monocyte count;
PAAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.54	0.41	1.3e-7	Depression;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.57	6.21	0.45	4.83e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13979800	chr9:140469108	WDR85	-0.72	-7.32	-0.51	1.35e-11	Obesity-related traits;
PAAD	cis	rs8105895	0.935	rs2043315	chr19:22252823	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.64	-7.41	-0.51	8.3e-12	Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.54	5.08	0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs901683	0.850	rs80222863	chr10:46016975	C/T	cg16908948	chr10:45500256	ZNF22	0.79	4.27	0.33	3.44e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.46	-4.75	-0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg05250797	chr16:70222502	NA	0.84	6.38	0.46	1.99e-9	IgE levels;
PAAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg22325292	chr17:80708367	FN3K	0.65	4.45	0.34	1.67e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.27	-0.33	3.49e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7250872	0.578	rs12460105	chr19:1848957	A/G	cg10370574	chr19:1840461	REXO1	-0.51	-4.77	-0.36	4.37e-6	Bipolar disorder;
PAAD	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs17073641	0.500	rs9959681	chr18:62465040	A/G	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg07797805	chr20:25387977	GINS1	-0.37	-4.46	-0.34	1.56e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs75920871	0.925	rs76523703	chr11:116749509	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.79	-4.44	-0.34	1.73e-5	Subjective well-being;
PAAD	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.55	4.95	0.37	1.97e-6	White matter hyperintensity burden;
PAAD	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg11266682	chr4:10021025	SLC2A9	-0.64	-5.93	-0.43	1.96e-8	Schizophrenia (age at onset);
PAAD	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.48	-4.39	-0.34	2.14e-5	Asthma;
PAAD	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-9.14	-0.6	3.84e-16	Body mass index;
PAAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12612619	0.704	rs11680633	chr2:27224209	T/C	cg00617064	chr2:27272375	NA	-0.45	-4.8	-0.36	3.78e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs1198430	0.562	rs10799795	chr1:23773998	C/A	cg24580199	chr1:23763081	ASAP3	0.55	4.79	0.36	4e-6	Total cholesterol levels;
PAAD	cis	rs3809060	0.959	rs2301253	chr11:32457774	G/A	cg27259320	chr11:32460587	WIT1	0.36	4.58	0.35	9.81e-6	Inguinal hernia;
PAAD	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.53	4.98	0.37	1.69e-6	Schizophrenia;
PAAD	cis	rs300774	1.000	rs300781	chr2:110385	G/A	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2412208	0.545	rs7414485	chr1:7121397	G/A	cg20434152	chr1:7120926	CAMTA1	-0.55	-6.36	-0.46	2.27e-9	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.48	4.28	0.33	3.24e-5	Age-related disease endophenotypes;
PAAD	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	1.02	12.42	0.71	6.67e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg00631329	chr6:26305371	NA	-0.49	-4.94	-0.37	2.07e-6	Educational attainment;
PAAD	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.59	5.97	0.44	1.62e-8	Ovarian reserve;
PAAD	cis	rs59104589	0.617	rs3755395	chr2:242294116	A/G	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.72	7.91	0.54	5.03e-13	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.5	5.06	0.38	1.17e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.76	7.25	0.51	1.98e-11	Cognitive function;
PAAD	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.69	5.92	0.43	2.11e-8	Diabetic retinopathy;
PAAD	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17376030	chr22:41985996	PMM1	-0.64	-4.4	-0.34	1.99e-5	Cannabis dependence symptom count;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.46	-0.52	6.17e-12	Hemoglobin concentration;
PAAD	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg08316699	chr6:150357289	NA	0.39	4.35	0.33	2.53e-5	Alopecia areata;
PAAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.44	-4.38	-0.33	2.19e-5	Type 2 diabetes;
PAAD	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs11811982	0.793	rs80313225	chr1:227510751	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.57	-5.22	-0.39	5.86e-7	Monocyte count;
PAAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.81	-10.19	-0.64	6.69e-19	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.28	0.33	3.29e-5	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21809007	chr19:6739524	TRIP10	0.64	6.34	0.46	2.42e-9	Obesity-related traits;
PAAD	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-5.15	-0.39	7.94e-7	Chronic sinus infection;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.61	-0.35	8.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9659323	0.670	rs12095067	chr1:119635733	A/T	cg17326555	chr1:119535693	NA	-0.38	-5.24	-0.39	5.24e-7	Body mass index;
PAAD	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.65	-7.05	-0.5	5.95e-11	Aortic root size;
PAAD	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg07810366	chr2:100720526	AFF3	-0.39	-4.87	-0.37	2.8e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs12620999	0.567	rs4663243	chr2:238102994	A/G	cg23555395	chr2:238036564	NA	-0.52	-5.92	-0.43	2.02e-8	Systemic lupus erythematosus;
PAAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	10.77	0.66	1.87e-20	Menopause (age at onset);
PAAD	cis	rs17155006	0.638	rs2074747	chr7:107744735	G/A	cg05962710	chr7:107745446	LAMB4	-0.54	-7.13	-0.5	3.71e-11	Pneumococcal bacteremia;
PAAD	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.32e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg14019146	chr3:50243930	SLC38A3	-0.53	-4.35	-0.33	2.45e-5	Menarche (age at onset);
PAAD	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01200585	chr1:228362443	C1orf69	-0.49	-5.53	-0.41	1.35e-7	Diastolic blood pressure;
PAAD	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.02	-0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs287982	1.000	rs287981	chr2:9971562	A/G	cg01119585	chr2:10571959	NA	-0.38	-4.39	-0.34	2.08e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.89	0.37	2.5e-6	Lung cancer in ever smokers;
PAAD	cis	rs34599045	0.901	rs12239648	chr1:152879091	A/T	cg07796016	chr1:152779584	LCE1C	-0.91	-4.58	-0.35	9.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.47e-7	Total body bone mineral density;
PAAD	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-6.97	-0.49	9.18e-11	Morning vs. evening chronotype;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg26987697	chr4:47916498	NFXL1	0.58	6.82	0.48	2.07e-10	Alzheimer's disease (survival time);
PAAD	trans	rs3758141	0.858	rs1116017	chr8:18717366	T/C	cg02479022	chr8:22250005	SLC39A14	-1.05	-6.45	-0.46	1.4e-9	Body mass index (change over time) in gastrointestinal cancer;
PAAD	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.71	7.65	0.53	2.1e-12	Menarche (age at onset);
PAAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.61	5.47	0.41	1.8e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.51	4.99	0.37	1.66e-6	Lung cancer;
PAAD	cis	rs4740619	0.869	rs10738406	chr9:15712636	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.42	-0.34	1.89e-5	Body mass index;
PAAD	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.53	-5.32	-0.4	3.57e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12304921	0.935	rs224587	chr12:51397433	T/C	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg02462569	chr6:150064036	NUP43	-0.45	-5.0	-0.38	1.58e-6	Lung cancer;
PAAD	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.52	-5.65	-0.42	7.83e-8	Migraine;
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs4356203	0.905	rs589319	chr11:17202597	G/A	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.28	-0.33	3.34e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.77	5.5	0.41	1.59e-7	Gut microbiome composition (summer);
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.41	0.52	8.13e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	7.37	0.51	1.03e-11	Colorectal cancer;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.68	7.09	0.5	4.71e-11	Cystic fibrosis severity;
PAAD	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg15049549	chr3:48732213	IP6K2	-0.57	-4.54	-0.35	1.15e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2562456	0.833	rs55875743	chr19:21566195	G/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs12476592	0.602	rs7571325	chr2:63785914	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg04165759	chr1:150448943	RPRD2	-0.54	-5.69	-0.42	6.3e-8	Migraine;
PAAD	cis	rs12900413	0.959	rs28430604	chr15:90313782	C/T	cg24249390	chr15:90295951	MESP1	-0.44	-4.26	-0.33	3.54e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.9	10.77	0.66	1.9e-20	Tonsillectomy;
PAAD	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-6.05	-0.44	1.07e-8	Oropharynx cancer;
PAAD	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.34	0.33	2.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9463078	0.803	rs9463083	chr6:45272062	T/G	cg25276700	chr6:44698697	NA	-0.46	-5.32	-0.4	3.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7189233	0.955	rs7189726	chr16:53497774	C/T	cg00221382	chr16:54322308	NA	-0.28	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.48	0.41	1.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.73	-5.99	-0.44	1.49e-8	Neuroticism;
PAAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg10589385	chr1:150898437	SETDB1	0.35	4.32	0.33	2.84e-5	Melanoma;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg10534938	chr5:1868639	NA	0.46	6.06	0.44	1.01e-8	Cardiovascular disease risk factors;
PAAD	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.33	-4.44	-0.34	1.72e-5	Oropharynx cancer;
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.42	-0.46	1.66e-9	Lung cancer;
PAAD	cis	rs7178572	0.568	rs12901297	chr15:77386675	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.32	-0.33	2.77e-5	Type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg09835421	chr16:68378352	PRMT7	-1.1	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg25722041	chr1:8623473	RERE	0.5	4.29	0.33	3.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.7	-7.59	-0.52	2.98e-12	Prudent dietary pattern;
PAAD	cis	rs7567389	0.626	rs11683344	chr2:127956252	A/C	cg11380483	chr2:127933992	NA	0.55	5.15	0.39	7.9e-7	Self-rated health;
PAAD	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-4.46	-0.34	1.59e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.09	-0.55	1.77e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.45	-0.34	1.67e-5	Coronary artery disease;
PAAD	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg17595323	chr11:93583763	C11orf90	-0.35	-4.46	-0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.26	-0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs2415984	0.579	rs1494097	chr14:46960552	T/C	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7577696	0.889	rs212730	chr2:32471673	G/T	cg02381751	chr2:32503542	YIPF4	0.43	4.7	0.36	5.68e-6	Inflammatory biomarkers;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.68	0.36	6.2e-6	Longevity;
PAAD	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg02683114	chr2:24398427	C2orf84	-0.53	-5.19	-0.39	6.52e-7	Asthma;
PAAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg14346243	chr4:90757452	SNCA	-0.5	-4.39	-0.34	2.14e-5	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19655006	chr2:172750994	SLC25A12	0.64	7.3	0.51	1.46e-11	Monocyte percentage of white cells;
PAAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg09324608	chr17:30823087	MYO1D	0.47	4.68	0.36	6.21e-6	Schizophrenia;
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.33	-0.33	2.71e-5	Tonsillectomy;
PAAD	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.87	14.08	0.75	2.37e-29	Coronary artery disease;
PAAD	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.47	4.46	0.34	1.58e-5	Pulse pressure;
PAAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg19592336	chr6:28129416	ZNF389	0.62	4.39	0.34	2.12e-5	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg04254540	chr16:71951199	KIAA0174	-0.58	-5.01	-0.38	1.52e-6	Coronary artery disease;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.58	6.45	0.46	1.43e-9	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.764	rs73599521	chr16:67733322	G/A	cg27539214	chr16:67997921	SLC12A4	-0.67	-4.5	-0.34	1.34e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg14631576	chr9:95140430	CENPP	-0.62	-5.96	-0.44	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.23	-0.64	5.01e-19	Blood trace element (Zn levels);
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg22764044	chr5:178986830	RUFY1	-0.5	-5.3	-0.39	4.01e-7	Lung cancer;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs11264736	0.507	rs1832582	chr1:154025492	G/A	cg06419659	chr1:153600132	S100A13;S100A1	-0.43	-4.35	-0.33	2.47e-5	Lentiform nucleus volume;
PAAD	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Androgen levels;
PAAD	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.43	-4.98	-0.37	1.74e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2016586	0.929	rs4821440	chr22:36114274	T/C	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	6.13	0.45	7.11e-9	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.93	8.9	0.59	1.53e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs7071247	0.915	rs3014205	chr10:105262185	G/A	cg20028483	chr10:104949090	NT5C2	0.67	4.85	0.37	2.97e-6	Platelet aggregation;
PAAD	cis	rs7236492	0.748	rs76617579	chr18:77200655	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-5.64	-0.42	7.88e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9398803	0.624	rs1455739	chr6:126631789	A/T	cg19875578	chr6:126661172	C6orf173	-0.51	-4.81	-0.36	3.57e-6	Male-pattern baldness;
PAAD	cis	rs2290419	0.730	rs79721202	chr11:68941192	T/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg07617317	chr6:118971624	C6orf204	0.54	4.56	0.35	1.04e-5	Diastolic blood pressure;
PAAD	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg16342193	chr10:102329863	NA	-0.79	-8.65	-0.57	6.96e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	6.71	0.48	3.71e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03007208	chr19:36266554	SNX26	0.59	6.64	0.47	5.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.59	5.12	0.38	9.24e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	6.02	0.44	1.26e-8	Lung cancer in ever smokers;
PAAD	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg24241305	chr13:114826075	RASA3	-0.61	-4.68	-0.35	6.41e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-1.17	-9.63	-0.62	2e-17	Obesity-related traits;
PAAD	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.93	-0.37	2.1e-6	High light scatter reticulocyte count;
PAAD	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg22134325	chr11:66188745	NPAS4	0.42	5.17	0.39	7.41e-7	Airway imaging phenotypes;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.5	5.1	0.38	9.88e-7	Lung cancer;
PAAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg11288833	chr15:55489084	RSL24D1	0.58	4.77	0.36	4.21e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26897989	chr16:1907736	C16orf73	-0.52	-4.69	-0.36	6.08e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9287604	1.000	rs10176744	chr2:237778830	A/T	cg15065627	chr2:237796583	NA	-0.53	-4.38	-0.33	2.17e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	1.09	16.58	0.8	6.45e-36	Menarche (age at onset);
PAAD	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.37	-0.4	2.96e-7	Height;
PAAD	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg07159951	chr1:45983175	PRDX1	0.46	5.21	0.39	6.15e-7	High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.83	0.54	7.85e-13	Prudent dietary pattern;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.5	4.85	0.37	2.98e-6	Airway imaging phenotypes;
PAAD	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.46	-5.62	-0.41	8.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.65	-0.35	7.02e-6	Aortic root size;
PAAD	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.79	-8.73	-0.58	4.16e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs914615	0.552	rs4276914	chr1:155142229	G/A	cg18645493	chr1:154167437	MIR190B	0.46	4.52	0.34	1.25e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-1.06	-14.84	-0.77	2.29e-31	Breast cancer;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg17541715	chr7:1216824	NA	-0.46	-5.21	-0.39	6.1e-7	Longevity;Endometriosis;
PAAD	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs3857067	0.550	rs1848795	chr4:95005053	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.23	0.73	4.49e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.62	-5.86	-0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs1570884	0.714	rs2038881	chr13:50135177	A/G	cg03651054	chr13:50194643	NA	0.38	5.32	0.4	3.64e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.69	-0.42	6.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.96	11.8	0.69	3.28e-23	Bone mineral density;
PAAD	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.77	4.31	0.33	2.95e-5	Childhood ear infection;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.55	-5.24	-0.39	5.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg15145965	chr22:50218605	BRD1	-0.55	-4.59	-0.35	9.29e-6	Schizophrenia;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.45	0.61	5.97e-17	Prudent dietary pattern;
PAAD	cis	rs11853189	1.000	rs2867933	chr15:78574787	C/T	cg22935921	chr15:78556834	DNAJA4	-0.78	-5.32	-0.4	3.58e-7	Red cell distribution width;
PAAD	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg02527881	chr3:46936655	PTH1R	0.38	4.47	0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.87	7.8	0.53	9.09e-13	Coronary artery disease;
PAAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.44	6.03	0.44	1.18e-8	Insulin-like growth factors;
PAAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.55	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07677032	chr17:61819896	STRADA	0.52	5.39	0.4	2.6e-7	Prudent dietary pattern;
PAAD	cis	rs12753920	0.775	rs1384613	chr1:92675361	T/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.47	-4.44	-0.34	1.75e-5	Systemic lupus erythematosus;
PAAD	cis	rs7165102	1.000	rs11071846	chr15:65792839	C/T	cg22900193	chr15:65823441	PTPLAD1	-0.47	-4.51	-0.34	1.29e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7922314	0.571	rs61865693	chr10:64730074	G/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs4924935	0.748	rs9915894	chr17:18752778	T/C	cg26306683	chr17:18585705	ZNF286B	0.62	4.58	0.35	9.44e-6	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.86	9.04	0.59	6.68e-16	Corneal astigmatism;
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-7.85	-0.54	7e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.7	6.5	0.47	1.08e-9	Primary sclerosing cholangitis;
PAAD	cis	rs731174	0.559	rs10908375	chr1:38194094	G/C	cg06917450	chr1:38156652	C1orf109	-0.58	-4.96	-0.37	1.85e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.57	-6.52	-0.47	1e-9	Body fat percentage;
PAAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.37	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg02734326	chr4:10020555	SLC2A9	-0.5	-4.95	-0.37	1.98e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg02555727	chr12:129281546	SLC15A4	0.46	4.86	0.37	2.96e-6	Systemic lupus erythematosus;
PAAD	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg00105475	chr2:10696890	NA	-0.63	-6.61	-0.47	6.06e-10	Prostate cancer;
PAAD	cis	rs6460942	0.597	rs10273045	chr7:12519371	T/C	cg06484146	chr7:12443880	VWDE	-0.79	-4.94	-0.37	2.01e-6	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.92	0.54	4.68e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.48	0.57	1.82e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21171335	chr12:122356390	WDR66	0.61	6.51	0.47	1.03e-9	Mean corpuscular volume;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg26138144	chr22:38071188	LGALS1	0.5	5.55	0.41	1.24e-7	Fat distribution (HIV);
PAAD	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs258892	0.895	rs11960081	chr5:72064490	C/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg01267373	chr18:77410094	NA	0.43	4.69	0.36	6.08e-6	Monocyte count;
PAAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg05110241	chr16:68378359	PRMT7	-0.99	-7.82	-0.54	8.36e-13	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07050772	chr17:48423262	XYLT2	0.66	7.09	0.5	4.66e-11	Myopia (pathological);
PAAD	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.32	-0.56	4.61e-14	Mean corpuscular volume;
PAAD	cis	rs16975963	0.843	rs73027451	chr19:38375666	C/T	cg08679971	chr19:38281047	NA	0.5	4.84	0.37	3.22e-6	Longevity;
PAAD	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg08219700	chr8:58056026	NA	-0.74	-4.91	-0.37	2.38e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02656959	chr1:21786446	NBPF3	-0.64	-6.47	-0.46	1.26e-9	Smoking initiation;
PAAD	cis	rs1478897	0.898	rs2248696	chr8:11393803	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.36	-0.33	2.35e-5	Systemic lupus erythematosus;
PAAD	cis	rs1035491	0.715	rs10057925	chr5:63926262	T/G	cg01791865	chr5:63954708	NA	0.52	5.54	0.41	1.28e-7	Body mass index;
PAAD	cis	rs4919087	0.590	rs701821	chr10:99038562	G/A	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-10.36	-0.64	2.37e-19	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.66	0.57	6.44e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.65	-7.39	-0.51	9.32e-12	Iron status biomarkers;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.84	-0.54	7.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.81	-5.48	-0.41	1.71e-7	Red cell distribution width;
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-5.79	-0.43	3.82e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs8077577	0.708	rs3829590	chr17:18134265	C/A	cg03916694	chr17:18150707	FLII	-0.39	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.65	-6.86	-0.49	1.65e-10	Longevity;
PAAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11051970	0.655	rs7298381	chr12:32530257	G/T	cg02745156	chr12:32552066	NA	0.38	4.34	0.33	2.59e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6466055	0.649	rs111563282	chr7:104898327	G/C	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs9322817	0.691	rs2499660	chr6:105285750	T/C	cg02098413	chr6:105308735	HACE1	0.41	5.25	0.39	4.95e-7	Thyroid stimulating hormone;
PAAD	cis	rs375066	0.935	rs432454	chr19:44398831	C/G	cg08633290	chr19:44405433	NA	-0.58	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs7766436	0.767	rs13206434	chr6:22608883	A/G	cg13666174	chr6:22585274	NA	-0.46	-4.66	-0.35	6.97e-6	Coronary artery disease;
PAAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.754	rs58338799	chr19:21521811	G/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg08992911	chr2:238395768	MLPH	0.59	5.64	0.42	8.14e-8	Prostate cancer;
PAAD	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.74	7.31	0.51	1.44e-11	Asthma;
PAAD	cis	rs10821973	0.527	rs4636536	chr10:63979147	C/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.3	-0.33	3.06e-5	Hypothyroidism;
PAAD	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.69	6.59	0.47	6.78e-10	Recombination rate (males);
PAAD	cis	rs2882667	0.690	rs176381	chr5:138196731	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.22	-0.51	2.38e-11	Colorectal cancer;
PAAD	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.71	7.89	0.54	5.61e-13	Longevity;
PAAD	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.8e-7	Resting heart rate;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg17178900	chr1:205818956	PM20D1	0.45	4.37	0.33	2.3e-5	Parkinson's disease;
PAAD	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.91	7.75	0.53	1.24e-12	Triglycerides;
PAAD	cis	rs35160687	0.509	rs13024436	chr2:86534521	G/A	cg10973622	chr2:86423274	IMMT	-0.44	-4.99	-0.38	1.63e-6	Night sleep phenotypes;
PAAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.66	-7.24	-0.51	2.13e-11	Huntington's disease progression;
PAAD	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.67	-7.68	-0.53	1.84e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg27211696	chr2:191398769	TMEM194B	0.44	4.34	0.33	2.55e-5	Urinary metabolites;
PAAD	cis	rs1912528	0.752	rs769665	chr4:140867638	G/A	cg11128457	chr4:140864437	MAML3	-0.32	-4.31	-0.33	2.91e-5	Educational attainment (years of education);
PAAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg27478167	chr7:817139	HEATR2	0.71	5.46	0.41	1.86e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.29	0.39	4.18e-7	Personality dimensions;
PAAD	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-5.23	-0.39	5.62e-7	Morning vs. evening chronotype;
PAAD	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-4.32	-0.33	2.81e-5	Height;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.78e-6	Lung cancer;
PAAD	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg14952266	chr13:112191215	NA	-0.44	-5.05	-0.38	1.25e-6	Hepatitis;
PAAD	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg22029157	chr1:209979665	IRF6	-0.67	-6.13	-0.45	7.36e-9	Coronary artery disease;
PAAD	cis	rs881375	0.501	rs10156413	chr9:123867782	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	5.42	0.4	2.26e-7	Rheumatoid arthritis;
PAAD	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg10006428	chr1:248814059	OR2T27	0.41	4.8	0.36	3.84e-6	Common traits (Other);
PAAD	cis	rs7243821	1.000	rs11664326	chr18:52645462	G/A	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs747650	0.504	rs11039081	chr11:47093465	C/G	cg19486271	chr11:47235900	DDB2	0.68	6.29	0.45	3.26e-9	Acne (severe);
PAAD	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg08390786	chr10:135334061	NA	-0.62	-4.96	-0.37	1.86e-6	Gout;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25843013	chr17:61507284	NA	-0.66	-6.57	-0.47	7.49e-10	Obesity-related traits;
PAAD	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	0.86	5.36	0.4	3.07e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg14393609	chr7:65229607	NA	-0.49	-4.26	-0.33	3.54e-5	Aortic root size;
PAAD	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg04289385	chr6:36355825	ETV7	-0.46	-4.59	-0.35	9.22e-6	Platelet distribution width;
PAAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.46	5.9	0.43	2.31e-8	Psoriasis;
PAAD	trans	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg10523679	chr1:76189770	ACADM	-0.53	-4.98	-0.37	1.72e-6	Daytime sleep phenotypes;
PAAD	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs7765175	0.631	rs9481341	chr6:113664182	G/A	cg19037598	chr6:113666021	NA	-0.42	-4.49	-0.34	1.43e-5	Coronary artery calcification;
PAAD	cis	rs3736485	0.844	rs67524810	chr15:51805291	A/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.21e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.46	5.26	0.39	4.75e-7	Testicular germ cell tumor;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.91	11.77	0.69	3.91e-23	Menarche (age at onset);
PAAD	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg07741184	chr6:167504864	NA	-0.36	-4.76	-0.36	4.48e-6	Primary biliary cholangitis;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg02404636	chr22:31891804	SFI1	-0.6	-5.32	-0.4	3.61e-7	Colorectal cancer;
PAAD	trans	rs1146751	0.674	rs515207	chr3:84926866	A/G	cg17330251	chr7:94953956	PON1	0.69	6.42	0.46	1.63e-9	Photic sneeze reflex;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.63	8.16	0.55	1.17e-13	Hypertriglyceridemia;
PAAD	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg10856724	chr12:34555212	NA	0.42	4.3	0.33	3.09e-5	Morning vs. evening chronotype;
PAAD	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.61	-0.53	2.71e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.17	0.5	3.09e-11	Renal function-related traits (BUN);
PAAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg08439880	chr3:133502540	NA	-0.47	-5.18	-0.39	6.97e-7	Iron status biomarkers;
PAAD	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	4.98e-7	Alzheimer's disease (survival time);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1879734	0.636	rs12043690	chr1:54175629	T/C	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg17524180	chr13:113633600	MCF2L	-0.44	-4.73	-0.36	5.12e-6	Systolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23229228	chr3:98312354	CPOX	0.57	6.44	0.46	1.49e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.58e-13	Eotaxin levels;
PAAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.66	7.96	0.54	3.71e-13	Iron status biomarkers (transferrin levels);
PAAD	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.7	0.36	5.84e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7945718	0.621	rs10831895	chr11:12683327	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg04282723	chr11:975233	AP2A2	-0.64	-6.74	-0.48	3.08e-10	Primary biliary cholangitis;
PAAD	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.47	-0.41	1.77e-7	Metabolite levels;
PAAD	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs1075232	1.000	rs56396205	chr15:31678385	G/A	cg15751117	chr15:30700112	NA	0.94	4.75	0.36	4.59e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg18833306	chr6:118973337	C6orf204	-0.54	-4.45	-0.34	1.62e-5	Diastolic blood pressure;
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs10274279	0.660	rs4716759	chr7:157374986	T/C	cg09270525	chr7:157391030	PTPRN2	0.6	5.61	0.41	9.42e-8	Myopia (pathological);
PAAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.59	-5.46	-0.4	1.94e-7	Breast cancer;Mosquito bite size;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.77	-8.19	-0.55	9.91e-14	Menopause (age at onset);
PAAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.43	5.18	0.39	7.05e-7	Plateletcrit;
PAAD	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.52	5.19	0.39	6.76e-7	Multiple myeloma (IgH translocation);
PAAD	trans	rs901683	0.850	rs79319916	chr10:46073980	C/T	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg21130718	chr4:1044621	NA	0.53	4.57	0.35	1.02e-5	Recombination rate (females);
PAAD	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg26751094	chr13:95954534	ABCC4	-0.46	-4.99	-0.38	1.63e-6	Blood metabolite levels;
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.06	0.44	1.04e-8	Lung cancer;
PAAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.32	0.33	2.81e-5	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11467738	chr7:98972733	ARPC1B	0.69	7.42	0.52	7.55e-12	Myopia (pathological);
PAAD	cis	rs5769765	0.773	rs9616751	chr22:50222236	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.61	-4.27	-0.33	3.4e-5	Schizophrenia;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg13397359	chr6:42928475	GNMT	0.88	10.47	0.65	1.16e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.7	-6.46	-0.46	1.35e-9	Total body bone mineral density;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.54	-5.2	-0.39	6.32e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg26174226	chr8:58114915	NA	-0.66	-5.9	-0.43	2.31e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5009270	0.512	rs1024411	chr7:112247692	G/A	cg25550468	chr7:112262557	NA	0.5	4.55	0.35	1.09e-5	Osteoarthritis (hip);
PAAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	4.84	0.37	3.17e-6	Body mass index;
PAAD	cis	rs493733	0.527	rs689691	chr3:16401146	T/C	cg27252855	chr3:16189891	NA	0.46	4.63	0.35	7.75e-6	Urate levels (BMI interaction);
PAAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.56	7.07	0.5	5.29e-11	Schizophrenia;
PAAD	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.77	8.63	0.57	7.55e-15	Systemic lupus erythematosus;
PAAD	cis	rs5756391	0.546	rs5756405	chr22:37310954	A/G	cg21209356	chr22:37319042	CSF2RB	0.37	4.56	0.35	1.05e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-0.88	-9.56	-0.61	3.06e-17	Body mass index;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03646922	chr17:4167316	ANKFY1	-0.61	-7.08	-0.5	5.11e-11	Body fat percentage;
PAAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.79	9.17	0.6	3.09e-16	Diastolic blood pressure;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg10729496	chr3:10149963	C3orf24	-0.88	-7.43	-0.52	7.16e-12	Alzheimer's disease;
PAAD	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg00982548	chr2:198649783	BOLL	-0.79	-5.67	-0.42	7.11e-8	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02984792	chr7:155365383	NA	0.59	6.44	0.46	1.47e-9	Smoking initiation;
PAAD	cis	rs1421334	0.631	rs62508302	chr8:30831329	T/C	cg00964221	chr8:30240029	NA	0.43	4.28	0.33	3.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.74	10.13	0.63	9.38e-19	Glomerular filtration rate (creatinine);
PAAD	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.44	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-5.24	-0.39	5.37e-7	Daytime sleep phenotypes;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg24699146	chr1:24152579	HMGCL	-0.47	-4.99	-0.37	1.67e-6	Immature fraction of reticulocytes;
PAAD	cis	rs727479	0.502	rs7167936	chr15:51499545	A/G	cg18154567	chr15:51464013	NA	-0.42	-4.35	-0.33	2.49e-5	Estradiol levels;
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.58	-5.45	-0.4	1.99e-7	Menarche (age at onset);
PAAD	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg05341575	chr12:125625032	AACS	-0.5	-4.82	-0.36	3.43e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg03004497	chr11:58874207	FAM111B	-0.52	-4.39	-0.34	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24891414	chr2:175436409	WIPF1	-0.65	-6.84	-0.49	1.8e-10	Obesity-related traits;
PAAD	cis	rs8099014	1.000	rs6566970	chr18:56122507	A/G	cg12907477	chr18:56117327	MIR122	0.53	4.4	0.34	1.99e-5	Platelet count;
PAAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26973953	chr16:1412266	GNPTG	0.59	6.83	0.48	1.89e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs501120	1.000	rs559580	chr10:44752078	C/T	cg09554077	chr10:44749378	NA	-0.51	-6.62	-0.47	5.86e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg09597638	chr17:3907349	NA	0.86	9.12	0.59	4.29e-16	Type 2 diabetes;
PAAD	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg05861140	chr6:150128134	PCMT1	-0.5	-5.34	-0.4	3.4e-7	Lung cancer;
PAAD	cis	rs2274459	0.572	rs116454384	chr6:33646375	C/T	cg06253072	chr6:33679850	C6orf125	0.72	5.08	0.38	1.11e-6	Obesity (extreme);
PAAD	cis	rs11997175	0.597	rs6988880	chr8:33594504	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	6.39	0.46	1.9e-9	Body mass index;
PAAD	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.32	0.71	1.26e-24	Cognitive ability;
PAAD	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg06386533	chr2:46925753	SOCS5	0.52	4.3	0.33	3.09e-5	Height;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	6.0	0.44	1.4e-8	Prudent dietary pattern;
PAAD	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.61	-0.47	6.28e-10	Retinal vascular caliber;
PAAD	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.19	0.55	9.75e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg00149659	chr3:10157352	C3orf10	0.55	4.38	0.33	2.17e-5	Alzheimer's disease;
PAAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.53	-6.0	-0.44	1.38e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18337803	chr17:48638187	CACNA1G	0.68	7.35	0.51	1.15e-11	Myopia (pathological);
PAAD	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.62	6.03	0.44	1.22e-8	Bone properties (heel);
PAAD	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg05338066	chr1:7812865	CAMTA1	0.64	4.8	0.36	3.8e-6	Inflammatory bowel disease;
PAAD	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00300879	chr1:26503847	CNKSR1	0.3	4.58	0.35	9.77e-6	Height;
PAAD	cis	rs4679121	0.643	rs55868716	chr3:126149806	A/C	cg05485589	chr3:126194908	ZXDC	-0.99	-4.77	-0.36	4.26e-6	Pursuit maintenance gain;
PAAD	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.12	-0.38	9.02e-7	Monocyte count;
PAAD	cis	rs787274	0.867	rs786981	chr9:115457856	T/G	cg13803584	chr9:115635662	SNX30	0.93	6.21	0.45	4.85e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.08	-0.5	4.98e-11	Morning vs. evening chronotype;
PAAD	cis	rs73206853	0.543	rs7972256	chr12:110575444	G/A	cg12870014	chr12:110450643	ANKRD13A	0.71	4.68	0.35	6.35e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8083432	0.800	rs7228750	chr18:22714149	G/A	cg13981356	chr18:22006370	IMPACT	0.61	4.41	0.34	1.95e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg02799478	chr19:58090259	ZNF416	-0.48	-4.32	-0.33	2.76e-5	Uric acid clearance;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.5e-5	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.34e-7	Bipolar disorder;
PAAD	cis	rs7551345	0.853	rs6672651	chr1:31849209	C/G	cg17086398	chr1:31896392	SERINC2	-0.54	-4.75	-0.36	4.6e-6	Schizophrenia;
PAAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.74	8.71	0.58	4.73e-15	Emphysema distribution in smoking;
PAAD	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.35	6.57	0.47	7.4e-10	Type 2 diabetes;
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13870426	chr17:30244630	NA	-0.73	-7.23	-0.51	2.15e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.56	-5.82	-0.43	3.36e-8	Coronary artery disease;
PAAD	cis	rs735539	0.521	rs9552278	chr13:21352318	C/T	cg27499820	chr13:21296301	IL17D	0.55	4.91	0.37	2.35e-6	Dental caries;
PAAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.83	-10.37	-0.64	2.15e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs4959799	1.000	rs61439128	chr6:3291116	C/A	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.82e-5	Survival in rectal cancer;
PAAD	cis	rs4704187	0.687	rs1477933	chr5:74437153	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9287719	0.649	rs10207885	chr2:10733188	C/T	cg00105475	chr2:10696890	NA	0.62	6.48	0.47	1.2e-9	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14403398	chr17:17942860	ATPAF2;C17orf39	0.63	6.31	0.46	2.93e-9	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.91	-7.2	-0.5	2.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.56	6.28	0.45	3.36e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.53	4.81	0.36	3.61e-6	Schizophrenia;
PAAD	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.84	8.98	0.59	9.54e-16	Corneal astigmatism;
PAAD	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs13033859	0.655	rs10171965	chr2:199144	G/A	cg12623918	chr2:306882	NA	0.46	4.53	0.34	1.21e-5	Mitochondrial DNA levels;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg02725872	chr8:58115012	NA	0.7	5.1	0.38	1e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2677744	0.563	rs8024249	chr15:91494249	T/C	cg07236925	chr15:91498269	RCCD1	-0.52	-4.44	-0.34	1.74e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.91	-11.09	-0.67	2.66e-21	Dental caries;
PAAD	cis	rs9815354	0.516	rs115135603	chr3:42031622	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs75920871	0.841	rs77250716	chr11:116877353	T/C	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg24154853	chr7:158122151	PTPRN2	0.71	7.23	0.51	2.19e-11	Calcium levels;
PAAD	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.75	-0.36	4.69e-6	Height;
PAAD	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs597480	1.000	rs597480	chr11:85436868	C/G	cg11817631	chr11:85522609	SYTL2	0.44	4.26	0.33	3.63e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6782025	0.794	rs638343	chr3:120713671	T/A	cg16417163	chr3:121280760	NA	0.45	4.63	0.35	7.76e-6	Aging (facial);
PAAD	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-5.79	-0.43	3.92e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs28489187	0.617	rs233097	chr1:85825473	G/C	cg16011679	chr1:85725395	C1orf52	0.47	4.41	0.34	1.94e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11671653	1.000	rs11672504	chr19:10831360	T/C	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18364779	chr6:26104403	HIST1H4C	0.46	4.61	0.35	8.42e-6	Schizophrenia;
PAAD	cis	rs6594713	0.837	rs17327964	chr5:112729116	C/G	cg12552261	chr5:112820674	MCC	-0.6	-4.35	-0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs11264799	0.765	rs7531547	chr1:157623267	G/T	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.54	-4.95	-0.37	1.93e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3736485	0.966	rs10519312	chr15:51912971	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.65	6.5	0.47	1.07e-9	Coronary artery disease;
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.87	10.68	0.65	3.17e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7084783	0.538	rs11191734	chr10:105338128	C/T	cg09754828	chr10:105363329	SH3PXD2A	0.47	4.6	0.35	8.96e-6	Fear of pain;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05962718	chr1:93545112	MTF2	-0.63	-6.31	-0.46	2.92e-9	Lung cancer in ever smokers;
PAAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg10253484	chr15:75165896	SCAMP2	-0.53	-4.79	-0.36	3.96e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8103278	0.507	rs522769	chr19:46284520	G/A	cg12641515	chr19:46296257	DMWD	0.48	4.73	0.36	4.99e-6	Coronary artery disease;
PAAD	cis	rs4666360	1.000	rs4666359	chr2:20335614	G/A	cg23291376	chr2:20336282	NA	-0.39	-4.31	-0.33	2.89e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.18	0.64	6.88e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.47	-0.34	1.52e-5	Breast cancer;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg03983715	chr16:68378420	PRMT7	-0.66	-4.48	-0.34	1.44e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs838147	0.844	rs2307019	chr19:49244220	G/A	cg13540341	chr19:49222985	MAMSTR	0.44	4.98	0.37	1.69e-6	Dietary macronutrient intake;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.57	5.49	0.41	1.62e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg05785598	chr3:49045655	WDR6	0.43	5.26	0.39	4.75e-7	Parkinson's disease;
PAAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.7	-6.11	-0.44	7.9e-9	Coronary artery disease;
PAAD	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	4.85	0.37	3.02e-6	Height;
PAAD	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.49	-5.55	-0.41	1.25e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg02887458	chr19:19495540	GATAD2A	0.55	5.13	0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.72	-5.85	-0.43	2.86e-8	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg10705379	chr10:99080932	FRAT1	-0.46	-5.2	-0.39	6.34e-7	Monocyte count;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-6.4	-0.46	1.84e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg14926445	chr8:58193284	C8orf71	0.69	5.07	0.38	1.17e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73198895	chr3:128565161	A/G	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.41e-5	Dental caries;
PAAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg13870426	chr17:30244630	NA	-0.74	-6.55	-0.47	8.33e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3106136	0.649	rs11097426	chr4:95309450	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.09	0.38	1.07e-6	Capecitabine sensitivity;
PAAD	cis	rs7654585	0.886	rs1466281	chr4:25936665	G/A	cg10409131	chr4:25915609	C4orf52	0.62	5.66	0.42	7.17e-8	Obesity-related traits;
PAAD	cis	rs6782025	1.000	rs7627978	chr3:121131137	A/T	cg16417163	chr3:121280760	NA	-0.42	-4.29	-0.33	3.17e-5	Aging (facial);
PAAD	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.89e-5	Height;
PAAD	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.44	-0.52	6.86e-12	Hemoglobin concentration;
PAAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.1	-0.5	4.55e-11	Gut microbiome composition (summer);
PAAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20893717	chr7:100318190	EPO	0.44	4.95	0.37	1.96e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs17007417	0.704	rs13385492	chr2:72072937	A/G	cg07540421	chr2:71115680	NA	-0.49	-4.32	-0.33	2.81e-5	Nonalcoholic steatohepatitis-derived hepatocellular carcinoma;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.89	-10.37	-0.64	2.23e-19	Coronary artery disease;
PAAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16447950	chr5:562315	NA	-0.64	-5.65	-0.42	7.65e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-5.98	-0.44	1.56e-8	Lymphocyte counts;
PAAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.71e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.49	5.3	0.39	4.05e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.26	-0.33	3.61e-5	Vitiligo;
PAAD	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg09659197	chr4:152720779	NA	0.45	6.04	0.44	1.12e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.76	6.47	0.46	1.29e-9	Pulmonary function decline;
PAAD	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg00149659	chr3:10157352	C3orf10	0.9	6.83	0.48	1.87e-10	Alzheimer's disease;
PAAD	cis	rs35740288	0.929	rs11556865	chr15:86303180	C/G	cg07943548	chr15:86304357	KLHL25	-0.58	-4.9	-0.37	2.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.71	-0.8	3.03e-36	Height;
PAAD	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.07	-0.44	9.66e-9	Crohn's disease;
PAAD	cis	rs1190596	0.830	rs3736807	chr14:102552775	T/G	cg23904247	chr14:102554826	HSP90AA1	-0.5	-5.67	-0.42	7.11e-8	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg21918786	chr6:109611834	NA	-0.45	-4.91	-0.37	2.31e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs59901009	0.517	rs7940348	chr11:10018842	C/G	cg06876053	chr11:9810051	SBF2	-0.34	-4.5	-0.34	1.34e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg10395934	chr14:104002654	TRMT61A	0.56	5.72	0.42	5.49e-8	Body mass index;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	7.31	0.51	1.41e-11	Renal function-related traits (BUN);
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs7094131	0.523	rs10741008	chr10:22882344	T/G	cg19500236	chr10:22911537	PIP4K2A	0.45	4.96	0.37	1.9e-6	Obesity-related traits;
PAAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg14343924	chr8:8086146	FLJ10661	-0.67	-5.51	-0.41	1.49e-7	Mood instability;
PAAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.12	-0.38	9.2e-7	Personality dimensions;
PAAD	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1062746	0.520	rs67174101	chr16:87328817	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-6.25	-0.45	3.85e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4959799	1.000	rs55829773	chr6:3291397	C/G	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.78e-5	Survival in rectal cancer;
PAAD	cis	rs12799264	1.000	rs2178682	chr11:19975460	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg03433033	chr1:76189801	ACADM	0.51	5.3	0.39	4.07e-7	Daytime sleep phenotypes;
PAAD	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg07741184	chr6:167504864	NA	-0.46	-5.63	-0.42	8.58e-8	Crohn's disease;
PAAD	cis	rs9842133	0.587	rs7652323	chr3:179660640	C/T	cg18765712	chr3:179670323	PEX5L	0.5	4.52	0.34	1.24e-5	Blood metabolite levels;
PAAD	cis	rs6828577	0.862	rs299005	chr4:119595364	G/A	cg02775129	chr4:119771670	NA	-0.49	-4.25	-0.33	3.72e-5	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs795484	0.926	rs556081	chr12:118732675	C/T	cg16572268	chr12:118583242	PEBP1	0.48	4.79	0.36	3.99e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.63	-0.35	7.86e-6	Total body bone mineral density;
PAAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.54	7.69	0.53	1.71e-12	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.88	6.93	0.49	1.09e-10	Atopic dermatitis;
PAAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg06697600	chr4:7070879	GRPEL1	0.88	4.45	0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.72	-8.35	-0.56	3.82e-14	Colorectal cancer;
PAAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs9487051	0.597	rs351730	chr6:109510766	C/T	cg21918786	chr6:109611834	NA	-0.41	-4.31	-0.33	2.9e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg24747557	chr10:131355152	MGMT	-0.47	-4.92	-0.37	2.18e-6	Response to temozolomide;
PAAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.03e-8	Lung cancer;
PAAD	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.65	-4.71	-0.36	5.55e-6	Vitiligo;
PAAD	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg16342193	chr10:102329863	NA	-0.82	-8.64	-0.57	7.06e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.58	4.98	0.37	1.68e-6	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15556553	chr1:17765043	RCC2	0.66	7.42	0.52	7.76e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg21546286	chr11:48923668	NA	0.51	5.23	0.39	5.59e-7	HDL cholesterol;
PAAD	cis	rs11700980	0.551	rs34161405	chr21:30113840	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18621852	chr3:10150065	C3orf24	-0.68	-5.99	-0.44	1.44e-8	Alzheimer's disease;
PAAD	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.67	-7.14	-0.5	3.68e-11	Glomerular filtration rate;
PAAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.97	-12.97	-0.72	2.29e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3771514	0.543	rs10187567	chr2:70673055	C/T	cg18150120	chr2:71134936	VAX2	-0.39	-4.63	-0.35	7.9e-6	Obesity-related traits;
PAAD	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg17366294	chr4:99064904	C4orf37	0.44	4.81	0.36	3.58e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-1.09	-7.91	-0.54	4.88e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22396632	chr1:3079212	PRDM16	-0.41	-4.28	-0.33	3.35e-5	Migraine;
PAAD	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.95	11.37	0.68	4.72e-22	Primary sclerosing cholangitis;
PAAD	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg12560992	chr17:57184187	TRIM37	0.63	4.85	0.37	3.06e-6	Vitamin D levels;
PAAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.54	4.72	0.36	5.24e-6	Coronary artery disease;
PAAD	cis	rs10991814	0.920	rs77732008	chr9:94014752	G/A	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.73	-0.53	1.4e-12	Exhaled nitric oxide output;
PAAD	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.19	0.39	6.53e-7	Multiple sclerosis;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.63	-0.42	8.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-5.43	-0.4	2.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	5.57	0.41	1.12e-7	Mood instability;
PAAD	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.69	7.59	0.52	3.04e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2992756	0.663	rs2992763	chr1:18804386	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.71	-0.36	5.53e-6	Breast cancer;
PAAD	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.59	-8.66	-0.57	6.53e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg24053715	chr22:38214548	NA	0.58	5.26	0.39	4.77e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg13444538	chr7:158905317	VIPR2	-0.48	-4.48	-0.34	1.44e-5	Facial morphology (factor 20);
PAAD	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg15478930	chr2:27652102	NRBP1	-0.53	-4.37	-0.33	2.26e-5	Blood metabolite levels;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.46	5.33	0.4	3.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.91	0.37	2.34e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg11271282	chr2:238384023	NA	0.57	4.4	0.34	2.01e-5	Prostate cancer;
PAAD	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg14440974	chr22:39074834	NA	-0.51	-5.6	-0.41	9.64e-8	Menopause (age at onset);
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18621852	chr3:10150065	C3orf24	0.52	4.94	0.37	2.02e-6	Alzheimer's disease;
PAAD	cis	rs6466055	0.720	rs1204077	chr7:104984019	T/C	cg04380332	chr7:105027541	SRPK2	0.65	7.33	0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.78	-0.36	4.06e-6	Triglycerides;
PAAD	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-5.44	-0.4	2.1e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.68	6.79	0.48	2.37e-10	Colorectal cancer;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.78	-8.24	-0.56	7.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.47	4.35	0.33	2.49e-5	Red blood cell count;
PAAD	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	5.61	0.41	9.48e-8	Multiple sclerosis;
PAAD	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.39	0.46	1.89e-9	Triglyceride levels;
PAAD	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg01631408	chr1:248437212	OR2T33	-0.62	-5.27	-0.39	4.63e-7	Common traits (Other);
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg04717802	chr22:42394638	WBP2NL	0.48	4.6	0.35	8.73e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg20893579	chr22:38215064	NA	0.47	4.73	0.36	5.1e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.4	0.34	2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	5.75	0.42	4.86e-8	Lung cancer in ever smokers;
PAAD	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg24069376	chr3:38537580	EXOG	0.4	4.82	0.36	3.49e-6	Electrocardiographic conduction measures;
PAAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.72	6.68	0.48	4.23e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs2555155	0.840	rs11040911	chr11:6551889	C/A	cg10208301	chr11:6592745	DNHD1	-0.44	-4.45	-0.34	1.67e-5	DNA methylation (variation);
PAAD	cis	rs941024	0.651	rs73117233	chr12:56040936	T/C	cg20737382	chr12:56040096	NA	-0.74	-4.56	-0.35	1.03e-5	Conotruncal heart defects (inherited effects);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22377810	chr6:64279158	NA	-0.69	-7.46	-0.52	6.08e-12	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-7.12	-0.5	4.12e-11	Neuroticism;
PAAD	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.6	5.15	0.39	7.93e-7	Neutrophil percentage of white cells;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg19601865	chr12:132687172	GALNT9	0.45	4.6	0.35	8.9e-6	Anti-saccade response;
PAAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.77	6.92	0.49	1.17e-10	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-4.63	-0.35	7.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-5.33	-0.4	3.45e-7	Total body bone mineral density;
PAAD	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.85	0.66	1.16e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.59	-5.85	-0.43	2.85e-8	Longevity;Endometriosis;
PAAD	cis	rs2916733	0.607	rs2922824	chr8:6313369	T/G	cg02465761	chr8:6735510	DEFB1	0.47	4.53	0.35	1.18e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-5.79	-0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.47	-6.03	-0.44	1.22e-8	Height;
PAAD	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	8.54	0.57	1.33e-14	Lymphocyte counts;
PAAD	cis	rs9659323	0.745	rs10923723	chr1:119544002	G/A	cg17326555	chr1:119535693	NA	-0.46	-6.24	-0.45	4.09e-9	Body mass index;
PAAD	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.15e-10	HDL cholesterol;
PAAD	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.5	5.04	0.38	1.33e-6	Colorectal cancer;
PAAD	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.79	8.3	0.56	5.2e-14	Coronary artery disease;
PAAD	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.32	0.33	2.85e-5	Educational attainment;
PAAD	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.87	5.62	0.41	8.76e-8	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg05042697	chr2:10830656	NOL10	-0.48	-4.76	-0.36	4.44e-6	Prostate cancer;
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg05579598	chr16:88989069	CBFA2T3	0.52	7.87	0.54	6.22e-13	Social autistic-like traits;
PAAD	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7619427	0.507	rs9311347	chr3:44011358	A/G	cg12796028	chr3:44040206	NA	0.53	4.59	0.35	9.38e-6	Schizophrenia;
PAAD	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.57	-7.57	-0.52	3.31e-12	Urate levels in overweight individuals;
PAAD	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs2271001	0.910	rs4756990	chr11:19141210	C/T	cg00161556	chr11:19138045	ZDHHC13	0.52	5.6	0.41	9.77e-8	Gut microbiome composition (winter);
PAAD	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.68	-7.06	-0.5	5.52e-11	Platelet distribution width;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.45	0.4	1.98e-7	Alzheimer's disease;
PAAD	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.75	10.1	0.63	1.13e-18	Coronary artery disease;
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.48	-0.34	1.45e-5	Lung cancer;
PAAD	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.76	7.91	0.54	4.91e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	4.4	0.34	1.99e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10121009	0.610	rs10814228	chr9:35332215	A/G	cg11846315	chr9:35647073	NA	-0.48	-4.4	-0.34	2.03e-5	Parkinson's disease;
PAAD	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.48	-0.71	4.65e-25	Ulcerative colitis;
PAAD	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.75	-8.98	-0.59	9.7e-16	Motion sickness;
PAAD	cis	rs2120991	0.935	rs11170725	chr12:54246522	A/C	cg23795217	chr12:54812000	ITGA5	0.34	4.47	0.34	1.53e-5	Biliary atresia;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.84	-8.51	-0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg15331088	chr8:600555	NA	-0.75	-4.62	-0.35	7.96e-6	IgG glycosylation;
PAAD	cis	rs1800469	0.965	rs12983775	chr19:41857439	G/A	cg08477640	chr19:41863820	B9D2	0.7	7.38	0.51	9.78e-12	Colorectal cancer;
PAAD	cis	rs12304921	0.639	rs2306732	chr12:51455739	G/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.58	-0.35	9.51e-6	Type 2 diabetes;
PAAD	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg15128208	chr22:42549153	NA	0.53	4.6	0.35	8.69e-6	Birth weight;
PAAD	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.64	0.42	8.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17407555	0.683	rs7676442	chr4:10272591	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	4.46	0.34	1.59e-5	Schizophrenia (age at onset);
PAAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9398803	0.698	rs853970	chr6:127063983	A/G	cg19875578	chr6:126661172	C6orf173	-0.43	-4.41	-0.34	1.94e-5	Male-pattern baldness;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg19640130	chr10:64028056	RTKN2	-0.37	-4.44	-0.34	1.74e-5	Rheumatoid arthritis;
PAAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs35955747	0.869	rs8143002	chr22:31587191	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-4.78	-0.36	4.09e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.92	-8.69	-0.58	5.52e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15563057	chr5:139493612	PURA	0.59	6.79	0.48	2.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	trans	rs801193	0.844	rs732465	chr7:65998450	T/C	cg26939375	chr7:64535504	NA	0.67	7.5	0.52	4.9e-12	Aortic root size;
PAAD	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1507153	0.549	rs236862	chr6:79334972	T/C	cg05283184	chr6:79620031	NA	0.36	4.32	0.33	2.76e-5	Sjögren's syndrome;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.85	0.43	2.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	6.25	0.45	3.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.73	-8.06	-0.55	2.04e-13	Blood metabolite levels;
PAAD	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.76	-5.51	-0.41	1.51e-7	Coronary artery disease;
PAAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01200585	chr1:228362443	C1orf69	-0.5	-5.66	-0.42	7.17e-8	Diastolic blood pressure;
PAAD	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.48	5.46	0.4	1.89e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.53	-7.09	-0.5	4.64e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs28489187	0.683	rs233050	chr1:85837793	T/C	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	7.33	0.51	1.27e-11	Alzheimer's disease;
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg22307297	chr20:60903441	LAMA5	-0.43	-4.67	-0.35	6.5e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg07362569	chr17:61921086	SMARCD2	0.44	4.97	0.37	1.81e-6	Height;
PAAD	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20769334	chr22:50913335	SBF1	0.55	6.54	0.47	8.69e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12595025	1	rs12595025	chr15:91520131	C/T	cg23684204	chr15:91497937	RCCD1	0.7	4.48	0.34	1.46e-5	Mean platelet volume;
PAAD	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	0.6	5.44	0.4	2.08e-7	Red blood cell count;
PAAD	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg11204139	chr17:3907470	NA	0.85	9.03	0.59	7.19e-16	Type 2 diabetes;
PAAD	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.92	0.49	1.19e-10	Lung cancer in ever smokers;
PAAD	cis	rs71636778	0.543	rs113002196	chr1:27200156	T/C	cg12203394	chr1:27248618	NUDC	0.63	4.39	0.34	2.14e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg23463467	chr20:60627584	TAF4	0.4	4.33	0.33	2.73e-5	Body mass index;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.59	-5.99	-0.44	1.43e-8	Iron status biomarkers;
PAAD	cis	rs6499755	0.901	rs4784522	chr16:55348749	C/T	cg02859129	chr16:55357253	IRX6	0.32	4.28	0.33	3.24e-5	Hypospadias;
PAAD	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.89	7.27	0.51	1.73e-11	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-16.22	-0.8	5.75e-35	Schizophrenia;
PAAD	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.62	-0.41	9e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.48	-0.34	1.44e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs367943	0.608	rs4705564	chr5:112980196	G/C	cg12552261	chr5:112820674	MCC	0.55	5.85	0.43	2.85e-8	Type 2 diabetes;
PAAD	cis	rs1043763	0.826	rs73219860	chr12:122625755	A/G	cg26218692	chr12:122497826	BCL7A	-0.55	-5.11	-0.38	9.55e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs12413624	0.791	rs1002525	chr10:120304062	G/A	cg06592982	chr10:119443899	NA	-0.36	-4.25	-0.33	3.71e-5	Pancreatic cancer;
PAAD	cis	rs4662592	0.628	rs13005793	chr2:128920741	A/G	cg17144508	chr2:128283727	IWS1	-0.54	-4.25	-0.33	3.67e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	4.28	0.33	3.24e-5	Height;
PAAD	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg05935833	chr10:81318306	SFTPA2	-0.51	-4.47	-0.34	1.54e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28595532	0.641	rs72670213	chr4:119281608	G/T	cg21605333	chr4:119757512	SEC24D	1.42	7.52	0.52	4.52e-12	Cannabis dependence symptom count;
PAAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.87	8.38	0.56	3.24e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.61	7.28	0.51	1.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg23281280	chr6:28129359	ZNF389	0.52	4.63	0.35	7.7e-6	Parkinson's disease;
PAAD	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-8.45	-0.57	2.21e-14	Total body bone mineral density;
PAAD	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.71	-9.16	-0.6	3.27e-16	Asthma;
PAAD	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.92	-0.37	2.25e-6	Recombination rate (females);
PAAD	cis	rs4668356	0.881	rs7591214	chr2:171977532	G/T	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs9646944	0.501	rs12991737	chr2:103018128	T/A	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	9.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.93	10.63	0.65	4.4e-20	Colorectal adenoma (advanced);
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs59888335	0.830	rs67899930	chr3:80507565	C/T	cg21735741	chr3:80819488	NA	0.59	5.15	0.39	7.84e-7	Schizophrenia;
PAAD	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.68	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs501120	0.564	rs1626459	chr10:44691548	T/C	cg09554077	chr10:44749378	NA	0.44	5.71	0.42	5.72e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3026101	0.671	rs8077933	chr17:5299674	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.49	6.17	0.45	5.82e-9	Childhood ear infection;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.43	4.41	0.34	1.98e-5	Longevity;Endometriosis;
PAAD	cis	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg05299278	chr17:33885742	SLFN14	0.42	5.04	0.38	1.32e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22617703	chr20:62551362	DNAJC5	-0.66	-6.76	-0.48	2.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg22467129	chr15:76604101	ETFA	0.53	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs4704187	0.687	rs1903838	chr5:74479999	G/A	cg03227963	chr5:74354835	NA	0.49	4.71	0.36	5.55e-6	Response to amphetamines;
PAAD	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg05805236	chr11:65401703	PCNXL3	0.44	4.67	0.35	6.51e-6	Acne (severe);
PAAD	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.8	10.21	0.64	5.98e-19	Alcohol dependence;
PAAD	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs8105895	0.935	rs8108976	chr19:22251701	C/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.97	-6.78	-0.48	2.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4823006	0.713	rs6005975	chr22:29454477	A/G	cg23896685	chr22:29451551	ZNRF3	0.48	5.08	0.38	1.1e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.78	10.15	0.64	8.52e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs761746	0.960	rs5998042	chr22:31953962	T/C	cg01338084	chr22:32026380	PISD	0.52	4.7	0.36	5.74e-6	Intelligence;
PAAD	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.7	6.54	0.47	8.82e-10	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg10589385	chr1:150898437	SETDB1	0.39	4.81	0.36	3.57e-6	Melanoma;
PAAD	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	1.18	15.4	0.78	7.49e-33	Ewing sarcoma;
PAAD	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02850602	chr12:83150597	TMTC2	0.66	7.32	0.51	1.35e-11	Smoking initiation;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.44	5.57	0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.28	0.6	1.63e-16	Mortality in heart failure;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.6	-5.2	-0.39	6.2e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2671540	0.574	rs10733798	chr10:65656976	A/G	cg19573236	chr10:65733388	NA	0.57	4.54	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.76	7.79	0.53	9.68e-13	Menarche (age at onset);
PAAD	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg10985347	chr2:127963512	CYP27C1	0.47	4.7	0.36	5.67e-6	Protein C levels;
PAAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.08	-19.24	-0.84	1.44e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4462272	0.527	rs6584354	chr10:102007714	A/C	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.25e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.85	9.38	0.61	8.81e-17	IgG glycosylation;
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.54	-0.35	1.14e-5	Tonsillectomy;
PAAD	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.32	0.6	1.25e-16	Prudent dietary pattern;
PAAD	cis	rs8040855	0.627	rs11631548	chr15:85619248	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.26	0.6	1.84e-16	Cognitive function;
PAAD	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.5	6.37	0.46	2.12e-9	Crohn's disease;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg05627522	chr15:75251581	NA	0.47	5.64	0.42	8.12e-8	Breast cancer;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13198984	chr17:80129470	CCDC57	-0.4	-4.8	-0.36	3.75e-6	Life satisfaction;
PAAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.51	4.35	0.33	2.47e-5	Cocaine dependence;
PAAD	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg01028140	chr2:1542097	TPO	-0.81	-6.34	-0.46	2.51e-9	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs6694672	0.867	rs571106	chr1:197256688	G/T	cg26994526	chr18:47719735	MYO5B	-0.85	-6.53	-0.47	9.07e-10	Asthma;
PAAD	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	4.26	0.33	3.64e-5	Personality dimensions;
PAAD	cis	rs58521262	0.556	rs289338	chr19:23151425	C/T	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.64	-6.08	-0.44	9.16e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.34	4.87	0.37	2.83e-6	Asthma;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.41	0.82	5.02e-38	Prudent dietary pattern;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.75	9.89	0.63	4e-18	Cardiovascular disease risk factors;
PAAD	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs2491441	1.000	rs2500119	chr1:183799009	A/G	cg08905629	chr1:183188297	LAMC2	-0.47	-4.48	-0.34	1.49e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	5.21	0.39	6.16e-7	Initial pursuit acceleration;
PAAD	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.45	-5.16	-0.39	7.5e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	4.93	0.37	2.09e-6	Total cholesterol levels;
PAAD	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.56	5.33	0.4	3.42e-7	Platelet count;
PAAD	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.86	6.86	0.49	1.67e-10	Prostate cancer;
PAAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.98	10.42	0.65	1.63e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg14851468	chr5:179071604	C5orf60	0.49	5.2	0.39	6.23e-7	Lung cancer;
PAAD	cis	rs9487051	0.646	rs9487049	chr6:109615905	A/T	cg01475377	chr6:109611718	NA	-0.4	-4.3	-0.33	2.98e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.58	-0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.64	5.4	0.4	2.55e-7	Lymphocyte counts;
PAAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.2	0.39	6.35e-7	Myeloid white cell count;
PAAD	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.86	-10.12	-0.63	9.87e-19	Coronary artery disease;
PAAD	cis	rs4690686	0.808	rs6553945	chr4:177270965	T/C	cg17059388	chr4:177262070	NA	0.54	5.25	0.39	5.07e-7	Essential tremor;
PAAD	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.54	4.84	0.37	3.14e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.17e-8	Life satisfaction;
PAAD	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.06	-0.38	1.19e-6	Mood instability;
PAAD	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06850241	chr22:41845214	NA	0.57	4.92	0.37	2.22e-6	Vitiligo;
PAAD	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.68	0.36	6.23e-6	Electrocardiographic conduction measures;
PAAD	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-4.28	-0.33	3.33e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11871801	0.918	rs36005199	chr17:40597555	A/G	cg21692620	chr17:40835849	CNTNAP1	-0.46	-4.75	-0.36	4.64e-6	Crohn's disease;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-4.67	-0.35	6.55e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg09659197	chr4:152720779	NA	0.37	5.29	0.39	4.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.77	8.39	0.56	3.2e-14	Blood metabolite levels;
PAAD	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-7.15	-0.5	3.5e-11	Colorectal cancer;
PAAD	cis	rs362296	0.698	rs362266	chr4:3259632	C/G	cg08886695	chr4:3369023	RGS12	0.53	5.01	0.38	1.49e-6	Parental longevity (mother's age at death);
PAAD	cis	rs79146658	0.736	rs11884950	chr2:179746213	C/T	cg17765952	chr2:179737173	CCDC141	0.63	4.72	0.36	5.37e-6	Diastolic blood pressure;
PAAD	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.7	7.39	0.51	9.02e-12	Colorectal cancer;
PAAD	cis	rs11264213	0.901	rs116757422	chr1:36349560	G/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950881	1.000	rs950881	chr2:102932512	G/T	cg20060108	chr2:102954350	IL1RL1	0.61	4.78	0.36	4.17e-6	Allergy;
PAAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg12623918	chr2:306882	NA	0.45	4.59	0.35	9.32e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.94	12.33	0.71	1.22e-24	Prudent dietary pattern;
PAAD	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.45	-5.69	-0.42	6.39e-8	Lewy body disease;
PAAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.97	11.01	0.67	4.16e-21	Parkinson's disease;
PAAD	cis	rs3112530	1.000	rs160066	chr5:152727358	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.19	-0.39	6.65e-7	Ulcerative colitis;
PAAD	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.57	-5.7	-0.42	5.93e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.53	-4.62	-0.35	8.09e-6	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09835421	chr16:68378352	PRMT7	-1.18	-8.67	-0.58	6.19e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.5	0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.45	-4.28	-0.33	3.33e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.59	6.1	0.44	8.31e-9	High light scatter reticulocyte count;
PAAD	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg10006428	chr1:248814059	OR2T27	0.42	4.93	0.37	2.14e-6	Common traits (Other);
PAAD	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.39	-4.67	-0.35	6.47e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	1.04	14.58	0.76	1.1e-30	Metabolite levels;
PAAD	cis	rs73526541	0.541	rs76940447	chr8:1070632	A/G	cg20458277	chr8:1053508	NA	0.57	4.28	0.33	3.25e-5	Verbal memory performance (immediate recall change);
PAAD	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.03	-0.5	6.65e-11	Alcohol dependence;
PAAD	cis	rs12136530	0.577	rs12120180	chr1:19791441	C/T	cg20786524	chr1:18954525	NA	-0.38	-4.68	-0.36	6.2e-6	Lead levels in blood;
PAAD	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.85	9.55	0.61	3.19e-17	Schizophrenia;
PAAD	cis	rs3733829	0.600	rs3869575	chr19:41317887	G/A	cg05624199	chr19:41168318	NA	-0.27	-4.36	-0.33	2.4e-5	Smoking behavior;
PAAD	cis	rs6844506	0.738	rs3121384	chr4:185218841	G/A	cg12654155	chr4:185238627	NA	0.47	4.5	0.34	1.34e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.53	-4.65	-0.35	7.07e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs427941	0.632	rs201493	chr7:101754865	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.4	0.34	2.06e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.53	-4.65	-0.35	7.25e-6	Testicular germ cell tumor;
PAAD	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.98	6.64	0.47	5.29e-10	Schizophrenia;
PAAD	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.08	-0.44	9.2e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.52	5.29	0.39	4.14e-7	Resting heart rate;
PAAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06850241	chr22:41845214	NA	-0.48	-4.84	-0.37	3.14e-6	Vitiligo;
PAAD	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	9.64	0.62	1.82e-17	Cognitive test performance;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs75920871	0.925	rs7112191	chr11:116902056	G/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.28	-0.33	3.34e-5	Subjective well-being;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.55	6.91	0.49	1.24e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.85	6.52	0.47	9.58e-10	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs9982086	0.557	rs216763	chr21:27312930	A/T	cg04970570	chr5:87990145	NA	0.56	6.3	0.46	3.02e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.7	-6.13	-0.45	7.21e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.49	-6.51	-0.47	1.04e-9	Schizophrenia;
PAAD	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.77	8.26	0.56	6.56e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18538332	chr22:24372958	LOC391322	-0.75	-7.71	-0.53	1.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg18833306	chr6:118973337	C6orf204	-0.45	-4.62	-0.35	8.13e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2446066	0.872	rs2694847	chr12:53785028	A/G	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00142150	chr22:38071001	LGALS1	0.8	9.02	0.59	7.44e-16	Fat distribution (HIV);
PAAD	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.71	-6.92	-0.49	1.16e-10	White matter hyperintensity burden;
PAAD	cis	rs8077577	0.708	rs4556848	chr17:18134867	C/G	cg16794390	chr17:18148240	FLII	-0.52	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.46	0.34	1.6e-5	Myopia (pathological);
PAAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2051773	0.567	rs11024113	chr11:17042444	G/A	cg15084286	chr11:17036142	PLEKHA7	0.56	5.0	0.38	1.58e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg01489032	chr8:143877656	NA	-0.4	-4.56	-0.35	1.05e-5	Urinary tract infection frequency;
PAAD	cis	rs2239785	0.959	rs129423	chr22:36657329	A/G	cg15716373	chr22:36655542	APOL1	-0.45	-4.25	-0.33	3.64e-5	Glomerulosclerosis;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7619833	0.592	rs4973756	chr3:27248190	C/T	cg02860705	chr3:27208620	NA	0.4	4.3	0.33	3.06e-5	Breast cancer;
PAAD	cis	rs9905704	0.633	rs2018966	chr17:56477565	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	6.31	0.46	2.89e-9	Post bronchodilator FEV1;
PAAD	cis	rs6510489	0.527	rs60038395	chr19:35952895	A/G	cg15479752	chr19:35940862	FFAR2	-0.46	-4.41	-0.34	1.95e-5	Bipolar disorder;
PAAD	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.83	-8.03	-0.55	2.45e-13	Breast cancer;
PAAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.24	0.39	5.39e-7	Bone mineral density;
PAAD	cis	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg15676455	chr3:128564943	NA	-0.8	-4.62	-0.35	8.2e-6	Dental caries;
PAAD	cis	rs4811196	0.536	rs238308	chr20:36415026	C/T	cg04608177	chr20:37230389	C20orf95	0.38	4.34	0.33	2.58e-5	Bone mineral density;
PAAD	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.6	-5.97	-0.44	1.62e-8	Calcium levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24739679	chr1:193304834	NA	-0.61	-6.41	-0.46	1.75e-9	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.77	8.47	0.57	1.94e-14	Childhood ear infection;
PAAD	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16639922	chr3:9975056	IL17RC;CRELD1	0.69	6.71	0.48	3.57e-10	Obesity-related traits;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg20295408	chr7:1910781	MAD1L1	0.55	5.36	0.4	3.04e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg02683114	chr2:24398427	C2orf84	-0.58	-5.61	-0.41	9.44e-8	Asthma;
PAAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26209169	chr5:1316264	NA	0.36	4.3	0.33	3.05e-5	Lung cancer;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.51	-0.41	1.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.58	5.25	0.39	5.09e-7	Coronary artery disease;
PAAD	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg20731937	chr12:48336164	NA	0.51	4.26	0.33	3.62e-5	Longevity (90 years and older);
PAAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.59	-6.92	-0.49	1.16e-10	Longevity;Endometriosis;
PAAD	cis	rs7932354	0.583	rs7943866	chr11:46881954	C/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.6	-5.32	-0.4	3.58e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs72960926	1.000	rs72959000	chr6:75134312	A/T	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.41	-4.71	-0.36	5.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.26	-0.39	4.72e-7	Inflammatory bowel disease;
PAAD	cis	rs2281636	1.000	rs2804418	chr10:101512094	A/C	cg05149213	chr10:101381631	SLC25A28	-0.48	-4.58	-0.35	9.64e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11677722	chr19:39881393	MED29;PAF1	0.66	7.14	0.5	3.56e-11	Monocyte percentage of white cells;
PAAD	cis	rs10878977	0.542	rs60964256	chr12:69815151	A/G	cg13322954	chr12:69198953	NA	0.68	4.32	0.33	2.79e-5	Colorectal cancer;
PAAD	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02743256	chr7:2109353	MAD1L1	-0.76	-5.53	-0.41	1.4e-7	Neuroticism;
PAAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.9e-7	Rheumatoid arthritis;
PAAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.55	7.19	0.5	2.76e-11	Multiple system atrophy;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.66	-5.93	-0.43	1.92e-8	Renal function-related traits (BUN);
PAAD	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.52	-6.42	-0.46	1.66e-9	Total body bone mineral density;
PAAD	cis	rs6142102	0.625	rs6142068	chr20:32557172	C/T	cg06115741	chr20:33292138	TP53INP2	-0.56	-4.92	-0.37	2.24e-6	Skin pigmentation;
PAAD	cis	rs11807834	0.522	rs754666	chr1:230250182	T/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.68	-5.28	-0.39	4.46e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs10267417	0.603	rs1557772	chr7:19908535	A/C	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.51	-5.15	-0.39	7.9e-7	Subjective well-being;
PAAD	cis	rs58521262	0.556	rs289300	chr19:23175330	T/C	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs28374715	0.541	rs16971454	chr15:41361138	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-5.5	-0.41	1.6e-7	Ulcerative colitis;
PAAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs1797885	0.763	rs9862177	chr3:12519202	C/T	cg07775309	chr3:12595852	NA	0.42	4.5	0.34	1.33e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg05373962	chr22:49881684	NA	-0.58	-5.37	-0.4	2.9e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.71	-0.36	5.43e-6	Parkinson's disease;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs597583	0.502	rs3016797	chr11:117409884	G/C	cg27161313	chr11:117392002	DSCAML1	-0.8	-5.27	-0.39	4.58e-7	Putamen volume;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.37	-0.4	2.83e-7	Cognitive function;
PAAD	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.88	-7.54	-0.52	3.95e-12	Lung disease severity in cystic fibrosis;
PAAD	trans	rs2249625	0.739	rs490471	chr6:72716225	A/G	cg04413069	chr12:9800446	LOC374443	-0.57	-6.31	-0.46	2.91e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg01064725	chr1:204461714	NA	-0.5	-4.5	-0.34	1.36e-5	Schizophrenia;
PAAD	trans	rs10479334	0.850	rs11746749	chr5:104956139	C/T	cg08355344	chr17:62340723	TEX2	1.19	6.4	0.46	1.86e-9	Personality traits in bipolar disorder;
PAAD	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.02	-0.38	1.43e-6	Mean corpuscular volume;
PAAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.6	-0.35	8.8e-6	Lung cancer in ever smokers;
PAAD	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.27	0.33	3.39e-5	Bipolar disorder;
PAAD	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-4.92	-0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.2e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.12	0.59	4.33e-16	Menopause (age at onset);
PAAD	cis	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg01304814	chr3:48885189	PRKAR2A	0.56	4.46	0.34	1.59e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg00800038	chr16:89945340	TCF25	-0.8	-4.52	-0.34	1.23e-5	Skin colour saturation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21577260	chr17:73285714	SLC25A19	0.56	6.4	0.46	1.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2281845	0.560	rs12079819	chr1:201085420	G/A	cg22815214	chr1:201083145	CACNA1S	0.58	4.87	0.37	2.72e-6	Permanent tooth development;
PAAD	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg24699146	chr1:24152579	HMGCL	-0.44	-4.43	-0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg17644776	chr2:200775616	C2orf69	-0.52	-4.3	-0.33	3e-5	Schizophrenia;
PAAD	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.56	5.99	0.44	1.47e-8	Mean corpuscular volume;
PAAD	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs564309	1.000	rs505129	chr1:228586829	T/C	cg01328119	chr1:228783545	DUSP5P	0.69	4.62	0.35	8.03e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs71636778	1.000	rs71636778	chr1:27104612	T/C	cg12203394	chr1:27248618	NUDC	0.62	4.39	0.34	2.15e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-5.11	-0.38	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.6	-0.47	6.57e-10	Triglycerides;
PAAD	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.35	-0.33	2.44e-5	Blood metabolite levels;
PAAD	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.54	5.77	0.42	4.27e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06760068	chr1:6845484	CAMTA1	0.69	7.39	0.51	9.33e-12	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.2e-11	Life satisfaction;
PAAD	cis	rs3106136	0.814	rs6825005	chr4:95277009	T/C	cg11021082	chr4:95130006	SMARCAD1	0.63	6.03	0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.6	5.63	0.42	8.27e-8	Schizophrenia;
PAAD	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.22	0.6	2.26e-16	Post bronchodilator FEV1;
PAAD	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg22089800	chr15:90895588	ZNF774	0.57	5.48	0.41	1.76e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg04482110	chr17:41364121	TMEM106A	0.38	4.37	0.33	2.29e-5	Menopause (age at onset);
PAAD	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-8.12	-0.55	1.52e-13	Prostate cancer;
PAAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.94	12.47	0.71	5.12e-25	Menopause (age at onset);
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg02696790	chr15:75250997	RPP25	-0.37	-4.29	-0.33	3.11e-5	Breast cancer;
PAAD	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.84	0.54	7.21e-13	Mean platelet volume;
PAAD	cis	rs2637266	0.783	rs846627	chr10:78539556	A/G	cg18941641	chr10:78392320	NA	0.37	4.44	0.34	1.73e-5	Pulmonary function;
PAAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.54	6.31	0.46	2.96e-9	Schizophrenia;
PAAD	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-4.25	-0.33	3.69e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg20003494	chr4:90757398	SNCA	-0.4	-4.53	-0.35	1.16e-5	Dementia with Lewy bodies;
PAAD	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg21300403	chr2:198650112	BOLL	0.49	4.39	0.34	2.15e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg13611204	chr9:139324423	INPP5E	-0.52	-4.27	-0.33	3.43e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.67	0.35	6.46e-6	Bone mineral density;
PAAD	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.37	0.46	2.1e-9	Coffee consumption (cups per day);
PAAD	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg09760422	chr2:128146352	NA	-0.35	-6.25	-0.45	3.95e-9	Protein C levels;
PAAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.83	9.5	0.61	4.29e-17	Metabolic syndrome;
PAAD	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.38	0.33	2.18e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg01942863	chr7:99769432	GPC2	0.49	4.61	0.35	8.48e-6	Coronary artery disease;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	5.29	0.39	4.18e-7	Total body bone mineral density;
PAAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg14458575	chr2:238380390	NA	0.56	4.65	0.35	7.01e-6	Prostate cancer;
PAAD	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.99	0.49	7.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.53	-0.35	1.16e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.9	-0.37	2.45e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-5.05	-0.38	1.26e-6	Chronic sinus infection;
PAAD	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.8	-5.89	-0.43	2.36e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9649465	0.806	rs6971297	chr7:123293342	A/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.81	-0.36	3.58e-6	Migraine;
PAAD	trans	rs10500871	1.000	rs1829576	chr11:20225651	C/T	cg02956962	chr6:161097311	NA	0.62	6.3	0.46	3.02e-9	Educational attainment;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.46	-0.34	1.58e-5	Response to amphetamines;
PAAD	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.72	4.76	0.36	4.45e-6	Major depressive disorder;
PAAD	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg20406979	chr6:167373233	NA	0.37	4.76	0.36	4.53e-6	Crohn's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14475035	chr2:111883501	BCL2L11	0.66	7.11	0.5	4.31e-11	Smoking initiation;
PAAD	cis	rs7678296	1.000	rs73126352	chr4:37215817	G/A	cg06805348	chr4:37245195	KIAA1239	0.65	4.83	0.36	3.34e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7534824	0.556	rs61780323	chr1:101433407	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	4.81	0.36	3.54e-6	Refractive astigmatism;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.76	5.45	0.4	2.03e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.63	6.78	0.48	2.52e-10	Bladder cancer;
PAAD	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.7	8.61	0.57	8.38e-15	Endometriosis;
PAAD	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg12560992	chr17:57184187	TRIM37	0.63	4.85	0.37	3.06e-6	Vitamin D levels;
PAAD	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.65	-7.28	-0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs692804	0.514	rs530294	chr11:119989572	T/A	cg19363546	chr11:120110701	POU2F3	0.69	4.35	0.33	2.51e-5	Blood protein levels;
PAAD	trans	rs12406019	0.548	rs11162415	chr1:78612934	G/A	cg20826526	chr3:156266748	SSR3	-0.65	-6.3	-0.46	3.08e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg13047869	chr3:10149882	C3orf24	0.7	5.88	0.43	2.48e-8	Alzheimer's disease;
PAAD	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13870426	chr17:30244630	NA	-0.64	-6.17	-0.45	5.94e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18020381	chr5:162864458	CCNG1	0.63	6.31	0.46	2.96e-9	Obesity-related traits;
PAAD	cis	rs6782025	0.794	rs3845849	chr3:120789300	C/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg03233332	chr7:66118400	NA	0.42	4.49	0.34	1.4e-5	Aortic root size;
PAAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	1.02	5.25	0.39	5.1e-7	Plasma clusterin levels;
PAAD	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.88	-0.49	1.43e-10	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.69	7.48	0.52	5.66e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.81	-9.12	-0.59	4.16e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.74	-7.67	-0.53	1.86e-12	DNA methylation (variation);
PAAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg27121462	chr16:89883253	FANCA	0.46	4.81	0.36	3.62e-6	Vitiligo;
PAAD	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	1.12	18.58	0.83	5.98e-41	Colorectal adenoma (advanced);
PAAD	cis	rs72827839	0.779	rs72827858	chr17:46474361	A/G	cg23391107	chr17:45924227	SP6	0.53	5.09	0.38	1.04e-6	Ease of getting up in the morning;
PAAD	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg07784872	chr16:85687041	KIAA0182	-0.53	-4.5	-0.34	1.33e-5	Platelet distribution width;
PAAD	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg27411982	chr8:10470053	RP1L1	-0.54	-5.91	-0.43	2.18e-8	Neuroticism;
PAAD	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg16479474	chr6:28041457	NA	0.42	4.26	0.33	3.64e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21016266	chr12:122356598	WDR66	0.62	6.82	0.48	1.99e-10	Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.38	4.76	0.36	4.38e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.87	11.44	0.68	3.02e-22	Body mass index;
PAAD	cis	rs4719841	0.662	rs6980357	chr7:25994009	A/G	cg10085138	chr7:25991722	NA	0.26	4.65	0.35	7.06e-6	Triglyceride levels;
PAAD	cis	rs3112530	0.901	rs2615153	chr5:152619755	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.86	-4.57	-0.35	1.02e-5	Aging (time to event);
PAAD	cis	rs13011075	0.553	rs6546403	chr2:68632262	C/T	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.68	6.12	0.44	7.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs780142	0.672	rs8037458	chr15:62832158	C/T	cg12918536	chr15:62891943	NA	0.37	4.48	0.34	1.45e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg00601450	chr5:74908170	NA	0.48	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.62	6.22	0.45	4.61e-9	Hemoglobin concentration;
PAAD	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.59	5.95	0.43	1.74e-8	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04625536	chr6:42533006	UBR2	0.66	7.74	0.53	1.27e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg26876637	chr1:152193138	HRNR	-0.84	-6.04	-0.44	1.16e-8	Atopic dermatitis;
PAAD	cis	rs12523822	0.830	rs11752169	chr6:154957447	T/C	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.58	-0.47	7.07e-10	Mood instability;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-11.92	-0.7	1.49e-23	Ulcerative colitis;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.26e-8	Life satisfaction;
PAAD	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.7	7.05	0.5	5.77e-11	Schizophrenia;
PAAD	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg07068956	chr7:100330872	ZAN	-0.71	-5.37	-0.4	2.95e-7	Other erythrocyte phenotypes;
PAAD	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.58	-4.94	-0.37	2.04e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs4662592	0.554	rs11675183	chr2:128859082	A/G	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.74	-0.36	4.95e-6	Resting heart rate;
PAAD	cis	rs9463078	0.585	rs1748242	chr6:45163350	T/C	cg18551225	chr6:44695536	NA	0.43	4.47	0.34	1.49e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg02023728	chr11:77925099	USP35	0.44	4.63	0.35	7.73e-6	Alzheimer's disease (survival time);
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg24699146	chr1:24152579	HMGCL	-0.52	-5.42	-0.4	2.3e-7	Immature fraction of reticulocytes;
PAAD	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg03934865	chr2:198174659	NA	-0.46	-4.56	-0.35	1.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg07395648	chr5:131743802	NA	-0.64	-6.62	-0.47	5.73e-10	Blood metabolite levels;
PAAD	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.31	-0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.41	5.0	0.38	1.57e-6	Blood protein levels;
PAAD	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.95	10.19	0.64	6.5e-19	Monocyte percentage of white cells;
PAAD	cis	rs508970	0.556	rs593276	chr11:60918735	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.54	4.27	0.33	3.47e-5	Bone mineral density (spine);
PAAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.22	0.39	5.78e-7	Ulcerative colitis;
PAAD	cis	rs4740619	0.630	rs2987020	chr9:15986028	C/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg06917634	chr15:78832804	PSMA4	0.53	4.92	0.37	2.21e-6	Sudden cardiac arrest;
PAAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.79	0.42	3.94e-8	Tonsillectomy;
PAAD	cis	rs1359582	0.793	rs4934415	chr10:90375019	A/G	cg15661332	chr10:90342814	RNLS	0.55	4.96	0.37	1.83e-6	Depressive and manic episodes in bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05916588	chr19:3700332	PIP5K1C	-0.72	-6.44	-0.46	1.52e-9	Neuroticism;
PAAD	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.46	4.68	0.36	6.25e-6	Obesity-related traits;
PAAD	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg22134325	chr11:66188745	NPAS4	0.38	4.4	0.34	2.06e-5	Airway imaging phenotypes;
PAAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	1.36	7.1	0.5	4.51e-11	Skin colour saturation;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.22	-0.39	5.83e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.8	-8.45	-0.57	2.26e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.53	5.78	0.42	4.01e-8	Testicular germ cell tumor;
PAAD	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.55	-6.1	-0.44	8.32e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg19792802	chr11:65647270	CTSW	-0.44	-5.86	-0.43	2.78e-8	DNA methylation (variation);
PAAD	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.62e-7	Bipolar disorder;
PAAD	cis	rs962856	0.756	rs4671800	chr2:67622348	T/C	cg09028215	chr2:67624308	ETAA1	-0.53	-4.52	-0.34	1.24e-5	Pancreatic cancer;
PAAD	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.4	-5.92	-0.43	2.1e-8	Subjective well-being;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs6141769	0.518	rs2377665	chr20:31309054	T/C	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.87	-0.37	2.77e-6	Subjective well-being;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02071572	chr4:1403502	NA	0.43	5.9	0.43	2.28e-8	Obesity-related traits;
PAAD	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.25	-0.6	1.96e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.96	10.94	0.66	6.65e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.86	0.37	2.87e-6	Diisocyanate-induced asthma;
PAAD	cis	rs939584	1.000	rs2867114	chr2:651380	C/T	cg14515364	chr2:636606	NA	-0.47	-4.38	-0.33	2.2e-5	Body mass index;
PAAD	cis	rs7247513	0.964	rs1864083	chr19:12707302	T/C	cg01871581	chr19:12707946	ZNF490	-0.9	-11.1	-0.67	2.4e-21	Bipolar disorder;
PAAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg07153921	chr17:41440717	NA	-0.4	-4.32	-0.33	2.81e-5	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17800473	chr17:31255522	TMEM98	0.58	6.4	0.46	1.87e-9	Monocyte percentage of white cells;
PAAD	cis	rs2712431	0.554	rs2010054	chr3:128305302	A/G	cg16766828	chr3:128327626	NA	-0.46	-5.87	-0.43	2.65e-8	Monocyte chemoattractant protein-1 levels;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13012494	chr21:47604986	C21orf56	0.47	4.97	0.37	1.76e-6	Testicular germ cell tumor;
PAAD	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg05555928	chr11:63887634	MACROD1	-0.58	-5.6	-0.41	9.91e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17655565	1.000	rs17655565	chr12:52691958	T/C	cg02645295	chr12:52705424	NA	-0.46	-4.25	-0.33	3.72e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.42	5.24	0.39	5.29e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6681460	0.549	rs11208908	chr1:67036636	C/T	cg02459107	chr1:67143332	SGIP1	0.66	7.11	0.5	4.24e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg15733309	chr7:157513707	PTPRN2	0.6	7.13	0.5	3.79e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	6.07	0.44	9.86e-9	Mood instability;
PAAD	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.23	-0.51	2.22e-11	Acylcarnitine levels;
PAAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.73	7.4	0.51	8.49e-12	Cognitive function;
PAAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01171360	chr6:293285	DUSP22	-0.63	-6.43	-0.46	1.55e-9	Menopause (age at onset);
PAAD	cis	rs3857067	0.934	rs1509941	chr4:95018784	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.49	5.84	0.43	3.1e-8	Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.44	-4.72	-0.36	5.29e-6	Psoriasis;
PAAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-6.81	-0.48	2.08e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs438034	0.746	rs12126024	chr1:214769701	G/C	cg16144317	chr1:214725524	PTPN14	0.42	4.45	0.34	1.65e-5	Response to antineoplastic agents;
PAAD	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00791764	chr4:53727839	RASL11B	0.51	4.41	0.34	1.96e-5	Optic nerve measurement (cup area);
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg04733911	chr16:78082701	NA	0.48	4.83	0.37	3.25e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs11614333	0.920	rs6488726	chr12:15045157	C/T	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg11707556	chr5:10655725	ANKRD33B	0.64	7.03	0.5	6.43e-11	Coronary artery disease;
PAAD	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.79	-5.1	-0.38	9.95e-7	Yeast infection;
PAAD	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg18612461	chr15:75251733	NA	0.44	4.69	0.36	6.17e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	4.72	0.36	5.29e-6	Height;
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.89	-15.18	-0.78	2.85e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg23024343	chr7:107201750	COG5	0.57	4.29	0.33	3.13e-5	Coronary artery disease;
PAAD	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.43	4.42	0.34	1.86e-5	Interstitial lung disease;
PAAD	cis	rs2882667	0.690	rs185956	chr5:138230263	A/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.44	4.31	0.33	2.95e-5	Blood pressure;
PAAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-7.37	-0.51	1.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg04398451	chr17:18023971	MYO15A	-0.85	-9.77	-0.62	8.57e-18	Total body bone mineral density;
PAAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg06740227	chr12:86229804	RASSF9	-0.5	-4.55	-0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs28489187	0.683	rs233093	chr1:85823120	C/T	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.84	-9.88	-0.63	4.28e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13370280	chr6:137539688	IFNGR1	0.59	6.39	0.46	1.88e-9	Response to antipsychotic treatment;
PAAD	cis	rs6065	0.618	rs16942618	chr17:4877358	G/A	cg02990439	chr17:4875527	CAMTA2	-0.9	-4.7	-0.36	5.67e-6	Platelet count;
PAAD	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg19264203	chr11:92714893	MTNR1B	-0.42	-4.78	-0.36	4.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs16857609	0.564	rs13406698	chr2:218283085	A/G	cg15335768	chr2:218268053	DIRC3	-0.49	-5.01	-0.38	1.47e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs6586111	0.647	rs76120037	chr10:82371930	C/G	cg03086067	chr10:82368399	SH2D4B	-0.39	-4.37	-0.33	2.28e-5	Capecitabine sensitivity;
PAAD	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.64	-6.18	-0.45	5.62e-9	Itch intensity from mosquito bite;
PAAD	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-5.97	-0.44	1.61e-8	Response to antipsychotic treatment;
PAAD	cis	rs12681963	0.688	rs4262289	chr8:30049104	C/T	cg23406830	chr8:30012838	DCTN6	-0.72	-4.34	-0.33	2.56e-5	Migraine;
PAAD	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.46	5.38	0.4	2.74e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg26174226	chr8:58114915	NA	0.6	4.48	0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg02297831	chr4:17616191	MED28	0.61	6.19	0.45	5.22e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg02640540	chr1:67518911	SLC35D1	0.5	4.44	0.34	1.73e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg06740227	chr12:86229804	RASSF9	0.53	4.87	0.37	2.73e-6	Major depressive disorder;
PAAD	cis	rs877529	0.967	rs139407	chr22:39552075	G/A	cg13455509	chr22:39551605	NA	-0.45	-4.47	-0.34	1.55e-5	Multiple myeloma;
PAAD	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	4.47	0.34	1.53e-5	IgG glycosylation;
PAAD	cis	rs78707713	0.841	rs12242391	chr10:71201504	C/T	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.41e-7	Venous thromboembolism;
PAAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	8.96	0.59	1.11e-15	Personality dimensions;
PAAD	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-5.01	-0.38	1.49e-6	Neuroticism;
PAAD	cis	rs7094131	0.549	rs10219113	chr10:22875788	T/C	cg19500236	chr10:22911537	PIP4K2A	0.44	4.81	0.36	3.68e-6	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16066221	chr17:28512115	CCDC55	-0.74	-7.49	-0.52	5.27e-12	Obesity-related traits;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18713687	chr3:195489789	MUC4	0.72	5.22	0.39	5.88e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.25	0.33	3.78e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs2882667	0.893	rs10044672	chr5:138290479	C/G	cg09476006	chr5:138032270	NA	0.36	4.46	0.34	1.58e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.66	-6.17	-0.45	5.82e-9	Platelet distribution width;
PAAD	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.57	4.5	0.34	1.33e-5	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs9462846	0.959	rs9471960	chr6:42884750	A/C	cg02353165	chr6:42928485	GNMT	0.54	4.31	0.33	2.89e-5	Blood protein levels;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.86	-0.37	2.88e-6	Resting heart rate;
PAAD	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.66	5.65	0.42	7.66e-8	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.77	0.42	4.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-5.69	-0.42	6.32e-8	Schizophrenia;
PAAD	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.12	0.5	3.97e-11	Diastolic blood pressure;
PAAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-5.4	-0.4	2.57e-7	Coronary artery disease;
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg24220031	chr2:73402428	NA	-0.32	-4.62	-0.35	8.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.5	-5.36	-0.4	3.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-4.48	-0.34	1.47e-5	Vitiligo;
PAAD	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg08501292	chr6:25962987	TRIM38	0.88	4.79	0.36	3.88e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.6	5.75	0.42	4.73e-8	Schizophrenia;
PAAD	cis	rs17125944	0.556	rs11625479	chr14:53354172	A/C	cg00686598	chr14:53173677	PSMC6	-0.85	-5.25	-0.39	4.97e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.73	-7.6	-0.52	2.8e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.89	-9.34	-0.6	1.11e-16	Obesity-related traits;
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.59	4.7	0.36	5.69e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9637454	1.000	rs1971937	chr3:178318745	A/G	cg17610889	chr3:177464075	NA	0.39	4.66	0.35	6.95e-6	Hippocampal sclerosis;
PAAD	cis	rs4751058	0.578	rs7099230	chr10:130856644	C/T	cg04854917	chr10:131378330	MGMT	-0.48	-4.31	-0.33	2.96e-5	Vitamin D levels;
PAAD	cis	rs77831929	0.739	rs2634071	chr4:111669220	C/T	cg18064927	chr4:111531975	NA	0.48	4.45	0.34	1.64e-5	Atrial fibrillation;
PAAD	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.46	4.27	0.33	3.42e-5	Age-related disease endophenotypes;
PAAD	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.56	-0.35	1.06e-5	Diastolic blood pressure;
PAAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg01852476	chr1:2232063	SKI	-0.28	-4.62	-0.35	8.28e-6	Ulcerative colitis;
PAAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg23083516	chr15:85180758	SCAND2	0.38	4.28	0.33	3.36e-5	P wave terminal force;
PAAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg18769074	chr3:133464867	TF	0.44	5.28	0.39	4.45e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs630539	1.000	rs630539	chr17:40693344	A/G	cg20669292	chr17:40823420	PLEKHH3	0.47	4.46	0.34	1.6e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.79	-0.36	4.01e-6	Type 2 diabetes;
PAAD	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.74	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	6.3	0.45	3.13e-9	Personality dimensions;
PAAD	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.6	0.47	6.42e-10	Total body bone mineral density;
PAAD	cis	rs7705042	0.865	rs9324866	chr5:141497650	A/G	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.18	-0.39	7.07e-7	Asthma;
PAAD	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg06766960	chr11:133703094	NA	-0.55	-5.59	-0.41	1.04e-7	Childhood ear infection;
PAAD	cis	rs12791968	0.765	rs17181389	chr11:44996996	G/T	cg11846598	chr11:44996168	LOC221122	-0.78	-7.0	-0.49	7.74e-11	Inhibitory control;
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg26205652	chr12:48591994	NA	0.77	6.97	0.49	9.25e-11	Longevity (90 years and older);
PAAD	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.98	-7.99	-0.54	3.06e-13	Blood protein levels;
PAAD	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.58	4.69	0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.08	0.63	1.27e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg26898376	chr11:64110657	CCDC88B	-0.44	-4.75	-0.36	4.71e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02284587	chr1:64971218	CACHD1	-0.62	-6.33	-0.46	2.58e-9	Smoking initiation;
PAAD	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-4.68	-0.36	6.17e-6	Menarche (age at onset);
PAAD	cis	rs2271001	0.955	rs7111105	chr11:19155554	A/C	cg00161556	chr11:19138045	ZDHHC13	-0.51	-5.14	-0.38	8.52e-7	Gut microbiome composition (winter);
PAAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.83	-0.48	1.89e-10	Personality dimensions;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18621852	chr3:10150065	C3orf24	0.64	5.51	0.41	1.5e-7	Alzheimer's disease;
PAAD	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.57	-5.96	-0.43	1.73e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.58	-5.71	-0.42	5.72e-8	Coronary artery disease or large artery stroke;
PAAD	cis	rs1419980	0.730	rs78184649	chr12:7741552	C/G	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs75920871	0.925	rs17120241	chr11:116915020	T/C	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-7.25	-0.51	1.95e-11	Vitiligo;
PAAD	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.14	14.22	0.76	1.02e-29	Colorectal cancer;
PAAD	cis	rs10821973	0.527	rs6479797	chr10:64016463	C/G	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.21	21.2	0.86	3e-47	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.03	0.44	1.19e-8	Height;
PAAD	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.95	5.34	0.4	3.3e-7	Parkinson's disease;
PAAD	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.58	0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs1595825	0.732	rs79207930	chr2:198423111	G/T	cg00982548	chr2:198649783	BOLL	-0.64	-4.27	-0.33	3.42e-5	Ulcerative colitis;
PAAD	cis	rs10768122	0.642	rs7942395	chr11:35362952	A/G	cg13971030	chr11:35366721	SLC1A2	0.46	5.49	0.41	1.68e-7	Vitiligo;
PAAD	cis	rs9649465	0.967	rs10487806	chr7:123314446	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.76	0.36	4.39e-6	Migraine;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6604026	0.656	rs34389767	chr1:93373780	T/G	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.71e-8	Multiple sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03195230	chr11:64073135	ESRRA	0.65	6.74	0.48	3.07e-10	Myopia (pathological);
PAAD	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg02415014	chr8:143852576	LYNX1	0.37	4.36	0.33	2.42e-5	Urinary tract infection frequency;
PAAD	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg07636037	chr3:49044803	WDR6	-0.56	-4.5	-0.34	1.36e-5	Menarche (age at onset);
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.16	0.5	3.22e-11	Eosinophil percentage of white cells;
PAAD	trans	rs4981053	0.553	rs12897278	chr14:20487504	T/A	cg09283223	chr16:30066971	ALDOA	0.62	6.42	0.46	1.62e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12016809	chr21:47604291	C21orf56	-0.41	-4.3	-0.33	3.04e-5	Testicular germ cell tumor;
PAAD	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.48	4.59	0.35	9.16e-6	Eosinophilic esophagitis;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs134594	0.806	rs134641	chr22:29483583	A/G	cg01361351	chr22:29467363	NA	-0.4	-4.38	-0.33	2.18e-5	Birth weight;
PAAD	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs895470	0.584	rs2393253	chr12:118146230	A/G	cg11944746	chr12:117457846	FBXW8	-0.44	-4.56	-0.35	1.06e-5	Gut microbiome composition (winter);
PAAD	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.54	0.41	1.3e-7	Alzheimer's disease (late onset);
PAAD	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg06207120	chr15:45996521	NA	0.31	4.46	0.34	1.56e-5	Waist circumference;Weight;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25214090	chr10:38739885	LOC399744	0.66	7.19	0.5	2.76e-11	Corneal astigmatism;
PAAD	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15202251	chr7:100183972	FBXO24;LRCH4	-0.67	-6.8	-0.48	2.22e-10	Primary biliary cholangitis;
PAAD	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07640645	chr4:175204879	FBXO8;KIAA1712	-0.56	-6.47	-0.46	1.27e-9	Body fat percentage;
PAAD	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg26816564	chr1:7831052	VAMP3	0.75	5.75	0.42	4.86e-8	Inflammatory bowel disease;
PAAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-7.79	-0.53	9.57e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs11191205	1.000	rs11191205	chr10:103831598	G/A	cg15320455	chr10:103880129	LDB1	0.58	4.69	0.36	6.02e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1656368	0.726	rs73154309	chr3:158214621	C/T	cg16708174	chr3:158430962	RARRES1	0.59	5.34	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2241685	0.850	rs7591787	chr2:1942841	C/T	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.56	-5.64	-0.42	8.05e-8	Urate levels;
PAAD	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.51	-0.34	1.29e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg27029450	chr22:50098074	NA	0.68	4.62	0.35	8.09e-6	Natriuretic peptide levels;
PAAD	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.64	-0.35	7.4e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs17293817	0.562	rs11250484	chr10:1417599	G/T	cg02408697	chr10:1416920	ADARB2	-0.47	-4.31	-0.33	2.9e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06850241	chr22:41845214	NA	0.54	5.08	0.38	1.1e-6	Vitiligo;
PAAD	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg12560992	chr17:57184187	TRIM37	0.67	5.04	0.38	1.31e-6	Vitamin D levels;
PAAD	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg14843632	chr5:14870594	ANKH	-0.51	-5.63	-0.42	8.41e-8	Blood metabolite levels;
PAAD	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.87e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.64	-0.35	7.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.5	-6.23	-0.45	4.46e-9	Lewy body disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16419686	chr13:114903650	NA	0.66	7.3	0.51	1.51e-11	Smoking initiation;
PAAD	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg12935359	chr14:103987150	CKB	-0.52	-5.61	-0.41	9.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.34	0.33	2.64e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3996993	0.597	rs10948728	chr6:52723635	C/T	cg00536792	chr6:53530503	KLHL31	-0.42	-4.43	-0.34	1.8e-5	Hemoglobin concentration;
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg00431813	chr7:1051703	C7orf50	0.51	4.26	0.33	3.6e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73019876	0.747	rs7258834	chr19:22228121	A/G	cg11619707	chr19:22235551	ZNF257	-0.43	-4.74	-0.36	4.85e-6	Testicular germ cell tumor;
PAAD	cis	rs11168618	0.846	rs7958521	chr12:48877400	G/A	cg01881778	chr12:48919444	OR8S1	-0.49	-4.91	-0.37	2.34e-6	Adiponectin levels;
PAAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg11833968	chr6:79620685	NA	-0.43	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg27511599	chr7:32358540	NA	0.76	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs3753841	0.752	rs12138977	chr1:103393457	C/T	cg24495344	chr1:103574097	COL11A1	0.4	4.32	0.33	2.78e-5	Glaucoma (primary angle closure);
PAAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7713065	0.836	rs2057657	chr5:131809316	A/G	cg14196790	chr5:131705035	SLC22A5	-0.56	-5.09	-0.38	1.05e-6	Lung function (FEV1/FVC);
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08744769	chr2:70142523	MXD1	0.67	7.77	0.53	1.11e-12	Metabolite levels  (X-11787);
PAAD	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg15956490	chr3:53032818	SFMBT1	0.78	4.37	0.33	2.27e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg06636551	chr8:101224915	SPAG1	0.59	7.55	0.52	3.65e-12	Atrioventricular conduction;
PAAD	cis	rs4900538	0.827	rs1046651	chr14:102971016	T/C	cg01761236	chr14:102990251	NA	0.38	4.43	0.34	1.82e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.92	0.59	1.35e-15	Lung cancer;
PAAD	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-4.97	-0.37	1.77e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg08562672	chr19:21860753	NA	0.45	4.68	0.36	6.24e-6	Pain;
PAAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.81	-8.73	-0.58	4.31e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-7.23	-0.51	2.15e-11	Asthma;
PAAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs9859260	0.616	rs9867473	chr3:195831098	A/C	cg01181863	chr3:195395398	SDHAP2	-0.51	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs8112211	0.731	rs3745952	chr19:38818299	C/T	cg14299480	chr19:38876666	GGN	-0.62	-6.01	-0.44	1.3e-8	Blood protein levels;
PAAD	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.69	-0.36	5.92e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25412641	chr6:157877120	ZDHHC14	-0.59	-6.3	-0.46	3.07e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.73	5.22	0.39	5.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.7	7.13	0.5	3.78e-11	Sudden cardiac arrest;
PAAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.61	0.57	8.59e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6005807	0.543	rs12168849	chr22:29202063	A/G	cg15103426	chr22:29168792	CCDC117	0.64	4.75	0.36	4.73e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg12568669	chr8:11666485	FDFT1	-0.31	-5.21	-0.39	6.19e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	5.9	0.43	2.27e-8	Body mass index;
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.41	5.45	0.4	2.02e-7	Vitiligo;
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.58	-7.29	-0.51	1.59e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.29	0.68	7.35e-22	Platelet count;
PAAD	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg11783602	chr8:55087084	NA	-0.65	-7.4	-0.51	8.83e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.33	0.33	2.66e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	trans	rs901683	1.000	rs36100685	chr10:46086854	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.4	-0.34	2.03e-5	Testicular germ cell tumor;
PAAD	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-5.36	-0.4	3.01e-7	Caffeine consumption;
PAAD	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.44	0.34	1.72e-5	Lung cancer;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg18279126	chr7:2041391	MAD1L1	0.55	5.55	0.41	1.27e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs11112613	0.609	rs11112636	chr12:106047204	G/A	cg03607813	chr12:105948248	NA	0.78	5.6	0.41	9.55e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.96	8.02	0.55	2.64e-13	Neutrophil percentage of white cells;
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg20821713	chr7:1055600	C7orf50	-0.52	-4.48	-0.34	1.49e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.49	4.48	0.34	1.46e-5	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg03517284	chr6:25882590	NA	0.49	4.28	0.33	3.31e-5	Iron status biomarkers;
PAAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-4.74	-0.36	4.83e-6	Bipolar disorder;
PAAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.07	0.38	1.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg16447950	chr5:562315	NA	-0.51	-4.8	-0.36	3.71e-6	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.02e-8	Electrocardiographic conduction measures;
PAAD	cis	rs2286379	0.626	rs10848560	chr12:1839492	C/T	cg05227549	chr12:1770782	NA	-0.44	-5.09	-0.38	1.03e-6	Blood pressure (smoking interaction);
PAAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.47	5.98	0.44	1.5e-8	Childhood ear infection;
PAAD	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-1.01	-8.59	-0.57	9.88e-15	Blood trace element (Zn levels);
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.83	6.64	0.47	5.31e-10	Lung function (FEV1/FVC);
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg16606324	chr3:10149918	C3orf24	0.85	6.07	0.44	9.91e-9	Alzheimer's disease;
PAAD	cis	rs2070677	0.627	rs2987797	chr10:135379934	G/A	cg08390786	chr10:135334061	NA	-0.66	-5.54	-0.41	1.29e-7	Gout;
PAAD	cis	rs6142102	0.602	rs68051854	chr20:32701956	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.9	0.37	2.4e-6	Skin pigmentation;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.35	0.4	3.16e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10821973	0.550	rs10761614	chr10:63975930	C/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg17554472	chr22:41940697	POLR3H	0.57	4.27	0.33	3.41e-5	Vitiligo;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.45	-4.79	-0.36	3.96e-6	Longevity;Endometriosis;
PAAD	cis	rs17221323	1.000	rs17221323	chr10:618685	A/G	cg16386425	chr10:429943	DIP2C	-0.63	-5.39	-0.4	2.61e-7	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs3747547	0.892	rs11789186	chr9:37975114	A/C	cg13774184	chr9:37916125	SHB	-0.59	-4.27	-0.33	3.47e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg06917634	chr15:78832804	PSMA4	-0.48	-4.66	-0.35	6.89e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	5.72	0.42	5.57e-8	Total body bone mineral density;
PAAD	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.7	4.54	0.35	1.13e-5	Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.42	0.34	1.88e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-6.4	-0.46	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-1.1	-12.68	-0.72	1.32e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.07	0.38	1.16e-6	Body mass index;
PAAD	cis	rs7624766	0.743	rs12637922	chr3:160537813	A/T	cg22637730	chr3:160473554	PPM1L	-0.51	-4.61	-0.35	8.35e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	trans	rs1850744	0.702	rs2077679	chr4:9608089	G/A	cg08077071	chr2:157176106	NA	0.92	6.33	0.46	2.65e-9	Economic and political preferences;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg18279126	chr7:2041391	MAD1L1	-0.61	-6.27	-0.45	3.49e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16747999	chr8:95653174	ESRP1	0.57	6.42	0.46	1.67e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4588572	0.561	rs10942858	chr5:77803267	A/C	cg18281939	chr5:77783895	LHFPL2	0.43	4.94	0.37	2.03e-6	Triglycerides;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26056348	chr7:75932317	HSPB1	0.67	7.55	0.52	3.7e-12	Myopia (pathological);
PAAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.58	6.04	0.44	1.16e-8	Dupuytren's disease;
PAAD	cis	rs58521262	0.556	rs459820	chr19:23131783	C/T	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.49	-0.76	1.99e-30	Headache;
PAAD	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.57	5.22	0.39	5.73e-7	Blood metabolite levels;
PAAD	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.82	8.78	0.58	3.18e-15	Height;
PAAD	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg22916017	chr11:64110731	CCDC88B	0.47	4.54	0.35	1.13e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.52	4.55	0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-6.74	-0.48	3.03e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4356203	0.870	rs214909	chr11:17243278	T/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs12134245	0.527	rs6681073	chr1:92022597	A/C	cg25838465	chr1:92012736	NA	-0.43	-4.49	-0.34	1.38e-5	Breast cancer;
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.83	9.14	0.6	3.73e-16	Prostate cancer;
PAAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.3	0.33	3.04e-5	Breast cancer;
PAAD	cis	rs2286379	0.743	rs10848561	chr12:1839493	A/G	cg05227549	chr12:1770782	NA	-0.42	-4.69	-0.36	6.15e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.57	-6.86	-0.49	1.61e-10	Total body bone mineral density;
PAAD	cis	rs7624766	0.695	rs1839019	chr3:160578472	A/G	cg22637730	chr3:160473554	PPM1L	0.53	4.73	0.36	4.99e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	cis	rs11051970	0.559	rs113700251	chr12:32562271	G/A	cg24626660	chr12:32551988	NA	0.44	4.67	0.35	6.44e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17458653	chr2:179345078	MIR548N;PLEKHA3	0.64	6.71	0.48	3.6e-10	Myopia (pathological);
PAAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.54	0.61	3.39e-17	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg02367709	chr17:66097352	LOC651250	0.44	4.42	0.34	1.9e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.69	-0.42	6.4e-8	Total cholesterol levels;
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.64	-0.42	8.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10501293	0.828	rs17497596	chr11:43102898	A/G	cg03447554	chr11:43094025	NA	0.45	4.53	0.34	1.19e-5	Cognitive performance;
PAAD	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg00409905	chr10:38381863	ZNF37A	0.62	5.32	0.4	3.67e-7	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.73	-8.23	-0.55	8.09e-14	Dental caries;
PAAD	cis	rs12913538	1.000	rs11071676	chr15:62889661	C/T	cg09983546	chr15:62884068	NA	-0.71	-8.01	-0.54	2.73e-13	Sleep depth;
PAAD	cis	rs62025270	0.632	rs62022942	chr15:86258568	A/T	cg13263323	chr15:86062960	AKAP13	0.48	4.39	0.34	2.14e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	cis	rs72827839	1.000	rs17624626	chr17:46535805	G/A	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg02951883	chr7:2050386	MAD1L1	0.58	5.67	0.42	6.96e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6460942	0.659	rs28366613	chr7:12512167	C/T	cg06484146	chr7:12443880	VWDE	-0.91	-5.29	-0.39	4.16e-7	Coronary artery disease;
PAAD	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.26e-6	Hepatitis;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs1595825	0.786	rs1902247	chr2:198492826	C/T	cg10547527	chr2:198650123	BOLL	-0.66	-4.6	-0.35	8.87e-6	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21532408	chr13:101241430	NA	0.68	7.35	0.51	1.12e-11	Smoking initiation;
PAAD	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.69	5.61	0.41	9.33e-8	Heart failure;
PAAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.87	8.15	0.55	1.23e-13	Menarche (age at onset);
PAAD	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg16447950	chr5:562315	NA	-0.52	-4.93	-0.37	2.14e-6	Obesity-related traits;
PAAD	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg12454169	chr2:30669597	LCLAT1	0.75	6.2	0.45	5.19e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.87	-0.37	2.82e-6	Triglycerides;
PAAD	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.84	9.06	0.59	6.01e-16	Schizophrenia;
PAAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg25753631	chr6:25732923	NA	-0.47	-4.39	-0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.74	7.16	0.5	3.25e-11	Asthma;
PAAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.95	8.35	0.56	3.87e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.07	13.78	0.75	1.53e-28	Testicular germ cell tumor;
PAAD	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg12633918	chr20:23549525	CST9L	-0.4	-4.43	-0.34	1.78e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg07952391	chr2:88470173	THNSL2	-0.5	-4.82	-0.36	3.43e-6	Response to metformin (IC50);
PAAD	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-9.21	-0.6	2.41e-16	Prostate cancer;
PAAD	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.95	11.59	0.68	1.21e-22	Coronary artery disease;
PAAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg12257692	chr3:49977190	RBM6	0.35	4.46	0.34	1.59e-5	Body mass index;
PAAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.53	-4.34	-0.33	2.58e-5	Iron status biomarkers;
PAAD	cis	rs7833986	0.538	rs72653960	chr8:56996675	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	4.33	0.33	2.73e-5	Height;
PAAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.63	7.06	0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs7976059	0.505	rs303795	chr12:52245938	C/T	cg13698196	chr12:52257893	NA	-0.37	-4.45	-0.34	1.68e-5	Urate levels;
PAAD	cis	rs7688540	0.760	rs28460123	chr4:240208	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.38	0.33	2.22e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.61	5.33	0.4	3.41e-7	Neutrophil percentage of white cells;
PAAD	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.97	6.54	0.47	8.67e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg23033748	chr14:75592666	NEK9	0.4	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.93	-8.17	-0.55	1.09e-13	Other erythrocyte phenotypes;
PAAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1178968	0.818	rs6957049	chr7:72754037	G/A	cg25889504	chr7:72793014	NA	0.58	4.26	0.33	3.59e-5	Triglyceride levels;
PAAD	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.67	6.95	0.49	1.01e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg23024343	chr7:107201750	COG5	0.57	4.8	0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6942407	0.649	rs6975202	chr7:86860382	C/A	cg02420886	chr7:86849541	C7orf23	0.59	4.6	0.35	8.86e-6	Food allergy;
PAAD	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.09	0.38	1.03e-6	Prostate cancer;
PAAD	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.79	8.07	0.55	2e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg00717180	chr2:96193071	NA	-0.62	-7.56	-0.52	3.56e-12	Coronary artery disease;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.83	-0.43	3.21e-8	Menarche (age at onset);
PAAD	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.71	8.42	0.56	2.56e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.83	-7.42	-0.52	7.6e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06634786	chr22:41940651	POLR3H	-0.65	-5.14	-0.38	8.28e-7	Vitiligo;
PAAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.73	-7.75	-0.53	1.2e-12	DNA methylation (variation);
PAAD	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg08601574	chr20:25228251	PYGB	0.5	5.09	0.38	1.04e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs17083533	1.000	rs79973667	chr6:121684159	T/C	cg13516479	chr6:122016629	NA	-0.82	-4.48	-0.34	1.44e-5	Heart rate;
PAAD	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6976053	0.810	rs2405975	chr7:100508212	T/C	cg22425096	chr7:100417404	EPHB4	0.49	4.35	0.33	2.51e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-7.83	-0.54	7.78e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg23093090	chr10:104574429	C10orf26	-0.43	-4.72	-0.36	5.31e-6	Arsenic metabolism;
PAAD	cis	rs57994353	0.568	rs10870166	chr9:139316916	C/G	cg21253087	chr9:139290292	SNAPC4	0.52	4.58	0.35	9.65e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.42	0.4	2.24e-7	Caffeine consumption;
PAAD	cis	rs2031532	0.544	rs12429813	chr13:50038080	G/A	cg08779649	chr13:50194554	NA	0.33	4.35	0.33	2.5e-5	Cardiac hypertrophy;
PAAD	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-6.03	-0.44	1.19e-8	Rheumatoid arthritis;
PAAD	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg02389323	chr16:88786976	FAM38A	0.98	6.3	0.46	3.01e-9	Plateletcrit;
PAAD	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg16342193	chr10:102329863	NA	-0.79	-8.64	-0.57	7.12e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.37	-0.4	2.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg23018236	chr17:30244563	NA	-0.62	-4.35	-0.33	2.52e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg27205649	chr11:78285834	NARS2	-0.6	-4.43	-0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7945718	0.622	rs4643058	chr11:12689454	C/T	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.57	-6.24	-0.45	4.14e-9	Electroencephalogram traits;
PAAD	cis	rs7301016	1.000	rs7301016	chr12:62886123	A/G	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11189177	chr17:1065204	ABR	0.65	7.15	0.5	3.39e-11	Smoking initiation;
PAAD	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.91	7.07	0.5	5.33e-11	Axial length;
PAAD	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg09796270	chr17:17721594	SREBF1	0.48	5.16	0.39	7.45e-7	Total body bone mineral density;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.42	-0.52	7.56e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.6e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.56	-5.3	-0.39	4.04e-7	Diastolic blood pressure;
PAAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.68	0.35	6.36e-6	Breast cancer;
PAAD	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.01	0.38	1.5e-6	Migraine;
PAAD	cis	rs9320282	0.587	rs1546721	chr6:109625796	T/C	cg21918786	chr6:109611834	NA	-0.46	-5.15	-0.39	7.87e-7	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.79	-9.04	-0.59	6.9e-16	Age at first birth;
PAAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14180030	chr9:123475675	MEGF9	-0.39	-4.42	-0.34	1.88e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	trans	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg19694781	chr19:47549865	TMEM160	0.74	7.59	0.52	3.07e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs901683	1.000	rs10508896	chr10:46030643	A/G	cg23720331	chr10:123873670	TACC2	-0.84	-6.66	-0.48	4.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg21565972	chr17:80109576	CCDC57	0.47	5.1	0.38	9.95e-7	Life satisfaction;
PAAD	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.41	0.65	1.72e-19	Bladder cancer;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	1.0	8.75	0.58	3.75e-15	Alzheimer's disease;
PAAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs6867913	1.000	rs12519447	chr5:141457161	G/A	cg23435118	chr5:141488016	NDFIP1	0.47	4.4	0.34	2.04e-5	Asthma;
PAAD	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-6.8	-0.48	2.27e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg04520793	chr17:42248056	ASB16	0.43	5.18	0.39	6.88e-7	Total body bone mineral density;
PAAD	cis	rs58521262	0.516	rs10408398	chr19:23095426	A/G	cg02350677	chr19:23254381	NA	-0.27	-4.56	-0.35	1.04e-5	Testicular germ cell tumor;
PAAD	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg10705379	chr10:99080932	FRAT1	-0.45	-5.15	-0.39	7.9e-7	Monocyte count;
PAAD	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.56	4.92	0.37	2.22e-6	Life satisfaction;
PAAD	cis	rs1468333	0.694	rs7719684	chr5:137614085	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.79	0.43	3.83e-8	Resting heart rate;
PAAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.84	-10.17	-0.64	7.38e-19	Ulcerative colitis;
PAAD	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16265012	chr19:7964574	LRRC8E	0.52	6.49	0.47	1.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.67	5.25	0.39	4.93e-7	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.07	0.44	9.99e-9	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.85	10.0	0.63	2.11e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.7	5.54	0.41	1.28e-7	Height;
PAAD	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs986417	0.818	rs7156107	chr14:61059153	C/G	cg27398547	chr14:60952738	C14orf39	-0.58	-4.49	-0.34	1.4e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12582317	chr17:55822272	NA	0.71	8.7	0.58	5.07e-15	Schizophrenia;
PAAD	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.46	5.02	0.38	1.45e-6	Pneumonia;
PAAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.49	5.25	0.39	4.94e-7	Lung cancer;
PAAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg10556349	chr10:835070	NA	0.58	4.64	0.35	7.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs17824933	1.000	rs12797044	chr11:60768018	T/A	cg27098804	chr11:60776124	CD6	0.45	4.44	0.34	1.75e-5	Multiple sclerosis;
PAAD	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.92	7.08	0.5	4.86e-11	Axial length;
PAAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.8	-0.53	8.95e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs7945718	0.592	rs10765985	chr11:12676468	G/A	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.08e-5	Educational attainment (years of education);
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.88	-10.2	-0.64	6.31e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10267417	0.603	rs4236297	chr7:19910884	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.64	-4.83	-0.36	3.36e-6	Diastolic blood pressure;
PAAD	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.69	-5.68	-0.42	6.57e-8	Neuroticism;
PAAD	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.76	7.95	0.54	3.99e-13	Gout;
PAAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.71	4.76	0.36	4.39e-6	Yeast infection;
PAAD	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.43	0.61	6.74e-17	Morning vs. evening chronotype;
PAAD	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg27490568	chr2:178487706	NA	0.49	5.18	0.39	6.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs73195822	0.542	rs73206866	chr12:110816505	A/G	cg12870014	chr12:110450643	ANKRD13A	1.0	5.22	0.39	5.67e-7	Itch intensity from mosquito bite;
PAAD	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg04450456	chr4:17643702	FAM184B	0.46	5.0	0.38	1.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg08036796	chr19:5034282	KDM4B	0.46	4.44	0.34	1.7e-5	Monocyte percentage of white cells;
PAAD	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.56	-4.95	-0.37	1.94e-6	P wave terminal force;
PAAD	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22396632	chr1:3079212	PRDM16	-0.42	-4.42	-0.34	1.87e-5	Migraine;
PAAD	cis	rs2839627	0.638	rs73233314	chr21:44297774	G/T	cg03543861	chr21:44258195	NA	0.6	4.37	0.33	2.31e-5	Information processing speed;
PAAD	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.3	8.51	0.57	1.56e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7715811	0.913	rs6869474	chr5:13768691	C/T	cg07548982	chr5:13769939	DNAH5	-0.65	-6.14	-0.45	6.79e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	1.16	13.08	0.73	1.17e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	0.99	6.46	0.46	1.37e-9	IgG glycosylation;
PAAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.82	6.48	0.47	1.22e-9	Small cell lung carcinoma;
PAAD	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	0.93	6.03	0.44	1.18e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11613048	0.897	rs6487885	chr12:30344688	T/C	cg03476860	chr12:30948794	NA	-0.35	-4.3	-0.33	3.03e-5	Major depressive disorder;
PAAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.79	6.49	0.47	1.13e-9	Activated partial thromboplastin time;
PAAD	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07362569	chr17:61921086	SMARCD2	0.61	7.17	0.5	2.98e-11	Prudent dietary pattern;
PAAD	cis	rs11669133	1.000	rs75162188	chr19:11131403	T/C	cg25243385	chr19:11167475	SMARCA4	0.98	4.59	0.35	9.11e-6	LDL cholesterol;
PAAD	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	cis	rs8060686	0.641	rs7195605	chr16:67989523	T/C	cg01866162	chr16:67596514	CTCF	0.58	4.38	0.33	2.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.1	-12.68	-0.72	1.32e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg23093090	chr10:104574429	C10orf26	0.41	4.86	0.37	2.87e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs4605213	0.528	rs12951858	chr17:49328627	C/G	cg25022915	chr17:49243257	NME2;NME1-NME2	0.36	4.63	0.35	7.74e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.6	7.03	0.5	6.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.46	0.34	1.59e-5	Self-reported allergy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13006227	chr2:62132614	COMMD1	0.7	7.39	0.51	9.18e-12	Obesity-related traits;
PAAD	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg10556349	chr10:835070	NA	0.6	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.12	-0.38	9.03e-7	Joint mobility (Beighton score);
PAAD	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs11892454	0.544	rs34921778	chr2:26011810	A/G	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.8e-5	Heschl's gyrus morphology;
PAAD	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.76	5.54	0.41	1.31e-7	Major depressive disorder;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.39e-10	Life satisfaction;
PAAD	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	0.99	11.72	0.69	5.11e-23	Testicular germ cell tumor;
PAAD	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.71	0.66	2.64e-20	Smoking behavior;
PAAD	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg01370759	chr7:2701419	TTYH3	0.64	4.42	0.34	1.85e-5	Neuroticism;
PAAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.92	-0.37	2.18e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.66	6.31	0.46	2.84e-9	Pulse pressure;
PAAD	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.57	5.92	0.43	2.1e-8	Neuroticism;
PAAD	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg12623918	chr2:306882	NA	0.48	5.05	0.38	1.23e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs1912528	0.814	rs769674	chr4:140881964	A/T	cg11128457	chr4:140864437	MAML3	-0.33	-4.43	-0.34	1.83e-5	Educational attainment (years of education);
PAAD	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-7.08	-0.5	5.04e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.95	0.54	3.95e-13	Prudent dietary pattern;
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.13	-0.38	8.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs501120	0.584	rs11238890	chr10:44669226	A/T	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.2	0.39	6.27e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg06637938	chr14:75390232	RPS6KL1	0.64	6.3	0.45	3.06e-9	IgG glycosylation;
PAAD	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.58	5.77	0.42	4.21e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-4.52	-0.34	1.25e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.42	-0.34	1.89e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.67	-6.21	-0.45	4.83e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	8.31	0.56	4.82e-14	Homoarginine levels;
PAAD	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg22437258	chr11:111473054	SIK2	0.63	6.24	0.45	4.11e-9	Primary sclerosing cholangitis;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.54	-5.49	-0.41	1.66e-7	Iron status biomarkers;
PAAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.6	-5.32	-0.4	3.58e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg17346650	chr17:80929145	B3GNTL1	0.47	5.8	0.43	3.64e-8	Glycated hemoglobin levels;
PAAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs911119	0.913	rs3004145	chr20:23582876	C/G	cg16589663	chr20:23618590	CST3	-0.8	-6.97	-0.49	8.9e-11	Chronic kidney disease;
PAAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	4.75	0.36	4.59e-6	Airway imaging phenotypes;
PAAD	cis	rs3764563	1.000	rs601410	chr19:15693247	C/T	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-8.71	-0.58	4.89e-15	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04384181	chr14:61189551	SIX4	-0.63	-6.35	-0.46	2.38e-9	Smoking initiation;
PAAD	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.61	-5.0	-0.38	1.59e-6	Neuroblastoma;
PAAD	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg20744362	chr22:50050164	C22orf34	0.67	7.64	0.53	2.21e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.78	-9.03	-0.59	7.42e-16	Menopause (age at onset);
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.61	-8.36	-0.56	3.61e-14	Longevity;Endometriosis;
PAAD	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.32	0.56	4.68e-14	Dupuytren's disease;
PAAD	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.49	4.63	0.35	7.83e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg26727032	chr16:67993705	SLC12A4	0.61	4.36	0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.43	-4.45	-0.34	1.68e-5	Iron status biomarkers;
PAAD	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	4.43	0.34	1.8e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.85	11.03	0.67	3.8e-21	Height;
PAAD	cis	rs1789882	1	rs1789882	chr4:100235053	A/G	cg12011299	chr4:100065546	ADH4	-0.54	-4.58	-0.35	9.66e-6	Alcohol dependence;
PAAD	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg27094323	chr7:1216898	NA	-0.56	-6.96	-0.49	9.39e-11	Longevity;Endometriosis;
PAAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg09835421	chr16:68378352	PRMT7	-1.0	-6.46	-0.46	1.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.95	-0.49	1e-10	Lung cancer;
PAAD	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7247513	1.000	rs8104385	chr19:12700284	G/A	cg01871581	chr19:12707946	ZNF490	-0.83	-9.96	-0.63	2.64e-18	Bipolar disorder;
PAAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg16205897	chr5:131564050	P4HA2	-0.5	-5.41	-0.4	2.42e-7	Blood metabolite levels;
PAAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02071572	chr4:1403502	NA	0.36	4.6	0.35	8.8e-6	Longevity;
PAAD	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.52	5.37	0.4	2.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6681460	0.932	rs523188	chr1:67174422	A/G	cg02459107	chr1:67143332	SGIP1	0.69	6.66	0.48	4.68e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.05	0.38	1.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.65	6.6	0.47	6.44e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.57	7.29	0.51	1.61e-11	Multiple system atrophy;
PAAD	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.66	5.64	0.42	7.93e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1642645	0.757	rs6600394	chr1:42472453	T/C	cg01990334	chr1:42801334	FOXJ3	-0.62	-5.74	-0.42	5.04e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.65	-6.4	-0.46	1.79e-9	Pubertal anthropometrics;
PAAD	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.35	-4.47	-0.34	1.52e-5	Educational attainment (years of education);
PAAD	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg16576597	chr16:28551801	NUPR1	0.63	6.97	0.49	9.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs13272623	0.502	rs268627	chr8:71561041	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.58	-4.3	-0.33	3.08e-5	IgG glycosylation;
PAAD	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.85	-8.4	-0.56	2.86e-14	Body mass index;
PAAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs8112211	0.689	rs2304177	chr19:38795159	G/A	cg14299480	chr19:38876666	GGN	-0.52	-4.46	-0.34	1.57e-5	Blood protein levels;
PAAD	cis	rs9815354	0.680	rs79239400	chr3:42030249	C/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9322817	0.583	rs9391227	chr6:105158634	T/A	cg02098413	chr6:105308735	HACE1	-0.44	-5.54	-0.41	1.33e-7	Thyroid stimulating hormone;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15233734	chr6:37450823	C6orf129	-0.66	-6.95	-0.49	1.01e-10	Obesity-related traits;
PAAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.53	5.37	0.4	2.95e-7	Social autistic-like traits;
PAAD	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg27236539	chr20:62289627	RTEL1	0.57	4.65	0.35	7.24e-6	Atopic dermatitis;
PAAD	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.45	6.98	0.49	8.69e-11	IgG glycosylation;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg07202610	chr7:1142643	C7orf50	-0.66	-5.11	-0.38	9.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.75	0.42	4.78e-8	Colorectal cancer;
PAAD	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	6.46	0.46	1.33e-9	Lung cancer in ever smokers;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	4.33	0.33	2.7e-5	Tonsillectomy;
PAAD	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.93e-5	Total body bone mineral density;
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05025164	chr4:1340916	KIAA1530	0.76	7.85	0.54	7.08e-13	Longevity;
PAAD	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.6	6.78	0.48	2.45e-10	High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs780142	0.672	rs8039781	chr15:62836025	A/G	cg12918536	chr15:62891943	NA	0.36	4.45	0.34	1.68e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs11264213	0.591	rs274728	chr1:36493420	T/C	cg27506609	chr1:36549197	TEKT2	-1.1	-6.59	-0.47	6.81e-10	Schizophrenia;
PAAD	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg10437265	chr15:77819839	NA	0.43	4.78	0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.95	6.67	0.48	4.37e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.81	8.14	0.55	1.29e-13	Testicular germ cell tumor;
PAAD	cis	rs7624766	0.743	rs1378655	chr3:160527078	T/G	cg22637730	chr3:160473554	PPM1L	0.52	4.66	0.35	6.77e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	6.31	0.46	2.87e-9	Adiposity;
PAAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.61	0.57	8.85e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg00579200	chr11:133705235	NA	-0.48	-5.36	-0.4	2.97e-7	Childhood ear infection;
PAAD	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.59	6.19	0.45	5.43e-9	Obesity-related traits;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.65	5.34	0.4	3.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.62	0.62	2.05e-17	Electrocardiographic conduction measures;
PAAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06544989	chr22:39130855	UNC84B	0.52	5.43	0.4	2.19e-7	Menopause (age at onset);
PAAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.12	-13.28	-0.73	3.25e-27	Cognitive function;
PAAD	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.67	6.11	0.44	7.87e-9	Platelet count;
PAAD	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg00277334	chr10:82204260	NA	-0.58	-5.85	-0.43	2.96e-8	Post bronchodilator FEV1;
PAAD	cis	rs6679454	0.845	rs9645409	chr1:58374317	G/C	cg17491850	chr1:57888480	DAB1	-0.36	-4.32	-0.33	2.78e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.54	-4.92	-0.37	2.18e-6	Menopause (age at onset);
PAAD	cis	rs75920871	1.000	rs1473324	chr11:116821918	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.86	-9.68	-0.62	1.47e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs4280164	0.708	rs78269053	chr14:24794314	A/G	cg07162820	chr14:24837146	NFATC4	0.39	4.53	0.34	1.18e-5	Parent of origin effect on language impairment (paternal);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00931497	chr10:124767499	IKZF5;ACADSB	-0.69	-6.36	-0.46	2.21e-9	Lung cancer in ever smokers;
PAAD	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.58	-4.99	-0.38	1.64e-6	Common traits (Other);
PAAD	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-13.99	-0.75	4.26e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.48	-4.73	-0.36	5.19e-6	Mortality in heart failure;
PAAD	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg15017067	chr4:17643749	FAM184B	-0.39	-4.27	-0.33	3.39e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	6.1	0.44	8.37e-9	Height;
PAAD	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9341808	0.556	rs2223875	chr6:81045452	C/T	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs988913	0.581	rs2134537	chr6:54858006	C/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	9.22	0.6	2.26e-16	Response to antipsychotic treatment;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg16506815	chr2:162101123	NA	-0.71	-9.11	-0.59	4.35e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg18279126	chr7:2041391	MAD1L1	0.51	4.99	0.38	1.61e-6	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.51	-0.41	1.49e-7	Mean platelet volume;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.85	-10.39	-0.64	1.89e-19	Aortic root size;
PAAD	cis	rs6594713	0.533	rs4705464	chr5:112993214	C/G	cg12552261	chr5:112820674	MCC	-0.73	-4.64	-0.35	7.52e-6	Brain cytoarchitecture;
PAAD	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs1847202	0.927	rs13081361	chr3:72947895	T/C	cg25664220	chr3:72788482	NA	-0.44	-4.69	-0.36	5.93e-6	Motion sickness;
PAAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg06740227	chr12:86229804	RASSF9	0.58	5.67	0.42	7.13e-8	Major depressive disorder;
PAAD	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.8	6.62	0.47	5.72e-10	Alzheimer's disease;
PAAD	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.46	-0.34	1.57e-5	Menopause (age at onset);
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462027	0.628	rs10947521	chr6:34689377	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.4	0.4	2.51e-7	Systemic lupus erythematosus;
PAAD	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.83	-7.92	-0.54	4.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg11993925	chr19:44307056	LYPD5	-0.5	-6.68	-0.48	4.23e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.95	8.72	0.58	4.4e-15	Gut microbiome composition (summer);
PAAD	cis	rs12625057	0.541	rs11086668	chr20:57785057	C/T	cg17286326	chr20:57796491	ZNF831	-0.72	-4.45	-0.34	1.62e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs300774	0.858	rs444497	chr2:123332	C/G	cg21211680	chr2:198530	NA	-0.64	-5.84	-0.43	3e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg07703079	chr11:430292	ANO9	0.93	5.8	0.43	3.68e-8	Body mass index;
PAAD	cis	rs2290416	0.792	rs3812444	chr8:144693261	G/A	cg13191508	chr8:144600686	ZC3H3	-0.92	-4.52	-0.34	1.23e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14967020	chr22:45277475	PHF21B	-0.66	-7.24	-0.51	2.07e-11	Obesity-related traits;
PAAD	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.63	6.52	0.47	9.75e-10	Testicular germ cell tumor;
PAAD	cis	rs797680	0.789	rs797671	chr1:93700363	C/A	cg04535902	chr1:92947332	GFI1	-0.46	-4.43	-0.34	1.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg07220939	chr11:64358617	SLC22A12	0.44	4.72	0.36	5.42e-6	Urate levels in obese individuals;
PAAD	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.14	5.58	0.41	1.07e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.72	5.22	0.39	5.72e-7	Major depressive disorder;
PAAD	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg06784991	chr1:53308768	ZYG11A	0.27	4.25	0.33	3.67e-5	Monocyte count;
PAAD	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19350812	chr19:10676864	KRI1	-0.67	-6.55	-0.47	8.35e-10	Lung cancer in ever smokers;
PAAD	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.79	9.1	0.59	4.64e-16	Eosinophil percentage of white cells;
PAAD	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.24e-7	Multiple sclerosis;
PAAD	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.79	0.53	9.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.72	-0.42	5.41e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08432650	chr20:43104474	TTPAL	0.56	6.29	0.45	3.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.85	-9.77	-0.62	8.36e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13560548	chr3:10150139	C3orf24	0.62	5.47	0.41	1.78e-7	Alzheimer's disease;
PAAD	cis	rs4343996	0.692	rs1546742	chr7:3456210	C/A	cg21248987	chr7:3385318	SDK1	0.47	5.06	0.38	1.21e-6	Motion sickness;
PAAD	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.69e-5	Schizophrenia;
PAAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	5.61	0.41	9.34e-8	Response to bleomycin (chromatid breaks);
PAAD	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-5.28	-0.39	4.44e-7	Schizophrenia (age at onset);
PAAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	trans	rs901683	0.850	rs79022473	chr10:46101768	C/T	cg07567308	chr20:3149320	ProSAPiP1	0.73	6.32	0.46	2.78e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg06606381	chr12:133084897	FBRSL1	0.99	6.35	0.46	2.35e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.79	9.54	0.61	3.33e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6009527	0.762	rs2318940	chr22:49573394	G/A	cg12746016	chr22:49560550	NA	0.5	4.95	0.37	1.98e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs1497828	0.956	rs2646833	chr1:217545039	A/G	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.41	-0.46	1.7e-9	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs288342	0.832	rs288307	chr2:183652094	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.62	-0.35	8.18e-6	Recurrent major depressive disorder;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg05457628	chr5:178986728	RUFY1	0.56	5.39	0.4	2.68e-7	Lung cancer;
PAAD	cis	rs786425	0.740	rs7397160	chr12:124196219	G/A	cg16237390	chr12:124156159	TCTN2	0.46	4.26	0.33	3.52e-5	Pubertal anthropometrics;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18941864	chr2:234851397	TRPM8	-0.74	-7.26	-0.51	1.87e-11	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg14440974	chr22:39074834	NA	-0.57	-6.62	-0.47	5.68e-10	Menopause (age at onset);
PAAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.18	10.21	0.64	5.76e-19	Vitiligo;
PAAD	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg03371404	chr2:241525653	CAPN10	-0.58	-4.71	-0.36	5.66e-6	Bipolar disorder;
PAAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-6.25	-0.45	4e-9	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18621852	chr3:10150065	C3orf24	0.61	5.3	0.39	4.02e-7	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13906646	chr6:166892921	RPS6KA2	0.6	7.39	0.51	9.33e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.3	0.33	3.02e-5	Iron status biomarkers;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.63	-0.35	7.67e-6	Mood instability;
PAAD	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg18338521	chr10:69995036	NA	0.36	4.62	0.35	8.21e-6	Optic disc area;
PAAD	cis	rs1443512	0.588	rs1975473	chr12:54334625	G/A	cg25382128	chr12:54346509	NA	-0.55	-4.81	-0.36	3.55e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg08200582	chr11:442649	ANO9	0.57	4.83	0.37	3.24e-6	Systemic lupus erythematosus;
PAAD	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.79	9.15	0.6	3.43e-16	Blood metabolite ratios;
PAAD	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg03098721	chr1:84464084	TTLL7	0.48	4.64	0.35	7.57e-6	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs1320331	chr2:622161	G/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs2882667	0.728	rs10037071	chr5:138277847	A/G	cg09476006	chr5:138032270	NA	0.46	5.74	0.42	4.94e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10220806	chr22:39174683	DNAL4	-0.66	-6.51	-0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg01631408	chr1:248437212	OR2T33	-0.56	-5.26	-0.39	4.86e-7	Common traits (Other);
PAAD	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	12.52	0.71	3.78e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.64	6.85	0.49	1.7e-10	Longevity;
PAAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.51	-0.57	1.59e-14	Bone mineral density;
PAAD	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.51	-4.85	-0.37	2.99e-6	Vitiligo;
PAAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg20270320	chr8:101225902	SPAG1	0.45	4.37	0.33	2.26e-5	Atrioventricular conduction;
PAAD	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.91	0.37	2.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.48	-5.44	-0.4	2.11e-7	Body mass index;
PAAD	cis	rs7714584	1.000	rs73284141	chr5:150266086	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg03338584	chr11:507455	RNH1	0.54	4.29	0.33	3.23e-5	Systemic lupus erythematosus;
PAAD	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs986417	1.000	rs2224410	chr14:60970531	T/C	cg27398547	chr14:60952738	C14orf39	0.9	6.22	0.45	4.68e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.62	5.87	0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.81	8.07	0.55	2.03e-13	Height;
PAAD	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.56	5.37	0.4	2.86e-7	Body mass index;Social communication problems;
PAAD	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	10.39	0.64	1.95e-19	Testicular germ cell tumor;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg07236798	chr8:131455818	NA	0.66	6.67	0.48	4.37e-10	Primary biliary cholangitis;
PAAD	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	9.44	0.61	6.13e-17	Hip circumference adjusted for BMI;
PAAD	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.57	6.44	0.46	1.49e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24547092	chr6:37467765	C6orf129	0.67	7.74	0.53	1.29e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	cis	rs6901004	0.803	rs1022092	chr6:111427286	G/A	cg19980771	chr6:110798022	SLC22A16	0.33	4.26	0.33	3.52e-5	Blood metabolite levels;
PAAD	cis	rs17655565	1.000	rs2276399	chr12:52705269	G/A	cg02645295	chr12:52705424	NA	-0.46	-4.39	-0.34	2.14e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.71	-5.4	-0.4	2.46e-7	Vitiligo;
PAAD	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.77	7.37	0.51	1.04e-11	Gout;
PAAD	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	1.21	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	trans	rs75583333	0.570	rs11957969	chr5:159626792	T/C	cg14222307	chr15:61097246	RORA	-0.82	-6.36	-0.46	2.2e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.34	0.33	2.54e-5	Diastolic blood pressure;
PAAD	cis	rs3018712	0.517	rs10791994	chr11:68513246	A/G	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	4.74	0.36	4.88e-6	Joint mobility (Beighton score);
PAAD	cis	rs1359582	0.793	rs2182304	chr10:90398927	C/T	cg15661332	chr10:90342814	RNLS	0.57	5.03	0.38	1.38e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg19500275	chr17:80737654	TBCD	0.51	4.3	0.33	3.03e-5	Glycated hemoglobin levels;
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.98	11.5	0.68	2.06e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.51	0.52	4.77e-12	Platelet distribution width;
PAAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5742933	0.857	rs13021611	chr2:190564764	A/T	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.33e-5	Ferritin levels;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.33	0.56	4.42e-14	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05902531	chr12:58239324	CTDSP2	0.65	7.7	0.53	1.6e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.66	-0.53	2e-12	Response to antipsychotic treatment;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.94	-15.68	-0.79	1.42e-33	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07146535	chr1:63782988	NA	0.58	6.57	0.47	7.46e-10	Immature fraction of reticulocytes;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06799790	chr17:61951754	CSH2	-0.45	-4.69	-0.36	6.13e-6	Height;
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg16926213	chr1:1841314	NA	0.39	4.64	0.35	7.6e-6	Body mass index;
PAAD	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	4.28	0.33	3.31e-5	Personality dimensions;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg03101763	chr11:65319844	LTBP3	-0.87	-4.42	-0.34	1.86e-5	Height;
PAAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg16147221	chr4:10020634	SLC2A9	0.48	4.37	0.33	2.28e-5	Bone mineral density;
PAAD	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.54	4.47	0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.62	5.96	0.44	1.67e-8	Obesity-related traits;
PAAD	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg01191920	chr7:158217561	PTPRN2	0.69	7.45	0.52	6.51e-12	Obesity-related traits;
PAAD	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.7	-6.91	-0.49	1.25e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9659323	0.650	rs12086486	chr1:119489042	A/G	cg17326555	chr1:119535693	NA	-0.36	-4.37	-0.33	2.32e-5	Body mass index;
PAAD	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.5	-4.31	-0.33	2.9e-5	Resting heart rate;
PAAD	cis	rs12714314	0.718	rs2060197	chr2:1956021	T/A	cg22350835	chr2:1868857	MYT1L	0.51	4.91	0.37	2.37e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.92e-16	Motion sickness;
PAAD	cis	rs2790216	0.901	rs1988578	chr10:60003200	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.52	-5.62	-0.41	8.86e-8	Life satisfaction;
PAAD	cis	rs111342015	0.803	rs7832	chr6:43193877	A/G	cg17076780	chr6:43251928	TTBK1	-0.59	-4.32	-0.33	2.85e-5	Breast cancer;
PAAD	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg19442545	chr10:75533431	FUT11	-0.43	-4.37	-0.33	2.33e-5	Inflammatory bowel disease;
PAAD	cis	rs7101378	0.577	rs1912235	chr11:108898072	T/G	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.6	-5.95	-0.43	1.77e-8	Systemic sclerosis;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg22868518	chr11:507468	RNH1	-0.92	-4.95	-0.37	1.93e-6	Body mass index;
PAAD	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.23	-0.51	2.16e-11	Coronary artery disease;
PAAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3736485	0.966	rs8041514	chr15:51866054	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.56	-5.54	-0.41	1.32e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.59	-8.99	-0.59	9.38e-16	Schizophrenia;
PAAD	cis	rs3981351	0.797	rs3814231	chr10:115481018	A/G	cg24846397	chr10:115438155	CASP7	0.55	5.14	0.39	8.15e-7	Obesity-related traits;
PAAD	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.36	-0.33	2.4e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs3857067	0.967	rs1355240	chr4:95019353	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-5.42	-0.4	2.34e-7	QT interval;
PAAD	cis	rs2526932	0.625	rs2526898	chr14:73053549	C/A	cg13588403	chr14:73209128	DPF3	-0.4	-5.32	-0.4	3.66e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.08	-0.38	1.11e-6	Bipolar disorder;
PAAD	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.62	5.95	0.43	1.82e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.6	6.5	0.47	1.06e-9	High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.9	10.71	0.66	2.66e-20	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09489090	chr16:8768506	ABAT	0.61	6.46	0.46	1.33e-9	Myopia (pathological);
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg04234412	chr22:24373322	LOC391322	-0.59	-4.75	-0.36	4.58e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.9	8.69	0.58	5.48e-15	Methadone dose in opioid dependence;
PAAD	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs10768122	0.865	rs3794086	chr11:35329809	G/T	cg13971030	chr11:35366721	SLC1A2	-0.38	-4.33	-0.33	2.72e-5	Vitiligo;
PAAD	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg11204139	chr17:3907470	NA	-0.85	-9.13	-0.6	4.03e-16	Type 2 diabetes;
PAAD	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05666200	chr11:89790683	NA	-0.56	-4.32	-0.33	2.78e-5	White blood cell types;
PAAD	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	5.47	0.41	1.79e-7	Caffeine consumption;
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg06915872	chr16:87998081	BANP	0.52	4.62	0.35	8.24e-6	Menopause (age at onset);
PAAD	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.38	-0.33	2.2e-5	IgG glycosylation;
PAAD	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06850241	chr22:41845214	NA	-0.55	-5.04	-0.38	1.32e-6	Vitiligo;
PAAD	cis	rs11650494	0.516	rs9900373	chr17:47512945	C/G	cg08112188	chr17:47440006	ZNF652	1.27	6.24	0.45	4.18e-9	Prostate cancer;
PAAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-4.85	-0.37	3.04e-6	Type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.66	-0.48	4.78e-10	Breast cancer;
PAAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.87	7.09	0.5	4.82e-11	Gut microbiome composition (summer);
PAAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-1.03	-14.28	-0.76	6.93e-30	Breast cancer;
PAAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.87	0.43	2.66e-8	Rheumatoid arthritis;
PAAD	cis	rs12136530	0.625	rs4912086	chr1:19730181	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.65	6.03	0.44	1.17e-8	Androgen levels;
PAAD	cis	rs2834256	0.517	rs7280365	chr21:34952583	G/C	cg14850771	chr21:34775459	IFNGR2	0.4	4.33	0.33	2.75e-5	Red cell distribution width;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15611164	chr12:129277819	SLC15A4	-0.68	-6.48	-0.47	1.18e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.1	-0.44	8.25e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00166722	chr3:10149974	C3orf24	-0.75	-6.65	-0.47	4.85e-10	Alzheimer's disease;
PAAD	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg21823605	chr1:152486609	CRCT1	-0.49	-6.29	-0.45	3.14e-9	Hair morphology;
PAAD	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.78	4.59	0.35	9.27e-6	Body mass index;
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg22029157	chr1:209979665	IRF6	0.7	6.79	0.48	2.36e-10	Coronary artery disease;
PAAD	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg00428638	chr19:7224713	INSR	0.51	5.59	0.41	1e-7	Hypothyroidism;
PAAD	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.8	8.06	0.55	2.13e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.86	10.08	0.63	1.27e-18	Tuberculosis;
PAAD	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.64	0.42	8.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.61	4.75	0.36	4.72e-6	Serum sulfate level;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09010629	chr14:91007720	TTC7B	-0.68	-6.95	-0.49	1.03e-10	Obesity-related traits;
PAAD	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.68	6.97	0.49	8.99e-11	Breast cancer;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.28	-0.45	3.3e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.84	7.36	0.51	1.06e-11	Waist circumference;
PAAD	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.86	0.62	4.78e-18	Smoking behavior;
PAAD	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.5	0.71	4.16e-25	Cognitive ability;
PAAD	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.45	5.34	0.4	3.28e-7	Psoriasis;
PAAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	1.1	13.91	0.75	6.95e-29	Breast cancer;
PAAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.33e-5	Coronary artery disease;
PAAD	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg01267373	chr18:77410094	NA	0.42	4.34	0.33	2.54e-5	Monocyte count;
PAAD	cis	rs4589502	1.000	rs58084996	chr15:67123357	T/C	cg12317470	chr15:67143691	NA	0.82	4.66	0.35	6.95e-6	Lung cancer (smoking interaction);
PAAD	cis	rs7715811	1.000	rs6860236	chr5:13762013	C/T	cg07548982	chr5:13769939	DNAH5	-0.65	-6.33	-0.46	2.62e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs375066	0.762	rs1073654	chr19:44411420	T/C	cg08633290	chr19:44405433	NA	0.54	5.16	0.39	7.61e-7	Breast cancer;
PAAD	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg07677032	chr17:61819896	STRADA	0.45	4.31	0.33	2.9e-5	Height;
PAAD	cis	rs4759375	0.510	rs10846522	chr12:123828229	T/A	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg08345082	chr10:99160200	RRP12	-0.29	-4.25	-0.33	3.7e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11825064	0.673	rs80332462	chr11:134496895	C/T	cg06603561	chr11:134479413	NA	-1.1	-6.6	-0.47	6.57e-10	Seasonality;
PAAD	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.44	6.87	0.49	1.52e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.27	-0.33	3.44e-5	Schizophrenia;
PAAD	cis	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg04796828	chr8:10452854	NA	-0.36	-4.3	-0.33	3.01e-5	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.83e-13	Motion sickness;
PAAD	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.6	5.95	0.43	1.79e-8	Blood metabolite levels;
PAAD	cis	rs375066	0.762	rs62114648	chr19:44414816	T/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.28	-0.45	3.33e-9	Breast cancer;
PAAD	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs11159840	0.609	rs2767534	chr14:88587167	T/C	cg18078958	chr14:88630771	NA	-0.41	-5.08	-0.38	1.09e-6	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs1656368	0.690	rs73154313	chr3:158225485	T/C	cg16708174	chr3:158430962	RARRES1	0.6	5.44	0.4	2.07e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-8.67	-0.58	6e-15	Exhaled nitric oxide output;
PAAD	cis	rs501120	0.584	rs61857486	chr10:44719361	A/G	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.91	7.51	0.52	4.74e-12	Eotaxin levels;
PAAD	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.87	5.79	0.42	3.95e-8	Tonometry;
PAAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.93	9.41	0.61	7.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.49	-5.13	-0.38	8.9e-7	Colorectal cancer;
PAAD	cis	rs8049603	0.812	rs5731	chr16:23197545	C/G	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-1.0	-10.82	-0.66	1.36e-20	Blood metabolite levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04556515	chr14:93690055	UBR7	-0.74	-7.04	-0.5	6.04e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg01966878	chr4:90757139	SNCA	-0.6	-4.7	-0.36	5.88e-6	Neuroticism;
PAAD	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.67	-0.42	7.12e-8	Coronary artery calcification;
PAAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.0	0.38	1.55e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs7823896	0.722	rs6990184	chr8:110292400	T/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.7	5.52	0.41	1.42e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.58	5.33	0.4	3.41e-7	Self-reported allergy;
PAAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.57	6.09	0.44	9e-9	Menopause (age at onset);
PAAD	cis	rs16958440	0.867	rs28587821	chr18:44687906	G/A	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18337363	chr3:52569053	NT5DC2	0.48	5.18	0.39	6.97e-7	Electroencephalogram traits;
PAAD	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg08632701	chr21:37451849	NA	-0.59	-6.06	-0.44	1.01e-8	Mitral valve prolapse;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.57	6.04	0.44	1.14e-8	Testicular germ cell tumor;
PAAD	trans	rs17744291	1.000	rs17744291	chr18:45756074	A/G	cg13337658	chr8:19796561	LPL	-1.12	-6.29	-0.45	3.28e-9	Pediatric bone mineral density (femoral neck);
PAAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg10518543	chr12:38710700	ALG10B	0.52	5.01	0.38	1.51e-6	Morning vs. evening chronotype;
PAAD	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.79	-0.43	3.89e-8	Calcium levels;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg02725872	chr8:58115012	NA	-0.6	-4.93	-0.37	2.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.62	5.99	0.44	1.44e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.42	-6.26	-0.45	3.7e-9	Breast cancer;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg11062466	chr8:58055876	NA	0.69	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.72	5.1	0.38	9.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.61	-0.47	6.03e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10990312	chr2:85108373	C2orf89	0.6	6.76	0.48	2.81e-10	Monocyte percentage of white cells;
PAAD	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg01064725	chr1:204461714	NA	0.51	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg14515779	chr1:101123966	NA	0.4	4.45	0.34	1.65e-5	Monocyte count;
PAAD	cis	rs6496932	0.663	rs4843051	chr15:85904138	A/G	cg19183879	chr15:85880815	NA	-0.6	-5.59	-0.41	1.03e-7	Central corneal thickness;Corneal structure;
PAAD	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.96	7.8	0.53	9.17e-13	Eotaxin levels;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.61	4.97	0.37	1.76e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.6	-6.34	-0.46	2.43e-9	Caffeine consumption;
PAAD	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12560992	chr17:57184187	TRIM37	0.52	4.61	0.35	8.34e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.52	5.54	0.41	1.29e-7	Life satisfaction;
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg15691649	chr6:25882328	NA	-0.52	-4.67	-0.35	6.48e-6	Blood metabolite levels;
PAAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg15017067	chr4:17643749	FAM184B	-0.41	-4.78	-0.36	4.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17293817	0.617	rs2387658	chr10:1423905	A/C	cg02408697	chr10:1416920	ADARB2	-0.5	-4.52	-0.34	1.22e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10045504	0.502	rs72746051	chr5:38759817	G/A	cg15396434	chr5:38725168	NA	-0.87	-6.17	-0.45	5.9e-9	Night sleep phenotypes;
PAAD	cis	rs1997066	0.831	rs57936493	chr10:106824174	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.92	0.43	2.03e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs2013441	0.613	rs12451841	chr17:20004875	G/A	cg25070565	chr17:20044324	CYTSB	-0.46	-4.74	-0.36	4.96e-6	Obesity-related traits;
PAAD	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.23	0.6	2.24e-16	Bipolar disorder;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg19337854	chr7:99768885	GPC2	0.49	4.45	0.34	1.64e-5	Platelet count;
PAAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.6	-5.99	-0.44	1.43e-8	Coronary artery disease;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.63	7.89	0.54	5.64e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	1.13	12.34	0.71	1.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-7.12	-0.5	4.07e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-4.61	-0.35	8.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg15123519	chr2:136567270	LCT	0.37	4.53	0.35	1.18e-5	Mosquito bite size;
PAAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.54	-6.9	-0.49	1.29e-10	Height;
PAAD	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg20913747	chr6:44695427	NA	-0.68	-6.73	-0.48	3.17e-10	Total body bone mineral density;
PAAD	cis	rs4356203	0.870	rs7342262	chr11:17285807	A/G	cg15432903	chr11:17409602	KCNJ11	-0.47	-4.77	-0.36	4.32e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-1.49	-9.02	-0.59	7.87e-16	Depression;
PAAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09241243	chr14:64970743	ZBTB25;ZBTB1	0.58	6.29	0.45	3.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.67	6.61	0.47	6.14e-10	Height;
PAAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg01942863	chr7:99769432	GPC2	-0.47	-4.44	-0.34	1.75e-5	Coronary artery disease;
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.72	8.43	0.56	2.49e-14	Height;
PAAD	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.64	6.21	0.45	4.72e-9	Breast cancer;
PAAD	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.61	6.24	0.45	4.2e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Lymphocyte counts;
PAAD	cis	rs288342	0.832	rs288300	chr2:183657279	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.62	-0.35	8.18e-6	Recurrent major depressive disorder;
PAAD	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.63	6.59	0.47	6.95e-10	Childhood ear infection;
PAAD	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg08704250	chr15:31115839	NA	-0.62	-8.49	-0.57	1.75e-14	Huntington's disease progression;
PAAD	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.56	4.96	0.37	1.86e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.39	-0.34	2.11e-5	Body mass index;
PAAD	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg14254433	chr6:34482411	PACSIN1	-0.9	-5.93	-0.43	1.97e-8	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.66	5.33	0.4	3.45e-7	Bipolar disorder;
PAAD	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.62	0.57	8.28e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg14388049	chr10:71211838	TSPAN15	-0.52	-5.27	-0.39	4.52e-7	Venous thromboembolism;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.5	-4.36	-0.33	2.34e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-1.0	-9.84	-0.62	5.46e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg22168087	chr7:27702803	HIBADH	-0.58	-5.65	-0.42	7.86e-8	Hypospadias;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.57	4.35	0.33	2.49e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg01305830	chr4:1604576	NA	0.49	4.75	0.36	4.73e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	1.11	5.3	0.39	4.07e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.77	8.46	0.57	2.02e-14	Lung cancer;
PAAD	cis	rs9361491	0.608	rs2321769	chr6:79437960	G/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.67	4.98	0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg07943548	chr15:86304357	KLHL25	0.65	5.55	0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.48	6.11	0.44	7.94e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10426930	0.621	rs72990138	chr19:5018217	T/A	cg25246084	chr19:4971487	KDM4B	-0.46	-4.5	-0.34	1.34e-5	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.91	-8.82	-0.58	2.52e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.58	5.97	0.44	1.64e-8	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg00280220	chr17:61926910	NA	0.43	4.43	0.34	1.83e-5	Prudent dietary pattern;
PAAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.67	-0.53	1.97e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14821842	chr8:118532860	MED30	0.65	6.6	0.47	6.62e-10	Obesity-related traits;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.62	6.62	0.47	5.91e-10	Mean corpuscular volume;
PAAD	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.59	4.6	0.35	8.89e-6	Coronary artery disease;
PAAD	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	4.66	0.35	6.83e-6	Resting heart rate;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg10616300	chr11:66138557	SLC29A2	0.32	4.25	0.33	3.65e-5	Educational attainment (years of education);
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.44	-0.34	1.69e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.88	-0.37	2.64e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.75	0.74	1.79e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg24375607	chr4:120327624	NA	0.5	5.18	0.39	6.89e-7	Corneal astigmatism;
PAAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.75	5.61	0.41	9.15e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg08821874	chr11:1495128	HCCA2	0.63	6.56	0.47	7.97e-10	Educational attainment (years of education);
PAAD	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg25155006	chr6:37138205	PIM1	-0.52	-4.58	-0.35	9.6e-6	QRS duration;
PAAD	cis	rs13242816	1.000	rs13247987	chr7:116113344	A/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-5.55	-0.41	1.26e-7	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.43	0.65	1.47e-19	Platelet count;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg20848291	chr7:100343083	ZAN	-0.93	-7.85	-0.54	6.88e-13	Other erythrocyte phenotypes;
PAAD	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.58	0.35	9.53e-6	Thyroid stimulating hormone;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23393521	chr2:171571097	LOC440925;SP5	0.57	6.45	0.46	1.39e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg24053715	chr22:38214548	NA	0.61	6.06	0.44	1.04e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg12310025	chr6:25882481	NA	-0.52	-4.65	-0.35	7.25e-6	Iron status biomarkers;
PAAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg26497354	chr6:109612229	NA	0.43	4.61	0.35	8.52e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg05717871	chr11:638507	DRD4	-0.57	-4.65	-0.35	7.26e-6	Systemic lupus erythematosus;
PAAD	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg14582100	chr15:45693742	SPATA5L1	-0.55	-7.77	-0.53	1.08e-12	Homoarginine levels;
PAAD	cis	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg21775007	chr8:11205619	TDH	-0.5	-4.67	-0.35	6.67e-6	Triglycerides;
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg06883089	chr1:45254480	BEST4	0.36	4.63	0.35	7.94e-6	High light scatter reticulocyte count;
PAAD	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.83	-9.75	-0.62	9.61e-18	Height;
PAAD	cis	rs1198430	0.500	rs968280	chr1:23801965	A/T	cg19827787	chr1:23763612	ASAP3	0.5	4.54	0.35	1.12e-5	Total cholesterol levels;
PAAD	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.43	4.74	0.36	4.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs8060686	0.858	rs28563117	chr16:67782130	C/T	cg09835421	chr16:68378352	PRMT7	-0.64	-4.42	-0.34	1.85e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg21951975	chr1:209979733	IRF6	0.57	5.33	0.4	3.55e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.8	0.58	2.82e-15	Lung cancer;
PAAD	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg15571903	chr15:79123663	NA	-0.46	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg17346650	chr17:80929145	B3GNTL1	0.46	5.62	0.41	8.93e-8	Glycated hemoglobin levels;
PAAD	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-1.03	-13.12	-0.73	8.8e-27	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.45	-4.92	-0.37	2.24e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.68	-6.56	-0.47	7.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.91	-6.61	-0.47	6.05e-10	Atopic dermatitis;
PAAD	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg21890820	chr11:65308645	LTBP3	-0.6	-6.76	-0.48	2.78e-10	Plateletcrit;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg07167872	chr1:205819463	PM20D1	0.58	4.72	0.36	5.24e-6	Prostate-specific antigen levels;
PAAD	cis	rs2555155	0.870	rs10839575	chr11:6551635	G/C	cg10208301	chr11:6592745	DNHD1	-0.43	-4.39	-0.34	2.15e-5	DNA methylation (variation);
PAAD	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.76	7.77	0.53	1.08e-12	Breast cancer;
PAAD	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.82	-8.84	-0.58	2.18e-15	Osteoporosis;
PAAD	cis	rs72901758	0.768	rs11650317	chr17:76251306	A/T	cg11439826	chr17:76250004	NA	0.46	4.57	0.35	1.01e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg05341575	chr12:125625032	AACS	-0.47	-4.38	-0.33	2.23e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.07e-6	Cognitive function;
PAAD	cis	rs4704187	0.687	rs4703655	chr5:74455063	A/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26820223	chr1:150898727	SETDB1	-0.74	-6.38	-0.46	2.02e-9	Neuroticism;
PAAD	cis	rs901683	0.850	rs76491632	chr10:45966598	T/C	cg16908948	chr10:45500256	ZNF22	0.82	4.34	0.33	2.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.76	8.84	0.58	2.22e-15	Breast cancer;
PAAD	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.17	0.5	2.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.52	-4.57	-0.35	1.01e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2221894	0.959	rs8180944	chr8:28904086	G/T	cg20212339	chr8:28908912	HMBOX1	-0.49	-5.21	-0.39	6.06e-7	Obesity-related traits;
PAAD	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg00522288	chr12:125625016	AACS	-0.5	-5.06	-0.38	1.19e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06984061	chr22:46431879	NA	-0.57	-6.68	-0.48	4.33e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	6.86	0.49	1.67e-10	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs7195605	chr16:67989523	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.16	-0.45	6.13e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.73	7.4	0.51	8.65e-12	Obesity-related traits;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.48	0.41	1.75e-7	Platelet count;
PAAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.67	-6.35	-0.46	2.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.59	-6.61	-0.47	6.16e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs16858210	0.648	rs57604063	chr3:183578689	A/T	cg25686905	chr3:183603175	PARL	-0.39	-4.51	-0.34	1.31e-5	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22022671	chr5:83253023	EDIL3	0.55	6.77	0.48	2.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	7.8	0.53	9.12e-13	Menarche (age at onset);
PAAD	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.73	-7.51	-0.52	4.61e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4704187	0.687	rs6860441	chr5:74389799	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs3136739	0.558	rs7000303	chr8:41993563	T/G	cg12054981	chr8:42037387	PLAT	0.62	4.63	0.35	7.92e-6	Plasma plasminogen activator levels;
PAAD	cis	rs9361491	0.534	rs10943568	chr6:79404207	G/T	cg05283184	chr6:79620031	NA	-0.4	-4.94	-0.37	2.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17683430	0.614	rs2006253	chr22:32530256	A/C	cg00543991	chr22:32367038	NA	0.71	5.28	0.39	4.43e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.8	7.88	0.54	5.82e-13	Corneal astigmatism;
PAAD	cis	rs965469	0.603	rs6051849	chr20:3404860	C/G	cg25506879	chr20:3388711	C20orf194	-0.56	-4.97	-0.37	1.82e-6	IFN-related cytopenia;
PAAD	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	4.72	0.36	5.3e-6	Skin pigmentation;
PAAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.51	-5.92	-0.43	2.04e-8	Breast cancer;
PAAD	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.67	-5.53	-0.41	1.34e-7	Colorectal cancer;
PAAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26796135	chr15:45671001	LOC145663;GATM	-0.5	-4.49	-0.34	1.39e-5	Homoarginine levels;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.75	8.31	0.56	4.97e-14	Lung cancer;
PAAD	cis	rs4343996	0.967	rs7785994	chr7:3351810	T/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs797680	0.856	rs4847408	chr1:93791437	C/G	cg04535902	chr1:92947332	GFI1	-0.48	-4.67	-0.35	6.53e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs17824933	0.806	rs11230565	chr11:60776711	A/G	cg16817237	chr11:60793675	NA	0.53	6.24	0.45	4.21e-9	Multiple sclerosis;
PAAD	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg05585544	chr11:47624801	NA	-0.42	-4.52	-0.34	1.25e-5	Subjective well-being;
PAAD	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.61	5.72	0.42	5.54e-8	Height;
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.85	-6.78	-0.48	2.56e-10	Lung function (FEV1/FVC);
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.24	0.39	5.33e-7	Electroencephalogram traits;
PAAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3996993	0.809	rs2894802	chr6:52656169	T/G	cg20803780	chr6:52668592	GSTA1	-0.35	-4.5	-0.34	1.37e-5	Hemoglobin concentration;
PAAD	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.16	-0.39	7.74e-7	Body mass index;
PAAD	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.59	5.18	0.39	6.8e-7	Common traits (Other);
PAAD	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	5.6	0.41	9.55e-8	Eye color traits;
PAAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg25554036	chr4:6271136	WFS1	0.73	7.18	0.5	2.83e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.52	5.2	0.39	6.42e-7	Platelet count;
PAAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.76	-0.36	4.51e-6	Eosinophil percentage of white cells;
PAAD	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg00531865	chr16:30841666	NA	-0.5	-4.44	-0.34	1.71e-5	Dementia with Lewy bodies;
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.77	-8.06	-0.55	2.13e-13	Prostate cancer;
PAAD	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg17346650	chr17:80929145	B3GNTL1	0.45	5.48	0.41	1.73e-7	Glycated hemoglobin levels;
PAAD	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.86	9.78	0.62	7.97e-18	Resting heart rate;
PAAD	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.15	-0.5	3.37e-11	Response to antipsychotic treatment;
PAAD	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg16342193	chr10:102329863	NA	-0.75	-8.22	-0.55	8.42e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00568507	chr1:150980987	FAM63A;PRUNE	-0.76	-6.55	-0.47	8.24e-10	Neuroticism;
PAAD	cis	rs1472147	1.000	rs67476247	chr7:128504788	A/G	cg10778310	chr7:128509080	NA	-0.41	-4.76	-0.36	4.46e-6	Calcium levels;
PAAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg15017067	chr4:17643749	FAM184B	0.43	5.01	0.38	1.48e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs9900972	0.918	rs8065102	chr17:76876735	T/C	cg00961940	chr17:76876995	TIMP2	0.58	5.24	0.39	5.27e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.92	11.5	0.68	2.03e-22	Pulse pressure;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.41e-13	Height;
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg05132306	chr1:1846340	CALML6	-0.43	-4.94	-0.37	2.02e-6	Body mass index;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.63	-0.42	8.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.51	-4.64	-0.35	7.6e-6	Kawasaki disease;
PAAD	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.63	-5.84	-0.43	3.09e-8	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs1011018	0.910	rs12673068	chr7:139434215	T/G	cg03224163	chr7:139420300	HIPK2	-0.6	-4.27	-0.33	3.47e-5	Systolic blood pressure;
PAAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg14829360	chr17:73884958	NA	-0.64	-6.14	-0.45	6.86e-9	Psoriasis;
PAAD	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.48	-4.29	-0.33	3.13e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.59	0.35	9.23e-6	Neuroticism;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.37e-7	Life satisfaction;
PAAD	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.75	-0.74	1.84e-28	Primary sclerosing cholangitis;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2241685	0.680	rs11695699	chr2:1954444	G/A	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.92	-8.31	-0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24605529	chr2:203879461	NBEAL1	-0.67	-7.32	-0.51	1.38e-11	Smoking initiation;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03315484	chr5:137688433	KDM3B	0.6	6.72	0.48	3.52e-10	Immature fraction of reticulocytes;
PAAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.44	5.17	0.39	7.24e-7	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg17800788	chr1:21766015	NBPF3	0.41	4.49	0.34	1.39e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.66	5.37	0.4	2.88e-7	Pediatric autoimmune diseases;
PAAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.3e-5	Parkinson's disease;
PAAD	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.67	6.98	0.49	8.37e-11	Glomerular filtration rate;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg00738919	chr7:1100172	C7orf50	0.54	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-8.07	-0.55	2.02e-13	Type 2 diabetes;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.99	10.88	0.66	9.38e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.34	-0.33	2.56e-5	Cystic fibrosis severity;
PAAD	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.47	-5.16	-0.39	7.5e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg18769074	chr3:133464867	TF	0.41	4.57	0.35	9.89e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.74	7.74	0.53	1.26e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2252790	1.000	rs3021301	chr6:116670364	A/G	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.46	4.4	0.34	2.04e-5	Acylcarnitine levels;
PAAD	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.8	-0.53	9.29e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.94	7.62	0.53	2.54e-12	Initial pursuit acceleration;
PAAD	cis	rs2030114	0.848	rs8043891	chr16:51608642	T/C	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg27490568	chr2:178487706	NA	0.39	4.41	0.34	1.93e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7619427	0.908	rs9682281	chr3:44082811	A/T	cg12796028	chr3:44040206	NA	-0.6	-4.33	-0.33	2.74e-5	Schizophrenia;
PAAD	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.81	-10.16	-0.64	7.7e-19	Height;
PAAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.69	8.73	0.58	4.25e-15	Eye color traits;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01320969	chr11:67980788	SUV420H1	-0.6	-6.45	-0.46	1.44e-9	Warfarin maintenance dose;
PAAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.79	-0.36	3.86e-6	Vitiligo;
PAAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg19847866	chr10:1019161	NA	-0.6	-4.64	-0.35	7.32e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg26169700	chr22:42538906	CYP2D7P1	-0.64	-4.28	-0.33	3.27e-5	Birth weight;
PAAD	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.68	7.53	0.52	4.24e-12	N-glycan levels;
PAAD	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.54	-5.67	-0.42	7.11e-8	Schizophrenia;
PAAD	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.98	5.73	0.42	5.31e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4704187	0.687	rs4345300	chr5:74376571	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs243505	0.733	rs9987055	chr7:148501758	G/A	cg09806900	chr7:148480153	CUL1	0.52	4.88	0.37	2.63e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.4	-0.34	2.02e-5	Educational attainment;
PAAD	cis	rs10791323	0.604	rs7928888	chr11:133703696	A/C	cg14349672	chr11:133703707	NA	-0.55	-6.38	-0.46	2.07e-9	Childhood ear infection;
PAAD	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	cis	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-8.92	-0.59	1.38e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs988913	0.723	rs7761785	chr6:55002037	C/T	cg03513858	chr6:54763001	FAM83B	0.4	4.35	0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg21236500	chr9:139779897	TRAF2	0.38	4.37	0.33	2.25e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26751440	chr16:3714412	TRAP1	0.44	4.28	0.33	3.28e-5	Body mass index (adult);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06002616	chr8:101225028	SPAG1	0.46	5.38	0.4	2.74e-7	Atrioventricular conduction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05047465	chr10:27793441	RAB18	0.59	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg15443732	chr18:74961078	GALR1	0.73	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.99	-0.49	8.12e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.45	5.16	0.39	7.64e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23025395	chr11:18127696	SAAL1	0.61	6.89	0.49	1.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	5.52	0.41	1.4e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.46	-0.52	6.3e-12	Height;
PAAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg18099408	chr3:52552593	STAB1	0.49	5.57	0.41	1.14e-7	Electroencephalogram traits;
PAAD	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg20673841	chr7:107026890	COG5	-0.5	-4.29	-0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.48	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.78	8.85	0.58	2.1e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2120243	0.510	rs10936087	chr3:157106628	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.32	0.33	2.77e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.47	-0.34	1.53e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14119001	chr9:139324193	INPP5E	-0.62	-5.58	-0.41	1.09e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg18557086	chr17:2304670	MNT	-0.55	-6.46	-0.46	1.35e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.45	4.33	0.33	2.73e-5	Mean corpuscular volume;
PAAD	cis	rs13424612	0.965	rs34789127	chr2:240952002	C/T	cg12807937	chr2:240965920	NDUFA10	-0.46	-4.52	-0.34	1.24e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.53	-5.18	-0.39	6.84e-7	Multiple myeloma;
PAAD	cis	rs7627468	1.000	rs7627468	chr3:121946099	A/G	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.25e-5	Kidney stones;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.71	-0.36	5.55e-6	Bipolar disorder;
PAAD	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	1.16	6.15	0.45	6.57e-9	Mitochondrial DNA levels;
PAAD	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.51	-4.92	-0.37	2.27e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.4	-4.53	-0.35	1.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg08501292	chr6:25962987	TRIM38	0.92	4.47	0.34	1.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg17178900	chr1:205818956	PM20D1	-0.49	-4.86	-0.37	2.85e-6	Parkinson's disease;
PAAD	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.57	7.48	0.52	5.39e-12	Hypertriglyceridemia;
PAAD	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg14593290	chr7:50529359	DDC	0.49	4.67	0.35	6.69e-6	Malaria;
PAAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg14393609	chr7:65229607	NA	0.47	5.0	0.38	1.55e-6	Aortic root size;
PAAD	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.85	-10.0	-0.63	2.05e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.64	-0.42	8.16e-8	Psoriasis;
PAAD	cis	rs28489187	0.706	rs233113	chr1:85786299	T/A	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg03627880	chr6:151815985	C6orf97	-0.48	-4.55	-0.35	1.11e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.92	7.85	0.54	7.05e-13	Eotaxin levels;
PAAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs10214930	0.697	rs6462036	chr7:27641063	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20865740	chr3:119063744	CDGAP	-0.63	-6.47	-0.46	1.3e-9	Obesity-related traits;
PAAD	cis	rs55692468	0.570	rs10193625	chr2:153314204	C/T	cg22159341	chr2:152893963	CACNB4	-0.45	-4.35	-0.33	2.46e-5	Intraocular pressure;
PAAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.64	4.3	0.33	3.06e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9810890	1.000	rs73198855	chr3:128512664	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg21479132	chr6:26055353	NA	0.84	4.62	0.35	7.99e-6	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs72777070	0.803	rs67630365	chr2:9794655	G/A	cg14973360	chr2:9800511	NA	-0.52	-4.32	-0.33	2.83e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs3771514	1.000	rs3771514	chr2:70697667	G/A	cg22701032	chr2:70484527	PCYOX1	-0.54	-4.91	-0.37	2.31e-6	Obesity-related traits;
PAAD	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.62	-0.35	8.17e-6	Systolic blood pressure;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22162314	chr17:61951766	CSH2	-0.59	-5.9	-0.43	2.23e-8	Height;
PAAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs367943	0.637	rs6859521	chr5:113007423	C/T	cg12552261	chr5:112820674	MCC	0.59	5.81	0.43	3.5e-8	Type 2 diabetes;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01765077	chr12:122356316	WDR66	0.62	6.51	0.47	1.03e-9	Mean corpuscular volume;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg23188684	chr11:67383651	NA	0.48	5.02	0.38	1.45e-6	Mean corpuscular volume;
PAAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg05554000	chr7:158905015	VIPR2	-0.6	-4.68	-0.35	6.38e-6	Facial morphology (factor 20);
PAAD	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg09754948	chr16:28834200	ATXN2L	0.51	5.11	0.38	9.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg23387468	chr7:139079360	LUC7L2	-0.4	-5.02	-0.38	1.45e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12760731	0.623	rs721289	chr1:178395682	A/G	cg00404053	chr1:178313656	RASAL2	0.67	5.66	0.42	7.16e-8	Obesity-related traits;
PAAD	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg19090574	chr1:205240910	TMCC2	-0.39	-4.29	-0.33	3.23e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.58	-5.1	-0.38	9.82e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.87	0.37	2.73e-6	Schizophrenia;
PAAD	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.53	-6.35	-0.46	2.3e-9	Systemic lupus erythematosus;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.71	0.36	5.46e-6	Bipolar disorder;
PAAD	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.52	4.95	0.37	1.96e-6	Metabolic traits;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg11335335	chr11:637885	DRD4	-0.37	-5.45	-0.4	2.01e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.27	-0.39	4.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.38e-8	Cognitive function;
PAAD	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.85	-0.37	3e-6	Coronary artery disease;
PAAD	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.97	-14.14	-0.75	1.69e-29	Dental caries;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.54	0.57	1.29e-14	Platelet count;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg23978390	chr7:1156363	C7orf50	0.51	5.19	0.39	6.74e-7	Longevity;Endometriosis;
PAAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.39	-0.34	2.08e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg13611204	chr9:139324423	INPP5E	-0.56	-4.77	-0.36	4.21e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24463073	chr6:118973353	C6orf204	-0.6	-6.49	-0.47	1.13e-9	Smoking initiation;
PAAD	cis	rs9810890	1.000	rs56063711	chr3:128585715	C/G	cg18531004	chr3:128564980	NA	-0.83	-5.36	-0.4	2.98e-7	Dental caries;
PAAD	cis	rs12935418	0.616	rs1127390	chr16:81010073	C/T	cg16651780	chr16:81037892	C16orf61	0.67	6.19	0.45	5.31e-9	Mean corpuscular volume;
PAAD	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.48	5.43	0.4	2.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-1.2	-5.45	-0.4	1.98e-7	Pediatric areal bone mineral density (radius);
PAAD	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg14393609	chr7:65229607	NA	0.44	4.26	0.33	3.62e-5	Aortic root size;
PAAD	cis	rs7173419	0.607	rs1448488	chr15:28216857	C/T	cg20906524	chr15:28200668	OCA2	-0.47	-5.52	-0.41	1.45e-7	Eye color;
PAAD	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg09163369	chr1:210001066	C1orf107	-0.65	-6.01	-0.44	1.34e-8	Orofacial clefts;
PAAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.61	7.02	0.49	7.02e-11	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs1497828	1.000	rs1391286	chr1:217561510	C/T	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg02117656	chr17:79614917	TSPAN10	-0.55	-5.56	-0.41	1.2e-7	Eye color traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26156179	chr3:178969440	KCNMB3	-0.7	-7.04	-0.5	6.35e-11	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.92	7.85	0.54	6.79e-13	Alzheimer's disease;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.39	-0.46	1.96e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.59	-5.92	-0.43	2.05e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17021463	0.673	rs1426566	chr4:95292086	T/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.46	0.4	1.93e-7	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs595018	0.505	rs11230501	chr11:60598075	G/T	cg07588442	chr11:60673866	PRPF19	0.65	4.56	0.35	1.04e-5	Wegener's granulomatosis;
PAAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg10518543	chr12:38710700	ALG10B	0.51	4.89	0.37	2.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg10819733	chr22:24237672	NA	-0.63	-6.96	-0.49	9.54e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg16928487	chr17:17741425	SREBF1	0.38	5.07	0.38	1.15e-6	Total body bone mineral density;
PAAD	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.58	-5.67	-0.42	7.02e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19001794	chr17:1958162	HIC1	-0.58	-6.42	-0.46	1.68e-9	Body fat percentage;
PAAD	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	trans	rs901683	1.000	rs35036712	chr10:46046710	C/A	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs642743	0.967	rs584309	chr10:105956776	A/G	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.72	0.36	5.21e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.68	-4.51	-0.34	1.28e-5	Lung cancer in ever smokers;
PAAD	cis	rs7577696	0.925	rs212717	chr2:32461640	G/A	cg02381751	chr2:32503542	YIPF4	0.43	4.6	0.35	8.96e-6	Inflammatory biomarkers;
PAAD	cis	rs7084783	0.500	rs10883892	chr10:105397102	C/T	cg09754828	chr10:105363329	SH3PXD2A	0.46	4.49	0.34	1.42e-5	Fear of pain;
PAAD	cis	rs11159086	0.793	rs1029699	chr14:74941493	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.3	-0.39	4.03e-7	Advanced glycation end-product levels;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg04160749	chr8:58172571	NA	-0.72	-4.91	-0.37	2.38e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.76	8.05	0.55	2.25e-13	Prostate cancer;
PAAD	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	trans	rs5417	0.636	rs2074218	chr17:7156186	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.66	-6.66	-0.48	4.81e-10	Diastolic blood pressure;
PAAD	cis	rs11260013	0.904	rs12973523	chr19:7758260	G/C	cg04764898	chr19:7562249	C19orf45	0.42	4.36	0.33	2.42e-5	Blood protein levels;
PAAD	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-4.56	-0.35	1.05e-5	Bipolar disorder;
PAAD	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.97	9.7	0.62	1.3e-17	Cisplatin-induced ototoxicity;
PAAD	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg07162820	chr14:24837146	NFATC4	0.36	4.78	0.36	4.15e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs7631605	0.905	rs12629462	chr3:37226969	A/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.49e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15676241	chr5:52285231	ITGA2	0.75	9.0	0.59	8.52e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.7	6.79	0.48	2.31e-10	Neuroticism;
PAAD	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.76	-7.34	-0.51	1.21e-11	Breast cancer;
PAAD	trans	rs901683	1.000	rs9422439	chr10:46040473	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.59	5.31	0.4	3.83e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.75	0.42	4.67e-8	Personality dimensions;
PAAD	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-5.1	-0.38	1e-6	Bladder cancer;
PAAD	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02743256	chr7:2109353	MAD1L1	-0.76	-6.26	-0.45	3.81e-9	Bipolar disorder;
PAAD	cis	rs1008126	0.642	rs2528876	chr7:103137747	C/T	cg04218035	chr7:103086829	SLC26A5	0.31	4.3	0.33	3.09e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.32	-4.61	-0.35	8.41e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg02770688	chr6:168491649	NA	0.48	4.98	0.37	1.73e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg22800045	chr5:56110881	MAP3K1	0.71	5.93	0.43	2e-8	Type 2 diabetes;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.91	11.24	0.67	1.05e-21	Menarche (age at onset);
PAAD	trans	rs61931739	0.621	rs843785	chr12:33729308	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.63	4.92	0.37	2.2e-6	Fat distribution (HIV);
PAAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.58	0.57	1.06e-14	Menopause (age at onset);
PAAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.75e-5	Monobrow;
PAAD	cis	rs7084921	0.521	rs11592640	chr10:101878409	C/T	cg04359915	chr10:101825029	CPN1	-0.28	-4.31	-0.33	2.88e-5	Bone mineral density;
PAAD	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.09	0.38	1.03e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg00908766	chr1:109817496	CELSR2	-0.54	-5.85	-0.43	2.95e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.47	-0.34	1.53e-5	Height;
PAAD	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-7.37	-0.51	1.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs55986470	0.763	rs2280034	chr2:239438298	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-4.67	-0.35	6.66e-6	Chronotype;
PAAD	cis	rs2278796	0.752	rs6677763	chr1:204951540	A/G	cg09852221	chr1:205912646	SLC26A9	-0.37	-4.29	-0.33	3.11e-5	Mean platelet volume;
PAAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg20243544	chr17:37824526	PNMT	0.54	4.71	0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg01200585	chr1:228362443	C1orf69	-0.55	-5.74	-0.42	4.99e-8	Parkinson's disease;
PAAD	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.67	6.93	0.49	1.12e-10	Retinal vascular caliber;
PAAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.46	5.93	0.43	1.98e-8	Ulcerative colitis;
PAAD	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.48	-4.63	-0.35	7.73e-6	Menarche (age at onset);
PAAD	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg00546117	chr1:8445545	RERE	-0.47	-4.77	-0.36	4.28e-6	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04703844	chr8:74207197	RPL7;RDH10	0.61	6.79	0.48	2.4e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9398803	0.624	rs1338840	chr6:126629425	G/A	cg19875578	chr6:126661172	C6orf173	0.53	5.09	0.38	1.04e-6	Male-pattern baldness;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg08557624	chr6:5378917	FARS2	-0.49	-6.43	-0.46	1.56e-9	Energy expenditure (24h);
PAAD	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg16576597	chr16:28551801	NUPR1	-0.65	-6.51	-0.47	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22258538	chr11:14403163	NA	-0.33	-4.38	-0.33	2.2e-5	Mitochondrial DNA levels;
PAAD	cis	rs7217780	0.569	rs230956	chr17:15202205	T/C	cg20358362	chr17:14248304	HS3ST3B1	0.52	4.27	0.33	3.37e-5	Preterm birth (maternal effect);
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.65	4.47	0.34	1.5e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8112211	1.000	rs73043010	chr19:38823202	T/G	cg14299480	chr19:38876666	GGN	-0.56	-6.95	-0.49	1e-10	Blood protein levels;
PAAD	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg14343924	chr8:8086146	FLJ10661	-0.57	-4.84	-0.37	3.14e-6	Mood instability;
PAAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg15017067	chr4:17643749	FAM184B	0.4	4.44	0.34	1.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg03989125	chr22:38214979	NA	-0.65	-6.67	-0.48	4.5e-10	Glioblastoma;Glioma;
PAAD	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.15	0.5	3.37e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.57	5.94	0.43	1.88e-8	Dupuytren's disease;
PAAD	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.51	4.87	0.37	2.82e-6	Neutrophil percentage of white cells;
PAAD	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.65	-5.55	-0.41	1.22e-7	Lymphocyte counts;
PAAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.78	0.48	2.56e-10	Coronary artery disease;
PAAD	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.6	5.96	0.44	1.69e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.14e-10	Cutaneous nevi;
PAAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.56	0.65	6.64e-20	Smoking behavior;
PAAD	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.76	0.36	4.52e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.11	-0.44	8.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-6.91	-0.49	1.25e-10	Colorectal cancer;
PAAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.74	-9.46	-0.61	5.44e-17	Vitiligo;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.88	0.58	1.79e-15	Lung cancer;
PAAD	cis	rs17023223	0.537	rs2765531	chr1:119585497	A/G	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg25274157	chr19:19626576	NDUFA13;TSSK6	-0.4	-4.38	-0.34	2.16e-5	Bipolar disorder;
PAAD	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg18898632	chr2:242989856	NA	-0.85	-6.95	-0.49	1.02e-10	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09650158	chr5:137911165	HSPA9	0.71	7.72	0.53	1.41e-12	Myopia (pathological);
PAAD	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7752195	0.643	rs76426173	chr6:25317752	T/C	cg26336265	chr6:25042955	NA	0.86	4.81	0.36	3.54e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg09355652	chr11:64668475	ATG2A	0.49	4.57	0.35	1.01e-5	Breast cancer;
PAAD	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.21	0.39	5.99e-7	HIV-1 control;
PAAD	cis	rs4704187	0.663	rs28539749	chr5:74533902	G/A	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs75920871	0.925	rs11827828	chr11:116755584	A/G	cg04087571	chr11:116723030	SIK3	0.43	4.37	0.33	2.29e-5	Subjective well-being;
PAAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg19680485	chr15:31195859	MTMR15	-0.44	-4.27	-0.33	3.49e-5	Huntington's disease progression;
PAAD	cis	rs1801239	0.500	rs11254280	chr10:16969084	C/T	cg00939682	chr10:16933505	CUBN	0.59	5.4	0.4	2.51e-7	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs7714584	1.000	rs2880791	chr5:150267376	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs58521262	0.556	rs289345	chr19:23148881	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg24253500	chr15:84953950	NA	0.41	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs17007417	0.704	rs57300461	chr2:72072695	A/G	cg07540421	chr2:71115680	NA	-0.5	-4.39	-0.34	2.12e-5	Nonalcoholic steatohepatitis-derived hepatocellular carcinoma;
PAAD	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2980439	0.517	rs17594065	chr8:8105405	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.56	-0.41	1.16e-7	Neuroticism;
PAAD	cis	rs9810890	1.000	rs78460081	chr3:128446113	A/G	cg15676455	chr3:128564943	NA	-0.81	-4.78	-0.36	4.09e-6	Dental caries;
PAAD	trans	rs901683	1.000	rs34618850	chr10:46087863	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.53	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.54	5.69	0.42	6.35e-8	Menopause (age at onset);
PAAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg05725404	chr16:58534157	NDRG4	-0.79	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.83	-8.73	-0.58	4.2e-15	Coronary artery disease;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.3	-0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs17533156	0.612	rs62078287	chr17:75128493	C/T	cg11416367	chr17:75137675	SEC14L1	0.51	4.29	0.33	3.17e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.44	6.21	0.45	4.71e-9	Vitiligo;
PAAD	cis	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg15571903	chr15:79123663	NA	-0.44	-5.74	-0.42	5.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg21775007	chr8:11205619	TDH	-0.48	-4.36	-0.33	2.43e-5	Triglycerides;
PAAD	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg22815214	chr1:201083145	CACNA1S	0.61	5.96	0.44	1.71e-8	Permanent tooth development;
PAAD	cis	rs2952768	1.000	rs2248061	chr2:208495059	C/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6e-8	Life satisfaction;
PAAD	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.58	6.13	0.45	7.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg23460851	chr4:1604456	NA	0.42	4.56	0.35	1.04e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs10865541	0.571	rs7567345	chr2:3382614	T/G	cg21040360	chr2:3383326	TTC15	0.43	4.81	0.36	3.66e-6	Obesity-related traits;
PAAD	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg14515779	chr1:101123966	NA	-0.54	-6.72	-0.48	3.38e-10	Monocyte count;
PAAD	cis	rs9857275	0.527	rs12695734	chr3:141183258	A/G	cg25967872	chr3:141205623	RASA2	0.5	4.4	0.34	2.04e-5	Prion diseases;
PAAD	cis	rs988913	1.000	rs9370342	chr6:54820670	C/A	cg03513858	chr6:54763001	FAM83B	-0.42	-4.59	-0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg01796438	chr3:11312864	ATG7	-0.57	-4.5	-0.34	1.33e-5	Circulating chemerin levels;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg09913449	chr8:42400586	C8orf40	0.48	5.12	0.38	9.02e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg13777783	chr17:79615861	NA	0.41	4.3	0.33	3.04e-5	Eye color traits;
PAAD	cis	rs4388249	0.687	rs2300995	chr5:109082425	G/A	cg17395555	chr5:108820864	NA	0.32	4.4	0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.7	-7.03	-0.5	6.61e-11	Alcohol dependence;
PAAD	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-0.9	-9.1	-0.59	4.85e-16	Lymphocyte counts;
PAAD	cis	rs13053817	0.950	rs13056528	chr22:29829333	C/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.51	4.39	0.34	2.09e-5	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.36	-0.46	2.24e-9	Triglycerides;
PAAD	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.65	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02985541	chr2:219472218	PLCD4	0.3	4.67	0.35	6.57e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.07	-0.55	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.66	6.18	0.45	5.61e-9	Subjective well-being;
PAAD	cis	rs9283706	0.689	rs11956654	chr5:66318196	A/G	cg11590213	chr5:66331682	MAST4	0.57	4.68	0.35	6.33e-6	Coronary artery disease;
PAAD	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.5	-4.52	-0.34	1.23e-5	Red blood cell count;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs7508	0.512	rs2283109	chr8:17878572	T/C	cg08627089	chr8:17753878	FGL1	-0.44	-4.35	-0.33	2.46e-5	Atrial fibrillation;
PAAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.6	-5.13	-0.38	8.87e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-5.5	-0.41	1.54e-7	Menarche (age at onset);
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.63	-0.35	7.66e-6	Lung cancer;
PAAD	cis	rs9463078	0.565	rs6922660	chr6:45059674	C/A	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.26e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.88	0.49	1.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.95	-5.92	-0.43	2.09e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16262614	chr3:133464971	TF	0.46	5.06	0.38	1.2e-6	Iron status biomarkers;
PAAD	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg15628303	chr1:26608928	UBXN11	0.71	7.13	0.5	3.72e-11	Obesity-related traits;
PAAD	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.22	0.39	5.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.8	6.1	0.44	8.43e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.8	0.66	1.52e-20	Platelet count;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.76	5.54	0.41	1.31e-7	Major depressive disorder;
PAAD	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.63	-5.93	-0.43	2.01e-8	Aortic root size;
PAAD	trans	rs9409082	0.684	rs7866767	chr9:108982379	C/T	cg07010948	chr13:79181613	NA	-0.33	-6.29	-0.45	3.24e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg20607287	chr7:12443886	VWDE	-0.92	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs7715811	0.913	rs73749951	chr5:13762514	G/A	cg07548982	chr5:13769939	DNAH5	-0.67	-6.28	-0.45	3.44e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.68	-7.79	-0.53	9.94e-13	White blood cell count (basophil);
PAAD	cis	rs282587	0.569	rs408826	chr13:113415268	G/A	cg19217778	chr13:113420270	ATP11A	-0.54	-4.33	-0.33	2.71e-5	Glycated hemoglobin levels;
PAAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.69	7.51	0.52	4.7e-12	Bone mineral density;
PAAD	cis	rs7924005	0.787	rs10905876	chr10:6174601	C/T	cg17191567	chr10:6178319	NA	0.59	5.32	0.4	3.66e-7	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-5.29	-0.39	4.21e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11363097	chr8:39792086	IDO2	0.58	6.35	0.46	2.33e-9	Smoking initiation;
PAAD	cis	rs3026101	0.671	rs739767	chr17:5290681	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.54	-5.0	-0.38	1.58e-6	Dental caries;
PAAD	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.43	-0.46	1.53e-9	Hip circumference;
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-5.21	-0.39	5.94e-7	Total body bone mineral density;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22162314	chr17:61951766	CSH2	-0.51	-5.16	-0.39	7.75e-7	Height;
PAAD	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg04990556	chr1:26633338	UBXN11	0.64	4.69	0.36	5.95e-6	Obesity-related traits;
PAAD	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.77	7.5	0.52	4.82e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs3106136	0.681	rs13126976	chr4:95303472	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08113595	chr19:35770164	USF2	0.62	7.9	0.54	5.17e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26306683	chr17:18585705	ZNF286B	0.55	4.28	0.33	3.27e-5	Pancreatic cancer;
PAAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.3	0.33	3.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs12936587	0.811	rs12945496	chr17:17537197	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-4.52	-0.34	1.22e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg13206674	chr6:150067644	NUP43	0.6	5.5	0.41	1.56e-7	Lung cancer;
PAAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg26044340	chr1:207277291	C4BPA	-0.75	-4.94	-0.37	2.06e-6	C4b binding protein levels;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs1507153	0.847	rs9361422	chr6:79377738	C/G	cg05283184	chr6:79620031	NA	-0.38	-4.58	-0.35	9.75e-6	Sjögren's syndrome;
PAAD	cis	rs6785206	0.614	rs61008956	chr3:128525709	C/T	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg09237302	chr4:906077	GAK	-0.42	-4.4	-0.34	2.03e-5	Type 2 diabetes;
PAAD	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.58	0.35	9.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.55	5.96	0.44	1.7e-8	Bladder cancer;
PAAD	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2455826	0.521	rs13062323	chr3:15817502	T/G	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.88	-0.37	2.64e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.85	9.0	0.59	8.84e-16	Educational attainment;
PAAD	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.81	-0.36	3.6e-6	Red cell distribution width;
PAAD	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg17551891	chr7:1960795	MAD1L1	-0.49	-4.61	-0.35	8.56e-6	Neuroticism;
PAAD	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.71	-0.36	5.66e-6	Educational attainment (years of education);
PAAD	cis	rs508970	0.556	rs478336	chr11:60912700	C/T	cg24692310	chr11:60915630	VPS37C	0.35	4.89	0.37	2.53e-6	Rheumatoid arthritis;
PAAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.9	-9.53	-0.61	3.51e-17	DNA methylation (variation);
PAAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.48	5.05	0.38	1.24e-6	Lung cancer;
PAAD	cis	rs4722166	0.598	rs35658589	chr7:22800435	C/A	cg05472934	chr7:22766657	IL6	0.63	7.14	0.5	3.52e-11	Lung cancer;
PAAD	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.51	-4.36	-0.33	2.43e-5	Cocaine dependence;
PAAD	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg09010748	chr1:235293032	TOMM20	-0.41	-4.42	-0.34	1.86e-5	Adiposity;
PAAD	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.72	-0.58	4.43e-15	Body mass index;
PAAD	cis	rs773506	0.863	rs2482338	chr9:94037873	A/G	cg14446406	chr9:93919335	NA	0.3	4.29	0.33	3.13e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.52	4.76	0.36	4.49e-6	Corneal astigmatism;
PAAD	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.77	-8.04	-0.55	2.35e-13	Cognitive function;
PAAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg17845761	chr1:175162550	KIAA0040	-0.28	-4.28	-0.33	3.35e-5	Alcohol dependence;
PAAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg24737193	chr18:12778029	NA	0.63	5.42	0.4	2.31e-7	Inflammatory skin disease;
PAAD	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.67	8.67	0.58	5.9e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26752657	chr1:75199075	CRYZ;TYW3	0.55	5.3	0.39	4.03e-7	Resistin levels;
PAAD	cis	rs9815354	0.638	rs113712591	chr3:42050624	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.15	0.45	6.49e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	1.08	15.07	0.77	5.83e-32	Breast cancer;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.12	9.49	0.61	4.55e-17	Vitiligo;
PAAD	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.7	-6.89	-0.49	1.38e-10	Retinal vascular caliber;
PAAD	cis	rs1190596	0.525	rs28607975	chr14:102718419	A/G	cg23904247	chr14:102554826	HSP90AA1	0.43	4.97	0.37	1.81e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13870426	chr17:30244630	NA	-0.75	-7.35	-0.51	1.11e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs2885056	0.843	rs11085740	chr19:10694244	C/T	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.55	-4.56	-0.35	1.03e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.5	-5.43	-0.4	2.18e-7	Schizophrenia;
PAAD	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-5.62	-0.41	9.03e-8	Mean platelet volume;
PAAD	cis	rs1144333	0.655	rs17097837	chr1:76462166	G/A	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.89	-9.25	-0.6	1.98e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.45	7.02	0.49	6.95e-11	IgG glycosylation;
PAAD	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.73	7.12	0.5	3.98e-11	Asthma;
PAAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.47	0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg03264133	chr6:25882463	NA	-0.56	-4.71	-0.36	5.62e-6	Iron status biomarkers;
PAAD	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.95	10.74	0.66	2.3e-20	Obesity;Body mass index;
PAAD	cis	rs9535307	0.929	rs9535316	chr13:50312397	G/A	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.65	4.86	0.37	2.89e-6	Obesity-related traits;
PAAD	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.73	5.11	0.38	9.56e-7	HDL cholesterol levels;
PAAD	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.72	-8.34	-0.56	4.1e-14	Pulse pressure;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.9	-10.68	-0.65	3.28e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.8	0.36	3.83e-6	Longevity;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.83	-0.36	3.32e-6	Aortic root size;
PAAD	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg03115019	chr17:80708279	FN3K	0.52	4.67	0.35	6.71e-6	Glycated hemoglobin levels;
PAAD	cis	rs17433710	0.500	rs72711557	chr1:162669776	G/A	cg14210287	chr1:161695659	FCRLB	-0.74	-4.68	-0.36	6.19e-6	Dupuytren's disease;
PAAD	cis	rs3747547	0.818	rs7027014	chr9:37943571	T/C	cg13774184	chr9:37916125	SHB	-0.58	-4.26	-0.33	3.63e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg09127314	chr1:152161683	NA	-0.73	-4.74	-0.36	4.79e-6	Atopic dermatitis;
PAAD	cis	rs11250714	0.845	rs11250698	chr10:1688704	G/A	cg10435618	chr10:838112	NA	-0.48	-4.43	-0.34	1.82e-5	Gut microbiome composition (summer);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg12121965	chr21:46293563	PTTG1IP	0.64	6.44	0.46	1.48e-9	Primary biliary cholangitis;
PAAD	cis	rs375066	0.870	rs7258418	chr19:44383083	G/C	cg11993925	chr19:44307056	LYPD5	0.52	6.68	0.48	4.19e-10	Breast cancer;
PAAD	cis	rs16958440	0.867	rs75934126	chr18:44679781	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.39	0.4	2.59e-7	Sitting height ratio;
PAAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.57	5.1	0.38	1.02e-6	Life satisfaction;
PAAD	cis	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.52	4.36	0.33	2.36e-5	Depression;
PAAD	cis	rs12760731	0.565	rs35926996	chr1:178075351	A/G	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6691722	0.543	rs12034846	chr1:24699589	G/A	cg18323236	chr1:24743029	NIPAL3	0.43	4.57	0.35	9.98e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs11811982	0.793	rs115576012	chr1:227476031	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6681460	0.934	rs4655628	chr1:67052609	T/C	cg02459107	chr1:67143332	SGIP1	0.76	7.46	0.52	6.1e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-15.33	-0.78	1.14e-32	Height;
PAAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	5.46	0.41	1.88e-7	Glomerular filtration rate;
PAAD	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg25364880	chr3:44379878	C3orf23	-0.59	-5.77	-0.42	4.22e-8	Depressive symptoms;
PAAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.98	0.59	9.66e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4356203	0.905	rs6486354	chr11:17200108	T/C	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.28	-0.33	3.34e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1075265	0.568	rs10865277	chr2:54302002	T/C	cg04546899	chr2:54196757	PSME4	0.35	5.15	0.39	7.85e-7	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19728485	chr2:11295717	PQLC3	-0.64	-6.66	-0.48	4.78e-10	Smoking initiation;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg20302533	chr7:39170763	POU6F2	0.47	7.46	0.52	6.34e-12	IgG glycosylation;
PAAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	1.25	11.58	0.68	1.26e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.66	6.29	0.45	3.26e-9	Parkinson's disease;
PAAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg21496419	chr19:44306685	LYPD5	0.44	5.43	0.4	2.15e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4234284	1.000	rs5001789	chr3:126974392	C/T	cg27326032	chr3:127006922	NA	-0.5	-5.02	-0.38	1.43e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.74	7.8	0.53	9.12e-13	Mosquito bite size;
PAAD	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs10214930	0.697	rs12539707	chr7:27626165	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs7765175	0.698	rs9488154	chr6:113664674	G/A	cg19037598	chr6:113666021	NA	-0.44	-4.63	-0.35	7.87e-6	Coronary artery calcification;
PAAD	cis	rs2147959	0.824	rs10916313	chr1:228625882	C/G	cg02753203	chr1:228287806	NA	-0.59	-4.7	-0.36	5.76e-6	Adult asthma;
PAAD	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.67	-6.13	-0.45	7.26e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01868382	chr3:182698721	DCUN1D1	-0.64	-6.52	-0.47	9.62e-10	Smoking initiation;
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg16362232	chr11:430036	ANO9	0.82	4.53	0.34	1.18e-5	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02492405	chr8:71197103	NCOA2	0.65	7.33	0.51	1.31e-11	Smoking initiation;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.12	-0.38	9.31e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.88e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.75	8.77	0.58	3.32e-15	Methadone dose in opioid dependence;
PAAD	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.85	0.49	1.7e-10	Total body bone mineral density;
PAAD	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.5	-4.35	-0.33	2.51e-5	Acne (severe);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11538176	chr7:157053075	UBE3C	-0.52	-6.4	-0.46	1.8e-9	Monocyte percentage of white cells;
PAAD	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.8	8.41	0.56	2.74e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.24	-0.39	5.21e-7	Schizophrenia;
PAAD	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.41	0.51	8.39e-12	Multiple sclerosis;
PAAD	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.35	0.4	3.15e-7	Mean platelet volume;
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	7.03	0.5	6.5e-11	Renal function-related traits (BUN);
PAAD	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.86	9.11	0.59	4.42e-16	Body mass index;
PAAD	cis	rs2236267	0.726	rs4904428	chr14:88610516	T/C	cg18078958	chr14:88630771	NA	-0.5	-6.37	-0.46	2.09e-9	Food antigen IgG levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03768017	chr4:185747375	ACSL1	0.61	6.54	0.47	8.9e-10	Myopia (pathological);
PAAD	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.95	-13.52	-0.74	7.53e-28	Post bronchodilator FEV1;
PAAD	cis	rs62264129	0.500	rs56008438	chr3:112034103	A/G	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.32	-0.33	2.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg02900213	chr11:20385756	HTATIP2	0.46	4.34	0.33	2.6e-5	Pursuit maintenance gain;
PAAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	6.62	0.47	5.93e-10	Height;
PAAD	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.53	-4.97	-0.37	1.82e-6	Hirschsprung disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.7	8.16	0.55	1.2e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.54	-5.45	-0.4	1.99e-7	Iron status biomarkers;
PAAD	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg26876637	chr1:152193138	HRNR	-0.82	-6.13	-0.45	7.36e-9	Atopic dermatitis;
PAAD	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.51	-5.94	-0.43	1.91e-8	Mean arterial pressure;
PAAD	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	1.05	10.78	0.66	1.75e-20	Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05297105	chr12:56123171	CD63	0.67	7.45	0.52	6.5e-12	Myopia (pathological);
PAAD	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.63	-5.48	-0.41	1.75e-7	Common traits (Other);
PAAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg25276700	chr6:44698697	NA	0.45	4.36	0.33	2.42e-5	Total body bone mineral density;
PAAD	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.85	9.28	0.6	1.6e-16	Colorectal cancer;
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.54	-4.34	-0.33	2.59e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs427943	1.000	rs407133	chr21:46571889	C/G	cg06618935	chr21:46677482	NA	-0.36	-4.26	-0.33	3.56e-5	Body mass index;
PAAD	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1678618	0.617	rs1871450	chr10:73772014	G/A	cg20897136	chr10:74034667	DDIT4	0.37	4.35	0.33	2.5e-5	Smoking behavior;
PAAD	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg16306870	chr3:194868790	C3orf21	0.55	5.22	0.39	5.71e-7	Non-small cell lung cancer;
PAAD	cis	rs9857275	0.501	rs11716776	chr3:141203980	G/A	cg25967872	chr3:141205623	RASA2	0.49	4.3	0.33	3.05e-5	Prion diseases;
PAAD	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.51	-5.19	-0.39	6.73e-7	Red blood cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27557946	chr6:75953366	COX7A2	0.72	7.55	0.52	3.75e-12	Obesity-related traits;
PAAD	cis	rs2393895	0.630	rs7900283	chr10:64332495	C/T	cg09343192	chr10:65132857	JMJD1C;MIR1296	-0.73	-4.5	-0.34	1.36e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.56	-6.08	-0.44	9.2e-9	Sense of smell;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26526983	chr16:12136938	RUNDC2A	0.56	6.51	0.47	1.04e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7627468	0.837	rs6764544	chr3:121948114	G/A	cg03198317	chr3:121949109	CASR	0.51	4.59	0.35	9.19e-6	Kidney stones;
PAAD	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.76	8.64	0.57	7.11e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.61	-0.41	9.31e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4739066	0.579	rs77106515	chr8:63860297	A/G	cg20602954	chr8:63776762	NKAIN3	0.79	5.11	0.38	9.49e-7	Myocardial infarction;
PAAD	cis	rs6499755	0.739	rs31099	chr16:55370907	G/A	cg02859129	chr16:55357253	IRX6	0.37	5.19	0.39	6.78e-7	Hypospadias;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21016266	chr12:122356598	WDR66	-0.64	-7.05	-0.5	5.83e-11	Mean corpuscular volume;
PAAD	cis	rs13070279	0.655	rs35281203	chr3:71801535	G/A	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.56	-5.83	-0.43	3.21e-8	Testicular germ cell tumor;
PAAD	cis	rs1419980	0.730	rs11054545	chr12:7726853	G/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs747650	0.504	rs7935346	chr11:47008379	A/G	cg19486271	chr11:47235900	DDB2	-0.59	-5.76	-0.42	4.49e-8	Acne (severe);
PAAD	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.76	8.37	0.56	3.51e-14	Heart rate;
PAAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg07395648	chr5:131743802	NA	-0.47	-4.3	-0.33	3.09e-5	Blood metabolite levels;
PAAD	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.91	-9.17	-0.6	3.14e-16	Asthma;
PAAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.49	-0.41	1.67e-7	Neuroticism;
PAAD	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg24747557	chr10:131355152	MGMT	0.51	5.87	0.43	2.58e-8	Response to temozolomide;
PAAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.49	-6.23	-0.45	4.33e-9	Height;
PAAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs282587	0.569	rs7986147	chr13:113398784	A/C	cg04656015	chr13:113407548	ATP11A	0.54	4.34	0.33	2.54e-5	Glycated hemoglobin levels;
PAAD	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7707921	1.000	rs6888977	chr5:81533735	C/T	cg21483461	chr5:81570383	RPS23	0.51	4.31	0.33	2.96e-5	Breast cancer;
PAAD	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-16.24	-0.8	5.06e-35	Ulcerative colitis;
PAAD	cis	rs4740619	0.836	rs7859780	chr9:15622520	G/C	cg14451791	chr9:16040625	NA	-0.38	-4.36	-0.33	2.43e-5	Body mass index;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09949816	chr15:34503491	C15orf29	-0.58	-6.36	-0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-5.6	-0.41	9.65e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7894051	0.764	rs11101725	chr10:135194608	A/G	cg24905316	chr10:135186343	ECHS1	-0.73	-4.45	-0.34	1.65e-5	Lifespan;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6142102	0.961	rs4911405	chr20:32674967	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.29	0.33	3.19e-5	Skin pigmentation;
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.93	0.63	3.18e-18	Platelet count;
PAAD	cis	rs6137287	0.855	rs6137286	chr20:21179752	C/T	cg04219410	chr20:21106687	PLK1S1	-0.38	-4.29	-0.33	3.17e-5	Height;
PAAD	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.44e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00149659	chr3:10157352	C3orf10	0.56	4.46	0.34	1.61e-5	Alzheimer's disease;
PAAD	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Bladder cancer;
PAAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.6	4.83	0.36	3.36e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1015291	0.680	rs1388677	chr12:19994112	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	4.61	0.35	8.42e-6	Lymphocyte counts;
PAAD	cis	rs10804591	0.666	rs2811460	chr3:129306067	G/C	cg18548199	chr3:129281892	PLXND1	-0.54	-4.73	-0.36	5.05e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20999901	chr10:105615046	SH3PXD2A	0.59	6.54	0.47	8.65e-10	Metabolite levels  (X-11787);
PAAD	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.55	-4.97	-0.37	1.79e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.57	-0.47	7.66e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.62	5.88	0.43	2.54e-8	Mood instability;
PAAD	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.32	-0.33	2.78e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25631650	chr19:633157	POLRMT	0.69	8.02	0.55	2.67e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg11779900	chr17:80519722	FOXK2	-0.48	-4.98	-0.37	1.74e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg20673091	chr1:2541236	MMEL1	-0.85	-10.16	-0.64	7.82e-19	Ulcerative colitis;
PAAD	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.78	-6.06	-0.44	1.02e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-4.53	-0.34	1.19e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.71	-6.78	-0.48	2.45e-10	Resting heart rate;
PAAD	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.34	9.69	0.62	1.38e-17	Diabetic retinopathy;
PAAD	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24249390	chr15:90295951	MESP1	0.52	5.53	0.41	1.35e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.78	8.94	0.59	1.2e-15	Hemoglobin concentration;
PAAD	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg04896959	chr15:78267971	NA	0.65	5.11	0.38	9.4e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg10596483	chr8:143751796	JRK	-0.48	-4.25	-0.33	3.75e-5	Urinary tract infection frequency;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13521891	chr12:95466445	NR2C1	0.57	6.31	0.46	2.85e-9	Monocyte percentage of white cells;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.85	-9.1	-0.59	4.68e-16	Menopause (age at onset);
PAAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg23283495	chr1:209979779	IRF6	0.78	7.07	0.5	5.37e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.39	0.61	8.36e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6460942	0.544	rs34644264	chr7:12536090	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs4272720	0.855	rs2377692	chr10:50230347	A/T	cg07637213	chr10:50820604	CHAT;SLC18A3	0.4	4.31	0.33	2.96e-5	Platelet count;Plateletcrit;
PAAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.72	-0.42	5.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg13047869	chr3:10149882	C3orf24	0.66	5.23	0.39	5.6e-7	Alzheimer's disease;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.44	4.55	0.35	1.08e-5	Longevity;Endometriosis;
PAAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.76	-6.78	-0.48	2.44e-10	Blood pressure (smoking interaction);
PAAD	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.44	0.56	2.31e-14	Bipolar disorder;
PAAD	cis	rs4273100	1.000	rs16960158	chr17:19163052	A/C	cg18093559	chr17:18951025	GRAP	-0.5	-4.25	-0.33	3.68e-5	Schizophrenia;
PAAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10214930	0.752	rs2391454	chr7:27690624	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg23281280	chr6:28129359	ZNF389	0.59	4.56	0.35	1.05e-5	Parkinson's disease;
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.56	6.71	0.48	3.64e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg06740227	chr12:86229804	RASSF9	0.58	5.27	0.39	4.52e-7	Major depressive disorder;
PAAD	cis	rs10958605	0.761	rs1455362	chr8:40037749	A/T	cg14545590	chr8:40388592	ZMAT4	0.42	4.75	0.36	4.64e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.74	5.18	0.39	6.91e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg25753631	chr6:25732923	NA	-0.46	-5.06	-0.38	1.21e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.77	-8.04	-0.55	2.31e-13	Cognitive test performance;
PAAD	cis	rs2031532	0.587	rs4942830	chr13:50019376	A/T	cg08779649	chr13:50194554	NA	0.36	4.88	0.37	2.68e-6	Cardiac hypertrophy;
PAAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	11.9	0.69	1.67e-23	Smoking behavior;
PAAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7188861	0.681	rs1345880	chr16:11404857	G/T	cg16532467	chr16:11454386	NA	-0.56	-4.31	-0.33	2.96e-5	HDL cholesterol;
PAAD	cis	rs9463078	0.702	rs9369530	chr6:45024911	G/A	cg25276700	chr6:44698697	NA	-0.51	-5.7	-0.42	6.06e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00147160	chr1:26503991	CNKSR1	0.44	6.8	0.48	2.21e-10	Height;
PAAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06307176	chr5:131281290	NA	0.49	4.49	0.34	1.41e-5	Life satisfaction;
PAAD	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg05484376	chr2:27715224	FNDC4	-0.44	-4.4	-0.34	2.03e-5	Total body bone mineral density;
PAAD	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-7.83	-0.54	7.7e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19530576	chr14:99947768	SETD3;CCNK	0.65	7.72	0.53	1.45e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg08648136	chr8:956695	NA	0.53	5.72	0.42	5.54e-8	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.68	-0.35	6.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	4.29	0.33	3.17e-5	Menarche (age at onset);
PAAD	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.55	5.82	0.43	3.44e-8	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.28	-0.56	5.81e-14	Total body bone mineral density;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.12	-0.5	3.96e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.74	5.68	0.42	6.71e-8	Alzheimer's disease;
PAAD	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.49	5.09	0.38	1.04e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.57	-6.55	-0.47	8.31e-10	Monocyte count;
PAAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-5.49	-0.41	1.66e-7	Height;
PAAD	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.13e-5	Pain;
PAAD	cis	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg05084668	chr3:125655381	ALG1L	-0.41	-4.55	-0.35	1.1e-5	Blood pressure (smoking interaction);
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg15193198	chr20:60906057	LAMA5	-0.53	-5.48	-0.41	1.73e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-5.26	-0.39	4.75e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	7.81	0.54	8.7e-13	Lymphocyte percentage of white cells;
PAAD	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs642743	0.967	rs789970	chr10:105977721	A/G	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.75	0.36	4.74e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6028335	0.674	rs12625983	chr20:37603936	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	0.62	4.64	0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg11949866	chr1:10754891	CASZ1	0.54	4.3	0.33	3.05e-5	Ewing sarcoma;
PAAD	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.63	0.42	8.67e-8	HDL cholesterol;
PAAD	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.54	5.8	0.43	3.72e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg02023728	chr11:77925099	USP35	0.43	4.35	0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.45	4.33	0.33	2.7e-5	Mean corpuscular volume;
PAAD	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg14219918	chr9:127249562	NR5A1	0.35	4.62	0.35	8.18e-6	Menarche (age at onset);
PAAD	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27571409	chr4:89551700	HERC3	-0.62	-6.54	-0.47	8.78e-10	Obesity-related traits;
PAAD	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs9447004	1.000	rs6907989	chr6:74504074	A/T	cg22208108	chr6:74363775	SLC17A5	-0.45	-4.39	-0.34	2.12e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg24733560	chr20:60626293	TAF4	0.41	4.7	0.36	5.84e-6	Body mass index;
PAAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs13182402	1.000	rs35115612	chr5:125926839	T/C	cg07897069	chr5:126564606	NA	0.66	4.39	0.34	2.09e-5	Osteoporosis;
PAAD	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.45	-4.36	-0.33	2.37e-5	Waist circumference;Hip circumference;
PAAD	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg15123519	chr2:136567270	LCT	-0.37	-4.53	-0.34	1.19e-5	Mosquito bite size;
PAAD	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-4.3	-0.33	3.01e-5	Vitiligo;
PAAD	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.35	-0.33	2.46e-5	Lewy body disease;
PAAD	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.46	6.03	0.44	1.18e-8	Childhood ear infection;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.85	0.37	3.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.46	4.45	0.34	1.62e-5	Hepatocellular carcinoma;
PAAD	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.38	4.59	0.35	9.29e-6	Inflammatory bowel disease;
PAAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.52	-4.86	-0.37	2.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22707563	chr2:10615905	NA	0.69	7.34	0.51	1.22e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.9	-0.37	2.41e-6	Height;
PAAD	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.8	9.7	0.62	1.33e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg00999904	chr2:3704751	ALLC	0.58	5.9	0.43	2.31e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.6	-5.67	-0.42	6.88e-8	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23333220	chr15:64679825	TRIP4	0.61	6.51	0.47	1.06e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10411262	0.746	rs314660	chr19:47172845	T/C	cg13467550	chr19:47212573	PRKD2	0.54	5.34	0.4	3.29e-7	Tonsillectomy;
PAAD	cis	rs11761408	0.585	rs1134489	chr7:5257573	G/A	cg02820836	chr7:4652842	NA	-0.72	-4.35	-0.33	2.52e-5	Mean corpuscular volume;
PAAD	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg15571903	chr15:79123663	NA	-0.42	-5.19	-0.39	6.71e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4234798	1.000	rs4234797	chr4:7219907	C/T	cg18431297	chr4:7219810	SORCS2	0.4	4.9	0.37	2.47e-6	Insulin-like growth factors;
PAAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-4.81	-0.36	3.67e-6	Blood metabolite levels;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg04025244	chr7:32766748	LOC441208	-0.65	-6.8	-0.48	2.28e-10	Alcohol dependence;
PAAD	cis	rs8077577	0.747	rs62072544	chr17:18243873	C/T	cg16794390	chr17:18148240	FLII	0.5	4.3	0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.52	-4.25	-0.33	3.77e-5	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg17541715	chr7:1216824	NA	-0.52	-5.72	-0.42	5.48e-8	Longevity;Endometriosis;
PAAD	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-0.91	-6.82	-0.48	2.06e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.59	-6.0	-0.44	1.36e-8	Multiple myeloma;
PAAD	cis	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg20159608	chr7:32802032	NA	-0.59	-6.04	-0.44	1.14e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.91e-6	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.76	4.31	0.33	2.93e-5	Coronary artery disease;
PAAD	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg14784868	chr12:69753453	YEATS4	0.52	4.33	0.33	2.69e-5	Response to diuretic therapy;
PAAD	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.7	-8.0	-0.54	2.95e-13	Bone mineral density;
PAAD	cis	rs2272306	0.539	rs7304044	chr12:53536169	G/A	cg26639820	chr12:53242815	KRT78	-0.45	-4.29	-0.33	3.2e-5	Obesity-related traits;
PAAD	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg09659197	chr4:152720779	NA	0.36	5.45	0.4	1.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg20406979	chr6:167373233	NA	0.34	4.57	0.35	1.01e-5	Crohn's disease;
PAAD	cis	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg27395922	chr11:50257633	LOC441601	0.42	4.49	0.34	1.39e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	1.02	9.59	0.61	2.54e-17	Blood protein levels;
PAAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.37	0.33	2.27e-5	Diastolic blood pressure;
PAAD	cis	rs7243821	0.921	rs57490890	chr18:52628518	T/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs8077577	0.747	rs62072511	chr17:18193157	G/A	cg16794390	chr17:18148240	FLII	0.51	4.4	0.34	2.06e-5	Obesity-related traits;
PAAD	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	1.32	6.26	0.45	3.71e-9	Prostate cancer;
PAAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg06521852	chr22:38141419	TRIOBP	0.44	4.66	0.35	6.98e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6782025	0.837	rs1683978	chr3:120672324	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.34	0.6	1.13e-16	Bipolar disorder;
PAAD	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.59	6.54	0.47	8.87e-10	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.67	-6.21	-0.45	4.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.55	-6.5	-0.47	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9395066	0.527	rs55893720	chr6:44955716	G/T	cg18551225	chr6:44695536	NA	-0.43	-4.41	-0.34	1.91e-5	Height;
PAAD	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.6	7.3	0.51	1.46e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.79	9.95	0.63	2.9e-18	Vitiligo;
PAAD	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.45	-6.81	-0.48	2.08e-10	Cutaneous nevi;
PAAD	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.68	6.87	0.49	1.54e-10	Height;
PAAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.81	8.79	0.58	3.03e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg01475735	chr3:40494733	NA	-0.45	-4.38	-0.33	2.22e-5	Renal cell carcinoma;
PAAD	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.66	-6.53	-0.47	9.36e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.94	-7.99	-0.54	3.09e-13	Dupuytren's disease;
PAAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.2	0.5	2.56e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg24585817	chr7:64895279	NA	0.45	4.45	0.34	1.66e-5	Aortic root size;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg07648498	chr16:89883185	FANCA	-0.47	-4.61	-0.35	8.49e-6	Vitiligo;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg19784903	chr17:45786737	TBKBP1	-0.55	-5.99	-0.44	1.47e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10073892	0.703	rs10038372	chr5:101639664	A/G	cg17280723	chr5:101634495	NA	0.41	4.38	0.34	2.16e-5	Cognitive decline (age-related);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21679509	chr7:28219613	JAZF1	0.62	6.29	0.45	3.19e-9	Smoking initiation;
PAAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.43	5.47	0.41	1.79e-7	Psoriasis;
PAAD	cis	rs7873102	0.654	rs6476667	chr9:37975002	G/A	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs2662368	0.542	rs66519361	chr5:77115609	A/C	cg02570643	chr5:77531473	AP3B1	-0.42	-4.56	-0.35	1.04e-5	Platelet distribution width;
PAAD	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg23587288	chr2:27483067	SLC30A3	-0.8	-6.62	-0.47	5.82e-10	Blood metabolite levels;
PAAD	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg03098721	chr1:84464084	TTLL7	0.48	4.44	0.34	1.7e-5	Obesity-related traits;
PAAD	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.43	0.52	7.27e-12	Menarche (age at onset);
PAAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs4740619	0.619	rs10756739	chr9:16036716	G/C	cg14451791	chr9:16040625	NA	-0.43	-4.94	-0.37	2.06e-6	Body mass index;
PAAD	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg19257562	chr1:2043853	PRKCZ	0.51	6.32	0.46	2.82e-9	Height;
PAAD	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg04257695	chr17:30186438	C17orf79	-0.59	-4.69	-0.36	6.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg23920097	chr1:209922102	NA	-0.46	-4.48	-0.34	1.44e-5	Red blood cell count;
PAAD	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg23033748	chr14:75592666	NEK9	0.4	5.08	0.38	1.09e-6	Height;
PAAD	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	IgG glycosylation;
PAAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg04738700	chr2:239367308	NA	0.46	5.01	0.38	1.51e-6	Multiple system atrophy;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg18531004	chr3:128564980	NA	-0.89	-5.02	-0.38	1.43e-6	Dental caries;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.78	-0.42	4.1e-8	Life satisfaction;
PAAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.87	-10.74	-0.66	2.25e-20	Aortic root size;
PAAD	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	10.54	0.65	7.79e-20	Monocyte count;
PAAD	cis	rs7756389	1	rs7756389	chr6:114064674	G/A	cg13100190	chr6:114053961	NA	0.39	4.57	0.35	1.02e-5	Body mass index;
PAAD	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.82	-7.88	-0.54	5.75e-13	Response to hepatitis C treatment;
PAAD	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg00750074	chr16:89608354	SPG7	-0.56	-5.32	-0.4	3.66e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.84	-0.43	3e-8	Rheumatoid arthritis;
PAAD	cis	rs9287719	0.601	rs12996735	chr2:10716716	C/A	cg12757816	chr2:10669957	NA	-0.44	-4.51	-0.34	1.3e-5	Prostate cancer;
PAAD	cis	rs13100165	1.000	rs4676907	chr3:73274961	G/A	cg07385778	chr3:72320634	NA	-0.29	-4.51	-0.34	1.3e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.29	7.42	0.52	7.89e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs508970	0.540	rs98696	chr11:60921094	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg01831904	chr17:28903510	LRRC37B2	0.91	6.4	0.46	1.83e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7804356	0.871	rs3757654	chr7:26711104	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-4.38	-0.33	2.2e-5	Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13114166	chr1:28241026	RPA2	0.64	6.91	0.49	1.27e-10	Myopia (pathological);
PAAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.65	6.82	0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs7853377	0.760	rs2576362	chr9:86572575	G/T	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg14440974	chr22:39074834	NA	-0.53	-5.92	-0.43	2.04e-8	Menopause (age at onset);
PAAD	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.81	-8.64	-0.57	7.07e-15	Colorectal cancer;
PAAD	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg22827986	chr11:48284249	OR4X1	-0.43	-5.27	-0.39	4.56e-7	Migraine - clinic-based;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg16606324	chr3:10149918	C3orf24	-0.52	-4.45	-0.34	1.62e-5	Alzheimer's disease;
PAAD	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.78	-4.69	-0.36	5.95e-6	Type 2 diabetes;
PAAD	cis	rs9888739	1.000	rs36001237	chr16:31318257	A/T	cg02256631	chr16:31342952	ITGAM	-0.53	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.72	7.75	0.53	1.19e-12	Colorectal cancer;
PAAD	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.39	4.14e-7	Breast cancer;
PAAD	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs950037	0.710	rs786913	chr1:89295330	A/G	cg13109106	chr1:89333529	GTF2B	-0.47	-4.48	-0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	12.05	0.7	6.98e-24	Body mass index (adult);
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.94	12.53	0.71	3.5e-25	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg10932868	chr11:921992	NA	0.45	4.84	0.37	3.21e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.95	0.37	1.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.49	-4.62	-0.35	8.08e-6	Obesity-related traits;
PAAD	cis	rs10875746	0.551	rs3185921	chr12:48734731	C/T	cg26205652	chr12:48591994	NA	0.76	7.0	0.49	7.85e-11	Longevity (90 years and older);
PAAD	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg02696790	chr15:75250997	RPP25	-0.45	-5.18	-0.39	7.02e-7	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-7.92	-0.54	4.77e-13	Longevity;Endometriosis;
PAAD	cis	rs4845552	1.000	rs28635377	chr1:153479846	C/T	cg15998505	chr1:153479701	NA	-0.49	-4.43	-0.34	1.82e-5	Hippocampal atrophy;
PAAD	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Neutrophil percentage of white cells;
PAAD	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.5	4.78	0.36	4.11e-6	Hip circumference;
PAAD	cis	rs9463078	0.565	rs1797145	chr6:45155782	C/A	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22601191	chr20:60968625	CABLES2	-0.58	-5.17	-0.39	7.24e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.91	11.37	0.68	4.61e-22	Migraine;
PAAD	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.33	-0.4	3.55e-7	Educational attainment (years of education);
PAAD	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg23093090	chr10:104574429	C10orf26	-0.43	-4.72	-0.36	5.31e-6	Arsenic metabolism;
PAAD	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.24	-0.39	5.38e-7	Schizophrenia;
PAAD	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.57	5.34	0.4	3.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg02696790	chr15:75250997	RPP25	0.4	4.66	0.35	6.96e-6	Caffeine consumption;
PAAD	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.57	6.72	0.48	3.42e-10	Bipolar disorder;
PAAD	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.24	4.39	0.34	2.1e-5	Schizophrenia;
PAAD	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.3	-0.39	4.02e-7	Bipolar disorder;
PAAD	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-7.03	-0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.81	9.61	0.61	2.19e-17	Morning vs. evening chronotype;
PAAD	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.2	-0.39	6.34e-7	Mood instability;
PAAD	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg07202610	chr7:1142643	C7orf50	-0.66	-5.04	-0.38	1.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg10006428	chr1:248814059	OR2T27	0.43	5.01	0.38	1.49e-6	Common traits (Other);
PAAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2882667	0.654	rs700626	chr5:138117938	A/G	cg09476006	chr5:138032270	NA	-0.48	-6.31	-0.46	2.98e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg19442545	chr10:75533431	FUT11	-0.51	-5.32	-0.4	3.68e-7	Inflammatory bowel disease;
PAAD	cis	rs783540	0.934	rs803747	chr15:83258096	A/G	cg00614314	chr15:82944287	LOC80154	0.43	4.35	0.33	2.47e-5	Schizophrenia;
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.12	-0.5	4.08e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73198806	chr3:128465094	A/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs7588746	0.621	rs1816541	chr2:201151011	T/C	cg23649088	chr2:200775458	C2orf69	-0.51	-4.8	-0.36	3.69e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.5	5.14	0.38	8.4e-7	Lymphocyte counts;
PAAD	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.58	5.04	0.38	1.29e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10186876	0.697	rs11900511	chr2:44141849	T/C	cg09541576	chr2:44873248	C2orf34	-0.44	-4.52	-0.34	1.21e-5	Hand grip strength;
PAAD	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.66	6.43	0.46	1.58e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg21906605	chr1:21766650	NBPF3	0.44	4.29	0.33	3.16e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.66	4.61	0.35	8.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25580268	chr14:39572780	SEC23A	0.72	6.64	0.47	5.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.91	7.5	0.52	4.85e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs6987853	1.000	rs6987853	chr8:42457450	T/C	cg09913449	chr8:42400586	C8orf40	0.48	5.15	0.39	7.95e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	4.88	0.37	2.61e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1419980	0.730	rs12229835	chr12:7762227	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs901683	1.000	rs78913745	chr10:46019911	A/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.81	0.62	6.54e-18	Total body bone mineral density;
PAAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg19413350	chr8:57351067	NA	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18329780	chr15:57884048	GCOM1	0.63	6.32	0.46	2.72e-9	Smoking initiation;
PAAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg20243544	chr17:37824526	PNMT	0.54	4.91	0.37	2.3e-6	Self-reported allergy;
PAAD	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.36	4.44	0.34	1.7e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.72	-8.33	-0.56	4.48e-14	Height;
PAAD	cis	rs72843506	0.656	rs77314146	chr17:19907140	C/T	cg05625806	chr17:19284432	MAPK7	0.67	4.35	0.33	2.44e-5	Schizophrenia;
PAAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg25452165	chr22:42524984	CYP2D6	-0.53	-4.84	-0.37	3.18e-6	Schizophrenia;
PAAD	cis	rs54211	0.536	rs470081	chr22:39713105	C/T	cg05872129	chr22:39784769	NA	-0.69	-4.55	-0.35	1.1e-5	Sudden cardiac arrest;
PAAD	cis	rs2292030	1	rs2292030	chr5:132161294	G/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.51	-0.34	1.27e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12639258	0.961	rs6414428	chr3:46518003	A/G	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.5	-4.38	-0.33	2.23e-5	Eotaxin levels;
PAAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs4739066	0.579	rs77106515	chr8:63860297	A/G	cg25248160	chr8:63776642	NKAIN3	0.74	4.77	0.36	4.27e-6	Myocardial infarction;
PAAD	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg24553058	chr2:113831203	IL1F10	0.45	4.98	0.37	1.71e-6	Protein quantitative trait loci;
PAAD	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.59	6.45	0.46	1.39e-9	Obesity-related traits;
PAAD	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg07747251	chr5:1868357	NA	0.56	6.26	0.45	3.82e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.11	-0.38	9.65e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01913764	chr12:69080605	NUP107	-0.67	-6.59	-0.47	6.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.7	6.68	0.48	4.15e-10	Breast cancer;
PAAD	cis	rs4740619	0.935	rs4741535	chr9:15727144	A/G	cg14451791	chr9:16040625	NA	-0.4	-4.63	-0.35	7.77e-6	Body mass index;
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg03808351	chr9:123631620	PHF19	0.48	5.19	0.39	6.52e-7	Rheumatoid arthritis;
PAAD	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg12395012	chr8:11607386	GATA4	0.44	4.37	0.33	2.3e-5	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.34	-0.4	3.33e-7	Retinal vascular caliber;
PAAD	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.18e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7786877	0.545	rs73156234	chr7:100234744	C/T	cg00334542	chr7:100209784	MOSPD3	-0.69	-5.14	-0.38	8.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.94	0.37	2.06e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.2	-0.39	6.47e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2236918	0.664	rs1776146	chr1:242040577	A/T	cg17736920	chr1:242011382	EXO1	0.54	5.29	0.39	4.16e-7	Menopause (age at onset);
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	6.03	0.44	1.2e-8	Lymphocyte counts;
PAAD	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.94	8.22	0.55	8.29e-14	Triglycerides;
PAAD	cis	rs10970976	0.647	rs10738890	chr9:32458081	T/C	cg14296220	chr9:32431791	ACO1	0.45	4.37	0.33	2.33e-5	Asthma;
PAAD	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.98	12.05	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.95	0.54	3.94e-13	Response to antipsychotic treatment;
PAAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.56	0.35	1.04e-5	Asthma;
PAAD	cis	rs2147904	0.934	rs2786487	chr1:42368339	C/G	cg16685388	chr1:42384056	HIVEP3	-0.4	-4.67	-0.35	6.5e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs10090774	0.965	rs72685787	chr8:141960115	C/G	cg02508881	chr8:142216119	NA	0.41	4.33	0.33	2.68e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.58	-6.33	-0.46	2.58e-9	Huntington's disease progression;
PAAD	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg16419906	chr5:132167176	NA	-0.42	-4.34	-0.33	2.55e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.02	-0.75	3.55e-29	Primary sclerosing cholangitis;
PAAD	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg02887458	chr19:19495540	GATAD2A	0.55	5.08	0.38	1.09e-6	Bipolar disorder;
PAAD	cis	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.51	0.61	4.03e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17135859	1.000	rs7707681	chr5:112996226	A/T	cg12552261	chr5:112820674	MCC	0.73	4.62	0.35	8.28e-6	F-cell distribution;
PAAD	cis	rs2271001	0.955	rs12270581	chr11:19179901	A/G	cg00161556	chr11:19138045	ZDHHC13	0.5	5.39	0.4	2.59e-7	Gut microbiome composition (winter);
PAAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-1.04	-16.92	-0.81	9.08e-37	Height;
PAAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08439880	chr3:133502540	NA	-0.5	-5.34	-0.4	3.38e-7	Iron status biomarkers;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21047206	chr1:145076221	PDE4DIP	-0.46	-6.38	-0.46	1.98e-9	Body fat percentage;
PAAD	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.47	-4.28	-0.33	3.31e-5	Gut microbiome composition (summer);
PAAD	trans	rs61931739	0.613	rs12425430	chr12:33663185	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-6.35	-0.46	2.31e-9	Morning vs. evening chronotype;
PAAD	trans	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-6.51	-0.47	1.06e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.98	-10.75	-0.66	2.17e-20	Motion sickness;
PAAD	cis	rs1468333	0.964	rs2967786	chr5:137547675	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.58	6.15	0.45	6.55e-9	Resting heart rate;
PAAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg18736775	chr8:18248649	NAT2	-0.78	-6.37	-0.46	2.1e-9	Blood metabolite levels;
PAAD	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.34	4.3	0.33	3.02e-5	Body mass index in non-asthmatics;
PAAD	cis	rs4739066	0.579	rs12541047	chr8:63879476	T/G	cg25248160	chr8:63776642	NKAIN3	0.76	4.84	0.37	3.16e-6	Myocardial infarction;
PAAD	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg02415014	chr8:143852576	LYNX1	0.34	4.49	0.34	1.37e-5	Urinary tract infection frequency;
PAAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg20344442	chr15:51633704	GLDN	0.45	4.54	0.35	1.14e-5	Hormone measurements;
PAAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.27e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.646	rs13203365	chr6:109614810	G/T	cg01475377	chr6:109611718	NA	-0.4	-4.3	-0.33	2.98e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.62	0.41	8.78e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg27113419	chr16:58533979	NDRG4	-0.73	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg26876637	chr1:152193138	HRNR	-0.87	-6.5	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.661	rs67620169	chr7:104895639	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.82	7.41	0.52	8.11e-12	Corneal astigmatism;
PAAD	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.19	0.5	2.73e-11	Eye color traits;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	4.98	0.37	1.74e-6	Tonsillectomy;
PAAD	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg09168692	chr1:7887560	PER3	-0.44	-4.4	-0.34	2.02e-5	Inflammatory bowel disease;
PAAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.28	-0.39	4.49e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs875971	0.617	rs810400	chr7:66022889	G/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.76	-0.48	2.84e-10	Lung cancer;
PAAD	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs922692	0.776	rs11857532	chr15:78968268	A/C	cg00540400	chr15:79124168	NA	-0.42	-4.74	-0.36	4.96e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.26	-0.39	4.85e-7	Common traits (Other);
PAAD	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-1.1	-12.68	-0.72	1.32e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08886695	chr4:3369023	RGS12	-0.46	-4.57	-0.35	1.01e-5	Serum sulfate level;
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg07559730	chr19:53497048	ZNF702P	0.52	5.55	0.41	1.25e-7	Psoriasis;
PAAD	cis	rs16975963	0.644	rs59426132	chr19:38092770	T/G	cg14218481	chr19:38281219	NA	0.42	4.51	0.34	1.28e-5	Longevity;
PAAD	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg09998033	chr7:158218633	PTPRN2	0.76	9.05	0.59	6.46e-16	Obesity-related traits;
PAAD	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17252645	chr8:143867129	LY6D	-0.47	-4.57	-0.35	1.01e-5	Urinary tract infection frequency;
PAAD	cis	rs10947428	0.522	rs6457740	chr6:33697125	A/G	cg13859433	chr6:33739653	LEMD2	-0.52	-4.67	-0.35	6.56e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg25558440	chr8:11882962	NA	-0.48	-4.39	-0.34	2.14e-5	Neuroticism;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-4.55	-0.35	1.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.54	5.75	0.42	4.8e-8	Menopause (age at onset);
PAAD	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg06565975	chr8:143823917	SLURP1	-0.24	-5.2	-0.39	6.27e-7	Urinary tract infection frequency;
PAAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.31	0.4	3.81e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12438356	0.536	rs56071524	chr15:69745852	A/G	cg02395280	chr15:69606596	PAQR5	-0.44	-4.27	-0.33	3.4e-5	CTACK levels;
PAAD	cis	rs16854884	0.710	rs9829796	chr3:143801416	C/T	cg06585982	chr3:143692056	C3orf58	0.59	5.66	0.42	7.33e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs17655565	0.581	rs7958384	chr12:52767429	T/C	cg22980804	chr12:52818037	KRT75	-0.49	-4.35	-0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-5.55	-0.41	1.23e-7	Cognitive function;
PAAD	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-11.35	-0.68	5.11e-22	Height;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.51	6.02	0.44	1.24e-8	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg09835421	chr16:68378352	PRMT7	-0.64	-5.29	-0.39	4.15e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2790216	1.000	rs2590344	chr10:60013067	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-5.84	-0.43	3.07e-8	Blood protein levels;
PAAD	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Mosquito bite size;
PAAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.19	0.5	2.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg03289416	chr15:75166202	SCAMP2	0.52	5.34	0.4	3.4e-7	Breast cancer;
PAAD	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.38	0.33	2.21e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs62264129	0.500	rs4682400	chr3:112045215	T/C	cg01411366	chr3:112012867	SLC9A10	-0.3	-4.8	-0.36	3.81e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg10395934	chr14:104002654	TRMT61A	0.56	5.7	0.42	5.96e-8	Body mass index;
PAAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.86	-8.9	-0.59	1.53e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17749072	chr10:28822384	WAC	0.57	6.44	0.46	1.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.76	8.73	0.58	4.14e-15	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs1135642	1.000	rs1135642	chr4:77953009	A/G	cg06046430	chr4:77819534	ANKRD56	-0.69	-4.27	-0.33	3.44e-5	Food addiction;
PAAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.3	15.05	0.77	6.29e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs7804356	0.871	rs212838	chr7:26698194	T/C	cg03456212	chr7:26904342	SKAP2	0.55	4.39	0.34	2.11e-5	Type 1 diabetes;
PAAD	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg03233332	chr7:66118400	NA	-0.4	-4.34	-0.33	2.6e-5	Aortic root size;
PAAD	cis	rs4523957	0.583	rs2641443	chr17:2036162	G/A	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.53	4.54	0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs1539053	1.000	rs12079319	chr1:58101205	C/T	cg20292791	chr1:58089357	DAB1	-0.55	-5.46	-0.41	1.88e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.61	-0.65	4.86e-20	Breast cancer;
PAAD	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg06569542	chr10:98946673	SLIT1	0.5	5.06	0.38	1.2e-6	Monocyte count;
PAAD	cis	rs1561176	1.000	rs11771240	chr7:155008469	A/G	cg08570118	chr7:155025533	NA	-0.54	-4.8	-0.36	3.75e-6	Personality dimensions;
PAAD	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.7	-0.36	5.79e-6	Asthma;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.8	-8.69	-0.58	5.35e-15	Menopause (age at onset);
PAAD	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.69	6.29	0.45	3.22e-9	Platelet count;
PAAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg00944433	chr1:107599041	PRMT6	0.39	4.52	0.34	1.22e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	1.05	11.09	0.67	2.67e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.72	7.35	0.51	1.11e-11	Coronary artery disease;
PAAD	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.71	-7.55	-0.52	3.72e-12	Lymphocyte percentage of white cells;
PAAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.35	4.27	0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.36	3.66e-6	Type 2 diabetes;
PAAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-6.03	-0.44	1.19e-8	Bipolar disorder;
PAAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg20933634	chr6:27740509	NA	0.8	7.31	0.51	1.4e-11	Parkinson's disease;
PAAD	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg02493740	chr2:85810744	VAMP5	-0.44	-4.9	-0.37	2.45e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.56	-0.61	3.08e-17	Schizophrenia;
PAAD	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg01759136	chr6:27242945	NA	0.37	4.48	0.34	1.44e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg00531865	chr16:30841666	NA	0.5	4.83	0.36	3.27e-6	Dementia with Lewy bodies;
PAAD	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.4	-0.46	1.79e-9	Leprosy;
PAAD	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.73	7.97	0.54	3.55e-13	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07808546	chr1:52456429	RAB3B	0.61	7.08	0.5	4.98e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.78	9.06	0.59	6.04e-16	Eosinophil percentage of white cells;
PAAD	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs6964492	0.552	rs10272293	chr7:134414120	G/A	cg22430036	chr7:134592620	CALD1	-0.51	-4.62	-0.35	8.09e-6	Tonsillectomy;
PAAD	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.6	6.18	0.45	5.62e-9	Lung cancer;
PAAD	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.4	-0.51	8.43e-12	Total body bone mineral density;
PAAD	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8105895	0.935	rs10407173	chr19:22246663	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9039	1.000	rs17567434	chr16:9221447	C/G	cg08831531	chr16:9218945	NA	-0.62	-6.21	-0.45	4.9e-9	Menopause (age at onset);
PAAD	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.18	0.39	6.92e-7	Motion sickness;
PAAD	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs10037758	0.618	rs11486638	chr5:128280269	T/C	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24331312	chr11:44971833	TP53I11	-0.58	-6.63	-0.47	5.6e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.5	5.1	0.38	1e-6	Height;
PAAD	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg16964102	chr10:135390573	NA	-0.45	-4.74	-0.36	4.88e-6	Obesity-related traits;
PAAD	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.2	0.6	2.65e-16	Bipolar disorder;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg19337854	chr7:99768885	GPC2	0.5	4.72	0.36	5.31e-6	Platelet count;
PAAD	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	4.99	0.38	1.62e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg05643964	chr20:62369504	LIME1	-0.53	-4.96	-0.37	1.86e-6	Prostate cancer;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs35995292	0.857	rs6946859	chr7:38957432	A/G	cg19327137	chr7:38886074	VPS41	0.42	4.27	0.33	3.48e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg06917450	chr1:38156652	C1orf109	-0.49	-4.35	-0.33	2.44e-5	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg14171944	chr9:126323477	DENND1A	0.54	6.49	0.47	1.13e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.58	-5.59	-0.41	1.05e-7	Red cell distribution width;
PAAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.59	-4.46	-0.34	1.6e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.58	-5.65	-0.42	7.86e-8	Systolic blood pressure;
PAAD	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.59	6.71	0.48	3.6e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13242816	1.000	rs34936262	chr7:116160022	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.76	-8.24	-0.56	7.41e-14	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20040626	chr14:34266747	NPAS3	-0.51	-6.39	-0.46	1.9e-9	Monocyte percentage of white cells;
PAAD	cis	rs7131987	0.675	rs1436322	chr12:29554805	A/G	cg09582351	chr12:29534625	ERGIC2	0.33	4.73	0.36	5.16e-6	QT interval;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg07703079	chr11:430292	ANO9	0.9	5.74	0.42	5.06e-8	Body mass index;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21369679	chr16:47007757	DNAJA2	0.61	7.07	0.5	5.37e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.31	-0.33	2.98e-5	Menopause (age at onset);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03321319	chr22:22222323	MAPK1	0.55	6.52	0.47	9.72e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.75	8.79	0.58	2.93e-15	Emphysema distribution in smoking;
PAAD	cis	rs7119038	0.509	rs10892258	chr11:118579865	A/G	cg08498647	chr11:118550644	TREH	-0.4	-4.43	-0.34	1.81e-5	Sjögren's syndrome;
PAAD	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg02415014	chr8:143852576	LYNX1	-0.46	-5.44	-0.4	2.1e-7	Urinary tract infection frequency;
PAAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.35	15.11	0.77	4.39e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs79149102	0.579	rs67538199	chr15:75361650	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-7.46	-0.52	6.36e-12	Lung cancer;
PAAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.98	-13.47	-0.74	1.01e-27	Height;
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2131877	1.000	rs2131877	chr3:194858374	C/T	cg19760965	chr3:194868843	C3orf21	0.43	4.54	0.35	1.14e-5	Non-small cell lung cancer;
PAAD	cis	rs2835872	0.758	rs1709832	chr21:39038167	A/C	cg06728970	chr21:39037746	KCNJ6	0.55	6.46	0.46	1.31e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs11051970	0.559	rs11051992	chr12:32564667	G/T	cg24626660	chr12:32551988	NA	0.43	4.63	0.35	7.88e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	0.89	8.77	0.58	3.37e-15	Exhaled nitric oxide output;
PAAD	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg16586182	chr3:47516702	SCAP	-0.7	-7.96	-0.54	3.72e-13	Colorectal cancer;
PAAD	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.3	-0.46	3.05e-9	Morning vs. evening chronotype;
PAAD	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	6.56	0.47	8.06e-10	Schizophrenia;
PAAD	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.74	0.42	4.97e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg16083429	chr3:49237500	CCDC36	0.45	4.32	0.33	2.83e-5	Menarche (age at onset);
PAAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	cis	rs2422052	0.639	rs2113589	chr2:118647316	A/G	cg22545206	chr2:118617499	NA	0.45	4.41	0.34	1.94e-5	Mosquito bite size;
PAAD	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.54	5.39	0.4	2.66e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.51	0.65	9.45e-20	Total body bone mineral density;
PAAD	cis	rs2016586	0.802	rs5999977	chr22:36116097	T/G	cg26342177	chr22:36113512	APOL5	-0.49	-4.8	-0.36	3.71e-6	Body mass index;
PAAD	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.63	-0.35	7.83e-6	Resting heart rate;
PAAD	cis	rs859767	0.501	rs1123184	chr2:135431057	C/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.66	-0.35	6.75e-6	Neuroticism;
PAAD	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg21565972	chr17:80109576	CCDC57	0.48	5.23	0.39	5.58e-7	Life satisfaction;
PAAD	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	High light scatter reticulocyte count;
PAAD	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.74	6.93	0.49	1.09e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11997175	0.558	rs9792124	chr8:33797689	A/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.15	0.45	6.56e-9	Body mass index;
PAAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg06585982	chr3:143692056	C3orf58	0.57	5.54	0.41	1.29e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg04025307	chr7:1156635	C7orf50	0.7	4.95	0.37	1.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17135859	0.715	rs4705572	chr5:113056464	A/G	cg12552261	chr5:112820674	MCC	0.7	4.82	0.36	3.4e-6	F-cell distribution;
PAAD	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg12560992	chr17:57184187	TRIM37	-0.63	-4.71	-0.36	5.64e-6	Vitamin D levels;
PAAD	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.48	-4.61	-0.35	8.49e-6	Mean platelet volume;
PAAD	cis	rs12153243	0.714	rs66524576	chr5:142895661	G/A	cg13907255	chr5:142895549	NA	-0.49	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.38	4.81	0.36	3.64e-6	Migraine;
PAAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.29e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19947233	chr4:90032727	TIGD2	0.55	6.4	0.46	1.79e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	5.19	0.39	6.56e-7	Tonsillectomy;
PAAD	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs35955747	0.869	rs131219	chr22:31760250	T/C	cg02404636	chr22:31891804	SFI1	0.55	5.55	0.41	1.23e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.5	-4.84	-0.37	3.14e-6	Menarche (age at onset);
PAAD	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg27490568	chr2:178487706	NA	0.42	4.35	0.33	2.46e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg22089800	chr15:90895588	ZNF774	0.52	4.91	0.37	2.29e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.38	-4.69	-0.36	6.02e-6	Schizophrenia;
PAAD	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.48	5.0	0.38	1.55e-6	Longevity;Endometriosis;
PAAD	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.17	0.5	3e-11	Eye color traits;
PAAD	cis	rs2992756	0.663	rs2992732	chr1:18802825	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg20085588	chr10:81316188	SFTPA2	0.38	4.35	0.33	2.51e-5	Post bronchodilator FEV1;
PAAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.03	-0.38	1.35e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg10437265	chr15:77819839	NA	-0.38	-4.3	-0.33	3.01e-5	Type 2 diabetes;
PAAD	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.62	-4.36	-0.33	2.39e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	-0.65	-4.53	-0.35	1.17e-5	Lung cancer in ever smokers;
PAAD	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.92	-9.6	-0.61	2.34e-17	Urate levels in obese individuals;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg01075559	chr1:2537774	MMEL1	-0.5	-5.35	-0.4	3.18e-7	Ulcerative colitis;
PAAD	cis	rs7577696	0.853	rs212698	chr2:32442997	A/C	cg02381751	chr2:32503542	YIPF4	0.43	4.54	0.35	1.12e-5	Inflammatory biomarkers;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-5.35	-0.4	3.25e-7	Renal function-related traits (BUN);
PAAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg13918804	chr1:2043761	PRKCZ	0.41	5.38	0.4	2.82e-7	Height;
PAAD	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27502766	chr2:88926899	EIF2AK3	-0.81	-7.32	-0.51	1.32e-11	Neuroticism;
PAAD	cis	rs7187994	0.848	rs34457873	chr16:84782871	T/G	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs1350666	0.608	rs1460010	chr4:75255571	A/T	cg19308222	chr4:75230391	EREG	0.48	4.29	0.33	3.22e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg19847866	chr10:1019161	NA	-0.59	-4.68	-0.35	6.34e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.42	6.26	0.45	3.79e-9	Information processing speed;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.54	-5.35	-0.4	3.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.66	-7.24	-0.51	2.07e-11	N-glycan levels;
PAAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	1.97e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.18	10.27	0.64	4.14e-19	Vitiligo;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03760483	chr17:6899297	ALOX12	0.44	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.26e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2190422	0.651	rs2965086	chr7:103084913	C/T	cg04218035	chr7:103086829	SLC26A5	0.35	5.02	0.38	1.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.49	4.37	0.33	2.33e-5	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg15693483	chr7:1102177	C7orf50	0.44	4.98	0.37	1.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg17541715	chr7:1216824	NA	-0.4	-4.49	-0.34	1.43e-5	Longevity;Endometriosis;
PAAD	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.54	6.16	0.45	6.26e-9	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.61	4.58	0.35	9.56e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02792140	chr19:3505953	FZR1	0.58	6.35	0.46	2.34e-9	Monocyte percentage of white cells;
PAAD	cis	rs11958404	0.615	rs7711271	chr5:157452268	C/G	cg05962755	chr5:157440814	NA	0.56	5.31	0.4	3.85e-7	IgG glycosylation;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg00280220	chr17:61926910	NA	0.4	4.27	0.33	3.5e-5	Prudent dietary pattern;
PAAD	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.56	-5.91	-0.43	2.2e-8	Lung cancer;
PAAD	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg01620082	chr3:125678407	NA	-1.51	-8.83	-0.58	2.39e-15	Squamous cell lung carcinoma;
PAAD	cis	rs7925523	0.891	rs59371352	chr11:61450295	G/A	cg12472022	chr11:61462803	DAGLA	0.7	5.67	0.42	7e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-5.94	-0.43	1.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs136211	0.929	rs6000262	chr22:36770038	A/G	cg11153328	chr22:36877737	TXN2	-0.52	-4.7	-0.36	5.73e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs91	0.575	rs6971202	chr7:24427007	C/T	cg13313214	chr7:23749942	STK31	-0.43	-4.48	-0.34	1.43e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.48	-4.58	-0.35	9.78e-6	Diastolic blood pressure;
PAAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs57994353	0.568	rs10870171	chr9:139318530	C/T	cg21253087	chr9:139290292	SNAPC4	0.52	4.58	0.35	9.65e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	5.26	0.39	4.76e-7	Mood instability;
PAAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.67	-4.87	-0.37	2.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20893717	chr7:100318190	EPO	0.44	4.9	0.37	2.48e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg20913747	chr6:44695427	NA	-0.66	-6.54	-0.47	8.62e-10	Total body bone mineral density;
PAAD	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg24110177	chr3:50126178	RBM5	0.53	4.6	0.35	8.9e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1497828	0.956	rs5002693	chr1:217530191	T/A	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.03	-0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.62	-0.35	8.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.93	0.37	2.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs394563	0.690	rs372205	chr6:149775267	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.35	-4.74	-0.36	4.9e-6	Dupuytren's disease;
PAAD	cis	rs10885582	0.818	rs11196793	chr10:116346929	T/C	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.07	-0.38	1.12e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7922314	0.571	rs61865696	chr10:64732765	T/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.9	7.77	0.53	1.11e-12	Alzheimer's disease;
PAAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.86	7.24	0.51	2.05e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20814179	chr4:940893	TMEM175	0.75	9.18	0.6	2.99e-16	Sjögren's syndrome;
PAAD	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.59	0.41	1.03e-7	Ileal carcinoids;
PAAD	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.79	9.42	0.61	6.81e-17	White blood cell count (basophil);
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.4	0.82	5.47e-38	Height;
PAAD	cis	rs2882667	0.690	rs825677	chr5:138104770	T/C	cg09476006	chr5:138032270	NA	-0.46	-5.91	-0.43	2.11e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8133932	0.701	rs9653791	chr21:47303328	G/A	cg13695288	chr21:47294981	PCBP3	-0.46	-4.5	-0.34	1.37e-5	Schizophrenia;
PAAD	cis	rs4795519	0.736	rs12941092	chr17:22154100	T/C	cg22648282	chr17:21454238	C17orf51	-0.55	-5.28	-0.39	4.44e-7	Chronic myeloid leukemia;
PAAD	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.51	1.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs2882667	0.690	rs1703212	chr5:138078552	A/G	cg09476006	chr5:138032270	NA	-0.49	-6.4	-0.46	1.86e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.91	7.91	0.54	5.02e-13	Gut microbiome composition (summer);
PAAD	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.51	-0.65	9.26e-20	Cognitive function;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	7.01	0.49	7.46e-11	Schizophrenia;
PAAD	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.69	-6.98	-0.49	8.54e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.92e-6	Oral cavity cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24546680	chr1:3773665	DFFB;KIAA0562	-0.76	-6.77	-0.48	2.59e-10	Neuroticism;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.74	-0.36	4.92e-6	Lymphocyte counts;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01897796	chr15:59225903	SLTM	-0.63	-6.77	-0.48	2.67e-10	Smoking initiation;
PAAD	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs438465	1.000	rs2997878	chr6:169883429	T/G	cg11181693	chr6:169825345	NA	-0.54	-4.25	-0.33	3.65e-5	Corneal astigmatism;
PAAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg05110241	chr16:68378359	PRMT7	-1.18	-8.69	-0.58	5.3e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.17	-0.45	5.81e-9	Asthma;
PAAD	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.88	-11.05	-0.67	3.23e-21	Dental caries;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.71	8.08	0.55	1.91e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg15654264	chr1:150340011	RPRD2	0.49	4.8	0.36	3.79e-6	Migraine;
PAAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg22815214	chr1:201083145	CACNA1S	0.65	6.72	0.48	3.37e-10	Permanent tooth development;
PAAD	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg23682824	chr7:23144976	KLHL7	0.46	4.26	0.33	3.6e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.94	-10.67	-0.65	3.54e-20	Tonsillectomy;
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07157834	chr1:205819609	PM20D1	0.59	5.78	0.42	4.01e-8	Parkinson's disease;
PAAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg10494973	chr17:80897199	TBCD	-0.53	-4.98	-0.37	1.7e-6	Breast cancer;
PAAD	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.57	6.64	0.47	5.29e-10	Schizophrenia;
PAAD	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg26929925	chr5:138714136	SLC23A1	-0.52	-4.83	-0.37	3.24e-6	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.47	-5.07	-0.38	1.15e-6	Educational attainment;
PAAD	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.32	-0.4	3.68e-7	Daytime sleep phenotypes;
PAAD	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.73	-9.16	-0.6	3.36e-16	Educational attainment;
PAAD	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg14329783	chr7:75779857	NA	0.74	4.46	0.34	1.6e-5	Mononucleosis;
PAAD	trans	rs11989843	0.636	rs16889365	chr8:118071538	C/T	cg24636944	chr5:92615296	NA	0.49	6.31	0.46	2.91e-9	Obesity-related traits;
PAAD	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.85	8.96	0.59	1.08e-15	Anterior chamber depth;
PAAD	cis	rs116248771	0.690	rs73156439	chr3:158359462	G/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.63	6.05	0.44	1.06e-8	Diastolic blood pressure;
PAAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.81	-8.07	-0.55	2e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12431939	0.762	rs60294020	chr14:51704821	C/A	cg23942311	chr14:51606299	NA	-0.6	-5.0	-0.38	1.55e-6	Cancer;
PAAD	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	5.5	0.41	1.58e-7	Blood protein levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09964670	chr19:5720572	TMEM146;LONP1	0.6	6.8	0.48	2.25e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg18370025	chr7:2749541	AMZ1	-0.36	-4.25	-0.33	3.73e-5	Height;
PAAD	cis	rs10887741	0.646	rs11202499	chr10:89433211	C/G	cg13926569	chr10:89418898	PAPSS2	0.48	4.82	0.36	3.49e-6	Exercise (leisure time);
PAAD	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	4.95	0.37	1.91e-6	Depressive symptoms;
PAAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.72	0.36	5.23e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-13.03	-0.73	1.59e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg01851573	chr8:8652454	MFHAS1	-0.49	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.66	-0.35	6.8e-6	Height;
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg25037394	chr1:24152592	HMGCL	-0.41	-4.45	-0.34	1.66e-5	Immature fraction of reticulocytes;
PAAD	cis	rs10865541	0.934	rs6738333	chr2:3403404	T/C	cg21040360	chr2:3383326	TTC15	-0.44	-4.55	-0.35	1.1e-5	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	1.03e-18	Response to antipsychotic treatment;
PAAD	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.01	0.49	7.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg04143805	chr16:89395205	ANKRD11	-0.36	-4.27	-0.33	3.39e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.61	-5.47	-0.41	1.82e-7	Type 2 diabetes;
PAAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.76	8.1	0.55	1.7e-13	Coronary artery disease;
PAAD	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.89	0.43	2.45e-8	Lymphocyte counts;
PAAD	cis	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.57	4.26	0.33	3.54e-5	Systolic blood pressure;
PAAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.63	7.18	0.5	2.84e-11	High light scatter reticulocyte count;
PAAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.36	0.4	3e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.53	-5.4	-0.4	2.53e-7	Testicular germ cell tumor;
PAAD	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.59	-6.95	-0.49	9.96e-11	Renal function-related traits (BUN);
PAAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.5	-5.62	-0.42	8.68e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.63	6.89	0.49	1.38e-10	Longevity;
PAAD	cis	rs8067287	0.634	rs7225344	chr17:16840498	C/T	cg26910001	chr17:16838321	NA	0.46	4.64	0.35	7.42e-6	Diabetic kidney disease;
PAAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.57	5.74	0.42	4.88e-8	Obesity-related traits;
PAAD	cis	rs6466055	0.777	rs10277120	chr7:104834417	A/T	cg04380332	chr7:105027541	SRPK2	0.65	7.33	0.51	1.26e-11	Schizophrenia;
PAAD	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1862626	0.506	rs4700008	chr5:56044186	A/G	cg14703610	chr5:56206110	C5orf35	0.51	4.72	0.36	5.35e-6	Cancer (pleiotropy);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04859477	chr1:113249989	RHOC	0.6	6.91	0.49	1.26e-10	Metabolite levels  (X-11787);
PAAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.71	0.36	5.63e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs12304921	1.000	rs73092537	chr12:51358517	G/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.37	-0.33	2.33e-5	Type 2 diabetes;
PAAD	cis	rs9913156	0.748	rs7213896	chr17:4562082	G/A	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07362569	chr17:61921086	SMARCD2	0.57	6.56	0.47	7.91e-10	Prudent dietary pattern;
PAAD	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg00522288	chr12:125625016	AACS	-0.49	-4.88	-0.37	2.66e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.36	0.33	2.36e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.64	4.94	0.37	2.04e-6	Alzheimer's disease;
PAAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.81	7.65	0.53	2.12e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg17650747	chr5:1873721	NA	0.43	4.34	0.33	2.56e-5	Cardiovascular disease risk factors;
PAAD	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg27234864	chr13:21295941	IL17D	0.62	5.43	0.4	2.2e-7	Dental caries;
PAAD	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.31	0.4	3.8e-7	Diabetic kidney disease;
PAAD	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.45	4.36	0.33	2.34e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg09796270	chr17:17721594	SREBF1	0.45	4.86	0.37	2.85e-6	Total body bone mineral density;
PAAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.63	-6.62	-0.47	5.83e-10	Schizophrenia;
PAAD	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14625594	chr9:129291374	NA	0.67	7.14	0.5	3.53e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.63	7.12	0.5	4.1e-11	Emphysema distribution in smoking;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27297192	chr10:134578999	INPP5A	0.62	5.58	0.41	1.07e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.57	6.7	0.48	3.91e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg09659197	chr4:152720779	NA	-0.39	-5.65	-0.42	7.69e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9372498	1.000	rs9372498	chr6:118572486	T/A	cg15607664	chr12:57630422	NDUFA4L2	-0.81	-7.67	-0.53	1.92e-12	Diastolic blood pressure;
PAAD	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg22134325	chr11:66188745	NPAS4	0.38	4.61	0.35	8.37e-6	Airway imaging phenotypes;
PAAD	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-5.23	-0.39	5.6e-7	Bipolar disorder;
PAAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	7.02	0.49	6.95e-11	Monocyte count;
PAAD	cis	rs1062746	0.527	rs12934628	chr16:87335161	A/G	cg02258303	chr16:87377426	FBXO31	-0.66	-6.73	-0.48	3.21e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg16591659	chr17:78472290	NA	-0.47	-4.5	-0.34	1.34e-5	Fractional excretion of uric acid;
PAAD	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.81	6.67	0.48	4.52e-10	Pulmonary function decline;
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.69	0.36	6.13e-6	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.515	rs77823653	chr22:46762266	C/T	cg24881330	chr22:46731750	TRMU	1.27	6.21	0.45	4.94e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.43	4.89	0.37	2.59e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9463078	0.585	rs7757282	chr6:45302654	A/G	cg18551225	chr6:44695536	NA	-0.41	-4.38	-0.33	2.22e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.57	0.57	1.1e-14	Rheumatoid arthritis;
PAAD	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg19217778	chr13:113420270	ATP11A	0.66	4.53	0.35	1.17e-5	Glycated hemoglobin levels;
PAAD	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	5.81	0.43	3.62e-8	Cognitive test performance;
PAAD	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.57	-5.16	-0.39	7.45e-7	Myeloid white cell count;
PAAD	cis	rs10875746	0.768	rs10875724	chr12:48420253	C/A	cg26205652	chr12:48591994	NA	0.84	8.04	0.55	2.31e-13	Longevity (90 years and older);
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.64	-0.35	7.49e-6	Life satisfaction;
PAAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg05555928	chr11:63887634	MACROD1	-0.44	-4.91	-0.37	2.37e-6	Platelet count;
PAAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg14191688	chr11:70257035	CTTN	0.54	4.6	0.35	8.87e-6	Coronary artery disease;
PAAD	cis	rs4417704	0.551	rs6753109	chr2:241877597	C/T	cg26818257	chr2:241905806	NA	-0.51	-5.41	-0.4	2.35e-7	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16238207	chr2:101181112	PDCL3	-0.62	-6.34	-0.46	2.52e-9	Obesity-related traits;
PAAD	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.82	6.52	0.47	9.67e-10	Ulcerative colitis;
PAAD	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg01422370	chr2:73384389	NA	0.33	4.52	0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg21518248	chr2:162101506	NA	0.55	5.94	0.43	1.88e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.8e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.82	8.7	0.58	4.99e-15	Blood protein levels;
PAAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.96	12.56	0.71	2.83e-25	Menopause (age at onset);
PAAD	cis	rs258892	0.843	rs16901045	chr5:72033986	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.58	4.42	0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg08632701	chr21:37451849	NA	-0.59	-6.15	-0.45	6.47e-9	Mitral valve prolapse;
PAAD	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg13010199	chr12:38710504	ALG10B	0.51	4.68	0.35	6.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs8016982	0.662	rs9806020	chr14:81668555	A/C	cg01989461	chr14:81687754	GTF2A1	0.57	4.62	0.35	8.25e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.33	-0.33	2.72e-5	Life satisfaction;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg16606324	chr3:10149918	C3orf24	0.63	5.03	0.38	1.35e-6	Alzheimer's disease;
PAAD	cis	rs1329189	0.834	rs7898238	chr10:130000881	C/T	cg17972361	chr10:130010134	NA	-0.47	-4.83	-0.37	3.24e-6	Orofacial clefts;
PAAD	cis	rs2735413	0.875	rs8055298	chr16:78084868	C/G	cg04733911	chr16:78082701	NA	0.56	5.96	0.44	1.67e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.58	7.31	0.51	1.39e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.15	0.39	7.79e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.62	-5.58	-0.41	1.1e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7551345	0.851	rs12136523	chr1:31808253	C/T	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs9304742	0.540	rs10416138	chr19:53465152	C/T	cg02440177	chr19:53496695	ZNF702P	-0.51	-4.54	-0.35	1.16e-5	Psoriasis;
PAAD	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.5	5.34	0.4	3.34e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.94	7.57	0.52	3.3e-12	Bipolar disorder;
PAAD	cis	rs2637266	0.905	rs1907313	chr10:78338072	A/G	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.41e-6	Pulmonary function;
PAAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg21171335	chr12:122356390	WDR66	-0.5	-4.96	-0.37	1.83e-6	Mean corpuscular volume;
PAAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg26071806	chr7:100318239	EPO	-0.46	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-8.5	-0.57	1.61e-14	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.46	0.41	1.87e-7	Life satisfaction;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg11062466	chr8:58055876	NA	0.67	5.06	0.38	1.18e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	4.84	0.37	3.15e-6	Adiposity;
PAAD	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.63	5.81	0.43	3.53e-8	Refractive astigmatism;
PAAD	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg03199926	chr20:60860733	OSBPL2	-0.35	-4.42	-0.34	1.86e-5	Colorectal cancer;
PAAD	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05555928	chr11:63887634	MACROD1	0.47	5.36	0.4	3.01e-7	Platelet count;
PAAD	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg09654669	chr8:57350985	NA	-0.54	-4.6	-0.35	8.82e-6	Obesity-related traits;
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg07068956	chr7:100330872	ZAN	-0.61	-4.9	-0.37	2.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6466055	0.739	rs10953474	chr7:104923005	A/G	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	4.34	0.33	2.62e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg05185784	chr16:90016020	DEF8	0.5	4.92	0.37	2.25e-6	Squamous cell carcinoma;
PAAD	cis	rs955333	0.543	rs11155985	chr6:154933077	G/C	cg20019720	chr6:154832845	CNKSR3	0.32	4.32	0.33	2.83e-5	Diabetic kidney disease;
PAAD	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.47	4.79	0.36	3.9e-6	Type 2 diabetes;
PAAD	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.91	-7.47	-0.52	5.91e-12	Orofacial clefts;
PAAD	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.5	-0.41	1.59e-7	Neuroticism;
PAAD	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.4	-4.39	-0.34	2.08e-5	Lung cancer;
PAAD	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.42	6.34	0.46	2.51e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.57	4.99	0.38	1.63e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg01620082	chr3:125678407	NA	-0.92	-6.64	-0.47	5.21e-10	Depression;
PAAD	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.81	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.91	-7.09	-0.5	4.83e-11	Initial pursuit acceleration;
PAAD	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg27394845	chr17:28928406	LRRC37B2	0.61	4.45	0.34	1.68e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-4.74	-0.36	4.77e-6	Eosinophil percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11649268	chr17:2322610	METT10D	-0.71	-7.53	-0.52	4.18e-12	Obesity-related traits;
PAAD	cis	rs728616	0.558	rs61859215	chr10:82151148	G/A	cg19423196	chr10:82049429	MAT1A	0.51	4.87	0.37	2.73e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-5.38	-0.4	2.82e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06028605	chr16:24865363	SLC5A11	-0.52	-6.29	-0.45	3.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg04034577	chr2:241836375	C2orf54	-0.36	-5.21	-0.39	6.14e-7	Urinary metabolites;
PAAD	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.72	8.07	0.55	2.01e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2e-5	Life satisfaction;
PAAD	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.9	7.46	0.52	6.27e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2016586	0.895	rs4821437	chr22:36113450	T/A	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.58	5.93	0.43	1.92e-8	Systolic blood pressure;
PAAD	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.5	5.09	0.38	1.03e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.82	0.36	3.39e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.68	-0.36	6.21e-6	Height;
PAAD	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.69e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.85	10.29	0.64	3.5e-19	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10703506	chr12:109576250	ACACB	-0.66	-6.75	-0.48	2.95e-10	Obesity-related traits;
PAAD	cis	rs282587	0.502	rs416703	chr13:113399219	A/G	cg04656015	chr13:113407548	ATP11A	0.54	4.31	0.33	2.88e-5	Glycated hemoglobin levels;
PAAD	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.79	8.98	0.59	9.97e-16	Hemoglobin concentration;
PAAD	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-6.33	-0.46	2.58e-9	Type 2 diabetes;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21334191	chr3:148856448	HPS3	-0.54	-6.51	-0.47	1.04e-9	Energy expenditure (24h);
PAAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg02820901	chr13:113351484	ATP11A	0.7	4.71	0.36	5.53e-6	Glycated hemoglobin levels;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	5.41	0.4	2.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.68	7.74	0.53	1.27e-12	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	14.72	0.77	4.77e-31	Schizophrenia;
PAAD	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.8	8.3	0.56	5.23e-14	Uric acid levels;
PAAD	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.37	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-4.65	-0.35	7.1e-6	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg15181151	chr6:150070149	PCMT1	0.6	6.53	0.47	9.18e-10	Lung cancer;
PAAD	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg02770688	chr6:168491649	NA	0.46	4.83	0.37	3.25e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	6.83	0.48	1.96e-10	Systemic lupus erythematosus;
PAAD	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.59	5.58	0.41	1.1e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.82	-8.74	-0.58	3.99e-15	DNA methylation (variation);
PAAD	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg01324507	chr7:1177794	C7orf50	0.55	4.32	0.33	2.81e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg03315344	chr16:75512273	CHST6	-0.69	-5.7	-0.42	5.95e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-5.78	-0.42	4.03e-8	Type 2 diabetes;
PAAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22947322	chr17:47091978	IGF2BP1	0.38	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg06618935	chr21:46677482	NA	-0.54	-6.7	-0.48	3.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.66	-7.29	-0.51	1.54e-11	Mononucleosis;
PAAD	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7896729	0.943	rs56821071	chr10:5348791	C/T	cg07902545	chr10:6194255	PFKFB3	-0.44	-4.55	-0.35	1.08e-5	Intelligence;
PAAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.74	-7.22	-0.51	2.37e-11	Cognitive function;
PAAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.49	5.47	0.41	1.8e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	6.52	0.47	9.76e-10	Adiposity;
PAAD	cis	rs7224685	0.637	rs35618711	chr17:4229258	A/T	cg09695851	chr17:3907499	NA	0.61	4.91	0.37	2.33e-6	Type 2 diabetes;
PAAD	cis	rs2414095	0.527	rs8041967	chr15:51544324	G/A	cg21478137	chr15:51532386	CYP19A1	0.54	5.5	0.41	1.58e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg20607287	chr7:12443886	VWDE	-0.6	-4.72	-0.36	5.32e-6	Coronary artery disease;
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.51	-0.47	1.01e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg00555438	chr3:195578280	NA	-0.56	-5.54	-0.41	1.31e-7	Pancreatic cancer;
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Body mass index;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Osteoarthritis;
PAAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.57	6.21	0.45	4.83e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.58	-5.56	-0.41	1.16e-7	Monocyte count;
PAAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-5.99	-0.44	1.43e-8	Body mass index;
PAAD	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg23534315	chr17:78082725	GAA	-0.51	-4.8	-0.36	3.79e-6	Yeast infection;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14831746	chr12:49961631	MCRS1	0.57	6.38	0.46	2.06e-9	Energy expenditure (24h);
PAAD	trans	rs3733631	1.000	rs3796951	chr4:104628158	A/T	cg11176159	chr1:28213800	NA	0.48	6.4	0.46	1.87e-9	Menarche (age at onset);
PAAD	cis	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg18867708	chr6:26865862	GUSBL1	0.44	4.39	0.34	2.09e-5	Schizophrenia;
PAAD	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.61	-7.93	-0.54	4.5e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.28	0.39	4.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg19761014	chr17:28927070	LRRC37B2	0.92	5.59	0.41	1.05e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13150344	chr11:67889062	CHKA	0.71	7.38	0.51	9.38e-12	Myopia (pathological);
PAAD	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.67	7.27	0.51	1.8e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.34	0.81	7.65e-38	Height;
PAAD	cis	rs9857275	0.527	rs12695736	chr3:141205465	T/C	cg25967872	chr3:141205623	RASA2	0.49	4.3	0.33	3.05e-5	Prion diseases;
PAAD	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg17105886	chr17:28927953	LRRC37B2	0.76	4.82	0.36	3.4e-6	Body mass index;
PAAD	cis	rs10992853	0.504	rs62573993	chr9:96385086	G/C	cg13787134	chr9:96362102	PHF2	0.39	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-5.1	-0.38	9.93e-7	Schizophrenia;
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09256448	chr16:638327	NA	0.44	4.55	0.35	1.1e-5	Height;
PAAD	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg18721089	chr20:30220636	NA	-0.5	-4.32	-0.33	2.76e-5	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg10600917	chr12:121163489	ACADS	-0.52	-4.27	-0.33	3.37e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs11124272	0.761	rs4952244	chr2:32036625	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-4.61	-0.35	8.34e-6	Interleukin-18 levels;
PAAD	cis	rs9815354	1.000	rs1716984	chr3:41965532	G/A	cg03022575	chr3:42003672	ULK4	-0.81	-5.82	-0.43	3.32e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7713065	0.840	rs10067603	chr5:131803868	A/G	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.17	-0.39	7.19e-7	Lung function (FEV1/FVC);
PAAD	cis	rs1035491	0.720	rs10940001	chr5:63960187	C/T	cg01791865	chr5:63954708	NA	0.5	5.2	0.39	6.39e-7	Body mass index;
PAAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg03885332	chr11:832357	CD151	-0.46	-5.37	-0.4	2.91e-7	Mean platelet volume;
PAAD	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg15440763	chr7:158190612	PTPRN2	0.48	4.76	0.36	4.46e-6	Obesity-related traits;
PAAD	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.7	8.94	0.59	1.22e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.9	-9.18	-0.6	3e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	11.22	0.67	1.15e-21	Primary sclerosing cholangitis;
PAAD	cis	rs9462027	0.628	rs9469899	chr6:34793124	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.59	-0.35	9.37e-6	Systemic lupus erythematosus;
PAAD	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04850017	chr11:63683019	RCOR2	0.39	4.36	0.33	2.39e-5	Pulse pressure;
PAAD	cis	rs2077212	0.546	rs4415344	chr8:5973222	G/T	cg17754742	chr8:6400956	ANGPT2;MCPH1	-0.36	-4.39	-0.34	2.07e-5	Diabetic kidney disease;
PAAD	cis	rs9535307	0.745	rs1407440	chr13:50286218	T/C	cg04663916	chr13:50265991	EBPL	0.61	4.69	0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs34375054	0.573	rs35698828	chr12:125658603	C/T	cg25124228	chr12:125621409	AACS	-0.62	-5.52	-0.41	1.44e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.57	-4.86	-0.37	2.88e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7326068	0.595	rs2762988	chr13:21370780	T/A	cg27234864	chr13:21295941	IL17D	0.6	5.11	0.38	9.56e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.72	-9.56	-0.61	3.08e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.75e-9	Cognitive function;
PAAD	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.37	0.51	1.01e-11	Hemoglobin concentration;
PAAD	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.77e-7	Carotid intima media thickness;
PAAD	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg23002658	chr20:52824474	PFDN4	-0.57	-6.52	-0.47	9.85e-10	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.41	7.26	0.51	1.88e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3779195	0.858	rs3779196	chr7:97990106	T/C	cg21770322	chr7:97807741	LMTK2	0.53	4.9	0.37	2.41e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.43	4.66	0.35	7.01e-6	Life satisfaction;
PAAD	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.44	0.61	6.17e-17	Cognitive test performance;
PAAD	cis	rs11779988	0.630	rs7821469	chr8:17894388	G/C	cg08627089	chr8:17753878	FGL1	-0.44	-4.36	-0.33	2.42e-5	Breast cancer;
PAAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.85	10.32	0.64	2.99e-19	Methadone dose in opioid dependence;
PAAD	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs73206853	0.841	rs73205085	chr12:110627912	C/G	cg12870014	chr12:110450643	ANKRD13A	0.81	4.47	0.34	1.52e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.05	12.8	0.72	6.58e-26	Schizophrenia;
PAAD	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	4.33	0.33	2.68e-5	Height;
PAAD	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.56	4.6	0.35	8.7e-6	Body mass index;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10578696	chr1:65532742	NA	0.68	8.43	0.56	2.51e-14	Immature fraction of reticulocytes;
PAAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg02966332	chr20:62369605	LIME1	-0.48	-4.52	-0.34	1.24e-5	Prostate cancer;
PAAD	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.56	-5.46	-0.4	1.89e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	7.04	0.5	6.26e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg00576331	chr11:65640516	EFEMP2	-0.62	-5.46	-0.4	1.92e-7	DNA methylation (variation);
PAAD	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.81	0.36	3.65e-6	Cognitive ability;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg03115019	chr17:80708279	FN3K	-0.67	-7.16	-0.5	3.26e-11	Glycated hemoglobin levels;
PAAD	cis	rs9346353	0.737	rs9360400	chr6:70444927	C/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.47	-0.34	1.51e-5	Sleep duration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06157539	chr18:32621265	MAPRE2	0.52	7.07	0.5	5.35e-11	Monocyte percentage of white cells;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.52	5.34	0.4	3.27e-7	Testicular germ cell tumor;
PAAD	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg06393558	chr11:69982916	ANO1	-0.61	-6.04	-0.44	1.14e-8	Survival in rectal cancer;
PAAD	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.71	5.09	0.38	1.06e-6	Type 2 diabetes;
PAAD	cis	rs2120243	0.845	rs2305619	chr3:157154861	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.49	5.42	0.4	2.28e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.44	-0.34	1.73e-5	Breast cancer;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg15764593	chr10:829463	NA	-0.79	-4.3	-0.33	3.09e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2241047	0.526	rs738034	chr22:17594915	A/G	cg06707910	chr22:17640812	CECR5;CECR4	-0.26	-4.36	-0.33	2.4e-5	Blood protein levels;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg23119463	chr10:134592391	INPP5A	-0.47	-4.36	-0.33	2.39e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.46	4.81	0.36	3.54e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg21130718	chr4:1044621	NA	0.55	4.51	0.34	1.3e-5	Recombination rate (females);
PAAD	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.03	11.94	0.7	1.37e-23	Breast cancer;
PAAD	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-5.84	-0.43	3.09e-8	Vitiligo;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg02462569	chr6:150064036	NUP43	-0.51	-5.81	-0.43	3.46e-8	Lung cancer;
PAAD	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg10434728	chr15:90938212	IQGAP1	0.44	4.54	0.35	1.13e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.8	-7.6	-0.52	2.86e-12	DNA methylation (variation);
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.45	6.27	0.45	3.48e-9	Cardiovascular disease risk factors;
PAAD	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.85	7.17	0.5	3.02e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.87	12.46	0.71	5.44e-25	Bone mineral density;
PAAD	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.56	-0.35	1.06e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19346786	chr7:2764209	NA	-0.37	-5.05	-0.38	1.26e-6	Height;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.64	6.29	0.45	3.21e-9	Myopia (pathological);
PAAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.25	4.45	0.34	1.66e-5	IgG glycosylation;
PAAD	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.73	-0.36	5.18e-6	Height;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07648498	chr16:89883185	FANCA	0.68	6.83	0.48	1.87e-10	Vitiligo;
PAAD	cis	rs11871801	0.958	rs8081779	chr17:40571395	G/A	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.71	-0.36	5.57e-6	Crohn's disease;
PAAD	cis	rs9652601	0.845	rs7184615	chr16:11165542	G/C	cg04616529	chr16:11181986	CLEC16A	0.45	5.1	0.38	9.97e-7	Systemic lupus erythematosus;
PAAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.93	8.82	0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.71	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.57	6.78	0.48	2.5e-10	Schizophrenia;
PAAD	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.78	-0.53	1.03e-12	Colorectal cancer;
PAAD	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.6	-4.59	-0.35	9.39e-6	QRS complex (12-leadsum);
PAAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg17775713	chr3:133465469	TF	0.49	5.48	0.41	1.72e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs11811982	0.793	rs79608947	chr1:227508929	G/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.72	7.06	0.5	5.57e-11	Schizophrenia;
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.66	-8.44	-0.56	2.37e-14	Body mass index;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.73	-7.8	-0.53	9.19e-13	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02430102	chr11:57424823	CLP1	0.61	6.97	0.49	9.28e-11	Monocyte percentage of white cells;
PAAD	cis	rs9401295	0.546	rs9320716	chr6:98256949	A/C	cg00987395	chr6:98934664	NA	-0.36	-4.26	-0.33	3.59e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.72	-5.87	-0.43	2.67e-8	Gallbladder cancer;
PAAD	cis	rs6594713	0.921	rs7729269	chr5:112720394	A/G	cg12552261	chr5:112820674	MCC	0.64	5.17	0.39	7.23e-7	Brain cytoarchitecture;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00166722	chr3:10149974	C3orf24	0.84	7.22	0.51	2.35e-11	Alzheimer's disease;
PAAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.79	-10.47	-0.65	1.19e-19	Bone mineral density;
PAAD	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg05309399	chr4:106552544	FLJ20184	-0.57	-4.6	-0.35	8.66e-6	Post bronchodilator FEV1;
PAAD	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-9.62	-0.62	2.15e-17	Morning vs. evening chronotype;
PAAD	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg06569542	chr10:98946673	SLIT1	-0.51	-5.76	-0.42	4.61e-8	Monocyte count;
PAAD	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.74	6.99	0.49	8.14e-11	Obesity-related traits;
PAAD	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.53	-4.65	-0.35	7.24e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.31	4.4	0.34	2.06e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1912528	0.783	rs10000502	chr4:140864757	G/T	cg11128457	chr4:140864437	MAML3	-0.32	-4.28	-0.33	3.28e-5	Educational attainment (years of education);
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg26060667	chr1:247681242	NA	0.46	5.53	0.41	1.34e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.58	6.7	0.48	3.83e-10	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg14019146	chr3:50243930	SLC38A3	0.49	5.23	0.39	5.43e-7	Menarche (age at onset);
PAAD	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.51	5.16	0.39	7.65e-7	Ovarian reserve;
PAAD	cis	rs11051970	0.879	rs2651379	chr12:32581778	A/G	cg24626660	chr12:32551988	NA	0.38	4.3	0.33	3.06e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.47	4.88	0.37	2.6e-6	Longevity;
PAAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.85e-10	Glomerular filtration rate;
PAAD	trans	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg07817883	chr1:32538562	TMEM39B	1.65	7.51	0.52	4.65e-12	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.56	-7.64	-0.53	2.24e-12	Renal cell carcinoma;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.8	-7.81	-0.54	8.56e-13	Schizophrenia;
PAAD	cis	rs72960926	0.744	rs4282374	chr6:74899318	T/C	cg03266952	chr6:74778945	NA	-1.18	-6.6	-0.47	6.43e-10	Metabolite levels (MHPG);
PAAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg10556349	chr10:835070	NA	0.59	4.99	0.38	1.61e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.58	5.85	0.43	2.87e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14138549	chr9:117932648	DEC1	-0.65	-6.98	-0.49	8.49e-11	Obesity-related traits;
PAAD	cis	rs2302729	0.625	rs13328976	chr12:2831151	C/T	cg19945202	chr12:2788847	CACNA1C	0.57	4.56	0.35	1.04e-5	Sleep quality;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.65	-6.41	-0.46	1.75e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.5	-4.43	-0.34	1.81e-5	Triglyceride levels;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.52	4.97	0.37	1.82e-6	Lung cancer;
PAAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs2274459	0.749	rs2281831	chr6:33695815	G/A	cg06253072	chr6:33679850	C6orf125	0.6	4.56	0.35	1.07e-5	Obesity (extreme);
PAAD	cis	rs3736485	0.932	rs28795073	chr15:51927562	C/T	cg19558802	chr15:51695713	GLDN	-0.43	-4.28	-0.33	3.35e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.14	-0.45	7.03e-9	Electroencephalogram traits;
PAAD	cis	rs8060686	0.920	rs60769312	chr16:67732186	C/T	cg09835421	chr16:68378352	PRMT7	-0.93	-5.32	-0.4	3.69e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.75	7.29	0.51	1.61e-11	Neuroticism;
PAAD	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.66	8.26	0.56	6.61e-14	Lipoprotein (a) levels;
PAAD	cis	rs2834188	0.538	rs2026253	chr21:34687966	A/T	cg04842828	chr21:34696676	IFNAR1	0.48	5.09	0.38	1.04e-6	Narcolepsy;
PAAD	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.55	5.92	0.43	2.09e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.86	-6.57	-0.47	7.52e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12681963	0.614	rs7001629	chr8:30060789	C/A	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.9	0.37	2.39e-6	Electroencephalogram traits;
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg20965017	chr5:231967	SDHA	0.59	4.25	0.33	3.67e-5	Breast cancer;
PAAD	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	7.0	0.49	7.87e-11	Cognitive ability;
PAAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.85	6.71	0.48	3.67e-10	Lung disease severity in cystic fibrosis;
PAAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.63	-6.86	-0.49	1.6e-10	Coronary artery disease;
PAAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg07517944	chr15:51633816	GLDN	0.43	4.43	0.34	1.79e-5	Hormone measurements;
PAAD	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08564027	chr20:61660810	NA	-0.82	-7.59	-0.52	2.98e-12	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	5.26	0.39	4.82e-7	Mood instability;
PAAD	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.7	0.42	6.1e-8	Lung cancer;
PAAD	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg23254163	chr1:152506842	NA	0.5	4.94	0.37	2.08e-6	Hair morphology;
PAAD	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg00262122	chr8:11665843	FDFT1	0.48	4.57	0.35	9.86e-6	Neuroticism;
PAAD	cis	rs9361491	0.608	rs9352631	chr6:79462197	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	4.26	0.33	3.59e-5	Total cholesterol levels;
PAAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.35	0.4	3.19e-7	Personality dimensions;
PAAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.93	9.83	0.62	5.98e-18	Tonsillectomy;
PAAD	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.45	-4.58	-0.35	9.75e-6	Immature fraction of reticulocytes;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.83	10.17	0.64	7.53e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	5.84	0.43	3.03e-8	Adiposity;
PAAD	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26926768	chr12:34528122	NA	0.38	4.43	0.34	1.77e-5	Morning vs. evening chronotype;
PAAD	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-5.86	-0.43	2.76e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12431939	1.000	rs67113863	chr14:51653103	G/C	cg23942311	chr14:51606299	NA	-0.73	-5.88	-0.43	2.57e-8	Cancer;
PAAD	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	4.99e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs7264396	0.887	rs2236159	chr20:34102189	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	5.77	0.42	4.23e-8	Adiposity;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11099041	chr3:119041385	CDGAP	0.59	6.69	0.48	4.05e-10	Monocyte percentage of white cells;
PAAD	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg09366796	chr5:75012313	C5orf37	-0.47	-4.26	-0.33	3.54e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.6	5.53	0.41	1.33e-7	Schizophrenia;
PAAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22633769	chr20:60982531	CABLES2	0.5	4.88	0.37	2.65e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs59888335	0.928	rs6767410	chr3:80699208	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.68	-0.35	6.26e-6	Schizophrenia;
PAAD	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg21665744	chr7:39171113	POU6F2	0.28	4.38	0.34	2.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2738048	0.545	rs2738045	chr8:6823568	T/C	cg04178011	chr8:6876155	DEFA3;DEFA1B;DEFA1	0.42	4.31	0.33	2.96e-5	IgA nephropathy;
PAAD	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.98	-15.31	-0.78	1.3e-32	Height;
PAAD	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.39	4.59	0.35	9.25e-6	Endometriosis;
PAAD	cis	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.4	-0.4	2.49e-7	Mononucleosis;
PAAD	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.49	-0.34	1.4e-5	Resting heart rate;
PAAD	cis	rs6782025	0.837	rs663363	chr3:120690269	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs36093844	1.000	rs11234452	chr11:85576801	C/T	cg25872744	chr11:85566296	CCDC83	-0.55	-4.44	-0.34	1.72e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09730735	chr3:46594000	LRRC2	0.65	7.43	0.52	7.34e-12	Smoking initiation;
PAAD	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg08601574	chr20:25228251	PYGB	0.57	5.79	0.42	3.99e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg13722127	chr7:150037890	RARRES2	0.52	5.2	0.39	6.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg09324608	chr17:30823087	MYO1D	0.47	4.71	0.36	5.48e-6	Schizophrenia;
PAAD	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.55	-5.83	-0.43	3.15e-8	Testicular germ cell tumor;
PAAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.77	-7.3	-0.51	1.51e-11	DNA methylation (variation);
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg21698718	chr17:80085957	CCDC57	0.44	5.01	0.38	1.47e-6	Life satisfaction;
PAAD	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.63	-5.77	-0.42	4.37e-8	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.43	-0.56	2.48e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.53	-0.34	1.19e-5	Alcohol dependence;
PAAD	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.36	-0.4	2.97e-7	Mean corpuscular volume;
PAAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00292662	chr22:38071168	LGALS1	0.65	6.81	0.48	2.14e-10	Fat distribution (HIV);
PAAD	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13736263	chr10:102778909	PDZD7	0.59	6.51	0.47	1.04e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg16591659	chr17:78472290	NA	0.47	4.45	0.34	1.67e-5	Fractional excretion of uric acid;
PAAD	cis	rs2034088	0.930	rs9907540	chr17:448042	A/G	cg01214346	chr17:406501	NA	-0.48	-4.98	-0.37	1.7e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.64	-6.04	-0.44	1.16e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26633994	chr19:57791739	ZNF460	-0.7	-6.32	-0.46	2.75e-9	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg21427119	chr20:30132790	HM13	-0.56	-5.21	-0.39	5.97e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.76	6.0	0.44	1.42e-8	Coronary artery disease;
PAAD	cis	rs6460942	0.908	rs6978367	chr7:12232347	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.4	0.4	2.48e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs931127	0.554	rs11227261	chr11:65462843	C/G	cg06492744	chr11:65406254	SIPA1	0.31	4.6	0.35	8.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs863345	0.565	rs10908668	chr1:158501933	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs72960926	0.744	rs72950546	chr6:74907293	A/T	cg03266952	chr6:74778945	NA	-1.15	-6.52	-0.47	9.89e-10	Metabolite levels (MHPG);
PAAD	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.62	5.33	0.4	3.41e-7	Lymphocyte counts;
PAAD	cis	rs12153243	0.714	rs17342167	chr5:142895830	A/G	cg13907255	chr5:142895549	NA	-0.49	-4.46	-0.34	1.62e-5	Migraine;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12072333	chr7:134896347	WDR91	-0.76	-6.58	-0.47	7.33e-10	Neuroticism;
PAAD	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.51	-4.61	-0.35	8.47e-6	Lung cancer;
PAAD	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg20893579	chr22:38215064	NA	0.52	4.81	0.36	3.53e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.92	7.6	0.52	2.82e-12	Total cholesterol levels;
PAAD	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg10589385	chr1:150898437	SETDB1	0.41	5.12	0.38	9.25e-7	Melanoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08703971	chr14:64194118	SGPP1	0.67	7.55	0.52	3.72e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2518049	0.539	rs10795250	chr10:5164836	A/G	cg13585175	chr10:5228106	AKR1CL1	0.45	4.83	0.36	3.27e-6	Metabolic traits;
PAAD	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.5	-4.95	-0.37	1.98e-6	Multiple sclerosis;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg17650747	chr5:1873721	NA	0.46	4.7	0.36	5.78e-6	Cardiovascular disease risk factors;
PAAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg22349387	chr12:9600060	DDX12	-0.4	-4.32	-0.33	2.77e-5	Breast size;
PAAD	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.79	7.71	0.53	1.56e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg15571903	chr15:79123663	NA	-0.47	-6.11	-0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs941024	0.651	rs55847809	chr12:56048922	C/T	cg20737382	chr12:56040096	NA	-0.73	-4.65	-0.35	7.25e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs3806308	1.000	rs3806308	chr1:20142866	C/T	cg13843611	chr1:20143089	RNF186	0.52	5.31	0.4	3.88e-7	Ulcerative colitis;
PAAD	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	7.78	0.53	1.02e-12	Cognitive test performance;
PAAD	cis	rs3925075	0.524	rs889549	chr16:31266951	C/T	cg02846316	chr16:31340340	ITGAM	0.42	4.84	0.37	3.1e-6	IgA nephropathy;
PAAD	cis	rs11168618	0.626	rs2731091	chr12:48880381	A/G	cg05152354	chr12:48152931	RAPGEF3	0.54	4.78	0.36	4.04e-6	Adiponectin levels;
PAAD	cis	rs8040855	0.825	rs4843021	chr15:85694548	A/G	cg08123816	chr15:85640762	PDE8A	0.4	4.62	0.35	7.98e-6	Bulimia nervosa;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.35	-0.33	2.45e-5	IgG glycosylation;
PAAD	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.61	6.17	0.45	5.87e-9	Schizophrenia;
PAAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.27	0.56	6.12e-14	Schizophrenia;
PAAD	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg27411982	chr8:10470053	RP1L1	0.51	5.65	0.42	7.71e-8	Neuroticism;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	1.71	9.48	0.61	4.78e-17	Height;
PAAD	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg16434002	chr17:42200994	HDAC5	0.65	6.02	0.44	1.23e-8	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	6.03	0.44	1.21e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs7714584	1.000	rs61270113	chr5:150226263	G/A	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.48	4.48	0.34	1.47e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.52	-5.13	-0.38	8.81e-7	Iron status biomarkers;
PAAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg03538708	chr1:25844672	NA	0.53	5.42	0.4	2.32e-7	Erythrocyte sedimentation rate;
PAAD	trans	rs901683	1.000	rs12763205	chr10:45986495	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.58	5.61	0.41	9.18e-8	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.34	0.46	2.47e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.42	-4.25	-0.33	3.67e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.21	15.64	0.79	1.84e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs6473252	0.584	rs12542283	chr8:81820942	A/G	cg08595989	chr8:81827712	NA	-0.34	-4.75	-0.36	4.73e-6	Breast cancer;
PAAD	cis	rs10090774	0.965	rs12680723	chr8:141994803	A/G	cg02508881	chr8:142216119	NA	-0.42	-4.43	-0.34	1.81e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.5	0.34	1.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	5.5	0.41	1.56e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.58	6.13	0.45	7.2e-9	Schizophrenia;
PAAD	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.44	-0.4	2.09e-7	Response to antipsychotic treatment;
PAAD	cis	rs9463078	0.625	rs1329710	chr6:44969125	T/C	cg25276700	chr6:44698697	NA	-0.55	-6.3	-0.46	3.04e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	6.53	0.47	9.47e-10	Mood instability;
PAAD	cis	rs7627468	0.770	rs9875101	chr3:121968090	A/G	cg03198317	chr3:121949109	CASR	0.48	4.42	0.34	1.88e-5	Kidney stones;
PAAD	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.77e-11	Asthma;
PAAD	cis	rs35164067	0.708	rs1051738	chr19:10577843	G/T	cg24189696	chr19:10585866	NA	0.42	4.44	0.34	1.75e-5	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.44	0.46	1.49e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1885364	0.626	rs9613514	chr22:28093392	A/C	cg17187762	chr22:28070120	NA	-0.35	-4.29	-0.33	3.14e-5	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
PAAD	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.08	5.82	0.43	3.43e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.62	-6.11	-0.44	7.94e-9	Red cell distribution width;
PAAD	cis	rs11718455	0.591	rs6765212	chr3:43931484	C/T	cg00181669	chr3:44000978	NA	-0.55	-5.83	-0.43	3.17e-8	Coronary artery disease;
PAAD	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.66	-7.56	-0.52	3.56e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.41	-0.46	1.78e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg12437481	chr16:420112	MRPL28	-0.85	-8.66	-0.57	6.32e-15	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6715793	0.839	rs7584473	chr2:33421017	T/G	cg26672287	chr2:33391915	LTBP1	-0.4	-4.48	-0.34	1.48e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg10018233	chr7:150070692	REPIN1	0.64	6.55	0.47	8.32e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs16975963	0.793	rs12460735	chr19:38313550	C/T	cg08679971	chr19:38281047	NA	0.54	5.09	0.38	1.04e-6	Longevity;
PAAD	cis	rs7932354	0.528	rs10838654	chr11:47095511	G/C	cg19486271	chr11:47235900	DDB2	-0.56	-5.57	-0.41	1.14e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs863345	0.604	rs11265021	chr1:158511810	A/T	cg12129480	chr1:158549410	OR10X1	0.43	5.02	0.38	1.43e-6	Pneumococcal bacteremia;
PAAD	cis	rs11892454	0.544	rs10490569	chr2:26001427	T/C	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.49	-0.68	2.25e-22	Coronary artery disease;
PAAD	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg16205897	chr5:131564050	P4HA2	0.41	4.43	0.34	1.8e-5	Blood metabolite levels;
PAAD	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg19254793	chr6:44695348	NA	-0.47	-4.5	-0.34	1.32e-5	Total body bone mineral density;
PAAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.62	-0.35	8.15e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.44	-0.34	1.71e-5	Height;
PAAD	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	1.07	9.54	0.61	3.32e-17	IgG glycosylation;
PAAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22117172	chr7:91764530	CYP51A1	0.33	4.4	0.34	2.03e-5	Breast cancer;
PAAD	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.59	-0.47	6.88e-10	HDL cholesterol;
PAAD	cis	rs498136	0.966	rs2046494	chr11:69378833	C/T	cg24388239	chr11:68438018	NA	0.42	4.41	0.34	1.96e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg14458575	chr2:238380390	NA	-0.55	-4.71	-0.36	5.5e-6	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg11764359	chr7:65958608	NA	0.77	5.23	0.39	5.56e-7	Diabetic kidney disease;
PAAD	cis	rs992157	0.932	rs10194082	chr2:219188577	C/T	cg00012203	chr2:219082015	ARPC2	0.59	5.91	0.43	2.14e-8	Colorectal cancer;
PAAD	cis	rs13242816	1.000	rs34424131	chr7:116119002	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg14008862	chr17:28927542	LRRC37B2	0.79	5.31	0.4	3.84e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.87	-0.58	1.82e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27094323	chr7:1216898	NA	-0.51	-5.99	-0.44	1.46e-8	Longevity;Endometriosis;
PAAD	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-11.84	-0.69	2.48e-23	Schizophrenia;
PAAD	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.63	-6.04	-0.44	1.16e-8	Colorectal cancer;
PAAD	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.55	-5.69	-0.42	6.3e-8	Alcohol dependence;
PAAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg14393609	chr7:65229607	NA	0.46	4.56	0.35	1.03e-5	Aortic root size;
PAAD	cis	rs9581857	0.547	rs17753763	chr13:28077734	A/G	cg22138327	chr13:27999177	GTF3A	0.85	5.33	0.4	3.51e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.76	-8.33	-0.56	4.49e-14	Mean platelet volume;
PAAD	cis	rs11020478	0.681	rs1944108	chr11:93464175	A/C	cg10523193	chr11:93463762	SNORA25	0.41	4.25	0.33	3.78e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg10253484	chr15:75165896	SCAMP2	0.6	5.46	0.41	1.88e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg09835421	chr16:68378352	PRMT7	-0.79	-6.54	-0.47	8.61e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg10183150	chr4:120222239	C4orf3	-0.38	-5.33	-0.4	3.55e-7	Corneal astigmatism;
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.54	0.35	1.13e-5	Tonsillectomy;
PAAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg11949866	chr1:10754891	CASZ1	0.53	4.27	0.33	3.39e-5	Ewing sarcoma;
PAAD	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.34	4.78	0.36	4.03e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.85	7.0	0.49	7.61e-11	Pulmonary function decline;
PAAD	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.45	-5.71	-0.42	5.8e-8	Panic disorder;
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.49e-9	Lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18827097	chr2:3522506	ADI1	0.57	6.55	0.47	8.39e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.71	7.39	0.51	9.33e-12	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.62	-7.01	-0.49	7.42e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.83	-6.63	-0.47	5.63e-10	Pulmonary function decline;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02571204	chr10:114591733	NA	0.57	6.78	0.48	2.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7264396	0.943	rs224395	chr20:34109427	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.78	-0.42	4.18e-8	Total cholesterol levels;
PAAD	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg05579598	chr16:88989069	CBFA2T3	0.59	9.39	0.61	8.61e-17	Social autistic-like traits;
PAAD	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.75	5.25	0.39	5.01e-7	Carotid intima media thickness;
PAAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg12193833	chr17:30244370	NA	-0.66	-4.75	-0.36	4.59e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.45	-4.43	-0.34	1.77e-5	Pursuit maintenance gain;
PAAD	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-6.87	-0.49	1.51e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	4.98	0.37	1.69e-6	Cognitive test performance;
PAAD	cis	rs13011075	0.535	rs7598360	chr2:68630925	A/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-8.04	-0.55	2.37e-13	Body mass index;
PAAD	cis	rs6578985	1.000	rs2585	chr11:2150444	T/C	cg12383159	chr11:1262597	MUC5B	-0.45	-4.33	-0.33	2.7e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.74	9.96	0.63	2.59e-18	Lipoprotein (a) levels;
PAAD	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.02	-0.38	1.43e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.84	-0.43	3.1e-8	Mood instability;
PAAD	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.8	-6.05	-0.44	1.09e-8	Coronary artery disease;
PAAD	cis	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg21775007	chr8:11205619	TDH	0.79	7.7	0.53	1.64e-12	Retinal vascular caliber;
PAAD	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.57	-0.41	1.11e-7	Neuroticism;
PAAD	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg01718231	chr17:29326311	RNF135	-0.67	-6.49	-0.47	1.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg19254793	chr6:44695348	NA	-0.47	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14269918	chr9:88005849	NA	-0.65	-6.67	-0.48	4.41e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs8067287	0.595	rs62065423	chr17:16828571	C/T	cg26910001	chr17:16838321	NA	-0.67	-6.08	-0.44	9.52e-9	Diabetic kidney disease;
PAAD	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18507615	chr3:47324013	KIF9;KLHL18	0.56	6.29	0.45	3.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg08999081	chr20:33150536	PIGU	0.6	6.6	0.47	6.31e-10	Height;
PAAD	cis	rs2562456	0.833	rs1781867	chr19:21487170	T/C	cg21994712	chr19:21861136	NA	-0.44	-4.26	-0.33	3.53e-5	Pain;
PAAD	cis	rs1842579	0.658	rs11161676	chr1:86269261	A/T	cg14090374	chr1:85667233	SYDE2	-0.49	-4.25	-0.33	3.65e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.66	6.45	0.46	1.41e-9	Schizophrenia;
PAAD	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13476313	chr9:127244764	NR5A1	-0.31	-5.03	-0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.97	-10.27	-0.64	3.99e-19	Corneal astigmatism;
PAAD	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.84	9.58	0.61	2.7e-17	Menarche (age at onset);
PAAD	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.72	-0.36	5.4e-6	Obesity-related traits;
PAAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.63	6.18	0.45	5.66e-9	Pancreatic cancer;
PAAD	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs12431939	1.000	rs7148508	chr14:51635137	G/A	cg23942311	chr14:51606299	NA	-0.72	-5.71	-0.42	5.85e-8	Cancer;
PAAD	cis	rs7766436	0.583	rs72831211	chr6:22560161	C/T	cg13666174	chr6:22585274	NA	-0.51	-4.28	-0.33	3.33e-5	Coronary artery disease;
PAAD	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg05528293	chr18:74961138	GALR1	0.61	4.93	0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.85	0.62	5.28e-18	Total body bone mineral density;
PAAD	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.63	-5.85	-0.43	2.92e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg20790798	chr5:1857306	NA	-0.49	-5.4	-0.4	2.5e-7	Cardiovascular disease risk factors;
PAAD	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg16898833	chr6:26189333	HIST1H4D	0.73	4.37	0.33	2.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.66	7.13	0.5	3.74e-11	Crohn's disease;
PAAD	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.88	-10.18	-0.64	6.86e-19	Blood protein levels;
PAAD	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg01267373	chr18:77410094	NA	0.42	4.34	0.33	2.54e-5	Monocyte count;
PAAD	cis	rs7771547	0.574	rs9394361	chr6:36551370	A/C	cg07856975	chr6:36356162	ETV7	0.56	5.75	0.42	4.76e-8	Platelet distribution width;
PAAD	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.39	-4.67	-0.35	6.58e-6	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.94	5.91	0.43	2.17e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg15331088	chr8:600555	NA	-0.76	-4.64	-0.35	7.49e-6	IgG glycosylation;
PAAD	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	6.73	0.48	3.25e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs4908768	0.657	rs12144099	chr1:8816175	G/A	cg25722041	chr1:8623473	RERE	0.51	4.38	0.33	2.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs747650	0.532	rs7128650	chr11:47047059	A/G	cg19486271	chr11:47235900	DDB2	-0.68	-6.29	-0.45	3.26e-9	Acne (severe);
PAAD	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg02135003	chr7:105160482	PUS7	-0.72	-5.92	-0.43	2.04e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.67	6.94	0.49	1.07e-10	Mood instability;
PAAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.38	-5.07	-0.38	1.14e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg23346134	chr3:49453900	TCTA	-0.47	-5.02	-0.38	1.45e-6	Menarche (age at onset);
PAAD	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.63	6.94	0.49	1.06e-10	Testicular germ cell tumor;
PAAD	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-8.34	-0.56	4.26e-14	Neuroticism;
PAAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-4.47	-0.34	1.54e-5	Blood metabolite levels;
PAAD	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.8	10.13	0.63	9.34e-19	Morning vs. evening chronotype;
PAAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.99	11.89	0.69	1.87e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.3e-16	Diabetic kidney disease;
PAAD	cis	rs13242816	1.000	rs6979182	chr7:116119345	T/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs35160687	0.798	rs2367233	chr2:86541666	A/C	cg10973622	chr2:86423274	IMMT	-0.44	-4.76	-0.36	4.5e-6	Night sleep phenotypes;
PAAD	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg00184732	chr15:51633821	GLDN	0.39	4.25	0.33	3.75e-5	Hormone measurements;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg20007245	chr22:24372913	LOC391322	-0.69	-6.9	-0.49	1.32e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs114540395	0.858	rs17767748	chr10:103285900	A/G	cg21381511	chr10:104264849	SUFU	0.86	4.32	0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs116248771	0.739	rs16829290	chr3:158392278	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs939584	0.935	rs2867123	chr2:624524	C/G	cg03610516	chr2:642275	NA	0.63	5.58	0.41	1.08e-7	Body mass index;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.53	-6.07	-0.44	9.98e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg23281280	chr6:28129359	ZNF389	0.5	4.44	0.34	1.69e-5	Parkinson's disease;
PAAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg01800442	chr17:74086473	EXOC7	0.54	4.37	0.33	2.33e-5	Psoriasis;
PAAD	cis	rs7168592	1.000	rs2012387	chr15:101734080	C/T	cg24254196	chr15:101719523	CHSY1	-0.65	-4.64	-0.35	7.4e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	5.0	0.38	1.53e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg15790184	chr11:494944	RNH1	0.8	4.3	0.33	3.04e-5	Body mass index;
PAAD	trans	rs901683	1.000	rs35824277	chr10:46030477	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg12633918	chr20:23549525	CST9L	0.45	4.99	0.38	1.63e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.71	-6.01	-0.44	1.34e-8	Blood protein levels;
PAAD	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.77	7.56	0.52	3.6e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg17796960	chr10:135278976	LOC619207	-0.4	-4.52	-0.34	1.24e-5	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.78	-7.46	-0.52	6.04e-12	Platelet distribution width;
PAAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.59	8.2	0.55	9.12e-14	Primary biliary cholangitis;
PAAD	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.56	-0.35	1.05e-5	Morning vs. evening chronotype;
PAAD	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg05338066	chr1:7812865	CAMTA1	0.55	4.56	0.35	1.05e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg05627522	chr15:75251581	NA	-0.41	-4.97	-0.37	1.76e-6	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.95	10.2	0.64	6.18e-19	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.96	12.26	0.71	1.86e-24	Menopause (age at onset);
PAAD	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-6.3	-0.45	3.1e-9	Morning vs. evening chronotype;
PAAD	cis	rs2882667	0.654	rs7710300	chr5:138170482	T/C	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.83	-5.24	-0.39	5.32e-7	Lung cancer in ever smokers;
PAAD	cis	rs1912528	0.783	rs769662	chr4:140868894	G/A	cg11128457	chr4:140864437	MAML3	-0.34	-4.52	-0.34	1.26e-5	Educational attainment (years of education);
PAAD	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-5.5	-0.41	1.61e-7	Thyroid stimulating hormone;
PAAD	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.31	0.33	2.9e-5	Renal cell carcinoma;
PAAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.64	0.57	7.06e-15	Personality dimensions;
PAAD	cis	rs73058052	0.597	rs7251877	chr19:50097547	A/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.6	-5.12	-0.38	9e-7	Fibrinogen levels;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg16850897	chr7:100343110	ZAN	-0.81	-7.02	-0.49	6.93e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg10556349	chr10:835070	NA	0.57	4.95	0.37	1.98e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.65	-8.37	-0.56	3.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9409082	0.798	rs7020068	chr9:108925071	A/G	cg07010948	chr13:79181613	NA	-0.34	-6.38	-0.46	2.07e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.76	-5.02	-0.38	1.46e-6	Platelet distribution width;
PAAD	cis	rs1298908	0.897	rs2573326	chr10:82013146	T/C	cg01528321	chr10:82214614	TSPAN14	0.52	4.65	0.35	7.21e-6	Diabetic kidney disease;
PAAD	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg14906510	chr12:7781169	NA	-0.61	-4.38	-0.34	2.17e-5	HDL cholesterol levels;
PAAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14895029	chr7:2775587	GNA12	-0.44	-4.26	-0.33	3.64e-5	Height;
PAAD	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.56	6.05	0.44	1.07e-8	Mean corpuscular volume;
PAAD	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg00750074	chr16:89608354	SPG7	0.57	5.69	0.42	6.27e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg09307838	chr4:120376055	NA	0.78	8.67	0.58	5.94e-15	Corneal astigmatism;
PAAD	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.87	10.66	0.65	3.7799999999999997e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-1.09	-8.96	-0.59	1.1e-15	Blood trace element (Zn levels);
PAAD	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7713065	0.797	rs3846730	chr5:131806780	C/T	cg14196790	chr5:131705035	SLC22A5	-0.52	-4.82	-0.36	3.47e-6	Lung function (FEV1/FVC);
PAAD	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg12568669	chr8:11666485	FDFT1	-0.31	-5.24	-0.39	5.37e-7	Monocyte count;
PAAD	trans	rs320203	0.741	rs2995192	chr9:104780164	G/T	cg27499259	chr13:28400924	NA	0.97	6.35	0.46	2.4e-9	Mucinous ovarian carcinoma;
PAAD	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.49	-4.54	-0.35	1.12e-5	Tonsillectomy;
PAAD	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.51	5.62	0.41	8.8e-8	Height;
PAAD	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.73	6.35	0.46	2.32e-9	Inflammatory skin disease;
PAAD	cis	rs3784262	0.740	rs12917536	chr15:58288247	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-5.74	-0.42	4.94e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.5	4.6	0.35	8.85e-6	Renal cell carcinoma;
PAAD	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	1.06	18.95	0.84	7.31e-42	Urate levels in lean individuals;
PAAD	cis	rs2904967	0.636	rs239256	chr11:64987391	C/T	cg21890820	chr11:65308645	LTBP3	-0.54	-5.29	-0.39	4.24e-7	Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs12533831	0.627	rs2257073	chr7:150883287	A/G	cg25403974	chr7:150105495	LOC728743	-0.47	-4.37	-0.33	2.33e-5	Childhood ear infection;
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.93	15.97	0.79	2.49e-34	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20669266	chr11:68080670	LRP5	0.61	6.29	0.45	3.17e-9	Myopia (pathological);
PAAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01200585	chr1:228362443	C1orf69	-0.5	-5.66	-0.42	7.28e-8	Diastolic blood pressure;
PAAD	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.47	4.32	0.33	2.84e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35123781	0.518	rs13160670	chr5:138969179	G/A	cg26929925	chr5:138714136	SLC23A1	-0.54	-4.82	-0.36	3.39e-6	Schizophrenia;
PAAD	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.7	-6.03	-0.44	1.18e-8	Schizophrenia;
PAAD	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg10167463	chr7:75959203	YWHAG	-0.5	-4.9	-0.37	2.43e-6	Multiple sclerosis;
PAAD	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs12257961	0.675	rs4748157	chr10:15346564	A/G	cg10616319	chr10:15468812	NA	0.44	4.34	0.33	2.57e-5	Selective IgA deficiency;
PAAD	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg23649088	chr2:200775458	C2orf69	-0.64	-4.9	-0.37	2.42e-6	Schizophrenia;
PAAD	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg06917634	chr15:78832804	PSMA4	-0.45	-4.43	-0.34	1.82e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.28	10.39	0.64	1.9e-19	Uric acid levels;
PAAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg12923728	chr3:195709715	SDHAP1	-0.57	-5.49	-0.41	1.62e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs12127679	0.614	rs12124292	chr1:244172130	G/T	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs990171	0.954	rs6543137	chr2:103065908	T/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.33	0.33	2.72e-5	Lymphocyte counts;
PAAD	cis	rs4478858	0.735	rs12129941	chr1:31871958	C/G	cg18939081	chr1:31884902	SERINC2	0.47	5.26	0.39	4.76e-7	Alcohol dependence;
PAAD	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9463078	0.585	rs7754378	chr6:44863106	A/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-4.42	-0.34	1.9e-5	Multiple sclerosis;
PAAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.37	-5.78	-0.42	4.15e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.67	-7.92	-0.54	4.64e-13	Huntington's disease progression;
PAAD	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-4.28	-0.33	3.35e-5	Red blood cell count;
PAAD	cis	rs11159086	0.941	rs12434836	chr14:74935590	C/T	cg10195687	chr14:74926396	NA	-0.45	-4.86	-0.37	2.85e-6	Advanced glycation end-product levels;
PAAD	cis	rs300774	0.920	rs378161	chr2:192983	A/T	cg21211680	chr2:198530	NA	0.7	6.34	0.46	2.49e-9	Suicide attempts in bipolar disorder;
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.74	-0.48	3.13e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs12780845	0.931	rs7085460	chr10:17248667	G/C	cg00857480	chr10:17188594	TRDMT1	0.35	4.39	0.34	2.1e-5	Homocysteine levels;
PAAD	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.52	0.57	1.43e-14	Bipolar disorder;
PAAD	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.65	4.61	0.35	8.32e-6	Parkinson's disease;
PAAD	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.55	-6.5	-0.47	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.53	-0.57	1.37e-14	Coffee consumption (cups per day);
PAAD	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.53	5.75	0.42	4.85e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.5	-4.49	-0.34	1.39e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg07202610	chr7:1142643	C7orf50	-0.68	-5.69	-0.42	6.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.44	-0.34	1.71e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-5.02	-0.38	1.42e-6	Asthma;
PAAD	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-5.02	-0.38	1.43e-6	Reticulocyte count;
PAAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.38	-7.59	-0.52	3.05e-12	Mean corpuscular volume;
PAAD	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg08632701	chr21:37451849	NA	-0.53	-4.93	-0.37	2.11e-6	Mitral valve prolapse;
PAAD	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.52	6.97	0.49	8.82e-11	Life satisfaction;
PAAD	cis	rs8105895	0.935	rs7252220	chr19:22245564	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-1.06	-14.93	-0.77	1.35e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19945202	chr12:2788847	CACNA1C	-0.45	-4.72	-0.36	5.42e-6	Quantitative traits;
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg14092988	chr3:52407081	DNAH1	0.38	4.85	0.37	3.01e-6	Electroencephalogram traits;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26418147	chr1:205743515	RAB7L1	-0.5	-6.09	-0.44	8.92e-9	Menarche (age at onset);
PAAD	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.48	-4.66	-0.35	6.89e-6	Urinary tract infection frequency;
PAAD	cis	rs10804591	1.000	rs6785282	chr3:129339500	C/G	cg18548199	chr3:129281892	PLXND1	0.54	4.6	0.35	8.67e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13798912	chr7:905769	UNC84A	0.6	4.34	0.33	2.58e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.6	-7.75	-0.53	1.25e-12	Schizophrenia;
PAAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-5.15	-0.39	7.99e-7	P wave terminal force;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26935649	chr19:19369669	HAPLN4	-0.72	-7.79	-0.53	9.76e-13	Obesity-related traits;
PAAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.61	-7.56	-0.52	3.52e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs11657217	0.502	rs4442854	chr17:77698224	C/T	cg06901238	chr17:77706717	ENPP7	0.67	7.2	0.5	2.62e-11	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.65	6.19	0.45	5.22e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs965469	0.779	rs6037534	chr20:3269832	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-8.88	-0.58	1.8e-15	Total body bone mineral density;
PAAD	cis	rs11618212	0.955	rs1324748	chr13:106090664	T/A	cg05762221	chr13:106912912	NA	-0.52	-4.41	-0.34	1.97e-5	Myopia (pathological);
PAAD	cis	rs35084382	1.000	rs2431663	chr5:172196711	A/C	cg09799633	chr5:172199460	DUSP1	-1.01	-5.35	-0.4	3.19e-7	Optic cup area;
PAAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06394585	chr2:148777915	ORC4L	0.68	8.03	0.55	2.48e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.06e-5	Tuberculosis;
PAAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg19630374	chr17:18023558	MYO15A	0.45	4.83	0.36	3.29e-6	Total body bone mineral density;
PAAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.37	0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs7534824	0.582	rs41312670	chr1:101443431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs13361707	0.666	rs59585832	chr5:40744038	C/T	cg04002187	chr5:40835754	RPL37	-0.48	-4.33	-0.33	2.67e-5	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-4.59	-0.35	9.08e-6	Blood protein levels;
PAAD	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.67	7.47	0.52	5.78e-12	Menopause (age at onset);
PAAD	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23158103	chr7:148848205	ZNF398	-0.61	-5.65	-0.42	7.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg19906760	chr14:78227687	SNW1;C14orf178	0.58	6.57	0.47	7.41e-10	Metabolite levels  (X-11787);
PAAD	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg27565382	chr3:53032988	SFMBT1	0.72	4.3	0.33	3.06e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-4.98	-0.37	1.72e-6	Menarche (age at onset);
PAAD	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	8.01	0.54	2.86e-13	Schizophrenia;
PAAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.96	0.66	5.7e-21	Smoking behavior;
PAAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.98	8.99	0.59	9.01e-16	Gut microbiome composition (summer);
PAAD	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg02404636	chr22:31891804	SFI1	-0.61	-5.49	-0.41	1.68e-7	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	11.44	0.68	3e-22	Platelet count;
PAAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg05697835	chr1:2722811	NA	0.39	4.41	0.34	1.95e-5	Ulcerative colitis;
PAAD	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg01855803	chr7:66767839	STAG3L4;PMS2L4	0.62	6.53	0.47	9.31e-10	Triglycerides;
PAAD	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg07371521	chr5:154026371	NA	-0.51	-6.62	-0.47	5.87e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2997447	0.894	rs41311276	chr1:26387625	A/C	cg24519413	chr1:26490540	NA	0.56	5.02	0.38	1.45e-6	QRS complex (12-leadsum);
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs4764124	0.556	rs247347	chr12:14914785	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.49	5.41	0.4	2.38e-7	Pubertal anthropometrics;
PAAD	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	0.66	7.28	0.51	1.68e-11	Diastolic blood pressure;
PAAD	cis	rs7577696	0.850	rs428002	chr2:32487774	G/A	cg02381751	chr2:32503542	YIPF4	0.43	4.66	0.35	6.96e-6	Inflammatory biomarkers;
PAAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.44	4.32	0.33	2.81e-5	Renal cell carcinoma;
PAAD	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.26	-0.33	3.51e-5	Breast cancer;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg26690034	chr1:75198963	CRYZ;TYW3	0.51	4.68	0.36	6.25e-6	Resistin levels;
PAAD	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.45	-5.52	-0.41	1.4e-7	Lewy body disease;
PAAD	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.28	-0.33	3.31e-5	Bipolar disorder;
PAAD	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.7	7.63	0.53	2.43e-12	Colorectal cancer;
PAAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.52	-5.89	-0.43	2.45e-8	Tonsillectomy;
PAAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.46	-4.66	-0.35	6.99e-6	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18802048	chr17:55948689	CUEDC1	-0.76	-7.76	-0.53	1.14e-12	Obesity-related traits;
PAAD	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs4713675	0.510	rs943470	chr6:33654591	G/C	cg14003231	chr6:33640908	ITPR3	0.37	4.99	0.38	1.62e-6	Plateletcrit;
PAAD	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.45e-9	Schizophrenia;
PAAD	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.87	-0.43	2.59e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs2249625	0.739	rs9293862	chr6:72809986	C/T	cg04413069	chr12:9800446	LOC374443	-0.59	-6.51	-0.47	1.02e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.26	0.45	3.72e-9	Hip circumference;
PAAD	cis	rs2279817	0.818	rs34421778	chr1:17984859	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-5.99	-0.44	1.45e-8	Neuroticism;
PAAD	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08858875	chr6:86388188	SNHG5;SNORD50B;SNORD50A	0.61	6.97	0.49	8.97e-11	Myopia (pathological);
PAAD	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.08	-19.18	-0.84	1.99e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg24747557	chr10:131355152	MGMT	-0.43	-4.29	-0.33	3.12e-5	Response to temozolomide;
PAAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs3753841	0.832	rs10874660	chr1:103324532	A/C	cg24495344	chr1:103574097	COL11A1	-0.4	-4.74	-0.36	4.78e-6	Glaucoma (primary angle closure);
PAAD	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16417436	chr16:28758564	NA	0.46	4.39	0.34	2.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.36	-4.64	-0.35	7.42e-6	Permanent tooth development;
PAAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.76e-7	Alcohol dependence;
PAAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06799790	chr17:61951754	CSH2	-0.45	-4.66	-0.35	6.73e-6	Height;
PAAD	cis	rs3857067	1.000	rs2865330	chr4:95004716	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01145284	chr2:10580628	ODC1	0.45	6.35	0.46	2.33e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.76	-5.28	-0.39	4.34e-7	Red cell distribution width;
PAAD	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg11547950	chr5:77652471	NA	0.93	7.91	0.54	5.01e-13	Triglycerides;
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.77	8.63	0.57	7.72e-15	Longevity;
PAAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	6.81	0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11264799	0.603	rs12733062	chr1:157585932	C/A	cg18268488	chr1:157545234	FCRL4	0.47	5.47	0.41	1.85e-7	IgA nephropathy;
PAAD	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.74	-6.09	-0.44	8.84e-9	Coronary artery disease;
PAAD	cis	rs2594989	1.000	rs2595002	chr3:11373700	G/A	cg01796438	chr3:11312864	ATG7	-0.7	-5.58	-0.41	1.09e-7	Circulating chemerin levels;
PAAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.41	4.91	0.37	2.32e-6	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg27205649	chr11:78285834	NARS2	-0.6	-4.43	-0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs5756391	0.503	rs9607395	chr22:37315742	C/T	cg16356956	chr22:37317934	CSF2RB	0.38	4.7	0.36	5.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.67	7.24	0.51	2.03e-11	Lung cancer;
PAAD	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg17764715	chr19:33622953	WDR88	0.65	6.06	0.44	1.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.58	-4.62	-0.35	8.03e-6	Corneal structure;
PAAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg03538708	chr1:25844672	NA	-0.53	-5.39	-0.4	2.62e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg04415270	chr2:102091202	RFX8	-0.58	-7.38	-0.51	9.61e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg21483461	chr5:81570383	RPS23	-0.52	-4.92	-0.37	2.18e-6	Breast cancer;
PAAD	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg06521852	chr22:38141419	TRIOBP	0.43	4.55	0.35	1.11e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.6	5.03	0.38	1.4e-6	Iron status biomarkers;
PAAD	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.9	10.84	0.66	1.18e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.75	7.27	0.51	1.73e-11	Corneal astigmatism;
PAAD	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.69	-0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs1619661	0.530	rs1627329	chr10:44691633	A/G	cg09554077	chr10:44749378	NA	0.33	4.91	0.37	2.32e-6	QT interval (ambient particulate matter interaction);
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg08888203	chr3:10149979	C3orf24	0.76	6.92	0.49	1.19e-10	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.6	-5.24	-0.39	5.23e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.77	0.42	4.36e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs2790216	1.000	rs1999997	chr10:59996969	A/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.79	-0.36	3.99e-6	Prevalent atrial fibrillation;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg21280719	chr6:42927975	GNMT	-0.41	-6.06	-0.44	1.05e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11563648	0.553	rs1419418	chr7:127048713	G/T	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15829619	chr15:42782927	NA	-0.59	-6.71	-0.48	3.69e-10	Body fat percentage;
PAAD	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.6	-6.92	-0.49	1.17e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg18370025	chr7:2749541	AMZ1	-0.36	-4.27	-0.33	3.38e-5	Height;
PAAD	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg24375607	chr4:120327624	NA	0.55	5.25	0.39	5.15e-7	Corneal astigmatism;
PAAD	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.32	-0.46	2.7e-9	Bipolar disorder;
PAAD	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg22508957	chr16:3507546	NAT15	0.81	6.24	0.45	4.11e-9	Tuberculosis;
PAAD	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg15654264	chr1:150340011	RPRD2	0.51	5.05	0.38	1.26e-6	Migraine;
PAAD	cis	rs72772090	0.539	rs11742261	chr5:96167608	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.53	-0.47	9.09e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs990171	0.955	rs4851008	chr2:103026611	G/C	cg03938978	chr2:103052716	IL18RAP	0.46	4.58	0.35	9.67e-6	Lymphocyte counts;
PAAD	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg04990556	chr1:26633338	UBXN11	-0.5	-4.29	-0.33	3.11e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17669899	chr17:29151515	CRLF3	-0.62	-7.36	-0.51	1.07e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg07148914	chr20:33460835	GGT7	0.47	4.55	0.35	1.11e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12963246	chr6:28129442	ZNF389	0.54	4.32	0.33	2.81e-5	Cardiac Troponin-T levels;
PAAD	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg03318428	chr22:46971703	NA	0.35	4.25	0.33	3.77e-5	Urate levels in obese individuals;
PAAD	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.16	14.87	0.77	1.91e-31	Schizophrenia;
PAAD	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg08632701	chr21:37451849	NA	-0.58	-5.67	-0.42	7.06e-8	Mitral valve prolapse;
PAAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.5	-6.34	-0.46	2.47e-9	Abdominal aortic aneurysm;
PAAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.94	-8.23	-0.56	7.91e-14	Other erythrocyte phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09979956	chr2:190648634	ORMDL1;PMS1	0.66	6.77	0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.77	0.42	4.21e-8	IgG glycosylation;
PAAD	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.68e-5	Total body bone mineral density;
PAAD	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs941873	0.904	rs4980067	chr10:81136129	C/A	cg09469691	chr10:81107165	PPIF	0.63	6.99	0.49	8.03e-11	Height;
PAAD	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg05085585	chr16:30420623	ZNF771	-0.43	-4.4	-0.34	2.01e-5	Tonsillectomy;
PAAD	cis	rs4073221	0.654	rs35642807	chr3:18275420	T/C	cg07694806	chr3:18168406	NA	-0.66	-4.77	-0.36	4.3e-6	Parkinson's disease;
PAAD	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.85	11.03	0.67	3.8e-21	Height;
PAAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.56	7.7	0.53	1.66e-12	Height;
PAAD	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.24	0.51	2.03e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.46	-4.64	-0.35	7.5e-6	Ulcerative colitis;
PAAD	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.89	-0.37	2.57e-6	Cervical cancer;
PAAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.95	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.53	-0.47	9.14e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1395	0.778	rs1439767	chr2:27389634	A/G	cg23587288	chr2:27483067	SLC30A3	-0.86	-7.35	-0.51	1.11e-11	Blood metabolite levels;
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg12483801	chr4:183727862	NA	0.77	5.75	0.42	4.79e-8	Pediatric autoimmune diseases;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg20243544	chr17:37824526	PNMT	0.58	5.01	0.38	1.51e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs1075232	1.000	rs16956707	chr15:31641633	G/A	cg15751117	chr15:30700112	NA	0.87	4.62	0.35	8.05e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg08917208	chr2:24149416	ATAD2B	0.53	4.62	0.35	8.21e-6	Lymphocyte counts;
PAAD	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg01620082	chr3:125678407	NA	-1.0	-7.33	-0.51	1.29e-11	Depression;
PAAD	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.87e-8	Acne (severe);
PAAD	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.58	4.38	0.33	2.23e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg27394845	chr17:28928406	LRRC37B2	0.67	4.59	0.35	9.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23158103	chr7:148848205	ZNF398	0.65	6.56	0.47	7.76e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.04	0.38	1.3e-6	Childhood ear infection;
PAAD	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg19980929	chr12:42632907	YAF2	0.63	7.59	0.52	2.99e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7534824	0.543	rs1074739	chr1:101362371	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg00277334	chr10:82204260	NA	-0.59	-5.36	-0.4	3.07e-7	Post bronchodilator FEV1;
PAAD	cis	rs2882667	0.690	rs825748	chr5:138136067	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg03538708	chr1:25844672	NA	-0.53	-5.39	-0.4	2.6e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs3981351	0.624	rs12415607	chr10:115438204	A/C	cg24846397	chr10:115438155	CASP7	0.51	4.4	0.34	2.03e-5	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08681365	chr8:101170048	SPAG1	0.65	6.48	0.47	1.2e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04174070	chr7:75624163	TMEM120A	0.6	7.26	0.51	1.84e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg08132940	chr7:1081526	C7orf50	0.58	4.41	0.34	1.97e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6908034	0.607	rs73376680	chr6:19808099	G/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.99	-0.38	1.61e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.57	4.28	0.33	3.34e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg26071806	chr7:100318239	EPO	-0.42	-4.25	-0.33	3.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.64	7.36	0.51	1.09e-11	Carotid intima media thickness;
PAAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg11204139	chr17:3907470	NA	0.84	8.59	0.57	9.7e-15	Type 2 diabetes;
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg23119463	chr10:134592391	INPP5A	-0.48	-4.87	-0.37	2.72e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs427941	0.632	rs201500	chr7:101757806	G/C	cg06246474	chr7:101738831	CUX1	0.43	4.28	0.33	3.24e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.37	-0.46	2.14e-9	Hip circumference;
PAAD	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.8	7.64	0.53	2.25e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg18765565	chr5:669397	TPPP	0.44	4.78	0.36	4.18e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9397240	0.789	rs9384303	chr6:155557068	T/C	cg06694381	chr6:155569200	TIAM2	-0.48	-4.33	-0.33	2.66e-5	Life satisfaction;
PAAD	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.56	5.43	0.4	2.22e-7	Parkinson's disease;
PAAD	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.8e-7	Interstitial lung disease;
PAAD	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs488248	0.574	rs61972597	chr13:106591220	G/T	cg03898952	chr13:107069935	NA	0.7	4.48	0.34	1.48e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg04154034	chr17:28927549	LRRC37B2	0.64	4.27	0.33	3.45e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73019876	0.869	rs1859093	chr19:22143339	T/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.44	0.34	1.7e-5	Tonsillectomy;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.7	-6.86	-0.49	1.62e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01283332	chr5:1856932	NA	-0.43	-4.52	-0.34	1.22e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.71	6.82	0.48	2.02e-10	Parkinson's disease;
PAAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13476313	chr9:127244764	NR5A1	0.31	4.9	0.37	2.46e-6	Menarche (age at onset);
PAAD	trans	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.71	6.18	0.45	5.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg18538332	chr22:24372958	LOC391322	-0.62	-5.85	-0.43	2.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.98	10.96	0.66	5.82e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.01	-0.44	1.3e-8	Schizophrenia;
PAAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.61	6.71	0.48	3.57e-10	Schizophrenia;
PAAD	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg06307176	chr5:131281290	NA	-0.58	-5.15	-0.39	7.93e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.65	0.57	6.65e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08439880	chr3:133502540	NA	-0.57	-6.08	-0.44	9.12e-9	Iron status biomarkers;
PAAD	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.66	6.83	0.48	1.87e-10	Uric acid levels;
PAAD	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg25364880	chr3:44379878	C3orf23	0.56	5.48	0.41	1.7e-7	Depressive symptoms;
PAAD	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg20887711	chr4:1340912	KIAA1530	0.55	5.68	0.42	6.71e-8	Longevity;
PAAD	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs1497828	0.956	rs2646839	chr1:217553421	G/A	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.19	0.39	6.69e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10214930	0.697	rs12155430	chr7:27671296	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-5.23	-0.39	5.59e-7	Total body bone mineral density;
PAAD	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg23153227	chr6:27725408	NA	0.5	4.81	0.36	3.61e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	1.05	6.88	0.49	1.5e-10	Fat distribution (HIV);
PAAD	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.66	6.38	0.46	1.99e-9	Schizophrenia;
PAAD	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.61	0.47	6.19e-10	Schizophrenia;
PAAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg24733560	chr20:60626293	TAF4	0.44	5.3	0.4	3.97e-7	Body mass index;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.74	8.69	0.58	5.29e-15	Height;
PAAD	cis	rs939584	0.935	rs12997450	chr2:630113	C/T	cg03610516	chr2:642275	NA	0.63	5.45	0.4	2.03e-7	Body mass index;
PAAD	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.6	6.02	0.44	1.23e-8	Triglyceride levels;
PAAD	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	5.32	0.4	3.61e-7	Colorectal cancer;
PAAD	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.65	9.71	0.62	1.24e-17	Endometriosis;
PAAD	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.61	5.48	0.41	1.74e-7	Type 2 diabetes;
PAAD	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.8	0.43	3.65e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs950037	0.638	rs12740480	chr1:89352612	T/A	cg13109106	chr1:89333529	GTF2B	0.51	4.92	0.37	2.27e-6	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs2221894	1.000	rs6985217	chr8:28813155	C/T	cg20212339	chr8:28908912	HMBOX1	0.53	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17831467	chr10:99400413	PI4K2A	-0.79	-7.01	-0.49	7.3e-11	Neuroticism;
PAAD	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.76	5.71	0.42	5.81e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs12997796	0.503	rs10173742	chr2:87010603	C/G	cg25203885	chr2:87302643	LOC285074	-0.79	-5.53	-0.41	1.36e-7	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.29	-0.33	3.12e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs922692	0.715	rs11632102	chr15:79086057	G/A	cg24739098	chr15:79297159	RASGRF1	0.36	4.61	0.35	8.57e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9788721	0.504	rs6495314	chr15:78960529	A/C	cg00540400	chr15:79124168	NA	-0.42	-4.81	-0.36	3.66e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.91	11.96	0.7	1.19e-23	Prudent dietary pattern;
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22633769	chr20:60982531	CABLES2	0.42	4.27	0.33	3.45e-5	Colorectal cancer;
PAAD	cis	rs501120	1.000	rs687175	chr10:44751910	C/T	cg09554077	chr10:44749378	NA	-0.51	-6.72	-0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.39	-0.46	1.93e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.62	6.51	0.47	1.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.41	-0.34	1.91e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs7264396	0.887	rs1886696	chr20:34055706	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.81e-8	Total cholesterol levels;
PAAD	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.76	-14.47	-0.76	2.24e-30	Longevity;Endometriosis;
PAAD	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.93	-7.15	-0.5	3.42e-11	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00931619	chr1:6052495	NPHP4	0.73	7.6	0.52	2.81e-12	Obesity-related traits;
PAAD	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg15660573	chr17:549704	VPS53	-0.45	-4.26	-0.33	3.63e-5	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03533382	chr5:126853128	PRRC1	0.61	6.67	0.48	4.43e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.54	4.35	0.33	2.51e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs790110	1.000	rs2668336	chr3:122384469	T/A	cg15869492	chr17:36907295	NA	-1.05	-6.52	-0.47	9.94e-10	Acoustic startle blink response;
PAAD	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.65	6.7	0.48	3.81e-10	Testicular germ cell tumor;
PAAD	cis	rs8053891	0.756	rs35259348	chr16:72003952	G/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.71	-0.36	5.47e-6	Coronary artery disease;
PAAD	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.66	7.09	0.5	4.79e-11	Longevity;
PAAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	6.06	0.44	1.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg22467129	chr15:76604101	ETFA	0.53	4.96	0.37	1.86e-6	Blood metabolite levels;
PAAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg27284194	chr4:1044797	NA	0.48	4.69	0.36	6e-6	Obesity-related traits;
PAAD	cis	rs9398803	0.713	rs9401891	chr6:126894135	G/T	cg19875578	chr6:126661172	C6orf173	0.45	4.68	0.36	6.2e-6	Male-pattern baldness;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.5	-0.34	1.32e-5	Platelet count;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.92	-8.05	-0.55	2.24e-13	Other erythrocyte phenotypes;
PAAD	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.26	-0.39	4.73e-7	Schizophrenia;
PAAD	cis	rs501120	0.584	rs10900000	chr10:44694892	G/A	cg09554077	chr10:44749378	NA	0.5	5.64	0.42	8.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.66	6.65	0.47	5.03e-10	Obesity-related traits;
PAAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Tonsillectomy;Mean corpuscular volume;
PAAD	cis	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg00614314	chr15:82944287	LOC80154	0.56	5.85	0.43	2.96e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg08975724	chr8:8085496	FLJ10661	0.49	4.53	0.34	1.2e-5	Mood instability;
PAAD	cis	rs6076065	0.723	rs743022	chr20:23401129	G/C	cg11657817	chr20:23433608	CST11	0.49	5.04	0.38	1.28e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs877529	0.967	rs6001455	chr22:39547962	C/T	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs7396835	0.551	rs10750098	chr11:116705568	G/T	cg07537095	chr11:116228957	NA	0.58	4.43	0.34	1.79e-5	Quantitative traits;
PAAD	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.9	-11.06	-0.67	3.06e-21	Prudent dietary pattern;
PAAD	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20155440	chr7:64838783	ZNF92	-0.75	-6.35	-0.46	2.38e-9	Neuroticism;
PAAD	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.91e-9	IgG glycosylation;
PAAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.22	-0.39	5.72e-7	Initial pursuit acceleration;
PAAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg09324608	chr17:30823087	MYO1D	0.43	4.39	0.34	2.14e-5	Schizophrenia;
PAAD	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg12072164	chr19:44306565	LYPD5	-0.43	-4.56	-0.35	1.03e-5	Reading or mathematical ability;
PAAD	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.89	-11.22	-0.67	1.15e-21	Bipolar disorder;
PAAD	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg07884673	chr3:53033167	SFMBT1	0.71	4.5	0.34	1.37e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.12	-0.38	9.32e-7	Pulmonary function;
PAAD	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-4.3	-0.33	3.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.05	-0.38	1.24e-6	Systolic blood pressure;
PAAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg03340356	chr1:67600835	NA	0.52	5.94	0.43	1.84e-8	Psoriasis;
PAAD	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs2514805	0.803	rs2340023	chr8:95157476	C/T	cg25183890	chr8:94929275	PDP1	0.7	4.52	0.34	1.24e-5	Diisocyanate-induced asthma;
PAAD	cis	rs11825064	0.666	rs73596941	chr11:134495285	A/G	cg02089395	chr11:134479357	NA	-0.83	-5.51	-0.41	1.51e-7	Seasonality;
PAAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg18721089	chr20:30220636	NA	-0.62	-5.11	-0.38	9.46e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.2	5.95	0.43	1.81e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.77e-14	Dupuytren's disease;
PAAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.6	5.54	0.41	1.32e-7	Monocyte count;
PAAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.86	7.42	0.52	7.91e-12	Recombination rate (females);
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg08888203	chr3:10149979	C3orf24	0.83	6.11	0.44	8.14e-9	Alzheimer's disease;
PAAD	cis	rs10090774	0.965	rs34496768	chr8:141958190	T/A	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.44	4.75	0.36	4.73e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg22110888	chr17:80059540	CCDC57	-0.41	-4.34	-0.33	2.64e-5	Life satisfaction;
PAAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.95	9.94	0.63	2.94e-18	Blood metabolite levels;
PAAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.01e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg24565620	chr2:194026	NA	-0.64	-4.62	-0.35	8.12e-6	Blood protein levels;
PAAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.49	8.53e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.48	-4.79	-0.36	3.89e-6	Breast cancer;
PAAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.66	-7.1	-0.5	4.39e-11	Bone mineral density;
PAAD	cis	rs11250714	0.845	rs4880890	chr10:1681656	G/A	cg10435618	chr10:838112	NA	-0.5	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg22027985	chr11:4115532	RRM1	0.51	4.63	0.35	7.74e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg10935138	chr17:73851978	WBP2	0.48	4.29	0.33	3.11e-5	White matter hyperintensity burden;
PAAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg05110241	chr16:68378359	PRMT7	-1.17	-8.25	-0.56	6.87e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.54	0.41	1.33e-7	Total body bone mineral density;
PAAD	cis	rs12767760	0.714	rs7475851	chr10:99322061	G/C	cg25247692	chr10:99313390	UBTD1	-0.51	-4.96	-0.37	1.88e-6	Obesity-related traits;
PAAD	cis	rs35164067	0.853	rs12983921	chr19:10547226	C/T	cg24189696	chr19:10585866	NA	0.46	5.0	0.38	1.56e-6	Inflammatory bowel disease;
PAAD	cis	rs6445967	1.000	rs2292673	chr3:58301901	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.33	0.33	2.71e-5	Platelet count;
PAAD	cis	rs35955747	0.870	rs7289189	chr22:31657182	C/T	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.76	-0.42	4.53e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	6.86e-7	Pulmonary function;
PAAD	cis	rs2790216	1.000	rs2254545	chr10:60034981	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04771938	chr2:97405809	LMAN2L	0.54	6.3	0.46	3e-9	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23463186	chr10:82263737	TSPAN14	-0.66	-6.78	-0.48	2.46e-10	Obesity-related traits;
PAAD	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06850241	chr22:41845214	NA	-0.6	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.93	9.82	0.62	6.2e-18	Testicular germ cell tumor;
PAAD	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.73	-9.67	-0.62	1.53e-17	Asthma;
PAAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.08	-0.38	1.07e-6	Cognitive test performance;
PAAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.7	0.48	3.88e-10	Personality dimensions;
PAAD	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.11	-0.59	4.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.62e-7	Type 2 diabetes;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg11218175	chr11:495084	RNH1	0.85	4.79	0.36	3.93e-6	Body mass index;
PAAD	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	4.51	0.34	1.3e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.86	6.38	0.46	2.06e-9	Iron status biomarkers;
PAAD	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg13639189	chr17:80606880	WDR45L	0.45	4.38	0.33	2.21e-5	Breast cancer;
PAAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg15193198	chr20:60906057	LAMA5	-0.52	-5.14	-0.38	8.44e-7	Colorectal cancer;
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16083429	chr3:49237500	CCDC36	-0.47	-5.11	-0.38	9.65e-7	Menarche (age at onset);
PAAD	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.82	-8.01	-0.54	2.74e-13	Breast cancer;
PAAD	cis	rs9434723	1.000	rs9434723	chr1:9292282	C/T	cg04199779	chr1:9294473	H6PD	0.59	5.25	0.39	5.07e-7	Height;
PAAD	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs210138	1.000	rs210138	chr6:33542538	C/T	cg04201373	chr6:33551533	GGNBP1	-0.62	-4.88	-0.37	2.67e-6	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg15556689	chr8:8085844	FLJ10661	0.72	6.98	0.49	8.7e-11	Morning vs. evening chronotype;
PAAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.78	-6.25	-0.45	3.96e-9	Coronary artery disease;
PAAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.19	0.5	2.8e-11	Rheumatoid arthritis;
PAAD	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.63e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-11.2	-0.67	1.32e-21	Heart rate;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.43	4.31	0.33	2.92e-5	Longevity;Endometriosis;
PAAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23274123	chr1:229478617	C1orf96	-0.62	-7.26	-0.51	1.82e-11	Body fat percentage;
PAAD	trans	rs9980	0.547	rs732021	chr16:69542478	C/G	cg25981920	chr8:144203483	NA	-0.87	-6.95	-0.49	9.94e-11	Blood osmolality (transformed sodium);
PAAD	cis	rs7631605	0.905	rs11716414	chr3:37258835	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.46e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.67	-4.73	-0.36	5.17e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg21351543	chr2:191399470	TMEM194B	-0.67	-4.87	-0.37	2.79e-6	Diastolic blood pressure;
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.66	7.29	0.51	1.62e-11	Longevity;
PAAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg14346243	chr4:90757452	SNCA	-0.49	-4.28	-0.33	3.24e-5	Neuroticism;
PAAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.82	6.99	0.49	8.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs11945232	0.624	rs9654160	chr4:88377324	G/C	cg23841344	chr4:88312519	HSD17B11	-0.57	-4.57	-0.35	9.93e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.04	-0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.63	-0.47	5.57e-10	Mood instability;
PAAD	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg23024343	chr7:107201750	COG5	0.56	4.52	0.34	1.22e-5	Coronary artery disease;
PAAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.71	7.98	0.54	3.21e-13	Colorectal cancer;
PAAD	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg23950597	chr19:37808831	NA	-0.75	-5.09	-0.38	1.02e-6	Coronary artery calcification;
PAAD	cis	rs245880	0.740	rs245885	chr7:29188554	A/G	cg17163760	chr7:29186267	CPVL	-0.52	-6.21	-0.45	4.76e-9	Warfarin maintenance dose;
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg03999872	chr20:62272968	STMN3	0.48	4.65	0.35	7.21e-6	Prostate cancer;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.39	-5.77	-0.42	4.32e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.45	-4.42	-0.34	1.89e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs146817970	1	rs146817970	chr5:81512947	TA/T	cg21483461	chr5:81570383	RPS23	-0.57	-4.74	-0.36	4.94e-6	Breast cancer;
PAAD	cis	rs9558996	0.796	rs9555340	chr13:107937106	A/G	cg09252360	chr13:107220595	ARGLU1	0.56	4.55	0.35	1.11e-5	Carboplatin disposition in epthelial ovarian cancer;
PAAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.98	-13.32	-0.73	2.54e-27	Height;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.88	-0.58	1.8e-15	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08827079	chr19:35225142	ZNF181	0.57	6.32	0.46	2.8e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.4	5.18	0.39	6.9e-7	Alcohol dependence;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08677398	chr8:58056175	NA	0.68	4.66	0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11825685	0.579	rs3019631	chr11:134541267	G/C	cg06603561	chr11:134479413	NA	-0.56	-4.88	-0.37	2.63e-6	IgG glycosylation;
PAAD	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.66	-0.35	6.72e-6	Prevalent atrial fibrillation;
PAAD	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-5.66	-0.42	7.5e-8	Homocysteine levels;
PAAD	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg03684893	chr10:554711	DIP2C	0.44	4.45	0.34	1.68e-5	Psychosis in Alzheimer's disease;
PAAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-14.75	-0.77	3.95e-31	Height;
PAAD	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg22467129	chr15:76604101	ETFA	0.53	4.99	0.38	1.64e-6	Blood metabolite levels;
PAAD	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg04234412	chr22:24373322	LOC391322	-0.73	-8.12	-0.55	1.49e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26926768	chr12:34528122	NA	0.38	4.6	0.35	8.8e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.68	-7.3	-0.51	1.52e-11	Aortic root size;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	11.86	0.69	2.2e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.21	0.45	4.89e-9	Bladder cancer;
PAAD	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.87	0.49	1.54e-10	Resting heart rate;
PAAD	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg03684893	chr10:554711	DIP2C	-0.44	-4.7	-0.36	5.8e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.5	5.02	0.38	1.4e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg06375148	chr1:209958343	C1orf74	0.44	4.35	0.33	2.53e-5	Monobrow;
PAAD	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.56	-6.56	-0.47	8.15e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs3736485	0.966	rs12592889	chr15:51795172	G/A	cg08986416	chr15:51914746	DMXL2	-0.44	-4.26	-0.33	3.63e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.75	-8.63	-0.57	7.7e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.71	10.85	0.66	1.14e-20	Breast cancer;
PAAD	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg08316699	chr6:150357289	NA	0.38	4.39	0.34	2.14e-5	Alopecia areata;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-5.07	-0.38	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.61	-5.34	-0.4	3.36e-7	Resistin levels;
PAAD	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.45	0.4	1.97e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.09e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6722613	0.775	rs934612	chr2:25530687	G/A	cg10614445	chr2:25526696	DNMT3A	-0.43	-4.34	-0.33	2.58e-5	Ossification of the posterior longitudinal ligament of the spine;
PAAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg04330084	chr7:123175371	IQUB	-0.53	-5.07	-0.38	1.12e-6	Migraine;
PAAD	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.44e-5	Blood metabolite levels;
PAAD	cis	rs9788721	0.614	rs951984	chr15:78720915	T/A	cg18825076	chr15:78729989	IREB2	-0.69	-6.48	-0.47	1.22e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.58	4.98	0.37	1.68e-6	Red blood cell count;
PAAD	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18373354	chr11:130029684	ST14	-0.69	-6.8	-0.48	2.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.92	8.47	0.57	1.96e-14	Bipolar disorder;
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg17052926	chr7:915758	C7orf20	0.43	4.44	0.34	1.72e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7873102	0.654	rs10758466	chr9:37969035	T/A	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs5756391	0.568	rs11705450	chr22:37317529	A/G	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	8.14	0.55	1.33e-13	Cognitive test performance;
PAAD	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-12.49	-0.71	4.35e-25	Height;
PAAD	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.4e-8	Coronary artery disease;
PAAD	cis	rs9815354	0.951	rs6599168	chr3:41750323	T/C	cg03022575	chr3:42003672	ULK4	0.87	6.29	0.45	3.2e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs58521262	0.556	rs396653	chr19:23121284	A/C	cg03433597	chr19:22806448	NA	-0.25	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs11892454	0.515	rs10198667	chr2:26020876	T/G	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.51	7.28	0.51	1.69e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.83	9.01	0.59	8.31e-16	Mortality in heart failure;
PAAD	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.55	4.95	0.37	1.96e-6	Lung cancer;
PAAD	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.53	-5.66	-0.42	7.4e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg22467129	chr15:76604101	ETFA	-0.55	-5.3	-0.39	4.01e-7	Blood metabolite levels;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg05038881	chr1:10490043	APITD1	0.42	5.02	0.38	1.4e-6	Prostate cancer;
PAAD	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.5	4.32	0.33	2.82e-5	Alcohol dependence (age at onset);
PAAD	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.82	7.9	0.54	5.24e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04730839	chr6:42985884	KLHDC3	0.55	6.34	0.46	2.53e-9	Smoking initiation;
PAAD	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.41	5.16	0.39	7.52e-7	Corneal astigmatism;
PAAD	cis	rs9659323	0.689	rs10923716	chr1:119536119	C/T	cg17326555	chr1:119535693	NA	-0.38	-4.69	-0.36	6e-6	Body mass index;
PAAD	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg15192750	chr16:69999425	NA	0.74	5.8	0.43	3.78e-8	IgE levels;
PAAD	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.82	9.39	0.61	8.48e-17	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27313690	chr10:21634014	NA	-0.64	-6.49	-0.47	1.13e-9	Obesity-related traits;
PAAD	cis	rs4148087	1.000	rs28494082	chr21:43634547	A/G	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg02071572	chr4:1403502	NA	0.37	4.4	0.34	2.06e-5	Obesity-related traits;
PAAD	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs6137287	0.924	rs4815025	chr20:21142523	C/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.69	-7.52	-0.52	4.54e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.97	-8.67	-0.58	6.12e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.59	6.43	0.46	1.57e-9	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.13e-9	Alzheimer's disease;
PAAD	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.07e-6	Myopia (pathological);
PAAD	cis	rs7555006	0.671	rs11580026	chr1:51476003	A/T	cg06082920	chr1:51796003	TTC39A	0.47	4.59	0.35	9.21e-6	Headache;
PAAD	cis	rs10044254	0.614	rs35167698	chr5:15737297	T/C	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs4343996	0.764	rs10951155	chr7:3359684	C/T	cg22326929	chr7:3991559	SDK1	0.39	4.25	0.33	3.78e-5	Motion sickness;
PAAD	trans	rs901683	1.000	rs17157928	chr10:46048229	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.88	-8.72	-0.58	4.48e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.85	10.27	0.64	4.13e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg13374026	chr7:158955107	NA	0.45	4.25	0.33	3.75e-5	Facial morphology (factor 20);
PAAD	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg02297831	chr4:17616191	MED28	-0.6	-5.65	-0.42	7.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg11995313	chr8:8860691	ERI1	0.5	5.03	0.38	1.35e-6	Joint mobility (Beighton score);
PAAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.56	-5.21	-0.39	6.19e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18621852	chr3:10150065	C3orf24	0.69	6.02	0.44	1.29e-8	Alzheimer's disease;
PAAD	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg16205897	chr5:131564050	P4HA2	-0.43	-4.58	-0.35	9.64e-6	Breast cancer;
PAAD	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.64	-4.48	-0.34	1.49e-5	LDL cholesterol levels;
PAAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg13722127	chr7:150037890	RARRES2	0.52	5.2	0.39	6.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.74	7.9	0.54	5.18e-13	Menopause (age at onset);
PAAD	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.94	-9.32	-0.6	1.26e-16	Obesity-related traits;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.49	5.42	0.4	2.32e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18297960	chr7:1142765	C7orf50	-0.58	-4.61	-0.35	8.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.91	7.07	0.5	5.33e-11	Axial length;
PAAD	cis	rs78761021	0.792	rs62064479	chr17:9794101	G/C	cg26853458	chr17:9805074	RCVRN	0.73	8.49	0.57	1.78e-14	Type 2 diabetes;
PAAD	cis	rs12304921	0.549	rs10876140	chr12:51513322	T/C	cg18059802	chr12:51347058	HIGD1C	-0.61	-4.82	-0.36	3.5e-6	Type 2 diabetes;
PAAD	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27266822	chr1:16073415	TMEM82	0.57	6.32	0.46	2.79e-9	Body fat percentage;
PAAD	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.92	-9.65	-0.62	1.72e-17	Coronary artery disease;
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg01299579	chr2:10830716	NOL10	-0.62	-6.39	-0.46	1.96e-9	Prostate cancer;
PAAD	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09061317	chr1:28995172	GMEB1	0.56	6.51	0.47	1.03e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7631605	0.935	rs4647218	chr3:37042082	A/G	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-8.48	-0.57	1.82e-14	Colorectal cancer;
PAAD	cis	rs6494488	0.500	rs72741393	chr15:64820156	C/G	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg20673091	chr1:2541236	MMEL1	0.72	7.5	0.52	5.07e-12	Ulcerative colitis;
PAAD	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.63	-6.03	-0.44	1.19e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.5	0.61	4.39e-17	Psoriasis;
PAAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	5.06	0.38	1.17e-6	Menarche (age at onset);
PAAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg17366294	chr4:99064904	C4orf37	0.6	6.34	0.46	2.51e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs4668356	0.892	rs2356600	chr2:171956263	G/A	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg23950597	chr19:37808831	NA	-0.77	-5.2	-0.39	6.28e-7	Coronary artery calcification;
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs11807834	0.522	rs2057231	chr1:230231546	T/C	cg00566187	chr1:230250356	GALNT2	-0.6	-6.33	-0.46	2.64e-9	Schizophrenia;
PAAD	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.93	9.88	0.63	4.28e-18	Multiple sclerosis;
PAAD	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.32	-0.46	2.69e-9	Schizophrenia;
PAAD	trans	rs9409082	0.715	rs7025685	chr9:108951075	C/T	cg07010948	chr13:79181613	NA	-0.35	-6.63	-0.47	5.56e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.53	-4.38	-0.33	2.22e-5	Atopic dermatitis;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg22875332	chr1:76189707	ACADM	0.76	4.5	0.34	1.34e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-8.79	-0.58	2.96e-15	Electrocardiographic conduction measures;
PAAD	cis	rs986417	0.688	rs1950317	chr14:61022789	T/G	cg27398547	chr14:60952738	C14orf39	0.86	5.89	0.43	2.38e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs2092319	0.649	rs1890174	chr1:26026561	G/C	cg02327719	chr1:26185386	C1orf135	-0.77	-4.4	-0.34	2.01e-5	Nose morphology;
PAAD	cis	rs8077577	0.708	rs3862147	chr17:18133713	G/T	cg16794390	chr17:18148240	FLII	-0.52	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.8	-9.47	-0.61	5.28e-17	Eosinophil percentage of white cells;
PAAD	cis	rs4352251	0.543	rs1192828	chr2:101912120	C/A	cg01660407	chr2:101008576	CHST10	0.55	4.42	0.34	1.9e-5	Adiponectin levels (BMI-adjusted);Adiponectin levels;
PAAD	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.59	-8.44	-0.57	2.28e-14	Huntington's disease progression;
PAAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.9	0.66	8.63e-21	Homoarginine levels;
PAAD	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs17155006	0.691	rs403731	chr7:107744217	C/T	cg05962710	chr7:107745446	LAMB4	0.58	7.95	0.54	3.95e-13	Pneumococcal bacteremia;
PAAD	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	5.89	0.43	2.37e-8	Homocysteine levels;
PAAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.52	5.14	0.38	8.48e-7	Longevity;
PAAD	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-6.56	-0.47	8.05e-10	Mood instability;
PAAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.6	6.12	0.44	7.58e-9	Multiple sclerosis;
PAAD	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19530883	chr19:5903870	NDUFA11;VMAC	0.66	6.6	0.47	6.57e-10	Obesity-related traits;
PAAD	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.62	4.94	0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Blood protein levels;
PAAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.48	-4.92	-0.37	2.19e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg03315344	chr16:75512273	CHST6	-0.66	-8.12	-0.55	1.51e-13	Dupuytren's disease;
PAAD	cis	rs1198430	0.683	rs1198433	chr1:23756695	A/G	cg19827787	chr1:23763612	ASAP3	0.59	4.88	0.37	2.67e-6	Total cholesterol levels;
PAAD	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg07617317	chr6:118971624	C6orf204	0.55	4.58	0.35	9.49e-6	Diastolic blood pressure;
PAAD	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg27449745	chr7:23145252	KLHL7	-0.53	-4.75	-0.36	4.74e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg00631329	chr6:26305371	NA	-0.48	-4.85	-0.37	2.97e-6	Educational attainment;
PAAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.73	-7.59	-0.52	3.06e-12	Magnesium levels;
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg02841227	chr6:26021843	HIST1H4A	-0.45	-4.36	-0.33	2.42e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs755249	0.567	rs61783378	chr1:39777159	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.63	-0.35	7.67e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.13	-0.38	8.88e-7	Subjective well-being;
PAAD	cis	rs1697938	0.590	rs2455314	chr5:40939291	C/T	cg22359217	chr5:41925772	FBXO4	0.46	4.58	0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.58	6.33	0.46	2.59e-9	Mean corpuscular volume;
PAAD	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.64	-6.58	-0.47	7.04e-10	Beta-trace protein levels;
PAAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.87	8.01	0.54	2.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg03959625	chr15:84868606	LOC388152	0.46	4.7	0.36	5.69e-6	Schizophrenia;
PAAD	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-5.21	-0.39	6.05e-7	QT interval;
PAAD	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.17	-0.39	7.22e-7	Reticulocyte count;
PAAD	trans	rs62179067	0.867	rs112102451	chr2:179917893	T/A	cg13380624	chr19:7735426	NA	-0.73	-6.72	-0.48	3.37e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.72	7.19	0.5	2.76e-11	Alcohol dependence;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg07336987	chr11:625147	MUPCDH	-0.38	-4.73	-0.36	5.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg22143856	chr6:28129313	ZNF389	0.67	5.31	0.4	3.81e-7	Depression;
PAAD	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg11764359	chr7:65958608	NA	0.55	5.08	0.38	1.1e-6	Corneal structure;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.72	-0.48	3.42e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg05373962	chr22:49881684	NA	-0.5	-4.89	-0.37	2.56e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.48	4.4	0.34	2.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.84e-18	Cognitive function;
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.8	-8.81	-0.58	2.73e-15	Prostate cancer;
PAAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08754654	chr5:154026448	NA	-0.42	-6.37	-0.46	2.13e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg05627522	chr15:75251581	NA	0.59	7.26	0.51	1.9e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg06636001	chr8:8085503	FLJ10661	0.77	7.65	0.53	2.11e-12	Mood instability;
PAAD	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg06569542	chr10:98946673	SLIT1	0.51	5.8	0.43	3.66e-8	Monocyte count;
PAAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.77	-0.42	4.23e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06850241	chr22:41845214	NA	-0.52	-4.75	-0.36	4.74e-6	Vitiligo;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.59	6.25	0.45	3.86e-9	Lung cancer;
PAAD	cis	rs12136530	0.593	rs12404783	chr1:19735885	A/C	cg03321592	chr1:19991676	HTR6	0.5	4.32	0.33	2.84e-5	Lead levels in blood;
PAAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.93	10.04	0.63	1.69e-18	Cognitive function;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs12484776	0.729	rs8140695	chr22:40531506	T/A	cg07138101	chr22:40742427	ADSL	0.58	4.32	0.33	2.81e-5	Uterine fibroids;
PAAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.19	0.5	2.68e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Lung cancer in ever smokers;
PAAD	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.57	5.34	0.4	3.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs5771225	0.563	rs1129880	chr22:50694297	A/G	cg08875078	chr22:50639485	SELO	0.49	4.37	0.33	2.29e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg21859623	chr20:33103246	DYNLRB1	0.47	4.46	0.34	1.59e-5	Height;
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg00118712	chr10:131686819	EBF3	-0.51	-4.94	-0.37	2.03e-6	Vitamin D levels;
PAAD	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.66	-6.35	-0.46	2.31e-9	Fibrinogen levels;
PAAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs4747197	1.000	rs4747198	chr10:73568406	C/G	cg04506911	chr10:72937119	NA	0.4	4.39	0.34	2.15e-5	Progranulin levels;
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.73	9.35	0.6	1.04e-16	Bone mineral density;
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg16300553	chr8:8131077	NA	0.36	4.27	0.33	3.48e-5	Mood instability;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs4742903	0.901	rs10122512	chr9:106898410	C/T	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.86	7.79	0.53	9.77e-13	Coronary artery disease;
PAAD	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.85	6.99	0.49	7.96e-11	Pulmonary function decline;
PAAD	cis	rs1075232	0.826	rs12437800	chr15:31671432	A/G	cg01030201	chr15:31746330	NA	-1.03	-4.29	-0.33	3.23e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.38	-0.56	3.34e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10916814	0.610	rs4655223	chr1:20901688	C/G	cg04087271	chr1:20915334	CDA	0.38	4.68	0.36	6.23e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07145255	chr5:59995354	DEPDC1B	0.69	7.94	0.54	4.19e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1345301	0.552	rs67880537	chr2:102864106	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.46	-0.34	1.58e-5	Waist circumference;
PAAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.69	0.58	5.35e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.54	-4.9	-0.37	2.42e-6	Asthma;
PAAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.98	13.82	0.75	1.2e-28	Multiple system atrophy;
PAAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg14440974	chr22:39074834	NA	-0.55	-6.81	-0.48	2.18e-10	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-7.02	-0.5	6.74e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	4.87	0.37	2.79e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.23	0.51	2.17e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12767760	0.681	rs11814566	chr10:99316063	T/C	cg25247692	chr10:99313390	UBTD1	-0.51	-4.96	-0.37	1.88e-6	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.41	-6.24	-0.45	4.24e-9	Subjective well-being;
PAAD	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg19753864	chr2:38320028	NA	0.41	4.5	0.34	1.32e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg21929781	chr1:2537748	MMEL1	0.43	4.57	0.35	1.01e-5	Ulcerative colitis;
PAAD	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	5.03	0.38	1.4e-6	Educational attainment;
PAAD	cis	rs288326	0.561	rs74942055	chr2:183793653	A/G	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.73	6.92	0.49	1.21e-10	Methadone dose in opioid dependence;
PAAD	cis	rs59888335	0.929	rs13090495	chr3:80866404	T/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs7312774	0.618	rs726943	chr12:107331647	A/G	cg16260113	chr12:107380972	MTERFD3	1.21	7.35	0.51	1.17e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.52	7.32	0.51	1.35e-11	Diastolic blood pressure;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.88	6.25	0.45	3.96e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.71	-0.36	5.54e-6	Height;
PAAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.46	4.67	0.35	6.52e-6	Body mass index;
PAAD	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg25833597	chr17:30823145	MYO1D	0.51	4.64	0.35	7.57e-6	Schizophrenia;
PAAD	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg02367709	chr17:66097352	LOC651250	0.43	4.43	0.34	1.82e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.72	8.05	0.55	2.24e-13	Colorectal cancer;
PAAD	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-4.81	-0.36	3.57e-6	Pancreatic cancer;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg23107878	chr1:152161397	NA	0.45	4.54	0.35	1.15e-5	Inflammatory skin disease;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13198984	chr17:80129470	CCDC57	0.43	5.48	0.41	1.73e-7	Life satisfaction;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.25	0.39	5.13e-7	Bipolar disorder;
PAAD	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg27506609	chr1:36549197	TEKT2	0.68	4.73	0.36	5.05e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.81	6.03	0.44	1.21e-8	Alzheimer's disease;
PAAD	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg23024343	chr7:107201750	COG5	0.56	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg03684893	chr10:554711	DIP2C	-0.51	-4.99	-0.38	1.64e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00079375	chr15:79125835	NA	0.44	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.42	-6.37	-0.46	2.17e-9	Mean corpuscular volume;
PAAD	cis	rs136211	0.895	rs755470	chr22:36774904	C/T	cg11153328	chr22:36877737	TXN2	-0.53	-4.85	-0.37	3.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.99	-10.27	-0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg24747557	chr10:131355152	MGMT	-0.51	-5.41	-0.4	2.45e-7	Response to temozolomide;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.67	-0.42	6.9e-8	Life satisfaction;
PAAD	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.42	0.52	7.78e-12	Menopause (age at onset);
PAAD	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.84	6.46	0.46	1.32e-9	Axial length;
PAAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg11962587	chr1:145515913	GNRHR2;PEX11B	-0.52	-4.95	-0.37	1.98e-6	HIV-1 control;
PAAD	cis	rs6594713	0.605	rs11241213	chr5:112851088	T/A	cg12552261	chr5:112820674	MCC	0.76	5.3	0.39	4.09e-7	Brain cytoarchitecture;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-7.62	-0.53	2.48e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg14440974	chr22:39074834	NA	-0.61	-6.91	-0.49	1.27e-10	Menopause (age at onset);
PAAD	cis	rs8077577	0.945	rs11653988	chr17:18088833	C/T	cg16794390	chr17:18148240	FLII	0.57	4.71	0.36	5.61e-6	Obesity-related traits;
PAAD	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg11232448	chr19:2858854	NA	-0.49	-4.72	-0.36	5.2e-6	Total cholesterol levels;
PAAD	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/C	cg07580975	chr1:200843333	NA	0.47	4.51	0.34	1.3e-5	Epilepsy;
PAAD	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg14393609	chr7:65229607	NA	0.47	4.93	0.37	2.09e-6	Aortic root size;
PAAD	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.7e-8	Daytime sleep phenotypes;
PAAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	4.99	0.37	1.66e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.55	-4.67	-0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs317865	0.867	rs9946	chr4:16163221	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	6.3	0.45	3.12e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21659725	chr3:3221576	CRBN	0.67	6.63	0.47	5.58e-10	Menarche (age at onset);
PAAD	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-4.43	-0.34	1.81e-5	Ovarian reserve;
PAAD	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.76	-7.17	-0.5	2.99e-11	Platelet distribution width;
PAAD	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-9.95	-0.63	2.76e-18	Electrocardiographic conduction measures;
PAAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs11614333	0.920	rs10846075	chr12:15032618	C/T	cg00431549	chr12:15039025	MGP	0.36	4.29	0.33	3.15e-5	Hand grip strength;
PAAD	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15235185	chr1:193028809	TROVE2;UCHL5	0.58	6.31	0.46	2.93e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1042026	0.848	rs1039151	chr4:100192782	G/T	cg09112717	chr4:100009950	ADH5	-0.51	-4.59	-0.35	9.37e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.55	6.08	0.44	9.28e-9	Obesity-related traits;
PAAD	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.85	-0.49	1.69e-10	Atrioventricular conduction;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09891221	chr13:94956235	GPC6	-0.52	-6.31	-0.46	2.91e-9	Monocyte percentage of white cells;
PAAD	cis	rs89107	0.688	rs283085	chr6:118603267	C/A	cg18833306	chr6:118973337	C6orf204	0.47	5.48	0.41	1.77e-7	Cardiac structure and function;
PAAD	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	trans	rs1483035	0.623	rs7671138	chr4:156460954	G/A	cg00585174	chr10:134499472	INPP5A	0.51	6.77	0.48	2.67e-10	Influenza A (H1N1) severity;
PAAD	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg00257455	chr1:65530538	NA	-0.4	-4.35	-0.33	2.46e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg23331303	chr5:5135948	NA	0.46	6.45	0.46	1.43e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.21	-0.39	6.01e-7	Resting heart rate;
PAAD	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg13852791	chr20:30311386	BCL2L1	0.62	4.43	0.34	1.77e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg20302533	chr7:39170763	POU6F2	-0.45	-6.35	-0.46	2.36e-9	IgG glycosylation;
PAAD	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.69	0.48	3.97e-10	High light scatter reticulocyte count;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg12623918	chr2:306882	NA	0.48	4.91	0.37	2.34e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.59	6.2	0.45	5e-9	Schizophrenia;
PAAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24549020	chr5:56110836	MAP3K1	0.71	5.17	0.39	7.31e-7	Initial pursuit acceleration;
PAAD	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs745080	0.603	rs17725312	chr14:53065714	C/T	cg23333723	chr14:53022898	GPR137C	-0.56	-4.37	-0.33	2.31e-5	Orofacial clefts;
PAAD	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.84	-6.35	-0.46	2.41e-9	Coronary artery calcification;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.92	8.11	0.55	1.58e-13	Alzheimer's disease;
PAAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.88	9.73	0.62	1.09e-17	Cognitive function;
PAAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10935720	chr17:41132628	AARSD1;RUNDC1	0.55	6.48	0.47	1.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs6466055	0.589	rs66482905	chr7:104974206	T/G	cg04380332	chr7:105027541	SRPK2	0.51	5.08	0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.91	-0.37	2.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.47	-4.97	-0.37	1.8e-6	Dilated cardiomyopathy;
PAAD	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.51	-6.37	-0.46	2.18e-9	Lewy body disease;
PAAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg10820045	chr2:198174542	NA	-0.44	-4.4	-0.34	2.03e-5	Dermatomyositis;
PAAD	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.95	-0.81	7.35e-37	Myeloid white cell count;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13394060	chr9:140704065	EHMT1	-0.69	-6.33	-0.46	2.63e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.9	-9.62	-0.62	2.13e-17	Cognitive function;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg11905131	chr22:24372483	LOC391322	-0.51	-4.52	-0.34	1.26e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg12661370	chr5:149340060	SLC26A2	0.65	5.42	0.4	2.28e-7	HIV-1 control;
PAAD	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg17796960	chr10:135278976	LOC619207	-0.45	-5.2	-0.39	6.48e-7	Systemic lupus erythematosus;
PAAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg18110333	chr6:292329	DUSP22	-0.63	-6.34	-0.46	2.49e-9	Menopause (age at onset);
PAAD	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.23	5.52	0.41	1.43e-7	Urinary tract infection frequency;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg00024416	chr22:24240387	NA	-0.49	-4.93	-0.37	2.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.83	-0.43	3.25e-8	Life satisfaction;
PAAD	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-4.63	-0.35	7.7e-6	IFN-related cytopenia;
PAAD	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18404041	chr3:52824283	ITIH1	0.42	4.33	0.33	2.75e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg09127314	chr1:152161683	NA	-0.72	-5.04	-0.38	1.29e-6	Atopic dermatitis;
PAAD	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.67	-5.96	-0.44	1.69e-8	Diabetic retinopathy;
PAAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.68	5.73	0.42	5.2100000000000003e-08	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg15117754	chr3:10150083	C3orf24	0.74	6.58	0.47	7.24e-10	Alzheimer's disease;
PAAD	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.88	10.13	0.64	9.22e-19	Ulcerative colitis;
PAAD	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23571288	chr13:26828759	CDK8	-0.72	-6.56	-0.47	7.85e-10	Lung cancer in ever smokers;
PAAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02071572	chr4:1403502	NA	0.35	4.48	0.34	1.46e-5	Longevity;
PAAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.89	-9.36	-0.6	9.78e-17	DNA methylation (variation);
PAAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg24053715	chr22:38214548	NA	0.63	6.03	0.44	1.21e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.73	-7.11	-0.5	4.3e-11	Platelet distribution width;
PAAD	cis	rs9815354	0.812	rs73079324	chr3:41864564	T/C	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.49	5.44	0.4	2.08e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6537837	0.838	rs3737182	chr1:110091271	C/T	cg05049280	chr1:110155535	GNAT2	0.45	4.68	0.36	6.22e-6	Major depressive disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14983993	chr14:20937849	PNP	-0.71	-6.34	-0.46	2.46e-9	Neuroticism;
PAAD	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.78	9.69	0.62	1.4e-17	Iron status biomarkers (transferrin levels);
PAAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg00745463	chr17:30367425	LRRC37B	-0.5	-4.34	-0.33	2.59e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Body mass index;
PAAD	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs1198430	0.562	rs10917384	chr1:23798312	C/A	cg24580199	chr1:23763081	ASAP3	0.5	4.35	0.33	2.48e-5	Total cholesterol levels;
PAAD	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.75	-5.25	-0.39	5.01e-7	Carotid intima media thickness;
PAAD	cis	rs7561149	0.934	rs13006510	chr2:179682878	C/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.45	4.33	0.33	2.67e-5	QT interval;
PAAD	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.59	-0.35	9.33e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.18	-0.45	5.76e-9	Schizophrenia;
PAAD	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg20636351	chr8:55087400	NA	-0.81	-8.7	-0.58	5.2e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg00262122	chr8:11665843	FDFT1	-0.53	-4.78	-0.36	4.07e-6	Neuroticism;
PAAD	cis	rs2579500	0.807	rs6576976	chr2:97246667	T/C	cg09304357	chr2:97220596	NA	-0.47	-5.05	-0.38	1.25e-6	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg25809561	chr17:30822961	MYO1D	0.56	5.97	0.44	1.63e-8	Schizophrenia;
PAAD	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.55	-5.24	-0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.65	7.99	0.54	3.17e-13	Schizophrenia;
PAAD	cis	rs500891	0.574	rs13196407	chr6:84120820	G/A	cg08257003	chr6:84140564	ME1	0.35	4.27	0.33	3.47e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs375066	0.935	rs10414702	chr19:44380536	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.67	0.48	4.36e-10	Breast cancer;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg03303774	chr4:1407052	NA	0.33	4.26	0.33	3.64e-5	Obesity-related traits;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg19500098	chr13:21900506	NA	0.6	6.61	0.47	6.16e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.72	7.34	0.51	1.23e-11	Response to antidepressants and depression;
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.42e-19	Menopause (age at onset);
PAAD	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg01657329	chr11:68192670	LRP5	-0.64	-4.65	-0.35	7.05e-6	Monobrow;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01282078	chr16:12139025	RUNDC2A	0.53	6.35	0.46	2.42e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4740619	0.556	rs2987098	chr9:16017488	A/T	cg14451791	chr9:16040625	NA	-0.36	-4.25	-0.33	3.68e-5	Body mass index;
PAAD	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg08999081	chr20:33150536	PIGU	0.54	5.82	0.43	3.35e-8	Height;
PAAD	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.8	9.7	0.62	1.33e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	0.94	6.96	0.49	9.55e-11	Prostate cancer;
PAAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00300879	chr1:26503847	CNKSR1	0.28	4.26	0.33	3.53e-5	Height;
PAAD	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg23912435	chr1:150601613	ENSA	0.52	4.83	0.36	3.3e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.32	0.33	2.81e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg07785726	chr13:50159788	RCBTB1	0.62	6.72	0.48	3.41e-10	Iris heterochromicity;
PAAD	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.58e-5	Aortic root size;
PAAD	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26876637	chr1:152193138	HRNR	0.89	6.91	0.49	1.26e-10	Atopic dermatitis;
PAAD	trans	rs901683	1.000	rs35934513	chr10:46059781	C/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs818427	0.684	rs42427	chr5:112176325	G/A	cg06941702	chr5:112196734	SRP19	-0.5	-4.45	-0.34	1.67e-5	Total body bone mineral density;
PAAD	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.43	5.54	0.41	1.27e-7	Height;
PAAD	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg05791153	chr7:19748676	TWISTNB	0.72	5.5	0.41	1.58e-7	Thyroid stimulating hormone;
PAAD	cis	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.08	0.38	1.08e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs7960581	0.722	rs75620838	chr12:99182821	G/A	cg17109042	chr12:99139387	ANKS1B	-0.71	-4.67	-0.35	6.52e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs732765	0.657	rs28567642	chr14:75235371	G/T	cg17347104	chr14:75034677	LTBP2	0.56	4.29	0.33	3.1e-5	Non-small cell lung cancer;
PAAD	cis	rs7168353	0.519	rs7162381	chr15:93636440	T/G	cg02918577	chr15:93633145	RGMA	0.37	4.98	0.37	1.7e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Body mass index;
PAAD	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.39	-4.69	-0.36	5.97e-6	Prostate cancer;
PAAD	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	5.64	0.42	8.11e-8	Lung cancer in ever smokers;
PAAD	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg22437258	chr11:111473054	SIK2	0.48	4.65	0.35	7.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.62	7.35	0.51	1.12e-11	Prostate cancer;
PAAD	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.56	-5.33	-0.4	3.56e-7	Strep throat;
PAAD	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg18721089	chr20:30220636	NA	-0.58	-5.18	-0.39	6.85e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg14008862	chr17:28927542	LRRC37B2	-0.78	-4.79	-0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs9715521	0.712	rs58171535	chr4:59847742	T/A	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.59	5.03	0.38	1.37e-6	RR interval (heart rate);
PAAD	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7894051	0.764	rs12242667	chr10:135192346	G/C	cg19176072	chr10:135083742	ADAM8	-0.96	-4.65	-0.35	7.09e-6	Lifespan;
PAAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg05082376	chr22:42548792	NA	-0.52	-5.65	-0.42	7.67e-8	Cognitive function;
PAAD	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	5.72	0.42	5.39e-8	Alzheimer's disease (late onset);
PAAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.54	6.95	0.49	9.84e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08704250	chr15:31115839	NA	-0.6	-8.19	-0.55	9.63e-14	Huntington's disease progression;
PAAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg11143131	chr5:131608246	PDLIM4	-0.46	-4.7	-0.36	5.89e-6	Blood metabolite levels;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg21724239	chr8:58056113	NA	0.68	5.41	0.4	2.43e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11605275	0.818	rs35645523	chr11:20046171	G/A	cg14835545	chr11:20032148	NAV2	-0.79	-4.39	-0.34	2.12e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.55	5.77	0.42	4.34e-8	Diastolic blood pressure;
PAAD	cis	rs990171	0.687	rs6751949	chr2:103125138	G/A	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs2137920	0.685	rs1125517	chr10:50243539	C/T	cg02657375	chr10:50863136	CHAT	0.57	4.6	0.35	8.95e-6	Migraine with aura;
PAAD	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg08999081	chr20:33150536	PIGU	-0.49	-5.33	-0.4	3.5e-7	Height;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	5.39	0.4	2.6e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-7.01	-0.49	7.22e-11	Eye color traits;
PAAD	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg12568669	chr8:11666485	FDFT1	0.31	5.41	0.4	2.37e-7	Monocyte count;
PAAD	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.05	-0.59	6.5e-16	Height;
PAAD	cis	rs59918340	0.738	rs7017848	chr8:142222374	A/G	cg16341495	chr8:142228727	SLC45A4	-0.58	-5.89	-0.43	2.42e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.73	-9.32	-0.6	1.27e-16	Asthma;
PAAD	cis	rs9361491	0.508	rs9352613	chr6:79424433	C/T	cg05283184	chr6:79620031	NA	0.4	5.0	0.38	1.55e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.85	-10.28	-0.64	3.67e-19	Height;
PAAD	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg23093090	chr10:104574429	C10orf26	-0.43	-4.56	-0.35	1.04e-5	Arsenic metabolism;
PAAD	cis	rs2882667	0.720	rs56044552	chr5:138176954	T/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg11477892	chr4:106580295	NA	-0.55	-4.52	-0.34	1.22e-5	Post bronchodilator FEV1;
PAAD	cis	rs732765	0.657	rs28461601	chr14:75228488	T/C	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.53	-5.01	-0.38	1.48e-6	White matter hyperintensity burden;
PAAD	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg02569219	chr17:2266849	SGSM2	0.52	4.32	0.33	2.82e-5	Total body bone mineral density;
PAAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.9	7.28	0.51	1.64e-11	Tuberculosis;
PAAD	cis	rs818427	0.548	rs154344	chr5:112248738	T/C	cg06941702	chr5:112196734	SRP19	0.57	5.25	0.39	4.99e-7	Total body bone mineral density;
PAAD	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.5	4.78	0.36	4.06e-6	Hepatocellular carcinoma;
PAAD	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg23283495	chr1:209979779	IRF6	0.62	5.82	0.43	3.4e-8	Coronary artery disease;
PAAD	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg20933634	chr6:27740509	NA	0.46	4.43	0.34	1.77e-5	Parkinson's disease;
PAAD	cis	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg16898833	chr6:26189333	HIST1H4D	0.63	4.75	0.36	4.62e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg07617317	chr6:118971624	C6orf204	0.56	4.72	0.36	5.38e-6	Diastolic blood pressure;
PAAD	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg26205652	chr12:48591994	NA	0.95	9.67	0.62	1.57e-17	Longevity (90 years and older);
PAAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.31	0.46	2.95e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs9810890	0.850	rs73196955	chr3:128430599	C/A	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.88	5.69	0.42	6.26e-8	Blood protein levels;
PAAD	cis	rs12799264	0.822	rs2585781	chr11:19976712	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.72	0.36	5.25e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg07395648	chr5:131743802	NA	-0.58	-5.18	-0.39	7e-7	Breast cancer;
PAAD	cis	rs7144011	0.654	rs2218783	chr14:79847785	C/A	cg18311665	chr14:79483171	NRXN3	0.35	4.52	0.34	1.24e-5	Waist circumference;Hip circumference;
PAAD	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg21918786	chr6:109611834	NA	0.45	4.92	0.37	2.21e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-6.71	-0.48	3.61e-10	Initial pursuit acceleration;
PAAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.44	0.46	1.52e-9	Tonsillectomy;
PAAD	cis	rs12410462	0.551	rs2819516	chr1:227637092	A/G	cg23173402	chr1:227635558	NA	0.52	4.41	0.34	1.92e-5	Major depressive disorder;
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg18612461	chr15:75251733	NA	0.62	7.42	0.52	7.85e-12	Breast cancer;
PAAD	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	1.06	11.82	0.69	2.77e-23	Ulcerative colitis;
PAAD	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg01759136	chr6:27242945	NA	0.4	4.35	0.33	2.44e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3981351	0.797	rs12766891	chr10:115460714	G/A	cg24846397	chr10:115438155	CASP7	-0.58	-5.46	-0.41	1.86e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg22467129	chr15:76604101	ETFA	0.51	4.76	0.36	4.45e-6	Blood metabolite levels;
PAAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.28	-0.45	3.31e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.76	-9.53	-0.61	3.69e-17	Educational attainment;
PAAD	cis	rs740698	0.522	rs1024653	chr17:60791818	A/C	cg13195520	chr17:60813227	MARCH10	-0.46	-4.66	-0.35	6.81e-6	Pulse pressure;
PAAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg19413350	chr8:57351067	NA	-0.48	-4.61	-0.35	8.33e-6	Obesity-related traits;
PAAD	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14089512	chr10:102106757	SCD	0.56	6.32	0.46	2.72e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22897198	chr6:36391250	PXT1	0.76	6.81	0.48	2.13e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg16342193	chr10:102329863	NA	0.83	8.95	0.59	1.19e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2790216	0.950	rs1199097	chr10:59950010	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-8.17	-0.55	1.09e-13	Depression;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.83	-9.91	-0.63	3.57e-18	Monocyte percentage of white cells;
PAAD	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.61	6.26	0.45	3.75e-9	Sjögren's syndrome;
PAAD	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg01528321	chr10:82214614	TSPAN14	0.97	10.33	0.64	2.8e-19	Post bronchodilator FEV1;
PAAD	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.54	5.97	0.44	1.6e-8	Mean corpuscular volume;
PAAD	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs11696501	0.637	rs2093090	chr20:44205464	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-5.87	-0.43	2.68e-8	Brain structure;
PAAD	cis	rs8040855	0.658	rs4842864	chr15:85644546	C/A	cg08123816	chr15:85640762	PDE8A	-0.41	-4.93	-0.37	2.15e-6	Bulimia nervosa;
PAAD	cis	rs75920871	0.764	rs4938326	chr11:116905464	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.85	-4.42	-0.34	1.86e-5	Subjective well-being;
PAAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.82	7.74	0.53	1.29e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg01262667	chr19:19385393	TM6SF2	0.47	5.3	0.4	3.95e-7	Tonsillectomy;
PAAD	cis	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.43	-0.4	2.18e-7	Mononucleosis;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg10729496	chr3:10149963	C3orf24	-0.88	-6.32	-0.46	2.69e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	7.04e-11	Life satisfaction;
PAAD	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg10395934	chr14:104002654	TRMT61A	0.56	5.73	0.42	5.35e-8	Body mass index;
PAAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg02792821	chr20:44451783	NA	0.34	4.4	0.34	2.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4450131	0.522	rs3781451	chr10:126355477	G/A	cg20435097	chr10:126320824	FAM53B	0.49	5.01	0.38	1.52e-6	White blood cell count (basophil);
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg26309111	chr7:23720005	C7orf46	-0.43	-4.89	-0.37	2.49e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg27411982	chr8:10470053	RP1L1	-0.49	-5.47	-0.41	1.84e-7	Neuroticism;
PAAD	cis	rs4740619	0.774	rs7868779	chr9:15709795	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.51	-0.34	1.3e-5	Body mass index;
PAAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs9463078	0.804	rs6458428	chr6:45179815	A/C	cg25276700	chr6:44698697	NA	-0.5	-5.73	-0.42	5.32e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.72	-6.08	-0.44	9.4e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg07068956	chr7:100330872	ZAN	0.53	4.75	0.36	4.62e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg06728252	chr6:26598149	ABT1	-0.43	-4.99	-0.38	1.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.53	-0.52	4.09e-12	Total body bone mineral density;
PAAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg19636519	chr7:99541626	NA	0.41	4.58	0.35	9.53e-6	Coronary artery disease;
PAAD	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.47	-0.46	1.26e-9	Response to antipsychotic treatment;
PAAD	trans	rs901683	1.000	rs34081402	chr10:45994427	C/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.61	5.78	0.42	4.12e-8	Prudent dietary pattern;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.69	-0.36	6.02e-6	Lung cancer;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.83	9.41	0.61	7.49e-17	Iron status biomarkers;
PAAD	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg08992911	chr2:238395768	MLPH	0.66	5.27	0.39	4.61e-7	Prostate cancer;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg04089426	chr11:65307791	LTBP3	1.1	5.13	0.38	8.84e-7	Height;
PAAD	cis	rs2070677	0.877	rs1581935	chr10:135360448	T/G	cg20169779	chr10:135381914	SYCE1	0.75	6.83	0.48	1.95e-10	Gout;
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.42	0.4	2.28e-7	Bipolar disorder;
PAAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg16257655	chr7:1659720	NA	0.41	4.27	0.33	3.44e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.48	4.42	0.34	1.86e-5	Triglycerides;
PAAD	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg04717802	chr22:42394638	WBP2NL	0.52	4.44	0.34	1.69e-5	Birth weight;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20001876	chr14:65747802	NA	0.61	6.54	0.47	8.98e-10	Warfarin maintenance dose;
PAAD	cis	rs757081	0.658	rs214076	chr11:17300257	T/C	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.73	-0.36	5.12e-6	Systolic blood pressure;
PAAD	cis	rs10121009	0.635	rs10814225	chr9:35319587	T/C	cg11846315	chr9:35647073	NA	-0.48	-4.46	-0.34	1.58e-5	Parkinson's disease;
PAAD	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg10932868	chr11:921992	NA	0.45	4.79	0.36	4.01e-6	Alzheimer's disease (late onset);
PAAD	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.58	6.12	0.44	7.62e-9	Colorectal cancer;
PAAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-5.56	-0.41	1.19e-7	Calcium levels;
PAAD	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg14851468	chr5:179071604	C5orf60	0.54	5.41	0.4	2.38e-7	Lung cancer;
PAAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg25124228	chr12:125621409	AACS	-0.64	-5.87	-0.43	2.66e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	6.0	0.44	1.41e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.47	-4.66	-0.35	6.85e-6	Type 1 diabetes;
PAAD	cis	rs35955747	0.869	rs5997971	chr22:31792292	C/T	cg02404636	chr22:31891804	SFI1	-0.55	-5.43	-0.4	2.15e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg13175981	chr1:150552382	MCL1	-0.55	-5.02	-0.38	1.42e-6	Urate levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20979042	chr8:144387646	NA	0.48	6.45	0.46	1.43e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27023595	chr16:4873863	GLYR1	-0.57	-6.88	-0.49	1.46e-10	Monocyte percentage of white cells;
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	-0.49	-4.37	-0.33	2.29e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6137287	0.824	rs754332	chr20:21177898	G/A	cg04219410	chr20:21106687	PLK1S1	-0.39	-4.41	-0.34	1.92e-5	Height;
PAAD	cis	rs6718203	0.818	rs70953653	chr2:60703726	A/G	cg10480506	chr2:60280451	NA	0.68	4.51	0.34	1.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-1.04	-9.58	-0.61	2.67e-17	Cisplatin-induced ototoxicity;
PAAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.66	7.42	0.52	7.52e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.9e-5	Rheumatoid arthritis;
PAAD	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg14709524	chr16:89940631	TCF25	0.88	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg02493740	chr2:85810744	VAMP5	-0.44	-4.9	-0.37	2.45e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2120991	0.967	rs7133456	chr12:54268206	G/A	cg25640699	chr12:54070114	ATP5G2	-0.42	-4.48	-0.34	1.44e-5	Biliary atresia;
PAAD	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.589	rs56251298	chr7:104956516	G/T	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs12432203	1.000	rs72622426	chr14:51731304	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.65	-0.35	7.08e-6	Cancer;
PAAD	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.63	-0.42	8.28e-8	Pulmonary function;
PAAD	trans	rs9982086	0.557	rs2829987	chr21:27309346	G/C	cg04970570	chr5:87990145	NA	0.6	6.35	0.46	2.34e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs2290419	0.504	rs117786030	chr11:68939448	A/G	cg17042914	chr11:68898666	NA	-0.77	-4.39	-0.34	2.08e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg15654264	chr1:150340011	RPRD2	-0.58	-6.11	-0.44	7.82e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.68	-7.04	-0.5	6.05e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg22710661	chr11:17411071	KCNJ11	0.45	4.53	0.35	1.18e-5	Type 2 diabetes;
PAAD	cis	rs17407555	0.633	rs10022367	chr4:10277093	C/A	cg00071950	chr4:10020882	SLC2A9	0.49	5.16	0.39	7.46e-7	Schizophrenia (age at onset);
PAAD	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg15436174	chr10:43711423	RASGEF1A	0.56	5.22	0.39	5.88e-7	Hirschsprung disease;
PAAD	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs78761021	0.867	rs17676067	chr17:9791375	C/T	cg26853458	chr17:9805074	RCVRN	-0.71	-8.0	-0.54	2.89e-13	Type 2 diabetes;
PAAD	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.54	4.79	0.36	4.01e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6691722	0.503	rs3765425	chr1:24699872	G/C	cg18323236	chr1:24743029	NIPAL3	0.45	4.82	0.36	3.48e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-4.26	-0.33	3.57e-5	Putamen volume;
PAAD	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg14440974	chr22:39074834	NA	-0.6	-7.33	-0.51	1.27e-11	Menopause (age at onset);
PAAD	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.48	4.36	0.33	2.37e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.86	9.15	0.6	3.45e-16	Corneal astigmatism;
PAAD	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg18281939	chr5:77783895	LHFPL2	0.5	6.47	0.46	1.26e-9	Triglycerides;
PAAD	cis	rs748404	0.578	rs2012467	chr15:43690565	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.48	0.34	1.43e-5	Lung cancer;
PAAD	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.66	-6.61	-0.47	6.14e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs116248771	0.739	rs73156425	chr3:158345677	G/A	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg03115019	chr17:80708279	FN3K	0.57	5.55	0.41	1.23e-7	Glycated hemoglobin levels;
PAAD	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.51	-6.22	-0.45	4.58e-9	Sitting height ratio;
PAAD	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg11783602	chr8:55087084	NA	0.59	6.57	0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs2790216	1.000	rs1769042	chr10:59956734	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.61	-5.4	-0.4	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.65	-6.19	-0.45	5.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.13	-0.38	8.65e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	1.04	10.89	0.66	9.04e-21	Primary sclerosing cholangitis;
PAAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg01341218	chr17:43662625	NA	-0.86	-8.63	-0.57	7.61e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	4.61	0.35	8.54e-6	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg19767477	chr5:127420684	SLC12A2	-0.57	-4.55	-0.35	1.11e-5	Ileal carcinoids;
PAAD	cis	rs501120	0.584	rs1680636	chr10:44675941	G/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.76	-6.18	-0.45	5.51e-9	Coronary artery disease;
PAAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.5	-5.45	-0.4	2.02e-7	Platelet distribution width;
PAAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.48	4.48	0.34	1.43e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.49e-5	Life satisfaction;
PAAD	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.92	11.09	0.67	2.6e-21	Mean corpuscular volume;
PAAD	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12963246	chr6:28129442	ZNF389	0.58	4.57	0.35	9.95e-6	Depression;
PAAD	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	4.55	0.35	1.09e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.8	8.58	0.57	1.02e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.53	-0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg02487422	chr3:49467188	NICN1	0.44	4.43	0.34	1.76e-5	Resting heart rate;
PAAD	cis	rs10267417	0.603	rs10263094	chr7:19872801	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	4.5	0.34	1.32e-5	Night sleep phenotypes;
PAAD	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg13859433	chr6:33739653	LEMD2	-0.65	-4.54	-0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13047869	chr3:10149882	C3orf24	0.83	6.85	0.49	1.75e-10	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg13560548	chr3:10150139	C3orf24	0.57	5.14	0.39	8.21e-7	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17994379	chr17:43025264	KIF18B	0.58	6.62	0.47	5.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.84	-0.37	3.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs258892	1.000	rs258886	chr5:72303788	A/T	cg21869765	chr5:72125136	TNPO1	-0.63	-4.66	-0.35	6.75e-6	Small cell lung carcinoma;
PAAD	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-1.14	-13.24	-0.73	4.23e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg26876637	chr1:152193138	HRNR	-0.86	-6.3	-0.46	3.04e-9	Atopic dermatitis;
PAAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.51	5.02	0.38	1.4e-6	Mean corpuscular volume;
PAAD	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4903604	0.505	rs11623595	chr14:78037547	A/G	cg18872420	chr14:78023429	SPTLC2	0.42	4.42	0.34	1.87e-5	Gut microbiome composition (winter);
PAAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	cis	rs11235843	0.929	rs4944029	chr11:73407603	T/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.78	7.75	0.53	1.25e-12	Retinal vascular caliber;
PAAD	trans	rs61931739	0.649	rs2263218	chr12:33729679	C/G	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.91	10.21	0.64	5.74e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs282587	0.597	rs408247	chr13:113405738	C/A	cg02820901	chr13:113351484	ATP11A	-0.65	-4.92	-0.37	2.27e-6	Glycated hemoglobin levels;
PAAD	cis	rs1869026	0.501	rs10460459	chr2:121349751	T/C	cg20067049	chr2:121345149	NA	-0.47	-4.49	-0.34	1.41e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	2.02e-11	Dupuytren's disease;
PAAD	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.57	-0.35	1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg22710661	chr11:17411071	KCNJ11	0.44	4.28	0.33	3.33e-5	Type 2 diabetes;
PAAD	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	0.96	11.34	0.68	5.68e-22	Testicular germ cell tumor;
PAAD	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg18551225	chr6:44695536	NA	-0.72	-7.29	-0.51	1.59e-11	Total body bone mineral density;
PAAD	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	4.35	0.33	2.46e-5	Total cholesterol levels;
PAAD	cis	rs4662750	0.580	rs4662743	chr2:128350808	A/G	cg09760422	chr2:128146352	NA	-0.35	-5.14	-0.38	8.34e-7	Renal cell carcinoma;
PAAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg12311346	chr5:56204834	C5orf35	-0.62	-5.39	-0.4	2.64e-7	Coronary artery disease;
PAAD	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg26585981	chr11:48327164	OR4S1	0.5	4.44	0.34	1.72e-5	Migraine - clinic-based;
PAAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.47	5.05	0.38	1.28e-6	Lung cancer;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs12431939	0.598	rs12437085	chr14:51728941	G/T	cg23942311	chr14:51606299	NA	0.54	4.99	0.38	1.63e-6	Cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20740203	chr10:93878178	CPEB3	0.75	6.59	0.47	6.82e-10	Neuroticism;
PAAD	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.56	-4.88	-0.37	2.64e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs600626	0.529	rs11236525	chr11:75467545	C/G	cg24262691	chr11:75473276	NA	0.69	5.79	0.43	3.89e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.57	-7.79	-0.53	9.77e-13	Primary biliary cholangitis;
PAAD	cis	rs41308713	0.681	rs8116426	chr20:37034643	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.18	5.69	0.42	6.41e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg01329690	chr21:38580129	DSCR9	-0.32	-4.46	-0.34	1.6e-5	Eye color traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22569836	chr15:43028916	CDAN1	-0.78	-6.62	-0.47	5.71e-10	Neuroticism;
PAAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.94	8.38	0.56	3.31e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg03387256	chr10:90750898	FAS;ACTA2	-0.58	-6.48	-0.47	1.18e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.97e-5	Age-related disease endophenotypes;
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.41	4.54	0.35	1.14e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35000415	0.938	rs12706861	chr7:128616582	C/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21178979	chr7:1889533	MAD1L1	0.41	4.51	0.34	1.31e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg22827986	chr11:48284249	OR4X1	0.36	4.75	0.36	4.59e-6	Migraine - clinic-based;
PAAD	cis	rs216026	0.689	rs216052	chr12:2766942	A/G	cg19945202	chr12:2788847	CACNA1C	0.56	4.38	0.33	2.17e-5	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg11088901	chr6:166572345	T	-0.49	-4.51	-0.34	1.28e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.64	7.35	0.51	1.17e-11	Dupuytren's disease;
PAAD	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-4.81	-0.36	3.56e-6	Vitiligo;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.78	-0.58	3.19e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.67	6.33	0.46	2.57e-9	Asthma;
PAAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg10820045	chr2:198174542	NA	0.44	4.42	0.34	1.89e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg24220031	chr2:73402428	NA	-0.34	-4.87	-0.37	2.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-5.06	-0.38	1.19e-6	Bone mineral density (spine);
PAAD	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.67	-6.0	-0.44	1.37e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3787159	0.655	rs487769	chr20:56931055	C/T	cg15032960	chr20:56888536	RAB22A	-0.4	-4.25	-0.33	3.73e-5	Systolic blood pressure;
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.47	5.91	0.43	2.13e-8	Prostate cancer;
PAAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.76	8.97	0.59	1.01e-15	Emphysema distribution in smoking;
PAAD	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.7	0.48	3.85e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7624766	0.709	rs7642371	chr3:160493607	C/G	cg22637730	chr3:160473554	PPM1L	0.55	5.08	0.38	1.09e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs375066	0.935	rs373168	chr19:44430869	C/T	cg21496419	chr19:44306685	LYPD5	0.4	4.86	0.37	2.88e-6	Breast cancer;
PAAD	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg20243544	chr17:37824526	PNMT	-0.51	-4.79	-0.36	4.01e-6	Self-reported allergy;
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.88	-11.09	-0.67	2.58e-21	Total body bone mineral density;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21862992	chr11:68658383	NA	0.44	4.66	0.35	6.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-6.79	-0.48	2.34e-10	Lymphocyte counts;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12786490	chr17:34055277	NA	0.61	6.54	0.47	8.96e-10	Smoking initiation;
PAAD	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-4.29	-0.33	3.19e-5	Skin colour saturation;
PAAD	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.46	-0.34	1.6e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.69	0.58	5.5e-15	Rheumatoid arthritis;
PAAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg20003494	chr4:90757398	SNCA	-0.65	-6.07	-0.44	9.86e-9	Neuroticism;
PAAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.49	-6.23	-0.45	4.33e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.06	-0.38	1.18e-6	Life satisfaction;
PAAD	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.27	17.42	0.82	4.82e-38	Schizophrenia;
PAAD	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.61	5.59	0.41	1.01e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.8	4.83	0.36	3.28e-6	Obesity-related traits;
PAAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg00944433	chr1:107599041	PRMT6	0.42	4.66	0.35	6.83e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg00012203	chr2:219082015	ARPC2	0.6	5.79	0.43	3.82e-8	Colorectal cancer;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg10110953	chr20:30865763	KIF3B	-0.59	-6.59	-0.47	6.63e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.89	7.6	0.52	2.89e-12	IgG glycosylation;
PAAD	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.62	6.24	0.45	4.11e-9	Testicular germ cell tumor;
PAAD	cis	rs1468734	0.929	rs12925484	chr16:5006524	C/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.53	-4.39	-0.34	2.12e-5	Cancer;
PAAD	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-5.5	-0.41	1.55e-7	Personality dimensions;
PAAD	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.73	6.91	0.49	1.24e-10	Obesity-related traits;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21621759	chr6:90348302	LYRM2	0.4	4.41	0.34	1.93e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.46	3.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.56	-6.22	-0.45	4.52e-9	Longevity;
PAAD	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.3	-0.51	1.52e-11	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg00071950	chr4:10020882	SLC2A9	-0.68	-6.3	-0.45	3.08e-9	Schizophrenia (age at onset);
PAAD	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.54	5.74	0.42	4.99e-8	Red blood cell count;
PAAD	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg14583973	chr4:3374767	RGS12	0.39	6.09	0.44	8.93e-9	Serum sulfate level;
PAAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg24053715	chr22:38214548	NA	0.61	6.05	0.44	1.09e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.89	10.59	0.65	5.76e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.42	-4.92	-0.37	2.19e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.9	8.53	0.57	1.36e-14	Response to diuretic therapy;
PAAD	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17376030	chr22:41985996	PMM1	0.64	4.57	0.35	1e-5	Vitiligo;
PAAD	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.25	0.33	3.65e-5	Height;
PAAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.01	-0.49	7.19e-11	Gut microbiome composition (summer);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.88	-9.74	-0.62	1.02e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2885056	0.891	rs73016785	chr19:10688939	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.48	-7.99	-0.54	3.05e-13	Mean corpuscular volume;
PAAD	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.15	10.44	0.65	1.45e-19	Lymphocyte percentage of white cells;
PAAD	cis	rs9652601	0.691	rs12917716	chr16:11189148	G/C	cg04616529	chr16:11181986	CLEC16A	0.39	4.65	0.35	7.03e-6	Systemic lupus erythematosus;
PAAD	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.61	-7.06	-0.5	5.58e-11	Testicular germ cell tumor;
PAAD	cis	rs1198430	0.562	rs7522616	chr1:23794914	A/G	cg19827787	chr1:23763612	ASAP3	0.48	4.44	0.34	1.74e-5	Total cholesterol levels;
PAAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.97	9.43	0.61	6.69e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-4.59	-0.35	9.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00809820	chr17:80708513	TBCD;FN3K	-0.45	-4.39	-0.34	2.07e-5	Glycated hemoglobin levels;
PAAD	cis	rs11696501	0.843	rs6065830	chr20:44141024	T/G	cg11783356	chr20:44313418	WFDC10B	-0.67	-5.94	-0.43	1.89e-8	Brain structure;
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.84	-12.7	-0.72	1.17e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16784566	chr4:3514627	LRPAP1	0.58	6.9	0.49	1.3e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.13	0.55	1.41e-13	Menopause (age at onset);
PAAD	cis	rs17461620	1.000	rs11791066	chr9:88869630	A/G	cg13456106	chr9:88897068	ISCA1	-0.61	-4.35	-0.33	2.48e-5	Diisocyanate-induced asthma;
PAAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.98	10.42	0.65	1.63e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.8	-7.62	-0.53	2.56e-12	Breast cancer;
PAAD	cis	rs2290402	0.536	rs2335172	chr4:855282	G/A	cg09237302	chr4:906077	GAK	-0.43	-4.57	-0.35	1e-5	Type 2 diabetes;
PAAD	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg19507638	chr5:93509721	C5orf36	-0.63	-4.26	-0.33	3.55e-5	Diabetic retinopathy;
PAAD	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.73	-7.24	-0.51	2.1e-11	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg12046867	chr14:103022105	NA	-0.63	-4.96	-0.37	1.85e-6	Platelet count;
PAAD	cis	rs375066	0.901	rs12977303	chr19:44377669	G/A	cg08633290	chr19:44405433	NA	-0.58	-5.59	-0.41	1.04e-7	Breast cancer;
PAAD	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg20503657	chr10:835505	NA	0.49	5.13	0.38	8.73e-7	Survival in rectal cancer;
PAAD	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg02404636	chr22:31891804	SFI1	0.65	5.99	0.44	1.49e-8	Colorectal cancer;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-1.03	-6.55	-0.47	8.5e-10	IgG glycosylation;
PAAD	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.57	7.73	0.53	1.36e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.92	10.09	0.63	1.18e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.67	-7.37	-0.51	1.04e-11	Blood metabolite levels;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg23131131	chr22:24373011	LOC391322	-0.57	-5.35	-0.4	3.15e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs939584	1.000	rs12476198	chr2:625347	T/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-1.02	-7.66	-0.53	2.01e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs16976116	0.901	rs28478777	chr15:55512746	G/T	cg11288833	chr15:55489084	RSL24D1	0.58	4.44	0.34	1.73e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11811982	0.793	rs11804807	chr1:227354001	C/A	cg24860534	chr1:227506868	CDC42BPA	0.51	4.99	0.38	1.62e-6	Optic disc area;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg24689585	chr15:22957012	CYFIP1	-0.67	-6.61	-0.47	6.15e-10	Primary biliary cholangitis;
PAAD	cis	rs28489187	0.706	rs2268667	chr1:85793746	A/G	cg16011679	chr1:85725395	C1orf52	-0.57	-5.46	-0.4	1.92e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.69	-0.36	6.16e-6	Glomerular filtration rate;
PAAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-9.8	-0.62	7.09e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.9	10.92	0.66	7.61e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27000687	chr8:92130454	LRRC69	0.62	6.81	0.48	2.11e-10	Smoking initiation;
PAAD	cis	rs375066	0.967	rs441344	chr19:44404682	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.53	5.42	0.4	2.25e-7	Major depressive disorder;
PAAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.62	6.62	0.47	5.66e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.65	7.24	0.51	2.12e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs78761021	0.838	rs62066054	chr17:9782028	G/A	cg26853458	chr17:9805074	RCVRN	0.67	7.72	0.53	1.46e-12	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-1.19	-7.85	-0.54	6.86e-13	Opioid sensitivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16689907	chr19:6364594	CLPP	-0.57	-6.29	-0.45	3.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg05283184	chr6:79620031	NA	-0.6	-7.64	-0.53	2.23e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg16342193	chr10:102329863	NA	-0.81	-8.99	-0.59	9.33e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg09659197	chr4:152720779	NA	0.4	5.27	0.39	4.62e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.59	6.88	0.49	1.47e-10	Dementia with Lewy bodies;
PAAD	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.48	6.07	0.44	9.61e-9	Crohn's disease;
PAAD	cis	rs17155006	0.746	rs435522	chr7:107748701	A/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-7.4	-0.51	8.61e-12	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs4841899	1.000	rs10745373	chr9:137424784	T/C	cg21123355	chr9:136844644	VAV2	0.33	4.35	0.33	2.51e-5	Stem cell factor levels;
PAAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.8	8.29	0.56	5.44e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.85	8.65	0.57	6.88e-15	Corneal astigmatism;
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.48	5.26	0.39	4.9e-7	Life satisfaction;
PAAD	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg23587288	chr2:27483067	SLC30A3	-0.71	-6.67	-0.48	4.47e-10	Blood metabolite levels;
PAAD	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg25418670	chr11:30344373	C11orf46	-0.61	-5.77	-0.42	4.23e-8	Morning vs. evening chronotype;
PAAD	cis	rs4906172	1.000	rs4906172	chr14:102454933	C/A	cg23904247	chr14:102554826	HSP90AA1	0.42	4.66	0.35	6.84e-6	Menopause (age at onset);
PAAD	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg02376097	chr19:46275166	DMPK	-0.57	-5.71	-0.42	5.7e-8	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09960727	chr20:39765952	PLCG1	0.65	6.44	0.46	1.47e-9	Obesity-related traits;
PAAD	cis	rs2952768	1.000	rs2952768	chr2:208494234	A/G	cg22329743	chr2:208688774	PLEKHM3	0.22	4.41	0.34	1.92e-5	Opioid sensitivity;
PAAD	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.89	0.43	2.36e-8	Ileal carcinoids;
PAAD	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg05805236	chr11:65401703	PCNXL3	-0.46	-5.27	-0.39	4.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg05110241	chr16:68378359	PRMT7	-1.1	-7.89	-0.54	5.54e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg12315302	chr6:26189340	HIST1H4D	0.86	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.82	-0.54	8.44e-13	Hemoglobin concentration;
PAAD	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg24179445	chr10:102496915	NA	0.56	6.04	0.44	1.12e-8	Alzheimer's disease;
PAAD	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.64	0.35	7.37e-6	Blood protein levels;
PAAD	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.49	-5.22	-0.39	5.81e-7	Metabolite levels;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.78	-8.72	-0.58	4.43e-15	Height;
PAAD	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.66	6.43	0.46	1.55e-9	Corneal astigmatism;
PAAD	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.88	7.14	0.5	3.53e-11	Obesity-related traits;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	7.52	0.52	4.33e-12	Renal function-related traits (BUN);
PAAD	cis	rs13144136	0.687	rs7677121	chr4:10654107	G/T	cg10242279	chr4:10666415	CLNK	-0.49	-6.44	-0.46	1.52e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.78	-0.42	4.13e-8	Testicular germ cell tumor;
PAAD	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	1.24	12.8	0.72	6.56e-26	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.62	5.84	0.43	3.11e-8	Menopause (age at onset);
PAAD	cis	rs3018712	0.700	rs2513295	chr11:68447893	C/T	cg02340541	chr11:68451699	GAL	-0.57	-4.57	-0.35	1.02e-5	Total body bone mineral density;
PAAD	cis	rs4455778	0.580	rs7804423	chr7:49118270	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15552239	chr22:36623087	APOL2	-0.64	-6.48	-0.47	1.24e-9	Obesity-related traits;
PAAD	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.1	14.49	0.76	1.99e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg05342682	chr7:94953680	PON1	-0.53	-4.6	-0.35	8.78e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.9	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.35	0.4	3.15e-7	Monocyte percentage of white cells;
PAAD	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.19	-0.39	6.52e-7	Joint mobility (Beighton score);
PAAD	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs13144136	0.748	rs12502077	chr4:10667802	A/C	cg10242279	chr4:10666415	CLNK	-0.37	-4.58	-0.35	9.68e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg04844267	chr4:1394941	NA	-0.4	-4.53	-0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	6.19	0.45	5.36e-9	Blood protein levels;
PAAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg04398451	chr17:18023971	MYO15A	-0.53	-5.02	-0.38	1.42e-6	Lymphocyte counts;
PAAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.33	-0.4	3.42e-7	Initial pursuit acceleration;
PAAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.41e-6	Parkinson's disease;
PAAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Menopause (age at onset);
PAAD	cis	rs74181299	0.806	rs1009360	chr2:65276049	T/C	cg20592124	chr2:65290738	CEP68	0.51	4.93	0.37	2.16e-6	Pulse pressure;
PAAD	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg25469923	chr1:4087182	NA	0.54	4.34	0.33	2.63e-5	Interleukin-17 levels;
PAAD	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Acylcarnitine levels;
PAAD	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.87	-9.14	-0.6	3.72e-16	Body mass index;
PAAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.13	-0.5	3.79e-11	Personality dimensions;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.59	4.52	0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.69	6.15	0.45	6.47e-9	Inflammatory skin disease;
PAAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg00540400	chr15:79124168	NA	-0.69	-8.78	-0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs42648	0.536	rs39270	chr7:89772626	A/T	cg27367526	chr7:89841692	STEAP2	-0.31	-4.34	-0.33	2.61e-5	Homocysteine levels;
PAAD	cis	rs59888335	0.862	rs12633364	chr3:80548364	T/G	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.21	0.55	8.64e-14	Hypertriglyceridemia;
PAAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg22338127	chr1:209979572	IRF6	0.54	4.36	0.33	2.35e-5	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13976753	chr1:24681532	GRHL3	-0.68	-6.73	-0.48	3.3e-10	Obesity-related traits;
PAAD	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.57	5.75	0.42	4.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.44	0.61	6.32e-17	Bladder cancer;
PAAD	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.89	-0.37	2.56e-6	Blood metabolite levels;
PAAD	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.59	5.58	0.41	1.1e-7	White matter hyperintensity burden;
PAAD	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-4.5	-0.34	1.37e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg22442454	chr1:209979470	IRF6	0.5	4.27	0.33	3.46e-5	Coronary artery disease;
PAAD	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.84	6.5	0.47	1.07e-9	Axial length;
PAAD	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg09127314	chr1:152161683	NA	-0.63	-4.36	-0.33	2.42e-5	Atopic dermatitis;
PAAD	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.68	7.96	0.54	3.81e-13	Metabolite levels;
PAAD	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg23254163	chr1:152506842	NA	0.62	7.1	0.5	4.57e-11	Hair morphology;
PAAD	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg15226275	chr6:116381976	FRK	0.41	7.5	0.52	4.85e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.47	4.81	0.36	3.55e-6	Red blood cell count;
PAAD	cis	rs2377058	0.924	rs76762453	chr16:89723602	G/A	cg03605463	chr16:89740564	NA	-0.62	-5.83	-0.43	3.15e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	1.02	6.73	0.48	3.24e-10	Fat distribution (HIV);
PAAD	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.41	0.34	1.98e-5	Tonsillectomy;
PAAD	cis	rs28493229	0.708	rs10407889	chr19:41161078	T/C	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.53	-5.53	-0.41	1.37e-7	Lung cancer;
PAAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg07212818	chr11:638076	DRD4	-0.77	-6.97	-0.49	8.85e-11	Systemic lupus erythematosus;
PAAD	cis	rs1419980	0.730	rs116906540	chr12:7751202	A/C	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg06815965	chr1:205818668	PM20D1	0.65	7.47	0.52	5.76e-12	Menarche (age at onset);
PAAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.59	4.88	0.37	2.71e-6	Schizophrenia;
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.8	8.68	0.58	5.84e-15	Prostate cancer;
PAAD	trans	rs901683	1.000	rs35506889	chr10:46084637	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7172971	0.638	rs7165458	chr15:42382864	A/G	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs621942	0.718	rs631249	chr11:85823284	A/G	cg07180834	chr11:85838833	NA	-0.47	-4.89	-0.37	2.59e-6	Tourette syndrome;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.01	0.38	1.47e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.49	-4.95	-0.37	1.99e-6	Mortality in heart failure;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.52	5.22	0.39	5.8e-7	Mean corpuscular volume;
PAAD	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.62	-0.35	8.12e-6	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25559849	chr10:134145543	LRRC27	0.69	7.11	0.5	4.28e-11	Obesity-related traits;
PAAD	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg17644776	chr2:200775616	C2orf69	-0.63	-4.7	-0.36	5.75e-6	Schizophrenia;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	5.47	0.41	1.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-6.98	-0.49	8.52e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	6.8	0.48	2.19e-10	Platelet count;
PAAD	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.63	-5.57	-0.41	1.15e-7	Mean corpuscular volume;
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.54	0.35	1.14e-5	IgG glycosylation;
PAAD	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03812309	chr1:46938281	NA	0.32	4.32	0.33	2.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.64	6.45	0.46	1.43e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.0	4.53	0.35	1.17e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	4.5	0.34	1.32e-5	Educational attainment (years of education);
PAAD	trans	rs4815879	1.000	rs11699124	chr20:5940278	C/T	cg22510814	chr11:68773285	MRGPRF	-1.08	-6.39	-0.46	1.89e-9	Preeclampsia;
PAAD	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg13002189	chr3:66846049	NA	0.47	4.53	0.34	1.18e-5	Type 2 diabetes;
PAAD	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.84	-9.27	-0.6	1.7e-16	Obesity-related traits;
PAAD	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg08975724	chr8:8085496	FLJ10661	0.68	6.83	0.48	1.87e-10	Triglycerides;
PAAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14180030	chr9:123475675	MEGF9	-0.48	-5.15	-0.39	7.98e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00933542	chr6:150070202	PCMT1	0.54	5.74	0.42	5.05e-8	Lung cancer;
PAAD	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg02415014	chr8:143852576	LYNX1	-0.52	-6.31	-0.46	2.89e-9	Urinary tract infection frequency;
PAAD	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.99	-0.49	8.33e-11	Psoriasis;
PAAD	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg00277334	chr10:82204260	NA	-0.53	-6.09	-0.44	8.63e-9	Sarcoidosis;
PAAD	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.67	7.64	0.53	2.21e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	1.01	5.37	0.4	2.92e-7	Body mass index;
PAAD	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.78	-8.03	-0.55	2.45e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.36	0.33	2.34e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2061333	0.500	rs2284980	chr19:44633474	T/C	cg18700516	chr19:44507157	ZNF230	-0.78	-5.44	-0.4	2.11e-7	Alzheimer's disease;
PAAD	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg00666640	chr1:248458726	OR2T12	-0.48	-4.76	-0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.35	0.6	1.06e-16	Response to antipsychotic treatment;
PAAD	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.6	6.05	0.44	1.07e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.51	-0.41	1.51e-7	Alcohol dependence;
PAAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.86	10.27	0.64	3.99e-19	Menopause (age at onset);
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	0.98	6.61	0.47	6.01e-10	IgG glycosylation;
PAAD	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.76	0.48	2.77e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg26071806	chr7:100318239	EPO	-0.5	-4.99	-0.38	1.61e-6	Other erythrocyte phenotypes;
PAAD	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.88	-9.78	-0.62	8.07e-18	Obesity-related traits;
PAAD	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg25382128	chr12:54346509	NA	-0.45	-4.56	-0.35	1.06e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg18769074	chr3:133464867	TF	0.42	4.79	0.36	3.86e-6	Iron status biomarkers;
PAAD	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs17407555	0.683	rs6823180	chr4:10275831	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	4.43	0.34	1.76e-5	Schizophrenia (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03313700	chr2:157172795	NA	-0.6	-6.6	-0.47	6.31e-10	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.77	0.36	4.28e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11245990	chr11:68621969	NA	0.38	4.98	0.37	1.72e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs727479	0.502	rs4775932	chr15:51498539	A/G	cg21478137	chr15:51532386	CYP19A1	0.48	4.89	0.37	2.57e-6	Estradiol levels;
PAAD	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.49	5.07	0.38	1.15e-6	Social autistic-like traits;
PAAD	cis	rs12612619	0.732	rs2304681	chr2:27315252	G/A	cg00617064	chr2:27272375	NA	0.5	5.17	0.39	7.37e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs490234	0.812	rs2416971	chr9:128466113	A/G	cg14078157	chr9:128172775	NA	-0.45	-5.16	-0.39	7.74e-7	Mean arterial pressure;
PAAD	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.95	0.37	1.94e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg04705435	chr11:17411270	KCNJ11	-0.47	-4.5	-0.34	1.37e-5	Type 2 diabetes;
PAAD	cis	rs3996993	0.780	rs2290758	chr6:52662153	G/A	cg20803780	chr6:52668592	GSTA1	-0.35	-4.5	-0.34	1.37e-5	Hemoglobin concentration;
PAAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08219700	chr8:58056026	NA	0.67	5.21	0.39	6.13e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9646944	0.501	rs3771158	chr2:103009894	A/G	cg20060108	chr2:102954350	IL1RL1	0.53	4.31	0.33	2.87e-5	Blood protein levels;
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg00599163	chr2:162100495	NA	0.52	7.43	0.52	7.17e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.79	6.81	0.48	2.17e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg24112000	chr20:60950667	NA	-0.46	-5.19	-0.39	6.51e-7	Pelvic organ prolapse;
PAAD	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Calcium levels;
PAAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg06115741	chr20:33292138	TP53INP2	0.63	6.33	0.46	2.59e-9	Coronary artery disease;
PAAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.79	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18800042	chr5:141238690	PCDH1	0.54	6.34	0.46	2.46e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg25204440	chr1:209979598	IRF6	0.59	4.76	0.36	4.54e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg08992911	chr2:238395768	MLPH	0.6	5.03	0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs17152411	1.000	rs61873277	chr10:126619331	C/A	cg07906193	chr10:126599966	NA	0.7	5.54	0.41	1.28e-7	Height;
PAAD	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09640425	chr7:158790006	NA	-0.5	-5.62	-0.41	8.81e-8	Facial morphology (factor 20);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24640272	chr11:68671964	MRPL21;IGHMBP2	0.6	6.46	0.46	1.32e-9	Monocyte percentage of white cells;
PAAD	trans	rs901683	1.000	rs71494791	chr10:45978331	C/T	cg14076390	chr17:34947837	DHRS11	0.93	6.81	0.48	2.08e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10267417	0.603	rs10242559	chr7:19898042	C/T	cg05791153	chr7:19748676	TWISTNB	0.67	4.73	0.36	5.1e-6	Night sleep phenotypes;
PAAD	cis	rs6976053	0.727	rs9691107	chr7:100517687	T/C	cg10426581	chr7:100472382	SRRT	0.46	4.55	0.35	1.08e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.35	-0.33	2.46e-5	Lewy body disease;
PAAD	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.4	-0.34	2.05e-5	Resting heart rate;
PAAD	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.71	5.36	0.4	3.01e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.75	8.67	0.58	6.01e-15	Lewy body disease;
PAAD	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.56	-5.86	-0.43	2.79e-8	Menopause (age at onset);
PAAD	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.03	-0.5	6.54e-11	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18204584	chr2:223185249	NA	0.58	6.91	0.49	1.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6604026	0.656	rs2774952	chr1:93355246	A/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs8018808	1.000	rs176767	chr14:77865614	A/G	cg20045696	chr14:77926864	AHSA1	0.51	4.98	0.37	1.69e-6	Myeloid white cell count;
PAAD	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.55	6.56	0.47	7.94e-10	Multiple sclerosis;
PAAD	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.91	11.12	0.67	2.19e-21	Sudden cardiac arrest;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08691740	chr5:179125478	CANX	0.58	6.55	0.47	8.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.6	-5.76	-0.42	4.43e-8	Eye color traits;
PAAD	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.91	10.93	0.66	6.81e-21	Schizophrenia;
PAAD	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13012494	chr21:47604986	C21orf56	0.48	5.08	0.38	1.07e-6	Testicular germ cell tumor;
PAAD	cis	rs17092148	0.887	rs6059919	chr20:33151545	G/T	cg16810054	chr20:33298113	TP53INP2	-0.56	-4.25	-0.33	3.68e-5	Neuroticism;
PAAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.74	8.54	0.57	1.28e-14	Methadone dose in opioid dependence;
PAAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg09471204	chr22:42347991	LOC339674	-0.36	-4.61	-0.35	8.3e-6	Cognitive function;
PAAD	cis	rs17338417	0.590	rs75294059	chr13:115079045	C/A	cg16085744	chr13:114744531	NA	-0.77	-4.3	-0.33	3.1e-5	Prudent dietary pattern;
PAAD	cis	rs501120	1.000	rs554565	chr10:44755448	G/A	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	0.85	6.74	0.48	3.1e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg09839279	chr12:125627357	AACS	-0.48	-4.61	-0.35	8.47e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.03	-0.38	1.36e-6	Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.56	-5.49	-0.41	1.63e-7	Prudent dietary pattern;
PAAD	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.89	4.77	0.36	4.27e-6	Childhood ear infection;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg24398023	chr3:49449349	RHOA;TCTA	-0.61	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26926768	chr12:34528122	NA	-0.38	-4.57	-0.35	9.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.54	0.35	1.12e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18699730	chr10:101086115	NA	-0.56	-6.45	-0.46	1.44e-9	Obesity-related traits;
PAAD	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-4.49	-0.34	1.4e-5	Blood protein levels;
PAAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg27087555	chr16:88793112	FAM38A	-1.27	-8.7	-0.58	5.02e-15	Plateletcrit;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg05309399	chr4:106552544	FLJ20184	-0.54	-4.28	-0.33	3.34e-5	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03634887	chr16:66730948	CMTM4	0.65	7.55	0.52	3.8e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7188861	0.510	rs35307035	chr16:11402908	G/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.97	8.24	0.56	7.23e-14	IgG glycosylation;
PAAD	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg06496078	chr12:107350075	C12orf23	-0.46	-4.58	-0.35	9.61e-6	Total body bone mineral density;
PAAD	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.82	-7.39	-0.51	8.92e-12	Blood pressure (smoking interaction);
PAAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg07703079	chr11:430292	ANO9	0.91	5.71	0.42	5.67e-8	Body mass index;
PAAD	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.67	0.42	6.98e-8	Body mass index;
PAAD	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.74e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.61	6.39	0.46	1.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.9	10.99	0.67	4.82e-21	Coronary artery disease;
PAAD	cis	rs7614311	0.639	rs73119035	chr3:63993966	A/G	cg11282156	chr3:63428840	SYNPR	-0.57	-4.33	-0.33	2.71e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27006027	chr19:33165562	ANKRD27;RGS9BP	0.58	6.46	0.46	1.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg15331088	chr8:600555	NA	0.62	4.29	0.33	3.17e-5	IgG glycosylation;
PAAD	cis	rs1364705	1.000	rs12676931	chr8:120279927	A/C	cg09273054	chr8:120220131	MAL2	-0.47	-5.37	-0.4	2.96e-7	Hippocampal atrophy;
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.64	6.5	0.47	1.1e-9	Multiple sclerosis;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.9	-12.37	-0.71	9.03e-25	Prudent dietary pattern;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.45	-5.12	-0.38	9.1e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	2.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.81	-9.46	-0.61	5.64e-17	DNA methylation (variation);
PAAD	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg20169779	chr10:135381914	SYCE1	-0.45	-4.66	-0.35	7e-6	Obesity-related traits;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.52	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	trans	rs9409082	0.748	rs59846341	chr9:108933239	T/A	cg07010948	chr13:79181613	NA	-0.35	-6.54	-0.47	9.04e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16807097	chr12:56660896	COQ10A	0.57	6.36	0.46	2.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.48	-4.35	-0.33	2.48e-5	Vitiligo;
PAAD	cis	rs3892630	0.500	rs35170371	chr19:33355081	G/A	cg16174234	chr19:33463305	C19orf40;CCDC123	-0.52	-4.42	-0.34	1.86e-5	Red blood cell traits;
PAAD	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.81	-6.22	-0.45	4.67e-9	Obesity;Body mass index;
PAAD	cis	rs7534824	0.625	rs12563134	chr1:101468558	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.67	-4.68	-0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs11825685	0.775	rs115695236	chr11:134569427	A/T	cg02089395	chr11:134479357	NA	-0.69	-4.53	-0.34	1.19e-5	IgG glycosylation;
PAAD	cis	rs4234284	0.965	rs13095826	chr3:126942965	T/G	cg27326032	chr3:127006922	NA	-0.44	-4.36	-0.33	2.38e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.18	0.39	7e-7	Tonsillectomy;
PAAD	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.7	7.66	0.53	2.06e-12	Prostate cancer;
PAAD	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26926768	chr12:34528122	NA	0.37	4.32	0.33	2.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs3931020	0.772	rs1409785	chr1:75248122	G/A	cg26752657	chr1:75199075	CRYZ;TYW3	0.49	4.75	0.36	4.57e-6	Resistin levels;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg00035636	chr13:21900591	NA	0.61	6.21	0.45	4.73e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg08566640	chr11:64091735	NA	0.59	6.62	0.47	5.74e-10	Height;
PAAD	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.83	7.06	0.5	5.68e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs795484	1.000	rs795484	chr12:118589862	T/C	cg16572268	chr12:118583242	PEBP1	-0.5	-4.92	-0.37	2.27e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs922692	1.000	rs72743199	chr15:78975855	A/T	cg00540400	chr15:79124168	NA	-0.45	-5.0	-0.38	1.55e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.07	-0.67	2.98e-21	Total body bone mineral density;
PAAD	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs6460942	0.597	rs76749787	chr7:12172960	C/T	cg20607287	chr7:12443886	VWDE	-0.6	-4.33	-0.33	2.7e-5	Coronary artery disease;
PAAD	cis	rs7011049	1.000	rs72643599	chr8:53854434	A/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg18827107	chr12:86230957	RASSF9	0.4	4.26	0.33	3.52e-5	Major depressive disorder;
PAAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs60154123	1.000	rs12138216	chr1:210480361	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.23	0.39	5.41e-7	Coronary artery disease;
PAAD	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.67	8.79	0.58	2.92e-15	Birth weight;
PAAD	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg13271783	chr10:134563150	INPP5A	-0.4	-4.58	-0.35	9.46e-6	Gait speed in old age;
PAAD	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.75e-5	Systolic blood pressure;
PAAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg00999904	chr2:3704751	ALLC	-0.41	-4.62	-0.35	8.21e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	5.33	0.4	3.53e-7	Joint mobility (Beighton score);
PAAD	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg10729496	chr3:10149963	C3orf24	0.91	6.88	0.49	1.47e-10	Alzheimer's disease;
PAAD	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.55	-5.84	-0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs58521262	0.530	rs289352	chr19:23145270	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs9810890	1.000	rs73196987	chr3:128453382	A/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	trans	rs6726292	0.690	rs77090785	chr2:55137822	A/G	cg01624197	chr14:92252480	TC2N	-0.59	-6.52	-0.47	9.96e-10	Obesity (extreme);
PAAD	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	8.51	0.57	1.52e-14	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg12215294	chr3:40350768	EIF1B	0.49	4.77	0.36	4.29e-6	Renal cell carcinoma;
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg12310025	chr6:25882481	NA	-0.53	-4.36	-0.33	2.35e-5	Iron status biomarkers;
PAAD	cis	rs4356203	0.905	rs7946010	chr11:17176057	G/A	cg15432903	chr11:17409602	KCNJ11	0.44	4.53	0.35	1.16e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.82	-8.72	-0.58	4.65e-15	DNA methylation (variation);
PAAD	cis	rs2274459	1.000	rs12189725	chr6:33703394	G/T	cg06253072	chr6:33679850	C6orf125	0.61	4.71	0.36	5.45e-6	Obesity (extreme);
PAAD	cis	rs4690686	1.000	rs4690686	chr4:177242959	C/T	cg17059388	chr4:177262070	NA	0.46	4.45	0.34	1.64e-5	Essential tremor;
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.6	-0.35	8.74e-6	Obesity-related traits;
PAAD	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.48e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2725236	0.520	rs6838095	chr4:88909436	C/T	cg23656380	chr20:60877581	ADRM1	-0.61	-6.3	-0.46	2.98e-9	Caffeine consumption;
PAAD	cis	rs13011075	0.529	rs13005709	chr2:68629900	T/A	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.58	7.69	0.53	1.67e-12	Primary biliary cholangitis;
PAAD	cis	rs9463078	0.625	rs538801	chr6:44875762	A/T	cg25276700	chr6:44698697	NA	0.54	6.1	0.44	8.24e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg08856118	chr10:27389908	ANKRD26	-0.4	-4.31	-0.33	2.88e-5	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23858731	chr12:76117668	NA	-0.54	-6.56	-0.47	8.1e-10	Monocyte percentage of white cells;
PAAD	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.75	4.77	0.36	4.28e-6	Optic nerve measurement (cup area);
PAAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.95	-0.37	1.91e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Subjective well-being;
PAAD	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.49	5.12	0.38	9.07e-7	Type 2 diabetes;
PAAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg12639453	chr1:2035780	PRKCZ	0.52	5.49	0.41	1.66e-7	Height;
PAAD	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.97	11.48	0.68	2.37e-22	Breast cancer;
PAAD	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg22705602	chr4:152727874	NA	-0.42	-4.27	-0.33	3.44e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.59	-6.87	-0.49	1.51e-10	Lung cancer;
PAAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.8	9.01	0.59	7.92e-16	Schizophrenia;
PAAD	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26926768	chr12:34528122	NA	0.4	4.85	0.37	3.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.35	-0.4	3.15e-7	P wave terminal force;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04723886	chr5:1468204	LPCAT1	0.58	6.65	0.47	4.85e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11135910	0.680	rs7835900	chr8:25922078	A/G	cg24923694	chr8:25905747	NA	0.35	4.25	0.33	3.77e-5	Prostate cancer;
PAAD	cis	rs747650	0.532	rs4587689	chr11:47129854	A/C	cg19486271	chr11:47235900	DDB2	0.69	6.51	0.47	1.03e-9	Acne (severe);
PAAD	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-5.84	-0.43	3e-8	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.27	0.39	4.52e-7	Major depressive disorder;
PAAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.88	-10.58	-0.65	6.14e-20	Total body bone mineral density;
PAAD	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1113500	0.548	rs6583062	chr1:108656463	G/A	cg06207961	chr1:108661230	NA	0.45	4.51	0.34	1.3e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs59888335	0.964	rs10511108	chr3:80714827	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg24634471	chr8:143751801	JRK	-0.52	-4.97	-0.37	1.81e-6	Urinary tract infection frequency;
PAAD	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.79	9.04	0.59	6.74e-16	Breast cancer;
PAAD	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.59	-7.23	-0.51	2.17e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07450135	chr3:13521524	HDAC11	0.74	7.78	0.53	1.01e-12	Obesity-related traits;
PAAD	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.56	5.52	0.41	1.43e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg23254163	chr1:152506842	NA	0.59	6.86	0.49	1.65e-10	Hair morphology;
PAAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.47	5.84	0.43	3e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10214930	0.697	rs12700822	chr7:27645426	G/T	cg22168087	chr7:27702803	HIBADH	0.48	4.5	0.34	1.37e-5	Hypospadias;
PAAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.66	-5.37	-0.4	2.94e-7	Obesity (extreme);
PAAD	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.88	-10.88	-0.66	9.35e-21	Sudden cardiac arrest;
PAAD	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.75	-0.66	2.15e-20	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg15383120	chr6:291909	DUSP22	-0.65	-7.05	-0.5	5.72e-11	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg14008862	chr17:28927542	LRRC37B2	0.79	5.37	0.4	2.9e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1864585	0.660	rs73208788	chr8:10679096	C/G	cg07969676	chr8:10590641	NA	0.56	4.54	0.35	1.15e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	1.07	14.87	0.77	1.86e-31	Breast cancer;
PAAD	trans	rs7172971	0.688	rs75734921	chr15:42386630	G/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01585852	chr22:24235823	MIF	-0.44	-4.74	-0.36	4.8e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs58521262	0.556	rs2173179	chr19:23195094	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg27494647	chr7:150038898	RARRES2	0.43	4.48	0.34	1.47e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09970590	chr15:37379321	MEIS2	0.54	6.78	0.48	2.52e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg20761395	chr17:511517	VPS53	-0.72	-7.19	-0.5	2.73e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-5.62	-0.41	8.76e-8	Ulcerative colitis;
PAAD	cis	rs9866391	0.679	rs9857275	chr3:141078188	C/A	cg00789793	chr3:141329863	RASA2	0.53	4.49	0.34	1.42e-5	Myopia;
PAAD	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.62	6.01	0.44	1.33e-8	Lymphocyte counts;
PAAD	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.8	-0.53	9.16e-13	Total cholesterol levels;
PAAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.81	9.79	0.62	7.46e-18	N-glycan levels;
PAAD	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg08992911	chr2:238395768	MLPH	0.52	5.4	0.4	2.55e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.13	0.38	8.62e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	1.11	12.69	0.72	1.25e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg21483461	chr5:81570383	RPS23	0.52	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg05250797	chr16:70222502	NA	0.83	6.37	0.46	2.14e-9	IgE levels;
PAAD	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-6.28	-0.45	3.4e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.45	4.89	0.37	2.56e-6	Triglycerides;
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.16	-0.39	7.76e-7	Mortality in heart failure;
PAAD	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg05425664	chr17:57184151	TRIM37	-0.53	-4.61	-0.35	8.37e-6	Testicular germ cell tumor;
PAAD	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	ch.8.33884649F	chr8:33765107	NA	0.6	6.01	0.44	1.32e-8	Body mass index;
PAAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs9595066	0.548	rs9562537	chr13:44755787	G/A	cg04068111	chr13:44716778	NA	-0.51	-5.56	-0.41	1.2e-7	Schizophrenia;
PAAD	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.92	-0.49	1.17e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg16898833	chr6:26189333	HIST1H4D	0.78	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.71	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.84	0.37	3.18e-6	Lung cancer;
PAAD	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.7	-0.36	5.82e-6	Menarche (age at onset);
PAAD	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs227833	0.739	rs663933	chr6:44660748	A/G	cg20913747	chr6:44695427	NA	0.47	4.99	0.38	1.6e-6	Monobrow;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.83	9.1	0.59	4.72e-16	Prostate cancer;
PAAD	trans	rs2230624	1.000	rs76823085	chr1:11883548	A/T	cg23654206	chr19:3683811	PIP5K1C	-0.86	-6.32	-0.46	2.75e-9	Mosquito bite size;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13198984	chr17:80129470	CCDC57	-0.4	-4.78	-0.36	4.1e-6	Life satisfaction;
PAAD	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.73	7.24	0.51	2.14e-11	Corneal astigmatism;
PAAD	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.56	-7.02	-0.49	7.03e-11	Lewy body disease;
PAAD	cis	rs1942	0.785	rs10851404	chr15:41634070	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.61	-7.06	-0.5	5.47e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs16975963	0.843	rs73041004	chr19:38263430	T/C	cg14218481	chr19:38281219	NA	0.44	4.66	0.35	6.78e-6	Longevity;
PAAD	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs367943	0.712	rs255861	chr5:112745327	G/A	cg12552261	chr5:112820674	MCC	0.66	6.73	0.48	3.2e-10	Type 2 diabetes;
PAAD	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2599510	0.811	rs2710628	chr2:32758353	A/C	cg02381751	chr2:32503542	YIPF4	0.51	5.29	0.39	4.14e-7	Interleukin-18 levels;
PAAD	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs4343996	1.000	rs6959702	chr7:3356286	G/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.14	-0.38	8.24e-7	Motion sickness;
PAAD	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg23920097	chr1:209922102	NA	-0.48	-4.33	-0.33	2.69e-5	Red blood cell count;
PAAD	cis	rs9658691	0.607	rs9658786	chr10:90776349	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.58	4.47	0.34	1.49e-5	Mosquito bite size;
PAAD	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.16e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.9	0.43	2.24e-8	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26151000	chr1:35450650	NA	0.59	6.5	0.47	1.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7550636	0.808	rs3900531	chr1:192814574	A/C	cg05576974	chr1:193028138	TROVE2;UCHL5	0.47	4.28	0.33	3.26e-5	Coronary artery calcification;
PAAD	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.4	-0.46	1.8e-9	Breast cancer;
PAAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg04450456	chr4:17643702	FAM184B	-0.48	-5.0	-0.38	1.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.62	5.58	0.41	1.08e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.23	0.39	5.62e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	1.04	12.67	0.72	1.42e-25	Breast cancer;
PAAD	cis	rs8105895	0.935	rs62110988	chr19:22259956	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs57994353	0.667	rs11145930	chr9:139304016	C/T	cg21253087	chr9:139290292	SNAPC4	0.49	4.59	0.35	9.17e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg11993925	chr19:44307056	LYPD5	0.5	6.7	0.48	3.86e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.44	4.54	0.35	1.15e-5	Pulmonary function;
PAAD	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs1800469	0.965	rs11668109	chr19:41863777	A/C	cg09537434	chr19:41945824	ATP5SL	-0.54	-4.99	-0.38	1.63e-6	Colorectal cancer;
PAAD	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg25753631	chr6:25732923	NA	-0.43	-4.63	-0.35	7.89e-6	Iron status biomarkers;
PAAD	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-1.01	-12.96	-0.72	2.45e-26	Refractive error;
PAAD	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.41	0.51	8.36e-12	Mean platelet volume;
PAAD	cis	rs10861342	1.000	rs2888841	chr12:105493750	C/T	cg23923672	chr12:105501055	KIAA1033	0.76	4.43	0.34	1.76e-5	IgG glycosylation;
PAAD	trans	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg01620082	chr3:125678407	NA	-1.12	-6.48	-0.47	1.22e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22580275	chr10:816999	NA	-0.74	-8.73	-0.58	4.21e-15	Obesity-related traits;
PAAD	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	4.74	0.36	4.88e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6681460	0.866	rs996123	chr1:67025343	T/C	cg02459107	chr1:67143332	SGIP1	0.75	6.86	0.49	1.63e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs2594989	0.943	rs4365605	chr3:11452793	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-4.33	-0.33	2.75e-5	Circulating chemerin levels;
PAAD	cis	rs2457480	0.852	rs61857485	chr10:44719292	C/T	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;
PAAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg03983715	chr16:68378420	PRMT7	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.51	-5.62	-0.41	8.77e-8	Testicular germ cell tumor;
PAAD	cis	rs4740619	0.619	rs1887666	chr9:16032313	C/T	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.62	5.28	0.39	4.36e-7	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.68	0.58	5.8e-15	Platelet count;
PAAD	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.73	-7.61	-0.53	2.72e-12	Type 2 diabetes;
PAAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	1.15	13.51	0.74	8.21e-28	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10992558	chr1:95369272	CNN3	-0.7	-7.51	-0.52	4.66e-12	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.15	-13.64	-0.74	3.68e-28	Type 1 diabetes nephropathy;
PAAD	cis	rs7259965	0.839	rs11083595	chr19:41489004	G/C	cg20630647	chr19:41531805	NA	0.51	4.67	0.35	6.44e-6	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	0.96	7.02	0.49	7.04e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17482712	chr5:218077	CCDC127;SDHA	-0.52	-6.51	-0.47	1.04e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	5.31	0.4	3.86e-7	Mood instability;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18364779	chr6:26104403	HIST1H4C	0.44	4.43	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs258892	0.895	rs153320	chr5:72138452	C/T	cg21869765	chr5:72125136	TNPO1	-0.76	-5.18	-0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-4.96	-0.37	1.84e-6	Subjective well-being;
PAAD	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg24687543	chr11:63912206	MACROD1	-0.53	-4.76	-0.36	4.46e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09078754	chr16:22387754	NA	0.62	6.78	0.48	2.45e-10	Smoking initiation;
PAAD	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg25233709	chr10:116636983	FAM160B1	0.45	5.74	0.42	4.92e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg22546130	chr22:19950026	COMT	-0.33	-5.16	-0.39	7.52e-7	Blood metabolite levels;
PAAD	trans	rs61931739	0.620	rs61927753	chr12:33699277	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.48	-0.52	5.62e-12	Morning vs. evening chronotype;
PAAD	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.6	4.91	0.37	2.34e-6	Lung function (FEV1/FVC);
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg02696790	chr15:75250997	RPP25	0.36	4.3	0.33	3.08e-5	Breast cancer;
PAAD	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs6499129	1.000	rs9933206	chr16:67539022	C/T	cg10189135	chr16:67516162	ATP6V0D1	0.58	4.51	0.34	1.26e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.53	5.03	0.38	1.39e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1413885	0.525	rs1334878	chr1:65846124	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.79	0.36	4e-6	Anticoagulant levels;
PAAD	cis	rs7172971	0.688	rs79897861	chr15:42381832	T/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21545522	chr1:205238299	TMCC2	0.48	4.28	0.33	3.32e-5	Red blood cell count;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.52	-0.41	1.45e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg19337854	chr7:99768885	GPC2	-0.49	-5.11	-0.38	9.59e-7	Coronary artery disease;
PAAD	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.68	7.12	0.5	4.11e-11	Height;
PAAD	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg14169450	chr9:139327907	INPP5E	0.6	6.2	0.45	5.15e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs76533333	0.607	rs34809726	chr13:113386338	G/A	cg02820901	chr13:113351484	ATP11A	-0.75	-4.56	-0.35	1.04e-5	Red cell distribution width;
PAAD	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-5.5	-0.41	1.54e-7	High light scatter reticulocyte count;
PAAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs287982	0.932	rs9973654	chr2:9962568	C/A	cg01119585	chr2:10571959	NA	0.42	4.65	0.35	7.18e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.32	-0.33	2.81e-5	Menopause (age at onset);
PAAD	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs7243821	1.000	rs8092207	chr18:52647161	T/G	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.93	8.32	0.56	4.57e-14	Obesity-related traits;
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg03060546	chr3:49711283	APEH	0.54	5.37	0.4	2.91e-7	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg09317036	chr8:144635547	GSDMD	0.48	4.34	0.33	2.58e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	4.42	0.34	1.83e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.56	-6.73	-0.48	3.26e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07157834	chr1:205819609	PM20D1	0.59	5.78	0.42	4.01e-8	Parkinson's disease;
PAAD	cis	rs8060686	0.668	rs255048	chr16:68012849	C/T	cg09835421	chr16:68378352	PRMT7	-0.99	-5.59	-0.41	1.01e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.79	0.42	3.98e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs89107	0.967	rs4946333	chr6:118565665	A/G	cg21191810	chr6:118973309	C6orf204	-0.42	-5.54	-0.41	1.29e-7	Cardiac structure and function;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.45	-4.83	-0.37	3.23e-6	Bipolar disorder;
PAAD	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.55	8.03	0.55	2.48e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs227833	0.955	rs227836	chr6:44682740	C/G	cg20913747	chr6:44695427	NA	0.56	5.69	0.42	6.28e-8	Monobrow;
PAAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg11764359	chr7:65958608	NA	0.8	5.51	0.41	1.51e-7	Diabetic kidney disease;
PAAD	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.66	0.35	6.74e-6	Electroencephalogram traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06445916	chr8:42268472	NA	0.56	6.41	0.46	1.77e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.96	-0.37	1.84e-6	Diabetic retinopathy;
PAAD	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.81	-6.08	-0.44	9.48e-9	Atopic dermatitis;
PAAD	cis	rs12801636	0.557	rs3741378	chr11:65408937	C/T	cg24147428	chr11:65409760	SIPA1	-0.53	-4.29	-0.33	3.17e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.59	-6.63	-0.47	5.62e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.64	4.91	0.37	2.29e-6	Coronary artery disease;
PAAD	cis	rs75920871	1.000	rs7934763	chr11:116792357	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.79	-4.48	-0.34	1.44e-5	Subjective well-being;
PAAD	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.64	-6.54	-0.47	8.66e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-6.43	-0.46	1.56e-9	Body mass index (adult);
PAAD	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg10183150	chr4:120222239	C4orf3	-0.41	-5.76	-0.42	4.54e-8	Corneal astigmatism;
PAAD	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.88e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1014246	0.826	rs7921785	chr10:118470658	G/C	cg14471191	chr10:117818509	GFRA1	0.38	4.34	0.33	2.54e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7534824	0.625	rs7414132	chr1:101526413	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.61	0.35	8.61e-6	Refractive astigmatism;
PAAD	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg22143635	chr11:980567	AP2A2	-0.52	-5.56	-0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs9283706	0.548	rs10044452	chr5:66302605	C/T	cg11590213	chr5:66331682	MAST4	0.56	4.56	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs13144136	0.687	rs11723092	chr4:10651891	G/A	cg10242279	chr4:10666415	CLNK	-0.49	-6.31	-0.46	2.87e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20823026	chr2:366113	NA	-0.63	-6.32	-0.46	2.73e-9	Obesity-related traits;
PAAD	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	6.84	0.49	1.81e-10	Body mass index (adult);
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.83	-10.37	-0.64	2.25e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.68	-6.38	-0.46	2.07e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	-0.57	-5.14	-0.38	8.24e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs2492906	0.600	rs2637332	chr10:28067196	G/A	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.86	0.37	2.94e-6	Alzheimer's disease;
PAAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.53	-0.34	1.19e-5	Alcohol dependence;
PAAD	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.5	6.63	0.47	5.48e-10	Thyroid hormone levels;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	8.16e-9	Lung cancer;
PAAD	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.84	6.71	0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs1015291	0.708	rs2638401	chr12:20006985	C/T	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.86	7.77	0.53	1.06e-12	Coronary artery disease;
PAAD	cis	rs12432203	1.000	rs72622444	chr14:51748811	C/T	cg23942311	chr14:51606299	NA	-0.78	-5.18	-0.39	6.98e-7	Cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19307543	chr8:2091425	MYOM2	-0.65	-6.7	-0.48	3.78e-10	Obesity-related traits;
PAAD	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.92e-7	Ulcerative colitis;
PAAD	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.43	4.79	0.36	3.91e-6	Refractive error;
PAAD	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.58	-6.9	-0.49	1.32e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	4.98e-7	Pulmonary function;
PAAD	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg14515779	chr1:101123966	NA	-0.53	-6.3	-0.45	3.12e-9	Monocyte count;
PAAD	cis	rs863345	0.967	rs6697568	chr1:158520466	T/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.43	-0.34	1.8e-5	Aortic root size;
PAAD	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg07828024	chr6:149772892	ZC3H12D	0.31	4.4	0.34	2.04e-5	Dupuytren's disease;
PAAD	cis	rs6688613	1.000	rs6699520	chr1:166955405	G/C	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	5.98e-6	Plateletcrit;
PAAD	cis	rs12754538	0.715	rs4440881	chr1:8689006	T/C	cg06159269	chr1:8767347	RERE	0.4	4.7	0.36	5.67e-6	Subjective well-being;
PAAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12296532	chr17:79482181	NA	0.6	6.82	0.48	2.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg08198773	chr8:1697536	NA	0.45	5.01	0.38	1.49e-6	Systolic blood pressure;
PAAD	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-1.14	-5.87	-0.43	2.6e-8	Inflammatory biomarkers;
PAAD	cis	rs6987853	0.563	rs2974312	chr8:42455846	C/T	cg09913449	chr8:42400586	C8orf40	0.52	5.82	0.43	3.33e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.67	8.15	0.55	1.21e-13	Dupuytren's disease;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-7.93	-0.54	4.45e-13	Longevity;Endometriosis;
PAAD	cis	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg21775007	chr8:11205619	TDH	0.46	4.26	0.33	3.62e-5	Neuroticism;
PAAD	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg24053715	chr22:38214548	NA	-0.57	-5.85	-0.43	2.97e-8	Glioblastoma;Glioma;
PAAD	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg11057378	chr10:81107060	PPIF	0.52	6.24	0.45	4.07e-9	Height;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg07841815	chr7:100318223	EPO	-0.48	-4.54	-0.35	1.15e-5	Other erythrocyte phenotypes;
PAAD	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10982256	0.817	rs2297815	chr9:117266965	C/T	cg12877860	chr9:117266580	DFNB31	0.43	4.34	0.33	2.6e-5	Bipolar disorder;
PAAD	cis	rs12521260	0.564	rs12523613	chr5:37872318	A/G	cg23111106	chr5:38772401	NA	0.4	4.59	0.35	9.25e-6	Asthma;
PAAD	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg08886695	chr4:3369023	RGS12	0.45	4.4	0.34	2.04e-5	Parental longevity (mother's age at death);
PAAD	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg26138144	chr22:38071188	LGALS1	0.54	5.83	0.43	3.18e-8	Fat distribution (HIV);
PAAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	6.9e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7219021	0.926	rs10468570	chr17:46862085	G/A	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.43	-0.34	1.77e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.91	10.76	0.66	2.04e-20	White blood cell count;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	1.01	12.79	0.72	6.87e-26	Developmental language disorder (linguistic errors);
PAAD	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.6	-0.35	9.03e-6	Body mass index;
PAAD	cis	rs2017305	0.915	rs1962431	chr10:70762331	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.0	-0.38	1.57e-6	Depression (quantitative trait);
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg02440177	chr19:53496695	ZNF702P	-0.67	-7.07	-0.5	5.31e-11	Psoriasis;
PAAD	cis	rs4713118	1.000	rs4713118	chr6:27676794	A/G	cg23281280	chr6:28129359	ZNF389	0.49	4.34	0.33	2.61e-5	Parkinson's disease;
PAAD	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03344030	chr19:48673649	LIG1	0.63	6.85	0.49	1.72e-10	Myopia (pathological);
PAAD	cis	rs686320	0.667	rs550015	chr11:65186348	A/G	cg21890820	chr11:65308645	LTBP3	-0.84	-5.55	-0.41	1.21e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.89	10.69	0.66	2.97e-20	Menarche (age at onset);
PAAD	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs1903068	0.819	rs10517343	chr4:56002267	T/A	cg20092376	chr4:56023423	NA	0.41	4.26	0.33	3.6e-5	Endometriosis;
PAAD	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.88	6.74	0.48	3.01e-10	Left atrial antero-posterior diameter;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7508679	0.692	rs10413734	chr19:7227871	T/G	cg09779027	chr19:7224513	INSR	-0.56	-5.6	-0.41	9.64e-8	Hypothyroidism;
PAAD	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.6	-5.41	-0.4	2.42e-7	Myeloid white cell count;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs10214930	0.647	rs6966587	chr7:27690363	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-1.07	-7.48	-0.52	5.52e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg03340356	chr1:67600835	NA	0.52	5.74	0.42	5.05e-8	Psoriasis;
PAAD	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg08029281	chr1:67600428	NA	0.47	5.82	0.43	3.37e-8	Psoriasis;
PAAD	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	1.54	9.46	0.61	5.4e-17	Age-related hearing impairment;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.51	4.92	0.37	2.19e-6	Longevity;
PAAD	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.65	6.39	0.46	1.93e-9	Corneal astigmatism;
PAAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.65	4.86	0.37	2.96e-6	Fat distribution (HIV);
PAAD	cis	rs2120243	0.874	rs2316708	chr3:157150299	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	5.6	0.41	9.96e-8	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg21951975	chr1:209979733	IRF6	0.56	5.47	0.41	1.81e-7	Coronary artery disease;
PAAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12667521	chr19:29218732	NA	0.61	5.36	0.4	3.06e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs317865	1.000	rs4635814	chr4:16151148	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.92	6.01	0.44	1.35e-8	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Electroencephalogram traits;
PAAD	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg21300403	chr2:198650112	BOLL	0.52	4.6	0.35	8.97e-6	Intracranial aneurysm;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.5	-7.33	-0.51	1.3e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg09835421	chr16:68378352	PRMT7	-1.14	-8.37	-0.56	3.47e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.54	5.13	0.38	8.7e-7	Platelet count;
PAAD	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs73206853	0.841	rs11829321	chr12:110864593	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12760731	0.623	rs7530725	chr1:178385456	G/A	cg00404053	chr1:178313656	RASAL2	0.68	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.92	-0.43	2.04e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.58	-5.97	-0.44	1.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3734905	1.000	rs73239071	chr6:170006133	A/C	cg11181693	chr6:169825345	NA	-0.83	-5.2	-0.39	6.28e-7	HIV-1 control;
PAAD	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.84	-0.37	3.15e-6	Blood pressure;
PAAD	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.72	5.24	0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg16950941	chr11:66035639	RAB1B	-0.6	-4.72	-0.36	5.38e-6	Electroencephalogram traits;
PAAD	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.81	0.36	3.64e-6	Obesity-related traits;
PAAD	cis	rs2882667	0.690	rs6596453	chr5:138151891	T/G	cg09476006	chr5:138032270	NA	-0.45	-5.67	-0.42	7.05e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.99	0.63	2.2e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.09	8.45	0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.48	4.4	0.34	2e-5	Diastolic blood pressure;
PAAD	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg16736954	chr20:23401023	NAPB	0.75	4.29	0.33	3.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.47	-4.46	-0.34	1.56e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07395648	chr5:131743802	NA	-0.51	-4.66	-0.35	6.82e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.71	-7.49	-0.52	5.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.47	-4.66	-0.35	6.8e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.74	9.0	0.59	8.49e-16	Lung cancer;
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	4.93	0.37	2.15e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg07395648	chr5:131743802	NA	0.51	4.28	0.33	3.26e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05564831	chr3:52568323	NT5DC2	0.41	4.54	0.35	1.15e-5	Electroencephalogram traits;
PAAD	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.72	6.34	0.46	2.46e-9	Platelet count;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.87	-12.96	-0.72	2.34e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg17848003	chr1:3704513	LRRC47	0.41	4.38	0.33	2.22e-5	Red cell distribution width;
PAAD	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg23018236	chr17:30244563	NA	0.58	4.8	0.36	3.78e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	0.58	5.59	0.41	1.04e-7	YKL-40 levels;
PAAD	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.27	-0.6	1.71e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6585424	0.850	rs75804987	chr10:81932509	C/T	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15369054	chr17:80825471	TBCD	0.54	5.49	0.41	1.64e-7	Breast cancer;
PAAD	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg26513180	chr16:89883248	FANCA	-0.43	-4.53	-0.34	1.19e-5	Vitiligo;
PAAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.78	9.28	0.6	1.58e-16	Emphysema distribution in smoking;
PAAD	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.3	-9.36	-0.6	1.01e-16	Blood pressure (smoking interaction);
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	5.77	0.42	4.25e-8	Mood instability;
PAAD	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09009506	chr2:28216851	BRE	0.42	4.61	0.35	8.6e-6	Body mass index;
PAAD	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.72	6.18	0.45	5.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.62	-7.67	-0.53	1.89e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.58	-5.8	-0.43	3.71e-8	Coronary artery disease;
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.35	12.77	0.72	7.83e-26	Corneal structure;
PAAD	cis	rs2133450	0.967	rs67921811	chr3:7342220	C/T	cg19930620	chr3:7340148	GRM7	-0.44	-4.6	-0.35	8.85e-6	Early response to risperidone in schizophrenia;
PAAD	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.68	-7.84	-0.54	7.4e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16209045	chr19:2328691	SPPL2B;LSM7	0.64	6.34	0.46	2.53e-9	Obesity-related traits;
PAAD	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.68	8.19	0.55	9.89e-14	Dupuytren's disease;
PAAD	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg04607699	chr11:48328132	OR4S1	0.53	5.02	0.38	1.43e-6	Migraine - clinic-based;
PAAD	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.56	4.97	0.37	1.75e-6	Life satisfaction;
PAAD	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.5	-5.36	-0.4	2.98e-7	Testicular germ cell tumor;
PAAD	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20487152	chr13:99095054	FARP1	-0.44	-4.38	-0.33	2.19e-5	Neuroticism;
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14801290	chr10:27793116	RAB18	0.59	6.5	0.47	1.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.65	-0.35	7.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg26618903	chr10:100175079	PYROXD2	-0.49	-5.07	-0.38	1.15e-6	Metabolite levels;
PAAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.63	-0.42	8.39e-8	Iron status biomarkers;
PAAD	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs11031096	0.966	rs725518	chr11:4128845	G/A	cg18678763	chr11:4115507	RRM1	0.42	4.33	0.33	2.66e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3026101	0.671	rs8066702	chr17:5310121	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.96	0.44	1.71e-8	Body mass index;
PAAD	cis	rs28493229	1.000	rs28493229	chr19:41224204	G/C	cg11601297	chr19:41224147	ITPKC;ADCK4	0.43	4.53	0.34	1.2e-5	Kawasaki disease;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg00031303	chr3:195681400	NA	0.67	6.64	0.47	5.13e-10	Pancreatic cancer;
PAAD	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.54	6.27	0.45	3.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.81	8.9	0.59	1.61e-15	Colorectal cancer;
PAAD	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.31	-0.4	3.84e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.66	-6.4	-0.46	1.82e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.98	-5.2	-0.39	6.24e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10950821	0.770	rs34603556	chr7:20691047	T/C	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.51	-0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs61677309	1.000	rs56140791	chr11:118167190	T/C	cg15548380	chr1:19984784	NBL1	-0.61	-6.42	-0.46	1.62e-9	Lung cancer in ever smokers;
PAAD	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.5	4.69	0.36	6.09e-6	Uric acid clearance;
PAAD	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10887741	0.966	rs7085195	chr10:89429897	T/C	cg13926569	chr10:89418898	PAPSS2	0.47	4.73	0.36	5.17e-6	Exercise (leisure time);
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg13699009	chr12:122356056	WDR66	-0.45	-6.61	-0.47	6.03e-10	Mean corpuscular volume;
PAAD	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg01489032	chr8:143877656	NA	0.44	4.54	0.35	1.15e-5	Urinary tract infection frequency;
PAAD	cis	rs4356203	0.905	rs7946165	chr11:17078627	T/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04717802	chr22:42394638	WBP2NL	-0.42	-4.46	-0.34	1.56e-5	Cognitive function;
PAAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.58	5.85	0.43	2.86e-8	Breast cancer;
PAAD	cis	rs1797885	0.714	rs299659	chr3:12552506	A/G	cg07775309	chr3:12595852	NA	0.4	4.39	0.34	2.12e-5	Immature fraction of reticulocytes;
PAAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.85	-10.09	-0.63	1.23e-18	Total body bone mineral density;
PAAD	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-4.33	-0.33	2.69e-5	Multiple sclerosis;
PAAD	cis	rs8067545	0.559	rs3874846	chr17:20297545	T/G	cg13482628	chr17:19912719	NA	0.56	5.33	0.4	3.56e-7	Schizophrenia;
PAAD	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg19630374	chr17:18023558	MYO15A	0.49	5.34	0.4	3.29e-7	Total body bone mineral density;
PAAD	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.45	-4.48	-0.34	1.46e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg01622416	chr21:31310508	GRIK1	-0.43	-4.35	-0.33	2.53e-5	Pancreatic cancer;
PAAD	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg27455613	chr17:80820699	TBCD	-0.47	-4.7	-0.36	5.81e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4849845	0.704	rs4848580	chr2:121001117	A/G	cg17460441	chr2:121199791	NA	0.39	4.33	0.33	2.68e-5	Mean platelet volume;
PAAD	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.64	4.51	0.34	1.29e-5	Mean platelet volume;
PAAD	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.96	8.16	0.55	1.15e-13	Body mass index;
PAAD	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.66e-7	Subjective well-being;
PAAD	cis	rs1419980	0.730	rs11054886	chr12:7772948	C/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Urinary tract infection frequency;
PAAD	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.42	-4.88	-0.37	2.68e-6	Coronary artery disease;
PAAD	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.02	0.5	6.72e-11	Lung cancer in ever smokers;
PAAD	cis	rs2814331	0.766	rs2492733	chr10:88058923	C/G	cg08962038	chr10:88022859	GRID1	-0.57	-4.26	-0.33	3.61e-5	Balding;
PAAD	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs28472312	0.667	rs3922668	chr16:28992646	G/A	cg16576597	chr16:28551801	NUPR1	-0.48	-5.11	-0.38	9.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.37	0.46	2.16e-9	Body mass index;
PAAD	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.67	6.76	0.48	2.78e-10	Tourette syndrome;
PAAD	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.29	0.51	1.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg07202610	chr7:1142643	C7orf50	-0.76	-5.33	-0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg19401529	chr3:49056140	DALRD3	0.52	4.32	0.33	2.81e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs1109501	0.734	rs28827921	chr4:71416425	T/C	cg25553522	chr4:71388589	AMTN	0.53	4.51	0.34	1.29e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.36	5.03	0.38	1.36e-6	Age at first birth;
PAAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.76	-8.39	-0.56	3.08e-14	Type 2 diabetes;
PAAD	cis	rs4072705	0.614	rs35929043	chr9:127234356	T/C	cg13476313	chr9:127244764	NR5A1	0.33	4.99	0.38	1.6e-6	Menarche (age at onset);
PAAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg24642844	chr7:1081250	C7orf50	-0.97	-5.28	-0.39	4.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.58	4.61	0.35	8.53e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.93	6.1	0.44	8.26e-9	Blood protein levels;
PAAD	cis	rs2610025	0.694	rs2610037	chr8:57443017	T/C	cg25937216	chr8:58172855	NA	0.45	4.29	0.33	3.19e-5	Suicide in bipolar disorder;
PAAD	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.86	-8.72	-0.58	4.44e-15	Exhaled nitric oxide output;
PAAD	cis	rs3018712	0.590	rs11228330	chr11:68485219	A/G	cg23009355	chr11:68451396	GAL	-0.47	-4.48	-0.34	1.48e-5	Total body bone mineral density;
PAAD	cis	rs10991814	0.557	rs773519	chr9:93944244	C/T	cg14446406	chr9:93919335	NA	-0.42	-4.84	-0.37	3.1e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-4.94	-0.37	2.05e-6	Morning vs. evening chronotype;
PAAD	cis	rs1508086	0.695	rs7004789	chr8:57805185	T/G	cg10342016	chr8:57802622	NA	-0.25	-4.39	-0.34	2.09e-5	Hand grip strength;
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.39	4.42	0.34	1.84e-5	High light scatter reticulocyte count;
PAAD	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.54	-5.36	-0.4	2.97e-7	Mean platelet volume;
PAAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-1.09	-14.33	-0.76	5.16e-30	Total body bone mineral density;
PAAD	cis	rs2286503	0.839	rs2240728	chr7:22852499	C/T	cg11367502	chr7:22862612	TOMM7	0.52	5.28	0.39	4.4e-7	Fibrinogen;
PAAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.76	-0.42	4.5e-8	Diabetic kidney disease;
PAAD	cis	rs7714584	1.000	rs1863998	chr5:150271753	A/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.58	6.72	0.48	3.43e-10	Bipolar disorder;
PAAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.01e-5	Alcohol dependence;
PAAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg26174226	chr8:58114915	NA	-0.69	-6.17	-0.45	6.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.55	6.49	0.47	1.14e-9	Monobrow;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16093752	chr17:79989682	RAC3	-0.64	-6.39	-0.46	1.96e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs804279	0.535	rs804260	chr8:11631906	A/G	cg12395012	chr8:11607386	GATA4	-0.6	-5.95	-0.43	1.77e-8	Polycystic ovary syndrome;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07946583	chr12:77158144	ZDHHC17	0.6	6.92	0.49	1.16e-10	Metabolite levels  (X-11787);
PAAD	cis	rs12144049	0.622	rs2146114	chr1:152390621	C/G	cg25605289	chr1:151974222	NA	-0.37	-4.45	-0.34	1.66e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg02640540	chr1:67518911	SLC35D1	-0.5	-4.32	-0.33	2.82e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00520393	chr6:7313623	SSR1	0.57	6.54	0.47	9.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	8.66	0.57	6.32e-15	Lymphocyte counts;
PAAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg08029281	chr1:67600428	NA	-0.44	-5.34	-0.4	3.26e-7	Psoriasis;
PAAD	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.21	0.45	4.8e-9	Body mass index;
PAAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13065560	0.562	rs6786732	chr3:38920203	C/T	cg01426195	chr3:39028469	NA	-0.51	-5.24	-0.39	5.18e-7	Interleukin-18 levels;
PAAD	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs8113142	0.581	rs4804849	chr19:29164489	A/C	cg04546413	chr19:29218101	NA	0.42	4.25	0.33	3.73e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.7	6.93	0.49	1.11e-10	Coronary artery disease;
PAAD	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-5.91	-0.43	2.18e-8	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.26	-0.39	4.87e-7	Life satisfaction;
PAAD	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26926768	chr12:34528122	NA	0.4	4.82	0.36	3.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs2288884	0.943	rs75722407	chr19:52525242	C/T	cg24368865	chr19:51538134	KLK12	0.49	4.43	0.34	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
PAAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg09324608	chr17:30823087	MYO1D	0.46	4.5	0.34	1.32e-5	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.67	5.49	0.41	1.64e-7	Prostate cancer;
PAAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.13	13.31	0.73	2.71e-27	Cognitive function;
PAAD	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Dermatomyositis;
PAAD	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg26597838	chr10:835615	NA	0.51	5.54	0.41	1.29e-7	Survival in rectal cancer;
PAAD	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg19264203	chr11:92714893	MTNR1B	-0.38	-4.45	-0.34	1.62e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.36	-4.26	-0.33	3.51e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg02732134	chr10:101732382	DNMBP	-0.65	-7.02	-0.49	7.04e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06853376	chr5:125937059	PHAX	0.59	6.31	0.46	2.97e-9	Primary biliary cholangitis;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg21724239	chr8:58056113	NA	0.67	5.15	0.39	7.94e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22009489	chr2:241075960	MYEOV2	0.56	6.33	0.46	2.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg25972092	chr12:117363249	FBXW8	0.79	6.16	0.45	6.26e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.69	-6.86	-0.49	1.63e-10	Blood metabolite levels;
PAAD	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg21951975	chr1:209979733	IRF6	0.38	4.64	0.35	7.47e-6	Monobrow;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs900145	0.906	rs1384027	chr11:13295920	A/T	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs1499972	0.941	rs62263114	chr3:117617722	T/A	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.53	-4.46	-0.34	1.6e-5	Cystic fibrosis severity;
PAAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg26536354	chr8:144654954	C8orf73	0.62	4.31	0.33	2.94e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	4.25	0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.1	0.44	8.22e-9	Height;
PAAD	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.83	5.78	0.42	4.02e-8	Migraine;Coronary artery disease;
PAAD	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg14191688	chr11:70257035	CTTN	0.56	5.18	0.39	7.05e-7	Coronary artery disease;
PAAD	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.52	5.02	0.38	1.42e-6	High light scatter reticulocyte count;
PAAD	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg07220939	chr11:64358617	SLC22A12	-0.45	-4.73	-0.36	5.07e-6	Urate levels in obese individuals;
PAAD	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02876066	chr19:18632993	ELL	-0.62	-6.4	-0.46	1.84e-9	Smoking initiation;
PAAD	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.8	0.53	9.26e-13	Motion sickness;
PAAD	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg00864171	chr11:67383662	NA	-0.49	-5.11	-0.38	9.56e-7	Mean corpuscular volume;
PAAD	cis	rs8095374	1.000	rs8095374	chr18:43793488	A/G	cg20581250	chr18:44676959	HDHD2	0.46	4.32	0.33	2.78e-5	Clinical laboratory measurements;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10788939	chr5:106956089	EFNA5	-0.51	-6.52	-0.47	1e-9	Energy expenditure (24h);
PAAD	cis	rs4679121	0.642	rs56071014	chr3:126173986	C/A	cg05485589	chr3:126194908	ZXDC	-0.88	-4.4	-0.34	2.02e-5	Pursuit maintenance gain;
PAAD	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.88	-12.78	-0.72	7.31e-26	Cystic fibrosis severity;
PAAD	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs2017305	0.831	rs117065500	chr10:70764118	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.0	-0.38	1.57e-6	Depression (quantitative trait);
PAAD	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg13446199	chr8:143762866	PSCA	0.39	4.63	0.35	7.8e-6	Urinary tract infection frequency;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03438904	chr3:197518158	LRCH3	0.67	7.29	0.51	1.61e-11	Myopia (pathological);
PAAD	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.56	0.41	1.18e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.48	-4.26	-0.33	3.52e-5	Parkinson's disease;
PAAD	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.73	6.29	0.45	3.2e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7631605	0.840	rs11915301	chr3:37133853	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.66	-0.35	6.89e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg04810063	chr16:88703634	IL17C	0.54	5.13	0.38	8.66e-7	Menopause (age at onset);
PAAD	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.09	0.44	9.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15275019	chr12:72057673	THAP2;ZFC3H1	-0.71	-6.36	-0.46	2.29e-9	Neuroticism;
PAAD	cis	rs7119038	0.818	rs4938572	chr11:118740931	C/T	cg19308663	chr11:118741387	NA	-0.65	-5.18	-0.39	6.94e-7	Sjögren's syndrome;
PAAD	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.6	7.03	0.5	6.53e-11	Aortic root size;
PAAD	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg12907477	chr18:56117327	MIR122	0.61	4.77	0.36	4.3e-6	Platelet count;
PAAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.46	-0.52	6.17e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08866402	chr21:45719804	PFKL	-0.76	-6.67	-0.48	4.51e-10	Neuroticism;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg02555727	chr12:129281546	SLC15A4	0.46	4.86	0.37	2.96e-6	Systemic lupus erythematosus;
PAAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Blood metabolite levels;
PAAD	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10174575	chr1:24932046	C1orf130	0.66	6.46	0.46	1.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-1.27	-11.22	-0.67	1.17e-21	Obesity-related traits;
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg09667013	chr22:42394590	WBP2NL	0.53	4.62	0.35	8.15e-6	Birth weight;
PAAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4740619	0.655	rs10810487	chr9:15943629	A/G	cg14451791	chr9:16040625	NA	-0.44	-5.05	-0.38	1.23e-6	Body mass index;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27297192	chr10:134578999	INPP5A	0.6	5.19	0.39	6.55e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.71	8.37	0.56	3.42e-14	Height;
PAAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.9	9.14	0.6	3.67e-16	Methadone dose in opioid dependence;
PAAD	cis	rs11264799	0.598	rs72708402	chr1:157719073	C/T	cg18268488	chr1:157545234	FCRL4	0.65	5.76	0.42	4.46e-8	IgA nephropathy;
PAAD	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-4.28	-0.33	3.32e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg17771515	chr6:154831774	CNKSR3	0.6	4.32	0.33	2.79e-5	Lipoprotein (a) levels;
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.69	-6.31	-0.46	2.91e-9	Blood metabolite levels;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg01214346	chr17:406501	NA	-0.52	-4.97	-0.37	1.76e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg15226751	chr1:10001911	LZIC	0.38	4.29	0.33	3.19e-5	Hepatocellular carcinoma;
PAAD	cis	rs3787159	0.523	rs541029	chr20:56877484	A/G	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs939584	1.000	rs7569210	chr2:631462	G/A	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.98	-0.63	2.37e-18	Vitiligo;
PAAD	trans	rs1015213	0.609	rs78422554	chr8:52879600	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg10556349	chr10:835070	NA	0.59	5.28	0.39	4.42e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.49	-5.1	-0.38	1.01e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4704187	0.687	rs1345705	chr5:74507007	C/A	cg03227963	chr5:74354835	NA	0.53	5.09	0.38	1.04e-6	Response to amphetamines;
PAAD	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-7.98	-0.54	3.31e-13	Squamous cell lung carcinoma;
PAAD	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.69	-0.36	6.01e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.5	4.71	0.36	5.52e-6	Neutrophil percentage of white cells;
PAAD	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	1.11	7.33	0.51	1.27e-11	Obesity (early onset extreme);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25934548	chr3:126736686	PLXNA1	0.58	6.92	0.49	1.19e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg14024328	chr4:719362	PCGF3	-0.57	-5.83	-0.43	3.25e-8	White blood cell count;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27527479	chr19:21324750	ZNF431	-0.68	-6.36	-0.46	2.28e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	1.11	7.8	0.53	9.29e-13	IgG glycosylation;
PAAD	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.71	6.82	0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.09	0.67	2.52e-21	Primary sclerosing cholangitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03609847	chr4:529442	PIGG	-0.62	-6.67	-0.48	4.54e-10	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25976004	chr4:56815073	CEP135	0.68	7.22	0.51	2.28e-11	Myopia (pathological);
PAAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.77	-6.46	-0.46	1.31e-9	Inflammatory skin disease;
PAAD	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs6585424	1.000	rs56190825	chr10:81934736	C/T	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg14146966	chr2:61757674	XPO1	0.42	5.28	0.39	4.48e-7	Tuberculosis;
PAAD	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.53	-0.41	1.38e-7	Personality dimensions;
PAAD	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg21174375	chr14:64681225	SYNE2	0.33	4.37	0.33	2.25e-5	Atrial fibrillation;
PAAD	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.92e-17	Electrocardiographic conduction measures;
PAAD	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-6.78	-0.48	2.46e-10	Schizophrenia (age at onset);
PAAD	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.74	9.18	0.6	2.96e-16	Height;
PAAD	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg15084286	chr11:17036142	PLEKHA7	0.54	4.84	0.37	3.16e-6	Systolic blood pressure;
PAAD	cis	rs2790216	1.000	rs1416766	chr10:59978237	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg15309053	chr8:964076	NA	0.62	7.13	0.5	3.9e-11	Schizophrenia;
PAAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.48	-5.78	-0.42	4.02e-8	Psoriasis;
PAAD	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.63	-6.65	-0.47	4.88e-10	Multiple myeloma (IgH translocation);
PAAD	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs4343996	0.747	rs7457146	chr7:3465254	A/C	cg21248987	chr7:3385318	SDK1	0.49	5.3	0.4	3.97e-7	Motion sickness;
PAAD	cis	rs7551345	0.853	rs61780773	chr1:31838253	C/T	cg17086398	chr1:31896392	SERINC2	-0.54	-4.75	-0.36	4.6e-6	Schizophrenia;
PAAD	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.82	8.5	0.57	1.62e-14	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.91	-6.24	-0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Intracranial aneurysm;
PAAD	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.48	5.86	0.43	2.73e-8	Sitting height ratio;
PAAD	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	0.33	4.29	0.33	3.15e-5	Renal function-related traits (BUN);
PAAD	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg12661370	chr5:149340060	SLC26A2	0.64	5.49	0.41	1.68e-7	HIV-1 control;
PAAD	cis	rs7945718	0.621	rs7939509	chr11:12688130	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg27490568	chr2:178487706	NA	0.43	4.53	0.35	1.16e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4742903	0.875	rs2122581	chr9:107008811	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.86	0.37	2.84e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg20406979	chr6:167373233	NA	-0.31	-4.29	-0.33	3.16e-5	Crohn's disease;
PAAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.69	-5.68	-0.42	6.57e-8	Neuroticism;
PAAD	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.58	-6.66	-0.48	4.83e-10	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.46	4.66	0.35	6.83e-6	Breast cancer;
PAAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	7.05	0.5	5.8200000000000003e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.69	-7.3	-0.51	1.48e-11	Post bronchodilator FEV1;
PAAD	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.64	6.21	0.45	4.9e-9	Hip circumference;
PAAD	cis	rs939584	1.000	rs6746275	chr2:635857	C/A	cg03610516	chr2:642275	NA	0.56	4.92	0.37	2.25e-6	Body mass index;
PAAD	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.9	-8.73	-0.58	4.32e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg20607287	chr7:12443886	VWDE	-0.72	-6.48	-0.47	1.23e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs137887	0.817	rs137888	chr22:50464496	G/A	cg23116504	chr22:50470537	TTLL8	-0.51	-4.98	-0.37	1.68e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4073221	0.654	rs13101165	chr3:18311376	T/A	cg07694806	chr3:18168406	NA	-0.62	-4.58	-0.35	9.43e-6	Parkinson's disease;
PAAD	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg18721089	chr20:30220636	NA	-0.62	-4.97	-0.37	1.79e-6	Monocyte count;
PAAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.82e-6	Biliary atresia;
PAAD	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	7.4	0.51	8.5e-12	IgG glycosylation;
PAAD	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg05868516	chr6:26286170	HIST1H4H	0.5	4.49	0.34	1.4e-5	Educational attainment;
PAAD	cis	rs5758659	0.789	rs2413684	chr22:42574830	C/T	cg15128208	chr22:42549153	NA	-0.5	-4.97	-0.37	1.82e-6	Cognitive function;
PAAD	cis	rs7824557	0.527	rs4841495	chr8:10958824	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.59	-0.35	9.09e-6	Retinal vascular caliber;
PAAD	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.26	0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.58	6.26	0.45	3.8e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.8	-5.81	-0.43	3.5e-8	Vitiligo;
PAAD	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.71	-0.36	5.66e-6	Glomerular filtration rate;
PAAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.93e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6657811	0.602	rs11577931	chr1:109820884	A/G	cg04981315	chr1:110768719	KCNC4	-0.72	-4.39	-0.34	2.08e-5	HDL cholesterol;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg21784768	chr11:537496	LRRC56	-0.82	-4.26	-0.33	3.55e-5	Body mass index;
PAAD	cis	rs6800768	0.663	rs62253424	chr3:24093919	C/A	cg10674438	chr3:24145617	LOC152024	-0.47	-4.35	-0.33	2.46e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.67	-6.76	-0.48	2.78e-10	Tourette syndrome;
PAAD	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.73	-5.95	-0.43	1.81e-8	Schizophrenia;
PAAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg25833597	chr17:30823145	MYO1D	0.55	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23018873	chr11:94501467	AMOTL1	-0.63	-6.3	-0.46	2.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-4.88	-0.37	2.7e-6	Gut microbiome composition (summer);
PAAD	cis	rs1355223	0.768	rs11032806	chr11:34692305	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.45	-4.63	-0.35	7.7e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9527	0.518	rs4633383	chr10:104795723	T/G	cg14737131	chr10:104680354	CNNM2	0.66	5.94	0.43	1.84e-8	Arsenic metabolism;
PAAD	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.85	10.79	0.66	1.65e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-5.93	-0.43	1.94e-8	Monocyte count;
PAAD	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	6.08	0.44	9.16e-9	Ileal carcinoids;
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg11601000	chr22:42348013	LOC339674	-0.4	-4.5	-0.34	1.32e-5	Cognitive function;
PAAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.64	5.32	0.4	3.71e-7	Diastolic blood pressure;
PAAD	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg23283495	chr1:209979779	IRF6	0.62	5.9	0.43	2.3e-8	Coronary artery disease;
PAAD	cis	rs10982213	1.000	rs2274161	chr9:117186027	T/C	cg00078025	chr9:117159975	NA	0.61	4.62	0.35	8.22e-6	Interleukin-6 levels;
PAAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.78	4.63	0.35	7.86e-6	Body mass index;
PAAD	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.97	8.24	0.56	7.23e-14	IgG glycosylation;
PAAD	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26224664	chr14:101693935	NA	-0.66	-7.46	-0.52	6.32e-12	Body mass index (alcohol intake interaction);
PAAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg27490568	chr2:178487706	NA	0.44	4.76	0.36	4.55e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-5.63	-0.42	8.5e-8	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12928939	0.911	rs8051878	chr16:71818431	C/G	cg03805757	chr16:71968109	PKD1L3	-0.56	-4.95	-0.37	1.91e-6	Post bronchodilator FEV1;
PAAD	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.64	7.07	0.5	5.2e-11	Coronary artery disease;
PAAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg19223190	chr17:80058835	NA	-0.54	-5.44	-0.4	2.09e-7	Life satisfaction;
PAAD	cis	rs3764400	0.567	rs12600980	chr17:46187141	C/T	cg24322968	chr17:46507895	SKAP1	-0.87	-5.3	-0.39	4.06e-7	Body mass index;
PAAD	cis	rs17169635	0.819	rs28485360	chr7:134489230	T/G	cg02516134	chr7:134575187	CALD1	-0.44	-4.47	-0.34	1.53e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg23752985	chr2:85803571	VAMP8	0.59	6.3	0.46	3.02e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.53	-4.52	-0.34	1.22e-5	Diastolic blood pressure;
PAAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-7.94	-0.54	4.17e-13	Total body bone mineral density;
PAAD	cis	rs990171	0.538	rs6543155	chr2:103114895	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.49	-0.34	1.41e-5	Lymphocyte counts;
PAAD	cis	rs13008299	1.000	rs11689927	chr2:29248604	A/T	cg07342545	chr2:28616193	FOSL2	0.48	4.33	0.33	2.71e-5	Diastolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg13406893	chr12:131568647	GPR133	-0.45	-4.46	-0.34	1.59e-5	Longevity;
PAAD	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg01578996	chr19:57752011	ZNF805	0.46	4.47	0.34	1.55e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.74	0.36	4.78e-6	Electroencephalogram traits;
PAAD	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.56	-6.71	-0.48	3.58e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.73	7.32	0.51	1.31e-11	Schizophrenia;
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.58	4.32	0.33	2.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	1.49	9.69	0.62	1.36e-17	Age-related hearing impairment;
PAAD	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.19	8.5	0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.6	-0.35	8.97e-6	Asthma;
PAAD	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.75	-9.72	-0.62	1.17e-17	Body mass index;
PAAD	cis	rs787274	1.000	rs787278	chr9:115473531	C/A	cg13803584	chr9:115635662	SNX30	0.78	4.37	0.33	2.31e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.27e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg00280220	chr17:61926910	NA	0.43	4.61	0.35	8.41e-6	Prudent dietary pattern;
PAAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.47	8.42	0.56	2.57e-14	Multiple system atrophy;
PAAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19346786	chr7:2764209	NA	-0.31	-4.29	-0.33	3.12e-5	Height;
PAAD	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.76	9.11	0.59	4.5e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg00450029	chr8:599525	NA	-0.8	-5.48	-0.41	1.74e-7	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.19	8.9	0.59	1.59e-15	Lymphocyte counts;
PAAD	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg10578991	chr7:12443926	VWDE	-0.5	-4.38	-0.33	2.17e-5	Coronary artery disease;
PAAD	cis	rs12519773	0.526	rs4551051	chr5:92518724	T/C	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.79e-5	Migraine;
PAAD	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2229238	0.911	rs4390168	chr1:154509096	A/G	cg21262032	chr1:154437693	IL6R	-0.46	-4.8	-0.36	3.81e-6	Coronary heart disease;
PAAD	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.41	-0.61	7.61e-17	Venous thromboembolism;
PAAD	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.38	8.26e-7	Serum sulfate level;
PAAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	5.11e-7	Coronary artery disease;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg08439880	chr3:133502540	NA	-0.49	-5.31	-0.4	3.76e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24468199	chr11:65410028	SIPA1	-0.52	-4.59	-0.35	9.36e-6	Blood pressure (age interaction);
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.54	5.45	0.4	2.04e-7	Bipolar disorder;
PAAD	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg14440974	chr22:39074834	NA	0.58	6.78	0.48	2.5e-10	Menopause (age at onset);
PAAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.34	-0.33	2.59e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg25164009	chr13:61490935	NA	-0.51	-5.74	-0.42	5.04e-8	Polychlorinated biphenyl levels;
PAAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7156960	1.000	rs7152893	chr14:76711185	T/G	cg13981132	chr14:76734493	NA	-0.49	-4.76	-0.36	4.44e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs112990264	1.000	rs111755419	chr1:213015210	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.43	4.81	0.36	3.57e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs375066	0.934	rs411803	chr19:44432840	C/T	cg21496419	chr19:44306685	LYPD5	-0.41	-5.03	-0.38	1.37e-6	Breast cancer;
PAAD	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.63	-6.98	-0.49	8.58e-11	Colorectal cancer;
PAAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.62	-6.71	-0.48	3.59e-10	Type 2 diabetes;
PAAD	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg18357526	chr6:26021779	HIST1H4A	0.65	6.64	0.47	5.22e-10	Height;
PAAD	cis	rs5756391	0.546	rs4821561	chr22:37311877	A/G	cg16356956	chr22:37317934	CSF2RB	-0.38	-4.62	-0.35	7.97e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg08353955	chr11:69289746	NA	0.87	6.21	0.45	4.93e-9	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.79	7.03	0.5	6.46e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg19254793	chr6:44695348	NA	-0.48	-4.49	-0.34	1.43e-5	Total body bone mineral density;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg02869306	chr7:64672164	INTS4L1	0.5	5.86	0.43	2.79e-8	Calcium levels;
PAAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-4.75	-0.36	4.68e-6	Mean platelet volume;
PAAD	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	7.45	0.52	6.61e-12	Neuroticism;
PAAD	cis	rs4523957	0.553	rs2131702	chr17:2025458	T/C	cg16513277	chr17:2031491	SMG6	-0.67	-7.01	-0.49	7.19e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1879734	0.636	rs12025857	chr1:54175360	C/T	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg22907277	chr7:1156413	C7orf50	0.67	4.84	0.37	3.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08864240	chr6:39895717	MOCS1	-0.61	-6.42	-0.46	1.66e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.53e-9	Cognitive function;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs10501293	1.000	rs4755695	chr11:43108344	C/A	cg03447554	chr11:43094025	NA	-0.51	-5.09	-0.38	1.04e-6	Cognitive performance;
PAAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.16	0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.42	-0.34	1.87e-5	Fear of minor pain;
PAAD	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.37	0.4	2.84e-7	Mean platelet volume;
PAAD	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.79	-0.42	3.94e-8	Eye color traits;
PAAD	cis	rs16975963	0.843	rs241955	chr19:38278677	A/G	cg08679971	chr19:38281047	NA	0.49	4.7	0.36	5.68e-6	Longevity;
PAAD	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.56	5.68	0.42	6.75e-8	Systolic blood pressure;
PAAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.69	-0.53	1.69e-12	Height;
PAAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.97	6.87	0.49	1.56e-10	Alzheimer's disease;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.43	5.99	0.44	1.44e-8	Vitiligo;
PAAD	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.31	0.64	3.13e-19	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2735413	0.802	rs6564504	chr16:78095419	G/T	cg04733911	chr16:78082701	NA	0.55	5.67	0.42	7.1e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg00319359	chr11:70116639	PPFIA1	0.74	4.65	0.35	7.06e-6	Coronary artery disease;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.65	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.24	7.0	0.49	7.78e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.27	-0.33	3.45e-5	Total body bone mineral density;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg00933542	chr6:150070202	PCMT1	0.55	5.97	0.44	1.57e-8	Lung cancer;
PAAD	cis	rs914615	0.552	rs7556304	chr1:155139509	T/C	cg20311333	chr1:155197753	GBAP1	0.44	4.29	0.33	3.17e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-6.58	-0.47	7.19e-10	Body mass index;
PAAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg14711859	chr11:8959438	ASCL3	0.5	5.99	0.44	1.47e-8	Hematocrit;
PAAD	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg20169779	chr10:135381914	SYCE1	0.56	5.26	0.39	4.91e-7	Obesity-related traits;
PAAD	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg10820045	chr2:198174542	NA	-0.48	-4.9	-0.37	2.45e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.9e-7	Resting heart rate;
PAAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	0.98	5.0	0.38	1.56e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg25037394	chr1:24152592	HMGCL	0.41	4.51	0.34	1.31e-5	Immature fraction of reticulocytes;
PAAD	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.48	-4.27	-0.33	3.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11608897	chr2:85766394	MAT2A	0.65	6.63	0.47	5.5e-10	Obesity-related traits;
PAAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.67	-0.35	6.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.21e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs427941	0.632	rs201505	chr7:101760287	T/C	cg06246474	chr7:101738831	CUX1	0.43	4.28	0.33	3.24e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg08601574	chr20:25228251	PYGB	-0.66	-7.26	-0.51	1.91e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs6028335	0.825	rs67320351	chr20:37782150	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.37	-0.33	2.29e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs16944613	0.510	rs11636695	chr15:91152911	C/G	cg15547629	chr15:90437138	AP3S2	0.51	4.34	0.33	2.58e-5	Colorectal cancer;
PAAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.95	-10.95	-0.66	6.16e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12946454	0.521	rs66827053	chr17:43250653	A/G	cg10701640	chr17:43249399	NA	0.64	7.19	0.5	2.67e-11	Systolic blood pressure;
PAAD	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	7.63	0.53	2.38e-12	Neuroticism;
PAAD	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.15	8.55	0.57	1.22e-14	Lymphocyte counts;
PAAD	cis	rs60733400	0.509	rs56814247	chr1:2622489	A/G	cg20673091	chr1:2541236	MMEL1	-0.91	-10.61	-0.65	4.95e-20	Multiple sclerosis;
PAAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs12760731	0.623	rs12023044	chr1:178407772	G/A	cg00404053	chr1:178313656	RASAL2	0.65	5.43	0.4	2.17e-7	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.1	-0.38	1e-6	Pulmonary function;
PAAD	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.78	8.35	0.56	3.9e-14	Mean corpuscular volume;
PAAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg02380750	chr20:61661411	NA	0.36	4.44	0.34	1.71e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.87	-0.37	2.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Body mass index;
PAAD	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	1.11	10.58	0.65	5.89e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.13	-17.01	-0.81	5.21e-37	Prudent dietary pattern;
PAAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	4.25	0.33	3.72e-5	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10768690	chr6:24645875	KIAA0319	0.61	7.65	0.53	2.1e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs332507	0.830	rs1846891	chr3:124399397	A/G	cg05980111	chr3:124395277	KALRN	0.42	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs2051773	0.567	rs12794156	chr11:17063005	G/C	cg15432903	chr11:17409602	KCNJ11	-0.51	-4.37	-0.33	2.26e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs58521262	0.519	rs12461496	chr19:22925785	T/C	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg27094323	chr7:1216898	NA	-0.43	-5.0	-0.38	1.58e-6	Longevity;Endometriosis;
PAAD	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg17366294	chr4:99064904	C4orf37	-0.46	-5.15	-0.39	7.79e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.23	0.39	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg07061783	chr6:25882402	NA	-0.48	-4.65	-0.35	7.28e-6	Blood metabolite levels;
PAAD	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg06191203	chr2:152266755	RIF1	0.51	4.65	0.35	7.04e-6	Lung cancer;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.76	9.5	0.61	4.45e-17	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg19337854	chr7:99768885	GPC2	0.45	4.71	0.36	5.6e-6	Coronary artery disease;
PAAD	cis	rs7508	0.612	rs10112857	chr8:17917888	A/G	cg08627089	chr8:17753878	FGL1	-0.42	-4.29	-0.33	3.12e-5	Atrial fibrillation;
PAAD	cis	rs939584	1.000	rs10193244	chr2:647580	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg12923728	chr3:195709715	SDHAP1	0.63	4.8	0.36	3.71e-6	Red cell distribution width;
PAAD	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20661391	chr2:169048192	STK39	0.61	6.34	0.46	2.53e-9	Smoking initiation;
PAAD	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg05562828	chr17:3906858	NA	0.54	5.94	0.43	1.85e-8	Type 2 diabetes;
PAAD	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.4	4.82	0.36	3.39e-6	Thyroid stimulating hormone;
PAAD	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23281280	chr6:28129359	ZNF389	-0.71	-5.66	-0.42	7.28e-8	Depression;
PAAD	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.85	8.85	0.58	2.05e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03676636	chr4:99064102	C4orf37	-0.34	-6.18	-0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg00024416	chr22:24240387	NA	0.52	4.62	0.35	8.04e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs12136530	0.577	rs4481878	chr1:19791086	C/A	cg20786524	chr1:18954525	NA	0.39	4.72	0.36	5.32e-6	Lead levels in blood;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.57	-0.35	1.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg19223190	chr17:80058835	NA	0.52	5.39	0.4	2.7e-7	Life satisfaction;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18337363	chr3:52569053	NT5DC2	0.48	5.17	0.39	7.13e-7	Hemoglobin concentration;
PAAD	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	trans	rs901683	1.000	rs75712637	chr10:45988192	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27138727	chr3:107150777	NA	0.64	7.54	0.52	3.97e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.34	4.57	0.35	9.95e-6	Breast cancer;
PAAD	trans	rs6694672	1.000	rs6695300	chr1:197098143	G/C	cg26994526	chr18:47719735	MYO5B	-0.86	-6.45	-0.46	1.38e-9	Asthma;
PAAD	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg09065629	chr16:1709722	CRAMP1L	0.42	4.44	0.34	1.72e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	0.75	5.12	0.38	8.92e-7	Body mass index;
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.58	6.41	0.46	1.71e-9	Testicular germ cell tumor;
PAAD	cis	rs12580194	0.593	rs11171435	chr12:55758053	T/C	cg06899799	chr12:56650233	ANKRD52	0.33	4.36	0.33	2.39e-5	Cancer;
PAAD	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg20243544	chr17:37824526	PNMT	0.49	4.37	0.33	2.32e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	5.65	0.42	7.74e-8	Response to antipsychotic treatment;
PAAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg04826882	chr13:114838756	RASA3	-0.68	-5.35	-0.4	3.2e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.7	-8.31	-0.56	5.07e-14	Huntington's disease progression;
PAAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs8170	0.603	rs3745187	chr19:17414126	C/T	cg04749549	chr19:17459798	NA	-0.45	-4.85	-0.37	3.02e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.86	9.11	0.59	4.42e-16	Body mass index;
PAAD	cis	rs1359582	0.757	rs814635	chr10:90412191	C/T	cg15661332	chr10:90342814	RNLS	0.54	4.72	0.36	5.22e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs2882667	0.690	rs10515504	chr5:138222994	C/G	cg09476006	chr5:138032270	NA	-0.46	-5.75	-0.42	4.7e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg17372657	chr7:1216933	NA	-0.36	-4.63	-0.35	7.93e-6	Longevity;Endometriosis;
PAAD	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.41	-0.34	1.96e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.66	-6.31	-0.46	2.96e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12935418	0.583	rs2602449	chr16:81024273	C/T	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.5	-4.82	-0.36	3.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.58	-4.36	-0.33	2.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs829661	0.894	rs2609959	chr2:30875330	A/G	cg12454169	chr2:30669597	LCLAT1	0.66	5.06	0.38	1.21e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.53	-4.85	-0.37	3.01e-6	DNA methylation (variation);
PAAD	cis	rs747650	0.504	rs4269876	chr11:47109463	T/A	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.45	3.07e-9	Acne (severe);
PAAD	cis	rs35160687	0.640	rs13015186	chr2:86485578	A/G	cg10973622	chr2:86423274	IMMT	0.45	4.96	0.37	1.89e-6	Night sleep phenotypes;
PAAD	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg20742385	chr13:113633654	MCF2L	-0.43	-4.33	-0.33	2.71e-5	Systolic blood pressure;
PAAD	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg14196790	chr5:131705035	SLC22A5	0.46	4.96	0.37	1.83e-6	Blood metabolite levels;
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.67	7.22	0.51	2.27e-11	Age at first birth;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08322747	chr16:2347298	ABCA3	0.63	6.74	0.48	3.12e-10	Warfarin maintenance dose;
PAAD	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg19442545	chr10:75533431	FUT11	-0.51	-5.29	-0.39	4.23e-7	Inflammatory bowel disease;
PAAD	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg21518248	chr2:162101506	NA	-0.72	-9.75	-0.62	9.73e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg21253087	chr9:139290292	SNAPC4	0.46	4.45	0.34	1.65e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs761746	0.695	rs3804087	chr22:32079303	C/T	cg01338084	chr22:32026380	PISD	-0.64	-5.44	-0.4	2.05e-7	Intelligence;
PAAD	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg27499820	chr13:21296301	IL17D	-0.53	-5.17	-0.39	7.18e-7	Dental caries;
PAAD	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.64	-0.35	7.51e-6	IgG glycosylation;
PAAD	cis	rs6894268	0.762	rs4701139	chr5:179033094	G/A	cg26135573	chr5:179059668	NA	0.71	6.06	0.44	1.02e-8	Eating disorders;
PAAD	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.73	8.21	0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.4	0.34	2.01e-5	Triglycerides;
PAAD	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.39	-4.73	-0.36	5.08e-6	Uric acid levels;
PAAD	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.38	-0.34	2.16e-5	Metabolite levels;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.53	-6.46	-0.46	1.32e-9	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs8073060	0.654	rs11650473	chr17:33864632	A/G	cg19694781	chr19:47549865	TMEM160	0.79	6.96	0.49	9.73e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.55	5.06	0.38	1.22e-6	Schizophrenia;
PAAD	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg27211696	chr2:191398769	TMEM194B	0.44	4.32	0.33	2.81e-5	Urinary metabolites;
PAAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.64	7.68	0.53	1.76e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg19254793	chr6:44695348	NA	-0.45	-4.41	-0.34	1.92e-5	Total body bone mineral density;
PAAD	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg10437265	chr15:77819839	NA	0.4	4.54	0.35	1.13e-5	Type 2 diabetes;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg07564188	chr1:165667906	ALDH9A1	0.71	6.57	0.47	7.61e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.48	5.83	0.43	3.17e-8	Vitiligo;
PAAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.53	-5.29	-0.39	4.17e-7	IgG glycosylation;
PAAD	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	1.15	10.67	0.65	3.55e-20	Colorectal cancer;
PAAD	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg18833306	chr6:118973337	C6orf204	0.41	4.28	0.33	3.29e-5	Electrocardiographic conduction measures;
PAAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	6.82	0.48	2.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07549630	chr12:97300822	NEDD1	0.59	6.57	0.47	7.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.63	-6.75	-0.48	2.97e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg15117754	chr3:10150083	C3orf24	-0.64	-5.98	-0.44	1.51e-8	Alzheimer's disease;
PAAD	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	7.23	0.51	2.2e-11	Lung cancer in ever smokers;
PAAD	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.59	-0.35	9.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-6.16	-0.45	6.12e-9	Personality dimensions;
PAAD	trans	rs9328321	0.580	rs9378431	chr6:5580951	C/G	cg25203007	chr1:24126017	GALE	0.48	6.35	0.46	2.35e-9	Obesity (early onset extreme);
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Bipolar disorder;
PAAD	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.6	-5.22	-0.39	5.88e-7	Common traits (Other);
PAAD	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.57	5.52	0.41	1.41e-7	Asthma;
PAAD	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-10.41	-0.65	1.73e-19	Blood trace element (Zn levels);
PAAD	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.84	9.93	0.63	3.26e-18	Blood metabolite ratios;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg26174226	chr8:58114915	NA	-0.59	-4.29	-0.33	3.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs802075	0.765	rs2180723	chr6:49598810	C/T	cg20364632	chr6:49636226	NA	-0.47	-5.32	-0.4	3.68e-7	Bone mineral density (hip) and age at menarche;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09568924	chr4:17277892	NA	0.63	7.13	0.5	3.8e-11	Smoking initiation;
PAAD	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.65	-6.74	-0.48	3.1e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs61931739	0.649	rs12426686	chr12:33714473	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	8.45	0.57	2.24e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg15443732	chr18:74961078	GALR1	0.59	5.44	0.4	2.13e-7	Obesity-related traits;
PAAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.45	-4.72	-0.36	5.38e-6	Coronary artery disease;
PAAD	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	1.29	9.2	0.6	2.66e-16	Prostate cancer;
PAAD	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.66	7.01	0.49	7.26e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.21	-0.39	5.96e-7	Monocyte percentage of white cells;
PAAD	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg01426195	chr3:39028469	NA	0.64	6.4	0.46	1.8e-9	Handedness;
PAAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg03037974	chr15:76606532	NA	-0.52	-6.11	-0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.24	-0.39	5.21e-7	Schizophrenia;
PAAD	trans	rs80215559	0.661	rs115740542	chr6:26123502	T/C	cg21435394	chr14:105648024	NUDT14	0.96	7.16	0.5	3.31e-11	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.78	8.1	0.55	1.66e-13	Alzheimer's disease (late onset);
PAAD	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.63	6.75	0.48	2.91e-10	Longevity;
PAAD	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.76	7.93	0.54	4.41e-13	Gut microbiome composition (winter);
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.79	6.94	0.49	1.04e-10	Exhaled nitric oxide levels;
PAAD	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.88	0.63	4.42e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.61	5.43	0.4	2.19e-7	White matter hyperintensity burden;
PAAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg14440974	chr22:39074834	NA	-0.56	-6.46	-0.46	1.36e-9	Menopause (age at onset);
PAAD	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.2	-0.45	5.18e-9	Monocyte count;
PAAD	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg25650185	chr19:21324782	ZNF431	-0.51	-4.58	-0.35	9.63e-6	Pain;
PAAD	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.56	-7.04	-0.5	6.22e-11	Lewy body disease;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.95	7.23	0.51	2.22e-11	Alzheimer's disease;
PAAD	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.23	0.39	5.64e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg25360861	chr19:22235199	ZNF257	0.42	5.06	0.38	1.17e-6	Telomere length;
PAAD	cis	rs9595066	0.667	rs6561164	chr13:44726453	T/C	cg04068111	chr13:44716778	NA	0.4	4.61	0.35	8.44e-6	Schizophrenia;
PAAD	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.83	-0.36	3.33e-6	Bipolar disorder;
PAAD	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	1.04	9.76	0.62	8.91e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.46	5.94	0.43	1.88e-8	Psoriasis;
PAAD	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.29	-0.33	3.16e-5	Height;
PAAD	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.77	-7.87	-0.54	6.26e-13	Body mass index;
PAAD	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.48	-5.14	-0.38	8.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.35	-4.49	-0.34	1.42e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1190596	0.525	rs12896377	chr14:102713581	T/C	cg23904247	chr14:102554826	HSP90AA1	0.42	4.88	0.37	2.6e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.53	4.75	0.36	4.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7765175	0.698	rs3851201	chr6:113677076	T/C	cg19037598	chr6:113666021	NA	-0.44	-4.77	-0.36	4.29e-6	Coronary artery calcification;
PAAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.5	6.38	0.46	2.02e-9	Childhood ear infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16654143	chr19:45579842	ZNF296	0.64	7.07	0.5	5.4e-11	Monocyte percentage of white cells;
PAAD	cis	rs11191193	0.935	rs2305192	chr10:103560321	T/C	cg11685391	chr10:103594334	KCNIP2	-0.33	-4.3	-0.33	3.02e-5	Educational attainment;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.65	5.44	0.4	2.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.57	-0.35	1.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11771526	0.579	rs2116669	chr7:32428454	C/T	cg27511599	chr7:32358540	NA	0.74	4.6	0.35	8.93e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13563793	chr20:25677582	ZNF337	0.57	6.6	0.47	6.59e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62045849	0.546	rs71395385	chr16:89196279	A/G	cg03605463	chr16:89740564	NA	1.12	5.07	0.38	1.14e-6	Red blood cell count;
PAAD	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-5.79	-0.43	3.84e-8	Ileal carcinoids;
PAAD	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.49	-4.39	-0.34	2.15e-5	Morning vs. evening chronotype;
PAAD	cis	rs7101378	0.557	rs7948895	chr11:108892607	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.31	-0.33	2.91e-5	IgG glycosylation;
PAAD	cis	rs11811982	0.793	rs11812048	chr1:227511074	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg23352942	chr3:46931381	PTH1R	-0.48	-4.86	-0.37	2.86e-6	Birth weight;
PAAD	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.47	0.41	1.8e-7	Ileal carcinoids;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.51	5.04	0.38	1.3e-6	Menarche (age at onset);
PAAD	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.2	-0.39	6.45e-7	Personality dimensions;
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg02683114	chr2:24398427	C2orf84	0.54	5.16	0.39	7.7300000000000005e-07	Asthma;
PAAD	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg01851573	chr8:8652454	MFHAS1	0.6	5.19	0.39	6.59e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs950880	0.710	rs873022	chr2:102955683	G/T	cg23450938	chr2:102972792	NA	0.45	4.8	0.36	3.78e-6	Serum protein levels (sST2);
PAAD	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg26876637	chr1:152193138	HRNR	-0.79	-5.41	-0.4	2.4e-7	Atopic dermatitis;
PAAD	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg01884057	chr2:25150051	NA	-0.45	-5.53	-0.41	1.39e-7	Body mass index in non-asthmatics;
PAAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.7e-6	Personality dimensions;
PAAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.79	9.19	0.6	2.7e-16	Diastolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13230077	chr9:70490060	CBWD3;CBWD5	-0.69	-6.45	-0.46	1.39e-9	Neuroticism;
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.53	-5.16	-0.39	7.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.67	0.58	6.06e-15	Menopause (age at onset);
PAAD	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg14146966	chr2:61757674	XPO1	0.39	4.81	0.36	3.55e-6	Tuberculosis;
PAAD	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-6.1	-0.44	8.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg15192750	chr16:69999425	NA	0.72	5.57	0.41	1.15e-7	IgE levels;
PAAD	cis	rs9918079	0.560	rs10008975	chr4:15624571	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg13514324	chr8:145755804	MGC70857;KIAA1688	-0.28	-4.25	-0.33	3.66e-5	Age at first birth;
PAAD	cis	rs727479	0.597	rs6493487	chr15:51513729	C/T	cg21478137	chr15:51532386	CYP19A1	0.57	5.94	0.43	1.83e-8	Estradiol levels;
PAAD	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.92	-5.66	-0.42	7.36e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.67	-6.09	-0.44	9.05e-9	Mean corpuscular volume;
PAAD	cis	rs1879734	0.731	rs7555617	chr1:54158155	A/C	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-1.51	-9.85	-0.62	5.32e-18	Depression;
PAAD	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.69	0.36	6.01e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.53	-0.34	1.19e-5	Height;
PAAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs17655565	0.537	rs7975165	chr12:52805198	G/C	cg22980804	chr12:52818037	KRT75	-0.58	-5.38	-0.4	2.7e-7	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06850241	chr22:41845214	NA	0.56	4.95	0.37	1.91e-6	Vitiligo;
PAAD	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13647721	chr17:30228624	UTP6	0.58	4.46	0.34	1.56e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.47	-4.71	-0.36	5.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.89	10.61	0.65	4.9e-20	Longevity;
PAAD	cis	rs6496932	0.865	rs4842879	chr15:85924888	A/G	cg19183879	chr15:85880815	NA	0.55	4.63	0.35	7.67e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg07371521	chr5:154026371	NA	0.5	6.62	0.47	5.91e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.91e-6	Vitiligo;
PAAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.54	-0.47	8.87e-10	Hip circumference;
PAAD	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.68e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24822001	chr3:43732329	ABHD5	0.64	7.12	0.5	4.05e-11	Myopia (pathological);
PAAD	cis	rs7627468	0.837	rs7618100	chr3:121950120	G/C	cg03198317	chr3:121949109	CASR	0.52	4.61	0.35	8.6e-6	Kidney stones;
PAAD	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg16964102	chr10:135390573	NA	-0.43	-4.51	-0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs1572438	0.965	rs3799324	chr6:859376	G/A	cg13447295	chr6:887704	NA	-0.52	-4.74	-0.36	4.86e-6	Aging;
PAAD	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg02135003	chr7:105160482	PUS7	-0.7	-5.57	-0.41	1.12e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	1.1	12.23	0.7	2.25e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.65	-7.0	-0.49	7.49e-11	Menarche (age at onset);
PAAD	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg05250797	chr16:70222502	NA	-0.75	-5.97	-0.44	1.59e-8	IgE levels;
PAAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.57	-5.17	-0.39	7.39e-7	Life satisfaction;
PAAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg25833597	chr17:30823145	MYO1D	0.5	4.77	0.36	4.35e-6	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.0	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.96	-9.78	-0.62	7.8e-18	Systemic lupus erythematosus;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26549601	chr10:134560360	INPP5A	-0.51	-4.92	-0.37	2.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-1.14	-8.15	-0.55	1.26e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.61	-7.32	-0.51	1.36e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.71	-10.71	-0.66	2.65e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs28647808	1.000	rs28478220	chr9:136273312	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs3126085	0.515	rs11204996	chr1:152364612	C/A	cg26876637	chr1:152193138	HRNR	-0.6	-4.48	-0.34	1.43e-5	Atopic dermatitis;
PAAD	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg21905437	chr5:178450457	ZNF879	0.69	5.94	0.43	1.9e-8	Pubertal anthropometrics;
PAAD	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.55	-4.55	-0.35	1.1e-5	Facial morphology (factor 19);
PAAD	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.89	-0.37	2.57e-6	Menopause (age at onset);
PAAD	cis	rs10782582	0.758	rs7519526	chr1:76380954	A/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.4	-4.26	-0.33	3.6e-5	Daytime sleep phenotypes;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg19598514	chr11:442149	ANO9	-0.52	-4.26	-0.33	3.51e-5	Systemic lupus erythematosus;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07532067	chr3:150481511	SIAH2	0.68	6.48	0.47	1.21e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg08317243	chr16:87101592	NA	-0.51	-4.87	-0.37	2.77e-6	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15210612	chr3:98312534	CPOX	0.69	6.76	0.48	2.78e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.53	5.85	0.43	2.94e-8	Heart rate;
PAAD	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.72	7.66	0.53	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs939584	1.000	rs10865548	chr2:631606	A/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-0.96	-6.04	-0.44	1.14e-8	Thyroid stimulating hormone;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg16405210	chr4:1374714	KIAA1530	0.5	5.26	0.39	4.72e-7	Obesity-related traits;
PAAD	cis	rs72901758	0.768	rs11655421	chr17:76251518	T/A	cg26068271	chr17:76253126	NA	0.53	5.07	0.38	1.16e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.55	-11.19	-0.67	1.43e-21	Atopic dermatitis;
PAAD	cis	rs67478160	0.584	rs2295151	chr14:104193099	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.61	-6.33	-0.46	2.59e-9	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.97	0.44	1.58e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	1.01	10.86	0.66	1.06e-20	Platelet distribution width;
PAAD	cis	rs58521262	0.729	rs12608610	chr19:23066915	C/T	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.71	-0.42	5.84e-8	Personality dimensions;
PAAD	cis	rs6782025	0.837	rs1683975	chr3:120654508	T/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs10512697	0.772	rs13176060	chr5:3522987	C/T	cg19473799	chr5:3511975	NA	-1.03	-4.6	-0.35	8.95e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26711794	chr12:112450906	ERP29;TMEM116	0.58	6.42	0.46	1.65e-9	Monocyte percentage of white cells;
PAAD	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg25952890	chr19:58913133	NA	0.68	5.69	0.42	6.21e-8	Mean platelet volume;
PAAD	cis	rs12431939	0.744	rs12888250	chr14:51669195	C/G	cg23942311	chr14:51606299	NA	0.51	4.41	0.34	1.94e-5	Cancer;
PAAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.38	4.4	0.34	2.02e-5	Fat distribution (HIV);
PAAD	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.86	9.11	0.59	4.38e-16	Anterior chamber depth;
PAAD	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg07313626	chr1:247681931	NA	0.46	4.76	0.36	4.5e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.49	4.8	0.36	3.82e-6	Brain structure;
PAAD	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.34	-0.4	3.37e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg17810781	chr1:201082982	CACNA1S	0.43	5.15	0.39	7.98e-7	Permanent tooth development;
PAAD	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.9	6.65	0.47	4.94e-10	Iron status biomarkers;
PAAD	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.59	5.58	0.41	1.09e-7	Platelet count;
PAAD	cis	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg11251234	chr10:101825055	CPN1	-0.32	-4.79	-0.36	3.95e-6	Bone mineral density;
PAAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.71	8.22	0.55	8.28e-14	Height;
PAAD	cis	rs7326068	0.610	rs2772169	chr13:21314725	T/C	cg27499820	chr13:21296301	IL17D	0.57	5.34	0.4	3.39e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg16928487	chr17:17741425	SREBF1	-0.38	-5.01	-0.38	1.49e-6	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.59	-6.15	-0.45	6.69e-9	Blood metabolite levels;
PAAD	cis	rs669446	0.558	rs620851	chr1:44110489	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-4.38	-0.33	2.22e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	1.13	6.12	0.44	7.48e-9	Plasma clusterin levels;
PAAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35955747	0.934	rs131200	chr22:31703272	T/C	cg07548257	chr22:31686466	PIK3IP1	0.36	4.3	0.33	3.03e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.88	10.93	0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.34	-0.33	2.61e-5	Height;
PAAD	cis	rs16910800	0.953	rs7122949	chr11:23203530	C/T	cg20040320	chr11:23191996	NA	0.62	5.38	0.4	2.77e-7	Cancer;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.56	-6.33	-0.46	2.58e-9	Educational attainment;
PAAD	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.4	-0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs8077577	0.689	rs62072543	chr17:18243872	G/A	cg16794390	chr17:18148240	FLII	0.5	4.3	0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs2133450	0.745	rs9311986	chr3:7369342	C/G	cg19930620	chr3:7340148	GRM7	0.47	5.24	0.39	5.26e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.82	6.47	0.46	1.28e-9	Small cell lung carcinoma;
PAAD	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs12935418	0.672	rs9938541	chr16:81045228	T/G	cg16651780	chr16:81037892	C16orf61	0.65	6.13	0.45	7.13e-9	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg01075559	chr1:2537774	MMEL1	0.5	5.21	0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg03938978	chr2:103052716	IL18RAP	0.47	4.78	0.36	4.02e-6	Blood protein levels;
PAAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.64	5.82	0.43	3.35e-8	Coronary artery disease;
PAAD	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.74	7.06	0.5	5.47e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.87	-10.95	-0.66	6.13e-21	Aortic root size;
PAAD	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.81	-0.36	3.63e-6	Hirschsprung disease;
PAAD	cis	rs1419980	0.730	rs11054890	chr12:7773096	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.6	5.85	0.43	2.85e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6547631	0.592	rs2070966	chr2:85922860	G/T	cg24620635	chr2:85921963	GNLY	0.42	5.55	0.41	1.21e-7	Blood protein levels;
PAAD	cis	rs6893807	0.778	rs1501673	chr5:87963600	G/A	cg02225085	chr5:87975992	LOC645323	-0.71	-5.26	-0.39	4.9e-7	Body mass index;
PAAD	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs12586317	0.728	rs2415288	chr14:35807508	T/C	cg16230307	chr14:35515116	FAM177A1	0.7	6.79	0.48	2.41e-10	Psoriasis;
PAAD	cis	rs3736485	0.903	rs9944241	chr15:51898058	T/C	cg19558802	chr15:51695713	GLDN	-0.43	-4.34	-0.33	2.63e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.57	-6.88	-0.49	1.44e-10	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.85	-0.43	2.92e-8	Rheumatoid arthritis;
PAAD	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.62	-5.21	-0.39	6.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.65	7.35	0.51	1.15e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.91	-8.21	-0.55	8.92e-14	Gut microbiome composition (summer);
PAAD	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.37e-7	Life satisfaction;
PAAD	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.99	11.93	0.7	1.39e-23	Breast cancer;
PAAD	cis	rs6942407	0.545	rs6465101	chr7:86859065	C/G	cg02420886	chr7:86849541	C7orf23	0.61	4.77	0.36	4.32e-6	Food allergy;
PAAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.45	5.79	0.43	3.85e-8	Ulcerative colitis;
PAAD	cis	rs2834188	0.889	rs1467849	chr21:34682069	G/T	cg04842828	chr21:34696676	IFNAR1	0.49	4.63	0.35	7.89e-6	Narcolepsy;
PAAD	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.61	-0.35	8.48e-6	Total body bone mineral density;
PAAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.84	-10.17	-0.64	7.38e-19	Ulcerative colitis;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.34e-6	Prudent dietary pattern;
PAAD	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs10949834	0.824	rs2285025	chr7:73529976	T/C	cg07137043	chr7:73588983	EIF4H	-0.6	-4.51	-0.34	1.29e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	0.94	10.03	0.63	1.77e-18	Tonsillectomy;
PAAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.03	0.38	1.37e-6	Total body bone mineral density;
PAAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg08132940	chr7:1081526	C7orf50	0.59	4.35	0.33	2.5e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.56	4.51	0.34	1.31e-5	Personality dimensions;
PAAD	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.64	-5.81	-0.43	3.46e-8	Coronary artery disease;
PAAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.46	-5.41	-0.4	2.41e-7	Rheumatoid arthritis;
PAAD	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg03910582	chr17:19030146	GRAPL	0.45	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg10990685	chr12:120720139	NME2P1	-0.66	-6.57	-0.47	7.39e-10	Primary biliary cholangitis;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.03	-16.91	-0.81	9.53e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	5.71	0.42	5.89e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg00277334	chr10:82204260	NA	-0.59	-5.94	-0.43	1.89e-8	Post bronchodilator FEV1;
PAAD	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	0.88	5.34	0.4	3.26e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs12476592	0.602	rs2292793	chr2:63661280	A/G	cg10828910	chr2:63850056	LOC388955	0.52	4.49	0.34	1.42e-5	Childhood ear infection;
PAAD	cis	rs17213965	0.789	rs4781688	chr16:15865189	C/A	cg03653601	chr16:16156039	ABCC1	-0.38	-4.43	-0.34	1.81e-5	Waist-hip ratio;
PAAD	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg01765077	chr12:122356316	WDR66	-0.49	-4.73	-0.36	5.16e-6	Mean corpuscular volume;
PAAD	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg06609049	chr19:2785107	THOP1	0.91	10.16	0.64	7.86e-19	Total cholesterol levels;
PAAD	cis	rs354225	0.544	rs10182538	chr2:54808251	T/A	cg01766943	chr2:54829624	SPTBN1	0.52	4.82	0.36	3.42e-6	Schizophrenia;
PAAD	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg02569219	chr17:2266849	SGSM2	0.56	5.47	0.41	1.79e-7	Proinsulin levels;
PAAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.76	-8.62	-0.57	8.24e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg01631408	chr1:248437212	OR2T33	-0.62	-5.59	-0.41	1.03e-7	Common traits (Other);
PAAD	cis	rs375066	0.935	rs422457	chr19:44409411	A/T	cg08633290	chr19:44405433	NA	-0.58	-5.57	-0.41	1.12e-7	Breast cancer;
PAAD	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.45	4.3	0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs7172971	0.688	rs75734921	chr15:42386630	G/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Birth weight;
PAAD	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-1.05	-11.57	-0.68	1.3e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs12935418	0.583	rs2911150	chr16:81028799	C/T	cg16651780	chr16:81037892	C16orf61	0.65	6.09	0.44	8.68e-9	Mean corpuscular volume;
PAAD	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	trans	rs10861342	1.000	rs11112397	chr12:105568381	T/C	cg11421182	chr20:36153479	BLCAP	-0.55	-6.89	-0.49	1.4e-10	IgG glycosylation;
PAAD	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg23463467	chr20:60627584	TAF4	0.48	5.18	0.39	7.03e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.82e-17	Aortic root size;
PAAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg05110241	chr16:68378359	PRMT7	-0.83	-6.84	-0.49	1.8e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.47	4.28	0.33	3.29e-5	Red cell distribution width;
PAAD	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg02404636	chr22:31891804	SFI1	-0.59	-5.41	-0.4	2.4e-7	Colorectal cancer;
PAAD	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg17644776	chr2:200775616	C2orf69	-0.65	-4.35	-0.33	2.48e-5	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg18939081	chr1:31884902	SERINC2	0.5	5.71	0.42	5.66e-8	Alcohol dependence;
PAAD	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs7210086	0.768	rs4072716	chr17:70640933	T/C	cg04206342	chr17:70636940	NA	-0.43	-5.48	-0.41	1.77e-7	Ulcerative colitis;
PAAD	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs113779084	0.637	rs10464198	chr7:11970052	T/C	cg15090509	chr7:11872073	THSD7A	0.37	4.61	0.35	8.44e-6	Educational attainment (years of education);
PAAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.78	8.72	0.58	4.44e-15	Type 2 diabetes;
PAAD	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.61	6.31	0.46	2.83e-9	Testicular germ cell tumor;
PAAD	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.71	6.72	0.48	3.35e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs11794666	0.872	rs56311456	chr9:31713619	T/C	cg05628366	chr6:35744188	C6orf126	0.96	6.46	0.46	1.37e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4454254	0.734	rs62527033	chr8:141048736	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.32	-4.33	-0.33	2.66e-5	Pulse pressure;
PAAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.11e-7	Glomerular filtration rate;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg15025200	chr1:152161237	NA	0.46	4.35	0.33	2.52e-5	Inflammatory skin disease;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.74	-10.06	-0.63	1.49e-18	Iron status biomarkers;
PAAD	cis	rs6076065	0.723	rs6137940	chr20:23397491	G/C	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	6.7	0.48	3.74e-10	Renal function-related traits (BUN);
PAAD	cis	rs7580658	1.000	rs7580658	chr2:128159261	G/A	cg10985347	chr2:127963512	CYP27C1	0.5	4.54	0.35	1.12e-5	Protein C levels;
PAAD	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg16584676	chr17:46985605	UBE2Z	0.57	5.77	0.42	4.29e-8	Type 2 diabetes;
PAAD	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg20761395	chr17:511517	VPS53	-0.49	-4.67	-0.35	6.51e-6	Prostate cancer;
PAAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12963246	chr6:28129442	ZNF389	0.56	4.52	0.34	1.21e-5	Parkinson's disease;
PAAD	cis	rs3736757	0.846	rs12071631	chr1:184708274	A/G	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs900145	0.817	rs2279284	chr11:13298750	C/T	cg15603424	chr11:13300592	ARNTL	-0.54	-4.63	-0.35	7.91e-6	Menarche (age at onset);
PAAD	cis	rs41311933	0.656	rs72758196	chr9:123820313	G/A	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20283971	chr3:196295364	WDR53;FBXO45	-0.73	-6.38	-0.46	2.02e-9	Neuroticism;
PAAD	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.31	-0.33	2.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05960932	chr3:119118715	CDGAP	0.56	6.3	0.46	3.13e-9	Smoking initiation;
PAAD	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.7e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.86	0.54	6.38e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma;
PAAD	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06753367	chr22:24256600	NA	-0.4	-4.39	-0.34	2.08e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3736485	0.673	rs8033234	chr15:51956117	T/C	cg08986416	chr15:51914746	DMXL2	-0.47	-4.36	-0.33	2.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10884103	chr2:24302756	TP53I3	0.63	7.59	0.52	3.06e-12	Smoking initiation;
PAAD	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-4.95	-0.37	1.97e-6	Height;
PAAD	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.79	-8.14	-0.55	1.32e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg27121462	chr16:89883253	FANCA	0.85	4.27	0.33	3.38e-5	Skin colour saturation;
PAAD	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.52	4.9	0.37	2.46e-6	Eosinophilic esophagitis;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01901780	chr16:75590245	TMEM231	0.6	6.35	0.46	2.41e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.44	4.33	0.33	2.69e-5	Response to mepolizumab in severe asthma;
PAAD	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.19	0.45	5.39e-9	Post bronchodilator FEV1;
PAAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.75	-7.64	-0.53	2.23e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00078270	chr7:2005255	MAD1L1	-0.66	-6.3	-0.46	3.08e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs829661	0.739	rs1252640	chr2:30739298	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.4	0.34	2.03e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.61	4.99	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.52	0.34	1.25e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg18769074	chr3:133464867	TF	0.4	5.07	0.38	1.15e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	13.95	0.75	5.38e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg02297831	chr4:17616191	MED28	0.53	4.91	0.37	2.32e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg16205897	chr5:131564050	P4HA2	-0.42	-4.56	-0.35	1.05e-5	Breast cancer;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.84	-0.43	3.03e-8	Coronary artery calcification;
PAAD	cis	rs7671266	0.532	rs7349721	chr4:10042562	A/T	cg11266682	chr4:10021025	SLC2A9	0.53	4.57	0.35	1.02e-5	Cardiovascular disease risk factors;
PAAD	cis	rs2885056	0.843	rs35769432	chr19:10695824	G/A	cg06392426	chr19:10676186	KRI1	0.54	5.26	0.39	4.89e-7	Red cell distribution width;
PAAD	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.68	6.42	0.46	1.64e-9	Total body bone mineral density;
PAAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-8.58	-0.57	1e-14	Total body bone mineral density;
PAAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.34	15.67	0.79	1.5e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.39	-0.4	2.62e-7	Response to antipsychotic treatment;
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.91	9.81	0.62	6.75e-18	Cleft lip with or without cleft palate;
PAAD	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg05425664	chr17:57184151	TRIM37	0.58	5.51	0.41	1.47e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19467586	chr17:45266599	CDC27	-0.62	-6.79	-0.48	2.37e-10	Smoking initiation;
PAAD	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.69	7.17	0.5	3.02e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.48	-5.06	-0.38	1.18e-6	Height;
PAAD	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.49	-5.4	-0.4	2.47e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.69	7.23	0.51	2.16e-11	Colorectal cancer;
PAAD	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.6	-6.4	-0.46	1.86e-9	Pulmonary function;
PAAD	cis	rs2457480	0.778	rs1704217	chr10:44729307	T/C	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;
PAAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.44	-0.34	1.69e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg21565972	chr17:80109576	CCDC57	0.48	5.09	0.38	1.06e-6	Life satisfaction;
PAAD	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs881827	1.000	rs2839337	chr21:47987167	C/T	cg14789911	chr21:47582049	C21orf56	0.44	4.5	0.34	1.32e-5	Lymphocyte counts;
PAAD	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.05	-0.44	1.06e-8	Diastolic blood pressure;
PAAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.21	-10.01	-0.63	2.02e-18	Breast cancer;
PAAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.62	-8.25	-0.56	7.2e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21478105	chr12:97384251	NA	-0.62	-6.3	-0.46	3e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19734811	chr2:177134269	MTX2	0.65	6.37	0.46	2.16e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Colorectal cancer;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg13854012	chr2:162103682	NA	0.49	5.64	0.42	8.02e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.61	4.69	0.36	5.95e-6	Cholesterol, total;
PAAD	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.54	5.04	0.38	1.33e-6	Resting heart rate;
PAAD	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs1075265	0.783	rs6545376	chr2:54214822	C/A	cg04546899	chr2:54196757	PSME4	0.37	5.64	0.42	8.12e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.74	-0.36	4.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	4.71	0.36	5.49e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	4.29	0.33	3.17e-5	Menarche (age at onset);
PAAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg08562672	chr19:21860753	NA	0.41	4.28	0.33	3.31e-5	Pain;
PAAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.47	6.04	0.44	1.13e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg02376097	chr19:46275166	DMPK	-0.48	-4.9	-0.37	2.4e-6	Coronary artery disease;
PAAD	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.14	0.38	8.45e-7	Schizophrenia;
PAAD	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467603	0.925	rs1892251	chr6:25769349	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.75	-4.93	-0.37	2.15e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.75	5.5	0.41	1.57e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.71	-0.36	5.61e-6	Bipolar disorder;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16262614	chr3:133464971	TF	0.51	5.46	0.4	1.94e-7	Iron status biomarkers;
PAAD	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.73	8.25	0.56	7.04e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs9810890	1.000	rs73198878	chr3:128542084	G/A	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs9346649	0.802	rs1109191	chr6:168495750	G/A	cg02770688	chr6:168491649	NA	-0.48	-5.11	-0.38	9.74e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.6	-6.93	-0.49	1.11e-10	Facial morphology (factor 20);
PAAD	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-4.6	-0.35	8.92e-6	Breast cancer;
PAAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg11812906	chr14:75593930	NEK9	0.49	4.8	0.36	3.79e-6	Caffeine consumption;
PAAD	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.7	8.82	0.58	2.44e-15	Dupuytren's disease;
PAAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg07395648	chr5:131743802	NA	-0.5	-4.42	-0.34	1.91e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs714515	0.511	rs9425301	chr1:172363815	A/C	cg13446689	chr1:172328377	DNM3	-0.39	-4.6	-0.35	8.97e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg11993925	chr19:44307056	LYPD5	-0.45	-6.08	-0.44	9.32e-9	Breast cancer;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.94e-7	Alzheimer's disease;
PAAD	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.69	-6.01	-0.44	1.34e-8	Lymphocyte percentage of white cells;
PAAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Tonsillectomy;
PAAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.94	-0.49	1.04e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.52e-8	Mean corpuscular volume;
PAAD	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg17764715	chr19:33622953	WDR88	0.63	5.87	0.43	2.65e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs288326	0.561	rs77318535	chr2:183857319	C/T	cg09997497	chr2:183902928	NCKAP1	1.04	6.21	0.45	4.81e-9	Blood protein levels;
PAAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.59	-5.41	-0.4	2.43e-7	Platelet count;
PAAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.54	-5.19	-0.39	6.78e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg04160749	chr8:58172571	NA	-0.65	-4.58	-0.35	9.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9918079	0.560	rs13147590	chr4:15621188	A/G	cg16509355	chr4:15471240	CC2D2A	0.34	4.32	0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs6691722	0.544	rs7551707	chr1:24696892	G/A	cg18323236	chr1:24743029	NIPAL3	0.43	4.62	0.35	8.09e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.67	-6.31	-0.46	2.85e-9	Diisocyanate-induced asthma;
PAAD	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11578532	chr1:161008127	TSTD1	0.43	4.88	0.37	2.65e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11264213	0.901	rs12031138	chr1:36407806	C/T	cg27506609	chr1:36549197	TEKT2	-0.74	-5.19	-0.39	6.56e-7	Schizophrenia;
PAAD	cis	rs12044355	0.865	rs2487453	chr1:231863204	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	4.27	0.33	3.39e-5	Alzheimer's disease;
PAAD	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.89	-7.54	-0.52	3.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.14	7.03	0.5	6.4e-11	Lung cancer in ever smokers;
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-6.29	-0.45	3.27e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10203711	0.509	rs72996355	chr2:239591620	A/C	cg21103250	chr2:238707312	RBM44	0.43	4.41	0.34	1.97e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11794666	0.799	rs1445648	chr9:31745845	T/C	cg05628366	chr6:35744188	C6orf126	0.95	6.64	0.47	5.34e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.65	-4.52	-0.34	1.25e-5	LDL cholesterol levels;
PAAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg23283495	chr1:209979779	IRF6	0.63	5.89	0.43	2.37e-8	Coronary artery disease;
PAAD	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg04106633	chr4:1044584	NA	0.51	4.72	0.36	5.2e-6	Recombination rate (males);
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-1.18	-9.42	-0.61	7.16e-17	Initial pursuit acceleration;
PAAD	cis	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.25	-0.33	3.67e-5	Eotaxin levels;
PAAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	1.26	11.54	0.68	1.62e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.56	-4.95	-0.37	1.96e-6	Glycated hemoglobin levels;
PAAD	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.79	9.62	0.62	2.07e-17	White blood cell count (basophil);
PAAD	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.62	-6.39	-0.46	1.94e-9	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15388430	chr22:43010952	POLDIP3;RNU12	0.73	7.61	0.53	2.65e-12	Obesity-related traits;
PAAD	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.53	5.3	0.4	3.96e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg13611204	chr9:139324423	INPP5E	-0.55	-4.7	-0.36	5.85e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2562456	0.793	rs279807	chr19:21465822	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.38	-0.33	2.19e-5	Pain;
PAAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg16205897	chr5:131564050	P4HA2	-0.44	-4.72	-0.36	5.27e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.27	0.39	4.59e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.02	-0.75	3.37e-29	Primary sclerosing cholangitis;
PAAD	cis	rs1035491	0.715	rs2002628	chr5:63919470	C/T	cg01791865	chr5:63954708	NA	-0.52	-5.49	-0.41	1.65e-7	Body mass index;
PAAD	trans	rs12714314	0.708	rs12714311	chr2:1967192	G/A	cg17170872	chr1:91487911	ZNF644	-0.75	-6.36	-0.46	2.24e-9	Type 2 diabetes (age of onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09828226	chr1:1500093	SSU72	0.61	6.56	0.47	8.08e-10	Smoking initiation;
PAAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg18833306	chr6:118973337	C6orf204	-0.54	-4.45	-0.34	1.62e-5	Diastolic blood pressure;
PAAD	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.23	-0.64	5.01e-19	Blood trace element (Zn levels);
PAAD	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.64	0.65	4.04e-20	Heart rate;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg13047869	chr3:10149882	C3orf24	0.8	5.97	0.44	1.64e-8	Alzheimer's disease;
PAAD	cis	rs9463078	0.546	rs12205071	chr6:45021215	C/G	cg25276700	chr6:44698697	NA	0.46	5.24	0.39	5.2e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg06636372	chr16:89349979	ANKRD11	-0.8	-4.91	-0.37	2.36e-6	Red blood cell count;
PAAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09835421	chr16:68378352	PRMT7	-1.19	-8.53	-0.57	1.34e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.46	5.87	0.43	2.58e-8	Renal cell carcinoma;
PAAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg01503450	chr10:980765	NA	-0.53	-4.33	-0.33	2.68e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7618915	0.962	rs2272088	chr3:52456973	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-4.6	-0.35	8.94e-6	Bipolar disorder;
PAAD	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2980439	0.517	rs793753	chr8:8105359	T/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.97	-0.37	1.78e-6	Neuroticism;
PAAD	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.55	7.4	0.51	8.48e-12	Primary biliary cholangitis;
PAAD	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.75	7.06	0.5	5.46e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.33	-0.51	1.27e-11	Body mass index;
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg19847866	chr10:1019161	NA	-0.6	-4.64	-0.35	7.32e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg08755490	chr11:65554678	OVOL1	0.62	4.77	0.36	4.37e-6	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs7103411	0.592	rs11030087	chr11:27646246	T/C	cg10635145	chr11:27742435	BDNF	0.34	4.28	0.33	3.27e-5	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4740619	0.619	rs4741558	chr9:16038787	G/T	cg14451791	chr9:16040625	NA	-0.43	-4.95	-0.37	1.94e-6	Body mass index;
PAAD	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.8	-8.87	-0.58	1.87e-15	Iron status biomarkers;
PAAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19165942	chr1:35222920	GJB5	0.63	6.53	0.47	9.52e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	6.74	0.48	3.05e-10	Renal function-related traits (BUN);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17783359	chr5:79869215	NA	-0.7	-6.99	-0.49	8.11e-11	Obesity-related traits;
PAAD	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs735539	0.521	rs9552289	chr13:21427839	C/T	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.51	-5.9	-0.43	2.31e-8	Orofacial clefts;
PAAD	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	8.12	0.55	1.51e-13	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.83	8.64	0.57	7.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	1.01	10.84	0.66	1.21e-20	Homoarginine levels;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.67	7.51	0.52	4.59e-12	Mean corpuscular volume;
PAAD	trans	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg17830980	chr10:43048298	ZNF37B	0.69	8.08	0.55	1.84e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2797685	0.786	rs72632093	chr1:7897988	G/A	cg00864860	chr1:7907996	UTS2	-0.63	-4.98	-0.37	1.7e-6	Crohn's disease;
PAAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.54	4.9	0.37	2.42e-6	Mean platelet volume;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.49	5.73	0.42	5.23e-8	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.97	-8.49	-0.57	1.69e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.44	4.96	0.37	1.84e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg26893134	chr6:116381904	FRK	-0.45	-7.42	-0.52	7.7e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg21438018	chr1:76262537	MSH4	-0.48	-4.46	-0.34	1.58e-5	Daytime sleep phenotypes;
PAAD	cis	rs10849432	0.850	rs4764547	chr12:6378212	A/G	cg19998991	chr12:6420036	PLEKHG6	-0.63	-4.28	-0.33	3.36e-5	Colorectal cancer;
PAAD	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.83	9.88	0.63	4.41e-18	Coronary artery disease;
PAAD	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17105737	chr19:639777	FGF22	-0.57	-6.49	-0.47	1.15e-9	Body fat percentage;
PAAD	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.58	5.69	0.42	6.37e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg23682824	chr7:23144976	KLHL7	0.47	4.27	0.33	3.46e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03173713	chr6:34213442	HMGA1	-0.49	-6.51	-0.47	1.01e-9	Myopia (pathological);
PAAD	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	8.38	0.56	3.29e-14	Bipolar disorder;
PAAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs11892454	0.604	rs13418772	chr2:25942605	G/A	cg25181710	chr2:26045287	ASXL2	0.39	4.49	0.34	1.43e-5	Heschl's gyrus morphology;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.86	10.17	0.64	7.44e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg04450456	chr4:17643702	FAM184B	-0.41	-4.27	-0.33	3.44e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.51	-5.62	-0.41	8.82e-8	Migraine;
PAAD	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.21	-0.39	6.04e-7	Chronic sinus infection;
PAAD	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg16606324	chr3:10149918	C3orf24	0.79	6.22	0.45	4.6e-9	Alzheimer's disease;
PAAD	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.69	-6.11	-0.44	8.19e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.77	-0.62	8.57e-18	Response to antipsychotic treatment;
PAAD	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.24	-17.75	-0.82	7.15e-39	Triglycerides;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg25952890	chr19:58913133	NA	0.67	5.7	0.42	5.94e-8	Mean platelet volume;
PAAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.49	0.41	1.65e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg05650719	chr12:132293520	NA	-0.45	-4.65	-0.35	7.22e-6	Migraine;
PAAD	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.22	-0.51	2.27e-11	Response to antipsychotic treatment;
PAAD	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg06780032	chr1:8272277	NA	-0.33	-4.31	-0.33	2.96e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.91	-10.67	-0.65	3.38e-20	Refractive error;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs350729	0.649	rs80039329	chr2:53176417	C/A	cg24639469	chr1:4837462	AJAP1	0.63	6.37	0.46	2.14e-9	Bronchodilator response in asthma;
PAAD	cis	rs10792830	0.897	rs2028338	chr11:85846796	C/T	cg07180834	chr11:85838833	NA	-0.59	-6.93	-0.49	1.11e-10	Psychosis and Alzheimer's disease;
PAAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg02734326	chr4:10020555	SLC2A9	0.49	4.97	0.37	1.77e-6	Bone mineral density;
PAAD	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs17601876	0.545	rs17523284	chr15:51538723	G/A	cg21478137	chr15:51532386	CYP19A1	0.51	4.97	0.37	1.82e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.78	-4.66	-0.35	6.74e-6	Cholesterol, total;
PAAD	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.63	-6.13	-0.44	7.4e-9	Primary sclerosing cholangitis;
PAAD	cis	rs3996993	0.809	rs12528332	chr6:52687392	G/A	cg20803780	chr6:52668592	GSTA1	0.34	4.25	0.33	3.75e-5	Hemoglobin concentration;
PAAD	cis	rs731174	0.592	rs11264093	chr1:38194156	G/A	cg06917450	chr1:38156652	C1orf109	-0.58	-4.96	-0.37	1.85e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.59	5.79	0.43	3.88e-8	Acylcarnitine levels;
PAAD	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg10437265	chr15:77819839	NA	0.42	4.8	0.36	3.72e-6	Type 2 diabetes;
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg07068956	chr7:100330872	ZAN	-0.64	-4.98	-0.37	1.73e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg26816564	chr1:7831052	VAMP3	0.75	5.77	0.42	4.21e-8	Inflammatory bowel disease;
PAAD	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg08501292	chr6:25962987	TRIM38	0.85	4.82	0.36	3.38e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.44	5.59	0.41	1.02e-7	Vitiligo;
PAAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg15123519	chr2:136567270	LCT	-0.39	-4.66	-0.35	6.86e-6	Mosquito bite size;
PAAD	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg10072921	chr12:121022843	NA	0.44	5.35	0.4	3.12e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs4455778	0.580	rs4541847	chr7:49109824	C/G	cg26309511	chr7:48887640	NA	-0.38	-4.76	-0.36	4.44e-6	Lung cancer in never smokers;
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.72	0.58	4.51e-15	Lung cancer;
PAAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs8044476	0.837	rs71386977	chr16:72756598	G/C	cg00207534	chr16:71929512	KIAA0174	0.68	4.5	0.34	1.35e-5	Blood protein levels;
PAAD	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg20893579	chr22:38215064	NA	-0.45	-4.84	-0.37	3.18e-6	Glioblastoma;Glioma;
PAAD	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.87	-11.35	-0.68	5.12e-22	Heart rate;
PAAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.36	-4.33	-0.33	2.71e-5	Crohn's disease;
PAAD	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.76	8.15	0.55	1.24e-13	Blood metabolite levels;
PAAD	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.65	7.39	0.51	9.22e-12	Atrial fibrillation;
PAAD	cis	rs7945718	0.621	rs6485977	chr11:12678387	C/T	cg25843174	chr11:12811716	TEAD1	0.31	4.57	0.35	9.91e-6	Educational attainment (years of education);
PAAD	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs7737355	0.738	rs7710364	chr5:130842724	T/C	cg06307176	chr5:131281290	NA	0.49	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg01494348	chr8:144660395	NAPRT1	0.98	6.95	0.49	9.82e-11	Attention deficit hyperactivity disorder;
PAAD	cis	rs10982213	0.953	rs10759699	chr9:117180493	G/A	cg00078025	chr9:117159975	NA	0.63	4.69	0.36	5.98e-6	Interleukin-6 levels;
PAAD	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.62	-6.08	-0.44	9.22e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs58521262	0.556	rs289323	chr19:23157215	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-1.07	-9.28	-0.6	1.67e-16	Blood trace element (Zn levels);
PAAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.8	7.24	0.51	2.07e-11	Breast cancer;
PAAD	cis	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-6.18	-0.45	5.58e-9	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.44	0.65	1.42e-19	Cannabis dependence symptom count;
PAAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.45	0.57	2.17e-14	Schizophrenia;
PAAD	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.6	6.23	0.45	4.42e-9	Crohn's disease;
PAAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.79	-9.89	-0.63	4.18e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg00576331	chr11:65640516	EFEMP2	-0.44	-4.35	-0.33	2.51e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.86	5.73	0.42	5.24e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	5.96	0.44	1.7e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.67	6.54	0.47	8.66e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10267417	0.657	rs12668709	chr7:19858946	T/G	cg05791153	chr7:19748676	TWISTNB	0.79	5.02	0.38	1.44e-6	Night sleep phenotypes;
PAAD	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg04663916	chr13:50265991	EBPL	0.68	5.66	0.42	7.4e-8	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13686143	chr2:201828163	ORC2L	0.63	7.12	0.5	4.07e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg11266682	chr4:10021025	SLC2A9	-0.65	-5.78	-0.42	4.19e-8	Schizophrenia (age at onset);
PAAD	cis	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.9	-0.37	2.41e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.82	0.48	1.97e-10	Morning vs. evening chronotype;
PAAD	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.54	-4.69	-0.36	6.04e-6	Monocyte count;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16080015	chr7:5085479	RBAK	-0.62	-6.46	-0.46	1.37e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs11811982	0.793	rs75284290	chr1:227450092	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.77	-8.28	-0.56	5.88e-14	Cognitive function;
PAAD	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19882132	chr14:106167949	NA	-0.6	-5.35	-0.4	3.15e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.68	-0.42	6.78e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.44	4.57	0.35	1.02e-5	Lymphocyte counts;
PAAD	cis	rs5753037	0.702	rs140101	chr22:30128380	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-4.43	-0.34	1.79e-5	Type 1 diabetes;
PAAD	cis	rs10887741	0.966	rs2077695	chr10:89435483	T/C	cg13926569	chr10:89418898	PAPSS2	0.46	4.61	0.35	8.52e-6	Exercise (leisure time);
PAAD	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.59	8.17	0.55	1.14e-13	Primary biliary cholangitis;
PAAD	cis	rs288342	0.797	rs288312	chr2:183649266	T/C	cg02625481	chr2:183667124	NA	-0.46	-4.55	-0.35	1.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs2278796	0.697	rs11240323	chr1:204952737	T/C	cg04862289	chr1:204966208	NFASC	0.46	4.92	0.37	2.22e-6	Mean platelet volume;
PAAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg20933634	chr6:27740509	NA	0.66	6.26	0.45	3.7e-9	Parkinson's disease;
PAAD	cis	rs9933309	0.916	rs57953994	chr16:88846803	G/A	cg27661460	chr16:88844969	FAM38A	-0.57	-6.43	-0.46	1.57e-9	Glycated hemoglobin levels;
PAAD	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.4	0.51	8.8e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.71	-6.15	-0.45	6.48e-9	Diabetic retinopathy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16800785	chr6:26247099	HIST1H4G	-0.54	-6.49	-0.47	1.15e-9	Monocyte percentage of white cells;
PAAD	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.73	0.42	5.15e-8	Alzheimer's disease;
PAAD	cis	rs4729127	1.000	rs57515158	chr7:94007842	T/G	cg20814616	chr7:94014465	NA	-0.61	-4.53	-0.35	1.17e-5	Intelligence;
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.74	-7.68	-0.53	1.86e-12	DNA methylation (variation);
PAAD	cis	rs727479	0.545	rs10459592	chr15:51536141	G/T	cg21478137	chr15:51532386	CYP19A1	-0.63	-7.22	-0.51	2.29e-11	Estradiol levels;
PAAD	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.57	6.16	0.45	6.24e-9	Tonsillectomy;
PAAD	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02556042	chr12:117471086	NA	0.47	4.82	0.36	3.52e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.57	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.77	-8.25	-0.56	6.98e-14	Menarche (age at onset);
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26549601	chr10:134560360	INPP5A	-0.49	-4.7	-0.36	5.91e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4148087	0.725	rs28476477	chr21:43631874	T/C	cg08841829	chr21:43638893	ABCG1	-0.64	-5.5	-0.41	1.56e-7	Eating disorder in bipolar disorder;
PAAD	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg11498726	chr8:26250323	BNIP3L	-0.54	-5.06	-0.38	1.17e-6	Red cell distribution width;
PAAD	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.68	6.51	0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.83	0.36	3.32e-6	Schizophrenia;
PAAD	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.87	10.99	0.67	4.92e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.07	0.44	9.71e-9	Coffee consumption (cups per day);
PAAD	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06771106	chr2:113671356	IL1F7	0.63	6.46	0.46	1.33e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg11416102	chr8:651193	ERICH1	-0.96	-5.8	-0.43	3.69e-8	IgG glycosylation;
PAAD	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs367943	0.712	rs10062004	chr5:112694914	T/C	cg12552261	chr5:112820674	MCC	0.65	6.35	0.46	2.41e-9	Type 2 diabetes;
PAAD	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg04545296	chr12:48745243	ZNF641	0.36	4.53	0.34	1.2e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs3779195	0.627	rs6967728	chr7:97915637	A/G	cg21770322	chr7:97807741	LMTK2	0.53	4.62	0.35	8.2e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.38	0.46	1.98e-9	Neuroticism;
PAAD	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg03989125	chr22:38214979	NA	-0.53	-5.48	-0.41	1.77e-7	Glioblastoma;Glioma;
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-5.76	-0.42	4.59e-8	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Breast cancer;
PAAD	cis	rs4605213	0.528	rs8069453	chr17:49261750	T/C	cg25022915	chr17:49243257	NME2;NME1-NME2	0.35	4.47	0.34	1.5e-5	Height;
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg08017634	chr8:144659831	NAPRT1	0.84	4.92	0.37	2.23e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs847851	1.000	rs57951780	chr6:34852891	C/T	cg13196216	chr6:34231128	NA	-0.6	-4.83	-0.37	3.25e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg23387468	chr7:139079360	LUC7L2	0.38	4.29	0.33	3.17e-5	Diisocyanate-induced asthma;
PAAD	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.3	11.28	0.68	8.02e-22	Uric acid levels;
PAAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13012494	chr21:47604986	C21orf56	0.51	5.25	0.39	5.1e-7	Testicular germ cell tumor;
PAAD	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg10494973	chr17:80897199	TBCD	-0.54	-5.08	-0.38	1.07e-6	Breast cancer;
PAAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00152838	chr16:24741724	TNRC6A	-0.51	-4.3	-0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6137287	0.924	rs6047282	chr20:21146468	A/T	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg03871329	chr12:110338662	TCHP	0.63	4.59	0.35	9.08e-6	Neuroticism;
PAAD	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.37	0.4	2.89e-7	Resting heart rate;
PAAD	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.78	7.77	0.53	1.08e-12	Corneal astigmatism;
PAAD	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg11946769	chr3:48343235	NME6	-0.52	-4.96	-0.37	1.87e-6	Educational attainment (years of education);
PAAD	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.61	-6.73	-0.48	3.23e-10	Coronary artery disease;
PAAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26841017	chr5:34929960	DNAJC21	0.63	6.36	0.46	2.21e-9	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20299151	chr14:100758864	SLC25A29	-0.64	-6.99	-0.49	8.32e-11	Monocyte percentage of white cells;
PAAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.53	-0.57	1.39e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.86	9.42	0.61	7.2e-17	Cognitive function;
PAAD	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.32e-12	Height;
PAAD	cis	rs2735413	0.918	rs1922612	chr16:78052983	G/C	cg04733911	chr16:78082701	NA	-0.46	-4.44	-0.34	1.73e-5	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2555155	1.000	rs2555155	chr11:6522804	G/A	cg24637308	chr11:6592297	DNHD1	0.48	4.94	0.37	2e-6	DNA methylation (variation);
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.48	-5.91	-0.43	2.11e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg17372223	chr3:52568218	NT5DC2	-0.52	-5.29	-0.39	4.17e-7	Bipolar disorder;
PAAD	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.42	4.32	0.33	2.8e-5	Coronary artery disease;
PAAD	cis	rs55962025	0.804	rs362268	chr4:3242148	C/G	cg08886695	chr4:3369023	RGS12	0.45	4.26	0.33	3.54e-5	Parental longevity (mother's age at death);
PAAD	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg02493740	chr2:85810744	VAMP5	-0.45	-5.07	-0.38	1.14e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg14404164	chr7:157455790	PTPRN2	-0.61	-4.29	-0.33	3.17e-5	Colorectal cancer;
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg01097406	chr16:89675127	NA	-0.35	-4.26	-0.33	3.53e-5	Vitiligo;
PAAD	cis	rs41271473	0.687	rs4388674	chr1:228878563	A/G	cg10167378	chr1:228756711	NA	0.54	4.61	0.35	8.42e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs863345	0.967	rs12121983	chr1:158510273	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.9	-0.37	2.38e-6	Pneumococcal bacteremia;
PAAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-5.03	-0.38	1.37e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.45	4.39	0.34	2.15e-5	Mean corpuscular volume;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14235155	chr9:124796449	TTLL11	-0.55	-6.36	-0.46	2.21e-9	Immature fraction of reticulocytes;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.55	-5.57	-0.41	1.1e-7	Iron status biomarkers;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	0.39	4.66	0.35	6.78e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4713118	1.000	rs13215072	chr6:27677728	A/G	cg20933634	chr6:27740509	NA	0.68	6.45	0.46	1.44e-9	Parkinson's disease;
PAAD	cis	rs11700980	0.551	rs56852856	chr21:30114177	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg27535305	chr1:53392650	SCP2	-0.4	-4.26	-0.33	3.55e-5	Monocyte count;
PAAD	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	6.44	0.46	1.47e-9	Blood protein levels;
PAAD	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23158103	chr7:148848205	ZNF398	-0.59	-5.79	-0.42	3.97e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.41	5.07	0.38	1.12e-6	Iron status biomarkers;
PAAD	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34375054	0.687	rs12303572	chr12:125611271	G/T	cg25124228	chr12:125621409	AACS	-0.63	-6.31	-0.46	2.83e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.97	-0.37	1.78e-6	Pubertal anthropometrics;
PAAD	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.73	7.28	0.51	1.65e-11	Mosquito bite size;
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.57	-6.6	-0.47	6.32e-10	Mean corpuscular volume;
PAAD	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg19623624	chr10:135278901	LOC619207	-0.42	-4.41	-0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Electroencephalogram traits;
PAAD	cis	rs9472414	0.680	rs9472335	chr6:44709967	G/A	cg20913747	chr6:44695427	NA	0.49	4.59	0.35	9.08e-6	Height;
PAAD	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg08498647	chr11:118550644	TREH	-0.44	-4.31	-0.33	2.95e-5	Sjögren's syndrome;
PAAD	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.05	0.38	1.27e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.54	5.38	0.4	2.71e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	0.85	4.99	0.38	1.62e-6	Alzheimer's disease (late onset);
PAAD	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.59e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.57	-5.77	-0.42	4.41e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.89	9.44	0.61	6.23e-17	Testicular germ cell tumor;
PAAD	cis	rs9715521	0.691	rs60007977	chr4:59847637	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04798574	chr3:148847295	HPS3	0.59	6.72	0.48	3.36e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7168353	0.519	rs725458	chr15:93634933	A/G	cg02918577	chr15:93633145	RGMA	-0.36	-4.72	-0.36	5.41e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg27499820	chr13:21296301	IL17D	0.57	5.36	0.4	2.99e-7	PR segment;
PAAD	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.74e-7	Motion sickness;
PAAD	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	1.08	5.41	0.4	2.44e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.46	-0.4	1.92e-7	Personality dimensions;
PAAD	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18364779	chr6:26104403	HIST1H4C	0.44	4.43	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.83	-0.43	3.14e-8	HDL cholesterol;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.64	-0.42	8.1e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4704187	0.687	rs10942729	chr5:74364300	C/T	cg03227963	chr5:74354835	NA	0.49	4.86	0.37	2.94e-6	Response to amphetamines;
PAAD	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3774830	0.743	rs11728680	chr4:5462247	A/G	cg26943120	chr4:5472116	STK32B	0.36	4.4	0.34	2.02e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.99	-0.38	1.63e-6	Lung cancer;
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg16300553	chr8:8131077	NA	-0.36	-4.35	-0.33	2.47e-5	Joint mobility (Beighton score);
PAAD	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.78	8.36	0.56	3.71e-14	Neuroticism;Neuroticism (multi-trait analysis);
PAAD	cis	rs61861422	0.516	rs12767762	chr10:134443032	A/G	cg15908580	chr10:134496731	INPP5A	-0.57	-4.95	-0.37	1.96e-6	Primary sclerosing cholangitis;
PAAD	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.62	7.27	0.51	1.75e-11	HDL cholesterol levels;
PAAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.57	-6.4	-0.46	1.87e-9	Platelet distribution width;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15606692	chr11:124669480	C11orf61	0.62	6.75	0.48	2.94e-10	Pancreatic cancer;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg26597838	chr10:835615	NA	0.75	7.27	0.51	1.81e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.61	5.34	0.4	3.26e-7	Dialysis-related mortality;
PAAD	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.51	-5.67	-0.42	6.92e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.59	-0.41	1.03e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.61	-6.62	-0.47	5.88e-10	Calcium levels;
PAAD	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00908189	chr16:619842	PIGQ	0.75	7.74	0.53	1.29e-12	Height;
PAAD	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-0.87	-8.74	-0.58	3.92e-15	Exhaled nitric oxide output;
PAAD	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.15	15.69	0.79	1.38e-33	Body mass index;
PAAD	cis	rs1178968	0.901	rs7779909	chr7:72751966	G/T	cg25889504	chr7:72793014	NA	0.58	4.3	0.33	3.08e-5	Triglyceride levels;
PAAD	cis	rs9532580	0.524	rs80223071	chr13:41136477	C/T	cg21288729	chr13:41239152	FOXO1	0.54	4.32	0.33	2.81e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.65	7.77	0.53	1.12e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8032158	0.963	rs12102020	chr15:56125578	G/A	cg02198044	chr15:56286336	NEDD4	-0.52	-5.49	-0.41	1.68e-7	Keloid;
PAAD	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.78e-5	Neuroticism;
PAAD	cis	rs8032158	1.000	rs7176225	chr15:56126857	G/A	cg02198044	chr15:56286336	NEDD4	-0.52	-5.49	-0.41	1.68e-7	Keloid;
PAAD	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.43	-4.25	-0.33	3.68e-5	Height;
PAAD	cis	rs4711350	0.723	rs684119	chr6:33662667	C/T	cg13859433	chr6:33739653	LEMD2	0.76	4.73	0.36	5.11e-6	Schizophrenia;
PAAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-14.05	-0.75	2.83e-29	Coronary artery disease;
PAAD	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.95	-11.18	-0.67	1.52e-21	Monocyte count;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.29	0.33	3.12e-5	Iron status biomarkers;
PAAD	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg00677455	chr12:58241039	CTDSP2	0.55	5.77	0.42	4.23e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06854502	chr1:19923593	C1orf151	0.58	6.39	0.46	1.94e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.6	5.83	0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs3781663	0.500	rs7931752	chr11:70022846	T/C	cg11157765	chr11:69982996	ANO1	0.6	5.01	0.38	1.5e-6	Survival in rectal cancer;
PAAD	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.37	-0.4	2.96e-7	Height;
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg03605463	chr16:89740564	NA	-0.47	-4.48	-0.34	1.47e-5	Vitiligo;
PAAD	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	1.18	9.49	0.61	4.47e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	6.41	0.46	1.78e-9	Cognitive test performance;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.86	-7.93	-0.54	4.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.6	6.99	0.49	8.31e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08219700	chr8:58056026	NA	0.67	5.38	0.4	2.71e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.84	-9.93	-0.63	3.2e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg26898376	chr11:64110657	CCDC88B	0.56	5.91	0.43	2.13e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.3	-5.13	-0.38	8.62e-7	Caffeine consumption;
PAAD	cis	rs10486158	0.617	rs7794008	chr7:7383553	A/T	cg01821684	chr7:6415217	RAC1	-0.35	-4.3	-0.33	3.04e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs349045	0.560	rs10416177	chr19:44301543	G/T	cg12072164	chr19:44306565	LYPD5	-0.44	-4.58	-0.35	9.52e-6	Reading or mathematical ability;
PAAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg21698718	chr17:80085957	CCDC57	0.4	4.31	0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	6.39	0.46	1.96e-9	Breast cancer;
PAAD	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19671926	chr4:122722719	EXOSC9	0.52	5.11	0.38	9.6e-7	Type 2 diabetes;
PAAD	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-4.77	-0.36	4.26e-6	Joint mobility (Beighton score);
PAAD	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.67	7.69	0.53	1.69e-12	Body mass index;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.82	0.36	3.49e-6	Vitiligo;
PAAD	cis	rs28489187	0.706	rs233058	chr1:85798865	G/T	cg16011679	chr1:85725395	C1orf52	0.52	4.88	0.37	2.71e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09289335	chr20:42144161	L3MBTL	0.56	6.43	0.46	1.53e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg06102954	chr21:42741788	MX2	-0.48	-4.73	-0.36	5.15e-6	Melanoma;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.65	8.46	0.57	2.06e-14	Iron status biomarkers;
PAAD	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.68	-6.82	-0.48	2.01e-10	Cancer;
PAAD	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.5	5.37	0.4	2.95e-7	Carotid intima media thickness;
PAAD	cis	rs7191439	0.522	rs4597303	chr16:88763561	T/C	cg02389323	chr16:88786976	FAM38A	0.93	4.87	0.37	2.73e-6	Plateletcrit;
PAAD	cis	rs761746	0.881	rs12484606	chr22:31937476	C/T	cg01338084	chr22:32026380	PISD	-0.48	-4.35	-0.33	2.47e-5	Intelligence;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.73	5.22	0.39	5.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.87	-0.37	2.8e-6	High light scatter reticulocyte count;
PAAD	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	0.81	6.3	0.46	3.1e-9	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12781834	chr17:40169085	DNAJC7;NKIRAS2	-0.8	-7.02	-0.49	6.75e-11	Neuroticism;
PAAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg07153921	chr17:41440717	NA	-0.4	-4.26	-0.33	3.58e-5	Menopause (age at onset);
PAAD	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.05	-0.67	3.41e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.85	9.86	0.62	4.98e-18	Iron status biomarkers;
PAAD	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.64	-6.9	-0.49	1.34e-10	Dilated cardiomyopathy;
PAAD	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg13770153	chr20:60521292	NA	-0.5	-4.95	-0.37	1.97e-6	Body mass index;
PAAD	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.58	5.7	0.42	6.12e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.65	4.75	0.36	4.76e-6	Neuroticism;
PAAD	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.93	6.87	0.49	1.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg06002616	chr8:101225028	SPAG1	0.48	5.69	0.42	6.48e-8	Atrioventricular conduction;
PAAD	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.24	10.69	0.66	3.1e-20	Uric acid levels;
PAAD	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.75e-6	Height;
PAAD	cis	rs950169	0.649	rs12901010	chr15:84699034	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.69	0.48	4.07e-10	Schizophrenia;
PAAD	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.66	5.89	0.43	2.39e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.43	-4.74	-0.36	4.95e-6	Testicular germ cell tumor;
PAAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.12	0.44	7.71e-9	Major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22266764	chr19:2740123	SLC39A3	0.76	7.64	0.53	2.27e-12	Obesity-related traits;
PAAD	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs1499972	0.941	rs817507	chr3:117681065	A/C	cg07612923	chr3:117604196	NA	-1.08	-7.2	-0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12304921	0.882	rs67106267	chr12:51352452	T/C	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs732505	1.000	rs732505	chr19:5582535	G/A	cg26242866	chr19:5711310	LONP1	1.05	5.77	0.42	4.39e-8	vWF and FVIII levels;
PAAD	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg26939375	chr7:64535504	NA	0.73	8.42	0.56	2.62e-14	Aortic root size;
PAAD	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.54	-0.41	1.33e-7	Prevalent atrial fibrillation;
PAAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.65e-6	Cognitive function;
PAAD	cis	rs72827839	0.846	rs16953461	chr17:46261736	G/T	cg23391107	chr17:45924227	SP6	-0.62	-5.31	-0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.64	0.47	5.29e-10	Gut microbiota (bacterial taxa);
PAAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.67	6.68	0.48	4.33e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.45	4.68	0.35	6.32e-6	Educational attainment;
PAAD	cis	rs2278796	0.608	rs11240332	chr1:204969317	C/T	cg04862289	chr1:204966208	NFASC	0.46	4.94	0.37	2.05e-6	Mean platelet volume;
PAAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	4.97	0.37	1.78e-6	Mood instability;
PAAD	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-5.19	-0.39	6.5e-7	Total body bone mineral density;
PAAD	trans	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg20587970	chr11:113659929	NA	-1.09	-8.42	-0.56	2.54e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.37	-4.69	-0.36	6.15e-6	Schizophrenia;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.82	9.18	0.6	3.04e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg15485101	chr11:133734466	NA	0.37	4.31	0.33	2.92e-5	Parkinson's disease;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.84	8.91	0.59	1.51e-15	Sudden cardiac arrest;
PAAD	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs10214930	0.650	rs4348389	chr7:27628950	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg14146966	chr2:61757674	XPO1	-0.38	-4.69	-0.36	5.99e-6	Tuberculosis;
PAAD	cis	rs73416724	1.000	rs78567061	chr6:43293446	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11696501	0.688	rs4810461	chr20:44278445	G/A	cg11783356	chr20:44313418	WFDC10B	-0.61	-5.2	-0.39	6.46e-7	Brain structure;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg15181151	chr6:150070149	PCMT1	0.61	6.65	0.47	4.89e-10	Lung cancer;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.59	4.75	0.36	4.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Resting heart rate;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg00614314	chr15:82944287	LOC80154	0.52	4.92	0.37	2.22e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg13312174	chr5:178288687	ZNF354B	-0.59	-6.06	-0.44	1.02e-8	Sleep duration;
PAAD	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.57	4.83	0.36	3.32e-6	Obesity-related traits;
PAAD	cis	rs1421334	0.647	rs10954771	chr8:30859050	C/T	cg00964221	chr8:30240029	NA	0.47	4.41	0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09580920	chr13:20532768	ZMYM2	-0.74	-6.61	-0.47	6.1e-10	Neuroticism;
PAAD	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	0.96	7.2	0.5	2.61e-11	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20322766	chr2:7999224	NA	-0.66	-6.7	-0.48	3.74e-10	Obesity-related traits;
PAAD	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs516243	0.688	rs6540942	chr1:10737932	C/T	cg02903756	chr1:10750680	CASZ1	-0.43	-4.58	-0.35	9.79e-6	Migraine - clinic-based;
PAAD	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	5.72	0.42	5.41e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.57	-7.37	-0.51	1.04e-11	Menopause (age at onset);
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg13191508	chr8:144600686	ZC3H3	-0.82	-4.74	-0.36	4.9100000000000004e-06	Attention deficit hyperactivity disorder;
PAAD	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.47	4.87	0.37	2.81e-6	Major depressive disorder;
PAAD	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg08125733	chr17:73851984	WBP2	0.93	8.14	0.55	1.3e-13	Psoriasis;
PAAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.63	-7.07	-0.5	5.14e-11	Eye color traits;
PAAD	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.71	5.06	0.38	1.18e-6	Type 2 diabetes;
PAAD	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.79	8.8	0.58	2.84e-15	Heart rate;
PAAD	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg22771759	chr13:24902376	NA	0.43	4.33	0.33	2.75e-5	Obesity-related traits;
PAAD	cis	rs11037575	0.739	rs12283558	chr11:43712694	A/C	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.601	rs12996735	chr2:10716716	C/A	cg00105475	chr2:10696890	NA	0.64	6.8	0.48	2.29e-10	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01934142	chr4:39368026	RFC1	-0.64	-6.31	-0.46	2.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg04851639	chr8:1020857	NA	-0.58	-6.88	-0.49	1.47e-10	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg05313129	chr8:58192883	C8orf71	-0.65	-6.13	-0.45	7.23e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1376303	1.000	rs1376303	chr7:32955265	A/G	cg00566949	chr7:32927892	KBTBD2	0.51	4.31	0.33	2.91e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs80021398	chr10:46039383	A/G	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12820395	chr1:25071353	CLIC4	-0.71	-7.05	-0.5	5.83e-11	Lung cancer in ever smokers;
PAAD	cis	rs7188861	0.861	rs2032931	chr16:11444469	C/T	cg01510278	chr16:11456238	NA	-0.44	-4.34	-0.33	2.63e-5	HDL cholesterol;
PAAD	cis	rs4780401	0.655	rs11648550	chr16:11787714	C/G	cg01061890	chr16:11836724	TXNDC11	0.52	5.19	0.39	6.75e-7	Rheumatoid arthritis;
PAAD	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.47	5.53	0.41	1.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs59888335	0.858	rs7432886	chr3:80986116	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7873102	0.654	rs10114319	chr9:37960393	G/A	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	8.17e-8	Brain structure;
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.58	6.22	0.45	4.47e-9	Lung cancer;
PAAD	cis	rs11250714	0.770	rs11250694	chr10:1683666	G/A	cg10435618	chr10:838112	NA	-0.51	-4.49	-0.34	1.41e-5	Gut microbiome composition (summer);
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg24101359	chr6:42928495	GNMT	0.64	6.73	0.48	3.21e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg21823605	chr1:152486609	CRCT1	0.54	7.08	0.5	4.87e-11	Plantar warts;
PAAD	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.62	5.83	0.43	3.27e-8	Refractive astigmatism;
PAAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.02	0.38	1.42e-6	Type 2 diabetes;
PAAD	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-7.51	-0.52	4.58e-12	Axial length;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07696884	chr20:50310579	ATP9A	0.6	6.61	0.47	6.12e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg04165759	chr1:150448943	RPRD2	0.51	5.28	0.39	4.29e-7	Morning vs. evening chronotype;
PAAD	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.81	-0.79	6.49e-34	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10581256	chr10:43133692	ZNF33B	0.72	6.56	0.47	8.04e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.47	0.46	1.25e-9	Rheumatoid arthritis;
PAAD	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.63	-0.47	5.49e-10	Response to antipsychotic treatment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23885512	chr19:45515293	RELB	0.55	6.62	0.47	5.9e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14159672	chr1:205819179	PM20D1	0.55	5.36	0.4	3.03e-7	Parkinson's disease;
PAAD	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-9.32	-0.6	1.24e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg13264159	chr8:625131	ERICH1	0.7	4.64	0.35	7.48e-6	IgG glycosylation;
PAAD	cis	rs2085601	0.542	rs13143981	chr4:89989715	A/G	cg17769793	chr4:89976368	FAM13A	0.44	5.5	0.41	1.6e-7	Hair greying;
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.07	-0.38	1.14e-6	Prudent dietary pattern;
PAAD	cis	rs8027181	0.710	rs34117151	chr15:73097221	T/A	cg25632853	chr15:73088954	NA	0.4	4.31	0.33	2.88e-5	Triglyceride levels;
PAAD	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23708337	chr7:1209742	NA	0.64	4.46	0.34	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7011049	1.000	rs113124539	chr8:53854321	G/A	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.67	5.39	0.4	2.64e-7	Exhaled nitric oxide output;
PAAD	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg10820045	chr2:198174542	NA	0.45	4.46	0.34	1.6e-5	Dermatomyositis;
PAAD	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.09	-0.38	1.03e-6	Pulmonary function;
PAAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.51	5.14	0.38	8.5e-7	Bone mineral density;
PAAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg25930673	chr12:123319894	HIP1R	1.21	6.08	0.44	9.3e-9	Adiponectin levels;
PAAD	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.4	4.44	0.34	1.7e-5	High light scatter reticulocyte count;
PAAD	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.24	-0.39	5.2e-7	Reticulocyte count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05181282	chr17:2496653	PAFAH1B1	0.63	7.04	0.5	6.04e-11	Metabolite levels  (X-11787);
PAAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg03808351	chr9:123631620	PHF19	0.42	4.39	0.34	2.1e-5	Rheumatoid arthritis;
PAAD	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.47	-0.52	5.96e-12	Hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09526975	chr10:13390462	SEPHS1	0.67	6.77	0.48	2.7e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg11395062	chr17:14139857	CDRT15	0.59	6.05	0.44	1.1e-8	Temperament;
PAAD	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.66	-0.48	4.83e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.63	6.09	0.44	8.97e-9	Adiposity;
PAAD	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.6	-5.48	-0.41	1.75e-7	Prostate cancer;
PAAD	cis	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg02743256	chr7:2109353	MAD1L1	-0.51	-4.32	-0.33	2.79e-5	Coronary artery disease;
PAAD	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.48	4.72	0.36	5.42e-6	HDL cholesterol;
PAAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg14196790	chr5:131705035	SLC22A5	0.48	4.92	0.37	2.18e-6	Blood metabolite levels;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.96	12.42	0.71	6.83e-25	Menarche (age at onset);
PAAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg01815783	chr4:1047043	NA	-0.45	-4.41	-0.34	1.93e-5	Recombination rate (females);
PAAD	cis	rs6138152	0.841	rs8182947	chr20:23811186	C/T	cg16589663	chr20:23618590	CST3	-0.61	-4.33	-0.33	2.72e-5	Blood protein levels;
PAAD	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.6	0.35	8.89e-6	Serum sulfate level;
PAAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.85	9.79	0.62	7.37e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08677398	chr8:58056175	NA	0.71	4.93	0.37	2.14e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg02117656	chr17:79614917	TSPAN10	-0.58	-6.32	-0.46	2.72e-9	Eye color traits;
PAAD	cis	rs4780401	0.755	rs8191297	chr16:11766986	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.87	-0.43	2.61e-8	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg12458913	chr13:53173898	NA	0.48	4.82	0.36	3.42e-6	Lewy body disease;
PAAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.51	4.87	0.37	2.82e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg14092988	chr3:52407081	DNAH1	0.42	5.21	0.39	6.08e-7	Bipolar disorder;
PAAD	cis	rs12144049	0.662	rs4297299	chr1:152401886	G/C	cg25605289	chr1:151974222	NA	-0.35	-4.35	-0.33	2.45e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg18357526	chr6:26021779	HIST1H4A	0.66	6.56	0.47	8.03e-10	Blood metabolite levels;
PAAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg07371521	chr5:154026371	NA	0.54	6.88	0.49	1.43e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.88	0.58	1.76e-15	Menopause (age at onset);
PAAD	cis	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	4.25	0.33	3.78e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg09835421	chr16:68378352	PRMT7	-1.14	-8.38	-0.56	3.22e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2274459	0.841	rs10456075	chr6:33681603	G/A	cg06253072	chr6:33679850	C6orf125	0.64	4.89	0.37	2.58e-6	Obesity (extreme);
PAAD	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg16591659	chr17:78472290	NA	0.47	4.68	0.36	6.21e-6	Fractional excretion of uric acid;
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg17372657	chr7:1216933	NA	-0.38	-4.85	-0.37	3e-6	Longevity;Endometriosis;
PAAD	cis	rs12586317	0.576	rs6571702	chr14:35650558	C/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.62	-0.35	8.05e-6	Psoriasis;
PAAD	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.28e-5	Total body bone mineral density;
PAAD	cis	rs6743226	0.548	rs886811	chr2:242397292	G/A	cg10021735	chr2:242295487	FARP2	0.5	4.48	0.34	1.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.44	4.37	0.33	2.31e-5	IgG glycosylation;
PAAD	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.48	5.34	0.4	3.31e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20891565	chr18:20513124	RBBP8	0.58	6.42	0.46	1.66e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.35	4.94	0.37	2.07e-6	Breast cancer;
PAAD	cis	rs7301016	1.000	rs10877856	chr12:62870536	C/G	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs3106136	0.678	rs11097418	chr4:95287916	C/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs7243821	0.921	rs58061952	chr18:52630087	T/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg03037974	chr15:76606532	NA	0.51	5.9	0.43	2.27e-8	Blood metabolite levels;
PAAD	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.95	-11.08	-0.67	2.83e-21	Gut microbiome composition (winter);
PAAD	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg19980929	chr12:42632907	YAF2	0.63	7.54	0.52	4.01e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg21145140	chr5:110409467	TSLP	0.43	4.31	0.33	2.88e-5	Eosinophilic esophagitis;
PAAD	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg10072921	chr12:121022843	NA	-0.35	-4.54	-0.35	1.13e-5	High light scatter reticulocyte count;
PAAD	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.58e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.68	9.05	0.59	6.29e-16	Hemoglobin concentration;
PAAD	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.31	-0.4	3.88e-7	Blood metabolite levels;
PAAD	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.61	4.9	0.37	2.46e-6	Information processing speed;
PAAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.53	5.72	0.42	5.55e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg05625103	chr10:2543513	NA	0.58	5.99	0.44	1.46e-8	Age-related hearing impairment;
PAAD	trans	rs12714314	0.957	rs10190598	chr2:1955017	T/C	cg17170872	chr1:91487911	ZNF644	-0.76	-6.3	-0.46	3.12e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.95	0.54	3.84e-13	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.61	0.41	9.37e-8	Prudent dietary pattern;
PAAD	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.92	0.49	1.15e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-5.03	-0.38	1.38e-6	Blood pressure;
PAAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.1e-6	Parkinson's disease;
PAAD	cis	rs501120	0.535	rs10900002	chr10:44697564	A/T	cg09554077	chr10:44749378	NA	0.44	5.23	0.39	5.61e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs6142102	0.625	rs6142056	chr20:32541155	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.71	0.36	5.45e-6	Skin pigmentation;
PAAD	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg07810366	chr2:100720526	AFF3	0.36	4.76	0.36	4.54e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.41	-6.17	-0.45	5.78e-9	Mean corpuscular volume;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-5.78	-0.42	4.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg05212510	chr18:77623544	KCNG2	-0.44	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg14926445	chr8:58193284	C8orf71	-0.77	-6.08	-0.44	9.14e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs3736757	1.000	rs4469687	chr1:184679019	A/G	cg05045817	chr1:184633523	NA	0.44	4.71	0.36	5.64e-6	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg04482110	chr17:41364121	TMEM106A	0.38	4.37	0.33	2.29e-5	Menopause (age at onset);
PAAD	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.57	6.32	0.46	2.77e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.59	5.36	0.4	3.06e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.58	5.93	0.43	2e-8	Coronary artery disease;
PAAD	cis	rs2147959	0.831	rs7555386	chr1:228630589	C/G	cg02753203	chr1:228287806	NA	-0.6	-4.84	-0.37	3.16e-6	Adult asthma;
PAAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.6	-0.52	2.77e-12	Height;
PAAD	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11169225	0.590	rs7305534	chr12:50341610	T/C	cg23855989	chr12:50355821	AQP5	0.4	4.36	0.33	2.38e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg01064725	chr1:204461714	NA	-0.5	-4.75	-0.36	4.76e-6	Schizophrenia;
PAAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.7	-6.11	-0.44	8.06e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07685180	chr8:600429	NA	0.98	6.49	0.47	1.15e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.73	0.48	3.25e-10	Alzheimer's disease;
PAAD	cis	rs1577917	0.687	rs34618171	chr6:86811165	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.14	-0.5	3.66e-11	Response to antipsychotic treatment;
PAAD	cis	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24719901	chr15:55489235	RSL24D1	0.49	4.89	0.37	2.54e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg27455613	chr17:80820699	TBCD	-0.5	-4.98	-0.37	1.7e-6	Reticulocyte count;
PAAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg25319279	chr11:5960081	NA	0.68	7.13	0.5	3.81e-11	DNA methylation (variation);
PAAD	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.61	6.3	0.46	3.01e-9	Height;
PAAD	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22857025	chr5:266934	NA	-1.3	-10.09	-0.63	1.18e-18	Breast cancer;
PAAD	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7626444	1.000	rs7626444	chr3:196504902	G/C	cg17657502	chr3:196358703	NA	-0.36	-4.34	-0.33	2.64e-5	Monocyte count;
PAAD	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00684032	chr4:1343700	KIAA1530	0.46	4.82	0.36	3.39e-6	Obesity-related traits;
PAAD	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.78	-8.65	-0.57	6.68e-15	Handedness;
PAAD	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg04851639	chr8:1020857	NA	-0.64	-8.11	-0.55	1.5700000000000001e-13	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs89107	0.550	rs11758454	chr6:118848799	A/C	cg21191810	chr6:118973309	C6orf204	0.39	4.57	0.35	1.01e-5	Cardiac structure and function;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02071572	chr4:1403502	NA	0.48	6.17	0.45	5.97e-9	Longevity;
PAAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Calcium levels;
PAAD	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.4	-0.4	2.55e-7	Height;
PAAD	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg25558440	chr8:11882962	NA	-0.45	-4.33	-0.33	2.74e-5	Triglycerides;
PAAD	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.35	4.67	0.35	6.45e-6	Schizophrenia;
PAAD	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.51	-5.14	-0.38	8.26e-7	Schizophrenia;
PAAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg06740227	chr12:86229804	RASSF9	0.5	4.95	0.37	1.91e-6	Major depressive disorder;
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.88	-10.15	-0.64	8.36e-19	Iron status biomarkers;
PAAD	cis	rs713477	0.845	rs4898863	chr14:55910284	T/A	cg13175173	chr14:55914753	NA	-0.33	-4.46	-0.34	1.61e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.67	-6.34	-0.46	2.49e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7828089	0.819	rs11136021	chr8:22244672	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	4.36	0.33	2.41e-5	Verbal declarative memory;
PAAD	cis	rs7631605	0.905	rs7611106	chr3:37017024	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2651899	0.934	rs3795268	chr1:3089976	G/A	cg07622451	chr1:3079886	PRDM16	-0.39	-4.52	-0.34	1.23e-5	Migraine;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg11416102	chr8:651193	ERICH1	0.95	5.94	0.43	1.9e-8	IgG glycosylation;
PAAD	cis	rs375066	0.868	rs368079	chr19:44393356	C/T	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg11783602	chr8:55087084	NA	-0.64	-7.7	-0.53	1.6e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.84	11.8	0.69	3.18e-23	Bone mineral density;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.7	4.97	0.37	1.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16521836	chr3:113775302	QTRTD1;KIAA1407	0.6	6.39	0.46	1.93e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg21496419	chr19:44306685	LYPD5	-0.35	-4.53	-0.35	1.17e-5	Breast cancer;
PAAD	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.72e-5	Self-reported allergy;
PAAD	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.69	7.43	0.52	7.5e-12	Blood protein levels;
PAAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.69	9.33	0.6	1.19e-16	Eye color traits;
PAAD	cis	rs113123495	0.609	rs806711	chr19:5618654	C/T	cg26242866	chr19:5711310	LONP1	0.97	5.2	0.39	6.46e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.54	6.72	0.48	3.43e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg22189786	chr22:42395067	WBP2NL	0.51	4.3	0.33	2.99e-5	Birth weight;
PAAD	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-7.42	-0.52	7.91e-12	Heart rate;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs6074578	0.597	rs7353361	chr20:134400	G/A	cg16931068	chr20:139680	DEFB127	0.39	5.01	0.38	1.49e-6	Hirschsprung disease;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.54	-0.35	1.14e-5	Tonsillectomy;
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.64	6.73	0.48	3.25e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2278796	0.697	rs2278798	chr1:204949767	A/G	cg17947172	chr1:204966197	NFASC	0.4	4.67	0.35	6.61e-6	Mean platelet volume;
PAAD	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg01028140	chr2:1542097	TPO	-1.13	-9.19	-0.6	2.8e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.76	-8.63	-0.57	7.8e-15	Lewy body disease;
PAAD	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.73	-6.06	-0.44	1.03e-8	Schizophrenia;
PAAD	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.88	11.21	0.67	1.22e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.69	7.17	0.5	3.09e-11	Colorectal cancer;
PAAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.63	4.67	0.35	6.44e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs6850606	0.599	rs12510763	chr4:42868639	G/A	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.57e-11	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg26939375	chr7:64535504	NA	-0.74	-8.62	-0.57	8.02e-15	Aortic root size;
PAAD	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.7	5.25	0.39	4.94e-7	Coronary artery calcification;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14159672	chr1:205819179	PM20D1	0.52	5.03	0.38	1.37e-6	Parkinson's disease;
PAAD	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.56	0.57	1.13e-14	Corneal astigmatism;
PAAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.95	-0.54	3.82e-13	Mood instability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00145849	chr4:39699494	UBE2K	0.55	6.39	0.46	1.95e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg05083358	chr7:2394359	EIF3B	-0.69	-5.18	-0.39	6.89e-7	Multiple sclerosis;
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.21	-0.5	2.47e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-5.32	-0.4	3.61e-7	Cognitive function;
PAAD	cis	rs3026101	0.671	rs886361	chr17:5292762	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg10705379	chr10:99080932	FRAT1	-0.46	-5.23	-0.39	5.65e-7	Monocyte count;
PAAD	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs7762544	0.756	rs1969767	chr6:41364110	A/G	cg18315060	chr6:41374532	NA	0.55	4.36	0.33	2.41e-5	Periodontitis;
PAAD	cis	rs1075265	0.933	rs2042143	chr2:54343514	C/T	cg04546899	chr2:54196757	PSME4	0.32	4.53	0.34	1.21e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25632853	chr15:73088954	NA	0.4	4.55	0.35	1.08e-5	Triglyceride levels;
PAAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.49	-4.75	-0.36	4.58e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04852280	chr1:26496234	ZNF593	0.61	6.71	0.48	3.56e-10	Monocyte percentage of white cells;
PAAD	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.45	4.61	0.35	8.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.65	5.8	0.43	3.66e-8	Corneal astigmatism;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-6.44	-0.46	1.52e-9	Lymphocyte counts;
PAAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.53	-0.34	1.2e-5	IgG glycosylation;
PAAD	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg10395934	chr14:104002654	TRMT61A	0.48	4.67	0.35	6.65e-6	Body mass index;
PAAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	8.1	0.55	1.68e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.72	8.16	0.55	1.16e-13	Educational attainment;
PAAD	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.95	10.02	0.63	1.83e-18	Multiple sclerosis;
PAAD	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.36	4.73	0.36	5.05e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	1.13	14.27	0.76	7.42e-30	Height;
PAAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.37	0.33	2.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.39	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.55	5.11	0.38	9.57e-7	Resting heart rate;
PAAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs2274459	1.000	rs35445446	chr6:33716745	C/T	cg06253072	chr6:33679850	C6orf125	0.68	4.6	0.35	8.93e-6	Obesity (extreme);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08283932	chr20:43280707	ADA	-0.71	-7.4	-0.51	8.56e-12	Smoking initiation;
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg15181151	chr6:150070149	PCMT1	0.54	5.74	0.42	4.94e-8	Lung cancer;
PAAD	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.87	-9.98	-0.63	2.31e-18	Coronary artery disease;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.33	6.17	0.45	5.95e-9	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg22827986	chr11:48284249	OR4X1	-0.44	-5.54	-0.41	1.31e-7	Migraine - clinic-based;
PAAD	cis	rs1957429	0.520	rs66511472	chr14:65330330	C/A	cg23373153	chr14:65346875	NA	-1.21	-5.92	-0.43	2.06e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.69	-6.96	-0.49	9.67e-11	White matter hyperintensity burden;
PAAD	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.86	7.24	0.51	2.1e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6718203	0.730	rs45474996	chr2:60723905	G/A	cg10480506	chr2:60280451	NA	0.67	4.46	0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg16606324	chr3:10149918	C3orf24	0.54	4.63	0.35	7.77e-6	Alzheimer's disease;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-0.75	-5.97	-0.44	1.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17601876	0.814	rs3889391	chr15:51558422	G/A	cg19946085	chr15:51559439	CYP19A1	-0.47	-4.26	-0.33	3.58e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg06917634	chr15:78832804	PSMA4	-0.44	-4.32	-0.33	2.79e-5	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.47	-0.34	1.52e-5	Response to amphetamines;
PAAD	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg06057569	chr22:50219754	BRD1	0.59	4.3	0.33	3.1e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9659323	1.000	rs56897173	chr1:119515732	G/A	cg26570165	chr1:119541833	NA	-0.45	-4.56	-0.35	1.05e-5	Body mass index;
PAAD	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.77	7.6	0.52	2.81e-12	Coronary artery disease;
PAAD	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.52	7.0	0.49	7.61e-11	Ewing sarcoma;
PAAD	cis	rs11811982	0.793	rs74683900	chr1:227226260	C/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.75	0.36	4.71e-6	Optic disc area;
PAAD	cis	rs288342	0.642	rs432527	chr2:183615138	C/T	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg00522288	chr12:125625016	AACS	-0.6	-6.54	-0.47	8.81e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20016874	chr14:55518446	MAPK1IP1L	0.57	6.43	0.46	1.59e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1358748	0.522	rs11208997	chr1:67560956	C/T	cg02640540	chr1:67518911	SLC35D1	0.7	4.68	0.35	6.27e-6	Tuberculosis;
PAAD	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.32	-0.46	2.72e-9	Menopause (age at onset);
PAAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.07	0.38	1.16e-6	Melanoma;
PAAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg23281280	chr6:28129359	ZNF389	0.51	4.33	0.33	2.75e-5	Parkinson's disease;
PAAD	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.59	-0.35	9.33e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg22710661	chr11:17411071	KCNJ11	0.45	4.53	0.35	1.18e-5	Type 2 diabetes;
PAAD	cis	rs375066	0.935	rs384522	chr19:44405044	A/T	cg11993925	chr19:44307056	LYPD5	0.51	6.43	0.46	1.6e-9	Breast cancer;
PAAD	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg27511599	chr7:32358540	NA	0.8	4.67	0.35	6.52e-6	Body mass index;
PAAD	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.78	9.65	0.62	1.79e-17	Bladder cancer;
PAAD	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.64	5.82	0.43	3.32e-8	Obesity-related traits;
PAAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13012494	chr21:47604986	C21orf56	0.47	4.96	0.37	1.83e-6	Testicular germ cell tumor;
PAAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	4.77	0.36	4.23e-6	Asthma;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg05585544	chr11:47624801	NA	-0.52	-5.93	-0.43	1.94e-8	Subjective well-being;
PAAD	cis	rs2882667	0.690	rs825669	chr5:138066947	A/T	cg09476006	chr5:138032270	NA	-0.46	-5.91	-0.43	2.18e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs62408225	1.000	rs62408222	chr6:90948476	A/G	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.3	0.46	3.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.34	6.27	0.45	3.56e-9	Type 2 diabetes;
PAAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg24565620	chr2:194026	NA	-0.55	-4.75	-0.36	4.77e-6	Blood protein levels;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.78e-5	Cognitive function;
PAAD	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs727479	0.502	rs3825800	chr15:51506663	A/C	cg21478137	chr15:51532386	CYP19A1	0.45	4.47	0.34	1.55e-5	Estradiol levels;
PAAD	cis	rs8005172	0.676	rs4445832	chr14:88410227	G/C	cg18078958	chr14:88630771	NA	0.46	5.61	0.41	9.12e-8	Parkinson's disease;
PAAD	cis	rs17761864	0.791	rs72817574	chr17:2078890	G/A	cg16513277	chr17:2031491	SMG6	0.47	4.64	0.35	7.34e-6	Esophageal cancer (squamous cell);
PAAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.31	-0.33	2.94e-5	Height;
PAAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg05785598	chr3:49045655	WDR6	0.42	5.17	0.39	7.39e-7	Parkinson's disease;
PAAD	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg02910952	chr12:132569714	EP400NL	-0.62	-4.7	-0.36	5.68e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg14092571	chr14:90743983	NA	0.51	4.87	0.37	2.73e-6	Mortality in heart failure;
PAAD	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	1.13	6.12	0.44	7.48e-9	Plasma clusterin levels;
PAAD	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg08992911	chr2:238395768	MLPH	0.7	6.99	0.49	7.97e-11	Prostate cancer;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs10450586	0.932	rs7482097	chr11:27327167	G/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg05697835	chr1:2722811	NA	-0.44	-4.93	-0.37	2.16e-6	Ulcerative colitis;
PAAD	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg06212747	chr3:49208901	KLHDC8B	0.6	4.69	0.36	5.95e-6	Menarche (age at onset);
PAAD	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.75	-0.48	2.89e-10	Total body bone mineral density;
PAAD	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.57	4.79	0.36	3.91e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs9398803	0.687	rs12208811	chr6:126926898	T/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg04106633	chr4:1044584	NA	0.53	4.91	0.37	2.37e-6	Recombination rate (males);
PAAD	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	7.41	0.52	7.97e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.76	-0.36	4.45e-6	Initial pursuit acceleration;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06815965	chr1:205818668	PM20D1	0.73	8.14	0.55	1.31e-13	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16714605	chr19:10765132	ILF3;LOC147727	0.6	7.1	0.5	4.49e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg14583973	chr4:3374767	RGS12	0.34	4.96	0.37	1.83e-6	Mean platelet volume;
PAAD	cis	rs727479	0.760	rs8024515	chr15:51532276	T/C	cg21478137	chr15:51532386	CYP19A1	0.62	6.99	0.49	8.04e-11	Estradiol levels;
PAAD	cis	rs4443100	0.832	rs4434089	chr22:23383863	A/G	cg14186256	chr22:23484241	RTDR1	-0.49	-4.36	-0.33	2.35e-5	Serum parathyroid hormone levels;
PAAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg15847926	chr7:2749597	AMZ1	-0.37	-4.43	-0.34	1.82e-5	Height;
PAAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.58	-5.49	-0.41	1.68e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs35084382	1.000	rs114503346	chr5:172192350	C/T	cg09799633	chr5:172199460	DUSP1	-0.95	-4.34	-0.33	2.56e-5	Optic cup area;
PAAD	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.68	7.64	0.53	2.26e-12	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09690373	chr8:29120781	KIF13B	-0.63	-6.35	-0.46	2.37e-9	Smoking initiation;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-6.61	-0.47	6.18e-10	Lymphocyte counts;
PAAD	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.6	5.84	0.43	3.07e-8	Alcohol dependence;
PAAD	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.68	-5.33	-0.4	3.49e-7	Obesity-related traits;
PAAD	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg06740227	chr12:86229804	RASSF9	0.5	4.94	0.37	2.07e-6	Major depressive disorder;
PAAD	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.6	5.83	0.43	3.2e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg10589385	chr1:150898437	SETDB1	0.37	4.63	0.35	7.93e-6	Melanoma;
PAAD	cis	rs6882716	0.591	rs10044607	chr5:10806058	G/A	cg14521931	chr5:10832172	NA	-0.9	-6.05	-0.44	1.09e-8	Alcohol consumption (maxi-drinks);
PAAD	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.6	6.36	0.46	2.2e-9	Mean platelet volume;
PAAD	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg08079166	chr15:68083412	MAP2K5	-0.54	-4.99	-0.38	1.61e-6	Restless legs syndrome;
PAAD	cis	rs9399135	0.627	rs6930223	chr6:135424203	G/T	cg24558204	chr6:135376177	HBS1L	0.47	4.77	0.36	4.24e-6	Red blood cell count;
PAAD	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-7.18	-0.5	2.88e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.53	-4.69	-0.36	5.93e-6	Kawasaki disease;
PAAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.48	0.34	1.44e-5	Mean corpuscular volume;
PAAD	trans	rs875971	0.660	rs801217	chr7:66010577	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.65	-8.23	-0.56	7.84e-14	Schizophrenia;
PAAD	cis	rs12580194	0.593	rs7960760	chr12:55722311	A/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.29	0.33	3.12e-5	Cancer;
PAAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.67	6.73	0.48	3.21e-10	Primary sclerosing cholangitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13268919	chr11:842945	TSPAN4;POLR2L	0.63	6.31	0.46	2.86e-9	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13517398	chr18:19180670	ESCO1	-0.77	-6.54	-0.47	8.88e-10	Neuroticism;
PAAD	cis	rs7224314	1.000	rs8072527	chr17:65367220	A/G	cg01507342	chr17:65387096	PITPNC1	-0.6	-5.4	-0.4	2.51e-7	Diisocyanate-induced asthma;
PAAD	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.73	-6.36	-0.46	2.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-7.36	-0.51	1.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7580658	0.554	rs2069915	chr2:128178378	G/A	cg21855830	chr2:127963489	CYP27C1	0.46	4.37	0.33	2.31e-5	Protein C levels;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg01097406	chr16:89675127	NA	-0.35	-4.3	-0.33	3.1e-5	Vitiligo;
PAAD	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15844609	chr19:38806846	YIF1B	0.62	6.79	0.48	2.36e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs72901758	0.768	rs55730737	chr17:76250777	T/A	cg26068271	chr17:76253126	NA	0.53	5.06	0.38	1.18e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9944275	0.860	rs12902991	chr15:97201833	A/G	cg23969200	chr15:97326567	SPATA8	0.66	4.37	0.33	2.27e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg06781209	chr11:61594997	FADS2	-0.52	-4.49	-0.34	1.39e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.19	0.6	2.74e-16	Parkinson's disease;
PAAD	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg14098780	chr14:51061306	ATL1	0.48	4.31	0.33	2.89e-5	Cancer;
PAAD	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.11	0.55	1.61e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17154702	0.506	rs74525088	chr8:8628413	A/T	cg01851573	chr8:8652454	MFHAS1	0.9	6.69	0.48	4.09e-10	Neurocognitive impairment in HIV-1 infection (continuous);
PAAD	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.74	6.56	0.47	7.87e-10	Breast cancer;
PAAD	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs11671005	0.696	rs73066211	chr19:58997079	C/T	cg25952890	chr19:58913133	NA	0.74	5.7	0.42	6.16e-8	Mean platelet volume;
PAAD	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.73	-6.73	-0.48	3.22e-10	Asthma;
PAAD	cis	rs6940638	0.637	rs13217239	chr6:27254967	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.04	-0.38	1.33e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-6.08	-0.44	9.18e-9	Multiple myeloma (IgH translocation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23630158	chr17:74722648	C17orf95;JMJD6	0.66	6.7	0.48	3.78e-10	Obesity-related traits;
PAAD	cis	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg00400743	chr4:148603008	PRMT10	-0.71	-4.48	-0.34	1.48e-5	Pulse pressure;
PAAD	cis	rs3781663	0.500	rs10160730	chr11:70021687	T/C	cg11157765	chr11:69982996	ANO1	0.6	5.01	0.38	1.5e-6	Survival in rectal cancer;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.91	6.91	0.49	1.28e-10	Alzheimer's disease;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg07153921	chr17:41440717	NA	0.42	4.48	0.34	1.45e-5	Menopause (age at onset);
PAAD	cis	rs12754538	1.000	rs12754538	chr1:8473813	A/G	cg06159269	chr1:8767347	RERE	-0.4	-4.71	-0.36	5.49e-6	Subjective well-being;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21061731	chr11:44116994	EXT2	-0.69	-6.46	-0.46	1.35e-9	Lung cancer in ever smokers;
PAAD	cis	rs9487051	0.834	rs351728	chr6:109549099	T/C	cg21918786	chr6:109611834	NA	-0.41	-4.54	-0.35	1.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.39	-0.34	2.12e-5	Mean corpuscular volume;
PAAD	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.48	0.41	1.76e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.54	-5.45	-0.4	2.02e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01776495	chr12:6858115	MLF2	-0.58	-6.34	-0.46	2.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg07154921	chr7:157260426	NA	0.44	4.26	0.33	3.6e-5	Body mass index;
PAAD	cis	rs12541635	1.000	rs1366965	chr8:107085224	T/A	cg10147462	chr8:107024639	NA	-0.44	-4.62	-0.35	8.06e-6	Age of smoking initiation;
PAAD	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.49	-5.28	-0.39	4.45e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.81	-0.36	3.53e-6	Prevalent atrial fibrillation;
PAAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.49	0.34	1.39e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-7.79	-0.53	9.63e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.55e-21	Breast cancer;
PAAD	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.06	-0.55	2.15e-13	Brugada syndrome;
PAAD	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.75	-8.03	-0.55	2.45e-13	Height;
PAAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.87	10.19	0.64	6.73e-19	Tuberculosis;
PAAD	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-5.75	-0.42	4.73e-8	Blood protein levels;
PAAD	cis	rs11696501	0.694	rs6073825	chr20:44258217	T/C	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.59	-7.34	-0.51	1.2e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.53	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.49	-4.28	-0.33	3.25e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.75	8.4	0.56	2.96e-14	Longevity;
PAAD	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.68	6.63	0.47	5.63e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.74	5.16	0.39	7.5e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.51	-0.47	1.03e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.68	-6.6	-0.47	6.6e-10	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.79	8.58	0.57	1.04e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9972944	0.639	rs2052153	chr17:63800382	G/T	cg07283582	chr17:63770753	CCDC46	-0.59	-7.02	-0.49	6.99e-11	Total body bone mineral density;
PAAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg10018233	chr7:150070692	REPIN1	0.66	7.05	0.5	5.99e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-11.79	-0.69	3.38e-23	Blood trace element (Zn levels);
PAAD	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.54	4.39	0.34	2.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6466055	0.661	rs7776832	chr7:104886669	T/C	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.2	0.6	2.63e-16	Gut microbiome composition (summer);
PAAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.43	-0.46	1.56e-9	Aortic root size;
PAAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11025523	0.904	rs10833311	chr11:20379638	C/T	cg01397325	chr11:20386022	HTATIP2	0.37	4.72	0.36	5.31e-6	Obesity-related traits;
PAAD	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.49	5.76	0.42	4.58e-8	Height;
PAAD	cis	rs7255045	0.788	rs2290689	chr19:12958360	T/C	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09525994	chr12:48512905	PFKM	0.64	7.2	0.5	2.64e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg02250501	chr15:90694978	NA	-0.46	-4.3	-0.33	2.98e-5	Rheumatoid arthritis;
PAAD	cis	rs9815354	1.000	rs9820192	chr3:41889281	G/A	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-9.54	-0.61	3.36e-17	Total body bone mineral density;
PAAD	cis	rs1593	0.532	rs11132388	chr4:187219418	T/C	cg14349977	chr4:187219430	NA	-0.41	-4.37	-0.33	2.29e-5	Activated partial thromboplastin time;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.37	0.71	9.36e-25	Prudent dietary pattern;
PAAD	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01402698	chr19:50373141	AKT1S1	0.68	7.98	0.54	3.32e-13	Monocyte percentage of white cells;
PAAD	cis	rs6681460	1.000	rs4655648	chr1:67114309	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.47	0.52	5.7e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg22710661	chr11:17411071	KCNJ11	0.42	4.42	0.34	1.86e-5	Type 2 diabetes;
PAAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs990171	0.513	rs7573566	chr2:103115205	T/C	cg13897122	chr2:103039542	IL18RAP	-0.48	-5.31	-0.4	3.91e-7	Lymphocyte counts;
PAAD	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg06609049	chr19:2785107	THOP1	1.16	15.8	0.79	6.98e-34	Total cholesterol levels;
PAAD	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-8.11	-0.55	1.5700000000000001e-13	Colorectal cancer;
PAAD	cis	rs2120243	1.000	rs9289982	chr3:157144444	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.78	0.36	4.09e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	trans	rs901683	0.850	rs73291113	chr10:46095065	G/C	cg07935355	chr19:50391064	TBC1D17	1.11	6.3	0.46	2.98e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.44	-0.34	1.71e-5	Height;
PAAD	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.11	0.55	1.61e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs17601876	0.814	rs28637352	chr15:51559666	C/A	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs4253772	0.575	rs2007797	chr22:46803374	G/A	cg24881330	chr22:46731750	TRMU	0.98	4.93	0.37	2.11e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2834506	0.521	rs2243982	chr21:35901290	C/T	cg16756527	chr21:35891075	RCAN1	0.33	4.43	0.34	1.78e-5	Cancer;
PAAD	cis	rs6494488	0.500	rs72741320	chr15:64721745	C/A	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.62e-6	Coronary artery disease;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.59	4.75	0.36	4.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.61	-5.93	-0.43	1.95e-8	Ear protrusion;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg06815965	chr1:205818668	PM20D1	0.65	7.43	0.52	7.29e-12	Menarche (age at onset);
PAAD	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.74	-6.98	-0.49	8.52e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6132905	0.590	rs7270022	chr20:2615108	T/C	cg23469025	chr20:2645106	IDH3B	0.6	4.35	0.33	2.47e-5	Mumps;
PAAD	cis	rs1468333	0.667	rs10515499	chr5:137705218	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14851468	chr5:179071604	C5orf60	0.47	4.84	0.37	3.22e-6	Lung cancer;
PAAD	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07054040	chr15:37393282	MEIS2	-0.72	-6.7	-0.48	3.73e-10	Neuroticism;
PAAD	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.49	-5.09	-0.38	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs62238980	0.522	rs62238977	chr22:32573224	G/C	cg02631450	chr22:32366979	NA	1.1	5.34	0.4	3.29e-7	Childhood ear infection;
PAAD	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	10.84	0.66	1.23e-20	Menarche (age at onset);
PAAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-7.6	-0.52	2.86e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.64	-6.0	-0.44	1.37e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08677398	chr8:58056175	NA	0.65	4.39	0.34	2.13e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg08888203	chr3:10149979	C3orf24	0.71	5.4	0.4	2.54e-7	Alzheimer's disease;
PAAD	cis	rs863345	0.604	rs2051450	chr1:158464062	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.9	-0.37	2.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	9.39	0.61	8.28e-17	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05663655	chr7:107532014	DLD	0.63	7.13	0.5	3.85e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs639012	0.621	rs542126	chr11:85811238	A/G	cg07180834	chr11:85838833	NA	-0.41	-4.58	-0.35	9.56e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg23306229	chr2:178417860	TTC30B	0.61	4.36	0.33	2.4e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs71520386	0.846	rs35247857	chr7:22820520	G/A	cg04907244	chr7:22894795	SNORD93	0.49	4.27	0.33	3.5e-5	Fibrinogen levels;
PAAD	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.01	-0.38	1.52e-6	Mean corpuscular volume;
PAAD	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24829772	chr8:18577488	PSD3	-0.62	-6.67	-0.48	4.47e-10	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg27182935	chr16:89790473	ZNF276	-0.69	-4.37	-0.33	2.28e-5	Skin colour saturation;
PAAD	trans	rs9409082	0.684	rs7865367	chr9:108978073	A/G	cg07010948	chr13:79181613	NA	-0.34	-6.37	-0.46	2.09e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.62	-6.76	-0.48	2.81e-10	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.9	-6.67	-0.48	4.36e-10	Psoriasis vulgaris;
PAAD	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs2790216	1.000	rs1630731	chr10:59959530	T/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.76	-6.18	-0.45	5.51e-9	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.01	14.4	0.76	3.4e-30	Heart rate;
PAAD	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.43	6.35	0.46	2.32e-9	Neuroticism;
PAAD	cis	rs6782025	0.837	rs4510329	chr3:120791626	C/G	cg16417163	chr3:121280760	NA	0.48	4.98	0.37	1.67e-6	Aging (facial);
PAAD	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg00601450	chr5:74908170	NA	0.48	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03732293	chr1:179335087	C1orf125	0.58	6.32	0.46	2.73e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.54	-5.14	-0.38	8.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	9.68	0.62	1.5e-17	Personality dimensions;
PAAD	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg11941060	chr3:133502564	NA	-0.52	-5.4	-0.4	2.5e-7	Iron status biomarkers;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg04369109	chr6:150039330	LATS1	-0.46	-4.63	-0.35	7.88e-6	Lung cancer;
PAAD	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.55	-0.57	1.25e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.75	-8.14	-0.55	1.32e-13	Prudent dietary pattern;
PAAD	cis	rs7551345	0.853	rs12133730	chr1:31752752	G/A	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg09659197	chr4:152720779	NA	-0.46	-6.15	-0.45	6.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg22764639	chr12:106532701	NUAK1	0.43	4.57	0.35	9.83e-6	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04798574	chr3:148847295	HPS3	0.61	6.52	0.47	9.67e-10	Myopia (pathological);
PAAD	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg10356904	chr22:49881777	NA	-0.5	-5.37	-0.4	2.94e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-1.06	-7.37	-0.51	1e-11	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03575163	chr10:104503671	C10orf26	-0.68	-6.55	-0.47	8.21e-10	Neuroticism;
PAAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	1.21	15.77	0.79	8.21e-34	Longevity;
PAAD	cis	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg27411982	chr8:10470053	RP1L1	0.48	5.58	0.41	1.07e-7	Myopia (pathological);
PAAD	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.75	7.46	0.52	6.31e-12	HIV-1 control;
PAAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.5	-5.79	-0.42	3.98e-8	Personality dimensions;
PAAD	trans	rs1527934	0.568	rs17735738	chr8:117357096	C/G	cg22862450	chr1:40025411	LOC728448	0.57	6.3	0.46	3.02e-9	Systemic juvenile idiopathic arthritis;
PAAD	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-4.75	-0.36	4.62e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.97	13.46	0.74	1.11e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.82	6.24	0.45	4.07e-9	Alzheimer's disease;
PAAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg02475695	chr16:616220	NHLRC4	0.45	5.12	0.38	9.18e-7	Height;
PAAD	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.58	6.15	0.45	6.58e-9	Bladder cancer;
PAAD	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	7.14	0.5	3.5e-11	Eosinophil percentage of white cells;
PAAD	trans	rs901683	1.000	rs34539215	chr10:46087378	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01765077	chr12:122356316	WDR66	0.59	6.76	0.48	2.71e-10	Mean corpuscular volume;
PAAD	cis	rs6834538	1.000	rs6533627	chr4:113479135	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.5	-4.57	-0.35	1e-5	Free thyroxine concentration;
PAAD	cis	rs3996993	0.809	rs12524918	chr6:52736180	T/C	cg20803780	chr6:52668592	GSTA1	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;
PAAD	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.98	-7.99	-0.54	3.06e-13	Blood protein levels;
PAAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg09324608	chr17:30823087	MYO1D	0.48	4.83	0.36	3.32e-6	Schizophrenia;
PAAD	cis	rs73019876	0.869	rs2666457	chr19:22126880	T/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs1499972	0.941	rs73183041	chr3:117610500	C/A	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs2814982	0.605	rs35429796	chr6:34474639	G/T	cg17674042	chr6:34482479	PACSIN1	-1.26	-7.44	-0.52	6.8e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.68	-4.87	-0.37	2.82e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116175783	0.557	rs62188138	chr2:162267446	T/C	cg08807892	chr2:162101083	NA	-0.65	-4.77	-0.36	4.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.59	6.03	0.44	1.2e-8	Reticulocyte count;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12955076	chr3:186389477	HRG	0.43	4.37	0.33	2.32e-5	Myopia (pathological);
PAAD	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.66	7.08	0.5	5.1e-11	Crohn's disease;
PAAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.69	-7.39	-0.51	9.32e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26856871	chr21:45363775	AGPAT3	-0.68	-6.88	-0.49	1.47e-10	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg12215294	chr3:40350768	EIF1B	0.45	4.37	0.33	2.3e-5	Renal cell carcinoma;
PAAD	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.15	18.41	0.83	1.6e-40	Platelet distribution width;
PAAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg03037974	chr15:76606532	NA	0.54	6.41	0.46	1.75e-9	Blood metabolite levels;
PAAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.51	0.57	1.54e-14	Menopause (age at onset);
PAAD	cis	rs17750015	0.733	rs12454365	chr18:54396215	G/A	cg18434998	chr18:54306185	TXNL1	-0.54	-5.27	-0.39	4.56e-7	Depression and alcohol dependence;
PAAD	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.35	-0.4	3.19e-7	Retinal vascular caliber;
PAAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg08632701	chr21:37451849	NA	-0.6	-6.17	-0.45	5.8e-9	Mitral valve prolapse;
PAAD	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1198430	0.562	rs7523811	chr1:23789567	C/T	cg24580199	chr1:23763081	ASAP3	-0.54	-4.71	-0.36	5.51e-6	Total cholesterol levels;
PAAD	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.6	-4.44	-0.34	1.74e-5	Subjective well-being;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.62	-5.76	-0.42	4.59e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.77	8.91	0.59	1.45e-15	Eosinophil percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12940923	0.529	rs9908667	chr17:56377467	G/C	cg26072851	chr17:56296444	MKS1	-0.61	-5.09	-0.38	1.04e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-4.31	-0.33	2.97e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.64	6.79	0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17376030	chr22:41985996	PMM1	0.69	4.78	0.36	4.08e-6	Vitiligo;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24375287	chr13:50366190	KPNA3	-0.65	-6.36	-0.46	2.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.68	5.97	0.44	1.62e-8	Diabetic retinopathy;
PAAD	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.57	-5.46	-0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.55	-7.4	-0.51	8.47e-12	Height;
PAAD	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg27411982	chr8:10470053	RP1L1	0.47	5.17	0.39	7.26e-7	Retinal vascular caliber;
PAAD	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.31	-0.51	1.44e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.25	0.45	4.03e-9	Bladder cancer;
PAAD	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg14349672	chr11:133703707	NA	0.58	6.63	0.47	5.64e-10	Childhood ear infection;
PAAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.51	-5.86	-0.43	2.79e-8	Colorectal or endometrial cancer;
PAAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg25487775	chr2:162093969	NA	0.49	4.82	0.36	3.39e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs258892	0.895	rs13181437	chr5:72051657	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg14926445	chr8:58193284	C8orf71	-0.72	-5.54	-0.41	1.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-6.39	-0.46	1.92e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.46	5.94	0.43	1.91e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.54	-5.99	-0.44	1.42e-8	Neuroticism;
PAAD	cis	rs425535	0.757	rs352027	chr4:74793922	A/C	cg01447579	chr4:74847100	PF4	-0.67	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.86	9.34	0.6	1.12e-16	Schizophrenia;
PAAD	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-6.44	-0.46	1.45e-9	Pancreatic cancer;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg20778547	chr7:4456403	NA	-0.61	-4.92	-0.37	2.22e-6	Borderline personality disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04121115	chr1:54519230	C1orf83;TMEM59	-0.76	-6.46	-0.46	1.33e-9	Neuroticism;
PAAD	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.51	5.78	0.42	4.13e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.81	-8.51	-0.57	1.59e-14	DNA methylation (variation);
PAAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.85	-0.43	2.98e-8	Retinal vascular caliber;
PAAD	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.97	12.37	0.71	9.13e-25	Menarche (age at onset);
PAAD	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.61	6.49	0.47	1.13e-9	Caffeine consumption;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04582541	chr7:148844610	ZNF398	0.62	7.07	0.5	5.16e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.71	7.63	0.53	2.38e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.97	12.48	0.71	4.83e-25	Menopause (age at onset);
PAAD	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.5	-4.95	-0.37	1.91e-6	Multiple myeloma;
PAAD	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.58	-6.66	-0.48	4.83e-10	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.31	-0.33	2.9e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.53	5.11	0.38	9.54e-7	High light scatter reticulocyte count;
PAAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg15443732	chr18:74961078	GALR1	0.61	5.59	0.41	1.01e-7	Obesity-related traits;
PAAD	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.47	-4.51	-0.34	1.32e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322817	0.503	rs6571205	chr6:105208813	A/C	cg02098413	chr6:105308735	HACE1	-0.44	-5.57	-0.41	1.15e-7	Thyroid stimulating hormone;
PAAD	cis	rs12476592	0.602	rs11125978	chr2:63809602	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs6715793	0.630	rs6739323	chr2:33388342	A/G	cg26672287	chr2:33391915	LTBP1	-0.38	-4.46	-0.34	1.6e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.43	-0.4	2.24e-7	Lung cancer;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg18654377	chr3:49208889	KLHDC8B	0.46	4.27	0.33	3.46e-5	Menarche (age at onset);
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.84	-9.35	-0.6	1.07e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg06241208	chr11:30344200	C11orf46	-0.49	-4.48	-0.34	1.48e-5	Morning vs. evening chronotype;
PAAD	cis	rs7715811	1.000	rs6554812	chr5:13762972	T/C	cg07548982	chr5:13769939	DNAH5	-0.64	-6.23	-0.45	4.43e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg23708337	chr7:1209742	NA	0.63	4.53	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg04165759	chr1:150448943	RPRD2	0.5	5.19	0.39	6.58e-7	Migraine;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg05627522	chr15:75251581	NA	0.59	7.21	0.5	2.45e-11	Breast cancer;
PAAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg09177884	chr7:1199841	ZFAND2A	-0.62	-4.95	-0.37	1.99e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.66	-0.48	4.83e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.8	-4.71	-0.36	5.48e-6	Skin colour saturation;
PAAD	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.26	-0.39	4.73e-7	Monocyte percentage of white cells;
PAAD	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.41	-0.34	1.93e-5	Coronary artery disease;
PAAD	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg12317470	chr15:67143691	NA	0.82	4.38	0.34	2.17e-5	Lung cancer (smoking interaction);
PAAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	7.37	0.51	1.03e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.78	4.91	0.37	2.29e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3981351	0.797	rs12414006	chr10:115461485	A/G	cg24846397	chr10:115438155	CASP7	-0.58	-5.46	-0.41	1.86e-7	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs76610941	chr3:128524526	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Body mass index;
PAAD	cis	rs4838594	0.563	rs3853762	chr10:49678456	G/C	cg17291251	chr10:49678358	ARHGAP22	0.48	4.62	0.35	8.06e-6	Daytime sleep phenotypes;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg04733989	chr22:42467013	NAGA	0.47	4.75	0.36	4.59e-6	Cognitive function;
PAAD	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg00540400	chr15:79124168	NA	0.68	8.51	0.57	1.58e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.94	7.21	0.5	2.47e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.44	-0.34	1.69e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7264396	0.887	rs4911503	chr20:34063095	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.8	-0.43	3.7e-8	Total cholesterol levels;
PAAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.33	-0.33	2.65e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.01	0.38	1.47e-6	Migraine;
PAAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.56	4.66	0.35	6.89e-6	RR interval (heart rate);
PAAD	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg19817882	chr1:226075069	LEFTY1	-0.44	-4.48	-0.34	1.44e-5	Preschool internalizing problems;
PAAD	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.52	0.41	1.42e-7	Lung cancer;
PAAD	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	1.02	10.74	0.66	2.19e-20	Platelet distribution width;
PAAD	cis	rs911119	0.955	rs17751897	chr20:23592714	T/C	cg16589663	chr20:23618590	CST3	0.8	6.92	0.49	1.15e-10	Chronic kidney disease;
PAAD	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.63	6.85	0.49	1.71e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg20848291	chr7:100343083	ZAN	-0.76	-6.55	-0.47	8.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13012494	chr21:47604986	C21orf56	0.48	5.02	0.38	1.4e-6	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.6	-5.79	-0.43	3.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.29	0.33	3.19e-5	Major depressive disorder;
PAAD	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.78	6.61	0.47	6.25e-10	Recombination rate (females);
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.74	7.21	0.5	2.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.73	8.04	0.55	2.39e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4690686	1.000	rs2278904	chr4:177248622	C/G	cg17059388	chr4:177262070	NA	-0.44	-4.32	-0.33	2.85e-5	Essential tremor;
PAAD	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.06	-0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg02244288	chr16:89573955	SPG7	-0.35	-4.51	-0.34	1.3e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg19630374	chr17:18023558	MYO15A	-0.55	-5.9	-0.43	2.31e-8	Total body bone mineral density;
PAAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.78	7.63	0.53	2.42e-12	Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg14092988	chr3:52407081	DNAH1	0.58	7.48	0.52	5.59e-12	Bipolar disorder;
PAAD	cis	rs6074578	0.535	rs6077293	chr20:138620	A/C	cg16931068	chr20:139680	DEFB127	0.39	5.26	0.39	4.85e-7	Hirschsprung disease;
PAAD	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.51	4.56	0.35	1.06e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21646471	chr2:242523971	THAP4	0.5	4.33	0.33	2.69e-5	Prostate cancer;
PAAD	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.35	0.33	2.49e-5	Iron status biomarkers;
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg02462569	chr6:150064036	NUP43	-0.42	-4.6	-0.35	8.97e-6	Testicular germ cell tumor;
PAAD	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.96	5.86	0.43	2.76e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	cis	rs757081	0.648	rs7108316	chr11:17275035	T/C	cg04705435	chr11:17411270	KCNJ11	-0.53	-5.26	-0.39	4.83e-7	Systolic blood pressure;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.01	-17.81	-0.82	4.82e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6782228	0.606	rs2712381	chr3:128338600	A/C	cg16766828	chr3:128327626	NA	-0.48	-6.59	-0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7714584	1.000	rs11167526	chr5:150332481	G/A	cg22134413	chr5:150180641	NA	1.04	6.37	0.46	2.11e-9	Crohn's disease;
PAAD	cis	rs55665837	0.539	rs10766196	chr11:14913131	A/G	cg19336497	chr11:14380999	RRAS2	-0.42	-4.45	-0.34	1.68e-5	Vitamin D levels;
PAAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.83	0.36	3.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4478858	0.775	rs59865338	chr1:31706643	A/G	cg00250761	chr1:31883323	NA	-0.51	-5.85	-0.43	2.88e-8	Alcohol dependence;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-0.71	-4.84	-0.37	3.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.72	6.39	0.46	1.94e-9	Menarche (age at onset);
PAAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.28	0.56	5.98e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.51	-0.34	1.29e-5	Total body bone mineral density;
PAAD	cis	rs35123781	0.580	rs431184	chr5:138962408	G/A	cg26929925	chr5:138714136	SLC23A1	-0.53	-4.91	-0.37	2.36e-6	Schizophrenia;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13327859	chr12:104359478	TDG	-0.64	-6.61	-0.47	6.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.91	-0.43	2.14e-8	Androgen levels;
PAAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.09	0.5	4.64e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.63	-7.21	-0.5	2.51e-11	Vitiligo;
PAAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.86	-9.42	-0.61	7.12e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs941873	0.904	rs4980067	chr10:81136129	C/A	cg08514558	chr10:81106712	PPIF	0.48	5.73	0.42	5.29e-8	Height;
PAAD	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.8	8.77	0.58	3.36e-15	Schizophrenia;
PAAD	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	cis	rs4455778	0.580	rs59806378	chr7:49129934	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg13397359	chr6:42928475	GNMT	0.61	4.56	0.35	1.04e-5	Blood protein levels;
PAAD	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg24053715	chr22:38214548	NA	-0.51	-5.32	-0.4	3.66e-7	Glioblastoma;Glioma;
PAAD	cis	rs7922314	0.571	rs16917953	chr10:64720043	G/T	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.85	0.37	2.96e-6	Cognitive ability;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg08284496	chr17:37894027	GRB7	0.25	4.28	0.33	3.31e-5	Asthma;
PAAD	cis	rs72960926	1.000	rs72958964	chr6:75124792	C/T	cg03266952	chr6:74778945	NA	-1.01	-5.37	-0.4	2.92e-7	Metabolite levels (MHPG);
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.62	-6.81	-0.48	2.18e-10	Age at first birth;
PAAD	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg07164556	chr1:145727247	PDZK1	0.87	4.85	0.37	3.03e-6	Mitochondrial DNA levels;
PAAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.86	-8.48	-0.57	1.8e-14	Asthma;
PAAD	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.41	4.57	0.35	9.84e-6	Coronary artery disease;
PAAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs9535307	0.929	rs2038608	chr13:50272027	A/C	cg03658251	chr13:50265850	EBPL	0.83	5.28	0.39	4.38e-7	Obesity-related traits;
PAAD	cis	rs818427	0.508	rs6867243	chr5:112100027	G/A	cg06941702	chr5:112196734	SRP19	-0.48	-4.45	-0.34	1.66e-5	Total body bone mineral density;
PAAD	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs12532960	0.731	rs16880576	chr7:42378648	A/G	cg27332053	chr7:42446175	NA	0.57	4.32	0.33	2.82e-5	Inflammatory biomarkers;
PAAD	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.82	-7.99	-0.54	3.1e-13	Breast cancer;
PAAD	cis	rs11264213	0.901	rs630364	chr1:36449304	C/T	cg27506609	chr1:36549197	TEKT2	0.73	5.2	0.39	6.3e-7	Schizophrenia;
PAAD	cis	rs30380	0.690	rs2042381	chr5:96188666	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.5	4.97	0.37	1.79e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.69	5.23	0.39	5.64e-7	Diastolic blood pressure;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.94	-10.05	-0.63	1.57e-18	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6494488	0.500	rs72744729	chr15:65038484	G/A	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs12530845	1.000	rs12531468	chr7:135336264	T/G	cg23117316	chr7:135346802	PL-5283	-0.38	-4.29	-0.33	3.17e-5	Red blood cell traits;
PAAD	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs9463078	0.510	rs11964325	chr6:45053617	G/A	cg18551225	chr6:44695536	NA	-0.42	-4.39	-0.34	2.09e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.78	-0.42	4.14e-8	Airway imaging phenotypes;
PAAD	cis	rs859767	1.000	rs859767	chr2:135341200	A/G	cg12500956	chr2:135428796	TMEM163	0.32	4.8	0.36	3.75e-6	Neuroticism;
PAAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-6.38	-0.46	2.05e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg08999081	chr20:33150536	PIGU	-0.49	-5.32	-0.4	3.7e-7	Height;
PAAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.45	0.57	2.16e-14	Menopause (age at onset);
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.5	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg01426195	chr3:39028469	NA	-0.6	-5.6	-0.41	9.99e-8	Handedness;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.85	0.54	7.08e-13	Metabolite levels;
PAAD	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16447950	chr5:562315	NA	-0.73	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg14146966	chr2:61757674	XPO1	-0.37	-4.65	-0.35	7.15e-6	Tuberculosis;
PAAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg07153921	chr17:41440717	NA	-0.42	-4.41	-0.34	1.94e-5	Menopause (age at onset);
PAAD	cis	rs12257961	0.549	rs56276505	chr10:15382499	G/A	cg10616319	chr10:15468812	NA	0.46	4.43	0.34	1.83e-5	Selective IgA deficiency;
PAAD	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs4523957	0.583	rs2760744	chr17:2017029	T/C	cg16513277	chr17:2031491	SMG6	-0.59	-6.1	-0.44	8.4e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg19131313	chr8:1704013	NA	-0.41	-4.46	-0.34	1.59e-5	Systolic blood pressure;
PAAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg05082376	chr22:42548792	NA	-0.54	-5.51	-0.41	1.53e-7	Cognitive function;
PAAD	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.22	-0.45	4.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs899997	0.906	rs6495317	chr15:78991716	A/C	cg04896959	chr15:78267971	NA	-0.59	-5.33	-0.4	3.43e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1468734	0.929	rs59640658	chr16:5006541	T/C	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.53	-4.39	-0.34	2.12e-5	Cancer;
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18173908	chr7:129710284	KLHDC10	0.66	6.56	0.47	7.86e-10	Obesity-related traits;
PAAD	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.33	-0.33	2.66e-5	Life satisfaction;
PAAD	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.15	0.39	8.12e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg12705353	chr12:122356852	WDR66	0.44	4.43	0.34	1.79e-5	Mean corpuscular volume;
PAAD	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg11214348	chr21:47283868	PCBP3	-0.49	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.81	-7.02	-0.49	6.79e-11	Blood pressure (smoking interaction);
PAAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.89	10.11	0.63	1.08e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.06	-0.55	2.13e-13	Prostate cancer;
PAAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.54	0.35	1.12e-5	Breast cancer;
PAAD	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.59	5.23	0.39	5.59e-7	Coronary heart disease;
PAAD	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg03392386	chr11:133800800	IGSF9B	0.46	4.73	0.36	5.15e-6	Parkinson's disease;
PAAD	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.09	-0.63	1.19e-18	Response to antipsychotic treatment;
PAAD	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	7.48	0.52	5.67e-12	Mood instability;
PAAD	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.81e-6	Type 2 diabetes;
PAAD	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.55	-0.41	1.23e-7	Atrioventricular conduction;
PAAD	cis	rs2133450	1.000	rs62234959	chr3:7345896	G/C	cg19930620	chr3:7340148	GRM7	-0.44	-4.57	-0.35	9.85e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.44	5.06	0.38	1.21e-6	Cystic fibrosis severity;
PAAD	cis	rs8014252	0.803	rs2877672	chr14:71036259	T/C	cg11204974	chr14:71022665	NA	-0.7	-4.71	-0.36	5.64e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.57	0.47	7.67e-10	Blood protein levels;
PAAD	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.96	10.04	0.63	1.61e-18	Corneal astigmatism;
PAAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg04738700	chr2:239367308	NA	-0.54	-5.4	-0.4	2.5e-7	Multiple system atrophy;
PAAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.75	0.58	3.75e-15	Parkinson's disease;
PAAD	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.38	6.79	0.48	2.42e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.88e-8	Subjective well-being;
PAAD	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg12458913	chr13:53173898	NA	0.56	5.44	0.4	2.12e-7	Lewy body disease;
PAAD	cis	rs7731390	0.510	rs58395458	chr5:131800975	T/A	cg14196790	chr5:131705035	SLC22A5	-0.6	-4.37	-0.33	2.3e-5	IgG glycosylation;
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.99e-9	Lung cancer;
PAAD	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.56	5.77	0.42	4.29e-8	Mean corpuscular volume;
PAAD	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs8112449	0.719	rs7249459	chr19:10537092	C/T	cg03722295	chr19:10519375	NA	0.33	4.47	0.34	1.53e-5	Multiple sclerosis;Gastritis;
PAAD	cis	rs10078	0.559	rs6893791	chr5:430413	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.72	5.37	0.4	2.85e-7	Fat distribution (HIV);
PAAD	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.13	-0.59	4.05e-16	Mortality in heart failure;
PAAD	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.44	4.65	0.35	7.01e-6	Educational attainment;
PAAD	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06307176	chr5:131281290	NA	0.57	4.97	0.37	1.81e-6	Life satisfaction;
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	4.64	0.35	7.37e-6	Total body bone mineral density;
PAAD	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.57	-4.81	-0.36	3.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019216	0.500	rs2880292	chr17:21869537	A/G	cg22648282	chr17:21454238	C17orf51	-0.59	-6.04	-0.44	1.15e-8	Pelvic organ prolapse;
PAAD	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.49	5.26	0.39	4.92e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.72	5.89	0.43	2.36e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.93	10.06	0.63	1.49e-18	Cognitive function;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.33	4.25	0.33	3.75e-5	Renal function-related traits (BUN);
PAAD	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.8	-6.65	-0.47	4.93e-10	Pancreatic cancer;
PAAD	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg10932868	chr11:921992	NA	0.45	4.79	0.36	4.01e-6	Alzheimer's disease (late onset);
PAAD	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-10.27	-0.64	4.04e-19	Height;
PAAD	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.86	-10.14	-0.64	8.75e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-5.28	-0.39	4.37e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-4.8	-0.36	3.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01046593	chr21:45079544	HSF2BP;RRP1B	0.59	6.4	0.46	1.79e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.64	7.05	0.5	6.01e-11	Smoking initiation;
PAAD	cis	rs6466055	0.589	rs11978288	chr7:104643470	C/T	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06850241	chr22:41845214	NA	0.56	4.8	0.36	3.76e-6	Vitiligo;
PAAD	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg05250797	chr16:70222502	NA	0.78	5.83	0.43	3.24e-8	IgE levels;
PAAD	cis	rs1529711	0.636	rs11673064	chr19:10955925	A/C	cg16667279	chr19:11591998	ELAVL3	-0.56	-4.57	-0.35	1.02e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.6	5.89	0.43	2.42e-8	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-7.58	-0.52	3.11e-12	Neuroticism;
PAAD	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.53	-5.89	-0.43	2.41e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs597583	0.760	rs688968	chr11:117406739	C/G	cg27161313	chr11:117392002	DSCAML1	-0.72	-6.17	-0.45	5.94e-9	Putamen volume;
PAAD	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.43	-5.12	-0.38	8.95e-7	Uric acid levels;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.47	5.38	0.4	2.77e-7	Testicular germ cell tumor;
PAAD	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg10356904	chr22:49881777	NA	-0.47	-4.81	-0.36	3.58e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1371614	0.635	rs9309559	chr2:27141515	G/T	cg00617064	chr2:27272375	NA	-0.42	-4.34	-0.33	2.58e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.85	-4.43	-0.34	1.79e-5	Mononucleosis;
PAAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg23346134	chr3:49453900	TCTA	0.46	4.93	0.37	2.15e-6	Menarche (age at onset);
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg13264159	chr8:625131	ERICH1	0.77	5.37	0.4	2.91e-7	IgG glycosylation;
PAAD	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.58	4.42	0.34	1.86e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	trans	rs12986445	0.843	rs10209507	chr2:26004418	T/C	cg17419660	chr11:1950354	TNNT3	0.82	6.69	0.48	3.98e-10	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
PAAD	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg10018233	chr7:150070692	REPIN1	0.67	7.69	0.53	1.72e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.61	-5.33	-0.4	3.48e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.78	5.98	0.44	1.5e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs4144027	0.875	rs6576010	chr14:104349602	A/G	cg19582115	chr14:103436037	CDC42BPB	0.49	4.58	0.35	9.72e-6	Blood metabolite levels;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg14789911	chr21:47582049	C21orf56	0.53	5.27	0.39	4.59e-7	Testicular germ cell tumor;
PAAD	cis	rs142802669	1	rs142802669	chr3:41869427	A/C	cg03022575	chr3:42003672	ULK4	0.82	6.28	0.45	3.3e-9	Immunoglobulin light chain (AL) amyloidosis;
PAAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg25364880	chr3:44379878	C3orf23	0.54	5.29	0.39	4.23e-7	Depressive symptoms;
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.64	7.42	0.52	7.58e-12	Vitiligo;
PAAD	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.32	-6.05	-0.44	1.1e-8	Type 2 diabetes;
PAAD	cis	rs11638352	0.661	rs1365457	chr15:44460802	A/G	cg10011062	chr15:43941034	CATSPER2	1.17	4.39	0.34	2.15e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs10885582	0.781	rs10749168	chr10:116301983	T/C	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs778371	0.749	rs2675965	chr2:233793736	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.1	-0.44	8.26e-9	Schizophrenia;
PAAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg14092988	chr3:52407081	DNAH1	0.5	6.31	0.46	2.85e-9	Bipolar disorder;
PAAD	cis	rs9976767	0.896	rs9975920	chr21:43818656	A/G	cg23042151	chr21:43824109	UBASH3A	-0.36	-4.37	-0.33	2.25e-5	Type 1 diabetes;
PAAD	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.9	-9.5	-0.61	4.42e-17	Inhibitory control;
PAAD	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg13611204	chr9:139324423	INPP5E	-0.56	-4.8	-0.36	3.78e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg22532475	chr10:104410764	TRIM8	-0.38	-4.6	-0.35	8.69e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs2790216	0.950	rs767009	chr10:59998602	G/T	cg20442379	chr10:60024634	IPMK	-0.59	-4.47	-0.34	1.5e-5	Inflammatory bowel disease;
PAAD	cis	rs10186876	0.833	rs7587561	chr2:44180796	G/A	cg09541576	chr2:44873248	C2orf34	-0.47	-4.8	-0.36	3.7e-6	Hand grip strength;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.64	-9.98	-0.63	2.31e-18	Diastolic blood pressure;
PAAD	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg10006428	chr1:248814059	OR2T27	0.41	4.8	0.36	3.84e-6	Common traits (Other);
PAAD	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.14e-15	Prostate cancer;
PAAD	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.08	8.51	0.57	1.51e-14	Vitiligo;
PAAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.54	-7.76	-0.53	1.18e-12	Homoarginine levels;
PAAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05025164	chr4:1340916	KIAA1530	0.61	6.1	0.44	8.25e-9	Obesity-related traits;
PAAD	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.65	-7.6	-0.52	2.77e-12	Airway imaging phenotypes;
PAAD	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.58	7.36	0.51	1.07e-11	Multiple system atrophy;
PAAD	cis	rs375066	0.935	rs407731	chr19:44418077	A/G	cg11993925	chr19:44307056	LYPD5	-0.49	-6.24	-0.45	4.14e-9	Breast cancer;
PAAD	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.63	6.83	0.48	1.94e-10	Lung cancer;
PAAD	cis	rs17155006	0.655	rs450722	chr7:107726014	G/A	cg05962710	chr7:107745446	LAMB4	-0.44	-5.46	-0.41	1.89e-7	Pneumococcal bacteremia;
PAAD	cis	rs7550636	0.780	rs1775692	chr1:192807179	A/G	cg05576974	chr1:193028138	TROVE2;UCHL5	0.43	4.36	0.33	2.43e-5	Coronary artery calcification;
PAAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg14500798	chr7:98100126	NA	0.42	4.27	0.33	3.42e-5	Breast cancer;
PAAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.92	-7.96	-0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	trans	rs1233491	1	rs1233491	chr6:29461730	G/C	cg06606381	chr12:133084897	FBRSL1	-1.49	-9.78	-0.62	8.08e-18	Cutaneous lupus erythematosus;
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.66	-0.35	6.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg20295408	chr7:1910781	MAD1L1	0.55	5.36	0.4	3.04e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs73416724	0.544	rs6930150	chr6:43249510	C/A	cg17076780	chr6:43251928	TTBK1	0.66	5.63	0.42	8.56e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg03732007	chr1:2071316	PRKCZ	-0.47	-5.1	-0.38	1e-6	Height;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.7	5.23	0.39	5.41e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7071247	0.915	rs3740474	chr10:105274941	C/T	cg06423925	chr10:105883847	C10orf78	0.55	4.39	0.34	2.09e-5	Platelet aggregation;
PAAD	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs2857891	1.000	rs2595501	chr11:6955340	G/A	cg04053776	chr11:6947353	ZNF215	0.49	4.29	0.33	3.15e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	trans	rs901683	1.000	rs35070150	chr10:46079833	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg04450456	chr4:17643702	FAM184B	0.47	4.64	0.35	7.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	1.4	7.09	0.5	4.7e-11	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.37	-0.46	2.17e-9	Morning vs. evening chronotype;
PAAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Gut microbiome composition (summer);
PAAD	cis	rs2286503	0.839	rs2270108	chr7:22862131	A/C	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03115019	chr17:80708279	FN3K	0.52	4.63	0.35	7.88e-6	Glycated hemoglobin levels;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.46	4.57	0.35	9.86e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.58	6.48	0.47	1.19e-9	Blood metabolite levels;
PAAD	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg23912435	chr1:150601613	ENSA	-0.5	-4.65	-0.35	7.24e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08932106	chr10:23003259	PIP4K2A	0.44	4.42	0.34	1.86e-5	Monocyte percentage of white cells;
PAAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.68	7.18	0.5	2.84e-11	Coronary artery disease;
PAAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg08088566	chr11:430123	ANO9	0.88	5.53	0.41	1.39e-7	Body mass index;
PAAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.98	-0.37	1.74e-6	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25016364	chr7:152457024	ACTR3B	0.59	6.69	0.48	3.98e-10	Metabolite levels  (X-11787);
PAAD	cis	rs62408225	0.963	rs1321859	chr6:91011673	C/T	cg03795776	chr6:90687632	BACH2	0.45	4.63	0.35	7.9e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.58	-8.38	-0.56	3.34e-14	Huntington's disease progression;
PAAD	cis	rs7591163	1.000	rs4487084	chr2:228713179	G/A	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	9.64	0.62	1.87e-17	Tonsillectomy;
PAAD	cis	rs12136530	0.593	rs10917443	chr1:19724079	A/C	cg03321592	chr1:19991676	HTR6	0.5	4.44	0.34	1.71e-5	Lead levels in blood;
PAAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-4.66	-0.35	6.89e-6	Blood metabolite levels;
PAAD	cis	rs4662592	0.554	rs35615728	chr2:128903862	G/T	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs12431939	0.626	rs10138856	chr14:51712712	G/A	cg23942311	chr14:51606299	NA	0.51	4.67	0.35	6.52e-6	Cancer;
PAAD	cis	rs1499972	1.000	rs1499972	chr3:117719538	A/C	cg07612923	chr3:117604196	NA	-0.98	-6.67	-0.48	4.45e-10	Schizophrenia;
PAAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.97	11.56	0.68	1.44e-22	Cognitive function;
PAAD	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg01236616	chr12:121019343	POP5	0.46	4.3	0.33	3.03e-5	High light scatter reticulocyte count;
PAAD	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs962856	0.719	rs12713597	chr2:67621067	T/C	cg09028215	chr2:67624308	ETAA1	-0.53	-4.52	-0.34	1.24e-5	Pancreatic cancer;
PAAD	cis	rs1497828	1.000	rs2646845	chr1:217559136	G/A	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.6	-4.99	-0.38	1.63e-6	Gut microbiome composition (summer);
PAAD	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg05479556	chr5:449004	EXOC3	-0.45	-4.75	-0.36	4.62e-6	Fat distribution (HIV);
PAAD	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg08601574	chr20:25228251	PYGB	0.57	5.73	0.42	5.34e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.89	12.5	0.71	4.07e-25	Vitiligo;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.4	-0.46	1.84e-9	Bipolar disorder;
PAAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg03700679	chr2:178418002	TTC30B	-0.53	-4.3	-0.33	3e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7071247	1.000	rs7071247	chr10:105257786	G/T	cg18199807	chr10:106074281	ITPRIP	0.67	4.4	0.34	2.06e-5	Platelet aggregation;
PAAD	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg00823993	chr13:113535758	ATP11A	0.66	5.94	0.43	1.87e-8	Interstitial lung disease;
PAAD	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.48	4.46	0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.5	-0.34	1.33e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8014252	0.711	rs58069917	chr14:71043557	C/T	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg14768367	chr16:72042858	DHODH	-0.86	-6.77	-0.48	2.64e-10	Blood protein levels;
PAAD	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811528	0.591	rs11770552	chr7:2709471	C/T	cg11411865	chr7:2701802	TTYH3	0.55	4.79	0.36	3.94e-6	Schizophrenia;
PAAD	cis	rs134594	0.885	rs134677	chr22:29503887	T/C	cg01361351	chr22:29467363	NA	-0.39	-4.36	-0.33	2.38e-5	Birth weight;
PAAD	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg08648136	chr8:956695	NA	0.41	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg25319279	chr11:5960081	NA	0.57	5.67	0.42	6.9e-8	DNA methylation (variation);
PAAD	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.2	0.39	6.47e-7	Monocyte percentage of white cells;
PAAD	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07069089	chr16:25026173	ARHGAP17	-0.76	-6.83	-0.48	1.91e-10	Neuroticism;
PAAD	cis	rs7853377	0.689	rs1831757	chr9:86509330	T/C	cg03531853	chr9:86535572	KIF27	0.42	4.42	0.34	1.9e-5	Height;
PAAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs2077654	0.822	rs12280242	chr11:17433737	C/T	cg25308976	chr11:17434268	ABCC8	0.92	6.22	0.45	4.51e-9	Gout;
PAAD	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg26248373	chr2:1572462	NA	-1.04	-9.33	-0.6	1.18e-16	IgG glycosylation;
PAAD	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg12215294	chr3:40350768	EIF1B	0.48	5.01	0.38	1.52e-6	Renal cell carcinoma;
PAAD	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	5.72	0.42	5.61e-8	Vitiligo;
PAAD	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.25	-0.45	4.01e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.7	-5.67	-0.42	6.99e-8	Coronary artery disease;
PAAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.82	6.46	0.46	1.32e-9	Brain cytoarchitecture;
PAAD	cis	rs2562456	0.755	rs11670868	chr19:21556415	T/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.59	5.94	0.43	1.84e-8	Menopause (age at onset);
PAAD	cis	rs6028335	0.610	rs12626028	chr20:37553900	G/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.66	-4.94	-0.37	2.08e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs1620921	0.505	rs9458032	chr6:161210205	G/T	cg01280913	chr6:161186852	NA	-0.46	-5.0	-0.38	1.55e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.81	-0.36	3.61e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10865541	0.935	rs12999423	chr2:3392513	T/C	cg21040360	chr2:3383326	TTC15	-0.44	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg27411982	chr8:10470053	RP1L1	0.42	4.63	0.35	7.86e-6	Neuroticism;
PAAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg19486271	chr11:47235900	DDB2	-0.59	-6.04	-0.44	1.16e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2272990	0.558	rs6907943	chr6:3078266	A/C	cg21083467	chr6:3077041	RIPK1	0.81	4.67	0.35	6.62e-6	Preschool internalizing problems;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.72	6.94	0.49	1.08e-10	Platelet count;
PAAD	cis	rs9652601	1.000	rs9652601	chr16:11174365	G/A	cg04616529	chr16:11181986	CLEC16A	0.48	5.13	0.38	8.67e-7	Systemic lupus erythematosus;
PAAD	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg21775007	chr8:11205619	TDH	-0.58	-5.16	-0.39	7.48e-7	Triglycerides;
PAAD	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7873102	0.654	rs10973634	chr9:37995845	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.83	7.81	0.54	8.48e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg07202610	chr7:1142643	C7orf50	-0.72	-5.46	-0.4	1.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.44	-4.52	-0.34	1.24e-5	Plateletcrit;
PAAD	cis	rs62238980	0.708	rs62238979	chr22:32577514	C/A	cg00543991	chr22:32367038	NA	1.21	6.6	0.47	6.29e-10	Childhood ear infection;
PAAD	cis	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.82	-6.89	-0.49	1.4e-10	Cancer;
PAAD	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.66	7.79	0.53	9.6e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.62	-5.89	-0.43	2.36e-8	Subjective well-being;
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg22338127	chr1:209979572	IRF6	0.55	4.57	0.35	1e-5	Coronary artery disease;
PAAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs600626	0.947	rs559355	chr11:75451281	A/T	cg24262691	chr11:75473276	NA	0.49	4.59	0.35	9.13e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.88	9.09	0.59	5.1e-16	Schizophrenia;
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.5	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.71	7.92	0.54	4.68e-13	Melanoma;
PAAD	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.63	-6.93	-0.49	1.1e-10	Colorectal cancer;
PAAD	cis	rs2235642	0.583	rs73497551	chr16:1571811	T/C	cg06970076	chr16:1560791	IFT140	0.52	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs2289328	0.882	rs7164581	chr15:40645098	C/G	cg13931752	chr15:40660718	DISP2	-0.58	-5.26	-0.39	4.92e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.73	-9.13	-0.6	3.9e-16	Dental caries;
PAAD	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.19	0.45	5.28e-9	Schizophrenia;
PAAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg11204139	chr17:3907470	NA	0.85	9.03	0.59	7.19e-16	Type 2 diabetes;
PAAD	cis	rs12935418	0.616	rs8047785	chr16:80969352	T/C	cg16651780	chr16:81037892	C16orf61	0.57	4.61	0.35	8.33e-6	Mean corpuscular volume;
PAAD	cis	rs1153858	0.623	rs17618637	chr15:45653394	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	4.52	0.34	1.25e-5	Homoarginine levels;
PAAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.35	-0.4	3.23e-7	Gut microbiome composition (summer);
PAAD	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.56	-5.15	-0.39	7.78e-7	Corneal structure;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.75	-8.77	-0.58	3.34e-15	Lung function (FVC);
PAAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.75e-17	Rheumatoid arthritis;
PAAD	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.46	-0.57	2.04e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg25902810	chr10:99078978	FRAT1	-0.59	-5.39	-0.4	2.62e-7	Monocyte count;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg08888203	chr3:10149979	C3orf24	0.68	6.21	0.45	4.87e-9	Alzheimer's disease;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs7512552	0.525	rs2298161	chr1:150237624	A/G	cg17724175	chr1:150552817	MCL1	-0.42	-5.05	-0.38	1.26e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.72	7.82	0.54	8.16e-13	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.45	5.28	0.39	4.46e-7	Immature fraction of reticulocytes;
PAAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.3	-0.56	5.32e-14	Morning vs. evening chronotype;
PAAD	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.66	0.35	6.91e-6	Height;
PAAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.55	0.47	8.4e-10	Mood instability;
PAAD	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2281845	0.560	rs12079819	chr1:201085420	G/A	cg08885800	chr1:201084119	NA	0.5	4.39	0.34	2.07e-5	Permanent tooth development;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.4	-4.42	-0.34	1.84e-5	Type 2 diabetes;
PAAD	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.68	-6.01	-0.44	1.3e-8	Vitamin D levels;
PAAD	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg02389323	chr16:88786976	FAM38A	0.9	4.79	0.36	3.93e-6	Plateletcrit;
PAAD	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.44	5.61	0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg00105475	chr2:10696890	NA	-0.74	-8.56	-0.57	1.16e-14	Prostate cancer;
PAAD	cis	rs61884328	0.777	rs17790336	chr11:47127549	G/T	cg23433285	chr11:47201945	PACSIN3	0.8	4.27	0.33	3.49e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.43	4.42	0.34	1.87e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg12379764	chr21:47803548	PCNT	0.46	4.45	0.34	1.66e-5	Lymphocyte counts;
PAAD	cis	rs12304921	0.748	rs56353532	chr12:51364732	G/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.31	-0.33	2.91e-5	Type 2 diabetes;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.6	6.8	0.48	2.27e-10	Longevity;Endometriosis;
PAAD	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.07	0.38	1.15e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg14403583	chr14:105418241	AHNAK2	-0.74	-7.91	-0.54	4.87e-13	Rheumatoid arthritis;
PAAD	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg20935368	chr5:178288625	ZNF354B	0.52	5.07	0.38	1.14e-6	Sleep duration;
PAAD	cis	rs7809615	0.901	rs11973801	chr7:99102911	A/G	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.2	0.39	6.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.72	5.95	0.43	1.78e-8	Weight;
PAAD	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-6.29	-0.45	3.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.79	8.08	0.55	1.87e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2555155	1.000	rs2723620	chr11:6523657	A/G	cg24637308	chr11:6592297	DNHD1	0.48	4.97	0.37	1.75e-6	DNA methylation (variation);
PAAD	cis	rs7894051	1.000	rs7070635	chr10:135190127	T/C	cg19176072	chr10:135083742	ADAM8	-0.86	-4.31	-0.33	2.96e-5	Lifespan;
PAAD	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg23465465	chr6:26364728	BTN3A2	-0.87	-5.01	-0.38	1.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs2555155	0.806	rs10769697	chr11:6547407	A/G	cg11185456	chr11:6592066	DNHD1	-0.43	-4.61	-0.35	8.61e-6	DNA methylation (variation);
PAAD	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg08975724	chr8:8085496	FLJ10661	-0.71	-7.1	-0.5	4.37e-11	Morning vs. evening chronotype;
PAAD	cis	rs10267417	0.603	rs13245108	chr7:19910053	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg08917208	chr2:24149416	ATAD2B	0.47	4.25	0.33	3.77e-5	Asthma;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs2252790	1.000	rs957529	chr6:116604549	C/T	cg18764771	chr6:116381957	FRK	-0.26	-4.41	-0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.95	-7.18	-0.5	2.84e-11	Multiple sclerosis;
PAAD	cis	rs3812111	0.525	rs9387388	chr6:116568915	G/T	cg18828861	chr6:116576566	TSPYL4	0.48	5.03	0.38	1.38e-6	Age-related macular degeneration;
PAAD	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg04257695	chr17:30186438	C17orf79	0.73	5.14	0.38	8.23e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.78	9.07	0.59	5.56e-16	Height;
PAAD	cis	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.43	-0.34	1.78e-5	Blood metabolite levels;
PAAD	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg26318627	chr11:63887540	MACROD1	-0.44	-4.39	-0.34	2.15e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9810890	0.850	rs73196977	chr3:128450224	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.49	6.02	0.44	1.27e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.58	6.8	0.48	2.22e-10	Calcium levels;
PAAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.59	6.02	0.44	1.26e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg23465465	chr6:26364728	BTN3A2	-0.74	-4.4	-0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg07636037	chr3:49044803	WDR6	0.55	4.36	0.33	2.43e-5	Menarche (age at onset);
PAAD	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.86	-0.49	1.59e-10	Chronic sinus infection;
PAAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.63	0.42	8.51e-8	Personality dimensions;
PAAD	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.58	7.63	0.53	2.34e-12	Primary biliary cholangitis;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.35e-6	Lung cancer;
PAAD	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.8	0.48	2.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.45	-4.72	-0.36	5.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg09127314	chr1:152161683	NA	0.71	5.2	0.39	6.43e-7	Atopic dermatitis;
PAAD	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6e-8	Life satisfaction;
PAAD	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.48	4.62	0.35	8.13e-6	Mean corpuscular volume;
PAAD	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.68	7.74	0.53	1.27e-12	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10248584	chr11:86666552	FZD4	0.64	6.59	0.47	6.84e-10	Myopia (pathological);
PAAD	cis	rs9462027	0.606	rs9462024	chr6:34772793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.59	-6.03	-0.44	1.22e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.44	-4.61	-0.35	8.38e-6	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
PAAD	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.82	6.34	0.46	2.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg19445457	chr11:5799446	OR52N5	-0.52	-4.7	-0.36	5.8e-6	DNA methylation (variation);
PAAD	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg20007245	chr22:24372913	LOC391322	-0.8	-8.36	-0.56	3.79e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg00024416	chr22:24240387	NA	-0.49	-4.98	-0.37	1.7e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7808424	0.651	rs3779546	chr7:116934200	G/A	cg00307073	chr7:116502428	CAPZA2	0.69	4.42	0.34	1.85e-5	Coronary heart disease;
PAAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.6	6.38	0.46	2e-9	Huntington's disease progression;
PAAD	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.96	13.89	0.75	7.82e-29	Intelligence (multi-trait analysis);
PAAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	10.8	0.66	1.59e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.15	-0.39	7.88e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.6	5.94	0.43	1.87e-8	Post bronchodilator FEV1;
PAAD	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg14171486	chr1:155139557	NA	-0.32	-4.42	-0.34	1.89e-5	Serum magnesium levels;
PAAD	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.67	-8.73	-0.58	4.29e-15	Schizophrenia;
PAAD	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.87	8.63	0.57	7.5e-15	Corneal astigmatism;
PAAD	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.21	15.93	0.79	3.24e-34	IgG glycosylation;
PAAD	cis	rs7904985	0.793	rs11201995	chr10:88120096	G/A	cg07322936	chr10:88137208	NA	-0.54	-4.91	-0.37	2.33e-6	Barrett's esophagus;
PAAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs6715793	0.934	rs1947444	chr2:33391901	G/A	cg26672287	chr2:33391915	LTBP1	-0.4	-4.47	-0.34	1.54e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg00999904	chr2:3704751	ALLC	0.63	6.71	0.48	3.62e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg15192750	chr16:69999425	NA	0.74	5.77	0.42	4.4e-8	IgE levels;
PAAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.61	-4.62	-0.35	8.05e-6	Breast cancer;
PAAD	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg14515779	chr1:101123966	NA	-0.53	-6.52	-0.47	9.88e-10	Monocyte count;
PAAD	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.7	-0.36	5.87e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73416724	1.000	rs77538445	chr6:43285773	A/C	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2834188	1.000	rs1018741	chr21:34686345	G/A	cg04842828	chr21:34696676	IFNAR1	0.46	4.41	0.34	1.91e-5	Narcolepsy;
PAAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg21951975	chr1:209979733	IRF6	0.37	4.38	0.33	2.22e-5	Monobrow;
PAAD	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg24848339	chr3:12840334	CAND2	0.43	4.65	0.35	7.15e-6	QRS complex (12-leadsum);
PAAD	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.73	-0.48	3.34e-10	Systolic blood pressure;
PAAD	cis	rs1903068	0.853	rs17773240	chr4:55999781	T/C	cg09978860	chr4:56023921	NA	0.41	4.45	0.34	1.67e-5	Endometriosis;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg25487775	chr2:162093969	NA	0.56	5.49	0.41	1.61e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg02023728	chr11:77925099	USP35	-0.45	-4.46	-0.34	1.59e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.49	-5.36	-0.4	2.97e-7	Platelet distribution width;
PAAD	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.55	5.77	0.42	4.34e-8	Diastolic blood pressure;
PAAD	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.82	10.71	0.66	2.74e-20	Menopause (age at onset);
PAAD	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	10.84	0.66	1.18e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg08934286	chr12:123463762	ARL6IP4;OGFOD2	-0.46	-4.72	-0.36	5.35e-6	Platelet count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00308133	chr19:1401118	GAMT	-0.64	-6.32	-0.46	2.73e-9	Smoking initiation;
PAAD	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg17771515	chr6:154831774	CNKSR3	0.63	4.53	0.34	1.2e-5	Lipoprotein (a) levels;
PAAD	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs34156428	0.657	rs7939889	chr11:16773043	C/T	cg15111638	chr11:16631993	NA	-0.43	-4.37	-0.33	2.29e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10840007	chr14:105487572	CDCA4	0.61	6.54	0.47	9.03e-10	Myopia (pathological);
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.64	8.36	0.56	3.7e-14	Hypertriglyceridemia;
PAAD	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.8	0.53	9.35e-13	Mean platelet volume;
PAAD	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	4.75	0.36	4.58e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.52	0.41	1.4e-7	Coronary heart disease;
PAAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	6.9	0.49	1.32e-10	Type 2 diabetes;
PAAD	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.62	8.28	0.56	5.73e-14	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.67	-8.21	-0.55	8.63e-14	Menopause (age at onset);
PAAD	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.58	-5.19	-0.39	6.79e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.77e-7	Vitiligo;
PAAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.62	0.47	5.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs939584	1.000	rs6728726	chr2:623976	A/G	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.9	-0.37	2.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs16958440	1.000	rs62096466	chr18:44636171	T/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs12714314	0.834	rs4241293	chr2:1953555	A/G	cg22350835	chr2:1868857	MYT1L	0.48	4.76	0.36	4.47e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.68	7.17	0.5	2.99e-11	Blood protein levels;
PAAD	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.82	-8.89	-0.58	1.62e-15	Menopause (age at onset);
PAAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg08125733	chr17:73851984	WBP2	0.82	7.5	0.52	5.05e-12	Psoriasis;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs4900538	0.827	rs1046651	chr14:102971016	T/C	cg05150608	chr14:102990211	NA	0.38	4.5	0.34	1.35e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.71e-6	Breast cancer;
PAAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.24	0.39	5.33e-7	Rheumatoid arthritis;
PAAD	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg26898376	chr11:64110657	CCDC88B	0.54	5.76	0.42	4.63e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.56	7.65	0.53	2.09e-12	IgA nephropathy;
PAAD	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.81	6.54	0.47	8.83e-10	Monocyte percentage of white cells;
PAAD	cis	rs9322817	0.691	rs1455935	chr6:105230312	C/G	cg02098413	chr6:105308735	HACE1	-0.43	-5.48	-0.41	1.73e-7	Thyroid stimulating hormone;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.59	6.29	0.45	3.14e-9	Lung cancer;
PAAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.5	5.24	0.39	5.39e-7	Menopause (age at onset);
PAAD	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg27205649	chr11:78285834	NARS2	0.6	4.32	0.33	2.83e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3736757	0.967	rs6677073	chr1:184656801	T/C	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.92	9.88	0.63	4.46e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.77	-0.48	2.63e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg15485101	chr11:133734466	NA	-0.41	-4.29	-0.33	3.16e-5	Parkinson's disease;
PAAD	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.52	5.11	0.38	9.49e-7	Menarche (age at onset);
PAAD	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.81	9.16	0.6	3.29e-16	Bladder cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20429722	chr11:74353553	POLD3	-0.62	-7.56	-0.52	3.55e-12	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs17083533	1.000	rs116966373	chr6:121685417	G/A	cg13516479	chr6:122016629	NA	-0.82	-4.48	-0.34	1.44e-5	Heart rate;
PAAD	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.55	4.46	0.34	1.6e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.42	4.57	0.35	9.9e-6	HDL cholesterol levels;
PAAD	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.48	-5.0	-0.38	1.54e-6	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg03209412	chr4:183728196	NA	0.68	6.1	0.44	8.22e-9	Pediatric autoimmune diseases;
PAAD	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg02527881	chr3:46936655	PTH1R	0.37	4.26	0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs58521262	0.505	rs289348	chr19:23147440	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.87	0.49	1.56e-10	Eye color traits;
PAAD	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg02640540	chr1:67518911	SLC35D1	0.56	4.8	0.36	3.69e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.26e-8	Alcohol dependence;
PAAD	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg08213375	chr14:104286397	PPP1R13B	0.48	6.54	0.47	9e-10	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15027249	chr19:15490215	AKAP8	0.64	6.87	0.49	1.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-6.99	-0.49	8.09e-11	Menarche (age at onset);
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.86	10.92	0.66	7.63e-21	Prudent dietary pattern;
PAAD	cis	rs16895831	0.583	rs62414592	chr6:42516867	G/A	cg10605015	chr6:42532144	UBR2	-0.7	-4.93	-0.37	2.08e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.42	4.53	0.34	1.18e-5	Longevity;Endometriosis;
PAAD	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg09127314	chr1:152161683	NA	-0.71	-4.93	-0.37	2.15e-6	Atopic dermatitis;
PAAD	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.43	0.34	1.77e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10687131	chr2:20871002	GDF7	-0.34	-4.25	-0.33	3.72e-5	Abdominal aortic aneurysm;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08359200	chr15:78236860	NA	-0.66	-7.45	-0.52	6.5e-12	Smoking initiation;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.49	5.06	0.38	1.21e-6	Height;
PAAD	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg15443732	chr18:74961078	GALR1	0.73	5.99	0.44	1.48e-8	Obesity-related traits;
PAAD	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.02	-0.7	8.01e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02743256	chr7:2109353	MAD1L1	-0.73	-5.17	-0.39	7.21e-7	Neuroticism;
PAAD	cis	rs10768122	0.642	rs3847619	chr11:35360747	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-5.22	-0.39	5.9e-7	Vitiligo;
PAAD	cis	rs3112530	0.901	rs2926286	chr5:152649498	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg05665937	chr4:1216051	CTBP1	0.42	4.3	0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.72e-5	Self-reported allergy;
PAAD	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.45	-0.34	1.62e-5	Blood metabolite levels;
PAAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.13	-0.45	7.3e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg18281939	chr5:77783895	LHFPL2	-0.51	-5.76	-0.42	4.59e-8	Triglycerides;
PAAD	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg05110241	chr16:68378359	PRMT7	-0.73	-5.7	-0.42	5.93e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.21	0.39	6.05e-7	Birth weight;
PAAD	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.59	6.04	0.44	1.12e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
PAAD	cis	rs16854884	0.770	rs1445417	chr3:143808972	A/T	cg06585982	chr3:143692056	C3orf58	0.56	5.43	0.4	2.19e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.05	-0.5	5.95e-11	Aortic root size;
PAAD	cis	rs829661	0.645	rs6759818	chr2:30780707	G/T	cg12454169	chr2:30669597	LCLAT1	0.6	4.31	0.33	2.91e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs783540	1.000	rs803688	chr15:83216793	A/G	cg00614314	chr15:82944287	LOC80154	0.45	4.59	0.35	9.37e-6	Schizophrenia;
PAAD	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg00864171	chr11:67383662	NA	-0.49	-5.29	-0.39	4.16e-7	Mean corpuscular volume;
PAAD	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg24687543	chr11:63912206	MACROD1	-0.58	-4.7	-0.36	5.79e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17102423	0.723	rs11158573	chr14:65579370	A/G	cg11161011	chr14:65562177	MAX	-0.58	-5.26	-0.39	4.71e-7	Obesity-related traits;
PAAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs1419980	0.730	rs6488512	chr12:7766382	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs499368	0.519	rs216247	chr12:310571	C/T	cg23063825	chr12:298151	NA	-0.49	-5.86	-0.43	2.72e-8	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Intracranial aneurysm;
PAAD	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.83e-7	Monocyte count;
PAAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.49	5.01	0.38	1.49e-6	Brain structure;
PAAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-17.72	-0.82	8.24e-39	Height;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.77	10.07	0.63	1.36e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	1.06	10.67	0.65	3.52e-20	Post bronchodilator FEV1;
PAAD	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.66	8.97	0.59	1.05e-15	Hemoglobin concentration;
PAAD	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg00530320	chr1:46809349	NSUN4	0.75	7.92	0.54	4.54e-13	Menopause (age at onset);
PAAD	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-4.97	-0.37	1.8e-6	Oropharynx cancer;
PAAD	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.79	-0.75	1.47e-28	Primary sclerosing cholangitis;
PAAD	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg03999872	chr20:62272968	STMN3	0.64	5.93	0.43	1.94e-8	Atopic dermatitis;
PAAD	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.51	-5.68	-0.42	6.6e-8	Neuroticism;
PAAD	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg09242541	chr1:10490025	APITD1	0.41	5.06	0.38	1.19e-6	Prostate cancer;
PAAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg19630374	chr17:18023558	MYO15A	-0.46	-4.79	-0.36	4e-6	Total body bone mineral density;
PAAD	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.64	6.95	0.49	9.84e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg26950739	chr16:89183275	ACSF3	0.76	5.35	0.4	3.17e-7	Red blood cell count;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9469890	0.604	rs76452512	chr6:34504388	G/C	cg14254433	chr6:34482411	PACSIN1	-0.9	-5.88	-0.43	2.51e-8	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-4.93	-0.37	2.12e-6	Schizophrenia (age at onset);
PAAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg05627522	chr15:75251581	NA	-0.4	-4.82	-0.36	3.38e-6	Systemic lupus erythematosus;
PAAD	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.46	4.34	0.33	2.57e-5	Endometrial cancer;
PAAD	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2415984	0.579	rs2817548	chr14:46969149	A/T	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg14349672	chr11:133703707	NA	-0.6	-6.97	-0.49	9.12e-11	Childhood ear infection;
PAAD	cis	rs7873102	0.654	rs870410	chr9:37978583	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg03517284	chr6:25882590	NA	-0.59	-4.91	-0.37	2.34e-6	Iron status biomarkers;
PAAD	cis	rs7853377	0.723	rs13290882	chr9:86497334	G/A	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13415434	chr3:49044522	P4HTM;WDR6	0.68	8.68	0.58	5.64e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.96	-7.72	-0.53	1.44e-12	Vitiligo;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs34138033	chr10:46046512	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.48	4.66	0.35	6.79e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg19680485	chr15:31195859	MTMR15	0.44	4.33	0.33	2.73e-5	Huntington's disease progression;
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.52	5.01	0.38	1.52e-6	Resistin levels;
PAAD	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.14	-0.38	8.36e-7	Fear of minor pain;
PAAD	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	1.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.75	-5.65	-0.42	7.71e-8	Mean platelet volume;
PAAD	cis	rs4478858	0.743	rs11578422	chr1:31707298	C/T	cg18939081	chr1:31884902	SERINC2	0.47	5.32	0.4	3.71e-7	Alcohol dependence;
PAAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.49	-4.26	-0.33	3.63e-5	Aortic root size;
PAAD	cis	rs4148087	0.860	rs9976024	chr21:43641657	A/G	cg08841829	chr21:43638893	ABCG1	0.72	4.87	0.37	2.8e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.72	-5.23	-0.39	5.48e-7	Vitiligo;
PAAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.43e-12	Calcium levels;
PAAD	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.93	-11.4	-0.68	3.87e-22	Bone mineral density;
PAAD	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.87	5.36	0.4	3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.47	4.67	0.35	6.7e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.82	6.97	0.49	8.97e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.67	8.23	0.56	7.91e-14	Lipoprotein (a) levels;
PAAD	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.68	-7.83	-0.54	7.81e-13	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-7.68	-0.53	1.77e-12	Morning vs. evening chronotype;
PAAD	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg02696790	chr15:75250997	RPP25	-0.38	-4.59	-0.35	9.15e-6	Systemic lupus erythematosus;
PAAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-4.51	-0.34	1.28e-5	Fat distribution (HIV);
PAAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-5.33	-0.4	3.53e-7	Ulcerative colitis;
PAAD	cis	rs9463078	0.608	rs608941	chr6:44888740	C/T	cg25276700	chr6:44698697	NA	-0.54	-6.12	-0.44	7.68e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg11477892	chr4:106580295	NA	-0.55	-4.42	-0.34	1.89e-5	Post bronchodilator FEV1;
PAAD	cis	rs58521262	0.516	rs1842018	chr19:23095233	A/G	cg02350677	chr19:23254381	NA	-0.27	-4.67	-0.35	6.63e-6	Testicular germ cell tumor;
PAAD	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.75	8.69	0.58	5.24e-15	Lewy body disease;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.34e-6	Lung cancer;
PAAD	cis	rs9469890	0.604	rs78871484	chr6:34503677	T/C	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08569242	chr17:66508525	PRKAR1A	0.56	6.66	0.48	4.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.87	7.54	0.52	4.03e-12	Alzheimer's disease;
PAAD	cis	rs2115386	1.000	rs2115386	chr19:7196565	C/T	cg00428638	chr19:7224713	INSR	0.47	4.89	0.37	2.49e-6	Diabetic retinopathy;
PAAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-1.09	-14.07	-0.75	2.55e-29	Total body bone mineral density;
PAAD	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg16584676	chr17:46985605	UBE2Z	0.51	5.01	0.38	1.53e-6	Type 2 diabetes;
PAAD	cis	rs9677476	0.587	rs6710104	chr2:232171195	G/A	cg07929768	chr2:232055508	NA	0.42	5.03	0.38	1.34e-6	Food antigen IgG levels;
PAAD	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.7	6.25	0.45	4.03e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs78707713	0.524	rs10823377	chr10:71213327	G/A	cg12610070	chr10:71211762	TSPAN15	-0.54	-8.04	-0.55	2.4e-13	Venous thromboembolism;
PAAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.02	0.49	7.02e-11	Hip circumference adjusted for BMI;
PAAD	trans	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg23167506	chr7:1303302	NA	0.38	6.61	0.47	6.21e-10	Menopause (age at onset);
PAAD	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.11	0.38	9.6e-7	Colorectal cancer;
PAAD	cis	rs116248771	0.739	rs12185969	chr3:158360880	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs9467603	1.000	rs1892250	chr6:25769024	T/C	cg23465465	chr6:26364728	BTN3A2	-0.78	-4.64	-0.35	7.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg26816564	chr1:7831052	VAMP3	0.82	6.12	0.44	7.46e-9	Inflammatory bowel disease;
PAAD	cis	rs2019960	0.759	rs2720697	chr8:129173118	C/G	cg15331705	chr8:129180010	NA	-0.44	-5.77	-0.42	4.37e-8	Hodgkin's lymphoma;Multiple sclerosis;
PAAD	cis	rs17095355	1.000	rs752584	chr10:111682934	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.36	-0.33	2.41e-5	Biliary atresia;
PAAD	cis	rs790123	0.711	rs2650961	chr3:122396818	A/G	cg15604389	chr3:122379662	NA	-0.47	-5.33	-0.4	3.52e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg21918786	chr6:109611834	NA	-0.59	-6.51	-0.47	1.04e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg11062466	chr8:58055876	NA	0.72	5.3	0.39	4.05e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg23920097	chr1:209922102	NA	-0.45	-4.39	-0.34	2.15e-5	Red blood cell count;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg14159672	chr1:205819179	PM20D1	0.58	5.33	0.4	3.48e-7	White blood cell types;
PAAD	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs13144136	0.710	rs10516208	chr4:10661734	C/T	cg10242279	chr4:10666415	CLNK	0.47	5.84	0.43	3.08e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21545522	chr1:205238299	TMCC2	0.48	4.57	0.35	1.01e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.44	-4.48	-0.34	1.46e-5	Iron status biomarkers;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg21775007	chr8:11205619	TDH	0.48	4.6	0.35	8.86e-6	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08776913	chr2:187451704	NA	0.6	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg22189786	chr22:42395067	WBP2NL	0.4	4.31	0.33	2.96e-5	Cognitive function;
PAAD	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	1.07	17.95	0.82	2.16e-39	Colorectal adenoma (advanced);
PAAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.67	-6.81	-0.48	2.18e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg04398451	chr17:18023971	MYO15A	-1.08	-15.08	-0.77	5.19e-32	Total body bone mineral density;
PAAD	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2249694	0.538	rs2026047	chr10:135329616	C/T	cg16964102	chr10:135390573	NA	-0.51	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg20673841	chr7:107026890	COG5	0.5	4.34	0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs10821973	0.527	rs4559572	chr10:63974950	C/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.46	5.9	0.43	2.31e-8	Psoriasis;
PAAD	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg15192750	chr16:69999425	NA	0.74	5.77	0.42	4.4e-8	IgE levels;
PAAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.89	-0.37	2.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.83	9.45	0.61	5.99e-17	Total body bone mineral density;
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg04520793	chr17:42248056	ASB16	0.46	6.3	0.46	2.99e-9	Total body bone mineral density;
PAAD	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg10820045	chr2:198174542	NA	0.49	5.09	0.38	1.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.67	-6.99	-0.49	8.13e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg23985595	chr17:80112537	CCDC57	0.44	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.9	-6.16	-0.45	6.13e-9	Alzheimer's disease (late onset);
PAAD	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.28	0.33	3.27e-5	Diabetic retinopathy;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs12760731	0.720	rs1397185	chr1:178381698	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.4	-0.51	8.41e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.8	9.28	0.6	1.6e-16	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22244076	chr20:33872703	EIF6	0.6	7.01	0.49	7.44e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.35	0.33	2.49e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.76	-7.71	-0.53	1.51e-12	Pancreatic cancer;
PAAD	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.39	-0.46	1.88e-9	Breast cancer;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.9	11.73	0.69	4.86e-23	Total body bone mineral density;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.8	-5.96	-0.44	1.66e-8	Coronary artery calcification;
PAAD	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.63	3.93e-18	Vitiligo;
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.58	-5.8	-0.43	3.79e-8	Multiple sclerosis;Ankylosing spondylitis;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05025164	chr4:1340916	KIAA1530	0.51	4.98	0.37	1.71e-6	Obesity-related traits;
PAAD	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg10183150	chr4:120222239	C4orf3	-0.37	-5.2	-0.39	6.47e-7	Educational attainment;
PAAD	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg18833306	chr6:118973337	C6orf204	-0.49	-5.68	-0.42	6.71e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg00262122	chr8:11665843	FDFT1	-0.66	-5.78	-0.42	4.01e-8	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00647863	chr15:101472753	LRRK1	0.59	6.9	0.49	1.3100000000000001e-10	Smoking initiation;
PAAD	cis	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs9333029	0.591	rs12406866	chr1:47381971	G/T	cg08644498	chr1:46502608	NA	-0.47	-4.35	-0.33	2.44e-5	Blood metabolite levels;
PAAD	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.75	8.19	0.55	9.82e-14	Menopause (age at onset);
PAAD	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs909002	0.886	rs7512805	chr1:32134763	C/T	cg13919466	chr1:32135498	COL16A1	-0.41	-4.49	-0.34	1.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs501120	0.584	rs2664856	chr10:44702967	G/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg10645314	chr2:3704589	ALLC	-0.42	-4.51	-0.34	1.29e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg05805236	chr11:65401703	PCNXL3	-0.59	-6.31	-0.46	2.95e-9	Acne (severe);
PAAD	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20458811	chr8:144631810	NA	-0.43	-5.85	-0.43	2.89e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg17551891	chr7:1960795	MAD1L1	-0.51	-4.72	-0.36	5.39e-6	Neuroticism;
PAAD	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4666360	1.000	rs4666360	chr2:20335709	G/A	cg23291376	chr2:20336282	NA	-0.39	-4.31	-0.33	2.89e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.66	-0.35	6.8e-6	Height;
PAAD	cis	rs1468333	0.567	rs10072318	chr5:137646221	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25809561	chr17:30822961	MYO1D	0.66	7.34	0.51	1.21e-11	Schizophrenia;
PAAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg16031515	chr1:205743344	RAB7L1	0.44	5.2	0.39	6.24e-7	Menarche (age at onset);
PAAD	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.46	0.65	1.26e-19	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg20917491	chr3:195578259	NA	0.45	4.49	0.34	1.39e-5	Pancreatic cancer;
PAAD	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs847851	0.958	rs9380469	chr6:34877314	A/G	cg13196216	chr6:34231128	NA	-0.62	-4.99	-0.38	1.62e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499755	0.965	rs9888978	chr16:55352984	T/G	cg02859129	chr16:55357253	IRX6	0.34	4.55	0.35	1.07e-5	Hypospadias;
PAAD	trans	rs1015213	0.737	rs118182194	chr8:52882763	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26035689	chr8:63582931	NKAIN3	-0.53	-6.74	-0.48	3.07e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg04287289	chr16:89883240	FANCA	0.62	6.86	0.49	1.66e-10	Vitiligo;
PAAD	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	4.94	0.37	2.02e-6	Educational attainment;
PAAD	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.81	7.89	0.54	5.65e-13	Corneal astigmatism;
PAAD	cis	rs834811	0.865	rs844327	chr7:135898043	G/T	cg01726295	chr7:135938950	NA	0.39	4.27	0.33	3.46e-5	Post-traumatic stress disorder;
PAAD	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.61	5.82	0.43	3.31e-8	Subjective well-being;
PAAD	trans	rs1015213	0.609	rs117407615	chr8:52872186	T/A	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.07e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.26e-5	Height;
PAAD	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs901683	0.850	rs112184470	chr10:46093302	G/A	cg13065504	chr15:42448234	PLA2G4F	0.8	6.53	0.47	9.11e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.17	0.5	3e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-4.62	-0.35	8.16e-6	Testicular germ cell tumor;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07706279	chr3:39149020	GORASP1;TTC21A	-0.7	-7.21	-0.5	2.44e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7172971	0.688	rs77332371	chr15:42378650	A/G	cg07013680	chr15:42186124	SPTBN5	0.53	4.29	0.33	3.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs73071352	0.577	rs73075228	chr3:42049629	T/G	cg03022575	chr3:42003672	ULK4	0.92	6.21	0.45	4.92e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09586322	chr1:32706085	MTMR9L	0.65	6.8	0.48	2.22e-10	Myopia (pathological);
PAAD	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg18357526	chr6:26021779	HIST1H4A	0.65	6.6	0.47	6.44e-10	Height;
PAAD	cis	rs6088813	1.000	rs6088799	chr20:33934301	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.36	-0.4	3.04e-7	Height;
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.59	-5.39	-0.4	2.58e-7	Acylcarnitine levels;
PAAD	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09597638	chr17:3907349	NA	-0.88	-10.11	-0.63	1.07e-18	Type 2 diabetes;
PAAD	cis	rs11669133	1.000	rs17001075	chr19:11105593	A/G	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-5.38	-0.4	2.72e-7	Schizophrenia;
PAAD	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.71	-6.55	-0.47	8.4e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg19847866	chr10:1019161	NA	0.45	4.37	0.33	2.26e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs6604026	0.698	rs4847384	chr1:93382279	T/C	cg17283838	chr1:93427260	FAM69A	-0.64	-5.95	-0.43	1.79e-8	Multiple sclerosis;
PAAD	cis	rs12304921	1.000	rs224568	chr12:51386548	A/G	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.34	-0.33	2.55e-5	Type 2 diabetes;
PAAD	cis	rs7264396	0.943	rs1810742	chr20:34109718	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.72	-0.42	5.59e-8	Total cholesterol levels;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.47	4.97	0.37	1.75e-6	Longevity;Endometriosis;
PAAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.69	-4.98	-0.37	1.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.27	-0.39	4.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06850241	chr22:41845214	NA	0.57	5.06	0.38	1.2e-6	Vitiligo;
PAAD	cis	rs6674176	0.551	rs7555	chr1:44456742	C/T	cg12908607	chr1:44402522	ARTN	0.69	4.41	0.34	1.95e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2278796	0.639	rs6661192	chr1:204971413	A/G	cg17947172	chr1:204966197	NFASC	0.43	4.68	0.35	6.26e-6	Mean platelet volume;
PAAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.87	0.37	2.74e-6	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18268492	chr10:99185986	PGAM1	0.55	6.44	0.46	1.45e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13732083	chr21:47605072	C21orf56	0.49	4.88	0.37	2.64e-6	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.92	-8.95	-0.59	1.13e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-5.36	-0.4	3.02e-7	Initial pursuit acceleration;
PAAD	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs9896052	0.614	rs6501803	chr17:73450225	C/T	cg25649188	chr17:73499917	CASKIN2	0.59	4.64	0.35	7.42e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs10982213	1.000	rs7875632	chr9:117181322	G/A	cg00078025	chr9:117159975	NA	0.63	4.69	0.36	5.98e-6	Interleukin-6 levels;
PAAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-5.52	-0.41	1.44e-7	Personality dimensions;
PAAD	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg02421172	chr7:1938701	MAD1L1	0.57	4.26	0.33	3.58e-5	Bipolar disorder;
PAAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg11833968	chr6:79620685	NA	0.41	4.28	0.33	3.29e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg09760422	chr2:128146352	NA	-0.35	-5.85	-0.43	2.93e-8	Protein C levels;
PAAD	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.56	2.93e-14	Morning vs. evening chronotype;
PAAD	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.54	9.53	0.61	3.53e-17	Cutaneous nevi;
PAAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.63e-6	Childhood ear infection;
PAAD	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg11380483	chr2:127933992	NA	-0.5	-5.19	-0.39	6.59e-7	Self-rated health;
PAAD	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Mean platelet volume;
PAAD	cis	rs4343996	0.967	rs4316064	chr7:3358580	A/G	cg21248987	chr7:3385318	SDK1	0.43	4.74	0.36	4.88e-6	Motion sickness;
PAAD	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	6.45	0.46	1.38e-9	Coronary artery disease;
PAAD	cis	rs7127900	1.000	rs11043133	chr11:2232665	G/A	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs4751006	0.543	rs2890130	chr10:128783848	T/C	cg05702161	chr10:128779687	DOCK1	-1.23	-6.98	-0.49	8.36e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.54	-4.95	-0.37	1.92e-6	Blood metabolite levels;
PAAD	cis	rs58521262	0.556	rs289336	chr19:23152235	G/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.62	5.52	0.41	1.4e-7	Coronary heart disease;
PAAD	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06850241	chr22:41845214	NA	0.57	5.03	0.38	1.38e-6	Vitiligo;
PAAD	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.58	5.16	0.39	7.74e-7	Mean platelet volume;
PAAD	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg15123519	chr2:136567270	LCT	-0.36	-4.47	-0.34	1.52e-5	Mosquito bite size;
PAAD	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.61	-5.15	-0.39	7.91e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.76	8.78	0.58	3.12e-15	Total body bone mineral density;
PAAD	cis	rs4740619	0.935	rs1509310	chr9:15733836	G/A	cg14451791	chr9:16040625	NA	-0.4	-4.66	-0.35	6.8e-6	Body mass index;
PAAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.63	-5.48	-0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs7684253	0.548	rs13106200	chr4:57718195	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-4.51	-0.34	1.31e-5	Migraine;
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13147522	chr11:68228078	SAPS3	0.57	6.48	0.47	1.22e-9	Monocyte percentage of white cells;
PAAD	cis	rs3136441	1.000	rs5896	chr11:46745003	C/T	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg07469887	chr10:131262384	NA	-0.42	-4.88	-0.37	2.61e-6	Response to temozolomide;
PAAD	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07204739	chr1:228238553	WNT3A	0.64	6.89	0.49	1.35e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.95	7.54	0.52	3.92e-12	Iron status biomarkers;
PAAD	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23598886	chr18:12777645	NA	-0.77	-6.47	-0.46	1.28e-9	Inflammatory skin disease;
PAAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.33	5.84	0.43	3.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21089646	chr5:179373290	NA	-0.66	-6.5	-0.47	1.08e-9	Obesity-related traits;
PAAD	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21646471	chr2:242523971	THAP4	0.63	4.84	0.37	3.19e-6	Prostate cancer;
PAAD	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.73	8.41	0.56	2.83e-14	Blood metabolite ratios;
PAAD	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14080001	chr15:75940555	SNX33	0.55	6.45	0.46	1.38e-9	Response to antipsychotic treatment;
PAAD	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.95	10.38	0.64	2.05e-19	Multiple sclerosis;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.62	6.78	0.48	2.44e-10	Mean corpuscular volume;
PAAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg19000871	chr14:103996768	TRMT61A	-0.46	-4.91	-0.37	2.28e-6	Reticulocyte count;
PAAD	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg10705379	chr10:99080932	FRAT1	0.44	5.19	0.39	6.56e-7	Monocyte count;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.04	-0.44	1.14e-8	Schizophrenia;
PAAD	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22920873	chr7:139025153	C7orf55	0.65	6.73	0.48	3.22e-10	Myopia (pathological);
PAAD	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg10871876	chr19:53194124	ZNF83	0.55	4.7	0.36	5.76e-6	Response to paliperidone in schizophrenia (PANSS score);
PAAD	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg01075559	chr1:2537774	MMEL1	0.5	5.33	0.4	3.47e-7	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.26	-0.39	4.87e-7	Life satisfaction;
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7619427	1.000	rs6788179	chr3:44062007	G/A	cg03918530	chr3:44155650	MIR138-1	0.56	4.46	0.34	1.58e-5	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg18612461	chr15:75251733	NA	-0.41	-4.82	-0.36	3.49e-6	Systemic lupus erythematosus;
PAAD	cis	rs7210086	0.948	rs17780256	chr17:70642923	A/C	cg04206342	chr17:70636940	NA	-0.36	-4.35	-0.33	2.48e-5	Ulcerative colitis;
PAAD	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.88	0.43	2.49e-8	Lung cancer;
PAAD	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.29e-5	Renal cell carcinoma;
PAAD	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.71	0.36	5.46e-6	Breast cancer;
PAAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.76	7.15	0.5	3.34e-11	Cleft lip with or without cleft palate;
PAAD	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3736485	0.934	rs11635592	chr15:51859786	A/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.81	-6.66	-0.48	4.75e-10	Pulmonary function decline;
PAAD	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg04731861	chr2:219085781	ARPC2	-0.37	-4.43	-0.34	1.82e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg27449745	chr7:23145252	KLHL7	-0.55	-4.91	-0.37	2.33e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.44	-4.34	-0.33	2.57e-5	Tonsillectomy;
PAAD	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs9535307	0.719	rs1198315	chr13:50370168	C/T	cg03658251	chr13:50265850	EBPL	-0.82	-5.62	-0.42	8.68e-8	Obesity-related traits;
PAAD	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg06780032	chr1:8272277	NA	-0.33	-4.3	-0.33	3.06e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7873102	0.630	rs16934708	chr9:38000647	C/T	cg03528946	chr9:38069800	SHB	-0.5	-5.04	-0.38	1.28e-6	Brain structure;
PAAD	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.55	6.81	0.48	2.16e-10	Atrioventricular conduction;
PAAD	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg11189052	chr15:85197271	WDR73	-0.54	-4.36	-0.33	2.36e-5	P wave terminal force;
PAAD	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.48	-5.33	-0.4	3.49e-7	Heart rate;
PAAD	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.87	-0.49	1.59e-10	Atrioventricular conduction;
PAAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-8.99	-0.59	8.94e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.43	-4.28	-0.33	3.27e-5	Ulcerative colitis;
PAAD	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04640216	chr11:63439065	ATL3	0.61	6.36	0.46	2.22e-9	Myopia (pathological);
PAAD	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg10820045	chr2:198174542	NA	-0.46	-4.62	-0.35	8.24e-6	Intracranial aneurysm;
PAAD	cis	rs6715793	0.839	rs4670828	chr2:33406035	G/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg07648498	chr16:89883185	FANCA	-0.46	-4.36	-0.33	2.4e-5	Vitiligo;
PAAD	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.65	5.88	0.43	2.55e-8	Schizophrenia;
PAAD	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.63	-6.76	-0.48	2.71e-10	Caffeine consumption;
PAAD	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.56	6.58	0.47	7.3e-10	Schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00912939	chr7:102036598	PRKRIP1	0.56	6.39	0.46	1.96e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs939584	1.000	rs7608050	chr2:652247	G/A	cg14515364	chr2:636606	NA	-0.46	-4.29	-0.33	3.16e-5	Body mass index;
PAAD	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg00806126	chr19:22604979	ZNF98	-0.45	-5.45	-0.4	2e-7	Pain;
PAAD	cis	rs4939490	0.639	rs2905517	chr11:60768044	G/A	cg16817237	chr11:60793675	NA	-0.39	-5.69	-0.42	6.31e-8	Multiple sclerosis;
PAAD	cis	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-4.47	-0.34	1.54e-5	Myopia (pathological);
PAAD	cis	rs73388146	0.772	rs4712888	chr6:25147518	C/T	cg19882886	chr6:25043046	NA	-1.05	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.45	-4.28	-0.33	3.3e-5	Renal cell carcinoma;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg00024416	chr22:24240387	NA	0.64	6.58	0.47	7.25e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs12431939	1.000	rs60593258	chr14:51662280	T/A	cg23942311	chr14:51606299	NA	-0.61	-4.94	-0.37	2.05e-6	Cancer;
PAAD	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.71	6.94	0.49	1.05e-10	Alcohol dependence;
PAAD	cis	rs1468734	1.000	rs873645	chr16:5005280	A/T	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.86	-0.54	6.68e-13	Colorectal cancer;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.46	4.62	0.35	8.27e-6	Electroencephalogram traits;
PAAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.62	-5.57	-0.41	1.11e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13560548	chr3:10150139	C3orf24	0.52	4.47	0.34	1.49e-5	Alzheimer's disease;
PAAD	cis	rs7582720	1.000	rs72932746	chr2:203663498	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.5	0.52	4.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.62	-5.0	-0.38	1.54e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg25418670	chr11:30344373	C11orf46	-0.67	-6.45	-0.46	1.41e-9	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08413026	chr12:132380000	ULK1	0.5	6.38	0.46	2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.8	8.3	0.56	5.36e-14	Gout;
PAAD	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg12395012	chr8:11607386	GATA4	0.44	4.28	0.33	3.31e-5	Neuroticism;
PAAD	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.85	9.12	0.59	4.34e-16	Colorectal cancer;
PAAD	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg06606381	chr12:133084897	FBRSL1	-1.47	-9.27	-0.6	1.72e-16	Depression;
PAAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	5.48	0.41	1.69e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.41	0.52	8e-12	Menopause (age at onset);
PAAD	cis	rs6604026	0.698	rs10874744	chr1:93306317	G/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.82	-0.43	3.42e-8	Multiple sclerosis;
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg00277334	chr10:82204260	NA	-0.61	-5.51	-0.41	1.48e-7	Post bronchodilator FEV1;
PAAD	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs1355223	0.902	rs286861	chr11:34718424	A/T	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-4.3	-0.33	2.99e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.76	8.94	0.59	1.22e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6669119	1.000	rs9439746	chr1:19111857	T/C	cg19637330	chr1:19110922	NA	0.81	5.1	0.38	9.98e-7	Percentage gas trapping;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01551511	chr11:74303530	POLD3	0.56	6.3	0.46	3.04e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs682748	0.846	rs60388951	chr5:17134319	C/G	cg23987134	chr5:17158319	LOC285696	-0.35	-4.33	-0.33	2.7e-5	Hippocampal atrophy;
PAAD	cis	rs300774	0.844	rs300729	chr2:131788	C/G	cg23649280	chr2:140451	NA	0.46	4.28	0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.83	6.57	0.47	7.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg11271282	chr2:238384023	NA	0.65	4.89	0.37	2.57e-6	Prostate cancer;
PAAD	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg11995313	chr8:8860691	ERI1	-0.52	-5.14	-0.39	8.16e-7	Joint mobility (Beighton score);
PAAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07562135	chr19:39340654	HNRNPL	-0.66	-6.84	-0.49	1.84e-10	Smoking initiation;
PAAD	cis	rs16866587	0.536	rs72961212	chr2:179783470	C/T	cg22657780	chr2:180725907	ZNF385B;MIR1258	-0.83	-4.37	-0.33	2.33e-5	Psychosis proneness (revised physical anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
PAAD	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.57	5.92	0.43	2.05e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11168618	0.686	rs11168574	chr12:48838969	T/A	cg01881778	chr12:48919444	OR8S1	-0.5	-4.97	-0.37	1.8e-6	Adiponectin levels;
PAAD	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.45e-7	Crohn's disease;
PAAD	cis	rs13424612	0.965	rs58652766	chr2:240904884	G/A	cg01812947	chr2:240904978	NDUFA10	0.59	5.13	0.38	8.83e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs59104589	0.583	rs61689231	chr2:242244583	G/A	cg04488487	chr2:242709673	NA	0.57	4.31	0.33	2.9e-5	Fibrinogen levels;
PAAD	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs2637266	0.777	rs2637254	chr10:78312002	G/A	cg18941641	chr10:78392320	NA	0.36	4.29	0.33	3.15e-5	Pulmonary function;
PAAD	cis	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg06307176	chr5:131281290	NA	0.51	4.45	0.34	1.64e-5	Life satisfaction;
PAAD	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg01631408	chr1:248437212	OR2T33	-0.58	-5.17	-0.39	7.43e-7	Common traits (Other);
PAAD	cis	rs2659067	1.000	rs1654523	chr19:51485194	C/T	cg06707544	chr19:51487229	KLK7	-0.77	-4.42	-0.34	1.85e-5	Blood protein levels;
PAAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg21951975	chr1:209979733	IRF6	0.41	5.15	0.39	8e-7	Monobrow;
PAAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.38	4.56	0.35	1.05e-5	Rheumatoid arthritis;
PAAD	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.81	-0.36	3.55e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs2594989	0.670	rs9845397	chr3:11470263	C/T	cg01796438	chr3:11312864	ATG7	-0.59	-4.44	-0.34	1.7e-5	Circulating chemerin levels;
PAAD	cis	rs2492906	0.600	rs2637321	chr10:28074687	G/C	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.74	-7.38	-0.51	9.5e-12	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12491688	chr15:44580831	CASC4	0.64	6.47	0.46	1.28e-9	Obesity-related traits;
PAAD	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg11822372	chr1:151115635	SEMA6C	0.61	5.71	0.42	5.63e-8	Childhood ear infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16036305	chr1:115053835	TRIM33	0.72	7.81	0.54	8.47e-13	Myopia (pathological);
PAAD	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.5	4.87	0.37	2.75e-6	Longevity;
PAAD	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.53	5.68	0.42	6.51e-8	Major depressive disorder;
PAAD	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.7	-5.69	-0.42	6.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.55	-7.43	-0.52	7.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14119001	chr9:139324193	INPP5E	-0.6	-5.39	-0.4	2.69e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1903068	0.785	rs10013228	chr4:55997340	A/G	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.71e-5	Endometriosis;
PAAD	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.53	-4.59	-0.35	9.21e-6	Schizophrenia;
PAAD	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.45	-0.34	1.68e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs282587	0.597	rs1756075	chr13:113396211	T/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs1198430	1.000	rs1198434	chr1:23758134	A/G	cg22040403	chr1:23858016	E2F2	0.72	4.58	0.35	9.53e-6	Total cholesterol levels;
PAAD	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.23	-0.39	5.63e-7	Tonsillectomy;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.6	-6.62	-0.47	5.87e-10	Lung cancer;
PAAD	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg07168214	chr17:7380112	ZBTB4	-0.64	-5.95	-0.43	1.8e-8	IgM levels;
PAAD	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg11251234	chr10:101825055	CPN1	-0.31	-4.67	-0.35	6.65e-6	Bone mineral density;
PAAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02034447	chr16:89574710	SPG7	0.5	4.76	0.36	4.45e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg18939081	chr1:31884902	SERINC2	0.5	5.71	0.42	5.66e-8	Alcohol dependence;
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg08835956	chr7:39171034	POU6F2	0.35	5.91	0.43	2.21e-8	IgG glycosylation;
PAAD	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.47	-5.34	-0.4	3.37e-7	Body mass index;
PAAD	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.83	6.38	0.46	2.02e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.5	-6.18	-0.45	5.61e-9	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg00531865	chr16:30841666	NA	-0.53	-5.25	-0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs58521262	0.505	rs428612	chr19:23122604	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.4	-0.34	2.07e-5	Testicular germ cell tumor;
PAAD	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg02811702	chr13:24901961	NA	-0.56	-6.04	-0.44	1.12e-8	Obesity-related traits;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18207214	chr5:125880253	ALDH7A1	-0.54	-6.36	-0.46	2.28e-9	Energy expenditure (24h);
PAAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Calcium levels;
PAAD	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs35000415	0.938	rs35188261	chr7:128683539	G/A	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.59	5.12	0.38	9.11e-7	Common traits (Other);
PAAD	cis	rs7916697	0.947	rs7916410	chr10:69995667	T/C	cg18338521	chr10:69995036	NA	0.36	4.5	0.34	1.37e-5	Optic disc area;
PAAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg19847866	chr10:1019161	NA	0.66	6.71	0.48	3.59e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg13444538	chr7:158905317	VIPR2	-0.7	-5.2	-0.39	6.4e-7	Myopia (pathological);
PAAD	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18337363	chr3:52569053	NT5DC2	0.44	4.47	0.34	1.49e-5	Electroencephalogram traits;
PAAD	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.48	5.23	0.39	5.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.51	-5.7	-0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00151565	chr1:173961904	RC3H1	-0.61	-6.33	-0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg20893579	chr22:38215064	NA	0.49	4.61	0.35	8.39e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg04450456	chr4:17643702	FAM184B	-0.56	-6.43	-0.46	1.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.39	4.9	0.37	2.47e-6	Pulmonary function;
PAAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg14388049	chr10:71211838	TSPAN15	-0.47	-4.89	-0.37	2.5e-6	Thrombosis;
PAAD	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7771547	0.855	rs4713987	chr6:36599010	T/C	cg07856975	chr6:36356162	ETV7	0.47	5.26	0.39	4.8e-7	Platelet distribution width;
PAAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.58	-0.35	9.54e-6	Renal cell carcinoma;
PAAD	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.5	-4.91	-0.37	2.37e-6	Mortality in heart failure;
PAAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.8	-4.71	-0.36	5.48e-6	Skin colour saturation;
PAAD	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg15956490	chr3:53032818	SFMBT1	0.72	4.27	0.33	3.37e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg00717180	chr2:96193071	NA	-0.62	-6.89	-0.49	1.38e-10	HDL cholesterol;
PAAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.57	-0.35	1.01e-5	IgG glycosylation;
PAAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.76	9.03	0.59	7.32e-16	Emphysema distribution in smoking;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13080195	chr4:83719908	SCD5	0.65	6.51	0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg13722127	chr7:150037890	RARRES2	0.65	6.84	0.48	1.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg04398451	chr17:18023971	MYO15A	0.49	5.05	0.38	1.28e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg25456477	chr12:86230367	RASSF9	0.49	4.33	0.33	2.65e-5	Major depressive disorder;
PAAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg12458913	chr13:53173898	NA	0.48	4.82	0.36	3.42e-6	Lewy body disease;
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.93	0.43	1.98e-8	Blood metabolite levels;
PAAD	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.71	4.62	0.35	8.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-6.0	-0.44	1.4e-8	Diabetic retinopathy;
PAAD	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs13424612	0.839	rs13848	chr2:240946766	A/G	cg01812947	chr2:240904978	NDUFA10	0.54	4.9	0.37	2.4e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs58521262	0.556	rs2548894	chr19:23192678	T/G	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.61	7.43	0.52	7.49e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs11264799	0.648	rs72710036	chr1:157788473	G/A	cg18268488	chr1:157545234	FCRL4	0.68	5.34	0.4	3.26e-7	IgA nephropathy;
PAAD	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.53	-5.16	-0.39	7.7e-7	Mortality in heart failure;
PAAD	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.56	-0.47	7.95e-10	Educational attainment;
PAAD	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.77e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg24253500	chr15:84953950	NA	0.59	6.77	0.48	2.59e-10	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg21698718	chr17:80085957	CCDC57	-0.48	-5.37	-0.4	2.83e-7	Life satisfaction;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.74	-0.48	3.12e-10	Lymphocyte counts;
PAAD	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.5	0.57	1.62e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-6.89	-0.49	1.39e-10	Morning vs. evening chronotype;
PAAD	cis	rs11209002	0.956	rs2013772	chr1:67581445	A/T	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg12074985	chr10:99080756	FRAT1	-0.41	-4.28	-0.33	3.35e-5	Monocyte count;
PAAD	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg07154921	chr7:157260426	NA	0.44	4.32	0.33	2.77e-5	Body mass index;
PAAD	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.8	-0.53	9.16e-13	Total cholesterol levels;
PAAD	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg12927641	chr6:109611667	NA	-0.45	-4.98	-0.37	1.71e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg21479132	chr6:26055353	NA	0.65	4.32	0.33	2.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.99	-8.45	-0.57	2.21e-14	Initial pursuit acceleration;
PAAD	cis	rs959260	1.000	rs2033607	chr17:73367288	A/G	cg20590849	chr17:73267439	MIF4GD	-0.53	-4.32	-0.33	2.79e-5	Systemic lupus erythematosus;
PAAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg21448613	chr3:49828315	CDH29	0.44	4.29	0.33	3.16e-5	Menarche (age at onset);
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.31	4.32	0.33	2.76e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg20607287	chr7:12443886	VWDE	-0.73	-5.7	-0.42	6.04e-8	Coronary artery disease;
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs8063160	0.688	rs12924124	chr16:89791126	C/T	cg07984980	chr16:89898383	SPIRE2	0.92	4.91	0.37	2.33e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.53	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.78	9.53	0.61	3.63e-17	Ulcerative colitis;
PAAD	cis	rs6844506	0.701	rs1704848	chr4:185234083	C/G	cg12654155	chr4:185238627	NA	-0.52	-5.1	-0.38	9.92e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.86	8.04	0.55	2.36e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.41	5.17	0.39	7.2e-7	Sitting height ratio;
PAAD	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.44	5.61	0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6923462	0.935	rs5009024	chr6:7786611	C/G	cg04616797	chr6:7542118	DSP	0.68	4.75	0.36	4.75e-6	Lung function (forced vital capacity);
PAAD	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06850241	chr22:41845214	NA	0.57	5.03	0.38	1.38e-6	Vitiligo;
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03812309	chr1:46938281	NA	0.31	4.25	0.33	3.69e-5	High light scatter reticulocyte count;
PAAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.86	0.43	2.84e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7818688	0.697	rs112076731	chr8:95978121	C/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg07166546	chr14:35805898	NA	-0.29	-4.26	-0.33	3.6e-5	Psoriasis;
PAAD	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.74	-8.16	-0.55	1.19e-13	Schizophrenia;
PAAD	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.41	0.34	1.96e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.53	5.34	0.4	3.27e-7	Blood metabolite levels;
PAAD	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.13	0.38	8.65e-7	Personality dimensions;
PAAD	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.1	-0.5	4.35e-11	Morning vs. evening chronotype;
PAAD	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.13	0.45	7.22e-9	Lung cancer in ever smokers;
PAAD	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.52	-5.06	-0.38	1.18e-6	IgG glycosylation;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg22029157	chr1:209979665	IRF6	0.72	6.95	0.49	9.81e-11	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg04154034	chr17:28927549	LRRC37B2	0.68	4.38	0.33	2.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg23464041	chr6:33663938	ITPR3	0.47	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.66	7.09	0.5	4.63e-11	Blood protein levels;
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.59	-6.69	-0.48	4.11e-10	Prostate cancer;
PAAD	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-4.94	-0.37	2.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-5.22	-0.39	5.9e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07645888	chr2:62932961	EHBP1	0.63	6.59	0.47	6.93e-10	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04734688	chr11:17229674	NA	-0.75	-6.76	-0.48	2.78e-10	Neuroticism;
PAAD	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs17123764	0.710	rs12299505	chr12:50019894	T/C	cg14846292	chr12:49726500	C1QL4	-0.69	-4.54	-0.35	1.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.86	-0.62	4.94e-18	Monocyte percentage of white cells;
PAAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.32e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.85	9.51	0.61	3.99e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.49e-10	Body mass index;
PAAD	cis	rs3747547	0.818	rs16934639	chr9:37943092	T/C	cg13774184	chr9:37916125	SHB	-0.58	-4.26	-0.33	3.63e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs6494488	0.500	rs72744740	chr15:65050491	C/G	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs802075	1.000	rs802070	chr6:49656358	A/G	cg20364632	chr6:49636226	NA	-0.52	-6.03	-0.44	1.21e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg17551891	chr7:1960795	MAD1L1	-0.49	-4.55	-0.35	1.09e-5	Neuroticism;
PAAD	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	cis	rs9341808	0.500	rs2223873	chr6:81048288	A/G	cg08355045	chr6:80787529	NA	0.41	5.06	0.38	1.19e-6	Sitting height ratio;
PAAD	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	9.9	0.63	3.79e-18	Response to antipsychotic treatment;
PAAD	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg07099767	chr17:78039528	CCDC40	-0.54	-4.58	-0.35	9.66e-6	Yeast infection;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27436995	chr16:743998	FBXL16	-0.36	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.53	0.35	1.17e-5	Educational attainment;
PAAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.53	-0.47	9.44e-10	Bone mineral density;
PAAD	cis	rs6942407	0.546	rs2074757	chr7:86794121	G/A	cg02420886	chr7:86849541	C7orf23	0.63	4.79	0.36	3.85e-6	Food allergy;
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13866156	chr1:1669148	SLC35E2	-0.79	-9.06	-0.59	6.16e-16	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17791867	chr7:112579927	C7orf60	0.67	7.77	0.53	1.09e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6604026	0.656	rs12060952	chr1:93381273	T/C	cg17283838	chr1:93427260	FAM69A	0.63	5.81	0.43	3.59e-8	Multiple sclerosis;
PAAD	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.53	-5.09	-0.38	1.02e-6	Mean platelet volume;
PAAD	cis	rs732765	0.734	rs888418	chr14:75119296	C/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.29	0.33	3.22e-5	Non-small cell lung cancer;
PAAD	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	0.850	rs80174235	chr10:46091818	G/C	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.07e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04722914	chr2:242255165	HDLBP;SEPT2	0.62	7.18	0.5	2.89e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.89	-0.43	2.41e-8	Calcium levels;
PAAD	cis	rs876084	0.505	rs4407921	chr8:121156585	C/T	cg06265175	chr8:121136014	COL14A1	0.46	4.47	0.34	1.55e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg13444538	chr7:158905317	VIPR2	0.48	4.37	0.33	2.25e-5	Facial morphology (factor 20);
PAAD	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-6.31	-0.46	2.91e-9	Hypospadias;
PAAD	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-5.72	-0.42	5.41e-8	Schizophrenia (age at onset);
PAAD	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.51	-5.34	-0.4	3.26e-7	Interleukin-18 levels;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03404566	chr17:6899310	ALOX12	0.44	4.67	0.35	6.47e-6	Tonsillectomy;
PAAD	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.71	-0.42	5.86e-8	Tonsillectomy;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.44	-6.34	-0.46	2.5e-9	Breast cancer;
PAAD	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.57	5.89	0.43	2.34e-8	Anxiety disorder;
PAAD	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	-0.79	-5.12	-0.38	8.97e-7	Lung cancer in ever smokers;
PAAD	cis	rs508970	0.556	rs678305	chr11:60915438	T/C	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.55	5.43	0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg26338869	chr17:61819248	STRADA	-0.64	-6.4	-0.46	1.82e-9	Prudent dietary pattern;
PAAD	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.15	0.39	8.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4704187	0.687	rs10058460	chr5:74498715	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.63	4.81	0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg26071806	chr7:100318239	EPO	-0.48	-4.69	-0.36	6.09e-6	Other erythrocyte phenotypes;
PAAD	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	1.05	15.29	0.78	1.48e-32	Menarche (age at onset);
PAAD	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg09210956	chr2:1358730	SNTG2	-0.53	-4.31	-0.33	2.89e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18337363	chr3:52569053	NT5DC2	0.41	4.36	0.33	2.4e-5	Bipolar disorder;
PAAD	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.87	-6.95	-0.49	1e-10	Atopic dermatitis;
PAAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.01	0.59	8.14e-16	Menopause (age at onset);
PAAD	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg24450063	chr1:156163899	SLC25A44	1.17	17.79	0.82	5.56e-39	Testicular germ cell tumor;
PAAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.44	-4.25	-0.33	3.74e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.81	9.38	0.61	8.77e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.66	-5.77	-0.42	4.23e-8	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22626041	chr1:175162049	KIAA0040	-0.75	-6.97	-0.49	9.06e-11	Neuroticism;
PAAD	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.98	8.21	0.55	8.91e-14	Neutrophil percentage of white cells;
PAAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.56	-5.36	-0.4	3e-7	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04130928	chr5:176449623	ZNF346	0.59	6.7	0.48	3.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs282587	0.569	rs282562	chr13:113375249	T/G	cg02820901	chr13:113351484	ATP11A	0.64	4.67	0.35	6.45e-6	Glycated hemoglobin levels;
PAAD	cis	rs2446066	0.872	rs34148420	chr12:53798808	T/C	cg14275095	chr12:52828633	KRT75	-0.57	-4.27	-0.33	3.41e-5	Red blood cell count;
PAAD	cis	rs9356171	0.572	rs11756250	chr6:164325686	A/G	cg25752492	chr6:164341247	NA	-0.47	-5.18	-0.39	7.01e-7	Diisocyanate-induced asthma;
PAAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Depression;
PAAD	cis	rs7631605	0.905	rs1392749	chr3:37205191	A/G	cg17445812	chr3:36986805	TRANK1	-0.33	-4.43	-0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13920768	chr9:133557644	PRDM12	0.56	6.35	0.46	2.4e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.18	-10.17	-0.64	7.45e-19	Vitiligo;
PAAD	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19732469	chr14:96968481	PAPOLA	0.57	6.52	0.47	9.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.88	-0.37	2.62e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs494459	0.929	rs627391	chr11:118573916	A/T	cg08498647	chr11:118550644	TREH	-0.42	-5.21	-0.39	6.01e-7	Height;
PAAD	cis	rs3126085	0.560	rs67661262	chr1:152368016	A/C	cg26876637	chr1:152193138	HRNR	-0.63	-4.7	-0.36	5.8e-6	Atopic dermatitis;
PAAD	cis	rs911119	0.866	rs2405393	chr20:23569392	G/C	cg16589663	chr20:23618590	CST3	0.79	6.77	0.48	2.7e-10	Chronic kidney disease;
PAAD	cis	rs7814319	0.838	rs2643342	chr8:97234255	A/G	cg20787634	chr8:97240163	UQCRB	-0.61	-6.3	-0.45	3.12e-9	Lung function (FVC);
PAAD	cis	rs4751006	0.543	rs76831503	chr10:128770022	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.92	-0.49	1.16e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.72	-9.44	-0.61	6.36e-17	Rheumatoid arthritis;
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg13206674	chr6:150067644	NUP43	0.61	6.41	0.46	1.71e-9	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.72	0.36	5.21e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.89	11.24	0.67	1.05e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1144	0.537	rs2470944	chr7:104585516	G/C	cg04380332	chr7:105027541	SRPK2	-0.65	-6.89	-0.49	1.35e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.32	-0.56	4.66e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.44	-5.98	-0.44	1.5e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs7719624	0.545	rs12521108	chr5:135409124	G/A	cg16684184	chr5:135415129	NA	-0.46	-5.92	-0.43	2.04e-8	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs2455826	0.521	rs9865689	chr3:15859822	C/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg20503657	chr10:835505	NA	0.54	5.69	0.42	6.22e-8	Survival in rectal cancer;
PAAD	cis	rs7593730	0.636	rs6743795	chr2:161122134	A/G	cg22609984	chr2:161126801	NA	0.51	4.4	0.34	2.02e-5	Type 2 diabetes;
PAAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.53	5.4	0.4	2.57e-7	Platelet count;
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg02951883	chr7:2050386	MAD1L1	0.58	5.67	0.42	6.96e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg14703610	chr5:56206110	C5orf35	0.61	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg14003231	chr6:33640908	ITPR3	0.36	4.55	0.35	1.07e-5	Height;
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg19429281	chr19:53496738	ZNF702P	-0.61	-6.41	-0.46	1.73e-9	Psoriasis;
PAAD	cis	rs11078597	0.731	rs1317708	chr17:1639965	G/A	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.4e-8	Serum albumin level;
PAAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs8084125	1.000	rs62105169	chr18:74945193	A/G	cg05528293	chr18:74961138	GALR1	0.61	5.04	0.38	1.32e-6	Obesity-related traits;
PAAD	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.71	7.27	0.51	1.78e-11	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.99	8.78	0.58	3.19e-15	Bipolar disorder;
PAAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.71	-6.4	-0.46	1.87e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.48	-0.41	1.76e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07693037	chr3:128216748	NA	0.6	6.65	0.47	4.95e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.5	5.13	0.38	8.66e-7	Red blood cell count;
PAAD	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05264915	chr2:210867333	RPE	-0.62	-6.58	-0.47	7.08e-10	Smoking initiation;
PAAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg13918804	chr1:2043761	PRKCZ	0.43	5.88	0.43	2.51e-8	Height;
PAAD	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg21890820	chr11:65308645	LTBP3	1.69	10.49	0.65	1.03e-19	Height;
PAAD	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.7	6.06	0.44	1.03e-8	Diabetic retinopathy;
PAAD	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.26	-0.39	4.8e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4702	0.591	rs7183988	chr15:91428589	T/G	cg00630237	chr15:91433507	FES	0.5	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.37	1.66e-6	Body mass index;
PAAD	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-1.2	-9.88	-0.63	4.47e-18	Obesity-related traits;
PAAD	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.29	0.39	4.27e-7	Red blood cell count;
PAAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.81e-6	Height;
PAAD	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg14703610	chr5:56206110	C5orf35	-0.57	-5.3	-0.39	4.04e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.81	-6.6	-0.47	6.36e-10	Chronic kidney disease;
PAAD	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs8005172	0.750	rs7157799	chr14:88427075	A/G	cg18078958	chr14:88630771	NA	0.46	5.34	0.4	3.31e-7	Parkinson's disease;
PAAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg11057378	chr10:81107060	PPIF	0.48	5.53	0.41	1.39e-7	Height;
PAAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.75	10.17	0.64	7.43e-19	Coronary artery disease;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg15510373	chr7:100224934	TFR2	-0.61	-4.9	-0.37	2.39e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.41	-0.34	1.98e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9395066	0.545	rs35357222	chr6:44940552	C/G	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	4.67	0.35	6.59e-6	Depressive symptoms;
PAAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26926768	chr12:34528122	NA	0.37	4.32	0.33	2.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs6066835	0.867	rs11907586	chr20:47374058	G/A	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg08994789	chr17:28903642	LRRC37B2	0.55	4.64	0.35	7.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-4.85	-0.37	3.01e-6	Pancreatic cancer;
PAAD	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.5	-0.34	1.37e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.53	-5.54	-0.41	1.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	0.71	4.81	0.36	3.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8105895	0.935	rs6511316	chr19:22237629	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg08773314	chr2:239334832	ASB1	0.41	6.96	0.49	9.49e-11	Multiple system atrophy;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg05717871	chr11:638507	DRD4	-0.59	-5.51	-0.41	1.48e-7	Systemic lupus erythematosus;
PAAD	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.88	-8.69	-0.58	5.54e-15	Exhaled nitric oxide output;
PAAD	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.14	11.06	0.67	3.16e-21	Cognitive test performance;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11320690	chr20:17550474	DSTN	0.63	6.9	0.49	1.35e-10	Monocyte percentage of white cells;
PAAD	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg19264203	chr11:92714893	MTNR1B	0.4	4.62	0.35	7.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9287719	0.649	rs10929677	chr2:10717548	A/G	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.76	-10.42	-0.65	1.61e-19	Iron status biomarkers;
PAAD	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg01620082	chr3:125678407	NA	-0.96	-6.79	-0.48	2.32e-10	Depression;
PAAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.56	-7.64	-0.53	2.25e-12	Renal cell carcinoma;
PAAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.45	-0.4	1.97e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs72960926	0.744	rs72954314	chr6:74939737	A/G	cg03266952	chr6:74778945	NA	-1.17	-6.5	-0.47	1.08e-9	Metabolite levels (MHPG);
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs3736757	1.000	rs12043236	chr1:184685197	G/A	cg05045817	chr1:184633523	NA	0.44	4.71	0.36	5.64e-6	Obesity-related traits;
PAAD	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16447950	chr5:562315	NA	0.67	5.96	0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07157834	chr1:205819609	PM20D1	0.55	5.34	0.4	3.28e-7	Parkinson's disease;
PAAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.22	-0.39	5.9e-7	Mean corpuscular volume;
PAAD	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg08676812	chr11:65308423	LTBP3	0.81	5.46	0.4	1.93e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.16	0.39	7.66e-7	Educational attainment;
PAAD	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.54	5.08	0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.75	8.32	0.56	4.77e-14	Schizophrenia;
PAAD	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg23531748	chr20:60969906	CABLES2	0.47	4.68	0.35	6.29e-6	Colorectal cancer;
PAAD	cis	rs1678618	0.556	rs1261886	chr10:73778640	G/A	cg20897136	chr10:74034667	DDIT4	0.35	4.33	0.33	2.75e-5	Smoking behavior;
PAAD	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg01612440	chr4:3296283	NA	0.46	4.52	0.34	1.26e-5	Serum sulfate level;
PAAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs501120	0.706	rs1657346	chr10:44777560	G/C	cg09554077	chr10:44749378	NA	0.42	4.41	0.34	1.93e-5	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.49	-0.34	1.4e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.61	-6.23	-0.45	4.46e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg04106633	chr4:1044584	NA	0.52	4.91	0.37	2.36e-6	Recombination rate (males);
PAAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22159483	chr17:1588198	PRPF8	0.64	6.95	0.49	1.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.66	7.02	0.49	7.08e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11741688	0.720	rs4700981	chr5:178389116	A/T	cg20935368	chr5:178288625	ZNF354B	-0.45	-4.63	-0.35	7.85e-6	Sleep duration;
PAAD	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg04851639	chr8:1020857	NA	-0.54	-6.05	-0.44	1.07e-8	Schizophrenia;
PAAD	cis	rs12442242	0.522	rs16966213	chr15:38361447	C/T	cg19084031	chr15:38361362	NA	0.96	5.9	0.43	2.24e-8	Total body bone mineral density;
PAAD	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.08e-15	Exhaled nitric oxide output;
PAAD	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.97	-9.89	-0.63	4.16e-18	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00352397	chr1:45477801	UROD;HECTD3	0.61	6.97	0.49	8.86e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.67	-0.42	7.08e-8	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg21565972	chr17:80109576	CCDC57	0.5	5.51	0.41	1.51e-7	Life satisfaction;
PAAD	cis	rs9322817	0.691	rs4460239	chr6:105325562	C/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Tonsillectomy;
PAAD	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.88	9.48	0.61	4.77e-17	Corneal astigmatism;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17251097	chr10:81838583	LOC219347;C10orf57	-0.52	-4.98	-0.37	1.72e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-1.17	-8.1	-0.55	1.65e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.29	-0.39	4.14e-7	Mononucleosis;
PAAD	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.38	-0.56	3.29e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.84	-7.42	-0.52	7.66e-12	IgG glycosylation;
PAAD	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.52	6.02	0.44	1.23e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.69	-7.39	-0.51	9.14e-12	Blood metabolite levels;
PAAD	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.73	8.24	0.56	7.64e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.45	4.85	0.37	3.07e-6	Testicular germ cell tumor;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg21970626	chr13:21893289	NA	-0.66	-8.82	-0.58	2.48e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg25309567	chr17:79516362	C17orf70	-0.45	-4.35	-0.33	2.53e-5	Eye color traits;
PAAD	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.43	-6.38	-0.46	2e-9	Breast cancer;
PAAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg00071950	chr4:10020882	SLC2A9	0.51	4.46	0.34	1.59e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.87	-7.46	-0.52	6.34e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs425535	0.757	rs164616	chr4:74798566	A/G	cg01447579	chr4:74847100	PF4	0.66	4.32	0.33	2.86e-5	Blood protein levels;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.06e-10	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.5	4.49	0.34	1.4e-5	Corneal astigmatism;
PAAD	cis	rs4356203	0.543	rs214081	chr11:17299654	G/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.5	-0.34	1.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg26876637	chr1:152193138	HRNR	-0.86	-6.38	-0.46	1.98e-9	Atopic dermatitis;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17283889	chr5:1573743	SDHAP3	0.54	6.41	0.46	1.77e-9	Pancreatic cancer;
PAAD	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-5.46	-0.4	1.93e-7	Electrocardiographic conduction measures;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25674838	chr17:41856568	C17orf105;DUSP3	-0.63	-6.4	-0.46	1.81e-9	Smoking initiation;
PAAD	cis	rs6604026	0.656	rs11164835	chr1:93379093	A/G	cg17283838	chr1:93427260	FAM69A	-0.63	-5.82	-0.43	3.37e-8	Multiple sclerosis;
PAAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.53	-6.75	-0.48	2.88e-10	Height;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18621852	chr3:10150065	C3orf24	0.69	6.02	0.44	1.29e-8	Alzheimer's disease;
PAAD	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.46e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg15181151	chr6:150070149	PCMT1	0.53	5.67	0.42	7.1e-8	Lung cancer;
PAAD	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.74	-0.42	5.04e-8	Response to antipsychotic treatment;
PAAD	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.72	-9.15	-0.6	3.57e-16	Educational attainment;
PAAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.58	6.68	0.48	4.3e-10	Major depressive disorder;
PAAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg00206168	chr11:65308501	LTBP3	0.52	5.4	0.4	2.5e-7	Bone mineral density;
PAAD	cis	rs4704187	0.687	rs6866661	chr5:74534372	A/G	cg03227963	chr5:74354835	NA	0.49	4.78	0.36	4.07e-6	Response to amphetamines;
PAAD	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.45	4.33	0.33	2.71e-5	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26267791	chr3:48343031	NME6	0.69	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.35	-0.33	2.46e-5	Asthma (childhood onset);
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.48	-0.57	1.85e-14	Longevity;Endometriosis;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22482690	chr17:47019901	SNF8	0.43	4.54	0.35	1.15e-5	Type 2 diabetes;
PAAD	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.88	7.01	0.49	7.44e-11	Prostate cancer;
PAAD	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.66	-7.25	-0.51	2e-11	Menopause (age at onset);
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.54	6.28	0.45	3.39e-9	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12165864	chr7:66369176	NA	-0.8	-4.96	-0.37	1.89e-6	Diabetic kidney disease;
PAAD	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.43	-5.08	-0.38	1.1e-6	Uric acid levels;
PAAD	cis	rs2885056	0.891	rs892081	chr19:10680684	G/T	cg04833646	chr19:10679720	CDKN2D	1.02	10.2	0.64	6.02e-19	Red cell distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24859484	chr2:174830050	SP3	0.63	6.3	0.46	3.02e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05777319	chr3:97483919	ARL6	0.64	7.51	0.52	4.64e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3996993	0.809	rs6458892	chr6:52737138	C/T	cg20803780	chr6:52668592	GSTA1	-0.36	-4.6	-0.35	8.91e-6	Hemoglobin concentration;
PAAD	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.57	-0.41	1.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.95	12.29	0.71	1.51e-24	Menopause (age at onset);
PAAD	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6663390	0.510	rs6540445	chr1:208081467	A/G	cg00387621	chr1:208086895	NA	-0.74	-4.53	-0.35	1.17e-5	Facial morphology (factor 18);
PAAD	cis	rs9815354	0.857	rs7652369	chr3:42020973	T/G	cg03022575	chr3:42003672	ULK4	0.7	4.86	0.37	2.9e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.66	5.35	0.4	3.17e-7	Morning vs. evening chronotype;
PAAD	cis	rs6499755	0.841	rs31082	chr16:55361493	C/T	cg02859129	chr16:55357253	IRX6	0.37	5.11	0.38	9.74e-7	Hypospadias;
PAAD	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.64	-5.88	-0.43	2.56e-8	Breast size;
PAAD	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg23331303	chr5:5135948	NA	-0.46	-6.44	-0.46	1.47e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.51	5.1	0.38	9.81e-7	Height;
PAAD	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.97	6.86	0.49	1.6e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3733418	0.860	rs13129396	chr4:165936346	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.57	-5.15	-0.39	8.05e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.71	10.2	0.64	6.16e-19	Crohn's disease;
PAAD	cis	rs732765	0.734	rs9323602	chr14:75182008	A/G	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	5.65	0.42	7.7e-8	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08120289	chr20:35807421	RPN2;C20orf132	0.61	6.61	0.47	6.1e-10	Monocyte percentage of white cells;
PAAD	cis	rs4899554	0.640	rs72719935	chr14:75724345	C/T	cg18117039	chr14:75741733	NA	0.4	4.65	0.35	7.23e-6	Inflammatory bowel disease;
PAAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	5.3	0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.43	4.65	0.35	7.15e-6	Breast cancer;
PAAD	cis	rs2997447	0.846	rs61775416	chr1:26393329	C/T	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.93	11.11	0.67	2.36e-21	Longevity;
PAAD	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.69	-5.98	-0.44	1.51e-8	Diabetic retinopathy;
PAAD	trans	rs901683	0.850	rs17157861	chr10:45990925	T/C	cg11747279	chr17:21096632	NA	0.91	6.76	0.48	2.77e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.66	7.12	0.5	4.12e-11	Blood protein levels;
PAAD	cis	rs2030114	0.531	rs1072859	chr16:51593379	G/A	cg03758633	chr16:51611768	NA	0.51	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.04	0.38	1.33e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg03037974	chr15:76606532	NA	0.58	6.95	0.49	1.01e-10	Blood metabolite levels;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.46	-4.63	-0.35	7.82e-6	Inflammatory skin disease;
PAAD	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg06287003	chr12:125626642	AACS	-0.46	-4.51	-0.34	1.27e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	1.15	5.48	0.41	1.71e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg23083516	chr15:85180758	SCAND2	-0.39	-4.43	-0.34	1.82e-5	P wave terminal force;
PAAD	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg16419906	chr5:132167176	NA	-0.66	-5.23	-0.39	5.6e-7	Breast cancer;
PAAD	cis	rs9815354	1.000	rs9842305	chr3:41998412	G/A	cg03022575	chr3:42003672	ULK4	-0.76	-5.57	-0.41	1.12e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs3774830	0.714	rs7657964	chr4:5466327	C/G	cg26943120	chr4:5472116	STK32B	-0.34	-4.29	-0.33	3.17e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.82	-8.56	-0.57	1.18e-14	Body mass index;
PAAD	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17467752	chr17:38218738	THRA	-0.52	-4.64	-0.35	7.39e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg18736775	chr8:18248649	NAT2	-0.56	-5.12	-0.38	9.22e-7	Total cholesterol levels;
PAAD	cis	rs2290419	0.730	rs59374155	chr11:68940308	G/C	cg17042914	chr11:68898666	NA	-0.76	-4.37	-0.33	2.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.46	-4.61	-0.35	8.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.54	-6.13	-0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.86	-9.91	-0.63	3.64e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	5.21	0.39	6.01e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg21951975	chr1:209979733	IRF6	-0.62	-5.47	-0.41	1.82e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.62	-5.02	-0.38	1.43e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15564428	chr3:101498201	FAM55C	0.69	6.96	0.49	9.54e-11	Obesity-related traits;
PAAD	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg27478167	chr7:817139	HEATR2	0.7	5.33	0.4	3.42e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-6.76	-0.48	2.85e-10	Body mass index (adult);
PAAD	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-10.28	-0.64	3.75e-19	Morning vs. evening chronotype;
PAAD	cis	rs800160	0.777	rs2173888	chr11:2357108	C/G	cg09785033	chr11:2336066	TSPAN32	-0.55	-4.64	-0.35	7.44e-6	Bacteremia;
PAAD	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	4.34	0.33	2.57e-5	Refractive astigmatism;
PAAD	cis	rs7631605	0.819	rs11129745	chr3:36968873	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.67	0.35	6.71e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg08619932	chr19:49200058	FUT2	0.58	6.54	0.47	8.74e-10	Dietary macronutrient intake;
PAAD	cis	rs2882667	0.690	rs1059110	chr5:138266546	G/A	cg09476006	chr5:138032270	NA	0.45	5.51	0.41	1.47e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg22153407	chr1:230290089	GALNT2	-0.47	-4.63	-0.35	7.67e-6	Coronary artery disease;
PAAD	cis	rs2594989	0.887	rs2443717	chr3:11521493	T/C	cg01796438	chr3:11312864	ATG7	-0.56	-4.34	-0.33	2.56e-5	Circulating chemerin levels;
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.68	6.95	0.49	1e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00142150	chr22:38071001	LGALS1	0.71	7.85	0.54	6.86e-13	Fat distribution (HIV);
PAAD	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg02734326	chr4:10020555	SLC2A9	-0.41	-4.26	-0.33	3.59e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg08807892	chr2:162101083	NA	0.67	7.49	0.52	5.1e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg26850624	chr5:429559	AHRR	0.92	4.64	0.35	7.55e-6	Breast cancer;
PAAD	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06850241	chr22:41845214	NA	-0.48	-4.84	-0.37	3.14e-6	Vitiligo;
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26850624	chr5:429559	AHRR	-0.86	-10.98	-0.67	5.19e-21	Cystic fibrosis severity;
PAAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.45	-0.4	1.97e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg22674798	chr1:3096360	PRDM16	-0.45	-6.01	-0.44	1.32e-8	Migraine;
PAAD	cis	rs7580658	0.637	rs4560059	chr2:127972228	T/C	cg09760422	chr2:128146352	NA	-0.33	-5.49	-0.41	1.67e-7	Protein C levels;
PAAD	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg12310025	chr6:25882481	NA	0.43	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs6028335	0.610	rs12624452	chr20:37554781	G/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.66	-4.94	-0.37	2.08e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs6782228	0.585	rs2712392	chr3:128424257	G/A	cg16766828	chr3:128327626	NA	-0.42	-5.53	-0.41	1.36e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg19413350	chr8:57351067	NA	-0.48	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.5	0.34	1.36e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.64	-8.2	-0.55	9.49e-14	Body mass index;
PAAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.28	0.39	4.45e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg10356904	chr22:49881777	NA	-0.53	-4.94	-0.37	2.05e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.72	-6.34	-0.46	2.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs16966918	0.579	rs974126	chr13:106268824	A/G	cg17388689	chr13:107140685	NA	0.72	4.37	0.33	2.29e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg01942863	chr7:99769432	GPC2	0.49	4.61	0.35	8.48e-6	Coronary artery disease;
PAAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.63	-6.18	-0.45	5.55e-9	Obesity-related traits;
PAAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2131877	0.830	rs62290347	chr3:194852620	A/G	cg16306870	chr3:194868790	C3orf21	0.49	4.35	0.33	2.49e-5	Non-small cell lung cancer;
PAAD	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg23024343	chr7:107201750	COG5	-0.52	-4.43	-0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs5756391	0.546	rs5750338	chr22:37316125	G/A	cg16356956	chr22:37317934	CSF2RB	0.39	4.67	0.35	6.49e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26646903	chr3:186285208	TBCCD1	-0.77	-7.17	-0.5	3.01e-11	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21277988	chr19:8578919	ZNF414	-0.74	-6.59	-0.47	6.87e-10	Neuroticism;
PAAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-4.67	-0.35	6.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg25173405	chr17:45401733	C17orf57	0.5	4.97	0.37	1.76e-6	Multiple sclerosis or amyotrophic lateral sclerosis;
PAAD	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg05250797	chr16:70222502	NA	0.8	6.08	0.44	9.08e-9	IgE levels;
PAAD	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.96	9.98	0.63	2.38e-18	Corneal astigmatism;
PAAD	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.82	-0.36	3.48e-6	Mean platelet volume;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.92	-7.19	-0.5	2.79e-11	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27293549	chr4:103266755	SLC39A8	0.68	7.44	0.52	6.78e-12	Myopia (pathological);
PAAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg09017928	chr7:158110068	PTPRN2	0.49	4.77	0.36	4.3e-6	Calcium levels;
PAAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.73	8.58	0.57	1.05e-14	Type 2 diabetes;
PAAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.87	10.9	0.66	8.38e-21	Methadone dose in opioid dependence;
PAAD	cis	rs11051970	0.559	rs73086036	chr12:32564585	C/T	cg24626660	chr12:32551988	NA	0.43	4.63	0.35	7.88e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11951692	chr20:3761938	SPEF1	0.72	8.43	0.56	2.52e-14	Myopia (pathological);
PAAD	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.53	-0.47	9.27e-10	Retinal vascular caliber;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.58	-0.35	9.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2294025	0.833	rs13256826	chr8:134116227	C/T	cg21764050	chr8:134251118	NDRG1	-0.44	-4.28	-0.33	3.28e-5	Graves' disease;
PAAD	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg23346134	chr3:49453900	TCTA	0.43	4.31	0.33	2.98e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.99	11.9	0.69	1.76e-23	Breast cancer;
PAAD	cis	rs3106136	0.843	rs6532479	chr4:95259235	C/A	cg11021082	chr4:95130006	SMARCAD1	0.62	6.0	0.44	1.4e-8	Capecitabine sensitivity;
PAAD	cis	rs91	0.633	rs2722395	chr7:24429520	T/C	cg13313214	chr7:23749942	STK31	-0.46	-4.67	-0.35	6.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg03004497	chr11:58874207	FAM111B	-0.52	-4.39	-0.34	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs7301016	0.948	rs7303825	chr12:62921978	A/G	cg11441379	chr12:63026424	NA	0.84	6.07	0.44	9.66e-9	IgG glycosylation;
PAAD	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.42	4.27	0.33	3.36e-5	Height;
PAAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.72	0.36	5.36e-6	Personality dimensions;
PAAD	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.07e-8	Platelet count;
PAAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg19192590	chr2:178524533	PDE11A	0.41	4.74	0.36	4.85e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.16	0.39	7.72e-7	Lung cancer;
PAAD	cis	rs900145	0.861	rs11022742	chr11:13296561	T/C	cg15603424	chr11:13300592	ARNTL	-0.54	-4.63	-0.35	7.91e-6	Menarche (age at onset);
PAAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.51	-5.6	-0.41	9.67e-8	Coronary artery disease;
PAAD	cis	rs16975963	0.843	rs3848624	chr19:38262816	C/T	cg25793785	chr19:38281423	NA	0.57	4.75	0.36	4.69e-6	Longevity;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg16590910	chr6:42928470	GNMT	0.55	5.5	0.41	1.54e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg02696790	chr15:75250997	RPP25	0.37	4.29	0.33	3.22e-5	Breast cancer;
PAAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg02038168	chr22:39784481	NA	-0.62	-4.73	-0.36	5.14e-6	IgG glycosylation;
PAAD	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.85	7.51	0.52	4.78e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.71	7.26	0.51	1.9e-11	Response to antipsychotic treatment;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2730260	0.537	rs3793223	chr7:158863574	C/A	cg13444538	chr7:158905317	VIPR2	-0.7	-5.21	-0.39	6.16e-7	Myopia (pathological);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04580334	chr1:45805972	MUTYH;TOE1	-0.75	-6.45	-0.46	1.38e-9	Neuroticism;
PAAD	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.51	-5.69	-0.42	6.41e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4568126	0.845	rs10934487	chr3:118950505	C/A	cg02741226	chr3:118892305	UPK1B	-0.45	-4.39	-0.34	2.11e-5	Survival in pancreatic cancer;
PAAD	cis	rs6025261	0.735	rs6099357	chr20:55508611	A/G	cg04763273	chr20:55502381	NA	0.46	5.24	0.39	5.2e-7	Verbal memory performance (delayed recall level);
PAAD	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.11e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs6076065	0.723	rs743024	chr20:23342476	C/T	cg11657817	chr20:23433608	CST11	-0.5	-5.24	-0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.35	-4.69	-0.36	6.13e-6	Vitiligo;
PAAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	11.55	0.68	1.5e-22	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.53	4.71	0.36	5.56e-6	Type 2 diabetes;
PAAD	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	1.04	14.81	0.77	2.69e-31	Metabolite levels;
PAAD	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.39e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.56	-5.14	-0.38	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.61	4.87	0.37	2.82e-6	Cholesterol, total;
PAAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg21361702	chr7:150065534	REPIN1	0.56	4.71	0.36	5.57e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12530134	0.523	rs7762088	chr6:170794570	T/C	cg07257824	chr6:170732353	NA	0.73	4.95	0.37	1.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg18279126	chr7:2041391	MAD1L1	-0.56	-5.84	-0.43	3.07e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	9.03	0.59	7.3e-16	Motion sickness;
PAAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.61	7.83	0.54	7.64e-13	Monobrow;
PAAD	cis	rs6445525	0.967	rs7648741	chr3:65996570	T/C	cg06109867	chr3:66002991	MAGI1	-0.46	-4.61	-0.35	8.35e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg07541023	chr7:19748670	TWISTNB	0.54	4.33	0.33	2.71e-5	Thyroid stimulating hormone;
PAAD	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.37	0.46	2.18e-9	Cognitive ability;
PAAD	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.75	-6.02	-0.44	1.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg24213567	chr19:53496664	ZNF702P	-0.49	-5.08	-0.38	1.08e-6	Psoriasis;
PAAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.73	-7.54	-0.52	4.06e-12	DNA methylation (variation);
PAAD	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.55	-7.37	-0.51	1.05e-11	Renal cell carcinoma;
PAAD	cis	rs9912789	0.687	rs9892874	chr17:79188303	G/C	cg14413466	chr17:79170920	AZI1	-0.56	-7.95	-0.54	3.82e-13	Frontotemporal dementia;
PAAD	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg12661370	chr5:149340060	SLC26A2	0.63	5.42	0.4	2.32e-7	HIV-1 control;
PAAD	cis	rs1371614	0.632	rs6738528	chr2:27149258	T/A	cg00617064	chr2:27272375	NA	0.43	4.57	0.35	1.02e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.8	-9.08	-0.59	5.38e-16	Menarche (age at onset);
PAAD	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.3	-0.4	3.98e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13198984	chr17:80129470	CCDC57	0.39	4.9	0.37	2.4e-6	Life satisfaction;
PAAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05595602	chr1:1343077	MRPL20	0.57	6.39	0.46	1.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg04160749	chr8:58172571	NA	-0.59	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	6.49	0.47	1.15e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.51e-18	Platelet count;
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg06145435	chr7:1022769	CYP2W1	0.33	4.26	0.33	3.5e-5	Longevity;Endometriosis;
PAAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg03303774	chr4:1407052	NA	0.5	6.21	0.45	4.94e-9	Obesity-related traits;
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.87	-10.8	-0.66	1.54e-20	Body mass index;
PAAD	cis	rs7224685	0.608	rs12602456	chr17:4273483	C/T	cg05562828	chr17:3906858	NA	0.49	4.66	0.35	6.93e-6	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.1	0.55	1.7e-13	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.65	7.83	0.54	7.7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg16040993	chr19:53496440	ZNF702P	-0.46	-4.6	-0.35	8.81e-6	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04935181	chr1:47133953	ATPAF1	0.67	6.96	0.49	9.35e-11	Obesity-related traits;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.65	7.02	0.49	6.89e-11	Lung cancer;
PAAD	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg13515842	chr9:127215440	GPR144	-0.44	-4.76	-0.36	4.42e-6	Menarche (age at onset);
PAAD	cis	rs9900972	0.877	rs8064344	chr17:76876974	C/T	cg00961940	chr17:76876995	TIMP2	0.58	5.37	0.4	2.91e-7	Obesity-related traits;
PAAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg03161606	chr19:29218774	NA	0.58	4.38	0.33	2.24e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.44	-0.61	6.03e-17	Venous thromboembolism;
PAAD	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.48	4.4	0.34	2.04e-5	Breast cancer;
PAAD	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.58	-6.51	-0.47	1.06e-9	Menopause (age at onset);
PAAD	cis	rs7011192	0.793	rs7017953	chr8:10524054	G/A	cg04501334	chr8:10513686	RP1L1	-0.8	-5.51	-0.41	1.53e-7	Suicide;
PAAD	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-4.52	-0.34	1.25e-5	Type 2 diabetes;
PAAD	trans	rs61677309	1.000	rs56346212	chr11:118172342	T/A	cg15548380	chr1:19984784	NBL1	-0.64	-6.53	-0.47	9.25e-10	Lung cancer in ever smokers;
PAAD	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.55	-0.52	3.65e-12	Response to antipsychotic treatment;
PAAD	cis	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg21775007	chr8:11205619	TDH	-0.48	-4.42	-0.34	1.85e-5	Neuroticism;
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.36	0.4	3.08e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.6	9.04	0.59	6.69e-16	Hypertriglyceridemia;
PAAD	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-4.89	-0.37	2.56e-6	Intelligence;
PAAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-6.48	-0.47	1.21e-9	Bipolar disorder;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs77633900	0.772	rs16968196	chr15:76682238	C/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10214930	0.625	rs6462037	chr7:27641100	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15762182	chr17:36998014	C17orf98	-0.65	-6.87	-0.49	1.57e-10	Obesity-related traits;
PAAD	cis	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.41	-0.4	2.39e-7	Mononucleosis;
PAAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg25452165	chr22:42524984	CYP2D6	0.48	4.44	0.34	1.75e-5	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg24739098	chr15:79297159	RASGRF1	-0.35	-4.37	-0.33	2.26e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs77741769	0.892	rs2133638	chr12:121374264	C/T	cg02403541	chr12:121454288	C12orf43	0.52	5.4	0.4	2.55e-7	Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg23346134	chr3:49453900	TCTA	0.46	4.66	0.35	6.72e-6	Menarche (age at onset);
PAAD	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.64	-0.57	7.28e-15	Electrocardiographic conduction measures;
PAAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	11.5	0.68	2.06e-22	Tonsillectomy;
PAAD	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.59	5.54	0.41	1.29e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.86	10.16	0.64	7.88e-19	Blood protein levels;
PAAD	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.16e-8	Vitiligo;
PAAD	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06850241	chr22:41845214	NA	0.58	5.12	0.38	9.16e-7	Vitiligo;
PAAD	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.94	10.19	0.64	6.39e-19	Corneal astigmatism;
PAAD	cis	rs12476592	0.530	rs79442148	chr2:64229455	T/A	cg10828910	chr2:63850056	LOC388955	-0.52	-4.29	-0.33	3.18e-5	Childhood ear infection;
PAAD	cis	rs13011075	0.535	rs13034825	chr2:68630297	C/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.91	0.54	4.87e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2718812	0.740	rs12637070	chr3:133341508	T/G	cg08439880	chr3:133502540	NA	-0.41	-4.37	-0.33	2.3e-5	Iron status biomarkers;
PAAD	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.49	-5.37	-0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg21433313	chr16:3507492	NAT15	-0.5	-5.05	-0.38	1.24e-6	Body mass index (adult);
PAAD	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg02071572	chr4:1403502	NA	0.39	4.66	0.35	6.85e-6	Obesity-related traits;
PAAD	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	4.4	0.34	2e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2279817	0.863	rs13376020	chr1:18016402	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.78	-0.42	4.02e-8	Neuroticism;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-7.06	-0.5	5.51e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	0.51	4.59	0.35	9.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg10168330	chr8:27262164	PTK2B	-0.38	-4.56	-0.35	1.04e-5	Neuroticism;
PAAD	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg20761395	chr17:511517	VPS53	0.48	4.69	0.36	6.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.53	-0.57	1.38e-14	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08114521	chr19:36705969	ZNF146;ZNF565	0.63	6.79	0.48	2.32e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.56	6.11	0.44	8.14e-9	Major depressive disorder;
PAAD	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs6842047	0.611	rs12186257	chr4:187183498	G/C	cg09526685	chr4:187126073	CYP4V2	0.74	6.12	0.44	7.45e-9	Blood protein levels;
PAAD	cis	rs1982963	0.627	rs17124901	chr14:52488009	C/T	cg20550154	chr14:52487779	NID2	0.6	5.02	0.38	1.46e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg10072921	chr12:121022843	NA	-0.36	-4.73	-0.36	5.13e-6	High light scatter reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05398940	chr16:89351098	ANKRD11	-0.65	-6.76	-0.48	2.8e-10	Obesity-related traits;
PAAD	cis	rs5751901	0.614	rs5760485	chr22:24986473	A/G	cg08808123	chr22:24999002	GGT1	-0.44	-4.66	-0.35	6.93e-6	Protein quantitative trait loci;
PAAD	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg00228799	chr9:131580591	ENDOG	0.62	5.92	0.43	2.07e-8	Blood metabolite levels;
PAAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg23464041	chr6:33663938	ITPR3	0.47	4.25	0.33	3.68e-5	Schizophrenia;
PAAD	cis	rs258892	0.895	rs10041942	chr5:72049964	T/C	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.43	-4.89	-0.37	2.56e-6	Bipolar disorder;
PAAD	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.39e-7	Body mass index;
PAAD	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26042024	chr8:135610009	ZFAT;ZFATAS	-0.6	-6.39	-0.46	1.92e-9	Obesity-related traits;
PAAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.61	0.35	8.41e-6	Breast cancer;
PAAD	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.26	0.39	4.87e-7	Tonsillectomy;
PAAD	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg16110827	chr15:48056943	SEMA6D	-0.51	-5.48	-0.41	1.71e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs7131987	0.675	rs3847678	chr12:29551560	A/C	cg09582351	chr12:29534625	ERGIC2	0.33	4.77	0.36	4.32e-6	QT interval;
PAAD	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs1997066	0.831	rs73338293	chr10:106796207	A/T	cg17321814	chr10:106440892	SORCS3	0.63	4.26	0.33	3.57e-5	Diabetic kidney disease;
PAAD	cis	rs1468734	1.000	rs35659917	chr16:5003592	G/A	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.95	-0.37	1.96e-6	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs35160687	0.901	rs13017338	chr2:86501553	T/C	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.86	11.07	0.67	2.89e-21	Height;
PAAD	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg11547950	chr5:77652471	NA	0.9	7.89	0.54	5.52e-13	Triglycerides;
PAAD	cis	rs8102476	0.703	rs4803899	chr19:38727640	A/T	cg14131526	chr19:38747285	PPP1R14A	0.47	4.83	0.36	3.36e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg22189786	chr22:42395067	WBP2NL	0.45	4.77	0.36	4.34e-6	Cognitive function;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.19	-0.7	2.93e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.63	0.35	7.84e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.48	-4.92	-0.37	2.25e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg22189786	chr22:42395067	WBP2NL	0.59	5.75	0.42	4.85e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2e-27	Height;
PAAD	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg12310025	chr6:25882481	NA	0.45	4.25	0.33	3.76e-5	Blood metabolite levels;
PAAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs7101378	0.577	rs10789709	chr11:108895109	A/G	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-4.99	-0.37	1.66e-6	IgG glycosylation;
PAAD	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs988913	0.723	rs4715520	chr6:54995995	A/G	cg03513858	chr6:54763001	FAM83B	0.39	4.27	0.33	3.37e-5	Menarche (age at onset);
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.46	-5.05	-0.38	1.23e-6	Testicular germ cell tumor;
PAAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	0.47	4.38	0.33	2.18e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.76	7.56	0.52	3.54e-12	Calcium levels;
PAAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Depression;
PAAD	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs6804624	0.654	rs2700657	chr3:99178245	C/T	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs10916814	0.610	rs1890004	chr1:20899066	T/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs501120	0.584	rs629213	chr10:44736784	C/T	cg09554077	chr10:44749378	NA	0.46	5.51	0.41	1.51e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2070997	0.607	rs2261468	chr9:133708873	T/C	cg11464064	chr9:133710261	ABL1	0.62	4.33	0.33	2.68e-5	Response to amphetamines;
PAAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.03	0.44	1.19e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4356203	0.905	rs7938820	chr11:17077452	C/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.4	0.34	2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.74	-8.46	-0.57	2.01e-14	Airway imaging phenotypes;
PAAD	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs9815354	0.904	rs7647561	chr3:41848627	T/A	cg03022575	chr3:42003672	ULK4	0.8	5.99	0.44	1.43e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.85	-11.35	-0.68	5.11e-22	Height;
PAAD	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	4.99	0.38	1.64e-6	Educational attainment;
PAAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs654384	0.613	rs4236342	chr7:4177712	A/C	cg27574739	chr7:4176374	SDK1	-0.53	-5.2	-0.39	6.39e-7	Positive affect;
PAAD	cis	rs3747547	0.818	rs7027227	chr9:37929809	C/G	cg13774184	chr9:37916125	SHB	0.59	4.44	0.34	1.74e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.45	-4.49	-0.34	1.41e-5	Tonsillectomy;
PAAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg06492744	chr11:65406254	SIPA1	0.44	5.39	0.4	2.69e-7	Blood pressure (age interaction);
PAAD	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg18357526	chr6:26021779	HIST1H4A	0.56	5.33	0.4	3.45e-7	Schizophrenia;
PAAD	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.04	-0.55	2.39e-13	Brugada syndrome;
PAAD	cis	rs7192380	0.895	rs2917670	chr16:69758963	T/C	cg05250797	chr16:70222502	NA	-0.52	-4.52	-0.34	1.25e-5	Sjögren's syndrome;
PAAD	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs7101378	0.577	rs7126518	chr11:108897856	A/G	cg10976287	chr11:108093109	ATM;NPAT	-0.47	-4.73	-0.36	5.07e-6	IgG glycosylation;
PAAD	trans	rs67702392	0.629	rs6140765	chr20:8827814	C/G	cg13311803	chr7:101930366	SH2B2	-0.71	-6.72	-0.48	3.45e-10	Daytime sleep phenotypes;
PAAD	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg10483660	chr13:112241077	NA	0.55	5.06	0.38	1.18e-6	Menarche (age at onset);
PAAD	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.41	4.38	0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.748	rs662250	chr2:219374117	T/A	cg02985541	chr2:219472218	PLCD4	0.31	4.77	0.36	4.37e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.93	-7.87	-0.54	6.33e-13	Diastolic blood pressure;
PAAD	cis	rs3736485	0.966	rs2124876	chr15:51906162	T/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.71e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.26	-4.28	-0.33	3.33e-5	Monocyte percentage of white cells;
PAAD	cis	rs527409	1.000	rs9436173	chr1:58748624	C/G	cg26345888	chr1:58716257	DAB1	-0.66	-4.5	-0.34	1.35e-5	Kawasaki disease;
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16618003	chr1:65432492	JAK1	0.63	7.38	0.51	9.65e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	1.03	10.76	0.66	1.94e-20	Blood trace element (Zn levels);
PAAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14180030	chr9:123475675	MEGF9	-0.44	-4.94	-0.37	2e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.84	8.14	0.55	1.35e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg11833968	chr6:79620685	NA	-0.43	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.42	-0.4	2.25e-7	Height;
PAAD	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg13897122	chr2:103039542	IL18RAP	0.37	4.59	0.35	9.09e-6	Asthma;
PAAD	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.88	-6.25	-0.45	3.92e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.52	5.1	0.38	9.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.38	-4.51	-0.34	1.29e-5	Tonsillectomy;
PAAD	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg15557168	chr22:42548783	NA	-0.44	-4.49	-0.34	1.39e-5	Cognitive function;
PAAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg14393609	chr7:65229607	NA	0.72	7.94	0.54	4.04e-13	Aortic root size;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.55	5.95	0.43	1.79e-8	Renal function-related traits (BUN);
PAAD	cis	rs1413885	0.516	rs10158872	chr1:65836230	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.58	0.41	1.07e-7	Anticoagulant levels;
PAAD	trans	rs3935740	0.649	rs28608908	chr15:81619816	A/T	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.62e-5	Platelet count;
PAAD	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg21419209	chr3:44054225	NA	0.62	6.11	0.44	7.99e-9	Coronary artery disease;
PAAD	cis	rs1419980	0.730	rs11525576	chr12:7752041	A/G	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.03	-0.38	1.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7084783	0.500	rs4918024	chr10:105341860	G/C	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.6	0.35	8.93e-6	Fear of pain;
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.65	0.65	3.91e-20	Prudent dietary pattern;
PAAD	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.31	0.4	3.89e-7	Lung cancer;
PAAD	cis	rs6066835	0.867	rs6095276	chr20:47363230	C/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-6.3	-0.46	3.03e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg24213567	chr19:53496664	ZNF702P	-0.48	-4.94	-0.37	2.04e-6	Psoriasis;
PAAD	cis	rs1227969	0.706	rs1665581	chr10:71262048	G/T	cg12610070	chr10:71211762	TSPAN15	-0.37	-5.56	-0.41	1.18e-7	Response to taxane treatment (placlitaxel);
PAAD	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg21823605	chr1:152486609	CRCT1	0.51	6.27	0.45	3.59e-9	Hair morphology;
PAAD	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg13444538	chr7:158905317	VIPR2	0.55	5.18	0.39	7.09e-7	Facial morphology (factor 20);
PAAD	cis	rs4690686	0.500	rs17062797	chr4:177262063	G/A	cg17059388	chr4:177262070	NA	0.61	6.01	0.44	1.31e-8	Essential tremor;
PAAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.13	14.65	0.77	7.27e-31	Subjective well-being;
PAAD	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.66	0.35	6.73e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg12639453	chr1:2035780	PRKCZ	0.57	6.04	0.44	1.12e-8	Height;
PAAD	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.54	-6.35	-0.46	2.34e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	7.72	0.53	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.7	5.61	0.41	9.41e-8	Alzheimer's disease;
PAAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.59	-5.42	-0.4	2.26e-7	Breast cancer;
PAAD	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.38	-0.4	2.75e-7	Mood instability;
PAAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.72	11.26	0.67	9.09e-22	Breast cancer;
PAAD	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.53	-5.03	-0.38	1.35e-6	White matter hyperintensity burden;
PAAD	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.59	5.97	0.44	1.59e-8	Schizophrenia;
PAAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.93	0.43	1.94e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg10729496	chr3:10149963	C3orf24	0.91	7.5	0.52	4.96e-12	Alzheimer's disease;
PAAD	cis	rs13102973	0.646	rs7670551	chr4:135895130	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-1.16	-7.16	-0.5	3.26e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.75	-5.57	-0.41	1.1e-7	Triglycerides;
PAAD	cis	rs12365397	0.526	rs11037263	chr11:43161203	A/C	cg03447554	chr11:43094025	NA	0.59	6.59	0.47	6.8e-10	Migraine;
PAAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg22143856	chr6:28129313	ZNF389	0.64	4.94	0.37	2.06e-6	Depression;
PAAD	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs89107	0.688	rs283087	chr6:118596207	C/T	cg18833306	chr6:118973337	C6orf204	0.48	5.62	0.41	8.81e-8	Cardiac structure and function;
PAAD	cis	rs4343996	0.967	rs4722674	chr7:3357188	C/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.95	8.26	0.56	6.67e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.13	-8.93	-0.59	1.28e-15	Mitochondrial DNA levels;
PAAD	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.71	0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.5	5.93	0.43	1.94e-8	Height;
PAAD	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg16341495	chr8:142228727	SLC45A4	0.47	4.46	0.34	1.59e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg16818395	chr3:128274084	NA	0.54	4.77	0.36	4.25e-6	Dental caries;
PAAD	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg05082376	chr22:42548792	NA	-0.55	-5.66	-0.42	7.19e-8	Cognitive function;
PAAD	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg07930552	chr6:133119739	C6orf192	0.86	4.81	0.36	3.67e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs72772787	1.000	rs12096473	chr1:248016894	C/T	cg08944170	chr1:248100614	OR2L13	0.59	4.5	0.34	1.35e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs901683	0.850	rs34081552	chr10:45971156	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.52e-8	Lung cancer;
PAAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.47	4.92	0.37	2.23e-6	Type 2 diabetes;
PAAD	cis	rs1371614	0.655	rs509047	chr2:27128529	T/C	cg00617064	chr2:27272375	NA	0.44	4.61	0.35	8.47e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.84	9.48	0.61	4.75e-17	Prudent dietary pattern;
PAAD	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.86	8.81	0.58	2.71e-15	Corneal astigmatism;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg22325292	chr17:80708367	FN3K	0.65	4.48	0.34	1.49e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg06209491	chr1:40138402	NT5C1A	-0.64	-5.93	-0.43	1.95e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg00450029	chr8:599525	NA	-0.77	-5.23	-0.39	5.42e-7	IgG glycosylation;
PAAD	trans	rs61931739	0.649	rs1068864	chr12:33733119	A/C	cg26384229	chr12:38710491	ALG10B	0.69	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06026331	chr20:60912101	LAMA5	0.5	4.64	0.35	7.52e-6	Colorectal cancer;
PAAD	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.73	0.36	5.03e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs959260	1.000	rs7216423	chr17:73365671	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg26497354	chr6:109612229	NA	-0.43	-4.32	-0.33	2.82e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.85	9.87	0.62	4.62e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.74	-7.56	-0.52	3.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg23346134	chr3:49453900	TCTA	0.47	4.72	0.36	5.33e-6	Menarche (age at onset);
PAAD	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg23435118	chr5:141488016	NDFIP1	-0.53	-5.26	-0.39	4.86e-7	Crohn's disease;
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg16590910	chr6:42928470	GNMT	0.52	5.27	0.39	4.59e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.88	10.08	0.63	1.26e-18	Gout;
PAAD	cis	rs2017305	0.834	rs12244293	chr10:70783580	A/G	cg25290552	chr10:70751067	KIAA1279	-0.85	-5.49	-0.41	1.67e-7	Depression (quantitative trait);
PAAD	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.87	7.91	0.54	4.84e-13	Coronary artery disease;
PAAD	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.61	0.47	6.14e-10	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06537625	chr1:31538931	PUM1	0.64	6.39	0.46	1.87e-9	Obesity-related traits;
PAAD	cis	rs2992756	0.663	rs1316327	chr1:18802387	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.76	7.41	0.52	8e-12	Schizophrenia;
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.79	-0.43	3.9e-8	Ulcerative colitis;
PAAD	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg07469887	chr10:131262384	NA	-0.41	-4.65	-0.35	7.19e-6	Response to temozolomide;
PAAD	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg09168692	chr1:7887560	PER3	0.5	4.76	0.36	4.53e-6	Inflammatory bowel disease;
PAAD	cis	rs818427	0.635	rs2229992	chr5:112162854	C/T	cg07820702	chr5:112228657	REEP5	-0.52	-4.72	-0.36	5.24e-6	Total body bone mineral density;
PAAD	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg00806126	chr19:22604979	ZNF98	-0.39	-4.97	-0.37	1.8e-6	Pain;
PAAD	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg15117754	chr3:10150083	C3orf24	0.65	5.46	0.41	1.89e-7	Alzheimer's disease;
PAAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.48	-5.03	-0.38	1.37e-6	Platelet distribution width;
PAAD	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.06e-7	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.34	-0.51	1.21e-11	Cognitive function;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27436995	chr16:743998	FBXL16	-0.37	-4.52	-0.34	1.24e-5	Height;
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.53	-5.23	-0.39	5.49e-7	Schizophrenia;
PAAD	cis	rs2412208	0.839	rs2412214	chr1:7089674	C/T	cg26570804	chr1:6352357	ACOT7	0.55	5.16	0.39	7.49e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.72	-6.95	-0.49	9.98e-11	Alcohol dependence;
PAAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-5.61	-0.41	9.29e-8	Schizophrenia;
PAAD	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.96	8.87	0.58	1.85e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.76	5.8	0.43	3.71e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg23346134	chr3:49453900	TCTA	-0.55	-5.24	-0.39	5.19e-7	Menarche (age at onset);
PAAD	cis	rs10512697	0.892	rs62336107	chr5:3539570	T/C	cg19473799	chr5:3511975	NA	-1.01	-4.54	-0.35	1.13e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	5.7	0.42	6.09e-8	Neuroticism;
PAAD	trans	rs901683	0.850	rs79022473	chr10:46101768	C/T	cg12869334	chr8:37699360	GPR124	0.94	6.46	0.46	1.35e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg11949866	chr1:10754891	CASZ1	0.52	4.32	0.33	2.76e-5	Ewing sarcoma;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.84	-7.86	-0.54	6.73e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.57	6.45	0.46	1.38e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg23387468	chr7:139079360	LUC7L2	0.4	4.62	0.35	8.27e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.51	-6.42	-0.46	1.66e-9	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19037555	chr13:47371605	ESD	0.54	6.41	0.46	1.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.43	-5.01	-0.38	1.48e-6	Mean arterial pressure;
PAAD	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.51	4.68	0.35	6.41e-6	Mean corpuscular volume;
PAAD	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg09455208	chr3:40491958	NA	0.48	6.2	0.45	4.97e-9	Renal cell carcinoma;
PAAD	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07883956	chr15:85523842	PDE8A	-0.64	-6.35	-0.46	2.3e-9	Smoking initiation;
PAAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.65	-4.39	-0.34	2.11e-5	Skin colour saturation;
PAAD	cis	rs9810890	1.000	rs73207974	chr3:128568455	T/C	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	1.13	6.12	0.44	7.48e-9	Plasma clusterin levels;
PAAD	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.88	-0.43	2.54e-8	Menarche (age at onset);
PAAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00864171	chr11:67383662	NA	0.55	5.82	0.43	3.37e-8	Mean corpuscular volume;
PAAD	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg24253500	chr15:84953950	NA	0.54	6.21	0.45	4.9e-9	Schizophrenia;
PAAD	cis	rs6142102	0.625	rs6141432	chr20:32548597	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05252892	chr5:154320678	MRPL22	0.59	6.59	0.47	6.71e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6474412	0.581	rs10087172	chr8:42616868	T/C	cg07164722	chr1:247587378	NLRP3	0.6	6.52	0.47	9.65e-10	Smoking behavior;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02676523	chr16:4027674	ADCY9	0.71	8.89	0.58	1.61e-15	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg03938978	chr2:103052716	IL18RAP	0.66	8.41	0.56	2.8e-14	Asthma;
PAAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg05643964	chr20:62369504	LIME1	-0.51	-4.73	-0.36	5.01e-6	Prostate cancer;
PAAD	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.37	0.46	2.18e-9	Cognitive ability;
PAAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg18551225	chr6:44695536	NA	-0.58	-5.11	-0.38	9.66e-7	Total body bone mineral density;
PAAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg10494973	chr17:80897199	TBCD	-0.55	-4.63	-0.35	7.73e-6	Breast cancer;
PAAD	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg08999081	chr20:33150536	PIGU	-0.51	-5.45	-0.4	2.01e-7	Height;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.07	0.59	5.64e-16	Platelet count;
PAAD	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.53	5.55	0.41	1.26e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4356203	0.905	rs214906	chr11:17181340	C/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg07202610	chr7:1142643	C7orf50	-0.66	-5.13	-0.38	8.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01324437	chr2:98206175	ANKRD36B	0.63	6.62	0.47	5.75e-10	Obesity-related traits;
PAAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg17724175	chr1:150552817	MCL1	-0.47	-5.28	-0.39	4.36e-7	Tonsillectomy;
PAAD	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg16419906	chr5:132167176	NA	0.43	4.47	0.34	1.55e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg03098721	chr1:84464084	TTLL7	0.45	4.29	0.33	3.1e-5	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27482485	chr17:7210796	EIF5A	0.59	6.71	0.48	3.62e-10	Obesity-related traits;
PAAD	cis	rs59888335	0.862	rs35583855	chr3:80637473	G/T	cg21735741	chr3:80819488	NA	0.58	5.01	0.38	1.46e-6	Schizophrenia;
PAAD	cis	rs11037575	0.715	rs7926355	chr11:43704515	T/G	cg24662154	chr11:44118094	EXT2	-0.43	-4.3	-0.33	2.99e-5	Neuroblastoma;
PAAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg05725404	chr16:58534157	NDRG4	-0.78	-4.77	-0.36	4.2e-6	Schizophrenia;
PAAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.63	-0.35	7.84e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.32e-6	Parkinson's disease;
PAAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg23759393	chr7:158110405	PTPRN2	0.35	4.25	0.33	3.67e-5	Response to amphetamines;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg11416102	chr8:651193	ERICH1	0.87	5.42	0.4	2.29e-7	IgG glycosylation;
PAAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg26898376	chr11:64110657	CCDC88B	0.45	4.74	0.36	4.77e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10579840	chr8:99306110	NIPAL2	0.6	6.7	0.48	3.79e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-4.91	-0.37	2.36e-6	Reticulocyte count;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6585424	1.000	rs35483545	chr10:81939173	T/C	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg02683114	chr2:24398427	C2orf84	-0.54	-5.31	-0.4	3.8e-7	Asthma;
PAAD	cis	rs9462846	0.919	rs12202901	chr6:42828550	A/T	cg13397359	chr6:42928475	GNMT	0.59	4.81	0.36	3.62e-6	Blood protein levels;
PAAD	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.23	-0.6	2.19e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2327429	0.519	rs6906375	chr6:134152627	C/G	cg06643013	chr6:134217242	NA	0.4	4.43	0.34	1.79e-5	Coronary artery disease;
PAAD	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg02580895	chr19:2754563	NA	-0.56	-4.73	-0.36	5.03e-6	Total cholesterol levels;
PAAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.78	-4.69	-0.36	5.95e-6	Type 2 diabetes;
PAAD	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.85	-8.81	-0.58	2.64e-15	Multiple sclerosis;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg22633769	chr20:60982531	CABLES2	0.42	4.28	0.33	3.25e-5	Pelvic organ prolapse;
PAAD	cis	rs17407555	0.657	rs6856199	chr4:10271592	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	4.93	0.37	2.13e-6	Schizophrenia (age at onset);
PAAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg03959625	chr15:84868606	LOC388152	0.48	5.19	0.39	6.62e-7	Schizophrenia;
PAAD	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Height;
PAAD	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.48	5.42	0.4	2.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.38	-0.33	2.21e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.63	-6.28	-0.45	3.3e-9	Fibrinogen levels;
PAAD	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.58	-5.54	-0.41	1.29e-7	Height;
PAAD	cis	rs6088813	1.000	rs4911492	chr20:33951799	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-5.51	-0.41	1.47e-7	Mean corpuscular volume;
PAAD	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14169450	chr9:139327907	INPP5E	0.55	5.5	0.41	1.57e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg12927641	chr6:109611667	NA	-0.41	-4.33	-0.33	2.67e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.35	-4.25	-0.33	3.71e-5	Prostate cancer;
PAAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg06375148	chr1:209958343	C1orf74	0.53	5.66	0.42	7.46e-8	Monobrow;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-6.27	-0.45	3.58e-9	Lymphocyte counts;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.73	-7.5	-0.52	4.96e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2834902	0.578	rs8133297	chr21:36685095	C/T	cg04915566	chr21:36421472	RUNX1	-0.33	-4.43	-0.34	1.81e-5	Corneal curvature;
PAAD	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.54	-6.13	-0.45	7.35e-9	Lung cancer;
PAAD	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg02117656	chr17:79614917	TSPAN10	0.69	7.9	0.54	5.31e-13	Eye color traits;
PAAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg11601000	chr22:42348013	LOC339674	-0.4	-4.5	-0.34	1.32e-5	Cognitive function;
PAAD	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.5	-4.52	-0.34	1.24e-5	Blood protein levels;
PAAD	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.8	-0.36	3.76e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	1.03e-18	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-6.6	-0.47	6.44e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.44	4.36	0.33	2.43e-5	Chronic sinus infection;
PAAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.62	-5.44	-0.4	2.13e-7	Mean corpuscular volume;
PAAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.0	-0.44	1.41e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6006893	1.000	rs6006893	chr22:45253895	C/T	cg21293611	chr22:45064211	PRR5	-0.66	-4.38	-0.33	2.21e-5	Binge eating behaviour in bipolar disorder;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg02869306	chr7:64672164	INTS4L1	0.41	4.82	0.36	3.46e-6	Aortic root size;
PAAD	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.24	0.6	2.04e-16	Mortality in heart failure;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs4764124	0.535	rs11056182	chr12:14925724	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	5.51	0.41	1.52e-7	Pubertal anthropometrics;
PAAD	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.91	-11.86	-0.69	2.15e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs4499344	0.805	rs12978075	chr19:33067852	T/C	cg22980127	chr19:33182716	NUDT19	0.46	4.27	0.33	3.49e-5	Mean platelet volume;
PAAD	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.52	-4.96	-0.37	1.9e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg00738919	chr7:1100172	C7orf50	0.68	5.04	0.38	1.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg25487775	chr2:162093969	NA	0.76	8.71	0.58	4.67e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7319311	0.565	rs7991436	chr13:111026440	G/A	cg05272587	chr13:111038400	COL4A2	0.62	5.56	0.41	1.21e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	11.99	0.7	1e-23	Menarche (age at onset);
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-5.69	-0.42	6.41e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.57	-7.38	-0.51	9.67e-12	Lewy body disease;
PAAD	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.53	5.59	0.41	1.03e-7	Red blood cell count;
PAAD	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	1.26	6.81	0.48	2.08e-10	Severe influenza A (H1N1) infection;
PAAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg21130718	chr4:1044621	NA	-0.56	-4.82	-0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs9914578	1.000	rs9915112	chr17:2007826	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-5.27	-0.39	4.6e-7	Body mass index;
PAAD	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.56	-5.56	-0.41	1.2e-7	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.7	8.38	0.56	3.34e-14	Lung cancer;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg00280220	chr17:61926910	NA	0.43	4.52	0.34	1.23e-5	Prudent dietary pattern;
PAAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-1.04	-17.03	-0.81	4.78e-37	Height;
PAAD	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs16958440	0.737	rs16958699	chr18:44654846	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.75	-0.48	2.9e-10	Platelet distribution width;
PAAD	cis	rs7633770	0.622	rs34063921	chr3:46689922	A/G	cg11219411	chr3:46661640	NA	-0.53	-6.01	-0.44	1.33e-8	Coronary artery disease;
PAAD	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.15	-16.03	-0.79	1.72e-34	Schizophrenia;
PAAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.58	8.79	0.58	3.01e-15	Hypertriglyceridemia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01227359	chr2:209119189	IDH1	-0.7	-6.33	-0.46	2.55e-9	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09502511	chr6:30539237	ABCF1	-0.72	-6.4	-0.46	1.78e-9	Neuroticism;
PAAD	cis	rs2252790	1.000	rs2232470	chr6:116575083	C/A	cg26893134	chr6:116381904	FRK	-0.29	-4.54	-0.35	1.14e-5	Fast beta electroencephalogram;
PAAD	cis	rs7714584	1.000	rs7715981	chr5:150258107	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg03264133	chr6:25882463	NA	-0.54	-4.61	-0.35	8.34e-6	Iron status biomarkers;
PAAD	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg11143131	chr5:131608246	PDLIM4	0.47	4.39	0.34	2.11e-5	Breast cancer;
PAAD	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-9.09	-0.59	4.95e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg20849893	chr7:64541193	NA	-0.49	-4.79	-0.36	3.95e-6	Calcium levels;
PAAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.11e-8	Coronary artery disease;
PAAD	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.85	0.43	2.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.52	5.09	0.38	1.06e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs593531	0.571	rs3862799	chr11:74050262	C/A	cg15670924	chr11:73669256	DNAJB13	-0.43	-4.4	-0.34	2.06e-5	Neuroticism;
PAAD	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.49	0.41	1.68e-7	Schizophrenia;
PAAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.72	11.0	0.67	4.63e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs564309	0.867	rs34673199	chr1:228531074	G/A	cg01328119	chr1:228783545	DUSP5P	0.71	4.41	0.34	1.98e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs2882667	0.690	rs2662543	chr5:138234130	G/T	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs16975963	0.644	rs73033139	chr19:38091685	A/C	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73416724	1.000	rs79009481	chr6:43343239	T/C	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7567389	0.504	rs1568278	chr2:128190195	G/A	cg11380483	chr2:127933992	NA	0.48	4.6	0.35	8.96e-6	Self-rated health;
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.29	0.68	7.35e-22	Platelet count;
PAAD	cis	rs9361491	0.608	rs7382311	chr6:79455943	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg19257562	chr1:2043853	PRKCZ	0.48	5.93	0.43	1.93e-8	Height;
PAAD	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg20607287	chr7:12443886	VWDE	-0.75	-5.51	-0.41	1.53e-7	Coronary artery disease;
PAAD	cis	rs7945718	0.621	rs6485978	chr11:12678415	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs60154123	0.504	rs11119458	chr1:210491097	T/A	cg23283495	chr1:209979779	IRF6	0.68	5.56	0.41	1.21e-7	Coronary artery disease;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.94	-0.43	1.85e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs900145	0.906	rs1384025	chr11:13296446	G/T	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.64	-6.68	-0.48	4.14e-10	Coronary artery disease;
PAAD	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-4.51	-0.34	1.31e-5	Lung cancer;
PAAD	cis	rs13256369	0.671	rs59003218	chr8:8554921	G/A	cg06671706	chr8:8559999	CLDN23	0.62	5.98	0.44	1.56e-8	Obesity-related traits;
PAAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.77	-8.31	-0.56	4.91e-14	Blood metabolite levels;
PAAD	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.86	6.48	0.47	1.23e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg20159608	chr7:32802032	NA	-0.6	-6.45	-0.46	1.42e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.44	0.34	1.74e-5	Bone mineral density;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	6.77	0.48	2.57e-10	Renal function-related traits (BUN);
PAAD	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg05562828	chr17:3906858	NA	-0.55	-6.08	-0.44	9.35e-9	Type 2 diabetes;
PAAD	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.88	-0.37	2.64e-6	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.92	11.37	0.68	4.5e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9810890	1.000	rs114366529	chr3:128564604	A/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg10729496	chr3:10149963	C3orf24	0.84	6.58	0.47	7.29e-10	Alzheimer's disease;
PAAD	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.68	7.53	0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.81	-8.26	-0.56	6.44e-14	Tonsillectomy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00730794	chr14:24617010	PSME2;RNF31	0.61	6.63	0.47	5.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs7553864	0.835	rs719015	chr1:87611710	A/G	cg08371190	chr1:87598514	LOC339524	-0.31	-4.46	-0.34	1.6e-5	Smoking behavior;
PAAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg03732007	chr1:2071316	PRKCZ	-0.52	-5.63	-0.42	8.45e-8	Height;
PAAD	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12703710	chr1:146522416	NA	0.62	7.02	0.49	6.88e-11	Body fat percentage;
PAAD	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.4	-5.1	-0.38	9.95e-7	Prostate cancer;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.41	-0.52	7.98e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.66	4.88	0.37	2.69e-6	Exhaled nitric oxide output;
PAAD	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26306683	chr17:18585705	ZNF286B	-0.61	-4.57	-0.35	1.02e-5	Pancreatic cancer;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg02524346	chr8:600233	NA	1.17	8.34	0.56	4.05e-14	IgG glycosylation;
PAAD	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg05250797	chr16:70222502	NA	0.87	6.64	0.47	5.28e-10	IgE levels;
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.63	-7.38	-0.51	9.54e-12	Lung cancer;
PAAD	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.19	0.39	6.66e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-5.17	-0.39	7.12e-7	Subjective well-being;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.85	-10.39	-0.64	1.88e-19	Menopause (age at onset);
PAAD	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	7.87	0.54	6.11e-13	Schizophrenia;
PAAD	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.21e-5	Educational attainment (years of education);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13859861	chr7:44163228	POLD2	0.59	6.38	0.46	2.01e-9	Monocyte percentage of white cells;
PAAD	trans	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg26939375	chr7:64535504	NA	0.7	7.95	0.54	3.91e-13	Aortic root size;
PAAD	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22601191	chr20:60968625	CABLES2	0.69	6.43	0.46	1.57e-9	Colorectal cancer;
PAAD	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1941184	0.759	rs12185410	chr18:29024156	T/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-5.09	-0.38	1.05e-6	Dental caries;
PAAD	cis	rs2718812	1.000	rs2718813	chr3:133399212	A/G	cg12372414	chr3:134319805	KY	-0.41	-4.48	-0.34	1.44e-5	Iron status biomarkers;
PAAD	cis	rs73086581	0.680	rs11908158	chr20:3936672	G/T	cg02187196	chr20:3869020	PANK2	0.51	4.29	0.33	3.17e-5	Response to antidepressants in depression;
PAAD	cis	rs13242816	1.000	rs55977427	chr7:116110768	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs91	0.575	rs2722397	chr7:24428024	T/C	cg13313214	chr7:23749942	STK31	-0.47	-4.85	-0.37	3.06e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	9.81	0.62	6.61e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1800469	0.928	rs12462166	chr19:41857404	T/C	cg08477640	chr19:41863820	B9D2	0.71	7.64	0.53	2.22e-12	Colorectal cancer;
PAAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	10.03	0.63	1.7e-18	Testicular germ cell tumor;
PAAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.84	9.73	0.62	1.05e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg05082376	chr22:42548792	NA	0.51	5.61	0.41	9.47e-8	Cognitive function;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs427941	0.632	rs201509	chr7:101765002	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.42	0.34	1.86e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-0.87	-13.17	-0.73	6.58e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.85	-0.43	2.91e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17376030	chr22:41985996	PMM1	-0.61	-4.44	-0.34	1.74e-5	Vitiligo;
PAAD	cis	rs8179	0.645	rs6954221	chr7:92283262	A/G	cg03496780	chr7:92466842	CDK6	-0.51	-4.85	-0.37	3.05e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	1.05	15.14	0.78	3.63e-32	Height;
PAAD	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.32	-0.4	3.66e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7260598	0.539	rs115746110	chr19:24063975	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.74	6.35	0.46	2.4e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs35955747	0.934	rs131200	chr22:31703272	T/C	cg02404636	chr22:31891804	SFI1	0.49	4.89	0.37	2.53e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.68e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg10193763	chr2:225306901	NA	0.53	4.68	0.35	6.38e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg17385448	chr1:15911702	AGMAT	0.35	4.31	0.33	2.88e-5	Systolic blood pressure;
PAAD	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.79	9.34	0.6	1.11e-16	Selective IgA deficiency;
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg05861140	chr6:150128134	PCMT1	-0.57	-6.49	-0.47	1.15e-9	Lung cancer;
PAAD	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg02640540	chr1:67518911	SLC35D1	0.55	4.65	0.35	7.09e-6	Lymphocyte percentage of white cells;
PAAD	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.12	10.23	0.64	5.14e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs6494488	0.500	rs72741381	chr15:64806561	G/A	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.93	7.88	0.54	5.98e-13	Alzheimer's disease;
PAAD	cis	rs10450586	0.932	rs10767626	chr11:27306545	G/A	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.71	0.58	4.72e-15	Schizophrenia;
PAAD	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.61	-4.42	-0.34	1.85e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg21269045	chr12:125625041	AACS	-0.49	-4.67	-0.35	6.47e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.48	5.35	0.4	3.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg03894339	chr8:19674705	INTS10	1.14	8.1	0.55	1.67e-13	Lipid metabolism phenotypes;
PAAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.33	0.33	2.71e-5	Renal cell carcinoma;
PAAD	cis	rs11064881	1.000	rs11064881	chr12:120146925	A/G	cg17717091	chr12:120541617	RAB35	0.79	4.45	0.34	1.68e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs965469	0.762	rs6515783	chr20:3245006	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.36	-0.33	2.43e-5	IFN-related cytopenia;
PAAD	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.82	-6.42	-0.46	1.66e-9	Weight;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs258892	0.947	rs250517	chr5:72200626	G/C	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.49	4.78	0.36	4.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs6065	0.867	rs1859433	chr17:4850312	G/C	cg02990439	chr17:4875527	CAMTA2	-0.85	-4.38	-0.33	2.19e-5	Platelet count;
PAAD	cis	rs11700980	0.551	rs11701765	chr21:30115651	C/T	cg24692254	chr21:30365293	RNF160	0.7	5.13	0.38	8.73e-7	QRS complex (12-leadsum);
PAAD	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs9462027	1.000	rs9296133	chr6:34777533	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-4.76	-0.36	4.41e-6	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.4e-9	Lung cancer;
PAAD	cis	rs2085601	0.542	rs1708684	chr4:89961779	A/C	cg17769793	chr4:89976368	FAM13A	0.44	5.57	0.41	1.13e-7	Hair greying;
PAAD	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg01631408	chr1:248437212	OR2T33	-0.56	-5.01	-0.38	1.48e-6	Common traits (Other);
PAAD	cis	rs9287604	0.909	rs11685464	chr2:237784610	G/C	cg15065627	chr2:237796583	NA	-0.51	-4.29	-0.33	3.21e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27663799	chr12:49504641	LMBR1L	-0.63	-7.67	-0.53	1.91e-12	Body fat percentage;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg07061783	chr6:25882402	NA	-0.67	-6.22	-0.45	4.53e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg02389323	chr16:88786976	FAM38A	0.9	4.78	0.36	4.02e-6	Plateletcrit;
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg05304507	chr6:116381966	FRK	-0.44	-8.47	-0.57	1.95e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.29	-0.33	3.19e-5	Crohn's disease;
PAAD	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.44	5.07	0.38	1.15e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.73	-0.36	5.11e-6	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg14703610	chr5:56206110	C5orf35	-0.58	-5.57	-0.41	1.11e-7	Initial pursuit acceleration;
PAAD	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.76	-5.28	-0.39	4.34e-7	Red cell distribution width;
PAAD	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.52	-4.69	-0.36	6.1e-6	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs13102973	0.617	rs11734991	chr4:135885411	T/G	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09431544	chr19:14629187	DNAJB1	0.66	6.96	0.49	9.64e-11	Primary biliary cholangitis;
PAAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg23346134	chr3:49453900	TCTA	-0.47	-4.99	-0.38	1.63e-6	Menarche (age at onset);
PAAD	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.6	5.44	0.4	2.06e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7766436	0.614	rs12660581	chr6:22564435	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs881301	1.000	rs881301	chr8:38332318	A/G	cg17120578	chr8:38329836	NA	-0.43	-4.63	-0.35	7.69e-6	Response to cognitive-behavioural therapy in anxiety disorder;
PAAD	cis	rs2073499	0.872	rs78671882	chr3:50411188	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.75	4.63	0.35	7.78e-6	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg26818257	chr2:241905806	NA	0.42	4.28	0.33	3.34e-5	Urinary metabolites;
PAAD	cis	rs364477	0.762	rs9299104	chr9:1001254	C/T	cg13952963	chr9:998547	NA	-0.59	-4.47	-0.34	1.54e-5	Major depressive disorder;
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg02869306	chr7:64672164	INTS4L1	0.41	4.81	0.36	3.68e-6	Aortic root size;
PAAD	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.67	-6.51	-0.47	1.03e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10510102	0.608	rs4486560	chr10:123604355	A/G	cg09536375	chr10:123735128	NSMCE4A	-0.36	-4.56	-0.35	1.05e-5	Breast cancer;
PAAD	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs6494488	0.500	rs61117068	chr15:64959634	G/T	cg16425858	chr15:64791681	ZNF609	0.93	4.93	0.37	2.11e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.22	0.55	8.29e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.52	4.91	0.37	2.3e-6	Hirschsprung disease;
PAAD	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.46	-4.41	-0.34	1.93e-5	Cognitive ability (multi-trait analysis);
PAAD	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.72	-8.33	-0.56	4.31e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg24739098	chr15:79297159	RASGRF1	0.36	4.82	0.36	3.52e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg09835421	chr16:68378352	PRMT7	-0.85	-6.89	-0.49	1.42e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-8.93	-0.59	1.3e-15	Exhaled nitric oxide output;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg14725641	chr11:61582763	MIR1908;FADS1	0.43	4.25	0.33	3.74e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.65	0.35	7.22e-6	Corneal astigmatism;
PAAD	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg09455208	chr3:40491958	NA	-0.41	-5.21	-0.39	6.11e-7	Renal cell carcinoma;
PAAD	trans	rs2880058	0.788	rs6659759	chr1:162037609	T/C	cg22816059	chr5:422114	AHRR	-0.62	-6.49	-0.47	1.12e-9	QT interval;
PAAD	cis	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23463467	chr20:60627584	TAF4	0.41	4.31	0.33	2.92e-5	Body mass index;
PAAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	1.08	15.14	0.78	3.6e-32	Breast cancer;
PAAD	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.69e-6	Thyroid stimulating hormone;
PAAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg21191810	chr6:118973309	C6orf204	0.43	5.49	0.41	1.63e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.13e-9	Educational attainment;
PAAD	cis	rs6689305	0.674	rs11166322	chr1:100210815	A/G	cg22872634	chr1:100462710	SLC35A3	-0.5	-4.36	-0.33	2.39e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19734811	chr2:177134269	MTX2	-0.62	-6.7	-0.48	3.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs501120	0.584	rs11238923	chr10:44701232	A/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.53	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg15571903	chr15:79123663	NA	-0.47	-6.11	-0.44	8.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7172677	0.961	rs34511319	chr15:75429717	A/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.72	-0.36	5.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.56	5.81	0.43	3.56e-8	Total body bone mineral density;
PAAD	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg15352829	chr14:105391018	PLD4	-0.54	-7.32	-0.51	1.32e-11	Rheumatoid arthritis;
PAAD	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg23254163	chr1:152506842	NA	0.59	6.86	0.49	1.65e-10	Hair morphology;
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.87	-12.67	-0.72	1.45e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg21890820	chr11:65308645	LTBP3	0.65	7.8	0.53	8.94e-13	Bone mineral density;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-4.78	-0.36	4.03e-6	Glycated hemoglobin levels;
PAAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg21300403	chr2:198650112	BOLL	0.49	4.36	0.33	2.38e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.67	-7.44	-0.52	7.02e-12	Age at first birth;
PAAD	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.39	5.11	0.38	9.53e-7	Educational attainment (years of education);
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg15117754	chr3:10150083	C3orf24	0.6	5.68	0.42	6.57e-8	Alzheimer's disease;
PAAD	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg08886695	chr4:3369023	RGS12	0.53	4.98	0.37	1.71e-6	Parental longevity (mother's age at death);
PAAD	cis	rs1075265	0.836	rs1421622	chr2:54289781	C/T	cg26149131	chr2:54343179	ACYP2	0.46	4.31	0.33	2.93e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg19052272	chr2:3704530	ALLC	-0.55	-6.43	-0.46	1.59e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs58847779	0.536	rs739140	chr22:38115556	G/A	cg05691152	chr22:38092978	TRIOBP	0.49	4.27	0.33	3.4e-5	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.38	5.22	0.39	5.67e-7	Schizophrenia;
PAAD	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.29	0.33	3.11e-5	Depression;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5.07e-7	Life satisfaction;
PAAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.7	5.57	0.41	1.13e-7	Schizophrenia;
PAAD	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-6.07	-0.44	9.79e-9	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.39	0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-5.69	-0.42	6.46e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.53	-0.41	1.39e-7	Vitamin D levels;
PAAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.72	10.21	0.64	5.86e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg24829409	chr8:58192753	C8orf71	-0.9	-7.99	-0.54	3.21e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-4.71	-0.36	5.51e-6	Asthma;
PAAD	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs721399	0.524	rs7005648	chr8:18278208	T/A	cg18736775	chr8:18248649	NAT2	0.65	4.96	0.37	1.85e-6	Blood metabolite levels;
PAAD	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	11.22	0.67	1.14e-21	Smoking behavior;
PAAD	cis	rs375066	0.762	rs1073653	chr19:44411543	G/A	cg21496419	chr19:44306685	LYPD5	-0.42	-4.93	-0.37	2.17e-6	Breast cancer;
PAAD	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.61	-0.35	8.59e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2795502	0.630	rs873300	chr10:43537155	C/T	cg20628663	chr10:43360327	NA	0.73	5.32	0.4	3.66e-7	Blood protein levels;
PAAD	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.97	-6.82	-0.48	2.07e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg05861140	chr6:150128134	PCMT1	-0.46	-5.06	-0.38	1.19e-6	Lung cancer;
PAAD	cis	rs58521262	0.556	rs289337	chr19:23151790	A/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.68	6.86	0.49	1.64e-10	Colorectal cancer;
PAAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.89	-9.82	-0.62	6.39e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.6	-0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.8	6.64	0.47	5.37e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-4.79	-0.36	3.99e-6	Neuroticism;
PAAD	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.69	-6.84	-0.48	1.84e-10	Schizophrenia;
PAAD	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.62	-8.49	-0.57	1.72e-14	Crohn's disease;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg14092571	chr14:90743983	NA	0.53	5.1	0.38	9.91e-7	Mortality in heart failure;
PAAD	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs2296225	0.722	rs900037	chr1:21057788	C/T	cg24673385	chr1:21051448	SH2D5	0.45	4.33	0.33	2.72e-5	Eosinophilic esophagitis;
PAAD	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.8	0.48	2.26e-10	Total body bone mineral density;
PAAD	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.75	9.52	0.61	3.9e-17	Height;
PAAD	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	1.2	13.91	0.75	6.78e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg08501292	chr6:25962987	TRIM38	0.84	4.76	0.36	4.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg23250157	chr14:64679961	SYNE2	0.51	5.2	0.39	6.39e-7	Atrial fibrillation;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14322429	chr3:119298585	ADPRH	0.62	6.68	0.48	4.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-1.36	-10.13	-0.63	9.61e-19	Schizophrenia;
PAAD	cis	rs7172971	0.688	rs7176459	chr15:42381215	G/A	cg07013680	chr15:42186124	SPTBN5	0.55	4.32	0.33	2.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1642645	0.872	rs604145	chr1:42445113	T/C	cg01990334	chr1:42801334	FOXJ3	-0.65	-5.7	-0.42	5.99e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.59	0.52	2.97e-12	Alzheimer's disease;
PAAD	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg03999872	chr20:62272968	STMN3	-0.65	-6.15	-0.45	6.69e-9	Atopic dermatitis;
PAAD	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs375066	0.935	rs439665	chr19:44414467	G/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18002896	chr8:144465845	RHPN1	0.65	6.35	0.46	2.32e-9	Primary biliary cholangitis;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg23912435	chr1:150601613	ENSA	0.5	4.65	0.35	7.24e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23000153	chr5:1212434	SLC6A19	-0.66	-6.48	-0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.63	9.4	0.61	7.92e-17	Asthma (sex interaction);
PAAD	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.74	0.48	3.11e-10	Schizophrenia;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.68	-0.35	6.37e-6	Lung cancer;
PAAD	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.35	-0.51	1.11e-11	Total body bone mineral density;
PAAD	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.48	4.66	0.35	6.78e-6	Blood pressure;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.66	-7.34	-0.51	1.22e-11	Total body bone mineral density;
PAAD	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.97	-0.37	1.81e-6	Mean corpuscular volume;
PAAD	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg00035074	chr7:2701567	TTYH3	0.66	4.56	0.35	1.06e-5	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg15181151	chr6:150070149	PCMT1	0.59	6.58	0.47	7.27e-10	Lung cancer;
PAAD	cis	rs7627468	0.837	rs9850411	chr3:121937353	C/T	cg17240004	chr3:121949083	CASR	0.51	4.7	0.36	5.91e-6	Kidney stones;
PAAD	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27087555	chr16:88793112	FAM38A	-1.07	-5.67	-0.42	7.1e-8	Plateletcrit;
PAAD	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs16910800	0.689	rs56101126	chr11:23188861	T/A	cg20040320	chr11:23191996	NA	-0.82	-6.89	-0.49	1.4e-10	Cancer;
PAAD	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.88	-10.84	-0.66	1.22e-20	Body mass index;
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.68	6.28	0.45	3.38e-9	Platelet count;
PAAD	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.12	9.49	0.61	4.55e-17	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24162330	chr15:28520159	HERC2	0.57	6.36	0.46	2.27e-9	Smoking initiation;
PAAD	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Corneal structure;
PAAD	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg24220031	chr2:73402428	NA	-0.43	-6.6	-0.47	6.53e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.6	-0.35	8.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10821973	0.527	rs2116584	chr10:63979938	A/C	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.4	0.34	2.02e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.58	6.09	0.44	8.76e-9	Longevity;
PAAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	8.39	0.56	3.07e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.68	-6.38	-0.46	2.07e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg26552733	chr10:5542941	CALML5	0.74	4.32	0.33	2.8e-5	Major depressive disorder;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.78	-5.62	-0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs73206853	0.841	rs73191839	chr12:110967652	G/T	cg12870014	chr12:110450643	ANKRD13A	0.77	4.88	0.37	2.66e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18789337	chr6:114180353	MARCKS	0.58	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg00147160	chr1:26503991	CNKSR1	0.42	4.51	0.34	1.3e-5	Height;
PAAD	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs72827839	0.802	rs4794321	chr17:46028844	T/C	cg23391107	chr17:45924227	SP6	-0.59	-5.07	-0.38	1.16e-6	Ease of getting up in the morning;
PAAD	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg05895507	chr15:77155635	SCAPER	0.41	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.86	10.01	0.63	2e-18	Menopause (age at onset);
PAAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.57	-6.71	-0.48	3.55e-10	Psoriasis;
PAAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35160687	0.712	rs2303358	chr2:86478664	T/C	cg10973622	chr2:86423274	IMMT	-0.44	-4.89	-0.37	2.51e-6	Night sleep phenotypes;
PAAD	trans	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg26501369	chr6:133561814	EYA4	-0.85	-6.54	-0.47	8.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg09237302	chr4:906077	GAK	0.47	6.19	0.45	5.4e-9	Systemic sclerosis;
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.7	-5.86	-0.43	2.7e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.54	5.26	0.39	4.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs881952	0.791	rs842759	chr2:60878203	A/T	cg02739593	chr2:60880222	NA	0.49	4.48	0.34	1.44e-5	Glucose homeostasis traits;
PAAD	cis	rs10982213	0.953	rs10817602	chr9:117160921	A/G	cg00078025	chr9:117159975	NA	0.59	4.31	0.33	2.94e-5	Interleukin-6 levels;
PAAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg10547527	chr2:198650123	BOLL	-0.72	-4.77	-0.36	4.36e-6	Ulcerative colitis;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08677398	chr8:58056175	NA	0.68	4.66	0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.45	-6.66	-0.48	4.72e-10	Breast cancer;
PAAD	cis	rs17601876	0.814	rs8039089	chr15:51561328	T/G	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg26935685	chr1:15502881	TMEM51	-0.5	-4.26	-0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	1.08	15.29	0.78	1.5e-32	Metabolite levels;
PAAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.58	5.44	0.4	2.09e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2944755	0.723	rs13273553	chr8:141588265	C/G	cg08632810	chr8:141609470	EIF2C2	-0.37	-4.62	-0.35	8.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.66	-7.85	-0.54	6.81e-13	Vitiligo;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg04156016	chr5:1868137	NA	0.49	4.93	0.37	2.09e-6	Cardiovascular disease risk factors;
PAAD	cis	rs1539053	0.966	rs11578358	chr1:58097794	C/T	cg00026909	chr1:58089001	DAB1	0.67	7.64	0.53	2.23e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.54	4.35	0.33	2.51e-5	HDL cholesterol;
PAAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.41	-0.34	1.94e-5	Red blood cell count;
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg11335335	chr11:637885	DRD4	-0.37	-5.08	-0.38	1.11e-6	Systemic lupus erythematosus;
PAAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.43	4.91	0.37	2.28e-6	Psoriasis;
PAAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.45	-4.59	-0.35	9.14e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg17178900	chr1:205818956	PM20D1	0.47	4.59	0.35	9.37e-6	Parkinson's disease;
PAAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.62	-7.44	-0.52	7.03e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.7	-7.69	-0.53	1.73e-12	Alcohol dependence;
PAAD	cis	rs2882667	0.537	rs10057545	chr5:138431008	G/A	cg22797968	chr5:138629998	MATR3	0.46	4.66	0.35	6.84e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.15	10.44	0.65	1.45e-19	Lymphocyte percentage of white cells;
PAAD	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.79	-0.43	3.89e-8	YKL-40 levels;
PAAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs42648	0.564	rs17863031	chr7:89805813	A/G	cg27367526	chr7:89841692	STEAP2	-0.34	-4.76	-0.36	4.52e-6	Homocysteine levels;
PAAD	cis	rs66530629	0.874	rs10903102	chr1:25122839	C/G	cg01905478	chr1:25040257	NA	-0.48	-5.31	-0.4	3.81e-7	Plateletcrit;
PAAD	cis	rs9487051	0.646	rs11153165	chr6:109622159	G/A	cg21918786	chr6:109611834	NA	-0.52	-5.54	-0.41	1.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	7.59	0.52	2.99e-12	Schizophrenia;
PAAD	cis	rs1277203	0.559	rs10857972	chr1:109384436	A/G	cg08274380	chr1:109419600	GPSM2	-0.51	-4.25	-0.33	3.71e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7165102	1.000	rs7163482	chr15:65739683	C/T	cg22900193	chr15:65823441	PTPLAD1	0.47	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.47	5.06	0.38	1.21e-6	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.96	10.54	0.65	7.53e-20	Corneal astigmatism;
PAAD	cis	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg21546286	chr11:48923668	NA	-0.48	-4.97	-0.37	1.76e-6	HDL cholesterol;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.98	0.54	3.25e-13	Alzheimer's disease;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.38	-0.34	2.16e-5	Platelet count;
PAAD	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.6	6.38	0.46	1.98e-9	Bladder cancer;
PAAD	cis	rs4523957	0.583	rs2760740	chr17:2020989	A/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.51	-0.47	1.03e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.58	-6.3	-0.45	3.09e-9	Pelvic organ prolapse;
PAAD	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.83	10.39	0.64	1.91e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7715811	1.000	rs1502050	chr5:13779743	A/G	cg07548982	chr5:13769939	DNAH5	-0.52	-4.98	-0.37	1.71e-6	Subclinical atherosclerosis traits (other);
PAAD	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.4	12.89	0.72	3.66e-26	Uric acid levels;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg14926445	chr8:58193284	C8orf71	-0.69	-5.01	-0.38	1.5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.5	2.45e-11	Schizophrenia;
PAAD	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24110177	chr3:50126178	RBM5	-0.61	-6.89	-0.49	1.38e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs59888335	0.895	rs6548724	chr3:80811140	T/C	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07177430	chr11:3400574	ZNF195	0.72	8.26	0.56	6.6e-14	Myopia (pathological);
PAAD	cis	rs10851411	0.559	rs56172155	chr15:42882182	C/T	cg21293051	chr15:42870591	STARD9	0.59	4.7	0.36	5.8e-6	Glucose homeostasis traits;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs12760731	0.623	rs6688546	chr1:178332511	A/G	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01110552	chr10:103578627	MGEA5	0.6	6.54	0.47	9.04e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.44	-0.34	1.7e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg21483415	chr3:195448197	MUC20	0.45	4.3	0.33	3.1e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.59	-5.48	-0.41	1.74e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs251130	0.915	rs253975	chr5:110863262	G/A	cg11925263	chr5:110849104	STARD4	0.38	4.58	0.35	9.7e-6	Menarche (age at onset);
PAAD	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.63	0.42	8.3e-8	Lung cancer in ever smokers;
PAAD	cis	rs367943	0.698	rs9764191	chr5:112961088	T/C	cg12552261	chr5:112820674	MCC	0.49	4.94	0.37	2.07e-6	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-10.44	-0.65	1.41e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg02462569	chr6:150064036	NUP43	0.46	4.92	0.37	2.27e-6	Lung cancer;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.35	-0.4	3.16e-7	Type 2 diabetes;
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.47	-0.34	1.52e-5	Response to amphetamines;
PAAD	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.48	4.66	0.35	6.74e-6	Crohn's disease;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg14926445	chr8:58193284	C8orf71	-0.66	-5.42	-0.4	2.3e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10929159	0.928	rs9636243	chr2:236925259	C/T	cg14226755	chr2:236923322	AGAP1	0.28	4.48	0.34	1.45e-5	Parkinson's disease;
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1711745	0.702	rs2995805	chr9:115454618	T/C	cg13803584	chr9:115635662	SNX30	0.93	6.21	0.45	4.85e-9	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
PAAD	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.81	9.88	0.63	4.42e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.99	0.49	7.95e-11	Longevity;Endometriosis;
PAAD	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg21064579	chr19:49206444	FUT2	0.45	4.87	0.37	2.74e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
PAAD	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg22875332	chr1:76189707	ACADM	-0.47	-4.73	-0.36	5.1e-6	Daytime sleep phenotypes;
PAAD	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg07150166	chr2:30669952	LCLAT1	0.75	5.36	0.4	3.1e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.97	-6.63	-0.47	5.6e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7873102	0.654	rs4878736	chr9:38013224	G/C	cg03528946	chr9:38069800	SHB	-0.5	-5.01	-0.38	1.52e-6	Brain structure;
PAAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg10483660	chr13:112241077	NA	0.53	4.91	0.37	2.34e-6	Menarche (age at onset);
PAAD	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.57	6.16	0.45	6.3e-9	Menopause (age at onset);
PAAD	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.66	-0.35	6.87e-6	Fear of minor pain;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.61	-5.87	-0.43	2.64e-8	Coronary artery disease;
PAAD	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg00262122	chr8:11665843	FDFT1	0.53	5.04	0.38	1.32e-6	Neuroticism;
PAAD	cis	rs6065	0.737	rs16954304	chr17:4871518	T/C	cg02990439	chr17:4875527	CAMTA2	-0.95	-4.85	-0.37	3.05e-6	Platelet count;
PAAD	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg08992911	chr2:238395768	MLPH	0.6	5.2	0.39	6.38e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.61	5.88	0.43	2.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2016586	0.894	rs2413367	chr22:36101861	A/T	cg26342177	chr22:36113512	APOL5	-0.48	-4.82	-0.36	3.4e-6	Body mass index;
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.7	0.42	6.02e-8	Immature fraction of reticulocytes;
PAAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.44	4.36	0.33	2.34e-5	Dupuytren's disease;
PAAD	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg17552801	chr10:99332121	ANKRD2	-0.45	-4.45	-0.34	1.66e-5	Metabolite levels;
PAAD	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18996663	chr14:55595768	LGALS3	0.58	6.76	0.48	2.71e-10	Myopia (pathological);
PAAD	cis	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Lung cancer in ever smokers;
PAAD	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.6	-5.95	-0.43	1.78e-8	Red cell distribution width;
PAAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.25	0.45	3.99e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4605213	0.528	rs11079947	chr17:49301788	G/A	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs490234	0.966	rs638168	chr9:128435256	G/A	cg14078157	chr9:128172775	NA	0.4	4.43	0.34	1.8e-5	Mean arterial pressure;
PAAD	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.69	5.71	0.42	5.82e-8	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16999636	chr17:46534794	NA	0.61	6.94	0.49	1.06e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg02344993	chr17:57696989	CLTC	0.59	4.78	0.36	4.11e-6	Hemoglobin concentration;
PAAD	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.44	4.27	0.33	3.38e-5	Red blood cell count;
PAAD	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg00071950	chr4:10020882	SLC2A9	-0.73	-6.59	-0.47	6.68e-10	Schizophrenia (age at onset);
PAAD	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.74	-8.99	-0.59	9.02e-16	Educational attainment;
PAAD	cis	rs72960926	0.744	rs11754787	chr6:74915037	A/T	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg27490568	chr2:178487706	NA	0.45	5.02	0.38	1.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs1371614	0.545	rs3769137	chr2:27169490	C/T	cg00617064	chr2:27272375	NA	0.46	4.78	0.36	4.08e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12599982	chr1:44399894	ARTN	0.48	5.21	0.39	5.94e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-1.05	-11.02	-0.67	4.03e-21	Platelet distribution width;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09981013	chr16:88008551	BANP	0.59	6.82	0.48	2.01e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.91	7.53	0.52	4.14e-12	Gastritis;
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.2	7.39	0.51	8.89e-12	Body mass index;
PAAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.25	0.64	4.56e-19	Smoking behavior;
PAAD	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg25547332	chr5:131281432	NA	0.53	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg07689907	chr11:61582574	FADS1	0.56	5.0	0.38	1.59e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.48	5.25	0.39	4.97e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.67	-0.53	1.93e-12	Neuroticism;
PAAD	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.49	6.57	0.47	7.66e-10	Renal cell carcinoma;
PAAD	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.78e-7	Mammographic density (dense area);
PAAD	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.17	6.35	0.46	2.4e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.79	-0.43	3.87e-8	Coronary artery calcification;
PAAD	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.81	0.48	2.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.68	8.3	0.56	5.27e-14	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.72	6.98	0.49	8.62e-11	Hip circumference;
PAAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.34	-0.33	2.55e-5	Menarche (age at onset);
PAAD	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.75	7.65	0.53	2.1e-12	Retinal vascular caliber;
PAAD	cis	rs4343996	1.000	rs12700789	chr7:3358276	T/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06728306	chr21:35445589	MRPS6;SLC5A3	0.58	6.49	0.47	1.13e-9	Metabolite levels  (X-11787);
PAAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.54	-6.96	-0.49	9.71e-11	Height;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg02696790	chr15:75250997	RPP25	-0.41	-4.75	-0.36	4.64e-6	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.79	9.23	0.6	2.21e-16	Morning vs. evening chronotype;
PAAD	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.56	5.52	0.41	1.42e-7	Osteoporosis;
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.8	0.58	2.78e-15	Lung cancer;
PAAD	cis	rs7224314	1.000	rs8072471	chr17:65367062	C/T	cg01507342	chr17:65387096	PITPNC1	-0.6	-5.4	-0.4	2.51e-7	Diisocyanate-induced asthma;
PAAD	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg04106633	chr4:1044584	NA	0.69	5.82	0.43	3.45e-8	Recombination rate (females);
PAAD	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.4	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.96e-8	Personality dimensions;
PAAD	cis	rs60154123	0.730	rs12040684	chr1:210472053	C/T	cg25204440	chr1:209979598	IRF6	0.62	5.13	0.38	8.55e-7	Coronary artery disease;
PAAD	cis	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg21605333	chr4:119757512	SEC24D	0.78	5.88	0.43	2.48e-8	Cannabis dependence symptom count;
PAAD	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.89	5.85	0.43	2.85e-8	Major depressive disorder;
PAAD	cis	rs2016586	0.773	rs5999962	chr22:36105655	T/C	cg26342177	chr22:36113512	APOL5	-0.46	-4.61	-0.35	8.56e-6	Body mass index;
PAAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs136211	0.929	rs2413399	chr22:36766481	A/G	cg11153328	chr22:36877737	TXN2	-0.49	-4.47	-0.34	1.53e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.8	0.48	2.21e-10	Exhaled nitric oxide levels;
PAAD	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	1.3	7.11	0.5	4.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg25401027	chr5:176370377	UIMC1	0.56	5.55	0.41	1.24e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05651688	chr1:35734284	ZMYM4	0.67	6.63	0.47	5.48e-10	Obesity-related traits;
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg07313626	chr1:247681931	NA	-0.48	-4.97	-0.37	1.79e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2671540	0.547	rs6479943	chr10:65647219	T/C	cg19573236	chr10:65733388	NA	-0.56	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	8.44	0.56	2.34e-14	Personality dimensions;
PAAD	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.53	-5.98	-0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.56	-4.85	-0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.64	6.97	0.49	9.13e-11	Blood protein levels;
PAAD	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00152838	chr16:24741724	TNRC6A	-0.51	-4.27	-0.33	3.47e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05124441	chr3:12045979	SYN2	-0.59	-6.44	-0.46	1.51e-9	Smoking initiation;
PAAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	7.8	0.53	9.39e-13	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.73	-6.26	-0.45	3.75e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.77	0.58	3.36e-15	Corneal astigmatism;
PAAD	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg04415270	chr2:102091202	RFX8	0.58	7.57	0.52	3.39e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Red blood cell count;
PAAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08085267	chr17:45401833	C17orf57	-0.66	-6.94	-0.49	1.07e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.62e-5	Platelet count;
PAAD	cis	rs9616064	0.813	rs28448546	chr22:46971294	G/T	cg03318428	chr22:46971703	NA	0.41	4.7	0.36	5.76e-6	Urate levels in obese individuals;
PAAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.61	5.88	0.43	2.49e-8	Bipolar disorder;
PAAD	cis	rs2415984	0.579	rs10135740	chr14:46957379	G/A	cg14871534	chr14:47121158	RPL10L	-0.52	-5.29	-0.39	4.19e-7	Number of children ever born;
PAAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.63	-5.27	-0.39	4.64e-7	Coronary artery disease;
PAAD	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg11995313	chr8:8860691	ERI1	-0.51	-5.1	-0.38	1e-6	Mood instability;
PAAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.99	13.11	0.73	9.32e-27	Menopause (age at onset);
PAAD	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.76	8.98	0.59	9.98e-16	Morning vs. evening chronotype;
PAAD	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.56	4.77	0.36	4.25e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	trans	rs9810890	0.702	rs73207972	chr3:128568186	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.48	6.9	0.49	1.34e-10	Mean corpuscular volume;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	1.02	14.11	0.75	2.03e-29	Menarche (age at onset);
PAAD	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg12310025	chr6:25882481	NA	0.43	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.18	0.39	7.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs116248771	0.739	rs4680448	chr3:158349978	C/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	trans	rs17396122	1.000	rs60710459	chr2:48687857	A/G	cg03908676	chr11:10590282	LYVE1	0.83	6.29	0.45	3.23e-9	Schizophrenia;
PAAD	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.7	-4.87	-0.37	2.72e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg01181863	chr3:195395398	SDHAP2	-0.95	-9.03	-0.59	7.27e-16	Pancreatic cancer;
PAAD	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.64	-4.64	-0.35	7.39e-6	Neuroticism;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7588746	0.621	rs2060122	chr2:201153177	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.38	-0.4	2.72e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.58	5.72	0.42	5.6e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6604026	0.656	rs2481712	chr1:93351477	G/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8040855	0.756	rs12909477	chr15:85689875	C/A	cg08123816	chr15:85640762	PDE8A	0.42	5.02	0.38	1.42e-6	Bulimia nervosa;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.51	-5.7	-0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.63	5.78	0.42	4e-8	Red blood cell count;
PAAD	cis	rs818427	0.896	rs351770	chr5:112199199	C/A	cg06941702	chr5:112196734	SRP19	-0.52	-4.91	-0.37	2.29e-6	Total body bone mineral density;
PAAD	cis	rs12799264	0.915	rs12796068	chr11:19976473	A/G	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22192301	chr11:1674088	HCCA2	-0.71	-6.4	-0.46	1.85e-9	Lung cancer in ever smokers;
PAAD	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.56	-7.03	-0.5	6.41e-11	Atrioventricular conduction;
PAAD	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs2061333	0.557	rs10413195	chr19:44634903	A/G	cg18700516	chr19:44507157	ZNF230	-0.78	-5.37	-0.4	2.95e-7	Alzheimer's disease;
PAAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.88	-10.3	-0.64	3.37e-19	Ulcerative colitis;
PAAD	cis	rs501120	0.584	rs7082177	chr10:44698630	G/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.69	-5.61	-0.41	9.28e-8	Non-small cell lung cancer;
PAAD	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg24053715	chr22:38214548	NA	-0.55	-5.36	-0.4	3.01e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	1.03	7.25	0.51	2e-11	Alzheimer's disease;
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg12143784	chr7:64541923	NA	-0.33	-4.26	-0.33	3.51e-5	Aortic root size;
PAAD	cis	rs13242816	1.000	rs12668226	chr7:116187690	A/C	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.55	-0.52	3.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.5	-0.34	1.34e-5	Eotaxin levels;
PAAD	cis	rs2302729	0.932	rs10774053	chr12:2791132	A/G	cg19945202	chr12:2788847	CACNA1C	-0.68	-6.04	-0.44	1.12e-8	Sleep quality;
PAAD	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.11	14.98	0.77	1e-31	Cognitive function;
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs57786342	0.901	rs72731554	chr14:69260371	T/A	cg03189333	chr14:69283534	NA	-0.59	-4.32	-0.33	2.76e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.69	-6.82	-0.48	1.99e-10	Menarche (age at onset);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg27094323	chr7:1216898	NA	-0.54	-6.6	-0.47	6.48e-10	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22856765	chr8:42693384	THAP1	-0.66	-7.07	-0.5	5.35e-11	Obesity-related traits;
PAAD	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg21191810	chr6:118973309	C6orf204	0.46	5.85	0.43	2.95e-8	Electrocardiographic conduction measures;
PAAD	cis	rs1891275	0.551	rs2421624	chr10:93416416	A/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs75920871	0.858	rs888245	chr11:116723737	C/G	cg04087571	chr11:116723030	SIK3	-0.44	-4.5	-0.34	1.33e-5	Subjective well-being;
PAAD	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.1	-0.63	1.15e-18	Response to antipsychotic treatment;
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15640870	chr8:145731409	GPT	-0.45	-4.41	-0.34	1.92e-5	Age at first birth;
PAAD	cis	rs755249	0.567	rs72661925	chr1:39669537	T/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11078597	0.731	rs1317708	chr17:1639965	G/A	cg18436246	chr17:1640651	WDR81	0.85	7.73	0.53	1.4e-12	Serum albumin level;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-1.14	-8.63	-0.57	7.72e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.88	8.35	0.56	3.84e-14	Menarche (age at onset);
PAAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-5.03	-0.38	1.39e-6	Subjective well-being;
PAAD	cis	rs7121446	0.521	rs12293988	chr11:121852633	C/T	cg13820391	chr11:121835505	NA	0.46	4.28	0.33	3.35e-5	Cardiovascular risk factors (age interaction);
PAAD	cis	rs1012068	0.924	rs5994449	chr22:32304179	T/A	cg01338084	chr22:32026380	PISD	0.58	5.15	0.39	8.06e-7	Chronic hepatitis C infection;
PAAD	cis	rs9646944	0.501	rs10172116	chr2:103087573	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs990171	0.538	rs4851012	chr2:103115915	A/G	cg13897122	chr2:103039542	IL18RAP	0.48	5.33	0.4	3.53e-7	Lymphocyte counts;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.6	-5.77	-0.42	4.2e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2916733	0.547	rs3020275	chr8:6313900	A/G	cg02465761	chr8:6735510	DEFB1	0.45	4.37	0.33	2.32e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.74	5.83	0.43	3.18e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.75	9.33	0.6	1.22e-16	Body mass index;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	9.07e-9	Lung cancer;
PAAD	cis	rs17407555	0.657	rs10489076	chr4:10270848	T/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.21	0.39	6.17e-7	Schizophrenia (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02668984	chr17:48172022	PDK2	0.68	7.77	0.53	1.1e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6494488	0.500	rs72741343	chr15:64766998	G/A	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs9462027	0.606	rs9394248	chr6:34739875	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.3	-0.33	3.08e-5	Systemic lupus erythematosus;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.64	-6.1	-0.44	8.35e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.53	-5.58	-0.41	1.1e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.81	-8.85	-0.58	2.1e-15	Obesity-related traits;
PAAD	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.71	-8.31	-0.56	4.83e-14	Facial morphology (factor 20);
PAAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	trans	rs6694672	0.867	rs616675	chr1:197257556	C/T	cg26994526	chr18:47719735	MYO5B	-0.85	-6.53	-0.47	9.07e-10	Asthma;
PAAD	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg05304507	chr6:116381966	FRK	0.33	6.19	0.45	5.46e-9	Total cholesterol levels;
PAAD	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.6	0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs796364	0.570	rs35733345	chr2:200647533	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-4.95	-0.37	1.96e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.84	9.68	0.62	1.47e-17	Prudent dietary pattern;
PAAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg21395723	chr22:39101663	GTPBP1	-0.46	-4.68	-0.35	6.36e-6	Menopause (age at onset);
PAAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.75	0.42	4.75e-8	Schizophrenia;
PAAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.45	0.52	6.52e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.5	5.8	0.43	3.79e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11853189	0.873	rs117636273	chr15:78556895	G/A	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs62238980	1.000	rs117536534	chr22:32585631	T/C	cg00543991	chr22:32367038	NA	1.19	6.64	0.47	5.11e-10	Childhood ear infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19678730	chr12:9280567	NA	-0.58	-6.98	-0.49	8.51e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg04265051	chr11:68079686	LRP5	-0.35	-4.27	-0.33	3.37e-5	Mean corpuscular volume;
PAAD	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	0.92	11.34	0.68	5.68e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.59e-21	Ulcerative colitis;
PAAD	trans	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg24842760	chr6:133561719	EYA4	-0.85	-6.73	-0.48	3.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7188861	0.813	rs1541700	chr16:11445818	T/C	cg01510278	chr16:11456238	NA	-0.43	-4.28	-0.33	3.3e-5	HDL cholesterol;
PAAD	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.62	-6.66	-0.48	4.73e-10	Menarche (age at onset);
PAAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg09835421	chr16:68378352	PRMT7	-1.18	-8.6	-0.57	9.4e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.73	4.99	0.38	1.64e-6	Carotid intima media thickness;
PAAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.56	-5.56	-0.41	1.2e-7	Childhood ear infection;
PAAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.7	6.96	0.49	9.3e-11	Body mass index;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.79	-8.6	-0.57	9e-15	Menopause (age at onset);
PAAD	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.02	-0.44	1.24e-8	Menopause (age at onset);
PAAD	cis	rs2139634	0.965	rs11719033	chr3:46529063	G/C	cg23009419	chr3:46618597	LRRC2;TDGF1	0.32	4.56	0.35	1.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg11766577	chr21:47581405	C21orf56	-0.43	-4.86	-0.37	2.96e-6	Testicular germ cell tumor;
PAAD	cis	rs7567389	0.677	rs72845975	chr2:128086274	C/T	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs9287604	1.000	rs842114	chr2:237795934	C/T	cg15065627	chr2:237796583	NA	-0.54	-4.49	-0.34	1.41e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.49	-4.48	-0.34	1.45e-5	Gut microbiome composition (summer);
PAAD	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11158902	chr4:6536914	NA	0.57	6.47	0.46	1.27e-9	Body fat percentage;
PAAD	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.58	5.99	0.44	1.44e-8	Crohn's disease;
PAAD	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.78	-0.36	4.12e-6	Mood instability;
PAAD	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.68	-7.03	-0.5	6.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg00450029	chr8:599525	NA	0.82	5.24	0.39	5.38e-7	IgG glycosylation;
PAAD	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-6.23	-0.45	4.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg05338066	chr1:7812865	CAMTA1	0.65	5.01	0.38	1.53e-6	Inflammatory bowel disease;
PAAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.53	5.84	0.43	3.02e-8	Type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24745816	chr2:217472042	NA	0.61	6.76	0.48	2.73e-10	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12122509	chr17:2206981	SRR;SMG6	0.58	6.91	0.49	1.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	8.93	0.59	1.32e-15	Parkinson's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19643344	chr1:236030490	LYST	-0.65	-6.4	-0.46	1.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11700980	0.515	rs12481795	chr21:30113730	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg03209412	chr4:183728196	NA	0.92	7.69	0.53	1.76e-12	Pediatric autoimmune diseases;
PAAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.54	-5.17	-0.39	7.33e-7	Daytime sleep phenotypes;
PAAD	cis	rs1011108	0.812	rs1148956	chr2:26801586	G/A	cg18742855	chr2:26800399	C2orf70	0.6	7.36	0.51	1.06e-11	Periodontal microbiota;
PAAD	cis	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.28	-0.39	4.31e-7	Mononucleosis;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18337363	chr3:52569053	NT5DC2	0.42	4.4	0.34	2.06e-5	Bipolar disorder;
PAAD	trans	rs3131082	1	rs3131082	chr6:28983274	G/C	cg01620082	chr3:125678407	NA	-1.59	-9.86	-0.62	4.78e-18	Tuberculosis;
PAAD	cis	rs795943	0.527	rs11109059	chr12:78653562	G/T	cg00023351	chr12:79187938	NA	0.7	4.82	0.36	3.47e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6137287	0.924	rs4625995	chr20:21147968	G/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg21479132	chr6:26055353	NA	0.85	4.27	0.33	3.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs564309	0.681	rs1188473	chr1:228612444	A/G	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	5.14	0.38	8.35e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.54	4.89	0.37	2.56e-6	Corneal structure;
PAAD	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg24296786	chr1:45957014	TESK2	-0.53	-5.13	-0.38	8.86e-7	Homocysteine levels;
PAAD	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.73	0.48	3.19e-10	Lung cancer in ever smokers;
PAAD	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.58	6.8	0.48	2.24e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.58	4.95	0.37	1.93e-6	Response to diuretic therapy;
PAAD	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg01966878	chr4:90757139	SNCA	-0.6	-4.7	-0.36	5.88e-6	Neuroticism;
PAAD	cis	rs4740619	0.689	rs10756726	chr9:15958680	A/C	cg14451791	chr9:16040625	NA	-0.43	-4.83	-0.36	3.35e-6	Body mass index;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.33	-0.51	1.27e-11	Body mass index;
PAAD	cis	rs621942	0.583	rs805454	chr11:85832784	C/G	cg07180834	chr11:85838833	NA	-0.48	-5.03	-0.38	1.38e-6	Tourette syndrome;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.74	-7.55	-0.52	3.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg05110241	chr16:68378359	PRMT7	1.01	6.53	0.47	9.3e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.47	4.25	0.33	3.67e-5	Tuberculosis;
PAAD	cis	rs2139634	0.783	rs11720094	chr3:46559911	G/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.36	-4.28	-0.33	3.25e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.84	-9.16	-0.6	3.24e-16	DNA methylation (variation);
PAAD	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg09242541	chr1:10490025	APITD1	-0.44	-5.49	-0.41	1.64e-7	Prostate cancer;
PAAD	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.31	0.4	3.8e-7	Migraine;
PAAD	cis	rs939584	1.000	rs6735024	chr2:630509	T/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.51	6.49	0.47	1.14e-9	Huntington's disease progression;
PAAD	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.69	7.7	0.53	1.66e-12	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-8.01	-0.54	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg08835956	chr7:39171034	POU6F2	0.37	5.93	0.43	2.01e-8	IgG glycosylation;
PAAD	cis	rs258892	0.739	rs34667	chr5:72160050	T/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg14393609	chr7:65229607	NA	0.62	6.52	0.47	9.92e-10	Aortic root size;
PAAD	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg16586182	chr3:47516702	SCAP	0.65	7.07	0.5	5.13e-11	Colorectal cancer;
PAAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.64	0.35	7.61e-6	Bone mineral density;
PAAD	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg10534938	chr5:1868639	NA	0.47	6.13	0.45	7.14e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.14	0.38	8.22e-7	Morning vs. evening chronotype;
PAAD	cis	rs6136489	0.583	rs6136477	chr20:1922534	G/C	cg19358608	chr20:1924565	NA	-0.35	-4.29	-0.33	3.12e-5	Platelet distribution width;Mean platelet volume;
PAAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.81	9.0	0.59	8.64e-16	Coronary artery disease;
PAAD	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg16898833	chr6:26189333	HIST1H4D	0.88	4.71	0.36	5.43e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.08	-0.44	9.33e-9	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg10729496	chr3:10149963	C3orf24	0.84	6.58	0.47	7.29e-10	Alzheimer's disease;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg09017928	chr7:158110068	PTPRN2	0.59	5.35	0.4	3.25e-7	Response to amphetamines;
PAAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.62	8.18	0.55	1.07e-13	Renal cell carcinoma;
PAAD	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg12639453	chr1:2035780	PRKCZ	0.55	5.27	0.39	4.59e-7	Height;
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg23985595	chr17:80112537	CCDC57	0.45	5.67	0.42	6.87e-8	Life satisfaction;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg22954621	chr10:13514626	BEND7	0.74	7.26	0.51	1.87e-11	Body mass index;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg06609049	chr19:2785107	THOP1	0.92	10.45	0.65	1.3e-19	Total cholesterol levels;
PAAD	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06481639	chr22:41940642	POLR3H	-0.62	-4.29	-0.33	3.21e-5	Vitiligo;
PAAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	5.11e-7	Coronary artery disease;
PAAD	cis	rs595018	0.505	rs7106391	chr11:60608443	A/G	cg07588442	chr11:60673866	PRPF19	0.65	4.47	0.34	1.55e-5	Wegener's granulomatosis;
PAAD	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg12395012	chr8:11607386	GATA4	-0.58	-6.95	-0.49	1e-10	Testicular germ cell tumor;
PAAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.02	11.06	0.67	3.04e-21	IgG glycosylation;
PAAD	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	8.09	0.55	1.78e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg11547950	chr5:77652471	NA	0.92	7.75	0.53	1.19e-12	Triglycerides;
PAAD	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg06883089	chr1:45254480	BEST4	0.34	4.28	0.33	3.28e-5	High light scatter reticulocyte count;
PAAD	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.3	-0.33	3.08e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	1.04	15.45	0.78	5.69e-33	Platelet distribution width;
PAAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.43	5.64	0.42	8.01e-8	Monobrow;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.61	5.9	0.43	2.28e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg14019146	chr3:50243930	SLC38A3	-0.41	-4.25	-0.33	3.73e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg11859384	chr17:80120422	CCDC57	-0.55	-5.83	-0.43	3.15e-8	Life satisfaction;
PAAD	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14019695	chr9:139328340	INPP5E	0.57	4.94	0.37	2.02e-6	White blood cell count;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19208700	chr12:117257305	RNFT2	-0.61	-7.05	-0.5	6.01e-11	Body fat percentage;
PAAD	cis	rs2587695	0.904	rs2579623	chr2:120298350	A/T	cg05839767	chr2:119914248	C1QL2	-0.4	-4.25	-0.33	3.76e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs12681288	0.695	rs6559205	chr8:973607	G/A	cg08648136	chr8:956695	NA	0.5	5.38	0.4	2.79e-7	Schizophrenia;
PAAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg22947322	chr17:47091978	IGF2BP1	0.39	4.43	0.34	1.77e-5	Type 2 diabetes;
PAAD	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.57	-4.74	-0.36	4.98e-6	Schizophrenia;
PAAD	cis	rs367943	0.665	rs4705560	chr5:112977073	T/G	cg12552261	chr5:112820674	MCC	0.53	5.54	0.41	1.29e-7	Type 2 diabetes;
PAAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.57	-6.79	-0.48	2.38e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.46	5.4	0.4	2.53e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.84	0.37	3.18e-6	Menopause (age at onset);
PAAD	cis	rs75757892	0.544	rs9505142	chr6:7318441	C/G	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs4662592	0.554	rs13012263	chr2:128930883	G/A	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.88	-11.24	-0.67	1.04e-21	Total body bone mineral density;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.67	7.25	0.51	1.99e-11	Longevity;
PAAD	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9549328	0.577	rs4907478	chr13:113618487	A/G	cg17524180	chr13:113633600	MCF2L	-0.42	-4.48	-0.34	1.49e-5	Systolic blood pressure;
PAAD	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.7	6.58	0.47	7.02e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.59	5.29	0.39	4.28e-7	Type 2 diabetes;
PAAD	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg24565620	chr2:194026	NA	0.66	5.37	0.4	2.84e-7	Blood protein levels;
PAAD	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg26220594	chr1:19110978	NA	0.58	4.57	0.35	1.01e-5	Percentage gas trapping;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08585380	chr6:86388840	SNORD50B;SNHG5	0.58	6.52	0.47	1e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.49	4.63	0.35	7.68e-6	HDL cholesterol;
PAAD	cis	rs2573652	0.755	rs11637186	chr15:100519652	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.61	-6.34	-0.46	2.5e-9	Height;
PAAD	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08817983	chr4:3391423	RGS12	0.39	4.36	0.33	2.41e-5	Mean platelet volume;
PAAD	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg26116260	chr4:7069785	GRPEL1	0.46	4.59	0.35	9.05e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
PAAD	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.38	-4.55	-0.35	1.08e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs793571	0.822	rs17302045	chr15:59199937	T/G	cg08898775	chr15:59042684	ADAM10	-0.38	-4.31	-0.33	2.9e-5	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.66	-8.41	-0.56	2.74e-14	Schizophrenia;
PAAD	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.81	9.43	0.61	6.48e-17	Hemoglobin concentration;
PAAD	cis	rs78761021	0.867	rs7222481	chr17:9785187	G/C	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.04e-13	Type 2 diabetes;
PAAD	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.69	0.42	6.36e-8	Coronary artery disease;
PAAD	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.95	13.23	0.73	4.46e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.64	-7.64	-0.53	2.24e-12	Mean arterial pressure;
PAAD	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.59	6.14	0.45	6.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg22963979	chr7:1858916	MAD1L1	-0.55	-5.61	-0.41	9.11e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg27557946	chr6:75953366	COX7A2	-0.55	-6.36	-0.46	2.22e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.6	-0.41	9.92e-8	Triglycerides;
PAAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.51	-5.77	-0.42	4.34e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.71e-7	Vitiligo;
PAAD	cis	rs1042026	0.848	rs6824253	chr4:100159499	A/G	cg09112717	chr4:100009950	ADH5	-0.53	-4.8	-0.36	3.69e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg00184732	chr15:51633821	GLDN	0.45	4.63	0.35	7.65e-6	Hormone measurements;
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.83	-9.03	-0.59	7.16e-16	DNA methylation (variation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06321424	chr2:219575502	TTLL4	0.7	7.38	0.51	9.6e-12	Obesity-related traits;
PAAD	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.35	-0.4	3.22e-7	Mean corpuscular volume;
PAAD	cis	rs10849004	1.000	rs1468765	chr12:4296894	A/T	cg03803796	chr12:3575061	NA	0.5	4.26	0.33	3.64e-5	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs7187994	0.895	rs12598223	chr16:84783873	A/G	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg17346650	chr17:80929145	B3GNTL1	0.51	6.65	0.47	5.04e-10	Glycated hemoglobin levels;
PAAD	cis	rs1355223	0.573	rs1097403	chr11:34730083	C/T	cg11622362	chr11:34938112	PDHX;APIP	-0.44	-4.46	-0.34	1.58e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.69	6.69	0.48	4.04e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg08589418	chr20:61993913	CHRNA4	0.51	4.26	0.33	3.62e-5	Atopic dermatitis;
PAAD	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg05215272	chr17:6899095	ALOX12	0.42	4.8	0.36	3.75e-6	Blood metabolite levels;
PAAD	cis	rs2120991	0.967	rs6580968	chr12:54261440	T/C	cg25640699	chr12:54070114	ATP5G2	-0.43	-4.46	-0.34	1.6e-5	Biliary atresia;
PAAD	cis	rs4906172	1.000	rs1741155	chr14:102428398	A/G	cg23904247	chr14:102554826	HSP90AA1	0.4	4.32	0.33	2.83e-5	Menopause (age at onset);
PAAD	cis	rs1499972	0.618	rs62264778	chr3:117653627	G/T	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg06307176	chr5:131281290	NA	-0.49	-4.41	-0.34	1.95e-5	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.65	7.58	0.52	3.18e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg23387468	chr7:139079360	LUC7L2	0.38	4.31	0.33	2.95e-5	Diisocyanate-induced asthma;
PAAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-4.45	-0.34	1.62e-5	Multiple sclerosis;Ankylosing spondylitis;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg13047869	chr3:10149882	C3orf24	0.56	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.79	9.25	0.6	1.93e-16	Colorectal cancer;
PAAD	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg14906510	chr12:7781169	NA	0.62	4.52	0.34	1.22e-5	HDL cholesterol levels;
PAAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12913538	0.519	rs7168691	chr15:62888952	A/T	cg09983546	chr15:62884068	NA	0.77	6.84	0.49	1.78e-10	Sleep depth;
PAAD	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.79	0.62	7.63e-18	Chronic sinus infection;
PAAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg00334542	chr7:100209784	MOSPD3	0.76	5.61	0.41	9.31e-8	Other erythrocyte phenotypes;
PAAD	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.93	-6.83	-0.48	1.91e-10	Psoriasis vulgaris;
PAAD	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.89e-5	Height;
PAAD	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.55	7.36	0.51	1.08e-11	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.66	6.75	0.48	2.91e-10	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg21724239	chr8:58056113	NA	0.67	5.17	0.39	7.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg19930314	chr7:98593876	TRRAP	-0.49	-4.65	-0.35	7.08e-6	Breast cancer;
PAAD	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	6.09e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs922692	0.715	rs11632102	chr15:79086057	G/A	cg15571903	chr15:79123663	NA	-0.41	-5.16	-0.39	7.66e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.67	0.35	6.46e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.71	5.48	0.41	1.7e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg04717802	chr22:42394638	WBP2NL	0.41	4.46	0.34	1.57e-5	Intelligence;
PAAD	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg26205652	chr12:48591994	NA	-0.64	-4.68	-0.36	6.25e-6	Lung cancer;
PAAD	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-10.57	-0.65	6.5e-20	Platelet distribution width;
PAAD	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.48	-4.45	-0.34	1.68e-5	Inflammatory bowel disease;
PAAD	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg05621596	chr22:47072043	GRAMD4	-0.93	-9.5	-0.61	4.32e-17	Urate levels in obese individuals;
PAAD	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-5.2	-0.39	6.35e-7	Coronary artery disease;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.74	6.94	0.49	1.07e-10	Cleft lip with or without cleft palate;
PAAD	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	1.01	14.17	0.75	1.34e-29	Heart rate;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18621852	chr3:10150065	C3orf24	0.66	5.77	0.42	4.38e-8	Alzheimer's disease;
PAAD	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs795484	0.963	rs1726392	chr12:118598925	A/G	cg16572268	chr12:118583242	PEBP1	-0.47	-4.6	-0.35	8.81e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.55	-5.79	-0.42	3.94e-8	Life satisfaction;
PAAD	trans	rs795484	0.963	rs1726392	chr12:118598925	A/G	cg06703803	chr12:110811045	ANAPC7	-0.59	-6.45	-0.46	1.44e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7165102	1.000	rs600193	chr15:65729409	A/G	cg22900193	chr15:65823441	PTPLAD1	-0.48	-4.56	-0.35	1.03e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg15736062	chr7:158136485	PTPRN2	0.49	4.52	0.34	1.22e-5	Calcium levels;
PAAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.7	-0.42	5.99e-8	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17808901	chr3:39093368	WDR48	0.67	7.59	0.52	3.07e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg25833597	chr17:30823145	MYO1D	0.53	5.09	0.38	1.04e-6	Schizophrenia;
PAAD	cis	rs10929159	0.928	rs6431418	chr2:236919559	C/T	cg14226755	chr2:236923322	AGAP1	0.28	4.51	0.34	1.28e-5	Parkinson's disease;
PAAD	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg26031613	chr14:104095156	KLC1	0.52	4.77	0.36	4.27e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.61	-0.35	8.57e-6	Mean corpuscular volume;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14159672	chr1:205819179	PM20D1	0.51	5.04	0.38	1.29e-6	Parkinson's disease;
PAAD	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.71	-0.48	3.59e-10	Retinal vascular caliber;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04301623	chr19:5681171	HSD11B1L;C19orf70	0.71	7.01	0.49	7.29e-11	Obesity-related traits;
PAAD	cis	rs8032158	0.963	rs16976600	chr15:56154635	C/T	cg02198044	chr15:56286336	NEDD4	-0.5	-5.22	-0.39	5.68e-7	Keloid;
PAAD	cis	rs2072883	0.646	rs4822254	chr22:43436594	G/A	cg16973406	chr22:43265991	NA	0.35	4.26	0.33	3.59e-5	Schizophrenia;
PAAD	cis	rs9392556	0.666	rs62394175	chr6:4104898	C/T	cg04447621	chr6:3849475	FAM50B	0.51	4.28	0.33	3.32e-5	Blood metabolite levels;
PAAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.77	7.25	0.51	1.96e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.09	-0.38	1.07e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.61	-5.54	-0.41	1.31e-7	White blood cell count;
PAAD	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.8	-7.13	-0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06756667	chr1:205180740	DSTYK	-0.81	-7.11	-0.5	4.29e-11	Neuroticism;
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg07068956	chr7:100330872	ZAN	-0.71	-5.37	-0.4	2.95e-7	Other erythrocyte phenotypes;
PAAD	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.48	-4.76	-0.36	4.39e-6	Bipolar disorder;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg11335335	chr11:637885	DRD4	-0.38	-5.51	-0.41	1.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.57	6.71	0.48	3.6e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.74	-7.79	-0.53	9.99e-13	Obesity-related traits;
PAAD	cis	rs300774	0.925	rs300726	chr2:132490	C/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	trans	rs901683	1.000	rs36070902	chr10:45983977	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs859767	0.709	rs7575742	chr2:135429002	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.93	11.0	0.67	4.59e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs4287000	0.802	rs10761246	chr9:96387795	C/T	cg13787134	chr9:96362102	PHF2	0.38	4.47	0.34	1.52e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.04e-15	Personality dimensions;
PAAD	cis	rs9487051	0.646	rs55677234	chr6:109621974	G/A	cg21918786	chr6:109611834	NA	-0.52	-5.54	-0.41	1.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.68	6.53	0.47	9.17e-10	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg12215294	chr3:40350768	EIF1B	-0.48	-4.77	-0.36	4.23e-6	Renal cell carcinoma;
PAAD	cis	rs13102973	0.864	rs7435952	chr4:135900983	C/T	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.36	0.6	1e-16	Parkinson's disease;
PAAD	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg01028140	chr2:1542097	TPO	-0.89	-8.05	-0.55	2.17e-13	IgG glycosylation;
PAAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.18	-0.39	6.84e-7	High light scatter reticulocyte count;
PAAD	cis	rs9283706	0.608	rs13189948	chr5:66355306	A/G	cg11590213	chr5:66331682	MAST4	0.6	4.65	0.35	7.27e-6	Coronary artery disease;
PAAD	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.43	6.73	0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	7.54	0.52	4e-12	HIV-1 control;
PAAD	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-5.52	-0.41	1.42e-7	Coronary artery disease;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	1.14	17.02	0.81	5.05e-37	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.96	-0.37	1.88e-6	Mean corpuscular volume;
PAAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.8	12.5	0.71	4.05e-25	Schizophrenia;
PAAD	cis	rs3925075	0.500	rs11645526	chr16:31268239	A/G	cg02846316	chr16:31340340	ITGAM	0.44	5.08	0.38	1.08e-6	IgA nephropathy;
PAAD	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.45	5.22	0.39	5.77e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.99	0.38	1.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg21951975	chr1:209979733	IRF6	0.57	5.33	0.4	3.55e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.59	5.93	0.43	1.97e-8	Eosinophil percentage of white cells;
PAAD	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg20060109	chr17:81052770	NA	-0.44	-4.36	-0.33	2.36e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.33	0.56	4.34e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.55	-4.78	-0.36	4.05e-6	Schizophrenia;
PAAD	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.67	5.19	0.39	6.53e-7	Alzheimer's disease (survival time);
PAAD	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg24097872	chr10:5724021	NA	0.57	4.78	0.36	4.03e-6	Childhood ear infection;
PAAD	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-6.28	-0.45	3.32e-9	Eye color traits;
PAAD	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.05e-6	Resting heart rate;
PAAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	8.01e-9	Schizophrenia;
PAAD	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.85	0.49	1.76e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.69	7.61	0.53	2.74e-12	Aortic root size;
PAAD	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.61	5.34	0.4	3.29e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.96	8.47	0.57	1.93e-14	Initial pursuit acceleration;
PAAD	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.73	-7.29	-0.51	1.59e-11	Uric acid clearance;
PAAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.73	8.34	0.56	4.27e-14	Huntington's disease progression;
PAAD	cis	rs6908034	0.607	rs34109983	chr6:19808042	G/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.56	-5.42	-0.4	2.27e-7	P wave terminal force;
PAAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg02475695	chr16:616220	NHLRC4	0.46	5.34	0.4	3.28e-7	Height;
PAAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.81	9.38	0.61	8.87e-17	Aortic root size;
PAAD	cis	rs494459	0.838	rs581045	chr11:118632522	C/T	cg08498647	chr11:118550644	TREH	-0.34	-4.25	-0.33	3.72e-5	Height;
PAAD	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.61	0.35	8.59e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-5.23	-0.39	5.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg09654669	chr8:57350985	NA	-0.56	-5.26	-0.39	4.73e-7	Obesity-related traits;
PAAD	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	6.62	0.47	5.95e-10	Body mass index;
PAAD	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.85	-9.63	-0.62	2.03e-17	Superior crus of antihelix expression;
PAAD	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.66	-0.53	2.06e-12	Migraine;Coronary artery disease;
PAAD	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg00012203	chr2:219082015	ARPC2	0.6	5.72	0.42	5.45e-8	Colorectal cancer;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27436995	chr16:743998	FBXL16	-0.37	-4.54	-0.35	1.14e-5	Height;
PAAD	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg23250157	chr14:64679961	SYNE2	0.52	5.46	0.41	1.87e-7	Atrial fibrillation;
PAAD	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06850241	chr22:41845214	NA	-0.58	-5.14	-0.38	8.27e-7	Vitiligo;
PAAD	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.81	-0.36	3.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.81	9.17	0.6	3.2e-16	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05875032	chr22:18593364	TUBA8	0.66	7.06	0.5	5.57e-11	Obesity-related traits;
PAAD	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4740619	0.716	rs1927697	chr9:15934102	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg07873178	chr11:65307616	LTBP3	0.96	4.51	0.34	1.27e-5	Height;
PAAD	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	9.94	0.63	3.1e-18	Response to antipsychotic treatment;
PAAD	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.26	-13.88	-0.75	7.95e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs6547631	0.622	rs1866141	chr2:85925386	T/C	cg24620635	chr2:85921963	GNLY	0.43	5.62	0.41	9.09e-8	Blood protein levels;
PAAD	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg22467129	chr15:76604101	ETFA	0.51	4.79	0.36	4e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02522523	chr12:113573421	RASAL1	0.64	6.43	0.46	1.56e-9	Obesity-related traits;
PAAD	cis	rs3771514	0.543	rs4852596	chr2:70681496	G/T	cg18150120	chr2:71134936	VAX2	-0.39	-4.63	-0.35	7.9e-6	Obesity-related traits;
PAAD	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.55	-4.25	-0.33	3.66e-5	Coronary artery disease;
PAAD	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.34	4.25	0.33	3.76e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg26939375	chr7:64535504	NA	0.76	8.79	0.58	2.98e-15	Aortic root size;
PAAD	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.65	0.72	1.64e-25	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs4073221	0.789	rs35407649	chr3:18231373	C/A	cg07694806	chr3:18168406	NA	-0.81	-5.06	-0.38	1.19e-6	Parkinson's disease;
PAAD	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.3e-7	Monocyte percentage of white cells;
PAAD	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.6	6.5	0.47	1.08e-9	Colorectal cancer;
PAAD	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg21775007	chr8:11205619	TDH	-0.48	-4.35	-0.33	2.45e-5	Neuroticism;
PAAD	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.69	7.67	0.53	1.9e-12	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs3112530	1.000	rs2349576	chr5:152638038	C/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.94	-5.25	-0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs58521262	0.505	rs457741	chr19:23140579	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.84	9.53	0.61	3.61e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg19761014	chr17:28927070	LRRC37B2	0.93	5.13	0.38	8.62e-7	Body mass index;
PAAD	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	5.4	0.4	2.56e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.76	-8.08	-0.55	1.89e-13	Aortic root size;
PAAD	cis	rs643506	0.874	rs1633471	chr11:111690331	A/G	cg09085632	chr11:111637200	PPP2R1B	0.52	4.44	0.34	1.73e-5	Breast cancer;
PAAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21221695	chr4:72188145	SLC4A4	-0.52	-6.45	-0.46	1.44e-9	Energy expenditure (24h);
PAAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.68	9.91	0.63	3.53e-18	Huntington's disease progression;
PAAD	cis	rs16975963	0.843	rs112628349	chr19:38268238	G/C	cg14218481	chr19:38281219	NA	0.44	4.66	0.35	6.78e-6	Longevity;
PAAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Breast cancer;
PAAD	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.49	4.39	0.34	2.07e-5	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.04	9.16	0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs780142	0.812	rs28630979	chr15:62826258	A/G	cg12918536	chr15:62891943	NA	0.37	4.43	0.34	1.76e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg17644776	chr2:200775616	C2orf69	0.67	5.4	0.4	2.54e-7	Schizophrenia;
PAAD	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs12431939	0.762	rs60616710	chr14:51704361	A/T	cg23942311	chr14:51606299	NA	-0.6	-5.0	-0.38	1.55e-6	Cancer;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg20913747	chr6:44695427	NA	-0.59	-6.59	-0.47	6.98e-10	Total body bone mineral density;
PAAD	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.46	4.42	0.34	1.87e-5	High light scatter reticulocyte count;
PAAD	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.52	-4.48	-0.34	1.47e-5	Obesity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17543425	chr5:167181519	ODZ2	-0.52	-6.66	-0.48	4.64e-10	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.38e-10	Life satisfaction;
PAAD	cis	rs1529711	0.636	rs56753835	chr19:10929150	G/C	cg16667279	chr19:11591998	ELAVL3	-0.62	-4.76	-0.36	4.54e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.82	9.17	0.6	3.18e-16	Metabolic syndrome;
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.39	-0.51	9.06e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-4.71	-0.36	5.63e-6	Coronary artery disease;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.59	6.76	0.48	2.71e-10	Mean corpuscular volume;
PAAD	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.48	6.07	0.44	9.61e-9	Crohn's disease;
PAAD	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.19e-5	Educational attainment;
PAAD	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-4.97	-0.37	1.8e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.64	6.13	0.44	7.41e-9	Asthma;
PAAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.89	-8.4	-0.56	3e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.58	6.17	0.45	6.03e-9	Lung cancer;
PAAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.63	7.11	0.5	4.34e-11	High light scatter reticulocyte count;
PAAD	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.25	-0.33	3.78e-5	Body mass index;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.61e-8	Height;
PAAD	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg02250501	chr15:90694978	NA	-0.46	-4.31	-0.33	2.87e-5	Rheumatoid arthritis;
PAAD	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.42	0.56	2.54e-14	Menopause (age at onset);
PAAD	cis	rs12304921	0.935	rs79907213	chr12:51354694	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg15309053	chr8:964076	NA	0.42	4.5	0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.77	8.39	0.56	3.2e-14	Blood metabolite levels;
PAAD	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	9.97	0.63	2.44e-18	Response to antipsychotic treatment;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg11601000	chr22:42348013	LOC339674	0.45	5.34	0.4	3.26e-7	Cognitive function;
PAAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.78	-8.9	-0.59	1.55e-15	Coronary artery disease;
PAAD	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg09127314	chr1:152161683	NA	-0.75	-5.4	-0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.35	-5.57	-0.41	1.11e-7	Urate levels in overweight individuals;
PAAD	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.56	8.21	0.55	8.82e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.93	12.27	0.71	1.75e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg13206674	chr6:150067644	NUP43	0.72	7.78	0.53	1.02e-12	Lung cancer;
PAAD	cis	rs6929137	0.666	rs6904261	chr6:151939627	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.4	-0.34	2.03e-5	Bone mineral density (spine);
PAAD	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2249694	0.878	rs2987792	chr10:135371466	T/C	cg20169779	chr10:135381914	SYCE1	0.47	4.72	0.36	5.41e-6	Obesity-related traits;
PAAD	cis	rs7567389	0.719	rs6430936	chr2:128007686	A/C	cg11380483	chr2:127933992	NA	-0.47	-4.68	-0.36	6.22e-6	Self-rated health;
PAAD	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.59e-7	Bladder cancer;
PAAD	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-6.19	-0.45	5.37e-9	Rheumatoid arthritis;
PAAD	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg21419209	chr3:44054225	NA	-0.59	-5.89	-0.43	2.42e-8	Coronary artery disease;
PAAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.75e-6	Personality dimensions;
PAAD	cis	rs9633835	0.504	rs7938308	chr11:13320533	C/T	cg15603424	chr11:13300592	ARNTL	-0.51	-4.55	-0.35	1.09e-5	Body mass index;
PAAD	cis	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.5	-4.92	-0.37	2.22e-6	Corneal structure;
PAAD	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg25482853	chr8:67687455	SGK3	1.03	7.65	0.53	2.12e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	4.33	0.33	2.7e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.42	-0.34	1.9e-5	Glomerular filtration rate;
PAAD	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg22437258	chr11:111473054	SIK2	-0.51	-4.97	-0.37	1.79e-6	Primary sclerosing cholangitis;
PAAD	cis	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21773710	chr5:180688230	TRIM52	0.62	7.23	0.51	2.23e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs61784830	0.710	rs61783251	chr1:46368087	G/C	cg22524514	chr11:65779676	CST6	1.07	7.1	0.5	4.44e-11	Iron status biomarkers (total iron binding capacity);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02610550	chr13:74708579	KLF12	-0.61	-6.65	-0.47	5.01e-10	Myopia (pathological);
PAAD	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg06585982	chr3:143692056	C3orf58	0.7	7.13	0.5	3.74e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg05315796	chr3:52349193	DNAH1	0.43	4.8	0.36	3.76e-6	Bipolar disorder;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11310125	chr2:113239311	TTL	0.54	6.37	0.46	2.09e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.53	-5.75	-0.42	4.71e-8	Coronary artery disease;
PAAD	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.49	-0.41	1.66e-7	Triglycerides;
PAAD	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg03264133	chr6:25882463	NA	0.44	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17641971	0.708	rs10957317	chr8:49888870	C/T	cg00325661	chr8:49890786	NA	-0.48	-4.91	-0.37	2.32e-6	Blood metabolite levels;
PAAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.51	-0.34	1.31e-5	Personality dimensions;
PAAD	cis	rs3112530	0.901	rs1462122	chr5:152658548	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.83	-4.44	-0.34	1.73e-5	Aging (time to event);
PAAD	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.02	0.38	1.42e-6	Aortic root size;
PAAD	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs11669133	1.000	rs11672595	chr19:11094494	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg05725404	chr16:58534157	NDRG4	-0.81	-5.12	-0.38	9.11e-7	Schizophrenia;
PAAD	cis	rs7591351	0.788	rs4952779	chr2:46060375	G/A	cg16240781	chr2:45234379	SIX2	-0.36	-4.27	-0.33	3.46e-5	Pathological gambling;
PAAD	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs11811982	0.793	rs74978094	chr1:227502659	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.72	5.36	0.4	3.05e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.87	10.63	0.65	4.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.81	-7.23	-0.51	2.23e-11	Cancer;
PAAD	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.71	6.02e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19346786	chr7:2764209	NA	-0.39	-5.32	-0.4	3.66e-7	Height;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.4	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs1570884	0.539	rs7999363	chr13:50111368	A/G	cg08779649	chr13:50194554	NA	0.34	4.25	0.33	3.65e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.97	-9.82	-0.62	6.23e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Body mass index;
PAAD	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-1.16	-7.16	-0.5	3.26e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.62	-6.29	-0.45	3.15e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs787274	1.000	rs10733594	chr9:115552630	T/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.6	5.72	0.42	5.47e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.52	4.64	0.35	7.54e-6	Systemic lupus erythematosus;
PAAD	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg10664184	chr19:17420304	DDA1	0.47	4.39	0.34	2.15e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	trans	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.59	-0.47	6.81e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7894051	0.681	rs2185747	chr10:135191460	T/G	cg24905316	chr10:135186343	ECHS1	-0.73	-4.45	-0.34	1.65e-5	Lifespan;
PAAD	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg27506609	chr1:36549197	TEKT2	0.7	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg23435118	chr5:141488016	NDFIP1	0.52	5.61	0.41	9.52e-8	Asthma;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7624766	0.743	rs7643513	chr3:160479592	T/C	cg22637730	chr3:160473554	PPM1L	0.55	4.96	0.37	1.87e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs4757319	0.537	rs10832436	chr11:15430222	A/G	cg03245590	chr11:15329459	NA	0.45	5.33	0.4	3.53e-7	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22816651	chr3:47554949	C3orf75	-0.64	-6.47	-0.46	1.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4343996	0.870	rs4443553	chr7:3378635	T/C	cg21248987	chr7:3385318	SDK1	-0.51	-5.58	-0.41	1.06e-7	Motion sickness;
PAAD	cis	rs9308433	0.553	rs1048791	chr1:214511519	T/C	cg06198575	chr1:214491504	SMYD2	0.6	5.58	0.41	1.05e-7	IgG glycosylation;
PAAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg05110241	chr16:68378359	PRMT7	-1.11	-7.76	-0.53	1.15e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg20761395	chr17:511517	VPS53	0.52	5.18	0.39	7.1e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.37	7.07	0.5	5.19e-11	Psoriasis vulgaris;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg09760422	chr2:128146352	NA	0.4	6.25	0.45	4.04e-9	Self-rated health;
PAAD	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg13263323	chr15:86062960	AKAP13	-0.62	-7.2	-0.5	2.61e-11	Coronary artery disease;
PAAD	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.77	8.24	0.56	7.64e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00864171	chr11:67383662	NA	-0.52	-5.24	-0.39	5.4e-7	Mean corpuscular volume;
PAAD	cis	rs501916	0.634	rs1561483	chr15:48069488	A/C	cg16110827	chr15:48056943	SEMA6D	-0.52	-5.57	-0.41	1.12e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs757081	0.507	rs10832727	chr11:17065289	A/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.93	-0.37	2.13e-6	Systolic blood pressure;
PAAD	cis	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.48	-0.34	1.44e-5	Eotaxin levels;
PAAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.42	-4.74	-0.36	4.84e-6	Breast cancer;
PAAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg06883089	chr1:45254480	BEST4	0.33	4.26	0.33	3.51e-5	High light scatter reticulocyte count;
PAAD	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2562456	0.833	rs11670815	chr19:21539317	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.51	-0.57	1.55e-14	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg11764359	chr7:65958608	NA	0.8	5.23	0.39	5.44e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23966214	chr17:48203188	SAMD14	0.62	6.74	0.48	3.16e-10	Smoking initiation;
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1723838	0.826	rs1792186	chr11:73571340	T/C	cg26954736	chr11:73693896	UCP2	1.04	4.61	0.35	8.51e-6	Obesity-related traits;
PAAD	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.09	-0.38	1.04e-6	Systemic lupus erythematosus;
PAAD	cis	rs6963495	0.872	rs116979167	chr7:105222451	C/A	cg19920283	chr7:105172520	RINT1	0.71	4.3	0.33	3.1e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9581857	0.615	rs61622854	chr13:28023194	T/A	cg22138327	chr13:27999177	GTF3A	0.68	4.62	0.35	8.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg00976097	chr5:421733	AHRR	-0.53	-5.08	-0.38	1.11e-6	Cystic fibrosis severity;
PAAD	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.69	8.99	0.59	9.04e-16	Hemoglobin concentration;
PAAD	cis	rs42648	0.596	rs194518	chr7:89853149	G/A	cg27367526	chr7:89841692	STEAP2	-0.32	-4.36	-0.33	2.38e-5	Homocysteine levels;
PAAD	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg10556349	chr10:835070	NA	0.56	4.77	0.36	4.21e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.37	0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.29	0.45	3.28e-9	Lung cancer;
PAAD	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.38	5.19	0.39	6.6e-7	Permanent tooth development;
PAAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.77	-8.0	-0.54	2.89e-13	Blood metabolite levels;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg07212818	chr11:638076	DRD4	-0.78	-6.84	-0.49	1.8e-10	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.75	-7.18	-0.5	2.9100000000000002e-11	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08284066	chr5:128793387	NA	0.62	7.22	0.51	2.38e-11	Smoking initiation;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.84	6.43	0.46	1.59e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-4.95	-0.37	1.96e-6	Bipolar disorder;
PAAD	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.57	-4.99	-0.38	1.61e-6	Pursuit maintenance gain;
PAAD	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg11336860	chr13:112575966	NA	-0.42	-5.73	-0.42	5.2e-8	Axial length;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.53	-6.69	-0.48	3.99e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg05895507	chr15:77155635	SCAPER	-0.39	-4.35	-0.33	2.51e-5	Blood metabolite levels;
PAAD	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.82	10.38	0.64	2.02e-19	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg26031613	chr14:104095156	KLC1	-0.47	-5.2	-0.39	6.24e-7	Schizophrenia;
PAAD	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.79	-0.42	3.96e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12582317	chr17:55822272	NA	0.71	8.68	0.58	5.55e-15	Schizophrenia;
PAAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.64	-7.16	-0.5	3.17e-11	Type 2 diabetes;
PAAD	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg24053715	chr22:38214548	NA	0.59	5.44	0.4	2.09e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	1.04	8.1	0.55	1.66e-13	IgG glycosylation;
PAAD	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg04265051	chr11:68079686	LRP5	0.37	4.57	0.35	9.96e-6	Mean corpuscular volume;
PAAD	cis	rs988913	0.958	rs1503140	chr6:54810766	A/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.59	-0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs2114646	1.000	rs2114646	chr2:170624221	C/T	cg17598339	chr2:170624727	NA	0.51	4.5	0.34	1.35e-5	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.27	0.39	4.54e-7	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.35	0.51	1.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg19680485	chr15:31195859	MTMR15	-0.48	-4.86	-0.37	2.94e-6	Huntington's disease progression;
PAAD	cis	rs12760731	0.565	rs12037925	chr1:178160268	C/T	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs2514805	0.568	rs2513784	chr8:95126478	T/C	cg25183890	chr8:94929275	PDP1	0.67	4.75	0.36	4.66e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.49	-5.37	-0.4	2.92e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs12311304	0.965	rs12307666	chr12:15388204	A/G	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.86e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs75757892	0.544	rs56027081	chr6:7318149	A/G	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs2864527	0.522	rs72939227	chr18:9249117	G/A	cg07372824	chr18:9017748	NA	-0.56	-4.53	-0.34	1.21e-5	Dental caries;
PAAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.86	0.37	2.85e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3026101	0.671	rs1065482	chr17:5284719	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.62	0.42	8.72e-8	Body mass index;
PAAD	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.72	0.77	4.64e-31	Chronic sinus infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27100511	chr14:105927968	MTA1	-0.62	-7.14	-0.5	3.51e-11	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05774229	chr11:76033097	NA	0.56	6.63	0.47	5.62e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs941898	0.781	rs2146026	chr14:100581068	A/G	cg26002632	chr14:100625216	DEGS2	-0.36	-4.89	-0.37	2.58e-6	White matter hyperintensity burden;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27595580	chr7:117828179	NAA38	-0.51	-7.01	-0.49	7.19e-11	Energy expenditure (24h);
PAAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.07	-0.44	9.81e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg21724239	chr8:58056113	NA	0.72	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg21479132	chr6:26055353	NA	0.98	5.51	0.41	1.53e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.92e-6	Iron status biomarkers;
PAAD	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg20893579	chr22:38215064	NA	-0.46	-4.62	-0.35	7.98e-6	Glioblastoma;Glioma;
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.55	-4.94	-0.37	2e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.72	-5.23	-0.39	5.57e-7	Major depressive disorder;
PAAD	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.93	0.37	2.13e-6	Myopia (pathological);
PAAD	cis	rs9463078	0.774	rs7740083	chr6:45274742	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.32	-0.4	3.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.39	0.56	3.03e-14	Dupuytren's disease;
PAAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	1.0	15.75	0.79	9.29e-34	Height;
PAAD	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	7.32	0.51	1.34e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.48	-4.84	-0.37	3.13e-6	Blood metabolite levels;
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00864171	chr11:67383662	NA	0.6	6.29	0.45	3.17e-9	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16595246	chr2:48009933	MSH6	-0.56	-6.41	-0.46	1.72e-9	Body fat percentage;
PAAD	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-4.96	-0.37	1.91e-6	Cervical cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04109349	chr1:245317172	KIF26B	0.64	7.33	0.51	1.3e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.52	-0.41	1.45e-7	Chronic sinus infection;
PAAD	cis	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.52	-0.41	1.42e-7	HDL cholesterol;
PAAD	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.62	-6.91	-0.49	1.23e-10	Monocyte count;
PAAD	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.38	4.8	0.36	3.8e-6	Prostate cancer;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-5.6	-0.41	9.98e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs151997	0.671	rs3991902	chr5:50203749	A/T	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs4704187	0.617	rs12656177	chr5:74354422	G/A	cg03227963	chr5:74354835	NA	0.5	4.83	0.36	3.36e-6	Response to amphetamines;
PAAD	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06002616	chr8:101225028	SPAG1	0.46	5.4	0.4	2.54e-7	Atrioventricular conduction;
PAAD	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg06599209	chr2:1746509	PXDN	-0.27	-4.44	-0.34	1.72e-5	Response to antipsychotic treatment;
PAAD	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	1.07	9.33	0.6	1.17e-16	Orofacial clefts;
PAAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg14343924	chr8:8086146	FLJ10661	-0.54	-4.42	-0.34	1.86e-5	Systolic blood pressure;
PAAD	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg26138144	chr22:38071188	LGALS1	0.39	4.51	0.34	1.32e-5	Fat distribution (HIV);
PAAD	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-1.15	-4.89	-0.37	2.54e-6	Breast cancer;
PAAD	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	8.01	0.54	2.8e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.75	5.97	0.44	1.57e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72960926	0.744	rs9359077	chr6:74982166	T/C	cg03266952	chr6:74778945	NA	-0.93	-5.73	-0.42	5.1e-8	Metabolite levels (MHPG);
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.67	8.06	0.55	2.04e-13	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg20243544	chr17:37824526	PNMT	-0.54	-4.67	-0.35	6.45e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg01448562	chr3:133502909	NA	-0.48	-4.89	-0.37	2.49e-6	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06355830	chr22:20104768	TRMT2A;RANBP1	-0.65	-7.16	-0.5	3.28e-11	Smoking initiation;
PAAD	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.83	-0.48	1.93e-10	Retinal vascular caliber;
PAAD	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg09163369	chr1:210001066	C1orf107	0.71	6.75	0.48	2.99e-10	Orofacial clefts;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21974750	chr19:55794478	BRSK1	-0.57	-6.55	-0.47	8.45e-10	Monocyte percentage of white cells;
PAAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-4.36	-0.33	2.42e-5	Tonsillectomy;
PAAD	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.12	0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg09659197	chr4:152720779	NA	-0.47	-6.53	-0.47	9.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg22134325	chr11:66188745	NPAS4	0.38	4.4	0.34	2.06e-5	Airway imaging phenotypes;
PAAD	cis	rs10850408	0.768	rs7961916	chr12:115355126	C/A	cg05726002	chr12:115341178	NA	-0.4	-4.83	-0.37	3.25e-6	Alzheimer's disease;
PAAD	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg03934865	chr2:198174659	NA	-0.45	-4.56	-0.35	1.02e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg18898632	chr2:242989856	NA	-0.8	-5.69	-0.42	6.32e-8	Obesity-related traits;
PAAD	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg14459158	chr9:96720562	NA	0.35	4.59	0.35	9.24e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2117029	0.586	rs10875931	chr12:49573296	G/A	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.49	5.03	0.38	1.39e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.81	-0.36	3.57e-6	Lung cancer;
PAAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg00080972	chr5:178986291	RUFY1	-0.49	-4.69	-0.36	6.03e-6	Lung cancer;
PAAD	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.71	0.48	3.55e-10	Height;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg08219700	chr8:58056026	NA	0.71	5.33	0.4	3.42e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3925075	0.515	rs4459557	chr16:31361643	G/C	cg02846316	chr16:31340340	ITGAM	0.43	5.05	0.38	1.25e-6	IgA nephropathy;
PAAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg09835421	chr16:68378352	PRMT7	-0.86	-6.92	-0.49	1.19e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.55	4.26	0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg23250157	chr14:64679961	SYNE2	0.53	5.36	0.4	3.09e-7	Atrial fibrillation;
PAAD	cis	rs367943	0.637	rs6891711	chr5:113009026	G/T	cg12552261	chr5:112820674	MCC	-0.58	-5.88	-0.43	2.54e-8	Type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs11955175	1.000	rs111310950	chr5:40641951	G/T	cg17351974	chr5:40835760	RPL37	0.81	4.7	0.36	5.85e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg05338066	chr1:7812865	CAMTA1	0.47	4.27	0.33	3.39e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.91	-0.37	2.37e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3096490	0.765	rs3096510	chr4:109947316	G/A	cg08760493	chr4:109994039	COL25A1	0.39	4.39	0.34	2.15e-5	Body mass index;
PAAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	-0.7	-4.93	-0.37	2.11e-6	Lung cancer in ever smokers;
PAAD	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.64	0.35	7.5e-6	Breast cancer;
PAAD	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.59	4.33	0.33	2.7e-5	Bipolar disorder;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg26939375	chr7:64535504	NA	0.61	6.47	0.46	1.25e-9	Calcium levels;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.6	-6.58	-0.47	7.01e-10	Tonsillectomy;
PAAD	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg20611126	chr15:45927050	SQRDL	0.63	6.86	0.49	1.65e-10	Smoking initiation;
PAAD	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.8	8.52	0.57	1.46e-14	Prostate cancer;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Electroencephalogram traits;
PAAD	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.78	9.31	0.6	1.37e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.86	10.15	0.64	8.58e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg18279126	chr7:2041391	MAD1L1	0.53	5.21	0.39	6.12e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62229266	0.659	rs2026259	chr21:37430627	A/G	cg12218747	chr21:37451666	NA	-0.49	-5.44	-0.4	2.1e-7	Mitral valve prolapse;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22097599	chr2:70934701	ADD2	0.58	6.39	0.46	1.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg00490450	chr3:139108681	COPB2	-0.63	-5.55	-0.41	1.21e-7	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.64	-0.42	8.15e-8	Lung cancer;
PAAD	cis	rs4886755	0.967	rs12440225	chr15:76313121	G/A	cg11595411	chr15:76351713	C15orf27	-0.47	-4.39	-0.34	2.1e-5	Urate levels in obese individuals;
PAAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg00579200	chr11:133705235	NA	0.44	4.7	0.36	5.72e-6	Childhood ear infection;
PAAD	cis	rs9372149	0.508	rs9372154	chr6:107493984	T/C	cg26808436	chr6:108492696	NR2E1	0.31	4.36	0.33	2.35e-5	Childhood and early adolescence aggressive behavior;
PAAD	cis	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg27395922	chr11:50257633	LOC441601	-0.42	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.71	8.93	0.59	1.32e-15	Dupuytren's disease;
PAAD	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg10281770	chr17:80606947	WDR45L	0.88	10.75	0.66	2.05e-20	Breast cancer;
PAAD	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs1997066	0.831	rs73344338	chr10:106829842	A/C	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.59	-7.05	-0.5	5.8e-11	Pubertal anthropometrics;
PAAD	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.91	-0.49	1.24e-10	Neuroticism;
PAAD	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg26939375	chr7:64535504	NA	0.8	9.5	0.61	4.36e-17	Aortic root size;
PAAD	cis	rs72627123	1.000	rs72627124	chr14:74369128	A/G	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.58	-5.27	-0.39	4.58e-7	Primary biliary cholangitis;
PAAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2001970	1.000	rs8051023	chr16:55250351	T/C	cg06138439	chr16:54973128	NA	0.27	4.26	0.33	3.5e-5	Visceral fat;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.62	5.14	0.38	8.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs901683	0.850	rs76040096	chr10:46094626	C/T	cg12869334	chr8:37699360	GPR124	1.07	7.26	0.51	1.91e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.73	-0.48	3.22e-10	Lung cancer;
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09596239	chr2:130940036	SMPD4;FAM128B	-0.55	-6.35	-0.46	2.39e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14119001	chr9:139324193	INPP5E	-0.54	-4.75	-0.36	4.63e-6	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.26e-8	Alcohol dependence;
PAAD	cis	rs9810890	1.000	rs73198862	chr3:128524945	C/T	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14252954	chr1:114889371	NA	0.59	6.65	0.47	4.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3106136	0.564	rs60428594	chr4:95103466	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.68	-6.14	-0.45	6.81e-9	Capecitabine sensitivity;
PAAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.41	-0.34	1.93e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.44	-4.58	-0.35	9.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-6.04	-0.44	1.12e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.52	-5.41	-0.4	2.44e-7	Height;
PAAD	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs2221894	0.922	rs7837237	chr8:28876221	T/C	cg20212339	chr8:28908912	HMBOX1	-0.5	-5.22	-0.39	5.71e-7	Obesity-related traits;
PAAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-4.59	-0.35	9.41e-6	Height;
PAAD	trans	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg24842760	chr6:133561719	EYA4	-0.88	-6.65	-0.47	4.93e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg22338127	chr1:209979572	IRF6	0.54	4.36	0.33	2.35e-5	Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05025164	chr4:1340916	KIAA1530	-0.54	-5.29	-0.39	4.1e-7	Obesity-related traits;
PAAD	cis	rs6908034	0.607	rs73376681	chr6:19808175	A/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9815354	0.951	rs9817510	chr3:41813108	C/T	cg03022575	chr3:42003672	ULK4	0.77	5.71	0.42	5.8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.95	7.65	0.53	2.13e-12	Triglycerides;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.83	9.08	0.59	5.3e-16	Prostate cancer;
PAAD	cis	rs3136441	0.892	rs11606992	chr11:46931941	A/T	cg19486271	chr11:47235900	DDB2	0.66	5.06	0.38	1.19e-6	HDL cholesterol;
PAAD	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.6	7.15	0.5	3.41e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs7624766	0.555	rs2049215	chr3:160512424	C/A	cg22637730	chr3:160473554	PPM1L	0.53	4.58	0.35	9.59e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14106250	chr13:77600956	FBXL3	-0.66	-6.84	-0.49	1.83e-10	Smoking initiation;
PAAD	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg23912435	chr1:150601613	ENSA	0.5	4.65	0.35	7.24e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02359409	chr6:42947317	PEX6	-0.52	-5.25	-0.39	5.02e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.68	-6.1	-0.44	8.31e-9	Mortality in heart failure;
PAAD	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.52	4.62	0.35	8.3e-6	Corneal astigmatism;
PAAD	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.04	-0.38	1.3e-6	Bipolar disorder;
PAAD	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.08	-0.55	1.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg15847926	chr7:2749597	AMZ1	-0.38	-4.53	-0.34	1.18e-5	Height;
PAAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-5.18	-0.39	6.87e-7	Mean platelet volume;
PAAD	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg01851573	chr8:8652454	MFHAS1	0.6	4.67	0.35	6.5e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.66	-0.42	7.34e-8	Schizophrenia;
PAAD	cis	rs2997447	0.761	rs17163588	chr1:26450009	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg21922841	chr17:72744131	SLC9A3R1	0.43	5.35	0.4	3.19e-7	Monocyte count;
PAAD	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	7.24	0.51	2.05e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4234284	0.501	rs2358559	chr3:127046788	A/G	cg25436886	chr3:127056972	NA	0.34	4.56	0.35	1.07e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.97	13.45	0.74	1.19e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Electroencephalogram traits;
PAAD	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.71	-0.36	5.52e-6	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03655940	chr16:15737228	MIR484;NDE1;KIAA0430	0.67	6.7	0.48	3.88e-10	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.41	0.34	1.96e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.61	-8.06	-0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1018697	1.000	rs7088711	chr10:104559266	A/G	cg04362960	chr10:104952993	NT5C2	-0.6	-6.16	-0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs12282928	0.959	rs1158897	chr11:48273340	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.22	-0.45	4.61e-9	Migraine - clinic-based;
PAAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.87	11.7	0.69	6.04e-23	Vitiligo;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.19	-0.64	6.49e-19	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1468333	0.592	rs217272	chr5:137486426	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	4.95	0.37	1.99e-6	Resting heart rate;
PAAD	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-6.33	-0.46	2.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.49	-0.34	1.4e-5	Mood instability;
PAAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-1.01	-7.11	-0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-4.81	-0.36	3.58e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg00105475	chr2:10696890	NA	-0.64	-7.16	-0.5	3.24e-11	Prostate cancer;
PAAD	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg01426195	chr3:39028469	NA	0.72	6.68	0.48	4.34e-10	Handedness;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs7105860	1	rs7105860	chr11:27306364	G/C	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs6693295	0.877	rs2787970	chr1:246231670	T/C	cg26013412	chr1:247094486	AHCTF1	-0.66	-4.65	-0.35	7.2e-6	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs78761021	0.720	rs874306	chr17:9797994	G/A	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs9567406	1.000	rs9567405	chr13:44876010	G/A	cg08635097	chr13:44833857	NA	-0.64	-4.36	-0.33	2.36e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.37	-4.39	-0.34	2.13e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.75	-9.27	-0.6	1.71e-16	Prudent dietary pattern;
PAAD	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg08501292	chr6:25962987	TRIM38	0.77	4.36	0.33	2.34e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.68	9.05	0.59	6.29e-16	Hemoglobin concentration;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs2133450	0.712	rs1546236	chr3:7366676	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10181419	chr2:264120	ACP1;SH3YL1	0.63	6.65	0.47	4.84e-10	Myopia (pathological);
PAAD	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.47	-0.41	1.78e-7	Monocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.6	0.57	8.94e-15	Menopause (age at onset);
PAAD	cis	rs2010672	0.500	rs4261511	chr15:91151276	C/G	cg15547629	chr15:90437138	AP3S2	-0.52	-4.43	-0.34	1.76e-5	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs5756391	0.782	rs4821557	chr22:37299499	A/G	cg16356956	chr22:37317934	CSF2RB	0.37	4.64	0.35	7.62e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg17385448	chr1:15911702	AGMAT	0.39	4.73	0.36	5.13e-6	Systolic blood pressure;
PAAD	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.75	-0.36	4.72e-6	Height;
PAAD	cis	rs16975963	0.843	rs241955	chr19:38278677	A/G	cg25793785	chr19:38281423	NA	0.58	4.89	0.37	2.52e-6	Longevity;
PAAD	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg02631450	chr22:32366979	NA	0.95	5.24	0.39	5.34e-7	Childhood ear infection;
PAAD	cis	rs793571	0.876	rs4774315	chr15:59202598	G/T	cg08898775	chr15:59042684	ADAM10	-0.38	-4.37	-0.33	2.27e-5	Schizophrenia;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg22903657	chr4:1355424	KIAA1530	0.44	4.54	0.35	1.15e-5	Obesity-related traits;
PAAD	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.23	-0.51	2.19e-11	Total cholesterol levels;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07234876	chr8:600039	NA	-1.06	-6.79	-0.48	2.31e-10	IgG glycosylation;
PAAD	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.52	-5.25	-0.39	4.97e-7	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.65	0.35	7.16e-6	Lung cancer;
PAAD	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg11262906	chr1:85462892	MCOLN2	0.65	4.99	0.37	1.65e-6	Serum sulfate level;
PAAD	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.63	7.24	0.51	2.13e-11	Testicular germ cell tumor;
PAAD	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.77	7.66	0.53	2.01e-12	Response to diuretic therapy;
PAAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24729792	chr2:113192114	RGPD8;RGPD5	0.57	4.68	0.36	6.18e-6	Yeast infection;
PAAD	cis	rs501120	0.810	rs473501	chr10:44749171	G/A	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg22916017	chr11:64110731	CCDC88B	-0.4	-4.7	-0.36	5.74e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	4.98	0.37	1.74e-6	Height;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg17328964	chr8:145687451	CYHR1	0.53	5.55	0.41	1.21e-7	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-7.36	-0.51	1.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.72e-6	Oral cavity cancer;
PAAD	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.49	-4.5	-0.34	1.32e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg14926445	chr8:58193284	C8orf71	0.61	4.66	0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.51	-5.39	-0.4	2.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9039	0.959	rs12925781	chr16:9216914	A/G	cg08831531	chr16:9218945	NA	0.6	6.03	0.44	1.2e-8	Menopause (age at onset);
PAAD	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.76	6.54	0.47	8.72e-10	Schizophrenia;
PAAD	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.69	7.7	0.53	1.59e-12	Schizophrenia;
PAAD	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg12369402	chr1:90227771	NA	-0.45	-4.48	-0.34	1.45e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.62	4.57	0.35	1.01e-5	Vitiligo;
PAAD	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.72	8.13	0.55	1.37e-13	Morning vs. evening chronotype;
PAAD	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.53	4.41	0.34	1.93e-5	Red blood cell count;
PAAD	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg05555928	chr11:63887634	MACROD1	-0.72	-5.65	-0.42	7.66e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs11168618	0.703	rs4760721	chr12:48925724	A/C	cg01881778	chr12:48919444	OR8S1	-0.51	-5.56	-0.41	1.2e-7	Adiponectin levels;
PAAD	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.47	-7.15	-0.5	3.4e-11	Cutaneous nevi;
PAAD	cis	rs2422052	0.566	rs13428113	chr2:118846885	T/C	cg22545206	chr2:118617499	NA	0.46	4.88	0.37	2.62e-6	Mosquito bite size;
PAAD	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs57024841	0.756	rs7040970	chr9:139859013	T/C	cg00693599	chr9:139836323	FBXW5	-0.49	-4.64	-0.35	7.6e-6	Beta-trace protein levels;
PAAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg19413350	chr8:57351067	NA	0.48	4.52	0.34	1.24e-5	Obesity-related traits;
PAAD	cis	rs2839627	0.683	rs6586259	chr21:44315266	G/A	cg03543861	chr21:44258195	NA	0.65	4.75	0.36	4.7e-6	Information processing speed;
PAAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.69	-0.36	6.05e-6	Type 2 diabetes;
PAAD	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.79	-8.64	-0.57	7.22e-15	Morning vs. evening chronotype;
PAAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg22549504	chr19:17448937	GTPBP3	0.55	4.27	0.33	3.46e-5	Systemic lupus erythematosus;
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02296904	chr4:877321	GAK	-0.61	-6.45	-0.46	1.42e-9	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs350729	0.503	rs2082175	chr2:53176540	C/T	cg07782112	chr2:53107842	NA	-0.39	-4.82	-0.36	3.48e-6	Bronchodilator response in asthma;
PAAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg19257562	chr1:2043853	PRKCZ	0.42	5.02	0.38	1.45e-6	Height;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs6421571	0.565	rs10892263	chr11:118587319	T/C	cg04176122	chr11:118779835	BCL9L	0.39	4.36	0.33	2.42e-5	Primary biliary cholangitis;
PAAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg23281280	chr6:28129359	ZNF389	0.52	4.63	0.35	7.7e-6	Parkinson's disease;
PAAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.67	-0.35	6.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg22815214	chr1:201083145	CACNA1S	-0.52	-4.27	-0.33	3.47e-5	Permanent tooth development;
PAAD	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.88	-0.37	2.67e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.59	-5.83	-0.43	3.14e-8	Rheumatoid arthritis;
PAAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-6.0	-0.44	1.4e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4343996	0.902	rs4722693	chr7:3374312	C/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.15	-0.39	7.95e-7	Motion sickness;
PAAD	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.69	-0.36	6.15e-6	Menarche (age at onset);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg21943376	chr11:118800953	NA	-0.58	-6.36	-0.46	2.24e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11024102	1.000	rs11024102	chr11:17008605	T/C	cg15084286	chr11:17036142	PLEKHA7	0.51	4.68	0.36	6.25e-6	Glaucoma (primary angle closure);
PAAD	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.88	10.51	0.65	8.99e-20	Metabolic syndrome;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.58	-5.92	-0.43	2.02e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg27478167	chr7:817139	HEATR2	-0.6	-4.78	-0.36	4.17e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11563648	0.535	rs6962137	chr7:127026342	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-6.99	-0.49	7.93e-11	Longevity;Endometriosis;
PAAD	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg21479132	chr6:26055353	NA	0.98	5.87	0.43	2.61e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6942407	0.546	rs6465093	chr7:86764877	G/A	cg02420886	chr7:86849541	C7orf23	0.59	4.61	0.35	8.46e-6	Food allergy;
PAAD	cis	rs17135859	1.000	rs2195374	chr5:112998733	G/A	cg12552261	chr5:112820674	MCC	0.66	4.36	0.33	2.38e-5	F-cell distribution;
PAAD	cis	rs6679454	0.801	rs61770276	chr1:58334322	T/C	cg17491850	chr1:57888480	DAB1	-0.39	-4.34	-0.33	2.56e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg11494091	chr17:61959527	GH2	0.53	4.45	0.34	1.67e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3996993	0.724	rs1009063	chr6:52623505	T/A	cg00536792	chr6:53530503	KLHL31	0.47	4.93	0.37	2.15e-6	Hemoglobin concentration;
PAAD	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg25730555	chr22:47059586	GRAMD4	0.46	4.47	0.34	1.52e-5	Urate levels in obese individuals;
PAAD	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06634786	chr22:41940651	POLR3H	0.67	5.1	0.38	1.01e-6	Vitiligo;
PAAD	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.01	-0.44	1.34e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6460942	0.908	rs6978857	chr7:12232665	A/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs6988985	0.678	rs28571827	chr8:144003207	G/A	cg10324643	chr8:143916377	GML	0.42	4.68	0.35	6.27e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.66	-0.48	4.69e-10	Triglycerides;
PAAD	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.94	7.79	0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.66	6.81	0.48	2.13e-10	Orofacial clefts;
PAAD	cis	rs62264129	0.500	rs56294743	chr3:112028863	G/A	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.25	-0.33	3.72e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.6	-5.71	-0.42	5.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.52	5.2	0.39	6.33e-7	Mean corpuscular volume;
PAAD	cis	rs113779084	0.690	rs13247118	chr7:11983362	C/T	cg24676244	chr7:11872050	THSD7A	0.37	4.25	0.33	3.71e-5	Educational attainment (years of education);
PAAD	cis	rs16975963	0.843	rs11083442	chr19:38427528	C/A	cg08679971	chr19:38281047	NA	0.56	5.36	0.4	3.07e-7	Longevity;
PAAD	cis	rs2075671	0.818	rs10953303	chr7:100365613	G/T	cg00334542	chr7:100209784	MOSPD3	-0.63	-4.58	-0.35	9.68e-6	Other erythrocyte phenotypes;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg19337854	chr7:99768885	GPC2	0.53	4.88	0.37	2.63e-6	Lung function (FEV1/FVC);
PAAD	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.47	0.41	1.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg14345882	chr6:26364793	BTN3A2	0.38	4.38	0.33	2.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg05110241	chr16:68378359	PRMT7	-1.08	-7.73	-0.53	1.35e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23463467	chr20:60627584	TAF4	0.41	4.35	0.33	2.51e-5	Body mass index;
PAAD	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg13944838	chr5:179740914	GFPT2	-0.76	-7.66	-0.53	2.07e-12	Height;
PAAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg25309567	chr17:79516362	C17orf70	-0.42	-4.25	-0.33	3.72e-5	Eye color traits;
PAAD	cis	rs800160	0.582	rs2521286	chr11:2341971	G/A	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.5	-0.34	1.33e-5	Bacteremia;
PAAD	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19374947	chr2:264754	SH3YL1;ACP1	-0.65	-6.61	-0.47	6.22e-10	Smoking initiation;
PAAD	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	6.1	0.44	8.58e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.41	5.25	0.39	5.12e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.4	-0.4	2.52e-7	Subjective well-being;
PAAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg04025307	chr7:1156635	C7orf50	0.64	4.3	0.33	3.06e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.51	-4.85	-0.37	3.08e-6	Mean platelet volume;
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg24154853	chr7:158122151	PTPRN2	0.79	7.37	0.51	1.03e-11	Response to amphetamines;
PAAD	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.92	-12.38	-0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-4.65	-0.35	7.09e-6	Mood instability;
PAAD	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.61	-6.17	-0.45	6.01e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg19760965	chr3:194868843	C3orf21	0.45	4.69	0.36	5.95e-6	Non-small cell lung cancer;
PAAD	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-4.72	-0.36	5.35e-6	Post bronchodilator FEV1;
PAAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-5.38	-0.4	2.79e-7	Schizophrenia;
PAAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg25452165	chr22:42524984	CYP2D6	0.51	4.93	0.37	2.15e-6	Schizophrenia;
PAAD	cis	rs4742903	0.904	rs1507512	chr9:107004948	A/G	cg14250997	chr9:106856677	SMC2	0.44	4.8	0.36	3.81e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg00166722	chr3:10149974	C3orf24	0.71	6.34	0.46	2.5e-9	Alzheimer's disease;
PAAD	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg09659197	chr4:152720779	NA	0.42	5.51	0.41	1.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.83	-0.37	3.25e-6	Height;
PAAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.84	0.37	3.17e-6	Breast cancer;
PAAD	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs62264129	0.500	rs62278765	chr3:112024739	A/G	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.8	-0.36	3.83e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.59	4.97	0.37	1.78e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg21479132	chr6:26055353	NA	-0.81	-4.5	-0.34	1.32e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg06740227	chr12:86229804	RASSF9	0.52	4.61	0.35	8.57e-6	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17827632	chr1:161087992	PFDN2;NIT1	0.57	6.52	0.47	9.95e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06217245	chr20:33103252	DYNLRB1	0.4	4.83	0.36	3.35e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.48	-0.34	1.44e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12760731	0.565	rs7541122	chr1:178199214	G/C	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18878441	chr2:81694367	NA	0.63	6.8	0.48	2.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07402062	chr16:89894098	SPIRE2	0.39	4.83	0.36	3.26e-6	Vitiligo;
PAAD	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.49	-5.15	-0.39	8.13e-7	Type 2 diabetes;
PAAD	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.63	5.97	0.44	1.58e-8	Colorectal cancer;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.7	-0.48	3.86e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg07856975	chr6:36356162	ETV7	0.57	6.42	0.46	1.64e-9	Platelet distribution width;
PAAD	cis	rs2415984	0.622	rs55833034	chr14:46825055	C/A	cg14871534	chr14:47121158	RPL10L	-0.5	-5.64	-0.42	8.15e-8	Number of children ever born;
PAAD	cis	rs17002988	0.568	rs2867008	chr4:79084236	A/C	cg07442568	chr4:78980533	FRAS1	0.67	5.53	0.41	1.4e-7	Uric acid levels;
PAAD	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.45	0.4	2.03e-7	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg02631450	chr22:32366979	NA	1.07	5.76	0.42	4.59e-8	Childhood ear infection;
PAAD	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.6	0.47	6.5e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.8	-5.68	-0.42	6.53e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11696501	0.688	rs6073861	chr20:44325708	G/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs4150161	1.000	rs4150161	chr16:84214236	T/C	cg10106505	chr16:84220380	TAF1C	-0.8	-4.83	-0.36	3.27e-6	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	trans	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg00717180	chr2:96193071	NA	-0.62	-7.2	-0.5	2.61e-11	Height;
PAAD	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg01528321	chr10:82214614	TSPAN14	0.68	6.05	0.44	1.06e-8	Post bronchodilator FEV1;
PAAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.47	0.41	1.85e-7	Menarche (age at onset);
PAAD	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.55	4.84	0.37	3.1e-6	Menopause (age at onset);
PAAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	9.32	0.6	1.25e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.99	-0.38	1.6e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs731174	0.559	rs66536721	chr1:38195582	A/G	cg06917450	chr1:38156652	C1orf109	-0.59	-5.03	-0.38	1.39e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.67	-6.44	-0.46	1.46e-9	Refractive astigmatism;
PAAD	cis	rs1371614	0.523	rs12468761	chr2:27183793	G/A	cg00617064	chr2:27272375	NA	0.5	5.23	0.39	5.45e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg27121462	chr16:89883253	FANCA	0.78	4.63	0.35	7.65e-6	Skin colour saturation;
PAAD	cis	rs6785206	0.554	rs76550538	chr3:128530709	G/T	cg19205850	chr3:128446370	RAB7A	0.76	5.43	0.4	2.17e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs1371614	0.611	rs4665922	chr2:27133934	G/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	6.52	0.47	9.92e-10	Adiposity;
PAAD	cis	rs7011049	1.000	rs72648403	chr8:53854848	T/C	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-4.88	-0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs4356203	0.905	rs11821773	chr11:17117354	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.45	-0.34	1.66e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	4.84	0.37	3.16e-6	Bone mineral density;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18765753	chr7:1198926	ZFAND2A	-0.54	-4.4	-0.34	2.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg02463844	chr16:88152170	NA	-0.3	-5.27	-0.39	4.61e-7	Menopause (age at onset);
PAAD	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Breast cancer;
PAAD	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-8.99	-0.59	8.97e-16	Type 2 diabetes;
PAAD	cis	rs516243	0.715	rs498504	chr1:10739372	A/C	cg02903756	chr1:10750680	CASZ1	-0.43	-4.64	-0.35	7.32e-6	Migraine - clinic-based;
PAAD	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.85	7.18	0.5	2.89e-11	Bipolar disorder;
PAAD	cis	rs6908034	0.547	rs78296116	chr6:19756305	C/A	cg02682789	chr6:19804855	NA	0.79	4.35	0.33	2.46e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg04160749	chr8:58172571	NA	-0.59	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg27411982	chr8:10470053	RP1L1	0.42	4.41	0.34	1.95e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.4	0.51	8.5e-12	Alzheimer's disease;
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.37	-0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg02645295	chr12:52705424	NA	-0.5	-4.78	-0.36	4.11e-6	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.78	-7.09	-0.5	4.84e-11	Systemic lupus erythematosus;
PAAD	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.3	0.64	3.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg02795151	chr17:7402630	POLR2A	0.63	5.58	0.41	1.05e-7	Androgen levels;
PAAD	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg17326555	chr1:119535693	NA	-0.35	-4.37	-0.33	2.24e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.54	4.59	0.35	9.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg17346650	chr17:80929145	B3GNTL1	0.43	5.16	0.39	7.61e-7	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	4.81	0.36	3.55e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.3	-0.39	4.1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	1.41	7.39	0.51	9.27e-12	Prostate cancer;
PAAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.57	-0.35	1.02e-5	Major depressive disorder;
PAAD	cis	rs11037575	0.739	rs4359199	chr11:43721500	T/C	cg24662154	chr11:44118094	EXT2	-0.42	-4.37	-0.33	2.33e-5	Neuroblastoma;
PAAD	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg12633918	chr20:23549525	CST9L	-0.42	-4.63	-0.35	7.63e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg17372657	chr7:1216933	NA	-0.35	-4.3	-0.33	3.03e-5	Longevity;Endometriosis;
PAAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.51	5.13	0.38	8.73e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg09659197	chr4:152720779	NA	-0.38	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-6.55	-0.47	8.32e-10	Vitiligo;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.86	7.17	0.5	3.03e-11	Alzheimer's disease;
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg16926213	chr1:1841314	NA	-0.36	-4.52	-0.34	1.25e-5	Body mass index;
PAAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg10494973	chr17:80897199	TBCD	-0.58	-4.79	-0.36	3.95e-6	Breast cancer;
PAAD	cis	rs7081476	0.737	rs12415447	chr10:27488884	A/G	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs2017305	0.834	rs12250707	chr10:70779436	C/T	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.37	-0.4	2.83e-7	Depression (quantitative trait);
PAAD	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.52	0.47	9.87e-10	Response to antipsychotic treatment;
PAAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs4704187	0.687	rs1363579	chr5:74510353	G/T	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.67	-7.3	-0.51	1.47e-11	Blood metabolite levels;
PAAD	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.75	7.08	0.5	5.01e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs3790455	0.610	rs1171563	chr1:156456529	T/G	cg14087168	chr1:156450669	MEF2D	-0.39	-4.3	-0.33	3.03e-5	Migraine;
PAAD	cis	rs7102705	0.531	rs56040001	chr11:69139986	A/G	cg22842048	chr11:68773591	MRGPRF	0.65	4.74	0.36	4.78e-6	Breast size;
PAAD	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	1.01	6.87	0.49	1.54e-10	Prostate cancer;
PAAD	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.53e-6	Life satisfaction;
PAAD	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02884024	chr20:58515388	C20orf177;PPP1R3D	-0.76	-6.73	-0.48	3.28e-10	Neuroticism;
PAAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-13.55	-0.74	6.24e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs732765	0.689	rs10139925	chr14:75123076	C/T	cg17347104	chr14:75034677	LTBP2	0.55	4.74	0.36	4.94e-6	Non-small cell lung cancer;
PAAD	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs4704187	0.687	rs1477937	chr5:74524837	A/G	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.14	0.38	8.45e-7	Menarche (age at onset);
PAAD	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.63	-5.85	-0.43	2.88e-8	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs7301016	0.948	rs10877870	chr12:62923955	A/G	cg11441379	chr12:63026424	NA	0.84	6.07	0.44	9.66e-9	IgG glycosylation;
PAAD	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-1.11	-9.49	-0.61	4.72e-17	Blood trace element (Zn levels);
PAAD	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.14	15.71	0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg25251562	chr2:3704773	ALLC	-0.52	-5.96	-0.44	1.7e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.09	9.44	0.61	6.32e-17	Platelet count;
PAAD	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.59	5.7	0.42	6.07e-8	Obesity-related traits;
PAAD	cis	rs3925075	0.515	rs11864632	chr16:31182455	G/C	cg02846316	chr16:31340340	ITGAM	-0.4	-4.46	-0.34	1.6e-5	IgA nephropathy;
PAAD	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	7.26	0.51	1.87e-11	Schizophrenia;
PAAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.44e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs1468333	1.000	rs2906128	chr5:137550054	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.26	0.45	3.68e-9	Resting heart rate;
PAAD	cis	rs4006360	0.575	rs7502215	chr17:39306261	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.43	4.31	0.33	2.87e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs290268	0.803	rs1333634	chr9:93567503	T/A	cg02608019	chr9:93564028	SYK	0.61	5.79	0.43	3.87e-8	Platelet count;
PAAD	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	5.64	0.42	8.17e-8	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16262614	chr3:133464971	TF	-0.41	-4.31	-0.33	2.87e-5	Iron status biomarkers;
PAAD	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.36	-0.33	2.34e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13939156	chr17:80058883	NA	-0.43	-4.65	-0.35	7.02e-6	Life satisfaction;
PAAD	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.56	-5.05	-0.38	1.27e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg14008862	chr17:28927542	LRRC37B2	0.86	6.15	0.45	6.56e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	7.83e-7	Schizophrenia;
PAAD	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.52	-5.05	-0.38	1.23e-6	Metabolic syndrome;
PAAD	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg08999081	chr20:33150536	PIGU	0.48	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.59	6.08	0.44	9.3e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.48	-4.87	-0.37	2.79e-6	Type 2 diabetes;
PAAD	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg22153463	chr1:85462885	MCOLN2	0.72	5.36	0.4	3.01e-7	Serum sulfate level;
PAAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg05484376	chr2:27715224	FNDC4	0.44	4.55	0.35	1.1e-5	Total body bone mineral density;
PAAD	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.95	9.19	0.6	2.81e-16	Psoriasis;
PAAD	cis	rs11668609	0.505	rs114268224	chr19:24061855	G/A	cg09235885	chr19:23456588	NA	0.63	4.35	0.33	2.45e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg08053846	chr7:100769605	SERPINE1	-0.47	-5.0	-0.38	1.6e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10166090	chr14:68162924	RDH11	0.59	6.5	0.47	1.07e-9	Smoking initiation;
PAAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.5	6.1	0.44	8.36e-9	Monobrow;
PAAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.96	10.45	0.65	1.34e-19	Multiple myeloma;
PAAD	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-1.18	-18.4	-0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.8	-6.56	-0.47	7.92e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg23250157	chr14:64679961	SYNE2	0.53	5.5	0.41	1.54e-7	Atrial fibrillation;
PAAD	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-4.99	-0.38	1.63e-6	Vitiligo;
PAAD	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.05	-0.55	2.22e-13	Inflammatory bowel disease;
PAAD	cis	rs12935418	0.616	rs2549859	chr16:81027003	A/G	cg16651780	chr16:81037892	C16orf61	-0.63	-5.8	-0.43	3.65e-8	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18308252	chr10:5855585	GDI2	0.69	7.43	0.52	7.12e-12	Myopia (pathological);
PAAD	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg24793722	chr4:824416	NA	-0.36	-4.42	-0.34	1.85e-5	Systemic sclerosis;
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg01831904	chr17:28903510	LRRC37B2	0.83	6.15	0.45	6.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.79	7.08	0.5	5.08e-11	Exhaled nitric oxide levels;
PAAD	cis	rs970548	0.779	rs2310783	chr10:45972810	G/C	cg15590007	chr10:45870220	ALOX5	0.46	4.81	0.36	3.6e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg25753631	chr6:25732923	NA	-0.43	-4.87	-0.37	2.73e-6	Iron status biomarkers;
PAAD	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.84	-9.96	-0.63	2.66e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg17252645	chr8:143867129	LY6D	0.51	4.84	0.37	3.1e-6	Urinary tract infection frequency;
PAAD	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.09e-6	Life satisfaction;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg04398451	chr17:18023971	MYO15A	0.61	5.85	0.43	2.95e-8	Body mass index;
PAAD	trans	rs3749237	0.964	rs2276864	chr3:49894030	T/C	cg21659725	chr3:3221576	CRBN	0.74	6.99	0.49	8e-11	Resting heart rate;
PAAD	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.71	7.01	0.49	7.32e-11	Coronary artery disease;
PAAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.88	0.54	5.76e-13	Lung cancer in ever smokers;
PAAD	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs4704187	0.617	rs2035192	chr5:74407231	T/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.49	5.05	0.38	1.28e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.51	5.56	0.41	1.17e-7	Testicular germ cell tumor;
PAAD	cis	rs2601828	0.507	rs11076804	chr16:4104389	C/G	cg16420089	chr16:4736869	MGRN1	0.45	4.29	0.33	3.12e-5	Partial epilepsies;
PAAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.71	8.96	0.59	1.1e-15	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.75e-17	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.53	5.01	0.38	1.48e-6	White matter hyperintensity burden;
PAAD	cis	rs11112613	0.609	rs11112632	chr12:106041887	A/G	cg03607813	chr12:105948248	NA	-0.8	-5.48	-0.41	1.7e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-1.03	-5.42	-0.4	2.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.06	-6.73	-0.48	3.23e-10	Mitochondrial DNA levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24630593	chr17:77082929	ENGASE	-0.56	-6.61	-0.47	6.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg14926445	chr8:58193284	C8orf71	-0.71	-5.57	-0.41	1.11e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7771547	0.723	rs9394363	chr6:36558964	A/G	cg07856975	chr6:36356162	ETV7	0.46	4.96	0.37	1.85e-6	Platelet distribution width;
PAAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.52	5.34	0.4	3.34e-7	Personality dimensions;
PAAD	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.58	5.91	0.43	2.2e-8	Systolic blood pressure;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	trans	rs350729	0.649	rs1077945	chr2:53193333	T/G	cg24639469	chr1:4837462	AJAP1	0.66	6.36	0.46	2.29e-9	Bronchodilator response in asthma;
PAAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.67	0.42	6.9e-8	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.9	-8.35	-0.56	4.02e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.93	-11.12	-0.67	2.17e-21	Cognitive function;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19648896	chr11:65337773	SSSCA1	-0.75	-6.41	-0.46	1.76e-9	Neuroticism;
PAAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg00310523	chr12:86230176	RASSF9	0.43	4.54	0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs9810890	1.000	rs56003071	chr3:128596048	T/C	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.5e-5	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23323627	chr1:153895881	GATAD2B	0.59	6.41	0.46	1.74e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.4	4.75	0.36	4.72e-6	HIV-1 susceptibility;
PAAD	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs11250464	0.517	rs2387668	chr10:1432003	C/T	cg08668359	chr10:1443807	ADARB2	0.49	4.32	0.33	2.77e-5	Radiation response;
PAAD	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg15873301	chr3:12045459	SYN2	0.46	4.82	0.36	3.52e-6	Plateletcrit;Lymphocyte counts;White blood cell count;
PAAD	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.4	2.58e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.58	-5.45	-0.4	1.99e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs1359582	0.881	rs2901950	chr10:90362099	A/G	cg15661332	chr10:90342814	RNLS	0.56	5.04	0.38	1.29e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs3007168	0.951	rs8022611	chr14:51658932	G/C	cg23942311	chr14:51606299	NA	0.59	4.36	0.33	2.36e-5	Cancer;
PAAD	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-4.26	-0.33	3.64e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs4523957	0.855	rs12602764	chr17:2123200	A/T	cg16513277	chr17:2031491	SMG6	-0.49	-4.96	-0.37	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13870426	chr17:30244630	NA	-0.6	-5.93	-0.43	1.97e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg19090574	chr1:205240910	TMCC2	-0.41	-4.42	-0.34	1.86e-5	Red blood cell count;
PAAD	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.57	-7.1	-0.5	4.52e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg05309399	chr4:106552544	FLJ20184	-0.53	-4.25	-0.33	3.7e-5	Post bronchodilator FEV1;
PAAD	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg01868782	chr6:126071099	HEY2	-0.38	-4.46	-0.34	1.6e-5	Brugada syndrome;
PAAD	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg09211372	chr6:168490623	NA	-0.45	-4.8	-0.36	3.79e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.61	7.62	0.53	2.47e-12	Schizophrenia;
PAAD	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-4.72	-0.36	5.31e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7113874	0.802	rs7941510	chr11:8677063	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-4.52	-0.34	1.25e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg21951975	chr1:209979733	IRF6	0.55	5.1	0.38	1.02e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11714801	chr19:41859555	TGFB1	-0.64	-6.48	-0.47	1.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.72	-6.07	-0.44	9.63e-9	Schizophrenia;
PAAD	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg02820901	chr13:113351484	ATP11A	-0.62	-4.29	-0.33	3.18e-5	Glycated hemoglobin levels;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg00567479	chr2:242295999	FARP2	0.6	6.59	0.47	6.68e-10	Smoking initiation;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.57	5.41	0.4	2.39e-7	Electroencephalogram traits;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.56	-0.35	1.06e-5	Cognitive function;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.49	8.09	0.55	1.77e-13	IgG glycosylation;
PAAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg22143856	chr6:28129313	ZNF389	0.52	4.51	0.34	1.27e-5	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07833644	chr2:27440142	CAD	0.66	7.68	0.53	1.82e-12	Metabolite levels  (X-11787);
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.81	10.58	0.65	5.83e-20	Vitiligo;
PAAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.76	-6.02	-0.44	1.27e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-4.77	-0.36	4.2e-6	Cervical cancer;
PAAD	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg08632701	chr21:37451849	NA	0.61	6.44	0.46	1.5e-9	Mitral valve prolapse;
PAAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg24849736	chr1:201084428	NA	0.44	4.37	0.33	2.31e-5	Permanent tooth development;
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg01831904	chr17:28903510	LRRC37B2	0.8	4.92	0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs9815354	0.953	rs1717003	chr3:41937000	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.83	-0.43	3.27e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.68	0.35	6.37e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4356203	0.875	rs7125607	chr11:17096150	T/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.37	-0.33	2.27e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9392556	0.510	rs613028	chr6:4102139	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.63	-5.77	-0.42	4.23e-8	Blood metabolite levels;
PAAD	cis	rs757081	0.684	rs214071	chr11:17305294	T/G	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.69	-0.36	6.03e-6	Systolic blood pressure;
PAAD	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	9.5	0.61	4.3e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.63	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg21994712	chr19:21861136	NA	0.48	4.58	0.35	9.72e-6	Pain;
PAAD	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.62	5.63	0.42	8.58e-8	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.63	-9.46	-0.61	5.5e-17	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26549601	chr10:134560360	INPP5A	-0.43	-4.3	-0.33	3.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322817	0.653	rs4132193	chr6:105168358	C/T	cg02098413	chr6:105308735	HACE1	-0.41	-5.14	-0.38	8.36e-7	Thyroid stimulating hormone;
PAAD	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg04990556	chr1:26633338	UBXN11	0.67	4.96	0.37	1.85e-6	Obesity-related traits;
PAAD	cis	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.56	-0.35	1.06e-5	Eotaxin levels;
PAAD	cis	rs900145	1.000	rs900146	chr11:13293887	C/T	cg15603424	chr11:13300592	ARNTL	0.53	4.76	0.36	4.38e-6	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02872018	chr2:192746213	NA	-0.58	-6.38	-0.46	1.99e-9	Smoking initiation;
PAAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.04	-0.59	6.74e-16	Calcium levels;
PAAD	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.65	0.42	7.73e-8	Ileal carcinoids;
PAAD	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg24053715	chr22:38214548	NA	-0.51	-4.94	-0.37	2.06e-6	Glioblastoma;Glioma;
PAAD	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08754654	chr5:154026448	NA	-0.43	-6.56	-0.47	7.83e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.67	4.85	0.37	3.03e-6	Mean platelet volume;
PAAD	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	1.07	6.42	0.46	1.64e-9	Plateletcrit;
PAAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.26	-0.45	3.77e-9	IgG glycosylation;
PAAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.73	-7.38	-0.51	9.8e-12	Neurofibrillary tangles;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	5.97	0.44	1.6e-8	Mean platelet volume;
PAAD	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg10432947	chr4:2062441	NAT8L	0.52	4.5	0.34	1.33e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.86	0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.44	-5.04	-0.38	1.31e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-13.85	-0.75	9.9e-29	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17315732	chr12:28060132	NA	-0.62	-6.53	-0.47	9.39e-10	Obesity-related traits;
PAAD	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.56	4.98	0.37	1.71e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7804356	0.651	rs7803699	chr7:26814173	T/C	cg03456212	chr7:26904342	SKAP2	-0.6	-5.1	-0.38	1.02e-6	Type 1 diabetes;
PAAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.45	5.09	0.38	1.04e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7567389	0.677	rs11680877	chr2:128090450	A/G	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	6.36	0.46	2.28e-9	Personality dimensions;
PAAD	cis	rs9649465	0.934	rs718781	chr7:123313573	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.05	11.22	0.67	1.16e-21	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19863459	chr19:4639366	TNFAIP8L1	0.67	6.54	0.47	9.01e-10	Obesity-related traits;
PAAD	trans	rs901683	0.850	rs80222863	chr10:46016975	C/T	cg11747279	chr17:21096632	NA	0.88	6.67	0.48	4.45e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14325169	chr10:60145452	TFAM	-0.64	-6.29	-0.45	3.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs288326	0.561	rs79908577	chr2:183712172	T/G	cg09997497	chr2:183902928	NCKAP1	0.85	4.8	0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs6032067	0.609	rs1011536	chr20:43793370	A/G	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	6.78	0.48	2.54e-10	Mood instability;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg10729496	chr3:10149963	C3orf24	0.84	6.31	0.46	2.87e-9	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs939584	1.000	rs2867115	chr2:651382	T/C	cg03610516	chr2:642275	NA	-0.6	-5.54	-0.41	1.33e-7	Body mass index;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.56e-10	Life satisfaction;
PAAD	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	9.9	0.63	3.93e-18	Cognitive test performance;
PAAD	cis	rs58521262	0.556	rs291773	chr19:23208098	T/C	cg02350677	chr19:23254381	NA	0.26	4.58	0.35	9.61e-6	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.92	9.76	0.62	9.1e-18	Cognitive function;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg27094323	chr7:1216898	NA	-0.41	-4.46	-0.34	1.58e-5	Longevity;Endometriosis;
PAAD	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	5.12	0.38	9.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg02795151	chr17:7402630	POLR2A	0.63	5.48	0.41	1.71e-7	Androgen levels;
PAAD	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.48	-0.41	1.75e-7	Schizophrenia;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.83	-7.98	-0.54	3.38e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09807746	chr1:2209140	SKI	0.62	6.92	0.49	1.2e-10	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03629577	chr8:146228461	ZNF252;C8orf77	0.63	7.07	0.5	5.14e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73086581	0.891	rs11907503	chr20:3887590	C/T	cg02187196	chr20:3869020	PANK2	0.59	4.87	0.37	2.74e-6	Response to antidepressants in depression;
PAAD	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.84	-9.46	-0.61	5.66e-17	Height;
PAAD	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.85	4.37	0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.68	-6.4	-0.46	1.83e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.62	6.04	0.44	1.16e-8	Breast cancer;
PAAD	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg22532475	chr10:104410764	TRIM8	-0.41	-4.71	-0.36	5.55e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg20893579	chr22:38215064	NA	-0.54	-5.85	-0.43	2.9e-8	Glioblastoma;Glioma;
PAAD	cis	rs4287000	0.802	rs10122270	chr9:96390131	A/G	cg13787134	chr9:96362102	PHF2	0.38	4.35	0.33	2.46e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs10267836	0.920	rs17159410	chr7:30779725	G/A	cg17421561	chr7:31726639	C7orf16	-0.76	-4.75	-0.36	4.63e-6	Glucose homeostasis traits;
PAAD	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.92	5.92	0.43	2.11e-8	Major depressive disorder;
PAAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-16.89	-0.81	1.06e-36	Height;
PAAD	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.67	6.49	0.47	1.16e-9	Coronary artery disease;
PAAD	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.65	6.69	0.48	4.01e-10	Menarche (age at onset);
PAAD	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg23920097	chr1:209922102	NA	0.54	5.15	0.39	8e-7	Red blood cell count;
PAAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	1.07	9.42	0.61	6.97e-17	Eosinophil percentage of granulocytes;
PAAD	cis	rs10488172	0.857	rs17167144	chr7:133239042	A/G	cg10665199	chr7:133106180	EXOC4	-0.56	-4.56	-0.35	1.04e-5	Tonometry;
PAAD	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg02683114	chr2:24398427	C2orf84	-0.45	-4.83	-0.36	3.36e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.8e-13	Monocyte percentage of white cells;
PAAD	cis	rs4800452	0.549	rs9947743	chr18:20708321	G/A	cg26136497	chr18:20735537	CABLES1	-0.48	-4.34	-0.33	2.58e-5	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg17105886	chr17:28927953	LRRC37B2	0.69	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17407555	0.683	rs7435841	chr4:10278552	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	4.48	0.34	1.44e-5	Schizophrenia (age at onset);
PAAD	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.55	4.88	0.37	2.61e-6	Schizophrenia;
PAAD	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg16794390	chr17:18148240	FLII	-0.59	-4.82	-0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg07395648	chr5:131743802	NA	-0.48	-4.3	-0.33	2.99e-5	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15181807	chr11:66445392	RBM4B	-0.61	-6.31	-0.46	2.87e-9	Smoking initiation;
PAAD	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-4.49	-0.34	1.39e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	7.49	0.52	5.23e-12	Renal function-related traits (BUN);
PAAD	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.46	-0.8	1.35e-35	Height;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.64	-4.45	-0.34	1.66e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6539267	0.775	rs11112997	chr12:106842558	T/C	cg02476566	chr12:106696527	TCP11L2	0.45	4.31	0.33	2.88e-5	Tourette syndrome;
PAAD	cis	rs7765175	0.573	rs6920652	chr6:113618048	G/A	cg19037598	chr6:113666021	NA	-0.4	-4.39	-0.34	2.12e-5	Coronary artery calcification;
PAAD	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg26169700	chr22:42538906	CYP2D7P1	0.6	4.34	0.33	2.63e-5	Birth weight;
PAAD	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	1.0	7.08	0.5	5.04e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	5.89	0.43	2.42e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg23463467	chr20:60627584	TAF4	0.44	4.84	0.37	3.15e-6	Body mass index;
PAAD	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg00864860	chr1:7907996	UTS2	0.54	4.82	0.36	3.38e-6	Crohn's disease;
PAAD	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.5e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07628044	chr2:70520858	SNRPG	0.63	6.63	0.47	5.48e-10	Myopia (pathological);
PAAD	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.82	7.81	0.54	8.61e-13	Response to hepatitis C treatment;
PAAD	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Morning vs. evening chronotype;
PAAD	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.54	0.35	1.12e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.27	-0.33	3.46e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.36	4.74	0.36	4.95e-6	Age at first birth;
PAAD	cis	rs2594989	0.943	rs9822446	chr3:11420780	C/G	cg01796438	chr3:11312864	ATG7	-0.65	-5.02	-0.38	1.4e-6	Circulating chemerin levels;
PAAD	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg09835421	chr16:68378352	PRMT7	-0.99	-5.19	-0.39	6.51e-7	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg08779649	chr13:50194554	NA	0.41	5.63	0.42	8.64e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-4.46	-0.34	1.61e-5	Coronary artery disease;
PAAD	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.53	5.52	0.41	1.43e-7	Pancreatic cancer;
PAAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.55e-21	Breast cancer;
PAAD	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg18833306	chr6:118973337	C6orf204	0.43	4.45	0.34	1.67e-5	Electrocardiographic conduction measures;
PAAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg21155852	chr7:2048760	MAD1L1	0.46	4.4	0.34	2.03e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-6.58	-0.47	7.06e-10	Educational attainment;
PAAD	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg25922239	chr6:33757077	LEMD2	0.63	6.57	0.47	7.47e-10	Crohn's disease;
PAAD	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.54	6.35	0.46	2.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.51	5.04	0.38	1.33e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.55	4.71	0.36	5.44e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg14703610	chr5:56206110	C5orf35	0.62	5.73	0.42	5.13e-8	Coronary artery disease;
PAAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.54	-5.95	-0.43	1.79e-8	Total body bone mineral density;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.9	6.75	0.48	2.92e-10	Alzheimer's disease;
PAAD	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg21427119	chr20:30132790	HM13	-0.64	-5.39	-0.4	2.68e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7772697	0.632	rs7775412	chr6:149423554	T/C	cg21368479	chr6:149415018	NA	0.41	4.32	0.33	2.77e-5	Diabetic retinopathy;
PAAD	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.49	-7.87	-0.54	6.18e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.65	8.95	0.59	1.16e-15	Height;
PAAD	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9657904	0.724	rs1443102	chr3:105525291	T/G	cg16975614	chr3:105601834	NA	-0.47	-4.5	-0.34	1.32e-5	Multiple sclerosis;
PAAD	cis	rs9657904	0.774	rs10804442	chr3:105519212	C/T	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.89e-6	Multiple sclerosis;
PAAD	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13393754	chr6:114292725	HDAC2	0.64	6.96	0.49	9.47e-11	Myopia (pathological);
PAAD	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.89	11.22	0.67	1.15e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.68	7.02	0.49	6.87e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg14019146	chr3:50243930	SLC38A3	0.49	5.14	0.38	8.26e-7	Body mass index;
PAAD	cis	rs72960926	1.000	rs11751231	chr6:75138811	T/C	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.8	-5.81	-0.43	3.57e-8	Vitiligo;
PAAD	cis	rs7771547	0.692	rs9366909	chr6:36552869	G/A	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.71	6.53	0.47	9.1e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs67257959	0.708	rs1979260	chr19:17193551	C/T	cg19418318	chr19:17219073	MYO9B	-0.32	-4.66	-0.35	6.88e-6	Selective IgA deficiency;
PAAD	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg13160058	chr8:26243215	BNIP3L	-0.37	-4.6	-0.35	8.98e-6	Red cell distribution width;
PAAD	cis	rs11811982	0.793	rs115332333	chr1:227329006	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs3892630	0.558	rs4588103	chr19:33352770	G/A	cg16174234	chr19:33463305	C19orf40;CCDC123	-0.5	-4.29	-0.33	3.11e-5	Red blood cell traits;
PAAD	cis	rs516243	0.660	rs284309	chr1:10737673	C/T	cg02903756	chr1:10750680	CASZ1	-0.43	-4.63	-0.35	7.71e-6	Migraine - clinic-based;
PAAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.7	6.83	0.48	1.91e-10	Blood metabolite levels;
PAAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.21	-0.45	4.95e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.66	-7.08	-0.5	4.91e-11	Metabolic syndrome;
PAAD	cis	rs2120991	0.967	rs7305034	chr12:54262854	T/A	cg25640699	chr12:54070114	ATP5G2	-0.42	-4.48	-0.34	1.44e-5	Biliary atresia;
PAAD	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.37	-0.33	2.33e-5	Fear of minor pain;
PAAD	cis	rs9377188	0.547	rs6901019	chr6:149415039	C/T	cg21368479	chr6:149415018	NA	0.42	4.55	0.35	1.11e-5	Cancer;
PAAD	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.68	-6.2	-0.45	4.99e-9	Diabetic retinopathy;
PAAD	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg26875137	chr12:53738046	NA	-0.47	-4.7	-0.36	5.72e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.9	-9.18	-0.6	3.03e-16	Asthma;
PAAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.58	5.64	0.42	8.19e-8	Mood instability;
PAAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.55	-6.08	-0.44	9.48e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg11262906	chr1:85462892	MCOLN2	0.59	4.65	0.35	7.3e-6	Serum sulfate level;
PAAD	cis	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.83	-0.37	3.25e-6	Neuroticism;
PAAD	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg02527881	chr3:46936655	PTH1R	0.39	4.54	0.35	1.15e-5	Colorectal cancer;
PAAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.26	0.51	1.85e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-4.63	-0.35	7.87e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.3	0.4	3.97e-7	Ovarian reserve;
PAAD	cis	rs11690462	0.534	rs6546949	chr2:26592429	T/C	cg13255216	chr2:26625047	C2orf39	-0.43	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.5	4.58	0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.38e-8	QT interval;
PAAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18099408	chr3:52552593	STAB1	0.41	4.38	0.33	2.18e-5	Bipolar disorder;
PAAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs8018808	0.936	rs10140302	chr14:77855693	C/A	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg13918804	chr1:2043761	PRKCZ	-0.36	-4.71	-0.36	5.57e-6	Height;
PAAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.27	0.39	4.6e-7	Multiple sclerosis;
PAAD	cis	rs1667255	1.000	rs2704058	chr18:29157568	A/G	cg18808318	chr18:29669225	NA	-0.43	-4.25	-0.33	3.66e-5	Retinol levels;
PAAD	cis	rs4455778	0.538	rs6583514	chr7:49123556	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg21546286	chr11:48923668	NA	-0.45	-4.71	-0.36	5.48e-6	Height;
PAAD	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.91	-0.54	4.8e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg14343924	chr8:8086146	FLJ10661	0.56	4.92	0.37	2.21e-6	Mood instability;
PAAD	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.42	-0.52	7.8e-12	Eosinophil percentage of white cells;
PAAD	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.04	0.38	1.32e-6	Parkinson's disease;
PAAD	trans	rs9409082	0.715	rs34575265	chr9:108943801	C/T	cg07010948	chr13:79181613	NA	-0.34	-6.43	-0.46	1.54e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-1.37	-9.93	-0.63	3.3e-18	Schizophrenia;
PAAD	cis	rs9443645	0.527	rs9718121	chr6:79729887	T/A	cg05283184	chr6:79620031	NA	-0.37	-4.7	-0.36	5.81e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23273333	chr1:217262889	ESRRG	-0.69	-6.41	-0.46	1.71e-9	Lung cancer in ever smokers;
PAAD	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg10820045	chr2:198174542	NA	-0.49	-4.98	-0.37	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16262614	chr3:133464971	TF	0.46	5.11	0.38	9.54e-7	Iron status biomarkers;
PAAD	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.8	8.2	0.55	9.43e-14	Alzheimer's disease (late onset);
PAAD	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg15841412	chr13:111365552	ING1	0.52	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.93	9.2	0.6	2.59e-16	Post bronchodilator FEV1;
PAAD	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg22189786	chr22:42395067	WBP2NL	0.4	4.29	0.33	3.2e-5	Cognitive function;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.54	-0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs4936891	0.577	rs4936885	chr11:123905876	C/A	cg22125253	chr11:123886957	OR10G4	-0.43	-4.27	-0.33	3.38e-5	Male fertility;
PAAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs3771514	0.543	rs6720258	chr2:70700281	A/C	cg18150120	chr2:71134936	VAX2	-0.39	-4.42	-0.34	1.89e-5	Obesity-related traits;
PAAD	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg15145965	chr22:50218605	BRD1	0.6	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	trans	rs4678145	1.000	rs17843768	chr3:124448385	C/A	cg03983498	chr1:55107291	C1orf175	1.1	7.02	0.49	6.96e-11	Coronary artery disease;
PAAD	cis	rs16975963	0.644	rs73031322	chr19:38040879	C/A	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.33	0.46	2.56e-9	Educational attainment;
PAAD	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg26597838	chr10:835615	NA	0.97	7.61	0.53	2.73e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.8	-8.37	-0.56	3.45e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.66	-0.48	4.75e-10	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg00945038	chr17:61921165	SMARCD2	-0.38	-4.52	-0.34	1.25e-5	Prudent dietary pattern;
PAAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14019695	chr9:139328340	INPP5E	0.62	5.48	0.41	1.77e-7	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.68	10.06	0.63	1.43e-18	Airflow obstruction;
PAAD	cis	rs300774	1.000	rs300797	chr2:107140	G/A	cg23649280	chr2:140451	NA	-0.52	-5.0	-0.38	1.57e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs939584	0.825	rs7564708	chr2:639055	T/C	cg03610516	chr2:642275	NA	0.61	5.47	0.41	1.77e-7	Body mass index;
PAAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg15832094	chr12:132266778	SFRS8	0.48	4.63	0.35	7.85e-6	Migraine;
PAAD	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.53	-6.17	-0.45	5.85e-9	Dilated cardiomyopathy;
PAAD	cis	rs9463078	0.966	rs9357471	chr6:45090977	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.69	-0.42	6.34e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	4.69	0.36	5.93e-6	Lymphocyte counts;
PAAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg23024343	chr7:107201750	COG5	0.6	5.11	0.38	9.63e-7	Coronary artery disease;
PAAD	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.31	-0.4	3.78e-7	Mononucleosis;
PAAD	cis	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.27	-0.33	3.38e-5	Breast cancer;
PAAD	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg21770322	chr7:97807741	LMTK2	-0.52	-5.7	-0.42	6.09e-8	Breast cancer;
PAAD	cis	rs802075	0.837	rs12215137	chr6:49645870	A/C	cg20364632	chr6:49636226	NA	-0.46	-5.2	-0.39	6.45e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.89	-0.37	2.55e-6	HDL cholesterol;
PAAD	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg24562669	chr7:97807699	LMTK2	-0.63	-8.52	-0.57	1.49e-14	Breast cancer;
PAAD	cis	rs6681460	0.528	rs4655498	chr1:67039245	T/G	cg02459107	chr1:67143332	SGIP1	0.66	7.11	0.5	4.24e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg06375148	chr1:209958343	C1orf74	-0.63	-4.58	-0.35	9.64e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg23920097	chr1:209922102	NA	-0.5	-4.53	-0.34	1.18e-5	Red blood cell count;
PAAD	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.58e-5	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.62	-0.35	8.12e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17095355	0.818	rs10884921	chr10:111776248	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.71	7.2	0.5	2.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg01329690	chr21:38580129	DSCR9	0.37	5.02	0.38	1.46e-6	Eye color traits;
PAAD	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.55	5.04	0.38	1.32e-6	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02071572	chr4:1403502	NA	-0.49	-6.34	-0.46	2.47e-9	Longevity;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27418564	chr15:44581614	CASC4	-0.48	-4.53	-0.35	1.17e-5	Lung cancer in ever smokers;
PAAD	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs3106136	0.647	rs6532483	chr4:95293558	A/T	cg11021082	chr4:95130006	SMARCAD1	0.48	4.59	0.35	9.13e-6	Capecitabine sensitivity;
PAAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg19257562	chr1:2043853	PRKCZ	-0.42	-5.0	-0.38	1.55e-6	Height;
PAAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.45	-0.52	6.39e-12	Cognitive function;
PAAD	cis	rs1570155	1.000	rs6456347	chr6:20391323	C/A	cg03881924	chr6:20404342	E2F3	0.44	4.5	0.34	1.32e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.39	-4.95	-0.37	1.93e-6	Waist circumference;
PAAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.93	-8.77	-0.58	3.33e-15	Asthma;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.55	-0.47	8.36e-10	Menarche (age at onset);
PAAD	cis	rs1678618	0.615	rs12418	chr10:73773014	A/G	cg20897136	chr10:74034667	DDIT4	-0.37	-4.38	-0.34	2.16e-5	Smoking behavior;
PAAD	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-8.45	-0.57	2.18e-14	Total body bone mineral density;
PAAD	cis	rs16854884	0.632	rs59287916	chr3:143638337	G/A	cg06585982	chr3:143692056	C3orf58	0.72	7.79	0.53	9.51e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs2016266	0.896	rs3741663	chr12:53664015	G/A	cg26875137	chr12:53738046	NA	0.38	4.31	0.33	2.94e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.84	-9.67	-0.62	1.52e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.83	0.48	1.91e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.52	4.74	0.36	4.94e-6	Total body bone mineral density;
PAAD	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg16205897	chr5:131564050	P4HA2	0.42	4.53	0.35	1.17e-5	Blood metabolite levels;
PAAD	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs9913156	0.748	rs56364707	chr17:4562579	A/T	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg15621731	chr19:5074616	KDM4B	0.33	4.65	0.35	7.23e-6	Monocyte percentage of white cells;
PAAD	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.63	-0.47	5.38e-10	Colorectal cancer;
PAAD	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs58521262	0.519	rs11667397	chr19:22941191	T/A	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.33e-5	Testicular germ cell tumor;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg19357499	chr8:144660631	NAPRT1	0.86	5.87	0.43	2.64e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.57	-6.16	-0.45	6.3e-9	Pelvic organ prolapse;
PAAD	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.05	0.5	6e-11	Coffee consumption (cups per day);
PAAD	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.41	4.83	0.36	3.3e-6	Tonsillectomy;
PAAD	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs806794	0.810	rs62396185	chr6:26180634	G/C	cg00631329	chr6:26305371	NA	-0.44	-4.44	-0.34	1.73e-5	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg24687543	chr11:63912206	MACROD1	0.48	4.49	0.34	1.42e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg27094323	chr7:1216898	NA	-0.45	-5.38	-0.4	2.8e-7	Longevity;Endometriosis;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.65	6.91	0.49	1.27e-10	Mean corpuscular volume;
PAAD	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.73	8.37	0.56	3.59e-14	Blood metabolite ratios;
PAAD	cis	rs4704187	0.687	rs6453112	chr5:74389901	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.75	6.26	0.45	3.67e-9	Prostate cancer;
PAAD	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg05627522	chr15:75251581	NA	0.52	6.08	0.44	9.34e-9	Breast cancer;
PAAD	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.61	-5.97	-0.44	1.63e-8	Systemic sclerosis;
PAAD	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.7	0.48	3.9e-10	Triglycerides;
PAAD	cis	rs71636778	0.631	rs12747620	chr1:27182261	A/G	cg12203394	chr1:27248618	NUDC	0.63	4.55	0.35	1.08e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg12463550	chr7:65579703	CRCP	0.51	4.84	0.37	3.12e-6	Aortic root size;
PAAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.56	0.35	1.06e-5	Renal cell carcinoma;
PAAD	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	1.2	7.11	0.5	4.19e-11	Skin colour saturation;
PAAD	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.62	-4.52	-0.34	1.23e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01228352	chr3:150329615	SELT	0.59	6.61	0.47	5.97e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.58	5.35	0.4	3.2e-7	Total body bone mineral density;
PAAD	cis	rs6681460	0.800	rs539014	chr1:67211887	C/T	cg02459107	chr1:67143332	SGIP1	-0.69	-6.48	-0.47	1.21e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs412050	0.547	rs61763401	chr22:22139847	C/T	cg17089214	chr22:22089827	YPEL1	0.67	4.54	0.35	1.12e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs3782123	0.539	rs10902111	chr11:241489	C/T	cg25796445	chr11:207425	RIC8A;BET1L	0.81	5.15	0.39	7.83e-7	Glycated hemoglobin levels;Red cell distribution width;
PAAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-1.42	-10.38	-0.64	1.99e-19	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15453345	chr1:166844942	TADA1	-0.66	-6.48	-0.47	1.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.58	5.23	0.39	5.5e-7	Schizophrenia;
PAAD	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.68	6.7	0.48	3.73e-10	Lymphocyte counts;
PAAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.94	-10.61	-0.65	5.15e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	1.03	6.51	0.47	1.05e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.72	0.66	2.6e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10450586	0.769	rs11029933	chr11:27328804	A/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.93	9.51	0.61	3.97e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.07	-8.28	-0.56	5.92e-14	Diabetic kidney disease;
PAAD	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg19423196	chr10:82049429	MAT1A	0.57	4.39	0.34	2.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1468734	1.000	rs4786567	chr16:5001034	A/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.58	-0.35	9.75e-6	Cancer;
PAAD	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg22771759	chr13:24902376	NA	0.43	4.27	0.33	3.43e-5	Obesity-related traits;
PAAD	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg21855830	chr2:127963489	CYP27C1	0.46	4.47	0.34	1.5e-5	Protein C levels;
PAAD	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.52	-0.41	1.45e-7	Atopic dermatitis;
PAAD	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg02917321	chr22:38215204	NA	0.48	4.6	0.35	8.77e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-5.22	-0.39	5.83e-7	Menarche (age at onset);
PAAD	trans	rs11818629	1.000	rs11818629	chr10:130137105	A/G	cg03942932	chr6:106441441	NA	0.96	6.31	0.46	2.9e-9	HIV-1 control;
PAAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg10018233	chr7:150070692	REPIN1	0.65	7.0	0.49	7.84e-11	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25152368	chr1:2985692	PRDM16;FLJ42875	0.65	6.67	0.48	4.39e-10	Obesity-related traits;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.83	9.38	0.61	9.02e-17	Menarche (age at onset);
PAAD	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.75	-7.32	-0.51	1.31e-11	DNA methylation (variation);
PAAD	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11890956	chr21:40555474	PSMG1	1.07	11.66	0.69	7.43e-23	Cognitive function;
PAAD	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.64	-0.35	7.39e-6	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14769556	chr2:65314733	RAB1A	0.56	6.29	0.45	3.17e-9	Smoking initiation;
PAAD	cis	rs4523957	0.820	rs57307236	chr17:2159502	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.51	-0.41	1.53e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13755373	chr14:103059017	RCOR1	0.65	6.36	0.46	2.22e-9	Obesity-related traits;
PAAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs6782025	1.000	rs9849118	chr3:121132268	A/T	cg16417163	chr3:121280760	NA	0.48	4.88	0.37	2.61e-6	Aging (facial);
PAAD	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.55	6.78	0.48	2.51e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.51	-4.91	-0.37	2.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-1.03	-8.28	-0.56	5.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg10935138	chr17:73851978	WBP2	0.81	7.13	0.5	3.8e-11	Psoriasis;
PAAD	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg12310025	chr6:25882481	NA	0.44	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs965469	0.603	rs6115892	chr20:3411569	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.54	-0.35	1.14e-5	IFN-related cytopenia;
PAAD	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg19760965	chr3:194868843	C3orf21	0.44	4.71	0.36	5.48e-6	Non-small cell lung cancer;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg25905881	chr15:51634250	GLDN	0.54	4.86	0.37	2.9e-6	Hormone measurements;
PAAD	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	1.05	6.88	0.49	1.5e-10	Fat distribution (HIV);
PAAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.52	5.6	0.41	9.85e-8	Age at first birth;
PAAD	cis	rs62025270	0.632	rs74025655	chr15:86217550	C/A	cg13263323	chr15:86062960	AKAP13	0.49	4.39	0.34	2.14e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.56	5.98	0.44	1.54e-8	Monocyte percentage of white cells;
PAAD	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg12658694	chr1:38397304	INPP5B	0.62	6.85	0.49	1.72e-10	Coronary artery disease;
PAAD	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg08099141	chr12:7053170	C12orf57	0.43	4.4	0.34	2.01e-5	IgG glycosylation;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg05861140	chr6:150128134	PCMT1	-0.49	-5.13	-0.38	8.71e-7	Lung cancer;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg08219700	chr8:58056026	NA	0.72	5.3	0.4	3.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs6666805	chr1:158498305	G/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.58	6.68	0.48	4.3e-10	Major depressive disorder;
PAAD	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.43	0.4	2.17e-7	Menarche (age at onset);
PAAD	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11264799	0.765	rs12144103	chr1:157620499	A/G	cg18268488	chr1:157545234	FCRL4	0.42	4.53	0.34	1.2e-5	IgA nephropathy;
PAAD	cis	rs950037	0.710	rs786912	chr1:89301123	C/T	cg13109106	chr1:89333529	GTF2B	-0.47	-4.57	-0.35	1e-5	Coronary artery disease;
PAAD	cis	rs4750440	0.671	rs4237438	chr10:14018768	A/C	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.51	-0.34	1.31e-5	Adiponectin levels;
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.56	0.41	1.17e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg05082376	chr22:42548792	NA	-0.53	-5.41	-0.4	2.35e-7	Cognitive function;
PAAD	cis	rs3747547	1.000	rs7028246	chr9:37917602	A/G	cg13774184	chr9:37916125	SHB	-0.61	-4.3	-0.33	3e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.79	5.89	0.43	2.4e-8	Initial pursuit acceleration;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-4.77	-0.36	4.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.52e-6	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12129839	chr17:69581517	NA	0.6	6.49	0.47	1.16e-9	Myopia (pathological);
PAAD	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.96	-6.32	-0.46	2.73e-9	Post bronchodilator FEV1;
PAAD	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	cis	rs11811982	0.744	rs115766366	chr1:227520001	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4792901	0.802	rs55989313	chr17:41606248	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.27	-0.33	3.46e-5	Dupuytren's disease;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg10729496	chr3:10149963	C3orf24	0.89	7.46	0.52	6.35e-12	Alzheimer's disease;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.95	-16.1	-0.79	1.17e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.97	12.68	0.72	1.39e-25	Menopause (age at onset);
PAAD	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.6	-6.16	-0.45	6.28e-9	Schizophrenia;
PAAD	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.82	-6.09	-0.44	8.9e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg23250157	chr14:64679961	SYNE2	0.51	5.36	0.4	2.99e-7	Atrial fibrillation;
PAAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg03538708	chr1:25844672	NA	-0.5	-5.08	-0.38	1.09e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.49	5.27	0.39	4.57e-7	Platelet distribution width;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.68	7.27	0.51	1.73e-11	Iron status biomarkers;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.79	-6.19	-0.45	5.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8014252	0.803	rs8006487	chr14:71011934	G/A	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.9	0.37	2.42e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.49	-0.41	1.68e-7	Life satisfaction;
PAAD	cis	rs2120991	0.792	rs7955233	chr12:54263011	C/T	cg23795217	chr12:54812000	ITGA5	0.32	4.44	0.34	1.73e-5	Biliary atresia;
PAAD	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg26939375	chr7:64535504	NA	0.61	6.41	0.46	1.77e-9	Calcium levels;
PAAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.33e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.61	0.35	8.6e-6	Personality dimensions;
PAAD	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.68	7.91	0.54	5.02e-13	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10605130	chr8:27491257	SCARA3	0.69	6.88	0.49	1.49e-10	Obesity-related traits;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg20007245	chr22:24372913	LOC391322	0.72	6.85	0.49	1.76e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.67	-0.48	4.4e-10	Lung cancer;
PAAD	cis	rs1035491	0.574	rs10461497	chr5:63942398	A/G	cg01791865	chr5:63954708	NA	0.55	5.98	0.44	1.53e-8	Body mass index;
PAAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg10356904	chr22:49881777	NA	-0.48	-4.7	-0.36	5.76e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09376583	chr16:88111425	NA	-0.49	-4.29	-0.33	3.22e-5	Menopause (age at onset);
PAAD	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg21922841	chr17:72744131	SLC9A3R1	-0.4	-5.26	-0.39	4.72e-7	Monocyte count;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.92	11.05	0.67	3.36e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.49	-4.71	-0.36	5.47e-6	Urinary tract infection frequency;
PAAD	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.74	-8.26	-0.56	6.74e-14	Morning vs. evening chronotype;
PAAD	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.36	0.46	2.2e-9	Hip circumference;
PAAD	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs16857609	0.564	rs13388148	chr2:218281500	T/G	cg15335768	chr2:218268053	DIRC3	-0.48	-5.09	-0.38	1.03e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18364779	chr6:26104403	HIST1H4C	0.45	4.34	0.33	2.62e-5	Schizophrenia;
PAAD	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.25	0.33	3.72e-5	Resting heart rate;
PAAD	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.57	6.47	0.46	1.24e-9	Platelet distribution width;
PAAD	cis	rs9535307	0.929	rs7984061	chr13:50337340	G/A	cg03658251	chr13:50265850	EBPL	0.83	5.68	0.42	6.7e-8	Obesity-related traits;
PAAD	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg08501292	chr6:25962987	TRIM38	0.89	4.91	0.37	2.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4906332	1.000	rs35771849	chr14:103981942	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.42	-0.4	2.29e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.87e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg27511599	chr7:32358540	NA	0.72	4.39	0.34	2.09e-5	Body mass index;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.3e-6	Height;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.49	-6.76	-0.48	2.81e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-6.13	-0.45	7.06e-9	Fibrinogen levels;
PAAD	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-4.79	-0.36	3.98e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.41	-0.34	1.93e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.43	-5.41	-0.4	2.4e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.7	8.57	0.57	1.09e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8014252	0.803	rs17113651	chr14:71061836	T/C	cg11204974	chr14:71022665	NA	-0.73	-4.85	-0.37	3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.11	0.5	4.35e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	7.0	0.49	7.83e-11	Mean platelet volume;
PAAD	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	5.35	0.4	3.15e-7	Multiple sclerosis;
PAAD	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.41	-5.9	-0.43	2.25e-8	QT interval;
PAAD	cis	rs8077577	0.638	rs4386179	chr17:18134774	A/G	cg16794390	chr17:18148240	FLII	-0.54	-4.6	-0.35	8.94e-6	Obesity-related traits;
PAAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.69	4.9	0.37	2.44e-6	Inflammatory bowel disease;
PAAD	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.51	5.26	0.39	4.76e-7	Red blood cell count;
PAAD	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.87	-14.44	-0.76	2.56e-30	Obesity-related traits;
PAAD	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.67	5.37	0.4	2.85e-7	Obesity (extreme);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06483575	chr20:2464696	ZNF343	-0.67	-6.49	-0.47	1.15e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.84	-9.12	-0.59	4.29e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.64	-6.62	-0.47	5.93e-10	Colorectal cancer;
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.62	-5.83	-0.43	3.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	9.18	0.6	2.95e-16	Response to antipsychotic treatment;
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg04520793	chr17:42248056	ASB16	-0.47	-6.32	-0.46	2.8e-9	Total body bone mineral density;
PAAD	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.6	5.7	0.42	6.14e-8	White matter hyperintensity burden;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09047553	chr11:19138639	ZDHHC13	0.65	6.66	0.48	4.68e-10	Obesity-related traits;
PAAD	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	1.05	12.98	0.73	2.15e-26	Breast cancer;
PAAD	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-6.5	-0.47	1.12e-9	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.6	-6.1	-0.44	8.43e-9	Glioblastoma;
PAAD	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg21770322	chr7:97807741	LMTK2	0.75	11.39	0.68	4e-22	Breast cancer;
PAAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-5.95	-0.43	1.81e-8	Monocyte count;
PAAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.58	6.05	0.44	1.07e-8	Huntington's disease progression;
PAAD	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09604110	chr6:116422028	NT5DC1	0.66	7.5	0.52	5.07e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-9.02	-0.59	7.67e-16	Type 2 diabetes;
PAAD	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg23024343	chr7:107201750	COG5	0.59	4.91	0.37	2.34e-6	Osteoarthritis;
PAAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-4.96	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.28	0.33	3.27e-5	Neuroticism;
PAAD	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.35	-0.64	2.51e-19	Response to antipsychotic treatment;
PAAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.74	-8.66	-0.57	6.54e-15	Childhood ear infection;
PAAD	cis	rs2229238	0.911	rs6681207	chr1:154517217	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.65e-6	Coronary heart disease;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg11062466	chr8:58055876	NA	0.65	4.72	0.36	5.27e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg23018236	chr17:30244563	NA	-0.6	-4.78	-0.36	4.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.49	5.03	0.38	1.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.86	9.35	0.6	1.07e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.37	4.42	0.34	1.84e-5	Sitting height ratio;
PAAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.83	10.04	0.63	1.6e-18	Menopause (age at onset);
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg01320130	chr1:67600311	NA	0.56	6.25	0.45	3.91e-9	Psoriasis;
PAAD	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.76	9.14	0.6	3.84e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg19784903	chr17:45786737	TBKBP1	-0.55	-5.99	-0.44	1.47e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg00717180	chr2:96193071	NA	-0.63	-7.63	-0.53	2.44e-12	HDL cholesterol;
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg06026331	chr20:60912101	LAMA5	-0.6	-5.57	-0.41	1.12e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.72	-6.23	-0.45	4.41e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9880406	0.833	rs938389	chr3:126058762	C/T	cg11830761	chr3:126007485	NA	-0.5	-4.38	-0.33	2.19e-5	Macular telangiectasia type 2;
PAAD	cis	rs3981351	0.833	rs2227310	chr10:115489152	C/G	cg24846397	chr10:115438155	CASP7	-0.54	-5.06	-0.38	1.18e-6	Obesity-related traits;
PAAD	cis	rs112591243	0.614	rs78654337	chr21:47824372	A/G	cg26904215	chr21:47823096	PCNT	-0.9	-4.62	-0.35	8.24e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.54	5.54	0.41	1.28e-7	Longevity;Endometriosis;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.57	-6.12	-0.44	7.53e-9	Eosinophil percentage of white cells;
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	0.32	4.85	0.37	3.09e-6	Cystic fibrosis severity;
PAAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.52	-5.91	-0.43	2.15e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-6.3	-0.46	3.12e-9	Triglycerides;
PAAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.7	8.27	0.56	6.4e-14	Eye color traits;
PAAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg16341495	chr8:142228727	SLC45A4	0.58	5.61	0.41	9.53e-8	Immature fraction of reticulocytes;
PAAD	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.78	4.84	0.37	3.13e-6	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.5	-5.73	-0.42	5.32e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-4.69	-0.36	6.02e-6	Blood protein levels;
PAAD	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.05	-0.38	1.23e-6	Monocyte percentage of white cells;
PAAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19784903	chr17:45786737	TBKBP1	0.53	5.76	0.42	4.44e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.54	6.58	0.47	7.32e-10	Multiple sclerosis;
PAAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg13468214	chr4:1046988	NA	-0.54	-5.16	-0.39	7.51e-7	Recombination rate (females);
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg02404636	chr22:31891804	SFI1	0.64	6.18	0.45	5.53e-9	Colorectal cancer;
PAAD	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs1144333	0.850	rs1251274	chr1:76288587	T/C	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.9	9.99	0.63	2.23e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.45	-4.69	-0.36	6.04e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.47	0.57	1.97e-14	Dupuytren's disease;
PAAD	trans	rs6869841	0.839	rs12517520	chr5:172948513	G/A	cg03237218	chr17:33760527	SLFN12	0.69	6.91	0.49	1.23e-10	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs11168618	0.810	rs6580671	chr12:48841057	G/A	cg01881778	chr12:48919444	OR8S1	-0.5	-4.97	-0.37	1.8e-6	Adiponectin levels;
PAAD	cis	rs357618	1.000	rs165352	chr5:150856107	T/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.59	5.88	0.43	2.46e-8	Tonsillectomy;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.49	-0.34	1.37e-5	Life satisfaction;
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07234876	chr8:600039	NA	1.03	7.65	0.53	2.17e-12	IgG glycosylation;
PAAD	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.54	6.28	0.45	3.35e-9	Platelet count;
PAAD	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg27490568	chr2:178487706	NA	0.41	4.25	0.33	3.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.51	-5.3	-0.4	3.98e-7	Male-pattern baldness;
PAAD	cis	rs57994353	0.568	rs1130635	chr9:139317869	A/G	cg21253087	chr9:139290292	SNAPC4	0.5	4.41	0.34	1.91e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg17644776	chr2:200775616	C2orf69	-0.65	-5.08	-0.38	1.11e-6	Schizophrenia;
PAAD	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg00717180	chr2:96193071	NA	-0.62	-7.04	-0.5	6.33e-11	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg22535103	chr8:58192502	C8orf71	-1.25	-11.41	-0.68	3.61e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg04165759	chr1:150448943	RPRD2	-0.54	-5.49	-0.41	1.61e-7	Migraine;
PAAD	cis	rs2327429	0.519	rs2876224	chr6:134153509	G/A	cg06296503	chr6:134217401	NA	0.44	4.58	0.35	9.47e-6	Coronary artery disease;
PAAD	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.62	-0.47	5.8e-10	Total body bone mineral density;
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg00981651	chr20:44574847	PCIF1	0.43	4.55	0.35	1.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg14008862	chr17:28927542	LRRC37B2	0.79	4.77	0.36	4.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35160687	0.842	rs1863051	chr2:86559148	A/C	cg10973622	chr2:86423274	IMMT	0.41	4.8	0.36	3.78e-6	Night sleep phenotypes;
PAAD	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	14.22	0.76	9.87e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.58	0.35	9.67e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16089233	chr7:129461722	NA	0.59	6.82	0.48	2.04e-10	Smoking initiation;
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.75	-10.08	-0.63	1.28e-18	Iron status biomarkers;
PAAD	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.68	0.62	1.48e-17	Rheumatoid arthritis;
PAAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.92	-7.15	-0.5	3.33e-11	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18190824	chr5:14721026	ANKH	-0.67	-7.1	-0.5	4.37e-11	Obesity-related traits;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg07371452	chr16:139780	C16orf35	0.6	6.44	0.46	1.52e-9	Educational attainment (years of education);
PAAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.99	-14.28	-0.76	7.08e-30	Post bronchodilator FEV1;
PAAD	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.09	-0.5	4.8e-11	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.75	6.58	0.47	7.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	4.99	0.38	1.62e-6	Blood metabolite levels;
PAAD	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg22153463	chr1:85462885	MCOLN2	-0.72	-5.31	-0.4	3.74e-7	Serum sulfate level;
PAAD	cis	rs458685	0.636	rs420091	chr21:31185447	G/A	cg24620508	chr21:31310605	GRIK1	-0.49	-4.55	-0.35	1.07e-5	Breast cancer;
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg04267008	chr7:1944627	MAD1L1	0.76	7.91	0.54	4.93e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	1.17	12.0	0.7	9.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg14830002	chr1:247616686	OR2B11	0.59	4.86	0.37	2.89e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs73019876	0.901	rs450298	chr19:22229969	A/C	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.03e-8	Lung cancer;
PAAD	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs3747547	0.818	rs7859715	chr9:37948322	A/C	cg13774184	chr9:37916125	SHB	-0.57	-4.26	-0.33	3.57e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	6.89	0.49	1.37e-10	Educational attainment;
PAAD	cis	rs8133932	0.701	rs9637207	chr21:47283359	A/G	cg13695288	chr21:47294981	PCBP3	-0.48	-4.76	-0.36	4.57e-6	Schizophrenia;
PAAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg10356904	chr22:49881777	NA	-0.53	-5.55	-0.41	1.26e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.7	-0.48	3.86e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11584989	chr19:19387371	SF4	-0.82	-7.19	-0.5	2.76e-11	Bipolar disorder;
PAAD	cis	rs12523822	0.957	rs6937986	chr6:154959109	C/T	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.61	6.4	0.46	1.84e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs1419980	0.730	rs11054952	chr12:7784509	G/T	cg25828445	chr12:7781288	NA	-0.86	-4.42	-0.34	1.87e-5	HDL cholesterol levels;
PAAD	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.37	4.76	0.36	4.45e-6	Educational attainment (years of education);
PAAD	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-0.94	-4.63	-0.35	7.88e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs11168351	0.927	rs11168342	chr12:48383797	G/T	cg21466736	chr12:48725269	NA	-0.51	-4.8	-0.36	3.81e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.49e-8	Menopause (age at onset);
PAAD	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.85	-7.05	-0.5	5.99e-11	Triglycerides;
PAAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg05484376	chr2:27715224	FNDC4	0.46	4.76	0.36	4.55e-6	Total body bone mineral density;
PAAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.4	-0.61	7.69e-17	Calcium levels;
PAAD	cis	rs4073221	0.654	rs13063618	chr3:18294897	T/C	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.98	-5.69	-0.42	6.2e-8	Longevity;Endometriosis;
PAAD	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg25838818	chr2:108905173	SULT1C2	-0.5	-5.04	-0.38	1.3e-6	Blood pressure;
PAAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.66	-6.56	-0.47	7.91e-10	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.74	-8.07	-0.55	2.03e-13	Migraine;Coronary artery disease;
PAAD	cis	rs17227506	0.730	rs36106719	chr8:13457693	G/C	cg02718516	chr8:13424094	C8orf48	-0.32	-4.26	-0.33	3.59e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.86	-4.8	-0.36	3.8e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs11825064	0.774	rs2000861	chr11:134496258	A/G	cg02089395	chr11:134479357	NA	-0.66	-4.52	-0.34	1.25e-5	Seasonality;
PAAD	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.46	5.64	0.42	7.89e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14169450	chr9:139327907	INPP5E	0.49	4.36	0.33	2.39e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-5.14	-0.38	8.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg03077836	chr2:9347292	ASAP2	0.95	6.94	0.49	1.05e-10	Lung function (FEV1/FVC);
PAAD	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg20169779	chr10:135381914	SYCE1	0.46	4.45	0.34	1.66e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg02493740	chr2:85810744	VAMP5	0.45	5.07	0.38	1.14e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg16926213	chr1:1841314	NA	0.38	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.32e-5	Skin colour saturation;
PAAD	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.74	-8.04	-0.55	2.36e-13	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.66	-7.83	-0.54	7.76e-13	Vitiligo;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.56	-6.03	-0.44	1.17e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.82	6.78	0.48	2.53e-10	Total cholesterol levels;
PAAD	cis	rs75920871	0.623	rs56016514	chr11:116961588	G/A	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs77437330	0.730	rs2269618	chr6:112040666	C/T	cg08926365	chr6:112007564	FYN	0.88	4.54	0.35	1.13e-5	Skin pigmentation;
PAAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.73	-6.23	-0.45	4.45e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.48	6.92	0.49	1.18e-10	Oropharynx cancer;
PAAD	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg26031613	chr14:104095156	KLC1	-0.55	-5.47	-0.41	1.84e-7	Reticulocyte count;
PAAD	cis	rs6782228	0.606	rs7627549	chr3:128353079	G/A	cg16766828	chr3:128327626	NA	-0.49	-6.6	-0.47	6.35e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6867032	0.527	rs4975720	chr5:2010455	C/G	cg26168224	chr5:2018326	NA	0.81	9.71	0.62	1.25e-17	Gut microbiome composition (winter);
PAAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg04106633	chr4:1044584	NA	-0.65	-5.46	-0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-1.02	-11.01	-0.67	4.23e-21	Breast cancer;
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg19630374	chr17:18023558	MYO15A	0.46	4.81	0.36	3.61e-6	Total body bone mineral density;
PAAD	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg10395934	chr14:104002654	TRMT61A	0.54	5.45	0.4	2.02e-7	Body mass index;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.7	0.36	5.89e-6	Electroencephalogram traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23878101	chr20:60813426	OSBPL2	0.63	6.95	0.49	1.02e-10	Monocyte percentage of white cells;
PAAD	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.86	10.64	0.65	4.04e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg19623624	chr10:135278901	LOC619207	0.42	4.44	0.34	1.73e-5	Systemic lupus erythematosus;
PAAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14895029	chr7:2775587	GNA12	-0.45	-4.25	-0.33	3.7e-5	Height;
PAAD	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.72	7.26	0.51	1.9e-11	Renal function-related traits (BUN);
PAAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.79	8.25	0.56	7.17e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.7	7.55	0.52	3.85e-12	Melanoma;
PAAD	cis	rs943466	0.614	rs4711345	chr6:33730954	G/A	cg18005901	chr6:33739558	LEMD2	-0.45	-4.28	-0.33	3.25e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.7	-4.82	-0.36	3.48e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs41311933	0.831	rs79516694	chr9:123766526	A/C	cg13567360	chr9:123745713	C5	-0.72	-4.59	-0.35	9.12e-6	Coronary artery disease;
PAAD	cis	rs6715793	0.772	rs62146726	chr2:33431529	C/G	cg26672287	chr2:33391915	LTBP1	-0.41	-4.81	-0.36	3.55e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.51	0.41	1.48e-7	Prudent dietary pattern;
PAAD	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.84	7.33	0.51	1.26e-11	Alzheimer's disease;
PAAD	cis	rs7631605	0.905	rs17810211	chr3:37113405	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.64	-6.09	-0.44	9e-9	Schizophrenia;
PAAD	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg09789173	chr7:4769017	FOXK1	0.75	8.01	0.54	2.76e-13	Mosquito bite size;
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.94	8.01	0.54	2.75e-13	Alzheimer's disease;
PAAD	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.51	-4.75	-0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6782228	1.000	rs7429360	chr3:128364797	A/G	cg15607142	chr3:128420513	NA	-0.44	-4.68	-0.36	6.24e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.24	-0.64	4.86e-19	Response to antipsychotic treatment;
PAAD	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.9	11.03	0.67	3.81e-21	Dental caries;
PAAD	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.22	-0.55	8.42e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs11811982	0.793	rs79098346	chr1:227220437	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.75	0.36	4.71e-6	Optic disc area;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14159672	chr1:205819179	PM20D1	0.63	6.65	0.47	4.91e-10	Prostate cancer;
PAAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.5	4.9	0.37	2.39e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.51	-4.42	-0.34	1.89e-5	Obesity;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.67	-0.48	4.46e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15664640	chr17:80829946	TBCD	0.68	5.95	0.43	1.74e-8	Breast cancer;
PAAD	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.57	-0.47	7.41e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7927592	0.645	rs7950900	chr11:68293545	G/A	cg20283391	chr11:68216788	NA	-0.52	-4.8	-0.36	3.75e-6	Total body bone mineral density;
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.78	-8.35	-0.56	3.85e-14	Prostate cancer;
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg10224037	chr5:178157518	ZNF354A	0.64	4.95	0.37	1.95e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07648498	chr16:89883185	FANCA	0.68	6.94	0.49	1.05e-10	Vitiligo;
PAAD	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.58	-0.41	1.06e-7	Metabolite levels (Pyroglutamine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14860928	chr4:859328	GAK	-0.69	-7.22	-0.51	2.36e-11	Obesity-related traits;
PAAD	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-8.37	-0.56	3.51e-14	Colorectal cancer;
PAAD	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.44	0.61	6.28e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs6460942	0.908	rs78780802	chr7:12233216	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.28	-0.33	3.24e-5	Schizophrenia;
PAAD	cis	rs1555895	0.576	rs4881536	chr10:848058	A/G	cg26597838	chr10:835615	NA	0.46	4.9	0.37	2.44e-6	Survival in rectal cancer;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.51	-5.81	-0.43	3.54e-8	Cardiovascular disease risk factors;
PAAD	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.29	-0.33	3.21e-5	Total body bone mineral density;
PAAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.96	-6.46	-0.46	1.36e-9	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg19402173	chr7:128379420	CALU	-0.64	-7.54	-0.52	3.95e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.68	-0.48	4.28e-10	Parkinson's disease;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.67	7.56	0.52	3.57e-12	Bone mineral density;
PAAD	cis	rs758324	0.853	rs1604082	chr5:131176917	A/G	cg06307176	chr5:131281290	NA	0.52	4.54	0.35	1.14e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.41	4.81	0.36	3.68e-6	Total body bone mineral density;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.49	-6.01	-0.44	1.3e-8	Lymphocyte counts;
PAAD	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg03989125	chr22:38214979	NA	-0.54	-5.58	-0.41	1.07e-7	Glioblastoma;Glioma;
PAAD	cis	rs7688540	0.800	rs12506277	chr4:287649	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.65	0.35	7.1e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.03	0.44	1.19e-8	Platelet count;
PAAD	cis	rs727479	0.543	rs1065778	chr15:51520206	T/C	cg21478137	chr15:51532386	CYP19A1	0.54	5.25	0.39	4.96e-7	Estradiol levels;
PAAD	cis	rs7091957	0.875	rs4880419	chr10:134456109	C/T	cg26549601	chr10:134560360	INPP5A	0.41	4.5	0.34	1.36e-5	Gait speed in old age;
PAAD	cis	rs656900	0.692	rs7171819	chr15:80108019	A/G	cg02196730	chr15:80188777	MTHFS	0.5	5.54	0.41	1.3e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.59	5.36	0.4	3.1e-7	Breast cancer;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg17541715	chr7:1216824	NA	-0.57	-6.87	-0.49	1.51e-10	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg10729496	chr3:10149963	C3orf24	0.93	8.04	0.55	2.4e-13	Alzheimer's disease;
PAAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.83	7.87	0.54	6.17e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.89	-9.07	-0.59	5.75e-16	Asthma;
PAAD	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.33	0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.39	-5.64	-0.42	7.96e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.7	-7.93	-0.54	4.35e-13	Renal function-related traits (BUN);
PAAD	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg23682824	chr7:23144976	KLHL7	0.48	4.58	0.35	9.62e-6	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23983551	chr3:47021148	NBEAL2	0.65	7.23	0.51	2.14e-11	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg09835421	chr16:68378352	PRMT7	-0.67	-5.2	-0.39	6.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.94	10.64	0.65	4.28e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.49	-4.89	-0.37	2.5e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Height;
PAAD	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg01338255	chr20:30176054	NA	0.48	4.4	0.34	1.99e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs1256061	0.624	rs1152577	chr14:64697485	T/G	cg23250157	chr14:64679961	SYNE2	0.56	5.62	0.41	8.76e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg11874272	chr3:121773564	CD86	-0.42	-4.37	-0.33	2.29e-5	Multiple sclerosis;
PAAD	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.8	-10.07	-0.63	1.34e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs5009270	0.524	rs11763427	chr7:112162843	C/T	cg23628563	chr7:112262597	NA	0.6	4.92	0.37	2.19e-6	Osteoarthritis (hip);
PAAD	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg14196790	chr5:131705035	SLC22A5	0.41	4.3	0.33	3.06e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.61	6.07	0.44	9.84e-9	Blood protein levels;
PAAD	cis	rs3764400	0.508	rs55696440	chr17:46271146	G/A	cg10706073	chr17:46328419	SKAP1	-1.07	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.54	-0.35	1.15e-5	Eosinophil percentage of white cells;
PAAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg05110241	chr16:68378359	PRMT7	-0.9	-7.29	-0.51	1.59e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.99	6.98	0.49	8.79e-11	Major depressive disorder;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.46	6.36	0.46	2.24e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg16342193	chr10:102329863	NA	-0.76	-8.17	-0.55	1.1e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.58	-0.35	9.55e-6	Post bronchodilator FEV1;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05799013	chr16:3451666	ZNF174;ZNF434	-0.68	-6.73	-0.48	3.32e-10	Lung cancer in ever smokers;
PAAD	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.95	-10.59	-0.65	5.64e-20	Headache;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.79	5.28	0.39	4.3e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs501120	0.513	rs1680639	chr10:44701754	T/G	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.72	0.36	5.36e-6	Pancreatic cancer;
PAAD	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.47	-0.41	1.82e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-7.85	-0.54	6.91e-13	Systemic lupus erythematosus;
PAAD	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.35	0.4	3.14e-7	Educational attainment;
PAAD	cis	rs7487075	0.619	rs11183483	chr12:46826481	C/T	cg14671384	chr12:47219920	SLC38A4	0.43	4.28	0.33	3.24e-5	Itch intensity from mosquito bite;
PAAD	cis	rs76793172	0.920	rs113577760	chr19:46365177	T/C	cg13320842	chr19:46175254	GIPR	0.63	4.68	0.35	6.36e-6	Eosinophil counts;
PAAD	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.75	-7.38	-0.51	9.72e-12	Multiple sclerosis;
PAAD	cis	rs2109514	0.902	rs7810505	chr7:116111078	G/T	cg19719915	chr7:115928094	NA	-0.45	-4.36	-0.33	2.38e-5	Prevalent atrial fibrillation;
PAAD	cis	rs12612619	0.658	rs77920959	chr2:27151590	T/C	cg00617064	chr2:27272375	NA	-0.43	-4.62	-0.35	8.19e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg27565382	chr3:53032988	SFMBT1	0.8	4.7	0.36	5.77e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.98e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.71	-7.77	-0.53	1.1e-12	Lung cancer;
PAAD	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.27	0.51	1.74e-11	IgG glycosylation;
PAAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs617219	0.710	rs2607142	chr5:78557948	T/C	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-1.17	-13.0	-0.73	1.88e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.68	7.55	0.52	3.74e-12	Total body bone mineral density;
PAAD	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.89	-0.49	1.42e-10	Morning vs. evening chronotype;
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.25	-0.51	1.95e-11	Longevity;
PAAD	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-6.84	-0.49	1.77e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs10465746	0.570	rs6658559	chr1:84467412	A/G	cg10977910	chr1:84465055	TTLL7	0.51	4.6	0.35	8.87e-6	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.5	-5.43	-0.4	2.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35785195	0.593	rs35746281	chr12:114236586	C/T	cg24771877	chr12:114234123	NA	0.64	5.13	0.38	8.7e-7	Daytime sleep phenotypes;
PAAD	cis	rs569214	0.685	rs2582370	chr8:27508543	C/T	cg04264299	chr8:27491209	SCARA3	0.5	4.47	0.34	1.53e-5	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.6	7.43	0.52	7.18e-12	Multiple system atrophy;
PAAD	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.39	13.52	0.74	7.43e-28	Corneal structure;
PAAD	cis	rs11113894	0.901	rs34076646	chr12:108859505	A/G	cg06834313	chr12:108851556	NA	-0.76	-4.6	-0.35	8.71e-6	Obesity-related traits;
PAAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.39	-0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.29e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.77	-6.65	-0.47	4.92e-10	Other erythrocyte phenotypes;
PAAD	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.7	-4.8	-0.36	3.82e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.56	5.83	0.43	3.27e-8	Cognitive function;
PAAD	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.81	-0.43	3.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.39	4.4	0.34	2.02e-5	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22622667	chr10:134790769	NA	-0.65	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.86	10.67	0.65	3.45e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.25	-0.51	2.02e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11112613	0.648	rs11112635	chr12:106047112	A/G	cg03607813	chr12:105948248	NA	0.65	5.41	0.4	2.41e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg03983476	chr2:10830698	NOL10	0.6	6.09	0.44	8.69e-9	Prostate cancer;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.35	-0.33	2.48e-5	Life satisfaction;
PAAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg05585544	chr11:47624801	NA	-0.43	-4.65	-0.35	7.24e-6	Subjective well-being;
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg19784903	chr17:45786737	TBKBP1	-0.6	-6.57	-0.47	7.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1105228	0.731	rs1547709	chr6:165705488	T/C	cg20535254	chr6:165714960	C6orf118	0.42	4.28	0.33	3.29e-5	Number of pregnancies;Number of children;
PAAD	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.5	-4.72	-0.36	5.31e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg08926642	chr1:7887455	PER3	0.48	4.25	0.33	3.77e-5	Inflammatory bowel disease;
PAAD	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.95	-7.33	-0.51	1.25e-11	Monocyte percentage of white cells;
PAAD	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	5.11	0.38	9.7e-7	Myopia (pathological);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22948236	chr19:590538	HCN2	-0.62	-6.53	-0.47	9.55e-10	Smoking initiation;
PAAD	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg14196790	chr5:131705035	SLC22A5	0.44	4.79	0.36	3.87e-6	Breast cancer;
PAAD	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg12184421	chr1:167409136	CD247	0.37	4.31	0.33	2.96e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg15309053	chr8:964076	NA	0.49	5.49	0.41	1.63e-7	Schizophrenia;
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.63	6.77	0.48	2.61e-10	Mean corpuscular volume;
PAAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.11	-8.91	-0.59	1.44e-15	Diabetic kidney disease;
PAAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.53	4.86	0.37	2.91e-6	Blood metabolite levels;
PAAD	cis	rs6028335	0.674	rs59072291	chr20:37622010	T/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.64	-0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg01236616	chr12:121019343	POP5	0.46	4.29	0.33	3.18e-5	High light scatter reticulocyte count;
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg18279126	chr7:2041391	MAD1L1	0.59	5.75	0.42	4.74e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	-0.43	-5.96	-0.44	1.68e-8	Oropharynx cancer;
PAAD	cis	rs9346353	0.737	rs11970363	chr6:70470516	C/T	cg03001484	chr6:70507230	LMBRD1	0.3	4.36	0.33	2.35e-5	Sleep duration;
PAAD	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.62	-5.99	-0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.649	rs815044	chr12:33722209	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.56	6.05	0.44	1.07e-8	Mean corpuscular volume;
PAAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.7	-0.36	5.77e-6	Mean corpuscular volume;
PAAD	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.51	-0.68	1.89e-22	Chronic sinus infection;
PAAD	cis	rs12612619	0.732	rs714513	chr2:27206474	T/C	cg00617064	chr2:27272375	NA	-0.49	-5.19	-0.39	6.6e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-13.91	-0.75	6.69e-29	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.49	4.73	0.36	5.09e-6	Menopause (age at onset);
PAAD	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg00666640	chr1:248458726	OR2T12	0.6	4.74	0.36	4.9100000000000004e-06	Common traits (Other);
PAAD	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.6	-6.31	-0.46	2.88e-9	Cognitive function;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg02869306	chr7:64672164	INTS4L1	-0.42	-4.84	-0.37	3.13e-6	Calcium levels;
PAAD	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01087645	chr16:28503407	CLN3	-0.78	-6.74	-0.48	3.06e-10	Neuroticism;
PAAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.66	-0.35	6.8e-6	Height;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.86	-9.17	-0.6	3.13e-16	Menopause (age at onset);
PAAD	cis	rs7631605	0.875	rs9879135	chr3:37132279	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08342675	chr2:201676391	BZW1	0.66	6.77	0.48	2.65e-10	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg20312557	chr2:97357134	FER1L5	-0.88	-4.59	-0.35	9.25e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7897654	0.651	rs7085854	chr10:104650251	T/C	cg14737131	chr10:104680354	CNNM2	0.42	4.27	0.33	3.47e-5	Schizophrenia;
PAAD	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.87	0.49	1.54e-10	Resting heart rate;
PAAD	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg08501292	chr6:25962987	TRIM38	0.91	5.45	0.4	1.95e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	1.0	8.14	0.55	1.34e-13	Triglycerides;
PAAD	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg16898833	chr6:26189333	HIST1H4D	0.92	4.81	0.36	3.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.71	4.9	0.37	2.43e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.39	-4.34	-0.33	2.62e-5	Mean platelet volume;
PAAD	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.82	-0.43	3.33e-8	Primary biliary cholangitis;
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.75	-0.42	4.68e-8	YKL-40 levels;
PAAD	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg10547527	chr2:198650123	BOLL	-0.68	-4.73	-0.36	5.15e-6	Ulcerative colitis;
PAAD	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.75	-0.36	4.65e-6	Endometrial cancer;
PAAD	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.23	-0.39	5.57e-7	Glomerular filtration rate;
PAAD	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	6.3	0.46	3.02e-9	Schizophrenia;
PAAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	6.89	0.49	1.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.28e-11	Menopause (age at onset);
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg10365880	chr10:102089681	PKD2L1	0.67	4.47	0.34	1.55e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.96	11.4	0.68	3.87e-22	Breast cancer;
PAAD	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.23	0.39	5.48e-7	Alzheimer's disease (survival time);
PAAD	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.83	-6.53	-0.47	9.08e-10	Blood protein levels;
PAAD	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-4.37	-0.33	2.25e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.5	-0.34	1.35e-5	Body mass index;
PAAD	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.04	-0.44	1.13e-8	Menopause (age at onset);
PAAD	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.64	10.23	0.64	5.29e-19	Migraine;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.59	5.96	0.44	1.72e-8	White matter hyperintensity burden;
PAAD	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.46	5.57	0.41	1.13e-7	Monocyte count;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.72	6.44	0.46	1.48e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg22800045	chr5:56110881	MAP3K1	-0.96	-7.78	-0.53	1.05e-12	Initial pursuit acceleration;
PAAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.52	0.57	1.49e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs112990264	1.000	rs113501484	chr1:213015383	G/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg19264203	chr11:92714893	MTNR1B	0.4	4.56	0.35	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.49	4.92	0.37	2.21e-6	Mean corpuscular volume;
PAAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs9616064	0.688	rs117095143	chr22:46973214	T/C	cg03318428	chr22:46971703	NA	0.4	4.47	0.34	1.52e-5	Urate levels in obese individuals;
PAAD	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.68	-0.35	6.33e-6	Biliary atresia;
PAAD	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg08898775	chr15:59042684	ADAM10	0.41	5.39	0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg09839279	chr12:125627357	AACS	-0.48	-4.56	-0.35	1.03e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs818427	0.896	rs712665	chr5:112227799	C/T	cg06941702	chr5:112196734	SRP19	-0.51	-4.77	-0.36	4.35e-6	Total body bone mineral density;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg02696790	chr15:75250997	RPP25	0.42	4.97	0.37	1.82e-6	Breast cancer;
PAAD	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg06636551	chr8:101224915	SPAG1	0.59	7.55	0.52	3.65e-12	Atrioventricular conduction;
PAAD	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8067354	0.574	rs1296279	chr17:57965731	G/A	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs6594713	0.533	rs71577456	chr5:112956751	C/G	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs735539	0.521	rs9550675	chr13:21466641	C/A	cg27234864	chr13:21295941	IL17D	0.62	4.95	0.37	1.99e-6	Dental caries;
PAAD	cis	rs11264799	0.765	rs67070092	chr1:157622973	T/A	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.43	-4.28	-0.33	3.3e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg18209359	chr17:80159595	CCDC57	0.43	4.3	0.33	3.02e-5	Life satisfaction;
PAAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1018697	1.000	rs6584525	chr10:104551981	G/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg01064725	chr1:204461714	NA	0.5	4.62	0.35	8.23e-6	Schizophrenia;
PAAD	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.66	-5.83	-0.43	3.23e-8	Type 2 diabetes;
PAAD	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg27449745	chr7:23145252	KLHL7	-0.59	-5.3	-0.4	3.93e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06141120	chr3:183852978	EIF2B5	0.63	6.34	0.46	2.5e-9	Obesity-related traits;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-0.58	-4.37	-0.33	2.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08219700	chr8:58056026	NA	0.68	5.21	0.39	6.08e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.53	4.68	0.35	6.28e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14105680	chr2:113676235	IL1F7	-0.73	-7.84	-0.54	7.26e-13	Obesity-related traits;
PAAD	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.12	-0.38	9.25e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.72	5.64	0.42	8.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12511469	0.505	rs1873369	chr4:155408478	C/A	cg22744079	chr4:155410860	DCHS2	0.45	4.76	0.36	4.48e-6	Fibrinogen;
PAAD	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.59	-0.41	1.05e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg05625103	chr10:2543513	NA	0.57	5.94	0.43	1.86e-8	Age-related hearing impairment;
PAAD	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg14393609	chr7:65229607	NA	-0.63	-6.88	-0.49	1.5e-10	Cotinine glucuronidation;
PAAD	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg00262122	chr8:11665843	FDFT1	-0.53	-4.44	-0.34	1.75e-5	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs75820736	chr10:46076236	C/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg21361702	chr7:150065534	REPIN1	0.62	5.1	0.38	1.01e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg20913747	chr6:44695427	NA	0.67	6.38	0.46	2.05e-9	Total body bone mineral density;
PAAD	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.62	6.01	0.44	1.34e-8	Schizophrenia;
PAAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-8.57	-0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.45e-7	Monocyte percentage of white cells;
PAAD	cis	rs4924935	0.543	rs1737939	chr17:18848023	A/G	cg26306683	chr17:18585705	ZNF286B	0.52	5.08	0.38	1.09e-6	Pancreatic cancer;
PAAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.84	-6.85	-0.49	1.75e-10	Psoriasis;
PAAD	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15403654	chr17:7747012	KDM6B	0.58	6.58	0.47	7.21e-10	Monocyte percentage of white cells;
PAAD	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.54e-17	White blood cell count (basophil);
PAAD	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg25649188	chr17:73499917	CASKIN2	0.47	4.62	0.35	8.1e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs2455826	0.521	rs13095037	chr3:15898516	T/C	cg13420985	chr3:16524424	RFTN1	-0.45	-4.3	-0.33	3e-5	Inflammatory skin disease;
PAAD	cis	rs7631605	0.870	rs11129746	chr3:37001972	C/G	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg11941060	chr3:133502564	NA	-0.62	-6.38	-0.46	2.07e-9	Iron status biomarkers;
PAAD	cis	rs12541635	1.000	rs1864320	chr8:107088979	C/T	cg10147462	chr8:107024639	NA	0.44	4.66	0.35	6.93e-6	Age of smoking initiation;
PAAD	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.74	-5.64	-0.42	8.02e-8	Mean platelet volume;
PAAD	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg18431297	chr4:7219810	SORCS2	-0.39	-4.66	-0.35	6.92e-6	Insulin-like growth factors;
PAAD	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.7	6.16	0.45	6.31e-9	Pubertal anthropometrics;
PAAD	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.74	-8.02	-0.55	2.62e-13	Sudden cardiac arrest;
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1075265	0.633	rs28653587	chr2:54219572	C/G	cg04546899	chr2:54196757	PSME4	0.31	4.69	0.36	6.13e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg05554000	chr7:158905015	VIPR2	-0.55	-5.02	-0.38	1.46e-6	Facial morphology (factor 20);
PAAD	cis	rs2286503	0.966	rs2286507	chr7:22854760	T/C	cg04907244	chr7:22894795	SNORD93	-0.43	-5.33	-0.4	3.51e-7	Fibrinogen;
PAAD	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.54e-10	Total body bone mineral density;
PAAD	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.6	6.04	0.44	1.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.23	0.81	1.41e-37	Prudent dietary pattern;
PAAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg06026331	chr20:60912101	LAMA5	0.62	4.96	0.37	1.88e-6	Colorectal cancer;
PAAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.89	10.86	0.66	1.06e-20	Aortic root size;
PAAD	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.87	-0.49	1.55e-10	Total body bone mineral density;
PAAD	cis	rs3206736	0.541	rs6964650	chr7:34964947	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.52	-4.97	-0.37	1.79e-6	Diastolic blood pressure;
PAAD	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.61	7.54	0.52	3.92e-12	Inflammatory bowel disease;
PAAD	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.53	-4.69	-0.36	5.97e-6	Atopic dermatitis;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg02696790	chr15:75250997	RPP25	0.37	4.29	0.33	3.22e-5	Breast cancer;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-7.82	-0.54	8.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.55	5.7	0.42	6.16e-8	Schizophrenia;
PAAD	cis	rs2712184	0.683	rs2541403	chr2:217637885	A/G	cg05032264	chr2:217675019	NA	0.53	6.07	0.44	1e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.8	7.16	0.5	3.22e-11	Cognitive function;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.29e-16	Asthma (childhood onset);
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11245990	chr11:68621969	NA	0.36	4.73	0.36	5.13e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.58	-0.47	7.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs62179067	0.867	rs76097715	chr2:179993153	C/T	cg23458843	chr12:58136445	AGAP2	0.96	6.39	0.46	1.94e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.85	6.39	0.46	1.89e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs17095355	0.901	rs61579832	chr10:111766275	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.69	-4.71	-0.36	5.5e-6	Biliary atresia;
PAAD	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28489187	0.617	rs7547571	chr1:85884091	G/T	cg16011679	chr1:85725395	C1orf52	-0.45	-4.49	-0.34	1.38e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg05234568	chr11:5960015	NA	-0.73	-7.87	-0.54	6.01e-13	DNA methylation (variation);
PAAD	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg19192590	chr2:178524533	PDE11A	0.43	5.14	0.38	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-10.75	-0.66	2.16e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs76419734	0.558	rs4324546	chr4:106526987	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.56	-0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs800160	0.777	rs11600971	chr11:2343441	G/T	cg09785033	chr11:2336066	TSPAN32	-0.5	-4.32	-0.33	2.83e-5	Bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14573099	chr2:101761014	TBC1D8	-0.63	-6.4	-0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.53	-4.47	-0.34	1.49e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10547527	chr2:198650123	BOLL	0.49	4.35	0.33	2.48e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1982963	0.627	rs77101097	chr14:52494300	C/T	cg20550154	chr14:52487779	NID2	0.6	5.02	0.38	1.46e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.73	-0.36	5.12e-6	HDL cholesterol;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.84	5.72	0.42	5.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	4.53	0.34	1.2e-5	Iron status biomarkers;
PAAD	cis	rs12612619	0.579	rs6756245	chr2:27083489	C/T	cg12368169	chr2:27073192	DPYSL5	0.43	4.47	0.34	1.5e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg13269407	chr22:46450107	C22orf26;LOC150381	0.54	4.85	0.37	3.03e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	4.95	0.37	1.94e-6	Lung cancer in ever smokers;
PAAD	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25650185	chr19:21324782	ZNF431	-0.49	-4.49	-0.34	1.4e-5	Pain;
PAAD	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg21153622	chr11:89784906	NA	-0.56	-6.41	-0.46	1.76e-9	HDL cholesterol;
PAAD	cis	rs748404	0.578	rs1058298	chr15:43700930	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	5.05	0.38	1.24e-6	Lung cancer;
PAAD	cis	rs1801239	1.000	rs74375025	chr10:16947664	G/A	cg00939682	chr10:16933505	CUBN	0.69	4.72	0.36	5.39e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg12218747	chr21:37451666	NA	-0.47	-5.12	-0.38	9.29e-7	Mitral valve prolapse;
PAAD	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg00071950	chr4:10020882	SLC2A9	0.52	4.58	0.35	9.8200000000000008e-06	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.45	-5.05	-0.38	1.23e-6	Post-traumatic stress disorder;
PAAD	cis	rs9810890	0.702	rs73207972	chr3:128568186	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg21479132	chr6:26055353	NA	0.99	6.01	0.44	1.31e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg07153921	chr17:41440717	NA	-0.41	-4.29	-0.33	3.14e-5	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.9	11.74	0.69	4.54e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.52	-5.89	-0.43	2.37e-8	Migraine;
PAAD	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	8.0	0.54	2.94e-13	Monocyte percentage of white cells;
PAAD	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.48	0.34	1.43e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg23241863	chr10:102295624	HIF1AN	0.47	4.32	0.33	2.84e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg03983715	chr16:68378420	PRMT7	-0.97	-7.16	-0.5	3.22e-11	Schizophrenia;
PAAD	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.88	-10.32	-0.64	2.89e-19	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17150246	chr1:161068070	KLHDC9	0.62	7.19	0.5	2.68e-11	Metabolite levels  (X-11787);
PAAD	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	7.46	0.52	6.36e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.89	10.95	0.66	5.99e-21	Dental caries;
PAAD	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	4.37	0.33	2.26e-5	Depressive symptoms;
PAAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs54211	0.536	rs470081	chr22:39713105	C/T	cg24399712	chr22:39784796	NA	-0.62	-4.38	-0.33	2.22e-5	Sudden cardiac arrest;
PAAD	cis	rs11590090	1.000	rs12732455	chr1:113310684	G/A	cg25707805	chr1:113285387	NA	0.35	4.74	0.36	4.92e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg24737193	chr18:12778029	NA	0.63	5.33	0.4	3.48e-7	Inflammatory skin disease;
PAAD	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.26	0.39	4.73e-7	Type 2 diabetes;
PAAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg21351543	chr2:191399470	TMEM194B	-0.64	-4.87	-0.37	2.76e-6	Diastolic blood pressure;
PAAD	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs732765	0.734	rs10136897	chr14:75173392	T/G	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg01528321	chr10:82214614	TSPAN14	0.97	10.33	0.64	2.8e-19	Post bronchodilator FEV1;
PAAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.75	5.89	0.43	2.35e-8	Methadone dose in opioid dependence;
PAAD	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.63	4.88	0.37	2.64e-6	Gut microbiome composition (summer);
PAAD	cis	rs7534824	0.625	rs61782081	chr1:101507074	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.69	0.36	6.06e-6	Refractive astigmatism;
PAAD	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.37	-4.37	-0.33	2.33e-5	Pubertal anthropometrics;
PAAD	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg17644776	chr2:200775616	C2orf69	-0.68	-5.92	-0.43	2.02e-8	Schizophrenia;
PAAD	cis	rs7945718	0.592	rs6416153	chr11:12684263	A/G	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09470230	chr10:72972137	UNC5B	0.61	6.8	0.48	2.24e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	1.18	13.27	0.73	3.45e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg14146966	chr2:61757674	XPO1	0.37	4.67	0.35	6.57e-6	Tuberculosis;
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	4.94	0.37	2e-6	Bipolar disorder;
PAAD	cis	rs4705952	0.832	rs763595	chr5:131863244	A/G	cg05209330	chr5:131550942	P4HA2	0.51	4.3	0.33	3.09e-5	C-reactive protein levels;
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg10978503	chr1:24200527	CNR2	-0.47	-5.5	-0.41	1.57e-7	Immature fraction of reticulocytes;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.98	-13.01	-0.73	1.8e-26	Menarche (age at onset);
PAAD	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.52	4.8	0.36	3.76e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg17749961	chr2:30669863	LCLAT1	0.72	6.02	0.44	1.23e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg02683114	chr2:24398427	C2orf84	0.45	5.22	0.39	5.69e-7	Asthma;
PAAD	cis	rs798766	0.909	rs744658	chr4:1755074	C/T	cg01305830	chr4:1604576	NA	-0.49	-4.51	-0.34	1.3e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs476633	0.708	rs3986303	chr15:41443179	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.29	-0.56	5.65e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1879734	0.636	rs1879733	chr1:54175971	T/C	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs7172971	0.511	rs8042630	chr15:42398358	C/A	cg07013680	chr15:42186124	SPTBN5	0.45	4.4	0.34	1.99e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg05709478	chr1:6581295	PLEKHG5	0.76	4.9	0.37	2.44e-6	Body mass index;
PAAD	cis	rs72827839	0.744	rs16955463	chr17:46399497	G/T	cg23391107	chr17:45924227	SP6	0.53	5.03	0.38	1.35e-6	Ease of getting up in the morning;
PAAD	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.51	-0.34	1.28e-5	Inflammatory bowel disease;
PAAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg10011062	chr15:43941034	CATSPER2	0.7	4.29	0.33	3.15e-5	Lung cancer in ever smokers;
PAAD	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg02404636	chr22:31891804	SFI1	0.58	5.42	0.4	2.33e-7	Colorectal cancer;
PAAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.51	-5.32	-0.4	3.69e-7	Breast cancer;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.77	7.47	0.52	5.77e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21643547	chr1:205240462	TMCC2	-0.44	-5.15	-0.39	8.05e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs116248771	0.739	rs6768636	chr3:158347565	C/T	cg16708174	chr3:158430962	RARRES1	-0.72	-5.43	-0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.45	4.7	0.36	5.85e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.8	0.48	2.29e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs9462027	0.628	rs10738078	chr6:34693917	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.37	0.4	2.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs7823896	0.722	rs16879296	chr8:110331093	A/G	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg15448220	chr1:150897856	SETDB1	-0.56	-5.77	-0.42	4.38e-8	Tonsillectomy;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.52	4.54	0.35	1.13e-5	Depressive symptoms;
PAAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	cis	rs9918079	0.560	rs4557256	chr4:15626647	A/C	cg16509355	chr4:15471240	CC2D2A	-0.33	-4.34	-0.33	2.61e-5	Obesity-related traits;
PAAD	cis	rs7260329	0.713	rs4803414	chr19:41486082	T/C	cg23925301	chr19:41220945	ADCK4	-0.57	-4.88	-0.37	2.66e-6	Smoking behavior;
PAAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.57	6.39	0.46	1.95e-9	Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10390589	chr19:47634047	SAE1	0.6	6.46	0.46	1.32e-9	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12379764	chr21:47803548	PCNT	-0.47	-4.44	-0.34	1.71e-5	Testicular germ cell tumor;
PAAD	cis	rs8014252	0.803	rs2018131	chr14:71062432	T/C	cg11204974	chr14:71022665	NA	-0.58	-4.28	-0.33	3.24e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4287000	0.771	rs12002044	chr9:96389861	C/G	cg13787134	chr9:96362102	PHF2	0.38	4.44	0.34	1.75e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg08029281	chr1:67600428	NA	0.47	5.82	0.43	3.37e-8	Psoriasis;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.86	7.52	0.52	4.37e-12	Alzheimer's disease;
PAAD	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.62e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs863345	0.967	rs11265025	chr1:158513286	T/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.91	-0.37	2.35e-6	Pneumococcal bacteremia;
PAAD	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-0.99	-5.46	-0.41	1.87e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	7.36	0.51	1.09e-11	Post bronchodilator FEV1;
PAAD	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.67	6.31	0.46	2.95e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs11675636	0.571	rs72617028	chr2:136989616	G/T	cg27075654	chr16:1503444	CLCN7	0.73	6.35	0.46	2.31e-9	Alcohol dependence;
PAAD	cis	rs909341	0.909	rs2253829	chr20:62373079	G/C	cg03999872	chr20:62272968	STMN3	-0.68	-5.97	-0.44	1.62e-8	Atopic dermatitis;
PAAD	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg20503657	chr10:835505	NA	0.51	5.38	0.4	2.82e-7	Survival in rectal cancer;
PAAD	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg02640540	chr1:67518911	SLC35D1	-0.61	-4.83	-0.37	3.24e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.49	4.78	0.36	4.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07362569	chr17:61921086	SMARCD2	-0.49	-5.93	-0.43	2e-8	Prudent dietary pattern;
PAAD	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	7.13	0.5	3.76e-11	Hip circumference;
PAAD	cis	rs282587	0.569	rs432522	chr13:113400015	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-5.02	-0.38	1.4e-6	Glycated hemoglobin levels;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.76	-7.63	-0.53	2.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7551345	0.853	rs34556466	chr1:31759991	T/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.75	-0.36	4.73e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14647335	chr7:55712936	LOC442308	-0.58	-6.44	-0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg06138931	chr13:21896616	NA	-0.64	-4.33	-0.33	2.67e-5	White matter hyperintensity burden;
PAAD	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-1.09	-7.66	-0.53	1.98e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg00105475	chr2:10696890	NA	-0.63	-6.67	-0.48	4.39e-10	Prostate cancer;
PAAD	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-5.15	-0.39	8.08e-7	Lung cancer in ever smokers;
PAAD	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.84	6.83	0.48	1.88e-10	Chronic kidney disease;
PAAD	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00210098	chr3:12883308	SNORA7A;RPL32	-0.7	-6.85	-0.49	1.7e-10	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.69	-0.42	6.37e-8	Life satisfaction;
PAAD	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.24	12.59	0.71	2.37e-25	Post bronchodilator FEV1;
PAAD	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.91	11.46	0.68	2.65e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.53	5.13	0.38	8.55e-7	Testicular germ cell tumor;
PAAD	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.56	6.08	0.44	9.13e-9	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.7	0.72	1.19e-25	Chronic sinus infection;
PAAD	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	1.08	6.77	0.48	2.68e-10	Skin colour saturation;
PAAD	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.65	8.95	0.59	1.19e-15	Breast size;
PAAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg03037974	chr15:76606532	NA	0.54	6.43	0.46	1.57e-9	Blood metabolite levels;
PAAD	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg00022866	chr11:64108440	CCDC88B	0.33	4.5	0.34	1.36e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-10.71	-0.66	2.78e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs73198271	1.000	rs4841030	chr8:8607011	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.35	-0.46	2.4e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.66	-6.94	-0.49	1.05e-10	Schizophrenia;
PAAD	cis	rs863345	0.604	rs11265016	chr1:158503785	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	trans	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg26939375	chr7:64535504	NA	-0.77	-9.2	-0.6	2.63e-16	Aortic root size;
PAAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.08	-0.59	5.39e-16	Type 2 diabetes;
PAAD	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.72	0.42	5.37e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.77	-7.96	-0.54	3.6e-13	DNA methylation (variation);
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg06565975	chr8:143823917	SLURP1	-0.22	-4.83	-0.36	3.26e-6	Urinary tract infection frequency;
PAAD	cis	rs501120	1.000	rs534079	chr10:44752558	G/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	5.41	0.4	2.42e-7	Blood protein levels;
PAAD	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7945705	0.967	rs11042082	chr11:8839229	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.74	7.67	0.53	1.95e-12	Hemoglobin concentration;
PAAD	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs2279433	chr10:45954807	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9936833	1.000	rs9925757	chr16:86401931	G/A	cg03554962	chr16:86404423	NA	0.37	4.34	0.33	2.56e-5	Barrett's esophagus;
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg01831904	chr17:28903510	LRRC37B2	0.88	6.03	0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6460942	0.597	rs10273045	chr7:12519371	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.93	-0.37	2.17e-6	Coronary artery disease;
PAAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.85	8.65	0.57	6.94e-15	Coronary artery disease;
PAAD	trans	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg26939375	chr7:64535504	NA	-0.74	-8.63	-0.57	7.64e-15	Aortic root size;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg07341007	chr3:195489909	MUC4	0.63	4.95	0.37	1.97e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13647721	chr17:30228624	UTP6	-0.59	-4.74	-0.36	4.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11997175	0.655	rs4380889	chr8:33663381	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	5.34	0.4	3.29e-7	Body mass index;
PAAD	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.13	0.38	8.63e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6076065	0.723	rs6076073	chr20:23414489	G/A	cg11657817	chr20:23433608	CST11	0.47	4.72	0.36	5.28e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.58	-4.41	-0.34	1.91e-5	Birth weight;
PAAD	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-5.79	-0.43	3.82e-8	Cervical cancer;
PAAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.55	0.47	8.49e-10	Bladder cancer;
PAAD	cis	rs2455799	0.927	rs9821921	chr3:15798246	A/G	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Mean platelet volume;
PAAD	cis	rs11214966	1	rs11214966	chr11:114231255	C/T	cg00557402	chr11:114466517	FAM55D	-0.71	-4.81	-0.36	3.58e-6	Asthma;
PAAD	cis	rs508970	0.578	rs688607	chr11:60918223	C/T	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs533581	0.789	rs1673931	chr16:88976477	T/C	cg08698997	chr16:88989212	CBFA2T3	0.48	5.72	0.42	5.56e-8	Social autistic-like traits;
PAAD	cis	rs7127900	1.000	rs4076054	chr11:2231341	G/A	cg25635251	chr11:2234043	NA	0.85	7.58	0.52	3.18e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.94	11.14	0.67	1.87e-21	Primary sclerosing cholangitis;
PAAD	cis	rs12476592	0.602	rs2166497	chr2:63800159	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	8.04e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.33	-0.4	3.45e-7	Schizophrenia;
PAAD	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.8	8.58	0.57	1e-14	Calcium levels;
PAAD	cis	rs59888335	0.895	rs67854364	chr3:80834657	T/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-7.24	-0.51	2.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Tonsillectomy;Mean corpuscular volume;
PAAD	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.78	8.28	0.56	5.84e-14	Mean corpuscular volume;
PAAD	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.75	7.98	0.54	3.36e-13	Schizophrenia;
PAAD	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.22	7.14	0.5	3.63e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg13072238	chr3:49761600	GMPPB	0.4	4.26	0.33	3.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs863345	0.604	rs12063320	chr1:158499423	A/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21325040	chr11:113926596	NA	0.65	7.3	0.51	1.48e-11	Smoking initiation;
PAAD	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs7678296	1.000	rs17575590	chr4:37226024	G/T	cg06805348	chr4:37245195	KIAA1239	0.63	4.87	0.37	2.72e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.56	-0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg11380483	chr2:127933992	NA	0.9	9.0	0.59	8.56e-16	Protein C levels;
PAAD	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.52	-4.83	-0.36	3.26e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-11.95	-0.7	1.29e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06946541	chr16:57769688	KATNB1	-0.68	-6.43	-0.46	1.54e-9	Neuroticism;
PAAD	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7508	0.546	rs382752	chr8:17898383	A/G	cg20050877	chr8:17487895	PDGFRL	-0.49	-4.37	-0.33	2.26e-5	Atrial fibrillation;
PAAD	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.74	7.16	0.5	3.27e-11	Retinal vascular caliber;
PAAD	trans	rs901683	0.850	rs17157890	chr10:46020652	T/C	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg14256234	chr1:113217181	MOV10	0.57	4.33	0.33	2.7e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
PAAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg22800045	chr5:56110881	MAP3K1	0.97	7.57	0.52	3.38e-12	Type 2 diabetes;
PAAD	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.69	4.96	0.37	1.88e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.24	0.67	1.02e-21	Menopause (age at onset);
PAAD	cis	rs892961	0.966	rs4386185	chr17:75400891	G/A	cg05865280	chr17:75406074	SEPT9	0.69	9.59	0.61	2.58e-17	Airflow obstruction;
PAAD	cis	rs950881	0.932	rs13431828	chr2:102954653	C/T	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.66	6.44	0.46	1.49e-9	Schizophrenia;
PAAD	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	cis	rs7172971	0.688	rs75441807	chr15:42382436	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs75920871	0.800	rs17120251	chr11:116923488	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-5.27	-0.39	4.56e-7	Subjective well-being;
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-4.71	-0.36	5.6e-6	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.92	10.86	0.66	1.1e-20	Coronary artery disease;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs1140227	0.502	rs10789304	chr1:41587412	A/T	cg03387723	chr1:41708464	SCMH1	-0.51	-5.3	-0.4	3.97e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.76	-0.42	4.56e-8	Total cholesterol levels;
PAAD	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs6942407	0.640	rs4728690	chr7:86854004	A/G	cg02420886	chr7:86849541	C7orf23	0.61	5.13	0.38	8.68e-7	Food allergy;
PAAD	trans	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg20607287	chr7:12443886	VWDE	0.73	5.68	0.42	6.76e-8	Coronary artery disease;
PAAD	cis	rs4144027	0.967	rs72712857	chr14:104362673	T/C	cg19582115	chr14:103436037	CDC42BPB	-0.46	-4.43	-0.34	1.8e-5	Blood metabolite levels;
PAAD	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.47	5.09	0.38	1.04e-6	Age of smoking initiation;
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg18888403	chr1:24152774	HMGCL	0.42	4.79	0.36	4e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	1.01	11.73	0.69	4.85e-23	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg26898376	chr11:64110657	CCDC88B	0.44	4.71	0.36	5.46e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg00750074	chr16:89608354	SPG7	-0.6	-5.62	-0.41	8.83e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.61	6.31	0.46	2.87e-9	Crohn's disease;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.6	5.26	0.39	4.72e-7	Retinal vascular caliber;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg04160749	chr8:58172571	NA	-0.63	-4.5	-0.34	1.35e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	1.05	7.08	0.5	5.03e-11	IgG glycosylation;
PAAD	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg24565620	chr2:194026	NA	0.66	5.22	0.39	5.68e-7	Blood protein levels;
PAAD	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.23	-0.39	5.65e-7	Mean corpuscular volume;
PAAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.42	4.72	0.36	5.29e-6	Type 2 diabetes;
PAAD	cis	rs2882667	0.690	rs1848505	chr5:138182530	C/T	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg10556349	chr10:835070	NA	0.71	5.32	0.4	3.6e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2735413	0.958	rs1922611	chr16:78053121	C/T	cg04733911	chr16:78082701	NA	-0.52	-4.88	-0.37	2.7e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.92	7.6	0.52	2.82e-12	Total cholesterol levels;
PAAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.88	-8.69	-0.58	5.43e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.62	6.27	0.45	3.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.69	4.8	0.36	3.81e-6	Lung cancer in ever smokers;
PAAD	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-5.85	-0.43	2.88e-8	Systolic blood pressure;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg14789911	chr21:47582049	C21orf56	0.51	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-7.01	-0.49	7.14e-11	Parkinson's disease;
PAAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.86	8.12	0.55	1.49e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs58521262	0.519	rs12608978	chr19:23007554	A/G	cg07749055	chr19:23076870	NA	-0.61	-4.63	-0.35	7.81e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg15674680	chr20:60982522	CABLES2	-0.47	-4.28	-0.33	3.33e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.45	4.33	0.33	2.72e-5	Malaria;
PAAD	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.76	7.22	0.51	2.34e-11	Neuroticism;
PAAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.8	-0.48	2.19e-10	Aortic root size;
PAAD	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg00531865	chr16:30841666	NA	-0.59	-4.99	-0.38	1.65e-6	Multiple myeloma;
PAAD	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs8099014	1.000	rs4940701	chr18:56110158	A/T	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.54	5.11	0.38	9.54e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.82	-6.11	-0.44	7.94e-9	Coronary artery calcification;
PAAD	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg10932868	chr11:921992	NA	0.45	4.75	0.36	4.63e-6	Alzheimer's disease (late onset);
PAAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.8	9.76	0.62	9.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.33	0.33	2.67e-5	Self-reported allergy;
PAAD	cis	rs2594989	0.622	rs2442794	chr3:11551001	A/G	cg02835301	chr3:11609216	VGLL4	-0.48	-4.27	-0.33	3.36e-5	Circulating chemerin levels;
PAAD	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.45	6.8	0.48	2.25e-10	Information processing speed;
PAAD	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.67	-0.62	1.52e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.73	-7.51	-0.52	4.76e-12	Blood metabolite levels;
PAAD	cis	rs1075265	0.584	rs10164409	chr2:54168004	T/C	cg04546899	chr2:54196757	PSME4	0.31	4.62	0.35	8.08e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01765077	chr12:122356316	WDR66	0.71	7.36	0.51	1.1e-11	Mean corpuscular volume;
PAAD	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg09597638	chr17:3907349	NA	-0.73	-7.91	-0.54	4.85e-13	Type 2 diabetes;
PAAD	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg11143131	chr5:131608246	PDLIM4	0.55	5.33	0.4	3.44e-7	Blood metabolite levels;
PAAD	cis	rs76866386	0.892	rs79835740	chr2:44056148	A/T	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.85	-5.04	-0.38	1.32e-6	Cholesterol, total;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg25037394	chr1:24152592	HMGCL	0.42	4.59	0.35	9.25e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-4.46	-0.34	1.59e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.62	-6.03	-0.44	1.17e-8	Inflammatory bowel disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04500099	chr12:95610991	FGD6;VEZT	0.57	6.54	0.47	8.65e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.97	8.9	0.59	1.57e-15	Migraine;
PAAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.37	4.32	0.33	2.78e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4740619	0.868	rs10732335	chr9:15862077	A/C	cg14451791	chr9:16040625	NA	-0.39	-4.38	-0.33	2.24e-5	Body mass index;
PAAD	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg21427119	chr20:30132790	HM13	-0.52	-4.81	-0.36	3.62e-6	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.53	-5.45	-0.4	2.03e-7	Height;
PAAD	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.52	-0.34	1.22e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg11439826	chr17:76250004	NA	0.43	4.27	0.33	3.42e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.47	-5.3	-0.39	4e-7	Schizophrenia;
PAAD	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.81	8.0	0.54	2.92e-13	Lymphocyte counts;
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg00576331	chr11:65640516	EFEMP2	-0.47	-4.46	-0.34	1.59e-5	Eosinophil percentage of white cells;
PAAD	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	4.64	0.35	7.54e-6	Free thyroxine concentration;
PAAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.56	4.44	0.34	1.69e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs12044355	0.929	rs6696914	chr1:231853480	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.2	0.39	6.32e-7	Alzheimer's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20592691	chr13:60447453	DIAPH3	-0.55	-6.29	-0.45	3.15e-9	Energy expenditure (24h);
PAAD	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.16	-0.45	6.18e-9	Bipolar disorder;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg03543861	chr21:44258195	NA	-0.57	-4.28	-0.33	3.28e-5	Information processing speed;
PAAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-6.16	-0.45	6.12e-9	Personality dimensions;
PAAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.77	7.63	0.53	2.33e-12	Asthma;
PAAD	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.71	8.47	0.57	1.99e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.76	-6.99	-0.49	8.22e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.48	5.0	0.38	1.55e-6	Longevity;Endometriosis;
PAAD	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.45	4.68	0.36	6.23e-6	Platelet count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15007803	chr2:190306096	WDR75	0.68	6.76	0.48	2.71e-10	Obesity-related traits;
PAAD	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.66	0.42	7.38e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.76	-7.29	-0.51	1.55e-11	Cognitive function;
PAAD	trans	rs6828577	0.560	rs114938210	chr4:119457257	A/T	cg26518628	chr1:97050305	NA	-0.71	-6.32	-0.46	2.81e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.52	4.98	0.37	1.7e-6	Mortality in heart failure;
PAAD	trans	rs12190007	0.547	rs3006179	chr6:169822467	C/G	cg13891898	chr3:128484036	RAB7A	0.6	6.55	0.47	8.5e-10	Obesity-related traits;
PAAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.59	-5.93	-0.43	1.96e-8	Height;
PAAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.48	-4.6	-0.35	8.92e-6	Male sexual orientation;
PAAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.47	0.34	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg10437265	chr15:77819839	NA	-0.43	-4.92	-0.37	2.26e-6	Type 2 diabetes;
PAAD	trans	rs62179067	0.708	rs62176023	chr2:179915552	T/G	cg21380341	chr12:94543978	PLXNC1	-0.74	-6.79	-0.48	2.39e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.77	8.14	0.55	1.29e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.55	-6.37	-0.46	2.09e-9	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.82	9.03	0.59	7.1e-16	Colorectal cancer;
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.5	4.83	0.36	3.37e-6	Total body bone mineral density;
PAAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.78	0.48	2.56e-10	Coronary artery disease;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26549601	chr10:134560360	INPP5A	-0.44	-4.43	-0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.57	-7.16	-0.5	3.23e-11	Educational attainment;
PAAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg04450456	chr4:17643702	FAM184B	0.49	5.42	0.4	2.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg07677032	chr17:61819896	STRADA	0.55	5.23	0.39	5.53e-7	Prudent dietary pattern;
PAAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.56	5.38	0.4	2.8e-7	Eosinophil percentage of white cells;
PAAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg03938978	chr2:103052716	IL18RAP	0.61	5.14	0.38	8.25e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-10.55	-0.65	7.34e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg03605463	chr16:89740564	NA	0.8	8.4	0.56	2.91e-14	Vitiligo;
PAAD	cis	rs4729127	1.000	rs17166212	chr7:94008385	A/G	cg20814616	chr7:94014465	NA	-0.6	-4.41	-0.34	1.96e-5	Intelligence;
PAAD	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.81	0.54	8.78e-13	Monocyte percentage of white cells;
PAAD	cis	rs4450131	1.000	rs10444190	chr10:126375608	G/C	cg20435097	chr10:126320824	FAM53B	-0.49	-5.49	-0.41	1.65e-7	White blood cell count (basophil);
PAAD	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-1.02	-13.23	-0.73	4.64e-27	Refractive error;
PAAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg00206168	chr11:65308501	LTBP3	0.5	5.21	0.39	5.93e-7	Bone mineral density;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.79	-8.57	-0.57	1.1e-14	Prudent dietary pattern;
PAAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Breast cancer;
PAAD	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	10.33	0.64	2.8e-19	Post bronchodilator FEV1;
PAAD	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg10072921	chr12:121022843	NA	-0.44	-5.29	-0.39	4.12e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg01475377	chr6:109611718	NA	-0.43	-4.74	-0.36	4.93e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.56	-5.52	-0.41	1.46e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.01	-0.49	7.14e-11	Parkinson's disease;
PAAD	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.44	-5.11	-0.38	9.72e-7	Height;
PAAD	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.39	4.02e-7	Male-pattern baldness;
PAAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.54	0.35	1.14e-5	Bipolar disorder;
PAAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.55	-0.52	3.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	1.05	12.94	0.72	2.66e-26	Breast cancer;
PAAD	cis	rs3745672	0.590	rs79219764	chr19:12169962	G/A	cg11321965	chr19:12780562	MORG1;C19orf56	-1.03	-4.66	-0.35	6.79e-6	Multiple sclerosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15947940	chr1:39957129	BMP8A	-0.76	-6.95	-0.49	1.01e-10	Neuroticism;
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04798676	chr3:196230670	RNF168	-0.62	-6.34	-0.46	2.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20910303	chr4:147443095	SLC10A7	0.59	6.34	0.46	2.54e-9	Pancreatic cancer;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.34	-0.46	2.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs863345	0.625	rs12075903	chr1:158458932	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.33	0.4	3.47e-7	Prostate cancer;
PAAD	cis	rs3206736	0.514	rs1649236	chr7:35004134	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg09699651	chr6:150184138	LRP11	0.4	4.26	0.33	3.62e-5	Lung cancer;
PAAD	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22162314	chr17:61951766	CSH2	-0.59	-6.0	-0.44	1.41e-8	Height;
PAAD	cis	rs7923609	0.778	rs7075195	chr10:65050659	A/G	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.34	-0.33	2.58e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg10090792	chr1:38198142	EPHA10	-0.43	-4.53	-0.34	1.21e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs332507	0.830	rs10804562	chr3:124377196	C/T	cg05980111	chr3:124395277	KALRN	0.44	4.32	0.33	2.79e-5	Plateletcrit;
PAAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.78	9.35	0.6	1.04e-16	Emphysema distribution in smoking;
PAAD	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.62	6.47	0.46	1.29e-9	Caffeine consumption;
PAAD	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.65	-0.53	2.13e-12	Migraine;Coronary artery disease;
PAAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17422427	chr2:241507521	RNPEPL1	0.61	6.71	0.48	3.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.67	6.77	0.48	2.58e-10	Osteoporosis;
PAAD	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.86	-10.96	-0.66	5.66e-21	Aortic root size;
PAAD	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.64	-5.88	-0.43	2.46e-8	Breast size;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17757117	chr3:129158717	IFT122;MBD4	-0.63	-6.51	-0.47	1.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs643506	0.874	rs640651	chr11:111728911	A/G	cg09085632	chr11:111637200	PPP2R1B	0.51	4.31	0.33	2.87e-5	Breast cancer;
PAAD	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.6	7.05	0.5	5.78e-11	Aortic root size;
PAAD	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.71	-0.66	2.64e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs17407555	1.000	rs10489073	chr4:10272788	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-4.33	-0.33	2.68e-5	Schizophrenia (age at onset);
PAAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg23957660	chr17:17878224	LRRC48	0.37	4.32	0.33	2.77e-5	Total body bone mineral density;
PAAD	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.08	0.63	1.28e-18	Smoking behavior;
PAAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14895029	chr7:2775587	GNA12	-0.46	-4.68	-0.36	6.2e-6	Height;
PAAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.29e-6	Rheumatoid arthritis;
PAAD	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16417436	chr16:28758564	NA	-0.47	-4.38	-0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	1.04	6.18	0.45	5.72e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg07157834	chr1:205819609	PM20D1	0.61	4.99	0.38	1.6e-6	Prostate-specific antigen levels;
PAAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.53	0.61	3.7e-17	Rheumatoid arthritis;
PAAD	cis	rs12476592	1.000	rs12476592	chr2:63850098	G/C	cg10828910	chr2:63850056	LOC388955	-0.55	-4.27	-0.33	3.37e-5	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.86	10.89	0.66	9.14e-21	Prudent dietary pattern;
PAAD	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.0	-0.44	1.41e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs457162	0.521	rs430538	chr6:118612879	C/T	cg21191810	chr6:118973309	C6orf204	0.67	4.65	0.35	7.21e-6	QT interval;
PAAD	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-1.16	-9.37	-0.61	9.46e-17	Obesity-related traits;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs1883415	0.552	rs2143083	chr6:24507054	C/T	cg20631270	chr6:24437470	GPLD1	0.5	4.47	0.34	1.49e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2904967	0.598	rs2904978	chr11:65000478	A/G	cg21890820	chr11:65308645	LTBP3	0.52	5.0	0.38	1.59e-6	Mean corpuscular volume;
PAAD	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.53	-6.35	-0.46	2.32e-9	Lewy body disease;
PAAD	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg02917321	chr22:38215204	NA	0.44	4.53	0.34	1.2e-5	Glioblastoma;Glioma;
PAAD	cis	rs4740619	0.592	rs3008715	chr9:16015713	A/G	cg14451791	chr9:16040625	NA	-0.37	-4.33	-0.33	2.73e-5	Body mass index;
PAAD	cis	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg21353292	chr2:16079983	MYCN	-0.53	-5.42	-0.4	2.32e-7	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18851817	chr12:32908822	YARS2	0.61	6.82	0.48	2.06e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.06e-5	Tuberculosis;
PAAD	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg10556349	chr10:835070	NA	0.61	4.38	0.33	2.24e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	7.97	0.54	3.59e-13	Alzheimer's disease;
PAAD	cis	rs829661	0.948	rs829662	chr2:30726551	G/C	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg17810781	chr1:201082982	CACNA1S	0.38	4.51	0.34	1.3e-5	Permanent tooth development;
PAAD	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg08109568	chr15:31115862	NA	-0.71	-7.92	-0.54	4.56e-13	Huntington's disease progression;
PAAD	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.58	-5.8	-0.43	3.63e-8	Inflammatory bowel disease;
PAAD	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.82	9.44	0.61	6.19e-17	Coronary artery disease;
PAAD	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.49	0.57	1.72e-14	Coffee consumption (cups per day);
PAAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15128208	chr22:42549153	NA	-0.44	-4.36	-0.33	2.41e-5	Cognitive function;
PAAD	cis	rs7714584	1.000	rs2344180	chr5:150267357	T/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.73	-6.01	-0.44	1.32e-8	Neuroticism;
PAAD	cis	rs654384	0.510	rs597831	chr7:4166769	T/A	cg27574739	chr7:4176374	SDK1	0.46	4.4	0.34	2.03e-5	Positive affect;
PAAD	cis	rs183266	0.673	rs78010105	chr14:77494722	C/T	cg01682506	chr14:77422843	NA	-1.16	-5.49	-0.41	1.61e-7	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs71520386	0.561	rs10274260	chr7:22844846	A/G	cg04907244	chr7:22894795	SNORD93	0.44	4.71	0.36	5.55e-6	Fibrinogen levels;
PAAD	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-4.4	-0.34	2.02e-5	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03558676	chr16:842185	CHTF18	0.58	7.06	0.5	5.65e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.34	4.68	0.36	6.21e-6	Asthma;
PAAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg22549504	chr19:17448937	GTPBP3	0.54	4.29	0.33	3.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs329648	0.571	rs510306	chr11:133774863	G/T	cg12362517	chr11:133800685	IGSF9B	-0.62	-6.96	-0.49	9.46e-11	Parkinson's disease;
PAAD	cis	rs3736757	1.000	rs2333716	chr1:184707353	T/C	cg05045817	chr1:184633523	NA	0.42	4.55	0.35	1.1e-5	Obesity-related traits;
PAAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.67	-5.17	-0.39	7.23e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.87	-7.69	-0.53	1.76e-12	Obesity;Body mass index;
PAAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.59	6.91	0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.44	4.96	0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.54	-6.12	-0.44	7.57e-9	Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03105452	chr13:29233076	POMP	0.7	7.27	0.51	1.73e-11	Obesity-related traits;
PAAD	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.58	6.69	0.48	4.01e-10	Aortic root size;
PAAD	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-4.32	-0.33	2.78e-5	Total body bone mineral density;
PAAD	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.38	0.4	2.75e-7	HDL cholesterol;
PAAD	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.77	-5.72	-0.42	5.55e-8	Coronary artery calcification;
PAAD	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	2.98e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg11266682	chr4:10021025	SLC2A9	0.61	4.95	0.37	1.97e-6	Blood metabolite levels;
PAAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs58521262	0.556	rs453743	chr19:23121640	G/A	cg03433597	chr19:22806448	NA	-0.25	-4.48	-0.34	1.46e-5	Testicular germ cell tumor;
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21518248	chr2:162101506	NA	0.6	6.58	0.47	7.35e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7922314	0.571	rs16917991	chr10:64737762	A/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00078270	chr7:2005255	MAD1L1	0.53	6.38	0.46	2e-9	Body fat percentage;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg24213567	chr19:53496664	ZNF702P	-0.44	-4.61	-0.35	8.6e-6	Psoriasis;
PAAD	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs11892454	0.515	rs13405775	chr2:26026986	C/T	cg03373490	chr2:26702396	OTOF	0.5	4.28	0.33	3.23e-5	Heschl's gyrus morphology;
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.45	-0.46	1.44e-9	Monocyte count;
PAAD	cis	rs4646450	0.588	rs17161695	chr7:98964706	T/A	cg18809830	chr7:99032528	PTCD1	-0.82	-4.46	-0.34	1.57e-5	Blood metabolite levels;
PAAD	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.55	-4.25	-0.33	3.66e-5	Coronary artery disease;
PAAD	cis	rs12773846	0.506	rs34625822	chr10:126272875	A/G	cg04949429	chr10:126290192	LHPP	0.66	5.74	0.42	4.95e-8	Subcutaneous adipose tissue;
PAAD	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs72627123	1.000	rs72627123	chr14:74368331	A/G	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-0.74	-5.9	-0.43	2.22e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.7	-6.38	-0.46	1.99e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Body mass index;
PAAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22482690	chr17:47019901	SNF8	0.49	5.25	0.39	5.01e-7	Type 2 diabetes;
PAAD	cis	rs13242816	1.000	rs3807987	chr7:116179834	G/A	cg16553024	chr7:116138462	CAV2	-0.64	-4.47	-0.34	1.55e-5	P wave duration;
PAAD	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.57	-7.13	-0.5	3.88e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-6.27	-0.45	3.55e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.51	0.34	1.27e-5	Lung cancer in ever smokers;
PAAD	cis	rs7922314	0.571	rs16917977	chr10:64729208	T/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.4	4.9	0.37	2.41e-6	Pulmonary function;
PAAD	cis	rs2637266	0.905	rs60809084	chr10:78374431	A/C	cg18941641	chr10:78392320	NA	0.37	4.33	0.33	2.65e-5	Pulmonary function;
PAAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg14024328	chr4:719362	PCGF3	-0.57	-5.83	-0.43	3.25e-8	White blood cell count;
PAAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg09796270	chr17:17721594	SREBF1	0.42	4.64	0.35	7.48e-6	Total body bone mineral density;
PAAD	cis	rs11811982	0.793	rs79084700	chr1:227390836	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4662750	0.580	rs7558838	chr2:128351346	T/C	cg09760422	chr2:128146352	NA	0.35	5.23	0.39	5.49e-7	Renal cell carcinoma;
PAAD	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.64	6.57	0.47	7.63e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg00262122	chr8:11665843	FDFT1	0.47	4.31	0.33	2.93e-5	Retinal vascular caliber;
PAAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.89	-10.42	-0.65	1.6e-19	Total body bone mineral density;
PAAD	cis	rs561655	0.545	rs11234556	chr11:85849411	T/C	cg07180834	chr11:85838833	NA	-0.44	-4.91	-0.37	2.29e-6	Alzheimer's disease (late onset);
PAAD	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg23461800	chr14:103021989	NA	-0.62	-4.91	-0.37	2.3e-6	Platelet count;
PAAD	cis	rs6681460	0.649	rs967322	chr1:67003446	C/T	cg02459107	chr1:67143332	SGIP1	0.56	5.0	0.38	1.53e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs6782025	0.802	rs2331711	chr3:121053447	G/T	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.4	-0.4	2.47e-7	Total cholesterol levels;
PAAD	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.5	5.18	0.39	7.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg08601574	chr20:25228251	PYGB	0.7	6.51	0.47	1.05e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg14393609	chr7:65229607	NA	0.47	4.69	0.36	6.06e-6	Aortic root size;
PAAD	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.58	-0.47	7.3e-10	Retinal vascular caliber;
PAAD	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.86	-4.95	-0.37	1.91e-6	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.55	-0.47	8.43e-10	Morning vs. evening chronotype;
PAAD	cis	rs16958440	0.867	rs77149690	chr18:44697143	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.44	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs12935418	0.583	rs2549837	chr16:81023115	G/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.32e-8	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02985541	chr2:219472218	PLCD4	0.29	4.44	0.34	1.74e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.72	7.78	0.53	1.03e-12	Lung cancer;
PAAD	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg18721089	chr20:30220636	NA	-0.63	-5.06	-0.38	1.22e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.95	0.43	1.79e-8	Prudent dietary pattern;
PAAD	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.64	6.06	0.44	1.03e-8	Aortic root size;
PAAD	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.48	-6.06	-0.44	1.03e-8	Crohn's disease;
PAAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg03959625	chr15:84868606	LOC388152	0.49	5.41	0.4	2.42e-7	Schizophrenia;
PAAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg24130564	chr14:104152367	KLC1	-0.48	-4.62	-0.35	8.17e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg07701084	chr6:150067640	NUP43	0.52	4.47	0.34	1.53e-5	Lung cancer;
PAAD	cis	rs7172677	1.000	rs8032261	chr15:75424012	A/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.73	-0.36	5.05e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs5742933	0.750	rs10197331	chr2:190632838	A/C	cg04003228	chr2:190539410	ANKAR	-0.52	-4.32	-0.33	2.83e-5	Ferritin levels;
PAAD	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.5	4.84	0.37	3.2e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg15017067	chr4:17643749	FAM184B	0.43	4.91	0.37	2.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg11764359	chr7:65958608	NA	0.79	5.22	0.39	5.85e-7	Diabetic kidney disease;
PAAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.51	-7.57	-0.52	3.42e-12	Diastolic blood pressure;
PAAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.27	0.33	3.48e-5	Iron status biomarkers;
PAAD	cis	rs2274459	0.915	rs12192035	chr6:33720065	T/C	cg06253072	chr6:33679850	C6orf125	0.71	5.03	0.38	1.37e-6	Obesity (extreme);
PAAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.6	7.25	0.51	1.95e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.62	-0.35	8.27e-6	Platelet count;
PAAD	cis	rs4668356	1.000	rs73027220	chr2:171865877	A/C	cg13882835	chr2:172017928	TLK1	0.88	4.66	0.35	6.86e-6	Cognitive performance;
PAAD	cis	rs10214930	0.624	rs13244903	chr7:27688911	A/G	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13603112	chr9:121929811	DBC1	-0.57	-6.52	-0.47	9.64e-10	Monocyte percentage of white cells;
PAAD	cis	rs10073892	0.662	rs10040933	chr5:101639818	G/A	cg17280723	chr5:101634495	NA	0.41	4.38	0.34	2.16e-5	Cognitive decline (age-related);
PAAD	cis	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.57	4.42	0.34	1.9e-5	Depression;
PAAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.58	6.39	0.46	1.92e-9	Mean corpuscular volume;
PAAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.33	0.6	1.17e-16	Cognitive function;
PAAD	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg13002189	chr3:66846049	NA	-0.48	-4.75	-0.36	4.58e-6	Type 2 diabetes;
PAAD	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.77	-7.0	-0.49	7.77e-11	Schizophrenia;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.89	0.43	2.44e-8	Prudent dietary pattern;
PAAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.56	5.34	0.4	3.31e-7	Schizophrenia;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16083429	chr3:49237500	CCDC36	-0.46	-5.11	-0.38	9.63e-7	Menarche (age at onset);
PAAD	cis	rs2000999	0.524	rs36125653	chr16:72190805	G/A	cg00207534	chr16:71929512	KIAA0174	0.73	4.54	0.35	1.15e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.54	-0.47	8.67e-10	Eye color traits;
PAAD	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.68	4.38	0.33	2.21e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.68	7.4	0.51	8.85e-12	Longevity;
PAAD	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg19418318	chr19:17219073	MYO9B	0.49	5.75	0.42	4.83e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.72	0.62	1.12e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs4343996	0.714	rs10268837	chr7:3467366	T/C	cg21248987	chr7:3385318	SDK1	0.49	5.27	0.39	4.52e-7	Motion sickness;
PAAD	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg05805236	chr11:65401703	PCNXL3	-0.43	-4.41	-0.34	1.93e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.4	-4.52	-0.34	1.21e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.78	12.48	0.71	4.84e-25	Breast cancer;
PAAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.37	0.46	2.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21010450	chr1:150186031	NA	0.62	7.06	0.5	5.64e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.53	5.52	0.41	1.44e-7	Longevity;Endometriosis;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg16362232	chr11:430036	ANO9	0.94	5.72	0.42	5.59e-8	Body mass index;
PAAD	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg06883089	chr1:45254480	BEST4	0.36	4.51	0.34	1.27e-5	High light scatter reticulocyte count;
PAAD	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.65	-5.65	-0.42	7.56e-8	Systemic lupus erythematosus;
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-5.12	-0.38	9.16e-7	Total body bone mineral density;
PAAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.6	-0.35	8.97e-6	Height;
PAAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.46	-4.85	-0.37	3.02e-6	Major depressive disorder;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg17120908	chr11:65337727	SSSCA1	-1.0	-4.67	-0.35	6.61e-6	Height;
PAAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.62	6.6	0.47	6.4e-10	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.7	-6.14	-0.45	6.8e-9	Pubertal anthropometrics;
PAAD	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg26248373	chr2:1572462	NA	-1.04	-7.92	-0.54	4.67e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21963583	chr11:68658836	MRPL21	0.54	5.87	0.43	2.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	4.99	0.38	1.64e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs73198271	0.515	rs17629935	chr8:8619381	A/T	cg01851573	chr8:8652454	MFHAS1	0.94	6.66	0.48	4.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs42648	0.535	rs39198	chr7:89733818	T/C	cg27367526	chr7:89841692	STEAP2	-0.32	-4.39	-0.34	2.1e-5	Homocysteine levels;
PAAD	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg04330084	chr7:123175371	IQUB	0.49	4.25	0.33	3.75e-5	Plateletcrit;Platelet count;
PAAD	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.81	-8.74	-0.58	3.93e-15	Mortality in heart failure;
PAAD	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.63	6.08	0.44	9.45e-9	Corneal astigmatism;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs8027181	0.682	rs11637168	chr15:73100694	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.54	5.06	0.38	1.22e-6	Triglyceride levels;
PAAD	cis	rs74544699	1.000	rs353029	chr4:74776804	C/T	cg06834998	chr4:74847824	PF4	1.1	4.3	0.33	3.08e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs735539	0.521	rs2147347	chr13:21410468	C/T	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-9.35	-0.6	1.04e-16	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.61	7.22	0.51	2.29e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.56	6.44	0.46	1.48e-9	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23615959	chr11:3818253	NUP98;PGAP2	0.57	6.29	0.45	3.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.75	-8.89	-0.58	1.69e-15	Body mass index;
PAAD	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.64	6.3	0.46	3.1e-9	Smooth-surface caries;
PAAD	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs11264799	0.554	rs59424684	chr1:157586990	G/A	cg18268488	chr1:157545234	FCRL4	0.48	5.17	0.39	7.39e-7	IgA nephropathy;
PAAD	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	1.06	6.63	0.47	5.59e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.71	5.58	0.41	1.05e-7	Pulmonary function decline;
PAAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.69	-7.49	-0.52	5.25e-12	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23335946	chr1:185125966	C1orf25;C1orf26	0.62	7.0	0.49	7.75e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg18612461	chr15:75251733	NA	0.58	7.27	0.51	1.76e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.6	5.64	0.42	8.17e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12760731	0.720	rs12037817	chr1:178261750	A/G	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-4.45	-0.34	1.63e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.68	5.09	0.38	1.06e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg19418458	chr7:158789849	NA	0.46	4.38	0.33	2.17e-5	Facial morphology (factor 20);
PAAD	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10740039	0.583	rs9415613	chr10:62507394	G/A	cg02922035	chr10:62493342	NA	-0.51	-4.34	-0.33	2.56e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg05132306	chr1:1846340	CALML6	-0.44	-5.23	-0.39	5.63e-7	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03316474	chr1:151138495	SCNM1;LYSMD1	0.66	7.41	0.52	7.97e-12	Monocyte percentage of white cells;
PAAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.8	-0.62	6.86e-18	Type 2 diabetes;
PAAD	cis	rs7301016	1.000	rs10877859	chr12:62873873	G/A	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg15478930	chr2:27652102	NRBP1	0.46	4.27	0.33	3.45e-5	Total body bone mineral density;
PAAD	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.59	6.08	0.44	9.36e-9	Coronary artery disease;
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg25204440	chr1:209979598	IRF6	0.61	5.4	0.4	2.47e-7	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18253802	chr6:135501780	MYB	0.65	6.48	0.47	1.23e-9	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.83	8.82	0.58	2.48e-15	Anterior chamber depth;
PAAD	trans	rs901683	0.850	rs112297763	chr10:46069436	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.79	0.48	2.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19205498	chr12:133431064	CHFR	-0.7	-7.39	-0.51	9.05e-12	Obesity-related traits;
PAAD	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.29	-0.45	3.22e-9	Morning vs. evening chronotype;
PAAD	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.9	-0.43	2.31e-8	Schizophrenia;
PAAD	cis	rs10895547	0.712	rs1487911	chr11:103775113	C/A	cg06560282	chr11:103830847	PDGFD	0.37	4.44	0.34	1.69e-5	LDL cholesterol;
PAAD	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg10589385	chr1:150898437	SETDB1	0.36	4.41	0.34	1.91e-5	Melanoma;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg23093090	chr10:104574429	C10orf26	0.44	4.54	0.35	1.12e-5	Arsenic metabolism;
PAAD	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.37	4.95	0.37	1.92e-6	Oropharynx cancer;
PAAD	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.76	8.73	0.58	4.27e-15	Height;
PAAD	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.38	-0.46	2.04e-9	Bipolar disorder;
PAAD	cis	rs2252790	0.859	rs2640853	chr6:116677818	C/G	cg18764771	chr6:116381957	FRK	-0.27	-4.4	-0.34	2.04e-5	Fast beta electroencephalogram;
PAAD	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.47	-0.34	1.52e-5	Systemic lupus erythematosus;
PAAD	cis	rs8032158	0.927	rs7179116	chr15:56174827	A/G	cg02198044	chr15:56286336	NEDD4	-0.48	-4.85	-0.37	2.97e-6	Keloid;
PAAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg11494091	chr17:61959527	GH2	0.51	4.44	0.34	1.75e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.62	-5.51	-0.41	1.48e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg15181151	chr6:150070149	PCMT1	0.6	6.5	0.47	1.09e-9	Lung cancer;
PAAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.764	rs10948187	chr6:44921320	A/G	cg25276700	chr6:44698697	NA	0.47	5.3	0.39	4.06e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13389213	chr19:58838502	ZSCAN22	0.7	6.3	0.46	3.04e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg10729496	chr3:10149963	C3orf24	-0.9	-7.5	-0.52	4.92e-12	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20593274	chr14:21860732	SNORD9;CHD8	-0.76	-7.68	-0.53	1.83e-12	Obesity-related traits;
PAAD	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.5	0.57	1.6e-14	Bipolar disorder;
PAAD	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.48	6.92	0.49	1.18e-10	Oropharynx cancer;
PAAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.71	-7.52	-0.52	4.4e-12	Colorectal cancer;
PAAD	trans	rs901683	0.571	rs73292811	chr10:46114121	A/G	cg13039199	chr15:92455658	SLCO3A1	1.29	6.46	0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2521634	0.818	rs4722345	chr7:24362531	G/A	cg15037663	chr7:24797835	DFNA5	-0.48	-4.45	-0.34	1.68e-5	Periodontitis;
PAAD	cis	rs13424612	0.896	rs878925	chr2:240918502	A/G	cg01812947	chr2:240904978	NDUFA10	0.57	4.92	0.37	2.2e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9463078	0.546	rs1284972	chr6:45077398	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.81	-10.0	-0.63	2.06e-18	Obesity-related traits;
PAAD	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.65	-5.7	-0.42	5.97e-8	Type 2 diabetes;
PAAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.27	0.39	4.53e-7	Rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	1.03	9.2	0.6	2.61e-16	Neutrophil percentage of white cells;
PAAD	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.89	10.36	0.64	2.27e-19	White blood cell count;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-6.08	-0.44	9.47e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2242663	0.654	rs2282640	chr11:66245851	G/T	cg16756854	chr11:66116455	B3GNT1	-0.33	-4.25	-0.33	3.75e-5	Bipolar disorder;
PAAD	trans	rs6694672	1.000	rs7554757	chr1:196973054	A/T	cg26994526	chr18:47719735	MYO5B	-0.86	-6.43	-0.46	1.6e-9	Asthma;
PAAD	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg21573476	chr21:45109991	RRP1B	-0.56	-4.74	-0.36	4.87e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4743820	0.503	rs10991791	chr9:93921505	T/C	cg14446406	chr9:93919335	NA	-0.37	-5.08	-0.38	1.11e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg21479132	chr6:26055353	NA	0.93	5.23	0.39	5.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg19196401	chr6:110721138	DDO	-0.49	-5.41	-0.4	2.36e-7	Platelet distribution width;
PAAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg00383909	chr3:49044727	WDR6	0.52	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.76	0.42	4.48e-8	Coronary artery disease;
PAAD	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.46	-4.8	-0.36	3.78e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs4148087	0.790	rs4148099	chr21:43639591	A/C	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg09835421	chr16:68378352	PRMT7	-1.1	-8.22	-0.55	8.24e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12432903	chr7:1882776	MAD1L1	0.63	4.32	0.33	2.82e-5	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.98e-6	Coronary artery disease;
PAAD	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg15309053	chr8:964076	NA	0.51	5.67	0.42	6.84e-8	Schizophrenia;
PAAD	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.8	0.58	2.77e-15	Colorectal cancer;
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.41	0.34	1.96e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs2273156	0.500	rs75741665	chr14:35566040	A/T	cg14523979	chr14:35838413	NA	-0.73	-4.74	-0.36	4.84e-6	Immunoglobulin light chain (AL) amyloidosis;
PAAD	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.63	4.74	0.36	4.94e-6	Thyroid stimulating hormone;
PAAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg14343924	chr8:8086146	FLJ10661	0.54	4.63	0.35	7.66e-6	Mood instability;
PAAD	cis	rs10512697	0.655	rs34560950	chr5:3512343	G/A	cg19473799	chr5:3511975	NA	-1.13	-5.21	-0.39	6.03e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	10.08	0.63	1.27e-18	Response to antipsychotic treatment;
PAAD	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg17764715	chr19:33622953	WDR88	0.66	6.21	0.45	4.73e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17286258	chr2:198299746	SF3B1	-0.64	-6.34	-0.46	2.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg06565975	chr8:143823917	SLURP1	-0.22	-4.9	-0.37	2.42e-6	Urinary tract infection frequency;
PAAD	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg06042504	chr8:55087323	NA	-0.77	-8.67	-0.58	6.01e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-4.98	-0.37	1.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6991838	0.806	rs35024820	chr8:66463531	C/T	cg15971335	chr8:66515592	ARMC1	0.45	4.54	0.35	1.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26926768	chr12:34528122	NA	0.38	4.6	0.35	8.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	6.58	0.47	7.08e-10	Body mass index;
PAAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.56	0.47	7.9e-10	Personality dimensions;
PAAD	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.61	6.1	0.44	8.58e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs6782228	0.565	rs12695509	chr3:128417044	A/T	cg16766828	chr3:128327626	NA	-0.46	-6.2	-0.45	5.03e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg14847009	chr1:175162515	KIAA0040	0.3	4.84	0.37	3.12e-6	Alcohol dependence;
PAAD	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	1.0	12.5	0.71	4.2e-25	Breast cancer;
PAAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.63	6.04	0.44	1.13e-8	Uric acid clearance;
PAAD	cis	rs2952768	0.729	rs9679258	chr2:208457978	G/A	cg22329743	chr2:208688774	PLEKHM3	0.26	4.89	0.37	2.56e-6	Opioid sensitivity;
PAAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg01815783	chr4:1047043	NA	-0.41	-4.45	-0.34	1.68e-5	Recombination rate (males);
PAAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.81	7.15	0.5	3.48e-11	Psoriasis;
PAAD	cis	rs4740619	0.509	rs74864879	chr9:15633072	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.15e-5	Body mass index;
PAAD	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.51	-0.41	1.52e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.93	0.49	1.11e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72772090	0.539	rs72773981	chr5:96156059	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.24	-0.45	4.08e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.76	6.07	0.44	9.89e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.07	0.55	2.03e-13	Schizophrenia;
PAAD	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg18939081	chr1:31884902	SERINC2	0.45	5.24	0.39	5.23e-7	Alcohol dependence;
PAAD	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.58	5.01	0.38	1.47e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.9	-10.92	-0.66	7.31e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg23024343	chr7:107201750	COG5	0.57	4.82	0.36	3.45e-6	Coronary artery disease;
PAAD	cis	rs59888335	0.830	rs13065636	chr3:80524551	C/A	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg01831904	chr17:28903510	LRRC37B2	0.78	5.92	0.43	2.04e-8	Body mass index;
PAAD	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-6.59	-0.47	6.83e-10	Coffee consumption (cups per day);
PAAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs10029851	0.645	rs17039240	chr4:109625082	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	0.48	4.53	0.34	1.18e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18947032	chr10:70748274	KIAA1279	-0.6	-6.32	-0.46	2.78e-9	Smoking initiation;
PAAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg12072164	chr19:44306565	LYPD5	0.4	4.34	0.33	2.6e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.6	6.36	0.46	2.23e-9	Morning vs. evening chronotype;
PAAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg16680214	chr1:154839983	KCNN3	-0.4	-4.46	-0.34	1.55e-5	Schizophrenia;
PAAD	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.88	11.15	0.67	1.77e-21	Mean corpuscular volume;
PAAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.53	5.71	0.42	5.69e-8	Obesity-related traits;
PAAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.84	-9.12	-0.59	4.29e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.08	0.7	5.72e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.5	5.14	0.39	8.16e-7	Major depressive disorder;
PAAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.29	0.39	4.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.73	-7.65	-0.53	2.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.6	4.65	0.35	7.31e-6	Resting heart rate;
PAAD	cis	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg27411982	chr8:10470053	RP1L1	0.42	4.5	0.34	1.35e-5	Neuroticism;
PAAD	cis	rs61759167	0.710	rs12745073	chr1:3094672	A/G	cg22396632	chr1:3079212	PRDM16	-0.56	-5.48	-0.41	1.73e-7	Motion sickness;
PAAD	cis	rs2555155	0.935	rs61151131	chr11:6521391	C/T	cg24637308	chr11:6592297	DNHD1	0.49	5.11	0.38	9.48e-7	DNA methylation (variation);
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg09594475	chr20:60884601	LAMA5	0.47	4.42	0.34	1.89e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.78	6.28	0.45	3.38e-9	Left atrial antero-posterior diameter;
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs501120	0.564	rs2804036	chr10:44680405	A/G	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.56	5.94	0.43	1.88e-8	Longevity;
PAAD	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03037974	chr15:76606532	NA	-0.47	-5.5	-0.41	1.55e-7	Blood metabolite levels;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg06219351	chr7:158114137	PTPRN2	-0.82	-7.51	-0.52	4.66e-12	Response to amphetamines;
PAAD	trans	rs901683	1.000	rs35294227	chr10:46006798	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.04	-0.5	6.14e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg26816564	chr1:7831052	VAMP3	0.62	4.86	0.37	2.88e-6	Inflammatory bowel disease;
PAAD	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg04389838	chr3:44770851	ZNF501	-0.51	-4.34	-0.33	2.6e-5	Depressive symptoms;
PAAD	cis	rs2694528	0.841	rs79299974	chr5:60350961	A/G	cg11474532	chr5:59995715	DEPDC1B	0.89	4.99	0.37	1.66e-6	Parkinson's disease;
PAAD	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.44	-0.34	1.7e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg12641515	chr19:46296257	DMWD	0.48	4.73	0.36	5.16e-6	Coronary artery disease;
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-4.92	-0.37	2.18e-6	Longevity;
PAAD	cis	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05841967	chr7:117824643	NAA38	0.49	4.35	0.33	2.49e-5	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg23018236	chr17:30244563	NA	0.68	5.1	0.38	9.82e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg24110177	chr3:50126178	RBM5	-0.45	-4.52	-0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-1.15	-12.76	-0.72	8.45e-26	Hair shape;
PAAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.37	5.51	0.41	1.49e-7	Educational attainment (years of education);
PAAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.61	-5.96	-0.44	1.71e-8	Systolic blood pressure;
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.76	0.48	2.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.85	-8.97	-0.59	1.06e-15	Body mass index;
PAAD	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.5	-5.24	-0.39	5.33e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12476592	0.602	rs262483	chr2:63877246	G/C	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg15691649	chr6:25882328	NA	-0.51	-5.03	-0.38	1.35e-6	Blood metabolite levels;
PAAD	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg26318627	chr11:63887540	MACROD1	-0.47	-4.7	-0.36	5.82e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.19e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg07313626	chr1:247681931	NA	0.49	5.18	0.39	6.83e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg24053715	chr22:38214548	NA	0.64	5.98	0.44	1.55e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg05562828	chr17:3906858	NA	0.52	5.42	0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg22189786	chr22:42395067	WBP2NL	0.4	4.29	0.33	3.2e-5	Cognitive function;
PAAD	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.54	5.0	0.38	1.6e-6	Platelet count;
PAAD	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg02917321	chr22:38215204	NA	-0.46	-4.99	-0.38	1.61e-6	Glioblastoma;Glioma;
PAAD	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg02459107	chr1:67143332	SGIP1	-0.76	-7.45	-0.52	6.43e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.66	6.22	0.45	4.69e-9	Parkinson's disease;
PAAD	cis	rs4919669	0.668	rs3961457	chr10:104429639	G/A	cg05885577	chr10:104597359	CYP17A1	0.54	4.34	0.33	2.63e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
PAAD	trans	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.62	0.57	8.14e-15	Bipolar disorder;
PAAD	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs959260	1.000	rs930298	chr17:73404666	T/G	cg20590849	chr17:73267439	MIF4GD	-0.53	-4.27	-0.33	3.49e-5	Systemic lupus erythematosus;
PAAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg20887711	chr4:1340912	KIAA1530	0.55	5.68	0.42	6.71e-8	Longevity;
PAAD	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.6	5.47	0.41	1.82e-7	Platelet count;
PAAD	cis	rs9595066	1.000	rs9595066	chr13:44706268	C/T	cg04068111	chr13:44716778	NA	-0.52	-5.72	-0.42	5.44e-8	Schizophrenia;
PAAD	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg26893134	chr6:116381904	FRK	-0.45	-7.27	-0.51	1.79e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6796502	0.500	rs7624422	chr3:46873667	C/T	cg22309949	chr3:46792192	NA	-0.58	-4.36	-0.33	2.35e-5	Breast cancer;
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.2	11.24	0.67	1.03e-21	Platelet count;
PAAD	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	1.14	8.55	0.57	1.23e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2718812	0.904	rs2718809	chr3:133409418	A/G	cg11941060	chr3:133502564	NA	0.46	4.9	0.37	2.42e-6	Iron status biomarkers;
PAAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.66	7.15	0.5	3.37e-11	Leprosy;
PAAD	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	6.3	0.46	3.01e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.19	9.02	0.59	7.58e-16	Alzheimer's disease;
PAAD	cis	rs13111989	1.000	rs13111989	chr4:177542973	A/G	cg11287292	chr4:178277261	NEIL3	-0.54	-4.39	-0.34	2.13e-5	HIV-1 viral setpoint;
PAAD	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg01420254	chr6:26195488	NA	0.98	6.74	0.48	3.11e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.68	-0.36	6.24e-6	Bone mineral density;
PAAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	5.69	0.42	6.36e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6942407	0.546	rs4140847	chr7:86783263	A/T	cg02420886	chr7:86849541	C7orf23	0.63	4.79	0.36	3.85e-6	Food allergy;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14641984	chr9:95482641	BICD2	0.66	6.71	0.48	3.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs11958404	0.615	rs7717217	chr5:157447749	C/T	cg05962755	chr5:157440814	NA	0.57	5.42	0.4	2.34e-7	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.3	-0.51	1.54e-11	Neuroticism;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg27644672	chr7:1858694	MAD1L1	-0.43	-4.67	-0.35	6.67e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.04	0.44	1.12e-8	Menopause (age at onset);
PAAD	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.91	-0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs62264129	0.500	rs62278771	chr3:112030789	G/A	cg21206816	chr3:112013079	SLC9A10	-0.26	-4.33	-0.33	2.68e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs11794666	0.872	rs17181894	chr9:31722913	A/C	cg05628366	chr6:35744188	C6orf126	0.95	6.29	0.45	3.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.43	-0.46	1.57e-9	Lung cancer;
PAAD	cis	rs11020478	0.600	rs10831082	chr11:93381048	G/T	cg10523193	chr11:93463762	SNORA25	-0.42	-4.33	-0.33	2.72e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.79	-9.59	-0.61	2.57e-17	Height;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg25457927	chr22:38595422	NA	-0.39	-5.6	-0.41	9.86e-8	Breast cancer;
PAAD	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.83	-9.33	-0.6	1.17e-16	Metabolic syndrome;
PAAD	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04815174	chr22:38857852	NA	0.63	6.56	0.47	7.85e-10	Myopia (pathological);
PAAD	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg05347473	chr6:146136440	FBXO30	-0.52	-5.08	-0.38	1.09e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg24747557	chr10:131355152	MGMT	0.44	4.83	0.36	3.34e-6	Response to temozolomide;
PAAD	cis	rs322458	0.573	rs470738	chr3:120612970	G/A	cg16417163	chr3:121280760	NA	0.46	4.73	0.36	5.01e-6	Aging (facial);
PAAD	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg07099767	chr17:78039528	CCDC40	-0.55	-4.67	-0.35	6.62e-6	Yeast infection;
PAAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.63	7.13	0.5	3.77e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.56	0.57	1.18e-14	Initial pursuit acceleration;
PAAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg15017067	chr4:17643749	FAM184B	0.42	4.98	0.37	1.7e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-1.33	-10.66	-0.65	3.72e-20	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg27411982	chr8:10470053	RP1L1	0.46	5.02	0.38	1.41e-6	Retinal vascular caliber;
PAAD	cis	rs73388146	0.772	rs4712888	chr6:25147518	C/T	cg08126211	chr6:24357720	KAAG1;DCDC2	0.84	4.52	0.34	1.24e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.28	8.73	0.58	4.21e-15	Opioid sensitivity;
PAAD	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9377188	0.810	rs6931744	chr6:149355301	A/T	cg21368479	chr6:149415018	NA	0.41	4.63	0.35	7.84e-6	Cancer;
PAAD	cis	rs1160297	0.576	rs1451456	chr2:53092604	A/C	cg07782112	chr2:53107842	NA	0.35	4.31	0.33	2.87e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.67e-6	Migraine;
PAAD	cis	rs17539620	0.702	rs17085528	chr6:154876716	T/G	cg20019720	chr6:154832845	CNKSR3	0.52	7.31	0.51	1.42e-11	Lipoprotein (a) levels;
PAAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.42	4.28	0.33	3.23e-5	Plateletcrit;Mean corpuscular volume;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19750992	chr13:100814377	PCCA	-0.54	-6.3	-0.46	3.11e-9	Energy expenditure (24h);
PAAD	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.77	6.18	0.45	5.53e-9	Height;
PAAD	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	6.09	0.44	8.91e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg19761014	chr17:28927070	LRRC37B2	0.71	5.15	0.39	7.86e-7	Body mass index;
PAAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg26727032	chr16:67993705	SLC12A4	0.68	4.7	0.36	5.79e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.52	5.32	0.4	3.71e-7	Colorectal cancer;
PAAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	7.62	0.53	2.47e-12	Bone mineral density;
PAAD	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.39	-0.46	1.96e-9	Neuroticism;
PAAD	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.64	-0.53	2.29e-12	Morning vs. evening chronotype;
PAAD	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg17366294	chr4:99064904	C4orf37	-0.46	-5.14	-0.38	8.47e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.45	-0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	5.49	0.41	1.64e-7	Height;
PAAD	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7804356	0.626	rs7795074	chr7:26742154	T/C	cg03456212	chr7:26904342	SKAP2	0.59	5.09	0.38	1.07e-6	Type 1 diabetes;
PAAD	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg27411982	chr8:10470053	RP1L1	0.42	4.41	0.34	1.99e-5	Morning vs. evening chronotype;
PAAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.53	6.41	0.46	1.78e-9	Sitting height ratio;
PAAD	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.37	9.34	0.6	1.1e-16	Diabetic retinopathy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04013393	chr1:19578177	MRTO4;KIAA0090	0.68	7.21	0.5	2.52e-11	Myopia (pathological);
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.65	-0.53	2.11e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs12044355	0.927	rs17748239	chr1:231834901	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-5.35	-0.4	3.23e-7	Alzheimer's disease;
PAAD	cis	rs939317	0.635	rs865809	chr3:183997735	C/T	cg09405238	chr3:183994500	ECE2	-0.54	-5.12	-0.38	9.23e-7	Menarche (age at onset);
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.56	-5.81	-0.43	3.51e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.51	4.47	0.34	1.49e-5	Total body bone mineral density;
PAAD	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.75	6.32	0.46	2.82e-9	Pulmonary function decline;
PAAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	11.27	0.67	8.78e-22	Bone mineral density;
PAAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.88	4.76	0.36	4.4e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs5756391	0.782	rs735563	chr22:37296931	G/A	cg16356956	chr22:37317934	CSF2RB	0.36	4.51	0.34	1.27e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2117029	0.586	rs7954521	chr12:49545640	G/A	cg05368762	chr12:50135785	TMBIM6	0.45	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.6	6.46	0.46	1.34e-9	High light scatter reticulocyte count;
PAAD	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.49	-0.34	1.38e-5	Menarche (age at onset);
PAAD	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.02	0.38	1.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1190552	0.894	rs2236349	chr14:102963640	G/A	cg18135206	chr14:102964638	TECPR2	0.69	5.33	0.4	3.52e-7	Blood protein levels;
PAAD	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	5.82	0.43	3.43e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.57	5.86	0.43	2.75e-8	Coronary artery disease;
PAAD	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg05627522	chr15:75251581	NA	-0.52	-6.39	-0.46	1.94e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.98	-0.59	9.92e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg00024416	chr22:24240387	NA	-0.55	-5.69	-0.42	6.3e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg26394196	chr10:1453818	ADARB2	-0.6	-6.75	-0.48	2.89e-10	Radiation response;
PAAD	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.64	5.34	0.4	3.38e-7	Type 2 diabetes;
PAAD	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg22143856	chr6:28129313	ZNF389	0.53	4.86	0.37	2.85e-6	Parkinson's disease;
PAAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.98	11.65	0.69	8.29e-23	Gestational age at birth (maternal effect);
PAAD	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg09659197	chr4:152720779	NA	-0.39	-5.57	-0.41	1.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg09760422	chr2:128146352	NA	-0.32	-5.51	-0.41	1.52e-7	Protein C levels;
PAAD	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg14686297	chr22:46650375	NA	0.43	4.37	0.33	2.26e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.42	-6.2	-0.45	5.05e-9	Subjective well-being;
PAAD	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.62	-6.13	-0.45	7.21e-9	Ovarian reserve;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.68	0.48	4.29e-10	Height;
PAAD	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.83	7.19	0.5	2.69e-11	Recombination rate (females);
PAAD	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.85	0.43	2.89e-8	Coronary artery disease;
PAAD	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg20406979	chr6:167373233	NA	0.37	4.76	0.36	4.53e-6	Crohn's disease;
PAAD	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.9	-0.49	1.3100000000000001e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.5	0.34	1.34e-5	Height;
PAAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.29	0.39	4.24e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.49	6.12	0.44	7.73e-9	Crohn's disease;
PAAD	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.34	-4.26	-0.33	3.57e-5	Longevity;Endometriosis;
PAAD	cis	rs9659323	1.000	rs11584380	chr1:119517420	C/T	cg17326555	chr1:119535693	NA	-0.41	-5.43	-0.4	2.2e-7	Body mass index;
PAAD	cis	rs41294858	1.000	rs76267242	chr6:135417460	G/T	cg24558204	chr6:135376177	HBS1L	0.68	4.28	0.33	3.35e-5	Red blood cell count;
PAAD	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.69	7.46	0.52	6.31e-12	Hemoglobin concentration;
PAAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.62	5.28	0.39	4.36e-7	Coronary artery disease;
PAAD	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.89	-0.49	1.42e-10	Migraine;Coronary artery disease;
PAAD	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.99	-0.38	1.63e-6	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg00666640	chr1:248458726	OR2T12	0.52	5.15	0.39	8.14e-7	Common traits (Other);
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08219700	chr8:58056026	NA	-0.75	-5.77	-0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.37	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.53e-11	Eye color traits;
PAAD	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	1.02	6.69	0.48	4.04e-10	Lymphocyte counts;
PAAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs3748682	0.731	rs3891572	chr1:38298876	C/T	cg12658694	chr1:38397304	INPP5B	0.47	4.45	0.34	1.63e-5	Hypothyroidism;
PAAD	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.47	-4.31	-0.33	2.89e-5	Gut microbiome composition (summer);
PAAD	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.42e-6	Triglycerides;
PAAD	cis	rs2131877	0.830	rs60922537	chr3:194842785	C/G	cg16306870	chr3:194868790	C3orf21	0.52	5.21	0.39	6e-7	Non-small cell lung cancer;
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.74	-0.48	3.04e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.44	-0.4	2.04e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.89	-0.37	2.5e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.59	5.66	0.42	7.29e-8	Endometrial cancer;
PAAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg20578329	chr17:80767326	TBCD	-0.53	-4.34	-0.33	2.58e-5	Breast cancer;
PAAD	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.46	0.34	1.6e-5	Resting heart rate;
PAAD	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.85	10.25	0.64	4.54e-19	Lung cancer;
PAAD	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg17646820	chr3:66848679	NA	0.42	4.35	0.33	2.44e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.54	4.26	0.33	3.57e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.66	-0.42	7.19e-8	Crohn's disease;
PAAD	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg10523679	chr1:76189770	ACADM	-0.52	-4.94	-0.37	2.05e-6	Daytime sleep phenotypes;
PAAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.58	5.59	0.41	1.04e-7	Multiple sclerosis;
PAAD	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.68	-7.02	-0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg01422370	chr2:73384389	NA	0.39	5.1	0.38	9.98e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg21855830	chr2:127963489	CYP27C1	0.46	4.49	0.34	1.38e-5	Protein C levels;
PAAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.51	-0.34	1.32e-5	Breast cancer;
PAAD	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.37	-0.46	2.16e-9	Neuroticism;
PAAD	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01370129	chr11:61735138	FTH1	0.64	6.36	0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.89	9.54	0.61	3.34e-17	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01289902	chr10:75174282	ANXA7	0.56	6.39	0.46	1.9e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs2131877	0.830	rs952586	chr3:194842322	G/A	cg24618514	chr3:194868507	C3orf21	0.48	4.78	0.36	4.17e-6	Non-small cell lung cancer;
PAAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.7	7.44	0.52	6.93e-12	Multiple sclerosis;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg22903657	chr4:1355424	KIAA1530	0.43	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs73198844	chr3:128503044	G/A	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.39	4.05e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6782025	0.958	rs575913	chr3:121202758	G/A	cg16417163	chr3:121280760	NA	-0.48	-4.85	-0.37	3e-6	Aging (facial);
PAAD	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.3	0.33	3.06e-5	Educational attainment (years of education);
PAAD	cis	rs10980854	1.000	rs10759495	chr9:114054773	A/G	cg13570660	chr9:114287300	ZNF483	-0.7	-4.27	-0.33	3.46e-5	Menarche (age at onset);
PAAD	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-5.15	-0.39	7.81e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12935418	0.583	rs2113197	chr16:81025506	T/A	cg16651780	chr16:81037892	C16orf61	-0.64	-6.0	-0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.84	8.91	0.59	1.45e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.56	-0.52	3.55e-12	Retinal vascular caliber;
PAAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.7	5.81	0.43	3.46e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12127944	1.000	rs4615904	chr1:205477463	A/T	cg08473693	chr1:205342340	NA	-0.71	-4.61	-0.35	8.37e-6	IgG glycosylation;
PAAD	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs714031	0.900	rs5757762	chr22:40064581	C/T	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.44	-0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg21775007	chr8:11205619	TDH	0.52	4.89	0.37	2.58e-6	Neuroticism;
PAAD	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	cis	rs17824933	0.848	rs11230559	chr11:60769534	T/C	cg27098804	chr11:60776124	CD6	0.45	4.39	0.34	2.09e-5	Multiple sclerosis;
PAAD	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg09796270	chr17:17721594	SREBF1	0.42	4.54	0.35	1.13e-5	Total body bone mineral density;
PAAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.65	-5.12	-0.38	9.09e-7	Vitiligo;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg16006841	chr5:176797999	RGS14	0.82	9.49	0.61	4.48e-17	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs6466055	0.661	rs4406343	chr7:104918313	A/G	cg04380332	chr7:105027541	SRPK2	-0.51	-5.07	-0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg18721089	chr20:30220636	NA	-0.62	-5.12	-0.38	9.14e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00864171	chr11:67383662	NA	0.46	4.83	0.36	3.31e-6	Mean corpuscular volume;
PAAD	cis	rs6421571	0.565	rs10892263	chr11:118587319	T/C	cg08498647	chr11:118550644	TREH	0.41	4.37	0.33	2.33e-5	Primary biliary cholangitis;
PAAD	cis	rs58653258	0.554	rs2802981	chr1:234975561	T/C	cg03518729	chr1:235147744	NA	0.45	4.26	0.33	3.5e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-10.76	-0.66	1.95e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs12600304	0.646	rs4784875	chr16:58016322	T/C	cg08699646	chr16:58019359	TEPP	0.39	4.51	0.34	1.3e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg07606381	chr6:8435919	SLC35B3	-0.55	-5.89	-0.43	2.43e-8	Motion sickness;
PAAD	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg03871329	chr12:110338662	TCHP	-0.66	-4.89	-0.37	2.55e-6	Neuroticism;
PAAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.62	-0.41	8.93e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-7.69	-0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs9361491	0.609	rs9448538	chr6:79438448	G/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg06565975	chr8:143823917	SLURP1	-0.22	-5.29	-0.39	4.25e-7	Urinary tract infection frequency;
PAAD	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs8014252	0.803	rs7145530	chr14:71036510	T/C	cg11204974	chr14:71022665	NA	-0.71	-4.54	-0.35	1.12e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-0.44	-4.31	-0.33	2.95e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14119001	chr9:139324193	INPP5E	0.59	5.29	0.39	4.21e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.18	-0.39	6.86e-7	Monocyte percentage of white cells;
PAAD	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.38	5.31	0.4	3.91e-7	Blood protein levels;
PAAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.77	8.6	0.57	8.94e-15	Huntington's disease progression;
PAAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs8037137	0.915	rs2290202	chr15:91512267	G/T	cg23684204	chr15:91497937	RCCD1	0.79	5.05	0.38	1.26e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.95	-0.37	1.96e-6	Body mass index;
PAAD	cis	rs427941	0.632	rs201478	chr7:101746964	G/C	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.72	0.53	1.45e-12	Resting heart rate;
PAAD	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg23024343	chr7:107201750	COG5	0.56	4.61	0.35	8.46e-6	Coronary artery disease;
PAAD	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.54	-5.6	-0.41	9.98e-8	Daytime sleep phenotypes;
PAAD	cis	rs258892	0.895	rs10052974	chr5:72067869	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.52	-5.88	-0.43	2.53e-8	Migraine;
PAAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.84	-9.86	-0.62	4.83e-18	Tuberculosis;
PAAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.01e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.46	5.56	0.41	1.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.77	-6.79	-0.48	2.42e-10	Vitiligo;
PAAD	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg07002422	chr16:996172	LMF1	-0.98	-12.08	-0.7	5.79e-24	Non-glioblastoma glioma;Glioblastoma;Glioma;
PAAD	cis	rs6942407	0.592	rs56327053	chr7:86748539	G/A	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.75	8.71	0.58	4.68e-15	Noise-induced hearing loss;
PAAD	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg26571870	chr16:85723150	GINS2	-0.42	-4.58	-0.35	9.62e-6	Platelet distribution width;
PAAD	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.98e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.8	6.05	0.44	1.06e-8	Initial pursuit acceleration;
PAAD	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.49	5.77	0.42	4.28e-8	Alcohol dependence;
PAAD	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.37	-0.46	2.08e-9	Triglycerides;
PAAD	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.89	-8.34	-0.56	4.25e-14	Breast cancer;
PAAD	cis	rs829661	0.947	rs844194	chr2:30753803	T/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.04	0.38	1.29e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04362095	chr11:63592001	C11orf84	-0.53	-4.88	-0.37	2.68e-6	Platelet count;
PAAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22260415	chr17:4935130	NA	0.62	6.61	0.47	6.2e-10	Obesity-related traits;
PAAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg03340356	chr1:67600835	NA	0.52	6.42	0.46	1.64e-9	Psoriasis;
PAAD	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg09579323	chr1:150459698	TARS2	-0.45	-4.3	-0.33	3.01e-5	Migraine;
PAAD	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.52e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg10705379	chr10:99080932	FRAT1	0.37	4.34	0.33	2.62e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.51	-0.57	1.54e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg13903179	chr13:21900392	NA	0.59	6.19	0.45	5.38e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg05313129	chr8:58192883	C8orf71	0.64	5.62	0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.72	-7.62	-0.53	2.53e-12	Age at first birth;
PAAD	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.65	-0.35	7.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9876781	0.967	rs9864815	chr3:48434063	G/A	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.57	-0.47	7.72e-10	Lung cancer;
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13012494	chr21:47604986	C21orf56	0.47	4.97	0.37	1.76e-6	Testicular germ cell tumor;
PAAD	cis	rs17539620	0.702	rs59661885	chr6:154875787	T/C	cg20019720	chr6:154832845	CNKSR3	0.53	7.52	0.52	4.33e-12	Lipoprotein (a) levels;
PAAD	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg27234864	chr13:21295941	IL17D	0.6	5.43	0.4	2.19e-7	Dental caries;
PAAD	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.89	0.49	1.42e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.54	0.61	3.49e-17	Response to antipsychotic treatment;
PAAD	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.78	9.14	0.6	3.79e-16	Blood metabolite ratios;
PAAD	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg19792802	chr11:65647270	CTSW	0.36	4.62	0.35	8.13e-6	DNA methylation (variation);
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-0.84	-12.16	-0.7	3.44e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9944275	0.860	rs57576120	chr15:97215935	A/C	cg23969200	chr15:97326567	SPATA8	0.77	4.74	0.36	4.85e-6	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	IgG glycosylation;
PAAD	cis	rs74181299	0.653	rs2723091	chr2:65302017	C/T	cg20592124	chr2:65290738	CEP68	0.49	4.6	0.35	8.92e-6	Pulse pressure;
PAAD	cis	rs42648	0.564	rs12154563	chr7:89828226	G/T	cg27367526	chr7:89841692	STEAP2	-0.32	-4.49	-0.34	1.42e-5	Homocysteine levels;
PAAD	cis	rs7084783	0.967	rs7094488	chr10:105326249	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.44	4.6	0.35	8.85e-6	Fear of pain;
PAAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg07212818	chr11:638076	DRD4	-0.71	-6.01	-0.44	1.32e-8	Systemic lupus erythematosus;
PAAD	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.93	5.81	0.43	3.53e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.48	-5.15	-0.39	7.78e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.56	7.36	0.51	1.1e-11	Renal cell carcinoma;
PAAD	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg14361252	chr13:111465457	NA	-0.39	-4.35	-0.33	2.51e-5	Coronary artery disease;
PAAD	cis	rs5756391	0.568	rs5756407	chr22:37316259	A/G	cg16356956	chr22:37317934	CSF2RB	0.37	4.6	0.35	8.85e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.46	-4.44	-0.34	1.72e-5	Vitiligo;
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10509185	chr10:134504666	INPP5A	0.57	6.92	0.49	1.2e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.14	-0.39	8.18e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.95	0.49	1.01e-10	Systemic lupus erythematosus;
PAAD	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.87	-0.72	4.16e-26	Primary sclerosing cholangitis;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	5.91	0.43	2.14e-8	Height;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.96	-13.61	-0.74	4.2e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.92	10.22	0.64	5.58e-19	Blood metabolite levels;
PAAD	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14015726	chr22:40807049	MKL1	-0.66	-6.51	-0.47	1.03e-9	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.43	5.4	0.4	2.49e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.53	5.35	0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg21523528	chr20:32077966	CBFA2T2	0.53	4.37	0.33	2.32e-5	Height;
PAAD	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.69	-6.82	-0.48	2.02e-10	Educational attainment;
PAAD	trans	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg14171944	chr9:126323477	DENND1A	0.53	6.52	0.47	9.85e-10	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg26205652	chr12:48591994	NA	0.45	4.33	0.33	2.7e-5	Plateletcrit;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09648091	chr16:2264881	PGP	-0.63	-6.57	-0.47	7.43e-10	Smoking initiation;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	0.673	rs117332547	chr15:45695763	G/C	cg26924012	chr15:45694286	SPATA5L1	0.75	4.38	0.33	2.23e-5	Homoarginine levels;
PAAD	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg16989719	chr2:238392110	NA	-0.35	-4.36	-0.33	2.43e-5	Prostate cancer;
PAAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.73	11.29	0.68	7.75e-22	Breast cancer;
PAAD	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg19254793	chr6:44695348	NA	-0.47	-4.47	-0.34	1.5e-5	Total body bone mineral density;
PAAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.3	-0.33	3.07e-5	Height;
PAAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.62	6.45	0.46	1.44e-9	Retinal vascular caliber;
PAAD	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.35	0.4	3.22e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7562790	0.571	rs4670146	chr2:36651561	G/C	cg01206211	chr2:36825736	FEZ2	0.43	4.27	0.33	3.48e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.34	4.63	0.35	7.84e-6	Height;
PAAD	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.62	-6.54	-0.47	8.7e-10	Beta-trace protein levels;
PAAD	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.61	5.45	0.4	1.95e-7	Dialysis-related mortality;
PAAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2236267	0.726	rs12897529	chr14:88582916	A/G	cg18078958	chr14:88630771	NA	0.51	6.4	0.46	1.8e-9	Food antigen IgG levels;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg12705353	chr12:122356852	WDR66	0.51	5.09	0.38	1.05e-6	Mean corpuscular volume;
PAAD	cis	rs6834538	0.858	rs6816782	chr4:113559353	T/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.53	0.35	1.17e-5	Free thyroxine concentration;
PAAD	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.52	-5.1	-0.38	1.01e-6	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-6.25	-0.45	3.88e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07362569	chr17:61921086	SMARCD2	-0.55	-6.95	-0.49	9.83e-11	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.81	9.96	0.63	2.62e-18	Height;
PAAD	cis	rs11264213	0.901	rs2791962	chr1:36371168	T/C	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24729481	chr1:43833600	ELOVL1	0.56	6.32	0.46	2.72e-9	Monocyte percentage of white cells;
PAAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	4.86	0.37	2.84e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg03989125	chr22:38214979	NA	-0.51	-4.83	-0.36	3.31e-6	Glioblastoma;Glioma;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	7.88	0.54	5.73e-13	Alzheimer's disease;
PAAD	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.62	5.95	0.43	1.74e-8	Uric acid clearance;
PAAD	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-12.04	-0.7	7.09e-24	Primary sclerosing cholangitis;
PAAD	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.72	7.66	0.53	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04320405	chr7:131012679	MKLN1	0.59	6.79	0.48	2.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs314370	0.573	rs221005	chr7:100401433	A/G	cg10426581	chr7:100472382	SRRT	0.58	5.76	0.42	4.5e-8	Resting heart rate;
PAAD	cis	rs8005172	0.663	rs7493001	chr14:88529064	A/G	cg18078958	chr14:88630771	NA	0.37	4.56	0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs4937076	1.000	rs4937076	chr11:125826702	G/A	cg25857886	chr11:126098838	FAM118B	0.42	4.28	0.33	3.3e-5	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg09127314	chr1:152161683	NA	0.74	5.43	0.4	2.14e-7	Atopic dermatitis;
PAAD	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.8	-7.18	-0.5	2.94e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg12929805	chr1:2399054	NA	-0.41	-4.38	-0.33	2.19e-5	Non-obstructive azoospermia;
PAAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.73	7.27	0.51	1.8e-11	Urate levels in lean individuals;
PAAD	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.38e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg01097406	chr16:89675127	NA	-0.37	-4.58	-0.35	9.54e-6	Vitiligo;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs7627468	1.000	rs11721042	chr3:121936267	A/G	cg17240004	chr3:121949083	CASR	0.51	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.33	0.51	1.28e-11	Obesity-related traits;
PAAD	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.73	6.98	0.49	8.55e-11	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.24	-0.39	5.27e-7	Mean corpuscular volume;
PAAD	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg00750074	chr16:89608354	SPG7	-0.55	-5.13	-0.38	8.79e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs3026101	0.671	rs57406064	chr17:5300183	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs12808519	0.688	rs3168175	chr11:69586070	A/C	cg27032427	chr11:69587568	NA	-0.69	-5.2	-0.39	6.22e-7	Urate levels in overweight individuals;
PAAD	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg22437258	chr11:111473054	SIK2	-0.51	-4.92	-0.37	2.2e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.68	7.59	0.52	2.98e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.47	-6.88	-0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	4.98	0.37	1.73e-6	Tonsillectomy;
PAAD	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs375066	0.935	rs397913	chr19:44398940	C/T	cg21496419	chr19:44306685	LYPD5	-0.38	-4.58	-0.35	9.53e-6	Breast cancer;
PAAD	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.8	7.08	0.5	4.87e-11	Exhaled nitric oxide levels;
PAAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.68	8.07	0.55	2.03e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.56	-5.8	-0.43	3.78e-8	Type 2 diabetes;
PAAD	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.6	-0.47	6.4e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg13736514	chr6:26305472	NA	-0.48	-5.37	-0.4	2.86e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.57e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	11.09	0.67	2.54e-21	IgG glycosylation;
PAAD	cis	rs16958440	0.867	rs75228657	chr18:44741063	A/G	cg17192377	chr18:44677553	HDHD2	1.02	5.67	0.42	7.11e-8	Sitting height ratio;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.41	0.82	5.02e-38	Prudent dietary pattern;
PAAD	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10500715	0.715	rs4910089	chr11:10003249	A/G	cg06875754	chr11:10328428	ADM	0.34	4.65	0.35	7.06e-6	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12165864	chr7:66369176	NA	0.8	5.22	0.39	5.81e-7	Diabetic kidney disease;
PAAD	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.53	0.41	1.37e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-5.53	-0.41	1.36e-7	Gut microbiome composition (summer);
PAAD	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.63	0.65	4.33e-20	Electrocardiographic conduction measures;
PAAD	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15128208	chr22:42549153	NA	-0.43	-4.41	-0.34	1.94e-5	Cognitive function;
PAAD	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.54	-0.41	1.33e-7	Life satisfaction;
PAAD	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.63	-5.61	-0.41	9.41e-8	Lung cancer;
PAAD	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	8.13	0.55	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg23752985	chr2:85803571	VAMP8	-0.53	-5.46	-0.4	1.9e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.71	5.11	0.38	9.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg06464468	chr11:65414413	SIPA1	-0.52	-4.25	-0.33	3.77e-5	Blood pressure (age interaction);
PAAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.75	-8.58	-0.57	1.05e-14	Huntington's disease progression;
PAAD	cis	rs1075232	1.000	rs12438318	chr15:31680445	G/A	cg15751117	chr15:30700112	NA	0.94	4.75	0.36	4.59e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs35160687	0.712	rs17438687	chr2:86479287	G/T	cg10973622	chr2:86423274	IMMT	-0.44	-4.9	-0.37	2.41e-6	Night sleep phenotypes;
PAAD	cis	rs12935418	0.583	rs2549861	chr16:81028304	G/T	cg16651780	chr16:81037892	C16orf61	-0.65	-6.2	-0.45	5.13e-9	Mean corpuscular volume;
PAAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.75	9.32	0.6	1.3e-16	Bone mineral density;
PAAD	cis	rs7084783	0.519	rs1047425	chr10:105345201	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.44	4.39	0.34	2.08e-5	Fear of pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24309256	chr3:28390795	AZI2	-0.77	-6.69	-0.48	3.95e-10	Neuroticism;
PAAD	cis	rs12889267	0.770	rs2319627	chr14:21565189	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	-0.53	-4.82	-0.36	3.51e-6	Hematocrit;Resting heart rate;
PAAD	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.61	4.68	0.35	6.36e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-5.67	-0.42	6.9e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs3007168	1.000	rs2999360	chr14:51605429	G/A	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.77	0.58	3.36e-15	Lung cancer;
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg01616529	chr11:638424	DRD4	-0.65	-5.83	-0.43	3.24e-8	Systemic lupus erythematosus;
PAAD	cis	rs372883	0.935	rs1153294	chr21:30701096	A/G	cg24692254	chr21:30365293	RNF160	-0.43	-4.32	-0.33	2.77e-5	Pancreatic cancer;
PAAD	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	5.05	0.38	1.25e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.49	5.85	0.43	2.97e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs528301	0.584	rs7604640	chr2:45121466	G/A	cg15393275	chr2:45165193	NA	-0.45	-4.78	-0.36	4.09e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.67	4.86	0.37	2.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7646881	0.812	rs59957986	chr3:158458913	G/A	cg19483011	chr3:158453295	NA	-0.61	-4.86	-0.37	2.92e-6	Tetralogy of Fallot;
PAAD	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.72	7.66	0.53	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-5.29	-0.39	4.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.833	rs62107547	chr19:21524047	A/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg14758556	chr20:62440591	NA	0.51	4.5	0.34	1.34e-5	Atopic dermatitis;
PAAD	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.6	5.89	0.43	2.39e-8	Height;
PAAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.82	-10.31	-0.64	3.19e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	trans	rs901683	0.702	rs4418752	chr10:46102971	A/G	cg07935355	chr19:50391064	TBC1D17	1.34	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22359362	chr1:24104798	C1orf128	-0.73	-6.41	-0.46	1.71e-9	Neuroticism;
PAAD	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.5	-5.81	-0.43	3.53e-8	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.56	-5.41	-0.4	2.46e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.61	-6.29	-0.45	3.28e-9	Coronary artery disease;
PAAD	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.26	-9.82	-0.62	6.18e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.9	-8.36	-0.56	3.8e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.68	-0.42	6.66e-8	Longevity;Endometriosis;
PAAD	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg02454025	chr1:11042201	C1orf127	1.26	15.5	0.78	4.24e-33	Ewing sarcoma;
PAAD	cis	rs3753841	0.714	rs1993822	chr1:103392363	C/A	cg24495344	chr1:103574097	COL11A1	0.39	4.25	0.33	3.71e-5	Glaucoma (primary angle closure);
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg21665744	chr7:39171113	POU6F2	0.35	6.01	0.44	1.31e-8	IgG glycosylation;
PAAD	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14019695	chr9:139328340	INPP5E	0.48	4.5	0.34	1.33e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.74	0.42	5.08e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg05925327	chr15:68127851	NA	-0.64	-5.81	-0.43	3.49e-8	Restless legs syndrome;
PAAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.66	0.48	4.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg18833306	chr6:118973337	C6orf204	0.47	5.36	0.4	3.03e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.62	-4.84	-0.37	3.15e-6	Sjögren's syndrome;
PAAD	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.49	5.1	0.38	9.8e-7	Body mass index;
PAAD	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.27	0.33	3.45e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.23	-0.6	2.13e-16	Exhaled nitric oxide output;
PAAD	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.58	6.54	0.47	8.97e-10	Coronary artery disease;
PAAD	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.56	4.51	0.34	1.28e-5	Response to antidepressants in depression;
PAAD	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.61	-6.85	-0.49	1.7e-10	Tonsillectomy;
PAAD	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg23465465	chr6:26364728	BTN3A2	0.79	4.41	0.34	1.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17813221	chr2:147344944	PABPC1P2	0.63	6.52	0.47	9.91e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.52	0.52	4.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.44	4.37	0.33	2.31e-5	Longevity;Endometriosis;
PAAD	trans	rs62179067	0.708	rs62175986	chr2:179876509	A/G	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg05562828	chr17:3906858	NA	-0.54	-6.11	-0.44	7.89e-9	Type 2 diabetes;
PAAD	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.61	4.66	0.35	6.96e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg18279126	chr7:2041391	MAD1L1	-0.61	-5.92	-0.43	2.06e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg12215294	chr3:40350768	EIF1B	0.5	5.08	0.38	1.11e-6	Renal cell carcinoma;
PAAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg27284194	chr4:1044797	NA	0.48	4.38	0.33	2.18e-5	Obesity-related traits;
PAAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg00555438	chr3:195578280	NA	0.51	4.8	0.36	3.79e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg05163071	chr3:108476540	RETNLB	0.96	6.83	0.48	1.88e-10	Dental caries;
PAAD	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.96	11.02	0.67	4e-21	Monocyte count;
PAAD	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-5.38	-0.4	2.77e-7	Neuroticism;
PAAD	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.75	7.65	0.53	2.09e-12	Brugada syndrome;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.78	10.16	0.64	7.67e-19	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.64	-0.42	8.07e-8	Total cholesterol levels;
PAAD	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.37	-0.4	2.95e-7	Mood instability;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.86	-6.14	-0.45	6.87e-9	Schizophrenia;
PAAD	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs1015291	0.836	rs951062	chr12:19988377	C/T	cg25401612	chr12:20009446	NA	-0.51	-5.0	-0.38	1.54e-6	Diastolic blood pressure;
PAAD	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.55	5.93	0.43	1.96e-8	Mean corpuscular volume;
PAAD	cis	rs965469	0.779	rs2236119	chr20:3303576	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs9323205	0.954	rs7150336	chr14:51584596	A/T	cg23942311	chr14:51606299	NA	-0.5	-4.54	-0.35	1.15e-5	Cancer;
PAAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg14393609	chr7:65229607	NA	0.5	4.99	0.38	1.63e-6	Aortic root size;
PAAD	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg27205649	chr11:78285834	NARS2	0.61	4.36	0.33	2.36e-5	Alzheimer's disease (survival time);
PAAD	cis	rs72960926	1.000	rs16884854	chr6:75107223	C/T	cg03266952	chr6:74778945	NA	-1.26	-6.71	-0.48	3.67e-10	Metabolite levels (MHPG);
PAAD	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.54	-4.71	-0.36	5.45e-6	Mean corpuscular volume;
PAAD	cis	rs12044355	0.892	rs1538974	chr1:231828596	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.04	-0.38	1.32e-6	Alzheimer's disease;
PAAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.6	6.38	0.46	2e-9	Huntington's disease progression;
PAAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.55	5.05	0.38	1.24e-6	Height;
PAAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg17077180	chr1:38461687	NA	-0.61	-7.18	-0.5	2.84e-11	Coronary artery disease;
PAAD	cis	rs17095355	0.818	rs59339754	chr10:111800116	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.47	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.68	7.43	0.52	7.23e-12	Personality dimensions;
PAAD	cis	rs6987853	0.563	rs2923406	chr8:42448873	G/T	cg09913449	chr8:42400586	C8orf40	0.52	5.88	0.43	2.54e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.87	-9.69	-0.62	1.39e-17	Mortality in heart failure;
PAAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg14343924	chr8:8086146	FLJ10661	-0.53	-4.51	-0.34	1.3e-5	Neuroticism;
PAAD	cis	rs2017305	0.749	rs115363198	chr10:70791472	C/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.46	-0.4	1.93e-7	Depression (quantitative trait);
PAAD	cis	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg21546286	chr11:48923668	NA	-0.45	-4.75	-0.36	4.63e-6	HDL cholesterol;
PAAD	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.81	-0.36	3.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs66530629	0.874	rs10903102	chr1:25122839	C/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.69	-0.36	6.16e-6	Plateletcrit;
PAAD	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	11.76	0.69	4.07e-23	Platelet count;
PAAD	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.54	-0.41	1.31e-7	Life satisfaction;
PAAD	cis	rs7213347	0.555	rs2760751	chr17:2028106	A/G	cg15816464	chr17:2026533	SMG6	0.52	5.6	0.41	9.67e-8	Total body bone mineral density;
PAAD	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.39	5.57	0.41	1.15e-7	Educational attainment (years of education);
PAAD	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.52	-5.31	-0.4	3.81e-7	Body mass index;
PAAD	cis	rs469727	0.554	rs149191	chr5:112252258	A/G	cg06941702	chr5:112196734	SRP19	0.5	4.71	0.36	5.57e-6	Attention deficit hyperactivity disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02356600	chr15:73345745	NEO1	-0.59	-7.05	-0.5	5.72e-11	Body fat percentage;
PAAD	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg05625103	chr10:2543513	NA	0.62	6.59	0.47	6.91e-10	Age-related hearing impairment;
PAAD	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs3764563	0.935	rs1654592	chr19:15690296	T/A	cg20725493	chr19:15740067	CYP4F8	0.96	5.26	0.39	4.92e-7	Inflammatory biomarkers;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06915872	chr16:87998081	BANP	0.57	5.09	0.38	1.03e-6	Menopause (age at onset);
PAAD	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.71	-0.66	2.64e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.29	0.6	1.55e-16	Cognitive test performance;
PAAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.07e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.99	-0.59	8.9e-16	Diabetic kidney disease;
PAAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-6.68	-0.48	4.34e-10	Coronary artery disease;
PAAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.66	-7.58	-0.52	3.2e-12	Huntington's disease progression;
PAAD	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.67	7.06	0.5	5.69e-11	Coronary artery disease;
PAAD	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.08	6.88	0.49	1.45e-10	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10929159	0.964	rs36000283	chr2:236934189	G/C	cg14226755	chr2:236923322	AGAP1	0.29	4.62	0.35	8.12e-6	Parkinson's disease;
PAAD	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.3e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	6.06	0.44	1.01e-8	Neutrophil percentage of white cells;
PAAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.69	7.86	0.54	6.44e-13	Emphysema distribution in smoking;
PAAD	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22629493	chr21:34961221	DONSON	0.58	6.49	0.47	1.12e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.47e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8077577	0.945	rs62073608	chr17:18071448	T/C	cg16794390	chr17:18148240	FLII	0.58	4.88	0.37	2.68e-6	Obesity-related traits;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.49	4.74	0.36	4.8e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg19000871	chr14:103996768	TRMT61A	-0.46	-4.95	-0.37	1.92e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.69	7.07	0.5	5.33e-11	Menarche (age at onset);
PAAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.78	9.0	0.59	8.64e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2790216	0.950	rs2790184	chr10:60041534	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs820218	0.926	rs820135	chr17:73674977	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.52	4.49	0.34	1.43e-5	Rotator cuff tears;
PAAD	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02637302	chr17:79670369	MRPL12	-0.75	-6.48	-0.47	1.22e-9	Neuroticism;
PAAD	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.53	5.6	0.41	9.73e-8	Bladder cancer;
PAAD	cis	rs6466055	0.612	rs10247691	chr7:104692291	T/C	cg04380332	chr7:105027541	SRPK2	-0.51	-4.98	-0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg10395934	chr14:104002654	TRMT61A	0.54	5.44	0.4	2.09e-7	Body mass index;
PAAD	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs3764400	0.564	rs1452663	chr17:46293386	C/G	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.17	17.98	0.82	1.89e-39	Multiple myeloma;
PAAD	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.57	5.25	0.39	5.06e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08711118	chr3:126327472	TXNRD3IT1	-0.66	-6.96	-0.49	9.41e-11	Obesity-related traits;
PAAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.43	0.4	2.18e-7	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17855130	chr1:164819399	PBX1	-0.64	-6.48	-0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.77	-5.7	-0.42	6e-8	Coronary artery calcification;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.39	0.34	2.12e-5	Parkinson's disease;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg15192750	chr16:69999425	NA	0.78	5.9	0.43	2.23e-8	IgE levels;
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.17	-0.5	3.09e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg18612461	chr15:75251733	NA	0.41	4.82	0.36	3.39e-6	Systemic lupus erythematosus;
PAAD	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.68	-7.96	-0.54	3.81e-13	Alcohol dependence;
PAAD	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.43	-0.34	1.79e-5	Total body bone mineral density;
PAAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.96	8.44	0.56	2.32e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg07784872	chr16:85687041	KIAA0182	0.53	4.32	0.33	2.79e-5	Platelet distribution width;
PAAD	cis	rs818427	0.964	rs495794	chr5:112201094	A/G	cg06941702	chr5:112196734	SRP19	-0.46	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.42	-5.6	-0.41	9.77e-8	Prostate cancer;
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.72	0.58	4.47e-15	Lung cancer;
PAAD	cis	rs400736	0.740	rs225129	chr1:8094164	T/A	cg25007680	chr1:8021821	PARK7	0.64	6.3	0.45	3.11e-9	Response to antidepressants and depression;
PAAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22633769	chr20:60982531	CABLES2	0.56	4.94	0.37	2.04e-6	Colorectal cancer;
PAAD	cis	rs7084783	0.538	rs1077016	chr10:105333242	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.54	0.35	1.16e-5	Fear of pain;
PAAD	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs13082711	0.954	rs67282221	chr3:27552752	T/A	cg02860705	chr3:27208620	NA	0.71	6.4	0.46	1.79e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-5.69	-0.42	6.43e-8	Crohn's disease;
PAAD	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.47	-0.34	1.5e-5	Recombination measurement;
PAAD	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.9	-10.86	-0.66	1.1e-20	Metabolic syndrome;
PAAD	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs9842133	0.512	rs1056103	chr3:179639392	T/C	cg18765712	chr3:179670323	PEX5L	-0.51	-4.42	-0.34	1.85e-5	Blood metabolite levels;
PAAD	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.53	-5.21	-0.39	5.98e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.9	6.93	0.49	1.13e-10	D-dimer levels;
PAAD	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.65	0.42	7.57e-8	Eosinophil percentage of white cells;
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg09915433	chr19:53449742	NA	-0.82	-11.79	-0.69	3.42e-23	Psoriasis;
PAAD	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7260598	0.539	rs11670271	chr19:24066723	G/A	cg09235885	chr19:23456588	NA	-0.62	-4.32	-0.33	2.76e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19626725	chr5:178986131	RUFY1	-0.49	-5.09	-0.38	1.06e-6	Lung cancer;
PAAD	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs17002988	0.568	rs10008931	chr4:79087705	A/G	cg07442568	chr4:78980533	FRAS1	-0.67	-5.49	-0.41	1.63e-7	Uric acid levels;
PAAD	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg02917321	chr22:38215204	NA	-0.45	-4.87	-0.37	2.82e-6	Glioblastoma;Glioma;
PAAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.56	-5.56	-0.41	1.2e-7	Childhood ear infection;
PAAD	cis	rs337161	0.765	rs425473	chr1:220938568	A/G	cg09023136	chr1:220959637	MOSC1	-0.56	-4.3	-0.33	3.04e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.49	5.64	0.42	8.23e-8	Coronary artery disease;
PAAD	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.9	8.3	0.56	5.16e-14	Obesity-related traits;
PAAD	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.61	4.28	0.33	3.31e-5	Lipoprotein (a) levels;
PAAD	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs776905	0.540	rs488703	chr13:113770876	G/A	cg09069900	chr13:113776964	F10	-0.56	-4.6	-0.35	8.96e-6	Blood protein levels;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08439880	chr3:133502540	NA	-0.59	-6.32	-0.46	2.7e-9	Iron status biomarkers;
PAAD	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs595018	0.505	rs11822479	chr11:60597302	C/T	cg07588442	chr11:60673866	PRPF19	0.66	4.52	0.34	1.25e-5	Wegener's granulomatosis;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.41	-0.52	8.22e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs59104589	0.521	rs56697150	chr2:242430085	C/A	cg19488206	chr2:242435732	STK25	0.45	4.45	0.34	1.65e-5	Fibrinogen levels;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg13047869	chr3:10149882	C3orf24	0.82	7.28	0.51	1.64e-11	Alzheimer's disease;
PAAD	cis	rs4845552	0.767	rs6587743	chr1:153481717	C/T	cg15998505	chr1:153479701	NA	0.54	4.48	0.34	1.43e-5	Hippocampal atrophy;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg11416102	chr8:651193	ERICH1	-0.86	-4.7	-0.36	5.74e-6	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9810890	1.000	rs116479497	chr3:128545382	G/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.45	4.55	0.35	1.07e-5	Motion sickness;
PAAD	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-7.47	-0.52	5.86e-12	QT interval;
PAAD	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.72	-7.46	-0.52	6.23e-12	Schizophrenia;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.79	-7.37	-0.51	1e-11	Gout;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.53	-5.35	-0.4	3.2e-7	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.43	-4.67	-0.35	6.61e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs77880822	0.562	rs7262435	chr20:1226251	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	4.43	0.34	1.83e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.6	-5.82	-0.43	3.31e-8	Coronary artery disease;
PAAD	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	1.17	18.29	0.83	3.06e-40	Gut microbiome composition (winter);
PAAD	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.51	5.29	0.39	4.18e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.12	9.68	0.62	1.45e-17	Vitiligo;
PAAD	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.52	5.53	0.41	1.35e-7	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg13010199	chr12:38710504	ALG10B	-0.61	-5.14	-0.38	8.22e-7	Morning vs. evening chronotype;
PAAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.49	-4.81	-0.36	3.57e-6	Visceral fat;
PAAD	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.27	-0.33	3.48e-5	Dupuytren's disease;
PAAD	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg03989125	chr22:38214979	NA	0.53	5.4	0.4	2.56e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06111305	chr13:98086784	RAP2A	0.7	6.47	0.46	1.25e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.7	0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.53	6.61	0.47	6.25e-10	Crohn's disease;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.04	0.44	1.11e-8	Lung cancer;
PAAD	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.63	5.24	0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.66	7.47	0.52	5.78e-12	Mean corpuscular volume;
PAAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.69	7.05	0.5	5.9e-11	Menarche (age at onset);
PAAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10267417	0.603	rs17142124	chr7:19903631	C/G	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-5.26	-0.39	4.92e-7	Daytime sleep phenotypes;
PAAD	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.64	-0.35	7.57e-6	Toenail selenium levels;
PAAD	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2017305	0.915	rs79202414	chr10:70739235	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.63	-5.92	-0.43	2.05e-8	Breast size;
PAAD	cis	rs9463078	0.585	rs12208924	chr6:45342051	C/T	cg25276700	chr6:44698697	NA	0.45	5.12	0.38	9.02e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg16205897	chr5:131564050	P4HA2	0.41	4.38	0.33	2.21e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs2790216	1.000	rs1769044	chr10:59958956	C/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg07338119	chr7:157211683	NA	-0.43	-4.38	-0.33	2.21e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg06917634	chr15:78832804	PSMA4	-0.47	-4.58	-0.35	9.42e-6	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg04844267	chr4:1394941	NA	0.45	5.12	0.38	8.98e-7	Longevity;
PAAD	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.13	0.5	3.83e-11	Coffee consumption (cups per day);
PAAD	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg20913747	chr6:44695427	NA	-0.66	-6.49	-0.47	1.12e-9	Total body bone mineral density;
PAAD	cis	rs256277	0.657	rs154119	chr5:111375089	T/C	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.55	-5.3	-0.4	3.93e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.6	5.04	0.38	1.3e-6	Cystic fibrosis severity;
PAAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg25251562	chr2:3704773	ALLC	-0.47	-5.38	-0.4	2.8e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.64	-7.85	-0.54	6.89e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.58	6.67	0.48	4.42e-10	Bipolar disorder;
PAAD	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.83	10.27	0.64	3.95e-19	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-8.66	-0.57	6.49e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.47	4.6	0.35	8.95e-6	Dupuytren's disease;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-7.28	-0.51	1.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg01426195	chr3:39028469	NA	-0.65	-6.53	-0.47	9.26e-10	Handedness;
PAAD	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg22467129	chr15:76604101	ETFA	0.53	4.98	0.37	1.68e-6	Blood metabolite levels;
PAAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.63	6.43	0.46	1.58e-9	Hemoglobin concentration;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	1.0	6.66	0.48	4.63e-10	IgG glycosylation;
PAAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.5	0.57	1.62e-14	Glomerular filtration rate (creatinine);
PAAD	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.74	-0.36	4.95e-6	Resting heart rate;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg13385521	chr17:29058706	SUZ12P	-0.72	-4.76	-0.36	4.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3771514	1.000	rs3771514	chr2:70697667	G/A	cg21989299	chr2:70484546	PCYOX1	-0.5	-4.45	-0.34	1.65e-5	Obesity-related traits;
PAAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.76	-0.42	4.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.68	-7.35	-0.51	1.14e-11	DNA methylation (variation);
PAAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.2	-0.39	6.2e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.18	0.6	3.03e-16	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01255329	chr4:3512459	NA	0.61	6.33	0.46	2.64e-9	Smoking initiation;
PAAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.68	7.84	0.54	7.15e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg01181863	chr3:195395398	SDHAP2	-0.98	-9.24	-0.6	2.12e-16	Pancreatic cancer;
PAAD	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg10556349	chr10:835070	NA	0.59	4.97	0.37	1.79e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.63	-6.18	-0.45	5.72e-9	Lung cancer;
PAAD	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.69	7.3	0.51	1.52e-11	Blood protein levels;
PAAD	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.7	-7.9	-0.54	5.16e-13	Schizophrenia;
PAAD	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg27411982	chr8:10470053	RP1L1	0.41	4.43	0.34	1.82e-5	Retinal vascular caliber;
PAAD	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.5	4.4	0.34	1.99e-5	Height;
PAAD	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.61	6.4	0.46	1.86e-9	Testicular germ cell tumor;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.03	13.07	0.73	1.21e-26	Cognitive ability;
PAAD	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.53	-0.35	1.16e-5	Biliary atresia;
PAAD	cis	rs7264396	0.832	rs224378	chr20:34088764	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg09582351	chr12:29534625	ERGIC2	-0.37	-4.82	-0.36	3.5e-6	QT interval;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	6.33	0.46	2.56e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg09168692	chr1:7887560	PER3	-0.43	-4.43	-0.34	1.79e-5	Inflammatory bowel disease;
PAAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.69	6.71	0.48	3.53e-10	Prostate cancer;
PAAD	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	5.98e-6	Plateletcrit;
PAAD	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.56	6.03	0.44	1.2e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs340025	0.562	rs3784607	chr15:60918417	C/T	cg00200653	chr15:60883225	RORA	0.48	4.28	0.33	3.31e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.79	-0.42	3.97e-8	Menarche (age at onset);
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg19642007	chr11:1944464	TNNT3	-0.35	-4.28	-0.33	3.29e-5	Alzheimer's disease (late onset);
PAAD	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.39	0.46	1.97e-9	Body mass index;
PAAD	cis	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg15676455	chr3:128564943	NA	-0.8	-4.62	-0.35	8.2e-6	Dental caries;
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.8	-8.41	-0.56	2.8e-14	Prostate cancer;
PAAD	cis	rs9810890	1.000	rs9862012	chr3:128572219	C/T	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs8179	0.700	rs42041	chr7:92246744	C/G	cg03496780	chr7:92466842	CDK6	0.49	4.53	0.35	1.17e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.59	-6.19	-0.45	5.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7688540	0.800	rs73793597	chr4:255905	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	4.77	0.36	4.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs12145833	0.920	rs12354170	chr1:243457776	G/T	cg02356786	chr1:243265016	LOC731275	0.68	4.68	0.35	6.32e-6	Obesity (early onset extreme);
PAAD	cis	rs61759167	0.955	rs2075968	chr1:3081241	C/T	cg22396632	chr1:3079212	PRDM16	-0.56	-5.37	-0.4	2.93e-7	Motion sickness;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.05	0.55	2.26e-13	Lung cancer;
PAAD	cis	rs6604026	0.616	rs17380789	chr1:93387519	C/T	cg17283838	chr1:93427260	FAM69A	0.61	5.59	0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.88	-0.37	2.64e-6	Platelet count;
PAAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.36	-0.33	2.43e-5	Tonsillectomy;
PAAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg14500798	chr7:98100126	NA	0.42	4.27	0.33	3.4e-5	Breast cancer;
PAAD	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.77	7.63	0.53	2.35e-12	Asthma;
PAAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.78	8.56	0.57	1.19e-14	Total body bone mineral density;
PAAD	cis	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.55	-4.68	-0.35	6.32e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.81	0.58	2.58e-15	Corneal astigmatism;
PAAD	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2085601	0.566	rs60535906	chr4:89987607	C/T	cg17769793	chr4:89976368	FAM13A	0.44	5.5	0.41	1.6e-7	Hair greying;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-5.56	-0.41	1.18e-7	Bipolar disorder;
PAAD	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg05555928	chr11:63887634	MACROD1	-0.58	-5.57	-0.41	1.12e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	5.76	0.42	4.56e-8	Testicular germ cell tumor;
PAAD	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.71	-8.16	-0.55	1.19e-13	Colorectal cancer;
PAAD	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.76	8.13	0.55	1.42e-13	Prostate cancer;
PAAD	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00290607	chr11:67383545	NA	0.48	4.75	0.36	4.73e-6	Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.54	4.26	0.33	3.62e-5	Coronary artery disease;
PAAD	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg11802864	chr11:65308245	LTBP3	0.79	5.58	0.41	1.09e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.95	7.97	0.54	3.58e-13	Alzheimer's disease;
PAAD	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.47	4.43	0.34	1.82e-5	Red blood cell count;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg18876405	chr7:65276391	NA	-0.6	-6.82	-0.48	2.04e-10	Calcium levels;
PAAD	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.51	5.62	0.41	8.91e-8	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg27094323	chr7:1216898	NA	-0.5	-5.93	-0.43	1.94e-8	Longevity;Endometriosis;
PAAD	cis	rs8095374	0.935	rs11082513	chr18:43747153	C/T	cg20581250	chr18:44676959	HDHD2	0.48	4.52	0.34	1.23e-5	Clinical laboratory measurements;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.75	9.25	0.6	1.98e-16	Bladder cancer;
PAAD	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.54	-5.5	-0.41	1.56e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg22442454	chr1:209979470	IRF6	0.54	4.41	0.34	1.91e-5	Coronary artery disease;
PAAD	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.54	-0.35	1.13e-5	Mood instability;
PAAD	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.78	-10.77	-0.66	1.91e-20	Cannabis dependence symptom count;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg26939375	chr7:64535504	NA	-0.73	-8.17	-0.55	1.12e-13	Calcium levels;
PAAD	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg08975724	chr8:8085496	FLJ10661	0.66	6.61	0.47	6.05e-10	Neuroticism;
PAAD	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.55	4.71	0.36	5.5e-6	Prostate cancer;
PAAD	cis	rs1329189	1.000	rs2225257	chr10:130006024	G/A	cg17972361	chr10:130010134	NA	-0.46	-4.74	-0.36	4.9e-6	Orofacial clefts;
PAAD	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs939584	1.000	rs6719980	chr2:651507	T/C	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg08853572	chr16:1843915	IGFALS	-0.26	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs12780845	1.000	rs3752950	chr10:17203356	G/T	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg00173435	chr12:106696525	TCP11L2	-0.5	-4.99	-0.37	1.66e-6	Tourette syndrome;
PAAD	cis	rs7792596	1.000	rs6465411	chr7:94003260	T/C	cg20814616	chr7:94014465	NA	-0.44	-4.6	-0.35	8.91e-6	Intelligence;
PAAD	cis	rs732765	0.657	rs73303999	chr14:75235746	T/A	cg17347104	chr14:75034677	LTBP2	0.56	4.38	0.33	2.24e-5	Non-small cell lung cancer;
PAAD	cis	rs375066	0.762	rs1073653	chr19:44411543	G/A	cg11993925	chr19:44307056	LYPD5	-0.51	-6.28	-0.45	3.33e-9	Breast cancer;
PAAD	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.36	0.46	2.2e-9	Hip circumference;
PAAD	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg03885332	chr11:832357	CD151	-0.45	-5.34	-0.4	3.33e-7	Mean platelet volume;
PAAD	cis	rs60624478	0.671	rs10800074	chr1:165088731	A/T	cg25031777	chr1:164528501	PBX1	0.52	4.41	0.34	1.95e-5	Response to methotrexate in juvenile idiopathic arthritis;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.53	5.59	0.41	1.03e-7	Life satisfaction;
PAAD	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg20893579	chr22:38215064	NA	-0.56	-5.96	-0.44	1.71e-8	Glioblastoma;Glioma;
PAAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-4.44	-0.34	1.73e-5	Vitiligo;
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.47	4.31	0.33	2.89e-5	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.76	0.42	4.52e-8	Menopause (age at onset);
PAAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.62	-4.38	-0.33	2.2e-5	Depression;
PAAD	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg11395062	chr17:14139857	CDRT15	0.56	5.64	0.42	8.17e-8	Temperament;
PAAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Breast cancer;
PAAD	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.81	-7.85	-0.54	6.74e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg10645314	chr2:3704589	ALLC	-0.42	-4.5	-0.34	1.35e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.65	-0.53	2.12e-12	Coffee consumption (cups per day);
PAAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.2	12.13	0.7	4.25e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg03264133	chr6:25882463	NA	0.44	4.37	0.33	2.31e-5	Schizophrenia;
PAAD	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.83	10.48	0.65	1.08e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs8014252	0.614	rs28612538	chr14:71025206	G/A	cg11204974	chr14:71022665	NA	-0.73	-4.96	-0.37	1.85e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg14003231	chr6:33640908	ITPR3	0.36	4.62	0.35	8.01e-6	Plateletcrit;
PAAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg19680485	chr15:31195859	MTMR15	-0.45	-4.57	-0.35	1e-5	Huntington's disease progression;
PAAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs12612619	0.704	rs2384572	chr2:27324751	G/T	cg00617064	chr2:27272375	NA	-0.48	-4.62	-0.35	8.05e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.52	-0.52	4.55e-12	Neuroticism;
PAAD	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.03	9.42	0.61	6.88e-17	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.13	15.48	0.78	4.8e-33	Cognitive function;
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.76	4.83	0.36	3.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03768727	chr12:121659614	P2RX4	0.56	7.14	0.5	3.52e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg07061783	chr6:25882402	NA	0.49	4.68	0.35	6.37e-6	Blood metabolite levels;
PAAD	cis	rs16895831	0.519	rs12200153	chr6:42577712	C/T	cg10605015	chr6:42532144	UBR2	0.66	5.0	0.38	1.59e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.81	0.62	6.47e-18	Cognitive function;
PAAD	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs12311304	0.965	rs7955309	chr12:15368198	T/C	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.75e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.68	7.21	0.5	2.49e-11	Obesity-related traits;
PAAD	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.49	-4.61	-0.35	8.45e-6	Coronary artery disease;
PAAD	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg02917321	chr22:38215204	NA	-0.46	-4.97	-0.37	1.81e-6	Glioblastoma;Glioma;
PAAD	cis	rs6499755	0.932	rs714507	chr16:55339777	C/T	cg02859129	chr16:55357253	IRX6	0.33	4.55	0.35	1.07e-5	Hypospadias;
PAAD	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs988913	1.000	rs4715492	chr6:54835178	C/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	4.8	0.36	3.69e-6	Height;
PAAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg24112000	chr20:60950667	NA	-0.76	-7.98	-0.54	3.38e-13	Colorectal cancer;
PAAD	cis	rs3106136	0.843	rs6826671	chr4:95271881	T/C	cg11021082	chr4:95130006	SMARCAD1	0.59	5.59	0.41	1.03e-7	Capecitabine sensitivity;
PAAD	cis	rs10932679	0.708	rs741382	chr2:217682247	C/T	cg05032264	chr2:217675019	NA	0.57	4.55	0.35	1.08e-5	Pulse pressure;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.89	6.34	0.46	2.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28655083	0.529	rs285022	chr16:77099730	T/C	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.57	5.9	0.43	2.27e-8	Multiple sclerosis;
PAAD	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.83	0.36	3.36e-6	Diastolic blood pressure;
PAAD	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.64	6.41	0.46	1.74e-9	Schizophrenia;
PAAD	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.83	-10.58	-0.65	5.98e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs112556034	chr16:68045724	C/T	cg09835421	chr16:68378352	PRMT7	-1.1	-6.35	-0.46	2.33e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg15193198	chr20:60906057	LAMA5	0.6	6.81	0.48	2.09e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.55	5.49	0.41	1.68e-7	Plateletcrit;Platelet count;
PAAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg23506979	chr15:79090958	ADAMTS7	0.27	4.52	0.34	1.23e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.57	5.33	0.4	3.51e-7	Mean platelet volume;
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18357526	chr6:26021779	HIST1H4A	0.68	6.7	0.48	3.91e-10	Blood metabolite levels;
PAAD	cis	rs9469890	0.604	rs77186075	chr6:34504478	C/T	cg14254433	chr6:34482411	PACSIN1	-0.9	-5.88	-0.43	2.51e-8	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.8	9.0	0.59	8.64e-16	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01273150	chr12:109125569	CORO1C	0.57	6.34	0.46	2.53e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.46	4.57	0.35	1.01e-5	Mean platelet volume;
PAAD	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg19673125	chr6:150240577	RAET1G	0.41	5.81	0.43	3.49e-8	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.73	-0.36	4.98e-6	Lung cancer;
PAAD	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.85	9.09	0.59	5.02e-16	Body mass index;
PAAD	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg14393609	chr7:65229607	NA	0.67	7.42	0.52	7.82e-12	Aortic root size;
PAAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg24399712	chr22:39784796	NA	-0.61	-5.75	-0.42	4.67e-8	IgG glycosylation;
PAAD	cis	rs72627123	0.500	rs2068773	chr14:74300586	A/T	cg19860245	chr14:74300557	NA	-0.82	-6.74	-0.48	3.02e-10	Morning vs. evening chronotype;
PAAD	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.76	-5.3	-0.4	3.92e-7	Monocyte percentage of white cells;
PAAD	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.9	-10.85	-0.66	1.17e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.46	-4.38	-0.34	2.16e-5	Multiple sclerosis;
PAAD	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.67	0.35	6.69e-6	Menopause (age at onset);
PAAD	cis	rs9398803	0.673	rs1262557	chr6:127054588	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.55	-0.35	1.09e-5	Male-pattern baldness;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg26174226	chr8:58114915	NA	-0.69	-4.72	-0.36	5.37e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg23346134	chr3:49453900	TCTA	0.42	4.39	0.34	2.09e-5	Menarche (age at onset);
PAAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg01075559	chr1:2537774	MMEL1	-0.54	-5.6	-0.41	9.83e-8	Ulcerative colitis;
PAAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.53	4.32	0.33	2.8e-5	Vitamin D levels;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.44e-9	Lung cancer;
PAAD	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg19978312	chr5:179634688	RASGEF1C	0.65	4.84	0.37	3.17e-6	LDL cholesterol;
PAAD	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.12	0.5	4.09e-11	Lung cancer in ever smokers;
PAAD	cis	rs2120243	0.533	rs62278578	chr3:157055867	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.3	0.33	3.03e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg25566285	chr7:158114605	PTPRN2	0.85	8.73	0.58	4.27e-15	Calcium levels;
PAAD	cis	rs3762637	0.941	rs9289192	chr3:122076115	C/G	cg24169773	chr3:122142474	KPNA1	-0.64	-4.33	-0.33	2.66e-5	LDL cholesterol levels;
PAAD	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.59	-0.35	9.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.32	-4.32	-0.33	2.76e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs13024765	0.550	rs76708314	chr2:225182401	A/G	cg22455342	chr2:225449267	CUL3	0.49	4.59	0.35	9.06e-6	Platelet-derived growth factor BB levels;
PAAD	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg10985347	chr2:127963512	CYP27C1	0.49	4.8	0.36	3.82e-6	Protein C levels;
PAAD	cis	rs11615916	0.790	rs11612349	chr12:62717558	G/A	cg11441379	chr12:63026424	NA	0.65	4.4	0.34	2.06e-5	Pulmonary function decline;
PAAD	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg22875332	chr1:76189707	ACADM	-0.51	-5.12	-0.38	9.3e-7	Daytime sleep phenotypes;
PAAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs1450679	0.891	rs3758293	chr9:106855246	C/G	cg21169611	chr9:106856078	SMC2	0.7	4.26	0.33	3.61e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.54	5.31	0.4	3.78e-7	Resistin levels;
PAAD	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.72e-11	Obesity-related traits;
PAAD	cis	rs6908034	0.607	rs73376650	chr6:19805506	T/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12909921	chr17:37558512	FBXL20	0.65	7.57	0.52	3.27e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs746265	0.759	rs62002276	chr15:39588417	C/T	cg10099207	chr15:39544144	C15orf54	0.56	4.29	0.33	3.23e-5	PR interval;
PAAD	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.13	-0.38	8.81e-7	Joint mobility (Beighton score);
PAAD	cis	rs868943	0.528	rs9488864	chr6:116505669	C/T	cg18764771	chr6:116381957	FRK	0.27	4.45	0.34	1.62e-5	Total cholesterol levels;
PAAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.78	0.58	3.2e-15	Lung cancer;
PAAD	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	6.18	0.45	5.61e-9	Hip circumference;
PAAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.84	-0.54	7.22e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs17095355	1.000	rs7073969	chr10:111753798	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.32	-0.33	2.82e-5	Biliary atresia;
PAAD	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-4.91	-0.37	2.28e-6	Common traits (Other);
PAAD	cis	rs7688540	0.800	rs12510827	chr4:252804	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	4.88	0.37	2.63e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs71520386	0.846	rs17778126	chr7:22818959	T/C	cg04907244	chr7:22894795	SNORD93	0.5	4.26	0.33	3.51e-5	Fibrinogen levels;
PAAD	cis	rs210648	0.961	rs210609	chr6:117833361	T/A	cg21104965	chr6:117869453	DCBLD1	0.43	4.41	0.34	1.96e-5	Economic and political preferences;
PAAD	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12232835	chr3:183979215	ECE2;CAMK2N2	-0.63	-6.38	-0.46	1.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs901683	0.850	rs75748332	chr10:46065143	A/C	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg08562672	chr19:21860753	NA	-0.47	-4.93	-0.37	2.14e-6	Pain;
PAAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.57	6.29	0.45	3.28e-9	Blood metabolite levels;
PAAD	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.31	0.33	2.89e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.83	8.33	0.56	4.43e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.48	-0.34	1.45e-5	Aortic root size;
PAAD	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.62	-6.65	-0.47	4.98e-10	Neuroticism;
PAAD	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.51	-5.71	-0.42	5.74e-8	Metabolite levels;
PAAD	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.67	5.11	0.38	9.5e-7	Alzheimer's disease (survival time);
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.81	0.36	3.56e-6	Major depressive disorder;
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.63	6.03	0.44	1.21e-8	Blood metabolite levels;
PAAD	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.5	4.69	0.36	5.98e-6	Airway imaging phenotypes;
PAAD	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg09211372	chr6:168490623	NA	-0.45	-4.75	-0.36	4.66e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.33	-0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.59	-5.22	-0.39	5.77e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10267417	0.603	rs2214318	chr7:19899150	G/A	cg05791153	chr7:19748676	TWISTNB	0.68	4.79	0.36	4.01e-6	Night sleep phenotypes;
PAAD	cis	rs7101378	0.577	rs6589044	chr11:108893911	T/A	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	IgG glycosylation;
PAAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17848003	chr1:3704513	LRRC47	0.4	4.32	0.33	2.84e-5	Red cell distribution width;
PAAD	cis	rs89107	0.688	rs283082	chr6:118605441	A/C	cg18833306	chr6:118973337	C6orf204	0.48	5.75	0.42	4.73e-8	Cardiac structure and function;
PAAD	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.52	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg10820045	chr2:198174542	NA	-0.45	-4.4	-0.34	2.01e-5	Dermatomyositis;
PAAD	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs17539620	0.702	rs57887580	chr6:154877530	C/T	cg20019720	chr6:154832845	CNKSR3	0.52	7.29	0.51	1.58e-11	Lipoprotein (a) levels;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.04	-0.38	1.33e-6	Obesity-related traits;
PAAD	cis	rs2061333	0.557	rs28446946	chr19:44607619	T/C	cg20607764	chr19:44506953	ZNF230	-0.69	-4.91	-0.37	2.37e-6	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14853282	chr4:2626239	FAM193A	-0.67	-6.75	-0.48	2.91e-10	Obesity-related traits;
PAAD	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.73	-8.19	-0.55	9.98e-14	Schizophrenia;
PAAD	cis	rs59888335	1.000	rs60381750	chr3:80752104	G/T	cg21735741	chr3:80819488	NA	0.55	4.82	0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.13	0.5	3.82e-11	Alzheimer's disease;
PAAD	cis	rs12568771	1.000	rs12568771	chr1:17613809	A/G	cg01790353	chr1:17674483	PADI4	0.4	4.43	0.34	1.77e-5	IgA nephropathy;
PAAD	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.8	0.43	3.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.92e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	5.09	0.38	1.05e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs600550	0.520	rs11560911	chr11:60090369	G/A	cg05040360	chr11:60102449	MS4A6E	-0.44	-5.09	-0.38	1.05e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.54	5.72	0.42	5.4e-8	Huntington's disease progression;
PAAD	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.79	8.5	0.57	1.66e-14	Prostate cancer;
PAAD	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	4.81	0.36	3.63e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.52	-0.34	1.25e-5	Joint mobility (Beighton score);
PAAD	cis	rs9463078	0.804	rs9472418	chr6:44968072	C/G	cg25276700	chr6:44698697	NA	-0.5	-5.88	-0.43	2.46e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.72	8.46	0.57	2.1e-14	Hand grip strength;
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1997066	0.831	rs73342215	chr10:106819078	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs2526932	1.000	rs2803962	chr14:73083240	A/G	cg13588403	chr14:73209128	DPF3	-0.46	-5.63	-0.42	8.48e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.97	9.96	0.63	2.63e-18	Smoking behavior;
PAAD	cis	rs17608059	0.611	rs62052300	chr17:13916799	G/A	cg27005118	chr17:13972210	COX10	-0.37	-4.9	-0.37	2.48e-6	Temperament;
PAAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg18809830	chr7:99032528	PTCD1	-1.22	-5.29	-0.39	4.25e-7	Blood metabolite levels;
PAAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg23346134	chr3:49453900	TCTA	0.46	4.93	0.37	2.1e-6	Childhood ear infection;
PAAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.7	-8.88	-0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18944702	chr10:25507099	GPR158	-0.59	-6.55	-0.47	8.55e-10	Obesity-related traits;
PAAD	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.97	-0.49	8.91e-11	Eye color traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12422026	chr1:53516572	SCP2	0.57	6.49	0.47	1.17e-9	Smoking initiation;
PAAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs11892454	0.544	rs7571093	chr2:25992894	C/G	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-5.66	-0.42	7.36e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.6	5.94	0.43	1.9e-8	Blood metabolite levels;
PAAD	cis	rs3764563	1.000	rs586608	chr19:15694168	C/T	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg12310025	chr6:25882481	NA	0.44	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.81	4.91	0.37	2.28e-6	Obesity-related traits;
PAAD	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.8	8.52	0.57	1.48e-14	Osteoporosis;
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.51	5.21	0.39	6.13e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.68	0.48	4.27e-10	Coffee consumption (cups per day);
PAAD	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.97	-8.55	-0.57	1.2e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.59	0.35	9.26e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4936891	0.563	rs78158860	chr11:123890220	A/G	cg22125253	chr11:123886957	OR10G4	0.46	4.63	0.35	7.79e-6	Male fertility;
PAAD	cis	rs6142102	0.602	rs6141433	chr20:32548862	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.96	12.28	0.71	1.59e-24	Menopause (age at onset);
PAAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.92	-11.09	-0.67	2.61e-21	IgG glycosylation;
PAAD	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.55	-5.83	-0.43	3.29e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.67	0.35	6.64e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2421770	0.701	rs7119757	chr11:35257316	G/A	cg13971030	chr11:35366721	SLC1A2	-0.49	-5.01	-0.38	1.51e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs57339844	1	rs57339844	chr2:86118276	GTT/G	cg22670485	chr2:85581999	ELMOD3;RETSAT	0.43	4.41	0.34	1.91e-5	Mean platelet volume;
PAAD	cis	rs10905065	0.898	rs4748916	chr10:5820394	A/G	cg11519256	chr10:5708881	ASB13	-0.48	-4.31	-0.33	2.89e-5	Menopause (age at onset);
PAAD	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.9	12.27	0.71	1.78e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.26	-0.45	3.82e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.84	-0.58	2.25e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg04844267	chr4:1394941	NA	0.45	5.15	0.39	8.14e-7	Longevity;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.81	7.13	0.5	3.84e-11	Exhaled nitric oxide levels;
PAAD	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.62	-6.99	-0.49	8.12e-11	Cancer;
PAAD	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.6	-6.4	-0.46	1.86e-9	HDL cholesterol;
PAAD	cis	rs12986413	0.624	rs3786970	chr19:2141150	C/G	cg09261902	chr19:2140048	AP3D1	0.6	5.92	0.43	2.11e-8	Height;
PAAD	cis	rs4605213	0.528	rs11868199	chr17:49311334	T/C	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.5	-0.34	1.32e-5	Platelet count;
PAAD	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg04398451	chr17:18023971	MYO15A	0.75	7.83	0.54	7.67e-13	Total body bone mineral density;
PAAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg10494973	chr17:80897199	TBCD	0.56	4.58	0.35	9.57e-6	Breast cancer;
PAAD	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.21	-0.5	2.49e-11	Total cholesterol levels;
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.44	-0.56	2.3e-14	Height;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.54	5.91	0.43	2.14e-8	Testicular germ cell tumor;
PAAD	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.53	5.65	0.42	7.69e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.95	-6.07	-0.44	9.58e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.8e-7	Blood metabolite levels;
PAAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg19847866	chr10:1019161	NA	-0.59	-4.68	-0.35	6.34e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.62	-4.44	-0.34	1.71e-5	Vitiligo;
PAAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg01815783	chr4:1047043	NA	-0.45	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	5.89	0.43	2.41e-8	Total body bone mineral density;
PAAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.72	-7.17	-0.5	3.13e-11	Body mass index;
PAAD	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.47	0.41	1.79e-7	Caffeine consumption;
PAAD	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg05768032	chr16:30646687	NA	0.55	5.0	0.38	1.55e-6	Multiple myeloma;
PAAD	cis	rs216303	1.000	rs216295	chr12:6154206	C/T	cg12895370	chr12:6755816	ACRBP	0.49	4.38	0.33	2.21e-5	Low vWF levels;
PAAD	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.12e-9	Type 2 diabetes;
PAAD	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.42	6.62	0.47	5.73e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.11	8.96	0.59	1.12e-15	Cannabis dependence symptom count;
PAAD	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs78543474	chr3:128561638	T/C	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs7537660	0.636	rs10749635	chr1:248014615	C/T	cg20507276	chr1:248100600	OR2L13	0.45	5.16	0.39	7.57e-7	Platelet distribution width;
PAAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg23283495	chr1:209979779	IRF6	0.78	7.08	0.5	5.02e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs2221894	0.922	rs11136054	chr8:28855102	C/T	cg20212339	chr8:28908912	HMBOX1	0.47	4.88	0.37	2.6e-6	Obesity-related traits;
PAAD	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.64	-0.35	7.33e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.8	-0.62	6.86e-18	Type 2 diabetes;
PAAD	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.77	6.97	0.49	9.26e-11	Body mass index;
PAAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg15571903	chr15:79123663	NA	0.48	6.27	0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.64	7.32	0.51	1.37e-11	Atrial fibrillation;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.55	-5.69	-0.42	6.34e-8	Tonsillectomy;
PAAD	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg16447950	chr5:562315	NA	-0.52	-4.93	-0.37	2.14e-6	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.83	9.3	0.6	1.46e-16	Mortality in heart failure;
PAAD	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.65	7.07	0.5	5.18e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.58	-6.27	-0.45	3.62e-9	Pelvic organ prolapse;
PAAD	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.56	-5.04	-0.38	1.29e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg01097406	chr16:89675127	NA	0.37	4.43	0.34	1.81e-5	Vitiligo;
PAAD	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg06307176	chr5:131281290	NA	0.51	4.47	0.34	1.52e-5	Life satisfaction;
PAAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.55	4.49	0.34	1.39e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs12464483	1.000	rs12464483	chr2:30888924	G/A	cg17749961	chr2:30669863	LCLAT1	0.75	4.76	0.36	4.48e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.71e-14	Dupuytren's disease;
PAAD	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg04330084	chr7:123175371	IQUB	0.55	4.85	0.37	2.96e-6	Plateletcrit;Platelet count;
PAAD	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.86	-10.81	-0.66	1.42e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9659323	0.689	rs7545737	chr1:119533823	C/T	cg17326555	chr1:119535693	NA	0.36	4.49	0.34	1.43e-5	Body mass index;
PAAD	cis	rs10943724	0.679	rs480295	chr6:81233876	A/G	cg19323245	chr6:80716898	TTK	-0.46	-4.81	-0.36	3.55e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg16586182	chr3:47516702	SCAP	-0.64	-6.93	-0.49	1.14e-10	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07159124	chr3:62234072	PTPRG	-0.56	-6.8	-0.48	2.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs10872587	0.500	rs362832	chr6:146660624	G/A	cg23711669	chr6:146136114	FBXO30	0.62	4.73	0.36	5.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2552220	0.616	rs10503358	chr8:6016142	C/T	cg13720284	chr8:6940591	NA	-0.42	-4.4	-0.34	2e-5	Interleukin-8 levels;
PAAD	cis	rs2137920	0.685	rs12768497	chr10:50239161	C/T	cg02657375	chr10:50863136	CHAT	-0.55	-4.41	-0.34	1.96e-5	Migraine with aura;
PAAD	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.91	9.55	0.61	3.21e-17	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.76	-5.19	-0.39	6.68e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.89	8.34	0.56	4.07e-14	Gestational age at birth (maternal effect);
PAAD	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.5	5.26	0.39	4.87e-7	Bladder cancer;
PAAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.93	-11.27	-0.67	8.4e-22	Refractive error;
PAAD	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg06917450	chr1:38156652	C1orf109	-0.51	-4.48	-0.34	1.49e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.63	6.23	0.45	4.43e-9	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02254876	chr3:42922351	NA	0.59	6.61	0.47	6.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07701084	chr6:150067640	NUP43	0.62	6.24	0.45	4.19e-9	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.52	5.55	0.41	1.25e-7	Menarche (age at onset);
PAAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.89	6.26	0.45	3.67e-9	Initial pursuit acceleration;
PAAD	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.17	0.5	3.08e-11	Body mass index;
PAAD	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14169450	chr9:139327907	INPP5E	0.55	4.77	0.36	4.24e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.57	5.46	0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.89	10.37	0.64	2.23e-19	Monocyte count;
PAAD	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.11	0.55	1.5700000000000001e-13	Bipolar disorder;
PAAD	cis	rs8105895	0.935	rs10408150	chr19:22245225	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.83	-6.85	-0.49	1.73e-10	Alzheimer's disease;
PAAD	cis	rs2835810	0.915	rs7276166	chr21:38930508	C/T	cg08269941	chr21:38337048	HLCS	-0.47	-4.27	-0.33	3.4e-5	Metabolic syndrome;
PAAD	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.3	-0.33	2.98e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.61	4.95	0.37	1.91e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.13	0.55	1.36e-13	Alzheimer's disease;
PAAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.66	-6.44	-0.46	1.45e-9	Body mass index;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.65	-6.34	-0.46	2.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.47	4.53	0.34	1.21e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.87	-9.07	-0.59	5.59e-16	Obesity-related traits;
PAAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.81	5.22	0.39	5.75e-7	Body mass index;
PAAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.78	-9.49	-0.61	4.68e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.37	4.43	0.34	1.8e-5	Sitting height ratio;
PAAD	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.47	-4.89	-0.37	2.5e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18357526	chr6:26021779	HIST1H4A	0.73	7.74	0.53	1.29e-12	Height;
PAAD	cis	rs75920871	0.800	rs75904569	chr11:116988313	A/G	cg04087571	chr11:116723030	SIK3	-0.45	-4.68	-0.36	6.24e-6	Subjective well-being;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.88	10.69	0.66	3.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.81	7.57	0.52	3.38e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.71	7.58	0.52	3.19e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.51	5.29	0.39	4.21e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.48	-4.62	-0.35	8.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9361491	0.608	rs9361425	chr6:79454678	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.86	-8.97	-0.59	1.04e-15	Multiple sclerosis;
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg23018236	chr17:30244563	NA	-0.58	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6681460	0.546	rs1359462	chr1:67169201	C/A	cg02459107	chr1:67143332	SGIP1	0.61	5.85	0.43	2.89e-8	Presence of antiphospholipid antibodies;
PAAD	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26710055	chr3:15468825	EAF1;METTL6	0.55	6.58	0.47	7.26e-10	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.83e-7	Monocyte count;
PAAD	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.44	-4.79	-0.36	4e-6	Motion sickness;
PAAD	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	6.86	0.49	1.63e-10	Neuroticism;
PAAD	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.75	-8.87	-0.58	1.88e-15	Body mass index;
PAAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	5.91	0.43	2.13e-8	Response to antipsychotic treatment;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.15	-0.45	6.43e-9	Lung cancer;
PAAD	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.56	5.86	0.43	2.77e-8	Subjective well-being;
PAAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.83	8.78	0.58	3.22e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.38	0.56	3.29e-14	Homoarginine levels;
PAAD	trans	rs901683	1.000	rs76422608	chr10:46041945	G/C	cg12869334	chr8:37699360	GPR124	0.98	6.79	0.48	2.32e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-7.3	-0.51	1.48e-11	Total cholesterol levels;
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg22153463	chr1:85462885	MCOLN2	0.64	4.97	0.37	1.81e-6	Serum sulfate level;
PAAD	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg13736514	chr6:26305472	NA	-0.58	-6.15	-0.45	6.5e-9	Educational attainment;
PAAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.49	-0.82	3.11e-38	Height;
PAAD	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg22027985	chr11:4115532	RRM1	-0.44	-4.29	-0.33	3.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs77956314	0.901	rs118117321	chr12:117414790	C/G	cg02017074	chr12:117425053	FBXW8	-1.08	-5.17	-0.39	7.3e-7	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs4719841	0.662	rs4574742	chr7:25995063	A/G	cg24254488	chr7:25991654	NA	-0.31	-4.32	-0.33	2.79e-5	Triglyceride levels;
PAAD	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.22	0.45	4.63e-9	Personality dimensions;
PAAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.47	5.87	0.43	2.66e-8	Childhood ear infection;
PAAD	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg16926213	chr1:1841314	NA	0.38	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs4676482	0.529	rs17792215	chr3:39257756	A/C	cg02254461	chr3:39195904	CSRNP1	0.71	4.5	0.34	1.34e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg13264159	chr8:625131	ERICH1	-0.71	-4.7	-0.36	5.73e-6	IgG glycosylation;
PAAD	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs10885582	0.874	rs10885583	chr10:116330773	C/T	cg17056676	chr10:116301354	ABLIM1	-0.37	-4.9	-0.37	2.44e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.58	5.58	0.41	1.09e-7	Mortality in heart failure;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg21698718	chr17:80085957	CCDC57	0.4	4.27	0.33	3.47e-5	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg24053715	chr22:38214548	NA	0.59	5.44	0.4	2.09e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6494488	0.500	rs72744739	chr15:65049926	T/C	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.7	5.78	0.42	4.19e-8	Neuroticism;
PAAD	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg22532475	chr10:104410764	TRIM8	0.4	4.56	0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14019695	chr9:139328340	INPP5E	0.59	5.15	0.39	8.05e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.14e-8	Major depressive disorder;
PAAD	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.37	0.33	2.32e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg11993925	chr19:44307056	LYPD5	0.5	6.66	0.48	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.46	4.39	0.34	2.09e-5	Schizophrenia;
PAAD	cis	rs28489187	0.683	rs6576764	chr1:85866411	A/T	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg14092988	chr3:52407081	DNAH1	0.41	5.29	0.39	4.1e-7	Bipolar disorder;
PAAD	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg22134325	chr11:66188745	NPAS4	0.42	5.17	0.39	7.41e-7	Airway imaging phenotypes;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg10729496	chr3:10149963	C3orf24	0.95	8.06	0.55	2.12e-13	Alzheimer's disease;
PAAD	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg11232448	chr19:2858854	NA	-0.45	-4.47	-0.34	1.51e-5	Total cholesterol levels;
PAAD	cis	rs3736485	0.934	rs8038203	chr15:51870683	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	1.04	12.48	0.71	4.84e-25	Longevity;
PAAD	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.95	-7.69	-0.53	1.75e-12	Blood protein levels;
PAAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.44	-0.65	1.44e-19	Ulcerative colitis;
PAAD	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.12	-0.44	7.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg15654264	chr1:150340011	RPRD2	-0.46	-4.41	-0.34	1.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6074578	0.740	rs1858599	chr20:147917	A/C	cg16931068	chr20:139680	DEFB127	0.4	5.26	0.39	4.78e-7	Hirschsprung disease;
PAAD	cis	rs5877	0.568	rs1951627	chr1:173891817	C/T	cg14047008	chr1:173887011	SERPINC1	-0.46	-4.55	-0.35	1.1e-5	Subjective well-being (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09732432	chr5:61602737	KIF2A	-0.5	-6.72	-0.48	3.46e-10	Body fat percentage;
PAAD	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.96	11.33	0.68	6e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10140922	0.966	rs762010	chr14:35816665	C/T	cg07166546	chr14:35805898	NA	-0.33	-4.74	-0.36	4.95e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg26818257	chr2:241905806	NA	0.42	4.49	0.34	1.43e-5	Urinary metabolites;
PAAD	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg09634455	chr11:8337396	NA	0.38	4.32	0.33	2.82e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.546	rs9369529	chr6:45004533	T/C	cg25276700	chr6:44698697	NA	0.46	5.32	0.4	3.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg21479132	chr6:26055353	NA	0.92	5.57	0.41	1.13e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1499972	0.529	rs1154693	chr3:117804154	C/T	cg07612923	chr3:117604196	NA	0.72	5.16	0.39	7.48e-7	Schizophrenia;
PAAD	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.53	-4.9	-0.37	2.44e-6	Schizophrenia;
PAAD	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg22089800	chr15:90895588	ZNF774	-0.57	-5.23	-0.39	5.64e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.23	0.6	2.18e-16	Hemoglobin concentration;
PAAD	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.74	7.19	0.5	2.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	1.1	6.32	0.46	2.8e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.54	-6.76	-0.48	2.74e-10	Dupuytren's disease;
PAAD	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg01987362	chr5:1827066	NA	0.48	4.3	0.33	3e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4748857	0.947	rs10828426	chr10:23602901	C/T	cg18853376	chr10:23633759	C10orf67	0.51	4.53	0.34	1.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs507080	0.922	rs4938524	chr11:118552074	G/T	cg08498647	chr11:118550644	TREH	-0.37	-4.36	-0.33	2.38e-5	Serum metabolite levels;
PAAD	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.98	6.41	0.46	1.74e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs1529711	0.636	rs34464972	chr19:10969134	G/A	cg18582342	chr19:11591989	ELAVL3	-0.63	-5.1	-0.38	1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.51	0.41	1.51e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13876163	chr1:45140495	C1orf228;TMEM53	0.57	6.83	0.48	1.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2952768	0.965	rs2254137	chr2:208444028	C/A	cg22329743	chr2:208688774	PLEKHM3	-0.23	-4.48	-0.34	1.47e-5	Opioid sensitivity;
PAAD	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.09	-0.5	4.76e-11	Morning vs. evening chronotype;
PAAD	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.57	4.56	0.35	1.04e-5	Neutrophil percentage of white cells;
PAAD	cis	rs114540395	0.858	rs77325250	chr10:103320638	G/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.27	-0.33	3.42e-5	Schizophrenia;
PAAD	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.02	0.49	6.94e-11	Eye color traits;
PAAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg09324608	chr17:30823087	MYO1D	0.61	6.5	0.47	1.07e-9	Schizophrenia;
PAAD	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.79	0.58	3.06e-15	Colorectal cancer;
PAAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.74	0.58	3.97e-15	Parkinson's disease;
PAAD	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	0.93	7.39	0.51	9.15e-12	Prostate cancer;
PAAD	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.59	-6.38	-0.46	2.03e-9	Eye color traits;
PAAD	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.39	-5.01	-0.38	1.53e-6	Educational attainment (years of education);
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.83	-0.58	2.35e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg08677398	chr8:58056175	NA	0.61	4.53	0.34	1.21e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs55692468	0.520	rs62180799	chr2:153302108	G/A	cg04681845	chr2:153283485	FMNL2	0.44	5.43	0.4	2.15e-7	Intraocular pressure;
PAAD	cis	rs7823896	0.722	rs67974558	chr8:110323449	A/G	cg02458499	chr8:110280928	NUDCD1	0.68	4.4	0.34	2e-5	Myopia (pathological);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15714321	chr21:38739180	DYRK1A	-0.64	-6.68	-0.48	4.32e-10	Smoking initiation;
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.41	-0.52	8.04e-12	Total body bone mineral density;
PAAD	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.74	8.1	0.55	1.71e-13	Schizophrenia;
PAAD	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-5.87	-0.43	2.58e-8	Menarche (age at onset);
PAAD	cis	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg21546286	chr11:48923668	NA	-0.52	-5.4	-0.4	2.52e-7	HDL cholesterol;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.47	-5.18	-0.39	7.1e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs2882667	0.654	rs1095374	chr5:138095206	A/G	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7236492	0.872	rs78536295	chr18:77229738	G/A	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7620363	0.859	rs12485408	chr3:34088635	C/T	cg02064073	chr3:33155252	CRTAP	-0.53	-4.53	-0.35	1.18e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs4740619	0.619	rs1328277	chr9:16029126	G/C	cg14451791	chr9:16040625	NA	-0.46	-5.28	-0.39	4.32e-7	Body mass index;
PAAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg04738700	chr2:239367308	NA	0.4	4.34	0.33	2.55e-5	Multiple system atrophy;
PAAD	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.45	-6.04	-0.44	1.15e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs818427	0.548	rs395858	chr5:112187356	G/A	cg06941702	chr5:112196734	SRP19	-0.53	-5.1	-0.38	9.9e-7	Total body bone mineral density;
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg02462569	chr6:150064036	NUP43	-0.49	-5.52	-0.41	1.44e-7	Lung cancer;
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6604026	0.541	rs6698082	chr1:93390645	G/A	cg17283838	chr1:93427260	FAM69A	0.62	5.69	0.42	6.24e-8	Multiple sclerosis;
PAAD	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg10587741	chr22:38071170	LGALS1	0.61	6.84	0.49	1.82e-10	Fat distribution (HIV);
PAAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.42	4.8	0.36	3.84e-6	Type 2 diabetes;
PAAD	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21178979	chr7:1889533	MAD1L1	0.4	4.36	0.33	2.35e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15132922	chr3:9974529	IL17RC;CRELD1	-0.56	-6.29	-0.45	3.21e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1270639	0.778	rs2906934	chr7:157451447	G/A	cg13357408	chr7:157437802	PTPRN2	1.15	10.51	0.65	9.15e-20	Colorectal cancer;
PAAD	cis	rs6460942	0.908	rs73301032	chr7:12256799	C/G	cg20607287	chr7:12443886	VWDE	-0.6	-4.84	-0.37	3.17e-6	Coronary artery disease;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.47	-0.46	1.26e-9	Lymphocyte counts;
PAAD	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.9	10.1	0.63	1.11e-18	Total cholesterol levels;
PAAD	cis	rs735539	0.517	rs7325243	chr13:21133294	G/A	cg27499820	chr13:21296301	IL17D	0.52	5.03	0.38	1.36e-6	Dental caries;
PAAD	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.33	-0.46	2.66e-9	Exhaled nitric oxide output;
PAAD	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs1012068	0.960	rs12167583	chr22:32269711	C/T	cg01338084	chr22:32026380	PISD	0.59	5.34	0.4	3.32e-7	Chronic hepatitis C infection;
PAAD	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.66	-0.65	3.61e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.8	-9.17	-0.6	3.18e-16	Sudden cardiac arrest;
PAAD	cis	rs7713065	0.765	rs11741543	chr5:131771315	G/T	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.6	-0.35	8.93e-6	Lung function (FEV1/FVC);
PAAD	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg26876637	chr1:152193138	HRNR	-0.82	-6.13	-0.45	7.36e-9	Atopic dermatitis;
PAAD	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.92	0.75	6.57e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2070677	0.597	rs1410898	chr10:135295455	G/T	cg20169779	chr10:135381914	SYCE1	0.54	5.02	0.38	1.45e-6	Gout;
PAAD	cis	rs1198430	0.683	rs1198433	chr1:23756695	A/G	cg27447006	chr1:23763279	ASAP3	0.64	4.98	0.37	1.73e-6	Total cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05417788	chr2:749191	NA	0.59	6.59	0.47	6.91e-10	Smoking initiation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25579867	chr5:10647125	ANKRD33B	0.56	6.41	0.46	1.77e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20831041	chr11:464554	PTDSS2	0.57	6.53	0.47	9.26e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg17595323	chr11:93583763	C11orf90	0.34	4.27	0.33	3.48e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08877624	chr8:141521446	CHRAC1	0.56	6.38	0.46	1.99e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.47	0.41	1.84e-7	Coronary artery disease;
PAAD	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-4.29	-0.33	3.19e-5	Skin colour saturation;
PAAD	cis	rs9907295	0.591	rs78655848	chr17:34183956	G/A	cg19411729	chr17:34207663	CCL5	-0.55	-4.97	-0.37	1.75e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg23387401	chr17:4582204	PELP1	-0.47	-4.68	-0.35	6.31e-6	Lymphocyte counts;
PAAD	cis	rs959260	0.920	rs4789187	chr17:73394784	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.86	10.14	0.64	8.92e-19	Ulcerative colitis;
PAAD	cis	rs4742903	0.870	rs1354894	chr9:106975237	G/A	cg14250997	chr9:106856677	SMC2	0.43	4.54	0.35	1.12e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07234876	chr8:600039	NA	1.09	7.86	0.54	6.54e-13	IgG glycosylation;
PAAD	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-1.05	-11.02	-0.67	4.03e-21	Platelet distribution width;
PAAD	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.99	0.49	8.31e-11	Lung cancer in ever smokers;
PAAD	cis	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	9.95	0.63	2.85e-18	Menopause (age at onset);
PAAD	trans	rs78177980	1.000	rs79824818	chr15:93500223	G/T	cg06020529	chr3:44170067	NA	-1.14	-6.84	-0.49	1.81e-10	Schizophrenia;
PAAD	cis	rs1371614	0.635	rs9309558	chr2:27141504	C/T	cg00617064	chr2:27272375	NA	0.45	4.7	0.36	5.67e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs12530134	0.523	rs7762088	chr6:170794570	T/C	cg18217622	chr6:170732253	NA	0.79	5.53	0.41	1.37e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.77	5.59	0.41	1e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-4.29	-0.33	3.14e-5	Platelet count;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	7.76	0.53	1.16e-12	Height;
PAAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg15145965	chr22:50218605	BRD1	-0.66	-5.9	-0.43	2.26e-8	Schizophrenia;
PAAD	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.37	-4.26	-0.33	3.57e-5	Intelligence;
PAAD	cis	rs6782025	1.000	rs4346498	chr3:121098235	T/G	cg16417163	chr3:121280760	NA	-0.48	-4.88	-0.37	2.61e-6	Aging (facial);
PAAD	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	4.31	0.33	2.95e-5	Hip circumference;
PAAD	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg08648136	chr8:956695	NA	0.42	4.53	0.34	1.18e-5	Schizophrenia;
PAAD	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.37	4.64	0.35	7.5e-6	Calcium levels;
PAAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.72	-6.23	-0.45	4.41e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.46	6.13	0.45	7.35e-9	Breast cancer;Mosquito bite size;
PAAD	cis	rs7551345	0.951	rs875787	chr1:31711409	T/C	cg17086398	chr1:31896392	SERINC2	0.48	4.27	0.33	3.46e-5	Schizophrenia;
PAAD	cis	rs3736485	0.844	rs76092251	chr15:51803193	A/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.3	-0.33	3.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.97	12.47	0.71	5.08e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg07416916	chr2:36825888	FEZ2	0.46	4.49	0.34	1.41e-5	Height;
PAAD	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.58	5.97	0.44	1.6e-8	Homocysteine levels;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg11143131	chr5:131608246	PDLIM4	0.48	4.54	0.35	1.14e-5	Breast cancer;
PAAD	cis	rs7191439	0.790	rs8060966	chr16:88777329	A/G	cg27087555	chr16:88793112	FAM38A	-1.02	-6.31	-0.46	2.96e-9	Plateletcrit;
PAAD	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.53	5.14	0.39	8.17e-7	Common traits (Other);
PAAD	cis	rs4845459	0.967	rs6693105	chr1:152590663	C/T	cg03277515	chr1:153321198	PGLYRP4	-0.39	-4.6	-0.35	8.88e-6	Psoriasis;
PAAD	cis	rs6867913	0.556	rs11955859	chr5:141464894	C/T	cg23435118	chr5:141488016	NDFIP1	0.52	4.46	0.34	1.57e-5	Asthma;
PAAD	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs17155006	1.000	rs17155006	chr7:107757843	A/G	cg05962710	chr7:107745446	LAMB4	-0.53	-6.73	-0.48	3.23e-10	Pneumococcal bacteremia;
PAAD	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg15192750	chr16:69999425	NA	0.8	6.05	0.44	1.07e-8	IgE levels;
PAAD	cis	rs7941600	0.581	rs12278189	chr11:9359844	G/T	cg19415743	chr11:9336845	TMEM41B	0.94	5.91	0.43	2.18e-8	Coronary artery disease;
PAAD	cis	rs6445967	1.000	rs1913715	chr3:58308214	G/A	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.56	-0.41	1.18e-7	White blood cell count;
PAAD	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.45	-4.55	-0.35	1.08e-5	Calcium levels;
PAAD	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg17308606	chr9:130706144	FAM102A	0.48	4.44	0.34	1.71e-5	Glaucoma (primary angle closure);
PAAD	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.68	5.52	0.41	1.43e-7	Brain cytoarchitecture;
PAAD	cis	rs829661	0.947	rs829641	chr2:30700235	C/T	cg12454169	chr2:30669597	LCLAT1	0.64	4.89	0.37	2.51e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg22349387	chr12:9600060	DDX12	-0.41	-4.27	-0.33	3.44e-5	Breast size;
PAAD	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg00922110	chr4:57842668	C4orf14	-0.44	-4.73	-0.36	4.99e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.67	6.59	0.47	6.79e-10	Total body bone mineral density;
PAAD	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-5.92	-0.43	2.07e-8	Cervical cancer;
PAAD	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.79	-9.42	-0.61	6.81e-17	White blood cell count (basophil);
PAAD	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.87	6.87	0.49	1.54e-10	Axial length;
PAAD	cis	rs4740619	0.661	rs10810488	chr9:15943931	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.05	-0.38	1.23e-6	Body mass index;
PAAD	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.5	-5.81	-0.43	3.53e-8	Mean corpuscular volume;
PAAD	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg10183150	chr4:120222239	C4orf3	-0.3	-4.34	-0.33	2.58e-5	Diastolic blood pressure;
PAAD	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg00864860	chr1:7907996	UTS2	-0.52	-4.55	-0.35	1.11e-5	Crohn's disease;
PAAD	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg24739098	chr15:79297159	RASGRF1	0.36	4.62	0.35	8.14e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg01631408	chr1:248437212	OR2T33	0.57	5.0	0.38	1.58e-6	Common traits (Other);
PAAD	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.59	5.86	0.43	2.73e-8	Systolic blood pressure;
PAAD	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.04e-5	Migraine;
PAAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	4.25	0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs9487051	0.646	rs7773490	chr6:109623048	T/C	cg01475377	chr6:109611718	NA	-0.4	-4.3	-0.33	2.98e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.63	5.35	0.4	3.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.95	-7.65	-0.53	2.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.69	6.63	0.47	5.55e-10	Lymphocyte counts;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-5.64	-0.42	8.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-1.18	-11.28	-0.68	7.91e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.66	4.89	0.37	2.56e-6	Alzheimer's disease;
PAAD	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg13606994	chr1:44402422	ARTN	-0.43	-4.42	-0.34	1.86e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.71	-6.33	-0.46	2.63e-9	Coronary artery disease;
PAAD	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-5.15	-0.39	8.1e-7	Coronary artery disease;
PAAD	cis	rs1878047	0.665	rs12972826	chr19:51775531	G/A	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg14329783	chr7:75779857	NA	0.8	4.76	0.36	4.51e-6	Mononucleosis;
PAAD	cis	rs76866386	0.892	rs56266464	chr2:44054991	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.85	-5.04	-0.38	1.32e-6	Cholesterol, total;
PAAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.96	0.59	1.11e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg02071572	chr4:1403502	NA	0.37	4.29	0.33	3.11e-5	Obesity-related traits;
PAAD	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.39	5.46	0.4	1.89e-7	Educational attainment (years of education);
PAAD	cis	rs11825064	0.510	rs74765580	chr11:134517903	A/G	cg02089395	chr11:134479357	NA	-0.93	-5.96	-0.44	1.68e-8	Seasonality;
PAAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.27	0.45	3.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.7	-0.58	5.06e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.57	-4.54	-0.35	1.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6782025	0.837	rs597415	chr3:120719256	A/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg27141850	chr2:20869434	GDF7	0.4	4.71	0.36	5.43e-6	Abdominal aortic aneurysm;
PAAD	cis	rs3106136	0.843	rs11727030	chr4:95262665	A/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.1	0.44	8.48e-9	Capecitabine sensitivity;
PAAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.45	-4.67	-0.35	6.56e-6	Menopause (age at onset);
PAAD	cis	rs13092825	1.000	rs17259475	chr3:113308145	C/T	cg18753928	chr3:113234510	CCDC52	-0.46	-4.43	-0.34	1.81e-5	Dental caries;
PAAD	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.67	-6.88	-0.49	1.45e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.58	6.01	0.44	1.31e-8	Testicular germ cell tumor;
PAAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.54	5.2	0.39	6.27e-7	Facial morphology (factor 20);
PAAD	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.54	5.69	0.42	6.48e-8	Tonsillectomy;
PAAD	cis	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11642909	chr3:160170189	NA	-0.47	-4.27	-0.33	3.43e-5	Primary biliary cholangitis;
PAAD	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg14003231	chr6:33640908	ITPR3	0.36	4.62	0.35	8.01e-6	Plateletcrit;
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.44e-7	Cognitive function;
PAAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg06915872	chr16:87998081	BANP	0.52	4.62	0.35	8.24e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg14008862	chr17:28927542	LRRC37B2	0.8	5.37	0.4	2.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs1105228	0.644	rs9457059	chr6:165699810	G/A	cg20535254	chr6:165714960	C6orf118	-0.42	-4.4	-0.34	1.99e-5	Number of pregnancies;Number of children;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05000123	chr14:20937394	PNP	0.58	6.32	0.46	2.73e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.47	4.45	0.34	1.62e-5	Renal cell carcinoma;
PAAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg19784903	chr17:45786737	TBKBP1	0.53	5.88	0.43	2.53e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.95	-10.4	-0.64	1.84e-19	Parkinson's disease;
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.59	7.29	0.51	1.55e-11	Iron status biomarkers;
PAAD	cis	rs3126085	0.515	rs6668321	chr1:152353940	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.91	-0.37	2.37e-6	Atopic dermatitis;
PAAD	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.9	4.89	0.37	2.56e-6	Childhood ear infection;
PAAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg18944383	chr4:111397179	ENPEP	0.73	8.09	0.55	1.78e-13	Coronary artery disease;
PAAD	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg18171855	chr10:2543474	NA	0.41	4.28	0.33	3.26e-5	Age-related hearing impairment;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.81	5.65	0.42	7.78e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	7.27	0.51	1.78e-11	Leprosy;
PAAD	cis	rs12620999	0.627	rs7570274	chr2:238103614	G/C	cg23555395	chr2:238036564	NA	-0.48	-5.44	-0.4	2.13e-7	Systemic lupus erythematosus;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18207214	chr5:125880253	ALDH7A1	0.64	6.59	0.47	6.96e-10	Smoking initiation;
PAAD	cis	rs7567389	0.719	rs6430936	chr2:128007686	A/C	cg09760422	chr2:128146352	NA	-0.39	-5.94	-0.43	1.9e-8	Self-rated health;
PAAD	trans	rs7824557	0.527	rs4841495	chr8:10958824	T/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.97	-0.49	8.81e-11	Retinal vascular caliber;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.63	5.14	0.38	8.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	6.94	0.49	1.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21206133	chr1:151511319	TUFT1	0.64	6.45	0.46	1.42e-9	Lung cancer in ever smokers;
PAAD	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.82	-7.97	-0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.86e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6987853	0.527	rs2974298	chr8:42376477	T/C	cg09913449	chr8:42400586	C8orf40	-0.52	-5.99	-0.44	1.45e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs73206853	0.534	rs13313219	chr12:110509461	G/A	cg12870014	chr12:110450643	ANKRD13A	0.85	5.06	0.38	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16262614	chr3:133464971	TF	0.48	5.29	0.39	4.23e-7	Iron status biomarkers;
PAAD	cis	rs34226255	1.000	rs34226255	chr19:16430447	T/G	cg26918011	chr19:16634068	CHERP	0.53	4.51	0.34	1.31e-5	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg03651054	chr13:50194643	NA	0.43	5.7	0.42	6.05e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg11410649	chr1:24122853	GALE	-0.62	-4.47	-0.34	1.49e-5	Psoriasis vulgaris;
PAAD	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg17366294	chr4:99064904	C4orf37	-0.46	-5.15	-0.39	7.79e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.39	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	cis	rs16944613	0.510	rs11636571	chr15:91143857	A/G	cg15547629	chr15:90437138	AP3S2	-0.51	-4.42	-0.34	1.9e-5	Colorectal cancer;
PAAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg10356904	chr22:49881777	NA	-0.46	-4.59	-0.35	9.36e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	5.62	0.41	8.81e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg15660573	chr17:549704	VPS53	-0.62	-5.73	-0.42	5.28e-8	Prostate cancer;
PAAD	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.45	6.0	0.44	1.41e-8	Ulcerative colitis;
PAAD	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg25050447	chr17:78165522	CARD14	0.35	4.36	0.33	2.35e-5	Yeast infection;
PAAD	cis	rs7713065	0.765	rs4235802	chr5:131782837	C/A	cg14196790	chr5:131705035	SLC22A5	0.45	4.43	0.34	1.82e-5	Lung function (FEV1/FVC);
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.88	6.62	0.47	5.8e-10	Alzheimer's disease;
PAAD	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg03684893	chr10:554711	DIP2C	0.51	4.79	0.36	3.97e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.22	0.39	5.77e-7	Mean platelet volume;
PAAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.3	-5.81	-0.43	3.47e-8	Urinary metabolites;
PAAD	cis	rs3814231	0.531	rs12769185	chr10:115484200	T/G	cg24846397	chr10:115438155	CASP7	-0.47	-4.41	-0.34	1.91e-5	Vitiligo;
PAAD	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg05805236	chr11:65401703	PCNXL3	-0.43	-4.41	-0.34	1.93e-5	Eosinophil percentage of white cells;
PAAD	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	1.95	10.97	0.66	5.61e-21	Cannabis dependence symptom count;
PAAD	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.52	6.05	0.44	1.07e-8	Mean arterial pressure;
PAAD	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	4.94	0.37	2.08e-6	Educational attainment;
PAAD	cis	rs75920871	0.589	rs73008568	chr11:117065007	C/G	cg20748955	chr11:118016902	SCN4B	0.7	4.49	0.34	1.38e-5	Subjective well-being;
PAAD	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	1.17	13.64	0.74	3.65e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	0.88	4.47	0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs11235843	0.714	rs7128512	chr11:73372299	A/G	cg18195628	chr11:73498948	MRPL48	-0.65	-4.37	-0.33	2.29e-5	Hand grip strength;
PAAD	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.45	-4.36	-0.33	2.38e-5	Mean platelet volume;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs3026101	0.671	rs56018748	chr17:5316939	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	6.02	0.44	1.28e-8	Body mass index;
PAAD	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.48	6.87	0.49	1.56e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg03983715	chr16:68378420	PRMT7	-0.89	-6.32	-0.46	2.76e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.46e-7	Life satisfaction;
PAAD	cis	rs300774	0.858	rs300712	chr2:138903	A/T	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs847851	0.958	rs9380469	chr6:34877314	A/G	cg05379947	chr6:35436047	RPL10A	0.52	4.31	0.33	2.9e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.06	-0.38	1.17e-6	Menopause (age at onset);
PAAD	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.08	-7.97	-0.54	3.48e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg18612461	chr15:75251733	NA	0.58	7.27	0.51	1.76e-11	Breast cancer;
PAAD	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	5e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg13821571	chr21:34406537	NA	-0.46	-4.46	-0.34	1.57e-5	Gastritis;
PAAD	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg20673841	chr7:107026890	COG5	0.5	4.34	0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs9535307	0.858	rs2025263	chr13:50308847	C/T	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs3733418	0.860	rs72697987	chr4:165953917	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-5.2	-0.39	6.39e-7	Obesity-related traits;
PAAD	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg08898775	chr15:59042684	ADAM10	0.41	5.39	0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs752010	0.630	rs12134174	chr1:42105942	C/T	cg06885757	chr1:42089581	HIVEP3	0.58	6.26	0.45	3.7e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.52	-6.29	-0.45	3.27e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.37	8.81	0.58	2.64e-15	Atopic dermatitis;
PAAD	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1414896	1.000	rs10874910	chr1:95707567	C/T	cg20701556	chr1:95698924	RWDD3	-0.29	-4.5	-0.34	1.36e-5	Non-alcoholic fatty liver disease histology (AST);
PAAD	cis	rs7577696	0.597	rs212690	chr2:32437631	C/G	cg02381751	chr2:32503542	YIPF4	0.51	4.91	0.37	2.37e-6	Inflammatory biomarkers;
PAAD	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.46	0.71	5.4e-25	Chronic sinus infection;
PAAD	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11671664	0.732	rs67775326	chr19:46160969	A/G	cg13320842	chr19:46175254	GIPR	0.67	5.63	0.42	8.49e-8	Type 2 diabetes;Body mass index;Body mass index (SNP x SNP interaction);
PAAD	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg03805757	chr16:71968109	PKD1L3	-0.57	-4.34	-0.33	2.57e-5	Blood protein levels;
PAAD	cis	rs1329189	0.954	rs10764762	chr10:129993586	A/G	cg17972361	chr10:130010134	NA	-0.45	-4.68	-0.35	6.26e-6	Orofacial clefts;
PAAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg26497354	chr6:109612229	NA	-0.43	-4.6	-0.35	8.89e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.54	8.2	0.55	9.33e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.6	-4.9	-0.37	2.46e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg22861794	chr10:5032070	AKR1C2	0.8	4.55	0.35	1.1e-5	Major depressive disorder;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.85	-0.37	3.07e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.33	-0.46	2.68e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.76	-7.52	-0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2518049	0.519	rs4881402	chr10:5168530	T/G	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.63	6.25	0.45	3.98e-9	Coronary artery disease;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs78411303	0.584	rs7652006	chr3:122377999	G/A	cg17380795	chr3:122379686	NA	0.75	5.53	0.41	1.36e-7	Periodontitis (CDC/AAP);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17567562	chr3:47687980	SMARCC1	0.57	6.52	0.47	9.8e-10	Smoking initiation;
PAAD	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	1.04	6.64	0.47	5.29e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.6	-5.36	-0.4	3.05e-7	Lung cancer;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13053783	chr1:1334803	CCNL2;LOC148413	0.58	6.39	0.46	1.95e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.85	11.11	0.67	2.33e-21	Vitiligo;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.06	0.55	2.1e-13	Alzheimer's disease;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.74	7.66	0.53	2.06e-12	Menarche (age at onset);
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg15117754	chr3:10150083	C3orf24	0.67	5.58	0.41	1.07e-7	Alzheimer's disease;
PAAD	cis	rs2229238	0.911	rs112394421	chr1:154512008	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	trans	rs35213789	0.768	rs6979355	chr7:69384562	A/G	cg13714459	chr15:78730363	IREB2	1.0	6.56	0.47	8.01e-10	Childhood ear infection;
PAAD	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.63	6.57	0.47	7.74e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs4845552	1.000	rs28632016	chr1:153479905	A/G	cg15998505	chr1:153479701	NA	-0.49	-4.43	-0.34	1.82e-5	Hippocampal atrophy;
PAAD	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg21584241	chr15:63341463	TPM1	0.67	4.9	0.37	2.38e-6	Orofacial clefts;
PAAD	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg11143131	chr5:131608246	PDLIM4	0.48	4.74	0.36	4.95e-6	Blood metabolite levels;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg04522676	chr10:134968826	NA	0.48	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9395066	0.529	rs12529490	chr6:45018251	A/C	cg25276700	chr6:44698697	NA	0.5	5.48	0.41	1.7e-7	Height;
PAAD	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	5.16	0.39	7.76e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg09699651	chr6:150184138	LRP11	0.5	5.1	0.38	9.84e-7	Lung cancer;
PAAD	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.6	0.52	2.81e-12	Morning vs. evening chronotype;
PAAD	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.89	0.49	1.39e-10	IgG glycosylation;
PAAD	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.44	5.64	0.42	8.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg09659197	chr4:152720779	NA	-0.47	-6.36	-0.46	2.22e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12153243	0.686	rs768010	chr5:142934382	C/T	cg13907255	chr5:142895549	NA	-0.58	-4.97	-0.37	1.76e-6	Migraine;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.92	7.93	0.54	4.42e-13	Alzheimer's disease;
PAAD	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14159672	chr1:205819179	PM20D1	-0.52	-5.02	-0.38	1.44e-6	Parkinson's disease;
PAAD	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.54	4.52	0.34	1.22e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.12	-0.55	1.46e-13	Inflammatory bowel disease;
PAAD	cis	rs12599426	1.000	rs12599426	chr16:35088131	T/C	cg08331635	chr16:34430078	NA	-0.66	-4.66	-0.35	6.72e-6	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg14345882	chr6:26364793	BTN3A2	-0.62	-4.69	-0.36	6.1e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg21922841	chr17:72744131	SLC9A3R1	-0.4	-5.22	-0.39	5.92e-7	Monocyte count;
PAAD	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-4.91	-0.37	2.31e-6	Monocyte percentage of white cells;
PAAD	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.63	9.06	0.59	5.91e-16	Airflow obstruction;
PAAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.43	4.5	0.34	1.36e-5	Vitiligo;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs793571	0.915	rs4775101	chr15:59218094	C/T	cg08898775	chr15:59042684	ADAM10	-0.38	-4.4	-0.34	2.03e-5	Schizophrenia;
PAAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.76	-8.12	-0.55	1.52e-13	Rheumatoid arthritis;
PAAD	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.63	-4.86	-0.37	2.87e-6	Osteoarthritis;
PAAD	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg13590414	chr9:128173245	NA	-0.48	-4.87	-0.37	2.78e-6	Mean arterial pressure;
PAAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.45	4.31	0.33	2.86e-5	Menarche (age at onset);
PAAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.7	-0.36	5.91e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.66	-7.24	-0.51	2.13e-11	Huntington's disease progression;
PAAD	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg05872129	chr22:39784769	NA	-0.69	-6.21	-0.45	4.86e-9	IgG glycosylation;
PAAD	cis	rs3736485	0.966	rs7161973	chr15:51854163	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg00383909	chr3:49044727	WDR6	-0.52	-4.44	-0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg25364880	chr3:44379878	C3orf23	0.68	5.47	0.41	1.79e-7	IgG glycosylation;
PAAD	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.3	10.05	0.63	1.55e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26876637	chr1:152193138	HRNR	0.84	6.24	0.45	4.18e-9	Atopic dermatitis;
PAAD	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.97	10.22	0.64	5.6e-19	Multiple sclerosis;
PAAD	cis	rs6782228	0.675	rs4857918	chr3:128383960	T/C	cg16766828	chr3:128327626	NA	-0.45	-5.98	-0.44	1.57e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.85	6.94	0.49	1.04e-10	Pulmonary function decline;
PAAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs13242816	1.000	rs67652573	chr7:116109958	T/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg06883089	chr1:45254480	BEST4	0.37	4.6	0.35	8.66e-6	High light scatter reticulocyte count;
PAAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.77	-9.62	-0.62	2.09e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg14393609	chr7:65229607	NA	-0.67	-7.33	-0.51	1.28e-11	Aortic root size;
PAAD	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.96	10.51	0.65	9.24e-20	Alcohol dependence;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg23985595	chr17:80112537	CCDC57	0.44	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.32e-6	Renal cell carcinoma;
PAAD	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg26205652	chr12:48591994	NA	0.96	9.64	0.62	1.86e-17	Longevity (90 years and older);
PAAD	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02743256	chr7:2109353	MAD1L1	-0.73	-6.08	-0.44	9.33e-9	Bipolar disorder;
PAAD	cis	rs59888335	0.830	rs67409597	chr3:80558513	G/A	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs4841398	0.657	rs9987390	chr8:10462188	G/T	cg27411982	chr8:10470053	RP1L1	-0.53	-4.42	-0.34	1.87e-5	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22373676	chr13:30374285	UBL3	0.54	6.37	0.46	2.13e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.96	-7.8	-0.53	9.18e-13	Blood protein levels;
PAAD	trans	rs61931739	0.620	rs4323992	chr12:33693639	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.48	-0.52	5.62e-12	Morning vs. evening chronotype;
PAAD	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.92	11.81	0.69	3.09e-23	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6689305	0.545	rs12046903	chr1:100242500	C/G	cg22872634	chr1:100462710	SLC35A3	-0.45	-4.38	-0.33	2.2e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg03395511	chr6:291903	DUSP22	-0.77	-8.2	-0.55	9.26e-14	Menopause (age at onset);
PAAD	cis	rs12681288	0.578	rs73176535	chr8:971916	C/T	cg04851639	chr8:1020857	NA	-0.54	-6.12	-0.44	7.42e-9	Schizophrenia;
PAAD	cis	rs9907295	0.591	rs9908928	chr17:34189017	A/G	cg19411729	chr17:34207663	CCL5	-0.55	-4.97	-0.37	1.75e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs7236492	0.748	rs11663202	chr18:77209180	T/C	cg15644404	chr18:77186268	NFATC1	-0.89	-6.23	-0.45	4.44e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs877282	0.520	rs12360072	chr10:813082	C/T	cg15764593	chr10:829463	NA	-0.49	-4.69	-0.36	6.07e-6	Uric acid levels;
PAAD	cis	rs89107	0.688	rs422833	chr6:118608971	T/C	cg18833306	chr6:118973337	C6orf204	0.5	5.71	0.42	5.77e-8	Cardiac structure and function;
PAAD	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	0.56	6.06	0.44	1.02e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00339695	chr16:24857497	SLC5A11	0.46	4.34	0.33	2.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04905755	chr2:18635845	NA	-0.55	-6.58	-0.47	7.02e-10	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs8032158	1.000	rs8026172	chr15:56125182	T/A	cg02198044	chr15:56286336	NEDD4	-0.52	-5.49	-0.41	1.68e-7	Keloid;
PAAD	cis	rs6942407	0.546	rs2108271	chr7:86805372	G/A	cg02420886	chr7:86849541	C7orf23	0.65	5.02	0.38	1.45e-6	Food allergy;
PAAD	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.09	0.38	1.03e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.69	6.47	0.46	1.25e-9	Lymphocyte counts;
PAAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg10547527	chr2:198650123	BOLL	-0.72	-4.77	-0.36	4.36e-6	Ulcerative colitis;
PAAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs34375054	0.672	rs2291247	chr12:125618953	C/G	cg00522288	chr12:125625016	AACS	-0.54	-5.97	-0.44	1.58e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.97e-6	Caffeine consumption;
PAAD	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	5.92e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
PAAD	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg01244601	chr4:120671846	NA	-0.49	-4.27	-0.33	3.47e-5	Corneal astigmatism;
PAAD	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.52	5.19	0.39	6.58e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.62	-7.17	-0.5	3.09e-11	Longevity;Endometriosis;
PAAD	cis	rs3734905	1.000	rs12526225	chr6:169861325	T/C	cg11181693	chr6:169825345	NA	-0.88	-5.55	-0.41	1.26e-7	HIV-1 control;
PAAD	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.18	-0.39	6.88e-7	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17152850	chr2:178627834	PDE11A	0.59	7.32	0.51	1.38e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.41	0.65	1.75e-19	Smoking behavior;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10450921	chr16:1470887	C16orf91	-0.76	-6.61	-0.47	5.99e-10	Neuroticism;
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.53	5.15	0.39	8.1e-7	Trans fatty acid levels;
PAAD	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg18135206	chr14:102964638	TECPR2	0.59	4.62	0.35	8.29e-6	Blood protein levels;
PAAD	cis	rs8112211	0.834	rs4312417	chr19:38797189	A/G	cg14299480	chr19:38876666	GGN	-0.52	-6.83	-0.48	1.9e-10	Blood protein levels;
PAAD	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.41e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6681849	0.897	rs4477285	chr1:94876928	G/A	cg17801055	chr1:95285809	SLC44A3	-0.43	-4.28	-0.33	3.3e-5	Platelet distribution width;
PAAD	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.72	-0.42	5.41e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg00700412	chr12:58011837	NA	0.46	4.94	0.37	2.02e-6	Multiple sclerosis;
PAAD	cis	rs1351164	0.688	rs34587525	chr2:218253689	G/A	cg15335768	chr2:218268053	DIRC3	-0.4	-4.31	-0.33	2.93e-5	Height;
PAAD	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-6.5	-0.47	1.12e-9	Schizophrenia;
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.6	6.13	0.45	7.33e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11807834	0.522	rs4582798	chr1:230239628	C/T	cg09847368	chr1:230250326	GALNT2	-0.67	-8.24	-0.56	7.35e-14	Schizophrenia;
PAAD	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.56	6.35	0.46	2.37e-9	Mean corpuscular volume;
PAAD	cis	rs7189233	0.956	rs62048490	chr16:53456276	T/C	cg00221382	chr16:54322308	NA	-0.29	-4.5	-0.34	1.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.26	-0.51	1.85e-11	Mosquito bite size;
PAAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.95	12.38	0.71	8.49e-25	Menopause (age at onset);
PAAD	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg00071950	chr4:10020882	SLC2A9	0.48	4.25	0.33	3.71e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07930192	chr7:1003750	NA	0.41	4.99	0.38	1.61e-6	Longevity;Endometriosis;
PAAD	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.53	-0.52	4.25e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg00806126	chr19:22604979	ZNF98	0.39	4.8	0.36	3.68e-6	Pain;
PAAD	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg04450456	chr4:17643702	FAM184B	0.44	4.47	0.34	1.52e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs66530629	1.000	rs1316829	chr1:25051225	C/T	cg22509179	chr1:25234806	RUNX3	0.49	4.35	0.33	2.5e-5	Plateletcrit;
PAAD	cis	rs7631605	0.875	rs4678932	chr3:37096303	T/G	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.29e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg20302533	chr7:39170763	POU6F2	0.45	6.98	0.49	8.69e-11	IgG glycosylation;
PAAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg16147221	chr4:10020634	SLC2A9	0.47	4.37	0.33	2.33e-5	Bone mineral density;
PAAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg05342682	chr7:94953680	PON1	-0.51	-4.6	-0.35	8.84e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.54	5.35	0.4	3.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg12639453	chr1:2035780	PRKCZ	0.55	5.3	0.4	3.94e-7	Height;
PAAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg24253500	chr15:84953950	NA	0.57	6.55	0.47	8.35e-10	Schizophrenia;
PAAD	cis	rs2658782	0.704	rs2658766	chr11:93232229	G/A	cg15737290	chr11:93063684	CCDC67	0.75	6.47	0.46	1.3e-9	Pulmonary function decline;
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.34e-13	Prostate cancer;
PAAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.01e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.28	7.24	0.51	2.12e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg00976097	chr5:421733	AHRR	-0.62	-5.62	-0.41	8.86e-8	Cystic fibrosis severity;
PAAD	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg20628663	chr10:43360327	NA	0.52	4.29	0.33	3.13e-5	Blood protein levels;
PAAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-4.39	-0.34	2.14e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.841	rs55951950	chr12:110800254	A/T	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg18279126	chr7:2041391	MAD1L1	0.56	5.7	0.42	6.16e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10982213	1.000	rs4979383	chr9:117182089	A/C	cg00078025	chr9:117159975	NA	0.63	4.69	0.36	5.98e-6	Interleukin-6 levels;
PAAD	cis	rs11264799	0.594	rs1998816	chr1:157782979	A/T	cg18268488	chr1:157545234	FCRL4	0.55	4.57	0.35	1e-5	IgA nephropathy;
PAAD	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.78	5.12	0.38	9.27e-7	Body mass index;
PAAD	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs12999616	0.602	rs17489259	chr2:98392302	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	5.74	0.42	4.99e-8	Colorectal cancer;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg27094323	chr7:1216898	NA	-0.41	-4.75	-0.36	4.62e-6	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	10.07	0.63	1.36e-18	Response to antipsychotic treatment;
PAAD	cis	rs2073300	1.000	rs6114138	chr20:23457350	G/A	cg12062639	chr20:23401060	NAPB	0.92	5.08	0.38	1.09e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg21132104	chr15:45694354	SPATA5L1	0.5	4.68	0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.35	-0.33	2.49e-5	Menarche (age at onset);
PAAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg17346650	chr17:80929145	B3GNTL1	0.41	4.98	0.37	1.7e-6	Glycated hemoglobin levels;
PAAD	cis	rs66530629	0.874	rs9332415	chr1:25098245	T/C	cg01905478	chr1:25040257	NA	-0.46	-5.03	-0.38	1.35e-6	Plateletcrit;
PAAD	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.51	5.13	0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg09168692	chr1:7887560	PER3	0.5	4.9	0.37	2.47e-6	Inflammatory bowel disease;
PAAD	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg00255919	chr5:131827918	IRF1	-0.62	-7.72	-0.53	1.47e-12	Asthma (sex interaction);
PAAD	cis	rs11669133	1.000	rs75864794	chr19:11090841	C/T	cg18582342	chr19:11591989	ELAVL3	-0.66	-4.43	-0.34	1.81e-5	LDL cholesterol;
PAAD	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-7.2	-0.5	2.58e-11	Menarche (age at onset);
PAAD	cis	rs7534824	0.543	rs17408457	chr1:101385693	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	cis	rs10821973	0.527	rs55832840	chr10:64026314	G/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.41	-0.34	1.95e-5	Hypothyroidism;
PAAD	cis	rs7173419	0.607	rs12915936	chr15:28223836	A/G	cg20906524	chr15:28200668	OCA2	-0.46	-5.3	-0.4	3.93e-7	Eye color;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17791617	chr10:79628941	DLG5	0.6	7.35	0.51	1.14e-11	Body fat percentage;
PAAD	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.08	-0.44	9.46e-9	Systolic blood pressure;
PAAD	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.93	0.37	2.09e-6	Diastolic blood pressure;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.9	0.54	5.27e-13	Prudent dietary pattern;
PAAD	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg20813462	chr7:2646259	IQCE	0.61	4.41	0.34	1.95e-5	Urate levels in lean individuals;
PAAD	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.09e-15	Morning vs. evening chronotype;
PAAD	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.62	5.87	0.43	2.6e-8	Mood instability;
PAAD	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg10518543	chr12:38710700	ALG10B	0.52	4.97	0.37	1.81e-6	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs3762318	0.525	rs4655520	chr1:67591660	G/A	cg02640540	chr1:67518911	SLC35D1	0.62	4.39	0.34	2.12e-5	Leprosy;
PAAD	cis	rs9815354	0.812	rs56994465	chr3:42061606	A/G	cg03022575	chr3:42003672	ULK4	0.79	5.65	0.42	7.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg15181151	chr6:150070149	PCMT1	-0.55	-5.83	-0.43	3.25e-8	Lung cancer;
PAAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7553864	0.835	rs719015	chr1:87611710	A/G	cg08732750	chr1:87598351	LOC339524	-0.29	-4.56	-0.35	1.06e-5	Smoking behavior;
PAAD	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs10950821	0.770	rs7783959	chr7:20682513	A/C	cg21202529	chr7:20656503	ABCB5	-0.49	-4.69	-0.36	6.01e-6	Response to statin therapy;
PAAD	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-4.42	-0.34	1.85e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg00579200	chr11:133705235	NA	-0.46	-4.97	-0.37	1.77e-6	Childhood ear infection;
PAAD	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs4906332	1.000	rs8004501	chr14:103981662	G/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.42	-0.4	2.29e-7	Coronary artery disease;
PAAD	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs375066	0.935	rs10406290	chr19:44378877	G/T	cg08633290	chr19:44405433	NA	-0.57	-5.75	-0.42	4.82e-8	Breast cancer;
PAAD	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg18769074	chr3:133464867	TF	-0.4	-4.61	-0.35	8.57e-6	Iron status biomarkers;
PAAD	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.82	-9.26	-0.6	1.82e-16	Superior crus of antihelix expression;
PAAD	cis	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg06100899	chr20:44035415	DBNDD2;SYS1-DBNDD2	0.5	4.6	0.35	9.01e-6	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
PAAD	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg15478930	chr2:27652102	NRBP1	0.53	4.36	0.33	2.41e-5	Blood metabolite levels;
PAAD	cis	rs6715793	0.869	rs17641180	chr2:33421637	A/G	cg26672287	chr2:33391915	LTBP1	-0.4	-4.64	-0.35	7.54e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg02795151	chr17:7402630	POLR2A	0.62	5.81	0.43	3.6e-8	Androgen levels;
PAAD	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.57	-5.93	-0.43	1.95e-8	Menarche (age at onset);
PAAD	cis	rs17681684	0.505	rs62064492	chr17:9803713	G/A	cg26853458	chr17:9805074	RCVRN	0.88	9.79	0.62	7.59e-18	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.43	4.81	0.36	3.6e-6	Breast cancer;
PAAD	cis	rs3736485	0.966	rs7182977	chr15:51854130	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.67	0.53	1.9e-12	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27203200	chr16:67193754	TRADD;FBXL8	0.63	7.32	0.51	1.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.66e-7	Lung cancer;
PAAD	cis	rs7809615	0.901	rs12535424	chr7:99053816	G/A	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.58	-5.42	-0.4	2.28e-7	Strep throat;
PAAD	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs7580658	0.588	rs2069920	chr2:128179646	T/C	cg10985347	chr2:127963512	CYP27C1	0.51	4.99	0.37	1.65e-6	Protein C levels;
PAAD	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg23465465	chr6:26364728	BTN3A2	0.79	4.4	0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.51	4.73	0.36	5.09e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.84	0.37	3.23e-6	Breast cancer;
PAAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.48	-0.34	1.43e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.58	6.51	0.47	1.02e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg18196295	chr10:418757	DIP2C	-0.45	-4.63	-0.35	7.81e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00945244	chr7:75115667	POM121C	-0.76	-6.34	-0.46	2.53e-9	Neuroticism;
PAAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.45	-4.57	-0.35	1.02e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2455826	0.563	rs12714919	chr3:15840201	A/G	cg13420985	chr3:16524424	RFTN1	-0.46	-4.33	-0.33	2.66e-5	Inflammatory skin disease;
PAAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg26528668	chr16:1614120	IFT140	0.49	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	6.09	0.44	9e-9	Blood protein levels;
PAAD	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg10818794	chr15:86012489	AKAP13	-0.44	-4.7	-0.36	5.88e-6	Interstitial lung disease;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg21130718	chr4:1044621	NA	0.51	4.92	0.37	2.27e-6	Recombination rate (males);
PAAD	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14076496	chr14:93651637	C14orf109;MOAP1	0.64	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.08	-0.44	9.2e-9	Crohn's disease;
PAAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.47	-4.31	-0.33	2.87e-5	Obesity-related traits;
PAAD	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.5	5.44	0.4	2.11e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.82	-0.48	2.06e-10	Post bronchodilator FEV1;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25952543	chr19:44598268	ZNF224	0.57	6.71	0.48	3.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.92	9.88	0.63	4.46e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.41	4.69	0.36	6.1e-6	Inflammatory bowel disease;
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Body mass index;
PAAD	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg11494091	chr17:61959527	GH2	0.54	4.33	0.33	2.68e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9315702	0.639	rs9548836	chr13:40165698	A/G	cg21142158	chr13:40229689	COG6	-0.49	-4.79	-0.36	3.85e-6	Hippocampal atrophy;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.57	5.41	0.4	2.39e-7	Electroencephalogram traits;
PAAD	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg03615921	chr16:89375284	ANKRD11	-0.69	-4.44	-0.34	1.75e-5	Joint mobility (Beighton score);
PAAD	cis	rs10155981	0.510	rs41398948	chr7:22591226	A/T	cg05062323	chr7:22590069	NA	0.84	4.91	0.37	2.37e-6	Bilirubin levels;
PAAD	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.65	6.32	0.46	2.73e-9	Orofacial clefts;
PAAD	cis	rs346785	0.692	rs6501883	chr17:74289908	A/G	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs7312933	0.509	rs1920685	chr12:42428674	A/G	cg19980929	chr12:42632907	YAF2	0.48	4.25	0.33	3.68e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs911119	0.954	rs116786204	chr20:23599918	T/G	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.61	0.53	2.69e-12	Mean platelet volume;
PAAD	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.67	6.7	0.48	3.9e-10	Blood protein levels;
PAAD	cis	rs1413885	0.516	rs11208637	chr1:65836553	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.58	0.41	1.07e-7	Anticoagulant levels;
PAAD	trans	rs901683	1.000	rs71496623	chr10:46085866	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16083429	chr3:49237500	CCDC36	-0.47	-5.13	-0.38	8.61e-7	Menarche (age at onset);
PAAD	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.52	-5.07	-0.38	1.13e-6	Mortality in heart failure;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02071572	chr4:1403502	NA	0.5	6.51	0.47	1.04e-9	Longevity;
PAAD	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.48	-0.34	1.45e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.41	-0.34	1.94e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg08390786	chr10:135334061	NA	-0.65	-5.46	-0.41	1.88e-7	Gout;
PAAD	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.07	-0.38	1.15e-6	Subjective well-being;
PAAD	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs27434	0.583	rs34759	chr5:96153133	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.53	-0.41	1.38e-7	Ankylosing spondylitis;
PAAD	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.71	6.74	0.48	3.09e-10	Anterior chamber depth;
PAAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-5.92	-0.43	2.06e-8	Blood metabolite levels;
PAAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.61	0.61	2.2e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.12	16.08	0.79	1.3e-34	Menarche (age at onset);
PAAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg18944383	chr4:111397179	ENPEP	0.73	8.06	0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg23947450	chr7:900037	UNC84A	-0.53	-4.37	-0.33	2.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10090774	1.000	rs12542138	chr8:141833938	G/A	cg02508881	chr8:142216119	NA	0.39	4.25	0.33	3.68e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.74	8.57	0.57	1.08e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.73	0.62	1.07e-17	Lymphocyte counts;
PAAD	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.56	-6.95	-0.49	9.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.93	-6.52	-0.47	1e-9	IgG glycosylation;
PAAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs4523957	0.583	rs2957926	chr17:2024030	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7077446	0.760	rs4291608	chr10:103756750	A/G	cg19008088	chr10:102890038	TLX1;TLX1NB	-0.48	-4.55	-0.35	1.09e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7084783	0.500	rs9521	chr10:105358458	C/G	cg09754828	chr10:105363329	SH3PXD2A	-0.47	-4.81	-0.36	3.54e-6	Fear of pain;
PAAD	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Diabetic kidney disease;
PAAD	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg04520793	chr17:42248056	ASB16	0.41	4.72	0.36	5.4e-6	Total body bone mineral density;
PAAD	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.69	6.22	0.45	4.51e-9	Mean platelet volume;
PAAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.29	-0.51	1.57e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs6715793	0.563	rs11124309	chr2:33416210	G/A	cg26672287	chr2:33391915	LTBP1	0.37	4.33	0.33	2.75e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6733011	0.519	rs12712037	chr2:99463025	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.33	-0.33	2.7e-5	Bipolar disorder;
PAAD	cis	rs4356203	0.875	rs667984	chr11:17200766	C/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.27	-0.33	3.45e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.52	5.08	0.38	1.08e-6	Cognitive function;
PAAD	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.47	5.87	0.43	2.62e-8	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.56	6.03	0.44	1.18e-8	Menopause (age at onset);
PAAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.41	5.54	0.41	1.32e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg12193833	chr17:30244370	NA	-0.66	-4.96	-0.37	1.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.55	5.36	0.4	3.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28489187	0.597	rs1001604	chr1:85879524	C/G	cg16011679	chr1:85725395	C1orf52	-0.5	-4.73	-0.36	5.01e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7082209	0.877	rs7914042	chr10:44807243	C/T	cg13191911	chr10:44806660	NA	-0.96	-5.07	-0.38	1.14e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.33	-0.33	2.72e-5	Renal cell carcinoma;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg16606324	chr3:10149918	C3orf24	0.55	4.73	0.36	4.99e-6	Alzheimer's disease;
PAAD	cis	rs1075265	0.756	rs698854	chr2:54053921	G/C	cg04546899	chr2:54196757	PSME4	0.3	4.43	0.34	1.8e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs9517320	0.633	rs35368417	chr13:99121347	T/C	cg20487152	chr13:99095054	FARP1	0.48	5.01	0.38	1.52e-6	Longevity;
PAAD	cis	rs2882667	0.690	rs700618	chr5:138088118	C/T	cg09476006	chr5:138032270	NA	-0.46	-5.86	-0.43	2.79e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg03989125	chr22:38214979	NA	-0.56	-5.6	-0.41	9.7e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-1.04	-10.94	-0.66	6.69e-21	Platelet distribution width;
PAAD	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.64	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.62	5.89	0.43	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-5.25	-0.39	5.06e-7	Resting heart rate;
PAAD	cis	rs30380	0.553	rs27527	chr5:96151968	C/A	cg16492584	chr5:96139282	ERAP1	-0.5	-4.43	-0.34	1.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.81	-0.48	2.13e-10	Neuroticism;
PAAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.18	-0.45	5.57e-9	Height;
PAAD	cis	rs4668356	1.000	rs2723250	chr2:171871244	T/C	cg13882835	chr2:172017928	TLK1	0.88	4.66	0.35	6.86e-6	Cognitive performance;
PAAD	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg18479299	chr3:125709523	NA	-0.56	-4.25	-0.33	3.76e-5	Blood pressure (smoking interaction);
PAAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	7.4	0.51	8.68e-12	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03647317	chr4:187891568	NA	-0.54	-6.53	-0.47	9.31e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg01304814	chr3:48885189	PRKAR2A	1.02	5.4	0.4	2.54e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11754995	chr8:90914634	OSGIN2	-0.56	-6.32	-0.46	2.81e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg05785598	chr3:49045655	WDR6	0.41	4.88	0.37	2.62e-6	Parkinson's disease;
PAAD	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.56	3.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.68	5.16	0.39	7.78e-7	Body mass index;
PAAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.81	-8.45	-0.57	2.17e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs883565	0.740	rs2293312	chr3:39111140	C/A	cg01426195	chr3:39028469	NA	-0.67	-7.13	-0.5	3.75e-11	Handedness;
PAAD	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs642743	0.967	rs624159	chr10:105939451	C/A	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.25	0.33	3.75e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-4.96	-0.37	1.87e-6	Resting heart rate;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.56	-6.26	-0.45	3.79e-9	Mean corpuscular volume;
PAAD	cis	rs682748	0.810	rs62349989	chr5:17111970	A/T	cg23987134	chr5:17158319	LOC285696	-0.37	-4.68	-0.35	6.37e-6	Hippocampal atrophy;
PAAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.43	4.71	0.36	5.61e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.56	-5.66	-0.42	7.26e-8	Coronary artery disease;
PAAD	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg12923728	chr3:195709715	SDHAP1	-0.88	-8.17	-0.55	1.1e-13	Pancreatic cancer;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.51	-0.57	1.55e-14	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.13	-0.38	8.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.61	-5.23	-0.39	5.51e-7	Corneal structure;
PAAD	trans	rs12979813	1.000	rs3810307	chr19:11332570	T/A	cg03333546	chr19:13263065	IER2	-0.87	-6.31	-0.46	2.85e-9	HDL cholesterol;
PAAD	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.79	-0.81	1.95e-36	Myeloid white cell count;
PAAD	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	8.22	0.55	8.38e-14	Exhaled nitric oxide output;
PAAD	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.48	5.14	0.38	8.28e-7	Type 2 diabetes;
PAAD	cis	rs16867321	0.951	rs1901749	chr2:181350633	G/A	cg23363182	chr2:181467187	NA	-0.49	-4.41	-0.34	1.95e-5	Obesity;
PAAD	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs2133450	0.712	rs1033006	chr3:7369624	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.31	-0.4	3.84e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs3104888	0.831	rs7820564	chr8:96635210	A/G	cg13909214	chr8:95653899	ESRP1	-0.46	-4.36	-0.33	2.4e-5	Daytime sleep phenotypes;
PAAD	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg21775007	chr8:11205619	TDH	-0.56	-5.02	-0.38	1.44e-6	Neuroticism;
PAAD	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.38	-0.33	2.18e-5	Height;
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.28	-0.33	3.35e-5	Skin colour saturation;
PAAD	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.7	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.09	0.59	4.91e-16	Menopause (age at onset);
PAAD	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg10253484	chr15:75165896	SCAMP2	0.48	4.65	0.35	7.12e-6	Systemic lupus erythematosus;
PAAD	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg20761395	chr17:511517	VPS53	-0.5	-4.86	-0.37	2.85e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.86	0.58	1.95e-15	Motion sickness;
PAAD	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg22601191	chr20:60968625	CABLES2	-0.6	-5.7	-0.42	5.93e-8	Colorectal cancer;
PAAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.83e-5	Bone mineral density;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.55	-0.52	3.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs73388146	0.685	rs6456651	chr6:25148011	A/C	cg12883629	chr6:25042497	NA	-0.44	-4.4	-0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg00262122	chr8:11665843	FDFT1	0.58	5.24	0.39	5.4e-7	Neuroticism;
PAAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.51	-0.41	1.5e-7	Bladder cancer;
PAAD	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.76	-0.62	8.83e-18	Blood trace element (Zn levels);
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg13444538	chr7:158905317	VIPR2	0.53	5.02	0.38	1.44e-6	Facial morphology (factor 20);
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg13047869	chr3:10149882	C3orf24	0.56	4.96	0.37	1.87e-6	Alzheimer's disease;
PAAD	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	5.7	0.42	6.14e-8	Lung cancer;
PAAD	cis	rs12986445	0.843	rs10209507	chr2:26004418	T/C	cg12476443	chr2:26624228	C2orf39	0.63	4.5	0.34	1.32e-5	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
PAAD	cis	rs4790333	0.813	rs2926992	chr17:2256026	C/A	cg02569219	chr17:2266849	SGSM2	0.61	5.82	0.43	3.38e-8	Proinsulin levels;
PAAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.49	-5.2	-0.39	6.4e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.82	-5.48	-0.41	1.72e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
PAAD	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg09344028	chr17:70110421	NA	0.54	6.92	0.49	1.18e-10	Thyroid hormone levels;
PAAD	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg10856724	chr12:34555212	NA	-0.42	-4.26	-0.33	3.51e-5	Morning vs. evening chronotype;
PAAD	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg19682013	chr15:45996608	NA	0.33	4.39	0.34	2.12e-5	Waist circumference;Weight;
PAAD	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.67	-7.01	-0.49	7.17e-11	Iron status biomarkers;
PAAD	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.67	6.83	0.48	1.87e-10	Obesity-related traits;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg03909863	chr11:638404	DRD4	-0.6	-5.49	-0.41	1.61e-7	Systemic lupus erythematosus;
PAAD	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.66	6.93	0.49	1.09e-10	Testicular germ cell tumor;
PAAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.85	-7.76	-0.53	1.18e-12	Pancreatic cancer;
PAAD	cis	rs8062405	0.722	rs28729187	chr16:28626966	T/C	cg16576597	chr16:28551801	NUPR1	-0.7	-7.27	-0.51	1.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.65	0.42	7.82e-8	Prostate cancer;
PAAD	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.56e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg09127314	chr1:152161683	NA	0.5	5.0	0.38	1.54e-6	Inflammatory skin disease;
PAAD	cis	rs859767	0.741	rs6713239	chr2:135434849	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.46	-0.34	1.57e-5	Neuroticism;
PAAD	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12760731	0.720	rs11805590	chr1:178308911	A/G	cg00404053	chr1:178313656	RASAL2	0.7	4.82	0.36	3.39e-6	Obesity-related traits;
PAAD	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.92	10.69	0.66	3.03e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg16964102	chr10:135390573	NA	-0.53	-5.22	-0.39	5.88e-7	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11173999	chr4:147096909	LSM6	-0.8	-6.7	-0.48	3.76e-10	Neuroticism;
PAAD	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-4.59	-0.35	9.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11741688	1.000	rs11741688	chr5:178395850	G/C	cg13312174	chr5:178288687	ZNF354B	0.51	5.22	0.39	5.9e-7	Sleep duration;
PAAD	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	8.07e-6	Breast cancer;
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg13607699	chr17:42295918	UBTF	0.61	5.32	0.4	3.64e-7	Total body bone mineral density;
PAAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.08	-0.44	9.38e-9	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-10.04	-0.63	1.68e-18	Response to antipsychotic treatment;
PAAD	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11676855	1.000	rs11889801	chr2:235902470	T/C	cg14917874	chr2:235941519	SH3BP4	0.51	4.84	0.37	3.19e-6	Dialysis-related mortality;
PAAD	cis	rs12799264	1.000	rs12272708	chr11:19974501	T/C	cg17303119	chr11:19974895	NAV2	-0.71	-4.76	-0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.66	6.45	0.46	1.44e-9	Coronary artery disease;
PAAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-7.72	-0.53	1.41e-12	Airway imaging phenotypes;
PAAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg09835421	chr16:68378352	PRMT7	-1.0	-6.5	-0.47	1.11e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs939584	1.000	rs10172769	chr2:646345	G/A	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7707921	0.881	rs17243791	chr5:81322547	A/G	cg21483461	chr5:81570383	RPS23	-0.51	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.19	0.39	6.72e-7	Migraine;
PAAD	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs2278796	0.608	rs11240332	chr1:204969317	C/T	cg17947172	chr1:204966197	NFASC	0.39	4.44	0.34	1.7e-5	Mean platelet volume;
PAAD	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.64	-6.23	-0.45	4.45e-9	Sudden cardiac arrest;
PAAD	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15492422	chr19:2328553	SPPL2B;LSM7	0.56	6.39	0.46	1.93e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.16	-0.5	3.18e-11	Hemoglobin concentration;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	8.11	0.55	1.5700000000000001e-13	Renal function-related traits (BUN);
PAAD	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04021884	chr10:38299653	ZNF33A	0.68	7.18	0.5	2.95e-11	Obesity-related traits;
PAAD	cis	rs2278796	0.697	rs11240323	chr1:204952737	T/C	cg17947172	chr1:204966197	NFASC	0.43	4.86	0.37	2.9e-6	Mean platelet volume;
PAAD	cis	rs1950626	0.743	rs12889283	chr14:101466001	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.99	12.28	0.71	1.68e-24	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.7	7.52	0.52	4.5e-12	Platelet distribution width;
PAAD	cis	rs757081	0.648	rs11024231	chr11:17287250	G/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.45	-0.4	1.99e-7	Systolic blood pressure;
PAAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg01320130	chr1:67600311	NA	0.56	6.35	0.46	2.42e-9	Psoriasis;
PAAD	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg00376283	chr12:123451042	ABCB9	0.69	6.52	0.47	9.77e-10	Platelet count;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs747650	0.504	rs10769226	chr11:46984803	A/G	cg19486271	chr11:47235900	DDB2	-0.63	-6.08	-0.44	9.21e-9	Acne (severe);
PAAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.7	6.74	0.48	3.01e-10	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17945195	chr7:99698344	MCM7;AP4M1	0.62	7.04	0.5	6.05e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.82e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.97	-13.33	-0.73	2.38e-27	Height;
PAAD	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	1.06	8.23	0.56	7.69e-14	Menopause (age at onset);
PAAD	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.76	6.76	0.48	2.72e-10	Intraocular pressure;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.34	-0.33	2.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.7	7.45	0.52	6.66e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	1.0	9.13	0.6	3.97e-16	Triglycerides;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07961444	chr7:75544359	POR	0.59	6.47	0.46	1.29e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.83	-0.48	1.9e-10	Lymphocyte counts;
PAAD	cis	rs35955747	0.902	rs2413048	chr22:31686102	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.6	-6.29	-0.45	3.27e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.84	8.51	0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-4.65	-0.35	7.01e-6	Schizophrenia (age at onset);
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg13264159	chr8:625131	ERICH1	-0.62	-4.34	-0.33	2.55e-5	IgG glycosylation;
PAAD	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg11143131	chr5:131608246	PDLIM4	0.51	5.13	0.38	8.83e-7	Blood metabolite levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12267933	chr2:228176991	COL4A3	-0.7	-6.69	-0.48	3.92e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2236267	0.726	rs1940532	chr14:88612417	C/T	cg18078958	chr14:88630771	NA	0.46	5.94	0.43	1.88e-8	Food antigen IgG levels;
PAAD	cis	rs4774830	0.744	rs117596592	chr15:56188307	T/G	cg24530489	chr15:56299380	NA	-1.14	-4.9	-0.37	2.38e-6	Delta-5 desaturase activity;
PAAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	trans	rs901683	1.000	rs17157884	chr10:46015942	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg01815783	chr4:1047043	NA	-0.45	-4.41	-0.34	1.93e-5	Recombination rate (females);
PAAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs1497406	0.744	rs7538966	chr1:16504549	T/C	cg20167471	chr1:16528984	ARHGEF19	0.48	4.79	0.36	3.97e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.58	-5.3	-0.4	3.97e-7	Cognitive function;
PAAD	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.93	-0.37	2.15e-6	Pulmonary function;
PAAD	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.43	-5.37	-0.4	2.91e-7	Lewy body disease;
PAAD	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg04156016	chr5:1868137	NA	0.44	4.49	0.34	1.38e-5	Cardiovascular disease risk factors;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.64	-7.0	-0.49	7.52e-11	Lung cancer;
PAAD	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg05709478	chr1:6581295	PLEKHG5	0.73	4.66	0.35	6.81e-6	Body mass index;
PAAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	trans	rs61931739	0.649	rs815047	chr12:33726459	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/T	cg13240639	chr22:30162856	UCRC;ZMAT5	-0.85	-4.33	-0.33	2.72e-5	Lymphocyte counts;
PAAD	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.56	-6.46	-0.46	1.37e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.65	0.57	6.65e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg12062639	chr20:23401060	NAPB	1.02	5.03	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg16590910	chr6:42928470	GNMT	0.56	5.73	0.42	5.17e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.72	0.42	5.38e-8	Response to antipsychotic treatment;
PAAD	cis	rs904092	0.720	rs1229967	chr4:100207578	G/C	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.91	10.72	0.66	2.54e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.85	0.62	5.34e-18	Chronic sinus infection;
PAAD	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg05150608	chr14:102990211	NA	0.41	4.81	0.36	3.66e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.61e-6	Myopia (pathological);
PAAD	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.6	6.17	0.45	5.94e-9	Migraine;
PAAD	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg27478167	chr7:817139	HEATR2	-0.78	-5.9	-0.43	2.27e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg14345882	chr6:26364793	BTN3A2	0.65	4.35	0.33	2.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs829661	1.000	rs829631	chr2:30746128	C/T	cg12454169	chr2:30669597	LCLAT1	0.65	5.01	0.38	1.48e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg15212455	chr7:39170539	POU6F2	-0.31	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17253939	chr21:33032168	SOD1	-0.77	-6.57	-0.47	7.43e-10	Neuroticism;
PAAD	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.95	-10.09	-0.63	1.19e-18	Asthma;
PAAD	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.81	-0.36	3.63e-6	Primary sclerosing cholangitis;
PAAD	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-6.66	-0.48	4.8e-10	Height;
PAAD	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.72	-7.76	-0.53	1.14e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.59	-6.29	-0.45	3.14e-9	Hematocrit;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg12946560	chr15:90892448	GABARAPL3	0.63	6.38	0.46	2.07e-9	Body mass index;
PAAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg02841227	chr6:26021843	HIST1H4A	-0.44	-4.56	-0.35	1.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg18806716	chr10:30721971	MAP3K8	0.48	4.5	0.34	1.33e-5	Itch intensity from mosquito bite;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.79	-8.16	-0.55	1.2e-13	Menopause (age at onset);
PAAD	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.87	8.7	0.58	5.2e-15	Response to hepatitis C treatment;
PAAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.95	-8.08	-0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.42	-0.34	1.89e-5	Lung cancer in ever smokers;
PAAD	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.76	9.08	0.59	5.4e-16	Breast cancer;
PAAD	cis	rs490234	0.841	rs2790035	chr9:128439923	C/T	cg14078157	chr9:128172775	NA	0.46	5.27	0.39	4.5e-7	Mean arterial pressure;
PAAD	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.81	0.43	3.54e-8	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07292445	chr17:27055725	NEK8	0.67	7.11	0.5	4.26e-11	Myopia (pathological);
PAAD	cis	rs17592366	0.517	rs60007157	chr14:35312272	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	5.38	0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.45	-5.58	-0.41	1.09e-7	Longevity;Endometriosis;
PAAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.82	8.78	0.58	3.22e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.57	4.81	0.36	3.55e-6	Alcohol dependence (age at onset);
PAAD	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.55	4.48	0.34	1.44e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs1997066	0.831	rs61163220	chr10:106826599	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg22437258	chr11:111473054	SIK2	-0.54	-5.33	-0.4	3.46e-7	Primary sclerosing cholangitis;
PAAD	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.8	6.16	0.45	6.27e-9	Lung function (FEV1/FVC);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14036097	chr4:190862158	FRG1	0.54	6.51	0.47	1.06e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs59888335	0.929	rs12631794	chr3:80863413	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17213048	chr8:124332861	ATAD2	-0.57	-6.58	-0.47	7.25e-10	Energy expenditure (24h);
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1977584	0.725	rs1332626	chr10:45402198	G/A	cg04218760	chr10:45406644	TMEM72	0.36	4.48	0.34	1.46e-5	Selective IgA deficiency;
PAAD	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg15211996	chr1:2936768	ACTRT2	0.46	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg12486944	chr17:80159399	CCDC57	-0.5	-4.38	-0.33	2.21e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11235843	0.929	rs11235844	chr11:73379075	G/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.67	-0.35	6.58e-6	Mean corpuscular volume;
PAAD	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg24994893	chr17:41561184	DHX8	-0.44	-4.52	-0.34	1.25e-5	Menopause (age at onset);
PAAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	4.49	0.34	1.42e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-7.29	-0.51	1.57e-11	Body mass index (adult);
PAAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-1.03	-9.22	-0.6	2.29e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.38	0.56	3.26e-14	Bone mineral density;
PAAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.57	5.81	0.43	3.57e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.12e-15	Personality dimensions;
PAAD	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg25233709	chr10:116636983	FAM160B1	0.43	5.58	0.41	1.08e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs375066	0.620	rs349049	chr19:44301400	T/C	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs5756391	0.568	rs2075940	chr22:37318446	G/A	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09592463	chr17:40995321	PSME3;AOC2	0.69	7.66	0.53	2.01e-12	Smoking initiation;
PAAD	cis	rs17286411	0.750	rs4788450	chr16:71955400	T/G	cg16558253	chr16:72132732	DHX38	-0.4	-4.32	-0.33	2.8e-5	Blood protein levels;
PAAD	cis	rs60617249	0.542	rs6593252	chr7:50929594	A/G	cg15805451	chr7:51135775	COBL	-0.43	-4.65	-0.35	7.24e-6	Major depression and alcohol dependence;
PAAD	cis	rs75920871	1.000	rs61907591	chr11:116796855	T/A	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.79	-5.01	-0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2229238	0.911	rs6672087	chr1:154516122	A/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.62e-6	Coronary heart disease;
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.67	8.42	0.56	2.6e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.49	6.28	0.45	3.31e-9	Childhood ear infection;
PAAD	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.13	0.45	7.18e-9	Lymphocyte counts;Red cell distribution width;
PAAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.81	9.0	0.59	8.64e-16	Coronary artery disease;
PAAD	cis	rs6604026	0.656	rs2774954	chr1:93363525	G/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg23649088	chr2:200775458	C2orf69	0.45	4.49	0.34	1.4e-5	Asthma (bronchodilator response);
PAAD	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.48	0.57	1.82e-14	Coffee consumption (cups per day);
PAAD	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg20731937	chr12:48336164	NA	0.51	4.31	0.33	2.92e-5	Longevity (90 years and older);
PAAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.25	-0.33	3.7e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6537837	0.668	rs12044778	chr1:110084408	C/T	cg05049280	chr1:110155535	GNAT2	0.48	4.95	0.37	1.95e-6	Major depressive disorder;
PAAD	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg18370025	chr7:2749541	AMZ1	-0.39	-4.73	-0.36	5e-6	Height;
PAAD	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.14	-13.53	-0.74	6.97e-28	Type 1 diabetes nephropathy;
PAAD	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.61	0.35	8.61e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.7	-7.18	-0.5	2.93e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.47	4.88	0.37	2.68e-6	Longevity;
PAAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.64	4.79	0.36	3.87e-6	Fat distribution (HIV);
PAAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.91	-9.29	-0.6	1.5e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	cis	rs35000415	0.938	rs71581958	chr7:128665542	C/T	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	5.29	0.39	4.24e-7	Homocysteine levels;
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg21951975	chr1:209979733	IRF6	-0.4	-5.05	-0.38	1.25e-6	Monobrow;
PAAD	cis	rs9815354	1.000	rs1716685	chr3:41925301	C/T	cg03022575	chr3:42003672	ULK4	0.74	5.43	0.4	2.21e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.88	11.35	0.68	5.23e-22	Methadone dose in opioid dependence;
PAAD	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg06138931	chr13:21896616	NA	0.8	8.89	0.59	1.62e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.53	4.63	0.35	7.74e-6	Primary sclerosing cholangitis;
PAAD	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg08501292	chr6:25962987	TRIM38	-0.89	-5.4	-0.4	2.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.46	4.61	0.35	8.39e-6	Obesity-related traits;
PAAD	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2120991	0.901	rs6580966	chr12:54260941	T/C	cg23795217	chr12:54812000	ITGA5	-0.3	-4.34	-0.33	2.62e-5	Biliary atresia;
PAAD	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1468734	1.000	rs4786567	chr16:5001034	A/G	cg06510647	chr16:5006106	NA	0.55	4.98	0.37	1.74e-6	Cancer;
PAAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19784903	chr17:45786737	TBKBP1	-0.54	-5.72	-0.42	5.49e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17095355	0.818	rs72828263	chr10:111785703	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.47	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.54	-4.7	-0.36	5.86e-6	Tonsillectomy;
PAAD	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-7.88	-0.54	5.8e-13	Vitiligo;
PAAD	cis	rs11871801	1.000	rs6503703	chr17:40592207	A/T	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.58	-6.33	-0.46	2.57e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.44	5.05	0.38	1.27e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.65	4.93	0.37	2.1e-6	Breast cancer;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.37	0.64	2.21e-19	Platelet count;
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.47	-0.34	1.53e-5	Height;
PAAD	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.36	-5.06	-0.38	1.2e-6	Pulse pressure;
PAAD	cis	rs8014252	0.803	rs74062733	chr14:70995394	A/G	cg11204974	chr14:71022665	NA	-0.77	-5.04	-0.38	1.3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.46	-4.47	-0.34	1.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-5.67	-0.42	7.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	1.34	8.49	0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.74	8.38	0.56	3.23e-14	Bipolar disorder and schizophrenia;
PAAD	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.05	-0.5	5.91e-11	Triglycerides;
PAAD	cis	rs9322817	0.653	rs9486002	chr6:105162823	A/G	cg02098413	chr6:105308735	HACE1	-0.42	-5.25	-0.39	5.14e-7	Thyroid stimulating hormone;
PAAD	cis	rs4332037	0.805	rs4721142	chr7:1918079	T/C	cg00749118	chr7:1938791	MAD1L1	0.58	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg06599209	chr2:1746509	PXDN	0.25	4.27	0.33	3.47e-5	Response to antipsychotic treatment;
PAAD	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg11995313	chr8:8860691	ERI1	-0.52	-5.27	-0.39	4.7e-7	Joint mobility (Beighton score);
PAAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs9633835	0.504	rs7924734	chr11:13350747	A/G	cg15603424	chr11:13300592	ARNTL	-0.53	-4.31	-0.33	2.93e-5	Body mass index;
PAAD	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs787274	1.000	rs10739373	chr9:115593239	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs2017305	0.915	rs76003924	chr10:70660037	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.08	-0.38	1.08e-6	Depression (quantitative trait);
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.88	-10.23	-0.64	5.27e-19	Ulcerative colitis;
PAAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.67	-7.65	-0.53	2.2e-12	Huntington's disease progression;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.61	0.41	9.37e-8	Prudent dietary pattern;
PAAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.61	-0.35	8.51e-6	Height;
PAAD	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg24110177	chr3:50126178	RBM5	-0.82	-9.14	-0.6	3.72e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg11995313	chr8:8860691	ERI1	-0.5	-5.0	-0.38	1.57e-6	Joint mobility (Beighton score);
PAAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.36	15.59	0.78	2.44e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.3	-4.33	-0.33	2.67e-5	Urate levels in overweight individuals;
PAAD	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.29	-5.2	-0.39	6.37e-7	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.72	4.84	0.37	3.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.62	6.26	0.45	3.68e-9	Body mass index;
PAAD	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.44	4.27	0.33	3.45e-5	Red blood cell count;
PAAD	cis	rs11694441	0.618	rs56352452	chr2:119576890	T/C	cg14634534	chr2:119616825	NA	-0.41	-4.48	-0.34	1.46e-5	Monobrow;
PAAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.94	9.84	0.62	5.56e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.08	0.38	1.07e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.69	7.31	0.51	1.46e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07685180	chr8:600429	NA	0.8	5.07	0.38	1.13e-6	IgG glycosylation;
PAAD	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg14851346	chr12:38532713	NA	-0.45	-4.44	-0.34	1.76e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.61	-6.48	-0.47	1.22e-9	Brugada syndrome;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.04e-5	Migraine;
PAAD	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.53	5.02	0.38	1.45e-6	Red blood cell count;
PAAD	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.5	-6.26	-0.45	3.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg02228675	chr17:40259724	DHX58	-0.44	-4.88	-0.37	2.71e-6	Fibrinogen levels;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	10.13	0.63	9.44e-19	Platelet count;
PAAD	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg19486271	chr11:47235900	DDB2	-0.55	-5.61	-0.41	9.51e-8	Total body bone mineral density;
PAAD	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.46	-0.34	1.6e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12304921	0.816	rs67478184	chr12:51508050	C/T	cg18059802	chr12:51347058	HIGD1C	-0.7	-5.59	-0.41	1.03e-7	Type 2 diabetes;
PAAD	cis	rs1997066	0.831	rs73342219	chr10:106820145	C/A	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs642743	0.967	rs479879	chr10:105945985	A/C	cg23130731	chr10:105978651	MIR609;C10orf79	0.26	4.91	0.37	2.35e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs9409082	0.798	rs12684029	chr9:108924139	T/A	cg07010948	chr13:79181613	NA	-0.34	-6.29	-0.45	3.2e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06307176	chr5:131281290	NA	0.49	4.49	0.34	1.41e-5	Life satisfaction;
PAAD	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	1.04	7.11	0.5	4.15e-11	Mitochondrial DNA levels;
PAAD	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg08994789	chr17:28903642	LRRC37B2	0.53	4.37	0.33	2.27e-5	Body mass index;
PAAD	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.52	-4.46	-0.34	1.6e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4234284	1.000	rs4350879	chr3:126974456	T/G	cg27326032	chr3:127006922	NA	-0.45	-4.54	-0.35	1.12e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs76866386	1.000	rs41360247	chr2:44073656	C/T	cg26706238	chr2:44066206	ABCG5;ABCG8	0.94	5.55	0.41	1.22e-7	Cholesterol, total;
PAAD	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg05627522	chr15:75251581	NA	-0.53	-6.44	-0.46	1.45e-9	Systemic lupus erythematosus;
PAAD	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg03367679	chr17:38183553	MED24;SNORD124	-0.33	-4.39	-0.34	2.12e-5	White blood cell count;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg11062466	chr8:58055876	NA	0.67	4.81	0.36	3.66e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	7.24	0.51	2.05e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs71435601	0.657	rs503105	chr2:21315664	C/T	cg05709196	chr2:20449227	PUM2	0.54	4.26	0.33	3.59e-5	Cholesterol, total;
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.58	5.93	0.43	2.01e-8	Menarche (age at onset);
PAAD	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.27	0.51	1.76e-11	Alzheimer's disease;
PAAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg24733560	chr20:60626293	TAF4	0.52	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs728616	0.510	rs61860860	chr10:81758572	G/A	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.76	-0.36	4.43e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7631605	0.905	rs11717564	chr3:37220888	T/A	cg17445812	chr3:36986805	TRANK1	0.33	4.45	0.34	1.64e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12304921	1.000	rs7397068	chr12:51401904	C/G	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.39	-0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.92	-0.37	2.21e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg22029157	chr1:209979665	IRF6	0.67	6.02	0.44	1.27e-8	Coronary artery disease;
PAAD	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.92	6.72	0.48	3.39e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg17326555	chr1:119535693	NA	0.36	4.62	0.35	8.06e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7786877	0.545	rs73156234	chr7:100234744	C/T	cg20848291	chr7:100343083	ZAN	-0.82	-6.92	-0.49	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs3812111	0.525	rs9387388	chr6:116568915	G/T	cg05304507	chr6:116381966	FRK	-0.26	-4.38	-0.33	2.23e-5	Age-related macular degeneration;
PAAD	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.57	-0.35	1.02e-5	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15324256	chr3:113775233	QTRTD1;KIAA1407	-0.64	-6.45	-0.46	1.38e-9	Smoking initiation;
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09082480	chr16:83997636	OSGIN1	-0.64	-6.48	-0.47	1.23e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-5.28	-0.39	4.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg01631684	chr10:65280961	REEP3	-0.44	-4.48	-0.34	1.44e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1075265	0.756	rs805423	chr2:54127041	C/T	cg04546899	chr2:54196757	PSME4	0.32	4.77	0.36	4.25e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg03805757	chr16:71968109	PKD1L3	-0.55	-4.87	-0.37	2.81e-6	Post bronchodilator FEV1;
PAAD	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.42	4.56	0.35	1.06e-5	Pulse pressure;
PAAD	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.58	-5.24	-0.39	5.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg23587288	chr2:27483067	SLC30A3	-0.63	-5.53	-0.41	1.34e-7	Blood metabolite levels;
PAAD	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg12661370	chr5:149340060	SLC26A2	0.63	5.48	0.41	1.7e-7	HIV-1 control;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.93	15.22	0.78	2.27e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.72	-6.6	-0.47	6.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg10494973	chr17:80897199	TBCD	0.47	4.77	0.36	4.32e-6	Breast cancer;
PAAD	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.82	7.42	0.52	7.63e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs747650	0.504	rs7114683	chr11:47077246	T/A	cg19486271	chr11:47235900	DDB2	-0.68	-6.29	-0.45	3.26e-9	Acne (severe);
PAAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg27490568	chr2:178487706	NA	0.42	4.47	0.34	1.53e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13870426	chr17:30244630	NA	-0.56	-5.58	-0.41	1.07e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	1.33	6.91	0.49	1.27e-10	Prostate cancer;
PAAD	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.2	0.6	2.7e-16	Bipolar disorder;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.55	-6.8	-0.48	2.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2061333	0.557	rs28446946	chr19:44607619	T/C	cg18700516	chr19:44507157	ZNF230	-0.77	-5.55	-0.41	1.24e-7	Alzheimer's disease;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.52	-5.38	-0.4	2.74e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17539620	0.702	rs6937366	chr6:154878832	T/A	cg20019720	chr6:154832845	CNKSR3	0.56	7.81	0.54	8.78e-13	Lipoprotein (a) levels;
PAAD	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg12963246	chr6:28129442	ZNF389	0.56	4.53	0.34	1.18e-5	Parkinson's disease;
PAAD	cis	rs4979906	1.000	rs7086586	chr10:79459524	C/T	cg07817648	chr10:79422355	NA	-0.6	-5.41	-0.4	2.38e-7	Mortality in heart failure;
PAAD	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.89	-10.8	-0.66	1.6e-20	Refractive error;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	4.36	0.33	2.38e-5	Vitiligo;
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg22861794	chr10:5032070	AKR1C2	0.86	4.85	0.37	3.03e-6	Major depressive disorder;
PAAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.61	-8.49	-0.57	1.72e-14	Height;
PAAD	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.36	-0.33	2.42e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7925523	0.891	rs9735635	chr11:61490880	C/A	cg12472022	chr11:61462803	DAGLA	0.59	4.36	0.33	2.43e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs4704187	0.663	rs1422697	chr5:74445817	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.76	-6.3	-0.46	3.03e-9	Monocyte count;
PAAD	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg08698997	chr16:88989212	CBFA2T3	0.5	5.87	0.43	2.65e-8	Social autistic-like traits;
PAAD	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg08135965	chr6:41755394	TOMM6	0.49	4.94	0.37	2e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	1.0	7.08	0.5	5.04e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.64	6.17	0.45	5.86e-9	Blood metabolite levels;
PAAD	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs1468734	0.929	rs12925484	chr16:5006524	C/G	cg06510647	chr16:5006106	NA	0.61	5.69	0.42	6.3e-8	Cancer;
PAAD	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg03315344	chr16:75512273	CHST6	0.57	4.82	0.36	3.39e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.01e-9	Life satisfaction;
PAAD	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.44	-0.34	1.75e-5	Testicular germ cell tumor;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02817925	chr19:1046325	ABCA7	0.59	7.04	0.5	6.27e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs16933812	0.510	rs4880048	chr9:36989054	A/G	cg13738729	chr9:36989127	PAX5	-0.56	-8.14	-0.55	1.29e-13	Obesity-related traits;
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.89	12.79	0.72	7.05e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.76	-7.51	-0.52	4.76e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.08	0.44	9.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg14703610	chr5:56206110	C5orf35	0.58	5.55	0.41	1.25e-7	Coronary artery disease;
PAAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.9	-0.37	2.45e-6	Schizophrenia;
PAAD	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-4.32	-0.33	2.79e-5	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.59	-5.3	-0.39	4.01e-7	White blood cell count;
PAAD	cis	rs9976767	0.792	rs2839508	chr21:43845294	A/G	cg23042151	chr21:43824109	UBASH3A	-0.41	-5.3	-0.39	4e-7	Type 1 diabetes;
PAAD	cis	rs9810890	1.000	rs115394279	chr3:128493714	C/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg14159672	chr1:205819179	PM20D1	-0.59	-4.27	-0.33	3.36e-5	Prostate-specific antigen levels;
PAAD	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg04117972	chr1:227635322	NA	0.7	4.62	0.35	8.02e-6	Major depressive disorder;
PAAD	cis	rs2229238	0.911	rs7551873	chr1:154505857	A/G	cg21262032	chr1:154437693	IL6R	0.46	4.86	0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg26247942	chr15:43984922	CKMT1A	0.36	4.62	0.35	7.97e-6	Schizophrenia;
PAAD	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.97	5.59	0.41	1.03e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.91	7.7	0.53	1.6e-12	Alzheimer's disease;
PAAD	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.86	9.04	0.59	6.68e-16	Corneal astigmatism;
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.42e-19	Menopause (age at onset);
PAAD	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26926768	chr12:34528122	NA	0.39	4.66	0.35	6.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg20744362	chr22:50050164	C22orf34	0.59	7.17	0.5	3.07e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs77880822	0.562	rs117037219	chr20:1233306	C/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.52	6.46	0.46	1.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13242816	1.000	rs56309428	chr7:116150137	G/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg21698718	chr17:80085957	CCDC57	-0.4	-4.35	-0.33	2.52e-5	Life satisfaction;
PAAD	cis	rs2213920	1.000	rs2213920	chr9:118271584	C/T	cg13918206	chr9:118159781	DEC1	0.78	5.55	0.41	1.23e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.5	4.65	0.35	7.08e-6	Height;
PAAD	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.35	-0.33	2.44e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg13919466	chr1:32135498	COL16A1	-0.39	-4.52	-0.34	1.23e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2069837	0.515	rs62449526	chr7:22797667	T/C	cg05472934	chr7:22766657	IL6	0.62	4.74	0.36	4.79e-6	Longevity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06867065	chr19:51871233	CLDND2	-0.71	-7.66	-0.53	1.99e-12	Smoking initiation;
PAAD	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg14345882	chr6:26364793	BTN3A2	0.66	4.41	0.34	1.94e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	1.0	8.94	0.59	1.26e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs3812111	0.677	rs1204796	chr6:116541503	T/C	cg18828861	chr6:116576566	TSPYL4	-0.39	-4.31	-0.33	2.97e-5	Age-related macular degeneration;
PAAD	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg26876637	chr1:152193138	HRNR	-0.72	-5.46	-0.41	1.88e-7	Atopic dermatitis;
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.7	6.7	0.48	3.82e-10	Blood metabolite levels;
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.97	8.32	0.56	4.62e-14	Initial pursuit acceleration;
PAAD	cis	rs34375054	0.525	rs7398636	chr12:125598604	G/C	cg09839279	chr12:125627357	AACS	-0.47	-4.48	-0.34	1.45e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.92	-10.42	-0.65	1.5700000000000001e-19	Gut microbiome composition (winter);
PAAD	cis	rs8060686	0.748	rs3785098	chr16:67993643	T/C	cg05110241	chr16:68378359	PRMT7	-0.78	-6.21	-0.45	4.95e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.78	8.76	0.58	3.54e-15	Heart rate;
PAAD	cis	rs7274811	0.744	rs3213183	chr20:32262962	C/T	cg21523528	chr20:32077966	CBFA2T2	0.55	4.54	0.35	1.14e-5	Height;
PAAD	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.47	-0.46	1.27e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg20159608	chr7:32802032	NA	-0.59	-6.11	-0.44	8.17e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.52	-6.48	-0.47	1.21e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12611820	1.000	rs35523868	chr2:2479473	A/C	cg16092829	chr2:2336971	NA	0.46	4.36	0.33	2.36e-5	Vitamin B levels in ischemic stroke;
PAAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.21	0.8	5.83e-35	Prudent dietary pattern;
PAAD	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs9677476	0.657	rs7604042	chr2:232135541	A/T	cg07929768	chr2:232055508	NA	0.37	4.4	0.34	2.07e-5	Food antigen IgG levels;
PAAD	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.8	7.61	0.53	2.75e-12	Vitamin D levels;
PAAD	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs8027181	0.682	rs890354	chr15:73100924	C/G	cg25632853	chr15:73088954	NA	0.4	4.3	0.33	3.01e-5	Triglyceride levels;
PAAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.97	10.66	0.65	3.62e-20	Parkinson's disease;
PAAD	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg10871876	chr19:53194124	ZNF83	-0.51	-4.46	-0.34	1.59e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01511804	chr14:74318438	PTGR2	0.67	6.77	0.48	2.59e-10	Obesity-related traits;
PAAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-4.61	-0.35	8.57e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs2384207	0.818	rs34326408	chr12:113647337	T/C	cg22376712	chr12:113623594	C12orf52;DDX54	0.6	5.28	0.39	4.47e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6256	1.000	rs6256	chr11:13514053	G/T	cg11976911	chr11:13509032	NA	-0.63	-4.73	-0.36	5.14e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg08888203	chr3:10149979	C3orf24	0.88	7.71	0.53	1.53e-12	Alzheimer's disease;
PAAD	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.17	-0.39	7.23e-7	Mortality in heart failure;
PAAD	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg07150166	chr2:30669952	LCLAT1	0.76	5.74	0.42	5.01e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.91	0.43	2.21e-8	Prudent dietary pattern;
PAAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.3	-5.24	-0.39	5.36e-7	Caffeine consumption;
PAAD	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.53	-4.51	-0.34	1.28e-5	Dementia with Lewy bodies;
PAAD	cis	rs933688	0.526	rs2973468	chr5:90540879	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.65	-4.45	-0.34	1.62e-5	Smoking behavior;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6674176	0.551	rs72683978	chr1:44470675	T/G	cg12908607	chr1:44402522	ARTN	0.75	4.25	0.33	3.73e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.07	5.19	0.39	6.52e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.77	8.69	0.58	5.28e-15	Type 2 diabetes;
PAAD	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.5	-4.97	-0.37	1.82e-6	Fibrinogen levels;
PAAD	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg21775007	chr8:11205619	TDH	-0.53	-4.81	-0.36	3.59e-6	Triglycerides;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.76	5.46	0.41	1.86e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs9422439	chr10:46040473	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.57	4.86	0.37	2.9e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7219021	0.892	rs66866087	chr17:46849323	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.33	-0.33	2.73e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs111342015	0.803	rs75660024	chr6:43193281	A/G	cg17076780	chr6:43251928	TTBK1	0.59	4.32	0.33	2.85e-5	Breast cancer;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.73	-13.09	-0.73	1.07e-26	Longevity;Endometriosis;
PAAD	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.6	-0.35	8.98e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs17407555	0.632	rs12510726	chr4:10271067	T/A	cg11266682	chr4:10021025	SLC2A9	0.41	4.3	0.33	3.08e-5	Schizophrenia (age at onset);
PAAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.64	-6.65	-0.47	5e-10	Childhood ear infection;
PAAD	trans	rs901683	1.000	rs35070150	chr10:46079833	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4144743	1.000	rs2317385	chr17:45329682	G/A	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.46	4.74	0.36	4.9e-6	Ulcerative colitis;
PAAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10504390	0.656	rs17395816	chr8:66634526	C/T	cg21696208	chr8:66556075	MTFR1	0.99	4.69	0.36	6.1e-6	IgG glycosylation;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.49	-4.91	-0.37	2.32e-6	Testicular germ cell tumor;
PAAD	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.46	0.34	1.59e-5	Calcium levels;
PAAD	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.6	6.22	0.45	4.58e-9	Colorectal cancer;
PAAD	cis	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg21546286	chr11:48923668	NA	0.55	5.79	0.43	3.82e-8	HDL cholesterol;
PAAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg09835421	chr16:68378352	PRMT7	-1.14	-8.21	-0.55	8.64e-14	HDL cholesterol;
PAAD	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.74e-6	Pain;
PAAD	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg10631289	chr15:39006617	NA	0.47	4.55	0.35	1.09e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9913156	0.748	rs55981776	chr17:4561401	T/C	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.44	-4.58	-0.35	9.52e-6	Resting heart rate;
PAAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26926768	chr12:34528122	NA	0.37	4.58	0.35	9.79e-6	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.65	-6.84	-0.49	1.82e-10	Capecitabine sensitivity;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.29	0.51	1.6e-11	Response to antipsychotic treatment;
PAAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg21191810	chr6:118973309	C6orf204	-0.51	-4.9	-0.37	2.45e-6	Diastolic blood pressure;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.74	7.21	0.5	2.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.93	-8.6	-0.57	9.38e-15	Asthma;
PAAD	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.64	-6.19	-0.45	5.43e-9	Rheumatoid arthritis;
PAAD	cis	rs58521262	0.519	rs2080969	chr19:22980918	A/T	cg07749055	chr19:23076870	NA	-0.58	-4.37	-0.33	2.25e-5	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs8112211	0.911	rs2270095	chr19:38840896	A/G	cg14299480	chr19:38876666	GGN	-0.58	-7.41	-0.52	8.11e-12	Blood protein levels;
PAAD	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg09796270	chr17:17721594	SREBF1	-0.49	-5.4	-0.4	2.48e-7	Total body bone mineral density;
PAAD	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg12126869	chr10:346505	DIP2C	-0.75	-4.58	-0.35	9.43e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.53	-0.47	9.14e-10	Brain structure;
PAAD	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	9.13	0.6	4.01e-16	Cognitive test performance;
PAAD	cis	rs3925075	0.531	rs4597342	chr16:31343769	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.47	0.41	1.77e-7	IgA nephropathy;
PAAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.24	-0.39	5.2e-7	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24839145	chr8:5028854	NA	-0.58	-6.3	-0.46	3.05e-9	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16704802	chr16:8768425	ABAT	0.61	6.99	0.49	8.23e-11	Monocyte percentage of white cells;
PAAD	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.42	0.46	1.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs7552393	0.595	rs6576949	chr1:84273341	A/C	cg10977910	chr1:84465055	TTLL7	0.59	5.52	0.41	1.41e-7	Select biomarker traits;
PAAD	cis	rs608114	0.623	rs17055672	chr6:96358415	C/A	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17076539	chr3:57204284	NA	0.66	6.56	0.47	7.96e-10	Obesity-related traits;
PAAD	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg14146966	chr2:61757674	XPO1	-0.39	-4.89	-0.37	2.53e-6	Tuberculosis;
PAAD	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.48	5.03	0.38	1.37e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg18551225	chr6:44695536	NA	0.69	7.84	0.54	7.25e-13	Total body bone mineral density;
PAAD	cis	rs12453682	0.568	rs3794712	chr17:37791487	A/C	cg00129232	chr17:37814104	STARD3	-0.76	-6.11	-0.44	8.06e-9	Mean corpuscular hemoglobin;Red blood cell count;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.45	4.52	0.34	1.23e-5	Longevity;Endometriosis;
PAAD	cis	rs35740288	0.770	rs56092539	chr15:86182512	A/G	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg12639453	chr1:2035780	PRKCZ	-0.56	-6.06	-0.44	1.03e-8	Height;
PAAD	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg13857086	chr12:6580257	VAMP1	0.59	4.28	0.33	3.24e-5	Hip geometry;
PAAD	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg19978312	chr5:179634688	RASGEF1C	0.43	4.32	0.33	2.81e-5	LDL cholesterol;
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg03909863	chr11:638404	DRD4	-0.69	-6.1	-0.44	8.42e-9	Systemic lupus erythematosus;
PAAD	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.41e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs13006833	0.739	rs291472	chr2:191190605	A/G	cg27211696	chr2:191398769	TMEM194B	0.44	4.32	0.33	2.81e-5	Urinary metabolites;
PAAD	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg00806126	chr19:22604979	ZNF98	0.4	5.02	0.38	1.4e-6	Pain;
PAAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg20243544	chr17:37824526	PNMT	0.49	4.33	0.33	2.69e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.66	6.5	0.47	1.11e-9	Corneal astigmatism;
PAAD	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.17	15.03	0.77	7.3e-32	Type 1 diabetes nephropathy;
PAAD	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.89	11.58	0.68	1.21e-22	Body mass index;
PAAD	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.11	9.42	0.61	6.97e-17	Red blood cell traits;
PAAD	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-4.38	-0.33	2.24e-5	Vitiligo;
PAAD	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.71	-8.33	-0.56	4.39e-14	Bladder cancer;
PAAD	cis	rs17266958	0.786	rs111564587	chr9:83245510	C/T	cg13911576	chr9:84174038	NA	0.8	4.31	0.33	2.94e-5	Preschool internalizing problems;
PAAD	cis	rs7660520	0.623	rs4455461	chr4:183744854	G/A	cg12483801	chr4:183727862	NA	0.66	4.41	0.34	1.95e-5	Pediatric autoimmune diseases;
PAAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.86	8.07	0.55	1.98e-13	Homoarginine levels;
PAAD	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg05084668	chr3:125655381	ALG1L	-0.39	-4.35	-0.33	2.52e-5	Blood pressure (smoking interaction);
PAAD	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.6	5.77	0.42	4.28e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg11062466	chr8:58055876	NA	0.7	4.9	0.37	2.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg27478167	chr7:817139	HEATR2	0.63	4.68	0.35	6.35e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.06	-6.51	-0.47	1.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14090510	chr7:64839023	ZNF92	0.63	7.07	0.5	5.38e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg03989125	chr22:38214979	NA	-0.67	-7.05	-0.5	5.92e-11	Glioblastoma;Glioma;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08677398	chr8:58056175	NA	0.62	4.63	0.35	7.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-6.17	-0.45	5.85e-9	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24558718	chr10:853215	NA	-0.69	-6.96	-0.49	9.38e-11	Obesity-related traits;
PAAD	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.79	8.71	0.58	4.92e-15	Total body bone mineral density;
PAAD	cis	rs10851478	0.558	rs17478785	chr15:49740304	A/C	cg08060515	chr15:49448048	GALK2;COPS2	0.55	5.12	0.38	9.24e-7	Oral cavity cancer;
PAAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.28	0.64	3.88e-19	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.52	-5.34	-0.4	3.38e-7	Idiopathic osteonecrosis of the femoral head;
PAAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.64	4.35	0.33	2.5e-5	Vitiligo;
PAAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.77	-7.83	-0.54	7.9e-13	Colorectal adenoma (advanced);
PAAD	cis	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.69	-0.36	6.1e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27066296	chr11:68170970	LRP5	-0.65	-6.59	-0.47	6.79e-10	Obesity-related traits;
PAAD	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.76	-0.36	4.49e-6	Kawasaki disease;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg09357268	chr20:43379437	KCNK15	-0.44	-4.75	-0.36	4.67e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.72	5.17	0.39	7.32e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6693295	0.536	rs2788013	chr1:246241892	C/T	cg11798871	chr1:246315928	SMYD3	-0.77	-5.57	-0.41	1.11e-7	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07157834	chr1:205819609	PM20D1	0.74	7.7	0.53	1.65e-12	Monocyte percentage of white cells;
PAAD	cis	rs1075265	0.584	rs1862122	chr2:54280129	G/T	cg04546899	chr2:54196757	PSME4	-0.35	-5.12	-0.38	8.93e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg15117754	chr3:10150083	C3orf24	-0.65	-5.5	-0.41	1.56e-7	Alzheimer's disease;
PAAD	cis	rs1966248	0.656	rs6569906	chr6:134132333	T/A	cg17736819	chr6:133783020	EYA4	0.45	4.62	0.35	8.29e-6	Coronary artery disease;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.72	7.15	0.5	3.34e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs6694672	1.000	rs7541429	chr1:197099485	A/G	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-8.42	-0.56	2.68e-14	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7711186	0.786	rs11748909	chr5:178021743	A/G	cg17371294	chr5:178012716	COL23A1	-0.83	-4.43	-0.34	1.78e-5	Urate levels in obese individuals;
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	4.37	0.33	2.27e-5	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.91	-5.63	-0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg07423050	chr13:99094983	FARP1	0.38	4.3	0.33	3.07e-5	Longevity;
PAAD	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.3	0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs939584	1.000	rs7558910	chr2:645122	C/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg21419209	chr3:44054225	NA	-0.75	-7.72	-0.53	1.46e-12	Coronary artery disease;
PAAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.72	-0.36	5.25e-6	Daytime sleep phenotypes;
PAAD	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.81	-7.91	-0.54	4.98e-13	Response to hepatitis C treatment;
PAAD	cis	rs9810890	1.000	rs73198878	chr3:128542084	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-4.62	-0.35	7.98e-6	Dilated cardiomyopathy;
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.25	-0.39	5.04e-7	Lung cancer;
PAAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.7	0.42	6.1e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs60154123	0.504	rs11119458	chr1:210491097	T/A	cg21951975	chr1:209979733	IRF6	0.55	4.7	0.36	5.78e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20661391	chr2:169048192	STK39	-0.7	-7.35	-0.51	1.13e-11	Obesity-related traits;
PAAD	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.6	5.39	0.4	2.59e-7	Diastolic blood pressure;
PAAD	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.85	6.05	0.44	1.08e-8	White matter integrity;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg23033748	chr14:75592666	NEK9	0.4	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg04362095	chr11:63592001	C11orf84	-0.46	-4.27	-0.33	3.38e-5	Platelet count;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.48	4.55	0.35	1.08e-5	Uric acid levels;
PAAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.44	-4.3	-0.33	2.99e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.84	-0.37	3.17e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02602472	chr10:115425233	NRAP	0.62	6.77	0.48	2.6200000000000003e-10	Smoking initiation;
PAAD	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs950881	0.932	rs10189526	chr2:102937883	C/T	cg20060108	chr2:102954350	IL1RL1	0.56	4.44	0.34	1.73e-5	Allergy;
PAAD	cis	rs7646881	1.000	rs73015652	chr3:158451383	A/G	cg19483011	chr3:158453295	NA	-0.63	-5.43	-0.4	2.22e-7	Tetralogy of Fallot;
PAAD	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.12	0.5	4.03e-11	Response to antipsychotic treatment;
PAAD	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg09163369	chr1:210001066	C1orf107	0.7	6.64	0.47	5.11e-10	Orofacial clefts;
PAAD	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs790123	0.711	rs2650961	chr3:122396818	A/G	cg17380795	chr3:122379686	NA	-0.41	-4.58	-0.35	9.7e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.59	-6.61	-0.47	6.16e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg04851639	chr8:1020857	NA	-0.65	-8.11	-0.55	1.6e-13	Schizophrenia;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.55	5.92	0.43	2.06e-8	Longevity;Endometriosis;
PAAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.25	0.45	3.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.72	7.1	0.5	4.55e-11	Schizophrenia;
PAAD	cis	rs1400816	0.850	rs2028671	chr2:172852839	C/T	cg23624723	chr2:173292262	ITGA6	-0.76	-4.45	-0.34	1.62e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.62	5.66	0.42	7.22e-8	Coronary artery disease;
PAAD	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Intracranial aneurysm;
PAAD	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.75	6.42	0.46	1.65e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg10818794	chr15:86012489	AKAP13	0.49	5.25	0.39	5.06e-7	Bulimia nervosa;
PAAD	cis	rs10214930	0.813	rs2391447	chr7:27674564	G/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs35955747	0.838	rs5997900	chr22:31580346	C/A	cg02404636	chr22:31891804	SFI1	-0.48	-4.78	-0.36	4.09e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs790123	0.541	rs12330293	chr3:122383035	G/A	cg15604389	chr3:122379662	NA	0.58	4.72	0.36	5.23e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	8.35	0.56	3.98e-14	Mean corpuscular hemoglobin;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06756217	chr11:1092321	MUC2	-0.55	-6.94	-0.49	1.07e-10	Monocyte percentage of white cells;
PAAD	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.89	-7.38	-0.51	9.43e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.79	-7.73	-0.53	1.37e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07750655	chr16:5121855	ALG1	0.61	6.88	0.49	1.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.45	-4.31	-0.33	2.87e-5	Red blood cell count;
PAAD	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.3	-0.33	3.05e-5	Body mass index;
PAAD	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg20487152	chr13:99095054	FARP1	-0.45	-4.36	-0.33	2.36e-5	Longevity;
PAAD	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg15105011	chr4:940614	TMEM175	-0.51	-5.72	-0.42	5.52e-8	Parkinson's disease;
PAAD	cis	rs1075265	0.722	rs2111623	chr2:53984957	C/T	cg04546899	chr2:54196757	PSME4	-0.3	-4.49	-0.34	1.38e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	1.29	8.28	0.56	5.73e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.71	-0.36	5.65e-6	Breast cancer;
PAAD	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.44	-4.38	-0.34	2.16e-5	Resting heart rate;
PAAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg09796270	chr17:17721594	SREBF1	-0.5	-5.61	-0.41	9.44e-8	Total body bone mineral density;
PAAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.61	5.51	0.41	1.51e-7	Retinal vascular caliber;
PAAD	cis	rs2790216	1.000	rs2153281	chr10:59972453	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg04881008	chr7:29726226	LOC646762	-0.63	-6.58	-0.47	7.06e-10	Alcohol dependence;
PAAD	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.93	-0.43	1.98e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.21	0.39	6e-7	Renal function-related traits (BUN);
PAAD	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg08523384	chr5:141488047	NDFIP1	-0.63	-5.83	-0.43	3.16e-8	Crohn's disease;
PAAD	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.53	5.02	0.38	1.4e-6	Blood metabolite levels;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg01114163	chr5:1856713	NA	-0.42	-4.38	-0.33	2.19e-5	Cardiovascular disease risk factors;
PAAD	cis	rs4656958	0.930	rs1855186	chr1:160886892	C/T	cg02985724	chr1:159915429	IGSF9	-0.51	-4.33	-0.33	2.73e-5	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.78	-9.2	-0.6	2.65e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	0.74	5.93	0.43	1.93e-8	Blood protein levels;
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.39	-4.33	-0.33	2.7e-5	Age at first birth;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08474990	chr2:32289415	SPAST	-0.75	-6.74	-0.48	3.17e-10	Neuroticism;
PAAD	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg02404636	chr22:31891804	SFI1	-0.57	-5.19	-0.39	6.76e-7	Colorectal cancer;
PAAD	trans	rs9372498	0.901	rs1630266	chr6:118612943	G/A	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs2117029	0.586	rs10875929	chr12:49568388	A/C	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.83	8.77	0.58	3.32e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2211560	0.789	rs12760377	chr1:61280789	C/G	cg00575674	chr1:61314297	NA	-0.51	-4.61	-0.35	8.49e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg05372495	chr19:1063624	ABCA7	-0.51	-4.53	-0.34	1.21e-5	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12799264	1.000	rs11025341	chr11:19979526	A/T	cg17303119	chr11:19974895	NAV2	-0.71	-4.76	-0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.51	-4.98	-0.37	1.68e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.62	-0.35	8.18e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.85	-9.83	-0.62	6.05e-18	Superior crus of antihelix expression;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00630583	chr12:133264314	PXMP2;POLE	0.63	6.81	0.48	2.17e-10	Myopia (pathological);
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.99e-6	Body mass index;
PAAD	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg18551225	chr6:44695536	NA	-0.65	-7.7	-0.53	1.63e-12	Total body bone mineral density;
PAAD	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg17120908	chr11:65337727	SSSCA1	-0.56	-5.74	-0.42	4.89e-8	Bone mineral density;
PAAD	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	0.8	4.35	0.33	2.51e-5	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg16701003	chr16:89028210	CBFA2T3	0.61	5.93	0.43	1.94e-8	Social autistic-like traits;
PAAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.88	7.36	0.51	1.07e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12599982	chr1:44399894	ARTN	0.44	4.72	0.36	5.29e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.67	-4.63	-0.35	7.78e-6	Platelet distribution width;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07304068	chr3:47823820	SMARCC1	0.62	6.98	0.49	8.51e-11	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04279596	chr4:120133691	USP53	0.72	7.34	0.51	1.21e-11	Obesity-related traits;
PAAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00339695	chr16:24857497	SLC5A11	0.46	4.31	0.33	2.87e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.24	0.56	7.48e-14	Rheumatoid arthritis;
PAAD	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.15	0.45	6.53e-9	Rheumatoid arthritis;
PAAD	cis	rs3857067	0.550	rs4600885	chr4:95003947	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg21546286	chr11:48923668	NA	-0.44	-4.63	-0.35	7.76e-6	HDL cholesterol;
PAAD	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.52	5.15	0.39	7.95e-7	Common traits (Other);
PAAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg18370025	chr7:2749541	AMZ1	-0.41	-5.07	-0.38	1.14e-6	Height;
PAAD	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg15733309	chr7:157513707	PTPRN2	0.65	7.77	0.53	1.11e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	4.52	0.34	1.21e-5	Blood protein levels;
PAAD	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.51	-5.1	-0.38	1.01e-6	Eotaxin levels;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs1572438	0.760	rs7766707	chr6:869501	C/T	cg21062780	chr6:887772	NA	-0.44	-4.48	-0.34	1.44e-5	Aging;
PAAD	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.41	-0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.72	-0.42	5.44e-8	Daytime sleep phenotypes;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg06016156	chr8:1399969	NA	-0.59	-4.39	-0.34	2.14e-5	Triglycerides;
PAAD	cis	rs58521262	0.729	rs7255375	chr19:23060095	C/G	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs58521262	0.929	rs62122474	chr19:23106752	G/C	cg22640819	chr19:22990650	NA	0.36	4.3	0.33	2.99e-5	Testicular germ cell tumor;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08439880	chr3:133502540	NA	-0.59	-6.61	-0.47	6.15e-10	Iron status biomarkers;
PAAD	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.52	0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.54	5.29	0.39	4.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.99	8.76	0.58	3.5e-15	Bipolar disorder;
PAAD	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs375066	0.934	rs2191564	chr19:44367611	T/C	cg08633290	chr19:44405433	NA	-0.58	-5.85	-0.43	2.88e-8	Breast cancer;
PAAD	cis	rs9951602	0.920	rs4799257	chr18:76664054	C/T	cg00806245	chr18:76673096	NA	-0.76	-5.94	-0.43	1.89e-8	Obesity-related traits;
PAAD	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19904058	chr10:135279010	LOC619207	-0.63	-7.61	-0.53	2.62e-12	Systemic lupus erythematosus;
PAAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.14	-0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3126085	0.560	rs12568784	chr1:152323132	G/T	cg26876637	chr1:152193138	HRNR	-0.72	-5.48	-0.41	1.75e-7	Atopic dermatitis;
PAAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg06606381	chr12:133084897	FBRSL1	-1.06	-7.25	-0.51	2e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7155603	1.000	rs7155603	chr14:75960536	A/G	cg01624173	chr14:75981868	NA	-0.76	-6.46	-0.46	1.35e-9	Rheumatoid arthritis;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg07362569	chr17:61921086	SMARCD2	0.4	4.48	0.34	1.48e-5	Height;
PAAD	cis	rs11203032	1.000	rs17117088	chr10:90961799	G/A	cg16672925	chr10:90967113	CH25H	0.78	5.94	0.43	1.84e-8	Heart failure;
PAAD	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.63	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg18898632	chr2:242989856	NA	-0.73	-4.98	-0.37	1.72e-6	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7301016	0.948	rs11614822	chr12:62931690	T/G	cg11441379	chr12:63026424	NA	0.85	6.17	0.45	5.8e-9	IgG glycosylation;
PAAD	cis	rs2252790	0.764	rs2027851	chr6:116681682	C/G	cg18764771	chr6:116381957	FRK	-0.26	-4.29	-0.33	3.22e-5	Fast beta electroencephalogram;
PAAD	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.67	-4.73	-0.36	5.17e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17554472	chr22:41940697	POLR3H	0.59	4.25	0.33	3.65e-5	Vitiligo;
PAAD	cis	rs28655083	0.673	rs1872509	chr16:77058990	G/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-4.83	-0.36	3.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	4.58	0.35	9.63e-6	Mood instability;
PAAD	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-8.28	-0.56	5.95e-14	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17378483	chr4:6911009	TBC1D14	0.54	6.29	0.45	3.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg04330084	chr7:123175371	IQUB	-0.52	-4.62	-0.35	8.24e-6	Plateletcrit;Platelet count;
PAAD	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg07703079	chr11:430292	ANO9	0.8	4.47	0.34	1.53e-5	Body mass index;
PAAD	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7567389	0.677	rs11680949	chr2:128123562	C/G	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.49	0.34	1.42e-5	Lung cancer in ever smokers;
PAAD	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg18078177	chr20:47281410	PREX1	0.9	6.17	0.45	6.03e-9	Tonometry;
PAAD	cis	rs11811982	0.793	rs76872038	chr1:227375617	G/A	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.65	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-5.7	-0.42	6.18e-8	Longevity;Endometriosis;
PAAD	cis	rs959260	1.000	rs9892325	chr17:73394449	A/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs17169635	0.819	rs6467560	chr7:134501992	C/G	cg02516134	chr7:134575187	CALD1	-0.43	-4.47	-0.34	1.5e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg21269045	chr12:125625041	AACS	-0.48	-4.64	-0.35	7.34e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23880822	chr15:26026172	ATP10A	-0.63	-6.49	-0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg17650747	chr5:1873721	NA	0.46	4.7	0.36	5.78e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.34	4.64	0.35	7.6e-6	Vitiligo;
PAAD	cis	rs11811982	0.793	rs116389194	chr1:227302921	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-1.0	-6.86	-0.49	1.59e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg01411142	chr8:19674711	INTS10	0.78	4.99	0.38	1.64e-6	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12365107	chr3:52720035	GNL3;PBRM1	-0.71	-7.32	-0.51	1.37e-11	Smoking initiation;
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25613910	chr11:112150832	NA	0.62	6.97	0.49	9.14e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.49	0.41	1.69e-7	Mood instability;
PAAD	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.24	-0.39	5.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg16339924	chr4:17578868	LAP3	0.48	4.31	0.33	2.89e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.49	4.26	0.33	3.51e-5	Height;
PAAD	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.62	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.74	-8.02	-0.55	2.68e-13	Eye color traits;
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.49	-0.47	1.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16097330	chr5:171615472	STK10	0.62	7.05	0.5	5.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8005172	0.750	rs2165567	chr14:88453186	A/G	cg18078958	chr14:88630771	NA	0.48	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg24220031	chr2:73402428	NA	-0.43	-6.6	-0.47	6.49e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.75	8.19	0.55	1.01e-13	Psoriasis;
PAAD	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.17	0.5	3.09e-11	Renal function-related traits (BUN);
PAAD	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	1.09	15.75	0.79	9.53e-34	Systemic lupus erythematosus;
PAAD	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg25075503	chr6:89673509	RNGTT	0.6	6.31	0.46	2.85e-9	Iris heterochromicity;
PAAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg10356904	chr22:49881777	NA	-0.47	-4.53	-0.35	1.16e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2514805	0.803	rs2262592	chr8:95155550	A/G	cg25183890	chr8:94929275	PDP1	0.7	4.52	0.34	1.24e-5	Diisocyanate-induced asthma;
PAAD	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg03268063	chr7:1337281	NA	-0.5	-4.4	-0.34	2.01e-5	Neuroticism;
PAAD	cis	rs7904985	1.000	rs12358144	chr10:88114486	C/G	cg07322936	chr10:88137208	NA	-0.48	-4.32	-0.33	2.76e-5	Barrett's esophagus;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03433394	chr3:42623829	SEC22C	-0.67	-7.12	-0.5	3.98e-11	Smoking initiation;
PAAD	cis	rs722864	0.744	rs3820835	chr2:173966589	T/A	cg09210666	chr2:173941575	ZAK	0.47	4.44	0.34	1.75e-5	Lung cancer;
PAAD	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05848660	chr14:74975983	LTBP2	0.57	6.56	0.47	8.02e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg00101154	chr16:420108	MRPL28	-0.69	-6.59	-0.47	6.65e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.8	-8.94	-0.59	1.25e-15	Multiple sclerosis;Ankylosing spondylitis;
PAAD	cis	rs863345	0.625	rs11265006	chr1:158498485	C/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg09179987	chr1:167433047	CD247	0.49	5.72	0.42	5.5e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg02696790	chr15:75250997	RPP25	0.4	4.73	0.36	5.01e-6	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14372919	chr6:110012632	AKD1;FIG4	-0.7	-6.74	-0.48	3.06e-10	Neuroticism;
PAAD	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.4	-5.52	-0.41	1.46e-7	Permanent tooth development;
PAAD	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.83	8.11	0.55	1.59e-13	Post bronchodilator FEV1;
PAAD	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.39e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-1.1	-8.11	-0.55	1.61e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1883415	0.553	rs760907	chr6:24479873	T/C	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.48	4.81	0.36	3.58e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.41	-0.52	8.32e-12	Neuroticism;
PAAD	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.47	-4.66	-0.35	6.77e-6	Vitamin D levels;
PAAD	cis	rs10783615	0.719	rs1975471	chr12:54336981	A/G	cg25382128	chr12:54346509	NA	-0.55	-4.76	-0.36	4.47e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.81	-0.62	6.5e-18	Coronary artery disease;
PAAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.82	-7.2	-0.5	2.62e-11	Gut microbiome composition (summer);
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg19223190	chr17:80058835	NA	0.54	5.57	0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.77	-9.54	-0.61	3.4e-17	Height;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.49	-7.57	-0.52	3.28e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg16964102	chr10:135390573	NA	0.43	4.57	0.35	9.88e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.43	-0.46	1.56e-9	Aortic root size;
PAAD	cis	rs11614333	0.959	rs1861698	chr12:14993854	A/G	cg00431549	chr12:15039025	MGP	-0.38	-4.48	-0.34	1.45e-5	Hand grip strength;
PAAD	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg01868782	chr6:126071099	HEY2	0.41	4.33	0.33	2.65e-5	Brugada syndrome;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.76	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.77	-7.85	-0.54	7.04e-13	Cholesterol, total;
PAAD	trans	rs7137515	0.501	rs4375507	chr12:82468233	A/C	cg13865810	chr9:101706936	COL15A1	0.56	6.39	0.46	1.91e-9	IgG glycosylation;
PAAD	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg14440974	chr22:39074834	NA	-0.54	-6.58	-0.47	6.99e-10	Menopause (age at onset);
PAAD	cis	rs59888335	1.000	rs13078352	chr3:80725427	C/A	cg21735741	chr3:80819488	NA	0.55	4.82	0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs11671005	0.779	rs3752112	chr19:58992220	T/G	cg25952890	chr19:58913133	NA	0.73	5.65	0.42	7.82e-8	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03954918	chr16:12278468	SNX29	-0.62	-6.6	-0.47	6.35e-10	Obesity-related traits;
PAAD	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.53	5.58	0.41	1.09e-7	Migraine;Coronary artery disease;
PAAD	cis	rs28493229	0.708	rs10408065	chr19:41161096	T/C	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.67	-6.44	-0.46	1.45e-9	Coronary artery disease;
PAAD	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg16083429	chr3:49237500	CCDC36	-0.49	-4.77	-0.36	4.19e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg06634786	chr22:41940651	POLR3H	0.68	4.99	0.38	1.65e-6	Vitiligo;
PAAD	cis	rs288326	0.561	rs79074459	chr2:183767098	T/C	cg09997497	chr2:183902928	NCKAP1	0.96	5.36	0.4	3.1e-7	Blood protein levels;
PAAD	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg01489032	chr8:143877656	NA	0.46	4.96	0.37	1.83e-6	Urinary tract infection frequency;
PAAD	trans	rs7172971	0.688	rs8029713	chr15:42387118	A/G	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10426930	0.738	rs2613757	chr19:5062405	T/C	cg08036796	chr19:5034282	KDM4B	-0.45	-4.55	-0.35	1.08e-5	Monocyte percentage of white cells;
PAAD	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.75	6.99	0.49	8.28e-11	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.58	6.43	0.46	1.6e-9	Platelet distribution width;
PAAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.59	-7.08	-0.5	4.93e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.57	-0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.62	6.8	0.48	2.22e-10	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.84	7.0	0.49	7.61e-11	Alzheimer's disease;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg12705353	chr12:122356852	WDR66	0.45	4.54	0.35	1.14e-5	Mean corpuscular volume;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg11764359	chr7:65958608	NA	0.8	5.1	0.38	1.01e-6	Diabetic kidney disease;
PAAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.05	-0.44	1.11e-8	Lymphocyte counts;
PAAD	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15892658	chr11:33757569	CD59	-0.79	-6.96	-0.49	9.67e-11	Neuroticism;
PAAD	cis	rs2327429	0.541	rs11154750	chr6:134156979	A/T	cg06643013	chr6:134217242	NA	0.4	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs6558530	0.777	rs3812477	chr8:1734452	C/G	cg19131313	chr8:1704013	NA	-0.41	-4.55	-0.35	1.1e-5	Systolic blood pressure;
PAAD	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	6.61	0.47	6.03e-10	Coronary artery disease;
PAAD	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.21	17.64	0.82	1.3e-38	Triglycerides;
PAAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.8	12.45	0.71	5.71e-25	Schizophrenia;
PAAD	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.93	-0.43	1.97e-8	Coronary artery calcification;
PAAD	cis	rs654384	0.898	rs1077472	chr7:4175323	G/A	cg27574739	chr7:4176374	SDK1	-0.48	-4.72	-0.36	5.22e-6	Positive affect;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.55	-4.94	-0.37	2.04e-6	Monocyte count;
PAAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	1.13	13.14	0.73	7.65e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.56	5.3	0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.8	-8.74	-0.58	4.02e-15	Lung cancer;
PAAD	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.4e-8	Coronary artery disease;
PAAD	cis	rs4780401	0.967	rs11075011	chr16:11828282	T/A	cg01061890	chr16:11836724	TXNDC11	-0.52	-5.1	-0.38	9.89e-7	Rheumatoid arthritis;
PAAD	cis	rs12936587	0.777	rs12942708	chr17:17528011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.47	4.41	0.34	1.92e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg26174226	chr8:58114915	NA	-0.59	-4.42	-0.34	1.9e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.93	6.37	0.46	2.12e-9	Thyroid stimulating hormone;
PAAD	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg10011062	chr15:43941034	CATSPER2	0.76	4.4	0.34	2.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg04520793	chr17:42248056	ASB16	-0.43	-5.18	-0.39	6.88e-7	Total body bone mineral density;
PAAD	cis	rs2882667	0.654	rs700617	chr5:138087979	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.92	-0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	5.52	0.41	1.45e-7	Lung cancer in ever smokers;
PAAD	cis	rs802075	0.967	rs554805	chr6:49653451	A/G	cg20364632	chr6:49636226	NA	-0.52	-6.06	-0.44	1.04e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20458811	chr8:144631810	NA	-0.44	-5.87	-0.43	2.7e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg20850873	chr3:10149803	C3orf24	0.53	4.27	0.33	3.38e-5	Alzheimer's disease;
PAAD	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg16583315	chr14:65563665	MAX	-0.42	-4.45	-0.34	1.68e-5	Obesity-related traits;
PAAD	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg12215294	chr3:40350768	EIF1B	0.47	4.95	0.37	1.91e-6	Renal cell carcinoma;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.81	7.51	0.52	4.56e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	9.01	0.59	8.05e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg00228799	chr9:131580591	ENDOG	0.64	6.37	0.46	2.11e-9	Blood metabolite levels;
PAAD	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.85	0.49	1.67e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Intracranial aneurysm;
PAAD	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.8	9.58	0.61	2.7e-17	Metabolic syndrome;
PAAD	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg05973401	chr12:123451056	ABCB9	0.5	4.56	0.35	1.05e-5	Platelet count;
PAAD	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.81	-6.75	-0.48	2.94e-10	Diabetic kidney disease;
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.55	-0.41	1.23e-7	Total body bone mineral density;
PAAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.47	5.05	0.38	1.28e-6	Lung cancer;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg10534938	chr5:1868639	NA	0.47	6.11	0.44	7.92e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg05785598	chr3:49045655	WDR6	0.42	5.22	0.39	5.87e-7	Parkinson's disease;
PAAD	cis	rs59888335	0.929	rs66506603	chr3:80895775	G/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs68170813	0.652	rs17404067	chr7:107168119	G/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	0.9	8.61	0.57	8.4e-15	Blood protein levels;
PAAD	cis	rs6537837	0.793	rs17575742	chr1:110083603	C/A	cg05049280	chr1:110155535	GNAT2	0.42	4.48	0.34	1.49e-5	Major depressive disorder;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.88	-9.91	-0.63	3.7e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-5.01	-0.38	1.51e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg10985347	chr2:127963512	CYP27C1	0.48	4.73	0.36	5.12e-6	Protein C levels;
PAAD	cis	rs300774	0.858	rs423038	chr2:129486	A/C	cg21211680	chr2:198530	NA	-0.6	-5.69	-0.42	6.45e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.52	-6.06	-0.44	1.03e-8	Breast cancer;
PAAD	cis	rs1042026	0.848	rs975833	chr4:100201739	G/C	cg21548116	chr4:100009993	ADH5	-0.48	-4.25	-0.33	3.78e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.66	-6.27	-0.45	3.47e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg14132834	chr19:41945861	ATP5SL	0.52	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.83e-7	Crohn's disease;
PAAD	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs863345	0.604	rs1342947	chr1:158459714	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.8	-0.36	3.73e-6	Pneumococcal bacteremia;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.75	-4.83	-0.36	3.3e-6	IgG glycosylation;
PAAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg15660573	chr17:549704	VPS53	-0.76	-7.67	-0.53	1.94e-12	Prostate cancer;
PAAD	cis	rs6141769	0.542	rs28536730	chr20:31301954	A/C	cg13636640	chr20:31349939	DNMT3B	-0.49	-4.64	-0.35	7.32e-6	Subjective well-being;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.52	4.86	0.37	2.93e-6	Schizophrenia;
PAAD	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.13	-0.38	8.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg04721828	chr11:48285200	OR4X1	-0.42	-5.51	-0.41	1.48e-7	Migraine - clinic-based;
PAAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.56	-6.87	-0.49	1.57e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26675523	chr3:47044166	NBEAL2	-0.72	-6.64	-0.47	5.15e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs2562456	0.833	rs4429400	chr19:21520965	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.63	-7.28	-0.51	1.65e-11	Huntington's disease progression;
PAAD	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg14515779	chr1:101123966	NA	0.4	4.45	0.34	1.66e-5	Monocyte count;
PAAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	5.39	0.4	2.69e-7	Rheumatoid arthritis;
PAAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs12304921	1.000	rs66744607	chr12:51336491	T/C	cg18059802	chr12:51347058	HIGD1C	-0.7	-5.6	-0.41	9.84e-8	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24741700	chr11:107729645	SLC35F2	0.7	7.85	0.54	7.03e-13	Monocyte percentage of white cells;
PAAD	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg20628663	chr10:43360327	NA	0.66	4.78	0.36	4.15e-6	Blood protein levels;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg08992911	chr2:238395768	MLPH	0.59	5.17	0.39	7.23e-7	Prostate cancer;
PAAD	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg17099306	chr13:50123645	RCBTB1	-0.42	-4.27	-0.33	3.44e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg00280220	chr17:61926910	NA	0.42	4.37	0.33	2.31e-5	Prudent dietary pattern;
PAAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg25753631	chr6:25732923	NA	0.49	5.56	0.41	1.19e-7	Iron status biomarkers;
PAAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.49	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1941184	0.500	rs1460598	chr18:29028491	G/A	cg03238162	chr18:29027701	DSG3	0.41	4.57	0.35	9.93e-6	Parkinson's disease (age of onset);
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg21421171	chr8:145755615	MGC70857;KIAA1688	-0.29	-4.88	-0.37	2.71e-6	Age at first birth;
PAAD	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg24623649	chr8:11872141	NA	0.43	4.25	0.33	3.66e-5	Monocyte count;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17744375	chr7:4243286	SDK1	0.54	6.32	0.46	2.74e-9	Body fat percentage;
PAAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	4.78	0.36	4.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg03999872	chr20:62272968	STMN3	-0.76	-7.08	-0.5	4.94e-11	Atopic dermatitis;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg04810063	chr16:88703634	IL17C	-0.57	-5.19	-0.39	6.56e-7	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.7	7.97	0.54	3.51e-13	Colorectal cancer;
PAAD	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg22903657	chr4:1355424	KIAA1530	-0.5	-4.78	-0.36	4.06e-6	Obesity-related traits;
PAAD	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.6	-6.42	-0.46	1.62e-9	Calcium levels;
PAAD	cis	rs9581857	0.547	rs9579094	chr13:28081495	G/A	cg22138327	chr13:27999177	GTF3A	0.83	5.34	0.4	3.29e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6774494	0.959	rs1522278	chr3:169075078	G/A	cg01324963	chr3:169781717	GPR160	-0.43	-4.26	-0.33	3.52e-5	Nasopharyngeal carcinoma;
PAAD	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-6.16	-0.45	6.1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.62	0.47	5.94e-10	Educational attainment;
PAAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.53	0.47	9.14e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg22189786	chr22:42395067	WBP2NL	0.64	5.3	0.39	4.01e-7	Birth weight;
PAAD	cis	rs4835937	0.588	rs7726011	chr5:127321694	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.51	4.26	0.33	3.63e-5	Cancer;
PAAD	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.57	-5.55	-0.41	1.27e-7	Multiple sclerosis;
PAAD	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.82	9.67	0.62	1.56e-17	Ulcerative colitis;
PAAD	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs288342	0.797	rs192618	chr2:183627504	A/G	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.58	-5.72	-0.42	5.57e-8	Crohn's disease;
PAAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg03983715	chr16:68378420	PRMT7	-0.95	-7.14	-0.5	3.61e-11	Schizophrenia;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.68	7.51	0.52	4.71e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg03934865	chr2:198174659	NA	0.43	4.32	0.33	2.82e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg03340356	chr1:67600835	NA	0.63	6.79	0.48	2.35e-10	Psoriasis;
PAAD	cis	rs2019216	0.605	rs34542118	chr17:21989708	T/A	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.5e-5	Pelvic organ prolapse;
PAAD	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.46	-0.34	1.58e-5	Response to amphetamines;
PAAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.88	10.69	0.66	2.98e-20	Menopause (age at onset);
PAAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	1.28	13.0	0.73	1.9e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg06917634	chr15:78832804	PSMA4	-0.46	-4.67	-0.35	6.66e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6066835	1.000	rs6125428	chr20:47292823	C/G	cg18078177	chr20:47281410	PREX1	0.99	4.7	0.36	5.72e-6	Multiple myeloma;
PAAD	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg20893579	chr22:38215064	NA	-0.47	-4.78	-0.36	4.08e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24015594	chr6:33539338	NA	0.62	6.93	0.49	1.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.15	-0.45	6.48e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg04725166	chr1:7887271	PER3	-0.61	-5.7	-0.42	6.01e-8	Crohn's disease;
PAAD	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.8	9.38	0.61	9.08e-17	Lewy body disease;
PAAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg26174226	chr8:58114915	NA	-0.6	-4.99	-0.38	1.64e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.42	0.61	7.21e-17	Rheumatoid arthritis;
PAAD	cis	rs4751006	0.543	rs61875504	chr10:128772592	C/T	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs10864907	0.742	rs11123154	chr2:113733431	G/A	cg17804723	chr2:114300030	NA	-0.37	-4.25	-0.33	3.72e-5	Pulmonary function;
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09256448	chr16:638327	NA	0.42	4.36	0.33	2.37e-5	Height;
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.59	6.96	0.49	9.75e-11	Aortic root size;
PAAD	cis	rs17824933	0.887	rs12790976	chr11:60767420	T/G	cg27098804	chr11:60776124	CD6	0.43	4.4	0.34	2.07e-5	Multiple sclerosis;
PAAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg21130718	chr4:1044621	NA	0.54	4.58	0.35	9.43e-6	Recombination rate (females);
PAAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.81	8.63	0.57	7.79e-15	Obesity-related traits;
PAAD	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.16e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4748857	0.947	rs4748851	chr10:23565338	T/C	cg18853376	chr10:23633759	C10orf67	0.51	4.53	0.34	1.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.7	6.11	0.44	8.18e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg18964960	chr10:1102726	WDR37	0.86	4.33	0.33	2.67e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs901683	1.000	rs36100685	chr10:46086854	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9826463	0.757	rs73240316	chr3:142266061	A/G	cg20824294	chr3:142316082	PLS1	0.43	4.87	0.37	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.56	0.47	8.1e-10	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.04	-14.8	-0.77	2.97e-31	Chronic sinus infection;
PAAD	cis	rs3026101	0.671	rs8081480	chr17:5282761	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	5.34	0.4	3.34e-7	Body mass index;
PAAD	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08948820	chr6:36562537	SFRS3	-0.68	-7.11	-0.5	4.35e-11	Lung cancer in ever smokers;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg10207240	chr12:122356781	WDR66	0.55	5.78	0.42	4.11e-8	Mean corpuscular volume;
PAAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs2275731	0.897	rs45578234	chr10:16536176	G/A	cg04254609	chr10:16479192	PTER	-0.55	-5.44	-0.4	2.06e-7	Bone fracture in osteoporosis;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-1.05	-13.57	-0.74	5.38e-28	Urate levels;
PAAD	cis	rs2034088	0.930	rs9907540	chr17:448042	A/G	cg04370829	chr17:406249	NA	-0.55	-5.4	-0.4	2.49e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs1625975	0.557	rs1665685	chr10:73416482	A/G	cg26005973	chr10:72643678	PCBD1	-0.73	-4.45	-0.34	1.63e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg02917321	chr22:38215204	NA	0.48	4.81	0.36	3.65e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1371614	0.566	rs10203050	chr2:27186561	C/T	cg00617064	chr2:27272375	NA	0.5	5.23	0.39	5.45e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg13736514	chr6:26305472	NA	-0.59	-6.19	-0.45	5.26e-9	Educational attainment;
PAAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.77	-7.68	-0.53	1.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6065	0.618	rs4790719	chr17:4881434	A/G	cg02990439	chr17:4875527	CAMTA2	0.88	4.53	0.35	1.17e-5	Platelet count;
PAAD	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	7.9	0.54	5.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	12.37	0.71	9.36e-25	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.07	6.28	0.45	3.42e-9	Body mass index;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg16590910	chr6:42928470	GNMT	0.49	4.98	0.37	1.74e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	1.09	6.82	0.48	1.97e-10	Skin colour saturation;
PAAD	cis	rs11615916	0.790	rs17659736	chr12:62706333	C/A	cg11441379	chr12:63026424	NA	0.65	4.4	0.34	2.06e-5	Pulmonary function decline;
PAAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.71	0.42	5.73e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.58	6.33	0.46	2.6e-9	Longevity;Endometriosis;
PAAD	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-8.51	-0.57	1.57e-14	Vitiligo;
PAAD	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.46	-0.41	1.87e-7	Adiposity;
PAAD	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.61	-4.26	-0.33	3.5e-5	Vitiligo;
PAAD	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.44	5.65	0.42	7.78e-8	Panic disorder;
PAAD	cis	rs6942407	0.546	rs2373387	chr7:86745948	T/G	cg02420886	chr7:86849541	C7orf23	0.6	4.7	0.36	5.89e-6	Food allergy;
PAAD	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg10589385	chr1:150898437	SETDB1	0.37	4.55	0.35	1.11e-5	Melanoma;
PAAD	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.53	-4.72	-0.36	5.39e-6	Prion diseases;
PAAD	cis	rs9810890	1.000	rs73198883	chr3:128543187	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.69	-7.1	-0.5	4.48e-11	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.85	-0.58	2.07e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.86	13.25	0.73	4.08e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6496044	0.507	rs62022863	chr15:86162053	C/G	cg13263323	chr15:86062960	AKAP13	0.53	5.58	0.41	1.09e-7	Interstitial lung disease;
PAAD	cis	rs16975963	0.843	rs11672257	chr19:38439362	A/G	cg14218481	chr19:38281219	NA	0.49	5.1	0.38	1.01e-6	Longevity;
PAAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.66	7.02	0.49	7.05e-11	Mean corpuscular volume;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.55	-5.85	-0.43	2.86e-8	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg09127314	chr1:152161683	NA	0.53	4.62	0.35	8.2e-6	Atopic dermatitis;
PAAD	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg02917321	chr22:38215204	NA	0.45	4.59	0.35	9.32e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs9467711	0.651	rs13198474	chr6:25874423	G/A	cg01620082	chr3:125678407	NA	-1.47	-8.08	-0.55	1.83e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2124910	0.683	rs2864101	chr19:52008530	G/A	cg14953197	chr19:52005651	SIGLEC12	0.49	5.24	0.39	5.2e-7	Blood protein levels;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.66	-7.18	-0.5	2.82e-11	Iron status biomarkers;
PAAD	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs500492	0.542	rs2573148	chr16:1073372	C/T	cg08892068	chr16:1497180	CLCN7	0.59	4.26	0.33	3.54e-5	Polycystic ovary syndrome;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg26554054	chr8:600488	NA	0.91	6.0	0.44	1.4e-8	IgG glycosylation;
PAAD	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs288326	0.561	rs77535302	chr2:183870045	T/A	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg12623918	chr2:306882	NA	0.46	4.8	0.36	3.71e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.66	-6.98	-0.49	8.57e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg14346243	chr4:90757452	SNCA	-0.51	-4.46	-0.34	1.59e-5	Neuroticism;
PAAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.46	-4.36	-0.33	2.4e-5	Monocyte count;
PAAD	cis	rs73252553	0.548	rs4697563	chr4:25313117	T/C	cg04009456	chr4:25379436	ANAPC4	0.4	4.49	0.34	1.39e-5	Cannabis dependence symptom count;
PAAD	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.63	-4.37	-0.33	2.34e-5	Smoking behavior;
PAAD	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.7	8.2	0.55	9.46e-14	Alcohol dependence;
PAAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg21709803	chr11:61594965	FADS2	-0.54	-4.41	-0.34	1.94e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-1.01	-9.71	-0.62	1.22e-17	Corneal structure;
PAAD	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-4.32	-0.33	2.78e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8040855	0.597	rs12902942	chr15:85584804	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs2839627	0.638	rs7281701	chr21:44277296	C/T	cg03543861	chr21:44258195	NA	0.58	4.32	0.33	2.86e-5	Information processing speed;
PAAD	cis	rs6496932	0.755	rs12905673	chr15:85889771	C/T	cg19183879	chr15:85880815	NA	-0.54	-4.82	-0.36	3.42e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.76e-7	Alcohol dependence;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12049462	chr2:201983419	CFLAR	0.53	6.5	0.47	1.07e-9	Immature fraction of reticulocytes;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg21871583	chr3:15374148	SH3BP5	-0.68	-7.07	-0.5	5.27e-11	Blood protein levels;
PAAD	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.51	-5.8	-0.43	3.7e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-5.7	-0.42	6.04e-8	Schizophrenia;
PAAD	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.15e-10	HDL cholesterol;
PAAD	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.1	6.76	0.48	2.79e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6694270	0.529	rs12041777	chr1:19109193	T/C	cg19637330	chr1:19110922	NA	-0.65	-5.22	-0.39	5.66e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.34	0.33	2.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	0.67	7.27	0.51	1.78e-11	Leprosy;
PAAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg03676636	chr4:99064102	C4orf37	0.25	4.25	0.33	3.65e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.21	17.64	0.82	1.3e-38	Triglycerides;
PAAD	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs3916	0.637	rs11065200	chr12:121109832	T/C	cg21892295	chr12:121157589	UNC119B	-0.41	-4.63	-0.35	7.74e-6	Urinary metabolites (H-NMR features);
PAAD	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs58521262	0.556	rs289317	chr19:23161297	C/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg07469887	chr10:131262384	NA	-0.48	-6.05	-0.44	1.06e-8	Response to temozolomide;
PAAD	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.56	5.18	0.39	6.86e-7	Schizophrenia;
PAAD	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.9	8.64	0.57	7.09e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg21419209	chr3:44054225	NA	-0.73	-7.49	-0.52	5.2e-12	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26859392	chr3:10143019	FANCD2;C3orf24	0.66	7.35	0.51	1.17e-11	Smoking initiation;
PAAD	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.61	5.57	0.41	1.11e-7	Red blood cell count;
PAAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.45	-4.46	-0.34	1.61e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.64	6.96	0.49	9.68e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs11615916	0.790	rs113296466	chr12:62687161	C/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.46	-4.52	-0.34	1.26e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	trans	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg14171944	chr9:126323477	DENND1A	-0.55	-6.57	-0.47	7.49e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.13	-0.5	3.74e-11	Neuroticism;
PAAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs72960926	0.744	rs16884715	chr6:75056816	A/G	cg13997649	chr6:74171430	MTO1	0.73	4.25	0.33	3.73e-5	Metabolite levels (MHPG);
PAAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.51	-0.34	1.27e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.69	7.91	0.54	4.83e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg26876637	chr1:152193138	HRNR	-0.83	-6.16	-0.45	6.2e-9	Atopic dermatitis;
PAAD	cis	rs6466055	0.625	rs7794036	chr7:104870448	T/C	cg04380332	chr7:105027541	SRPK2	0.5	4.81	0.36	3.67e-6	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.97	0.54	3.57e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18297960	chr7:1142765	C7orf50	-0.55	-4.4	-0.34	2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.56	0.65	6.85e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs288342	0.832	rs288240	chr2:183644191	T/C	cg02625481	chr2:183667124	NA	-0.46	-4.69	-0.36	6.16e-6	Recurrent major depressive disorder;
PAAD	cis	rs4141404	0.737	rs5998067	chr22:32043630	C/T	cg02404636	chr22:31891804	SFI1	-0.59	-5.59	-0.41	1.05e-7	Paclitaxel-induced neuropathy;
PAAD	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.71	-0.66	2.64e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg12373951	chr3:133503437	NA	0.45	5.64	0.42	8.16e-8	Alcohol consumption (transferrin glycosylation);
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.82	-9.01	-0.59	8.37e-16	Menopause (age at onset);
PAAD	trans	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg15770106	chr1:208133116	NA	-0.63	-6.33	-0.46	2.65e-9	Corneal structure;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16118817	chr19:4792497	FEM1A	0.47	6.29	0.45	3.13e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.72	8.6	0.57	9.17e-15	Breast cancer;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11248182	chr5:138774785	DNAJC18	0.6	6.44	0.46	1.47e-9	Pancreatic cancer;
PAAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.07	-18.7	-0.83	3.04e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.42	-0.34	1.83e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg16147221	chr4:10020634	SLC2A9	0.46	4.25	0.33	3.66e-5	Bone mineral density;
PAAD	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg27234864	chr13:21295941	IL17D	0.61	5.3	0.39	4.05e-7	Dental caries;
PAAD	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg23465465	chr6:26364728	BTN3A2	0.62	4.25	0.33	3.69e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.64	6.97	0.49	8.97e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg11143131	chr5:131608246	PDLIM4	-0.5	-5.01	-0.38	1.51e-6	Blood metabolite levels;
PAAD	cis	rs2147959	0.882	rs6666241	chr1:228629759	A/G	cg00655913	chr1:228633920	NA	0.51	4.65	0.35	7.07e-6	Adult asthma;
PAAD	cis	rs89107	0.641	rs376875	chr6:118611592	C/T	cg21191810	chr6:118973309	C6orf204	0.43	6.04	0.44	1.16e-8	Cardiac structure and function;
PAAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.54	-5.22	-0.39	5.91e-7	Monocyte count;
PAAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.69	-9.97	-0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs4356203	0.870	rs603618	chr11:17246362	G/C	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	8.11	0.55	1.59e-13	Height;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03425468	chr1:155164676	MIR92B	0.54	6.38	0.46	1.99e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs4742903	0.765	rs4743700	chr9:107005468	C/T	cg14250997	chr9:106856677	SMC2	0.46	5.05	0.38	1.28e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.07	0.38	1.15e-6	Body mass index;
PAAD	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.54	-0.41	1.29e-7	Schizophrenia;
PAAD	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.56	6.07	0.44	9.81e-9	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.91	-11.48	-0.68	2.31e-22	Menopause (age at onset);
PAAD	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-4.67	-0.35	6.55e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs17683430	0.681	rs12157575	chr22:32543338	T/C	cg02631450	chr22:32366979	NA	0.62	4.34	0.33	2.58e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2340727	0.604	rs3767637	chr1:161817024	C/A	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg05627522	chr15:75251581	NA	-0.52	-6.41	-0.46	1.74e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.37	0.46	2.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg24585817	chr7:64895279	NA	0.44	4.39	0.34	2.12e-5	Aortic root size;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg02462569	chr6:150064036	NUP43	-0.44	-4.77	-0.36	4.24e-6	Testicular germ cell tumor;
PAAD	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.38	9.4	0.61	8.03e-17	Diabetic retinopathy;
PAAD	cis	rs9535307	0.584	rs61961500	chr13:50392624	G/C	cg03658251	chr13:50265850	EBPL	-0.76	-4.65	-0.35	7.14e-6	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs73196961	chr3:128436383	T/C	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs2916733	0.530	rs1867385	chr8:6306024	A/G	cg01691696	chr8:6734962	DEFB1	0.51	4.47	0.34	1.55e-5	Epirubicin-induced leukopenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06017847	chr8:103665964	KLF10	0.7	6.42	0.46	1.63e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3736485	0.934	rs4775956	chr15:51882638	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg19847866	chr10:1019161	NA	0.74	7.83	0.54	7.73e-13	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg23920097	chr1:209922102	NA	-0.49	-4.39	-0.34	2.11e-5	Red blood cell count;
PAAD	cis	rs2562456	0.793	rs3853837	chr19:21601974	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.56	-5.27	-0.39	4.54e-7	Aortic root size;
PAAD	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	4.92	0.37	2.26e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13348293	chr10:28821714	WAC	0.59	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.61	-6.14	-0.45	7e-9	Glioblastoma;
PAAD	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.89	-11.03	-0.67	3.76e-21	Dental caries;
PAAD	cis	rs9815354	1.000	rs1716664	chr3:41948378	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.79	-0.42	3.97e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg10705379	chr10:99080932	FRAT1	0.38	4.41	0.34	1.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.78	-7.25	-0.51	1.96e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs1529711	0.500	rs1865124	chr19:10878144	C/T	cg18543610	chr13:100627929	NA	-0.63	-6.39	-0.46	1.94e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs988712	0.921	rs6484317	chr11:27598421	A/C	cg10635145	chr11:27742435	BDNF	0.35	4.26	0.33	3.53e-5	Obesity;
PAAD	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.94	4.78	0.36	4.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.0	12.14	0.7	3.97e-24	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg07725925	chr16:89976287	TCF25	0.66	4.29	0.33	3.19e-5	Skin colour saturation;
PAAD	cis	rs8060686	0.764	rs73597575	chr16:67677001	C/T	cg05110241	chr16:68378359	PRMT7	-0.96	-4.63	-0.35	7.7e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs586313	1.000	rs586313	chr11:133874712	C/T	cg19966618	chr11:134123407	THYN1;ACAD8	-0.55	-4.54	-0.35	1.12e-5	Granulocyte-colony stimulating factor levels;
PAAD	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg26338869	chr17:61819248	STRADA	-0.69	-7.43	-0.52	7.5e-12	Prudent dietary pattern;
PAAD	cis	rs12753569	1.000	rs12753569	chr1:76484014	G/T	cg00791851	chr1:76518896	NA	-0.41	-4.28	-0.33	3.35e-5	Personality dimensions;
PAAD	cis	rs12681963	0.688	rs7009988	chr8:30082463	A/G	cg23406830	chr8:30012838	DCTN6	-0.72	-4.75	-0.36	4.75e-6	Migraine;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg11810498	chr9:130477698	PTRH1;TTC16	0.56	6.29	0.45	3.24e-9	Hemostatic factors and hematological phenotypes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13552506	chr1:946444	NA	0.67	7.64	0.53	2.25e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.58	6.86	0.49	1.65e-10	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09612454	chr21:34539778	C21orf54	-0.65	-6.62	-0.47	5.67e-10	Obesity-related traits;
PAAD	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.65	-6.37	-0.46	2.11e-9	Breast cancer;
PAAD	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg22532475	chr10:104410764	TRIM8	0.34	4.39	0.34	2.1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg10932868	chr11:921992	NA	0.45	4.75	0.36	4.63e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	5.71	0.42	5.64e-8	Mood instability;
PAAD	cis	rs4740619	0.635	rs10810479	chr9:15930536	T/G	cg14451791	chr9:16040625	NA	-0.4	-4.51	-0.34	1.28e-5	Body mass index;
PAAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs9888739	1.000	rs6565228	chr16:31329280	G/A	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.84	5.68	0.42	6.64e-8	Anti-saccade response;
PAAD	cis	rs9900972	0.877	rs8082025	chr17:76876464	C/T	cg20937029	chr17:76870563	TIMP2	0.59	5.24	0.39	5.32e-7	Obesity-related traits;
PAAD	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg16205897	chr5:131564050	P4HA2	-0.47	-4.93	-0.37	2.12e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg04018571	chr2:96874059	STARD7	-0.64	-6.31	-0.46	2.9e-9	Body mass index;
PAAD	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg24687543	chr11:63912206	MACROD1	0.63	5.48	0.41	1.75e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4523957	0.928	rs8077545	chr17:2184555	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.09	8.63	0.57	7.57e-15	Diabetic kidney disease;
PAAD	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg08877591	chr19:11648452	CNN1	-0.74	-4.89	-0.37	2.49e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10778556	chr1:24113913	C1orf128	-0.79	-8.35	-0.56	4.02e-14	Obesity-related traits;
PAAD	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07884487	chr3:69789167	MITF	0.65	6.49	0.47	1.17e-9	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.74e-6	Iron status biomarkers;
PAAD	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg05791153	chr7:19748676	TWISTNB	0.64	4.91	0.37	2.34e-6	Thyroid stimulating hormone;
PAAD	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.36	4.78	0.36	4.19e-6	Calcium levels;
PAAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.47	-5.19	-0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg05110241	chr16:68378359	PRMT7	-1.3	-9.01	-0.59	8.33e-16	Schizophrenia;
PAAD	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg20582800	chr6:43612764	RSPH9	-0.56	-4.44	-0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.91	0.37	2.28e-6	Lymphocyte counts;
PAAD	cis	rs2029362	0.688	rs7938467	chr11:27502675	C/G	cg10635145	chr11:27742435	BDNF	-0.31	-4.47	-0.34	1.51e-5	Total body bone mineral density;
PAAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.82	-7.56	-0.52	3.48e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.46	-5.21	-0.39	6.1e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.1	-0.44	8.6e-9	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.64	-0.35	7.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-7.59	-0.52	2.96e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.78	6.49	0.47	1.15e-9	Glioblastoma;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13521891	chr12:95466445	NR2C1	0.55	6.41	0.46	1.76e-9	Metabolite levels  (X-11787);
PAAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24729792	chr2:113192114	RGPD8;RGPD5	0.58	4.84	0.37	3.12e-6	Yeast infection;
PAAD	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg26585981	chr11:48327164	OR4S1	-0.49	-4.27	-0.33	3.39e-5	Migraine - clinic-based;
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg08888203	chr3:10149979	C3orf24	0.78	5.69	0.42	6.3e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.58	-4.76	-0.36	4.42e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.6	-0.35	8.83e-6	Resting heart rate;
PAAD	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.43	4.4	0.34	2.02e-5	Calcium levels;
PAAD	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg17252645	chr8:143867129	LY6D	-0.41	-4.27	-0.33	3.44e-5	Urinary tract infection frequency;
PAAD	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.25e-5	Obesity-related traits;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26418147	chr1:205743515	RAB7L1	-0.5	-5.98	-0.44	1.53e-8	Menarche (age at onset);
PAAD	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.65	-7.46	-0.52	6.22e-12	Vitamin D levels;
PAAD	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg05890377	chr2:74357713	NA	0.87	9.19	0.6	2.83e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg07701084	chr6:150067640	NUP43	0.71	7.53	0.52	4.24e-12	Lung cancer;
PAAD	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.56	5.45	0.4	1.94e-7	Platelet count;
PAAD	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.61	6.74	0.48	3.1e-10	Lung cancer;
PAAD	cis	rs10821973	0.527	rs4979778	chr10:63981919	G/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg06917450	chr1:38156652	C1orf109	-0.5	-4.35	-0.33	2.45e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.18	-0.39	7.04e-7	Height;
PAAD	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs58521262	0.556	rs289329	chr19:23155167	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs55863869	0.892	rs2627040	chr2:179601975	C/T	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.79	4.25	0.33	3.65e-5	QT interval;
PAAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.52	-0.47	9.68e-10	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs11723436	0.552	rs13123289	chr4:120865401	G/A	cg09307838	chr4:120376055	NA	0.48	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs16858210	0.542	rs12636826	chr3:183558581	G/C	cg25686905	chr3:183603175	PARL	-0.38	-4.39	-0.34	2.15e-5	Menopause (age at onset);
PAAD	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.85	8.87	0.58	1.89e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.79	0.66	1.69e-20	Tonsillectomy;
PAAD	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.65	-5.93	-0.43	1.95e-8	Crohn's disease;
PAAD	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.09	-0.38	1.06e-6	Height;
PAAD	cis	rs1692580	0.807	rs263535	chr1:2177727	T/C	cg04315214	chr1:2043799	PRKCZ	-0.41	-4.76	-0.36	4.44e-6	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06544989	chr22:39130855	UNC84B	0.49	4.79	0.36	3.86e-6	Menopause (age at onset);
PAAD	cis	rs7508	0.553	rs7828234	chr8:17883400	G/A	cg08627089	chr8:17753878	FGL1	-0.45	-4.48	-0.34	1.45e-5	Atrial fibrillation;
PAAD	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.78	7.47	0.52	5.96e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.54	5.1	0.38	9.94e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.45	-4.62	-0.35	7.98e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	13.71	0.74	2.39e-28	Testicular germ cell tumor;
PAAD	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.66	7.56	0.52	3.52e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	trans	rs10905099	1.000	rs10905099	chr10:7089016	A/G	cg17689490	chr10:128952444	DOCK1;FAM196A	0.92	6.3	0.46	3.04e-9	Orofacial clefts;
PAAD	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg10495392	chr1:46806563	NSUN4	0.46	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.5	-4.71	-0.36	5.65e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05470809	chr4:175205489	KIAA1712;FBXO8	0.58	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7695597	0.643	rs2665730	chr4:185172104	G/T	cg12654155	chr4:185238627	NA	0.42	4.39	0.34	2.11e-5	Night sleep phenotypes;
PAAD	cis	rs5753037	0.702	rs140100	chr22:30128240	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-4.35	-0.33	2.53e-5	Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg17848003	chr1:3704513	LRRC47	0.39	4.28	0.33	3.31e-5	Red cell distribution width;
PAAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.71	-0.36	5.48e-6	Neuroticism;
PAAD	cis	rs2712184	0.875	rs1015784	chr2:217681833	G/C	cg05032264	chr2:217675019	NA	-0.59	-6.54	-0.47	8.69e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03605463	chr16:89740564	NA	0.53	5.16	0.39	7.74e-7	Vitiligo;
PAAD	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg14019146	chr3:50243930	SLC38A3	-0.53	-4.31	-0.33	2.89e-5	Menarche (age at onset);
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg27121462	chr16:89883253	FANCA	0.43	4.65	0.35	7.09e-6	Vitiligo;
PAAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs1572591	0.512	rs4112527	chr13:102119656	A/G	cg09276445	chr13:102106423	ITGBL1	-0.46	-6.22	-0.45	4.49e-9	Psychosis (atypical);
PAAD	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg03808351	chr9:123631620	PHF19	0.42	4.4	0.34	2.07e-5	Rheumatoid arthritis;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg21130718	chr4:1044621	NA	0.51	4.5	0.34	1.35e-5	Recombination rate (females);
PAAD	cis	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.97e-6	Mononucleosis;
PAAD	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.81	9.81	0.62	6.69e-18	Colorectal cancer;
PAAD	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	7.71	0.53	1.54e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg18370025	chr7:2749541	AMZ1	0.39	4.59	0.35	9.11e-6	Height;
PAAD	cis	rs859767	0.741	rs7571113	chr2:135427392	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-4.36	-0.33	2.39e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.64	6.32	0.46	2.8e-9	Platelet count;
PAAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	6.12	0.44	7.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10768122	0.865	rs3794090	chr11:35323890	A/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.34	-0.33	2.63e-5	Vitiligo;
PAAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.71	-5.84	-0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07362569	chr17:61921086	SMARCD2	-0.44	-5.08	-0.38	1.09e-6	Prudent dietary pattern;
PAAD	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.3	-9.41	-0.61	7.56e-17	Blood pressure (smoking interaction);
PAAD	cis	rs1561176	1.000	rs11768000	chr7:155009198	G/T	cg08570118	chr7:155025533	NA	-0.53	-4.79	-0.36	3.97e-6	Personality dimensions;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9595066	0.627	rs4942290	chr13:44757339	C/T	cg04068111	chr13:44716778	NA	-0.48	-5.17	-0.39	7.42e-7	Schizophrenia;
PAAD	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg21918786	chr6:109611834	NA	-0.52	-5.47	-0.41	1.78e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg25833597	chr17:30823145	MYO1D	0.53	5.01	0.38	1.52e-6	Schizophrenia;
PAAD	cis	rs11807834	0.522	rs12086717	chr1:230255859	C/T	cg09847368	chr1:230250326	GALNT2	-0.68	-8.26	-0.56	6.73e-14	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27221554	chr8:29924188	TMEM66	-0.63	-6.56	-0.47	7.8e-10	Obesity-related traits;
PAAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15664640	chr17:80829946	TBCD	-0.66	-4.58	-0.35	9.55e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg00571178	chr13:114841904	RASA3	-0.58	-4.86	-0.37	2.9e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs9913156	0.748	rs72835635	chr17:4563127	A/G	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs9462027	0.628	rs7752522	chr6:34760583	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.03	-0.38	1.39e-6	Systemic lupus erythematosus;
PAAD	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.76	0.36	4.5e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6494488	0.500	rs34758599	chr15:64706332	A/G	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.61e-6	Coronary artery disease;
PAAD	cis	rs4454254	0.634	rs11166942	chr8:141025859	T/C	cg07454640	chr8:140990901	TRAPPC9	0.49	4.99	0.38	1.61e-6	Pulse pressure;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-6.6	-0.47	6.51e-10	Lymphocyte counts;
PAAD	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-4.65	-0.35	7.04e-6	Mood instability;
PAAD	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.67	-7.12	-0.5	4e-11	Glycated hemoglobin levels;
PAAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	4.31	0.33	2.96e-5	Personality dimensions;
PAAD	cis	rs4740619	0.967	rs7032755	chr9:15640025	G/T	cg14080542	chr9:15553451	C9orf93	0.44	4.29	0.33	3.12e-5	Body mass index;
PAAD	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg13798912	chr7:905769	UNC84A	0.64	4.5	0.34	1.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg07541023	chr7:19748670	TWISTNB	0.6	4.41	0.34	1.91e-5	Thyroid stimulating hormone;
PAAD	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg26876637	chr1:152193138	HRNR	0.86	6.75	0.48	2.87e-10	Atopic dermatitis;
PAAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.48	-4.62	-0.35	8.01e-6	Brugada syndrome;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg24846343	chr22:24311635	DDTL	-0.66	-5.94	-0.43	1.85e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Alcohol dependence;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.76	-7.51	-0.52	4.64e-12	Prudent dietary pattern;
PAAD	cis	rs540425	0.572	rs217389	chr7:44599206	A/G	cg14633139	chr7:44645728	OGDH	0.44	4.32	0.33	2.83e-5	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.73	-4.71	-0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.77	-5.83	-0.43	3.16e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg27478167	chr7:817139	HEATR2	-0.72	-5.65	-0.42	7.77e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.14	0.45	6.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg09389931	chr14:103748217	NA	-0.4	-4.35	-0.33	2.53e-5	Coronary artery disease;
PAAD	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg05144285	chr7:158935647	VIPR2	-0.56	-4.28	-0.33	3.31e-5	Height;
PAAD	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg02887458	chr19:19495540	GATAD2A	0.49	4.64	0.35	7.56e-6	Bipolar disorder;
PAAD	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.51	4.49	0.34	1.41e-5	Dental caries;
PAAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-4.67	-0.35	6.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg17372223	chr3:52568218	NT5DC2	-0.51	-5.03	-0.38	1.4e-6	Bipolar disorder;
PAAD	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.12	0.44	7.56e-9	Ileal carcinoids;
PAAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg09654669	chr8:57350985	NA	-0.53	-5.0	-0.38	1.54e-6	Obesity-related traits;
PAAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg23601416	chr22:19950040	COMT	-0.3	-4.64	-0.35	7.52e-6	Blood metabolite levels;
PAAD	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.2	-0.39	6.36e-7	Mean platelet volume;
PAAD	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.84	9.43	0.61	6.4e-17	Tuberculosis;
PAAD	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.89	10.51	0.65	9.03e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg17385448	chr1:15911702	AGMAT	0.38	4.67	0.35	6.59e-6	Systolic blood pressure;
PAAD	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.82	10.16	0.64	8.12e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.6	6.57	0.47	7.61e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.79	7.99	0.54	3.13e-13	Coronary artery disease;
PAAD	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	1.13	17.82	0.82	4.61e-39	Colorectal adenoma (advanced);
PAAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03676636	chr4:99064102	C4orf37	0.31	5.57	0.41	1.12e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg09491104	chr22:46646882	C22orf40	-0.89	-4.88	-0.37	2.7e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg22029157	chr1:209979665	IRF6	0.68	6.37	0.46	2.16e-9	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	cis	rs7562790	0.597	rs7419733	chr2:36652027	G/C	cg01206211	chr2:36825736	FEZ2	0.45	4.45	0.34	1.67e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.74	-7.9	-0.54	5.2e-13	Blood metabolite levels;
PAAD	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg10072921	chr12:121022843	NA	-0.39	-4.88	-0.37	2.7e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg22705602	chr4:152727874	NA	0.52	5.4	0.4	2.47e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05742564	chr16:23568708	UBFD1;EARS2	0.57	6.62	0.47	5.77e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs59888335	0.858	rs1878762	chr3:80992543	G/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg02734326	chr4:10020555	SLC2A9	0.52	5.18	0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.09	-0.38	1.06e-6	Subjective well-being;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26418147	chr1:205743515	RAB7L1	0.5	5.98	0.44	1.5e-8	Menarche (age at onset);
PAAD	cis	rs6499755	0.712	rs31090	chr16:55363628	A/G	cg02859129	chr16:55357253	IRX6	0.35	4.87	0.37	2.79e-6	Hypospadias;
PAAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg07725925	chr16:89976287	TCF25	0.77	4.28	0.33	3.26e-5	Skin colour saturation;
PAAD	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2020921	0.510	rs79305352	chr8:41977708	C/G	cg12054981	chr8:42037387	PLAT	0.79	5.03	0.38	1.36e-6	Plasma plasminogen activator levels;
PAAD	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26816564	chr1:7831052	VAMP3	0.79	6.26	0.45	3.72e-9	Inflammatory bowel disease;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22653602	chr6:90529138	MDN1	0.51	5.46	0.41	1.87e-7	Vitiligo;Type 1 diabetes;
PAAD	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.43	4.46	0.34	1.6e-5	Type 2 diabetes;
PAAD	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.64	-8.98	-0.59	9.49e-16	Breast cancer;
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg15997130	chr1:24165203	NA	0.59	6.2	0.45	5.14e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6923462	0.877	rs9942510	chr6:7800306	G/A	cg20969151	chr6:7787925	BMP6	-0.57	-4.39	-0.34	2.13e-5	Lung function (forced vital capacity);
PAAD	cis	rs2997447	0.846	rs2997445	chr1:26390154	C/T	cg24519413	chr1:26490540	NA	0.48	4.44	0.34	1.72e-5	QRS complex (12-leadsum);
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	6.01	0.44	1.29e-8	Lung function (FEV1/FVC);
PAAD	cis	rs7551345	0.853	rs10493047	chr1:31741777	C/T	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.83	6.89	0.49	1.39e-10	Recombination rate (females);
PAAD	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	1.23	12.9	0.72	3.56e-26	Post bronchodilator FEV1;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20099018	chr17:40169396	DNAJC7;NKIRAS2	-0.69	-7.0	-0.49	7.65e-11	Smoking initiation;
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg24879335	chr3:133465180	TF	0.55	5.92	0.43	2.1e-8	Iron status biomarkers;
PAAD	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg14343924	chr8:8086146	FLJ10661	0.52	4.65	0.35	7.29e-6	Mood instability;
PAAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.62	-5.43	-0.4	2.14e-7	Initial pursuit acceleration;
PAAD	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.48	-4.81	-0.36	3.58e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	7.58	0.52	3.1e-12	Alzheimer's disease;
PAAD	cis	rs1364705	1.000	rs61600037	chr8:120225613	T/C	cg09273054	chr8:120220131	MAL2	0.45	5.2	0.39	6.3e-7	Hippocampal atrophy;
PAAD	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.82	-9.89	-0.63	4.17e-18	Eosinophil percentage of white cells;
PAAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09695851	chr17:3907499	NA	-0.67	-6.92	-0.49	1.2e-10	Type 2 diabetes;
PAAD	cis	rs12042938	0.507	rs1655302	chr1:231731528	T/C	cg21875980	chr1:231553510	EGLN1	-0.46	-4.37	-0.33	2.31e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg01426195	chr3:39028469	NA	-0.74	-8.54	-0.57	1.33e-14	Handedness;
PAAD	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.73	-8.72	-0.58	4.64e-15	Dental caries;
PAAD	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg21775007	chr8:11205619	TDH	-0.56	-4.89	-0.37	2.53e-6	Neuroticism;
PAAD	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.98	8.63	0.57	7.49e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1499972	0.527	rs4688086	chr3:117943857	C/T	cg07612923	chr3:117604196	NA	-0.66	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs9815354	0.680	rs73073266	chr3:42021116	A/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07940793	chr17:79603854	NPLOC4	0.59	7.04	0.5	6.21e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs300774	0.925	rs300707	chr2:141324	G/T	cg23649280	chr2:140451	NA	-0.5	-4.8	-0.36	3.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.94	-0.37	2.03e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg06026331	chr20:60912101	LAMA5	-0.6	-5.56	-0.41	1.17e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.7	4.83	0.36	3.34e-6	Platelet distribution width;
PAAD	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.49	0.41	1.65e-7	Tonsillectomy;
PAAD	cis	rs863345	0.604	rs10908651	chr1:158451272	A/C	cg12129480	chr1:158549410	OR10X1	0.41	4.69	0.36	6.05e-6	Pneumococcal bacteremia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08056863	chr19:11266458	SPC24	-0.79	-6.84	-0.49	1.78e-10	Neuroticism;
PAAD	cis	rs797680	0.861	rs612037	chr1:93682878	G/A	cg04535902	chr1:92947332	GFI1	-0.47	-4.46	-0.34	1.61e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.26	-0.33	3.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg21625146	chr5:486483	SLC9A3	0.33	4.77	0.36	4.25e-6	Cystic fibrosis severity;
PAAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6684514	0.961	rs112017075	chr1:156327716	G/A	cg16558208	chr1:156270281	VHLL	0.47	4.45	0.34	1.63e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.77	-0.42	4.31e-8	Menarche (age at onset);
PAAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs728616	0.614	rs57342950	chr10:82105081	G/A	cg19423196	chr10:82049429	MAT1A	0.48	4.75	0.36	4.61e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg12738979	chr1:100436069	SLC35A3	-0.57	-6.34	-0.46	2.45e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.5	4.64	0.35	7.59e-6	Schizophrenia;
PAAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.35	0.33	2.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg27539214	chr16:67997921	SLC12A4	-0.62	-4.7	-0.36	5.87e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.31	-0.33	2.91e-5	Renal cell carcinoma;
PAAD	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-7.62	-0.53	2.52e-12	Response to antipsychotic treatment;
PAAD	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.15	-9.41	-0.61	7.55e-17	Post bronchodilator FEV1;
PAAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.31	4.3	0.33	2.99e-5	Migraine;
PAAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08480854	chr16:1498490	CLCN7	0.54	4.97	0.37	1.82e-6	Bone mineral density;
PAAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.55	-4.57	-0.35	1.02e-5	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
PAAD	cis	rs13070279	1.000	rs13070279	chr3:71824685	G/A	cg03457142	chr3:71804859	EIF4E3	-0.54	-4.31	-0.33	2.91e-5	Monocyte count;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.68	-6.28	-0.45	3.41e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg25324976	chr17:61989376	CSHL1	-0.53	-4.27	-0.33	3.44e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15345369	chr2:10262827	RRM2	0.57	6.4	0.46	1.78e-9	Myopia (pathological);
PAAD	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.56	-6.05	-0.44	1.1e-8	Schizophrenia;
PAAD	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.48	5.16	0.39	7.44e-7	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17771610	chr13:45011050	TSC22D1	0.64	6.62	0.47	5.74e-10	Obesity-related traits;
PAAD	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg00864171	chr11:67383662	NA	0.52	5.28	0.39	4.43e-7	Mean corpuscular volume;
PAAD	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg08992911	chr2:238395768	MLPH	0.58	5.23	0.39	5.41e-7	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs3857067	0.740	rs10024198	chr4:95060602	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.55	-5.27	-0.39	4.69e-7	QT interval;
PAAD	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.75	8.77	0.58	3.31e-15	Prostate cancer;
PAAD	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	5.97e-10	HDL cholesterol;
PAAD	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.57	-5.95	-0.43	1.79e-8	Cognitive function;
PAAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.67	5.66	0.42	7.23e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.48	-4.95	-0.37	1.97e-6	Motion sickness;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.87	9.3	0.6	1.4e-16	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.83	-0.43	3.22e-8	Prudent dietary pattern;
PAAD	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.56	5.2	0.39	6.44e-7	Corneal astigmatism;
PAAD	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.5e-12	Resting heart rate;
PAAD	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03454375	chr15:34660076	LPCAT4	0.58	6.53	0.47	9.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.66	0.42	7.5e-8	Personality dimensions;
PAAD	cis	rs288342	0.763	rs409343	chr2:183610406	C/T	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.56	0.57	1.16e-14	Homoarginine levels;
PAAD	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.7	10.38	0.64	2.07e-19	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15750102	chr4:107237686	AIMP1;TBCK	0.61	6.66	0.48	4.65e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.51	8.41	0.56	2.8e-14	IgG glycosylation;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg26557270	chr6:116382179	FRK	-0.3	-5.17	-0.39	7.17e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.48	4.47	0.34	1.5e-5	Acylcarnitine levels;
PAAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.58	-5.62	-0.42	8.69e-8	Monocyte count;
PAAD	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.68	-0.35	6.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs900145	0.773	rs4146388	chr11:13306605	C/T	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg08632701	chr21:37451849	NA	-0.59	-6.15	-0.45	6.47e-9	Mitral valve prolapse;
PAAD	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.8	7.11	0.5	4.16e-11	Coronary artery disease;
PAAD	cis	rs508970	0.556	rs519296	chr11:60919754	G/A	cg24692310	chr11:60915630	VPS37C	0.33	4.55	0.35	1.11e-5	Rheumatoid arthritis;
PAAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.57	6.08	0.44	9.09e-9	Menopause (age at onset);
PAAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.33	0.64	2.84e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.49	5.42	0.4	2.25e-7	Immature fraction of reticulocytes;
PAAD	cis	rs608114	0.623	rs601581	chr6:96363607	A/C	cg03043157	chr6:97010903	FHL5	0.93	4.88	0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.48	4.6	0.35	9.01e-6	Diastolic blood pressure;
PAAD	cis	rs17461620	1.000	rs17461620	chr9:88963008	C/T	cg13456106	chr9:88897068	ISCA1	0.61	4.37	0.33	2.31e-5	Diisocyanate-induced asthma;
PAAD	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.71	6.62	0.47	5.75e-10	Primary sclerosing cholangitis;
PAAD	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-8.16	-0.55	1.19e-13	Colorectal cancer;
PAAD	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.62	-4.63	-0.35	7.81e-6	Thyroid stimulating hormone;
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09826364	chr7:158789723	NA	-0.4	-5.18	-0.39	7.02e-7	Facial morphology (factor 20);
PAAD	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2637266	0.596	rs2579723	chr10:78246092	A/G	cg18941641	chr10:78392320	NA	0.36	4.26	0.33	3.57e-5	Pulmonary function;
PAAD	cis	rs2244497	0.698	rs228872	chr17:64498276	C/T	cg26726141	chr17:64612159	PRKCA	0.52	4.83	0.36	3.36e-6	Neuroticism;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04674792	chr15:44116616	MFAP1	-0.58	-5.55	-0.41	1.22e-7	Lung cancer in ever smokers;
PAAD	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg25155006	chr6:37138205	PIM1	-0.53	-4.67	-0.35	6.5e-6	QRS duration;
PAAD	cis	rs2414856	0.510	rs73456908	chr15:64995104	G/A	cg16425858	chr15:64791681	ZNF609	0.89	5.06	0.38	1.2e-6	Pulse pressure;Systolic blood pressure;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.56	6.04	0.44	1.12e-8	Longevity;Endometriosis;
PAAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.75	-5.12	-0.38	9.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	1.57	8.95	0.59	1.18e-15	Cannabis dependence symptom count;
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg05717871	chr11:638507	DRD4	-0.59	-5.19	-0.39	6.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg11783602	chr8:55087084	NA	-0.64	-7.73	-0.53	1.35e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.62	-6.42	-0.46	1.69e-9	Leprosy;
PAAD	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.05	-0.38	1.28e-6	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.62e-8	Obesity-related traits;
PAAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.46	5.15	0.39	7.84e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.82e-6	Lymphocyte counts;
PAAD	cis	rs6001982	0.915	rs17002030	chr22:40989374	C/T	cg07138101	chr22:40742427	ADSL	-0.74	-4.46	-0.34	1.59e-5	Breast cancer;
PAAD	cis	rs1198430	0.759	rs946267	chr1:23747703	A/T	cg19827787	chr1:23763612	ASAP3	0.55	4.68	0.36	6.2e-6	Total cholesterol levels;
PAAD	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.72	-10.22	-0.64	5.61e-19	Breast cancer;
PAAD	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg04520793	chr17:42248056	ASB16	0.41	4.92	0.37	2.22e-6	Total body bone mineral density;
PAAD	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.72	-6.94	-0.49	1.08e-10	Recombination rate (males);
PAAD	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.47	4.59	0.35	9.1e-6	Longevity;
PAAD	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12808519	0.688	rs3740640	chr11:69587583	C/T	cg26765567	chr11:69587473	NA	0.49	4.63	0.35	7.79e-6	Urate levels in overweight individuals;
PAAD	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg15733309	chr7:157513707	PTPRN2	0.72	8.42	0.56	2.59e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg10985347	chr2:127963512	CYP27C1	0.49	4.98	0.37	1.7e-6	Protein C levels;
PAAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19346786	chr7:2764209	NA	-0.38	-5.29	-0.39	4.12e-7	Height;
PAAD	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.98e-6	Coronary artery disease;
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.67	5.19	0.39	6.5e-7	Blood protein levels;
PAAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.48	5.09	0.38	1.07e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs58521262	0.556	rs424913	chr19:23122426	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.64	-0.35	7.33e-6	Testicular germ cell tumor;
PAAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.63	7.05	0.5	5.9e-11	High light scatter reticulocyte count;
PAAD	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.5	-4.68	-0.35	6.32e-6	Malaria;
PAAD	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.51	5.17	0.39	7.15e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-5.62	-0.41	8.87e-8	Cognitive function;
PAAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-6.59	-0.47	6.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-6.07	-0.44	9.71e-9	Blood pressure (smoking interaction);
PAAD	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2564921	0.513	rs12638195	chr3:52876639	G/A	cg12820946	chr3:52029954	RPL29	-0.49	-4.27	-0.33	3.44e-5	Height;
PAAD	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg01884057	chr2:25150051	NA	-0.36	-4.44	-0.34	1.75e-5	Body mass index in non-asthmatics;
PAAD	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.69	-7.25	-0.51	1.93e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04838064	chr6:57181606	PRIM2	-0.68	-6.57	-0.47	7.72e-10	Neuroticism;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg05585544	chr11:47624801	NA	0.46	5.13	0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs273573	0.643	rs1848394	chr11:31009078	A/G	cg21705394	chr11:30344510	C11orf46	0.46	4.37	0.33	2.25e-5	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22371845	chr8:140718096	NA	0.59	6.58	0.47	7.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.93	0.59	1.31e-15	Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg23024343	chr7:107201750	COG5	0.57	4.75	0.36	4.64e-6	Coronary artery disease;
PAAD	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg20630647	chr19:41531805	NA	-0.56	-4.32	-0.33	2.8e-5	Coronary artery disease;
PAAD	cis	rs6585424	1.000	rs3851055	chr10:81938096	T/C	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs493733	0.596	rs690014	chr3:16402559	A/G	cg27252855	chr3:16189891	NA	0.43	4.56	0.35	1.05e-5	Urate levels (BMI interaction);
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg16606324	chr3:10149918	C3orf24	0.64	4.87	0.37	2.83e-6	Alzheimer's disease;
PAAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg07527105	chr16:88053339	BANP	-0.43	-4.39	-0.34	2.08e-5	Menopause (age at onset);
PAAD	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg08992911	chr2:238395768	MLPH	0.55	5.25	0.39	4.98e-7	Prostate cancer;
PAAD	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.77	8.66	0.57	6.47e-15	Height;
PAAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.72	-8.29	-0.56	5.6e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.74	8.46	0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-8.71	-0.58	4.7e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06115741	chr20:33292138	TP53INP2	0.6	6.23	0.45	4.47e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg04317338	chr11:64019027	PLCB3	-0.72	-5.45	-0.4	2e-7	Mean platelet volume;
PAAD	cis	rs2421770	0.532	rs10836374	chr11:35345764	A/G	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.62	5.84	0.43	3.02e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.57	-5.69	-0.42	6.27e-8	P wave terminal force;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25203627	chr1:231886200	TSNAX-DISC1;DISC1	-0.61	-6.73	-0.48	3.26e-10	Obesity-related traits;
PAAD	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.52	-0.34	1.24e-5	Height;
PAAD	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23015897	chr19:48103819	NA	0.75	7.66	0.53	2.01e-12	Obesity-related traits;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.37	-5.24	-0.39	5.2e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.47	-7.14	-0.5	3.65e-11	Cutaneous nevi;
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27603082	chr10:134405566	INPP5A	-0.39	-4.73	-0.36	5.13e-6	Gait speed in old age;
PAAD	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.76e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11264213	0.901	rs2791961	chr1:36371419	C/G	cg27506609	chr1:36549197	TEKT2	-0.73	-5.1	-0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.53	-5.1	-0.38	9.94e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.52	-4.68	-0.35	6.3e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.88	9.48	0.61	4.77e-17	Corneal astigmatism;
PAAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00300879	chr1:26503847	CNKSR1	-0.29	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs2279817	0.818	rs74061959	chr1:18016162	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-6.04	-0.44	1.13e-8	Neuroticism;
PAAD	cis	rs62025270	0.576	rs62022925	chr15:86236066	A/G	cg13263323	chr15:86062960	AKAP13	0.51	4.62	0.35	8.16e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.75	-6.22	-0.45	4.67e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.59	-5.65	-0.42	7.67e-8	Subjective well-being;
PAAD	cis	rs3026101	0.671	rs3026115	chr17:5285222	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.66	0.42	7.47e-8	Body mass index;
PAAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg24213567	chr19:53496664	ZNF702P	-0.47	-4.8	-0.36	3.7e-6	Psoriasis;
PAAD	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.31	-0.33	2.88e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19346786	chr7:2764209	NA	-0.35	-4.89	-0.37	2.57e-6	Height;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg00576331	chr11:65640516	EFEMP2	-0.49	-4.95	-0.37	1.95e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.79	-0.36	3.94e-6	Lymphocyte counts;
PAAD	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.49	4.81	0.36	3.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.5	-4.7	-0.36	5.69e-6	Endometrial cancer;
PAAD	cis	rs9616064	0.638	rs738244	chr22:46946127	C/T	cg03318428	chr22:46971703	NA	0.4	4.82	0.36	3.52e-6	Urate levels in obese individuals;
PAAD	cis	rs34421088	0.506	rs2117616	chr8:11145911	A/G	cg20279283	chr8:11566863	GATA4	0.44	4.29	0.33	3.2e-5	Neuroticism;
PAAD	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.69	-9.15	-0.6	3.57e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg06241208	chr11:30344200	C11orf46	-0.49	-4.48	-0.34	1.48e-5	Morning vs. evening chronotype;
PAAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.92	-0.59	1.39e-15	Morning vs. evening chronotype;
PAAD	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.51	4.79	0.36	3.99e-6	Height;
PAAD	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg04106633	chr4:1044584	NA	0.63	5.29	0.39	4.22e-7	Recombination rate (females);
PAAD	cis	rs3026101	0.671	rs739766	chr17:5290599	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12541635	0.966	rs2217391	chr8:107063126	A/G	cg10147462	chr8:107024639	NA	0.43	4.66	0.35	6.83e-6	Age of smoking initiation;
PAAD	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg20744362	chr22:50050164	C22orf34	0.59	7.54	0.52	3.87e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg14758556	chr20:62440591	NA	0.51	4.42	0.34	1.89e-5	Atopic dermatitis;
PAAD	cis	rs4523957	0.523	rs2760746	chr17:2034806	G/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg23283495	chr1:209979779	IRF6	0.78	7.08	0.5	5.02e-11	Cleft lip with or without cleft palate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03208214	chr14:71786911	NA	0.6	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs740474	0.544	rs2299024	chr5:140880765	G/C	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.51	6.26	0.45	3.67e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.93	10.37	0.64	2.19e-19	Testicular germ cell tumor;
PAAD	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.48	5.26	0.39	4.89e-7	Life satisfaction;
PAAD	cis	rs7684253	0.548	rs13108002	chr4:57718253	C/T	cg24291500	chr4:57773398	REST	-0.45	-4.83	-0.36	3.36e-6	Migraine;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08219700	chr8:58056026	NA	0.67	5.15	0.39	7.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.66	-0.53	2.06e-12	Migraine;Coronary artery disease;
PAAD	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg07099767	chr17:78039528	CCDC40	-0.51	-4.86	-0.37	2.87e-6	Yeast infection;
PAAD	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.6	5.98	0.44	1.51e-8	Monocyte count;
PAAD	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.86	-8.73	-0.58	4.35e-15	Chronic sinus infection;
PAAD	cis	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00166722	chr3:10149974	C3orf24	0.71	6.47	0.46	1.25e-9	Alzheimer's disease;
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.35	0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.06	9.94	0.63	2.98e-18	Red blood cell traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01398415	chr1:226309536	NA	0.58	6.41	0.46	1.71e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.63	-6.9	-0.49	1.33e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.98	-8.4	-0.56	2.93e-14	Gut microbiome composition (summer);
PAAD	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.52	4.52	0.34	1.22e-5	Morning vs. evening chronotype;
PAAD	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.75	-4.49	-0.34	1.4e-5	Toenail selenium levels;
PAAD	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.94	0.37	2.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg18209359	chr17:80159595	CCDC57	0.51	5.13	0.38	8.74e-7	Life satisfaction;
PAAD	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.57	-5.82	-0.43	3.33e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9535307	0.929	rs3851162	chr13:50354150	T/G	cg04663916	chr13:50265991	EBPL	0.61	4.53	0.35	1.18e-5	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.43	5.41	0.4	2.36e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg15956490	chr3:53032818	SFMBT1	0.78	4.39	0.34	2.16e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg09835421	chr16:68378352	PRMT7	-0.78	-6.48	-0.47	1.2e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg12807937	chr2:240965920	NDUFA10	-0.46	-4.54	-0.35	1.12e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.77	-0.36	4.26e-6	Aortic root size;
PAAD	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg05373962	chr22:49881684	NA	-0.42	-4.31	-0.33	2.88e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg22467129	chr15:76604101	ETFA	0.53	4.96	0.37	1.89e-6	Blood metabolite levels;
PAAD	cis	rs59888335	0.858	rs9831092	chr3:81010223	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-8.04	-0.55	2.3e-13	Body mass index;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.71	7.66	0.53	2.03e-12	Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	5.98	0.44	1.52e-8	Educational attainment;
PAAD	cis	rs939584	1.000	rs6760543	chr2:622388	G/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs9896052	0.614	rs4073989	chr17:73450862	G/A	cg25649188	chr17:73499917	CASKIN2	0.59	4.6	0.35	8.84e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs7487075	0.578	rs4768118	chr12:46784744	T/C	cg09447675	chr12:46877466	NA	-0.48	-4.39	-0.34	2.15e-5	Itch intensity from mosquito bite;
PAAD	trans	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.06e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs965469	0.779	rs6037541	chr20:3287704	G/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.41e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04887735	chr14:68690954	RAD51L1	0.61	6.53	0.47	9.41e-10	Smoking initiation;
PAAD	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.44	5.2	0.39	6.37e-7	Systemic lupus erythematosus;
PAAD	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.79	-0.48	2.42e-10	Response to antipsychotic treatment;
PAAD	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg15192750	chr16:69999425	NA	0.76	5.99	0.44	1.48e-8	IgE levels;
PAAD	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg22654517	chr2:96458247	NA	0.39	4.65	0.35	7.01e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg25566285	chr7:158114605	PTPRN2	0.84	8.67	0.58	6.13e-15	Calcium levels;
PAAD	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.84	-6.76	-0.48	2.74e-10	Putamen volume;
PAAD	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.55	-6.09	-0.44	8.65e-9	Metabolite levels;
PAAD	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	6.4	0.46	1.85e-9	Total body bone mineral density;
PAAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.96	-10.11	-0.63	1.06e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg01851573	chr8:8652454	MFHAS1	-0.5	-4.86	-0.37	2.84e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg07469887	chr10:131262384	NA	0.42	5.0	0.38	1.56e-6	Response to temozolomide;
PAAD	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.55	5.39	0.4	2.67e-7	Mortality in heart failure;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.57	4.86	0.37	2.96e-6	Common traits (Other);
PAAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-4.39	-0.34	2.15e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.8	-0.53	9.1e-13	Initial pursuit acceleration;
PAAD	cis	rs6256	1.000	rs11022872	chr11:13564845	C/T	cg11976911	chr11:13509032	NA	-0.67	-5.18	-0.39	7.06e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs288342	0.763	rs369573	chr2:183615273	G/A	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg09796270	chr17:17721594	SREBF1	0.44	4.73	0.36	5.12e-6	Total body bone mineral density;
PAAD	cis	rs17776563	0.959	rs17197194	chr15:89111610	G/A	cg27664085	chr15:89157815	NA	0.32	4.29	0.33	3.11e-5	Thyroid hormone levels;
PAAD	cis	rs11191193	1.000	rs11191193	chr10:103802408	A/G	cg11685391	chr10:103594334	KCNIP2	-0.33	-4.4	-0.34	2e-5	Educational attainment;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18617333	chr8:143808383	C8orf55	0.64	7.04	0.5	6.14e-11	Myopia (pathological);
PAAD	cis	rs6074578	0.535	rs6086289	chr20:138615	G/A	cg16931068	chr20:139680	DEFB127	0.39	5.26	0.39	4.85e-7	Hirschsprung disease;
PAAD	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.96	5.89	0.43	2.41e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.52	5.71	0.42	5.74e-8	Major depressive disorder;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg02555727	chr12:129281546	SLC15A4	0.46	4.92	0.37	2.18e-6	Systemic lupus erythematosus;
PAAD	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.52	6.72	0.48	3.4e-10	Sitting height ratio;
PAAD	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg13722127	chr7:150037890	RARRES2	0.67	6.97	0.49	9.16e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13102973	0.931	rs4561977	chr4:135848936	T/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg26752003	chr8:145688521	CYHR1	0.68	7.8	0.53	9.17e-13	Age at first birth;
PAAD	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.9	9.94	0.63	3.07e-18	Resting heart rate;
PAAD	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.81	8.51	0.57	1.57e-14	Uric acid levels;
PAAD	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg06028605	chr16:24865363	SLC5A11	-0.36	-4.64	-0.35	7.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-11.13	-0.67	2.02e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg22109262	chr4:17578738	LAP3	-0.71	-6.37	-0.46	2.1e-9	Blood protein levels;
PAAD	cis	rs282587	0.569	rs282595	chr13:113379930	A/G	cg02820901	chr13:113351484	ATP11A	0.66	4.99	0.38	1.6e-6	Glycated hemoglobin levels;
PAAD	cis	rs728616	0.867	rs1983776	chr10:81663695	C/T	cg19423196	chr10:82049429	MAT1A	0.59	4.32	0.33	2.76e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.66	5.75	0.42	4.71e-8	Schizophrenia;
PAAD	cis	rs965604	0.965	rs13180	chr15:78789488	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-4.52	-0.34	1.23e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4843185	0.699	rs11865	chr16:85709316	A/G	cg26571870	chr16:85723150	GINS2	-0.46	-5.71	-0.42	5.62e-8	Platelet distribution width;
PAAD	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg26031613	chr14:104095156	KLC1	0.48	4.48	0.34	1.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg08601574	chr20:25228251	PYGB	-0.46	-4.43	-0.34	1.76e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.48	-0.34	1.44e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18920858	chr17:64617748	PRKCA	-0.6	-6.42	-0.46	1.67e-9	Obesity-related traits;
PAAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.13	13.31	0.73	2.71e-27	Cognitive function;
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.16	-0.39	7.56e-7	Body mass index;
PAAD	cis	rs412658	0.504	rs10404322	chr19:22110669	A/G	cg23859931	chr19:22123797	NA	-0.47	-4.8	-0.36	3.75e-6	Telomere length;
PAAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg09226986	chr6:160852328	SLC22A3	-0.48	-4.49	-0.34	1.41e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg17372657	chr7:1216933	NA	-0.37	-4.78	-0.36	4.06e-6	Longevity;Endometriosis;
PAAD	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.78	0.48	2.54e-10	Response to antipsychotic treatment;
PAAD	cis	rs3747547	1.000	rs11788065	chr9:37925826	G/C	cg13774184	chr9:37916125	SHB	-0.66	-4.42	-0.34	1.85e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.93	11.59	0.68	1.18e-22	Pulse pressure;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.72	-7.93	-0.54	4.44e-13	Renal function-related traits (BUN);
PAAD	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.68	5.46	0.41	1.87e-7	Prostate cancer;
PAAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.8	-4.6	-0.35	8.9e-6	Skin colour saturation;
PAAD	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.59	-5.92	-0.43	2.09e-8	Pulmonary function;
PAAD	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.6	6.03	0.44	1.21e-8	Colorectal cancer;
PAAD	cis	rs12311304	0.932	rs12312583	chr12:15371606	A/G	cg08258403	chr12:15378311	NA	0.35	4.41	0.34	1.94e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18402987	chr7:1209562	NA	0.44	4.41	0.34	1.98e-5	Longevity;Endometriosis;
PAAD	cis	rs9315204	0.853	rs520313	chr13:33686575	A/G	cg22534336	chr13:33112922	N4BP2L2	-0.53	-4.27	-0.33	3.43e-5	Intracranial aneurysm;
PAAD	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.93	-9.87	-0.62	4.71e-18	Coronary artery disease;
PAAD	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg14582100	chr15:45693742	SPATA5L1	0.44	6.75	0.48	2.9e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.37	-0.33	2.26e-5	Mean corpuscular volume;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.24	-0.39	5.38e-7	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.71	0.36	5.58e-6	Serum sulfate level;
PAAD	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg10556349	chr10:835070	NA	-0.61	-4.99	-0.38	1.65e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17758439	chr6:99849304	SFRS18	-0.55	-6.52	-0.47	9.93e-10	Energy expenditure (24h);
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.92	9.92	0.63	3.38e-18	Prudent dietary pattern;
PAAD	cis	rs11009175	0.615	rs6481819	chr10:33299459	T/C	cg00146027	chr10:33299147	NA	-0.4	-4.87	-0.37	2.81e-6	Depression (quantitative trait);
PAAD	cis	rs58521262	0.585	rs461390	chr19:23130419	G/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs3781663	0.526	rs6592468	chr11:70019047	G/A	cg11157765	chr11:69982996	ANO1	0.6	5.01	0.38	1.5e-6	Survival in rectal cancer;
PAAD	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.7	7.75	0.53	1.22e-12	Body mass index;
PAAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.86	-5.54	-0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg19090574	chr1:205240910	TMCC2	-0.41	-4.39	-0.34	2.1e-5	Red blood cell count;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.68	0.58	5.77e-15	Corneal astigmatism;
PAAD	cis	rs829661	1.000	rs2593457	chr2:30869144	G/A	cg12454169	chr2:30669597	LCLAT1	0.63	4.69	0.36	6e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.58	-4.75	-0.36	4.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg08057985	chr22:42470123	FAM109B	0.36	4.33	0.33	2.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg09835421	chr16:68378352	PRMT7	-0.7	-5.5	-0.41	1.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	4.49	0.34	1.4e-5	Educational attainment;
PAAD	cis	rs7631605	0.905	rs58129217	chr3:37011624	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11671653	0.688	rs11671888	chr19:10838381	C/T	cg18582342	chr19:11591989	ELAVL3	-0.64	-4.3	-0.33	3.1e-5	LDL cholesterol;
PAAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.49	-0.68	2.25e-22	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15447662	chr7:55979688	ZNF713	-0.71	-7.5	-0.52	4.92e-12	Obesity-related traits;
PAAD	cis	rs6987853	0.731	rs10958717	chr8:42351585	G/C	cg09913449	chr8:42400586	C8orf40	-0.43	-4.54	-0.35	1.14e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.78	-0.42	4.13e-8	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.33	-0.33	2.72e-5	Mood instability;
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.31	0.33	2.96e-5	Menopause (age at onset);
PAAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg00334542	chr7:100209784	MOSPD3	-0.7	-5.3	-0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.94	12.58	0.71	2.46e-25	Menopause (age at onset);
PAAD	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.52	-4.92	-0.37	2.24e-6	Multiple sclerosis;
PAAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg03517284	chr6:25882590	NA	0.55	5.04	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.46	-4.32	-0.33	2.77e-5	Airflow obstruction;
PAAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs76917914	0.589	rs12552242	chr9:100866201	A/C	cg21225548	chr9:100864335	TRIM14	-0.53	-6.01	-0.44	1.34e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-9.57	-0.61	2.78e-17	Gut microbiome composition (summer);
PAAD	trans	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg01620082	chr3:125678407	NA	-1.42	-8.14	-0.55	1.3e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.64	-7.37	-0.51	1.02e-11	Bipolar disorder;
PAAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20242975	chr19:9940709	UBL5	0.7	6.43	0.46	1.58e-9	Neuroticism;
PAAD	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.66	4.61	0.35	8.45e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.7	7.54	0.52	4e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-5.86	-0.43	2.79e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.48	-5.27	-0.39	4.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.95	-0.37	1.93e-6	Fear of minor pain;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12045531	chr12:49259487	RND1	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs4740619	0.619	rs10738428	chr9:16046489	T/C	cg14451791	chr9:16040625	NA	-0.46	-5.19	-0.39	6.54e-7	Body mass index;
PAAD	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.41	5.05	0.38	1.25e-6	Body mass index in non-asthmatics;
PAAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg21994712	chr19:21861136	NA	-0.52	-5.05	-0.38	1.23e-6	Pain;
PAAD	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg14092571	chr14:90743983	NA	0.46	4.6	0.35	8.67e-6	Mortality in heart failure;
PAAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg02117656	chr17:79614917	TSPAN10	-0.58	-6.32	-0.46	2.72e-9	Eye color traits;
PAAD	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-1.05	-18.94	-0.84	7.51e-42	Urate levels in lean individuals;
PAAD	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs11671005	0.656	rs11671092	chr19:59009109	T/C	cg25952890	chr19:58913133	NA	0.65	4.71	0.36	5.43e-6	Mean platelet volume;
PAAD	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.65	-6.86	-0.49	1.6e-10	Post bronchodilator FEV1;
PAAD	cis	rs2997447	0.761	rs2783711	chr1:26428864	G/A	cg24519413	chr1:26490540	NA	0.51	4.58	0.35	9.81e-6	QRS complex (12-leadsum);
PAAD	cis	rs990171	0.913	rs1558627	chr2:102984684	G/A	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs7082209	0.838	rs800332	chr10:44806670	C/A	cg13191911	chr10:44806660	NA	0.84	5.43	0.4	2.19e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-8.83	-0.58	2.37e-15	Morning vs. evening chronotype;
PAAD	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.42	-0.34	1.86e-5	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs13242816	1.000	rs12672717	chr7:116128270	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg10434728	chr15:90938212	IQGAP1	0.44	4.55	0.35	1.08e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg02196730	chr15:80188777	MTHFS	0.49	5.06	0.38	1.2e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg06057569	chr22:50219754	BRD1	0.74	5.62	0.41	8.86e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2882667	0.690	rs4835703	chr5:138150737	T/G	cg09476006	chr5:138032270	NA	-0.45	-5.67	-0.42	7.05e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.28	7.35	0.51	1.15e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs4908768	0.629	rs4908517	chr1:8887005	T/A	cg25722041	chr1:8623473	RERE	0.51	4.43	0.34	1.81e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg22442454	chr1:209979470	IRF6	0.51	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs2834288	0.500	rs881231	chr21:35322829	C/T	cg22542663	chr21:34915757	GART;SON	0.42	4.26	0.33	3.6e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg21994712	chr19:21861136	NA	0.46	4.48	0.34	1.46e-5	Pain;
PAAD	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-6.96	-0.49	9.5e-11	Colorectal cancer;
PAAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg06873352	chr17:61820015	STRADA	-0.7	-7.92	-0.54	4.6e-13	Prudent dietary pattern;
PAAD	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg23719950	chr11:63933701	MACROD1	0.65	4.77	0.36	4.31e-6	Mean platelet volume;
PAAD	cis	rs427941	0.703	rs201435	chr7:101732865	G/C	cg06246474	chr7:101738831	CUX1	0.44	4.47	0.34	1.54e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.7	7.64	0.53	2.3e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7833787	1.000	rs6586778	chr8:18706170	G/C	cg17701159	chr8:18705777	PSD3	-0.45	-5.25	-0.39	5.02e-7	Obesity-related traits;
PAAD	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg12623918	chr2:306882	NA	0.45	4.68	0.35	6.29e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg16558253	chr16:72132732	DHX38	-0.46	-4.71	-0.36	5.53e-6	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.83	8.06	0.55	2.04e-13	Cognitive function;
PAAD	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.98	7.17	0.5	3.08e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg24213567	chr19:53496664	ZNF702P	0.48	5.02	0.38	1.43e-6	Psoriasis;
PAAD	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.37	0.46	2.09e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg03289416	chr15:75166202	SCAMP2	0.57	6.01	0.44	1.31e-8	Breast cancer;
PAAD	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05372578	chr7:8301660	ICA1	0.59	6.73	0.48	3.26e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg09659197	chr4:152720779	NA	0.4	5.41	0.4	2.36e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.28	6.99	0.49	8.08e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg01047959	chr19:17666446	GLT25D1	0.47	4.26	0.33	3.52e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	1.03	6.98	0.49	8.47e-11	IgG glycosylation;
PAAD	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.61	5.83	0.43	3.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.82	9.46	0.61	5.38e-17	Breast cancer;
PAAD	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg03948781	chr1:205179583	DSTYK	0.46	4.27	0.33	3.44e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-11.22	-0.67	1.13e-21	Height;
PAAD	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-1.0	-12.89	-0.72	3.68e-26	Refractive error;
PAAD	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg24519413	chr1:26490540	NA	0.44	5.46	0.4	1.94e-7	Height;
PAAD	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg04154034	chr17:28927549	LRRC37B2	0.69	4.43	0.34	1.82e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg00543991	chr22:32367038	NA	-1.15	-6.98	-0.49	8.71e-11	Childhood ear infection;
PAAD	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26031613	chr14:104095156	KLC1	0.43	4.37	0.33	2.31e-5	Coronary artery disease;
PAAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.4	5.14	0.38	8.22e-7	Colorectal cancer;
PAAD	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.72e-6	Migraine;
PAAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.95	-9.65	-0.62	1.71e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09437909	chr19:58975129	NA	-0.6	-6.63	-0.47	5.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27347003	chr16:28915665	ATP2A1	0.6	6.75	0.48	2.97e-10	Smoking initiation;
PAAD	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg01181863	chr3:195395398	SDHAP2	-0.92	-8.73	-0.58	4.22e-15	Pancreatic cancer;
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg16586182	chr3:47516702	SCAP	-0.71	-8.37	-0.56	3.52e-14	Colorectal cancer;
PAAD	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg07943548	chr15:86304357	KLHL25	-0.65	-5.75	-0.42	4.69e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	5.81	0.43	3.57e-8	Schizophrenia;
PAAD	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg16083429	chr3:49237500	CCDC36	-0.43	-4.27	-0.33	3.45e-5	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.31e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8018808	0.905	rs11159259	chr14:77892393	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23983436	chr11:842963	TSPAN4;POLR2L	0.62	6.98	0.49	8.45e-11	Monocyte percentage of white cells;
PAAD	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.45	-0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg24565620	chr2:194026	NA	-0.63	-5.47	-0.41	1.81e-7	Blood protein levels;
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24940950	chr17:70739702	SLC39A11	0.43	4.59	0.35	9.33e-6	Smoking initiation;
PAAD	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.69	0.53	1.68e-12	IgG glycosylation;
PAAD	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg01812401	chr14:102979275	NA	0.39	4.32	0.33	2.78e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-6.14	-0.45	6.75e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-4.75	-0.36	4.59e-6	Neuroticism;
PAAD	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19904058	chr10:135279010	LOC619207	-0.48	-5.82	-0.43	3.44e-8	Systemic lupus erythematosus;
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.15	0.39	7.96e-7	Prostate cancer;
PAAD	cis	rs30380	0.587	rs469674	chr5:96130015	G/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.24	-0.39	5.35e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs67257959	0.708	rs10406406	chr19:17198073	C/T	cg19418318	chr19:17219073	MYO9B	0.31	4.41	0.34	1.91e-5	Selective IgA deficiency;
PAAD	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg23254163	chr1:152506842	NA	0.6	6.86	0.49	1.62e-10	Hair morphology;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06839777	chr6:122720676	HSF2	0.64	7.24	0.51	2.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.87	-10.77	-0.66	1.91e-20	Bipolar disorder;
PAAD	cis	rs4356203	0.783	rs7113964	chr11:17255921	C/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs72781680	0.533	rs34668726	chr2:23895901	C/G	cg08917208	chr2:24149416	ATAD2B	1.03	8.19	0.55	1.01e-13	Lymphocyte counts;
PAAD	cis	rs4455778	0.580	rs4492325	chr7:49096154	G/A	cg26309511	chr7:48887640	NA	0.37	4.49	0.34	1.38e-5	Lung cancer in never smokers;
PAAD	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.57	-5.2	-0.39	6.35e-7	Diastolic blood pressure;
PAAD	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.46	4.45	0.34	1.68e-5	Pancreatic cancer;
PAAD	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg07617317	chr6:118971624	C6orf204	0.55	4.61	0.35	8.48e-6	Diastolic blood pressure;
PAAD	cis	rs755249	0.567	rs4660751	chr1:39905873	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.68	-0.35	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.54	4.77	0.36	4.2e-6	Lung cancer;
PAAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22601191	chr20:60968625	CABLES2	0.6	5.3	0.39	4.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.81e-7	Bipolar disorder;
PAAD	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-11.72	-0.69	5.28e-23	Height;
PAAD	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg09509183	chr1:209979624	IRF6	0.55	5.34	0.4	3.34e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.73	6.44	0.46	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.26	-0.33	3.54e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.39	-4.57	-0.35	1.01e-5	Pubertal anthropometrics;
PAAD	cis	rs941898	0.781	rs3783336	chr14:100592182	C/T	cg26002632	chr14:100625216	DEGS2	-0.36	-4.84	-0.37	3.1e-6	White matter hyperintensity burden;
PAAD	cis	rs1371614	0.545	rs13035643	chr2:27173341	G/A	cg00617064	chr2:27272375	NA	0.45	4.6	0.35	8.67e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.56	-6.88	-0.49	1.44e-10	Educational attainment;
PAAD	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.98	-8.07	-0.55	1.93e-13	Triglycerides;
PAAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.67	6.15	0.45	6.62e-9	Menarche (age at onset);
PAAD	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg20085588	chr10:81316188	SFTPA2	0.39	4.26	0.33	3.55e-5	Post bronchodilator FEV1;
PAAD	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.73	7.73	0.53	1.33e-12	Blood metabolite levels;
PAAD	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg13263323	chr15:86062960	AKAP13	-0.6	-7.0	-0.49	7.66e-11	Interstitial lung disease;
PAAD	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.44	10.07	0.63	1.37e-18	Opioid sensitivity;
PAAD	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs9535307	0.929	rs1407441	chr13:50290990	T/C	cg03658251	chr13:50265850	EBPL	0.81	5.61	0.41	9.52e-8	Obesity-related traits;
PAAD	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.8e-10	Resting heart rate;
PAAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg27225680	chr17:73760817	GALK1	-0.55	-6.62	-0.47	5.94e-10	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23344964	chr5:83121170	NA	0.54	6.73	0.48	3.29e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.77	8.51	0.57	1.54e-14	Lung cancer;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-5.04	-0.38	1.3e-6	Vitiligo;
PAAD	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg15556689	chr8:8085844	FLJ10661	-0.77	-7.59	-0.52	2.92e-12	Neuroticism;
PAAD	cis	rs6141769	0.542	rs6058845	chr20:31323919	G/T	cg13636640	chr20:31349939	DNMT3B	0.5	4.66	0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs3733346	0.510	rs6815138	chr4:941290	A/C	cg08222618	chr4:941054	TMEM175	0.72	9.17	0.6	3.22e-16	Sjögren's syndrome;
PAAD	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.24	0.39	5.39e-7	Coronary artery disease;
PAAD	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg24739098	chr15:79297159	RASGRF1	0.34	4.3	0.33	3.02e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.54	-4.79	-0.36	3.86e-6	Blood metabolite levels;
PAAD	cis	rs2617583	0.935	rs2975223	chr5:1443603	T/C	cg07151155	chr5:1473589	LPCAT1	-0.49	-4.86	-0.37	2.89e-6	Breast cancer;
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7219021	0.961	rs9901447	chr17:46872346	C/T	cg12314713	chr17:47074576	IGF2BP1	-0.36	-4.45	-0.34	1.66e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.76	0.36	4.52e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs757978	0.777	rs75590598	chr2:242185654	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-4.65	-0.35	7.1e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12599982	chr1:44399894	ARTN	0.44	4.35	0.33	2.52e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg06900676	chr2:61293330	KIAA1841	0.92	6.51	0.47	1.03e-9	Lung function (FEV1/FVC);
PAAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.08	10.12	0.63	9.99e-19	Red blood cell traits;
PAAD	cis	rs12282928	0.917	rs1503175	chr11:48269192	A/G	cg04721828	chr11:48285200	OR4X1	-0.48	-6.07	-0.44	9.67e-9	Migraine - clinic-based;
PAAD	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg25809561	chr17:30822961	MYO1D	-0.45	-4.65	-0.35	7.19e-6	Schizophrenia;
PAAD	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg18548263	chr11:66383669	RBM14	-0.71	-6.49	-0.47	1.15e-9	Blood protein levels;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	10.8	0.66	1.56e-20	Platelet count;
PAAD	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg16558253	chr16:72132732	DHX38	0.42	4.27	0.33	3.41e-5	Prostate cancer;
PAAD	cis	rs939584	0.935	rs6725549	chr2:630323	C/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14180030	chr9:123475675	MEGF9	-0.46	-5.12	-0.38	9.14e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs72960926	1.000	rs56168999	chr6:75121136	A/G	cg13435101	chr6:74171350	MTO1	0.82	4.25	0.33	3.73e-5	Metabolite levels (MHPG);
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.88	10.34	0.64	2.57e-19	Iron status biomarkers;
PAAD	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.88	9.74	0.62	9.98e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-1.17	-9.62	-0.62	2.05e-17	Obesity-related traits;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26839863	chr10:21814793	C10orf140	0.43	4.76	0.36	4.47e-6	Monocyte percentage of white cells;
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.69	-6.71	-0.48	3.64e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.34	0.64	2.62e-19	Cognitive test performance;
PAAD	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg06217071	chr17:408420	NA	0.61	6.69	0.48	4.09e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6681460	1.000	rs6681460	chr1:67123057	C/T	cg02459107	chr1:67143332	SGIP1	-0.76	-7.58	-0.52	3.18e-12	Presence of antiphospholipid antibodies;
PAAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.79	7.86	0.54	6.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs901683	1.000	rs34897497	chr10:46024677	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14213160	chr19:18496259	GDF15	-0.63	-6.56	-0.47	7.93e-10	Obesity-related traits;
PAAD	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	4.68	0.36	6.19e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20740102	chr2:147933072	NA	-0.54	-6.52	-0.47	9.97e-10	Energy expenditure (24h);
PAAD	cis	rs939584	1.000	rs4854348	chr2:647760	A/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs11811982	0.793	rs7535648	chr1:227306556	C/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-5.76	-0.42	4.59e-8	Schizophrenia;
PAAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg16205897	chr5:131564050	P4HA2	0.49	5.46	0.41	1.88e-7	Blood metabolite levels;
PAAD	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.45	-4.44	-0.34	1.73e-5	Type 2 diabetes;
PAAD	cis	rs300774	1.000	rs300774	chr2:112496	G/T	cg23649280	chr2:140451	NA	0.47	4.31	0.33	2.93e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs6066835	0.702	rs6095228	chr20:47279876	A/G	cg18078177	chr20:47281410	PREX1	-0.82	-4.48	-0.34	1.48e-5	Multiple myeloma;
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.76	7.09	0.5	4.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.57	5.66	0.42	7.47e-8	Type 2 diabetes;
PAAD	cis	rs939584	1.000	rs4854345	chr2:638190	C/T	cg14515364	chr2:636606	NA	-0.47	-4.28	-0.33	3.26e-5	Body mass index;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05962325	chr11:107992005	ACAT1	-0.64	-6.29	-0.45	3.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.95	-0.37	1.91e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.44	-4.28	-0.33	3.25e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4774830	0.744	rs62046392	chr15:56312554	C/G	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09065629	chr16:1709722	CRAMP1L	0.49	5.25	0.39	5.15e-7	Coronary artery disease;
PAAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.74	8.77	0.58	3.38e-15	Emphysema distribution in smoking;
PAAD	cis	rs2421770	0.532	rs7105829	chr11:35345626	C/T	cg13971030	chr11:35366721	SLC1A2	0.55	5.22	0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg02877791	chr2:177005403	NA	0.44	4.33	0.33	2.67e-5	IgG glycosylation;
PAAD	cis	rs747650	0.504	rs10838652	chr11:47077837	C/T	cg19486271	chr11:47235900	DDB2	-0.68	-6.29	-0.45	3.26e-9	Acne (severe);
PAAD	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.76e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.7	-6.19	-0.45	5.24e-9	Blood trace element (Zn levels);
PAAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.84e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7998202	0.667	rs2104789	chr13:113365398	G/A	cg02820901	chr13:113351484	ATP11A	0.72	4.84	0.37	3.16e-6	Glycated hemoglobin levels;
PAAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg19192590	chr2:178524533	PDE11A	0.4	4.63	0.35	7.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-1.12	-6.04	-0.44	1.13e-8	Inflammatory biomarkers;
PAAD	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg15764593	chr10:829463	NA	-0.75	-6.07	-0.44	9.67e-9	Uric acid levels;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg20850873	chr3:10149803	C3orf24	0.56	4.42	0.34	1.84e-5	Alzheimer's disease;
PAAD	cis	rs6594713	0.744	rs6874175	chr5:112663398	G/A	cg12552261	chr5:112820674	MCC	0.58	4.82	0.36	3.44e-6	Brain cytoarchitecture;
PAAD	trans	rs350729	0.649	rs62140321	chr2:53174072	A/T	cg24639469	chr1:4837462	AJAP1	0.63	6.37	0.46	2.14e-9	Bronchodilator response in asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24495844	chr11:17411043	KCNJ11	0.56	6.54	0.47	9.01e-10	Monocyte percentage of white cells;
PAAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	6.34	0.46	2.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.68	-8.69	-0.58	5.25e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.57	-0.41	1.15e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs2070677	0.877	rs2987791	chr10:135370060	G/C	cg20169779	chr10:135381914	SYCE1	0.79	7.64	0.53	2.28e-12	Gout;
PAAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	8.63	0.57	7.51e-15	Longevity;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.87	-8.06	-0.55	2.04e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.58	-5.09	-0.38	1.05e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.25	-0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11951515	0.508	rs1366410	chr5:43601610	C/A	cg01983248	chr5:43482804	C5orf28	-0.31	-4.42	-0.34	1.86e-5	Metabolite levels  (X-11787);
PAAD	cis	rs2834188	0.924	rs2850015	chr21:34697264	T/C	cg04842828	chr21:34696676	IFNAR1	0.43	4.25	0.33	3.73e-5	Narcolepsy;
PAAD	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.51	-4.98	-0.37	1.73e-6	Menarche (age at onset);
PAAD	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-4.9	-0.37	2.47e-6	Mood instability;
PAAD	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg20607287	chr7:12443886	VWDE	-0.67	-5.11	-0.38	9.68e-7	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.61	6.42	0.46	1.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg11232448	chr19:2858854	NA	-0.49	-4.86	-0.37	2.86e-6	Total cholesterol levels;
PAAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.9	5.77	0.42	4.25e-8	Diabetic kidney disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27200190	chr17:35766714	ACACA;TADA2A	0.62	7.06	0.5	5.61e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7715811	1.000	rs10039621	chr5:13772457	C/T	cg07548982	chr5:13769939	DNAH5	-0.57	-5.47	-0.41	1.77e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg26205652	chr12:48591994	NA	0.45	4.33	0.33	2.7e-5	Plateletcrit;
PAAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-5.51	-0.41	1.47e-7	Mean corpuscular volume;
PAAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg13266496	chr6:110720918	DDO	-0.44	-4.61	-0.35	8.31e-6	Platelet distribution width;
PAAD	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.54	-6.75	-0.48	2.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7627468	1.000	rs12490055	chr3:121929686	G/A	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg06970076	chr16:1560791	IFT140	0.64	5.7	0.42	6.18e-8	Coronary artery disease;
PAAD	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.69	-6.9	-0.49	1.3e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg26497354	chr6:109612229	NA	0.44	4.76	0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs9907295	0.748	rs4251769	chr17:34164527	C/T	cg16983627	chr17:34238386	NA	-0.56	-4.37	-0.33	2.33e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.7	-5.09	-0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.68	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs4478858	0.647	rs1007013	chr1:31710270	C/T	cg18939081	chr1:31884902	SERINC2	0.48	5.17	0.39	7.29e-7	Alcohol dependence;
PAAD	cis	rs8031584	0.752	rs34722914	chr15:31191991	G/A	cg14829155	chr15:31115871	NA	-0.67	-7.3	-0.51	1.46e-11	Huntington's disease progression;
PAAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.38	-0.4	2.79e-7	Cognitive function;
PAAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.37	-0.33	2.34e-5	Breast cancer;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18621852	chr3:10150065	C3orf24	0.61	5.14	0.38	8.3e-7	Alzheimer's disease;
PAAD	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-4.26	-0.33	3.58e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.38	0.56	3.27e-14	Dupuytren's disease;
PAAD	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.35	-0.33	2.47e-5	Daytime sleep phenotypes;
PAAD	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.71	6.73	0.48	3.27e-10	Parkinson's disease;
PAAD	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.61	-5.27	-0.39	4.59e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg17830980	chr10:43048298	ZNF37B	0.68	8.03	0.55	2.43e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg24053715	chr22:38214548	NA	-0.51	-4.94	-0.37	2.06e-6	Glioblastoma;Glioma;
PAAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.63	0.35	7.84e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7818688	0.697	rs11781397	chr8:95974506	G/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg06131755	chr6:160182447	ACAT2	0.52	4.51	0.34	1.31e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Bladder cancer;
PAAD	cis	rs10214930	0.651	rs42111	chr7:27722581	G/C	cg22168087	chr7:27702803	HIBADH	-0.46	-4.29	-0.33	3.23e-5	Hypospadias;
PAAD	cis	rs59888335	0.858	rs13059315	chr3:80918103	A/T	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.52	-5.93	-0.43	1.94e-8	Total body bone mineral density;
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.48	-0.34	1.44e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.67	-0.53	1.94e-12	Parkinson's disease;
PAAD	cis	rs9815354	0.903	rs7373694	chr3:42012719	G/A	cg03022575	chr3:42003672	ULK4	-0.73	-5.38	-0.4	2.76e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	6.3	0.45	3.12e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg27490568	chr2:178487706	NA	0.41	4.4	0.34	2.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs17014483	0.822	rs3017895	chr4:89649491	C/T	cg04308882	chr22:32368489	NA	-0.94	-6.3	-0.46	3.02e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.51	6.11	0.44	8.19e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.57	-0.35	1.01e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.6	6.02	0.44	1.28e-8	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07752472	chr3:136471634	STAG1	-0.63	-6.41	-0.46	1.75e-9	Smoking initiation;
PAAD	cis	rs55728055	0.661	rs75785548	chr22:31991363	C/T	cg01338084	chr22:32026380	PISD	1.61	8.57	0.57	1.12e-14	Age-related hearing impairment;
PAAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.92	9.04	0.59	6.86e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Vitiligo;
PAAD	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg25838818	chr2:108905173	SULT1C2	-0.6	-5.75	-0.42	4.72e-8	Lobe size;
PAAD	cis	rs11051970	0.546	rs11051989	chr12:32560890	A/G	cg24626660	chr12:32551988	NA	0.43	4.63	0.35	7.74e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg05309399	chr4:106552544	FLJ20184	0.54	4.29	0.33	3.16e-5	Post bronchodilator FEV1;
PAAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.85	-0.37	3.07e-6	Depression;
PAAD	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.52	-4.25	-0.33	3.68e-5	Body mass index;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.86	5.93	0.43	1.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2290416	0.892	rs2278898	chr8:144691512	G/C	cg13191508	chr8:144600686	ZC3H3	-0.9	-4.87	-0.37	2.82e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.57	7.12	0.5	3.95e-11	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.55	-5.01	-0.38	1.51e-6	Testicular germ cell tumor;
PAAD	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.71	7.65	0.53	2.19e-12	Cognitive function;
PAAD	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.36	4.35	0.33	2.49e-5	Electrocardiographic conduction measures;
PAAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6681460	0.576	rs6588203	chr1:66990851	C/T	cg02459107	chr1:67143332	SGIP1	0.51	4.49	0.34	1.41e-5	Presence of antiphospholipid antibodies;
PAAD	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg01851573	chr8:8652454	MFHAS1	-0.45	-4.59	-0.35	9.07e-6	Mood instability;
PAAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.61	0.57	8.41e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.85	7.17	0.5	3.02e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6688613	1.000	rs6699159	chr1:166946072	T/C	cg07049167	chr1:166818506	POGK	0.48	4.79	0.36	3.92e-6	Refractive astigmatism;
PAAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.09e-5	Renal cell carcinoma;
PAAD	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg06307176	chr5:131281290	NA	-0.54	-4.7	-0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.68e-5	Skin colour saturation;
PAAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.35	15.11	0.77	4.39e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs7816613	0.920	rs4734582	chr8:102702607	A/C	cg20585841	chr8:102729926	NCALD	0.69	6.58	0.47	7.16e-10	Age-related hearing impairment;
PAAD	cis	rs6908034	0.882	rs6456259	chr6:19761718	A/G	cg02682789	chr6:19804855	NA	0.64	4.56	0.35	1.04e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs4077515	0.806	rs11145839	chr9:139285137	A/C	cg14169450	chr9:139327907	INPP5E	0.56	5.74	0.42	4.9e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3806308	0.900	rs3820333	chr1:20142270	G/A	cg13843611	chr1:20143089	RNF186	0.53	5.41	0.4	2.43e-7	Ulcerative colitis;
PAAD	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.84	6.45	0.46	1.44e-9	Axial length;
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.55	5.46	0.4	1.94e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.52	-5.05	-0.38	1.25e-6	Breast cancer;
PAAD	cis	rs30380	0.632	rs26496	chr5:96137882	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.22	-0.39	5.87e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.46	4.26	0.33	3.56e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12826942	0.959	rs34507359	chr12:42736831	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	4.95	0.37	1.95e-6	Coronary artery disease;
PAAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg00450029	chr8:599525	NA	0.86	6.17	0.45	5.9e-9	IgG glycosylation;
PAAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg05785598	chr3:49045655	WDR6	-0.41	-4.84	-0.37	3.16e-6	Parkinson's disease;
PAAD	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg13263323	chr15:86062960	AKAP13	-0.61	-6.87	-0.49	1.51e-10	Coronary artery disease;
PAAD	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg10437265	chr15:77819839	NA	0.42	4.8	0.36	3.72e-6	Type 2 diabetes;
PAAD	cis	rs288342	0.832	rs288306	chr2:183652286	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.62	-0.35	8.18e-6	Recurrent major depressive disorder;
PAAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg17845761	chr1:175162550	KIAA0040	-0.28	-4.28	-0.33	3.35e-5	Alcohol dependence;
PAAD	cis	rs2412488	1.000	rs17082782	chr4:54306440	A/T	cg19408398	chr4:54243328	FIP1L1	-0.5	-4.37	-0.33	2.3e-5	DNA methylation (variation);
PAAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.7	7.38	0.51	9.46e-12	Colorectal cancer;
PAAD	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9462027	1.000	rs6457796	chr6:34828553	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-4.73	-0.36	5.01e-6	Systemic lupus erythematosus;
PAAD	cis	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.89e-7	HDL cholesterol;
PAAD	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.82	9.85	0.62	5.19e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.42	-4.46	-0.34	1.58e-5	Breast cancer;
PAAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-14.77	-0.77	3.61e-31	Coronary artery disease;
PAAD	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg05872129	chr22:39784769	NA	0.68	5.23	0.39	5.47e-7	IgG glycosylation;
PAAD	cis	rs990171	1.000	rs2272129	chr2:103040249	C/T	cg03938978	chr2:103052716	IL18RAP	0.44	4.3	0.33	3.09e-5	Lymphocyte counts;
PAAD	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg06775570	chr1:201857621	SHISA4	-0.39	-4.36	-0.33	2.41e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg17372223	chr3:52568218	NT5DC2	0.56	5.43	0.4	2.18e-7	Bipolar disorder;
PAAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.73	-8.54	-0.57	1.26e-14	Eye color traits;
PAAD	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.93	10.98	0.67	5.11e-21	IgG glycosylation;
PAAD	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26926768	chr12:34528122	NA	0.39	4.63	0.35	7.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg14003231	chr6:33640908	ITPR3	0.35	4.44	0.34	1.69e-5	Plateletcrit;
PAAD	cis	rs2152924	0.539	rs1765756	chr1:110007652	G/A	cg08704217	chr1:110036942	CYB561D1	-0.56	-4.7	-0.36	5.66e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7580717	0.529	rs6739959	chr2:232048319	G/A	cg07929768	chr2:232055508	NA	0.36	4.26	0.33	3.61e-5	Multiple myeloma;
PAAD	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	1.13	6.36	0.46	2.25e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg15847926	chr7:2749597	AMZ1	-0.39	-4.8	-0.36	3.81e-6	Height;
PAAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.83	0.66	1.26e-20	Homoarginine levels;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.66	-0.35	7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.95	0.37	1.93e-6	Depression;
PAAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.71	6.34	0.46	2.55e-9	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg00543991	chr22:32367038	NA	1.18	7.2	0.5	2.62e-11	Childhood ear infection;
PAAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.36	-0.33	2.4e-5	Post bronchodilator FEV1;
PAAD	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.13	-0.5	3.74e-11	Schizophrenia;
PAAD	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.48	-5.08	-0.38	1.08e-6	Platelet count;
PAAD	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg12447832	chr2:3383257	TTC15	-0.35	-4.33	-0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.93	7.71	0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg05577437	chr8:1586825	DLGAP2	0.39	4.42	0.34	1.89e-5	Systolic blood pressure;
PAAD	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.44	-0.34	1.7e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9815354	1.000	rs4408846	chr3:41753679	A/G	cg03022575	chr3:42003672	ULK4	0.84	6.09	0.44	8.73e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6976053	0.935	rs4727470	chr7:100509201	A/G	cg22425096	chr7:100417404	EPHB4	0.51	4.36	0.33	2.37e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs10878977	0.542	rs12368608	chr12:69814447	C/G	cg13322954	chr12:69198953	NA	0.68	4.32	0.33	2.79e-5	Colorectal cancer;
PAAD	cis	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg21775007	chr8:11205619	TDH	-0.47	-4.35	-0.33	2.47e-5	Neuroticism;
PAAD	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.77e-7	Carotid intima media thickness;
PAAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.74	-6.1	-0.44	8.41e-9	Inflammatory skin disease;
PAAD	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.87	11.83	0.69	2.7e-23	Metabolite levels;
PAAD	cis	rs62400317	0.701	rs12195339	chr6:44796179	T/C	cg20913747	chr6:44695427	NA	-0.61	-5.64	-0.42	7.95e-8	Total body bone mineral density;
PAAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg10705379	chr10:99080932	FRAT1	-0.46	-5.28	-0.39	4.47e-7	Monocyte count;
PAAD	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.55	4.44	0.34	1.76e-5	Blood protein levels;
PAAD	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.8	0.53	8.96e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.49	-5.35	-0.4	3.12e-7	Age of smoking initiation;
PAAD	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.61	6.34	0.46	2.48e-9	Body mass index;
PAAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.9	12.77	0.72	7.7e-26	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg11494091	chr17:61959527	GH2	-0.93	-12.06	-0.7	6.27e-24	Prudent dietary pattern;
PAAD	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.86	9.96	0.63	2.75e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg16306870	chr3:194868790	C3orf21	0.42	4.34	0.33	2.56e-5	Non-small cell lung cancer;
PAAD	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.82	9.88	0.63	4.35e-18	Bladder cancer;
PAAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.68	-6.54	-0.47	8.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs761746	0.960	rs5753733	chr22:32027922	A/G	cg01338084	chr22:32026380	PISD	0.5	4.41	0.34	1.91e-5	Intelligence;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.36	3.3e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14169450	chr9:139327907	INPP5E	0.57	5.86	0.43	2.73e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.51	5.53	0.41	1.37e-7	Dementia with Lewy bodies;
PAAD	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.21	0.39	5.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.16	14.37	0.76	4.08e-30	Schizophrenia;
PAAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg23283495	chr1:209979779	IRF6	0.8	7.4	0.51	8.82e-12	Coronary artery disease;
PAAD	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg05805236	chr11:65401703	PCNXL3	0.53	5.48	0.41	1.7e-7	Acne (severe);
PAAD	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	4.42	0.34	1.87e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs939584	1.000	rs7570232	chr2:621185	T/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.76	7.98	0.54	3.38e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7551222	0.613	rs10900592	chr1:204460681	T/C	cg01064725	chr1:204461714	NA	-0.5	-4.38	-0.33	2.23e-5	Schizophrenia;
PAAD	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg03568305	chr17:38183559	MED24;SNORD124	0.36	4.79	0.36	4.01e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.04	0.38	1.31e-6	Childhood ear infection;
PAAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.44	4.45	0.34	1.62e-5	Coronary artery disease;
PAAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.77	7.51	0.52	4.75e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.37	-5.77	-0.42	4.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.67	6.67	0.48	4.37e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg24154853	chr7:158122151	PTPRN2	0.69	7.13	0.5	3.72e-11	Calcium levels;
PAAD	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.49	-0.65	1.07e-19	Breast cancer;
PAAD	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg17385448	chr1:15911702	AGMAT	0.36	4.29	0.33	3.22e-5	Systolic blood pressure;
PAAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.71	7.71	0.53	1.53e-12	Longevity;
PAAD	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.87	-10.84	-0.66	1.25e-20	Body mass index;
PAAD	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg15145965	chr22:50218605	BRD1	0.58	4.95	0.37	1.96e-6	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs990171	0.837	rs1568681	chr2:103014696	C/T	cg03938978	chr2:103052716	IL18RAP	0.44	4.36	0.33	2.41e-5	Lymphocyte counts;
PAAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.69	0.42	6.25e-8	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27474095	chr4:85594115	WDFY3	-0.63	-6.49	-0.47	1.15e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg04154034	chr17:28927549	LRRC37B2	-0.66	-4.79	-0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs988913	1.000	rs6922438	chr6:54841383	A/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.81	-0.36	3.62e-6	Menarche (age at onset);
PAAD	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg10578991	chr7:12443926	VWDE	-0.5	-4.32	-0.33	2.77e-5	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.4	-0.4	2.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.39	5.76	0.42	4.62e-8	Educational attainment (years of education);
PAAD	cis	rs2278796	1.000	rs2278796	chr1:204951209	C/T	cg17947172	chr1:204966197	NFASC	0.41	4.59	0.35	9.39e-6	Mean platelet volume;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.7	7.28	0.51	1.71e-11	Monocyte count;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.73	7.58	0.52	3.18e-12	Height;
PAAD	cis	rs58521262	0.556	rs289347	chr19:23147938	A/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.26e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.85	11.05	0.67	3.29e-21	Vitiligo;
PAAD	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.81	-5.03	-0.38	1.34e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg23601416	chr22:19950040	COMT	-0.3	-4.64	-0.35	7.52e-6	Blood metabolite levels;
PAAD	cis	rs7172689	0.908	rs58076056	chr15:81567576	G/A	cg05624577	chr15:81411055	NA	-0.57	-4.32	-0.33	2.77e-5	Inattentive symptoms;
PAAD	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3106136	0.843	rs724260	chr4:95260685	A/G	cg11021082	chr4:95130006	SMARCAD1	0.63	6.07	0.44	9.71e-9	Capecitabine sensitivity;
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.59	6.68	0.48	4.34e-10	Prostate cancer;
PAAD	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.01	-0.7	8.69e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg04398451	chr17:18023971	MYO15A	0.62	5.93	0.43	1.95e-8	Body mass index;
PAAD	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg05697835	chr1:2722811	NA	0.43	4.92	0.37	2.22e-6	Ulcerative colitis;
PAAD	cis	rs9581857	0.512	rs9581874	chr13:28086956	A/G	cg22138327	chr13:27999177	GTF3A	0.83	5.45	0.4	2.01e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.69	7.59	0.52	2.98e-12	Aortic root size;
PAAD	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.43	-0.4	2.14e-7	Total body bone mineral density;
PAAD	cis	rs3784262	0.528	rs11071367	chr15:58354152	G/A	cg12031962	chr15:58353849	ALDH1A2	0.41	4.92	0.37	2.2e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs11203032	0.831	rs10887932	chr10:90966996	C/G	cg16672925	chr10:90967113	CH25H	0.79	6.26	0.45	3.73e-9	Heart failure;
PAAD	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg01475377	chr6:109611718	NA	-0.46	-5.16	-0.39	7.59e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.77	5.87	0.43	2.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-7.13	-0.5	3.88e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg16386425	chr10:429943	DIP2C	-0.56	-5.71	-0.42	5.89e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg20487152	chr13:99095054	FARP1	0.64	5.79	0.43	3.82e-8	Neuroticism;
PAAD	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.82	-0.84	1.55e-41	Ulcerative colitis;
PAAD	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.82	5.49	0.41	1.65e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.49	5.13	0.38	8.74e-7	Male-pattern baldness;
PAAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg13722127	chr7:150037890	RARRES2	0.55	5.35	0.4	3.13e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.62	-0.41	9.09e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.89	-6.97	-0.49	9.14e-11	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07904983	chr20:17511988	BFSP1	-0.67	-6.61	-0.47	6.09e-10	Smoking initiation;
PAAD	cis	rs3764563	0.935	rs667386	chr19:15695617	T/C	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.49	4.71	0.36	5.5e-6	Hip circumference;
PAAD	cis	rs7084921	0.552	rs2862990	chr10:101876364	A/G	cg04359915	chr10:101825029	CPN1	0.28	4.37	0.33	2.3e-5	Bone mineral density;
PAAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.28	-0.39	4.49e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.87	4.71	0.36	5.5e-6	Childhood ear infection;
PAAD	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.98	10.29	0.64	3.62e-19	Platelet distribution width;
PAAD	cis	rs6558530	0.579	rs6558528	chr8:1703063	C/T	cg08198773	chr8:1697536	NA	0.43	4.78	0.36	4.11e-6	Systolic blood pressure;
PAAD	cis	rs910187	0.571	rs3746490	chr20:45801712	G/A	cg27589058	chr20:45804311	EYA2	-0.47	-4.97	-0.37	1.78e-6	Migraine;
PAAD	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.48	-4.57	-0.35	9.91e-6	Mean platelet volume;
PAAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.64	0.62	1.9e-17	Total body bone mineral density;
PAAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg20243544	chr17:37824526	PNMT	0.54	4.39	0.34	2.11e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg01181863	chr3:195395398	SDHAP2	-0.95	-9.13	-0.59	4.09e-16	Pancreatic cancer;
PAAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg13770153	chr20:60521292	NA	-0.46	-4.37	-0.33	2.33e-5	Body mass index;
PAAD	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.6	0.41	9.93e-8	Bipolar disorder;
PAAD	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.03	11.94	0.7	1.37e-23	Breast cancer;
PAAD	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg20243544	chr17:37824526	PNMT	0.53	4.53	0.35	1.18e-5	Self-reported allergy;
PAAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.52	-0.34	1.25e-5	Obesity-related traits;
PAAD	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg11673840	chr17:47092156	IGF2BP1	0.55	6.7	0.48	3.81e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.01	-0.54	2.75e-13	Brugada syndrome;
PAAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-4.66	-0.35	6.72e-6	Mean corpuscular volume;
PAAD	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg04877966	chr15:75135169	ULK3	0.54	4.7	0.36	5.74e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.78	5.84	0.43	3.11e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg09659197	chr4:152720779	NA	0.46	6.27	0.45	3.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.49	5.31	0.4	3.82e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg23335576	chr14:104009727	NA	-0.77	-7.0	-0.49	7.75e-11	Bone mineral density;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg12799086	chr7:99724835	MBLAC1	-0.59	-6.77	-0.48	2.6200000000000003e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4281086	0.965	rs4473997	chr8:10372248	C/T	cg01072821	chr8:10382165	T-SP1	-0.45	-4.29	-0.33	3.16e-5	Obesity-related traits;
PAAD	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.66	6.36	0.46	2.23e-9	Asthma;
PAAD	trans	rs12127679	0.614	rs12067035	chr1:244171584	G/A	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19346786	chr7:2764209	NA	-0.35	-5.0	-0.38	1.53e-6	Height;
PAAD	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.54	0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg22189786	chr22:42395067	WBP2NL	0.4	4.29	0.33	3.2e-5	Cognitive function;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.83	8.7	0.58	5.16e-15	Prudent dietary pattern;
PAAD	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.59	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.78	6.33	0.46	2.61e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg01064725	chr1:204461714	NA	-0.51	-4.86	-0.37	2.94e-6	Schizophrenia;
PAAD	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg04450456	chr4:17643702	FAM184B	0.47	4.64	0.35	7.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg14345882	chr6:26364793	BTN3A2	0.56	4.97	0.37	1.82e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs939584	0.935	rs12714413	chr2:642253	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg19163074	chr7:65112434	INTS4L2	0.48	4.47	0.34	1.53e-5	Aortic root size;
PAAD	cis	rs8176704	0.702	rs11244086	chr9:136191787	A/G	cg24267699	chr9:136151359	ABO	0.83	4.6	0.35	8.94e-6	Coagulation factor levels;Low vWF levels;
PAAD	cis	rs35785195	0.593	rs35746281	chr12:114236586	C/T	cg08193681	chr12:114234200	NA	0.56	4.38	0.33	2.18e-5	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg05313129	chr8:58192883	C8orf71	-0.63	-5.28	-0.39	4.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.76	7.67	0.53	1.93e-12	Colorectal cancer;
PAAD	cis	rs11076805	0.529	rs450054	chr16:4148689	A/G	cg01959050	chr16:4170088	NA	0.53	5.14	0.39	8.18e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.4	-5.01	-0.38	1.51e-6	Corneal astigmatism;
PAAD	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.67	-7.78	-0.53	1.05e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg23750338	chr8:142222470	SLC45A4	0.57	6.33	0.46	2.61e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg14146966	chr2:61757674	XPO1	-0.37	-4.69	-0.36	6.02e-6	Tuberculosis;
PAAD	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg12568669	chr8:11666485	FDFT1	-0.3	-4.77	-0.36	4.21e-6	Retinal vascular caliber;
PAAD	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.7	-6.14	-0.45	7.04e-9	Triglycerides;
PAAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs28647808	1.000	rs4962145	chr9:136275188	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-0.67	-8.86	-0.58	1.99e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.52	-0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg13844237	chr9:128284824	MAPKAP1	-0.37	-4.4	-0.34	2.06e-5	Mean arterial pressure;
PAAD	cis	rs10878977	0.542	rs11177653	chr12:69802927	C/T	cg13322954	chr12:69198953	NA	0.62	4.3	0.33	3.02e-5	Colorectal cancer;
PAAD	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.44	-4.81	-0.36	3.53e-6	Pneumonia;
PAAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs17641971	0.684	rs12680366	chr8:49930674	T/C	cg00325661	chr8:49890786	NA	0.48	4.71	0.36	5.58e-6	Blood metabolite levels;
PAAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg21496419	chr19:44306685	LYPD5	0.39	4.98	0.37	1.7e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.56	-5.65	-0.42	7.7e-8	Multiple myeloma;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.76	9.17	0.6	3.11e-16	Vitiligo;
PAAD	cis	rs2271001	0.910	rs1546327	chr11:19139622	G/C	cg00161556	chr11:19138045	ZDHHC13	0.53	5.86	0.43	2.83e-8	Gut microbiome composition (winter);
PAAD	cis	rs34779708	0.771	rs3867218	chr10:35527543	T/C	cg03585969	chr10:35415529	CREM	0.52	4.89	0.37	2.49e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg03999872	chr20:62272968	STMN3	0.48	4.37	0.33	2.31e-5	Prostate cancer;
PAAD	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.84	7.47	0.52	6e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs7568458	0.783	rs7591175	chr2:85738374	G/T	cg17127132	chr2:85788382	GGCX	0.46	4.48	0.34	1.46e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg21181453	chr9:130700954	DPM2	0.41	4.56	0.35	1.05e-5	Glaucoma (primary angle closure);
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg17633681	chr16:88106987	BANP	0.6	7.25	0.51	1.96e-11	Menopause (age at onset);
PAAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg02574844	chr11:5959923	NA	-0.68	-6.24	-0.45	4.12e-9	DNA methylation (variation);
PAAD	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg20913747	chr6:44695427	NA	-0.7	-7.01	-0.49	7.21e-11	Total body bone mineral density;
PAAD	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-5.09	-0.38	1.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.66	-6.2	-0.45	5.04e-9	Fractional excretion of uric acid;
PAAD	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.51	5.08	0.38	1.11e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg17385448	chr1:15911702	AGMAT	0.37	4.34	0.33	2.61e-5	Systolic blood pressure;
PAAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs8396	1.000	rs8396	chr4:159630817	C/T	cg11637968	chr4:159732036	FNIP2	0.28	4.41	0.34	1.92e-5	Acylcarnitine levels;Blood metabolite levels;Blood protein levels;Metabolic traits;Metabolite levels;
PAAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.41	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.49	5.65	0.42	7.7e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs61542988	0.570	rs62448268	chr7:22829464	G/A	cg11367502	chr7:22862612	TOMM7	0.6	5.66	0.42	7.22e-8	Fibrinogen levels;
PAAD	cis	rs7742824	0.917	rs2015676	chr6:44075124	G/A	cg21657043	chr6:44035552	NA	0.44	4.78	0.36	4.03e-6	Major depressive disorder;
PAAD	cis	rs377457	1.000	rs4843575	chr16:85735642	G/A	cg07784872	chr16:85687041	KIAA0182	-0.76	-7.76	-0.53	1.14e-12	Type 2 diabetes;
PAAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.13	-0.45	7.25e-9	Type 2 diabetes;
PAAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.78	6.75	0.48	2.97e-10	Cisplatin-induced ototoxicity;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg16590910	chr6:42928470	GNMT	0.54	5.34	0.4	3.29e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11638815	0.626	rs1313492	chr15:83272955	A/G	cg00614314	chr15:82944287	LOC80154	0.48	4.78	0.36	4.13e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg09582351	chr12:29534625	ERGIC2	-0.32	-4.44	-0.34	1.72e-5	QT interval;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.67	7.58	0.52	3.19e-12	Menarche (age at onset);
PAAD	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.66	-6.75	-0.48	2.93e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19346786	chr7:2764209	NA	-0.4	-4.78	-0.36	4.05e-6	Height;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2412208	0.785	rs6690584	chr1:7078434	G/T	cg26570804	chr1:6352357	ACOT7	-0.48	-4.3	-0.33	3.02e-5	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.65	-4.88	-0.37	2.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs713477	0.505	rs4901561	chr14:55888578	T/C	cg13175173	chr14:55914753	NA	-0.37	-4.76	-0.36	4.54e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.55	-5.05	-0.38	1.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.5	-0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg23346134	chr3:49453900	TCTA	0.44	4.44	0.34	1.75e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	4.41	0.34	1.94e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.63e-6	Height;
PAAD	cis	rs6804624	0.676	rs2670332	chr3:99160639	C/T	cg02646433	chr3:99218170	NA	0.42	4.35	0.33	2.5e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs4356203	0.870	rs7935219	chr11:17168187	G/C	cg15432903	chr11:17409602	KCNJ11	0.41	4.26	0.33	3.57e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg14829360	chr17:73884958	NA	-0.66	-5.86	-0.43	2.83e-8	Psoriasis;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.52	5.34	0.4	3.35e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg19223190	chr17:80058835	NA	0.52	5.34	0.4	3.31e-7	Life satisfaction;
PAAD	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.6	-6.27	-0.45	3.55e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg03732007	chr1:2071316	PRKCZ	-0.48	-5.12	-0.38	8.95e-7	Height;
PAAD	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.53	5.14	0.38	8.37e-7	Rheumatoid arthritis;
PAAD	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.57	-0.52	3.28e-12	Diastolic blood pressure;
PAAD	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9810890	1.000	rs73196996	chr3:128458416	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.55	-4.99	-0.38	1.61e-6	White blood cell count;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.86	0.43	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg06569542	chr10:98946673	SLIT1	0.5	5.06	0.38	1.2e-6	Monocyte count;
PAAD	cis	rs62247992	0.698	rs11707725	chr3:43123393	G/C	cg12239580	chr3:43073058	FAM198A	0.43	4.27	0.33	3.42e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.49	5.42	0.4	2.32e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs72960926	1.000	rs11751225	chr6:75138754	T/C	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.79	6.68	0.48	4.21e-10	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.77	0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.65	6.33	0.46	2.59e-9	White matter hyperintensity burden;
PAAD	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.42	-5.14	-0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.44	-4.26	-0.33	3.56e-5	Monobrow;
PAAD	cis	rs1351164	0.947	rs57004880	chr2:218272581	A/C	cg15335768	chr2:218268053	DIRC3	-0.47	-5.28	-0.39	4.31e-7	Height;
PAAD	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14685355	chr22:22090132	YPEL1	0.59	7.45	0.52	6.45e-12	Monocyte percentage of white cells;
PAAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.86	-0.37	2.91e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2016586	0.860	rs5755920	chr22:36103270	G/C	cg26342177	chr22:36113512	APOL5	-0.42	-4.36	-0.33	2.42e-5	Body mass index;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.54	-6.76	-0.48	2.76e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2526932	0.625	rs2526904	chr14:73049848	G/A	cg13588403	chr14:73209128	DPF3	-0.41	-5.43	-0.4	2.22e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.76	-0.36	4.43e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg18964960	chr10:1102726	WDR37	0.6	4.25	0.33	3.75e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg13722127	chr7:150037890	RARRES2	0.61	6.18	0.45	5.5e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-7.75	-0.53	1.24e-12	Monocyte percentage of white cells;
PAAD	cis	rs210138	1.000	rs210137	chr6:33542478	C/T	cg04201373	chr6:33551533	GGNBP1	0.62	4.88	0.37	2.67e-6	Testicular germ cell tumor;
PAAD	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.48	-5.52	-0.41	1.4e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8060686	0.764	rs73599521	chr16:67733322	G/A	cg05110241	chr16:68378359	PRMT7	-0.96	-5.45	-0.4	1.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12376770	chr5:133512872	SKP1	0.61	6.53	0.47	9.43e-10	Myopia (pathological);
PAAD	cis	rs72960926	0.744	rs72969227	chr6:75055450	C/T	cg13997649	chr6:74171430	MTO1	0.77	4.31	0.33	2.9e-5	Metabolite levels (MHPG);
PAAD	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.07	7.05	0.5	5.71e-11	Body mass index;
PAAD	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.85	0.49	1.72e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg16444942	chr12:129309117	SLC15A4	-0.7	-4.26	-0.33	3.53e-5	Systemic lupus erythematosus;
PAAD	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg11262906	chr1:85462892	MCOLN2	0.61	4.85	0.37	2.98e-6	Serum sulfate level;
PAAD	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg26205652	chr12:48591994	NA	0.96	9.64	0.62	1.86e-17	Longevity (90 years and older);
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg19429281	chr19:53496738	ZNF702P	-0.61	-6.41	-0.46	1.73e-9	Psoriasis;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs7804356	0.651	rs17372780	chr7:26804018	C/G	cg03456212	chr7:26904342	SKAP2	0.57	4.94	0.37	1.99e-6	Type 1 diabetes;
PAAD	cis	rs7714584	1.000	rs4958426	chr5:150278346	A/C	cg22134413	chr5:150180641	NA	1.04	6.64	0.47	5.2400000000000005e-10	Crohn's disease;
PAAD	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	7.63	0.53	2.35e-12	Hemoglobin concentration;
PAAD	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.53	-5.82	-0.43	3.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.62	-8.36	-0.56	3.78e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.67	6.76	0.48	2.82e-10	Orofacial clefts;
PAAD	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.62	-5.62	-0.41	9.06e-8	Cognitive test performance;
PAAD	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.89	0.66	9.1e-21	Menopause (age at onset);
PAAD	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.56	4.79	0.36	4.01e-6	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs6789094	chr3:128591267	G/C	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg26708280	chr2:190649305	PMS1;ORMDL1	0.6	6.91	0.49	1.23e-10	Metabolite levels  (X-11787);
PAAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.74	0.48	3.11e-10	Schizophrenia;
PAAD	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-1.03	-6.99	-0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg14329783	chr7:75779857	NA	0.78	4.59	0.35	9.16e-6	Mononucleosis;
PAAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg03684893	chr10:554711	DIP2C	-0.44	-4.66	-0.35	6.74e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg10223061	chr2:219282414	VIL1	0.44	4.67	0.35	6.66e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03092607	chr2:96068514	FAHD2A	0.55	6.32	0.46	2.78e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs73082363	0.786	rs3172494	chr3:48731487	G/T	cg19401529	chr3:49056140	DALRD3	0.93	5.27	0.39	4.66e-7	Coronary artery disease;
PAAD	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg24623649	chr8:11872141	NA	-0.47	-4.54	-0.35	1.12e-5	Monocyte count;
PAAD	cis	rs6076065	0.632	rs9753757	chr20:23412856	A/T	cg11657817	chr20:23433608	CST11	0.44	4.27	0.33	3.43e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6142102	0.961	rs2268089	chr20:32667298	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	4.8	0.36	3.78e-6	Skin pigmentation;
PAAD	cis	rs4427176	0.765	rs10095667	chr8:9615019	G/T	cg03024720	chr8:9765601	NA	-0.47	-4.39	-0.34	2.07e-5	Mosquito bite size;
PAAD	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg10396713	chr8:602097	NA	-0.66	-4.45	-0.34	1.64e-5	IgG glycosylation;
PAAD	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.75	7.5	0.52	4.82e-12	Corneal astigmatism;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs7071247	0.915	rs10883875	chr10:105259917	T/C	cg14553436	chr10:104822996	CNNM2	0.65	4.52	0.34	1.21e-5	Platelet aggregation;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg19413350	chr8:57351067	NA	-0.46	-4.34	-0.33	2.56e-5	Obesity-related traits;
PAAD	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.91	-9.8	-0.62	7.25e-18	Cognitive function;
PAAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13490635	chr8:30242021	RBPMS	0.4	4.47	0.34	1.54e-5	Metabolite levels  (X-11787);
PAAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.52	5.18	0.39	7.02e-7	Platelet count;
PAAD	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg10985347	chr2:127963512	CYP27C1	0.45	4.5	0.34	1.34e-5	Protein C levels;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	trans	rs60280813	0.702	rs7914222	chr10:99666275	C/T	cg07859640	chr5:140480507	PCDHB3	-1.07	-6.39	-0.46	1.92e-9	Lung cancer in never smokers;
PAAD	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg23093090	chr10:104574429	C10orf26	-0.46	-5.09	-0.38	1.05e-6	Waist circumference;Hip circumference;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26908755	chr19:8373137	CD320	-0.72	-7.93	-0.54	4.43e-13	Smoking initiation;
PAAD	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4751058	0.526	rs10764842	chr10:130861658	A/C	cg27413539	chr10:131576096	NA	0.56	5.6	0.41	1e-7	Vitamin D levels;
PAAD	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-1.1	-5.75	-0.42	4.72e-8	Inflammatory biomarkers;
PAAD	cis	rs28489187	0.706	rs2300637	chr1:85822772	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg14349672	chr11:133703707	NA	-0.47	-5.01	-0.38	1.48e-6	Childhood ear infection;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg27382599	chr21:38445384	PIGP;TTC3	0.55	6.45	0.46	1.38e-9	Immature fraction of reticulocytes;
PAAD	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg05935833	chr10:81318306	SFTPA2	-0.52	-4.27	-0.33	3.48e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.43	0.4	2.23e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg09913449	chr8:42400586	C8orf40	-0.43	-4.63	-0.35	7.65e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1468333	1.000	rs2057831	chr5:137535133	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.3	0.45	3.07e-9	Resting heart rate;
PAAD	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.1	9.41	0.61	7.47e-17	Red blood cell traits;
PAAD	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.45	5.34	0.4	3.3e-7	Immature fraction of reticulocytes;
PAAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg06375148	chr1:209958343	C1orf74	-0.63	-4.55	-0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.68	0.36	6.23e-6	Neuroticism;
PAAD	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.94	-0.37	2e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.84	-4.46	-0.34	1.61e-5	Plasma clusterin levels;
PAAD	cis	rs8060686	0.641	rs77996485	chr16:68137420	C/G	cg09835421	chr16:68378352	PRMT7	-1.1	-6.35	-0.46	2.33e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg21581312	chr15:35529473	LOC723972	-0.6	-6.71	-0.48	3.59e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg09597638	chr17:3907349	NA	0.71	7.46	0.52	6.32e-12	Type 2 diabetes;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.64	-8.12	-0.55	1.52e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.47	4.35	0.33	2.46e-5	White matter hyperintensity burden;
PAAD	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg00125455	chr20:44574271	PCIF1	0.42	4.34	0.33	2.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	5.42	0.4	2.24e-7	Schizophrenia;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.48	5.33	0.4	3.47e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.37	-4.76	-0.36	4.45e-6	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg15117754	chr3:10150083	C3orf24	0.61	5.78	0.42	4.14e-8	Alzheimer's disease;
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-4.92	-0.37	2.26e-6	Height;
PAAD	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg27490568	chr2:178487706	NA	0.39	4.34	0.33	2.64e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	1.21	10.2	0.64	6.21e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.98	13.7	0.74	2.52e-28	Menarche (age at onset);
PAAD	cis	rs1190596	0.549	rs11621083	chr14:102559538	T/A	cg23904247	chr14:102554826	HSP90AA1	-0.5	-5.52	-0.41	1.46e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13560548	chr3:10150139	C3orf24	0.59	5.18	0.39	6.87e-7	Alzheimer's disease;
PAAD	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.58e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg16591659	chr17:78472290	NA	-0.5	-4.71	-0.36	5.62e-6	Fractional excretion of uric acid;
PAAD	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.76	9.44	0.61	6.36e-17	Lymphocyte counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22109331	chr1:212003961	LPGAT1	-0.82	-7.52	-0.52	4.54e-12	Neuroticism;
PAAD	cis	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg02356786	chr1:243265016	LOC731275	1.06	6.67	0.48	4.56e-10	Obesity (early onset extreme);
PAAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg15628303	chr1:26608928	UBXN11	-0.41	-4.36	-0.33	2.34e-5	Height;
PAAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg23947450	chr7:900037	UNC84A	0.53	4.51	0.34	1.3e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg22189786	chr22:42395067	WBP2NL	0.53	4.42	0.34	1.89e-5	Birth weight;
PAAD	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.77	5.42	0.4	2.33e-7	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.75	7.75	0.53	1.2e-12	Prostate cancer;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.86	7.21	0.5	2.47e-11	Pulmonary function decline;
PAAD	cis	rs11129295	0.618	rs2371150	chr3:27806147	A/G	cg21473142	chr3:27762095	EOMES	-0.27	-4.47	-0.34	1.53e-5	Multiple sclerosis;
PAAD	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg15841412	chr13:111365552	ING1	-0.58	-4.95	-0.37	1.99e-6	Coronary artery disease;
PAAD	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	4.72	0.36	5.35e-6	Bipolar disorder;
PAAD	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	1.01	14.15	0.75	1.52e-29	Heart rate;
PAAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.88	-10.03	-0.63	1.76e-18	Body mass index;
PAAD	cis	rs7873102	0.654	rs2266015	chr9:37981628	T/C	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs3736485	0.966	rs4775959	chr15:51891636	T/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07701084	chr6:150067640	NUP43	0.64	6.33	0.46	2.6e-9	Testicular germ cell tumor;
PAAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.78	9.92	0.63	3.49e-18	Bone mineral density;
PAAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	1.07	14.53	0.76	1.48e-30	Headache;
PAAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.77	-9.0	-0.59	8.39e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg16447950	chr5:562315	NA	-0.47	-4.58	-0.35	9.73e-6	Obesity-related traits;
PAAD	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.5	-6.12	-0.44	7.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.69	-7.46	-0.52	6.16e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13560548	chr3:10150139	C3orf24	0.52	4.73	0.36	5e-6	Alzheimer's disease;
PAAD	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.73	-8.07	-0.55	1.94e-13	Morning vs. evening chronotype;
PAAD	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.81	0.48	2.08e-10	Exhaled nitric oxide levels;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg21565972	chr17:80109576	CCDC57	0.58	6.72	0.48	3.39e-10	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24861013	chr2:114733020	NA	0.63	6.75	0.48	2.91e-10	Smoking initiation;
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg09677638	chr11:61582810	MIR1908;FADS1	0.56	4.94	0.37	2.07e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg21194808	chr1:2205498	SKI	0.5	5.5	0.41	1.56e-7	Coronary artery disease;
PAAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg02428538	chr16:24856791	SLC5A11	-0.57	-4.43	-0.34	1.79e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.49	5.72	0.42	5.49e-8	Platelet distribution width;
PAAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.79	7.03	0.5	6.46e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.71	-9.06	-0.59	6.09e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.73	8.48	0.57	1.8e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.47	4.29	0.33	3.11e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg20487152	chr13:99095054	FARP1	-0.46	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg21573476	chr21:45109991	RRP1B	0.54	4.43	0.34	1.77e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg00540400	chr15:79124168	NA	0.7	8.88	0.58	1.71e-15	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.8	8.34	0.56	4.27e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.09	-0.38	1.06e-6	Bipolar disorder;
PAAD	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-1.22	-11.93	-0.7	1.4e-23	Developmental language disorder (linguistic errors);
PAAD	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg20583945	chr8:144636462	GSDMD	0.57	4.94	0.37	2e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs17032980	0.910	rs7603586	chr2:67327915	C/T	cg06994420	chr2:66672553	MEIS1	-0.51	-4.46	-0.34	1.56e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs35160687	0.901	rs13020869	chr2:86523360	C/T	cg10973622	chr2:86423274	IMMT	0.42	4.89	0.37	2.56e-6	Night sleep phenotypes;
PAAD	cis	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.76	7.21	0.5	2.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.01	17.81	0.82	4.82e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg08888203	chr3:10149979	C3orf24	0.85	7.04	0.5	6.21e-11	Alzheimer's disease;
PAAD	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.79	-0.42	3.96e-8	Androgen levels;
PAAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	4.69	0.36	5.91e-6	Asthma;
PAAD	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.72	4.45	0.34	1.64e-5	IgG glycosylation;
PAAD	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.41	-0.34	1.92e-5	Resting heart rate;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg27532560	chr4:187881888	NA	-0.6	-7.43	-0.52	7.18e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg08317243	chr16:87101592	NA	-0.51	-4.93	-0.37	2.14e-6	Menopause (age at onset);
PAAD	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7326068	0.557	rs4331211	chr13:21125299	T/C	cg27499820	chr13:21296301	IL17D	0.51	5.03	0.38	1.36e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	4.25	0.33	3.66e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg19223190	chr17:80058835	NA	0.53	5.38	0.4	2.8e-7	Life satisfaction;
PAAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg02376097	chr19:46275166	DMPK	-0.56	-5.68	-0.42	6.71e-8	Coronary artery disease;
PAAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg26668828	chr6:292823	DUSP22	-0.68	-7.08	-0.5	4.9e-11	Menopause (age at onset);
PAAD	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg08999081	chr20:33150536	PIGU	0.54	5.69	0.42	6.47e-8	Coronary artery disease;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.91	11.09	0.67	2.56e-21	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	11.22	0.67	1.17e-21	Platelet count;
PAAD	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-4.46	-0.34	1.59e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg12458913	chr13:53173898	NA	0.43	4.48	0.34	1.48e-5	Lewy body disease;
PAAD	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.65	6.89	0.49	1.38e-10	Schizophrenia;
PAAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.64	-7.48	-0.52	5.6e-12	Bipolar disorder;
PAAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg05132306	chr1:1846340	CALML6	-0.42	-4.97	-0.37	1.8e-6	Body mass index;
PAAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.63	-5.63	-0.42	8.59e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.65	-6.92	-0.49	1.18e-10	Schizophrenia;
PAAD	cis	rs3931020	0.616	rs277381	chr1:75266815	T/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.64	-5.63	-0.42	8.41e-8	Resistin levels;
PAAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg13798912	chr7:905769	UNC84A	0.57	4.37	0.33	2.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg10818794	chr15:86012489	AKAP13	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg25114630	chr15:101792522	CHSY1	0.6	5.22	0.39	5.91e-7	Corneal structure;
PAAD	cis	rs7255	0.538	rs2289081	chr2:20881840	G/C	cg07755735	chr2:20870362	GDF7	-0.5	-5.59	-0.41	1.02e-7	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11084035	chr11:62414045	GANAB	0.6	6.69	0.48	3.98e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.82	7.65	0.53	2.08e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs6558530	0.932	rs9022	chr8:1710977	A/C	cg19131313	chr8:1704013	NA	-0.43	-4.8	-0.36	3.81e-6	Systolic blood pressure;
PAAD	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg14055004	chr2:241860995	NA	0.29	4.51	0.34	1.29e-5	Joint mobility (Beighton score);
PAAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs2070997	0.756	rs3134875	chr9:133710072	G/C	cg11464064	chr9:133710261	ABL1	0.68	4.31	0.33	2.95e-5	Response to amphetamines;
PAAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg11204139	chr17:3907470	NA	-0.68	-6.91	-0.49	1.24e-10	Type 2 diabetes;
PAAD	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.4	4.92	0.37	2.23e-6	Sitting height ratio;
PAAD	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.13	0.5	3.88e-11	Obesity-related traits;
PAAD	cis	rs6466055	0.720	rs1204056	chr7:104957761	G/A	cg04380332	chr7:105027541	SRPK2	0.64	7.33	0.51	1.3e-11	Schizophrenia;
PAAD	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.42	4.29	0.33	3.18e-5	Height;
PAAD	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.56	5.95	0.43	1.75e-8	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.87	-10.15	-0.64	8.25e-19	Resting heart rate;
PAAD	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg24296786	chr1:45957014	TESK2	0.54	5.07	0.38	1.14e-6	Homocysteine levels;
PAAD	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.61	-8.52	-0.57	1.43e-14	Endometriosis;
PAAD	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg07701084	chr6:150067640	NUP43	-0.53	-4.73	-0.36	5.08e-6	Lung cancer;
PAAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-4.97	-0.37	1.78e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.63	-4.63	-0.35	7.81e-6	Post bronchodilator FEV1;
PAAD	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06850241	chr22:41845214	NA	-0.52	-4.82	-0.36	3.42e-6	Vitiligo;
PAAD	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.45	-4.29	-0.33	3.17e-5	Red blood cell traits;
PAAD	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.49	-4.86	-0.37	2.87e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05564831	chr3:52568323	NT5DC2	-0.44	-4.81	-0.36	3.61e-6	Bipolar disorder;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg20821713	chr7:1055600	C7orf50	-0.38	-4.35	-0.33	2.44e-5	Longevity;Endometriosis;
PAAD	cis	rs728616	1.000	rs56317427	chr10:81861934	T/C	cg19423196	chr10:82049429	MAT1A	0.55	4.3	0.33	3.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2659067	0.614	rs2739419	chr19:51484562	A/G	cg19471655	chr19:51487109	KLK7	-0.89	-4.91	-0.37	2.28e-6	Blood protein levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24968176	chr7:98509723	TRRAP	0.73	6.36	0.46	2.23e-9	Neuroticism;
PAAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg06740227	chr12:86229804	RASSF9	0.49	4.34	0.33	2.6e-5	Major depressive disorder;
PAAD	cis	rs2421770	0.701	rs4756201	chr11:35263138	C/T	cg13971030	chr11:35366721	SLC1A2	0.47	4.83	0.36	3.27e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.65	-4.29	-0.33	3.22e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
PAAD	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg19090574	chr1:205240910	TMCC2	-0.4	-4.27	-0.33	3.46e-5	Red blood cell count;
PAAD	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg26031613	chr14:104095156	KLC1	-0.56	-5.74	-0.42	5.02e-8	Reticulocyte count;
PAAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.47	-4.67	-0.35	6.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.65	-6.52	-0.47	9.89e-10	IgG glycosylation;
PAAD	cis	rs6929137	0.632	rs11759768	chr6:151955481	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-4.48	-0.34	1.48e-5	Bone mineral density (spine);
PAAD	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05666828	chr4:146403874	SMAD1	0.7	7.1	0.5	4.44e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.56	-0.41	1.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg16928487	chr17:17741425	SREBF1	0.32	4.44	0.34	1.69e-5	Total body bone mineral density;
PAAD	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg27234864	chr13:21295941	IL17D	-0.6	-5.24	-0.39	5.27e-7	Dental caries;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21184281	chr2:3174771	NA	0.6	6.31	0.46	2.94e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.87	-11.05	-0.67	3.38e-21	Aortic root size;
PAAD	cis	rs2997447	0.723	rs61776623	chr1:26474490	A/G	cg24519413	chr1:26490540	NA	0.56	4.97	0.37	1.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.95	6.39	0.46	1.96e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.14	17.22	0.81	1.56e-37	Testicular germ cell tumor;
PAAD	cis	rs883565	0.606	rs6763607	chr3:39091596	C/G	cg01426195	chr3:39028469	NA	-0.68	-7.65	-0.53	2.16e-12	Handedness;
PAAD	cis	rs6537837	0.793	rs17575798	chr1:110086451	G/A	cg05049280	chr1:110155535	GNAT2	0.41	4.35	0.33	2.44e-5	Major depressive disorder;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-4.54	-0.35	1.13e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.39	0.46	1.88e-9	Personality dimensions;
PAAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.55	5.05	0.38	1.25e-6	Schizophrenia;
PAAD	cis	rs7727544	0.505	rs721121	chr5:131406433	T/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.59	0.35	9.3e-6	Blood metabolite levels;
PAAD	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg27395922	chr11:50257633	LOC441601	-0.43	-4.62	-0.35	8.05e-6	Coronary artery disease;
PAAD	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg05484376	chr2:27715224	FNDC4	0.45	4.41	0.34	1.97e-5	Oral cavity cancer;
PAAD	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14582108	chr9:138439003	OBP2A	0.48	4.46	0.34	1.61e-5	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.17	0.55	1.12e-13	Alzheimer's disease;
PAAD	cis	rs13006833	0.668	rs291449	chr2:191177467	A/G	cg27211696	chr2:191398769	TMEM194B	-0.46	-4.53	-0.34	1.21e-5	Urinary metabolites;
PAAD	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.95e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.49	4.84	0.37	3.21e-6	Testicular germ cell tumor;
PAAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg14196790	chr5:131705035	SLC22A5	0.46	4.87	0.37	2.82e-6	Blood metabolite levels;
PAAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-6.72	-0.48	3.43e-10	Bipolar disorder;
PAAD	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.52	-0.52	4.46e-12	HDL cholesterol;
PAAD	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg13560548	chr3:10150139	C3orf24	0.53	4.71	0.36	5.49e-6	Alzheimer's disease;
PAAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.67	4.61	0.35	8.34e-6	Vitiligo;
PAAD	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.41	0.51	8.39e-12	Educational attainment;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.59	0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	0.82	6.37	0.46	2.09e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.54	5.18	0.39	6.96e-7	Multiple myeloma;
PAAD	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.57	6.17	0.45	5.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11037575	0.900	rs1878764	chr11:43746594	A/G	cg24662154	chr11:44118094	EXT2	0.43	4.42	0.34	1.91e-5	Neuroblastoma;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg00277334	chr10:82204260	NA	-0.61	-6.01	-0.44	1.35e-8	Post bronchodilator FEV1;
PAAD	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26926768	chr12:34528122	NA	0.4	4.93	0.37	2.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg06697600	chr4:7070879	GRPEL1	0.88	4.45	0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322817	0.691	rs2168394	chr6:105259152	C/T	cg02098413	chr6:105308735	HACE1	-0.43	-5.4	-0.4	2.56e-7	Thyroid stimulating hormone;
PAAD	cis	rs4790333	0.677	rs2447099	chr17:2268139	G/C	cg02569219	chr17:2266849	SGSM2	0.61	5.81	0.43	3.46e-8	Proinsulin levels;
PAAD	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg00206168	chr11:65308501	LTBP3	0.53	5.5	0.41	1.54e-7	Bone mineral density;
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.48	0.34	1.48e-5	Asthma;
PAAD	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg01422370	chr2:73384389	NA	0.35	4.79	0.36	4.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.61	-8.36	-0.56	3.61e-14	Longevity;Endometriosis;
PAAD	cis	rs2117029	0.586	rs11168884	chr12:49539892	C/T	cg05368762	chr12:50135785	TMBIM6	0.45	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9395066	0.545	rs7749865	chr6:44918406	T/C	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.31	-0.33	2.95e-5	Fear of minor pain;
PAAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.59	4.94	0.37	2.07e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19346786	chr7:2764209	NA	-0.39	-5.14	-0.39	8.17e-7	Height;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg03989125	chr22:38214979	NA	-0.66	-6.86	-0.49	1.64e-10	Glioblastoma;Glioma;
PAAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg00310523	chr12:86230176	RASSF9	-0.38	-4.39	-0.34	2.11e-5	Major depressive disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25517427	chr17:12921477	ELAC2	0.6	6.59	0.47	6.64e-10	Myopia (pathological);
PAAD	cis	rs9715521	0.645	rs6838685	chr4:59843420	A/C	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19327137	chr7:38886074	VPS41	0.41	4.25	0.33	3.77e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs6541297	0.757	rs642235	chr1:230325027	C/G	cg05784532	chr1:230284198	GALNT2	-0.58	-4.38	-0.33	2.24e-5	Coronary artery disease;
PAAD	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.65	6.37	0.46	2.14e-9	Blood metabolite levels;
PAAD	cis	rs931127	0.658	rs12787843	chr11:65477306	A/C	cg05805236	chr11:65401703	PCNXL3	-0.48	-5.35	-0.4	3.21e-7	Systemic lupus erythematosus;
PAAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg27478167	chr7:817139	HEATR2	-0.65	-5.1	-0.38	9.95e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg09659197	chr4:152720779	NA	0.43	5.25	0.39	4.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs5756391	0.568	rs5756407	chr22:37316259	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	4.93	0.37	2.12e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.47	4.42	0.34	1.86e-5	Depression;
PAAD	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.54	-5.69	-0.42	6.3e-8	Daytime sleep phenotypes;
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7084921	0.552	rs2862991	chr10:101876736	C/G	cg04359915	chr10:101825029	CPN1	-0.28	-4.31	-0.33	2.88e-5	Bone mineral density;
PAAD	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.64	0.35	7.31e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.55	5.59	0.41	1.03e-7	Resistin levels;
PAAD	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.51	-4.88	-0.37	2.62e-6	Psoriasis;
PAAD	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.24	-0.39	5.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.49	-5.8	-0.43	3.78e-8	Iron status biomarkers;
PAAD	cis	rs6681460	1.000	rs10889641	chr1:67138367	C/T	cg02459107	chr1:67143332	SGIP1	0.78	7.72	0.53	1.42e-12	Presence of antiphospholipid antibodies;
PAAD	trans	rs795484	0.963	rs795483	chr12:118590579	T/C	cg06703803	chr12:110811045	ANAPC7	-0.59	-6.45	-0.46	1.44e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.88	-7.87	-0.54	6.2e-13	Gut microbiome composition (summer);
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.57	0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.59	6.51	0.47	1.05e-9	Testicular germ cell tumor;
PAAD	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs11078597	0.731	rs4989024	chr17:1639719	A/G	cg18436246	chr17:1640651	WDR81	0.85	7.73	0.53	1.4e-12	Serum albumin level;
PAAD	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	7.96	0.54	3.68e-13	Prudent dietary pattern;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg25487775	chr2:162093969	NA	0.75	8.66	0.57	6.35e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.47	0.34	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg01585852	chr22:24235823	MIF	-0.48	-4.99	-0.38	1.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7552393	0.636	rs1830825	chr1:84279785	C/T	cg10977910	chr1:84465055	TTLL7	0.59	5.7	0.42	6.07e-8	Select biomarker traits;
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg08355456	chr11:67383691	NA	0.49	4.9	0.37	2.47e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18621852	chr3:10150065	C3orf24	0.64	5.63	0.42	8.31e-8	Alzheimer's disease;
PAAD	cis	rs4455778	0.580	rs34230450	chr7:49118157	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.56	-6.34	-0.46	2.49e-9	Vitiligo;
PAAD	cis	rs1364705	1.000	rs13262685	chr8:120226145	A/G	cg09273054	chr8:120220131	MAL2	0.41	4.74	0.36	4.84e-6	Hippocampal atrophy;
PAAD	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.67	6.24	0.45	4.17e-9	Asperger disorder;
PAAD	cis	rs6700896	0.500	rs12043772	chr1:66135034	T/A	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.06	9.24	0.6	2.09e-16	Vitiligo;
PAAD	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg08975724	chr8:8085496	FLJ10661	0.69	7.0	0.49	7.52e-11	Neuroticism;
PAAD	cis	rs6893807	1.000	rs6893807	chr5:87965021	C/T	cg02225085	chr5:87975992	LOC645323	0.63	4.71	0.36	5.66e-6	Body mass index;
PAAD	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.47	4.53	0.34	1.21e-5	Proinsulin levels;
PAAD	cis	rs2952768	1.000	rs2551938	chr2:208496390	A/G	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg09060608	chr5:178986726	RUFY1	-0.65	-7.01	-0.49	7.48e-11	Lung cancer;
PAAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.47	-4.39	-0.34	2.09e-5	Monocyte count;
PAAD	cis	rs6539288	0.933	rs10746070	chr12:107304459	C/T	cg16260113	chr12:107380972	MTERFD3	0.41	4.46	0.34	1.57e-5	Total body bone mineral density;
PAAD	cis	rs62408225	1.000	rs1504215	chr6:91006227	G/A	cg03795776	chr6:90687632	BACH2	0.46	4.47	0.34	1.51e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs9361491	0.608	rs9352618	chr6:79442428	C/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg12486944	chr17:80159399	CCDC57	-0.5	-4.38	-0.33	2.21e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-7.2	-0.5	2.56e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.88	11.2	0.67	1.32e-21	Prudent dietary pattern;
PAAD	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.96	0.44	1.71e-8	Platelet count;
PAAD	cis	rs7264396	0.623	rs6119609	chr20:34039394	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	4.48	0.34	1.48e-5	Total cholesterol levels;
PAAD	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg24053715	chr22:38214548	NA	0.64	5.78	0.42	4.03e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg08317243	chr16:87101592	NA	-0.52	-4.94	-0.37	2.04e-6	Menopause (age at onset);
PAAD	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.72	7.21	0.51	2.39e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.48	-4.74	-0.36	4.78e-6	Male sexual orientation;
PAAD	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs12935418	0.616	rs11859567	chr16:80969848	A/G	cg16651780	chr16:81037892	C16orf61	0.57	4.61	0.35	8.33e-6	Mean corpuscular volume;
PAAD	cis	rs7243821	0.921	rs55641586	chr18:52635316	T/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg22143635	chr11:980567	AP2A2	0.52	5.49	0.41	1.62e-7	Alzheimer's disease (late onset);
PAAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.49	4.76	0.36	4.43e-6	Platelet count;
PAAD	cis	rs630539	0.793	rs1878388	chr17:40761628	A/G	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.75	-10.51	-0.65	9.18e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs7765175	0.698	rs3851199	chr6:113666719	T/C	cg19037598	chr6:113666021	NA	-0.41	-4.39	-0.34	2.1e-5	Coronary artery calcification;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01154930	chr17:78074970	GAA	0.63	7.39	0.51	9.12e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg10920065	chr6:169824652	NA	-0.47	-4.65	-0.35	7.05e-6	Obesity-related traits;
PAAD	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.47	-5.19	-0.39	6.6e-7	Heart rate;
PAAD	cis	rs7555006	0.621	rs11588271	chr1:51470242	G/A	cg06082920	chr1:51796003	TTC39A	-0.46	-4.56	-0.35	1.06e-5	Headache;
PAAD	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.92	-9.76	-0.62	8.89e-18	Parkinson's disease;
PAAD	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.53	5.19	0.39	6.59e-7	Blood metabolite levels;
PAAD	cis	rs6066835	0.702	rs6066807	chr20:47267144	C/T	cg18078177	chr20:47281410	PREX1	1.11	5.12	0.38	9.22e-7	Multiple myeloma;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.73	-7.15	-0.5	3.46e-11	White matter hyperintensity burden;
PAAD	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg11657440	chr19:46296263	DMWD	0.64	4.76	0.36	4.43e-6	Eosinophil counts;
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs9567406	1.000	rs4941492	chr13:44869069	C/T	cg08635097	chr13:44833857	NA	-0.65	-4.57	-0.35	9.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7922314	0.571	rs11818787	chr10:64750045	C/A	cg08989932	chr10:65390526	NA	-1.02	-4.93	-0.37	2.11e-6	Cutaneous psoriasis;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg07362569	chr17:61921086	SMARCD2	-0.45	-5.05	-0.38	1.25e-6	Height;
PAAD	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	1.16	9.23	0.6	2.2e-16	Inflammatory bowel disease;
PAAD	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.48	-0.41	1.72e-7	Mood instability;
PAAD	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg17796960	chr10:135278976	LOC619207	0.39	4.42	0.34	1.87e-5	Systemic lupus erythematosus;
PAAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs7083	0.716	rs687740	chr11:117177603	A/C	cg06114171	chr11:117561139	DSCAML1	0.36	4.26	0.33	3.51e-5	Blood protein levels;
PAAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	1.08	15.3	0.78	1.39e-32	Breast cancer;
PAAD	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg06740227	chr12:86229804	RASSF9	0.48	4.58	0.35	9.77e-6	Major depressive disorder;
PAAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.76	0.36	4.52e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg04257695	chr17:30186438	C17orf79	0.56	4.35	0.33	2.52e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.12	0.5	3.95e-11	Type 2 diabetes;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.61	6.82	0.48	1.99e-10	Longevity;Endometriosis;
PAAD	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4253772	0.515	rs6008784	chr22:46774317	T/C	cg09491104	chr22:46646882	C22orf40	-0.95	-5.68	-0.42	6.65e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg07416916	chr2:36825888	FEZ2	-0.48	-4.76	-0.36	4.47e-6	Height;
PAAD	cis	rs728616	0.717	rs111403425	chr10:81820542	C/T	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs795484	0.610	rs2936839	chr12:118580315	T/C	cg16572268	chr12:118583242	PEBP1	-0.55	-5.29	-0.39	4.23e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs58365266	1.000	rs58365266	chr3:195813757	C/T	cg12923728	chr3:195709715	SDHAP1	-0.56	-4.46	-0.34	1.56e-5	Red cell distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09381022	chr4:120465302	PDE5A	0.58	6.91	0.49	1.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10274279	0.688	rs4716762	chr7:157403939	C/T	cg09270525	chr7:157391030	PTPRN2	0.7	5.11	0.38	9.67e-7	Myopia (pathological);
PAAD	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg06713675	chr4:122721982	EXOSC9	0.47	4.58	0.35	9.53e-6	Type 2 diabetes;
PAAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.85	-8.68	-0.58	5.81e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg19337854	chr7:99768885	GPC2	0.44	4.48	0.34	1.46e-5	Coronary artery disease;
PAAD	cis	rs9463078	0.809	rs6899845	chr6:45043352	A/C	cg25276700	chr6:44698697	NA	-0.47	-5.46	-0.4	1.9e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7082209	1.000	rs12265086	chr10:44811340	C/T	cg13191911	chr10:44806660	NA	-0.9	-5.08	-0.38	1.07e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14180030	chr9:123475675	MEGF9	-0.43	-4.83	-0.36	3.29e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.88	-10.02	-0.63	1.81e-18	Morning vs. evening chronotype;
PAAD	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg02683114	chr2:24398427	C2orf84	-0.53	-5.19	-0.39	6.52e-7	Asthma;
PAAD	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.7	-6.87	-0.49	1.54e-10	Platelet distribution width;
PAAD	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg06307176	chr5:131281290	NA	-0.52	-4.57	-0.35	9.9e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1371614	0.635	rs6706127	chr2:27140741	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.59	6.29	0.45	3.27e-9	Lung cancer;
PAAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg15571903	chr15:79123663	NA	0.48	6.25	0.45	4.03e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14019695	chr9:139328340	INPP5E	0.5	4.68	0.35	6.33e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg08859206	chr1:53392774	SCP2	0.49	4.6	0.35	8.93e-6	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22559002	chr17:63898392	CCDC46	-0.68	-6.79	-0.48	2.37e-10	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs2790216	0.802	rs7092649	chr10:60005202	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.14	-8.24	-0.56	7.39e-14	Height;
PAAD	cis	rs8016982	0.559	rs8009888	chr14:81718381	C/T	cg01989461	chr14:81687754	GTF2A1	0.59	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.61	5.48	0.41	1.71e-7	Corneal astigmatism;
PAAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg19413350	chr8:57351067	NA	-0.46	-4.36	-0.33	2.43e-5	Obesity-related traits;
PAAD	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.08	-11.57	-0.68	1.32e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.27	-0.6	1.76e-16	Type 2 diabetes;
PAAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.87e-6	Bone mineral density;
PAAD	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg06637938	chr14:75390232	RPS6KL1	0.45	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.6	6.14	0.45	6.71e-9	Ovarian reserve;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	4.99	0.38	1.62e-6	Rheumatoid arthritis;
PAAD	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.57	5.77	0.42	4.31e-8	Menopause (age at onset);
PAAD	cis	rs4073221	0.654	rs34712810	chr3:18288343	C/A	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.55e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.84	-0.37	3.1e-6	Neuroticism;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.75	0.58	3.89e-15	Alzheimer's disease;
PAAD	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-5.85	-0.43	2.87e-8	Mean corpuscular volume;
PAAD	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06850241	chr22:41845214	NA	-0.48	-4.36	-0.33	2.42e-5	Vitiligo;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg10818794	chr15:86012489	AKAP13	-0.6	-4.87	-0.37	2.72e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.67	-0.53	1.93e-12	Neuroticism;
PAAD	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg23254163	chr1:152506842	NA	0.6	6.92	0.49	1.2e-10	Hair morphology;
PAAD	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-6.95	-0.49	1.01e-10	Type 2 diabetes;
PAAD	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.64	-6.53	-0.47	9.52e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.59e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17123764	0.892	rs12314795	chr12:50147864	G/A	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07631383	chr7:131012765	MKLN1	0.69	8.12	0.55	1.45e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.77	9.18	0.6	2.88e-16	Alcohol dependence;
PAAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg00334542	chr7:100209784	MOSPD3	-0.7	-5.3	-0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15942142	chr2:201374895	KCTD18	-0.62	-6.37	-0.46	2.1e-9	Smoking initiation;
PAAD	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.78	-8.94	-0.59	1.22e-15	Colorectal cancer;
PAAD	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.52	0.34	1.24e-5	Personality dimensions;
PAAD	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2030114	1.000	rs2030113	chr16:51610013	A/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg01119278	chr6:110721349	DDO	-0.64	-7.21	-0.5	2.5e-11	Platelet distribution width;
PAAD	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.62	5.85	0.43	2.96e-8	Mean corpuscular volume;
PAAD	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.54	0.41	1.33e-7	Rheumatoid arthritis;
PAAD	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg12288994	chr5:1860383	NA	0.6	6.78	0.48	2.48e-10	Cardiovascular disease risk factors;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg08501292	chr6:25962987	TRIM38	0.87	4.7	0.36	5.75e-6	Lung cancer in ever smokers;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg22868518	chr11:507468	RNH1	-0.91	-4.78	-0.36	4.17e-6	Body mass index;
PAAD	cis	rs1816752	0.704	rs7995968	chr13:24966892	C/T	cg02811702	chr13:24901961	NA	-0.52	-5.31	-0.4	3.82e-7	Obesity-related traits;
PAAD	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.94	8.13	0.55	1.44e-13	Inflammatory bowel disease;
PAAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.68	0.53	1.84e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.69	7.02	0.49	6.9e-11	Schizophrenia;
PAAD	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg22153407	chr1:230290089	GALNT2	-0.46	-4.46	-0.34	1.59e-5	Coronary artery disease;
PAAD	cis	rs6066835	1.000	rs6063311	chr20:47325315	C/T	cg18078177	chr20:47281410	PREX1	0.97	4.69	0.36	6.14e-6	Multiple myeloma;
PAAD	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs80064395	1.000	rs80064395	chr3:196372546	C/T	cg20534585	chr3:196373598	LRRC33	0.87	5.1	0.38	9.87e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg20673841	chr7:107026890	COG5	-0.49	-4.41	-0.34	1.92e-5	Coronary artery disease;
PAAD	cis	rs9616064	0.502	rs9627507	chr22:46965687	C/T	cg05621596	chr22:47072043	GRAMD4	-0.51	-4.98	-0.37	1.69e-6	Urate levels in obese individuals;
PAAD	cis	rs6496667	0.600	rs62019401	chr15:91071855	C/T	cg22089800	chr15:90895588	ZNF774	0.63	4.79	0.36	3.85e-6	Rheumatoid arthritis;
PAAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.9	8.55	0.57	1.24e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg23442198	chr4:187126114	CYP4V2	0.64	4.36	0.33	2.43e-5	Blood protein levels;
PAAD	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg16898833	chr6:26189333	HIST1H4D	0.63	4.75	0.36	4.62e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.41	4.26	0.33	3.63e-5	Schizophrenia;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.77	9.08	0.59	5.3e-16	Bladder cancer;
PAAD	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg18370025	chr7:2749541	AMZ1	-0.38	-4.68	-0.36	6.23e-6	Height;
PAAD	cis	rs2239785	0.959	rs136163	chr22:36657628	T/G	cg15716373	chr22:36655542	APOL1	-0.47	-4.4	-0.34	2.01e-5	Glomerulosclerosis;
PAAD	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-5.09	-0.38	1.04e-6	Mean platelet volume;
PAAD	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.51	5.28	0.39	4.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2131877	0.701	rs57357728	chr3:194832106	G/A	cg21937377	chr3:194868750	C3orf21	0.49	4.77	0.36	4.3e-6	Non-small cell lung cancer;
PAAD	cis	rs4073582	0.964	rs801742	chr11:65914766	C/A	cg14036092	chr11:66035641	RAB1B	0.63	5.15	0.39	7.82e-7	Gout;
PAAD	cis	rs642743	0.967	rs687557	chr10:105989509	T/A	cg10697286	chr10:106209748	CCDC147	0.41	4.25	0.33	3.65e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6604026	0.630	rs2263247	chr1:93364067	T/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	7.43	0.52	7.27e-12	Menarche (age at onset);
PAAD	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs498136	0.831	rs12806763	chr11:69358817	C/T	cg24388239	chr11:68438018	NA	-0.45	-4.45	-0.34	1.63e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.43	-6.48	-0.47	1.21e-9	Breast cancer;
PAAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.78e-5	Monobrow;
PAAD	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.71	7.11	0.5	4.22e-11	Alcohol dependence;
PAAD	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg14191688	chr11:70257035	CTTN	0.56	5.18	0.39	7.05e-7	Coronary artery disease;
PAAD	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg07943548	chr15:86304357	KLHL25	-0.66	-5.67	-0.42	7.14e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.6	5.12	0.38	9.06e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg15192750	chr16:69999425	NA	0.74	5.77	0.42	4.4e-8	IgE levels;
PAAD	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg27490568	chr2:178487706	NA	0.39	4.34	0.33	2.64e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.55	5.21	0.39	6.08e-7	Methadone dose in opioid dependence;
PAAD	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	5.46	0.41	1.87e-7	Joint mobility (Beighton score);
PAAD	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs3809060	0.810	rs10742277	chr11:32452925	C/G	cg27259320	chr11:32460587	WIT1	-0.35	-4.4	-0.34	1.99e-5	Inguinal hernia;
PAAD	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.55	-5.7	-0.42	5.91e-8	Hyperactive-impulsive symptoms;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08460590	chr17:7495881	FXR2	0.58	7.24	0.51	2.08e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.04	-0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1497828	1.000	rs2810777	chr1:217559619	A/C	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	trans	rs9409082	0.748	rs60185676	chr9:108931012	T/C	cg07010948	chr13:79181613	NA	-0.35	-6.54	-0.47	9.04e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs943466	1.000	rs55775340	chr6:33751784	C/G	cg04704449	chr6:33738291	NA	-0.47	-4.92	-0.37	2.22e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg25200586	chr1:148000763	NA	-0.61	-6.35	-0.46	2.36e-9	Hip geometry;
PAAD	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg06815965	chr1:205818668	PM20D1	0.58	6.4	0.46	1.85e-9	Menarche (age at onset);
PAAD	cis	rs2997447	0.846	rs3008415	chr1:26404441	C/T	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.26	0.64	4.39e-19	Smoking behavior;
PAAD	cis	rs79839061	0.667	rs13104885	chr4:827368	G/C	cg07828340	chr4:882639	GAK	1.13	5.77	0.42	4.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.62	-8.43	-0.56	2.43e-14	Renal cell carcinoma;
PAAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.76	6.0	0.44	1.36e-8	Methadone dose in opioid dependence;
PAAD	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.49	4.45	0.34	1.66e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg19090574	chr1:205240910	TMCC2	-0.43	-4.65	-0.35	7.11e-6	Red blood cell count;
PAAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.78	9.28	0.6	1.58e-16	Emphysema distribution in smoking;
PAAD	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.0	-0.63	2.08e-18	Blood trace element (Zn levels);
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.03	-18.35	-0.83	2.23e-40	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg18833306	chr6:118973337	C6orf204	-0.55	-4.61	-0.35	8.3e-6	Diastolic blood pressure;
PAAD	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg00147160	chr1:26503991	CNKSR1	0.37	4.29	0.33	3.19e-5	QRS complex (12-leadsum);
PAAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg18402987	chr7:1209562	NA	1.05	5.35	0.4	3.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.85	7.0	0.49	7.8e-11	Initial pursuit acceleration;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20845748	chr21:45719832	PFKL	0.63	6.41	0.46	1.71e-9	Myopia (pathological);
PAAD	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.97	7.99	0.54	3.13e-13	Eosinophilic esophagitis;
PAAD	cis	rs2030114	0.531	rs8052429	chr16:51598560	A/G	cg03758633	chr16:51611768	NA	0.51	4.98	0.37	1.68e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-5.72	-0.42	5.6e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg24881330	chr22:46731750	TRMU	1.12	5.36	0.4	2.98e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7714584	1.000	rs1896708	chr5:150245076	A/T	cg22134413	chr5:150180641	NA	0.75	5.18	0.39	6.9e-7	Crohn's disease;
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg17178900	chr1:205818956	PM20D1	0.45	4.35	0.33	2.45e-5	Parkinson's disease;
PAAD	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.46	-4.68	-0.36	6.22e-6	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg13939156	chr17:80058883	NA	-0.41	-4.34	-0.33	2.54e-5	Life satisfaction;
PAAD	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg03938978	chr2:103052716	IL18RAP	0.49	5.04	0.38	1.32e-6	Blood protein levels;
PAAD	cis	rs28829049	0.861	rs2147946	chr1:19368887	C/T	cg17445618	chr1:19577962	KIAA0090;MRTO4	-0.48	-4.37	-0.33	2.31e-5	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg26554054	chr8:600488	NA	-1.0	-6.22	-0.45	4.58e-9	IgG glycosylation;
PAAD	cis	rs41271473	0.687	rs4388674	chr1:228878563	A/G	cg16512390	chr1:228756714	NA	0.57	4.82	0.36	3.52e-6	Chronic lymphocytic leukemia;
PAAD	trans	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg16973527	chr15:70767570	NA	0.4	6.36	0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg21535247	chr6:8435926	SLC35B3	-0.5	-4.8	-0.36	3.79e-6	Motion sickness;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg22663859	chr13:21900854	NA	0.56	6.39	0.46	1.89e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs13006833	0.668	rs2136566	chr2:191141283	C/T	cg27211696	chr2:191398769	TMEM194B	0.45	4.53	0.34	1.19e-5	Urinary metabolites;
PAAD	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.79	-9.29	-0.6	1.53e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs469727	0.514	rs149130	chr5:112267095	G/A	cg06941702	chr5:112196734	SRP19	0.47	4.33	0.33	2.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07930192	chr7:1003750	NA	0.41	4.99	0.38	1.61e-6	Longevity;Endometriosis;
PAAD	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.45	-4.45	-0.34	1.63e-5	Red cell distribution width;Platelet distribution width;
PAAD	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs1572438	0.931	rs9406099	chr6:867030	A/G	cg13447295	chr6:887704	NA	-0.6	-6.01	-0.44	1.3e-8	Aging;
PAAD	cis	rs755249	0.567	rs113214136	chr1:39874539	G/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	trans	rs79220007	1.000	rs79220007	chr6:26098474	T/C	cg21435394	chr14:105648024	NUDT14	0.96	7.16	0.5	3.31e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.86	0.49	1.67e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3753841	0.832	rs7540247	chr1:103243769	T/A	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg09835421	chr16:68378352	PRMT7	-0.93	-5.18	-0.39	6.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg06297367	chr7:4456341	NA	0.63	4.88	0.37	2.6e-6	Borderline personality disorder;
PAAD	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.29	0.33	3.18e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8099014	0.911	rs8092394	chr18:56127755	A/T	cg12907477	chr18:56117327	MIR122	0.55	4.48	0.34	1.46e-5	Platelet count;
PAAD	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg26373071	chr5:1325741	CLPTM1L	0.5	5.23	0.39	5.5e-7	Lung cancer;
PAAD	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.69	-6.51	-0.47	1.04e-9	Plateletcrit;Platelet count;
PAAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.31	13.64	0.74	3.56e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs507080	0.807	rs7926944	chr11:118559828	T/C	cg08498647	chr11:118550644	TREH	-0.37	-4.26	-0.33	3.64e-5	Serum metabolite levels;
PAAD	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg09998033	chr7:158218633	PTPRN2	-0.76	-7.88	-0.54	5.88e-13	Obesity-related traits;
PAAD	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.68	8.58	0.57	1.05e-14	Educational attainment;
PAAD	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg13010199	chr12:38710504	ALG10B	0.7	7.3	0.51	1.46e-11	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg19847866	chr10:1019161	NA	-0.52	-4.25	-0.33	3.76e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs1656368	0.655	rs73172134	chr3:158198365	A/G	cg16708174	chr3:158430962	RARRES1	0.62	5.52	0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-7.01	-0.49	7.19e-11	Vitamin D levels;
PAAD	cis	rs6547631	0.622	rs10210321	chr2:85928128	A/C	cg24620635	chr2:85921963	GNLY	0.41	5.39	0.4	2.59e-7	Blood protein levels;
PAAD	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.03	0.7	7.45e-24	Mean corpuscular volume;
PAAD	cis	rs1419980	0.643	rs11054919	chr12:7778109	C/G	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.5	0.34	1.36e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.86	9.96	0.63	2.7e-18	Resting heart rate;
PAAD	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08975724	chr8:8085496	FLJ10661	0.49	4.65	0.35	7.03e-6	Mood instability;
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.71	7.28	0.51	1.7e-11	Menarche (age at onset);
PAAD	cis	rs28719689	0.803	rs10103190	chr8:1269326	C/T	cg22761795	chr8:1265118	NA	0.91	6.75	0.48	2.86e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2073300	1.000	rs6048825	chr20:23457671	T/C	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs59888335	0.858	rs4258921	chr3:81001010	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg08992911	chr2:238395768	MLPH	0.87	7.09	0.5	4.85e-11	Prostate cancer;
PAAD	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg22029157	chr1:209979665	IRF6	0.7	6.16	0.45	6.27e-9	Coronary artery disease;
PAAD	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.63	5.1	0.38	1.01e-6	Bipolar disorder;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg26338869	chr17:61819248	STRADA	0.5	4.73	0.36	5.18e-6	Height;
PAAD	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	1.14	7.71	0.53	1.53e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-4.34	-0.33	2.6e-5	Blood protein levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07646714	chr11:34378884	ABTB2	-0.56	-6.61	-0.47	6.03e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.82	9.12	0.59	4.25e-16	Anterior chamber depth;
PAAD	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.48	-5.13	-0.38	8.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg02023728	chr11:77925099	USP35	-0.44	-4.3	-0.33	3.07e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.24	0.45	4.12e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9333029	0.524	rs4262476	chr1:47411689	C/A	cg08644498	chr1:46502608	NA	-0.49	-4.51	-0.34	1.31e-5	Blood metabolite levels;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg11211951	chr8:145729740	GPT	0.48	5.44	0.4	2.06e-7	Age at first birth;
PAAD	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.81	-0.36	3.53e-6	Body mass index;
PAAD	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.83	0.36	3.36e-6	Diastolic blood pressure;
PAAD	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.96	11.02	0.67	3.92e-21	IgG glycosylation;
PAAD	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.75	-5.75	-0.42	4.63e-8	Mean platelet volume;
PAAD	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.69	6.44	0.46	1.51e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs13006833	0.635	rs291460	chr2:191181585	G/A	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14396892	chr9:96623032	NA	-0.38	-4.25	-0.33	3.72e-5	DNA methylation (variation);
PAAD	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.56	-0.41	1.19e-7	Bladder cancer;
PAAD	cis	rs727479	0.962	rs7173595	chr15:51533736	C/T	cg21478137	chr15:51532386	CYP19A1	0.62	6.97	0.49	9.21e-11	Estradiol levels;
PAAD	cis	rs4796354	0.556	rs9904665	chr17:6703183	G/A	cg12642237	chr17:6703447	TEKT1	-0.35	-4.28	-0.33	3.32e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2835872	0.758	rs8134288	chr21:39036989	T/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs72960926	0.744	rs79176890	chr6:75162791	C/A	cg13435101	chr6:74171350	MTO1	0.92	4.47	0.34	1.54e-5	Metabolite levels (MHPG);
PAAD	cis	rs62264129	0.500	rs56294743	chr3:112028863	G/A	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.92	-0.37	2.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg23920097	chr1:209922102	NA	-0.54	-5.15	-0.39	8e-7	Red blood cell count;
PAAD	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.36	-0.46	2.29e-9	Menopause (age at onset);
PAAD	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.57	5.69	0.42	6.48e-8	Systolic blood pressure;
PAAD	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg14515779	chr1:101123966	NA	-0.41	-4.47	-0.34	1.5e-5	Monocyte count;
PAAD	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.64	-6.12	-0.44	7.58e-9	Subjective well-being;
PAAD	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.87	11.12	0.67	2.12e-21	Height;
PAAD	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg25558440	chr8:11882962	NA	0.47	4.29	0.33	3.12e-5	Retinal vascular caliber;
PAAD	cis	rs2017305	0.748	rs111271520	chr10:70771172	C/G	cg25290552	chr10:70751067	KIAA1279	-0.9	-4.92	-0.37	2.22e-6	Depression (quantitative trait);
PAAD	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg24747557	chr10:131355152	MGMT	-0.47	-5.04	-0.38	1.31e-6	Response to temozolomide;
PAAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg14349672	chr11:133703707	NA	-0.57	-6.71	-0.48	3.54e-10	Childhood ear infection;
PAAD	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg26874164	chr19:58962979	ZNF324B	0.53	5.05	0.38	1.26e-6	Uric acid clearance;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17541922	chr11:86511813	PRSS23	-0.66	-7.55	-0.52	3.65e-12	Body fat percentage;
PAAD	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.48	5.59	0.41	1.03e-7	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.63	-6.2	-0.45	5.06e-9	Blood metabolite levels;
PAAD	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg03517284	chr6:25882590	NA	-0.52	-4.26	-0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.66	-8.9	-0.59	1.54e-15	Eye color traits;
PAAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs4343996	0.869	rs6651070	chr7:3465411	G/C	cg21248987	chr7:3385318	SDK1	0.49	5.42	0.4	2.26e-7	Motion sickness;
PAAD	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.39	-4.26	-0.33	3.56e-5	Glomerular filtration rate;
PAAD	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg04990556	chr1:26633338	UBXN11	-0.64	-4.82	-0.36	3.42e-6	Obesity-related traits;
PAAD	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	trans	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg01620082	chr3:125678407	NA	-1.34	-7.46	-0.52	6.11e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.72	-7.22	-0.51	2.3e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.8	8.82	0.58	2.45e-15	Asperger disorder;
PAAD	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg12315302	chr6:26189340	HIST1H4D	0.66	4.45	0.34	1.67e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	4.34	0.33	2.61e-5	Body mass index;
PAAD	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg00631329	chr6:26305371	NA	-0.41	-4.41	-0.34	1.91e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs7165170	0.507	rs4932352	chr15:91145800	C/T	cg15547629	chr15:90437138	AP3S2	-0.5	-4.39	-0.34	2.15e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg15117754	chr3:10150083	C3orf24	0.69	6.02	0.44	1.26e-8	Alzheimer's disease;
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.67	7.2	0.5	2.61e-11	Mean corpuscular volume;
PAAD	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg17351974	chr5:40835760	RPL37	0.87	4.9	0.37	2.44e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.66	7.06	0.5	5.66e-11	Dupuytren's disease;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-6.11	-0.44	8.17e-9	Electroencephalogram traits;
PAAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg00522288	chr12:125625016	AACS	-0.56	-5.79	-0.43	3.86e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg20673841	chr7:107026890	COG5	-0.49	-4.4	-0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-7.0	-0.49	7.51e-11	Cognitive function;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.89	-7.25	-0.51	1.96e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.6	0.61	2.33e-17	Total body bone mineral density;
PAAD	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-5.67	-0.42	6.9e-8	Pancreatic cancer;
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.68	7.2	0.5	2.58e-11	Vitiligo;
PAAD	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.67	-0.53	1.86e-12	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.77	8.99	0.59	9.42e-16	Lung cancer;
PAAD	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg27394845	chr17:28928406	LRRC37B2	0.69	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21153342	chr3:186144610	NA	0.38	4.44	0.34	1.71e-5	Myopia (pathological);
PAAD	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00791764	chr4:53727839	RASL11B	0.54	4.63	0.35	7.83e-6	Optic nerve measurement (cup area);
PAAD	cis	rs12136530	0.593	rs881247	chr1:19733320	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.74	-0.36	4.88e-6	Lead levels in blood;
PAAD	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg06606381	chr12:133084897	FBRSL1	1.0	6.35	0.46	2.4e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.36	-0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg19337854	chr7:99768885	GPC2	0.44	4.58	0.35	9.55e-6	Coronary artery disease;
PAAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.69	7.04	0.5	6.35e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg05110241	chr16:68378359	PRMT7	-0.98	-7.81	-0.54	8.77e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.4	0.4	2.54e-7	Ileal carcinoids;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05819912	chr4:170945459	MFAP3L	0.63	6.69	0.48	4.01e-10	Smoking initiation;
PAAD	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-4.68	-0.35	6.38e-6	Vitiligo;
PAAD	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg20893579	chr22:38215064	NA	-0.56	-6.01	-0.44	1.33e-8	Glioblastoma;Glioma;
PAAD	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.17	0.39	7.43e-7	Prostate cancer;
PAAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.76	-8.09	-0.55	1.78e-13	Prostate cancer;
PAAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.82	-8.08	-0.55	1.82e-13	Breast cancer;
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.96	0.49	9.34e-11	Cystic fibrosis severity;
PAAD	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.81	-7.5	-0.52	4.93e-12	Exhaled nitric oxide output;
PAAD	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.04	-0.38	1.31e-6	Fear of minor pain;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.97	-11.76	-0.69	4.22e-23	Menarche (age at onset);
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg26338869	chr17:61819248	STRADA	-0.62	-6.2	-0.45	5.04e-9	Prudent dietary pattern;
PAAD	cis	rs11807834	0.522	rs2057233	chr1:230232790	G/A	cg00566187	chr1:230250356	GALNT2	-0.61	-6.5	-0.47	1.07e-9	Schizophrenia;
PAAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg08975724	chr8:8085496	FLJ10661	0.77	7.69	0.53	1.72e-12	Mood instability;
PAAD	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-0.94	-9.17	-0.6	3.08e-16	Exhaled nitric oxide output;
PAAD	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.53	-6.68	-0.48	4.31e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.42	5.12	0.38	9.13e-7	Corneal astigmatism;
PAAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.68	-6.2	-0.45	5.09e-9	Total body bone mineral density;
PAAD	cis	rs35955747	0.934	rs5997981	chr22:31808827	A/G	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.63	-0.35	7.84e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02294249	chr13:34392492	RFC3	0.63	6.46	0.46	1.37e-9	Myopia (pathological);
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs5753618	0.504	rs5749295	chr22:31932895	A/T	cg02404636	chr22:31891804	SFI1	0.68	7.03	0.5	6.59e-11	Colorectal cancer;
PAAD	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.75	-8.55	-0.57	1.23e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.73	-7.61	-0.53	2.72e-12	Type 2 diabetes;
PAAD	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.64	5.5	0.41	1.55e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs2997447	0.706	rs61776622	chr1:26469035	A/G	cg24519413	chr1:26490540	NA	0.57	5.0	0.38	1.57e-6	QRS complex (12-leadsum);
PAAD	cis	rs17152411	0.895	rs17151676	chr10:126583640	T/C	cg07906193	chr10:126599966	NA	0.74	5.34	0.4	3.28e-7	Height;
PAAD	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg02228675	chr17:40259724	DHX58	-0.47	-5.77	-0.42	4.31e-8	Fibrinogen levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25565098	chr17:8286577	RPL26	0.66	6.94	0.49	1.08e-10	Obesity-related traits;
PAAD	cis	rs12908161	1.000	rs3803405	chr15:85383640	G/A	cg17507749	chr15:85114479	UBE2QP1	0.65	6.26	0.45	3.68e-9	Schizophrenia;
PAAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs72681920	0.881	rs12502056	chr4:100116074	G/A	cg12011299	chr4:100065546	ADH4	-0.8	-4.58	-0.35	9.67e-6	Alcohol dependence;
PAAD	cis	rs4740619	0.592	rs723756	chr9:16005751	G/A	cg14451791	chr9:16040625	NA	0.38	4.62	0.35	7.97e-6	Body mass index;
PAAD	cis	rs793571	0.779	rs28641638	chr15:59215233	C/T	cg05156742	chr15:59063176	FAM63B	0.59	4.8	0.36	3.68e-6	Schizophrenia;
PAAD	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.53	4.96	0.37	1.91e-6	Insulin levels in response to oral glucose tolerance test (30 minutes);
PAAD	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27478035	chr2:175260614	CIR1;SCRN3	0.58	6.38	0.46	2.07e-9	Metabolite levels  (X-11787);
PAAD	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.48	-4.68	-0.36	6.18e-6	Pancreatic cancer;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-4.64	-0.35	7.47e-6	Myopia (pathological);
PAAD	cis	rs2290416	0.792	rs3812444	chr8:144693261	G/A	cg01494348	chr8:144660395	NAPRT1	0.98	4.31	0.33	2.92e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg23033748	chr14:75592666	NEK9	-0.43	-5.13	-0.38	8.58e-7	Height;
PAAD	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.73	7.19	0.5	2.72e-11	Schizophrenia;
PAAD	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg24504843	chr4:56896641	CEP135	0.54	6.35	0.46	2.39e-9	Serum protein levels (sST2);
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	cis	rs1903068	0.925	rs1551645	chr4:55994314	T/G	cg20092376	chr4:56023423	NA	0.49	4.85	0.37	3.01e-6	Endometriosis;
PAAD	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2016586	0.863	rs5755931	chr22:36120323	A/G	cg26342177	chr22:36113512	APOL5	-0.5	-5.0	-0.38	1.58e-6	Body mass index;
PAAD	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg26935685	chr1:15502881	TMEM51	-0.5	-4.27	-0.33	3.39e-5	Systolic blood pressure;
PAAD	cis	rs9463078	0.631	rs6458427	chr6:45179804	G/A	cg25276700	chr6:44698697	NA	-0.54	-5.97	-0.44	1.59e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs13102973	0.682	rs6535054	chr4:135886055	A/C	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs4795519	0.784	rs12948753	chr17:22166949	A/G	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs11651753	0.561	rs35336840	chr17:45966108	A/G	cg24458315	chr17:46148407	CBX1	0.41	4.58	0.35	9.65e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg26516362	chr5:178986906	RUFY1	0.55	6.1	0.44	8.42e-9	Lung cancer;
PAAD	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	4.72	0.36	5.42e-6	Height;
PAAD	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.52	4.97	0.37	1.77e-6	Mortality in heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09250423	chr16:4717752	MGRN1	0.57	6.29	0.45	3.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6782025	0.837	rs3914744	chr3:120850676	T/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs7395662	1.000	rs8189391	chr11:48859789	A/G	cg21546286	chr11:48923668	NA	0.56	5.85	0.43	2.85e-8	HDL cholesterol;
PAAD	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.5	-5.36	-0.4	2.98e-7	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg03676636	chr4:99064102	C4orf37	0.25	4.25	0.33	3.65e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg07159951	chr1:45983175	PRDX1	0.44	4.88	0.37	2.67e-6	High light scatter reticulocyte count;
PAAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.78	-5.89	-0.43	2.42e-8	Initial pursuit acceleration;
PAAD	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.49e-11	Retinal vascular caliber;
PAAD	cis	rs600550	0.558	rs4444096	chr11:60094004	G/C	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.76	6.06	0.44	1.02e-8	Blood protein levels;
PAAD	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg23461800	chr14:103021989	NA	-0.58	-4.43	-0.34	1.8e-5	Platelet count;
PAAD	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg14345882	chr6:26364793	BTN3A2	0.73	4.83	0.36	3.27e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.731	rs62239005	chr22:32593371	A/G	cg00543991	chr22:32367038	NA	1.1	5.84	0.43	3.1e-8	Childhood ear infection;
PAAD	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.31	0.71	1.32e-24	Chronic sinus infection;
PAAD	cis	rs73058052	0.597	rs16981329	chr19:50097932	G/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.53	-4.54	-0.35	1.13e-5	Fibrinogen levels;
PAAD	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs6864727	1.000	rs6864727	chr5:137247940	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.53	-5.13	-0.38	8.85e-7	Atrial fibrillation;
PAAD	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg07159951	chr1:45983175	PRDX1	-0.44	-4.88	-0.37	2.67e-6	High light scatter reticulocyte count;
PAAD	cis	rs941408	0.963	rs2537854	chr19:2786726	A/C	cg11232448	chr19:2858854	NA	-0.48	-4.63	-0.35	7.69e-6	Total cholesterol levels;
PAAD	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7651511	1.000	rs9843866	chr3:141246337	G/A	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9652601	0.959	rs2058531	chr16:11172109	T/C	cg04616529	chr16:11181986	CLEC16A	0.47	5.1	0.38	1e-6	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.69	-0.42	6.37e-8	Life satisfaction;
PAAD	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-7.31	-0.51	1.45e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.54	5.37	0.4	2.91e-7	Parkinson's disease;
PAAD	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-4.72	-0.36	5.3e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2652834	0.898	rs10162675	chr15:63370358	T/C	cg05507819	chr15:63340323	TPM1	-0.84	-5.7	-0.42	6.12e-8	HDL cholesterol;
PAAD	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.38	-4.68	-0.36	6.23e-6	Blood metabolite levels;
PAAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Calcium levels;
PAAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg12215294	chr3:40350768	EIF1B	-0.45	-4.46	-0.34	1.57e-5	Renal cell carcinoma;
PAAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.74	-5.4	-0.4	2.47e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg15571903	chr15:79123663	NA	0.39	4.79	0.36	3.91e-6	Coronary artery disease;
PAAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg03037974	chr15:76606532	NA	-0.53	-6.26	-0.45	3.66e-9	Blood metabolite levels;
PAAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.39	5.11	0.38	9.53e-7	Educational attainment (years of education);
PAAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs7924005	0.891	rs11593335	chr10:6160702	A/T	cg17191567	chr10:6178319	NA	-0.63	-5.52	-0.41	1.41e-7	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	0.98	6.9	0.49	1.29e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.34	-0.33	2.55e-5	Lung cancer;
PAAD	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg07166546	chr14:35805898	NA	0.3	4.56	0.35	1.06e-5	Psoriasis;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs2882667	0.622	rs34645817	chr5:138152633	A/G	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg22633769	chr20:60982531	CABLES2	-0.51	-4.55	-0.35	1.07e-5	Colorectal cancer;
PAAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs6449957	0.832	rs960383	chr5:67450986	A/G	cg23036683	chr5:67512108	NA	0.49	4.51	0.34	1.27e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.44	-0.34	1.7e-5	Lung cancer;
PAAD	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.67	-8.44	-0.57	2.29e-14	Coronary artery disease;
PAAD	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.71	-6.86	-0.49	1.67e-10	Schizophrenia;
PAAD	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.06	-0.55	2.07e-13	Mean corpuscular volume;
PAAD	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg16386425	chr10:429943	DIP2C	-0.41	-4.27	-0.33	3.44e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg08601574	chr20:25228251	PYGB	-0.54	-5.51	-0.41	1.47e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.42	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07741184	chr6:167504864	NA	-0.35	-4.53	-0.34	1.2e-5	Primary biliary cholangitis;
PAAD	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.7	5.63	0.42	8.55e-8	Vitiligo;
PAAD	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.66	8.63	0.57	7.72e-15	Schizophrenia;
PAAD	cis	rs10768122	1.000	rs1570215	chr11:35289683	A/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	1.99e-5	Vitiligo;
PAAD	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-5.46	-0.4	1.93e-7	Personality dimensions;
PAAD	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2694528	0.841	rs75979228	chr5:60228016	A/C	cg11474532	chr5:59995715	DEPDC1B	0.88	4.87	0.37	2.79e-6	Parkinson's disease;
PAAD	cis	rs8018808	0.905	rs4903586	chr14:77938633	C/G	cg20045696	chr14:77926864	AHSA1	-0.54	-5.23	-0.39	5.64e-7	Myeloid white cell count;
PAAD	cis	rs17407555	0.909	rs11732042	chr4:10246448	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.47	-0.34	1.53e-5	Schizophrenia (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20905902	chr20:3748417	C20orf27	-0.59	-7.03	-0.5	6.59e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.67	-0.35	6.68e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.59	-0.47	6.88e-10	HDL cholesterol;
PAAD	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.31	0.6	1.39e-16	Psoriasis;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.6	-6.99	-0.49	8.14e-11	Longevity;Endometriosis;
PAAD	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	8.49	0.57	1.75e-14	Platelet count;
PAAD	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7084921	0.579	rs11597870	chr10:101847857	T/C	cg04359915	chr10:101825029	CPN1	-0.33	-4.99	-0.38	1.62e-6	Bone mineral density;
PAAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.75	-4.47	-0.34	1.53e-5	Tuberculosis;
PAAD	cis	rs9842133	0.960	rs7647870	chr3:179668356	A/G	cg18765712	chr3:179670323	PEX5L	-0.47	-4.51	-0.34	1.3e-5	Blood metabolite levels;
PAAD	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg05585544	chr11:47624801	NA	-0.42	-4.6	-0.35	9.01e-6	Neuroticism;
PAAD	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg09659197	chr4:152720779	NA	-0.35	-5.23	-0.39	5.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-12.92	-0.72	3.11e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-4.74	-0.36	4.86e-6	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.38	-5.35	-0.4	3.13e-7	Schizophrenia;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg14443077	chr11:68606701	CPT1A	-0.7	-6.38	-0.46	2.06e-9	Blood protein levels;
PAAD	cis	rs6563943	1.000	rs9934700	chr16:83638734	C/T	cg01935413	chr16:83636749	CDH13	0.59	5.5	0.41	1.6e-7	Height;
PAAD	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg00571178	chr13:114841904	RASA3	-0.55	-4.73	-0.36	5.16e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.75	-8.28	-0.56	5.79e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg17385448	chr1:15911702	AGMAT	0.38	4.68	0.35	6.27e-6	Systolic blood pressure;
PAAD	cis	rs10826182	0.588	rs12247015	chr10:60145079	A/G	cg23243718	chr10:60144880	TFAM	-0.49	-4.62	-0.35	8.12e-6	Midgestational circulating levels of PCBs;
PAAD	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.48	4.64	0.35	7.47e-6	HDL cholesterol;
PAAD	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs4965869	0.824	rs4965868	chr15:101976044	G/T	cg12371147	chr15:101978424	PCSK6	-0.5	-4.42	-0.34	1.9e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6066835	0.867	rs6090900	chr20:47364120	C/A	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs1499972	0.941	rs62263076	chr3:117599798	C/T	cg07612923	chr3:117604196	NA	1.04	7.02	0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.51	5.04	0.38	1.29e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.73	-7.26	-0.51	1.89e-11	Paraoxonase activity;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.99	0.44	1.47e-8	Joint mobility (Beighton score);
PAAD	cis	rs11825064	0.720	rs7128710	chr11:134497143	G/A	cg06603561	chr11:134479413	NA	-0.94	-6.21	-0.45	4.86e-9	Seasonality;
PAAD	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.37	-0.4	2.93e-7	Schizophrenia;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs9463078	0.754	rs9349309	chr6:45025814	G/T	cg25276700	chr6:44698697	NA	-0.51	-5.7	-0.42	6.06e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.23	-0.39	5.41e-7	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23784313	chr12:15942613	EPS8	0.58	6.91	0.49	1.27e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6908034	0.546	rs74514942	chr6:19810520	G/A	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs6708331	0.517	rs12999042	chr2:70366811	C/T	cg01613454	chr2:70366299	NA	0.44	4.64	0.35	7.51e-6	Obesity-related traits;
PAAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg21361702	chr7:150065534	REPIN1	0.57	4.78	0.36	4.18e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.78	0.42	4.1e-8	Life satisfaction;
PAAD	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg26528668	chr16:1614120	IFT140	0.55	5.15	0.39	7.84e-7	Coronary artery disease;
PAAD	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.99	-15.25	-0.78	1.94e-32	Height;
PAAD	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09618640	chr6:161258421	NA	-0.67	-6.63	-0.47	5.59e-10	Primary biliary cholangitis;
PAAD	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.59	5.99	0.44	1.48e-8	Obesity;
PAAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.74	10.13	0.63	9.5e-19	Glomerular filtration rate (creatinine);
PAAD	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.48	-4.71	-0.36	5.52e-6	Mean platelet volume;
PAAD	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2211560	0.689	rs10437076	chr1:61261157	C/T	cg00575674	chr1:61314297	NA	-0.53	-4.63	-0.35	7.66e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs12928939	1.000	rs12928939	chr16:71800045	G/A	cg03805757	chr16:71968109	PKD1L3	-0.58	-5.26	-0.39	4.9e-7	Post bronchodilator FEV1;
PAAD	trans	rs9409082	0.627	rs13284782	chr9:108919742	A/C	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.08e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	11.19	0.67	1.37e-21	Ulcerative colitis;
PAAD	cis	rs6715793	0.868	rs17641062	chr2:33414661	A/G	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.52	6.27	0.45	3.52e-9	Alcohol dependence;
PAAD	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg00700412	chr12:58011837	NA	0.44	4.61	0.35	8.42e-6	Multiple sclerosis;
PAAD	cis	rs11018874	0.735	rs4307680	chr11:89900630	A/C	cg05041596	chr11:89867385	NAALAD2	0.66	4.83	0.36	3.31e-6	White blood cell types;
PAAD	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.55	-6.22	-0.45	4.67e-9	Post-traumatic stress disorder;
PAAD	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg22437258	chr11:111473054	SIK2	0.63	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.08	0.5	4.91e-11	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21948194	chr5:95097306	RHOBTB3	0.54	6.4	0.46	1.87e-9	Smoking initiation;
PAAD	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.53	-4.85	-0.37	3.06e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg21929781	chr1:2537748	MMEL1	-0.48	-5.11	-0.38	9.41e-7	Ulcerative colitis;
PAAD	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	1.12	5.78	0.42	4.14e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg16099169	chr2:106886729	NA	-0.77	-7.8	-0.53	9.14e-13	Facial morphology (factor 23);
PAAD	cis	rs7009516	0.716	rs4559243	chr8:24221015	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.41	4.91	0.37	2.37e-6	Hair greying;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25152348	chr22:50946712	NCAPH2;LMF2	-0.59	-6.31	-0.46	2.91e-9	Myopia (pathological);
PAAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg06131755	chr6:160182447	ACAT2	0.54	4.43	0.34	1.82e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7715811	1.000	rs67731984	chr5:13774014	G/A	cg07548982	chr5:13769939	DNAH5	-0.57	-5.4	-0.4	2.57e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.95	-8.2	-0.55	9.48e-14	Body mass index;
PAAD	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.98	-0.37	1.73e-6	Menarche (age at onset);
PAAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-1.06	-15.06	-0.77	5.88e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.58	4.92	0.37	2.23e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs902774	1.000	rs73108453	chr12:53276900	A/G	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-7.37	-0.51	1.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6442522	0.678	rs13059607	chr3:15507408	C/T	cg16303742	chr3:15540471	COLQ	0.48	5.15	0.39	7.94e-7	Uric acid levels;
PAAD	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg01064725	chr1:204461714	NA	-0.56	-5.44	-0.4	2.08e-7	Schizophrenia;
PAAD	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.0	-0.38	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg05707623	chr12:122985044	ZCCHC8	0.63	4.5	0.34	1.35e-5	Body mass index;
PAAD	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg21361702	chr7:150065534	REPIN1	0.54	4.43	0.34	1.77e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-9.01	-0.59	8.03e-16	Total body bone mineral density;
PAAD	cis	rs11700980	0.551	rs2832008	chr21:30109998	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.76	-7.75	-0.53	1.25e-12	Itch intensity from mosquito bite;
PAAD	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.54	5.57	0.41	1.13e-7	Rheumatoid arthritis;
PAAD	cis	rs2882667	0.690	rs1828187	chr5:138172220	A/G	cg09476006	chr5:138032270	NA	0.46	5.89	0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7729723	0.653	rs7726234	chr5:137754695	T/C	cg26069252	chr5:137800343	EGR1	-0.46	-4.29	-0.33	3.18e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg14019695	chr9:139328340	INPP5E	0.59	5.15	0.39	7.81e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2415984	0.600	rs2415958	chr14:46806262	C/G	cg14871534	chr14:47121158	RPL10L	-0.49	-5.42	-0.4	2.27e-7	Number of children ever born;
PAAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.81	0.48	2.13e-10	Schizophrenia;
PAAD	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg22153407	chr1:230290089	GALNT2	-0.47	-4.9	-0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	2.97e-7	Migraine;
PAAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	1.04	11.61	0.69	1.01e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Cardiac Troponin-T levels;
PAAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.57	5.17	0.39	7.34e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.62	-0.47	5.84e-10	Breast cancer;
PAAD	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs986417	1.000	rs10148202	chr14:61055940	C/T	cg27398547	chr14:60952738	C14orf39	-0.83	-5.31	-0.4	3.82e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.7	6.12	0.44	7.48e-9	Platelet count;
PAAD	cis	rs7255	0.538	rs2289081	chr2:20881840	G/C	cg09074113	chr2:20870087	GDF7	-0.41	-4.54	-0.35	1.16e-5	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-5.84	-0.43	2.99e-8	Neuroticism;
PAAD	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05555409	chr3:42641750	NKTR	0.59	7.04	0.5	6.12e-11	Immature fraction of reticulocytes;
PAAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	6.31	0.46	2.86e-9	Lung function (FEV1/FVC);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06019722	chr3:69101353	TMF1	0.61	6.87	0.49	1.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg00147172	chr22:46423604	NA	0.32	4.28	0.33	3.32e-5	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg23216685	chr1:86174607	ZNHIT6	-0.38	-5.99	-0.44	1.46e-8	Urate levels in overweight individuals;
PAAD	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.59	-6.05	-0.44	1.06e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.72	6.62	0.47	5.69e-10	Endometrial cancer;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg00945038	chr17:61921165	SMARCD2	-0.42	-4.82	-0.36	3.39e-6	Prudent dietary pattern;
PAAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg01299579	chr2:10830716	NOL10	0.6	6.44	0.46	1.45e-9	Prostate cancer;
PAAD	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg24881330	chr22:46731750	TRMU	1.16	5.73	0.42	5.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24926775	chr1:151584391	SNX27	0.63	7.5	0.52	4.87e-12	Metabolite levels  (X-11787);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14318734	chr19:7504667	ARHGEF18	-0.62	-6.53	-0.47	9.49e-10	Obesity-related traits;
PAAD	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.46	-0.34	1.61e-5	Triglycerides;
PAAD	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.43	0.4	2.15e-7	Bone mineral density;
PAAD	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.19	0.55	1.01e-13	Platelet count;
PAAD	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg02696790	chr15:75250997	RPP25	-0.45	-5.18	-0.39	7.02e-7	Systemic lupus erythematosus;
PAAD	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.07	0.5	5.4e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg21589280	chr1:85930151	DDAH1	-0.57	-4.36	-0.33	2.37e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.73	-8.38	-0.56	3.24e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.61	-6.5	-0.47	1.12e-9	Monocyte count;
PAAD	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06850241	chr22:41845214	NA	0.49	4.31	0.33	2.95e-5	Vitiligo;
PAAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.84	-10.9	-0.66	8.55e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs7577696	0.924	rs7586448	chr2:32268640	C/G	cg02381751	chr2:32503542	YIPF4	-0.42	-4.56	-0.35	1.04e-5	Inflammatory biomarkers;
PAAD	cis	rs2562456	0.520	rs279793	chr19:21455774	C/T	cg08562672	chr19:21860753	NA	-0.46	-4.5	-0.34	1.37e-5	Pain;
PAAD	cis	rs3106136	0.681	rs7658390	chr4:95304083	C/T	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.34	0.33	2.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.29	0.45	3.21e-9	Alzheimer's disease;
PAAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg10591111	chr5:226296	SDHA	-0.71	-5.43	-0.4	2.24e-7	Breast cancer;
PAAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg00717180	chr2:96193071	NA	-0.68	-8.15	-0.55	1.22e-13	Coronary artery disease;
PAAD	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.36	-0.33	2.38e-5	Resting heart rate;
PAAD	cis	rs7705042	0.865	rs413214	chr5:141530157	G/A	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.61	-0.35	8.47e-6	Asthma;
PAAD	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs76917914	0.820	rs2281732	chr9:100845007	A/G	cg21225548	chr9:100864335	TRIM14	-0.52	-5.37	-0.4	2.91e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg03482866	chr13:111040579	COL4A2	0.45	4.36	0.33	2.43e-5	White matter hyperintensity burden;
PAAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14019695	chr9:139328340	INPP5E	-0.57	-4.96	-0.37	1.84e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	trans	rs1944766	0.501	rs10963525	chr9:18218157	C/T	cg03469079	chr22:38054892	PDXP	0.66	6.42	0.46	1.65e-9	Fat distribution (HIV);
PAAD	cis	rs12906542	0.516	rs894301	chr15:78297525	G/A	cg23683012	chr15:78369302	TBC1D2B	0.69	5.15	0.39	8.04e-7	Breast cancer;
PAAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs2147959	0.882	rs4653552	chr1:228628138	A/G	cg00655913	chr1:228633920	NA	0.51	4.67	0.35	6.51e-6	Adult asthma;
PAAD	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.76	-0.42	4.57e-8	Gut microbiome composition (summer);
PAAD	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg03989125	chr22:38214979	NA	-0.55	-5.6	-0.41	9.75e-8	Glioblastoma;Glioma;
PAAD	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-5.72	-0.42	5.45e-8	Longevity;
PAAD	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg09659197	chr4:152720779	NA	0.43	5.57	0.41	1.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12523822	0.871	rs11155995	chr6:154959409	T/A	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs41311933	1.000	rs16910253	chr9:123748830	G/C	cg13567360	chr9:123745713	C5	-0.72	-4.69	-0.36	6.15e-6	Coronary artery disease;
PAAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs12612619	0.667	rs7605526	chr2:27345484	A/G	cg00617064	chr2:27272375	NA	-0.46	-4.66	-0.35	6.73e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.83	9.23	0.6	2.17e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.06	0.44	1.04e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2412208	0.959	rs2412210	chr1:7092549	C/T	cg26570804	chr1:6352357	ACOT7	0.47	4.5	0.34	1.36e-5	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs8077059	1.000	rs2058104	chr17:55816722	A/G	cg12582317	chr17:55822272	NA	0.52	4.86	0.37	2.85e-6	Sex hormone-binding globulin levels;
PAAD	trans	rs9409082	0.635	rs12684013	chr9:108998114	C/T	cg07010948	chr13:79181613	NA	-0.34	-6.29	-0.45	3.16e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	6.36	0.46	2.2e-9	Cognitive test performance;
PAAD	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs2117029	0.586	rs2114846	chr12:49548276	G/A	cg05368762	chr12:50135785	TMBIM6	0.44	4.39	0.34	2.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.75	7.42	0.52	7.88e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.73e-11	Asthma;
PAAD	cis	rs6782228	0.606	rs2811488	chr3:128336517	C/T	cg16766828	chr3:128327626	NA	-0.48	-6.59	-0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg09658497	chr7:2847517	GNA12	-0.43	-4.6	-0.35	8.99e-6	Height;
PAAD	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.71	7.8	0.53	9.21e-13	Multiple myeloma (IgH translocation);
PAAD	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg04450456	chr4:17643702	FAM184B	0.47	4.89	0.37	2.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14146583	chr9:130689749	PIP5KL1	-0.67	-6.42	-0.46	1.65e-9	Lung cancer in ever smokers;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg26338869	chr17:61819248	STRADA	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.87	8.93	0.59	1.27e-15	Multiple sclerosis;
PAAD	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg08436684	chr16:88034427	BANP	-0.49	-4.33	-0.33	2.65e-5	Menopause (age at onset);
PAAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4662592	0.589	rs74488130	chr2:128907375	T/A	cg03222009	chr2:129077232	HS6ST1	-0.47	-4.47	-0.34	1.52e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	trans	rs2790216	0.951	rs1769022	chr10:59929004	A/G	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs7561149	0.902	rs6729746	chr2:179649349	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.47	4.71	0.36	5.57e-6	QT interval;
PAAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg05342682	chr7:94953680	PON1	-0.52	-4.65	-0.35	7.15e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.64	-6.88	-0.49	1.45e-10	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.01e-6	Lung cancer;
PAAD	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.29e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.56	-5.99	-0.44	1.43e-8	Menopause (age at onset);
PAAD	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg03264133	chr6:25882463	NA	0.51	5.05	0.38	1.27e-6	Blood metabolite levels;
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.85	6.48	0.46	1.24e-9	Gut microbiome composition (summer);
PAAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg03538708	chr1:25844672	NA	-0.52	-5.39	-0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.42	-4.98	-0.37	1.7e-6	Body mass index;
PAAD	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg17644776	chr2:200775616	C2orf69	0.5	4.37	0.33	2.29e-5	Schizophrenia;
PAAD	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.29e-7	Obesity (extreme);
PAAD	trans	rs901683	1.000	rs78661209	chr10:46074939	G/A	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.62	7.08	0.5	4.87e-11	Testicular germ cell tumor;
PAAD	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.56	-5.54	-0.41	1.29e-7	Coronary artery disease;
PAAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg11143131	chr5:131608246	PDLIM4	-0.51	-5.12	-0.38	8.99e-7	Blood metabolite levels;
PAAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg16316162	chr8:144660157	NAPRT1	-0.95	-4.75	-0.36	4.75e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.63	0.57	7.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg18964960	chr10:1102726	WDR37	0.85	4.62	0.35	8.05e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.76	9.23	0.6	2.24e-16	Monocyte percentage of white cells;
PAAD	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.51	-5.16	-0.39	7.6e-7	Resting heart rate;
PAAD	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-7.61	-0.53	2.62e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10905065	0.766	rs11598374	chr10:5826986	T/C	cg18989491	chr10:6185502	PFKFB3	0.48	4.34	0.33	2.55e-5	Menopause (age at onset);
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg00277334	chr10:82204260	NA	0.57	5.08	0.38	1.11e-6	Post bronchodilator FEV1;
PAAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg20893579	chr22:38215064	NA	0.49	4.85	0.37	3.08e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg09835421	chr16:68378352	PRMT7	0.65	4.97	0.37	1.82e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	1.17	12.0	0.7	9.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg23461800	chr14:103021989	NA	-0.61	-4.62	-0.35	8.09e-6	Platelet count;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.33	0.81	8.1e-38	Height;
PAAD	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg17633681	chr16:88106987	BANP	0.65	8.23	0.56	7.88e-14	Menopause (age at onset);
PAAD	cis	rs10916814	1.000	rs10916820	chr1:20903792	A/T	cg04087271	chr1:20915334	CDA	0.38	4.42	0.34	1.85e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.57	-5.59	-0.41	1.01e-7	Reticulocyte count;
PAAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.49	-6.52	-0.47	9.83e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10821973	0.527	rs10740066	chr10:63976416	T/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.56	5.89	0.43	2.39e-8	Dupuytren's disease;
PAAD	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	9.66	0.62	1.69e-17	Cognitive test performance;
PAAD	cis	rs8014252	0.803	rs1959477	chr14:71034216	A/G	cg11204974	chr14:71022665	NA	-0.7	-4.71	-0.36	5.64e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.57	-6.48	-0.47	1.22e-9	Prostate cancer;
PAAD	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.36	-0.51	1.05e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.55	-6.27	-0.45	3.49e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg19847866	chr10:1019161	NA	0.72	7.58	0.52	3.09e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg04289385	chr6:36355825	ETV7	0.46	4.77	0.36	4.24e-6	Platelet distribution width;
PAAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14180030	chr9:123475675	MEGF9	-0.42	-4.72	-0.36	5.31e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.3	0.39	4.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg06057569	chr22:50219754	BRD1	0.67	5.06	0.38	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.85	-0.43	2.88e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg22029157	chr1:209979665	IRF6	0.73	7.06	0.5	5.54e-11	Coronary artery disease;
PAAD	cis	rs721399	0.539	rs10089958	chr8:18269343	A/G	cg18736775	chr8:18248649	NAT2	-0.61	-4.63	-0.35	7.76e-6	Blood metabolite levels;
PAAD	cis	rs9535307	1.000	rs2897770	chr13:50325070	A/G	cg04663916	chr13:50265991	EBPL	0.59	4.43	0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.61	-4.62	-0.35	8.05e-6	Breast cancer;
PAAD	cis	rs1434579	0.897	rs2037903	chr19:44945136	G/A	cg23218533	chr19:44645662	ZNF234	-0.51	-4.3	-0.33	2.99e-5	Tuberculosis;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.32	-0.4	3.69e-7	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13464496	chr1:28100114	STX12	0.59	6.44	0.46	1.48e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.61	0.41	9.3e-8	Personality dimensions;
PAAD	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.75	-7.69	-0.53	1.69e-12	Blood metabolite levels;
PAAD	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.0	-0.38	1.57e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg11630242	chr17:19881632	AKAP10	-0.47	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.69	4.74	0.36	4.84e-6	Vitiligo;
PAAD	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg03060546	chr3:49711283	APEH	0.54	5.4	0.4	2.5e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.59	0.41	1.04e-7	Lung cancer in ever smokers;
PAAD	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.93	-8.57	-0.57	1.08e-14	Body mass index;
PAAD	cis	rs3747547	1.000	rs72724184	chr9:37916731	C/T	cg13774184	chr9:37916125	SHB	-0.64	-4.5	-0.34	1.36e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.8	-8.37	-0.56	3.45e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23544223	chr18:12777786	NA	0.68	5.81	0.43	3.54e-8	Inflammatory skin disease;
PAAD	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.45	-5.12	-0.38	9.23e-7	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16528022	chr14:65438707	RAB15	0.64	6.34	0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.79	-0.36	3.99e-6	Total body bone mineral density;
PAAD	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17347941	chr15:79387269	NA	0.39	4.39	0.34	2.09e-5	Refractive error;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01283332	chr5:1856932	NA	-0.44	-4.6	-0.35	8.68e-6	Cardiovascular disease risk factors;
PAAD	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11995313	chr8:8860691	ERI1	0.52	5.27	0.39	4.64e-7	Joint mobility (Beighton score);
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.78	-0.42	4.02e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg24101359	chr6:42928495	GNMT	0.58	4.72	0.36	5.36e-6	Blood protein levels;
PAAD	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.71	6.4	0.46	1.79e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.54	-5.09	-0.38	1.03e-6	Coronary artery disease;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.05	-0.38	1.28e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.73	0.58	4.16e-15	Lung cancer;
PAAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.73	0.53	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg15017067	chr4:17643749	FAM184B	0.42	4.63	0.35	7.66e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.68	-0.35	6.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.97	7.85	0.54	6.87e-13	Vitiligo;
PAAD	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.71	-6.03	-0.44	1.21e-8	Type 2 diabetes;
PAAD	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg12092346	chr18:77659572	KCNG2	0.58	4.29	0.33	3.17e-5	Opioid sensitivity;
PAAD	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.66	-6.09	-0.44	8.77e-9	Multiple myeloma;
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.37	-4.5	-0.34	1.35e-5	Abdominal aortic aneurysm;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.91	-0.37	2.34e-6	Body mass index;
PAAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg21929781	chr1:2537748	MMEL1	0.54	5.7	0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.98e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.8	-8.87	-0.58	1.87e-15	Iron status biomarkers;
PAAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.67	0.62	1.54e-17	Total body bone mineral density;
PAAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg21890820	chr11:65308645	LTBP3	0.64	7.73	0.53	1.4e-12	Bone mineral density;
PAAD	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	4.73	0.36	5.03e-6	Schizophrenia;
PAAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg14008862	chr17:28927542	LRRC37B2	-0.66	-4.93	-0.37	2.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg10534938	chr5:1868639	NA	0.45	5.97	0.44	1.62e-8	Cardiovascular disease risk factors;
PAAD	cis	rs7202877	0.656	rs6564245	chr16:75308899	A/G	cg03315344	chr16:75512273	CHST6	-0.56	-4.75	-0.36	4.67e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg21775007	chr8:11205619	TDH	0.48	4.25	0.33	3.76e-5	Systolic blood pressure;
PAAD	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.89	-10.2	-0.64	6.31e-19	Cognitive function;
PAAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg06393558	chr11:69982916	ANO1	-0.61	-6.04	-0.44	1.14e-8	Survival in rectal cancer;
PAAD	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.84	9.1	0.59	4.89e-16	Metabolic syndrome;
PAAD	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.98	-10.15	-0.64	8.43e-19	Systemic lupus erythematosus;
PAAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24229701	chr12:130821962	PIWIL1	0.41	4.29	0.33	3.21e-5	Menopause (age at onset);
PAAD	cis	rs4780401	0.933	rs11075010	chr16:11826013	C/T	cg01061890	chr16:11836724	TXNDC11	-0.53	-5.14	-0.38	8.28e-7	Rheumatoid arthritis;
PAAD	cis	rs73019876	0.803	rs2522102	chr19:22144295	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg08807892	chr2:162101083	NA	-0.67	-7.49	-0.52	5.1e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7567389	0.535	rs4150416	chr2:128046548	C/A	cg09760422	chr2:128146352	NA	-0.38	-6.22	-0.45	4.51e-9	Self-rated health;
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.41	-0.34	1.95e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg21546286	chr11:48923668	NA	0.49	4.95	0.37	1.95e-6	HDL cholesterol;
PAAD	trans	rs11212737	0.818	rs2624135	chr11:108513693	T/G	cg13462821	chr8:86214814	NA	-0.55	-6.47	-0.46	1.27e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.57	5.11	0.38	9.75e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.79	9.13	0.6	3.94e-16	Morning vs. evening chronotype;
PAAD	cis	rs10821973	0.527	rs1432415	chr10:63975339	T/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.38	-0.33	2.19e-5	Neuroticism;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.67	0.35	6.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.05	0.38	1.24e-6	Axial length;
PAAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04362095	chr11:63592001	C11orf84	-0.51	-4.57	-0.35	1.01e-5	Platelet count;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.65	5.38	0.4	2.81e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg24213567	chr19:53496664	ZNF702P	-0.49	-5.08	-0.38	1.08e-6	Psoriasis;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.81	6.84	0.49	1.78e-10	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg14393609	chr7:65229607	NA	0.44	4.32	0.33	2.78e-5	Aortic root size;
PAAD	cis	rs27434	0.583	rs193482	chr5:96157846	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.62	6.68	0.48	4.18e-10	Longevity;
PAAD	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-4.26	-0.33	3.54e-5	Schizophrenia;
PAAD	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs2017305	0.915	rs78544199	chr10:70777871	A/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.83	-9.3	-0.6	1.41e-16	Caffeine consumption;
PAAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.6	0.35	8.92e-6	Type 2 diabetes;
PAAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.76	-8.11	-0.55	1.59e-13	DNA methylation (variation);
PAAD	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.49	-4.39	-0.34	2.09e-5	Asthma;
PAAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.48	6.22	0.45	4.65e-9	Childhood ear infection;
PAAD	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	5.07	0.38	1.16e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.7	-5.92	-0.43	2.08e-8	Type 2 diabetes;
PAAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.48	6.19	0.45	5.39e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs78707713	0.841	rs7475662	chr10:71210744	G/C	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.53	0.34	1.19e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.41	-0.4	2.38e-7	Initial pursuit acceleration;
PAAD	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-7.54	-0.52	3.96e-12	Menarche (age at onset);
PAAD	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg09127314	chr1:152161683	NA	0.74	5.43	0.4	2.14e-7	Atopic dermatitis;
PAAD	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.48	-5.16	-0.39	7.62e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg18551225	chr6:44695536	NA	0.7	7.0	0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs11618113	0.634	rs11619434	chr13:111185674	A/G	cg11688093	chr13:111178359	RAB20	0.78	4.83	0.37	3.23e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.62	6.99	0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.62	5.98	0.44	1.5e-8	Prudent dietary pattern;
PAAD	cis	rs9942416	0.585	rs253407	chr5:74926778	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.47	-4.55	-0.35	1.11e-5	Age-related disease endophenotypes;
PAAD	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg27246729	chr12:121163418	ACADS	0.44	4.91	0.37	2.29e-6	Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7960581	0.585	rs12815614	chr12:99169676	C/T	cg17109042	chr12:99139387	ANKS1B	0.65	4.39	0.34	2.1e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs501120	0.564	rs1509931	chr10:44682080	C/T	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	4.84	0.37	3.17e-6	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.88	-9.96	-0.63	2.63e-18	Cancer (pleiotropy);
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.84	9.14	0.6	3.72e-16	DNA methylation (variation);
PAAD	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.47	-4.97	-0.37	1.78e-6	Body mass index;
PAAD	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg23791538	chr6:167370224	RNASET2	0.8	9.57	0.61	2.83e-17	Graves' disease;
PAAD	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6988985	0.678	rs28659182	chr8:143999919	T/A	cg10324643	chr8:143916377	GML	0.4	4.48	0.34	1.43e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs4389656	0.625	rs7712516	chr5:6745571	A/T	cg10857441	chr5:6722123	POLS	-0.44	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21349401	chr20:34681500	NA	0.56	6.31	0.46	2.87e-9	Monocyte percentage of white cells;
PAAD	cis	rs7828089	0.902	rs7837811	chr8:22264309	G/C	cg12081754	chr8:22256438	SLC39A14	0.42	4.25	0.33	3.75e-5	Verbal declarative memory;
PAAD	cis	rs7336332	0.891	rs927578	chr13:28075022	G/T	cg22138327	chr13:27999177	GTF3A	0.74	5.2	0.39	6.38e-7	Weight;
PAAD	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.7	8.47	0.57	1.97e-14	Dupuytren's disease;
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg05373962	chr22:49881684	NA	-0.51	-4.91	-0.37	2.33e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.64	0.57	7.39e-15	Chronic sinus infection;
PAAD	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.51	-0.47	1.02e-9	Schizophrenia;
PAAD	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.72	8.2	0.55	9.32e-14	Age-related hearing impairment;
PAAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.98	7.77	0.53	1.09e-12	Gut microbiome composition (summer);
PAAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	1.0	15.88	0.79	4.28e-34	Height;
PAAD	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.5	4.31	0.33	2.89e-5	Height;
PAAD	cis	rs6723108	0.702	rs55920206	chr2:135432066	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.66	-0.35	6.75e-6	Type 2 diabetes;
PAAD	cis	rs11811982	0.793	rs74896174	chr1:227512973	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07402062	chr16:89894098	SPIRE2	0.39	4.81	0.36	3.57e-6	Vitiligo;
PAAD	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.5	5.24	0.39	5.2e-7	Type 2 diabetes;
PAAD	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.48	-4.54	-0.35	1.12e-5	Inflammatory bowel disease;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18337363	chr3:52569053	NT5DC2	0.43	4.32	0.33	2.78e-5	Bipolar disorder;
PAAD	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg08648136	chr8:956695	NA	0.46	4.91	0.37	2.38e-6	Schizophrenia;
PAAD	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.18	0.55	1.06e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.43	-4.32	-0.33	2.75e-5	Aortic root size;
PAAD	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-1.02	-9.35	-0.6	1.04e-16	IgG glycosylation;
PAAD	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.91	-0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg05717871	chr11:638507	DRD4	-0.59	-5.19	-0.39	6.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.84	-9.99	-0.63	2.18e-18	Brugada syndrome;
PAAD	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.09e-15	Morning vs. evening chronotype;
PAAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs62179067	0.708	rs17362972	chr2:179909467	C/T	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.98e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.49	-0.34	1.37e-5	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02659055	chr5:180670537	GNB2L1;SNORD95	0.68	7.62	0.53	2.49e-12	Myopia (pathological);
PAAD	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.64	-8.16	-0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.61	4.56	0.35	1.03e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	1.0	8.75	0.58	3.75e-15	Alzheimer's disease;
PAAD	trans	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.91	-0.54	4.8e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs10214930	0.723	rs56139857	chr7:27678971	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs76866386	1.000	rs11887534	chr2:44066247	G/C	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.96	-5.58	-0.41	1.05e-7	Cholesterol, total;
PAAD	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15506890	chr2:3487001	NA	-0.79	-8.24	-0.56	7.37e-14	Neurofibrillary tangles;
PAAD	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2036402	0.911	rs13179576	chr5:156367257	A/G	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.23e-5	Hypertriglyceridemia;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	5.04e-14	Prudent dietary pattern;
PAAD	cis	rs7127900	0.950	rs7121039	chr11:2232911	C/G	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs1018697	0.966	rs10748831	chr10:104558743	T/C	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-7.25	-0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.51	-4.89	-0.37	2.57e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.68	7.14	0.5	3.68e-11	Longevity;
PAAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.74	6.92	0.49	1.16e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.69	6.63	0.47	5.48e-10	Obesity-related traits;
PAAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.53	-5.39	-0.4	2.67e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.94	-0.37	2.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	1.08	12.78	0.72	7.1e-26	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg09796270	chr17:17721594	SREBF1	-0.47	-5.24	-0.39	5.32e-7	Total body bone mineral density;
PAAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.46	5.87	0.43	2.63e-8	Cystic fibrosis severity;
PAAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.89	-0.37	2.58e-6	Bipolar disorder;
PAAD	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-12.22	-0.7	2.38e-24	Height;
PAAD	cis	rs10090774	0.965	rs12550497	chr8:141945517	T/C	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-1.14	-16.06	-0.79	1.48e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16417436	chr16:28758564	NA	0.45	4.32	0.33	2.85e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg00083206	chr6:110721305	DDO	-0.48	-5.06	-0.38	1.17e-6	Platelet distribution width;
PAAD	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg03318428	chr22:46971703	NA	0.35	4.25	0.33	3.77e-5	Urate levels in obese individuals;
PAAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg19413350	chr8:57351067	NA	-0.46	-4.28	-0.33	3.34e-5	Obesity-related traits;
PAAD	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-5.8	-0.43	3.65e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6787391	0.505	rs9822274	chr3:4757846	T/C	cg11584376	chr3:4789075	ITPR1	-0.48	-5.31	-0.4	3.8e-7	Breast cancer;
PAAD	cis	rs1075265	0.730	rs7601692	chr2:53932669	T/G	cg04546899	chr2:54196757	PSME4	0.32	4.67	0.35	6.61e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.44	-0.34	1.69e-5	Educational attainment;
PAAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.96	12.63	0.72	1.9e-25	Menopause (age at onset);
PAAD	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg14433983	chr11:636460	DRD4	-0.45	-4.69	-0.36	6.14e-6	Systemic lupus erythematosus;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01985446	chr10:80830536	ZMIZ1	-0.55	-6.31	-0.46	2.83e-9	Height;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.88	11.1	0.67	2.5e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.63	6.99	0.49	8.14e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.89	-0.54	5.37e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8010715	0.771	rs2277481	chr14:24587545	A/G	cg23112188	chr14:24563095	PCK2	-0.5	-5.51	-0.41	1.49e-7	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.49	4.92	0.37	2.25e-6	Menopause (age at onset);
PAAD	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.13	0.5	3.73e-11	Educational attainment;
PAAD	cis	rs2031532	0.544	rs9526563	chr13:50045749	C/T	cg08779649	chr13:50194554	NA	0.35	4.77	0.36	4.26e-6	Cardiac hypertrophy;
PAAD	cis	rs7627468	1.000	rs4303826	chr3:121939975	G/A	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg14580859	chr9:123691850	NA	0.38	4.25	0.33	3.66e-5	Rheumatoid arthritis;
PAAD	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg27471124	chr11:109292789	C11orf87	0.28	4.95	0.37	1.91e-6	Schizophrenia;
PAAD	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg26597838	chr10:835615	NA	-0.75	-6.58	-0.47	7.08e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.44	0.52	6.97e-12	Eosinophil percentage of white cells;
PAAD	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322817	0.691	rs7753202	chr6:105215289	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-5.49	-0.41	1.63e-7	Thyroid stimulating hormone;
PAAD	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.97e-16	Cannabis dependence symptom count;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-6.6	-0.47	6.3e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	1.01	7.37	0.51	1.01e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs714515	0.586	rs4916264	chr1:172450760	C/T	cg13446689	chr1:172328377	DNM3	-0.44	-5.36	-0.4	3.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg05895507	chr15:77155635	SCAPER	0.36	4.43	0.34	1.78e-5	Blood metabolite levels;
PAAD	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.47	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg07395648	chr5:131743802	NA	0.52	4.37	0.33	2.26e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.56	5.29	0.39	4.23e-7	Type 2 diabetes;
PAAD	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg22535103	chr8:58192502	C8orf71	-0.52	-4.78	-0.36	4.02e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.53	4.34	0.33	2.64e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg01475377	chr6:109611718	NA	-0.41	-4.4	-0.34	2e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.76	5.96	0.43	1.73e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-1.18	-13.49	-0.74	9.21e-28	Hair shape;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00031967	chr7:43769114	C7orf44	0.58	6.91	0.49	1.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	5.18	0.39	7.01e-7	Neuroticism;
PAAD	cis	rs593531	0.571	rs10793081	chr11:74092403	T/C	cg15851278	chr11:73669449	DNAJB13	-0.37	-4.5	-0.34	1.36e-5	Neuroticism;
PAAD	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11997175	0.603	rs6468205	chr8:33778642	T/A	ch.8.33884649F	chr8:33765107	NA	0.59	5.97	0.44	1.63e-8	Body mass index;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.71	8.06	0.55	2.07e-13	Height;
PAAD	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg11783602	chr8:55087084	NA	-0.64	-7.73	-0.53	1.35e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16447950	chr5:562315	NA	-0.64	-5.65	-0.42	7.65e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10793968	0.688	rs4237120	chr9:133630128	A/G	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs72960926	0.744	rs117811116	chr6:74898143	C/A	cg03266952	chr6:74778945	NA	-1.18	-6.6	-0.47	6.43e-10	Metabolite levels (MHPG);
PAAD	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg21855830	chr2:127963489	CYP27C1	0.44	4.28	0.33	3.3e-5	Protein C levels;
PAAD	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.3e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.56	-5.92	-0.43	2.08e-8	Life satisfaction;
PAAD	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.86	7.85	0.54	6.99e-13	Coronary artery disease;
PAAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.51	-5.21	-0.39	6.16e-7	Schizophrenia;
PAAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg05697835	chr1:2722811	NA	0.38	4.32	0.33	2.81e-5	Ulcerative colitis;
PAAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.57	6.32	0.46	2.79e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7173419	0.607	rs4278697	chr15:28223372	A/G	cg20906524	chr15:28200668	OCA2	-0.47	-5.57	-0.41	1.11e-7	Eye color;
PAAD	trans	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg06606381	chr12:133084897	FBRSL1	1.02	6.32	0.46	2.69e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09361491	chr1:47070176	MKNK1	0.56	6.53	0.47	9.3e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg15145296	chr3:125709740	NA	-0.63	-4.7	-0.36	5.73e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Bone mineral density;
PAAD	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.95	-6.17	-0.45	5.91e-9	Alzheimer's disease;
PAAD	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg23465465	chr6:26364728	BTN3A2	0.68	4.27	0.33	3.42e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.55	-5.18	-0.39	6.94e-7	Menarche (age at onset);
PAAD	cis	rs4653767	0.573	rs708772	chr1:226912891	A/G	cg05049329	chr1:226924846	ITPKB	0.42	5.51	0.41	1.48e-7	Parkinson's disease;
PAAD	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.58	6.71	0.48	3.66e-10	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18791223	chr7:157985780	PTPRN2	-0.71	-7.32	-0.51	1.36e-11	Obesity-related traits;
PAAD	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg09659197	chr4:152720779	NA	0.36	5.3	0.39	3.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4679121	0.642	rs55708952	chr3:126188912	A/G	cg05485589	chr3:126194908	ZXDC	-0.88	-4.39	-0.34	2.09e-5	Pursuit maintenance gain;
PAAD	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.68	4.91	0.37	2.3e-6	LDL cholesterol levels;
PAAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.63	-5.77	-0.42	4.24e-8	Obesity-related traits;
PAAD	cis	rs7853377	0.800	rs10868080	chr9:86626769	T/A	cg03531853	chr9:86535572	KIF27	-0.44	-4.62	-0.35	8.09e-6	Height;
PAAD	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.48	-5.51	-0.41	1.52e-7	Neuroticism;
PAAD	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.39	0.64	1.93e-19	Breast cancer;
PAAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.78	8.31	0.56	4.95e-14	Longevity;
PAAD	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.92	-7.54	-0.52	4.07e-12	Gut microbiome composition (summer);
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.26	0.56	6.47e-14	Rheumatoid arthritis;
PAAD	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs1942	0.813	rs11070327	chr15:41602866	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.62	-7.17	-0.5	3.11e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.3	8.51	0.57	1.56e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-4.66	-0.35	6.93e-6	Blood metabolite levels;
PAAD	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg23587288	chr2:27483067	SLC30A3	-0.66	-5.89	-0.43	2.4e-8	Blood metabolite levels;
PAAD	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg24375607	chr4:120327624	NA	0.43	4.42	0.34	1.83e-5	Diastolic blood pressure;
PAAD	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.48	4.57	0.35	9.85e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs8105895	0.935	rs62111034	chr19:22284720	A/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.53	-0.41	1.38e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs787274	1.000	rs787297	chr9:115542133	G/T	cg13803584	chr9:115635662	SNX30	-0.93	-6.54	-0.47	8.85e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	10.13	0.63	9.44e-19	Platelet count;
PAAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	Trans fatty acid levels;
PAAD	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.7	7.1	0.5	4.4e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg10818794	chr15:86012489	AKAP13	0.43	4.66	0.35	6.8e-6	Coronary artery disease;
PAAD	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg23682824	chr7:23144976	KLHL7	0.48	4.41	0.34	1.96e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs2594989	0.779	rs62245949	chr3:11575969	C/G	cg02835301	chr3:11609216	VGLL4	0.47	4.41	0.34	1.97e-5	Circulating chemerin levels;
PAAD	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg01388757	chr2:102091195	RFX8	-0.61	-8.1	-0.55	1.62e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19965948	chr4:79472807	ANXA3	0.58	6.32	0.46	2.7e-9	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13961709	chr14:74486189	C14orf45;ENTPD5	0.69	8.3	0.56	5.24e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.03	-0.44	1.17e-8	Body mass index;
PAAD	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.84	-10.37	-0.64	2.2e-19	Dental caries;
PAAD	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg04450456	chr4:17643702	FAM184B	0.52	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg21523528	chr20:32077966	CBFA2T2	0.51	4.31	0.33	2.96e-5	Height;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.84	-9.14	-0.6	3.83e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg05717871	chr11:638507	DRD4	-0.6	-5.13	-0.38	8.66e-7	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18204762	chr7:98741983	SMURF1	0.71	8.58	0.57	1.03e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.64	6.85	0.49	1.67e-10	Mean corpuscular volume;
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg06569542	chr10:98946673	SLIT1	-0.51	-5.61	-0.41	9.29e-8	Monocyte count;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.78	-6.31	-0.46	2.89e-9	Alzheimer's disease;
PAAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.63	-7.32	-0.51	1.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06250549	chr16:85196757	NA	0.53	6.88	0.49	1.46e-10	Smoking initiation;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.57	6.16	0.45	6.17e-9	Lung cancer;
PAAD	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6136489	0.710	rs13042885	chr20:1924707	A/G	cg19358608	chr20:1924565	NA	0.31	4.32	0.33	2.77e-5	Platelet distribution width;Mean platelet volume;
PAAD	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg26875137	chr12:53738046	NA	0.42	4.58	0.35	9.8e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.54	5.55	0.41	1.23e-7	Major depressive disorder;
PAAD	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg21855830	chr2:127963489	CYP27C1	0.44	4.27	0.33	3.46e-5	Protein C levels;
PAAD	cis	rs8258	0.927	rs693147	chr11:117266754	A/C	cg15227623	chr11:117232454	CEP164	0.56	5.19	0.39	6.53e-7	Pulse pressure;
PAAD	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.11	-0.5	4.29e-11	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg12757816	chr2:10669957	NA	0.45	4.72	0.36	5.29e-6	Prostate cancer;
PAAD	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1801251	0.727	rs35853577	chr2:233558879	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	6.44	0.46	1.52e-9	Coronary artery disease;
PAAD	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.74	-9.56	-0.61	3.03e-17	Educational attainment;
PAAD	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-7.38	-0.51	9.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs6496044	0.963	rs6496050	chr15:86069250	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	7e-6	Interstitial lung disease;
PAAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14983362	chr11:118901610	SLC37A4	0.64	7.22	0.51	2.28e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg20302533	chr7:39170763	POU6F2	0.45	6.92	0.49	1.17e-10	IgG glycosylation;
PAAD	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.13	-0.38	8.62e-7	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25745663	chr12:109535838	UNG	0.59	6.48	0.47	1.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.51	-4.71	-0.36	5.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.6	-6.95	-0.49	1e-10	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs793571	0.915	rs4775101	chr15:59218094	C/T	cg05156742	chr15:59063176	FAM63B	-0.6	-5.21	-0.39	6.03e-7	Schizophrenia;
PAAD	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.58	6.06	0.44	1.02e-8	Testicular germ cell tumor;
PAAD	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.61	0.47	6.17e-10	Primary sclerosing cholangitis;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07362569	chr17:61921086	SMARCD2	-0.5	-6.03	-0.44	1.17e-8	Prudent dietary pattern;
PAAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.39	4.26	0.33	3.58e-5	Male-pattern baldness;
PAAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12165864	chr7:66369176	NA	-0.76	-5.22	-0.39	5.71e-7	Diabetic kidney disease;
PAAD	cis	rs4740619	0.776	rs10962121	chr9:15702704	G/T	cg14451791	chr9:16040625	NA	0.39	4.35	0.33	2.46e-5	Body mass index;
PAAD	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.52	-4.73	-0.36	5.03e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4343996	1.000	rs4343996	chr7:3362642	G/A	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.18e-7	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13985868	chr9:116102304	WDR31	0.67	6.59	0.47	6.74e-10	Obesity-related traits;
PAAD	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg14343924	chr8:8086146	FLJ10661	-0.69	-5.77	-0.42	4.21e-8	Mood instability;
PAAD	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.63	-0.35	7.65e-6	Tuberculosis;
PAAD	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.99	0.49	8.01e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg19137606	chr10:38146164	ZNF248	0.92	6.45	0.46	1.41e-9	Airflow obstruction;
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg08057985	chr22:42470123	FAM109B	-0.36	-4.26	-0.33	3.57e-5	Schizophrenia;
PAAD	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg20406979	chr6:167373233	NA	-0.37	-5.09	-0.38	1.05e-6	Crohn's disease;
PAAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.54e-6	Bipolar disorder;
PAAD	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg07166546	chr14:35805898	NA	-0.32	-4.79	-0.36	3.94e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7617773	0.823	rs9839446	chr3:48194666	T/A	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg03805757	chr16:71968109	PKD1L3	-0.57	-4.35	-0.33	2.52e-5	Blood protein levels;
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.36	-0.33	2.42e-5	Schizophrenia;
PAAD	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg23752985	chr2:85803571	VAMP8	-0.56	-6.28	-0.45	3.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-6.11	-0.44	7.85e-9	Type 2 diabetes;
PAAD	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg00806126	chr19:22604979	ZNF98	0.41	5.29	0.39	4.2e-7	Pain;
PAAD	cis	rs9810890	1.000	rs73196964	chr3:128436391	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs11159086	0.793	rs11625502	chr14:74935012	G/A	cg10195687	chr14:74926396	NA	-0.47	-5.35	-0.4	3.18e-7	Advanced glycation end-product levels;
PAAD	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg17105886	chr17:28927953	LRRC37B2	0.85	5.2	0.39	6.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8014252	0.803	rs11158863	chr14:70981166	G/T	cg11204974	chr14:71022665	NA	0.73	4.96	0.37	1.84e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19494762	chr3:184279498	EPHB3	-0.66	-6.57	-0.47	7.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	trans	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.63	-6.49	-0.47	1.16e-9	Diastolic blood pressure;
PAAD	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.53	4.78	0.36	4.02e-6	Depression;
PAAD	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.62	-6.26	-0.45	3.8e-9	Height;
PAAD	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.74	7.39	0.51	9.22e-12	Resting heart rate;
PAAD	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26926768	chr12:34528122	NA	0.36	4.53	0.34	1.19e-5	Morning vs. evening chronotype;
PAAD	cis	rs317865	0.737	rs73234644	chr4:16190661	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.67	0.48	4.54e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.66	10.01	0.63	2e-18	Asthma (sex interaction);
PAAD	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg23665729	chr3:49977591	RBM6	0.66	4.26	0.33	3.52e-5	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg17759274	chr19:39260954	NA	0.37	4.41	0.34	1.98e-5	Heart rate;
PAAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg02390115	chr1:21767211	NBPF3	0.49	5.16	0.39	7.76e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.97	-8.31	-0.56	5.04e-14	Alzheimer's disease;
PAAD	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.85	7.13	0.5	3.75e-11	Pulmonary function decline;
PAAD	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.65	-5.85	-0.43	2.95e-8	Vitamin D levels;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.93	-0.37	2.16e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21827969	chr4:56212299	SRD5A3	0.63	7.22	0.51	2.27e-11	Metabolite levels  (X-11787);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15285217	chr17:4425752	SPNS2	-0.7	-7.19	-0.5	2.79e-11	Obesity-related traits;
PAAD	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs732765	0.734	rs10142036	chr14:75126992	T/A	cg01090926	chr14:75137805	KIAA0317	0.48	4.37	0.33	2.34e-5	Non-small cell lung cancer;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg27455613	chr17:80820699	TBCD	-0.46	-4.63	-0.35	7.83e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.82	-6.76	-0.48	2.75e-10	Cancer;
PAAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.5	4.77	0.36	4.34e-6	Parkinson's disease;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.75	-5.29	-0.39	4.12e-7	Lung cancer;
PAAD	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-11.51	-0.68	1.91e-22	Height;
PAAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	9.11	0.59	4.5e-16	Bone mineral density;
PAAD	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.42	-0.34	1.86e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.5	5.14	0.38	8.36e-7	Corneal astigmatism;
PAAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg12963246	chr6:28129442	ZNF389	0.56	4.51	0.34	1.3e-5	Parkinson's disease;
PAAD	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg13512537	chr8:22265999	SLC39A14	-0.48	-4.99	-0.38	1.62e-6	Verbal declarative memory;
PAAD	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11890956	chr21:40555474	PSMG1	-0.56	-5.73	-0.42	5.26e-8	Menarche (age at onset);
PAAD	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.27	-0.33	3.4e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg10856724	chr12:34555212	NA	-0.47	-4.85	-0.37	3.03e-6	Morning vs. evening chronotype;
PAAD	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.62	-5.81	-0.43	3.56e-8	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06614423	chr17:26989072	SDF2;SUPT6H	0.63	7.01	0.49	7.14e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.33	-0.33	2.7e-5	QT interval;
PAAD	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg18551225	chr6:44695536	NA	-0.6	-5.74	-0.42	4.96e-8	Total body bone mineral density;
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.69	8.17	0.55	1.09e-13	Age at first birth;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2133450	0.780	rs6443102	chr3:7354957	T/G	cg19930620	chr3:7340148	GRM7	-0.45	-4.73	-0.36	5.14e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs4979906	1.000	rs7915428	chr10:79460613	G/A	cg07817648	chr10:79422355	NA	-0.59	-5.4	-0.4	2.56e-7	Mortality in heart failure;
PAAD	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg10820045	chr2:198174542	NA	0.43	4.34	0.33	2.56e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.86	8.4	0.56	2.97e-14	Exhaled nitric oxide output;
PAAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.75	-7.98	-0.54	3.33e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03115019	chr17:80708279	FN3K	0.47	4.29	0.33	3.19e-5	Glycated hemoglobin levels;
PAAD	cis	rs225245	1.000	rs225245	chr17:33946107	A/G	cg05299278	chr17:33885742	SLFN14	0.39	4.55	0.35	1.11e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs35000415	0.745	rs117473643	chr7:128698186	G/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19800427	chr7:117067978	ASZ1	0.54	6.33	0.46	2.6e-9	Smoking initiation;
PAAD	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg27490568	chr2:178487706	NA	0.42	4.61	0.35	8.48e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.85	-10.39	-0.64	1.89e-19	Aortic root size;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg20639618	chr4:183729073	NA	0.62	5.19	0.39	6.78e-7	Pediatric autoimmune diseases;
PAAD	cis	rs58847779	0.536	rs739140	chr22:38115556	G/A	cg12325455	chr22:38092876	TRIOBP	0.51	4.28	0.33	3.25e-5	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.58	-5.32	-0.4	3.7e-7	Corneal structure;
PAAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.61	-8.49	-0.57	1.74e-14	Huntington's disease progression;
PAAD	cis	rs11615916	0.790	rs17660079	chr12:62716547	T/C	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs1885364	0.740	rs9608641	chr22:28093712	G/A	cg17187762	chr22:28070120	NA	0.35	4.52	0.34	1.26e-5	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14993964	chr7:97824766	LMTK2	0.67	6.88	0.49	1.43e-10	Smoking initiation;
PAAD	cis	rs72827839	0.846	rs16954078	chr17:46306127	T/A	cg23391107	chr17:45924227	SP6	0.63	5.34	0.4	3.39e-7	Ease of getting up in the morning;
PAAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg10935138	chr17:73851978	WBP2	0.94	7.78	0.53	1.05e-12	Psoriasis;
PAAD	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.6	6.11	0.44	7.86e-9	White matter hyperintensity burden;
PAAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.85	-10.28	-0.64	3.67e-19	Height;
PAAD	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg14784868	chr12:69753453	YEATS4	0.75	5.14	0.38	8.29e-7	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.68	-5.62	-0.41	8.79e-8	Bone mineral density;
PAAD	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09065629	chr16:1709722	CRAMP1L	0.48	5.22	0.39	5.76e-7	Coronary artery disease;
PAAD	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg27234864	chr13:21295941	IL17D	-0.53	-4.65	-0.35	7.1e-6	Dental caries;
PAAD	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg07150166	chr2:30669952	LCLAT1	0.65	4.82	0.36	3.5e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22541911	chr12:51785465	GALNT6	0.68	6.76	0.48	2.84e-10	Obesity-related traits;
PAAD	cis	rs7082209	1.000	rs12265306	chr10:44811617	C/G	cg13191911	chr10:44806660	NA	-0.92	-5.33	-0.4	3.45e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.71	6.98	0.49	8.58e-11	Blood protein levels;
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.69	7.5	0.52	5.01e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.34	0.4	3.38e-7	Height;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16464704	chr1:26249489	NA	0.61	6.8	0.48	2.29e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.49	-4.69	-0.36	6.06e-6	Type 2 diabetes;
PAAD	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.6	5.0	0.38	1.57e-6	Pubertal anthropometrics;
PAAD	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.75	-0.36	4.6e-6	Bipolar disorder;
PAAD	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg25790453	chr13:113633590	MCF2L	-0.39	-4.73	-0.36	5.16e-6	Systolic blood pressure;
PAAD	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.6	-5.85	-0.43	2.87e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-4.75	-0.36	4.61e-6	Cystic fibrosis severity;
PAAD	cis	rs9896052	0.500	rs7406077	chr17:73450015	T/A	cg25649188	chr17:73499917	CASKIN2	0.59	4.6	0.35	8.84e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg11262906	chr1:85462892	MCOLN2	0.6	4.76	0.36	4.41e-6	Serum sulfate level;
PAAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg09699651	chr6:150184138	LRP11	0.4	4.27	0.33	3.47e-5	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13418935	chr3:48282474	ZNF589	0.66	6.58	0.47	7.25e-10	Obesity-related traits;
PAAD	cis	rs8032158	0.963	rs1912402	chr15:56161919	C/T	cg02198044	chr15:56286336	NEDD4	-0.48	-5.09	-0.38	1.02e-6	Keloid;
PAAD	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg01426195	chr3:39028469	NA	-0.45	-4.73	-0.36	5e-6	Verbal declarative memory;
PAAD	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs7976059	0.895	rs12367434	chr12:52247915	C/T	cg13698196	chr12:52257893	NA	0.6	7.2	0.5	2.57e-11	Urate levels;
PAAD	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg10513866	chr5:139070639	NA	0.73	6.27	0.45	3.55e-9	Schizophrenia;
PAAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg16386425	chr10:429943	DIP2C	0.46	4.75	0.36	4.67e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	4.55	0.35	1.08e-5	Height;
PAAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00982548	chr2:198649783	BOLL	-0.88	-6.32	-0.46	2.71e-9	Ulcerative colitis;
PAAD	cis	rs2456568	0.695	rs7942055	chr11:93691063	A/C	cg19264203	chr11:92714893	MTNR1B	-0.42	-4.82	-0.36	3.4e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.68e-5	Total body bone mineral density;
PAAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.92	10.78	0.66	1.8e-20	Total body bone mineral density;
PAAD	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.91	11.9	0.69	1.74e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.38	4.56	0.35	1.06e-5	Uric acid levels;
PAAD	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.83	-0.43	3.18e-8	QT interval;
PAAD	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.56	4.71	0.36	5.48e-6	Prostate cancer;
PAAD	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.07	9.37	0.61	9.33e-17	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13775913	chr17:7297869	PLSCR3	-0.58	-7.01	-0.49	7.39e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.48	-4.5	-0.34	1.32e-5	Endometrial cancer;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13047869	chr3:10149882	C3orf24	0.67	5.55	0.41	1.26e-7	Alzheimer's disease;
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg25204440	chr1:209979598	IRF6	0.63	5.57	0.41	1.13e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg15691649	chr6:25882328	NA	0.52	4.64	0.35	7.4e-6	Blood metabolite levels;
PAAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	7.95	0.54	3.95e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14259520	chr10:89577736	ATAD1;CFLP1	0.72	6.82	0.48	1.99e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg23920097	chr1:209922102	NA	-0.49	-4.37	-0.33	2.3e-5	Red blood cell count;
PAAD	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.53	-6.01	-0.44	1.31e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9826463	0.702	rs73228758	chr3:142320559	A/G	cg20824294	chr3:142316082	PLS1	0.43	4.82	0.36	3.41e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13198984	chr17:80129470	CCDC57	0.44	5.45	0.4	1.95e-7	Life satisfaction;
PAAD	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.75	-5.68	-0.42	6.68e-8	Coronary artery calcification;
PAAD	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27467552	chr22:50353597	PIM3	-0.5	-5.0	-0.38	1.54e-6	Ulcerative colitis;
PAAD	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg02820901	chr13:113351484	ATP11A	0.73	4.76	0.36	4.48e-6	Glycated hemoglobin levels;
PAAD	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg13429435	chr10:81271195	EIF5AL1	-0.4	-4.39	-0.34	2.1e-5	Sarcoidosis;
PAAD	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.78	-7.37	-0.51	1.03e-11	Platelet distribution width;
PAAD	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg26875137	chr12:53738046	NA	-0.51	-4.97	-0.37	1.75e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-4.51	-0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg19781863	chr12:62918364	MON2	0.75	4.41	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.56	-4.82	-0.36	3.39e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2491441	1.000	rs2491441	chr1:183802259	T/C	cg08905629	chr1:183188297	LAMC2	-0.45	-4.25	-0.33	3.75e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18337363	chr3:52569053	NT5DC2	0.46	5.25	0.39	5.12e-7	Electroencephalogram traits;
PAAD	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg03115019	chr17:80708279	FN3K	0.5	4.49	0.34	1.41e-5	Glycated hemoglobin levels;
PAAD	cis	rs757081	0.533	rs7949405	chr11:17085192	A/C	cg15084286	chr11:17036142	PLEKHA7	0.55	4.87	0.37	2.76e-6	Systolic blood pressure;
PAAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.72	8.24	0.56	7.54e-14	Cisplatin-induced ototoxicity;
PAAD	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.47	4.77	0.36	4.27e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg16898833	chr6:26189333	HIST1H4D	0.99	5.11	0.38	9.51e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg02917321	chr22:38215204	NA	0.5	4.96	0.37	1.83e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.56	-6.25	-0.45	4.01e-9	Facial morphology (factor 20);
PAAD	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.49	5.66	0.42	7.22e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg22467129	chr15:76604101	ETFA	-0.52	-4.83	-0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.5e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.7	-7.35	-0.51	1.14e-11	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09775785	chr19:1863133	KLF16	0.57	6.58	0.47	7.04e-10	Monocyte percentage of white cells;
PAAD	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.46	-7.48	-0.52	5.61e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21862992	chr11:68658383	NA	0.44	4.68	0.36	6.18e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.86	8.95	0.59	1.16e-15	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.23e-6	Bipolar disorder;
PAAD	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-5.0	-0.38	1.58e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg09315469	chr11:101762317	ANGPTL5	-0.61	-6.55	-0.47	8.44e-10	Alcohol dependence;
PAAD	cis	rs7674212	0.531	rs2866416	chr4:103880711	G/C	cg16532752	chr4:104119610	CENPE	-0.48	-4.38	-0.33	2.21e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.74	-0.42	5.03e-8	Coronary artery disease;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg10864074	chr7:100318194	EPO	-0.48	-4.7	-0.36	5.71e-6	Other erythrocyte phenotypes;
PAAD	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.75	8.74	0.58	4.07e-15	Colorectal cancer;
PAAD	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.92	-0.37	2.25e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7631605	0.905	rs7615363	chr3:37006262	A/G	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.62	-8.91	-0.59	1.44e-15	Breast cancer;
PAAD	cis	rs939584	0.668	rs13008590	chr2:630788	A/G	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs3026101	0.624	rs11869800	chr17:5307781	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15528579	chr12:70094300	BEST3	-0.63	-6.54	-0.47	8.93e-10	Obesity-related traits;
PAAD	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10793968	0.748	rs10901277	chr9:133609581	A/T	cg01474677	chr9:133586259	NA	-0.57	-4.45	-0.34	1.67e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.78	-6.63	-0.47	5.6e-10	Other erythrocyte phenotypes;
PAAD	cis	rs6921919	0.789	rs13210258	chr6:28308671	G/T	cg23153227	chr6:27725408	NA	0.5	4.35	0.33	2.45e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6976053	0.935	rs7803865	chr7:100505792	C/T	cg22425096	chr7:100417404	EPHB4	-0.51	-4.32	-0.33	2.83e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.45e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.48	5.93	0.43	1.98e-8	Childhood ear infection;
PAAD	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.5	5.94	0.43	1.9e-8	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09065629	chr16:1709722	CRAMP1L	0.44	4.57	0.35	1.01e-5	Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs28644480	chr15:65026932	C/G	cg16425858	chr15:64791681	ZNF609	0.93	4.85	0.37	3.04e-6	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs35750365	chr10:46013143	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.84	-0.58	2.17e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.56	-0.57	1.15e-14	Longevity;Endometriosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06630098	chr19:16683316	SLC35E1	0.56	6.33	0.46	2.57e-9	Monocyte percentage of white cells;
PAAD	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg00543991	chr22:32367038	NA	1.18	7.22	0.51	2.29e-11	Childhood ear infection;
PAAD	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	1.3	17.37	0.82	6.31e-38	Post bronchodilator FEV1;
PAAD	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.37	9.34	0.6	1.13e-16	Diabetic retinopathy;
PAAD	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16490896	chr11:72853324	FCHSD2	0.6	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11112613	0.609	rs17037380	chr12:106036708	C/T	cg03607813	chr12:105948248	NA	0.79	5.78	0.42	4.08e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7084921	0.552	rs12780023	chr10:101874829	C/T	cg04359915	chr10:101825029	CPN1	-0.28	-4.37	-0.33	2.3e-5	Bone mineral density;
PAAD	cis	rs6604026	0.656	rs2811600	chr1:93334138	C/T	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14169450	chr9:139327907	INPP5E	-0.56	-5.72	-0.42	5.48e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs507080	0.922	rs555356	chr11:118558078	G/T	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	5.44	0.4	2.06e-7	Monocyte count;
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.16	0.55	1.15e-13	Schizophrenia;
PAAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.87	-0.43	2.68e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06307176	chr5:131281290	NA	-0.51	-4.68	-0.35	6.4e-6	Life satisfaction;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18621852	chr3:10150065	C3orf24	0.6	4.57	0.35	1e-5	Alzheimer's disease;
PAAD	cis	rs7715811	1.000	rs6554813	chr5:13763039	G/A	cg07548982	chr5:13769939	DNAH5	-0.64	-6.2	-0.45	5.1e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs682748	0.846	rs62347963	chr5:17133766	G/A	cg23987134	chr5:17158319	LOC285696	-0.35	-4.48	-0.34	1.44e-5	Hippocampal atrophy;
PAAD	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.6	7.07	0.5	5.38e-11	Aortic root size;
PAAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01616529	chr11:638424	DRD4	-0.63	-5.65	-0.42	7.83e-8	Systemic lupus erythematosus;
PAAD	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg10645314	chr2:3704589	ALLC	0.75	7.65	0.53	2.12e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg21361702	chr7:150065534	REPIN1	0.55	4.67	0.35	6.55e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg04851639	chr8:1020857	NA	-0.64	-8.14	-0.55	1.3e-13	Schizophrenia;
PAAD	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	6.91	0.49	1.22e-10	Hip circumference;
PAAD	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg12935359	chr14:103987150	CKB	-0.52	-5.6	-0.41	9.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg12940439	chr1:67600707	NA	-0.38	-4.6	-0.35	8.73e-6	Psoriasis;
PAAD	cis	rs9463078	0.653	rs1411148	chr6:45043618	A/G	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs16975963	0.644	rs11666662	chr19:38154702	A/T	cg14218481	chr19:38281219	NA	-0.43	-4.47	-0.34	1.53e-5	Longevity;
PAAD	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.55e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8044868	0.887	rs12449073	chr16:72171004	A/T	cg16579770	chr16:72058938	DHODH	0.42	4.39	0.34	2.14e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.59	-5.9	-0.43	2.27e-8	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20477591	chr5:67595709	PIK3R1	-0.66	-6.62	-0.47	5.78e-10	Obesity-related traits;
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg00976097	chr5:421733	AHRR	-0.53	-5.05	-0.38	1.23e-6	Cystic fibrosis severity;
PAAD	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg19781863	chr12:62918364	MON2	0.75	4.41	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.36e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4356203	0.905	rs10832743	chr11:17216480	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.37	-0.33	2.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.66	-6.18	-0.45	5.59e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-5.44	-0.4	2.07e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.65	-0.35	7.28e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg26727032	chr16:67993705	SLC12A4	0.67	5.84	0.43	3.06e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18918637	chr1:228607587	NA	-0.6	-6.35	-0.46	2.33e-9	Obesity-related traits;
PAAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23043162	chr7:113927529	NA	0.59	6.66	0.48	4.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs12928939	0.815	rs10500560	chr16:71681153	G/A	cg03805757	chr16:71968109	PKD1L3	-0.62	-5.46	-0.41	1.86e-7	Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	5.98e-6	Lung cancer;
PAAD	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.7	-6.14	-0.45	7.04e-9	Triglycerides;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18809274	chr6:108427575	NA	0.61	6.49	0.47	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg04705435	chr11:17411270	KCNJ11	0.6	6.31	0.46	2.85e-9	Type 2 diabetes;
PAAD	cis	rs4356203	0.870	rs214900	chr11:17227762	A/G	cg15432903	chr11:17409602	KCNJ11	0.43	4.56	0.35	1.06e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2051773	0.567	rs12288579	chr11:17039910	G/A	cg15084286	chr11:17036142	PLEKHA7	0.55	4.87	0.37	2.72e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-1.06	-11.51	-0.68	1.94e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs62284572	0.850	rs116168720	chr3:141856494	G/A	cg24126633	chr3:141762963	NA	-0.79	-4.57	-0.35	9.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg10210715	chr6:160221411	PNLDC1	-0.47	-4.31	-0.33	2.89e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs57994353	0.568	rs4400498	chr9:139305007	C/T	cg21253087	chr9:139290292	SNAPC4	0.54	4.62	0.35	7.98e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4233366	0.959	rs2070901	chr1:161185058	G/T	cg13853198	chr1:161185092	FCER1G	0.33	5.07	0.38	1.15e-6	Asthma;
PAAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-4.76	-0.36	4.4e-6	Metabolite levels;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.55	-0.41	1.26e-7	Lung cancer;
PAAD	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.55	5.1	0.38	9.85e-7	Total body bone mineral density;
PAAD	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.67	4.68	0.36	6.24e-6	Vitiligo;
PAAD	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs1499972	0.517	rs9815484	chr3:117637295	A/G	cg07612923	chr3:117604196	NA	-0.63	-4.94	-0.37	2.06e-6	Schizophrenia;
PAAD	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg24053715	chr22:38214548	NA	0.59	5.68	0.42	6.61e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs66530629	0.917	rs6604979	chr1:25099438	A/C	cg22509179	chr1:25234806	RUNX3	0.5	4.78	0.36	4.12e-6	Plateletcrit;
PAAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-1.01	-16.14	-0.79	8.84e-35	Recombination rate (males);
PAAD	cis	rs357618	1.000	rs357624	chr5:150848701	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs72960926	0.744	rs3846756	chr6:75061918	A/T	cg13997649	chr6:74171430	MTO1	0.86	4.73	0.36	5.01e-6	Metabolite levels (MHPG);
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs346785	0.965	rs443970	chr17:74303370	G/A	cg09812376	chr17:74270190	QRICH2	-0.43	-5.87	-0.43	2.66e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.98	0.37	1.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.57	5.46	0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.87	9.73	0.62	1.05e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs71520386	0.632	rs1029738	chr7:22874047	C/A	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22430790	chr14:52117833	FRMD6	0.52	6.35	0.46	2.33e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg09211372	chr6:168490623	NA	-0.44	-4.57	-0.35	9.91e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7155603	0.700	rs17103360	chr14:75959341	A/G	cg01624173	chr14:75981868	NA	0.65	5.61	0.41	9.4e-8	Rheumatoid arthritis;
PAAD	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.63	4.67	0.35	6.47e-6	Systolic blood pressure;
PAAD	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-4.42	-0.34	1.86e-5	Thyroid stimulating hormone;
PAAD	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Mean corpuscular volume;
PAAD	cis	rs1032355	0.558	rs7698547	chr4:100529085	C/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.48	-4.67	-0.35	6.68e-6	Blood metabolite levels;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.53	-0.41	1.37e-7	Systemic lupus erythematosus;
PAAD	cis	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg00806245	chr18:76673096	NA	-0.73	-5.19	-0.39	6.71e-7	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg06565975	chr8:143823917	SLURP1	-0.26	-5.44	-0.4	2.13e-7	Urinary tract infection frequency;
PAAD	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.47	5.03	0.38	1.37e-6	Lung cancer;
PAAD	cis	rs1497828	0.956	rs2810768	chr1:217563928	T/C	cg04411442	chr1:217543379	NA	0.49	4.78	0.36	4.14e-6	Dialysis-related mortality;
PAAD	cis	rs2075671	0.818	rs10953303	chr7:100365613	G/T	cg15510373	chr7:100224934	TFR2	-0.58	-4.72	-0.36	5.37e-6	Other erythrocyte phenotypes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24176037	chr6:134274008	TBPL1	-0.67	-6.5	-0.47	1.1e-9	Lung cancer in ever smokers;
PAAD	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg26566046	chr12:80083628	PAWR	0.6	6.46	0.46	1.33e-9	Iris heterochromicity;
PAAD	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.42	-6.19	-0.45	5.36e-9	Subjective well-being;
PAAD	cis	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.28	-0.39	4.4e-7	Mononucleosis;
PAAD	cis	rs78761021	0.867	rs7213983	chr17:9792115	C/T	cg26853458	chr17:9805074	RCVRN	-0.71	-8.34	-0.56	4.25e-14	Type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.59	5.18	0.39	7.09e-7	Height;
PAAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.25	0.67	9.6e-22	Menopause (age at onset);
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.48	4.41	0.34	1.93e-5	Age-related disease endophenotypes;
PAAD	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.41	5.08	0.38	1.1e-6	Corneal astigmatism;
PAAD	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg27455613	chr17:80820699	TBCD	-0.5	-4.98	-0.37	1.7e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs215088	0.917	rs215085	chr16:16067820	T/C	cg08996506	chr16:16070868	ABCC1	0.37	4.4	0.34	2.01e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.73	6.12	0.44	7.51e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg26513180	chr16:89883248	FANCA	-0.43	-4.55	-0.35	1.08e-5	Vitiligo;
PAAD	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.6	5.01	0.38	1.46e-6	Red blood cell count;
PAAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.5	-6.3	-0.45	3.08e-9	Height;
PAAD	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.56	-6.69	-0.48	4.06e-10	Schizophrenia;
PAAD	trans	rs3094146	1	rs3094146	chr6:29970960	G/C	cg06606381	chr12:133084897	FBRSL1	-1.47	-9.17	-0.6	3.13e-16	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06223186	chr7:1544111	INTS1	0.69	7.55	0.52	3.84e-12	Myopia (pathological);
PAAD	cis	rs6681460	1.000	rs7521111	chr1:67121634	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg15017067	chr4:17643749	FAM184B	0.43	4.97	0.37	1.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798766	1.000	rs798744	chr4:1714684	C/A	cg01305830	chr4:1604576	NA	-0.45	-4.37	-0.33	2.26e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2006771	0.765	rs6518752	chr22:31999127	A/G	cg02404636	chr22:31891804	SFI1	0.47	4.35	0.33	2.49e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg06569542	chr10:98946673	SLIT1	-0.52	-5.85	-0.43	2.92e-8	Monocyte count;
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22601191	chr20:60968625	CABLES2	-0.66	-5.94	-0.43	1.87e-8	Colorectal cancer;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.26	-0.39	4.8e-7	Life satisfaction;
PAAD	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg00944433	chr1:107599041	PRMT6	0.41	4.63	0.35	7.93e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs3768644	0.607	rs2241057	chr2:72361960	A/G	cg04940582	chr2:72356976	CYP26B1	0.56	4.41	0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.3	0.33	3.04e-5	Iron status biomarkers;
PAAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.32	0.33	2.83e-5	Total body bone mineral density;
PAAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg02487422	chr3:49467188	NICN1	0.46	4.73	0.36	5.06e-6	Resting heart rate;
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg11062466	chr8:58055876	NA	0.8	5.11	0.38	9.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.42	-0.4	2.31e-7	Lung cancer;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.7	-0.42	6.01e-8	Life satisfaction;
PAAD	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg25809561	chr17:30822961	MYO1D	0.67	7.14	0.5	3.69e-11	Schizophrenia;
PAAD	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7766436	0.687	rs10485012	chr6:22607026	A/C	cg13666174	chr6:22585274	NA	-0.43	-4.44	-0.34	1.73e-5	Coronary artery disease;
PAAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg07689907	chr11:61582574	FADS1	0.46	4.53	0.34	1.19e-5	Trans fatty acid levels;
PAAD	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.77	8.67	0.58	6.19e-15	Vitiligo;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06855334	chr11:18610462	UEVLD	-0.68	-6.35	-0.46	2.33e-9	Lung cancer in ever smokers;
PAAD	cis	rs730532	0.556	rs1032578	chr14:52523900	C/T	cg00766845	chr14:52536022	NID2	-0.63	-4.56	-0.35	1.07e-5	Pulmonary function;
PAAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.69	-0.36	6.09e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.89	4.87	0.37	2.82e-6	Childhood ear infection;
PAAD	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.49	-5.23	-0.39	5.6e-7	Ulcerative colitis;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg20639618	chr4:183729073	NA	0.65	5.23	0.39	5.59e-7	Pediatric autoimmune diseases;
PAAD	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs1413885	1.000	rs10736401	chr1:65816294	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	4.6	0.35	8.91e-6	Anticoagulant levels;
PAAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg04154034	chr17:28927549	LRRC37B2	0.7	4.75	0.36	4.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.5	5.35	0.4	3.2e-7	Tonsillectomy;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg13264159	chr8:625131	ERICH1	-0.8	-5.3	-0.4	3.93e-7	IgG glycosylation;
PAAD	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs13424612	1.000	rs10189996	chr2:240908800	G/A	cg01812947	chr2:240904978	NDUFA10	0.59	5.13	0.38	8.83e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.84	7.94	0.54	4.12e-13	Dilated cardiomyopathy;
PAAD	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.58e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.25	-0.73	3.96e-27	Primary sclerosing cholangitis;
PAAD	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg16558253	chr16:72132732	DHX38	0.52	4.25	0.33	3.64e-5	Blood protein levels;
PAAD	cis	rs10186876	0.561	rs10175281	chr2:44195272	G/C	cg14673618	chr2:45170322	SIX3	0.29	4.42	0.34	1.9e-5	Hand grip strength;
PAAD	cis	rs13011075	0.535	rs13028920	chr2:68629916	C/T	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.71	-7.11	-0.5	4.28e-11	Alcohol dependence;
PAAD	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg27182935	chr16:89790473	ZNF276	-0.86	-4.26	-0.33	3.63e-5	Skin colour saturation;
PAAD	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs2147959	0.831	rs7555386	chr1:228630589	C/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.49	-0.34	1.43e-5	Adult asthma;
PAAD	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.46	4.85	0.37	3.07e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.44	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.73	0.62	1.06e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs3779195	0.585	rs58699591	chr7:97876704	C/T	cg21770322	chr7:97807741	LMTK2	-0.53	-4.45	-0.34	1.65e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7009516	0.669	rs13251418	chr8:24246832	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.78	-0.42	4.17e-8	Hair greying;
PAAD	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.63	-6.35	-0.46	2.31e-9	Adiposity;
PAAD	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg16419906	chr5:132167176	NA	-0.64	-5.05	-0.38	1.25e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs13424612	0.839	rs4149548	chr2:240933241	A/G	cg24154722	chr2:241858322	NA	0.45	4.32	0.33	2.86e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.53	0.41	1.35e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.68	6.22	0.45	4.52e-9	Vitamin D levels;
PAAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.68	-6.99	-0.49	7.92e-11	Schizophrenia;
PAAD	cis	rs12949688	0.627	rs4793572	chr17:55834387	A/G	cg12582317	chr17:55822272	NA	0.5	5.88	0.43	2.45e-8	Schizophrenia;
PAAD	cis	rs12986413	0.651	rs35751290	chr19:2139357	A/G	cg09261902	chr19:2140048	AP3D1	0.59	5.96	0.44	1.67e-8	Height;
PAAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs4937076	1.000	rs2186754	chr11:125828097	A/G	cg25857886	chr11:126098838	FAM118B	0.45	4.67	0.35	6.57e-6	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg24565620	chr2:194026	NA	-0.69	-5.28	-0.39	4.4e-7	Blood protein levels;
PAAD	cis	rs1816752	0.740	rs6490924	chr13:25007052	G/A	cg02811702	chr13:24901961	NA	-0.49	-4.98	-0.37	1.69e-6	Obesity-related traits;
PAAD	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg15571903	chr15:79123663	NA	-0.46	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.47	4.52	0.34	1.25e-5	Ulcerative colitis;
PAAD	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	5.07	0.38	1.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg18200150	chr17:30822561	MYO1D	0.8	12.42	0.71	6.94e-25	Schizophrenia;
PAAD	cis	rs288342	0.832	rs208393	chr2:183649428	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.69	-0.36	6.16e-6	Recurrent major depressive disorder;
PAAD	cis	rs2031532	0.544	rs2407691	chr13:50037956	T/C	cg08779649	chr13:50194554	NA	0.34	4.47	0.34	1.54e-5	Cardiac hypertrophy;
PAAD	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.85	6.79	0.48	2.4e-10	Prostate cancer;
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.75	-8.9	-0.59	1.53e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs58521262	0.556	rs399132	chr19:23180700	C/A	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.62	6.22	0.45	4.6e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19027545	chr1:12082091	MIIP	-0.7	-6.39	-0.46	1.92e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.52	5.36	0.4	3.02e-7	Menopause (age at onset);
PAAD	trans	rs2790216	0.901	rs1698385	chr10:59928918	C/A	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.57	7.78	0.53	1.05e-12	Renal cell carcinoma;
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.43	4.49	0.34	1.42e-5	Caffeine consumption;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.77	8.98	0.59	9.71e-16	Lung cancer;
PAAD	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-9.99	-0.63	2.25e-18	Chronic sinus infection;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.91	11.67	0.69	7.34e-23	Menarche (age at onset);
PAAD	cis	rs9646944	0.501	rs36049530	chr2:103079988	T/C	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg14784868	chr12:69753453	YEATS4	0.53	4.47	0.34	1.51e-5	Response to diuretic therapy;
PAAD	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-13.62	-0.74	4.04e-28	Dental caries;
PAAD	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.71	-0.36	5.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg01620082	chr3:125678407	NA	-1.08	-6.29	-0.45	3.28e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg13207630	chr7:32358064	NA	0.78	4.31	0.33	2.89e-5	Body mass index;
PAAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-1.17	-9.63	-0.62	2e-17	Obesity-related traits;
PAAD	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-8.5	-0.57	1.61e-14	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg13722127	chr7:150037890	RARRES2	0.66	6.94	0.49	1.08e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.84	-7.87	-0.54	6.3e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.79	-8.67	-0.58	5.99e-15	Sudden cardiac arrest;
PAAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.75e-5	Monobrow;
PAAD	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg11271282	chr2:238384023	NA	-0.53	-4.5	-0.34	1.36e-5	Prostate cancer;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg07648498	chr16:89883185	FANCA	-0.46	-4.4	-0.34	2.05e-5	Vitiligo;
PAAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg26174226	chr8:58114915	NA	-0.69	-6.17	-0.45	6.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.82	-6.25	-0.45	3.85e-9	Coronary artery calcification;
PAAD	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.69	6.46	0.46	1.36e-9	Endometrial cancer;
PAAD	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.25	0.56	6.94e-14	Corneal astigmatism;
PAAD	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7180079	0.544	rs11071804	chr15:64975763	C/G	cg18210365	chr15:65066710	RBPMS2	0.5	4.4	0.34	2.06e-5	Monocyte count;
PAAD	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.41	4.43	0.34	1.78e-5	Fibrinogen levels;
PAAD	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.65	-5.03	-0.38	1.35e-6	Breast cancer;
PAAD	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17467752	chr17:38218738	THRA	0.54	4.83	0.36	3.28e-6	Myeloid white cell count;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs2506028	1.000	rs2506028	chr10:43444534	A/G	cg20628663	chr10:43360327	NA	-0.36	-4.28	-0.33	3.32e-5	Blood protein levels;
PAAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.18	-0.5	2.94e-11	Personality dimensions;
PAAD	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg01334972	chr11:72463230	ARAP1	0.69	5.06	0.38	1.22e-6	Type 2 diabetes;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.8	-0.43	3.78e-8	Prudent dietary pattern;
PAAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22633769	chr20:60982531	CABLES2	0.51	4.72	0.36	5.29e-6	Colorectal cancer;
PAAD	cis	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.98	-0.37	1.72e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.86	10.38	0.64	2.06e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.72	-0.48	3.41e-10	Total body bone mineral density;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.63	2.52e-18	Prudent dietary pattern;
PAAD	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.78	-8.08	-0.55	1.86e-13	Neuroticism;
PAAD	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.46e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.64	-7.79	-0.53	9.88e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg02297831	chr4:17616191	MED28	-0.62	-5.85	-0.43	2.97e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.07	-0.5	5.28e-11	Psoriasis;
PAAD	cis	rs62025270	0.632	rs62022924	chr15:86235507	A/G	cg13263323	chr15:86062960	AKAP13	0.51	4.62	0.35	8.16e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-7.46	-0.52	6.25e-12	Total body bone mineral density;
PAAD	cis	rs11638815	0.626	rs1313492	chr15:83272955	A/G	cg06459070	chr15:83331441	AP3B2	-0.37	-4.32	-0.33	2.81e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs2526932	0.625	rs2526947	chr14:73057259	G/T	cg13588403	chr14:73209128	DPF3	-0.4	-5.46	-0.4	1.93e-7	C-reactive protein and white blood cell count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18654971	chr5:54469363	MIR449C;CDC20B	0.6	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00173787	chr1:156698861	C1orf66;ISG20L2	0.64	7.23	0.51	2.22e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.82	-0.66	1.33e-20	Platelet distribution width;
PAAD	cis	rs66530629	0.874	rs7548438	chr1:25098341	C/T	cg22509179	chr1:25234806	RUNX3	-0.49	-4.54	-0.35	1.16e-5	Plateletcrit;
PAAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26796135	chr15:45671001	LOC145663;GATM	-0.47	-4.34	-0.33	2.62e-5	Homoarginine levels;
PAAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.5e-7	Restless legs syndrome;
PAAD	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.72	-8.21	-0.55	8.8e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.71	7.27	0.51	1.79e-11	Urate levels in lean individuals;
PAAD	cis	rs10214930	0.813	rs6462033	chr7:27618685	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.98	5.64	0.42	8.26e-8	Schizophrenia;
PAAD	cis	rs2286503	0.966	rs2286507	chr7:22854760	T/C	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.25e-5	Fibrinogen;
PAAD	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.56	5.48	0.41	1.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs747650	0.504	rs7938169	chr11:46971539	T/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24553691	chr21:47706090	MCM3AP;C21orf57	0.59	6.68	0.48	4.15e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06850241	chr22:41845214	NA	0.55	5.05	0.38	1.24e-6	Vitiligo;
PAAD	cis	rs7247513	0.964	rs4804200	chr19:12710752	C/G	cg01871581	chr19:12707946	ZNF490	-0.87	-11.04	-0.67	3.49e-21	Bipolar disorder;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Body mass index;
PAAD	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	6.96	0.49	9.56e-11	Response to antipsychotic treatment;
PAAD	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs4343996	0.967	rs4722663	chr7:3350567	C/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.21	-0.39	6.18e-7	Motion sickness;
PAAD	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.09	0.67	2.52e-21	Primary sclerosing cholangitis;
PAAD	cis	rs863345	0.901	rs863365	chr1:158551329	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.93	-0.37	2.11e-6	Pneumococcal bacteremia;
PAAD	cis	rs9487051	0.646	rs13203365	chr6:109614810	G/T	cg21918786	chr6:109611834	NA	-0.52	-5.54	-0.41	1.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.63	5.52	0.41	1.43e-7	Schizophrenia;
PAAD	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16414030	chr3:133502952	NA	-0.5	-5.06	-0.38	1.2e-6	Iron status biomarkers;
PAAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.8	-8.98	-0.59	9.66e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-4.56	-0.35	1.07e-5	Asthma;
PAAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10511378	1.000	rs1520115	chr3:118182377	C/T	cg12580583	chr3:119012721	CDGAP	-0.51	-4.28	-0.33	3.31e-5	Obesity-related traits;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.7	7.64	0.53	2.33e-12	Bipolar disorder and schizophrenia;
PAAD	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.82	-8.85	-0.58	2.16e-15	Facial morphology (factor 23);
PAAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4722585	0.640	rs12700708	chr7:26186015	T/C	cg03781084	chr7:26191726	NFE2L3	-0.49	-4.67	-0.35	6.59e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7719624	0.756	rs2302038	chr5:135397018	A/G	cg16684184	chr5:135415129	NA	0.41	5.05	0.38	1.27e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.09	0.44	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs11264799	0.501	rs849827	chr1:157545231	G/T	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23065793	chr3:169684395	LOC100128164;SEC62	0.66	6.73	0.48	3.29e-10	Obesity-related traits;
PAAD	trans	rs10511378	1.000	rs1520115	chr3:118182377	C/T	cg01584401	chr7:99063876	ATP5J2	-0.77	-7.15	-0.5	3.45e-11	Obesity-related traits;
PAAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs7561149	1.000	rs7591782	chr2:179693013	C/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.48	4.52	0.34	1.22e-5	QT interval;
PAAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs6604026	0.617	rs12059883	chr1:93381108	T/C	cg13858687	chr1:93297071	RPL5	0.48	4.36	0.33	2.34e-5	Multiple sclerosis;
PAAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.36	0.46	2.22e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.84	-10.23	-0.64	5.24e-19	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13389575	chr13:48890413	RB1	0.64	7.47	0.52	5.79e-12	Body fat percentage;
PAAD	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-7.3	-0.51	1.49e-11	Hemoglobin concentration;
PAAD	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.31	6.0	0.44	1.37e-8	Type 2 diabetes;
PAAD	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.64	-7.02	-0.49	6.93e-11	Colorectal cancer;
PAAD	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg08992911	chr2:238395768	MLPH	0.72	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.31	-0.56	4.9e-14	Longevity;Endometriosis;
PAAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.58	-6.76	-0.48	2.78e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg17595323	chr11:93583763	C11orf90	0.35	4.31	0.33	2.91e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.76	-7.05	-0.5	5.93e-11	Height;
PAAD	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg10820045	chr2:198174542	NA	0.44	4.25	0.33	3.75e-5	Dermatomyositis;
PAAD	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.61	-0.41	9.36e-8	Atrioventricular conduction;
PAAD	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.61	-0.41	9.48e-8	Schizophrenia;
PAAD	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.52	4.3	0.33	3.08e-5	Red blood cell count;
PAAD	cis	rs34845616	0.514	rs11822562	chr11:133690456	A/C	cg06766960	chr11:133703094	NA	0.61	5.21	0.39	5.99e-7	Hand grip strength;
PAAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg13870426	chr17:30244630	NA	-0.74	-6.56	-0.47	7.9e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.97	-11.15	-0.67	1.8e-21	Tonsillectomy;
PAAD	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.53	5.3	0.39	4e-7	Pulmonary function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18876314	chr1:234836447	NA	-0.67	-6.96	-0.49	9.54e-11	Obesity-related traits;
PAAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg15145965	chr22:50218605	BRD1	-0.56	-4.95	-0.37	1.94e-6	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.2	0.39	6.48e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.94	-11.05	-0.67	3.25e-21	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10795014	chr3:122137615	NA	-0.68	-6.63	-0.47	5.56e-10	Obesity-related traits;
PAAD	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.61	6.18	0.45	5.53e-9	Advanced glycation end-product levels;
PAAD	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg27529037	chr20:44575021	PCIF1	0.51	5.16	0.39	7.59e-7	Metabolite levels;
PAAD	cis	rs8051149	0.625	rs74039983	chr16:87882539	A/G	cg01412419	chr16:87856264	NA	0.56	5.03	0.38	1.39e-6	Blood metabolite levels;
PAAD	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	1.0	13.92	0.75	6.46e-29	Heart rate;
PAAD	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.38	11.01	0.67	4.28e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs9469913	0.542	rs75398113	chr6:34728071	G/C	cg14254433	chr6:34482411	PACSIN1	-0.82	-4.79	-0.36	3.99e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs863345	0.548	rs1032352	chr1:158493154	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	LDL cholesterol;
PAAD	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.96	-10.07	-0.63	1.35e-18	Monocyte percentage of white cells;
PAAD	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.22	0.55	8.42e-14	Coffee consumption (cups per day);
PAAD	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg04844267	chr4:1394941	NA	-0.44	-4.98	-0.37	1.7e-6	Obesity-related traits;
PAAD	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.46	6.63	0.47	5.41e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06441946	chr5:145583671	RBM27	0.66	7.51	0.52	4.7e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14059830	chr9:125878907	C9orf45	-0.72	-7.09	-0.5	4.83e-11	Obesity-related traits;
PAAD	cis	rs6141769	0.866	rs12481717	chr20:31215664	G/A	cg13636640	chr20:31349939	DNMT3B	0.57	4.65	0.35	7.12e-6	Subjective well-being;
PAAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.87	10.74	0.66	2.25e-20	Aortic root size;
PAAD	cis	rs7766436	0.614	rs11753751	chr6:22567273	C/T	cg13666174	chr6:22585274	NA	-0.51	-4.31	-0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.93	-0.37	2.17e-6	QT interval;
PAAD	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.86	10.67	0.65	3.45e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12082871	chr5:141017675	RELL2;HDAC3	0.54	6.65	0.47	4.91e-10	Metabolite levels  (X-11787);
PAAD	cis	rs11966931	1.000	rs17528993	chr6:108114633	C/G	cg13784235	chr6:108495865	NR2E1	-0.33	-4.27	-0.33	3.37e-5	Neutrophil percentage of white cells;
PAAD	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.29	7.42	0.52	7.89e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.15	0.39	7.96e-7	Prostate cancer;
PAAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.21e-5	Major depressive disorder;
PAAD	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.37	-0.33	2.26e-5	Ulcerative colitis;
PAAD	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.55	6.55	0.47	8.44e-10	Total body bone mineral density;
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.5	-5.02	-0.38	1.45e-6	Vitiligo;
PAAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.5	4.85	0.37	2.99e-6	Parkinson's disease;
PAAD	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.35	5.49	0.41	1.68e-7	Blood metabolite levels;
PAAD	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26031613	chr14:104095156	KLC1	1.16	15.6	0.78	2.35e-33	Body mass index;
PAAD	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.01	12.7	0.72	1.23e-25	Cognitive ability;
PAAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.58	-5.31	-0.4	3.83e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.68	6.35	0.46	2.33e-9	Subjective well-being;
PAAD	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg21775007	chr8:11205619	TDH	-0.45	-4.3	-0.33	3.1e-5	Triglycerides;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg00864860	chr1:7907996	UTS2	0.61	5.42	0.4	2.25e-7	Crohn's disease;
PAAD	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg21892295	chr12:121157589	UNC119B	-0.41	-4.91	-0.37	2.35e-6	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09296044	chr15:43477606	CCNDBP1	0.58	6.66	0.48	4.66e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg22089800	chr15:90895588	ZNF774	0.61	5.78	0.42	4.14e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	1.02	10.99	0.67	4.73e-21	Ulcerative colitis;
PAAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg16083429	chr3:49237500	CCDC36	-0.43	-4.36	-0.33	2.36e-5	Menarche (age at onset);
PAAD	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.51	4.75	0.36	4.64e-6	Hepatocellular carcinoma;
PAAD	cis	rs7188861	0.724	rs34437200	chr16:11391710	G/A	cg16532467	chr16:11454386	NA	-0.54	-4.32	-0.33	2.76e-5	HDL cholesterol;
PAAD	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.58	4.95	0.37	1.93e-6	Response to diuretic therapy;
PAAD	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.26	-0.45	3.73e-9	Acne (severe);
PAAD	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg27511599	chr7:32358540	NA	0.75	4.53	0.34	1.21e-5	Body mass index;
PAAD	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.53	-0.88	2.62e-50	Myeloid white cell count;
PAAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.73	7.96	0.54	3.65e-13	Longevity;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.47	-0.41	1.85e-7	Lung cancer;
PAAD	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs7264396	0.943	rs1810741	chr20:34109715	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.89	-0.43	2.43e-8	Total cholesterol levels;
PAAD	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.89	11.29	0.68	7.51e-22	Mean corpuscular volume;
PAAD	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-5.46	-0.41	1.87e-7	Reticulocyte count;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg13870426	chr17:30244630	NA	-0.73	-7.39	-0.51	9.23e-12	Hip circumference adjusted for BMI;
PAAD	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.72	6.91	0.49	1.22e-10	Resting heart rate;
PAAD	cis	rs8077577	1.000	rs62073606	chr17:18069142	G/A	cg16794390	chr17:18148240	FLII	0.56	4.66	0.35	6.8e-6	Obesity-related traits;
PAAD	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg26174226	chr8:58114915	NA	-0.61	-5.01	-0.38	1.53e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.91	0.37	2.28e-6	Lymphocyte counts;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20696912	chr3:183146011	MCF2L2	-0.66	-6.65	-0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7395662	0.674	rs7124275	chr11:48162305	C/T	cg21546286	chr11:48923668	NA	-0.5	-5.2	-0.39	6.21e-7	HDL cholesterol;
PAAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.55	-0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs17407555	0.738	rs73212898	chr4:10121994	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-4.87	-0.37	2.8e-6	Schizophrenia (age at onset);
PAAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.84	-9.21	-0.6	2.5e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.88	6.88	0.49	1.44e-10	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.74e-7	Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.73	7.9	0.54	5.2e-13	Melanoma;
PAAD	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg21892295	chr12:121157589	UNC119B	-0.39	-4.58	-0.35	9.69e-6	Mean corpuscular volume;
PAAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.76	8.44	0.56	2.33e-14	Coronary artery disease;
PAAD	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg10011062	chr15:43941034	CATSPER2	-0.9	-5.56	-0.41	1.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs35785195	0.593	rs12831240	chr12:114243590	A/G	cg24771877	chr12:114234123	NA	0.64	5.03	0.38	1.38e-6	Daytime sleep phenotypes;
PAAD	cis	rs17162190	0.698	rs6693662	chr1:26821230	A/G	cg17456097	chr1:26900765	RPS6KA1	0.6	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs28830936	0.966	rs11635415	chr15:42133502	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.86e-10	Diastolic blood pressure;
PAAD	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.13	-0.38	8.64e-7	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg15017067	chr4:17643749	FAM184B	0.41	4.82	0.36	3.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2120991	0.967	rs2577864	chr12:54287161	A/G	cg25640699	chr12:54070114	ATP5G2	0.43	4.58	0.35	9.64e-6	Biliary atresia;
PAAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg09222892	chr1:25734099	RHCE	-0.46	-4.54	-0.35	1.16e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-4.6	-0.35	8.83e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9815354	1.000	rs7617397	chr3:41959037	T/C	cg03022575	chr3:42003672	ULK4	-0.82	-5.91	-0.43	2.21e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.78	6.94	0.49	1.04e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs501120	0.657	rs617542	chr10:44743636	G/A	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg00717180	chr2:96193071	NA	-0.6	-6.62	-0.47	5.92e-10	HDL cholesterol;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	1.13	8.12	0.55	1.46e-13	IgG glycosylation;
PAAD	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.27e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.4	4.92	0.37	2.27e-6	Red cell distribution width;
PAAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.7	7.06	0.5	5.52e-11	Schizophrenia;
PAAD	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.9	-10.9	-0.66	8.46e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12935418	0.561	rs2287991	chr16:81040555	G/T	cg16651780	chr16:81037892	C16orf61	0.63	5.87	0.43	2.64e-8	Mean corpuscular volume;
PAAD	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	8.7	0.58	5.03e-15	Multiple sclerosis;
PAAD	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.69	7.26	0.51	1.89e-11	Menopause (age at onset);
PAAD	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg16316162	chr8:144660157	NAPRT1	0.94	6.86	0.49	1.63e-10	Attention deficit hyperactivity disorder;
PAAD	cis	rs12760731	0.720	rs12741848	chr1:178334941	A/G	cg00404053	chr1:178313656	RASAL2	0.68	5.48	0.41	1.72e-7	Obesity-related traits;
PAAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.61	-5.87	-0.43	2.7e-8	Psoriasis;
PAAD	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	7.76	0.53	1.18e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.83	9.51	0.61	4e-17	Metabolic syndrome;
PAAD	cis	rs2221894	0.960	rs1877501	chr8:28809951	A/G	cg20212339	chr8:28908912	HMBOX1	0.51	5.42	0.4	2.31e-7	Obesity-related traits;
PAAD	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.84	11.48	0.68	2.25e-22	Emphysema distribution in smoking;
PAAD	cis	rs9309711	0.961	rs4296457	chr2:3470595	G/A	cg25811867	chr2:3488468	NA	0.49	4.5	0.34	1.32e-5	Neurofibrillary tangles;
PAAD	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg19510604	chr15:74901076	CLK3	0.53	4.35	0.33	2.51e-5	Blood trace element (Zn levels);
PAAD	cis	rs2422052	1.000	rs2422052	chr2:118651764	G/C	cg22545206	chr2:118617499	NA	0.55	5.69	0.42	6.39e-8	Mosquito bite size;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05025164	chr4:1340916	KIAA1530	-0.52	-5.11	-0.38	9.49e-7	Obesity-related traits;
PAAD	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.13	-16.8	-0.81	1.79e-36	IgG glycosylation;
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	5.95e-6	Lung cancer;
PAAD	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.95	12.82	0.72	5.7e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg00147160	chr1:26503991	CNKSR1	0.39	4.47	0.34	1.53e-5	QRS complex (12-leadsum);
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.62	8.06	0.55	2.03e-13	Rheumatoid arthritis;
PAAD	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg18538332	chr22:24372958	LOC391322	-0.63	-4.65	-0.35	7.24e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg17385448	chr1:15911702	AGMAT	0.35	4.36	0.33	2.36e-5	Systolic blood pressure;
PAAD	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg01064725	chr1:204461714	NA	-0.51	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs2036402	0.911	rs12654554	chr5:156366296	T/C	cg21915449	chr5:156456672	HAVCR1	-0.39	-4.38	-0.33	2.23e-5	Hypertriglyceridemia;
PAAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg01075559	chr1:2537774	MMEL1	-0.54	-5.59	-0.41	1.01e-7	Multiple sclerosis;
PAAD	cis	rs6850606	0.537	rs1450930	chr4:42880575	C/G	cg24533989	chr4:42659536	ATP8A1	0.49	4.25	0.33	3.71e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.44	0.4	2.04e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg10290764	chr8:4849399	CSMD1	-0.4	-6.63	-0.47	5.44e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1519814	0.581	rs1879150	chr8:121011233	A/T	cg22335954	chr8:121166405	COL14A1	-0.64	-4.95	-0.37	1.98e-6	Breast cancer;
PAAD	cis	rs1419980	0.730	rs9634124	chr12:7734192	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.07e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.13	16.06	0.79	1.49e-34	Cognitive function;
PAAD	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.42	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	1.48	8.58	0.57	1.02e-14	Cannabis dependence symptom count;
PAAD	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	11.79	0.69	3.44e-23	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.79	-0.53	9.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.63	-6.62	-0.47	5.88e-10	Body mass index;
PAAD	cis	rs1468333	0.964	rs10479180	chr5:137581901	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.2	0.45	4.98e-9	Resting heart rate;
PAAD	trans	rs3763048	0.963	rs9790867	chr5:169455225	A/C	cg18340188	chr6:162863505	PARK2	0.6	6.29	0.45	3.22e-9	IgG glycosylation;
PAAD	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.42	-0.34	1.85e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7752195	0.558	rs76152345	chr6:25198735	G/A	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	5.79	0.43	3.92e-8	Total cholesterol levels;
PAAD	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11490944	chr10:103334150	NA	0.61	7.32	0.51	1.31e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-0.88	-8.3	-0.56	5.12e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7339483	0.867	rs7339599	chr19:24427154	A/C	cg00460763	chr19:23944615	RPSAP58	0.71	4.43	0.34	1.76e-5	Discordance in emotional problems in monozygotic twins;
PAAD	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	4.38	0.33	2.19e-5	Uric acid levels;
PAAD	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg16602846	chr15:78114278	NA	-0.39	-4.36	-0.33	2.39e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs15676	1.000	rs10988125	chr9:131572903	A/G	cg00228799	chr9:131580591	ENDOG	0.64	6.5	0.47	1.11e-9	Blood metabolite levels;
PAAD	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-5.94	-0.43	1.86e-8	Subjective well-being;
PAAD	cis	rs17092148	1.000	rs7265992	chr20:33525407	G/A	cg16810054	chr20:33298113	TP53INP2	0.56	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.86	-9.11	-0.59	4.42e-16	Body mass index;
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.96	-7.2	-0.5	2.61e-11	Initial pursuit acceleration;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs2997447	0.846	rs3008230	chr1:26401331	A/G	cg24519413	chr1:26490540	NA	0.5	4.64	0.35	7.33e-6	QRS complex (12-leadsum);
PAAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	4.26	0.33	3.55e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs13720	0.556	rs151335	chr20:57579950	A/G	cg23907860	chr20:57583709	CTSZ	-0.66	-5.41	-0.4	2.4e-7	Platelet distribution width;
PAAD	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.04	0.5	6.2e-11	Lung cancer in ever smokers;
PAAD	cis	rs6834538	0.597	rs13146963	chr4:113558602	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	5.57	0.41	1.11e-7	Rheumatoid arthritis;
PAAD	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg08992911	chr2:238395768	MLPH	1.05	4.98	0.37	1.73e-6	Prostate cancer;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.71	-0.48	3.54e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06799790	chr17:61951754	CSH2	-0.46	-4.89	-0.37	2.56e-6	Height;
PAAD	cis	rs7795096	0.743	rs9648729	chr7:151537759	G/C	cg17008978	chr7:151542804	PRKAG2	0.43	5.05	0.38	1.26e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg01426195	chr3:39028469	NA	0.62	6.1	0.44	8.34e-9	Handedness;
PAAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00981651	chr20:44574847	PCIF1	0.43	4.68	0.35	6.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.56	5.76	0.42	4.59e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg18621852	chr3:10150065	C3orf24	0.58	4.5	0.34	1.36e-5	Alzheimer's disease;
PAAD	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.87	-0.37	2.75e-6	Menopause (age at onset);
PAAD	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.83	-9.63	-0.62	1.98e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg18279126	chr7:2041391	MAD1L1	0.61	6.27	0.45	3.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg23241863	chr10:102295624	HIF1AN	0.47	4.32	0.33	2.84e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9472414	0.680	rs9472331	chr6:44699354	C/G	cg20913747	chr6:44695427	NA	0.54	5.01	0.38	1.5e-6	Height;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.62	6.55	0.47	8.49e-10	Bladder cancer;
PAAD	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg17737388	chr1:85724454	C1orf52	0.49	4.25	0.33	3.78e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg06697600	chr4:7070879	GRPEL1	0.88	4.45	0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	6.29	0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs367943	0.712	rs26964	chr5:112738532	T/C	cg12552261	chr5:112820674	MCC	0.66	6.64	0.47	5.26e-10	Type 2 diabetes;
PAAD	cis	rs2120991	0.967	rs7306498	chr12:54259701	A/G	cg21845580	chr12:53472882	SPRYD3	0.48	4.62	0.35	8.23e-6	Biliary atresia;
PAAD	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.64	-0.35	7.47e-6	Tuberculosis;
PAAD	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg16342193	chr10:102329863	NA	-0.73	-7.66	-0.53	2.01e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs6980507	0.523	rs2974294	chr8:42369473	C/T	cg09913449	chr8:42400586	C8orf40	-0.52	-5.99	-0.44	1.46e-8	Glycated hemoglobin levels;
PAAD	cis	rs4704187	0.687	rs6858969	chr5:74379281	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg08382946	chr5:1082689	SLC12A7	-0.46	-4.27	-0.33	3.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4666360	1.000	rs4233757	chr2:20336077	G/A	cg23291376	chr2:20336282	NA	-0.4	-4.47	-0.34	1.53e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg10434728	chr15:90938212	IQGAP1	0.44	4.61	0.35	8.34e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg06637938	chr14:75390232	RPS6KL1	0.48	4.72	0.36	5.38e-6	Height;
PAAD	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg23912435	chr1:150601613	ENSA	0.52	4.83	0.36	3.3e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.54	-0.47	8.97e-10	Plateletcrit;Platelet count;
PAAD	cis	rs939584	0.932	rs13022337	chr2:632609	A/G	cg03610516	chr2:642275	NA	0.62	5.49	0.41	1.68e-7	Body mass index;
PAAD	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.46	-4.5	-0.34	1.32e-5	Sitting height ratio;
PAAD	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.54	0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14182682	chr14:57857589	NAA30	0.61	6.57	0.47	7.57e-10	Pancreatic cancer;
PAAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.56	0.57	1.13e-14	Schizophrenia;
PAAD	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.69	-4.57	-0.35	9.93e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4743820	0.603	rs1887370	chr9:93927076	G/A	cg14446406	chr9:93919335	NA	-0.37	-4.84	-0.37	3.16e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg08036796	chr19:5034282	KDM4B	0.46	4.43	0.34	1.8e-5	Monocyte percentage of white cells;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.52	6.59	0.47	6.72e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.12e-8	Total body bone mineral density;
PAAD	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.07	0.38	1.16e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.51	4.82	0.36	3.49e-6	Pulse pressure;
PAAD	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	1.09	8.76	0.58	3.63e-15	Inflammatory bowel disease;
PAAD	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg07148914	chr20:33460835	GGT7	-0.45	-4.43	-0.34	1.81e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.56	-0.47	7.85e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs6782228	0.606	rs2811489	chr3:128337371	A/G	cg16766828	chr3:128327626	NA	0.48	6.59	0.47	6.69e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.87	-0.37	2.74e-6	Lung cancer;
PAAD	cis	rs863345	0.504	rs857698	chr1:158561166	A/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs2073300	1.000	rs6048833	chr20:23462185	G/A	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7083	0.653	rs573442	chr11:117177920	T/C	cg06114171	chr11:117561139	DSCAML1	-0.37	-4.3	-0.33	2.98e-5	Blood protein levels;
PAAD	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.64	4.62	0.35	8.26e-6	Vitiligo;
PAAD	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.86	10.01	0.63	1.91e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.13	-0.38	8.69e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12582317	chr17:55822272	NA	0.69	8.37	0.56	3.47e-14	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg21523564	chr15:75251491	NA	0.42	4.35	0.33	2.44e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.74	-4.39	-0.34	2.12e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.49	-4.36	-0.33	2.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg06632027	chr4:90757378	SNCA	-0.53	-4.68	-0.35	6.33e-6	Neuroticism;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	8.54	0.57	1.33e-14	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.91	6.91	0.49	1.28e-10	Alzheimer's disease;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10023613	chr17:42248099	ASB16	-0.3	-4.28	-0.33	3.35e-5	Total body bone mineral density;
PAAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15145965	chr22:50218605	BRD1	0.6	4.9	0.37	2.44e-6	Schizophrenia;
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg21698718	chr17:80085957	CCDC57	0.45	5.11	0.38	9.61e-7	Life satisfaction;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg00934597	chr7:893267	UNC84A	-0.47	-4.4	-0.34	2.06e-5	Subjective well-being;
PAAD	cis	rs4965359	0.665	rs11247257	chr15:101596646	A/G	cg02262866	chr15:101593693	LRRK1	0.47	4.53	0.35	1.17e-5	Central corneal thickness;
PAAD	cis	rs7772697	0.635	rs9498210	chr6:149410132	C/T	cg21368479	chr6:149415018	NA	0.41	4.39	0.34	2.1e-5	Diabetic retinopathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08085208	chr14:75348779	DLST	0.66	6.48	0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs367943	0.698	rs7728525	chr5:112972215	C/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs713477	1.000	rs10782426	chr14:55890702	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.36	-0.33	2.4e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.68	7.45	0.52	6.48e-12	Resting heart rate;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.52	-5.49	-0.41	1.61e-7	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.97	10.39	0.64	1.92e-19	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg15212455	chr7:39170539	POU6F2	0.49	6.84	0.48	1.84e-10	IgG glycosylation;
PAAD	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.78	7.83	0.54	7.64e-13	Uric acid levels;
PAAD	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.07	0.38	1.16e-6	Lung function (FEV1/FVC);
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg00024416	chr22:24240387	NA	-0.64	-6.98	-0.49	8.73e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs322144	0.967	rs322141	chr19:11426639	C/A	cg22357700	chr19:11805638	NA	0.45	4.33	0.33	2.71e-5	Breast cancer;
PAAD	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23248424	chr5:179741104	GFPT2	-0.75	-7.73	-0.53	1.39e-12	Height;
PAAD	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.59	6.55	0.47	8.21e-10	Coronary artery disease;
PAAD	cis	rs3931020	0.772	rs11485555	chr1:75186509	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.56	5.64	0.42	8.25e-8	Resistin levels;
PAAD	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg15816464	chr17:2026533	SMG6	-0.51	-5.66	-0.42	7.37e-8	Total body bone mineral density;
PAAD	cis	rs9463078	0.608	rs6925017	chr6:44950828	T/C	cg25276700	chr6:44698697	NA	-0.54	-6.12	-0.44	7.56e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg15685922	chr1:156045208	MEX3A	-0.65	-7.43	-0.52	7.17e-12	Ischemic stroke;
PAAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.6	6.29	0.45	3.28e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg06569542	chr10:98946673	SLIT1	0.47	4.87	0.37	2.78e-6	Monocyte count;
PAAD	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg27411982	chr8:10470053	RP1L1	-0.52	-5.66	-0.42	7.17e-8	Retinal vascular caliber;
PAAD	cis	rs9395066	0.545	rs12209076	chr6:44833423	G/A	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.41	4.48	0.34	1.45e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-9.85	-0.62	5.09e-18	Response to antipsychotic treatment;
PAAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg08975724	chr8:8085496	FLJ10661	-0.71	-7.26	-0.51	1.82e-11	Morning vs. evening chronotype;
PAAD	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg15816464	chr17:2026533	SMG6	0.49	5.34	0.4	3.4e-7	Total body bone mineral density;
PAAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.89	6.02	0.44	1.25e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg04156016	chr5:1868137	NA	0.44	4.45	0.34	1.66e-5	Cardiovascular disease risk factors;
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg08619932	chr19:49200058	FUT2	0.57	6.19	0.45	5.4e-9	Dietary macronutrient intake;
PAAD	cis	rs7165102	1.000	rs8023716	chr15:65744861	C/G	cg22900193	chr15:65823441	PTPLAD1	0.46	4.46	0.34	1.59e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg19257562	chr1:2043853	PRKCZ	-0.38	-4.55	-0.35	1.1e-5	Height;
PAAD	cis	rs8187707	0.570	rs57256140	chr10:101766362	T/C	cg23679471	chr10:102473810	NA	0.61	4.27	0.33	3.43e-5	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	4.83	0.36	3.36e-6	Tonsillectomy;
PAAD	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05158566	chr1:171711606	VAMP4	0.59	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4740619	0.870	rs10962149	chr9:15773953	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.37	-0.33	2.3e-5	Body mass index;
PAAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.33	5.84	0.43	3.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-9.11	-0.59	4.39e-16	Mortality in heart failure;
PAAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	7.49	0.52	5.16e-12	Parkinson's disease;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-4.85	-0.37	2.99e-6	Neuroticism;
PAAD	cis	rs6547631	0.594	rs7908	chr2:85925756	C/G	cg24620635	chr2:85921963	GNLY	0.42	5.55	0.41	1.23e-7	Blood protein levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05787193	chr1:84543369	PRKACB	-0.58	-6.66	-0.48	4.67e-10	Body fat percentage;
PAAD	cis	rs8113142	0.551	rs66806140	chr19:29151702	C/T	cg04546413	chr19:29218101	NA	0.4	4.25	0.33	3.68e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-5.49	-0.41	1.61e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.56	5.27	0.39	4.52e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs758324	0.947	rs173812	chr5:131319460	A/G	cg06307176	chr5:131281290	NA	-0.61	-5.15	-0.39	8.05e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg17346650	chr17:80929145	B3GNTL1	0.46	5.62	0.41	8.93e-8	Glycated hemoglobin levels;
PAAD	cis	rs10887741	0.532	rs791883	chr10:89409287	A/T	cg13926569	chr10:89418898	PAPSS2	-0.54	-5.54	-0.41	1.29e-7	Exercise (leisure time);
PAAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg26850624	chr5:429559	AHRR	-0.5	-4.85	-0.37	3.05e-6	Fat distribution (HIV);
PAAD	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	5.73	0.42	5.23e-8	Schizophrenia;
PAAD	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.48	-5.32	-0.4	3.69e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.81	8.51	0.57	1.57e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8067287	0.640	rs62065424	chr17:16828650	A/G	cg26910001	chr17:16838321	NA	-0.67	-6.08	-0.44	9.52e-9	Diabetic kidney disease;
PAAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-5.27	-0.39	4.67e-7	Response to metformin (IC50);
PAAD	trans	rs62179067	0.708	rs62176023	chr2:179915552	T/G	cg13380624	chr19:7735426	NA	-0.77	-7.01	-0.49	7.26e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.61	5.84	0.43	3.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg26668713	chr11:65405903	SIPA1	0.62	5.72	0.42	5.43e-8	Blood pressure (age interaction);
PAAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	11.06	0.67	3.14e-21	Menopause (age at onset);
PAAD	cis	rs302972	0.826	rs303011	chr6:25080848	A/C	cg01382804	chr6:25931017	SLC17A2	-0.8	-4.47	-0.34	1.54e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.78	9.56	0.61	2.96e-17	Bladder cancer;
PAAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7246760	1.000	rs56357664	chr19:9903399	C/T	cg16876255	chr19:9731953	ZNF561	0.94	4.49	0.34	1.42e-5	Pursuit maintenance gain;
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg10207240	chr12:122356781	WDR66	-0.55	-5.93	-0.43	1.93e-8	Mean corpuscular volume;
PAAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	7.5	0.52	4.97e-12	Multiple sclerosis;
PAAD	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.63	7.37	0.51	1.04e-11	Obesity-related traits;
PAAD	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.91	-10.15	-0.64	8.21e-19	Obesity-related traits;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg24101359	chr6:42928495	GNMT	0.66	7.12	0.5	4.07e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.61	-6.64	-0.47	5.18e-10	Coronary artery disease;
PAAD	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.59	5.89	0.43	2.34e-8	Joint mobility (Beighton score);
PAAD	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs11129295	0.618	rs9878720	chr3:27812594	A/G	cg21473142	chr3:27762095	EOMES	-0.26	-4.42	-0.34	1.89e-5	Multiple sclerosis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03752689	chr1:209958185	C1orf74	0.6	6.72	0.48	3.39e-10	Metabolite levels  (X-11787);
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg07148879	chr3:32443279	CMTM7	0.57	6.3	0.46	3.06e-9	Morning vs. evening chronotype;
PAAD	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs509477	0.887	rs595309	chr18:32562402	A/G	cg23791764	chr18:32556832	MAPRE2	0.58	4.75	0.36	4.74e-6	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.55	7.55	0.52	3.82e-12	Electrocardiographic conduction measures;
PAAD	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.59	0.41	1.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.47	4.38	0.33	2.21e-5	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.61	9.62	0.62	2.05e-17	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06544989	chr22:39130855	UNC84B	-0.43	-4.35	-0.33	2.51e-5	Menopause (age at onset);
PAAD	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.55	5.4	0.4	2.52e-7	Parkinson's disease;
PAAD	cis	rs7250872	0.568	rs8101970	chr19:1835625	C/T	cg23684787	chr19:1848742	REXO1	-0.53	-4.33	-0.33	2.69e-5	Bipolar disorder;
PAAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	1.03	12.65	0.72	1.6e-25	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg12615879	chr12:58013172	SLC26A10	0.41	4.64	0.35	7.38e-6	Multiple sclerosis;
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg04154034	chr17:28927549	LRRC37B2	0.74	5.04	0.38	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03676636	chr4:99064102	C4orf37	0.34	5.79	0.42	3.95e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.04	-0.5	6.07e-11	Colorectal cancer;
PAAD	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg04482110	chr17:41364121	TMEM106A	-0.38	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.69	7.62	0.53	2.48e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg26876637	chr1:152193138	HRNR	-0.85	-6.21	-0.45	4.86e-9	Atopic dermatitis;
PAAD	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.43	-4.44	-0.34	1.71e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg00049323	chr5:472564	LOC25845	0.42	4.97	0.37	1.76e-6	Cystic fibrosis severity;
PAAD	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.47	4.32	0.33	2.84e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg01075559	chr1:2537774	MMEL1	-0.53	-5.56	-0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12826209	chr6:26865740	GUSBL1	0.51	4.72	0.36	5.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4077515	0.839	rs4307445	chr9:139279776	C/G	cg14169450	chr9:139327907	INPP5E	0.56	5.74	0.42	4.9e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.97	-0.37	1.8e-6	Blood metabolite levels;
PAAD	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.45	0.71	5.5e-25	Cognitive ability;
PAAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg03094675	chr11:5960213	NA	-0.54	-4.82	-0.36	3.46e-6	DNA methylation (variation);
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.51	-0.34	1.29e-5	Tonsillectomy;
PAAD	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg08079166	chr15:68083412	MAP2K5	-0.58	-5.36	-0.4	3.09e-7	Restless legs syndrome;
PAAD	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.55	-4.53	-0.35	1.17e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	4.49	0.34	1.38e-5	Mood instability;
PAAD	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg16586182	chr3:47516702	SCAP	0.65	7.18	0.5	2.9e-11	Colorectal cancer;
PAAD	cis	rs4678145	1.000	rs17282057	chr3:124446077	T/C	cg07063911	chr3:125197837	SNX4	0.7	4.26	0.33	3.52e-5	Coronary artery disease;
PAAD	cis	rs5751901	1.000	rs5751901	chr22:24992266	C/T	cg15363607	chr22:24998974	GGT1	0.5	5.37	0.4	2.89e-7	Protein quantitative trait loci;
PAAD	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.25	-0.39	5.07e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg19904058	chr10:135279010	LOC619207	-0.36	-5.08	-0.38	1.11e-6	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg19217778	chr13:113420270	ATP11A	0.64	4.45	0.34	1.64e-5	Glycated hemoglobin levels;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.66	6.74	0.48	3.04e-10	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23330828	chr3:129611968	TMCC1	0.66	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg00999904	chr2:3704751	ALLC	-0.39	-4.49	-0.34	1.4e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.52	5.27	0.39	4.5e-7	Interleukin-18 levels;
PAAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.89	0.37	2.57e-6	Breast cancer;
PAAD	cis	rs16958440	0.867	rs76922914	chr18:44688454	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg22162314	chr17:61951766	CSH2	0.58	5.88	0.43	2.51e-8	Height;
PAAD	cis	rs7255045	0.743	rs10426080	chr19:12957850	A/G	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg07202610	chr7:1142643	C7orf50	-0.67	-5.55	-0.41	1.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs72753537	0.679	rs72751595	chr9:100587948	C/T	cg13688889	chr9:100608707	NA	-0.58	-4.26	-0.33	3.56e-5	Papillary thyroid cancer;Differentiated thyroid cancer;
PAAD	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	1.92e-11	Dupuytren's disease;
PAAD	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.08	-6.66	-0.48	4.78e-10	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08219700	chr8:58056026	NA	0.67	5.21	0.39	6.13e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.47	-5.12	-0.38	9.09e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00487848	chr12:132263715	SFRS8	-0.54	-6.37	-0.46	2.14e-9	Monocyte percentage of white cells;
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.68	0.69	6.67e-23	Platelet count;
PAAD	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg20917491	chr3:195578259	NA	0.48	4.87	0.37	2.78e-6	Pancreatic cancer;
PAAD	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.48	4.66	0.35	6.83e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.14	0.39	8.19e-7	HIV-1 control;
PAAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg09491104	chr22:46646882	C22orf40	-0.85	-5.32	-0.4	3.64e-7	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02920514	chr3:195610120	TNK2	0.53	6.6	0.47	6.58e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25043602	chr13:113489734	ATP11A	0.62	6.81	0.48	2.13e-10	Warfarin maintenance dose;
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.75	8.69	0.58	5.38e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17099076	chr12:62997412	MIRLET7I;C12orf61	-0.59	-6.75	-0.48	2.86e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.57	-0.52	3.31e-12	Blood metabolite levels;
PAAD	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	5.48	0.41	1.71e-7	Multiple sclerosis;
PAAD	cis	rs7577696	0.524	rs805831	chr2:32484228	C/G	cg02381751	chr2:32503542	YIPF4	0.51	4.9	0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.8	-5.25	-0.39	4.98e-7	Anti-saccade response;
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21016266	chr12:122356598	WDR66	-0.64	-7.15	-0.5	3.47e-11	Mean corpuscular volume;
PAAD	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.47	4.42	0.34	1.84e-5	Optic cup area;
PAAD	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	4.79	0.36	3.9e-6	Educational attainment;
PAAD	cis	rs9463078	0.546	rs1284982	chr6:45081821	C/T	cg25276700	chr6:44698697	NA	-0.44	-5.04	-0.38	1.33e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6785206	0.504	rs9875958	chr3:128497092	G/A	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs2882667	0.654	rs825760	chr5:138139974	G/T	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg17077180	chr1:38461687	NA	0.58	7.11	0.5	4.29e-11	Coronary artery disease;
PAAD	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.97	-11.86	-0.69	2.2e-23	Menarche (age at onset);
PAAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg06219351	chr7:158114137	PTPRN2	-0.82	-7.51	-0.52	4.66e-12	Response to amphetamines;
PAAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.61	6.25	0.45	3.89e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.59	5.01	0.38	1.49e-6	Common traits (Other);
PAAD	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.63	6.04	0.44	1.16e-8	Vitamin D levels;
PAAD	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.59	6.78	0.48	2.51e-10	Coronary artery disease;
PAAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.67	4.6	0.35	8.69e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08164334	chr1:19229453	ALDH4A1	0.59	6.97	0.49	9.09e-11	Monocyte percentage of white cells;
PAAD	cis	rs9810890	1.000	rs73198895	chr3:128565161	A/G	cg18531004	chr3:128564980	NA	-0.88	-4.58	-0.35	9.45e-6	Dental caries;
PAAD	cis	rs59888335	0.862	rs1013409	chr3:80562851	T/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg14631576	chr9:95140430	CENPP	-0.47	-4.67	-0.35	6.44e-6	Height;
PAAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.6	6.66	0.48	4.64e-10	Major depressive disorder;
PAAD	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18357526	chr6:26021779	HIST1H4A	0.55	4.83	0.36	3.29e-6	Height;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.49	-0.34	1.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg15733309	chr7:157513707	PTPRN2	0.63	7.83	0.54	7.79e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.74	-0.42	4.88e-8	Coronary artery calcification;
PAAD	cis	rs2004318	1.000	rs74742124	chr19:55134572	T/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg04851639	chr8:1020857	NA	-0.64	-8.11	-0.55	1.5700000000000001e-13	Schizophrenia;
PAAD	cis	rs2131877	0.830	rs62290329	chr3:194843634	G/A	cg19760965	chr3:194868843	C3orf21	0.51	4.89	0.37	2.49e-6	Non-small cell lung cancer;
PAAD	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01805347	chr1:39457128	AKIRIN1	0.62	6.41	0.46	1.77e-9	Myopia (pathological);
PAAD	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.03	-6.28	-0.45	3.36e-9	Mitochondrial DNA levels;
PAAD	cis	rs58521262	0.519	rs73026827	chr19:22932452	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs35740288	0.822	rs11638720	chr15:86229273	C/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02773019	chr3:135684688	PPP2R3A	0.6	7.13	0.5	3.87e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.92	7.74	0.53	1.3e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23009452	chr2:25264872	EFR3B	0.67	6.98	0.49	8.78e-11	Myopia (pathological);
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13047869	chr3:10149882	C3orf24	0.84	7.0	0.49	7.6e-11	Alzheimer's disease;
PAAD	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.73	5.22	0.39	5.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs797680	0.856	rs535760	chr1:93728758	T/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.3	-0.33	3.1e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.7	6.62	0.47	5.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.87	-10.08	-0.63	1.25e-18	Ulcerative colitis;
PAAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.26	-0.33	3.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.64	-5.88	-0.43	2.5e-8	Monocyte count;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.47e-6	Lung cancer;
PAAD	cis	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.78e-6	Mortality in heart failure;
PAAD	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg09941381	chr10:64027924	RTKN2	-0.37	-4.49	-0.34	1.43e-5	Rheumatoid arthritis;
PAAD	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	6.22	0.45	4.58e-9	Blood protein levels;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg09699651	chr6:150184138	LRP11	0.4	4.27	0.33	3.47e-5	Lung cancer;
PAAD	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.71	8.12	0.55	1.48e-13	Colorectal cancer;
PAAD	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg14773178	chr5:1868261	NA	0.35	4.62	0.35	8.25e-6	Cardiovascular disease risk factors;
PAAD	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.86	-8.03	-0.55	2.45e-13	Serum albumin level;
PAAD	cis	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg05338066	chr1:7812865	CAMTA1	0.64	4.86	0.37	2.88e-6	Inflammatory bowel disease;
PAAD	cis	rs2278796	1.000	rs12124296	chr1:204945618	G/A	cg17947172	chr1:204966197	NFASC	0.41	4.43	0.34	1.79e-5	Mean platelet volume;
PAAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg11802864	chr11:65308245	LTBP3	-0.44	-4.4	-0.34	2.03e-5	Bone mineral density;
PAAD	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.01	-0.44	1.34e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg16774013	chr18:77160150	NFATC1	0.6	6.71	0.48	3.71e-10	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs11159086	1.000	rs8006909	chr14:74944788	C/T	cg10195687	chr14:74926396	NA	-0.47	-5.06	-0.38	1.17e-6	Advanced glycation end-product levels;
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg16176600	chr6:116381609	FRK	0.3	4.33	0.33	2.73e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-15.03	-0.77	7.06e-32	Ulcerative colitis;
PAAD	cis	rs7678555	0.540	rs1503542	chr4:120861474	G/A	cg09307838	chr4:120376055	NA	0.46	4.28	0.33	3.29e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-4.68	-0.35	6.32e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg10011062	chr15:43941034	CATSPER2	0.81	4.69	0.36	5.93e-6	Lung cancer in ever smokers;
PAAD	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.76	-5.79	-0.43	3.92e-8	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	ch.5.1443044F	chr5:76332945	AGGF1	0.6	6.3	0.46	3.04e-9	Smoking initiation;
PAAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.66	0.62	1.66e-17	Cognitive function;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03247208	chr2:39005648	GEMIN6	-0.65	-6.42	-0.46	1.64e-9	Lung cancer in ever smokers;
PAAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg14092988	chr3:52407081	DNAH1	0.42	5.25	0.39	5.02e-7	Bipolar disorder;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	6.67	0.48	4.41e-10	Renal function-related traits (BUN);
PAAD	cis	rs939584	0.932	rs13387091	chr2:650980	G/A	cg03610516	chr2:642275	NA	-0.6	-5.4	-0.4	2.52e-7	Body mass index;
PAAD	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-10.28	-0.64	3.85e-19	Electrocardiographic conduction measures;
PAAD	cis	rs939584	1.000	rs6744653	chr2:628524	A/G	cg14515364	chr2:636606	NA	0.47	4.35	0.33	2.5e-5	Body mass index;
PAAD	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-6.17	-0.45	5.85e-9	Dilated cardiomyopathy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26138937	chr11:71823887	C11orf51	0.6	6.3	0.46	3.11e-9	Myopia (pathological);
PAAD	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	cis	rs78707713	0.891	rs80137017	chr10:71237382	C/T	cg12610070	chr10:71211762	TSPAN15	-0.6	-5.58	-0.41	1.05e-7	Venous thromboembolism;
PAAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.12	0.59	4.33e-16	Menopause (age at onset);
PAAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.71	-0.36	5.43e-6	Parkinson's disease;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.43e-6	Prudent dietary pattern;
PAAD	trans	rs4657482	0.606	rs3790655	chr1:165862323	T/A	cg03151810	chr8:144371745	NA	-0.51	-6.32	-0.46	2.7e-9	Testicular germ cell tumor;
PAAD	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.17	0.55	1.1e-13	Bladder cancer;
PAAD	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg02683114	chr2:24398427	C2orf84	0.51	4.99	0.38	1.62e-6	Asthma;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.89	-7.62	-0.53	2.51e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs72827839	1.000	rs72827834	chr17:46413819	G/A	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs2997447	0.723	rs2802338	chr1:26475257	G/A	cg24519413	chr1:26490540	NA	0.52	4.73	0.36	5.1e-6	QRS complex (12-leadsum);
PAAD	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs7264396	0.832	rs224381	chr20:34097136	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg08835956	chr7:39171034	POU6F2	0.33	5.7	0.42	6.11e-8	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.94	9.77	0.62	8.62e-18	Blood metabolite levels;
PAAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	4.9	0.37	2.39e-6	Menarche (age at onset);
PAAD	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg20893579	chr22:38215064	NA	0.49	4.61	0.35	8.39e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.51	4.49	0.34	1.4e-5	Total body bone mineral density;
PAAD	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.89	-0.43	2.37e-8	Mood instability;
PAAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	1.01	9.02	0.59	7.82e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7627468	0.739	rs9874845	chr3:121954304	A/T	cg03198317	chr3:121949109	CASR	0.48	4.45	0.34	1.64e-5	Kidney stones;
PAAD	cis	rs4936891	0.520	rs61908592	chr11:123871602	G/T	cg22125253	chr11:123886957	OR10G4	-0.43	-4.26	-0.33	3.57e-5	Male fertility;
PAAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg15145965	chr22:50218605	BRD1	0.62	5.21	0.39	6.1e-7	Schizophrenia;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.68	-8.83	-0.58	2.37e-15	Monocyte percentage of white cells;
PAAD	cis	rs3857067	0.550	rs28858161	chr4:95003641	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.46	5.9	0.43	2.3e-8	Renal cell carcinoma;
PAAD	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg21419209	chr3:44054225	NA	-0.76	-7.85	-0.54	6.76e-13	Coronary artery disease;
PAAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.55	5.17	0.39	7.28e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg13647721	chr17:30228624	UTP6	0.59	4.81	0.36	3.57e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.0	-0.49	7.5e-11	Colorectal cancer;
PAAD	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.43e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs9815354	1.000	rs9830469	chr3:41762535	A/G	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	8.3	0.56	5.2e-14	Hemoglobin concentration;
PAAD	cis	rs2073499	1.000	rs78020607	chr3:50254624	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.67	5.52	0.41	1.42e-7	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10546754	chr11:77348025	CLNS1A	-0.67	-6.44	-0.46	1.5e-9	Lung cancer in ever smokers;
PAAD	cis	rs639012	0.582	rs1898895	chr11:85837669	T/C	cg07180834	chr11:85838833	NA	-0.44	-4.65	-0.35	7.19e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3136441	1.000	rs2070850	chr11:46741495	C/T	cg19486271	chr11:47235900	DDB2	0.62	4.63	0.35	7.65e-6	HDL cholesterol;
PAAD	cis	rs2882667	0.690	rs160404	chr5:138084269	A/G	cg09476006	chr5:138032270	NA	0.45	5.63	0.42	8.27e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7752195	0.643	rs116090114	chr6:25257785	C/T	cg26336265	chr6:25042955	NA	0.78	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs427941	0.935	rs451352	chr7:101807338	T/A	cg06721601	chr7:101762633	CUX1	0.45	4.66	0.35	6.77e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.49	-4.6	-0.35	8.89e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs704	0.790	rs708100	chr17:26688663	G/A	cg10342447	chr17:26645325	TMEM97	-0.36	-4.57	-0.35	1e-5	Osteoprotegerin levels;
PAAD	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.36	-0.4	3.03e-7	Reticulocyte count;
PAAD	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.28	-0.39	4.42e-7	Height;
PAAD	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg19413350	chr8:57351067	NA	-0.5	-4.58	-0.35	9.62e-6	Obesity-related traits;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg17674042	chr6:34482479	PACSIN1	-0.93	-6.49	-0.47	1.12e-9	Pubertal anthropometrics;Coronary artery disease;
PAAD	trans	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.34	0.46	2.47e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.91	8.13	0.55	1.41e-13	Monocyte percentage of white cells;
PAAD	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10214930	0.706	rs10081338	chr7:27698588	G/T	cg22168087	chr7:27702803	HIBADH	-0.49	-4.42	-0.34	1.85e-5	Hypospadias;
PAAD	cis	rs10887741	0.532	rs2762522	chr10:89415541	A/G	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.13	-0.38	8.66e-7	Exercise (leisure time);
PAAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3736485	0.966	rs11070862	chr15:51902227	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.71e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25125898	chr5:5422196	KIAA0947	0.67	8.02	0.55	2.71e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.64	5.84	0.43	3.04e-8	Mean corpuscular volume;
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.52	-4.62	-0.35	7.99e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg21929781	chr1:2537748	MMEL1	0.54	5.65	0.42	7.85e-8	Ulcerative colitis;
PAAD	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.28	12.54	0.71	3.28e-25	Corneal structure;
PAAD	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	7.7	0.53	1.62e-12	Coronary artery disease;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.75	-10.13	-0.63	9.38e-19	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18364678	chr10:103586829	KCNIP2	-0.72	-7.45	-0.52	6.71e-12	Obesity-related traits;
PAAD	cis	rs8112211	0.731	rs3745951	chr19:38817486	A/G	cg14299480	chr19:38876666	GGN	-0.63	-6.08	-0.44	9.17e-9	Blood protein levels;
PAAD	cis	rs3764563	0.932	rs617436	chr19:15693151	T/C	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg15644404	chr18:77186268	NFATC1	-0.89	-6.2	-0.45	5.19e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.67	-0.53	1.86e-12	Exhaled nitric oxide output;
PAAD	cis	rs72634258	0.716	rs12067391	chr1:8163858	G/T	cg26816564	chr1:7831052	VAMP3	-0.61	-5.19	-0.39	6.75e-7	Inflammatory bowel disease;
PAAD	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg10183150	chr4:120222239	C4orf3	0.38	5.3	0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg15309053	chr8:964076	NA	0.43	4.81	0.36	3.6e-6	Schizophrenia;
PAAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.89	0.69	1.84e-23	Smoking behavior;
PAAD	cis	rs78411303	0.584	rs16833348	chr3:122377976	T/C	cg17380795	chr3:122379686	NA	0.76	5.6	0.41	9.76e-8	Periodontitis (CDC/AAP);
PAAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.09	0.38	1.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg04362095	chr11:63592001	C11orf84	-0.5	-4.45	-0.34	1.68e-5	Platelet count;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg23752985	chr2:85803571	VAMP8	0.51	5.7	0.42	5.96e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.79	8.47	0.57	1.96e-14	Mean corpuscular volume;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.74	-7.95	-0.54	3.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.49	5.91	0.43	2.18e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.71	-5.76	-0.42	4.54e-8	Diisocyanate-induced asthma;
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg26027780	chr6:27100370	HIST1H2AG;HIST1H2BJ	0.52	4.36	0.33	2.4e-5	Educational attainment;
PAAD	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg12661370	chr5:149340060	SLC26A2	0.64	5.52	0.41	1.4e-7	HIV-1 control;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	cis	rs457162	0.643	rs283089	chr6:118589974	C/T	cg21191810	chr6:118973309	C6orf204	0.74	4.9	0.37	2.46e-6	QT interval;
PAAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg00999904	chr2:3704751	ALLC	-0.81	-8.13	-0.55	1.39e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4450131	0.522	rs11245328	chr10:126358413	G/A	cg20435097	chr10:126320824	FAM53B	0.53	5.44	0.4	2.08e-7	White blood cell count (basophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00127732	chr19:42757846	ERF	0.59	6.63	0.47	5.5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg24553058	chr2:113831203	IL1F10	0.45	4.98	0.37	1.71e-6	Protein quantitative trait loci;
PAAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg21770322	chr7:97807741	LMTK2	0.51	7.05	0.5	5.98e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.59	-5.18	-0.39	6.94e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.56	-0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.72	7.93	0.54	4.33e-13	Body mass index;
PAAD	cis	rs4740619	0.689	rs10810507	chr9:15955369	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.75	-4.91	-0.37	2.37e-6	Lung cancer;
PAAD	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.79	6.47	0.46	1.25e-9	Monocyte percentage of white cells;
PAAD	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.7	-0.8	3.19e-36	Height;
PAAD	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.83	-4.41	-0.34	1.95e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs7929679	0.551	rs10836303	chr11:34792702	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.49	5.36	0.4	2.99e-7	Longevity;Endometriosis;
PAAD	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.52	5.85	0.43	2.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg21300403	chr2:198650112	BOLL	-0.49	-4.36	-0.33	2.37e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.34	0.56	4.26e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.44	-4.56	-0.35	1.03e-5	Calcium levels;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.793	rs77762169	chr1:227509201	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg01503450	chr10:980765	NA	-0.57	-5.03	-0.38	1.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.58	-5.42	-0.4	2.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11245990	chr11:68621969	NA	0.38	5.0	0.38	1.58e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.78	5.84	0.43	3.11e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs58521262	0.530	rs289353	chr19:23144589	C/T	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg10090792	chr1:38198142	EPHA10	-0.41	-4.43	-0.34	1.81e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg10871876	chr19:53194124	ZNF83	0.62	5.51	0.41	1.48e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg03615921	chr16:89375284	ANKRD11	-0.73	-4.48	-0.34	1.45e-5	Joint mobility (Beighton score);
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.49	6.96	0.49	9.34e-11	Mean corpuscular volume;
PAAD	cis	rs7688540	0.511	rs76125013	chr4:195282	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.92	0.37	2.19e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg17372223	chr3:52568218	NT5DC2	0.56	5.62	0.41	9.01e-8	Bipolar disorder;
PAAD	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.99	12.39	0.71	8.24e-25	Coronary artery disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11697258	chr17:61919381	SMARCD2	-0.61	-6.87	-0.49	1.57e-10	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21314839	chr13:114782035	RASA3	0.58	7.29	0.51	1.55e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.69	-0.42	6.36e-8	Monocyte count;
PAAD	cis	rs791888	0.667	rs2762520	chr10:89414845	A/G	cg13926569	chr10:89418898	PAPSS2	-0.57	-5.84	-0.43	3.1e-8	Magnesium levels;
PAAD	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs684232	0.644	rs870183	chr17:599811	A/G	cg15660573	chr17:549704	VPS53	-0.64	-5.96	-0.44	1.66e-8	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9982086	0.557	rs177294	chr21:27287244	T/C	cg04970570	chr5:87990145	NA	0.6	6.35	0.46	2.34e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.45	4.27	0.33	3.42e-5	High light scatter reticulocyte count;
PAAD	cis	rs9322817	0.691	rs2499659	chr6:105286124	A/T	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.22e-6	Mortality in heart failure;
PAAD	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.73	-7.11	-0.5	4.3e-11	Platelet distribution width;
PAAD	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.67	-7.2	-0.5	2.53e-11	Body mass index;
PAAD	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg11232448	chr19:2858854	NA	-0.48	-4.71	-0.36	5.59e-6	Total cholesterol levels;
PAAD	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.9	0.37	2.47e-6	Ovarian reserve;
PAAD	cis	rs4629180	0.538	rs6746761	chr2:102122390	G/T	cg04415270	chr2:102091202	RFX8	-0.55	-6.95	-0.49	1e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.7	8.76	0.58	3.64e-15	Cancer;
PAAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg19847866	chr10:1019161	NA	0.53	4.39	0.34	2.08e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.41	-0.4	2.39e-7	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20656871	chr2:239085063	ILKAP	-0.54	-6.44	-0.46	1.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs939584	1.000	rs4854339	chr2:623212	T/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs116248771	0.739	rs2082159	chr3:158359667	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs72828912	0.634	rs9358745	chr6:24053389	T/C	cg10859177	chr4:189973211	NA	0.69	6.45	0.46	1.38e-9	Squamous cell lung carcinoma;
PAAD	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.56	4.64	0.35	7.36e-6	Lymphocyte counts;
PAAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg01605746	chr5:669925	TPPP	0.39	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6987853	0.966	rs1947297	chr8:42453023	A/G	cg09913449	chr8:42400586	C8orf40	0.49	5.41	0.4	2.35e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg11271282	chr2:238384023	NA	0.59	4.59	0.35	9.37e-6	Prostate cancer;
PAAD	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.66	-7.14	-0.5	3.68e-11	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs1642645	0.831	rs3856259	chr1:42475503	T/C	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.29	-0.33	3.16e-5	Height;
PAAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.76	7.89	0.54	5.41e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.66	-7.17	-0.5	3.01e-11	Aortic root size;
PAAD	cis	rs2004318	1.000	rs113405276	chr19:55065801	G/A	cg03320607	chr19:54800032	LILRA3	-1.1	-6.09	-0.44	9.04e-9	Blood protein levels;
PAAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.71	8.4	0.56	2.94e-14	Bone mineral density;
PAAD	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg08975724	chr8:8085496	FLJ10661	0.69	7.06	0.5	5.7e-11	Neuroticism;
PAAD	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg08975724	chr8:8085496	FLJ10661	0.7	7.28	0.51	1.66e-11	Neuroticism;
PAAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.6	7.46	0.52	6.06e-12	Multiple system atrophy;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs8025118	0.583	rs7166607	chr15:79548995	G/A	cg11862246	chr15:78730200	IREB2	-0.51	-4.26	-0.33	3.54e-5	Cognitive function;
PAAD	cis	rs7101378	0.599	rs1509709	chr11:108900874	G/A	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.93	0.43	1.98e-8	Blood metabolite levels;
PAAD	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.31	-4.74	-0.36	4.79e-6	Red cell distribution width;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.52	4.64	0.35	7.56e-6	Lung cancer;
PAAD	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg09579323	chr1:150459698	TARS2	0.46	4.39	0.34	2.12e-5	Migraine;
PAAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg16083429	chr3:49237500	CCDC36	0.45	4.35	0.33	2.46e-5	Menarche (age at onset);
PAAD	cis	rs13401620	0.503	rs7596327	chr2:120952127	T/G	cg20969643	chr2:120002986	STEAP3	-0.5	-4.54	-0.35	1.13e-5	Breast size;
PAAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.39	-5.85	-0.43	2.98e-8	Educational attainment (years of education);
PAAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.83	0.36	3.31e-6	Breast cancer;
PAAD	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.87	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.91	6.24	0.45	4.08e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12780845	1.000	rs7894268	chr10:17199830	A/C	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs34375054	0.672	rs2291247	chr12:125618953	C/G	cg05341575	chr12:125625032	AACS	-0.45	-4.32	-0.33	2.76e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg03209809	chr3:126422892	CHCHD6	0.6	6.56	0.47	8.16e-10	Thyroid cancer;
PAAD	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.31	-4.74	-0.36	4.79e-6	Red cell distribution width;
PAAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg15640734	chr5:494837	SLC9A3	-0.44	-4.28	-0.33	3.32e-5	Cystic fibrosis severity;
PAAD	cis	rs78761021	0.755	rs17743980	chr17:9793839	G/A	cg26853458	chr17:9805074	RCVRN	0.73	8.49	0.57	1.78e-14	Type 2 diabetes;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.69	7.05	0.5	5.99e-11	Menarche (age at onset);
PAAD	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.79	10.15	0.64	8.57e-19	Morning vs. evening chronotype;
PAAD	cis	rs477895	0.582	rs71456310	chr11:64128494	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	5.16	0.39	7.44e-7	Mean platelet volume;
PAAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6681460	1.000	rs1329978	chr1:67116231	C/T	cg02459107	chr1:67143332	SGIP1	0.78	7.61	0.53	2.65e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.8	-0.36	3.76e-6	Lung cancer;
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.66	-6.03	-0.44	1.17e-8	Blood metabolite levels;
PAAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg14196790	chr5:131705035	SLC22A5	-0.49	-5.25	-0.39	5.09e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.32	4.31	0.33	2.93e-5	Dupuytren's disease;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.1	-0.55	1.71e-13	Brugada syndrome;
PAAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg21361702	chr7:150065534	REPIN1	0.59	4.94	0.37	2.08e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.5	6.16e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1497828	0.956	rs2815224	chr1:217529327	T/C	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.56	4.77	0.36	4.31e-6	Interleukin-17 levels;
PAAD	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.05	15.47	0.78	5.03e-33	Height;
PAAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25809561	chr17:30822961	MYO1D	0.66	7.25	0.51	1.93e-11	Schizophrenia;
PAAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.88	9.49	0.61	4.47e-17	Adiponectin levels;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.59	-6.75	-0.48	2.97e-10	Lung cancer;
PAAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.96	10.98	0.67	5.06e-21	Parkinson's disease;
PAAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.63	8.18	0.55	1.06e-13	Renal cell carcinoma;
PAAD	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg09168692	chr1:7887560	PER3	-0.43	-4.4	-0.34	2.04e-5	Inflammatory bowel disease;
PAAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.82	0.36	3.4e-6	Breast cancer;
PAAD	cis	rs13242816	1.000	rs36125850	chr7:116039918	C/T	cg16553024	chr7:116138462	CAV2	-0.66	-4.48	-0.34	1.45e-5	P wave duration;
PAAD	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.53	-5.21	-0.39	6.09e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.71	8.09	0.55	1.77e-13	Height;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7742824	0.917	rs6922473	chr6:44098287	G/A	cg21657043	chr6:44035552	NA	0.43	4.73	0.36	5.17e-6	Major depressive disorder;
PAAD	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.67	7.3	0.51	1.48e-11	Resting heart rate;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs3540	0.883	rs6496676	chr15:90988384	A/T	cg22089800	chr15:90895588	ZNF774	0.62	5.86	0.43	2.73e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.68	-5.33	-0.4	3.53e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.69	-7.1	-0.5	4.51e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.51	0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs10500715	0.715	rs10840335	chr11:9982745	T/A	cg06875754	chr11:10328428	ADM	-0.32	-4.36	-0.33	2.35e-5	Pancreatic cancer;
PAAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.33	0.68	5.94e-22	Menopause (age at onset);
PAAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-9.95	-0.63	2.91e-18	Headache;
PAAD	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	1.1	10.66	0.65	3.76e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.49	6.82	0.48	2.02e-10	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.07	0.38	1.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.46	4.66	0.35	6.96e-6	Motion sickness;
PAAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.6	0.57	9.29e-15	Schizophrenia;
PAAD	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg10556349	chr10:835070	NA	0.56	4.81	0.36	3.61e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.64	-0.35	7.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg21918786	chr6:109611834	NA	-0.41	-4.54	-0.35	1.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-6.78	-0.48	2.45e-10	Bipolar disorder;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg10544611	chr16:67998164	SLC12A4	-0.61	-4.31	-0.33	2.96e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-5.74	-0.42	5.05e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1372356	0.816	rs8019631	chr14:88520702	G/T	cg18078958	chr14:88630771	NA	0.49	6.18	0.45	5.74e-9	Food antigen IgG levels;
PAAD	cis	rs6142102	0.961	rs2377957	chr20:32554473	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.68e-5	Skin pigmentation;
PAAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.24	-4.39	-0.34	2.11e-5	IgG glycosylation;
PAAD	cis	rs66530629	0.917	rs11249178	chr1:25171719	G/C	cg22509179	chr1:25234806	RUNX3	0.49	4.55	0.35	1.1e-5	Plateletcrit;
PAAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg01064725	chr1:204461714	NA	-0.51	-4.88	-0.37	2.61e-6	Schizophrenia;
PAAD	cis	rs8062405	0.625	rs8060365	chr16:28911309	C/A	cg16576597	chr16:28551801	NUPR1	-0.65	-6.51	-0.47	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs733175	0.951	rs6846692	chr4:10031133	C/G	cg11266682	chr4:10021025	SLC2A9	0.59	5.07	0.38	1.14e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.02	-0.44	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg06375148	chr1:209958343	C1orf74	0.63	5.42	0.4	2.25e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.74	7.99	0.54	3.05e-13	Melanoma;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-6.54	-0.47	8.89e-10	Lymphocyte counts;
PAAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.25	-0.39	4.98e-7	Aortic root size;
PAAD	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg10820045	chr2:198174542	NA	0.47	4.75	0.36	4.67e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.58	-5.52	-0.41	1.44e-7	Psoriasis;
PAAD	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	8.05	0.55	2.23e-13	Lung function (FEV1/FVC);
PAAD	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.62	6.39	0.46	1.88e-9	Testicular germ cell tumor;
PAAD	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.53	-0.34	1.19e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	8.94e-7	Motion sickness;
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg07202610	chr7:1142643	C7orf50	-0.67	-5.55	-0.41	1.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg20913747	chr6:44695427	NA	-0.7	-6.96	-0.49	9.52e-11	Total body bone mineral density;
PAAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg16083429	chr3:49237500	CCDC36	0.46	4.48	0.34	1.43e-5	Menarche (age at onset);
PAAD	cis	rs360071	0.528	rs360093	chr1:226064745	G/T	cg01472176	chr1:226074946	LEFTY1	0.58	5.77	0.42	4.29e-8	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs425535	0.757	rs487834	chr4:74795131	C/T	cg01447579	chr4:74847100	PF4	0.67	4.57	0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg13207630	chr7:32358064	NA	0.91	4.49	0.34	1.39e-5	Body mass index;
PAAD	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg22906224	chr7:99728672	NA	-0.64	-5.68	-0.42	6.68e-8	Coronary artery disease;
PAAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.62	-7.58	-0.52	3.19e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.73	6.19	0.45	5.37e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.54	5.62	0.41	8.92e-8	Subjective well-being;
PAAD	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.51	0.41	1.53e-7	Coronary heart disease;
PAAD	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg13870426	chr17:30244630	NA	-0.72	-5.74	-0.42	4.92e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.93	6.93	0.49	1.12e-10	Plateletcrit;
PAAD	cis	rs1497828	0.956	rs1007736	chr1:217547852	C/T	cg04411442	chr1:217543379	NA	0.5	4.94	0.37	2.05e-6	Dialysis-related mortality;
PAAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.56	6.14	0.45	6.95e-9	Menopause (age at onset);
PAAD	cis	rs8032158	0.702	rs11632977	chr15:56131609	T/C	cg02198044	chr15:56286336	NEDD4	-0.43	-4.42	-0.34	1.86e-5	Keloid;
PAAD	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.92	7.62	0.53	2.6e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.72	-5.71	-0.42	5.76e-8	Type 2 diabetes;
PAAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.95	-7.57	-0.52	3.29e-12	Initial pursuit acceleration;
PAAD	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.39	-4.52	-0.34	1.23e-5	Pubertal anthropometrics;
PAAD	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg26876637	chr1:152193138	HRNR	-0.8	-5.6	-0.41	9.89e-8	Atopic dermatitis;
PAAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	6.62	0.47	5.96e-10	Initial pursuit acceleration;
PAAD	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg08601574	chr20:25228251	PYGB	-0.66	-7.26	-0.51	1.91e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.8	8.58	0.57	1.04e-14	Calcium levels;
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg04775059	chr7:64541387	NA	0.56	5.81	0.43	3.62e-8	Calcium levels;
PAAD	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.39	-0.4	2.62e-7	QT interval;
PAAD	cis	rs6466055	0.661	rs1558048	chr7:104829241	G/C	cg04380332	chr7:105027541	SRPK2	0.51	4.99	0.38	1.6e-6	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-4.62	-0.35	8.25e-6	Subjective well-being;
PAAD	cis	rs863345	0.565	rs59188837	chr1:158500636	C/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.77	-6.76	-0.48	2.84e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg11062466	chr8:58055876	NA	0.65	4.72	0.36	5.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs965469	0.843	rs6037580	chr20:3351374	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg14393609	chr7:65229607	NA	0.63	6.83	0.48	1.93e-10	Aortic root size;
PAAD	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg24076588	chr1:18808559	KLHDC7A	0.4	4.72	0.36	5.2e-6	Breast cancer;
PAAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.76	-0.36	4.5e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16925697	chr17:55055258	SCPEP1	0.65	6.56	0.47	7.75e-10	Obesity-related traits;
PAAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg04482110	chr17:41364121	TMEM106A	0.4	4.49	0.34	1.38e-5	Menopause (age at onset);
PAAD	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.92	-0.37	2.27e-6	Mean corpuscular volume;
PAAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-5.13	-0.38	8.54e-7	Menarche (age at onset);
PAAD	trans	rs62179067	0.708	rs62176021	chr2:179909130	C/G	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs6585424	1.000	rs12268619	chr10:81920660	A/C	cg19423196	chr10:82049429	MAT1A	0.44	4.52	0.34	1.23e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6597981	0.675	rs1138714	chr11:825110	A/G	cg21775979	chr11:780331	NA	-0.46	-4.55	-0.35	1.08e-5	Breast cancer;
PAAD	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7705042	0.865	rs449454	chr5:141533062	A/G	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.57	-0.35	1.01e-5	Asthma;
PAAD	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.04	0.38	1.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9815354	1.000	rs6789260	chr3:41776350	G/C	cg03022575	chr3:42003672	ULK4	0.76	5.44	0.4	2.13e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg23083516	chr15:85180758	SCAND2	0.38	4.28	0.33	3.36e-5	P wave terminal force;
PAAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	8.19	0.55	9.75e-14	Menopause (age at onset);
PAAD	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.2	-0.5	2.63e-11	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21577260	chr17:73285714	SLC25A19	0.58	6.29	0.45	3.18e-9	Myopia (pathological);
PAAD	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9314614	0.789	rs2977795	chr8:6709805	G/A	cg27319216	chr8:6693540	XKR5	-0.34	-4.49	-0.34	1.37e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs2790457	0.771	rs2800737	chr10:28943072	T/C	cg05705492	chr10:28955341	NA	-0.46	-4.48	-0.34	1.49e-5	Multiple myeloma;
PAAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.92e-7	Prostate cancer;
PAAD	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.33	-0.51	1.3e-11	Neuroticism;
PAAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.2	0.6	2.65e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs988913	0.957	rs932452	chr6:54801928	C/T	cg03513858	chr6:54763001	FAM83B	-0.48	-5.34	-0.4	3.27e-7	Menarche (age at onset);
PAAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-5.23	-0.39	5.46e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-6.64	-0.47	5.19e-10	Parkinson's disease;
PAAD	cis	rs6076065	0.723	rs6083088	chr20:23343793	G/T	cg11657817	chr20:23433608	CST11	0.5	5.21	0.39	6.17e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.92	-9.47	-0.61	5.31e-17	Response to antineoplastic agents;
PAAD	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.43	-4.27	-0.33	3.37e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	9.39	0.61	8.48e-17	Ulcerative colitis;
PAAD	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	1.19	13.72	0.74	2.19e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs6501435	1.000	rs9898123	chr17:69082074	G/A	cg00193521	chr17:68133597	NA	0.43	4.27	0.33	3.44e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs6424115	0.771	rs2229586	chr1:24200903	G/C	cg15997130	chr1:24165203	NA	0.58	6.09	0.44	8.96e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2075671	0.818	rs10953302	chr7:100365567	C/T	cg20848291	chr7:100343083	ZAN	-0.75	-6.14	-0.45	6.95e-9	Other erythrocyte phenotypes;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg11271282	chr2:238384023	NA	0.52	4.81	0.36	3.65e-6	Prostate cancer;
PAAD	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.78	-9.22	-0.6	2.38e-16	White blood cell count (basophil);
PAAD	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs829661	0.793	rs829565	chr2:30693733	T/C	cg12454169	chr2:30669597	LCLAT1	0.64	4.4	0.34	2.03e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.29	0.64	3.56e-19	Platelet count;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11955344	chr2:20550531	NA	0.74	6.57	0.47	7.43e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg04154034	chr17:28927549	LRRC37B2	0.64	4.27	0.33	3.45e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.04	0.44	1.13e-8	Menopause (age at onset);
PAAD	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.69	-6.24	-0.45	4.07e-9	Diabetic retinopathy;
PAAD	cis	rs6688613	1.000	rs6427049	chr1:166956593	C/T	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.38e-6	Birth weight;
PAAD	cis	rs56309584	0.755	rs11655903	chr17:8141324	T/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.45	-4.52	-0.34	1.26e-5	Initial pursuit acceleration;
PAAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-4.25	-0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.09	-0.38	1.03e-6	Obesity-related traits;
PAAD	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.53	4.89	0.37	2.54e-6	Multiple sclerosis;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	4.79	0.36	3.92e-6	Obesity-related traits;
PAAD	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg15556689	chr8:8085844	FLJ10661	0.61	6.1	0.44	8.26e-9	Joint mobility (Beighton score);
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.98	-0.49	8.58e-11	Life satisfaction;
PAAD	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg22134325	chr11:66188745	NPAS4	0.32	4.71	0.36	5.44e-6	Airway imaging phenotypes;
PAAD	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.46	-0.34	1.61e-5	Colorectal cancer;
PAAD	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg10006428	chr1:248814059	OR2T27	0.37	4.45	0.34	1.66e-5	Common traits (Other);
PAAD	cis	rs7646881	0.812	rs73017540	chr3:158460788	T/A	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.61	6.04	0.44	1.14e-8	Monocyte count;
PAAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02244288	chr16:89573955	SPG7	-0.33	-4.31	-0.33	2.9e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg07148914	chr20:33460835	GGT7	0.51	4.95	0.37	1.98e-6	Coronary artery disease;
PAAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-1.05	-8.86	-0.58	1.98e-15	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12847295	chr10:102974725	NA	0.59	6.57	0.47	7.53e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs77633900	0.772	rs2078437	chr15:76669580	A/G	cg21673338	chr15:77095150	SCAPER	0.85	4.37	0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Gut microbiome composition (summer);
PAAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.85	6.4	0.46	1.78e-9	Blood protein levels;
PAAD	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.78	0.48	2.52e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.67	7.42	0.52	7.82e-12	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs859767	0.501	rs1568121	chr2:135406606	G/A	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg02106180	chr16:845767	CHTF18	0.45	5.16	0.39	7.68e-7	Mean corpuscular volume;
PAAD	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-6.52	-0.47	9.79e-10	Morning vs. evening chronotype;
PAAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.59	6.23	0.45	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9942416	0.582	rs66787104	chr5:75015698	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.43	4.28	0.33	3.24e-5	Age-related disease endophenotypes;
PAAD	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.47	6.14	0.45	6.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg07454742	chr17:42254645	ASB16;C17orf65	-0.4	-4.45	-0.34	1.66e-5	Total body bone mineral density;
PAAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.37e-10	Coronary artery disease;
PAAD	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-1.05	-7.17	-0.5	3.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg21828629	chr1:205913422	SLC26A9	-0.4	-4.36	-0.33	2.37e-5	Cystic fibrosis-related diabetes;
PAAD	cis	rs10493340	1.000	rs41290154	chr1:63605304	G/A	cg08634298	chr1:64337861	ROR1	-0.46	-4.5	-0.34	1.33e-5	Blood pressure;
PAAD	cis	rs4739066	0.579	rs12547848	chr8:63879389	G/A	cg12194929	chr8:63776755	NKAIN3	0.74	4.59	0.35	9.11e-6	Myocardial infarction;
PAAD	cis	rs3736485	0.934	rs17609791	chr15:51874824	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg20744362	chr22:50050164	C22orf34	0.68	8.3	0.56	5.32e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3112530	1.000	rs300328	chr5:152703035	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.83	-4.37	-0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.56	0.47	7.79e-10	Coronary artery disease;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg23298862	chr7:158159286	PTPRN2	0.57	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.96	-0.37	1.83e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.5	6.43	0.46	1.56e-9	Prostate cancer;
PAAD	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg14191688	chr11:70257035	CTTN	0.56	5.18	0.39	7.05e-7	Coronary artery disease;
PAAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg25922239	chr6:33757077	LEMD2	0.49	4.66	0.35	6.9e-6	Essential tremor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11029301	chr3:10206731	IRAK2	0.7	6.94	0.49	1.04e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.61	-5.57	-0.41	1.12e-7	IgG glycosylation;
PAAD	cis	rs7853377	0.723	rs10868071	chr9:86532613	A/T	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.64	7.27	0.51	1.72e-11	Dupuytren's disease;
PAAD	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg10978503	chr1:24200527	CNR2	-0.38	-4.4	-0.34	2.06e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.45e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg00999904	chr2:3704751	ALLC	-0.81	-8.1	-0.55	1.67e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg10820045	chr2:198174542	NA	0.44	4.25	0.33	3.75e-5	Dermatomyositis;
PAAD	cis	rs66530629	0.874	rs6692599	chr1:25094714	T/C	cg01905478	chr1:25040257	NA	-0.46	-5.03	-0.38	1.35e-6	Plateletcrit;
PAAD	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.81	-7.79	-0.53	9.71e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs73206853	0.764	rs61227741	chr12:110598319	G/T	cg12870014	chr12:110450643	ANKRD13A	0.71	4.47	0.34	1.55e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.48	5.23	0.39	5.45e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2286379	0.749	rs10773991	chr12:1885306	C/T	cg05227549	chr12:1770782	NA	-0.43	-5.01	-0.38	1.49e-6	Blood pressure (smoking interaction);
PAAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.54	7.34	0.51	1.17e-11	Renal cell carcinoma;
PAAD	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg21194808	chr1:2205498	SKI	0.43	4.28	0.33	3.34e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22044901	chr15:68126292	NA	0.61	6.44	0.46	1.47e-9	Myopia (pathological);
PAAD	cis	rs308971	0.656	rs307582	chr3:12085149	T/C	cg02700894	chr3:12045449	SYN2	0.63	5.35	0.4	3.11e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.47	4.33	0.33	2.67e-5	Diastolic blood pressure;
PAAD	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.62	-6.65	-0.47	4.98e-10	Neuroticism;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-5.47	-0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	6.07	0.44	9.85e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3026101	0.624	rs12601818	chr17:5320438	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	6.29	0.45	3.14e-9	Body mass index;
PAAD	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.41	4.35	0.33	2.48e-5	Monocyte percentage of white cells;
PAAD	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.74	7.64	0.53	2.29e-12	High light scatter reticulocyte percentage of red cells;Plateletcrit;
PAAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.83	11.31	0.68	6.62e-22	Emphysema distribution in smoking;
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.72	10.31	0.64	3.1400000000000002e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.65	6.97	0.49	9.08e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.2	-17.5	-0.82	3e-38	Ulcerative colitis;
PAAD	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.01	-14.4	-0.76	3.4e-30	Heart rate;
PAAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg26727032	chr16:67993705	SLC12A4	0.7	5.38	0.4	2.81e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.83	7.06	0.5	5.55e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.6	4.55	0.35	1.09e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-4.56	-0.35	1.05e-5	Rheumatoid arthritis;
PAAD	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg16903589	chr10:116417809	ABLIM1	0.43	4.26	0.33	3.55e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg17724175	chr1:150552817	MCL1	-0.51	-5.77	-0.42	4.27e-8	Tonsillectomy;
PAAD	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg27490568	chr2:178487706	NA	0.44	4.91	0.37	2.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.68	-0.53	1.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg09177884	chr7:1199841	ZFAND2A	-0.73	-6.11	-0.44	7.88e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.14	-0.6	3.74e-16	Mortality in heart failure;
PAAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.61	-6.06	-0.44	1.02e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.95	6.73	0.48	3.32e-10	Psoriasis vulgaris;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24517875	chr10:134538559	INPP5A	-0.62	-6.57	-0.47	7.5e-10	Obesity-related traits;
PAAD	cis	rs1982963	0.585	rs77091361	chr14:52486961	C/T	cg20550154	chr14:52487779	NID2	0.55	4.36	0.33	2.42e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.63	-5.94	-0.43	1.85e-8	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	1.92e-13	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02925840	chr1:180992110	STX6	0.63	6.46	0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs61884328	0.733	rs78998999	chr11:47228403	A/T	cg23433285	chr11:47201945	PACSIN3	0.85	4.48	0.34	1.46e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs76878669	0.583	rs8187658	chr11:66134085	C/T	cg10685839	chr11:66611485	RCE1	0.46	4.25	0.33	3.65e-5	Educational attainment (years of education);
PAAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg05791153	chr7:19748676	TWISTNB	0.54	4.46	0.34	1.62e-5	Thyroid stimulating hormone;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg07212818	chr11:638076	DRD4	-0.68	-6.52	-0.47	9.64e-10	Systemic lupus erythematosus;
PAAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.71	8.45	0.57	2.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6718203	1.000	rs918053	chr2:60630016	T/C	cg10480506	chr2:60280451	NA	0.8	4.49	0.34	1.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.7	7.65	0.53	2.09e-12	Melanoma;
PAAD	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.79	9.84	0.62	5.67e-18	Colorectal cancer;
PAAD	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.44	5.38	0.4	2.77e-7	Iron status biomarkers;
PAAD	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Myopia (pathological);
PAAD	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.49	5.03	0.38	1.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.5	-4.35	-0.33	2.49e-5	Acne (severe);
PAAD	cis	rs7696796	0.662	rs17309350	chr4:183175899	C/T	cg03209412	chr4:183728196	NA	0.59	4.9	0.37	2.42e-6	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09978128	chr17:8339376	NDEL1	0.69	8.24	0.56	7.38e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg21535247	chr6:8435926	SLC35B3	-0.5	-4.82	-0.36	3.43e-6	Motion sickness;
PAAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.82	0.36	3.39e-6	Breast cancer;
PAAD	cis	rs2936519	0.929	rs2978930	chr8:6638292	T/A	cg22103414	chr8:6638082	NA	-0.41	-4.31	-0.33	2.91e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.56	5.42	0.4	2.34e-7	Systemic lupus erythematosus;
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg14433983	chr11:636460	DRD4	-0.47	-4.95	-0.37	1.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.9	0.37	2.41e-6	Schizophrenia;
PAAD	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.85	-0.37	2.97e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg16961492	chr6:46101741	ENPP4	-0.38	-4.6	-0.35	8.95e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13898584	chr4:144434443	SMARCA5	-0.74	-6.75	-0.48	2.95e-10	Neuroticism;
PAAD	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.58	-4.51	-0.34	1.31e-5	QRS complex (12-leadsum);
PAAD	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.65	7.07	0.5	5.24e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	11.99	0.7	1e-23	Menarche (age at onset);
PAAD	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.78	-0.36	4.02e-6	Testicular germ cell tumor;
PAAD	cis	rs11811982	0.744	rs115302983	chr1:227376624	G/T	cg24860534	chr1:227506868	CDC42BPA	0.47	4.43	0.34	1.82e-5	Optic disc area;
PAAD	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.59	6.42	0.46	1.67e-9	Bladder cancer;
PAAD	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg23281280	chr6:28129359	ZNF389	0.5	4.43	0.34	1.76e-5	Parkinson's disease;
PAAD	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg12046867	chr14:103022105	NA	-0.57	-4.77	-0.36	4.19e-6	Platelet count;
PAAD	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12612619	0.732	rs13021112	chr2:27259794	G/A	cg00617064	chr2:27272375	NA	-0.54	-5.69	-0.42	6.28e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.67	-0.35	6.64e-6	Breast cancer;
PAAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs2594989	1.000	rs388407	chr3:11320709	C/T	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg06740227	chr12:86229804	RASSF9	0.6	5.88	0.43	2.45e-8	Major depressive disorder;
PAAD	cis	rs116248771	0.549	rs4680461	chr3:158454160	C/G	cg16708174	chr3:158430962	RARRES1	0.79	5.79	0.43	3.81e-8	diarrhoeal disease at age 2;
PAAD	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.02	0.38	1.4e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.85	0.43	2.92e-8	Eye color traits;
PAAD	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs10901513	1.000	rs10901513	chr10:127699936	T/C	cg22975853	chr10:127789788	ADAM12	0.41	4.31	0.33	2.95e-5	Visceral fat;
PAAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.83	7.5	0.52	5e-12	Glomerular filtration rate (creatinine);
PAAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg06740227	chr12:86229804	RASSF9	0.59	5.37	0.4	2.95e-7	Major depressive disorder;
PAAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.59	-7.23	-0.51	2.22e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6942407	0.592	rs757961	chr7:86849510	T/C	cg02420886	chr7:86849541	C7orf23	0.69	5.33	0.4	3.47e-7	Food allergy;
PAAD	cis	rs1359582	0.757	rs1214468	chr10:90413865	A/T	cg15661332	chr10:90342814	RNLS	0.56	4.91	0.37	2.35e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs9356171	0.572	rs2281407	chr6:164325926	C/T	cg25752492	chr6:164341247	NA	-0.47	-5.22	-0.39	5.87e-7	Diisocyanate-induced asthma;
PAAD	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg16434002	chr17:42200994	HDAC5	0.63	5.7	0.42	6.09e-8	Total body bone mineral density;
PAAD	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.63	0.42	8.59e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.75	-0.77	4.04e-31	Height;
PAAD	cis	rs367943	0.547	rs11241218	chr5:112958258	T/C	cg12552261	chr5:112820674	MCC	0.51	5.07	0.38	1.17e-6	Type 2 diabetes;
PAAD	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.72	6.68	0.48	4.23e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.87	-7.37	-0.51	1.02e-11	IgG glycosylation;
PAAD	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg04362960	chr10:104952993	NT5C2	-0.51	-4.63	-0.35	7.82e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.73	0.53	1.4e-12	Morning vs. evening chronotype;
PAAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg02478829	chr6:26598070	ABT1	-0.47	-4.67	-0.35	6.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	4.87	0.37	2.78e-6	Renal function-related traits (BUN);
PAAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs10821973	0.527	rs7092746	chr10:63971245	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-4.27	-0.33	3.4e-5	Hypothyroidism;
PAAD	cis	rs9322817	0.583	rs9377667	chr6:105154880	G/A	cg02098413	chr6:105308735	HACE1	-0.43	-5.52	-0.41	1.45e-7	Thyroid stimulating hormone;
PAAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg22875332	chr1:76189707	ACADM	-0.51	-5.06	-0.38	1.17e-6	Daytime sleep phenotypes;
PAAD	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16576597	chr16:28551801	NUPR1	0.67	7.5	0.52	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs74161807	0.561	rs2901112	chr10:118398877	T/A	cg10511988	chr10:118891706	VAX1	0.39	4.64	0.35	7.31e-6	Loneliness (multivariate analysis);Loneliness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17440014	chr11:43755653	HSD17B12	-0.67	-6.58	-0.47	7.05e-10	Obesity-related traits;
PAAD	trans	rs62179067	0.708	rs4435492	chr2:179896416	G/A	cg13380624	chr19:7735426	NA	-0.74	-7.09	-0.5	4.64e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg14329783	chr7:75779857	NA	0.77	4.78	0.36	4.15e-6	Mononucleosis;
PAAD	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg20636351	chr8:55087400	NA	-0.82	-8.79	-0.58	2.96e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg09835421	chr16:68378352	PRMT7	-0.66	-5.15	-0.39	7.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10214930	0.723	rs6960834	chr7:27635986	G/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg00976097	chr5:421733	AHRR	-0.65	-5.82	-0.43	3.42e-8	Cystic fibrosis severity;
PAAD	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.88	6.24	0.45	4.06e-9	Height;
PAAD	cis	rs6684428	0.706	rs12138137	chr1:56325176	C/T	cg11651538	chr1:56320950	NA	-0.53	-4.57	-0.35	9.95e-6	Airflow obstruction;
PAAD	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.94	-0.37	2.04e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg26174226	chr8:58114915	NA	-0.63	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg07168214	chr17:7380112	ZBTB4	-0.66	-5.83	-0.43	3.16e-8	Androgen levels;
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.46	-5.8	-0.43	3.69e-8	Prostate cancer;
PAAD	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.33	-0.33	2.65e-5	Menarche (age at onset);
PAAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg10589385	chr1:150898437	SETDB1	0.39	4.85	0.37	3.09e-6	Melanoma;
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.84	-0.43	3.06e-8	Tonsillectomy;
PAAD	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs73416724	1.000	rs77626494	chr6:43286886	C/T	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.71	-7.63	-0.53	2.42e-12	Platelet distribution width;
PAAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs246395	0.932	rs193549	chr5:149500236	C/T	cg26247309	chr5:149501835	PDGFRB	0.38	4.52	0.34	1.23e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.61	0.53	2.64e-12	Motion sickness;
PAAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.69	-0.42	6.28e-8	Personality dimensions;
PAAD	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2274459	0.841	rs12203688	chr6:33693624	G/T	cg06253072	chr6:33679850	C6orf125	-0.61	-4.7	-0.36	5.76e-6	Obesity (extreme);
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg00431813	chr7:1051703	C7orf50	-0.41	-5.13	-0.38	8.67e-7	Longevity;Endometriosis;
PAAD	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg12633918	chr20:23549525	CST9L	0.43	4.39	0.34	2.07e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2131877	0.913	rs9825498	chr3:194848021	G/C	cg21937377	chr3:194868750	C3orf21	0.46	4.75	0.36	4.58e-6	Non-small cell lung cancer;
PAAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg09835421	chr16:68378352	PRMT7	-1.13	-8.57	-0.57	1.1e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.64	0.35	7.51e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.7	-9.04	-0.59	6.62e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	5.47	0.41	1.82e-7	Mean platelet volume;
PAAD	cis	rs4150161	0.591	rs4150159	chr16:84214338	C/A	cg10106505	chr16:84220380	TAF1C	-1.1	-6.09	-0.44	9.03e-9	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs740474	0.569	rs9324851	chr5:140884527	A/G	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.31	4.66	0.35	6.94e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24139931	chr18:74091393	ZNF516	-0.62	-6.25	-0.45	4.04e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-5.67	-0.42	7.09e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.68	6.84	0.49	1.81e-10	Capecitabine sensitivity;
PAAD	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.58	0.35	9.72e-6	Asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06988775	chr7:128864367	AHCYL2	0.63	6.42	0.46	1.66e-9	Obesity-related traits;
PAAD	cis	rs55883249	0.505	rs2357157	chr2:9758217	A/G	cg23886495	chr2:9695866	ADAM17	0.46	4.46	0.34	1.56e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg02549819	chr16:58548995	SETD6	0.92	4.64	0.35	7.63e-6	Schizophrenia;
PAAD	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.72	5.95	0.43	1.74e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.2	-7.43	-0.52	7.17e-12	Plateletcrit;
PAAD	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.52	-0.34	1.23e-5	Joint mobility (Beighton score);
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg10729496	chr3:10149963	C3orf24	0.88	7.58	0.52	3.18e-12	Alzheimer's disease;
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.84	10.03	0.63	1.7e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2730260	0.537	rs73169246	chr7:158890593	C/T	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.44	-4.88	-0.37	2.61e-6	Mean arterial pressure;
PAAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.21e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09695851	chr17:3907499	NA	-0.68	-6.91	-0.49	1.22e-10	Type 2 diabetes;
PAAD	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.85	9.85	0.62	5.13e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg16606324	chr3:10149918	C3orf24	0.73	5.23	0.39	5.44e-7	Alzheimer's disease;
PAAD	cis	rs939584	1.000	rs7558910	chr2:645122	C/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.7	-0.48	3.89e-10	Triglycerides;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13791938	chr3:42623511	SEC22C	0.6	6.92	0.49	1.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.92e-6	Type 2 diabetes;
PAAD	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.9	-0.37	2.48e-6	Triglycerides;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg24101359	chr6:42928495	GNMT	0.55	5.59	0.41	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.23	0.84	1.52e-42	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-5.55	-0.41	1.23e-7	Cognitive function;
PAAD	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.43	-4.34	-0.33	2.54e-5	Red blood cell count;
PAAD	cis	rs2271001	1.000	rs2271001	chr11:19167850	A/G	cg00161556	chr11:19138045	ZDHHC13	0.5	5.5	0.41	1.56e-7	Gut microbiome composition (winter);
PAAD	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.64	7.71	0.53	1.52e-12	Weight;
PAAD	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.53	5.67	0.42	6.85e-8	Bladder cancer;
PAAD	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.91	0.37	2.38e-6	Height;
PAAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.33	-4.31	-0.33	2.92e-5	Abdominal aortic aneurysm;
PAAD	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	cg25843174	chr11:12811716	TEAD1	0.38	5.67	0.42	6.97e-8	Educational attainment (years of education);
PAAD	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.61	-5.12	-0.38	9.21e-7	Plateletcrit;
PAAD	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.7	-7.37	-0.51	1.01e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22430734	chr17:35849794	DUSP14	0.58	6.43	0.46	1.58e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4951018	0.821	rs11240547	chr1:205632932	A/G	cg26354017	chr1:205819088	PM20D1	0.47	4.3	0.33	3.02e-5	Prostate-specific antigen levels;
PAAD	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.91	11.86	0.69	2.22e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg07959070	chr22:50026188	C22orf34	-0.38	-4.52	-0.34	1.23e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg14393609	chr7:65229607	NA	-0.67	-7.44	-0.52	6.95e-12	Calcium levels;
PAAD	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.44	0.46	1.46e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.92	12.25	0.7	2.01e-24	Body mass index;
PAAD	cis	rs4722166	0.598	rs7804146	chr7:22800929	C/G	cg05472934	chr7:22766657	IL6	0.64	7.37	0.51	1.01e-11	Lung cancer;
PAAD	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.38	-5.3	-0.39	4.05e-7	QT interval;
PAAD	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg21427119	chr20:30132790	HM13	-0.78	-6.0	-0.44	1.42e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.72	-4.78	-0.36	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.39	-5.46	-0.41	1.87e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.65	9.97	0.63	2.53e-18	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.83	-9.81	-0.62	6.67e-18	DNA methylation (variation);
PAAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg24253500	chr15:84953950	NA	0.42	4.39	0.34	2.1e-5	Schizophrenia;
PAAD	cis	rs2229238	0.911	rs61559765	chr1:154518349	T/C	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.62e-6	Coronary heart disease;
PAAD	cis	rs6466055	0.720	rs1204060	chr7:104963064	T/C	cg04380332	chr7:105027541	SRPK2	0.64	7.33	0.51	1.3e-11	Schizophrenia;
PAAD	cis	rs507080	0.883	rs563549	chr11:118558953	G/A	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg22189786	chr22:42395067	WBP2NL	0.4	4.31	0.33	2.96e-5	Cognitive function;
PAAD	cis	rs17824933	1.000	rs17824933	chr11:60760612	C/G	cg16817237	chr11:60793675	NA	0.47	5.63	0.42	8.64e-8	Multiple sclerosis;
PAAD	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.0	0.49	7.74e-11	Coffee consumption (cups per day);
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg17328964	chr8:145687451	CYHR1	-0.53	-5.55	-0.41	1.25e-7	Age at first birth;
PAAD	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	4.3	0.33	3.04e-5	Thyroid stimulating hormone;
PAAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6715793	0.869	rs4670245	chr2:33406249	C/G	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.27	-0.33	3.44e-5	Tuberculosis;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	6.48	0.47	1.22e-9	Renal function-related traits (BUN);
PAAD	cis	rs757081	0.658	rs214101	chr11:17289354	A/G	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.67	-0.42	6.9e-8	Systolic blood pressure;
PAAD	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg14500798	chr7:98100126	NA	0.43	4.56	0.35	1.03e-5	Breast cancer;
PAAD	cis	rs8044995	0.568	rs112086775	chr16:68310917	A/C	cg09835421	chr16:68378352	PRMT7	-1.29	-8.99	-0.59	9.26e-16	Schizophrenia;
PAAD	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg14393609	chr7:65229607	NA	-0.48	-4.9	-0.37	2.44e-6	Aortic root size;
PAAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg11657440	chr19:46296263	DMWD	-0.65	-5.53	-0.41	1.37e-7	Coronary artery disease;
PAAD	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	7.41	0.52	7.97e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.18	-0.39	6.92e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.12	0.55	1.51e-13	Lung cancer in ever smokers;
PAAD	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	2.01e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.89	0.66	8.71e-21	Menopause (age at onset);
PAAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.48	-5.97	-0.44	1.64e-8	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27228276	chr1:151119210	SEMA6C	0.64	6.39	0.46	1.96e-9	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1982963	0.572	rs61971550	chr14:52478669	T/G	cg20550154	chr14:52487779	NID2	0.57	4.55	0.35	1.11e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs12754538	0.961	rs12095124	chr1:8482032	T/C	cg06159269	chr1:8767347	RERE	0.37	4.4	0.34	2.06e-5	Subjective well-being;
PAAD	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg05552183	chr6:42928497	GNMT	0.7	7.66	0.53	1.99e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.62	-6.01	-0.44	1.32e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.68	-7.33	-0.51	1.25e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg21823605	chr1:152486609	CRCT1	-0.49	-6.06	-0.44	1.05e-8	Hair morphology;
PAAD	cis	rs10450586	0.932	rs10450561	chr11:27309956	C/T	cg10370305	chr11:27303972	NA	-0.37	-4.54	-0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22663240	chr12:56473408	ERBB3	0.6	6.82	0.48	1.99e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1359582	0.767	rs2861428	chr10:90371332	T/C	cg15661332	chr10:90342814	RNLS	0.55	4.86	0.37	2.95e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg23153227	chr6:27725408	NA	0.43	4.29	0.33	3.21e-5	Depression;
PAAD	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg22467129	chr15:76604101	ETFA	-0.5	-4.6	-0.35	9e-6	Blood metabolite levels;
PAAD	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.67	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9467160	0.871	rs13205780	chr6:24448687	C/T	cg16211469	chr6:24423932	MRS2	0.53	5.29	0.39	4.21e-7	Liver enzyme levels;
PAAD	cis	rs6782025	1.000	rs7634611	chr3:121133525	A/G	cg16417163	chr3:121280760	NA	-0.48	-4.88	-0.37	2.61e-6	Aging (facial);
PAAD	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08626939	chr2:227656417	IRS1	0.65	6.72	0.48	3.35e-10	Obesity-related traits;
PAAD	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.82	5.88	0.43	2.56e-8	Iron status biomarkers;
PAAD	cis	rs1329189	1.000	rs7098293	chr10:129994176	G/C	cg17972361	chr10:130010134	NA	-0.46	-4.73	-0.36	5.18e-6	Orofacial clefts;
PAAD	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.72	-6.96	-0.49	9.36e-11	Platelet distribution width;
PAAD	cis	rs10925040	0.666	rs10737808	chr1:247622940	C/T	cg14830002	chr1:247616686	OR2B11	-0.43	-4.51	-0.34	1.27e-5	Tumor necrosis factor beta levels;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs58521262	0.519	rs12609516	chr19:23009337	C/T	cg07749055	chr19:23076870	NA	-0.61	-4.63	-0.35	7.81e-6	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.69	-5.58	-0.41	1.07e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.61	0.41	9.53e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.67	6.44	0.46	1.45e-9	Coronary artery disease;
PAAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.09	0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.94	7.23	0.51	2.2e-11	Alzheimer's disease;
PAAD	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.9e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.59	-5.27	-0.39	4.53e-7	Mean corpuscular volume;
PAAD	cis	rs5015933	0.736	rs10125995	chr9:128145942	C/T	cg14078157	chr9:128172775	NA	-0.41	-4.7	-0.36	5.69e-6	Body mass index;
PAAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.77	7.25	0.51	1.96e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.64	-0.57	7.33e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs11958404	0.615	rs7704746	chr5:157450601	C/G	cg05962755	chr5:157440814	NA	0.55	5.3	0.4	3.96e-7	IgG glycosylation;
PAAD	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.5	4.97	0.37	1.78e-6	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21127189	chr4:39368001	RFC1	0.7	6.89	0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg10818794	chr15:86012489	AKAP13	0.51	5.6	0.41	9.82e-8	Coronary artery disease;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.78	-8.37	-0.56	3.57e-14	Menopause (age at onset);
PAAD	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg06071746	chr17:57297518	GDPD1	0.3	4.55	0.35	1.1e-5	Cognitive test performance;
PAAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.73	7.32	0.51	1.36e-11	HIV-1 control;
PAAD	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.61	-6.04	-0.44	1.16e-8	Post bronchodilator FEV1;
PAAD	cis	rs372883	0.530	rs11088110	chr21:30543373	G/A	cg24692254	chr21:30365293	RNF160	-0.51	-4.74	-0.36	4.86e-6	Pancreatic cancer;
PAAD	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	1.1	7.25	0.51	1.97e-11	Obesity (early onset extreme);
PAAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	7.05e-7	Tuberculosis;
PAAD	cis	rs654384	0.778	rs2342506	chr7:4176234	G/A	cg27574739	chr7:4176374	SDK1	-0.51	-4.78	-0.36	4.07e-6	Positive affect;
PAAD	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.56	5.19	0.39	6.6e-7	Retinal vascular caliber;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.82	9.1	0.59	4.63e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.54	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs910039	0.556	rs7773451	chr6:17512830	C/T	cg22959611	chr6:18122991	NHLRC1	0.45	4.36	0.33	2.41e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs1912528	0.814	rs769675	chr4:140880109	T/C	cg11128457	chr4:140864437	MAML3	-0.33	-4.42	-0.34	1.86e-5	Educational attainment (years of education);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08884247	chr17:36957996	CCDC49	-0.58	-6.61	-0.47	6.22e-10	Obesity-related traits;
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.27	-0.51	1.8e-11	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.57e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	8.22e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs77633900	0.772	rs172244	chr15:76722769	A/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.59	-4.38	-0.34	2.16e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11807834	0.522	rs2078219	chr1:230242962	A/G	cg00566187	chr1:230250356	GALNT2	0.65	6.88	0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.61	-0.47	6.14e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg02580895	chr19:2754563	NA	-0.53	-4.35	-0.33	2.45e-5	Total cholesterol levels;
PAAD	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-4.25	-0.33	3.68e-5	Height;
PAAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg00999904	chr2:3704751	ALLC	-0.81	-8.08	-0.55	1.91e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4273100	0.790	rs60166680	chr17:19277544	C/G	cg18093559	chr17:18951025	GRAP	-0.52	-4.38	-0.33	2.17e-5	Schizophrenia;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	0.92	6.22	0.45	4.67e-9	IgG glycosylation;
PAAD	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs3106136	0.678	rs6419132	chr4:95286541	G/C	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg11822372	chr1:151115635	SEMA6C	0.61	4.91	0.37	2.34e-6	Blood trace element (Cu levels);
PAAD	cis	rs6473252	0.546	rs7816651	chr8:81822709	A/T	cg08595989	chr8:81827712	NA	-0.33	-4.51	-0.34	1.31e-5	Breast cancer;
PAAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs721399	0.539	rs10103148	chr8:18267429	A/C	cg18736775	chr8:18248649	NAT2	-0.61	-4.54	-0.35	1.13e-5	Blood metabolite levels;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.97	8.36	0.56	3.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg03808351	chr9:123631620	PHF19	0.41	4.31	0.33	2.97e-5	Rheumatoid arthritis;
PAAD	cis	rs13092825	1.000	rs13074313	chr3:113273634	A/C	cg18753928	chr3:113234510	CCDC52	0.47	4.52	0.34	1.22e-5	Dental caries;
PAAD	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.47	4.32	0.33	2.82e-5	Height;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-1.27	-12.02	-0.7	8.34e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg10207240	chr12:122356781	WDR66	0.58	6.07	0.44	9.88e-9	Mean corpuscular volume;
PAAD	cis	rs12752838	0.777	rs11121245	chr1:8916224	T/C	cg24027679	chr1:9086621	SLC2A7	0.37	4.4	0.34	2.01e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.76	-6.25	-0.45	3.9e-9	Pancreatic cancer;
PAAD	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.68	-7.85	-0.54	6.97e-13	Educational attainment;
PAAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.52	-4.25	-0.33	3.77e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.23	-0.6	2.13e-16	Exhaled nitric oxide output;
PAAD	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg26874164	chr19:58962979	ZNF324B	0.54	5.05	0.38	1.26e-6	Uric acid clearance;
PAAD	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs138453830	1	rs138453830	chr13:28739055	A/AT	cg14731225	chr13:28717375	PAN3	-0.94	-4.78	-0.36	4.14e-6	Hepcidin/transferrin saturation ratio;
PAAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg06060754	chr5:176797920	RGS14	0.63	6.4	0.46	1.8e-9	Urate levels in lean individuals;
PAAD	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.69	-0.42	6.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.5	-5.14	-0.39	8.21e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6681460	0.649	rs1415974	chr1:67005503	C/T	cg02459107	chr1:67143332	SGIP1	-0.55	-4.96	-0.37	1.89e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs258892	0.895	rs2338792	chr5:72066860	G/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.61	-6.11	-0.44	7.98e-9	Post bronchodilator FEV1;
PAAD	cis	rs2239785	0.958	rs136160	chr22:36657119	C/G	cg15716373	chr22:36655542	APOL1	-0.46	-4.43	-0.34	1.82e-5	Glomerulosclerosis;
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg21665744	chr7:39171113	POU6F2	0.34	5.61	0.41	9.27e-8	IgG glycosylation;
PAAD	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.54	0.47	8.91e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg12564285	chr5:131593104	PDLIM4	0.47	4.86	0.37	2.89e-6	Blood metabolite levels;
PAAD	cis	rs597583	0.575	rs11216435	chr11:117388932	C/T	cg27161313	chr11:117392002	DSCAML1	-0.67	-5.64	-0.42	8.13e-8	Putamen volume;
PAAD	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.6	4.48	0.34	1.45e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12304921	0.810	rs56087503	chr12:51354506	A/C	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.71	-0.36	5.56e-6	Dupuytren's disease;
PAAD	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.16	0.39	7.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.89	10.61	0.65	4.9e-20	Longevity;
PAAD	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.54	-4.68	-0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.58	-7.73	-0.53	1.37e-12	Endometriosis;
PAAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09640425	chr7:158790006	NA	-0.5	-5.62	-0.41	8.81e-8	Facial morphology (factor 20);
PAAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg02404636	chr22:31891804	SFI1	-0.6	-5.89	-0.43	2.34e-8	Paclitaxel-induced neuropathy;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12013930	chr2:219264803	CTDSP1	0.73	6.6	0.47	6.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg14092988	chr3:52407081	DNAH1	0.54	6.88	0.49	1.49e-10	Bipolar disorder;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.46	4.93	0.37	2.14e-6	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg19318889	chr4:1322082	MAEA	0.43	4.54	0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg04362095	chr11:63592001	C11orf84	0.51	4.65	0.35	7.22e-6	Platelet count;
PAAD	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.63	6.75	0.48	2.87e-10	Bladder cancer;
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Electroencephalogram traits;
PAAD	trans	rs75583333	0.502	rs6868909	chr5:159646689	C/T	cg14222307	chr15:61097246	RORA	-0.8	-6.37	-0.46	2.17e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-5.53	-0.41	1.36e-7	Cognitive function;
PAAD	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg09491104	chr22:46646882	C22orf40	-1.01	-6.08	-0.44	9.17e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.51	4.82	0.36	3.51e-6	Diastolic blood pressure;
PAAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg17986701	chr20:44574422	PCIF1	0.57	5.93	0.43	1.96e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.36	-0.33	2.36e-5	Educational attainment;
PAAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.64	0.35	7.37e-6	Bipolar disorder;
PAAD	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs732765	0.734	rs10137800	chr14:75170286	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	4.25	0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.6	5.48	0.41	1.75e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.68	-7.29	-0.51	1.57e-11	Age at first birth;
PAAD	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.2	-0.39	6.39e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21659014	chr4:183245254	ODZ3	0.63	6.47	0.46	1.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26926768	chr12:34528122	NA	-0.38	-4.78	-0.36	4.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg10820045	chr2:198174542	NA	0.53	5.3	0.39	4e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.66	-6.89	-0.49	1.39e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.61	-8.49	-0.57	1.72e-14	Height;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9888739	0.920	rs9923767	chr16:31305290	A/G	cg02256631	chr16:31342952	ITGAM	-0.55	-4.45	-0.34	1.64e-5	Systemic lupus erythematosus;
PAAD	trans	rs11212737	0.765	rs878190	chr11:108508777	C/T	cg13462821	chr8:86214814	NA	0.58	6.74	0.48	3.06e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1075265	0.669	rs805330	chr2:54148331	C/A	cg04546899	chr2:54196757	PSME4	0.34	5.05	0.38	1.23e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg22835712	chr2:102737379	NA	-0.45	-4.31	-0.33	2.89e-5	Lymphocyte counts;
PAAD	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.63	6.16	0.45	6.29e-9	Uric acid clearance;
PAAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.94	-8.17	-0.55	1.14e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg11843238	chr5:131593191	PDLIM4	0.5	4.65	0.35	7.25e-6	Acylcarnitine levels;
PAAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg25456477	chr12:86230367	RASSF9	0.48	4.29	0.33	3.21e-5	Major depressive disorder;
PAAD	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.91	-0.37	2.33e-6	Tuberculosis;
PAAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.12	-0.67	2.17e-21	Rheumatoid arthritis;
PAAD	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.29e-8	Alcohol dependence;
PAAD	cis	rs3106136	0.843	rs1344612	chr4:95265228	G/A	cg11021082	chr4:95130006	SMARCAD1	0.59	5.87	0.43	2.7e-8	Capecitabine sensitivity;
PAAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.61	-5.89	-0.43	2.44e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27400644	chr1:27248126	NUDC	0.57	6.31	0.46	2.95e-9	Monocyte percentage of white cells;
PAAD	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg23985595	chr17:80112537	CCDC57	0.45	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs113779084	0.661	rs12537849	chr7:11970559	C/T	cg15090509	chr7:11872073	THSD7A	-0.37	-4.65	-0.35	7.08e-6	Educational attainment (years of education);
PAAD	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.47	-0.34	1.51e-5	Joint mobility (Beighton score);
PAAD	cis	rs722864	0.750	rs17710065	chr2:174005866	C/G	cg09210666	chr2:173941575	ZAK	0.5	4.68	0.36	6.25e-6	Lung cancer;
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.65	0.42	7.54e-8	Platelet count;
PAAD	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-1.1	-11.66	-0.69	7.53e-23	Longevity;
PAAD	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-1.1	-8.11	-0.55	1.61e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.51	5.65	0.42	7.8e-8	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg15117754	chr3:10150083	C3orf24	0.67	5.77	0.42	4.36e-8	Alzheimer's disease;
PAAD	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.49	0.41	1.64e-7	Alcohol dependence;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.71	10.08	0.63	1.27e-18	Huntington's disease progression;
PAAD	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg12935359	chr14:103987150	CKB	-0.52	-5.43	-0.4	2.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.9	-7.29	-0.51	1.63e-11	Orofacial clefts;
PAAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.64	8.77	0.58	3.39e-15	Height;
PAAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.94	5.6	0.41	9.65e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs11867129	1.000	rs4787277	chr16:2368169	C/T	cg05196366	chr16:3239155	NA	-0.47	-4.46	-0.34	1.55e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
PAAD	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs78761021	0.651	rs731540	chr17:9799127	G/A	cg26853458	chr17:9805074	RCVRN	0.76	8.4	0.56	3.02e-14	Type 2 diabetes;
PAAD	cis	rs9463078	0.866	rs9395084	chr6:45220175	T/C	cg25276700	chr6:44698697	NA	-0.5	-5.89	-0.43	2.34e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs17407555	0.683	rs7435841	chr4:10278552	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.13	0.38	8.89e-7	Schizophrenia (age at onset);
PAAD	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.56	6.37	0.46	2.16e-9	Mean corpuscular volume;
PAAD	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05585630	chr7:157510462	PTPRN2	-0.79	-9.24	-0.6	2.09e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.52	4.31	0.33	2.9e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6782025	0.837	rs4381881	chr3:120827617	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	trans	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg09659197	chr4:152720779	NA	0.4	5.08	0.38	1.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11603691	0.711	rs10792091	chr11:57119156	T/C	cg17237962	chr11:57479805	MED19;TMX2	0.8	4.35	0.33	2.51e-5	Low high density lipoprotein cholesterol levels;
PAAD	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.51	5.95	0.43	1.75e-8	Airway imaging phenotypes;
PAAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.07	-0.44	9.92e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs7833787	1.000	rs7007413	chr8:18705432	A/G	cg17701159	chr8:18705777	PSD3	0.45	5.31	0.4	3.87e-7	Obesity-related traits;
PAAD	cis	rs642743	0.967	rs593151	chr10:105935979	A/G	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.58	0.35	9.68e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.86	9.26	0.6	1.82e-16	Body mass index;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.52	5.06	0.38	1.17e-6	Resistin levels;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg01299579	chr2:10830716	NOL10	0.61	6.38	0.46	2.04e-9	Prostate cancer;
PAAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg02766259	chr12:125626809	AACS	-0.3	-4.34	-0.33	2.57e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg21178979	chr7:1889533	MAD1L1	-0.41	-4.43	-0.34	1.78e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.67	4.87	0.37	2.83e-6	Plateletcrit;
PAAD	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs80346118	0.636	rs6012533	chr20:47416665	T/A	cg20907517	chr20:47894756	C20orf199;ZNFX1;SNORD12C	-0.59	-4.42	-0.34	1.9e-5	Diastolic blood pressure;
PAAD	cis	rs6976053	0.846	rs34005963	chr7:100501755	G/A	cg22425096	chr7:100417404	EPHB4	0.49	4.35	0.33	2.51e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.64	7.25	0.51	1.92e-11	Vitiligo;
PAAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg05110241	chr16:68378359	PRMT7	-1.35	-10.31	-0.64	3.22e-19	Magnesium levels;
PAAD	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.74	-0.36	4.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg03948781	chr1:205179583	DSTYK	-0.48	-4.55	-0.35	1.1e-5	Platelet count;
PAAD	cis	rs2555155	0.837	rs2723631	chr11:6537730	A/G	cg11185456	chr11:6592066	DNHD1	0.43	4.56	0.35	1.04e-5	DNA methylation (variation);
PAAD	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.69	6.01	0.44	1.35e-8	Menarche (age at onset);
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg20778547	chr7:4456403	NA	0.61	4.73	0.36	5e-6	Borderline personality disorder;
PAAD	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.85	8.45	0.57	2.24e-14	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27611857	chr2:99347979	MGAT4A	-0.64	-6.38	-0.46	1.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2229238	0.911	rs3811449	chr1:154517504	G/A	cg21262032	chr1:154437693	IL6R	-0.47	-4.99	-0.38	1.62e-6	Coronary heart disease;
PAAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.72	-7.75	-0.53	1.22e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg20761395	chr17:511517	VPS53	0.52	5.51	0.41	1.48e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.66	-5.74	-0.42	5.02e-8	Menarche (age at onset);
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs61884328	0.777	rs61897784	chr11:47154514	A/G	cg23433285	chr11:47201945	PACSIN3	0.81	4.56	0.35	1.05e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.7	-7.13	-0.5	3.8e-11	Neurofibrillary tangles;
PAAD	cis	rs12936587	0.755	rs111966500	chr17:17548844	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-4.63	-0.35	7.86e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg08371190	chr1:87598514	LOC339524	0.44	5.92	0.43	2.07e-8	Smoking behavior;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg26554054	chr8:600488	NA	-1.06	-6.98	-0.49	8.41e-11	IgG glycosylation;
PAAD	cis	rs76793172	1.000	rs7249022	chr19:46354558	G/A	cg13320842	chr19:46175254	GIPR	0.63	4.84	0.37	3.21e-6	Eosinophil counts;
PAAD	trans	rs7955901	0.761	rs907721	chr12:71436037	T/C	cg13798885	chr4:13968277	NA	-0.48	-6.38	-0.46	2.04e-9	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15561356	chr20:61904111	ARFGAP1	0.58	6.5	0.47	1.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58521262	0.556	rs291774	chr19:23209200	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.44	5.6	0.41	9.73e-8	Crohn's disease;
PAAD	cis	rs4668356	1.000	rs16859176	chr2:171993126	G/A	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.63	6.37	0.46	2.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs783540	0.872	rs2678445	chr15:83246141	T/A	cg00614314	chr15:82944287	LOC80154	0.46	4.65	0.35	7.09e-6	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26876637	chr1:152193138	HRNR	0.88	6.87	0.49	1.57e-10	Atopic dermatitis;
PAAD	cis	rs317865	0.737	rs73234667	chr4:16240097	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.92	6.11	0.44	7.86e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.6	0.47	6.31e-10	Coffee consumption (cups per day);
PAAD	cis	rs6466055	0.589	rs7792628	chr7:105009612	A/G	cg04380332	chr7:105027541	SRPK2	-0.48	-4.68	-0.35	6.33e-6	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg20243544	chr17:37824526	PNMT	0.53	4.66	0.35	6.82e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs959260	0.748	rs4789178	chr17:73368242	C/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg27411982	chr8:10470053	RP1L1	0.48	5.58	0.41	1.07e-7	Neuroticism;
PAAD	cis	rs2882667	0.628	rs311606	chr5:138045240	G/A	cg09476006	chr5:138032270	NA	0.51	6.47	0.46	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs728616	1.000	rs56317427	chr10:81861934	T/C	cg05935833	chr10:81318306	SFTPA2	-0.71	-5.02	-0.38	1.4e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.52	0.47	9.87e-10	Response to antipsychotic treatment;
PAAD	cis	rs8049634	0.798	rs11639837	chr16:84231041	C/T	cg26466773	chr16:84211947	TAF1C	0.5	4.43	0.34	1.82e-5	Small cell lung carcinoma;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg18281939	chr5:77783895	LHFPL2	0.5	5.63	0.42	8.36e-8	Triglycerides;
PAAD	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg02016764	chr4:38805732	TLR1	-0.56	-4.4	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg18518183	chr2:172544446	DYNC1I2	0.5	4.5	0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.64	-0.35	7.53e-6	Colorectal cancer;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.68	7.59	0.52	2.98e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs7714584	1.000	rs2217266	chr5:150272621	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.94	-10.16	-0.64	7.72e-19	Morning vs. evening chronotype;
PAAD	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.09	-10.17	-0.64	7.57e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.61	-6.19	-0.45	5.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs61931739	0.649	rs708144	chr12:33731158	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.27	0.51	1.79e-11	Morning vs. evening chronotype;
PAAD	cis	rs58521262	0.556	rs290582	chr19:23198103	C/T	cg02350677	chr19:23254381	NA	-0.25	-4.26	-0.33	3.6e-5	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg17372657	chr7:1216933	NA	-0.36	-4.46	-0.34	1.59e-5	Longevity;Endometriosis;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.91	8.03	0.55	2.42e-13	Alzheimer's disease;
PAAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-6.97	-0.49	9.01e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4450131	0.898	rs3824805	chr10:126320721	C/T	cg20435097	chr10:126320824	FAM53B	-0.53	-5.95	-0.43	1.77e-8	White blood cell count (basophil);
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg07061783	chr6:25882402	NA	0.54	5.08	0.38	1.07e-6	Blood metabolite levels;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18561881	chr1:207627541	CR2	-0.64	-6.44	-0.46	1.52e-9	Primary biliary cholangitis;
PAAD	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-8.42	-0.56	2.54e-14	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.65	7.43	0.52	7.12e-12	Dupuytren's disease;
PAAD	cis	rs282587	0.569	rs377748	chr13:113405482	C/T	cg02820901	chr13:113351484	ATP11A	-0.65	-4.92	-0.37	2.27e-6	Glycated hemoglobin levels;
PAAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.86	-9.28	-0.6	1.62e-16	Colorectal cancer;
PAAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-11.01	-0.67	4.37e-21	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	trans	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg14171944	chr9:126323477	DENND1A	0.54	6.44	0.46	1.49e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	trans	rs3733631	1.000	rs3733631	chr4:104641103	G/C	cg21490444	chr5:171095097	NA	0.72	6.35	0.46	2.32e-9	Menarche (age at onset);
PAAD	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06850241	chr22:41845214	NA	-0.56	-5.43	-0.4	2.15e-7	Vitiligo;
PAAD	cis	rs212524	1.000	rs212525	chr1:21584585	A/G	cg23992472	chr1:21503364	EIF4G3	0.44	4.45	0.34	1.66e-5	Height;
PAAD	cis	rs1198430	0.599	rs10917382	chr1:23780639	G/A	cg19827787	chr1:23763612	ASAP3	0.55	5.11	0.38	9.41e-7	Total cholesterol levels;
PAAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.65	7.78	0.53	1.02e-12	Weight;
PAAD	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.63	-0.57	7.6e-15	Morning vs. evening chronotype;
PAAD	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.79	-0.36	3.93e-6	Educational attainment;
PAAD	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.49	-4.72	-0.36	5.23e-6	Obesity-related traits;
PAAD	cis	rs9646944	0.501	rs7586983	chr2:103028066	C/T	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.46	4.47	0.34	1.54e-5	Breast cancer;
PAAD	cis	rs8053891	0.625	rs12921355	chr16:72014687	T/A	cg16558253	chr16:72132732	DHX38	-0.53	-4.75	-0.36	4.6e-6	Coronary artery disease;
PAAD	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.43	4.49	0.34	1.39e-5	QRS complex (12-leadsum);
PAAD	cis	rs7873907	0.621	rs7036107	chr9:92177897	A/G	cg13866320	chr9:91977542	SEMA4D	0.47	4.57	0.35	9.96e-6	Fibrinogen levels;
PAAD	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.99	14.13	0.75	1.74e-29	Heart rate;
PAAD	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs116175783	0.557	rs16845844	chr2:162265270	C/T	cg08807892	chr2:162101083	NA	0.65	4.77	0.36	4.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs354225	0.544	rs11902987	chr2:54805587	C/T	cg01766943	chr2:54829624	SPTBN1	0.53	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.93	9.86	0.62	5.05e-18	Inhibitory control;
PAAD	cis	rs2421770	0.561	rs11033081	chr11:35363885	C/G	cg13971030	chr11:35366721	SLC1A2	-0.56	-5.37	-0.4	2.83e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg11783602	chr8:55087084	NA	-0.49	-5.05	-0.38	1.24e-6	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.58	-4.69	-0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg14343924	chr8:8086146	FLJ10661	0.5	4.26	0.33	3.57e-5	Systolic blood pressure;
PAAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg13175981	chr1:150552382	MCL1	0.55	5.11	0.38	9.72e-7	Blood protein levels;
PAAD	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1800469	0.965	rs11668109	chr19:41863777	A/C	cg08477640	chr19:41863820	B9D2	0.73	7.71	0.53	1.49e-12	Colorectal cancer;
PAAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.82e-7	Blood metabolite levels;
PAAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.32	0.33	2.79e-5	Total body bone mineral density;
PAAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.61	-0.41	9.37e-8	Monocyte percentage of white cells;
PAAD	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.84	-0.37	3.21e-6	Body mass index;
PAAD	cis	rs527409	1.000	rs583128	chr1:58733021	C/T	cg26345888	chr1:58716257	DAB1	-0.69	-4.73	-0.36	4.98e-6	Kawasaki disease;
PAAD	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6494488	0.500	rs72742997	chr15:65009527	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.63	-5.19	-0.39	6.55e-7	Fibrinogen levels;
PAAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg03808351	chr9:123631620	PHF19	0.47	5.15	0.39	8.09e-7	Rheumatoid arthritis;
PAAD	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.41	7.67	0.53	1.89e-12	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.03e-9	Monobrow;
PAAD	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs2030114	0.768	rs35779486	chr16:51597162	T/C	cg03758633	chr16:51611768	NA	0.5	4.49	0.34	1.38e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg04154034	chr17:28927549	LRRC37B2	0.72	4.27	0.33	3.4e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg21625146	chr5:486483	SLC9A3	-0.42	-5.49	-0.41	1.66e-7	Cystic fibrosis severity;
PAAD	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.11	-0.5	4.24e-11	Protein C levels;
PAAD	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.72	5.75	0.42	4.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	8.34	0.56	4.22e-14	Hemoglobin concentration;
PAAD	cis	rs8049040	0.564	rs310335	chr16:71573918	T/A	cg08717414	chr16:71523259	ZNF19	-0.5	-4.59	-0.35	9.11e-6	Blood protein levels;
PAAD	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.97e-6	Mononucleosis;
PAAD	cis	rs12304921	1.000	rs224568	chr12:51386548	A/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.46	-0.4	1.92e-7	Type 2 diabetes;
PAAD	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	4.25	0.33	3.78e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.51	4.45	0.34	1.64e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.42	-0.4	2.25e-7	Glomerular filtration rate;
PAAD	cis	rs10203711	0.509	rs11684544	chr2:239601424	G/A	cg03761885	chr2:238707879	RBM44	0.47	4.41	0.34	1.95e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4668356	1.000	rs9752051	chr2:172023824	G/A	cg13882835	chr2:172017928	TLK1	0.86	4.4	0.34	2.05e-5	Cognitive performance;
PAAD	cis	rs3026101	0.671	rs8067917	chr17:5278307	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.49	5.25	0.39	5.13e-7	Body mass index;
PAAD	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.53	-5.4	-0.4	2.55e-7	Height;
PAAD	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg25902810	chr10:99078978	FRAT1	-0.64	-5.96	-0.44	1.68e-8	Monocyte count;
PAAD	cis	rs9361491	0.608	rs9352617	chr6:79441654	A/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.86	-0.37	2.84e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg10072921	chr12:121022843	NA	-0.35	-4.66	-0.35	6.87e-6	High light scatter reticulocyte count;
PAAD	cis	rs7172971	0.511	rs2167295	chr15:42396877	C/A	cg07013680	chr15:42186124	SPTBN5	0.45	4.55	0.35	1.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.76	-8.12	-0.55	1.47e-13	Blood metabolite levels;
PAAD	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.64	6.26	0.45	3.74e-9	Ovarian reserve;
PAAD	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg07154921	chr7:157260426	NA	0.44	4.25	0.33	3.71e-5	Body mass index;
PAAD	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1011108	0.518	rs935172	chr2:26804247	A/G	cg18742855	chr2:26800399	C2orf70	-0.48	-5.84	-0.43	3.06e-8	Periodontal microbiota;
PAAD	cis	rs3010562	0.872	rs6938463	chr6:167757981	G/A	cg20481416	chr6:167803413	NA	0.43	4.54	0.35	1.14e-5	Gut microbiome composition (summer and winter);
PAAD	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg18281939	chr5:77783895	LHFPL2	-0.47	-5.51	-0.41	1.51e-7	Triglycerides;
PAAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg04106633	chr4:1044584	NA	-0.65	-5.46	-0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs863345	0.625	rs4609418	chr1:158464728	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.56e-6	Tonsillectomy;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.68	-6.41	-0.46	1.72e-9	Platelet count;
PAAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.57	5.07	0.38	1.15e-6	Coronary artery disease;
PAAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg18769074	chr3:133464867	TF	0.42	4.97	0.37	1.76e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07685180	chr8:600429	NA	-0.82	-4.99	-0.38	1.65e-6	IgG glycosylation;
PAAD	trans	rs12714314	0.708	rs10199390	chr2:1968512	G/C	cg17170872	chr1:91487911	ZNF644	-0.75	-6.36	-0.46	2.21e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg03289416	chr15:75166202	SCAMP2	0.53	5.8	0.43	3.66e-8	Breast cancer;
PAAD	cis	rs6494488	0.500	rs56095421	chr15:64911405	C/T	cg16425858	chr15:64791681	ZNF609	0.95	4.53	0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.61	9.21	0.6	2.41e-16	Asthma (sex interaction);
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.83	0.58	2.31e-15	Lung cancer;
PAAD	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26876637	chr1:152193138	HRNR	-0.84	-6.31	-0.46	2.97e-9	Atopic dermatitis;
PAAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg05585544	chr11:47624801	NA	-0.52	-5.87	-0.43	2.7e-8	Subjective well-being;
PAAD	cis	rs9583531	0.891	rs9521906	chr13:111358000	T/G	cg24331049	chr13:111365604	ING1	-0.81	-5.41	-0.4	2.41e-7	Coronary artery disease;
PAAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.74	-7.76	-0.53	1.14e-12	Neurofibrillary tangles;
PAAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.65	-0.42	7.84e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.95	-8.3	-0.56	5.21e-14	Body mass index;
PAAD	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.57	4.62	0.35	8.16e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg24397884	chr7:158709396	WDR60	0.85	5.83	0.43	3.19e-8	Hippocampal volume;
PAAD	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.57	5.86	0.43	2.75e-8	Coronary artery disease;
PAAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	7.46	0.52	6.06e-12	Bone mineral density;
PAAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.71	5.83	0.43	3.22e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23003500	chr3:42543530	VIPR1	0.62	6.31	0.46	2.85e-9	Obesity-related traits;
PAAD	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg11812906	chr14:75593930	NEK9	-0.69	-8.1	-0.55	1.69e-13	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2583612	0.588	rs12650711	chr4:120676190	T/A	cg05550861	chr4:120222222	C4orf3	-0.73	-4.87	-0.37	2.8e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-4.82	-0.36	3.49e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.46	4.48	0.34	1.47e-5	Dupuytren's disease;
PAAD	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13798912	chr7:905769	UNC84A	0.58	4.35	0.33	2.53e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	9.12	0.59	4.33e-16	Neutrophil percentage of white cells;
PAAD	cis	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12760731	0.565	rs34041572	chr1:178184493	T/C	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.52	-5.07	-0.38	1.13e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg27449745	chr7:23145252	KLHL7	-0.59	-5.32	-0.4	3.7e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.74	-8.35	-0.56	3.94e-14	Childhood ear infection;
PAAD	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.57	5.42	0.4	2.3e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg25823085	chr7:87105416	ABCB4	0.45	4.29	0.33	3.16e-5	Gallbladder cancer;
PAAD	cis	rs987724	0.739	rs2874495	chr3:156682397	A/G	cg03445587	chr3:156544078	LEKR1	-0.47	-4.31	-0.33	2.87e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7945718	0.621	rs61879826	chr11:12684486	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.74	5.36	0.4	3.06e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.28	-0.51	1.64e-11	Chronic sinus infection;
PAAD	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-0.48	-4.77	-0.36	4.25e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	7.35	0.51	1.16e-11	Lymphocyte counts;
PAAD	cis	rs2327429	0.858	rs12207772	chr6:134189834	T/C	cg06296503	chr6:134217401	NA	0.48	4.95	0.37	1.96e-6	Coronary artery disease;
PAAD	cis	rs2268241	0.938	rs8133431	chr21:34796556	C/T	cg14850771	chr21:34775459	IFNGR2	0.93	7.45	0.52	6.66e-12	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg19442545	chr10:75533431	FUT11	-0.5	-5.27	-0.39	4.6e-7	Inflammatory bowel disease;
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.94	7.43	0.52	7.31e-12	Gut microbiome composition (summer);
PAAD	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg11547950	chr5:77652471	NA	0.92	8.0	0.54	2.89e-13	Triglycerides;
PAAD	cis	rs1400816	0.718	rs2028674	chr2:172798775	A/G	cg23624723	chr2:173292262	ITGA6	-0.77	-4.48	-0.34	1.45e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.47	-0.34	1.55e-5	Joint mobility (Beighton score);
PAAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23281280	chr6:28129359	ZNF389	0.67	5.26	0.39	4.75e-7	Parkinson's disease;
PAAD	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.37	-0.51	1.02e-11	Mood instability;
PAAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg11211951	chr8:145729740	GPT	-0.44	-5.08	-0.38	1.11e-6	Age at first birth;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.47	4.48	0.34	1.45e-5	Resistin levels;
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.65	-6.57	-0.47	7.37e-10	Eosinophil percentage of white cells;
PAAD	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg09127314	chr1:152161683	NA	-0.7	-5.28	-0.39	4.47e-7	Atopic dermatitis;
PAAD	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.53	-4.76	-0.36	4.44e-6	Height;
PAAD	cis	rs2004318	1.000	rs10423021	chr19:55119768	G/C	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs6700896	0.897	rs7541434	chr1:66168499	A/C	cg04111102	chr1:66153794	NA	-0.4	-4.42	-0.34	1.85e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7192380	0.651	rs72783115	chr16:69702839	G/A	cg05250797	chr16:70222502	NA	0.67	5.92	0.43	2.11e-8	Sjögren's syndrome;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.0	9.2	0.6	2.63e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10605130	chr8:27491257	SCARA3	0.64	7.13	0.5	3.89e-11	Monocyte percentage of white cells;
PAAD	cis	rs12612619	0.677	rs3754733	chr2:27249245	A/G	cg00617064	chr2:27272375	NA	-0.54	-5.64	-0.42	8.22e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg13468214	chr4:1046988	NA	0.52	4.89	0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.5	-5.69	-0.42	6.37e-8	Tuberculosis;
PAAD	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.73e-9	Coffee consumption (cups per day);
PAAD	cis	rs10044254	0.587	rs4312881	chr5:15739807	T/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-6.15	-0.45	6.48e-9	Vitamin D levels;
PAAD	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.66	-5.95	-0.43	1.74e-8	Lung cancer;
PAAD	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.33	-0.4	3.48e-7	Systolic blood pressure;
PAAD	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg21191810	chr6:118973309	C6orf204	-0.51	-4.86	-0.37	2.96e-6	Renal cell carcinoma;
PAAD	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.18	-0.39	6.94e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7737355	0.812	rs26003	chr5:130990384	T/C	cg06307176	chr5:131281290	NA	0.48	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg06217245	chr20:33103252	DYNLRB1	0.39	4.41	0.34	1.98e-5	Height;
PAAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18404041	chr3:52824283	ITIH1	0.42	4.49	0.34	1.4e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8063160	0.688	rs75570604	chr16:89846677	G/C	cg07984980	chr16:89898383	SPIRE2	0.86	4.86	0.37	2.94e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.56	-5.5	-0.41	1.54e-7	Crohn's disease;
PAAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg19318889	chr4:1322082	MAEA	0.62	6.37	0.46	2.18e-9	Longevity;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.53	-6.02	-0.44	1.27e-8	Heart rate;
PAAD	trans	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg26939375	chr7:64535504	NA	0.78	9.27	0.6	1.74e-16	Aortic root size;
PAAD	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.47	-4.72	-0.36	5.23e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg22027985	chr11:4115532	RRM1	-0.47	-4.27	-0.33	3.49e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07985704	chr6:108395859	OSTM1	-0.59	-6.43	-0.46	1.6e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg19413350	chr8:57351067	NA	-0.46	-4.58	-0.35	9.62e-6	Obesity-related traits;
PAAD	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	7.87e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20167471	chr1:16528984	ARHGEF19	-0.47	-4.66	-0.35	6.77e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	4.82	0.36	3.47e-6	Educational attainment;
PAAD	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs9876781	1.000	rs7635522	chr3:48423656	T/G	cg24898236	chr3:49228699	LOC646498	0.39	4.41	0.34	1.97e-5	Longevity;
PAAD	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05212510	chr18:77623544	KCNG2	-0.47	-4.74	-0.36	4.94e-6	Schizophrenia;
PAAD	cis	rs6066835	1.000	rs6125439	chr20:47314634	G/A	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	1.12	17.41	0.82	5.09e-38	Colorectal adenoma (advanced);
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.59	0.61	2.46e-17	Bladder cancer;
PAAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.77	8.62	0.57	7.92e-15	Total body bone mineral density;
PAAD	cis	rs2885056	0.891	rs2304160	chr19:10692129	G/A	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg20007245	chr22:24372913	LOC391322	-0.78	-8.16	-0.55	1.17e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4073221	0.628	rs34742900	chr3:18203974	T/G	cg07694806	chr3:18168406	NA	-0.61	-4.36	-0.33	2.37e-5	Parkinson's disease;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	4.55	0.35	1.09e-5	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-1.1	-10.58	-0.65	5.96e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs757978	0.929	rs111943976	chr2:242378905	T/C	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-4.93	-0.37	2.11e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-1.0	-6.65	-0.47	4.84e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	1.06	7.53	0.52	4.21e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg25753631	chr6:25732923	NA	-0.48	-4.45	-0.34	1.68e-5	Iron status biomarkers;
PAAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.2	0.45	5.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.39	5.03	0.38	1.35e-6	Longevity;Endometriosis;
PAAD	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.79	-0.36	3.96e-6	Neuroticism;
PAAD	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.84	-9.62	-0.62	2.14e-17	Height;
PAAD	cis	rs793571	0.822	rs2013117	chr15:59173310	C/T	cg05156742	chr15:59063176	FAM63B	-0.57	-4.65	-0.35	7.28e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg10729496	chr3:10149963	C3orf24	0.91	7.45	0.52	6.43e-12	Alzheimer's disease;
PAAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.55	0.57	1.21e-14	Rheumatoid arthritis;
PAAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs77880822	0.562	rs1323131	chr20:1243575	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1371614	0.632	rs4665929	chr2:27155849	G/T	cg00617064	chr2:27272375	NA	0.43	4.59	0.35	9.29e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg11879182	chr18:77439856	CTDP1	0.89	9.66	0.62	1.62e-17	Monocyte count;
PAAD	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	1.05	6.58	0.47	7.1e-10	Cognitive function;
PAAD	cis	rs76866386	1.000	rs115445558	chr2:44063098	G/C	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.96	-5.58	-0.41	1.05e-7	Cholesterol, total;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.58	0.71	2.51e-25	Prudent dietary pattern;
PAAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.96	-0.37	1.89e-6	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07177569	chr2:187454747	ITGAV	0.64	7.11	0.5	4.33e-11	Myopia (pathological);
PAAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.96	12.4	0.71	7.55e-25	Menopause (age at onset);
PAAD	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.32	0.46	2.78e-9	Crohn's disease;
PAAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	5.72	0.42	5.46e-8	Testicular germ cell tumor;
PAAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.8	8.99	0.59	9.27e-16	Lung cancer;
PAAD	cis	rs10901513	0.932	rs10901502	chr10:127683743	A/G	cg22975853	chr10:127789788	ADAM12	0.44	4.77	0.36	4.2e-6	Visceral fat;
PAAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Menopause (age at onset);
PAAD	cis	rs4321325	0.733	rs74707659	chr2:127945469	T/C	cg11380483	chr2:127933992	NA	0.71	5.3	0.39	4.05e-7	Protein C levels;
PAAD	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7539409	0.584	rs4907176	chr1:84166433	C/A	cg10977910	chr1:84465055	TTLL7	-0.95	-4.51	-0.34	1.3e-5	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-4.59	-0.35	9.26e-6	Mean corpuscular volume;
PAAD	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg13114125	chr14:105738426	BRF1	-0.55	-4.81	-0.36	3.67e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.9	0.54	5.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1697938	0.590	rs35642126	chr5:40936843	C/T	cg22359217	chr5:41925772	FBXO4	-0.46	-4.58	-0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.25	0.33	3.7e-5	Self-reported allergy;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.49	4.92	0.37	2.27e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs528301	0.707	rs338070	chr2:45175289	C/G	cg15393275	chr2:45165193	NA	-0.54	-6.13	-0.44	7.4e-9	Alcohol and nicotine co-dependence;
PAAD	cis	rs6137287	0.883	rs2252714	chr20:21223498	A/T	cg04219410	chr20:21106687	PLK1S1	0.43	4.81	0.36	3.6e-6	Height;
PAAD	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg18939081	chr1:31884902	SERINC2	0.5	5.72	0.42	5.53e-8	Alcohol dependence;
PAAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.82	8.01	0.54	2.74e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg02841227	chr6:26021843	HIST1H4A	0.43	4.29	0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	ch.11.42038R	chr11:967971	AP2A2	0.8	8.07	0.55	2.01e-13	Alzheimer's disease (late onset);
PAAD	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26926768	chr12:34528122	NA	0.4	4.92	0.37	2.27e-6	Morning vs. evening chronotype;
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	4.46	0.34	1.56e-5	Total body bone mineral density;
PAAD	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg18612461	chr15:75251733	NA	-0.52	-4.77	-0.36	4.21e-6	Blood trace element (Zn levels);
PAAD	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.85	0.49	1.68e-10	Obesity-related traits;
PAAD	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.98	-6.84	-0.49	1.84e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13560548	chr3:10150139	C3orf24	0.6	5.55	0.41	1.27e-7	Alzheimer's disease;
PAAD	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-5.09	-0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.72	6.56	0.47	7.87e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.87	-9.49	-0.61	4.47e-17	Coronary artery disease;
PAAD	trans	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg25214090	chr10:38739885	LOC399744	0.58	6.35	0.46	2.3e-9	Diastolic blood pressure;
PAAD	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs1879734	0.773	rs1554750	chr1:54135334	T/C	cg14659662	chr1:54151053	GLIS1	-0.4	-5.35	-0.4	3.12e-7	Mitral valve prolapse;
PAAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2662368	0.563	rs171706	chr5:77086405	T/A	cg16293892	chr5:77142620	NA	-0.44	-4.33	-0.33	2.7e-5	Platelet distribution width;
PAAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.25	-0.33	3.7e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.7	-7.63	-0.53	2.45e-12	Morning vs. evening chronotype;
PAAD	cis	rs71636778	0.631	rs34924059	chr1:27158844	G/T	cg12203394	chr1:27248618	NUDC	0.61	4.29	0.33	3.22e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg21546286	chr11:48923668	NA	-0.54	-5.54	-0.41	1.29e-7	HDL cholesterol;
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg10621924	chr7:39171070	POU6F2	0.28	4.67	0.35	6.64e-6	IgG glycosylation;
PAAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.48	5.5	0.41	1.56e-7	Rheumatoid arthritis;
PAAD	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-5.41	-0.4	2.44e-7	Itch intensity from mosquito bite;
PAAD	cis	rs2882667	0.690	rs1651032	chr5:138078840	C/T	cg09476006	chr5:138032270	NA	-0.49	-6.4	-0.46	1.86e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.69	-8.16	-0.55	1.17e-13	Huntington's disease progression;
PAAD	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg10985347	chr2:127963512	CYP27C1	0.49	4.98	0.37	1.7e-6	Protein C levels;
PAAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs12773846	0.537	rs36096707	chr10:126272248	C/T	cg04949429	chr10:126290192	LHPP	0.64	5.59	0.41	1e-7	Subcutaneous adipose tissue;
PAAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.85	-8.72	-0.58	4.59e-15	Post bronchodilator FEV1;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.44	4.41	0.34	1.98e-5	Renal function-related traits (BUN);
PAAD	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg01431908	chr1:46668882	C1orf190;POMGNT1	0.44	4.86	0.37	2.85e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg08175591	chr14:101176152	NA	0.36	4.51	0.34	1.27e-5	Platelet count;
PAAD	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-5.42	-0.4	2.3e-7	Electroencephalogram traits;
PAAD	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.5	5.17	0.39	7.4e-7	Lewy body disease;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.6	-6.76	-0.48	2.74e-10	Age at first birth;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	1.01	14.09	0.75	2.32e-29	Menarche (age at onset);
PAAD	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg24154853	chr7:158122151	PTPRN2	0.7	7.18	0.5	2.9e-11	Calcium levels;
PAAD	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.75	9.35	0.6	1.07e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.55	-6.11	-0.44	8.16e-9	Body mass index;
PAAD	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.83	-8.7	-0.58	5.06e-15	Body mass index;
PAAD	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs62025270	0.848	rs2554	chr15:86302643	T/C	cg13263323	chr15:86062960	AKAP13	0.59	5.52	0.41	1.42e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.83	-10.37	-0.64	2.23e-19	Menopause (age at onset);
PAAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg18612461	chr15:75251733	NA	0.66	8.17	0.55	1.12e-13	Breast cancer;
PAAD	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg26876637	chr1:152193138	HRNR	-0.85	-6.12	-0.44	7.65e-9	Atopic dermatitis;
PAAD	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg10645314	chr2:3704589	ALLC	-0.57	-4.93	-0.37	2.16e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1996152	0.543	rs9906415	chr17:72389282	A/G	cg10907148	chr17:72948349	C17orf28	-0.5	-4.28	-0.33	3.34e-5	Interleukin-12p70 levels;
PAAD	cis	rs6681460	0.934	rs10889635	chr1:67075575	G/A	cg02459107	chr1:67143332	SGIP1	0.78	8.08	0.55	1.84e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs6681460	0.898	rs1032634	chr1:67195192	C/G	cg02459107	chr1:67143332	SGIP1	-0.7	-6.65	-0.47	5.06e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs6909834	0.636	rs9381391	chr6:12781416	T/C	cg17869960	chr6:12718530	PHACTR1	-0.35	-4.31	-0.33	2.87e-5	Gait speed in old age;
PAAD	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-0.93	-6.15	-0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs11514810	0.655	rs11514808	chr7:1426401	G/A	cg23358612	chr7:1275258	UNCX	-0.42	-4.68	-0.35	6.38e-6	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
PAAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.78	0.53	1.03e-12	Personality dimensions;
PAAD	cis	rs282587	0.597	rs450351	chr13:113394987	C/T	cg19217778	chr13:113420270	ATP11A	-0.55	-4.34	-0.33	2.6e-5	Glycated hemoglobin levels;
PAAD	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.61	-0.41	9.15e-8	Response to antipsychotic treatment;
PAAD	cis	rs6132905	0.590	rs77686753	chr20:2602757	G/A	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg03938978	chr2:103052716	IL18RAP	0.51	5.18	0.39	6.86e-7	Blood protein levels;
PAAD	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-1.2	-8.51	-0.57	1.52e-14	Height;
PAAD	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg04257695	chr17:30186438	C17orf79	0.62	5.09	0.38	1.05e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.68	-6.3	-0.46	3.03e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs797680	0.598	rs3754186	chr1:93711782	T/A	cg04535902	chr1:92947332	GFI1	0.46	4.64	0.35	7.39e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs1419980	0.558	rs2192239	chr12:7758000	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg07856975	chr6:36356162	ETV7	0.48	5.56	0.41	1.19e-7	Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16370716	chr1:161129255	USP21	0.6	6.85	0.49	1.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.85	-0.49	1.75e-10	Menopause (age at onset);
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg02841227	chr6:26021843	HIST1H4A	0.48	4.71	0.36	5.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4356203	0.870	rs214922	chr11:17237123	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6715793	0.836	rs62146679	chr2:33401797	T/A	cg26672287	chr2:33391915	LTBP1	-0.37	-4.33	-0.33	2.74e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7714584	1.000	rs1896707	chr5:150245129	C/T	cg22134413	chr5:150180641	NA	0.71	4.99	0.38	1.6e-6	Crohn's disease;
PAAD	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.6	-6.19	-0.45	5.23e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.47	4.93	0.37	2.11e-6	Type 2 diabetes;
PAAD	cis	rs11159086	1.000	rs4903233	chr14:74963994	C/G	cg10195687	chr14:74926396	NA	-0.42	-4.6	-0.35	8.7e-6	Advanced glycation end-product levels;
PAAD	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.67	-8.35	-0.56	3.84e-14	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg07648498	chr16:89883185	FANCA	-0.5	-4.82	-0.36	3.47e-6	Vitiligo;
PAAD	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg03318428	chr22:46971703	NA	0.35	4.25	0.33	3.77e-5	Urate levels in obese individuals;
PAAD	cis	rs988913	0.541	rs9464196	chr6:54997649	A/G	cg03513858	chr6:54763001	FAM83B	0.39	4.55	0.35	1.11e-5	Menarche (age at onset);
PAAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.33	-10.22	-0.64	5.52e-19	Breast cancer;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.5	5.08	0.38	1.08e-6	Height;
PAAD	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-6.52	-0.47	9.73e-10	Morning vs. evening chronotype;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.55	5.14	0.39	8.2e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.57	4.86	0.37	2.9e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6142102	0.602	rs2268079	chr20:32596750	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.93	0.37	2.18e-6	Skin pigmentation;
PAAD	cis	rs1977584	0.778	rs58414517	chr10:45403172	C/T	cg04218760	chr10:45406644	TMEM72	0.35	4.47	0.34	1.52e-5	Selective IgA deficiency;
PAAD	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.47	-5.0	-0.38	1.58e-6	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg27447006	chr1:23763279	ASAP3	0.62	5.54	0.41	1.3e-7	Total cholesterol levels;
PAAD	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-10.97	-0.66	5.31e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Body mass index;
PAAD	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg20636351	chr8:55087400	NA	-0.65	-6.14	-0.45	6.72e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.73	8.07	0.55	2e-13	Melanoma;
PAAD	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-13.15	-0.73	7.6e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg24747557	chr10:131355152	MGMT	0.46	4.53	0.34	1.2e-5	Response to temozolomide;
PAAD	cis	rs6908034	0.607	rs74573060	chr6:19806032	T/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.54	5.3	0.39	4.04e-7	Menarche (age at onset);
PAAD	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.65	6.61	0.47	5.99e-10	Smooth-surface caries;
PAAD	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.6	5.29	0.39	4.23e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.15	0.39	7.84e-7	Personality dimensions;
PAAD	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.49	7.07	0.5	5.13e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg02869306	chr7:64672164	INTS4L1	0.5	6.06	0.44	1.03e-8	Calcium levels;
PAAD	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.98	11.99	0.7	9.75e-24	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22551357	chr5:81046408	SSBP2	0.63	6.34	0.46	2.5e-9	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21057613	chr15:57668547	CGNL1	0.59	6.51	0.47	1.03e-9	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04751069	chr16:89787483	ZNF276;C16orf7	-0.69	-6.91	-0.49	1.28e-10	Smoking initiation;
PAAD	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg20742385	chr13:113633654	MCF2L	-0.42	-4.36	-0.33	2.4e-5	Systolic blood pressure;
PAAD	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.71	7.88	0.54	6e-13	Motion sickness;
PAAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg02574844	chr11:5959923	NA	-0.63	-6.17	-0.45	5.92e-9	DNA methylation (variation);
PAAD	cis	rs3753841	0.832	rs1318755	chr1:103340513	G/A	cg24495344	chr1:103574097	COL11A1	0.4	4.58	0.35	9.48e-6	Glaucoma (primary angle closure);
PAAD	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg19949948	chr17:19361230	NA	0.43	4.51	0.34	1.27e-5	Schizophrenia;
PAAD	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.58	-5.65	-0.42	7.78e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.49	5.01	0.38	1.49e-6	Major depressive disorder;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19277050	chr1:24069823	TCEB3	-0.7	-7.27	-0.51	1.72e-11	Primary biliary cholangitis;
PAAD	cis	rs2835872	0.758	rs1787401	chr21:39038893	C/T	cg06728970	chr21:39037746	KCNJ6	0.54	6.32	0.46	2.7e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	6.07	0.44	9.54e-9	Blood metabolite levels;
PAAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg24375607	chr4:120327624	NA	-0.55	-5.02	-0.38	1.4e-6	Corneal astigmatism;
PAAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.42	-4.66	-0.35	6.87e-6	Metabolite levels;
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg21918786	chr6:109611834	NA	0.44	4.86	0.37	2.89e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs929596	0.531	rs2741022	chr2:234514273	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.31	-0.33	2.92e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.6	-8.65	-0.57	6.97e-15	Thrombosis;
PAAD	cis	rs76297747	1	rs76297747	chr18:44665657	A/G	cg17192377	chr18:44677553	HDHD2	0.95	5.13	0.38	8.64e-7	Response to paliperidone in schizophrenia (Multivariate);
PAAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg14219918	chr9:127249562	NR5A1	0.37	5.0	0.38	1.54e-6	Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.8	0.43	3.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01616529	chr11:638424	DRD4	-0.61	-5.58	-0.41	1.1e-7	Systemic lupus erythematosus;
PAAD	cis	rs13011075	0.535	rs6546398	chr2:68630417	G/C	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs4455778	0.580	rs7808248	chr7:49125067	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs7731390	0.541	rs7447266	chr5:131602533	C/T	cg07395648	chr5:131743802	NA	-0.77	-4.58	-0.35	9.54e-6	IgG glycosylation;
PAAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg15352829	chr14:105391018	PLD4	-0.58	-8.11	-0.55	1.6e-13	Rheumatoid arthritis;
PAAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	6.1	0.44	8.46e-9	Blood metabolite levels;
PAAD	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.56	-6.97	-0.49	9.15e-11	Atrioventricular conduction;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14604386	chr6:119670882	MAN1A1	-0.59	-6.37	-0.46	2.11e-9	Body fat percentage;
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg08835956	chr7:39171034	POU6F2	0.32	4.91	0.37	2.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.61	-6.56	-0.47	8.13e-10	Height;
PAAD	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	cis	rs2882667	0.690	rs1039789	chr5:138171423	T/C	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.53	-5.24	-0.39	5.18e-7	Eosinophil percentage of white cells;
PAAD	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg02734326	chr4:10020555	SLC2A9	0.51	5.14	0.38	8.29e-7	Bone mineral density;
PAAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.55	-0.41	1.26e-7	Lung cancer;
PAAD	cis	rs6908034	0.607	rs73376657	chr6:19805960	C/T	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	4.76	0.36	4.47e-6	Menarche (age at onset);
PAAD	cis	rs1499972	0.941	rs55958116	chr3:117672772	C/T	cg07612923	chr3:117604196	NA	1.08	7.2	0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.54	5.14	0.38	8.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.55	-0.47	8.31e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4455778	0.538	rs7779474	chr7:49107537	A/G	cg26309511	chr7:48887640	NA	0.38	4.56	0.35	1.05e-5	Lung cancer in never smokers;
PAAD	cis	rs73082363	0.541	rs73078357	chr3:48695834	T/C	cg19401529	chr3:49056140	DALRD3	0.8	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.25	-0.51	1.99e-11	Response to antipsychotic treatment;
PAAD	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.39e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.5	4.56	0.35	1.03e-5	Self-reported allergy;
PAAD	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg03934865	chr2:198174659	NA	-0.46	-4.56	-0.35	1.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.87	9.89	0.63	4.11e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg14789911	chr21:47582049	C21orf56	-0.53	-5.56	-0.41	1.18e-7	Testicular germ cell tumor;
PAAD	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.64	6.85	0.49	1.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg04450456	chr4:17643702	FAM184B	-0.49	-5.03	-0.38	1.39e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.5	5.11	0.38	9.38e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-4.76	-0.36	4.38e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.18e-22	Parkinson's disease;
PAAD	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.53	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs57244997	0.582	rs73030432	chr6:162439864	G/A	cg17173639	chr6:162384350	PARK2	-0.66	-5.1	-0.38	9.81e-7	Mosquito bite size;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12379764	chr21:47803548	PCNT	-0.55	-5.59	-0.41	1.02e-7	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	8.41	0.56	2.84e-14	Alzheimer's disease;
PAAD	cis	rs2252790	1.000	rs12195680	chr6:116647428	C/G	cg18764771	chr6:116381957	FRK	0.26	4.36	0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-5.4	-0.4	2.49e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg02071572	chr4:1403502	NA	0.4	4.9	0.37	2.39e-6	Obesity-related traits;
PAAD	cis	rs1497828	0.956	rs2818975	chr1:217550732	T/G	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.99	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.83	-0.54	7.88e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17337917	chr4:96102203	UNC5C	-0.67	-6.74	-0.48	3.11e-10	Obesity-related traits;
PAAD	cis	rs6840360	1.000	rs6535821	chr4:152678974	T/C	cg09659197	chr4:152720779	NA	0.37	5.25	0.39	5.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.85	6.57	0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg03910582	chr17:19030146	GRAPL	0.45	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14019695	chr9:139328340	INPP5E	0.57	6.14	0.45	6.81e-9	Monocyte percentage of white cells;
PAAD	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.94	14.2	0.76	1.13e-29	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.74	4.76	0.36	4.55e-6	White matter integrity;
PAAD	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.51	5.8	0.43	3.67e-8	Heart rate;
PAAD	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-6.66	-0.48	4.69e-10	Vitiligo;
PAAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.68	7.43	0.52	7.23e-12	Personality dimensions;
PAAD	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.36	-0.33	2.42e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs375066	0.935	rs450308	chr19:44422358	C/A	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.73	7.82	0.54	8.13e-13	Type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg01815783	chr4:1047043	NA	-0.53	-4.28	-0.33	3.27e-5	Recombination rate (females);
PAAD	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.34	-0.4	3.36e-7	Glomerular filtration rate;
PAAD	cis	rs17162190	0.659	rs12024530	chr1:26812298	G/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.73	0.36	5.19e-6	Mean corpuscular volume;
PAAD	cis	rs4073221	0.654	rs7372790	chr3:18297289	C/T	cg07694806	chr3:18168406	NA	-0.64	-4.68	-0.35	6.33e-6	Parkinson's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11972327	chr1:8419796	RERE	-0.63	-7.24	-0.51	2.03e-11	Monocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.56	6.11	0.44	8.12e-9	Menopause (age at onset);
PAAD	cis	rs6766510	1.000	rs56013339	chr3:12543198	G/A	cg07775309	chr3:12595852	NA	-0.67	-4.31	-0.33	2.92e-5	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.4	-0.46	1.82e-9	Mean corpuscular volume;
PAAD	cis	rs9463078	0.739	rs6458425	chr6:45173857	C/G	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.8	-9.69	-0.62	1.36e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg11062466	chr8:58055876	NA	0.68	5.09	0.38	1.02e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.77	-0.36	4.26e-6	Aortic root size;
PAAD	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg01388757	chr2:102091195	RFX8	0.72	8.94	0.59	1.21e-15	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg23947450	chr7:900037	UNC84A	0.56	4.59	0.35	9.38e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.8	8.79	0.58	2.98e-15	Caffeine consumption;
PAAD	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.87	8.6	0.57	9.18e-15	Blood protein levels;
PAAD	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.67	8.15	0.55	1.22e-13	Dupuytren's disease;
PAAD	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-1.03	-14.32	-0.76	5.45e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.79	-8.98	-0.59	9.73e-16	Colorectal cancer;
PAAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.64	6.11	0.44	7.97e-9	Schizophrenia;
PAAD	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.68	-7.56	-0.52	3.54e-12	Schizophrenia;
PAAD	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.67	8.76	0.58	3.67e-15	Subjective well-being;Cardiovascular disease risk factors;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6894268	0.751	rs11741546	chr5:179026909	T/A	cg26135573	chr5:179059668	NA	0.51	4.37	0.33	2.29e-5	Eating disorders;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.73	0.36	4.99e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	7.42	0.52	7.65e-12	Gastritis;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.46	-0.46	1.35e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.85	-9.84	-0.62	5.57e-18	Iron status biomarkers;
PAAD	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.07	-0.7	5.93e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs669446	0.591	rs586339	chr1:44137257	C/A	cg12908607	chr1:44402522	ARTN	-0.45	-4.6	-0.35	8.88e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-7.13	-0.5	3.78e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs78761021	0.867	rs17676097	chr17:9791549	A/G	cg26853458	chr17:9805074	RCVRN	0.71	8.3	0.56	5.23e-14	Type 2 diabetes;
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.48	-5.49	-0.41	1.66e-7	Age at first birth;
PAAD	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.58	-5.28	-0.39	4.41e-7	Monocyte count;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.67	-8.45	-0.57	2.16e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg16068336	chr17:48637367	CACNA1G	-0.51	-4.51	-0.34	1.28e-5	Type 2 diabetes;
PAAD	cis	rs4787491	0.729	rs4238960	chr16:30038648	G/C	cg06015834	chr16:30021696	DOC2A	-0.41	-4.35	-0.33	2.46e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.73	-6.36	-0.46	2.27e-9	Educational attainment;
PAAD	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.93	-0.43	1.99e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	12.14	0.7	3.82e-24	Smoking behavior;
PAAD	cis	rs59888335	0.862	rs6778408	chr3:80568589	A/T	cg21735741	chr3:80819488	NA	-0.59	-5.13	-0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.4	0.34	2.07e-5	Neuroticism;
PAAD	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.95e-7	Monocyte percentage of white cells;
PAAD	cis	rs6499755	0.768	rs31095	chr16:55367230	C/T	cg02859129	chr16:55357253	IRX6	0.37	5.16	0.39	7.5e-7	Hypospadias;
PAAD	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.65	-6.49	-0.47	1.16e-9	Ear protrusion;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	1.16	9.63	0.62	2.01e-17	Initial pursuit acceleration;
PAAD	cis	rs10901513	0.932	rs11244742	chr10:127666587	C/A	cg22975853	chr10:127789788	ADAM12	0.44	4.73	0.36	5.07e-6	Visceral fat;
PAAD	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs7255436	0.965	rs2042900	chr19:8439702	T/C	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.77	-0.36	4.28e-6	HDL cholesterol;
PAAD	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg10356904	chr22:49881777	NA	-0.51	-4.84	-0.37	3.11e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-1.21	-7.26	-0.51	1.86e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg17633681	chr16:88106987	BANP	0.65	8.29	0.56	5.72e-14	Menopause (age at onset);
PAAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.53	5.24	0.39	5.19e-7	Menopause (age at onset);
PAAD	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs564309	0.867	rs12735877	chr1:228568201	G/A	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg10183150	chr4:120222239	C4orf3	0.37	5.18	0.39	6.93e-7	Corneal astigmatism;
PAAD	cis	rs10958605	0.761	rs2925035	chr8:40045822	A/G	cg14545590	chr8:40388592	ZMAT4	-0.42	-4.66	-0.35	6.99e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.25e-5	Breast cancer;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-6.12	-0.44	7.46e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg00522288	chr12:125625016	AACS	0.56	6.12	0.44	7.77e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	5.38	0.4	2.73e-7	Mean platelet volume;
PAAD	cis	rs10516089	0.504	rs34467172	chr5:171141167	C/T	cg21066063	chr5:171570130	STK10	0.36	4.27	0.33	3.44e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.84	8.75	0.58	3.69e-15	Corneal astigmatism;
PAAD	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.53	5.77	0.42	4.28e-8	Mean corpuscular volume;
PAAD	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg20673841	chr7:107026890	COG5	-0.54	-4.66	-0.35	6.99e-6	Coronary artery disease;
PAAD	cis	rs2387326	1.000	rs34558168	chr10:129932106	T/C	cg16087940	chr10:129947807	NA	-0.51	-4.34	-0.33	2.6e-5	Select biomarker traits;
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg00614314	chr15:82944287	LOC80154	0.53	5.6	0.41	9.84e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg03805757	chr16:71968109	PKD1L3	-0.38	-4.33	-0.33	2.68e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	5.19	0.39	6.56e-7	Neuroticism;
PAAD	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.7	6.36	0.46	2.24e-9	Schizophrenia;
PAAD	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.81	-7.82	-0.54	7.99e-13	Corneal astigmatism;
PAAD	trans	rs901683	0.850	rs73291121	chr10:46097404	A/G	cg13065504	chr15:42448234	PLA2G4F	0.8	6.54	0.47	8.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-7.19	-0.5	2.73e-11	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.4	0.61	8.11e-17	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.9	-12.07	-0.7	6.17e-24	Prudent dietary pattern;
PAAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.95	-13.04	-0.73	1.47e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61759167	0.742	rs61759178	chr1:3098489	T/C	cg22396632	chr1:3079212	PRDM16	-0.5	-4.77	-0.36	4.25e-6	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25290633	chr10:101601462	ABCC2	-0.64	-6.71	-0.48	3.64e-10	Obesity-related traits;
PAAD	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg00531865	chr16:30841666	NA	-0.53	-4.82	-0.36	3.52e-6	Dementia with Lewy bodies;
PAAD	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.5	-4.91	-0.37	2.34e-6	Bipolar disorder;
PAAD	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.06	9.24	0.6	2.09e-16	Vitiligo;
PAAD	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.02	0.5	6.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05347473	chr6:146136440	FBXO30	0.47	4.44	0.34	1.74e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-5.39	-0.4	2.62e-7	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05477027	chr19:46295590	DMWD	0.58	6.39	0.46	1.94e-9	Response to antipsychotic treatment;
PAAD	cis	rs6604026	0.630	rs2481711	chr1:93346572	C/T	cg17283838	chr1:93427260	FAM69A	-0.61	-5.63	-0.42	8.64e-8	Multiple sclerosis;
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-8.91	-0.59	1.44e-15	Prostate cancer;
PAAD	cis	rs375066	0.935	rs426534	chr19:44412583	T/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.24	0.39	5.26e-7	Heart rate;
PAAD	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg02404636	chr22:31891804	SFI1	0.6	5.41	0.4	2.36e-7	Colorectal cancer;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg15320075	chr8:145703422	NA	-0.7	-7.6	-0.52	2.88e-12	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.41	-0.46	1.69e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs76866386	0.786	rs4076834	chr2:44081627	T/G	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.77	-4.95	-0.37	1.97e-6	Cholesterol, total;
PAAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03610000	chr11:128392383	ETS1	0.61	6.29	0.45	3.2e-9	Myopia (pathological);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19558860	chr14:93582779	ITPK1	0.66	6.48	0.47	1.2e-9	Smoking initiation;
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.79	0.58	3.02e-15	Lung cancer;
PAAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg09796270	chr17:17721594	SREBF1	-0.46	-5.11	-0.38	9.65e-7	Total body bone mineral density;
PAAD	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.86	-0.37	2.85e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg10011062	chr15:43941034	CATSPER2	-0.84	-5.17	-0.39	7.38e-7	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg04154034	chr17:28927549	LRRC37B2	0.68	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7922314	0.571	rs16917994	chr10:64740148	C/T	cg08989932	chr10:65390526	NA	-0.87	-4.37	-0.33	2.29e-5	Cutaneous psoriasis;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg03101763	chr11:65319844	LTBP3	-0.87	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg09324608	chr17:30823087	MYO1D	0.48	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg12288994	chr5:1860383	NA	0.6	6.75	0.48	2.86e-10	Cardiovascular disease risk factors;
PAAD	cis	rs12681288	0.695	rs6559205	chr8:973607	G/A	cg04851639	chr8:1020857	NA	-0.57	-6.6	-0.47	6.52e-10	Schizophrenia;
PAAD	cis	rs9905704	0.633	rs757484	chr17:56457097	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs11696501	0.947	rs6073759	chr20:44115498	A/T	cg11783356	chr20:44313418	WFDC10B	-0.63	-5.38	-0.4	2.74e-7	Brain structure;
PAAD	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.67e-7	Personality dimensions;
PAAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.47	4.8	0.36	3.84e-6	Immature fraction of reticulocytes;
PAAD	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.83	10.38	0.64	2.05e-19	Height;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg04632378	chr13:21900426	NA	0.69	7.47	0.52	5.92e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-4.55	-0.35	1.1e-5	Vitiligo;
PAAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.97e-6	Neuroticism;
PAAD	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.7	9.34	0.6	1.12e-16	Hemoglobin concentration;
PAAD	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg07930192	chr7:1003750	NA	0.6	7.68	0.53	1.83e-12	Longevity;Endometriosis;
PAAD	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.8	-0.36	3.84e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-4.68	-0.36	6.23e-6	IgG glycosylation;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09597638	chr17:3907349	NA	0.64	6.34	0.46	2.53e-9	Type 2 diabetes;
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	5.21	0.39	6.05e-7	Bipolar disorder;
PAAD	cis	rs6834538	0.894	rs4383675	chr4:113572619	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	4.52	0.34	1.24e-5	Free thyroxine concentration;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	5.03	0.38	1.39e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.09	0.44	8.72e-9	Menopause (age at onset);
PAAD	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg01021169	chr22:30184971	ASCC2	-0.46	-4.63	-0.35	7.76e-6	Type 1 diabetes;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15103050	chr10:90582504	ANKRD22	-0.63	-6.61	-0.47	5.97e-10	Obesity-related traits;
PAAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg21951975	chr1:209979733	IRF6	0.42	5.24	0.39	5.17e-7	Monobrow;
PAAD	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg00599163	chr2:162100495	NA	0.52	7.43	0.52	7.17e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.44	0.46	1.47e-9	IgG glycosylation;
PAAD	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.62	-6.88	-0.49	1.44e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg22764044	chr5:178986830	RUFY1	0.47	4.75	0.36	4.7e-6	Lung cancer;
PAAD	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs11159086	0.793	rs11850070	chr14:74954278	C/T	cg10195687	chr14:74926396	NA	-0.47	-5.23	-0.39	5.55e-7	Advanced glycation end-product levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21638053	chr5:52127619	ITGA1	0.66	7.21	0.5	2.47e-11	Smoking initiation;
PAAD	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg04398451	chr17:18023971	MYO15A	0.72	7.74	0.53	1.32e-12	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg24562669	chr7:97807699	LMTK2	-0.69	-9.87	-0.62	4.75e-18	Breast cancer;
PAAD	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg10547527	chr2:198650123	BOLL	-0.62	-4.45	-0.34	1.66e-5	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	5.67	0.42	7.08e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs939584	0.877	rs62105307	chr2:633661	A/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs7873102	0.654	rs2243401	chr9:37977990	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.75	-6.96	-0.49	9.36e-11	Coronary artery disease;
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.43	-5.26	-0.39	4.9e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg16558253	chr16:72132732	DHX38	-0.51	-4.59	-0.35	9.24e-6	Coronary artery disease;
PAAD	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.98	-8.25	-0.56	6.98e-14	Dupuytren's disease;
PAAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.46	0.52	6.25e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.4	-4.62	-0.35	8.25e-6	Inflammatory bowel disease;
PAAD	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.59	-4.62	-0.35	8.04e-6	Vitiligo;
PAAD	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.69	6.28	0.45	3.32e-9	Obesity-related traits;
PAAD	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Vitiligo;
PAAD	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.68	7.56	0.52	3.54e-12	Schizophrenia;
PAAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.98	-0.37	1.74e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13198984	chr17:80129470	CCDC57	-0.43	-5.44	-0.4	2.04e-7	Life satisfaction;
PAAD	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg08132940	chr7:1081526	C7orf50	0.61	4.53	0.35	1.17e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.57	6.21	0.45	4.74e-9	Carotid intima media thickness;
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg12573674	chr2:1569213	NA	-0.61	-4.95	-0.37	1.96e-6	IgG glycosylation;
PAAD	cis	rs7071247	0.915	rs3014205	chr10:105262185	G/A	cg06423925	chr10:105883847	C10orf78	0.6	4.59	0.35	9.25e-6	Platelet aggregation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18966810	chr2:134368695	NA	0.54	6.42	0.46	1.63e-9	Smoking initiation;
PAAD	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs8095374	0.967	rs9947316	chr18:43777831	T/G	cg20581250	chr18:44676959	HDHD2	0.45	4.28	0.33	3.3e-5	Clinical laboratory measurements;
PAAD	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.51	6.17	0.45	5.86e-9	Sitting height ratio;
PAAD	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg10395934	chr14:104002654	TRMT61A	0.51	4.97	0.37	1.75e-6	Body mass index;
PAAD	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.8e-10	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.48e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg16898833	chr6:26189333	HIST1H4D	0.58	4.46	0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs16958440	0.867	rs78720782	chr18:44664015	A/T	cg17192377	chr18:44677553	HDHD2	0.95	5.13	0.38	8.64e-7	Sitting height ratio;
PAAD	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg10374248	chr10:99083645	NA	0.47	4.35	0.33	2.52e-5	Monocyte count;
PAAD	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg09877947	chr5:131593287	PDLIM4	0.53	5.01	0.38	1.53e-6	Blood metabolite levels;
PAAD	cis	rs317865	0.737	rs73234629	chr4:16169776	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.01	6.79	0.48	2.37e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg05785598	chr3:49045655	WDR6	-0.42	-4.96	-0.37	1.89e-6	Parkinson's disease;
PAAD	cis	rs950037	0.710	rs384804	chr1:89227512	T/C	cg13109106	chr1:89333529	GTF2B	-0.46	-4.4	-0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs6834538	0.597	rs10022515	chr4:113537710	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.48	0.34	1.46e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.59	-7.96	-0.54	3.72e-13	Longevity;
PAAD	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.56	0.41	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	4.79	0.36	3.99e-6	Asthma;
PAAD	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.73	4.83	0.36	3.28e-6	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.74	7.36	0.51	1.08e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.67	-8.86	-0.58	1.98e-15	Late-onset Alzheimer's disease;
PAAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg10518543	chr12:38710700	ALG10B	-0.52	-5.19	-0.39	6.69e-7	Morning vs. evening chronotype;
PAAD	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.64	-0.42	8.05e-8	Urate levels in overweight individuals;
PAAD	cis	rs2004318	1.000	rs112038446	chr19:55118574	T/C	cg03320607	chr19:54800032	LILRA3	-1.01	-5.64	-0.42	8.18e-8	Blood protein levels;
PAAD	cis	rs9810890	1.000	rs73198861	chr3:128516182	A/G	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.51	-6.44	-0.46	1.5e-9	Schizophrenia;
PAAD	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg17099306	chr13:50123645	RCBTB1	-0.45	-4.53	-0.34	1.21e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.64	7.35	0.51	1.17e-11	Dupuytren's disease;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.4	-0.34	2.03e-5	Eosinophil percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10068432	chr13:52586372	ALG11;ATP7B	-0.85	-7.63	-0.53	2.4e-12	Neuroticism;
PAAD	trans	rs7395662	0.674	rs7124275	chr11:48162305	C/T	cg00717180	chr2:96193071	NA	-0.61	-7.14	-0.5	3.68e-11	HDL cholesterol;
PAAD	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg07725925	chr16:89976287	TCF25	0.68	4.45	0.34	1.66e-5	Skin colour saturation;
PAAD	cis	rs1198430	0.599	rs10917382	chr1:23780639	G/A	cg27447006	chr1:23763279	ASAP3	0.69	6.06	0.44	1e-8	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg04738700	chr2:239367308	NA	0.46	5.15	0.39	7.98e-7	Multiple system atrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09124213	chr11:62432393	SNORA57;C11orf48;METTL12	0.61	6.41	0.46	1.75e-9	Obesity-related traits;
PAAD	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg04415270	chr2:102091202	RFX8	-0.51	-6.47	-0.46	1.29e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs12893597	1.000	rs35788287	chr14:76814313	A/G	cg20290672	chr14:76816747	NA	-0.51	-4.46	-0.34	1.57e-5	Maximal oxygen uptake response;
PAAD	cis	rs8024058	0.919	rs2350270	chr15:89171891	C/T	cg00367546	chr15:89165046	AEN	0.66	5.66	0.42	7.2e-8	Night sleep phenotypes;
PAAD	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg08835956	chr7:39171034	POU6F2	0.37	5.93	0.43	2.01e-8	IgG glycosylation;
PAAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-4.43	-0.34	1.77e-5	Total body bone mineral density;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg05304507	chr6:116381966	FRK	-0.42	-7.96	-0.54	3.73e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.42	-4.26	-0.33	3.58e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg07701084	chr6:150067640	NUP43	0.62	5.99	0.44	1.43e-8	Testicular germ cell tumor;
PAAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.43	6.59	0.47	6.94e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.69	-0.36	6.06e-6	Type 2 diabetes;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs727479	0.790	rs56170250	chr15:51532281	G/A	cg21478137	chr15:51532386	CYP19A1	0.68	7.78	0.53	1.02e-12	Estradiol levels;
PAAD	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg14196790	chr5:131705035	SLC22A5	0.42	4.61	0.35	8.55e-6	Breast cancer;
PAAD	cis	rs287982	1.000	rs287977	chr2:9970018	T/C	cg01119585	chr2:10571959	NA	-0.38	-4.39	-0.34	2.09e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg22517653	chr1:2918612	NA	0.64	5.09	0.38	1.04e-6	Plateletcrit;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.71	-7.77	-0.53	1.1e-12	Lung cancer;
PAAD	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.47	-4.95	-0.37	1.93e-6	Height;
PAAD	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg07856975	chr6:36356162	ETV7	0.48	5.5	0.41	1.55e-7	Platelet distribution width;
PAAD	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg01796438	chr3:11312864	ATG7	-0.67	-5.13	-0.38	8.85e-7	Circulating chemerin levels;
PAAD	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27174420	chr16:15820903	MYH11	-0.41	-4.44	-0.34	1.74e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12410462	0.636	rs1495849	chr1:227736363	G/A	cg23173402	chr1:227635558	NA	0.54	4.25	0.33	3.65e-5	Major depressive disorder;
PAAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg04450456	chr4:17643702	FAM184B	0.49	5.29	0.39	4.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs3779195	0.929	rs2906184	chr7:97939987	T/A	cg21770322	chr7:97807741	LMTK2	-0.54	-4.62	-0.35	8.1e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.82	8.34	0.56	4.11e-14	Methadone dose in opioid dependence;
PAAD	cis	rs1499972	0.938	rs861001	chr3:117720355	C/T	cg07612923	chr3:117604196	NA	1.02	6.94	0.49	1.07e-10	Schizophrenia;
PAAD	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs66530629	0.958	rs3131502	chr1:25066448	A/G	cg22509179	chr1:25234806	RUNX3	-0.49	-4.6	-0.35	8.75e-6	Plateletcrit;
PAAD	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.77	7.8	0.53	9.21e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.54	4.73	0.36	5.19e-6	Corneal astigmatism;
PAAD	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-1.25	-9.28	-0.6	1.63e-16	Blood pressure (smoking interaction);
PAAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.54	5.17	0.39	7.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg06781209	chr11:61594997	FADS2	-0.52	-4.45	-0.34	1.62e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs901683	1.000	rs17157825	chr10:45958676	G/A	cg12869334	chr8:37699360	GPR124	0.97	6.48	0.47	1.23e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.54	5.58	0.41	1.1e-7	Dupuytren's disease;
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.84	-7.99	-0.54	3.17e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg26727032	chr16:67993705	SLC12A4	-0.68	-5.79	-0.43	3.87e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.47	5.25	0.39	5.03e-7	Prevalent atrial fibrillation;
PAAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.55	5.76	0.42	4.57e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.7	7.26	0.51	1.88e-11	Morning vs. evening chronotype;
PAAD	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.0	-0.49	7.5e-11	Colorectal cancer;
PAAD	cis	rs1977584	0.725	rs1332624	chr10:45402325	A/G	cg04218760	chr10:45406644	TMEM72	-0.38	-5.01	-0.38	1.53e-6	Selective IgA deficiency;
PAAD	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.59	-0.35	9.04e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.96	7.03	0.5	6.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.24	-0.39	5.4e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.72	-6.91	-0.49	1.22e-10	Platelet distribution width;
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg21951975	chr1:209979733	IRF6	0.57	5.71	0.42	5.78e-8	Coronary artery disease;
PAAD	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg22482690	chr17:47019901	SNF8	0.43	4.52	0.34	1.22e-5	Type 2 diabetes;
PAAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.36	-0.33	2.4e-5	Post bronchodilator FEV1;
PAAD	cis	rs7487075	0.619	rs11183478	chr12:46824066	G/A	cg14671384	chr12:47219920	SLC38A4	0.46	4.58	0.35	9.73e-6	Itch intensity from mosquito bite;
PAAD	cis	rs2271001	0.542	rs1503501	chr11:19198018	C/T	cg00161556	chr11:19138045	ZDHHC13	-0.43	-4.34	-0.33	2.63e-5	Gut microbiome composition (winter);
PAAD	cis	rs4819143	0.517	rs454268	chr21:47373114	G/A	cg20357416	chr21:47294739	PCBP3	0.49	4.42	0.34	1.87e-5	Insulin resistance/response;
PAAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg22947322	chr17:47091978	IGF2BP1	0.38	4.45	0.34	1.65e-5	Type 2 diabetes;
PAAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.74	6.08	0.44	9.39e-9	Obesity-related traits;
PAAD	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.52	6.1	0.44	8.58e-9	Fibrinogen levels;
PAAD	cis	rs9324022	0.722	rs111475476	chr14:101165917	C/T	cg18089426	chr14:101175970	NA	0.72	5.18	0.39	6.96e-7	Plateletcrit;
PAAD	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-7.25	-0.51	2e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg02555727	chr12:129281546	SLC15A4	0.49	5.21	0.39	6e-7	Systemic lupus erythematosus;
PAAD	cis	rs317865	1.000	rs317865	chr4:16156666	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.65	4.77	0.36	4.28e-6	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg11598736	chr3:195384522	SDHAP2	0.67	4.47	0.34	1.5e-5	Lung disease severity in cystic fibrosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06395392	chr16:89406307	ANKRD11	-0.55	-6.95	-0.49	1.01e-10	Monocyte percentage of white cells;
PAAD	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00982548	chr2:198649783	BOLL	-0.67	-4.81	-0.36	3.59e-6	Ulcerative colitis;
PAAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19346786	chr7:2764209	NA	-0.39	-4.73	-0.36	5.11e-6	Height;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg11218175	chr11:495084	RNH1	0.76	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.48	-4.33	-0.33	2.65e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2790216	1.000	rs2790218	chr10:59997301	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg18984983	chr10:135342936	CYP2E1	0.47	4.34	0.33	2.58e-5	Gout;
PAAD	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.62	6.67	0.48	4.43e-10	Type 2 diabetes;
PAAD	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg23034840	chr1:205782522	SLC41A1	0.77	5.87	0.43	2.62e-8	Prostate-specific antigen levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23743543	chr13:31839589	B3GALTL	-0.57	-6.32	-0.46	2.77e-9	Monocyte percentage of white cells;
PAAD	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.51	-5.33	-0.4	3.46e-7	Type 2 diabetes;
PAAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.72	5.92	0.43	2.08e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.59	-5.64	-0.42	7.92e-8	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06770877	chr13:31897247	B3GALTL	0.62	6.29	0.45	3.23e-9	Smoking initiation;
PAAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.48	-4.97	-0.37	1.78e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.49	-5.71	-0.42	5.78e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1625975	0.681	rs4747178	chr10:73404602	A/G	cg26005973	chr10:72643678	PCBD1	0.72	5.05	0.38	1.23e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4936323	0.504	rs10891812	chr11:115096431	T/C	cg04055981	chr11:115044050	NA	0.48	4.64	0.35	7.44e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.09	-0.38	1.05e-6	Reticulocyte count;
PAAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.21	12.3	0.71	1.45e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg26597838	chr10:835615	NA	-0.67	-6.22	-0.45	4.7e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.14	17.58	0.82	1.82e-38	Cognitive function;
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06745885	chr16:68345000	PRMT7;SLC7A6OS	-0.63	-6.39	-0.46	1.9e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-5.44	-0.4	2.05e-7	Eye color traits;
PAAD	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.78	7.81	0.54	8.7e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	0.83	10.13	0.63	9.35e-19	Breast cancer;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.57	-5.79	-0.43	3.86e-8	Prostate cancer;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.56	-0.41	1.21e-7	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27359469	chr6:133116721	C6orf192	-0.64	-6.59	-0.47	6.8e-10	Obesity-related traits;
PAAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.5	0.47	1.07e-9	Lung cancer in ever smokers;
PAAD	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.69	-7.34	-0.51	1.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	1.05	6.61	0.47	6.08e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs11676676	1.000	rs737478	chr2:109769146	C/T	cg23046629	chr2:109745841	LOC100287216;SH3RF3	0.54	4.46	0.34	1.59e-5	Pediatric bone mineral density (spine);
PAAD	cis	rs7567389	0.677	rs10496661	chr2:128090144	G/T	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.79	-0.36	3.96e-6	Primary sclerosing cholangitis;
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg19223190	chr17:80058835	NA	-0.54	-5.6	-0.41	9.57e-8	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.51	-0.47	1.04e-9	Lung cancer;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.79	-8.83	-0.58	2.3e-15	Iron status biomarkers;
PAAD	cis	rs9463078	0.605	rs927658	chr6:45168053	T/C	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.66	6.49	0.47	1.12e-9	Tuberculosis;
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg08885800	chr1:201084119	NA	0.78	8.81	0.58	2.64e-15	Permanent tooth development;
PAAD	cis	rs62045849	0.557	rs6500532	chr16:89174133	A/C	cg26950739	chr16:89183275	ACSF3	0.87	5.53	0.41	1.38e-7	Red blood cell count;
PAAD	cis	rs6604026	0.656	rs7515257	chr1:93393718	G/A	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs1419980	0.730	rs78352721	chr12:7758689	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11245990	chr11:68621969	NA	0.38	4.91	0.37	2.35e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg04165759	chr1:150448943	RPRD2	0.49	5.01	0.38	1.5e-6	Migraine;
PAAD	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs282587	0.569	rs9604415	chr13:113393615	G/T	cg19217778	chr13:113420270	ATP11A	-0.55	-4.34	-0.33	2.6e-5	Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03508643	chr3:100428398	TFG	0.71	7.55	0.52	3.7e-12	Obesity-related traits;
PAAD	cis	rs31872	0.526	rs810277	chr5:140452494	A/G	cg19650706	chr5:140594406	PCDHB13	-0.59	-5.22	-0.39	5.7e-7	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	5.93	0.43	1.98e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6009527	1.000	rs4315635	chr22:49571530	G/T	cg12746016	chr22:49560550	NA	-0.46	-4.9	-0.37	2.38e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.47	-4.5	-0.34	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.72	7.29	0.51	1.58e-11	DNA methylation (variation);
PAAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06656553	chr16:89960601	TCF25	-0.86	-4.78	-0.36	4.18e-6	Skin colour saturation;
PAAD	cis	rs11615916	0.790	rs17716130	chr12:62674735	C/G	cg11441379	chr12:63026424	NA	0.66	4.39	0.34	2.09e-5	Pulmonary function decline;
PAAD	cis	rs375066	0.551	rs2099356	chr19:44315196	T/C	cg11993925	chr19:44307056	LYPD5	-0.43	-4.64	-0.35	7.32e-6	Breast cancer;
PAAD	cis	rs10267417	0.603	rs6969717	chr7:19908081	T/C	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.45	5.69	0.42	6.42e-8	Childhood ear infection;
PAAD	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.89	8.08	0.55	1.83e-13	Exhaled nitric oxide output;
PAAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs1419980	0.730	rs11054743	chr12:7757137	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg04087571	chr11:116723030	SIK3	-0.44	-6.19	-0.45	5.44e-9	Subjective well-being;
PAAD	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg19825600	chr2:3704501	ALLC	-0.5	-4.7	-0.36	5.69e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3736485	0.966	rs2124876	chr15:51906162	T/C	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.51e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-9.58	-0.61	2.62e-17	Height;
PAAD	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg20936604	chr3:58311152	NA	-0.77	-4.56	-0.35	1.04e-5	Cholesterol, total;
PAAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01200585	chr1:228362443	C1orf69	-0.5	-5.66	-0.42	7.17e-8	Diastolic blood pressure;
PAAD	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg02631450	chr22:32366979	NA	1.02	5.56	0.41	1.19e-7	Childhood ear infection;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg10829427	chr3:9885775	RPUSD3	-0.57	-6.29	-0.45	3.25e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6065	0.618	rs4790716	chr17:4865928	G/A	cg02990439	chr17:4875527	CAMTA2	-0.95	-4.87	-0.37	2.82e-6	Platelet count;
PAAD	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg18551225	chr6:44695536	NA	-0.7	-7.12	-0.5	4.1e-11	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.74	-0.36	4.92e-6	Biliary atresia;
PAAD	cis	rs8067287	0.802	rs11650590	chr17:16836300	C/T	cg26910001	chr17:16838321	NA	-0.66	-5.97	-0.44	1.65e-8	Diabetic kidney disease;
PAAD	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs6504950	0.720	rs9913784	chr17:52989071	A/T	cg18040354	chr17:53800484	TMEM100	0.48	4.44	0.34	1.7e-5	Breast cancer;
PAAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.71e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25161331	chr21:43230617	PRDM15	0.54	6.41	0.46	1.74e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg15997130	chr1:24165203	NA	0.59	6.2	0.45	5.14e-9	Immature fraction of reticulocytes;
PAAD	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg24053715	chr22:38214548	NA	-0.53	-5.36	-0.4	3.05e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7567389	0.719	rs4150404	chr2:128050000	A/G	cg11380483	chr2:127933992	NA	-0.46	-4.63	-0.35	7.73e-6	Self-rated health;
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.62	7.88	0.54	5.69e-13	Hypertriglyceridemia;
PAAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.59	7.52	0.52	4.33e-12	Diastolic blood pressure;
PAAD	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.46	4.28	0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.88	-0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs4144743	1.000	rs11871407	chr17:45331358	C/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-7.06	-0.5	5.5e-11	Breast cancer;
PAAD	cis	rs6594713	0.732	rs7718616	chr5:112727603	C/T	cg12552261	chr5:112820674	MCC	0.6	4.48	0.34	1.45e-5	Brain cytoarchitecture;
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.78	8.34	0.56	4.28e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.61	5.85	0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.56	-5.24	-0.39	5.21e-7	Serum sulfate level;
PAAD	cis	rs9333029	0.524	rs4233506	chr1:47396930	T/C	cg08644498	chr1:46502608	NA	-0.47	-4.36	-0.33	2.41e-5	Blood metabolite levels;
PAAD	cis	rs1371614	0.635	rs12612520	chr2:27137307	C/T	cg00617064	chr2:27272375	NA	0.45	4.72	0.36	5.23e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13732083	chr21:47605072	C21orf56	0.46	4.49	0.34	1.41e-5	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.64	6.73	0.48	3.25e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-1.0	-12.45	-0.71	5.67e-25	Breast cancer;
PAAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg21433313	chr16:3507492	NAT15	0.93	7.62	0.53	2.58e-12	Tuberculosis;
PAAD	trans	rs901683	1.000	rs35506889	chr10:46084637	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.4	-0.4	2.57e-7	Mean corpuscular volume;
PAAD	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg10011062	chr15:43941034	CATSPER2	-0.76	-4.4	-0.34	2.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg26071806	chr7:100318239	EPO	-0.48	-4.92	-0.37	2.22e-6	Other erythrocyte phenotypes;
PAAD	cis	rs12760731	0.720	rs12039605	chr1:178433368	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg14515779	chr1:101123966	NA	-0.55	-6.44	-0.46	1.49e-9	Monocyte count;
PAAD	cis	rs12286929	0.583	rs10458966	chr11:115102758	T/C	cg04055981	chr11:115044050	NA	0.46	4.47	0.34	1.52e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-5.63	-0.42	8.59e-8	Primary biliary cholangitis;
PAAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg25452165	chr22:42524984	CYP2D6	0.61	5.8	0.43	3.75e-8	Schizophrenia;
PAAD	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg26618903	chr10:100175079	PYROXD2	-0.42	-4.87	-0.37	2.81e-6	Metabolite levels;
PAAD	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs300774	0.800	rs300716	chr2:136844	G/A	cg21211680	chr2:198530	NA	-0.6	-5.69	-0.42	6.45e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.42	5.63	0.42	8.44e-8	Insulin-like growth factors;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg27094323	chr7:1216898	NA	-0.47	-5.58	-0.41	1.07e-7	Longevity;Endometriosis;
PAAD	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs4343996	0.967	rs4295560	chr7:3356072	G/A	cg21248987	chr7:3385318	SDK1	-0.48	-5.28	-0.39	4.36e-7	Motion sickness;
PAAD	cis	rs9646944	0.540	rs12712148	chr2:103025547	G/A	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.25	-0.39	5e-7	Tonsillectomy;
PAAD	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg21869046	chr19:41225005	ITPKC	0.5	5.18	0.39	6.9e-7	Kawasaki disease;
PAAD	cis	rs1006703	0.544	rs8067516	chr17:3838248	T/C	cg06463185	chr17:3833770	ATP2A3	-0.9	-7.44	-0.52	6.91e-12	Glucose homeostasis traits;
PAAD	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs375066	0.870	rs7258418	chr19:44383083	G/C	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.11e-7	Breast cancer;
PAAD	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.45	-6.82	-0.48	1.97e-10	Subjective well-being;
PAAD	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg10595753	chr17:80898281	TBCD	-0.47	-4.28	-0.33	3.28e-5	Glycated hemoglobin levels;
PAAD	cis	rs10901513	0.932	rs4420176	chr10:127676198	A/G	cg22975853	chr10:127789788	ADAM12	-0.42	-4.41	-0.34	1.95e-5	Visceral fat;
PAAD	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg19792802	chr11:65647270	CTSW	0.53	6.91	0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-10.87	-0.66	1.03e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg18132916	chr6:79620363	NA	-0.46	-4.71	-0.36	5.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.62	8.28	0.56	5.73e-14	Crohn's disease;
PAAD	cis	rs6718203	1.000	rs56202165	chr2:60630635	C/A	cg10480506	chr2:60280451	NA	0.8	4.49	0.34	1.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12599982	chr1:44399894	ARTN	0.41	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.44	4.37	0.33	2.32e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs3806308	0.966	rs10917548	chr1:20143548	A/G	cg13843611	chr1:20143089	RNF186	0.52	5.34	0.4	3.38e-7	Ulcerative colitis;
PAAD	cis	rs3753841	0.798	rs12406439	chr1:103240351	C/T	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	cis	rs75757892	0.504	rs114679106	chr6:7325508	G/T	cg02954307	chr6:7269328	NA	0.5	4.27	0.33	3.44e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.7	7.66	0.53	1.99e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4740619	0.630	rs2382542	chr9:15988358	A/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.17e-5	Body mass index;
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.95	-0.43	1.77e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs16958440	0.867	rs57744138	chr18:44700482	A/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	9.97	0.63	2.44e-18	Response to antipsychotic treatment;
PAAD	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.62	5.63	0.42	8.45e-8	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14707898	chr6:41888549	MED20;BYSL	0.51	6.32	0.46	2.73e-9	Monocyte percentage of white cells;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.45	4.27	0.33	3.37e-5	Subjective well-being;
PAAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.79	-8.06	-0.55	2.15e-13	DNA methylation (variation);
PAAD	cis	rs12760731	0.565	rs2095133	chr1:178198612	C/G	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	0.87	10.24	0.64	4.98e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-1.06	-10.01	-0.63	1.97e-18	IgG glycosylation;
PAAD	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.7	-0.42	6.12e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06850241	chr22:41845214	NA	-0.61	-5.37	-0.4	2.93e-7	Vitiligo;
PAAD	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27068297	chr22:50451975	IL17REL	0.45	4.58	0.35	9.73e-6	Ulcerative colitis;
PAAD	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.17	9.06	0.59	6.07e-16	Mitochondrial DNA levels;
PAAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.52	5.28	0.39	4.31e-7	IgG glycosylation;
PAAD	cis	rs1018836	0.828	rs4140679	chr8:91584269	A/C	cg16814680	chr8:91681699	NA	-0.74	-8.2	-0.55	9.27e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg11342046	chr2:242641489	ING5	0.63	7.23	0.51	2.25e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18448224	chr18:68098183	NA	-0.61	-6.41	-0.46	1.72e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg10223061	chr2:219282414	VIL1	0.37	4.39	0.34	2.1e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.72	6.37	0.46	2.18e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs2718058	0.515	rs1584611	chr7:37874039	T/C	cg15028436	chr7:37888078	TXNDC3	0.44	4.42	0.34	1.87e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.53	5.29	0.39	4.14e-7	Systemic lupus erythematosus;
PAAD	cis	rs2242663	0.581	rs2511224	chr11:66262606	T/C	cg16756854	chr11:66116455	B3GNT1	0.34	4.38	0.33	2.2e-5	Bipolar disorder;
PAAD	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.06	-0.44	1.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6681460	0.565	rs1536112	chr1:67107225	C/T	cg02459107	chr1:67143332	SGIP1	-0.51	-4.98	-0.37	1.72e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg09659197	chr4:152720779	NA	0.32	4.46	0.34	1.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.36	0.76	4.3e-30	Headache;
PAAD	cis	rs793571	0.822	rs10518992	chr15:59203615	T/C	cg05156742	chr15:59063176	FAM63B	0.59	4.73	0.36	5.17e-6	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08898568	chr1:17338409	ATP13A2	0.6	6.45	0.46	1.43e-9	Myopia (pathological);
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.86	-9.29	-0.6	1.57e-16	Menopause (age at onset);
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-5.16	-0.39	7.45e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-1.11	-8.21	-0.55	8.68e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11068784	chr4:2277713	ZFYVE28	0.55	6.37	0.46	2.09e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.78	-11.27	-0.67	8.73e-22	Birth weight;
PAAD	cis	rs4074493	0.859	rs6541250	chr1:231173427	C/T	cg22172038	chr1:231176991	FAM89A	0.51	4.81	0.36	3.54e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.3	7.98	0.54	3.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg10411590	chr13:21900810	NA	0.63	7.49	0.52	5.16e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.54	-0.47	8.82e-10	Bone mineral density;
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7539409	0.667	rs10874407	chr1:84188082	G/A	cg10977910	chr1:84465055	TTLL7	-0.73	-4.34	-0.33	2.64e-5	Alzheimer's disease;
PAAD	cis	rs8133949	0.953	rs7278166	chr21:43427540	C/T	cg27108998	chr21:43275314	PRDM15	0.47	4.46	0.34	1.57e-5	Hand grip strength;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26078244	chr5:1112110	SLC12A7	0.58	6.52	0.47	9.77e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-5.52	-0.41	1.41e-7	Longevity;Endometriosis;
PAAD	cis	rs6494488	0.500	rs72741368	chr15:64794772	G/C	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs56011263	0.512	rs12502944	chr4:736054	G/A	cg05835009	chr4:710272	PCGF3	0.64	5.28	0.39	4.34e-7	White blood cell count;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4074493	0.963	rs4074492	chr1:231172439	G/A	cg22172038	chr1:231176991	FAM89A	0.53	4.83	0.36	3.29e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.4	-8.32	-0.56	4.61e-14	Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.83	-8.7	-0.58	5.06e-15	Body mass index;
PAAD	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg14583973	chr4:3374767	RGS12	-0.35	-5.17	-0.39	7.34e-7	Parental longevity (mother's age at death);
PAAD	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.56	5.95	0.43	1.75e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-5.28	-0.39	4.33e-7	Mean corpuscular volume;
PAAD	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.64	6.12	0.44	7.48e-9	Blood metabolite levels;
PAAD	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.68	6.35	0.46	2.4e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.628	rs10150072	chr14:103977605	C/T	cg12935359	chr14:103987150	CKB	-0.73	-8.51	-0.57	1.51e-14	Body mass index;
PAAD	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg21174375	chr14:64681225	SYNE2	0.34	4.38	0.33	2.17e-5	Atrial fibrillation;
PAAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13476313	chr9:127244764	NR5A1	0.31	5.03	0.38	1.36e-6	Menarche (age at onset);
PAAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-10.99	-0.67	4.8e-21	Coronary artery disease;
PAAD	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.84	-8.81	-0.58	2.66e-15	Obesity-related traits;
PAAD	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.5	-5.22	-0.39	5.87e-7	Type 2 diabetes;
PAAD	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.86	-11.18	-0.67	1.49e-21	Subjective well-being (multi-trait analysis);
PAAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg15145965	chr22:50218605	BRD1	0.59	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs1891275	0.551	rs7088831	chr10:93412452	A/G	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg21479132	chr6:26055353	NA	0.99	6.01	0.44	1.31e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.87	0.49	1.5e-10	Systemic lupus erythematosus;
PAAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.59	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs2908197	0.806	rs2961047	chr7:75935056	A/G	cg22830091	chr7:75961684	YWHAG	-0.57	-6.47	-0.46	1.29e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7301016	0.817	rs7302456	chr12:62997643	G/T	cg11441379	chr12:63026424	NA	0.9	6.49	0.47	1.13e-9	IgG glycosylation;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.68	0.53	1.82e-12	Prudent dietary pattern;
PAAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-9.08	-0.59	5.48e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs2882667	0.690	rs17207772	chr5:138241820	C/G	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.23e-6	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04531202	chr16:86588934	MTHFSD;FLJ30679	0.58	6.63	0.47	5.54e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73206853	0.698	rs56327628	chr12:111117931	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.63	0.35	7.81e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.59	-5.67	-0.42	7.06e-8	Monocyte count;
PAAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.16	-0.45	6.2e-9	Total body bone mineral density;
PAAD	cis	rs7040024	0.754	rs28865678	chr9:854012	C/G	cg14021170	chr9:826657	NA	-0.44	-4.27	-0.33	3.4e-5	Testicular germ cell tumor;Testicular cancer;
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg21565972	chr17:80109576	CCDC57	-0.58	-6.75	-0.48	2.85e-10	Life satisfaction;
PAAD	cis	rs12936587	0.601	rs7223430	chr17:17556490	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-5.33	-0.4	3.52e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs80142506	chr15:64995147	G/C	cg16425858	chr15:64791681	ZNF609	0.96	4.85	0.37	3.02e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg08501292	chr6:25962987	TRIM38	0.85	4.82	0.36	3.38e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.56	5.6	0.41	9.75e-8	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.81	-0.36	3.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg02475695	chr16:616220	NHLRC4	0.45	5.12	0.38	8.97e-7	Height;
PAAD	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.96	-0.37	1.84e-6	Diabetic retinopathy;
PAAD	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg04450456	chr4:17643702	FAM184B	0.47	4.89	0.37	2.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Systolic blood pressure;
PAAD	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.51	5.51	0.41	1.51e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21984481	chr17:79567631	NPLOC4	-0.64	-7.75	-0.53	1.2e-12	Eye color traits;
PAAD	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	4.51	0.34	1.3e-5	Thyroid stimulating hormone;
PAAD	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.8	0.81	1.82e-36	Schizophrenia;
PAAD	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-10.52	-0.65	8.78e-20	Height;
PAAD	cis	rs10982213	1.000	rs7875262	chr9:117181237	C/T	cg00078025	chr9:117159975	NA	0.66	5.12	0.38	9.17e-7	Interleukin-6 levels;
PAAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.22	-9.99	-0.63	2.24e-18	Breast cancer;
PAAD	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.59	-5.89	-0.43	2.35e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6066835	0.867	rs6095278	chr20:47363413	C/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.91	8.89	0.59	1.61e-15	Exhaled nitric oxide output;
PAAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.82	-0.43	3.45e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.59	0.47	6.74e-10	Body mass index;
PAAD	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg18084798	chr19:33555255	RHPN2	0.45	4.75	0.36	4.6e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	1.01	10.63	0.65	4.4e-20	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.42	-0.4	2.24e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1371614	0.632	rs7589627	chr2:27159786	C/T	cg00617064	chr2:27272375	NA	-0.43	-4.53	-0.34	1.19e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.88	-8.18	-0.55	1.06e-13	Exhaled nitric oxide output;
PAAD	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-10.2	-0.64	6.14e-19	Obesity-related traits;
PAAD	cis	rs7534824	0.625	rs6686202	chr1:101493078	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.71	0.36	5.52e-6	Refractive astigmatism;
PAAD	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	9.49	0.61	4.65e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg05791153	chr7:19748676	TWISTNB	0.62	4.66	0.35	6.99e-6	Thyroid stimulating hormone;
PAAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17848003	chr1:3704513	LRRC47	0.41	4.42	0.34	1.86e-5	Red cell distribution width;
PAAD	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.5	-4.93	-0.37	2.18e-6	Corneal structure;
PAAD	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	cis	rs8070740	0.731	rs980406	chr17:5338783	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.59	0.35	9.18e-6	Menopause (age at onset);
PAAD	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg27499820	chr13:21296301	IL17D	0.53	5.0	0.38	1.54e-6	Dental caries;
PAAD	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.53	-5.25	-0.39	5.14e-7	Adiposity;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.82	6.21	0.45	4.77e-9	Alzheimer's disease;
PAAD	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.7	6.16	0.45	6.21e-9	Blood protein levels;
PAAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg15847926	chr7:2749597	AMZ1	-0.39	-4.82	-0.36	3.46e-6	Height;
PAAD	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg04809136	chr2:24300158	SF3B14	-0.39	-4.48	-0.34	1.43e-5	Quantitative traits;
PAAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.75	-12.74	-0.72	9.51e-26	Longevity;Endometriosis;
PAAD	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.76	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.57	6.42	0.46	1.64e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg26071806	chr7:100318239	EPO	-0.49	-4.88	-0.37	2.62e-6	Other erythrocyte phenotypes;
PAAD	cis	rs4764124	0.615	rs1012683	chr12:14951050	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.54	6.24	0.45	4.2e-9	Pubertal anthropometrics;
PAAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.35	4.31	0.33	2.91e-5	Personality dimensions;
PAAD	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	1.0	12.43	0.71	6.55e-25	Breast cancer;
PAAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-4.41	-0.34	1.95e-5	Systemic lupus erythematosus;
PAAD	cis	rs12042052	1.000	rs6696779	chr1:232920825	G/A	cg02191044	chr1:232940990	KIAA1383	0.91	4.48	0.34	1.44e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4743820	0.620	rs55934624	chr9:93917285	T/G	cg14446406	chr9:93919335	NA	0.5	6.03	0.44	1.21e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.71	-7.21	-0.5	2.43e-11	DNA methylation (variation);
PAAD	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg12315302	chr6:26189340	HIST1H4D	0.8	4.38	0.33	2.2e-5	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg24747557	chr10:131355152	MGMT	-0.51	-5.42	-0.4	2.32e-7	Response to temozolomide;
PAAD	cis	rs863345	0.604	rs10797012	chr1:158465485	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.81	8.6	0.57	9.4e-15	Uric acid levels;
PAAD	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.64	0.42	8.16e-8	HIV-1 control;
PAAD	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.63	6.93	0.49	1.1e-10	Alcohol dependence;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08677398	chr8:58056175	NA	0.62	4.63	0.35	7.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs4234284	1.000	rs13074166	chr3:126957297	T/A	cg27326032	chr3:127006922	NA	-0.49	-4.98	-0.37	1.71e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	7.61	0.53	2.68e-12	Cognitive test performance;
PAAD	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg21205071	chr1:161993677	OLFML2B	0.47	4.34	0.33	2.64e-5	IgG glycosylation;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.9	0.43	2.25e-8	Subjective well-being;
PAAD	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.67	7.01	0.49	7.39e-11	Height;
PAAD	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg05250797	chr16:70222502	NA	0.79	5.95	0.43	1.74e-8	IgE levels;
PAAD	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-5.4	-0.4	2.57e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06815965	chr1:205818668	PM20D1	0.72	8.26	0.56	6.48e-14	Menarche (age at onset);
PAAD	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-1.12	-7.78	-0.53	1.05e-12	Opioid sensitivity;
PAAD	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	1.01	7.68	0.53	1.83e-12	Dental caries;
PAAD	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.23	0.45	4.3e-9	Hip circumference;
PAAD	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.46	4.88	0.37	2.68e-6	Age of smoking initiation;
PAAD	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.46	4.79	0.36	4.01e-6	Menopause (age at onset);
PAAD	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.17	0.39	7.33e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.56	5.29	0.39	4.23e-7	Type 2 diabetes;
PAAD	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.28	-0.39	4.49e-7	Mean corpuscular volume;
PAAD	cis	rs909002	0.849	rs10798879	chr1:32096815	T/C	cg13919466	chr1:32135498	COL16A1	-0.41	-4.61	-0.35	8.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9646944	0.501	rs10174323	chr2:103012781	C/A	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.46	-7.04	-0.5	6.13e-11	Cutaneous nevi;
PAAD	cis	rs859767	0.737	rs2280219	chr2:135351764	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.51	-0.34	1.28e-5	Neuroticism;
PAAD	trans	rs320203	0.741	rs1935378	chr9:104781885	A/G	cg27499259	chr13:28400924	NA	-0.97	-6.35	-0.46	2.4e-9	Mucinous ovarian carcinoma;
PAAD	cis	rs863345	0.504	rs857714	chr1:158566972	C/T	cg12129480	chr1:158549410	OR10X1	0.42	4.78	0.36	4.07e-6	Pneumococcal bacteremia;
PAAD	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg21890820	chr11:65308645	LTBP3	0.97	7.78	0.53	1.02e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg16586182	chr3:47516702	SCAP	-0.76	-8.89	-0.58	1.7e-15	Colorectal cancer;
PAAD	cis	rs6499755	0.712	rs31101	chr16:55371678	G/A	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.67	7.74	0.53	1.31e-12	Vitiligo;
PAAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.43	-4.8	-0.36	3.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10214930	0.813	rs12700829	chr7:27687102	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21721701	chr11:47739669	FNBP4	-0.53	-6.5	-0.47	1.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.68	7.87	0.54	6.12e-13	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2637266	0.935	rs1907300	chr10:78325091	A/G	cg18941641	chr10:78392320	NA	0.39	4.64	0.35	7.42e-6	Pulmonary function;
PAAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.47	4.73	0.36	5.2e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13701615	chr5:271609	PDCD6	0.58	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg11547950	chr5:77652471	NA	0.86	7.11	0.5	4.26e-11	Triglycerides;
PAAD	cis	rs6460942	0.597	rs7798779	chr7:12543490	A/G	cg06484146	chr7:12443880	VWDE	-0.77	-4.91	-0.37	2.36e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.08	0.38	1.09e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.89	-10.46	-0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.52	-0.41	1.41e-7	Alcohol dependence;
PAAD	cis	rs2790216	1.000	rs2590321	chr10:59996693	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg05132306	chr1:1846340	CALML6	-0.42	-4.97	-0.37	1.8e-6	Body mass index;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02071572	chr4:1403502	NA	-0.4	-5.05	-0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg01605746	chr5:669925	TPPP	0.39	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.5	5.17	0.39	7.4e-7	Lewy body disease;
PAAD	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.65	6.22	0.45	4.51e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.67	7.09	0.5	4.65e-11	Aortic root size;
PAAD	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.08	11.6	0.69	1.09e-22	Blood pressure (smoking interaction);
PAAD	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-7.83	-0.54	7.75e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs900145	0.817	rs10832012	chr11:13293248	G/T	cg15603424	chr11:13300592	ARNTL	0.55	4.39	0.34	2.07e-5	Menarche (age at onset);
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.78	-8.84	-0.58	2.19e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.47	5.94	0.43	1.89e-8	Childhood ear infection;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs988913	0.706	rs10948880	chr6:54882003	G/T	cg03513858	chr6:54763001	FAM83B	-0.39	-4.25	-0.33	3.74e-5	Menarche (age at onset);
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.91	-0.43	2.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9463078	0.550	rs7769231	chr6:45284921	A/G	cg25276700	chr6:44698697	NA	-0.54	-6.05	-0.44	1.08e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg23759393	chr7:158110405	PTPRN2	0.37	4.48	0.34	1.48e-5	Response to amphetamines;
PAAD	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	6.36	0.46	2.21e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.73	7.37	0.51	9.98e-12	Lung cancer;
PAAD	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.39	-0.68	4.02e-22	Coronary artery disease;
PAAD	cis	rs3753841	0.832	rs34310235	chr1:103274082	T/C	cg24495344	chr1:103574097	COL11A1	0.39	4.53	0.34	1.18e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs6537837	1.000	rs7355157	chr1:110129835	T/C	cg05049280	chr1:110155535	GNAT2	0.45	4.5	0.34	1.33e-5	Major depressive disorder;
PAAD	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg08601574	chr20:25228251	PYGB	0.64	6.96	0.49	9.66e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.78	-7.59	-0.52	3.06e-12	Urate levels in lean individuals;
PAAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-4.59	-0.35	9.31e-6	Joint mobility (Beighton score);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25195100	chr20:61903949	ARFGAP1	0.56	6.36	0.46	2.28e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7639513	0.520	rs12714875	chr3:12731007	T/G	cg23032965	chr3:12705835	RAF1	0.89	7.8	0.53	9.28e-13	Itch intensity from mosquito bite;
PAAD	cis	rs597480	0.747	rs4944538	chr11:85518123	T/C	cg11817631	chr11:85522609	SYTL2	0.49	4.7	0.36	5.71e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.91	11.01	0.67	4.29e-21	Menarche (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24706213	chr1:109633347	TMEM167B	0.74	8.14	0.55	1.32e-13	Myopia (pathological);
PAAD	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.43	-0.4	2.18e-7	Bipolar disorder;
PAAD	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.47	-5.0	-0.38	1.56e-6	Menopause (age at onset);
PAAD	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.42	-6.6	-0.47	6.29e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg21795699	chr17:15903687	ZSWIM7;TTC19	-0.66	-6.69	-0.48	4e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.52	-4.77	-0.36	4.36e-6	Height;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.27	-7.77	-0.53	1.09e-12	Body mass index;
PAAD	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs300774	1.000	rs300772	chr2:117230	C/T	cg21211680	chr2:198530	NA	-0.64	-5.81	-0.43	3.55e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.13	-16.59	-0.8	6.22e-36	Cognitive function;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.78	-5.84	-0.43	3.03e-8	Coronary artery calcification;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05789608	chr1:205180802	DSTYK	0.58	6.5	0.47	1.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg06241208	chr11:30344200	C11orf46	-0.49	-4.43	-0.34	1.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.54	-0.35	1.15e-5	Breast cancer;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	1.09	6.36	0.46	2.27e-9	Body mass index;
PAAD	trans	rs34112283	0.592	rs13011344	chr2:144186545	T/G	cg10530280	chr1:167759869	MPZL1	-0.66	-6.46	-0.46	1.32e-9	Neuroticism;
PAAD	cis	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg21546286	chr11:48923668	NA	-0.44	-4.62	-0.35	8.14e-6	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20201566	chr12:110011335	MMAB;MVK	-0.8	-7.11	-0.5	4.35e-11	Neuroticism;
PAAD	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.8	-5.09	-0.38	1.06e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	6.87	0.49	1.57e-10	Renal function-related traits (BUN);
PAAD	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg24330906	chr2:85765176	MAT2A	0.59	5.82	0.43	3.29e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.45	-4.32	-0.33	2.78e-5	Breast cancer;
PAAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg15061591	chr7:98625706	SMURF1	-0.48	-4.35	-0.33	2.5e-5	Breast cancer;
PAAD	cis	rs12136530	0.593	rs9287047	chr1:19736534	T/C	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.82	-5.8	-0.43	3.77e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.57	-6.37	-0.46	2.11e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg01324507	chr7:1177794	C7orf50	0.55	4.33	0.33	2.7e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg02734326	chr4:10020555	SLC2A9	0.52	5.15	0.39	8.13e-7	Bone mineral density;
PAAD	cis	rs2051773	0.567	rs6486347	chr11:17050008	A/G	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.57	5.06	0.38	1.22e-6	Life satisfaction;
PAAD	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg02666820	chr17:700054	NA	0.78	5.63	0.42	8.41e-8	Type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.75	11.54	0.68	1.58e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.43	-0.34	1.83e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.69	6.71	0.48	3.53e-10	Prostate cancer;
PAAD	cis	rs12799264	1.000	rs2165801	chr11:19975906	A/C	cg17303119	chr11:19974895	NAV2	-0.71	-4.76	-0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.67	-5.94	-0.43	1.85e-8	Birth weight;
PAAD	cis	rs2790216	0.950	rs2455577	chr10:59964707	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2790216	1.000	rs2440850	chr10:60011731	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg09179987	chr1:167433047	CD247	0.48	5.52	0.41	1.42e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs7960581	0.722	rs35187145	chr12:99172819	T/C	cg17109042	chr12:99139387	ANKS1B	-0.69	-4.46	-0.34	1.55e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.89	10.24	0.64	4.78e-19	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.74	11.26	0.67	8.81e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg01620082	chr3:125678407	NA	-1.01	-6.54	-0.47	8.78e-10	Depression;
PAAD	cis	rs477692	0.648	rs10829603	chr10:131327351	T/G	cg07469887	chr10:131262384	NA	-0.44	-5.06	-0.38	1.2e-6	Response to temozolomide;
PAAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.59	-5.85	-0.43	2.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.54e-5	Renal cell carcinoma;
PAAD	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.59	-4.44	-0.34	1.75e-5	Thyroid stimulating hormone;
PAAD	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-4.25	-0.33	3.74e-5	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.02	0.59	7.54e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.52	-5.1	-0.38	9.76e-7	Itch intensity from mosquito bite;
PAAD	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.08	-0.44	9.5e-9	Bipolar disorder;
PAAD	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.7	7.45	0.52	6.53e-12	Colorectal cancer;
PAAD	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg08886695	chr4:3369023	RGS12	-0.49	-4.78	-0.36	4.17e-6	Serum sulfate level;
PAAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.57	5.3	0.39	4.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg14343924	chr8:8086146	FLJ10661	-0.68	-5.93	-0.43	1.98e-8	Mood instability;
PAAD	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.84	6.44	0.46	1.5e-9	Atopic dermatitis;
PAAD	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.63	6.51	0.47	1.02e-9	Myopia (pathological);
PAAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg07979401	chr6:33739406	LEMD2	-0.52	-4.31	-0.33	2.93e-5	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24184221	chr17:6555443	MED31;C17orf100	0.64	6.77	0.48	2.66e-10	Obesity-related traits;
PAAD	cis	rs55665837	0.539	rs10500804	chr11:14910273	A/C	cg16394018	chr11:14927549	NA	0.39	4.32	0.33	2.78e-5	Vitamin D levels;
PAAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg25452165	chr22:42524984	CYP2D6	0.58	5.2	0.39	6.45e-7	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg14830002	chr1:247616686	OR2B11	0.56	4.56	0.35	1.03e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg15117754	chr3:10150083	C3orf24	0.75	6.52	0.47	9.9e-10	Alzheimer's disease;
PAAD	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs2290419	0.730	rs76699054	chr11:68945532	G/A	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg14583973	chr4:3374767	RGS12	0.42	6.32	0.46	2.74e-9	Serum sulfate level;
PAAD	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.48	4.82	0.36	3.5e-6	Anterior chamber depth;
PAAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg15478930	chr2:27652102	NRBP1	0.48	4.28	0.33	3.31e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.51	2.4e-11	Schizophrenia;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.64	5.05	0.38	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.62	-0.35	8.27e-6	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07348587	chr4:25915958	C4orf52	0.62	6.55	0.47	8.59e-10	Myopia (pathological);
PAAD	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.92	-0.37	2.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg09579323	chr1:150459698	TARS2	0.45	4.29	0.33	3.23e-5	Migraine;
PAAD	cis	rs9815354	0.723	rs12152489	chr3:42060402	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.15	0.45	6.49e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11954230	chr10:105677556	OBFC1	0.69	7.85	0.54	7.11e-13	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22359535	chr19:59087367	MGC2752	0.59	6.82	0.48	2.03e-10	Monocyte percentage of white cells;
PAAD	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg03006477	chr6:74432658	CD109	0.44	4.41	0.34	1.94e-5	Blood protein levels;Calcium levels;
PAAD	trans	rs350729	0.649	rs12474068	chr2:53175654	G/A	cg24639469	chr1:4837462	AJAP1	0.63	6.37	0.46	2.14e-9	Bronchodilator response in asthma;
PAAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs4704187	0.595	rs6859176	chr5:74379425	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22396632	chr1:3079212	PRDM16	-0.42	-4.42	-0.34	1.87e-5	Migraine;
PAAD	cis	rs2415984	0.579	rs17740937	chr14:46959273	A/G	cg14871534	chr14:47121158	RPL10L	-0.51	-5.17	-0.39	7.35e-7	Number of children ever born;
PAAD	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg08501292	chr6:25962987	TRIM38	0.97	5.29	0.39	4.28e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27012203	chr1:11865920	CLCN6;MTHFR	0.63	6.58	0.47	7.04e-10	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.34	-0.33	2.56e-5	Life satisfaction;
PAAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14180030	chr9:123475675	MEGF9	-0.48	-5.2	-0.39	6.26e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	5.0	0.38	1.59e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg01868782	chr6:126071099	HEY2	0.45	5.35	0.4	3.14e-7	Brugada syndrome;
PAAD	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg21565972	chr17:80109576	CCDC57	0.57	6.53	0.47	9.31e-10	Life satisfaction;
PAAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14442939	chr10:27389572	ANKRD26	0.58	5.28	0.39	4.36e-7	Breast cancer;
PAAD	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.6	6.01	0.44	1.31e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg23024343	chr7:107201750	COG5	0.56	4.54	0.35	1.14e-5	Coronary artery disease;
PAAD	cis	rs2926621	1.000	rs2926621	chr18:73620170	G/T	cg08035942	chr18:72921337	TSHZ1;ZADH2	0.47	4.31	0.33	2.97e-5	Night sleep phenotypes;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.71	5.93	0.43	2e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg10587741	chr22:38071170	LGALS1	0.61	6.9	0.49	1.34e-10	Fat distribution (HIV);
PAAD	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.64	6.22	0.45	4.55e-9	Colorectal cancer;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg07636037	chr3:49044803	WDR6	-0.66	-4.26	-0.33	3.51e-5	Menarche (age at onset);
PAAD	cis	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg20092376	chr4:56023423	NA	-0.51	-5.53	-0.41	1.34e-7	Endometriosis;
PAAD	cis	rs6580110	0.714	rs9324791	chr5:154078556	T/C	cg17263206	chr5:154071247	NA	0.54	5.82	0.43	3.32e-8	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg10223061	chr2:219282414	VIL1	0.4	4.84	0.37	3.22e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1682825	0.615	rs5026889	chr3:10777448	C/G	cg03414471	chr3:11600889	VGLL4	0.5	4.27	0.33	3.48e-5	Economic and political preferences (feminism/equality);
PAAD	cis	rs1864585	0.520	rs73208781	chr8:10677498	A/C	cg21775007	chr8:11205619	TDH	-0.57	-4.43	-0.34	1.79e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs2072732	0.706	rs12564456	chr1:2936386	C/G	cg22517653	chr1:2918612	NA	-0.59	-4.83	-0.36	3.29e-6	Plateletcrit;
PAAD	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.82	7.42	0.52	7.63e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08479957	chr14:102227593	PPP2R5C	0.59	6.87	0.49	1.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8105895	0.935	rs62111032	chr19:22281349	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg11204139	chr17:3907470	NA	0.81	8.14	0.55	1.31e-13	Type 2 diabetes;
PAAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg06131755	chr6:160182447	ACAT2	0.51	4.48	0.34	1.46e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	1.49	9.69	0.62	1.36e-17	Age-related hearing impairment;
PAAD	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg08917208	chr2:24149416	ATAD2B	-0.49	-4.3	-0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1539053	1.000	rs1983454	chr1:58096379	G/T	cg00026909	chr1:58089001	DAB1	-0.69	-8.01	-0.54	2.75e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg26695010	chr11:65641043	EFEMP2	-0.64	-5.72	-0.42	5.62e-8	DNA methylation (variation);
PAAD	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.86	-8.06	-0.55	2.13e-13	Colorectal adenoma (advanced);
PAAD	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg11266682	chr4:10021025	SLC2A9	0.61	5.39	0.4	2.63e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.87	5.7	0.42	6.15e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.72	5.82	0.43	3.29e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62264129	0.525	rs62278769	chr3:112027201	C/T	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.8	-0.36	3.83e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg10434728	chr15:90938212	IQGAP1	0.43	4.46	0.34	1.58e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.44	-5.82	-0.43	3.39e-8	White blood cell count;
PAAD	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg22467129	chr15:76604101	ETFA	-0.54	-5.09	-0.38	1.03e-6	Blood metabolite levels;
PAAD	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg27565382	chr3:53032988	SFMBT1	0.73	4.29	0.33	3.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg16898833	chr6:26189333	HIST1H4D	0.87	4.7	0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg05874882	chr4:1763078	NA	-0.36	-5.08	-0.38	1.07e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.98	8.21	0.55	8.91e-14	Neutrophil percentage of white cells;
PAAD	cis	rs56873913	0.904	rs3760708	chr19:50084596	G/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.51	-4.3	-0.33	3.06e-5	Schizophrenia;
PAAD	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg05250797	chr16:70222502	NA	0.78	6.09	0.44	9.02e-9	IgE levels;
PAAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.13	-0.73	8.47e-27	Height;
PAAD	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.59	5.8	0.43	3.79e-8	Tonsillectomy;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15823423	chr11:63884524	FLRT1;MACROD1	-0.67	-6.34	-0.46	2.55e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.73	-0.36	5.16e-6	HDL cholesterol;
PAAD	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.48	-0.34	1.45e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.67	-0.42	6.98e-8	Blood metabolite levels;
PAAD	cis	rs1497828	1.000	rs1391285	chr1:217561468	C/T	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs3126085	0.515	rs6668764	chr1:152349078	C/T	cg26876637	chr1:152193138	HRNR	0.69	5.39	0.4	2.69e-7	Atopic dermatitis;
PAAD	cis	rs8016982	0.559	rs10133562	chr14:81732758	C/T	cg01989461	chr14:81687754	GTF2A1	-0.56	-4.32	-0.33	2.79e-5	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05121093	chr17:74668089	NA	-0.64	-6.39	-0.46	1.91e-9	Lung cancer in ever smokers;
PAAD	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg24519413	chr1:26490540	NA	0.5	4.63	0.35	7.8e-6	Height;
PAAD	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg08222618	chr4:941054	TMEM175	0.8	10.54	0.65	7.89e-20	Sjögren's syndrome;
PAAD	cis	rs2274459	1.000	rs13200063	chr6:33730171	C/A	cg06253072	chr6:33679850	C6orf125	0.68	4.83	0.36	3.25e-6	Obesity (extreme);
PAAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.73	6.7	0.48	3.77e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs4218	0.531	rs12101733	chr15:59339765	G/A	cg25595834	chr15:59156878	NA	0.42	4.32	0.33	2.85e-5	Social communication problems;
PAAD	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.76	4.45	0.34	1.65e-5	Body mass index;
PAAD	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6681460	0.549	rs7525509	chr1:67031968	C/T	cg02459107	chr1:67143332	SGIP1	0.66	7.09	0.5	4.82e-11	Presence of antiphospholipid antibodies;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24748867	chr2:223185320	NA	-0.67	-7.04	-0.5	6.13e-11	Smoking initiation;
PAAD	cis	rs2899832	0.789	rs7154637	chr14:35723566	C/G	cg09327582	chr14:35236912	BAZ1A	-0.55	-4.57	-0.35	1.01e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.85	-9.57	-0.61	2.92e-17	Mortality in heart failure;
PAAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.75	8.34	0.56	4.24e-14	Longevity;
PAAD	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.83	6.74	0.48	3.01e-10	Chronic kidney disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04408225	chr14:95623684	DICER1;FLJ45244	0.6	6.36	0.46	2.28e-9	Myopia (pathological);
PAAD	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.8	-8.16	-0.55	1.17e-13	Menopause (age at onset);
PAAD	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.66	-5.71	-0.42	5.66e-8	Obesity-related traits;
PAAD	cis	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.4	0.34	2.04e-5	Depression;
PAAD	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.57	5.46	0.41	1.87e-7	Mosquito bite size;
PAAD	cis	rs2562456	0.833	rs11667361	chr19:21539382	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg00400743	chr4:148603008	PRMT10	-0.7	-4.35	-0.33	2.48e-5	Pulse pressure;
PAAD	cis	rs4938330	0.552	rs3882895	chr11:117090545	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg10034588	chr2:232392055	NMUR1	-0.35	-4.25	-0.33	3.72e-5	Height;
PAAD	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg08897044	chr19:12950850	MAST1	-0.36	-4.64	-0.35	7.5e-6	Mean corpuscular volume;
PAAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	5.05	0.38	1.28e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.52	-4.52	-0.34	1.23e-5	IgG glycosylation;
PAAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.52	0.47	9.6e-10	Rheumatoid arthritis;
PAAD	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.75	8.48	0.57	1.87e-14	Corneal astigmatism;
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.8	8.56	0.57	1.14e-14	Obesity-related traits;
PAAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg19413350	chr8:57351067	NA	-0.46	-4.58	-0.35	9.8e-6	Obesity-related traits;
PAAD	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.47	-4.45	-0.34	1.64e-5	Fractional excretion of uric acid;
PAAD	cis	rs1695315	1	rs1695315	chr3:3153339	G/A	cg21594961	chr3:3152916	IL5RA	-0.48	-5.21	-0.39	6.11e-7	Eosinophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.27	0.39	4.51e-7	Type 2 diabetes;
PAAD	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg22153407	chr1:230290089	GALNT2	0.5	5.19	0.39	6.61e-7	Coronary artery disease;
PAAD	cis	rs4740619	0.836	rs10810462	chr9:15889634	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.52	-0.34	1.21e-5	Body mass index;
PAAD	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg15193198	chr20:60906057	LAMA5	0.59	6.77	0.48	2.67e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs4965869	0.866	rs4965865	chr15:101975597	C/T	cg12371147	chr15:101978424	PCSK6	-0.48	-4.29	-0.33	3.17e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg16434002	chr17:42200994	HDAC5	0.62	5.7	0.42	6.01e-8	Total body bone mineral density;
PAAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg13722127	chr7:150037890	RARRES2	0.6	5.75	0.42	4.82e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7172971	0.688	rs8029713	chr15:42387118	A/G	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.98	8.18	0.55	1.07e-13	Neutrophil percentage of white cells;
PAAD	cis	rs183266	0.800	rs17810962	chr14:77483382	A/G	cg01682506	chr14:77422843	NA	-0.92	-4.46	-0.34	1.6e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-8.91	-0.59	1.45e-15	Vitiligo;
PAAD	cis	rs12136530	0.593	rs10917443	chr1:19724079	A/C	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.8	-0.36	3.76e-6	Lead levels in blood;
PAAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg06740227	chr12:86229804	RASSF9	-0.51	-4.64	-0.35	7.56e-6	Major depressive disorder;
PAAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	6.02	0.44	1.25e-8	Schizophrenia;
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12153243	0.714	rs55848514	chr5:142902056	C/T	cg13907255	chr5:142895549	NA	-0.52	-4.81	-0.36	3.57e-6	Migraine;
PAAD	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.71	-0.36	5.57e-6	Resting heart rate;
PAAD	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.73	-5.37	-0.4	2.83e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg01620082	chr3:125678407	NA	-1.08	-6.3	-0.46	3.02e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.49	-5.07	-0.38	1.16e-6	Daytime sleep phenotypes;
PAAD	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg24747557	chr10:131355152	MGMT	-0.45	-4.95	-0.37	1.98e-6	Response to temozolomide;
PAAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-1.07	-14.83	-0.77	2.5e-31	Total body bone mineral density;
PAAD	cis	rs7092929	0.883	rs611890	chr10:3585733	T/C	cg14308648	chr10:3568949	NA	0.66	4.86	0.37	2.91e-6	Coronary artery calcification;
PAAD	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg08835956	chr7:39171034	POU6F2	0.37	5.93	0.43	2.01e-8	IgG glycosylation;
PAAD	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg20913747	chr6:44695427	NA	-0.68	-6.5	-0.47	1.08e-9	Total body bone mineral density;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.58	-5.73	-0.42	5.22e-8	Lung cancer;
PAAD	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	1.12	9.34	0.6	1.14e-16	Height;
PAAD	cis	rs950881	0.932	rs72823621	chr2:102925435	C/T	cg20060108	chr2:102954350	IL1RL1	0.59	4.41	0.34	1.91e-5	Allergy;
PAAD	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.21e-17	Electrocardiographic conduction measures;
PAAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.89	8.86	0.58	2.01e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs4073221	0.860	rs36087209	chr3:18217600	G/C	cg07694806	chr3:18168406	NA	-0.83	-4.96	-0.37	1.86e-6	Parkinson's disease;
PAAD	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg22815214	chr1:201083145	CACNA1S	0.61	5.39	0.4	2.67e-7	Permanent tooth development;
PAAD	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.53	-4.27	-0.33	3.43e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.7	-8.79	-0.58	2.97e-15	Menopause (age at onset);
PAAD	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.83	-5.66	-0.42	7.42e-8	Triglycerides;
PAAD	cis	rs2342371	0.720	rs61345811	chr3:196143030	C/T	cg08209042	chr3:196295218	WDR53;FBXO45	-0.61	-4.77	-0.36	4.27e-6	Fat distribution (HIV);
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.11	0.44	7.97e-9	Platelet count;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.61	5.85	0.43	2.96e-8	Schizophrenia;
PAAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1075265	0.597	rs11694711	chr2:54199061	C/A	cg04546899	chr2:54196757	PSME4	0.3	4.61	0.35	8.53e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.55	5.07	0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg11441379	chr12:63026424	NA	0.81	6.23	0.45	4.33e-9	IgG glycosylation;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.43	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg09127314	chr1:152161683	NA	0.75	5.48	0.41	1.73e-7	Atopic dermatitis;
PAAD	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg07469887	chr10:131262384	NA	0.38	4.42	0.34	1.86e-5	Response to temozolomide;
PAAD	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg02820901	chr13:113351484	ATP11A	-0.67	-5.2	-0.39	6.46e-7	Glycated hemoglobin levels;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg16040993	chr19:53496440	ZNF702P	-0.45	-4.59	-0.35	9.06e-6	Psoriasis;
PAAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.03	-0.7	7.61e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8018808	0.791	rs2205190	chr14:77886723	T/G	cg20045696	chr14:77926864	AHSA1	0.55	5.5	0.41	1.59e-7	Myeloid white cell count;
PAAD	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.73	-0.42	5.34e-8	Resting heart rate;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.76	-8.16	-0.55	1.16e-13	Prudent dietary pattern;
PAAD	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg00522288	chr12:125625016	AACS	-0.56	-5.93	-0.43	1.96e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg05082376	chr22:42548792	NA	0.51	5.6	0.41	9.98e-8	Cognitive function;
PAAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg05872129	chr22:39784769	NA	-0.71	-5.63	-0.42	8.44e-8	IgG glycosylation;
PAAD	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg13468214	chr4:1046988	NA	-0.5	-5.38	-0.4	2.82e-7	Recombination rate (males);
PAAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11955175	0.717	rs112304996	chr5:40867592	A/T	cg04002187	chr5:40835754	RPL37	0.88	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.54	5.44	0.4	2.12e-7	Aortic root size;
PAAD	cis	rs2790457	0.958	rs2790444	chr10:28825689	C/T	cg05705492	chr10:28955341	NA	-0.45	-4.46	-0.34	1.59e-5	Multiple myeloma;
PAAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.43	-0.34	1.8e-5	Aortic root size;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs988913	0.957	rs9475100	chr6:54840233	C/T	cg03513858	chr6:54763001	FAM83B	-0.46	-5.04	-0.38	1.31e-6	Menarche (age at onset);
PAAD	cis	rs4356203	0.870	rs214925	chr11:17234584	C/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.54	-0.35	1.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.29	0.39	4.11e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10044254	0.614	rs4574543	chr5:15740147	G/A	cg07238450	chr5:15720153	FBXL7	-0.55	-5.09	-0.38	1.03e-6	Asthma (corticosteroid response);
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	4.81	0.36	3.57e-6	Blood metabolite levels;
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg03289416	chr15:75166202	SCAMP2	0.53	5.6	0.41	9.81e-8	Breast cancer;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23708337	chr7:1209742	NA	0.48	4.89	0.37	2.53e-6	Longevity;Endometriosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09680012	chr2:128569063	WDR33	0.66	7.65	0.53	2.14e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg10616300	chr11:66138557	SLC29A2	0.35	4.74	0.36	4.81e-6	Educational attainment (years of education);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15712577	chr12:130926978	RIMBP2	0.62	7.28	0.51	1.65e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.1	-0.77	4.66e-32	Height;
PAAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.64	-6.44	-0.46	1.45e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.59	6.49	0.47	1.17e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.63	8.3	0.56	5.28e-14	Crohn's disease;
PAAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	5.81	0.43	3.62e-8	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08529186	chr19:42807008	PAFAH1B3;PRR19	0.63	6.96	0.49	9.56e-11	Monocyte percentage of white cells;
PAAD	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg10483660	chr13:112241077	NA	0.53	4.91	0.37	2.34e-6	Menarche (age at onset);
PAAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.91	10.42	0.65	1.62e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg21191810	chr6:118973309	C6orf204	0.44	5.55	0.41	1.24e-7	Electrocardiographic conduction measures;
PAAD	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.65	-7.55	-0.52	3.84e-12	Airway imaging phenotypes;
PAAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.27	0.33	3.41e-5	Breast cancer;
PAAD	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs639012	0.771	rs561655	chr11:85800279	A/G	cg07180834	chr11:85838833	NA	0.49	5.39	0.4	2.58e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs757978	0.733	rs11684403	chr2:242414874	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.75	-4.67	-0.35	6.71e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.61	-5.7	-0.42	6.1e-8	White matter hyperintensity burden;
PAAD	cis	rs9283706	0.562	rs6881240	chr5:66331471	G/A	cg11590213	chr5:66331682	MAST4	0.57	4.6	0.35	8.82e-6	Coronary artery disease;
PAAD	cis	rs6076065	0.723	rs2252824	chr20:23354748	C/T	cg11657817	chr20:23433608	CST11	0.52	5.04	0.38	1.29e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg04257695	chr17:30186438	C17orf79	0.73	5.14	0.38	8.23e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6076065	0.723	rs6137949	chr20:23418217	T/G	cg11657817	chr20:23433608	CST11	0.49	4.79	0.36	3.99e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.32	-0.4	3.59e-7	Reticulocyte count;
PAAD	cis	rs10924309	0.924	rs2008747	chr1:245860418	C/A	cg00036263	chr1:245852353	KIF26B	-0.63	-5.37	-0.4	2.87e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg23127183	chr11:57508653	C11orf31	-0.49	-4.25	-0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.43	-4.58	-0.35	9.51e-6	Platelet count;
PAAD	cis	rs990171	0.955	rs6708413	chr2:103063369	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.81	9.04	0.59	6.78e-16	Obesity-related traits;
PAAD	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs6681460	0.932	rs492109	chr1:67187133	C/A	cg02459107	chr1:67143332	SGIP1	-0.7	-6.5	-0.47	1.11e-9	Presence of antiphospholipid antibodies;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17515702	chr17:76210520	BIRC5;EPR1	-0.57	-6.29	-0.45	3.17e-9	Body fat percentage;
PAAD	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.97	4.77	0.36	4.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.86	-0.43	2.82e-8	QT interval;
PAAD	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg19673125	chr6:150240577	RAET1G	0.41	5.8	0.43	3.71e-8	Lung cancer;
PAAD	cis	rs6782025	0.837	rs617721	chr3:120743016	G/A	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.76	9.29	0.6	1.52e-16	Bladder cancer;
PAAD	cis	rs6715793	0.592	rs11681694	chr2:33431520	A/G	cg26672287	chr2:33391915	LTBP1	-0.37	-4.3	-0.33	3.01e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg03321592	chr1:19991676	HTR6	0.5	4.44	0.34	1.71e-5	Lead levels in blood;
PAAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg23346134	chr3:49453900	TCTA	-0.45	-4.9	-0.37	2.48e-6	Menarche (age at onset);
PAAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.18	0.39	6.84e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg14146966	chr2:61757674	XPO1	0.39	4.82	0.36	3.49e-6	Tuberculosis;
PAAD	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg12386194	chr3:101231763	SENP7	0.52	5.29	0.39	4.15e-7	Colorectal cancer;
PAAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs1497828	0.956	rs9441482	chr1:217571282	T/A	cg04411442	chr1:217543379	NA	0.52	5.09	0.38	1.02e-6	Dialysis-related mortality;
PAAD	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.64	-5.58	-0.41	1.09e-7	Schizophrenia;
PAAD	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.68	-0.42	6.65e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05140895	chr6:41514099	FOXP4	0.56	6.52	0.47	9.9e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.61	7.44	0.52	6.94e-12	Multiple sclerosis;
PAAD	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg08017634	chr8:144659831	NAPRT1	0.73	4.27	0.33	3.47e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.58	5.06	0.38	1.21e-6	AIDS;
PAAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.87	-6.08	-0.44	9.24e-9	Breast cancer;
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Bipolar disorder;
PAAD	cis	rs6594713	0.759	rs6880552	chr5:112745597	A/T	cg19863003	chr5:112257612	REEP5	-0.5	-4.25	-0.33	3.74e-5	Brain cytoarchitecture;
PAAD	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.83	-9.68	-0.62	1.47e-17	Body mass index;
PAAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg13736514	chr6:26305472	NA	-0.46	-4.98	-0.37	1.67e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg24733560	chr20:60626293	TAF4	0.53	6.6	0.47	6.44e-10	Body mass index;
PAAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.72	8.0	0.54	3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.95	11.06	0.67	3.1e-21	Blood protein levels;
PAAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg09835421	chr16:68378352	PRMT7	-1.16	-8.32	-0.56	4.58e-14	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.52	0.47	9.93e-10	Lung cancer;
PAAD	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg20085588	chr10:81316188	SFTPA2	0.4	4.27	0.33	3.41e-5	Post bronchodilator FEV1;
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.7	7.69	0.53	1.68e-12	Longevity;
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs9652601	0.959	rs2041670	chr16:11174652	G/A	cg04616529	chr16:11181986	CLEC16A	0.48	5.11	0.38	9.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.85	9.96	0.63	2.6e-18	Monocyte count;
PAAD	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.81	-8.62	-0.57	8.12e-15	Colorectal cancer;
PAAD	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.03	0.44	1.22e-8	Lung cancer in ever smokers;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.22	-5.59	-0.41	1.04e-7	Skin colour saturation;
PAAD	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs1539053	0.966	rs11578358	chr1:58097794	C/T	cg20292791	chr1:58089357	DAB1	0.51	4.87	0.37	2.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg27211696	chr2:191398769	TMEM194B	0.44	4.34	0.33	2.55e-5	Urinary metabolites;
PAAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.85	0.62	5.28e-18	Total body bone mineral density;
PAAD	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg23018236	chr17:30244563	NA	0.67	4.99	0.38	1.64e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg12740337	chr6:28058973	ZSCAN12L1	-0.51	-4.44	-0.34	1.69e-5	Depression;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg00450029	chr8:599525	NA	-0.85	-5.36	-0.4	3e-7	IgG glycosylation;
PAAD	cis	rs4713118	1.000	rs9468195	chr6:27676309	A/G	cg20933634	chr6:27740509	NA	0.68	6.45	0.46	1.44e-9	Parkinson's disease;
PAAD	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.56	-6.23	-0.45	4.27e-9	Post bronchodilator FEV1;
PAAD	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.5	4.83	0.36	3.3e-6	Fractional excretion of uric acid;
PAAD	cis	rs13242816	0.881	rs12706091	chr7:116130783	G/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs10044254	0.537	rs11951416	chr5:15688051	G/A	cg07238450	chr5:15720153	FBXL7	-0.52	-4.92	-0.37	2.25e-6	Asthma (corticosteroid response);
PAAD	cis	rs2440012	0.586	rs7492279	chr13:19417086	A/G	cg08120511	chr13:19412184	LOC284232	0.66	4.49	0.34	1.39e-5	Longevity;
PAAD	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.36	0.46	2.22e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg02841227	chr6:26021843	HIST1H4A	0.52	5.1	0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6782025	0.737	rs6787282	chr3:121039541	G/A	cg16417163	chr3:121280760	NA	-0.46	-4.97	-0.37	1.8e-6	Aging (facial);
PAAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.52	5.04	0.38	1.31e-6	Hirschsprung disease;
PAAD	cis	rs78411303	0.584	rs7630095	chr3:122378633	A/G	cg17380795	chr3:122379686	NA	0.76	5.7	0.42	6.05e-8	Periodontitis (CDC/AAP);
PAAD	cis	rs5009270	0.539	rs3111455	chr7:112160927	G/A	cg23628563	chr7:112262597	NA	0.58	4.73	0.36	5.12e-6	Osteoarthritis (hip);
PAAD	cis	rs597583	0.806	rs685425	chr11:117429728	C/T	cg27161313	chr11:117392002	DSCAML1	-0.73	-6.18	-0.45	5.76e-9	Putamen volume;
PAAD	cis	rs2327429	0.789	rs12202017	chr6:134173151	A/G	cg06296503	chr6:134217401	NA	0.5	5.14	0.39	8.15e-7	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs790110	1.000	rs790110	chr3:122384020	T/G	cg22468055	chr3:122334227	PARP15	0.84	4.67	0.35	6.47e-6	Acoustic startle blink response;
PAAD	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.47	-5.37	-0.4	2.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.7	-5.58	-0.41	1.08e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.51	5.2	0.39	6.38e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10899021	1.000	rs7935426	chr11:74363890	C/T	cg25880958	chr11:74394337	NA	-0.86	-5.58	-0.41	1.08e-7	Response to metformin (IC50);
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.72	8.36	0.56	3.74e-14	Height;
PAAD	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg17385448	chr1:15911702	AGMAT	-0.36	-4.29	-0.33	3.22e-5	Systolic blood pressure;
PAAD	cis	rs1497828	0.956	rs2815229	chr1:217535088	T/C	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs564309	0.681	rs7513530	chr1:228619083	G/A	cg00655913	chr1:228633920	NA	0.55	4.34	0.33	2.58e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.42	-4.29	-0.33	3.23e-5	Mean corpuscular volume;
PAAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg21130718	chr4:1044621	NA	0.57	4.81	0.36	3.53e-6	Recombination rate (females);
PAAD	cis	rs7326068	0.558	rs4770071	chr13:21330883	C/G	cg27499820	chr13:21296301	IL17D	0.57	5.24	0.39	5.32e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg00631329	chr6:26305371	NA	-0.49	-4.9	-0.37	2.46e-6	Educational attainment;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg06131755	chr6:160182447	ACAT2	0.55	4.96	0.37	1.9e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg05341575	chr12:125625032	AACS	0.53	5.14	0.38	8.47e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.93	-0.59	1.28e-15	Body mass index;
PAAD	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.85	-9.17	-0.6	3.12e-16	Osteoporosis;
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg10978503	chr1:24200527	CNR2	0.51	6.08	0.44	9.47e-9	Immature fraction of reticulocytes;
PAAD	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.52	5.68	0.42	6.8e-8	Prevalent atrial fibrillation;
PAAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg06789500	chr7:2109450	MAD1L1	0.43	4.35	0.33	2.47e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg15282417	chr9:129245246	FAM125B	0.37	4.56	0.35	1.06e-5	Intraocular pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05485520	chr3:45883628	LZTFL1	0.64	7.12	0.5	4.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.87	5.13	0.38	8.91e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9832625	0.582	rs1025644	chr3:29331859	A/G	cg06712285	chr3:29990487	RBMS3	0.77	5.32	0.4	3.63e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09544549	chr22:36697013	MYH9	-0.53	-6.85	-0.49	1.75e-10	Monocyte percentage of white cells;
PAAD	cis	rs7731390	0.558	rs78399358	chr5:131719696	C/G	cg07395648	chr5:131743802	NA	-0.67	-4.28	-0.33	3.36e-5	IgG glycosylation;
PAAD	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-7.98	-0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg16329650	chr2:213403929	ERBB4	0.55	4.89	0.37	2.54e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg10820045	chr2:198174542	NA	0.48	4.92	0.37	2.28e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.82e-7	Schizophrenia;
PAAD	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.8	0.48	2.21e-10	Exhaled nitric oxide levels;
PAAD	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.14	0.5	3.66e-11	Coffee consumption (cups per day);
PAAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg00701064	chr4:6280414	WFS1	0.87	10.0	0.63	2.15e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.54	-6.4	-0.46	1.82e-9	Alcohol dependence;
PAAD	cis	rs59191668	0.809	rs6494322	chr15:62816383	A/G	cg12918536	chr15:62891943	NA	0.33	4.28	0.33	3.32e-5	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07362569	chr17:61921086	SMARCD2	0.58	6.58	0.47	7.06e-10	Prudent dietary pattern;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg05564831	chr3:52568323	NT5DC2	0.46	4.88	0.37	2.7e-6	Bipolar disorder;
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.42	4.58	0.35	9.67e-6	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01803717	chr1:8939106	ENO1	-0.72	-6.32	-0.46	2.72e-9	Neuroticism;
PAAD	cis	rs7481584	0.962	rs11024708	chr11:2968809	A/G	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.42	4.6	0.35	8.8e-6	Calcium levels;
PAAD	cis	rs1997066	0.831	rs73342214	chr10:106819036	G/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.68e-10	Total body bone mineral density;
PAAD	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	6.99	0.49	8.04e-11	Body mass index;
PAAD	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg05338066	chr1:7812865	CAMTA1	-0.55	-4.64	-0.35	7.47e-6	Inflammatory bowel disease;
PAAD	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg26876637	chr1:152193138	HRNR	-0.85	-6.18	-0.45	5.52e-9	Atopic dermatitis;
PAAD	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.56	4.61	0.35	8.41e-6	Response to antidepressants in depression;
PAAD	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.57e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.55	-0.35	1.1e-5	Aortic root size;
PAAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.3	-0.39	4.09e-7	Monocyte count;
PAAD	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.83	-7.44	-0.52	6.89e-12	Pancreatic cancer;
PAAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.87	9.86	0.62	4.86e-18	Parkinson's disease;
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.77	-5.72	-0.42	5.59e-8	Initial pursuit acceleration;
PAAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.61	7.5	0.52	4.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.78	8.95	0.59	1.14e-15	Eosinophil percentage of white cells;
PAAD	cis	rs3096299	0.838	rs3096319	chr16:89402634	C/G	cg00750074	chr16:89608354	SPG7	-0.49	-4.71	-0.36	5.58e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.54	5.1	0.38	1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.54	-5.45	-0.4	2e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs3112530	1.000	rs300331	chr5:152723200	C/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23635374	chr11:75273068	SERPINH1	0.58	6.69	0.48	4.03e-10	Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.68	0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	7.79	0.53	9.56e-13	Menarche (age at onset);
PAAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	1.04	14.02	0.75	3.45e-29	Breast cancer;
PAAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg09854653	chr6:163834903	QKI	0.69	4.45	0.34	1.65e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3826795	0.530	rs7256047	chr19:46796033	T/C	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.67	4.9	0.37	2.4e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	1.13	6.12	0.44	7.48e-9	Plasma clusterin levels;
PAAD	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.74	-7.47	-0.52	6.01e-12	Lung cancer;
PAAD	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg09399716	chr2:46890238	NA	-0.51	-4.51	-0.34	1.29e-5	Height;
PAAD	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.4	0.51	8.8e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-8.01	-0.54	2.76e-13	Coffee consumption (cups per day);
PAAD	cis	rs941408	0.515	rs1736192	chr19:2784678	G/A	cg06609049	chr19:2785107	THOP1	1.16	15.5	0.78	4.28e-33	Total cholesterol levels;
PAAD	trans	rs4864201	0.598	rs2391532	chr4:130749015	C/T	cg08471972	chr13:51844375	FAM124A	-0.56	-6.46	-0.46	1.31e-9	Obesity;
PAAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.96	-12.25	-0.7	1.97e-24	Height;
PAAD	cis	rs12476592	0.602	rs959195	chr2:63804125	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg23460851	chr4:1604456	NA	-0.44	-4.47	-0.34	1.51e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.52	-4.94	-0.37	2.05e-6	Coronary artery disease;
PAAD	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg04415270	chr2:102091202	RFX8	-0.65	-8.53	-0.57	1.37e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs134594	0.769	rs134672	chr22:29501278	T/G	cg01361351	chr22:29467363	NA	-0.38	-4.33	-0.33	2.65e-5	Birth weight;
PAAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.55	-0.41	1.22e-7	Schizophrenia;
PAAD	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg10820045	chr2:198174542	NA	0.48	4.79	0.36	3.98e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20247102	chr3:141206102	RASA2	0.73	7.8	0.53	9.32e-13	Myopia (pathological);
PAAD	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.33	-0.4	3.45e-7	Schizophrenia;
PAAD	cis	rs71557345	1	rs71557345	chr6:26680698	G/A	cg16898833	chr6:26189333	HIST1H4D	0.94	4.45	0.34	1.66e-5	Breast cancer;
PAAD	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.56	-0.52	3.6e-12	Colorectal cancer;
PAAD	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.41	-0.34	1.96e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.91	-0.49	1.23e-10	Type 2 diabetes;
PAAD	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg24296786	chr1:45957014	TESK2	0.52	4.79	0.36	3.97e-6	Homocysteine levels;
PAAD	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.52	-5.21	-0.39	6.06e-7	Ulcerative colitis;
PAAD	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.41	0.34	1.98e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.37	4.73	0.36	5.09e-6	Educational attainment (years of education);
PAAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.47	5.85	0.43	2.98e-8	Crohn's disease;
PAAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499129	0.867	rs1862689	chr16:67419152	C/T	cg09395969	chr16:67918001	EDC4;NRN1L	0.64	4.56	0.35	1.05e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.53	4.34	0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.59	-5.72	-0.42	5.36e-8	Crohn's disease;
PAAD	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06634786	chr22:41940651	POLR3H	0.69	5.1	0.38	1.01e-6	Vitiligo;
PAAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.62	0.41	8.91e-8	Mean corpuscular hemoglobin;
PAAD	trans	rs1075265	0.575	rs2692531	chr2:54003777	A/G	cg16115072	chr17:25938812	KSR1	0.59	6.32	0.46	2.7e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-12.46	-0.71	5.46e-25	Corneal structure;
PAAD	cis	rs2671540	0.547	rs7095208	chr10:65637760	T/C	cg19573236	chr10:65733388	NA	-0.57	-4.51	-0.34	1.29e-5	Coronary artery disease;
PAAD	cis	rs4455778	0.580	rs4270912	chr7:49112335	T/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.73	-10.23	-0.64	5.27e-19	Eosinophil percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16029838	chr7:44530503	NUDCD3	0.64	6.66	0.48	4.74e-10	Smoking initiation;
PAAD	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	4.92	0.37	2.2e-6	Oropharynx cancer;
PAAD	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg15621731	chr19:5074616	KDM4B	0.31	4.46	0.34	1.61e-5	Monocyte percentage of white cells;
PAAD	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.12	-0.5	4.08e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1801239	1.000	rs1801240	chr10:16918997	T/C	cg00939682	chr10:16933505	CUBN	0.69	5.2	0.39	6.31e-7	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg10556349	chr10:835070	NA	-0.67	-5.16	-0.39	7.55e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.32e-27	Height;
PAAD	cis	rs16975963	0.644	rs112666969	chr19:38047645	G/A	cg08679971	chr19:38281047	NA	0.46	4.53	0.34	1.19e-5	Longevity;
PAAD	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg23719950	chr11:63933701	MACROD1	-0.7	-4.91	-0.37	2.28e-6	Mean platelet volume;
PAAD	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9888739	1.000	rs9928749	chr16:31306320	T/C	cg02256631	chr16:31342952	ITGAM	-0.55	-4.45	-0.34	1.64e-5	Systemic lupus erythematosus;
PAAD	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg21300403	chr2:198650112	BOLL	-0.49	-4.41	-0.34	1.95e-5	Intracranial aneurysm;
PAAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs13011075	0.535	rs115843438	chr2:68635524	G/C	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs2279817	0.818	rs11582250	chr1:17994234	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.62	-5.71	-0.42	5.85e-8	Neuroticism;
PAAD	cis	rs2735413	0.918	rs7197254	chr16:78063353	C/G	cg04733911	chr16:78082701	NA	-0.53	-5.52	-0.41	1.41e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg02462569	chr6:150064036	NUP43	-0.55	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.61	6.21	0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg10705379	chr10:99080932	FRAT1	-0.46	-5.23	-0.39	5.65e-7	Monocyte count;
PAAD	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg20406979	chr6:167373233	NA	0.38	4.94	0.37	2.03e-6	Crohn's disease;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg11218175	chr11:495084	RNH1	0.76	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-5.16	-0.39	7.51e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg08132940	chr7:1081526	C7orf50	0.55	4.27	0.33	3.4e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00149659	chr3:10157352	C3orf10	0.56	4.46	0.34	1.61e-5	Alzheimer's disease;
PAAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.54	-5.49	-0.41	1.67e-7	White blood cell count;
PAAD	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg00253185	chr1:247542119	NA	0.55	4.57	0.35	1e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.94	-10.13	-0.63	9.72e-19	Corneal astigmatism;
PAAD	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.45	7.14	0.5	3.62e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	0.66	4.59	0.35	9.05e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6880778	0.505	rs12658567	chr5:40391932	G/T	cg05240017	chr5:40756081	TTC33	-0.5	-4.32	-0.33	2.77e-5	Inflammatory bowel disease;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.51	5.34	0.4	3.38e-7	Blood metabolite levels;
PAAD	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	1.06	6.63	0.47	5.59e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.69	4.86	0.37	2.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg26597838	chr10:835615	NA	0.54	5.93	0.43	1.93e-8	Survival in rectal cancer;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	1.18	8.6	0.57	9.35e-15	IgG glycosylation;
PAAD	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg07117364	chr1:16154769	NA	0.46	4.38	0.33	2.21e-5	Dilated cardiomyopathy;
PAAD	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg21419209	chr3:44054225	NA	0.7	6.99	0.49	7.91e-11	Coronary artery disease;
PAAD	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1198430	0.602	rs12401753	chr1:23762679	A/G	cg19827787	chr1:23763612	ASAP3	0.53	4.98	0.37	1.71e-6	Total cholesterol levels;
PAAD	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.73	0.58	4.25e-15	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg05083358	chr7:2394359	EIF3B	-0.78	-5.64	-0.42	7.9e-8	Multiple sclerosis;
PAAD	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg10631289	chr15:39006617	NA	0.46	4.55	0.35	1.1e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.44e-5	Ulcerative colitis;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18337363	chr3:52569053	NT5DC2	0.44	4.47	0.34	1.49e-5	Electroencephalogram traits;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg19418318	chr19:17219073	MYO9B	0.45	5.34	0.4	3.35e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.55	-0.35	1.1e-5	Menarche (age at onset);
PAAD	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg00647317	chr7:50633725	DDC	0.46	4.76	0.36	4.4e-6	Systemic sclerosis;
PAAD	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.49	4.74	0.36	4.85e-6	Airway imaging phenotypes;
PAAD	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.72	7.18	0.5	2.85e-11	Schizophrenia;
PAAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	11.01	0.67	4.36e-21	Menopause (age at onset);
PAAD	cis	rs9283706	0.689	rs1030231	chr5:66317265	A/G	cg11590213	chr5:66331682	MAST4	0.58	4.68	0.35	6.43e-6	Coronary artery disease;
PAAD	cis	rs7714584	1.000	rs57001853	chr5:150272452	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg00745463	chr17:30367425	LRRC37B	0.62	4.8	0.36	3.75e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19623624	chr10:135278901	LOC619207	-0.54	-5.48	-0.41	1.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg10820045	chr2:198174542	NA	-0.44	-4.4	-0.34	2.03e-5	Dermatomyositis;
PAAD	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs7264396	0.887	rs4911510	chr20:34093153	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.81	-9.69	-0.62	1.41e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	1.05	14.57	0.76	1.16e-30	Breast cancer;
PAAD	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg17201900	chr20:34330562	RBM39	0.64	4.45	0.34	1.63e-5	Total cholesterol levels;
PAAD	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.12	14.72	0.77	4.82e-31	Primary sclerosing cholangitis;
PAAD	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.53	5.65	0.42	7.63e-8	Fibrinogen levels;
PAAD	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg11335335	chr11:637885	DRD4	-0.38	-5.53	-0.41	1.36e-7	Systemic lupus erythematosus;
PAAD	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg06917634	chr15:78832804	PSMA4	-0.47	-4.55	-0.35	1.08e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg20893579	chr22:38215064	NA	-0.48	-5.15	-0.39	7.85e-7	Glioblastoma;Glioma;
PAAD	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23082867	chr19:19030255	DDX49;COPE	0.66	6.79	0.48	2.41e-10	Obesity-related traits;
PAAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.68	9.38	0.61	8.95e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.52	-5.88	-0.43	2.5e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	4.99e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs8077577	0.731	rs11869952	chr17:18221713	T/C	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.8	-0.43	3.77e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11958404	0.546	rs7727054	chr5:157442692	G/A	cg05962755	chr5:157440814	NA	0.56	5.44	0.4	2.09e-7	IgG glycosylation;
PAAD	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.78	9.08	0.59	5.25e-16	Heart rate;
PAAD	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.27	0.39	4.53e-7	Educational attainment;
PAAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg16928487	chr17:17741425	SREBF1	-0.34	-4.65	-0.35	7.16e-6	Total body bone mineral density;
PAAD	cis	rs73198271	0.515	rs77703937	chr8:8629129	G/A	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.7	6.7	0.48	3.82e-10	Blood metabolite levels;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.61	-4.32	-0.33	2.79e-5	Hypertriglyceridemia;
PAAD	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg14583973	chr4:3374767	RGS12	-0.37	-5.63	-0.42	8.51e-8	Parental longevity (mother's age at death);
PAAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg01851573	chr8:8652454	MFHAS1	0.44	4.37	0.33	2.3e-5	Mood instability;
PAAD	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.69	-7.94	-0.54	4.12e-13	White blood cell count (basophil);
PAAD	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	4.49	0.34	1.38e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg15193198	chr20:60906057	LAMA5	0.55	6.22	0.45	4.64e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.98e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03923535	chr7:1197113	ZFAND2A	0.45	4.64	0.35	7.46e-6	Longevity;Endometriosis;
PAAD	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.41	-4.28	-0.33	3.36e-5	Aortic root size;
PAAD	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg15674680	chr20:60982522	CABLES2	0.58	5.07	0.38	1.16e-6	Colorectal cancer;
PAAD	cis	rs7631605	0.875	rs11927149	chr3:37166061	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.67	7.16	0.5	3.22e-11	Iron status biomarkers;
PAAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg21191810	chr6:118973309	C6orf204	-0.52	-5.13	-0.38	8.86e-7	Renal cell carcinoma;
PAAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.84	-10.17	-0.64	7.38e-19	Ulcerative colitis;
PAAD	cis	rs7804356	0.871	rs4719877	chr7:26736220	A/G	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.71	-5.02	-0.38	1.44e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.24	0.45	4.11e-9	Menopause (age at onset);
PAAD	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12794691	chr3:111805077	C3orf52	-0.76	-6.37	-0.46	2.19e-9	Neuroticism;
PAAD	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.41	-5.11	-0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-7.44	-0.52	6.95e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg27490568	chr2:178487706	NA	0.44	4.91	0.37	2.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.79	9.13	0.6	3.92e-16	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs4705952	1.000	rs4705952	chr5:131839618	A/G	cg21138405	chr5:131827807	IRF1	-0.34	-4.3	-0.33	3.04e-5	C-reactive protein levels;
PAAD	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12292205	chr6:26970375	C6orf41	0.53	5.25	0.39	4.93e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14105680	chr2:113676235	IL1F7	0.69	7.32	0.51	1.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg05935833	chr10:81318306	SFTPA2	-0.67	-4.65	-0.35	7.15e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.37	0.46	2.14e-9	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15761531	chr3:52737578	GLT8D1	-0.63	-6.33	-0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg06569542	chr10:98946673	SLIT1	0.47	4.77	0.36	4.19e-6	Monocyte count;
PAAD	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg16589663	chr20:23618590	CST3	0.85	7.26	0.51	1.85e-11	Chronic kidney disease;
PAAD	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs3996993	0.809	rs10948722	chr6:52663813	A/G	cg20803780	chr6:52668592	GSTA1	0.35	4.27	0.33	3.5e-5	Hemoglobin concentration;
PAAD	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg05555928	chr11:63887634	MACROD1	-0.79	-5.75	-0.42	4.68e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10943724	0.679	rs541841	chr6:81231798	C/G	cg19323245	chr6:80716898	TTK	-0.46	-4.79	-0.36	3.93e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.64e-9	Educational attainment;
PAAD	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg02250501	chr15:90694978	NA	0.46	4.41	0.34	1.96e-5	Rheumatoid arthritis;
PAAD	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.75	11.54	0.68	1.58e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	trans	rs3020418	0.826	rs2144026	chr6:152362334	G/A	cg09520904	chr11:69462943	CCND1	-0.51	-6.29	-0.45	3.22e-9	Height;
PAAD	cis	rs9364554	0.691	rs3918285	chr6:160868654	C/T	cg25313204	chr6:160768801	SLC22A3	0.54	4.87	0.37	2.72e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.52	5.12	0.38	8.97e-7	Parkinson's disease;
PAAD	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.39	-0.4	2.66e-7	Diabetic kidney disease;
PAAD	cis	rs11997175	0.655	rs7833512	chr8:33662884	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	5.34	0.4	3.29e-7	Body mass index;
PAAD	cis	rs630539	0.655	rs9916569	chr17:40791351	C/G	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.72	7.31	0.51	1.4e-11	Bipolar disorder;
PAAD	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	11.19	0.67	1.38e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs73416724	1.000	rs76658194	chr6:43357601	C/T	cg17076780	chr6:43251928	TTBK1	0.58	4.63	0.35	7.74e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg23958373	chr8:599963	NA	-1.19	-8.06	-0.55	2.09e-13	IgG glycosylation;
PAAD	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.55	5.11	0.38	9.57e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.48	0.41	1.75e-7	Alcohol dependence;
PAAD	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.94	0.54	4.24e-13	Alzheimer's disease;
PAAD	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs2221894	0.511	rs4732899	chr8:28894395	C/T	cg20212339	chr8:28908912	HMBOX1	0.43	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.8	9.3	0.6	1.42e-16	Diastolic blood pressure;
PAAD	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg02100629	chr10:71892760	AIFM2	-0.39	-4.49	-0.34	1.42e-5	Blood protein levels;
PAAD	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg17524265	chr8:144659883	NAPRT1	0.87	4.38	0.33	2.22e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	6.02	0.44	1.23e-8	Cognitive test performance;
PAAD	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.55	0.65	7.4e-20	Smoking behavior;
PAAD	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2479106	0.892	rs2458490	chr9:126598435	T/C	cg16191174	chr9:126692580	DENND1A	0.57	5.25	0.39	5.04e-7	Polycystic ovary syndrome;
PAAD	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg26924012	chr15:45694286	SPATA5L1	0.46	4.29	0.33	3.15e-5	Uric acid levels;
PAAD	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg20487152	chr13:99095054	FARP1	0.47	4.99	0.38	1.65e-6	Longevity;
PAAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.89	-10.77	-0.66	1.81e-20	Menopause (age at onset);
PAAD	cis	rs1018836	0.739	rs6993715	chr8:91531188	G/C	cg16814680	chr8:91681699	NA	-0.86	-10.6	-0.65	5.41e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1656368	0.655	rs11710813	chr3:158206114	C/T	cg16708174	chr3:158430962	RARRES1	0.62	5.52	0.41	1.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs901683	0.702	rs113019116	chr10:46093939	A/G	cg13065504	chr15:42448234	PLA2G4F	0.8	6.54	0.47	8.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4908760	0.864	rs12136766	chr1:8663821	C/T	cg20416874	chr1:8611966	RERE	-0.46	-4.4	-0.34	2.01e-5	Vitiligo;
PAAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.81	4.67	0.35	6.55e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.78	-5.56	-0.41	1.18e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16823105	chr6:97372572	KLHL32	0.6	6.57	0.47	7.38e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2033711	0.936	rs882609	chr19:58991479	G/A	cg26874164	chr19:58962979	ZNF324B	0.47	4.37	0.33	2.33e-5	Uric acid clearance;
PAAD	cis	rs10958369	0.575	rs11776806	chr8:54426695	C/T	cg12485204	chr8:54507357	NA	-0.42	-4.33	-0.33	2.73e-5	Response to antineoplastic agents;
PAAD	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.99e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.64	-5.7	-0.42	5.95e-8	Mean corpuscular volume;
PAAD	cis	rs35110281	0.517	rs11701973	chr21:44979671	G/A	cg21573476	chr21:45109991	RRP1B	-0.46	-4.33	-0.33	2.66e-5	Mean corpuscular volume;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg15674680	chr20:60982522	CABLES2	-0.48	-4.39	-0.34	2.13e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg02376097	chr19:46275166	DMPK	-0.57	-5.81	-0.43	3.52e-8	Coronary artery disease;
PAAD	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg05578865	chr17:80554007	FOXK2	0.43	4.25	0.33	3.77e-5	Breast cancer;
PAAD	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.84	5.84	0.43	3.1e-8	Migraine;Coronary artery disease;
PAAD	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19904058	chr10:135279010	LOC619207	-0.63	-7.61	-0.53	2.62e-12	Systemic lupus erythematosus;
PAAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg07703079	chr11:430292	ANO9	0.91	5.71	0.42	5.67e-8	Body mass index;
PAAD	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.62	7.01	0.49	7.44e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1499972	0.713	rs9861346	chr3:117508846	C/T	cg07612923	chr3:117604196	NA	-0.88	-5.68	-0.42	6.63e-8	Schizophrenia;
PAAD	cis	rs7577696	0.962	rs2365555	chr2:32280699	C/T	cg02381751	chr2:32503542	YIPF4	0.42	4.46	0.34	1.61e-5	Inflammatory biomarkers;
PAAD	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-7.45	-0.52	6.64e-12	Exhaled nitric oxide output;
PAAD	cis	rs17023223	0.553	rs72691108	chr1:119762175	G/A	cg17326555	chr1:119535693	NA	-0.39	-4.41	-0.34	1.97e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.56	0.41	1.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.48	5.01	0.38	1.46e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27261538	chr8:29884942	NA	-0.64	-6.53	-0.47	9.48e-10	Smoking initiation;
PAAD	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg04398451	chr17:18023971	MYO15A	-0.87	-8.54	-0.57	1.28e-14	Total body bone mineral density;
PAAD	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg21775007	chr8:11205619	TDH	0.51	4.6	0.35	8.72e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs9462027	0.959	rs205262	chr6:34563164	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.29	-0.33	3.13e-5	Systemic lupus erythematosus;
PAAD	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.86	-9.5	-0.61	4.36e-17	Mortality in heart failure;
PAAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg21395723	chr22:39101663	GTPBP1	0.46	4.78	0.36	4.11e-6	Menopause (age at onset);
PAAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg11766577	chr21:47581405	C21orf56	0.4	4.5	0.34	1.34e-5	Testicular germ cell tumor;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg02696790	chr15:75250997	RPP25	0.47	5.57	0.41	1.1e-7	Caffeine consumption;
PAAD	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.64	6.49	0.47	1.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.46	4.25	0.33	3.76e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs16958440	1.000	rs60228288	chr18:44640412	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg10589385	chr1:150898437	SETDB1	0.39	4.8	0.36	3.8e-6	Melanoma;
PAAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12993477	chr11:506911	RNH1	0.7	7.5	0.52	5.05e-12	Myopia (pathological);
PAAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.73	10.63	0.65	4.48e-20	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.67	-6.5	-0.47	1.09e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03042113	chr11:65430511	RELA	0.66	7.71	0.53	1.49e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67689854	0.526	rs111460975	chr16:89434541	A/G	cg26546229	chr16:89385611	ANKRD11	0.77	5.02	0.38	1.45e-6	Stromal-cell-derived factor 1 alpha levels;
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg07313626	chr1:247681931	NA	-0.45	-4.64	-0.35	7.59e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg20003494	chr4:90757398	SNCA	-0.65	-6.07	-0.44	9.86e-9	Neuroticism;
PAAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg13611204	chr9:139324423	INPP5E	-0.57	-4.84	-0.37	3.15e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.41	-0.34	1.94e-5	Mean corpuscular volume;
PAAD	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.21	-0.45	4.87e-9	Migraine - clinic-based;
PAAD	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.28	-14.26	-0.76	7.7e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.61	5.25	0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.96	5.98	0.44	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10750165	0.692	rs1466051	chr11:119653461	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18732042	chr10:62023637	ANK3	-0.64	-6.29	-0.45	3.15e-9	Obesity-related traits;
PAAD	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.67	-0.62	1.57e-17	Blood trace element (Zn levels);
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	6.71	0.48	3.63e-10	Renal function-related traits (BUN);
PAAD	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	4.83	0.36	3.26e-6	Hirschsprung disease;
PAAD	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg07157834	chr1:205819609	PM20D1	0.56	4.25	0.33	3.74e-5	Basophil percentage of granulocytes;
PAAD	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg20092376	chr4:56023423	NA	0.46	4.77	0.36	4.3e-6	Endometriosis;
PAAD	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.47	-4.53	-0.34	1.21e-5	Blood metabolite levels;
PAAD	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	1.01	8.14	0.55	1.33e-13	Axial length;
PAAD	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg25790453	chr13:113633590	MCF2L	-0.4	-4.75	-0.36	4.66e-6	Systolic blood pressure;
PAAD	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg20935368	chr5:178288625	ZNF354B	0.53	5.21	0.39	5.94e-7	Sleep duration;
PAAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg09324608	chr17:30823087	MYO1D	0.53	5.6	0.41	9.97e-8	Schizophrenia;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.64	7.23	0.51	2.22e-11	Systemic lupus erythematosus;
PAAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.49	5.95	0.43	1.79e-8	Vitiligo;
PAAD	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.87	7.92	0.54	4.64e-13	Coronary artery disease;
PAAD	cis	rs9914578	1.000	rs9914578	chr17:2005136	C/G	cg16513277	chr17:2031491	SMG6	-0.59	-5.35	-0.4	3.23e-7	Body mass index;
PAAD	cis	rs6504950	0.745	rs9914088	chr17:52979985	T/C	cg18040354	chr17:53800484	TMEM100	0.48	4.29	0.33	3.14e-5	Breast cancer;
PAAD	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs755249	0.567	rs60323161	chr1:39710459	T/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.18	-0.39	7.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg05342682	chr7:94953680	PON1	-0.52	-4.65	-0.35	7.15e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.4	-0.51	8.43e-12	Diastolic blood pressure;
PAAD	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg27411982	chr8:10470053	RP1L1	-0.48	-5.35	-0.4	3.16e-7	Systolic blood pressure;
PAAD	cis	rs11671005	0.736	rs11668201	chr19:59003632	A/T	cg25952890	chr19:58913133	NA	0.66	5.28	0.39	4.35e-7	Mean platelet volume;
PAAD	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs863345	0.967	rs10908685	chr1:158524436	T/A	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs73206853	0.764	rs55991901	chr12:110962702	C/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.69	0.36	5.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.44	-5.07	-0.38	1.15e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1364705	0.910	rs13274578	chr8:120314864	T/C	cg09273054	chr8:120220131	MAL2	0.47	5.37	0.4	2.95e-7	Hippocampal atrophy;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.56	5.89	0.43	2.39e-8	Schizophrenia;
PAAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg17724175	chr1:150552817	MCL1	-0.61	-6.97	-0.49	9.23e-11	Urate levels;
PAAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg22433210	chr17:43662623	NA	-0.73	-7.25	-0.51	2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg00310523	chr12:86230176	RASSF9	0.42	4.46	0.34	1.56e-5	Major depressive disorder;
PAAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.54	4.6	0.35	8.67e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg20893579	chr22:38215064	NA	-0.47	-4.7	-0.36	5.86e-6	Glioblastoma;Glioma;
PAAD	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.21	6.46	0.46	1.37e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.43	4.33	0.33	2.68e-5	Bipolar disorder;
PAAD	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.47	-4.75	-0.36	4.6e-6	Menarche (age at onset);
PAAD	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.32	-0.4	3.65e-7	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg15181151	chr6:150070149	PCMT1	0.61	6.65	0.47	4.89e-10	Lung cancer;
PAAD	cis	rs11825064	0.562	rs7119913	chr11:134502223	A/C	cg06603561	chr11:134479413	NA	0.92	5.83	0.43	3.2e-8	Seasonality;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.75	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg14851468	chr5:179071604	C5orf60	0.47	5.01	0.38	1.51e-6	Lung cancer;
PAAD	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.52	5.41	0.4	2.37e-7	Height;
PAAD	cis	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg08992911	chr2:238395768	MLPH	0.53	5.43	0.4	2.17e-7	Prostate cancer;
PAAD	cis	rs190369	0.681	rs368680	chr16:79582931	G/T	cg08305942	chr16:79692354	NA	0.43	4.54	0.35	1.14e-5	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;
PAAD	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg15047889	chr8:124780837	FAM91A1	-0.69	-5.39	-0.4	2.63e-7	Pancreatic cancer;
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12286929	0.577	rs7101437	chr11:115063641	A/G	cg04055981	chr11:115044050	NA	-0.46	-4.6	-0.35	8.89e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg25952890	chr19:58913133	NA	-0.65	-5.47	-0.41	1.8e-7	Mean platelet volume;
PAAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.67	-10.1	-0.63	1.14e-18	Huntington's disease progression;
PAAD	cis	rs8077889	0.871	rs9893111	chr17:41915767	G/A	cg26893861	chr17:41843967	DUSP3	0.9	7.42	0.52	7.76e-12	Triglycerides;
PAAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.24	-0.39	5.22e-7	Life satisfaction;
PAAD	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg04990556	chr1:26633338	UBXN11	0.63	4.58	0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs6066835	0.867	rs6095271	chr20:47356176	C/G	cg18078177	chr20:47281410	PREX1	1.03	5.24	0.39	5.35e-7	Multiple myeloma;
PAAD	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.46	4.34	0.33	2.57e-5	Endometrial cancer;
PAAD	cis	rs8179	0.645	rs11765954	chr7:92280695	A/G	cg03496780	chr7:92466842	CDK6	0.49	4.56	0.35	1.03e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01267941	chr12:57623452	SHMT2	0.65	7.45	0.52	6.6e-12	Myopia (pathological);
PAAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.9	-0.37	2.41e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.54	5.87	0.43	2.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07329135	chr8:121824488	SNTB1	-0.84	-7.21	-0.5	2.47e-11	Neuroticism;
PAAD	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13870426	chr17:30244630	NA	-0.57	-5.58	-0.41	1.09e-7	Height;
PAAD	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.01	-0.38	1.5e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg24881330	chr22:46731750	TRMU	1.19	6.12	0.44	7.65e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.82	4.97	0.37	1.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs965469	0.779	rs6037548	chr20:3299299	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.4	0.4	2.52e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.79	9.35	0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	trans	rs901683	1.000	rs78363416	chr10:46046134	T/G	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg07777115	chr5:623756	CEP72	0.67	4.25	0.33	3.67e-5	Breast cancer;
PAAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.78	-9.09	-0.59	5.06e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.34	4.47	0.34	1.52e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs8112211	0.731	rs11673012	chr19:38823971	C/A	cg14299480	chr19:38876666	GGN	-0.65	-6.12	-0.44	7.52e-9	Blood protein levels;
PAAD	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.78	8.99	0.59	9.15e-16	Heart rate;
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs12541635	1.000	rs1366969	chr8:107092851	A/T	cg10147462	chr8:107024639	NA	-0.46	-4.8	-0.36	3.83e-6	Age of smoking initiation;
PAAD	cis	rs78761021	0.685	rs17744107	chr17:9795735	C/G	cg26853458	chr17:9805074	RCVRN	-0.74	-8.59	-0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Systemic lupus erythematosus;
PAAD	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.61	6.66	0.48	4.76e-10	Tonsillectomy;
PAAD	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.82	0.43	3.45e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.87	-11.03	-0.67	3.77e-21	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.99	0.44	1.46e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.25	-0.56	7.02e-14	Inflammatory bowel disease;
PAAD	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.75	5.75	0.42	4.8e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2562456	0.833	rs57250002	chr19:21526850	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.73	8.57	0.57	1.12e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs73787773	0.867	rs73227501	chr5:111488908	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.76	-4.55	-0.35	1.09e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.83e-6	Monocyte percentage of white cells;
PAAD	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.86	-0.43	2.77e-8	Height;
PAAD	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.82	-0.43	3.42e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19317265	chr18:12702832	PSMG2;CEP76	-0.72	-6.71	-0.48	3.53e-10	Neuroticism;
PAAD	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11995313	chr8:8860691	ERI1	0.5	5.09	0.38	1.05e-6	Joint mobility (Beighton score);
PAAD	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg02376097	chr19:46275166	DMPK	-0.59	-5.79	-0.43	3.86e-8	Coronary artery disease;
PAAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg24053715	chr22:38214548	NA	0.59	5.5	0.41	1.57e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.58	6.33	0.46	2.59e-9	Mean corpuscular volume;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg26554054	chr8:600488	NA	1.04	6.67	0.48	4.48e-10	IgG glycosylation;
PAAD	cis	rs2235573	0.789	rs4821733	chr22:38449394	A/G	cg03989125	chr22:38214979	NA	0.46	4.57	0.35	1.01e-5	Glioblastoma;Glioma;
PAAD	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg15585409	chr19:12750806	NA	-0.47	-4.27	-0.33	3.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
PAAD	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg00042356	chr1:8021962	PARK7	0.73	5.04	0.38	1.33e-6	Inflammatory bowel disease;
PAAD	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs12304921	0.683	rs55987825	chr12:51443387	G/A	cg18059802	chr12:51347058	HIGD1C	-0.65	-5.06	-0.38	1.2e-6	Type 2 diabetes;
PAAD	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.58	-6.12	-0.44	7.58e-9	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.24	-9.8	-0.62	7.2e-18	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05055833	chr15:25459305	SNORD115-15;SNORD115-21;SNORD115-25	-0.59	-6.52	-0.47	9.57e-10	Obesity-related traits;
PAAD	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.41	5.05	0.38	1.25e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg14631576	chr9:95140430	CENPP	-0.47	-4.64	-0.35	7.41e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.53	-0.52	4.14e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg23898951	chr10:4511903	NA	0.77	4.56	0.35	1.05e-5	Major depressive disorder;
PAAD	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg02297831	chr4:17616191	MED28	-0.62	-5.85	-0.43	2.97e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg17524180	chr13:113633600	MCF2L	-0.49	-5.14	-0.38	8.27e-7	Systolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15813570	chr14:64854563	MTHFD1	0.68	7.74	0.53	1.29e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9659323	1.000	rs6680737	chr1:119521631	G/A	cg26570165	chr1:119541833	NA	-0.47	-4.75	-0.36	4.67e-6	Body mass index;
PAAD	cis	rs859767	0.851	rs842351	chr2:135343037	A/G	cg12500956	chr2:135428796	TMEM163	0.32	4.73	0.36	5.04e-6	Neuroticism;
PAAD	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.68	4.4	0.34	2.03e-5	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg10729496	chr3:10149963	C3orf24	0.83	6.67	0.48	4.52e-10	Alzheimer's disease;
PAAD	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg04165759	chr1:150448943	RPRD2	-0.53	-5.48	-0.41	1.72e-7	Migraine;
PAAD	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.68	7.01	0.49	7.38e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	0.887	rs2236160	chr20:34101821	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs2882667	0.620	rs3789151	chr5:138145460	C/T	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg09835421	chr16:68378352	PRMT7	-0.61	-4.48	-0.34	1.46e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7084921	0.526	rs12771250	chr10:101776784	A/T	cg04359915	chr10:101825029	CPN1	-0.33	-4.99	-0.38	1.61e-6	Bone mineral density;
PAAD	cis	rs6256	0.932	rs75849294	chr11:13501392	G/A	cg11976911	chr11:13509032	NA	-0.68	-5.26	-0.39	4.89e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs78411303	0.584	rs7629611	chr3:122378133	A/G	cg17380795	chr3:122379686	NA	0.76	5.7	0.42	6.05e-8	Periodontitis (CDC/AAP);
PAAD	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00791764	chr4:53727839	RASL11B	0.52	4.46	0.34	1.61e-5	Optic nerve measurement (cup area);
PAAD	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg19980929	chr12:42632907	YAF2	0.64	7.56	0.52	3.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg21269045	chr12:125625041	AACS	-0.46	-4.67	-0.35	6.46e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.63	0.62	1.93e-17	Smoking behavior;
PAAD	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.25	17.15	0.81	2.29e-37	Schizophrenia;
PAAD	cis	rs10768122	1.000	rs7105505	chr11:35296846	A/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.4	-0.34	2.01e-5	Vitiligo;
PAAD	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00006032	chr14:66974439	GPHN	0.65	7.56	0.52	3.49e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2327429	0.519	rs2876224	chr6:134153509	G/A	cg06643013	chr6:134217242	NA	0.41	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg23093090	chr10:104574429	C10orf26	-0.44	-4.58	-0.35	9.57e-6	Arsenic metabolism;
PAAD	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.57	-5.44	-0.4	2.06e-7	Obesity-related traits;
PAAD	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.42	5.31	0.4	3.82e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.84	-7.94	-0.54	4.06e-13	Colorectal adenoma (advanced);
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73196954	chr3:128429909	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.49	6.95	0.49	1.03e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	9.98	0.63	2.42e-18	Cognitive test performance;
PAAD	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	1.16	12.67	0.72	1.41e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg22815214	chr1:201083145	CACNA1S	0.59	4.85	0.37	3.01e-6	Permanent tooth development;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-6.11	-0.44	7.82e-9	Coronary artery disease;
PAAD	cis	rs10887741	0.532	rs791885	chr10:89410546	A/T	cg13926569	chr10:89418898	PAPSS2	0.51	5.16	0.39	7.65e-7	Exercise (leisure time);
PAAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg01448562	chr3:133502909	NA	0.5	4.9	0.37	2.43e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.42	4.87	0.37	2.75e-6	Total body bone mineral density;
PAAD	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg19442545	chr10:75533431	FUT11	-0.5	-5.08	-0.38	1.09e-6	Inflammatory bowel disease;
PAAD	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.99	6.7	0.48	3.75e-10	Prostate cancer;
PAAD	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.72e-6	Height;
PAAD	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg20592124	chr2:65290738	CEP68	0.46	4.47	0.34	1.54e-5	Pulse pressure;
PAAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg14348967	chr4:10160060	NA	-0.4	-4.68	-0.35	6.33e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.99	9.0	0.59	8.69e-16	Iron status biomarkers;
PAAD	cis	rs9810890	0.702	rs73207972	chr3:128568186	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg09455208	chr3:40491958	NA	-0.42	-5.61	-0.41	9.48e-8	Renal cell carcinoma;
PAAD	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.84	8.11	0.55	1.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7173419	0.607	rs1800411	chr15:28211921	A/G	cg20906524	chr15:28200668	OCA2	0.46	5.43	0.4	2.15e-7	Eye color;
PAAD	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.12	15.49	0.78	4.45e-33	Schizophrenia;
PAAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26071963	chr14:88945568	PTPN21	-0.62	-7.18	-0.5	2.95e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.45	-4.65	-0.35	7.16e-6	Tonsillectomy;
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27603082	chr10:134405566	INPP5A	-0.45	-4.8	-0.36	3.77e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.69	7.39	0.51	8.95e-12	Triglyceride levels;
PAAD	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg23346134	chr3:49453900	TCTA	0.41	4.35	0.33	2.44e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.36	4.64	0.35	7.47e-6	Educational attainment (years of education);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19765451	chr1:94702724	ARHGAP29	0.62	6.58	0.47	7.25e-10	Myopia (pathological);
PAAD	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.49	-4.37	-0.33	2.29e-5	Multiple sclerosis;
PAAD	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.71	7.4	0.51	8.76e-12	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10252462	chr9:34458891	C9orf25;DNAI1	0.58	6.53	0.47	9.53e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.67	6.9	0.49	1.35e-10	Colorectal cancer;
PAAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.61e-7	Life satisfaction;
PAAD	cis	rs6466055	0.576	rs4602821	chr7:104611876	C/T	cg04380332	chr7:105027541	SRPK2	-0.48	-4.5	-0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs7131987	0.676	rs10843407	chr12:29550244	A/G	cg09582351	chr12:29534625	ERGIC2	0.35	4.92	0.37	2.2e-6	QT interval;
PAAD	cis	rs9657904	0.774	rs4894953	chr3:105520184	T/C	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.89e-6	Multiple sclerosis;
PAAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.74	8.67	0.58	5.96e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.62	4.31	0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg25204440	chr1:209979598	IRF6	0.58	4.6	0.35	8.67e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg02527881	chr3:46936655	PTH1R	0.37	4.28	0.33	3.28e-5	Colorectal cancer;
PAAD	cis	rs16975963	0.644	rs73033139	chr19:38091685	A/C	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08261032	chr1:23886002	ID3	0.62	6.99	0.49	8.27e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-9.2	-0.6	2.69e-16	Total body bone mineral density;
PAAD	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.47	5.17	0.39	7.27e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.56	4.74	0.36	4.84e-6	Cystic fibrosis severity;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01756814	chr4:111119868	ELOVL6	0.67	6.31	0.46	2.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg16205897	chr5:131564050	P4HA2	-0.41	-4.45	-0.34	1.64e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-4.54	-0.35	1.11e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.77	-7.48	-0.52	5.45e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.49	4.89	0.37	2.49e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.19	-0.5	2.73e-11	Morning vs. evening chronotype;
PAAD	cis	rs17155006	0.664	rs6974722	chr7:107738836	T/C	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs59888335	0.858	rs7638662	chr3:80988918	G/A	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	7.22	0.51	2.28e-11	Total body bone mineral density;
PAAD	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.37	-0.33	2.31e-5	Resting heart rate;
PAAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg17178900	chr1:205818956	PM20D1	0.5	4.81	0.36	3.65e-6	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	trans	rs901683	1.000	rs71496624	chr10:46085949	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7071247	0.915	rs3014204	chr10:105260229	G/T	cg14553436	chr10:104822996	CNNM2	0.67	4.87	0.37	2.82e-6	Platelet aggregation;
PAAD	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.69	0.42	6.25e-8	Response to antipsychotic treatment;
PAAD	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-8.3	-0.56	5.37e-14	Coronary artery disease;
PAAD	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.59	-6.06	-0.44	1e-8	Lung function (FVC);
PAAD	cis	rs2030114	1.000	rs2030112	chr16:51610335	G/C	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg23283495	chr1:209979779	IRF6	0.64	6.17	0.45	6.02e-9	Coronary artery disease;
PAAD	cis	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg27395922	chr11:50257633	LOC441601	0.43	4.67	0.35	6.46e-6	Coronary artery disease;
PAAD	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg16342193	chr10:102329863	NA	-0.75	-8.14	-0.55	1.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.79	-7.97	-0.54	3.57e-13	Paraoxonase activity;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.88	8.03	0.55	2.55e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs793571	1.000	rs793571	chr15:59141706	A/G	cg05156742	chr15:59063176	FAM63B	0.64	5.36	0.4	3.04e-7	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.58e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.91	-0.37	2.3e-6	Retinal vascular caliber;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	8.59	0.57	9.78e-15	Alzheimer's disease;
PAAD	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg13565585	chr5:132299512	AFF4	0.71	5.6	0.41	9.71e-8	Apolipoprotein A-IV levels;
PAAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.72	9.21	0.6	2.54e-16	Coronary artery disease;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg20007245	chr22:24372913	LOC391322	-0.71	-7.02	-0.49	7.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg08648136	chr8:956695	NA	0.42	4.62	0.35	7.98e-6	Schizophrenia;
PAAD	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.31	0.46	2.86e-9	Calcium levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22862193	chr5:86564070	RASA1	0.68	6.32	0.46	2.76e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.56	5.16	0.39	7.48e-7	Resting heart rate;
PAAD	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg11890956	chr21:40555474	PSMG1	-0.55	-5.63	-0.42	8.35e-8	Menarche (age at onset);
PAAD	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	7.85	0.54	7.02e-13	Cognitive test performance;
PAAD	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.39	13.4	0.74	1.56e-27	Corneal structure;
PAAD	cis	rs7534824	0.583	rs6577225	chr1:101506126	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	4.68	0.36	6.22e-6	Refractive astigmatism;
PAAD	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.27	7.74	0.53	1.31e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.69	6.46	0.46	1.37e-9	Mood instability;
PAAD	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.43	5.3	0.4	3.97e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.46	-5.22	-0.39	5.73e-7	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg14926445	chr8:58193284	C8orf71	-0.69	-5.43	-0.4	2.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.91	7.94	0.54	4.1e-13	IgG glycosylation;
PAAD	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg18281939	chr5:77783895	LHFPL2	0.51	6.57	0.47	7.42e-10	Triglycerides;
PAAD	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg03277515	chr1:153321198	PGLYRP4	0.39	4.57	0.35	9.96e-6	Psoriasis;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-1.01	-16.82	-0.81	1.58e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.79	-8.53	-0.57	1.38e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.76	8.97	0.59	1.04e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2252790	0.794	rs1204808	chr6:116550917	A/G	cg18764771	chr6:116381957	FRK	-0.27	-4.62	-0.35	8.09e-6	Fast beta electroencephalogram;
PAAD	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg19000871	chr14:103996768	TRMT61A	0.5	5.75	0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg17372223	chr3:52568218	NT5DC2	-0.47	-4.71	-0.36	5.48e-6	Bipolar disorder;
PAAD	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.51	0.41	1.47e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2019216	0.605	rs11654492	chr17:22008649	A/C	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.54e-5	Pelvic organ prolapse;
PAAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg16928487	chr17:17741425	SREBF1	0.33	4.48	0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs1723838	0.826	rs2511262	chr11:73566340	C/T	cg26954736	chr11:73693896	UCP2	1.04	4.61	0.35	8.51e-6	Obesity-related traits;
PAAD	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-8.57	-0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg12641515	chr19:46296257	DMWD	0.47	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.32	-0.56	4.61e-14	Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-7.91	-0.54	4.88e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.23	-0.39	5.64e-7	Total body bone mineral density;
PAAD	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.11	-0.44	8.19e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15793563	chr11:910950	CHID1	0.64	6.43	0.46	1.6e-9	Primary biliary cholangitis;
PAAD	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.38	4.52	0.34	1.22e-5	Colorectal cancer;
PAAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.81	7.28	0.51	1.7e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs4740619	0.647	rs10738415	chr9:15824475	T/A	cg14451791	chr9:16040625	NA	-0.37	-4.32	-0.33	2.85e-5	Body mass index;
PAAD	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06850241	chr22:41845214	NA	-0.51	-4.62	-0.35	8.12e-6	Vitiligo;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.66	-6.8	-0.48	2.22e-10	Menopause (age at onset);
PAAD	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg12568669	chr8:11666485	FDFT1	-0.3	-5.18	-0.39	6.99e-7	Myopia (pathological);
PAAD	cis	rs6032067	0.683	rs34508373	chr20:43788087	T/C	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg14440974	chr22:39074834	NA	-0.57	-6.64	-0.47	5.23e-10	Menopause (age at onset);
PAAD	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg17650747	chr5:1873721	NA	0.46	4.65	0.35	7.17e-6	Cardiovascular disease risk factors;
PAAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.64	6.44	0.46	1.52e-9	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21097640	chr13:28195548	POLR1D;LNX2	0.66	7.34	0.51	1.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.52	5.36	0.4	2.98e-7	Longevity;Endometriosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14924826	chr10:112679428	NCRNA00081;SHOC2	-0.65	-6.47	-0.46	1.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs111342015	1.000	rs77971038	chr6:43204357	T/A	cg17076780	chr6:43251928	TTBK1	0.7	4.69	0.36	5.96e-6	Breast cancer;
PAAD	cis	rs7551345	0.618	rs12691486	chr1:31880154	C/G	cg17086398	chr1:31896392	SERINC2	-0.61	-4.43	-0.34	1.8e-5	Schizophrenia;
PAAD	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg14003231	chr6:33640908	ITPR3	0.36	4.74	0.36	4.89e-6	Plateletcrit;
PAAD	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.85	7.6	0.52	2.77e-12	Coronary artery disease;
PAAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg01075559	chr1:2537774	MMEL1	0.49	5.32	0.4	3.7e-7	Ulcerative colitis;
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg00334542	chr7:100209784	MOSPD3	-0.75	-5.5	-0.41	1.58e-7	Other erythrocyte phenotypes;
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg22963979	chr7:1858916	MAD1L1	-0.6	-5.97	-0.44	1.65e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	trans	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.7	7.59	0.52	2.95e-12	Melanoma;
PAAD	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.55	-4.34	-0.33	2.6e-5	Coronary artery disease;
PAAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.72	-0.36	5.33e-6	Mood instability;
PAAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg03188948	chr7:1209495	NA	1.1	5.47	0.41	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.9	-0.37	2.44e-6	Vitiligo;
PAAD	cis	rs883565	0.740	rs7624734	chr3:39108503	G/A	cg01426195	chr3:39028469	NA	-0.67	-7.13	-0.5	3.75e-11	Handedness;
PAAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg00262122	chr8:11665843	FDFT1	0.62	5.38	0.4	2.77e-7	Neuroticism;
PAAD	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs2835872	0.758	rs1709818	chr21:39036211	T/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.15	0.45	6.6e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs12760731	0.623	rs6701584	chr1:178290509	C/T	cg00404053	chr1:178313656	RASAL2	0.63	5.17	0.39	7.26e-7	Obesity-related traits;
PAAD	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg05555928	chr11:63887634	MACROD1	0.72	5.15	0.39	8.13e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg06609049	chr19:2785107	THOP1	0.92	10.45	0.65	1.3e-19	Total cholesterol levels;
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.73	7.58	0.52	3.18e-12	Height;
PAAD	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.4	4.82	0.36	3.39e-6	Thyroid stimulating hormone;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg06565975	chr8:143823917	SLURP1	0.22	4.97	0.37	1.79e-6	Urinary tract infection frequency;
PAAD	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs2030114	0.768	rs35040650	chr16:51597716	G/T	cg03758633	chr16:51611768	NA	0.51	4.56	0.35	1.05e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.86	6.01	0.44	1.33e-8	Crohn's disease;
PAAD	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs35160687	0.545	rs1863050	chr2:86558376	G/A	cg10973622	chr2:86423274	IMMT	-0.44	-4.99	-0.38	1.63e-6	Night sleep phenotypes;
PAAD	cis	rs302972	0.826	rs303011	chr6:25080848	A/C	cg09546929	chr6:25930894	SLC17A2	-0.77	-4.33	-0.33	2.69e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.46	4.31	0.33	2.96e-5	Recombination measurement;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13427810	chr9:116990636	COL27A1	-0.64	-6.78	-0.48	2.54e-10	Obesity-related traits;
PAAD	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.22	-0.45	4.52e-9	Migraine - clinic-based;
PAAD	cis	rs2092319	0.649	rs3014708	chr1:26008172	T/C	cg02327719	chr1:26185386	C1orf135	-0.79	-4.71	-0.36	5.62e-6	Nose morphology;
PAAD	cis	rs10838687	0.673	rs6485716	chr11:46981646	A/G	cg19486271	chr11:47235900	DDB2	-0.57	-4.39	-0.34	2.09e-5	Proinsulin levels;
PAAD	cis	rs12282928	0.959	rs12790767	chr11:48332171	G/A	cg04721828	chr11:48285200	OR4X1	0.48	6.09	0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg01283332	chr5:1856932	NA	-0.43	-4.48	-0.34	1.45e-5	Cardiovascular disease risk factors;
PAAD	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.57	-4.59	-0.35	9.26e-6	Facial morphology (factor 19);
PAAD	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg17749961	chr2:30669863	LCLAT1	0.59	4.57	0.35	1.01e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs9532580	0.614	rs61963261	chr13:41142295	C/T	cg21288729	chr13:41239152	FOXO1	0.59	4.62	0.35	8.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	6.09	0.44	8.65e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg04520793	chr17:42248056	ASB16	-0.49	-6.72	-0.48	3.48e-10	Total body bone mineral density;
PAAD	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs682748	0.846	rs12186747	chr5:17155432	G/A	cg23987134	chr5:17158319	LOC285696	-0.36	-4.51	-0.34	1.29e-5	Hippocampal atrophy;
PAAD	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.57	6.19	0.45	5.44e-9	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.52	0.41	1.41e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.71	5.86	0.43	2.84e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7771547	0.723	rs9368938	chr6:36549752	A/G	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.02	0.49	7.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3784262	0.643	rs2453280	chr15:58368379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.55	6.75	0.48	2.87e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.98e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.91	6.93	0.49	1.15e-10	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.45	4.49	0.34	1.41e-5	Aortic root size;
PAAD	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.47	-0.41	1.85e-7	Mean corpuscular volume;
PAAD	cis	rs89107	0.551	rs2078383	chr6:118706643	C/T	cg21191810	chr6:118973309	C6orf204	0.37	4.31	0.33	2.94e-5	Cardiac structure and function;
PAAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.74	0.58	4.04e-15	Personality dimensions;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.71	6.91	0.49	1.23e-10	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-5.07	-0.38	1.12e-6	Lung cancer in ever smokers;
PAAD	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg27211696	chr2:191398769	TMEM194B	0.44	4.32	0.33	2.81e-5	Urinary metabolites;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg04520793	chr17:42248056	ASB16	-0.49	-6.76	-0.48	2.82e-10	Total body bone mineral density;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.75	-7.84	-0.54	7.47e-13	Blood metabolite levels;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg00049323	chr5:472564	LOC25845	-0.47	-4.82	-0.36	3.5e-6	Cystic fibrosis severity;
PAAD	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.4	4.37	0.33	2.32e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10009236	chr16:128016	MPG	0.62	6.78	0.48	2.54e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23708337	chr7:1209742	NA	0.46	4.88	0.37	2.71e-6	Longevity;Endometriosis;
PAAD	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-9.76	-0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg08029281	chr1:67600428	NA	0.45	5.54	0.41	1.31e-7	Psoriasis;
PAAD	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs11669133	1.000	rs115291362	chr19:11119292	C/T	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs9326726	0.566	rs286753	chr5:107401603	A/T	cg19779370	chr5:108084990	FER	-0.59	-4.87	-0.37	2.78e-6	Resting heart rate;
PAAD	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg20607764	chr19:44506953	ZNF230	0.51	4.62	0.35	8.26e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.76	-8.41	-0.56	2.75e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03320005	chr20:62886973	PCMTD2	-0.64	-6.36	-0.46	2.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-4.93	-0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.76	-8.35	-0.56	3.97e-14	Neuroticism;
PAAD	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.47	0.34	1.52e-5	Lung cancer;
PAAD	cis	rs501916	0.634	rs1561479	chr15:48070157	C/G	cg16110827	chr15:48056943	SEMA6D	-0.51	-5.48	-0.41	1.71e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.59	6.68	0.48	4.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.68	-7.11	-0.5	4.35e-11	DNA methylation (variation);
PAAD	cis	rs6066835	0.764	rs6066843	chr20:47372817	C/G	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26926768	chr12:34528122	NA	-0.39	-4.74	-0.36	4.8e-6	Morning vs. evening chronotype;
PAAD	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-18.17	-0.83	6.2e-40	Exhaled nitric oxide output;
PAAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01200585	chr1:228362443	C1orf69	-0.49	-5.53	-0.41	1.35e-7	Diastolic blood pressure;
PAAD	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs5758659	0.789	rs2413684	chr22:42574830	C/T	cg22189786	chr22:42395067	WBP2NL	-0.44	-4.41	-0.34	1.97e-5	Cognitive function;
PAAD	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.63	7.06	0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg11608241	chr8:8085544	FLJ10661	-0.52	-4.31	-0.33	2.97e-5	Cervical cancer;
PAAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.67	-8.04	-0.55	2.37e-13	Bone mineral density;
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg23283495	chr1:209979779	IRF6	0.67	6.42	0.46	1.61e-9	Coronary artery disease;
PAAD	cis	rs2133450	0.712	rs17698091	chr3:7371151	T/C	cg19930620	chr3:7340148	GRM7	-0.5	-5.59	-0.41	1.04e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.86	9.6	0.61	2.4e-17	Tonsillectomy;
PAAD	cis	rs11247915	0.600	rs72649360	chr1:26662904	C/T	cg15628303	chr1:26608928	UBXN11	0.66	6.6	0.47	6.48e-10	Obesity-related traits;
PAAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg03909863	chr11:638404	DRD4	-0.68	-5.68	-0.42	6.52e-8	Systemic lupus erythematosus;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08439880	chr3:133502540	NA	-0.5	-5.34	-0.4	3.29e-7	Iron status biomarkers;
PAAD	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.39	-5.45	-0.4	1.96e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.97	10.97	0.66	5.58e-21	Parkinson's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25032375	chr2:61293268	KIAA1841	-0.69	-7.2	-0.5	2.65e-11	Smoking initiation;
PAAD	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.64	-7.03	-0.5	6.7e-11	Height;
PAAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.64	8.48	0.57	1.84e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	1.14	16.13	0.79	9.38e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10332296	chr1:42928798	NA	0.56	6.33	0.46	2.65e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.62	8.24	0.56	7.39e-14	Systemic lupus erythematosus;
PAAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg26668713	chr11:65405903	SIPA1	0.62	5.61	0.41	9.41e-8	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg25204440	chr1:209979598	IRF6	0.63	5.6	0.41	9.76e-8	Coronary artery disease;
PAAD	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.04	0.5	6.03e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.61	0.57	8.56e-15	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.66	6.34	0.46	2.52e-9	Pulse pressure;
PAAD	cis	rs4750440	0.702	rs11258774	chr10:14029701	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs2133450	0.526	rs62234956	chr3:7344222	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.75	-7.13	-0.5	3.74e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs427943	0.864	rs367986	chr21:46588104	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.46	-4.53	-0.35	1.17e-5	Body mass index;
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27297192	chr10:134578999	INPP5A	0.64	6.09	0.44	8.66e-9	Migraine;
PAAD	cis	rs4699052	0.507	rs7662107	chr4:104258396	C/T	cg16532752	chr4:104119610	CENPE	-0.5	-4.32	-0.33	2.84e-5	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.98	8.28	0.56	5.74e-14	Initial pursuit acceleration;
PAAD	cis	rs7072216	0.687	rs7097625	chr10:100158922	A/T	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.99	4.98	0.37	1.69e-6	Breast cancer;
PAAD	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	8.23	0.56	7.96e-14	Longevity;
PAAD	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.4	0.4	2.48e-7	Lung cancer in ever smokers;
PAAD	cis	rs11614333	0.919	rs12307494	chr12:14991023	G/A	cg00431549	chr12:15039025	MGP	-0.38	-4.44	-0.34	1.69e-5	Hand grip strength;
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg02555727	chr12:129281546	SLC15A4	0.44	4.71	0.36	5.63e-6	Systemic lupus erythematosus;
PAAD	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.57	-5.46	-0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg23034840	chr1:205782522	SLC41A1	-0.76	-5.83	-0.43	3.14e-8	Prostate-specific antigen levels;
PAAD	cis	rs6066835	1.000	rs73138221	chr20:47349525	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs10450586	0.863	rs7115157	chr11:27301586	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.13e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24693982	chr6:144508735	STX11	-0.62	-6.82	-0.48	2.02e-10	Obesity-related traits;
PAAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	2.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg25902810	chr10:99078978	FRAT1	-0.6	-5.54	-0.41	1.31e-7	Monocyte count;
PAAD	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.32e-5	Iron status biomarkers;
PAAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg14440974	chr22:39074834	NA	-0.56	-6.52	-0.47	9.62e-10	Menopause (age at onset);
PAAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.57	-4.91	-0.37	2.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.73	-7.34	-0.51	1.2e-11	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02829609	chr19:19030005	COPE;DDX49	0.66	7.27	0.51	1.8e-11	Myopia (pathological);
PAAD	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.16	0.45	6.36e-9	Electrocardiographic conduction measures;
PAAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg09491104	chr22:46646882	C22orf40	0.76	5.09	0.38	1.03e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.6	0.47	6.47e-10	Schizophrenia;
PAAD	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs755249	0.567	rs67408364	chr1:39618556	A/G	cg14018543	chr1:39659967	MACF1	-0.51	-4.35	-0.33	2.44e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs643506	0.874	rs613292	chr11:111668805	C/T	cg09085632	chr11:111637200	PPP2R1B	0.57	4.91	0.37	2.29e-6	Breast cancer;
PAAD	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.54	-5.11	-0.38	9.67e-7	Blood protein levels;
PAAD	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.59	5.72	0.42	5.39e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12760731	0.565	rs12037429	chr1:178224741	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02071572	chr4:1403502	NA	0.37	4.65	0.35	7.19e-6	Longevity;
PAAD	cis	rs2415984	0.715	rs2600812	chr14:46951737	G/T	cg14871534	chr14:47121158	RPL10L	0.46	4.62	0.35	8.06e-6	Number of children ever born;
PAAD	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg12046867	chr14:103022105	NA	-0.65	-5.32	-0.4	3.72e-7	Platelet count;
PAAD	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	trans	rs901683	0.850	rs74874679	chr10:46050733	A/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs818427	1.000	rs712668	chr5:112197637	T/G	cg06941702	chr5:112196734	SRP19	-0.45	-4.36	-0.33	2.35e-5	Total body bone mineral density;
PAAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-4.41	-0.34	1.91e-5	Schizophrenia;
PAAD	cis	rs1198430	0.562	rs10799795	chr1:23773998	C/A	cg19827787	chr1:23763612	ASAP3	0.55	5.11	0.38	9.41e-7	Total cholesterol levels;
PAAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg14829360	chr17:73884958	NA	-0.61	-5.81	-0.43	3.63e-8	Psoriasis;
PAAD	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.47	0.46	1.24e-9	Morning vs. evening chronotype;
PAAD	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3743102	0.591	rs78104714	chr15:83381199	C/G	cg00614314	chr15:82944287	LOC80154	-0.7	-4.72	-0.36	5.21e-6	Colorectal adenoma (advanced);
PAAD	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.79	-4.27	-0.33	3.4e-5	Cholesterol, total;
PAAD	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.57	-5.96	-0.43	1.73e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.95	-8.3	-0.56	5.21e-14	Body mass index;
PAAD	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	5.29	0.39	4.11e-7	Total body bone mineral density;
PAAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg19131313	chr8:1704013	NA	-0.42	-4.49	-0.34	1.38e-5	Systolic blood pressure;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2790216	1.000	rs2590315	chr10:59986492	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9810890	0.850	rs13322981	chr3:128571735	G/A	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12427896	chr2:111880694	BCL2L11	0.62	7.0	0.49	7.58e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.75	8.82	0.58	2.46e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs2031532	0.544	rs35980977	chr13:50057936	A/G	cg08779649	chr13:50194554	NA	0.36	4.87	0.37	2.73e-6	Cardiac hypertrophy;
PAAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.42	-4.99	-0.38	1.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.55	-0.35	1.1e-5	Aortic root size;
PAAD	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.55	-5.78	-0.42	4.05e-8	Fibrinogen levels;
PAAD	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.16	-0.39	7.74e-7	Body mass index;
PAAD	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs735539	0.521	rs2762985	chr13:21384371	G/T	cg27234864	chr13:21295941	IL17D	0.58	4.8	0.36	3.81e-6	Dental caries;
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg25287198	chr4:183728479	NA	0.86	7.08	0.5	4.92e-11	Pediatric autoimmune diseases;
PAAD	cis	rs4450131	0.500	rs2362515	chr10:126336158	C/T	cg20435097	chr10:126320824	FAM53B	0.5	4.76	0.36	4.39e-6	White blood cell count (basophil);
PAAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg11766577	chr21:47581405	C21orf56	-0.4	-4.47	-0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg01750375	chr20:43343365	WISP2	0.4	4.96	0.37	1.87e-6	Positive affect;
PAAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-4.9	-0.37	2.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.23	0.56	7.74e-14	Lung cancer;
PAAD	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.98	-6.16	-0.45	6.3e-9	Post bronchodilator FEV1;
PAAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs863345	0.564	rs4614256	chr1:158464611	T/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	1.18	18.36	0.83	2.06e-40	Gut microbiome composition (winter);
PAAD	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg02404636	chr22:31891804	SFI1	-0.57	-5.01	-0.38	1.5e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.72	-6.59	-0.47	6.85e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.58	6.01	0.44	1.3e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs17407555	0.779	rs17475461	chr4:10287677	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-5.22	-0.39	5.71e-7	Schizophrenia (age at onset);
PAAD	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg10437265	chr15:77819839	NA	0.4	4.38	0.34	2.16e-5	Type 2 diabetes;
PAAD	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	1.14	7.68	0.53	1.77e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.88	-9.55	-0.61	3.28e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.65	-6.64	-0.47	5.36e-10	Schizophrenia;
PAAD	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.02	9.2	0.6	2.67e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs11191270	1.000	rs4919624	chr10:104021085	A/G	cg15320455	chr10:103880129	LDB1	0.56	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.59	-6.81	-0.48	2.09e-10	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19753255	chr1:45476701	HECTD3;UROD	0.63	6.94	0.49	1.06e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	5.0	0.38	1.55e-6	Mean platelet volume;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg08436684	chr16:88034427	BANP	-0.52	-4.41	-0.34	1.91e-5	Menopause (age at onset);
PAAD	cis	rs8121916	1.000	rs4814115	chr20:12406658	A/T	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	7.91	0.54	5.01e-13	Post bronchodilator FEV1;
PAAD	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13870426	chr17:30244630	NA	-0.59	-5.8	-0.43	3.73e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1468333	0.724	rs12514307	chr5:137612143	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.79	0.43	3.83e-8	Resting heart rate;
PAAD	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.22	0.51	2.35e-11	IgG glycosylation;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06799790	chr17:61951754	CSH2	-0.45	-4.59	-0.35	9.16e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15605011	chr1:110162477	AMPD2	0.59	6.34	0.46	2.44e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg18196295	chr10:418757	DIP2C	0.47	5.12	0.38	9.31e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.23	-0.55	8.08e-14	Hemoglobin concentration;
PAAD	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	4.65	0.35	7.07e-6	Cognitive test performance;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1468333	1.000	rs2864	chr5:137523430	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.23	0.45	4.37e-9	Resting heart rate;
PAAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.58	5.43	0.4	2.18e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg15798862	chr7:76129360	DTX2	-0.5	-6.71	-0.48	3.56e-10	Multiple sclerosis;
PAAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.66	7.33	0.51	1.24e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23059868	chr1:1649451	CDK11A;CDK11B	-0.7	-7.29	-0.51	1.57e-11	Obesity-related traits;
PAAD	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg00531865	chr16:30841666	NA	-0.52	-5.08	-0.38	1.09e-6	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14797887	chr15:56757312	MNS1	0.61	7.42	0.52	7.72e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11195062	0.766	rs4918489	chr10:112034446	A/G	cg19214408	chr10:111981687	MXI1	-0.45	-4.51	-0.34	1.27e-5	Multiple myeloma;
PAAD	cis	rs6460942	0.597	rs6977059	chr7:12535157	T/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs6041	0.822	rs3093233	chr13:113758130	A/G	cg09069900	chr13:113776964	F10	-0.57	-4.8	-0.36	3.84e-6	End-stage coagulation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02829609	chr19:19030005	COPE;DDX49	0.6	7.03	0.5	6.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3784262	0.679	rs8031578	chr15:58369145	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.62	-7.86	-0.54	6.42e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Immature fraction of reticulocytes;
PAAD	cis	rs3747547	0.892	rs17439509	chr9:38016419	A/C	cg13774184	chr9:37916125	SHB	-0.62	-4.53	-0.35	1.16e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg06812019	chr5:1143331	NA	0.45	4.28	0.33	3.28e-5	Gut microbiome composition (winter);
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09699651	chr6:150184138	LRP11	0.6	6.44	0.46	1.5e-9	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg04369109	chr6:150039330	LATS1	0.45	4.47	0.34	1.5e-5	Lung cancer;
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg21280719	chr6:42927975	GNMT	0.38	5.42	0.4	2.32e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.81	-9.12	-0.59	4.16e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs858239	0.512	rs55788996	chr7:23192849	G/A	cg23682824	chr7:23144976	KLHL7	0.51	4.49	0.34	1.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs425535	0.757	rs434988	chr4:74794801	G/A	cg01447579	chr4:74847100	PF4	0.65	4.37	0.33	2.26e-5	Blood protein levels;
PAAD	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-5.93	-0.43	1.94e-8	Longevity;
PAAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	6.16	0.45	6.09e-9	Menopause (age at onset);
PAAD	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg19486271	chr11:47235900	DDB2	-0.55	-5.53	-0.41	1.36e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg07959490	chr17:80112427	CCDC57	0.36	4.29	0.33	3.18e-5	Life satisfaction;
PAAD	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.62	-0.47	5.74e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11615916	0.720	rs73135257	chr12:62666217	C/T	cg11441379	chr12:63026424	NA	0.69	4.43	0.34	1.78e-5	Pulmonary function decline;
PAAD	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.39	5.11	0.38	9.53e-7	Educational attainment (years of education);
PAAD	cis	rs1012068	0.662	rs5753816	chr22:32312842	T/C	cg01338084	chr22:32026380	PISD	0.56	5.07	0.38	1.15e-6	Chronic hepatitis C infection;
PAAD	cis	rs9463078	0.691	rs9349313	chr6:45119782	T/C	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-12.09	-0.7	5.26e-24	Height;
PAAD	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.66	7.1	0.5	4.59e-11	Aortic root size;
PAAD	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg17326555	chr1:119535693	NA	0.41	5.03	0.38	1.37e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg05585544	chr11:47624801	NA	-0.47	-5.24	-0.39	5.39e-7	Subjective well-being;
PAAD	cis	rs9549328	0.917	rs4907573	chr13:113648742	C/G	cg08614441	chr13:113633676	MCF2L	-0.43	-4.29	-0.33	3.13e-5	Systolic blood pressure;
PAAD	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.29e-7	Monocyte percentage of white cells;
PAAD	cis	rs9810890	1.000	rs73198847	chr3:128507476	C/G	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.5	-4.69	-0.36	6.13e-6	Daytime sleep phenotypes;
PAAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.34	0.4	3.3e-7	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.86	9.51	0.61	4.11e-17	Prudent dietary pattern;
PAAD	cis	rs7561149	0.934	rs13006510	chr2:179682878	C/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.53	5.35	0.4	3.25e-7	QT interval;
PAAD	cis	rs965469	1.000	rs6139064	chr20:3277050	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.74	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Calcium levels;
PAAD	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg18196295	chr10:418757	DIP2C	0.4	4.26	0.33	3.57e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg25809561	chr17:30822961	MYO1D	0.68	7.5	0.52	4.91e-12	Schizophrenia;
PAAD	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg19753864	chr2:38320028	NA	-0.39	-4.25	-0.33	3.65e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs11264799	0.598	rs3818813	chr1:157718325	G/T	cg18268488	chr1:157545234	FCRL4	-0.62	-5.77	-0.42	4.35e-8	IgA nephropathy;
PAAD	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.68	6.95	0.49	1e-10	Response to antidepressants and depression;
PAAD	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.42e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.67	-0.35	6.56e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg00579200	chr11:133705235	NA	-0.49	-5.53	-0.41	1.37e-7	Childhood ear infection;
PAAD	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.87e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27008843	chr19:2353320	SPPL2B	0.54	6.51	0.47	1.03e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs11101442	0.563	rs11101446	chr10:49947197	A/C	cg25838091	chr10:50887934	C10orf53	0.34	4.42	0.34	1.84e-5	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13198984	chr17:80129470	CCDC57	-0.45	-5.66	-0.42	7.44e-8	Life satisfaction;
PAAD	cis	rs4786125	0.665	rs6500857	chr16:6903364	C/T	cg03623568	chr16:6915990	A2BP1	-0.48	-4.85	-0.37	3.03e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.63	5.46	0.4	1.93e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.59	6.08	0.44	9.49e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-5.06	-0.38	1.2e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg08048268	chr3:133502702	NA	0.49	5.96	0.44	1.72e-8	Iron status biomarkers;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26690034	chr1:75198963	CRYZ;TYW3	0.53	4.9	0.37	2.47e-6	Resistin levels;
PAAD	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg06115741	chr20:33292138	TP53INP2	-0.48	-4.76	-0.36	4.44e-6	Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg14952266	chr13:112191215	NA	0.45	5.18	0.39	7.09e-7	Hepatitis;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg19223190	chr17:80058835	NA	0.51	5.27	0.39	4.61e-7	Life satisfaction;
PAAD	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.36	0.33	2.42e-5	Iron status biomarkers;
PAAD	cis	rs12042052	0.793	rs10910625	chr1:232940447	C/T	cg02903907	chr1:232941055	KIAA1383	-0.76	-4.57	-0.35	1e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg00898013	chr13:113819073	PROZ	-0.84	-7.21	-0.5	2.48e-11	Platelet distribution width;
PAAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23158103	chr7:148848205	ZNF398	-0.61	-5.96	-0.44	1.66e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.43	-0.52	7.4e-12	Response to antipsychotic treatment;
PAAD	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.75	7.8	0.53	9.42e-13	Asperger disorder;
PAAD	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.9	-0.54	5.08e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg04154034	chr17:28927549	LRRC37B2	0.79	4.61	0.35	8.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2730260	0.736	rs73169215	chr7:158833701	T/C	cg02254261	chr7:158964346	NA	-0.6	-4.58	-0.35	9.72e-6	Myopia (pathological);
PAAD	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.48	4.54	0.35	1.11e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs8060686	0.641	rs7195605	chr16:67989523	T/C	cg05110241	chr16:68378359	PRMT7	-0.79	-6.3	-0.46	3.01e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03762994	chr17:6899332	ALOX12	0.48	4.94	0.37	2.07e-6	Tonsillectomy;
PAAD	cis	rs17209837	0.607	rs1014283	chr7:87076587	C/A	cg00919237	chr7:87102261	ABCB4	-0.78	-6.51	-0.47	1.04e-9	Gallbladder cancer;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.86	-0.37	2.92e-6	Height;
PAAD	cis	rs11264799	0.598	rs79853736	chr1:157732091	A/C	cg18268488	chr1:157545234	FCRL4	0.64	5.56	0.41	1.19e-7	IgA nephropathy;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg26014466	chr7:809109	HEATR2	-0.67	-7.42	-0.52	7.59e-12	Subjective well-being;
PAAD	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.74e-13	Monocyte percentage of white cells;
PAAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.4	5.95	0.43	1.77e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11958404	0.615	rs6884132	chr5:157437035	G/A	cg05962755	chr5:157440814	NA	0.58	5.45	0.4	2.02e-7	IgG glycosylation;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.09	-0.38	1.04e-6	Monocyte percentage of white cells;
PAAD	cis	rs787274	0.867	rs786968	chr9:115449110	C/T	cg13803584	chr9:115635662	SNX30	0.8	4.68	0.36	6.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs669446	0.561	rs516790	chr1:44081712	G/T	cg12908607	chr1:44402522	ARTN	0.46	4.92	0.37	2.26e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.45	-0.46	1.41e-9	Neuroticism;
PAAD	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.83	8.24	0.56	7.33e-14	Vitamin D levels;
PAAD	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.44	-0.34	1.73e-5	Diastolic blood pressure;
PAAD	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.38	0.51	9.43e-12	Lung cancer in ever smokers;
PAAD	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05491587	chr18:77659695	KCNG2	-0.44	-4.25	-0.33	3.74e-5	Schizophrenia;
PAAD	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg21395723	chr22:39101663	GTPBP1	0.46	4.74	0.36	4.98e-6	Menopause (age at onset);
PAAD	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-1.04	-9.19	-0.6	2.7e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs8112211	0.648	rs34989303	chr19:38817876	G/A	cg01275006	chr19:38876250	GGN	-0.89	-5.63	-0.42	8.45e-8	Blood protein levels;
PAAD	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg01047959	chr19:17666446	GLT25D1	0.47	4.26	0.33	3.55e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.54	-5.64	-0.42	8.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.91	5.39	0.4	2.69e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg12661370	chr5:149340060	SLC26A2	0.65	5.42	0.4	2.33e-7	HIV-1 control;
PAAD	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg26570165	chr1:119541833	NA	-0.48	-4.3	-0.33	3.08e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs308971	0.563	rs167408	chr3:12088448	A/G	cg15873301	chr3:12045459	SYN2	0.63	4.41	0.34	1.92e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.61	6.0	0.44	1.38e-8	Blood protein levels;
PAAD	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg27411982	chr8:10470053	RP1L1	0.4	4.39	0.34	2.09e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.6	-5.56	-0.41	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.51	7.94	0.54	4.06e-13	Mean corpuscular volume;
PAAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.53	4.92	0.37	2.23e-6	Multiple sclerosis;
PAAD	cis	rs9649465	0.935	rs1506641	chr7:123390143	G/A	cg04330084	chr7:123175371	IQUB	-0.49	-4.62	-0.35	8.05e-6	Migraine;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg04287289	chr16:89883240	FANCA	0.93	4.63	0.35	7.71e-6	Skin colour saturation;
PAAD	cis	rs1507153	0.551	rs236859	chr6:79333116	G/A	cg05283184	chr6:79620031	NA	0.36	4.32	0.33	2.86e-5	Sjögren's syndrome;
PAAD	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.56	-5.33	-0.4	3.56e-7	Strep throat;
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19749445	chr14:92493378	TRIP11	0.65	6.37	0.46	2.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.51	5.64	0.42	7.88e-8	Obesity-related traits;
PAAD	cis	rs3960554	0.696	rs10952869	chr7:75846453	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-4.39	-0.34	2.08e-5	Eotaxin levels;
PAAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg23506979	chr15:79090958	ADAMTS7	0.25	4.3	0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.43	0.46	1.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg00012203	chr2:219082015	ARPC2	0.6	5.78	0.42	4.04e-8	Colorectal cancer;
PAAD	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg20487152	chr13:99095054	FARP1	0.46	4.82	0.36	3.42e-6	Longevity;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.73	5.49	0.41	1.66e-7	Alzheimer's disease;
PAAD	cis	rs7594192	0.744	rs12624206	chr2:199365358	C/T	cg03163783	chr2:200326591	SATB2	-0.32	-4.36	-0.33	2.34e-5	Educational attainment;
PAAD	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.63	6.04	0.44	1.12e-8	Itch intensity from mosquito bite;
PAAD	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.68	8.61	0.57	8.76e-15	Coronary artery disease;
PAAD	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.11	-0.38	9.66e-7	Reticulocyte count;
PAAD	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg15571903	chr15:79123663	NA	0.39	4.79	0.36	3.91e-6	Coronary artery disease;
PAAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg05110241	chr16:68378359	PRMT7	0.77	5.18	0.39	6.91e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg17372657	chr7:1216933	NA	-0.38	-4.74	-0.36	4.79e-6	Longevity;Endometriosis;
PAAD	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.67	7.08	0.5	4.88e-11	Platelet distribution width;
PAAD	cis	rs8067287	0.625	rs11656106	chr17:16854385	T/C	cg26910001	chr17:16838321	NA	-0.48	-4.62	-0.35	8.18e-6	Diabetic kidney disease;
PAAD	cis	rs7646881	0.812	rs75107964	chr3:158458751	G/A	cg19483011	chr3:158453295	NA	-0.59	-4.43	-0.34	1.78e-5	Tetralogy of Fallot;
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.5	-0.34	1.35e-5	Body mass index;
PAAD	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg05144285	chr7:158935647	VIPR2	0.49	4.35	0.33	2.53e-5	Height;
PAAD	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.46	4.51	0.34	1.3e-5	Dupuytren's disease;
PAAD	cis	rs9815354	0.951	rs17060938	chr3:41759191	T/C	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.82	8.75	0.58	3.68e-15	Body mass index;
PAAD	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.93	-9.67	-0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg18364678	chr10:103586829	KCNIP2	0.66	6.31	0.46	2.85e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.44	0.34	1.75e-5	Alzheimer's disease;
PAAD	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.82	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1539053	0.932	rs11207086	chr1:58117341	A/C	cg20292791	chr1:58089357	DAB1	-0.49	-4.69	-0.36	6.05e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs6674176	0.551	rs2486013	chr1:44420248	C/T	cg12908607	chr1:44402522	ARTN	0.63	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.47	4.58	0.35	9.47e-6	Urate levels in obese individuals;
PAAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.8e-13	Blood protein levels;
PAAD	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-5.34	-0.4	3.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.38	0.51	9.49e-12	Menarche (age at onset);
PAAD	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg14515779	chr1:101123966	NA	0.39	4.26	0.33	3.54e-5	Monocyte count;
PAAD	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg11204139	chr17:3907470	NA	0.61	5.77	0.42	4.36e-8	Type 2 diabetes;
PAAD	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.45	-0.34	1.68e-5	Longevity;Endometriosis;
PAAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.7	6.62	0.47	5.82e-10	Initial pursuit acceleration;
PAAD	cis	rs12912251	0.591	rs3102119	chr15:39003601	C/T	cg10631289	chr15:39006617	NA	0.48	4.31	0.33	2.89e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg19980929	chr12:42632907	YAF2	0.56	6.51	0.47	1.02e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs834603	0.569	rs834602	chr7:47446215	A/C	cg25767859	chr7:47859324	PKD1L1;C7orf69	-0.5	-5.05	-0.38	1.24e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08048268	chr3:133502702	NA	-0.5	-6.3	-0.45	3.07e-9	Iron status biomarkers;
PAAD	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.99	-6.11	-0.44	7.93e-9	Lung cancer in ever smokers;
PAAD	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.65	6.42	0.46	1.67e-9	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg04106633	chr4:1044584	NA	0.58	5.02	0.38	1.42e-6	Recombination rate (females);
PAAD	cis	rs11252688	0.867	rs2123347	chr10:4765850	A/G	cg03822858	chr10:4066499	NA	0.68	4.28	0.33	3.3e-5	Major depressive disorder;
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.55	-5.93	-0.43	1.93e-8	IgG glycosylation;
PAAD	cis	rs4716602	1.000	rs4716602	chr7:156166549	G/A	cg04090468	chr7:156181990	NA	0.54	5.35	0.4	3.2e-7	Anti-saccade response;
PAAD	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	5.04	0.38	1.31e-6	Platelet count;
PAAD	trans	rs901683	1.000	rs12772485	chr10:46011421	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.62	-0.47	5.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2004318	1.000	rs73612484	chr19:55118956	T/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg15816464	chr17:2026533	SMG6	0.48	5.36	0.4	3e-7	Total body bone mineral density;
PAAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs593531	0.513	rs7930193	chr11:74031557	G/T	cg23327896	chr11:73669290	DNAJB13	0.36	4.84	0.37	3.13e-6	Neuroticism;
PAAD	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.59	5.42	0.4	2.25e-7	IgG glycosylation;
PAAD	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12908607	chr1:44402522	ARTN	-0.72	-6.74	-0.48	3.04e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.72	5.03	0.38	1.36e-6	Iron status biomarkers;
PAAD	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.46	-0.41	1.87e-7	Type 2 diabetes;
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.26	-0.39	4.71e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01427869	chr13:113580562	NA	-0.55	-6.3	-0.46	3.07e-9	Immature fraction of reticulocytes;
PAAD	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs4638749	1.000	rs7586216	chr2:108882775	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.93	-0.37	2.14e-6	Blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21899138	chr3:52720056	GNL3;PBRM1	0.64	6.8	0.48	2.27e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.87	0.49	1.55e-10	Renal function-related traits (BUN);
PAAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.38	-0.33	2.23e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.86	10.11	0.63	1.04e-18	Blood metabolite ratios;
PAAD	cis	rs6669119	1.000	rs9439747	chr1:19111912	G/C	cg19637330	chr1:19110922	NA	0.81	5.1	0.38	9.98e-7	Percentage gas trapping;
PAAD	cis	rs9361491	0.578	rs9359345	chr6:79469916	A/C	cg05283184	chr6:79620031	NA	-0.4	-4.73	-0.36	5.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.53	5.34	0.4	3.4e-7	Eosinophil percentage of white cells;
PAAD	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.9	0.37	2.47e-6	Ovarian reserve;
PAAD	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg21238619	chr17:78079768	GAA	0.41	4.9	0.37	2.47e-6	Yeast infection;
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs951366	0.677	rs1775140	chr1:205672107	C/CA	cg17178900	chr1:205818956	PM20D1	-0.58	-4.43	-0.34	1.76e-5	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.77e-7	Life satisfaction;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-5.5	-0.41	1.58e-7	Bipolar disorder;
PAAD	cis	rs9463078	0.528	rs11966936	chr6:45053672	T/C	cg25276700	chr6:44698697	NA	0.45	5.18	0.39	6.98e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg08562672	chr19:21860753	NA	0.46	4.77	0.36	4.36e-6	Pain;
PAAD	cis	rs6489882	0.966	rs10744791	chr12:113410316	C/T	cg20102336	chr12:113376681	OAS3	-0.45	-4.33	-0.33	2.71e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg00280220	chr17:61926910	NA	-0.41	-4.44	-0.34	1.73e-5	Prudent dietary pattern;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg15693483	chr7:1102177	C7orf50	0.37	4.39	0.34	2.08e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.73	6.98	0.49	8.69e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9333029	0.524	rs12047326	chr1:47405653	T/C	cg08644498	chr1:46502608	NA	0.49	4.51	0.34	1.31e-5	Blood metabolite levels;
PAAD	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.64	-6.15	-0.45	6.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.78	7.06	0.5	5.68e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs12773846	0.537	rs78095737	chr10:126273367	C/T	cg04949429	chr10:126290192	LHPP	0.66	5.74	0.42	4.95e-8	Subcutaneous adipose tissue;
PAAD	cis	rs3787159	0.523	rs6070418	chr20:56872751	G/A	cg15032960	chr20:56888536	RAB22A	0.41	4.4	0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg11874272	chr3:121773564	CD86	-0.43	-4.57	-0.35	1.01e-5	Multiple sclerosis;
PAAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.66	5.77	0.42	4.28e-8	Coronary artery disease;
PAAD	cis	rs12311304	0.965	rs10846159	chr12:15363407	A/G	cg08258403	chr12:15378311	NA	0.37	4.71	0.36	5.49e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-6.79	-0.48	2.42e-10	Bipolar disorder;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.22	-0.39	5.9e-7	Cognitive function;
PAAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg09796270	chr17:17721594	SREBF1	0.43	4.64	0.35	7.42e-6	Total body bone mineral density;
PAAD	cis	rs6460942	0.908	rs6978367	chr7:12232347	A/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg25635251	chr11:2234043	NA	0.8	7.71	0.53	1.57e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg07148914	chr20:33460835	GGT7	-0.48	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.47	5.61	0.41	9.21e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg19442545	chr10:75533431	FUT11	-0.54	-5.58	-0.41	1.08e-7	Inflammatory bowel disease;
PAAD	cis	rs6604026	0.656	rs2811594	chr1:93343282	A/G	cg17283838	chr1:93427260	FAM69A	-0.63	-5.82	-0.43	3.37e-8	Multiple sclerosis;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.11	0.38	9.36e-7	Alzheimer's disease;
PAAD	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.93	10.41	0.64	1.75e-19	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.52	-0.47	9.94e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.38	-0.4	2.79e-7	Blood metabolite levels;
PAAD	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-5.94	-0.43	1.9e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs11696501	0.688	rs6032419	chr20:44297963	T/A	cg11783356	chr20:44313418	WFDC10B	-0.56	-4.9	-0.37	2.42e-6	Brain structure;
PAAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.59	-8.01	-0.54	2.81e-13	Height;
PAAD	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.52	0.34	1.22e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg23033748	chr14:75592666	NEK9	-0.43	-5.46	-0.4	1.92e-7	Height;
PAAD	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1042026	0.813	rs10008281	chr4:100142302	C/A	cg21548116	chr4:100009993	ADH5	-0.5	-4.25	-0.33	3.78e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.57	4.92	0.37	2.2e-6	Life satisfaction;
PAAD	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.58	5.33	0.4	3.43e-7	Corneal structure;
PAAD	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg26248373	chr2:1572462	NA	-1.08	-9.5	-0.61	4.23e-17	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs9815354	1.000	rs2625668	chr3:41905930	T/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.71	7.11	0.5	4.31e-11	Platelet count;
PAAD	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.56	-0.35	1.05e-5	Rheumatoid arthritis;
PAAD	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.57	-6.18	-0.45	5.74e-9	Pelvic organ prolapse;
PAAD	cis	rs2120243	0.534	rs35004310	chr3:157113800	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.32	0.33	2.77e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs1443512	0.588	rs1975473	chr12:54334625	G/A	cg08974225	chr12:53574518	CSAD;ZNF740	0.56	4.38	0.33	2.19e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.47	-5.2	-0.39	6.42e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00137585	chr16:3450828	ZNF174;ZNF434	-0.75	-8.96	-0.59	1.08e-15	Body fat percentage;
PAAD	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.4	5.06	0.38	1.19e-6	Electrocardiographic conduction measures;
PAAD	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.57	5.22	0.39	5.73e-7	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27507545	chr10:103880405	LDB1	0.63	6.99	0.49	8.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.47	4.89	0.37	2.57e-6	Bladder cancer;
PAAD	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg15676125	chr6:33679581	C6orf125	0.47	4.49	0.34	1.4e-5	Plateletcrit;
PAAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-4.77	-0.36	4.25e-6	Total cholesterol levels;
PAAD	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.46	-5.11	-0.38	9.46e-7	Alzheimer's disease;
PAAD	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.51	-5.12	-0.38	9.15e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.47	5.57	0.41	1.1e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.78	-6.66	-0.48	4.79e-10	Other erythrocyte phenotypes;
PAAD	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.45	5.41	0.4	2.39e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.4	-0.68	3.75e-22	Chronic sinus infection;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.51	-6.49	-0.47	1.17e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg19163074	chr7:65112434	INTS4L2	0.48	4.47	0.34	1.53e-5	Aortic root size;
PAAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.98	-0.44	1.52e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7188861	0.861	rs1968268	chr16:11446223	G/A	cg01510278	chr16:11456238	NA	-0.43	-4.27	-0.33	3.38e-5	HDL cholesterol;
PAAD	cis	rs9467603	0.858	rs1937126	chr6:25769608	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.75	-4.93	-0.37	2.15e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24405498	chr19:1556284	MEX3D	0.55	6.57	0.47	7.39e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg23024343	chr7:107201750	COG5	0.57	4.57	0.35	9.87e-6	Coronary artery disease;
PAAD	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.59	5.06	0.38	1.2e-6	Response to diuretic therapy;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg07873178	chr11:65307616	LTBP3	0.97	4.52	0.34	1.24e-5	Height;
PAAD	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.57e-7	Subjective well-being;
PAAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs2278796	1.000	rs12124296	chr1:204945618	G/A	cg04862289	chr1:204966208	NFASC	0.45	4.51	0.34	1.28e-5	Mean platelet volume;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.41	-0.46	1.72e-9	Electroencephalogram traits;
PAAD	cis	rs7101378	0.540	rs1848755	chr11:108903872	C/A	cg10610482	chr11:108093212	ATM;NPAT	-0.46	-4.4	-0.34	2.04e-5	IgG glycosylation;
PAAD	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.59	5.39	0.4	2.68e-7	Obesity-related traits;
PAAD	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg14019695	chr9:139328340	INPP5E	0.47	4.34	0.33	2.55e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10109570	chr16:1832978	NUBP2;SPSB3	-0.72	-6.36	-0.46	2.22e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17717750	chr20:62494328	C20orf135	-0.67	-6.78	-0.48	2.49e-10	Obesity-related traits;
PAAD	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.46	-4.41	-0.34	1.95e-5	Menarche (age at onset);
PAAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.85	5.93	0.43	1.92e-8	Initial pursuit acceleration;
PAAD	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.83	-0.43	3.27e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8005172	0.808	rs12878534	chr14:88479054	A/T	cg18078958	chr14:88630771	NA	0.5	5.88	0.43	2.55e-8	Parkinson's disease;
PAAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg25251562	chr2:3704773	ALLC	-0.46	-5.3	-0.4	3.96e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.85	8.72	0.58	4.4e-15	Cognitive function;
PAAD	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg10556349	chr10:835070	NA	0.63	4.43	0.34	1.8e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs2671540	0.547	rs7918756	chr10:65633900	G/T	cg19573236	chr10:65733388	NA	0.56	4.43	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.43e-19	Prudent dietary pattern;
PAAD	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs17683430	0.681	rs12159823	chr22:32563229	A/G	cg02631450	chr22:32366979	NA	0.7	4.81	0.36	3.6e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7804356	0.822	rs73061894	chr7:26802085	T/C	cg03456212	chr7:26904342	SKAP2	-0.55	-4.51	-0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs1007738	0.507	rs4752969	chr11:47185510	A/G	cg19486271	chr11:47235900	DDB2	0.62	5.79	0.43	3.91e-8	Bone mineral density (hip);
PAAD	cis	rs375066	0.935	rs398193	chr19:44420420	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	1.08	14.51	0.76	1.71e-30	Headache;
PAAD	cis	rs77880822	0.665	rs74559766	chr20:1209992	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs11624221	0.812	rs8003288	chr14:21125034	C/T	cg00657582	chr14:21904906	CHD8	0.44	4.42	0.34	1.85e-5	Blood protein levels;
PAAD	cis	rs35955747	0.840	rs9621221	chr22:31616169	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-4.78	-0.36	4.09e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.51	4.81	0.36	3.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6929137	0.600	rs7751941	chr6:151946658	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.56	-4.78	-0.36	4.14e-6	Bone mineral density (spine);
PAAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.55	5.98	0.44	1.52e-8	Post bronchodilator FEV1;
PAAD	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg09127314	chr1:152161683	NA	-0.61	-4.26	-0.33	3.53e-5	Atopic dermatitis;
PAAD	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg11367502	chr7:22862612	TOMM7	0.52	5.07	0.38	1.14e-6	Fibrinogen;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8067354	0.574	rs1295923	chr17:57960436	A/G	cg02344993	chr17:57696989	CLTC	0.55	4.42	0.34	1.91e-5	Hemoglobin concentration;
PAAD	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.45	7.39	0.51	9.01e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.69	5.74	0.42	4.93e-8	Common traits (Other);
PAAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg17401720	chr7:158221031	PTPRN2	0.48	5.1	0.38	9.79e-7	Obesity-related traits;
PAAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg15017067	chr4:17643749	FAM184B	0.44	5.19	0.39	6.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.29	-0.33	3.21e-5	Total body bone mineral density;
PAAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-15.15	-0.78	3.42e-32	Height;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.76	-7.92	-0.54	4.78e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg05555928	chr11:63887634	MACROD1	-0.57	-5.52	-0.41	1.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg00450029	chr8:599525	NA	0.76	5.0	0.38	1.55e-6	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg24154853	chr7:158122151	PTPRN2	0.79	7.37	0.51	1.03e-11	Response to amphetamines;
PAAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.52	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.74	8.25	0.56	7.09e-14	Colorectal cancer;
PAAD	cis	rs4740619	0.689	rs1410446	chr9:15927795	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.44	-0.34	1.72e-5	Body mass index;
PAAD	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg26205652	chr12:48591994	NA	0.96	9.64	0.62	1.86e-17	Longevity (90 years and older);
PAAD	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.53	5.17	0.39	7.41e-7	Squamous cell lung carcinoma;
PAAD	cis	rs9581857	0.547	rs7989917	chr13:28071271	G/A	cg22138327	chr13:27999177	GTF3A	0.79	5.45	0.4	2.03e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs1799810	0.523	rs11683986	chr2:128196398	A/G	cg11380483	chr2:127933992	NA	-0.45	-4.3	-0.33	2.99e-5	Self-rated health;
PAAD	cis	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg08172304	chr8:145620073	CPSF1;MIR939	-0.61	-6.37	-0.46	2.09e-9	Alcohol dependence;
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.68	6.65	0.47	4.95e-10	Prostate cancer;
PAAD	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.36	-0.33	2.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	6.36	0.46	2.29e-9	Retinal vascular caliber;
PAAD	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.64	-0.53	2.21e-12	Hemoglobin concentration;
PAAD	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.74	0.36	4.82e-6	Height;
PAAD	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	6.98	0.49	8.47e-11	Educational attainment;
PAAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.77	-8.7	-0.58	5.06e-15	Height;
PAAD	cis	rs34845616	0.520	rs1793680	chr11:133798762	C/T	cg18057887	chr11:133800913	IGSF9B	0.53	5.44	0.4	2.11e-7	Hand grip strength;
PAAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.54	5.35	0.4	3.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62408225	1.000	rs2021716	chr6:90941289	C/T	cg24360137	chr6:90598826	NA	-0.42	-4.25	-0.33	3.76e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.92	-0.49	1.21e-10	Triglycerides;
PAAD	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.43e-9	Fuchs's corneal dystrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22501899	chr17:41133082	AARSD1;RUNDC1	0.6	6.58	0.47	7.21e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg10729496	chr3:10149963	C3orf24	0.77	6.31	0.46	2.83e-9	Alzheimer's disease;
PAAD	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs11807834	0.505	rs7537621	chr1:230236401	C/T	cg00566187	chr1:230250356	GALNT2	-0.61	-6.49	-0.47	1.13e-9	Schizophrenia;
PAAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg02734326	chr4:10020555	SLC2A9	0.44	4.55	0.35	1.1e-5	Bone mineral density;
PAAD	cis	rs1190596	0.558	rs7154553	chr14:102686183	A/G	cg23904247	chr14:102554826	HSP90AA1	0.42	4.81	0.36	3.53e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2061333	0.500	rs2284980	chr19:44633474	T/C	cg20607764	chr19:44506953	ZNF230	-0.8	-5.53	-0.41	1.36e-7	Alzheimer's disease;
PAAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg21823605	chr1:152486609	CRCT1	0.49	6.14	0.45	6.82e-9	Hair morphology;
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg12288994	chr5:1860383	NA	0.75	9.68	0.62	1.48e-17	Cardiovascular disease risk factors;
PAAD	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg24110177	chr3:50126178	RBM5	0.6	4.62	0.35	8.25e-6	Menarche (age at onset);
PAAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.72	-7.01	-0.49	7.27e-11	Urate levels in lean individuals;
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06028808	chr11:68637592	NA	-0.49	-6.0	-0.44	1.42e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg12285409	chr2:9614722	IAH1	0.86	6.38	0.46	2.03e-9	Lung function (FEV1/FVC);
PAAD	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg11874272	chr3:121773564	CD86	-0.42	-4.41	-0.34	1.97e-5	Multiple sclerosis;
PAAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs17155006	0.664	rs402113	chr7:107743664	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-7.15	-0.5	3.38e-11	Pneumococcal bacteremia;
PAAD	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg18764771	chr6:116381957	FRK	0.4	7.01	0.49	7.26e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg15117754	chr3:10150083	C3orf24	0.75	6.21	0.45	4.89e-9	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg23708337	chr7:1209742	NA	0.62	4.39	0.34	2.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20893717	chr7:100318190	EPO	0.43	4.73	0.36	4.99e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.86	-9.1	-0.59	4.87e-16	Body mass index;
PAAD	cis	rs7508679	0.769	rs12610987	chr19:7219697	T/C	cg00428638	chr19:7224713	INSR	0.59	6.15	0.45	6.5e-9	Hypothyroidism;
PAAD	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg03732007	chr1:2071316	PRKCZ	0.45	4.26	0.33	3.59e-5	Height;
PAAD	cis	rs1109501	0.734	rs28881884	chr4:71415627	T/C	cg25553522	chr4:71388589	AMTN	0.53	4.51	0.34	1.29e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg01059385	chr22:42394853	WBP2NL	-0.46	-4.97	-0.37	1.79e-6	Cognitive function;
PAAD	cis	rs1075265	0.730	rs2111868	chr2:54186053	A/G	cg04546899	chr2:54196757	PSME4	0.33	5.03	0.38	1.34e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg05341575	chr12:125625032	AACS	-0.47	-4.27	-0.33	3.42e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8044476	0.945	rs12922589	chr16:72789604	C/T	cg00207534	chr16:71929512	KIAA0174	0.68	4.68	0.35	6.41e-6	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg19761014	chr17:28927070	LRRC37B2	0.94	6.43	0.46	1.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.86	9.28	0.6	1.62e-16	Total body bone mineral density;
PAAD	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.15	-0.39	8.06e-7	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg01868782	chr6:126071099	HEY2	0.38	4.38	0.33	2.19e-5	Brugada syndrome;
PAAD	cis	rs10915437	0.566	rs9426494	chr1:4206288	C/T	cg27165836	chr1:4193882	NA	-0.47	-4.84	-0.37	3.2e-6	Migraine - clinic-based;
PAAD	cis	rs2004318	1.000	rs78389389	chr19:55071704	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.1	-0.44	8.24e-9	Blood protein levels;
PAAD	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.71	-8.59	-0.57	9.92e-15	Body mass index;
PAAD	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2908197	1.000	rs2908197	chr7:75937049	C/T	cg22830091	chr7:75961684	YWHAG	0.59	6.65	0.47	4.86e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.81	-11.5	-0.68	2.03e-22	Colorectal cancer;
PAAD	cis	rs1572438	0.931	rs9406099	chr6:867030	A/G	cg21062780	chr6:887772	NA	-0.49	-5.16	-0.39	7.76e-7	Aging;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.56	-5.4	-0.4	2.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.35	0.6	1.05e-16	Response to antipsychotic treatment;
PAAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.64	-6.68	-0.48	4.23e-10	Body mass index;
PAAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg06740227	chr12:86229804	RASSF9	0.5	4.94	0.37	2.07e-6	Major depressive disorder;
PAAD	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.93	-8.6	-0.57	9.38e-15	Asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25978090	chr4:2011084	WHSC2	0.58	7.1	0.5	4.52e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg14196790	chr5:131705035	SLC22A5	0.57	6.54	0.47	9e-10	Blood metabolite levels;
PAAD	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.67	7.11	0.5	4.15e-11	Triglyceride levels;
PAAD	cis	rs1075232	0.826	rs12438813	chr15:31705913	C/T	cg01030201	chr15:31746330	NA	-1.09	-4.47	-0.34	1.54e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs4679121	0.643	rs76799318	chr3:126146169	T/C	cg05485589	chr3:126194908	ZXDC	-0.99	-4.77	-0.36	4.26e-6	Pursuit maintenance gain;
PAAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.79	-9.05	-0.59	6.3e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs427941	0.632	rs201469	chr7:101743932	C/G	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.77	-6.46	-0.46	1.34e-9	Coronary artery disease;
PAAD	cis	rs608114	0.623	rs17720183	chr6:96355879	T/C	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.59	-5.41	-0.4	2.4e-7	Obesity-related traits;
PAAD	cis	rs9287719	0.649	rs6730247	chr2:10725888	G/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs6906287	0.647	rs28655926	chr6:118688962	A/G	cg21191810	chr6:118973309	C6orf204	0.43	5.49	0.41	1.63e-7	Electrocardiographic conduction measures;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	7.28	0.51	1.65e-11	Lung function (FEV1/FVC);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09086037	chr5:14488255	TRIO	0.56	6.98	0.49	8.64e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.85	0.37	3.07e-6	Longevity;
PAAD	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.3	0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg21351543	chr2:191399470	TMEM194B	-0.57	-4.39	-0.34	2.12e-5	Diastolic blood pressure;
PAAD	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-7.07	-0.5	5.21e-11	Mood instability;
PAAD	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.79	6.72	0.48	3.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs58653258	0.554	rs2488211	chr1:234974238	T/C	cg03518729	chr1:235147744	NA	0.46	4.36	0.33	2.37e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-1.12	-14.71	-0.77	4.92e-31	Migraine;
PAAD	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg14008862	chr17:28927542	LRRC37B2	0.87	6.27	0.45	3.59e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg10856724	chr12:34555212	NA	-0.43	-4.53	-0.35	1.17e-5	Morning vs. evening chronotype;
PAAD	cis	rs12776158	0.901	rs35355528	chr10:71216268	A/G	cg12610070	chr10:71211762	TSPAN15	-0.51	-5.0	-0.38	1.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	6.14	0.45	6.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9463078	0.585	rs1285013	chr6:45165208	C/A	cg25276700	chr6:44698697	NA	0.46	5.3	0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg08601574	chr20:25228251	PYGB	0.52	5.18	0.39	6.96e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg13225830	chr1:9527173	NA	0.37	4.3	0.33	3.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.83	9.14	0.6	3.73e-16	Prostate cancer;
PAAD	cis	rs4742903	0.935	rs1413341	chr9:106973013	C/T	cg14250997	chr9:106856677	SMC2	0.44	4.68	0.36	6.19e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.26	-0.39	4.81e-7	P wave terminal force;
PAAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.58	6.65	0.47	5.1e-10	Blood metabolite levels;
PAAD	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	1.12	14.94	0.77	1.27e-31	Total cholesterol levels;
PAAD	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	5.45	0.4	1.97e-7	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg00791764	chr4:53727839	RASL11B	0.53	4.56	0.35	1.06e-5	Optic nerve measurement (cup area);
PAAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg16083429	chr3:49237500	CCDC36	-0.42	-4.45	-0.34	1.64e-5	Parkinson's disease;
PAAD	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.47	-4.45	-0.34	1.62e-5	Breast cancer;
PAAD	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.42	-6.38	-0.46	2.03e-9	Subjective well-being;
PAAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg14703610	chr5:56206110	C5orf35	-0.55	-5.03	-0.38	1.38e-6	Initial pursuit acceleration;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg11494091	chr17:61959527	GH2	0.84	9.94	0.63	2.95e-18	Prudent dietary pattern;
PAAD	trans	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.3	-0.46	3.05e-9	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.56	0.47	8.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg06392426	chr19:10676186	KRI1	0.71	6.87	0.49	1.54e-10	Red cell distribution width;
PAAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg23346134	chr3:49453900	TCTA	0.44	4.38	0.34	2.17e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs17162190	0.698	rs4970466	chr1:26849312	G/A	cg17456097	chr1:26900765	RPS6KA1	0.6	5.02	0.38	1.41e-6	Mean corpuscular volume;
PAAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg21951975	chr1:209979733	IRF6	0.6	5.46	0.41	1.87e-7	Coronary artery disease;
PAAD	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.83	-0.43	3.16e-8	Life satisfaction;
PAAD	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	3.98e-27	Heart rate;
PAAD	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg20003494	chr4:90757398	SNCA	-0.45	-4.86	-0.37	2.88e-6	Dementia with Lewy bodies;
PAAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.77	9.51	0.61	4.13e-17	Bone mineral density;
PAAD	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.58	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg12568669	chr8:11666485	FDFT1	0.31	5.21	0.39	6.03e-7	Monocyte count;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg00945038	chr17:61921165	SMARCD2	0.43	4.95	0.37	1.98e-6	Prudent dietary pattern;
PAAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.3	0.64	3.31e-19	Total body bone mineral density;
PAAD	cis	rs7092929	0.882	rs645838	chr10:3560515	A/G	cg14308648	chr10:3568949	NA	0.7	5.05	0.38	1.26e-6	Coronary artery calcification;
PAAD	cis	rs733175	0.855	rs10006397	chr4:10036140	C/A	cg11266682	chr4:10021025	SLC2A9	0.55	4.73	0.36	4.99e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.67	6.9	0.49	1.32e-10	Response to antidepressants and depression;
PAAD	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.56	5.68	0.42	6.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg03910582	chr17:19030146	GRAPL	-0.49	-4.83	-0.37	3.24e-6	Schizophrenia;
PAAD	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9913156	0.748	rs7213896	chr17:4562082	G/A	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs3857067	0.901	rs4693368	chr4:95046907	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.66	-0.35	6.75e-6	QT interval;
PAAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.95	0.54	3.92e-13	Parkinson's disease;
PAAD	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs6142102	1.000	rs4911409	chr20:32710710	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.29	0.33	3.22e-5	Skin pigmentation;
PAAD	cis	rs4751058	0.526	rs10829563	chr10:130859036	A/G	cg27413539	chr10:131576096	NA	-0.58	-5.75	-0.42	4.8e-8	Vitamin D levels;
PAAD	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.75	-7.66	-0.53	2e-12	Prostate cancer;
PAAD	cis	rs151997	0.538	rs62367392	chr5:50270298	T/C	cg06027927	chr5:50259733	NA	0.73	6.41	0.46	1.73e-9	Callous-unemotional behaviour;
PAAD	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	11.14	0.67	1.89e-21	Smoking behavior;
PAAD	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.51	-5.06	-0.38	1.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2415984	0.538	rs4595715	chr14:46967541	C/T	cg14871534	chr14:47121158	RPL10L	-0.49	-5.09	-0.38	1.05e-6	Number of children ever born;
PAAD	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.28	-0.56	5.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg06375148	chr1:209958343	C1orf74	0.65	4.85	0.37	3.02e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.56	5.02	0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6800768	0.663	rs7428009	chr3:24094151	A/C	cg10674438	chr3:24145617	LOC152024	-0.47	-4.38	-0.33	2.24e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.59	-0.41	1.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.43	0.4	2.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72960926	0.744	rs72964239	chr6:74874498	C/A	cg03266952	chr6:74778945	NA	-1.17	-7.07	-0.5	5.29e-11	Metabolite levels (MHPG);
PAAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.67	6.13	0.45	7.27e-9	Tuberculosis;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.84	-6.76	-0.48	2.74e-10	Putamen volume;
PAAD	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg02297831	chr4:17616191	MED28	0.6	5.71	0.42	5.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10885582	0.967	rs11196790	chr10:116330497	G/A	cg17056676	chr10:116301354	ABLIM1	-0.36	-4.84	-0.37	3.16e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.97	0.37	1.79e-6	Height;
PAAD	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.44	-5.91	-0.43	2.19e-8	White blood cell count;
PAAD	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg15226275	chr6:116381976	FRK	0.3	5.49	0.41	1.65e-7	Total cholesterol levels;
PAAD	cis	rs10915437	1.000	rs10915437	chr1:4183006	A/G	cg27165836	chr1:4193882	NA	0.45	4.52	0.34	1.24e-5	Migraine - clinic-based;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.24	0.39	5.38e-7	Lung cancer in ever smokers;
PAAD	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.7	5.99	0.44	1.46e-8	Inflammatory skin disease;
PAAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.45	-0.46	1.44e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs738144	0.542	rs5757273	chr22:39157394	G/C	cg06022373	chr22:39101656	GTPBP1	-0.76	-4.48	-0.34	1.45e-5	IgG glycosylation;
PAAD	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs12614435	0.510	rs746578	chr2:179605180	C/T	cg26153162	chr2:179751100	CCDC141	0.48	4.29	0.33	3.22e-5	Atrial fibrillation;
PAAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.82	-5.83	-0.43	3.19e-8	Yeast infection;
PAAD	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.3	7.99	0.54	3.17e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7792596	0.539	rs34680645	chr7:94005301	T/C	cg20814616	chr7:94014465	NA	-0.57	-4.25	-0.33	3.76e-5	Intelligence;
PAAD	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06634786	chr22:41940651	POLR3H	0.68	4.99	0.38	1.65e-6	Vitiligo;
PAAD	cis	rs7896691	0.925	rs6602024	chr10:3155237	A/G	cg15228268	chr10:3146741	PFKP	-0.72	-4.67	-0.35	6.64e-6	Disc degeneration (lumbar);
PAAD	cis	rs1878047	0.665	rs12972888	chr19:51775714	C/G	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg16701003	chr16:89028210	CBFA2T3	0.56	5.65	0.42	7.79e-8	Social autistic-like traits;
PAAD	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.48	4.7	0.36	5.73e-6	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-0.64	-4.79	-0.36	3.97e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg18490616	chr2:88469792	THNSL2	-0.45	-4.34	-0.33	2.57e-5	Response to metformin (IC50);
PAAD	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs941873	0.904	rs4980067	chr10:81136129	C/A	cg11057378	chr10:81107060	PPIF	0.48	5.59	0.41	1.02e-7	Height;
PAAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs11657217	0.677	rs8067469	chr17:77698322	G/A	cg06901238	chr17:77706717	ENPP7	0.67	7.2	0.5	2.62e-11	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.58	6.39	0.46	1.93e-9	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg20893579	chr22:38215064	NA	0.48	4.76	0.36	4.48e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.51	-0.47	1.04e-9	Plateletcrit;Platelet count;
PAAD	cis	rs8070740	0.898	rs4239056	chr17:5324406	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.75	0.36	4.6e-6	Menopause (age at onset);
PAAD	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.49	-5.02	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg00666640	chr1:248458726	OR2T12	0.61	4.82	0.36	3.46e-6	Common traits (Other);
PAAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-5.33	-0.4	3.56e-7	Gut microbiome composition (summer);
PAAD	cis	rs655641	0.539	rs867611	chr11:85776544	G/A	cg07180834	chr11:85838833	NA	-0.46	-4.91	-0.37	2.35e-6	Platelet count;
PAAD	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	1.03	7.44	0.52	6.76e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6715793	0.839	rs4670778	chr2:33402015	C/T	cg26672287	chr2:33391915	LTBP1	-0.45	-5.22	-0.39	5.71e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg20933634	chr6:27740509	NA	0.63	4.74	0.36	4.87e-6	Parkinson's disease;
PAAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4740619	0.619	rs943788	chr9:16031886	G/A	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.64	6.56	0.47	8.16e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.49	-4.46	-0.34	1.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.01	-0.49	7.33e-11	Life satisfaction;
PAAD	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg01868782	chr6:126071099	HEY2	0.44	5.18	0.39	7.07e-7	Brugada syndrome;
PAAD	cis	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07240877	chr1:238649445	LOC339535	0.45	4.43	0.34	1.78e-5	Pancreatic cancer;
PAAD	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg12205435	chr5:138714322	SLC23A1	0.54	4.88	0.37	2.69e-6	Esophageal squamous cell carcinoma;
PAAD	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.72	7.44	0.52	6.96e-12	Body mass index;
PAAD	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.74e-9	Coffee consumption (cups per day);
PAAD	cis	rs714515	0.586	rs5029889	chr1:172451591	T/C	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.43	-0.46	1.6e-9	Morning vs. evening chronotype;
PAAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg23033748	chr14:75592666	NEK9	0.41	4.99	0.37	1.67e-6	Height;
PAAD	cis	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.11	-0.63	1.1e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3787159	0.547	rs511145	chr20:56903898	A/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.1e-5	Systolic blood pressure;
PAAD	cis	rs113123495	0.609	rs2436499	chr19:5638054	C/T	cg26242866	chr19:5711310	LONP1	-1.07	-5.27	-0.39	4.67e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.5	-5.35	-0.4	3.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.75	-0.74	1.84e-28	Primary sclerosing cholangitis;
PAAD	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.18	0.6	2.96e-16	Hemoglobin concentration;
PAAD	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs5756391	0.568	rs2280976	chr22:37318426	C/T	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3126085	0.560	rs1858485	chr1:152334530	A/G	cg26876637	chr1:152193138	HRNR	-0.68	-5.15	-0.39	8.05e-7	Atopic dermatitis;
PAAD	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.54	4.48	0.34	1.44e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg18944383	chr4:111397179	ENPEP	0.65	7.57	0.52	3.39e-12	Coronary artery disease;
PAAD	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg13870426	chr17:30244630	NA	-0.72	-5.03	-0.38	1.36e-6	Height;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.78	5.87	0.43	2.69e-8	Alzheimer's disease;
PAAD	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg15654264	chr1:150340011	RPRD2	0.53	5.1	0.38	1.02e-6	Migraine;
PAAD	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.14	-14.33	-0.76	5.25e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-4.53	-0.34	1.21e-5	Vitiligo;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.08	-19.24	-0.84	1.44e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35955747	0.902	rs7287402	chr22:31654823	A/G	cg02404636	chr22:31891804	SFI1	0.49	4.94	0.37	2.03e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.47	-4.5	-0.34	1.35e-5	Mean platelet volume;
PAAD	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.79	9.13	0.6	3.94e-16	Morning vs. evening chronotype;
PAAD	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.51e-5	Life satisfaction;
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg27644672	chr7:1858694	MAD1L1	-0.42	-4.59	-0.35	9.14e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.54	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.6	6.36	0.46	2.27e-9	Body mass index;
PAAD	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg26318627	chr11:63887540	MACROD1	0.44	4.49	0.34	1.41e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg01942863	chr7:99769432	GPC2	0.5	4.71	0.36	5.57e-6	Coronary artery disease;
PAAD	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg14254433	chr6:34482411	PACSIN1	-0.96	-6.13	-0.44	7.37e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.2	12.33	0.71	1.17e-24	Corneal structure;
PAAD	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs1878047	0.665	rs10425711	chr19:51780434	A/C	cg14884932	chr19:51774451	NA	0.4	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-5.21	-0.39	6.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs11614333	1.000	rs61922971	chr12:15064739	G/A	cg00431549	chr12:15039025	MGP	-0.38	-4.59	-0.35	9.11e-6	Hand grip strength;
PAAD	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.6	-6.28	-0.45	3.43e-9	HDL cholesterol;
PAAD	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg24555670	chr8:18244502	NA	0.54	4.68	0.35	6.35e-6	Blood metabolite levels;
PAAD	cis	rs7561273	0.545	rs12613951	chr2:24361962	G/A	cg04809136	chr2:24300158	SF3B14	0.46	5.22	0.39	5.88e-7	Quantitative traits;
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.45	-0.34	1.65e-5	Tonsillectomy;
PAAD	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.65	7.02	0.49	6.83e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.9	0.69	1.72e-23	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.25	-0.33	3.67e-5	Neuroticism;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.99	8.3	0.56	5.16e-14	Blood trace element (Zn levels);
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.49	4.7	0.36	5.79e-6	Resistin levels;
PAAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17152411	0.817	rs4478950	chr10:126596425	T/C	cg07906193	chr10:126599966	NA	0.53	4.76	0.36	4.48e-6	Height;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15485665	chr17:47677567	SPOP	0.62	6.62	0.47	5.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.76	7.86	0.54	6.7e-13	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg03538708	chr1:25844672	NA	0.53	5.42	0.4	2.32e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.3	-0.39	4.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg03808351	chr9:123631620	PHF19	0.46	4.6	0.35	8.87e-6	Rheumatoid arthritis;
PAAD	cis	rs35955747	0.601	rs7289941	chr22:31884405	C/T	cg02404636	chr22:31891804	SFI1	0.57	5.54	0.41	1.31e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.34	0.4	3.32e-7	Morning vs. evening chronotype;
PAAD	cis	rs950881	0.867	rs56179005	chr2:102974328	G/A	cg03938978	chr2:103052716	IL18RAP	0.54	4.45	0.34	1.63e-5	Allergy;
PAAD	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-0.93	-6.19	-0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.91	5.45	0.4	2.02e-7	Tuberculosis;
PAAD	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs12136530	0.593	rs12121189	chr1:19740421	G/A	cg01468656	chr1:19991678	HTR6	0.5	4.47	0.34	1.54e-5	Lead levels in blood;
PAAD	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg25838465	chr1:92012736	NA	-0.48	-4.72	-0.36	5.35e-6	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10924309	0.737	rs6701023	chr1:245854503	C/G	cg00036263	chr1:245852353	KIF26B	0.64	6.15	0.45	6.7e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.5	-0.34	1.33e-5	Breast cancer;
PAAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.73	7.73	0.53	1.38e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.66	6.38	0.46	2e-9	IgG glycosylation;
PAAD	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.92	7.28	0.51	1.71e-11	Migraine;Coronary artery disease;
PAAD	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.82	-0.43	3.38e-8	Colorectal cancer;
PAAD	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.58	5.63	0.42	8.39e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11558328	chr11:46722331	ARHGAP1;ZNF408	-0.7	-7.37	-0.51	9.98e-12	Lung cancer in ever smokers;
PAAD	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs360071	0.528	rs360093	chr1:226064745	G/T	cg11967457	chr1:226128626	LEFTY2	0.53	5.28	0.39	4.34e-7	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.13	-0.45	7.25e-9	Type 2 diabetes;
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.81	9.44	0.61	6.35e-17	Coronary artery disease;
PAAD	cis	rs4740619	0.530	rs10810524	chr9:16036646	C/T	cg14451791	chr9:16040625	NA	-0.43	-4.94	-0.37	2.06e-6	Body mass index;
PAAD	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.91	9.56	0.61	3.05e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3743832	0.865	rs8044742	chr16:9182253	A/G	cg08831531	chr16:9218945	NA	-0.44	-4.55	-0.35	1.08e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg26924012	chr15:45694286	SPATA5L1	0.49	4.48	0.34	1.49e-5	Uric acid levels;
PAAD	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2455826	0.521	rs2455845	chr3:15768293	T/C	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs5771225	0.563	rs6010220	chr22:50693554	A/G	cg16473166	chr22:50639996	SELO	0.62	5.68	0.42	6.68e-8	Late-onset Alzheimer's disease;
PAAD	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.45	4.45	0.34	1.68e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00981651	chr20:44574847	PCIF1	-0.43	-4.71	-0.36	5.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg21601837	chr3:125900065	ALDH1L1	-0.48	-5.19	-0.39	6.72e-7	Metabolite levels;
PAAD	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.82	-8.9	-0.59	1.59e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.46	-0.34	1.58e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.75	-0.48	2.85e-10	Glomerular filtration rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00814065	chr16:2265398	PGP	0.63	6.41	0.46	1.71e-9	Myopia (pathological);
PAAD	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.46	-5.71	-0.42	5.87e-8	Lewy body disease;
PAAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.91	11.29	0.68	7.49e-22	Aortic root size;
PAAD	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-4.36	-0.33	2.36e-5	Red blood cell count;
PAAD	trans	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08418111	chr11:18433745	LDHC	0.6	6.44	0.46	1.52e-9	Calcium levels;
PAAD	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg23216685	chr1:86174607	ZNHIT6	-0.31	-4.61	-0.35	8.45e-6	Urate levels in overweight individuals;
PAAD	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.64	6.19	0.45	5.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.0	14.2	0.76	1.14e-29	Heart rate;
PAAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.31	0.51	1.38e-11	Obesity-related traits;
PAAD	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.67e-7	Personality dimensions;
PAAD	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg08992911	chr2:238395768	MLPH	0.74	5.66	0.42	7.38e-8	Prostate cancer;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs8105895	0.877	rs2163837	chr19:22242236	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05585630	chr7:157510462	PTPRN2	-0.79	-9.12	-0.59	4.23e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.48	6.38	0.46	2.07e-9	Multiple sclerosis;
PAAD	cis	rs3857067	0.967	rs1509942	chr4:95013440	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg11952622	chr19:58962976	ZNF324B	0.48	4.61	0.35	8.42e-6	Uric acid clearance;
PAAD	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs28498503	0.718	rs73971133	chr18:76652861	G/A	cg16580499	chr18:76739559	SALL3	-0.66	-4.7	-0.36	5.76e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs922182	0.633	rs16947621	chr15:64271660	C/G	cg24729988	chr15:64271149	DAPK2	0.46	4.39	0.34	2.15e-5	Blood protein levels;
PAAD	cis	rs4722166	0.598	rs4722178	chr7:22798650	T/C	cg05472934	chr7:22766657	IL6	0.65	7.69	0.53	1.71e-12	Lung cancer;
PAAD	cis	rs72960926	1.000	rs72958987	chr6:75129721	T/G	cg13435101	chr6:74171350	MTO1	0.93	4.66	0.35	6.93e-6	Metabolite levels (MHPG);
PAAD	cis	rs7246865	0.510	rs1130222	chr19:17170885	C/T	cg19418318	chr19:17219073	MYO9B	0.35	5.01	0.38	1.5e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg01620082	chr3:125678407	NA	-1.49	-8.29	-0.56	5.63e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.62	-4.98	-0.37	1.68e-6	Lung cancer;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg01759136	chr6:27242945	NA	0.41	4.4	0.34	2.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.25	0.33	3.75e-5	Platelet count;
PAAD	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.36	-0.4	2.99e-7	Total body bone mineral density;
PAAD	cis	rs11702148	0.552	rs11701506	chr21:34904352	T/A	cg14850771	chr21:34775459	IFNGR2	0.44	4.56	0.35	1.04e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.27	-0.45	3.6e-9	Bone mineral density;
PAAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.89	-8.67	-0.58	5.95e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg14926445	chr8:58193284	C8orf71	-0.65	-4.55	-0.35	1.11e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg03188948	chr7:1209495	NA	0.51	4.35	0.33	2.44e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg15693483	chr7:1102177	C7orf50	0.39	4.7	0.36	5.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs7260538	0.773	rs2200238	chr19:41527265	G/A	cg13322449	chr19:42300200	CEACAM3	0.4	4.53	0.34	1.19e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.97	0.63	2.5e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.44	-0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs362296	0.530	rs3129316	chr4:3287906	A/G	cg14583973	chr4:3374767	RGS12	0.41	6.24	0.45	4.09e-9	Parental longevity (mother's age at death);
PAAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.52	5.36	0.4	3.02e-7	Menopause (age at onset);
PAAD	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-0.93	-9.16	-0.6	3.37e-16	Exhaled nitric oxide output;
PAAD	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs72960926	1.000	rs72950597	chr6:74921367	T/C	cg03266952	chr6:74778945	NA	-1.1	-6.57	-0.47	7.44e-10	Metabolite levels (MHPG);
PAAD	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.69	-0.42	6.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2916733	0.530	rs2251956	chr8:6288879	A/T	cg01691696	chr8:6734962	DEFB1	-0.55	-4.74	-0.36	4.83e-6	Epirubicin-induced leukopenia;
PAAD	cis	rs6061231	0.654	rs2427322	chr20:60979370	T/C	cg10925829	chr20:60860984	OSBPL2	-0.47	-5.06	-0.38	1.19e-6	Colorectal cancer;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg07527105	chr16:88053339	BANP	-0.42	-4.48	-0.34	1.45e-5	Menopause (age at onset);
PAAD	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg02917321	chr22:38215204	NA	0.49	4.72	0.36	5.24e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.44	-5.58	-0.41	1.08e-7	Lewy body disease;
PAAD	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.73	0.53	1.34e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15434853	chr3:52570586	NT5DC2;LOC440957	-0.6	-7.27	-0.51	1.77e-11	Body fat percentage;
PAAD	cis	rs988913	0.601	rs4715493	chr6:54844974	C/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.73	-0.36	5.01e-6	Menarche (age at onset);
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.46	-4.51	-0.34	1.31e-5	Iron status biomarkers;
PAAD	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.17	0.55	1.13e-13	Schizophrenia;
PAAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg21300403	chr2:198650112	BOLL	-0.64	-4.25	-0.33	3.71e-5	Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20786246	chr2:72377174	NA	0.68	8.69	0.58	5.51e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.9	7.85	0.54	6.93e-13	Alzheimer's disease;
PAAD	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.09	-0.5	4.66e-11	Parkinson's disease;
PAAD	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	4.4	0.34	2.02e-5	Total body bone mineral density;
PAAD	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.79	9.29	0.6	1.55e-16	Total body bone mineral density;
PAAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.01	-0.49	7.19e-11	Gut microbiome composition (summer);
PAAD	cis	rs9907295	0.591	rs3760327	chr17:34163387	C/G	cg19411729	chr17:34207663	CCL5	-0.55	-4.97	-0.37	1.75e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg11380483	chr2:127933992	NA	-0.48	-4.61	-0.35	8.57e-6	Self-rated health;
PAAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	6.82	0.48	1.97e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg23860436	chr12:58378763	NA	0.49	4.67	0.35	6.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.76	7.9	0.54	5.17e-13	Schizophrenia;
PAAD	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.88	-13.3	-0.73	2.9e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06915872	chr16:87998081	BANP	0.46	4.31	0.33	2.87e-5	Menopause (age at onset);
PAAD	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.98	-10.88	-0.66	9.25e-21	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.4	-0.34	2.05e-5	Metabolite levels;
PAAD	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.75	6.7	0.48	3.84e-10	Schizophrenia;
PAAD	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-8.45	-0.57	2.21e-14	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs901683	1.000	rs3764990	chr10:45956828	G/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.47	-0.46	1.3e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.56	-0.61	2.93e-17	Alzheimer's disease (late onset);
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg17541715	chr7:1216824	NA	-0.47	-5.26	-0.39	4.8e-7	Longevity;Endometriosis;
PAAD	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23200970	chr4:111119917	ELOVL6	0.61	7.27	0.51	1.8e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.53	-5.41	-0.4	2.43e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10901513	0.932	rs10901493	chr10:127670411	A/G	cg22975853	chr10:127789788	ADAM12	0.45	4.78	0.36	4.17e-6	Visceral fat;
PAAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.62	5.07	0.38	1.15e-6	Gut microbiome composition (summer);
PAAD	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.75	6.76	0.48	2.72e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1355223	0.533	rs1597960	chr11:34726969	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.44	4.44	0.34	1.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Body mass index;
PAAD	cis	rs6142102	0.961	rs909884	chr20:32646063	G/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-4.72	-0.36	5.24e-6	Schizophrenia;
PAAD	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.78	-0.48	2.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20447079	chr7:50658381	GRB10	-0.58	-6.7	-0.48	3.9e-10	Monocyte percentage of white cells;
PAAD	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.53	6.04	0.44	1.11e-8	Educational attainment;
PAAD	cis	rs1042026	0.813	rs9995799	chr4:100138538	C/A	cg09112717	chr4:100009950	ADH5	-0.56	-4.75	-0.36	4.7e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg19318889	chr4:1322082	MAEA	0.66	6.92	0.49	1.18e-10	Longevity;
PAAD	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs4747197	1.000	rs4747197	chr10:73566203	A/T	cg04506911	chr10:72937119	NA	0.4	4.38	0.33	2.2e-5	Progranulin levels;
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg25070565	chr17:20044324	CYTSB	0.45	4.35	0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg08917208	chr2:24149416	ATAD2B	0.49	4.3	0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.62	5.07	0.38	1.14e-6	Response to antidepressants in depression;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07733620	chr16:9184485	C16orf72	-0.64	-6.3	-0.46	3.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7688540	0.511	rs75433628	chr4:178352	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs8112211	0.834	rs3178327	chr19:38798086	T/C	cg14299480	chr19:38876666	GGN	-0.52	-6.86	-0.49	1.65e-10	Blood protein levels;
PAAD	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg00459043	chr17:30771460	PSMD11	-0.56	-4.62	-0.35	8.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9467603	0.920	rs13213957	chr6:25786226	T/C	cg21479132	chr6:26055353	NA	0.86	4.3	0.33	3.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26926768	chr12:34528122	NA	0.41	4.84	0.37	3.23e-6	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg18621852	chr3:10150065	C3orf24	0.62	5.33	0.4	3.48e-7	Alzheimer's disease;
PAAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.44	4.4	0.34	2.06e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.4	4.35	0.33	2.48e-5	Mean platelet volume;
PAAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.64	-5.73	-0.42	5.33e-8	Personality dimensions;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.67	5.59	0.41	1.04e-7	Alzheimer's disease;
PAAD	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg21994712	chr19:21861136	NA	-0.46	-4.5	-0.34	1.32e-5	Pain;
PAAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	6.48	0.47	1.22e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	1.04	12.73	0.72	1.03e-25	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.84	9.46	0.61	5.64e-17	Ulcerative colitis;
PAAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.71	8.1	0.55	1.64e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.44	4.68	0.35	6.38e-6	Plateletcrit;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.66	6.94	0.49	1.08e-10	Lung cancer;
PAAD	cis	rs8060686	0.920	rs76841123	chr16:67683564	C/G	cg09835421	chr16:68378352	PRMT7	-0.95	-4.88	-0.37	2.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7219021	0.892	rs9913867	chr17:46849602	G/T	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.33	-0.33	2.73e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg18131467	chr2:239335373	ASB1	-0.64	-4.55	-0.35	1.07e-5	Chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23196133	chr17:7388063	ZBTB4;POLR2A	-0.55	-6.47	-0.46	1.26e-9	Body fat percentage;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.66e-5	Life satisfaction;
PAAD	cis	rs7246865	0.510	rs2305756	chr19:17169936	C/T	cg19418318	chr19:17219073	MYO9B	0.37	5.36	0.4	3.05e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.51	8.78	0.58	3.19e-15	IgG glycosylation;
PAAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-5.82	-0.43	3.43e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.48	-0.34	1.49e-5	Obesity (extreme);
PAAD	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07741184	chr6:167504864	NA	-0.35	-4.63	-0.35	7.8e-6	Primary biliary cholangitis;
PAAD	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.39	0.34	2.08e-5	Asthma;
PAAD	cis	rs11264799	0.639	rs12563971	chr1:157755427	C/G	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.42	5.72	0.42	5.53e-8	Schizophrenia;
PAAD	trans	rs1075265	0.620	rs10192626	chr2:53988022	A/G	cg16115072	chr17:25938812	KSR1	0.61	6.62	0.47	5.77e-10	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26571478	chr10:21436607	C10orf113;NEBL	-0.39	-4.52	-0.34	1.22e-5	Monocyte percentage of white cells;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.53e-9	Cognitive function;
PAAD	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.66	6.95	0.49	9.81e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.38e-12	Calcium levels;
PAAD	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-4.27	-0.33	3.42e-5	Total body bone mineral density;
PAAD	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.57	5.83	0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.91	-12.02	-0.7	8.01e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6540	0.744	rs2686874	chr11:259234	G/C	cg20282913	chr11:252683	PSMD13	-1.01	-4.32	-0.33	2.76e-5	Endometriosis;
PAAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.88	9.32	0.6	1.26e-16	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.83	6.68	0.48	4.29e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.08	-15.74	-0.79	9.8e-34	Myeloid white cell count;
PAAD	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.72	4.7	0.36	5.87e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs10512697	0.655	rs2396982	chr5:3504934	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08942682	chr3:197409980	KIAA0226	0.65	7.6	0.52	2.85e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.51	-4.76	-0.36	4.53e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4918918	0.624	rs10786201	chr10:97069543	C/G	cg14101359	chr10:97300930	SORBS1	0.41	4.42	0.34	1.83e-5	Suicide risk;
PAAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25280938	chr7:6543803	GRID2IP	-0.7	-6.75	-0.48	2.9e-10	Lung cancer in ever smokers;
PAAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs4792901	0.765	rs9894264	chr17:41577997	G/A	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	0.51	5.46	0.41	1.88e-7	Hypothyroidism;
PAAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06850241	chr22:41845214	NA	-0.57	-5.18	-0.39	6.82e-7	Vitiligo;
PAAD	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg14952266	chr13:112191215	NA	0.48	5.54	0.41	1.27e-7	Hepatitis;
PAAD	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg06636372	chr16:89349979	ANKRD11	-0.76	-4.8	-0.36	3.84e-6	Red blood cell count;
PAAD	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.7	6.93	0.49	1.15e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.46	-5.06	-0.38	1.2e-6	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.73	-5.84	-0.43	2.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.83	10.44	0.65	1.46e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg25114630	chr15:101792522	CHSY1	-0.6	-5.28	-0.39	4.35e-7	Corneal structure;
PAAD	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.14	0.39	8.19e-7	Height;
PAAD	cis	rs10493340	1.000	rs11583678	chr1:63602535	T/A	cg08634298	chr1:64337861	ROR1	-0.46	-4.5	-0.34	1.33e-5	Blood pressure;
PAAD	cis	rs73058052	0.542	rs10414643	chr19:50097784	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.57	-4.78	-0.36	4.06e-6	Fibrinogen levels;
PAAD	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg11380483	chr2:127933992	NA	-0.47	-4.89	-0.37	2.57e-6	Self-rated health;
PAAD	cis	rs7301016	0.901	rs7975109	chr12:62941643	C/T	cg19781863	chr12:62918364	MON2	0.73	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs8018808	1.000	rs8018808	chr14:77858336	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg01620082	chr3:125678407	NA	-1.51	-9.83	-0.62	6.02e-18	Depression;
PAAD	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg16419906	chr5:132167176	NA	-0.66	-5.26	-0.39	4.87e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs3753841	0.832	rs10782905	chr1:103251295	G/C	cg24495344	chr1:103574097	COL11A1	0.38	4.43	0.34	1.77e-5	Glaucoma (primary angle closure);
PAAD	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.92	11.14	0.67	1.9e-21	Coronary artery disease;
PAAD	cis	rs1419980	0.643	rs75509633	chr12:7768134	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.91	-8.8	-0.58	2.79e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.44	4.67	0.35	6.61e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs89107	1.000	rs283077	chr6:118569679	T/G	cg21191810	chr6:118973309	C6orf204	0.42	5.47	0.41	1.82e-7	Cardiac structure and function;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-1.2	-9.88	-0.63	4.47e-18	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.56	-5.66	-0.42	7.3900000000000007e-08	Childhood ear infection;
PAAD	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.46	5.06	0.38	1.2e-6	Age of smoking initiation;
PAAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg14343924	chr8:8086146	FLJ10661	0.46	4.3	0.33	3.02e-5	Mean corpuscular volume;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg03188948	chr7:1209495	NA	1.02	5.44	0.4	2.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-6.58	-0.47	7.06e-10	Morning vs. evening chronotype;
PAAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.21e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg20821713	chr7:1055600	C7orf50	-0.43	-4.58	-0.35	9.6e-6	Longevity;Endometriosis;
PAAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs7631605	0.846	rs11926768	chr3:36968347	C/T	cg17445812	chr3:36986805	TRANK1	-0.34	-4.52	-0.34	1.24e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.7	7.72	0.53	1.44e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.45	4.73	0.36	5.01e-6	Longevity;
PAAD	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.72	-0.48	3.47e-10	Myopia (pathological);
PAAD	cis	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg27411982	chr8:10470053	RP1L1	-0.5	-5.47	-0.41	1.79e-7	Retinal vascular caliber;
PAAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg17541715	chr7:1216824	NA	-0.44	-4.88	-0.37	2.65e-6	Longevity;Endometriosis;
PAAD	cis	rs939584	1.000	rs2867125	chr2:622827	T/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg25809561	chr17:30822961	MYO1D	0.58	6.01	0.44	1.32e-8	Schizophrenia;
PAAD	cis	rs4919087	0.590	rs1253396	chr10:99045230	C/T	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.57	-6.47	-0.46	1.29e-9	Prostate cancer;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-5.28	-0.39	4.3e-7	Longevity;Endometriosis;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.41	4.66	0.35	6.99e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.44	-6.64	-0.47	5.34e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.8	-0.53	8.95e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg04165759	chr1:150448943	RPRD2	-0.53	-5.6	-0.41	9.74e-8	Migraine;
PAAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg07153921	chr17:41440717	NA	-0.41	-4.31	-0.33	2.9e-5	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15081119	chr11:44971888	TP53I11	-0.77	-6.69	-0.48	3.97e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.51e-7	Life satisfaction;
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13732083	chr21:47605072	C21orf56	0.45	4.4	0.34	2.02e-5	Testicular germ cell tumor;
PAAD	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.93	-9.12	-0.59	4.25e-16	Exhaled nitric oxide output;
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.66	6.63	0.47	5.58e-10	Schizophrenia;
PAAD	cis	rs950037	0.686	rs444329	chr1:89234909	A/G	cg13109106	chr1:89333529	GTF2B	-0.47	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.72	-8.22	-0.55	8.5e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.57	5.87	0.43	2.66e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.73	-8.12	-0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.77	-0.36	4.2e-6	Colorectal cancer;
PAAD	cis	rs6066835	1.000	rs6066828	chr20:47344233	C/T	cg18078177	chr20:47281410	PREX1	0.97	4.87	0.37	2.82e-6	Multiple myeloma;
PAAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.7	-5.84	-0.43	3.04e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23281280	chr6:28129359	ZNF389	0.59	4.56	0.35	1.05e-5	Parkinson's disease;
PAAD	cis	rs375066	0.934	rs454813	chr19:44408973	A/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.84e-19	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.73	7.22	0.51	2.34e-11	Prudent dietary pattern;
PAAD	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg02344993	chr17:57696989	CLTC	0.62	5.2	0.39	6.47e-7	Hemoglobin concentration;
PAAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg19630374	chr17:18023558	MYO15A	-0.49	-5.18	-0.39	6.81e-7	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs59065735	chr3:128595566	C/T	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.18	0.45	5.7e-9	Hip circumference;
PAAD	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs10186876	0.542	rs6736282	chr2:44204717	A/G	cg09541576	chr2:44873248	C2orf34	0.43	4.48	0.34	1.48e-5	Hand grip strength;
PAAD	cis	rs3736485	0.934	rs28695624	chr15:51874928	A/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	8.23e-8	Blood metabolite levels;
PAAD	cis	rs2171564	0.537	rs9815847	chr3:112439054	G/A	cg18194305	chr3:113160637	WDR52	0.45	4.41	0.34	1.97e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs11264213	0.901	rs72661607	chr1:36331411	G/C	cg27506609	chr1:36549197	TEKT2	1.05	5.67	0.42	7e-8	Schizophrenia;
PAAD	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.86	8.66	0.57	6.54e-15	Uric acid levels;
PAAD	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.65	4.44	0.34	1.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.17	-0.45	5.96e-9	Schizophrenia;
PAAD	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.82	7.39	0.51	9.21e-12	Coronary artery disease;
PAAD	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs5769765	0.624	rs138843	chr22:50183162	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-4.91	-0.37	2.32e-6	Schizophrenia;
PAAD	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg23254163	chr1:152506842	NA	0.57	6.7	0.48	3.88e-10	Hair morphology;
PAAD	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs3106136	0.609	rs11097406	chr4:95146042	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.1	-0.44	8.32e-9	Capecitabine sensitivity;
PAAD	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.65	0.35	7.08e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.33	10.95	0.66	6.13e-21	Uric acid levels;
PAAD	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg07617317	chr6:118971624	C6orf204	0.52	4.37	0.33	2.31e-5	Renal cell carcinoma;
PAAD	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg04289385	chr6:36355825	ETV7	0.44	4.39	0.34	2.11e-5	Platelet distribution width;
PAAD	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg21775007	chr8:11205619	TDH	-0.58	-4.96	-0.37	1.9e-6	Neuroticism;
PAAD	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg21366198	chr4:185655624	MLF1IP	-0.5	-4.29	-0.33	3.17e-5	Kawasaki disease;
PAAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.83	-9.32	-0.6	1.3e-16	Caffeine consumption;
PAAD	cis	rs1419980	0.730	rs11561260	chr12:7739955	T/C	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.68	4.91	0.37	2.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.67	5.02	0.38	1.46e-6	Optic nerve measurement (cup area);
PAAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg24733560	chr20:60626293	TAF4	0.53	6.72	0.48	3.51e-10	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22105103	chr4:187893119	NA	0.6	6.45	0.46	1.38e-9	Smoking initiation;
PAAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs802075	0.764	rs13202956	chr6:49652613	C/T	cg20364632	chr6:49636226	NA	-0.54	-6.5	-0.47	1.08e-9	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	1.1	12.37	0.71	9.19e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.51	4.71	0.36	5.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.5	4.72	0.36	5.2e-6	Type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.35	16.96	0.81	7.15e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01990328	chr17:74675799	MXRA7	0.58	6.29	0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs6519955	0.722	rs7511186	chr22:46436973	T/A	cg05468064	chr22:46423449	NA	0.51	7.02	0.49	6.91e-11	Dupuytren's disease;
PAAD	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.51	-5.06	-0.38	1.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.46	5.59	0.41	1e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6137287	0.889	rs6047285	chr20:21150895	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg12615879	chr12:58013172	SLC26A10	-0.39	-4.36	-0.33	2.4e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.65	0.35	7.13e-6	Self-reported allergy;
PAAD	cis	rs73058052	0.597	rs10404887	chr19:50096421	C/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.59	-5.09	-0.38	1.04e-6	Fibrinogen levels;
PAAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.97	13.81	0.75	1.27e-28	Rheumatoid arthritis;
PAAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.36	-0.4	3.04e-7	Aortic root size;
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	5.11e-15	Menopause (age at onset);
PAAD	cis	rs11615916	0.790	rs73135269	chr12:62677397	G/A	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs9810890	1.000	rs73198886	chr3:128546420	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.05	-0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg11802864	chr11:65308245	LTBP3	1.35	6.76	0.48	2.76e-10	Height;
PAAD	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-7.63	-0.53	2.45e-12	Coronary artery disease;
PAAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.62	6.57	0.47	7.46e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.08	0.63	1.27e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22162314	chr17:61951766	CSH2	-0.61	-6.25	-0.45	4.03e-9	Height;
PAAD	cis	rs9395066	0.545	rs12209076	chr6:44833423	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs17095355	0.818	rs928213	chr10:111856224	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.73	-0.36	5.04e-6	Biliary atresia;
PAAD	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg05085585	chr16:30420623	ZNF771	-0.44	-4.46	-0.34	1.59e-5	Tonsillectomy;
PAAD	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.65	-6.97	-0.49	9.13e-11	Brugada syndrome;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs3813948	0.543	rs2808466	chr1:207273751	T/C	cg26044340	chr1:207277291	C4BPA	-0.76	-4.91	-0.37	2.33e-6	C4b binding protein levels;
PAAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.39	-0.34	2.15e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11129295	0.618	rs4680861	chr3:27812802	T/C	cg21473142	chr3:27762095	EOMES	0.27	4.49	0.34	1.4e-5	Multiple sclerosis;
PAAD	cis	rs7786877	0.545	rs73156234	chr7:100234744	C/T	cg16850897	chr7:100343110	ZAN	-0.62	-5.1	-0.38	1.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6887276	0.504	rs17764688	chr5:127346879	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.48	-4.94	-0.37	2.02e-6	Height;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.54	5.96	0.44	1.71e-8	Testicular germ cell tumor;
PAAD	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.78	-8.72	-0.58	4.52e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.19	-10.34	-0.64	2.55e-19	Post bronchodilator FEV1;
PAAD	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.84	-8.26	-0.56	6.53e-14	Body mass index;
PAAD	cis	rs2236521	0.632	rs35265388	chr20:60894278	C/T	cg03199926	chr20:60860733	OSBPL2	-0.42	-5.22	-0.39	5.69e-7	Pelvic organ prolapse;
PAAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.64	-6.13	-0.44	7.41e-9	Coronary artery disease;
PAAD	cis	rs35740288	0.822	rs11629690	chr15:86287724	G/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.76	-0.36	4.55e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg02475695	chr16:616220	NHLRC4	0.45	5.2	0.39	6.25e-7	Height;
PAAD	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.09	-0.5	4.77e-11	Menarche (age at onset);
PAAD	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.75	-6.48	-0.47	1.23e-9	Diastolic blood pressure;
PAAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21545522	chr1:205238299	TMCC2	0.48	4.38	0.33	2.17e-5	Red blood cell count;
PAAD	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg25809561	chr17:30822961	MYO1D	0.45	4.64	0.35	7.31e-6	Schizophrenia;
PAAD	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.56	-4.51	-0.34	1.29e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.74	-0.42	5.03e-8	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg26497354	chr6:109612229	NA	0.45	4.77	0.36	4.35e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg11663144	chr21:46675770	NA	-0.48	-5.95	-0.43	1.74e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg06697600	chr4:7070879	GRPEL1	0.95	5.86	0.43	2.74e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	0.98	6.9	0.49	1.29e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.71	-0.42	5.71e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.65	9.24	0.6	2.06e-16	Height;
PAAD	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.97	10.45	0.65	1.3e-19	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-5.41	-0.4	2.43e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.38	-4.3	-0.33	3.01e-5	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.49e-7	Life satisfaction;
PAAD	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.56	4.96	0.37	1.84e-6	Testicular germ cell tumor;
PAAD	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.02	-0.38	1.42e-6	Blood metabolite levels;
PAAD	cis	rs4073221	0.615	rs34648851	chr3:18234610	T/C	cg07694806	chr3:18168406	NA	-0.61	-4.4	-0.34	2e-5	Parkinson's disease;
PAAD	cis	rs6028335	0.877	rs66519365	chr20:37777053	A/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.37	-0.33	2.29e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.68	-6.1	-0.44	8.24e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg26248373	chr2:1572462	NA	-1.08	-7.53	-0.52	4.23e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg04719120	chr6:96025338	MANEA	0.53	4.37	0.33	2.33e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs3905000	1.000	rs2417565	chr9:107648458	G/A	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.56	-5.01	-0.38	1.48e-6	Lymphocyte counts;
PAAD	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs7300001	0.596	rs11064924	chr12:110510301	G/T	cg12870014	chr12:110450643	ANKRD13A	0.85	5.06	0.38	1.22e-6	Headache;
PAAD	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-1.07	-9.62	-0.62	2.05e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg16342193	chr10:102329863	NA	-0.77	-8.41	-0.56	2.7e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14631997	chr9:72128717	APBA1	0.61	6.86	0.49	1.61e-10	Smoking initiation;
PAAD	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg19767477	chr5:127420684	SLC12A2	0.56	4.49	0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs425535	0.653	rs416176	chr4:74826269	G/T	cg01447579	chr4:74847100	PF4	0.67	4.25	0.33	3.75e-5	Blood protein levels;
PAAD	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg14581129	chr12:53358946	NA	-1.2	-7.37	-0.51	1e-11	Prostate cancer;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg19268477	chr7:157951471	PTPRN2	0.43	4.29	0.33	3.11e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.61	-6.57	-0.47	7.48e-10	HDL cholesterol;
PAAD	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.78	10.39	0.64	1.9e-19	Coronary artery disease;
PAAD	cis	rs1878047	0.665	rs2898694	chr19:51779687	T/G	cg14884932	chr19:51774451	NA	-0.4	-4.34	-0.33	2.64e-5	Body mass index;
PAAD	cis	rs868943	0.554	rs34362666	chr6:116472705	C/T	cg18764771	chr6:116381957	FRK	0.27	4.42	0.34	1.89e-5	Total cholesterol levels;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg02696790	chr15:75250997	RPP25	0.37	4.29	0.33	3.11e-5	Breast cancer;
PAAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	1.1	13.8	0.75	1.36e-28	Breast cancer;
PAAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.64	0.47	5.12e-10	Schizophrenia;
PAAD	cis	rs13424612	0.930	rs6748327	chr2:240902511	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.95	-0.37	1.99e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.88	0.49	1.5e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs73198271	0.515	rs76653757	chr8:8624901	C/A	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg15017067	chr4:17643749	FAM184B	0.44	4.86	0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.54	-5.24	-0.39	5.39e-7	Schizophrenia;
PAAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.47	-5.19	-0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs1413885	0.548	rs6588136	chr1:65837119	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.53	0.41	1.38e-7	Anticoagulant levels;
PAAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.49	0.52	5.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg18833306	chr6:118973337	C6orf204	-0.55	-4.63	-0.35	7.94e-6	Diastolic blood pressure;
PAAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	6.01	0.44	1.31e-8	Initial pursuit acceleration;
PAAD	trans	rs901683	1.000	rs17157887	chr10:46020348	G/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg10932868	chr11:921992	NA	0.48	5.68	0.42	6.58e-8	Alzheimer's disease (late onset);
PAAD	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-7.14	-0.5	3.64e-11	Colorectal cancer;
PAAD	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.48	-4.46	-0.34	1.6e-5	HDL cholesterol;
PAAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg20003494	chr4:90757398	SNCA	-0.68	-6.43	-0.46	1.54e-9	Neuroticism;
PAAD	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-6.33	-0.46	2.6e-9	Blood metabolite levels;
PAAD	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	5.82	0.43	3.39e-8	Blood metabolite levels;
PAAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg12193833	chr17:30244370	NA	-0.63	-5.36	-0.4	3.08e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.64	-6.0	-0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.71	-0.53	1.54e-12	Sense of smell;
PAAD	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.66	6.62	0.47	5.85e-10	Platelet count;
PAAD	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-10.88	-0.66	9.2e-21	Primary sclerosing cholangitis;
PAAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.88	-7.86	-0.54	6.58e-13	Diastolic blood pressure;
PAAD	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.12	0.5	3.97e-11	Diastolic blood pressure;
PAAD	cis	rs16975963	0.843	rs73041045	chr19:38296026	C/T	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg06148736	chr22:18985691	NA	-0.36	-4.89	-0.37	2.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.58	-0.47	7.23e-10	Lung cancer;
PAAD	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg13870426	chr17:30244630	NA	-0.74	-6.55	-0.47	8.33e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs1903068	0.853	rs28838369	chr4:56007249	A/G	cg05132782	chr7:150126392	NA	0.44	6.29	0.45	3.17e-9	Endometriosis;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.78	-8.15	-0.55	1.26e-13	Prostate cancer;
PAAD	cis	rs9907295	0.636	rs4795088	chr17:34113210	G/A	cg13376404	chr17:34077293	GAS2L2	0.65	4.27	0.33	3.38e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-6.1	-0.44	8.21e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-5.38	-0.4	2.78e-7	Morning vs. evening chronotype;
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27436995	chr16:743998	FBXL16	-0.37	-4.45	-0.34	1.67e-5	Height;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg21237687	chr17:6899380	ALOX12	0.58	5.92	0.43	2.11e-8	Tonsillectomy;
PAAD	cis	rs863345	0.967	rs7512117	chr1:158532064	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg20045696	chr14:77926864	AHSA1	0.54	5.23	0.39	5.64e-7	Myeloid white cell count;
PAAD	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.63	6.62	0.47	5.8e-10	Testicular germ cell tumor;
PAAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg23283495	chr1:209979779	IRF6	0.78	7.08	0.5	5.02e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg12215294	chr3:40350768	EIF1B	-0.48	-4.53	-0.34	1.2e-5	Renal cell carcinoma;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07234876	chr8:600039	NA	-1.09	-7.6	-0.52	2.8e-12	IgG glycosylation;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg11939075	chr4:83956728	COPS4	-0.65	-6.82	-0.48	1.99e-10	Dental caries;
PAAD	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.62	5.64	0.42	8.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg01059385	chr22:42394853	WBP2NL	0.46	5.01	0.38	1.52e-6	Intelligence;
PAAD	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs7101378	0.521	rs11212865	chr11:108901192	C/T	cg10610482	chr11:108093212	ATM;NPAT	-0.46	-4.4	-0.34	2.04e-5	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00166722	chr3:10149974	C3orf24	0.74	6.55	0.47	8.29e-10	Alzheimer's disease;
PAAD	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg10434728	chr15:90938212	IQGAP1	-0.45	-4.52	-0.34	1.22e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-8.2	-0.55	9.13e-14	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.63	5.84	0.43	3.11e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.73	7.49	0.52	5.29e-12	Alcohol dependence;
PAAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	4.99	0.38	1.62e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.38e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs8099014	0.861	rs4940394	chr18:56134096	T/C	cg12907477	chr18:56117327	MIR122	0.6	4.54	0.35	1.14e-5	Platelet count;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg25250414	chr15:75871478	PTPN9	-0.6	-6.31	-0.46	2.84e-9	Educational attainment (years of education);
PAAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20215982	chr7:4825255	KIAA0415	0.57	6.4	0.46	1.83e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	5.85	0.43	2.92e-8	Eye color traits;
PAAD	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg14631576	chr9:95140430	CENPP	0.53	5.31	0.4	3.86e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs10821973	0.533	rs10740062	chr10:63975842	T/C	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.9	-9.06	-0.59	6.02e-16	Asthma;
PAAD	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.73	-8.02	-0.55	2.68e-13	Mean platelet volume;
PAAD	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.6	5.14	0.38	8.23e-7	Response to diuretic therapy;
PAAD	cis	rs2029362	0.901	rs11030042	chr11:27542328	G/A	cg10635145	chr11:27742435	BDNF	0.3	4.26	0.33	3.64e-5	Total body bone mineral density;
PAAD	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03324578	chr3:46887918	NA	0.66	7.8	0.53	8.96e-13	Immature fraction of reticulocytes;
PAAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.39	-0.34	2.14e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.58	-5.7	-0.42	6.18e-8	Adiposity;
PAAD	cis	rs2651899	0.934	rs3795268	chr1:3089976	G/A	cg22396632	chr1:3079212	PRDM16	0.49	4.98	0.37	1.69e-6	Migraine;
PAAD	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg16586182	chr3:47516702	SCAP	-0.47	-4.6	-0.35	8.94e-6	Birth weight;
PAAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.46	5.65	0.42	7.78e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.72	-0.53	1.42e-12	Hemoglobin concentration;
PAAD	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.37	-4.55	-0.35	1.07e-5	Menarche (age at onset);
PAAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg05342945	chr12:48394962	COL2A1	0.65	4.31	0.33	2.95e-5	Lung cancer;
PAAD	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg22637538	chr17:7348327	CHRNB1	0.48	5.37	0.4	2.92e-7	Height;
PAAD	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-5.43	-0.4	2.14e-7	Coronary artery disease;
PAAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg21546286	chr11:48923668	NA	-0.53	-5.52	-0.41	1.42e-7	HDL cholesterol;
PAAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.29	10.71	0.66	2.67e-20	Uric acid levels;
PAAD	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.63	-0.42	8.47e-8	Metabolite levels;
PAAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	1.13	16.88	0.81	1.09e-36	Breast cancer;
PAAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.99	7.44	0.52	6.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.45	-4.28	-0.33	3.33e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg14851346	chr12:38532713	NA	0.49	4.6	0.35	8.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	trans	rs901683	1.000	rs35424022	chr10:45976540	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22618164	chr12:122356400	WDR66	0.51	5.27	0.39	4.61e-7	Mean corpuscular volume;
PAAD	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg14008862	chr17:28927542	LRRC37B2	0.73	5.13	0.38	8.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7742824	1.000	rs2096199	chr6:44096014	G/A	cg21657043	chr6:44035552	NA	0.51	5.25	0.39	5.02e-7	Major depressive disorder;
PAAD	cis	rs2915864	0.655	rs35044637	chr5:141475973	C/T	cg24865955	chr5:141576963	NA	0.71	4.36	0.33	2.35e-5	Facial morphology (factor 20);
PAAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg20821713	chr7:1055600	C7orf50	-0.58	-5.85	-0.43	2.9e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.57	0.41	1.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.7	-6.52	-0.47	9.85e-10	Blood metabolite levels;
PAAD	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.99	14.76	0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03547487	chr7:26240458	CBX3;HNRNPA2B1	-0.76	-7.1	-0.5	4.59e-11	Neuroticism;
PAAD	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.84	-0.37	3.16e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07733129	chr7:23627111	CLK2P	0.36	4.49	0.34	1.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.54	-4.5	-0.34	1.36e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg03989125	chr22:38214979	NA	0.63	6.07	0.44	9.64e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg08514558	chr10:81106712	PPIF	-0.51	-6.09	-0.44	8.75e-9	Height;
PAAD	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.83	-0.43	3.18e-8	QT interval;
PAAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg24416232	chr10:134405482	INPP5A	-0.44	-4.62	-0.35	8.19e-6	Primary sclerosing cholangitis;
PAAD	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.61e-7	Monocyte count;
PAAD	cis	rs9463078	0.585	rs1285019	chr6:45167672	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-4.32	-0.33	2.86e-5	Dilated cardiomyopathy;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.86	0.58	2e-15	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg02421172	chr7:1938701	MAD1L1	0.52	4.28	0.33	3.29e-5	Bipolar disorder;
PAAD	cis	rs818427	0.737	rs464708	chr5:112154303	T/G	cg06941702	chr5:112196734	SRP19	-0.46	-4.28	-0.33	3.36e-5	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.89	6.39	0.46	1.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07314549	chr16:20817501	ERI2;LOC81691	-0.66	-7.76	-0.53	1.16e-12	Body fat percentage;
PAAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	1.04	14.42	0.76	3e-30	Height;
PAAD	cis	rs6710503	0.547	rs62140849	chr2:24746198	G/A	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.28	-0.51	1.63e-11	Neuroticism;
PAAD	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.51	4.85	0.37	3.06e-6	Itch intensity from mosquito bite;
PAAD	trans	rs4707930	0.578	rs2145546	chr6:72415931	A/G	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg07979401	chr6:33739406	LEMD2	0.54	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg27490568	chr2:178487706	NA	0.45	4.98	0.37	1.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs438465	0.947	rs438217	chr6:169815949	A/C	cg11181693	chr6:169825345	NA	-0.57	-4.38	-0.34	2.16e-5	Corneal astigmatism;
PAAD	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg05554000	chr7:158905015	VIPR2	-0.57	-4.96	-0.37	1.9e-6	Facial morphology (factor 20);
PAAD	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.61	5.71	0.42	5.63e-8	Childhood ear infection;
PAAD	cis	rs7217780	0.569	rs230961	chr17:15204990	C/T	cg13649519	chr17:15586170	TRIM16	-0.46	-4.26	-0.33	3.51e-5	Preterm birth (maternal effect);
PAAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.76	-6.96	-0.49	9.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.48	-5.04	-0.38	1.3e-6	Lung cancer;
PAAD	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg17552801	chr10:99332121	ANKRD2	-0.41	-4.26	-0.33	3.57e-5	Metabolite levels;
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.26	-0.39	4.79e-7	Tonsillectomy;
PAAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.63e-6	Personality dimensions;
PAAD	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.54	-0.41	1.28e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7326068	0.595	rs2785741	chr13:21421240	C/T	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.94	12.37	0.71	9.43e-25	Menopause (age at onset);
PAAD	cis	rs1957429	0.614	rs76809238	chr14:65380579	C/T	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.45	5.41	0.4	2.39e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-5.86	-0.43	2.81e-8	Response to antipsychotic treatment;
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06850241	chr22:41845214	NA	-0.51	-4.7	-0.36	5.81e-6	Vitiligo;
PAAD	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-4.86	-0.37	2.84e-6	Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg01620082	chr3:125678407	NA	-1.42	-8.12	-0.55	1.49e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.34	-0.33	2.6e-5	Mood instability;
PAAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.99	8.58	0.57	1.01e-14	Initial pursuit acceleration;
PAAD	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-1.1	-6.87	-0.49	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15607311	chr17:41020659	LOC90586	-0.67	-7.29	-0.51	1.62e-11	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.74	0.36	4.9100000000000004e-06	Height;
PAAD	cis	rs4731207	0.536	rs10254199	chr7:124655116	C/T	cg14311320	chr7:124405732	GPR37	-0.43	-4.51	-0.34	1.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg20607764	chr19:44506953	ZNF230	0.51	4.62	0.35	8.26e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.48	-4.85	-0.37	3.08e-6	Eosinophil percentage of white cells;
PAAD	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg26003909	chr8:143102224	NA	-0.34	-5.55	-0.41	1.24e-7	Amyotrophic lateral sclerosis;
PAAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.98	12.97	0.72	2.29e-26	Menopause (age at onset);
PAAD	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg14583973	chr4:3374767	RGS12	-0.37	-5.46	-0.41	1.87e-7	Parental longevity (mother's age at death);
PAAD	cis	rs12286929	0.933	rs11215381	chr11:115022233	T/C	cg04055981	chr11:115044050	NA	0.42	4.29	0.33	3.13e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.55	5.46	0.41	1.86e-7	Platelet count;
PAAD	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg18898632	chr2:242989856	NA	-0.81	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.55e-6	Migraine;
PAAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.63	0.35	7.91e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg16691251	chr5:66510806	NA	0.83	10.3	0.64	3.39e-19	Breast cancer;
PAAD	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs863345	0.967	rs1342944	chr1:158512923	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.99	-0.38	1.65e-6	Pneumococcal bacteremia;
PAAD	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.72	7.27	0.51	1.75e-11	Schizophrenia;
PAAD	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.88	0.49	1.44e-10	Body mass index;
PAAD	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.6	-5.32	-0.4	3.66e-7	Blood trace element (Cu levels);
PAAD	cis	rs75920871	0.640	rs61903395	chr11:116931907	A/G	cg04087571	chr11:116723030	SIK3	-0.44	-5.56	-0.41	1.17e-7	Subjective well-being;
PAAD	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg23093090	chr10:104574429	C10orf26	-0.45	-5.03	-0.38	1.38e-6	Waist circumference;Hip circumference;
PAAD	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg26876637	chr1:152193138	HRNR	0.87	7.15	0.5	3.44e-11	Atopic dermatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.6	6.44	0.46	1.52e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.26	0.39	4.89e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.86	-9.7	-0.62	1.25e-17	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17233202	chr15:82338518	MEX3B	0.67	7.05	0.5	5.75e-11	Obesity-related traits;
PAAD	cis	rs8077577	0.708	rs3889544	chr17:18133788	C/T	cg16794390	chr17:18148240	FLII	-0.52	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.74	-0.36	4.92e-6	Biliary atresia;
PAAD	cis	rs1879734	0.731	rs59020945	chr1:54162635	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.21	0.45	4.91e-9	Body mass index;
PAAD	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.67	0.35	6.5e-6	Parkinson's disease;
PAAD	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.65	5.29	0.39	4.13e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.58	5.91	0.43	2.12e-8	Coronary artery disease;
PAAD	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg00531865	chr16:30841666	NA	-0.67	-4.96	-0.37	1.88e-6	Diastolic blood pressure;
PAAD	cis	rs12304921	0.810	rs73090661	chr12:51355242	C/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.31	-0.33	2.91e-5	Type 2 diabetes;
PAAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.31	-0.33	2.88e-5	Cystic fibrosis severity;
PAAD	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.97	6.15	0.45	6.44e-9	Major depressive disorder;
PAAD	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.7	-7.98	-0.54	3.31e-13	Colorectal cancer;
PAAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.67	-0.35	6.68e-6	Type 2 diabetes;
PAAD	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.77	-0.48	2.6e-10	Menopause (age at onset);
PAAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.7	-7.99	-0.54	3.07e-13	Melanoma;
PAAD	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6700896	0.966	rs7542446	chr1:66091106	G/A	cg04111102	chr1:66153794	NA	0.46	5.09	0.38	1.03e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4690686	0.500	rs12501181	chr4:177264851	G/A	cg17059388	chr4:177262070	NA	0.61	6.09	0.44	8.67e-9	Essential tremor;
PAAD	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg02023728	chr11:77925099	USP35	0.43	4.35	0.33	2.46e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.68	-0.48	4.23e-10	Platelet distribution width;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg10729496	chr3:10149963	C3orf24	0.84	6.31	0.46	2.87e-9	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13437341	chr9:140676853	EHMT1	0.67	6.62	0.47	5.68e-10	Smoking initiation;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09354444	chr19:7701963	STXBP2	0.55	6.32	0.46	2.76e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.85e-6	Type 2 diabetes;
PAAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg04156016	chr5:1868137	NA	0.49	4.99	0.38	1.6e-6	Cardiovascular disease risk factors;
PAAD	trans	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg14136781	chr9:124087974	GSN	-0.81	-6.31	-0.46	2.95e-9	Red blood cell count;
PAAD	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.56	-4.94	-0.37	2.05e-6	P wave terminal force;
PAAD	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.45	6.22	0.45	4.68e-9	Congenital heart disease (maternal effect);
PAAD	cis	rs17021463	0.676	rs62320932	chr4:95307037	C/T	cg11021082	chr4:95130006	SMARCAD1	0.51	5.1	0.38	9.98e-7	Testicular germ cell tumor;
PAAD	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.59	-6.51	-0.47	1.05e-9	Hematocrit;
PAAD	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.66	6.43	0.46	1.55e-9	Corneal astigmatism;
PAAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-6.97	-0.49	9.15e-11	Lymphocyte counts;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg05564831	chr3:52568323	NT5DC2	-0.48	-5.06	-0.38	1.2e-6	Bipolar disorder;
PAAD	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.51	-4.41	-0.34	1.95e-5	Fibrinogen levels;
PAAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg14851346	chr12:38532713	NA	0.49	4.53	0.34	1.2e-5	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.62	6.98	0.49	8.68e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.64	7.21	0.5	2.43e-11	Coronary artery disease;
PAAD	trans	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg01957732	chr6:133561716	EYA4	-0.98	-7.15	-0.5	3.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.79	7.23	0.51	2.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7756089	0.510	rs57506541	chr6:11244154	C/A	cg27135788	chr10:104402556	NA	1.04	6.33	0.46	2.63e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00280220	chr17:61926910	NA	-0.44	-4.65	-0.35	7.23e-6	Prudent dietary pattern;
PAAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.67	5.83	0.43	3.27e-8	Breast cancer;
PAAD	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.56	4.98	0.37	1.71e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	7.51	0.52	4.61e-12	Height;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.54	-5.37	-0.4	2.85e-7	QT interval;
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.52	5.34	0.4	3.35e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19803550	chr17:1637391	WDR81	0.59	7.05	0.5	5.74e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg17127132	chr2:85788382	GGCX	-0.45	-4.48	-0.34	1.46e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.55	5.56	0.41	1.15e-7	Menopause (age at onset);
PAAD	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.68e-8	Retinal vascular caliber;
PAAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.69	6.72	0.48	3.41e-10	Tuberculosis;
PAAD	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.76	0.42	4.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.57	5.63	0.42	8.57e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg05207973	chr5:176823642	SLC34A1	-0.39	-4.68	-0.35	6.3e-6	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.81	-7.88	-0.54	6.01e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs4148087	0.696	rs9975490	chr21:43640066	C/G	cg08841829	chr21:43638893	ABCG1	-0.64	-4.31	-0.33	2.97e-5	Eating disorder in bipolar disorder;
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.69	7.58	0.52	3.09e-12	Aortic root size;
PAAD	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg21466736	chr12:48725269	NA	-0.52	-4.82	-0.36	3.44e-6	Glycated hemoglobin levels;
PAAD	cis	rs9815354	1.000	rs9874975	chr3:41764300	G/A	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs73416724	0.688	rs10498755	chr6:43330756	C/T	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg06522063	chr2:190306158	WDR75	-0.68	-6.84	-0.49	1.86e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs12042052	0.590	rs72752167	chr1:232922414	G/A	cg02903907	chr1:232941055	KIAA1383	0.85	4.6	0.35	8.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg15028436	chr7:37888078	TXNDC3	0.52	4.36	0.33	2.37e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2411984	0.581	rs11655704	chr17:47448172	C/T	cg08112188	chr17:47440006	ZNF652	-0.49	-4.49	-0.34	1.4e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.72	6.09	0.44	8.81e-9	Inflammatory skin disease;
PAAD	cis	rs1519814	1.000	rs6469902	chr8:121171911	A/T	cg22335954	chr8:121166405	COL14A1	-0.6	-5.35	-0.4	3.12e-7	Breast cancer;
PAAD	cis	rs6681460	0.649	rs1415984	chr1:67002117	A/G	cg02459107	chr1:67143332	SGIP1	0.55	5.0	0.38	1.56e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.01	0.81	5.21e-37	Prudent dietary pattern;
PAAD	cis	rs6449957	0.966	rs73126520	chr5:67475425	C/T	cg23036683	chr5:67512108	NA	0.45	4.28	0.33	3.33e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-4.76	-0.36	4.47e-6	Schizophrenia;
PAAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.73	8.3	0.56	5.22e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.46	4.77	0.36	4.22e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.48	8.55	0.57	1.2e-14	Multiple system atrophy;
PAAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg20243544	chr17:37824526	PNMT	0.53	4.6	0.35	8.75e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.55	-5.01	-0.38	1.48e-6	Myeloid white cell count;
PAAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21016266	chr12:122356598	WDR66	0.67	7.3	0.51	1.49e-11	Mean corpuscular volume;
PAAD	cis	rs1420338	0.933	rs1362460	chr7:34147964	C/T	cg01275685	chr7:34179230	BMPER	-0.54	-5.17	-0.39	7.25e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs62229266	0.659	rs2026259	chr21:37430627	A/G	cg08632701	chr21:37451849	NA	-0.62	-6.74	-0.48	3.13e-10	Mitral valve prolapse;
PAAD	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg16928487	chr17:17741425	SREBF1	0.36	4.88	0.37	2.65e-6	Total body bone mineral density;
PAAD	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.54	-5.19	-0.39	6.57e-7	Mean platelet volume;
PAAD	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg04809136	chr2:24300158	SF3B14	0.42	4.98	0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs6604026	0.656	rs2774950	chr1:93353527	T/C	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.71	-9.16	-0.6	3.27e-16	Asthma;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.93	11.83	0.69	2.69e-23	Menarche (age at onset);
PAAD	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.84	-6.77	-0.48	2.68e-10	Coronary artery disease;
PAAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	1.26	11.54	0.68	1.62e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs11671653	0.688	rs112508627	chr19:10842063	A/G	cg16667279	chr19:11591998	ELAVL3	-0.72	-4.68	-0.36	6.18e-6	LDL cholesterol;
PAAD	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.39	-0.51	8.9e-12	Total cholesterol levels;
PAAD	cis	rs2481665	0.904	rs2481677	chr1:62632571	G/A	cg18591186	chr1:62594603	INADL	-0.64	-5.73	-0.42	5.27e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-5.3	-0.39	4.1e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg18898632	chr2:242989856	NA	-0.81	-6.45	-0.46	1.39e-9	Obesity-related traits;
PAAD	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.38	-0.4	2.72e-7	Glomerular filtration rate;
PAAD	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7809615	1.000	rs7809615	chr7:99184778	G/T	cg12290671	chr7:99195819	NA	-0.91	-5.3	-0.4	3.96e-7	Blood metabolite ratios;
PAAD	trans	rs11806316	0.622	rs2798464	chr1:115771616	A/G	cg19624425	chr14:61721650	NA	0.51	6.54	0.47	8.69e-10	Coronary artery disease;
PAAD	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.87	8.13	0.55	1.37e-13	Breast cancer;
PAAD	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-1.26	-11.13	-0.67	2.04e-21	Obesity-related traits;
PAAD	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs2744375	0.544	rs2744365	chr6:7552020	A/G	cg27023638	chr6:7288726	SSR1	-0.41	-4.26	-0.33	3.56e-5	Resting heart rate;
PAAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2271001	0.955	rs4757760	chr11:19166892	C/G	cg00161556	chr11:19138045	ZDHHC13	0.52	5.55	0.41	1.25e-7	Gut microbiome composition (winter);
PAAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.65	5.8	0.43	3.7e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.96	0.66	5.7e-21	Smoking behavior;
PAAD	cis	rs7818688	0.697	rs11783985	chr8:95979886	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.52	0.41	1.43e-7	Parkinson's disease;
PAAD	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.82	0.62	6.33e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs12576326	1.000	rs12576326	chr11:44980383	A/G	cg07619142	chr11:44971049	TP53I11	-0.57	-5.54	-0.41	1.27e-7	Resting heart rate;
PAAD	cis	rs755249	0.567	rs72661927	chr1:39675322	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.65	7.43	0.52	7.12e-12	Dupuytren's disease;
PAAD	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg16339924	chr4:17578868	LAP3	-0.53	-4.57	-0.35	9.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4474465	0.920	rs7125628	chr11:78223028	C/G	cg27205649	chr11:78285834	NARS2	0.61	4.57	0.35	9.84e-6	Alzheimer's disease (survival time);
PAAD	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs3736485	0.934	rs17609693	chr15:51868000	T/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg02487422	chr3:49467188	NICN1	0.45	4.57	0.35	1e-5	Resting heart rate;
PAAD	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs2904967	1.000	rs509303	chr11:65093190	A/C	cg05057976	chr11:65779667	CST6	-0.52	-4.46	-0.34	1.6e-5	Mean corpuscular volume;
PAAD	cis	rs939584	1.000	rs10173167	chr2:646767	G/A	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.17	-10.08	-0.63	1.3e-18	Vitiligo;
PAAD	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.16	16.53	0.8	8.65e-36	Body mass index;
PAAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg04106633	chr4:1044584	NA	-0.65	-5.46	-0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.53	4.82	0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.84	-8.83	-0.58	2.39e-15	Morning vs. evening chronotype;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.57	6.56	0.47	8.1e-10	Mean corpuscular volume;
PAAD	cis	rs73416724	1.000	rs41281798	chr6:43325787	C/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg09355652	chr11:64668475	ATG2A	0.5	4.64	0.35	7.6e-6	Breast cancer;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-4.38	-0.34	2.16e-5	Aortic root size;
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg07061783	chr6:25882402	NA	0.51	4.79	0.36	4e-6	Blood metabolite levels;
PAAD	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs6074578	0.679	rs2298108	chr20:138125	G/T	cg16931068	chr20:139680	DEFB127	0.36	4.81	0.36	3.57e-6	Hirschsprung disease;
PAAD	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs12935418	0.616	rs2549858	chr16:81026994	G/A	cg16651780	chr16:81037892	C16orf61	-0.63	-5.8	-0.43	3.65e-8	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12165864	chr7:66369176	NA	-0.81	-5.16	-0.39	7.64e-7	Diabetic kidney disease;
PAAD	cis	rs2834902	0.578	rs2834897	chr21:36684244	C/T	cg04915566	chr21:36421472	RUNX1	-0.32	-4.27	-0.33	3.43e-5	Corneal curvature;
PAAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg04089426	chr11:65307791	LTBP3	1.1	5.13	0.38	8.84e-7	Height;
PAAD	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg26597838	chr10:835615	NA	0.47	5.04	0.38	1.33e-6	Survival in rectal cancer;
PAAD	cis	rs13424612	0.965	rs4149544	chr2:240943162	C/T	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.63	-0.35	7.8e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16173229	chr6:88302428	ORC3L	0.58	6.57	0.47	7.41e-10	Smoking initiation;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg07202610	chr7:1142643	C7orf50	-0.68	-5.49	-0.41	1.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg18944383	chr4:111397179	ENPEP	-0.59	-6.74	-0.48	3.16e-10	Height;
PAAD	cis	rs11997175	0.546	rs4545051	chr8:33608863	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	6.39	0.46	1.97e-9	Body mass index;
PAAD	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-11.13	-0.67	2.06e-21	Ulcerative colitis;
PAAD	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.52	-0.47	9.66e-10	Morning vs. evening chronotype;
PAAD	cis	rs10958369	0.871	rs10958370	chr8:54417710	T/A	cg12485204	chr8:54507357	NA	0.45	4.32	0.33	2.85e-5	Response to antineoplastic agents;
PAAD	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg25664220	chr3:72788482	NA	-0.49	-5.23	-0.39	5.57e-7	Motion sickness;
PAAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.95	-10.13	-0.63	9.36e-19	Blood metabolite levels;
PAAD	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg16589663	chr20:23618590	CST3	-0.79	-6.89	-0.49	1.38e-10	Chronic kidney disease;
PAAD	cis	rs876084	0.505	rs10108373	chr8:121126109	T/C	cg06265175	chr8:121136014	COL14A1	0.49	4.78	0.36	4.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg19787841	chr12:53845606	PCBP2	-0.44	-4.46	-0.34	1.57e-5	Height;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs116248771	0.739	rs73156495	chr3:158420547	C/T	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs72634258	0.786	rs6577468	chr1:8183921	T/C	cg26816564	chr1:7831052	VAMP3	0.61	4.9	0.37	2.4e-6	Inflammatory bowel disease;
PAAD	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.94	-9.66	-0.62	1.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.23	0.39	5.53e-7	Lung cancer;
PAAD	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.38	-4.39	-0.34	2.09e-5	Red blood cell traits;
PAAD	cis	rs818427	0.508	rs861674	chr5:112064475	A/T	cg06941702	chr5:112196734	SRP19	0.46	4.32	0.33	2.76e-5	Total body bone mineral density;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.95	12.24	0.7	2.12e-24	Menarche (age at onset);
PAAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-1.3	-10.86	-0.66	1.05e-20	Obesity-related traits;
PAAD	cis	rs78761021	0.898	rs55954208	chr17:9776157	A/C	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.2	-0.5	2.59e-11	Systolic blood pressure;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01469421	chr19:57999034	ZNF419	-0.57	-6.85	-0.49	1.72e-10	Body fat percentage;
PAAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg19592336	chr6:28129416	ZNF389	0.62	4.4	0.34	2.05e-5	Parkinson's disease;
PAAD	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs3931020	0.626	rs277402	chr1:75188321	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.59	-4.9	-0.37	2.46e-6	Resistin levels;
PAAD	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.43	-0.34	1.79e-5	Educational attainment;
PAAD	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.73	7.29	0.51	1.56e-11	HIV-1 control;
PAAD	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.03	7.19	0.5	2.81e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12599982	chr1:44399894	ARTN	-0.44	-4.82	-0.36	3.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg00262122	chr8:11665843	FDFT1	-0.51	-4.65	-0.35	7.08e-6	Retinal vascular caliber;
PAAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.69	-8.92	-0.59	1.41e-15	Menopause (age at onset);
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.76e-10	Plateletcrit;Platelet count;
PAAD	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.63	-5.68	-0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-0.72	-7.49	-0.52	5.33e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Intracranial aneurysm;
PAAD	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.41	-0.56	2.79e-14	Obesity-related traits;
PAAD	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg02132636	chr2:170551350	PHOSPHO2;KLHL23;C2orf77	0.57	4.43	0.34	1.78e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9815354	1.000	rs1717001	chr3:41934949	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.83	-0.43	3.27e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-6.67	-0.48	4.56e-10	Personality dimensions;
PAAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.54	5.13	0.38	8.76e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.83	9.03	0.59	7.05e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.75	-7.43	-0.52	7.16e-12	White matter hyperintensity burden;
PAAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.66	7.45	0.52	6.47e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.34	-0.33	2.55e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.76	8.78	0.58	3.12e-15	Total body bone mineral density;
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.63	6.02	0.44	1.28e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4900538	0.827	rs1046651	chr14:102971016	T/C	cg18135206	chr14:102964638	TECPR2	0.92	11.46	0.68	2.64e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs17824933	1.000	rs929230	chr11:60760971	C/T	cg27098804	chr11:60776124	CD6	0.44	4.42	0.34	1.87e-5	Multiple sclerosis;
PAAD	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs6499755	0.712	rs31110	chr16:55378505	A/G	cg02859129	chr16:55357253	IRX6	-0.34	-4.64	-0.35	7.4e-6	Hypospadias;
PAAD	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg17182837	chr8:41585554	ANK1	-0.41	-4.43	-0.34	1.82e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.73	8.43	0.56	2.44e-14	Metabolic syndrome;
PAAD	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg22089800	chr15:90895588	ZNF774	0.57	5.5	0.41	1.6e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	12.33	0.71	1.19e-24	Colorectal cancer;
PAAD	cis	rs72960926	1.000	rs72958964	chr6:75124792	C/T	cg13997649	chr6:74171430	MTO1	0.79	4.4	0.34	2.05e-5	Metabolite levels (MHPG);
PAAD	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.81	-0.36	3.58e-6	Bipolar disorder;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26418147	chr1:205743515	RAB7L1	0.48	5.45	0.4	2e-7	Menarche (age at onset);
PAAD	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg11062466	chr8:58055876	NA	0.68	5.06	0.38	1.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.75e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.89	-0.37	2.55e-6	Eotaxin levels;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.93	0.43	2.01e-8	Prudent dietary pattern;
PAAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.82	9.39	0.61	8.34e-17	Methadone dose in opioid dependence;
PAAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.78	-8.67	-0.58	6.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.49e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2275731	0.723	rs10904756	chr10:16547834	G/A	cg04254609	chr10:16479192	PTER	-0.42	-4.37	-0.33	2.25e-5	Bone fracture in osteoporosis;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02071572	chr4:1403502	NA	-0.48	-6.14	-0.45	6.99e-9	Obesity-related traits;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.59	5.74	0.42	4.93e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.56	-6.93	-0.49	1.12e-10	Multiple system atrophy;
PAAD	cis	rs595018	0.505	rs582246	chr11:60603647	C/T	cg07588442	chr11:60673866	PRPF19	-0.65	-4.56	-0.35	1.04e-5	Wegener's granulomatosis;
PAAD	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg24220031	chr2:73402428	NA	-0.35	-5.39	-0.4	2.62e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.64	-7.28	-0.51	1.71e-11	Schizophrenia;
PAAD	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-5.05	-0.38	1.27e-6	Vitiligo;
PAAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.07e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.52	0.41	1.43e-7	Alcohol dependence;
PAAD	cis	rs9549260	0.712	rs9532564	chr13:41160579	C/G	cg21288729	chr13:41239152	FOXO1	0.63	5.21	0.39	5.95e-7	Red blood cell count;
PAAD	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.13	0.38	8.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7631605	0.935	rs2241031	chr3:37090274	C/T	cg17445812	chr3:36986805	TRANK1	0.32	4.27	0.33	3.38e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs72634501	0.517	rs10788925	chr1:39594102	C/T	cg11070191	chr1:39582205	MACF1	0.52	4.7	0.36	5.69e-6	HDL cholesterol;
PAAD	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-6.27	-0.45	3.59e-9	Personality dimensions;
PAAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8062405	0.728	rs8056890	chr16:28897452	G/A	cg16576597	chr16:28551801	NUPR1	0.68	6.97	0.49	9.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs73019876	0.869	rs2359810	chr19:22152527	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10411590	chr13:21900810	NA	0.63	7.5	0.52	4.88e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06183831	chr1:9883466	CLSTN1	0.72	7.85	0.54	6.98e-13	Myopia (pathological);
PAAD	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg04865290	chr3:52927548	TMEM110	0.72	4.96	0.37	1.83e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.72	7.28	0.51	1.65e-11	Tonsillectomy;
PAAD	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg10437265	chr15:77819839	NA	-0.45	-5.19	-0.39	6.63e-7	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09784021	chr17:35766790	TADA2A;ACACA	0.57	6.41	0.46	1.76e-9	Monocyte percentage of white cells;
PAAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg05484376	chr2:27715224	FNDC4	0.44	4.48	0.34	1.47e-5	Oral cavity cancer;
PAAD	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.5	5.11	0.38	9.5e-7	Height;
PAAD	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg04165759	chr1:150448943	RPRD2	0.52	5.36	0.4	2.97e-7	Migraine;
PAAD	trans	rs4678145	1.000	rs4678145	chr3:124450081	G/C	cg03983498	chr1:55107291	C1orf175	1.06	6.63	0.47	5.58e-10	Coronary artery disease;
PAAD	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.96	0.49	9.77e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs62179067	0.708	rs75112171	chr2:179900609	C/A	cg13380624	chr19:7735426	NA	-0.75	-6.93	-0.49	1.1e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs12042938	0.505	rs1025526	chr1:231750641	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-4.69	-0.36	5.92e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs12044355	0.896	rs11122324	chr1:231859181	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.06	0.38	1.2e-6	Alzheimer's disease;
PAAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.45	4.33	0.33	2.67e-5	Renal cell carcinoma;
PAAD	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.45	0.46	1.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12127944	1.000	rs1538369	chr1:205476001	A/T	cg08473693	chr1:205342340	NA	-0.71	-4.61	-0.35	8.37e-6	IgG glycosylation;
PAAD	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.37	-4.43	-0.34	1.77e-5	Prostate cancer;
PAAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.55	6.75	0.48	2.97e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	0.832	rs224381	chr20:34097136	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03946896	chr1:44871606	RNF220	0.55	6.31	0.46	2.96e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg05585544	chr11:47624801	NA	-0.49	-5.43	-0.4	2.21e-7	Subjective well-being;
PAAD	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.73	-0.42	5.3e-8	Coronary artery disease;
PAAD	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg04415270	chr2:102091202	RFX8	0.49	6.06	0.44	1.02e-8	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.64	7.46	0.52	6.12e-12	Height;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.73	0.42	5.24e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs3857067	1.000	rs28840089	chr4:95000403	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg06131755	chr6:160182447	ACAT2	0.53	4.49	0.34	1.38e-5	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.13	-0.73	8.47e-27	Height;
PAAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.92	9.88	0.63	4.46e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.81	-0.54	8.52e-13	Leprosy;
PAAD	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg23331303	chr5:5135948	NA	0.46	6.52	0.47	9.96e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6494488	0.500	rs72742989	chr15:64994464	A/G	cg16425858	chr15:64791681	ZNF609	0.96	4.85	0.37	3.02e-6	Coronary artery disease;
PAAD	cis	rs256277	0.657	rs255910	chr5:111369892	A/G	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.61	-0.41	9.13e-8	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.58	5.63	0.42	8.52e-8	Prudent dietary pattern;
PAAD	cis	rs11105468	0.595	rs1438987	chr12:90535412	A/G	cg16962463	chr12:89968675	NA	0.37	4.27	0.33	3.46e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	6.28	0.45	3.35e-9	Blood protein levels;
PAAD	cis	rs4253772	0.505	rs111280202	chr22:46646063	C/A	cg24881330	chr22:46731750	TRMU	0.95	4.27	0.33	3.49e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.66	4.72	0.36	5.32e-6	Depression;
PAAD	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.21	0.55	8.74e-14	Hypertriglyceridemia;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.66	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.68	8.39	0.56	3.03e-14	Dupuytren's disease;
PAAD	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.78	7.64	0.53	2.3e-12	Bone mineral density;
PAAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.04	-0.38	1.31e-6	Fear of minor pain;
PAAD	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.91	-5.3	-0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-0.88	-13.84	-0.75	1.07e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg18833306	chr6:118973337	C6orf204	-0.58	-4.71	-0.36	5.46e-6	Diastolic blood pressure;
PAAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06850241	chr22:41845214	NA	0.61	5.41	0.4	2.43e-7	Vitiligo;
PAAD	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.54	-4.75	-0.36	4.57e-6	Pubertal anthropometrics;
PAAD	cis	rs955333	0.565	rs7770413	chr6:154904487	A/G	cg20019720	chr6:154832845	CNKSR3	0.39	4.83	0.37	3.25e-6	Diabetic kidney disease;
PAAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01123250	chr2:210673545	UNC80	-0.66	-6.41	-0.46	1.77e-9	Smoking initiation;
PAAD	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.2e-7	Coronary artery disease;
PAAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg19847866	chr10:1019161	NA	-0.57	-4.52	-0.34	1.24e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.52	-5.02	-0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.67	0.42	6.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg04106633	chr4:1044584	NA	0.54	4.31	0.33	2.98e-5	Recombination rate (females);
PAAD	cis	rs7009110	0.758	rs1911713	chr8:81266044	A/G	cg21158561	chr8:81178149	NA	-0.39	-4.3	-0.33	3.06e-5	Asthma and hay fever;
PAAD	cis	rs4740619	0.901	rs7024640	chr9:15705955	C/T	cg14451791	chr9:16040625	NA	-0.4	-4.52	-0.34	1.22e-5	Body mass index;
PAAD	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg26816564	chr1:7831052	VAMP3	-0.6	-5.09	-0.38	1.03e-6	Inflammatory bowel disease;
PAAD	cis	rs2371030	1.000	rs10184528	chr2:211575134	A/T	cg18417063	chr2:211583084	NA	-0.44	-4.28	-0.33	3.29e-5	Non-small cell lung cancer;
PAAD	cis	rs9361491	0.610	rs7758474	chr6:79469174	G/C	cg05283184	chr6:79620031	NA	-0.39	-4.73	-0.36	5.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.86	6.06	0.44	1.04e-8	Height;
PAAD	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-6.97	-0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs6733011	0.644	rs6719634	chr2:99460614	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.14	-0.38	8.28e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg19980929	chr12:42632907	YAF2	0.59	6.9	0.49	1.33e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	9.07	0.59	5.54e-16	Rheumatoid arthritis;
PAAD	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.44	-0.68	2.92e-22	Chronic sinus infection;
PAAD	cis	rs8112211	0.569	rs76086051	chr19:38811462	T/G	cg01275006	chr19:38876250	GGN	-0.74	-4.75	-0.36	4.58e-6	Blood protein levels;
PAAD	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg05627522	chr15:75251581	NA	0.47	5.84	0.43	3.03e-8	Breast cancer;
PAAD	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.59	8.17	0.55	1.14e-13	Primary biliary cholangitis;
PAAD	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.73	6.98	0.49	8.55e-11	Obesity-related traits;
PAAD	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg04705435	chr11:17411270	KCNJ11	0.66	6.84	0.49	1.81e-10	Type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	-0.64	-4.92	-0.37	2.19e-6	Breast cancer;
PAAD	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg02487422	chr3:49467188	NICN1	-0.46	-4.77	-0.36	4.22e-6	Resting heart rate;
PAAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.84	-0.43	3e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3753841	0.767	rs9787064	chr1:103215963	T/C	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-6.0	-0.44	1.36e-8	Personality dimensions;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg27189623	chr16:705930	WDR90	0.53	4.31	0.33	2.94e-5	Mean corpuscular volume;
PAAD	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.39	-4.65	-0.35	7.08e-6	Coronary artery disease;
PAAD	cis	rs375066	0.935	rs454559	chr19:44429120	C/T	cg08633290	chr19:44405433	NA	-0.55	-5.42	-0.4	2.31e-7	Breast cancer;
PAAD	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg04450456	chr4:17643702	FAM184B	0.51	5.64	0.42	7.97e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8038465	0.623	rs6495073	chr15:73947534	A/T	cg15420318	chr15:73925796	NPTN	0.48	4.68	0.35	6.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7246760	0.609	rs12459250	chr19:9909543	C/T	cg16876255	chr19:9731953	ZNF561	0.94	4.49	0.34	1.42e-5	Pursuit maintenance gain;
PAAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.81	7.39	0.51	8.92e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs950037	0.686	rs12057453	chr1:89341515	C/T	cg13109106	chr1:89333529	GTF2B	0.49	4.79	0.36	3.85e-6	Coronary artery disease;
PAAD	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg10223061	chr2:219282414	VIL1	-0.39	-4.64	-0.35	7.37e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06794263	chr15:93447445	CHD2	0.57	6.67	0.48	4.54e-10	Metabolite levels  (X-11787);
PAAD	cis	rs12780845	0.929	rs35932553	chr10:17213315	A/T	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.3	0.64	3.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg27478167	chr7:817139	HEATR2	-0.59	-4.65	-0.35	7.02e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20854551	chr18:61603789	NA	-0.69	-6.31	-0.46	2.9e-9	Neuroticism;
PAAD	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Breast cancer;
PAAD	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.73	8.01	0.54	2.84e-13	Gout;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.16	0.39	7.68e-7	Serum sulfate level;
PAAD	cis	rs9400467	0.506	rs12214933	chr6:111558006	A/G	cg15721981	chr6:111408429	SLC16A10	0.6	4.28	0.33	3.34e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg17325771	chr7:75508891	RHBDD2	0.3	4.26	0.33	3.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21640587	chr11:117668038	DSCAML1	0.43	4.27	0.33	3.38e-5	Myopia;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg02404636	chr22:31891804	SFI1	0.64	5.99	0.44	1.48e-8	Colorectal cancer;
PAAD	cis	rs17123764	0.710	rs11169133	chr12:50126058	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.66	0.42	7.17e-8	Restless legs syndrome;
PAAD	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs116248771	0.739	rs12633687	chr3:158338168	G/T	cg16708174	chr3:158430962	RARRES1	0.6	4.33	0.33	2.71e-5	diarrhoeal disease at age 2;
PAAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.94	10.97	0.66	5.42e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs988913	1.000	rs9367601	chr6:54839162	G/T	cg03513858	chr6:54763001	FAM83B	-0.43	-4.75	-0.36	4.68e-6	Menarche (age at onset);
PAAD	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.68	5.75	0.42	4.7e-8	Educational attainment;
PAAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs1190596	0.830	rs61992489	chr14:102553167	T/G	cg23904247	chr14:102554826	HSP90AA1	-0.5	-5.48	-0.41	1.69e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-5.99	-0.44	1.42e-8	Longevity;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg17987982	chr7:158820591	NA	-0.43	-4.74	-0.36	4.81e-6	Facial morphology (factor 20);
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg16606324	chr3:10149918	C3orf24	0.62	4.69	0.36	6.15e-6	Alzheimer's disease;
PAAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.49	6.25	0.45	4.04e-9	Huntington's disease progression;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4906332	1.000	rs4906332	chr14:103980134	A/T	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.35	-0.4	3.15e-7	Coronary artery disease;
PAAD	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.9	9.3	0.6	1.44e-16	Height;
PAAD	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.48	-4.63	-0.35	7.7e-6	Pancreatic cancer;
PAAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.82	-5.2	-0.39	6.45e-7	Tuberculosis;
PAAD	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg12486944	chr17:80159399	CCDC57	0.53	4.63	0.35	7.77e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.63	6.91	0.49	1.26e-10	Longevity;Endometriosis;
PAAD	cis	rs990171	0.511	rs2072509	chr2:103118337	G/C	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.96	10.26	0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg16667279	chr19:11591998	ELAVL3	-0.59	-4.53	-0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs12780845	0.931	rs67564104	chr10:17249545	C/T	cg00857480	chr10:17188594	TRDMT1	0.35	4.41	0.34	1.96e-5	Homocysteine levels;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-4.41	-0.34	1.98e-5	Self-reported allergy;
PAAD	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg13736514	chr6:26305472	NA	-0.47	-5.16	-0.39	7.7e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.38	4.4	0.34	2.02e-5	Fat distribution (HIV);
PAAD	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg05554000	chr7:158905015	VIPR2	-0.64	-5.28	-0.39	4.33e-7	Facial morphology (factor 20);
PAAD	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.78	5.74	0.42	4.92e-8	Vitiligo;
PAAD	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg19254793	chr6:44695348	NA	-0.44	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.86	9.79	0.62	7.72e-18	Body mass index;
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs10901513	0.932	rs10901503	chr10:127685323	C/T	cg22975853	chr10:127789788	ADAM12	0.43	4.58	0.35	9.51e-6	Visceral fat;
PAAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.06	-0.38	1.19e-6	Electroencephalogram traits;
PAAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-1.06	-14.84	-0.77	2.29e-31	Breast cancer;
PAAD	cis	rs9646944	0.501	rs12712144	chr2:102995600	C/G	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.69	-6.12	-0.44	7.78e-9	Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs275456	0.614	rs275458	chr5:6808767	C/A	cg10857441	chr5:6722123	POLS	-0.39	-4.59	-0.35	9.38e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.34	0.6	1.13e-16	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.5	5.99	0.44	1.48e-8	Height;
PAAD	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.47	-5.51	-0.41	1.52e-7	Coronary artery disease;
PAAD	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg23254163	chr1:152506842	NA	0.57	6.58	0.47	7.34e-10	Hair morphology;
PAAD	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.39	5.52	0.41	1.43e-7	Neuroticism;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg18833306	chr6:118973337	C6orf204	0.43	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.3	-0.33	3.02e-5	Cystic fibrosis severity;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.54	5.48	0.41	1.71e-7	Longevity;Endometriosis;
PAAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.56	-6.84	-0.49	1.82e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.53	4.92	0.37	2.24e-6	Eosinophilic esophagitis;
PAAD	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.56	-7.04	-0.5	6.22e-11	Lewy body disease;
PAAD	cis	rs13242816	1.000	rs17138714	chr7:116114274	C/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.85	-0.37	3.03e-6	P wave duration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20310435	chr2:179315647	PRKRA;MIR548N;DFNB59	-0.71	-6.5	-0.47	1.07e-9	Neuroticism;
PAAD	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	10.0	0.63	2.13e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02071572	chr4:1403502	NA	0.36	4.5	0.34	1.36e-5	Obesity-related traits;
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.56	-6.91	-0.49	1.25e-10	Monobrow;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.66	4.95	0.37	1.98e-6	Exhaled nitric oxide output;
PAAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	5.5	0.41	1.54e-7	Mood instability;
PAAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.08e-20	Electrocardiographic conduction measures;
PAAD	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.32e-6	Diastolic blood pressure;
PAAD	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs75920871	0.925	rs61903399	chr11:116942475	A/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg03805757	chr16:71968109	PKD1L3	-0.54	-4.79	-0.36	3.98e-6	Post bronchodilator FEV1;
PAAD	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.77	0.75	1.62e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.61	6.45	0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.53	-4.37	-0.33	2.32e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.84	-9.16	-0.6	3.23e-16	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04742505	chr7:72936528	BAZ1B	0.59	6.47	0.46	1.24e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg04682977	chr7:1062711	C7orf50;MIR339	1.01	6.33	0.46	2.61e-9	Atopic dermatitis;
PAAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg16586182	chr3:47516702	SCAP	-0.75	-8.78	-0.58	3.18e-15	Colorectal cancer;
PAAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.87	8.55	0.57	1.23e-14	Methadone dose in opioid dependence;
PAAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Magnesium levels;
PAAD	cis	rs6580110	0.793	rs9324792	chr5:154078564	A/G	cg17263206	chr5:154071247	NA	0.52	5.75	0.42	4.72e-8	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.79	9.25	0.6	1.94e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs863345	0.526	rs2051067	chr1:158507398	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs6834538	1.000	rs7665050	chr4:113521476	G/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.51	0.34	1.3e-5	Free thyroxine concentration;
PAAD	cis	rs496300	0.714	rs857569	chr21:44788512	A/G	cg18342814	chr21:45755740	C21orf2	-0.45	-4.26	-0.33	3.54e-5	Metabolic syndrome;
PAAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.58	-7.78	-0.53	1.04e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	1.04	9.33	0.6	1.23e-16	Monocyte percentage of white cells;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.57	-0.52	3.38e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11411865	chr7:2701802	TTYH3	0.61	4.34	0.33	2.62e-5	Bipolar disorder;
PAAD	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.9	11.74	0.69	4.54e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03689283	chr3:196668656	NCBP2;LOC152217	0.59	6.64	0.47	5.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.4	4.56	0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.41	5.2	0.39	6.39e-7	Colorectal cancer;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg10396713	chr8:602097	NA	0.72	4.98	0.37	1.7e-6	IgG glycosylation;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg01238044	chr22:24384105	GSTT1	-0.6	-5.77	-0.42	4.27e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg10518543	chr12:38710700	ALG10B	0.5	4.77	0.36	4.23e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg26818257	chr2:241905806	NA	-0.43	-4.29	-0.33	3.14e-5	Urinary metabolites;
PAAD	cis	rs56309584	0.874	rs7503199	chr17:8134275	C/T	cg25053252	chr17:7589358	TP53;WRAP53	-0.46	-4.28	-0.33	3.24e-5	Initial pursuit acceleration;
PAAD	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.72	-6.95	-0.49	9.98e-11	Alcohol dependence;
PAAD	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.46	0.65	1.26e-19	Morning vs. evening chronotype;
PAAD	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs10793968	0.748	rs2791741	chr9:133634645	G/A	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg05935833	chr10:81318306	SFTPA2	-0.52	-4.27	-0.33	3.48e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.15	0.39	7.94e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4739066	0.579	rs10957268	chr8:63944316	G/A	cg20602954	chr8:63776762	NKAIN3	0.68	4.5	0.34	1.33e-5	Myocardial infarction;
PAAD	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg03909863	chr11:638404	DRD4	-0.69	-6.1	-0.44	8.42e-9	Systemic lupus erythematosus;
PAAD	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.88	10.22	0.64	5.53e-19	Body mass index;
PAAD	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.41e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg22004693	chr7:99632812	ZKSCAN1	-0.41	-4.25	-0.33	3.76e-5	Interstitial lung disease;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.540	rs7282639	chr21:46491155	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.56	-4.71	-0.36	5.62e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.38	-4.44	-0.34	1.7e-5	HIV-1 susceptibility;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.59	6.09	0.44	8.98e-9	Lung cancer;
PAAD	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-5.02	-0.38	1.4e-6	Electroencephalogram traits;
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	6.92	0.49	1.17e-10	Systemic lupus erythematosus;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12169852	chr17:57231726	SKA2;PRR11	0.69	6.29	0.45	3.18e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg19592336	chr6:28129416	ZNF389	0.62	4.4	0.34	2.05e-5	Parkinson's disease;
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.69	5.18	0.39	7.08e-7	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15044146	chr17:35501295	ACACA	-0.64	-6.34	-0.46	2.5e-9	Obesity-related traits;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05564831	chr3:52568323	NT5DC2	0.45	4.87	0.37	2.81e-6	Bipolar disorder;
PAAD	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.73	-0.48	3.2e-10	Glomerular filtration rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17617527	chr5:142782415	NR3C1	0.64	6.43	0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.62	-5.74	-0.42	4.94e-8	Schizophrenia;
PAAD	cis	rs7429990	0.864	rs6777081	chr3:48155569	T/C	cg11946769	chr3:48343235	NME6	-0.52	-5.01	-0.38	1.52e-6	Educational attainment (years of education);
PAAD	trans	rs11794666	1.000	rs2375602	chr9:31668316	A/G	cg05628366	chr6:35744188	C6orf126	1.0	6.41	0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.52	-4.95	-0.37	1.91e-6	Mean platelet volume;
PAAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg03983476	chr2:10830698	NOL10	-0.62	-6.17	-0.45	5.82e-9	Prostate cancer;
PAAD	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.68	-6.93	-0.49	1.14e-10	Uric acid levels;
PAAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.95	8.18	0.55	1.03e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.73	-0.36	5.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.44	-4.25	-0.33	3.72e-5	Renal cell carcinoma;
PAAD	cis	rs7243821	0.921	rs7235521	chr18:52635956	A/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs62025270	0.547	rs8035496	chr15:86134332	T/C	cg13263323	chr15:86062960	AKAP13	0.47	4.46	0.34	1.58e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-8.03	-0.55	2.44e-13	Systemic lupus erythematosus;
PAAD	cis	rs1997066	0.831	rs73342217	chr10:106819285	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs16852403	0.619	rs10913509	chr1:178122784	C/G	cg00404053	chr1:178313656	RASAL2	0.45	4.36	0.33	2.38e-5	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.65	4.37	0.33	2.27e-5	Type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19828298	chr1:3713105	LRRC47	0.58	6.34	0.46	2.51e-9	Monocyte percentage of white cells;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21211367	chr2:162094118	NA	0.5	4.94	0.37	2.08e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-1.03	-6.5	-0.47	1.07e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.49	5.16	0.39	7.49e-7	Longevity;Endometriosis;
PAAD	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.52	0.34	1.26e-5	Educational attainment (years of education);
PAAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22947322	chr17:47091978	IGF2BP1	0.38	4.44	0.34	1.75e-5	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25439992	chr11:126173954	DCPS	0.68	7.4	0.51	8.87e-12	Myopia (pathological);
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.53	-4.66	-0.35	6.86e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.9	0.37	2.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12935418	0.672	rs9889194	chr16:81050817	T/C	cg16651780	chr16:81037892	C16orf61	0.67	6.28	0.45	3.31e-9	Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	2.02e-11	Dupuytren's disease;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.76	-8.9	-0.59	1.6e-15	Airway imaging phenotypes;
PAAD	cis	rs7742824	1.000	rs56168551	chr6:44104306	G/A	cg21657043	chr6:44035552	NA	0.48	4.79	0.36	3.94e-6	Major depressive disorder;
PAAD	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.82	-6.89	-0.49	1.4e-10	Cancer;
PAAD	cis	rs10450586	0.932	rs10767628	chr11:27310871	C/G	cg10370305	chr11:27303972	NA	0.38	4.55	0.35	1.1e-5	Total body bone mineral density;
PAAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-5.33	-0.4	3.5e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.45	5.64	0.42	8.22e-8	Crohn's disease;
PAAD	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.29	4.27	0.33	3.4e-5	Alopecia areata;
PAAD	cis	rs272000	0.636	rs175356	chr2:116610184	A/C	cg16071125	chr2:115972042	DPP10	0.45	4.33	0.33	2.74e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.51e-9	Bipolar disorder;
PAAD	cis	rs2016586	0.832	rs4820209	chr22:36104647	C/T	cg26342177	chr22:36113512	APOL5	0.44	4.62	0.35	8.24e-6	Body mass index;
PAAD	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.39	0.34	2.14e-5	IgG glycosylation;
PAAD	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg21238619	chr17:78079768	GAA	-0.38	-4.48	-0.34	1.44e-5	Yeast infection;
PAAD	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.87	-7.36	-0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.62	5.81	0.43	3.57e-8	Menopause (age at onset);
PAAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.82	10.25	0.64	4.56e-19	Methadone dose in opioid dependence;
PAAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8133932	0.637	rs7283688	chr21:47301354	T/A	cg13695288	chr21:47294981	PCBP3	-0.48	-4.7	-0.36	5.9e-6	Schizophrenia;
PAAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.94	13.28	0.73	3.34e-27	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg00035074	chr7:2701567	TTYH3	0.67	4.64	0.35	7.58e-6	Bipolar disorder;
PAAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.27	-0.39	4.6e-7	Menarche (age at onset);
PAAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.35	0.33	2.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg23119463	chr10:134592391	INPP5A	-0.46	-4.5	-0.34	1.36e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs12579720	0.909	rs7952739	chr12:20166338	C/T	cg17599586	chr22:32026779	PISD	-0.66	-6.37	-0.46	2.09e-9	Diastolic blood pressure;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg24101359	chr6:42928495	GNMT	0.55	5.59	0.41	1.02e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22301664	chr6:74072820	C6orf221	-0.66	-6.63	-0.47	5.59e-10	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01713535	chr14:57046409	C14orf101	-0.66	-7.39	-0.51	9.05e-12	Smoking initiation;
PAAD	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.52	0.41	1.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.78	6.71	0.48	3.68e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.8	-9.82	-0.62	6.31e-18	Height;
PAAD	cis	rs965469	0.779	rs6515791	chr20:3310443	C/G	cg25506879	chr20:3388711	C20orf194	-0.5	-4.27	-0.33	3.49e-5	IFN-related cytopenia;
PAAD	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-4.98	-0.37	1.7e-6	Systemic lupus erythematosus;
PAAD	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18005807	chr22:18506799	MICAL3	0.67	7.71	0.53	1.54e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.04	-0.44	1.15e-8	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-5.71	-0.42	5.82e-8	Prudent dietary pattern;
PAAD	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.31	0.73	2.74e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.75	-0.36	4.63e-6	Lung cancer;
PAAD	cis	rs57994353	0.568	rs10870151	chr9:139309584	G/A	cg21253087	chr9:139290292	SNAPC4	0.54	4.79	0.36	3.88e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg13647721	chr17:30228624	UTP6	0.59	4.81	0.36	3.57e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs4704187	0.687	rs7700965	chr5:74356857	T/C	cg03227963	chr5:74354835	NA	0.49	4.76	0.36	4.49e-6	Response to amphetamines;
PAAD	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.84	9.63	0.62	1.96e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7551345	1.000	rs6663779	chr1:31835527	C/T	cg17086398	chr1:31896392	SERINC2	-0.5	-4.53	-0.35	1.18e-5	Schizophrenia;
PAAD	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg04289385	chr6:36355825	ETV7	0.46	4.74	0.36	4.86e-6	Platelet distribution width;
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg15691649	chr6:25882328	NA	-0.48	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.61	-0.35	8.45e-6	Diastolic blood pressure;
PAAD	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.63	8.16	0.55	1.18e-13	Systemic lupus erythematosus;
PAAD	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	5.04	0.38	1.31e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.57	6.25	0.45	4.02e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12304921	0.748	rs73090630	chr12:51335813	G/A	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.29	-0.33	3.16e-5	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26306683	chr17:18585705	ZNF286B	0.56	5.54	0.41	1.32e-7	Educational attainment (years of education);
PAAD	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.17	-9.77	-0.62	8.57e-18	Vitiligo;
PAAD	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg03959625	chr15:84868606	LOC388152	-0.49	-5.37	-0.4	2.88e-7	Schizophrenia;
PAAD	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.96	5.32	0.4	3.57e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	8.61	0.57	8.67e-15	Cognitive test performance;
PAAD	cis	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs13242816	1.000	rs62471189	chr7:116101588	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-4.91	-0.37	2.32e-6	P wave duration;
PAAD	cis	rs7799006	0.582	rs11520750	chr7:2334025	G/C	cg08027265	chr7:2291960	NA	-0.44	-4.42	-0.34	1.85e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.36	4.74	0.36	4.89e-6	Plateletcrit;
PAAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.81	-8.76	-0.58	3.65e-15	Prostate cancer;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg20790798	chr5:1857306	NA	-0.48	-5.4	-0.4	2.52e-7	Cardiovascular disease risk factors;
PAAD	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.39	0.56	3.04e-14	Dupuytren's disease;
PAAD	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09695851	chr17:3907499	NA	0.63	5.9	0.43	2.23e-8	Type 2 diabetes;
PAAD	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.94	7.85	0.54	7.06e-13	Eosinophilic esophagitis;
PAAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg10356904	chr22:49881777	NA	-0.53	-5.05	-0.38	1.23e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg08219700	chr8:58056026	NA	0.69	5.22	0.39	5.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.73	-9.54	-0.61	3.48e-17	Asthma;
PAAD	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.28	0.33	3.35e-5	Red blood cell count;
PAAD	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	5.67	0.42	6.95e-8	Cervical cancer;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9.3e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00292662	chr22:38071168	LGALS1	0.51	4.47	0.34	1.5e-5	Fat distribution (HIV);
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg14515779	chr1:101123966	NA	0.48	6.22	0.45	4.58e-9	Monocyte count;
PAAD	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13198984	chr17:80129470	CCDC57	0.45	5.62	0.41	8.97e-8	Life satisfaction;
PAAD	cis	rs7243821	0.921	rs2000835	chr18:52590331	A/G	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.44e-7	Chin dimples;
PAAD	cis	rs11020478	0.562	rs694699	chr11:93473969	A/T	cg10523193	chr11:93463762	SNORA25	0.41	4.25	0.33	3.78e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28595532	0.547	rs1913576	chr4:119297789	C/T	cg21605333	chr4:119757512	SEC24D	1.38	7.33	0.51	1.25e-11	Cannabis dependence symptom count;
PAAD	cis	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.86	10.07	0.63	1.37e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	4.88	0.37	2.7e-6	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.85	-0.62	5.37e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs9815354	1.000	rs6803560	chr3:41824480	A/G	cg03022575	chr3:42003672	ULK4	0.75	5.55	0.41	1.22e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	4.37	0.33	2.32e-5	Schizophrenia;
PAAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg27121462	chr16:89883253	FANCA	0.46	4.89	0.37	2.49e-6	Vitiligo;
PAAD	cis	rs7932354	0.583	rs10838629	chr11:46906845	G/A	cg19486271	chr11:47235900	DDB2	-0.61	-5.92	-0.43	2.11e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs438465	0.853	rs394053	chr6:169808704	T/A	cg11181693	chr6:169825345	NA	-0.56	-4.31	-0.33	2.89e-5	Corneal astigmatism;
PAAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.82	-10.14	-0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs2279817	0.863	rs12753636	chr1:18013602	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.83	-0.43	3.26e-8	Neuroticism;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.86	6.61	0.47	6.05e-10	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.48	5.68	0.42	6.57e-8	Psoriasis;
PAAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.64	0.62	1.9e-17	Bladder cancer;
PAAD	cis	rs76917914	0.820	rs12554583	chr9:100812569	A/G	cg21225548	chr9:100864335	TRIM14	-0.55	-5.96	-0.44	1.71e-8	Immature fraction of reticulocytes;
PAAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.47	5.4	0.4	2.49e-7	Testicular germ cell tumor;
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg08807892	chr2:162101083	NA	-0.75	-10.03	-0.63	1.72e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.32	5.57	0.41	1.11e-7	Type 2 diabetes;
PAAD	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	1.16	9.81	0.62	6.62e-18	Height;
PAAD	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.2	0.5	2.58e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2415984	0.644	rs1669808	chr14:46930473	A/G	cg14871534	chr14:47121158	RPL10L	0.54	5.59	0.41	1.02e-7	Number of children ever born;
PAAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.59	6.67	0.48	4.41e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19443418	chr4:39482010	LOC401127	0.64	7.89	0.54	5.46e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.46	-4.76	-0.36	4.46e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2997447	0.761	rs61776582	chr1:26437262	A/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	5.93	0.43	1.98e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs593531	0.550	rs592644	chr11:74053547	C/T	cg15670924	chr11:73669256	DNAJB13	-0.43	-4.4	-0.34	2.06e-5	Neuroticism;
PAAD	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg20821713	chr7:1055600	C7orf50	-0.58	-5.02	-0.38	1.45e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	trans	rs6694672	1.000	rs7542397	chr1:197096720	G/A	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	1.03	7.33	0.51	1.26e-11	Alzheimer's disease;
PAAD	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.66	7.94	0.54	4.16e-13	Bone mineral density;
PAAD	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg13482628	chr17:19912719	NA	0.51	5.16	0.39	7.48e-7	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg20243544	chr17:37824526	PNMT	0.51	4.45	0.34	1.68e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.64	7.07	0.5	5.38e-11	Height;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg14008862	chr17:28927542	LRRC37B2	-0.81	-5.72	-0.42	5.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06900676	chr2:61293330	KIAA1841	0.58	6.42	0.46	1.63e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs12431939	0.779	rs2999381	chr14:51645368	T/C	cg23942311	chr14:51606299	NA	0.61	5.28	0.39	4.45e-7	Cancer;
PAAD	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.65	-6.13	-0.45	7.19e-9	Lymphocyte counts;
PAAD	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg03983715	chr16:68378420	PRMT7	-0.83	-5.95	-0.43	1.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg04851639	chr8:1020857	NA	-0.66	-8.22	-0.55	8.42e-14	Schizophrenia;
PAAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.03	-0.38	1.35e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8077059	0.959	rs3883322	chr17:55820399	G/A	cg12582317	chr17:55822272	NA	0.51	4.78	0.36	4.12e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs3764400	0.508	rs757353	chr17:46122270	A/G	cg24322968	chr17:46507895	SKAP1	0.83	5.27	0.39	4.54e-7	Body mass index;
PAAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.47	4.54	0.35	1.13e-5	Morning vs. evening chronotype;
PAAD	cis	rs2594989	1.000	rs2594978	chr3:11383347	C/A	cg01796438	chr3:11312864	ATG7	-0.67	-5.19	-0.39	6.51e-7	Circulating chemerin levels;
PAAD	trans	rs1233491	1	rs1233491	chr6:29461730	G/C	cg01620082	chr3:125678407	NA	-1.61	-10.05	-0.63	1.51e-18	Cutaneous lupus erythematosus;
PAAD	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.61	-5.37	-0.4	2.93e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.91	-10.46	-0.65	1.25e-19	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20668001	chr5:134235666	TXNDC15	0.61	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs6681460	0.625	rs6680364	chr1:67104834	G/A	cg02459107	chr1:67143332	SGIP1	0.54	5.06	0.38	1.22e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs1113500	0.748	rs1781048	chr1:108555050	A/T	cg06207961	chr1:108661230	NA	0.47	5.21	0.39	6.06e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6494488	0.500	rs72742966	chr15:64919179	G/A	cg16425858	chr15:64791681	ZNF609	0.92	4.55	0.35	1.08e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16526952	chr3:49131030	QRICH1	-0.77	-6.59	-0.47	6.65e-10	Neuroticism;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.71e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.65	5.29	0.39	4.18e-7	Cognitive function;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.22e-17	Electrocardiographic conduction measures;
PAAD	cis	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg21546286	chr11:48923668	NA	-0.57	-5.97	-0.44	1.62e-8	HDL cholesterol;
PAAD	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.02	6.93	0.49	1.1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.74	-0.36	4.81e-6	Eotaxin levels;
PAAD	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.8	0.77	2.97e-31	Chronic sinus infection;
PAAD	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.49	4.41	0.34	1.94e-5	Height;
PAAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg07517944	chr15:51633816	GLDN	0.44	4.44	0.34	1.7e-5	Hormone measurements;
PAAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.86	-0.43	2.8e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-4.57	-0.35	9.87e-6	Axial length;
PAAD	cis	rs9976767	0.932	rs9978717	chr21:43827765	A/G	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.59	-0.35	9.04e-6	Type 1 diabetes;
PAAD	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.61	-6.62	-0.47	5.88e-10	Calcium levels;
PAAD	cis	rs13070279	0.655	rs11927001	chr3:71795224	A/G	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg01529538	chr14:23388837	RBM23	0.54	5.18	0.39	7.07e-7	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.64	5.45	0.4	1.97e-7	Common traits (Other);
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	0.97	6.37	0.46	2.18e-9	IgG glycosylation;
PAAD	cis	rs7674212	0.581	rs10516496	chr4:103942165	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-4.39	-0.34	2.08e-5	Type 2 diabetes;
PAAD	cis	rs11615916	0.656	rs7958825	chr12:62825851	C/T	cg11441379	chr12:63026424	NA	0.76	4.77	0.36	4.28e-6	Pulmonary function decline;
PAAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.64	5.8	0.43	3.77e-8	Blood metabolite levels;
PAAD	cis	rs1005224	0.889	rs10132250	chr14:76124380	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.54	-4.62	-0.35	8.07e-6	Large artery stroke;
PAAD	cis	rs227833	0.837	rs679769	chr6:44674860	C/T	cg20913747	chr6:44695427	NA	0.47	5.08	0.38	1.07e-6	Monobrow;
PAAD	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.841	rs73599506	chr16:67712366	T/C	cg09835421	chr16:68378352	PRMT7	-0.66	-4.55	-0.35	1.11e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	1.0	9.76	0.62	8.82e-18	Psoriasis;
PAAD	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.68	7.96	0.54	3.74e-13	Systemic lupus erythematosus;
PAAD	cis	rs7688540	0.800	rs2353599	chr4:280426	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.46	4.59	0.35	9.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.67	6.8	0.48	2.19e-10	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03613717	chr10:121356708	TIAL1	0.66	7.63	0.53	2.41e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg21546286	chr11:48923668	NA	-0.46	-4.68	-0.36	6.17e-6	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg19163074	chr7:65112434	INTS4L2	0.44	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.93	-6.55	-0.47	8.2e-10	Body mass index;
PAAD	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	4.93	0.37	2.13e-6	Thyroid stimulating hormone;
PAAD	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs867529	0.722	rs67110763	chr2:88950916	A/C	cg26627705	chr2:89060884	NA	-0.45	-4.38	-0.33	2.19e-5	Height;
PAAD	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.48	-5.11	-0.38	9.75e-7	Motion sickness;
PAAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.39	0.34	2.09e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.86	10.77	0.66	1.9e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg03128945	chr5:622914	CEP72	-0.5	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.5	-4.46	-0.34	1.55e-5	Lung cancer;
PAAD	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs11581903	0.866	rs11591099	chr1:53056597	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.89	6.16	0.45	6.16e-9	Joint mobility (Beighton score);
PAAD	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.23	-0.86	2.6e-47	Myeloid white cell count;
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.75	8.83	0.58	2.38e-15	Morning vs. evening chronotype;
PAAD	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.71	5.38	0.4	2.79e-7	Diastolic blood pressure;
PAAD	cis	rs7804356	0.651	rs56374720	chr7:26815776	G/A	cg03456212	chr7:26904342	SKAP2	-0.59	-5.0	-0.38	1.54e-6	Type 1 diabetes;
PAAD	cis	rs757978	1.000	rs3732276	chr2:242343404	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.76	-4.64	-0.35	7.54e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg17633681	chr16:88106987	BANP	0.66	8.43	0.56	2.48e-14	Menopause (age at onset);
PAAD	cis	rs1957429	0.520	rs229669	chr14:65284391	T/C	cg23373153	chr14:65346875	NA	-1.13	-5.69	-0.42	6.47e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2275731	0.650	rs7904014	chr10:16547058	A/G	cg04254609	chr10:16479192	PTER	-0.42	-4.46	-0.34	1.57e-5	Bone fracture in osteoporosis;
PAAD	cis	rs7816613	0.920	rs16868196	chr8:102682242	A/G	cg20585841	chr8:102729926	NCALD	0.63	4.85	0.37	2.97e-6	Age-related hearing impairment;
PAAD	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.82	0.48	2.06e-10	Resting heart rate;
PAAD	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.48	-4.68	-0.35	6.33e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6708413	0.521	rs6543153	chr2:103114203	T/C	cg13897122	chr2:103039542	IL18RAP	-0.48	-5.31	-0.4	3.91e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg18279126	chr7:2041391	MAD1L1	0.57	5.6	0.41	9.9e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg00666640	chr1:248458726	OR2T12	0.48	4.9	0.37	2.42e-6	Common traits (Other);
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg25287198	chr4:183728479	NA	0.85	6.99	0.49	8.28e-11	Pediatric autoimmune diseases;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg02725872	chr8:58115012	NA	-0.64	-5.45	-0.4	1.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7714584	1.000	rs6862814	chr5:150245259	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.68	-7.68	-0.53	1.81e-12	White blood cell count (basophil);
PAAD	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.53	5.14	0.38	8.31e-7	Cognitive ability;
PAAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.85	6.25	0.45	3.93e-9	Breast cancer;
PAAD	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg06634786	chr22:41940651	POLR3H	0.68	4.99	0.38	1.65e-6	Vitiligo;
PAAD	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.52	-4.59	-0.35	9.06e-6	Waist circumference;Body mass index;
PAAD	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.42	-5.44	-0.4	2.07e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.77	-6.39	-0.46	1.89e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.95	5.03	0.38	1.4e-6	Childhood ear infection;
PAAD	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.68	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	trans	rs16977195	0.826	rs1845935	chr15:86828803	G/A	cg15572745	chr14:78870232	NRXN3	-1.2	-6.39	-0.46	1.95e-9	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg13047869	chr3:10149882	C3orf24	0.55	4.87	0.37	2.71e-6	Alzheimer's disease;
PAAD	trans	rs61931739	0.620	rs7138912	chr12:33701863	G/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-6.59	-0.47	6.77e-10	Colorectal cancer;
PAAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-6.08	-0.44	9.09e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	trans	rs901683	1.000	rs35918870	chr10:45998278	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4455778	0.580	rs4917034	chr7:49113788	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs12304921	0.935	rs79907213	chr12:51354694	C/T	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.81	0.36	3.59e-6	Menopause (age at onset);
PAAD	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	10.64	0.65	4.1e-20	Menopause (age at onset);
PAAD	cis	rs55883249	1.000	rs60319753	chr2:9767944	A/G	cg23886495	chr2:9695866	ADAM17	0.51	4.3	0.33	3.04e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg11461875	chr4:1768568	NA	0.37	4.31	0.33	2.97e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.61	-0.47	6.13e-10	Response to antipsychotic treatment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10231742	chr1:111991923	WDR77;ATP5F1	0.63	7.14	0.5	3.61e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12668415	chr12:133297765	PGAM5	-0.68	-6.61	-0.47	6.21e-10	Obesity-related traits;
PAAD	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg05519781	chr21:40033154	ERG	0.49	5.93	0.43	2e-8	Coronary artery disease;
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg08017634	chr8:144659831	NAPRT1	0.82	4.69	0.36	5.98e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.94	6.45	0.46	1.42e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg08501292	chr6:25962987	TRIM38	0.83	4.97	0.37	1.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg25837213	chr17:80849375	TBCD	0.46	4.46	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.53	5.54	0.41	1.32e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	trans	rs9372498	1.000	rs1889468	chr6:118599828	A/G	cg15607664	chr12:57630422	NDUFA4L2	-0.78	-7.56	-0.52	3.64e-12	Diastolic blood pressure;
PAAD	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	6.18	0.45	5.59e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.73	4.77	0.36	4.22e-6	Glycated hemoglobin levels;
PAAD	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg14515779	chr1:101123966	NA	0.49	6.29	0.45	3.24e-9	Monocyte count;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.74	9.35	0.6	1.09e-16	Breast cancer;
PAAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.46	-0.34	1.57e-5	Renal cell carcinoma;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	1.37	7.3	0.51	1.47e-11	Skin colour saturation;
PAAD	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.68	6.43	0.46	1.55e-9	Coronary artery disease;
PAAD	cis	rs986417	0.540	rs10144415	chr14:61112667	G/C	cg27398547	chr14:60952738	C14orf39	0.82	4.87	0.37	2.82e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.45	-4.36	-0.33	2.36e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02071572	chr4:1403502	NA	0.38	4.89	0.37	2.56e-6	Longevity;
PAAD	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg14515779	chr1:101123966	NA	-0.54	-6.82	-0.48	2.06e-10	Monocyte count;
PAAD	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-11.04	-0.67	3.54e-21	Heart rate;
PAAD	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg09796270	chr17:17721594	SREBF1	0.46	4.48	0.34	1.46e-5	Total body bone mineral density;
PAAD	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.51	-0.52	4.81e-12	Migraine;Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24074884	chr19:17356310	NR2F6	0.62	6.46	0.46	1.34e-9	Myopia (pathological);
PAAD	cis	rs3540	0.538	rs2074585	chr15:91009484	G/A	cg10434728	chr15:90938212	IQGAP1	0.46	4.55	0.35	1.09e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs35160687	0.901	rs35281683	chr2:86526372	T/C	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.85	-9.95	-0.63	2.83e-18	Iron status biomarkers;
PAAD	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg01475377	chr6:109611718	NA	-0.43	-4.74	-0.36	4.93e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.58	8.15	0.55	1.25e-13	Asthma (sex interaction);
PAAD	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.65	6.22	0.45	4.68e-9	Subjective well-being;
PAAD	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.44	-6.36	-0.46	2.26e-9	Melanoma;
PAAD	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg08484560	chr13:113413587	ATP11A	-0.43	-4.28	-0.33	3.36e-5	Platelet distribution width;
PAAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg14820908	chr5:178986412	RUFY1	-0.61	-6.39	-0.46	1.91e-9	Lung cancer;
PAAD	cis	rs2109514	0.967	rs55883210	chr7:116160524	G/A	cg19719915	chr7:115928094	NA	-0.45	-4.3	-0.33	3.06e-5	Prevalent atrial fibrillation;
PAAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05585630	chr7:157510462	PTPRN2	-0.8	-9.29	-0.6	1.56e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-7.39	-0.51	9.1e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	6.82	0.48	1.97e-10	Rheumatoid arthritis;
PAAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.36	4.26	0.33	3.62e-5	Schizophrenia;
PAAD	cis	rs4343996	1.000	rs6461994	chr7:3356483	C/G	cg21248987	chr7:3385318	SDK1	-0.45	-4.89	-0.37	2.49e-6	Motion sickness;
PAAD	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.76	-0.62	8.83e-18	Blood trace element (Zn levels);
PAAD	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg21419209	chr3:44054225	NA	-0.59	-5.85	-0.43	2.89e-8	Coronary artery disease;
PAAD	cis	rs4740619	0.716	rs1410444	chr9:15942632	C/G	cg14451791	chr9:16040625	NA	-0.43	-4.94	-0.37	2.04e-6	Body mass index;
PAAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00864171	chr11:67383662	NA	-0.55	-5.47	-0.41	1.77e-7	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14335767	chr8:124286570	ZHX1	-0.59	-6.83	-0.48	1.92e-10	Body fat percentage;
PAAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	1.06	11.17	0.67	1.56e-21	Eosinophil percentage of granulocytes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06652112	chr3:193853919	HES1	-0.67	-6.75	-0.48	2.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27297192	chr10:134578999	INPP5A	0.61	5.48	0.41	1.69e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg00459043	chr17:30771460	PSMD11	-0.56	-4.8	-0.36	3.8e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.75	8.45	0.57	2.17e-14	Lung cancer;
PAAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg16147221	chr4:10020634	SLC2A9	0.47	4.3	0.33	3e-5	Bone mineral density;
PAAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg10589385	chr1:150898437	SETDB1	0.37	4.58	0.35	9.58e-6	Melanoma;
PAAD	cis	rs10073892	0.830	rs28602449	chr5:101610006	G/A	cg17280723	chr5:101634495	NA	0.44	4.55	0.35	1.1e-5	Cognitive decline (age-related);
PAAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.56	5.7	0.42	6.14e-8	Testicular germ cell tumor;
PAAD	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.49	-4.39	-0.34	2.1e-5	Acne (severe);
PAAD	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.33	-0.4	3.55e-7	Height;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.42	-0.34	1.86e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.48	0.47	1.19e-9	Morning vs. evening chronotype;
PAAD	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.73	0.53	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	5.66	0.42	7.19e-8	Birth weight;
PAAD	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.14e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg15816464	chr17:2026533	SMG6	0.53	5.81	0.43	3.46e-8	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15345369	chr2:10262827	RRM2	0.54	6.47	0.46	1.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.64	-5.98	-0.44	1.54e-8	Multiple myeloma;
PAAD	cis	rs6466055	0.591	rs67505443	chr7:104893335	C/T	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg15764593	chr10:829463	NA	-0.88	-4.35	-0.33	2.49e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg01942863	chr7:99769432	GPC2	0.5	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.81	8.87	0.58	1.89e-15	Mortality in heart failure;
PAAD	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.97	4.65	0.35	7.11e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg26528668	chr16:1614120	IFT140	0.48	4.52	0.34	1.23e-5	Coronary artery disease;
PAAD	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.59	4.38	0.33	2.24e-5	Cholesterol, total;
PAAD	trans	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg01957732	chr6:133561716	EYA4	-0.94	-7.25	-0.51	1.95e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg22705602	chr4:152727874	NA	-0.48	-5.1	-0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1075265	0.868	rs1877906	chr2:54363837	A/G	cg04546899	chr2:54196757	PSME4	0.34	4.87	0.37	2.79e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.64	5.35	0.4	3.23e-7	Obesity (extreme);
PAAD	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.53	4.76	0.36	4.4e-6	Type 2 diabetes;
PAAD	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.37	-0.33	2.34e-5	Resting heart rate;
PAAD	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg23250157	chr14:64679961	SYNE2	0.5	5.26	0.39	4.72e-7	Atrial fibrillation;
PAAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.81	7.15	0.5	3.48e-11	Psoriasis;
PAAD	cis	rs75920871	0.623	rs11823889	chr11:116960403	G/A	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs58521262	0.556	rs158694	chr19:23202776	A/G	cg02350677	chr19:23254381	NA	0.26	4.51	0.34	1.3e-5	Testicular germ cell tumor;
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.49e-12	Aortic root size;
PAAD	cis	rs11669133	1.000	rs115126258	chr19:11075749	C/T	cg18582342	chr19:11591989	ELAVL3	-0.66	-4.43	-0.34	1.81e-5	LDL cholesterol;
PAAD	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg08923669	chr16:420230	MRPL28	-0.52	-4.55	-0.35	1.1e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-6.23	-0.45	4.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6782025	1.000	rs6787048	chr3:121141036	A/C	cg16417163	chr3:121280760	NA	-0.47	-4.85	-0.37	3.02e-6	Aging (facial);
PAAD	cis	rs6466055	0.589	rs6466035	chr7:104646899	C/T	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs77303548	chr3:128454766	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.52	-4.84	-0.37	3.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.74	7.68	0.53	1.84e-12	Menarche (age at onset);
PAAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-8.04	-0.55	2.37e-13	Body mass index;
PAAD	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.95	11.33	0.68	5.92e-22	Osteoporosis;
PAAD	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg00806126	chr19:22604979	ZNF98	-0.41	-4.95	-0.37	1.97e-6	Pain;
PAAD	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.87	-9.59	-0.61	2.54e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs728616	0.558	rs116434658	chr10:81754626	G/A	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.81	-0.36	3.68e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.81	-9.72	-0.62	1.11e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg01064725	chr1:204461714	NA	-0.51	-4.68	-0.35	6.29e-6	Schizophrenia;
PAAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.49	-0.41	1.62e-7	Blood metabolite levels;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01616529	chr11:638424	DRD4	-0.75	-6.76	-0.48	2.74e-10	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.84	-7.31	-0.51	1.41e-11	Coronary artery disease;
PAAD	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg18833306	chr6:118973337	C6orf204	0.44	4.68	0.36	6.23e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.54	-5.47	-0.41	1.79e-7	Interleukin-18 levels;
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.46	4.57	0.35	1.02e-5	Cognitive function;
PAAD	cis	rs11807834	0.522	rs4846832	chr1:230250676	G/A	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.44e-7	Cognitive function;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-6.19	-0.45	5.45e-9	Lymphocyte counts;
PAAD	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg01761236	chr14:102990251	NA	0.4	4.69	0.36	6.08e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.59	-5.42	-0.4	2.33e-7	Retinal vascular caliber;
PAAD	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg15145965	chr22:50218605	BRD1	0.61	5.24	0.39	5.26e-7	Schizophrenia;
PAAD	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.86	-7.3	-0.51	1.49e-11	Blood protein levels;
PAAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.29	0.39	4.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6703335	0.870	rs10803142	chr1:243598234	A/G	cg24809150	chr1:244211390	NA	0.42	4.27	0.33	3.41e-5	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg22532475	chr10:104410764	TRIM8	-0.4	-4.61	-0.35	8.51e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs6010044	0.609	rs8142140	chr22:51091914	C/T	cg00083937	chr22:51039805	MAPK8IP2	0.55	4.28	0.33	3.3e-5	Fibrinogen levels;Fibrinogen;
PAAD	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg02404636	chr22:31891804	SFI1	0.64	6.17	0.45	5.91e-9	Paclitaxel-induced neuropathy;
PAAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.51	5.8	0.43	3.77e-8	Vitiligo;
PAAD	cis	rs939584	1.000	rs6711039	chr2:624084	G/A	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.96	-10.03	-0.63	1.7e-18	Homoarginine levels;
PAAD	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.66	0.62	1.66e-17	Cognitive function;
PAAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.61	6.67	0.48	4.57e-10	Tonsillectomy;
PAAD	cis	rs6445967	1.000	rs13325699	chr3:58286870	T/C	cg23715586	chr3:58305044	RPP14	0.49	4.35	0.33	2.44e-5	Platelet count;
PAAD	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg21823605	chr1:152486609	CRCT1	0.48	6.05	0.44	1.07e-8	Hair morphology;
PAAD	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs12681963	0.688	rs10503864	chr8:30051213	C/T	cg23406830	chr8:30012838	DCTN6	0.66	4.26	0.33	3.62e-5	Migraine;
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-4.42	-0.34	1.87e-5	Tonsillectomy;
PAAD	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.62	-7.01	-0.49	7.39e-11	Colorectal cancer;
PAAD	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	1.25	10.71	0.66	2.72e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs34787248	1	rs34787248	chr6:28197886	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.44	4.68	0.35	6.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg11519256	chr10:5708881	ASB13	-0.56	-4.77	-0.36	4.23e-6	Menopause (age at onset);
PAAD	cis	rs58521262	0.519	rs12609223	chr19:22908115	C/T	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.625	rs73186025	chr7:104878705	C/T	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg24375607	chr4:120327624	NA	0.53	4.98	0.37	1.67e-6	Corneal astigmatism;
PAAD	cis	rs58521262	0.556	rs289362	chr19:23118399	A/G	cg22640819	chr19:22990650	NA	-0.28	-4.32	-0.33	2.79e-5	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.65	6.3	0.46	3.06e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg23033748	chr14:75592666	NEK9	0.43	5.26	0.39	4.9e-7	Height;
PAAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg15921436	chr17:44337874	NA	-0.65	-5.8	-0.43	3.81e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7742824	0.827	rs59842359	chr6:44105929	C/T	cg21657043	chr6:44035552	NA	0.49	4.86	0.37	2.89e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-4.89	-0.37	2.54e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.6	6.17	0.45	5.87e-9	Dupuytren's disease;
PAAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.5	-4.65	-0.35	7.04e-6	Monocyte count;
PAAD	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg01884057	chr2:25150051	NA	0.38	4.65	0.35	7.05e-6	Body mass index in non-asthmatics;
PAAD	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg26816564	chr1:7831052	VAMP3	-0.61	-5.22	-0.39	5.86e-7	Inflammatory bowel disease;
PAAD	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg22437258	chr11:111473054	SIK2	-0.64	-5.89	-0.43	2.4e-8	Primary sclerosing cholangitis;
PAAD	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.5	4.77	0.36	4.25e-6	Depression;
PAAD	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.77	9.56	0.61	2.96e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9322817	0.691	rs9391244	chr6:105257690	G/A	cg02098413	chr6:105308735	HACE1	-0.43	-5.4	-0.4	2.56e-7	Thyroid stimulating hormone;
PAAD	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.79	0.62	7.63e-18	Chronic sinus infection;
PAAD	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg01388757	chr2:102091195	RFX8	-0.59	-7.52	-0.52	4.55e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	1.02	7.92	0.54	4.72e-13	IgG glycosylation;
PAAD	cis	rs11638815	0.626	rs11633829	chr15:83326938	C/T	cg00614314	chr15:82944287	LOC80154	-0.51	-4.9	-0.37	2.38e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg23127183	chr11:57508653	C11orf31	-0.5	-4.33	-0.33	2.67e-5	Schizophrenia;
PAAD	cis	rs2414095	0.520	rs3784307	chr15:51506634	G/A	cg21478137	chr15:51532386	CYP19A1	0.45	4.51	0.34	1.28e-5	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	12.19	0.7	2.91e-24	Cognitive ability;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11718135	chr2:192110830	MYO1B	0.7	7.04	0.5	6.19e-11	Primary biliary cholangitis;
PAAD	cis	rs16975963	0.644	rs11083430	chr19:38139488	A/G	cg08679971	chr19:38281047	NA	0.46	4.49	0.34	1.38e-5	Longevity;
PAAD	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg14219918	chr9:127249562	NR5A1	0.33	4.31	0.33	2.9e-5	Menarche (age at onset);
PAAD	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.8	9.03	0.59	7.24e-16	Corneal astigmatism;
PAAD	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-8.94	-0.59	1.26e-15	Vitiligo;
PAAD	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.95	0.37	1.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.39	0.46	1.89e-9	Hip circumference;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg15117754	chr3:10150083	C3orf24	0.74	6.16	0.45	6.2e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.33	-0.46	2.68e-9	Longevity;
PAAD	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg12218747	chr21:37451666	NA	-0.58	-6.08	-0.44	9.36e-9	Mitral valve prolapse;
PAAD	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.93	6.08	0.44	9.49e-9	Major depressive disorder;
PAAD	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.48	4.58	0.35	9.59e-6	Uric acid levels;
PAAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs59888335	0.862	rs4416346	chr3:80611818	A/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg24687543	chr11:63912206	MACROD1	0.62	5.41	0.4	2.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs12803635	0.557	rs35121740	chr11:67175349	G/A	cg00983899	chr11:67290853	CABP2	-0.71	-4.27	-0.33	3.46e-5	Mean corpuscular volume;
PAAD	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg02734326	chr4:10020555	SLC2A9	-0.54	-5.34	-0.4	3.31e-7	Bone mineral density;
PAAD	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg12633918	chr20:23549525	CST9L	-0.44	-4.85	-0.37	2.99e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.56	0.35	1.03e-5	Menarche (age at onset);
PAAD	cis	rs2882667	0.690	rs6596456	chr5:138167497	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.59	-0.41	1.04e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.27	0.45	3.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg02780029	chr10:43622663	RET	-0.45	-4.51	-0.34	1.27e-5	Hirschsprung disease;
PAAD	cis	rs6563943	0.857	rs1833965	chr16:83636801	A/C	cg01935413	chr16:83636749	CDH13	-0.54	-5.07	-0.38	1.16e-6	Height;
PAAD	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg00666640	chr1:248458726	OR2T12	0.65	5.68	0.42	6.7e-8	Common traits (Other);
PAAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg10556349	chr10:835070	NA	0.52	4.31	0.33	2.92e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	6.9	0.49	1.29e-10	Body mass index (adult);
PAAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.72	9.08	0.59	5.31e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.75	-7.55	-0.52	3.69e-12	Superior crus of antihelix expression;
PAAD	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg27511599	chr7:32358540	NA	0.75	4.53	0.34	1.21e-5	Body mass index;
PAAD	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs7534824	0.625	rs17409422	chr1:101502386	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.71	0.36	5.52e-6	Refractive astigmatism;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.54	5.65	0.42	7.62e-8	Testicular germ cell tumor;
PAAD	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	4.44	0.34	1.74e-5	Height;
PAAD	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg09980403	chr19:12975529	MAST1	-0.28	-4.67	-0.35	6.51e-6	Mean corpuscular volume;
PAAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-6.28	-0.45	3.43e-9	Mood instability;
PAAD	cis	rs35123781	0.502	rs440662	chr5:139003472	T/C	cg26929925	chr5:138714136	SLC23A1	-0.49	-4.43	-0.34	1.79e-5	Schizophrenia;
PAAD	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.35	-0.33	2.44e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs35785195	0.593	rs12821514	chr12:114233825	G/A	cg11070030	chr12:114232702	NA	0.61	4.7	0.36	5.8e-6	Daytime sleep phenotypes;
PAAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.56	-5.63	-0.42	8.28e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.39	-0.76	3.65e-30	Primary sclerosing cholangitis;
PAAD	cis	rs4824093	0.544	rs7410765	chr22:50315924	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-4.34	-0.33	2.63e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08260549	chr8:21777063	XPO7	0.71	6.87	0.49	1.51e-10	Myopia (pathological);
PAAD	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.67	4.9	0.37	2.4e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.49	4.6	0.35	8.77e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg10856724	chr12:34555212	NA	0.43	4.46	0.34	1.56e-5	Morning vs. evening chronotype;
PAAD	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	7.04	0.5	6.34e-11	Response to antipsychotic treatment;
PAAD	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg14404164	chr7:157455790	PTPRN2	-0.61	-4.29	-0.33	3.17e-5	Colorectal cancer;
PAAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg06521852	chr22:38141419	TRIOBP	0.42	4.42	0.34	1.84e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.44	-0.34	1.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.26e-5	Height;
PAAD	cis	rs3206736	0.548	rs1637675	chr7:35000492	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.57	-5.15	-0.39	8.13e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.6	7.15	0.5	3.41e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg16342193	chr10:102329863	NA	-0.66	-6.19	-0.45	5.4e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.97e-16	Cannabis dependence symptom count;
PAAD	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.63	5.81	0.43	3.5e-8	Obesity-related traits;
PAAD	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg22134325	chr11:66188745	NPAS4	0.4	4.85	0.37	3e-6	Airway imaging phenotypes;
PAAD	cis	rs66530629	0.874	rs3120831	chr1:25094344	A/T	cg01905478	chr1:25040257	NA	-0.47	-5.14	-0.38	8.44e-7	Plateletcrit;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg07212818	chr11:638076	DRD4	-0.69	-6.75	-0.48	2.91e-10	Systemic lupus erythematosus;
PAAD	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.64	-5.94	-0.43	1.87e-8	Diisocyanate-induced asthma;
PAAD	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-16.85	-0.81	1.3e-36	Prudent dietary pattern;
PAAD	cis	rs2017305	1.000	rs955413	chr10:70702853	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13198984	chr17:80129470	CCDC57	0.41	5.12	0.38	9.01e-7	Life satisfaction;
PAAD	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg10006428	chr1:248814059	OR2T27	0.36	4.39	0.34	2.14e-5	Common traits (Other);
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04156016	chr5:1868137	NA	0.44	4.51	0.34	1.31e-5	Cardiovascular disease risk factors;
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06444125	chr16:30103218	TBX6	0.6	6.4	0.46	1.79e-9	Myopia (pathological);
PAAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg22549504	chr19:17448937	GTPBP3	0.54	4.29	0.33	3.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.68	5.41	0.4	2.38e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg14582100	chr15:45693742	SPATA5L1	0.36	5.22	0.39	5.73e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2834188	0.924	rs2409487	chr21:34684958	C/T	cg04842828	chr21:34696676	IFNAR1	0.49	4.63	0.35	7.89e-6	Narcolepsy;
PAAD	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs427941	0.703	rs201454	chr7:101740056	A/G	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.5	6.45	0.46	1.37e-9	IgA nephropathy;
PAAD	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg12288994	chr5:1860383	NA	0.59	6.88	0.49	1.5e-10	Cardiovascular disease risk factors;
PAAD	cis	rs6083	0.571	rs56010348	chr15:58848120	T/G	cg05156742	chr15:59063176	FAM63B	-0.59	-5.83	-0.43	3.21e-8	Schizophrenia;
PAAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Coronary artery disease;
PAAD	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.77	7.59	0.52	2.95e-12	Breast cancer;
PAAD	cis	rs16854884	0.770	rs7621079	chr3:143814500	G/C	cg06585982	chr3:143692056	C3orf58	0.5	4.98	0.37	1.7e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.52	6.55	0.47	8.53e-10	Schizophrenia;
PAAD	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.46	-0.34	1.59e-5	Pulmonary function;
PAAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs617219	0.710	rs2166344	chr5:78534134	T/G	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-4.36	-0.33	2.36e-5	Blood metabolite levels;
PAAD	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg05643964	chr20:62369504	LIME1	-0.52	-4.88	-0.37	2.65e-6	Prostate cancer;
PAAD	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	0.81	5.43	0.4	2.17e-7	Body mass index;
PAAD	cis	rs4908768	0.501	rs6577492	chr1:8575064	C/A	cg20416874	chr1:8611966	RERE	-0.45	-4.28	-0.33	3.31e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6541297	0.757	rs2760537	chr1:230326412	C/T	cg22153407	chr1:230290089	GALNT2	-0.47	-4.25	-0.33	3.74e-5	Coronary artery disease;
PAAD	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	5.39	0.4	2.63e-7	Total cholesterol levels;
PAAD	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg00129232	chr17:37814104	STARD3	0.61	4.47	0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.37	-13.09	-0.73	1.06e-26	Corneal structure;
PAAD	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.83	-9.42	-0.61	7.18e-17	Body mass index;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg12310025	chr6:25882481	NA	-0.52	-4.32	-0.33	2.86e-5	Iron status biomarkers;
PAAD	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg00576331	chr11:65640516	EFEMP2	-0.53	-4.57	-0.35	9.92e-6	Breast cancer;
PAAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.81	-0.43	3.57e-8	Monocyte count;
PAAD	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7594192	0.744	rs11681652	chr2:199366959	A/G	cg01558212	chr2:200327336	NA	0.34	4.37	0.33	2.28e-5	Educational attainment;
PAAD	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg07469887	chr10:131262384	NA	-0.45	-5.56	-0.41	1.19e-7	Response to temozolomide;
PAAD	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.5	-7.95	-0.54	3.87e-13	Cutaneous nevi;
PAAD	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg14092988	chr3:52407081	DNAH1	-0.43	-5.27	-0.39	4.55e-7	Bipolar disorder;
PAAD	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.65	-5.87	-0.43	2.59e-8	Breast cancer;
PAAD	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg14631576	chr9:95140430	CENPP	-0.53	-5.31	-0.4	3.86e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.75	7.69	0.53	1.69e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	5.28	0.39	4.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg00105475	chr2:10696890	NA	-0.65	-6.86	-0.49	1.67e-10	Prostate cancer;
PAAD	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg23024343	chr7:107201750	COG5	0.58	4.74	0.36	4.96e-6	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg16419906	chr5:132167176	NA	-0.66	-5.32	-0.4	3.71e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg08523384	chr5:141488047	NDFIP1	0.51	4.97	0.37	1.76e-6	Asthma;
PAAD	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg21775007	chr8:11205619	TDH	-0.71	-6.96	-0.49	9.39e-11	Retinal vascular caliber;
PAAD	cis	rs7224685	0.689	rs4508454	chr17:4198650	C/T	cg09695851	chr17:3907499	NA	-0.62	-5.17	-0.39	7.17e-7	Type 2 diabetes;
PAAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9361491	0.608	rs4706724	chr6:79462821	G/A	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg09796270	chr17:17721594	SREBF1	-0.5	-5.34	-0.4	3.38e-7	Lymphocyte counts;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.55	-5.01	-0.38	1.49e-6	Schizophrenia;
PAAD	cis	rs939584	0.825	rs5017303	chr2:630995	T/G	cg03610516	chr2:642275	NA	0.63	5.58	0.41	1.08e-7	Body mass index;
PAAD	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.49	-4.44	-0.34	1.73e-5	Tuberculosis;
PAAD	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-8.81	-0.58	2.68e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg18279126	chr7:2041391	MAD1L1	0.53	5.12	0.38	8.99e-7	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06753367	chr22:24256600	NA	-0.45	-4.85	-0.37	3.09e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.65	-5.7	-0.42	6.18e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.69	5.83	0.43	3.15e-8	Gut microbiome composition (summer);
PAAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.45	0.71	5.6e-25	Platelet count;
PAAD	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.51	6.21	0.45	4.85e-9	Sitting height ratio;
PAAD	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.51	5.95	0.43	1.74e-8	Mean arterial pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01985852	chr16:88772985	CTU2;RNF166	0.66	6.87	0.49	1.57e-10	Myopia (pathological);
PAAD	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg08439880	chr3:133502540	NA	0.43	4.86	0.37	2.89e-6	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs9810890	chr3:128652553	C/T	cg18531004	chr3:128564980	NA	-0.76	-4.89	-0.37	2.52e-6	Dental caries;
PAAD	trans	rs62179067	0.708	rs62175986	chr2:179876509	A/G	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.44	4.5	0.34	1.35e-5	Red blood cell count;
PAAD	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg04656015	chr13:113407548	ATP11A	0.55	4.51	0.34	1.27e-5	Glycated hemoglobin levels;
PAAD	cis	rs6466055	0.660	rs55712418	chr7:104846173	A/G	cg04380332	chr7:105027541	SRPK2	0.52	5.07	0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.61	6.3	0.46	3.01e-9	Height;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg15693483	chr7:1102177	C7orf50	0.47	5.15	0.39	7.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-4.58	-0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.29	0.39	4.19e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.6	-6.0	-0.44	1.4e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg18612461	chr15:75251733	NA	-0.58	-7.15	-0.5	3.34e-11	Systemic lupus erythematosus;
PAAD	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	7.45	0.52	6.51e-12	Lung cancer in ever smokers;
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.75	8.38	0.56	3.29e-14	Prostate cancer;
PAAD	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg09127314	chr1:152161683	NA	-0.71	-4.64	-0.35	7.51e-6	Atopic dermatitis;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg10137597	chr8:22132714	PIWIL2	0.49	5.81	0.43	3.57e-8	Hypertriglyceridemia;
PAAD	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.69	-7.46	-0.52	6.04e-12	Neuroticism;
PAAD	trans	rs6531296	0.722	rs9784441	chr4:34146884	C/T	cg06870266	chr13:43192608	NA	0.69	6.37	0.46	2.16e-9	Thoracic-to-hip circumference ratio;
PAAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.6	7.33	0.51	1.24e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg02049472	chr2:177466316	MIR1246	-0.41	-4.38	-0.33	2.22e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.07	-0.44	9.6e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg14061069	chr19:46274453	DMPK	0.6	5.29	0.39	4.22e-7	Eosinophil counts;
PAAD	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs9810890	1.000	rs73198887	chr3:128546426	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs13278732	0.500	rs34276726	chr8:99039263	A/G	cg27313044	chr8:99903985	NA	0.52	4.31	0.33	2.97e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg07313626	chr1:247681931	NA	0.47	4.86	0.37	2.91e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.52	5.22	0.39	5.75e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg17366294	chr4:99064904	C4orf37	0.65	6.02	0.44	1.26e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06307176	chr5:131281290	NA	0.51	4.66	0.35	6.9e-6	Life satisfaction;
PAAD	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Lymphocyte counts;
PAAD	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg13830646	chr11:65668067	FOSL1	0.9	6.33	0.46	2.61e-9	Lung function (FEV1/FVC);
PAAD	cis	rs3206736	0.548	rs1637673	chr7:34997850	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.72	-0.36	5.42e-6	Diastolic blood pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16944159	chr2:62132759	COMMD1	0.64	7.32	0.51	1.35e-11	Metabolite levels  (X-11787);
PAAD	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.6	6.29	0.45	3.22e-9	Type 2 diabetes;
PAAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.76	7.29	0.51	1.55e-11	Cognitive function;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs59698941	0.765	rs66822519	chr5:132167742	C/T	cg16419906	chr5:132167176	NA	-0.59	-4.43	-0.34	1.76e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs34746873	0.588	rs4738937	chr8:63024140	C/T	cg03779660	chr8:62745097	NA	0.48	4.3	0.33	3.08e-5	Neurofibrillary tangles;
PAAD	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.54	5.12	0.38	9.14e-7	Metabolic traits;
PAAD	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.89	0.37	2.52e-6	Lung cancer in ever smokers;
PAAD	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.55	5.17	0.39	7.41e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg15942720	chr14:51706980	TMX1	0.49	4.26	0.33	3.54e-5	Cancer;
PAAD	cis	rs4845552	0.767	rs28707433	chr1:153469765	G/A	cg15998505	chr1:153479701	NA	-0.48	-4.26	-0.33	3.59e-5	Hippocampal atrophy;
PAAD	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.52	5.43	0.4	2.22e-7	Type 2 diabetes;
PAAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.71	0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Alcohol dependence;
PAAD	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-4.44	-0.34	1.73e-5	Systemic lupus erythematosus;
PAAD	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.88	10.28	0.64	3.9e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg19131313	chr8:1704013	NA	0.48	5.02	0.38	1.41e-6	Systolic blood pressure;
PAAD	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.55e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.71	7.5	0.52	4.83e-12	Morning vs. evening chronotype;
PAAD	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.63	-6.17	-0.45	5.79e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg03910582	chr17:19030146	GRAPL	-0.5	-4.67	-0.35	6.5e-6	Schizophrenia;
PAAD	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.64	5.48	0.41	1.73e-7	Plateletcrit;
PAAD	cis	rs9659323	1.000	rs12073056	chr1:119508400	C/T	cg26570165	chr1:119541833	NA	-0.46	-4.63	-0.35	7.9e-6	Body mass index;
PAAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	4.68	0.35	6.42e-6	Asthma;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg13264159	chr8:625131	ERICH1	-0.77	-5.25	-0.39	5.15e-7	IgG glycosylation;
PAAD	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	1.1	8.61	0.57	8.58e-15	Iron status biomarkers;
PAAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.61	-5.57	-0.41	1.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg04482110	chr17:41364121	TMEM106A	0.4	4.6	0.35	8.92e-6	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.57	-0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.87	-7.05	-0.5	6e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11671653	1.000	rs78162577	chr19:10839195	C/T	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9810890	1.000	rs73196968	chr3:128438798	G/C	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.77	-8.75	-0.58	3.86e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Schizophrenia;
PAAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.68	7.09	0.5	4.74e-11	Pulse pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05562080	chr4:38666448	KLF3;FLJ13197	0.58	6.42	0.46	1.61e-9	Metabolite levels  (X-11787);
PAAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.48	5.62	0.41	8.95e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.43	-5.42	-0.4	2.33e-7	Thyroid stimulating hormone;
PAAD	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.67	6.36	0.46	2.25e-9	Hip circumference;
PAAD	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg01422370	chr2:73384389	NA	0.36	4.86	0.37	2.92e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.66	6.42	0.46	1.61e-9	Blood metabolite levels;
PAAD	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg07541023	chr7:19748670	TWISTNB	0.52	4.28	0.33	3.36e-5	Thyroid stimulating hormone;
PAAD	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04731861	chr2:219085781	ARPC2	0.37	4.37	0.33	2.31e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs10943724	0.713	rs10943720	chr6:81274336	C/T	cg19323245	chr6:80716898	TTK	-0.43	-4.48	-0.34	1.44e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-10.24	-0.64	4.74e-19	Headache;
PAAD	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8105895	0.877	rs2359833	chr19:22242221	T/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs73416724	1.000	rs41281796	chr6:43323917	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.75	-5.53	-0.41	1.33e-7	Coronary artery calcification;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24907970	chr5:65018155	NLN;SGTB	-0.78	-6.62	-0.47	5.82e-10	Neuroticism;
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg09654669	chr8:57350985	NA	-0.56	-5.18	-0.39	6.86e-7	Obesity-related traits;
PAAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg02734326	chr4:10020555	SLC2A9	0.53	5.26	0.39	4.82e-7	Bone mineral density;
PAAD	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.51	4.61	0.35	8.47e-6	Lung cancer;
PAAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.53	5.9	0.43	2.31e-8	Total body bone mineral density;
PAAD	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-5.76	-0.42	4.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs4272720	0.855	rs11814277	chr10:50226804	C/A	cg15329866	chr3:171455826	PLD1	0.77	6.7	0.48	3.75e-10	Platelet count;Plateletcrit;
PAAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.43	-0.4	2.2e-7	Other erythrocyte phenotypes;
PAAD	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.8	-0.48	2.3e-10	Retinal vascular caliber;
PAAD	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg02743256	chr7:2109353	MAD1L1	-0.62	-5.56	-0.41	1.2e-7	Neuroticism;
PAAD	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.55	-5.8	-0.43	3.75e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.4	0.34	1.99e-5	Tonsillectomy;
PAAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs2275731	0.805	rs11254022	chr10:16527690	T/C	cg04254609	chr10:16479192	PTER	-0.42	-4.3	-0.33	3.01e-5	Bone fracture in osteoporosis;
PAAD	cis	rs6574988	0.514	rs8020378	chr14:88624946	A/G	cg18078958	chr14:88630771	NA	-0.49	-4.3	-0.33	3.02e-5	Bipolar disorder;
PAAD	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.5	-0.52	4.89e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs7259965	0.804	rs8106966	chr19:41485821	G/A	cg20630647	chr19:41531805	NA	0.51	4.59	0.35	9.29e-6	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg22833807	chr22:36925177	EIF3D	0.58	6.44	0.46	1.46e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg20893579	chr22:38215064	NA	-0.55	-5.88	-0.43	2.53e-8	Glioblastoma;Glioma;
PAAD	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.98	11.72	0.69	5.13e-23	Breast cancer;
PAAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.8	8.31	0.56	5.07e-14	Alzheimer's disease (late onset);
PAAD	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg06131755	chr6:160182447	ACAT2	0.53	4.66	0.35	6.95e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg17346650	chr17:80929145	B3GNTL1	-0.34	-4.51	-0.34	1.28e-5	Glycated hemoglobin levels;
PAAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.69	-0.36	6.17e-6	Type 2 diabetes;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg13126279	chr21:47581558	C21orf56	0.38	4.35	0.33	2.5e-5	Testicular germ cell tumor;
PAAD	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg07978099	chr16:83986941	OSGIN1	0.53	4.54	0.35	1.12e-5	Pursuit maintenance gain;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19573456	chr19:16607087	C19orf44;CALR3	-0.62	-6.41	-0.46	1.78e-9	Smoking initiation;
PAAD	cis	rs11723436	0.545	rs13132107	chr4:120821994	T/C	cg09307838	chr4:120376055	NA	0.47	4.52	0.34	1.24e-5	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.42	-0.4	2.32e-7	Personality dimensions;
PAAD	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	5.37	0.4	2.92e-7	IgG glycosylation;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.6	-6.6	-0.47	6.32e-10	Vitiligo;
PAAD	cis	rs2286503	0.839	rs2270105	chr7:22862467	G/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs1572438	1.000	rs9328455	chr6:864095	C/T	cg21062780	chr6:887772	NA	-0.45	-4.42	-0.34	1.85e-5	Aging;
PAAD	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.1	0.38	1e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.58	5.89	0.43	2.42e-8	Multiple sclerosis;
PAAD	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.54	5.51	0.41	1.52e-7	Interleukin-18 levels;
PAAD	cis	rs73416724	1.000	rs79009481	chr6:43343239	T/C	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.57	-5.77	-0.42	4.24e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs11048434	0.518	rs34651717	chr12:9177750	C/A	cg04548204	chr12:9162872	KLRG1	0.39	4.38	0.33	2.23e-5	Sjögren's syndrome;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs643506	0.874	rs663511	chr11:111710034	T/C	cg09085632	chr11:111637200	PPP2R1B	0.54	4.55	0.35	1.11e-5	Breast cancer;
PAAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg02917321	chr22:38215204	NA	0.47	4.85	0.37	3.02e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2518049	0.539	rs4414120	chr10:5158570	G/A	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.43	-0.34	1.77e-5	Height;
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.74	-5.5	-0.41	1.59e-7	Initial pursuit acceleration;
PAAD	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.13	0.6	4.04e-16	Response to antipsychotic treatment;
PAAD	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.7	-6.09	-0.44	8.8e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17467752	chr17:38218738	THRA	0.5	4.54	0.35	1.12e-5	Asthma and hay fever;
PAAD	cis	rs9888739	0.591	rs4632147	chr16:31363381	C/T	cg15817542	chr16:31343056	ITGAM	-0.45	-4.39	-0.34	2.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg08992911	chr2:238395768	MLPH	0.74	5.61	0.41	9.46e-8	Prostate cancer;
PAAD	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.44	-4.98	-0.37	1.68e-6	Coronary artery disease;
PAAD	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg12647257	chr2:47043387	NA	0.44	4.29	0.33	3.11e-5	Height;
PAAD	cis	rs7264396	0.887	rs224360	chr20:34059675	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.54	-4.36	-0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg07061783	chr6:25882402	NA	-0.67	-6.28	-0.45	3.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.502	rs4837811	chr9:123901594	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	7.41	0.52	8.16e-12	Rheumatoid arthritis;
PAAD	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.53	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.64	-0.35	7.54e-6	Renal cell carcinoma;
PAAD	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg23708337	chr7:1209742	NA	0.7	5.19	0.39	6.76e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.7	7.49	0.52	5.17e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18138172	chr1:31191959	MATN1	-0.7	-7.19	-0.5	2.72e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.59	-0.47	6.93e-10	Exhaled nitric oxide output;
PAAD	cis	rs642743	0.967	rs569856	chr10:105942304	T/C	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.31	0.33	2.9e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.2	-0.64	6.32e-19	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg18888403	chr1:24152774	HMGCL	-0.38	-4.3	-0.33	3.1e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	8.15	0.55	1.26e-13	Menopause (age at onset);
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg19673125	chr6:150240577	RAET1G	0.42	5.9	0.43	2.26e-8	Testicular germ cell tumor;
PAAD	cis	rs290268	0.845	rs290266	chr9:93537952	T/A	cg02608019	chr9:93564028	SYK	0.56	5.42	0.4	2.25e-7	Platelet count;
PAAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.63	-6.67	-0.48	4.5e-10	Schizophrenia;
PAAD	cis	rs2455826	0.521	rs6442551	chr3:15810605	C/T	cg13420985	chr3:16524424	RFTN1	-0.47	-4.44	-0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg01851573	chr8:8652454	MFHAS1	-0.6	-5.24	-0.39	5.18e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00748821	chr4:83932227	LIN54	0.57	6.32	0.46	2.71e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.69	8.02	0.55	2.62e-13	Height;
PAAD	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg05250797	chr16:70222502	NA	0.86	6.69	0.48	4.02e-10	IgE levels;
PAAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.29e-8	Colorectal cancer;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.53	5.32	0.4	3.73e-7	Longevity;Endometriosis;
PAAD	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-5.24	-0.39	5.28e-7	Red cell distribution width;
PAAD	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.35	4.71	0.36	5.57e-6	Primary biliary cholangitis;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.84	0.62	5.68e-18	Prudent dietary pattern;
PAAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg09210956	chr2:1358730	SNTG2	-0.56	-4.28	-0.33	3.25e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs643506	0.874	rs4245045	chr11:111659924	A/G	cg09085632	chr11:111637200	PPP2R1B	0.56	4.94	0.37	2.08e-6	Breast cancer;
PAAD	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs4594175	0.926	rs10498421	chr14:51586412	A/G	cg14011500	chr6:126101974	NA	-0.7	-6.29	-0.45	3.19e-9	Cancer;
PAAD	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs73195822	0.649	rs73191857	chr12:111099721	C/T	cg12870014	chr12:110450643	ANKRD13A	0.97	5.19	0.39	6.56e-7	Itch intensity from mosquito bite;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg19223190	chr17:80058835	NA	-0.52	-5.47	-0.41	1.82e-7	Life satisfaction;
PAAD	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.73e-11	Asthma;
PAAD	cis	rs5756391	0.546	rs9607390	chr22:37314533	C/T	cg16356956	chr22:37317934	CSF2RB	0.38	4.71	0.36	5.64e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.54	-6.11	-0.44	8.13e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs367943	0.665	rs11950173	chr5:112960995	C/T	cg12552261	chr5:112820674	MCC	0.49	4.94	0.37	2.07e-6	Type 2 diabetes;
PAAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-6.6	-0.47	6.36e-10	Colorectal cancer;
PAAD	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	1.06	8.27	0.56	6.38e-14	Menopause (age at onset);
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg23093090	chr10:104574429	C10orf26	-0.42	-4.28	-0.33	3.36e-5	Colorectal cancer;
PAAD	cis	rs1419980	0.730	rs6488499	chr12:7740755	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17502267	chr15:59981239	BNIP2	-0.61	-7.2	-0.5	2.61e-11	Body fat percentage;
PAAD	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs11250464	0.517	rs2892335	chr10:1432136	T/G	cg08668359	chr10:1443807	ADARB2	0.49	4.35	0.33	2.46e-5	Radiation response;
PAAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg15017067	chr4:17643749	FAM184B	0.45	5.29	0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.54e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg15609812	chr20:47281632	PREX1	0.64	4.3	0.33	3.03e-5	Tonometry;
PAAD	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1570155	1.000	rs6456346	chr6:20391172	C/G	cg03881924	chr6:20404342	E2F3	0.44	4.46	0.34	1.6e-5	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.43	-5.34	-0.4	3.32e-7	Coronary artery disease;
PAAD	cis	rs9463078	0.546	rs10948198	chr6:45009164	T/C	cg18551225	chr6:44695536	NA	-0.43	-4.5	-0.34	1.32e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.65	6.74	0.48	3.08e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg04106633	chr4:1044584	NA	0.64	5.39	0.4	2.66e-7	Recombination rate (females);
PAAD	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg18281939	chr5:77783895	LHFPL2	-0.49	-5.65	-0.42	7.61e-8	Triglycerides;
PAAD	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.09	15.92	0.79	3.28e-34	Chronic sinus infection;
PAAD	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.4	4.8	0.36	3.77e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.54	6.77	0.48	2.6e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.28	-0.33	3.25e-5	Total body bone mineral density;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07930192	chr7:1003750	NA	0.39	4.83	0.36	3.3e-6	Longevity;Endometriosis;
PAAD	cis	rs4739066	0.579	rs76538830	chr8:63862919	C/A	cg20602954	chr8:63776762	NKAIN3	0.79	5.11	0.38	9.49e-7	Myocardial infarction;
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.95	-11.82	-0.69	2.85e-23	Systemic lupus erythematosus;
PAAD	cis	rs4704187	0.687	rs1345704	chr5:74489998	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2031532	0.587	rs61959992	chr13:50020280	C/G	cg08779649	chr13:50194554	NA	0.35	4.74	0.36	4.95e-6	Cardiac hypertrophy;
PAAD	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11245990	chr11:68621969	NA	0.37	4.77	0.36	4.23e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.42	5.27	0.39	4.64e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Height;
PAAD	cis	rs7210086	0.768	rs4075985	chr17:70640873	C/G	cg04206342	chr17:70636940	NA	-0.43	-5.48	-0.41	1.77e-7	Ulcerative colitis;
PAAD	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg26935685	chr1:15502881	TMEM51	-0.51	-4.31	-0.33	2.87e-5	Systolic blood pressure;
PAAD	cis	rs138918	1.000	rs138914	chr22:43555921	G/A	cg00343092	chr22:43547974	TSPO	0.55	6.52	0.47	9.72e-10	Monocyte count;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18621852	chr3:10150065	C3orf24	-0.63	-5.51	-0.41	1.48e-7	Alzheimer's disease;
PAAD	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.63	-5.19	-0.39	6.58e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.95	13.34	0.73	2.32e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.64	-7.43	-0.52	7.34e-12	Aortic root size;
PAAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.69	-0.58	5.3e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.5	-4.74	-0.36	4.85e-6	Mean platelet volume;
PAAD	cis	rs7631605	0.846	rs4431051	chr3:36992405	C/T	cg17445812	chr3:36986805	TRANK1	0.36	4.67	0.35	6.46e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25022560	chr1:205782239	SLC41A1	-0.72	-6.29	-0.45	3.17e-9	Neuroticism;
PAAD	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg00147172	chr22:46423604	NA	-0.38	-5.79	-0.43	3.92e-8	Dupuytren's disease;
PAAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06028605	chr16:24865363	SLC5A11	0.48	5.9	0.43	2.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs758324	0.812	rs667437	chr5:131275509	C/T	cg06307176	chr5:131281290	NA	-0.54	-4.7	-0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg09796270	chr17:17721594	SREBF1	0.44	4.79	0.36	3.86e-6	Total body bone mineral density;
PAAD	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06998765	chr14:75389618	RPS6KL1	0.28	4.75	0.36	4.61e-6	Caffeine consumption;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.94	-15.68	-0.79	1.42e-33	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.96	-6.42	-0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.68	-7.56	-0.52	3.64e-12	Renal function-related traits (BUN);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27169846	chr4:8012170	ABLIM2	0.5	6.87	0.49	1.53e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.06	-0.38	1.19e-6	Coronary artery disease;
PAAD	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.56	5.53	0.41	1.36e-7	Breast cancer;
PAAD	cis	rs2252790	0.859	rs1204826	chr6:116564388	A/G	cg18764771	chr6:116381957	FRK	-0.27	-4.63	-0.35	7.93e-6	Fast beta electroencephalogram;
PAAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12599982	chr1:44399894	ARTN	0.46	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg06609049	chr19:2785107	THOP1	0.97	11.4	0.68	3.91e-22	Total cholesterol levels;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg00738919	chr7:1100172	C7orf50	0.72	5.54	0.41	1.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.65	-6.02	-0.44	1.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-1.01	-6.96	-0.49	9.71e-11	Mitochondrial DNA levels;
PAAD	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.52	-6.67	-0.48	4.39e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.14	-14.09	-0.75	2.29e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.37	4.27	0.33	3.49e-5	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs12760731	0.623	rs10913550	chr1:178408795	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.43	0.4	2.17e-7	Obesity-related traits;
PAAD	cis	rs7818688	0.697	rs11783878	chr8:95979261	C/T	cg16049864	chr8:95962084	TP53INP1	-0.52	-4.3	-0.33	3.02e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.94	11.26	0.67	8.97e-22	Bone mineral density;
PAAD	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg01868782	chr6:126071099	HEY2	0.45	5.31	0.4	3.81e-7	Brugada syndrome;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05320259	chr20:25370897	ABHD12	0.61	6.41	0.46	1.73e-9	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.2e-5	Red blood cell count;
PAAD	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg07423050	chr13:99094983	FARP1	-0.49	-4.58	-0.35	9.62e-6	Obesity-related traits;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	1.09	15.75	0.79	9.53e-34	Systemic lupus erythematosus;
PAAD	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.69	7.79	0.53	9.55e-13	Height;
PAAD	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.7	-7.4	-0.51	8.56e-12	Coronary artery disease;
PAAD	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	cis	rs10885582	0.501	rs6585285	chr10:116280423	A/G	cg17056676	chr10:116301354	ABLIM1	-0.36	-4.58	-0.35	9.68e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg02725872	chr8:58115012	NA	-0.57	-4.76	-0.36	4.49e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg13002189	chr3:66846049	NA	0.52	5.07	0.38	1.13e-6	Type 2 diabetes;
PAAD	cis	rs2964802	0.505	rs13164697	chr5:10831212	C/T	cg14521931	chr5:10832172	NA	-0.47	-4.95	-0.37	1.99e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg11161846	chr1:160990452	F11R	-0.52	-5.18	-0.39	6.81e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg14092988	chr3:52407081	DNAH1	0.46	5.75	0.42	4.63e-8	Bipolar disorder;
PAAD	cis	rs7678296	0.730	rs73142753	chr4:37203570	T/G	cg06805348	chr4:37245195	KIAA1239	0.61	4.6	0.35	8.91e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7737355	0.853	rs31586	chr5:131000696	A/G	cg06307176	chr5:131281290	NA	0.51	4.41	0.34	1.98e-5	Life satisfaction;
PAAD	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg03700679	chr2:178418002	TTC30B	-0.54	-4.38	-0.33	2.23e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.55	-5.17	-0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.62	-6.75	-0.48	2.91e-10	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.69	-6.3	-0.46	3.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.65	-6.2	-0.45	5.07e-9	Osteoporosis;
PAAD	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.7	-8.0	-0.54	2.94e-13	Metabolic syndrome;
PAAD	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	trans	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg01620082	chr3:125678407	NA	-1.24	-7.47	-0.52	5.69e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs2587695	0.935	rs1992248	chr2:120283173	A/T	cg05839767	chr2:119914248	C1QL2	0.41	4.35	0.33	2.5e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.94	0.37	2.02e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6977660	0.941	rs4721825	chr7:19823427	A/C	cg05791153	chr7:19748676	TWISTNB	0.57	4.68	0.35	6.33e-6	Thyroid stimulating hormone;
PAAD	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-5.0	-0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs4481887	0.604	rs4642918	chr1:248411057	A/C	cg00666640	chr1:248458726	OR2T12	-0.6	-4.65	-0.35	7.28e-6	Common traits (Other);
PAAD	cis	rs8005172	0.593	rs28493180	chr14:88513175	T/C	cg18078958	chr14:88630771	NA	0.36	4.52	0.34	1.24e-5	Parkinson's disease;
PAAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.83	7.72	0.53	1.41e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.44	-4.52	-0.34	1.23e-5	Platelet distribution width;
PAAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg10494973	chr17:80897199	TBCD	0.57	4.61	0.35	8.6e-6	Breast cancer;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg26939375	chr7:64535504	NA	0.72	8.21	0.55	9.05e-14	Calcium levels;
PAAD	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.18	15.67	0.79	1.55e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg10437265	chr15:77819839	NA	-0.35	-4.3	-0.33	3.04e-5	Type 2 diabetes;
PAAD	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.69	-0.36	5.94e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1879734	0.636	rs17109200	chr1:54175548	A/G	cg14659662	chr1:54151053	GLIS1	-0.39	-5.53	-0.41	1.38e-7	Mitral valve prolapse;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.61	0.57	8.54e-15	Lung cancer;
PAAD	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.92	0.37	2.25e-6	Ovarian reserve;
PAAD	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg20628663	chr10:43360327	NA	-0.65	-4.61	-0.35	8.65e-6	Blood protein levels;
PAAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	6.62	0.47	5.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17742459	chr8:38710358	TACC1	-0.66	-6.86	-0.49	1.6e-10	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.99	8.79	0.58	2.93e-15	Bipolar disorder;
PAAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.27	-0.45	3.63e-9	IgG glycosylation;
PAAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg03983715	chr16:68378420	PRMT7	-0.97	-6.84	-0.49	1.79e-10	Schizophrenia;
PAAD	cis	rs258892	0.895	rs13167768	chr5:72034622	A/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs3131337	1	rs3131337	chr6:28796071	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.35	0.33	2.53e-5	Cold sores;
PAAD	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17331151	0.505	rs7644763	chr3:52546487	C/T	cg27565382	chr3:53032988	SFMBT1	-0.99	-4.99	-0.38	1.62e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26944981	chr17:30469748	RHOT1	-0.64	-6.4	-0.46	1.85e-9	Smoking initiation;
PAAD	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs17095355	1.000	rs12571872	chr10:111676114	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.34	-0.33	2.61e-5	Biliary atresia;
PAAD	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.94	-0.43	1.87e-8	Schizophrenia;
PAAD	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg22338127	chr1:209979572	IRF6	0.53	4.28	0.33	3.36e-5	Coronary artery disease;
PAAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.67	9.36	0.6	9.95e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg15956490	chr3:53032818	SFMBT1	0.83	4.83	0.37	3.24e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.06	6.33	0.46	2.57e-9	Body mass index;
PAAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.81	-8.62	-0.57	8.08e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72960926	0.661	rs62437421	chr6:75186723	G/C	cg03266952	chr6:74778945	NA	-0.91	-4.48	-0.34	1.47e-5	Metabolite levels (MHPG);
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg20849893	chr7:64541193	NA	0.5	4.91	0.37	2.35e-6	Calcium levels;
PAAD	cis	rs9463078	0.774	rs4373351	chr6:45276324	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.32	-0.4	3.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01585852	chr22:24235823	MIF	0.44	4.62	0.35	8.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.53	0.41	1.35e-7	Bipolar disorder;
PAAD	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.86	10.2	0.64	6.13e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	0.68	4.8	0.36	3.77e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04646986	chr4:71767974	MOBKL1A	-0.65	-6.31	-0.46	2.97e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg11519256	chr10:5708881	ASB13	0.59	5.09	0.38	1.05e-6	Childhood ear infection;
PAAD	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.52	-5.33	-0.4	3.47e-7	Height;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18966265	chr2:63277277	OTX1	-0.53	-6.34	-0.46	2.48e-9	Body fat percentage;
PAAD	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg18436246	chr17:1640651	WDR81	0.86	8.03	0.55	2.45e-13	Serum albumin level;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.53	-5.31	-0.4	3.84e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.61	-5.19	-0.39	6.5e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.79	9.26	0.6	1.87e-16	Morning vs. evening chronotype;
PAAD	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg08975724	chr8:8085496	FLJ10661	0.63	6.46	0.46	1.34e-9	Neuroticism;
PAAD	cis	rs367943	0.688	rs255877	chr5:112753584	A/G	cg12552261	chr5:112820674	MCC	0.67	6.74	0.48	3.09e-10	Type 2 diabetes;
PAAD	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg07648498	chr16:89883185	FANCA	0.54	5.36	0.4	3.01e-7	Vitiligo;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.74	-0.48	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg13379983	chr2:198649727	BOLL	-0.56	-4.29	-0.33	3.12e-5	Ulcerative colitis;
PAAD	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.77	7.8	0.53	8.98e-13	Uric acid levels;
PAAD	cis	rs728616	0.614	rs55720611	chr10:81790299	G/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-4.34	-0.33	2.61e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	1.02	12.35	0.71	1.03e-24	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.84	10.02	0.63	1.86e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.48	5.62	0.41	8.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs17083533	1.000	rs79351670	chr6:121677150	A/G	cg13516479	chr6:122016629	NA	-0.82	-4.48	-0.34	1.44e-5	Heart rate;
PAAD	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.5	6.4	0.46	1.8e-9	Schizophrenia;
PAAD	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.73	7.18	0.5	2.94e-11	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24242082	chr20:61448325	COL9A3	0.67	6.52	0.47	9.86e-10	Obesity-related traits;
PAAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.63	-0.47	5.46e-10	Triglycerides;
PAAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.35e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.8	9.57	0.61	2.82e-17	Body mass index;
PAAD	cis	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs6761276	0.505	rs13019891	chr2:113829869	G/T	cg12858261	chr2:113808755	IL1F8	0.64	5.86	0.43	2.8e-8	Protein quantitative trait loci;
PAAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.28	0.33	3.23e-5	Menarche (age at onset);
PAAD	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg25364880	chr3:44379878	C3orf23	0.58	5.38	0.4	2.73e-7	Depressive symptoms;
PAAD	cis	rs6908034	0.556	rs113071446	chr6:19810835	A/C	cg02682789	chr6:19804855	NA	0.82	4.76	0.36	4.49e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg04165759	chr1:150448943	RPRD2	-0.52	-5.44	-0.4	2.09e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.49	4.43	0.34	1.81e-5	Depression;
PAAD	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.73	-7.29	-0.51	1.55e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.78	8.12	0.55	1.44e-13	Corneal astigmatism;
PAAD	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01056775	chr4:187111940	CYP4V2	0.59	6.8	0.48	2.19e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs75920871	0.925	rs17120241	chr11:116915020	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.67	6.9	0.49	1.32e-10	Response to antidepressants and depression;
PAAD	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg22467129	chr15:76604101	ETFA	-0.52	-4.81	-0.36	3.66e-6	Blood metabolite levels;
PAAD	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.36e-7	Protein quantitative trait loci;
PAAD	trans	rs61931739	0.649	rs864174	chr12:33729352	C/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.88	-8.62	-0.57	8.05e-15	Blood protein levels;
PAAD	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg24053715	chr22:38214548	NA	-0.64	-6.72	-0.48	3.43e-10	Glioblastoma;Glioma;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.02	0.49	7.02e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.52	-5.66	-0.42	7.27e-8	Migraine;
PAAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg13722127	chr7:150037890	RARRES2	0.62	6.59	0.47	6.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.4	-8.33	-0.56	4.35e-14	Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.55	-4.87	-0.37	2.73e-6	Obesity-related traits;
PAAD	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-1.21	-12.05	-0.7	6.94e-24	Post bronchodilator FEV1;
PAAD	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.95	7.39	0.51	9.1e-12	Uric acid levels;
PAAD	cis	rs3026101	0.671	rs1143206	chr17:5284698	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.62	0.42	8.72e-8	Body mass index;
PAAD	cis	rs9992101	0.547	rs2137152	chr4:77411710	T/C	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.48	4.83	0.36	3.31e-6	Lewy body disease;
PAAD	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg01631408	chr1:248437212	OR2T33	0.55	5.19	0.39	6.74e-7	Common traits (Other);
PAAD	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	4.29	0.33	3.17e-5	Menarche (age at onset);
PAAD	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg27511599	chr7:32358540	NA	0.78	4.83	0.36	3.35e-6	Body mass index;
PAAD	trans	rs901683	1.000	rs12764652	chr10:45991978	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.82	6.42	0.46	1.68e-9	Mean platelet volume;
PAAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	4.98	0.37	1.69e-6	Height;
PAAD	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.91	-12.22	-0.7	2.41e-24	Body mass index;
PAAD	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg08648136	chr8:956695	NA	0.43	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg13256891	chr4:100009986	ADH5	0.42	4.27	0.33	3.37e-5	Alcohol dependence;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.59e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.32	-0.33	2.84e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg09699651	chr6:150184138	LRP11	0.41	4.29	0.33	3.16e-5	Lung cancer;
PAAD	trans	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg11421182	chr20:36153479	BLCAP	0.53	6.31	0.46	2.89e-9	IgG glycosylation;
PAAD	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.23	-0.39	5.47e-7	Chronic sinus infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20907105	chr6:52929905	FBXO9	0.54	6.31	0.46	2.92e-9	Monocyte percentage of white cells;
PAAD	cis	rs10501293	1.000	rs10501293	chr11:43086094	G/T	cg03447554	chr11:43094025	NA	0.52	5.16	0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	6.69	0.48	4e-10	Schizophrenia;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg17178900	chr1:205818956	PM20D1	0.86	10.8	0.66	1.52e-20	Menarche (age at onset);
PAAD	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg08601574	chr20:25228251	PYGB	0.57	5.79	0.42	3.99e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.95	0.72	2.57e-26	Prudent dietary pattern;
PAAD	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg00531865	chr16:30841666	NA	-0.64	-5.91	-0.43	2.18e-8	Multiple myeloma;
PAAD	cis	rs732765	0.644	rs10483860	chr14:75119507	G/C	cg17347104	chr14:75034677	LTBP2	0.64	5.46	0.4	1.9e-7	Non-small cell lung cancer;
PAAD	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	6.86e-8	Urinary metabolites;
PAAD	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.62	-7.57	-0.52	3.27e-12	Iron status biomarkers (transferrin levels);
PAAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9842133	0.587	rs10937013	chr3:179641851	A/C	cg18765712	chr3:179670323	PEX5L	-0.5	-4.41	-0.34	1.95e-5	Blood metabolite levels;
PAAD	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.76	6.53	0.47	9.38e-10	Pulmonary function decline;
PAAD	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.67	7.05	0.5	5.8e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs35955747	0.871	rs2013254	chr22:31690803	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg23241863	chr10:102295624	HIF1AN	0.5	4.52	0.34	1.25e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg25664220	chr3:72788482	NA	-0.54	-5.42	-0.4	2.3e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.68	-0.42	6.51e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg27478167	chr7:817139	HEATR2	-0.73	-5.77	-0.42	4.24e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg14003231	chr6:33640908	ITPR3	0.37	4.74	0.36	4.8e-6	Height;
PAAD	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	5.08	0.38	1.09e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.86	-10.63	-0.65	4.53e-20	Prudent dietary pattern;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	1.01	14.01	0.75	3.61e-29	Menarche (age at onset);
PAAD	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg00717180	chr2:96193071	NA	-0.56	-6.85	-0.49	1.75e-10	HDL cholesterol;
PAAD	cis	rs2147959	0.556	rs12401843	chr1:228725769	C/T	cg12437277	chr1:228743235	NA	-0.92	-4.54	-0.35	1.15e-5	Adult asthma;
PAAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	5.0	0.38	1.55e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02985541	chr2:219472218	PLCD4	0.31	4.68	0.35	6.32e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg25783544	chr11:47291846	MADD	0.54	4.35	0.33	2.51e-5	HDL cholesterol;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07648498	chr16:89883185	FANCA	0.67	6.73	0.48	3.3e-10	Vitiligo;
PAAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-5.56	-0.41	1.16e-7	Monocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21736089	chr19:3110171	GNA11	0.57	6.87	0.49	1.51e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.37	-0.33	2.3e-5	Fibrinogen levels;
PAAD	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-7.85	-0.54	6.83e-13	Chronic sinus infection;
PAAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.51	4.79	0.36	3.99e-6	Height;
PAAD	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg09127314	chr1:152161683	NA	0.71	5.2	0.39	6.43e-7	Atopic dermatitis;
PAAD	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs714031	1.000	rs4821909	chr22:40066418	T/C	cg21377881	chr22:40064566	CACNA1I	-0.44	-4.27	-0.33	3.48e-5	Schizophrenia;
PAAD	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg05562828	chr17:3906858	NA	0.49	5.39	0.4	2.65e-7	Type 2 diabetes;
PAAD	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.97	14.71	0.77	4.94e-31	Dental caries;
PAAD	trans	rs62179067	0.867	rs17454199	chr2:180001880	A/G	cg23458843	chr12:58136445	AGAP2	0.96	6.39	0.46	1.94e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.03	0.38	1.34e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg18621852	chr3:10150065	C3orf24	0.53	4.8	0.36	3.68e-6	Alzheimer's disease;
PAAD	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.9	7.2	0.5	2.6e-11	Chronic kidney disease;
PAAD	cis	rs7136716	0.541	rs78018194	chr12:7740587	T/C	cg25757697	chr12:8220002	C3AR1	-0.85	-4.27	-0.33	3.46e-5	Hematological and biochemical traits;
PAAD	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg12560992	chr17:57184187	TRIM37	0.68	5.1	0.38	1e-6	Vitamin D levels;
PAAD	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs4343996	0.902	rs4521670	chr7:3383603	C/T	cg21248987	chr7:3385318	SDK1	0.48	5.28	0.39	4.32e-7	Motion sickness;
PAAD	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg01851573	chr8:8652454	MFHAS1	0.6	5.08	0.38	1.08e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg21438018	chr1:76262537	MSH4	0.47	4.34	0.33	2.55e-5	Daytime sleep phenotypes;
PAAD	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.51	-4.53	-0.34	1.21e-5	Mean corpuscular volume;
PAAD	cis	rs9372498	0.536	rs62424175	chr6:118797381	T/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.02	-0.38	1.43e-6	Diastolic blood pressure;
PAAD	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg12395012	chr8:11607386	GATA4	-0.4	-4.45	-0.34	1.62e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg01966878	chr4:90757139	SNCA	-0.6	-4.7	-0.36	5.88e-6	Neuroticism;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs60624478	0.671	rs878395	chr1:165098921	T/A	cg25031777	chr1:164528501	PBX1	-0.57	-4.71	-0.36	5.48e-6	Response to methotrexate in juvenile idiopathic arthritis;
PAAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.18	-0.39	6.92e-7	High light scatter reticulocyte count;
PAAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.61	-6.04	-0.44	1.14e-8	Lymphocyte counts;
PAAD	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.73	-9.16	-0.6	3.27e-16	Educational attainment;
PAAD	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.65	0.42	7.66e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-6.67	-0.48	4.4e-10	Glomerular filtration rate;
PAAD	cis	rs12257961	0.548	rs10796282	chr10:15380825	C/T	cg10616319	chr10:15468812	NA	-0.47	-4.51	-0.34	1.27e-5	Selective IgA deficiency;
PAAD	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.01	-0.49	7.41e-11	Leprosy;
PAAD	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11249608	0.789	rs7733067	chr5:178425714	T/C	cg10208897	chr5:178548229	ADAMTS2	-0.57	-4.94	-0.37	2.08e-6	Pubertal anthropometrics;
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs9903692	0.505	rs208009	chr17:46229691	C/T	cg10706073	chr17:46328419	SKAP1	1.05	6.3	0.46	3e-9	Pulse pressure;
PAAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.71	-7.61	-0.53	2.68e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9361491	0.608	rs7767460	chr6:79437011	T/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs4273100	1.000	rs57433322	chr17:19141582	C/G	cg18093559	chr17:18951025	GRAP	-0.51	-4.35	-0.33	2.49e-5	Schizophrenia;
PAAD	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	4.74	0.36	4.87e-6	Menarche (age at onset);
PAAD	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.72	7.34	0.51	1.19e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12304921	0.872	rs17122760	chr12:51519106	A/G	cg18059802	chr12:51347058	HIGD1C	-0.64	-4.83	-0.36	3.32e-6	Type 2 diabetes;
PAAD	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.6	5.29	0.39	4.28e-7	Retinal vascular caliber;
PAAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-4.95	-0.37	1.91e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.47	6.14	0.45	6.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7567389	0.677	rs72845975	chr2:128086274	C/T	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs8044476	1.000	rs8044476	chr16:72800567	C/T	cg00207534	chr16:71929512	KIAA0174	-0.67	-4.59	-0.35	9.24e-6	Blood protein levels;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.37	4.33	0.33	2.69e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs6722456	1.000	rs78064232	chr2:134568742	G/A	cg06476693	chr11:130283454	ADAMTS8	0.81	6.4	0.46	1.85e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.54	-0.52	3.93e-12	Height;
PAAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.54	4.9	0.37	2.47e-6	Height;
PAAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.36	-0.46	2.22e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.88	-10.75	-0.66	2.11e-20	Ulcerative colitis;
PAAD	cis	rs11168618	0.740	rs4237859	chr12:48924675	A/G	cg01881778	chr12:48919444	OR8S1	-0.51	-5.48	-0.41	1.74e-7	Adiponectin levels;
PAAD	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg06697600	chr4:7070879	GRPEL1	0.79	5.16	0.39	7.63e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.44	-0.46	1.46e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2279817	0.863	rs12742364	chr1:18013430	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.83	-0.43	3.26e-8	Neuroticism;
PAAD	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg01851573	chr8:8652454	MFHAS1	0.57	4.97	0.37	1.76e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.43e-22	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04798676	chr3:196230670	RNF168	0.63	6.37	0.46	2.13e-9	Obesity-related traits;
PAAD	cis	rs2531992	0.563	rs2531988	chr16:4028417	T/G	cg05927578	chr16:4029543	ADCY9	0.7	5.91	0.43	2.12e-8	Waist circumference;
PAAD	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.87e-8	Acne (severe);
PAAD	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.62	7.03	0.5	6.48e-11	Resting heart rate;
PAAD	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg12908607	chr1:44402522	ARTN	-0.42	-4.62	-0.35	7.96e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04874074	chr1:6855140	CAMTA1	0.6	6.3	0.46	3.08e-9	Smoking initiation;
PAAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	-0.5	-4.45	-0.34	1.68e-5	Mean corpuscular volume;
PAAD	cis	rs939584	1.000	rs4854340	chr2:623216	G/A	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.93	8.33	0.56	4.33e-14	Gut microbiome composition (summer);
PAAD	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg01851573	chr8:8652454	MFHAS1	0.67	5.52	0.41	1.43e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg17830980	chr10:43048298	ZNF37B	0.68	7.89	0.54	5.43e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg02795151	chr17:7402630	POLR2A	0.63	5.58	0.41	1.05e-7	Androgen levels;
PAAD	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.78	-8.08	-0.55	1.82e-13	Parkinson's disease;
PAAD	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.76	9.97	0.63	2.57e-18	Late-onset Alzheimer's disease;
PAAD	cis	rs911119	0.955	rs55897275	chr20:23595953	A/T	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg01622416	chr21:31310508	GRIK1	-0.52	-4.95	-0.37	1.99e-6	Selective IgA deficiency;
PAAD	cis	rs4883201	0.536	rs1121401	chr12:9136622	A/T	cg15384867	chr12:8995808	A2ML1	-0.54	-4.32	-0.33	2.76e-5	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	1.23	15.54	0.78	3.4e-33	Ewing sarcoma;
PAAD	cis	rs375066	0.736	rs62114649	chr19:44416567	T/C	cg08633290	chr19:44405433	NA	0.54	5.16	0.39	7.61e-7	Breast cancer;
PAAD	trans	rs3130844	1	rs3130844	chr6:28916594	G/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Urinary tract infection frequency;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18878441	chr2:81694367	NA	-0.6	-6.39	-0.46	1.88e-9	Obesity-related traits;
PAAD	cis	rs3779195	0.585	rs73709460	chr7:97895254	C/T	cg21770322	chr7:97807741	LMTK2	-0.55	-4.39	-0.34	2.12e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.83	-9.38	-0.61	8.75e-17	Idiopathic membranous nephropathy;
PAAD	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg23205692	chr1:25664452	TMEM50A	0.52	4.98	0.37	1.67e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg02297831	chr4:17616191	MED28	-0.59	-5.45	-0.4	2e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	1.03	8.81	0.58	2.58e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.56	6.64	0.47	5.3e-10	Total body bone mineral density;
PAAD	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.84	6.46	0.46	1.32e-9	Axial length;
PAAD	cis	rs1692580	0.807	rs10910036	chr1:2183754	C/G	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.86	-0.37	2.92e-6	Coronary artery disease;
PAAD	cis	rs73388146	0.685	rs6456651	chr6:25148011	A/C	cg26336265	chr6:25042955	NA	-0.6	-4.65	-0.35	7.22e-6	Schizophrenia;
PAAD	cis	rs6762644	0.507	rs9823748	chr3:4765955	G/A	cg11584376	chr3:4789075	ITPR1	-0.4	-4.42	-0.34	1.88e-5	Breast cancer;
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg27532560	chr4:187881888	NA	-0.53	-6.44	-0.46	1.49e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs501916	0.634	rs3743286	chr15:48065792	A/G	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs16910800	1.000	rs7114414	chr11:23201509	A/G	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs6191	0.838	rs6877893	chr5:142727193	C/T	cg08845721	chr5:142780693	NR3C1	-0.4	-4.41	-0.34	1.93e-5	Night sleep phenotypes;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	cis	rs12431939	0.762	rs61109194	chr14:51698659	T/C	cg23942311	chr14:51606299	NA	-0.61	-5.2	-0.39	6.32e-7	Cancer;
PAAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.41	-0.34	1.96e-5	Glomerular filtration rate;
PAAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg23281280	chr6:28129359	ZNF389	0.51	4.33	0.33	2.75e-5	Parkinson's disease;
PAAD	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.63	-6.8	-0.48	2.2e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	4.67	0.35	6.56e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.59	4.69	0.36	6.01e-6	Red blood cell count;
PAAD	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.64	5.05	0.38	1.26e-6	Serum sulfate level;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26213561	chr10:21786348	MIR1915;C10orf114	0.63	7.11	0.5	4.23e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg03651054	chr13:50194643	NA	0.41	5.51	0.41	1.52e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.92	9.75	0.62	9.33e-18	Cognitive function;
PAAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	8.53	0.57	1.38e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.93	6.9	0.49	1.35e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9487051	0.646	rs11153167	chr6:109622582	A/T	cg01475377	chr6:109611718	NA	0.4	4.34	0.33	2.59e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.67	0.42	6.9e-8	Tonsillectomy;
PAAD	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.6	6.44	0.46	1.45e-9	Schizophrenia;
PAAD	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.61	-7.52	-0.52	4.55e-12	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg18551225	chr6:44695536	NA	-0.69	-6.95	-0.49	1.03e-10	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg07636037	chr3:49044803	WDR6	-0.56	-4.32	-0.33	2.84e-5	Menarche (age at onset);
PAAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg09835421	chr16:68378352	PRMT7	-0.97	-5.8	-0.43	3.78e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.41	-0.4	2.38e-7	Pulmonary function;
PAAD	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.53e-9	Bladder cancer;
PAAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg14829360	chr17:73884958	NA	0.54	5.27	0.39	4.56e-7	Psoriasis;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg10729496	chr3:10149963	C3orf24	0.63	5.46	0.4	1.89e-7	Alzheimer's disease;
PAAD	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs73069940	1.000	rs73069940	chr4:1236502	C/G	cg26210267	chr4:668877	ATP5I	0.75	4.29	0.33	3.22e-5	Type 2 diabetes;
PAAD	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.69	6.39	0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg21922841	chr17:72744131	SLC9A3R1	0.42	5.42	0.4	2.32e-7	Monocyte count;
PAAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.5	-6.23	-0.45	4.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.64	5.4	0.4	2.47e-7	Schizophrenia;
PAAD	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg14593290	chr7:50529359	DDC	-0.47	-4.96	-0.37	1.87e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs6743376	0.556	rs2515402	chr2:113820580	C/A	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg00738919	chr7:1100172	C7orf50	0.69	4.96	0.37	1.85e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3106136	0.649	rs4699410	chr4:95299486	T/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs6679454	1.000	rs11582988	chr1:58364553	C/T	cg17491850	chr1:57888480	DAB1	-0.39	-4.43	-0.34	1.79e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.81	7.44	0.52	6.86e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg15309053	chr8:964076	NA	0.49	5.48	0.41	1.72e-7	Schizophrenia;
PAAD	cis	rs1847202	0.963	rs34317383	chr3:72946652	A/C	cg25664220	chr3:72788482	NA	-0.44	-4.67	-0.35	6.54e-6	Motion sickness;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.62	-5.57	-0.41	1.15e-7	Tonsillectomy;
PAAD	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.38	-0.4	2.71e-7	White blood cell count;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20444341	chr6:157100278	ARID1B	0.68	7.02	0.49	6.72e-11	Obesity-related traits;
PAAD	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg24519413	chr1:26490540	NA	0.52	4.84	0.37	3.22e-6	Height;
PAAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.67	-0.35	6.7e-6	Body mass index;
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg02475695	chr16:616220	NHLRC4	0.49	5.67	0.42	7.01e-8	Height;
PAAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg14092988	chr3:52407081	DNAH1	0.43	5.09	0.38	1.06e-6	Electroencephalogram traits;
PAAD	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.84	-9.6	-0.61	2.36e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3112530	1.000	rs2973148	chr5:152643974	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20856030	chr4:162917677	FSTL5	0.59	6.33	0.46	2.56e-9	Lung cancer in ever smokers;
PAAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg11766577	chr21:47581405	C21orf56	-0.39	-4.32	-0.33	2.78e-5	Testicular germ cell tumor;
PAAD	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.4	-0.4	2.53e-7	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg10729496	chr3:10149963	C3orf24	0.88	7.31	0.51	1.42e-11	Alzheimer's disease;
PAAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.96	-8.21	-0.55	8.89e-14	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.71	7.02	0.5	6.73e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.68	-4.93	-0.37	2.09e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03088475	chr8:145981210	ZNF251	-0.64	-6.96	-0.49	9.65e-11	Smoking initiation;
PAAD	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.46	-5.9	-0.43	2.31e-8	Multiple sclerosis;
PAAD	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.36	-0.51	1.05e-11	Diastolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27187586	chr4:83932193	LIN54	0.56	6.29	0.45	3.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg11143131	chr5:131608246	PDLIM4	0.51	5.22	0.39	5.75e-7	Blood metabolite levels;
PAAD	cis	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.51	-0.34	1.28e-5	Eotaxin levels;
PAAD	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	7.72	0.53	1.44e-12	Chronic sinus infection;
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.88	-9.55	-0.61	3.28e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.59	4.76	0.36	4.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.99	12.56	0.71	2.78e-25	Breast cancer;
PAAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg05895507	chr15:77155635	SCAPER	-0.38	-4.82	-0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg20003494	chr4:90757398	SNCA	-0.72	-7.09	-0.5	4.66e-11	Neuroticism;
PAAD	cis	rs9810890	1.000	rs73198901	chr3:128566520	G/A	cg15676455	chr3:128564943	NA	-0.87	-4.88	-0.37	2.68e-6	Dental caries;
PAAD	cis	rs2412208	0.796	rs3986512	chr1:7090699	C/T	cg26570804	chr1:6352357	ACOT7	-0.56	-5.14	-0.38	8.29e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.05	0.38	1.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.84	9.14	0.6	3.73e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.29	-14.41	-0.76	3.26e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg15017067	chr4:17643749	FAM184B	0.41	4.67	0.35	6.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.5	4.64	0.35	7.54e-6	Schizophrenia;
PAAD	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg19510604	chr15:74901076	CLK3	0.52	4.31	0.33	2.92e-5	Blood trace element (Zn levels);
PAAD	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.9	0.43	2.24e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.6	7.9	0.54	5.11e-13	Bipolar disorder;
PAAD	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.82	7.19	0.5	2.74e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12760731	0.565	rs11585236	chr1:178108441	G/A	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs1903068	0.853	rs9312655	chr4:56002665	T/C	cg09978860	chr4:56023921	NA	0.38	4.34	0.33	2.61e-5	Endometriosis;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-5.61	-0.41	9.16e-8	Daytime sleep phenotypes;
PAAD	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.6	5.12	0.38	9.06e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10819733	chr22:24237672	NA	-0.52	-5.54	-0.41	1.33e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg04717802	chr22:42394638	WBP2NL	0.5	4.34	0.33	2.57e-5	Birth weight;
PAAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.42	0.34	1.89e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6735179	0.729	rs2382560	chr2:1762828	A/G	cg06599209	chr2:1746509	PXDN	0.25	4.25	0.33	3.75e-5	Response to antipsychotic treatment;
PAAD	cis	rs28493229	0.708	rs78084428	chr19:41160097	G/A	cg21869046	chr19:41225005	ITPKC	0.51	5.22	0.39	5.82e-7	Kawasaki disease;
PAAD	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg24130564	chr14:104152367	KLC1	0.47	4.58	0.35	9.81e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17407555	0.683	rs6852641	chr4:10275746	G/C	cg11266682	chr4:10021025	SLC2A9	0.41	4.25	0.33	3.67e-5	Schizophrenia (age at onset);
PAAD	cis	rs375066	0.935	rs446674	chr19:44421007	G/A	cg21496419	chr19:44306685	LYPD5	0.41	4.95	0.37	1.97e-6	Breast cancer;
PAAD	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg02353165	chr6:42928485	GNMT	0.6	4.81	0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.66	6.54	0.47	8.93e-10	Menarche (age at onset);
PAAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.61	-6.85	-0.49	1.76e-10	Bipolar disorder;
PAAD	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.68	7.53	0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg27499820	chr13:21296301	IL17D	-0.47	-4.57	-0.35	9.83e-6	Dental caries;
PAAD	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.44	-4.91	-0.37	2.3e-6	Mean arterial pressure;
PAAD	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.92	5.46	0.4	1.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02071572	chr4:1403502	NA	-0.43	-5.57	-0.41	1.1e-7	Obesity-related traits;
PAAD	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	7.93	0.54	4.29e-13	Eotaxin levels;
PAAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.7	-6.81	-0.48	2.18e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs89107	1.000	rs89107	chr6:118578043	G/A	cg18833306	chr6:118973337	C6orf204	0.47	5.16	0.39	7.52e-7	Cardiac structure and function;
PAAD	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg20487152	chr13:99095054	FARP1	0.62	5.43	0.4	2.2e-7	Neuroticism;
PAAD	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg26876637	chr1:152193138	HRNR	-0.83	-5.96	-0.44	1.65e-8	Atopic dermatitis;
PAAD	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.99	11.45	0.68	2.8e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2075671	0.903	rs62483592	chr7:100347449	G/A	cg03098644	chr7:100410630	EPHB4	0.6	4.35	0.33	2.49e-5	Other erythrocyte phenotypes;
PAAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg22705602	chr4:152727874	NA	-0.47	-4.75	-0.36	4.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.88	-8.71	-0.58	4.72e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg12165864	chr7:66369176	NA	0.72	4.63	0.35	7.75e-6	Diabetic kidney disease;
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.83	-0.36	3.29e-6	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.7	7.5	0.52	5.01e-12	IgG glycosylation;
PAAD	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.67	-7.52	-0.52	4.42e-12	Heart rate;
PAAD	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.39	-0.34	2.11e-5	Red blood cell count;
PAAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.64	0.35	7.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4662592	0.554	rs13009827	chr2:128912936	G/A	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.78	10.23	0.64	5.04e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.63	8.89	0.58	1.63e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.29	0.33	3.2e-5	Blood metabolite levels;
PAAD	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-4.37	-0.33	2.31e-5	Axial length;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13665263	chr7:135662016	MTPN;LUZP6	0.69	6.75	0.48	2.93e-10	Primary biliary cholangitis;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10214930	0.752	rs12540063	chr7:27661545	T/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs2882877	0.560	rs11568351	chr2:190445194	C/G	cg10752008	chr2:190445175	SLC40A1	-0.54	-4.56	-0.35	1.04e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13202913	0.581	rs12662412	chr6:151824309	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	4.61	0.35	8.32e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg18279126	chr7:2041391	MAD1L1	-0.52	-5.11	-0.38	9.69e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.38	-0.33	2.19e-5	Post bronchodilator FEV1;
PAAD	cis	rs10214930	0.697	rs6958747	chr7:27691863	C/T	cg22168087	chr7:27702803	HIBADH	-0.48	-4.57	-0.35	1.02e-5	Hypospadias;
PAAD	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.68	9.72	0.62	1.14e-17	Breast size;
PAAD	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.73	7.05	0.5	5.98e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.78	8.01	0.54	2.79e-13	Schizophrenia;
PAAD	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-5.64	-0.42	8.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.34	-0.33	2.61e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12612619	0.579	rs827884	chr2:27094842	C/G	cg12368169	chr2:27073192	DPYSL5	-0.41	-4.39	-0.34	2.14e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.78	10.22	0.64	5.52e-19	Iron status biomarkers;
PAAD	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.6	-6.39	-0.46	1.91e-9	Coronary artery disease;
PAAD	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.35	4.31	0.33	2.91e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg11802864	chr11:65308245	LTBP3	0.43	4.45	0.34	1.62e-5	Bone mineral density;
PAAD	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.52	-5.39	-0.4	2.59e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.71	11.28	0.67	8.06e-22	Breast cancer;
PAAD	cis	rs881301	1.000	rs881299	chr8:38332249	T/C	cg17120578	chr8:38329836	NA	-0.43	-4.57	-0.35	1e-5	Response to cognitive-behavioural therapy in anxiety disorder;
PAAD	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-0.85	-12.94	-0.72	2.74e-26	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs621559	0.535	rs841380	chr1:43558828	G/A	cg08853571	chr5:121305621	SRFBP1	0.62	6.52	0.47	9.87e-10	Telomere length;
PAAD	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.41	-4.9	-0.37	2.43e-6	HIV-1 susceptibility;
PAAD	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg22482690	chr17:47019901	SNF8	0.5	5.43	0.4	2.19e-7	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.62	6.21	0.45	4.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs375066	0.935	rs425221	chr19:44418544	C/T	cg08633290	chr19:44405433	NA	0.57	5.74	0.42	4.86e-8	Breast cancer;
PAAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg00262122	chr8:11665843	FDFT1	0.51	4.34	0.33	2.63e-5	Retinal vascular caliber;
PAAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-5.68	-0.42	6.57e-8	Neurofibrillary tangles;
PAAD	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	8.87	0.58	1.89e-15	Eotaxin levels;
PAAD	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg21483461	chr5:81570383	RPS23	0.52	4.93	0.37	2.17e-6	Breast cancer;
PAAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg10729496	chr3:10149963	C3orf24	0.89	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs9649465	0.967	rs10224062	chr7:123304609	G/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg23346134	chr3:49453900	TCTA	0.46	4.96	0.37	1.9e-6	Menarche (age at onset);
PAAD	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.83	6.78	0.48	2.49e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.6	-0.35	8.74e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.54	5.13	0.38	8.77e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.36	0.51	1.1e-11	Menopause (age at onset);
PAAD	cis	rs7804356	0.651	rs1468203	chr7:26791287	C/A	cg03456212	chr7:26904342	SKAP2	0.57	4.86	0.37	2.95e-6	Type 1 diabetes;
PAAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg24633833	chr3:10029261	TMEM111	0.58	4.27	0.33	3.5e-5	Alzheimer's disease;
PAAD	cis	rs71520386	0.632	rs9691076	chr7:22869361	A/C	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs9810890	1.000	rs73196968	chr3:128438798	G/C	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.47	4.33	0.33	2.74e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.44	4.25	0.33	3.74e-5	Primary sclerosing cholangitis;
PAAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg17775713	chr3:133465469	TF	0.5	5.67	0.42	6.9e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.24	0.67	1.04e-21	Platelet count;
PAAD	cis	rs7081476	0.737	rs113681814	chr10:27489683	C/T	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs11018874	0.808	rs71471032	chr11:89888921	A/T	cg05041596	chr11:89867385	NAALAD2	0.67	4.9	0.37	2.39e-6	White blood cell types;
PAAD	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.54	5.47	0.41	1.78e-7	Longevity;Endometriosis;
PAAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs4843185	0.669	rs4843506	chr16:85715440	T/A	cg26571870	chr16:85723150	GINS2	-0.45	-5.31	-0.4	3.85e-7	Platelet distribution width;
PAAD	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.48	0.47	1.19e-9	Morning vs. evening chronotype;
PAAD	cis	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.14e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26128977	chr13:50699776	DLEU2	-0.7	-6.35	-0.46	2.32e-9	Neuroticism;
PAAD	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-6.31	-0.46	2.88e-9	Morning vs. evening chronotype;
PAAD	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.81	-0.43	3.57e-8	Myopia (pathological);
PAAD	cis	rs17331151	0.505	rs35371456	chr3:52563462	C/T	cg27565382	chr3:53032988	SFMBT1	0.95	4.65	0.35	7.14e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg09835421	chr16:68378352	PRMT7	-1.01	-6.6	-0.47	6.45e-10	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09082664	chr4:23890701	PPARGC1A	0.64	6.37	0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs76917914	0.780	rs6478556	chr9:100842005	A/G	cg21225548	chr9:100864335	TRIM14	0.52	5.38	0.4	2.79e-7	Immature fraction of reticulocytes;
PAAD	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.27	0.56	6.24e-14	Homoarginine levels;
PAAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg16591659	chr17:78472290	NA	0.5	4.79	0.36	3.88e-6	Fractional excretion of uric acid;
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-11.11	-0.67	2.29e-21	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.64	6.59	0.47	6.78e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.47e-9	Hypospadias;
PAAD	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs10991814	0.925	rs75139635	chr9:93968324	A/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.13	9.78	0.62	7.85e-18	Vitiligo;
PAAD	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg08501292	chr6:25962987	TRIM38	0.9	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7714584	1.000	rs11739677	chr5:150294883	A/G	cg22134413	chr5:150180641	NA	1.01	6.63	0.47	5.64e-10	Crohn's disease;
PAAD	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg24375607	chr4:120327624	NA	0.58	5.36	0.4	3.06e-7	Educational attainment;
PAAD	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.47	-4.42	-0.34	1.84e-5	DNA methylation (variation);
PAAD	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.29	-0.51	1.55e-11	Migraine;Coronary artery disease;
PAAD	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.61	5.65	0.42	7.79e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2882667	0.893	rs10069961	chr5:138294568	A/G	cg09476006	chr5:138032270	NA	0.36	4.48	0.34	1.49e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2694528	0.841	rs74985265	chr5:60417457	G/T	cg11474532	chr5:59995715	DEPDC1B	1.0	5.34	0.4	3.26e-7	Parkinson's disease;
PAAD	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg20913747	chr6:44695427	NA	-0.7	-7.07	-0.5	5.22e-11	Total body bone mineral density;
PAAD	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.59	6.33	0.46	2.68e-9	Schizophrenia;
PAAD	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.93	-0.37	2.11e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.93	10.63	0.65	4.4e-20	Colorectal adenoma (advanced);
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2645694	1.000	rs2645694	chr4:77833947	C/T	cg03477792	chr4:77819574	ANKRD56	0.86	10.61	0.65	5.15e-20	Emphysema distribution in smoking;
PAAD	cis	rs7742824	1.000	rs57139546	chr6:44067745	T/C	cg21657043	chr6:44035552	NA	0.5	5.03	0.38	1.36e-6	Major depressive disorder;
PAAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.34	-0.4	3.35e-7	Menarche (age at onset);
PAAD	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg23435118	chr5:141488016	NDFIP1	-0.54	-5.3	-0.4	3.94e-7	Crohn's disease;
PAAD	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg06057569	chr22:50219754	BRD1	0.67	5.06	0.38	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-4.96	-0.37	1.84e-6	Systemic lupus erythematosus;
PAAD	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.37	4.42	0.34	1.84e-5	Sitting height ratio;
PAAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.9	14.15	0.75	1.59e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.09	-13.28	-0.73	3.26e-27	Type 1 diabetes nephropathy;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.79	6.29	0.45	3.19e-9	Alzheimer's disease;
PAAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17848003	chr1:3704513	LRRC47	0.4	4.32	0.33	2.84e-5	Red cell distribution width;
PAAD	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg02404636	chr22:31891804	SFI1	-0.61	-5.48	-0.41	1.69e-7	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05798147	chr6:127781063	C6orf174;KIAA0408	-0.51	-6.35	-0.46	2.33e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.81	-5.76	-0.42	4.58e-8	Yeast infection;
PAAD	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg09237302	chr4:906077	GAK	0.44	4.58	0.35	9.58e-6	Type 2 diabetes;
PAAD	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	5.86	0.43	2.76e-8	Lung cancer in ever smokers;
PAAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.75	-8.46	-0.57	2.02e-14	Childhood ear infection;
PAAD	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-4.7	-0.36	5.81e-6	Breast cancer;
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-6.06	-0.44	1.04e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03672602	chr19:19754555	GMIP	0.6	6.67	0.48	4.41e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg01620082	chr3:125678407	NA	-1.07	-6.4	-0.46	1.79e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.58	-0.41	1.1e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg23417306	chr2:180868811	CWC22	-0.48	-4.49	-0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.32	-0.4	3.6e-7	Reticulocyte count;
PAAD	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs4750440	0.585	rs4748069	chr10:14031188	A/G	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.27	-0.33	3.47e-5	Adiponectin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14029169	chr20:23619778	CST3	-0.64	-6.58	-0.47	7.14e-10	Obesity-related traits;
PAAD	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg20913747	chr6:44695427	NA	-0.64	-7.3	-0.51	1.48e-11	Total body bone mineral density;
PAAD	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	1.08	5.65	0.42	7.74e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4751058	0.526	rs10764842	chr10:130861658	A/C	cg04854917	chr10:131378330	MGMT	0.46	4.7	0.36	5.69e-6	Vitamin D levels;
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs78707713	0.841	rs75583483	chr10:71214798	A/G	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.29	-0.39	4.18e-7	Venous thromboembolism;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.33	4.44	0.34	1.7e-5	Vitiligo;
PAAD	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.78	9.4	0.61	7.84e-17	Brugada syndrome;
PAAD	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.37	0.4	2.95e-7	Coronary artery disease;
PAAD	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg04920474	chr2:44395004	PPM1B	0.45	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.68	-0.35	6.28e-6	Breast cancer;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1358748	0.522	rs1885276	chr1:67568824	G/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs1218282	0.655	rs17771893	chr13:79466495	C/T	cg04316526	chr13:78628464	NA	-0.85	-4.46	-0.34	1.6e-5	Response to statin therapy;
PAAD	cis	rs3112530	1.000	rs1462113	chr5:152693291	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.87	4.58	0.35	9.69e-6	Aging (time to event);
PAAD	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg14851346	chr12:38532713	NA	-0.45	-4.29	-0.33	3.23e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg10729496	chr3:10149963	C3orf24	0.62	5.36	0.4	3.08e-7	Alzheimer's disease;
PAAD	cis	rs476633	0.624	rs7175912	chr15:41555249	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-6.34	-0.46	2.54e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs3762637	0.941	rs9810999	chr3:122074391	G/A	cg24169773	chr3:122142474	KPNA1	-0.64	-4.33	-0.33	2.66e-5	LDL cholesterol levels;
PAAD	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18838207	chr2:190649256	PMS1;ORMDL1	0.57	6.35	0.46	2.4e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	5.24	0.39	5.29e-7	Neuroticism;
PAAD	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg23665729	chr3:49977591	RBM6	0.56	4.3	0.33	2.99e-5	Schizophrenia;
PAAD	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.76	0.48	2.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg08200582	chr11:442649	ANO9	0.52	4.52	0.34	1.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-5.22	-0.39	5.67e-7	Coronary artery disease or ischemic stroke;
PAAD	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg05187965	chr10:45406764	TMEM72	-0.38	-5.24	-0.39	5.3e-7	Mean corpuscular volume;
PAAD	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12292205	chr6:26970375	C6orf41	-0.48	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs55728055	1.000	rs16989427	chr22:32108475	C/T	cg01338084	chr22:32026380	PISD	1.53	8.44	0.57	2.27e-14	Age-related hearing impairment;
PAAD	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.7	0.72	1.19e-25	Chronic sinus infection;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.58	6.8	0.48	2.22e-10	Calcium levels;
PAAD	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg14196790	chr5:131705035	SLC22A5	0.45	4.9	0.37	2.46e-6	Blood metabolite levels;
PAAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04635671	chr19:35521163	SCN1B	0.6	6.8	0.48	2.21e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs55728055	0.661	rs61561528	chr22:31983071	A/G	cg01338084	chr22:32026380	PISD	1.6	8.24	0.56	7.56e-14	Age-related hearing impairment;
PAAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.63	-5.79	-0.43	3.83e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1497828	0.956	rs2132994	chr1:217548036	A/G	cg04411442	chr1:217543379	NA	-0.5	-4.94	-0.37	2.06e-6	Dialysis-related mortality;
PAAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.22	0.39	5.78e-7	Ulcerative colitis;
PAAD	cis	rs1797885	0.714	rs1618545	chr3:12560763	A/T	cg07775309	chr3:12595852	NA	-0.4	-4.4	-0.34	2.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg24848339	chr3:12840334	CAND2	0.48	5.0	0.38	1.55e-6	QRS complex (12-leadsum);
PAAD	cis	rs9907295	0.818	rs2306630	chr17:34182341	G/A	cg16983627	chr17:34238386	NA	-0.56	-4.37	-0.33	2.33e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.68	6.32	0.46	2.73e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23296645	chr12:56862258	SPRYD4	0.6	6.89	0.49	1.39e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg15445000	chr17:37608096	MED1	-0.44	-4.92	-0.37	2.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.52	-0.34	1.22e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg23119463	chr10:134592391	INPP5A	-0.44	-4.3	-0.33	3e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-7.38	-0.51	9.89e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.18	-0.45	5.56e-9	IgG glycosylation;
PAAD	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.79	-9.42	-0.61	6.81e-17	White blood cell count (basophil);
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.85	-13.06	-0.73	1.33e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.42	7.12	0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.18e-8	Lung cancer;
PAAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.56	6.65	0.47	5.05e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.69	7.64	0.53	2.22e-12	Cognitive function;
PAAD	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg08992911	chr2:238395768	MLPH	0.59	5.58	0.41	1.08e-7	Prostate cancer;
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.64	8.27	0.56	6.33e-14	Hypertriglyceridemia;
PAAD	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.36	9.24	0.6	2.07e-16	Diabetic retinopathy;
PAAD	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.38	0.4	2.75e-7	HDL cholesterol;
PAAD	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.46	4.55	0.35	1.11e-5	Carotid intima media thickness;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg26516362	chr5:178986906	RUFY1	-0.46	-5.36	-0.4	3.1e-7	Lung cancer;
PAAD	cis	rs6850606	0.537	rs6841802	chr4:42883198	T/C	cg24533989	chr4:42659536	ATP8A1	0.49	4.25	0.33	3.78e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18793088	chr1:201798611	IPO9	-0.66	-6.41	-0.46	1.71e-9	Lung cancer in ever smokers;
PAAD	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.51	5.32	0.4	3.7e-7	Schizophrenia;
PAAD	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg08999081	chr20:33150536	PIGU	0.51	5.59	0.41	1e-7	Height;
PAAD	cis	rs7119038	0.629	rs10892273	chr11:118602809	G/A	cg19308663	chr11:118741387	NA	0.51	4.32	0.33	2.75e-5	Sjögren's syndrome;
PAAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.52	5.21	0.39	5.96e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.54	0.61	3.36e-17	Lymphocyte counts;
PAAD	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	1.01	10.31	0.64	3.09e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.46	-4.91	-0.37	2.31e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.62	-0.35	7.96e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-7.95	-0.54	3.96e-13	Hemoglobin concentration;
PAAD	cis	rs621559	0.688	rs6692564	chr1:43668192	G/T	cg14851383	chr1:43888477	KIAA0467	-0.54	-4.29	-0.33	3.18e-5	Telomere length;
PAAD	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25250414	chr15:75871478	PTPN9	-0.56	-6.32	-0.46	2.77e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.58	-5.85	-0.43	2.97e-8	Schizophrenia;
PAAD	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.8e-6	Height;
PAAD	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.46	0.34	1.61e-5	Retinal vascular caliber;
PAAD	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.69	5.6	0.41	9.64e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.64	7.35	0.51	1.17e-11	Dupuytren's disease;
PAAD	cis	rs2230307	0.656	rs644835	chr1:100543962	A/G	cg24955406	chr1:100503596	HIAT1	0.8	5.1	0.38	9.79e-7	Carotid intima media thickness;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.83	-0.48	1.89e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-8.68	-0.58	5.56e-15	Morning vs. evening chronotype;
PAAD	cis	rs11887277	0.557	rs11126681	chr2:26963378	C/T	cg12368169	chr2:27073192	DPYSL5	0.41	4.28	0.33	3.33e-5	Obesity-related traits;
PAAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.51	0.34	1.27e-5	Total body bone mineral density;
PAAD	cis	rs17155006	0.702	rs399290	chr7:107725977	T/C	cg05962710	chr7:107745446	LAMB4	-0.37	-4.49	-0.34	1.4e-5	Pneumococcal bacteremia;
PAAD	trans	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.32	-0.46	2.69e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7873102	0.654	rs10814640	chr9:38014636	C/T	cg03528946	chr9:38069800	SHB	0.47	4.7	0.36	5.68e-6	Brain structure;
PAAD	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26378065	chr17:18585709	ZNF286B	-0.57	-4.33	-0.33	2.74e-5	Pancreatic cancer;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs4144743	1.000	rs35704663	chr17:45327321	T/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.77	-8.57	-0.57	1.07e-14	Lung cancer;
PAAD	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.81	-8.73	-0.58	4.31e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	1.05	10.78	0.66	1.75e-20	Post bronchodilator FEV1;
PAAD	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	1.07	11.18	0.67	1.52e-21	Platelet distribution width;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg07648498	chr16:89883185	FANCA	-0.47	-4.58	-0.35	9.78e-6	Vitiligo;
PAAD	cis	rs258892	0.895	rs13187277	chr5:72029986	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04332513	chr3:122135059	WDR5B	-0.73	-6.68	-0.48	4.31e-10	Neuroticism;
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.71	6.28	0.45	3.47e-9	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.26	-0.39	4.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.07	8.65	0.57	6.99e-15	Vitiligo;
PAAD	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.41	4.77	0.36	4.37e-6	Dilated cardiomyopathy;
PAAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.33	-0.33	2.68e-5	Height;
PAAD	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg15181151	chr6:150070149	PCMT1	0.61	6.77	0.48	2.61e-10	Lung cancer;
PAAD	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.52	-5.31	-0.4	3.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg06629702	chr1:2706960	NA	0.36	4.28	0.33	3.25e-5	Ulcerative colitis;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	7.78	0.53	1.03e-12	Prudent dietary pattern;
PAAD	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs3744728	0.579	rs9906182	chr17:6101256	G/A	cg08946332	chr17:6899888	ALOX12	-0.72	-4.28	-0.33	3.29e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.72	-7.59	-0.52	3e-12	Adiposity;
PAAD	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.15	-16.93	-0.81	8.5e-37	IgG glycosylation;
PAAD	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg14191688	chr11:70257035	CTTN	0.56	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.35	5.04	0.38	1.3e-6	Educational attainment (years of education);
PAAD	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11411865	chr7:2701802	TTYH3	0.68	4.88	0.37	2.6e-6	Bipolar disorder;
PAAD	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-8.7	-0.58	5.14e-15	Height;
PAAD	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.51	0.34	1.31e-5	Colorectal cancer;
PAAD	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs2239785	0.959	rs713929	chr22:36657596	A/G	cg15716373	chr22:36655542	APOL1	-0.46	-4.62	-0.35	8.05e-6	Glomerulosclerosis;
PAAD	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg06565975	chr8:143823917	SLURP1	-0.25	-5.08	-0.38	1.07e-6	Urinary tract infection frequency;
PAAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.14	-0.45	6.75e-9	Schizophrenia;
PAAD	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg24253500	chr15:84953950	NA	0.44	4.63	0.35	7.75e-6	Schizophrenia;
PAAD	cis	rs12799264	1.000	rs2585778	chr11:19975274	G/A	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs501120	0.657	rs646890	chr10:44741710	C/T	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.44	-4.68	-0.35	6.36e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	6.42	0.46	1.64e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.68	0.48	4.22e-10	Lung cancer in ever smokers;
PAAD	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg25722041	chr1:8623473	RERE	0.52	4.54	0.35	1.12e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	0.97	8.99	0.59	9.33e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs9467603	0.566	rs10214468	chr6:25789390	T/A	cg21479132	chr6:26055353	NA	0.78	5.14	0.38	8.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1043763	0.826	rs10847689	chr12:122613000	A/G	cg26218692	chr12:122497826	BCL7A	-0.62	-6.36	-0.46	2.27e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg15181151	chr6:150070149	PCMT1	0.6	6.56	0.47	8.06e-10	Lung cancer;
PAAD	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.39	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.47	-4.53	-0.34	1.2e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.34	1.19e-5	Menarche (age at onset);
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.67	6.84	0.49	1.8e-10	Menarche (age at onset);
PAAD	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-4.76	-0.36	4.53e-6	Total cholesterol levels;
PAAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.64	7.28	0.51	1.64e-11	Height;
PAAD	cis	rs5750830	0.594	rs6001566	chr22:39774448	A/G	cg05872129	chr22:39784769	NA	-0.86	-9.14	-0.6	3.73e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.76	0.36	4.43e-6	Asthma;
PAAD	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.88	10.73	0.66	2.45e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.96	7.62	0.53	2.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg00944433	chr1:107599041	PRMT6	-0.41	-4.66	-0.35	6.76e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.71	7.04	0.5	6.03e-11	Aortic root size;
PAAD	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.83	10.3	0.64	3.43e-19	Height;
PAAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.54e-6	Bipolar disorder;
PAAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg25452165	chr22:42524984	CYP2D6	0.58	5.2	0.39	6.45e-7	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14252954	chr1:114889371	NA	0.63	6.72	0.48	3.43e-10	Myopia (pathological);
PAAD	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg14582100	chr15:45693742	SPATA5L1	0.44	6.62	0.47	5.78e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.92	13.25	0.73	3.92e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.43	-4.31	-0.33	2.98e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs17169634	0.557	rs74495807	chr7:34088535	C/T	cg24927974	chr7:35078269	DPY19L1	-0.64	-4.81	-0.36	3.62e-6	Alzheimer's disease;
PAAD	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg05207973	chr5:176823642	SLC34A1	0.4	4.6	0.35	9.01e-6	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.73	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.56	-5.31	-0.4	3.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg14346243	chr4:90757452	SNCA	-0.5	-4.39	-0.34	2.14e-5	Neuroticism;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	0.7	5.53	0.41	1.4e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8040855	0.930	rs6496767	chr15:85702753	G/T	cg08123816	chr15:85640762	PDE8A	0.4	4.87	0.37	2.75e-6	Bulimia nervosa;
PAAD	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.58	5.49	0.41	1.68e-7	Corneal astigmatism;
PAAD	cis	rs4678145	1.000	rs4678145	chr3:124450081	G/C	cg07063911	chr3:125197837	SNX4	0.7	4.26	0.33	3.52e-5	Coronary artery disease;
PAAD	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.66e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.69	7.63	0.53	2.39e-12	Prostate cancer;
PAAD	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.24e-11	Life satisfaction;
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.65	-6.0	-0.44	1.4e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.42	-4.65	-0.35	7.24e-6	Lung cancer;
PAAD	cis	rs454510	1.000	rs454510	chr1:120195042	C/T	cg11530693	chr1:120165357	ZNF697	-0.56	-4.81	-0.36	3.53e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.95	10.45	0.65	1.37e-19	Breast cancer;
PAAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.87	6.02	0.44	1.26e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs56873913	0.904	rs3760708	chr19:50084596	G/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.52	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	5.75	0.42	4.71e-8	Mean platelet volume;
PAAD	cis	rs12935418	0.672	rs12446304	chr16:81046335	C/G	cg16651780	chr16:81037892	C16orf61	0.66	6.17	0.45	5.96e-9	Mean corpuscular volume;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.06	-0.44	1.02e-8	Personality dimensions;
PAAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg09835421	chr16:68378352	PRMT7	-0.95	-6.86	-0.49	1.67e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg23665729	chr3:49977591	RBM6	-0.59	-4.47	-0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs7989332	0.925	rs7329649	chr13:21050087	T/G	cg06710890	chr13:21477865	XPO4	0.44	4.41	0.34	1.95e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.86	-10.0	-0.63	2.1e-18	Menarche (age at onset);
PAAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.45	7.62	0.53	2.58e-12	Multiple system atrophy;
PAAD	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.52	-4.88	-0.37	2.61e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-4.82	-0.36	3.39e-6	Testicular germ cell tumor;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	0.77	7.98	0.54	3.36e-13	Myopia (pathological);
PAAD	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.54	-5.21	-0.39	5.92e-7	Gut microbiome composition (summer);
PAAD	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-1.08	-9.63	-0.62	1.97e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.24	-0.39	5.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.56	0.41	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-4.87	-0.37	2.83e-6	Osteoarthritis;
PAAD	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.67	7.55	0.52	3.76e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs863345	0.904	rs954677	chr1:158543277	G/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14937543	chr3:20081518	KAT2B	0.66	6.53	0.47	9.36e-10	Obesity-related traits;
PAAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.68	7.83	0.54	7.94e-13	Multiple sclerosis;
PAAD	cis	rs72960926	0.744	rs72950543	chr6:74907232	G/A	cg03266952	chr6:74778945	NA	-1.15	-6.5	-0.47	1.09e-9	Metabolite levels (MHPG);
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.46	10.7	0.66	2.8e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.65	-7.02	-0.49	6.9e-11	Iron status biomarkers;
PAAD	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs6494488	0.500	rs72742916	chr15:64850675	T/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg07952391	chr2:88470173	THNSL2	-0.54	-5.26	-0.39	4.84e-7	Response to metformin (IC50);
PAAD	trans	rs202065757	1	rs202065757	chr6:28766359	C/CAT	cg01620082	chr3:125678407	NA	-1.57	-9.97	-0.63	2.47e-18	Tuberculosis;
PAAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.63	-7.25	-0.51	1.97e-11	Bone mineral density;
PAAD	cis	rs4455778	0.580	rs10261034	chr7:49092554	C/A	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.6	5.68	0.42	6.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs558003	0.826	rs688462	chr13:51190422	C/G	cg24585282	chr13:51257555	NA	-0.67	-4.53	-0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.74	-7.31	-0.51	1.43e-11	Menopause (age at onset);
PAAD	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg26205652	chr12:48591994	NA	-0.95	-9.61	-0.61	2.29e-17	Longevity (90 years and older);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19276371	chr2:74590743	DCTN1	-0.64	-6.52	-0.47	9.56e-10	Obesity-related traits;
PAAD	cis	rs2439831	0.681	rs884704	chr15:43691150	T/C	cg10011062	chr15:43941034	CATSPER2	-0.88	-5.42	-0.4	2.29e-7	Lung cancer in ever smokers;
PAAD	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.57	6.49	0.47	1.16e-9	Mean corpuscular volume;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.66	7.03	0.5	6.71e-11	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24360773	chr3:23987459	NR1D2	0.71	7.35	0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg18850127	chr7:39170497	POU6F2	-0.54	-7.2	-0.5	2.64e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7264396	0.775	rs2296402	chr20:34054729	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.95	-0.43	1.78e-8	Total cholesterol levels;
PAAD	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs6132905	0.590	rs4815454	chr20:2624376	G/A	cg24848351	chr20:2622020	TMC2	-0.76	-5.54	-0.41	1.31e-7	Mumps;
PAAD	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.16	-0.39	7.51e-7	Initial pursuit acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20457193	chr1:32645180	TXLNA	0.6	7.0	0.49	7.83e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs757081	0.671	rs214070	chr11:17305317	T/A	cg15432903	chr11:17409602	KCNJ11	-0.65	-6.23	-0.45	4.31e-9	Systolic blood pressure;
PAAD	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.37	-0.4	2.92e-7	Bladder cancer;
PAAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.69	7.14	0.5	3.58e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10274279	1.000	rs6459798	chr7:157381735	C/T	cg09270525	chr7:157391030	PTPRN2	0.71	5.32	0.4	3.64e-7	Myopia (pathological);
PAAD	cis	rs75920871	1.000	rs11823013	chr11:116839535	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs28493229	0.708	rs10408309	chr19:41161189	T/G	cg21869046	chr19:41225005	ITPKC	0.52	5.29	0.39	4.16e-7	Kawasaki disease;
PAAD	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs8067287	0.762	rs62065418	chr17:16820938	G/A	cg26910001	chr17:16838321	NA	-0.68	-6.13	-0.44	7.4e-9	Diabetic kidney disease;
PAAD	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg16211469	chr6:24423932	MRS2	0.53	5.32	0.4	3.66e-7	Liver enzyme levels;
PAAD	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-4.78	-0.36	4.02e-6	Blood metabolite levels;
PAAD	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg10396713	chr8:602097	NA	0.72	5.05	0.38	1.24e-6	IgG glycosylation;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.03e-6	Bipolar disorder;
PAAD	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06850241	chr22:41845214	NA	-0.49	-4.26	-0.33	3.55e-5	Vitiligo;
PAAD	cis	rs2221894	0.881	rs6994074	chr8:28892893	T/G	cg20212339	chr8:28908912	HMBOX1	-0.5	-5.31	-0.4	3.8e-7	Obesity-related traits;
PAAD	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-4.26	-0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7713065	0.840	rs59041913	chr5:131788135	C/T	cg14196790	chr5:131705035	SLC22A5	-0.51	-4.93	-0.37	2.15e-6	Lung function (FEV1/FVC);
PAAD	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.5	4.75	0.36	4.63e-6	Hip circumference;
PAAD	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.59	-5.28	-0.39	4.39e-7	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22855876	chr2:27256034	TMEM214	-0.74	-6.39	-0.46	1.9e-9	Neuroticism;
PAAD	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.21	-0.39	6.17e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.61	5.03	0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs54211	0.908	rs137665	chr22:39735047	T/A	cg11247378	chr22:39784982	NA	-0.77	-4.47	-0.34	1.51e-5	Sudden cardiac arrest;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25116269	chr2:55509523	PRDXDD1P	-0.57	-6.51	-0.47	1.03e-9	Body fat percentage;
PAAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg27411982	chr8:10470053	RP1L1	0.43	4.79	0.36	3.97e-6	Retinal vascular caliber;
PAAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.14	10.5	0.65	1.01e-19	Initial pursuit acceleration;
PAAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.77	-7.43	-0.52	7.32e-12	Obesity-related traits;
PAAD	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.9	-0.37	2.47e-6	Neuroticism;
PAAD	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	6.48	0.47	1.22e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.6	-4.65	-0.35	7.05e-6	Mosquito bite size;
PAAD	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg14345882	chr6:26364793	BTN3A2	-0.39	-4.43	-0.34	1.81e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-4.28	-0.33	3.23e-5	Axial length;
PAAD	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.83	-9.63	-0.62	2.02e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg15212455	chr7:39170539	POU6F2	0.39	5.62	0.41	8.96e-8	IgG glycosylation;
PAAD	cis	rs9361491	0.608	rs9352627	chr6:79455586	T/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.12	10.23	0.64	5.14e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.7	-8.11	-0.55	1.54e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09640425	chr7:158790006	NA	-0.5	-5.62	-0.41	8.81e-8	Facial morphology (factor 20);
PAAD	cis	rs2221894	0.922	rs4732657	chr8:28755988	C/T	cg20212339	chr8:28908912	HMBOX1	0.49	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg04154034	chr17:28927549	LRRC37B2	-0.63	-4.47	-0.34	1.51e-5	Body mass index;
PAAD	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg02910952	chr12:132569714	EP400NL	0.62	4.7	0.36	5.68e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.96	-10.96	-0.66	5.77e-21	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.81	9.24	0.6	2.06e-16	Menarche (age at onset);
PAAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.35	15.59	0.78	2.47e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4704187	0.617	rs4704185	chr5:74471690	G/A	cg03227963	chr5:74354835	NA	0.5	4.79	0.36	3.97e-6	Response to amphetamines;
PAAD	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-5.15	-0.39	8.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	0.87	5.01	0.38	1.51e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.71	-0.42	5.85e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.3	-0.33	3.01e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg11335335	chr11:637885	DRD4	-0.38	-5.5	-0.41	1.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs911119	0.818	rs56077567	chr20:23591087	T/C	cg16589663	chr20:23618590	CST3	0.79	6.91	0.49	1.26e-10	Chronic kidney disease;
PAAD	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.56	-5.04	-0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg18538332	chr22:24372958	LOC391322	-0.51	-4.55	-0.35	1.08e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg01620082	chr3:125678407	NA	-1.44	-8.04	-0.55	2.32e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2073499	0.872	rs77097132	chr3:50301050	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.84	4.73	0.36	5.16e-6	Schizophrenia;
PAAD	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.56	-5.63	-0.42	8.29e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.62	5.8	0.43	3.74e-8	Mood instability;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.72	-5.99	-0.44	1.45e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.44	0.34	1.71e-5	Breast cancer;
PAAD	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.66	6.5	0.47	1.1e-9	Schizophrenia;
PAAD	cis	rs10267417	0.604	rs7785317	chr7:19853482	G/T	cg05791153	chr7:19748676	TWISTNB	-0.66	-5.01	-0.38	1.5e-6	Night sleep phenotypes;
PAAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg24253500	chr15:84953950	NA	0.56	6.54	0.47	9.05e-10	Schizophrenia;
PAAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.54	5.55	0.41	1.24e-7	Major depressive disorder;
PAAD	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04717802	chr22:42394638	WBP2NL	-0.42	-4.46	-0.34	1.58e-5	Cognitive function;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.62	0.57	8.14e-15	Prudent dietary pattern;
PAAD	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.51	-4.73	-0.36	5e-6	Hypospadias;
PAAD	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.9	-0.43	2.26e-8	Urate levels in overweight individuals;
PAAD	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.74	-0.36	4.94e-6	Dilated cardiomyopathy;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg21724239	chr8:58056113	NA	0.67	5.31	0.4	3.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs4462272	0.500	rs4919446	chr10:102039458	G/A	cg02250046	chr10:101825185	CPN1	-0.4	-4.33	-0.33	2.73e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1109501	0.734	rs34066179	chr4:71418908	C/T	cg25553522	chr4:71388589	AMTN	0.53	4.54	0.35	1.15e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.77	8.2	0.55	9.3e-14	Longevity;
PAAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg14515779	chr1:101123966	NA	-0.53	-6.67	-0.48	4.53e-10	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17300868	chr2:178130115	NFE2L2	0.63	6.77	0.48	2.65e-10	Obesity-related traits;
PAAD	cis	rs3867498	0.943	rs34975843	chr15:25066558	C/T	cg08194505	chr15:25684383	UBE3A	-0.66	-4.53	-0.35	1.16e-5	Pulmonary function;
PAAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.71	-8.17	-0.55	1.12e-13	Diastolic blood pressure;
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.87	10.04	0.63	1.66e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg22089800	chr15:90895588	ZNF774	0.58	5.61	0.41	9.11e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.63	6.88	0.49	1.45e-10	Resting heart rate;
PAAD	cis	rs16958440	0.867	rs9304342	chr18:44720199	T/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.31	-4.35	-0.33	2.47e-5	Dupuytren's disease;
PAAD	cis	rs13011075	0.646	rs7578358	chr2:68628724	T/C	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.79	-7.62	-0.53	2.58e-12	Body mass index (adult);
PAAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg05805236	chr11:65401703	PCNXL3	0.59	6.22	0.45	4.63e-9	Acne (severe);
PAAD	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.5	-4.68	-0.35	6.33e-6	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg07068956	chr7:100330872	ZAN	0.53	4.75	0.36	4.62e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg20917491	chr3:195578259	NA	0.59	5.7	0.42	5.95e-8	Pancreatic cancer;
PAAD	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.73	-8.02	-0.55	2.65e-13	Schizophrenia;
PAAD	cis	rs12450239	0.884	rs1877681	chr17:77448020	T/C	cg09567646	chr17:76962761	NA	-0.41	-4.33	-0.33	2.74e-5	Body mass index;
PAAD	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg06307176	chr5:131281290	NA	-0.49	-4.41	-0.34	1.95e-5	Life satisfaction;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19386169	chr12:133296477	PGAM5	0.62	6.37	0.46	2.1e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg10589385	chr1:150898437	SETDB1	0.39	4.85	0.37	3.09e-6	Melanoma;
PAAD	cis	rs2916733	0.607	rs2922822	chr8:6313733	A/G	cg02465761	chr8:6735510	DEFB1	0.47	4.53	0.35	1.18e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.49	0.76	1.99e-30	Headache;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27512974	chr6:11200925	NEDD9	-0.65	-6.76	-0.48	2.75e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.53	5.16	0.39	7.74e-7	Vitiligo;
PAAD	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.57	4.97	0.37	1.76e-6	Mean platelet volume;
PAAD	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.53	-5.86	-0.43	2.84e-8	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.34e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg19090574	chr1:205240910	TMCC2	-0.41	-4.28	-0.33	3.3e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg25930673	chr12:123319894	HIP1R	1.3	6.39	0.46	1.95e-9	Adiponectin levels;
PAAD	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg13002189	chr3:66846049	NA	0.53	5.16	0.39	7.51e-7	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-6.7	-0.48	3.74e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg26876637	chr1:152193138	HRNR	-0.82	-5.82	-0.43	3.3e-8	Atopic dermatitis;
PAAD	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg02580895	chr19:2754563	NA	-0.51	-4.44	-0.34	1.72e-5	Total cholesterol levels;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs11825685	0.887	rs4328229	chr11:134566548	G/A	cg02089395	chr11:134479357	NA	-0.69	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.59	-0.41	1.04e-7	Corneal astigmatism;
PAAD	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-1.07	-7.42	-0.52	7.68e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg24562669	chr7:97807699	LMTK2	0.65	9.61	0.61	2.25e-17	Breast cancer;
PAAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.88	10.71	0.66	2.65e-20	Methadone dose in opioid dependence;
PAAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-4.97	-0.37	1.76e-6	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.31	-0.33	2.88e-5	Cystic fibrosis severity;
PAAD	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs12576326	1.000	rs12576326	chr11:44980383	A/G	cg01859616	chr11:44970771	TP53I11	-0.45	-4.38	-0.33	2.24e-5	Resting heart rate;
PAAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs9535307	0.584	rs61961502	chr13:50393700	G/A	cg04663916	chr13:50265991	EBPL	-0.63	-4.38	-0.33	2.17e-5	Obesity-related traits;
PAAD	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.46	-4.69	-0.36	6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs3784262	0.527	rs1441815	chr15:58274229	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-4.25	-0.33	3.76e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg10556349	chr10:835070	NA	0.56	4.65	0.35	7.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.67	-6.54	-0.47	8.73e-10	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg23684204	chr15:91497937	RCCD1	0.71	5.77	0.42	4.32e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.46	-4.3	-0.33	2.99e-5	HDL cholesterol;
PAAD	cis	rs17125944	0.686	rs11157933	chr14:53349798	G/A	cg00686598	chr14:53173677	PSMC6	-0.83	-5.01	-0.38	1.49e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1561176	1.000	rs11771240	chr7:155008469	A/G	cg25063631	chr7:155025500	NA	-0.52	-4.34	-0.33	2.6e-5	Personality dimensions;
PAAD	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.58	6.07	0.44	1e-8	Longevity;
PAAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-0.98	-6.65	-0.47	5.05e-10	Breast cancer;
PAAD	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg09839279	chr12:125627357	AACS	-0.47	-4.44	-0.34	1.71e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9356171	0.539	rs11755754	chr6:164325492	A/G	cg25752492	chr6:164341247	NA	-0.47	-5.18	-0.39	7.01e-7	Diisocyanate-induced asthma;
PAAD	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.49	-0.41	1.63e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.77	-7.82	-0.54	8.06e-13	Menopause (age at onset);
PAAD	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg19264203	chr11:92714893	MTNR1B	0.42	4.77	0.36	4.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg15193198	chr20:60906057	LAMA5	-0.47	-5.22	-0.39	5.73e-7	Colorectal cancer;
PAAD	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.21	-0.39	6.01e-7	Mood instability;
PAAD	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg06386533	chr2:46925753	SOCS5	0.63	6.73	0.48	3.17e-10	Height;
PAAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.64	-7.55	-0.52	3.82e-12	Schizophrenia;
PAAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.71	8.27	0.56	6.34e-14	Multiple sclerosis;
PAAD	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.07	0.55	1.94e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg06453172	chr10:134556979	INPP5A	-0.53	-4.68	-0.35	6.39e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26837270	chr19:42746884	GSK3A	-0.75	-6.36	-0.46	2.23e-9	Neuroticism;
PAAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.84	9.43	0.61	6.4e-17	Resting heart rate;
PAAD	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg20283391	chr11:68216788	NA	0.53	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21862992	chr11:68658383	NA	0.44	4.68	0.36	6.18e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.63	-7.32	-0.51	1.34e-11	Systemic lupus erythematosus;
PAAD	cis	rs3112530	1.000	rs2964812	chr5:152650211	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs2916733	0.823	rs2440402	chr8:6321054	A/G	cg01691696	chr8:6734962	DEFB1	-0.54	-4.25	-0.33	3.65e-5	Epirubicin-induced leukopenia;
PAAD	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-7.3	-0.51	1.49e-11	Neuroticism;
PAAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.8	8.02	0.55	2.59e-13	Blood protein levels;
PAAD	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.62	-4.56	-0.35	1.03e-5	Vitiligo;
PAAD	cis	rs643506	0.845	rs607327	chr11:111695709	C/T	cg09085632	chr11:111637200	PPP2R1B	0.55	4.74	0.36	4.97e-6	Breast cancer;
PAAD	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.55	6.22	0.45	4.66e-9	White blood cell count (basophil);
PAAD	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.53	5.97	0.44	1.63e-8	Fibrinogen levels;
PAAD	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.86	0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg12568669	chr8:11666485	FDFT1	0.32	4.93	0.37	2.15e-6	Triglycerides;
PAAD	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg21775007	chr8:11205619	TDH	-0.47	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-5.94	-0.43	1.86e-8	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg24690094	chr11:67383802	NA	-0.5	-4.5	-0.34	1.32e-5	Mean corpuscular volume;
PAAD	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg03098721	chr1:84464084	TTLL7	0.46	4.33	0.33	2.68e-5	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.87	12.35	0.71	1.07e-24	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09060093	chr1:26202137	NA	0.62	6.82	0.48	2.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.45	-0.34	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4942783	0.647	rs9590972	chr13:31583488	A/G	cg22761482	chr13:31579400	NA	-0.44	-4.61	-0.35	8.45e-6	Subjective well-being;
PAAD	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.94e-8	Tonsillectomy;
PAAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-6.33	-0.46	2.55e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	6.39	0.46	1.91e-9	Type 2 diabetes;
PAAD	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-5.57	-0.41	1.11e-7	Crohn's disease;
PAAD	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18715297	chr3:122283210	PARP9;DTX3L	0.59	6.62	0.47	5.9e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11997175	0.653	rs7005254	chr8:33641781	A/T	ch.8.33884649F	chr8:33765107	NA	0.56	6.35	0.46	2.33e-9	Body mass index;
PAAD	cis	rs877529	0.625	rs714013	chr22:39533272	A/G	cg18708252	chr22:39545030	CBX7	-0.66	-6.89	-0.49	1.35e-10	Multiple myeloma;
PAAD	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.73	-6.19	-0.45	5.29e-9	Plateletcrit;Platelet count;
PAAD	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.73	7.47	0.52	5.87e-12	Uric acid levels;
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.34	0.4	3.26e-7	Total body bone mineral density;
PAAD	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.5	4.94	0.37	2.02e-6	Breast cancer;
PAAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg04287289	chr16:89883240	FANCA	0.62	6.77	0.48	2.69e-10	Vitiligo;
PAAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.43	0.61	6.76e-17	Cognitive function;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-4.44	-0.34	1.75e-5	Reticulocyte count;
PAAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02244288	chr16:89573955	SPG7	-0.34	-4.54	-0.35	1.15e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1413885	1.000	rs12060747	chr1:65814892	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	4.87	0.37	2.75e-6	Anticoagulant levels;
PAAD	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.7	-5.91	-0.43	2.16e-8	Fibrinogen levels;
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.54	5.28	0.39	4.31e-7	Menarche (age at onset);
PAAD	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.31	-0.33	2.94e-5	Lewy body disease;
PAAD	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg00228799	chr9:131580591	ENDOG	-0.64	-6.44	-0.46	1.49e-9	Blood metabolite levels;
PAAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17409405	chr7:5085485	RBAK	-0.63	-6.38	-0.46	2.04e-9	Smoking initiation;
PAAD	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.65	-5.94	-0.43	1.87e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg25008857	chr14:105974488	NA	0.39	4.26	0.33	3.62e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.57	-7.51	-0.52	4.64e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3981351	1.000	rs3981351	chr10:115515120	C/T	cg24846397	chr10:115438155	CASP7	0.49	4.54	0.35	1.14e-5	Obesity-related traits;
PAAD	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs112990264	1.000	rs77522721	chr1:213016784	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.74	-7.34	-0.51	1.19e-11	Handedness;
PAAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs11671005	0.737	rs11671033	chr19:58963669	G/T	cg25952890	chr19:58913133	NA	0.7	5.55	0.41	1.23e-7	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.58	-8.16	-0.55	1.18e-13	Asthma (sex interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01243992	chr20:31378276	DNMT3B	-0.66	-6.78	-0.48	2.51e-10	Obesity-related traits;
PAAD	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg05791153	chr7:19748676	TWISTNB	0.62	4.73	0.36	5.1e-6	Thyroid stimulating hormone;
PAAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.54	-4.78	-0.36	4.05e-6	Vitiligo;
PAAD	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.63	8.39	0.56	3.12e-14	Systemic lupus erythematosus;
PAAD	cis	rs7766436	0.540	rs6922087	chr6:22608798	G/A	cg13666174	chr6:22585274	NA	-0.47	-5.72	-0.42	5.48e-8	Coronary artery disease;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.65	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	6.13e-7	Bladder cancer;
PAAD	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.64	6.11	0.44	7.91e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg11211951	chr8:145729740	GPT	0.43	4.74	0.36	4.77e-6	Age at first birth;
PAAD	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg20893579	chr22:38215064	NA	-0.56	-6.01	-0.44	1.33e-8	Glioblastoma;Glioma;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	1.02	14.43	0.76	2.8e-30	Menarche (age at onset);
PAAD	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.5	4.9	0.37	2.4e-6	Pancreatic cancer;
PAAD	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg06627628	chr2:24431161	ITSN2	-0.58	-5.62	-0.41	9.08e-8	Sjögren's syndrome;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.69	-7.94	-0.54	4.22e-13	Iron status biomarkers;
PAAD	cis	rs1957429	0.520	rs77606588	chr14:65356268	G/A	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.15	-0.39	8.1e-7	Lung cancer;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	1.14	12.12	0.7	4.32e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs13380717	1.000	rs13380717	chr16:86904135	C/T	cg07769121	chr16:86543519	FOXF1	-0.57	-4.72	-0.36	5.35e-6	Sepsis in extremely premature infants;
PAAD	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg14515779	chr1:101123966	NA	-0.54	-6.63	-0.47	5.62e-10	Monocyte count;
PAAD	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.56	5.42	0.4	2.33e-7	Prostate cancer;
PAAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg05805236	chr11:65401703	PCNXL3	-0.47	-5.33	-0.4	3.54e-7	Systemic lupus erythematosus;
PAAD	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	4.6	0.35	8.98e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg12193833	chr17:30244370	NA	-0.63	-4.39	-0.34	2.12e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.94	10.05	0.63	1.56e-18	Cognitive function;
PAAD	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-7.93	-0.54	4.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.83	9.54	0.61	3.4e-17	Ulcerative colitis;
PAAD	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7713065	0.612	rs10060626	chr5:131803967	T/G	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.22	-0.39	5.91e-7	Lung function (FEV1/FVC);
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16262614	chr3:133464971	TF	0.41	4.28	0.33	3.31e-5	Iron status biomarkers;
PAAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg14349672	chr11:133703707	NA	-0.47	-5.07	-0.38	1.16e-6	Childhood ear infection;
PAAD	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-1.02	-10.75	-0.66	2.17e-20	Platelet distribution width;
PAAD	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04850017	chr11:63683019	RCOR2	0.39	4.44	0.34	1.72e-5	Pulse pressure;
PAAD	cis	rs12760731	0.565	rs12403070	chr1:178094429	A/G	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	1.02	13.84	0.75	1.07e-28	Multiple system atrophy;
PAAD	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00079375	chr15:79125835	NA	0.44	4.64	0.35	7.58e-6	Coronary artery disease;
PAAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.49	-4.26	-0.33	3.6e-5	Coronary artery disease;
PAAD	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg08886695	chr4:3369023	RGS12	0.53	5.11	0.38	9.64e-7	Serum sulfate level;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg02869306	chr7:64672164	INTS4L1	0.4	4.71	0.36	5.64e-6	Aortic root size;
PAAD	cis	rs7187994	0.672	rs11863406	chr16:84802666	T/G	cg07647771	chr16:84786436	USP10	-0.35	-4.25	-0.33	3.69e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	1.06	9.25	0.6	1.91e-16	Monocyte percentage of white cells;
PAAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.94	0.59	1.21e-15	Parkinson's disease;
PAAD	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.92	12.13	0.7	4.13e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg00717180	chr2:96193071	NA	-0.66	-8.36	-0.56	3.8e-14	Height;
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.44	4.72	0.36	5.39e-6	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03425219	chr11:18548609	TSG101	-0.61	-6.63	-0.47	5.49e-10	Myopia (pathological);
PAAD	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg21211680	chr2:198530	NA	0.76	6.11	0.44	7.89e-9	Suicide attempts in bipolar disorder;
PAAD	cis	rs11825685	0.579	rs3016427	chr11:134543085	A/G	cg06603561	chr11:134479413	NA	-0.58	-5.06	-0.38	1.17e-6	IgG glycosylation;
PAAD	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22799212	chr1:161102325	DEDD	-0.55	-6.36	-0.46	2.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs66468717	0.507	rs6598837	chr17:837797	A/T	cg16885779	chr17:840975	NXN	-0.44	-4.92	-0.37	2.23e-6	Caudate activity during reward;
PAAD	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.62	-6.69	-0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.75	6.93	0.49	1.13e-10	Platelet distribution width;
PAAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg13393036	chr8:95962371	TP53INP1	-0.54	-5.58	-0.41	1.08e-7	Type 2 diabetes;
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11614333	0.920	rs4763401	chr12:15020977	G/A	cg00431549	chr12:15039025	MGP	-0.36	-4.29	-0.33	3.21e-5	Hand grip strength;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.55	5.49	0.41	1.62e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.87	-0.37	2.74e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.32e-6	Parkinson's disease;
PAAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg14709524	chr16:89940631	TCF25	0.96	4.58	0.35	9.43e-6	Skin colour saturation;
PAAD	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.71	6.84	0.48	1.85e-10	Uric acid levels;
PAAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02244288	chr16:89573955	SPG7	-0.33	-4.26	-0.33	3.51e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs28489187	0.706	rs66811655	chr1:85831544	T/G	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.7	-6.68	-0.48	4.17e-10	Schizophrenia;
PAAD	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.38	-4.72	-0.36	5.34e-6	Electrocardiographic conduction measures;
PAAD	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.99	0.49	7.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg03999872	chr20:62272968	STMN3	0.64	5.86	0.43	2.73e-8	Atopic dermatitis;
PAAD	cis	rs1015291	0.708	rs1565592	chr12:19997502	T/G	cg25401612	chr12:20009446	NA	-0.57	-5.58	-0.41	1.08e-7	Diastolic blood pressure;
PAAD	cis	rs1863918	0.632	rs73340597	chr5:178478092	A/G	cg21905437	chr5:178450457	ZNF879	-0.48	-4.57	-0.35	1.01e-5	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	8.26	0.56	6.45e-14	Cognitive test performance;
PAAD	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg00071950	chr4:10020882	SLC2A9	0.62	5.22	0.39	5.71e-7	Blood metabolite levels;
PAAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-5.41	-0.4	2.39e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1610096	0.538	rs2279796	chr19:1059004	A/G	cg18950617	chr19:1066959	HMHA1	-0.49	-4.86	-0.37	2.88e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.5	4.39	0.34	2.08e-5	Height;
PAAD	cis	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg22101045	chr11:47927509	NA	0.53	4.25	0.33	3.67e-5	Axial length;
PAAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.69	-7.13	-0.5	3.8e-11	Menopause (age at onset);
PAAD	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.53	5.48	0.41	1.7e-7	Male-pattern baldness;
PAAD	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.93	-0.49	1.12e-10	Type 2 diabetes;
PAAD	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-1.12	-8.89	-0.58	1.66e-15	Post bronchodilator FEV1;
PAAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg02734326	chr4:10020555	SLC2A9	0.42	4.28	0.33	3.27e-5	Bone mineral density;
PAAD	cis	rs757081	0.648	rs214907	chr11:17244779	G/A	cg15432903	chr11:17409602	KCNJ11	-0.59	-6.05	-0.44	1.08e-8	Systolic blood pressure;
PAAD	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4478858	0.746	rs7520439	chr1:31688721	G/C	cg00250761	chr1:31883323	NA	0.4	4.46	0.34	1.61e-5	Alcohol dependence;
PAAD	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg19784903	chr17:45786737	TBKBP1	-0.5	-4.75	-0.36	4.58e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs959260	0.557	rs55762977	chr17:73309338	A/G	cg23244877	chr17:73518230	TSEN54	-0.5	-4.31	-0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	7.03	0.5	6.58e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-4.31	-0.33	2.92e-5	Educational attainment;
PAAD	cis	rs2908197	0.843	rs2961040	chr7:75946763	A/C	cg22830091	chr7:75961684	YWHAG	-0.59	-6.7	-0.48	3.75e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Monocyte percentage of white cells;
PAAD	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.08	-0.5	4.99e-11	Response to antipsychotic treatment;
PAAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.6	0.61	2.33e-17	Rheumatoid arthritis;
PAAD	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg12935359	chr14:103987150	CKB	-0.57	-5.79	-0.43	3.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs755249	0.567	rs4660603	chr1:39736334	C/G	cg14018543	chr1:39659967	MACF1	0.53	4.46	0.34	1.56e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg07777115	chr5:623756	CEP72	-0.52	-4.63	-0.35	7.77e-6	Cystic fibrosis severity;
PAAD	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.51	6.49	0.47	1.14e-9	Huntington's disease progression;
PAAD	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9810890	0.850	rs115970727	chr3:128559179	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg01815783	chr4:1047043	NA	0.4	4.31	0.33	2.93e-5	Recombination rate (males);
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25121810	chr14:103800166	EIF5	-0.63	-6.31	-0.46	2.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06850241	chr22:41845214	NA	0.56	5.1	0.38	9.91e-7	Vitiligo;
PAAD	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg01244601	chr4:120671846	NA	0.52	4.47	0.34	1.54e-5	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.47	-4.86	-0.37	2.86e-6	Breast cancer;
PAAD	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg04719120	chr6:96025338	MANEA	0.53	4.37	0.33	2.33e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.77	-0.36	4.27e-6	Personality dimensions;
PAAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.07	-8.18	-0.55	1.04e-13	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03448241	chr3:101540523	FAM55C	0.56	6.63	0.47	5.64e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13870426	chr17:30244630	NA	-0.67	-6.8	-0.48	2.27e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg26174226	chr8:58114915	NA	-0.56	-4.25	-0.33	3.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.83	-9.15	-0.6	3.54e-16	Prostate cancer;
PAAD	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg18612461	chr15:75251733	NA	-0.58	-7.2	-0.5	2.56e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs317865	1.000	rs317864	chr4:16157821	A/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	4.67	0.35	6.66e-6	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg18892244	chr7:807596	HEATR2	-0.69	-5.25	-0.39	4.95e-7	Initial pursuit acceleration;
PAAD	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg11271282	chr2:238384023	NA	0.51	4.73	0.36	5.11e-6	Prostate cancer;
PAAD	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.59	0.41	1.04e-7	Lung cancer in ever smokers;
PAAD	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-4.59	-0.35	9.13e-6	Schizophrenia;
PAAD	cis	rs12989701	0.935	rs12994284	chr2:127874020	T/C	cg08168897	chr2:127865431	BIN1	0.68	5.9	0.43	2.26e-8	Alzheimer's disease (late onset);
PAAD	cis	rs116248771	0.739	rs4679831	chr3:158320988	C/T	cg16708174	chr3:158430962	RARRES1	0.75	5.52	0.41	1.44e-7	diarrhoeal disease at age 2;
PAAD	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.3	0.39	4.02e-7	Lung cancer;
PAAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.89	-8.67	-0.58	5.95e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg01942863	chr7:99769432	GPC2	-0.47	-4.41	-0.34	1.95e-5	Coronary artery disease;
PAAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.7	6.74	0.48	3.01e-10	Parkinson's disease;
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg15691649	chr6:25882328	NA	-0.54	-5.09	-0.38	1.05e-6	Blood metabolite levels;
PAAD	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.71	6.96	0.49	9.66e-11	Lymphocyte counts;
PAAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4294134	0.608	rs11764262	chr7:135243932	T/G	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.68	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.4	-5.28	-0.39	4.32e-7	White blood cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14744537	chr18:52495740	RAB27B	0.68	6.71	0.48	3.7e-10	Obesity-related traits;
PAAD	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-4.33	-0.33	2.72e-5	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.15e-6	Lung cancer;
PAAD	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg17724175	chr1:150552817	MCL1	-0.51	-5.75	-0.42	4.65e-8	Tonsillectomy;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	1.09	16.1	0.79	1.17e-34	Menarche (age at onset);
PAAD	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.08	-0.38	1.07e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.58	-6.37	-0.46	2.09e-9	Cognitive function;
PAAD	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.9	11.41	0.68	3.53e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2221894	0.959	rs6558089	chr8:28894237	C/T	cg20212339	chr8:28908912	HMBOX1	-0.51	-5.46	-0.41	1.88e-7	Obesity-related traits;
PAAD	cis	rs71520386	0.796	rs71530697	chr7:22838753	A/G	cg04907244	chr7:22894795	SNORD93	0.51	4.47	0.34	1.49e-5	Fibrinogen levels;
PAAD	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg01528321	chr10:82214614	TSPAN14	-1.04	-8.14	-0.55	1.3e-13	Post bronchodilator FEV1;
PAAD	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	9.18e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg05577437	chr8:1586825	DLGAP2	-0.39	-4.29	-0.33	3.19e-5	Systolic blood pressure;
PAAD	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.71	-4.53	-0.34	1.21e-5	White matter integrity;
PAAD	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	1.1	9.82	0.62	6.23e-18	Orofacial clefts;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9913156	0.748	rs7215274	chr17:4561834	A/G	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs73019876	0.869	rs1988501	chr19:22175566	T/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.545	rs1832070	chr6:86483172	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	5.77	0.42	4.25e-8	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.25	0.56	6.81e-14	Prudent dietary pattern;
PAAD	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg00806126	chr19:22604979	ZNF98	-0.39	-4.79	-0.36	3.95e-6	Pain;
PAAD	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg21698718	chr17:80085957	CCDC57	-0.45	-4.94	-0.37	2.06e-6	Life satisfaction;
PAAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.56	0.61	3.02e-17	Menarche (age at onset);
PAAD	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg06569542	chr10:98946673	SLIT1	-0.54	-5.93	-0.43	1.95e-8	Monocyte count;
PAAD	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.68	-6.17	-0.45	5.8e-9	Response to antineoplastic agents;
PAAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.51	-7.54	-0.52	4.01e-12	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.57	-4.85	-0.37	2.98e-6	IgG glycosylation;
PAAD	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.26	0.39	4.82e-7	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08677398	chr8:58056175	NA	0.71	4.93	0.37	2.14e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.2	-0.45	5.02e-9	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.87e-6	Life satisfaction;
PAAD	cis	rs4713118	0.500	rs9461434	chr6:28102465	A/C	cg12963246	chr6:28129442	ZNF389	0.66	4.47	0.34	1.54e-5	Parkinson's disease;
PAAD	cis	rs1190596	0.525	rs8004474	chr14:102756498	T/C	cg23904247	chr14:102554826	HSP90AA1	0.42	4.82	0.36	3.43e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg00531865	chr16:30841666	NA	-0.53	-4.82	-0.36	3.52e-6	Dementia with Lewy bodies;
PAAD	cis	rs829661	0.947	rs829618	chr2:30748321	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs10450586	0.863	rs9299998	chr11:27338581	T/A	cg10370305	chr11:27303972	NA	0.39	4.82	0.36	3.5e-6	Total body bone mineral density;
PAAD	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.92	10.4	0.64	1.8e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.55	-5.89	-0.43	2.35e-8	Pancreatic cancer;
PAAD	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg25664220	chr3:72788482	NA	-0.69	-6.74	-0.48	3.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs752010	0.749	rs12141084	chr1:42117737	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.15	0.39	8.12e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.7	6.02	0.44	1.25e-8	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.53	-5.02	-0.38	1.42e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg15816464	chr17:2026533	SMG6	0.52	5.73	0.42	5.14e-8	Total body bone mineral density;
PAAD	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.65	6.89	0.49	1.37e-10	Coronary artery disease;
PAAD	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.62	5.44	0.4	2.07e-7	Response to diuretic therapy;
PAAD	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18849737	chr4:187475784	MTNR1A	-0.64	-6.77	-0.48	2.61e-10	Lung cancer in ever smokers;
PAAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg12315302	chr6:26189340	HIST1H4D	0.79	4.33	0.33	2.66e-5	Lung cancer in ever smokers;
PAAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.98	9.97	0.63	2.54e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg19567339	chr10:100142640	NA	0.42	4.59	0.35	9.41e-6	Metabolite levels;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.9	11.7	0.69	6.12e-23	Menarche (age at onset);
PAAD	cis	rs3736485	0.844	rs11070853	chr15:51784203	A/G	cg19558802	chr15:51695713	GLDN	-0.43	-4.36	-0.33	2.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs713587	0.520	rs493090	chr2:25303772	G/A	cg01884057	chr2:25150051	NA	-0.36	-4.41	-0.34	1.94e-5	Body mass index in non-asthmatics;
PAAD	cis	rs11807834	0.522	rs880329	chr1:230246886	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.47	-0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs17095355	1.000	rs734163	chr10:111698192	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.59	-4.31	-0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg06815965	chr1:205818668	PM20D1	0.63	7.13	0.5	3.87e-11	Menarche (age at onset);
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.92	-0.37	2.21e-6	Bipolar disorder;
PAAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg10547527	chr2:198650123	BOLL	-0.71	-4.77	-0.36	4.35e-6	Ulcerative colitis;
PAAD	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Lung cancer in ever smokers;
PAAD	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.75	-0.36	4.61e-6	Red cell distribution width;
PAAD	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	6.1	0.44	8.51e-9	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08172304	chr8:145620073	CPSF1;MIR939	0.6	6.5	0.47	1.07e-9	Smoking initiation;
PAAD	cis	rs7582720	0.945	rs72932723	chr2:203647646	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.47	0.52	5.81e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.29	0.56	5.61e-14	Menopause (age at onset);
PAAD	cis	rs1329189	1.000	rs1855649	chr10:130000031	A/G	cg17972361	chr10:130010134	NA	-0.47	-4.83	-0.37	3.24e-6	Orofacial clefts;
PAAD	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.83	0.43	3.25e-8	Coronary artery disease;
PAAD	cis	rs13248545	0.673	rs3739407	chr8:17612875	C/T	cg13252206	chr8:16970768	EFHA2	0.53	4.37	0.33	2.26e-5	Yeast infection;
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.54	-5.7	-0.42	5.96e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14169450	chr9:139327907	INPP5E	0.61	5.51	0.41	1.49e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.46	-6.34	-0.46	2.51e-9	Myeloid white cell count;
PAAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.83	8.57	0.57	1.08e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7678555	0.520	rs12506247	chr4:120844935	C/T	cg09307838	chr4:120376055	NA	0.47	4.54	0.35	1.15e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg14393609	chr7:65229607	NA	-0.43	-4.27	-0.33	3.36e-5	Aortic root size;
PAAD	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.69	5.45	0.4	2.02e-7	Neuroticism;
PAAD	cis	rs10392	0.568	rs6015979	chr20:37525463	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.63	-4.33	-0.33	2.75e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.72	-7.88	-0.54	5.69e-13	Eosinophil percentage of white cells;
PAAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	1.0	10.12	0.63	9.95e-19	Breast cancer;
PAAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs7213347	0.678	rs11658797	chr17:2088969	T/G	cg02569219	chr17:2266849	SGSM2	-0.5	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06907580	chr17:8093498	C17orf59	-0.75	-6.58	-0.47	7.35e-10	Neuroticism;
PAAD	cis	rs859767	0.501	rs1568120	chr2:135406890	A/G	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.94	0.37	2.05e-6	Blood metabolite levels;
PAAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.48	8.6	0.57	8.95e-15	Multiple system atrophy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23138817	chr14:105864896	NA	0.58	6.41	0.46	1.71e-9	Monocyte percentage of white cells;
PAAD	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.64	5.98	0.44	1.5e-8	Platelet count;
PAAD	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg12568669	chr8:11666485	FDFT1	-0.3	-5.16	-0.39	7.58e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.68	-7.01	-0.49	7.38e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs8031584	0.752	rs1852035	chr15:31184803	C/G	cg19680485	chr15:31195859	MTMR15	-0.51	-4.97	-0.37	1.75e-6	Huntington's disease progression;
PAAD	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.81	-8.78	-0.58	3.22e-15	Morning vs. evening chronotype;
PAAD	cis	rs56011263	0.532	rs17164964	chr4:745053	T/C	cg17689763	chr4:710664	PCGF3	-0.59	-5.8	-0.43	3.68e-8	White blood cell count;
PAAD	cis	rs2997447	0.802	rs61775415	chr1:26391849	A/C	cg24519413	chr1:26490540	NA	0.53	4.99	0.38	1.6e-6	QRS complex (12-leadsum);
PAAD	trans	rs901683	0.702	rs75758972	chr10:46081598	C/T	cg12869334	chr8:37699360	GPR124	1.07	7.26	0.51	1.91e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.32	-4.34	-0.33	2.56e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7631605	0.544	rs61493618	chr3:37173775	A/T	cg17445812	chr3:36986805	TRANK1	0.33	4.39	0.34	2.15e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.8	-0.43	3.67e-8	Monocyte count;
PAAD	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.52	-0.34	1.22e-5	Joint mobility (Beighton score);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11739721	chr1:65532755	NA	0.66	6.85	0.49	1.76e-10	Obesity-related traits;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.47	5.29	0.39	4.17e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	5.11e-15	Menopause (age at onset);
PAAD	cis	rs6460942	0.597	rs7808537	chr7:12520913	G/C	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.43	4.25	0.33	3.65e-5	Lung cancer;
PAAD	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.86	-7.99	-0.54	3.2e-13	Neurofibrillary tangles;
PAAD	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg21775007	chr8:11205619	TDH	-0.56	-4.86	-0.37	2.85e-6	Neuroticism;
PAAD	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.68	7.27	0.51	1.72e-11	Mean platelet volume;
PAAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.2	0.5	2.53e-11	Rheumatoid arthritis;
PAAD	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg22868518	chr11:507468	RNH1	-0.91	-4.78	-0.36	4.17e-6	Body mass index;
PAAD	cis	rs8105895	0.733	rs62111029	chr19:22276601	C/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs375066	0.901	rs1978723	chr19:44383800	C/T	cg08633290	chr19:44405433	NA	0.57	5.72	0.42	5.59e-8	Breast cancer;
PAAD	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg00898013	chr13:113819073	PROZ	-0.76	-6.03	-0.44	1.21e-8	Platelet distribution width;
PAAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg14851346	chr12:38532713	NA	-0.49	-4.69	-0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg24213567	chr19:53496664	ZNF702P	-0.48	-5.04	-0.38	1.32e-6	Psoriasis;
PAAD	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.74	6.42	0.46	1.67e-9	LDL cholesterol to HDL cholesterol ratio;
PAAD	cis	rs10950821	0.843	rs77476561	chr7:20650055	T/C	cg21202529	chr7:20656503	ABCB5	-0.46	-4.32	-0.33	2.83e-5	Response to statin therapy;
PAAD	trans	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg17031739	chr1:67600172	NA	-0.44	-4.59	-0.35	9.23e-6	Psoriasis;
PAAD	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.82	5.88	0.43	2.56e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg16584676	chr17:46985605	UBE2Z	0.58	5.73	0.42	5.2100000000000003e-08	Type 2 diabetes;
PAAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg23534315	chr17:78082725	GAA	0.49	4.67	0.35	6.6e-6	Yeast infection;
PAAD	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg15890332	chr12:107067104	RFX4	0.4	4.35	0.33	2.52e-5	Total body bone mineral density;
PAAD	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.95	9.1	0.59	4.65e-16	Psoriasis;
PAAD	cis	rs2555155	0.870	rs2555145	chr11:6534192	T/C	cg11185456	chr11:6592066	DNHD1	0.42	4.39	0.34	2.14e-5	DNA methylation (variation);
PAAD	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg03959625	chr15:84868606	LOC388152	-0.42	-4.26	-0.33	3.61e-5	P wave terminal force;
PAAD	cis	rs2320952	0.903	rs12941125	chr17:10486728	C/T	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.27e-5	Gut microbiome composition (winter);
PAAD	cis	rs9535307	0.522	rs55732704	chr13:50414205	G/A	cg03658251	chr13:50265850	EBPL	-0.76	-4.91	-0.37	2.33e-6	Obesity-related traits;
PAAD	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg21855205	chr11:67166421	PPP1CA	0.57	4.27	0.33	3.36e-5	Airway imaging phenotypes;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12127944	0.881	rs12125605	chr1:205460472	C/A	cg08473693	chr1:205342340	NA	-0.83	-4.67	-0.35	6.44e-6	IgG glycosylation;
PAAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg11143131	chr5:131608246	PDLIM4	-0.49	-4.97	-0.37	1.8e-6	Blood metabolite levels;
PAAD	cis	rs7627468	0.837	rs9850411	chr3:121937353	C/T	cg03198317	chr3:121949109	CASR	0.5	4.44	0.34	1.71e-5	Kidney stones;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07677032	chr17:61819896	STRADA	-0.49	-4.92	-0.37	2.2e-6	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.6	-6.24	-0.45	4.15e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg00717180	chr2:96193071	NA	-0.58	-6.41	-0.46	1.7e-9	HDL cholesterol;
PAAD	cis	rs7584330	0.518	rs74970394	chr2:238443483	C/T	cg14458575	chr2:238380390	NA	0.99	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13099106	chr12:120525172	CCDC64	0.67	7.43	0.52	7.4e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.73	7.78	0.53	1.03e-12	Schizophrenia;
PAAD	cis	rs758324	0.812	rs667419	chr5:131282064	A/G	cg06307176	chr5:131281290	NA	0.55	4.78	0.36	4.04e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg00255919	chr5:131827918	IRF1	0.6	8.44	0.57	2.27e-14	Asthma (sex interaction);
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg00049323	chr5:472564	LOC25845	-0.46	-4.78	-0.36	4.04e-6	Cystic fibrosis severity;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs319204	0.659	rs1380013	chr5:146235763	G/A	cg13983063	chr5:146258615	PPP2R2B	0.45	4.37	0.33	2.3e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06349179	chr1:205744577	RAB7L1	0.67	8.0	0.54	2.94e-13	Monocyte percentage of white cells;
PAAD	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.22	0.39	5.82e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg02631450	chr22:32366979	NA	1.07	5.75	0.42	4.85e-8	Childhood ear infection;
PAAD	trans	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg26939375	chr7:64535504	NA	0.72	8.42	0.56	2.57e-14	Aortic root size;
PAAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.34	0.33	2.56e-5	Total body bone mineral density;
PAAD	cis	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg13547474	chr4:80247281	NAA11	0.43	4.45	0.34	1.64e-5	Hair shape;Hair morphology;
PAAD	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.84	9.94	0.63	3e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg16898833	chr6:26189333	HIST1H4D	0.73	4.33	0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs412050	0.547	rs5999842	chr22:22214889	G/A	cg17089214	chr22:22089827	YPEL1	0.71	4.3	0.33	3.02e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.2	0.39	6.47e-7	Mean platelet volume;
PAAD	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-5.71	-0.42	5.87e-8	Mean corpuscular volume;
PAAD	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.48	-0.34	1.45e-5	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.63	4.31	0.33	2.88e-5	Skin colour saturation;
PAAD	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.64	-5.73	-0.42	5.33e-8	Personality dimensions;
PAAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7714584	1.000	rs10051924	chr5:150226639	T/C	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.09	16.35	0.8	2.6e-35	Body mass index (adult);
PAAD	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.75	-0.42	4.68e-8	YKL-40 levels;
PAAD	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.32	-0.6	1.29e-16	Mortality in heart failure;
PAAD	cis	rs6494488	0.500	rs56093925	chr15:64789799	C/T	cg16425858	chr15:64791681	ZNF609	0.86	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23281280	chr6:28129359	ZNF389	0.69	5.28	0.39	4.32e-7	Depression;
PAAD	cis	rs11892454	0.544	rs13382805	chr2:25997569	G/A	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.74	8.28	0.56	5.9e-14	Multiple sclerosis or amyotrophic lateral sclerosis;
PAAD	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.52	5.01	0.38	1.5e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg23221052	chr5:179740743	GFPT2	0.49	4.28	0.33	3.27e-5	TRAIL levels;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-5.62	-0.41	8.83e-8	Electroencephalogram traits;
PAAD	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg00738919	chr7:1100172	C7orf50	0.69	4.96	0.37	1.85e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs357618	1.000	rs357629	chr5:150850946	C/T	cg03212797	chr5:150827313	SLC36A1	0.52	4.53	0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.71	7.56	0.52	3.48e-12	Triglyceride levels;
PAAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.96	12.78	0.72	7.37e-26	Menarche (age at onset);
PAAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.01	-0.7	8.6e-24	Obesity-related traits;
PAAD	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs6594713	1.000	rs6594713	chr5:112715374	A/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.41	-0.34	1.94e-5	Glomerular filtration rate;
PAAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg05697835	chr1:2722811	NA	-0.42	-4.75	-0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs4662592	0.590	rs28372711	chr2:128848652	C/G	cg17144508	chr2:128283727	IWS1	-0.53	-4.3	-0.33	3.01e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg12215294	chr3:40350768	EIF1B	-0.46	-4.26	-0.33	3.56e-5	Renal cell carcinoma;
PAAD	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.74	6.9	0.49	1.28e-10	Psoriasis;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.83	0.54	7.84e-13	HIV-1 control;
PAAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg23283495	chr1:209979779	IRF6	0.6	5.3	0.4	3.97e-7	Coronary artery disease;
PAAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.92	13.25	0.73	3.92e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.63	-7.2	-0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg09179987	chr1:167433047	CD247	-0.49	-5.82	-0.43	3.32e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs10991814	1.000	rs76260934	chr9:93969276	G/C	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.55	5.99	0.44	1.49e-8	Bladder cancer;
PAAD	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs73416724	1.000	rs79329802	chr6:43387332	G/A	cg26312998	chr6:43337775	ZNF318	0.69	5.76	0.42	4.59e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-5.62	-0.41	9.01e-8	Alzheimer's disease (late onset);
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg04844267	chr4:1394941	NA	0.44	4.98	0.37	1.7e-6	Obesity-related traits;
PAAD	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Educational attainment;
PAAD	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.35	-0.33	2.5e-5	Life satisfaction;
PAAD	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	12.7	0.72	1.23e-25	Colorectal cancer;
PAAD	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg16926213	chr1:1841314	NA	0.39	4.64	0.35	7.6e-6	Body mass index;
PAAD	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg24330906	chr2:85765176	MAT2A	0.41	4.27	0.33	3.39e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg03676636	chr4:99064102	C4orf37	0.3	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg16434002	chr17:42200994	HDAC5	-0.43	-4.31	-0.33	2.94e-5	Total body bone mineral density;
PAAD	cis	rs4780401	0.632	rs8059262	chr16:11784129	G/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-5.02	-0.38	1.45e-6	Rheumatoid arthritis;
PAAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg13870426	chr17:30244630	NA	-0.74	-6.69	-0.48	4.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-1.01	-11.18	-0.67	1.49e-21	Gut microbiota (bacterial taxa);
PAAD	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.42	4.52	0.34	1.26e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.66	6.61	0.47	6.17e-10	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.71	-0.36	5.59e-6	Blood pressure;
PAAD	cis	rs2968864	1.000	rs2968854	chr7:150637834	C/T	cg06221570	chr7:150558377	ABP1	0.46	5.42	0.4	2.27e-7	QT interval;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26284300	chr6:90025968	GABRR2	-0.64	-6.78	-0.48	2.48e-10	Obesity-related traits;
PAAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.75	-7.35	-0.51	1.17e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs9810890	0.850	rs73196955	chr3:128430599	C/A	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.98	0.49	8.49e-11	Obesity-related traits;
PAAD	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.18	0.39	7.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs375066	0.967	rs8104290	chr19:44367338	A/G	cg11993925	chr19:44307056	LYPD5	0.52	6.68	0.48	4.13e-10	Breast cancer;
PAAD	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.53	5.56	0.41	1.19e-7	Male-pattern baldness;
PAAD	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs4343996	0.869	rs10232431	chr7:3511115	G/A	cg21248987	chr7:3385318	SDK1	0.49	5.35	0.4	3.24e-7	Motion sickness;
PAAD	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.49	6.13	0.45	7.07e-9	Crohn's disease;
PAAD	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg14515779	chr1:101123966	NA	-0.45	-4.8	-0.36	3.69e-6	Breast cancer;
PAAD	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.58	-5.7	-0.42	5.95e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs300774	0.925	rs300720	chr2:134472	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg08219700	chr8:58056026	NA	0.66	5.11	0.38	9.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.84e-9	Blood metabolite levels;
PAAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.98	10.42	0.65	1.63e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg23033748	chr14:75592666	NEK9	-0.43	-5.26	-0.39	4.76e-7	Height;
PAAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.81	-7.07	-0.5	5.29e-11	IgG glycosylation;
PAAD	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg23331303	chr5:5135948	NA	0.47	6.77	0.48	2.64e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.3	0.6	1.4e-16	Rheumatoid arthritis;
PAAD	cis	rs12986413	0.624	rs2238601	chr19:2140374	G/T	cg09261902	chr19:2140048	AP3D1	0.6	5.97	0.44	1.62e-8	Height;
PAAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg06740227	chr12:86229804	RASSF9	0.58	5.27	0.39	4.52e-7	Major depressive disorder;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	cis	rs6585424	1.000	rs11201966	chr10:81931780	T/C	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-4.62	-0.35	8.18e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.89	9.89	0.63	4.02e-18	Blood metabolite levels;
PAAD	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.67	-6.43	-0.46	1.58e-9	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg12491688	chr15:44580831	CASC4	0.62	6.45	0.46	1.44e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.59	-4.57	-0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02543470	chr2:105862877	NA	0.52	5.09	0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.5	-0.52	4.97e-12	Colorectal cancer;
PAAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.74	-8.14	-0.55	1.32e-13	Rheumatoid arthritis;
PAAD	cis	rs6976053	0.781	rs4729617	chr7:100473729	C/T	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	1.01	6.33	0.46	2.6e-9	Skin colour saturation;
PAAD	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg08219700	chr8:58056026	NA	0.7	5.58	0.41	1.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.81	8.03	0.55	2.53e-13	Corneal astigmatism;
PAAD	cis	rs77880822	0.562	rs117258308	chr20:1252017	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg16341495	chr8:142228727	SLC45A4	0.52	4.74	0.36	4.82e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg08807101	chr21:30365312	RNF160	-0.65	-5.33	-0.4	3.56e-7	Cognitive test performance;
PAAD	cis	rs7119038	0.865	rs4936443	chr11:118740864	C/T	cg04176122	chr11:118779835	BCL9L	-0.45	-4.55	-0.35	1.07e-5	Sjögren's syndrome;
PAAD	cis	rs35740288	0.929	rs11635081	chr15:86304260	G/A	cg07943548	chr15:86304357	KLHL25	-0.58	-4.96	-0.37	1.89e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg02287630	chr1:101361426	SLC30A7;EXTL2	0.52	4.43	0.34	1.82e-5	Breast cancer;
PAAD	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7084921	0.608	rs11597390	chr10:101861435	A/G	cg11251234	chr10:101825055	CPN1	0.29	4.38	0.33	2.21e-5	Bone mineral density;
PAAD	cis	rs3112530	0.901	rs149095	chr5:152727445	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.71	7.02	0.49	7.04e-11	Age-related hearing impairment;
PAAD	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.57	5.08	0.38	1.09e-6	Schizophrenia;
PAAD	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs10850408	0.882	rs10744835	chr12:115353849	C/T	cg05726002	chr12:115341178	NA	-0.39	-4.66	-0.35	6.98e-6	Alzheimer's disease;
PAAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg25309567	chr17:79516362	C17orf70	-0.42	-4.25	-0.33	3.67e-5	Eye color traits;
PAAD	cis	rs3812111	0.609	rs549332	chr6:116454588	C/T	cg05304507	chr6:116381966	FRK	0.25	4.25	0.33	3.66e-5	Age-related macular degeneration;
PAAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg17987982	chr7:158820591	NA	-0.41	-4.76	-0.36	4.5e-6	Facial morphology (factor 20);
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg24330906	chr2:85765176	MAT2A	0.44	4.44	0.34	1.71e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.38	4.46	0.34	1.58e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs76793172	0.660	rs4803852	chr19:46238926	G/T	cg13320842	chr19:46175254	GIPR	-0.56	-4.92	-0.37	2.24e-6	Eosinophil counts;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.53	-6.07	-0.44	9.98e-9	Cardiovascular disease risk factors;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-5.89	-0.43	2.34e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.55	-0.35	1.1e-5	LDL cholesterol levels;
PAAD	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	8.04e-8	Life satisfaction;
PAAD	cis	rs6681460	1.000	rs7524818	chr1:67072031	C/T	cg02459107	chr1:67143332	SGIP1	0.77	7.89	0.54	5.58e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.63	7.49	0.52	5.17e-12	Schizophrenia;
PAAD	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.44	0.4	2.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2320952	0.874	rs11657632	chr17:10488899	G/C	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg24112000	chr20:60950667	NA	-0.64	-7.18	-0.5	2.93e-11	Colorectal cancer;
PAAD	cis	rs117623576	0.941	rs17488859	chr10:32386072	A/G	cg03047570	chr10:32398778	NA	0.72	4.6	0.35	8.87e-6	Anti-saccade response;
PAAD	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.75	8.34	0.56	4.17e-14	Body mass index;
PAAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.21	-0.55	8.67e-14	Height;
PAAD	cis	rs9933309	0.916	rs57953994	chr16:88846803	G/A	cg04602696	chr16:88846723	FAM38A	0.52	4.53	0.34	1.19e-5	Glycated hemoglobin levels;
PAAD	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg24747557	chr10:131355152	MGMT	-0.44	-4.75	-0.36	4.73e-6	Response to temozolomide;
PAAD	cis	rs7255045	0.742	rs10420014	chr19:12960947	G/T	cg09980403	chr19:12975529	MAST1	0.29	4.25	0.33	3.76e-5	Mean corpuscular volume;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.64	-6.08	-0.44	9.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.87	10.33	0.64	2.71e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg11057378	chr10:81107060	PPIF	0.46	5.47	0.41	1.83e-7	Height;
PAAD	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.29e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg02811702	chr13:24901961	NA	0.51	5.51	0.41	1.48e-7	Obesity-related traits;
PAAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.69e-6	Height;
PAAD	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.63	5.06	0.38	1.21e-6	Putamen volume;
PAAD	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-8.93	-0.59	1.33e-15	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10681804	chr20:33433114	GGT7	-0.69	-7.25	-0.51	2e-11	Obesity-related traits;
PAAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.9	-9.66	-0.62	1.68e-17	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.63	8.48	0.57	1.89e-14	Renal cell carcinoma;
PAAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6942407	0.592	rs1981536	chr7:86747889	C/T	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.31	5.96	0.44	1.66e-8	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.697	rs12670771	chr7:27656590	T/C	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-4.82	-0.36	3.5e-6	Psoriasis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01059669	chr6:134496004	SGK1	0.63	7.12	0.5	4.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.88	13.56	0.74	5.76e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	trans	rs6453429	0.581	rs653275	chr5:78308731	C/T	cg25649038	chr6:6546777	LOC285780	-0.65	-6.52	-0.47	9.66e-10	Urinary metabolites;
PAAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.13	-0.6	3.9e-16	Type 2 diabetes;
PAAD	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg15208524	chr1:10270712	KIF1B	0.48	4.41	0.34	1.94e-5	Hepatocellular carcinoma;
PAAD	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.42	5.13	0.38	8.82e-7	Pulmonary function;
PAAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1329189	0.798	rs7074660	chr10:130003858	T/A	cg17972361	chr10:130010134	NA	-0.49	-5.0	-0.38	1.58e-6	Orofacial clefts;
PAAD	cis	rs2133450	0.712	rs9990258	chr3:7366452	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg09127314	chr1:152161683	NA	0.69	4.85	0.37	3.05e-6	Atopic dermatitis;
PAAD	cis	rs2131877	0.913	rs950256	chr3:194847752	C/T	cg16306870	chr3:194868790	C3orf21	0.42	4.35	0.33	2.46e-5	Non-small cell lung cancer;
PAAD	cis	rs11828289	0.607	rs78341320	chr11:23188865	C/T	cg20040320	chr11:23191996	NA	-0.78	-5.55	-0.41	1.27e-7	Cancer;
PAAD	cis	rs761746	0.739	rs5994420	chr22:32070751	A/G	cg01338084	chr22:32026380	PISD	0.64	5.31	0.4	3.9e-7	Intelligence;
PAAD	cis	rs457162	0.643	rs169465	chr6:118576987	T/G	cg21191810	chr6:118973309	C6orf204	0.7	4.46	0.34	1.56e-5	QT interval;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02071572	chr4:1403502	NA	0.51	6.54	0.47	8.65e-10	Longevity;
PAAD	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.5	-4.7	-0.36	5.71e-6	Hypospadias;
PAAD	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	1.26	15.59	0.78	2.46e-33	Ewing sarcoma;
PAAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.47	4.82	0.36	3.4e-6	Major depressive disorder;
PAAD	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.65	6.56	0.47	8.15e-10	Blood protein levels;
PAAD	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.84	-9.46	-0.61	5.44e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg18131467	chr2:239335373	ASB1	0.65	4.68	0.35	6.31e-6	Chronotype;
PAAD	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.34	0.33	2.59e-5	Blood protein levels;
PAAD	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.47	6.76	0.48	2.76e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.34	0.33	2.61e-5	Trans fatty acid levels;
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.81	-10.2	-0.64	6.05e-19	Vitiligo;
PAAD	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.76	7.9	0.54	5.29e-13	Schizophrenia;
PAAD	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.58	6.83	0.48	1.89e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	8.04	0.55	2.31e-13	Menopause (age at onset);
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.53	6.77	0.48	2.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5417	0.636	rs2074217	chr17:7150552	A/G	cg25256661	chr17:7137939	DVL2	-0.91	-9.58	-0.61	2.66e-17	Diastolic blood pressure;
PAAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.6	-6.71	-0.48	3.7e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18944135	chr10:131034897	NA	0.54	6.36	0.46	2.27e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg27234864	chr13:21295941	IL17D	-0.54	-4.68	-0.35	6.42e-6	Dental caries;
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.93	11.12	0.67	2.21e-21	Longevity;
PAAD	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg12935359	chr14:103987150	CKB	-0.53	-5.57	-0.41	1.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.87	-7.23	-0.51	2.2e-11	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.66	-5.26	-0.39	4.85e-7	Smoking behavior;
PAAD	cis	rs4704187	0.687	rs2059159	chr5:74451178	G/C	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15840638	chr15:79298691	RASGRF1	-0.66	-6.87	-0.49	1.53e-10	Obesity-related traits;
PAAD	cis	rs375066	0.762	rs12610287	chr19:44400663	T/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.28	-0.45	3.33e-9	Breast cancer;
PAAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg20356878	chr3:121714668	ILDR1	0.4	4.28	0.33	3.31e-5	Cognitive performance;
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg18281939	chr5:77783895	LHFPL2	0.51	6.51	0.47	1.03e-9	Triglycerides;
PAAD	cis	rs73568641	0.583	rs73570627	chr6:154064350	T/A	cg15658985	chr6:154448740	OPRM1	0.56	4.72	0.36	5.33e-6	Methadone dose in opioid dependence;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2864527	0.522	rs5011606	chr18:9260853	T/G	cg07372824	chr18:9017748	NA	-0.56	-4.53	-0.34	1.21e-5	Dental caries;
PAAD	cis	rs3796727	0.633	rs34978619	chr4:8613908	G/A	cg05284713	chr4:8621361	CPZ	-0.44	-4.36	-0.33	2.42e-5	Sporadic neuroblastoma;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.73	-0.36	5.11e-6	Mood instability;
PAAD	cis	rs7550636	0.760	rs1890974	chr1:192860144	G/A	cg05576974	chr1:193028138	TROVE2;UCHL5	0.45	4.33	0.33	2.65e-5	Coronary artery calcification;
PAAD	cis	rs7705042	0.828	rs6580224	chr5:141489306	A/G	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.25	-0.39	5.02e-7	Asthma;
PAAD	cis	rs496547	0.686	rs540180	chr11:118653629	T/G	cg19308663	chr11:118741387	NA	-0.46	-4.33	-0.33	2.71e-5	Hip minimal joint space width;
PAAD	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.96	9.89	0.63	4.03e-18	Homoarginine levels;
PAAD	cis	rs12304921	0.935	rs11169627	chr12:51348450	G/A	cg18059802	chr12:51347058	HIGD1C	-0.73	-5.99	-0.44	1.46e-8	Type 2 diabetes;
PAAD	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16417436	chr16:28758564	NA	0.48	4.39	0.34	2.08e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg27411982	chr8:10470053	RP1L1	-0.47	-5.13	-0.38	8.69e-7	Retinal vascular caliber;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19081571	chr1:1190137	UBE2J2	0.52	6.47	0.46	1.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	10.14	0.64	9.03e-19	Platelet count;
PAAD	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.86	5.53	0.41	1.39e-7	Systolic blood pressure;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.91	-11.66	-0.69	7.6e-23	Monocyte percentage of white cells;
PAAD	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.06	12.91	0.72	3.3e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.8	-9.94	-0.63	3.07e-18	Hemoglobin concentration;
PAAD	cis	rs727479	0.962	rs7175531	chr15:51534055	T/C	cg21478137	chr15:51532386	CYP19A1	0.61	6.9	0.49	1.3100000000000001e-10	Estradiol levels;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-0.93	-10.92	-0.66	7.28e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg12395012	chr8:11607386	GATA4	-0.4	-4.47	-0.34	1.53e-5	Neuroticism;
PAAD	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg09324608	chr17:30823087	MYO1D	0.55	5.66	0.42	7.21e-8	Schizophrenia;
PAAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.52	6.77	0.48	2.58e-10	Body mass index;
PAAD	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg06096015	chr1:231504339	EGLN1	-0.59	-6.46	-0.46	1.34e-9	Red blood cell count;
PAAD	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.46	0.57	2.09e-14	Alzheimer's disease;
PAAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	1.06	11.19	0.67	1.39e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg03805757	chr16:71968109	PKD1L3	-0.52	-4.68	-0.36	6.17e-6	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7539624	0.577	rs17739	chr1:223967953	C/T	cg11145399	chr1:224034478	TP53BP2	-0.42	-4.26	-0.33	3.52e-5	Schizophrenia;
PAAD	cis	rs6735179	0.648	rs6706107	chr2:1761661	C/A	cg06599209	chr2:1746509	PXDN	0.27	4.44	0.34	1.72e-5	Response to antipsychotic treatment;
PAAD	cis	rs2190422	0.505	rs2528859	chr7:103151772	A/G	cg04218035	chr7:103086829	SLC26A5	0.37	5.16	0.39	7.64e-7	Morning vs. evening chronotype;
PAAD	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.51	4.69	0.36	6.16e-6	Educational attainment;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg06375148	chr1:209958343	C1orf74	-0.65	-5.42	-0.4	2.28e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.59	6.29	0.45	3.22e-9	Lung cancer;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.81	9.06	0.59	6.11e-16	Lung cancer;
PAAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.87	8.19	0.55	1e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.59	7.21	0.5	2.52e-11	Monobrow;
PAAD	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.84	8.51	0.57	1.51e-14	Corneal astigmatism;
PAAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.43	0.34	1.76e-5	Blood metabolite levels;
PAAD	cis	rs7624766	0.585	rs9810290	chr3:160573380	T/C	cg22637730	chr3:160473554	PPM1L	0.51	4.81	0.36	3.6e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.98	13.58	0.74	5.08e-28	Eosinophil percentage of white cells;
PAAD	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.63	-0.42	8.31e-8	Menarche (age at onset);
PAAD	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.83e-13	Motion sickness;
PAAD	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.69	6.91	0.49	1.24e-10	Callous-unemotional behaviour;
PAAD	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.96	-0.37	1.87e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg18135206	chr14:102964638	TECPR2	-0.56	-4.35	-0.33	2.48e-5	Blood protein levels;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02071572	chr4:1403502	NA	0.44	5.68	0.42	6.68e-8	Obesity-related traits;
PAAD	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.24	21.01	0.86	8.44e-47	Testicular germ cell tumor;
PAAD	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.33	-0.4	3.5e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.89	-0.49	1.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs367943	0.608	rs7705084	chr5:112990748	G/A	cg12552261	chr5:112820674	MCC	0.58	6.15	0.45	6.61e-9	Type 2 diabetes;
PAAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg22143856	chr6:28129313	ZNF389	0.6	4.66	0.35	6.96e-6	Parkinson's disease;
PAAD	cis	rs59918340	0.738	rs7017848	chr8:142222374	A/G	cg16494567	chr8:142200140	DENND3	0.44	4.56	0.35	1.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.9	10.77	0.66	1.9e-20	Tonsillectomy;
PAAD	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.58	4.96	0.37	1.87e-6	Lymphocyte counts;
PAAD	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	4.7	0.36	5.79e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs10515808	0.558	rs76337519	chr5:159814239	C/T	cg04842426	chr7:136555777	CHRM2	-0.54	-6.34	-0.46	2.47e-9	Weight loss (gastric bypass surgery);
PAAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14606680	chr17:6347533	FAM64A	-0.64	-7.43	-0.52	7.3e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg19337854	chr7:99768885	GPC2	0.53	4.98	0.37	1.71e-6	Platelet count;
PAAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Menopause (age at onset);
PAAD	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.62	6.51	0.47	1.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg24449302	chr15:66679100	MAP2K1	-0.55	-6.39	-0.46	1.91e-9	Body fat percentage;
PAAD	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.44	-4.25	-0.33	3.67e-5	Crohn's disease;
PAAD	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg08853572	chr16:1843915	IGFALS	-0.25	-4.28	-0.33	3.26e-5	Blood metabolite levels;
PAAD	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.11	14.38	0.76	3.9e-30	Primary sclerosing cholangitis;
PAAD	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs911555	0.603	rs8016326	chr14:103846716	G/A	cg12935359	chr14:103987150	CKB	-0.62	-5.86	-0.43	2.8e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg26685658	chr5:74633012	HMGCR	-0.51	-4.3	-0.33	3.03e-5	Age-related disease endophenotypes;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg01763666	chr17:80159506	CCDC57	0.41	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.67	-0.35	6.56e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.46	5.85	0.43	2.94e-8	Renal cell carcinoma;
PAAD	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg10820045	chr2:198174542	NA	0.51	5.11	0.38	9.36e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs7202877	0.610	rs4888381	chr16:75356847	C/A	cg03315344	chr16:75512273	CHST6	0.61	5.03	0.38	1.35e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.62	-6.21	-0.45	4.75e-9	Facial morphology (factor 20);
PAAD	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg06970076	chr16:1560791	IFT140	0.56	4.91	0.37	2.28e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	16.23	0.8	5.23e-35	Prudent dietary pattern;
PAAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg20744362	chr22:50050164	C22orf34	0.65	7.82	0.54	8.14e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg15117754	chr3:10150083	C3orf24	0.66	5.46	0.41	1.87e-7	Alzheimer's disease;
PAAD	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg04545296	chr12:48745243	ZNF641	0.34	4.33	0.33	2.74e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.97	-10.79	-0.66	1.68e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs704	0.628	rs241775	chr17:26644668	C/T	cg10342447	chr17:26645325	TMEM97	0.49	5.97	0.44	1.59e-8	Osteoprotegerin levels;
PAAD	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	7.98	0.54	3.21e-13	Hemoglobin concentration;
PAAD	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.56	-4.65	-0.35	7.03e-6	Pursuit maintenance gain;
PAAD	cis	rs28489187	0.617	rs233118	chr1:85787967	C/T	cg16011679	chr1:85725395	C1orf52	-0.51	-4.76	-0.36	4.48e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.53	-5.71	-0.42	5.66e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.71	-7.04	-0.5	6.18e-11	Neurofibrillary tangles;
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.46e-6	Asthma;
PAAD	cis	rs12714314	0.957	rs2060195	chr2:1955801	A/G	cg22350835	chr2:1868857	MYT1L	0.48	4.76	0.36	4.47e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs8099014	0.911	rs4245269	chr18:56110730	G/A	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	cis	rs12753920	0.857	rs67605215	chr1:92672091	T/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.45	-4.3	-0.33	3.03e-5	Systemic lupus erythematosus;
PAAD	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg27478167	chr7:817139	HEATR2	0.71	5.46	0.41	1.86e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg02743256	chr7:2109353	MAD1L1	-0.62	-4.73	-0.36	5.01e-6	Bipolar disorder;
PAAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	4.85	0.37	3.08e-6	Prion diseases;
PAAD	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.92	12.0	0.7	9.29e-24	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.56	-5.01	-0.38	1.5e-6	Lymphocyte counts;
PAAD	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.57	5.08	0.38	1.09e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.09	0.38	1.04e-6	Bone mineral density;
PAAD	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.72	8.87	0.58	1.82e-15	Obesity (extreme);
PAAD	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-5.67	-0.42	7.12e-8	Menopause (age at onset);
PAAD	cis	rs9900972	0.918	rs6501258	chr17:76877824	T/A	cg00961940	chr17:76876995	TIMP2	0.57	5.31	0.4	3.84e-7	Obesity-related traits;
PAAD	cis	rs1539053	0.932	rs7544337	chr1:58108645	T/C	cg20292791	chr1:58089357	DAB1	-0.54	-5.24	-0.39	5.19e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg22338127	chr1:209979572	IRF6	-0.53	-4.3	-0.33	3.1e-5	Coronary artery disease;
PAAD	cis	rs6681460	0.932	rs659291	chr1:67180746	A/C	cg02459107	chr1:67143332	SGIP1	0.71	6.68	0.48	4.17e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	4.84	0.37	3.18e-6	Iron status biomarkers;
PAAD	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.96	14.25	0.76	8.56e-30	Dental caries;
PAAD	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9876781	1.000	rs6810060	chr3:48434748	T/C	cg24898236	chr3:49228699	LOC646498	0.39	4.37	0.33	2.34e-5	Longevity;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.39	0.46	1.92e-9	Alzheimer's disease;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.41	5.0	0.38	1.58e-6	Iron status biomarkers;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.73	7.29	0.51	1.56e-11	HIV-1 control;
PAAD	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.81	9.43	0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.96	9.07	0.59	5.8e-16	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg08888203	chr3:10149979	C3orf24	0.66	5.95	0.43	1.8e-8	Alzheimer's disease;
PAAD	cis	rs863345	0.604	rs6699473	chr1:158495209	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.7	6.78	0.48	2.49e-10	Recombination rate (males);
PAAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.76	-6.97	-0.49	8.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.74	9.23	0.6	2.14e-16	Coronary artery disease;
PAAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.5	0.34	1.35e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg15105011	chr4:940614	TMEM175	0.67	7.6	0.52	2.79e-12	Sjögren's syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21649919	chr6:792512	NA	-0.6	-6.42	-0.46	1.62e-9	Obesity-related traits;
PAAD	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg09760422	chr2:128146352	NA	-0.37	-6.57	-0.47	7.47e-10	Protein C levels;
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.74	7.55	0.52	3.77e-12	Height;
PAAD	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-1.12	-10.23	-0.64	5.25e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.43	-0.34	1.8e-5	Aortic root size;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg20909686	chr11:65554042	OVOL1	0.54	6.77	0.48	2.66e-10	Immature fraction of reticulocytes;
PAAD	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs797680	0.856	rs4847410	chr1:93802781	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.46	0.34	1.56e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg08601574	chr20:25228251	PYGB	-0.66	-7.2	-0.5	2.62e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.83	-8.37	-0.56	3.53e-14	Response to hepatitis C treatment;
PAAD	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.0	-0.44	1.41e-8	Crohn's disease;
PAAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22755785	chr19:44716462	ZNF227	0.56	6.56	0.47	7.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.72	7.69	0.53	1.67e-12	Colorectal cancer;
PAAD	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	4.26	0.33	3.52e-5	Platelet count;
PAAD	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-5.93	-0.43	1.96e-8	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg04257695	chr17:30186438	C17orf79	0.62	5.03	0.38	1.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg09839279	chr12:125627357	AACS	-0.51	-5.07	-0.38	1.17e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg18833306	chr6:118973337	C6orf204	0.46	4.93	0.37	2.17e-6	Electrocardiographic conduction measures;
PAAD	cis	rs11892454	0.515	rs10208202	chr2:26053576	T/C	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.82	4.85	0.37	3.03e-6	Schizophrenia;
PAAD	cis	rs35000415	0.938	rs13227075	chr7:128643297	T/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.6	0.35	8.71e-6	Educational attainment (years of education);
PAAD	cis	rs877529	1.000	rs139404	chr22:39547201	C/T	cg13455509	chr22:39551605	NA	-0.49	-4.81	-0.36	3.55e-6	Multiple myeloma;
PAAD	cis	rs12431939	1.000	rs11850391	chr14:51639759	A/G	cg23942311	chr14:51606299	NA	-0.71	-5.63	-0.42	8.34e-8	Cancer;
PAAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.15	-0.45	6.55e-9	Bipolar disorder;
PAAD	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.66	6.44	0.46	1.49e-9	Schizophrenia;
PAAD	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg08975724	chr8:8085496	FLJ10661	0.74	7.1	0.5	4.44e-11	Mood instability;
PAAD	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9659323	0.632	rs10923744	chr1:119613941	G/A	cg17326555	chr1:119535693	NA	-0.38	-5.38	-0.4	2.76e-7	Body mass index;
PAAD	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.56	6.3	0.45	3.07e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7567389	0.677	rs72848616	chr2:128135097	T/C	cg11380483	chr2:127933992	NA	0.45	4.45	0.34	1.63e-5	Self-rated health;
PAAD	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.54	-6.85	-0.49	1.75e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.95	0.66	6.14e-21	Smoking behavior;
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18357526	chr6:26021779	HIST1H4A	0.62	6.33	0.46	2.59e-9	Blood metabolite levels;
PAAD	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.14e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.85	9.1	0.59	4.79e-16	Body mass index;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01955286	chr3:125475060	NA	0.59	6.96	0.49	9.64e-11	Immature fraction of reticulocytes;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.78	-7.91	-0.54	4.9e-13	Menopause (age at onset);
PAAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.47e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.87	-6.89	-0.49	1.37e-10	Schizophrenia;
PAAD	cis	rs2131877	0.913	rs12634646	chr3:194842911	A/G	cg16306870	chr3:194868790	C3orf21	0.41	4.44	0.34	1.7e-5	Non-small cell lung cancer;
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg03909863	chr11:638404	DRD4	-0.57	-5.25	-0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg08886695	chr4:3369023	RGS12	-0.49	-4.67	-0.35	6.49e-6	Serum sulfate level;
PAAD	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	5.02	0.38	1.4e-6	Ovarian reserve;
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.55	-6.71	-0.48	3.63e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.64	8.48	0.57	1.84e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs10838687	0.673	rs11039035	chr11:46967415	G/T	cg19486271	chr11:47235900	DDB2	-0.57	-4.39	-0.34	2.15e-5	Proinsulin levels;
PAAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.48	-5.17	-0.39	7.32e-7	Life satisfaction;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg22189786	chr22:42395067	WBP2NL	0.51	5.67	0.42	6.97e-8	Intelligence;
PAAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.58	-4.97	-0.37	1.82e-6	Fibrinogen levels;
PAAD	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.75	8.34	0.56	4.17e-14	N-glycan levels;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg08698997	chr16:88989212	CBFA2T3	0.4	4.73	0.36	5.16e-6	Social autistic-like traits;
PAAD	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9372498	0.536	rs12333080	chr6:118845410	A/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg00106254	chr7:1943704	MAD1L1	-0.53	-4.63	-0.35	7.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg13374026	chr7:158955107	NA	0.45	4.25	0.33	3.75e-5	Facial morphology (factor 20);
PAAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg03676636	chr4:99064102	C4orf37	-0.25	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs728616	0.614	rs61859210	chr10:82131468	G/C	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg01631408	chr1:248437212	OR2T33	-0.6	-5.51	-0.41	1.53e-7	Common traits (Other);
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.86	7.17	0.5	3.03e-11	Alzheimer's disease;
PAAD	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.46	5.28	0.39	4.38e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.41	-0.4	2.45e-7	Personality dimensions;
PAAD	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.42	-6.57	-0.47	7.53e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs1997066	0.831	rs1349623	chr10:106825759	C/T	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs4908768	0.539	rs1381928	chr1:8690933	G/A	cg20416874	chr1:8611966	RERE	-0.43	-4.26	-0.33	3.55e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.55	5.63	0.42	8.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2421770	0.532	rs7115450	chr11:35344345	A/G	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	4.82	0.36	3.45e-6	Total body bone mineral density;
PAAD	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Bone mineral density;
PAAD	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.58	-5.47	-0.41	1.81e-7	Strep throat;
PAAD	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg22764639	chr12:106532701	NUAK1	0.42	4.26	0.33	3.51e-5	Total body bone mineral density;
PAAD	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.52	6.88	0.49	1.5e-10	Renal cell carcinoma;
PAAD	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.56	4.45	0.34	1.64e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg16501237	chr10:99081016	FRAT1	0.35	4.29	0.33	3.21e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.82	8.33	0.56	4.3e-14	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.82	-0.36	3.5e-6	Bipolar disorder;
PAAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs939584	0.735	rs62105303	chr2:632922	G/A	cg14515364	chr2:636606	NA	0.49	4.51	0.34	1.31e-5	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10668512	chr15:42565522	GANC;TMEM87A	0.57	6.38	0.46	2.03e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1941184	0.759	rs12185412	chr18:29024352	T/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs13418717	0.793	rs4663054	chr2:127639995	C/T	cg16909742	chr2:127635678	NA	-0.82	-4.6	-0.35	8.77e-6	Heart failure;
PAAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08228715	chr17:79895357	PYCR1	0.66	8.04	0.55	2.35e-13	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23733608	chr21:35261572	ITSN1	-0.66	-6.9	-0.49	1.32e-10	Obesity-related traits;
PAAD	cis	rs7651511	0.962	rs9822575	chr3:141314819	A/G	cg25967872	chr3:141205623	RASA2	0.53	4.8	0.36	3.82e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11051970	0.879	rs10844201	chr12:32575029	A/G	cg24626660	chr12:32551988	NA	0.4	4.56	0.35	1.04e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg20090143	chr19:45452003	APOC2	-0.4	-4.92	-0.37	2.22e-6	Blood protein levels;
PAAD	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.66	6.49	0.47	1.12e-9	Schizophrenia;
PAAD	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	1.03	7.06	0.5	5.61e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.27	-4.57	-0.35	1.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs300703	0.810	rs114594697	chr2:92999	C/T	cg21211680	chr2:198530	NA	-0.99	-7.04	-0.5	6.03e-11	Blood protein levels;
PAAD	cis	rs58521262	0.585	rs466772	chr19:23130984	G/C	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19825600	chr2:3704501	ALLC	-0.71	-5.88	-0.43	2.48e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.62e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00512709	chr22:42915904	RRP7A	0.59	6.82	0.48	2.06e-10	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg20487152	chr13:99095054	FARP1	0.46	4.94	0.37	2e-6	Longevity;
PAAD	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.47	-5.27	-0.39	4.64e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.8	5.65	0.42	7.54e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.63	7.62	0.53	2.47e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg10920065	chr6:169824652	NA	-0.47	-4.65	-0.35	7.02e-6	Obesity-related traits;
PAAD	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg16701003	chr16:89028210	CBFA2T3	0.51	5.32	0.4	3.71e-7	Social autistic-like traits;
PAAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	4.7	0.36	5.71e-6	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.65	7.55	0.52	3.71e-12	Bone mineral density;
PAAD	cis	rs3857067	0.967	rs1472984	chr4:95036553	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-4.47	-0.34	1.5e-5	QT interval;
PAAD	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg14146966	chr2:61757674	XPO1	-0.42	-5.16	-0.39	7.74e-7	Tuberculosis;
PAAD	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.99	-7.99	-0.54	3.17e-13	Blood protein levels;
PAAD	cis	rs73058052	1.000	rs73058052	chr19:50099422	C/T	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.84	-6.48	-0.47	1.19e-9	Fibrinogen levels;
PAAD	cis	rs10905065	0.829	rs6602278	chr10:5868361	A/G	cg11519256	chr10:5708881	ASB13	-0.53	-4.66	-0.35	6.86e-6	Menopause (age at onset);
PAAD	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.48	0.68	2.26e-22	Menopause (age at onset);
PAAD	cis	rs662064	0.963	rs1188529	chr1:10525914	A/T	cg07384165	chr1:10488281	NA	-0.49	-4.63	-0.35	7.83e-6	Asthma;
PAAD	cis	rs6496044	0.963	rs6496050	chr15:86069250	A/G	cg13263323	chr15:86062960	AKAP13	-0.53	-5.84	-0.43	3.1e-8	Interstitial lung disease;
PAAD	cis	rs72843506	0.586	rs73296067	chr17:19880301	G/A	cg05625806	chr17:19284432	MAPK7	0.62	4.26	0.33	3.58e-5	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11073833	chr1:153936127	SLC39A1	0.58	6.29	0.45	3.23e-9	Monocyte percentage of white cells;
PAAD	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.61	5.71	0.42	5.63e-8	Childhood ear infection;
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg20821713	chr7:1055600	C7orf50	-0.43	-4.56	-0.35	1.06e-5	Longevity;Endometriosis;
PAAD	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.61	-0.41	9.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.93	8.23	0.56	7.96e-14	Gut microbiome composition (summer);
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.04e-7	Glomerular filtration rate;
PAAD	cis	rs6494488	0.500	rs72742921	chr15:64855556	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs55728055	0.661	rs62237763	chr22:31947392	C/G	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05874913	chr2:160569340	MARCH7	-0.63	-6.63	-0.47	5.61e-10	Warfarin maintenance dose;
PAAD	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.61	-6.01	-0.44	1.3e-8	Post bronchodilator FEV1;
PAAD	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.4	-0.34	2.06e-5	Joint mobility (Beighton score);
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13560548	chr3:10150139	C3orf24	-0.6	-5.42	-0.4	2.27e-7	Alzheimer's disease;
PAAD	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-5.9	-0.43	2.33e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg25809561	chr17:30822961	MYO1D	0.56	5.97	0.44	1.63e-8	Schizophrenia;
PAAD	cis	rs72960926	1.000	rs11755340	chr6:75164320	G/T	cg13435101	chr6:74171350	MTO1	0.91	4.3	0.33	3.07e-5	Metabolite levels (MHPG);
PAAD	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.51	-4.54	-0.35	1.16e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg10113582	chr4:905918	GAK	0.37	4.29	0.33	3.21e-5	Systemic sclerosis;
PAAD	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.34	-0.46	2.45e-9	Breast cancer;
PAAD	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.76	7.56	0.52	3.48e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.59	6.3	0.46	3.04e-9	Educational attainment (years of education);
PAAD	cis	rs2412208	1.000	rs35447019	chr1:7093158	T/A	cg26570804	chr1:6352357	ACOT7	0.5	4.74	0.36	4.83e-6	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs714031	0.934	rs5750870	chr22:40067640	G/A	cg21377881	chr22:40064566	CACNA1I	-0.47	-4.61	-0.35	8.61e-6	Schizophrenia;
PAAD	cis	rs12760731	0.565	rs12048698	chr1:178136792	T/C	cg00404053	chr1:178313656	RASAL2	0.64	4.75	0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.9	0.37	2.4e-6	Interstitial lung disease;
PAAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.62	-6.64	-0.47	5.16e-10	Plateletcrit;
PAAD	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.43e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg16590910	chr6:42928470	GNMT	0.53	5.18	0.39	6.79e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs288342	0.832	rs288309	chr2:183651433	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.75	-0.36	4.74e-6	Recurrent major depressive disorder;
PAAD	cis	rs7516138	1.000	rs4240895	chr1:9713386	C/T	cg26573321	chr1:9711663	PIK3CD	0.51	5.18	0.39	6.93e-7	Monocyte count;
PAAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.74e-7	Tonsillectomy;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.96	10.45	0.65	1.33e-19	Blood metabolite levels;
PAAD	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg20243544	chr17:37824526	PNMT	0.53	4.73	0.36	5e-6	Self-reported allergy;
PAAD	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.78	-8.18	-0.55	1.05e-13	Prostate cancer;
PAAD	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.73	7.28	0.51	1.72e-11	Total body bone mineral density;
PAAD	cis	rs9361491	0.684	rs961680	chr6:79460619	T/A	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2992756	0.663	rs2992735	chr1:18800387	T/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs1797885	0.546	rs2450855	chr3:12602494	G/A	cg05638426	chr3:12878574	RPL32	-0.47	-4.42	-0.34	1.84e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg23241863	chr10:102295624	HIF1AN	0.47	4.32	0.33	2.84e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.93	0.37	2.1e-6	Menarche (age at onset);
PAAD	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	10.19	0.64	6.54e-19	Cognitive test performance;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.83	8.76	0.58	3.6e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	trans	rs6474412	0.664	rs7812298	chr8:42608579	C/T	cg07164722	chr1:247587378	NLRP3	0.62	6.67	0.48	4.46e-10	Smoking behavior;
PAAD	trans	rs528059	1.000	rs80277992	chr1:34196003	G/A	cg02711268	chr6:106808110	NA	1.1	6.33	0.46	2.58e-9	Intelligence;
PAAD	cis	rs3126085	0.560	rs2282303	chr1:152329435	C/T	cg26876637	chr1:152193138	HRNR	-0.71	-5.35	-0.4	3.11e-7	Atopic dermatitis;
PAAD	cis	rs925946	0.640	rs61888800	chr11:27722278	G/T	cg01418645	chr11:27679469	BDNF;BDNFOS	-0.52	-4.6	-0.35	8.77e-6	Body mass index;Weight;
PAAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.92	8.95	0.59	1.13e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.65	-5.93	-0.43	1.95e-8	Crohn's disease;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.57	5.12	0.38	9.1e-7	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11132698	chr1:895988	KLHL17;NOC2L	0.61	6.66	0.48	4.6e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-1.0	-12.37	-0.71	9.12e-25	Coronary artery disease;
PAAD	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs11700980	0.551	rs2832014	chr21:30110966	T/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg05895507	chr15:77155635	SCAPER	-0.43	-4.58	-0.35	9.46e-6	Blood metabolite levels;
PAAD	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg05784532	chr1:230284198	GALNT2	0.71	6.16	0.45	6.13e-9	Coronary artery disease;
PAAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.89	-10.44	-0.65	1.44e-19	Ulcerative colitis;
PAAD	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.6	-6.46	-0.46	1.35e-9	Red blood cell count;
PAAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg10356904	chr22:49881777	NA	-0.47	-4.69	-0.36	6.15e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3747547	0.818	rs16934640	chr9:37943164	C/T	cg13774184	chr9:37916125	SHB	-0.58	-4.26	-0.33	3.63e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.33	-4.79	-0.36	3.94e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.23	-0.45	4.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-9.03	-0.59	7.26e-16	Body mass index;
PAAD	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.51	-5.13	-0.38	8.91e-7	Motion sickness;
PAAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.59	-0.61	2.56e-17	Colorectal cancer;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.62	5.17	0.39	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2013441	0.613	rs9901125	chr17:20008929	A/G	cg13482628	chr17:19912719	NA	0.5	4.99	0.38	1.62e-6	Obesity-related traits;
PAAD	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.58	-0.35	9.58e-6	Bipolar disorder;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.73	-7.44	-0.52	6.99e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2506028	1.000	rs2506030	chr10:43447847	A/G	cg20628663	chr10:43360327	NA	-0.36	-4.25	-0.33	3.72e-5	Blood protein levels;
PAAD	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg11143131	chr5:131608246	PDLIM4	-0.5	-5.01	-0.38	1.5e-6	Blood metabolite levels;
PAAD	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.35	-0.4	3.17e-7	Subjective well-being;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17437086	chr5:1474074	LPCAT1	0.63	7.2	0.5	2.64e-11	Myopia (pathological);
PAAD	cis	rs11615916	0.656	rs117551406	chr12:62819361	G/A	cg11441379	chr12:63026424	NA	0.74	4.69	0.36	6.13e-6	Pulmonary function decline;
PAAD	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	6.04	0.44	1.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs258892	0.895	rs4254882	chr5:72031649	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7804356	0.871	rs6461963	chr7:26772491	G/A	cg03456212	chr7:26904342	SKAP2	0.53	4.37	0.33	2.25e-5	Type 1 diabetes;
PAAD	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-8.32	-0.56	4.74e-14	Bladder cancer;
PAAD	cis	rs7009110	0.706	rs7462675	chr8:81263962	C/A	cg21158561	chr8:81178149	NA	0.44	4.59	0.35	9.41e-6	Asthma and hay fever;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18856894	chr3:63850083	THOC7;ATXN7	0.74	6.96	0.49	9.53e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.56	-5.43	-0.4	2.23e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.2	0.55	9.34e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	5.89	0.43	2.36e-8	LDL cholesterol;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg03338584	chr11:507455	RNH1	0.56	4.39	0.34	2.15e-5	Systemic lupus erythematosus;
PAAD	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg07689907	chr11:61582574	FADS1	0.45	4.29	0.33	3.15e-5	Trans fatty acid levels;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.89	10.89	0.66	9.12e-21	Prudent dietary pattern;
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.39	-0.4	2.7e-7	Psoriasis;
PAAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.39	-0.4	2.59e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.08	0.55	1.82e-13	Lymphocyte counts;
PAAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg06375148	chr1:209958343	C1orf74	0.66	4.88	0.37	2.65e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.44	4.88	0.37	2.63e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.3	-0.39	4.1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs868943	0.582	rs12209373	chr6:116488925	G/A	cg18764771	chr6:116381957	FRK	0.27	4.37	0.33	2.33e-5	Total cholesterol levels;
PAAD	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.55	5.25	0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs4824093	0.544	rs7410274	chr22:50315928	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-4.29	-0.33	3.14e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.74	-0.42	5.03e-8	Coronary artery disease;
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.33	4.43	0.34	1.78e-5	Age at first birth;
PAAD	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.85	-9.66	-0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.74	8.36	0.56	3.71e-14	Corneal astigmatism;
PAAD	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.72	6.88	0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.57	5.62	0.41	9.03e-8	Osteoporosis;
PAAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.88	-0.58	1.77e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.53	-4.91	-0.37	2.3e-6	Red blood cell count;
PAAD	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	9.27	0.6	1.76e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg25008857	chr14:105974488	NA	0.39	4.28	0.33	3.23e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	6.12	0.44	7.53e-9	Renal function-related traits (BUN);
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg05457628	chr5:178986728	RUFY1	0.62	6.36	0.46	2.25e-9	Lung cancer;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-5.46	-0.4	1.9e-7	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01593134	chr8:142190049	DENND3	-0.68	-6.73	-0.48	3.32e-10	Smoking initiation;
PAAD	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.64e-9	Educational attainment;
PAAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.53	8.0	0.54	3.01e-13	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.77	0.36	4.26e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.83	-6.59	-0.47	6.95e-10	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.74	8.39	0.56	3.14e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.28e-6	Height;
PAAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.92e-6	Oral cavity cancer;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.72	8.52	0.57	1.47e-14	Height;
PAAD	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.95	-0.43	1.78e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.11	-0.77	4.46e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4343996	0.902	rs4336505	chr7:3373740	A/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.15	-0.39	7.95e-7	Motion sickness;
PAAD	cis	rs3106136	0.521	rs11724791	chr4:95077819	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-4.86	-0.37	2.84e-6	Capecitabine sensitivity;
PAAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg17372223	chr3:52568218	NT5DC2	0.5	4.68	0.35	6.41e-6	Bipolar disorder;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.45	0.4	2.04e-7	Prudent dietary pattern;
PAAD	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.77	7.85	0.54	7.12e-13	Coronary artery disease;
PAAD	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg01267373	chr18:77410094	NA	0.4	4.31	0.33	2.92e-5	Monocyte count;
PAAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg01851573	chr8:8652454	MFHAS1	-0.59	-4.74	-0.36	4.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.73	8.55	0.57	1.2e-14	Dental caries;
PAAD	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs4343996	0.967	rs10228723	chr7:3348120	A/G	cg21248987	chr7:3385318	SDK1	0.47	5.17	0.39	7.36e-7	Motion sickness;
PAAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.91	11.26	0.67	9.34e-22	Blood protein levels;
PAAD	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	4.92	0.37	2.23e-6	Multiple sclerosis or amyotrophic lateral sclerosis;
PAAD	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.41	-4.38	-0.34	2.16e-5	Prostate cancer;
PAAD	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.16e-8	Vitiligo;
PAAD	cis	rs2916733	0.793	rs2440399	chr8:6325975	G/T	cg01691696	chr8:6734962	DEFB1	-0.53	-4.25	-0.33	3.7e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg07166546	chr14:35805898	NA	-0.31	-4.75	-0.36	4.6e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg18370025	chr7:2749541	AMZ1	-0.42	-4.87	-0.37	2.82e-6	Height;
PAAD	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7551222	0.647	rs3014606	chr1:204464150	C/G	cg01064725	chr1:204461714	NA	0.54	4.51	0.34	1.28e-5	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.63	6.31	0.46	2.87e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.65	-5.16	-0.39	7.5e-7	IgG glycosylation;
PAAD	cis	rs4704187	0.640	rs74719230	chr5:74431888	G/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.26	-0.33	3.57e-5	QT interval;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25881719	chr18:74204135	NA	0.52	5.11	0.38	9.36e-7	Obesity-related traits;
PAAD	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.29	-4.35	-0.33	2.47e-5	Cystic fibrosis severity;
PAAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.13	13.26	0.73	3.68e-27	Cognitive function;
PAAD	cis	rs6074578	0.679	rs13043289	chr20:137114	A/G	cg16931068	chr20:139680	DEFB127	0.38	4.99	0.38	1.62e-6	Hirschsprung disease;
PAAD	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.23	-0.39	5.5e-7	QT interval;
PAAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04366801	chr1:26947443	NA	0.58	6.74	0.48	3.08e-10	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs6894268	0.762	rs4701136	chr5:179025550	A/G	cg26135573	chr5:179059668	NA	0.73	6.28	0.45	3.33e-9	Eating disorders;
PAAD	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.78	7.38	0.51	9.47e-12	Corneal astigmatism;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.51	5.41	0.4	2.4e-7	Lung cancer;
PAAD	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-7.85	-0.54	6.83e-13	Chronic sinus infection;
PAAD	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg21518248	chr2:162101506	NA	-0.44	-4.49	-0.34	1.43e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg12552261	chr5:112820674	MCC	0.64	6.44	0.46	1.5e-9	Type 2 diabetes;
PAAD	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	6.76	0.48	2.71e-10	Lung cancer in ever smokers;
PAAD	cis	rs4959799	1.000	rs60267481	chr6:3291109	C/T	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.82e-5	Survival in rectal cancer;
PAAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg12639453	chr1:2035780	PRKCZ	0.54	5.79	0.43	3.93e-8	Height;
PAAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg15628303	chr1:26608928	UBXN11	-0.4	-4.25	-0.33	3.66e-5	Height;
PAAD	cis	rs818427	0.963	rs153545	chr5:112238882	T/C	cg06941702	chr5:112196734	SRP19	0.48	4.44	0.34	1.76e-5	Total body bone mineral density;
PAAD	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.78	-9.22	-0.6	2.35e-16	Eye color traits;
PAAD	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs11037575	0.739	rs10838153	chr11:43723892	G/C	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2e-5	Neuroblastoma;
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg21565972	chr17:80109576	CCDC57	0.48	5.2	0.39	6.33e-7	Life satisfaction;
PAAD	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2718812	1.000	rs7626210	chr3:133398099	G/A	cg08048268	chr3:133502702	NA	0.43	5.24	0.39	5.18e-7	Iron status biomarkers;
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg04844267	chr4:1394941	NA	0.44	5.09	0.38	1.06e-6	Longevity;
PAAD	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.49	7.86	0.54	6.41e-13	Neuroticism;
PAAD	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	8.5	0.57	1.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.53	-6.1	-0.44	8.58e-9	Systemic lupus erythematosus;
PAAD	cis	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.8	-0.36	3.76e-6	Neuroticism;
PAAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg23281280	chr6:28129359	ZNF389	0.59	4.56	0.35	1.05e-5	Parkinson's disease;
PAAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg05754148	chr16:3507555	NAT15	0.72	5.16	0.39	7.44e-7	Tuberculosis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg05694744	chr17:8191820	RANGRF;SLC25A35	-0.64	-6.41	-0.46	1.73e-9	Primary biliary cholangitis;
PAAD	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.93	0.37	2.16e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7092929	0.882	rs535539	chr10:3574757	T/C	cg14308648	chr10:3568949	NA	0.67	5.02	0.38	1.4e-6	Coronary artery calcification;
PAAD	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs17152411	0.652	rs4246208	chr10:126654898	C/T	cg07081759	chr10:126330905	FAM53B	-0.41	-4.41	-0.34	1.96e-5	Height;
PAAD	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg21483461	chr5:81570383	RPS23	0.53	5.11	0.38	9.7e-7	Breast cancer;
PAAD	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.64	-6.42	-0.46	1.61e-9	Menopause (age at onset);
PAAD	cis	rs939584	0.935	rs6752706	chr2:629831	T/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs7737355	0.773	rs27450	chr5:131006082	A/G	cg06307176	chr5:131281290	NA	0.48	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs12484776	0.735	rs6001799	chr22:40539200	G/A	cg07138101	chr22:40742427	ADSL	0.6	4.45	0.34	1.68e-5	Uterine fibroids;
PAAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.87	12.49	0.71	4.51e-25	Bone mineral density;
PAAD	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg00431813	chr7:1051703	C7orf50	-0.35	-4.33	-0.33	2.71e-5	Longevity;Endometriosis;
PAAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	6.59	0.47	6.95e-10	Renal function-related traits (BUN);
PAAD	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-4.64	-0.35	7.49e-6	Mean corpuscular volume;
PAAD	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.11e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.87	-11.2	-0.67	1.32e-21	Heart rate;
PAAD	cis	rs1499972	0.941	rs62264816	chr3:117666232	C/G	cg07612923	chr3:117604196	NA	1.08	7.2	0.5	2.61e-11	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.48	-4.79	-0.36	3.93e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.1	-0.5	4.39e-11	Coronary artery disease;
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.67	0.35	6.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg14631576	chr9:95140430	CENPP	0.45	4.44	0.34	1.73e-5	Height;
PAAD	cis	rs2250644	0.510	rs2071509	chr10:90988250	C/G	cg06128509	chr10:91461539	KIF20B	-0.42	-4.26	-0.33	3.6e-5	Fibrinogen levels;
PAAD	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	trans	rs62179067	0.708	rs62175993	chr2:179905175	T/C	cg13380624	chr19:7735426	NA	-0.74	-7.09	-0.5	4.64e-11	Late-onset Alzheimer's disease;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07701084	chr6:150067640	NUP43	0.62	6.23	0.45	4.25e-9	Testicular germ cell tumor;
PAAD	cis	rs9039	0.550	rs12924785	chr16:9219285	T/G	cg08831531	chr16:9218945	NA	-0.4	-4.36	-0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.49	-4.56	-0.35	1.03e-5	Kawasaki disease;
PAAD	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.12	0.59	4.33e-16	Menopause (age at onset);
PAAD	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	1.07	6.81	0.48	2.1e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.81	6.02	0.44	1.23e-8	Height;
PAAD	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.64	5.53	0.41	1.36e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	trans	rs61931739	0.649	rs864173	chr12:33721422	A/C	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs8077889	0.750	rs76557360	chr17:41936842	G/A	cg26893861	chr17:41843967	DUSP3	0.86	6.2	0.45	5.2e-9	Triglycerides;
PAAD	cis	rs868943	0.582	rs9488861	chr6:116502405	A/G	cg18764771	chr6:116381957	FRK	0.29	4.87	0.37	2.78e-6	Total cholesterol levels;
PAAD	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.62	5.7	0.42	6.07e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14002714	chr14:56095810	KTN1	0.56	6.53	0.47	9.34e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.22	5.89	0.43	2.4e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.59	-0.82	1.73e-38	Height;
PAAD	cis	rs714031	0.934	rs4820386	chr22:40068051	C/T	cg21377881	chr22:40064566	CACNA1I	-0.47	-4.61	-0.35	8.61e-6	Schizophrenia;
PAAD	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.63	-0.42	8.38e-8	Joint mobility (Beighton score);
PAAD	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-6.48	-0.47	1.22e-9	Menopause (age at onset);
PAAD	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.04	-0.63	1.63e-18	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13198984	chr17:80129470	CCDC57	0.41	5.0	0.38	1.59e-6	Life satisfaction;
PAAD	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg09455208	chr3:40491958	NA	0.48	6.2	0.45	4.97e-9	Renal cell carcinoma;
PAAD	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.64	5.57	0.41	1.12e-7	Obesity-related traits;
PAAD	cis	rs2011503	0.509	rs73006705	chr19:19781917	A/G	cg11584989	chr19:19387371	SF4	0.86	6.41	0.46	1.74e-9	Bipolar disorder;
PAAD	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-7.36	-0.51	1.07e-11	Vitiligo;
PAAD	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg21496419	chr19:44306685	LYPD5	0.39	4.97	0.37	1.76e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg01426195	chr3:39028469	NA	-0.65	-6.41	-0.46	1.75e-9	Handedness;
PAAD	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.56	6.3	0.45	3.11e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg25566285	chr7:158114605	PTPRN2	0.83	8.51	0.57	1.55e-14	Calcium levels;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.8	-4.83	-0.36	3.34e-6	Obesity-related traits;
PAAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg06028605	chr16:24865363	SLC5A11	0.48	5.82	0.43	3.42e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg23254163	chr1:152506842	NA	0.61	7.03	0.5	6.38e-11	Hair morphology;
PAAD	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs2271001	0.955	rs7111105	chr11:19155554	A/C	cg25010752	chr1:116460862	NA	-0.52	-6.48	-0.47	1.2e-9	Gut microbiome composition (winter);
PAAD	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg18643199	chr10:82363313	SH2D4B	-0.64	-5.0	-0.38	1.58e-6	Post bronchodilator FEV1;
PAAD	cis	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg25886479	chr11:50257625	LOC441601	-0.42	-4.53	-0.35	1.16e-5	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.48	-0.34	1.44e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7302017	0.614	rs774533	chr12:62992001	G/A	cg22941953	chr12:62861114	MON2	-0.99	-4.45	-0.34	1.62e-5	Waist circumference;
PAAD	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	6.39	0.46	1.91e-9	Type 2 diabetes;
PAAD	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.25	-0.51	1.93e-11	Diastolic blood pressure;
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs10943724	0.704	rs12664602	chr6:81270201	T/C	cg19323245	chr6:80716898	TTK	-0.43	-4.54	-0.35	1.15e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.53	5.22	0.39	5.81e-7	Rheumatoid arthritis;
PAAD	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg00262122	chr8:11665843	FDFT1	0.57	5.1	0.38	1.02e-6	Morning vs. evening chronotype;
PAAD	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg14582100	chr15:45693742	SPATA5L1	0.42	6.52	0.47	9.97e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg19429281	chr19:53496738	ZNF702P	0.59	6.33	0.46	2.56e-9	Psoriasis;
PAAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.77	-8.04	-0.55	2.31e-13	Cognitive test performance;
PAAD	cis	rs9880772	0.683	rs6551228	chr3:27815535	C/G	cg21473142	chr3:27762095	EOMES	0.34	6.0	0.44	1.38e-8	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg04717802	chr22:42394638	WBP2NL	-0.49	-4.71	-0.36	5.56e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	0.5	4.52	0.34	1.23e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.58	-6.65	-0.47	5.09e-10	Colorectal cancer;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg02023728	chr11:77925099	USP35	-0.44	-4.54	-0.35	1.14e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg23649088	chr2:200775458	C2orf69	-0.94	-5.42	-0.4	2.28e-7	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.79	-0.48	2.42e-10	Life satisfaction;
PAAD	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13870426	chr17:30244630	NA	-0.73	-7.24	-0.51	2.13e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.72	-7.86	-0.54	6.65e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18357526	chr6:26021779	HIST1H4A	0.68	6.7	0.48	3.91e-10	Blood metabolite levels;
PAAD	cis	rs6887276	0.504	rs34145453	chr5:127347013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.47	-4.84	-0.37	3.14e-6	Height;
PAAD	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.88	-11.08	-0.67	2.77e-21	Heart rate;
PAAD	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg20503657	chr10:835505	NA	1.1	10.57	0.65	6.32e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20505218	chr17:80009845	GPS1;RFNG	0.61	6.96	0.49	9.7e-11	Metabolite levels  (X-11787);
PAAD	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.62	-0.35	8.18e-6	Resting heart rate;
PAAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.8	-8.71	-0.58	4.92e-15	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73196966	chr3:128436824	G/A	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.55	-0.35	1.07e-5	Bipolar disorder;
PAAD	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.71	7.58	0.52	3.24e-12	Blood protein levels;
PAAD	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.67	4.84	0.37	3.12e-6	Neuroticism;
PAAD	cis	rs7264396	0.887	rs2236164	chr20:34097353	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.6	-0.41	9.6e-8	Total cholesterol levels;
PAAD	cis	rs7567389	0.677	rs10850	chr2:128063945	T/C	cg09760422	chr2:128146352	NA	-0.39	-5.97	-0.44	1.62e-8	Self-rated health;
PAAD	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.55	-5.85	-0.43	2.91e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6494488	0.500	rs111737146	chr15:65004840	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg27121462	chr16:89883253	FANCA	0.47	5.04	0.38	1.29e-6	Vitiligo;
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.63	-6.57	-0.47	7.52e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg25828445	chr12:7781288	NA	0.74	5.26	0.39	4.71e-7	HDL cholesterol levels;
PAAD	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg26879891	chr1:152191343	HRNR	0.52	4.5	0.34	1.37e-5	Inflammatory skin disease;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg16898833	chr6:26189333	HIST1H4D	0.62	4.92	0.37	2.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs75920871	0.589	rs2306473	chr11:117097952	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.9	-5.39	-0.4	2.6e-7	Subjective well-being;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.4	4.95	0.37	1.93e-6	Iron status biomarkers;
PAAD	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg24268161	chr22:39747459	SYNGR1	-0.38	-4.57	-0.35	1.02e-5	Rheumatoid arthritis;
PAAD	cis	rs7765175	0.698	rs9320441	chr6:113668814	A/G	cg19037598	chr6:113666021	NA	-0.43	-4.65	-0.35	7.22e-6	Coronary artery calcification;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02284150	chr5:150004508	SYNPO	0.58	6.63	0.47	5.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg26513180	chr16:89883248	FANCA	0.41	4.38	0.33	2.22e-5	Vitiligo;
PAAD	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.82	8.58	0.57	1.04e-14	Uric acid levels;
PAAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.59	5.69	0.42	6.34e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4740619	0.619	rs943787	chr9:16031796	T/C	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.77	-14.8	-0.77	2.85e-31	Longevity;Endometriosis;
PAAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg05562828	chr17:3906858	NA	0.54	5.99	0.44	1.47e-8	Type 2 diabetes;
PAAD	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.6	4.96	0.37	1.85e-6	Response to antidepressants in depression;
PAAD	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg12568669	chr8:11666485	FDFT1	0.31	5.41	0.4	2.37e-7	Monocyte count;
PAAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.72	5.83	0.43	3.14e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1864585	0.520	rs12155811	chr8:10673513	C/T	cg21775007	chr8:11205619	TDH	-0.56	-4.45	-0.34	1.67e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.78	7.58	0.52	3.25e-12	HIV-1 control;
PAAD	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs72753537	0.679	rs12377722	chr9:100576065	C/T	cg13688889	chr9:100608707	NA	-0.59	-4.27	-0.33	3.49e-5	Papillary thyroid cancer;Differentiated thyroid cancer;
PAAD	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1468333	0.567	rs10080108	chr5:137655242	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.42	5.33	0.4	3.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	6.89	0.49	1.36e-10	Breast cancer;
PAAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs8060686	0.841	rs73599506	chr16:67712366	T/C	cg05110241	chr16:68378359	PRMT7	-0.73	-5.12	-0.38	9.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11112613	0.653	rs2374533	chr12:106047891	A/G	cg03607813	chr12:105948248	NA	0.79	5.74	0.42	4.93e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.63	0.42	8.31e-8	Lung cancer;
PAAD	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.94	-9.66	-0.62	1.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.04	-0.44	1.14e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg06217071	chr17:408420	NA	-0.63	-7.02	-0.49	6.88e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.39	4.72	0.36	5.42e-6	Colorectal cancer;
PAAD	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.05	0.38	1.27e-6	Blood protein levels;
PAAD	cis	rs2882667	0.690	rs825759	chr5:138125939	G/A	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg10518543	chr12:38710700	ALG10B	0.52	4.95	0.37	1.92e-6	Morning vs. evening chronotype;
PAAD	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.32	-0.33	2.81e-5	Ileal carcinoids;
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.89	-0.59	1.61e-15	Longevity;Endometriosis;
PAAD	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.13	0.5	3.83e-11	Obesity-related traits;
PAAD	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.72	0.42	5.57e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs3857067	1.000	rs7694631	chr4:95016931	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8054556	0.692	rs4788199	chr16:29970857	C/G	cg06015834	chr16:30021696	DOC2A	-0.4	-4.26	-0.33	3.55e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.69	5.1	0.38	1e-6	Mean platelet volume;
PAAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.1e-6	Parkinson's disease;
PAAD	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	6.5	0.47	1.1e-9	Type 2 diabetes;
PAAD	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.64	7.36	0.51	1.06e-11	Schizophrenia;
PAAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.91e-6	Triglycerides;
PAAD	cis	rs593531	0.614	rs486758	chr11:74058932	C/T	cg23327896	chr11:73669290	DNAJB13	-0.36	-4.64	-0.35	7.57e-6	Neuroticism;
PAAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg18898632	chr2:242989856	NA	-0.8	-5.69	-0.42	6.32e-8	Obesity-related traits;
PAAD	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.67	7.46	0.52	6.24e-12	Menopause (age at onset);
PAAD	cis	rs2282300	1.000	rs12575085	chr11:30428262	G/T	cg25418670	chr11:30344373	C11orf46	-0.49	-4.52	-0.34	1.26e-5	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.94	12.51	0.71	3.95e-25	Menopause (age at onset);
PAAD	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs8099014	1.000	rs4940698	chr18:56108914	G/A	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.88	-0.43	2.53e-8	Prostate cancer;
PAAD	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	trans	rs901683	1.000	rs9422650	chr10:46045761	G/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.47	-6.16	-0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7219021	1.000	rs72831853	chr17:46842575	A/T	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.17	-0.39	7.16e-7	Breast cancer;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.69	7.58	0.52	3.16e-12	Bone mineral density;
PAAD	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-7.95	-0.54	3.88e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.76	-12.08	-0.7	5.8e-24	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11632617	chr15:75315747	PPCDC	0.56	6.56	0.47	7.91e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg14709524	chr16:89940631	TCF25	0.99	4.61	0.35	8.56e-6	Skin colour saturation;
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.46	-4.4	-0.34	2.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.585	rs1285004	chr6:45098201	A/T	cg25276700	chr6:44698697	NA	0.46	5.44	0.4	2.06e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.68	5.35	0.4	3.18e-7	Breast cancer;
PAAD	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.41	-0.34	1.93e-5	Coronary artery disease;
PAAD	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.72	-7.08	-0.5	4.92e-11	Schizophrenia;
PAAD	cis	rs17032980	0.956	rs6546279	chr2:67311393	G/A	cg02551743	chr2:66673428	MEIS1	-0.5	-4.49	-0.34	1.39e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.9	6.97	0.49	9.02e-11	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs9815354	0.909	rs6794477	chr3:41920401	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg00105475	chr2:10696890	NA	0.72	7.72	0.53	1.47e-12	Prostate cancer;
PAAD	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.73	7.55	0.52	3.65e-12	Body mass index;
PAAD	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg06569542	chr10:98946673	SLIT1	0.49	4.87	0.37	2.78e-6	Monocyte count;
PAAD	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.53	-5.13	-0.38	8.71e-7	Height;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.86	-11.09	-0.67	2.62e-21	Vitiligo;
PAAD	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.6	-0.52	2.86e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.96	-13.54	-0.74	6.61e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.65	-6.58	-0.47	7.19e-10	White matter hyperintensity burden;
PAAD	cis	rs9361491	0.608	rs9343800	chr6:79461972	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.49	4.57	0.35	9.96e-6	Cisplatin-induced ototoxicity;
PAAD	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg19700328	chr14:106028568	NA	-0.64	-6.21	-0.45	4.86e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs12257961	0.579	rs6602844	chr10:15388129	T/G	cg10616319	chr10:15468812	NA	-0.47	-4.46	-0.34	1.56e-5	Selective IgA deficiency;
PAAD	cis	rs9638182	1.000	rs1051921	chr7:73007943	G/A	cg07467649	chr7:72856462	BAZ1B	0.49	4.26	0.33	3.52e-5	Triglycerides;
PAAD	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.64	6.3	0.46	3.12e-9	Smooth-surface caries;
PAAD	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.76	-8.86	-0.58	1.92e-15	White blood cell count (basophil);
PAAD	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.63	-0.35	7.89e-6	Rheumatoid arthritis;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.7	-7.54	-0.52	3.96e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.61	-5.68	-0.42	6.51e-8	White matter hyperintensity burden;
PAAD	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg15676125	chr6:33679581	C6orf125	0.46	4.49	0.34	1.42e-5	Plateletcrit;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.72	7.83	0.54	7.69e-13	Mean corpuscular volume;
PAAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.69	6.66	0.48	4.72e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	LDL cholesterol;
PAAD	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs1413885	1.000	rs1334881	chr1:65822517	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	4.7	0.36	5.84e-6	Anticoagulant levels;
PAAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00142150	chr22:38071001	LGALS1	0.86	9.58	0.61	2.64e-17	Fat distribution (HIV);
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.16	-0.39	7.67e-7	High light scatter reticulocyte count;
PAAD	cis	rs2030114	0.531	rs2647988	chr16:51594261	C/G	cg03758633	chr16:51611768	NA	0.51	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.7	6.87	0.49	1.53e-10	Uric acid levels;
PAAD	cis	rs2030114	0.531	rs2173454	chr16:51598869	A/G	cg03758633	chr16:51611768	NA	-0.51	-4.98	-0.37	1.68e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg03165014	chr13:102106348	ITGBL1	0.47	4.6	0.35	9.01e-6	Obesity-related traits;
PAAD	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.66	-10.63	-0.65	4.36e-20	Diastolic blood pressure;
PAAD	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg06565975	chr8:143823917	SLURP1	0.19	4.46	0.34	1.59e-5	Urinary tract infection frequency;
PAAD	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.47	4.4	0.34	2.02e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.71	-0.36	5.46e-6	Obesity-related traits;
PAAD	cis	rs2442825	0.540	rs35728233	chr3:9429194	C/T	cg26143413	chr3:9428045	THUMPD3	-0.54	-4.58	-0.35	9.64e-6	Cerebrospinal fluid clusterin levels;
PAAD	trans	rs7594645	1.000	rs60652129	chr2:207649313	A/C	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg21269045	chr12:125625041	AACS	-0.46	-4.67	-0.35	6.46e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs9393777	0.920	rs34196306	chr6:27425644	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.28	0.33	3.25e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	0.96	11.55	0.68	1.55e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.51	-4.85	-0.37	2.99e-6	Migraine;
PAAD	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.67	-0.35	6.61e-6	Myopia (pathological);
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.57	5.57	0.41	1.15e-7	Resistin levels;
PAAD	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg01362358	chr17:58117360	NA	-0.4	-4.7	-0.36	5.82e-6	Obesity-related traits;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.28	0.39	4.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2124910	1.000	rs4802807	chr19:52030448	A/G	cg12008991	chr19:52034861	SIGLEC6	0.38	5.06	0.38	1.19e-6	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.43	-4.25	-0.33	3.76e-5	Multiple sclerosis;
PAAD	cis	rs6604026	0.656	rs6604028	chr1:93378033	C/T	cg17283838	chr1:93427260	FAM69A	0.63	5.82	0.43	3.42e-8	Multiple sclerosis;
PAAD	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.4	0.34	2.01e-5	Intelligence (multi-trait analysis);Educational attainment (years of education);
PAAD	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.9	8.39	0.56	3.04e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.58	6.89	0.49	1.35e-10	Multiple sclerosis;
PAAD	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg06115741	chr20:33292138	TP53INP2	0.64	5.97	0.44	1.61e-8	Coronary artery disease;
PAAD	cis	rs1419980	0.730	rs11054939	chr12:7782439	C/G	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.93	-0.63	3.26e-18	Total body bone mineral density;
PAAD	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	4.94	0.37	2.08e-6	Lung function (FEV1/FVC);
PAAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg04160749	chr8:58172571	NA	-0.6	-4.45	-0.34	1.66e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.68	-8.62	-0.57	8.34e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7083	1.000	rs644215	chr11:117145918	T/A	cg26034313	chr11:117110208	RNF214	0.32	4.26	0.33	3.55e-5	Blood protein levels;
PAAD	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg21775007	chr8:11205619	TDH	-0.48	-4.57	-0.35	1e-5	Systolic blood pressure;
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-8.64	-0.57	7.33e-15	Prudent dietary pattern;
PAAD	cis	rs11264799	0.603	rs11799853	chr1:157557957	T/C	cg18268488	chr1:157545234	FCRL4	0.47	5.5	0.41	1.57e-7	IgA nephropathy;
PAAD	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg15047889	chr8:124780837	FAM91A1	-0.64	-5.0	-0.38	1.55e-6	Pancreatic cancer;
PAAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.58	-5.5	-0.41	1.57e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-16.78	-0.81	2.05e-36	Height;
PAAD	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg26685658	chr5:74633012	HMGCR	-0.52	-4.33	-0.33	2.73e-5	Age-related disease endophenotypes;
PAAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg01097406	chr16:89675127	NA	0.38	4.73	0.36	5.17e-6	Vitiligo;
PAAD	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg02531859	chr7:37888154	TXNDC3	-0.56	-4.49	-0.34	1.41e-5	Alzheimer's disease (late onset);
PAAD	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg15049549	chr3:48732213	IP6K2	0.52	4.46	0.34	1.61e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26926768	chr12:34528122	NA	0.37	4.26	0.33	3.52e-5	Morning vs. evening chronotype;
PAAD	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.62	-5.07	-0.38	1.12e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07428496	chr8:124026000	DERL1	-0.57	-6.93	-0.49	1.11e-10	Monocyte percentage of white cells;
PAAD	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs11123610	0.698	rs72769388	chr2:3725964	C/T	cg00999904	chr2:3704751	ALLC	-0.53	-5.83	-0.43	3.2e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.53	-0.34	1.18e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.74	8.53	0.57	1.41e-14	Huntington's disease progression;
PAAD	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg05625103	chr10:2543513	NA	-0.7	-6.29	-0.45	3.18e-9	Age-related hearing impairment;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg15181151	chr6:150070149	PCMT1	0.56	5.61	0.41	9.23e-8	Lung cancer;
PAAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg25204440	chr1:209979598	IRF6	0.63	4.87	0.37	2.73e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-10.03	-0.63	1.78e-18	Brugada syndrome;
PAAD	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.55	5.32	0.4	3.64e-7	Bone properties (heel);
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.48	-5.2	-0.39	6.32e-7	Age at first birth;
PAAD	cis	rs4417704	0.551	rs4675841	chr2:241876580	A/G	cg26818257	chr2:241905806	NA	0.49	5.27	0.39	4.53e-7	Joint mobility (Beighton score);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14795281	chr19:13953361	NA	-0.68	-7.15	-0.5	3.48e-11	Smoking initiation;
PAAD	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs62247992	0.686	rs114711402	chr3:43112319	A/T	cg12239580	chr3:43073058	FAM198A	0.55	4.72	0.36	5.35e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.01e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21518248	chr2:162101506	NA	0.68	7.61	0.53	2.72e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.71	-0.42	5.85e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.76	-8.07	-0.55	1.94e-13	Cognitive function;
PAAD	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg06131755	chr6:160182447	ACAT2	0.54	4.81	0.36	3.6e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.73	5.64	0.42	8.11e-8	Vitiligo;
PAAD	cis	rs116175783	0.557	rs3769968	chr2:162166151	A/C	cg08807892	chr2:162101083	NA	-0.69	-4.89	-0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg05564831	chr3:52568323	NT5DC2	0.45	4.61	0.35	8.5e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.05e-6	Diastolic blood pressure;
PAAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.23	18.04	0.83	1.31e-39	IgG glycosylation;
PAAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.55	6.14	0.45	6.96e-9	Cognitive function;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.5	5.04	0.38	1.3e-6	Longevity;Endometriosis;
PAAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	cis	rs732765	0.734	rs12893245	chr14:75168936	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs6424115	0.771	rs2502990	chr1:24205295	C/T	cg10978503	chr1:24200527	CNR2	0.51	6.06	0.44	1.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.48	-4.3	-0.33	3.06e-5	Testicular germ cell tumor;
PAAD	cis	rs600626	0.588	rs10899116	chr11:75476195	C/T	cg24262691	chr11:75473276	NA	0.81	6.41	0.46	1.74e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg27644672	chr7:1858694	MAD1L1	0.4	4.41	0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6088813	0.845	rs2378349	chr20:33925843	C/A	cg14752227	chr20:34000481	UQCC	0.55	5.51	0.41	1.53e-7	Height;
PAAD	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Blood metabolite levels;
PAAD	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg02887458	chr19:19495540	GATAD2A	-0.54	-4.78	-0.36	4.01e-6	Bipolar disorder;
PAAD	cis	rs6011002	0.808	rs1291211	chr20:62337622	A/G	cg01176363	chr20:62369445	LIME1	-0.78	-4.34	-0.33	2.61e-5	Dental caries;
PAAD	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Vitiligo;
PAAD	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.47	4.4	0.34	2.02e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.14	15.73	0.79	1.08e-33	Cognitive function;
PAAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.48	4.57	0.35	1.01e-5	Fractional excretion of uric acid;
PAAD	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.93	10.81	0.66	1.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.68	0.42	6.72e-8	Eosinophil percentage of white cells;
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.03	-0.44	1.18e-8	Fear of minor pain;
PAAD	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.43	4.75	0.36	4.71e-6	Life satisfaction;
PAAD	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.23	0.45	4.43e-9	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg14926445	chr8:58193284	C8orf71	-0.74	-4.84	-0.37	3.1e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg09582351	chr12:29534625	ERGIC2	-0.38	-5.44	-0.4	2.11e-7	QT interval;
PAAD	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg10820045	chr2:198174542	NA	0.44	4.4	0.34	2.03e-5	Dermatomyositis;
PAAD	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-5.58	-0.41	1.08e-7	Crohn's disease;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13560548	chr3:10150139	C3orf24	0.61	5.56	0.41	1.19e-7	Alzheimer's disease;
PAAD	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.45	-0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05886006	chr1:161359784	NA	0.6	6.84	0.49	1.82e-10	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	cis	rs4343996	0.566	rs4236326	chr7:3400105	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.33	-0.33	2.67e-5	Motion sickness;
PAAD	cis	rs2229238	0.866	rs61403567	chr1:154504927	T/C	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.59	-5.55	-0.41	1.26e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg24699146	chr1:24152579	HMGCL	0.54	5.8	0.43	3.63e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.58	5.31	0.4	3.83e-7	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2446066	0.524	rs2947337	chr12:53796998	G/A	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.3	-0.33	2.99e-5	Red blood cell count;
PAAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs797680	0.856	rs10874762	chr1:93639101	T/G	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.61	0.35	8.61e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.83	-10.02	-0.63	1.88e-18	Monocyte percentage of white cells;
PAAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2004318	0.850	rs111365792	chr19:55078730	C/T	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg15145296	chr3:125709740	NA	-0.68	-4.36	-0.33	2.39e-5	Blood pressure (smoking interaction);
PAAD	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg03303774	chr4:1407052	NA	0.41	5.12	0.38	9.28e-7	Longevity;
PAAD	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.39	-0.34	2.09e-5	Electroencephalogram traits;
PAAD	cis	rs6141769	0.518	rs28378056	chr20:31298317	G/C	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.69	-0.36	5.94e-6	Subjective well-being;
PAAD	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.3	-5.85	-0.43	2.91e-8	Type 2 diabetes;
PAAD	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-5.05	-0.38	1.24e-6	Inflammatory bowel disease;
PAAD	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs9535307	0.929	rs6561550	chr13:50249423	C/T	cg04663916	chr13:50265991	EBPL	0.59	4.61	0.35	8.42e-6	Obesity-related traits;
PAAD	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	8.03	0.55	2.42e-13	Psoriasis;
PAAD	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.37	5.51	0.41	1.51e-7	Educational attainment (years of education);
PAAD	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.32	-0.33	2.76e-5	Pulse pressure;
PAAD	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.75	7.78	0.53	1.05e-12	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7594192	0.744	rs12621458	chr2:199365595	C/G	cg01558212	chr2:200327336	NA	0.37	4.82	0.36	3.45e-6	Educational attainment;
PAAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.81	8.71	0.58	4.72e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9346353	0.675	rs9364050	chr6:70414263	G/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.93e-5	Sleep duration;
PAAD	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.97	0.44	1.59e-8	Coffee consumption (cups per day);
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18337363	chr3:52569053	NT5DC2	0.45	4.57	0.35	1.01e-5	Electroencephalogram traits;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14820908	chr5:178986412	RUFY1	0.55	5.34	0.4	3.32e-7	Lung cancer;
PAAD	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21030419	chr7:2354395	SNX8	-0.73	-7.18	-0.5	2.95e-11	Lung cancer in ever smokers;
PAAD	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.83	-9.01	-0.59	8.24e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2279817	0.780	rs11585339	chr1:18000120	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.75	-0.42	4.82e-8	Neuroticism;
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg01759136	chr6:27242945	NA	0.4	4.34	0.33	2.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	9.16	0.6	3.24e-16	Prudent dietary pattern;
PAAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25833597	chr17:30823145	MYO1D	0.6	5.95	0.43	1.74e-8	Schizophrenia;
PAAD	cis	rs12935418	0.672	rs1453328	chr16:81052845	G/A	cg16651780	chr16:81037892	C16orf61	0.69	6.36	0.46	2.27e-9	Mean corpuscular volume;
PAAD	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.76	0.36	4.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg12568669	chr8:11666485	FDFT1	0.33	4.64	0.35	7.52e-6	Myopia (pathological);
PAAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.1	-0.38	1.02e-6	Mood instability;
PAAD	cis	rs7922314	0.571	rs61865715	chr10:64737789	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.56	5.67	0.42	7.04e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.38	0.33	2.2e-5	Neuroticism;
PAAD	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.62	-5.55	-0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.85	0.49	1.67e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.49	4.41	0.34	1.93e-5	Acylcarnitine levels;
PAAD	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.57	-6.52	-0.47	9.74e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg11782729	chr17:576564	VPS53	-0.37	-4.29	-0.33	3.21e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.25	-5.35	-0.4	3.17e-7	Urinary tract infection frequency;
PAAD	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.25	-0.33	3.66e-5	Arsenic metabolism;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17233202	chr15:82338518	MEX3B	0.55	6.4	0.46	1.8e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg21724239	chr8:58056113	NA	0.71	5.35	0.4	3.14e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.1	-10.19	-0.64	6.54e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.6	6.27	0.45	3.6e-9	Type 2 diabetes;
PAAD	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg20503657	chr10:835505	NA	0.94	6.97	0.49	9.12e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.67	6.47	0.46	1.28e-9	Type 2 diabetes;
PAAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.85	9.71	0.62	1.23e-17	Resting heart rate;
PAAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg14196790	chr5:131705035	SLC22A5	0.5	5.46	0.4	1.9e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg03989125	chr22:38214979	NA	0.59	5.66	0.42	7.27e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.52e-7	Pulmonary function;
PAAD	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.66	5.14	0.39	8.14e-7	Blood protein levels;
PAAD	cis	rs11168618	0.904	rs7136845	chr12:48907029	C/T	cg01881778	chr12:48919444	OR8S1	-0.47	-4.71	-0.36	5.58e-6	Adiponectin levels;
PAAD	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	4.63	0.35	7.78e-6	Blood metabolite levels;
PAAD	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.77	-12.65	-0.72	1.63e-25	Breast cancer;
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.95	-12.35	-0.71	1.05e-24	Menopause (age at onset);
PAAD	cis	rs1468333	0.667	rs17538215	chr5:137752868	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	5.43	0.4	2.16e-7	Resting heart rate;
PAAD	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.68	-7.16	-0.5	3.15e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg14391382	chr7:866102	UNC84A	0.46	4.3	0.33	3.1e-5	Subjective well-being;
PAAD	cis	rs30380	1.000	rs30378	chr5:96121994	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-5.2	-0.39	6.44e-7	Menarche (age at onset);
PAAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.66	0.48	4.69e-10	Height;
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.73e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9652601	0.691	rs9888868	chr16:11183563	T/C	cg04616529	chr16:11181986	CLEC16A	0.39	4.69	0.36	6.09e-6	Systemic lupus erythematosus;
PAAD	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	5.42	0.4	2.27e-7	IgG glycosylation;
PAAD	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.24	10.69	0.66	3.1e-20	Uric acid levels;
PAAD	cis	rs1499972	0.878	rs1093463	chr3:117744762	C/T	cg07612923	chr3:117604196	NA	-1.06	-6.91	-0.49	1.28e-10	Schizophrenia;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg12034118	chr1:209979487	IRF6	0.53	4.92	0.37	2.24e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.8	-0.36	3.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.68	7.56	0.52	3.55e-12	Menopause (age at onset);
PAAD	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.84	9.94	0.63	3.09e-18	Ulcerative colitis;
PAAD	cis	rs6681460	0.549	rs6680968	chr1:67034661	C/T	cg02459107	chr1:67143332	SGIP1	0.66	7.11	0.5	4.24e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.89	7.44	0.52	7.01e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.95	11.29	0.68	7.63e-22	Multiple myeloma;
PAAD	cis	rs6494488	0.500	rs72744704	chr15:65011507	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs1198430	0.639	rs685059	chr1:23783185	C/G	cg27447006	chr1:23763279	ASAP3	0.65	5.0	0.38	1.58e-6	Total cholesterol levels;
PAAD	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg00599163	chr2:162100495	NA	0.38	4.79	0.36	3.93e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-4.94	-0.37	2.06e-6	Blood metabolite levels;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg07336987	chr11:625147	MUPCDH	-0.36	-4.48	-0.34	1.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.67	6.7	0.48	3.74e-10	Blood protein levels;
PAAD	cis	rs346785	0.692	rs8074821	chr17:74293099	A/G	cg09812376	chr17:74270190	QRICH2	-0.47	-5.97	-0.44	1.65e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs9876781	1.000	rs11712561	chr3:48435272	C/A	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs6142102	0.961	rs2284387	chr20:32644588	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.77	7.35	0.51	1.12e-11	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05816914	chr22:39080524	TOMM22	-0.52	-6.41	-0.46	1.77e-9	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.3	0.46	3.03e-9	Initial pursuit acceleration;
PAAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.35	14.66	0.77	6.72e-31	Eosinophil percentage of granulocytes;
PAAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Menopause (age at onset);
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26549601	chr10:134560360	INPP5A	-0.44	-4.6	-0.35	8.75e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-5.12	-0.38	9.02e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg09579323	chr1:150459698	TARS2	0.45	4.28	0.33	3.25e-5	Migraine;
PAAD	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.52	-0.61	3.95e-17	Response to antipsychotic treatment;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg13410755	chr7:128503275	ATP6V1F	0.57	6.73	0.48	3.29e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9810890	1.000	rs73196988	chr3:128453467	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.84	0.43	3.11e-8	Platelet count;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg16362232	chr11:430036	ANO9	0.91	5.59	0.41	1.01e-7	Body mass index;
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02071572	chr4:1403502	NA	0.34	4.25	0.33	3.77e-5	Longevity;
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.93	9.83	0.62	5.76e-18	Blood metabolite levels;
PAAD	cis	rs67385638	0.925	rs12417960	chr11:5265106	C/A	cg12559170	chr11:5275217	HBG2	0.55	5.4	0.4	2.47e-7	Hemoglobin levels;
PAAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.53	5.21	0.39	6.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2455799	0.559	rs7635539	chr3:15922908	A/G	cg13420985	chr3:16524424	RFTN1	0.49	4.45	0.34	1.63e-5	Mean platelet volume;
PAAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.63	-6.5	-0.47	1.07e-9	Body mass index;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg06131755	chr6:160182447	ACAT2	0.52	4.33	0.33	2.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.14	17.79	0.82	5.62e-39	Multiple myeloma;
PAAD	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs501120	0.564	rs2624682	chr10:44678240	C/T	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.84	8.99	0.59	9.01e-16	Anterior chamber depth;
PAAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg03959625	chr15:84868606	LOC388152	-0.48	-5.34	-0.4	3.33e-7	Schizophrenia;
PAAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.69	7.91	0.54	4.95e-13	Parkinson's disease;
PAAD	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.57	-5.7	-0.42	5.93e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.63	-6.76	-0.48	2.81e-10	Tonsillectomy;
PAAD	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs7631605	0.935	rs2302504	chr3:37116386	A/C	cg17445812	chr3:36986805	TRANK1	-0.32	-4.28	-0.33	3.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg00945038	chr17:61921165	SMARCD2	0.51	6.02	0.44	1.26e-8	Prudent dietary pattern;
PAAD	cis	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg11328875	chr14:50066018	PPIL5	0.56	4.67	0.35	6.46e-6	Subjective well-being;
PAAD	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg21366198	chr4:185655624	MLF1IP	0.5	4.49	0.34	1.42e-5	Kawasaki disease;
PAAD	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-4.28	-0.33	3.24e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2092319	0.649	rs807268	chr1:26066491	C/T	cg12446045	chr1:25857419	NA	-0.47	-4.31	-0.33	2.96e-5	Nose morphology;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg08835956	chr7:39171034	POU6F2	0.37	5.93	0.43	2.01e-8	IgG glycosylation;
PAAD	cis	rs13273891	1.000	rs7835676	chr8:58976148	G/T	cg05901852	chr8:59757290	TOX	-0.51	-4.87	-0.37	2.76e-6	Pit-and-Fissure caries;
PAAD	cis	rs117623576	0.715	rs11008755	chr10:32360053	C/T	cg03047570	chr10:32398778	NA	0.68	4.59	0.35	9.39e-6	Anti-saccade response;
PAAD	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.57	-0.35	9.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.51	-5.61	-0.41	9.27e-8	Migraine;
PAAD	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg20913747	chr6:44695427	NA	-0.66	-6.45	-0.46	1.38e-9	Total body bone mineral density;
PAAD	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.53	4.77	0.36	4.3e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg03983715	chr16:68378420	PRMT7	-0.73	-5.56	-0.41	1.18e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.27	-0.39	4.6e-7	Inflammatory bowel disease;
PAAD	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	8.17	0.55	1.12e-13	Menopause (age at onset);
PAAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.56	-0.41	1.18e-7	Ulcerative colitis;
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.69	-0.53	1.68e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.52	-5.22	-0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21826946	chr3:169755748	GPR160	0.59	6.57	0.47	7.37e-10	Monocyte percentage of white cells;
PAAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg19052272	chr2:3704530	ALLC	-0.57	-6.29	-0.45	3.24e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs899997	1.000	rs12907207	chr15:79031290	G/A	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13126279	chr21:47581558	C21orf56	-0.41	-4.66	-0.35	6.89e-6	Testicular germ cell tumor;
PAAD	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.76	6.9	0.49	1.29e-10	Asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22728323	chr8:37887713	EIF4EBP1	0.63	7.38	0.51	9.55e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.92	-7.91	-0.54	4.97e-13	Dupuytren's disease;
PAAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.45e-21	Height;
PAAD	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg20487152	chr13:99095054	FARP1	0.47	4.98	0.37	1.71e-6	Longevity;
PAAD	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.65	-0.35	7.06e-6	Aortic root size;
PAAD	cis	rs2790216	1.000	rs2790231	chr10:59989010	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.49	5.31	0.4	3.74e-7	Longevity;Endometriosis;
PAAD	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg01426195	chr3:39028469	NA	0.62	6.18	0.45	5.5e-9	Handedness;
PAAD	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.86	5.54	0.41	1.31e-7	Systolic blood pressure;
PAAD	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg14583973	chr4:3374767	RGS12	0.41	6.2	0.45	5.12e-9	Serum sulfate level;
PAAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.78	0.62	8.16e-18	Cognitive function;
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.62	-4.63	-0.35	7.81e-6	Thyroid stimulating hormone;
PAAD	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg08677398	chr8:58056175	NA	0.6	4.32	0.33	2.83e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16189954	chr22:29138267	HSCB;CHEK2	0.64	7.1	0.5	4.5e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs75920871	1.000	rs61905705	chr11:116883776	A/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs9616064	0.849	rs5768992	chr22:46983605	A/G	cg25730555	chr22:47059586	GRAMD4	-0.43	-4.34	-0.33	2.64e-5	Urate levels in obese individuals;
PAAD	cis	rs11958404	1.000	rs72816527	chr5:157409633	C/T	cg05962755	chr5:157440814	NA	1.03	8.15	0.55	1.25e-13	IgG glycosylation;
PAAD	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.89	-8.78	-0.58	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs17150703	0.722	rs586123	chr8:9786494	A/G	cg23209606	chr1:8515930	RERE	0.68	6.32	0.46	2.8e-9	Obesity (early onset extreme);
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7633770	0.664	rs34000414	chr3:46689958	G/A	cg11219411	chr3:46661640	NA	-0.51	-5.7	-0.42	5.96e-8	Coronary artery disease;
PAAD	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.97	8.24	0.56	7.23e-14	IgG glycosylation;
PAAD	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg23024343	chr7:107201750	COG5	0.56	4.63	0.35	7.74e-6	Coronary artery disease;
PAAD	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.71	-8.19	-0.55	1e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.59	-8.66	-0.57	6.53e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-4.59	-0.35	9.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs829661	0.793	rs829581	chr2:30678188	C/T	cg12454169	chr2:30669597	LCLAT1	0.67	4.51	0.34	1.28e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2562456	0.833	rs11671609	chr19:21525571	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg10374813	chr17:38183790	MED24;SNORD124	-0.42	-4.32	-0.33	2.84e-5	Myeloid white cell count;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01506766	chr13:46626746	ZC3H13	0.62	6.95	0.49	9.96e-11	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.51	-0.34	1.28e-5	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.92	9.66	0.62	1.65e-17	Nonalcoholic fatty liver disease;
PAAD	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.79	-6.83	-0.48	1.88e-10	Platelet distribution width;
PAAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg09796270	chr17:17721594	SREBF1	-0.49	-5.5	-0.41	1.59e-7	Total body bone mineral density;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg06268327	chr11:63885740	FLRT1;MACROD1	0.42	4.53	0.34	1.18e-5	Platelet count;
PAAD	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.48	5.22	0.39	5.65e-7	Pelvic organ prolapse;
PAAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	4.83	0.37	3.25e-6	Menarche (age at onset);
PAAD	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.81	-10.36	-0.64	2.37e-19	Morning vs. evening chronotype;
PAAD	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13582960	chr14:102771505	RAGE	-0.74	-6.63	-0.47	5.58e-10	Neuroticism;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13560548	chr3:10150139	C3orf24	0.54	4.86	0.37	2.92e-6	Alzheimer's disease;
PAAD	cis	rs11613048	0.862	rs1879424	chr12:30345839	G/T	cg03476860	chr12:30948794	NA	-0.35	-4.3	-0.33	3.04e-5	Major depressive disorder;
PAAD	cis	rs76866386	0.892	rs72875462	chr2:44079310	C/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.95	-5.51	-0.41	1.5e-7	Cholesterol, total;
PAAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.67	-5.17	-0.39	7.23e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10450586	0.897	rs10835160	chr11:27335588	G/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs12144049	0.595	rs11205007	chr1:152447733	G/T	cg25605289	chr1:151974222	NA	-0.35	-4.54	-0.35	1.14e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.89	-9.71	-0.62	1.24e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.57	5.36	0.4	2.98e-7	Type 2 diabetes;
PAAD	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg23387468	chr7:139079360	LUC7L2	0.37	4.55	0.35	1.07e-5	Diisocyanate-induced asthma;
PAAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	5.01	0.38	1.49e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.81	9.26	0.6	1.85e-16	Heart rate;
PAAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.86	0.43	2.77e-8	Bipolar disorder;
PAAD	cis	rs12282928	0.959	rs2007961	chr11:48273208	G/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.22	-0.45	4.61e-9	Migraine - clinic-based;
PAAD	cis	rs11671005	0.779	rs3794970	chr19:58986260	C/T	cg25952890	chr19:58913133	NA	-0.73	-5.84	-0.43	3.05e-8	Mean platelet volume;
PAAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.71	-0.66	2.64e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.63	5.7	0.42	5.92e-8	Coronary artery disease;
PAAD	cis	rs9463078	0.546	rs6458418	chr6:45014997	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.5	-0.34	1.33e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00810752	chr4:113277063	ALPK1	-0.65	-6.51	-0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg01759136	chr6:27242945	NA	0.42	4.52	0.34	1.23e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.49	5.74	0.42	5.07e-8	Electroencephalogram traits;
PAAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.01	0.7	8.62e-24	Menopause (age at onset);
PAAD	cis	rs8099014	0.834	rs4940699	chr18:56109007	A/C	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.83	7.87	0.54	6.17e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.72	-0.58	4.5e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06850241	chr22:41845214	NA	-0.6	-5.23	-0.39	5.53e-7	Vitiligo;
PAAD	cis	rs17221829	0.965	rs10830355	chr11:89443429	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-4.27	-0.33	3.41e-5	Anxiety in major depressive disorder;
PAAD	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg08992911	chr2:238395768	MLPH	0.74	5.68	0.42	6.62e-8	Prostate cancer;
PAAD	cis	rs397969	0.596	rs12450857	chr17:19895248	C/T	cg04132472	chr17:19861366	AKAP10	0.43	4.34	0.33	2.62e-5	Platelet count;
PAAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg17372223	chr3:52568218	NT5DC2	0.58	5.96	0.44	1.72e-8	Bipolar disorder;
PAAD	cis	rs7101378	0.538	rs1509710	chr11:108900583	G/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.21	-0.51	2.39e-11	Total body bone mineral density;
PAAD	cis	rs863345	0.604	rs12122663	chr1:158506724	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.64	-5.36	-0.4	3.06e-7	Diastolic blood pressure;
PAAD	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg18279126	chr7:2041391	MAD1L1	0.55	5.56	0.41	1.2e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs859767	0.741	rs6430529	chr2:135433023	G/T	cg12500956	chr2:135428796	TMEM163	-0.31	-4.35	-0.33	2.46e-5	Neuroticism;
PAAD	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.87	7.33	0.51	1.29e-11	Alzheimer's disease;
PAAD	cis	rs16975963	0.644	rs73031309	chr19:38031984	C/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.83	-7.15	-0.5	3.41e-11	Systemic lupus erythematosus;
PAAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.33	-0.46	2.68e-9	Schizophrenia;
PAAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.47	-4.88	-0.37	2.63e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs6694672	1.000	rs1332663	chr1:197109042	C/T	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.6	5.45	0.4	1.98e-7	Blood protein levels;
PAAD	cis	rs6137287	0.924	rs6047280	chr20:21143935	G/T	cg04219410	chr20:21106687	PLK1S1	0.41	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg06636001	chr8:8085503	FLJ10661	0.64	6.51	0.47	1.01e-9	Retinal vascular caliber;
PAAD	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg14345882	chr6:26364793	BTN3A2	0.57	4.52	0.34	1.21e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.36	-0.33	2.35e-5	Height;
PAAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.51	5.1	0.38	9.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	6.88	0.49	1.44e-10	Menopause (age at onset);
PAAD	cis	rs11807834	0.522	rs10864691	chr1:230240450	T/A	cg00566187	chr1:230250356	GALNT2	-0.64	-6.81	-0.48	2.16e-10	Schizophrenia;
PAAD	cis	rs6449957	1.000	rs6449957	chr5:67483732	T/C	cg23036683	chr5:67512108	NA	0.53	5.21	0.39	5.99e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs4148087	0.725	rs1378577	chr21:43619665	T/G	cg08841829	chr21:43638893	ABCG1	-0.54	-4.9	-0.37	2.48e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg19486271	chr11:47235900	DDB2	0.55	5.74	0.42	5.08e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6460942	0.908	rs6979124	chr7:12232551	G/T	cg06484146	chr7:12443880	VWDE	-0.79	-5.11	-0.38	9.51e-7	Coronary artery disease;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.87e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27352063	chr10:81107211	PPIF	0.49	4.53	0.34	1.21e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.76	5.34	0.4	3.38e-7	Phospholipid levels (plasma);
PAAD	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg13482628	chr17:19912719	NA	-0.51	-5.14	-0.38	8.49e-7	Obesity-related traits;
PAAD	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg16306870	chr3:194868790	C3orf21	0.42	4.34	0.33	2.56e-5	Non-small cell lung cancer;
PAAD	cis	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.69	-0.36	6.01e-6	Height;
PAAD	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.66	0.42	7.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.51	4.97	0.37	1.81e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs4234284	1.000	rs10934808	chr3:126979806	G/A	cg27326032	chr3:127006922	NA	-0.5	-5.03	-0.38	1.34e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.21e-6	Airway imaging phenotypes;
PAAD	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg23788917	chr6:8435910	SLC35B3	-0.59	-6.22	-0.45	4.51e-9	Motion sickness;
PAAD	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.29	-0.33	3.1e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-5.87	-0.43	2.64e-8	Bipolar disorder;
PAAD	cis	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73198843	chr3:128502514	G/A	cg15676455	chr3:128564943	NA	-0.76	-5.09	-0.38	1.02e-6	Dental caries;
PAAD	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.39	-4.28	-0.33	3.35e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3736485	0.966	rs2414114	chr15:51905781	T/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.71e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27511599	chr7:32358540	NA	0.76	4.53	0.34	1.21e-5	Body mass index;
PAAD	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.84	5.71	0.42	5.67e-8	Thyroid stimulating hormone;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02639808	chr4:77997188	CCNI	0.67	6.59	0.47	6.66e-10	Obesity-related traits;
PAAD	cis	rs13242816	1.000	rs7801950	chr7:116154783	C/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.91	-8.41	-0.56	2.8e-14	Migraine;
PAAD	cis	rs753628	1.000	rs753628	chr3:194559473	C/T	cg25871427	chr3:194836482	C3orf21	0.46	4.37	0.33	2.27e-5	Blood osmolality (transformed sodium);
PAAD	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.58	-6.23	-0.45	4.45e-9	Lung cancer;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg11601000	chr22:42348013	LOC339674	-0.48	-5.76	-0.42	4.61e-8	Intelligence;
PAAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.68	0.69	6.57e-23	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs1075265	0.633	rs3731967	chr2:54202448	A/T	cg04546899	chr2:54196757	PSME4	-0.32	-4.81	-0.36	3.61e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg14926445	chr8:58193284	C8orf71	-0.78	-6.13	-0.44	7.37e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg25008857	chr14:105974488	NA	0.39	4.28	0.33	3.23e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-9.72	-0.62	1.17e-17	Total body bone mineral density;
PAAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.61	7.0	0.49	7.81e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6066835	1.000	rs6125448	chr20:47353178	G/A	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	trans	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.42	0.46	1.62e-9	Calcium levels;
PAAD	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg10011062	chr15:43941034	CATSPER2	0.78	4.43	0.34	1.8e-5	Lung cancer in ever smokers;
PAAD	cis	rs2820914	0.668	rs11794514	chr9:7165934	G/A	cg13985597	chr9:6704574	NA	0.62	4.29	0.33	3.22e-5	Obesity-related traits;
PAAD	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06661988	chr16:1659592	IFT140	0.59	6.34	0.46	2.47e-9	Myopia (pathological);
PAAD	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg23682824	chr7:23144976	KLHL7	0.46	4.26	0.33	3.6e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg21855830	chr2:127963489	CYP27C1	0.46	4.49	0.34	1.38e-5	Protein C levels;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.86	-7.71	-0.53	1.54e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.19	0.39	6.74e-7	Obesity-related traits;
PAAD	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.65	-6.31	-0.46	2.85e-9	Morning vs. evening chronotype;
PAAD	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.38	-0.34	2.16e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs75920871	0.920	rs11216178	chr11:116766390	G/T	cg04087571	chr11:116723030	SIK3	-0.45	-4.6	-0.35	8.92e-6	Subjective well-being;
PAAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	6.93	0.49	1.15e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.95	7.55	0.52	3.73e-12	Vitiligo;
PAAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.47	5.85	0.43	2.9e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs13053817	0.948	rs67613029	chr22:29836569	T/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.58	-5.2	-0.39	6.29e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.19	-14.76	-0.77	3.77e-31	Ulcerative colitis;
PAAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.54	5.92	0.43	2.09e-8	Major depressive disorder;
PAAD	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-4.73	-0.36	5.12e-6	Height;
PAAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.25	4.5	0.34	1.33e-5	IgG glycosylation;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11141652	chr22:24348549	GSTTP1	0.51	4.92	0.37	2.26e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.26	6.97	0.49	8.9e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.33	0.68	5.94e-22	Menopause (age at onset);
PAAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.71	-6.81	-0.48	2.11e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg17848003	chr1:3704513	LRRC47	0.4	4.32	0.33	2.84e-5	Red cell distribution width;
PAAD	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	4.79	0.36	3.98e-6	Breast cancer;
PAAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.92	9.17	0.6	3.19e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg20487152	chr13:99095054	FARP1	0.47	4.98	0.37	1.71e-6	Longevity;
PAAD	cis	rs597480	0.864	rs10898410	chr11:85509806	A/G	cg11817631	chr11:85522609	SYTL2	0.45	4.48	0.34	1.46e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.59	-6.9	-0.49	1.3100000000000001e-10	Carotid intima media thickness;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	6.09	0.44	8.73e-9	Height;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.63	-6.82	-0.48	2.03e-10	Longevity;Endometriosis;
PAAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.63	-6.33	-0.46	2.62e-9	Ear protrusion;
PAAD	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg23231163	chr10:75533350	FUT11	-0.42	-5.18	-0.39	6.82e-7	Inflammatory bowel disease;
PAAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs6700896	0.500	rs11208707	chr1:66139513	C/T	cg04111102	chr1:66153794	NA	0.48	4.5	0.34	1.37e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.92	11.77	0.69	3.81e-23	Menarche (age at onset);
PAAD	cis	rs4148087	0.860	rs4148102	chr21:43641347	A/G	cg08841829	chr21:43638893	ABCG1	0.72	4.94	0.37	2e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg06217071	chr17:408420	NA	0.46	4.77	0.36	4.29e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	10.81	0.66	1.43e-20	Cognitive test performance;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.54	-0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35160687	0.623	rs35408390	chr2:86471782	C/T	cg10973622	chr2:86423274	IMMT	-0.5	-5.7	-0.42	5.95e-8	Night sleep phenotypes;
PAAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.86	8.58	0.57	1.04e-14	Cognitive function;
PAAD	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.33e-5	Coronary artery disease;
PAAD	cis	rs367943	0.665	rs10061922	chr5:112969775	G/T	cg12552261	chr5:112820674	MCC	0.5	4.96	0.37	1.86e-6	Type 2 diabetes;
PAAD	cis	rs9936833	0.963	rs9940614	chr16:86402846	A/G	cg03554962	chr16:86404423	NA	0.37	4.34	0.33	2.56e-5	Barrett's esophagus;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg24530489	chr15:56299380	NA	-0.92	-4.39	-0.34	2.07e-5	Delta-5 desaturase activity;
PAAD	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.54	4.99	0.37	1.66e-6	Resting heart rate;
PAAD	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	6.85	0.49	1.71e-10	Hip circumference;
PAAD	cis	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.29	-0.39	4.22e-7	Glomerular filtration rate;
PAAD	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg25070565	chr17:20044324	CYTSB	-0.46	-4.46	-0.34	1.57e-5	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20404643	chr11:1492543	HCCA2	0.57	6.35	0.46	2.31e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.55	-7.12	-0.5	4.06e-11	Height;
PAAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg24053715	chr22:38214548	NA	0.66	6.31	0.46	2.89e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-0.65	-6.89	-0.49	1.42e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4478858	0.684	rs17440445	chr1:31722562	C/T	cg00250761	chr1:31883323	NA	0.53	5.92	0.43	2.09e-8	Alcohol dependence;
PAAD	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-5.76	-0.42	4.6e-8	Fear of minor pain;
PAAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	0.97	6.29	0.45	3.28e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.42	6.26	0.45	3.79e-9	Information processing speed;
PAAD	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg14583973	chr4:3374767	RGS12	0.32	4.56	0.35	1.03e-5	Mean platelet volume;
PAAD	cis	rs6074578	0.679	rs2298109	chr20:138148	C/T	cg16931068	chr20:139680	DEFB127	0.37	5.0	0.38	1.56e-6	Hirschsprung disease;
PAAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.53	4.96	0.37	1.85e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs73416724	1.000	rs1214762	chr6:43355151	C/T	cg17076780	chr6:43251928	TTBK1	-0.58	-4.66	-0.35	6.99e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.68	-8.62	-0.57	8.34e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.58	-0.35	9.8e-6	Rheumatoid arthritis;
PAAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.53	5.2	0.39	6.22e-7	Multiple sclerosis;
PAAD	cis	rs9361491	0.608	rs4706723	chr6:79462736	C/G	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg08648136	chr8:956695	NA	0.48	5.11	0.38	9.7e-7	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25043538	chr11:63887437	MACROD1	-0.65	-6.35	-0.46	2.39e-9	Obesity-related traits;
PAAD	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.33	-0.56	4.52e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-1.06	-19.0	-0.84	5.4e-42	Urate levels in lean individuals;
PAAD	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg00083937	chr22:51039805	MAPK8IP2	0.47	4.41	0.34	1.93e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22290704	chr6:144167951	LTV1	0.6	6.29	0.45	3.14e-9	Smoking initiation;
PAAD	cis	rs2415984	0.540	rs1494095	chr14:46960671	T/C	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	10.31	0.64	3.23e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24503407	chr1:205819492	PM20D1	0.89	11.38	0.68	4.3e-22	Menarche (age at onset);
PAAD	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.6	6.21	0.45	4.81e-9	Crohn's disease;
PAAD	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg20295408	chr7:1910781	MAD1L1	0.62	5.98	0.44	1.54e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.87	-11.57	-0.68	1.33e-22	Height;
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg14440974	chr22:39074834	NA	0.56	6.32	0.46	2.76e-9	Menopause (age at onset);
PAAD	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg18093559	chr17:18951025	GRAP	0.47	4.96	0.37	1.83e-6	Schizophrenia;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg08493265	chr3:195539297	MUC4	0.53	4.26	0.33	3.59e-5	Lung disease severity in cystic fibrosis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00624375	chr12:110841656	ANAPC7	0.7	6.69	0.48	3.99e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.67	5.24	0.39	5.34e-7	Mosquito bite size;
PAAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg27542038	chr10:14027202	FRMD4A	0.43	4.52	0.34	1.25e-5	Adiponectin levels;
PAAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs4786125	0.626	rs6500859	chr16:6914358	A/T	cg03623568	chr16:6915990	A2BP1	-0.48	-4.78	-0.36	4.03e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg21546286	chr11:48923668	NA	-0.55	-5.68	-0.42	6.74e-8	HDL cholesterol;
PAAD	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg10090792	chr1:38198142	EPHA10	-0.41	-4.43	-0.34	1.81e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-5.08	-0.38	1.09e-6	Vitiligo;
PAAD	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	5.9	0.43	2.24e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10901513	0.896	rs2138277	chr10:127672039	G/T	cg22975853	chr10:127789788	ADAM12	-0.42	-4.44	-0.34	1.71e-5	Visceral fat;
PAAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.79	12.52	0.71	3.74e-25	Schizophrenia;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.58	5.92	0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7165102	0.770	rs635728	chr15:65789389	G/A	cg22900193	chr15:65823441	PTPLAD1	-0.47	-4.51	-0.34	1.29e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs4867766	0.871	rs2242419	chr5:173959332	C/T	cg20434911	chr5:173954559	NA	0.63	6.35	0.46	2.42e-9	Stroke;
PAAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.56	6.4	0.46	1.86e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs9913156	0.708	rs9915105	chr17:4568742	G/C	cg23387401	chr17:4582204	PELP1	-0.49	-4.95	-0.37	1.95e-6	Lymphocyte counts;
PAAD	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.03	6.73	0.48	3.18e-10	Body mass index;
PAAD	cis	rs138918	1.000	rs3937387	chr22:43555194	C/G	cg00343092	chr22:43547974	TSPO	-0.49	-5.83	-0.43	3.21e-8	Monocyte count;
PAAD	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.77e-5	Life satisfaction;
PAAD	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.23e-5	Testicular germ cell tumor;
PAAD	cis	rs507080	0.501	rs516503	chr11:118580348	C/T	cg08498647	chr11:118550644	TREH	-0.43	-5.37	-0.4	2.89e-7	Serum metabolite levels;
PAAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg10589385	chr1:150898437	SETDB1	-0.38	-4.63	-0.35	7.68e-6	Tonsillectomy;
PAAD	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.81e-7	White blood cell count;
PAAD	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.73	4.58	0.35	9.49e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.04	0.55	2.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.43	-6.65	-0.47	4.89e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg00976097	chr5:421733	AHRR	-0.49	-4.69	-0.36	6.12e-6	Cystic fibrosis severity;
PAAD	cis	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg23649088	chr2:200775458	C2orf69	-0.62	-4.68	-0.35	6.4e-6	Schizophrenia;
PAAD	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg20607287	chr7:12443886	VWDE	-0.6	-4.84	-0.37	3.17e-6	Coronary artery disease;
PAAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.27e-15	Emphysema distribution in smoking;
PAAD	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg09659197	chr4:152720779	NA	-0.37	-5.35	-0.4	3.18e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg08390786	chr10:135334061	NA	0.63	5.49	0.41	1.66e-7	Gout;
PAAD	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.25	-0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg05082376	chr22:42548792	NA	-0.53	-5.76	-0.42	4.52e-8	Cognitive function;
PAAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Depression;
PAAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.46	-4.87	-0.37	2.83e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs72828912	0.614	rs62400276	chr6:24040373	G/A	cg10859177	chr4:189973211	NA	0.74	6.87	0.49	1.51e-10	Squamous cell lung carcinoma;
PAAD	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg06131755	chr6:160182447	ACAT2	0.51	4.48	0.34	1.48e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17467752	chr17:38218738	THRA	0.7	6.81	0.48	2.17e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02767759	chr16:30366751	CD2BP2	0.68	8.04	0.55	2.31e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.82	-7.09	-0.5	4.62e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg22863700	chr5:28928346	NA	0.56	5.45	0.4	1.99e-7	Hip geometry;
PAAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.7	-7.61	-0.53	2.62e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.52	-5.35	-0.4	3.15e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.68	7.13	0.5	3.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.6e-5	Life satisfaction;
PAAD	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	-0.45	-4.26	-0.33	3.58e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-1.12	-7.97	-0.54	3.51e-13	Mitochondrial DNA levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10318621	chr3:44636619	ZNF660	0.59	6.64	0.47	5.29e-10	Smoking initiation;
PAAD	cis	rs11203032	0.831	rs11203022	chr10:90954068	G/A	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3736485	0.934	rs2899476	chr15:51903874	C/T	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.51e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg05082376	chr22:42548792	NA	0.4	4.27	0.33	3.4e-5	Intelligence;
PAAD	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.42	-4.36	-0.33	2.35e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs11992162	0.636	rs35995176	chr8:11809647	G/C	cg12395012	chr8:11607386	GATA4	0.41	4.35	0.33	2.5e-5	Monocyte count;
PAAD	cis	rs2814331	0.662	rs2814334	chr10:88001169	C/G	cg08962038	chr10:88022859	GRID1	-0.58	-4.51	-0.34	1.31e-5	Balding;
PAAD	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg21496419	chr19:44306685	LYPD5	-0.37	-4.62	-0.35	8e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.76	-0.48	2.75e-10	Coronary artery disease;
PAAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.34	0.4	3.3e-7	Rheumatoid arthritis;
PAAD	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.63	-6.06	-0.44	1.05e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg06569542	chr10:98946673	SLIT1	0.5	5.59	0.41	1.05e-7	Monocyte count;
PAAD	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.7	7.53	0.52	4.11e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.59	0.47	6.65e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg04257695	chr17:30186438	C17orf79	-0.57	-4.58	-0.35	9.6e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7017697	0.507	rs10113140	chr8:19684745	A/C	cg03894339	chr8:19674705	INTS10	-0.58	-4.48	-0.34	1.45e-5	Breast cancer;
PAAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.73	7.52	0.52	4.54e-12	Schizophrenia;
PAAD	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs17152411	0.652	rs2114834	chr10:126650186	A/G	cg04726013	chr10:126223236	LHPP	-0.3	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03923535	chr7:1197113	ZFAND2A	0.44	4.62	0.35	7.97e-6	Longevity;Endometriosis;
PAAD	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.15	0.5	3.39e-11	Eye color traits;
PAAD	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg14458575	chr2:238380390	NA	0.85	7.79	0.53	9.65e-13	Prostate cancer;
PAAD	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.89	11.24	0.67	1.05e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9646944	0.501	rs11465736	chr2:103067930	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs17152411	0.625	rs10901838	chr10:126623542	A/C	cg07081759	chr10:126330905	FAM53B	-0.4	-4.34	-0.33	2.58e-5	Height;
PAAD	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg10395934	chr14:104002654	TRMT61A	0.58	5.97	0.44	1.57e-8	Body mass index;
PAAD	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg07741184	chr6:167504864	NA	0.34	4.34	0.33	2.61e-5	Primary biliary cholangitis;
PAAD	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.94	13.19	0.73	5.9e-27	Intelligence (multi-trait analysis);
PAAD	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09065629	chr16:1709722	CRAMP1L	0.44	4.57	0.35	1.01e-5	Coronary artery disease;
PAAD	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg26898376	chr11:64110657	CCDC88B	0.44	4.7	0.36	5.68e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-1.05	-14.69	-0.77	5.67e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4073221	0.789	rs4688901	chr3:18219037	G/A	cg07694806	chr3:18168406	NA	-0.83	-4.97	-0.37	1.79e-6	Parkinson's disease;
PAAD	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.63	6.24	0.45	4.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg00786201	chr11:61583134	MIR1908;FADS1	0.49	4.83	0.36	3.31e-6	Trans fatty acid levels;
PAAD	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.69	-5.15	-0.39	8.12e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.57	4.98	0.37	1.7e-6	Serum parathyroid hormone levels;
PAAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.83	6.81	0.48	2.17e-10	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.71	-5.88	-0.43	2.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.98	6.7	0.48	3.76e-10	IgG glycosylation;
PAAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-6.96	-0.49	9.37e-11	Gut microbiome composition (summer);
PAAD	cis	rs116248771	0.739	rs73156488	chr3:158413942	C/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.51	-7.1	-0.5	4.42e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg15181151	chr6:150070149	PCMT1	0.59	6.38	0.46	2.01e-9	Lung cancer;
PAAD	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg01851573	chr8:8652454	MFHAS1	-0.45	-4.64	-0.35	7.31e-6	Neuroticism;
PAAD	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.45	-4.7	-0.36	5.69e-6	Dementia with Lewy bodies;
PAAD	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.39	4.59	0.35	9.35e-6	Intraocular pressure;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.58	4.62	0.35	8.1e-6	Alzheimer's disease;
PAAD	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs4986172	0.840	rs8067974	chr17:43232566	A/G	cg10701640	chr17:43249399	NA	0.43	5.54	0.41	1.29e-7	Height;
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg00106254	chr7:1943704	MAD1L1	0.53	5.15	0.39	7.86e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg05373962	chr22:49881684	NA	-0.5	-4.92	-0.37	2.22e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg23024343	chr7:107201750	COG5	0.57	4.67	0.35	6.67e-6	Coronary artery disease;
PAAD	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15744963	chr15:28520567	HERC2	0.6	7.22	0.51	2.27e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.13	10.13	0.63	9.66e-19	Cognitive test performance;
PAAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.81	-7.13	-0.5	3.86e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2017305	0.915	rs79841168	chr10:70778498	T/C	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs939584	1.000	rs7585056	chr2:631528	A/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.51	-5.29	-0.39	4.19e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.88	-7.23	-0.51	2.19e-11	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.79	5.83	0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9815354	0.857	rs6796078	chr3:42017820	A/T	cg03022575	chr3:42003672	ULK4	-0.72	-5.22	-0.39	5.67e-7	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg08975724	chr8:8085496	FLJ10661	-0.7	-7.35	-0.51	1.13e-11	Neuroticism;
PAAD	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.55	-5.39	-0.4	2.66e-7	Eosinophil percentage of white cells;
PAAD	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.75	-5.26	-0.39	4.74e-7	Carotid intima media thickness;
PAAD	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6494488	0.500	rs72744723	chr15:65020727	C/A	cg16425858	chr15:64791681	ZNF609	0.97	4.55	0.35	1.08e-5	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg09366796	chr5:75012313	C5orf37	0.49	4.45	0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17371170	chr6:168570358	NA	-0.65	-6.63	-0.47	5.48e-10	Obesity-related traits;
PAAD	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg02135003	chr7:105160482	PUS7	-0.92	-6.7	-0.48	3.84e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2882667	0.654	rs7709770	chr5:138149339	A/G	cg09476006	chr5:138032270	NA	-0.47	-6.04	-0.44	1.11e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg04165759	chr1:150448943	RPRD2	0.51	5.21	0.39	5.99e-7	Migraine;
PAAD	cis	rs12940923	0.529	rs2240261	chr17:56381389	C/T	cg26072851	chr17:56296444	MKS1	0.57	4.76	0.36	4.41e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs11811982	0.744	rs73102394	chr1:227576152	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.13	0.38	8.71e-7	Optic disc area;
PAAD	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs794728	0.522	rs1863957	chr5:173859366	G/A	cg20434911	chr5:173954559	NA	-0.46	-4.26	-0.33	3.51e-5	Depressive symptoms (SSRI exposure interaction);
PAAD	cis	rs4356203	0.905	rs214936	chr11:17191019	A/G	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs6733011	0.644	rs6542839	chr2:99464530	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	5.14	0.38	8.28e-7	Bipolar disorder;
PAAD	cis	rs6009527	1.000	rs737834	chr22:49573190	C/T	cg12746016	chr22:49560550	NA	0.47	4.75	0.36	4.73e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	5.43	0.4	2.14e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.78	-8.3	-0.56	5.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.59	7.4	0.51	8.44e-12	Crohn's disease;
PAAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg16083429	chr3:49237500	CCDC36	-0.4	-4.45	-0.34	1.66e-5	Menarche (age at onset);
PAAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.02	0.59	7.75e-16	Parkinson's disease;
PAAD	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg06728252	chr6:26598149	ABT1	-0.38	-4.54	-0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.98	12.92	0.72	3.08e-26	Menarche (age at onset);
PAAD	cis	rs17095355	0.584	rs12243027	chr10:111924817	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-4.87	-0.37	2.74e-6	Biliary atresia;
PAAD	cis	rs35079454	1	rs35079454	chr1:85780863	AG/A	cg16011679	chr1:85725395	C1orf52	0.53	5.01	0.38	1.52e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.77	5.63	0.42	8.64e-8	Vitiligo;
PAAD	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.93	7.88	0.54	5.98e-13	Alzheimer's disease;
PAAD	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.89	-5.95	-0.43	1.78e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs375066	0.935	rs425217	chr19:44393975	C/T	cg21496419	chr19:44306685	LYPD5	0.44	5.27	0.39	4.69e-7	Breast cancer;
PAAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.62	5.94	0.43	1.9e-8	Monocyte count;
PAAD	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.75	8.74	0.58	4.07e-15	Colorectal cancer;
PAAD	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	5.95	0.43	1.78e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs722599	0.501	rs10139347	chr14:75390135	T/C	cg08847533	chr14:75593920	NEK9	0.59	6.04	0.44	1.14e-8	IgG glycosylation;
PAAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.43	6.61	0.47	6e-10	Height;
PAAD	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.51	6.38	0.46	2.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg04415270	chr2:102091202	RFX8	-0.58	-7.57	-0.52	3.39e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.43	4.4	0.34	2.03e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg14843632	chr5:14870594	ANKH	-0.38	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg13859433	chr6:33739653	LEMD2	-0.65	-5.09	-0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-5.79	-0.43	3.93e-8	Asthma (bronchodilator response);
PAAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs901683	1.000	rs78220003	chr10:45988348	A/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg17524180	chr13:113633600	MCF2L	-0.49	-5.14	-0.38	8.27e-7	Systolic blood pressure;
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.16	-0.39	7.44e-7	Mood instability;
PAAD	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg04398451	chr17:18023971	MYO15A	0.53	4.91	0.37	2.31e-6	Lymphocyte counts;
PAAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.6	-6.4	-0.46	1.81e-9	Cognitive function;
PAAD	cis	rs6473252	0.544	rs10957987	chr8:81819762	A/C	cg08595989	chr8:81827712	NA	-0.34	-4.75	-0.36	4.73e-6	Breast cancer;
PAAD	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg22162314	chr17:61951766	CSH2	0.6	4.96	0.37	1.87e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg09127314	chr1:152161683	NA	-0.68	-4.49	-0.34	1.39e-5	Atopic dermatitis;
PAAD	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.51	-4.79	-0.36	3.88e-6	Response to temozolomide;
PAAD	cis	rs757081	0.648	rs214907	chr11:17244779	G/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.54	-0.41	1.31e-7	Systolic blood pressure;
PAAD	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg15841412	chr13:111365552	ING1	0.52	4.32	0.33	2.83e-5	Coronary artery disease;
PAAD	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.97	11.58	0.68	1.22e-22	Breast cancer;
PAAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.93	-7.35	-0.51	1.12e-11	Initial pursuit acceleration;
PAAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.68	7.46	0.52	6.1e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg25753631	chr6:25732923	NA	-0.49	-4.44	-0.34	1.71e-5	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20367479	chr3:171873675	FNDC3B	-0.69	-7.26	-0.51	1.89e-11	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg02631450	chr22:32366979	NA	1.03	5.61	0.41	9.46e-8	Childhood ear infection;
PAAD	cis	rs16958440	1.000	rs16958432	chr18:44631773	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.41	-0.34	1.98e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg21171335	chr12:122356390	WDR66	-0.5	-4.96	-0.37	1.83e-6	Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.89	11.54	0.68	1.56e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.94	9.87	0.62	4.71e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs116248771	0.691	rs2363658	chr3:158395866	G/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.84	-0.43	3.11e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12893428	chr3:195717962	SDHAP1	0.47	4.96	0.37	1.88e-6	Pancreatic cancer;
PAAD	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.53	-5.14	-0.38	8.47e-7	Mean platelet volume;
PAAD	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	8.86	0.58	1.94e-15	Bipolar disorder;
PAAD	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.13e-10	Testicular germ cell tumor;
PAAD	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7765175	0.598	rs1388219	chr6:113620699	C/T	cg19037598	chr6:113666021	NA	-0.41	-4.46	-0.34	1.61e-5	Coronary artery calcification;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27018013	chr16:2524149	TBC1D24	0.62	7.23	0.51	2.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11141652	chr22:24348549	GSTTP1	0.49	4.46	0.34	1.6e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.38e-5	Longevity (90 years and older);
PAAD	cis	rs72681920	0.881	rs12499710	chr4:100120992	A/T	cg12011299	chr4:100065546	ADH4	-0.8	-4.58	-0.35	9.67e-6	Alcohol dependence;
PAAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.61	6.77	0.48	2.66e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.71	-7.7	-0.53	1.65e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-4.78	-0.36	4.06e-6	Dilated cardiomyopathy;
PAAD	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	0.82	6.37	0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.55	6.29	0.45	3.27e-9	Mean corpuscular volume;
PAAD	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg00277334	chr10:82204260	NA	0.47	5.07	0.38	1.15e-6	Sarcoidosis;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	11.75	0.69	4.3e-23	Platelet count;
PAAD	cis	rs6893807	0.778	rs35991856	chr5:87968347	C/A	cg02225085	chr5:87975992	LOC645323	-0.69	-5.15	-0.39	8.03e-7	Body mass index;
PAAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.98	6.63	0.47	5.65e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs89107	1.000	rs9489327	chr6:118561889	T/C	cg18833306	chr6:118973337	C6orf204	0.48	5.3	0.39	4.03e-7	Cardiac structure and function;
PAAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.71	-7.3	-0.51	1.54e-11	Menopause (age at onset);
PAAD	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg01329690	chr21:38580129	DSCR9	-0.34	-4.54	-0.35	1.14e-5	Eye color traits;
PAAD	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.51	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg12700464	chr11:78128424	GAB2	-0.61	-4.58	-0.35	9.64e-6	Alzheimer's disease (survival time);
PAAD	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.6	5.56	0.41	1.2e-7	Refractive astigmatism;
PAAD	cis	rs7731390	0.614	rs3792884	chr5:131651261	C/T	cg07395648	chr5:131743802	NA	0.7	4.47	0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs2030114	1.000	rs7197626	chr16:51610785	A/T	cg03758633	chr16:51611768	NA	-0.58	-4.89	-0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10368981	chr8:26435313	DPYSL2	0.65	7.79	0.53	9.75e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72627123	1.000	rs45559033	chr14:74341124	G/A	cg19860245	chr14:74300557	NA	-0.74	-5.22	-0.39	5.89e-7	Morning vs. evening chronotype;
PAAD	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs12431939	1.000	rs11848143	chr14:51651560	T/A	cg23942311	chr14:51606299	NA	-0.72	-5.79	-0.43	3.89e-8	Cancer;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg02869306	chr7:64672164	INTS4L1	0.41	4.81	0.36	3.59e-6	Calcium levels;
PAAD	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.83	-10.51	-0.65	9e-20	Height;
PAAD	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.89	9.98	0.63	2.35e-18	Breast cancer;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg18209359	chr17:80159595	CCDC57	-0.49	-4.91	-0.37	2.28e-6	Life satisfaction;
PAAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg25566285	chr7:158114605	PTPRN2	0.83	8.76	0.58	3.6e-15	Calcium levels;
PAAD	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.44	-4.95	-0.37	1.91e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg09399716	chr2:46890238	NA	-0.5	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg11941060	chr3:133502564	NA	0.5	5.27	0.39	4.68e-7	Iron status biomarkers;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg10150615	chr22:24372951	LOC391322	-0.5	-4.55	-0.35	1.09e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.86	9.97	0.63	2.54e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg09376583	chr16:88111425	NA	-0.5	-4.38	-0.33	2.19e-5	Menopause (age at onset);
PAAD	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-9.7	-0.62	1.31e-17	Electrocardiographic conduction measures;
PAAD	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.87	-0.37	2.82e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg20578329	chr17:80767326	TBCD	-0.87	-5.57	-0.41	1.15e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.34	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.58	7.87	0.54	6.33e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4750440	0.706	rs1031753	chr10:14020110	T/C	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	1.99e-5	Adiponectin levels;
PAAD	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.9	5.68	0.42	6.7e-8	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.11	-0.5	4.12e-11	Life satisfaction;
PAAD	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.66	6.83	0.48	1.87e-10	Systemic lupus erythematosus;
PAAD	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.97	13.37	0.74	1.89e-27	Dental caries;
PAAD	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7246865	0.510	rs7254154	chr19:17178119	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.58	5.86	0.43	2.82e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01829450	chr3:135914745	MSL2	0.6	6.29	0.45	3.27e-9	Myopia (pathological);
PAAD	cis	rs10992471	0.580	rs10122383	chr9:95554675	A/G	cg14631576	chr9:95140430	CENPP	-0.51	-4.39	-0.34	2.15e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg12623918	chr2:306882	NA	0.46	4.81	0.36	3.58e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-8.67	-0.58	6.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.55	-5.1	-0.38	9.99e-7	Mean corpuscular volume;
PAAD	trans	rs901683	1.000	rs34309840	chr10:46039361	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.6	-6.29	-0.45	3.13e-9	Monocyte count;
PAAD	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg02770688	chr6:168491649	NA	0.47	4.82	0.36	3.45e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg23093090	chr10:104574429	C10orf26	-0.47	-5.74	-0.42	4.92e-8	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.84	8.39	0.56	3.14e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.86	8.56	0.57	1.18e-14	Response to hepatitis C treatment;
PAAD	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg02631450	chr22:32366979	NA	1.13	5.8	0.43	3.79e-8	Childhood ear infection;
PAAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs62236223	1	rs62236223	chr22:31863554	T/C	cg01338084	chr22:32026380	PISD	1.41	7.33	0.51	1.29e-11	Age-related hearing impairment;
PAAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg24130564	chr14:104152367	KLC1	-0.47	-4.6	-0.35	8.67e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.17	0.39	7.41e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg10589385	chr1:150898437	SETDB1	0.39	4.76	0.36	4.48e-6	Melanoma;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11225247	chr11:86086489	CCDC81	0.62	6.65	0.47	4.94e-10	Smoking initiation;
PAAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs12612619	0.732	rs11688708	chr2:27199608	T/G	cg00617064	chr2:27272375	NA	-0.45	-4.8	-0.36	3.78e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.54	4.56	0.35	1.07e-5	RR interval (heart rate);
PAAD	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-10.78	-0.66	1.74e-20	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12159575	chr19:4910274	UHRF1	0.67	7.69	0.53	1.73e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24663984	chr11:118230199	UBE4A	0.76	8.71	0.58	4.67e-15	Myopia (pathological);
PAAD	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2340727	0.668	rs7518743	chr1:161783307	C/T	cg25597117	chr1:161349116	NA	-0.61	-4.37	-0.33	2.28e-5	White blood cell count;Hematology traits;
PAAD	cis	rs3771514	0.543	rs3771515	chr2:70695562	C/T	cg18150120	chr2:71134936	VAX2	-0.38	-4.55	-0.35	1.09e-5	Obesity-related traits;
PAAD	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.61	-6.46	-0.46	1.33e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27573389	chr10:61618041	CCDC6	-0.65	-6.67	-0.48	4.42e-10	Obesity-related traits;
PAAD	cis	rs7577696	0.924	rs7370704	chr2:32257717	A/G	cg02381751	chr2:32503542	YIPF4	-0.46	-4.83	-0.36	3.31e-6	Inflammatory biomarkers;
PAAD	cis	rs2060793	0.506	rs10741658	chr11:14924736	T/C	cg25251204	chr11:14927456	NA	0.39	4.37	0.33	2.32e-5	Vitamin D levels;
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.16	-0.39	7.7300000000000005e-07	Bipolar disorder and schizophrenia;
PAAD	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.32	11.26	0.67	8.95e-22	Uric acid levels;
PAAD	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.81	-0.36	3.61e-6	Joint mobility (Beighton score);
PAAD	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg00255919	chr5:131827918	IRF1	0.6	8.44	0.57	2.27e-14	Asthma (sex interaction);
PAAD	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.94	-10.15	-0.64	8.22e-19	Parkinson's disease;
PAAD	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.16	0.45	6.13e-9	Coffee consumption (cups per day);
PAAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-5.2	-0.39	6.35e-7	Eosinophil percentage of white cells;
PAAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg00579200	chr11:133705235	NA	-0.46	-5.38	-0.4	2.71e-7	Childhood ear infection;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.65	-6.23	-0.45	4.3e-9	Colorectal cancer;
PAAD	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg01059385	chr22:42394853	WBP2NL	0.48	4.39	0.34	2.11e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg04106633	chr4:1044584	NA	0.7	5.85	0.43	2.91e-8	Recombination rate (females);
PAAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.64	-7.97	-0.54	3.52e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs8037137	0.571	rs3743445	chr15:91561182	C/T	cg23684204	chr15:91497937	RCCD1	0.76	4.47	0.34	1.5e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18364779	chr6:26104403	HIST1H4C	-0.47	-4.44	-0.34	1.72e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg24747557	chr10:131355152	MGMT	-0.44	-4.75	-0.36	4.73e-6	Response to temozolomide;
PAAD	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.22	0.6	2.36e-16	Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.37e-7	Life satisfaction;
PAAD	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.67	-4.37	-0.33	2.32e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.58	5.44	0.4	2.12e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg12757816	chr2:10669957	NA	-0.56	-6.0	-0.44	1.41e-8	Prostate cancer;
PAAD	cis	rs7742824	0.917	rs10085205	chr6:44084883	A/G	cg21657043	chr6:44035552	NA	-0.43	-4.6	-0.35	8.78e-6	Major depressive disorder;
PAAD	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs12042938	0.935	rs1094657	chr1:231773407	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	4.97	0.37	1.77e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.61	6.73	0.48	3.28e-10	White blood cell count (basophil);
PAAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg12373951	chr3:133503437	NA	-0.43	-5.42	-0.4	2.32e-7	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.86	0.43	2.74e-8	Eosinophil percentage of white cells;
PAAD	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.71	0.48	3.54e-10	Response to antipsychotic treatment;
PAAD	cis	rs12999616	0.817	rs35321033	chr2:98327812	T/C	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.6	4.82	0.36	3.44e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg20636351	chr8:55087400	NA	0.71	7.33	0.51	1.26e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7593730	0.636	rs3772071	chr2:161135544	C/T	cg22609984	chr2:161126801	NA	0.51	4.39	0.34	2.12e-5	Type 2 diabetes;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg08088566	chr11:430123	ANO9	0.87	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs16975963	0.644	rs78644049	chr19:38113042	T/A	cg08679971	chr19:38281047	NA	0.47	4.59	0.35	9.24e-6	Longevity;
PAAD	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg09659197	chr4:152720779	NA	0.45	5.2	0.39	6.43e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13198984	chr17:80129470	CCDC57	0.4	4.97	0.37	1.77e-6	Life satisfaction;
PAAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg08029281	chr1:67600428	NA	0.47	5.29	0.39	4.24e-7	Psoriasis;
PAAD	cis	rs1508086	0.695	rs10958508	chr8:57803673	A/C	cg10342016	chr8:57802622	NA	0.26	4.55	0.35	1.09e-5	Hand grip strength;
PAAD	cis	rs2882667	0.690	rs700625	chr5:138099597	A/T	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.44	-0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg10705379	chr10:99080932	FRAT1	-0.4	-4.57	-0.35	1.02e-5	Monocyte count;
PAAD	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.25	-0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06850241	chr22:41845214	NA	-0.55	-4.74	-0.36	4.93e-6	Vitiligo;
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg15693483	chr7:1102177	C7orf50	0.38	4.3	0.33	3.03e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35164067	1.000	rs34953890	chr19:10526854	C/A	cg24189696	chr19:10585866	NA	0.44	4.95	0.37	1.96e-6	Inflammatory bowel disease;
PAAD	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.98e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs73416724	0.688	rs77688577	chr6:43328629	A/G	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.65	-6.39	-0.46	1.94e-9	White matter hyperintensity burden;
PAAD	cis	rs7577696	0.785	rs3851310	chr2:32367986	G/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.69	-0.36	6.1e-6	Inflammatory biomarkers;
PAAD	cis	rs13424612	0.930	rs12478169	chr2:240951603	C/T	cg01812947	chr2:240904978	NDUFA10	0.56	4.9	0.37	2.41e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg00933542	chr6:150070202	PCMT1	0.58	5.95	0.43	1.76e-8	Lung cancer;
PAAD	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.84	10.29	0.64	3.54e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.96	-10.1	-0.63	1.14e-18	Monocyte percentage of white cells;
PAAD	cis	rs2908197	0.737	rs59755579	chr7:75992444	C/G	cg22830091	chr7:75961684	YWHAG	-0.6	-7.13	-0.5	3.85e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.48	-4.87	-0.37	2.74e-6	Height;
PAAD	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.7	6.61	0.47	6.17e-10	Lymphocyte counts;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.59	-6.08	-0.44	9.07e-9	Myopia;
PAAD	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.74	0.36	4.93e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	High light scatter reticulocyte count;
PAAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	trans	rs4272720	0.855	rs61848153	chr10:50230127	A/C	cg15329866	chr3:171455826	PLD1	0.77	6.7	0.48	3.75e-10	Platelet count;Plateletcrit;
PAAD	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs3112530	1.000	rs2964817	chr5:152645765	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs11825685	0.522	rs2096773	chr11:134539212	G/T	cg06603561	chr11:134479413	NA	-0.57	-5.03	-0.38	1.36e-6	IgG glycosylation;
PAAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.96	-11.15	-0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.46	4.56	0.35	1.05e-5	Mean corpuscular volume;
PAAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg03098644	chr7:100410630	EPHB4	0.59	4.52	0.34	1.24e-5	Other erythrocyte phenotypes;
PAAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.61	-7.19	-0.5	2.7e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1697938	0.590	rs1376181	chr5:40939557	A/G	cg22359217	chr5:41925772	FBXO4	-0.43	-4.28	-0.33	3.24e-5	Multiple system atrophy;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4142041	0.676	rs1916376	chr10:68645682	C/A	cg04444303	chr10:69634106	NA	-0.42	-4.32	-0.33	2.8e-5	Nicotine dependence;
PAAD	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg05272587	chr13:111038400	COL4A2	0.52	4.78	0.36	4.15e-6	White matter hyperintensity burden;
PAAD	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.56	-0.35	1.03e-5	Menarche (age at onset);
PAAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg12215294	chr3:40350768	EIF1B	-0.49	-4.89	-0.37	2.51e-6	Renal cell carcinoma;
PAAD	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg12963866	chr19:57752005	ZNF805	-0.5	-4.9	-0.37	2.41e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg05342682	chr7:94953680	PON1	0.54	4.69	0.36	6.16e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.68	-0.53	1.8e-12	Aortic root size;
PAAD	cis	rs7101378	0.500	rs1912236	chr11:108897971	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs2030114	0.531	rs59891648	chr16:51595251	T/A	cg03758633	chr16:51611768	NA	0.51	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.5	-5.29	-0.39	4.11e-7	Bladder cancer;
PAAD	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-4.27	-0.33	3.41e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg16558253	chr16:72132732	DHX38	0.43	4.7	0.36	5.84e-6	Fibrinogen levels;
PAAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00982548	chr2:198649783	BOLL	-0.79	-5.71	-0.42	5.83e-8	Ulcerative colitis;
PAAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.71	5.64	0.42	8.23e-8	Electroencephalogram traits;
PAAD	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.48	7.04	0.5	6.17e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.54	9.43	0.61	6.78e-17	Age-related hearing impairment;
PAAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.75	-0.42	4.85e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg23024343	chr7:107201750	COG5	0.58	4.79	0.36	3.9e-6	Osteoarthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07399355	chr1:155163013	MUC1	0.58	6.73	0.48	3.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg01503450	chr10:980765	NA	-0.57	-5.03	-0.38	1.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs6547631	0.622	rs6740635	chr2:85933527	C/G	cg24620635	chr2:85921963	GNLY	0.43	5.6	0.41	9.63e-8	Blood protein levels;
PAAD	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.97	0.44	1.59e-8	Coffee consumption (cups per day);
PAAD	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.84	8.91	0.59	1.45e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg09998033	chr7:158218633	PTPRN2	-0.78	-8.09	-0.55	1.75e-13	Obesity-related traits;
PAAD	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.76	-9.09	-0.59	5.09e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg14440974	chr22:39074834	NA	0.53	6.54	0.47	8.65e-10	Menopause (age at onset);
PAAD	cis	rs2070677	0.935	rs3020502	chr10:135381623	T/C	cg18984983	chr10:135342936	CYP2E1	-0.49	-4.53	-0.34	1.18e-5	Gout;
PAAD	cis	rs2004318	1.000	rs2781760	chr19:55140609	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24583131	chr6:18265189	DEK	0.65	7.19	0.5	2.74e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg09659197	chr4:152720779	NA	-0.47	-6.3	-0.45	3.08e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3764400	0.567	rs3897789	chr17:46312777	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06404838	chr11:117015391	PAFAH1B2	0.66	6.36	0.46	2.27e-9	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.85	10.21	0.64	5.71e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.98e-13	Rheumatoid arthritis;
PAAD	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg26031613	chr14:104095156	KLC1	-0.57	-6.15	-0.45	6.7e-9	Schizophrenia;
PAAD	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.02	0.59	7.8e-16	Motion sickness;
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.63	6.79	0.48	2.34e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg16876255	chr19:9731953	ZNF561	0.93	4.5	0.34	1.35e-5	Pursuit maintenance gain;
PAAD	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.16	0.45	6.14e-9	Mood instability;
PAAD	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.52	-0.34	1.23e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11892454	0.515	rs10168718	chr2:26053166	G/A	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.15	0.39	7.8e-7	Axial length;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg18281939	chr5:77783895	LHFPL2	0.5	5.6	0.41	9.55e-8	Triglycerides;
PAAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26549601	chr10:134560360	INPP5A	0.47	4.6	0.35	8.83e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.92	10.3	0.64	3.32e-19	Gestational age at birth (maternal effect);
PAAD	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg22143856	chr6:28129313	ZNF389	-0.55	-5.17	-0.39	7.4e-7	Parkinson's disease;
PAAD	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.7	6.24	0.45	4.17e-9	Platelet count;
PAAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.96	12.42	0.71	6.86e-25	Menopause (age at onset);
PAAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.02	0.38	1.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg14906510	chr12:7781169	NA	0.62	4.5	0.34	1.34e-5	HDL cholesterol levels;
PAAD	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.38	-0.56	3.37e-14	Aortic root size;
PAAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.65	-0.35	7.11e-6	Total body bone mineral density;
PAAD	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.41	0.61	7.49e-17	Post bronchodilator FEV1;
PAAD	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.83	-5.9	-0.43	2.26e-8	Gallbladder cancer;
PAAD	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2562456	0.833	rs62109225	chr19:21536663	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.32	-0.33	2.75e-5	Pain;
PAAD	cis	rs9810890	1.000	rs73198846	chr3:128505472	A/C	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs988913	0.581	rs1580891	chr6:54859092	C/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.84	-10.88	-0.66	9.22e-21	Breast cancer;
PAAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.86	10.99	0.67	4.87e-21	Height;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	-0.58	-6.33	-0.46	2.68e-9	Height;
PAAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs5009270	0.513	rs4478510	chr7:112220494	C/A	cg23628563	chr7:112262597	NA	0.65	5.48	0.41	1.69e-7	Osteoarthritis (hip);
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.77	6.77	0.48	2.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.73	8.56	0.57	1.18e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11245990	chr11:68621969	NA	0.38	4.84	0.37	3.15e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.62	-0.35	8.15e-6	Joint mobility (Beighton score);
PAAD	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg25547332	chr5:131281432	NA	-0.54	-4.28	-0.33	3.29e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg23281280	chr6:28129359	ZNF389	0.5	4.27	0.33	3.38e-5	Parkinson's disease;
PAAD	cis	rs713477	0.505	rs1953740	chr14:55886717	G/A	cg13175173	chr14:55914753	NA	-0.36	-4.7	-0.36	5.68e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	1.31	11.06	0.67	3.19e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-5.12	-0.38	9.02e-7	Educational attainment;
PAAD	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.84	9.67	0.62	1.57e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg01304814	chr3:48885189	PRKAR2A	0.98	5.65	0.42	7.67e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.79	8.29	0.56	5.65e-14	Schizophrenia;
PAAD	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg05585544	chr11:47624801	NA	-0.47	-5.21	-0.39	6.11e-7	Subjective well-being;
PAAD	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	5.97	0.44	1.62e-8	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg18490616	chr2:88469792	THNSL2	-0.44	-4.3	-0.33	3.08e-5	Response to metformin (IC50);
PAAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.89	8.56	0.57	1.17e-14	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg24154853	chr7:158122151	PTPRN2	0.8	7.42	0.52	7.71e-12	Response to amphetamines;
PAAD	cis	rs13065560	0.659	rs6599266	chr3:38926912	C/G	cg01426195	chr3:39028469	NA	-0.5	-5.04	-0.38	1.3e-6	Interleukin-18 levels;
PAAD	cis	rs800160	0.777	rs2106606	chr11:2357563	T/C	cg09785033	chr11:2336066	TSPAN32	-0.55	-4.64	-0.35	7.44e-6	Bacteremia;
PAAD	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.46	-8.38	-0.56	3.24e-14	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.69	7.21	0.5	2.46e-11	Morning vs. evening chronotype;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.45	-0.68	2.87e-22	Total body bone mineral density;
PAAD	cis	rs73206853	0.841	rs60219027	chr12:110759843	T/G	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.7	6.91	0.49	1.25e-10	Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	9.96	0.63	2.61e-18	Platelet count;
PAAD	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.65	0.35	7.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg09654669	chr8:57350985	NA	0.56	5.24	0.39	5.33e-7	Obesity-related traits;
PAAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg23912435	chr1:150601613	ENSA	0.5	4.67	0.35	6.69e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11992162	0.591	rs56001613	chr8:11809480	G/C	cg00262122	chr8:11665843	FDFT1	-0.49	-4.39	-0.34	2.1e-5	Monocyte count;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs4740619	0.569	rs2987042	chr9:16002556	C/T	cg14451791	chr9:16040625	NA	0.38	4.63	0.35	7.72e-6	Body mass index;
PAAD	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.34e-6	Daytime sleep phenotypes;
PAAD	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.77	-8.83	-0.58	2.32e-15	Breast cancer;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.1	10.17	0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg00750074	chr16:89608354	SPG7	-0.47	-4.53	-0.34	1.2e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.95	-0.43	1.76e-8	Bladder cancer;
PAAD	cis	rs4478858	0.743	rs11578422	chr1:31707298	C/T	cg00250761	chr1:31883323	NA	-0.52	-5.99	-0.44	1.44e-8	Alcohol dependence;
PAAD	cis	rs72827839	0.802	rs12951323	chr17:46027565	A/C	cg23391107	chr17:45924227	SP6	-0.59	-5.07	-0.38	1.16e-6	Ease of getting up in the morning;
PAAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.49	-4.92	-0.37	2.18e-6	Blood metabolite levels;
PAAD	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.71	5.02	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7873102	0.654	rs10814638	chr9:37997787	A/G	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg24733560	chr20:60626293	TAF4	0.58	7.49	0.52	5.2e-12	Body mass index;
PAAD	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.1	0.5	4.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg13918804	chr1:2043761	PRKCZ	0.43	5.67	0.42	7.02e-8	Height;
PAAD	cis	rs3733346	0.589	rs2290404	chr4:945225	A/G	cg20814179	chr4:940893	TMEM175	0.6	7.11	0.5	4.26e-11	Sjögren's syndrome;
PAAD	cis	rs66530629	0.834	rs11249171	chr1:25073571	A/C	cg01905478	chr1:25040257	NA	-0.48	-5.15	-0.39	8e-7	Plateletcrit;
PAAD	cis	rs13242816	1.000	rs17138750	chr7:116134170	A/G	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-7.72	-0.53	1.48e-12	Systemic lupus erythematosus;
PAAD	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg02404636	chr22:31891804	SFI1	-0.55	-5.34	-0.4	3.26e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.88	10.19	0.64	6.5e-19	Tonsillectomy;
PAAD	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	cis	rs17123764	0.605	rs7967624	chr12:50159519	A/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.03	-0.44	1.21e-8	Blood metabolite levels;
PAAD	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg10820045	chr2:198174542	NA	-0.45	-4.57	-0.35	1.02e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.61	0.35	8.33e-6	Melanoma;
PAAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.83	10.09	0.63	1.19e-18	Height;
PAAD	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.93	9.67	0.62	1.58e-17	Response to antineoplastic agents;
PAAD	cis	rs66530629	0.958	rs55965563	chr1:25050829	G/A	cg22509179	chr1:25234806	RUNX3	0.49	4.35	0.33	2.5e-5	Plateletcrit;
PAAD	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.2	-17.5	-0.82	3e-38	Ulcerative colitis;
PAAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.51	-6.25	-0.45	4.02e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg20913747	chr6:44695427	NA	-0.57	-5.43	-0.4	2.22e-7	Total body bone mineral density;
PAAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg14092988	chr3:52407081	DNAH1	0.42	5.31	0.4	3.76e-7	Bipolar disorder;
PAAD	cis	rs10214930	0.752	rs6966091	chr7:27660013	A/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.63	-4.67	-0.35	6.44e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7249921	0.728	rs1627280	chr19:35652248	C/T	cg11856182	chr19:35264148	ZNF599	-0.52	-4.42	-0.34	1.88e-5	Platelet count;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-4.34	-0.33	2.64e-5	Blood metabolite levels;
PAAD	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2031532	0.565	rs11619265	chr13:50057633	A/G	cg08779649	chr13:50194554	NA	0.36	4.87	0.37	2.75e-6	Cardiac hypertrophy;
PAAD	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	10.79	0.66	1.61e-20	Total body bone mineral density;
PAAD	cis	rs73019876	0.869	rs2522094	chr19:22125569	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.9	-4.6	-0.35	8.94e-6	Toenail selenium levels;
PAAD	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.98	0.54	3.22e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.79	-9.51	-0.61	4.19e-17	White blood cell count (basophil);
PAAD	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg00129232	chr17:37814104	STARD3	0.51	4.41	0.34	1.98e-5	Self-reported allergy;
PAAD	cis	rs4073221	0.789	rs35115317	chr3:18205159	G/A	cg07694806	chr3:18168406	NA	-0.84	-5.11	-0.38	9.66e-7	Parkinson's disease;
PAAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.79	-9.41	-0.61	7.27e-17	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg09242541	chr1:10490025	APITD1	0.34	4.37	0.33	2.29e-5	Breast size;
PAAD	cis	rs6908034	0.660	rs111231540	chr6:19802226	A/C	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	6.28	0.45	3.37e-9	Schizophrenia;
PAAD	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.74	-8.08	-0.55	1.89e-13	Eosinophil percentage of granulocytes;
PAAD	cis	rs939584	1.000	rs11127487	chr2:639900	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.59	6.43	0.46	1.6e-9	Lung cancer;
PAAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.89e-10	Glomerular filtration rate;
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.47	-7.51	-0.52	4.8e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.3	-0.39	4.01e-7	Life satisfaction;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg22663859	chr13:21900854	NA	0.59	6.4	0.46	1.82e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg06606381	chr12:133084897	FBRSL1	-0.93	-6.37	-0.46	2.18e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg21211367	chr2:162094118	NA	0.46	4.51	0.34	1.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.68	-5.9	-0.43	2.31e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs329648	0.553	rs10791337	chr11:133765127	A/C	cg03392386	chr11:133800800	IGSF9B	-0.52	-5.66	-0.42	7.26e-8	Parkinson's disease;
PAAD	cis	rs6908034	0.607	rs114146042	chr6:19807229	G/A	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg27494647	chr7:150038898	RARRES2	0.46	4.8	0.36	3.82e-6	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-1.51	-9.85	-0.62	5.32e-18	Depression;
PAAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Educational attainment;
PAAD	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg17480646	chr11:65405466	SIPA1	0.9	4.28	0.33	3.29e-5	Height;
PAAD	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.39	0.34	2.12e-5	Breast cancer;
PAAD	cis	rs528301	0.833	rs340498	chr2:45135885	A/C	cg15393275	chr2:45165193	NA	-0.46	-5.08	-0.38	1.11e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs876084	0.966	rs876083	chr8:121101533	C/T	cg22335954	chr8:121166405	COL14A1	-0.43	-4.32	-0.33	2.81e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	0.95	11.17	0.67	1.62e-21	Testicular germ cell tumor;
PAAD	cis	rs6787172	0.667	rs7627374	chr3:158190064	G/C	cg16708174	chr3:158430962	RARRES1	0.43	4.58	0.35	9.64e-6	Subjective well-being;
PAAD	cis	rs16858210	0.520	rs12633858	chr3:183549395	C/T	cg03417191	chr3:183542750	MAP6D1	-0.79	-6.01	-0.44	1.33e-8	Menopause (age at onset);
PAAD	cis	rs9488822	0.623	rs195518	chr6:116241693	A/G	cg18764771	chr6:116381957	FRK	0.29	4.62	0.35	8.12e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs9815354	0.812	rs73828505	chr3:42042714	C/T	cg03022575	chr3:42003672	ULK4	0.8	5.56	0.41	1.17e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.48	-4.42	-0.34	1.9e-5	Mean corpuscular volume;
PAAD	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg10729496	chr3:10149963	C3orf24	0.88	7.24	0.51	2.08e-11	Alzheimer's disease;
PAAD	cis	rs2997447	0.761	rs2802312	chr1:26430822	T/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs4740619	0.904	rs7049101	chr9:15640042	T/A	cg14451791	chr9:16040625	NA	-0.42	-5.02	-0.38	1.42e-6	Body mass index;
PAAD	cis	rs7402982	0.625	rs12905392	chr15:99199212	G/A	cg03437748	chr15:99193247	IGF1R	0.65	5.73	0.42	5.14e-8	Birth weight;
PAAD	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26433838	chr3:160167749	TRIM59	0.53	5.06	0.38	1.2e-6	Primary biliary cholangitis;
PAAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg22143856	chr6:28129313	ZNF389	0.48	4.5	0.34	1.32e-5	Parkinson's disease;
PAAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.7	-5.82	-0.43	3.45e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2882667	0.690	rs11749163	chr5:138262670	A/G	cg09476006	chr5:138032270	NA	0.47	6.05	0.44	1.09e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2645424	0.550	rs28577034	chr8:11708715	A/T	cg21281001	chr8:11725306	CTSB	0.53	4.71	0.36	5.65e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.78e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	6.74	0.48	3.14e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.87	10.51	0.65	8.98e-20	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.79	5.83	0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.48e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-4.5	-0.34	1.35e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.81e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.8	-0.43	3.68e-8	Bipolar disorder;
PAAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg04545296	chr12:48745243	ZNF641	0.35	4.4	0.34	2.07e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg07153921	chr17:41440717	NA	-0.43	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs7715811	1.000	rs1502052	chr5:13774908	G/A	cg09526469	chr5:14277668	TRIO	-0.39	-4.26	-0.33	3.61e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.84	9.93	0.63	3.26e-18	Blood metabolite ratios;
PAAD	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.68	7.55	0.52	3.71e-12	Menopause (age at onset);
PAAD	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.45	4.64	0.35	7.52e-6	Corneal astigmatism;
PAAD	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg17456097	chr1:26900765	RPS6KA1	0.52	4.62	0.35	8.11e-6	Glucose homeostasis traits;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.9	7.0	0.49	7.71e-11	Initial pursuit acceleration;
PAAD	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.67	-5.96	-0.44	1.69e-8	Diabetic retinopathy;
PAAD	cis	rs3764618	1.000	rs16981031	chr19:49497453	A/C	cg12515942	chr19:49552529	CGB8	-0.72	-4.39	-0.34	2.07e-5	Follicule stimulating hormone;
PAAD	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.58	5.5	0.41	1.55e-7	HDL cholesterol;
PAAD	cis	rs2073499	0.872	rs78671882	chr3:50411188	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.65	5.37	0.4	2.9e-7	Schizophrenia;
PAAD	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.98	12.41	0.71	7.11e-25	Bone mineral density;
PAAD	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg14515779	chr1:101123966	NA	0.49	6.29	0.45	3.24e-9	Monocyte count;
PAAD	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.76	9.28	0.6	1.61e-16	Alcohol dependence;
PAAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.65	4.43	0.34	1.78e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.52	-4.94	-0.37	2.06e-6	Red blood cell count;
PAAD	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	1.08	11.12	0.67	2.13e-21	Platelet distribution width;
PAAD	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.5	5.46	0.41	1.87e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.84	-5.41	-0.4	2.42e-7	Diabetic kidney disease;
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.31	0.46	2.85e-9	Platelet count;
PAAD	cis	rs910187	0.597	rs1883885	chr20:45795456	T/C	cg27589058	chr20:45804311	EYA2	-0.44	-4.39	-0.34	2.1e-5	Migraine;
PAAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg23298862	chr7:158159286	PTPRN2	0.56	4.72	0.36	5.41e-6	Response to amphetamines;
PAAD	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-4.86	-0.37	2.92e-6	Schizophrenia;
PAAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.07	0.38	1.13e-6	Rheumatoid arthritis;
PAAD	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.55	4.43	0.34	1.78e-5	Bone mineral density (spine);
PAAD	cis	rs10885582	0.774	rs11196782	chr10:116302495	A/G	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg13880726	chr7:1868755	MAD1L1	-0.48	-4.59	-0.35	9.21e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.64	-0.35	7.58e-6	Fractional excretion of uric acid;
PAAD	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.47	4.97	0.37	1.82e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	5.15	0.39	7.9e-7	Obesity-related traits;
PAAD	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg15556689	chr8:8085844	FLJ10661	0.61	5.5	0.41	1.6e-7	Neuroticism;
PAAD	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.49	6.06	0.44	1.04e-8	Crohn's disease;
PAAD	cis	rs11264213	0.901	rs72661613	chr1:36364781	A/G	cg27506609	chr1:36549197	TEKT2	1.09	6.04	0.44	1.11e-8	Schizophrenia;
PAAD	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.88	-0.58	1.75e-15	Exhaled nitric oxide output;
PAAD	cis	rs9715521	0.935	rs34361458	chr4:59838192	C/A	cg11281224	chr4:60001000	NA	-0.62	-5.94	-0.43	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.71	7.26	0.51	1.87e-11	Morning vs. evening chronotype;
PAAD	cis	rs6940116	1	rs6940116	chr6:27708732	A/G	cg20933634	chr6:27740509	NA	0.68	5.69	0.42	6.36e-8	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;
PAAD	cis	rs258892	0.895	rs11950735	chr5:72031813	G/C	cg21869765	chr5:72125136	TNPO1	-0.81	-5.54	-0.41	1.33e-7	Small cell lung carcinoma;
PAAD	cis	rs728616	0.867	rs78131725	chr10:81820919	C/G	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg08917208	chr2:24149416	ATAD2B	0.47	4.25	0.33	3.77e-5	Asthma;
PAAD	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.69	-5.87	-0.43	2.59e-8	Pubertal anthropometrics;
PAAD	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.84	-9.46	-0.61	5.66e-17	Height;
PAAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg14631576	chr9:95140430	CENPP	-0.62	-5.96	-0.44	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.63	7.24	0.51	2.13e-11	Testicular germ cell tumor;
PAAD	cis	rs7264396	0.887	rs736032	chr20:34048661	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg12568669	chr8:11666485	FDFT1	0.27	4.4	0.34	2.05e-5	Neuroticism;
PAAD	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7192380	0.651	rs13337236	chr16:69664919	T/A	cg05250797	chr16:70222502	NA	0.65	5.72	0.42	5.43e-8	Sjögren's syndrome;
PAAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg13722127	chr7:150037890	RARRES2	0.65	6.29	0.45	3.24e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.65	6.72	0.48	3.43e-10	Capecitabine sensitivity;
PAAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg25309567	chr17:79516362	C17orf70	-0.45	-4.35	-0.33	2.51e-5	Eye color traits;
PAAD	cis	rs6980507	0.523	rs2974293	chr8:42369455	C/T	cg09913449	chr8:42400586	C8orf40	-0.5	-5.59	-0.41	1.02e-7	Glycated hemoglobin levels;
PAAD	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.47	4.89	0.37	2.55e-6	Longevity;
PAAD	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg24053715	chr22:38214548	NA	-0.6	-6.16	-0.45	6.19e-9	Glioblastoma;Glioma;
PAAD	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.16	-0.5	3.2e-11	Response to antipsychotic treatment;
PAAD	cis	rs57709857	0.957	rs1488934	chr8:38133612	C/T	cg16625770	chr8:38300134	FGFR1	-0.46	-4.32	-0.33	2.76e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg25204440	chr1:209979598	IRF6	-0.64	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs2455601	1.000	rs2455601	chr11:8899400	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-5.15	-0.39	8.11e-7	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs55726902	0.506	rs1006476	chr12:48179347	C/T	cg14736327	chr12:48174669	SLC48A1	-0.68	-6.02	-0.44	1.24e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12482904	0.607	rs11203202	chr21:43825357	C/G	cg23042151	chr21:43824109	UBASH3A	-0.46	-5.8	-0.43	3.79e-8	Vitiligo;
PAAD	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.82	5.52	0.41	1.46e-7	Anti-saccade response;
PAAD	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.7	-7.85	-0.54	6.94e-13	Mean platelet volume;
PAAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.66	-0.53	2e-12	Height;
PAAD	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.98	10.1	0.63	1.15e-18	Longevity;
PAAD	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.33	12.28	0.71	1.67e-24	Uric acid levels;
PAAD	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.84	-10.65	-0.65	3.8e-20	Breast cancer;
PAAD	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg01489256	chr8:11204017	TDH	0.43	4.34	0.33	2.64e-5	Retinal vascular caliber;
PAAD	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.88	-9.04	-0.59	6.69e-16	Schizophrenia;
PAAD	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	7.47	0.52	5.86e-12	Multiple sclerosis;
PAAD	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	4.33	0.33	2.72e-5	Lipoprotein (a) levels;
PAAD	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.32	4.58	0.35	9.59e-6	Sitting height ratio;
PAAD	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg20673841	chr7:107026890	COG5	0.47	4.3	0.33	3.05e-5	Coronary artery disease;
PAAD	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.48	5.34	0.4	3.29e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.02	-0.49	6.89e-11	Response to antipsychotic treatment;
PAAD	trans	rs901683	1.000	rs113862353	chr10:46068586	A/G	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26354017	chr1:205819088	PM20D1	0.9	11.21	0.67	1.23e-21	Menarche (age at onset);
PAAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.4	4.67	0.35	6.49e-6	Fat distribution (HIV);
PAAD	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg14829360	chr17:73884958	NA	-0.67	-6.02	-0.44	1.25e-8	Psoriasis;
PAAD	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.81	-7.8	-0.53	8.94e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6065	0.618	rs4790718	chr17:4870893	G/A	cg02990439	chr17:4875527	CAMTA2	-0.96	-4.83	-0.37	3.24e-6	Platelet count;
PAAD	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.83	0.36	3.3e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10958605	0.761	rs2980815	chr8:40044598	A/G	cg14545590	chr8:40388592	ZMAT4	0.43	4.82	0.36	3.51e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.9	-9.59	-0.61	2.54e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg00988841	chr10:134556463	INPP5A	0.51	4.72	0.36	5.36e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs863345	0.604	rs60104403	chr1:158500847	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.96	-0.37	1.83e-6	Pneumococcal bacteremia;
PAAD	cis	rs74181299	0.684	rs2052261	chr2:65355270	G/A	cg20592124	chr2:65290738	CEP68	-0.47	-4.37	-0.33	2.27e-5	Pulse pressure;
PAAD	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24838063	chr12:130822603	PIWIL1	0.72	7.09	0.5	4.6e-11	Menopause (age at onset);
PAAD	cis	rs9325144	0.794	rs7963855	chr12:38914187	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-4.74	-0.36	4.79e-6	Morning vs. evening chronotype;
PAAD	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	1.15	15.52	0.78	3.68e-33	Total cholesterol levels;
PAAD	cis	rs3026101	0.671	rs1989946	chr17:5313152	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.96	0.44	1.71e-8	Body mass index;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.49	5.13	0.38	8.84e-7	Plasma plasminogen activator levels;
PAAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.55	-0.35	1.1e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs412658	0.670	rs1912576	chr19:22121293	T/C	cg08394602	chr19:22123885	NA	-0.49	-4.67	-0.35	6.48e-6	Telomere length;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.18	-0.39	6.93e-7	Mean corpuscular volume;
PAAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03647317	chr4:187891568	NA	-0.54	-6.75	-0.48	2.87e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.75	-5.25	-0.39	4.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs15676	0.783	rs6478851	chr9:131561110	G/A	cg00228799	chr9:131580591	ENDOG	-0.62	-5.94	-0.43	1.86e-8	Blood metabolite levels;
PAAD	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg08648136	chr8:956695	NA	0.43	4.59	0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.67	8.29	0.56	5.71e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg19025524	chr12:109796872	NA	-0.46	-4.31	-0.33	2.89e-5	Neuroticism;
PAAD	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg21211680	chr2:198530	NA	0.72	5.7	0.42	6e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.58	5.94	0.43	1.88e-8	Coronary artery disease;
PAAD	cis	rs7246760	1.000	rs12460571	chr19:9881746	C/A	cg16876255	chr19:9731953	ZNF561	0.93	4.59	0.35	9.12e-6	Pursuit maintenance gain;
PAAD	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.59	6.91	0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg12473912	chr3:136751656	NA	0.4	4.46	0.34	1.59e-5	Gestational age at birth (child effect);
PAAD	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.93	10.07	0.63	1.37e-18	Breast cancer;
PAAD	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg18005901	chr6:33739558	LEMD2	-0.56	-4.42	-0.34	1.86e-5	Plateletcrit;
PAAD	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	cis	rs793571	0.628	rs7171482	chr15:59106495	G/T	cg05156742	chr15:59063176	FAM63B	0.72	5.2	0.39	6.25e-7	Schizophrenia;
PAAD	cis	rs499368	0.519	rs216245	chr12:310419	G/T	cg23063825	chr12:298151	NA	0.49	5.59	0.41	1.05e-7	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.71	7.19	0.5	2.72e-11	Colorectal cancer;
PAAD	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.95	-0.54	3.95e-13	Height;
PAAD	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.64	-6.14	-0.45	6.93e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-1.07	-8.95	-0.59	1.13e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.19	-0.7	2.93e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.8	10.08	0.63	1.28e-18	Vitiligo;
PAAD	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.85	-4.69	-0.36	6.1e-6	Cholesterol, total;
PAAD	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06771106	chr2:113671356	IL1F7	-0.62	-6.74	-0.48	3.05e-10	Pulmonary function;
PAAD	cis	rs4239252	0.929	rs4796116	chr17:34168500	G/C	cg19411729	chr17:34207663	CCL5	-0.55	-4.97	-0.37	1.75e-6	Blood protein levels;
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.33	-4.3	-0.33	3.09e-5	Mean platelet volume;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs9584850	0.874	rs7988959	chr13:99104004	T/C	cg20487152	chr13:99095054	FARP1	0.58	5.0	0.38	1.59e-6	Neuroticism;
PAAD	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg24375607	chr4:120327624	NA	0.46	4.71	0.36	5.63e-6	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21512275	chr2:157198069	NA	0.58	6.42	0.46	1.62e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9535307	0.719	rs9562927	chr13:50363677	A/G	cg03658251	chr13:50265850	EBPL	0.79	5.27	0.39	4.5e-7	Obesity-related traits;
PAAD	cis	rs73206853	0.841	rs57216167	chr12:110940748	C/T	cg12870014	chr12:110450643	ANKRD13A	0.72	4.58	0.35	9.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Menopause (age at onset);
PAAD	cis	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg21546286	chr11:48923668	NA	-0.59	-6.13	-0.45	7.33e-9	HDL cholesterol;
PAAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.35	-0.68	5.25e-22	Height;
PAAD	cis	rs1468333	0.537	rs10479184	chr5:137753917	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.44	4.28	0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg01304814	chr3:48885189	PRKAR2A	0.91	4.6	0.35	8.95e-6	Cognitive function;
PAAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.55e-15	Eye color traits;
PAAD	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.8e-7	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.5	-4.47	-0.34	1.51e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.78	-0.48	2.46e-10	Post bronchodilator FEV1;
PAAD	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs7809615	0.901	rs11555142	chr7:99032593	G/T	cg12290671	chr7:99195819	NA	-0.99	-5.36	-0.4	3.02e-7	Blood metabolite ratios;
PAAD	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.4	4.74	0.36	4.9100000000000004e-06	HIV-1 susceptibility;
PAAD	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.02	-0.38	1.44e-6	Menopause (age at onset);
PAAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.88	10.37	0.64	2.16e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg00166722	chr3:10149974	C3orf24	0.71	6.36	0.46	2.29e-9	Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.59	4.26	0.33	3.5e-5	Alzheimer's disease (survival time);
PAAD	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg10818794	chr15:86012489	AKAP13	-0.61	-5.03	-0.38	1.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.38	-0.33	2.2e-5	Plateletcrit;
PAAD	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-1.03	-6.99	-0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.73	-8.28	-0.56	5.92e-14	Airway imaging phenotypes;
PAAD	cis	rs28595532	0.720	rs72670231	chr4:119312908	C/T	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.81	9.09	0.59	4.95e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13111989	1.000	rs1485770	chr4:177548221	G/A	cg11287292	chr4:178277261	NEIL3	-0.53	-4.33	-0.33	2.71e-5	HIV-1 viral setpoint;
PAAD	cis	rs9913156	0.748	rs7217849	chr17:4562165	G/C	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.36	9.4	0.61	7.91e-17	Atopic dermatitis;
PAAD	cis	rs6782025	0.837	rs1688684	chr3:120730219	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs11105468	0.701	rs10777218	chr12:90398262	C/T	cg16962463	chr12:89968675	NA	-0.48	-4.57	-0.35	1.02e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.66	6.87	0.49	1.53e-10	Eye color traits;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg19223190	chr17:80058835	NA	-0.55	-5.75	-0.42	4.78e-8	Life satisfaction;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11245990	chr11:68621969	NA	0.38	5.0	0.38	1.55e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg14789911	chr21:47582049	C21orf56	-0.47	-4.85	-0.37	3.07e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26956494	chr5:64313909	SDCCAG10	0.6	6.38	0.46	2.01e-9	Smoking initiation;
PAAD	cis	rs11159086	0.793	rs12433382	chr14:74949643	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.14	-0.38	8.25e-7	Advanced glycation end-product levels;
PAAD	cis	rs8005677	0.798	rs61977741	chr14:23400979	G/C	cg01529538	chr14:23388837	RBM23	0.48	4.78	0.36	4.08e-6	Cognitive ability (multi-trait analysis);
PAAD	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.27	19.35	0.84	7.73e-43	IgG glycosylation;
PAAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	4.78	0.36	4.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	10.08	0.63	1.27e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg20848291	chr7:100343083	ZAN	-0.76	-6.55	-0.47	8.58e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11475305	chr6:53663860	LRRC1	-0.6	-6.97	-0.49	9.13e-11	Monocyte percentage of white cells;
PAAD	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26876637	chr1:152193138	HRNR	0.87	6.83	0.48	1.91e-10	Atopic dermatitis;
PAAD	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg03989125	chr22:38214979	NA	-0.51	-5.23	-0.39	5.45e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg22134413	chr5:150180641	NA	0.71	5.15	0.39	7.87e-7	Crohn's disease;
PAAD	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs6796502	0.500	rs7636089	chr3:46873957	A/G	cg23231268	chr3:46792462	NA	-0.65	-4.68	-0.35	6.35e-6	Breast cancer;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18621852	chr3:10150065	C3orf24	0.5	4.68	0.35	6.26e-6	Alzheimer's disease;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.48	5.6	0.41	9.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.49	-5.24	-0.39	5.21e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.61	-7.54	-0.52	3.96e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.36	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg01657329	chr11:68192670	LRP5	-0.62	-4.4	-0.34	2.06e-5	Total body bone mineral density (age 45-60);
PAAD	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.55	-4.9	-0.37	2.42e-6	Retinal vascular caliber;
PAAD	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg24110177	chr3:50126178	RBM5	-0.6	-4.63	-0.35	7.91e-6	Menarche (age at onset);
PAAD	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.13	-0.38	8.56e-7	Alzheimer's disease;
PAAD	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	cis	rs7132746	0.620	rs61930068	chr12:86210857	T/C	cg18827107	chr12:86230957	RASSF9	-0.6	-4.97	-0.37	1.77e-6	Lewy body disease;
PAAD	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.86	8.1	0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs62238980	0.614	rs5998272	chr22:32560045	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.75	4.41	0.34	1.92e-5	Childhood ear infection;
PAAD	cis	rs4883201	0.536	rs7132930	chr12:9137288	C/T	cg24820250	chr12:10084936	CLEC2A	-0.54	-4.5	-0.34	1.35e-5	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg15017067	chr4:17643749	FAM184B	0.47	5.17	0.39	7.21e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.65	-6.01	-0.44	1.31e-8	Diisocyanate-induced asthma;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.47	5.98	0.44	1.5e-8	Childhood ear infection;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg06815965	chr1:205818668	PM20D1	0.7	8.05	0.55	2.23e-13	Menarche (age at onset);
PAAD	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.1	0.44	8.57e-9	Post bronchodilator FEV1;
PAAD	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg09127314	chr1:152161683	NA	-0.71	-4.93	-0.37	2.15e-6	Atopic dermatitis;
PAAD	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.48	-4.82	-0.36	3.42e-6	Body mass index;
PAAD	cis	rs597480	0.747	rs630613	chr11:85478997	G/A	cg11817631	chr11:85522609	SYTL2	-0.5	-4.93	-0.37	2.13e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.51	4.99	0.38	1.61e-6	Height;
PAAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.44	0.46	1.47e-9	IgG glycosylation;
PAAD	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.8	8.82	0.58	2.48e-15	Body mass index;
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg18110333	chr6:292329	DUSP22	-0.79	-8.15	-0.55	1.27e-13	Menopause (age at onset);
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg00976097	chr5:421733	AHRR	-0.44	-4.39	-0.34	2.09e-5	Cystic fibrosis severity;
PAAD	cis	rs4740619	0.619	rs10810518	chr9:16029175	T/A	cg14451791	chr9:16040625	NA	-0.46	-5.28	-0.39	4.32e-7	Body mass index;
PAAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.1	0.38	1.02e-6	Obesity-related traits;
PAAD	cis	rs7771547	0.603	rs72852338	chr6:36554240	A/C	cg07856975	chr6:36356162	ETV7	0.56	5.75	0.42	4.76e-8	Platelet distribution width;
PAAD	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs76419734	0.558	rs11721842	chr4:106521846	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.43	0.34	1.8e-5	Post bronchodilator FEV1;
PAAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.3	-0.39	4.02e-7	Bipolar disorder;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg11416102	chr8:651193	ERICH1	0.93	5.78	0.42	4.11e-8	IgG glycosylation;
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.03	0.38	1.36e-6	Longevity;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs34415465	chr10:45985580	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2637266	0.626	rs846619	chr10:78545449	A/G	cg18941641	chr10:78392320	NA	0.37	4.42	0.34	1.86e-5	Pulmonary function;
PAAD	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg10168330	chr8:27262164	PTK2B	0.37	4.45	0.34	1.62e-5	Neuroticism;
PAAD	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg00990874	chr7:1149470	C7orf50	-0.75	-5.87	-0.43	2.62e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.5	-5.81	-0.43	3.53e-8	Mean corpuscular volume;
PAAD	cis	rs28680850	0.541	rs28501642	chr8:1379528	G/A	cg06016156	chr8:1399969	NA	-0.61	-4.44	-0.34	1.69e-5	Triglycerides;
PAAD	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.6	-6.39	-0.46	1.89e-9	Calcium levels;
PAAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.47	5.68	0.42	6.73e-8	Permanent tooth development;
PAAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg26174226	chr8:58114915	NA	-0.57	-4.38	-0.33	2.2e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2133450	0.967	rs56342345	chr3:7351028	G/A	cg19930620	chr3:7340148	GRM7	-0.44	-4.62	-0.35	8.23e-6	Early response to risperidone in schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14156931	chr8:145515463	HSF1;BOP1	0.55	6.3	0.46	2.98e-9	Myopia (pathological);
PAAD	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.82	9.3	0.6	1.47e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.58	-4.93	-0.37	2.15e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg23029597	chr12:123009494	RSRC2	0.85	8.64	0.57	7.17e-15	Body mass index;
PAAD	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	1.01	12.55	0.71	3.08e-25	Breast cancer;
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.65	-0.47	4.92e-10	Lung cancer;
PAAD	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.46	5.11	0.38	9.67e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19627446	chr3:47844180	DHX30	-0.64	-6.38	-0.46	2.06e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.52	0.34	1.23e-5	Asthma;
PAAD	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg04165759	chr1:150448943	RPRD2	0.5	5.14	0.39	8.15e-7	Migraine;
PAAD	cis	rs4908768	0.579	rs56280806	chr1:8875542	G/A	cg00590817	chr1:8272081	NA	-0.39	-4.84	-0.37	3.17e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-7.39	-0.51	8.89e-12	Total body bone mineral density;
PAAD	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.54	-4.85	-0.37	3.09e-6	Lung cancer;
PAAD	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg00629941	chr15:75287862	SCAMP5	-0.57	-4.27	-0.33	3.36e-5	Blood trace element (Zn levels);
PAAD	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.6	5.01	0.38	1.46e-6	Red blood cell count;
PAAD	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg22916017	chr11:64110731	CCDC88B	0.48	4.58	0.35	9.74e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6496932	0.802	rs12439958	chr15:85853730	T/C	cg19183879	chr15:85880815	NA	0.53	4.89	0.37	2.53e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.81	-0.36	3.63e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.47	-5.1	-0.38	9.84e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.41	-4.68	-0.36	6.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Melanoma;
PAAD	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.55	5.95	0.43	1.75e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.967	rs10908682	chr1:158522760	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.97e-6	Pneumococcal bacteremia;
PAAD	cis	rs77106637	0.585	rs67260737	chr11:72458196	A/G	cg03713592	chr11:72463424	ARAP1	0.75	6.69	0.48	3.96e-10	Type 2 diabetes;
PAAD	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.55	-5.18	-0.39	7.08e-7	Dental caries;
PAAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs4862562	1.000	rs56235904	chr4:186603166	A/C	cg21367866	chr4:187563992	FAT1	0.84	4.3	0.33	3.01e-5	Cytokine-stimulated IL-6 production;Cytokine and corticosteroid-stimulated IL-6 production;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.51	-0.47	1.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg06307176	chr5:131281290	NA	0.48	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05041596	chr11:89867385	NAALAD2	0.7	5.79	0.43	3.86e-8	White blood cell types;
PAAD	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.8	8.98	0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg10932868	chr11:921992	NA	0.45	4.79	0.36	3.88e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.04	5.71	0.42	5.7e-8	Plateletcrit;
PAAD	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	1.57	9.43	0.61	6.71e-17	Age-related hearing impairment;
PAAD	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg23752985	chr2:85803571	VAMP8	0.53	6.25	0.45	3.93e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.94	-7.98	-0.54	3.28e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg04111992	chr7:158790115	NA	-0.51	-4.96	-0.37	1.83e-6	Facial morphology (factor 20);
PAAD	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.74	-9.59	-0.61	2.55e-17	Educational attainment;
PAAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs516243	0.687	rs284311	chr1:10737442	C/A	cg02903756	chr1:10750680	CASZ1	-0.43	-4.63	-0.35	7.71e-6	Migraine - clinic-based;
PAAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.58	6.49	0.47	1.16e-9	Blood metabolite levels;
PAAD	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg24747557	chr10:131355152	MGMT	-0.47	-5.04	-0.38	1.32e-6	Response to temozolomide;
PAAD	cis	rs370915	0.524	rs28826385	chr4:187769452	C/T	cg12892747	chr4:187813459	NA	-0.47	-4.79	-0.36	3.93e-6	Gout;
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13012494	chr21:47604986	C21orf56	0.46	4.76	0.36	4.39e-6	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.61	6.22	0.45	4.51e-9	Hemoglobin concentration;
PAAD	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.54	0.47	8.65e-10	Rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-1.22	-12.07	-0.7	5.9e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-4.37	-0.33	2.28e-5	Menopause (age at onset);
PAAD	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.87	10.1	0.63	1.11e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-6.0	-0.44	1.41e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg16989719	chr2:238392110	NA	-0.39	-5.07	-0.38	1.16e-6	Prostate cancer;
PAAD	cis	rs501120	0.564	rs61855758	chr10:44684854	T/C	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs11696501	0.947	rs6065829	chr20:44126608	C/G	cg11783356	chr20:44313418	WFDC10B	-0.66	-6.17	-0.45	5.96e-9	Brain structure;
PAAD	cis	rs3764400	0.567	rs67345313	chr17:46302201	T/C	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg02117656	chr17:79614917	TSPAN10	0.5	4.98	0.37	1.68e-6	Eye color traits;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.68	-0.36	6.21e-6	Bipolar disorder;
PAAD	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg01815783	chr4:1047043	NA	-0.41	-4.46	-0.34	1.59e-5	Recombination rate (males);
PAAD	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.61	-0.41	9.17e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.66	-6.32	-0.46	2.77e-9	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15154191	chr1:3527782	MEGF6	0.58	6.56	0.47	7.79e-10	Monocyte percentage of white cells;
PAAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.77	8.18	0.55	1.08e-13	DNA methylation (variation);
PAAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.91	10.95	0.66	6.01e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg18944383	chr4:111397179	ENPEP	-0.72	-7.87	-0.54	6.26e-13	Coronary artery disease;
PAAD	cis	rs7853377	0.800	rs296887	chr9:86595070	C/T	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg27411982	chr8:10470053	RP1L1	0.41	4.48	0.34	1.49e-5	Neuroticism;
PAAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	6.05	0.44	1.1e-8	Personality dimensions;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.63	5.85	0.43	2.92e-8	Diastolic blood pressure;
PAAD	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28489187	0.660	rs3949301	chr1:85863383	G/A	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01585852	chr22:24235823	MIF	-0.42	-4.52	-0.34	1.25e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.72	-6.68	-0.48	4.3e-10	Diabetic kidney disease;
PAAD	cis	rs9463078	0.546	rs10948198	chr6:45009164	T/C	cg25276700	chr6:44698697	NA	0.46	5.28	0.39	4.31e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs829661	1.000	rs829583	chr2:30677459	C/T	cg12454169	chr2:30669597	LCLAT1	0.66	4.94	0.37	2.02e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-4.96	-0.37	1.85e-6	Lung cancer;
PAAD	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.1	14.63	0.76	8.44e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-5.38	-0.4	2.72e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10991814	1.000	rs77233736	chr9:93994201	T/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26431815	chr8:668053	ERICH1	0.59	6.85	0.49	1.7e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg03128945	chr5:622914	CEP72	-0.5	-4.31	-0.33	2.89e-5	Obesity-related traits;
PAAD	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg22189786	chr22:42395067	WBP2NL	0.57	4.81	0.36	3.59e-6	Birth weight;
PAAD	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg13332499	chr17:408570	NA	0.64	7.11	0.5	4.27e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13242816	0.892	rs34205980	chr7:116078406	T/A	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.84	8.31	0.56	4.82e-14	Vitamin D levels;
PAAD	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs2421770	1.000	rs2421765	chr11:35321005	A/C	cg13971030	chr11:35366721	SLC1A2	0.53	6.41	0.46	1.77e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs9657904	0.813	rs2055557	chr3:105562238	T/C	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg19680485	chr15:31195859	MTMR15	-0.48	-4.86	-0.37	2.94e-6	Huntington's disease progression;
PAAD	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg14664628	chr15:75095509	CSK	-1.11	-12.78	-0.72	7.21e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	trans	rs901683	1.000	rs12763205	chr10:45986495	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs490234	0.841	rs512445	chr9:128329179	T/C	cg14078157	chr9:128172775	NA	0.44	4.94	0.37	2.03e-6	Mean arterial pressure;
PAAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26209169	chr5:1316264	NA	0.38	4.5	0.34	1.32e-5	Lung cancer;
PAAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.57	7.59	0.52	2.96e-12	Renal cell carcinoma;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs939584	1.000	rs6731688	chr2:630662	A/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg02264943	chr11:130785842	SNX19	0.4	4.8	0.36	3.69e-6	Schizophrenia;
PAAD	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-7.34	-0.51	1.19e-11	Mosquito bite size;
PAAD	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.6	-0.41	9.68e-8	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25632114	chr8:95732714	DPY19L4	0.59	6.79	0.48	2.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.43	-4.5	-0.34	1.37e-5	Inflammatory skin disease;
PAAD	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.7	7.59	0.52	2.98e-12	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg20590849	chr17:73267439	MIF4GD	0.53	4.3	0.33	3.05e-5	Systemic lupus erythematosus;
PAAD	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.55	5.84	0.43	3.11e-8	Fibrinogen levels;
PAAD	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.58	6.55	0.47	8.57e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.55	5.79	0.43	3.88e-8	Huntington's disease progression;
PAAD	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg11143131	chr5:131608246	PDLIM4	0.48	4.66	0.35	6.93e-6	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13216025	chr9:140512513	C9orf37;EHMT1	0.6	7.25	0.51	1.96e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg20826740	chr17:37024042	NA	0.42	4.54	0.35	1.13e-5	Height;
PAAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.96	12.31	0.71	1.35e-24	Menopause (age at onset);
PAAD	cis	rs9463078	0.764	rs9369513	chr6:44789476	T/C	cg25276700	chr6:44698697	NA	-0.45	-5.02	-0.38	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.33	-0.4	3.52e-7	Monocyte percentage of white cells;
PAAD	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.48	-6.07	-0.44	9.56e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06747863	chr12:118810789	TAOK3	0.57	6.44	0.46	1.45e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs1007738	0.542	rs11603373	chr11:47203245	C/T	cg19486271	chr11:47235900	DDB2	0.63	5.86	0.43	2.83e-8	Bone mineral density (hip);
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.59	-6.66	-0.48	4.63e-10	Height;
PAAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg22482690	chr17:47019901	SNF8	0.49	5.1	0.38	1.01e-6	Type 2 diabetes;
PAAD	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.73	5.21	0.39	6.17e-7	Major depressive disorder;
PAAD	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.84	6.95	0.49	1e-10	Bipolar disorder;
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.58e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.73	9.15	0.6	3.51e-16	Obesity (extreme);
PAAD	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11958594	chr17:80055299	FASN	0.63	7.06	0.5	5.69e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-12.71	-0.72	1.14e-25	Schizophrenia;
PAAD	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.78	6.87	0.49	1.52e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.57	6.7	0.48	3.86e-10	Pubertal anthropometrics;
PAAD	cis	rs2403221	0.963	rs17268414	chr11:9839856	G/T	cg06875754	chr11:10328428	ADM	0.37	4.34	0.33	2.58e-5	Smoking initiation;
PAAD	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17335372	chr4:845674	GAK	-0.72	-7.42	-0.52	7.77e-12	Obesity-related traits;
PAAD	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg14388049	chr10:71211838	TSPAN15	-0.47	-4.98	-0.37	1.69e-6	Thrombosis;
PAAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.16	-0.6	3.33e-16	Mean platelet volume;
PAAD	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg21918786	chr6:109611834	NA	0.48	5.19	0.39	6.52e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.37	-0.33	2.3e-5	Hemoglobin concentration;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.62	0.57	8.3e-15	Morning vs. evening chronotype;
PAAD	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs2133450	0.745	rs34225103	chr3:7370729	C/T	cg19930620	chr3:7340148	GRM7	-0.5	-5.59	-0.41	1.02e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	5.88	0.43	2.5e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08601984	chr6:112184093	FYN	-0.65	-6.37	-0.46	2.16e-9	Obesity-related traits;
PAAD	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.52	4.73	0.36	4.99e-6	Schizophrenia;
PAAD	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.35	0.56	3.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg07703079	chr11:430292	ANO9	0.9	5.74	0.42	5.06e-8	Body mass index;
PAAD	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.54	-5.02	-0.38	1.45e-6	Coronary artery disease;
PAAD	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.81	9.81	0.62	6.69e-18	Colorectal cancer;
PAAD	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.39	-0.61	8.33e-17	Pancreatic cancer;
PAAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.1	-0.44	8.47e-9	Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg02734326	chr4:10020555	SLC2A9	0.48	4.91	0.37	2.3e-6	Bone mineral density;
PAAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.62	0.35	8.01e-6	Iron status biomarkers;
PAAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.98e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs58653258	0.685	rs2786024	chr1:234978329	T/C	cg03518729	chr1:235147744	NA	0.45	4.31	0.33	2.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.59	5.79	0.43	3.93e-8	Multiple sclerosis;
PAAD	cis	rs2180233	0.712	rs12119359	chr1:30664457	A/G	cg06703062	chr1:31191648	MATN1	-0.54	-4.83	-0.36	3.33e-6	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg03989125	chr22:38214979	NA	-0.52	-5.53	-0.41	1.37e-7	Glioblastoma;Glioma;
PAAD	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-4.72	-0.36	5.26e-6	Mean corpuscular volume;
PAAD	cis	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg27411982	chr8:10470053	RP1L1	0.48	5.58	0.41	1.07e-7	Neuroticism;
PAAD	cis	rs854765	0.583	rs6502625	chr17:17848286	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.15	0.6	3.63e-16	Total body bone mineral density;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs35955747	0.749	rs2027982	chr22:31593435	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-4.91	-0.37	2.37e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg20283391	chr11:68216788	NA	-0.54	-5.23	-0.39	5.64e-7	Total body bone mineral density;
PAAD	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.02	0.49	6.83e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-1.26	-10.32	-0.64	2.94e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24008893	chr2:39627269	MAP4K3	-0.62	-6.31	-0.46	2.86e-9	Obesity-related traits;
PAAD	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.5	5.09	0.38	1.04e-6	Red blood cell count;
PAAD	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.1	0.63	1.16e-18	Platelet count;
PAAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.91	-8.65	-0.57	6.92e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.55	-5.67	-0.42	7.04e-8	Daytime sleep phenotypes;
PAAD	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.64	6.49	0.47	1.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	1.16	13.18	0.73	5.98e-27	Hair shape;
PAAD	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.95	8.19	0.55	1.02e-13	Alzheimer's disease;
PAAD	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.89	6.16	0.45	6.28e-9	Tonometry;
PAAD	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6715793	0.809	rs4670849	chr2:33406578	G/A	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg01620082	chr3:125678407	NA	-1.17	-6.98	-0.49	8.75e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-6.17	-0.45	5.8e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.46	0.57	2.05e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg25204440	chr1:209979598	IRF6	0.58	4.58	0.35	9.76e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.61	5.23	0.39	5.42e-7	Type 2 diabetes;
PAAD	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg22875332	chr1:76189707	ACADM	-0.52	-5.15	-0.39	7.97e-7	Daytime sleep phenotypes;
PAAD	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.8	-6.52	-0.47	1e-9	Putamen volume;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.68	6.46	0.46	1.35e-9	Prostate cancer;
PAAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.46	-4.63	-0.35	7.8e-6	Body mass index;
PAAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg21890820	chr11:65308645	LTBP3	0.64	7.84	0.54	7.38e-13	Bone mineral density;
PAAD	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17648103	chr11:33796228	FBXO3	0.62	6.99	0.49	8.06e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.79	5.85	0.43	2.85e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-4.98	-0.37	1.73e-6	Diastolic blood pressure;
PAAD	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg19486271	chr11:47235900	DDB2	-0.57	-5.76	-0.42	4.62e-8	Acne (severe);
PAAD	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23281280	chr6:28129359	ZNF389	0.7	5.42	0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg25809561	chr17:30822961	MYO1D	0.57	5.94	0.43	1.89e-8	Schizophrenia;
PAAD	cis	rs2735413	0.632	rs4436790	chr16:78097252	G/A	cg04733911	chr16:78082701	NA	0.54	5.18	0.39	6.91e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs72960926	0.744	rs56405366	chr6:75035257	T/C	cg03266952	chr6:74778945	NA	-1.12	-6.19	-0.45	5.46e-9	Metabolite levels (MHPG);
PAAD	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.77	0.36	4.3e-6	Self-reported allergy;
PAAD	cis	rs2529218	0.551	rs3095015	chr7:101420123	C/T	cg09205156	chr7:101991189	SPDYE6	0.55	4.7	0.36	5.79e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9810888	0.646	rs2633707	chr3:53709082	C/G	cg25215194	chr1:3706322	LRRC47	0.52	6.29	0.45	3.16e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;
PAAD	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4795519	0.704	rs28801437	chr17:22178576	T/C	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg08992911	chr2:238395768	MLPH	0.92	6.62	0.47	5.9e-10	Prostate cancer;
PAAD	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25214924	chr6:163517573	PACRG	-0.7	-7.25	-0.51	1.92e-11	Obesity-related traits;
PAAD	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.48	-6.78	-0.48	2.47e-10	Schizophrenia;
PAAD	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg14851346	chr12:38532713	NA	0.44	4.26	0.33	3.52e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.44	4.86	0.37	2.84e-6	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.68	-0.48	4.31e-10	Total body bone mineral density;
PAAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.71	5.66	0.42	7.31e-8	Height;
PAAD	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.23	-0.39	5.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg12463550	chr7:65579703	CRCP	0.87	5.63	0.42	8.56e-8	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.96	-0.49	9.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11235843	0.929	rs67488767	chr11:73432689	A/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg14250028	chr17:80897246	TBCD	-0.39	-4.4	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs438465	1.000	rs745398	chr6:169854753	A/G	cg11181693	chr6:169825345	NA	-0.56	-4.31	-0.33	2.97e-5	Corneal astigmatism;
PAAD	cis	rs4073221	0.654	rs35110494	chr3:18290188	C/A	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.52	4.81	0.36	3.6e-6	Height;
PAAD	cis	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Urinary tract infection frequency;
PAAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.7	8.88	0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.81	8.55	0.57	1.24e-14	Prostate cancer;
PAAD	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.75	5.69	0.42	6.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	4.77	0.36	4.31e-6	Homocysteine levels;
PAAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.54	6.11	0.44	8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.68	0.42	6.69e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.51	5.05	0.38	1.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11945232	0.624	rs35649088	chr4:88369786	C/T	cg23841344	chr4:88312519	HSD17B11	-0.57	-4.57	-0.35	9.93e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.48	-0.34	1.49e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-4.32	-0.33	2.78e-5	Vitiligo;
PAAD	cis	rs16857609	0.564	rs1478580	chr2:218291649	C/T	cg15335768	chr2:218268053	DIRC3	-0.49	-5.09	-0.38	1.05e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs4356203	0.840	rs7942094	chr11:17259409	A/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.65	-0.35	7.29e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3120667	0.790	rs1923509	chr1:152380128	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.43	-0.34	1.78e-5	Eating disorders;
PAAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.13	0.38	8.85e-7	Parkinson's disease;
PAAD	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-0.43	-4.26	-0.33	3.57e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs7165102	1.000	rs6494521	chr15:65739928	A/T	cg22900193	chr15:65823441	PTPLAD1	0.47	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg16898833	chr6:26189333	HIST1H4D	0.77	4.43	0.34	1.79e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg08219700	chr8:58056026	NA	0.73	5.81	0.43	3.5e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	7.8	0.53	9.36e-13	Eotaxin levels;
PAAD	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg12046867	chr14:103022105	NA	-0.64	-5.1	-0.38	9.88e-7	Platelet count;
PAAD	cis	rs7267348	0.579	rs6019867	chr20:48101910	G/A	cg03558299	chr20:47662597	CSE1L	-0.63	-4.25	-0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.81	-0.54	8.78e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.53	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.48	4.57	0.35	9.8200000000000008e-06	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.46	5.56	0.41	1.16e-7	Lung function (FEV1);
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs35955747	0.838	rs7285171	chr22:31598367	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-4.8	-0.36	3.78e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1035491	0.683	rs2366900	chr5:63923337	C/T	cg01791865	chr5:63954708	NA	0.51	5.47	0.41	1.79e-7	Body mass index;
PAAD	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	4.47	0.34	1.55e-5	Blood metabolite levels;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.58	6.36	0.46	2.28e-9	Cardiovascular disease risk factors;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12377026	chr5:180276718	ZFP62	-0.53	-6.53	-0.47	9.27e-10	Energy expenditure (24h);
PAAD	cis	rs8067545	0.750	rs1421174	chr17:19950190	G/T	cg13482628	chr17:19912719	NA	0.68	7.24	0.51	2.03e-11	Schizophrenia;
PAAD	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.56	-0.35	1.03e-5	Vitiligo;
PAAD	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg01851573	chr8:8652454	MFHAS1	0.62	5.33	0.4	3.42e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs75757892	0.544	rs113336062	chr6:7315518	G/A	cg02954307	chr6:7269328	NA	0.54	4.52	0.34	1.23e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.56	7.68	0.53	1.81e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg22143856	chr6:28129313	ZNF389	0.66	5.33	0.4	3.5e-7	Depression;
PAAD	cis	rs6142102	0.961	rs2268088	chr20:32649064	G/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-7.4	-0.51	8.69e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.67	7.51	0.52	4.59e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg00181669	chr3:44000978	NA	0.44	4.35	0.33	2.48e-5	Coronary artery disease;
PAAD	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.5	-4.28	-0.33	3.26e-5	Lymphocyte counts;
PAAD	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg04160749	chr8:58172571	NA	-0.65	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	1.14	10.42	0.65	1.5700000000000001e-19	Initial pursuit acceleration;
PAAD	cis	rs7923609	0.875	rs10761741	chr10:65066186	G/T	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.79e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.66	0.35	6.98e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3813948	0.543	rs11120218	chr1:207278451	C/T	cg26044340	chr1:207277291	C4BPA	-0.81	-5.1	-0.38	1.01e-6	C4b binding protein levels;
PAAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg01966878	chr4:90757139	SNCA	-0.64	-5.36	-0.4	3.05e-7	Neuroticism;
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-7.69	-0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg17644776	chr2:200775616	C2orf69	0.65	5.14	0.38	8.41e-7	Schizophrenia;
PAAD	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-4.77	-0.36	4.34e-6	Asthma;
PAAD	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg07220939	chr11:64358617	SLC22A12	0.43	4.39	0.34	2.12e-5	Urate levels in obese individuals;
PAAD	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	7.27	0.51	1.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg02264943	chr11:130785842	SNX19	0.38	4.25	0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs275456	0.614	rs275462	chr5:6805326	A/G	cg10857441	chr5:6722123	POLS	-0.39	-4.6	-0.35	8.83e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs1879734	0.636	rs12043520	chr1:54184097	G/A	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs7577696	0.889	rs2365558	chr2:32336657	C/T	cg02381751	chr2:32503542	YIPF4	-0.42	-4.59	-0.35	9.33e-6	Inflammatory biomarkers;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.98	-0.49	8.7e-11	Capecitabine sensitivity;
PAAD	cis	rs9715521	0.775	rs56957240	chr4:59847774	C/A	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10009908	chr4:135865451	NA	-0.6	-6.43	-0.46	1.56e-9	Obesity-related traits;
PAAD	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.69	6.35	0.46	2.33e-9	Endometrial cancer;
PAAD	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.67	-0.35	6.65e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.32	-0.76	5.53e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.5	5.44	0.4	2.04e-7	Longevity;Endometriosis;
PAAD	cis	rs3126085	0.515	rs10788836	chr1:152350135	A/T	cg26876637	chr1:152193138	HRNR	-0.65	-4.93	-0.37	2.12e-6	Atopic dermatitis;
PAAD	cis	rs7101378	0.577	rs1396910	chr11:108897500	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs4704187	0.687	rs1477934	chr5:74423243	A/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs11853189	0.938	rs75281351	chr15:78579650	C/T	cg22935921	chr15:78556834	DNAJA4	0.78	5.36	0.4	3.03e-7	Red cell distribution width;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26549601	chr10:134560360	INPP5A	-0.46	-4.36	-0.33	2.43e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.66	7.34	0.51	1.21e-11	Resting heart rate;
PAAD	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg10248100	chr7:872053	UNC84A	0.56	4.37	0.33	2.32e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.75	-4.61	-0.35	8.32e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs16854884	0.770	rs6784938	chr3:143817528	C/T	cg06585982	chr3:143692056	C3orf58	0.5	4.91	0.37	2.36e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.68	7.55	0.52	3.72e-12	Body mass index;
PAAD	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.64	-0.8	4.76e-36	Height;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.67	-11.13	-0.67	2.04e-21	Longevity;Endometriosis;
PAAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.64	-5.62	-0.41	9.07e-8	Psoriasis;
PAAD	cis	rs11892454	0.544	rs7599961	chr2:26006479	A/G	cg03373490	chr2:26702396	OTOF	0.5	4.29	0.33	3.23e-5	Heschl's gyrus morphology;
PAAD	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg08601574	chr20:25228251	PYGB	-0.46	-4.43	-0.34	1.76e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg16576597	chr16:28551801	NUPR1	0.67	7.62	0.53	2.57e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7508	0.512	rs3886398	chr8:17880616	T/C	cg08627089	chr8:17753878	FGL1	-0.44	-4.35	-0.33	2.46e-5	Atrial fibrillation;
PAAD	cis	rs10267417	0.603	rs10950761	chr7:19912106	C/T	cg05791153	chr7:19748676	TWISTNB	0.66	4.72	0.36	5.37e-6	Night sleep phenotypes;
PAAD	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg15628303	chr1:26608928	UBXN11	-0.48	-4.84	-0.37	3.17e-6	Obesity-related traits;
PAAD	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.57	0.47	7.55e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs950880	0.710	rs12905	chr2:102960007	G/A	cg23450938	chr2:102972792	NA	0.44	4.65	0.35	7.18e-6	Serum protein levels (sST2);
PAAD	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg06637938	chr14:75390232	RPS6KL1	0.45	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg04254540	chr16:71951199	KIAA0174	-0.45	-4.27	-0.33	3.41e-5	Fibrinogen levels;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	7.45	0.52	6.58e-12	Lymphocyte counts;
PAAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.24e-6	Tonsillectomy;
PAAD	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg06970076	chr16:1560791	IFT140	0.54	4.88	0.37	2.71e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.68	8.18	0.55	1.08e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.12	0.38	9.02e-7	Multiple sclerosis;
PAAD	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg04257695	chr17:30186438	C17orf79	-0.53	-4.32	-0.33	2.76e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.07	0.5	5.34e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.38	-4.7	-0.36	5.81e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7737355	0.812	rs181738	chr5:130820451	T/C	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21004924	chr7:2070409	MAD1L1	-0.62	-6.38	-0.46	1.99e-9	Obesity-related traits;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13800542	chr6:137113325	MAP3K5	0.73	7.42	0.52	7.52e-12	Myopia (pathological);
PAAD	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.68	5.89	0.43	2.39e-8	Common traits (Other);
PAAD	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.63	-0.35	7.65e-6	Tuberculosis;
PAAD	cis	rs2124910	1.000	rs1457098	chr19:52021537	A/G	cg14953197	chr19:52005651	SIGLEC12	0.37	4.3	0.33	3.08e-5	Blood protein levels;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.36	-4.29	-0.33	3.21e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg11779900	chr17:80519722	FOXK2	-0.49	-5.02	-0.38	1.41e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg07338119	chr7:157211683	NA	-0.43	-4.4	-0.34	2.02e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg22189786	chr22:42395067	WBP2NL	-0.61	-5.06	-0.38	1.18e-6	Birth weight;
PAAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08893839	chr5:154027129	NA	0.76	5.78	0.42	4.01e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.56	-5.69	-0.42	6.29e-8	Multiple myeloma;
PAAD	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.72	4.73	0.36	5.13e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg22143856	chr6:28129313	ZNF389	0.68	5.44	0.4	2.1e-7	Depression;
PAAD	cis	rs11750568	0.754	rs7717952	chr5:178454737	T/C	cg10208897	chr5:178548229	ADAMTS2	0.46	4.65	0.35	7.31e-6	Height;
PAAD	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.38	0.64	2.01e-19	Smoking behavior;
PAAD	cis	rs2904967	0.562	rs239255	chr11:64987128	G/A	cg11802864	chr11:65308245	LTBP3	-0.5	-4.5	-0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.97	-0.37	1.82e-6	Bone mineral density;
PAAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.81	7.15	0.5	3.48e-11	Psoriasis;
PAAD	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7554547	0.600	rs2273290	chr1:12018378	C/G	cg13216073	chr1:12042593	MFN2	0.44	4.8	0.36	3.71e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg05313129	chr8:58192883	C8orf71	-0.44	-4.31	-0.33	2.95e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.07	-0.44	9.66e-9	Crohn's disease;
PAAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.75	8.94	0.59	1.22e-15	Bladder cancer;
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-4.92	-0.37	2.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	1.3	10.9	0.66	8.17e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg27490568	chr2:178487706	NA	0.41	4.25	0.33	3.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs375066	0.935	rs408549	chr19:44425619	T/A	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs79839061	0.732	rs7657330	chr4:825156	C/T	cg07828340	chr4:882639	GAK	1.22	6.41	0.46	1.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.92e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs59888335	0.929	rs67132955	chr3:80887338	A/C	cg21735741	chr3:80819488	NA	0.55	4.86	0.37	2.92e-6	Schizophrenia;
PAAD	cis	rs7092929	0.574	rs10795050	chr10:3538655	C/G	cg14308648	chr10:3568949	NA	0.63	6.26	0.45	3.82e-9	Coronary artery calcification;
PAAD	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.48	-4.58	-0.35	9.49e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.45	-4.8	-0.36	3.79e-6	Bipolar disorder;
PAAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg06375148	chr1:209958343	C1orf74	0.63	4.74	0.36	4.86e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	7.66	0.53	2e-12	Mood instability;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13560548	chr3:10150139	C3orf24	-0.57	-4.5	-0.34	1.32e-5	Alzheimer's disease;
PAAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.68	8.11	0.55	1.5700000000000001e-13	Multiple sclerosis;
PAAD	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.67	7.01	0.49	7.39e-11	Height;
PAAD	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.45e-7	Monocyte percentage of white cells;
PAAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.57	5.33	0.4	3.49e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.59	4.97	0.37	1.77e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.32	0.33	2.77e-5	Bone mineral density;
PAAD	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.89	-0.54	5.37e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.94	12.27	0.71	1.73e-24	Menarche (age at onset);
PAAD	cis	rs60311166	1.000	rs934839	chr3:52683898	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	1.22	5.85	0.43	2.88e-8	CTACK levels;
PAAD	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg12143784	chr7:64541923	NA	0.33	4.26	0.33	3.51e-5	Aortic root size;
PAAD	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg17201900	chr20:34330562	RBM39	0.63	4.36	0.33	2.34e-5	Total cholesterol levels;
PAAD	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.83	-5.84	-0.43	3.04e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.43	-0.34	1.81e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.47	5.05	0.38	1.27e-6	Lung cancer;
PAAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg13918804	chr1:2043761	PRKCZ	0.36	4.87	0.37	2.82e-6	Height;
PAAD	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18850112	chr2:70329648	NA	0.58	6.77	0.48	2.58e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg14343924	chr8:8086146	FLJ10661	-0.5	-4.66	-0.35	6.86e-6	Joint mobility (Beighton score);
PAAD	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.74	8.83	0.58	2.4e-15	Morning vs. evening chronotype;
PAAD	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.58	-5.24	-0.39	5.19e-7	Obesity-related traits;
PAAD	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.37	9.57	0.61	2.81e-17	Diabetic retinopathy;
PAAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	6.2	0.45	5.08e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg27478167	chr7:817139	HEATR2	-0.7	-5.43	-0.4	2.22e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4908768	0.657	rs11121229	chr1:8831283	C/T	cg01329153	chr1:8417399	RERE	-0.52	-4.44	-0.34	1.74e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.28	7.35	0.51	1.15e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13198984	chr17:80129470	CCDC57	-0.43	-5.36	-0.4	3e-7	Life satisfaction;
PAAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.76	-8.79	-0.58	2.92e-15	Childhood ear infection;
PAAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.18e-10	Initial pursuit acceleration;
PAAD	cis	rs959260	1.000	rs4788889	chr17:73389126	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	trans	rs12714314	0.708	rs10203210	chr2:1966995	G/A	cg17170872	chr1:91487911	ZNF644	-0.75	-6.36	-0.46	2.24e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg00857998	chr1:205179979	DSTYK	-0.47	-4.53	-0.35	1.17e-5	Reticulocyte count;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01200585	chr1:228362443	C1orf69	0.56	6.24	0.45	4.15e-9	Diastolic blood pressure;
PAAD	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs939584	1.000	rs13021737	chr2:632348	A/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs2422052	0.527	rs2276695	chr2:118814868	A/G	cg22545206	chr2:118617499	NA	0.43	4.37	0.33	2.31e-5	Mosquito bite size;
PAAD	cis	rs7072216	0.687	rs11597425	chr10:100154202	G/T	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg19767477	chr5:127420684	SLC12A2	0.52	4.27	0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg19904058	chr10:135279010	LOC619207	-0.47	-5.7	-0.42	6e-8	Systemic lupus erythematosus;
PAAD	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.47	-5.12	-0.38	9.09e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg00543991	chr22:32367038	NA	1.13	7.12	0.5	4.06e-11	Childhood ear infection;
PAAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.57	-5.42	-0.4	2.3e-7	Monocyte count;
PAAD	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-0.92	-8.97	-0.59	1.01e-15	Exhaled nitric oxide output;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.56	-5.93	-0.43	1.92e-8	Lung cancer;
PAAD	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.67	-8.15	-0.55	1.25e-13	Dupuytren's disease;
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.8	8.99	0.59	9.27e-16	Lung cancer;
PAAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.55	-0.41	1.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.31	-0.33	2.92e-5	Aortic root size;
PAAD	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.81	5.21	0.39	5.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg09659197	chr4:152720779	NA	-0.42	-5.46	-0.4	1.93e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.53	-4.28	-0.33	3.31e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.48	4.3	0.33	3e-5	Arsenic metabolism;
PAAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg07959070	chr22:50026188	C22orf34	-0.39	-4.77	-0.36	4.25e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.92	-10.03	-0.63	1.76e-18	Parkinson's disease;
PAAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-9.86	-0.62	4.96e-18	Height;
PAAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg20849893	chr7:64541193	NA	0.55	5.4	0.4	2.55e-7	Calcium levels;
PAAD	cis	rs282587	0.569	rs7326827	chr13:113408866	T/C	cg02820901	chr13:113351484	ATP11A	-0.67	-5.14	-0.38	8.31e-7	Glycated hemoglobin levels;
PAAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.34	0.4	3.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	0.850	rs12774453	chr10:46038921	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	0.93	6.03	0.44	1.22e-8	Fat distribution (HIV);
PAAD	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.81	-7.57	-0.52	3.41e-12	DNA methylation (variation);
PAAD	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg00522288	chr12:125625016	AACS	-0.42	-4.5	-0.34	1.36e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.85	-6.86	-0.49	1.6e-10	Obesity-related traits;
PAAD	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.49	0.76	1.99e-30	Headache;
PAAD	cis	rs4704187	0.687	rs4235683	chr5:74415088	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2016586	0.796	rs5750158	chr22:36101567	T/C	cg26342177	chr22:36113512	APOL5	-0.43	-4.43	-0.34	1.81e-5	Body mass index;
PAAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4795519	0.528	rs8081588	chr17:22234406	A/G	cg22648282	chr17:21454238	C17orf51	-0.5	-5.2	-0.39	6.26e-7	Chronic myeloid leukemia;
PAAD	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.46	-0.41	1.88e-7	Bladder cancer;
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.51	5.29	0.39	4.19e-7	Blood metabolite levels;
PAAD	cis	rs11955175	1.000	rs11954639	chr5:40674979	A/G	cg17351974	chr5:40835760	RPL37	-0.78	-4.56	-0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.86	6.57	0.47	7.58e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg23711669	chr6:146136114	FBXO30	0.79	8.61	0.57	8.83e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.47	-0.34	1.49e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.93	-8.17	-0.55	1.09e-13	Other erythrocyte phenotypes;
PAAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.6	7.17	0.5	3.12e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg14926445	chr8:58193284	C8orf71	-0.66	-5.38	-0.4	2.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9913156	0.748	rs72835630	chr17:4562449	C/T	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.86	0.43	2.72e-8	Major depressive disorder;
PAAD	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.3	-4.66	-0.35	6.98e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10274279	0.614	rs12540318	chr7:157398102	C/T	cg26886268	chr7:157387156	PTPRN2	-0.73	-5.51	-0.41	1.52e-7	Myopia (pathological);
PAAD	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.88	-10.42	-0.65	1.65e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04016744	chr4:156874766	CTSO	0.56	6.29	0.45	3.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.62	5.34	0.4	3.34e-7	Resistin levels;
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.59	5.34	0.4	3.27e-7	Interleukin-17 levels;
PAAD	cis	rs12304921	1.000	rs12317171	chr12:51337669	C/T	cg04427360	chr12:51347099	HIGD1C	0.67	5.13	0.38	8.59e-7	Type 2 diabetes;
PAAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.47	-5.0	-0.38	1.56e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.26	-0.56	6.67e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs600626	0.947	rs10160784	chr11:75456055	T/C	cg24262691	chr11:75473276	NA	0.53	4.99	0.38	1.62e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs939584	0.825	rs5017303	chr2:630995	T/G	cg14515364	chr2:636606	NA	0.52	4.73	0.36	5.09e-6	Body mass index;
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.58	-5.53	-0.41	1.35e-7	Menarche (age at onset);
PAAD	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg16434002	chr17:42200994	HDAC5	0.63	5.92	0.43	2.09e-8	Total body bone mineral density;
PAAD	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.71	7.75	0.53	1.19e-12	Ulcerative colitis;
PAAD	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.97	11.66	0.69	7.8e-23	Osteoporosis;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.74	-0.36	4.82e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.54	-5.29	-0.39	4.11e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.24	-0.39	5.28e-7	Mean corpuscular volume;
PAAD	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.6	6.12	0.44	7.46e-9	Ovarian reserve;
PAAD	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.77	-8.77	-0.58	3.32e-15	Colorectal cancer;
PAAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06112835	chr11:68658793	MRPL21	0.61	5.97	0.44	1.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7631605	0.875	rs7372657	chr3:37101149	G/A	cg17445812	chr3:36986805	TRANK1	0.36	4.8	0.36	3.84e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9346455	0.614	rs2208845	chr6:71997278	T/C	cg27238071	chr6:71998145	OGFRL1	0.76	4.5	0.34	1.35e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.61	-6.92	-0.49	1.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.7	-7.14	-0.5	3.53e-11	Multiple sclerosis;
PAAD	cis	rs3136441	1.000	rs7941964	chr11:46805575	G/A	cg19486271	chr11:47235900	DDB2	-0.56	-4.58	-0.35	9.64e-6	HDL cholesterol;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	5.4	0.4	2.46e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.81	0.36	3.64e-6	Thyroid stimulating hormone;
PAAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.21	0.45	4.79e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs58521262	0.585	rs176456	chr19:23166966	G/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs818427	0.964	rs1093677	chr5:112218700	T/C	cg06941702	chr5:112196734	SRP19	0.46	4.33	0.33	2.72e-5	Total body bone mineral density;
PAAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	trans	rs7172971	0.688	rs76779748	chr15:42386385	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12737869	chr9:111696591	C9orf6;IKBKAP	0.6	6.78	0.48	2.47e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.52	-5.69	-0.42	6.42e-8	Longevity;
PAAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg18099408	chr3:52552593	STAB1	-0.48	-5.42	-0.4	2.29e-7	Electroencephalogram traits;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.43	-0.4	2.23e-7	Obesity-related traits;
PAAD	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	5.31	0.4	3.91e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7998202	0.567	rs914019	chr13:113352911	A/G	cg02820901	chr13:113351484	ATP11A	0.72	4.72	0.36	5.24e-6	Glycated hemoglobin levels;
PAAD	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.4	4.42	0.34	1.85e-5	Calcium levels;
PAAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg03676636	chr4:99064102	C4orf37	-0.26	-4.45	-0.34	1.66e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg09168692	chr1:7887560	PER3	-0.42	-4.33	-0.33	2.73e-5	Inflammatory bowel disease;
PAAD	cis	rs6743376	0.556	rs2472188	chr2:113820814	C/G	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.53	4.7	0.36	5.79e-6	Depression;
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.96	-10.09	-0.63	1.2e-18	Cancer (pleiotropy);
PAAD	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-4.36	-0.33	2.43e-5	Diabetic retinopathy;
PAAD	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.93	11.15	0.67	1.77e-21	Bone mineral density;
PAAD	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.83	8.25	0.56	7.05e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	6.58	0.47	7e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.91	12.22	0.7	2.41e-24	Body mass index;
PAAD	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg25801113	chr15:45476975	SHF	-0.41	-4.84	-0.37	3.17e-6	Uric acid levels;
PAAD	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.77	8.72	0.58	4.58e-15	Eosinophil percentage of white cells;
PAAD	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	8.53	0.57	1.37e-14	Prudent dietary pattern;
PAAD	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg11783602	chr8:55087084	NA	-0.64	-7.73	-0.53	1.35e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg23127183	chr11:57508653	C11orf31	0.51	4.34	0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg15676125	chr6:33679581	C6orf125	0.44	4.28	0.33	3.28e-5	Plateletcrit;
PAAD	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.93	9.43	0.61	6.56e-17	Response to antineoplastic agents;
PAAD	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg20673841	chr7:107026890	COG5	0.5	4.37	0.33	2.29e-5	Coronary artery disease;
PAAD	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.15	0.45	6.51e-9	Mean platelet volume;
PAAD	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.38	0.56	3.27e-14	Dupuytren's disease;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg15693483	chr7:1102177	C7orf50	0.49	5.39	0.4	2.64e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg04089426	chr11:65307791	LTBP3	0.93	4.6	0.35	8.85e-6	Height;
PAAD	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg08132940	chr7:1081526	C7orf50	0.6	4.5	0.34	1.34e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	6.36	0.46	2.23e-9	Body mass index;
PAAD	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg02404636	chr22:31891804	SFI1	-0.55	-5.34	-0.4	3.26e-7	Paclitaxel-induced neuropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23045046	chr3:183602931	PARL	0.65	6.71	0.48	3.59e-10	Obesity-related traits;
PAAD	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg06713675	chr4:122721982	EXOSC9	0.47	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg08132940	chr7:1081526	C7orf50	0.6	4.42	0.34	1.89e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2241685	0.834	rs11127299	chr2:1961787	A/G	cg22511877	chr2:1942942	MYT1L	-0.71	-4.85	-0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.65	-5.89	-0.43	2.38e-8	Serum sulfate level;
PAAD	cis	rs6976053	0.728	rs4729621	chr7:100519825	C/T	cg10426581	chr7:100472382	SRRT	0.43	4.34	0.33	2.63e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.29	-0.51	1.56e-11	Personality dimensions;
PAAD	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08893839	chr5:154027129	NA	-0.76	-6.12	-0.44	7.77e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg25019722	chr6:37503610	NA	-0.37	-4.26	-0.33	3.51e-5	Cognitive performance;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs17095355	1.000	rs12244557	chr10:111746142	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.65	-0.35	7.03e-6	Biliary atresia;
PAAD	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.54	5.84	0.43	3.04e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.52	-5.55	-0.41	1.23e-7	Tonsillectomy;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.98	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg14012564	chr10:47133876	LOC728643	0.66	6.31	0.46	2.86e-9	Blood protein levels;
PAAD	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg02795151	chr17:7402630	POLR2A	-0.58	-5.37	-0.4	2.96e-7	Androgen levels;
PAAD	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.0	0.44	1.39e-8	Red blood cell count;
PAAD	cis	rs9646944	0.685	rs13406331	chr2:102866644	G/A	cg20060108	chr2:102954350	IL1RL1	0.54	4.29	0.33	3.16e-5	Blood protein levels;
PAAD	cis	rs12453682	0.568	rs3794712	chr17:37791487	A/C	cg07936489	chr17:37558343	FBXL20	-0.58	-4.66	-0.35	6.85e-6	Mean corpuscular hemoglobin;Red blood cell count;
PAAD	cis	rs59888335	0.929	rs4321489	chr3:80853760	A/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg00450029	chr8:599525	NA	0.78	5.16	0.39	7.56e-7	IgG glycosylation;
PAAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg14349672	chr11:133703707	NA	-0.58	-6.81	-0.48	2.11e-10	Childhood ear infection;
PAAD	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.33	0.6	1.2e-16	Hemoglobin concentration;
PAAD	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg03037974	chr15:76606532	NA	0.52	5.94	0.43	1.91e-8	Blood metabolite levels;
PAAD	cis	rs3745672	0.590	rs10409622	chr19:12168750	C/G	cg11321965	chr19:12780562	MORG1;C19orf56	-1.03	-4.66	-0.35	6.79e-6	Multiple sclerosis;
PAAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.09	0.55	1.73e-13	Schizophrenia;
PAAD	cis	rs1977876	0.929	rs6679498	chr1:211712690	A/G	cg01575408	chr1:211752895	SLC30A1	0.55	4.56	0.35	1.04e-5	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs1468333	0.667	rs113322698	chr5:137769576	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.34	-0.46	2.44e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg10820045	chr2:198174542	NA	0.48	4.93	0.37	2.15e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.44	4.93	0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.78	9.16	0.6	3.35e-16	Lewy body disease;
PAAD	cis	rs7178572	0.539	rs4886849	chr15:77384002	T/C	cg22256960	chr15:77711686	NA	-0.54	-4.67	-0.35	6.5e-6	Type 2 diabetes;
PAAD	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg10547527	chr2:198650123	BOLL	0.49	4.31	0.33	2.98e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.91	0.59	1.44e-15	Lung cancer;
PAAD	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg17366294	chr4:99064904	C4orf37	0.46	5.07	0.38	1.14e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg12623918	chr2:306882	NA	-0.59	-4.58	-0.35	9.58e-6	Blood protein levels;
PAAD	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.68	-6.6	-0.47	6.63e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-5.66	-0.42	7.3900000000000007e-08	Fear of minor pain;
PAAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.6	-5.91	-0.43	2.18e-8	Obesity-related traits;
PAAD	cis	rs2274459	0.841	rs3818532	chr6:33679807	C/T	cg06253072	chr6:33679850	C6orf125	-0.64	-4.76	-0.36	4.43e-6	Obesity (extreme);
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26549601	chr10:134560360	INPP5A	0.49	4.79	0.36	3.94e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg15571903	chr15:79123663	NA	0.5	6.42	0.46	1.62e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.68	-7.73	-0.53	1.35e-12	Motion sickness;
PAAD	cis	rs2965280	1.000	rs2910412	chr19:34921161	A/G	cg00878516	chr19:35842853	FFAR1	-0.65	-4.27	-0.33	3.4e-5	Colorectal cancer;
PAAD	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs2271001	0.869	rs2042688	chr11:19186294	G/T	cg00161556	chr11:19138045	ZDHHC13	0.48	4.99	0.38	1.6e-6	Gut microbiome composition (winter);
PAAD	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.39	-0.34	2.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg02016764	chr4:38805732	TLR1	-0.62	-4.75	-0.36	4.61e-6	Breast cancer;
PAAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2411984	1.000	rs2411984	chr17:47445751	G/A	cg08112188	chr17:47440006	ZNF652	0.5	4.64	0.35	7.57e-6	Sex hormone-binding globulin levels;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg16406658	chr1:27816764	WASF2	-0.78	-6.77	-0.48	2.68e-10	Photic sneeze reflex;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	trans	rs9470794	0.790	rs1885324	chr6:38072827	G/C	cg12309348	chr17:32904255	C17orf102	0.58	6.37	0.46	2.16e-9	Type 2 diabetes;
PAAD	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	cis	rs802075	0.905	rs7746868	chr6:49642763	A/C	cg20364632	chr6:49636226	NA	0.51	5.86	0.43	2.73e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.75	6.67	0.48	4.49e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.84	-10.43	-0.65	1.55e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.47e-7	Total body bone mineral density;
PAAD	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.77	7.45	0.52	6.58e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8077059	0.885	rs9905339	chr17:55824331	A/G	cg12582317	chr17:55822272	NA	0.5	4.77	0.36	4.2e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.82	-9.57	-0.61	2.83e-17	Mean platelet volume;
PAAD	cis	rs10905065	0.648	rs4237365	chr10:5821484	T/G	cg11519256	chr10:5708881	ASB13	-0.51	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.85	-7.86	-0.54	6.59e-13	Exhaled nitric oxide output;
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg14393609	chr7:65229607	NA	0.62	6.71	0.48	3.62e-10	Calcium levels;
PAAD	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.67	6.73	0.48	3.25e-10	Body mass index;
PAAD	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.76	-5.27	-0.39	4.62e-7	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg27449745	chr7:23145252	KLHL7	-0.5	-4.4	-0.34	2.04e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7255045	0.788	rs2290689	chr19:12958360	T/C	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs3743102	0.591	rs17841171	chr15:83358388	C/T	cg00614314	chr15:82944287	LOC80154	0.8	5.78	0.42	4.19e-8	Colorectal adenoma (advanced);
PAAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg06740227	chr12:86229804	RASSF9	0.52	5.21	0.39	5.95e-7	Major depressive disorder;
PAAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.5	-5.01	-0.38	1.48e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.7	-5.99	-0.44	1.47e-8	Gut microbiome composition (summer);
PAAD	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.79	-0.42	3.96e-8	Androgen levels;
PAAD	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs3764400	0.567	rs16951519	chr17:46152291	G/A	cg10706073	chr17:46328419	SKAP1	-1.08	-6.38	-0.46	2.02e-9	Body mass index;
PAAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.7	-6.2	-0.45	5.18e-9	Menarche (age at onset);
PAAD	cis	rs9913156	0.841	rs7223840	chr17:4562150	T/C	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs2659067	1.000	rs2659067	chr19:51485622	A/G	cg27497839	chr19:51487305	KLK7	-0.84	-4.68	-0.35	6.34e-6	Blood protein levels;
PAAD	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.14	-0.64	8.97e-19	Response to antipsychotic treatment;
PAAD	cis	rs9472414	0.510	rs227853	chr6:44699746	T/C	cg20913747	chr6:44695427	NA	0.57	6.06	0.44	1e-8	Height;
PAAD	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg23173402	chr1:227635558	NA	0.7	4.67	0.35	6.45e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-1.22	-12.07	-0.7	5.9e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg21856205	chr7:94953877	PON1	0.54	4.38	0.34	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg22139774	chr2:100720529	AFF3	-0.36	-4.27	-0.33	3.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.46	6.05	0.44	1.08e-8	Childhood ear infection;
PAAD	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg10547527	chr2:198650123	BOLL	-0.64	-4.3	-0.33	3.02e-5	Ulcerative colitis;
PAAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	5.78	0.42	4.18e-8	Coronary artery disease;
PAAD	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.82	9.53	0.61	3.68e-17	Blood metabolite ratios;
PAAD	cis	rs2882667	0.690	rs288007	chr5:138230628	C/T	cg09476006	chr5:138032270	NA	0.43	5.35	0.4	3.15e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.91	12.36	0.71	9.71e-25	Prudent dietary pattern;
PAAD	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21250466	chr4:854474	GAK	0.64	6.98	0.49	8.65e-11	Warfarin maintenance dose;
PAAD	cis	rs3996993	0.724	rs2608631	chr6:52626269	C/T	cg00536792	chr6:53530503	KLHL31	0.45	4.55	0.35	1.07e-5	Hemoglobin concentration;
PAAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.63	-5.96	-0.44	1.72e-8	Body mass index;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18621852	chr3:10150065	C3orf24	0.64	5.51	0.41	1.5e-7	Alzheimer's disease;
PAAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	1.13	12.0	0.7	9.17e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.73	8.69	0.58	5.38e-15	Methadone dose in opioid dependence;
PAAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.55	6.7	0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06898199	chr7:128502890	ATP6V1F	0.63	7.34	0.51	1.18e-11	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17813221	chr2:147344944	PABPC1P2	-0.63	-6.4	-0.46	1.83e-9	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.24	-0.51	2.13e-11	Personality dimensions;
PAAD	cis	rs2398893	0.960	rs56335449	chr9:96748795	G/A	cg14459158	chr9:96720562	NA	0.33	4.27	0.33	3.44e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg26536354	chr8:144654954	C8orf73	0.72	4.34	0.33	2.56e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.94	6.17	0.45	6.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10373780	chr19:8455179	RAB11B	0.68	7.0	0.49	7.8e-11	Obesity-related traits;
PAAD	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs12773846	0.843	rs12785089	chr10:126274217	G/C	cg04949429	chr10:126290192	LHPP	0.5	5.01	0.38	1.51e-6	Subcutaneous adipose tissue;
PAAD	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg23331303	chr5:5135948	NA	0.47	6.65	0.47	4.94e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14219562	chr21:42617934	BACE2	-0.7	-6.82	-0.48	2.06e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.52	-7.93	-0.54	4.51e-13	Urinary metabolites;
PAAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg06740227	chr12:86229804	RASSF9	0.56	5.03	0.38	1.38e-6	Major depressive disorder;
PAAD	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11995313	chr8:8860691	ERI1	0.51	5.2	0.39	6.47e-7	Joint mobility (Beighton score);
PAAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.81	9.73	0.62	1.05e-17	Bladder cancer;
PAAD	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.52	-6.48	-0.47	1.21e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg00531865	chr16:30841666	NA	-0.52	-5.08	-0.38	1.09e-6	Dementia with Lewy bodies;
PAAD	cis	rs7631605	0.905	rs9852810	chr3:37068969	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.52	5.11	0.38	9.43e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg07648498	chr16:89883185	FANCA	0.46	4.32	0.33	2.78e-5	Vitiligo;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21178979	chr7:1889533	MAD1L1	0.4	4.42	0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.74	8.53	0.57	1.35e-14	Birth weight;
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.82	9.73	0.62	1.08e-17	Menopause (age at onset);
PAAD	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg23947450	chr7:900037	UNC84A	-0.56	-4.54	-0.35	1.14e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6831352	0.569	rs4148883	chr4:100066332	T/C	cg12011299	chr4:100065546	ADH4	0.47	5.45	0.4	1.99e-7	Alcohol dependence;
PAAD	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs9815354	0.680	rs7649989	chr3:41865843	A/C	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg14008862	chr17:28927542	LRRC37B2	0.86	6.21	0.45	4.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10991814	0.920	rs79043982	chr9:94012532	G/A	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs72960926	1.000	rs55958316	chr6:75103944	C/T	cg03266952	chr6:74778945	NA	-1.04	-5.63	-0.42	8.51e-8	Metabolite levels (MHPG);
PAAD	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.61	5.39	0.4	2.63e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.91e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.72	5.87	0.43	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg02734326	chr4:10020555	SLC2A9	-0.5	-5.13	-0.38	8.75e-7	Bone mineral density;
PAAD	cis	rs75920871	0.800	rs59700451	chr11:116982928	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.68	-0.35	6.38e-6	Subjective well-being;
PAAD	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7202877	0.519	rs4887811	chr16:75307251	C/T	cg03315344	chr16:75512273	CHST6	0.53	4.6	0.35	8.68e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg14393609	chr7:65229607	NA	-0.5	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9346353	0.713	rs2445957	chr6:70399894	T/C	cg03001484	chr6:70507230	LMBRD1	0.31	4.34	0.33	2.55e-5	Sleep duration;
PAAD	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06002616	chr8:101225028	SPAG1	0.46	5.39	0.4	2.58e-7	Atrioventricular conduction;
PAAD	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg19882132	chr14:106167949	NA	-0.55	-4.75	-0.36	4.73e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	6.7	0.48	3.77e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.69	7.02	0.5	6.75e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.73	7.46	0.52	6.23e-12	Schizophrenia;
PAAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg03098721	chr1:84464084	TTLL7	0.5	4.77	0.36	4.26e-6	Obesity-related traits;
PAAD	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	6.17	0.45	5.77e-9	Lung function (FEV1/FVC);
PAAD	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6700896	0.932	rs6678033	chr1:66077624	G/A	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.64e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.69	-6.56	-0.47	7.82e-10	Neurofibrillary tangles;
PAAD	cis	rs4321325	0.733	rs4284779	chr2:127946500	T/C	cg11380483	chr2:127933992	NA	0.69	5.18	0.39	7.04e-7	Protein C levels;
PAAD	cis	rs6906287	0.647	rs28655926	chr6:118688962	A/G	cg18833306	chr6:118973337	C6orf204	0.41	4.28	0.33	3.29e-5	Electrocardiographic conduction measures;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14099293	chr6:38607245	BTBD9	0.6	6.69	0.48	4.09e-10	Monocyte percentage of white cells;
PAAD	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg10885151	chr13:24270087	NA	0.39	4.38	0.33	2.18e-5	Obesity-related traits;
PAAD	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg18508148	chr11:34937573	PDHX;APIP	0.53	5.13	0.38	8.57e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14650175	chr8:141545624	EIF2C2	0.54	6.37	0.46	2.14e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.54	4.38	0.33	2.22e-5	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.76	-0.53	1.12e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4739066	0.579	rs77643961	chr8:63879716	A/G	cg12194929	chr8:63776755	NKAIN3	0.73	4.54	0.35	1.13e-5	Myocardial infarction;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.81	6.23	0.45	4.44e-9	Alzheimer's disease;
PAAD	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.31	-0.51	1.45e-11	Total cholesterol levels;
PAAD	cis	rs9346455	0.614	rs9364151	chr6:71997071	T/C	cg27238071	chr6:71998145	OGFRL1	0.76	4.5	0.34	1.35e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg04717802	chr22:42394638	WBP2NL	-0.52	-4.44	-0.34	1.69e-5	Birth weight;
PAAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg24733560	chr20:60626293	TAF4	0.51	6.5	0.47	1.09e-9	Body mass index;
PAAD	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg00999904	chr2:3704751	ALLC	-0.81	-8.06	-0.55	2.05e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.74	-0.36	4.84e-6	Body mass index;
PAAD	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7705042	0.796	rs1835965	chr5:141501771	G/A	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.45	5.96	0.43	1.73e-8	Childhood ear infection;
PAAD	cis	rs8053891	0.673	rs10492825	chr16:72018417	T/C	cg16558253	chr16:72132732	DHX38	-0.53	-4.74	-0.36	4.95e-6	Coronary artery disease;
PAAD	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.65	6.13	0.45	7.37e-9	Tourette syndrome;
PAAD	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-4.32	-0.33	2.82e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.55	-4.32	-0.33	2.75e-5	Urinary metabolites;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg17541715	chr7:1216824	NA	-0.55	-6.37	-0.46	2.17e-9	Longevity;Endometriosis;
PAAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	1.24	11.34	0.68	5.51e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs16975963	0.843	rs73041022	chr19:38272394	C/T	cg14218481	chr19:38281219	NA	0.44	4.6	0.35	8.92e-6	Longevity;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-4.41	-0.34	1.94e-5	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs990171	0.538	rs4851016	chr2:103120400	C/T	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs13102973	0.682	rs11938038	chr4:135894258	T/C	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05665937	chr4:1216051	CTBP1	0.48	5.03	0.38	1.34e-6	Obesity-related traits;
PAAD	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-6.59	-0.47	6.76e-10	Colorectal cancer;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.22	4.95	0.37	1.96e-6	Urinary tract infection frequency;
PAAD	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.84	6.15	0.45	6.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg04545296	chr12:48745243	ZNF641	0.36	4.61	0.35	8.42e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23475480	chr14:74413537	FAM161B	-0.72	-6.54	-0.47	8.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg07741184	chr6:167504864	NA	-0.37	-4.9	-0.37	2.42e-6	Primary biliary cholangitis;
PAAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.66	-5.11	-0.38	9.56e-7	Vitiligo;
PAAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg19930314	chr7:98593876	TRRAP	-0.5	-4.67	-0.35	6.47e-6	Breast cancer;
PAAD	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg20243544	chr17:37824526	PNMT	0.61	5.56	0.41	1.19e-7	Self-reported allergy;
PAAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg19784903	chr17:45786737	TBKBP1	0.46	4.81	0.36	3.62e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg27411982	chr8:10470053	RP1L1	-0.49	-5.55	-0.41	1.24e-7	Systolic blood pressure;
PAAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.57	-7.68	-0.53	1.78e-12	Renal cell carcinoma;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	7.72	0.53	1.48e-12	Prudent dietary pattern;
PAAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.56	-6.26	-0.45	3.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.98	-0.49	8.71e-11	Hip circumference;
PAAD	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg03989125	chr22:38214979	NA	-0.54	-5.58	-0.41	1.07e-7	Glioblastoma;Glioma;
PAAD	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.58	-0.41	1.08e-7	Colorectal cancer;
PAAD	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.61e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg08859206	chr1:53392774	SCP2	0.59	6.1	0.44	8.44e-9	Monocyte count;
PAAD	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4757319	0.515	rs4313573	chr11:15330598	A/G	cg03245590	chr11:15329459	NA	0.45	5.4	0.4	2.56e-7	Breast cancer;
PAAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.68	-7.69	-0.53	1.71e-12	Airway imaging phenotypes;
PAAD	cis	rs7594192	0.744	rs11681652	chr2:199366959	A/G	cg03163783	chr2:200326591	SATB2	0.33	4.4	0.34	2.02e-5	Educational attainment;
PAAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg16083429	chr3:49237500	CCDC36	0.46	4.48	0.34	1.43e-5	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg14440974	chr22:39074834	NA	-0.59	-7.15	-0.5	3.46e-11	Menopause (age at onset);
PAAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.83	-7.27	-0.51	1.73e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2457480	0.657	rs2624683	chr10:44679140	A/G	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10105999	chr11:65337913	SSSCA1	0.63	7.01	0.49	7.48e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.56	6.13	0.44	7.38e-9	Menopause (age at onset);
PAAD	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg25930673	chr12:123319894	HIP1R	1.21	6.08	0.44	9.3e-9	Adiponectin levels;
PAAD	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.79	0.48	2.38e-10	Exhaled nitric oxide levels;
PAAD	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg14393609	chr7:65229607	NA	0.46	4.89	0.37	2.53e-6	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17213010	chr2:74329809	TET3	-0.64	-6.8	-0.48	2.23e-10	Myopia (pathological);
PAAD	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.66	-7.42	-0.52	7.88e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12060982	chr7:102608657	FBXL13	0.56	6.5	0.47	1.06e-9	Smoking initiation;
PAAD	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.58	-0.47	7.21e-10	Total body bone mineral density;
PAAD	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.48	6.92	0.49	1.18e-10	Oropharynx cancer;
PAAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.83	9.11	0.59	4.47e-16	Tuberculosis;
PAAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.6	6.19	0.45	5.4e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1190596	0.830	rs4947	chr14:102550803	G/A	cg23904247	chr14:102554826	HSP90AA1	-0.49	-5.41	-0.4	2.44e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg00555438	chr3:195578280	NA	0.54	4.51	0.34	1.28e-5	Pancreatic cancer;
PAAD	cis	rs4356203	0.811	rs214920	chr11:17237949	A/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.51	-4.52	-0.34	1.25e-5	Lung cancer;
PAAD	cis	rs1358748	0.522	rs6588237	chr1:67558739	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	4.25	0.33	3.67e-5	Tuberculosis;
PAAD	cis	rs9303280	0.743	rs2941522	chr17:37910368	C/T	cg20243544	chr17:37824526	PNMT	-0.61	-5.9	-0.43	2.28e-8	Self-reported allergy;
PAAD	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.62	-5.25	-0.39	4.99e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg02404636	chr22:31891804	SFI1	0.64	5.93	0.43	1.99e-8	Colorectal cancer;
PAAD	cis	rs17152411	0.901	rs7098050	chr10:126657015	G/T	cg07906193	chr10:126599966	NA	0.7	5.54	0.41	1.33e-7	Height;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.95	-16.1	-0.79	1.17e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.94	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	cis	rs1957429	0.522	rs76721513	chr14:65403891	C/G	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.51	-5.16	-0.39	7.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.84	9.43	0.61	6.4e-17	Tuberculosis;
PAAD	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.94	-10.41	-0.65	1.67e-19	Parkinson's disease;
PAAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17264618	chr3:40429014	ENTPD3	0.35	4.33	0.33	2.65e-5	Renal cell carcinoma;
PAAD	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg18404041	chr3:52824283	ITIH1	0.44	4.86	0.37	2.91e-6	Electroencephalogram traits;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg12143784	chr7:64541923	NA	0.38	4.91	0.37	2.34e-6	Calcium levels;
PAAD	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.61	4.59	0.35	9.28e-6	Alzheimer's disease (survival time);
PAAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.43	6.63	0.47	5.64e-10	Height;
PAAD	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.71	6.07	0.44	9.76e-9	Schizophrenia;
PAAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg13859433	chr6:33739653	LEMD2	-0.67	-5.43	-0.4	2.16e-7	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.58	-0.47	7.16e-10	Response to antipsychotic treatment;
PAAD	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.22	-0.45	4.64e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.87	9.27	0.6	1.7e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.7	5.89	0.43	2.35e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs4595586	0.505	rs11609838	chr12:39413277	C/T	cg13010199	chr12:38710504	ALG10B	0.59	4.81	0.36	3.64e-6	Morning vs. evening chronotype;
PAAD	cis	rs4740619	1.000	rs4741524	chr9:15634249	A/T	cg14451791	chr9:16040625	NA	-0.37	-4.36	-0.33	2.34e-5	Body mass index;
PAAD	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.62	6.93	0.49	1.14e-10	Height;
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg07701084	chr6:150067640	NUP43	0.51	4.38	0.33	2.24e-5	Testicular germ cell tumor;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07157834	chr1:205819609	PM20D1	0.87	10.28	0.64	3.83e-19	Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01927065	chr2:97001301	NCAPH	-0.75	-6.6	-0.47	6.58e-10	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25974308	chr4:99852387	EIF4E	-0.76	-7.85	-0.54	6.75e-13	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14795528	chr7:157451260	PTPRN2	0.56	6.65	0.47	4.95e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg14686297	chr22:46650375	NA	0.43	4.33	0.33	2.71e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.5	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs743757	1.000	rs929047	chr3:50503170	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.73	5.04	0.38	1.29e-6	Diastolic blood pressure;
PAAD	cis	rs10512697	0.655	rs13178645	chr5:3501248	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.38	-0.34	2.16e-5	Post bronchodilator FEV1;
PAAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg10556349	chr10:835070	NA	0.6	5.07	0.38	1.12e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg16736954	chr20:23401023	NAPB	0.75	4.29	0.33	3.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg03060546	chr3:49711283	APEH	0.53	4.57	0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.89	-0.43	2.42e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7707921	1.000	rs79616997	chr5:81504600	G/T	cg21483461	chr5:81570383	RPS23	-0.57	-4.74	-0.36	4.94e-6	Breast cancer;
PAAD	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs939584	1.000	rs13007086	chr2:630034	A/T	cg03610516	chr2:642275	NA	0.63	5.45	0.4	2.03e-7	Body mass index;
PAAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg14393609	chr7:65229607	NA	0.47	5.01	0.38	1.52e-6	Aortic root size;
PAAD	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg11494091	chr17:61959527	GH2	0.52	4.31	0.33	2.87e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2790216	0.901	rs2486480	chr10:59999804	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg02961798	chr16:67687392	RLTPR	-0.39	-4.35	-0.33	2.5e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7291412	0.662	rs7292297	chr22:46458123	T/G	cg09693106	chr22:46449821	C22orf26;LOC150381	0.42	4.4	0.34	2e-5	Dupuytren's disease;Subjective well-being;
PAAD	trans	rs7569084	1.000	rs7583469	chr2:65651356	C/T	cg19155100	chr2:233748146	NGEF	-0.59	-6.32	-0.46	2.75e-9	Sum eosinophil basophil counts;
PAAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg03983715	chr16:68378420	PRMT7	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg03605463	chr16:89740564	NA	0.62	6.21	0.45	4.83e-9	Vitiligo;
PAAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs901683	1.000	rs34618850	chr10:46087863	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7180079	1.000	rs12903745	chr15:64632840	G/A	cg18210365	chr15:65066710	RBPMS2	0.64	4.92	0.37	2.24e-6	Monocyte count;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg02353165	chr6:42928485	GNMT	0.82	9.99	0.63	2.28e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.84	8.94	0.59	1.21e-15	Osteoporosis;
PAAD	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.51	-5.0	-0.38	1.56e-6	Mean platelet volume;
PAAD	cis	rs7246760	0.500	rs67257773	chr19:9997352	C/T	cg07515324	chr19:10461336	TYK2	-0.89	-4.62	-0.35	8.13e-6	Pursuit maintenance gain;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.97	10.89	0.66	8.76e-21	Parkinson's disease;
PAAD	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg06569542	chr10:98946673	SLIT1	0.51	5.68	0.42	6.62e-8	Monocyte count;
PAAD	cis	rs7696796	0.662	rs35865668	chr4:183179515	T/C	cg03209412	chr4:183728196	NA	-0.57	-4.71	-0.36	5.47e-6	Neuroticism;
PAAD	cis	rs7925523	0.891	rs11827215	chr11:61458595	G/A	cg12472022	chr11:61462803	DAGLA	0.62	5.11	0.38	9.33e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs6701037	0.522	rs7521981	chr1:175091151	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.39	-0.4	2.65e-7	Alcohol dependence;
PAAD	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	6.33	0.46	2.67e-9	Schizophrenia (age at onset);
PAAD	cis	rs6466055	0.612	rs60358227	chr7:104858640	A/G	cg04380332	chr7:105027541	SRPK2	0.47	4.53	0.35	1.17e-5	Schizophrenia;
PAAD	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg04450456	chr4:17643702	FAM184B	0.51	5.5	0.41	1.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.86	-6.33	-0.46	2.67e-9	Blood protein levels;
PAAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg11764359	chr7:65958608	NA	0.8	5.29	0.39	4.12e-7	Diabetic kidney disease;
PAAD	cis	rs9687846	0.877	rs3843467	chr5:55856375	A/C	cg15001016	chr5:55860904	NA	0.46	4.53	0.34	1.18e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07879540	chr7:75508716	RHBDD2	-0.67	-6.83	-0.48	1.94e-10	Lung cancer in ever smokers;
PAAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.87	10.21	0.64	5.7e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg20159608	chr7:32802032	NA	-0.56	-5.52	-0.41	1.46e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9815354	1.000	rs1613759	chr3:41906183	G/A	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-5.12	-0.38	9.15e-7	Personality dimensions;
PAAD	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.11e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.86	-0.37	2.92e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.57	-6.02	-0.44	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg05925327	chr15:68127851	NA	-0.49	-4.41	-0.34	1.94e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg24110177	chr3:50126178	RBM5	-0.61	-4.7	-0.36	5.67e-6	Menarche (age at onset);
PAAD	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.52	0.47	1.01e-9	Schizophrenia;
PAAD	cis	rs61884328	0.733	rs17197710	chr11:47225996	C/T	cg23433285	chr11:47201945	PACSIN3	-0.8	-4.45	-0.34	1.69e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.5	4.84	0.37	3.11e-6	Migraine;
PAAD	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.5	4.4	0.34	2e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.49e-8	Menopause (age at onset);
PAAD	cis	rs27434	0.583	rs151908	chr5:96156494	A/G	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.85	8.45	0.57	2.24e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg08088566	chr11:430123	ANO9	0.79	4.42	0.34	1.84e-5	Body mass index;
PAAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg03989125	chr22:38214979	NA	0.61	5.65	0.42	7.82e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9815354	0.953	rs1629462	chr3:41927452	G/C	cg03022575	chr3:42003672	ULK4	-0.82	-5.85	-0.43	2.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3764400	0.508	rs12601350	chr17:46120419	T/C	cg24322968	chr17:46507895	SKAP1	0.83	5.27	0.39	4.54e-7	Body mass index;
PAAD	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg16205897	chr5:131564050	P4HA2	-0.41	-4.32	-0.33	2.79e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs10792830	0.741	rs671686	chr11:85681479	C/G	cg07180834	chr11:85838833	NA	-0.49	-5.78	-0.42	4.04e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.66	-0.42	7.26e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg09760422	chr2:128146352	NA	-0.26	-4.29	-0.33	3.18e-5	Protein C levels;
PAAD	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg23358612	chr7:1275258	UNCX	-0.38	-4.53	-0.34	1.2e-5	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
PAAD	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg13482628	chr17:19912719	NA	0.66	6.72	0.48	3.38e-10	Schizophrenia;
PAAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg00701064	chr4:6280414	WFS1	0.77	6.76	0.48	2.83e-10	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.6	6.39	0.46	1.88e-9	Lung cancer;
PAAD	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.97	-0.37	1.82e-6	Total cholesterol levels;
PAAD	cis	rs643506	0.967	rs2850248	chr11:111644824	C/A	cg09085632	chr11:111637200	PPP2R1B	0.77	7.2	0.5	2.57e-11	Breast cancer;
PAAD	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-10.49	-0.65	1.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg17644776	chr2:200775616	C2orf69	-0.65	-5.08	-0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.58	0.61	2.75e-17	Prudent dietary pattern;
PAAD	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.36	-0.33	2.36e-5	Triglycerides;
PAAD	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs950880	0.710	rs3771171	chr2:102985950	T/C	cg23450938	chr2:102972792	NA	0.45	4.59	0.35	9.03e-6	Serum protein levels (sST2);
PAAD	cis	rs3787159	0.523	rs519141	chr20:56928207	G/C	cg15032960	chr20:56888536	RAB22A	-0.42	-4.51	-0.34	1.27e-5	Systolic blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15933914	chr2:234544462	UGT1A10;UGT1A8	0.59	6.32	0.46	2.74e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.69	-8.91	-0.59	1.49e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.52	-4.25	-0.33	3.77e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00370820	chr22:39101671	GTPBP1	-0.68	-6.91	-0.49	1.22e-10	Lung cancer in ever smokers;
PAAD	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.52	4.83	0.36	3.26e-6	Hirschsprung disease;
PAAD	cis	rs7578047	0.764	rs10210028	chr2:68642582	A/C	cg11308639	chr2:69098272	BMP10	-0.61	-4.32	-0.33	2.85e-5	Anger;
PAAD	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.58	8.22	0.55	8.12e-14	Thyroid hormone levels;
PAAD	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.58	-5.59	-0.41	1.04e-7	Blood protein levels;
PAAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.87	9.73	0.62	1.08e-17	Menopause (age at onset);
PAAD	cis	rs72960926	0.744	rs56168817	chr6:75043919	A/G	cg03266952	chr6:74778945	NA	-1.18	-6.55	-0.47	8.34e-10	Metabolite levels (MHPG);
PAAD	cis	rs4594175	0.926	rs4414399	chr14:51596929	G/T	cg23942311	chr14:51606299	NA	0.69	6.59	0.47	6.7e-10	Cancer;
PAAD	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-4.35	-0.33	2.46e-5	Myopia (pathological);
PAAD	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg11204139	chr17:3907470	NA	0.69	6.97	0.49	9.28e-11	Type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg04352962	chr1:209979756	IRF6	0.53	4.73	0.36	5.03e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg02135003	chr7:105160482	PUS7	-0.85	-6.68	-0.48	4.22e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs1775715	0.737	rs1023207	chr10:32094890	C/A	cg04359828	chr10:32216031	ARHGAP12	0.28	4.41	0.34	1.94e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs11871801	1.000	rs11867405	chr17:40570741	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.71	-0.36	5.47e-6	Crohn's disease;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.57	5.18	0.39	7.03e-7	RR interval (heart rate);
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg15181151	chr6:150070149	PCMT1	0.59	6.47	0.46	1.25e-9	Lung cancer;
PAAD	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.63	5.98	0.44	1.56e-8	Asthma;
PAAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg21361702	chr7:150065534	REPIN1	0.55	4.67	0.35	6.55e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.71	-0.48	3.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11137483	chr3:42695852	ZBTB47	0.62	6.65	0.47	4.9e-10	Myopia (pathological);
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.58	-5.91	-0.43	2.14e-8	Menarche (age at onset);
PAAD	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg06740227	chr12:86229804	RASSF9	0.56	5.27	0.39	4.62e-7	Major depressive disorder;
PAAD	trans	rs3733631	0.947	rs1351623	chr4:104587977	C/T	cg21490444	chr5:171095097	NA	0.77	6.31	0.46	2.87e-9	Menarche (age at onset);
PAAD	cis	rs2004318	0.850	rs61739171	chr19:55144623	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg02734326	chr4:10020555	SLC2A9	-0.51	-5.12	-0.38	9.24e-7	Bone mineral density;
PAAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg19337854	chr7:99768885	GPC2	0.45	4.76	0.36	4.43e-6	Coronary artery disease;
PAAD	cis	rs4835937	0.670	rs10064559	chr5:127329683	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	4.62	0.35	8.15e-6	Cancer;
PAAD	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.49	4.73	0.36	5.16e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.48	-6.36	-0.46	2.29e-9	Ulcerative colitis;
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.44	-4.54	-0.35	1.13e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.64	0.47	5.13e-10	Lung function (FEV1/FVC);
PAAD	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.68e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.13	12.34	0.71	1.11e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg10547527	chr2:198650123	BOLL	-0.72	-4.98	-0.37	1.68e-6	Ulcerative colitis;
PAAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg10090792	chr1:38198142	EPHA10	-0.43	-4.53	-0.34	1.21e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6921919	1.000	rs6921919	chr6:28325201	C/G	cg23153227	chr6:27725408	NA	0.55	4.59	0.35	9.15e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15025532	chr4:39460522	RPL9;LIAS	-0.6	-6.41	-0.46	1.71e-9	Smoking initiation;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg03101763	chr11:65319844	LTBP3	-0.87	-4.42	-0.34	1.86e-5	Height;
PAAD	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg00717180	chr2:96193071	NA	-0.61	-6.83	-0.48	1.96e-10	HDL cholesterol;
PAAD	cis	rs859767	0.540	rs6739706	chr2:135407409	A/C	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg23708337	chr7:1209742	NA	0.65	5.16	0.39	7.62e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7771547	0.723	rs35707365	chr6:36556634	C/A	cg07856975	chr6:36356162	ETV7	0.44	4.56	0.35	1.05e-5	Platelet distribution width;
PAAD	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs60154123	0.730	rs12034871	chr1:210475701	T/C	cg21951975	chr1:209979733	IRF6	0.5	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg26554054	chr8:600488	NA	-1.0	-6.7	-0.48	3.84e-10	IgG glycosylation;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23517954	chr2:162168615	PSMD14	-0.65	-6.32	-0.46	2.72e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.22	0.55	8.19e-14	Bipolar disorder;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg20007245	chr22:24372913	LOC391322	-0.65	-6.41	-0.46	1.71e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.52	-4.92	-0.37	2.27e-6	Testicular germ cell tumor;
PAAD	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg20129853	chr10:51489980	NA	0.46	4.75	0.36	4.6e-6	Prostate-specific antigen levels;
PAAD	cis	rs1351164	1.000	rs1351164	chr2:218271898	C/T	cg15335768	chr2:218268053	DIRC3	0.46	5.13	0.38	8.52e-7	Height;
PAAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg07979401	chr6:33739406	LEMD2	-0.53	-4.47	-0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.66	0.48	4.72e-10	Systemic lupus erythematosus;
PAAD	cis	rs740698	0.529	rs9895414	chr17:60793399	A/C	cg13195520	chr17:60813227	MARCH10	-0.51	-5.42	-0.4	2.32e-7	Pulse pressure;
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg18612461	chr15:75251733	NA	0.57	6.81	0.48	2.1e-10	Caffeine consumption;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.57	5.74	0.42	4.97e-8	Longevity;Endometriosis;
PAAD	cis	rs243505	0.762	rs10225300	chr7:148502007	G/C	cg09806900	chr7:148480153	CUL1	0.52	4.89	0.37	2.6e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12540874	0.524	rs7804365	chr7:50637148	A/C	cg00647317	chr7:50633725	DDC	0.42	4.35	0.33	2.48e-5	Systemic sclerosis;
PAAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.62	-6.51	-0.47	1.04e-9	Height;
PAAD	cis	rs787274	0.867	rs1711746	chr9:115452656	A/G	cg13803584	chr9:115635662	SNX30	0.84	4.99	0.38	1.64e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.46	-5.69	-0.42	6.25e-8	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.64	6.39	0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12304921	0.745	rs4768876	chr12:51432055	T/C	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.52	-0.34	1.24e-5	Type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg21130718	chr4:1044621	NA	0.54	4.58	0.35	9.43e-6	Recombination rate (females);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14847818	chr3:114328840	ZBTB20	-0.62	-7.16	-0.5	3.15e-11	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20877443	chr11:955120	AP2A2	-0.67	-7.01	-0.49	7.46e-11	Obesity-related traits;
PAAD	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.76	-6.91	-0.49	1.27e-10	Body mass index;
PAAD	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg09168692	chr1:7887560	PER3	-0.42	-4.28	-0.33	3.27e-5	Inflammatory bowel disease;
PAAD	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.41	0.61	7.59e-17	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.26e-5	Life satisfaction;
PAAD	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.45	4.8	0.36	3.73e-6	Age of smoking initiation;
PAAD	cis	rs12143943	0.934	rs12567161	chr1:204577832	G/A	cg11980944	chr1:205399731	NA	-0.42	-4.25	-0.33	3.74e-5	Cognitive performance;
PAAD	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.61	6.01	0.44	1.29e-8	Lymphocyte counts;
PAAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.62	8.12	0.55	1.48e-13	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25972526	chr1:202650506	SYT2	-0.68	-7.01	-0.49	7.37e-11	Obesity-related traits;
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.68	-0.42	6.77e-8	Longevity;Endometriosis;
PAAD	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.83	8.37	0.56	3.55e-14	Height;
PAAD	cis	rs2820292	0.804	rs2644120	chr1:201882277	C/G	cg11586189	chr1:201857591	SHISA4	0.42	4.55	0.35	1.07e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
PAAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.65	0.35	7.19e-6	Blood metabolite levels;
PAAD	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.82	5.91	0.43	2.18e-8	Height;
PAAD	cis	rs11853189	0.882	rs79052265	chr15:78556258	A/T	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-11.43	-0.68	3.26e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg04359915	chr10:101825029	CPN1	-0.35	-5.27	-0.39	4.68e-7	Bone mineral density;
PAAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.89	10.01	0.63	1.92e-18	Total cholesterol levels;
PAAD	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	4.29	0.33	3.13e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs6142102	0.625	rs2050208	chr20:32543573	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.36	3.54e-6	Skin pigmentation;
PAAD	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.9	5.68	0.42	6.7e-8	Schizophrenia;
PAAD	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19671926	chr4:122722719	EXOSC9	-0.69	-6.61	-0.47	6.19e-10	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.78	7.99	0.54	3.06e-13	Retinal vascular caliber;
PAAD	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.29e-8	Colorectal cancer;
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg03188948	chr7:1209495	NA	0.57	4.69	0.36	6.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1075265	0.584	rs7558126	chr2:54280984	A/G	cg04546899	chr2:54196757	PSME4	0.36	5.13	0.38	8.59e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg16576597	chr16:28551801	NUPR1	0.63	7.01	0.49	7.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg23947450	chr7:900037	UNC84A	-0.57	-4.69	-0.36	6.14e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg04117972	chr1:227635322	NA	0.61	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2120243	0.565	rs4680363	chr3:157150082	T/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	4.63	0.35	7.87e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs721399	0.539	rs12676857	chr8:18266572	T/C	cg18736775	chr8:18248649	NAT2	-0.59	-4.48	-0.34	1.44e-5	Blood metabolite levels;
PAAD	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.46	-0.46	1.35e-9	Hip circumference;
PAAD	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.22	17.97	0.82	1.97e-39	Total cholesterol levels;
PAAD	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.65	-7.45	-0.52	6.39e-12	Huntington's disease progression;
PAAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg23241863	chr10:102295624	HIF1AN	0.54	4.62	0.35	8.09e-6	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23980730	chr19:1749504	NA	0.53	6.35	0.46	2.34e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg06550200	chr5:1325588	CLPTM1L	0.64	6.55	0.47	8.54e-10	Lung cancer;
PAAD	cis	rs13177180	0.616	rs56104517	chr5:114976117	C/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-4.47	-0.34	1.5e-5	Conotruncal heart defects (inherited effects);
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.58	8.77	0.58	3.44e-15	Hypertriglyceridemia;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg06815965	chr1:205818668	PM20D1	0.61	6.89	0.49	1.38e-10	Menarche (age at onset);
PAAD	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.65	6.49	0.47	1.16e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26378065	chr17:18585709	ZNF286B	-0.57	-4.38	-0.33	2.19e-5	Pancreatic cancer;
PAAD	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-4.49	-0.34	1.38e-5	Red blood cell count;
PAAD	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.2	0.67	1.31e-21	Smoking behavior;
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13939156	chr17:80058883	NA	0.45	4.94	0.37	2.07e-6	Life satisfaction;
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	4.8	0.36	3.72e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12304921	0.683	rs55864652	chr12:51490334	C/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.46	-0.4	1.91e-7	Type 2 diabetes;
PAAD	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.59	4.85	0.37	3.03e-6	Atopic dermatitis;
PAAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg20243544	chr17:37824526	PNMT	0.5	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.64	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg27005118	chr17:13972210	COX10	-0.37	-4.79	-0.36	3.88e-6	Temperament;
PAAD	cis	rs4795519	0.736	rs2879768	chr17:22201257	T/C	cg22648282	chr17:21454238	C17orf51	-0.54	-5.04	-0.38	1.31e-6	Chronic myeloid leukemia;
PAAD	cis	rs7301016	0.948	rs12370404	chr12:62923340	T/C	cg19781863	chr12:62918364	MON2	0.74	4.37	0.33	2.28e-5	IgG glycosylation;
PAAD	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.55	5.01	0.38	1.48e-6	Height;
PAAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.71	-7.58	-0.52	3.19e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.37	-5.72	-0.42	5.38e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.03	0.38	1.36e-6	Educational attainment;
PAAD	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.46	-4.57	-0.35	9.96e-6	Sudden cardiac arrest;
PAAD	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.45	5.71	0.42	5.8e-8	Panic disorder;
PAAD	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg17736920	chr1:242011382	EXO1	0.54	5.31	0.4	3.77e-7	Menopause (age at onset);
PAAD	cis	rs72960926	0.744	rs72968273	chr6:74893673	C/A	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.76e-10	Metabolite levels (MHPG);
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.57	-6.43	-0.46	1.59e-9	Lung cancer;
PAAD	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10819733	chr22:24237672	NA	-0.58	-6.3	-0.45	3.1e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.87	8.63	0.57	7.5e-15	Corneal astigmatism;
PAAD	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	5.16	0.39	7.59e-7	Height;
PAAD	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.8	9.18	0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.36	4.72	0.36	5.42e-6	Permanent tooth development;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg19673125	chr6:150240577	RAET1G	0.33	4.29	0.33	3.19e-5	Lung cancer;
PAAD	cis	rs6142102	0.625	rs4911381	chr20:32550345	C/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.85	-0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs9810890	1.000	rs73196966	chr3:128436824	G/A	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.83	8.76	0.58	3.58e-15	Itch intensity from mosquito bite;
PAAD	cis	rs1190596	0.525	rs10145478	chr14:102720896	T/C	cg23904247	chr14:102554826	HSP90AA1	0.43	4.97	0.37	1.81e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7792596	0.861	rs4729124	chr7:93996776	A/G	cg20814616	chr7:94014465	NA	-0.44	-4.58	-0.35	9.72e-6	Intelligence;
PAAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.75	-0.53	1.23e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg09659197	chr4:152720779	NA	0.46	6.14	0.45	6.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs16958440	0.867	rs80106524	chr18:44676639	G/A	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14119001	chr9:139324193	INPP5E	-0.52	-4.63	-0.35	7.84e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.79	-7.85	-0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.48	5.17	0.39	7.42e-7	Vitiligo;
PAAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg24733560	chr20:60626293	TAF4	0.53	6.8	0.48	2.25e-10	Body mass index;
PAAD	cis	rs9880406	0.599	rs10934767	chr3:126032949	C/G	cg13708016	chr3:126007563	NA	-0.61	-6.26	-0.45	3.8e-9	Macular telangiectasia type 2;
PAAD	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.05	0.59	6.42e-16	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.64	4.33	0.33	2.73e-5	Vitiligo;
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.55	6.56	0.47	7.84e-10	Mean corpuscular volume;
PAAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.73	-7.66	-0.53	2.08e-12	Neurofibrillary tangles;
PAAD	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg14146966	chr2:61757674	XPO1	0.39	4.96	0.37	1.9e-6	Tuberculosis;
PAAD	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.6	-4.25	-0.33	3.67e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.77	8.04	0.55	2.36e-13	Corneal astigmatism;
PAAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.93	10.55	0.65	7.06e-20	Parkinson's disease;
PAAD	cis	rs939584	0.935	rs5017301	chr2:631096	G/A	cg03610516	chr2:642275	NA	0.59	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs8105895	0.935	rs10422289	chr19:22256060	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.64	6.97	0.49	8.97e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.68	-6.27	-0.45	3.58e-9	DNA methylation (variation);
PAAD	cis	rs597583	0.664	rs4936384	chr11:117398591	C/T	cg27161313	chr11:117392002	DSCAML1	-0.76	-6.36	-0.46	2.19e-9	Putamen volume;
PAAD	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.65	7.07	0.5	5.25e-11	Testicular germ cell tumor;
PAAD	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg16342193	chr10:102329863	NA	-0.75	-8.1	-0.55	1.7e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs72772787	1.000	rs72761021	chr1:248012975	T/A	cg03748376	chr1:248100585	OR2L13	0.53	4.29	0.33	3.15e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.96	9.77	0.62	8.55e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.3	0.33	3.08e-5	Total cholesterol levels;
PAAD	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.88	-7.86	-0.54	6.49e-13	Body mass index;
PAAD	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg23461800	chr14:103021989	NA	-0.62	-4.91	-0.37	2.3e-6	Platelet count;
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg20302533	chr7:39170763	POU6F2	0.5	6.95	0.49	1.03e-10	IgG glycosylation;
PAAD	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs11853189	0.938	rs79827225	chr15:78555982	A/G	cg22935921	chr15:78556834	DNAJA4	0.71	4.91	0.37	2.35e-6	Red cell distribution width;
PAAD	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.3	-0.33	3.04e-5	Interleukin-18 levels;
PAAD	cis	rs9810890	1.000	rs73198869	chr3:128530365	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg16434002	chr17:42200994	HDAC5	-0.57	-5.69	-0.42	6.37e-8	Total body bone mineral density;
PAAD	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.96	-0.37	1.86e-6	Recombination measurement;
PAAD	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.56	-6.13	-0.45	7.13e-9	Longevity;
PAAD	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.91e-7	Red blood cell count;
PAAD	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.6	-0.35	8.97e-6	Asthma;
PAAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg14440974	chr22:39074834	NA	-0.53	-6.45	-0.46	1.44e-9	Menopause (age at onset);
PAAD	cis	rs17761864	0.579	rs11650850	chr17:2055880	C/A	cg16513277	chr17:2031491	SMG6	0.42	4.32	0.33	2.8e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg20090143	chr19:45452003	APOC2	0.44	5.52	0.41	1.41e-7	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00812502	chr22:19109875	DGCR2	0.61	6.43	0.46	1.53e-9	Myopia (pathological);
PAAD	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg10856724	chr12:34555212	NA	0.43	4.46	0.34	1.56e-5	Morning vs. evening chronotype;
PAAD	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.49	4.75	0.36	4.61e-6	Red blood cell traits;
PAAD	trans	rs61677309	1.000	rs58520343	chr11:118155000	A/T	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs2814982	0.514	rs76499914	chr6:34469263	C/T	cg14254433	chr6:34482411	PACSIN1	-0.84	-6.16	-0.45	6.36e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.61	-7.74	-0.53	1.3e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7714584	1.000	rs12656600	chr5:150311872	A/G	cg22134413	chr5:150180641	NA	0.98	6.63	0.47	5.43e-10	Crohn's disease;
PAAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg19847866	chr10:1019161	NA	-0.58	-4.54	-0.35	1.16e-5	Eosinophil percentage of granulocytes;
PAAD	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs58521262	0.519	rs55897273	chr19:23002984	A/G	cg07749055	chr19:23076870	NA	-0.6	-4.58	-0.35	9.65e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.92	-8.05	-0.55	2.17e-13	Alzheimer's disease;
PAAD	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.32e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07971674	chr14:23388846	RBM23	-0.58	-6.84	-0.49	1.81e-10	Body fat percentage;
PAAD	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg10820045	chr2:198174542	NA	0.44	4.47	0.34	1.55e-5	Dermatomyositis;
PAAD	cis	rs6011002	1.000	rs56010802	chr20:62304114	G/C	cg18725573	chr20:62368956	LIME1	0.86	4.4	0.34	2.05e-5	Dental caries;
PAAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	5.96	0.44	1.65e-8	Personality dimensions;
PAAD	cis	rs6681460	0.649	rs1947083	chr1:67004801	G/A	cg02459107	chr1:67143332	SGIP1	0.56	5.0	0.38	1.53e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs8112211	0.599	rs2302182	chr19:38827960	T/C	cg01275006	chr19:38876250	GGN	-0.97	-6.05	-0.44	1.06e-8	Blood protein levels;
PAAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.51	4.78	0.36	4.08e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg19949948	chr17:19361230	NA	0.42	4.45	0.34	1.62e-5	Schizophrenia;
PAAD	cis	rs1519814	0.696	rs7813264	chr8:121032753	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-4.96	-0.37	1.88e-6	Breast cancer;
PAAD	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.73	7.52	0.52	4.46e-12	Uric acid levels;
PAAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs7577696	0.785	rs11683760	chr2:32364093	C/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.52	-0.34	1.22e-5	Inflammatory biomarkers;
PAAD	cis	rs2034650	0.544	rs8034416	chr15:40703339	C/T	cg05276125	chr15:40653601	DISP2	0.47	4.6	0.35	8.91e-6	Interstitial lung disease;
PAAD	trans	rs6694672	1.000	rs10922169	chr1:197101105	T/C	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg21300403	chr2:198650112	BOLL	-0.65	-4.36	-0.33	2.36e-5	Ulcerative colitis;
PAAD	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg18281939	chr5:77783895	LHFPL2	-0.5	-5.6	-0.41	9.98e-8	Triglycerides;
PAAD	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-8.28	-0.56	5.84e-14	Colorectal cancer;
PAAD	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14169450	chr9:139327907	INPP5E	0.6	5.39	0.4	2.64e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg27394845	chr17:28928406	LRRC37B2	0.63	4.3	0.33	3e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.67	-0.35	6.45e-6	Height;
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg12193833	chr17:30244370	NA	-0.64	-5.41	-0.4	2.36e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-8.12	-0.55	1.5e-13	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.65	-7.43	-0.52	7.46e-12	Prudent dietary pattern;
PAAD	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.94	-5.83	-0.43	3.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg14703610	chr5:56206110	C5orf35	0.63	5.76	0.42	4.45e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs4906332	0.966	rs34372508	chr14:103977515	G/A	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.35	-0.4	3.15e-7	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.65	-0.42	7.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2004318	1.000	rs2363868	chr19:55140934	C/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.69	-0.48	4.06e-10	Blood protein levels;
PAAD	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.36	-0.33	2.43e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.07	8.64	0.57	7.05e-15	Corneal structure;
PAAD	cis	rs9857275	0.788	rs13068065	chr3:141095724	G/A	cg00789793	chr3:141329863	RASA2	0.48	4.27	0.33	3.43e-5	Prion diseases;
PAAD	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13253111	0.624	rs7012030	chr8:28096346	C/T	cg26534493	chr8:28060551	NA	0.41	4.57	0.35	9.91e-6	Childhood body mass index;
PAAD	cis	rs7818688	0.697	rs112411609	chr8:95980854	C/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs834603	0.965	rs834601	chr7:47445812	T/C	cg23694490	chr7:47445681	TNS3	-0.36	-4.55	-0.35	1.1e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.6	-5.52	-0.41	1.45e-7	Menarche (age at onset);
PAAD	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.53	0.41	1.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-5.07	-0.38	1.14e-6	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.77	7.5	0.52	4.93e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2422052	0.654	rs1433530	chr2:118649083	G/A	cg22545206	chr2:118617499	NA	0.53	5.41	0.4	2.35e-7	Mosquito bite size;
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg08436684	chr16:88034427	BANP	-0.51	-4.37	-0.33	2.34e-5	Menopause (age at onset);
PAAD	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.36	4.83	0.36	3.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.45	0.46	1.4e-9	Height;
PAAD	cis	rs3787159	0.547	rs529313	chr20:56881636	A/G	cg15032960	chr20:56888536	RAB22A	-0.41	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01104198	chr2:203735673	ICA1L	0.64	7.18	0.5	2.87e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg02811702	chr13:24901961	NA	0.51	5.49	0.41	1.69e-7	Obesity-related traits;
PAAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg04166393	chr7:2884313	GNA12	0.5	4.3	0.33	3.01e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs10483554	0.580	rs12884913	chr14:49868551	A/G	cg10380165	chr14:50360598	ARF6	0.5	4.56	0.35	1.06e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.75	0.42	4.77e-8	Prudent dietary pattern;
PAAD	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-8.63	-0.57	7.78e-15	Coronary artery disease;
PAAD	cis	rs797680	0.964	rs547866	chr1:93725053	C/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.39	-0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs12714314	0.830	rs10207910	chr2:1963781	T/C	cg22350835	chr2:1868857	MYT1L	0.46	4.73	0.36	5.04e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.71	4.67	0.35	6.53e-6	Body mass index;
PAAD	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.06	0.55	2.07e-13	Lung cancer in ever smokers;
PAAD	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-1.06	-14.43	-0.76	2.89e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17554472	chr22:41940697	POLR3H	0.6	4.26	0.33	3.57e-5	Vitiligo;
PAAD	cis	rs300774	1.000	rs300781	chr2:110385	G/A	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.52	6.13	0.45	7.1e-9	Height;
PAAD	cis	rs13177180	0.671	rs10077239	chr5:114960881	T/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.46	-4.84	-0.37	3.11e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg26205652	chr12:48591994	NA	0.73	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23021076	chr3:64201741	PRICKLE2	-0.63	-6.59	-0.47	6.63e-10	Obesity-related traits;
PAAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg01017244	chr2:74357527	NA	0.84	6.99	0.49	8e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.84	-0.54	7.42e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg20007245	chr22:24372913	LOC391322	-0.75	-7.89	-0.54	5.4e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-8.57	-0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.25	-0.45	3.86e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg16434002	chr17:42200994	HDAC5	0.69	7.61	0.53	2.69e-12	Total body bone mineral density;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.58	7.33	0.51	1.3e-11	Hypertriglyceridemia;
PAAD	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	1.05	6.09	0.44	9.04e-9	Body mass index;
PAAD	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16872172	chr3:49449542	TCTA;RHOA	0.68	6.57	0.47	7.72e-10	Obesity-related traits;
PAAD	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-7.03	-0.5	6.37e-11	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07733620	chr16:9184485	C16orf72	0.68	6.82	0.48	2.02e-10	Obesity-related traits;
PAAD	cis	rs57024841	0.500	rs10116414	chr9:139831696	C/T	cg00693599	chr9:139836323	FBXW5	0.61	6.26	0.45	3.75e-9	Beta-trace protein levels;
PAAD	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg04106633	chr4:1044584	NA	0.63	5.36	0.4	3.04e-7	Recombination rate (females);
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.69	-0.42	6.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4713675	0.709	rs626156	chr6:33670482	A/G	cg25922239	chr6:33757077	LEMD2	-0.44	-4.4	-0.34	2.05e-5	Plateletcrit;
PAAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg21951975	chr1:209979733	IRF6	0.41	5.19	0.39	6.56e-7	Monobrow;
PAAD	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg10985347	chr2:127963512	CYP27C1	0.47	4.34	0.33	2.54e-5	Protein C levels;
PAAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg05110241	chr16:68378359	PRMT7	-1.01	-6.53	-0.47	9.3e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg27471124	chr11:109292789	C11orf87	0.22	4.42	0.34	1.91e-5	Schizophrenia;
PAAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.87e-22	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19927691	chr1:53685897	C1orf123	-0.74	-6.57	-0.47	7.7e-10	Neuroticism;
PAAD	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	6.95	0.49	9.88e-11	Hip circumference;
PAAD	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg24631222	chr15:78858424	CHRNA5	-0.72	-5.69	-0.42	6.47e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg18939081	chr1:31884902	SERINC2	-0.48	-5.7	-0.42	6.04e-8	Alcohol dependence;
PAAD	cis	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.5	4.46	0.34	1.59e-5	Depression;
PAAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5752326	0.558	rs737800	chr22:26863559	T/C	cg21431832	chr22:26875652	HPS4	-0.66	-4.47	-0.34	1.53e-5	Ischemic stroke;
PAAD	cis	rs863345	0.604	rs1342954	chr1:158464548	C/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.69e-6	Thyroid stimulating hormone;
PAAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.29	0.45	3.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.97	11.96	0.7	1.18e-23	Longevity;
PAAD	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg07168214	chr17:7380112	ZBTB4	-0.65	-6.1	-0.44	8.55e-9	Androgen levels;
PAAD	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.51	0.41	1.5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06797938	chr17:1466136	PITPNA	0.64	6.8	0.48	2.27e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.98	8.28	0.56	5.74e-14	Initial pursuit acceleration;
PAAD	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs12304921	0.639	rs970097	chr12:51479413	G/T	cg18059802	chr12:51347058	HIGD1C	0.63	5.18	0.39	6.86e-7	Type 2 diabetes;
PAAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.9	0.37	2.46e-6	Bone mineral density;
PAAD	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.25	-0.45	3.84e-9	Alcohol dependence;
PAAD	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-1.12	-6.51	-0.47	1.01e-9	Inflammatory biomarkers;
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07648498	chr16:89883185	FANCA	0.69	7.17	0.5	3.02e-11	Vitiligo;
PAAD	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg15956490	chr3:53032818	SFMBT1	0.78	4.39	0.34	2.16e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg02344993	chr17:57696989	CLTC	-0.58	-5.42	-0.4	2.3e-7	Hemoglobin concentration;
PAAD	cis	rs8133932	0.736	rs4819159	chr21:47285605	A/G	cg13695288	chr21:47294981	PCBP3	-0.47	-4.61	-0.35	8.65e-6	Schizophrenia;
PAAD	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	7.65	0.53	2.18e-12	Body mass index;
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-4.55	-0.35	1.1e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10012599	chr11:46744754	F2	0.64	6.36	0.46	2.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19003389	chr17:17876154	LRRC48;TOM1L2	0.66	7.16	0.5	3.19e-11	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-11.75	-0.69	4.34e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.77	0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg19486271	chr11:47235900	DDB2	0.59	6.03	0.44	1.21e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.58	6.24	0.45	4.07e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	NT-proBNP levels in acute coronary syndrome;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.04	-0.38	1.3e-6	Height;
PAAD	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.87	5.79	0.42	3.95e-8	Tonometry;
PAAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23158103	chr7:148848205	ZNF398	-0.49	-4.47	-0.34	1.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.94e-6	Breast cancer;
PAAD	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.66	5.83	0.43	3.26e-8	Response to diuretic therapy;
PAAD	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.54	-4.4	-0.34	2.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-1.71	-10.29	-0.64	3.66e-19	Cannabis dependence symptom count;
PAAD	cis	rs3806308	0.900	rs3820330	chr1:20142413	A/C	cg13843611	chr1:20143089	RNF186	-0.48	-4.61	-0.35	8.56e-6	Ulcerative colitis;
PAAD	cis	rs58521262	0.556	rs465933	chr19:23128203	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.4	4.36	0.33	2.36e-5	HDL cholesterol levels;
PAAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.86	9.24	0.6	2.06e-16	Cognitive function;
PAAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	5.42	0.4	2.28e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19859290	chr11:20618399	NA	-0.31	-4.37	-0.33	2.27e-5	Pursuit maintenance gain;
PAAD	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg23024343	chr7:107201750	COG5	-0.54	-4.5	-0.34	1.36e-5	Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.04	0.38	1.31e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.49	-0.47	1.12e-9	Life satisfaction;
PAAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.75	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg25833597	chr17:30823145	MYO1D	0.46	4.35	0.33	2.49e-5	Schizophrenia;
PAAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.45	-0.34	1.68e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs901683	1.000	rs35303148	chr10:45989254	G/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg11204139	chr17:3907470	NA	-0.69	-7.08	-0.5	4.91e-11	Type 2 diabetes;
PAAD	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.4	-0.34	2.04e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06636551	chr8:101224915	SPAG1	0.59	7.59	0.52	2.96e-12	Atrioventricular conduction;
PAAD	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs950880	0.710	rs12469506	chr2:102965871	C/T	cg23450938	chr2:102972792	NA	0.45	4.66	0.35	6.74e-6	Serum protein levels (sST2);
PAAD	cis	rs10958605	0.761	rs2980821	chr8:40028306	C/A	cg14545590	chr8:40388592	ZMAT4	0.42	4.59	0.35	9.12e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07167872	chr1:205819463	PM20D1	0.51	4.9	0.37	2.47e-6	Parkinson's disease;
PAAD	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.87	-10.11	-0.63	1.06e-18	Resting heart rate;
PAAD	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs593531	0.524	rs634608	chr11:74084729	G/A	cg15851278	chr11:73669449	DNAJB13	-0.36	-4.38	-0.33	2.22e-5	Neuroticism;
PAAD	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.77	8.85	0.58	2.04e-15	Heart rate;
PAAD	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs797680	0.821	rs2391254	chr1:93795166	A/T	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg26068271	chr17:76253126	NA	0.56	5.57	0.41	1.15e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg10820045	chr2:198174542	NA	-0.48	-4.8	-0.36	3.83e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs28489187	0.706	rs233108	chr1:85781720	C/T	cg16011679	chr1:85725395	C1orf52	0.53	5.01	0.38	1.52e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs17032980	0.866	rs2222849	chr2:67306032	G/C	cg02551743	chr2:66673428	MEIS1	-0.49	-4.39	-0.34	2.14e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26720427	chr11:85780129	PICALM	0.56	6.5	0.47	1.1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg04896959	chr15:78267971	NA	0.56	5.11	0.38	9.58e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.67	6.49	0.47	1.13e-9	Mosquito bite size;
PAAD	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.74	-5.81	-0.43	3.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs597539	0.597	rs35956171	chr11:68602735	G/C	cg06112835	chr11:68658793	MRPL21	-0.42	-4.26	-0.33	3.62e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg14440974	chr22:39074834	NA	-0.52	-6.31	-0.46	2.86e-9	Menopause (age at onset);
PAAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-4.58	-0.35	9.65e-6	Total body bone mineral density;
PAAD	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.82	8.77	0.58	3.33e-15	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.63	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg04520793	chr17:42248056	ASB16	0.4	4.66	0.35	6.76e-6	Total body bone mineral density;
PAAD	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.59	-5.12	-0.38	9.28e-7	Total body bone mineral density;
PAAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.89	-8.54	-0.57	1.32e-14	DNA methylation (variation);
PAAD	trans	rs1146751	0.649	rs1248819	chr3:84931669	T/G	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg00437311	chr19:37178174	NA	-0.7	-7.75	-0.53	1.24e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.73	0.53	1.4e-12	Personality dimensions;
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.45	4.23e-9	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.86	-8.41	-0.56	2.8e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg02841227	chr6:26021843	HIST1H4A	0.54	5.27	0.39	4.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.9	12.54	0.71	3.29e-25	Vitiligo;
PAAD	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.56	5.04	0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.02	-0.38	1.4e-6	Body mass index;
PAAD	cis	rs6496932	0.663	rs12915663	chr15:85905480	C/G	cg19183879	chr15:85880815	NA	-0.6	-5.59	-0.41	1.03e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	10.26	0.64	4.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.62	5.79	0.43	3.83e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg02811702	chr13:24901961	NA	0.5	5.42	0.4	2.28e-7	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-11.1	-0.67	2.44e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg12623918	chr2:306882	NA	0.59	4.36	0.33	2.41e-5	Blood protein levels;
PAAD	cis	rs9612	1.000	rs58896392	chr19:44269142	G/A	cg08581076	chr19:44259116	C19orf61	0.63	4.59	0.35	9.42e-6	Exhaled nitric oxide output;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.02	0.49	6.78e-11	Renal function-related traits (BUN);
PAAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg00253185	chr1:247542119	NA	0.5	4.27	0.33	3.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs6076065	1.000	rs2424553	chr20:23403939	A/G	cg12633918	chr20:23549525	CST9L	-0.42	-4.64	-0.35	7.59e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.6	6.55	0.47	8.47e-10	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05809734	chr21:45079336	HSF2BP;RRP1B	0.62	7.04	0.5	6.32e-11	Monocyte percentage of white cells;
PAAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.62	5.51	0.41	1.47e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.78e-5	Neuroticism;
PAAD	cis	rs4908768	0.501	rs4908761	chr1:8552219	G/A	cg20416874	chr1:8611966	RERE	-0.46	-4.44	-0.34	1.74e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9659323	0.670	rs12096179	chr1:119635723	T/C	cg26570165	chr1:119541833	NA	-0.47	-5.04	-0.38	1.31e-6	Body mass index;
PAAD	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg15017067	chr4:17643749	FAM184B	0.42	4.81	0.36	3.67e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.07	-18.31	-0.83	2.74e-40	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03158400	chr21:42688886	FAM3B	0.6	6.43	0.46	1.53e-9	Myopia (pathological);
PAAD	cis	rs2445762	0.600	rs12148492	chr15:51653193	A/C	cg00184732	chr15:51633821	GLDN	-0.46	-4.45	-0.34	1.69e-5	Hormone measurements;
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.79	9.06	0.59	6.17e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs7627468	1.000	rs4678172	chr3:121947525	T/G	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.67	6.69	0.48	3.95e-10	Menarche (age at onset);
PAAD	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-4.58	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.46	-4.69	-0.36	6.11e-6	Lymphocyte counts;
PAAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg14711859	chr11:8959438	ASCL3	-0.48	-4.38	-0.33	2.19e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	7.39	0.51	9.08e-12	Gastritis;
PAAD	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.46	0.34	1.59e-5	Lung cancer;
PAAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.34	0.4	3.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.48	7.54	0.52	3.92e-12	Alcoholic chronic pancreatitis;
PAAD	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.76	5.63	0.42	8.45e-8	Type 2 diabetes;
PAAD	cis	rs7945718	0.621	rs7481252	chr11:12681682	A/G	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.08e-5	Educational attainment (years of education);
PAAD	cis	rs863345	0.967	rs12080815	chr1:158533140	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.86	-0.37	2.91e-6	Pneumococcal bacteremia;
PAAD	cis	rs2292864	0.764	rs72825627	chr17:45386289	C/G	cg18085866	chr17:45331354	ITGB3	-0.96	-5.33	-0.4	3.46e-7	Left atrial antero-posterior diameter;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13939156	chr17:80058883	NA	-0.42	-4.57	-0.35	1.02e-5	Life satisfaction;
PAAD	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.73	7.14	0.5	3.66e-11	Schizophrenia;
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs10214930	0.813	rs6954905	chr7:27664825	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg00147172	chr22:46423604	NA	-0.4	-5.44	-0.4	2.04e-7	Dupuytren's disease;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.98	7.9	0.54	5.31e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs4889855	0.614	rs6565694	chr17:78501101	T/C	cg16591659	chr17:78472290	NA	-0.67	-6.22	-0.45	4.53e-9	Fractional excretion of uric acid;
PAAD	trans	rs894157	0.563	rs78320715	chr15:90255062	C/T	cg05600044	chr1:222721340	HHIPL2	0.98	6.41	0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs9616064	0.962	rs875778	chr22:46984306	T/C	cg25730555	chr22:47059586	GRAMD4	-0.43	-4.34	-0.33	2.64e-5	Urate levels in obese individuals;
PAAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg05082376	chr22:42548792	NA	-0.55	-5.66	-0.42	7.19e-8	Cognitive function;
PAAD	cis	rs9616064	0.849	rs28521630	chr22:46971620	C/T	cg03318428	chr22:46971703	NA	0.41	4.7	0.36	5.76e-6	Urate levels in obese individuals;
PAAD	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.4	-0.34	2.07e-5	Crohn's disease;
PAAD	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.71	-0.62	1.2e-17	Monocyte percentage of white cells;
PAAD	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.63	-5.19	-0.39	6.58e-7	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg20822818	chr11:119235062	USP2	-0.7	-6.81	-0.48	2.1e-10	Blood protein levels;
PAAD	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.55	0.57	1.2e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.7	7.59	0.52	2.98e-12	Schizophrenia;
PAAD	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.44	4.77	0.36	4.25e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	5.78	0.42	4.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19671926	chr4:122722719	EXOSC9	-0.64	-5.78	-0.42	4.16e-8	Type 2 diabetes;
PAAD	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.85	-9.39	-0.61	8.53e-17	Mortality in heart failure;
PAAD	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-4.71	-0.36	5.62e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg06115741	chr20:33292138	TP53INP2	0.56	4.72	0.36	5.3e-6	Skin pigmentation;
PAAD	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg09980403	chr19:12975529	MAST1	0.31	4.71	0.36	5.63e-6	Mean corpuscular volume;
PAAD	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.48	0.57	1.82e-14	Coffee consumption (cups per day);
PAAD	trans	rs2018683	0.711	rs1874977	chr7:28968083	A/G	cg23331303	chr5:5135948	NA	0.45	6.49	0.47	1.15e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.51	-0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg18595228	chr15:67193261	NA	-0.65	-4.44	-0.34	1.72e-5	Lung cancer (smoking interaction);
PAAD	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12578182	chr17:41132637	AARSD1;RUNDC1	0.69	7.0	0.49	7.64e-11	Obesity-related traits;
PAAD	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	6.21	0.45	4.88e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.95	11.22	0.67	1.15e-21	Primary sclerosing cholangitis;
PAAD	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	4.98	0.37	1.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7649275	0.882	rs7373113	chr3:53790054	A/C	cg21503701	chr3:53781065	CACNA1D	-0.52	-4.27	-0.33	3.47e-5	Trans fatty acid levels;
PAAD	cis	rs9567406	1.000	rs912591	chr13:44870739	C/T	cg08635097	chr13:44833857	NA	-0.64	-4.49	-0.34	1.41e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.95	0.37	1.91e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg20917491	chr3:195578259	NA	0.46	4.55	0.35	1.08e-5	Pancreatic cancer;
PAAD	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg16586182	chr3:47516702	SCAP	0.65	7.22	0.51	2.34e-11	Colorectal cancer;
PAAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.6	7.17	0.5	3.12e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.81	8.02	0.55	2.57e-13	Depressive symptoms;
PAAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.42	-0.34	1.9e-5	Glomerular filtration rate;
PAAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs7249698	1	rs7249698	chr19:17210615	G/A	cg19418318	chr19:17219073	MYO9B	0.37	4.79	0.36	4e-6	Breast cancer;
PAAD	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.62	-5.46	-0.41	1.87e-7	Type 2 diabetes;
PAAD	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-1.11	-7.58	-0.52	3.18e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1891275	0.601	rs7358034	chr10:93418764	T/C	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg08992911	chr2:238395768	MLPH	0.51	5.21	0.39	6.08e-7	Prostate cancer;
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg10864074	chr7:100318194	EPO	-0.49	-4.9	-0.37	2.44e-6	Other erythrocyte phenotypes;
PAAD	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.67	5.55	0.41	1.26e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs72960926	0.744	rs7765674	chr6:75127710	G/C	cg03266952	chr6:74778945	NA	0.64	4.44	0.34	1.71e-5	Metabolite levels (MHPG);
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg27094323	chr7:1216898	NA	-0.56	-6.68	-0.48	4.13e-10	Longevity;Endometriosis;
PAAD	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg27449745	chr7:23145252	KLHL7	-0.57	-5.01	-0.38	1.51e-6	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.23	0.6	2.21e-16	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.74e-7	Life satisfaction;
PAAD	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.4	-0.51	8.43e-12	Diastolic blood pressure;
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.86	11.19	0.67	1.44e-21	Body mass index;
PAAD	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg20487152	chr13:99095054	FARP1	0.47	5.03	0.38	1.36e-6	Longevity;
PAAD	cis	rs13242816	1.000	rs56180538	chr7:116079711	C/T	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg07703079	chr11:430292	ANO9	-0.83	-5.32	-0.4	3.57e-7	Body mass index;
PAAD	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	cis	rs28830936	0.966	rs890505	chr15:42129158	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.86e-10	Diastolic blood pressure;
PAAD	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13503143	chr2:109951470	SH3RF3	-0.69	-7.37	-0.51	9.99e-12	Obesity-related traits;
PAAD	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.44	4.53	0.34	1.18e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg08975724	chr8:8085496	FLJ10661	0.45	4.62	0.35	8.2e-6	Joint mobility (Beighton score);
PAAD	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.55	-4.89	-0.37	2.56e-6	Total body bone mineral density;
PAAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg08132940	chr7:1081526	C7orf50	0.61	4.46	0.34	1.58e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.35	-0.64	2.51e-19	Response to antipsychotic treatment;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20686432	chr4:184365613	CDKN2AIP	-0.65	-6.58	-0.47	7.32e-10	Smoking initiation;
PAAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg24253500	chr15:84953950	NA	0.58	6.81	0.48	2.12e-10	Schizophrenia;
PAAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg02841227	chr6:26021843	HIST1H4A	0.53	5.15	0.39	7.98e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11750568	0.902	rs11249612	chr5:178484261	T/C	cg10208897	chr5:178548229	ADAMTS2	-0.53	-4.86	-0.37	2.9e-6	Height;
PAAD	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.58e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg00626422	chr7:22894849	SNORD93	-0.54	-6.35	-0.46	2.41e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.38	-0.33	2.22e-5	Pain;
PAAD	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.46	4.34	0.33	2.64e-5	Diastolic blood pressure;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.72	7.59	0.52	3.05e-12	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04722914	chr2:242255165	HDLBP;SEPT2	0.69	7.66	0.53	2.07e-12	Myopia (pathological);
PAAD	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg01305830	chr4:1604576	NA	-0.5	-4.75	-0.36	4.58e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	5.06	0.38	1.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.69	-7.34	-0.51	1.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2835872	0.733	rs2850124	chr21:39036763	T/A	cg06728970	chr21:39037746	KCNJ6	0.51	5.87	0.43	2.7e-8	Electroencephalographic traits in alcoholism;
PAAD	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg11214348	chr21:47283868	PCBP3	0.48	4.29	0.33	3.18e-5	Schizophrenia;
PAAD	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.76	6.54	0.47	8.72e-10	Schizophrenia;
PAAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.75	0.53	1.23e-12	Yeast infection;
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs9659323	1.000	rs10923714	chr1:119512913	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.5	-0.41	1.55e-7	Body mass index;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11873113	chr11:86529655	NA	-0.65	-6.58	-0.47	7.04e-10	Lung cancer in ever smokers;
PAAD	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.67	-6.03	-0.44	1.21e-8	Mortality in heart failure;
PAAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg03714773	chr7:91764589	CYP51A1	0.32	4.31	0.33	2.93e-5	Breast cancer;
PAAD	cis	rs7631605	0.905	rs9852378	chr3:37038771	C/T	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.52	-5.14	-0.38	8.43e-7	Multiple myeloma;
PAAD	cis	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.59	-5.06	-0.38	1.2e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55728055	0.661	rs62237833	chr22:32012141	G/A	cg01338084	chr22:32026380	PISD	1.6	8.55	0.57	1.25e-14	Age-related hearing impairment;
PAAD	cis	rs7236492	0.872	rs112187368	chr18:77236259	G/A	cg15644404	chr18:77186268	NFATC1	-0.92	-6.04	-0.44	1.12e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.14	0.39	8.21e-7	Rheumatoid arthritis;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	0.97	6.31	0.46	2.85e-9	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.57	6.39	0.46	1.95e-9	Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.45	-4.7	-0.36	5.69e-6	Dementia with Lewy bodies;
PAAD	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg10253484	chr15:75165896	SCAMP2	0.58	5.34	0.4	3.29e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.68	-7.26	-0.51	1.92e-11	Post bronchodilator FEV1;
PAAD	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-9.66	-0.62	1.62e-17	Height;
PAAD	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg06632027	chr4:90757378	SNCA	-0.56	-5.23	-0.39	5.53e-7	Neuroticism;
PAAD	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg23018236	chr17:30244563	NA	0.66	4.77	0.36	4.19e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg00806245	chr18:76673096	NA	-0.7	-5.4	-0.4	2.52e-7	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.86	10.92	0.66	7.28e-21	Prudent dietary pattern;
PAAD	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg18612461	chr15:75251733	NA	-0.5	-4.53	-0.35	1.18e-5	Blood trace element (Zn levels);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19224673	chr16:74330485	PSMD7	-0.59	-7.1	-0.5	4.52e-11	Body fat percentage;
PAAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.85	-9.89	-0.63	4.12e-18	Coronary artery disease;
PAAD	cis	rs688181	0.621	rs1885452	chr6:158099317	C/G	cg17310882	chr6:158066609	ZDHHC14	-0.34	-4.3	-0.33	2.99e-5	Platelet distribution width;
PAAD	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2131877	0.913	rs9825498	chr3:194848021	G/C	cg19760965	chr3:194868843	C3orf21	0.44	4.59	0.35	9.33e-6	Non-small cell lung cancer;
PAAD	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg19640130	chr10:64028056	RTKN2	-0.38	-4.62	-0.35	8.24e-6	Rheumatoid arthritis;
PAAD	cis	rs10029851	0.617	rs6852328	chr4:109613948	C/T	cg16525761	chr4:109541525	LOC285456;RPL34	-0.47	-4.43	-0.34	1.81e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg24330906	chr2:85765176	MAT2A	0.58	5.75	0.42	4.67e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg13859433	chr6:33739653	LEMD2	0.65	4.41	0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg16083429	chr3:49237500	CCDC36	-0.44	-4.78	-0.36	4.17e-6	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21108553	chr6:28357838	ZSCAN12	-0.64	-6.44	-0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg03277515	chr1:153321198	PGLYRP4	-0.42	-4.95	-0.37	1.92e-6	Psoriasis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17043651	chr11:130165776	ZBTB44	-0.63	-6.61	-0.47	6.28e-10	Smoking initiation;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs7765175	0.698	rs1074617	chr6:113667707	G/A	cg19037598	chr6:113666021	NA	-0.4	-4.34	-0.33	2.61e-5	Coronary artery calcification;
PAAD	cis	rs4740619	0.555	rs3008742	chr9:15980555	A/G	cg14451791	chr9:16040625	NA	0.39	4.76	0.36	4.43e-6	Body mass index;
PAAD	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.68	-7.79	-0.53	9.94e-13	White blood cell count (basophil);
PAAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.37	-0.68	4.46e-22	Height;
PAAD	cis	rs13394619	0.840	rs11674605	chr2:11722575	A/G	cg07314298	chr2:11723111	GREB1	-0.63	-8.9	-0.59	1.6e-15	Endometriosis;
PAAD	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg08481491	chr3:125900108	ALDH1L1	-0.5	-5.35	-0.4	3.19e-7	Metabolite levels;
PAAD	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg04896959	chr15:78267971	NA	-0.59	-4.48	-0.34	1.43e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg09659197	chr4:152720779	NA	0.44	5.25	0.39	5.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4740619	0.630	rs1927699	chr9:15986487	A/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.32	-0.33	2.77e-5	Mood instability;
PAAD	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.82	5.27	0.39	4.69e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.5	-4.85	-0.37	3e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13637042	chr22:42228724	SREBF2	-0.74	-7.2	-0.5	2.63e-11	Lung cancer in ever smokers;
PAAD	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.6	0.57	9.26e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08175935	chr14:101348185	MIR127;MIR433;RTL1	-0.66	-7.03	-0.5	6.56e-11	Obesity-related traits;
PAAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg00944433	chr1:107599041	PRMT6	-0.44	-4.99	-0.37	1.67e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg09695851	chr17:3907499	NA	-0.67	-6.99	-0.49	8.11e-11	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs863345	0.967	rs2317957	chr1:158467487	A/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.64	0.62	1.91e-17	Lymphocyte counts;
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg24416232	chr10:134405482	INPP5A	-0.38	-4.77	-0.36	4.27e-6	Gait speed in old age;
PAAD	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.43	-0.46	1.6e-9	Schizophrenia (age at onset);
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.72	6.97	0.49	8.88e-11	Blood metabolite levels;
PAAD	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.31	-0.33	2.91e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg24076588	chr1:18808559	KLHDC7A	-0.41	-4.85	-0.37	3.03e-6	Breast cancer;
PAAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg07703079	chr11:430292	ANO9	0.8	4.51	0.34	1.28e-5	Body mass index;
PAAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.54	4.72	0.36	5.24e-6	Coronary artery disease;
PAAD	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.53	5.79	0.42	3.99e-8	Testicular germ cell tumor;
PAAD	cis	rs427941	0.703	rs201453	chr7:101739788	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07475247	chr7:102938279	PMPCB	0.7	8.43	0.56	2.45e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.82	7.89	0.54	5.61e-13	Corneal astigmatism;
PAAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	0.8	4.37	0.33	2.31e-5	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.41	-0.4	2.39e-7	Schizophrenia;
PAAD	cis	rs6466055	0.589	rs6947388	chr7:104639583	G/C	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg00401753	chr5:405986	AHRR;LOC100310782	1.06	4.82	0.36	3.42e-6	Breast cancer;
PAAD	cis	rs7616330	0.673	rs79847902	chr3:71045749	G/A	cg01511742	chr3:71112437	FOXP1	-0.82	-4.53	-0.35	1.17e-5	QT interval;
PAAD	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg16341495	chr8:142228727	SLC45A4	0.51	4.99	0.38	1.61e-6	Immature fraction of reticulocytes;
PAAD	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs3764563	0.799	rs2017776	chr19:15698229	T/C	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.72	0.62	1.12e-17	Total body bone mineral density;
PAAD	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg04450456	chr4:17643702	FAM184B	-0.46	-4.95	-0.37	1.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02972793	chr2:3322136	TSSC1	0.55	6.47	0.46	1.3e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13144136	0.687	rs13128842	chr4:10661991	T/A	cg10242279	chr4:10666415	CLNK	-0.47	-5.84	-0.43	3.07e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02196655	chr2:10830764	NOL10	-0.6	-6.15	-0.45	6.6e-9	Prostate cancer;
PAAD	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-6.96	-0.49	9.6e-11	Type 2 diabetes;
PAAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.49	4.43	0.34	1.77e-5	Height;
PAAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.6	7.01	0.49	7.25e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.51	-0.34	1.31e-5	Joint mobility (Beighton score);
PAAD	cis	rs2562456	0.558	rs62108173	chr19:21427188	C/T	cg08562672	chr19:21860753	NA	-0.47	-4.68	-0.35	6.33e-6	Pain;
PAAD	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.63	-6.94	-0.49	1.04e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09723155	chr17:79633271	C17orf90;CCDC137	0.63	7.3	0.51	1.47e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg22875332	chr1:76189707	ACADM	0.48	4.78	0.36	4.04e-6	Daytime sleep phenotypes;
PAAD	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-4.53	-0.34	1.19e-5	Inflammatory bowel disease;
PAAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.52	-0.52	4.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.47e-6	White blood cell count;
PAAD	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.81	8.48	0.57	1.87e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.81	8.86	0.58	1.92e-15	Mortality in heart failure;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.75e-6	Iron status biomarkers;
PAAD	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.73	6.44	0.46	1.5e-9	Recombination rate (females);
PAAD	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg11547950	chr5:77652471	NA	0.92	8.0	0.54	2.89e-13	Triglycerides;
PAAD	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg02415014	chr8:143852576	LYNX1	-0.52	-6.31	-0.46	2.89e-9	Urinary tract infection frequency;
PAAD	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	1.03	6.08	0.44	9.45e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1329189	1.000	rs10741149	chr10:130003530	C/T	cg17972361	chr10:130010134	NA	-0.48	-4.89	-0.37	2.49e-6	Orofacial clefts;
PAAD	cis	rs9463078	0.585	rs1521355	chr6:44932755	T/C	cg25276700	chr6:44698697	NA	-0.53	-5.93	-0.43	1.99e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.63	-5.64	-0.42	8.08e-8	Response to antineoplastic agents;
PAAD	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.66	7.06	0.5	5.51e-11	Schizophrenia;
PAAD	cis	rs375066	0.935	rs373168	chr19:44430869	C/T	cg11993925	chr19:44307056	LYPD5	0.51	6.45	0.46	1.39e-9	Breast cancer;
PAAD	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-12.28	-0.71	1.64e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1018697	0.966	rs10748832	chr10:104568480	G/A	cg04362960	chr10:104952993	NT5C2	0.59	5.99	0.44	1.48e-8	Colorectal adenoma (advanced);
PAAD	cis	rs2286503	0.839	rs2270103	chr7:22862722	C/T	cg11367502	chr7:22862612	TOMM7	0.52	5.25	0.39	5.04e-7	Fibrinogen;
PAAD	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.22	-0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27297192	chr10:134578999	INPP5A	0.63	6.12	0.44	7.59e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg11218175	chr11:495084	RNH1	0.77	4.44	0.34	1.69e-5	Body mass index;
PAAD	cis	rs2221894	0.960	rs7837112	chr8:28765493	T/G	cg20212339	chr8:28908912	HMBOX1	0.51	5.39	0.4	2.69e-7	Obesity-related traits;
PAAD	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	1.05	14.27	0.76	7.45e-30	Headache;
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.61	-4.53	-0.34	1.2e-5	Initial pursuit acceleration;
PAAD	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg09876464	chr15:85330779	ZNF592	0.45	4.5	0.34	1.36e-5	P wave terminal force;
PAAD	cis	rs61759167	1.000	rs11587518	chr1:3096925	T/A	cg22674798	chr1:3096360	PRDM16	0.4	4.65	0.35	7.29e-6	Motion sickness;
PAAD	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-4.52	-0.34	1.25e-5	Systolic blood pressure;
PAAD	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.39	4.69	0.36	5.96e-6	HIV-1 susceptibility;
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.85	6.24	0.45	4.18e-9	Breast cancer;
PAAD	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg07977153	chr11:1967958	MRPL23	-0.41	-4.29	-0.33	3.13e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.96	10.94	0.66	6.65e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.56	-5.42	-0.4	2.28e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg10006428	chr1:248814059	OR2T27	0.38	4.44	0.34	1.72e-5	Common traits (Other);
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg14664628	chr15:75095509	CSK	-0.46	-4.47	-0.34	1.55e-5	Caffeine consumption;
PAAD	cis	rs7627468	0.913	rs6763821	chr3:121930788	A/G	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.5	-4.7	-0.36	5.71e-6	Hypospadias;
PAAD	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg07220939	chr11:64358617	SLC22A12	-0.41	-4.45	-0.34	1.65e-5	Urate levels in obese individuals;
PAAD	trans	rs9372498	1.000	rs62421485	chr6:118576470	G/A	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg16262614	chr3:133464971	TF	0.46	5.13	0.38	8.84e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.96	8.68	0.58	5.71e-15	Bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26135722	chr3:42642776	NKTR	-0.71	-6.5	-0.47	1.1e-9	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17305834	chr11:118868656	CCDC84	0.63	6.46	0.46	1.37e-9	Myopia (pathological);
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	8.47	0.57	1.96e-14	Lymphocyte counts;
PAAD	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.21	0.6	2.53e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs6065	0.618	rs16942615	chr17:4875628	A/G	cg02990439	chr17:4875527	CAMTA2	-0.9	-4.7	-0.36	5.67e-6	Platelet count;
PAAD	cis	rs9677476	0.587	rs55782278	chr2:232154412	G/A	cg07929768	chr2:232055508	NA	0.41	4.83	0.37	3.24e-6	Food antigen IgG levels;
PAAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.59	6.03	0.44	1.19e-8	Aortic root size;
PAAD	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	0.89	8.41	0.56	2.8e-14	Breast cancer;
PAAD	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.37	4.45	0.34	1.67e-5	Pulmonary function;
PAAD	cis	rs9487051	0.646	rs9487049	chr6:109615905	A/T	cg21918786	chr6:109611834	NA	-0.52	-5.54	-0.41	1.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12956009	0.583	rs4452038	chr18:44856529	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.4	-0.34	2.06e-5	Educational attainment (years of education);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11270834	chr5:1463488	LPCAT1	0.57	6.39	0.46	1.94e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.64	-4.3	-0.33	3.02e-5	Vitiligo;
PAAD	cis	rs10274279	1.000	rs55941863	chr7:157372989	C/G	cg26886268	chr7:157387156	PTPRN2	-0.72	-5.5	-0.41	1.59e-7	Myopia (pathological);
PAAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.26	0.56	6.7e-14	Schizophrenia;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.56	5.61	0.41	9.29e-8	Longevity;Endometriosis;
PAAD	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	6.79	0.48	2.39e-10	Response to antipsychotic treatment;
PAAD	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg00700412	chr12:58011837	NA	-0.49	-5.4	-0.4	2.55e-7	Multiple sclerosis;
PAAD	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	5.62	0.41	8.84e-8	Psychosis and Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10752421	chr13:30107044	SLC7A1	0.55	6.53	0.47	9.53e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6565189	0.865	rs4350585	chr16:30505513	A/G	cg17640201	chr16:30407289	ZNF48	0.49	4.62	0.35	8.1e-6	Tonsillectomy;
PAAD	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg12549451	chr6:135224345	NA	0.41	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg00122941	chr17:4613640	ARRB2	-0.79	-7.82	-0.54	8.4e-13	Lymphocyte counts;
PAAD	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.51	-5.36	-0.4	2.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.3	0.45	3.09e-9	Lung cancer;
PAAD	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg26384229	chr12:38710491	ALG10B	0.68	7.06	0.5	5.6e-11	Morning vs. evening chronotype;
PAAD	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.65	5.44	0.4	2.09e-7	LDL cholesterol;
PAAD	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	4.53	0.34	1.18e-5	Menopause (age at onset);
PAAD	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg20913747	chr6:44695427	NA	-0.65	-6.44	-0.46	1.5e-9	Total body bone mineral density;
PAAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.57	-6.23	-0.45	4.3e-9	Menopause (age at onset);
PAAD	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	trans	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.99	0.49	8.27e-11	Response to antipsychotic treatment;
PAAD	cis	rs12612619	0.690	rs6754371	chr2:27315064	G/A	cg00617064	chr2:27272375	NA	-0.52	-5.31	-0.4	3.91e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg20243544	chr17:37824526	PNMT	0.53	4.79	0.36	3.91e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.05	0.55	2.26e-13	Prudent dietary pattern;
PAAD	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.52	5.28	0.39	4.46e-7	Schizophrenia;
PAAD	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.6	5.95	0.43	1.76e-8	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12150646	chr11:60928909	VPS37C	0.59	6.86	0.49	1.64e-10	Monocyte percentage of white cells;
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-4.77	-0.36	4.38e-6	Longevity;
PAAD	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.07	14.17	0.75	1.41e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12476592	0.602	rs262495	chr2:63848607	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.36	0.33	2.34e-5	Childhood ear infection;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.77	-8.03	-0.55	2.45e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.73	7.19	0.5	2.72e-11	Schizophrenia;
PAAD	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.77	-8.67	-0.58	5.89e-15	Lung cancer in ever smokers;
PAAD	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-6.07	-0.44	9.67e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10821973	0.527	rs4590753	chr10:63976449	C/T	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.52	5.05	0.38	1.23e-6	Parkinson's disease;
PAAD	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	6.23	0.45	4.33e-9	Lung cancer in ever smokers;
PAAD	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.75	-6.61	-0.47	6.07e-10	Body mass index;
PAAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs9463078	0.585	rs7757282	chr6:45302654	A/G	cg25276700	chr6:44698697	NA	0.47	5.45	0.4	1.95e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.56	5.73	0.42	5.1e-8	Aortic root size;
PAAD	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.55	6.0	0.44	1.42e-8	Bladder cancer;
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.88	-11.27	-0.67	8.44e-22	Total body bone mineral density;
PAAD	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.62	6.73	0.48	3.2e-10	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
PAAD	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.78	8.91	0.59	1.49e-15	Heart rate;
PAAD	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.79	6.03	0.44	1.2e-8	Crohn's disease;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-1.32	-12.46	-0.71	5.2e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg05528293	chr18:74961138	GALR1	0.52	4.94	0.37	2.07e-6	Obesity-related traits;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs72960926	0.744	rs72964291	chr6:74891874	C/G	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.76e-10	Metabolite levels (MHPG);
PAAD	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.32e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.79	-5.57	-0.41	1.1e-7	Coronary artery calcification;
PAAD	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg24053715	chr22:38214548	NA	-0.51	-4.94	-0.37	2.06e-6	Glioblastoma;Glioma;
PAAD	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg23153227	chr6:27725408	NA	0.49	4.67	0.35	6.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.8	-0.48	2.19e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.4	-0.34	2.05e-5	Morning vs. evening chronotype;
PAAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg02056144	chr12:54070517	ATP5G2	-0.51	-5.54	-0.41	1.29e-7	Height;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg11062466	chr8:58055876	NA	0.66	4.79	0.36	3.88e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg02794589	chr11:70049600	FADD	-0.54	-4.25	-0.33	3.78e-5	Survival in rectal cancer;
PAAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg25319279	chr11:5960081	NA	-0.6	-5.82	-0.43	3.41e-8	DNA methylation (variation);
PAAD	cis	rs11037575	0.739	rs12275247	chr11:43720350	G/C	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.75	-0.48	3e-10	Type 2 diabetes;
PAAD	cis	rs11825064	0.666	rs73596940	chr11:134495250	G/A	cg02089395	chr11:134479357	NA	-0.83	-5.51	-0.41	1.51e-7	Seasonality;
PAAD	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg06569542	chr10:98946673	SLIT1	-0.51	-5.76	-0.42	4.61e-8	Monocyte count;
PAAD	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg08601574	chr20:25228251	PYGB	0.63	6.95	0.49	9.87e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35260072	1	rs35260072	chr5:131630852	A/C	cg07395648	chr5:131743802	NA	-0.5	-4.32	-0.33	2.82e-5	Itch intensity from mosquito bite;
PAAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.68e-6	Personality dimensions;
PAAD	cis	rs41419946	1.000	rs41419946	chr1:165394087	A/T	cg24428232	chr1:166124419	MIR921;FAM78B	0.79	4.4	0.34	2e-5	Gut microbiome composition (winter);
PAAD	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.6	5.29	0.39	4.23e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	7.86	0.54	6.42e-13	Height;
PAAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.8	-5.93	-0.43	1.97e-8	Coronary artery calcification;
PAAD	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs71435601	0.574	rs1712248	chr2:21385778	C/G	cg05709196	chr2:20449227	PUM2	0.54	4.25	0.33	3.65e-5	Cholesterol, total;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.53	5.98	0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg07061783	chr6:25882402	NA	-0.53	-5.02	-0.38	1.45e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg16083429	chr3:49237500	CCDC36	-0.45	-4.73	-0.36	5.13e-6	Parkinson's disease;
PAAD	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg16434002	chr17:42200994	HDAC5	0.59	5.46	0.41	1.89e-7	Bone mineral density (hip);Bone mineral density (spine);
PAAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.64	6.07	0.44	9.89e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs61677309	1.000	rs66832804	chr11:118157049	T/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs2279817	0.863	rs871089	chr1:18017704	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.66	5.78	0.42	4.02e-8	Neuroticism;
PAAD	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg01102307	chr1:9340416	NA	-0.41	-4.29	-0.33	3.2e-5	Eosinophil percentage of white cells;
PAAD	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.8	-9.02	-0.59	7.58e-16	Sudden cardiac arrest;
PAAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg23947450	chr7:900037	UNC84A	-0.53	-4.5	-0.34	1.34e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.25	-0.33	3.67e-5	Eotaxin levels;
PAAD	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg00250761	chr1:31883323	NA	-0.54	-6.25	-0.45	3.84e-9	Alcohol dependence;
PAAD	cis	rs16854884	0.660	rs990320	chr3:143796305	T/C	cg06585982	chr3:143692056	C3orf58	0.59	5.66	0.42	7.33e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6466055	0.645	rs4730073	chr7:104855871	A/C	cg04380332	chr7:105027541	SRPK2	-0.6	-6.73	-0.48	3.29e-10	Schizophrenia;
PAAD	cis	rs728616	0.614	rs56080607	chr10:82105964	A/T	cg19423196	chr10:82049429	MAT1A	0.45	4.44	0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.85	-0.43	2.98e-8	Retinal vascular caliber;
PAAD	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04731861	chr2:219085781	ARPC2	-0.36	-4.33	-0.33	2.74e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Gut microbiome composition (summer);
PAAD	cis	rs4908760	0.563	rs4908518	chr1:8892577	A/G	cg20416874	chr1:8611966	RERE	-0.43	-4.26	-0.33	3.51e-5	Vitiligo;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.53	4.81	0.36	3.55e-6	Vitiligo;
PAAD	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.83	-0.36	3.29e-6	Atopic dermatitis;
PAAD	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg12310025	chr6:25882481	NA	0.46	4.56	0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs59888335	0.894	rs6548736	chr3:81010384	T/G	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg02404636	chr22:31891804	SFI1	0.64	5.88	0.43	2.57e-8	Colorectal cancer;
PAAD	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.43	4.94	0.37	2.08e-6	Refractive error;
PAAD	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.73	-7.43	-0.52	7.3e-12	Alcohol dependence;
PAAD	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.49	4.62	0.35	8e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6256	1.000	rs10500783	chr11:13573614	C/T	cg11976911	chr11:13509032	NA	-0.64	-5.05	-0.38	1.26e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg02398342	chr17:80708632	TBCD;FN3K	-0.61	-4.83	-0.36	3.32e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg08648136	chr8:956695	NA	0.52	5.7	0.42	5.95e-8	Schizophrenia;
PAAD	cis	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.87	-0.37	2.71e-6	HDL cholesterol;
PAAD	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg23024343	chr7:107201750	COG5	0.54	4.44	0.34	1.69e-5	Coronary artery disease;
PAAD	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.75	9.32	0.6	1.31e-16	Coronary artery disease;
PAAD	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.87	-6.23	-0.45	4.34e-9	Night sleep phenotypes;
PAAD	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg03030879	chr14:75389066	RPS6KL1	0.45	4.45	0.34	1.68e-5	Height;
PAAD	cis	rs2389339	0.773	rs13147191	chr4:117835714	C/G	cg21399832	chr4:117847410	NA	-0.33	-4.49	-0.34	1.41e-5	IgG glycosylation;
PAAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.68	-0.35	6.43e-6	Body mass index;
PAAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.63	6.8	0.48	2.25e-10	Longevity;
PAAD	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	9.1	0.59	4.9e-16	Ulcerative colitis;
PAAD	cis	rs9322817	0.513	rs2499661	chr6:105300074	C/G	cg02098413	chr6:105308735	HACE1	0.42	5.22	0.39	5.84e-7	Thyroid stimulating hormone;
PAAD	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2290402	0.536	rs17165130	chr4:875339	A/C	cg09237302	chr4:906077	GAK	0.44	4.57	0.35	1.01e-5	Type 2 diabetes;
PAAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg05555928	chr11:63887634	MACROD1	-0.43	-4.82	-0.36	3.46e-6	Platelet count;
PAAD	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg19423196	chr10:82049429	MAT1A	0.53	5.04	0.38	1.28e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.69	7.77	0.53	1.07e-12	Longevity;
PAAD	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-9.65	-0.62	1.73e-17	Height;
PAAD	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07565236	chr16:88869998	CDT1	0.62	6.82	0.48	2.02e-10	Myopia (pathological);
PAAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg02734326	chr4:10020555	SLC2A9	0.55	5.51	0.41	1.47e-7	Bone mineral density;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.48	0.57	1.87e-14	Lung cancer;
PAAD	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg00122941	chr17:4613640	ARRB2	0.83	8.25	0.56	7.11e-14	Lymphocyte counts;
PAAD	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	5.45	0.4	1.98e-7	Systemic lupus erythematosus;
PAAD	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.47	0.34	1.49e-5	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.49	-4.35	-0.33	2.44e-5	Iron status biomarkers;
PAAD	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs4450131	0.522	rs4465331	chr10:126400357	C/T	cg20435097	chr10:126320824	FAM53B	0.49	4.94	0.37	2.01e-6	White blood cell count (basophil);
PAAD	cis	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.04	-0.5	6.31e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.51	5.25	0.39	5.16e-7	Plasma plasminogen activator levels;
PAAD	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.23	0.51	2.14e-11	Lung cancer in ever smokers;
PAAD	cis	rs72960926	1.000	rs72956938	chr6:75092873	G/A	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.83	8.56	0.57	1.19e-14	Heart rate;
PAAD	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg04143805	chr16:89395205	ANKRD11	-0.36	-4.42	-0.34	1.86e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-4.72	-0.36	5.25e-6	Schizophrenia;
PAAD	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs62264129	0.500	rs55947719	chr3:112033323	A/T	cg01411366	chr3:112012867	SLC9A10	-0.3	-4.86	-0.37	2.84e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs12760731	0.565	rs11580064	chr1:178226520	A/G	cg00404053	chr1:178313656	RASAL2	0.67	5.22	0.39	5.81e-7	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs13434201	chr3:128609255	T/A	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg02353165	chr6:42928485	GNMT	-0.46	-4.61	-0.35	8.53e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	trans	rs35213789	0.768	rs6979355	chr7:69384562	A/G	cg16586192	chr15:63569620	APH1B	1.05	7.4	0.51	8.73e-12	Childhood ear infection;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.55	5.68	0.42	6.76e-8	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.34	-0.4	3.37e-7	Plateletcrit;
PAAD	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.44	4.58	0.35	9.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7873102	0.654	rs7043870	chr9:37956373	A/G	cg03528946	chr9:38069800	SHB	0.56	5.62	0.41	8.86e-8	Brain structure;
PAAD	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg17347104	chr14:75034677	LTBP2	-0.56	-4.64	-0.35	7.33e-6	Non-small cell lung cancer;
PAAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.56	5.25	0.39	5.11e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.61	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg03948781	chr1:205179583	DSTYK	0.49	4.53	0.34	1.21e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.49	0.34	1.38e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg10978503	chr1:24200527	CNR2	0.44	5.17	0.39	7.2e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4729127	1.000	rs60238694	chr7:94008118	C/T	cg20814616	chr7:94014465	NA	-0.6	-4.41	-0.34	1.96e-5	Intelligence;
PAAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg03303774	chr4:1407052	NA	0.48	6.02	0.44	1.27e-8	Obesity-related traits;
PAAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg20283391	chr11:68216788	NA	-0.53	-5.08	-0.38	1.08e-6	Total body bone mineral density;
PAAD	cis	rs8060686	0.925	rs13336189	chr16:67814152	C/A	cg09835421	chr16:68378352	PRMT7	-0.67	-4.55	-0.35	1.11e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.46	-5.77	-0.42	4.22e-8	Crohn's disease;
PAAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.11	14.98	0.77	1e-31	Cognitive function;
PAAD	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.68	8.48	0.57	1.79e-14	Inflammatory bowel disease;
PAAD	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.37	5.51	0.41	1.51e-7	Educational attainment (years of education);
PAAD	cis	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg16667279	chr19:11591998	ELAVL3	0.63	4.69	0.36	6.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.72	-8.14	-0.55	1.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.85	9.87	0.62	4.62e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.58	5.84	0.43	3.01e-8	Body mass index;
PAAD	cis	rs10901513	0.932	rs11244748	chr10:127670426	A/G	cg22975853	chr10:127789788	ADAM12	-0.42	-4.45	-0.34	1.64e-5	Visceral fat;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs34845616	0.520	rs1793680	chr11:133798762	C/T	cg03392386	chr11:133800800	IGSF9B	0.51	5.4	0.4	2.5e-7	Hand grip strength;
PAAD	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs77633900	0.772	rs157789	chr15:76805703	T/A	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.59	6.26	0.45	3.67e-9	Testicular germ cell tumor;
PAAD	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg08898775	chr15:59042684	ADAM10	0.34	4.36	0.33	2.42e-5	Schizophrenia;
PAAD	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	5.77	0.42	4.23e-8	Adiposity;
PAAD	cis	rs2387326	1.000	rs2387326	chr10:129933456	C/T	cg16087940	chr10:129947807	NA	-0.5	-4.33	-0.33	2.74e-5	Select biomarker traits;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg06175578	chr8:42249154	VDAC3	0.64	6.52	0.47	9.57e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.51	4.43	0.34	1.79e-5	Coronary artery disease;
PAAD	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg01620082	chr3:125678407	NA	1.09	7.12	0.5	4.08e-11	Depression;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.68	-7.46	-0.52	6.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs35110281	0.667	rs8133276	chr21:45126629	T/C	cg04455712	chr21:45112962	RRP1B	0.58	6.22	0.45	4.66e-9	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg13468214	chr4:1046988	NA	0.56	6.11	0.44	7.94e-9	Recombination rate (males);
PAAD	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs54211	0.572	rs79290	chr22:39685832	G/A	cg11247378	chr22:39784982	NA	-0.63	-4.53	-0.34	1.19e-5	Sudden cardiac arrest;
PAAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.71	-8.91	-0.59	1.43e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg19680485	chr15:31195859	MTMR15	0.44	4.34	0.33	2.63e-5	Huntington's disease progression;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05025164	chr4:1340916	KIAA1530	0.52	5.11	0.38	9.49e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.66	-8.23	-0.56	7.68e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-4.81	-0.36	3.55e-6	Mean platelet volume;
PAAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg09491104	chr22:46646882	C22orf40	-0.96	-9.08	-0.59	5.51e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.63	-0.35	7.65e-6	Tuberculosis;
PAAD	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg02313495	chr15:40398007	BMF	-0.54	-4.44	-0.34	1.71e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.44	-4.46	-0.34	1.62e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg02509370	chr12:49932779	KCNH3	-0.6	-6.9	-0.49	1.28e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7617773	0.962	rs6797587	chr3:48197614	A/G	cg11946769	chr3:48343235	NME6	-0.6	-6.07	-0.44	9.7e-9	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg01620082	chr3:125678407	NA	-1.48	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg02071572	chr4:1403502	NA	0.41	4.7	0.36	5.68e-6	Obesity-related traits;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.67	-6.87	-0.49	1.56e-10	Longevity;
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.42	-0.4	2.31e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.34e-8	Lung cancer;
PAAD	cis	rs308971	0.563	rs217049	chr3:12060917	C/T	cg15873301	chr3:12045459	SYN2	0.62	4.37	0.33	2.31e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7829975	0.539	rs35571782	chr8:8141823	A/C	cg08975724	chr8:8085496	FLJ10661	0.74	7.1	0.5	4.44e-11	Mood instability;
PAAD	cis	rs10267417	0.603	rs7804164	chr7:19905105	G/C	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.01	-0.38	1.52e-6	Longevity;
PAAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.23	-10.26	-0.64	4.2e-19	Breast cancer;
PAAD	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-4.91	-0.37	2.31e-6	Monocyte percentage of white cells;
PAAD	cis	rs6494488	0.500	rs72744710	chr15:65014078	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg03188948	chr7:1209495	NA	1.1	5.53	0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7572263	0.833	rs6710217	chr2:209050352	C/T	cg23998903	chr2:209048830	C2orf80	-0.47	-4.5	-0.34	1.36e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1519814	0.956	rs4133251	chr8:121166993	A/G	cg22335954	chr8:121166405	COL14A1	-0.61	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.61	6.88	0.49	1.48e-10	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg09654669	chr8:57350985	NA	-0.57	-5.13	-0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg09473613	chr1:24152604	HMGCL	0.42	4.28	0.33	3.24e-5	Immature fraction of reticulocytes;
PAAD	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg16926213	chr1:1841314	NA	-0.36	-4.44	-0.34	1.75e-5	Body mass index;
PAAD	cis	rs72960926	1.000	rs16884854	chr6:75107223	C/T	cg13997649	chr6:74171430	MTO1	0.86	4.59	0.35	9.13e-6	Metabolite levels (MHPG);
PAAD	cis	rs287982	0.932	rs58521916	chr2:9966470	C/T	cg01119585	chr2:10571959	NA	0.42	4.61	0.35	8.46e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs11811982	0.793	rs78634790	chr1:227610481	C/G	cg24860534	chr1:227506868	CDC42BPA	0.52	4.91	0.37	2.29e-6	Optic disc area;
PAAD	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.18	0.5	2.82e-11	Colorectal cancer;
PAAD	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	1.0	7.08	0.5	5.04e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs9463078	0.528	rs12208023	chr6:45024687	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.57	6.43	0.46	1.56e-9	IgG glycosylation;
PAAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.82	0.36	3.4e-6	Breast cancer;
PAAD	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.29	0.64	3.58e-19	Morning vs. evening chronotype;
PAAD	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs3131082	1	rs3131082	chr6:28983274	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.45	0.34	1.62e-5	Tuberculosis;
PAAD	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs11825685	0.887	rs4328229	chr11:134566548	G/A	cg06603561	chr11:134479413	NA	-0.84	-5.31	-0.4	3.76e-7	IgG glycosylation;
PAAD	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.75	0.42	4.86e-8	Coronary artery disease;
PAAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.47	-4.6	-0.35	8.76e-6	Airway imaging phenotypes;
PAAD	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs17266958	1.000	rs75048611	chr9:83223012	C/T	cg13911576	chr9:84174038	NA	0.81	4.36	0.33	2.39e-5	Preschool internalizing problems;
PAAD	cis	rs939584	0.735	rs13035713	chr2:633659	T/C	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs6496932	0.865	rs4842874	chr15:85866695	A/G	cg19183879	chr15:85880815	NA	0.53	4.33	0.33	2.71e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs7771547	0.723	rs9380582	chr6:36556730	T/C	cg07856975	chr6:36356162	ETV7	0.44	4.56	0.35	1.05e-5	Platelet distribution width;
PAAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.61	-5.91	-0.43	2.12e-8	Menopause (age at onset);
PAAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.81	-0.62	6.72e-18	Coronary artery disease;
PAAD	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.9e-10	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.74	4.98	0.37	1.68e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-6.73	-0.48	3.22e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1997066	0.831	rs76600271	chr10:106811591	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg09357268	chr20:43379437	KCNK15	0.44	4.71	0.36	5.5e-6	Obesity-related traits;
PAAD	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs10943724	0.679	rs549621	chr6:81228124	C/T	cg19323245	chr6:80716898	TTK	-0.46	-4.76	-0.36	4.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg23950597	chr19:37808831	NA	-0.75	-5.01	-0.38	1.5e-6	Coronary artery calcification;
PAAD	cis	rs55692468	0.606	rs6759772	chr2:153322724	C/T	cg04681845	chr2:153283485	FMNL2	-0.42	-5.08	-0.38	1.11e-6	Intraocular pressure;
PAAD	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg20913747	chr6:44695427	NA	-0.57	-5.43	-0.4	2.22e-7	Total body bone mineral density;
PAAD	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.19	15.04	0.77	6.94e-32	IgG glycosylation;
PAAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.87	9.31	0.6	1.37e-16	Tonsillectomy;
PAAD	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-4.25	-0.33	3.74e-5	Pulmonary function;
PAAD	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg15193198	chr20:60906057	LAMA5	0.52	5.57	0.41	1.13e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23158103	chr7:148848205	ZNF398	-0.6	-5.9	-0.43	2.3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.74	-0.36	4.84e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.66	5.55	0.41	1.25e-7	Obesity (extreme);
PAAD	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg08999081	chr20:33150536	PIGU	0.54	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.45	0.34	1.68e-5	Axial length;
PAAD	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.4	4.45	0.34	1.67e-5	Mean platelet volume;
PAAD	cis	rs375066	0.901	rs372491	chr19:44401793	G/A	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	trans	rs901683	0.557	rs34663276	chr10:45971360	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs10861342	0.786	rs11112386	chr12:105538758	A/G	cg11421182	chr20:36153479	BLCAP	-0.54	-6.36	-0.46	2.21e-9	IgG glycosylation;
PAAD	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	6.27	0.45	3.6e-9	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6466055	0.661	rs2079341	chr7:104904235	A/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.52	-4.59	-0.35	9.37e-6	Total body bone mineral density;
PAAD	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.86	5.38	0.4	2.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.6	-0.35	8.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg02344993	chr17:57696989	CLTC	0.6	4.96	0.37	1.9e-6	Hemoglobin concentration;
PAAD	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.31	0.6	1.37e-16	Psoriasis;
PAAD	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.53	5.73	0.42	5.24e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs875971	0.543	rs801191	chr7:66032955	G/A	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.66	-6.59	-0.47	6.79e-10	Urate levels in lean individuals;
PAAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22633769	chr20:60982531	CABLES2	0.51	4.89	0.37	2.49e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-6.32	-0.46	2.72e-9	Gallbladder cancer;
PAAD	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.66	6.39	0.46	1.97e-9	Asthma;
PAAD	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg01851573	chr8:8652454	MFHAS1	0.49	4.75	0.36	4.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.43	-0.34	1.82e-5	Platelet count;
PAAD	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.68	0.48	4.22e-10	Lung cancer in ever smokers;
PAAD	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.97	8.02	0.55	2.64e-13	Blood trace element (Cu levels);
PAAD	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-4.84	-0.37	3.16e-6	Colorectal cancer;
PAAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.93	11.58	0.68	1.24e-22	Pulse pressure;
PAAD	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.45	4.35	0.33	2.53e-5	Prostate-specific antigen levels;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11105468	0.623	rs7135505	chr12:90565181	T/C	cg16962463	chr12:89968675	NA	0.41	4.38	0.33	2.24e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg05110241	chr16:68378359	PRMT7	-0.77	-5.99	-0.44	1.44e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs557074	0.861	rs9405328	chr6:7166238	A/G	cg01785233	chr6:7260807	NA	0.48	4.31	0.33	2.89e-5	Monocyte count;
PAAD	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.26	-0.33	3.58e-5	Lung cancer;
PAAD	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg25547332	chr5:131281432	NA	0.53	4.28	0.33	3.32e-5	Life satisfaction;
PAAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg09873201	chr16:3507582	NAT15	-0.52	-4.58	-0.35	9.78e-6	Tuberculosis;
PAAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.43	0.4	2.21e-7	Platelet count;
PAAD	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.5	7.06	0.5	5.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg11764359	chr7:65958608	NA	0.67	4.68	0.35	6.31e-6	Diabetic kidney disease;
PAAD	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.78	-7.19	-0.5	2.74e-11	Vitamin D levels;
PAAD	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09597638	chr17:3907349	NA	0.73	7.75	0.53	1.22e-12	Type 2 diabetes;
PAAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.69	-0.53	1.69e-12	Height;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	4.96	0.37	1.89e-6	Tonsillectomy;
PAAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.17	-0.73	6.41e-27	Height;
PAAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	7.97	0.54	3.41e-13	Eye color traits;
PAAD	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg03948781	chr1:205179583	DSTYK	0.48	4.47	0.34	1.52e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-6.31	-0.46	2.83e-9	Body mass index;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.57e-6	Bipolar disorder;
PAAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.79	9.54	0.61	3.38e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.25	-7.65	-0.53	2.2e-12	Plateletcrit;
PAAD	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg03999872	chr20:62272968	STMN3	0.73	6.7	0.48	3.77e-10	Atopic dermatitis;
PAAD	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.34	-0.51	1.18e-11	Mood instability;
PAAD	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.4	5.0	0.38	1.58e-6	Pulmonary function;
PAAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.78	-6.91	-0.49	1.23e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg03264133	chr6:25882463	NA	0.44	4.32	0.33	2.75e-5	Schizophrenia;
PAAD	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-4.69	-0.36	6.14e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7792596	1.000	rs4729126	chr7:94007064	C/T	cg20814616	chr7:94014465	NA	0.44	4.5	0.34	1.37e-5	Intelligence;
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg00738919	chr7:1100172	C7orf50	0.66	4.91	0.37	2.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.63	-0.42	8.5e-8	Personality dimensions;
PAAD	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.47	4.44	0.34	1.74e-5	High light scatter reticulocyte count;
PAAD	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.63	-6.38	-0.46	2.02e-9	Pubertal anthropometrics;
PAAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.46	-7.37	-0.51	1.01e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg24842760	chr6:133561719	EYA4	-0.85	-6.73	-0.48	3.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.49	5.2	0.39	6.44e-7	Type 2 diabetes;
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	6.36	0.46	2.19e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg04545296	chr12:48745243	ZNF641	-0.36	-4.49	-0.34	1.4e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.68	-0.35	6.4e-6	Lung cancer;
PAAD	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.89	-8.38	-0.56	3.38e-14	Breast cancer;
PAAD	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg08589418	chr20:61993913	CHRNA4	-0.53	-4.59	-0.35	9.13e-6	Atopic dermatitis;
PAAD	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg20913747	chr6:44695427	NA	-0.67	-6.66	-0.48	4.74e-10	Total body bone mineral density;
PAAD	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14631462	chr10:31607925	ZEB1;LOC220930	0.62	6.41	0.46	1.75e-9	Obesity-related traits;
PAAD	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	1.01	11.82	0.69	2.75e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.46	-7.48	-0.52	5.54e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.74	8.04	0.55	2.37e-13	Systolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23288653	chr1:155145780	TRIM46;KRTCAP2	0.57	6.42	0.46	1.67e-9	Monocyte percentage of white cells;
PAAD	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.41	-0.4	2.38e-7	Pulmonary function;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.49	5.1	0.38	1.01e-6	Longevity;Endometriosis;
PAAD	cis	rs11966931	0.948	rs17528484	chr6:108095573	A/G	cg10566610	chr6:108093680	SCML4	0.5	4.67	0.35	6.45e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg11833968	chr6:79620685	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.51	5.55	0.41	1.24e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72960926	1.000	rs11751225	chr6:75138754	T/C	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.48	0.41	1.76e-7	Bipolar disorder;
PAAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.84	-0.82	4.14e-39	Height;
PAAD	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04850017	chr11:63683019	RCOR2	0.39	4.37	0.33	2.25e-5	Pulse pressure;
PAAD	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.54	5.68	0.42	6.61e-8	Migraine;Coronary artery disease;
PAAD	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.8	9.73	0.62	1.07e-17	Breast cancer;
PAAD	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.79	9.55	0.61	3.2e-17	Brugada syndrome;
PAAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.7	7.84	0.54	7.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.66	7.47	0.52	5.9e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg00262122	chr8:11665843	FDFT1	-0.58	-5.24	-0.39	5.17e-7	Neuroticism;
PAAD	cis	rs2997447	0.846	rs61775419	chr1:26395539	C/T	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.09	15.96	0.79	2.71e-34	Chronic sinus infection;
PAAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.5	-4.86	-0.37	2.94e-6	Esophageal squamous cell carcinoma;
PAAD	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs4742903	0.904	rs1507510	chr9:106985153	T/A	cg14250997	chr9:106856677	SMC2	0.46	4.87	0.37	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02743256	chr7:2109353	MAD1L1	0.78	6.78	0.48	2.48e-10	Bipolar disorder;
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.42	5.05	0.38	1.26e-6	Body mass index;
PAAD	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.69	6.65	0.47	4.91e-10	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs16975963	0.644	rs1478462	chr19:38147025	A/G	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.33e-5	Longevity;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.54	-0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	8.21	0.55	8.88e-14	Response to antipsychotic treatment;
PAAD	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.62	-5.41	-0.4	2.38e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00152838	chr16:24741724	TNRC6A	-0.51	-4.3	-0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg02264943	chr11:130785842	SNX19	0.37	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs375066	0.967	rs376328	chr19:44407487	A/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs13102973	0.600	rs13122485	chr4:135834437	G/A	cg14419869	chr4:135874104	NA	0.45	4.59	0.35	9.21e-6	Subjective well-being;
PAAD	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.79	-8.15	-0.55	1.27e-13	Cognitive function;
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	5.45	0.4	2.02e-7	Joint mobility (Beighton score);
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.43	4.88	0.37	2.71e-6	Bipolar disorder;
PAAD	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg01966878	chr4:90757139	SNCA	-0.46	-4.46	-0.34	1.59e-5	Dementia with Lewy bodies;
PAAD	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.18	-9.05	-0.59	6.5e-16	Alzheimer's disease (late onset);
PAAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg02734326	chr4:10020555	SLC2A9	0.48	4.91	0.37	2.3e-6	Bone mineral density;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs6921919	1.000	rs35875412	chr6:28331818	C/T	cg23153227	chr6:27725408	NA	0.54	4.33	0.33	2.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.35e-12	Height;
PAAD	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.57	5.52	0.41	1.4e-7	Multiple sclerosis;
PAAD	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-5.17	-0.39	7.32e-7	Personality dimensions;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg14926445	chr8:58193284	C8orf71	-0.66	-5.38	-0.4	2.73e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg21546286	chr11:48923668	NA	-0.43	-4.49	-0.34	1.41e-5	Coronary artery disease;
PAAD	cis	rs2853333	0.558	rs2284148	chr19:35765424	G/C	cg22238209	chr19:35800743	MAG	0.44	4.3	0.33	3.1e-5	Red blood cell count;
PAAD	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.73	8.1	0.55	1.63e-13	Menopause (age at onset);
PAAD	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg01017244	chr2:74357527	NA	0.85	7.81	0.54	8.53e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg10327424	chr1:202611933	SYT2	-0.43	-4.34	-0.33	2.63e-5	Mean platelet volume;
PAAD	trans	rs61931739	0.620	rs7979562	chr12:33707023	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs9469913	0.867	rs9469907	chr6:34810799	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.38	-0.33	2.18e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.32	0.4	3.68e-7	HIV-1 control;
PAAD	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.51	4.43	0.34	1.81e-5	Height;
PAAD	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg27205649	chr11:78285834	NARS2	0.64	4.72	0.36	5.32e-6	Alzheimer's disease (survival time);
PAAD	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs2016586	0.929	rs5755924	chr22:36114621	A/G	cg26342177	chr22:36113512	APOL5	-0.48	-4.73	-0.36	5.03e-6	Body mass index;
PAAD	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.91	0.37	2.34e-6	Asthma;
PAAD	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-1.05	-11.73	-0.69	5.02e-23	Obesity-related traits;
PAAD	cis	rs931127	0.836	rs523029	chr11:65476487	T/G	cg05805236	chr11:65401703	PCNXL3	-0.47	-5.16	-0.39	7.74e-7	Systemic lupus erythematosus;
PAAD	cis	rs965469	0.779	rs6051717	chr20:3270242	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	6.43	0.46	1.57e-9	Retinal vascular caliber;
PAAD	cis	rs6136489	0.583	rs6136492	chr20:1923972	C/T	cg19358608	chr20:1924565	NA	-0.35	-4.26	-0.33	3.53e-5	Platelet distribution width;Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08233142	chr19:11466009	LPPR2	0.64	6.3	0.46	3.04e-9	Obesity-related traits;
PAAD	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.77	5.17	0.39	7.41e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.58	-5.36	-0.4	2.97e-7	Cognitive function;
PAAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg02961798	chr16:67687392	RLTPR	-0.39	-4.33	-0.33	2.65e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs9815354	1.000	rs2272007	chr3:41996136	A/G	cg03022575	chr3:42003672	ULK4	-0.75	-5.48	-0.41	1.72e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.73	7.8	0.53	9e-13	Schizophrenia;
PAAD	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-1.03	-8.56	-0.57	1.17e-14	Blood trace element (Zn levels);
PAAD	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg23752985	chr2:85803571	VAMP8	0.55	6.18	0.45	5.58e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00917899	chr1:9599401	SLC25A33	0.73	7.35	0.51	1.16e-11	Obesity-related traits;
PAAD	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.58	-0.47	7.34e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	5.96	0.44	1.72e-8	LDL cholesterol;
PAAD	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.95	-9.27	-0.6	1.76e-16	Post bronchodilator FEV1;
PAAD	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs7091957	0.875	rs4880419	chr10:134456109	C/T	cg13271783	chr10:134563150	INPP5A	0.43	4.72	0.36	5.41e-6	Gait speed in old age;
PAAD	cis	rs2790216	1.000	rs2440848	chr10:59996403	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6460942	0.597	rs17544637	chr7:12521871	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs76793172	0.623	rs10775546	chr19:46267534	C/T	cg14061069	chr19:46274453	DMPK	0.55	4.77	0.36	4.32e-6	Eosinophil counts;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24003273	chr1:46112691	RPS15AP10;GPBP1L1	-0.66	-6.33	-0.46	2.62e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2446066	0.872	rs2694847	chr12:53785028	A/G	cg20591337	chr12:53693442	C12orf10	-0.63	-4.4	-0.34	2.05e-5	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.06e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.74e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.83	-9.08	-0.59	5.28e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg15841412	chr13:111365552	ING1	0.51	4.27	0.33	3.48e-5	Coronary artery disease;
PAAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21581312	chr15:35529473	LOC723972	-0.62	-6.61	-0.47	6.16e-10	Iris heterochromicity;
PAAD	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.81	4.91	0.37	2.28e-6	Obesity-related traits;
PAAD	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg27411982	chr8:10470053	RP1L1	-0.49	-5.38	-0.4	2.71e-7	Neuroticism;
PAAD	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.83	9.81	0.62	6.82e-18	Breast cancer;
PAAD	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg05577437	chr8:1586825	DLGAP2	0.39	4.42	0.34	1.89e-5	Systolic blood pressure;
PAAD	cis	rs2864527	0.522	rs8098544	chr18:9219317	C/T	cg07372824	chr18:9017748	NA	-0.57	-4.29	-0.33	3.17e-5	Dental caries;
PAAD	cis	rs12935418	0.552	rs2123626	chr16:81021810	T/C	cg16651780	chr16:81037892	C16orf61	-0.64	-5.93	-0.43	1.96e-8	Mean corpuscular volume;
PAAD	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-7.63	-0.53	2.34e-12	Monocyte percentage of white cells;
PAAD	cis	rs2281845	0.533	rs112365857	chr1:201097222	G/C	cg06714761	chr1:201096289	NA	0.38	5.04	0.38	1.32e-6	Permanent tooth development;
PAAD	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg10820045	chr2:198174542	NA	-0.43	-4.31	-0.33	2.95e-5	Dermatomyositis;
PAAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.95	12.32	0.71	1.24e-24	Menopause (age at onset);
PAAD	cis	rs17209837	1.000	rs45590633	chr7:87090480	C/T	cg00919237	chr7:87102261	ABCB4	-0.75	-4.96	-0.37	1.85e-6	Gallbladder cancer;
PAAD	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs5756391	0.568	rs4821569	chr22:37316873	A/G	cg21209356	chr22:37319042	CSF2RB	0.39	4.75	0.36	4.63e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.52	5.25	0.39	4.95e-7	Resting heart rate;
PAAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.57	5.49	0.41	1.63e-7	Neuroticism;
PAAD	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-1.06	-7.51	-0.52	4.66e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.69	8.03	0.55	2.43e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12267948	chr1:2986566	PRDM16	0.59	6.45	0.46	1.42e-9	Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg22467129	chr15:76604101	ETFA	0.51	4.78	0.36	4.05e-6	Blood metabolite levels;
PAAD	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg05552183	chr6:42928497	GNMT	0.7	5.85	0.43	2.96e-8	Blood protein levels;
PAAD	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.31	7.14	0.5	3.64e-11	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs9409082	0.666	rs67000576	chr9:108955969	A/G	cg07010948	chr13:79181613	NA	-0.34	-6.49	-0.47	1.14e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs8017423	0.529	rs12898020	chr14:90835752	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-4.43	-0.34	1.79e-5	Mortality in heart failure;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	11.78	0.69	3.7e-23	Platelet count;
PAAD	cis	rs8112211	1.000	rs12611255	chr19:38815483	T/C	cg14299480	chr19:38876666	GGN	-0.54	-6.93	-0.49	1.1e-10	Blood protein levels;
PAAD	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.6	-5.02	-0.38	1.44e-6	Atopic dermatitis;
PAAD	cis	rs114540395	0.858	rs77564076	chr10:103320818	C/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.27	-0.33	3.42e-5	Schizophrenia;
PAAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.43	4.43	0.34	1.82e-5	Red cell distribution width;
PAAD	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg26384229	chr12:38710491	ALG10B	0.49	4.37	0.33	2.33e-5	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg17470449	chr10:769945	NA	0.51	5.15	0.39	7.86e-7	Uric acid levels;
PAAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.96	9.33	0.6	1.17e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg19223190	chr17:80058835	NA	0.52	5.35	0.4	3.11e-7	Life satisfaction;
PAAD	cis	rs621942	0.635	rs34565850	chr11:85836356	G/A	cg07180834	chr11:85838833	NA	-0.48	-5.03	-0.38	1.38e-6	Tourette syndrome;
PAAD	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-1.06	-6.44	-0.46	1.48e-9	Schizophrenia;
PAAD	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09323570	chr18:74154105	ZNF516	0.43	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg01966878	chr4:90757139	SNCA	0.6	4.55	0.35	1.09e-5	Neuroticism;
PAAD	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg10183150	chr4:120222239	C4orf3	-0.37	-4.32	-0.33	2.76e-5	Corneal astigmatism;
PAAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.77	7.77	0.53	1.07e-12	Vitiligo;
PAAD	cis	rs635808	0.500	rs1964808	chr6:167172602	C/T	cg05573767	chr6:167171394	RPS6KA2	0.42	4.26	0.33	3.63e-5	Dental caries;
PAAD	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg00569896	chr4:204382	NA	-0.6	-4.65	-0.35	7.28e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09595537	chr4:668144	ATP5I	0.57	6.48	0.47	1.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg21300403	chr2:198650112	BOLL	-0.66	-4.36	-0.33	2.37e-5	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	9.27e-7	Motion sickness;
PAAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.44	-0.56	2.3e-14	Height;
PAAD	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-0.91	-8.99	-0.59	9.41e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg20169779	chr10:135381914	SYCE1	-0.45	-4.65	-0.35	7.01e-6	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs432925	0.572	rs2685120	chr16:342080	C/G	cg08823186	chr16:347294	AXIN1	0.5	4.63	0.35	7.94e-6	Morning vs. evening chronotype;
PAAD	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs501120	0.925	rs684521	chr10:44752523	G/A	cg09554077	chr10:44749378	NA	0.52	6.89	0.49	1.38e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg00540400	chr15:79124168	NA	-0.62	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.45	-4.52	-0.34	1.23e-5	PR interval;
PAAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.66	6.32	0.46	2.81e-9	Parkinson's disease;
PAAD	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21175976	chr8:11421337	BLK	-0.41	-4.47	-0.34	1.53e-5	Retinal vascular caliber;
PAAD	cis	rs501120	0.636	rs3123689	chr10:44773121	G/A	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.78	-9.47	-0.61	5.07e-17	Height;
PAAD	cis	rs2885056	0.891	rs73016785	chr19:10688939	C/T	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.89	-9.93	-0.63	3.29e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs151997	0.962	rs56170692	chr5:50247928	G/A	cg06027927	chr5:50259733	NA	0.67	6.74	0.48	3.1e-10	Callous-unemotional behaviour;
PAAD	cis	rs3764400	0.564	rs12602670	chr17:46104880	T/C	cg10706073	chr17:46328419	SKAP1	-1.02	-6.02	-0.44	1.25e-8	Body mass index;
PAAD	cis	rs11159840	0.567	rs17124105	chr14:88603841	C/T	cg18078958	chr14:88630771	NA	-0.42	-5.36	-0.4	3e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg08125733	chr17:73851984	WBP2	0.82	7.5	0.52	5.05e-12	Psoriasis;
PAAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg00106254	chr7:1943704	MAD1L1	0.49	4.29	0.33	3.18e-5	Schizophrenia;
PAAD	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.82	0.43	3.41e-8	Tonsillectomy;
PAAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.93	8.23	0.56	7.96e-14	Gut microbiome composition (summer);
PAAD	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs258892	0.947	rs4443401	chr5:72213483	G/A	cg21869765	chr5:72125136	TNPO1	0.75	5.12	0.38	8.97e-7	Small cell lung carcinoma;
PAAD	trans	rs6694672	0.717	rs12039586	chr1:196997452	C/G	cg26994526	chr18:47719735	MYO5B	-0.81	-6.47	-0.46	1.28e-9	Asthma;
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg11859384	chr17:80120422	CCDC57	0.48	4.85	0.37	3.04e-6	Life satisfaction;
PAAD	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.39	0.56	3.05e-14	Dupuytren's disease;
PAAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	4.95	0.37	1.98e-6	Neuroticism;
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.43	-0.52	7.46e-12	Body mass index;
PAAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4719841	0.662	rs4574742	chr7:25995063	A/G	cg10085138	chr7:25991722	NA	-0.26	-4.52	-0.34	1.25e-5	Triglyceride levels;
PAAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-9.11	-0.59	4.61e-16	Gut microbiome composition (summer);
PAAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.78	-8.58	-0.57	1.06e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.56	5.88	0.43	2.54e-8	Menopause (age at onset);
PAAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg11395062	chr17:14139857	CDRT15	0.58	5.9	0.43	2.26e-8	Temperament;
PAAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.7	7.36	0.51	1.05e-11	Pulse pressure;
PAAD	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg13565585	chr5:132299512	AFF4	0.68	4.97	0.37	1.78e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.34	0.46	2.46e-9	Alzheimer's disease;
PAAD	cis	rs11652874	0.614	rs11658082	chr17:31967697	G/T	cg21745612	chr17:32907636	TMEM132E;C17orf102	-0.46	-4.27	-0.33	3.5e-5	Severe gingival inflammation;
PAAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.66	-5.19	-0.39	6.68e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.72	7.97	0.54	3.47e-13	Melanoma;
PAAD	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.88	5.5	0.41	1.57e-7	Weight;
PAAD	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg09835421	chr16:68378352	PRMT7	-0.91	-7.36	-0.51	1.09e-11	Magnesium levels;
PAAD	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.44	6.03	0.44	1.18e-8	Insulin-like growth factors;
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.34	-4.49	-0.34	1.42e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg02820901	chr13:113351484	ATP11A	0.74	4.76	0.36	4.49e-6	Glycated hemoglobin levels;
PAAD	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.83	-9.41	-0.61	7.46e-17	Height;
PAAD	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.65	4.98	0.37	1.71e-6	Coronary artery disease;
PAAD	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.53	5.1	0.38	9.95e-7	Common traits (Other);
PAAD	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg13722127	chr7:150037890	RARRES2	0.54	5.5	0.41	1.58e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.08	0.38	1.07e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs7551222	0.714	rs4951401	chr1:204537648	G/A	cg01064725	chr1:204461714	NA	-0.55	-4.79	-0.36	3.85e-6	Schizophrenia;
PAAD	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.49	-4.49	-0.34	1.42e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.54	0.41	1.27e-7	Bipolar disorder;
PAAD	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg15997130	chr1:24165203	NA	0.55	5.74	0.42	4.88e-8	Immature fraction of reticulocytes;
PAAD	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.69	6.39	0.46	1.92e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.49	0.52	5.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03682872	chr6:158402912	SYNJ2	0.68	6.96	0.49	9.33e-11	Obesity-related traits;
PAAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.36	-0.56	3.79e-14	Bone mineral density;
PAAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	1.0	9.14	0.6	3.67e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs61776719	0.875	rs4072980	chr1:38456106	G/A	cg04673462	chr1:38461896	NA	-0.46	-6.07	-0.44	9.82e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.66	0.57	6.25e-15	Alzheimer's disease;
PAAD	cis	rs10958605	0.624	rs2925034	chr8:40046361	A/G	cg14545590	chr8:40388592	ZMAT4	0.4	4.28	0.33	3.34e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.79	-8.42	-0.56	2.59e-14	Obesity-related traits;
PAAD	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	6.99	0.49	8.24e-11	Renal function-related traits (BUN);
PAAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15557168	chr22:42548783	NA	-0.5	-5.21	-0.39	6.05e-7	Cognitive function;
PAAD	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.97	9.08	0.59	5.26e-16	Psoriasis;
PAAD	cis	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg24428760	chr20:32582025	RALY	-0.55	-6.38	-0.46	2.04e-9	Body fat percentage;
PAAD	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.19	20.5	0.86	1.35e-45	Myeloid white cell count;
PAAD	cis	rs13424612	1.000	rs1465880	chr2:240932326	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.76	-0.36	4.45e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs58749629	0.506	rs2903809	chr20:44552895	C/A	cg13694471	chr20:43595031	STK4	0.53	4.28	0.33	3.33e-5	Abdominal aortic aneurysm;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.52	5.17	0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg05585630	chr7:157510462	PTPRN2	-0.53	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.57	-7.04	-0.5	6.3e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.47	6.18	0.45	5.53e-9	Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.27	0.39	4.6e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg10253484	chr15:75165896	SCAMP2	0.57	5.09	0.38	1.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs71520386	0.607	rs28660425	chr7:22858151	C/T	cg04907244	chr7:22894795	SNORD93	0.5	5.43	0.4	2.17e-7	Fibrinogen levels;
PAAD	trans	rs932143	0.645	rs11179770	chr12:74134612	C/G	cg06753227	chr18:9475508	RALBP1	0.56	6.59	0.47	6.97e-10	Neuroticism;
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4523957	0.928	rs170045	chr17:2196905	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.45	-4.76	-0.36	4.54e-6	Dementia with Lewy bodies;
PAAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.4	-0.51	8.54e-12	Colorectal cancer;
PAAD	cis	rs1801239	0.786	rs111263197	chr10:16968542	T/C	cg00939682	chr10:16933505	CUBN	0.6	4.62	0.35	7.98e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg00106254	chr7:1943704	MAD1L1	0.55	5.11	0.38	9.68e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.52	-4.68	-0.36	6.22e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg23093090	chr10:104574429	C10orf26	-0.39	-4.44	-0.34	1.73e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.61e-5	Bipolar disorder;
PAAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.66	-0.48	4.61e-10	Mood instability;
PAAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	4.42	0.34	1.9e-5	Renal cell carcinoma;
PAAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	1.13	13.14	0.73	7.65e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs11671653	0.688	rs11669103	chr19:10848224	C/T	cg18582342	chr19:11591989	ELAVL3	-0.64	-4.26	-0.33	3.59e-5	LDL cholesterol;
PAAD	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.26e-9	Hip circumference;
PAAD	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.76	-0.79	9.06e-34	Height;
PAAD	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg06026331	chr20:60912101	LAMA5	0.47	4.35	0.33	2.52e-5	Colorectal cancer;
PAAD	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6762644	0.507	rs10212373	chr3:4762449	C/T	cg11584376	chr3:4789075	ITPR1	-0.41	-4.66	-0.35	6.97e-6	Breast cancer;
PAAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	LDL cholesterol;
PAAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg09835421	chr16:68378352	PRMT7	-0.8	-6.56	-0.47	7.9e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6988306	0.521	rs10505011	chr8:102597686	G/T	cg20585841	chr8:102729926	NCALD	-0.65	-4.65	-0.35	7.01e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg01585852	chr22:24235823	MIF	-0.46	-4.87	-0.37	2.76e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.97	13.31	0.73	2.77e-27	Heart rate;
PAAD	cis	rs6499755	0.712	rs31113	chr16:55379633	T/A	cg02859129	chr16:55357253	IRX6	0.34	4.75	0.36	4.58e-6	Hypospadias;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg21724239	chr8:58056113	NA	0.65	5.0	0.38	1.57e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.3	11.38	0.68	4.38e-22	Uric acid levels;
PAAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg14343924	chr8:8086146	FLJ10661	0.49	4.56	0.35	1.03e-5	Mood instability;
PAAD	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.76	-8.72	-0.58	4.49e-15	Handedness;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg02841227	chr6:26021843	HIST1H4A	0.52	5.07	0.38	1.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6005807	0.543	rs6005866	chr22:29162940	A/G	cg15103426	chr22:29168792	CCDC117	0.65	4.75	0.36	4.77e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs2415984	0.579	rs61993337	chr14:46965297	C/T	cg14871534	chr14:47121158	RPL10L	-0.49	-5.09	-0.38	1.05e-6	Number of children ever born;
PAAD	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg26174226	chr8:58114915	NA	0.64	5.7	0.42	6.12e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4450131	0.522	rs35645049	chr10:126368119	C/G	cg20435097	chr10:126320824	FAM53B	0.5	5.04	0.38	1.32e-6	White blood cell count (basophil);
PAAD	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg00717180	chr2:96193071	NA	0.57	6.42	0.46	1.64e-9	HDL cholesterol;
PAAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.54	-4.38	-0.33	2.23e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.47	4.39	0.34	2.11e-5	Bipolar disorder;
PAAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg21361702	chr7:150065534	REPIN1	0.6	5.0	0.38	1.57e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.2	17.8	0.82	5.17e-39	Testicular germ cell tumor;
PAAD	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg27205649	chr11:78285834	NARS2	0.58	4.37	0.33	2.26e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6594713	0.837	rs6887914	chr5:112711486	C/T	cg12552261	chr5:112820674	MCC	0.6	4.35	0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.94	5.83	0.43	3.24e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.55	5.34	0.4	3.29e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.51	4.61	0.35	8.49e-6	Lung cancer;
PAAD	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.24	-0.39	5.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg21300403	chr2:198650112	BOLL	-0.49	-4.36	-0.33	2.37e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg06026331	chr20:60912101	LAMA5	-0.62	-5.7	-0.42	6.17e-8	Colorectal cancer;
PAAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.34	0.33	2.54e-5	Asthma;
PAAD	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.61	-6.84	-0.49	1.82e-10	Corneal astigmatism;
PAAD	cis	rs5417	0.636	rs222851	chr17:7139238	G/A	cg13768953	chr17:7114967	DLG4	-0.39	-4.71	-0.36	5.52e-6	Diastolic blood pressure;
PAAD	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.56	5.53	0.41	1.39e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.85	0.66	1.16e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	6.49	0.47	1.12e-9	Schizophrenia;
PAAD	cis	rs55728055	0.661	rs16989760	chr22:31951808	A/G	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.66	6.45	0.46	1.44e-9	Coronary artery disease;
PAAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs6782025	0.837	rs1511432	chr3:120993591	G/A	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11665867	0.680	rs2604911	chr19:41296117	C/G	cg08367223	chr19:41255304	C19orf54;SNRPA	0.48	4.43	0.34	1.77e-5	Hematocrit;
PAAD	cis	rs2286379	0.777	rs10735003	chr12:1880385	C/T	cg05227549	chr12:1770782	NA	-0.43	-5.01	-0.38	1.49e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.84	0.49	1.78e-10	IgG glycosylation;
PAAD	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg23461800	chr14:103021989	NA	0.65	4.58	0.35	9.43e-6	Platelet count;
PAAD	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg02820901	chr13:113351484	ATP11A	0.7	4.64	0.35	7.34e-6	Glycated hemoglobin levels;
PAAD	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.29e-8	Colorectal cancer;
PAAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	1.23	11.9	0.69	1.76e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.69	0.48	4.01e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.76	6.06	0.44	1.02e-8	Blood protein levels;
PAAD	cis	rs7567389	0.677	rs7556675	chr2:128053747	C/T	cg09760422	chr2:128146352	NA	-0.39	-5.97	-0.44	1.62e-8	Self-rated health;
PAAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.59	5.92	0.43	2.01e-8	Ankylosing spondylitis;
PAAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.79	9.07	0.59	5.65e-16	Diastolic blood pressure;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.53	5.82	0.43	3.43e-8	Obesity-related traits;
PAAD	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.45	-5.89	-0.43	2.37e-8	Primary biliary cholangitis;
PAAD	cis	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22546437	chr19:47987707	KPTN	0.6	6.74	0.48	3.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg02743256	chr7:2109353	MAD1L1	-0.73	-5.79	-0.43	3.86e-8	Bipolar disorder;
PAAD	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.46	-4.29	-0.33	3.1e-5	Type 2 diabetes;
PAAD	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	1.19	8.79	0.58	3.01e-15	Lymphocyte counts;
PAAD	cis	rs2992756	0.663	rs1360916	chr1:18801697	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.22	0.45	4.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.34	4.65	0.35	7.04e-6	Bladder cancer;Urinary bladder cancer;
PAAD	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.61	0.57	8.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	1.08	9.35	0.6	1.07e-16	Orofacial clefts;
PAAD	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	6.65	0.47	5.08e-10	Body mass index;
PAAD	cis	rs2033908	0.620	rs1440272	chr11:12852309	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-4.65	-0.35	7.27e-6	Sitting height ratio;
PAAD	cis	rs6088813	1.000	rs6060402	chr20:34005240	T/C	cg14752227	chr20:34000481	UQCC	-0.5	-5.07	-0.38	1.12e-6	Height;
PAAD	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.56	7.16	0.5	3.26e-11	Ewing sarcoma;
PAAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg14709524	chr16:89940631	TCF25	0.73	4.25	0.33	3.73e-5	Skin colour saturation;
PAAD	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.98	10.47	0.65	1.15e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.74	-0.36	4.8e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14119001	chr9:139324193	INPP5E	-0.57	-5.18	-0.39	7.06e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6915773	0.800	rs9374860	chr6:98278033	A/G	cg00987395	chr6:98934664	NA	0.38	4.47	0.34	1.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.29	0.45	3.21e-9	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23731591	chr2:71222556	TEX261	0.66	6.85	0.49	1.73e-10	Obesity-related traits;
PAAD	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg01191920	chr7:158217561	PTPRN2	-0.79	-7.82	-0.54	8.39e-13	Obesity-related traits;
PAAD	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.56	-0.41	1.18e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11250714	0.845	rs4880901	chr10:1695199	C/T	cg10435618	chr10:838112	NA	-0.48	-4.46	-0.34	1.58e-5	Gut microbiome composition (summer);
PAAD	cis	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg14329783	chr7:75779857	NA	0.74	4.46	0.34	1.6e-5	Mononucleosis;
PAAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.78	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs911555	0.755	rs2765049	chr14:103975039	G/A	cg12935359	chr14:103987150	CKB	0.63	6.37	0.46	2.1e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg08601574	chr20:25228251	PYGB	-0.51	-4.91	-0.37	2.28e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg10207240	chr12:122356781	WDR66	-0.48	-4.98	-0.37	1.74e-6	Mean corpuscular volume;
PAAD	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg12568669	chr8:11666485	FDFT1	-0.27	-4.33	-0.33	2.69e-5	Monocyte count;
PAAD	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.45	-0.46	1.43e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.79	8.28	0.56	6.04e-14	Selective IgA deficiency;
PAAD	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.76	8.29	0.56	5.44e-14	Body mass index;
PAAD	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02543470	chr2:105862877	NA	-0.51	-4.92	-0.37	2.18e-6	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs73416724	1.000	rs111408004	chr6:43326139	T/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.82	10.42	0.65	1.59e-19	Breast cancer;
PAAD	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg03517284	chr6:25882590	NA	-0.5	-4.37	-0.33	2.3e-5	Iron status biomarkers;
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	-0.49	-4.88	-0.37	2.62e-6	Trans fatty acid levels;
PAAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.67	8.21	0.55	8.98e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs5771225	0.563	rs1129880	chr22:50694297	A/G	cg16473166	chr22:50639996	SELO	0.61	5.3	0.39	4.04e-7	Late-onset Alzheimer's disease;
PAAD	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg16558253	chr16:72132732	DHX38	0.48	4.99	0.38	1.65e-6	Prostate cancer;
PAAD	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs4356203	0.870	rs214910	chr11:17242789	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs17592366	0.517	rs4982222	chr14:35301997	T/C	cg09327582	chr14:35236912	BAZ1A	0.57	5.34	0.4	3.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.91	-9.33	-0.6	1.21e-16	Asthma;
PAAD	cis	rs17824933	0.943	rs2074230	chr11:60783804	C/T	cg27098804	chr11:60776124	CD6	0.43	4.29	0.33	3.22e-5	Multiple sclerosis;
PAAD	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg01796438	chr3:11312864	ATG7	-0.65	-4.8	-0.36	3.77e-6	Circulating chemerin levels;
PAAD	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-5.01	-0.38	1.51e-6	Diastolic blood pressure;
PAAD	cis	rs4742903	0.967	rs10991119	chr9:106905277	C/T	cg14250997	chr9:106856677	SMC2	-0.49	-5.4	-0.4	2.54e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg23283495	chr1:209979779	IRF6	0.47	5.45	0.4	1.96e-7	Monobrow;
PAAD	cis	rs7904519	0.967	rs6585201	chr10:114768783	C/T	cg17116091	chr10:114807157	TCF7L2	0.42	4.57	0.35	1.02e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.38e-11	Mitochondrial DNA levels;
PAAD	trans	rs901683	0.850	rs76040096	chr10:46094626	C/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.78	0.48	2.46e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.5	-4.91	-0.37	2.29e-6	Facial morphology (factor 20);
PAAD	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.36	-4.46	-0.34	1.61e-5	Dupuytren's disease;
PAAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.38	-4.75	-0.36	4.7e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-10.17	-0.64	7.45e-19	Vitiligo;
PAAD	cis	rs4668356	0.881	rs7580756	chr2:172040820	T/C	cg13882835	chr2:172017928	TLK1	0.93	4.53	0.34	1.19e-5	Cognitive performance;
PAAD	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.08	11.6	0.69	1.09e-22	Blood pressure (smoking interaction);
PAAD	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg13319975	chr6:146136371	FBXO30	0.52	4.5	0.34	1.32e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.35	4.31	0.33	2.87e-5	Body mass index in non-asthmatics;
PAAD	trans	rs2790216	0.851	rs1698387	chr10:59928997	T/C	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg25547332	chr5:131281432	NA	0.54	4.33	0.33	2.72e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8032158	1.000	rs28660477	chr15:56145267	T/C	cg02198044	chr15:56286336	NEDD4	-0.5	-5.22	-0.39	5.68e-7	Keloid;
PAAD	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.3	-0.46	2.99e-9	Morning vs. evening chronotype;
PAAD	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg14784868	chr12:69753453	YEATS4	0.59	5.16	0.39	7.54e-7	Response to diuretic therapy;
PAAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg17380795	chr3:122379686	NA	0.47	4.88	0.37	2.67e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg19442545	chr10:75533431	FUT11	-0.55	-5.75	-0.42	4.8e-8	Inflammatory bowel disease;
PAAD	cis	rs639012	0.607	rs573167	chr11:85831246	G/A	cg07180834	chr11:85838833	NA	-0.42	-4.49	-0.34	1.4e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.55	0.61	3.11e-17	Bladder cancer;
PAAD	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.73	0.48	3.18e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-1.06	-14.68	-0.77	6.06e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.89	-9.67	-0.62	1.52e-17	Colorectal cancer;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs863345	0.967	rs2157689	chr1:158459264	T/C	cg12129480	chr1:158549410	OR10X1	-0.41	-4.57	-0.35	9.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.66	7.15	0.5	3.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs76917914	0.820	rs7034147	chr9:100821691	T/G	cg21225548	chr9:100864335	TRIM14	-0.56	-5.81	-0.43	3.57e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs17539620	0.506	rs77962262	chr6:154845814	T/A	cg20019720	chr6:154832845	CNKSR3	0.64	6.66	0.48	4.77e-10	Lipoprotein (a) levels;
PAAD	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.47	-4.47	-0.34	1.5e-5	Stearic acid (18:0) levels;
PAAD	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-4.27	-0.33	3.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg20813462	chr7:2646259	IQCE	0.65	4.67	0.35	6.5e-6	Urate levels in lean individuals;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08677398	chr8:58056175	NA	0.66	4.57	0.35	1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7083	0.653	rs573442	chr11:117177920	T/C	cg26034313	chr11:117110208	RNF214	0.35	4.46	0.34	1.56e-5	Blood protein levels;
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.22	-0.51	2.32e-11	Response to amphetamines;
PAAD	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg10395934	chr14:104002654	TRMT61A	0.48	4.64	0.35	7.44e-6	Body mass index;
PAAD	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.56	4.84	0.37	3.17e-6	Mean platelet volume;
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.63	-6.57	-0.47	7.46e-10	Body mass index;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-6.46	-0.46	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-4.77	-0.36	4.28e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.09	10.17	0.64	7.3e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.53	4.87	0.37	2.72e-6	Platelet count;
PAAD	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg17509989	chr5:176798049	RGS14	0.9	10.39	0.64	1.94e-19	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.44	0.52	6.95e-12	HIV-1 control;
PAAD	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4557101	0.625	rs6800926	chr3:73534976	G/A	cg24173753	chr3:73529447	PDZRN3	0.36	4.44	0.34	1.72e-5	QT interval;
PAAD	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-6.95	-0.49	1e-10	Mood instability;
PAAD	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.7	0.48	3.75e-10	High light scatter reticulocyte count;
PAAD	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.94	-8.14	-0.55	1.29e-13	Vitiligo;
PAAD	cis	rs4764124	1.000	rs4764124	chr12:14966604	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.56	6.42	0.46	1.63e-9	Pubertal anthropometrics;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.71	0.42	5.74e-8	Bipolar disorder;
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.49	5.35	0.4	3.11e-7	Obesity-related traits;
PAAD	cis	rs9595066	0.564	rs12869383	chr13:44705441	G/A	cg04068111	chr13:44716778	NA	0.44	5.56	0.41	1.16e-7	Schizophrenia;
PAAD	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs3764400	0.567	rs2240120	chr17:46142144	C/T	cg24322968	chr17:46507895	SKAP1	0.87	5.3	0.39	4.06e-7	Body mass index;
PAAD	cis	rs35955747	0.871	rs5994392	chr22:31783906	T/A	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.74	-0.36	4.96e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13274775	chr6:74078997	OOEP	-0.59	-6.72	-0.48	3.34e-10	Obesity-related traits;
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.52	5.2	0.39	6.33e-7	Mean corpuscular volume;
PAAD	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg18551225	chr6:44695536	NA	-0.73	-7.33	-0.51	1.28e-11	Total body bone mineral density;
PAAD	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-4.6	-0.35	8.92e-6	Breast cancer;
PAAD	cis	rs61876865	0.644	rs61876891	chr11:9807841	A/G	cg17999319	chr11:10396922	NA	0.52	4.57	0.35	9.89e-6	Tonsillectomy;
PAAD	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.75	8.15	0.55	1.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13242816	1.000	rs35800921	chr7:116124041	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.42	-6.5	-0.47	1.07e-9	Cutaneous nevi;
PAAD	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.5	-0.41	1.55e-7	Reticulocyte count;
PAAD	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.64	5.85	0.43	2.93e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg21546286	chr11:48923668	NA	0.57	5.69	0.42	6.39e-8	HDL cholesterol;
PAAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.88	-9.64	-0.62	1.91e-17	Parkinson's disease;
PAAD	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.28	0.73	3.39e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11700980	0.551	rs2832032	chr21:30114790	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	1.01	14.09	0.75	2.32e-29	Menarche (age at onset);
PAAD	cis	rs11051970	0.636	rs325420	chr12:32571994	C/A	cg02745156	chr12:32552066	NA	0.43	4.44	0.34	1.7e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11955175	1.000	rs11960585	chr5:40662007	C/A	cg17351974	chr5:40835760	RPL37	0.81	4.66	0.35	6.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs59888335	0.734	rs12494644	chr3:80820333	A/G	cg21735741	chr3:80819488	NA	-0.55	-4.53	-0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs1497828	0.912	rs2646825	chr1:217539194	A/G	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.59	5.42	0.4	2.26e-7	Blood metabolite levels;
PAAD	cis	rs10916814	0.632	rs7545313	chr1:20902728	C/T	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	9.51	0.61	4.01e-17	Alzheimer's disease;
PAAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.49	4.72	0.36	5.33e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.72	-0.42	5.52e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09163117	chr2:239148697	HES6	0.64	7.04	0.5	6.06e-11	Monocyte percentage of white cells;
PAAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.84	6.34	0.46	2.47e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.77	7.25	0.51	1.96e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg24881330	chr22:46731750	TRMU	1.16	5.73	0.42	5.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.57	-6.16	-0.45	6.3e-9	Pelvic organ prolapse;
PAAD	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.86	6.38	0.46	2.06e-9	Iron status biomarkers;
PAAD	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg03522150	chr11:46969673	C11orf49	0.43	5.14	0.39	8.2e-7	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs1879734	0.731	rs6658245	chr1:54159005	T/C	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg18302933	chr2:88491318	NA	-0.39	-4.82	-0.36	3.52e-6	Response to metformin (IC50);
PAAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg23281280	chr6:28129359	ZNF389	0.54	4.86	0.37	2.92e-6	Parkinson's disease;
PAAD	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.58	7.32	0.51	1.34e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.59	-5.42	-0.4	2.26e-7	Acylcarnitine levels;
PAAD	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg00717180	chr2:96193071	NA	0.62	7.04	0.5	6.33e-11	HDL cholesterol;
PAAD	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg02683114	chr2:24398427	C2orf84	-0.53	-5.04	-0.38	1.33e-6	Asthma;
PAAD	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	10.26	0.64	4.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs6942407	0.592	rs4728689	chr7:86851097	T/G	cg02420886	chr7:86849541	C7orf23	0.69	5.33	0.4	3.47e-7	Food allergy;
PAAD	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-5.41	-0.4	2.45e-7	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg26513180	chr16:89883248	FANCA	0.66	7.7	0.53	1.57e-12	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26820233	chr16:838206	RPUSD1;CHTF18	-0.63	-7.32	-0.51	1.34e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.56	5.0	0.38	1.56e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	7.63	0.53	2.4e-12	Parkinson's disease;
PAAD	cis	rs7191439	0.584	rs11076698	chr16:88752693	T/G	cg27099511	chr16:88729703	MGC23284;MVD	-0.92	-4.85	-0.37	2.97e-6	Plateletcrit;
PAAD	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.59	-6.35	-0.46	2.35e-9	Lung cancer;
PAAD	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg01890435	chr5:442385	EXOC3;C5orf55	-0.5	-4.44	-0.34	1.72e-5	Cystic fibrosis severity;
PAAD	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.15e-10	HDL cholesterol;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs11563648	0.553	rs1419419	chr7:127016871	G/A	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg15764593	chr10:829463	NA	-0.88	-4.31	-0.33	2.94e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.78	-8.07	-0.55	1.96e-13	Sleep quality;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs6750047	0.678	rs4670811	chr2:38277376	C/A	cg19753864	chr2:38320028	NA	0.42	4.71	0.36	5.63e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.61	-6.6	-0.47	6.4e-10	Coronary artery disease;
PAAD	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.56	5.14	0.38	8.44e-7	Type 2 diabetes;
PAAD	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg07856975	chr6:36356162	ETV7	0.49	5.57	0.41	1.11e-7	Platelet distribution width;
PAAD	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9616064	1.000	rs9616064	chr22:46982293	T/C	cg05621596	chr22:47072043	GRAMD4	0.54	5.04	0.38	1.28e-6	Urate levels in obese individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15485665	chr17:47677567	SPOP	-0.65	-6.97	-0.49	9.15e-11	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs630539	1.000	rs7218686	chr17:40813865	T/C	cg20669292	chr17:40823420	PLEKHH3	-0.49	-4.43	-0.34	1.8e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.6	8.19	0.55	9.91e-14	Electrocardiographic conduction measures;
PAAD	cis	rs9810890	0.850	rs73198858	chr3:128514061	T/G	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.79	0.36	3.96e-6	Breast cancer;
PAAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.86	9.82	0.62	6.23e-18	Prudent dietary pattern;
PAAD	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.49	-4.66	-0.35	6.94e-6	Migraine;
PAAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg03538708	chr1:25844672	NA	-0.46	-4.7	-0.36	5.79e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7631605	0.905	rs4678943	chr3:37197355	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00262122	chr8:11665843	FDFT1	0.48	4.52	0.34	1.26e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-8.25	-0.56	6.99e-14	Response to antipsychotic treatment;
PAAD	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.56	5.13	0.38	8.68e-7	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.49	0.57	1.77e-14	Bipolar disorder;
PAAD	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.76	7.49	0.52	5.2e-12	Breast cancer;
PAAD	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.83	-0.43	3.16e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.56	7.34	0.51	1.17e-11	Schizophrenia;
PAAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.83	9.93	0.63	3.14e-18	Menopause (age at onset);
PAAD	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.28	0.45	3.46e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2034088	0.930	rs9907540	chr17:448042	A/G	cg20761395	chr17:511517	VPS53	0.47	4.54	0.35	1.13e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg05717871	chr11:638507	DRD4	-0.59	-5.64	-0.42	8.1e-8	Systemic lupus erythematosus;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.45	-0.34	1.64e-5	Response to amphetamines;
PAAD	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.36	0.33	2.41e-5	Breast cancer;
PAAD	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.65	-5.63	-0.42	8.61e-8	Type 2 diabetes;
PAAD	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.26	-0.39	4.76e-7	Vitamin D levels;
PAAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.92	11.5	0.68	2.03e-22	Pulse pressure;
PAAD	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.54	-0.35	1.14e-5	Arsenic metabolism;
PAAD	cis	rs1903068	0.925	rs1551642	chr4:55994210	T/C	cg20092376	chr4:56023423	NA	0.49	4.9	0.37	2.42e-6	Endometriosis;
PAAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.87	-0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-5.21	-0.39	6.08e-7	Blood pressure (smoking interaction);
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg15117754	chr3:10150083	C3orf24	0.7	6.3	0.46	3.02e-9	Alzheimer's disease;
PAAD	cis	rs1198430	0.636	rs2156087	chr1:23743581	C/G	cg24580199	chr1:23763081	ASAP3	-0.55	-4.93	-0.37	2.15e-6	Total cholesterol levels;
PAAD	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.47	-4.36	-0.33	2.41e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.61	6.5	0.47	1.06e-9	Menarche (age at onset);
PAAD	cis	rs2051773	0.538	rs4468326	chr11:17041034	A/G	cg15378786	chr11:17036137	PLEKHA7	0.51	4.38	0.34	2.16e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg00262122	chr8:11665843	FDFT1	0.49	4.3	0.33	3.04e-5	Retinal vascular caliber;
PAAD	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.39	-5.21	-0.39	6.19e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2274459	0.841	rs3818526	chr6:33660973	T/C	cg06253072	chr6:33679850	C6orf125	0.6	4.78	0.36	4.08e-6	Obesity (extreme);
PAAD	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg12463550	chr7:65579703	CRCP	0.76	5.19	0.39	6.62e-7	Diabetic kidney disease;
PAAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg02297831	chr4:17616191	MED28	-0.6	-5.7	-0.42	6.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.67	-0.42	6.83e-8	Androgen levels;
PAAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg00786201	chr11:61583134	MIR1908;FADS1	-0.46	-4.51	-0.34	1.31e-5	Trans fatty acid levels;
PAAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.76	7.92	0.54	4.75e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	9.73	0.62	1.09e-17	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.78	8.32	0.56	4.71e-14	Brugada syndrome;
PAAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14180030	chr9:123475675	MEGF9	-0.44	-4.99	-0.38	1.65e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg26384229	chr12:38710491	ALG10B	0.54	5.77	0.42	4.3e-8	Bladder cancer;
PAAD	cis	rs346785	0.692	rs4789274	chr17:74286106	C/T	cg09812376	chr17:74270190	QRICH2	-0.48	-5.95	-0.43	1.79e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4471226	1.000	rs9425449	chr1:176426953	C/T	cg26572392	chr10:24496943	KIAA1217	0.89	6.62	0.47	5.74e-10	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.58	6.44	0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.98	-0.37	1.72e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6662572	1.000	rs41310432	chr1:46083706	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	4.28	0.33	3.32e-5	Blood protein levels;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs9913156	0.793	rs55677157	chr17:4576620	C/T	cg19197139	chr17:4613644	ARRB2	0.88	8.72	0.58	4.6e-15	Lymphocyte counts;
PAAD	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.4	-0.68	3.75e-22	Chronic sinus infection;
PAAD	cis	rs6132905	0.590	rs78684001	chr20:2604244	G/C	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg02743256	chr7:2109353	MAD1L1	-0.66	-4.83	-0.36	3.31e-6	Bipolar disorder;
PAAD	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg09040174	chr2:113837401	NA	0.38	4.44	0.34	1.69e-5	Protein quantitative trait loci;
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.71	-4.81	-0.36	3.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	trans	rs7172971	0.688	rs74909369	chr15:42382241	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg19930314	chr7:98593876	TRRAP	-0.46	-4.38	-0.34	2.16e-5	Breast cancer;
PAAD	cis	rs116248771	0.739	rs73156415	chr3:158342695	C/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.77	-0.36	4.26e-6	Smoking behavior;
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.66	6.82	0.48	1.97e-10	Eye color traits;
PAAD	cis	rs6804624	0.654	rs2700652	chr3:99168238	G/A	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.69	-7.34	-0.51	1.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.43	4.67	0.35	6.61e-6	HDL cholesterol levels;
PAAD	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.66	-8.46	-0.57	2.12e-14	Birth weight;
PAAD	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg12633918	chr20:23549525	CST9L	-0.38	-4.25	-0.33	3.65e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg02734326	chr4:10020555	SLC2A9	0.53	5.22	0.39	5.72e-7	Bone mineral density;
PAAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.82	-7.16	-0.5	3.26e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.5	-4.39	-0.34	2.1e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2252790	1.000	rs2498710	chr6:116670636	G/A	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.92	0.37	2.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.66	6.34	0.46	2.42e-9	Blood metabolite levels;
PAAD	cis	rs10847980	0.590	rs839360	chr12:123283841	A/G	cg25930673	chr12:123319894	HIP1R	1.29	5.13	0.38	8.57e-7	Adiponectin levels;
PAAD	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg00961940	chr17:76876995	TIMP2	0.59	5.46	0.4	1.91e-7	Obesity-related traits;
PAAD	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs12410462	0.636	rs2819511	chr1:227698474	A/G	cg23173402	chr1:227635558	NA	0.56	4.34	0.33	2.61e-5	Major depressive disorder;
PAAD	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg05110241	chr16:68378359	PRMT7	-1.07	-7.93	-0.54	4.38e-13	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13966313	chr21:39628227	KCNJ15	-0.69	-7.33	-0.51	1.24e-11	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4918918	0.868	rs7900095	chr10:97119049	T/C	cg03417182	chr10:97121241	SORBS1	-0.46	-4.27	-0.33	3.42e-5	Suicide risk;
PAAD	cis	rs1507153	0.523	rs236886	chr6:79321534	A/C	cg05283184	chr6:79620031	NA	0.37	4.45	0.34	1.62e-5	Sjögren's syndrome;
PAAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.55	5.11	0.38	9.74e-7	Monocyte count;
PAAD	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg13332499	chr17:408570	NA	-0.61	-6.82	-0.48	2.04e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.76	5.85	0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.34	-4.94	-0.37	2.02e-6	Glomerular filtration rate;
PAAD	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.72	9.34	0.6	1.15e-16	Weight;
PAAD	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-7.0	-0.49	7.65e-11	Blood metabolite levels;
PAAD	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs61931739	0.578	rs61927759	chr12:33713297	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.52	-0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.45	5.4	0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.67	6.58	0.47	7.09e-10	Cancer;
PAAD	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg16898833	chr6:26189333	HIST1H4D	0.64	4.81	0.36	3.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs748404	0.578	rs538238	chr15:43585520	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.49	4.52	0.34	1.24e-5	Lung cancer;
PAAD	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.08	0.38	1.12e-6	Height;
PAAD	cis	rs939584	1.000	rs4854343	chr2:638107	G/A	cg03610516	chr2:642275	NA	0.6	5.4	0.4	2.52e-7	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03255265	chr17:36908169	PSMB3	-0.57	-6.7	-0.48	3.78e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.65	-6.19	-0.45	5.43e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9463078	0.546	rs11968042	chr6:45046735	A/G	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs507080	0.845	rs509641	chr11:118558952	T/C	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs9463078	0.691	rs9296458	chr6:45267183	T/C	cg25276700	chr6:44698697	NA	-0.53	-6.0	-0.44	1.38e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.55	-4.53	-0.35	1.17e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.95	6.65	0.47	4.97e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.35	-0.46	2.36e-9	Morning vs. evening chronotype;
PAAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-4.43	-0.34	1.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	5.03	0.38	1.37e-6	Bipolar disorder;
PAAD	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.59	-4.26	-0.33	3.51e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs75920871	1.000	rs61905677	chr11:116833655	T/G	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	5.97	0.44	1.62e-8	Body mass index;
PAAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.56	-5.11	-0.38	9.64e-7	Obesity-related traits;
PAAD	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.74	-7.94	-0.54	4.07e-13	Systemic lupus erythematosus;
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-4.42	-0.34	1.87e-5	Tonsillectomy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05398940	chr16:89351098	ANKRD11	-0.59	-6.91	-0.49	1.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.97	12.74	0.72	9.68e-26	Heart rate;
PAAD	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.8	-0.48	2.2e-10	Triglycerides;
PAAD	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.91	11.58	0.68	1.27e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.96	10.43	0.65	1.49e-19	Diastolic blood pressure;
PAAD	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg00579200	chr11:133705235	NA	-0.49	-5.5	-0.41	1.58e-7	Childhood ear infection;
PAAD	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	9.0	0.59	8.43e-16	Lymphocyte counts;
PAAD	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg08807892	chr2:162101083	NA	0.52	5.27	0.39	4.67e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs62264129	0.500	rs9816969	chr3:112037942	G/A	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.25	-0.33	3.72e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg08502239	chr17:9808122	RCVRN	0.57	6.83	0.48	1.93e-10	Educational attainment (years of education);
PAAD	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg21699342	chr2:239360505	ASB1	0.54	6.57	0.47	7.49e-10	Multiple system atrophy;
PAAD	cis	rs5756391	0.546	rs9607396	chr22:37315912	C/A	cg16356956	chr22:37317934	CSF2RB	0.38	4.71	0.36	5.64e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7824557	0.679	rs13279067	chr8:11135828	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.25	-0.33	3.66e-5	Retinal vascular caliber;
PAAD	cis	rs9652601	0.691	rs998592	chr16:11199678	A/G	cg04616529	chr16:11181986	CLEC16A	-0.36	-4.41	-0.34	1.92e-5	Systemic lupus erythematosus;
PAAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.8	-8.4	-0.56	2.94e-14	Coronary artery disease;
PAAD	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.43	0.56	2.52e-14	Corneal astigmatism;
PAAD	cis	rs950037	0.710	rs170038	chr1:89236694	G/A	cg13109106	chr1:89333529	GTF2B	-0.47	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs34156428	0.657	rs4757432	chr11:16789155	C/T	cg15111638	chr11:16631993	NA	0.42	4.36	0.33	2.35e-5	Coronary artery disease;
PAAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg05132306	chr1:1846340	CALML6	-0.43	-5.04	-0.38	1.29e-6	Body mass index;
PAAD	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg17541715	chr7:1216824	NA	-0.5	-5.68	-0.42	6.8e-8	Longevity;Endometriosis;
PAAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-4.41	-0.34	1.94e-5	Height;
PAAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	10.79	0.66	1.69e-20	Tonsillectomy;
PAAD	cis	rs254562	0.739	rs254577	chr5:134422204	C/T	cg19844653	chr5:133451294	TCF7	0.33	4.55	0.35	1.07e-5	Ulcerative colitis;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs10981012	0.504	rs57056300	chr9:114581974	A/G	cg14428669	chr9:114659192	UGCG	-0.59	-4.47	-0.34	1.51e-5	Coronary artery disease;
PAAD	cis	rs2120991	1.000	rs2120991	chr12:54270228	G/T	cg23795217	chr12:54812000	ITGA5	-0.34	-4.72	-0.36	5.3e-6	Biliary atresia;
PAAD	cis	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.52	-0.34	1.22e-5	Eotaxin levels;
PAAD	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.71	-7.47	-0.52	5.95e-12	Menarche (age at onset);
PAAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.15	-0.5	3.42e-11	Body mass index;
PAAD	cis	rs57994353	0.568	rs10747043	chr9:139318310	G/A	cg21253087	chr9:139290292	SNAPC4	0.52	4.58	0.35	9.65e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.29	-0.39	4.11e-7	Schizophrenia;
PAAD	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs9395066	0.509	rs6922772	chr6:45059584	G/A	cg25276700	chr6:44698697	NA	0.45	5.18	0.39	6.98e-7	Height;
PAAD	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.63	6.71	0.48	3.63e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02985541	chr2:219472218	PLCD4	0.32	4.98	0.37	1.68e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20459655	chr2:135675569	CCNT2	-0.54	-6.58	-0.47	7.35e-10	Body fat percentage;
PAAD	cis	rs1075232	1.000	rs12439239	chr15:31651718	G/A	cg15751117	chr15:30700112	NA	0.93	4.71	0.36	5.44e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs13424612	1.000	rs10189996	chr2:240908800	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.88	-0.37	2.63e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.79	-6.92	-0.49	1.15e-10	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-5.66	-0.42	7.45e-8	Coronary artery disease;
PAAD	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-5.13	-0.38	8.8e-7	Longevity;Endometriosis;
PAAD	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.42	0.34	1.85e-5	Alzheimer's disease (survival time);
PAAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg16341495	chr8:142228727	SLC45A4	0.61	6.21	0.45	4.84e-9	Immature fraction of reticulocytes;
PAAD	cis	rs818427	0.927	rs469760	chr5:112244777	G/A	cg06941702	chr5:112196734	SRP19	0.46	4.32	0.33	2.86e-5	Total body bone mineral density;
PAAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg14580859	chr9:123691850	NA	0.39	4.32	0.33	2.84e-5	Rheumatoid arthritis;
PAAD	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.82	9.91	0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs6076065	0.676	rs1419006	chr20:23336766	C/T	cg11657817	chr20:23433608	CST11	0.5	5.13	0.38	8.77e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs820218	0.962	rs820129	chr17:73668107	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.52	4.49	0.34	1.43e-5	Rotator cuff tears;
PAAD	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.48	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg08222618	chr4:941054	TMEM175	0.52	4.66	0.35	6.98e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.78	-6.67	-0.48	4.48e-10	Other erythrocyte phenotypes;
PAAD	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.44	-0.52	6.86e-12	Hemoglobin concentration;
PAAD	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg24044776	chr19:53454761	ZNF816A	-0.42	-4.52	-0.34	1.26e-5	Psoriasis;
PAAD	cis	rs7766436	0.767	rs11754964	chr6:22604737	G/T	cg13666174	chr6:22585274	NA	-0.52	-5.77	-0.42	4.26e-8	Coronary artery disease;
PAAD	cis	rs838147	0.844	rs12611203	chr19:49248295	G/A	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.7	6.2	0.45	5.14e-9	Platelet count;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg19130645	chr7:65235666	NA	0.44	4.57	0.35	9.86e-6	Calcium levels;
PAAD	cis	rs2131877	0.701	rs57357728	chr3:194832106	G/A	cg24618514	chr3:194868507	C3orf21	0.5	4.75	0.36	4.58e-6	Non-small cell lung cancer;
PAAD	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.56	5.41	0.4	2.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg03538708	chr1:25844672	NA	-0.51	-5.14	-0.38	8.45e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.65	-6.54	-0.47	8.72e-10	Birth weight;
PAAD	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.97	-9.62	-0.62	2.05e-17	Prostate cancer;
PAAD	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.46	6.71	0.48	3.6e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.68	6.44	0.46	1.48e-9	Lymphocyte counts;
PAAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg13175981	chr1:150552382	MCL1	-0.45	-4.29	-0.33	3.11e-5	Melanoma;
PAAD	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg18551225	chr6:44695536	NA	-0.62	-5.75	-0.42	4.64e-8	Total body bone mineral density;
PAAD	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg15556689	chr8:8085844	FLJ10661	0.74	7.59	0.52	2.98e-12	Neuroticism;
PAAD	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.75	8.08	0.55	1.82e-13	Heart rate;
PAAD	cis	rs2120243	0.539	rs1585080	chr3:157106982	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.43	0.34	1.82e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.27	0.33	3.39e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	4.99e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs311392	0.715	rs311394	chr8:55083332	C/A	cg06042504	chr8:55087323	NA	-0.72	-8.03	-0.55	2.45e-13	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg10589385	chr1:150898437	SETDB1	0.39	4.8	0.36	3.8e-6	Melanoma;
PAAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.07	-0.44	9.81e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.87	-11.39	-0.68	4.04e-22	Vitiligo;
PAAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg13770153	chr20:60521292	NA	-0.46	-4.37	-0.33	2.33e-5	Body mass index;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.49	5.48	0.41	1.77e-7	Calcium levels;
PAAD	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-4.92	-0.37	2.18e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.932	rs7811681	chr7:104928869	A/G	cg04380332	chr7:105027541	SRPK2	0.64	7.03	0.5	6.59e-11	Schizophrenia;
PAAD	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.9	-0.43	2.27e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg23995914	chr4:10459228	ZNF518B	-0.35	-4.3	-0.33	2.99e-5	Schizophrenia (age at onset);
PAAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.72	8.32	0.56	4.56e-14	Lung cancer;
PAAD	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.29	-12.32	-0.71	1.25e-24	Hip circumference adjusted for BMI;
PAAD	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06544989	chr22:39130855	UNC84B	0.5	5.13	0.38	8.86e-7	Menopause (age at onset);
PAAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.85	-10.09	-0.63	1.23e-18	Urinary electrolytes (magnesium/calcium ratio);
PAAD	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg26939375	chr7:64535504	NA	0.73	8.54	0.57	1.26e-14	Aortic root size;
PAAD	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.43	5.47	0.41	1.8e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35740288	0.929	rs11636821	chr15:86306005	T/G	cg07943548	chr15:86304357	KLHL25	-0.6	-5.16	-0.39	7.7e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11203032	0.831	rs4933496	chr10:90952338	T/C	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs4523957	0.583	rs2641438	chr17:2017786	C/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.62	0.47	5.9e-10	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.44	4.52	0.34	1.22e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.52	-5.73	-0.42	5.31e-8	Neuroticism;
PAAD	cis	rs7929679	0.521	rs10768097	chr11:34792902	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.51	-5.63	-0.42	8.47e-8	Calcium levels;
PAAD	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72772787	1.000	rs59203167	chr1:248014245	A/G	cg00785941	chr1:248100591	OR2L13	0.48	4.8	0.36	3.77e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg16006841	chr5:176797999	RGS14	0.69	6.8	0.48	2.3e-10	Urate levels in lean individuals;
PAAD	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.78	0.62	8.06e-18	Electrocardiographic conduction measures;
PAAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10819733	chr22:24237672	NA	-0.59	-6.93	-0.49	1.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg00717180	chr2:96193071	NA	0.58	6.4	0.46	1.8e-9	HDL cholesterol;
PAAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg10356904	chr22:49881777	NA	-0.5	-4.86	-0.37	2.87e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6256	1.000	rs12421404	chr11:13561788	C/T	cg11976911	chr11:13509032	NA	-0.67	-5.18	-0.39	7.06e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25851842	chr1:218519232	TGFB2	0.66	7.63	0.53	2.41e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21562809	chr5:67481946	NA	-0.7	-6.74	-0.48	3.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg10547527	chr2:198650123	BOLL	-0.73	-4.97	-0.37	1.8e-6	Ulcerative colitis;
PAAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.7	7.36	0.51	1.07e-11	Pulse pressure;
PAAD	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg23153227	chr6:27725408	NA	0.43	4.3	0.33	3.05e-5	Pulmonary function;
PAAD	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	1.13	5.54	0.41	1.29e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1879734	0.731	rs17388507	chr1:54187575	C/G	cg14659662	chr1:54151053	GLIS1	-0.34	-4.65	-0.35	7.26e-6	Mitral valve prolapse;
PAAD	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.61	5.35	0.4	3.21e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9463078	0.565	rs3799973	chr6:44823727	G/A	cg15420678	chr6:43901543	LOC100132354	-0.33	-4.33	-0.33	2.72e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg26513180	chr16:89883248	FANCA	-0.45	-4.58	-0.35	9.5e-6	Vitiligo;
PAAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.6	7.07	0.5	5.31e-11	Immature fraction of reticulocytes;
PAAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.44	4.55	0.35	1.11e-5	Height;
PAAD	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.88e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs959260	0.614	rs930296	chr17:73404168	C/T	cg14668889	chr17:73230827	NUP85	0.75	4.84	0.37	3.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.66	6.9	0.49	1.28e-10	Multiple sclerosis;
PAAD	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.63	6.2	0.45	5.01e-9	Breast cancer;
PAAD	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg00622658	chr8:10469796	RP1L1	-0.42	-4.38	-0.33	2.17e-5	Neuroticism;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg09060608	chr5:178986726	RUFY1	0.47	4.55	0.35	1.08e-5	Lung cancer;
PAAD	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.26	-0.33	3.55e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.97	-0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.62	5.22	0.39	5.71e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2944755	0.723	rs9694342	chr8:141587404	C/T	cg18491938	chr8:141590271	EIF2C2	-0.52	-4.97	-0.37	1.75e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.73	-0.87	1.74e-48	Myeloid white cell count;
PAAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.51	5.14	0.38	8.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs72960926	1.000	rs72969247	chr6:75071533	G/T	cg13997649	chr6:74171430	MTO1	0.8	4.49	0.34	1.42e-5	Metabolite levels (MHPG);
PAAD	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	12.59	0.71	2.31e-25	Colorectal cancer;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg17178900	chr1:205818956	PM20D1	0.46	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs2562456	0.916	rs1967182	chr19:21603139	C/G	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg00035074	chr7:2701567	TTYH3	0.63	4.25	0.33	3.76e-5	Bipolar disorder;
PAAD	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.93	7.34	0.51	1.22e-11	Bipolar disorder;
PAAD	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs59888335	0.825	rs67440238	chr3:80650019	A/G	cg21735741	chr3:80819488	NA	0.58	5.04	0.38	1.33e-6	Schizophrenia;
PAAD	cis	rs35740288	0.770	rs34048547	chr15:86181067	A/G	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs8077577	0.708	rs11867855	chr17:18262584	G/T	cg16794390	chr17:18148240	FLII	0.52	4.38	0.33	2.17e-5	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg11262906	chr1:85462892	MCOLN2	0.67	4.97	0.37	1.81e-6	Serum sulfate level;
PAAD	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg09695851	chr17:3907499	NA	0.84	8.96	0.59	1.12e-15	Type 2 diabetes;
PAAD	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg08992911	chr2:238395768	MLPH	0.86	6.04	0.44	1.12e-8	Prostate cancer;
PAAD	cis	rs9616064	0.849	rs5768992	chr22:46983605	A/G	cg05621596	chr22:47072043	GRAMD4	0.54	5.04	0.38	1.28e-6	Urate levels in obese individuals;
PAAD	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg00999904	chr2:3704751	ALLC	-0.49	-5.72	-0.42	5.42e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.57	5.43	0.4	2.19e-7	Joint mobility (Beighton score);
PAAD	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg12639453	chr1:2035780	PRKCZ	-0.51	-5.36	-0.4	3.06e-7	Height;
PAAD	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.75	8.75	0.58	3.83e-15	Blood metabolite ratios;
PAAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.76	-8.55	-0.57	1.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg24565620	chr2:194026	NA	0.65	5.18	0.39	7.06e-7	Blood protein levels;
PAAD	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs58521262	0.519	rs11085550	chr19:23007257	G/A	cg07749055	chr19:23076870	NA	-0.61	-4.63	-0.35	7.81e-6	Testicular germ cell tumor;
PAAD	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg03277515	chr1:153321198	PGLYRP4	0.42	5.01	0.38	1.52e-6	Psoriasis;
PAAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.81	9.29	0.6	1.57e-16	Methadone dose in opioid dependence;
PAAD	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06850241	chr22:41845214	NA	-0.49	-4.66	-0.35	7.01e-6	Vitiligo;
PAAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg03909863	chr11:638404	DRD4	-0.67	-5.62	-0.42	8.71e-8	Systemic lupus erythematosus;
PAAD	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs55863869	0.748	rs2291311	chr2:179629461	C/T	cg02880032	chr2:179629472	TTN	-0.68	-4.85	-0.37	3.02e-6	QT interval;
PAAD	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.63	-7.4	-0.51	8.52e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.48	-4.71	-0.36	5.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.28	-0.39	4.49e-7	Number of children ever born;
PAAD	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.7	0.36	5.76e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.36	-0.33	2.41e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.62	-5.89	-0.43	2.36e-8	Subjective well-being;
PAAD	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg20607287	chr7:12443886	VWDE	-0.64	-5.76	-0.42	4.59e-8	Coronary artery disease;
PAAD	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.57	5.77	0.42	4.34e-8	Extrinsic epigenetic age acceleration;
PAAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg13918804	chr1:2043761	PRKCZ	-0.37	-4.87	-0.37	2.8e-6	Height;
PAAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs62400317	0.701	rs12195339	chr6:44796179	T/C	cg18551225	chr6:44695536	NA	-0.7	-6.65	-0.47	4.98e-10	Total body bone mineral density;
PAAD	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.68	8.27	0.56	6.41e-14	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21996336	chr1:155288017	FDPS	-0.59	-6.61	-0.47	6.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.52	-5.66	-0.42	7.27e-8	Migraine;
PAAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.98	-11.54	-0.68	1.56e-22	Cognitive function;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16722058	chr22:39096493	JOSD1	0.56	6.36	0.46	2.19e-9	Monocyte percentage of white cells;
PAAD	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.63	-0.42	8.42e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.52	0.41	1.4e-7	Coronary heart disease;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9810890	1.000	rs73196983	chr3:128452500	G/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-10.45	-0.65	1.35e-19	Parkinson's disease;
PAAD	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18621852	chr3:10150065	C3orf24	0.67	6.08	0.44	9.09e-9	Alzheimer's disease;
PAAD	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.56	5.48	0.41	1.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-6.52	-0.47	9.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg19847866	chr10:1019161	NA	-0.54	-4.36	-0.33	2.35e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.11e-8	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.58	5.96	0.44	1.7e-8	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14461570	chr2:170683907	UBR3	0.65	6.65	0.47	5.08e-10	Myopia (pathological);
PAAD	cis	rs35300120	0.757	rs7518012	chr1:233651778	C/T	cg23054119	chr1:233659267	NA	-0.58	-5.36	-0.4	3.03e-7	Cognitive function;
PAAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.97	10.19	0.64	6.75e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9322817	0.540	rs2034823	chr6:105219573	A/T	cg02098413	chr6:105308735	HACE1	-0.44	-5.49	-0.41	1.63e-7	Thyroid stimulating hormone;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00280220	chr17:61926910	NA	0.45	4.87	0.37	2.83e-6	Prudent dietary pattern;
PAAD	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg22143856	chr6:28129313	ZNF389	0.65	5.02	0.38	1.43e-6	Depression;
PAAD	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.54	6.27	0.45	3.55e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.69	-7.64	-0.53	2.27e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.68	6.58	0.47	7.15e-10	Plateletcrit;Platelet count;
PAAD	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.39	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.58	4.35	0.33	2.48e-5	Fat distribution (HIV);
PAAD	cis	rs17407555	0.710	rs10939814	chr4:10273329	T/C	cg00071950	chr4:10020882	SLC2A9	0.44	4.63	0.35	7.73e-6	Schizophrenia (age at onset);
PAAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.55	4.63	0.35	7.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.62	-6.15	-0.45	6.42e-9	Post bronchodilator FEV1;
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.73	0.48	3.25e-10	Height;
PAAD	cis	rs1468333	0.691	rs35839251	chr5:137584080	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.75	0.42	4.81e-8	Resting heart rate;
PAAD	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs8014252	0.803	rs74062726	chr14:70986179	A/G	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	trans	rs9409082	0.748	rs35069298	chr9:108928152	A/C	cg07010948	chr13:79181613	NA	-0.34	-6.43	-0.46	1.54e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7165102	1.000	rs7165102	chr15:65888359	G/T	cg22900193	chr15:65823441	PTPLAD1	0.47	4.43	0.34	1.81e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg03098721	chr1:84464084	TTLL7	0.46	4.44	0.34	1.75e-5	Obesity-related traits;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.53	-5.98	-0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-1.02	-16.37	-0.8	2.32e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.48	6.1	0.44	8.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.49	4.53	0.34	1.19e-5	Height;
PAAD	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.68	5.04	0.38	1.3e-6	Bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03705926	chr19:6740952	TRIP10	-0.71	-6.38	-0.46	2.03e-9	Neuroticism;
PAAD	cis	rs7975161	0.572	rs7299669	chr12:104568919	C/T	cg25273343	chr12:104657179	TXNRD1	-0.88	-4.5	-0.34	1.36e-5	Toenail selenium levels;
PAAD	cis	rs6024905	0.565	rs6024991	chr20:36970167	C/G	cg07053727	chr20:36965646	BPI	-0.56	-6.43	-0.46	1.53e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.55	5.91	0.43	2.13e-8	Menopause (age at onset);
PAAD	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06972381	chr11:32851378	PRRG4	0.61	6.44	0.46	1.49e-9	Myopia (pathological);
PAAD	cis	rs7551345	0.671	rs12080531	chr1:31893370	G/A	cg18939081	chr1:31884902	SERINC2	-0.69	-4.41	-0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.81e-7	Total body bone mineral density;
PAAD	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg22834172	chr17:37774349	NA	0.56	6.42	0.46	1.62e-9	Thyroid cancer;
PAAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg20848291	chr7:100343083	ZAN	-0.79	-6.63	-0.47	5.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.25e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg08219700	chr8:58056026	NA	0.69	5.22	0.39	5.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg09760422	chr2:128146352	NA	-0.51	-9.18	-0.6	2.92e-16	Self-rated health;
PAAD	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.63	-4.77	-0.36	4.22e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs4662750	0.674	rs777437	chr2:128357647	C/T	cg09760422	chr2:128146352	NA	0.35	5.29	0.39	4.24e-7	Renal cell carcinoma;
PAAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg05082376	chr22:42548792	NA	-0.55	-5.69	-0.42	6.45e-8	Cognitive function;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27041875	chr19:13030336	SYCE2	0.63	7.14	0.5	3.54e-11	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	0.850	rs73198884	chr3:128543424	T/C	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs4979906	1.000	rs4979912	chr10:79463682	G/C	cg07817648	chr10:79422355	NA	-0.59	-5.41	-0.4	2.39e-7	Mortality in heart failure;
PAAD	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.35	6.57	0.47	7.48e-10	Type 2 diabetes;
PAAD	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	1.49	9.69	0.62	1.36e-17	Age-related hearing impairment;
PAAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-1.08	-12.5	-0.71	4.23e-25	Obesity-related traits;
PAAD	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.73	7.18	0.5	2.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13034020	0.522	rs12988616	chr2:61244663	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.57	4.3	0.33	3.02e-5	Hodgkin's lymphoma;
PAAD	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.48	-4.97	-0.37	1.78e-6	Motion sickness;
PAAD	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.63	-7.07	-0.5	5.3e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.75	6.46	0.46	1.31e-9	Morning vs. evening chronotype;
PAAD	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.58	-5.72	-0.42	5.57e-8	Crohn's disease;
PAAD	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	1.13	5.93	0.43	1.92e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.71	-5.91	-0.43	2.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2033711	0.936	rs882609	chr19:58991479	G/A	cg00825309	chr19:58991885	ZNF446	-0.78	-8.22	-0.55	8.19e-14	Uric acid clearance;
PAAD	cis	rs1559088	0.512	rs60197880	chr19:33562695	C/A	cg27124370	chr19:33622961	WDR88	0.53	4.3	0.33	3.03e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.91	-10.97	-0.66	5.32e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.66	-7.3	-0.51	1.51e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.39	0.51	9.15e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02985541	chr2:219472218	PLCD4	0.3	4.73	0.36	5.01e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.62	6.08	0.44	9.21e-9	Visceral fat;
PAAD	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.67	7.45	0.52	6.55e-12	Hemoglobin concentration;
PAAD	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg00945666	chr1:160990265	F11R	-0.38	-4.42	-0.34	1.9e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11865578	chr3:47043996	NBEAL2	0.62	7.51	0.52	4.62e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg17503389	chr5:90575422	NA	-0.6	-4.47	-0.34	1.54e-5	Smoking behavior;
PAAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs62025270	0.632	rs16943251	chr15:86235235	T/G	cg13263323	chr15:86062960	AKAP13	0.51	4.62	0.35	8.16e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs282587	0.569	rs403530	chr13:113396380	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg14515779	chr1:101123966	NA	-0.42	-4.69	-0.36	5.91e-6	Monocyte count;
PAAD	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	Trans fatty acid levels;
PAAD	cis	rs1468333	1.000	rs2906124	chr5:137528835	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.29	0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs1413885	0.516	rs10158873	chr1:65836244	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.58	0.41	1.07e-7	Anticoagulant levels;
PAAD	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.22	-0.45	4.61e-9	Bipolar disorder;
PAAD	cis	rs9810890	1.000	rs73198891	chr3:128553841	T/G	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.52	-8.87	-0.58	1.92e-15	Atopic dermatitis;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.62	6.18	0.45	5.76e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs499368	0.519	rs216247	chr12:310571	C/T	cg02925805	chr12:298484	NA	-0.48	-5.04	-0.38	1.3e-6	Blood metabolite levels;Metabolite levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23672291	chr13:45694820	GTF2F2	0.59	6.34	0.46	2.5e-9	Monocyte percentage of white cells;
PAAD	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.74	7.71	0.53	1.49e-12	Vitiligo;
PAAD	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.43e-8	QRS complex (12-leadsum);
PAAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.95	-10.04	-0.63	1.62e-18	Platelet count;
PAAD	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.79	-0.48	2.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.64	6.5	0.47	1.1e-9	Diastolic blood pressure;
PAAD	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17347941	chr15:79387269	NA	0.38	4.32	0.33	2.84e-5	Refractive error;
PAAD	cis	rs11051970	0.885	rs7309692	chr12:32538180	A/G	cg24626660	chr12:32551988	NA	0.41	4.99	0.38	1.65e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.83	8.65	0.57	6.83e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7537660	0.636	rs10749635	chr1:248014615	C/T	cg04028570	chr1:248100427	OR2L13	0.45	4.49	0.34	1.38e-5	Platelet distribution width;
PAAD	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.59	6.82	0.48	2.07e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs72960926	0.744	rs2756344	chr6:75101682	C/T	cg03266952	chr6:74778945	NA	0.71	4.61	0.35	8.64e-6	Metabolite levels (MHPG);
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	11.35	0.68	5.33e-22	Platelet count;
PAAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs8038465	0.615	rs6495074	chr15:73959013	A/G	cg15420318	chr15:73925796	NPTN	0.5	5.19	0.39	6.7e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.73	-8.17	-0.55	1.14e-13	Breast cancer;
PAAD	cis	rs2072732	0.756	rs77415878	chr1:2954047	C/G	cg22517653	chr1:2918612	NA	-0.61	-4.9	-0.37	2.44e-6	Plateletcrit;
PAAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-9.66	-0.62	1.65e-17	Obesity-related traits;
PAAD	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.68	7.86	0.54	6.71e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.76	7.81	0.54	8.51e-13	Mood instability;
PAAD	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-4.7	-0.36	5.88e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	4.26	0.33	3.5e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06544989	chr22:39130855	UNC84B	0.5	5.09	0.38	1.03e-6	Menopause (age at onset);
PAAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22338127	chr1:209979572	IRF6	0.52	4.29	0.33	3.14e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.57	5.65	0.42	7.56e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg05895507	chr15:77155635	SCAPER	0.41	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs282587	0.502	rs416018	chr13:113396488	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg14146966	chr2:61757674	XPO1	-0.36	-4.49	-0.34	1.4e-5	Tuberculosis;
PAAD	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg16447950	chr5:562315	NA	-0.69	-5.34	-0.4	3.31e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-1.39	-10.25	-0.64	4.59e-19	Schizophrenia;
PAAD	cis	rs7207591	1	rs7207591	chr17:40414862	A/G	cg24657463	chr17:40431527	NA	0.46	4.25	0.33	3.74e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg21546286	chr11:48923668	NA	-0.45	-4.83	-0.36	3.28e-6	HDL cholesterol;
PAAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.51	5.2	0.39	6.38e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.02	-0.38	1.43e-6	Monocyte percentage of white cells;
PAAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.61	7.39	0.51	9.28e-12	Vitiligo;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.84	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg08758996	chr17:66097529	LOC651250	-0.53	-4.92	-0.37	2.23e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1488864	0.614	rs10769688	chr11:6347072	A/G	cg07661923	chr11:6502690	FXC1;ARFIP2	0.55	4.47	0.34	1.54e-5	Smooth-surface caries;
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.22	-0.39	5.72e-7	Monocyte count;
PAAD	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.83	5.67	0.42	7.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs10413329	1.000	rs4926172	chr19:13108622	T/C	cg13338734	chr19:13113668	NFIX	0.38	5.0	0.38	1.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01585723	chr16:33734837	NA	0.43	4.47	0.34	1.49e-5	Menopause (age at onset);
PAAD	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	1.09	11.9	0.69	1.67e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg08807101	chr21:30365312	RNF160	-0.67	-5.35	-0.4	3.15e-7	Cognitive test performance;
PAAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.81	-10.14	-0.64	8.82e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.33	-0.56	4.44e-14	Longevity;Endometriosis;
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.69	-0.42	6.49e-8	Lung cancer;
PAAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg00786952	chr1:21763130	NA	0.52	5.13	0.38	8.58e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg24699146	chr1:24152579	HMGCL	0.54	5.8	0.43	3.63e-8	Immature fraction of reticulocytes;
PAAD	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg21300403	chr2:198650112	BOLL	0.49	4.32	0.33	2.75e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg08284496	chr17:37894027	GRB7	0.25	4.26	0.33	3.59e-5	Asthma;
PAAD	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.44	7.09	0.5	4.83e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.39	0.34	2.09e-5	Homoarginine levels;
PAAD	cis	rs58521262	0.585	rs463879	chr19:23130983	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg13962466	chr20:25176127	ENTPD6	0.67	5.97	0.44	1.64e-8	Colorectal or endometrial cancer;
PAAD	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1135642	0.596	rs734655	chr4:77906139	C/T	cg03477792	chr4:77819574	ANKRD56	0.69	4.41	0.34	1.97e-5	Food addiction;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.49	5.06	0.38	1.21e-6	Height;
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00933542	chr6:150070202	PCMT1	0.56	6.04	0.44	1.12e-8	Lung cancer;
PAAD	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg14003231	chr6:33640908	ITPR3	0.35	4.48	0.34	1.45e-5	Plateletcrit;
PAAD	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.58	5.61	0.41	9.41e-8	White matter hyperintensity burden;
PAAD	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.52	5.54	0.41	1.3e-7	Obesity-related traits;
PAAD	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.7	8.9	0.59	1.59e-15	Asthma;
PAAD	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.79	9.44	0.61	6.19e-17	Parkinson's disease;
PAAD	cis	rs35955747	0.633	rs5998002	chr22:31881169	A/G	cg02404636	chr22:31891804	SFI1	-0.56	-5.55	-0.41	1.26e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.09	16.15	0.79	8.74e-35	Height;
PAAD	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg05554000	chr7:158905015	VIPR2	0.57	5.07	0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.78	9.0	0.59	8.45e-16	Heart rate;
PAAD	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg26597838	chr10:835615	NA	0.53	5.81	0.43	3.59e-8	Survival in rectal cancer;
PAAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9972944	0.676	rs9303489	chr17:63784817	T/C	cg07283582	chr17:63770753	CCDC46	0.6	7.04	0.5	6.1e-11	Total body bone mineral density;
PAAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg10589385	chr1:150898437	SETDB1	-0.42	-4.95	-0.37	1.92e-6	Monocyte chemoattractant protein-1 levels;
PAAD	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs59888335	0.858	rs7648624	chr3:80947468	T/C	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs6011674	1.000	rs9808612	chr20:61868348	T/C	cg12002882	chr20:62461365	NA	-0.76	-4.56	-0.35	1.06e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs8056742	1.000	rs11648527	chr16:85093913	A/G	cg16399368	chr16:85517462	NA	0.49	4.34	0.33	2.55e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.68	0.48	4.26e-10	Morning vs. evening chronotype;
PAAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.96	-11.31	-0.68	6.5600000000000005e-22	Cognitive function;
PAAD	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	5.58	0.41	1.06e-7	Blood protein levels;
PAAD	cis	rs9364554	0.691	rs7769879	chr6:160865645	G/C	cg25313204	chr6:160768801	SLC22A3	0.54	4.87	0.37	2.72e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.94	-8.27	-0.56	6.39e-14	Alzheimer's disease;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg10132348	chr4:6784379	KIAA0232	0.68	6.61	0.47	6.27e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs635808	0.561	rs491700	chr6:167171838	A/G	cg05573767	chr6:167171394	RPS6KA2	-0.42	-4.4	-0.34	2e-5	Dental caries;
PAAD	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg22870899	chr14:65347138	NA	-0.53	-6.36	-0.46	2.28e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg17372223	chr3:52568218	NT5DC2	0.52	5.29	0.39	4.21e-7	Bipolar disorder;
PAAD	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-5.77	-0.42	4.4e-8	Migraine;Coronary artery disease;
PAAD	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.79	8.37	0.56	3.42e-14	Corneal astigmatism;
PAAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.63	-7.6	-0.52	2.91e-12	Aortic root size;
PAAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.52	5.71	0.42	5.74e-8	Major depressive disorder;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg13264159	chr8:625131	ERICH1	0.81	4.86	0.37	2.84e-6	IgG glycosylation;
PAAD	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.86	0.49	1.67e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg23093090	chr10:104574429	C10orf26	-0.46	-4.87	-0.37	2.72e-6	Arsenic metabolism;
PAAD	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.56	5.18	0.39	6.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.56	-0.35	1.03e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.6	-5.87	-0.43	2.66e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.8	8.3	0.56	5.23e-14	Uric acid levels;
PAAD	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.19e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.53	4.28	0.33	3.23e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12714314	0.756	rs11694479	chr2:1945525	A/G	cg22350835	chr2:1868857	MYT1L	0.49	4.75	0.36	4.58e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7173419	0.607	rs11636005	chr15:28220747	T/G	cg20906524	chr15:28200668	OCA2	-0.47	-5.42	-0.4	2.29e-7	Eye color;
PAAD	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg05250797	chr16:70222502	NA	0.86	6.69	0.48	4.02e-10	IgE levels;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.64	9.17	0.6	3.09e-16	IgG glycosylation;
PAAD	cis	rs7715811	1.000	rs12153762	chr5:13778890	A/G	cg07548982	chr5:13769939	DNAH5	-0.56	-5.33	-0.4	3.44e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.71	6.53	0.47	9.09e-10	Cognitive ability;
PAAD	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.67	-8.79	-0.58	2.92e-15	Birth weight;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.39	-0.4	2.62e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12843872	chr7:90894352	FZD1	0.64	7.49	0.52	5.26e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12613402	chr7:65958983	NA	-0.76	-6.71	-0.48	3.58e-10	Neuroticism;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs9815354	1.000	rs9840532	chr3:41885697	A/G	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.81	8.3	0.56	5.19e-14	Response to diuretic therapy;
PAAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg19418458	chr7:158789849	NA	0.6	5.2	0.39	6.41e-7	Facial morphology (factor 20);
PAAD	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.63	8.22	0.55	8.11e-14	Renal cell carcinoma;
PAAD	cis	rs9810890	1.000	rs73198874	chr3:128538514	A/T	cg18531004	chr3:128564980	NA	-0.87	-5.01	-0.38	1.5e-6	Dental caries;
PAAD	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.72	5.98	0.44	1.56e-8	Alzheimer's disease (late onset);
PAAD	cis	rs160189	0.788	rs7234119	chr18:77231787	A/G	cg15644404	chr18:77186268	NFATC1	-0.55	-4.66	-0.35	6.93e-6	Mean platelet volume;
PAAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg09835421	chr16:68378352	PRMT7	-0.91	-7.24	-0.51	2.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5009270	0.553	rs62476688	chr7:112232716	C/T	cg23628563	chr7:112262597	NA	0.64	5.61	0.41	9.32e-8	Osteoarthritis (hip);
PAAD	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.44	0.46	1.47e-9	Lung cancer in ever smokers;
PAAD	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-5.24	-0.39	5.19e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg10011062	chr15:43941034	CATSPER2	-0.84	-4.93	-0.37	2.1e-6	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	7.04	0.5	6.31e-11	Coronary artery disease;
PAAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-5.31	-0.4	3.91e-7	Body mass index;
PAAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.71	-7.6	-0.52	2.81e-12	Pulse pressure;
PAAD	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg24747557	chr10:131355152	MGMT	-0.39	-4.32	-0.33	2.86e-5	Response to temozolomide;
PAAD	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.78	9.12	0.59	4.13e-16	Eosinophil percentage of white cells;
PAAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.57	5.82	0.43	3.38e-8	Breast cancer;
PAAD	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.51	-6.71	-0.48	3.61e-10	Height;
PAAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.53	-5.53	-0.41	1.38e-7	Daytime sleep phenotypes;
PAAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.46	-4.66	-0.35	6.74e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-4.3	-0.33	3.03e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.7	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8023845	1.000	rs3759843	chr15:40453075	A/G	cg20259534	chr15:40453036	BUB1B	-0.73	-5.82	-0.43	3.37e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.48	-0.41	1.69e-7	Triglycerides;
PAAD	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg21951975	chr1:209979733	IRF6	0.52	5.07	0.38	1.14e-6	Coronary artery disease;
PAAD	cis	rs793571	0.822	rs1078001	chr15:59167865	G/A	cg08898775	chr15:59042684	ADAM10	-0.38	-4.3	-0.33	3.01e-5	Schizophrenia;
PAAD	cis	rs17401966	0.898	rs61784570	chr1:10258343	C/A	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.49e-5	Hepatocellular carcinoma;
PAAD	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.55e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.77	-7.55	-0.52	3.81e-12	Retinal vascular caliber;
PAAD	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.78	7.58	0.52	3.24e-12	Response to antineoplastic agents;
PAAD	cis	rs12311304	0.965	rs16910692	chr12:15370010	T/C	cg08258403	chr12:15378311	NA	0.37	4.69	0.36	6.06e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4363385	1.000	rs10888527	chr1:153001363	G/T	cg22204954	chr1:153085998	SPRR2F	-0.43	-4.35	-0.33	2.5e-5	Inflammatory skin disease;
PAAD	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.72	6.24	0.45	4.17e-9	Morning vs. evening chronotype;
PAAD	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.73	7.32	0.51	1.36e-11	HIV-1 control;
PAAD	cis	rs2790216	0.950	rs2590369	chr10:60047794	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.6	7.05	0.5	5.78e-11	Aortic root size;
PAAD	cis	rs375066	0.868	rs448829	chr19:44406321	T/C	cg08633290	chr19:44405433	NA	-0.56	-5.69	-0.42	6.4e-8	Breast cancer;
PAAD	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.69	7.06	0.5	5.5e-11	Platelet count;
PAAD	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-7.62	-0.53	2.48e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-11.08	-0.67	2.69e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg24737193	chr18:12778029	NA	0.66	5.81	0.43	3.52e-8	Inflammatory skin disease;
PAAD	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.78	-9.44	-0.61	6.23e-17	Hemoglobin concentration;
PAAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.59	-0.41	1.03e-7	Glomerular filtration rate;
PAAD	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs12780845	0.931	rs7095223	chr10:17250978	C/T	cg00857480	chr10:17188594	TRDMT1	0.35	4.41	0.34	1.96e-5	Homocysteine levels;
PAAD	cis	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg21546286	chr11:48923668	NA	-0.55	-5.77	-0.42	4.21e-8	HDL cholesterol;
PAAD	trans	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.47	5.02	0.38	1.41e-6	Lung cancer;
PAAD	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26381592	chr2:190649278	PMS1;ORMDL1	-0.63	-6.37	-0.46	2.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg04809787	chr17:7348339	CHRNB1	0.39	4.33	0.33	2.68e-5	Height;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg09835421	chr16:68378352	PRMT7	-1.03	-7.02	-0.49	7.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.52	5.53	0.41	1.38e-7	Bladder cancer;
PAAD	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg14952266	chr13:112191215	NA	0.44	5.01	0.38	1.47e-6	Hepatitis;
PAAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.21	19.58	0.85	2.15e-43	Exhaled nitric oxide output;
PAAD	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.29	0.51	1.56e-11	Educational attainment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23051282	chr17:78940161	RPTOR	0.54	6.39	0.46	1.97e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.54	-5.91	-0.43	2.16e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7845219	0.510	rs10113282	chr8:96038252	C/G	cg16049864	chr8:95962084	TP53INP1	-0.46	-4.97	-0.37	1.78e-6	Type 2 diabetes;
PAAD	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg27411982	chr8:10470053	RP1L1	0.49	5.02	0.38	1.42e-6	Retinal vascular caliber;
PAAD	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.54	5.12	0.38	9.11e-7	Uric acid clearance;
PAAD	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2494979	0.830	rs2691477	chr6:71327843	G/A	cg15045441	chr6:72130432	C6orf155	0.47	4.3	0.33	3.03e-5	Platelet distribution width;
PAAD	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.68	-6.79	-0.48	2.42e-10	Breast cancer;
PAAD	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg24618514	chr3:194868507	C3orf21	0.49	4.52	0.34	1.25e-5	Non-small cell lung cancer;
PAAD	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg02415014	chr8:143852576	LYNX1	-0.34	-4.43	-0.34	1.77e-5	Urinary tract infection frequency;
PAAD	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.67	7.55	0.52	3.73e-12	Motion sickness;
PAAD	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	7.99	0.54	3.13e-13	Height;
PAAD	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.82	-9.8	-0.62	7.24e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg13565585	chr5:132299512	AFF4	0.52	4.98	0.37	1.7e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02725872	chr8:58115012	NA	-0.61	-5.08	-0.38	1.08e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.504	rs6742601	chr2:238427940	C/G	cg11271282	chr2:238384023	NA	0.59	4.55	0.35	1.09e-5	Prostate cancer;
PAAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.9	-7.16	-0.5	3.26e-11	Orofacial clefts;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg26887379	chr1:12677936	DHRS3	0.59	6.62	0.47	5.93e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.5	5.54	0.41	1.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.93e-13	Response to antipsychotic treatment;
PAAD	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.4	4.94	0.37	2.01e-6	Schizophrenia;
PAAD	cis	rs11696501	0.688	rs6065859	chr20:44302697	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.79	9.26	0.6	1.87e-16	Morning vs. evening chronotype;
PAAD	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	8.61	0.57	8.52e-15	Exhaled nitric oxide output;
PAAD	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.6	-6.17	-0.45	5.79e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Body mass index;
PAAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.86	7.53	0.52	4.18e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-5.4	-0.4	2.46e-7	Reticulocyte count;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22047672	chr1:150275877	MRPS21	0.58	6.32	0.46	2.77e-9	Smoking initiation;
PAAD	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.49	5.6	0.41	1e-7	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	10.01	0.63	1.94e-18	Platelet count;
PAAD	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.65	6.19	0.45	5.22e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1519814	0.956	rs7016388	chr8:121101865	A/G	cg22335954	chr8:121166405	COL14A1	-0.6	-5.29	-0.39	4.23e-7	Breast cancer;
PAAD	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.46	0.34	1.6e-5	Myopia (pathological);
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg18279126	chr7:2041391	MAD1L1	0.57	5.74	0.42	4.92e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00290607	chr11:67383545	NA	0.48	4.75	0.36	4.62e-6	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20308189	chr12:122261415	SETD1B	0.57	6.51	0.47	1.01e-9	Body fat percentage;
PAAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs3136739	0.681	rs35416565	chr8:42000350	G/A	cg12054981	chr8:42037387	PLAT	0.66	4.78	0.36	4.08e-6	Plasma plasminogen activator levels;
PAAD	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	1.02	12.34	0.71	1.15e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs10851478	0.529	rs12901929	chr15:49675308	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.58	5.41	0.4	2.37e-7	Oral cavity cancer;
PAAD	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg12486944	chr17:80159399	CCDC57	0.5	4.45	0.34	1.65e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.64	0.35	7.48e-6	Body mass index;
PAAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg21565972	chr17:80109576	CCDC57	0.6	7.0	0.49	7.78e-11	Life satisfaction;
PAAD	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.04	-0.79	1.62e-34	Height;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.8	-8.29	-0.56	5.45e-14	Menopause (age at onset);
PAAD	cis	rs2147959	0.882	rs4653552	chr1:228628138	A/G	cg02753203	chr1:228287806	NA	-0.59	-4.76	-0.36	4.39e-6	Adult asthma;
PAAD	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11547950	chr5:77652471	NA	0.75	6.72	0.48	3.43e-10	Triglycerides;
PAAD	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.46	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.55	-5.62	-0.41	8.76e-8	Prostate cancer;
PAAD	cis	rs4294134	0.608	rs11763242	chr7:135242973	T/G	cg04619859	chr7:134855396	C7orf49	0.54	4.25	0.33	3.74e-5	Paget's disease;
PAAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.87	9.27	0.6	1.72e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2936519	0.556	rs2912023	chr8:6640209	C/T	cg22103414	chr8:6638082	NA	-0.34	-4.26	-0.33	3.52e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.54e-9	Lymphocyte counts;
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.66	-0.35	6.79e-6	Lung cancer;
PAAD	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg07220939	chr11:64358617	SLC22A12	0.43	4.43	0.34	1.8e-5	Urate levels in obese individuals;
PAAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs72960926	0.744	rs11757177	chr6:74871785	C/A	cg03266952	chr6:74778945	NA	-1.17	-7.07	-0.5	5.29e-11	Metabolite levels (MHPG);
PAAD	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.55	5.81	0.43	3.58e-8	Bladder cancer;
PAAD	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs629922	0.671	rs1184748	chr11:114037061	A/G	cg25009965	chr11:114031120	ZBTB16	0.49	4.39	0.34	2.13e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.91	-0.63	3.52e-18	Tonsillectomy;
PAAD	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.79	8.52	0.57	1.49e-14	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00766322	chr7:70252282	AUTS2	0.56	6.46	0.46	1.34e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	5.26	0.39	4.85e-7	Height;
PAAD	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.79	0.36	3.87e-6	Coronary artery disease;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11245990	chr11:68621969	NA	0.38	4.79	0.36	3.88e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04362095	chr11:63592001	C11orf84	-0.51	-4.66	-0.35	6.75e-6	Platelet count;
PAAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg03983715	chr16:68378420	PRMT7	-0.85	-6.26	-0.45	3.67e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg20913747	chr6:44695427	NA	-0.6	-6.73	-0.48	3.33e-10	Chin dimples;
PAAD	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg27411982	chr8:10470053	RP1L1	-0.49	-5.38	-0.4	2.8e-7	Retinal vascular caliber;
PAAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.12	-0.38	9.11e-7	Glomerular filtration rate;
PAAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg16341495	chr8:142228727	SLC45A4	0.54	5.16	0.39	7.69e-7	Immature fraction of reticulocytes;
PAAD	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.19	-0.39	6.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11203032	0.831	rs11203019	chr10:90952774	A/T	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Body mass index;
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	trans	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg01085265	chr4:37688416	RELL1	-0.63	-6.29	-0.45	3.28e-9	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.53	-6.41	-0.46	1.74e-9	Lewy body disease;
PAAD	cis	rs287982	1.000	rs2656329	chr2:9968344	C/T	cg01119585	chr2:10571959	NA	0.39	4.43	0.34	1.78e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.45	-0.4	1.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6011002	0.745	rs6011068	chr20:62364885	T/A	cg01176363	chr20:62369445	LIME1	-0.91	-4.28	-0.33	3.34e-5	Dental caries;
PAAD	cis	rs9581857	0.579	rs79653667	chr13:27961109	G/A	cg22138327	chr13:27999177	GTF3A	0.89	5.63	0.42	8.54e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.67	8.05	0.55	2.2e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.52	-0.47	9.94e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg08355456	chr11:67383691	NA	0.43	4.28	0.33	3.25e-5	Mean corpuscular volume;
PAAD	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg23985595	chr17:80112537	CCDC57	-0.54	-7.18	-0.5	2.82e-11	Life satisfaction;
PAAD	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg26174226	chr8:58114915	NA	-0.57	-4.38	-0.33	2.24e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.49	4.41	0.34	1.92e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.77	7.35	0.51	1.14e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23544223	chr18:12777786	NA	-0.72	-6.1	-0.44	8.28e-9	Inflammatory skin disease;
PAAD	cis	rs4481887	0.573	rs6689894	chr1:248409579	C/T	cg00666640	chr1:248458726	OR2T12	0.6	4.99	0.37	1.66e-6	Common traits (Other);
PAAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.97	-0.37	1.78e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.31	12.91	0.72	3.27e-26	Uric acid levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07080756	chr10:104192239	CUEDC2	0.61	7.0	0.49	7.85e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg00031303	chr3:195681400	NA	0.81	7.94	0.54	4.17e-13	Pancreatic cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11576217	chr1:204381098	PPP1R15B	0.67	7.92	0.54	4.77e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs831571	1.000	rs831571	chr3:64048297	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.56	4.72	0.36	5.27e-6	Type 2 diabetes;
PAAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-1.04	-14.59	-0.76	1.02e-30	Breast cancer;
PAAD	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.67	6.71	0.48	3.62e-10	Primary sclerosing cholangitis;
PAAD	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg06042504	chr8:55087323	NA	0.69	7.33	0.51	1.28e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.94	-0.43	1.88e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg20607287	chr7:12443886	VWDE	-0.77	-5.81	-0.43	3.47e-8	Coronary artery disease;
PAAD	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs1941184	0.759	rs7237765	chr18:29025068	T/A	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	trans	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg25214090	chr10:38739885	LOC399744	0.7	7.06	0.5	5.62e-11	Corneal astigmatism;
PAAD	cis	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.48	4.4	0.34	2.05e-5	Depression;
PAAD	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.75	-0.36	4.67e-6	Prevalent atrial fibrillation;
PAAD	cis	rs13223928	0.554	rs13438334	chr7:3156956	G/A	cg19214707	chr7:3157722	NA	-0.56	-5.13	-0.38	8.65e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs9503598	0.502	rs9405203	chr6:3433846	G/T	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg13206674	chr6:150067644	NUP43	0.61	6.52	0.47	1.01e-9	Lung cancer;
PAAD	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.59	4.54	0.35	1.16e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.81	-10.19	-0.64	6.42e-19	Height;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18621852	chr3:10150065	C3orf24	0.65	5.49	0.41	1.61e-7	Alzheimer's disease;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.66	-4.91	-0.37	2.36e-6	Initial pursuit acceleration;
PAAD	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg14003231	chr6:33640908	ITPR3	0.37	4.77	0.36	4.29e-6	Plateletcrit;
PAAD	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.76	-0.48	2.74e-10	Coffee consumption (cups per day);
PAAD	cis	rs7009516	0.692	rs9650408	chr8:24240670	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.48	-5.71	-0.42	5.82e-8	Hair greying;
PAAD	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.58	-5.85	-0.43	2.9e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2834902	0.633	rs2834894	chr21:36682379	T/C	cg04915566	chr21:36421472	RUNX1	-0.33	-4.49	-0.34	1.38e-5	Corneal curvature;
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg18171855	chr10:2543474	NA	0.41	4.29	0.33	3.17e-5	Age-related hearing impairment;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01068136	chr10:115614374	DCLRE1A;NHLRC2	-0.57	-6.57	-0.47	7.5e-10	Body fat percentage;
PAAD	cis	rs4774830	0.590	rs62045212	chr15:56251312	A/T	cg24530489	chr15:56299380	NA	-1.08	-4.51	-0.34	1.31e-5	Delta-5 desaturase activity;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-5.07	-0.38	1.12e-6	Longevity;Endometriosis;
PAAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.32	11.26	0.67	8.95e-22	Uric acid levels;
PAAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs6466055	0.565	rs2040915	chr7:104979558	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg23033748	chr14:75592666	NEK9	0.41	5.04	0.38	1.34e-6	Height;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.9	7.77	0.53	1.07e-12	Alzheimer's disease;
PAAD	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg02153584	chr22:29168773	CCDC117	-0.48	-4.43	-0.34	1.76e-5	Red cell distribution width;
PAAD	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg11070489	chr10:2125396	NA	-0.5	-6.56	-0.47	7.98e-10	Morning vs. evening chronotype;
PAAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.83	-0.48	1.89e-10	Coronary artery disease;
PAAD	cis	rs17032980	0.910	rs6750984	chr2:67326312	G/A	cg02551743	chr2:66673428	MEIS1	-0.49	-4.34	-0.33	2.55e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.82	-0.36	3.42e-6	Body mass index;
PAAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.86	7.42	0.52	7.91e-12	Recombination rate (females);
PAAD	cis	rs4478858	0.735	rs10914368	chr1:31847937	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.3	-0.46	3.05e-9	Alcohol dependence;
PAAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.41	-0.34	1.94e-5	Vitiligo;
PAAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.51	-5.56	-0.41	1.19e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7766436	0.727	rs2066339	chr6:22610612	T/C	cg13666174	chr6:22585274	NA	-0.46	-4.82	-0.36	3.44e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	trans	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg20641545	chr12:89984390	ATP2B1	-0.51	-6.31	-0.46	2.95e-9	Cancer;
PAAD	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg27449745	chr7:23145252	KLHL7	-0.52	-4.64	-0.35	7.36e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21175976	chr8:11421337	BLK	-0.41	-4.47	-0.34	1.55e-5	Neuroticism;
PAAD	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg05315796	chr3:52349193	DNAH1	-0.45	-4.81	-0.36	3.63e-6	Bipolar disorder;
PAAD	trans	rs62179067	0.708	rs62175990	chr2:179883455	C/G	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.63	5.93	0.43	1.96e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.72	7.23	0.51	2.16e-11	Urate levels in lean individuals;
PAAD	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs7072216	0.687	rs4551689	chr10:100157593	C/T	cg19567339	chr10:100142640	NA	-0.42	-4.48	-0.34	1.45e-5	Metabolite levels;
PAAD	cis	rs6734238	0.739	rs11123161	chr2:113845578	C/T	cg06156847	chr2:113672199	IL1F7	-0.43	-4.31	-0.33	2.96e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.45	0.4	2.04e-7	Bipolar disorder;
PAAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.66	4.73	0.36	5.15e-6	Depression;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg04902049	chr1:36622448	MAP7D1	0.57	6.31	0.46	2.95e-9	Response to antipsychotic treatment;
PAAD	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.93	5.52	0.41	1.41e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12612619	0.732	rs13032100	chr2:27233859	T/C	cg00617064	chr2:27272375	NA	-0.47	-4.99	-0.38	1.61e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs12431939	0.948	rs67116854	chr14:51670464	G/A	cg23942311	chr14:51606299	NA	-0.6	-4.88	-0.37	2.67e-6	Cancer;
PAAD	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4073221	0.789	rs67917716	chr3:18228007	C/A	cg07694806	chr3:18168406	NA	-0.81	-5.13	-0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg06740227	chr12:86229804	RASSF9	0.52	4.62	0.35	8.08e-6	Major depressive disorder;
PAAD	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg18764771	chr6:116381957	FRK	-0.34	-5.28	-0.39	4.45e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17347941	chr15:79387269	NA	0.38	4.33	0.33	2.73e-5	Refractive error;
PAAD	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.72	-6.29	-0.45	3.24e-9	Body mass index (adult);
PAAD	trans	rs5417	0.636	rs427784	chr17:7157516	C/T	cg15655154	chr3:113604241	GRAMD1C	-0.66	-6.6	-0.47	6.48e-10	Diastolic blood pressure;
PAAD	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-5.78	-0.42	4.07e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.44	5.7	0.42	6.08e-8	Childhood ear infection;
PAAD	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.23	-0.39	5.61e-7	Alcohol dependence;
PAAD	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.79	4.52	0.34	1.22e-5	Childhood ear infection;
PAAD	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.01	0.38	1.52e-6	Common traits (Other);
PAAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg07061783	chr6:25882402	NA	0.47	4.47	0.34	1.53e-5	Blood metabolite levels;
PAAD	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.62	-0.35	8.09e-6	Morning vs. evening chronotype;
PAAD	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.42	-4.74	-0.36	4.87e-6	Type 2 diabetes;
PAAD	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.78	7.23	0.51	2.22e-11	Breast cancer;
PAAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2076346	1.000	rs2076346	chr1:24083649	A/G	cg24451422	chr1:23751210	TCEA3	0.59	4.62	0.35	8.09e-6	Inflammatory skin disease;
PAAD	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg16928487	chr17:17741425	SREBF1	0.36	4.79	0.36	3.9e-6	Total body bone mineral density;
PAAD	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.49	-0.52	5.24e-12	Neuroticism;
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-4.74	-0.36	4.84e-6	Mean platelet volume;
PAAD	cis	rs9430161	0.611	rs2003046	chr1:11032827	C/A	cg02454025	chr1:11042201	C1orf127	1.26	16.02	0.79	1.88e-34	Ewing sarcoma;
PAAD	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.43	-5.2	-0.39	6.28e-7	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs990171	0.538	rs7591872	chr2:103112641	C/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.45	-0.34	1.64e-5	Lymphocyte counts;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.72	7.81	0.54	8.5e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs66731853	0.538	rs603412	chr1:20915418	C/G	cg04087271	chr1:20915334	CDA	-0.5	-6.04	-0.44	1.12e-8	Mean corpuscular volume;
PAAD	cis	rs4740619	0.836	rs10283865	chr9:15894943	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.55	-0.35	1.07e-5	Body mass index;
PAAD	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg01061890	chr16:11836724	TXNDC11	-0.51	-4.97	-0.37	1.81e-6	Rheumatoid arthritis;
PAAD	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.09	0.38	1.04e-6	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19494762	chr3:184279498	EPHB3	0.64	6.33	0.46	2.63e-9	Obesity-related traits;
PAAD	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.72	-6.37	-0.46	2.16e-9	Type 2 diabetes;
PAAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg12639453	chr1:2035780	PRKCZ	0.5	5.47	0.41	1.78e-7	Height;
PAAD	cis	rs11811982	0.793	rs114312101	chr1:227303589	T/A	cg24860534	chr1:227506868	CDC42BPA	0.49	4.4	0.34	2.05e-5	Optic disc area;
PAAD	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.35	-0.33	2.46e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg16031515	chr1:205743344	RAB7L1	-0.44	-4.97	-0.37	1.78e-6	Prostate-specific antigen levels;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg17372657	chr7:1216933	NA	-0.38	-4.85	-0.37	3e-6	Longevity;Endometriosis;
PAAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg04844267	chr4:1394941	NA	0.45	5.16	0.39	7.61e-7	Longevity;
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg01097406	chr16:89675127	NA	-0.37	-4.52	-0.34	1.24e-5	Vitiligo;
PAAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg00999904	chr2:3704751	ALLC	-0.39	-4.49	-0.34	1.39e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09837361	chr1:28996131	GMEB1	0.56	6.78	0.48	2.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.15	-9.15	-0.6	3.48e-16	Diabetic kidney disease;
PAAD	cis	rs863345	0.604	rs11265009	chr1:158498772	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.19	-0.39	6.62e-7	Pneumococcal bacteremia;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06799790	chr17:61951754	CSH2	-0.45	-4.61	-0.35	8.65e-6	Height;
PAAD	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.79	-0.36	3.87e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6142102	0.649	rs4911382	chr20:32553095	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs757978	1.000	rs80085676	chr2:242347907	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-4.9	-0.37	2.44e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.54	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	2.99e-5	Aortic root size;
PAAD	cis	rs7705042	0.793	rs1036207	chr5:141499041	A/G	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.18	-0.39	7.07e-7	Asthma;
PAAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.43	5.59	0.41	1.03e-7	Childhood ear infection;
PAAD	cis	rs6750047	0.573	rs162329	chr2:38318940	T/C	cg19753864	chr2:38320028	NA	0.44	4.93	0.37	2.11e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs3106136	0.681	rs1609423	chr4:95301949	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.06	0.38	1.19e-6	Capecitabine sensitivity;
PAAD	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg15123519	chr2:136567270	LCT	-0.39	-4.68	-0.35	6.31e-6	Mosquito bite size;
PAAD	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.6	5.29	0.39	4.23e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg15226275	chr6:116381976	FRK	0.36	6.6	0.47	6.61e-10	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7551345	1.000	rs35998242	chr1:31835901	C/A	cg17086398	chr1:31896392	SERINC2	-0.48	-4.37	-0.33	2.29e-5	Schizophrenia;
PAAD	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.77	9.35	0.6	1.05e-16	Bladder cancer;
PAAD	cis	rs1975974	1.000	rs1975974	chr17:21707060	A/G	cg18423549	chr17:21743878	NA	-0.52	-4.86	-0.37	2.89e-6	Psoriasis;
PAAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.73	0.36	4.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg21770322	chr7:97807741	LMTK2	-0.51	-5.81	-0.43	3.48e-8	Breast cancer;
PAAD	cis	rs9659323	1.000	rs10923715	chr1:119535334	A/T	cg17326555	chr1:119535693	NA	0.46	6.33	0.46	2.62e-9	Body mass index;
PAAD	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg10018233	chr7:150070692	REPIN1	0.64	6.55	0.47	8.32e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.77	0.36	4.23e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.47	0.41	1.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg05697835	chr1:2722811	NA	-0.42	-4.69	-0.36	6.07e-6	Ulcerative colitis;
PAAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.56	-5.29	-0.39	4.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.71	-7.22	-0.51	2.31e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7567389	0.677	rs7607907	chr2:128144286	C/T	cg09760422	chr2:128146352	NA	-0.39	-6.02	-0.44	1.29e-8	Self-rated health;
PAAD	cis	rs7646881	0.812	rs59192661	chr3:158459027	T/C	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs8005677	0.649	rs11629120	chr14:23458457	T/C	cg01529538	chr14:23388837	RBM23	-0.55	-5.33	-0.4	3.55e-7	Cognitive ability (multi-trait analysis);
PAAD	cis	rs11048434	0.518	rs4883206	chr12:9173765	C/T	cg04548204	chr12:9162872	KLRG1	0.38	4.27	0.33	3.39e-5	Sjögren's syndrome;
PAAD	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.94	-9.17	-0.6	3.08e-16	Exhaled nitric oxide output;
PAAD	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg20913747	chr6:44695427	NA	-0.7	-6.92	-0.49	1.18e-10	Total body bone mineral density;
PAAD	cis	rs62247992	0.640	rs627582	chr3:43112626	G/A	cg12239580	chr3:43073058	FAM198A	-0.45	-4.4	-0.34	2.01e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.91	0.37	2.33e-6	Interstitial lung disease;
PAAD	cis	rs7561149	1.000	rs7561149	chr2:179689856	T/C	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.55	5.62	0.41	9.01e-8	QT interval;
PAAD	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.46	-0.52	6.28e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00981651	chr20:44574847	PCIF1	0.44	4.77	0.36	4.21e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06747254	chr15:25471927	SNORD115-15;SNORD115-21;SNORD115-31	0.57	6.44	0.46	1.47e-9	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23711062	chr11:111636296	PPP2R1B	0.65	6.54	0.47	8.76e-10	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.12	-0.38	9.25e-7	Pulmonary function;
PAAD	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	5.35	0.4	3.22e-7	Joint mobility (Beighton score);
PAAD	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg20406979	chr6:167373233	NA	0.32	4.39	0.34	2.1e-5	Crohn's disease;
PAAD	cis	rs6191	0.935	rs10041520	chr5:142776684	T/C	cg08845721	chr5:142780693	NR3C1	-0.4	-4.47	-0.34	1.55e-5	Night sleep phenotypes;
PAAD	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.4	-0.34	2e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1468333	0.632	rs12514118	chr5:137656480	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.39	0.4	2.59e-7	Resting heart rate;
PAAD	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg20003494	chr4:90757398	SNCA	-0.41	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs13242816	1.000	rs56298491	chr7:116116687	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg14393609	chr7:65229607	NA	0.48	4.9	0.37	2.44e-6	Aortic root size;
PAAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	4.9	0.37	2.48e-6	Bone mineral density;
PAAD	cis	rs3026101	0.671	rs56344067	chr17:5316459	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.72	-8.25	-0.56	7e-14	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg10591111	chr5:226296	SDHA	0.7	5.44	0.4	2.08e-7	Breast cancer;
PAAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg14393609	chr7:65229607	NA	-0.67	-7.14	-0.5	3.59e-11	Aortic root size;
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-10.7	-0.66	2.82e-20	Age at first birth;
PAAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.53	-4.86	-0.37	2.93e-6	Height;
PAAD	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg25558440	chr8:11882962	NA	-0.46	-4.33	-0.33	2.74e-5	Triglycerides;
PAAD	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg23463467	chr20:60627584	TAF4	0.43	4.81	0.36	3.59e-6	Body mass index;
PAAD	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	1.04	7.87	0.54	6.31e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs2882667	0.654	rs1703211	chr5:138076276	G/A	cg09476006	chr5:138032270	NA	-0.46	-5.96	-0.44	1.7e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23814129	chr1:36930061	MRPS15	0.58	6.54	0.47	8.61e-10	Monocyte percentage of white cells;
PAAD	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-4.87	-0.37	2.75e-6	Facial morphology (factor 19);
PAAD	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.57	7.54	0.52	4.04e-12	Endometriosis;
PAAD	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.58	4.71	0.36	5.64e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs12327666	0.522	rs7248735	chr19:14130215	A/G	cg09538921	chr19:14142201	IL27RA	-0.6	-4.41	-0.34	1.93e-5	Obesity-related traits;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.63	-5.53	-0.41	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.62	6.14	0.45	6.79e-9	Monocyte count;
PAAD	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.16	-10.1	-0.63	1.14e-18	Vitiligo;
PAAD	cis	rs3736485	0.934	rs2414106	chr15:51868741	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.28	-0.33	3.35e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16361282	chr20:34742394	EPB41L1	0.62	6.3	0.46	3.05e-9	Obesity-related traits;
PAAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.95	7.96	0.54	3.73e-13	Tuberculosis;
PAAD	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.86e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg02380750	chr20:61661411	NA	0.38	4.47	0.34	1.52e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg23985595	chr17:80112537	CCDC57	0.45	5.78	0.42	4.1e-8	Life satisfaction;
PAAD	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.64	6.06	0.44	1.04e-8	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.71	6.87	0.49	1.57e-10	Parkinson's disease;
PAAD	cis	rs1419980	0.730	rs11054887	chr12:7772997	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.49	5.69	0.42	6.44e-8	Tuberculosis;
PAAD	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg27565382	chr3:53032988	SFMBT1	0.97	4.74	0.36	4.93e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.63	-6.06	-0.44	1.02e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.51	5.2	0.39	6.2e-7	Lewy body disease;
PAAD	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.7	6.71	0.48	3.57e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8067354	0.574	rs1292035	chr17:57989557	G/A	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.2	0.55	9.43e-14	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.47	-4.43	-0.34	1.76e-5	Uric acid levels;
PAAD	cis	rs7631605	0.905	rs7622170	chr3:37016576	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.35	-0.68	5.11e-22	Chronic sinus infection;
PAAD	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.29	-0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs2492906	0.515	rs2637328	chr10:27977627	A/G	cg25523538	chr10:28031957	MKX	0.51	4.39	0.34	2.11e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7534824	0.543	rs10493940	chr1:101377845	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.5	0.34	1.35e-5	Refractive astigmatism;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg20151045	chr17:35414114	AATF	0.59	6.47	0.46	1.29e-9	Educational attainment (years of education);
PAAD	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.82	-7.2	-0.5	2.63e-11	Body mass index;
PAAD	cis	rs1816752	0.583	rs6490918	chr13:25002115	G/A	cg02811702	chr13:24901961	NA	-0.49	-4.98	-0.37	1.69e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2555155	0.750	rs2262649	chr11:6517453	A/G	cg11185456	chr11:6592066	DNHD1	0.41	4.32	0.33	2.82e-5	DNA methylation (variation);
PAAD	cis	rs3764400	0.508	rs2240119	chr17:46111172	C/T	cg24322968	chr17:46507895	SKAP1	-0.89	-5.47	-0.41	1.78e-7	Body mass index;
PAAD	cis	rs990171	0.538	rs2075190	chr2:103118559	A/T	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg27411982	chr8:10470053	RP1L1	0.42	4.48	0.34	1.45e-5	Neuroticism;
PAAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg04450456	chr4:17643702	FAM184B	0.52	5.28	0.39	4.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs73019876	0.869	rs2214301	chr19:22154954	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.33	-0.33	2.67e-5	Testicular germ cell tumor;
PAAD	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs73019876	0.869	rs10412331	chr19:22150362	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.43	4.81	0.36	3.61e-6	Dietary macronutrient intake;
PAAD	cis	rs8112211	0.648	rs79381523	chr19:38816976	T/C	cg01275006	chr19:38876250	GGN	-0.8	-5.33	-0.4	3.41e-7	Blood protein levels;
PAAD	cis	rs9888739	0.668	rs9933520	chr16:31343386	A/G	cg15817542	chr16:31343056	ITGAM	-0.44	-4.3	-0.33	3.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg08898775	chr15:59042684	ADAM10	0.38	4.92	0.37	2.24e-6	Asperger disorder;
PAAD	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-6.88	-0.49	1.44e-10	Acylcarnitine levels;
PAAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.4	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22162314	chr17:61951766	CSH2	-0.61	-6.25	-0.45	4.03e-9	Height;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-1.32	-12.46	-0.71	5.2e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.55	5.05	0.38	1.24e-6	Height;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg10729496	chr3:10149963	C3orf24	0.82	6.84	0.49	1.83e-10	Alzheimer's disease;
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg13866156	chr1:1669148	SLC35E2	-0.81	-9.31	-0.6	1.32e-16	Body mass index;
PAAD	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-4.36	-0.33	2.34e-5	Blood protein levels;
PAAD	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26897989	chr16:1907736	C16orf73	-0.55	-4.92	-0.37	2.26e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs901683	1.000	rs17157825	chr10:45958676	G/A	cg16908948	chr10:45500256	ZNF22	0.82	4.34	0.33	2.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7247513	0.964	rs35235213	chr19:12713156	C/T	cg01871581	chr19:12707946	ZNF490	-0.87	-11.04	-0.67	3.49e-21	Bipolar disorder;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.41	-0.34	1.94e-5	Red blood cell count;
PAAD	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.92	-6.91	-0.49	1.26e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1075265	0.933	rs7607066	chr2:54337191	G/A	cg04546899	chr2:54196757	PSME4	0.33	4.57	0.35	1.01e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.69	-0.36	6.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs16958440	0.609	rs75911383	chr18:44716011	C/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs35955747	0.869	rs7286648	chr22:31539614	A/T	cg07969918	chr22:31682909	PIK3IP1	0.35	4.54	0.35	1.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.36	0.46	2.25e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2278796	0.752	rs6677763	chr1:204951540	A/G	cg17947172	chr1:204966197	NFASC	0.45	5.32	0.4	3.61e-7	Mean platelet volume;
PAAD	cis	rs6733011	0.519	rs12990579	chr2:99457447	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.27	-0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs12913538	1.000	rs4265758	chr15:62896297	T/G	cg09983546	chr15:62884068	NA	0.71	8.03	0.55	2.44e-13	Sleep depth;
PAAD	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg08601574	chr20:25228251	PYGB	-0.59	-6.42	-0.46	1.64e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg07648498	chr16:89883185	FANCA	-0.54	-5.36	-0.4	3.01e-7	Vitiligo;
PAAD	cis	rs3736485	0.934	rs882385	chr15:51882369	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.38	9.43	0.61	6.68e-17	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00578363	chr1:53925053	DMRTB1	0.65	7.11	0.5	4.2e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs375066	0.736	rs62114649	chr19:44416567	T/C	cg11993925	chr19:44307056	LYPD5	-0.51	-6.28	-0.45	3.33e-9	Breast cancer;
PAAD	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.49	4.76	0.36	4.46e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg05313129	chr8:58192883	C8orf71	-0.63	-5.5	-0.41	1.61e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.5	0.41	1.55e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.8	0.48	2.2e-10	Lung cancer;
PAAD	cis	rs35160687	0.722	rs6728029	chr2:86555381	C/T	cg10973622	chr2:86423274	IMMT	-0.46	-5.2	-0.39	6.3e-7	Night sleep phenotypes;
PAAD	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg10820045	chr2:198174542	NA	0.44	4.37	0.33	2.31e-5	Dermatomyositis;
PAAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.81	-7.9	-0.54	5.34e-13	Breast cancer;
PAAD	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.65	4.49	0.34	1.41e-5	Mean platelet volume;
PAAD	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs5753037	0.653	rs131282	chr22:30156608	A/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg04018474	chr16:31008003	STX1B	-0.27	-4.27	-0.33	3.49e-5	Dementia with Lewy bodies;
PAAD	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.35	4.49	0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg21665744	chr7:39171113	POU6F2	0.33	4.93	0.37	2.09e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg27417659	chr7:98567827	TRRAP	-0.46	-4.44	-0.34	1.72e-5	Breast cancer;
PAAD	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.37e-17	Response to antipsychotic treatment;
PAAD	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.64e-9	Educational attainment;
PAAD	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.49	5.09	0.38	1.06e-6	Body mass index;
PAAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.5	4.99	0.37	1.66e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs75920871	1.000	rs79974099	chr11:116802581	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg12923728	chr3:195709715	SDHAP1	-0.82	-6.46	-0.46	1.33e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.35	0.6	1.06e-16	Bipolar disorder;
PAAD	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg20406979	chr6:167373233	NA	-0.34	-4.5	-0.34	1.33e-5	Crohn's disease;
PAAD	trans	rs61677309	1.000	rs12576947	chr11:118158055	T/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs1018697	1.000	rs10748830	chr10:104548382	A/C	cg04362960	chr10:104952993	NT5C2	0.6	6.05	0.44	1.06e-8	Colorectal adenoma (advanced);
PAAD	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.72	-0.36	5.4e-6	Subjective well-being;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23394653	chr13:77601699	FBXL3	-0.74	-6.32	-0.46	2.72e-9	Neuroticism;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.54	5.1	0.38	1.01e-6	Blood metabolite levels;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.01	0.38	1.46e-6	Colorectal cancer;
PAAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs10962181	1.000	rs74308122	chr9:1557632	C/G	cg00250430	chr9:1051579	DMRT2	-0.56	-4.35	-0.33	2.46e-5	Superior frontal gyrus grey matter volume;
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03647317	chr4:187891568	NA	-0.51	-6.48	-0.47	1.23e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.28	0.45	3.41e-9	Coronary artery disease;
PAAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.55e-6	Migraine;
PAAD	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02106306	chr15:31620290	KLF13	-0.71	-7.03	-0.5	6.48e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg23442198	chr4:187126114	CYP4V2	0.6	4.32	0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.4	-0.56	2.91e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.59	-5.54	-0.41	1.33e-7	Crohn's disease;
PAAD	cis	rs4908768	0.501	rs6577513	chr1:8702753	G/A	cg20416874	chr1:8611966	RERE	-0.43	-4.26	-0.33	3.55e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.76	-0.42	4.63e-8	Retinal vascular caliber;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01810593	chr8:22464288	KIAA1967	0.62	6.37	0.46	2.11e-9	Smoking initiation;
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.74	6.83	0.48	1.95e-10	Obesity-related traits;
PAAD	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.76	5.98	0.44	1.51e-8	Serum sulfate level;
PAAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg11663144	chr21:46675770	NA	-0.48	-5.54	-0.41	1.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.08	0.38	1.09e-6	Total body bone mineral density;
PAAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	5.72	0.42	5.57e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18621852	chr3:10150065	C3orf24	0.68	5.97	0.44	1.64e-8	Alzheimer's disease;
PAAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.81	9.33	0.6	1.23e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-9.31	-0.6	1.38e-16	Height;
PAAD	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.81	9.96	0.63	2.7e-18	Morning vs. evening chronotype;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.76	8.54	0.57	1.28e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs1478898	0.569	rs2264306	chr8:11388449	G/A	cg00262122	chr8:11665843	FDFT1	-0.54	-4.62	-0.35	8.28e-6	Morning vs. evening chronotype;
PAAD	cis	rs6984449	0.516	rs7830251	chr8:19306522	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.4	5.26	0.39	4.91e-7	Educational attainment;
PAAD	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.44	-0.34	1.7e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs2204008	0.720	rs10880697	chr12:38594529	G/C	cg13010199	chr12:38710504	ALG10B	0.67	6.72	0.48	3.37e-10	Bladder cancer;
PAAD	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg22189786	chr22:42395067	WBP2NL	-0.53	-4.42	-0.34	1.89e-5	Birth weight;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.44	6.48	0.47	1.19e-9	Mean corpuscular volume;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg18888814	chr13:100300543	CLYBL	-0.54	-6.29	-0.45	3.15e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs990171	0.955	rs1573895	chr2:102982876	T/C	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.88e-5	Lymphocyte counts;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-6.78	-0.48	2.56e-10	Longevity;Endometriosis;
PAAD	cis	rs9346353	0.713	rs2445958	chr6:70400885	A/C	cg03001484	chr6:70507230	LMBRD1	0.31	4.34	0.33	2.55e-5	Sleep duration;
PAAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg20936604	chr3:58311152	NA	-0.77	-4.38	-0.34	2.17e-5	Cholesterol, total;
PAAD	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.62	-6.68	-0.48	4.32e-10	Neuroticism;
PAAD	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.36	5.17	0.39	7.16e-7	Esophageal adenocarcinoma;
PAAD	cis	rs9657904	0.774	rs7645021	chr3:105531169	C/A	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs9398803	0.723	rs853983	chr6:127046153	G/A	cg19875578	chr6:126661172	C6orf173	-0.46	-4.88	-0.37	2.67e-6	Male-pattern baldness;
PAAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	7.02	0.49	6.83e-11	Monocyte count;
PAAD	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.74	-6.79	-0.48	2.39e-10	Total body bone mineral density;
PAAD	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg21589280	chr1:85930151	DDAH1	-0.57	-4.43	-0.34	1.77e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	4.98	0.37	1.74e-6	Mood instability;
PAAD	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg05299278	chr17:33885742	SLFN14	0.42	5.02	0.38	1.45e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs17655565	0.581	rs2298794	chr12:52760732	G/A	cg22980804	chr12:52818037	KRT75	-0.48	-4.3	-0.33	3.08e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-1.06	-9.07	-0.59	5.78e-16	Orofacial clefts;
PAAD	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27467552	chr22:50353597	PIM3	0.52	5.25	0.39	5.07e-7	Ulcerative colitis;
PAAD	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.79	7.08	0.5	5.08e-11	Exhaled nitric oxide levels;
PAAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Coronary artery disease;
PAAD	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg03871329	chr12:110338662	TCHP	-0.64	-4.66	-0.35	6.91e-6	Neuroticism;
PAAD	cis	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Height;
PAAD	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.51e-5	Dental caries;
PAAD	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.32	-4.3	-0.33	3.09e-5	Dupuytren's disease;
PAAD	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.07	-10.14	-0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs3112530	0.748	rs2609673	chr5:152716371	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.88	-9.88	-0.63	4.3e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.54	-5.69	-0.42	6.3e-8	Daytime sleep phenotypes;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.65	-6.21	-0.45	4.75e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Resting heart rate;
PAAD	cis	rs5417	0.610	rs222843	chr17:7145981	T/C	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.74	-8.03	-0.55	2.44e-13	Diastolic blood pressure;
PAAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23158103	chr7:148848205	ZNF398	-0.62	-6.23	-0.45	4.46e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7071247	0.915	rs3014205	chr10:105262185	G/A	cg14553436	chr10:104822996	CNNM2	0.66	4.64	0.35	7.61e-6	Platelet aggregation;
PAAD	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	1.12	17.41	0.82	5.09e-38	Colorectal adenoma (advanced);
PAAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01200585	chr1:228362443	C1orf69	-0.5	-5.66	-0.42	7.17e-8	Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.37	10.26	0.64	4.36e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs300774	0.925	rs409572	chr2:153302	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg08029281	chr1:67600428	NA	0.51	5.48	0.41	1.69e-7	Psoriasis;
PAAD	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-1.14	-6.29	-0.45	3.26e-9	Inflammatory biomarkers;
PAAD	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.26	16.01	0.79	1.92e-34	Schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11412766	chr2:55276306	RTN4	0.58	6.99	0.49	8.12e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-7.08	-0.5	4.87e-11	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08740008	chr10:105373505	SH3PXD2A	-0.63	-6.32	-0.46	2.78e-9	Obesity-related traits;
PAAD	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg19787841	chr12:53845606	PCBP2	0.43	4.26	0.33	3.51e-5	Height;
PAAD	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.52	5.34	0.4	3.38e-7	Plasma plasminogen activator levels;
PAAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.53	-4.36	-0.33	2.39e-5	Body mass index;
PAAD	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.57	5.83	0.43	3.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.55	4.73	0.36	5.19e-6	Interleukin-17 levels;
PAAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg06217071	chr17:408420	NA	0.64	7.09	0.5	4.66e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs422249	0.593	rs174613	chr11:61628492	G/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.4	4.48	0.34	1.46e-5	Trans fatty acid levels;
PAAD	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg21565972	chr17:80109576	CCDC57	0.5	5.43	0.4	2.17e-7	Life satisfaction;
PAAD	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.54	-6.4	-0.46	1.82e-9	Alcohol dependence;
PAAD	cis	rs6466055	0.669	rs1142	chr7:104756326	C/T	cg04380332	chr7:105027541	SRPK2	-0.56	-6.21	-0.45	4.72e-9	Schizophrenia;
PAAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.74	7.83	0.54	7.86e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.74	-0.53	1.29e-12	Response to antipsychotic treatment;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg04450456	chr4:17643702	FAM184B	-0.47	-4.85	-0.37	3.08e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs75920871	1.000	rs61905706	chr11:116883777	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.77	-0.36	4.37e-6	Obesity-related traits;
PAAD	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.78	8.99	0.59	9.31e-16	Metabolic syndrome;
PAAD	cis	rs1042026	0.848	rs7669776	chr4:100177342	G/A	cg09112717	chr4:100009950	ADH5	-0.52	-4.69	-0.36	6.01e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg07677032	chr17:61819896	STRADA	0.45	4.32	0.33	2.83e-5	Height;
PAAD	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.06	9.89	0.63	4e-18	Red blood cell traits;
PAAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs2599510	0.783	rs13385788	chr2:32719692	G/C	cg02381751	chr2:32503542	YIPF4	0.5	5.09	0.38	1.03e-6	Interleukin-18 levels;
PAAD	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.61	5.62	0.41	8.73e-8	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg03983476	chr2:10830698	NOL10	-0.62	-6.18	-0.45	5.57e-9	Prostate cancer;
PAAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.48	-5.78	-0.42	4.18e-8	Colorectal cancer;
PAAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg13918804	chr1:2043761	PRKCZ	0.41	5.55	0.41	1.27e-7	Height;
PAAD	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.15e-11	Corneal astigmatism;
PAAD	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.1	0.38	1.02e-6	Lung cancer;
PAAD	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg05250797	chr16:70222502	NA	0.88	6.75	0.48	2.89e-10	IgE levels;
PAAD	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.36	4.34	0.33	2.61e-5	Pulmonary function;
PAAD	cis	rs988913	1.000	rs9475099	chr6:54839070	A/C	cg03513858	chr6:54763001	FAM83B	-0.46	-5.04	-0.38	1.31e-6	Menarche (age at onset);
PAAD	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.37	0.4	2.95e-7	Coronary artery disease;
PAAD	cis	rs16958440	0.867	rs79395141	chr18:44695680	A/G	cg17192377	chr18:44677553	HDHD2	1.05	5.57	0.41	1.11e-7	Sitting height ratio;
PAAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.83	-8.74	-0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg05309399	chr4:106552544	FLJ20184	-0.54	-4.28	-0.33	3.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg21929781	chr1:2537748	MMEL1	0.54	5.65	0.42	7.74e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.56	-4.89	-0.37	2.55e-6	Common traits (Other);
PAAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg14440974	chr22:39074834	NA	-0.54	-6.72	-0.48	3.49e-10	Menopause (age at onset);
PAAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.15	0.39	8.13e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg05834845	chr3:195489306	MUC4	0.68	5.12	0.38	9.02e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9463078	0.546	rs13207575	chr6:45020840	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.39	-0.34	2.13e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.31	-0.33	2.97e-5	Joint mobility (Beighton score);
PAAD	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg23465465	chr6:26364728	BTN3A2	0.86	4.99	0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10501293	0.675	rs7103629	chr11:43044427	T/A	cg03447554	chr11:43094025	NA	0.46	4.32	0.33	2.81e-5	Cognitive performance;
PAAD	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.95	13.34	0.73	2.32e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.86	10.76	0.66	1.99e-20	Vitiligo;
PAAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.66	-7.49	-0.52	5.19e-12	Huntington's disease progression;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg27490568	chr2:178487706	NA	0.44	4.91	0.37	2.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg18833306	chr6:118973337	C6orf204	0.58	4.45	0.34	1.68e-5	Diastolic blood pressure;
PAAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.79	-7.15	-0.5	3.32e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.62	6.15	0.45	6.54e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-7.67	-0.53	1.86e-12	Sudden cardiac arrest;
PAAD	cis	rs2446066	0.872	rs74090765	chr12:53792914	T/G	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.58	5.55	0.41	1.23e-7	Colorectal cancer;
PAAD	cis	rs4945082	1.000	rs4945082	chr11:76112085	A/T	cg07762054	chr11:75273187	SERPINH1	-0.8	-4.26	-0.33	3.6e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19765451	chr1:94702724	ARHGAP29	0.57	6.35	0.46	2.4e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.18	-10.17	-0.64	7.45e-19	Vitiligo;
PAAD	cis	rs10214930	0.671	rs12530626	chr7:27689808	A/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.78	-0.48	2.53e-10	Retinal vascular caliber;
PAAD	cis	rs3106136	0.872	rs28408371	chr4:95275182	T/C	cg11021082	chr4:95130006	SMARCAD1	0.59	5.59	0.41	1.03e-7	Capecitabine sensitivity;
PAAD	cis	rs2555155	0.808	rs11604960	chr11:6528619	T/G	cg11185456	chr11:6592066	DNHD1	0.43	4.65	0.35	7.14e-6	DNA methylation (variation);
PAAD	cis	rs55823223	0.648	rs9894383	chr17:73865657	T/G	cg14829360	chr17:73884958	NA	-0.66	-5.82	-0.43	3.43e-8	Psoriasis;
PAAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.89	11.14	0.67	1.86e-21	Coronary artery disease;
PAAD	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-6.67	-0.48	4.35e-10	Body mass index (adult);
PAAD	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg09179987	chr1:167433047	CD247	0.46	5.3	0.4	3.95e-7	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-5.95	-0.43	1.82e-8	Rheumatoid arthritis;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.78	8.7	0.58	4.93e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.73	7.23	0.51	2.26e-11	Prostate cancer;
PAAD	cis	rs9646944	0.501	rs10197310	chr2:103020030	A/T	cg20060108	chr2:102954350	IL1RL1	-0.53	-4.36	-0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg05647756	chr17:73805997	UNK	0.68	4.57	0.35	1.02e-5	Psoriasis;
PAAD	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg21827317	chr3:136751795	NA	0.48	5.06	0.38	1.18e-6	Gestational age at birth (child effect);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26428731	chr1:35334352	DLGAP3	0.73	8.23	0.56	7.75e-14	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs7945718	0.781	rs11022513	chr11:12840986	C/T	cg25843174	chr11:12811716	TEAD1	-0.38	-5.52	-0.41	1.45e-7	Educational attainment (years of education);
PAAD	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	1.04	12.41	0.71	7.41e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11696501	0.688	rs6073833	chr20:44279894	T/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs8010715	0.520	rs12435994	chr14:24589461	A/C	cg23112188	chr14:24563095	PCK2	-0.52	-5.82	-0.43	3.32e-8	IgG glycosylation;
PAAD	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg25364880	chr3:44379878	C3orf23	0.59	5.43	0.4	2.17e-7	Depressive symptoms;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.69	-4.93	-0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.97	-0.37	1.81e-6	Pulmonary function;
PAAD	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg10223061	chr2:219282414	VIL1	0.36	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25538450	chr19:1847778	REXO1	0.57	6.51	0.47	1.04e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10821973	0.527	rs1368158	chr10:64000878	T/G	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.66	-7.82	-0.54	8.3e-13	Vitiligo;
PAAD	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg00919237	chr7:87102261	ABCB4	-0.78	-6.32	-0.46	2.72e-9	Gallbladder cancer;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18402987	chr7:1209562	NA	0.55	5.55	0.41	1.25e-7	Longevity;Endometriosis;
PAAD	trans	rs901683	0.850	rs74914325	chr10:46097648	A/C	cg13065504	chr15:42448234	PLA2G4F	0.85	6.7	0.48	3.81e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs622217	0.806	rs376563	chr6:160851766	C/T	cg25313204	chr6:160768801	SLC22A3	-0.47	-4.86	-0.37	2.93e-6	Type 2 diabetes;
PAAD	cis	rs3206736	0.548	rs328902	chr7:35020843	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.51	-4.78	-0.36	4.1e-6	Diastolic blood pressure;
PAAD	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.56	-4.91	-0.37	2.37e-6	Common traits (Other);
PAAD	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-11.51	-0.68	1.95e-22	Cognitive function;
PAAD	cis	rs12286929	0.610	rs11606838	chr11:115042859	C/A	cg04055981	chr11:115044050	NA	0.43	4.58	0.35	9.81e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg11498726	chr8:26250323	BNIP3L	-0.53	-5.14	-0.38	8.52e-7	Red cell distribution width;
PAAD	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg23024343	chr7:107201750	COG5	0.56	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs10821973	0.527	rs4147233	chr10:63982668	A/G	cg09941381	chr10:64027924	RTKN2	-0.41	-4.33	-0.33	2.69e-5	Hypothyroidism;
PAAD	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.56	5.4	0.4	2.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3126085	0.560	rs2065954	chr1:152321344	T/G	cg26876637	chr1:152193138	HRNR	-0.68	-5.16	-0.39	7.62e-7	Atopic dermatitis;
PAAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.53	6.96	0.49	9.51e-11	Prostate cancer;
PAAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg09835421	chr16:68378352	PRMT7	-1.05	-7.99	-0.54	3.08e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg12757816	chr2:10669957	NA	-0.44	-4.44	-0.34	1.72e-5	Prostate cancer;
PAAD	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.65	8.17	0.55	1.11e-13	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg00262122	chr8:11665843	FDFT1	-0.49	-4.45	-0.34	1.65e-5	Retinal vascular caliber;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg15693483	chr7:1102177	C7orf50	0.34	4.29	0.33	3.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-4.66	-0.35	6.82e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.81	-7.8	-0.53	8.94e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.97	6.43	0.46	1.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg13263323	chr15:86062960	AKAP13	-0.62	-7.17	-0.5	3.02e-11	Interstitial lung disease;
PAAD	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	1.09	15.35	0.78	1.02e-32	Breast cancer;
PAAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg13798912	chr7:905769	UNC84A	0.59	4.51	0.34	1.3e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.76	8.94	0.59	1.25e-15	Colorectal cancer;
PAAD	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.57	0.35	9.83e-6	Bipolar disorder;
PAAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.71	-6.19	-0.45	5.38e-9	Menarche (age at onset);
PAAD	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg10820045	chr2:198174542	NA	-0.45	-4.54	-0.35	1.15e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	1.12	8.62	0.57	8.26e-15	Inflammatory bowel disease;
PAAD	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5.04e-13	HDL cholesterol;
PAAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg04450456	chr4:17643702	FAM184B	0.54	5.93	0.43	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-6.12	-0.44	7.71e-9	Monocyte count;
PAAD	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	1.08	9.51	0.61	4.08e-17	Orofacial clefts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11487977	chr19:9879695	ZNF846	0.63	7.13	0.5	3.85e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.41	-0.34	1.96e-5	Coronary artery disease;
PAAD	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1;
PAAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.46	0.61	5.55e-17	Rheumatoid arthritis;
PAAD	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-4.3	-0.33	3.1e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.9	0.59	1.52e-15	Motion sickness;
PAAD	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.34	-0.33	2.6e-5	Crohn's disease;
PAAD	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Breast cancer;
PAAD	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg23283495	chr1:209979779	IRF6	-0.66	-6.49	-0.47	1.13e-9	Coronary artery disease;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-10.37	-0.64	2.23e-19	Longevity;Endometriosis;
PAAD	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.43	-0.4	2.22e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4742903	0.935	rs1889284	chr9:106926980	C/T	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.95e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2073300	1.000	rs61080017	chr20:23457569	A/G	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.64	-0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg01851573	chr8:8652454	MFHAS1	0.53	4.5	0.34	1.34e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	1.08	8.0	0.54	2.96e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18843110	chr2:194142822	NA	0.56	6.99	0.49	8.33e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.16	-0.39	7.51e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs10186876	0.561	rs13009669	chr2:44195809	A/C	cg14673618	chr2:45170322	SIX3	0.29	4.48	0.34	1.46e-5	Hand grip strength;
PAAD	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.66	-7.46	-0.52	6.34e-12	Testicular germ cell tumor;
PAAD	cis	rs735539	0.521	rs2762991	chr13:21394071	T/A	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg16341495	chr8:142228727	SLC45A4	-0.45	-4.35	-0.33	2.53e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.88	0.37	2.62e-6	Myopia (pathological);
PAAD	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.88	10.38	0.64	2.1e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	5.59	0.41	1.03e-7	Mood instability;
PAAD	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg00614314	chr15:82944287	LOC80154	0.59	6.18	0.45	5.65e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.97	11.66	0.69	7.44e-23	Cognitive function;
PAAD	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg07689907	chr11:61582574	FADS1	0.45	4.47	0.34	1.54e-5	Trans fatty acid levels;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00981651	chr20:44574847	PCIF1	0.44	4.79	0.36	3.93e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg03060546	chr3:49711283	APEH	0.47	4.3	0.33	3.02e-5	Parkinson's disease;
PAAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.83	-7.13	-0.5	3.89e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1190552	0.846	rs11160683	chr14:102933347	A/G	cg18135206	chr14:102964638	TECPR2	0.65	5.26	0.39	4.9e-7	Blood protein levels;
PAAD	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.08	-11.57	-0.68	1.32e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs10905065	0.895	rs1567707	chr10:5853817	G/C	cg11519256	chr10:5708881	ASB13	-0.51	-4.43	-0.34	1.81e-5	Menopause (age at onset);
PAAD	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.75	-0.42	4.84e-8	Bipolar disorder;
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.57	-7.53	-0.52	4.25e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.73	6.44	0.46	1.5e-9	Breast cancer;
PAAD	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg24112000	chr20:60950667	NA	0.78	10.22	0.64	5.35e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.38	-4.33	-0.33	2.65e-5	Pubertal anthropometrics;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.46	-0.34	1.61e-5	Depression;
PAAD	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.83	-8.37	-0.56	3.43e-14	Corneal astigmatism;
PAAD	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.54	4.82	0.36	3.38e-6	Dialysis-related mortality;
PAAD	cis	rs4958741	0.522	rs7706345	chr5:153812108	A/G	cg20668321	chr5:153192843	GRIA1	-0.48	-4.39	-0.34	2.13e-5	Chin dimples;
PAAD	cis	rs6137287	0.889	rs13041255	chr20:21130707	T/C	cg04219410	chr20:21106687	PLK1S1	0.38	4.39	0.34	2.14e-5	Height;
PAAD	cis	rs17135859	1.000	rs10447258	chr5:113005906	T/C	cg12552261	chr5:112820674	MCC	0.7	4.61	0.35	8.52e-6	F-cell distribution;
PAAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-4.25	-0.33	3.72e-5	Renal cell carcinoma;
PAAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-5.12	-0.38	9.26e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	5.36	0.4	3.01e-7	Serum sulfate level;
PAAD	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01237263	chr17:21179546	NA	0.62	6.8	0.48	2.26e-10	Myopia (pathological);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02772682	chr19:7985923	SNAPC2	-0.7	-7.75	-0.53	1.19e-12	Lung cancer in ever smokers;
PAAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg27121462	chr16:89883253	FANCA	-0.43	-4.67	-0.35	6.57e-6	Vitiligo;
PAAD	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg05895507	chr15:77155635	SCAPER	-0.39	-4.52	-0.34	1.23e-5	Blood metabolite levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03238738	chr21:34852281	TMEM50B	-0.57	-6.57	-0.47	7.56e-10	Body fat percentage;
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg25204440	chr1:209979598	IRF6	0.61	5.28	0.39	4.47e-7	Coronary artery disease;
PAAD	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	1.04	14.73	0.77	4.4e-31	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg04362960	chr10:104952993	NT5C2	0.5	4.55	0.35	1.1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-6.28	-0.45	3.3e-9	Fibrinogen levels;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg06740227	chr12:86229804	RASSF9	-0.53	-4.84	-0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.46	-4.61	-0.35	8.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.0	12.18	0.7	3.08e-24	Dilated cardiomyopathy;
PAAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.8	-6.12	-0.44	7.72e-9	Yeast infection;
PAAD	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.65	-0.35	7.23e-6	Testicular germ cell tumor;
PAAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg21130718	chr4:1044621	NA	0.6	5.17	0.39	7.4e-7	Recombination rate (females);
PAAD	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg27490568	chr2:178487706	NA	0.41	4.25	0.33	3.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg11619707	chr19:22235551	ZNF257	0.58	5.78	0.42	4.12e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14180030	chr9:123475675	MEGF9	-0.44	-4.94	-0.37	2e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.46	5.13	0.38	8.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.75	8.93	0.59	1.3e-15	Type 2 diabetes;
PAAD	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.57	5.1	0.38	9.89e-7	White matter hyperintensity burden;
PAAD	cis	rs5009270	0.512	rs1024411	chr7:112247692	G/A	cg23628563	chr7:112262597	NA	0.64	5.62	0.41	9.09e-8	Osteoarthritis (hip);
PAAD	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg24634471	chr8:143751801	JRK	-0.51	-4.83	-0.36	3.37e-6	Urinary tract infection frequency;
PAAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg19592336	chr6:28129416	ZNF389	0.61	4.33	0.33	2.72e-5	Parkinson's disease;
PAAD	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.29	-0.39	4.26e-7	Tonsillectomy;
PAAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-1.09	-15.29	-0.78	1.48e-32	Breast cancer;
PAAD	cis	rs501120	0.584	rs12355852	chr10:44704280	G/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.66e-13	Prudent dietary pattern;
PAAD	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.93	-7.46	-0.52	6.1e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.49	-0.41	1.66e-7	Bipolar disorder;
PAAD	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.78	-11.03	-0.67	3.73e-21	Nonalcoholic fatty liver disease;
PAAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.8e-13	Blood protein levels;
PAAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.29e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.76	7.1	0.5	4.39e-11	Plateletcrit;Platelet count;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg23346134	chr3:49453900	TCTA	0.44	4.8	0.36	3.84e-6	Menarche (age at onset);
PAAD	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.47	4.85	0.37	3e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.63	-4.32	-0.33	2.82e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-4.7	-0.36	5.84e-6	Axial length;
PAAD	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.76	-8.87	-0.58	1.9e-15	Crohn's disease;
PAAD	cis	rs7619427	0.544	rs59081044	chr3:43967628	C/T	cg12796028	chr3:44040206	NA	-0.55	-4.77	-0.36	4.35e-6	Schizophrenia;
PAAD	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.7	-8.28	-0.56	5.76e-14	Educational attainment;
PAAD	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.88	0.63	4.23e-18	Morning vs. evening chronotype;
PAAD	trans	rs4471226	1.000	rs74546979	chr1:176423510	A/G	cg01325552	chr4:187025420	NA	0.84	6.34	0.46	2.48e-9	Fractional exhaled nitric oxide (childhood);
PAAD	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.65	-8.34	-0.56	4.22e-14	Inflammatory bowel disease;
PAAD	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.76	5.19	0.39	6.58e-7	Height;
PAAD	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.88	-6.79	-0.48	2.37e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg10541313	chr22:46663664	TTC38	0.9	4.41	0.34	1.91e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.56	-0.35	1.05e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	0.97	6.29	0.45	3.28e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg26174226	chr8:58114915	NA	-0.56	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg25251562	chr2:3704773	ALLC	0.55	6.45	0.46	1.41e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.49	-4.96	-0.37	1.84e-6	Mean corpuscular volume;
PAAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.61	-5.79	-0.43	3.92e-8	Blood metabolite levels;
PAAD	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg08632701	chr21:37451849	NA	-0.63	-7.03	-0.5	6.69e-11	Mitral valve prolapse;
PAAD	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.49	5.3	0.4	3.98e-7	Fibrinogen levels;
PAAD	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7591163	1.000	rs2056566	chr2:228713241	G/A	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	0.95	6.86	0.49	1.6e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7487075	0.576	rs10785635	chr12:47108817	A/T	cg14889069	chr12:47417292	NA	0.41	4.63	0.35	7.8e-6	Itch intensity from mosquito bite;
PAAD	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	1.02	7.2	0.5	2.53e-11	Gout;Renal underexcretion gout;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07076661	chr18:9136556	ANKRD12	-0.69	-7.14	-0.5	3.51e-11	Smoking initiation;
PAAD	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg03233332	chr7:66118400	NA	0.42	4.39	0.34	2.12e-5	Aortic root size;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.6	4.63	0.35	7.67e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.12e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	1.000	rs35172875	chr10:46004160	T/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.74	7.43	0.52	7.32e-12	Retinal vascular caliber;
PAAD	cis	rs10450586	0.932	rs10767634	chr11:27332474	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs75920871	0.925	rs61903417	chr11:116956157	T/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.82	11.12	0.67	2.22e-21	Emphysema distribution in smoking;
PAAD	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.91	-0.43	2.14e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg05562828	chr17:3906858	NA	0.6	6.4	0.46	1.78e-9	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg23083516	chr15:85180758	SCAND2	0.4	4.47	0.34	1.54e-5	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	trans	rs7172971	0.688	rs75615772	chr15:42386480	C/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05243641	chr2:240964548	NDUFA10	-0.65	-6.82	-0.48	2.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28374715	0.783	rs1866399	chr15:41571139	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-13.55	-0.74	6.2e-28	Ulcerative colitis;
PAAD	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.86e-9	Bladder cancer;
PAAD	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.69	-6.44	-0.46	1.46e-9	Height;
PAAD	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg02640540	chr1:67518911	SLC35D1	0.63	5.05	0.38	1.25e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg14146966	chr2:61757674	XPO1	0.39	4.67	0.35	6.52e-6	Tuberculosis;
PAAD	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-6.54	-0.47	8.61e-10	Colorectal cancer;
PAAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg18854424	chr1:2615690	NA	0.44	5.79	0.43	3.82e-8	Ulcerative colitis;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg16362232	chr11:430036	ANO9	0.9	5.4	0.4	2.56e-7	Body mass index;
PAAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs1371614	0.635	rs12612619	chr2:27137671	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg01612440	chr4:3296283	NA	0.42	4.28	0.33	3.33e-5	Serum sulfate level;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19887178	chr3:172429023	NCEH1	-0.79	-7.06	-0.5	5.55e-11	Neuroticism;
PAAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg07220939	chr11:64358617	SLC22A12	0.43	4.27	0.33	3.37e-5	Urate levels in obese individuals;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-1.07	-19.42	-0.84	5.26e-43	Urate levels in lean individuals;
PAAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.82	6.42	0.46	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.51	4.88	0.37	2.61e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.81	-0.43	3.5e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.75	8.81	0.58	2.64e-15	Colorectal cancer;
PAAD	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.86	9.99	0.63	2.24e-18	Monocyte percentage of white cells;
PAAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	4.72	0.36	5.37e-6	Hip circumference;
PAAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.84e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.65	6.73	0.48	3.17e-10	Testicular germ cell tumor;
PAAD	cis	rs939584	0.825	rs4423631	chr2:648758	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg10437265	chr15:77819839	NA	-0.38	-4.45	-0.34	1.62e-5	Type 2 diabetes;
PAAD	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.52	-5.19	-0.39	6.58e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	9.78	0.62	7.89e-18	Rheumatoid arthritis;
PAAD	cis	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg21546286	chr11:48923668	NA	0.55	5.65	0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.81	-8.41	-0.56	2.81e-14	Glaucoma (primary open-angle);
PAAD	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.8	-0.53	9.16e-13	Total cholesterol levels;
PAAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.09	8.6	0.57	8.91e-15	Cannabis dependence symptom count;
PAAD	cis	rs1797885	0.763	rs299660	chr3:12552628	A/C	cg07775309	chr3:12595852	NA	0.4	4.39	0.34	2.12e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.87	10.49	0.65	1.04e-19	Menopause (age at onset);
PAAD	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg09760422	chr2:128146352	NA	-0.41	-7.11	-0.5	4.24e-11	Protein C levels;
PAAD	cis	rs12145833	1.000	rs61833916	chr1:243469946	C/T	cg02356786	chr1:243265016	LOC731275	0.65	4.49	0.34	1.39e-5	Obesity (early onset extreme);
PAAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.78	9.96	0.63	2.62e-18	Alcohol dependence;
PAAD	cis	rs35160687	0.901	rs12478653	chr2:86535394	A/C	cg10973622	chr2:86423274	IMMT	-0.39	-4.53	-0.34	1.2e-5	Night sleep phenotypes;
PAAD	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.57	-6.86	-0.49	1.67e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg19337854	chr7:99768885	GPC2	-0.45	-4.63	-0.35	7.69e-6	Coronary artery disease;
PAAD	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	1.07	15.73	0.79	1.06e-33	Total body bone mineral density;
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.39	5.23	0.39	5.5e-7	Age at first birth;
PAAD	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20368979	chr4:73935086	COX18	0.63	6.98	0.49	8.62e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg08992911	chr2:238395768	MLPH	0.7	5.54	0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.52	-6.2	-0.45	5.09e-9	Psoriasis;
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.77	-5.72	-0.42	5.59e-8	Initial pursuit acceleration;
PAAD	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.72	7.06	0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg21280719	chr6:42927975	GNMT	-0.39	-5.66	-0.42	7.21e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs11887277	0.586	rs2252860	chr2:26987481	A/G	cg12368169	chr2:27073192	DPYSL5	-0.4	-4.31	-0.33	2.88e-5	Obesity-related traits;
PAAD	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.46	0.57	2.05e-14	Dupuytren's disease;
PAAD	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.29	-0.33	3.18e-5	Bipolar disorder;
PAAD	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.48	-4.94	-0.37	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1419980	0.730	rs6488490	chr12:7737379	G/A	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs2627282	0.577	rs341730	chr8:2772575	A/G	cg21769514	chr8:2743697	NA	0.41	4.37	0.33	2.3e-5	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.71	8.2	0.55	9.16e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.5	-5.2	-0.39	6.2e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.85	5.47	0.41	1.78e-7	Body mass index;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.67	7.07	0.5	5.16e-11	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16548348	chr22:19842481	GNB1L;C22orf29	0.68	7.56	0.52	3.55e-12	Myopia (pathological);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12495983	chr2:216867894	MREG	0.6	6.77	0.48	2.65e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs375066	0.935	rs368089	chr19:44399084	A/G	cg11993925	chr19:44307056	LYPD5	0.49	6.27	0.45	3.57e-9	Breast cancer;
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.64	6.17	0.45	5.86e-9	Blood metabolite levels;
PAAD	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.76	-9.24	-0.6	2.09e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7264396	0.623	rs6119609	chr20:34039394	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.54	-0.41	1.31e-7	Total cholesterol levels;
PAAD	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.11	9.6	0.61	2.39e-17	Red blood cell traits;
PAAD	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.89	-10.64	-0.65	4.14e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.85	8.2	0.55	9.09e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg06565975	chr8:143823917	SLURP1	0.22	4.61	0.35	8.3e-6	Urinary tract infection frequency;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14279997	chr9:95476582	BICD2	-0.66	-6.45	-0.46	1.43e-9	Obesity-related traits;
PAAD	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	7.8	0.53	9.11e-13	Retinal vascular caliber;
PAAD	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg25364880	chr3:44379878	C3orf23	0.54	5.42	0.4	2.33e-7	Depressive symptoms;
PAAD	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.67	-0.53	1.93e-12	Neuroticism;
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.88	11.71	0.69	5.7e-23	Vitiligo;
PAAD	cis	rs863345	0.967	rs12041218	chr1:158481574	A/G	cg12129480	chr1:158549410	OR10X1	-0.45	-5.26	-0.39	4.78e-7	Pneumococcal bacteremia;
PAAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.59	-5.72	-0.42	5.53e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.68	0.65	3.29e-20	Smoking behavior;
PAAD	cis	rs9346353	0.737	rs2061310	chr6:70429991	A/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.95e-5	Sleep duration;
PAAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.72	0.42	5.46e-8	Tonsillectomy;
PAAD	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	6.32	0.46	2.78e-9	Lymphocyte counts;
PAAD	cis	rs7551345	0.806	rs6685250	chr1:31734748	G/T	cg17086398	chr1:31896392	SERINC2	-0.5	-4.4	-0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-5.03	-0.38	1.34e-6	Height;
PAAD	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.04	0.44	1.11e-8	Schizophrenia;
PAAD	cis	rs7326068	0.610	rs4769134	chr13:21438871	G/A	cg27234864	chr13:21295941	IL17D	0.63	5.4	0.4	2.55e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-6.05	-0.44	1.09e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg15192750	chr16:69999425	NA	0.74	5.8	0.43	3.78e-8	IgE levels;
PAAD	cis	rs6466055	0.661	rs6954777	chr7:104925921	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg22800045	chr5:56110881	MAP3K1	0.59	4.71	0.36	5.65e-6	Coronary artery disease;
PAAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-5.03	-0.38	1.37e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.44	-0.46	1.5e-9	Lung cancer;
PAAD	cis	rs9314614	0.789	rs2951858	chr8:6713809	C/T	cg27319216	chr8:6693540	XKR5	0.38	5.07	0.38	1.12e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.89	-7.58	-0.52	3.08e-12	Alzheimer's disease;
PAAD	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.9	9.31	0.6	1.35e-16	Educational attainment;
PAAD	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.46	-5.74	-0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4073221	1.000	rs4073221	chr3:18277488	T/G	cg07694806	chr3:18168406	NA	-0.75	-5.07	-0.38	1.15e-6	Parkinson's disease;
PAAD	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.56	4.74	0.36	4.81e-6	Alcohol dependence (age at onset);
PAAD	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.97	-0.44	1.59e-8	Adiposity;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg13264159	chr8:625131	ERICH1	-0.72	-4.86	-0.37	2.91e-6	IgG glycosylation;
PAAD	trans	rs6532374	0.872	rs62307844	chr4:93469784	G/A	cg01163837	chr2:31457287	EHD3	-0.71	-6.3	-0.46	3.1e-9	Interleukin-12p70 levels;
PAAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7631605	0.846	rs4678555	chr3:36987573	C/G	cg17445812	chr3:36986805	TRANK1	0.34	4.57	0.35	1.01e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6005807	0.543	rs2294431	chr22:29177200	C/T	cg15103426	chr22:29168792	CCDC117	0.64	4.69	0.36	6.1e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.07	-18.36	-0.83	2.05e-40	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg23024343	chr7:107201750	COG5	0.56	4.61	0.35	8.46e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.56	5.92	0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.8	-0.36	3.76e-6	Lung cancer;
PAAD	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.9	-5.77	-0.42	4.33e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs12476592	0.602	rs187801	chr2:63867446	A/C	cg10828910	chr2:63850056	LOC388955	-0.53	-4.69	-0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg10072921	chr12:121022843	NA	-0.35	-4.56	-0.35	1.05e-5	High light scatter reticulocyte count;
PAAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg27499820	chr13:21296301	IL17D	0.5	4.74	0.36	4.78e-6	Dental caries;
PAAD	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs12282928	0.959	rs1354293	chr11:48264370	A/G	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.63	-5.36	-0.4	3.1e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.67	7.21	0.5	2.43e-11	Sjögren's syndrome;
PAAD	cis	rs8105895	0.935	rs62112362	chr19:22293113	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg11057378	chr10:81107060	PPIF	-0.51	-5.98	-0.44	1.52e-8	Height;
PAAD	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg14092571	chr14:90743983	NA	0.55	5.31	0.4	3.75e-7	Mortality in heart failure;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.74	-0.48	3.09e-10	Lung cancer;
PAAD	cis	rs17407555	0.909	rs56307229	chr4:10254655	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-4.38	-0.33	2.24e-5	Schizophrenia (age at onset);
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.43	-0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg17326555	chr1:119535693	NA	-0.44	-5.44	-0.4	2.05e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg20312557	chr2:97357134	FER1L5	-0.83	-4.43	-0.34	1.77e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.66	-7.7	-0.53	1.6e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19451221	chr20:1146033	PSMF1	-0.53	-6.44	-0.46	1.46e-9	Monocyte percentage of white cells;
PAAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.93	7.88	0.54	5.95e-13	Alzheimer's disease;
PAAD	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.6	5.32	0.4	3.63e-7	Parkinson's disease;
PAAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.39	0.46	1.95e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg12163867	chr12:51592794	POU6F1	-0.65	-6.6	-0.47	6.45e-10	Cisplatin-induced ototoxicity;
PAAD	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs10851411	0.559	rs17767270	chr15:42898612	A/G	cg21293051	chr15:42870591	STARD9	-0.58	-4.72	-0.36	5.35e-6	Glucose homeostasis traits;
PAAD	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg13691442	chr19:58878570	NA	0.59	5.98	0.44	1.56e-8	Uric acid clearance;
PAAD	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.85	-11.08	-0.67	2.72e-21	Height;
PAAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.29	-0.39	4.26e-7	Tonsillectomy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17278466	chr17:76798203	USP36	0.58	7.39	0.51	9.12e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.54	5.59	0.41	1.03e-7	Pelvic organ prolapse;
PAAD	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.35	-5.44	-0.4	2.07e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs12042052	1.000	rs6686747	chr1:232912743	T/C	cg02903907	chr1:232941055	KIAA1383	0.82	4.56	0.35	1.03e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2286379	0.804	rs7978362	chr12:1865574	G/C	cg05227549	chr12:1770782	NA	0.38	4.32	0.33	2.8e-5	Blood pressure (smoking interaction);
PAAD	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.73	-8.12	-0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg11517269	chr6:28058789	ZSCAN12L1	-0.54	-4.86	-0.37	2.87e-6	Depression;
PAAD	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.59	6.8	0.48	2.3e-10	Menarche (age at onset);
PAAD	cis	rs597539	0.597	rs35956171	chr11:68602735	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.62	-5.53	-0.41	1.35e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.17	-0.5	3.06e-11	Colorectal cancer;
PAAD	cis	rs939584	0.935	rs10166979	chr2:640701	A/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.75	6.78	0.48	2.5e-10	Inhibitory control;
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg00579200	chr11:133705235	NA	-0.47	-5.49	-0.41	1.68e-7	Childhood ear infection;
PAAD	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00125455	chr20:44574271	PCIF1	0.41	4.29	0.33	3.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26926768	chr12:34528122	NA	0.37	4.47	0.34	1.52e-5	Morning vs. evening chronotype;
PAAD	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs9463078	0.585	rs56138724	chr6:45048050	G/A	cg25276700	chr6:44698697	NA	0.44	5.12	0.38	8.92e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23022785	chr20:10153355	NA	0.55	6.31	0.46	2.86e-9	Monocyte percentage of white cells;
PAAD	cis	rs4218	0.531	rs10431791	chr15:59347358	G/A	cg25595834	chr15:59156878	NA	0.43	4.39	0.34	2.08e-5	Social communication problems;
PAAD	cis	rs2275565	0.810	rs17658475	chr1:237032167	T/G	cg17297354	chr1:237056641	MTR	-0.53	-4.74	-0.36	4.95e-6	Homocysteine levels;
PAAD	cis	rs12754538	0.777	rs1000184	chr1:8640831	G/C	cg06159269	chr1:8767347	RERE	0.42	4.85	0.37	3.03e-6	Subjective well-being;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10836716	chr7:73868151	GTF2IRD1	-0.72	-7.8	-0.53	9.08e-13	Smoking initiation;
PAAD	trans	rs2249625	0.771	rs484596	chr6:72756798	C/A	cg04413069	chr12:9800446	LOC374443	0.58	6.44	0.46	1.49e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.51	-5.05	-0.38	1.27e-6	Multiple myeloma;
PAAD	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg00383909	chr3:49044727	WDR6	0.44	4.48	0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg15956490	chr3:53032818	SFMBT1	0.78	4.39	0.34	2.16e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6466055	0.777	rs11765045	chr7:104922115	T/A	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.59	-5.91	-0.43	2.21e-8	Height;
PAAD	cis	rs10916814	0.589	rs7416238	chr1:20897240	A/G	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4281086	0.965	rs35483889	chr8:10378256	G/A	cg01072821	chr8:10382165	T-SP1	0.44	4.26	0.33	3.59e-5	Obesity-related traits;
PAAD	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.53	0.35	1.17e-5	Educational attainment;
PAAD	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.84	6.44	0.46	1.5e-9	Axial length;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08493265	chr3:195539297	MUC4	0.64	5.24	0.39	5.22e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg21281001	chr8:11725306	CTSB	-0.5	-4.47	-0.34	1.5e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs4740619	0.619	rs10810523	chr9:16034642	T/G	cg14451791	chr9:16040625	NA	-0.44	-5.11	-0.38	9.58e-7	Body mass index;
PAAD	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg19254793	chr6:44695348	NA	0.45	4.58	0.35	9.49e-6	Total body bone mineral density;
PAAD	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.92	-10.35	-0.64	2.5e-19	Chronic sinus infection;
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg07153921	chr17:41440717	NA	-0.42	-4.48	-0.34	1.47e-5	Menopause (age at onset);
PAAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14895029	chr7:2775587	GNA12	-0.45	-4.38	-0.33	2.17e-5	Height;
PAAD	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.51	-4.74	-0.36	4.84e-6	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg11764359	chr7:65958608	NA	-0.68	-4.44	-0.34	1.72e-5	Diabetic kidney disease;
PAAD	cis	rs11892454	0.515	rs10198667	chr2:26020876	T/G	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg09127314	chr1:152161683	NA	-0.61	-4.26	-0.33	3.53e-5	Atopic dermatitis;
PAAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.83	7.43	0.52	7.43e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg19217778	chr13:113420270	ATP11A	0.61	4.34	0.33	2.56e-5	Glycated hemoglobin levels;
PAAD	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg14036092	chr11:66035641	RAB1B	0.65	5.55	0.41	1.24e-7	Gout;
PAAD	cis	rs4879913	0.801	rs7047816	chr9:35591632	G/T	cg18130437	chr9:35658183	CCDC107;RMRP	-0.45	-4.38	-0.33	2.2e-5	Electroencephalogram traits;
PAAD	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Myopia (pathological);
PAAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.98	-11.3	-0.68	6.94e-22	Tonsillectomy;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs12754538	0.777	rs6675857	chr1:8652154	A/G	cg06159269	chr1:8767347	RERE	0.4	4.7	0.36	5.76e-6	Subjective well-being;
PAAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.5	-0.34	1.34e-5	Glomerular filtration rate;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17683126	chr8:97247889	UQCRB	-0.73	-6.43	-0.46	1.58e-9	Neuroticism;
PAAD	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.67	-5.8	-0.43	3.66e-8	Lung cancer;
PAAD	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg02344993	chr17:57696989	CLTC	0.58	5.37	0.4	2.83e-7	Hemoglobin concentration;
PAAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.18e-22	Parkinson's disease;
PAAD	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.59	-6.16	-0.45	6.32e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.35	6.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-6.54	-0.47	8.94e-10	Coronary artery disease;
PAAD	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.84	6.18	0.45	5.68e-9	Height;
PAAD	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06850241	chr22:41845214	NA	-0.54	-5.18	-0.39	7e-7	Vitiligo;
PAAD	cis	rs939584	0.877	rs6749087	chr2:629818	A/T	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.4	-4.61	-0.35	8.41e-6	Depression;
PAAD	cis	rs6142102	0.961	rs1555075	chr20:32610401	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg05555928	chr11:63887634	MACROD1	-0.6	-4.69	-0.36	6.12e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13560548	chr3:10150139	C3orf24	0.6	5.56	0.41	1.18e-7	Alzheimer's disease;
PAAD	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7247513	0.930	rs2861408	chr19:12702099	A/G	cg01871581	chr19:12707946	ZNF490	-0.86	-10.73	-0.66	2.38e-20	Bipolar disorder;
PAAD	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4787491	0.729	rs11544328	chr16:30037128	A/C	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.8	6.46	0.46	1.31e-9	Small cell lung carcinoma;
PAAD	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg22027985	chr11:4115532	RRM1	-0.44	-4.32	-0.33	2.79e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11700980	0.551	rs11700705	chr21:30117502	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-5.37	-0.4	2.85e-7	Systolic blood pressure;
PAAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.74	-7.36	-0.51	1.08e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.56	4.4	0.34	2e-5	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.93	-10.23	-0.64	4.99e-19	Parkinson's disease;
PAAD	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.7e-6	Neuroticism;
PAAD	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg19131313	chr8:1704013	NA	-0.41	-4.61	-0.35	8.6e-6	Systolic blood pressure;
PAAD	cis	rs10916814	0.632	rs10916817	chr1:20897294	C/T	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.86	-10.06	-0.63	1.49e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.51	5.17	0.39	7.33e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1559088	0.847	rs7255968	chr19:33601902	A/T	cg27124370	chr19:33622961	WDR88	0.67	6.13	0.45	7.31e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13242816	1.000	rs34652384	chr7:116157011	T/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.79	-0.36	4.01e-6	P wave duration;
PAAD	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.64	-6.29	-0.45	3.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4356203	0.905	rs7107283	chr11:17089403	A/G	cg15432903	chr11:17409602	KCNJ11	0.41	4.37	0.33	2.31e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-11.34	-0.68	5.41e-22	Primary sclerosing cholangitis;
PAAD	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.25	-0.51	1.93e-11	Psoriasis;
PAAD	cis	rs1891275	0.576	rs1891272	chr10:93426063	A/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.46	4.28	0.33	3.32e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.78	-6.93	-0.49	1.11e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs400736	0.562	rs12711516	chr1:8181227	G/C	cg25007680	chr1:8021821	PARK7	-0.51	-4.54	-0.35	1.14e-5	Response to antidepressants and depression;
PAAD	cis	rs13033859	0.526	rs6548221	chr2:295255	C/T	cg12623918	chr2:306882	NA	-0.55	-5.54	-0.41	1.29e-7	Mitochondrial DNA levels;
PAAD	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.3	-0.51	1.48e-11	Diastolic blood pressure;
PAAD	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	Cognitive function;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg18641463	chr7:2144579	MAD1L1	-0.45	-4.31	-0.33	2.89e-5	Schizophrenia;
PAAD	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.56	-0.35	1.06e-5	Coronary artery disease;
PAAD	cis	rs3206736	0.548	rs328891	chr7:35013517	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.76	-0.36	4.49e-6	Diastolic blood pressure;
PAAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	cis	rs6942407	0.592	rs886318	chr7:86746500	C/G	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs5753037	0.653	rs140133	chr22:30152522	G/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs2030114	0.821	rs2647981	chr16:51615715	A/G	cg03758633	chr16:51611768	NA	0.49	4.5	0.34	1.35e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg15628303	chr1:26608928	UBXN11	-0.41	-4.29	-0.33	3.21e-5	Height;
PAAD	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.77	-6.86	-0.49	1.62e-10	Blood pressure (smoking interaction);
PAAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg13611204	chr9:139324423	INPP5E	-0.58	-4.9	-0.37	2.47e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg23947450	chr7:900037	UNC84A	0.55	4.46	0.34	1.6e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg08029281	chr1:67600428	NA	0.45	5.47	0.41	1.85e-7	Psoriasis;
PAAD	cis	rs8181166	0.637	rs465486	chr9:89087650	C/A	cg14198768	chr9:89109504	NA	-0.29	-4.51	-0.34	1.31e-5	Height;
PAAD	cis	rs8077577	0.747	rs2294913	chr17:18202996	C/T	cg16794390	chr17:18148240	FLII	0.51	4.41	0.34	1.96e-5	Obesity-related traits;
PAAD	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.69	6.86	0.49	1.66e-10	Testicular germ cell tumor;
PAAD	cis	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16975963	0.843	rs241954	chr19:38277530	C/T	cg14218481	chr19:38281219	NA	0.41	4.33	0.33	2.65e-5	Longevity;
PAAD	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.02	-6.59	-0.47	6.64e-10	Body mass index;
PAAD	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	7.36	0.51	1.1e-11	IgG glycosylation;
PAAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10730208	chr12:58290540	NA	0.61	6.5	0.47	1.07e-9	Pancreatic cancer;
PAAD	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.71	-7.73	-0.53	1.4e-12	Alcohol dependence;
PAAD	cis	rs75920871	0.589	rs115787357	chr11:117064506	T/G	cg20748955	chr11:118016902	SCN4B	0.71	4.47	0.34	1.53e-5	Subjective well-being;
PAAD	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg04719120	chr6:96025338	MANEA	0.54	4.32	0.33	2.8e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs656900	0.715	rs673018	chr15:80115347	C/T	cg02196730	chr15:80188777	MTHFS	-0.44	-4.7	-0.36	5.9e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.35	-0.4	3.22e-7	Joint mobility (Beighton score);
PAAD	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.76	7.84	0.54	7.34e-13	Breast cancer;
PAAD	cis	rs375066	0.935	rs454559	chr19:44429120	C/T	cg11993925	chr19:44307056	LYPD5	0.5	6.36	0.46	2.2e-9	Breast cancer;
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.64	-7.25	-0.51	1.95e-11	Vitiligo;
PAAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	5.0	0.38	1.54e-6	Asthma;
PAAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3774830	0.714	rs7685158	chr4:5462776	C/T	cg26943120	chr4:5472116	STK32B	0.36	4.44	0.34	1.75e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.97	9.43	0.61	6.69e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.5	5.04	0.38	1.32e-6	Schizophrenia;
PAAD	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg21253087	chr9:139290292	SNAPC4	0.5	4.63	0.35	7.78e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.62	-6.53	-0.47	9.27e-10	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg20487152	chr13:99095054	FARP1	0.63	5.76	0.42	4.53e-8	Neuroticism;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01860947	chr19:15442741	NA	-0.56	-6.46	-0.46	1.37e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.48	4.26	0.33	3.54e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.74	8.25	0.56	6.85e-14	Prostate cancer;
PAAD	cis	rs6700896	0.931	rs2154384	chr1:66108517	C/T	cg04111102	chr1:66153794	NA	0.49	5.58	0.41	1.09e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22509189	chr2:225307070	NA	-0.48	-4.42	-0.34	1.9e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.44	-0.34	1.7e-5	Life satisfaction;
PAAD	cis	rs501120	0.584	rs2804031	chr10:44702928	T/G	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.61	-4.25	-0.33	3.75e-5	Depression;
PAAD	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg21191810	chr6:118973309	C6orf204	-0.52	-5.01	-0.38	1.52e-6	Diastolic blood pressure;
PAAD	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.62	-6.13	-0.45	7.07e-9	Post bronchodilator FEV1;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.7	7.76	0.53	1.17e-12	Blood metabolite levels;
PAAD	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg09491104	chr22:46646882	C22orf40	-1.01	-6.13	-0.44	7.41e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9857275	0.501	rs9849180	chr3:141254835	A/G	cg25967872	chr3:141205623	RASA2	0.49	4.3	0.33	3.05e-5	Prion diseases;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.84	9.49	0.61	4.67e-17	Schizophrenia;
PAAD	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.84	5.52	0.41	1.43e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs965469	0.779	rs967366	chr20:3266935	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg19257562	chr1:2043853	PRKCZ	0.46	5.44	0.4	2.04e-7	Height;
PAAD	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg06565975	chr8:143823917	SLURP1	-0.22	-4.68	-0.35	6.29e-6	Urinary tract infection frequency;
PAAD	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs7737355	0.812	rs31591	chr5:131005638	C/T	cg06307176	chr5:131281290	NA	0.48	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22162314	chr17:61951766	CSH2	-0.47	-4.83	-0.36	3.31e-6	Height;
PAAD	cis	rs2290419	0.730	rs78938716	chr11:68941774	T/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg10370574	chr19:1840461	REXO1	-0.48	-4.54	-0.35	1.12e-5	Bipolar disorder;
PAAD	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.59	-4.27	-0.33	3.37e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg14393609	chr7:65229607	NA	0.45	4.41	0.34	1.97e-5	Aortic root size;
PAAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs7804356	0.651	rs55649724	chr7:26804005	G/A	cg03456212	chr7:26904342	SKAP2	-0.57	-4.94	-0.37	1.99e-6	Type 1 diabetes;
PAAD	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.64	7.78	0.53	1.01e-12	Atrioventricular conduction;
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs75920871	0.925	rs7950381	chr11:116963897	C/A	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg11530693	chr1:120165357	ZNF697	0.65	5.75	0.42	4.85e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs35785195	0.633	rs1035774	chr12:114230856	G/C	cg08193681	chr12:114234200	NA	0.59	4.52	0.34	1.24e-5	Daytime sleep phenotypes;
PAAD	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg05627522	chr15:75251581	NA	-0.4	-4.69	-0.36	5.98e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.99	11.66	0.69	7.52e-23	Breast cancer;
PAAD	cis	rs4742903	0.875	rs10820609	chr9:106907332	G/A	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg18279126	chr7:2041391	MAD1L1	0.6	6.16	0.45	6.08e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9972944	0.651	rs9906040	chr17:63840825	A/G	cg07283582	chr17:63770753	CCDC46	-0.58	-6.87	-0.49	1.54e-10	Total body bone mineral density;
PAAD	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg06627628	chr2:24431161	ITSN2	-0.59	-5.76	-0.42	4.48e-8	Sjögren's syndrome;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-5.91	-0.43	2.18e-8	Prudent dietary pattern;
PAAD	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.62e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg00857998	chr1:205179979	DSTYK	0.47	4.25	0.33	3.68e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg08027265	chr7:2291960	NA	-0.67	-6.78	-0.48	2.54e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.37	9.57	0.61	2.81e-17	Diabetic retinopathy;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.33	0.81	8.1e-38	Height;
PAAD	cis	rs80346118	0.673	rs750085	chr20:47415898	T/C	cg20907517	chr20:47894756	C20orf199;ZNFX1;SNORD12C	-0.59	-4.42	-0.34	1.9e-5	Diastolic blood pressure;
PAAD	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.92	7.85	0.54	6.84e-13	Triglycerides;
PAAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg03037974	chr15:76606532	NA	0.52	6.04	0.44	1.16e-8	Blood metabolite levels;
PAAD	cis	rs3764400	0.517	rs7224461	chr17:46203430	C/G	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg09127314	chr1:152161683	NA	-0.71	-4.64	-0.35	7.51e-6	Atopic dermatitis;
PAAD	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg15592541	chr3:197519021	LRCH3	0.78	6.3	0.46	3.03e-9	Mean platelet volume;
PAAD	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs7945705	0.935	rs2243566	chr11:8852239	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.47	4.83	0.37	3.25e-6	Hemoglobin concentration;
PAAD	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs3026101	0.671	rs3026144	chr17:5316680	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.6	-6.17	-0.45	5.97e-9	Diastolic blood pressure;
PAAD	cis	rs4234798	1.000	rs4689653	chr4:7223319	T/G	cg18431297	chr4:7219810	SORCS2	0.4	4.77	0.36	4.3e-6	Insulin-like growth factors;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02636222	chr3:48956935	ARIH2;C3orf71	0.59	6.41	0.46	1.74e-9	Monocyte percentage of white cells;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg01585852	chr22:24235823	MIF	-0.47	-4.97	-0.37	1.79e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20776920	chr8:35091548	UNC5D	-0.64	-6.53	-0.47	9.11e-10	Obesity-related traits;
PAAD	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.23e-6	Type 2 diabetes;
PAAD	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.39	0.4	2.66e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2718812	0.792	rs1867503	chr3:133410648	G/A	cg08439880	chr3:133502540	NA	0.42	4.64	0.35	7.47e-6	Iron status biomarkers;
PAAD	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	5.86	0.43	2.84e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.36	-0.4	2.97e-7	Mean platelet volume;
PAAD	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-4.29	-0.33	3.12e-5	Tuberculosis;
PAAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4144027	0.904	rs10438243	chr14:104345822	A/G	cg19582115	chr14:103436037	CDC42BPB	0.5	4.66	0.35	6.74e-6	Blood metabolite levels;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-10.31	-0.64	3.1400000000000002e-19	Platelet distribution width;
PAAD	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg19401529	chr3:49056140	DALRD3	0.52	4.34	0.33	2.58e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs75920871	1.000	rs11820814	chr11:116765700	T/C	cg04087571	chr11:116723030	SIK3	-0.45	-4.6	-0.35	8.92e-6	Subjective well-being;
PAAD	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.44	4.52	0.34	1.25e-5	Age of smoking initiation;
PAAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg24733560	chr20:60626293	TAF4	0.44	5.34	0.4	3.37e-7	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16095542	chr1:155023359	ADAM15;DCST1	0.57	6.36	0.46	2.29e-9	Myopia (pathological);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16395248	chr17:78327565	RNF213;LOC100294362	0.57	6.41	0.46	1.69e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05146762	chr7:73868174	GTF2IRD1	0.57	6.62	0.47	5.84e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26926768	chr12:34528122	NA	-0.39	-4.64	-0.35	7.57e-6	Morning vs. evening chronotype;
PAAD	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13870426	chr17:30244630	NA	0.59	5.65	0.42	7.62e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg21419209	chr3:44054225	NA	-0.72	-7.23	-0.51	2.16e-11	Coronary artery disease;
PAAD	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.71	-7.34	-0.51	1.18e-11	Colorectal cancer;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg09197432	chr4:183729176	NA	0.64	5.85	0.43	2.85e-8	Pediatric autoimmune diseases;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg21226059	chr5:178986404	RUFY1	-0.56	-6.52	-0.47	9.71e-10	Lung cancer;
PAAD	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs12282928	0.625	rs924714	chr11:48215853	G/A	cg04721828	chr11:48285200	OR4X1	0.5	5.42	0.4	2.27e-7	Migraine - clinic-based;
PAAD	cis	rs1113500	0.541	rs6692571	chr1:108576684	G/A	cg06207961	chr1:108661230	NA	0.47	5.04	0.38	1.3e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs56046484	0.912	rs12914674	chr15:85663060	A/C	cg08123816	chr15:85640762	PDE8A	-0.5	-5.15	-0.39	7.93e-7	Testicular germ cell tumor;
PAAD	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.59	-5.57	-0.41	1.14e-7	Prostate cancer;
PAAD	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg10729496	chr3:10149963	C3orf24	0.81	6.65	0.47	5.09e-10	Alzheimer's disease;
PAAD	cis	rs1561288	0.681	rs2083115	chr2:25347391	T/C	cg02492873	chr2:25193821	DNAJC27	0.48	4.3	0.33	3.02e-5	Body mass index;
PAAD	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg09237302	chr4:906077	GAK	-0.43	-5.36	-0.4	3.08e-7	Systemic sclerosis;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.53	-4.98	-0.37	1.67e-6	Blood protein levels;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10186876	0.728	rs4953034	chr2:44143216	T/A	cg09541576	chr2:44873248	C2orf34	-0.45	-4.68	-0.35	6.42e-6	Hand grip strength;
PAAD	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.03e-11	Lung cancer in ever smokers;
PAAD	cis	rs11676676	0.935	rs11689009	chr2:109771373	T/C	cg23046629	chr2:109745841	LOC100287216;SH3RF3	0.54	4.46	0.34	1.59e-5	Pediatric bone mineral density (spine);
PAAD	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.8	6.53	0.47	9.14e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-7.79	-0.53	9.64e-13	Response to antipsychotic treatment;
PAAD	cis	rs11051970	0.636	rs188978	chr12:32570627	T/C	cg02745156	chr12:32552066	NA	0.43	4.44	0.34	1.73e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.57	7.78	0.53	1.05e-12	Renal cell carcinoma;
PAAD	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.46	4.99	0.38	1.62e-6	Age of smoking initiation;
PAAD	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.94	-0.43	1.84e-8	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.76	-8.46	-0.57	2.07e-14	Menopause (age at onset);
PAAD	cis	rs4851870	0.581	rs3754801	chr2:106493191	C/T	cg21551182	chr2:106399873	NCK2	0.44	4.53	0.34	1.2e-5	Addiction;
PAAD	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg22587600	chr2:46883368	NA	0.34	4.59	0.35	9.38e-6	Height;
PAAD	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg09579323	chr1:150459698	TARS2	0.45	4.26	0.33	3.57e-5	Migraine;
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg15691649	chr6:25882328	NA	-0.48	-4.25	-0.33	3.73e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg19445457	chr11:5799446	OR52N5	-0.52	-4.68	-0.35	6.39e-6	DNA methylation (variation);
PAAD	cis	rs564309	1.000	rs503203	chr1:228602660	G/C	cg01328119	chr1:228783545	DUSP5P	0.72	4.73	0.36	4.99e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-5.14	-0.38	8.45e-7	Height;
PAAD	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.76	-9.58	-0.61	2.64e-17	Educational attainment;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.81	5.86	0.43	2.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16975963	0.644	rs11665759	chr19:38039675	C/G	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.64	5.94	0.43	1.88e-8	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.55	5.07	0.38	1.16e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08057159	chr1:145507538	RBM8A	0.6	6.93	0.49	1.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22153463	chr1:85462885	MCOLN2	0.63	4.8	0.36	3.72e-6	Serum sulfate level;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.52	4.97	0.37	1.82e-6	Lung cancer;
PAAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.97e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg07557355	chr1:155904306	KIAA0907	-0.65	-6.5	-0.47	1.07e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.95	12.68	0.72	1.38e-25	Menarche (age at onset);
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg12193833	chr17:30244370	NA	-0.63	-5.36	-0.4	3.08e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg15847926	chr7:2749597	AMZ1	-0.42	-5.06	-0.38	1.18e-6	Height;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.67	7.07	0.5	5.16e-11	Mean corpuscular volume;
PAAD	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg24466277	chr1:23519622	HTR1D	0.57	5.39	0.4	2.65e-7	Height;
PAAD	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1519814	0.956	rs4369033	chr8:121138921	C/A	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.16e-12	Total cholesterol levels;
PAAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.24	14.46	0.76	2.36e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.83	-8.86	-0.58	1.94e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26876637	chr1:152193138	HRNR	0.89	6.91	0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.68	-0.36	6.18e-6	Aortic root size;
PAAD	cis	rs3764400	0.506	rs2036521	chr17:46328976	T/G	cg10706073	chr17:46328419	SKAP1	-1.09	-6.31	-0.46	2.86e-9	Body mass index;
PAAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	6.88	0.49	1.45e-10	Mood instability;
PAAD	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.38	-0.51	9.42e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.37	0.4	2.92e-7	Male-pattern baldness;
PAAD	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.03	-10.41	-0.65	1.7e-19	Chronic sinus infection;
PAAD	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.43	4.42	0.34	1.87e-5	Sarcoidosis;
PAAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs11892454	0.544	rs34921778	chr2:26011810	A/G	cg25181710	chr2:26045287	ASXL2	0.43	5.01	0.38	1.48e-6	Heschl's gyrus morphology;
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.45	-4.49	-0.34	1.41e-5	Tonsillectomy;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20203089	chr10:104155504	NFKB2	-0.66	-6.32	-0.46	2.69e-9	Lung cancer in ever smokers;
PAAD	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.09	0.38	1.03e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.64	-8.41	-0.56	2.72e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.2	5.95	0.43	1.81e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs17592366	0.517	rs10148967	chr14:35283744	G/A	cg09327582	chr14:35236912	BAZ1A	0.56	5.14	0.38	8.32e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.78	7.51	0.52	4.67e-12	Cognitive function;
PAAD	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg12700464	chr11:78128424	GAB2	0.59	4.31	0.33	2.98e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg15816464	chr17:2026533	SMG6	-0.52	-5.73	-0.42	5.14e-8	Total body bone mineral density;
PAAD	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.56	4.83	0.36	3.34e-6	Large artery stroke;
PAAD	cis	rs35955747	0.934	rs4820045	chr22:31785969	G/A	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.74	-0.36	4.96e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg00738919	chr7:1100172	C7orf50	0.69	5.24	0.39	5.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg03676636	chr4:99064102	C4orf37	0.32	4.82	0.36	3.4e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19355881	chr6:34759549	UHRF1BP1	0.55	6.29	0.45	3.26e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.64	6.35	0.46	2.38e-9	Platelet count;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00149659	chr3:10157352	C3orf10	0.55	4.35	0.33	2.53e-5	Alzheimer's disease;
PAAD	cis	rs28830936	1.000	rs11629678	chr15:41932530	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.56	-6.59	-0.47	6.8e-10	Diastolic blood pressure;
PAAD	cis	rs9815354	1.000	rs9839399	chr3:41928044	G/A	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg20243544	chr17:37824526	PNMT	0.56	5.08	0.38	1.1e-6	Self-reported allergy;
PAAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.47	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.65	-6.56	-0.47	8.05e-10	Ankylosing spondylitis;
PAAD	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09318120	chr6:149638382	MAP3K7IP2	0.62	6.36	0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-5.02	-0.38	1.46e-6	Testicular germ cell tumor;
PAAD	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg05484376	chr2:27715224	FNDC4	0.45	4.44	0.34	1.7e-5	Oral cavity cancer;
PAAD	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.79	0.36	3.94e-6	Depression;
PAAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg21395723	chr22:39101663	GTPBP1	0.4	4.32	0.33	2.8e-5	Menopause (age at onset);
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13357455	chr5:134240501	PCBD2	0.71	7.76	0.53	1.13e-12	Myopia (pathological);
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg27121462	chr16:89883253	FANCA	0.47	5.08	0.38	1.09e-6	Vitiligo;
PAAD	cis	rs1015291	0.708	rs2417811	chr12:20009432	A/T	cg25401612	chr12:20009446	NA	-0.54	-5.35	-0.4	3.12e-7	Diastolic blood pressure;
PAAD	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.49	-4.94	-0.37	2.02e-6	Severe influenza A (H1N1) infection;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg14537953	chr2:113808683	IL1F8	0.6	6.36	0.46	2.26e-9	Educational attainment (years of education);
PAAD	cis	rs847851	0.958	rs7753949	chr6:34882394	C/T	cg05379947	chr6:35436047	RPL10A	0.52	4.47	0.34	1.54e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs354225	0.544	rs4455200	chr2:54801591	T/A	cg01766943	chr2:54829624	SPTBN1	0.53	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.93	10.07	0.63	1.37e-18	Breast cancer;
PAAD	cis	rs6594713	0.577	rs10078214	chr5:112915702	A/C	cg12552261	chr5:112820674	MCC	0.63	5.44	0.4	2.1e-7	Brain cytoarchitecture;
PAAD	cis	rs4764124	0.556	rs247346	chr12:14914886	A/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.49	5.41	0.4	2.38e-7	Pubertal anthropometrics;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.67	0.53	1.95e-12	Prudent dietary pattern;
PAAD	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg08523384	chr5:141488047	NDFIP1	-0.64	-5.8	-0.43	3.71e-8	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18382590	chr9:131219195	ODF2	0.69	8.24	0.56	7.37e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6834538	0.597	rs2087111	chr4:113536080	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-5.34	-0.4	3.31e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07362569	chr17:61921086	SMARCD2	-0.5	-6.06	-0.44	1.05e-8	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.62	0.35	8.03e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg01099526	chr6:26124504	HIST1H2AC;HIST1H2BC	0.78	4.42	0.34	1.9e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-4.52	-0.34	1.25e-5	Coronary artery disease;
PAAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg11494091	chr17:61959527	GH2	0.51	4.32	0.33	2.76e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1539053	0.932	rs1404384	chr1:58109829	A/G	cg00026909	chr1:58089001	DAB1	0.63	7.02	0.49	6.79e-11	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg12935359	chr14:103987150	CKB	-0.72	-8.31	-0.56	4.87e-14	Body mass index;
PAAD	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg03264133	chr6:25882463	NA	-0.53	-4.25	-0.33	3.74e-5	Homocysteine levels;
PAAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg03959625	chr15:84868606	LOC388152	-0.46	-4.96	-0.37	1.84e-6	P wave terminal force;
PAAD	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.03	-16.67	-0.8	3.81e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.63	6.06	0.44	1.03e-8	IgG glycosylation;
PAAD	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg04920474	chr2:44395004	PPM1B	0.44	4.3	0.33	3.02e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.33	10.83	0.66	1.29e-20	Uric acid levels;
PAAD	cis	rs4621152	0.737	rs2888451	chr2:217904513	G/C	cg21875423	chr2:217559867	IGFBP5	-0.45	-4.47	-0.34	1.51e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.71	7.29	0.51	1.6e-11	Menarche (age at onset);
PAAD	cis	rs10186876	0.541	rs11124953	chr2:44191555	G/A	cg09541576	chr2:44873248	C2orf34	0.44	4.39	0.34	2.09e-5	Hand grip strength;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.68	0.48	4.34e-10	Height;
PAAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg14343924	chr8:8086146	FLJ10661	0.58	5.09	0.38	1.04e-6	Mood instability;
PAAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.67	7.39	0.51	9.25e-12	Melanoma;
PAAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.73	-5.98	-0.44	1.53e-8	Neuroticism;
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-5.97	-0.44	1.6e-8	Lung cancer;
PAAD	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.21e-6	Airway imaging phenotypes;
PAAD	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.78e-5	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08100565	chr3:140660748	SLC25A36	0.67	6.74	0.48	3.12e-10	Obesity-related traits;
PAAD	cis	rs7925908	0.659	rs4245100	chr11:131158907	A/G	cg13391028	chr11:130657123	NA	0.36	4.27	0.33	3.36e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);Glucocorticoid-induced osteonecrosis (time dependent analysis);
PAAD	cis	rs80346118	0.810	rs6095301	chr20:47428165	C/A	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.6	-4.39	-0.34	2.12e-5	Diastolic blood pressure;
PAAD	cis	rs10768122	1.000	rs12796856	chr11:35294797	C/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.28	-0.33	3.25e-5	Vitiligo;
PAAD	cis	rs3096299	0.629	rs12929744	chr16:89493580	G/C	cg26546229	chr16:89385611	ANKRD11	-0.48	-4.27	-0.33	3.47e-5	Multiple myeloma (IgH translocation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08914378	chr7:98923334	ARPC1A	0.58	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.52	6.07	0.44	9.78e-9	Multiple system atrophy;
PAAD	trans	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg14171944	chr9:126323477	DENND1A	0.54	6.49	0.47	1.13e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-5.63	-0.42	8.34e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs7646881	0.904	rs112493023	chr3:158448276	A/G	cg19483011	chr3:158453295	NA	-0.62	-5.27	-0.39	4.5e-7	Tetralogy of Fallot;
PAAD	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.48	5.05	0.38	1.27e-6	Schizophrenia;
PAAD	cis	rs6137287	0.847	rs2024937	chr20:21116302	A/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.28	0.33	3.33e-5	Height;
PAAD	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.02	-0.38	1.41e-6	Schizophrenia;
PAAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.56	-7.06	-0.5	5.64e-11	Lewy body disease;
PAAD	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.59	5.45	0.4	1.95e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.94	10.16	0.64	7.67e-19	Blood metabolite levels;
PAAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.42	5.58	0.41	1.1e-7	Alcohol dependence;
PAAD	cis	rs2555155	0.806	rs10769697	chr11:6547407	A/G	cg24637308	chr11:6592297	DNHD1	-0.47	-4.9	-0.37	2.46e-6	DNA methylation (variation);
PAAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg07527105	chr16:88053339	BANP	-0.44	-4.42	-0.34	1.85e-5	Menopause (age at onset);
PAAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.79	-9.19	-0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.66	-7.07	-0.5	5.21e-11	Aortic root size;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs757110	1.000	rs757110	chr11:17418477	C/A	cg04705435	chr11:17411270	KCNJ11	0.62	6.24	0.45	4.12e-9	Type 2 diabetes;
PAAD	cis	rs4455778	0.561	rs13243449	chr7:49129765	T/C	cg26309511	chr7:48887640	NA	0.39	4.82	0.36	3.5e-6	Lung cancer in never smokers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16876647	chr2:43451842	ZFP36L2	-0.61	-6.77	-0.48	2.67e-10	Smoking initiation;
PAAD	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg06697600	chr4:7070879	GRPEL1	0.88	4.45	0.34	1.66e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.41	-8.62	-0.57	7.95e-15	Mean corpuscular volume;
PAAD	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.7	6.95	0.49	1.01e-10	Lymphocyte counts;
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.44	0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg26248373	chr2:1572462	NA	-0.94	-6.11	-0.44	8.01e-9	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.55	-5.25	-0.39	4.99e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2309322	0.622	rs2309319	chr4:181239313	C/T	cg02185053	chr8:130952137	FAM49B	-0.81	-6.34	-0.46	2.44e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00049323	chr5:472564	LOC25845	-0.42	-4.95	-0.37	1.99e-6	Cystic fibrosis severity;
PAAD	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.48	11.59	0.68	1.16e-22	Atopic dermatitis;
PAAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.41	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.59	-4.27	-0.33	3.37e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg21546286	chr11:48923668	NA	-0.55	-5.68	-0.42	6.74e-8	HDL cholesterol;
PAAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.73	-8.7	-0.58	5.2e-15	Diastolic blood pressure;
PAAD	cis	rs59888335	1.000	rs12638412	chr3:80752361	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.73e-6	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs9469890	0.591	rs11754773	chr6:34577257	A/G	cg17674042	chr6:34482479	PACSIN1	-0.68	-4.38	-0.33	2.24e-5	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-0.98	-4.75	-0.36	4.69e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-7.12	-0.5	3.95e-11	Menarche (age at onset);
PAAD	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.49	0.34	1.39e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg26031613	chr14:104095156	KLC1	1.16	16.35	0.8	2.52e-35	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03931078	chr17:66453919	WIPI1	0.57	6.47	0.46	1.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.66	7.31	0.51	1.38e-11	Schizophrenia;
PAAD	cis	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg27395922	chr11:50257633	LOC441601	-0.47	-4.75	-0.36	4.74e-6	Coronary artery disease;
PAAD	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.72	-5.93	-0.43	1.96e-8	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.65	-9.96	-0.63	2.65e-18	Asthma (sex interaction);
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs41311933	1.000	rs41311863	chr9:123757620	G/C	cg13567360	chr9:123745713	C5	-0.72	-4.51	-0.34	1.31e-5	Coronary artery disease;
PAAD	cis	rs2279817	0.863	rs74061958	chr1:18015918	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.83	-0.43	3.26e-8	Neuroticism;
PAAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.23	-0.39	5.56e-7	Mean corpuscular volume;
PAAD	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg19337854	chr7:99768885	GPC2	0.46	4.27	0.33	3.43e-5	Platelet count;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg03289416	chr15:75166202	SCAMP2	0.52	5.69	0.42	6.41e-8	Breast cancer;
PAAD	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17710535	chr19:10819994	QTRT1	0.48	4.28	0.33	3.25e-5	Inflammatory skin disease;
PAAD	cis	rs4509693	0.882	rs7920113	chr10:102493848	A/T	cg24179445	chr10:102496915	NA	0.53	5.59	0.41	1.02e-7	Alzheimer's disease;
PAAD	cis	rs2252790	0.859	rs1204823	chr6:116563767	C/A	cg26893134	chr6:116381904	FRK	-0.29	-4.53	-0.35	1.17e-5	Fast beta electroencephalogram;
PAAD	cis	rs11016883	0.557	rs1978757	chr10:131502314	G/A	cg14312783	chr10:131504572	MGMT	0.51	5.25	0.39	5.11e-7	Waist-to-hip circumference ratio (ever vs never smoking interaction);
PAAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.04	0.38	1.29e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11811982	0.793	rs77783161	chr1:227490374	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.68	-6.74	-0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg10437265	chr15:77819839	NA	-0.38	-4.3	-0.33	3.01e-5	Type 2 diabetes;
PAAD	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs12295403	0.691	rs11607934	chr11:18689168	C/T	cg07538406	chr11:18686895	NA	-0.46	-4.29	-0.33	3.12e-5	Ovarian reserve;
PAAD	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	10.57	0.65	6.45e-20	Nonalcoholic fatty liver disease;
PAAD	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.65	-6.88	-0.49	1.43e-10	IgG glycosylation;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg17372223	chr3:52568218	NT5DC2	0.53	5.36	0.4	2.98e-7	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg05110241	chr16:68378359	PRMT7	-1.14	-8.25	-0.56	6.97e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12935418	0.672	rs2602423	chr16:81042028	G/T	cg16651780	chr16:81037892	C16orf61	-0.68	-6.48	-0.47	1.19e-9	Mean corpuscular volume;
PAAD	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.62	0.41	8.85e-8	Carotid intima media thickness;
PAAD	cis	rs10901513	0.861	rs10901496	chr10:127673483	G/C	cg22975853	chr10:127789788	ADAM12	0.43	4.65	0.35	7.3e-6	Visceral fat;
PAAD	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.59	-5.43	-0.4	2.17e-7	Blood metabolite levels;
PAAD	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg27489772	chr12:121021490	NA	-0.57	-5.07	-0.38	1.16e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.23	0.45	4.43e-9	Coffee consumption (cups per day);
PAAD	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.54	5.31	0.4	3.85e-7	Asthma;
PAAD	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.72	-0.42	5.48e-8	Mood instability;
PAAD	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.98	-12.68	-0.72	1.32e-25	Coronary artery disease;
PAAD	cis	rs7216064	0.813	rs12601919	chr17:65825374	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-5.66	-0.42	7.48e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs3905000	1.000	rs62568179	chr9:107643786	G/A	cg25813864	chr17:38334176	RAPGEFL1	0.87	6.51	0.47	1.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.79	4.89	0.37	2.5e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-0.97	-6.47	-0.46	1.3e-9	Post bronchodilator FEV1;
PAAD	cis	rs2075671	0.818	rs10953302	chr7:100365567	C/T	cg00334542	chr7:100209784	MOSPD3	-0.64	-4.65	-0.35	7.22e-6	Other erythrocyte phenotypes;
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg01097406	chr16:89675127	NA	-0.37	-4.55	-0.35	1.07e-5	Vitiligo;
PAAD	cis	rs2115386	0.717	rs8108661	chr19:7204619	A/C	cg09779027	chr19:7224513	INSR	0.47	4.77	0.36	4.32e-6	Diabetic retinopathy;
PAAD	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.59	5.18	0.39	6.99e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg15123519	chr2:136567270	LCT	-0.37	-4.51	-0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg09760422	chr2:128146352	NA	-0.45	-7.81	-0.53	8.83e-13	Protein C levels;
PAAD	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	5.05	0.38	1.27e-6	Blood protein levels;
PAAD	cis	rs2133450	0.712	rs35202421	chr3:7365899	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs59888335	0.858	rs6419743	chr3:80990477	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs959260	1.000	rs4789180	chr17:73374396	G/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg02230254	chr11:65586170	NA	-0.34	-5.04	-0.38	1.3e-6	Eosinophil percentage of white cells;
PAAD	cis	rs3018712	0.616	rs1893679	chr11:68450330	G/C	cg23009355	chr11:68451396	GAL	-0.52	-5.77	-0.42	4.34e-8	Total body bone mineral density;
PAAD	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.99	14.02	0.75	3.4e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs6674176	0.611	rs2428964	chr1:44372827	C/T	cg12908607	chr1:44402522	ARTN	-0.67	-4.59	-0.35	9.21e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.45	4.92	0.37	2.27e-6	Life satisfaction;
PAAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.67	0.58	6.13e-15	Platelet count;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18462168	chr15:22892545	CYFIP1	0.58	6.39	0.46	1.9e-9	Response to antipsychotic treatment;
PAAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.56	0.65	6.64e-20	Smoking behavior;
PAAD	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.47	4.52	0.34	1.22e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.83	-8.86	-0.58	1.94e-15	Body mass index;
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.64	6.63	0.47	5.48e-10	Resting heart rate;
PAAD	cis	rs1499972	0.941	rs62264783	chr3:117658033	G/A	cg07612923	chr3:117604196	NA	1.08	7.22	0.51	2.32e-11	Schizophrenia;
PAAD	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.56	-5.17	-0.39	7.36e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.6	4.47	0.34	1.53e-5	Neuroblastoma;
PAAD	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg08562672	chr19:21860753	NA	-0.45	-4.8	-0.36	3.68e-6	Pain;
PAAD	cis	rs11264213	1.000	rs11264211	chr1:36270607	A/G	cg27506609	chr1:36549197	TEKT2	0.69	4.73	0.36	5.01e-6	Schizophrenia;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	6.33	0.46	2.59e-9	Cognitive test performance;
PAAD	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.77	7.01	0.49	7.28e-11	Breast cancer;
PAAD	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.45	-0.34	1.68e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.56e-11	Retinal vascular caliber;
PAAD	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.66	5.64	0.42	7.93e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.45	-4.31	-0.33	2.95e-5	Multiple sclerosis;
PAAD	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.31	0.4	3.86e-7	Bipolar disorder;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18357526	chr6:26021779	HIST1H4A	0.68	6.65	0.47	4.9e-10	Blood metabolite levels;
PAAD	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.95	9.44	0.61	6.19e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.68	-0.48	4.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg09659197	chr4:152720779	NA	0.46	6.2	0.45	5.09e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12712415	chr6:91296969	MAP3K7	0.42	4.49	0.34	1.4e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.41	-4.33	-0.33	2.73e-5	Aortic root size;
PAAD	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg16964102	chr10:135390573	NA	-0.41	-4.34	-0.33	2.59e-5	Obesity-related traits;
PAAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.5	-5.45	-0.4	2.02e-7	Platelet distribution width;
PAAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg02117656	chr17:79614917	TSPAN10	0.54	5.43	0.4	2.17e-7	Eye color traits;
PAAD	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg10556349	chr10:835070	NA	0.6	4.97	0.37	1.77e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.87	0.37	2.78e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.77	-9.19	-0.6	2.83e-16	White blood cell count (basophil);
PAAD	cis	rs6694270	0.529	rs11261065	chr1:19106254	A/C	cg26220594	chr1:19110978	NA	-0.64	-5.31	-0.4	3.85e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10376725	chr14:64009472	PPP2R5E	0.57	6.62	0.47	5.93e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.48	4.47	0.34	1.49e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	1.57	9.72	0.62	1.15e-17	Age-related hearing impairment;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.62e-6	Cognitive function;
PAAD	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.67	-4.73	-0.36	5.17e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.908	rs6978877	chr7:12232690	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08893839	chr5:154027129	NA	0.76	5.78	0.42	4.01e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3996993	0.509	rs11752938	chr6:52675433	C/T	cg00536792	chr6:53530503	KLHL31	-0.42	-4.45	-0.34	1.68e-5	Hemoglobin concentration;
PAAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.49	-5.4	-0.4	2.55e-7	Insulin-like growth factors;
PAAD	cis	rs11264213	0.892	rs11263828	chr1:36298872	G/C	cg27506609	chr1:36549197	TEKT2	0.71	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs412050	0.547	rs112153746	chr22:22138691	G/A	cg17089214	chr22:22089827	YPEL1	0.67	4.54	0.35	1.12e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.7	8.26	0.56	6.47e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg13175981	chr1:150552382	MCL1	0.54	5.14	0.38	8.43e-7	Tonsillectomy;
PAAD	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg26816564	chr1:7831052	VAMP3	0.95	8.15	0.55	1.24e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6580110	0.793	rs9324792	chr5:154078564	A/G	cg05212464	chr5:154071076	NA	0.48	5.17	0.39	7.14e-7	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg04398451	chr17:18023971	MYO15A	-0.82	-9.2	-0.6	2.69e-16	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03881961	chr11:129939817	APLP2	-0.61	-6.37	-0.46	2.15e-9	Smoking initiation;
PAAD	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	1.04	12.73	0.72	1.03e-25	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.35	-0.33	2.49e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.94	-0.43	1.87e-8	Schizophrenia;
PAAD	cis	rs2493298	1.000	rs2493296	chr1:3327032	C/T	cg25052274	chr1:3321139	PRDM16	-0.55	-4.67	-0.35	6.66e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs17152411	1.000	rs17152374	chr10:126592644	T/C	cg07906193	chr10:126599966	NA	0.74	5.81	0.43	3.5e-8	Height;
PAAD	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg23254163	chr1:152506842	NA	0.6	6.92	0.49	1.19e-10	Hair morphology;
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.44	4.88	0.37	2.63e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg21395723	chr22:39101663	GTPBP1	0.44	4.58	0.35	9.81e-6	Menopause (age at onset);
PAAD	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.6	6.54	0.47	8.72e-10	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg15117754	chr3:10150083	C3orf24	-0.72	-6.21	-0.45	4.72e-9	Alzheimer's disease;
PAAD	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.37	-4.58	-0.35	9.58e-6	Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.94e-7	Alzheimer's disease;
PAAD	cis	rs12612619	0.732	rs3754734	chr2:27299598	G/T	cg00617064	chr2:27272375	NA	-0.56	-6.05	-0.44	1.1e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg22587600	chr2:46883368	NA	0.33	4.59	0.35	9.39e-6	Height;
PAAD	cis	rs7178572	0.568	rs7177533	chr15:77387923	C/T	cg22256960	chr15:77711686	NA	-0.54	-4.74	-0.36	4.95e-6	Type 2 diabetes;
PAAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.26	18.71	0.84	2.82e-41	IgG glycosylation;
PAAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.46	4.82	0.36	3.45e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25635316	chr7:23637023	CCDC126	0.55	6.52	0.47	9.69e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.4	-0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg00614314	chr15:82944287	LOC80154	-0.5	-5.04	-0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg18551225	chr6:44695536	NA	-0.64	-6.05	-0.44	1.08e-8	Total body bone mineral density;
PAAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg01620082	chr3:125678407	NA	-1.0	-7.33	-0.51	1.29e-11	Depression;
PAAD	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg18833306	chr6:118973337	C6orf204	0.52	5.66	0.42	7.25e-8	Electrocardiographic conduction measures;
PAAD	cis	rs288342	0.763	rs288239	chr2:183645816	C/G	cg02625481	chr2:183667124	NA	-0.46	-4.55	-0.35	1.08e-5	Recurrent major depressive disorder;
PAAD	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14813579	chr19:2328694	SPPL2B;LSM7	0.69	6.45	0.46	1.42e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.0	0.59	8.53e-16	Hemoglobin concentration;
PAAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.35	0.33	2.5e-5	Aortic root size;
PAAD	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.83	8.61	0.57	8.61e-15	Itch intensity from mosquito bite;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.85	-5.79	-0.43	3.9e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.92	-9.22	-0.6	2.38e-16	Strep throat;
PAAD	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg14583973	chr4:3374767	RGS12	-0.36	-5.49	-0.41	1.64e-7	Mean platelet volume;
PAAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.79	9.34	0.6	1.11e-16	Lewy body disease;
PAAD	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs2278796	0.918	rs11240324	chr1:204955319	G/A	cg04862289	chr1:204966208	NFASC	0.43	4.33	0.33	2.71e-5	Mean platelet volume;
PAAD	cis	rs3996993	0.703	rs4715323	chr6:52649246	T/G	cg20803780	chr6:52668592	GSTA1	-0.34	-4.26	-0.33	3.55e-5	Hemoglobin concentration;
PAAD	cis	rs61861422	0.516	rs12416102	chr10:134456648	G/T	cg20090690	chr10:134436459	INPP5A	0.6	5.23	0.39	5.46e-7	Primary sclerosing cholangitis;
PAAD	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg21269045	chr12:125625041	AACS	-0.45	-4.5	-0.34	1.37e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs9907295	0.591	rs4325615	chr17:34153383	G/A	cg19411729	chr17:34207663	CCL5	-0.53	-4.74	-0.36	4.92e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg16876255	chr19:9731953	ZNF561	0.94	4.42	0.34	1.85e-5	Pursuit maintenance gain;
PAAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.88	10.22	0.64	5.4e-19	Multiple system atrophy;
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.83	8.81	0.58	2.71e-15	DNA methylation (variation);
PAAD	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.73	7.56	0.52	3.55e-12	Body mass index;
PAAD	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	1.15	7.79	0.53	9.97e-13	Pediatric areal bone mineral density (radius);
PAAD	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.88	9.54	0.61	3.39e-17	Height;
PAAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09826364	chr7:158789723	NA	-0.37	-4.64	-0.35	7.55e-6	Facial morphology (factor 20);
PAAD	cis	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.31	-0.4	3.78e-7	Mononucleosis;
PAAD	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.5	-0.34	1.33e-5	Breast cancer;
PAAD	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16262614	chr3:133464971	TF	0.49	5.44	0.4	2.08e-7	Iron status biomarkers;
PAAD	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg14146966	chr2:61757674	XPO1	-0.38	-4.63	-0.35	7.65e-6	Tuberculosis;
PAAD	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.56	4.46	0.34	1.56e-5	Bone mineral density (spine);
PAAD	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg06637938	chr14:75390232	RPS6KL1	0.46	4.53	0.34	1.21e-5	Height;
PAAD	cis	rs12773846	0.537	rs12768101	chr10:126275630	C/T	cg04949429	chr10:126290192	LHPP	0.51	4.73	0.36	5.06e-6	Subcutaneous adipose tissue;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00152838	chr16:24741724	TNRC6A	-0.51	-4.34	-0.33	2.59e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg11062466	chr8:58055876	NA	0.68	4.8	0.36	3.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	5.85	0.43	2.91e-8	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.63	5.16	0.39	7.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.76	-10.23	-0.64	5.2e-19	Iron status biomarkers;
PAAD	cis	rs8077889	0.750	rs80053172	chr17:41936843	C/T	cg26893861	chr17:41843967	DUSP3	0.86	6.2	0.45	5.2e-9	Triglycerides;
PAAD	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg03538708	chr1:25844672	NA	0.52	5.26	0.39	4.89e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14019695	chr9:139328340	INPP5E	0.51	4.99	0.38	1.6e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8060686	0.858	rs9931366	chr16:67725347	C/G	cg05110241	chr16:68378359	PRMT7	-0.71	-4.95	-0.37	1.91e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.32	-0.33	2.81e-5	Type 2 diabetes;
PAAD	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	1.0	11.28	0.67	8.13e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg23024343	chr7:107201750	COG5	0.52	4.41	0.34	1.96e-5	Coronary artery disease;
PAAD	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg21361702	chr7:150065534	REPIN1	0.59	5.17	0.39	7.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.63	-7.15	-0.5	3.32e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg00806245	chr18:76673096	NA	-0.83	-5.83	-0.43	3.21e-8	Obesity-related traits;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.95	-8.49	-0.57	1.76e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg06042504	chr8:55087323	NA	-0.61	-5.89	-0.43	2.42e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.64	-0.35	7.48e-6	Mood instability;
PAAD	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg18128536	chr17:47092178	IGF2BP1	0.39	4.33	0.33	2.74e-5	Type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.29	0.56	5.61e-14	Menopause (age at onset);
PAAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg05895507	chr15:77155635	SCAPER	0.37	4.51	0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs10159528	0.691	rs7919936	chr10:87463258	C/A	cg03356747	chr10:88126089	GRID1	-0.38	-4.39	-0.34	2.07e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9337951	0.636	rs2487928	chr10:30323892	C/T	cg27036936	chr10:30305021	KIAA1462	0.39	4.49	0.34	1.41e-5	Pulse pressure;Coronary artery disease;
PAAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.59	5.34	0.4	3.26e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg22143856	chr6:28129313	ZNF389	0.65	5.11	0.38	9.57e-7	Depression;
PAAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	7.41	0.51	8.32e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg05342682	chr7:94953680	PON1	-0.52	-4.65	-0.35	7.07e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14201635	chr9:124030411	GSN	0.6	6.52	0.47	1e-9	Myopia (pathological);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23129613	chr7:150065255	REPIN1	0.62	7.14	0.5	3.68e-11	Metabolite levels  (X-11787);
PAAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.32	0.4	3.71e-7	Fat distribution (HIV);
PAAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.6	6.7	0.48	3.77e-10	Carotid intima media thickness;
PAAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.95	-13.21	-0.73	5.26e-27	Height;
PAAD	cis	rs656900	0.715	rs673079	chr15:80115406	G/A	cg02196730	chr15:80188777	MTHFS	-0.46	-4.82	-0.36	3.45e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.27	0.51	1.76e-11	Alzheimer's disease;
PAAD	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.98	8.63	0.57	7.52e-15	Bipolar disorder;
PAAD	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.58	5.99	0.44	1.48e-8	Bladder cancer;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.57	-7.74	-0.53	1.26e-12	Height;
PAAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.66	8.04	0.55	2.36e-13	Bone mineral density;
PAAD	cis	rs1468734	1.000	rs12919777	chr16:5004839	A/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26200001	chr6:56955042	ZNF451	-0.57	-6.45	-0.46	1.41e-9	Smoking initiation;
PAAD	cis	rs3736485	0.816	rs12443362	chr15:51874542	C/A	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg01444801	chr10:135216882	MTG1	0.59	5.38	0.4	2.82e-7	Systemic lupus erythematosus;
PAAD	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg06074448	chr4:187884817	NA	-0.65	-8.27	-0.56	6.14e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.78	-6.47	-0.46	1.25e-9	Lung disease severity in cystic fibrosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23291754	chr4:71767977	MOBKL1A	-0.63	-6.33	-0.46	2.66e-9	Smoking initiation;
PAAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.87	9.32	0.6	1.3e-16	Parkinson's disease;
PAAD	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.78	8.44	0.57	2.29e-14	Sudden cardiac arrest;
PAAD	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.61	-5.54	-0.41	1.32e-7	Red blood cell count;
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.34	-0.46	2.48e-9	Testicular germ cell tumor;
PAAD	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.55	-5.29	-0.39	4.11e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.83	-10.62	-0.65	4.85e-20	Breast cancer;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.9	6.56	0.47	8.16e-10	Alzheimer's disease;
PAAD	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg08992911	chr2:238395768	MLPH	0.66	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.57	5.7	0.42	6.17e-8	Resistin levels;
PAAD	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.7	-7.82	-0.54	8.01e-13	Eosinophil percentage of white cells;
PAAD	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.44	-0.4	2.09e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9810890	1.000	rs6796031	chr3:128593259	G/A	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-4.93	-0.37	2.16e-6	Schizophrenia (age at onset);
PAAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.47	5.38	0.4	2.77e-7	Testicular germ cell tumor;
PAAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.72	-9.01	-0.59	7.95e-16	Breast cancer;
PAAD	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.45	4.58	0.35	9.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.61	-8.8	-0.58	2.81e-15	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.5	-0.34	1.35e-5	Testicular germ cell tumor;
PAAD	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg25276700	chr6:44698697	NA	-0.4	-5.05	-0.38	1.25e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.78	0.48	2.48e-10	Platelet count;
PAAD	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.32e-7	Noise-induced hearing loss;
PAAD	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg01305830	chr4:1604576	NA	-0.49	-4.73	-0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg01942863	chr7:99769432	GPC2	0.48	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.49	-0.47	1.15e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.91	-0.54	4.96e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.84	7.94	0.54	4.22e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg18833306	chr6:118973337	C6orf204	0.42	4.41	0.34	1.92e-5	Electrocardiographic conduction measures;
PAAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.58	6.25	0.45	3.85e-9	Lung cancer;
PAAD	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg15192750	chr16:69999425	NA	0.81	6.36	0.46	2.27e-9	IgE levels;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.56	-7.18	-0.5	2.86e-11	Schizophrenia;
PAAD	cis	rs9333029	0.524	rs6659505	chr1:47380387	T/C	cg08644498	chr1:46502608	NA	-0.47	-4.33	-0.33	2.73e-5	Blood metabolite levels;
PAAD	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	8.23	0.56	7.97e-14	Neuroticism;
PAAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.77	-0.42	4.3e-8	Gut microbiome composition (summer);
PAAD	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.82	8.99	0.59	9.35e-16	Asperger disorder;
PAAD	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg20636351	chr8:55087400	NA	-0.75	-7.78	-0.53	1.06e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg07636037	chr3:49044803	WDR6	0.55	4.41	0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.35	5.42	0.4	2.32e-7	Schizophrenia;
PAAD	cis	rs258892	0.895	rs13174766	chr5:72057135	C/T	cg21869765	chr5:72125136	TNPO1	-0.79	-5.28	-0.39	4.39e-7	Small cell lung carcinoma;
PAAD	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg22875332	chr1:76189707	ACADM	0.52	5.12	0.38	8.97e-7	Daytime sleep phenotypes;
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Subjective well-being;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.87	0.58	1.84e-15	Lung cancer;
PAAD	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.51	-6.18	-0.45	5.58e-9	Iron status biomarkers;
PAAD	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg07506560	chr2:240697449	NA	0.6	6.22	0.45	4.52e-9	Obesity-related traits;
PAAD	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg03004497	chr11:58874207	FAM111B	-0.52	-4.39	-0.34	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.51	-4.61	-0.35	8.47e-6	Lung cancer;
PAAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.65	9.13	0.6	4.01e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg24642844	chr7:1081250	C7orf50	0.58	4.56	0.35	1.04e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg11812906	chr14:75593930	NEK9	0.51	5.04	0.38	1.33e-6	Caffeine consumption;
PAAD	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg02725872	chr8:58115012	NA	-0.6	-5.16	-0.39	7.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.9	-0.43	2.25e-8	Gut microbiome composition (summer);
PAAD	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.28	-5.04	-0.38	1.31e-6	Type 2 diabetes;
PAAD	cis	rs12136530	0.550	rs3790768	chr1:19698501	G/T	cg25104613	chr1:20649108	VWA5B1	-0.44	-4.93	-0.37	2.13e-6	Lead levels in blood;
PAAD	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.68	-0.35	6.37e-6	Height;
PAAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.64	5.27	0.39	4.65e-7	Schizophrenia;
PAAD	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg08632701	chr21:37451849	NA	-0.63	-6.91	-0.49	1.27e-10	Mitral valve prolapse;
PAAD	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg01620082	chr3:125678407	NA	0.92	6.64	0.47	5.21e-10	Depression;
PAAD	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg20243544	chr17:37824526	PNMT	-0.52	-4.46	-0.34	1.58e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs797680	0.856	rs11164902	chr1:93778794	A/G	cg04535902	chr1:92947332	GFI1	0.45	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.77	0.42	4.27e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.83	-8.79	-0.58	2.95e-15	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.86	10.55	0.65	7.15e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06002616	chr8:101225028	SPAG1	-0.48	-5.66	-0.42	7.45e-8	Atrioventricular conduction;
PAAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	trans	rs901683	1.000	rs79752400	chr10:46072088	G/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg10556349	chr10:835070	NA	0.6	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.74	7.86	0.54	6.44e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.74	0.58	3.97e-15	Parkinson's disease;
PAAD	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg19792802	chr11:65647270	CTSW	0.54	6.03	0.44	1.17e-8	Crohn's disease;
PAAD	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.81	5.97	0.44	1.6e-8	Vitiligo;
PAAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.06	0.55	2.05e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.8	-0.48	2.27e-10	Lung cancer;
PAAD	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.14	0.6	3.75e-16	Hemoglobin concentration;
PAAD	cis	rs7873102	0.654	rs7036516	chr9:38009406	C/T	cg03528946	chr9:38069800	SHB	-0.5	-4.97	-0.37	1.77e-6	Brain structure;
PAAD	cis	rs7572263	0.959	rs7583625	chr2:209048739	A/G	cg23998903	chr2:209048830	C2orf80	-0.48	-4.55	-0.35	1.1e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.92	-12.98	-0.73	2.14e-26	Dental caries;
PAAD	cis	rs7614311	0.636	rs3774702	chr3:63856870	G/A	cg22134162	chr3:63841271	THOC7	-0.54	-4.39	-0.34	2.13e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.71	-7.88	-0.54	5.82e-13	Renal function-related traits (BUN);
PAAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11563648	0.553	rs6957320	chr7:126998210	C/T	cg13381984	chr7:127881344	LEP	-0.29	-4.32	-0.33	2.77e-5	Resting heart rate;
PAAD	cis	rs8083432	0.866	rs35195345	chr18:22702153	C/T	cg13981356	chr18:22006370	IMPACT	0.59	4.31	0.33	2.88e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.49	4.4	0.34	2.03e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs8077577	0.895	rs62072465	chr17:18114494	C/G	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.58	6.15	0.45	6.41e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.47	-0.34	1.51e-5	Mood instability;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg04154034	chr17:28927549	LRRC37B2	0.68	4.62	0.35	8.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-10.38	-0.64	2.1e-19	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-0.8	-4.89	-0.37	2.54e-6	Lung cancer;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07332563	chr6:291687	DUSP22	-0.78	-8.37	-0.56	3.57e-14	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.49	-0.41	1.65e-7	Schizophrenia;
PAAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg26497354	chr6:109612229	NA	-0.47	-4.86	-0.37	2.87e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.88e-8	HIV-1 control;
PAAD	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg12757816	chr2:10669957	NA	0.46	4.89	0.37	2.57e-6	Prostate cancer;
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg19337854	chr7:99768885	GPC2	0.48	4.4	0.34	2.07e-5	Platelet count;
PAAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg10589385	chr1:150898437	SETDB1	0.39	4.83	0.36	3.36e-6	Melanoma;
PAAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24198009	chr11:10772774	CTR9	-0.58	-6.69	-0.48	4.03e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg16576597	chr16:28551801	NUPR1	-0.66	-6.72	-0.48	3.46e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg21448613	chr3:49828315	CDH29	0.44	4.29	0.33	3.16e-5	Menarche (age at onset);
PAAD	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs12781506	chr10:46038702	T/C	cg06308084	chr22:50493570	TTLL8	0.84	6.38	0.46	2e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.7	7.96	0.54	3.71e-13	Colorectal cancer;
PAAD	cis	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	4.48	0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg02244288	chr16:89573955	SPG7	-0.35	-4.54	-0.35	1.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs2061333	0.894	rs10853771	chr19:44629448	C/T	cg18700516	chr19:44507157	ZNF230	-0.65	-4.93	-0.37	2.14e-6	Alzheimer's disease;
PAAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22162314	chr17:61951766	CSH2	-0.53	-5.46	-0.41	1.88e-7	Height;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-8.52	-0.57	1.43e-14	Morning vs. evening chronotype;
PAAD	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.61	4.89	0.37	2.6e-6	Information processing speed;
PAAD	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.14	-0.38	8.26e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg10556349	chr10:835070	NA	0.67	4.74	0.36	4.84e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.95	8.02	0.55	2.56e-13	Vitiligo;
PAAD	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg09821211	chr3:195954098	OSTalpha	-0.64	-6.04	-0.44	1.13e-8	Fat distribution (HIV);
PAAD	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1667255	0.830	rs723744	chr18:29172476	G/T	cg18808318	chr18:29669225	NA	0.49	4.68	0.35	6.27e-6	Retinol levels;
PAAD	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03352830	chr11:487213	PTDSS2	0.86	4.34	0.33	2.63e-5	Body mass index;
PAAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg13397359	chr6:42928475	GNMT	-0.7	-5.8	-0.43	3.75e-8	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12219531	chr12:120966889	COQ5	0.62	7.12	0.5	3.99e-11	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01916762	chr5:59996028	DEPDC1B	0.62	7.17	0.5	2.99e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26926768	chr12:34528122	NA	-0.38	-4.55	-0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs1497828	1.000	rs2646837	chr1:217550380	T/C	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	trans	rs3905000	1.000	rs3890182	chr9:107647655	A/G	cg25813864	chr17:38334176	RAPGEFL1	-0.86	-6.44	-0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs4523957	0.719	rs1532292	chr17:2097483	T/G	cg16513277	chr17:2031491	SMG6	-0.53	-5.52	-0.41	1.43e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg11494091	chr17:61959527	GH2	0.52	4.4	0.34	1.99e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.55	-4.92	-0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.89	9.59	0.61	2.48e-17	Corneal astigmatism;
PAAD	cis	rs13034020	0.522	rs62150970	chr2:61244410	C/G	cg18625361	chr2:61244694	PEX13;PUS10	0.6	4.47	0.34	1.54e-5	Hodgkin's lymphoma;
PAAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg16083429	chr3:49237500	CCDC36	0.46	4.42	0.34	1.9e-5	Menarche (age at onset);
PAAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12963246	chr6:28129442	ZNF389	0.58	4.66	0.35	6.82e-6	Cardiac Troponin-T levels;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.53	5.23	0.39	5.55e-7	IgG glycosylation;
PAAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23463467	chr20:60627584	TAF4	0.41	4.32	0.33	2.79e-5	Body mass index;
PAAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.49	-4.52	-0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs4144743	1.000	rs7218524	chr17:45326565	A/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.52	5.54	0.41	1.3e-7	Life satisfaction;
PAAD	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19671926	chr4:122722719	EXOSC9	0.63	6.09	0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg08738300	chr3:44038990	NA	0.72	7.21	0.5	2.41e-11	Coronary artery disease;
PAAD	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg27539214	chr16:67997921	SLC12A4	-0.67	-5.34	-0.4	3.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.49	4.66	0.35	6.89e-6	Fractional excretion of uric acid;
PAAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	0.98	13.12	0.73	9.03e-27	Eosinophil percentage of white cells;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.64	-5.85	-0.43	2.92e-8	Renal function-related traits (BUN);
PAAD	trans	rs901683	1.000	rs901684	chr10:45966628	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	5.62	0.42	8.68e-8	Cognitive test performance;
PAAD	cis	rs1346081	0.786	rs1425645	chr4:68028175	C/T	cg04398282	chr4:68424256	STAP1	0.49	4.47	0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.61	-5.77	-0.42	4.21e-8	Malaria;
PAAD	cis	rs13177180	0.600	rs256989	chr5:114911565	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.43	4.61	0.35	8.59e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.46	5.43	0.4	2.14e-7	Atrioventricular conduction;
PAAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs9846480	0.565	rs13087441	chr3:138042669	A/G	cg22141751	chr3:138766134	NA	-0.43	-4.34	-0.33	2.62e-5	Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.82	8.42	0.56	2.56e-14	Cognitive function;
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.98	-12.71	-0.72	1.1e-25	Coronary artery disease;
PAAD	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg14132834	chr19:41945861	ATP5SL	0.5	4.79	0.36	3.87e-6	Height;
PAAD	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.78	8.62	0.57	8.13e-15	Obesity-related traits;
PAAD	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg09017928	chr7:158110068	PTPRN2	0.58	5.28	0.39	4.46e-7	Response to amphetamines;
PAAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg18612461	chr15:75251733	NA	0.66	8.17	0.55	1.12e-13	Breast cancer;
PAAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.72	9.37	0.61	9.55e-17	Bone mineral density;
PAAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.74	8.27	0.56	6.17e-14	Height;
PAAD	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg05373962	chr22:49881684	NA	-0.5	-4.89	-0.37	2.56e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs3206736	0.548	rs329240	chr7:35058440	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	0.48	4.65	0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.67	0.35	6.67e-6	Self-reported allergy;
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.39	0.4	2.68e-7	Total body bone mineral density;
PAAD	trans	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg17758363	chr20:13199787	NA	-0.85	-7.24	-0.51	2.06e-11	Red blood cell count;
PAAD	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.59	5.83	0.43	3.22e-8	Type 2 diabetes;
PAAD	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.66	-7.01	-0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.76	0.42	4.57e-8	Schizophrenia;
PAAD	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.72	-0.48	3.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.54	0.41	1.33e-7	Total body bone mineral density;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	4.74	0.36	4.84e-6	Body mass index;
PAAD	cis	rs57244997	0.556	rs73030428	chr6:162437606	T/C	cg17173639	chr6:162384350	PARK2	-0.68	-5.1	-0.38	9.82e-7	Mosquito bite size;
PAAD	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	9.68	0.62	1.48e-17	Cognitive test performance;
PAAD	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-6.72	-0.48	3.42e-10	Testicular germ cell tumor;
PAAD	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.05	-0.67	3.41e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	trans	rs901683	0.850	rs117668126	chr10:46062952	G/C	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.81	0.54	8.51e-13	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.61	5.78	0.42	4.19e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg08677398	chr8:58056175	NA	0.69	4.49	0.34	1.37e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.39	-5.27	-0.39	4.68e-7	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.85	10.23	0.64	5.2e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg15017067	chr4:17643749	FAM184B	0.41	4.67	0.35	6.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg19429281	chr19:53496738	ZNF702P	-0.6	-6.36	-0.46	2.27e-9	Psoriasis;
PAAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg18057887	chr11:133800913	IGSF9B	0.59	6.02	0.44	1.29e-8	Parkinson's disease;
PAAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg05643964	chr20:62369504	LIME1	-0.53	-4.81	-0.36	3.66e-6	Prostate cancer;
PAAD	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.48	-0.47	1.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs62238980	0.522	rs62238977	chr22:32573224	G/C	cg00543991	chr22:32367038	NA	1.21	6.61	0.47	6.04e-10	Childhood ear infection;
PAAD	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg09659197	chr4:152720779	NA	-0.41	-6.09	-0.44	8.86e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg00701064	chr4:6280414	WFS1	0.78	5.97	0.44	1.62e-8	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-6.51	-0.47	1.05e-9	QT interval;
PAAD	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.7	0.36	5.75e-6	Body mass index;
PAAD	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.49	0.41	1.66e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg10556349	chr10:835070	NA	0.56	4.65	0.35	7.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs42648	0.596	rs194511	chr7:89846727	A/G	cg27367526	chr7:89841692	STEAP2	-0.32	-4.36	-0.33	2.38e-5	Homocysteine levels;
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.74	8.23	0.56	7.82e-14	Prostate cancer;
PAAD	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.47	5.18	0.39	6.87e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.4	5.93	0.43	1.99e-8	Educational attainment (years of education);
PAAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs2790216	1.000	rs2790241	chr10:60015313	G/T	cg20442379	chr10:60024634	IPMK	-0.59	-4.56	-0.35	1.06e-5	Inflammatory bowel disease;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg01831904	chr17:28903510	LRRC37B2	0.89	6.07	0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4792901	0.802	rs9893137	chr17:41590928	C/T	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg14343924	chr8:8086146	FLJ10661	-0.65	-5.55	-0.41	1.24e-7	Neuroticism;
PAAD	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.55	5.95	0.43	1.76e-8	Bladder cancer;
PAAD	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.92	7.21	0.5	2.5e-11	Iron status biomarkers;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.76	-0.48	2.75e-10	Prudent dietary pattern;
PAAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.99	10.27	0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg08886695	chr4:3369023	RGS12	0.53	4.98	0.37	1.71e-6	Parental longevity (mother's age at death);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26410557	chr11:18610422	UEVLD	-0.63	-7.69	-0.53	1.71e-12	Body fat percentage;
PAAD	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.6	5.34	0.4	3.39e-7	Coronary heart disease;
PAAD	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-5.1	-0.38	1e-6	Osteoarthritis;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Birth weight;
PAAD	cis	rs6142102	0.961	rs2056990	chr20:32623464	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.62	5.22	0.39	5.71e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg17372223	chr3:52568218	NT5DC2	-0.47	-4.58	-0.35	9.75e-6	Bipolar disorder;
PAAD	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.13	7.13	0.5	3.78e-11	Lung cancer in ever smokers;
PAAD	cis	rs432925	0.625	rs2685119	chr16:341476	T/C	cg08823186	chr16:347294	AXIN1	0.49	4.59	0.35	9.06e-6	Morning vs. evening chronotype;
PAAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.65	6.32	0.46	2.76e-9	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.63	5.0	0.38	1.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.5	-0.52	4.92e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.58	7.72	0.53	1.48e-12	Hypertriglyceridemia;
PAAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.58	-6.12	-0.44	7.65e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg05110241	chr16:68378359	PRMT7	-0.74	-5.73	-0.42	5.28e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg27057461	chr7:158136379	PTPRN2	-0.48	-4.36	-0.33	2.35e-5	Response to amphetamines;
PAAD	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.42	-4.42	-0.34	1.89e-5	Arsenic metabolism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17437930	chr7:24619232	MPP6	0.58	6.47	0.46	1.27e-9	Smoking initiation;
PAAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.65	-0.35	7.11e-6	Total body bone mineral density;
PAAD	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg24747557	chr10:131355152	MGMT	-0.5	-5.15	-0.39	7.91e-7	Response to temozolomide;
PAAD	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.66	5.36	0.4	3.08e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg10729496	chr3:10149963	C3orf24	0.83	6.81	0.48	2.17e-10	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs863345	0.604	rs1894040	chr1:158456336	C/T	cg12129480	chr1:158549410	OR10X1	0.43	4.8	0.36	3.73e-6	Pneumococcal bacteremia;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.16	-0.45	6.07e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.5	-0.34	1.33e-5	Testicular germ cell tumor;
PAAD	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg12700464	chr11:78128424	GAB2	-0.62	-4.62	-0.35	8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg00579200	chr11:133705235	NA	-0.46	-4.98	-0.37	1.7e-6	Childhood ear infection;
PAAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.18e-7	Eye color traits;
PAAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg13777783	chr17:79615861	NA	-0.42	-4.33	-0.33	2.66e-5	Eye color traits;
PAAD	cis	rs10861661	0.963	rs10861662	chr12:107178653	A/C	cg15890332	chr12:107067104	RFX4	0.47	4.42	0.34	1.9e-5	Triglyceride levels;
PAAD	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg10864074	chr7:100318194	EPO	-0.47	-4.79	-0.36	3.86e-6	Other erythrocyte phenotypes;
PAAD	cis	rs62238980	0.708	rs62238979	chr22:32577514	C/A	cg02631450	chr22:32366979	NA	1.1	5.32	0.4	3.63e-7	Childhood ear infection;
PAAD	cis	rs9677476	0.818	rs13431424	chr2:232060553	G/A	cg07929768	chr2:232055508	NA	0.39	4.3	0.33	2.98e-5	Food antigen IgG levels;
PAAD	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.55	-5.32	-0.4	3.72e-7	Mortality in heart failure;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.54	-5.81	-0.43	3.52e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9810890	1.000	rs73196983	chr3:128452500	G/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.79	7.14	0.5	3.58e-11	Obesity-related traits;
PAAD	cis	rs7301016	1.000	rs7962519	chr12:62868885	T/G	cg19781863	chr12:62918364	MON2	0.75	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.42	-6.21	-0.45	4.82e-9	Subjective well-being;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20999427	chr12:24381595	SOX5	0.61	6.37	0.46	2.18e-9	Smoking initiation;
PAAD	cis	rs9581857	0.547	rs77005033	chr13:28109793	A/G	cg22138327	chr13:27999177	GTF3A	0.8	5.33	0.4	3.46e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.7	6.84	0.49	1.82e-10	Platelet distribution width;
PAAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.66	-0.42	7.33e-8	Cystic fibrosis severity;
PAAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.48	-4.42	-0.34	1.86e-5	Tuberculosis;
PAAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg10547527	chr2:198650123	BOLL	-0.73	-5.13	-0.38	8.91e-7	Ulcerative colitis;
PAAD	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.38	-0.33	2.18e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23515686	chr4:125638274	NA	-0.62	-6.33	-0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.74	8.12	0.55	1.51e-13	Menopause (age at onset);
PAAD	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.56	5.03	0.38	1.36e-6	Dialysis-related mortality;
PAAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.46	4.33	0.33	2.7e-5	Renal cell carcinoma;
PAAD	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg05528293	chr18:74961138	GALR1	0.61	4.93	0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.61	5.82	0.43	3.44e-8	Vitamin D levels;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18337363	chr3:52569053	NT5DC2	0.43	4.3	0.33	2.99e-5	Electroencephalogram traits;
PAAD	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.72	-7.94	-0.54	4.09e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.86	-0.43	2.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.37	9.72	0.62	1.14e-17	Opioid sensitivity;
PAAD	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16799897	chr16:3208876	NA	0.58	6.59	0.47	6.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs4740619	0.619	rs7040690	chr9:16038049	G/C	cg14451791	chr9:16040625	NA	-0.45	-5.11	-0.38	9.33e-7	Body mass index;
PAAD	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.97	-10.61	-0.65	5.14e-20	Coronary artery disease;
PAAD	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg10556349	chr10:835070	NA	0.59	4.81	0.36	3.59e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7084921	0.552	rs7098331	chr10:101877961	T/G	cg04359915	chr10:101825029	CPN1	-0.28	-4.31	-0.33	2.88e-5	Bone mineral density;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14967306	chr1:231377587	GNPAT;C1orf131	-0.71	-6.52	-0.47	9.76e-10	Lung cancer in ever smokers;
PAAD	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg23283495	chr1:209979779	IRF6	0.46	5.42	0.4	2.32e-7	Monobrow;
PAAD	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.65	6.72	0.48	3.5e-10	Obesity-related traits;
PAAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.55	4.49	0.34	1.39e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.49	-6.1	-0.44	8.38e-9	Urate levels in overweight individuals;
PAAD	cis	rs747650	0.504	rs7130947	chr11:47002005	C/A	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11811982	0.793	rs77251286	chr1:227512342	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-10.61	-0.65	5e-20	Ulcerative colitis;
PAAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.85	10.97	0.66	5.41e-21	Aortic root size;
PAAD	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	4.37	0.33	2.31e-5	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs56046484	1.000	rs56046484	chr15:85605427	G/T	cg08123816	chr15:85640762	PDE8A	-0.44	-4.59	-0.35	9.31e-6	Testicular germ cell tumor;
PAAD	cis	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg21546286	chr11:48923668	NA	-0.57	-6.01	-0.44	1.3e-8	HDL cholesterol;
PAAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12599982	chr1:44399894	ARTN	0.42	4.42	0.34	1.89e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23402429	chr2:28789613	PLB1	0.69	7.08	0.5	4.87e-11	Obesity-related traits;
PAAD	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.91	8.99	0.59	9.15e-16	Pulmonary function decline;
PAAD	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.81	-0.36	3.62e-6	Height;
PAAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg18612461	chr15:75251733	NA	-0.56	-6.92	-0.49	1.15e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg03959625	chr15:84868606	LOC388152	-0.44	-4.69	-0.36	6.15e-6	P wave terminal force;
PAAD	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.54	-0.35	1.15e-5	Educational attainment;
PAAD	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.53	-6.39	-0.46	1.88e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs28655083	0.529	rs1485794	chr16:77101977	A/G	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg11619707	chr19:22235551	ZNF257	0.58	5.82	0.43	3.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.58	0.57	1.03e-14	Menopause (age at onset);
PAAD	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.56	5.42	0.4	2.33e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg04520793	chr17:42248056	ASB16	-0.43	-5.1	-0.38	9.93e-7	Total body bone mineral density;
PAAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg24747557	chr10:131355152	MGMT	0.48	4.93	0.37	2.12e-6	Response to temozolomide;
PAAD	cis	rs8105895	0.935	rs2043317	chr19:22251096	T/C	cg20662725	chr19:22235022	ZNF257	-0.55	-4.39	-0.34	2.08e-5	Body mass index (change over time);
PAAD	cis	rs7795096	0.806	rs10277544	chr7:151540633	T/C	cg17008978	chr7:151542804	PRKAG2	0.41	4.84	0.37	3.11e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	trans	rs10040610	0.597	rs10462816	chr5:6416424	G/A	cg03377767	chr2:17997138	MSGN1	0.84	6.35	0.46	2.34e-9	Survival in microsatellite instability low/stable colorectal cancer;
PAAD	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06850241	chr22:41845214	NA	-0.51	-4.9	-0.37	2.38e-6	Vitiligo;
PAAD	cis	rs4243830	1.000	rs4243830	chr1:6577871	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-6.29	-0.45	3.16e-9	Body mass index;
PAAD	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.81	-8.86	-0.58	2.03e-15	Aortic root size;
PAAD	cis	rs9361491	0.508	rs7773448	chr6:79417356	C/T	cg05283184	chr6:79620031	NA	-0.4	-5.03	-0.38	1.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.624	rs6740245	chr2:10760902	T/C	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.02e-10	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14480858	chr9:4666499	C9orf68	0.57	6.31	0.46	2.95e-9	Myopia (pathological);
PAAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg05333889	chr7:157238977	NA	-0.44	-4.73	-0.36	5.17e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-7.96	-0.54	3.72e-13	Colorectal cancer;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg22868518	chr11:507468	RNH1	-0.93	-4.98	-0.37	1.67e-6	Body mass index;
PAAD	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-7.98	-0.54	3.31e-13	Colorectal cancer;
PAAD	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23281280	chr6:28129359	ZNF389	-0.69	-5.28	-0.39	4.32e-7	Depression;
PAAD	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.46	3.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.39	-4.89	-0.37	2.59e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.57	4.98	0.37	1.7e-6	Life satisfaction;
PAAD	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg02743256	chr7:2109353	MAD1L1	0.57	4.69	0.36	6.03e-6	Bipolar disorder;
PAAD	cis	rs458685	0.636	rs383479	chr21:31191663	G/A	cg24620508	chr21:31310605	GRIK1	-0.47	-4.34	-0.33	2.63e-5	Breast cancer;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg26174226	chr8:58114915	NA	-0.57	-4.42	-0.34	1.88e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg27478167	chr7:817139	HEATR2	-0.59	-4.68	-0.35	6.33e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs1371614	0.632	rs3769134	chr2:27150891	A/G	cg00617064	chr2:27272375	NA	-0.43	-4.51	-0.34	1.27e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16929692	chr11:117389301	DSCAML1	0.62	6.35	0.46	2.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.63	7.11	0.5	4.34e-11	High light scatter reticulocyte count;
PAAD	cis	rs116248771	0.739	rs78151625	chr3:158316726	T/C	cg16708174	chr3:158430962	RARRES1	0.75	5.48	0.41	1.75e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.51	-4.7	-0.36	5.72e-6	Menopause (age at onset);
PAAD	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg14196790	chr5:131705035	SLC22A5	0.59	6.58	0.47	7.17e-10	Blood metabolite levels;
PAAD	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1318772	1.000	rs26965	chr5:112739017	A/G	cg12552261	chr5:112820674	MCC	-0.56	-4.26	-0.33	3.53e-5	F-cell distribution;
PAAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.7	-7.16	-0.5	3.25e-11	Menopause (age at onset);
PAAD	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.41	-0.34	1.94e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2562456	0.520	rs25760	chr19:21394177	A/C	cg08562672	chr19:21860753	NA	-0.44	-4.26	-0.33	3.59e-5	Pain;
PAAD	cis	rs988913	1.000	rs9475106	chr6:54851455	G/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.94	-0.37	2.08e-6	Menarche (age at onset);
PAAD	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.32	0.51	1.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg03340356	chr1:67600835	NA	0.52	6.3	0.45	3.07e-9	Psoriasis;
PAAD	cis	rs1075265	0.840	rs805309	chr2:54196014	T/C	cg04546899	chr2:54196757	PSME4	0.37	5.56	0.41	1.17e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg16584676	chr17:46985605	UBE2Z	0.56	5.55	0.41	1.22e-7	Type 2 diabetes;
PAAD	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.87e-5	Total body bone mineral density;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs1499972	0.941	rs62264762	chr3:117634443	C/A	cg07612923	chr3:117604196	NA	1.09	7.18	0.5	2.9e-11	Schizophrenia;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.67	-5.72	-0.42	5.53e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.66	-6.12	-0.44	7.71e-9	Sum eosinophil basophil counts;
PAAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.83	8.75	0.58	3.81e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.44	-0.34	1.69e-5	Fat distribution (HIV);
PAAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24549020	chr5:56110836	MAP3K1	0.49	4.29	0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-5.23	-0.39	5.45e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg05110241	chr16:68378359	PRMT7	-1.02	-6.54	-0.47	8.68e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg14345882	chr6:26364793	BTN3A2	0.59	4.71	0.36	5.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg14180030	chr9:123475675	MEGF9	-0.41	-4.55	-0.35	1.09e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10267417	0.603	rs4634527	chr7:19911019	C/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.48	-5.23	-0.39	5.44e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.48	6.16	0.45	6.2e-9	Childhood ear infection;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg14433983	chr11:636460	DRD4	-0.46	-4.74	-0.36	4.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	5.66	0.42	7.37e-8	Breast cancer;
PAAD	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	1.07	6.99	0.49	8.19e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg00700412	chr12:58011837	NA	0.46	4.85	0.37	2.98e-6	Multiple sclerosis;
PAAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg27490568	chr2:178487706	NA	0.43	4.56	0.35	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	15.04	0.77	6.86e-32	Height;
PAAD	cis	rs2567519	0.961	rs2567516	chr17:70788884	G/A	cg26978064	chr17:70461791	NA	0.28	4.48	0.34	1.44e-5	Smoking initiation;
PAAD	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg11752832	chr7:134001865	SLC35B4	-0.49	-4.41	-0.34	1.96e-5	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs34670342	chr10:46066162	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7188861	0.768	rs60409583	chr16:11392098	C/T	cg16532467	chr16:11454386	NA	-0.54	-4.32	-0.33	2.76e-5	HDL cholesterol;
PAAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.25	-0.45	3.98e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.52	-5.99	-0.44	1.49e-8	Alcohol dependence;
PAAD	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs79839061	0.764	rs12646225	chr4:696848	C/T	cg15577924	chr4:515663	PIGG	0.66	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	5.61	0.41	9.26e-8	Joint mobility (Beighton score);
PAAD	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.84	10.07	0.63	1.39e-18	Hemoglobin concentration;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.29	0.51	1.56e-11	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00363114	chr11:113844663	HTR3A	0.56	6.5	0.47	1.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.58	0.57	1.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	8.23e-8	Life satisfaction;
PAAD	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10174797	chr19:8464628	RAB11B	0.58	5.59	0.41	1.05e-7	HDL cholesterol;
PAAD	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-14.46	-0.76	2.36e-30	Primary sclerosing cholangitis;
PAAD	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	0.49	4.36	0.33	2.42e-5	Testicular germ cell tumor;
PAAD	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.55	-4.91	-0.37	2.35e-6	Smoking behavior;
PAAD	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg18171855	chr10:2543474	NA	-0.66	-8.09	-0.55	1.73e-13	Age-related hearing impairment;
PAAD	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.71	-6.5	-0.47	1.08e-9	Menarche (age at onset);
PAAD	cis	rs329648	0.534	rs4937850	chr11:133764891	G/C	cg18057887	chr11:133800913	IGSF9B	0.64	7.16	0.5	3.22e-11	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27500918	chr16:2933308	FLYWCH2	0.67	6.71	0.48	3.56e-10	Obesity-related traits;
PAAD	cis	rs6708331	0.517	rs11890741	chr2:70360506	T/C	cg01613454	chr2:70366299	NA	0.44	4.63	0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.34	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs7746199	0.736	rs13217620	chr6:27653120	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.61	4.31	0.33	2.98e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4474465	1.000	rs4944202	chr11:78189558	T/C	cg12700464	chr11:78128424	GAB2	-0.61	-4.4	-0.34	2.07e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.78	8.14	0.55	1.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07648498	chr16:89883185	FANCA	-0.67	-6.87	-0.49	1.58e-10	Vitiligo;
PAAD	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg01059385	chr22:42394853	WBP2NL	0.48	4.39	0.34	2.11e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	6.18	0.45	5.48e-9	Monocyte percentage of white cells;
PAAD	cis	rs35955747	0.869	rs9621216	chr22:31590208	A/C	cg02404636	chr22:31891804	SFI1	-0.48	-4.78	-0.36	4.09e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.75e-6	Mortality in heart failure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01758115	chr16:48357692	LONP2	-0.62	-6.29	-0.45	3.15e-9	Obesity-related traits;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.82	-0.36	3.38e-6	Calcium levels;
PAAD	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs12893597	0.715	rs74639969	chr14:76832150	A/G	cg20290672	chr14:76816747	NA	-0.58	-4.97	-0.37	1.76e-6	Maximal oxygen uptake response;
PAAD	cis	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg20159608	chr7:32802032	NA	-0.53	-5.23	-0.39	5.55e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.61	-0.35	8.38e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.25	0.39	5.01e-7	Renal function-related traits (BUN);
PAAD	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs258892	0.895	rs10039408	chr5:72069110	G/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg05585544	chr11:47624801	NA	-0.42	-4.52	-0.34	1.25e-5	Subjective well-being;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06822966	chr2:110962741	NPHP1	-0.65	-6.32	-0.46	2.8e-9	Lung cancer in ever smokers;
PAAD	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.71	7.17	0.5	3.06e-11	Bipolar disorder;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.03e-6	Bipolar disorder;
PAAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.38	0.4	2.78e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10850408	0.848	rs7977406	chr12:115359424	C/T	cg05726002	chr12:115341178	NA	-0.4	-4.81	-0.36	3.57e-6	Alzheimer's disease;
PAAD	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs9364554	0.718	rs9365164	chr6:160856843	C/T	cg25313204	chr6:160768801	SLC22A3	0.48	4.26	0.33	3.63e-5	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg10934807	chr2:113191815	RGPD8;RGPD5	0.97	7.42	0.52	7.58e-12	Yeast infection;
PAAD	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.63	-0.62	2e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2124910	1.000	rs4802800	chr19:52021247	C/G	cg14953197	chr19:52005651	SIGLEC12	0.37	4.3	0.33	3.08e-5	Blood protein levels;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg07202610	chr7:1142643	C7orf50	-0.67	-5.56	-0.41	1.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.47	4.7	0.36	5.85e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08577743	chr9:38621011	C9orf122;ANKRD18A	0.55	6.46	0.46	1.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6782025	1.000	rs6782033	chr3:121138015	C/T	cg16417163	chr3:121280760	NA	-0.47	-4.85	-0.37	3.02e-6	Aging (facial);
PAAD	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg04520793	chr17:42248056	ASB16	0.44	4.86	0.37	2.86e-6	Total body bone mineral density;
PAAD	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.63	-7.19	-0.5	2.76e-11	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.82	-9.7	-0.62	1.26e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7113874	0.802	rs4291677	chr11:8680891	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.64	-0.35	7.54e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-0.73	-8.28	-0.56	6.04e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg20503657	chr10:835505	NA	0.51	5.35	0.4	3.21e-7	Survival in rectal cancer;
PAAD	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.54	-6.18	-0.45	5.58e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg22800045	chr5:56110881	MAP3K1	0.59	5.31	0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.87e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.88	-0.58	1.75e-15	Exhaled nitric oxide output;
PAAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg13639937	chr1:92012655	NA	-0.42	-4.46	-0.34	1.56e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.67	-8.06	-0.55	2.04e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs757081	0.533	rs7949405	chr11:17085192	A/C	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.05	-0.38	1.27e-6	Systolic blood pressure;
PAAD	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06544989	chr22:39130855	UNC84B	0.49	4.82	0.36	3.46e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg26685658	chr5:74633012	HMGCR	0.51	4.41	0.34	1.95e-5	Age-related disease endophenotypes;
PAAD	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.52	5.38	0.4	2.76e-7	Red blood cell count;
PAAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.69	7.1	0.5	4.36e-11	Morning vs. evening chronotype;
PAAD	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg12623918	chr2:306882	NA	0.62	4.63	0.35	7.79e-6	Blood protein levels;
PAAD	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg05768032	chr16:30646687	NA	0.54	4.82	0.36	3.42e-6	Multiple myeloma;
PAAD	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.97	-6.04	-0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg21361702	chr7:150065534	REPIN1	0.57	4.76	0.36	4.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg05484376	chr2:27715224	FNDC4	-0.47	-4.88	-0.37	2.64e-6	Oral cavity cancer;
PAAD	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg27234864	chr13:21295941	IL17D	0.62	5.24	0.39	5.26e-7	Dental caries;
PAAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	11.26	0.67	8.8e-22	Smoking behavior;
PAAD	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.46	-0.34	1.6e-5	Joint mobility (Beighton score);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07550016	chr4:1989575	WHSC2;MIR943	0.6	6.7	0.48	3.79e-10	Energy expenditure (24h);
PAAD	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs2147904	0.934	rs783625	chr1:42365548	C/T	cg16685388	chr1:42384056	HIVEP3	0.39	4.59	0.35	9.19e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs7771547	0.603	rs10947615	chr6:36599596	T/C	cg07856975	chr6:36356162	ETV7	0.56	5.91	0.43	2.21e-8	Platelet distribution width;
PAAD	cis	rs4704187	0.687	rs7720620	chr5:74366023	A/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.14	0.5	3.57e-11	Response to antipsychotic treatment;
PAAD	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.74	0.48	3.04e-10	Leprosy;
PAAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.4	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs6594713	0.518	rs34512273	chr5:112636743	C/G	cg12552261	chr5:112820674	MCC	0.56	4.44	0.34	1.72e-5	Brain cytoarchitecture;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-4.41	-0.34	1.94e-5	Lung cancer;
PAAD	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg07527105	chr16:88053339	BANP	-0.42	-4.35	-0.33	2.53e-5	Menopause (age at onset);
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg18279126	chr7:2041391	MAD1L1	0.58	5.84	0.43	3.09e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2694528	0.764	rs1816862	chr5:60011636	G/A	cg11474532	chr5:59995715	DEPDC1B	0.75	4.51	0.34	1.29e-5	Parkinson's disease;
PAAD	cis	rs740474	0.831	rs10477148	chr5:140989242	C/T	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.42	5.09	0.38	1.03e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg22827986	chr11:48284249	OR4X1	0.44	5.54	0.41	1.31e-7	Migraine - clinic-based;
PAAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.62	6.64	0.47	5.22e-10	Lung cancer;
PAAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	5.49	0.41	1.64e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.39	4.65	0.35	7.28e-6	Mean corpuscular volume;
PAAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.47	5.1	0.38	1.01e-6	Age of smoking initiation;
PAAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.53	6.75	0.48	2.94e-10	Schizophrenia;
PAAD	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.01	0.44	1.33e-8	Schizophrenia;
PAAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.79	6.9	0.49	1.35e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2422052	0.527	rs12466517	chr2:118830391	C/A	cg22545206	chr2:118617499	NA	-0.42	-4.28	-0.33	3.29e-5	Mosquito bite size;
PAAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.7	-7.5	-0.52	4.98e-12	Personality dimensions;
PAAD	cis	rs7627468	1.000	rs7647612	chr3:121933066	C/T	cg17240004	chr3:121949083	CASR	-0.52	-4.52	-0.34	1.22e-5	Kidney stones;
PAAD	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.91	11.57	0.68	1.34e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.16	-0.39	7.67e-7	High light scatter reticulocyte count;
PAAD	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	cis	rs6594713	0.533	rs6881949	chr5:112974340	T/C	cg12552261	chr5:112820674	MCC	0.75	4.9	0.37	2.4e-6	Brain cytoarchitecture;
PAAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.33	-0.4	3.45e-7	Aortic root size;
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg00262122	chr8:11665843	FDFT1	0.51	4.33	0.33	2.7e-5	Retinal vascular caliber;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06476034	chr17:6915753	RNASEK	-0.56	-6.73	-0.48	3.3e-10	Body fat percentage;
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg04854917	chr10:131378330	MGMT	-0.45	-4.68	-0.35	6.42e-6	Vitamin D levels;
PAAD	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.47e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07395648	chr5:131743802	NA	0.5	4.54	0.35	1.14e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-6.12	-0.44	7.51e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06307176	chr5:131281290	NA	0.51	4.61	0.35	8.43e-6	Life satisfaction;
PAAD	cis	rs7714584	1.000	rs3906528	chr5:150266718	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	0.98	7.92	0.54	4.79e-13	Vitiligo;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg11335335	chr11:637885	DRD4	-0.38	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.48e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.45	0.34	1.64e-5	Eosinophil percentage of white cells;
PAAD	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.41	-0.34	1.91e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg07153921	chr17:41440717	NA	-0.42	-4.44	-0.34	1.69e-5	Menopause (age at onset);
PAAD	cis	rs6804624	1.000	rs6807474	chr3:99165693	T/C	cg02646433	chr3:99218170	NA	0.41	4.26	0.33	3.52e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg13722127	chr7:150037890	RARRES2	-0.64	-6.95	-0.49	1.02e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs901683	1.000	rs34383275	chr10:46072877	C/T	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs621559	0.636	rs12731921	chr1:43679274	A/G	cg14851383	chr1:43888477	KIAA0467	0.55	4.36	0.33	2.41e-5	Telomere length;
PAAD	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg08135965	chr6:41755394	TOMM6	0.51	5.48	0.41	1.76e-7	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg11995313	chr8:8860691	ERI1	0.48	4.58	0.35	9.67e-6	Joint mobility (Beighton score);
PAAD	cis	rs600626	0.636	rs10899110	chr11:75452342	C/G	cg24262691	chr11:75473276	NA	0.74	6.1	0.44	8.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.71	-6.75	-0.48	2.9e-10	Platelet distribution width;
PAAD	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20918903	chr2:86668501	KDM3A	0.69	6.42	0.46	1.62e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.9	-6.24	-0.45	4.09e-9	Body mass index;
PAAD	cis	rs13070279	0.582	rs67109126	chr3:71799808	C/T	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.33	-0.33	2.66e-5	Monocyte count;
PAAD	cis	rs75920871	1.000	rs11823013	chr11:116839535	T/C	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	6.29	0.45	3.16e-9	Neuroticism;
PAAD	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.81	-7.67	-0.53	1.97e-12	DNA methylation (variation);
PAAD	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg15117754	chr3:10150083	C3orf24	0.77	6.86	0.49	1.6e-10	Alzheimer's disease;
PAAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12136530	0.577	rs12066114	chr1:19792527	A/G	cg20786524	chr1:18954525	NA	-0.37	-4.57	-0.35	9.96e-6	Lead levels in blood;
PAAD	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.3	0.6	1.42e-16	Morning vs. evening chronotype;
PAAD	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.5	-0.52	4.91e-12	Neuroticism;
PAAD	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg26876637	chr1:152193138	HRNR	-0.85	-6.21	-0.45	4.86e-9	Atopic dermatitis;
PAAD	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg12568669	chr8:11666485	FDFT1	0.28	4.4	0.34	2.07e-5	Systolic blood pressure;
PAAD	cis	rs1034435	0.662	rs10460766	chr22:48896580	G/A	cg05992904	chr22:48892994	FAM19A5	-0.52	-5.33	-0.4	3.46e-7	Late-onset Alzheimer's disease;
PAAD	cis	rs7771547	0.723	rs2145048	chr6:36557580	C/A	cg07856975	chr6:36356162	ETV7	0.44	4.56	0.35	1.05e-5	Platelet distribution width;
PAAD	cis	rs1256061	0.624	rs944046	chr14:64700299	G/A	cg23250157	chr14:64679961	SYNE2	0.56	5.74	0.42	5.05e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-0.84	-4.95	-0.37	1.99e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.09	0.38	1.03e-6	Childhood ear infection;
PAAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs35785195	0.593	rs12821514	chr12:114233825	G/A	cg23469448	chr12:114232746	NA	0.58	4.47	0.34	1.5e-5	Daytime sleep phenotypes;
PAAD	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.17	16.07	0.79	1.4e-34	Body mass index;
PAAD	cis	rs9296095	0.607	rs9469485	chr6:33514093	C/T	cg14003231	chr6:33640908	ITPR3	0.44	5.67	0.42	6.94e-8	Platelet count;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-6.28	-0.45	3.4e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-8.9	-0.59	1.53e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.44	4.38	0.33	2.24e-5	Blood pressure;
PAAD	cis	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.64	-4.38	-0.33	2.19e-5	Hypertriglyceridemia;
PAAD	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg26528668	chr16:1614120	IFT140	0.51	4.77	0.36	4.29e-6	Coronary artery disease;
PAAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg20933634	chr6:27740509	NA	0.76	6.96	0.49	9.44e-11	Breast cancer;
PAAD	cis	rs9467711	0.516	rs1165184	chr6:25836257	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.65	4.62	0.35	8.11e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	5.94	0.43	1.9e-8	Monocyte count;
PAAD	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg22138327	chr13:27999177	GTF3A	0.85	5.31	0.4	3.75e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg07741184	chr6:167504864	NA	-0.4	-4.84	-0.37	3.16e-6	Crohn's disease;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.71	-0.42	5.69e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.27	-0.39	4.63e-7	Mean corpuscular volume;
PAAD	cis	rs10929159	0.928	rs2123513	chr2:236920638	T/C	cg14226755	chr2:236923322	AGAP1	0.29	4.68	0.35	6.34e-6	Parkinson's disease;
PAAD	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.93	-11.56	-0.68	1.38e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07362569	chr17:61921086	SMARCD2	-0.44	-5.03	-0.38	1.34e-6	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs642743	0.595	rs703343	chr10:105989664	G/A	cg10697286	chr10:106209748	CCDC147	0.47	4.3	0.33	2.99e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.81	-9.25	-0.6	1.94e-16	Body mass index;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg23708337	chr7:1209742	NA	0.39	4.35	0.33	2.47e-5	Longevity;Endometriosis;
PAAD	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.69	-0.42	6.41e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18621852	chr3:10150065	C3orf24	0.67	5.84	0.43	3.09e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4523957	0.583	rs2641437	chr17:2019158	G/A	cg16513277	chr17:2031491	SMG6	-0.59	-6.18	-0.45	5.57e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25178798	chr8:145981145	ZNF251	0.67	6.37	0.46	2.17e-9	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.84	-10.66	-0.65	3.62e-20	Height;
PAAD	cis	rs6987853	0.933	rs6980507	chr8:42383084	A/G	cg09913449	chr8:42400586	C8orf40	0.5	5.5	0.41	1.56e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.33	-0.33	2.7e-5	Schizophrenia;
PAAD	cis	rs4780401	0.729	rs8045300	chr16:11769266	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.9	-0.43	2.27e-8	Rheumatoid arthritis;
PAAD	cis	rs7577696	0.962	rs34856365	chr2:32305000	A/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-5.06	-0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6424115	0.830	rs2502988	chr1:24205608	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.87e-8	Immature fraction of reticulocytes;
PAAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.55	5.95	0.43	1.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.85	11.77	0.69	3.95e-23	Bone mineral density;
PAAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.52	4.77	0.36	4.35e-6	Multiple sclerosis;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-4.85	-0.37	3.07e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg23283495	chr1:209979779	IRF6	0.63	5.66	0.42	7.21e-8	Coronary artery disease;
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg17178900	chr1:205818956	PM20D1	0.52	5.06	0.38	1.19e-6	Prostate-specific antigen levels;
PAAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.54	6.26	0.45	3.66e-9	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg20243544	chr17:37824526	PNMT	0.55	4.73	0.36	5.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.67	4.83	0.37	3.25e-6	LDL cholesterol levels;
PAAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.51	-5.62	-0.41	9.03e-8	Testicular germ cell tumor;
PAAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.41	0.4	2.42e-7	Lung cancer;
PAAD	cis	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg18085866	chr17:45331354	ITGB3	-0.74	-4.38	-0.33	2.22e-5	Left atrial antero-posterior diameter;
PAAD	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.78	7.88	0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.9	12.11	0.7	4.75e-24	Superior crus of antihelix expression;
PAAD	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.41	0.34	1.96e-5	HDL cholesterol;
PAAD	cis	rs11997175	0.625	rs4733171	chr8:33615617	C/G	ch.8.33884649F	chr8:33765107	NA	-0.57	-6.48	-0.47	1.18e-9	Body mass index;
PAAD	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.67	5.99	0.44	1.48e-8	Mean platelet volume;
PAAD	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	trans	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.32	0.46	2.75e-9	Calcium levels;
PAAD	cis	rs2885056	0.891	rs28367549	chr19:10689184	A/C	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Body mass index;
PAAD	cis	rs61861422	0.516	rs12416102	chr10:134456648	G/T	cg09421083	chr10:134358535	INPP5A	-0.53	-4.8	-0.36	3.8e-6	Primary sclerosing cholangitis;
PAAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	5.93	0.43	2.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	5.68	0.42	6.81e-8	Longevity;
PAAD	cis	rs643506	0.874	rs645411	chr11:111694490	T/C	cg09085632	chr11:111637200	PPP2R1B	0.57	4.84	0.37	3.22e-6	Breast cancer;
PAAD	cis	rs10214930	0.813	rs6462039	chr7:27666382	C/G	cg22168087	chr7:27702803	HIBADH	-0.49	-4.42	-0.34	1.85e-5	Hypospadias;
PAAD	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.22	0.39	5.74e-7	Motion sickness;
PAAD	cis	rs6499755	0.712	rs22747	chr16:55365908	A/C	cg02859129	chr16:55357253	IRX6	0.35	4.89	0.37	2.55e-6	Hypospadias;
PAAD	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.57	5.94	0.43	1.88e-8	Dupuytren's disease;
PAAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.75	-7.99	-0.54	3.2e-13	Blood metabolite levels;
PAAD	cis	rs7819412	0.593	rs11778398	chr8:10974243	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.41	-0.34	1.93e-5	Triglycerides;
PAAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.59	7.55	0.52	3.72e-12	Diastolic blood pressure;
PAAD	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	5.68	0.42	6.51e-8	Schizophrenia;
PAAD	cis	rs2120243	0.625	rs4482625	chr3:157096009	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	4.76	0.36	4.41e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.53	5.11	0.38	9.49e-7	Bipolar disorder;
PAAD	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg07257824	chr6:170732353	NA	0.75	5.59	0.41	1.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.11	-0.44	8.06e-9	Bipolar disorder;
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg08835956	chr7:39171034	POU6F2	0.33	5.75	0.42	4.75e-8	IgG glycosylation;
PAAD	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg12568669	chr8:11666485	FDFT1	-0.3	-4.71	-0.36	5.65e-6	Retinal vascular caliber;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.66	6.38	0.46	2.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs56046484	0.913	rs12906544	chr15:85576063	G/A	cg08123816	chr15:85640762	PDE8A	-0.5	-5.12	-0.38	9.22e-7	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	6.89	0.49	1.38e-10	Hip circumference;
PAAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.88	0.37	2.6e-6	Menopause (age at onset);
PAAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.48	-5.07	-0.38	1.17e-6	Height;
PAAD	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg16691251	chr5:66510806	NA	-0.68	-7.26	-0.51	1.83e-11	Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24616589	chr7:151038719	NUB1	-0.67	-6.68	-0.48	4.13e-10	Smoking initiation;
PAAD	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg09065629	chr16:1709722	CRAMP1L	0.48	5.07	0.38	1.12e-6	Coronary artery disease;
PAAD	cis	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg21546286	chr11:48923668	NA	-0.54	-5.55	-0.41	1.24e-7	HDL cholesterol;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg09060608	chr5:178986726	RUFY1	-0.55	-5.78	-0.42	4.18e-8	Lung cancer;
PAAD	cis	rs2555155	0.935	rs10839567	chr11:6520664	G/A	cg11185456	chr11:6592066	DNHD1	0.42	4.35	0.33	2.44e-5	DNA methylation (variation);
PAAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.93	0.43	1.94e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg18721089	chr20:30220636	NA	-0.81	-6.63	-0.47	5.63e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	4.97	0.37	1.78e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.49	-4.69	-0.36	6.06e-6	Menarche (age at onset);
PAAD	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.56	5.48	0.41	1.73e-7	Coronary artery disease;
PAAD	cis	rs2019216	0.500	rs71371082	chr17:21889647	T/C	cg22648282	chr17:21454238	C17orf51	-0.59	-6.04	-0.44	1.15e-8	Pelvic organ prolapse;
PAAD	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	8.09	0.55	1.79e-13	Lewy body disease;
PAAD	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.89	-5.81	-0.43	3.62e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6733011	0.519	rs11900176	chr2:99463536	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.46	4.56	0.35	1.04e-5	Bipolar disorder;
PAAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.46	-4.97	-0.37	1.75e-6	Bipolar disorder;
PAAD	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg04398451	chr17:18023971	MYO15A	0.73	7.73	0.53	1.37e-12	Total body bone mineral density;
PAAD	trans	rs528059	0.623	rs78833690	chr1:34194249	C/T	cg02711268	chr6:106808110	NA	1.1	6.3	0.46	3e-9	Intelligence;
PAAD	trans	rs100537	0.748	rs61800588	chr1:165392669	T/C	cg09024962	chr5:132707300	FSTL4	-0.35	-6.36	-0.46	2.28e-9	Menarche (age at onset);
PAAD	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.86	-0.37	2.92e-6	Retinal vascular caliber;
PAAD	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.26	0.39	4.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg23033748	chr14:75592666	NEK9	-0.41	-5.01	-0.38	1.5e-6	Height;
PAAD	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.7	10.86	0.66	1.07e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs8077577	0.943	rs62073603	chr17:18064316	C/T	cg16794390	chr17:18148240	FLII	0.62	5.07	0.38	1.12e-6	Obesity-related traits;
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.58	5.33	0.4	3.5e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.65	-7.39	-0.51	9.29e-12	IgG glycosylation;
PAAD	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg21724239	chr8:58056113	NA	0.71	5.35	0.4	3.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg13606994	chr1:44402422	ARTN	-0.46	-4.25	-0.33	3.74e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.65	6.33	0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs1018697	1.000	rs1018697	chr10:104549224	C/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.81e-5	Colorectal adenoma (advanced);
PAAD	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.65	-6.5	-0.47	1.08e-9	Body mass index;
PAAD	cis	rs10512697	0.655	rs13171097	chr5:3512130	G/A	cg19473799	chr5:3511975	NA	-1.12	-5.06	-0.38	1.2e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.61	-5.68	-0.42	6.64e-8	Blood protein levels;
PAAD	cis	rs12327666	0.522	rs7247679	chr19:14134172	T/C	cg09538921	chr19:14142201	IL27RA	-0.75	-5.43	-0.4	2.24e-7	Obesity-related traits;
PAAD	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.88	-10.88	-0.66	9.7e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg16606324	chr3:10149918	C3orf24	0.59	5.0	0.38	1.55e-6	Alzheimer's disease;
PAAD	cis	rs7077446	0.760	rs4291608	chr10:103756750	A/G	cg11685391	chr10:103594334	KCNIP2	-0.36	-4.37	-0.33	2.26e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.3e-6	Tuberculosis;
PAAD	cis	rs2880765	0.546	rs8042776	chr15:86055629	T/C	cg13263323	chr15:86062960	AKAP13	-0.5	-5.12	-0.38	9.32e-7	Coronary artery disease;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.46	4.54	0.35	1.16e-5	Electroencephalogram traits;
PAAD	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg20673091	chr1:2541236	MMEL1	0.7	7.53	0.52	4.26e-12	Ulcerative colitis;
PAAD	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg00686598	chr14:53173677	PSMC6	-0.92	-5.44	-0.4	2.1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs367943	0.608	rs4705463	chr5:112980273	C/G	cg12552261	chr5:112820674	MCC	0.56	5.85	0.43	2.9e-8	Type 2 diabetes;
PAAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.29e-9	Cardiovascular disease risk factors;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07032473	chr8:95274411	GEM	0.59	6.59	0.47	6.87e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.67	6.76	0.48	2.82e-10	Orofacial clefts;
PAAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.76	7.21	0.5	2.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4845459	0.967	rs1581803	chr1:152592281	A/C	cg02737307	chr1:152190020	HRNR	0.4	4.49	0.34	1.39e-5	Psoriasis;
PAAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg02696790	chr15:75250997	RPP25	0.36	4.3	0.33	3.06e-5	Breast cancer;
PAAD	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.71	-5.4	-0.4	2.46e-7	Vitiligo;
PAAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg04194840	chr16:58545502	NDRG4	0.72	4.29	0.33	3.11e-5	Schizophrenia;
PAAD	cis	rs55794721	0.672	rs78103988	chr1:25747655	C/T	cg03538708	chr1:25844672	NA	-0.51	-5.16	-0.39	7.72e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.44	-4.26	-0.33	3.5e-5	Height;
PAAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16447950	chr5:562315	NA	-0.67	-5.91	-0.43	2.15e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.4	-0.34	2.05e-5	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.74	5.3	0.4	3.93e-7	Vitiligo;
PAAD	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg21040360	chr2:3383326	TTC15	-0.43	-4.39	-0.34	2.15e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.53	4.75	0.36	4.76e-6	Multiple sclerosis;
PAAD	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.68	-0.35	6.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg16205897	chr5:131564050	P4HA2	-0.49	-5.48	-0.41	1.76e-7	Blood metabolite levels;
PAAD	cis	rs4795519	0.922	rs1515750	chr17:22196513	A/T	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.64	4.99	0.38	1.6e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.08	13.87	0.75	8.73e-29	Subjective well-being;
PAAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs116248771	0.739	rs73156478	chr3:158398716	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs9322817	0.691	rs9486015	chr6:105254000	C/T	cg02098413	chr6:105308735	HACE1	-0.43	-5.4	-0.4	2.56e-7	Thyroid stimulating hormone;
PAAD	cis	rs4742903	0.526	rs12341282	chr9:106913250	T/C	cg14250997	chr9:106856677	SMC2	-0.48	-5.25	-0.39	5.09e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs12989701	0.740	rs28434131	chr2:127850292	A/G	cg08168897	chr2:127865431	BIN1	0.7	5.98	0.44	1.5e-8	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg00543991	chr22:32367038	NA	1.06	6.97	0.49	8.81e-11	Childhood ear infection;
PAAD	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg17633681	chr16:88106987	BANP	0.66	8.39	0.56	3.09e-14	Menopause (age at onset);
PAAD	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg24692254	chr21:30365293	RNF160	-0.64	-5.45	-0.4	1.98e-7	Cognitive test performance;
PAAD	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.53	-5.15	-0.39	7.81e-7	Menarche (age at onset);
PAAD	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs7260329	0.670	rs6508963	chr19:41498733	A/G	cg06653635	chr19:40910092	PRX	-0.45	-4.31	-0.33	2.97e-5	Smoking behavior;
PAAD	cis	rs6137287	0.924	rs2180581	chr20:21151852	C/T	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg04154034	chr17:28927549	LRRC37B2	0.68	4.38	0.33	2.18e-5	Body mass index;
PAAD	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.59	-5.43	-0.4	2.14e-7	Total body bone mineral density;
PAAD	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg18612461	chr15:75251733	NA	-0.54	-4.69	-0.36	6.14e-6	Blood trace element (Zn levels);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14209793	chr10:105614994	SH3PXD2A	-0.8	-7.03	-0.5	6.7e-11	Neuroticism;
PAAD	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.65	6.09	0.44	8.81e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17106462	chr19:48956129	GRWD1	0.54	6.33	0.46	2.56e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.55	-5.06	-0.38	1.2e-6	Primary sclerosing cholangitis;
PAAD	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.51	5.68	0.42	6.6e-8	Prostate cancer;
PAAD	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.88	-10.28	-0.64	3.8e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.4	0.34	2e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg03513858	chr6:54763001	FAM83B	0.43	4.73	0.36	5.03e-6	Menarche (age at onset);
PAAD	cis	rs1998418	0.733	rs11245346	chr10:126425537	C/G	cg04944537	chr10:125428817	GPR26	-0.56	-4.99	-0.38	1.62e-6	Mean platelet volume;
PAAD	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.23	0.56	7.98e-14	Alzheimer's disease (late onset);
PAAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.13	-0.55	1.39e-13	Prostate cancer;
PAAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg26513180	chr16:89883248	FANCA	0.66	7.65	0.53	2.2e-12	Vitiligo;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.44	0.56	2.36e-14	Lung cancer;
PAAD	cis	rs3026101	0.671	rs3026140	chr17:5313522	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg02264943	chr11:130785842	SNX19	-0.36	-4.4	-0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.63	-6.57	-0.47	7.73e-10	Body mass index;
PAAD	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.28	0.45	3.34e-9	Personality dimensions;
PAAD	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.98	10.44	0.65	1.43e-19	Primary sclerosing cholangitis;
PAAD	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.09	0.5	4.71e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg26818257	chr2:241905806	NA	0.49	5.17	0.39	7.3e-7	Urinary metabolites;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12243255	chr3:39194549	CSRNP1	0.59	6.31	0.46	2.83e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1559088	0.512	rs34266236	chr19:33564874	C/A	cg27124370	chr19:33622961	WDR88	0.53	4.3	0.33	3.03e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.7	0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs9810890	1.000	rs73198820	chr3:128476794	G/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg05110241	chr16:68378359	PRMT7	-1.15	-7.99	-0.54	3.05e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.7	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.597	rs4721105	chr7:12534881	C/T	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.15	-0.39	7.97e-7	Migraine - clinic-based;
PAAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs13242816	1.000	rs17138747	chr7:116132670	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.71	7.49	0.52	5.16e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.45	4.66	0.35	6.99e-6	Joint mobility (Beighton score);
PAAD	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7922314	0.571	rs16918001	chr10:64749870	G/A	cg08989932	chr10:65390526	NA	-0.95	-4.69	-0.36	5.92e-6	Cutaneous psoriasis;
PAAD	cis	rs7487075	0.578	rs4258438	chr12:46809126	G/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.41	0.34	1.92e-5	Itch intensity from mosquito bite;
PAAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-4.55	-0.35	1.1e-5	Tonsillectomy;
PAAD	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.74	7.43	0.52	7.51e-12	Corneal astigmatism;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg00599163	chr2:162100495	NA	0.38	4.79	0.36	3.93e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11118396	chr8:142427930	NA	-0.74	-7.76	-0.53	1.13e-12	Smoking initiation;
PAAD	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.39	-4.74	-0.36	4.93e-6	Prostate cancer;
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.71	-6.92	-0.49	1.19e-10	Blood metabolite levels;
PAAD	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.77	-8.56	-0.57	1.16e-14	Schizophrenia;
PAAD	cis	rs786425	0.707	rs1051793	chr12:124144395	A/G	cg16237390	chr12:124156159	TCTN2	0.45	4.27	0.33	3.38e-5	Pubertal anthropometrics;
PAAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg00990874	chr7:1149470	C7orf50	-0.92	-8.68	-0.58	5.58e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg11380483	chr2:127933992	NA	0.72	5.69	0.42	6.21e-8	Protein C levels;
PAAD	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs7326068	0.610	rs2818985	chr13:21314209	G/T	cg27234864	chr13:21295941	IL17D	0.59	4.94	0.37	2.04e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg05084668	chr3:125655381	ALG1L	-0.53	-5.45	-0.4	1.98e-7	Blood pressure (smoking interaction);
PAAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg04287289	chr16:89883240	FANCA	0.61	6.7	0.48	3.83e-10	Vitiligo;
PAAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.39	4.05e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.49	9.65	0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.21	-0.39	6.12e-7	Monocyte count;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.06	12.5	0.71	4.11e-25	Breast cancer;
PAAD	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.45	4.62	0.35	7.98e-6	Resting heart rate;
PAAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-7.87	-0.54	6.26e-13	Body mass index;
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.49	4.42	0.34	1.9e-5	Platelet count;
PAAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.92	-0.59	1.39e-15	Total body bone mineral density;
PAAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.76	-8.07	-0.55	1.97e-13	DNA methylation (variation);
PAAD	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.13	-0.67	2.08e-21	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.69	7.0	0.49	7.81e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14270612	chr9:133738235	ABL1	-0.66	-6.61	-0.47	5.97e-10	Obesity-related traits;
PAAD	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.85	9.62	0.62	2.06e-17	Resting heart rate;
PAAD	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.83	9.21	0.6	2.47e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.58	-7.46	-0.52	6.06e-12	Lewy body disease;
PAAD	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1879734	0.731	rs6665257	chr1:54161087	T/C	cg14659662	chr1:54151053	GLIS1	-0.44	-5.95	-0.43	1.75e-8	Mitral valve prolapse;
PAAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.98e-6	Coronary artery disease;
PAAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.79	-0.36	4e-6	Alcohol dependence;
PAAD	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-5.42	-0.4	2.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Blood metabolite levels;
PAAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.65	-6.94	-0.49	1.08e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.49	4.91	0.37	2.38e-6	Type 2 diabetes;
PAAD	cis	rs2882667	0.690	rs7714455	chr5:138153970	T/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.55	-0.41	1.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.36	0.4	3.04e-7	Total body bone mineral density;
PAAD	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.66	5.63	0.42	8.32e-8	Bone mineral density;
PAAD	cis	rs2662368	0.563	rs254397	chr5:77084993	G/A	cg16293892	chr5:77142620	NA	-0.44	-4.33	-0.33	2.7e-5	Platelet distribution width;
PAAD	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.15	0.55	1.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10274279	1.000	rs73163816	chr7:157388126	C/G	cg26886268	chr7:157387156	PTPRN2	-0.73	-5.79	-0.43	3.87e-8	Myopia (pathological);
PAAD	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.54	-4.75	-0.36	4.65e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.56	4.96	0.37	1.84e-6	Testicular germ cell tumor;
PAAD	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.81	-6.16	-0.45	6.07e-9	Coronary artery calcification;
PAAD	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08270964	chr19:49652144	PPFIA3	0.65	7.32	0.51	1.31e-11	Monocyte percentage of white cells;
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg09242541	chr1:10490025	APITD1	0.43	5.26	0.39	4.82e-7	Prostate cancer;
PAAD	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.01	-0.38	1.51e-6	Reticulocyte count;
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg05132306	chr1:1846340	CALML6	-0.44	-5.17	-0.39	7.43e-7	Body mass index;
PAAD	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4862562	1.000	rs4862562	chr4:186602210	A/C	cg21367866	chr4:187563992	FAT1	0.84	4.3	0.33	3.01e-5	Cytokine-stimulated IL-6 production;Cytokine and corticosteroid-stimulated IL-6 production;
PAAD	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	4.99	0.38	1.61e-6	Oropharynx cancer;
PAAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.73	7.95	0.54	3.96e-13	Mood instability;
PAAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.47	-4.93	-0.37	2.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg03713592	chr11:72463424	ARAP1	0.6	5.46	0.4	1.91e-7	Body mass index;
PAAD	cis	rs7561149	0.902	rs3769858	chr2:179667806	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.49	4.9	0.37	2.41e-6	QT interval;
PAAD	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg14703610	chr5:56206110	C5orf35	0.64	5.93	0.43	1.99e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs694739	0.861	rs479552	chr11:64110683	G/C	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.49	0.52	5.37e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.62	-6.4	-0.46	1.81e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12311304	0.965	rs7965695	chr12:15368644	G/A	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.89e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs3743832	0.966	rs6498426	chr16:9182577	C/T	cg08831531	chr16:9218945	NA	-0.44	-4.61	-0.35	8.48e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-9.16	-0.6	3.34e-16	Mortality in heart failure;
PAAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.65	0.47	4.93e-10	Schizophrenia;
PAAD	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs9472414	0.510	rs227844	chr6:44692212	A/C	cg20913747	chr6:44695427	NA	0.59	5.98	0.44	1.57e-8	Height;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg26939375	chr7:64535504	NA	0.76	9.19	0.6	2.84e-16	Calcium levels;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.49	4.3	0.33	3.05e-5	Mean platelet volume;
PAAD	cis	rs643506	0.874	rs614144	chr11:111668619	A/T	cg09085632	chr11:111637200	PPP2R1B	0.53	4.6	0.35	8.7e-6	Breast cancer;
PAAD	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.48	-0.47	1.23e-9	Schizophrenia;
PAAD	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg08439880	chr3:133502540	NA	0.42	4.7	0.36	5.76e-6	Iron status biomarkers;
PAAD	cis	rs3747547	0.818	rs7023756	chr9:37946629	A/G	cg13774184	chr9:37916125	SHB	-0.57	-4.26	-0.33	3.57e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg01489256	chr8:11204017	TDH	0.43	4.27	0.33	3.42e-5	Retinal vascular caliber;
PAAD	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.69	0.48	3.99e-10	Smoking initiation;
PAAD	cis	rs507080	0.736	rs658676	chr11:118571123	C/T	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.76	0.58	3.49e-15	Bone mineral density;
PAAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.18	17.8	0.82	5.17e-39	Cognitive function;
PAAD	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.88	-0.37	2.67e-6	Height;
PAAD	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.52	5.11	0.38	9.39e-7	Menopause (age at onset);
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.55	5.28	0.39	4.48e-7	Testicular germ cell tumor;
PAAD	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.46	5.01	0.38	1.46e-6	Fibrinogen levels;
PAAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg02781088	chr2:113192302	RGPD8;RGPD5	0.94	6.79	0.48	2.39e-10	Yeast infection;
PAAD	cis	rs4356203	0.870	rs11024204	chr11:17249805	T/C	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.94	-8.5	-0.57	1.62e-14	Blood protein levels;
PAAD	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg17385448	chr1:15911702	AGMAT	0.38	4.68	0.35	6.27e-6	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg11204139	chr17:3907470	NA	0.66	6.83	0.48	1.95e-10	Type 2 diabetes;
PAAD	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	1.0	11.8	0.69	3.23e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.7	7.24	0.51	2.07e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg02683114	chr2:24398427	C2orf84	0.53	5.21	0.39	5.93e-7	Asthma;
PAAD	cis	rs6942407	0.592	rs2373389	chr7:86751777	C/A	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-6.9	-0.49	1.34e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.48	8.55	0.57	1.2e-14	Multiple system atrophy;
PAAD	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg06795125	chr2:108905320	SULT1C2	-0.47	-4.73	-0.36	4.99e-6	Lobe size;
PAAD	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.66	-4.85	-0.37	3e-6	Coronary artery disease;
PAAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	10.09	0.63	1.19e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.63	-4.37	-0.33	2.25e-5	Iris characteristics;
PAAD	cis	rs2880765	0.706	rs7172006	chr15:86053359	A/G	cg13263323	chr15:86062960	AKAP13	-0.53	-5.41	-0.4	2.41e-7	Coronary artery disease;
PAAD	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg20799917	chr2:38894198	GALM	-0.48	-4.26	-0.33	3.61e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.9	-8.35	-0.56	4.02e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.65	7.93	0.54	4.39e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.6	-7.1	-0.5	4.58e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.76	6.47	0.46	1.29e-9	Pulmonary function decline;
PAAD	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg16596103	chr2:233749413	NGEF	-0.43	-4.42	-0.34	1.9e-5	Schizophrenia;
PAAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.61	6.27	0.45	3.48e-9	Multiple sclerosis;
PAAD	cis	rs4764487	0.760	rs733700	chr12:6337974	A/G	cg08284733	chr12:6341482	CD9	0.41	4.42	0.34	1.89e-5	Mean platelet volume;
PAAD	cis	rs375066	0.935	rs397346	chr19:44399115	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.86	-0.43	2.76e-8	Breast cancer;
PAAD	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg09579323	chr1:150459698	TARS2	0.45	4.33	0.33	2.73e-5	Migraine;
PAAD	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.58	6.66	0.48	4.74e-10	Schizophrenia;
PAAD	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-9.0	-0.59	8.76e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4780401	0.728	rs8191288	chr16:11765614	G/A	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.84	-0.43	3.13e-8	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22798984	chr14:52456142	C14orf166	0.69	6.98	0.49	8.63e-11	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20634234	chr2:223520845	FARSB	0.65	7.46	0.52	6.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1723838	0.826	rs1466218	chr11:73589184	G/T	cg26954736	chr11:73693896	UCP2	1.03	4.58	0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg05110241	chr16:68378359	PRMT7	-1.13	-8.44	-0.56	2.35e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.47	-0.57	2e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.73	0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-5.67	-0.42	6.9e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.05e-15	Exhaled nitric oxide output;
PAAD	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	1.19	10.54	0.65	7.73e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg03938978	chr2:103052716	IL18RAP	0.68	8.55	0.57	1.2e-14	Asthma;
PAAD	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg16068336	chr17:48637367	CACNA1G	-0.53	-4.76	-0.36	4.44e-6	Type 2 diabetes;
PAAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg14440974	chr22:39074834	NA	-0.59	-7.15	-0.5	3.48e-11	Menopause (age at onset);
PAAD	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.04	-0.38	1.28e-6	Pulmonary function;
PAAD	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg05555928	chr11:63887634	MACROD1	-0.79	-5.75	-0.42	4.68e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg26935685	chr1:15502881	TMEM51	-0.55	-4.64	-0.35	7.56e-6	Systolic blood pressure;
PAAD	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg20893579	chr22:38215064	NA	-0.55	-5.77	-0.42	4.3e-8	Glioblastoma;Glioma;
PAAD	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.56	-5.01	-0.38	1.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-5.25	-0.39	5.02e-7	Daytime sleep phenotypes;
PAAD	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.56	-5.87	-0.43	2.64e-8	Hepatitis;
PAAD	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.61	6.04	0.44	1.14e-8	Monocyte count;
PAAD	cis	rs9463078	0.677	rs6458423	chr6:45140645	C/T	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg27490568	chr2:178487706	NA	0.39	4.31	0.33	2.97e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg10072921	chr12:121022843	NA	-0.36	-4.73	-0.36	5.13e-6	High light scatter reticulocyte count;
PAAD	cis	rs752010	0.749	rs10749841	chr1:42112054	G/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.08	0.38	1.07e-6	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.0	-0.38	1.55e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.51	-6.34	-0.46	2.43e-9	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00132135	chr12:107155510	RFX4	-0.6	-6.42	-0.46	1.61e-9	Obesity-related traits;
PAAD	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	0.83	5.48	0.41	1.73e-7	Systemic lupus erythematosus;
PAAD	cis	rs12541635	0.967	rs11997513	chr8:107093325	C/T	cg10147462	chr8:107024639	NA	-0.46	-4.8	-0.36	3.83e-6	Age of smoking initiation;
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg17294928	chr15:75287854	SCAMP5	0.44	4.5	0.34	1.33e-5	Caffeine consumption;
PAAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg18435832	chr15:45671155	LOC145663;GATM	0.45	4.27	0.33	3.41e-5	Homoarginine levels;
PAAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.76	-5.78	-0.42	4.09e-8	Mean platelet volume;
PAAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs9346353	1.000	rs9351772	chr6:70428200	C/T	cg03001484	chr6:70507230	LMBRD1	-0.32	-4.33	-0.33	2.72e-5	Sleep duration;
PAAD	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg11232448	chr19:2858854	NA	-0.47	-4.73	-0.36	5.1e-6	Total cholesterol levels;
PAAD	cis	rs3177980	0.673	rs73026213	chr1:169850374	T/C	cg18229820	chr1:169693534	SELE	0.48	4.27	0.33	3.38e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.71	4.9	0.37	2.43e-6	Vitiligo;
PAAD	cis	rs4764487	0.735	rs3181301	chr12:6345784	G/T	cg08284733	chr12:6341482	CD9	0.43	4.8	0.36	3.73e-6	Mean platelet volume;
PAAD	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18364779	chr6:26104403	HIST1H4C	0.52	5.25	0.39	5.15e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.32e-12	Height;
PAAD	cis	rs2279817	0.863	rs35871295	chr1:17984468	A/T	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-5.99	-0.44	1.45e-8	Neuroticism;
PAAD	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.9	-0.37	2.42e-6	Primary sclerosing cholangitis;
PAAD	cis	rs116248771	0.549	rs9849301	chr3:158444860	C/T	cg16708174	chr3:158430962	RARRES1	0.81	5.97	0.44	1.63e-8	diarrhoeal disease at age 2;
PAAD	cis	rs9463078	0.528	rs13211229	chr6:44912462	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.45	-0.34	1.64e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.94	10.16	0.64	7.67e-19	Blood metabolite levels;
PAAD	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg10616300	chr11:66138557	SLC29A2	0.33	4.41	0.34	1.91e-5	Educational attainment (years of education);
PAAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.16	-0.45	6.2e-9	Total body bone mineral density;
PAAD	cis	rs55788414	1.000	rs34242559	chr16:81180138	T/C	cg06400318	chr16:81190750	PKD1L2	-1.03	-6.35	-0.46	2.37e-9	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	0.94	5.86	0.43	2.74e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs757081	0.658	rs105290	chr11:17292068	T/C	cg15432903	chr11:17409602	KCNJ11	-0.53	-5.67	-0.42	7.14e-8	Systolic blood pressure;
PAAD	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.69	-7.97	-0.54	3.58e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.68	0.48	4.27e-10	Breast cancer;
PAAD	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.52	0.41	1.41e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23135900	chr13:50656378	DLEU1;DLEU2	0.6	6.62	0.47	5.91e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.44	4.27	0.33	3.38e-5	Red blood cell count;
PAAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.81	-9.04	-0.59	6.97e-16	Aortic root size;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.64e-5	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09996344	chr7:66093369	KCTD7	0.68	6.73	0.48	3.24e-10	Obesity-related traits;
PAAD	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.29	-0.51	1.54e-11	Mosquito bite size;
PAAD	cis	rs6594713	0.807	rs10477490	chr5:112687408	G/A	cg12552261	chr5:112820674	MCC	0.69	5.31	0.4	3.86e-7	Brain cytoarchitecture;
PAAD	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-5.16	-0.39	7.57e-7	Cognitive test performance;
PAAD	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg07701084	chr6:150067640	NUP43	-0.54	-4.83	-0.36	3.25e-6	Lung cancer;
PAAD	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.99	-10.72	-0.66	2.54e-20	Refractive error;
PAAD	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.68	-0.35	6.34e-6	Bipolar disorder;
PAAD	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.07	0.59	5.74e-16	Hemoglobin concentration;
PAAD	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs12476592	0.571	rs262475	chr2:63869045	A/T	cg10828910	chr2:63850056	LOC388955	0.52	4.58	0.35	9.5e-6	Childhood ear infection;
PAAD	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.32	4.54	0.35	1.16e-5	Migraine;
PAAD	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.7	-5.68	-0.42	6.69e-8	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6782228	1.000	rs35604103	chr3:128334852	C/T	cg15607142	chr3:128420513	NA	-0.43	-4.56	-0.35	1.05e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7156960	0.898	rs12884039	chr14:76717953	A/G	cg13981132	chr14:76734493	NA	0.51	4.94	0.37	2.03e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg15660573	chr17:549704	VPS53	-0.65	-5.99	-0.44	1.46e-8	Prostate cancer;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg00206168	chr11:65308501	LTBP3	1.71	9.54	0.61	3.33e-17	Height;
PAAD	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg14583973	chr4:3374767	RGS12	-0.36	-5.45	-0.4	1.97e-7	Mean platelet volume;
PAAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.82	-7.93	-0.54	4.45e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2030114	1.000	rs74017043	chr16:51612944	A/T	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.7	6.35	0.46	2.4e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg21238619	chr17:78079768	GAA	-0.51	-5.0	-0.38	1.55e-6	Yeast infection;
PAAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23281280	chr6:28129359	ZNF389	-0.7	-5.65	-0.42	7.56e-8	Depression;
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	5.56	0.41	1.2e-7	Body mass index;
PAAD	cis	rs258892	0.895	rs9293437	chr5:72041905	C/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.39	0.34	2.13e-5	Menarche (age at onset);
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.57	-7.18	-0.5	2.89e-11	Longevity;Endometriosis;
PAAD	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-6.59	-0.47	6.94e-10	Smoking initiation;
PAAD	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.54	-4.52	-0.34	1.24e-5	Heschl's gyrus morphology;
PAAD	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.74	0.48	3.03e-10	Rheumatoid arthritis;
PAAD	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.54	-7.2	-0.5	2.65e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg02917321	chr22:38215204	NA	-0.45	-4.87	-0.37	2.82e-6	Glioblastoma;Glioma;
PAAD	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.83	9.41	0.61	7.51e-17	Total body bone mineral density;
PAAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.55	6.16	0.45	6.29e-9	Major depressive disorder;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6681460	0.585	rs1359463	chr1:67169565	G/A	cg02459107	chr1:67143332	SGIP1	0.58	5.46	0.4	1.91e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs12594711	1	rs12594711	chr15:78793921	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-4.56	-0.35	1.04e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.51	4.75	0.36	4.77e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.88	10.67	0.65	3.47e-20	Menarche (age at onset);
PAAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.65	-7.75	-0.53	1.23e-12	Sense of smell;
PAAD	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.68	0.36	6.23e-6	Electrocardiographic conduction measures;
PAAD	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg06484146	chr7:12443880	VWDE	-0.63	-4.5	-0.34	1.34e-5	Coronary artery disease;
PAAD	cis	rs6011674	0.808	rs75318321	chr20:61844363	T/C	cg12207022	chr20:61734930	HAR1A;HAR1B	0.74	4.38	0.33	2.24e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg26695010	chr11:65641043	EFEMP2	-0.44	-4.27	-0.33	3.45e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.69	0.36	6e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs34845616	0.551	rs12576074	chr11:133686324	A/G	cg06766960	chr11:133703094	NA	-0.53	-4.31	-0.33	2.87e-5	Hand grip strength;
PAAD	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg19567339	chr10:100142640	NA	0.42	4.52	0.34	1.21e-5	Metabolite levels;
PAAD	cis	rs2594989	0.778	rs6764721	chr3:11470639	A/T	cg01796438	chr3:11312864	ATG7	-0.57	-4.43	-0.34	1.83e-5	Circulating chemerin levels;
PAAD	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.79	-8.61	-0.57	8.8e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6604026	0.656	rs11164835	chr1:93379093	A/G	cg13858687	chr1:93297071	RPL5	-0.48	-4.34	-0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg27494647	chr7:150038898	RARRES2	0.52	5.24	0.39	5.39e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg00621258	chr20:60781288	NA	0.67	4.34	0.33	2.61e-5	Obesity-related traits;
PAAD	cis	rs15676	0.733	rs2900269	chr9:131569878	G/T	cg00228799	chr9:131580591	ENDOG	0.65	6.17	0.45	5.97e-9	Blood metabolite levels;
PAAD	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.88	10.84	0.66	1.21e-20	Prudent dietary pattern;
PAAD	cis	rs9810890	1.000	rs73207976	chr3:128569020	C/T	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs787274	1.000	rs2153837	chr9:115463001	A/T	cg13803584	chr9:115635662	SNX30	0.94	5.24	0.39	5.35e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.55	-4.69	-0.36	5.99e-6	Type 2 diabetes;
PAAD	trans	rs901683	1.000	rs34574958	chr10:46087040	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3177980	0.560	rs16862745	chr1:169860199	C/T	cg18229820	chr1:169693534	SELE	0.48	4.25	0.33	3.77e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.67	9.02	0.59	7.65e-16	Hemoglobin concentration;
PAAD	cis	rs630539	0.793	rs7207936	chr17:40790311	T/G	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.88	10.93	0.66	6.97e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg05895507	chr15:77155635	SCAPER	0.36	4.32	0.33	2.77e-5	Blood metabolite levels;
PAAD	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.47	-5.17	-0.39	7.17e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs11650175	0.613	rs4790927	chr17:63786049	A/G	cg07283582	chr17:63770753	CCDC46	0.37	4.25	0.33	3.71e-5	Chin dimples;
PAAD	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17376030	chr22:41985996	PMM1	0.68	4.62	0.35	8.28e-6	Vitiligo;
PAAD	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg11494091	chr17:61959527	GH2	0.58	4.75	0.36	4.66e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg09376583	chr16:88111425	NA	-0.5	-4.4	-0.34	2.04e-5	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.69	5.44	0.4	2.09e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.97	-0.37	1.8e-6	Monocyte percentage of white cells;
PAAD	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.72	7.15	0.5	3.35e-11	HIV-1 control;
PAAD	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.52	4.58	0.35	9.47e-6	Lymphocyte counts;
PAAD	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.84	10.71	0.66	2.69e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.09	0.5	4.74e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.87	5.5	0.41	1.6e-7	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg10729496	chr3:10149963	C3orf24	0.84	6.58	0.47	7.29e-10	Alzheimer's disease;
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.34	0.4	3.26e-7	Total body bone mineral density;
PAAD	cis	rs12282928	0.959	rs2007961	chr11:48273208	G/C	cg22827986	chr11:48284249	OR4X1	-0.43	-5.37	-0.4	2.92e-7	Migraine - clinic-based;
PAAD	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.96	-9.84	-0.62	5.48e-18	Coronary artery disease;
PAAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.45	-4.52	-0.34	1.22e-5	Menarche (age at onset);
PAAD	cis	rs8067354	0.527	rs1292039	chr17:57974913	A/T	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.61	-5.92	-0.43	2.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.75	7.89	0.54	5.38e-13	Facial morphology (factor 20);
PAAD	cis	rs35160687	0.901	rs12999029	chr2:86502913	G/A	cg10973622	chr2:86423274	IMMT	0.42	4.85	0.37	2.98e-6	Night sleep phenotypes;
PAAD	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.81	9.64	0.62	1.86e-17	Colorectal cancer;
PAAD	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.5	4.96	0.37	1.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2282300	1.000	rs12796693	chr11:30429583	A/C	cg25418670	chr11:30344373	C11orf46	-0.48	-4.45	-0.34	1.67e-5	Morning vs. evening chronotype;
PAAD	cis	rs6850606	0.557	rs34045653	chr4:42868441	C/T	cg24533989	chr4:42659536	ATP8A1	0.5	4.28	0.33	3.27e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.54	4.9	0.37	2.39e-6	Mean corpuscular volume;
PAAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg08132940	chr7:1081526	C7orf50	0.59	4.29	0.33	3.12e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.42	6.18	0.45	5.71e-9	Subjective well-being;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.77	9.22	0.6	2.38e-16	Vitiligo;
PAAD	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.49	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg01299579	chr2:10830716	NOL10	0.44	4.35	0.33	2.45e-5	Prostate cancer;
PAAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.56	-5.4	-0.4	2.54e-7	Obesity-related traits;
PAAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg14433983	chr11:636460	DRD4	-0.45	-4.6	-0.35	8.9e-6	Systemic lupus erythematosus;
PAAD	cis	rs34421088	0.624	rs6986736	chr8:11584503	T/A	cg00262122	chr8:11665843	FDFT1	-0.56	-4.98	-0.37	1.72e-6	Neuroticism;
PAAD	cis	rs9815354	0.953	rs1717007	chr3:41942199	T/C	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.86e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.44	-4.56	-0.35	1.07e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-9.66	-0.62	1.65e-17	Obesity-related traits;
PAAD	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg23417306	chr2:180868811	CWC22	-0.48	-4.31	-0.33	2.91e-5	Schizophrenia;
PAAD	cis	rs11942476	0.619	rs4314271	chr4:21489423	A/C	cg14992154	chr4:20701870	PACRGL	0.59	4.5	0.34	1.33e-5	IgG glycosylation;
PAAD	trans	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg17830980	chr10:43048298	ZNF37B	0.69	8.08	0.55	1.83e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg16576597	chr16:28551801	NUPR1	0.63	6.81	0.48	2.13e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg04289385	chr6:36355825	ETV7	0.46	4.77	0.36	4.24e-6	Platelet distribution width;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.01	0.81	5.21e-37	Prudent dietary pattern;
PAAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg03538708	chr1:25844672	NA	-0.49	-5.04	-0.38	1.32e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2147959	0.739	rs11587839	chr1:228630979	C/T	cg18477163	chr1:228402036	OBSCN	-0.43	-4.49	-0.34	1.43e-5	Adult asthma;
PAAD	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.65	-6.21	-0.45	4.75e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2299587	0.841	rs3213605	chr8:17885091	T/C	cg08627089	chr8:17753878	FGL1	-0.45	-4.48	-0.34	1.45e-5	Economic and political preferences;
PAAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.87	10.19	0.64	6.55e-19	Coronary artery disease;
PAAD	cis	rs757978	1.000	rs7601738	chr2:242375813	A/T	cg03294028	chr2:242255774	SEPT2;HDLBP	0.8	4.93	0.37	2.11e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.61	6.41	0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.68	7.38	0.51	9.48e-12	Lung cancer;
PAAD	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg16447950	chr5:562315	NA	-0.52	-4.93	-0.37	2.11e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.93	0.49	1.11e-10	Alzheimer's disease;
PAAD	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg21994712	chr19:21861136	NA	-0.47	-4.61	-0.35	8.36e-6	Pain;
PAAD	cis	rs2421770	0.614	rs10742338	chr11:35277088	T/C	cg13971030	chr11:35366721	SLC1A2	-0.5	-4.87	-0.37	2.76e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.07	9.97	0.63	2.52e-18	Orofacial clefts;
PAAD	cis	rs2213920	1.000	rs9409169	chr9:118273407	A/G	cg13918206	chr9:118159781	DEC1	-0.89	-5.65	-0.42	7.58e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs941898	0.690	rs7157984	chr14:100625456	T/G	cg26002632	chr14:100625216	DEGS2	-0.42	-4.95	-0.37	1.94e-6	White matter hyperintensity burden;
PAAD	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.79	8.32	0.56	4.64e-14	Cognitive test performance;
PAAD	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg16810054	chr20:33298113	TP53INP2	-0.59	-4.62	-0.35	8.17e-6	Neuroticism;
PAAD	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg24112000	chr20:60950667	NA	-0.71	-9.32	-0.6	1.26e-16	Colorectal cancer;
PAAD	cis	rs558003	0.609	rs797482	chr13:51214613	A/G	cg24585282	chr13:51257555	NA	0.67	4.53	0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.7	-7.43	-0.52	7.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.58	4.69	0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7188861	0.724	rs1794019	chr16:11379775	T/C	cg01510278	chr16:11456238	NA	0.43	4.3	0.33	3.08e-5	HDL cholesterol;
PAAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg21929781	chr1:2537748	MMEL1	-0.54	-5.7	-0.42	6.07e-8	Ulcerative colitis;
PAAD	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.61	6.18	0.45	5.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12903285	1	rs12903285	chr15:78778953	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-4.55	-0.35	1.1e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.74e-7	Body mass index;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg27511599	chr7:32358540	NA	0.76	4.52	0.34	1.22e-5	Body mass index;
PAAD	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg07099767	chr17:78039528	CCDC40	0.46	4.37	0.33	2.32e-5	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.72	-0.36	5.25e-6	Height;
PAAD	cis	rs7189233	1.000	rs7189233	chr16:53455383	C/T	cg00221382	chr16:54322308	NA	-0.28	-4.38	-0.33	2.21e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg25664220	chr3:72788482	NA	-0.69	-7.1	-0.5	4.57e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.99	0.59	9.35e-16	Menopause (age at onset);
PAAD	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.66	-0.42	7.26e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg27499820	chr13:21296301	IL17D	0.52	4.66	0.35	6.72e-6	Dental caries;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-11.5	-0.68	2.06e-22	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26673775	chr3:50273532	GNAI2	0.67	6.53	0.47	9.49e-10	Obesity-related traits;
PAAD	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7624766	0.743	rs12486979	chr3:160483785	A/C	cg22637730	chr3:160473554	PPM1L	0.55	4.96	0.37	1.83e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs4921915	0.598	rs4646243	chr8:18247609	T/C	cg18736775	chr8:18248649	NAT2	-0.64	-4.66	-0.35	6.92e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.72	5.84	0.43	3.04e-8	Common traits (Other);
PAAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg07168214	chr17:7380112	ZBTB4	-0.63	-5.84	-0.43	3.11e-8	Androgen levels;
PAAD	trans	rs1326986	0.826	rs11011369	chr10:20030442	A/G	cg04724540	chr1:166916762	ILDR2	-1.05	-6.95	-0.49	1.03e-10	Ankylosing spondylitis;
PAAD	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.81	9.11	0.59	4.56e-16	Birth weight;
PAAD	cis	rs643506	0.874	rs631318	chr11:111677695	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.54	-4.69	-0.36	6.02e-6	Breast cancer;
PAAD	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	14.47	0.76	2.2e-30	Testicular germ cell tumor;
PAAD	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.36	-4.39	-0.34	2.1e-5	Cognitive performance;
PAAD	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.08	0.38	1.08e-6	HIV-1 control;
PAAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.63	-4.52	-0.34	1.26e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.41	-4.79	-0.36	3.94e-6	Mean arterial pressure;
PAAD	cis	rs10501293	0.917	rs10838003	chr11:43071988	T/A	cg03447554	chr11:43094025	NA	0.5	5.1	0.38	9.97e-7	Cognitive performance;
PAAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg02811702	chr13:24901961	NA	0.52	5.54	0.41	1.31e-7	Obesity-related traits;
PAAD	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.98e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02743256	chr7:2109353	MAD1L1	-0.71	-6.57	-0.47	7.56e-10	Neuroticism;
PAAD	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	IgG glycosylation;
PAAD	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.51	-4.65	-0.35	7.13e-6	Educational attainment (years of education);
PAAD	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.79	-9.35	-0.6	1.05e-16	Colorectal cancer;
PAAD	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.54e-6	Hypospadias;
PAAD	cis	rs11590090	0.906	rs6686669	chr1:113329866	G/A	cg25707805	chr1:113285387	NA	0.33	4.42	0.34	1.86e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.64	5.57	0.41	1.12e-7	Response to diuretic therapy;
PAAD	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.29	-0.33	3.1e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg01214346	chr17:406501	NA	0.45	4.28	0.33	3.32e-5	Prostate cancer;
PAAD	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.13	-0.38	8.77e-7	Subjective well-being;
PAAD	cis	rs55728055	0.661	rs16989278	chr22:31957167	A/G	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	cis	rs6442522	0.678	rs878945	chr3:15509327	C/G	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.13	-0.38	8.86e-7	Bipolar disorder;
PAAD	cis	rs1421334	0.647	rs1125841	chr8:30858054	C/T	cg00964221	chr8:30240029	NA	0.47	4.32	0.33	2.76e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.31	0.33	2.94e-5	Cancer;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.82	6.05	0.44	1.06e-8	Alzheimer's disease;
PAAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.62	0.41	8.97e-8	Tonsillectomy;
PAAD	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg00536532	chr6:33561449	C6orf227	-0.4	-4.29	-0.33	3.2e-5	Plateletcrit;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.11	0.81	2.86e-37	Height;
PAAD	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg20130138	chr11:64956067	CAPN1	0.62	4.47	0.34	1.5e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs11696501	0.637	rs6104298	chr20:44327774	A/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.49	-4.79	-0.36	4e-6	Prostate cancer;
PAAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg05110241	chr16:68378359	PRMT7	-1.01	-6.15	-0.45	6.53e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs800160	0.777	rs2521284	chr11:2341677	C/T	cg09785033	chr11:2336066	TSPAN32	0.54	4.5	0.34	1.33e-5	Bacteremia;
PAAD	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-4.7	-0.36	5.8e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs2030114	1.000	rs8063267	chr16:51615092	T/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.45	0.61	5.93e-17	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg27234864	chr13:21295941	IL17D	0.59	5.21	0.39	6.19e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg16898833	chr6:26189333	HIST1H4D	0.87	4.7	0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.46	-0.4	1.9e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.98	-9.75	-0.62	9.51e-18	Blood pressure (smoking interaction);
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.5	5.09	0.38	1.04e-6	Testicular germ cell tumor;
PAAD	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg18279126	chr7:2041391	MAD1L1	0.63	6.25	0.45	3.84e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.31	-0.46	2.86e-9	Neuroticism;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.43	4.54	0.35	1.16e-5	Longevity;Endometriosis;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.28	-7.69	-0.53	1.7e-12	Body mass index;
PAAD	cis	rs1371614	0.531	rs77562583	chr2:27151643	G/A	cg00617064	chr2:27272375	NA	-0.41	-4.4	-0.34	2e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs6604026	0.656	rs4561051	chr1:93391346	A/C	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02992252	chr1:23857546	E2F2	0.62	6.41	0.46	1.76e-9	Myopia (pathological);
PAAD	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.21	4.93	0.37	2.15e-6	Urinary tract infection frequency;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.68	-7.77	-0.53	1.1e-12	Iron status biomarkers;
PAAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-8.55	-0.57	1.23e-14	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.43	-4.5	-0.34	1.37e-5	Inflammatory skin disease;
PAAD	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.63	6.76	0.48	2.77e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg27182935	chr16:89790473	ZNF276	-0.69	-4.37	-0.33	2.28e-5	Skin colour saturation;
PAAD	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.43	4.33	0.33	2.68e-5	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.9	12.01	0.7	8.51e-24	Prudent dietary pattern;
PAAD	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-1.13	-12.49	-0.71	4.56e-25	Hair shape;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.36	-4.8	-0.36	3.76e-6	Lymphocyte counts;
PAAD	cis	rs8025118	0.583	rs12903363	chr15:79551676	A/T	cg11862246	chr15:78730200	IREB2	0.53	4.5	0.34	1.34e-5	Cognitive function;
PAAD	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.47	4.81	0.36	3.55e-6	Red blood cell count;
PAAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	6.88	0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg18939081	chr1:31884902	SERINC2	0.5	5.71	0.42	5.66e-8	Alcohol dependence;
PAAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.51	-6.68	-0.48	4.13e-10	Height;
PAAD	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.81	8.5	0.57	1.66e-14	Selective IgA deficiency;
PAAD	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg18551225	chr6:44695536	NA	-0.7	-6.97	-0.49	9.26e-11	Total body bone mineral density;
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.57	-5.33	-0.4	3.55e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg04160749	chr8:58172571	NA	-0.64	-4.66	-0.35	6.94e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.01	0.54	2.79e-13	Corneal astigmatism;
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.59	6.86	0.49	1.64e-10	Aortic root size;
PAAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.1	-6.39	-0.46	1.92e-9	Body mass index;
PAAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg02462569	chr6:150064036	NUP43	-0.43	-4.69	-0.36	6.08e-6	Lung cancer;
PAAD	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg26876637	chr1:152193138	HRNR	0.86	6.41	0.46	1.75e-9	Atopic dermatitis;
PAAD	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.64	5.8	0.43	3.77e-8	Blood metabolite levels;
PAAD	cis	rs9397240	0.789	rs10499303	chr6:155615239	G/A	cg06694381	chr6:155569200	TIAM2	-0.47	-4.38	-0.33	2.2e-5	Life satisfaction;
PAAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.29	-0.39	4.18e-7	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.09	16.15	0.79	8.74e-35	Height;
PAAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15534507	chr18:15165202	NA	0.49	6.62	0.47	5.87e-10	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs2882667	0.654	rs884469	chr5:138155959	G/C	cg09476006	chr5:138032270	NA	-0.49	-6.43	-0.46	1.54e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.61	-5.62	-0.41	9.01e-8	Cognitive function;
PAAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg17366294	chr4:99064904	C4orf37	-0.49	-5.3	-0.4	3.94e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	6.85	0.49	1.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.43	0.34	1.77e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg15017067	chr4:17643749	FAM184B	0.44	4.86	0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.52	-0.41	1.45e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs4757319	0.515	rs6486237	chr11:15334740	G/A	cg03245590	chr11:15329459	NA	-0.44	-5.3	-0.39	4.03e-7	Breast cancer;
PAAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg17764715	chr19:33622953	WDR88	0.59	5.55	0.41	1.23e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24102360	chr19:14801145	ZNF333	0.56	6.6	0.47	6.36e-10	Monocyte percentage of white cells;
PAAD	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.62	-0.35	8.25e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4764124	0.556	rs247326	chr12:14921740	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	5.51	0.41	1.52e-7	Pubertal anthropometrics;
PAAD	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.48	-5.27	-0.39	4.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	5.31	0.4	3.9e-7	Lung cancer in ever smokers;
PAAD	cis	rs2071303	0.502	rs9393686	chr6:26106601	C/A	cg21479132	chr6:26055353	NA	0.58	4.59	0.35	9.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.29	-0.33	3.14e-5	Menopause (age at onset);
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.4	6.12	0.44	7.51e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg12379764	chr21:47803548	PCNT	0.62	5.17	0.39	7.29e-7	Lymphocyte counts;
PAAD	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.58	-0.57	1e-14	Total body bone mineral density;
PAAD	cis	rs55728055	0.661	rs62237764	chr22:31947393	T/G	cg01338084	chr22:32026380	PISD	1.51	8.54	0.57	1.27e-14	Age-related hearing impairment;
PAAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.37	-0.33	2.32e-5	Asthma;
PAAD	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.55	-0.35	1.11e-5	Lung cancer in ever smokers;
PAAD	cis	rs4455778	0.580	rs4560745	chr7:49115412	G/T	cg26309511	chr7:48887640	NA	0.39	4.82	0.36	3.5e-6	Lung cancer in never smokers;
PAAD	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.52	-4.73	-0.36	5.12e-6	Red blood cell traits;
PAAD	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg02135003	chr7:105160482	PUS7	-0.83	-6.67	-0.48	4.55e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs897984	1.000	rs897984	chr16:30886643	T/C	cg00531865	chr16:30841666	NA	0.59	5.76	0.42	4.46e-8	Dementia with Lewy bodies;
PAAD	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg07828340	chr4:882639	GAK	1.24	6.25	0.45	3.84e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.52	-4.41	-0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.73	6.46	0.46	1.31e-9	Pediatric autoimmune diseases;
PAAD	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.09	8.69	0.58	5.25e-15	Vitiligo;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg10818794	chr15:86012489	AKAP13	-0.5	-5.57	-0.41	1.1e-7	Coronary artery disease;
PAAD	cis	rs10887741	0.532	rs1408378	chr10:89413960	G/A	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.13	-0.38	8.66e-7	Exercise (leisure time);
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.63	6.9	0.49	1.28e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs1455213	0.544	rs2702559	chr4:15168985	C/A	cg12377275	chr4:15005593	CPEB2	0.49	4.63	0.35	7.81e-6	Parental longevity (mother's age at death);
PAAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg25364880	chr3:44379878	C3orf23	0.58	5.4	0.4	2.48e-7	Depressive symptoms;
PAAD	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.85	8.68	0.58	5.76e-15	Corneal astigmatism;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-7.0	-0.49	7.76e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg16591659	chr17:78472290	NA	0.51	4.88	0.37	2.67e-6	Fractional excretion of uric acid;
PAAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.62	5.58	0.41	1.1e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.71	8.02	0.55	2.6e-13	Longevity;Endometriosis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06951450	chr11:126138433	FOXRED1;SRPR	-0.69	-7.28	-0.51	1.71e-11	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.65	7.61	0.53	2.75e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs56677333	1.000	rs59058429	chr8:6743800	C/T	cg02606480	chr8:6366994	ANGPT2;MCPH1	-0.78	-4.26	-0.33	3.58e-5	Psoriatic arthritis;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16102063	chr8:22298240	PPP3CC	0.55	6.58	0.47	7.34e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.35	-4.27	-0.33	3.41e-5	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.11	0.44	8.01e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	trans	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg19346786	chr7:2764209	NA	-0.36	-5.08	-0.38	1.11e-6	Height;
PAAD	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.54	4.91	0.37	2.31e-6	Blood metabolite levels;
PAAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg10207240	chr12:122356781	WDR66	0.53	5.63	0.42	8.42e-8	Mean corpuscular volume;
PAAD	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg26597838	chr10:835615	NA	0.49	5.31	0.4	3.89e-7	Survival in rectal cancer;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.54	0.61	3.39e-17	Electrocardiographic conduction measures;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01896656	chr7:786225	HEATR2	-0.55	-6.31	-0.46	2.94e-9	Monocyte percentage of white cells;
PAAD	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg19163074	chr7:65112434	INTS4L2	-0.47	-4.38	-0.33	2.18e-5	Aortic root size;
PAAD	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg08514558	chr10:81106712	PPIF	0.53	6.45	0.46	1.41e-9	Height;
PAAD	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.39	0.4	2.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg25837213	chr17:80849375	TBCD	-0.47	-4.5	-0.34	1.35e-5	Breast cancer;
PAAD	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.5	0.41	1.6e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.67	-4.27	-0.33	3.42e-5	White matter integrity;
PAAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.24	0.51	2.07e-11	Menopause (age at onset);
PAAD	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	10.07	0.63	1.36e-18	Response to antipsychotic treatment;
PAAD	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg05134918	chr12:132603531	EP400NL	-0.65	-5.19	-0.39	6.64e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.55	5.05	0.38	1.24e-6	Platelet count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05780074	chr4:83812365	SEC31A	-0.65	-6.41	-0.46	1.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7619833	0.542	rs11129287	chr3:27497310	C/T	cg02860705	chr3:27208620	NA	0.44	4.8	0.36	3.84e-6	Breast cancer;
PAAD	cis	rs282587	0.569	rs426765	chr13:113414798	A/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.97	-0.37	1.82e-6	Glycated hemoglobin levels;
PAAD	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.48	5.43	0.4	2.14e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs73198271	0.515	rs1589613	chr8:8626940	T/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg26662049	chr15:89903672	NA	-0.32	-4.28	-0.33	3.33e-5	Rheumatoid arthritis;
PAAD	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.52	-6.33	-0.46	2.55e-9	Sitting height ratio;
PAAD	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.83	10.02	0.63	1.81e-18	Lung cancer;
PAAD	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.74	0.58	3.97e-15	Cognitive test performance;
PAAD	cis	rs6494488	0.500	rs72741332	chr15:64744790	T/C	cg16425858	chr15:64791681	ZNF609	1.01	4.54	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.53	-5.03	-0.38	1.35e-6	Subjective well-being;
PAAD	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.51e-21	Ulcerative colitis;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16405210	chr4:1374714	KIAA1530	0.49	4.88	0.37	2.63e-6	Obesity-related traits;
PAAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Coronary artery disease;
PAAD	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.39	-5.52	-0.41	1.45e-7	Breast cancer;
PAAD	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.16e-9	Educational attainment;
PAAD	cis	rs66478310	0.623	rs4964249	chr12:108713584	A/C	cg04872675	chr12:108983234	NA	0.83	5.31	0.4	3.86e-7	Plasma clusterin levels;
PAAD	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg24565620	chr2:194026	NA	-0.67	-5.17	-0.39	7.43e-7	Blood protein levels;
PAAD	cis	rs72627123	1.000	rs17093474	chr14:74342413	A/G	cg19860245	chr14:74300557	NA	-0.77	-5.53	-0.41	1.36e-7	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg17201900	chr20:34330562	RBM39	-0.63	-4.4	-0.34	1.99e-5	Total cholesterol levels;
PAAD	cis	rs73206853	0.541	rs11837455	chr12:110505621	C/A	cg12870014	chr12:110450643	ANKRD13A	1.0	5.66	0.42	7.34e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.47	5.58	0.41	1.06e-7	Coronary artery disease;
PAAD	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.63	4.76	0.36	4.53e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg04717802	chr22:42394638	WBP2NL	0.52	4.44	0.34	1.69e-5	Birth weight;
PAAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg03255953	chr3:127056837	NA	-0.51	-5.73	-0.42	5.2100000000000003e-08	Interleukin-10 levels;Interleukin-13 levels;
PAAD	cis	rs757110	0.524	rs214067	chr11:17305831	A/C	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.69	-0.36	6.03e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08858875	chr6:86388188	SNHG5;SNORD50B;SNORD50A	0.54	6.34	0.46	2.47e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs507080	0.885	rs533144	chr11:118559247	C/A	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.61	6.4	0.46	1.84e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs72781680	0.566	rs6713865	chr2:23899807	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	5.81	0.43	3.52e-8	Lymphocyte counts;
PAAD	cis	rs2020921	0.510	rs12544318	chr8:41983076	A/G	cg17828057	chr8:42037527	PLAT	0.78	4.97	0.37	1.75e-6	Plasma plasminogen activator levels;
PAAD	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.54	6.08	0.44	9.31e-9	Educational attainment;
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-8.81	-0.58	2.73e-15	Prostate cancer;
PAAD	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.62	5.64	0.42	8.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.99	12.04	0.7	7.34e-24	Diastolic blood pressure;
PAAD	cis	rs6594713	0.921	rs7714760	chr5:112735231	T/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg09579323	chr1:150459698	TARS2	0.45	4.27	0.33	3.4e-5	Migraine;
PAAD	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-5.95	-0.43	1.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs4356203	0.905	rs9919540	chr11:17080333	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11084035	chr11:62414045	GANAB	0.66	7.09	0.5	4.6e-11	Myopia (pathological);
PAAD	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-1.1	-14.96	-0.77	1.12e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.65	-6.34	-0.46	2.5e-9	Breast cancer;
PAAD	cis	rs9463078	0.691	rs17288278	chr6:45298482	G/A	cg25276700	chr6:44698697	NA	0.54	6.05	0.44	1.08e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9395066	0.545	rs10948197	chr6:44967490	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.44	-0.4	2.08e-7	Height;
PAAD	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg26816564	chr1:7831052	VAMP3	0.95	6.85	0.49	1.75e-10	Inflammatory bowel disease;
PAAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg18769074	chr3:133464867	TF	0.41	4.68	0.36	6.2e-6	Iron status biomarkers;
PAAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg10547527	chr2:198650123	BOLL	-0.77	-5.48	-0.41	1.72e-7	Ulcerative colitis;
PAAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.52	-4.99	-0.38	1.64e-6	Mortality in heart failure;
PAAD	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.54	6.72	0.48	3.41e-10	Atrioventricular conduction;
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.01	-0.44	1.32e-8	Prostate cancer;
PAAD	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.82	-6.71	-0.48	3.53e-10	Diabetic kidney disease;
PAAD	cis	rs4658101	0.906	rs1192408	chr1:92069892	T/C	cg06318676	chr1:92077357	NA	0.42	4.62	0.35	8.12e-6	Optic disc area;Vertical cup-disc ratio;
PAAD	cis	rs8060686	0.858	rs7191129	chr16:67801391	A/G	cg05110241	chr16:68378359	PRMT7	-0.69	-5.12	-0.38	9.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7246760	0.500	rs4325679	chr19:9984679	T/G	cg07515324	chr19:10461336	TYK2	-0.85	-4.5	-0.34	1.35e-5	Pursuit maintenance gain;
PAAD	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-5.36	-0.4	2.97e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs2031532	0.544	rs9316454	chr13:50042484	T/G	cg08779649	chr13:50194554	NA	0.32	4.32	0.33	2.78e-5	Cardiac hypertrophy;
PAAD	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg10483660	chr13:112241077	NA	0.54	4.94	0.37	2e-6	Menarche (age at onset);
PAAD	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-4.57	-0.35	1e-5	Huntington's disease progression;
PAAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg21496419	chr19:44306685	LYPD5	0.44	5.43	0.4	2.15e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.46	5.61	0.41	9.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04004882	chr2:215674386	BARD1	0.65	4.55	0.35	1.07e-5	Neuroblastoma;
PAAD	cis	rs3106136	0.807	rs28716591	chr4:95274832	A/G	cg11021082	chr4:95130006	SMARCAD1	0.59	5.59	0.41	1.03e-7	Capecitabine sensitivity;
PAAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.51	-6.8	-0.48	2.28e-10	Renal cell carcinoma;
PAAD	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.48	0.52	5.66e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg21361702	chr7:150065534	REPIN1	0.57	4.85	0.37	3.08e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.86	10.66	0.65	3.7e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.72	8.02	0.55	2.63e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.3	0.33	3.05e-5	Skin colour saturation;
PAAD	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.68	6.39	0.46	1.95e-9	Corneal astigmatism;
PAAD	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs818427	0.528	rs153552	chr5:112233750	T/C	cg06941702	chr5:112196734	SRP19	0.58	5.68	0.42	6.64e-8	Total body bone mineral density;
PAAD	cis	rs2236521	0.632	rs35265388	chr20:60894278	C/T	cg09594475	chr20:60884601	LAMA5	0.52	5.64	0.42	8.13e-8	Pelvic organ prolapse;
PAAD	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	5.51	0.41	1.5e-7	Neuroticism;
PAAD	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.67	5.81	0.43	3.56e-8	Coronary heart disease;
PAAD	cis	rs2131877	0.871	rs58948928	chr3:194866789	C/A	cg24618514	chr3:194868507	C3orf21	0.48	4.39	0.34	2.12e-5	Non-small cell lung cancer;
PAAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs6906287	0.573	rs7757943	chr6:118697981	C/G	cg21191810	chr6:118973309	C6orf204	0.44	5.5	0.41	1.58e-7	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg22947322	chr17:47091978	IGF2BP1	-0.54	-7.12	-0.5	3.93e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.52	-6.26	-0.45	3.68e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.64	-8.18	-0.55	1.04e-13	Schizophrenia;
PAAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.69	-0.48	3.92e-10	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg15595755	chr5:1867978	NA	0.42	4.39	0.34	2.13e-5	Cardiovascular disease risk factors;
PAAD	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.36	-0.4	3.02e-7	Pulmonary function;
PAAD	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs10078	0.660	rs11746538	chr5:427466	A/C	cg24955955	chr5:415729	AHRR	0.62	4.53	0.34	1.19e-5	Fat distribution (HIV);
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07930192	chr7:1003750	NA	0.36	4.36	0.33	2.43e-5	Longevity;Endometriosis;
PAAD	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2051773	0.567	rs4517490	chr11:17043054	G/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.8	-0.36	3.8e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.99	0.7	9.92e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg14983838	chr19:29218262	NA	0.69	5.92	0.43	2.02e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.78	-5.22	-0.39	5.7e-7	Coronary artery calcification;
PAAD	cis	rs2004318	1.000	rs74368210	chr19:55134842	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08279599	chr5:138089148	CTNNA1	0.6	6.71	0.48	3.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.44	-0.34	1.72e-5	Initial pursuit acceleration;
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.5	4.85	0.37	3.07e-6	Longevity;
PAAD	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg16230307	chr14:35515116	FAM177A1	0.42	4.39	0.34	2.14e-5	Psoriasis;
PAAD	cis	rs6688613	0.840	rs6699294	chr1:166955174	G/A	cg07049167	chr1:166818506	POGK	0.62	6.09	0.44	8.77e-9	Refractive astigmatism;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-4.55	-0.35	1.1e-5	Electroencephalogram traits;
PAAD	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg19930314	chr7:98593876	TRRAP	-0.49	-4.71	-0.36	5.55e-6	Breast cancer;
PAAD	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg05562828	chr17:3906858	NA	-0.55	-6.31	-0.46	2.86e-9	Type 2 diabetes;
PAAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.85	0.43	2.92e-8	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs13242816	1.000	rs2024209	chr7:116135336	T/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs73416724	0.544	rs80320191	chr6:43238395	C/T	cg17076780	chr6:43251928	TTBK1	0.63	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10186876	0.522	rs7565148	chr2:44188396	T/G	cg09541576	chr2:44873248	C2orf34	0.43	4.37	0.33	2.25e-5	Hand grip strength;
PAAD	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11825685	0.887	rs78560583	chr11:134571795	G/A	cg06603561	chr11:134479413	NA	-0.71	-4.81	-0.36	3.65e-6	IgG glycosylation;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg17541715	chr7:1216824	NA	-0.57	-6.87	-0.49	1.51e-10	Longevity;Endometriosis;
PAAD	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.75	-7.32	-0.51	1.34e-11	White matter hyperintensity burden;
PAAD	cis	rs2790216	0.853	rs2790239	chr10:59983271	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.75	-6.47	-0.46	1.26e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.97	13.49	0.74	9.01e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg02781088	chr2:113192302	RGPD8;RGPD5	0.85	6.0	0.44	1.41e-8	Yeast infection;
PAAD	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.74	-6.57	-0.47	7.55e-10	Body mass index;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg04717802	chr22:42394638	WBP2NL	-0.41	-4.41	-0.34	1.94e-5	Cognitive function;
PAAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg19847866	chr10:1019161	NA	-0.57	-4.61	-0.35	8.39e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.59	0.35	9.19e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.7	6.87	0.49	1.55e-10	Breast cancer;
PAAD	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.41	0.51	8.39e-12	Educational attainment;
PAAD	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.96	10.53	0.65	7.96e-20	Multiple sclerosis;
PAAD	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs10121009	0.610	rs575102	chr9:35315735	T/C	cg11846315	chr9:35647073	NA	-0.48	-4.46	-0.34	1.58e-5	Parkinson's disease;
PAAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.09	0.38	1.03e-6	Axial length;
PAAD	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.65	-6.21	-0.45	4.83e-9	Plateletcrit;Platelet count;
PAAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.25	-0.39	5.14e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	4.47	0.34	1.5e-5	Tonsillectomy;
PAAD	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg09658497	chr7:2847517	GNA12	0.68	7.07	0.5	5.23e-11	Height;
PAAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.17	6.35	0.46	2.4e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.78	0.42	4.11e-8	Height;
PAAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg23109721	chr2:106886537	NA	-0.68	-6.27	-0.45	3.63e-9	Facial morphology (factor 23);
PAAD	cis	rs9434723	0.920	rs11801562	chr1:9293156	G/A	cg04199779	chr1:9294473	H6PD	0.56	4.87	0.37	2.78e-6	Height;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg02071572	chr4:1403502	NA	0.38	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.37	-0.46	2.13e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-9.49	-0.61	4.47e-17	Bone mineral density;
PAAD	cis	rs7731390	0.681	rs78721012	chr5:131641726	A/G	cg07395648	chr5:131743802	NA	-0.73	-4.55	-0.35	1.09e-5	IgG glycosylation;
PAAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14180030	chr9:123475675	MEGF9	-0.48	-5.2	-0.39	6.26e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2235573	0.673	rs5756894	chr22:38450136	C/A	cg24053715	chr22:38214548	NA	-0.44	-4.36	-0.33	2.41e-5	Glioblastoma;Glioma;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg25952890	chr19:58913133	NA	0.72	5.74	0.42	4.87e-8	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15611037	chr6:35387204	PPARD	-0.66	-6.67	-0.48	4.52e-10	Obesity-related traits;
PAAD	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.41	-5.47	-0.41	1.78e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg09659197	chr4:152720779	NA	0.36	5.29	0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7487075	0.619	rs4076247	chr12:46833450	A/C	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.82	8.68	0.58	5.57e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.54	-0.35	1.14e-5	Biliary atresia;
PAAD	cis	rs2286379	0.773	rs7974924	chr12:1872277	T/A	cg05227549	chr12:1770782	NA	0.39	4.48	0.34	1.44e-5	Blood pressure (smoking interaction);
PAAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg04287289	chr16:89883240	FANCA	0.63	6.98	0.49	8.68e-11	Vitiligo;
PAAD	cis	rs12144094	0.882	rs10494229	chr1:120229117	A/G	cg20995928	chr1:120229863	NA	0.53	4.81	0.36	3.67e-6	Height;
PAAD	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.36	0.33	2.4e-5	Educational attainment;
PAAD	cis	rs6596100	0.538	rs1393244	chr5:132186007	T/G	cg14825688	chr5:132208181	LEAP2	-0.66	-4.89	-0.37	2.59e-6	Breast cancer;
PAAD	cis	rs62400317	0.859	rs6927213	chr6:45206283	A/G	cg20913747	chr6:44695427	NA	0.57	4.96	0.37	1.88e-6	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05625955	chr6:170560994	NA	0.6	6.5	0.47	1.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs56046484	1.000	rs2304415	chr15:85618841	A/G	cg08123816	chr15:85640762	PDE8A	-0.44	-4.59	-0.35	9.31e-6	Testicular germ cell tumor;
PAAD	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.52	5.28	0.39	4.46e-7	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24535234	chr17:6939145	SLC16A13	-0.69	-6.95	-0.49	1e-10	Neuroticism;
PAAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05901451	chr6:126070800	HEY2	0.48	4.31	0.33	2.88e-5	Endometrial cancer;
PAAD	cis	rs1419980	0.730	rs11054554	chr12:7727746	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg10168330	chr8:27262164	PTK2B	0.46	5.42	0.4	2.3e-7	Neuroticism;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg18833306	chr6:118973337	C6orf204	-0.54	-4.44	-0.34	1.69e-5	Diastolic blood pressure;
PAAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-5.89	-0.43	2.35e-8	Total body bone mineral density;
PAAD	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.43	4.53	0.34	1.2e-5	Carotid intima media thickness;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.23	0.39	5.41e-7	Bipolar disorder;
PAAD	cis	rs9820070	1.000	rs9820070	chr3:187687074	A/C	cg18245890	chr3:187457316	BCL6	0.46	4.4	0.34	2.05e-5	Hematological and biochemical traits;
PAAD	cis	rs9916302	0.560	rs907094	chr17:37790371	G/A	cg20243544	chr17:37824526	PNMT	0.63	5.4	0.4	2.47e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.64	-5.73	-0.42	5.33e-8	Personality dimensions;
PAAD	cis	rs4594175	0.677	rs7149846	chr14:51739654	A/C	cg23942311	chr14:51606299	NA	0.6	5.74	0.42	4.89e-8	Cancer;
PAAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg00603274	chr11:61596626	FADS2	-0.47	-4.25	-0.33	3.74e-5	Red cell distribution width;Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg05313129	chr8:58192883	C8orf71	-0.61	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7192380	0.895	rs2917671	chr16:69758741	A/T	cg05250797	chr16:70222502	NA	-0.51	-4.47	-0.34	1.55e-5	Sjögren's syndrome;
PAAD	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.82	-8.54	-0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs1519814	0.740	rs4348544	chr8:121044090	T/C	cg22335954	chr8:121166405	COL14A1	-0.63	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg25382128	chr12:54346509	NA	-0.45	-4.6	-0.35	9.02e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.45	0.4	1.98e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.68	-7.46	-0.52	6.22e-12	Systemic lupus erythematosus;
PAAD	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs8068544	0.606	rs8082153	chr17:40172467	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.57	-7.88	-0.54	5.97e-13	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs11563648	0.553	rs4731355	chr7:127021472	A/G	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	6.08	0.44	9.1e-9	Mean platelet volume;
PAAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.83	-0.48	1.93e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg26014466	chr7:809109	HEATR2	-0.67	-7.42	-0.52	7.59e-12	Subjective well-being;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.86	8.64	0.57	7.18e-15	Cognitive function;
PAAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg24253500	chr15:84953950	NA	-0.48	-5.36	-0.4	3.08e-7	P wave terminal force;
PAAD	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.67	6.61	0.47	6.16e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2637266	0.600	rs2579754	chr10:78269798	T/G	cg18941641	chr10:78392320	NA	0.37	4.43	0.34	1.8e-5	Pulmonary function;
PAAD	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.6	0.52	2.81e-12	Morning vs. evening chronotype;
PAAD	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.6	6.3	0.46	3.01e-9	Lewy body disease;
PAAD	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Bladder cancer;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg16300553	chr8:8131077	NA	0.36	4.28	0.33	3.29e-5	Joint mobility (Beighton score);
PAAD	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.57	6.3	0.45	3.11e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs76866386	0.892	rs114938914	chr2:44055510	C/T	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.85	-5.04	-0.38	1.32e-6	Cholesterol, total;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10515155	chr17:81052671	NA	-0.73	-7.54	-0.52	3.94e-12	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg05347473	chr6:146136440	FBXO30	0.46	4.38	0.33	2.24e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.95	12.16	0.7	3.37e-24	Heart rate;
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.72	7.78	0.53	1.02e-12	Lung cancer;
PAAD	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.52	-5.15	-0.39	7.81e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.45	4.64	0.35	7.58e-6	Age of smoking initiation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14498227	chr11:70282774	NA	0.57	6.55	0.47	8.43e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1510510	0.690	rs1553842	chr2:239541874	A/G	cg16914508	chr2:239161102	PER2	-0.56	-4.32	-0.33	2.78e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-1.05	-11.57	-0.68	1.3e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs62238980	1.000	rs62239001	chr22:32590150	T/C	cg02631450	chr22:32366979	NA	1.02	4.98	0.37	1.72e-6	Childhood ear infection;
PAAD	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg26528668	chr16:1614120	IFT140	0.58	5.42	0.4	2.29e-7	Coronary artery disease;
PAAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-4.81	-0.36	3.68e-6	Mood instability;
PAAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.66	6.89	0.49	1.36e-10	Multiple sclerosis;
PAAD	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.91	0.59	1.48e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	1.09	12.42	0.71	6.62e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.723	rs6763508	chr3:41750989	T/C	cg03022575	chr3:42003672	ULK4	0.87	6.29	0.45	3.2e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-5.41	-0.4	2.42e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13599411	chr19:2236372	PLEKHJ1;SF3A2	0.63	6.97	0.49	9.08e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg03762994	chr17:6899332	ALOX12	0.51	5.37	0.4	2.91e-7	Blood metabolite levels;
PAAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.61	6.07	0.44	9.84e-9	Blood protein levels;
PAAD	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.85	6.48	0.47	1.21e-9	Axial length;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22038409	chr15:44096850	MFAP1	0.49	5.18	0.39	6.81e-7	Lung cancer in ever smokers;
PAAD	cis	rs35300120	0.796	rs79828374	chr1:233669867	T/G	cg23054119	chr1:233659267	NA	-0.54	-4.71	-0.36	5.5e-6	Cognitive function;
PAAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.71	7.64	0.53	2.27e-12	Calcium levels;
PAAD	cis	rs988913	0.813	rs1566723	chr6:54777833	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-5.2	-0.39	6.32e-7	Menarche (age at onset);
PAAD	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.44	4.47	0.34	1.52e-5	Tumor biomarkers;
PAAD	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg05144285	chr7:158935647	VIPR2	-0.54	-4.79	-0.36	3.97e-6	Height;
PAAD	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.41e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.62	5.56	0.41	1.17e-7	Blood metabolite levels;
PAAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-5.24	-0.39	5.28e-7	Red cell distribution width;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.69	5.36	0.4	3.02e-7	Alzheimer's disease;
PAAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg09839279	chr12:125627357	AACS	-0.5	-5.08	-0.38	1.1e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs939584	1.000	rs6755502	chr2:635721	A/G	cg14515364	chr2:636606	NA	0.51	4.83	0.36	3.36e-6	Body mass index;
PAAD	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.05	-0.67	3.41e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.26	-0.33	3.52e-5	Renal cell carcinoma;
PAAD	trans	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.75	5.39	0.4	2.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.52	-0.47	9.67e-10	Hip circumference;
PAAD	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.73	-7.29	-0.51	1.57e-11	Uric acid clearance;
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg19640517	chr22:41707109	ZC3H7B	0.5	4.26	0.33	3.53e-5	Vitiligo;
PAAD	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.41	4.56	0.35	1.03e-5	Thyroid hormone levels;
PAAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.6	-6.4	-0.46	1.86e-9	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.97	13.35	0.73	2.09e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.71	7.26	0.51	1.82e-11	Morning vs. evening chronotype;
PAAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.89	10.42	0.65	1.62e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg19192590	chr2:178524533	PDE11A	0.38	4.3	0.33	2.99e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.69	-7.09	-0.5	4.76e-11	Glycated hemoglobin levels;
PAAD	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.57	5.47	0.41	1.81e-7	Height;
PAAD	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.56	5.86	0.43	2.76e-8	Coronary artery disease;
PAAD	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.7	-6.88	-0.49	1.47e-10	Retinal vascular caliber;
PAAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg08027265	chr7:2291960	NA	-0.54	-5.4	-0.4	2.49e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	1.19	8.79	0.58	3.01e-15	Lymphocyte counts;
PAAD	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.57	5.77	0.42	4.39e-8	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20139898	chr1:26437522	PDIK1L	0.65	7.01	0.49	7.47e-11	Myopia (pathological);
PAAD	cis	rs59888335	0.929	rs1474205	chr3:80852640	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg02527881	chr3:46936655	PTH1R	-0.38	-4.45	-0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.9	-11.49	-0.68	2.25e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg10820045	chr2:198174542	NA	0.47	4.73	0.36	5.15e-6	Intracranial aneurysm;
PAAD	cis	rs8070740	0.731	rs1071648	chr17:5326089	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.74	0.36	4.84e-6	Menopause (age at onset);
PAAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg05085585	chr16:30420623	ZNF771	-0.45	-4.51	-0.34	1.27e-5	Tonsillectomy;
PAAD	cis	rs2286503	1.000	rs2286499	chr7:22857477	A/G	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.34e-5	Fibrinogen;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg05861140	chr6:150128134	PCMT1	-0.5	-5.25	-0.39	5.04e-7	Lung cancer;
PAAD	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.18	-0.39	6.91e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs1043763	0.784	rs28622891	chr12:122594033	A/G	cg26218692	chr12:122497826	BCL7A	-0.55	-5.13	-0.38	8.73e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.59	4.79	0.36	4.01e-6	Schizophrenia;
PAAD	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.8	7.08	0.5	4.87e-11	Exhaled nitric oxide levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04141691	chr16:3285501	ZNF200	0.66	7.02	0.49	6.8e-11	Obesity-related traits;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.93	11.54	0.68	1.62e-22	Menarche (age at onset);
PAAD	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-4.91	-0.37	2.35e-6	Neuroticism;
PAAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.13	-0.45	7.14e-9	Height;
PAAD	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg21918786	chr6:109611834	NA	0.44	5.08	0.38	1.12e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.49	4.26	0.33	3.51e-5	Height;
PAAD	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.53	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.47	0.61	5.3e-17	Gut microbiome composition (summer);
PAAD	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg05250797	chr16:70222502	NA	0.86	6.29	0.45	3.23e-9	IgE levels;
PAAD	cis	rs35740288	0.770	rs11638278	chr15:86211404	C/T	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22465281	chr5:65017296	NLN;SGTB	-0.57	-6.54	-0.47	9.05e-10	Myopia (pathological);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11090139	chr17:6347791	FAM64A	0.55	7.11	0.5	4.14e-11	Monocyte percentage of white cells;
PAAD	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg10705379	chr10:99080932	FRAT1	0.4	4.67	0.35	6.63e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.75	-6.73	-0.48	3.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00142150	chr22:38071001	LGALS1	0.53	4.64	0.35	7.52e-6	Fat distribution (HIV);
PAAD	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg14191688	chr11:70257035	CTTN	0.56	5.18	0.39	7.05e-7	Coronary artery disease;
PAAD	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg16898833	chr6:26189333	HIST1H4D	0.87	5.86	0.43	2.84e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.69	-0.36	6.09e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10885582	0.754	rs10885574	chr10:116296487	C/T	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13169073	chr7:6693334	NA	0.69	7.0	0.49	7.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg25382128	chr12:54346509	NA	-0.42	-4.3	-0.33	3.04e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.31	-0.33	2.97e-5	Mean corpuscular volume;
PAAD	cis	rs329648	1.000	rs329648	chr11:133765367	A/G	cg18057887	chr11:133800913	IGSF9B	0.58	6.24	0.45	4.12e-9	Parkinson's disease;
PAAD	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.59	5.54	0.41	1.29e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.36	0.56	3.65e-14	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg20592124	chr2:65290738	CEP68	0.47	4.49	0.34	1.41e-5	Pulse pressure;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03970501	chr16:22202118	NA	-0.78	-7.96	-0.54	3.73e-13	Lung cancer in ever smokers;
PAAD	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.51	4.49	0.34	1.39e-5	Airway imaging phenotypes;
PAAD	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.33	0.4	3.52e-7	Monocyte percentage of white cells;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg08679807	chr1:6338594	ACOT7	-0.56	-6.37	-0.46	2.11e-9	Alzheimer's disease (survival time);
PAAD	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	5.8	0.43	3.68e-8	Lung cancer;
PAAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.35	0.4	3.19e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08722104	chr11:47448306	PSMC3	0.75	9.1	0.59	4.89e-16	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27511599	chr7:32358540	NA	0.94	5.19	0.39	6.58e-7	Body mass index;
PAAD	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg26131911	chr1:33116503	RBBP4;ZBTB8OS	0.6	6.83	0.48	1.94e-10	Metabolite levels  (X-11787);
PAAD	cis	rs4862307	0.514	rs11736004	chr4:185013843	C/T	cg06737308	chr4:185021514	ENPP6	0.83	9.19	0.6	2.83e-16	Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg10168330	chr8:27262164	PTK2B	0.37	4.45	0.34	1.69e-5	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03324578	chr3:46887918	NA	0.68	6.9	0.49	1.29e-10	Obesity-related traits;
PAAD	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.46	-5.4	-0.4	2.53e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.57	-4.66	-0.35	6.94e-6	Type 2 diabetes;
PAAD	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.79	8.2	0.55	9.55e-14	Schizophrenia;
PAAD	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.71	-0.48	3.65e-10	Aortic root size;
PAAD	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.47	-0.34	1.51e-5	Retinal vascular caliber;
PAAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs501916	0.743	rs3743281	chr15:48056958	C/T	cg16110827	chr15:48056943	SEMA6D	-0.56	-5.7	-0.42	6.09e-8	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg02380750	chr20:61661411	NA	0.38	4.47	0.34	1.52e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg26597838	chr10:835615	NA	0.53	5.79	0.42	3.95e-8	Survival in rectal cancer;
PAAD	cis	rs6499755	0.712	rs31106	chr16:55376359	T/A	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs863345	0.967	rs11264989	chr1:158469271	A/G	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg00750074	chr16:89608354	SPG7	-0.52	-5.12	-0.38	9.22e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.88	-10.16	-0.64	8.03e-19	Iron status biomarkers;
PAAD	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.58	4.76	0.36	4.42e-6	Type 2 diabetes;
PAAD	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs1371614	0.632	rs4665363	chr2:27156416	T/G	cg00617064	chr2:27272375	NA	0.43	4.55	0.35	1.11e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-5.73	-0.42	5.31e-8	Total cholesterol levels;
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg15193198	chr20:60906057	LAMA5	0.56	6.42	0.46	1.61e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs7580717	0.893	rs6714129	chr2:232179657	A/G	cg07929768	chr2:232055508	NA	0.39	5.09	0.38	1.06e-6	Multiple myeloma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07698384	chr15:25684465	UBE3A	0.59	6.64	0.47	5.2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.49	-5.32	-0.4	3.66e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.27	-0.39	4.5e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-6.25	-0.45	3.89e-9	Personality dimensions;
PAAD	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Colorectal cancer;
PAAD	trans	rs61677309	1.000	rs3825051	chr11:118174629	A/G	cg15548380	chr1:19984784	NBL1	-0.62	-6.42	-0.46	1.62e-9	Lung cancer in ever smokers;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.88	-10.17	-0.64	7.46e-19	Iron status biomarkers;
PAAD	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.45	4.52	0.34	1.26e-5	Airway imaging phenotypes;
PAAD	cis	rs939584	1.000	rs12714415	chr2:651430	T/C	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg04154034	chr17:28927549	LRRC37B2	0.71	4.84	0.37	3.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.58	-5.31	-0.4	3.85e-7	Macular telangiectasia type 2;
PAAD	cis	rs1334894	1.000	rs7756437	chr6:35609814	T/C	cg07213720	chr6:35227408	ZNF76	-0.89	-4.85	-0.37	3.01e-6	Coronary artery disease;
PAAD	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.93	-10.92	-0.66	7.43e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.39	5.14	0.38	8.22e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.98	-6.19	-0.45	5.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.74e-8	Life satisfaction;
PAAD	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9398803	0.723	rs2793051	chr6:127064918	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.41	-0.34	1.95e-5	Male-pattern baldness;
PAAD	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.91	7.07	0.5	5.33e-11	Axial length;
PAAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg09796270	chr17:17721594	SREBF1	0.39	4.28	0.33	3.24e-5	Total body bone mineral density;
PAAD	cis	rs9815354	0.951	rs1619558	chr3:41914213	C/G	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs501120	0.584	rs11595159	chr10:44680608	T/C	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.34	-0.4	3.32e-7	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	11.95	0.7	1.3e-23	Platelet count;
PAAD	cis	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.38	-0.33	2.21e-5	Eotaxin levels;
PAAD	cis	rs11811982	0.744	rs115058698	chr1:227483194	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9810890	0.850	rs79042456	chr3:128517917	G/A	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	4.47	0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg09677638	chr11:61582810	MIR1908;FADS1	0.56	4.94	0.37	2.07e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.26	-5.17	-0.39	7.3e-7	Urinary metabolites;
PAAD	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02743256	chr7:2109353	MAD1L1	-0.76	-5.53	-0.41	1.4e-7	Neuroticism;
PAAD	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.44	-0.34	1.76e-5	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.41	-4.62	-0.35	8e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg13263691	chr18:77568018	NA	0.61	6.42	0.46	1.67e-9	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.72	7.89	0.54	5.37e-13	Dental caries;
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.09	0.38	1.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	1.01	14.2	0.76	1.16e-29	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg20630647	chr19:41531805	NA	0.37	4.28	0.33	3.35e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs9400467	0.506	rs12192718	chr6:111569151	T/A	cg15721981	chr6:111408429	SLC16A10	0.59	4.28	0.33	3.36e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg10547527	chr2:198650123	BOLL	-0.84	-5.58	-0.41	1.09e-7	Ulcerative colitis;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Diastolic blood pressure;
PAAD	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.72	7.46	0.52	6.04e-12	Body mass index;
PAAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Breast cancer;
PAAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg08992911	chr2:238395768	MLPH	0.73	5.42	0.4	2.3e-7	Prostate cancer;
PAAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.79	-7.14	-0.5	3.58e-11	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg14349672	chr11:133703707	NA	-0.56	-6.68	-0.48	4.14e-10	Childhood ear infection;
PAAD	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg21191810	chr6:118973309	C6orf204	-0.54	-5.04	-0.38	1.31e-6	Diastolic blood pressure;
PAAD	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.75e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.55	6.0	0.44	1.39e-8	Tonsillectomy;
PAAD	cis	rs9322817	0.691	rs9499954	chr6:105205826	C/T	cg02098413	chr6:105308735	HACE1	-0.42	-5.07	-0.38	1.15e-6	Thyroid stimulating hormone;
PAAD	cis	rs2576037	0.863	rs8097455	chr18:44593122	C/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.65	-0.35	7.04e-6	Personality dimensions;
PAAD	cis	rs3026101	0.671	rs28619210	chr17:5319053	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.9	-0.37	2.4e-6	Tuberculosis;
PAAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.56	-4.89	-0.37	2.58e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.99	-0.59	9.3e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.65	-6.31	-0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs6547631	0.628	rs2886768	chr2:85927555	A/C	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.55	5.63	0.42	8.36e-8	Interleukin-18 levels;
PAAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.76e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-9.73	-0.62	1.08e-17	Idiopathic membranous nephropathy;
PAAD	cis	rs9581857	0.547	rs7336332	chr13:28058404	A/G	cg22138327	chr13:27999177	GTF3A	0.78	5.45	0.4	1.94e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs17688076	0.558	rs12446418	chr16:68290200	G/A	cg09835421	chr16:68378352	PRMT7	-1.1	-6.38	-0.46	2.07e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02634712	chr18:19750909	GATA6	0.6	6.72	0.48	3.51e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.63	-9.41	-0.61	7.44e-17	Asthma (sex interaction);
PAAD	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-5.53	-0.41	1.38e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs77106637	0.530	rs1785212	chr11:72462375	T/C	cg03713592	chr11:72463424	ARAP1	0.73	6.57	0.47	7.6e-10	Type 2 diabetes;
PAAD	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.07	-0.67	3.02e-21	Hemostatic factors and hematological phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01989275	chr17:80367027	C17orf101	0.63	6.48	0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.76	-8.18	-0.55	1.07e-13	Cognitive function;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg02462569	chr6:150064036	NUP43	-0.46	-4.86	-0.37	2.92e-6	Lung cancer;
PAAD	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	4.53	0.34	1.2e-5	Total body bone mineral density;
PAAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04362095	chr11:63592001	C11orf84	-0.51	-4.64	-0.35	7.57e-6	Platelet count;
PAAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.83	9.5	0.61	4.32e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.37e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23615779	chr7:143077590	ZYX	0.55	6.58	0.47	7.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4792901	0.802	rs9908678	chr17:41581545	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.44	0.61	6.32e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.78	6.12	0.44	7.79e-9	HDL cholesterol;
PAAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg08662619	chr6:150070041	PCMT1	0.43	4.25	0.33	3.73e-5	Lung cancer;
PAAD	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg00262122	chr8:11665843	FDFT1	0.55	4.73	0.36	5.05e-6	Neuroticism;
PAAD	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg12935359	chr14:103987150	CKB	-0.44	-5.16	-0.39	7.66e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg13918804	chr1:2043761	PRKCZ	-0.39	-5.25	-0.39	4.96e-7	Height;
PAAD	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.47	-4.73	-0.36	4.98e-6	Menarche (age at onset);
PAAD	cis	rs354225	0.544	rs12713268	chr2:54808845	C/G	cg01766943	chr2:54829624	SPTBN1	-0.52	-4.83	-0.36	3.27e-6	Schizophrenia;
PAAD	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5756391	0.546	rs4821565	chr22:37314415	C/T	cg16356956	chr22:37317934	CSF2RB	-0.41	-5.0	-0.38	1.55e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6585424	1.000	rs12777867	chr10:81935530	C/T	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg10828910	chr2:63850056	LOC388955	-0.52	-4.47	-0.34	1.52e-5	Childhood ear infection;
PAAD	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.65	6.32	0.46	2.69e-9	IgG glycosylation;
PAAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.63	-5.24	-0.39	5.29e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	cis	rs17331151	0.505	rs71299613	chr3:52698805	G/A	cg27565382	chr3:53032988	SFMBT1	0.96	4.72	0.36	5.25e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg24623649	chr8:11872141	NA	0.43	4.27	0.33	3.43e-5	Systolic blood pressure;
PAAD	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.63	0.35	7.67e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7941600	0.643	rs11828205	chr11:9335284	T/A	cg19415743	chr11:9336845	TMEM41B	0.98	6.04	0.44	1.13e-8	Coronary artery disease;
PAAD	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-4.8	-0.36	3.72e-6	Mean platelet volume;
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-5.75	-0.42	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg23973274	chr1:155060172	NA	-0.42	-4.35	-0.33	2.5e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.15	9.49	0.61	4.73e-17	Left atrial antero-posterior diameter;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.58	6.25	0.45	3.92e-9	Lung cancer;
PAAD	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.46	-4.76	-0.36	4.53e-6	Metabolite levels;
PAAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg14507445	chr22:49886340	NA	-0.5	-4.56	-0.35	1.06e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs2923427	0.570	rs6988483	chr8:42351311	C/T	cg09913449	chr8:42400586	C8orf40	-0.44	-4.82	-0.36	3.45e-6	Mean corpuscular volume;
PAAD	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.85	-4.69	-0.36	6.1e-6	Cholesterol, total;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.15.415980F	chr15:41281446	INO80	-0.66	-6.54	-0.47	9e-10	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.46	-0.57	2.04e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6942407	0.546	rs7780698	chr7:86835731	T/G	cg02420886	chr7:86849541	C7orf23	0.65	4.91	0.37	2.28e-6	Food allergy;
PAAD	cis	rs6005551	0.843	rs134087	chr22:28067389	A/G	cg17187762	chr22:28070120	NA	-0.35	-4.38	-0.33	2.2e-5	Facial depth;
PAAD	cis	rs2885056	0.713	rs58713728	chr19:10679732	A/C	cg06392426	chr19:10676186	KRI1	0.58	5.78	0.42	4.1e-8	Red cell distribution width;
PAAD	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.97	0.37	1.79e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.64	4.64	0.35	7.35e-6	Blood protein levels;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.74	8.5	0.57	1.61e-14	Height;
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.64	-0.35	7.37e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg04673462	chr1:38461896	NA	-0.38	-4.65	-0.35	7.2e-6	Coronary artery disease;
PAAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02034447	chr16:89574710	SPG7	0.48	4.5	0.34	1.35e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.4	-5.19	-0.39	6.73e-7	Colorectal cancer;
PAAD	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.88	9.38	0.61	8.76e-17	Corneal astigmatism;
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21963583	chr11:68658836	MRPL21	0.54	5.87	0.43	2.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg08999081	chr20:33150536	PIGU	-0.54	-5.86	-0.43	2.83e-8	Height;
PAAD	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.47	6.61	0.47	6.22e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.88	10.9	0.66	8.34e-21	Prudent dietary pattern;
PAAD	cis	rs9815354	1.000	rs6807015	chr3:41754514	T/C	cg03022575	chr3:42003672	ULK4	0.85	6.15	0.45	6.48e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3745672	0.590	rs79343210	chr19:12169723	C/T	cg11321965	chr19:12780562	MORG1;C19orf56	-1.03	-4.66	-0.35	6.79e-6	Multiple sclerosis;
PAAD	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg14343924	chr8:8086146	FLJ10661	0.53	4.5	0.34	1.33e-5	Neuroticism;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-6.92	-0.49	1.19e-10	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.8	-0.36	3.69e-6	Breast cancer;
PAAD	trans	rs405795	0.661	rs2774179	chr13:89785876	G/A	cg27422345	chr7:1715242	NA	-0.99	-6.7	-0.48	3.73e-10	Yeast infection;
PAAD	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg10729496	chr3:10149963	C3orf24	0.96	8.11	0.55	1.58e-13	Alzheimer's disease;
PAAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.56	-5.92	-0.43	2.05e-8	Blood metabolite levels;
PAAD	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.54	5.36	0.4	2.99e-7	Mean corpuscular volume;
PAAD	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	0.98	5.92	0.43	2.07e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg21269045	chr12:125625041	AACS	-0.45	-4.36	-0.33	2.36e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs901683	1.000	rs9422658	chr10:46059667	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg20090690	chr10:134436459	INPP5A	0.51	4.32	0.33	2.75e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.86	7.2	0.5	2.6e-11	Pulmonary function decline;
PAAD	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.72	9.03	0.59	7.23e-16	Body mass index;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.69	7.92	0.54	4.56e-13	Height;
PAAD	cis	rs12282928	0.959	rs1158897	chr11:48273340	T/C	cg22827986	chr11:48284249	OR4X1	-0.43	-5.37	-0.4	2.92e-7	Migraine - clinic-based;
PAAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.7	-7.26	-0.51	1.84e-11	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10875658	chr9:73034460	NA	0.63	6.58	0.47	7.22e-10	Myopia (pathological);
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.18	-0.39	6.91e-7	Other erythrocyte phenotypes;
PAAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.66	-6.64	-0.47	5.34e-10	Body mass index;
PAAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.44	-5.16	-0.39	7.48e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.12	14.72	0.77	4.82e-31	Primary sclerosing cholangitis;
PAAD	cis	rs12612619	0.677	rs67100745	chr2:27250750	C/G	cg00617064	chr2:27272375	NA	-0.53	-5.58	-0.41	1.07e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	trans	rs148696809	1	rs148696809	chr6:28934352	T/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs9398803	0.698	rs1101563	chr6:127049198	T/C	cg19875578	chr6:126661172	C6orf173	-0.45	-4.75	-0.36	4.63e-6	Male-pattern baldness;
PAAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg08999081	chr20:33150536	PIGU	0.61	6.88	0.49	1.5e-10	Height;
PAAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	1.15	8.32	0.56	4.69e-14	IgG glycosylation;
PAAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.46	0.34	1.56e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg24879335	chr3:133465180	TF	0.58	6.5	0.47	1.07e-9	Iron status biomarkers;
PAAD	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg12568669	chr8:11666485	FDFT1	0.32	5.44	0.4	2.08e-7	Monocyte count;
PAAD	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.46	-4.76	-0.36	4.44e-6	Ulcerative colitis;
PAAD	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22162314	chr17:61951766	CSH2	-0.59	-5.94	-0.43	1.89e-8	Height;
PAAD	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg00614314	chr15:82944287	LOC80154	0.53	5.07	0.38	1.15e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-6.88	-0.49	1.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7638995	0.823	rs7610262	chr3:69169466	A/C	cg26574240	chr3:69171822	LMOD3	-0.75	-5.82	-0.43	3.3e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02639808	chr4:77997188	CCNI	0.63	7.04	0.5	6.04e-11	Monocyte percentage of white cells;
PAAD	cis	rs346785	0.640	rs9905488	chr17:74283535	A/G	cg09812376	chr17:74270190	QRICH2	0.46	5.77	0.42	4.38e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-5.14	-0.39	8.14e-7	Red blood cell count;
PAAD	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.69	-0.42	6.32e-8	Resting heart rate;
PAAD	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.29	-0.51	1.56e-11	Systolic blood pressure;
PAAD	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs62064224	1.000	rs62064224	chr17:30635115	G/A	cg25809561	chr17:30822961	MYO1D	0.54	5.65	0.42	7.68e-8	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs77106637	0.585	rs10898870	chr11:72456218	A/C	cg03713592	chr11:72463424	ARAP1	0.75	6.65	0.47	5.04e-10	Type 2 diabetes;
PAAD	trans	rs901683	0.867	rs35003524	chr10:46086781	C/T	cg14076390	chr17:34947837	DHRS11	0.92	6.67	0.48	4.4e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.38	4.44	0.34	1.74e-5	Fat distribution (HIV);
PAAD	cis	rs6834538	0.597	rs9307383	chr4:113529834	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.49	5.05	0.38	1.24e-6	Schizophrenia;
PAAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.99	7.05	0.5	5.9e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.95	12.83	0.72	5.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	6.98	0.49	8.56e-11	LDL cholesterol;
PAAD	cis	rs7326068	0.610	rs2314720	chr13:21313373	G/A	cg27499820	chr13:21296301	IL17D	0.57	5.34	0.4	3.39e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.68	0.42	6.64e-8	Educational attainment (years of education);
PAAD	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg19090574	chr1:205240910	TMCC2	-0.44	-4.81	-0.36	3.56e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.4	9.7	0.62	1.31e-17	Diabetic retinopathy;
PAAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.61	6.18	0.45	5.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09835421	chr16:68378352	PRMT7	-1.1	-8.13	-0.55	1.41e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	5.05	0.38	1.26e-6	Night sleep phenotypes;
PAAD	cis	rs939584	0.825	rs62105327	chr2:639060	T/A	cg03610516	chr2:642275	NA	0.61	5.47	0.41	1.77e-7	Body mass index;
PAAD	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.99	6.58	0.47	7.08e-10	Parkinson's disease;
PAAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg25790453	chr13:113633590	MCF2L	-0.38	-4.45	-0.34	1.64e-5	Systolic blood pressure;
PAAD	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs12432203	1.000	rs61987265	chr14:51728808	T/C	cg23942311	chr14:51606299	NA	-0.7	-4.82	-0.36	3.52e-6	Cancer;
PAAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.52	5.13	0.38	8.86e-7	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19045345	chr6:160222116	PNLDC1	-0.62	-6.55	-0.47	8.4e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.44	4.39	0.34	2.11e-5	Longevity;Endometriosis;
PAAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.82	7.13	0.5	3.78e-11	Recombination rate (females);
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.46	7.13	0.5	3.87e-11	IgG glycosylation;
PAAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10556349	chr10:835070	NA	0.67	5.2	0.39	6.22e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs3996993	0.809	rs72938170	chr6:52736385	C/T	cg20803780	chr6:52668592	GSTA1	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg20887711	chr4:1340912	KIAA1530	0.51	5.16	0.39	7.76e-7	Obesity-related traits;
PAAD	cis	rs899997	1.000	rs1383634	chr15:79029396	T/C	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.52	-5.56	-0.41	1.19e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-6.32	-0.46	2.79e-9	Colorectal cancer;
PAAD	cis	rs7833986	0.941	rs13249175	chr8:57058706	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	4.64	0.35	7.43e-6	Height;
PAAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.54	4.72	0.36	5.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17095355	0.818	rs4595478	chr10:111800145	T/C	cg00817464	chr10:111662876	XPNPEP1	0.65	4.86	0.37	2.94e-6	Biliary atresia;
PAAD	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.51	-5.03	-0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06002616	chr8:101225028	SPAG1	-0.4	-4.62	-0.35	8.17e-6	Atrioventricular conduction;
PAAD	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1;
PAAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.92	11.33	0.68	6.03e-22	Total body bone mineral density;
PAAD	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg06207120	chr15:45996521	NA	0.3	4.42	0.34	1.86e-5	Waist circumference;Weight;
PAAD	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.52	0.57	1.45e-14	Coffee consumption (cups per day);
PAAD	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs9377188	0.547	rs7761119	chr6:149411689	C/T	cg21368479	chr6:149415018	NA	0.41	4.47	0.34	1.49e-5	Cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10244268	chr16:46723088	ORC6L;VPS35	0.62	6.77	0.48	2.66e-10	Myopia (pathological);
PAAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg14343924	chr8:8086146	FLJ10661	0.56	4.97	0.37	1.82e-6	Mood instability;
PAAD	cis	rs59191668	0.900	rs7172243	chr15:62825649	G/C	cg12918536	chr15:62891943	NA	0.35	4.63	0.35	7.95e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg13397359	chr6:42928475	GNMT	0.62	4.84	0.37	3.14e-6	Blood protein levels;
PAAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18357526	chr6:26021779	HIST1H4A	0.6	6.1	0.44	8.43e-9	Blood metabolite levels;
PAAD	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.64	-6.5	-0.47	1.1e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	1.06	8.54	0.57	1.31e-14	Initial pursuit acceleration;
PAAD	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.77	6.81	0.48	2.08e-10	Coronary artery disease;
PAAD	cis	rs7165102	1.000	rs590958	chr15:65735707	T/G	cg22900193	chr15:65823441	PTPLAD1	0.47	4.45	0.34	1.66e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs4691139	0.658	rs1401398	chr4:165927732	A/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.4	-4.29	-0.33	3.11e-5	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	4.68	0.35	6.33e-6	Personality dimensions;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07152120	chr7:127560847	SND1	0.64	7.27	0.51	1.82e-11	Smoking initiation;
PAAD	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Blood protein levels;
PAAD	cis	rs9463078	0.585	rs4714848	chr6:45231135	A/G	cg25276700	chr6:44698697	NA	0.45	5.1	0.38	1.01e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.72	7.83	0.54	7.84e-13	Schizophrenia;
PAAD	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg20936604	chr3:58311152	NA	-0.74	-4.45	-0.34	1.64e-5	Cholesterol, total;
PAAD	cis	rs1334894	1.000	rs7754668	chr6:35590092	G/A	cg07213720	chr6:35227408	ZNF76	-0.88	-4.89	-0.37	2.59e-6	Coronary artery disease;
PAAD	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.37	4.83	0.36	3.35e-6	Calcium levels;
PAAD	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6088813	1.000	rs6142360	chr20:33960486	T/C	cg14752227	chr20:34000481	UQCC	-0.5	-4.98	-0.37	1.73e-6	Height;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs425535	0.757	rs352026	chr4:74796030	A/G	cg01447579	chr4:74847100	PF4	0.66	4.32	0.33	2.86e-5	Blood protein levels;
PAAD	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23158103	chr7:148848205	ZNF398	-0.63	-5.71	-0.42	5.89e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg20673841	chr7:107026890	COG5	0.5	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.98	-0.54	3.23e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4790333	1.000	rs2248821	chr17:2268311	G/A	cg02569219	chr17:2266849	SGSM2	0.63	6.08	0.44	9.28e-9	Proinsulin levels;
PAAD	cis	rs11024102	1.000	rs10766368	chr11:17014882	G/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.47	0.34	1.52e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg21191810	chr6:118973309	C6orf204	-0.51	-4.88	-0.37	2.71e-6	Diastolic blood pressure;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.26	0.45	3.8e-9	Lung cancer;
PAAD	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	4.7	0.36	5.68e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs371212078	1	rs371212078	chr9:86419282	CG/C	cg03531853	chr9:86535572	KIF27	0.43	4.32	0.33	2.82e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.51	5.4	0.4	2.47e-7	Motion sickness;
PAAD	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.5	4.74	0.36	4.87e-6	Pancreatic cancer;
PAAD	cis	rs642743	0.934	rs614406	chr10:105954650	G/C	cg03775802	chr10:105978702	MIR609;C10orf79	0.32	4.42	0.34	1.88e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-7.26	-0.51	1.88e-11	Morning vs. evening chronotype;
PAAD	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	4.37	0.33	2.31e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	trans	rs9409082	0.748	rs78381117	chr9:108951841	C/G	cg07010948	chr13:79181613	NA	-0.35	-6.53	-0.47	9.37e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.83	8.05	0.55	2.17e-13	Methadone dose in opioid dependence;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg08676812	chr11:65308423	LTBP3	1.56	8.06	0.55	2.15e-13	Height;
PAAD	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.53	-0.35	1.17e-5	Testicular germ cell tumor;
PAAD	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg18200150	chr17:30822561	MYO1D	0.57	7.34	0.51	1.24e-11	Schizophrenia;
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.41	4.28	0.33	3.25e-5	Obesity-related traits;
PAAD	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05654049	chr3:23852499	UBE2E1	-0.57	-6.65	-0.47	4.94e-10	Body fat percentage;
PAAD	cis	rs10821973	0.505	rs3815999	chr10:64005711	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs8067287	0.688	rs11652843	chr17:16843250	A/C	cg26910001	chr17:16838321	NA	-0.52	-4.85	-0.37	3.09e-6	Diabetic kidney disease;
PAAD	cis	rs9462027	0.540	rs2814951	chr6:34695081	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.37	-0.4	2.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.72	8.52	0.57	1.47e-14	Height;
PAAD	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.94	-7.03	-0.5	6.39e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	10.11	0.63	1.07e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg05895507	chr15:77155635	SCAPER	-0.39	-4.83	-0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs1198430	0.759	rs946267	chr1:23747703	A/T	cg27447006	chr1:23763279	ASAP3	0.59	4.67	0.35	6.52e-6	Total cholesterol levels;
PAAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.39	-0.34	2.11e-5	Breast cancer;
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16606324	chr3:10149918	C3orf24	0.78	6.31	0.46	2.83e-9	Alzheimer's disease;
PAAD	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.23	0.6	2.24e-16	Hemoglobin concentration;
PAAD	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.6	-6.17	-0.45	5.91e-9	Schizophrenia;
PAAD	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.39	-4.74	-0.36	4.93e-6	Prostate cancer;
PAAD	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.83	7.85	0.54	6.94e-13	Corneal astigmatism;
PAAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg04374321	chr14:90722782	PSMC1	0.53	4.3	0.33	3e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03439990	chr19:47164505	DACT3	0.56	6.31	0.46	2.83e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.65	0.57	6.91e-15	Lung cancer;
PAAD	cis	rs11718455	0.503	rs1404481	chr3:44006666	C/T	cg08738300	chr3:44038990	NA	0.41	4.31	0.33	2.88e-5	Coronary artery disease;
PAAD	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg00647317	chr7:50633725	DDC	0.39	4.28	0.33	3.26e-5	Body mass index;
PAAD	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08704250	chr15:31115839	NA	-0.59	-7.59	-0.52	2.92e-12	Huntington's disease progression;
PAAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.46	-4.69	-0.36	5.99e-6	Menarche (age at onset);
PAAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.79	0.43	3.84e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg09876464	chr15:85330779	ZNF592	0.45	4.42	0.34	1.87e-5	P wave terminal force;
PAAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.72	6.75	0.48	2.97e-10	Cognitive function;
PAAD	cis	rs56309584	0.755	rs72635516	chr17:8140097	T/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.44	-4.43	-0.34	1.76e-5	Initial pursuit acceleration;
PAAD	trans	rs12127679	0.688	rs12071931	chr1:244161933	C/G	cg03519879	chr14:74227499	C14orf43	0.89	6.97	0.49	9.21e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.16	0.39	7.68e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.98	5.74	0.42	5.07e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs73416724	1.000	rs111467122	chr6:43334547	C/T	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.17	0.5	3.02e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.59	-6.93	-0.49	1.14e-10	Urate levels;
PAAD	cis	rs8105895	1.000	rs79846980	chr19:22141343	T/C	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs13242816	1.000	rs3801994	chr7:116190469	G/A	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.3	4.69	0.36	6e-6	Alcohol dependence;
PAAD	cis	rs9535307	0.929	rs9316474	chr13:50313345	C/A	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.57	-6.7	-0.48	3.76e-10	Alzheimer's disease (late onset);
PAAD	cis	rs13253111	0.646	rs36046709	chr8:28078214	A/T	cg26534493	chr8:28060551	NA	0.45	4.93	0.37	2.13e-6	Childhood body mass index;
PAAD	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg08926642	chr1:7887455	PER3	0.58	4.47	0.34	1.53e-5	Inflammatory bowel disease;
PAAD	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg08562672	chr19:21860753	NA	0.44	4.52	0.34	1.22e-5	Pain;
PAAD	cis	rs10804591	1.000	rs2811437	chr3:129339045	A/C	cg18548199	chr3:129281892	PLXND1	-0.52	-4.36	-0.33	2.42e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	4.47	0.34	1.52e-5	Mean platelet volume;
PAAD	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.73	6.37	0.46	2.13e-9	Dilated cardiomyopathy;
PAAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg07298985	chr8:22133076	PIWIL2	0.4	4.25	0.33	3.71e-5	Hypertriglyceridemia;
PAAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	8.63	0.57	7.82e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-7.81	-0.53	8.88e-13	Monocyte percentage of white cells;
PAAD	cis	rs58521262	0.556	rs1676468	chr19:23213434	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.93	0.49	1.12e-10	Blood protein levels;
PAAD	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg14003231	chr6:33640908	ITPR3	-0.36	-4.56	-0.35	1.04e-5	Plateletcrit;
PAAD	cis	rs7115242	0.699	rs17174502	chr11:116759655	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.73	-4.51	-0.34	1.29e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs2412488	1.000	rs3765158	chr4:54327584	A/G	cg19408398	chr4:54243328	FIP1L1	-0.5	-4.37	-0.33	2.3e-5	DNA methylation (variation);
PAAD	cis	rs9810890	1.000	rs73198840	chr3:128502194	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4704187	0.687	rs4627970	chr5:74528776	G/A	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	8.69	0.58	5.41e-15	Personality dimensions;
PAAD	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.5	5.41	0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6473252	0.584	rs4739765	chr8:81821634	A/C	cg08595989	chr8:81827712	NA	-0.34	-4.75	-0.36	4.73e-6	Breast cancer;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg18769074	chr3:133464867	TF	0.43	5.19	0.39	6.62e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.33	0.33	2.71e-5	Lung cancer in ever smokers;
PAAD	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-6.56	-0.47	7.95e-10	Coronary artery disease;
PAAD	cis	rs9535307	0.584	rs61961506	chr13:50401701	C/A	cg03658251	chr13:50265850	EBPL	-0.72	-4.69	-0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg22800045	chr5:56110881	MAP3K1	0.61	4.74	0.36	4.81e-6	Coronary artery disease;
PAAD	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs12304921	0.683	rs3759406	chr12:51441751	A/G	cg18059802	chr12:51347058	HIGD1C	0.69	5.24	0.39	5.22e-7	Type 2 diabetes;
PAAD	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03610000	chr11:128392383	ETS1	-0.65	-6.6	-0.47	6.39e-10	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs42648	0.536	rs2158747	chr7:89798421	G/T	cg27367526	chr7:89841692	STEAP2	-0.35	-4.97	-0.37	1.82e-6	Homocysteine levels;
PAAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.13	0.38	8.86e-7	Menarche (age at onset);
PAAD	cis	rs9341808	0.558	rs3805911	chr6:80933996	A/C	cg08355045	chr6:80787529	NA	0.37	4.47	0.34	1.51e-5	Sitting height ratio;
PAAD	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7839488	0.823	rs6999061	chr8:121567440	A/G	cg14806103	chr8:121457329	MTBP;MRPL13	-0.45	-4.32	-0.33	2.8e-5	Myopia (pathological);
PAAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.68	0.65	3.29e-20	Smoking behavior;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.4	-0.51	8.56e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2790216	1.000	rs2590306	chr10:59976966	T/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg02780029	chr10:43622663	RET	-0.45	-4.52	-0.34	1.22e-5	Hirschsprung disease;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.44	7.26	0.51	1.82e-11	Mean corpuscular volume;
PAAD	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg21062780	chr6:887772	NA	0.55	5.7	0.42	5.95e-8	Aging;
PAAD	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg23387468	chr7:139079360	LUC7L2	0.38	4.29	0.33	3.17e-5	Diisocyanate-induced asthma;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07316743	chr22:19119296	TSSK2;DGCR14	0.55	6.65	0.47	4.95e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.17	-0.55	1.14e-13	Exhaled nitric oxide output;
PAAD	cis	rs3812111	0.774	rs509859	chr6:116423244	A/C	cg15226275	chr6:116381976	FRK	-0.23	-4.27	-0.33	3.43e-5	Age-related macular degeneration;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Body mass index;
PAAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.37	-0.33	2.34e-5	Breast cancer;
PAAD	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10482049	chr20:1099454	PSMF1	-0.81	-7.25	-0.51	1.96e-11	Neuroticism;
PAAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg14346243	chr4:90757452	SNCA	-0.55	-4.86	-0.37	2.86e-6	Neuroticism;
PAAD	cis	rs7678296	1.000	rs28385504	chr4:37200490	G/A	cg06805348	chr4:37245195	KIAA1239	0.62	4.64	0.35	7.47e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.78	9.64	0.62	1.9e-17	Bladder cancer;
PAAD	cis	rs9549260	0.753	rs61963266	chr13:41171036	G/A	cg21288729	chr13:41239152	FOXO1	0.59	4.91	0.37	2.35e-6	Red blood cell count;
PAAD	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.79	-0.36	3.97e-6	Triglycerides;
PAAD	cis	rs1561176	0.830	rs34684769	chr7:154991646	G/A	cg25063631	chr7:155025500	NA	-0.5	-4.36	-0.33	2.36e-5	Personality dimensions;
PAAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg05697835	chr1:2722811	NA	0.41	4.52	0.34	1.23e-5	Ulcerative colitis;
PAAD	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.69	4.74	0.36	4.96e-6	IgG glycosylation;
PAAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.62	7.64	0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.48	4.51	0.34	1.28e-5	Putamen volume;
PAAD	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7873102	0.571	rs776008	chr9:37921959	G/C	cg03528946	chr9:38069800	SHB	-0.49	-4.8	-0.36	3.83e-6	Brain structure;
PAAD	cis	rs10186876	0.762	rs7568481	chr2:44145374	G/T	cg09541576	chr2:44873248	C2orf34	-0.46	-4.77	-0.36	4.29e-6	Hand grip strength;
PAAD	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg13798912	chr7:905769	UNC84A	0.57	4.37	0.33	2.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.61	-7.28	-0.51	1.69e-11	Resting heart rate;
PAAD	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg06057569	chr22:50219754	BRD1	0.68	5.05	0.38	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4698775	0.739	rs2346835	chr4:110562243	A/G	cg05791136	chr4:110223969	COL25A1	-0.33	-4.4	-0.34	2.05e-5	Age-related macular degeneration;
PAAD	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.34	-0.33	2.6e-5	Coronary artery disease;
PAAD	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.62	-5.94	-0.43	1.84e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg12661370	chr5:149340060	SLC26A2	0.6	5.1	0.38	9.87e-7	HIV-1 control;
PAAD	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.58	-5.59	-0.41	1.01e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06753367	chr22:24256600	NA	-0.44	-4.73	-0.36	5.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.87	6.45	0.46	1.43e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg26876637	chr1:152193138	HRNR	0.88	6.97	0.49	8.91e-11	Atopic dermatitis;
PAAD	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg08975724	chr8:8085496	FLJ10661	-0.72	-6.82	-0.48	2.06e-10	Morning vs. evening chronotype;
PAAD	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg14583973	chr4:3374767	RGS12	0.34	4.96	0.37	1.83e-6	Mean platelet volume;
PAAD	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg01812947	chr2:240904978	NDUFA10	0.56	4.91	0.37	2.3e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs4343996	1.000	rs10238520	chr7:3341615	G/A	cg21248987	chr7:3385318	SDK1	0.47	5.18	0.39	7e-7	Motion sickness;
PAAD	cis	rs501120	0.584	rs11238915	chr10:44696665	C/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.25	-0.51	1.99e-11	Response to antipsychotic treatment;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg11196182	chr7:1989412	MAD1L1	0.4	4.27	0.33	3.46e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4448343	0.963	rs28620668	chr9:98267746	T/G	cg13428213	chr9:98267529	PTCH1	0.46	4.38	0.33	2.2e-5	Height;
PAAD	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs75920871	0.843	rs61905713	chr11:116909429	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs6460942	0.659	rs13247187	chr7:12551851	T/C	cg20607287	chr7:12443886	VWDE	-0.66	-4.38	-0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg11494091	chr17:61959527	GH2	0.51	4.32	0.33	2.76e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.63	4.92	0.37	2.24e-6	Serum sulfate level;
PAAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.28e-5	Total body bone mineral density;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.23	12.02	0.7	8.41e-24	Platelet count;
PAAD	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg03684893	chr10:554711	DIP2C	-0.49	-5.33	-0.4	3.53e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs1577917	0.523	rs1413724	chr6:86814549	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-7.07	-0.5	5.13e-11	Response to antipsychotic treatment;
PAAD	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs597583	0.789	rs3741280	chr11:117403235	G/T	cg27161313	chr11:117392002	DSCAML1	-0.55	-5.09	-0.38	1.05e-6	Putamen volume;
PAAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg12661370	chr5:149340060	SLC26A2	-0.65	-5.54	-0.41	1.3e-7	HIV-1 control;
PAAD	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Breast cancer;
PAAD	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg13332499	chr17:408570	NA	0.64	7.11	0.5	4.35e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg18279126	chr7:2041391	MAD1L1	0.61	6.3	0.45	3.08e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs804280	0.583	rs804262	chr8:11631504	C/T	cg12395012	chr8:11607386	GATA4	-0.64	-7.94	-0.54	4.13e-13	Myopia (pathological);
PAAD	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	1.04	11.01	0.67	4.29e-21	Platelet distribution width;
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg17848003	chr1:3704513	LRRC47	0.39	4.34	0.33	2.56e-5	Red cell distribution width;
PAAD	cis	rs258892	0.947	rs34955	chr5:72203628	T/C	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg10920065	chr6:169824652	NA	-0.46	-4.66	-0.35	6.98e-6	Obesity-related traits;
PAAD	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.58	5.79	0.43	3.88e-8	Crohn's disease;
PAAD	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg20891283	chr12:69753455	YEATS4	0.81	8.72	0.58	4.52e-15	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.86	-5.97	-0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.53	4.85	0.37	3.09e-6	Monocyte count;
PAAD	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-5.09	-0.38	1.06e-6	Bipolar disorder;
PAAD	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9472414	0.680	rs1418435	chr6:44710880	A/C	cg20913747	chr6:44695427	NA	0.49	4.59	0.35	9.08e-6	Height;
PAAD	cis	rs4757319	0.515	rs10832437	chr11:15433225	C/T	cg03245590	chr11:15329459	NA	0.43	5.19	0.39	6.66e-7	Breast cancer;
PAAD	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.66	-6.07	-0.44	9.95e-9	Urate levels in obese individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02334643	chr17:57643004	DHX40	0.68	6.82	0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg10395934	chr14:104002654	TRMT61A	0.49	4.69	0.36	5.97e-6	Body mass index;
PAAD	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1930961	1.000	rs5996946	chr22:25875988	T/G	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.46	4.37	0.33	2.3e-5	Mean platelet volume;
PAAD	trans	rs10500871	1.000	rs11025431	chr11:20216040	T/G	cg02956962	chr6:161097311	NA	0.6	6.31	0.46	2.89e-9	Educational attainment;
PAAD	cis	rs71520386	0.632	rs12532922	chr7:22860415	A/G	cg04907244	chr7:22894795	SNORD93	0.5	5.44	0.4	2.1e-7	Fibrinogen levels;
PAAD	cis	rs842828	1.000	rs842826	chr2:201245872	A/G	cg26842802	chr2:202125212	CASP8	-0.67	-4.81	-0.36	3.56e-6	Urate levels in lean individuals;
PAAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.36	5.57	0.41	1.11e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg11057378	chr10:81107060	PPIF	0.52	6.15	0.45	6.54e-9	Height;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg24006582	chr15:45444508	DUOX1	-0.69	-6.88	-0.49	1.46e-10	Uric acid levels;
PAAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.75	0.62	9.53e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.62	-0.47	5.68e-10	Homocysteine levels;
PAAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.68	-7.09	-0.5	4.64e-11	Height;
PAAD	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.75	11.75	0.69	4.44e-23	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.68	-6.44	-0.46	1.47e-9	IgG glycosylation;
PAAD	cis	rs9303280	0.743	rs2941522	chr17:37910368	C/T	cg00129232	chr17:37814104	STARD3	0.59	5.51	0.41	1.51e-7	Self-reported allergy;
PAAD	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.38	-4.76	-0.36	4.49e-6	Menarche (age at onset);
PAAD	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg21823605	chr1:152486609	CRCT1	0.5	6.34	0.46	2.5e-9	Hair morphology;
PAAD	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs911119	0.955	rs1555355	chr20:23594580	T/C	cg16589663	chr20:23618590	CST3	0.77	6.72	0.48	3.47e-10	Chronic kidney disease;
PAAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg06915872	chr16:87998081	BANP	0.47	4.41	0.34	1.96e-5	Menopause (age at onset);
PAAD	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-6.08	-0.44	9.21e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg05250797	chr16:70222502	NA	0.88	6.75	0.48	2.89e-10	IgE levels;
PAAD	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg04995300	chr3:66848608	NA	0.43	4.59	0.35	9.21e-6	Type 2 diabetes;
PAAD	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	5.04	0.38	1.32e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3736485	0.903	rs750162	chr15:51907153	A/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	7.22	0.51	2.37e-11	Height;
PAAD	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.83	-10.74	-0.66	2.28e-20	Breast cancer;
PAAD	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.84	0.49	1.81e-10	Body mass index;
PAAD	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.47	6.96	0.49	9.75e-11	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg19760965	chr3:194868843	C3orf21	0.45	4.69	0.36	5.95e-6	Non-small cell lung cancer;
PAAD	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg04395167	chr1:1895110	KIAA1751	-0.36	-4.36	-0.33	2.39e-5	Severe influenza A (H1N1) infection;
PAAD	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16417436	chr16:28758564	NA	0.45	4.44	0.34	1.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg14515779	chr1:101123966	NA	-0.54	-6.63	-0.47	5.62e-10	Monocyte count;
PAAD	cis	rs11971779	0.680	rs7785903	chr7:139122643	T/C	cg07862535	chr7:139043722	LUC7L2	0.65	5.01	0.38	1.51e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.49	-5.26	-0.39	4.85e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.58	6.63	0.47	5.6e-10	Mean corpuscular volume;
PAAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.03	0.44	1.19e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72960926	0.590	rs56343698	chr6:74749564	C/T	cg03266952	chr6:74778945	NA	-1.13	-7.22	-0.51	2.28e-11	Metabolite levels (MHPG);
PAAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.65	-0.35	7.29e-6	Menarche (age at onset);
PAAD	cis	rs58521262	0.556	rs289362	chr19:23118399	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.42	-0.34	1.87e-5	Testicular germ cell tumor;
PAAD	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.74	9.49	0.61	4.58e-17	Weight;
PAAD	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-1.18	-9.69	-0.62	1.38e-17	Obesity-related traits;
PAAD	cis	rs863345	0.604	rs1342950	chr1:158463723	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.92e-6	Pneumococcal bacteremia;
PAAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.53	-4.94	-0.37	2.04e-6	Total body bone mineral density;
PAAD	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.57	5.45	0.4	2.01e-7	Uric acid clearance;
PAAD	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.56	-6.84	-0.49	1.78e-10	Cognitive performance;
PAAD	cis	rs1975974	0.511	rs8078505	chr17:21755889	A/G	cg18423549	chr17:21743878	NA	-0.58	-5.26	-0.39	4.83e-7	Psoriasis;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06389934	chr2:203499669	FAM117B	-0.66	-6.59	-0.47	6.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg25173405	chr17:45401733	C17orf57	-0.49	-4.39	-0.34	2.15e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.75	0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg13207630	chr7:32358064	NA	0.78	4.29	0.33	3.13e-5	Body mass index;
PAAD	cis	rs5417	0.636	rs2074218	chr17:7156186	A/G	cg13768953	chr17:7114967	DLG4	0.4	4.83	0.37	3.24e-6	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13487210	chr9:104171791	ZNF189	-0.62	-6.37	-0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs9913156	0.748	rs72835630	chr17:4562449	C/T	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs501120	0.584	rs617019	chr10:44737246	A/G	cg09554077	chr10:44749378	NA	-0.48	-5.72	-0.42	5.53e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8033133	0.514	rs2554436	chr15:25292777	G/A	cg14481604	chr15:25334117	SNORD116-22	-0.44	-4.27	-0.33	3.48e-5	Blood osmolality (transformed sodium);
PAAD	cis	rs2544527	0.635	rs2693008	chr2:15913019	C/G	cg26669897	chr2:15909070	NA	-0.48	-4.83	-0.36	3.35e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg00901687	chr17:48585270	MYCBPAP	0.55	5.58	0.41	1.1e-7	Visceral fat;
PAAD	cis	rs6448119	0.621	rs4590011	chr4:22106866	C/T	cg26230338	chr4:22389934	GPR125	0.45	4.45	0.34	1.68e-5	Rheumatoid arthritis;
PAAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.81	-0.62	6.5e-18	Coronary artery disease;
PAAD	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.19	0.45	5.3300000000000004e-09	Alzheimer's disease (late onset);
PAAD	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10792830	0.741	rs1949221	chr11:85732690	A/G	cg07180834	chr11:85838833	NA	-0.52	-6.12	-0.44	7.71e-9	Psychosis and Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.56e-8	Life satisfaction;
PAAD	cis	rs1499972	0.941	rs56256549	chr3:117612102	A/G	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs10267417	0.603	rs10278800	chr7:19909594	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs2241685	0.621	rs11127304	chr2:1902622	G/A	cg22511877	chr2:1942942	MYT1L	-0.74	-5.05	-0.38	1.28e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs2637266	0.783	rs846633	chr10:78535744	A/C	cg18941641	chr10:78392320	NA	-0.37	-4.59	-0.35	9.37e-6	Pulmonary function;
PAAD	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.52	-5.04	-0.38	1.31e-6	Cancer;
PAAD	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg05895507	chr15:77155635	SCAPER	-0.4	-4.4	-0.34	2.06e-5	Blood metabolite levels;
PAAD	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.86	9.26	0.6	1.85e-16	Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg09760422	chr2:128146352	NA	-0.44	-7.59	-0.52	2.96e-12	Protein C levels;
PAAD	trans	rs3020418	1.000	rs926778	chr6:152355782	C/A	cg09520904	chr11:69462943	CCND1	-0.54	-6.62	-0.47	5.7e-10	Height;
PAAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.57	0.65	6.21e-20	Smoking behavior;
PAAD	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg07159951	chr1:45983175	PRDX1	0.45	5.1	0.38	9.94e-7	High light scatter reticulocyte count;
PAAD	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.69	-7.26	-0.51	1.82e-11	Leprosy;
PAAD	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.64	6.14	0.45	6.9e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg13047869	chr3:10149882	C3orf24	0.58	5.16	0.39	7.61e-7	Alzheimer's disease;
PAAD	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-8.73	-0.58	4.37e-15	Chronic sinus infection;
PAAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7771547	0.723	rs73423325	chr6:36554289	G/A	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.41	-5.07	-0.38	1.15e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1346	0.552	rs10791821	chr11:65368323	A/G	cg08755490	chr11:65554678	OVOL1	-0.5	-4.43	-0.34	1.79e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.89	11.13	0.67	1.98e-21	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.83	0.36	3.28e-6	Breast cancer;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	4.49	0.34	1.39e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg23601416	chr22:19950040	COMT	-0.3	-4.74	-0.36	4.92e-6	Blood metabolite levels;
PAAD	cis	rs375066	0.762	rs239939	chr19:44387967	A/T	cg11993925	chr19:44307056	LYPD5	0.51	6.28	0.45	3.33e-9	Breast cancer;
PAAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7092929	0.883	rs588410	chr10:3618792	T/C	cg14308648	chr10:3568949	NA	0.61	4.44	0.34	1.73e-5	Coronary artery calcification;
PAAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.75	6.93	0.49	1.12e-10	Breast cancer;
PAAD	cis	rs12134040	0.646	rs61835532	chr1:236511729	T/G	cg21399712	chr1:236511386	NA	-0.47	-4.32	-0.33	2.85e-5	Urate levels (BMI interaction);
PAAD	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.7	-5.75	-0.42	4.72e-8	Non-small cell lung cancer;
PAAD	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.66	5.7	0.42	6.19e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.97	0.44	1.58e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6456156	0.774	rs6916486	chr6:167530735	T/C	cg07741184	chr6:167504864	NA	-0.38	-4.9	-0.37	2.4e-6	Primary biliary cholangitis;
PAAD	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg10985347	chr2:127963512	CYP27C1	0.47	4.74	0.36	4.78e-6	Protein C levels;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.51	-4.74	-0.36	4.82e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg00031303	chr3:195681400	NA	0.67	6.64	0.47	5.13e-10	Pancreatic cancer;
PAAD	cis	rs4924935	0.887	rs2428380	chr17:18843089	C/A	cg26378065	chr17:18585709	ZNF286B	-0.63	-4.79	-0.36	3.85e-6	Pancreatic cancer;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-5.16	-0.39	7.49e-7	Electroencephalogram traits;
PAAD	cis	rs16858210	0.607	rs59321941	chr3:183571024	A/G	cg25686905	chr3:183603175	PARL	-0.4	-4.59	-0.35	9.06e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.62	0.69	9.95e-23	Smoking behavior;
PAAD	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.47	4.34	0.33	2.59e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.5e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.65	7.42	0.52	7.83e-12	Coronary artery disease;
PAAD	cis	rs9923856	0.542	rs11859698	chr16:11126735	C/T	cg04616529	chr16:11181986	CLEC16A	0.37	4.32	0.33	2.83e-5	Atopic dermatitis;Adult asthma;
PAAD	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.16	-6.51	-0.47	1.04e-9	Type 2 diabetes nephropathy;
PAAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg18200150	chr17:30822561	MYO1D	0.55	6.87	0.49	1.56e-10	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.13	0.55	1.41e-13	Menopause (age at onset);
PAAD	cis	rs2085601	0.542	rs1708660	chr4:89956164	A/G	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg20607287	chr7:12443886	VWDE	-0.7	-5.08	-0.38	1.08e-6	Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28655083	0.529	rs662101	chr16:77105405	G/T	cg06128999	chr16:77247126	NA	0.41	4.95	0.37	1.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg13535736	chr9:111863775	C9orf5	0.36	4.71	0.36	5.43e-6	Menarche (age at onset);
PAAD	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06309094	chr18:77676213	PQLC1	0.57	7.06	0.5	5.7e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg19752551	chr11:57585705	CTNND1	-0.54	-4.7	-0.36	5.69e-6	Schizophrenia;
PAAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.3	-0.4	3.98e-7	Schizophrenia;
PAAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs714027	0.525	rs6006274	chr22:30232843	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.47	-0.34	1.53e-5	Lymphocyte counts;
PAAD	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.92	10.79	0.66	1.61e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.52	0.57	1.43e-14	Bipolar disorder;
PAAD	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg27490568	chr2:178487706	NA	0.45	4.98	0.37	1.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.64	6.24	0.45	4.18e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs4455778	0.580	rs4917197	chr7:49075894	C/T	cg26309511	chr7:48887640	NA	0.39	4.84	0.37	3.19e-6	Lung cancer in never smokers;
PAAD	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.42	6.21	0.45	4.82e-9	Subjective well-being;
PAAD	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.41	-4.29	-0.33	3.14e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs59104589	0.521	rs886809	chr2:242397460	A/G	cg19488206	chr2:242435732	STK25	0.48	4.7	0.36	5.91e-6	Fibrinogen levels;
PAAD	cis	rs2147959	0.700	rs12725863	chr1:228630986	C/T	cg00655913	chr1:228633920	NA	0.51	4.65	0.35	7.14e-6	Adult asthma;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg16102063	chr8:22298240	PPP3CC	-0.57	-6.43	-0.46	1.55e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.39	-4.38	-0.33	2.21e-5	Hemoglobin concentration;
PAAD	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06606381	chr12:133084897	FBRSL1	-0.93	-6.54	-0.47	9.06e-10	Depression;
PAAD	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	8.52	0.57	1.42e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	5.53	0.41	1.35e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.65	0.42	7.53e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.82	0.54	8.21e-13	Prudent dietary pattern;
PAAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.92	11.82	0.69	2.85e-23	Menopause (age at onset);
PAAD	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.26	-13.68	-0.74	2.75e-28	Hip circumference adjusted for BMI;
PAAD	cis	rs6782025	0.837	rs60648200	chr3:120860470	A/G	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.02	0.5	6.74e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.8	7.35	0.51	1.12e-11	Obesity-related traits;
PAAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.19	0.5	2.69e-11	Eosinophil percentage of white cells;
PAAD	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05564831	chr3:52568323	NT5DC2	-0.44	-4.68	-0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6445525	0.738	rs6767345	chr3:66000105	T/C	cg06109867	chr3:66002991	MAGI1	-0.47	-4.33	-0.33	2.75e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.83	6.65	0.47	5.02e-10	Left atrial antero-posterior diameter;
PAAD	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg27478167	chr7:817139	HEATR2	0.7	5.36	0.4	3.05e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg16342193	chr10:102329863	NA	-0.77	-8.47	-0.57	1.91e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg27499820	chr13:21296301	IL17D	0.52	5.09	0.38	1.03e-6	Dental caries;
PAAD	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg08999081	chr20:33150536	PIGU	-0.49	-5.34	-0.4	3.27e-7	Height;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg15693483	chr7:1102177	C7orf50	0.41	4.55	0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.53	-5.26	-0.39	4.71e-7	Menarche (age at onset);
PAAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.96	-10.26	-0.64	4.19e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.57	4.99	0.38	1.64e-6	Height;
PAAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs2908197	0.866	rs2961048	chr7:75935008	A/T	cg22830091	chr7:75961684	YWHAG	-0.58	-6.55	-0.47	8.52e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg15571903	chr15:79123663	NA	-0.39	-4.86	-0.37	2.91e-6	Coronary artery disease;
PAAD	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.8	-7.1	-0.5	4.42e-11	Pancreatic cancer;
PAAD	cis	rs2885056	0.713	rs58713728	chr19:10679732	A/C	cg04833646	chr19:10679720	CDKN2D	1.02	10.28	0.64	3.77e-19	Red cell distribution width;
PAAD	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	6.76	0.48	2.81e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg22674798	chr1:3096360	PRDM16	0.38	4.44	0.34	1.69e-5	Migraine;
PAAD	cis	rs2637266	0.655	rs861744	chr10:78519132	T/G	cg18941641	chr10:78392320	NA	0.37	4.38	0.33	2.18e-5	Pulmonary function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12611439	chr6:38238063	BTBD9	-0.66	-6.75	-0.48	2.95e-10	Obesity-related traits;
PAAD	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg21130718	chr4:1044621	NA	0.54	4.48	0.34	1.44e-5	Recombination rate (females);
PAAD	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.68	6.97	0.49	8.99e-11	Breast cancer;
PAAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs1043763	0.826	rs11057509	chr12:122626381	G/A	cg26218692	chr12:122497826	BCL7A	-0.55	-5.05	-0.38	1.27e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg07423050	chr13:99094983	FARP1	-0.47	-4.57	-0.35	9.97e-6	Educational attainment (years of education);
PAAD	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.72	-6.88	-0.49	1.44e-10	Cognitive ability;
PAAD	cis	rs1903068	0.719	rs73236106	chr4:55996712	C/T	cg09978860	chr4:56023921	NA	0.4	4.32	0.33	2.8e-5	Endometriosis;
PAAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.7	-7.94	-0.54	4.06e-13	Huntington's disease progression;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18770345	chr3:129158763	IFT122;MBD4	-0.74	-6.55	-0.47	8.39e-10	Neuroticism;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.7	-7.75	-0.53	1.2e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-1.27	-10.06	-0.63	1.46e-18	Obesity-related traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09625946	chr12:133161308	FBRSL1	-0.71	-7.08	-0.5	5.06e-11	Primary biliary cholangitis;
PAAD	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.63	5.71	0.42	5.89e-8	Type 1 diabetes nephropathy;
PAAD	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.65	-7.58	-0.52	3.1e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8112211	0.599	rs11669131	chr19:38830966	T/C	cg14299480	chr19:38876666	GGN	-0.57	-4.8	-0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.61	-6.48	-0.47	1.18e-9	Brugada syndrome;
PAAD	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	cis	rs4740619	0.569	rs3008730	chr9:16008608	T/C	cg14451791	chr9:16040625	NA	0.39	4.54	0.35	1.13e-5	Body mass index;
PAAD	cis	rs7580658	0.864	rs34832797	chr2:128119441	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19549731	chr14:53173497	PSMC6	-0.69	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	cis	rs7714584	1.000	rs10051804	chr5:150226424	T/C	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs3736485	0.966	rs17609917	chr15:51911487	G/C	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.75	-0.48	2.9e-10	Neuroticism;
PAAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	10.57	0.65	6.41e-20	Smoking behavior;
PAAD	cis	rs6460942	0.597	rs4721106	chr7:12535053	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.61	-0.35	8.44e-6	Chronic sinus infection;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.79	-8.34	-0.56	4.18e-14	Menopause (age at onset);
PAAD	cis	rs2790216	0.805	rs2790227	chr10:60014288	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.24	-0.39	5.35e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg09796270	chr17:17721594	SREBF1	0.41	4.4	0.34	2e-5	Total body bone mineral density;
PAAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg13798912	chr7:905769	UNC84A	0.62	4.63	0.35	7.77e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg16590910	chr6:42928470	GNMT	-0.5	-5.14	-0.38	8.3e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14624294	chr10:3810173	NA	0.65	6.51	0.47	1.04e-9	Smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05446994	chr1:20960538	PINK1	0.57	6.39	0.46	1.97e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.62	6.71	0.48	3.71e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12438356	1.000	rs7167084	chr15:69588329	C/T	cg02375503	chr15:69591110	PAQR5	0.62	4.39	0.34	2.13e-5	CTACK levels;
PAAD	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg01426195	chr3:39028469	NA	-0.63	-6.2	-0.45	5.19e-9	Handedness;
PAAD	cis	rs4660214	0.671	rs16826068	chr1:39791876	G/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.41	-0.34	1.97e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg23254163	chr1:152506842	NA	-0.59	-6.98	-0.49	8.34e-11	Hair morphology;
PAAD	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.84	-0.54	7.53e-13	Neuroticism;
PAAD	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.43	4.59	0.35	9.39e-6	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.52	5.57	0.41	1.15e-7	Life satisfaction;
PAAD	cis	rs9888739	1.000	rs9940397	chr16:31303201	T/C	cg02256631	chr16:31342952	ITGAM	-0.53	-4.33	-0.33	2.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.64	-5.02	-0.38	1.46e-6	Rheumatoid arthritis;
PAAD	cis	rs821931	1.000	rs821947	chr10:108476051	T/G	cg16415058	chr10:108923781	SORCS1	0.37	4.35	0.33	2.52e-5	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
PAAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.54	6.76	0.48	2.82e-10	Atrioventricular conduction;
PAAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14169450	chr9:139327907	INPP5E	0.56	5.56	0.41	1.16e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10448954	chr16:89593394	SPG7	-0.62	-6.34	-0.46	2.44e-9	Obesity-related traits;
PAAD	cis	rs8127571	0.529	rs9306142	chr21:47225575	A/G	cg11214348	chr21:47283868	PCBP3	-0.52	-4.42	-0.34	1.85e-5	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg11008003	chr7:157255264	NA	0.41	5.66	0.42	7.29e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.46	4.56	0.35	1.03e-5	Dupuytren's disease;
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg08807892	chr2:162101083	NA	0.73	8.26	0.56	6.78e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg14343924	chr8:8086146	FLJ10661	-0.66	-5.69	-0.42	6.3e-8	Mood instability;
PAAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.94	-9.01	-0.59	8.23e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs728616	0.681	rs17677908	chr10:82049603	A/G	cg05935833	chr10:81318306	SFTPA2	-0.51	-4.47	-0.34	1.54e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1144713	0.606	rs1144718	chr12:32264702	T/C	cg01321189	chr12:32259338	BICD1	0.51	5.19	0.39	6.5e-7	Obesity-related traits;
PAAD	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.79	7.15	0.5	3.5e-11	Systemic lupus erythematosus;
PAAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-1.01	-11.96	-0.7	1.16e-23	Cognitive function;
PAAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.73	7.73	0.53	1.38e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10929159	0.928	rs10179607	chr2:236915645	C/G	cg14226755	chr2:236923322	AGAP1	0.3	4.82	0.36	3.46e-6	Parkinson's disease;
PAAD	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.61	-5.4	-0.4	2.57e-7	Mean corpuscular volume;
PAAD	cis	rs66530629	0.874	rs1890449	chr1:25075801	G/T	cg22509179	chr1:25234806	RUNX3	0.5	4.66	0.35	6.79e-6	Plateletcrit;
PAAD	cis	rs12760731	0.565	rs71628268	chr1:178151908	T/C	cg00404053	chr1:178313656	RASAL2	0.67	4.49	0.34	1.41e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg13903179	chr13:21900392	NA	0.6	6.36	0.46	2.27e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-5.92	-0.43	2.11e-8	Cognitive test performance;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg15208524	chr1:10270712	KIF1B	0.53	5.08	0.38	1.1e-6	Hepatocellular carcinoma;
PAAD	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.7	7.1	0.5	4.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg12705353	chr12:122356852	WDR66	0.43	4.36	0.33	2.4e-5	Mean corpuscular volume;
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.28	-0.51	1.7e-11	Longevity;
PAAD	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.75	0.62	9.4e-18	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07752472	chr3:136471634	STAG1	-0.62	-6.85	-0.49	1.73e-10	Myopia (pathological);
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.61	5.35	0.4	3.21e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8005172	0.750	rs10144207	chr14:88434134	C/T	cg18078958	chr14:88630771	NA	0.45	5.32	0.4	3.58e-7	Parkinson's disease;
PAAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg07599136	chr5:415885	AHRR	0.65	5.0	0.38	1.58e-6	Fat distribution (HIV);
PAAD	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.19e-8	Menopause (age at onset);
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.78	-9.43	-0.61	6.41e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-5.56	-0.41	1.21e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.72	7.57	0.52	3.44e-12	Blood protein levels;
PAAD	cis	rs1497828	0.956	rs3122364	chr1:217540360	A/G	cg04411442	chr1:217543379	NA	-0.48	-4.73	-0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg24829409	chr8:58192753	C8orf71	-0.69	-5.73	-0.42	5.2e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-1.07	-11.4	-0.68	3.9e-22	Blood pressure (smoking interaction);
PAAD	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.33	0.56	4.33e-14	Platelet count;
PAAD	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.29e-8	Alzheimer's disease (late onset);
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.45	5.05	0.38	1.27e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg11709110	chr19:1989583	BTBD2	0.44	4.42	0.34	1.91e-5	Coronary artery disease;
PAAD	cis	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg21546286	chr11:48923668	NA	0.54	5.68	0.42	6.62e-8	HDL cholesterol;
PAAD	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04156016	chr5:1868137	NA	0.46	4.68	0.35	6.4e-6	Cardiovascular disease risk factors;
PAAD	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg15676125	chr6:33679581	C6orf125	0.47	4.51	0.34	1.29e-5	Plateletcrit;
PAAD	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.47	4.91	0.37	2.33e-6	Menopause (age at onset);
PAAD	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-18.17	-0.83	6.2e-40	Exhaled nitric oxide output;
PAAD	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs901683	0.850	rs17157861	chr10:45990925	T/C	cg16908948	chr10:45500256	ZNF22	0.82	4.35	0.33	2.46e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.49	6.13	0.45	7.14e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.69	7.67	0.53	1.93e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-6.52	-0.47	9.81e-10	Body mass index;
PAAD	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.77	7.89	0.54	5.44e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg04165759	chr1:150448943	RPRD2	-0.51	-5.28	-0.39	4.29e-7	Migraine;
PAAD	cis	rs1903068	0.819	rs17711320	chr4:56000053	A/C	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.69e-5	Endometriosis;
PAAD	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg25401027	chr5:176370377	UIMC1	0.45	4.48	0.34	1.43e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.59	-5.86	-0.43	2.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22633769	chr20:60982531	CABLES2	0.5	4.66	0.35	6.74e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.37	-4.42	-0.34	1.88e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.49	5.27	0.39	4.53e-7	Motion sickness;
PAAD	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg21496419	chr19:44306685	LYPD5	-0.39	-4.98	-0.37	1.7e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs17407555	0.955	rs11734209	chr4:10170371	T/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-6.02	-0.44	1.26e-8	Schizophrenia (age at onset);
PAAD	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.52	4.81	0.36	3.58e-6	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.75	0.36	4.66e-6	Homoarginine levels;
PAAD	trans	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08418111	chr11:18433745	LDHC	0.6	6.31	0.46	2.86e-9	Calcium levels;
PAAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.3	0.46	3.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg00277334	chr10:82204260	NA	-0.59	-5.94	-0.43	1.89e-8	Post bronchodilator FEV1;
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg04352962	chr1:209979756	IRF6	0.55	4.89	0.37	2.56e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10774547	1.000	rs4766962	chr12:120863235	A/T	cg10072921	chr12:121022843	NA	-0.36	-4.53	-0.34	1.18e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
PAAD	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-8.52	-0.57	1.45e-14	Vitiligo;
PAAD	cis	rs8037137	0.915	rs12594752	chr15:91531995	C/T	cg23684204	chr15:91497937	RCCD1	0.8	4.86	0.37	2.93e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg07617317	chr6:118971624	C6orf204	0.56	4.65	0.35	7.19e-6	Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08912058	chr1:6313858	GPR153	-0.61	-6.51	-0.47	1.04e-9	Myopia (pathological);
PAAD	cis	rs30380	1.000	rs246454	chr5:96123264	C/A	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg26818257	chr2:241905806	NA	0.42	4.28	0.33	3.34e-5	Urinary metabolites;
PAAD	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.58	5.18	0.39	7.03e-7	Common traits (Other);
PAAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.91	-8.82	-0.58	2.52e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.33	-0.33	2.72e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	trans	rs901683	1.000	rs12761573	chr10:46079517	A/C	cg06308084	chr22:50493570	TTLL8	0.88	6.47	0.46	1.28e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.58	-7.45	-0.52	6.39e-12	Menopause (age at onset);
PAAD	cis	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.25	-0.33	3.77e-5	Triglycerides;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66530629	0.874	rs7535819	chr1:25173037	C/T	cg01905478	chr1:25040257	NA	0.47	5.26	0.39	4.77e-7	Plateletcrit;
PAAD	cis	rs5769707	0.967	rs12485195	chr22:50053871	G/A	cg20744362	chr22:50050164	C22orf34	0.58	7.37	0.51	9.94e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.48	-0.34	1.44e-5	Resting heart rate;
PAAD	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-7.54	-0.52	4.01e-12	Blood pressure (smoking interaction);
PAAD	cis	rs12304921	1.000	rs66518563	chr12:51358252	T/C	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.67	-0.42	6.89e-8	Type 2 diabetes;
PAAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.4	3.93e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg24375607	chr4:120327624	NA	0.42	4.28	0.33	3.26e-5	Diastolic blood pressure;
PAAD	cis	rs10793968	0.688	rs2789761	chr9:133635703	A/G	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15320075	chr8:145703422	NA	0.77	8.71	0.58	4.86e-15	Age at first birth;
PAAD	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.49	-5.22	-0.39	5.69e-7	Menarche (age at onset);
PAAD	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.73	-8.03	-0.55	2.43e-13	Airway imaging phenotypes;
PAAD	cis	rs71636778	0.631	rs113312820	chr1:27213079	A/G	cg12203394	chr1:27248618	NUDC	0.64	4.57	0.35	9.9e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	trans	rs875971	0.660	rs801190	chr7:66033033	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	1.01	8.8	0.58	2.83e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20167471	chr1:16528984	ARHGEF19	0.48	4.9	0.37	2.39e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg15181151	chr6:150070149	PCMT1	0.56	5.94	0.43	1.89e-8	Lung cancer;
PAAD	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.38	0.51	9.38e-12	Menarche (age at onset);
PAAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.65	5.4	0.4	2.57e-7	Gut microbiome composition (summer);
PAAD	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.47	-4.36	-0.33	2.37e-5	Endometrial cancer;
PAAD	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	5.06	0.38	1.21e-6	Mean platelet volume;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.77	-8.25	-0.56	6.96e-14	Menopause (age at onset);
PAAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg05333889	chr7:157238977	NA	-0.42	-4.41	-0.34	1.93e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12292205	chr6:26970375	C6orf41	0.47	4.51	0.34	1.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06580891	chr20:3189935	ITPA	0.66	6.75	0.48	2.94e-10	Obesity-related traits;
PAAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	Schizophrenia;
PAAD	cis	rs7580717	0.785	rs28541349	chr2:232153823	G/A	cg07929768	chr2:232055508	NA	0.49	5.53	0.41	1.35e-7	Multiple myeloma;
PAAD	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.29	7.42	0.52	7.89e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.87e-5	Dermatomyositis;
PAAD	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	4.85	0.37	3.01e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs35955747	0.934	rs5997966	chr22:31776246	C/T	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.75	-0.36	4.7e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg06569542	chr10:98946673	SLIT1	0.54	5.95	0.43	1.8e-8	Monocyte count;
PAAD	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.81	0.43	3.46e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg11630242	chr17:19881632	AKAP10	-0.49	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.71	-0.36	5.43e-6	Life satisfaction;
PAAD	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.83	0.36	3.33e-6	Breast cancer;
PAAD	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg04330084	chr7:123175371	IQUB	-0.52	-4.5	-0.34	1.34e-5	Plateletcrit;Platelet count;
PAAD	cis	rs2950393	0.804	rs1466382	chr12:57116834	A/G	cg04413986	chr12:57119373	NACA	-0.47	-4.33	-0.33	2.65e-5	Platelet distribution width;
PAAD	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg20406979	chr6:167373233	NA	-0.38	-5.14	-0.38	8.48e-7	Crohn's disease;
PAAD	cis	rs8112211	0.554	rs60082376	chr19:38843512	G/A	cg01275006	chr19:38876250	GGN	-0.98	-6.31	-0.46	2.84e-9	Blood protein levels;
PAAD	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.55	-7.87	-0.54	6.08e-13	Temperament;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.92	-0.37	2.23e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.01	0.38	1.46e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.45	-5.52	-0.41	1.4e-7	Lewy body disease;
PAAD	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg18939081	chr1:31884902	SERINC2	0.5	5.42	0.4	2.28e-7	Alcohol dependence;
PAAD	cis	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg21546286	chr11:48923668	NA	0.53	5.4	0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.51	-4.47	-0.34	1.55e-5	Obesity;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4148087	0.656	rs57137919	chr21:43639018	G/A	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg01529538	chr14:23388837	RBM23	0.57	5.76	0.42	4.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.68	-7.18	-0.5	2.96e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.64	-0.57	7.18e-15	Exhaled nitric oxide output;
PAAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.95	12.3	0.71	1.48e-24	Menopause (age at onset);
PAAD	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg02569458	chr12:86230093	RASSF9	0.43	4.61	0.35	8.58e-6	Major depressive disorder;
PAAD	cis	rs9395066	0.545	rs10948185	chr6:44901727	C/T	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22193559	chr5:43065115	NA	0.65	6.47	0.46	1.27e-9	Obesity-related traits;
PAAD	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg22437258	chr11:111473054	SIK2	-0.5	-4.87	-0.37	2.75e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.87	9.33	0.6	1.23e-16	Blood metabolite levels;
PAAD	cis	rs10991814	0.844	rs7860510	chr9:94128796	C/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.62	-0.47	5.92e-10	Lung cancer;
PAAD	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.83	-5.98	-0.44	1.55e-8	Coronary artery calcification;
PAAD	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg01851573	chr8:8652454	MFHAS1	0.54	4.52	0.34	1.22e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.89	6.31	0.46	2.91e-9	Opioid sensitivity;
PAAD	cis	rs1190596	0.558	rs3087686	chr14:102695563	A/G	cg23904247	chr14:102554826	HSP90AA1	0.46	5.39	0.4	2.68e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.74	4.68	0.35	6.35e-6	Lung cancer in ever smokers;
PAAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.85	10.29	0.64	3.5e-19	Ulcerative colitis;
PAAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	7.13	0.5	3.89e-11	Schizophrenia;
PAAD	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg09626299	chr10:82213104	TSPAN14	-0.41	-4.34	-0.33	2.54e-5	Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	6.17	0.45	5.8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2275565	0.809	rs4659727	chr1:237006914	A/G	cg17297354	chr1:237056641	MTR	-0.51	-4.56	-0.35	1.04e-5	Homocysteine levels;
PAAD	cis	rs7752195	0.643	rs78712602	chr6:25195517	C/T	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg05250797	chr16:70222502	NA	0.79	5.83	0.43	3.17e-8	IgE levels;
PAAD	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	4.54	0.35	1.14e-5	Red cell distribution width;Platelet distribution width;
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.46	5.44	0.4	2.06e-7	Immature fraction of reticulocytes;
PAAD	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.7	8.42	0.56	2.64e-14	Alcohol dependence;
PAAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.74	-6.99	-0.49	7.93e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg08888203	chr3:10149979	C3orf24	0.89	6.84	0.49	1.81e-10	Alzheimer's disease;
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19784903	chr17:45786737	TBKBP1	-0.51	-4.79	-0.36	3.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg04154034	chr17:28927549	LRRC37B2	0.64	4.27	0.33	3.45e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.5	-5.09	-0.38	1.05e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg01388757	chr2:102091195	RFX8	0.61	8.1	0.55	1.62e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.75	-6.96	-0.49	9.36e-11	Coronary artery disease;
PAAD	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.36	-0.4	3.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-9.09	-0.59	4.95e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs3764400	0.567	rs12946208	chr17:46312129	G/A	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs11172134	0.532	rs1800168	chr12:57592557	A/G	cg01515074	chr12:57585135	LRP1	0.47	4.53	0.34	1.18e-5	Urate levels in overweight individuals;
PAAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg14711859	chr11:8959438	ASCL3	-0.5	-5.75	-0.42	4.82e-8	Hematocrit;
PAAD	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.54	-5.88	-0.43	2.5e-8	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18621852	chr3:10150065	C3orf24	0.52	4.99	0.38	1.63e-6	Alzheimer's disease;
PAAD	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26695780	chr7:66021476	LOC493754	0.58	6.92	0.49	1.16e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1570884	0.539	rs4942842	chr13:50109285	A/C	cg03651054	chr13:50194643	NA	0.35	4.28	0.33	3.26e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-6.8	-0.48	2.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.73	7.94	0.54	4.19e-13	Mean corpuscular volume;
PAAD	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.76	-8.72	-0.58	4.49e-15	Handedness;
PAAD	cis	rs597583	0.806	rs11603340	chr11:117396527	C/G	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.25	-0.45	4e-9	Putamen volume;
PAAD	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-5.72	-0.42	5.37e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.5	0.34	1.34e-5	Educational attainment (years of education);
PAAD	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.43	-4.84	-0.37	3.2e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.35	5.29	0.39	4.2e-7	Alopecia areata;
PAAD	cis	rs4455778	0.600	rs56070219	chr7:49128237	A/T	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.65	-7.23	-0.51	2.14e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.44	-5.84	-0.43	3.07e-8	Obesity-related traits;
PAAD	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.55	-4.53	-0.34	1.18e-5	Corneal structure;
PAAD	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg01181863	chr3:195395398	SDHAP2	-0.93	-10.54	-0.65	7.51e-20	Bronchopulmonary dysplasia;
PAAD	cis	rs10885582	0.904	rs12772307	chr10:116343977	G/A	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.04	-0.38	1.29e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.9	-6.78	-0.48	2.48e-10	Initial pursuit acceleration;
PAAD	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.68	7.45	0.52	6.63e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.56	4.79	0.36	4e-6	Type 2 diabetes;
PAAD	cis	rs4740619	0.565	rs10756736	chr9:16032225	T/C	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.77	-8.06	-0.55	2.07e-13	DNA methylation (variation);
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.24	-0.39	5.22e-7	Life satisfaction;
PAAD	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.89	-9.25	-0.6	1.98e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg06241208	chr11:30344200	C11orf46	-0.49	-4.48	-0.34	1.48e-5	Morning vs. evening chronotype;
PAAD	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg12458913	chr13:53173898	NA	0.48	4.85	0.37	2.96e-6	Lewy body disease;
PAAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs7678296	1.000	rs7669536	chr4:37185787	C/T	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs8077577	0.747	rs62072537	chr17:18216100	G/A	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.87	-7.83	-0.54	7.73e-13	Coronary artery disease;
PAAD	cis	rs6028335	0.674	rs8120715	chr20:37598781	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.63	-4.71	-0.36	5.62e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.75	-7.53	-0.52	4.24e-12	Retinal vascular caliber;
PAAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.58	-7.2	-0.5	2.59e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-7.23	-0.51	2.23e-11	Heart rate;
PAAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.87	8.23	0.56	7.94e-14	Menarche (age at onset);
PAAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.42	4.66	0.35	6.86e-6	Type 2 diabetes;
PAAD	cis	rs1015291	0.806	rs2638431	chr12:19986746	A/G	cg25401612	chr12:20009446	NA	0.54	5.32	0.4	3.69e-7	Diastolic blood pressure;
PAAD	cis	rs1371614	0.545	rs3769136	chr2:27168743	C/T	cg00617064	chr2:27272375	NA	-0.46	-4.75	-0.36	4.64e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg14349672	chr11:133703707	NA	-0.57	-6.72	-0.48	3.39e-10	Childhood ear infection;
PAAD	cis	rs6921166	0.920	rs4946896	chr6:108395187	C/G	cg15666214	chr6:108438316	NA	0.7	4.27	0.33	3.44e-5	Major depressive disorder;
PAAD	cis	rs9581857	0.579	rs77509251	chr13:27959981	G/A	cg22138327	chr13:27999177	GTF3A	0.89	5.63	0.42	8.54e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs2147959	0.941	rs6426503	chr1:228651011	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.43	-0.34	1.83e-5	Adult asthma;
PAAD	cis	rs6756513	0.509	rs11686934	chr2:70172116	C/T	cg02498382	chr2:70120550	SNRNP27	0.41	4.26	0.33	3.57e-5	Breast cancer;Platelet count;
PAAD	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.83	9.45	0.61	5.99e-17	Total body bone mineral density;
PAAD	cis	rs6065	0.618	rs16942630	chr17:4878437	C/G	cg02990439	chr17:4875527	CAMTA2	-0.9	-4.7	-0.36	5.67e-6	Platelet count;
PAAD	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg16926213	chr1:1841314	NA	0.37	4.48	0.34	1.46e-5	Body mass index;
PAAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	5.4	0.4	2.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg16506815	chr2:162101123	NA	0.6	6.42	0.46	1.65e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02951971	chr14:50698663	SOS2	0.68	6.97	0.49	9.06e-11	Obesity-related traits;
PAAD	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.91	0.59	1.44e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-4.96	-0.37	1.85e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg22134325	chr11:66188745	NPAS4	0.29	4.7	0.36	5.82e-6	Airway imaging phenotypes;
PAAD	cis	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg05299278	chr17:33885742	SLFN14	0.43	5.08	0.38	1.08e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.9	8.88	0.58	1.74e-15	Orofacial clefts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08647453	chr16:88889618	GALNS	-0.6	-6.46	-0.46	1.33e-9	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.83	10.03	0.63	1.7e-18	Menopause (age at onset);
PAAD	cis	rs12579350	1.000	rs251763	chr12:5781382	C/T	cg17198308	chr12:6665108	IFFO1	0.49	4.47	0.34	1.53e-5	Panic disorder;
PAAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.84	8.66	0.57	6.45e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.67	-0.35	6.51e-6	Depression;
PAAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.55	6.0	0.44	1.37e-8	Type 2 diabetes;
PAAD	cis	rs7631605	0.846	rs57863333	chr3:37263719	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.28	0.33	3.28e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs761746	0.577	rs131245	chr22:32126763	T/C	cg01338084	chr22:32026380	PISD	0.6	5.34	0.4	3.37e-7	Intelligence;
PAAD	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.15	-0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg01102307	chr1:9340416	NA	0.45	4.68	0.36	6.22e-6	Eosinophil percentage of white cells;
PAAD	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.91	12.19	0.7	2.76e-24	Methadone dose in opioid dependence;
PAAD	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18986451	chr3:100428869	TFG	0.58	6.81	0.48	2.07e-10	Metabolite levels  (X-11787);
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2617583	0.868	rs2617596	chr5:1446719	C/G	cg07151155	chr5:1473589	LPCAT1	-0.46	-4.51	-0.34	1.29e-5	Breast cancer;
PAAD	cis	rs1595825	0.730	rs1902248	chr2:198492598	C/T	cg00982548	chr2:198649783	BOLL	-0.69	-4.69	-0.36	6e-6	Ulcerative colitis;
PAAD	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.48	-4.62	-0.35	8.02e-6	Menarche (age at onset);
PAAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.65	4.95	0.37	1.99e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs939584	1.000	rs6731348	chr2:630339	A/C	cg03610516	chr2:642275	NA	0.62	5.55	0.41	1.25e-7	Body mass index;
PAAD	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.6	6.98	0.49	8.79e-11	Dupuytren's disease;
PAAD	cis	rs8016947	0.524	rs35972543	chr14:35830295	A/T	cg03549618	chr14:35838977	NA	0.49	5.32	0.4	3.58e-7	Psoriasis;
PAAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.56	-5.21	-0.39	5.95e-7	Obesity-related traits;
PAAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg10193763	chr2:225306901	NA	0.53	4.68	0.35	6.38e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg20295408	chr7:1910781	MAD1L1	-0.52	-4.84	-0.37	3.11e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.52	4.59	0.35	9.38e-6	Obesity-related traits;
PAAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.28	-0.39	4.34e-7	Blood metabolite levels;
PAAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.0	-0.44	1.4e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs687432	0.688	rs12788387	chr11:57893347	A/C	cg02432159	chr15:75661014	MAN2C1	-0.62	-6.61	-0.47	6.23e-10	Parkinson's disease;
PAAD	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg01851573	chr8:8652454	MFHAS1	0.58	5.06	0.38	1.19e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21630368	chr11:85374883	CREBZF	0.59	6.36	0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs4819052	0.540	rs7282639	chr21:46491155	G/C	cg06618935	chr21:46677482	NA	0.51	5.43	0.4	2.19e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.13	-0.38	8.68e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.49e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg22587600	chr2:46883368	NA	-0.33	-4.35	-0.33	2.51e-5	Height;
PAAD	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-1.02	-8.44	-0.56	2.38e-14	Blood trace element (Zn levels);
PAAD	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.48	-5.88	-0.43	2.48e-8	Mean corpuscular volume;
PAAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.73	-7.26	-0.51	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs939584	0.935	rs13387939	chr2:637498	C/A	cg14515364	chr2:636606	NA	0.47	4.38	0.33	2.24e-5	Body mass index;
PAAD	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.69	4.89	0.37	2.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.79	9.48	0.61	4.75e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.78	-0.36	4.14e-6	Vitiligo;
PAAD	cis	rs4321325	0.733	rs13389505	chr2:127934888	T/C	cg11380483	chr2:127933992	NA	0.73	5.88	0.43	2.52e-8	Protein C levels;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg00531865	chr16:30841666	NA	0.56	4.33	0.33	2.64e-5	Dementia with Lewy bodies;
PAAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg22968622	chr17:43663579	NA	-1.01	-10.4	-0.64	1.81e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15988457	chr10:134467339	INPP5A	-0.69	-7.35	-0.51	1.13e-11	Obesity-related traits;
PAAD	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.61	-0.47	5.98e-10	Breast cancer;
PAAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.56	5.98	0.44	1.56e-8	Monocyte percentage of white cells;
PAAD	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.51	-5.07	-0.38	1.12e-6	Height;
PAAD	cis	rs859767	0.501	rs6742638	chr2:135407360	T/G	cg12500956	chr2:135428796	TMEM163	-0.33	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg21546286	chr11:48923668	NA	0.57	5.96	0.44	1.68e-8	HDL cholesterol;
PAAD	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-4.87	-0.37	2.8e-6	Blood metabolite levels;
PAAD	cis	rs11871801	0.918	rs34460267	chr17:40615865	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.48	-5.0	-0.38	1.55e-6	Crohn's disease;
PAAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg13379983	chr2:198649727	BOLL	0.56	4.34	0.33	2.56e-5	Ulcerative colitis;
PAAD	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg20913747	chr6:44695427	NA	-0.62	-7.06	-0.5	5.63e-11	Total body bone mineral density;
PAAD	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.72	0.48	3.38e-10	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.34	-0.4	3.36e-7	P wave terminal force;
PAAD	cis	rs4959799	0.744	rs7748151	chr6:3293554	A/G	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.77e-5	Survival in rectal cancer;
PAAD	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.67	6.88	0.49	1.48e-10	Response to hepatitis C treatment;
PAAD	cis	rs8060686	0.641	rs77996485	chr16:68137420	C/G	cg03983715	chr16:68378420	PRMT7	-0.86	-5.19	-0.39	6.56e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg27113419	chr16:58533979	NDRG4	-0.74	-4.6	-0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.12e-6	Pulmonary function;
PAAD	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg15123519	chr2:136567270	LCT	0.37	4.51	0.34	1.3e-5	Mosquito bite size;
PAAD	cis	rs863345	0.526	rs857718	chr1:158595142	T/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.72	-0.36	5.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.86	0.37	2.86e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2302729	1.000	rs2302729	chr12:2783972	T/C	cg19945202	chr12:2788847	CACNA1C	-0.58	-5.44	-0.4	2.1e-7	Sleep quality;
PAAD	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.55	-4.41	-0.34	1.99e-5	IFN-related cytopenia;
PAAD	cis	rs55637147	0.553	rs879646	chr11:57124196	C/T	cg06698926	chr11:57958183	OR9Q2	0.32	4.31	0.33	2.97e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-5.62	-0.41	8.83e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg17545662	chr6:170176663	C6orf70	0.62	4.35	0.33	2.46e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.87	5.99	0.44	1.43e-8	Thyroid stimulating hormone;
PAAD	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.7	8.09	0.55	1.75e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg00944433	chr1:107599041	PRMT6	0.42	4.9	0.37	2.4e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs2446066	0.818	rs7315782	chr12:53784913	G/A	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.83	-7.16	-0.5	3.18e-11	Vitiligo;
PAAD	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00791764	chr4:53727839	RASL11B	0.54	4.63	0.35	7.83e-6	Optic nerve measurement (cup area);
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg26338869	chr17:61819248	STRADA	0.5	4.66	0.35	6.96e-6	Height;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs1198430	0.636	rs2811963	chr1:23824242	A/C	cg22040403	chr1:23858016	E2F2	0.77	5.33	0.4	3.51e-7	Total cholesterol levels;
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	4.75	0.36	4.65e-6	Joint mobility (Beighton score);
PAAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.42	6.56	0.47	8.14e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.54	5.57	0.41	1.13e-7	Longevity;Endometriosis;
PAAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg11494091	chr17:61959527	GH2	0.51	4.28	0.33	3.25e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	9.9e-6	Renal cell carcinoma;
PAAD	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.71	-7.24	-0.51	2.06e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.73	-5.87	-0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg10932868	chr11:921992	NA	-0.5	-6.03	-0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.98	-11.88	-0.69	1.94e-23	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20669266	chr11:68080670	LRP5	0.59	6.4	0.46	1.79e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19388332	chr12:102091141	CHPT1	0.65	7.14	0.5	3.57e-11	Monocyte percentage of white cells;
PAAD	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.54	5.32	0.4	3.67e-7	Systolic blood pressure;
PAAD	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.58	-7.43	-0.52	7.22e-12	Lewy body disease;
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14248188	chr9:98273349	PTCH1	-0.55	-4.38	-0.33	2.18e-5	Neuroticism;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg00945038	chr17:61921165	SMARCD2	-0.48	-5.7	-0.42	5.96e-8	Prudent dietary pattern;
PAAD	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg04389838	chr3:44770851	ZNF501	-0.51	-4.4	-0.34	2.06e-5	Depressive symptoms;
PAAD	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6909834	0.636	rs1332840	chr6:12818865	G/C	cg17869960	chr6:12718530	PHACTR1	0.36	4.3	0.33	2.99e-5	Gait speed in old age;
PAAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.56	-5.32	-0.4	3.66e-7	Daytime sleep phenotypes;
PAAD	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.79	8.78	0.58	3.15e-15	Systemic lupus erythematosus;
PAAD	cis	rs9467160	0.765	rs793717	chr6:24444534	A/C	cg16211469	chr6:24423932	MRS2	-0.49	-4.74	-0.36	4.79e-6	Liver enzyme levels;
PAAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg00277334	chr10:82204260	NA	-0.6	-5.38	-0.4	2.73e-7	Post bronchodilator FEV1;
PAAD	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.14	14.58	0.76	1.1e-30	Primary sclerosing cholangitis;
PAAD	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg14784868	chr12:69753453	YEATS4	0.54	4.76	0.36	4.43e-6	Response to diuretic therapy;
PAAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.42	-5.41	-0.4	2.44e-7	Ulcerative colitis;
PAAD	cis	rs4704187	0.687	rs2112871	chr5:74469853	G/A	cg03227963	chr5:74354835	NA	0.49	4.71	0.36	5.55e-6	Response to amphetamines;
PAAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.75	-0.58	3.75e-15	Eye color traits;
PAAD	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs216303	0.642	rs216318	chr12:6139261	A/C	cg12895370	chr12:6755816	ACRBP	-0.57	-4.42	-0.34	1.87e-5	Low vWF levels;
PAAD	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-5.62	-0.42	8.69e-8	Ulcerative colitis;
PAAD	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.56	-5.7	-0.42	6.14e-8	Hepatitis;
PAAD	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg08886695	chr4:3369023	RGS12	0.48	4.6	0.35	8.67e-6	Parental longevity (mother's age at death);
PAAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs7250872	0.606	rs1078229	chr19:1826383	A/C	cg03309721	chr19:2236316	PLEKHJ1;SF3A2	-0.57	-4.46	-0.34	1.58e-5	Bipolar disorder;
PAAD	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.45	4.6	0.35	8.92e-6	Age of smoking initiation;
PAAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs7922314	0.571	rs74232928	chr10:64716130	C/T	cg08989932	chr10:65390526	NA	-0.89	-4.39	-0.34	2.09e-5	Cutaneous psoriasis;
PAAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg12205435	chr5:138714322	SLC23A1	-0.48	-4.41	-0.34	1.93e-5	Esophageal squamous cell carcinoma;
PAAD	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.33e-7	Male-pattern baldness;
PAAD	cis	rs6445525	1.000	rs4417899	chr3:65996110	T/C	cg06109867	chr3:66002991	MAGI1	-0.47	-4.68	-0.35	6.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10318197	chr8:141294172	TRAPPC9	0.56	6.43	0.46	1.57e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg02781088	chr2:113192302	RGPD8;RGPD5	0.91	6.68	0.48	4.32e-10	Yeast infection;
PAAD	cis	rs6604026	0.656	rs2811598	chr1:93336933	A/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs4759375	0.667	rs10773014	chr12:123842897	G/A	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.64	-7.0	-0.49	7.62e-11	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.13	0.38	8.57e-7	Multiple sclerosis;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16500173	chr3:185825565	ETV5	0.45	4.6	0.35	8.85e-6	Myopia (pathological);
PAAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-4.95	-0.37	1.93e-6	Type 2 diabetes;
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03309786	chr2:232574968	PTMA	0.59	6.5	0.47	1.08e-9	Myopia (pathological);
PAAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg13870426	chr17:30244630	NA	-0.74	-6.55	-0.47	8.33e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	9.89	0.63	4.02e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.78	4.33	0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs7608623	0.840	rs11674248	chr2:24154192	A/C	cg08917208	chr2:24149416	ATAD2B	-0.45	-4.38	-0.33	2.22e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.7	5.72	0.42	5.5e-8	Vitiligo;
PAAD	cis	rs9810890	1.000	rs9840633	chr3:128568202	C/A	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18297960	chr7:1142765	C7orf50	-0.55	-4.4	-0.34	2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.81	9.64	0.62	1.86e-17	Colorectal cancer;
PAAD	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.74	-0.36	4.92e-6	Smoking behavior;
PAAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg04450456	chr4:17643702	FAM184B	0.48	5.0	0.38	1.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.55	4.69	0.36	5.97e-6	Lymphocyte counts;
PAAD	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg24879335	chr3:133465180	TF	0.59	6.6	0.47	6.51e-10	Iron status biomarkers;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-5.01	-0.38	1.51e-6	Lymphocyte counts;
PAAD	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.5	-4.88	-0.37	2.67e-6	Mean corpuscular volume;
PAAD	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg16898833	chr6:26189333	HIST1H4D	0.76	4.3	0.33	3.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg06636001	chr8:8085503	FLJ10661	0.63	6.37	0.46	2.1e-9	Retinal vascular caliber;
PAAD	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.14	14.19	0.75	1.25e-29	Type 1 diabetes nephropathy;
PAAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08311172	chr2:69969004	ANXA4	-0.79	-6.8	-0.48	2.19e-10	Neuroticism;
PAAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.07	0.44	9.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs6466055	0.589	rs2097942	chr7:104725105	A/G	cg04380332	chr7:105027541	SRPK2	0.49	4.79	0.36	3.89e-6	Schizophrenia;
PAAD	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.77	7.6	0.52	2.81e-12	Coronary artery disease;
PAAD	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06307176	chr5:131281290	NA	-0.52	-4.69	-0.36	6.1e-6	Life satisfaction;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg05697835	chr1:2722811	NA	-0.39	-4.42	-0.34	1.9e-5	Ulcerative colitis;
PAAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg12292205	chr6:26970375	C6orf41	-0.56	-4.94	-0.37	2.02e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2117029	0.556	rs1057725	chr12:49522578	T/C	cg05368762	chr12:50135785	TMBIM6	0.44	4.32	0.33	2.82e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.5	4.41	0.34	1.98e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.02	-0.7	8.01e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg07748719	chr16:1272498	TPSG1	0.69	6.84	0.49	1.81e-10	Blood protein levels;
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.85	-13.26	-0.73	3.86e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.28	-0.33	3.3e-5	Mood instability;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11020665	chr12:120635258	RPLP0	-0.53	-6.56	-0.47	8.08e-10	Monocyte percentage of white cells;
PAAD	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg22800295	chr12:3386867	TSPAN9	-0.49	-4.64	-0.35	7.54e-6	Sleep quality;
PAAD	cis	rs7551222	0.646	rs2926536	chr1:204456983	T/G	cg01064725	chr1:204461714	NA	0.56	4.72	0.36	5.33e-6	Schizophrenia;
PAAD	trans	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg15770106	chr1:208133116	NA	-0.64	-6.36	-0.46	2.22e-9	Corneal structure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14049380	chr3:52805078	NEK4	0.62	7.12	0.5	4.08e-11	Myopia (pathological);
PAAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.6	-6.3	-0.46	3.05e-9	Corneal astigmatism;
PAAD	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg12454167	chr3:186435060	KNG1	0.46	5.01	0.38	1.49e-6	Blood protein levels;
PAAD	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.45	-5.17	-0.39	7.23e-7	Mean arterial pressure;
PAAD	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg19882132	chr14:106167949	NA	-0.51	-4.49	-0.34	1.4e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.48	-4.99	-0.38	1.62e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06851253	chr3:14166363	CHCHD4;TMEM43	0.57	6.31	0.46	2.91e-9	Monocyte percentage of white cells;
PAAD	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg22029157	chr1:209979665	IRF6	0.7	6.59	0.47	6.67e-10	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs9462027	0.628	rs2477508	chr6:34703695	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.43	5.11	0.38	9.46e-7	Systemic lupus erythematosus;
PAAD	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg08562672	chr19:21860753	NA	0.45	4.62	0.35	8.23e-6	Pain;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03338380	chr1:227058754	PSEN2	-0.65	-6.65	-0.47	5.03e-10	Smoking initiation;
PAAD	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.51	0.57	1.53e-14	Dupuytren's disease;
PAAD	cis	rs17023223	0.509	rs6668960	chr1:119600812	C/T	cg17326555	chr1:119535693	NA	-0.43	-5.32	-0.4	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs35883536	0.967	rs4908090	chr1:101135177	A/G	cg14515779	chr1:101123966	NA	-0.54	-6.83	-0.48	1.94e-10	Monocyte count;
PAAD	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-4.33	-0.33	2.66e-5	Skin colour saturation;
PAAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.59	5.73	0.42	5.35e-8	Endometrial cancer;
PAAD	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	4.42	0.34	1.83e-5	Cognitive test performance;
PAAD	cis	rs643506	0.874	rs687152	chr11:111721673	T/C	cg09085632	chr11:111637200	PPP2R1B	0.55	4.6	0.35	8.98e-6	Breast cancer;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg03395511	chr6:291903	DUSP22	-0.77	-8.19	-0.55	9.92e-14	Menopause (age at onset);
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.75	5.89	0.43	2.37e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.82	8.35	0.56	3.85e-14	Uric acid levels;
PAAD	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg12046867	chr14:103022105	NA	-0.65	-5.14	-0.38	8.36e-7	Platelet count;
PAAD	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12304921	0.810	rs73090661	chr12:51355242	C/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.19	-0.39	6.74e-7	Type 2 diabetes;
PAAD	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.55	-4.87	-0.37	2.78e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.11	-0.38	9.35e-7	Asthma;
PAAD	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg13444538	chr7:158905317	VIPR2	0.6	6.02	0.44	1.27e-8	Facial morphology (factor 20);
PAAD	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.81	8.86	0.58	1.92e-15	Mortality in heart failure;
PAAD	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg00546117	chr1:8445545	RERE	-0.46	-4.72	-0.36	5.28e-6	Crohn's disease;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.7	-7.55	-0.52	3.83e-12	Triglyceride levels;
PAAD	cis	rs7172971	0.638	rs74554336	chr15:42384521	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg09582351	chr12:29534625	ERGIC2	0.32	4.47	0.34	1.52e-5	QT interval;
PAAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.48	4.63	0.35	7.64e-6	Erythrocyte sedimentation rate;
PAAD	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.69	6.83	0.48	1.88e-10	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg20933634	chr6:27740509	NA	0.65	6.24	0.45	4.05e-9	Parkinson's disease;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg01426195	chr3:39028469	NA	0.62	6.06	0.44	1.03e-8	Handedness;
PAAD	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.14	-0.5	3.53e-11	Mood instability;
PAAD	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.72e-15	Dupuytren's disease;
PAAD	cis	rs9918079	0.560	rs6414767	chr4:15655721	A/G	cg16509355	chr4:15471240	CC2D2A	-0.33	-4.34	-0.33	2.61e-5	Obesity-related traits;
PAAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg16928487	chr17:17741425	SREBF1	-0.31	-4.27	-0.33	3.44e-5	Total body bone mineral density;
PAAD	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg26003909	chr8:143102224	NA	-0.36	-6.04	-0.44	1.16e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.38	5.63	0.42	8.27e-8	Educational attainment (years of education);
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg20893717	chr7:100318190	EPO	-0.46	-4.48	-0.34	1.48e-5	Other erythrocyte phenotypes;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.77	8.42	0.56	2.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.64	-7.04	-0.5	6.14e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs6796502	0.541	rs28440083	chr3:46881986	A/G	cg22309949	chr3:46792192	NA	-0.6	-4.8	-0.36	3.83e-6	Breast cancer;
PAAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg06079509	chr4:6304042	WFS1	0.47	4.3	0.33	3.09e-5	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.75	0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs9287719	0.649	rs11684537	chr2:10734832	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7567389	0.637	rs4150421	chr2:128044930	A/G	cg09760422	chr2:128146352	NA	-0.38	-5.93	-0.43	1.97e-8	Self-rated health;
PAAD	cis	rs7957197	0.873	rs7965349	chr12:121471931	C/T	cg13839391	chr12:121719066	CAMKK2	0.45	4.3	0.33	3.03e-5	Type 2 diabetes;
PAAD	cis	rs490234	0.756	rs1268539	chr9:128195657	C/A	cg14078157	chr9:128172775	NA	-0.46	-5.15	-0.39	7.83e-7	Mean arterial pressure;
PAAD	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.48	-5.31	-0.4	3.76e-7	Heart rate;
PAAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.78	-8.38	-0.56	3.33e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24196351	chr3:149182962	NA	0.58	6.79	0.48	2.38e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.76	0.42	4.43e-8	Response to antipsychotic treatment;
PAAD	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg09796270	chr17:17721594	SREBF1	0.44	5.0	0.38	1.56e-6	Total body bone mineral density;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07362569	chr17:61921086	SMARCD2	0.61	7.17	0.5	2.98e-11	Prudent dietary pattern;
PAAD	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.85	0.62	5.07e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-7.25	-0.51	1.95e-11	Idiopathic membranous nephropathy;
PAAD	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.72	10.96	0.66	5.66e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs10073892	0.703	rs59723886	chr5:101635199	A/G	cg17280723	chr5:101634495	NA	0.4	4.27	0.33	3.48e-5	Cognitive decline (age-related);
PAAD	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.83	-8.38	-0.56	3.28e-14	Multiple sclerosis;
PAAD	cis	rs11951515	0.508	rs7705166	chr5:43587448	G/T	cg01983248	chr5:43482804	C5orf28	-0.31	-4.42	-0.34	1.86e-5	Metabolite levels  (X-11787);
PAAD	cis	rs617219	0.737	rs12655567	chr5:78465698	C/G	cg24856658	chr5:78533917	JMY	-0.39	-4.41	-0.34	1.93e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs818427	0.964	rs351767	chr5:112200098	A/G	cg07820702	chr5:112228657	REEP5	0.5	4.65	0.35	7.16e-6	Total body bone mineral density;
PAAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.3	-0.33	3.02e-5	Mood instability;
PAAD	cis	rs3130844	1	rs3130844	chr6:28916594	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Urinary tract infection frequency;
PAAD	cis	rs308971	0.656	rs307563	chr3:12055011	G/T	cg15873301	chr3:12045459	SYN2	0.63	5.19	0.39	6.77e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg10820045	chr2:198174542	NA	-0.52	-5.21	-0.39	6.15e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.55	-5.46	-0.41	1.88e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg15691649	chr6:25882328	NA	0.48	4.37	0.33	2.27e-5	Blood metabolite levels;
PAAD	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21385522	chr1:16154831	NA	-0.58	-5.12	-0.38	9.2e-7	Dilated cardiomyopathy;
PAAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.62	6.57	0.47	7.62e-10	Multiple sclerosis;
PAAD	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs58521262	0.556	rs291769	chr19:23183941	T/C	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00982548	chr2:198649783	BOLL	-0.78	-5.62	-0.41	8.8e-8	Ulcerative colitis;
PAAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg22023784	chr20:54933826	C20orf108	0.61	6.57	0.47	7.47e-10	Smoking initiation;
PAAD	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg09491104	chr22:46646882	C22orf40	-0.95	-6.17	-0.45	6.05e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	8.9	0.59	1.54e-15	Lymphocyte counts;
PAAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.72	-8.23	-0.56	7.93e-14	Diastolic blood pressure;
PAAD	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.54	0.47	9e-10	Multiple sclerosis;
PAAD	cis	rs10090774	0.965	rs7843337	chr8:141962642	C/T	cg02508881	chr8:142216119	NA	0.43	4.53	0.34	1.2e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.31e-16	Asthma (childhood onset);
PAAD	trans	rs4234284	0.900	rs12491804	chr3:126983124	G/T	cg01353139	chr8:124170018	NA	0.58	6.3	0.46	2.98e-9	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs4908768	0.657	rs3938719	chr1:8804997	A/G	cg25722041	chr1:8623473	RERE	0.54	4.61	0.35	8.46e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.46	-0.34	1.61e-5	Life satisfaction;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.75	7.42	0.52	7.74e-12	Renal function-related traits (BUN);
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.51	-4.29	-0.33	3.21e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2555155	0.750	rs2262649	chr11:6517453	A/G	cg24637308	chr11:6592297	DNHD1	0.48	4.93	0.37	2.13e-6	DNA methylation (variation);
PAAD	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg24687543	chr11:63912206	MACROD1	0.58	4.66	0.35	6.8e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs35123781	0.502	rs195674	chr5:138927219	G/A	cg26929925	chr5:138714136	SLC23A1	-0.52	-4.6	-0.35	8.81e-6	Schizophrenia;
PAAD	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.74	7.31	0.51	1.44e-11	Asthma;
PAAD	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-1.1	-16.01	-0.79	1.99e-34	Systemic lupus erythematosus;
PAAD	cis	rs2908197	0.843	rs1076437	chr7:75939721	A/G	cg22830091	chr7:75961684	YWHAG	-0.6	-6.7	-0.48	3.72e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.48	-4.49	-0.34	1.37e-5	Migraine;
PAAD	cis	rs2790216	1.000	rs2790219	chr10:60013849	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg26875137	chr12:53738046	NA	0.43	4.69	0.36	6.01e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4144743	0.877	rs7223766	chr17:45326734	T/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg21130718	chr4:1044621	NA	0.54	4.6	0.35	8.76e-6	Recombination rate (females);
PAAD	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-5.81	-0.43	3.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg15448220	chr1:150897856	SETDB1	-0.66	-6.86	-0.49	1.66e-10	Tonsillectomy;
PAAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg22800045	chr5:56110881	MAP3K1	0.7	5.95	0.43	1.76e-8	Coronary artery disease;
PAAD	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.25	-0.6	1.96e-16	Response to antipsychotic treatment;
PAAD	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.37	5.1	0.38	9.96e-7	Schizophrenia;
PAAD	cis	rs6466055	0.661	rs6945585	chr7:104905277	T/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.14e-6	Schizophrenia;
PAAD	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.69	7.3	0.51	1.53e-11	Osteoporosis;
PAAD	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.39	0.34	2.15e-5	Trans fatty acid levels;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs112990264	0.881	rs116320981	chr1:212971404	C/T	cg01785514	chr1:212988523	TATDN3	1.4	8.85	0.58	2.08e-15	Itch intensity from mosquito bite;
PAAD	cis	rs11159086	0.793	rs17100414	chr14:74934621	T/C	cg10195687	chr14:74926396	NA	-0.47	-5.35	-0.4	3.18e-7	Advanced glycation end-product levels;
PAAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.54	-5.47	-0.41	1.77e-7	Type 2 diabetes;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg21698718	chr17:80085957	CCDC57	0.45	5.26	0.39	4.8e-7	Life satisfaction;
PAAD	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg18612461	chr15:75251733	NA	-0.56	-6.92	-0.49	1.15e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg19486271	chr11:47235900	DDB2	0.55	5.6	0.41	9.85e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.5	-0.34	1.34e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.61	4.76	0.36	4.39e-6	Weight;
PAAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg17306686	chr7:157230923	NA	0.38	4.79	0.36	3.85e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg03098644	chr7:100410630	EPHB4	-0.59	-5.03	-0.38	1.38e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg24747557	chr10:131355152	MGMT	0.5	5.31	0.4	3.9e-7	Response to temozolomide;
PAAD	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg18612461	chr15:75251733	NA	0.67	8.36	0.56	3.68e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-14.03	-0.75	3.25e-29	Height;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg21724239	chr8:58056113	NA	0.71	5.35	0.4	3.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.75	-8.38	-0.56	3.27e-14	Multiple sclerosis;
PAAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.67e-5	Menopause (age at onset);
PAAD	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg19404813	chr2:208988932	CRYGD	0.53	6.47	0.46	1.24e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs10494745	0.510	rs17550662	chr1:197108946	A/G	cg01445052	chr1:197886681	LHX9	0.75	4.44	0.34	1.7e-5	Blood protein levels;
PAAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs59888335	0.858	rs12630087	chr3:80935171	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.82	-8.94	-0.59	1.23e-15	Morning vs. evening chronotype;
PAAD	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg21892295	chr12:121157589	UNC119B	-0.44	-4.31	-0.33	2.91e-5	Urinary metabolites (H-NMR features);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14984066	chr15:22946914	CYFIP1	-0.62	-6.52	-0.47	9.61e-10	Obesity-related traits;
PAAD	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg02683114	chr2:24398427	C2orf84	0.62	6.99	0.49	8.3e-11	Asthma;
PAAD	cis	rs732765	0.734	rs17101722	chr14:75114321	G/C	cg17347104	chr14:75034677	LTBP2	0.58	4.88	0.37	2.68e-6	Non-small cell lung cancer;
PAAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.49	4.55	0.35	1.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs77633900	0.772	rs284902	chr15:76745687	G/C	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.2	0.45	5.19e-9	Coffee consumption (cups per day);
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.71	-7.31	-0.51	1.4e-11	Cognitive function;
PAAD	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg01851573	chr8:8652454	MFHAS1	0.66	5.76	0.42	4.52e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.59	-8.42	-0.56	2.62e-14	IgG glycosylation;
PAAD	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.7	-6.39	-0.46	1.97e-9	Blood protein levels;
PAAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs66530629	0.874	rs6667299	chr1:25158500	T/C	cg22509179	chr1:25234806	RUNX3	-0.51	-4.8	-0.36	3.73e-6	Plateletcrit;
PAAD	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg04121983	chr17:73511085	CASKIN2	0.75	4.6	0.35	8.74e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	1.0	11.8	0.69	3.16e-23	Menopause (age at onset);
PAAD	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.53	-5.18	-0.39	6.88e-7	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09695851	chr17:3907499	NA	0.74	7.92	0.54	4.61e-13	Type 2 diabetes;
PAAD	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.68e-7	Coronary heart disease;
PAAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.75	-8.34	-0.56	4.07e-14	Longevity;
PAAD	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.82	5.9	0.43	2.33e-8	Coronary artery calcification;
PAAD	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.16	-0.6	3.34e-16	Mean platelet volume;
PAAD	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.48	-9.33	-0.6	1.19e-16	Alzheimer's disease (late onset);
PAAD	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg21724239	chr8:58056113	NA	0.71	5.39	0.4	2.58e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.93	8.36	0.56	3.66e-14	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.9	7.47	0.52	5.73e-12	Alzheimer's disease;
PAAD	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.79	9.72	0.62	1.15e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06728437	chr2:208031766	KLF7	0.58	6.78	0.48	2.5e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26031613	chr14:104095156	KLC1	0.43	4.34	0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.71	7.1	0.5	4.41e-11	Urate levels in lean individuals;
PAAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.48	-4.51	-0.34	1.31e-5	Breast cancer;
PAAD	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg01631408	chr1:248437212	OR2T33	-0.57	-5.27	-0.39	4.68e-7	Common traits (Other);
PAAD	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.65	6.07	0.44	9.96e-9	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.89	10.47	0.65	1.2e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08439880	chr3:133502540	NA	-0.52	-5.68	-0.42	6.75e-8	Iron status biomarkers;
PAAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.57	0.35	1.02e-5	Asthma;
PAAD	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.57	5.38	0.4	2.78e-7	Primary sclerosing cholangitis;
PAAD	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.66	-0.53	2.05e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs89107	0.576	rs763254	chr6:118886615	T/C	cg21191810	chr6:118973309	C6orf204	0.38	4.52	0.34	1.25e-5	Cardiac structure and function;
PAAD	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.66	6.39	0.46	1.97e-9	Asthma;
PAAD	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-4.25	-0.33	3.77e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg10534938	chr5:1868639	NA	0.47	6.05	0.44	1.06e-8	Cardiovascular disease risk factors;
PAAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7551345	0.853	rs12750816	chr1:31721862	A/G	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs1823874	0.581	rs12905599	chr15:100339938	C/T	cg16400843	chr15:100339927	C15orf51	0.52	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-6.42	-0.46	1.61e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.68	7.66	0.53	1.98e-12	Multiple sclerosis;
PAAD	cis	rs6460942	0.597	rs76749787	chr7:12172960	C/T	cg06484146	chr7:12443880	VWDE	-0.65	-4.31	-0.33	2.9e-5	Coronary artery disease;
PAAD	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg09945482	chr18:12777974	NA	-0.59	-5.08	-0.38	1.1e-6	Inflammatory skin disease;
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.56	-5.23	-0.39	5.46e-7	Menarche (age at onset);
PAAD	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.96	-0.37	1.87e-6	Diastolic blood pressure;
PAAD	cis	rs4417704	0.578	rs4675842	chr2:241876480	C/G	cg26818257	chr2:241905806	NA	-0.5	-5.39	-0.4	2.68e-7	Joint mobility (Beighton score);
PAAD	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.46	0.34	1.59e-5	Self-reported allergy;
PAAD	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.11	13.71	0.74	2.32e-28	Colorectal cancer;
PAAD	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs900145	0.953	rs7109016	chr11:13293979	A/T	cg15603424	chr11:13300592	ARNTL	-0.52	-4.7	-0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs17539620	0.630	rs62432757	chr6:154854650	T/A	cg20019720	chr6:154832845	CNKSR3	0.57	5.94	0.43	1.85e-8	Lipoprotein (a) levels;
PAAD	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.59	5.66	0.42	7.29e-8	Joint mobility (Beighton score);
PAAD	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Body mass index;
PAAD	cis	rs9816226	0.591	rs57912727	chr3:185804583	A/C	cg00760338	chr3:185826511	ETV5	-0.72	-5.55	-0.41	1.26e-7	Obesity;Body mass index;
PAAD	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	0.8	5.36	0.4	3.01e-7	Body mass index;
PAAD	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.79	7.67	0.53	1.9e-12	Mean platelet volume;
PAAD	cis	rs4751058	0.526	rs7897117	chr10:130859730	A/G	cg09559163	chr10:130298860	NA	-0.38	-4.57	-0.35	1.02e-5	Vitamin D levels;
PAAD	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9888739	0.641	rs67898294	chr16:31362711	C/T	cg15817542	chr16:31343056	ITGAM	-0.45	-4.39	-0.34	2.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg08132940	chr7:1081526	C7orf50	-0.63	-4.4	-0.34	2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.56	-5.55	-0.41	1.26e-7	Childhood ear infection;
PAAD	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	6.78	0.48	2.51e-10	Body mass index (adult);
PAAD	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg00543991	chr22:32367038	NA	1.12	6.85	0.49	1.72e-10	Childhood ear infection;
PAAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.88	10.84	0.66	1.2e-20	Methadone dose in opioid dependence;
PAAD	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-5.88	-0.43	2.47e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.48	4.64	0.35	7.44e-6	Airway imaging phenotypes;
PAAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg14829360	chr17:73884958	NA	-0.68	-5.95	-0.43	1.82e-8	Psoriasis;
PAAD	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg15282417	chr9:129245246	FAM125B	0.38	4.72	0.36	5.34e-6	Intraocular pressure;
PAAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg04176122	chr11:118779835	BCL9L	-0.45	-4.48	-0.34	1.48e-5	Sjögren's syndrome;
PAAD	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg22101045	chr11:47927509	NA	0.57	4.38	0.33	2.21e-5	Intraocular pressure;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13242816	1.000	rs17138708	chr7:116109062	T/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.78	5.77	0.42	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.59	0.41	1.04e-7	Lung cancer in ever smokers;
PAAD	cis	rs4917300	0.692	rs7815624	chr8:143117893	G/A	cg26003909	chr8:143102224	NA	-0.35	-5.69	-0.42	6.3e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs6066835	1.000	rs6063314	chr20:47353106	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-1.12	-8.96	-0.59	1.07e-15	Post bronchodilator FEV1;
PAAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.74	7.83	0.54	7.9e-13	Total body bone mineral density;
PAAD	cis	rs12935418	0.616	rs13332902	chr16:81005800	T/C	cg16651780	chr16:81037892	C16orf61	0.65	6.23	0.45	4.37e-9	Mean corpuscular volume;
PAAD	cis	rs2252790	0.895	rs1204833	chr6:116572828	A/G	cg18764771	chr6:116381957	FRK	-0.28	-4.77	-0.36	4.38e-6	Fast beta electroencephalogram;
PAAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.96	10.04	0.63	1.67e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.68	0.36	6.23e-6	Neuroticism;
PAAD	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.87	5.48	0.41	1.7e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.63	6.1	0.44	8.36e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg12458913	chr13:53173898	NA	0.48	4.82	0.36	3.48e-6	Lewy body disease;
PAAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.54	6.02	0.44	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg16083429	chr3:49237500	CCDC36	-0.43	-4.36	-0.33	2.36e-5	Menarche (age at onset);
PAAD	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.64	0.35	7.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.44	-4.45	-0.34	1.69e-5	Body mass index;
PAAD	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.96	0.37	1.89e-6	Post bronchodilator FEV1;
PAAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.85	6.43	0.46	1.6e-9	Initial pursuit acceleration;
PAAD	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.2	-0.39	6.43e-7	Joint mobility (Beighton score);
PAAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.52	-0.41	1.45e-7	Common traits (Other);
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.52	5.05	0.38	1.27e-6	Parkinson's disease;
PAAD	cis	rs853679	0.567	rs16894106	chr6:28400339	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.67	-0.35	6.51e-6	Depression;
PAAD	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.06	0.38	1.18e-6	Blood protein levels;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg15117754	chr3:10150083	C3orf24	0.71	6.08	0.44	9.39e-9	Alzheimer's disease;
PAAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs13111989	1.000	rs13114008	chr4:177540142	G/T	cg11287292	chr4:178277261	NEIL3	-0.56	-4.53	-0.35	1.16e-5	HIV-1 viral setpoint;
PAAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.51	2.4e-11	Schizophrenia;
PAAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.55	6.8	0.48	2.22e-10	Psoriasis;
PAAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.81	0.43	3.5e-8	Tonsillectomy;
PAAD	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg00334542	chr7:100209784	MOSPD3	-0.69	-5.29	-0.39	4.24e-7	Other erythrocyte phenotypes;
PAAD	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg07648498	chr16:89883185	FANCA	-0.48	-4.84	-0.37	3.21e-6	Vitiligo;
PAAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.51	4.64	0.35	7.33e-6	Mean corpuscular volume;
PAAD	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg13736514	chr6:26305472	NA	-0.47	-5.16	-0.39	7.7e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs3935685	0.874	rs4595768	chr15:78006290	C/T	cg25212270	chr15:78015279	NA	0.41	4.32	0.33	2.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.65	8.17	0.55	1.14e-13	Prostate cancer;
PAAD	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.47	-4.71	-0.36	5.55e-6	Menarche (age at onset);
PAAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.6200000000000003e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	trans	rs2807544	0.527	rs12748696	chr1:15204750	G/C	cg01692572	chr8:144910787	PUF60	0.64	6.71	0.48	3.66e-10	Interleukin-2 levels;
PAAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2290419	0.667	rs74725872	chr11:68942650	A/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.57	-0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.51	-5.1	-0.38	9.9e-7	Diastolic blood pressure;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg09346030	chr10:13390377	SEPHS1	0.56	6.38	0.46	1.98e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.59	-0.52	3.01e-12	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg04106633	chr4:1044584	NA	0.66	5.46	0.4	1.9e-7	Recombination rate (females);
PAAD	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.59	-0.35	9.32e-6	IgG glycosylation;
PAAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg16147221	chr4:10020634	SLC2A9	0.48	4.37	0.33	2.29e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg24213567	chr19:53496664	ZNF702P	-0.42	-4.34	-0.33	2.61e-5	Psoriasis;
PAAD	cis	rs1572438	0.965	rs3799324	chr6:859376	G/A	cg21062780	chr6:887772	NA	-0.44	-4.27	-0.33	3.49e-5	Aging;
PAAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	12.15	0.7	3.68e-24	Bone mineral density;
PAAD	cis	rs2658782	0.901	rs11601056	chr11:93229161	C/T	cg15737290	chr11:93063684	CCDC67	-0.75	-5.55	-0.41	1.25e-7	Pulmonary function decline;
PAAD	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg17401720	chr7:158221031	PTPRN2	-0.38	-4.47	-0.34	1.54e-5	Obesity-related traits;
PAAD	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.15	0.39	8.12e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.82	5.14	0.38	8.43e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.57	5.34	0.4	3.34e-7	Schizophrenia;
PAAD	cis	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg21775007	chr8:11205619	TDH	-0.58	-4.52	-0.34	1.21e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.69	7.12	0.5	3.91e-11	Renal function-related traits (BUN);
PAAD	cis	rs8105895	0.935	rs959908	chr19:22281893	A/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg00579200	chr11:133705235	NA	-0.47	-5.07	-0.38	1.14e-6	Childhood ear infection;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.65	-6.49	-0.47	1.15e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg22963979	chr7:1858916	MAD1L1	-0.75	-8.81	-0.58	2.72e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.72	0.48	3.35e-10	Response to antipsychotic treatment;
PAAD	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.98	12.09	0.7	5.38e-24	Bone mineral density;
PAAD	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.73	-9.45	-0.61	6e-17	Educational attainment;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg15510373	chr7:100224934	TFR2	-0.53	-4.37	-0.33	2.32e-5	Other erythrocyte phenotypes;
PAAD	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.04	8.03	0.55	2.51e-13	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs10028187	0.822	rs2016847	chr4:154402835	C/T	cg24020152	chr4:154419554	KIAA0922	0.48	5.23	0.39	5.44e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-17.01	-0.81	5.14e-37	Height;
PAAD	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.61	5.71	0.42	5.63e-8	Height;
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.06	-0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs17135859	1.000	rs4705465	chr5:112993624	G/T	cg12552261	chr5:112820674	MCC	0.73	4.64	0.35	7.52e-6	F-cell distribution;
PAAD	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	5.22	0.39	5.87e-7	Joint mobility (Beighton score);
PAAD	cis	rs6499244	0.530	rs6499260	chr16:69864675	C/T	cg00738113	chr16:70207722	CLEC18C	-0.39	-4.26	-0.33	3.56e-5	Menarche (age at onset);
PAAD	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs9888739	0.668	rs58408589	chr16:31362741	A/G	cg15817542	chr16:31343056	ITGAM	-0.44	-4.28	-0.33	3.31e-5	Systemic lupus erythematosus;
PAAD	cis	rs9810890	1.000	rs56063711	chr3:128585715	C/G	cg15676455	chr3:128564943	NA	-0.73	-4.82	-0.36	3.43e-6	Dental caries;
PAAD	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.28	0.39	4.47e-7	Myeloid white cell count;
PAAD	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.44	-4.33	-0.33	2.67e-5	Schizophrenia;
PAAD	cis	rs4924544	1	rs4924544	chr15:41693455	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-7.77	-0.53	1.1e-12	Eosinophil percentage of white cells;
PAAD	cis	rs7537052	0.669	rs4652903	chr1:36642858	C/T	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.46	-0.4	1.92e-7	Schizophrenia;
PAAD	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.72	8.72	0.58	4.54e-15	Monocyte percentage of white cells;
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.25	0.64	4.48e-19	Platelet count;
PAAD	cis	rs9715521	0.645	rs13134207	chr4:59848379	G/T	cg11281224	chr4:60001000	NA	-0.54	-5.18	-0.39	6.84e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg08317243	chr16:87101592	NA	-0.52	-4.99	-0.38	1.64e-6	Menopause (age at onset);
PAAD	cis	rs2120991	0.967	rs10783611	chr12:54258980	G/A	cg21845580	chr12:53472882	SPRYD3	-0.46	-4.32	-0.33	2.84e-5	Biliary atresia;
PAAD	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.41	4.38	0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.38	-5.02	-0.38	1.45e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14162927	chr1:155145774	TRIM46;KRTCAP2	0.71	8.57	0.57	1.1e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.59	7.15	0.5	3.46e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg19254793	chr6:44695348	NA	0.44	4.26	0.33	3.62e-5	Total body bone mineral density;
PAAD	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.63	-7.59	-0.52	3.01e-12	HDL cholesterol;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg07212818	chr11:638076	DRD4	-0.7	-7.03	-0.5	6.38e-11	Systemic lupus erythematosus;
PAAD	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Red blood cell count;
PAAD	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.29	-0.33	3.21e-5	Schizophrenia;
PAAD	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.01	-0.38	1.49e-6	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg23346134	chr3:49453900	TCTA	0.41	4.35	0.33	2.51e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.9	9.88	0.63	4.4e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs3112530	1.000	rs2125515	chr5:152652976	A/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.92	5.07	0.38	1.13e-6	Aging (time to event);
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.64	6.67	0.48	4.57e-10	Cystic fibrosis severity;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.54	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg17328964	chr8:145687451	CYHR1	-0.59	-6.39	-0.46	1.93e-9	Age at first birth;
PAAD	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.72	-6.91	-0.49	1.22e-10	Platelet distribution width;
PAAD	cis	rs4908760	0.965	rs1884352	chr1:8537289	G/A	cg20416874	chr1:8611966	RERE	-0.45	-4.38	-0.33	2.21e-5	Vitiligo;
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg05304507	chr6:116381966	FRK	0.43	8.3	0.56	5.11e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg02196655	chr2:10830764	NOL10	0.55	5.62	0.41	8.75e-8	Prostate cancer;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25621393	chr5:149737060	TCOF1	-0.6	-6.39	-0.46	1.9e-9	Warfarin maintenance dose;
PAAD	cis	rs4372836	0.553	rs6706858	chr2:28992607	C/G	cg09009506	chr2:28216851	BRE	0.41	4.37	0.33	2.28e-5	Body mass index;
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.76	0.58	3.63e-15	Lung cancer;
PAAD	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg24375607	chr4:120327624	NA	0.54	5.04	0.38	1.3e-6	Corneal astigmatism;
PAAD	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.698	rs9400276	chr6:109647405	C/T	cg21918786	chr6:109611834	NA	-0.48	-5.33	-0.4	3.44e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11542086	chr8:79716756	IL7	0.68	7.13	0.5	3.76e-11	Primary biliary cholangitis;
PAAD	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.47	-4.86	-0.37	2.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.82	-10.33	-0.64	2.71e-19	Dental caries;
PAAD	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.83	0.36	3.36e-6	Diastolic blood pressure;
PAAD	cis	rs9896052	0.535	rs13341593	chr17:73433486	A/G	cg25649188	chr17:73499917	CASKIN2	0.56	4.32	0.33	2.82e-5	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.27	-0.33	3.36e-5	Systemic lupus erythematosus;
PAAD	cis	rs28595532	0.720	rs72670226	chr4:119304136	A/G	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.72	-7.46	-0.52	6.13e-12	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.81	10.14	0.64	8.77e-19	Morning vs. evening chronotype;
PAAD	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.4	-5.21	-0.39	5.93e-7	Colorectal cancer;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.12	0.59	4.21e-16	Alzheimer's disease;
PAAD	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	5.82	0.43	3.33e-8	Adiposity;
PAAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2274459	0.749	rs9469554	chr6:33648097	A/G	cg06253072	chr6:33679850	C6orf125	0.64	4.71	0.36	5.49e-6	Obesity (extreme);
PAAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg04387475	chr10:102747104	MRPL43;C10orf2	0.72	4.25	0.33	3.71e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs600626	0.529	rs58411334	chr11:75467350	G/T	cg24262691	chr11:75473276	NA	0.81	6.25	0.45	3.84e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg23752985	chr2:85803571	VAMP8	0.59	6.28	0.45	3.31e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.54	-5.59	-0.41	1.01e-7	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.65	6.56	0.47	7.93e-10	Ear protrusion;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.3e-5	Life satisfaction;
PAAD	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.71	5.02	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.93	0.37	2.12e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg05564831	chr3:52568323	NT5DC2	-0.47	-4.79	-0.36	3.98e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg18867708	chr6:26865862	GUSBL1	0.44	4.36	0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.67	0.42	6.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.08	0.5	5e-11	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.8e-8	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08149581	chr12:124901842	NCOR2	0.63	6.65	0.47	4.96e-10	Smoking initiation;
PAAD	cis	rs540425	0.572	rs217378	chr7:44608103	A/G	cg14633139	chr7:44645728	OGDH	0.44	4.4	0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.74	4.98	0.37	1.68e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.69	-6.24	-0.45	4.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26897989	chr16:1907736	C16orf73	-0.52	-4.69	-0.36	6.08e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.83	8.04	0.55	2.37e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.28	0.45	3.42e-9	Lung cancer;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-1.19	-9.38	-0.61	8.91e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.35e-14	Renal cell carcinoma;
PAAD	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	7.48	0.52	5.58e-12	Lymphocyte counts;
PAAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	5.0	0.38	1.59e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	8.1	0.55	1.67e-13	Prudent dietary pattern;
PAAD	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.97	7.42	0.52	7.72e-12	Eosinophilic esophagitis;
PAAD	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	4.77	0.36	4.23e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg09955084	chr16:413813	NA	0.29	4.75	0.36	4.64e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg07810366	chr2:100720526	AFF3	-0.37	-4.55	-0.35	1.07e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.54	0.35	1.12e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg16447950	chr5:562315	NA	-0.75	-6.5	-0.47	1.11e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg25457927	chr22:38595422	NA	-0.39	-5.6	-0.41	9.96e-8	Breast cancer;
PAAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01200585	chr1:228362443	C1orf69	-0.5	-5.66	-0.42	7.28e-8	Diastolic blood pressure;
PAAD	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.67	-7.44	-0.52	6.82e-12	Colorectal cancer;
PAAD	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.63	-6.26	-0.45	3.66e-9	Red cell distribution width;
PAAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.45	4.92	0.37	2.27e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12153243	0.714	rs6580286	chr5:142905354	T/C	cg13907255	chr5:142895549	NA	-0.52	-4.81	-0.36	3.57e-6	Migraine;
PAAD	cis	rs9880211	0.800	rs9873536	chr3:136474267	A/G	cg17177318	chr3:135913615	MSL2	0.56	4.26	0.33	3.64e-5	Body mass index;Height;
PAAD	cis	rs3784262	0.643	rs8030766	chr15:58369209	A/G	cg12031962	chr15:58353849	ALDH1A2	0.59	7.39	0.51	9.14e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12922317	0.927	rs3851005	chr16:12071213	C/T	cg08843971	chr16:11963173	GSPT1	-0.44	-4.83	-0.36	3.3e-6	Schizophrenia;
PAAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg03161606	chr19:29218774	NA	0.59	4.36	0.33	2.36e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.29	8.08	0.55	1.91e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2555155	1.000	rs2723620	chr11:6523657	A/G	cg10208301	chr11:6592745	DNHD1	0.42	4.38	0.33	2.23e-5	DNA methylation (variation);
PAAD	cis	rs6504950	0.705	rs9899545	chr17:52986845	T/C	cg18040354	chr17:53800484	TMEM100	0.49	4.27	0.33	3.39e-5	Breast cancer;
PAAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.29	0.33	3.13e-5	Menarche (age at onset);
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.85	6.96	0.49	9.65e-11	Lung function (FEV1/FVC);
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.24	0.56	7.33e-14	Lung cancer;
PAAD	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	9.02e-6	Menarche (age at onset);
PAAD	cis	rs10885997	0.626	rs4751996	chr10:118397894	A/G	cg09194742	chr10:118576158	NA	0.44	4.34	0.33	2.61e-5	Phospholipid levels (plasma);
PAAD	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg15145965	chr22:50218605	BRD1	0.72	4.51	0.34	1.31e-5	Schizophrenia;
PAAD	cis	rs12760731	0.565	rs10913516	chr1:178169493	G/A	cg00404053	chr1:178313656	RASAL2	0.7	5.09	0.38	1.03e-6	Obesity-related traits;
PAAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.62	6.1	0.44	8.36e-9	Blood protein levels;
PAAD	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.19	-0.55	1e-13	Brugada syndrome;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg24879335	chr3:133465180	TF	0.6	6.87	0.49	1.56e-10	Iron status biomarkers;
PAAD	cis	rs2415984	0.579	rs2254846	chr14:46973394	G/A	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg11802864	chr11:65308245	LTBP3	0.8	5.74	0.42	5.01e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs4924590	0.531	rs2114477	chr15:42227441	C/T	cg20935245	chr15:42234343	EHD4	-0.48	-5.38	-0.4	2.79e-7	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
PAAD	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-4.25	-0.33	3.74e-5	Breast cancer;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.4e-5	Iron status biomarkers;
PAAD	cis	rs5742933	0.948	rs5743063	chr2:190694449	A/G	cg04003228	chr2:190539410	ANKAR	-0.54	-4.26	-0.33	3.63e-5	Ferritin levels;
PAAD	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.5e-7	Restless legs syndrome;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg15181151	chr6:150070149	PCMT1	0.55	5.53	0.41	1.38e-7	Lung cancer;
PAAD	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.45	-5.11	-0.38	9.52e-7	Body mass index;
PAAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg03264133	chr6:25882463	NA	0.52	4.85	0.37	3.06e-6	Iron status biomarkers;
PAAD	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.18	0.5	2.84e-11	Neuroticism;
PAAD	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.47	-5.21	-0.39	5.97e-7	Cognitive function;
PAAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.6	-6.09	-0.44	8.9e-9	Blood metabolite levels;
PAAD	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.02	0.5	6.72e-11	Lung cancer in ever smokers;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	1.07	6.43	0.46	1.56e-9	Body mass index;
PAAD	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg26570165	chr1:119541833	NA	-0.47	-4.25	-0.33	3.67e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.71	-6.73	-0.48	3.31e-10	Monocyte count;
PAAD	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Lung cancer;
PAAD	cis	rs9558996	0.857	rs9514646	chr13:107935627	T/C	cg09252360	chr13:107220595	ARGLU1	0.57	4.27	0.33	3.46e-5	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs593982	0.719	rs555903	chr11:65466911	G/A	cg08755490	chr11:65554678	OVOL1	-1.16	-7.24	-0.51	2.05e-11	Atopic dermatitis;
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.21	-18.92	-0.84	8.69e-42	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs9595066	1.000	rs4942281	chr13:44708126	C/T	cg04068111	chr13:44716778	NA	-0.56	-5.96	-0.44	1.7e-8	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg18964960	chr10:1102726	WDR37	0.6	4.25	0.33	3.75e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg12215294	chr3:40350768	EIF1B	-0.47	-4.5	-0.34	1.34e-5	Renal cell carcinoma;
PAAD	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.38	-5.48	-0.41	1.69e-7	Cutaneous nevi;
PAAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.77	-11.07	-0.67	3.01e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-1.05	-13.32	-0.73	2.59e-27	Urate levels;
PAAD	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.48	4.54	0.35	1.11e-5	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs595018	0.505	rs7117870	chr11:60597424	C/T	cg23904249	chr11:60608951	CCDC86	0.7	5.18	0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-1.16	-8.17	-0.55	1.11e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs11209002	1.000	rs3762320	chr1:67588647	T/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10446143	chr21:44394730	PKNOX1	0.62	6.9	0.49	1.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs1227969	1.000	rs1227969	chr10:71263264	A/G	cg12610070	chr10:71211762	TSPAN15	0.29	4.27	0.33	3.44e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10793968	0.688	rs2313531	chr9:133635258	C/T	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.43	5.2	0.39	6.35e-7	Systemic lupus erythematosus;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-7.59	-0.52	3.06e-12	Systemic lupus erythematosus;
PAAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs6460942	0.659	rs6969309	chr7:12515847	T/C	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg03910582	chr17:19030146	GRAPL	-0.49	-4.7	-0.36	5.72e-6	Schizophrenia;
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg19784903	chr17:45786737	TBKBP1	0.45	4.4	0.34	2.02e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7551345	1.000	rs4949377	chr1:31758467	C/T	cg17086398	chr1:31896392	SERINC2	-0.48	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg25650185	chr19:21324782	ZNF431	-0.48	-4.38	-0.33	2.18e-5	Pain;
PAAD	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.94	-0.43	1.9e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.4	5.13	0.38	8.78e-7	Lewy body disease;
PAAD	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg01422370	chr2:73384389	NA	0.44	5.64	0.42	8.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.09	-0.44	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.33	-0.4	3.53e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.74	7.38	0.51	9.55e-12	Tonsillectomy;
PAAD	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.07	-6.97	-0.49	8.95e-11	Thyroid stimulating hormone;
PAAD	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.44	4.47	0.34	1.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg03037974	chr15:76606532	NA	0.52	6.03	0.44	1.21e-8	Blood metabolite levels;
PAAD	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.5	-0.34	1.37e-5	Height;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-8.16	-0.55	1.16e-13	Cognitive function;
PAAD	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg04289385	chr6:36355825	ETV7	0.44	4.42	0.34	1.87e-5	Platelet distribution width;
PAAD	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.17	0.45	5.95e-9	Lung cancer in ever smokers;
PAAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs1539053	0.899	rs12029004	chr1:58118080	G/A	cg00026909	chr1:58089001	DAB1	-0.63	-6.82	-0.48	2.05e-10	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26384229	chr12:38710491	ALG10B	0.73	8.29	0.56	5.43e-14	Morning vs. evening chronotype;
PAAD	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs78761021	0.860	rs12150379	chr17:9766484	G/A	cg26853458	chr17:9805074	RCVRN	0.7	8.08	0.55	1.89e-13	Type 2 diabetes;
PAAD	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.44	7.01	0.49	7.47e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.63	8.23	0.56	7.67e-14	Renal cell carcinoma;
PAAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.84	-0.43	3.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs9659323	0.632	rs10923743	chr1:119612632	C/T	cg26570165	chr1:119541833	NA	-0.52	-5.9	-0.43	2.28e-8	Body mass index;
PAAD	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg13207630	chr7:32358064	NA	0.78	4.29	0.33	3.13e-5	Body mass index;
PAAD	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg02683114	chr2:24398427	C2orf84	-0.55	-5.63	-0.42	8.46e-8	Asthma;
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg27490568	chr2:178487706	NA	0.44	4.84	0.37	3.19e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26876637	chr1:152193138	HRNR	0.88	6.78	0.48	2.48e-10	Atopic dermatitis;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1e-6	Lung cancer;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.99	6.48	0.47	1.22e-9	IgG glycosylation;
PAAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg05484376	chr2:27715224	FNDC4	0.48	4.85	0.37	3.03e-6	Total body bone mineral density;
PAAD	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.32	-0.56	4.66e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4073221	0.615	rs34827863	chr3:18207634	T/G	cg07694806	chr3:18168406	NA	-0.6	-4.32	-0.33	2.85e-5	Parkinson's disease;
PAAD	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg06569542	chr10:98946673	SLIT1	0.44	4.53	0.35	1.17e-5	Monocyte count;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg11601000	chr22:42348013	LOC339674	-0.49	-5.85	-0.43	2.86e-8	Intelligence;
PAAD	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	5.79	0.42	3.94e-8	Lung cancer in ever smokers;
PAAD	cis	rs6867913	0.556	rs6870643	chr5:141463805	C/G	cg23435118	chr5:141488016	NDFIP1	0.52	4.51	0.34	1.27e-5	Asthma;
PAAD	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.64	-5.99	-0.44	1.43e-8	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14875449	chr3:58318760	PXK	0.62	7.1	0.5	4.43e-11	Monocyte percentage of white cells;
PAAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.52	-5.42	-0.4	2.29e-7	Testicular germ cell tumor;
PAAD	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.71	9.25	0.6	1.91e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg19980929	chr12:42632907	YAF2	0.55	6.32	0.46	2.72e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.94	0.43	1.85e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62408225	0.890	rs2134814	chr6:90987512	C/G	cg03795776	chr6:90687632	BACH2	0.43	4.27	0.33	3.5e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4979906	1.000	rs11002247	chr10:79446901	T/C	cg07817648	chr10:79422355	NA	-0.55	-4.94	-0.37	2.01e-6	Mortality in heart failure;
PAAD	cis	rs73019876	0.869	rs2359813	chr19:22168141	C/T	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg15145965	chr22:50218605	BRD1	0.54	4.61	0.35	8.37e-6	Schizophrenia;
PAAD	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22509189	chr2:225307070	NA	-0.43	-4.26	-0.33	3.53e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.58	4.9	0.37	2.4e-6	Common traits (Other);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16477317	chr18:12702819	PSMG2;CEP76	-0.73	-6.49	-0.47	1.17e-9	Neuroticism;
PAAD	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-5.5	-0.41	1.54e-7	Personality dimensions;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.67	7.28	0.51	1.67e-11	Mean corpuscular volume;
PAAD	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.94	-8.17	-0.55	1.09e-13	Body mass index;
PAAD	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs11051970	1.000	rs6488051	chr12:32532733	G/C	cg02745156	chr12:32552066	NA	0.49	5.23	0.39	5.44e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs3206736	0.548	rs2108690	chr7:35082809	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.59	-0.35	9.27e-6	Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11156230	chr4:83351251	HNRPDL;ENOPH1	0.64	6.78	0.48	2.53e-10	Myopia (pathological);
PAAD	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg25401027	chr5:176370377	UIMC1	0.44	4.41	0.34	1.98e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs12145833	0.596	rs3926866	chr1:243437632	G/C	cg02356786	chr1:243265016	LOC731275	1.0	6.14	0.45	6.84e-9	Obesity (early onset extreme);
PAAD	cis	rs5009270	0.512	rs1024412	chr7:112247758	A/G	cg23628563	chr7:112262597	NA	0.64	5.62	0.41	9.09e-8	Osteoarthritis (hip);
PAAD	cis	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg09913449	chr8:42400586	C8orf40	-0.43	-4.63	-0.35	7.65e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.17	-0.45	5.9e-9	Body mass index;
PAAD	cis	rs8032158	1.000	rs11633313	chr15:56135709	A/G	cg02198044	chr15:56286336	NEDD4	-0.52	-5.51	-0.41	1.47e-7	Keloid;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg07202610	chr7:1142643	C7orf50	-0.65	-5.0	-0.38	1.59e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	11.15	0.67	1.78e-21	Smoking behavior;
PAAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-10.11	-0.63	1.08e-18	Total body bone mineral density;
PAAD	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.52	-4.35	-0.33	2.5e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.59	5.37	0.4	2.91e-7	Obesity-related traits;
PAAD	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-11.33	-0.68	5.88e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.73	8.27	0.56	6.18e-14	Colorectal cancer;
PAAD	cis	rs12920732	0.509	rs1541698	chr16:84794632	G/A	cg07647771	chr16:84786436	USP10	-0.31	-4.44	-0.34	1.7e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19933833	chr11:66247701	DPP3	0.65	6.99	0.49	7.92e-11	Myopia (pathological);
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg18209359	chr17:80159595	CCDC57	-0.46	-4.63	-0.35	7.91e-6	Life satisfaction;
PAAD	cis	rs617219	0.726	rs7717669	chr5:78452983	A/C	cg24856658	chr5:78533917	JMY	-0.39	-4.39	-0.34	2.14e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.43	-0.4	2.18e-7	Mononucleosis;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03760483	chr17:6899297	ALOX12	-0.43	-4.42	-0.34	1.83e-5	Tonsillectomy;
PAAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg26893134	chr6:116381904	FRK	0.45	7.34	0.51	1.17e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.51e-12	Lung disease severity in cystic fibrosis;
PAAD	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg00383909	chr3:49044727	WDR6	0.54	4.46	0.34	1.58e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs59888335	0.929	rs35672485	chr3:80857815	G/A	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs12220238	0.908	rs117056627	chr10:75932657	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	4.28	0.33	3.26e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs950881	0.932	rs3771180	chr2:102953617	G/T	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg17541715	chr7:1216824	NA	-0.54	-6.19	-0.45	5.39e-9	Longevity;Endometriosis;
PAAD	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.49	-4.91	-0.37	2.36e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-4.78	-0.36	4.04e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.45	-0.34	1.68e-5	Obesity (extreme);
PAAD	trans	rs901683	1.000	rs71496611	chr10:46021732	G/A	cg14076390	chr17:34947837	DHRS11	0.88	6.62	0.47	5.87e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.52	5.04	0.38	1.33e-6	Parkinson's disease;
PAAD	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.62	-5.89	-0.43	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.61	4.84	0.37	3.15e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg10845886	chr2:3471009	TTC15	-0.95	-9.32	-0.6	1.31e-16	Neurofibrillary tangles;
PAAD	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.76	-8.6	-0.57	9.13e-15	Handedness;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg14345882	chr6:26364793	BTN3A2	0.71	5.17	0.39	7.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs73416724	1.000	rs76649578	chr6:43388024	A/G	cg17076780	chr6:43251928	TTBK1	0.56	4.47	0.34	1.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg23283495	chr1:209979779	IRF6	0.66	6.43	0.46	1.56e-9	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03198275	chr3:126423056	CHCHD6	0.64	6.42	0.46	1.61e-9	Obesity-related traits;
PAAD	cis	rs7631605	0.518	rs6776697	chr3:36985664	C/T	cg10333520	chr3:36987040	TRANK1	0.41	5.66	0.42	7.16e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.63	-6.06	-0.44	1.04e-8	White matter hyperintensity burden;
PAAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6782025	0.837	rs2656048	chr3:121014635	A/G	cg16417163	chr3:121280760	NA	-0.44	-4.58	-0.35	9.43e-6	Aging (facial);
PAAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg03983715	chr16:68378420	PRMT7	-0.73	-5.18	-0.39	6.9e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg24330906	chr2:85765176	MAT2A	0.43	4.35	0.33	2.51e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg14700524	chr10:3282231	NA	0.32	4.47	0.34	1.53e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.93	-0.54	4.41e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg00982548	chr2:198649783	BOLL	0.71	5.05	0.38	1.26e-6	Ulcerative colitis;
PAAD	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg10935138	chr17:73851978	WBP2	0.9	7.45	0.52	6.6e-12	Psoriasis;
PAAD	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.72	7.18	0.5	2.9100000000000002e-11	Schizophrenia;
PAAD	cis	rs6141769	0.518	rs6058834	chr20:31316862	C/T	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.72	7.23	0.51	2.22e-11	Lung cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02836830	chr20:3767452	CENPB	0.63	6.87	0.49	1.56e-10	Myopia (pathological);
PAAD	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.78	7.58	0.52	3.14e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1927702	0.765	rs3008723	chr9:16009899	A/T	cg14451791	chr9:16040625	NA	-0.38	-4.51	-0.34	1.27e-5	Body mass index;
PAAD	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs9815354	1.000	rs7648578	chr3:41858731	C/T	cg03022575	chr3:42003672	ULK4	0.75	5.59	0.41	1.02e-7	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg10246881	chr20:60740550	SS18L1	-0.93	-6.47	-0.46	1.28e-9	Lung function (FEV1/FVC);
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.85	11.11	0.67	2.33e-21	Vitiligo;
PAAD	cis	rs17681684	0.565	rs62066045	chr17:9765023	T/C	cg26853458	chr17:9805074	RCVRN	0.72	7.25	0.51	1.94e-11	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg07747251	chr5:1868357	NA	0.59	6.43	0.46	1.6e-9	Cardiovascular disease risk factors;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg21399703	chr1:247681439	NA	-0.68	-6.5	-0.47	1.1e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.46	4.41	0.34	1.98e-5	Red cell distribution width;
PAAD	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg12384639	chr17:618140	VPS53	0.49	4.38	0.33	2.19e-5	Prostate cancer;
PAAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27431247	chr11:67888603	CHKA	0.62	6.45	0.46	1.38e-9	Myopia (pathological);
PAAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.73	5.98	0.44	1.52e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.58	-0.35	9.67e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.9	-9.61	-0.61	2.25e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.96	0.7	1.2e-23	Menopause (age at onset);
PAAD	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	4.99	0.38	1.61e-6	Ovarian reserve;
PAAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.78	-9.2	-0.6	2.65e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.67	0.53	1.9e-12	Menarche (age at onset);
PAAD	trans	rs3905000	0.588	rs13292582	chr9:107650430	A/G	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.07	0.44	9.88e-9	Menopause (age at onset);
PAAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.88	-11.09	-0.67	2.58e-21	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11248182	chr5:138774785	DNAJC18	0.65	6.56	0.47	7.84e-10	Obesity-related traits;
PAAD	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.91	9.46	0.61	5.47e-17	Multiple sclerosis;
PAAD	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	trans	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg16055075	chr10:135209199	MTG1	-0.92	-6.61	-0.47	6.22e-10	Red blood cell count;
PAAD	cis	rs2030114	0.731	rs11863139	chr16:51600659	A/G	cg03758633	chr16:51611768	NA	0.51	4.56	0.35	1.05e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.69	0.42	6.32e-8	Mean corpuscular volume;
PAAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.16e-32	Height;
PAAD	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg04165759	chr1:150448943	RPRD2	0.52	5.63	0.42	8.57e-8	Migraine;
PAAD	cis	rs412658	0.504	rs385774	chr19:22096075	G/A	cg23859931	chr19:22123797	NA	-0.45	-4.53	-0.34	1.18e-5	Telomere length;
PAAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6782025	0.837	rs9811698	chr3:120687694	G/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.54	5.05	0.38	1.27e-6	Schizophrenia;
PAAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs2718812	0.935	rs1006097	chr3:133411478	T/C	cg11941060	chr3:133502564	NA	0.46	4.91	0.37	2.37e-6	Iron status biomarkers;
PAAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.96	-7.92	-0.54	4.63e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-1.07	-8.89	-0.58	1.66e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.32	-0.4	3.68e-7	Daytime sleep phenotypes;
PAAD	cis	rs6679454	1.000	rs10889075	chr1:58361885	C/T	cg17491850	chr1:57888480	DAB1	-0.37	-4.34	-0.33	2.57e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs2191566	0.691	rs8104605	chr19:44589016	C/T	cg18700516	chr19:44507157	ZNF230	0.51	4.93	0.37	2.13e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	trans	rs901683	1.000	rs12772102	chr10:46081101	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.44	-0.34	1.7e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13198984	chr17:80129470	CCDC57	0.43	5.32	0.4	3.7e-7	Life satisfaction;
PAAD	cis	rs4664293	0.605	rs12991516	chr2:160442065	A/G	cg04215213	chr2:159602169	NA	-0.4	-4.45	-0.34	1.67e-5	Monocyte percentage of white cells;
PAAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.65	-7.23	-0.51	2.17e-11	Platelet distribution width;
PAAD	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.73	6.95	0.49	9.97e-11	Sum neutrophil eosinophil counts;
PAAD	cis	rs210648	0.739	rs9285420	chr6:117826724	C/G	cg21104965	chr6:117869453	DCBLD1	0.52	4.96	0.37	1.9e-6	Economic and political preferences;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg17178900	chr1:205818956	PM20D1	0.48	4.85	0.37	3.08e-6	Parkinson's disease;
PAAD	cis	rs30380	1.000	rs26510	chr5:96125910	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.42	4.47	0.34	1.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg07164556	chr1:145727247	PDZK1	-0.66	-4.5	-0.34	1.36e-5	Mitochondrial DNA levels;
PAAD	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.54	6.11	0.44	8.18e-9	Mean corpuscular volume;
PAAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg03959625	chr15:84868606	LOC388152	0.44	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg12560992	chr17:57184187	TRIM37	-0.97	-11.7	-0.69	6.08e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.64	-5.73	-0.42	5.11e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1355223	0.573	rs7127169	chr11:34727846	C/G	cg11622362	chr11:34938112	PDHX;APIP	0.44	4.44	0.34	1.69e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg08132940	chr7:1081526	C7orf50	0.63	4.6	0.35	8.96e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg27490568	chr2:178487706	NA	0.42	4.44	0.34	1.73e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.77	-0.42	4.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.34	0.4	3.27e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.63	-0.35	7.81e-6	Parkinson's disease;
PAAD	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-0.92	-6.25	-0.45	3.99e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg19254793	chr6:44695348	NA	-0.46	-4.32	-0.33	2.75e-5	Total body bone mineral density;
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg11601000	chr22:42348013	LOC339674	-0.43	-5.01	-0.38	1.5e-6	Cognitive function;
PAAD	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg00579200	chr11:133705235	NA	-0.49	-5.69	-0.42	6.42e-8	Childhood ear infection;
PAAD	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg10560079	chr2:191398806	TMEM194B	-0.78	-6.87	-0.49	1.52e-10	Diastolic blood pressure;
PAAD	trans	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.21e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.54	9.13	0.6	4.04e-16	Cutaneous nevi;
PAAD	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.62	6.29	0.45	3.27e-9	Blood protein levels;
PAAD	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.41	-4.61	-0.35	8.63e-6	Height;
PAAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-5.81	-0.43	3.54e-8	Bipolar disorder;
PAAD	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg08079166	chr15:68083412	MAP2K5	0.59	5.6	0.41	9.65e-8	Restless legs syndrome;
PAAD	cis	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19904058	chr10:135279010	LOC619207	-0.47	-5.7	-0.42	6e-8	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3743832	0.932	rs2313980	chr16:9221894	G/C	cg08831531	chr16:9218945	NA	-0.4	-4.27	-0.33	3.44e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.52	4.68	0.35	6.29e-6	Anxiety disorder;
PAAD	cis	rs72960926	1.000	rs16884733	chr6:75064563	A/G	cg13435101	chr6:74171350	MTO1	0.85	4.5	0.34	1.35e-5	Metabolite levels (MHPG);
PAAD	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-5.19	-0.39	6.68e-7	Blood pressure (smoking interaction);
PAAD	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.65	5.26	0.39	4.78e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg19630374	chr17:18023558	MYO15A	-0.45	-4.72	-0.36	5.4e-6	Total body bone mineral density;
PAAD	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg00717180	chr2:96193071	NA	0.58	6.55	0.47	8.6e-10	HDL cholesterol;
PAAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.56	5.69	0.42	6.49e-8	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.43	0.4	2.18e-7	Breast cancer;
PAAD	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.53	4.77	0.36	4.37e-6	Barrett's esophagus;
PAAD	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.74e-7	Motion sickness;
PAAD	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.99	13.52	0.74	7.64e-28	Menopause (age at onset);
PAAD	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-5.51	-0.41	1.51e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.74	-0.42	5.02e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs988913	0.957	rs9296771	chr6:54782274	T/A	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.52	-6.7	-0.48	3.77e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15145965	chr22:50218605	BRD1	0.63	5.41	0.4	2.35e-7	Schizophrenia;
PAAD	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.8	-0.43	3.78e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11563648	0.553	rs6467123	chr7:127015459	A/G	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.39	-4.33	-0.33	2.67e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	5.88	0.43	2.5e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg02569823	chr6:5851330	NA	0.63	6.65	0.47	4.84e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.41	5.56	0.41	1.2e-7	Primary biliary cholangitis;
PAAD	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.22	-0.45	4.61e-9	Neuroticism;
PAAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.36	-0.33	2.34e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12043807	chr9:99180432	ZNF367	0.74	6.75	0.48	2.96e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg21269045	chr12:125625041	AACS	-0.5	-4.79	-0.36	3.93e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.66	-4.6	-0.35	8.69e-6	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23092527	chr1:8703002	RERE	-0.7	-7.4	-0.51	8.56e-12	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	7.87	0.54	6.1e-13	Menopause (age at onset);
PAAD	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.63	-6.57	-0.47	7.52e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs2421770	0.827	rs2421823	chr11:35264055	C/T	cg13971030	chr11:35366721	SLC1A2	0.45	5.36	0.4	3.07e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.42	-4.99	-0.38	1.65e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg08200582	chr11:442649	ANO9	0.5	4.31	0.33	2.96e-5	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.54	6.01	0.44	1.33e-8	Heart rate;
PAAD	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg08501292	chr6:25962987	TRIM38	0.76	4.71	0.36	5.53e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-1.01	-5.79	-0.43	3.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs501120	0.543	rs800331	chr10:44806378	C/T	cg09554077	chr10:44749378	NA	0.39	4.91	0.37	2.36e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.89	12.56	0.71	2.95e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.7e-5	Systolic blood pressure;
PAAD	cis	rs12311304	1.000	rs1479407	chr12:15391524	G/T	cg08258403	chr12:15378311	NA	0.36	4.43	0.34	1.82e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.61	6.15	0.45	6.59e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.41	-0.34	1.98e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2229238	0.911	rs60368585	chr1:154509340	T/C	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.81	-7.01	-0.49	7.26e-11	Obesity-related traits;
PAAD	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.47	5.21	0.39	6.16e-7	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22865720	chr1:1981816	PRKCZ	0.6	6.43	0.46	1.57e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg13175981	chr1:150552382	MCL1	0.77	7.63	0.53	2.37e-12	Tonsillectomy;
PAAD	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg23283495	chr1:209979779	IRF6	0.66	5.72	0.42	5.48e-8	Coronary artery disease;
PAAD	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs375066	0.935	rs398964	chr19:44413884	G/A	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs73416724	1.000	rs74690967	chr6:43370915	C/T	cg26312998	chr6:43337775	ZNF318	0.69	5.72	0.42	5.39e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.46e-7	Morning vs. evening chronotype;
PAAD	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg17842918	chr13:113540400	ATP11A	-0.42	-4.71	-0.36	5.6e-6	Interstitial lung disease;
PAAD	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.64	-6.34	-0.46	2.47e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.7	9.99	0.63	2.16e-18	Primary biliary cholangitis;
PAAD	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.45	-4.82	-0.36	3.4e-6	Educational attainment;
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.86	-0.43	2.76e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg13903179	chr13:21900392	NA	0.63	7.04	0.5	6.04e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-6.99	-0.49	8.31e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs11809230	0.541	rs72938954	chr1:70144056	T/C	cg01791338	chr1:70606906	NA	0.77	4.87	0.37	2.78e-6	Cannabis use (initiation);
PAAD	cis	rs7072216	0.687	rs11189590	chr10:100154605	T/G	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.53	5.54	0.41	1.32e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg11271282	chr2:238384023	NA	0.59	4.59	0.35	9.37e-6	Prostate cancer;
PAAD	cis	rs116175783	0.557	rs1146025	chr2:162139812	G/A	cg08807892	chr2:162101083	NA	-0.68	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg16950941	chr11:66035639	RAB1B	0.69	5.92	0.43	2.03e-8	Gout;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg23708337	chr7:1209742	NA	0.39	4.29	0.33	3.11e-5	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.55	5.49	0.41	1.63e-7	Lung cancer;
PAAD	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg10006428	chr1:248814059	OR2T27	0.36	4.31	0.33	2.98e-5	Common traits (Other);
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4809627	1	rs4809627	chr20:45757655	C/T	cg27589058	chr20:45804311	EYA2	-0.41	-4.45	-0.34	1.63e-5	Type 2 diabetes;
PAAD	cis	rs1270639	0.732	rs1263558	chr7:157463080	C/T	cg13357408	chr7:157437802	PTPRN2	-0.98	-8.24	-0.56	7.22e-14	Colorectal cancer;
PAAD	cis	rs16975963	0.644	rs73033129	chr19:38080535	G/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs73416724	0.925	rs112053368	chr6:43382960	C/A	cg17076780	chr6:43251928	TTBK1	0.56	4.47	0.34	1.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.56	6.05	0.44	1.06e-8	Major depressive disorder;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.45	-6.81	-0.48	2.13e-10	Subjective well-being;
PAAD	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg13057898	chr1:3703894	LRRC47	0.4	4.25	0.33	3.69e-5	Red cell distribution width;
PAAD	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.46	4.28	0.33	3.28e-5	Endometrial cancer;
PAAD	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02556042	chr12:117471086	NA	0.45	4.62	0.35	8.2e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	0.87	9.22	0.6	2.26e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs375066	0.935	rs10406290	chr19:44378877	G/T	cg11993925	chr19:44307056	LYPD5	0.52	6.66	0.48	4.8e-10	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25642212	chr19:12848324	ASNA1	-0.74	-7.11	-0.5	4.3e-11	Neuroticism;
PAAD	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg22916017	chr11:64110731	CCDC88B	0.4	4.7	0.36	5.74e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.1	9.58	0.61	2.72e-17	Uric acid levels;
PAAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg03909863	chr11:638404	DRD4	-0.69	-5.58	-0.41	1.07e-7	Systemic lupus erythematosus;
PAAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg19257562	chr1:2043853	PRKCZ	-0.38	-4.41	-0.34	1.96e-5	Height;
PAAD	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs11105468	0.659	rs10858960	chr12:90523703	A/G	cg16962463	chr12:89968675	NA	-0.42	-4.4	-0.34	2.01e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.07	-0.44	9.98e-9	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03577460	chr14:24836084	NFATC4	-0.63	-6.78	-0.48	2.48e-10	Myopia (pathological);
PAAD	cis	rs11807834	0.522	rs4412597	chr1:230242755	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.44	-0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.57	6.44	0.46	1.49e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs73416724	0.688	rs77915916	chr6:43287722	A/T	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.75e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.01	14.16	0.75	1.44e-29	Heart rate;
PAAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.39	-0.4	2.62e-7	Personality dimensions;
PAAD	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.67	7.34	0.51	1.19e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10479542	0.671	rs13185115	chr5:178967126	A/G	cg26516362	chr5:178986906	RUFY1	0.42	4.62	0.35	8.19e-6	Lung cancer;
PAAD	cis	rs6750047	0.526	rs464603	chr2:38318131	G/C	cg19753864	chr2:38320028	NA	0.44	4.94	0.37	2.02e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.32	-6.0	-0.44	1.41e-8	Type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22288637	chr7:92464428	CDK6	0.71	6.29	0.45	3.23e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg08992911	chr2:238395768	MLPH	0.61	5.77	0.42	4.28e-8	Prostate cancer;
PAAD	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.47	4.29	0.33	3.13e-5	Tuberculosis;
PAAD	cis	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg08112188	chr17:47440006	ZNF652	1.29	6.48	0.47	1.2e-9	Prostate cancer;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs89107	0.688	rs283085	chr6:118603267	C/A	cg21191810	chr6:118973309	C6orf204	0.42	5.73	0.42	5.29e-8	Cardiac structure and function;
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg10864074	chr7:100318194	EPO	0.43	4.98	0.37	1.74e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs16933812	0.510	rs4880049	chr9:36989333	C/T	cg13738729	chr9:36989127	PAX5	-0.57	-8.19	-0.55	1e-13	Obesity-related traits;
PAAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	4.67	0.35	6.61e-6	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	cis	rs6540556	0.608	rs12129718	chr1:209912540	C/T	cg23920097	chr1:209922102	NA	-0.44	-4.25	-0.33	3.71e-5	Red blood cell count;
PAAD	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs883565	0.740	rs10510698	chr3:39107993	A/C	cg01426195	chr3:39028469	NA	-0.71	-8.18	-0.55	1.05e-13	Handedness;
PAAD	cis	rs708547	0.541	rs6554392	chr4:57739948	G/A	cg00922110	chr4:57842668	C4orf14	0.43	4.7	0.36	5.7e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06217245	chr20:33103252	DYNLRB1	0.4	4.88	0.37	2.7e-6	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08039050	chr6:11094291	LOC221710	0.6	6.69	0.48	4.04e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00075589	chr2:219524515	ZNF142;BCS1L	0.65	6.83	0.48	1.9e-10	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg05250797	chr16:70222502	NA	-0.6	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.01e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs9880406	0.641	rs72493123	chr3:126035132	T/C	cg13708016	chr3:126007563	NA	-0.54	-5.57	-0.41	1.15e-7	Macular telangiectasia type 2;
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10706454	chr1:27286944	C1orf172	-0.76	-6.67	-0.48	4.54e-10	Neuroticism;
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg07527105	chr16:88053339	BANP	-0.46	-4.61	-0.35	8.33e-6	Menopause (age at onset);
PAAD	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg16558253	chr16:72132732	DHX38	-0.56	-5.12	-0.38	9.26e-7	Coronary artery disease;
PAAD	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg23024343	chr7:107201750	COG5	0.55	4.55	0.35	1.1e-5	Osteoarthritis;
PAAD	cis	rs1075265	0.783	rs718872	chr2:54173706	T/A	cg04546899	chr2:54196757	PSME4	0.33	4.96	0.37	1.83e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.75	8.35	0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.41	-4.71	-0.36	5.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.62	7.15	0.5	3.44e-11	Aortic root size;
PAAD	cis	rs11615916	0.790	rs11614866	chr12:62667078	C/T	cg11441379	chr12:63026424	NA	0.69	4.52	0.34	1.25e-5	Pulmonary function decline;
PAAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	11.01	0.67	4.24e-21	Monocyte count;
PAAD	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg05627522	chr15:75251581	NA	-0.39	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.51	-6.54	-0.47	8.72e-10	Menopause (age at onset);
PAAD	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.46	5.11	0.38	9.73e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7853377	0.723	rs2780103	chr9:86574568	C/T	cg03531853	chr9:86535572	KIF27	0.42	4.37	0.33	2.32e-5	Height;
PAAD	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.44e-5	Height;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02725872	chr8:58115012	NA	-0.8	-6.41	-0.46	1.75e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.64	-5.12	-0.38	9.07e-7	Schizophrenia;
PAAD	cis	rs1075265	0.756	rs805367	chr2:54171093	G/T	cg04546899	chr2:54196757	PSME4	0.33	4.96	0.37	1.83e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16285380	chr3:126373980	NA	-0.65	-6.71	-0.48	3.66e-10	Smoking initiation;
PAAD	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.37	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7539409	0.831	rs10874417	chr1:84220731	C/T	cg10977910	chr1:84465055	TTLL7	-0.89	-6.13	-0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.65	-6.85	-0.49	1.7e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.88	-0.49	1.47e-10	Lung cancer;
PAAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg19744528	chr7:157553346	PTPRN2	0.39	4.25	0.33	3.78e-5	Body mass index;
PAAD	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg27411982	chr8:10470053	RP1L1	0.47	4.91	0.37	2.35e-6	Retinal vascular caliber;
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10214930	0.651	rs42085	chr7:27697939	C/A	cg22168087	chr7:27702803	HIBADH	-0.48	-4.57	-0.35	1.02e-5	Hypospadias;
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg07648498	chr16:89883185	FANCA	0.7	7.34	0.51	1.23e-11	Vitiligo;
PAAD	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg01701555	chr1:146544097	NA	0.39	4.36	0.33	2.38e-5	HIV-1 control;
PAAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.78	0.36	4.18e-6	Selective IgA deficiency;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.75	-6.61	-0.47	6.22e-10	Alzheimer's disease;
PAAD	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg27511599	chr7:32358540	NA	-0.73	-4.48	-0.34	1.45e-5	Body mass index;
PAAD	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.64	7.06	0.5	5.47e-11	Smoking initiation;
PAAD	cis	rs427943	0.778	rs28782181	chr21:46588817	G/A	cg06618935	chr21:46677482	NA	0.37	4.29	0.33	3.18e-5	Body mass index;
PAAD	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-8.77	-0.58	3.34e-15	Lung function (FVC);
PAAD	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.51	-4.45	-0.34	1.62e-5	Airflow obstruction;
PAAD	cis	rs2289328	0.825	rs35777573	chr15:40644246	T/A	cg13931752	chr15:40660718	DISP2	0.57	5.12	0.38	9.11e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.37	-4.51	-0.34	1.27e-5	Prostate cancer;
PAAD	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.57	0.41	1.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26549601	chr10:134560360	INPP5A	-0.44	-4.4	-0.34	2.06e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg03340356	chr1:67600835	NA	0.52	6.45	0.46	1.4e-9	Psoriasis;
PAAD	cis	rs4294134	0.545	rs11534080	chr7:135247528	C/T	cg04619859	chr7:134855396	C7orf49	0.56	4.37	0.33	2.33e-5	Paget's disease;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.45	0.4	1.95e-7	Life satisfaction;
PAAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.58	6.55	0.47	8.52e-10	Aortic root size;
PAAD	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.98	-0.59	9.92e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	cis	rs787274	1.000	rs7859381	chr9:115546649	C/T	cg13803584	chr9:115635662	SNX30	-0.98	-6.48	-0.47	1.2e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7301016	0.948	rs7303825	chr12:62921978	A/G	cg19781863	chr12:62918364	MON2	0.74	4.37	0.33	2.28e-5	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20290850	chr1:182070049	NA	0.61	7.3	0.51	1.53e-11	Smoking initiation;
PAAD	cis	rs939584	1.000	rs7608050	chr2:652247	G/A	cg03610516	chr2:642275	NA	-0.62	-5.77	-0.42	4.31e-8	Body mass index;
PAAD	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg21859623	chr20:33103246	DYNLRB1	0.45	4.26	0.33	3.62e-5	Height;
PAAD	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	10.72	0.66	2.55e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9646944	0.501	rs2075186	chr2:103057251	G/T	cg03938978	chr2:103052716	IL18RAP	0.5	4.28	0.33	3.28e-5	Blood protein levels;
PAAD	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.72	8.28	0.56	5.82e-14	Lung cancer;
PAAD	cis	rs7668190	1.000	rs7668190	chr4:55096270	A/T	cg17187183	chr4:55093834	PDGFRA	0.44	4.28	0.33	3.29e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6681460	0.966	rs7519747	chr1:67140723	T/C	cg02459107	chr1:67143332	SGIP1	0.78	7.68	0.53	1.82e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-5.72	-0.42	5.48e-8	Daytime sleep phenotypes;
PAAD	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg08732750	chr1:87598351	LOC339524	0.34	4.71	0.36	5.43e-6	Smoking behavior;
PAAD	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	8.2	0.55	9.48e-14	Coronary artery disease;
PAAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.52	-4.71	-0.36	5.66e-6	Schizophrenia;
PAAD	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.66	0.42	7.21e-8	Platelet count;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.61	-6.1	-0.44	8.51e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4450131	0.522	rs34209544	chr10:126350452	G/C	cg20435097	chr10:126320824	FAM53B	0.49	4.87	0.37	2.83e-6	White blood cell count (basophil);
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.87e-10	Lymphocyte counts;
PAAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg24253500	chr15:84953950	NA	0.44	4.59	0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.77	-7.58	-0.52	3.18e-12	Mosquito bite size;
PAAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg18016565	chr1:150552671	MCL1	-0.45	-4.44	-0.34	1.75e-5	Tonsillectomy;
PAAD	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.92	-9.87	-0.62	4.59e-18	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4845552	0.767	rs4272569	chr1:153493800	C/T	cg15998505	chr1:153479701	NA	-0.53	-4.5	-0.34	1.34e-5	Hippocampal atrophy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11078810	chr14:77843775	TMED8;C14orf174	-0.7	-6.4	-0.46	1.85e-9	Neuroticism;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.65	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.7	6.74	0.48	3.16e-10	Lung cancer (smoking interaction);
PAAD	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.58	6.74	0.48	3.04e-10	Height;
PAAD	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-5.63	-0.42	8.67e-8	Systemic lupus erythematosus;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.62	-0.35	8.17e-6	Longevity;Endometriosis;
PAAD	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg02841227	chr6:26021843	HIST1H4A	0.47	4.36	0.33	2.37e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.43	0.34	1.77e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.42	4.91	0.37	2.33e-6	Schizophrenia;
PAAD	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs6782025	1.000	rs7650658	chr3:121131376	C/T	cg16417163	chr3:121280760	NA	-0.47	-4.85	-0.37	3.03e-6	Aging (facial);
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg05082376	chr22:42548792	NA	-0.53	-5.76	-0.42	4.52e-8	Cognitive function;
PAAD	cis	rs990171	0.538	rs6741235	chr2:103117283	G/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.78	0.42	4.05e-8	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-7.54	-0.52	3.88e-12	Colorectal cancer;
PAAD	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg09455208	chr3:40491958	NA	0.46	5.97	0.44	1.58e-8	Renal cell carcinoma;
PAAD	cis	rs818427	0.826	rs439456	chr5:112205207	G/C	cg06941702	chr5:112196734	SRP19	-0.51	-4.76	-0.36	4.53e-6	Total body bone mineral density;
PAAD	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-1.09	-8.96	-0.59	1.1e-15	Blood trace element (Zn levels);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07580010	chr3:43664647	ANO10	-0.6	-7.08	-0.5	4.89e-11	Monocyte percentage of white cells;
PAAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg02734326	chr4:10020555	SLC2A9	-0.52	-4.88	-0.37	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.77	-9.06	-0.59	6.15e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.55	6.04	0.44	1.16e-8	Rheumatoid arthritis;
PAAD	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg03733263	chr8:22462867	KIAA1967	-0.8	-9.27	-0.6	1.69e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6669119	0.818	rs77775246	chr1:19099417	G/A	cg19637330	chr1:19110922	NA	0.84	5.02	0.38	1.43e-6	Percentage gas trapping;
PAAD	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15682851	chr17:44076429	STH;MAPT	-0.65	-6.82	-0.48	1.99e-10	Obesity-related traits;
PAAD	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Depression;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07685180	chr8:600429	NA	1.01	6.28	0.45	3.39e-9	IgG glycosylation;
PAAD	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.02e-11	Corneal astigmatism;
PAAD	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg02820901	chr13:113351484	ATP11A	0.72	4.69	0.36	5.94e-6	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.86	9.61	0.61	2.28e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg05511921	chr12:26999954	NA	-0.64	-6.67	-0.48	4.51e-10	Alcohol dependence;
PAAD	cis	rs282587	0.569	rs9604421	chr13:113410493	C/G	cg02820901	chr13:113351484	ATP11A	-0.64	-4.82	-0.36	3.44e-6	Glycated hemoglobin levels;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.49	5.18	0.39	7.03e-7	Longevity;Endometriosis;
PAAD	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg02462569	chr6:150064036	NUP43	-0.43	-4.62	-0.35	8.22e-6	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.94	11.23	0.67	1.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-5.21	-0.39	6e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.39	-0.4	2.62e-7	Personality dimensions;
PAAD	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg14181355	chr19:12984996	MAST1	-0.45	-4.45	-0.34	1.66e-5	Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.61	-0.41	9.31e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.69	6.84	0.48	1.84e-10	Asperger disorder;
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.75	-0.42	4.73e-8	Tonsillectomy;
PAAD	cis	rs16958440	0.867	rs75808931	chr18:44693042	C/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	1.03	13.56	0.74	6.01e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.76	7.81	0.54	8.8e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg26570165	chr1:119541833	NA	-0.47	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg00206168	chr11:65308501	LTBP3	0.51	5.33	0.4	3.54e-7	Bone mineral density;
PAAD	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg01851573	chr8:8652454	MFHAS1	0.56	4.91	0.37	2.37e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2e-27	Height;
PAAD	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.52	-0.41	1.44e-7	Atrioventricular conduction;
PAAD	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg16691251	chr5:66510806	NA	0.73	7.8	0.53	9.08e-13	Breast cancer;
PAAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg11608241	chr8:8085544	FLJ10661	0.47	4.44	0.34	1.7e-5	Neuroticism;
PAAD	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs58521262	0.585	rs457149	chr19:23130113	A/C	cg02350677	chr19:23254381	NA	-0.26	-4.62	-0.35	8e-6	Testicular germ cell tumor;
PAAD	cis	rs10887741	0.624	rs6586092	chr10:89428994	A/T	cg13926569	chr10:89418898	PAPSS2	0.49	4.96	0.37	1.9e-6	Exercise (leisure time);
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02475777	chr4:1388615	CRIPAK	-0.52	-5.0	-0.38	1.56e-6	Obesity-related traits;
PAAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.66	7.15	0.5	3.5e-11	Melanoma;
PAAD	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.53	-5.35	-0.4	3.17e-7	Temperament;
PAAD	cis	rs7172677	1.000	rs7172205	chr15:75424335	A/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.65	-0.35	7.01e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.57	-6.42	-0.46	1.68e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.77	-7.08	-0.5	4.93e-11	Height;
PAAD	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg01422370	chr2:73384389	NA	0.37	4.99	0.38	1.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg00400743	chr4:148603008	PRMT10	-0.71	-4.46	-0.34	1.61e-5	Pulse pressure;
PAAD	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	2.02e-11	Dupuytren's disease;
PAAD	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg25828445	chr12:7781288	NA	-0.75	-5.29	-0.39	4.23e-7	HDL cholesterol levels;
PAAD	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-4.51	-0.34	1.3e-5	Diastolic blood pressure;
PAAD	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.73	7.11	0.5	4.25e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.57	7.3	0.51	1.49e-11	Asthma (sex interaction);
PAAD	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.87	-8.3	-0.56	5.28e-14	Breast cancer;
PAAD	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.57	6.01	0.44	1.34e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs17655565	0.581	rs73094908	chr12:52767984	C/T	cg22980804	chr12:52818037	KRT75	-0.49	-4.35	-0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	8.08e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13323323	0.652	rs9825080	chr3:44251270	C/T	cg25364880	chr3:44379878	C3orf23	0.75	6.15	0.45	6.41e-9	IgG glycosylation;
PAAD	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.79	9.23	0.6	2.23e-16	Hemoglobin concentration;
PAAD	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg01489256	chr8:11204017	TDH	0.43	4.29	0.33	3.19e-5	Retinal vascular caliber;
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg10621924	chr7:39171070	POU6F2	-0.25	-4.35	-0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg26695010	chr11:65641043	EFEMP2	0.59	5.21	0.39	6.02e-7	DNA methylation (variation);
PAAD	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.78	-0.42	4.02e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.58	6.84	0.49	1.79e-10	Aortic root size;
PAAD	cis	rs12760731	0.641	rs11588490	chr1:178328139	T/A	cg00404053	chr1:178313656	RASAL2	0.71	5.27	0.39	4.54e-7	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16470957	chr3:50388565	TUSC4;CYB561D2	0.61	6.79	0.48	2.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.57	6.79	0.48	2.38e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.42	-5.12	-0.38	9.01e-7	Body mass index in non-asthmatics;
PAAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7572733	0.755	rs6716898	chr2:198944271	G/A	cg10820045	chr2:198174542	NA	0.43	4.29	0.33	3.18e-5	Dermatomyositis;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg10621924	chr7:39171070	POU6F2	0.37	5.74	0.42	4.95e-8	IgG glycosylation;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg03400443	chr2:74347616	NA	-0.5	-4.25	-0.33	3.72e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs12311304	0.965	rs767201	chr12:15370878	A/G	cg08258403	chr12:15378311	NA	-0.37	-4.65	-0.35	7.28e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.66	-4.58	-0.35	9.49e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.68	6.4	0.46	1.83e-9	Corneal astigmatism;
PAAD	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-7.9	-0.54	5.25e-13	Colorectal cancer;
PAAD	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.52	-4.84	-0.37	3.12e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.17	9.01	0.59	7.94e-16	Mitochondrial DNA levels;
PAAD	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.79	12.41	0.71	7.2e-25	Breast cancer;
PAAD	cis	rs2130392	0.886	rs6845294	chr4:185653826	G/A	cg21366198	chr4:185655624	MLF1IP	0.54	4.57	0.35	9.9e-6	Kawasaki disease;
PAAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.13	0.38	8.86e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35955747	0.902	rs12167361	chr22:31696278	G/C	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6076065	0.723	rs6137908	chr20:23344590	G/A	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	7.79e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.78	0.48	2.53e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.62	0.35	8.05e-6	Homocysteine levels;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11970133	chr7:45144099	TBRG4;SNORA5A	-0.64	-6.43	-0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.54	-6.39	-0.46	1.91e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.58	6.32	0.46	2.78e-9	Tonsillectomy;
PAAD	cis	rs722864	0.742	rs4972529	chr2:173952115	T/C	cg02927202	chr2:174821978	SP3	-0.45	-4.3	-0.33	3.01e-5	Lung cancer;
PAAD	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.04	-0.44	1.13e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.82	9.16	0.6	3.37e-16	Colorectal cancer;
PAAD	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg08999081	chr20:33150536	PIGU	-0.53	-5.77	-0.42	4.36e-8	Height;
PAAD	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05244029	chr16:67876213	CENPT;THAP11	-0.64	-6.29	-0.45	3.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.36	5.59	0.41	1.03e-7	IgG glycosylation;
PAAD	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.51	4.74	0.36	4.9e-6	Self-reported allergy;
PAAD	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.52	4.81	0.36	3.63e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-5.38	-0.4	2.82e-7	Monocyte count;
PAAD	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.79	-8.96	-0.59	1.09e-15	Caffeine consumption;
PAAD	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.86	6.64	0.47	5.2400000000000005e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.59	6.32	0.46	2.8e-9	Testicular germ cell tumor;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25043643	chr14:102609274	WDR20	-0.71	-6.62	-0.47	5.92e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.37e-8	Life satisfaction;
PAAD	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-1.0	-6.37	-0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.56	-5.91	-0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.78	5.28	0.39	4.34e-7	Mitochondrial DNA levels;
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg19223190	chr17:80058835	NA	0.52	5.45	0.4	1.96e-7	Life satisfaction;
PAAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24466479	chr2:17935221	SMC6;GEN1	-0.63	-6.4	-0.46	1.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11021810	chr14:89720620	FOXN3	-0.65	-6.45	-0.46	1.42e-9	Primary biliary cholangitis;
PAAD	cis	rs9463078	0.547	rs9472360	chr6:44747410	T/C	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18621852	chr3:10150065	C3orf24	0.61	5.4	0.4	2.55e-7	Alzheimer's disease;
PAAD	cis	rs89107	0.688	rs372237	chr6:118608979	G/T	cg21191810	chr6:118973309	C6orf204	0.46	6.3	0.46	3.04e-9	Cardiac structure and function;
PAAD	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg11441379	chr12:63026424	NA	0.88	6.41	0.46	1.78e-9	IgG glycosylation;
PAAD	cis	rs12754538	0.813	rs11121175	chr1:8435046	C/A	cg06159269	chr1:8767347	RERE	0.41	5.02	0.38	1.46e-6	Subjective well-being;
PAAD	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.1	14.49	0.76	1.99e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-6.54	-0.47	8.63e-10	Lymphocyte counts;
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.56	-0.41	1.2e-7	Prostate cancer;
PAAD	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	5.61	0.41	9.28e-8	Neuroticism;
PAAD	cis	rs6494488	0.500	rs72742972	chr15:64934117	C/T	cg16425858	chr15:64791681	ZNF609	0.93	4.53	0.35	1.18e-5	Coronary artery disease;
PAAD	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg08758996	chr17:66097529	LOC651250	-0.53	-4.49	-0.34	1.42e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23780683	chr11:65122410	TIGD3	0.6	6.59	0.47	6.74e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.73	7.04	0.5	6.19e-11	Monocyte count;
PAAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13236679	chr6:37467396	C6orf129	0.58	6.49	0.47	1.16e-9	Metabolite levels  (X-11787);
PAAD	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-7.54	-0.52	3.98e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	10.75	0.66	2.14e-20	Menopause (age at onset);
PAAD	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg10636054	chr15:40330586	SRP14	1.36	7.97	0.54	3.53e-13	Corneal curvature;
PAAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	8.57	0.57	1.07e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg22587600	chr2:46883368	NA	0.34	4.58	0.35	9.75e-6	Height;
PAAD	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg03678062	chr6:149772716	ZC3H12D	0.31	4.29	0.33	3.2e-5	Dupuytren's disease;
PAAD	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.88	4.75	0.36	4.71e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg10621924	chr7:39171070	POU6F2	0.37	5.7	0.42	6.11e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.78	-10.14	-0.64	8.85e-19	Vitiligo;
PAAD	cis	rs2718812	0.792	rs1867504	chr3:133410661	C/T	cg08048268	chr3:133502702	NA	-0.48	-5.93	-0.43	1.95e-8	Iron status biomarkers;
PAAD	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.71	-7.34	-0.51	1.18e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.5	5.73	0.42	5.14e-8	Major depressive disorder;
PAAD	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.31	-0.4	3.76e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.49	-4.63	-0.35	7.89e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6597981	0.592	rs28625355	chr11:736334	G/T	cg01741372	chr11:783889	NA	0.68	8.19	0.55	1.01e-13	Breast cancer;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08677398	chr8:58056175	NA	0.65	4.4	0.34	2.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05049329	chr1:226924846	ITPKB	0.54	7.24	0.51	2.05e-11	Parkinson's disease;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.83	0.48	1.88e-10	Eosinophil percentage of white cells;
PAAD	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg08975724	chr8:8085496	FLJ10661	0.76	7.47	0.52	5.88e-12	Systolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07520687	chr5:32461615	NA	-0.61	-6.36	-0.46	2.21e-9	Obesity-related traits;
PAAD	cis	rs6782025	0.837	rs59778278	chr3:120809596	C/A	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs3206736	0.548	rs7779894	chr7:35061509	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.6	-0.35	8.84e-6	Diastolic blood pressure;
PAAD	cis	rs2137920	0.685	rs12764806	chr10:50243391	G/T	cg02657375	chr10:50863136	CHAT	0.57	4.6	0.35	8.84e-6	Migraine with aura;
PAAD	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs57709857	0.957	rs60558877	chr8:38240498	G/A	cg16625770	chr8:38300134	FGFR1	-0.46	-4.3	-0.33	3.06e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs11264799	0.773	rs17676303	chr1:157679691	C/T	cg18268488	chr1:157545234	FCRL4	0.58	5.2	0.39	6.4e-7	IgA nephropathy;
PAAD	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.69	7.14	0.5	3.65e-11	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.45	-4.55	-0.35	1.08e-5	Calcium levels;
PAAD	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.62	5.08	0.38	1.1e-6	Alzheimer's disease (late onset);
PAAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.35	0.4	3.12e-7	Rheumatoid arthritis;
PAAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	1.02	6.33	0.46	2.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg05313129	chr8:58192883	C8orf71	-0.67	-6.08	-0.44	9.49e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.56	-5.24	-0.39	5.17e-7	Resting heart rate;
PAAD	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.58	-0.35	9.59e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs76917914	0.820	rs7869762	chr9:100814573	G/T	cg03040243	chr9:100819229	NANS	0.58	4.69	0.36	5.97e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.49	5.43	0.4	2.19e-7	Longevity;Endometriosis;
PAAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs3733346	0.589	rs2290404	chr4:945225	A/G	cg08222618	chr4:941054	TMEM175	0.68	8.75	0.58	3.69e-15	Sjögren's syndrome;
PAAD	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-4.94	-0.37	2.01e-6	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.89	-9.73	-0.62	1.05e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg13919466	chr1:32135498	COL16A1	-0.43	-4.9	-0.37	2.39e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg04844267	chr4:1394941	NA	0.44	4.97	0.37	1.75e-6	Longevity;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg15192750	chr16:69999425	NA	0.73	5.65	0.42	7.71e-8	IgE levels;
PAAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg18944383	chr4:111397179	ENPEP	0.73	8.11	0.55	1.54e-13	Coronary artery disease;
PAAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.59	7.58	0.52	3.14e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.66	-0.57	6.49e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg10541313	chr22:46663664	TTC38	0.9	4.41	0.34	1.91e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7829975	0.627	rs2979172	chr8:8310508	G/C	cg06636001	chr8:8085503	FLJ10661	0.69	7.12	0.5	4.1e-11	Mood instability;
PAAD	cis	rs4455778	0.580	rs4917032	chr7:49111505	T/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11172134	0.508	rs1800187	chr12:57587839	C/T	cg01515074	chr12:57585135	LRP1	-0.47	-4.51	-0.34	1.27e-5	Urate levels in overweight individuals;
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	11.44	0.68	3.02e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg25319279	chr11:5960081	NA	-0.59	-5.69	-0.42	6.4e-8	DNA methylation (variation);
PAAD	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.99	8.29	0.56	5.53e-14	Inflammatory bowel disease;
PAAD	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.77	7.56	0.52	3.6e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23972409	chr3:160282398	KPNA4	-0.69	-6.49	-0.47	1.12e-9	Neuroticism;
PAAD	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.15	0.39	8e-7	HIV-1 control;
PAAD	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.75	0.36	4.59e-6	Blood metabolite levels;
PAAD	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs58521262	0.556	rs289329	chr19:23155167	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.75	8.04	0.55	2.4e-13	Blood protein levels;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.5	5.05	0.38	1.25e-6	Height;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10819733	chr22:24237672	NA	-0.57	-6.21	-0.45	4.9e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.71	0.42	5.73e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08238777	chr8:30585635	GSR	-0.75	-6.45	-0.46	1.42e-9	Neuroticism;
PAAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg17987982	chr7:158820591	NA	-0.33	-4.25	-0.33	3.68e-5	Facial morphology (factor 20);
PAAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg09796270	chr17:17721594	SREBF1	-0.49	-5.45	-0.4	2.03e-7	Total body bone mineral density;
PAAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.75	-0.42	4.74e-8	Diabetic kidney disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10805667	chr11:71814220	LRTOMT;C11orf59	0.68	7.92	0.54	4.74e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.64	7.47	0.52	5.77e-12	Weight;
PAAD	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	4.64	0.35	7.46e-6	Vitiligo;
PAAD	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.7	-0.42	5.94e-8	Primary biliary cholangitis;
PAAD	cis	rs11807834	0.522	rs10864691	chr1:230240450	T/A	cg09847368	chr1:230250326	GALNT2	-0.67	-8.24	-0.56	7.35e-14	Schizophrenia;
PAAD	cis	rs2117029	0.553	rs11168909	chr12:49576875	G/A	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg20813462	chr7:2646259	IQCE	0.65	4.65	0.35	7.02e-6	Urate levels in lean individuals;
PAAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg06740227	chr12:86229804	RASSF9	0.48	4.67	0.35	6.66e-6	Major depressive disorder;
PAAD	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg25664220	chr3:72788482	NA	0.68	6.85	0.49	1.71e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17123764	0.892	rs12317778	chr12:50105637	T/C	cg14846292	chr12:49726500	C1QL4	-0.75	-4.38	-0.33	2.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.79	-7.73	-0.53	1.36e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg07617317	chr6:118971624	C6orf204	0.54	4.56	0.35	1.04e-5	Diastolic blood pressure;
PAAD	cis	rs28493229	0.708	rs10407431	chr19:41160870	T/C	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	cis	rs4743820	0.651	rs10739912	chr9:93929115	A/G	cg14446406	chr9:93919335	NA	-0.53	-6.4	-0.46	1.8e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg18898632	chr2:242989856	NA	-0.76	-5.89	-0.43	2.37e-8	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.46	0.57	2.09e-14	Alzheimer's disease;
PAAD	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.68	6.43	0.46	1.56e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-4.74	-0.36	4.79e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7714584	0.826	rs34005003	chr5:150225199	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.4	-0.4	2.54e-7	Fear of minor pain;
PAAD	cis	rs7547997	0.654	rs10158210	chr1:158311985	A/G	cg26014409	chr1:158324471	CD1E	0.38	4.72	0.36	5.28e-6	QRS duration;
PAAD	cis	rs7853377	0.800	rs296890	chr9:86595731	C/A	cg03531853	chr9:86535572	KIF27	0.44	4.62	0.35	8.09e-6	Height;
PAAD	cis	rs1371614	0.632	rs920437	chr2:27157396	G/A	cg00617064	chr2:27272375	NA	0.43	4.55	0.35	1.11e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.39	-4.89	-0.37	2.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9810890	1.000	rs73196971	chr3:128443606	G/C	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.97	8.41	0.56	2.71e-14	Triglycerides;
PAAD	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.8	9.26	0.6	1.88e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10121009	0.587	rs2281999	chr9:35381504	C/T	cg11846315	chr9:35647073	NA	-0.52	-4.68	-0.35	6.43e-6	Parkinson's disease;
PAAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.48	0.41	1.7e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs10500871	1.000	rs1829577	chr11:20225769	A/G	cg02956962	chr6:161097311	NA	0.62	6.3	0.46	3.02e-9	Educational attainment;
PAAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.78	8.53	0.57	1.35e-14	Aortic root size;
PAAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg03289416	chr15:75166202	SCAMP2	0.53	5.8	0.43	3.66e-8	Breast cancer;
PAAD	cis	rs17095355	0.818	rs12261598	chr10:111872175	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.73	-0.36	5.04e-6	Biliary atresia;
PAAD	cis	rs2649	0.518	rs4984250	chr15:63866834	A/T	cg22599514	chr15:63798201	USP3	0.59	4.97	0.37	1.82e-6	Aortic root size;
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.29e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.45	-4.57	-0.35	1e-5	Ovarian reserve;
PAAD	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.7	8.11	0.55	1.61e-13	Colorectal cancer;
PAAD	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.81	10.29	0.64	3.5e-19	Bone mineral density;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg15181151	chr6:150070149	PCMT1	0.57	6.11	0.44	7.85e-9	Lung cancer;
PAAD	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.61	-6.58	-0.47	7.08e-10	IgG glycosylation;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg00109300	chr6:143265806	HIVEP2	-0.67	-7.06	-0.5	5.53e-11	Dental caries;
PAAD	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.7	-0.8	3.19e-36	Height;
PAAD	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg21300403	chr2:198650112	BOLL	-0.48	-4.25	-0.33	3.69e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs829661	0.901	rs829663	chr2:30726536	T/A	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg19486271	chr11:47235900	DDB2	-0.59	-5.83	-0.43	3.18e-8	Acne (severe);
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.98	10.62	0.65	4.58e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg08079166	chr15:68083412	MAP2K5	0.65	5.14	0.38	8.42e-7	Restless legs syndrome;
PAAD	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.55	-4.68	-0.35	6.39e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.4	-0.34	2.01e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.25	-0.51	2.01e-11	Chronic sinus infection;
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.51	-4.67	-0.35	6.69e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11338003	chr12:54674114	HNRNPA1;HNRPA1L-2;CBX5	-0.69	-7.08	-0.5	5.11e-11	Lung cancer in ever smokers;
PAAD	cis	rs12432203	1.000	rs3935981	chr14:51730283	T/C	cg23942311	chr14:51606299	NA	-0.71	-4.88	-0.37	2.7e-6	Cancer;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.43	5.58	0.41	1.07e-7	Ulcerative colitis;
PAAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.92	-10.13	-0.63	9.76e-19	Blood metabolite levels;
PAAD	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.5	4.91	0.37	2.35e-6	Anterior chamber depth;
PAAD	cis	rs17155006	0.655	rs93619	chr7:107726833	C/T	cg05962710	chr7:107745446	LAMB4	-0.44	-5.44	-0.4	2.11e-7	Pneumococcal bacteremia;
PAAD	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg05805236	chr11:65401703	PCNXL3	-0.58	-6.17	-0.45	5.85e-9	Acne (severe);
PAAD	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.09	8.53	0.57	1.38e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg09835421	chr16:68378352	PRMT7	-1.18	-8.79	-0.58	2.95e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.28	0.56	5.76e-14	Prudent dietary pattern;
PAAD	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg03999872	chr20:62272968	STMN3	-0.73	-6.51	-0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs9972944	0.729	rs8067136	chr17:63762995	C/A	cg07283582	chr17:63770753	CCDC46	-0.56	-6.4	-0.46	1.82e-9	Total body bone mineral density;
PAAD	cis	rs9322817	0.691	rs2499658	chr6:105291412	A/G	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg10396713	chr8:602097	NA	-0.69	-4.46	-0.34	1.58e-5	IgG glycosylation;
PAAD	cis	rs6604026	0.656	rs2811593	chr1:93343891	C/T	cg17283838	chr1:93427260	FAM69A	0.61	5.75	0.42	4.82e-8	Multiple sclerosis;
PAAD	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.5	4.81	0.36	3.6e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11892454	0.544	rs7560314	chr2:26007959	G/T	cg25181710	chr2:26045287	ASXL2	0.43	5.01	0.38	1.48e-6	Heschl's gyrus morphology;
PAAD	cis	rs918959	0.793	rs16823637	chr2:181608398	A/C	cg05113709	chr2:182521874	CERKL	-0.95	-4.38	-0.33	2.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg02023728	chr11:77925099	USP35	0.51	5.18	0.39	7.09e-7	Testicular germ cell tumor;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18337363	chr3:52569053	NT5DC2	0.44	4.47	0.34	1.49e-5	Electroencephalogram traits;
PAAD	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.59	5.67	0.42	7.05e-8	Primary sclerosing cholangitis;
PAAD	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.66	-6.79	-0.48	2.31e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.3	0.46	3.04e-9	Alzheimer's disease;
PAAD	cis	rs728616	0.558	rs17616964	chr10:82137541	A/G	cg19423196	chr10:82049429	MAT1A	0.48	4.62	0.35	8.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11158559	0.865	rs1695778	chr14:65243476	C/T	cg22797773	chr14:65239943	SPTB	-0.53	-4.25	-0.33	3.67e-5	Obesity-related traits;
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg09594475	chr20:60884601	LAMA5	0.4	4.27	0.33	3.37e-5	Colorectal cancer;
PAAD	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.97	10.61	0.65	4.87e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.64	4.43	0.34	1.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22137270	chr8:140841474	TRAPPC9	-0.69	-7.13	-0.5	3.89e-11	Obesity-related traits;
PAAD	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.61	-5.74	-0.42	5.07e-8	Obesity-related traits;
PAAD	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg00990874	chr7:1149470	C7orf50	-0.55	-4.99	-0.38	1.62e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.23e-7	Ulcerative colitis;
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs755249	0.567	rs3768301	chr1:39870793	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9810890	1.000	rs77303548	chr3:128454766	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.74	9.6	0.61	2.36e-17	Asthma (childhood onset);
PAAD	cis	rs282587	0.597	rs12876520	chr13:113393566	C/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.96	-0.37	1.87e-6	Glycated hemoglobin levels;
PAAD	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg24881330	chr22:46731750	TRMU	1.15	5.07	0.38	1.16e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.54	5.03	0.38	1.37e-6	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg15128208	chr22:42549153	NA	0.52	4.52	0.34	1.23e-5	Birth weight;
PAAD	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.58	-5.32	-0.4	3.66e-7	Body mass index;
PAAD	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg00262122	chr8:11665843	FDFT1	0.52	4.87	0.37	2.76e-6	Morning vs. evening chronotype;
PAAD	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.57	-0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.53	-4.8	-0.36	3.74e-6	HDL cholesterol;
PAAD	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.71	7.6	0.52	2.77e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	1.04	8.28	0.56	5.81e-14	Vitiligo;
PAAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.89	6.19	0.45	5.47e-9	Initial pursuit acceleration;
PAAD	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg05562828	chr17:3906858	NA	0.61	6.76	0.48	2.73e-10	Type 2 diabetes;
PAAD	cis	rs7772697	0.632	rs9498215	chr6:149421083	C/T	cg21368479	chr6:149415018	NA	0.41	4.3	0.33	3.01e-5	Diabetic retinopathy;
PAAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.64	-8.61	-0.57	8.5e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs6142102	1.000	rs4911410	chr20:32710974	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.36	0.33	2.37e-5	Skin pigmentation;
PAAD	cis	rs1198430	0.683	rs7551124	chr1:23785760	C/T	cg19827787	chr1:23763612	ASAP3	0.56	4.6	0.35	8.88e-6	Total cholesterol levels;
PAAD	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.91	11.61	0.69	1.03e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	5.07	0.38	1.14e-6	Menarche (age at onset);
PAAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-9.54	-0.61	3.36e-17	Total body bone mineral density;
PAAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	8.59	0.57	9.5e-15	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07677032	chr17:61819896	STRADA	-0.56	-5.46	-0.41	1.89e-7	Prudent dietary pattern;
PAAD	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.88	10.03	0.63	1.72e-18	Adiposity;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg22040672	chr12:129299605	MGC16384;SLC15A4	0.43	4.31	0.33	2.92e-5	Systemic lupus erythematosus;
PAAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19346786	chr7:2764209	NA	-0.35	-4.7	-0.36	5.85e-6	Height;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.89	10.69	0.66	3.05e-20	Menarche (age at onset);
PAAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.11	-0.38	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.9e-10	Bladder cancer;
PAAD	cis	rs7243821	0.921	rs57801853	chr18:52632017	A/T	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.75	6.82	0.48	1.99e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10452333	chr10:81444403	LOC650623	0.53	5.16	0.39	7.66e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs901683	1.000	rs12769244	chr10:45959385	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.28e-11	Menopause (age at onset);
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg06815965	chr1:205818668	PM20D1	0.61	6.81	0.48	2.14e-10	Menarche (age at onset);
PAAD	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.6	4.47	0.34	1.5e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg23352942	chr3:46931381	PTH1R	-0.59	-6.55	-0.47	8.24e-10	Birth weight;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg14146966	chr2:61757674	XPO1	-0.37	-4.72	-0.36	5.29e-6	Tuberculosis;
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.55	-5.26	-0.39	4.77e-7	Tonsillectomy;
PAAD	cis	rs9913156	0.748	rs7213896	chr17:4562082	G/A	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs6879260	0.682	rs12173080	chr5:179741411	A/C	cg13944838	chr5:179740914	GFPT2	-0.75	-7.6	-0.52	2.9e-12	Height;
PAAD	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg16341495	chr8:142228727	SLC45A4	-0.52	-4.98	-0.37	1.68e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg20406979	chr6:167373233	NA	0.34	4.57	0.35	1.01e-5	Crohn's disease;
PAAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg10587741	chr22:38071170	LGALS1	-0.61	-6.82	-0.48	2.06e-10	Fat distribution (HIV);
PAAD	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4891159	0.548	rs948646	chr18:74118168	G/A	cg24786174	chr18:74118243	ZNF516	1.21	16.02	0.79	1.85e-34	Longevity;
PAAD	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.34	4.27	0.33	3.48e-5	Mean corpuscular volume;
PAAD	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.84	8.24	0.56	7.34e-14	Vitamin D levels;
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.74	-7.78	-0.53	1.01e-12	Age at first birth;
PAAD	cis	rs4845459	0.967	rs4112787	chr1:152551325	A/G	cg03277515	chr1:153321198	PGLYRP4	-0.4	-4.68	-0.36	6.19e-6	Psoriasis;
PAAD	cis	rs12304921	1.000	rs59546367	chr12:51345373	T/C	cg04427360	chr12:51347099	HIGD1C	-0.68	-5.22	-0.39	5.78e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02196458	chr15:90809250	NGRN	0.58	6.55	0.47	8.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	1.07	15.3	0.78	1.4e-32	Metabolite levels;
PAAD	trans	rs901683	1.000	rs34268168	chr10:45988526	G/A	cg11747279	chr17:21096632	NA	0.81	6.41	0.46	1.69e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg27411982	chr8:10470053	RP1L1	-0.47	-4.82	-0.36	3.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs818427	0.858	rs469727	chr5:112242968	A/G	cg06941702	chr5:112196734	SRP19	-0.51	-4.81	-0.36	3.63e-6	Total body bone mineral density;
PAAD	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg26248373	chr2:1572462	NA	-1.04	-9.45	-0.61	5.93e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg13540341	chr19:49222985	MAMSTR	0.41	4.51	0.34	1.3e-5	Dietary macronutrient intake;
PAAD	cis	rs6494488	0.500	rs72742943	chr15:64889463	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs939584	1.000	rs10865549	chr2:631759	G/A	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.5	4.99	0.37	1.66e-6	Height;
PAAD	cis	rs6466055	0.932	rs6466056	chr7:104929267	T/C	cg04380332	chr7:105027541	SRPK2	0.64	7.03	0.5	6.59e-11	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg03396347	chr1:1875803	NA	-0.64	-8.22	-0.55	8.4e-14	Body mass index;
PAAD	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.71	9.58	0.61	2.64e-17	Hemoglobin concentration;
PAAD	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg05791153	chr7:19748676	TWISTNB	-0.53	-4.36	-0.33	2.4e-5	Thyroid stimulating hormone;
PAAD	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.44	5.64	0.42	8.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.54	0.57	1.28e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg26816564	chr1:7831052	VAMP3	0.61	5.27	0.39	4.65e-7	Inflammatory bowel disease;
PAAD	cis	rs72960926	1.000	rs72960912	chr6:75144719	C/T	cg13997649	chr6:74171430	MTO1	0.88	4.66	0.35	6.9e-6	Metabolite levels (MHPG);
PAAD	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.94	10.47	0.65	1.15e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.8	8.06	0.55	2.13e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.79	-8.1	-0.55	1.63e-13	DNA methylation (variation);
PAAD	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.0	-12.15	-0.7	3.72e-24	Dilated cardiomyopathy;
PAAD	cis	rs4774830	0.744	rs62046391	chr15:56310688	C/T	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-9.35	-0.6	1.05e-16	Systemic lupus erythematosus;
PAAD	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.51	5.11	0.38	9.59e-7	Ovarian reserve;
PAAD	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.73	7.95	0.54	3.84e-13	Myeloid white cell count;
PAAD	cis	rs11264213	0.591	rs4653157	chr1:36543278	C/T	cg27506609	chr1:36549197	TEKT2	-0.8	-5.99	-0.44	1.44e-8	Schizophrenia;
PAAD	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.41	-5.52	-0.41	1.42e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.6	-6.32	-0.46	2.75e-9	Corneal astigmatism;
PAAD	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg06740227	chr12:86229804	RASSF9	0.52	4.8	0.36	3.78e-6	Major depressive disorder;
PAAD	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-5.31	-0.4	3.74e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg11802864	chr11:65308245	LTBP3	0.89	5.95	0.43	1.75e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg22325292	chr17:80708367	FN3K	0.63	4.26	0.33	3.59e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.93	-0.54	4.5e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8005172	0.676	rs10133753	chr14:88404382	T/C	cg18078958	chr14:88630771	NA	0.46	5.58	0.41	1.06e-7	Parkinson's disease;
PAAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.62	5.64	0.42	8.15e-8	Breast cancer;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg15117754	chr3:10150083	C3orf24	0.65	6.21	0.45	4.82e-9	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.61	5.41	0.4	2.41e-7	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg08975724	chr8:8085496	FLJ10661	-0.73	-7.26	-0.51	1.87e-11	Morning vs. evening chronotype;
PAAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	8.9	0.59	1.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.86	6.59	0.47	6.72e-10	Axial length;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02359409	chr6:42947317	PEX6	-0.47	-4.67	-0.35	6.51e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs501120	0.584	rs11511571	chr10:44727167	T/C	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.69	-7.87	-0.54	6.15e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.28	0.33	3.32e-5	Skin colour saturation;
PAAD	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg20742385	chr13:113633654	MCF2L	-0.46	-4.72	-0.36	5.26e-6	Systolic blood pressure;
PAAD	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.3	7.04	0.5	6.08e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-1.04	-14.15	-0.75	1.53e-29	Breast cancer;
PAAD	cis	rs35740288	0.694	rs17618909	chr15:86095462	A/C	cg07943548	chr15:86304357	KLHL25	-0.63	-5.49	-0.41	1.66e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.69	6.87	0.49	1.57e-10	Lymphocyte counts;
PAAD	trans	rs6869841	0.760	rs35834888	chr5:172954632	G/A	cg03237218	chr17:33760527	SLFN12	0.69	6.91	0.49	1.23e-10	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15486541	chr10:11505765	USP6NL	-0.62	-6.4	-0.46	1.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.16	8.33	0.56	4.31e-14	Alzheimer's disease;
PAAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.4	-0.34	2.07e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg18084798	chr19:33555255	RHPN2	0.47	5.03	0.38	1.36e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg01966878	chr4:90757139	SNCA	-0.45	-4.35	-0.33	2.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.83	0.62	6e-18	Prudent dietary pattern;
PAAD	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.74	-7.56	-0.52	3.61e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.5	-4.81	-0.36	3.68e-6	Inflammatory biomarkers;
PAAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg11764359	chr7:65958608	NA	-0.83	-5.26	-0.39	4.79e-7	Diabetic kidney disease;
PAAD	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.43	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg14847009	chr1:175162515	KIAA0040	0.3	4.54	0.35	1.13e-5	Alcohol dependence;
PAAD	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.61	8.1	0.55	1.7e-13	Crohn's disease;
PAAD	cis	rs73086581	1.000	rs17215529	chr20:3975402	A/G	cg02187196	chr20:3869020	PANK2	0.59	4.95	0.37	1.95e-6	Response to antidepressants in depression;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00914777	chr14:93651123	MOAP1;C14orf109	0.62	6.55	0.47	8.39e-10	Myopia (pathological);
PAAD	cis	rs10901513	0.932	rs35717616	chr10:127667376	C/G	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08439880	chr3:133502540	NA	-0.59	-6.6	-0.47	6.39e-10	Iron status biomarkers;
PAAD	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-7.45	-0.52	6.5e-12	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.69	-7.61	-0.53	2.73e-12	Melanoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22485171	chr5:169010600	CCDC99	0.64	7.52	0.52	4.47e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg20060109	chr17:81052770	NA	-0.44	-4.35	-0.33	2.46e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.63	-5.78	-0.42	4.07e-8	White matter hyperintensity burden;
PAAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.53	-4.45	-0.34	1.62e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs78761021	0.898	rs7216359	chr17:9775419	G/C	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs3126085	0.515	rs7514696	chr1:152363874	G/A	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.48	0.65	1.13e-19	Electrocardiographic conduction measures;
PAAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Gut microbiome composition (summer);
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	5.79	0.43	3.83e-8	Joint mobility (Beighton score);
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	11.75	0.69	4.3e-23	Platelet count;
PAAD	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg10932868	chr11:921992	NA	0.45	4.83	0.36	3.34e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.21e-6	Skin colour saturation;
PAAD	cis	rs9395066	0.545	rs4714828	chr6:44846008	A/G	cg25276700	chr6:44698697	NA	0.47	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.57	-5.4	-0.4	2.57e-7	Lymphocyte counts;
PAAD	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.57	4.98	0.37	1.73e-6	Height;
PAAD	cis	rs9287604	1.000	rs30104	chr2:237793812	C/T	cg15065627	chr2:237796583	NA	-0.53	-4.41	-0.34	1.91e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.88	6.86	0.49	1.61e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs11669133	1.000	rs78923731	chr19:11096376	C/G	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.57	5.92	0.43	2.09e-8	Dupuytren's disease;
PAAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.4e-5	Parkinson's disease;
PAAD	cis	rs11997175	0.536	rs10096323	chr8:33776507	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.27	0.45	3.64e-9	Body mass index;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg06996663	chr8:54756036	ATP6V1H	-0.69	-7.1	-0.5	4.59e-11	Body mass index;
PAAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.47	5.96	0.44	1.68e-8	Psoriasis;
PAAD	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.63	6.02	0.44	1.26e-8	Uric acid clearance;
PAAD	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg05228244	chr10:1102351	WDR37	0.86	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	4.56	0.35	1.04e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.41	-4.44	-0.34	1.7e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06850241	chr22:41845214	NA	-0.6	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg05082376	chr22:42548792	NA	-0.52	-5.6	-0.41	9.67e-8	Cognitive function;
PAAD	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.69	5.1	0.38	9.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs59888335	0.964	rs1850298	chr3:80729414	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.58	5.8	0.43	3.75e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Electroencephalogram traits;
PAAD	cis	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	trans	rs3733631	1.000	rs10007754	chr4:104627442	T/G	cg21490444	chr5:171095097	NA	0.79	6.68	0.48	4.25e-10	Menarche (age at onset);
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.49	0.57	1.71e-14	Alzheimer's disease;
PAAD	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	ch.8.33884649F	chr8:33765107	NA	0.6	6.62	0.47	5.94e-10	Body mass index;
PAAD	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg23912435	chr1:150601613	ENSA	0.49	4.51	0.34	1.27e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.9	-0.43	2.28e-8	QT interval;
PAAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-5.39	-0.4	2.58e-7	Coronary artery disease;
PAAD	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs17681684	0.565	rs62066034	chr17:9758829	A/G	cg26853458	chr17:9805074	RCVRN	0.75	7.97	0.54	3.56e-13	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.87e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.51	-5.05	-0.38	1.27e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.72	-6.97	-0.49	8.95e-11	Platelet distribution width;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17987358	chr18:74206810	NA	0.47	4.76	0.36	4.53e-6	Obesity-related traits;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg27246277	chr17:42084477	NAGS	-0.62	-7.1	-0.5	4.52e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-1.0	-12.74	-0.72	9.21e-26	Refractive error;
PAAD	cis	rs2594989	0.943	rs346070	chr3:11303874	T/C	cg01796438	chr3:11312864	ATG7	-0.65	-5.01	-0.38	1.49e-6	Circulating chemerin levels;
PAAD	cis	rs10276381	0.579	rs9648026	chr7:28161983	A/G	cg23620719	chr7:28220237	JAZF1	-0.8	-4.76	-0.36	4.46e-6	Crohn's disease;
PAAD	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg11143131	chr5:131608246	PDLIM4	-0.51	-5.19	-0.39	6.67e-7	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06307176	chr5:131281290	NA	0.57	4.92	0.37	2.2e-6	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs60154123	1.000	rs4844996	chr1:210476423	C/T	cg25204440	chr1:209979598	IRF6	0.58	4.64	0.35	7.42e-6	Coronary artery disease;
PAAD	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs8105895	0.867	rs116220423	chr19:22237041	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	1.03	13.59	0.74	5.04e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.63	5.77	0.42	4.24e-8	Obesity-related traits;
PAAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.63	-6.28	-0.45	3.35e-9	Post bronchodilator FEV1;
PAAD	cis	rs2718812	1.000	rs2718813	chr3:133399212	A/G	cg08439880	chr3:133502540	NA	0.41	4.62	0.35	8.2e-6	Iron status biomarkers;
PAAD	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs7009110	0.681	rs13275219	chr8:81259826	T/C	cg21158561	chr8:81178149	NA	0.41	4.25	0.33	3.71e-5	Asthma and hay fever;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg02725872	chr8:58115012	NA	-0.64	-5.45	-0.4	1.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11051970	0.918	rs73084101	chr12:32544339	A/C	cg24626660	chr12:32551988	NA	0.43	4.64	0.35	7.37e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.08	15.38	0.78	8.7e-33	Multiple system atrophy;
PAAD	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.46	-4.62	-0.35	8.18e-6	Type 2 diabetes;
PAAD	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.39	-10.8	-0.66	1.51e-20	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.57	4.68	0.35	6.33e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg19520763	chr3:38534710	NA	-0.34	-4.41	-0.34	1.95e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-1.02	-9.35	-0.6	1.04e-16	IgG glycosylation;
PAAD	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.24	-0.39	5.21e-7	Vitiligo;
PAAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.63	6.6	0.47	6.38e-10	Mood instability;
PAAD	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs3753841	0.798	rs4590689	chr1:103264964	G/A	cg24495344	chr1:103574097	COL11A1	0.37	4.31	0.33	2.95e-5	Glaucoma (primary angle closure);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15555402	chr12:19593456	AEBP2	0.67	7.16	0.5	3.27e-11	Primary biliary cholangitis;
PAAD	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs7168592	1.000	rs60161668	chr15:101732683	A/C	cg24254196	chr15:101719523	CHSY1	-0.66	-4.69	-0.36	6.02e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.74	7.6	0.52	2.89e-12	Obesity-related traits;
PAAD	cis	rs9815354	1.000	rs1716642	chr3:41965865	A/C	cg03022575	chr3:42003672	ULK4	-0.81	-5.75	-0.42	4.81e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9880772	0.602	rs9860067	chr3:27798275	G/A	cg21473142	chr3:27762095	EOMES	0.31	4.97	0.37	1.81e-6	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26031613	chr14:104095156	KLC1	0.43	4.3	0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.21	0.45	4.89e-9	Alzheimer's disease;
PAAD	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.48	-5.16	-0.39	7.7e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg24330906	chr2:85765176	MAT2A	0.43	4.33	0.33	2.66e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs8112211	0.689	rs76682100	chr19:38794786	T/G	cg01275006	chr19:38876250	GGN	-0.86	-5.53	-0.41	1.37e-7	Blood protein levels;
PAAD	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-1.06	-11.21	-0.67	1.24e-21	Platelet distribution width;
PAAD	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	4.97	0.37	1.75e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.55e-15	Eye color traits;
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.21	-0.5	2.45e-11	Coronary artery disease;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.67	-10.86	-0.66	1.07e-20	Longevity;Endometriosis;
PAAD	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg19510604	chr15:74901076	CLK3	0.52	4.4	0.34	1.99e-5	Blood trace element (Zn levels);
PAAD	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.7	6.94	0.49	1.06e-10	Total body bone mineral density;
PAAD	cis	rs721399	0.539	rs57180587	chr8:18269581	A/T	cg18736775	chr8:18248649	NAT2	-0.61	-4.63	-0.35	7.76e-6	Blood metabolite levels;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.07	-6.85	-0.49	1.69e-10	Body mass index;
PAAD	cis	rs60617249	0.579	rs6593249	chr7:50926250	A/G	cg15805451	chr7:51135775	COBL	-0.43	-4.61	-0.35	8.32e-6	Major depression and alcohol dependence;
PAAD	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	6.71	0.48	3.58e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.64	-7.67	-0.53	1.91e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4742903	0.967	rs10820599	chr9:106856691	T/G	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.12e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.43	-0.52	7.4e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.57	5.89	0.43	2.44e-8	Longevity;Endometriosis;
PAAD	cis	rs7567389	0.583	rs11683427	chr2:127956543	A/G	cg11380483	chr2:127933992	NA	0.53	4.99	0.38	1.64e-6	Self-rated health;
PAAD	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg23688817	chr7:87105293	ABCB4	0.56	4.66	0.35	6.95e-6	Gallbladder cancer;
PAAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg13611204	chr9:139324423	INPP5E	0.56	4.87	0.37	2.81e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.86	8.6	0.57	9.26e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-5.76	-0.42	4.49e-8	Total cholesterol levels;
PAAD	cis	rs11264213	1.000	rs11264203	chr1:36239234	C/T	cg27506609	chr1:36549197	TEKT2	0.68	4.68	0.36	6.21e-6	Schizophrenia;
PAAD	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg13660082	chr14:53194042	PSMC6	0.71	4.48	0.34	1.43e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.05	-6.77	-0.48	2.59e-10	Mitochondrial DNA levels;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.89	-0.49	1.42e-10	Migraine;Coronary artery disease;
PAAD	cis	rs501120	1.000	rs503859	chr10:44753560	G/C	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10541930	chr10:131909085	NA	-0.68	-6.9	-0.49	1.33e-10	Smoking initiation;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.9	-10.0	-0.63	2.11e-18	Prudent dietary pattern;
PAAD	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg14092571	chr14:90743983	NA	-0.53	-5.16	-0.39	7.76e-7	Mortality in heart failure;
PAAD	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.49	5.38	0.4	2.83e-7	Heart rate;
PAAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg14146966	chr2:61757674	XPO1	-0.42	-5.28	-0.39	4.33e-7	Tuberculosis;
PAAD	cis	rs2421770	0.927	rs11033052	chr11:35310138	C/T	cg13971030	chr11:35366721	SLC1A2	0.55	6.63	0.47	5.41e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.14	0.45	6.79e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg11416102	chr8:651193	ERICH1	0.94	5.9	0.43	2.27e-8	IgG glycosylation;
PAAD	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.47	-5.53	-0.41	1.38e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2221894	1.000	rs12674777	chr8:28843721	G/A	cg20212339	chr8:28908912	HMBOX1	0.53	5.68	0.42	6.68e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17871757	chr3:9781122	BRPF1	-0.69	-7.06	-0.5	5.65e-11	Obesity-related traits;
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09256448	chr16:638327	NA	0.41	4.28	0.33	3.31e-5	Height;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24110177	chr3:50126178	RBM5	0.6	6.39	0.46	1.97e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.53	-5.01	-0.38	1.5e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.85	-0.43	2.86e-8	Total cholesterol levels;
PAAD	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.5	4.54	0.35	1.15e-5	Menopause (age at onset);
PAAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg15017067	chr4:17643749	FAM184B	-0.43	-5.13	-0.38	8.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.82	9.38	0.61	8.7e-17	Metabolic syndrome;
PAAD	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.81	-9.0	-0.59	8.75e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.4	5.0	0.38	1.58e-6	Pulmonary function;
PAAD	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.4	-0.4	2.51e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	4.35	0.33	2.46e-5	Hypertriglyceridemia;
PAAD	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.95	-7.58	-0.52	3.24e-12	Blood protein levels;
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.7	7.14	0.5	3.5e-11	Lung cancer;
PAAD	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.12	-10.55	-0.65	7.3e-20	Lymphocyte percentage of white cells;
PAAD	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.63	0.47	5.37e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.72	-7.82	-0.54	8.21e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2133450	0.933	rs41412146	chr3:7341024	A/G	cg19930620	chr3:7340148	GRM7	-0.41	-4.39	-0.34	2.09e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.74	0.62	1.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs939584	1.000	rs35796073	chr2:636819	C/A	cg14515364	chr2:636606	NA	-0.5	-4.67	-0.35	6.69e-6	Body mass index;
PAAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2734839	0.964	rs4938017	chr11:113303929	C/T	cg14159747	chr11:113255604	NA	-0.43	-6.52	-0.47	9.56e-10	Information processing speed;
PAAD	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.76	-7.69	-0.53	1.71e-12	Pancreatic cancer;
PAAD	cis	rs11811982	0.793	rs11800777	chr1:227535532	C/A	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs30380	0.586	rs28119	chr5:96131733	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-5.15	-0.39	8.12e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.77	-6.38	-0.46	2.04e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg04450456	chr4:17643702	FAM184B	0.49	5.36	0.4	2.97e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	6.15	0.45	6.66e-9	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19168676	chr10:114204245	ZDHHC6	-0.64	-6.63	-0.47	5.47e-10	Obesity-related traits;
PAAD	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg03808351	chr9:123631620	PHF19	0.42	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.77	5.77	0.42	4.36e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6671926	1	rs6671926	chr1:227386971	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic cup area;Optic disc area;
PAAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.66	-7.82	-0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.93	-11.17	-0.67	1.55e-21	Eosinophil percentage of white cells;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg18093559	chr17:18951025	GRAP	0.47	4.68	0.36	6.24e-6	Schizophrenia;
PAAD	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	5.0	0.38	1.54e-6	Asthma;
PAAD	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	9.96	0.63	2.66e-18	Smoking behavior;
PAAD	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg08501292	chr6:25962987	TRIM38	0.74	4.46	0.34	1.57e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7072216	0.687	rs7924209	chr10:100155927	T/C	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.96	0.37	1.91e-6	Lung cancer in ever smokers;
PAAD	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-8.08	-0.55	1.87e-13	Dental caries;
PAAD	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.6	6.07	0.44	9.6e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.41	0.4	2.45e-7	Monocyte percentage of white cells;
PAAD	trans	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg24842760	chr6:133561719	EYA4	-0.9	-6.81	-0.48	2.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg17105886	chr17:28927953	LRRC37B2	0.66	4.43	0.34	1.83e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg19264203	chr11:92714893	MTNR1B	0.42	4.85	0.37	2.98e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.72	9.1	0.59	4.63e-16	Cardiovascular disease risk factors;
PAAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.49	-0.34	1.38e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.52	4.73	0.36	5.16e-6	Height;
PAAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.69	7.23	0.51	2.19e-11	Morning vs. evening chronotype;
PAAD	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.44	5.57	0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3018712	0.526	rs6591352	chr11:68487513	A/G	cg23009355	chr11:68451396	GAL	-0.44	-4.25	-0.33	3.75e-5	Total body bone mineral density;
PAAD	cis	rs3105169	0.733	rs1667644	chr8:100670473	A/G	cg18744668	chr8:99962347	OSR2	0.47	4.42	0.34	1.89e-5	Smoking initiation;
PAAD	cis	rs73206853	0.841	rs56117211	chr12:111123485	T/G	cg12870014	chr12:110450643	ANKRD13A	0.72	4.48	0.34	1.45e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.66	-0.35	6.84e-6	Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19346786	chr7:2764209	NA	-0.41	-5.19	-0.39	6.51e-7	Height;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg11062466	chr8:58055876	NA	0.69	4.79	0.36	3.92e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	8.31e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.99	7.9	0.54	5.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg03609598	chr5:56110824	MAP3K1	0.51	4.26	0.33	3.64e-5	Type 2 diabetes;
PAAD	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-5.33	-0.4	3.55e-7	Common traits (Other);
PAAD	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.47	-4.3	-0.33	3.06e-5	Response to temozolomide;
PAAD	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4513299	0.601	rs3132045	chr2:115005520	C/T	cg12978357	chr2:114426529	NA	-0.44	-4.4	-0.34	2.03e-5	Inflammatory biomarkers;
PAAD	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.28	-0.45	3.41e-9	Morning vs. evening chronotype;
PAAD	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8077059	1.000	rs8067868	chr17:55824949	C/T	cg12582317	chr17:55822272	NA	-0.49	-4.74	-0.36	4.86e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs56046484	0.956	rs35045545	chr15:85664951	A/G	cg08123816	chr15:85640762	PDE8A	-0.5	-5.15	-0.39	7.93e-7	Testicular germ cell tumor;
PAAD	cis	rs742132	0.520	rs113164182	chr6:25633829	A/C	cg03264133	chr6:25882463	NA	0.67	4.59	0.35	9.22e-6	Uric acid levels;
PAAD	cis	rs959260	1.000	rs4789183	chr17:73380221	G/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.54	0.47	8.78e-10	Morning vs. evening chronotype;
PAAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg06740227	chr12:86229804	RASSF9	0.52	5.21	0.39	5.95e-7	Major depressive disorder;
PAAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.56	-6.79	-0.48	2.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	4.3	0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs8112211	0.648	rs77862444	chr19:38820528	C/T	cg14299480	chr19:38876666	GGN	-0.53	-4.56	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.31e-8	Electroencephalogram traits;
PAAD	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.86	8.97	0.59	1.03e-15	Homoarginine levels;
PAAD	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.55	4.68	0.35	6.29e-6	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.38	-0.33	2.23e-5	Lung cancer;
PAAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg25251562	chr2:3704773	ALLC	0.69	7.4	0.51	8.55e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg23127183	chr11:57508653	C11orf31	0.49	4.29	0.33	3.21e-5	Schizophrenia;
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg19337854	chr7:99768885	GPC2	0.52	4.88	0.37	2.66e-6	Platelet count;
PAAD	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.95	-7.49	-0.52	5.31e-12	Blood protein levels;
PAAD	cis	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	4.79	0.36	3.95e-6	Schizophrenia (age at onset);
PAAD	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg05085585	chr16:30420623	ZNF771	0.45	4.46	0.34	1.61e-5	Tonsillectomy;
PAAD	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	trans	rs4325129	0.871	rs4656827	chr1:159460032	A/G	cg24759744	chr20:40627665	NA	0.59	6.78	0.48	2.53e-10	Obesity-related traits;
PAAD	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.22	-0.51	2.33e-11	Vitiligo;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg15331088	chr8:600555	NA	0.69	4.43	0.34	1.82e-5	IgG glycosylation;
PAAD	cis	rs4343996	0.902	rs12540305	chr7:3376072	A/T	cg21248987	chr7:3385318	SDK1	-0.47	-5.13	-0.38	8.67e-7	Motion sickness;
PAAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.74e-27	Height;
PAAD	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.6	-8.26	-0.56	6.57e-14	Eye color traits;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs752010	0.571	rs10890135	chr1:42054084	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	5.13	0.38	8.55e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.59	-4.44	-0.34	1.75e-5	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg26174226	chr8:58114915	NA	-0.62	-4.37	-0.33	2.32e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.72	6.94	0.49	1.07e-10	Schizophrenia;
PAAD	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.49	4.33	0.33	2.74e-5	Hypospadias;
PAAD	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.65	7.36	0.51	1.1e-11	Height;
PAAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15731816	chr14:75230414	YLPM1	0.62	6.89	0.49	1.36e-10	Response to antipsychotic treatment;
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.94	-7.94	-0.54	4.05e-13	Initial pursuit acceleration;
PAAD	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.58	5.59	0.41	1.03e-7	Asthma;
PAAD	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-4.69	-0.36	6.05e-6	Schizophrenia;
PAAD	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg00383909	chr3:49044727	WDR6	0.54	4.47	0.34	1.49e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.1	0.55	1.67e-13	Height;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02196655	chr2:10830764	NOL10	-0.6	-6.15	-0.45	6.6e-9	Prostate cancer;
PAAD	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.54	7.13	0.5	3.71e-11	Ewing sarcoma;
PAAD	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg00071950	chr4:10020882	SLC2A9	0.61	5.46	0.41	1.87e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg22029157	chr1:209979665	IRF6	-0.77	-6.5	-0.47	1.1e-9	Coronary artery disease;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.86	0.37	2.85e-6	Oropharynx cancer;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19626725	chr5:178986131	RUFY1	-0.49	-5.09	-0.38	1.06e-6	Lung cancer;
PAAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-6.44	-0.46	1.49e-9	Body mass index;
PAAD	cis	rs4523957	0.855	rs1231209	chr17:2124972	G/A	cg16513277	chr17:2031491	SMG6	-0.48	-4.81	-0.36	3.6e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.83	5.54	0.41	1.33e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg10818794	chr15:86012489	AKAP13	-0.6	-4.89	-0.37	2.5e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.56	6.0	0.44	1.42e-8	Lung cancer;
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12100965	chr1:1623803	CDK11B;LOC728661	0.57	6.39	0.46	1.91e-9	Pancreatic cancer;
PAAD	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.52	5.77	0.42	4.25e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.64	-5.62	-0.41	8.84e-8	Lung cancer;
PAAD	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.65	0.35	7.02e-6	Type 2 diabetes;
PAAD	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg15890332	chr12:107067104	RFX4	0.41	4.35	0.33	2.46e-5	Total body bone mineral density;
PAAD	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg16602846	chr15:78114278	NA	-0.42	-4.55	-0.35	1.1e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg20936604	chr3:58311152	NA	-0.81	-4.4	-0.34	2.03e-5	Cholesterol, total;
PAAD	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-12.63	-0.72	1.85e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.59	5.79	0.43	3.86e-8	Coronary artery disease;
PAAD	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08677398	chr8:58056175	NA	0.66	4.94	0.37	2.03e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.56	-7.55	-0.52	3.82e-12	Urate levels in overweight individuals;
PAAD	cis	rs59888335	0.929	rs13059859	chr3:80884685	C/T	cg21735741	chr3:80819488	NA	0.55	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs939584	1.000	rs6748821	chr2:629601	A/G	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.7	6.91	0.49	1.23e-10	Uric acid levels;
PAAD	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.36	-0.33	2.36e-5	Morning vs. evening chronotype;
PAAD	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26876637	chr1:152193138	HRNR	0.89	6.91	0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg07384165	chr1:10488281	NA	-0.48	-5.04	-0.38	1.28e-6	Breast size;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.20.661824R	chr20:32868459	AHCY	-0.68	-6.82	-0.48	2.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs58653258	0.614	rs822842	chr1:234973323	A/G	cg03518729	chr1:235147744	NA	0.46	4.36	0.33	2.37e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg24565620	chr2:194026	NA	0.55	4.52	0.34	1.22e-5	Blood protein levels;
PAAD	cis	rs962856	0.756	rs4671799	chr2:67622243	A/G	cg09028215	chr2:67624308	ETAA1	-0.53	-4.52	-0.34	1.24e-5	Pancreatic cancer;
PAAD	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.61	6.13	0.45	7.37e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs16895831	0.519	rs16895843	chr6:42541802	G/C	cg10605015	chr6:42532144	UBR2	-0.74	-5.57	-0.41	1.13e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-1.02	-12.29	-0.71	1.48e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg03934865	chr2:198174659	NA	-0.44	-4.49	-0.34	1.4e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9395066	0.545	rs4711807	chr6:44911652	G/A	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs4713118	1.000	rs13215072	chr6:27677728	A/G	cg23281280	chr6:28129359	ZNF389	0.49	4.34	0.33	2.61e-5	Parkinson's disease;
PAAD	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg22517653	chr1:2918612	NA	-0.63	-5.04	-0.38	1.33e-6	Plateletcrit;
PAAD	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.54	-0.41	1.28e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.56	6.23	0.45	4.38e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.49	-4.39	-0.34	2.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11828509	chr1:26146223	FAM54B	0.6	6.45	0.46	1.42e-9	Myopia (pathological);
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.48	5.26	0.39	4.72e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-4.46	-0.34	1.57e-5	Schizophrenia;
PAAD	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.46	-4.61	-0.35	8.62e-6	PR interval;
PAAD	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg09796270	chr17:17721594	SREBF1	-0.45	-5.14	-0.39	8.14e-7	Total body bone mineral density;
PAAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.78	-7.04	-0.5	6.35e-11	Inhibitory control;
PAAD	trans	rs901683	1.000	rs71494786	chr10:45970117	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.62	7.66	0.53	1.97e-12	Obesity (extreme);
PAAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.66	0.53	2.07e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73388146	0.685	rs6456651	chr6:25148011	A/C	cg08126211	chr6:24357720	KAAG1;DCDC2	0.6	4.29	0.33	3.11e-5	Schizophrenia;
PAAD	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.64	6.18	0.45	5.69e-9	Corneal astigmatism;
PAAD	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.93	10.81	0.66	1.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg23985595	chr17:80112537	CCDC57	0.53	7.18	0.5	2.84e-11	Life satisfaction;
PAAD	cis	rs2555155	0.602	rs2555143	chr11:6541580	G/T	cg24637308	chr11:6592297	DNHD1	-0.56	-5.48	-0.41	1.75e-7	DNA methylation (variation);
PAAD	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg11204139	chr17:3907470	NA	0.47	4.6	0.35	8.82e-6	Type 2 diabetes;
PAAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Calcium levels;
PAAD	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg23281280	chr6:28129359	ZNF389	-0.49	-4.45	-0.34	1.64e-5	Parkinson's disease;
PAAD	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.84	9.49	0.61	4.64e-17	Type 2 diabetes;
PAAD	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.96	-6.74	-0.48	3.15e-10	Body mass index;
PAAD	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.85	-11.22	-0.67	1.13e-21	Height;
PAAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg08079166	chr15:68083412	MAP2K5	-0.69	-5.5	-0.41	1.6e-7	Restless legs syndrome;
PAAD	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.83	0.36	3.32e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg01631408	chr1:248437212	OR2T33	-0.52	-4.55	-0.35	1.1e-5	Common traits (Other);
PAAD	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.55	-0.41	1.24e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7816613	0.850	rs28469577	chr8:102676942	C/T	cg20585841	chr8:102729926	NCALD	-0.59	-5.05	-0.38	1.27e-6	Age-related hearing impairment;
PAAD	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs9283706	0.513	rs7707409	chr5:66351889	A/G	cg11590213	chr5:66331682	MAST4	0.59	4.64	0.35	7.58e-6	Coronary artery disease;
PAAD	cis	rs7070678	0.625	rs2025855	chr10:29789738	G/A	cg24726783	chr10:29759454	SVIL	-0.48	-4.49	-0.34	1.38e-5	Platelet thrombus formation;
PAAD	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.54	-6.26	-0.45	3.75e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	4.61	0.35	8.32e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	6.99	0.49	8.31e-11	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.56	5.43	0.4	2.19e-7	Prudent dietary pattern;
PAAD	cis	rs2627282	0.772	rs2670073	chr8:2782789	A/G	cg21769514	chr8:2743697	NA	0.42	4.52	0.34	1.25e-5	Blood pressure measurement (high sodium intervention);
PAAD	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.81	9.43	0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg14926445	chr8:58193284	C8orf71	-0.77	-4.95	-0.37	1.94e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.75	-7.85	-0.54	6.83e-13	DNA methylation (variation);
PAAD	cis	rs77633900	0.772	rs2944377	chr15:76699652	C/A	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg18964960	chr10:1102726	WDR37	-0.64	-5.53	-0.41	1.39e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs939584	1.000	rs6760274	chr2:652272	G/A	cg14515364	chr2:636606	NA	-0.47	-4.31	-0.33	2.91e-5	Body mass index;
PAAD	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.4	-4.69	-0.36	5.91e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.58	-5.62	-0.42	8.69e-8	Monocyte count;
PAAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-7.35	-0.51	1.15e-11	Coronary artery disease;
PAAD	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	8.01	0.54	2.84e-13	Monocyte percentage of white cells;
PAAD	cis	rs10490913	1.000	rs7920469	chr10:120146503	G/A	cg04126427	chr10:120840676	EIF3A	-0.47	-4.85	-0.37	2.97e-6	Cancer;
PAAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.47	-6.02	-0.44	1.22e-8	Ulcerative colitis;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.51	-5.35	-0.4	3.11e-7	Obesity-related traits;
PAAD	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.69e-5	Schizophrenia;
PAAD	cis	rs11871801	1.000	rs72823064	chr17:40569974	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.48	-4.78	-0.36	4.09e-6	Crohn's disease;
PAAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg01489256	chr8:11204017	TDH	-0.44	-4.26	-0.33	3.61e-5	Retinal vascular caliber;
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11904590	chr7:65670474	TPST1	-0.77	-6.4	-0.46	1.83e-9	Neuroticism;
PAAD	cis	rs10768122	0.642	rs4756214	chr11:35365938	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-5.39	-0.4	2.58e-7	Vitiligo;
PAAD	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	7.44	0.52	6.86e-12	Leprosy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11963430	chr19:19729565	PBX4	0.64	6.6	0.47	6.42e-10	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg05082376	chr22:42548792	NA	-0.53	-5.16	-0.39	7.6e-7	Schizophrenia;
PAAD	cis	rs9315204	0.891	rs3742321	chr13:33704065	T/C	cg22534336	chr13:33112922	N4BP2L2	-0.52	-4.26	-0.33	3.55e-5	Intracranial aneurysm;
PAAD	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.37	-5.16	-0.39	7.51e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.46	-4.36	-0.33	2.37e-5	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.76e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg00879592	chr17:62400642	PECAM1	-0.55	-4.78	-0.36	4.15e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.07	0.5	5.4e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg26597838	chr10:835615	NA	0.41	4.47	0.34	1.52e-5	Survival in rectal cancer;
PAAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.88	9.32	0.6	1.24e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	4.46	0.34	1.56e-5	Mood instability;
PAAD	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	0.96	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg19930314	chr7:98593876	TRRAP	0.48	4.71	0.36	5.47e-6	Breast cancer;
PAAD	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.79	8.68	0.58	5.72e-15	Obesity-related traits;
PAAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.6	6.43	0.46	1.56e-9	Pancreatic cancer;
PAAD	cis	rs77880822	0.562	rs17717619	chr20:1256910	C/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.12	0.38	9.25e-7	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02984159	chr7:1199847	ZFAND2A	0.63	6.66	0.48	4.62e-10	Myopia (pathological);
PAAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.48	8.53	0.57	1.41e-14	Multiple system atrophy;
PAAD	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg26898376	chr11:64110657	CCDC88B	0.44	4.71	0.36	5.46e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs61884328	0.789	rs61898461	chr11:46858973	A/G	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs2072732	0.904	rs2993481	chr1:2973433	A/T	cg22517653	chr1:2918612	NA	-0.63	-4.85	-0.37	2.97e-6	Plateletcrit;
PAAD	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.65	4.9	0.37	2.39e-6	Diisocyanate-induced asthma;
PAAD	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	1.05	6.61	0.47	6.08e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.44	-4.27	-0.33	3.48e-5	Chronic sinus infection;
PAAD	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	trans	rs10511089	0.510	rs77137058	chr3:84747357	A/G	cg24892966	chr6:27526023	NA	0.61	6.35	0.46	2.31e-9	Brain structure;
PAAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	5.77	0.42	4.27e-8	Monocyte count;
PAAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg05110241	chr16:68378359	PRMT7	-1.11	-8.12	-0.55	1.47e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.46	-0.46	1.34e-9	Acne (severe);
PAAD	trans	rs61931739	0.546	rs7297354	chr12:33700556	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs11264799	0.731	rs12564172	chr1:157711702	T/C	cg18268488	chr1:157545234	FCRL4	0.65	5.83	0.43	3.22e-8	IgA nephropathy;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16083429	chr3:49237500	CCDC36	-0.47	-5.09	-0.38	1.03e-6	Menarche (age at onset);
PAAD	cis	rs8105895	0.935	rs7260331	chr19:22291771	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.38	-0.33	2.2e-5	Body mass index (change over time);
PAAD	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.74	0.42	5.08e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg20406979	chr6:167373233	NA	-0.37	-4.81	-0.36	3.61e-6	Crohn's disease;
PAAD	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.46	-0.34	1.61e-5	Blood metabolite levels;
PAAD	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.55	-5.05	-0.38	1.25e-6	Corneal structure;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13560548	chr3:10150139	C3orf24	0.56	5.03	0.38	1.34e-6	Alzheimer's disease;
PAAD	cis	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.1	-0.38	9.9e-7	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7552393	0.636	rs6680860	chr1:84283317	G/A	cg10977910	chr1:84465055	TTLL7	0.59	5.61	0.41	9.41e-8	Select biomarker traits;
PAAD	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.51	4.62	0.35	8.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7619427	0.544	rs9872047	chr3:43991630	C/T	cg12796028	chr3:44040206	NA	-0.54	-4.69	-0.36	6.03e-6	Schizophrenia;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.72	8.56	0.57	1.14e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6987853	0.686	rs55837592	chr8:42359974	T/C	cg09913449	chr8:42400586	C8orf40	-0.49	-5.43	-0.4	2.14e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.62	6.92	0.49	1.17e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.75	5.42	0.4	2.3e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg21479132	chr6:26055353	NA	-0.83	-5.15	-0.39	7.81e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg02462569	chr6:150064036	NUP43	-0.51	-5.42	-0.4	2.28e-7	Lung cancer;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.47	-5.39	-0.4	2.66e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-5.55	-0.41	1.22e-7	Mean platelet volume;
PAAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07362569	chr17:61921086	SMARCD2	0.63	8.0	0.54	2.88e-13	Prudent dietary pattern;
PAAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.4	0.34	2.03e-5	Aortic root size;
PAAD	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.45	-4.91	-0.37	2.33e-6	Prevalent atrial fibrillation;
PAAD	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-1.06	-7.5	-0.52	4.91e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.23	-0.56	7.92e-14	Height;
PAAD	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.95e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg08601574	chr20:25228251	PYGB	0.48	5.08	0.38	1.11e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.15	7.45	0.52	6.56e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.56	6.08	0.44	9.47e-9	Bladder cancer;
PAAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05957736	chr3:111579326	PHLDB2	0.69	6.72	0.48	3.5e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg09417038	chr21:47716443	C21orf57	0.59	6.41	0.46	1.76e-9	Testicular germ cell tumor;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg16071782	chr14:97031960	PAPOLA	-0.54	-6.66	-0.48	4.77e-10	Energy expenditure (24h);
PAAD	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.74	9.6	0.61	2.36e-17	Asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03750407	chr11:67159770	RAD9A	0.63	7.05	0.5	5.88e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.45	-0.34	1.64e-5	Diastolic blood pressure;
PAAD	cis	rs721399	0.513	rs35354956	chr8:18241319	T/C	cg18736775	chr8:18248649	NAT2	-0.81	-6.7	-0.48	3.77e-10	Blood metabolite levels;
PAAD	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs12550646	0.652	rs10090395	chr8:41666874	C/T	cg12180191	chr8:41686706	ANK1	0.46	4.39	0.34	2.08e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-6.16	-0.45	6.27e-9	Height;
PAAD	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs30380	0.632	rs27434	chr5:96129512	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.25	-0.39	4.93e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg03098721	chr1:84464084	TTLL7	0.48	4.64	0.35	7.6e-6	Obesity-related traits;
PAAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.61	-8.49	-0.57	1.74e-14	Huntington's disease progression;
PAAD	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg10871876	chr19:53194124	ZNF83	0.63	5.71	0.42	5.69e-8	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.6	-6.4	-0.46	1.86e-9	HDL cholesterol;
PAAD	cis	rs1008375	0.762	rs17499929	chr4:17590671	G/A	cg04450456	chr4:17643702	FAM184B	0.44	4.73	0.36	5.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs1468734	0.929	rs12929716	chr16:5006600	A/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.53	-4.39	-0.34	2.12e-5	Cancer;
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg20821713	chr7:1055600	C7orf50	-0.51	-4.43	-0.34	1.8e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg13206674	chr6:150067644	NUP43	-0.54	-5.03	-0.38	1.37e-6	Lung cancer;
PAAD	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg16810054	chr20:33298113	TP53INP2	0.56	4.59	0.35	9.1e-6	Melanoma;
PAAD	cis	rs7804356	0.651	rs1548481	chr7:26762983	C/G	cg03456212	chr7:26904342	SKAP2	0.56	4.75	0.36	4.67e-6	Type 1 diabetes;
PAAD	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.65	-6.19	-0.45	5.45e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.6	-6.08	-0.44	9.35e-9	Prostate cancer;
PAAD	cis	rs3772130	0.540	rs57791671	chr3:121608433	T/A	cg20356878	chr3:121714668	ILDR1	0.59	6.65	0.47	4.93e-10	Cognitive performance;
PAAD	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs55692468	0.540	rs4664586	chr2:153324071	C/T	cg24749089	chr2:153322823	FMNL2	0.27	4.53	0.35	1.17e-5	Intraocular pressure;
PAAD	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00142150	chr22:38071001	LGALS1	0.71	8.32	0.56	4.56e-14	Fat distribution (HIV);
PAAD	cis	rs501120	0.584	rs61857482	chr10:44716905	C/T	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	4.32	0.33	2.83e-5	Axial length;
PAAD	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg09491104	chr22:46646882	C22orf40	-1.01	-6.03	-0.44	1.2e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.41	1.75e-7	Obesity-related traits;
PAAD	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.14	0.6	3.82e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs11794666	0.929	rs11793865	chr9:31806986	A/G	cg05628366	chr6:35744188	C6orf126	1.12	6.81	0.48	2.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Acylcarnitine levels;
PAAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.48	-4.44	-0.34	1.69e-5	Menarche (age at onset);
PAAD	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.54	-0.41	1.31e-7	Colorectal cancer;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.76	0.36	4.56e-6	Bipolar disorder;
PAAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.8e-13	Blood protein levels;
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24199050	chr22:46692564	GTSE1;CN5H6.4	-0.75	-6.73	-0.48	3.34e-10	Neuroticism;
PAAD	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg08175591	chr14:101176152	NA	-0.38	-4.77	-0.36	4.28e-6	Platelet count;
PAAD	cis	rs7081476	0.737	rs4747594	chr10:27511043	C/G	cg20349793	chr10:26911186	NA	0.91	4.86	0.37	2.93e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.65	6.57	0.47	7.65e-10	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.58	5.76	0.42	4.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.66e-7	Blood metabolite levels;
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg19318889	chr4:1322082	MAEA	-0.42	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.16	-0.55	1.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg07153921	chr17:41440717	NA	-0.42	-4.49	-0.34	1.42e-5	Menopause (age at onset);
PAAD	cis	rs4073221	0.654	rs34059277	chr3:18293934	A/C	cg07694806	chr3:18168406	NA	-0.66	-4.77	-0.36	4.3e-6	Parkinson's disease;
PAAD	cis	rs988913	1.000	rs1503142	chr6:54818948	C/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.58	-5.79	-0.42	3.94e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3136739	0.681	rs80098805	chr8:41995314	G/A	cg17828057	chr8:42037527	PLAT	0.62	4.27	0.33	3.41e-5	Plasma plasminogen activator levels;
PAAD	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.88	-4.42	-0.34	1.86e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-4.52	-0.34	1.22e-5	Mean platelet volume;
PAAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg20893579	chr22:38215064	NA	-0.52	-5.48	-0.41	1.73e-7	Glioblastoma;Glioma;
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.67	-6.7	-0.48	3.79e-10	Blood metabolite levels;
PAAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg10818794	chr15:86012489	AKAP13	-0.57	-4.61	-0.35	8.31e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16930980	chr8:104427069	SLC25A32;DCAF13	0.61	6.93	0.49	1.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.42	-4.33	-0.33	2.7e-5	Aortic root size;
PAAD	cis	rs7752195	0.643	rs76266945	chr6:25240510	G/A	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg06569542	chr10:98946673	SLIT1	-0.51	-5.77	-0.42	4.31e-8	Monocyte count;
PAAD	cis	rs2242420	0.920	rs829406	chr1:21949462	A/G	cg04297819	chr1:22260125	HSPG2	0.5	4.51	0.34	1.32e-5	Hematological and biochemical traits;
PAAD	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9810890	1.000	rs73198823	chr3:128484405	G/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg07075026	chr17:47091521	IGF2BP1	0.39	5.08	0.38	1.11e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11332441	chr11:134122771	THYN1;ACAD8	-0.7	-6.44	-0.46	1.47e-9	Neuroticism;
PAAD	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.88	10.04	0.63	1.64e-18	Gout;
PAAD	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	4.72	0.36	5.21e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg00990874	chr7:1149470	C7orf50	-0.74	-5.78	-0.42	4.04e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.41	-5.23	-0.39	5.41e-7	Ulcerative colitis;
PAAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.09	-8.47	-0.57	1.95e-14	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg05484376	chr2:27715224	FNDC4	-0.43	-4.33	-0.33	2.65e-5	Oral cavity cancer;
PAAD	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg02404636	chr22:31891804	SFI1	0.63	5.82	0.43	3.33e-8	Colorectal cancer;
PAAD	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-5.7	-0.42	6.12e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1008126	0.600	rs2041006	chr7:103130805	A/G	cg04218035	chr7:103086829	SLC26A5	0.32	4.44	0.34	1.7e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg27094323	chr7:1216898	NA	0.44	5.13	0.38	8.67e-7	Longevity;Endometriosis;
PAAD	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs458685	0.636	rs456466	chr21:31185292	C/T	cg24620508	chr21:31310605	GRIK1	0.48	4.62	0.35	8.25e-6	Breast cancer;
PAAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-4.73	-0.36	5.14e-6	Gut microbiome composition (summer);
PAAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg16928487	chr17:17741425	SREBF1	0.33	4.25	0.33	3.72e-5	Total body bone mineral density;
PAAD	cis	rs72901758	0.739	rs72901754	chr17:76244398	G/A	cg26068271	chr17:76253126	NA	0.56	5.57	0.41	1.15e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg17372657	chr7:1216933	NA	-0.39	-5.11	-0.38	9.44e-7	Longevity;Endometriosis;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg15691649	chr6:25882328	NA	-0.54	-5.09	-0.38	1.05e-6	Blood metabolite levels;
PAAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.8	0.43	3.69e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.38	0.4	2.73e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg08999081	chr20:33150536	PIGU	-0.49	-5.34	-0.4	3.27e-7	Height;
PAAD	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg16898833	chr6:26189333	HIST1H4D	0.92	5.15	0.39	8.05e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg21724239	chr8:58056113	NA	0.65	5.0	0.38	1.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs738321	0.658	rs5756916	chr22:38507047	G/A	cg25457927	chr22:38595422	NA	-0.43	-6.17	-0.45	5.88e-9	Breast cancer;
PAAD	cis	rs1105228	1.000	rs1105228	chr6:165706473	T/C	cg20535254	chr6:165714960	C6orf118	0.5	5.07	0.38	1.16e-6	Number of pregnancies;Number of children;
PAAD	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg04850286	chr10:81895943	PLAC9	0.39	4.54	0.35	1.12e-5	Sarcoidosis;
PAAD	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg20169779	chr10:135381914	SYCE1	-0.75	-7.55	-0.52	3.84e-12	Gout;
PAAD	cis	rs6142102	0.580	rs4911139	chr20:32551535	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	4.95	0.37	1.98e-6	Skin pigmentation;
PAAD	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06307176	chr5:131281290	NA	0.54	4.67	0.35	6.67e-6	Life satisfaction;
PAAD	cis	rs1561176	0.830	rs11773201	chr7:154994653	G/A	cg08570118	chr7:155025533	NA	-0.49	-4.57	-0.35	9.88e-6	Personality dimensions;
PAAD	cis	rs9463078	0.838	rs9357470	chr6:45065613	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.56	-0.41	1.2e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg04450456	chr4:17643702	FAM184B	0.48	5.01	0.38	1.5e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58521262	0.556	rs55793718	chr19:23143098	A/T	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg13798575	chr9:95087839	CENPP;NOL8	0.47	4.3	0.33	3.09e-5	Height;
PAAD	cis	rs7631605	0.905	rs1399178	chr3:37258669	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.46e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs600231	0.554	rs1346	chr11:65337251	A/T	cg17120908	chr11:65337727	SSSCA1	-0.78	-6.69	-0.48	3.97e-10	Bone mineral density;
PAAD	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-4.29	-0.33	3.15e-5	Diabetic retinopathy;
PAAD	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg25251562	chr2:3704773	ALLC	-0.44	-5.06	-0.38	1.18e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23249710	chr6:117996544	NUS1	0.63	6.71	0.48	3.67e-10	Myopia (pathological);
PAAD	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-5.66	-0.42	7.29e-8	Colorectal cancer;
PAAD	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.69	7.0	0.49	7.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-4.52	-0.34	1.25e-5	Lung cancer;
PAAD	trans	rs901683	1.000	rs35670420	chr10:46088052	T/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs73419609	1.000	rs8028590	chr15:54742357	G/A	cg11288833	chr15:55489084	RSL24D1	-1.0	-4.34	-0.33	2.57e-5	Post-traumatic stress disorder;
PAAD	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg27494647	chr7:150038898	RARRES2	0.43	4.34	0.33	2.58e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.6	7.25	0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs2092319	0.649	rs2744773	chr1:26063043	G/A	cg02327719	chr1:26185386	C1orf135	-0.85	-4.9	-0.37	2.4e-6	Nose morphology;
PAAD	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg00666640	chr1:248458726	OR2T12	0.57	4.67	0.35	6.48e-6	Common traits (Other);
PAAD	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg12486944	chr17:80159399	CCDC57	-0.49	-4.31	-0.33	2.98e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs743757	0.557	rs2236950	chr3:50420554	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	4.79	0.36	3.86e-6	Diastolic blood pressure;
PAAD	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg01528321	chr10:82214614	TSPAN14	0.52	4.64	0.35	7.47e-6	Sarcoidosis;
PAAD	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg21466736	chr12:48725269	NA	-0.49	-4.52	-0.34	1.25e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.43	-0.34	1.77e-5	Testicular germ cell tumor;
PAAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.36	0.33	2.36e-5	Renal cell carcinoma;
PAAD	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.85	6.86	0.49	1.67e-10	Axial length;
PAAD	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg13590414	chr9:128173245	NA	-0.46	-4.68	-0.35	6.4e-6	Mean arterial pressure;
PAAD	cis	rs56309584	0.755	rs58532865	chr17:8139760	T/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.44	-4.43	-0.34	1.76e-5	Initial pursuit acceleration;
PAAD	cis	rs600550	0.588	rs2304934	chr11:60102396	A/G	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg04154034	chr17:28927549	LRRC37B2	0.67	4.27	0.33	3.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg00522288	chr12:125625016	AACS	-0.53	-5.63	-0.42	8.63e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs332507	0.830	rs2173852	chr3:124420102	C/G	cg05980111	chr3:124395277	KALRN	-0.42	-4.3	-0.33	3.06e-5	Plateletcrit;
PAAD	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg01868782	chr6:126071099	HEY2	0.36	4.25	0.33	3.77e-5	Brugada syndrome;
PAAD	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	1.54	9.47	0.61	5.18e-17	Age-related hearing impairment;
PAAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.75	9.59	0.61	2.58e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.52	0.41	1.41e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7580717	0.815	rs6753112	chr2:232187155	C/T	cg07929768	chr2:232055508	NA	0.38	5.33	0.4	3.55e-7	Multiple myeloma;
PAAD	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.47	4.54	0.35	1.15e-5	Crohn's disease;
PAAD	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-6.14	-0.45	6.89e-9	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs863345	0.967	rs1491196	chr1:158505506	T/A	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	1.02e-6	Pneumococcal bacteremia;
PAAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs35740288	0.618	rs11630755	chr15:86108737	A/G	cg07943548	chr15:86304357	KLHL25	-0.57	-5.88	-0.43	2.48e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs7598759	0.712	rs7424111	chr2:232335966	T/G	cg10034588	chr2:232392055	NMUR1	-0.39	-4.56	-0.35	1.06e-5	Noise-induced hearing loss;
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg07061783	chr6:25882402	NA	-0.49	-4.37	-0.33	2.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg27121462	chr16:89883253	FANCA	0.47	5.1	0.38	1.01e-6	Vitiligo;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.01	0.81	5.21e-37	Prudent dietary pattern;
PAAD	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg20243544	chr17:37824526	PNMT	0.5	4.38	0.33	2.19e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2139634	0.965	rs3934896	chr3:46527028	A/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.39	0.34	2.09e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.62	-5.15	-0.39	7.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.56	-5.72	-0.42	5.6e-8	Total body bone mineral density;
PAAD	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg23752985	chr2:85803571	VAMP8	0.55	6.21	0.45	4.72e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-5.68	-0.42	6.69e-8	Subjective well-being;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08462117	chr11:62432583	SNORA57;C11orf48;METTL12	0.59	6.65	0.47	4.94e-10	Metabolite levels  (X-11787);
PAAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg14393609	chr7:65229607	NA	-0.66	-7.28	-0.51	1.69e-11	Aortic root size;
PAAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.52	-7.6	-0.52	2.81e-12	Diastolic blood pressure;
PAAD	cis	rs12780845	0.931	rs11818636	chr10:17244898	C/T	cg00857480	chr10:17188594	TRDMT1	0.35	4.35	0.33	2.52e-5	Homocysteine levels;
PAAD	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	4.96	0.37	1.88e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20248954	chr1:202896457	KLHL12	0.59	6.8	0.48	2.27e-10	Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22210565	chr10:88281727	WAPAL	0.65	6.75	0.48	2.92e-10	Myopia (pathological);
PAAD	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.56	5.27	0.39	4.57e-7	Electroencephalogram traits;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18621852	chr3:10150065	C3orf24	-0.67	-5.8	-0.43	3.69e-8	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	cis	rs6604026	0.656	rs7417198	chr1:93391445	T/C	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg05110241	chr16:68378359	PRMT7	-0.94	-7.41	-0.52	8.1e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.48	-5.17	-0.39	7.2e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	6.83e-6	Coronary artery disease;
PAAD	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.18	17.2	0.81	1.75e-37	IgG glycosylation;
PAAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15128208	chr22:42549153	NA	0.43	4.41	0.34	1.94e-5	Cognitive function;
PAAD	cis	rs12612619	0.579	rs6753540	chr2:27080134	G/A	cg12368169	chr2:27073192	DPYSL5	-0.42	-4.32	-0.33	2.79e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg18551225	chr6:44695536	NA	-0.69	-7.05	-0.5	6.01e-11	Total body bone mineral density;
PAAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg17372223	chr3:52568218	NT5DC2	0.5	4.84	0.37	3.21e-6	Bipolar disorder;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg18279126	chr7:2041391	MAD1L1	0.6	5.9	0.43	2.28e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.75	0.66	2.18e-20	Bladder cancer;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1371614	0.632	rs3820823	chr2:27164806	C/T	cg00617064	chr2:27272375	NA	-0.4	-4.3	-0.33	2.99e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.91	10.24	0.64	4.94e-19	Total cholesterol levels;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7631605	0.905	rs9755599	chr3:37208192	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs16958440	1.000	rs62096471	chr18:44643814	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.47	4.44	0.34	1.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg13918804	chr1:2043761	PRKCZ	0.43	5.84	0.43	3.03e-8	Height;
PAAD	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg01557791	chr16:72042693	DHODH	-0.64	-6.1	-0.44	8.43e-9	Fibrinogen levels;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs258892	0.895	rs13164198	chr5:72051641	G/T	cg21869765	chr5:72125136	TNPO1	0.82	5.56	0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10029851	0.645	rs9996443	chr4:109619590	C/A	cg16525761	chr4:109541525	LOC285456;RPL34	-0.48	-4.49	-0.34	1.41e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10186876	0.728	rs13384238	chr2:44155986	A/G	cg09541576	chr2:44873248	C2orf34	-0.43	-4.52	-0.34	1.26e-5	Hand grip strength;
PAAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	6.84e-7	Pulmonary function;
PAAD	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18621852	chr3:10150065	C3orf24	0.68	5.94	0.43	1.89e-8	Alzheimer's disease;
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg05132306	chr1:1846340	CALML6	-0.43	-5.04	-0.38	1.3e-6	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06976003	chr16:4897242	UBN1;GLYR1	-0.76	-8.02	-0.55	2.59e-13	Smoking initiation;
PAAD	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg05820861	chr13:24882296	C1QTNF9	-0.44	-4.42	-0.34	1.88e-5	Obesity-related traits;
PAAD	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03611598	chr17:48586076	MYCBPAP	0.58	5.47	0.41	1.83e-7	Visceral fat;
PAAD	cis	rs7896471	0.546	rs7904171	chr10:101745560	T/G	cg10536120	chr10:101380212	SLC25A28	0.92	4.28	0.33	3.28e-5	Blood protein levels;
PAAD	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.92	9.84	0.62	5.42e-18	Corneal astigmatism;
PAAD	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg14583973	chr4:3374767	RGS12	0.37	5.72	0.42	5.43e-8	Serum sulfate level;
PAAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg05250797	chr16:70222502	NA	0.81	6.12	0.44	7.79e-9	IgE levels;
PAAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg09835421	chr16:68378352	PRMT7	-1.02	-7.62	-0.53	2.51e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1349882	0.588	rs1454383	chr2:52919630	C/A	cg08239893	chr2:52221668	NA	0.39	4.41	0.34	1.92e-5	Asymmetrical dimethylarginine levels;
PAAD	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg19197139	chr17:4613644	ARRB2	-0.84	-8.7	-0.58	5.06e-15	Lymphocyte counts;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg06114765	chr21:17102990	USP25	0.58	6.61	0.47	6.15e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09835421	chr16:68378352	PRMT7	1.19	8.27	0.56	6.07e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs9315702	0.934	rs9315701	chr13:40117992	A/G	cg26881651	chr13:39327640	FREM2	0.34	4.25	0.33	3.78e-5	Hippocampal atrophy;
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	1.08	15.33	0.78	1.2e-32	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.54	5.4	0.4	2.54e-7	Lung cancer;
PAAD	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.5	-5.58	-0.41	1.09e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.48	-4.73	-0.36	5.18e-6	Height;
PAAD	cis	rs375066	0.935	rs423752	chr19:44423195	G/A	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.26	-0.51	1.85e-11	Neuroticism;
PAAD	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.41	-0.34	1.93e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg18582342	chr19:11591989	ELAVL3	-0.74	-5.85	-0.43	2.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.97	6.79	0.48	2.41e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg15764593	chr10:829463	NA	-0.75	-5.98	-0.44	1.54e-8	Uric acid levels;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.18e-18	Cognitive function;
PAAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs4662592	0.554	rs11675183	chr2:128859082	A/G	cg17144508	chr2:128283727	IWS1	-0.54	-4.4	-0.34	2.07e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-1.35	-11.15	-0.67	1.85e-21	Obesity-related traits;
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.89	12.21	0.7	2.57e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.2	0.55	9.49e-14	Coffee consumption (cups per day);
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Breast cancer;
PAAD	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.64	-0.35	7.42e-6	Personality dimensions;
PAAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14180030	chr9:123475675	MEGF9	-0.46	-5.07	-0.38	1.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.5	-4.52	-0.34	1.25e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.24	-0.51	2.13e-11	Gut microbiome composition (summer);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26607991	chr16:669235	RAB40C	0.69	7.81	0.54	8.77e-13	Smoking initiation;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg19337854	chr7:99768885	GPC2	0.55	5.03	0.38	1.34e-6	Platelet count;
PAAD	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	5.91	0.43	2.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.97	0.49	8.99e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.77	-7.43	-0.52	7.32e-12	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.7	9.41	0.61	7.6e-17	Hemoglobin concentration;
PAAD	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg21855830	chr2:127963489	CYP27C1	0.46	4.38	0.34	2.16e-5	Protein C levels;
PAAD	cis	rs11811982	0.793	rs79235719	chr1:227510167	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21010031	chr14:79181274	NRXN3	-0.56	-6.3	-0.46	3.09e-9	Obesity-related traits;
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16434002	chr17:42200994	HDAC5	0.67	7.35	0.51	1.13e-11	Total body bone mineral density;
PAAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.43	-4.33	-0.33	2.68e-5	Vitiligo;
PAAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.97	11.1	0.67	2.47e-21	Parkinson's disease;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg02462569	chr6:150064036	NUP43	-0.49	-5.2	-0.39	6.31e-7	Lung cancer;
PAAD	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.76	4.31	0.33	2.93e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00240809	chr16:8715546	C16orf68	0.63	6.61	0.47	6.15e-10	Myopia (pathological);
PAAD	cis	rs12681288	1.000	rs2167505	chr8:1033877	A/C	cg04851639	chr8:1020857	NA	-0.64	-7.75	-0.53	1.24e-12	Schizophrenia;
PAAD	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs7301826	0.610	rs36051740	chr12:131292722	G/A	cg11011512	chr12:131303247	STX2	-0.46	-4.76	-0.36	4.5e-6	Plasma plasminogen activator levels;
PAAD	cis	rs7646881	0.767	rs73015669	chr3:158456318	C/A	cg19483011	chr3:158453295	NA	-0.72	-5.87	-0.43	2.63e-8	Tetralogy of Fallot;
PAAD	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	1.2	13.21	0.73	4.96e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg05627522	chr15:75251581	NA	0.47	5.43	0.4	2.15e-7	Breast cancer;
PAAD	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs300774	0.925	rs424939	chr2:128894	C/T	cg23649280	chr2:140451	NA	-0.46	-4.3	-0.33	3.02e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.82	-6.71	-0.48	3.55e-10	Initial pursuit acceleration;
PAAD	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg06569542	chr10:98946673	SLIT1	-0.52	-5.84	-0.43	3.01e-8	Monocyte count;
PAAD	cis	rs6844506	0.565	rs1087300	chr4:185226003	T/C	cg12654155	chr4:185238627	NA	-0.46	-4.44	-0.34	1.69e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.52	4.91	0.37	2.37e-6	Aortic root size;
PAAD	cis	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg04907244	chr7:22894795	SNORD93	-0.38	-4.37	-0.33	2.31e-5	Fibrinogen;
PAAD	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg23950597	chr19:37808831	NA	-0.76	-5.13	-0.38	8.56e-7	Coronary artery calcification;
PAAD	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.65	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26612217	chr16:21289750	CRYM	-0.71	-6.44	-0.46	1.49e-9	Neuroticism;
PAAD	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.84	10.63	0.65	4.34e-20	Heart rate;
PAAD	cis	rs4356203	0.905	rs214937	chr11:17189552	T/C	cg15432903	chr11:17409602	KCNJ11	0.42	4.39	0.34	2.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.49	4.58	0.35	9.6e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.52	5.13	0.38	8.77e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.36	0.56	3.79e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.52e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg00376283	chr12:123451042	ABCB9	0.69	6.46	0.46	1.36e-9	Platelet count;
PAAD	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.1	-0.38	9.77e-7	Mean corpuscular volume;
PAAD	cis	rs10121009	0.565	rs10758306	chr9:35431152	C/T	cg11846315	chr9:35647073	NA	-0.48	-4.3	-0.33	3.06e-5	Parkinson's disease;
PAAD	cis	rs360071	0.528	rs360097	chr1:226065755	C/A	cg25552768	chr1:226077287	LEFTY1	0.44	4.6	0.35	8.92e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs501120	0.850	rs642222	chr10:44770473	A/G	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.19	-0.55	9.88e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3136441	1.000	rs58561056	chr11:46728971	T/G	cg19486271	chr11:47235900	DDB2	0.64	4.83	0.36	3.37e-6	HDL cholesterol;
PAAD	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg09168692	chr1:7887560	PER3	-0.46	-4.4	-0.34	2.02e-5	Inflammatory bowel disease;
PAAD	cis	rs4965869	0.866	rs4965866	chr15:101975931	C/T	cg12371147	chr15:101978424	PCSK6	-0.5	-4.42	-0.34	1.9e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.35	0.8	2.65e-35	Prudent dietary pattern;
PAAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg24733560	chr20:60626293	TAF4	0.39	4.33	0.33	2.67e-5	Body mass index;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15831653	chr10:22292874	DNAJC1	0.48	5.57	0.41	1.13e-7	Monocyte percentage of white cells;
PAAD	cis	rs1865721	0.761	rs62089540	chr18:73218332	G/A	cg26385618	chr18:73139727	C18orf62	-0.45	-5.25	-0.39	4.98e-7	Intelligence;
PAAD	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.72	9.06	0.59	5.9e-16	Dupuytren's disease;
PAAD	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg10183150	chr4:120222239	C4orf3	-0.41	-5.67	-0.42	7.14e-8	Corneal astigmatism;
PAAD	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.51	5.32	0.4	3.57e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.82	-9.8	-0.62	7.24e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.55	-4.98	-0.37	1.7e-6	Menopause (age at onset);
PAAD	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg10596483	chr8:143751796	JRK	-0.48	-4.25	-0.33	3.76e-5	Urinary tract infection frequency;
PAAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.06	-0.44	1.02e-8	Personality dimensions;
PAAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.31	0.33	2.9e-5	Renal cell carcinoma;
PAAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs60154123	0.504	rs4844997	chr1:210486895	A/G	cg22029157	chr1:209979665	IRF6	0.68	5.92	0.43	2.06e-8	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08715135	chr8:126442747	TRIB1	0.56	6.53	0.47	9.1e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	4.43	0.34	1.76e-5	Hip circumference;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27175069	chr19:52395190	ZNF649	-0.58	-6.96	-0.49	9.32e-11	Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg08888203	chr3:10149979	C3orf24	1.08	7.81	0.54	8.69e-13	Alzheimer's disease;
PAAD	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.64	-5.64	-0.42	8.23e-8	Ovarian cancer in BRCA1 mutation carriers;
PAAD	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg12568669	chr8:11666485	FDFT1	0.26	4.35	0.33	2.52e-5	Neuroticism;
PAAD	cis	rs2124910	1.000	rs10419617	chr19:52031648	A/G	cg12008991	chr19:52034861	SIGLEC6	0.38	5.07	0.38	1.12e-6	Blood protein levels;
PAAD	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs2279817	0.735	rs71644064	chr1:18000044	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-5.68	-0.42	6.54e-8	Neuroticism;
PAAD	cis	rs12989701	1.000	rs13004848	chr2:127887560	C/T	cg08168897	chr2:127865431	BIN1	-0.63	-5.03	-0.38	1.38e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7071247	1.000	rs7071247	chr10:105257786	G/T	cg14553436	chr10:104822996	CNNM2	0.67	4.72	0.36	5.35e-6	Platelet aggregation;
PAAD	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.72	7.45	0.52	6.61e-12	Type 2 diabetes;
PAAD	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.78e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg01763666	chr17:80159506	CCDC57	0.42	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg17868515	chr10:100992068	HPSE2	-0.38	-4.46	-0.34	1.59e-5	Metabolite levels;
PAAD	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg10820045	chr2:198174542	NA	-0.43	-4.35	-0.33	2.47e-5	Dermatomyositis;
PAAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg13332499	chr17:408570	NA	0.63	6.9	0.49	1.28e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	6.66	0.48	4.8e-10	Lung function (FEV1/FVC);
PAAD	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.49	4.4	0.34	2.03e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.86	9.76	0.62	9.01e-18	Tonsillectomy;
PAAD	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.74	7.79	0.53	9.92e-13	Lung cancer;
PAAD	cis	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg22863700	chr5:28928346	NA	0.53	4.99	0.38	1.65e-6	Hip geometry;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24106040	chr1:44612654	NA	-0.63	-6.57	-0.47	7.62e-10	Obesity-related traits;
PAAD	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg05791153	chr7:19748676	TWISTNB	0.66	5.12	0.38	8.99e-7	Thyroid stimulating hormone;
PAAD	cis	rs287982	1.000	rs287976	chr2:9969688	G/T	cg01119585	chr2:10571959	NA	-0.38	-4.39	-0.34	2.08e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.57	5.77	0.42	4.37e-8	Ovarian reserve;
PAAD	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.77	-6.76	-0.48	2.8e-10	Exhaled nitric oxide output;
PAAD	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.72	6.71	0.48	3.65e-10	Obesity-related traits;
PAAD	cis	rs5417	0.775	rs367181	chr17:7160524	A/C	cg14660024	chr17:7154518	C17orf81;DULLARD	0.64	6.92	0.49	1.16e-10	Diastolic blood pressure;
PAAD	cis	rs11158559	0.865	rs911001	chr14:65240485	C/T	cg22797773	chr14:65239943	SPTB	-0.52	-4.3	-0.33	3.03e-5	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.75	-8.65	-0.57	7.01e-15	Prostate cancer;
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.57	7.6	0.52	2.76e-12	Hypertriglyceridemia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12927153	chr9:125133318	PTGS1	-0.78	-6.87	-0.49	1.52e-10	Neuroticism;
PAAD	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.72	7.47	0.52	5.75e-12	Body mass index;
PAAD	cis	rs4455778	0.580	rs6952050	chr7:49116354	A/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs7638995	0.583	rs75436443	chr3:69187535	C/T	cg26574240	chr3:69171822	LMOD3	-0.81	-4.74	-0.36	4.83e-6	Alzheimer's disease (late onset);
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04717802	chr22:42394638	WBP2NL	-0.42	-4.46	-0.34	1.56e-5	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24282422	chr3:125239067	SNX4	0.73	7.77	0.53	1.11e-12	Obesity-related traits;
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg19337854	chr7:99768885	GPC2	0.55	5.08	0.38	1.1e-6	Platelet count;
PAAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.29e-5	Iron status biomarkers;
PAAD	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg24585817	chr7:64895279	NA	0.45	4.45	0.34	1.66e-5	Aortic root size;
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg07362569	chr17:61921086	SMARCD2	0.43	4.83	0.37	3.24e-6	Height;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.55	4.78	0.36	4.05e-6	Acylcarnitine levels;
PAAD	cis	rs7070678	0.638	rs61849287	chr10:29795756	C/T	cg24726783	chr10:29759454	SVIL	-0.48	-4.58	-0.35	9.55e-6	Platelet thrombus formation;
PAAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	1.07	14.87	0.77	1.86e-31	Breast cancer;
PAAD	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg21419209	chr3:44054225	NA	-0.73	-7.61	-0.53	2.73e-12	Coronary artery disease;
PAAD	cis	rs9652601	0.691	rs7186145	chr16:11210878	G/A	cg04616529	chr16:11181986	CLEC16A	0.35	4.31	0.33	2.96e-5	Systemic lupus erythematosus;
PAAD	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.56	-6.19	-0.45	5.25e-9	Metabolite levels;
PAAD	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.91	-6.57	-0.47	7.42e-10	Blood protein levels;
PAAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg00531865	chr16:30841666	NA	0.6	4.49	0.34	1.38e-5	Dementia with Lewy bodies;
PAAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs34734847	0.933	rs7975067	chr12:121099454	G/A	cg27246729	chr12:121163418	ACADS	0.41	4.28	0.33	3.25e-5	Mean corpuscular volume;
PAAD	cis	rs8067287	0.554	rs56092540	chr17:16841417	C/T	cg26910001	chr17:16838321	NA	-0.58	-5.19	-0.39	6.79e-7	Diabetic kidney disease;
PAAD	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.79	-5.34	-0.4	3.4e-7	Coronary artery calcification;
PAAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.74	8.87	0.58	1.82e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6496932	1.000	rs4842872	chr15:85828056	C/T	cg19183879	chr15:85880815	NA	0.55	4.64	0.35	7.45e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.43	4.41	0.34	1.96e-5	Sarcoidosis;
PAAD	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.16	17.83	0.82	4.27e-39	Cognitive function;
PAAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24229701	chr12:130821962	PIWIL1	0.41	4.29	0.33	3.21e-5	Menopause (age at onset);
PAAD	cis	rs12776158	0.901	rs12414678	chr10:71214669	C/T	cg12610070	chr10:71211762	TSPAN15	-0.5	-4.79	-0.36	3.96e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.84	9.23	0.6	2.15e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs901683	0.850	rs77364880	chr10:45996100	G/A	cg13065504	chr15:42448234	PLA2G4F	0.83	6.45	0.46	1.43e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.51	-5.94	-0.43	1.91e-8	Mean arterial pressure;
PAAD	cis	rs7567389	0.504	rs41280570	chr2:128176230	C/T	cg09760422	chr2:128146352	NA	0.4	5.99	0.44	1.43e-8	Self-rated health;
PAAD	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	7.14	0.5	3.63e-11	IgG glycosylation;
PAAD	cis	rs8062405	0.573	rs7140	chr16:28995757	C/A	cg16576597	chr16:28551801	NUPR1	-0.56	-5.31	-0.4	3.74e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg05337019	chr1:16062361	SLC25A34	-0.51	-4.26	-0.33	3.5e-5	Systolic blood pressure;
PAAD	cis	rs42648	0.518	rs12535435	chr7:89830817	G/A	cg27367526	chr7:89841692	STEAP2	-0.32	-4.5	-0.34	1.37e-5	Homocysteine levels;
PAAD	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.54	5.52	0.41	1.43e-7	Resting heart rate;
PAAD	cis	rs6681460	1.000	rs6659968	chr1:67123459	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.85e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.95	7.23	0.51	2.22e-11	Alzheimer's disease;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg16205897	chr5:131564050	P4HA2	-0.43	-4.51	-0.34	1.3e-5	Acylcarnitine levels;
PAAD	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	0.94	8.81	0.58	2.69e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg00325661	chr8:49890786	NA	-0.54	-5.16	-0.39	7.54e-7	Blood metabolite levels;
PAAD	cis	rs9549328	0.837	rs4907572	chr13:113647321	G/A	cg25790453	chr13:113633590	MCF2L	-0.4	-4.69	-0.36	6.03e-6	Systolic blood pressure;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.61	7.37	0.51	1.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg10534938	chr5:1868639	NA	0.48	6.29	0.45	3.23e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg09491104	chr22:46646882	C22orf40	-0.92	-5.99	-0.44	1.44e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg23732368	chr3:48936262	SLC25A20	-0.53	-4.53	-0.34	1.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2898681	0.874	rs6852148	chr4:53750002	T/C	cg00791764	chr4:53727839	RASL11B	0.54	4.52	0.34	1.24e-5	Optic nerve measurement (cup area);
PAAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg22753661	chr15:79092743	ADAMTS7	0.51	4.34	0.33	2.62e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.47	-4.94	-0.37	2.02e-6	Platelet count;
PAAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.5	5.36	0.4	3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs7243821	0.847	rs2187412	chr18:52704561	C/T	cg16669619	chr18:52630472	NA	-0.44	-4.64	-0.35	7.61e-6	Chin dimples;
PAAD	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.56	5.36	0.4	2.99e-7	Schizophrenia;
PAAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17910375	chr12:57023577	BAZ2A	0.57	6.44	0.46	1.48e-9	Monocyte percentage of white cells;
PAAD	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	7.05	0.5	5.86e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.6	-8.26	-0.56	6.57e-14	Eye color traits;
PAAD	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.98	11.58	0.68	1.25e-22	Bone mineral density;
PAAD	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	cis	rs2076222	1.000	rs2076352	chr1:209801569	A/G	cg00257659	chr1:209800214	LAMB3	-1.23	-4.86	-0.37	2.9e-6	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
PAAD	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.34	-0.4	3.37e-7	Plateletcrit;
PAAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.57	-4.91	-0.37	2.35e-6	Obesity-related traits;
PAAD	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.14e-5	Testicular germ cell tumor;
PAAD	cis	rs2997447	0.846	rs2997446	chr1:26388241	C/G	cg24519413	chr1:26490540	NA	0.5	4.8	0.36	3.83e-6	QRS complex (12-leadsum);
PAAD	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs75920871	0.925	rs61903421	chr11:116961802	A/T	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	cis	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg25886479	chr11:50257625	LOC441601	-0.45	-4.56	-0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg01815783	chr4:1047043	NA	-0.44	-4.27	-0.33	3.4e-5	Recombination rate (females);
PAAD	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-6.01	-0.44	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg11967457	chr1:226128626	LEFTY2	-0.55	-5.71	-0.42	5.76e-8	Preschool internalizing problems;
PAAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs294958	0.761	rs294960	chr5:151566024	A/G	cg04453665	chr5:151504455	NA	0.45	4.85	0.37	3.07e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg03983476	chr2:10830698	NOL10	0.59	5.97	0.44	1.65e-8	Prostate cancer;
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg25204440	chr1:209979598	IRF6	0.63	5.83	0.43	3.15e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg22143856	chr6:28129313	ZNF389	0.51	4.75	0.36	4.74e-6	Parkinson's disease;
PAAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.96e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.51	-0.41	1.48e-7	Obesity-related traits;
PAAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	0.81	6.49	0.47	1.17e-9	Obesity-related traits;
PAAD	cis	rs12760731	0.623	rs2862378	chr1:178296566	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.2	0.39	6.41e-7	Obesity-related traits;
PAAD	cis	rs8049634	0.732	rs13332770	chr16:84232749	C/T	cg00961177	chr16:84213833	TAF1C	-0.45	-4.64	-0.35	7.38e-6	Small cell lung carcinoma;
PAAD	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.46	-5.24	-0.39	5.32e-7	Cognitive function;
PAAD	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.7	-5.91	-0.43	2.14e-8	Menarche (age at onset);
PAAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-4.46	-0.34	1.56e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg08917208	chr2:24149416	ATAD2B	0.52	4.53	0.34	1.2e-5	Lymphocyte counts;
PAAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	6.92	0.49	1.17e-10	Systemic lupus erythematosus;
PAAD	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.51	5.52	0.41	1.42e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg13919466	chr1:32135498	COL16A1	-0.42	-4.7	-0.36	5.84e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.74	8.18	0.55	1.05e-13	Menopause (age at onset);
PAAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.58	6.47	0.46	1.28e-9	Major depressive disorder;
PAAD	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	5.33	0.4	3.51e-7	Mean platelet volume;
PAAD	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs16895831	0.519	rs61298049	chr6:42540394	T/G	cg10605015	chr6:42532144	UBR2	-0.72	-5.48	-0.41	1.71e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.46	-0.34	1.6e-5	Plateletcrit;Platelet count;
PAAD	cis	rs7260598	0.581	rs116653454	chr19:24063556	A/G	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.9100000000000004e-06	Daytime sleep phenotypes;
PAAD	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.85	-4.57	-0.35	1.02e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.53	-6.07	-0.44	9.98e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg16103732	chr13:86370663	SLITRK6	-0.56	-6.76	-0.48	2.82e-10	Energy expenditure (24h);
PAAD	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	4.95	0.37	1.97e-6	Mood instability;
PAAD	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.53	4.99	0.38	1.64e-6	Eosinophilic esophagitis;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9395066	0.529	rs12529490	chr6:45018251	A/C	cg18551225	chr6:44695536	NA	-0.45	-4.5	-0.34	1.36e-5	Height;
PAAD	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs7534824	0.625	rs61780328	chr1:101458754	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs3764400	0.564	rs12602670	chr17:46104880	T/C	cg24322968	chr17:46507895	SKAP1	0.89	5.47	0.41	1.78e-7	Body mass index;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03923535	chr7:1197113	ZFAND2A	0.47	4.91	0.37	2.29e-6	Longevity;Endometriosis;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.53	-6.61	-0.47	6.21e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs8112211	0.911	rs2286476	chr19:38850759	G/A	cg14299480	chr19:38876666	GGN	-0.61	-7.73	-0.53	1.36e-12	Blood protein levels;
PAAD	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.12	0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg27394845	chr17:28928406	LRRC37B2	0.67	4.59	0.35	9.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs469568	0.543	rs11743204	chr5:178671014	T/C	cg08999896	chr5:178685787	ADAMTS2	0.55	5.67	0.42	6.82e-8	Stroke (pediatric);
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.71	-0.36	5.55e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs732765	0.689	rs8019690	chr14:75135142	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.44	-0.34	1.71e-5	Non-small cell lung cancer;
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.59	-4.59	-0.35	9.26e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs939584	1.000	rs5017300	chr2:631099	C/G	cg03610516	chr2:642275	NA	0.59	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg06815965	chr1:205818668	PM20D1	0.61	6.81	0.48	2.14e-10	Menarche (age at onset);
PAAD	cis	rs864537	1.000	rs840016	chr1:167408670	C/T	cg12184421	chr1:167409136	CD247	0.39	4.39	0.34	2.1e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	9.07	0.59	5.57e-16	Ulcerative colitis;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.53	4.45	0.34	1.68e-5	Systolic blood pressure;
PAAD	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg02478829	chr6:26598070	ABT1	-0.47	-4.67	-0.35	6.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg12633918	chr20:23549525	CST9L	0.44	4.88	0.37	2.68e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg24699146	chr1:24152579	HMGCL	0.55	5.84	0.43	3.1e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1126510	0.860	rs3760757	chr19:47129570	A/G	cg07844738	chr19:47129343	PTGIR	0.43	5.08	0.38	1.11e-6	Ulcerative colitis;
PAAD	cis	rs2446066	0.872	rs10876450	chr12:53811034	C/T	cg23431730	chr12:53887070	MAP3K12	0.63	4.58	0.35	9.46e-6	Red blood cell count;
PAAD	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.74	-0.36	4.86e-6	Total body bone mineral density;
PAAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.91	-8.65	-0.57	6.92e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg01489032	chr8:143877656	NA	-0.39	-4.46	-0.34	1.61e-5	Urinary tract infection frequency;
PAAD	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.21	0.39	5.98e-7	Educational attainment;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.82	-5.78	-0.42	4.13e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs863345	0.604	rs2873593	chr1:158504711	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg09127314	chr1:152161683	NA	-0.67	-4.66	-0.35	6.72e-6	Atopic dermatitis;
PAAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	4.41	0.34	1.91e-5	Platelet count;
PAAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.63	7.12	0.5	4.1e-11	Emphysema distribution in smoking;
PAAD	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.39	-0.64	1.91e-19	Heart rate;
PAAD	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg06636372	chr16:89349979	ANKRD11	-0.8	-4.91	-0.37	2.36e-6	Red blood cell count;
PAAD	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02071572	chr4:1403502	NA	0.48	6.31	0.46	2.83e-9	Longevity;
PAAD	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg06131755	chr6:160182447	ACAT2	0.52	4.33	0.33	2.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg21130718	chr4:1044621	NA	0.47	4.55	0.35	1.07e-5	Recombination rate (males);
PAAD	cis	rs16854884	0.710	rs1530479	chr3:143819653	C/T	cg06585982	chr3:143692056	C3orf58	0.53	4.98	0.37	1.74e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.69	-0.36	6.09e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3764400	0.564	rs1452663	chr17:46293386	C/G	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg10616300	chr11:66138557	SLC29A2	0.34	4.66	0.35	6.92e-6	Educational attainment (years of education);
PAAD	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg21565972	chr17:80109576	CCDC57	0.58	6.74	0.48	3.07e-10	Life satisfaction;
PAAD	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.48	4.46	0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.1	-0.5	4.55e-11	Gut microbiome composition (summer);
PAAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg09491104	chr22:46646882	C22orf40	-0.96	-9.19	-0.6	2.84e-16	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg10183150	chr4:120222239	C4orf3	-0.39	-5.25	-0.39	5.02e-7	Corneal astigmatism;
PAAD	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.58	5.68	0.42	6.6e-8	Bone properties (heel);
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02071572	chr4:1403502	NA	0.35	4.5	0.34	1.35e-5	Obesity-related traits;
PAAD	cis	rs597480	0.825	rs34525642	chr11:85511501	C/T	cg11817631	chr11:85522609	SYTL2	0.44	4.35	0.33	2.53e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-5.88	-0.43	2.56e-8	Personality dimensions;
PAAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.56	0.41	1.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg11062466	chr8:58055876	NA	0.69	5.18	0.39	6.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg27394845	chr17:28928406	LRRC37B2	0.62	4.44	0.34	1.71e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg14196790	chr5:131705035	SLC22A5	0.44	4.77	0.36	4.31e-6	Blood metabolite levels;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.9	11.51	0.68	1.93e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg21565972	chr17:80109576	CCDC57	-0.6	-6.98	-0.49	8.72e-11	Life satisfaction;
PAAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.75	7.82	0.54	8.43e-13	Height;
PAAD	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.54	-4.78	-0.36	4.01e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.6	6.2	0.45	5.19e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg08975724	chr8:8085496	FLJ10661	0.5	4.91	0.37	2.37e-6	Mood instability;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14241672	chr4:1714399	SLBP	0.62	6.63	0.47	5.48e-10	Myopia (pathological);
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg17541715	chr7:1216824	NA	-0.4	-4.41	-0.34	1.97e-5	Longevity;Endometriosis;
PAAD	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-12.71	-0.72	1.14e-25	Schizophrenia;
PAAD	cis	rs877529	0.967	rs139406	chr22:39551798	T/C	cg18708252	chr22:39545030	CBX7	-0.45	-4.37	-0.33	2.3e-5	Multiple myeloma;
PAAD	cis	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02384565	chr11:64578173	MEN1	0.64	6.45	0.46	1.42e-9	Myopia (pathological);
PAAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.94	12.37	0.71	9.43e-25	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18621852	chr3:10150065	C3orf24	0.63	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs116979167	0.575	rs818470	chr7:105165350	A/C	cg02135003	chr7:105160482	PUS7	-0.73	-6.38	-0.46	2.07e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11696501	0.843	rs6073768	chr20:44130146	A/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-5.73	-0.42	5.25e-8	Brain structure;
PAAD	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg13332499	chr17:408570	NA	0.72	9.32	0.6	1.29e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg06629702	chr1:2706960	NA	0.36	4.31	0.33	2.92e-5	Ulcerative colitis;
PAAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.64	6.86	0.49	1.59e-10	Leprosy;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.74	6.58	0.47	7.05e-10	Bronchopulmonary dysplasia;
PAAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.81	9.18	0.6	2.97e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs943072	0.834	rs10948096	chr6:43784803	A/G	cg01075005	chr6:42879409	NA	0.63	4.6	0.35	8.98e-6	Ulcerative colitis;
PAAD	cis	rs3996993	0.809	rs4715326	chr6:52657552	C/T	cg20803780	chr6:52668592	GSTA1	-0.35	-4.5	-0.34	1.37e-5	Hemoglobin concentration;
PAAD	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.55	-4.98	-0.37	1.7e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg21782813	chr7:2030301	MAD1L1	0.57	6.25	0.45	3.98e-9	Testicular germ cell tumor;
PAAD	cis	rs9463078	0.565	rs3799973	chr6:44823727	G/A	cg25276700	chr6:44698697	NA	0.45	5.43	0.4	2.24e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12760731	0.565	rs12027723	chr1:178090271	A/T	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg01362358	chr17:58117360	NA	0.39	4.43	0.34	1.76e-5	Hemoglobin concentration;
PAAD	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg21479132	chr6:26055353	NA	0.85	4.27	0.33	3.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.62	5.07	0.38	1.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2061333	0.557	rs8105860	chr19:44606928	A/G	cg18700516	chr19:44507157	ZNF230	-0.77	-5.55	-0.41	1.24e-7	Alzheimer's disease;
PAAD	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14119001	chr9:139324193	INPP5E	-0.51	-4.86	-0.37	2.88e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.6	5.85	0.43	2.85e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	16.26	0.8	4.49e-35	Prudent dietary pattern;
PAAD	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.63	7.81	0.53	8.91e-13	Educational attainment (years of education);
PAAD	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.11	-0.38	9.5e-7	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14774995	chr8:128841050	PVT1	-0.63	-6.69	-0.48	3.92e-10	Obesity-related traits;
PAAD	cis	rs7172677	0.737	rs58201389	chr15:75446835	G/A	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.7	-0.36	5.78e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6604026	0.656	rs9440134	chr1:93370813	C/T	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25511730	chr15:39696638	NA	0.66	7.34	0.51	1.19e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9581857	0.547	rs927579	chr13:28075079	A/G	cg22138327	chr13:27999177	GTF3A	0.85	5.33	0.4	3.51e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.61	-0.41	9.19e-8	Gut microbiome composition (summer);
PAAD	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg26875137	chr12:53738046	NA	-0.5	-5.02	-0.38	1.46e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.57	6.56	0.47	8.1e-10	Mean corpuscular volume;
PAAD	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg11204139	chr17:3907470	NA	0.68	6.78	0.48	2.47e-10	Type 2 diabetes;
PAAD	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.61	7.04	0.5	6.23e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03605463	chr16:89740564	NA	-0.53	-5.09	-0.38	1.07e-6	Vitiligo;
PAAD	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg18964960	chr10:1102726	WDR37	0.92	4.46	0.34	1.57e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07234876	chr8:600039	NA	1.0	7.73	0.53	1.39e-12	IgG glycosylation;
PAAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-1.11	-16.5	-0.8	1.09e-35	Breast cancer;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.68	-8.88	-0.58	1.71e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs863345	0.967	rs951135	chr1:158531633	A/T	cg12129480	chr1:158549410	OR10X1	0.44	4.95	0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25833597	chr17:30823145	MYO1D	0.52	5.05	0.38	1.23e-6	Schizophrenia;
PAAD	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg25114630	chr15:101792522	CHSY1	0.54	4.78	0.36	4.02e-6	Corneal structure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03563329	chr3:121554012	IQCB1;EAF2	0.65	6.5	0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.98	6.94	0.49	1.09e-10	Eosinophilic esophagitis;
PAAD	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26876637	chr1:152193138	HRNR	0.88	6.93	0.49	1.09e-10	Atopic dermatitis;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.52	-5.47	-0.41	1.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg21665744	chr7:39171113	POU6F2	0.34	4.95	0.37	1.91e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.67	0.53	1.88e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.5	-5.68	-0.42	6.66e-8	Personality dimensions;
PAAD	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg10871876	chr19:53194124	ZNF83	0.56	4.82	0.36	3.47e-6	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.75	-5.53	-0.41	1.33e-7	Coronary artery calcification;
PAAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg14346243	chr4:90757452	SNCA	-0.49	-4.28	-0.33	3.24e-5	Neuroticism;
PAAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.65	-0.35	7.17e-6	Alcohol dependence;
PAAD	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Diabetic kidney disease;
PAAD	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg19442545	chr10:75533431	FUT11	-0.43	-4.36	-0.33	2.36e-5	Inflammatory bowel disease;
PAAD	cis	rs73787773	0.867	rs17651424	chr5:111488600	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.74	-4.38	-0.34	2.16e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10861342	1.000	rs12316054	chr12:105569143	T/C	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.73	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs7752195	0.643	rs80331120	chr6:25204774	G/A	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.71	-8.01	-0.54	2.73e-13	Renal function-related traits (BUN);
PAAD	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-6.04	-0.44	1.14e-8	Lymphocyte counts;
PAAD	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.69	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07648498	chr16:89883185	FANCA	0.7	7.35	0.51	1.13e-11	Vitiligo;
PAAD	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	4.46	0.34	1.6e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7707921	0.881	rs4391141	chr5:81263522	T/A	cg21483461	chr5:81570383	RPS23	-0.55	-4.57	-0.35	9.93e-6	Breast cancer;
PAAD	cis	rs1499972	0.878	rs817512	chr3:117734787	T/C	cg07612923	chr3:117604196	NA	-1.03	-6.73	-0.48	3.29e-10	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12597422	0.522	rs55798112	chr16:53881136	T/C	cg16085531	chr16:54322938	NA	-0.33	-4.5	-0.34	1.34e-5	Eyebrow thickness;
PAAD	trans	rs9345521	0.967	rs4710496	chr6:65515520	C/T	cg26414000	chr1:85721327	C1orf52	0.5	6.32	0.46	2.73e-9	Iris color (a* coordinate);
PAAD	cis	rs1413885	0.516	rs6588137	chr1:65837282	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.53	0.41	1.38e-7	Anticoagulant levels;
PAAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.67	7.08	0.5	5.06e-11	Longevity;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.54	5.36	0.4	3.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg04165759	chr1:150448943	RPRD2	-0.51	-5.28	-0.39	4.29e-7	Migraine;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.67	-6.52	-0.47	9.8e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg00531865	chr16:30841666	NA	-0.64	-5.91	-0.43	2.18e-8	Multiple myeloma;
PAAD	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg08501292	chr6:25962987	TRIM38	0.77	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.53	-4.7	-0.36	5.73e-6	Glycated hemoglobin levels;
PAAD	cis	rs12304921	1.000	rs2269685	chr12:51417671	G/C	cg18059802	chr12:51347058	HIGD1C	-0.71	-5.55	-0.41	1.21e-7	Type 2 diabetes;
PAAD	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.85	8.84	0.58	2.18e-15	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20863698	chr2:232328446	NCL	0.6	6.66	0.48	4.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg10137597	chr8:22132714	PIWIL2	-0.48	-5.75	-0.42	4.76e-8	Hypertriglyceridemia;
PAAD	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.55	-0.52	3.77e-12	Response to antipsychotic treatment;
PAAD	cis	rs2988277	0.583	rs12036775	chr1:167437047	C/T	cg22356347	chr1:167427500	CD247	0.46	5.03	0.38	1.34e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1878047	0.589	rs8113446	chr19:51780061	T/G	cg14884932	chr19:51774451	NA	-0.4	-4.34	-0.33	2.64e-5	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14202907	chr1:41951185	EDN2	0.66	7.18	0.5	2.97e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg02733842	chr7:1102375	C7orf50	-0.64	-5.01	-0.38	1.47e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.67	-0.35	6.58e-6	Mean corpuscular volume;
PAAD	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-4.62	-0.35	7.98e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.58	6.53	0.47	9.18e-10	Menopause (age at onset);
PAAD	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg05895507	chr15:77155635	SCAPER	0.4	4.5	0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg23995914	chr4:10459228	ZNF518B	-0.4	-4.59	-0.35	9.11e-6	Schizophrenia (age at onset);
PAAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg17120908	chr11:65337727	SSSCA1	-0.57	-5.84	-0.43	3.02e-8	Bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19486023	chr11:64085683	PRDX5;TRMT112	-0.76	-6.63	-0.47	5.47e-10	Neuroticism;
PAAD	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.43	-5.4	-0.4	2.57e-7	Thyroid stimulating hormone;
PAAD	cis	rs6563943	1.000	rs6563943	chr16:83639335	A/G	cg01935413	chr16:83636749	CDH13	-0.53	-5.0	-0.38	1.54e-6	Height;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg14789911	chr21:47582049	C21orf56	-0.53	-5.63	-0.42	8.28e-8	Testicular germ cell tumor;
PAAD	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24249390	chr15:90295951	MESP1	-0.53	-5.58	-0.41	1.08e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23538755	chr19:2774549	SGTA	0.6	6.33	0.46	2.61e-9	Smoking initiation;
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg27394845	chr17:28928406	LRRC37B2	0.74	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4795519	0.628	rs7210692	chr17:22168852	A/G	cg22648282	chr17:21454238	C17orf51	-0.54	-5.49	-0.41	1.68e-7	Chronic myeloid leukemia;
PAAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg17372223	chr3:52568218	NT5DC2	0.49	4.78	0.36	4.1e-6	Bipolar disorder;
PAAD	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.4	-0.34	2.07e-5	Crohn's disease;
PAAD	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.44	0.65	1.4e-19	Cognitive test performance;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs9913156	0.894	rs28365158	chr17:4620928	T/C	cg19197139	chr17:4613644	ARRB2	0.84	8.48	0.57	1.84e-14	Lymphocyte counts;
PAAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.84	-0.37	3.23e-6	Breast cancer;
PAAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.89	9.91	0.63	3.57e-18	Calcium levels;
PAAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	7.59	0.52	3.01e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg07475973	chr22:42306951	NA	0.49	4.47	0.34	1.52e-5	Neuroticism;
PAAD	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs61332075	0.518	rs6749508	chr2:239456243	C/T	cg18131467	chr2:239335373	ASB1	-0.8	-5.49	-0.41	1.64e-7	Lung function (FEV1/FVC);
PAAD	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg21994712	chr19:21861136	NA	0.45	4.27	0.33	3.47e-5	Pain;
PAAD	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg13918804	chr1:2043761	PRKCZ	0.42	5.44	0.4	2.09e-7	Height;
PAAD	cis	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg15590007	chr10:45870220	ALOX5	0.57	5.71	0.42	5.81e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg12568669	chr8:11666485	FDFT1	0.27	4.38	0.33	2.2e-5	Morning vs. evening chronotype;
PAAD	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs6466055	0.636	rs66469172	chr7:104930875	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs6256	1.000	rs10832054	chr11:13550220	G/T	cg11976911	chr11:13509032	NA	0.67	4.93	0.37	2.12e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.97	-0.44	1.57e-8	Waist circumference adjusted for body mass index;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.83e-7	Total body bone mineral density;
PAAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.55	-6.02	-0.44	1.26e-8	Type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs3864277	0.510	rs31478	chr5:131423475	T/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.44	-0.34	1.72e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.77	-7.59	-0.52	2.94e-12	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00855626	chr19:5690231	RPL36	0.67	7.92	0.54	4.71e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.54	6.07	0.44	9.94e-9	Type 2 diabetes;
PAAD	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.03	-0.38	1.37e-6	Educational attainment (years of education);
PAAD	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-4.3	-0.33	3.09e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs288342	0.832	rs288311	chr2:183649700	C/T	cg02625481	chr2:183667124	NA	-0.46	-4.69	-0.36	6.16e-6	Recurrent major depressive disorder;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Body mass index;
PAAD	trans	rs553086	0.941	rs55643257	chr11:56700913	A/T	cg26329020	chr12:32909488	YARS2	0.65	6.31	0.46	2.86e-9	Fear of severe pain;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.45	0.61	6.02e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg00738919	chr7:1100172	C7orf50	0.72	5.21	0.39	6.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-5.91	-0.43	2.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.66	6.66	0.48	4.76e-10	Height;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs12999616	0.817	rs7425883	chr2:98331521	C/G	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.58	-0.47	7.26e-10	Colorectal cancer;
PAAD	cis	rs6681460	0.546	rs1325266	chr1:67160602	A/G	cg02459107	chr1:67143332	SGIP1	0.6	5.67	0.42	7.03e-8	Presence of antiphospholipid antibodies;
PAAD	cis	rs75920871	0.623	rs625145	chr11:116727936	A/T	cg04087571	chr11:116723030	SIK3	-0.45	-6.41	-0.46	1.72e-9	Subjective well-being;
PAAD	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg18551225	chr6:44695536	NA	-0.7	-6.94	-0.49	1.05e-10	Total body bone mineral density;
PAAD	cis	rs1018697	0.966	rs10748831	chr10:104558743	T/C	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.4	-0.61	7.69e-17	Calcium levels;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.51	0.47	1.04e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.85	0.49	1.72e-10	Body mass index;
PAAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg13374026	chr7:158955107	NA	0.53	5.15	0.39	7.94e-7	Facial morphology (factor 20);
PAAD	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-5.24	-0.39	5.34e-7	Monocyte percentage of white cells;
PAAD	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-5.19	-0.39	6.64e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.74	-9.93	-0.63	3.3e-18	Colorectal cancer;
PAAD	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg21918786	chr6:109611834	NA	-0.45	-4.91	-0.37	2.31e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.4	0.71	7.74e-25	Chronic sinus infection;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.61	-0.47	6.13e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs2718812	1.000	rs2718811	chr3:133399738	T/A	cg12372414	chr3:134319805	KY	-0.4	-4.32	-0.33	2.75e-5	Iron status biomarkers;
PAAD	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	7.79	0.53	9.62e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg12432903	chr7:1882776	MAD1L1	0.57	4.25	0.33	3.68e-5	Bipolar disorder;
PAAD	cis	rs2120991	1.000	rs10876513	chr12:54278222	C/T	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.25	-0.33	3.76e-5	Biliary atresia;
PAAD	cis	rs1941184	0.526	rs8099530	chr18:29030210	A/G	cg03238162	chr18:29027701	DSG3	-0.4	-4.51	-0.34	1.27e-5	Parkinson's disease (age of onset);
PAAD	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	1.07	15.29	0.78	1.53e-32	Metabolite levels;
PAAD	cis	rs2599510	0.811	rs62136345	chr2:32807223	G/T	cg02381751	chr2:32503542	YIPF4	0.54	5.39	0.4	2.58e-7	Interleukin-18 levels;
PAAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg01320130	chr1:67600311	NA	0.45	4.75	0.36	4.61e-6	Psoriasis;
PAAD	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	1.07	9.78	0.62	7.97e-18	Monocyte percentage of white cells;
PAAD	cis	rs35955747	0.869	rs5997971	chr22:31792292	C/T	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.74	-0.36	4.81e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.05	9.2	0.6	2.57e-16	Gut microbiome composition (summer);
PAAD	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs73198271	0.515	rs11906	chr8:8641259	C/T	cg01851573	chr8:8652454	MFHAS1	0.89	7.26	0.51	1.84e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg26338869	chr17:61819248	STRADA	0.48	4.65	0.35	7.1e-6	Height;
PAAD	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08731084	chr12:44229880	TMEM117	0.68	6.72	0.48	3.5e-10	Obesity-related traits;
PAAD	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.8	-7.19	-0.5	2.68e-11	Body mass index;
PAAD	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.75	4.25	0.33	3.7e-5	Coronary artery disease;
PAAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.66	-5.34	-0.4	3.35e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg16341495	chr8:142228727	SLC45A4	0.57	5.55	0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.86	-11.0	-0.67	4.39e-21	Height;
PAAD	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg10556349	chr10:835070	NA	0.66	5.24	0.39	5.26e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	4.52	0.34	1.22e-5	Mood instability;
PAAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.69	7.24	0.51	2.07e-11	Colorectal cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15974183	chr2:120436664	TMEM177	-0.6	-6.96	-0.49	9.36e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1519814	0.668	rs7836786	chr8:121006826	G/A	cg22335954	chr8:121166405	COL14A1	-0.63	-4.78	-0.36	4.07e-6	Breast cancer;
PAAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.49	0.34	1.38e-5	Trans fatty acid levels;
PAAD	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.58	0.47	7.33e-10	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	9.93e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg16810054	chr20:33298113	TP53INP2	0.58	4.68	0.36	6.23e-6	Neuroticism;
PAAD	cis	rs6141769	0.542	rs2064934	chr20:31314757	C/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.84	6.31	0.46	2.9e-9	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27108998	chr21:43275314	PRDM15	-0.61	-6.55	-0.47	8.32e-10	Obesity-related traits;
PAAD	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg14784868	chr12:69753453	YEATS4	0.73	7.48	0.52	5.56e-12	Blood protein levels;
PAAD	cis	rs2299587	0.786	rs3886397	chr8:17880625	C/T	cg08627089	chr8:17753878	FGL1	-0.44	-4.37	-0.33	2.3e-5	Economic and political preferences;
PAAD	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.86	9.83	0.62	6.02e-18	Sudden cardiac arrest;
PAAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-5.27	-0.39	4.67e-7	IgG glycosylation;
PAAD	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.61	-6.36	-0.46	2.25e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg00071950	chr4:10020882	SLC2A9	0.62	5.62	0.41	8.84e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.92	9.12	0.59	4.33e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	1.19	8.77	0.58	3.46e-15	Lymphocyte counts;
PAAD	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg09659197	chr4:152720779	NA	0.35	5.22	0.39	5.75e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.77	-7.83	-0.54	7.86e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs863345	0.967	rs10489834	chr1:158521034	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.55	4.56	0.35	1.03e-5	Interleukin-17 levels;
PAAD	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03358980	chr10:102770406	NA	-0.79	-7.39	-0.51	9.06e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.78	4.84	0.37	3.22e-6	IgG glycosylation;
PAAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.43	4.89	0.37	2.49e-6	Alzheimer's disease (late onset);
PAAD	cis	rs863345	0.967	rs1592256	chr1:158470596	C/T	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg18833306	chr6:118973337	C6orf204	-0.56	-4.51	-0.34	1.3e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.87	-6.29	-0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-6.39	-0.46	1.93e-9	Total cholesterol levels;
PAAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.57	6.31	0.46	2.94e-9	Blood metabolite levels;
PAAD	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg08523384	chr5:141488047	NDFIP1	-0.61	-5.63	-0.42	8.38e-8	Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24282422	chr3:125239067	SNX4	0.65	7.73	0.53	1.35e-12	Monocyte percentage of white cells;
PAAD	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg10395934	chr14:104002654	TRMT61A	0.49	4.75	0.36	4.7e-6	Body mass index;
PAAD	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-6.38	-0.46	2.02e-9	Body mass index (adult);
PAAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg24213567	chr19:53496664	ZNF702P	-0.42	-4.25	-0.33	3.68e-5	Psoriasis;
PAAD	cis	rs7896691	0.925	rs77187733	chr10:3151863	C/T	cg15228268	chr10:3146741	PFKP	0.9	4.75	0.36	4.72e-6	Disc degeneration (lumbar);
PAAD	cis	rs6496932	0.802	rs10163187	chr15:85870518	C/T	cg19183879	chr15:85880815	NA	0.52	4.76	0.36	4.56e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.69	-7.34	-0.51	1.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg05313129	chr8:58192883	C8orf71	0.64	5.39	0.4	2.65e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs655601	1.000	rs655601	chr5:180226673	G/T	cg13724780	chr5:180237085	MGAT1	-0.73	-4.47	-0.34	1.52e-5	Quantitative traits;
PAAD	cis	rs2997447	0.846	rs7520344	chr1:26397286	C/T	cg24519413	chr1:26490540	NA	0.52	4.8	0.36	3.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs9467603	1.000	rs13201341	chr6:25822661	C/T	cg21479132	chr6:26055353	NA	0.85	4.27	0.33	3.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.12	0.5	3.95e-11	Type 2 diabetes;
PAAD	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	5.27	0.39	4.57e-7	Height;
PAAD	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	7.26	0.51	1.84e-11	Body mass index (adult);
PAAD	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg06627628	chr2:24431161	ITSN2	-0.56	-5.53	-0.41	1.38e-7	Sjögren's syndrome;
PAAD	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.93	11.06	0.67	3.03e-21	Coronary artery disease;
PAAD	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg17868515	chr10:100992068	HPSE2	-0.4	-4.74	-0.36	4.83e-6	Metabolite levels;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg15736062	chr7:158136485	PTPRN2	0.5	4.59	0.35	9.13e-6	Calcium levels;
PAAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.49	-0.47	1.16e-9	Longevity;Endometriosis;
PAAD	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg25790453	chr13:113633590	MCF2L	-0.38	-4.51	-0.34	1.29e-5	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18091465	chr15:82551086	EFTUD1	-0.6	-6.94	-0.49	1.05e-10	Myopia (pathological);
PAAD	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.87	-6.95	-0.49	1e-10	Total cholesterol levels;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.69	8.1	0.55	1.63e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2457480	0.866	rs10160170	chr10:44692843	A/G	cg09554077	chr10:44749378	NA	0.38	4.77	0.36	4.2e-6	Coronary artery disease;
PAAD	trans	rs901683	0.867	rs34144887	chr10:46086393	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.59	-5.42	-0.4	2.26e-7	Breast cancer;
PAAD	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs7009516	0.846	rs13257546	chr8:24218697	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.44	5.42	0.4	2.29e-7	Hair greying;
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.64	-8.08	-0.55	1.83e-13	Body mass index;
PAAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Breast cancer;
PAAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.83	0.36	3.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg27335600	chr3:53528857	CACNA1D	-0.39	-4.34	-0.33	2.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg12870014	chr12:110450643	ANKRD13A	0.71	5.12	0.38	9.03e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2288912	0.620	rs875255	chr19:45493635	C/G	cg20090143	chr19:45452003	APOC2	-0.43	-5.37	-0.4	2.95e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg11062466	chr8:58055876	NA	0.73	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.65	8.58	0.57	1e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.72	-9.02	-0.59	7.87e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	0.744	rs16884715	chr6:75056816	A/G	cg03266952	chr6:74778945	NA	-0.99	-5.57	-0.41	1.14e-7	Metabolite levels (MHPG);
PAAD	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.79	6.38	0.46	2.06e-9	HDL cholesterol;
PAAD	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-4.33	-0.33	2.66e-5	Chronic sinus infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16951854	chr3:49449507	RHOA;TCTA	-0.68	-6.89	-0.49	1.4e-10	Smoking initiation;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.68	6.92	0.49	1.16e-10	Resistin levels;
PAAD	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.65	-6.19	-0.45	5.37e-9	Rheumatoid arthritis;
PAAD	cis	rs9398803	0.624	rs1455738	chr6:126636820	A/G	cg19875578	chr6:126661172	C6orf173	0.49	4.62	0.35	8.18e-6	Male-pattern baldness;
PAAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.54	5.11	0.38	9.62e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs57244997	0.725	rs73028496	chr6:162422243	A/G	cg17173639	chr6:162384350	PARK2	-0.59	-4.41	-0.34	1.94e-5	Mosquito bite size;
PAAD	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.62	4.94	0.37	2.03e-6	Cholesterol, total;
PAAD	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.08	0.55	1.82e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.48	4.3	0.33	3e-5	Arsenic metabolism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00815109	chr12:53645775	MFSD5	0.69	7.61	0.53	2.75e-12	Myopia (pathological);
PAAD	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.05	0.38	1.27e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.22e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.64	-5.4	-0.4	2.57e-7	Menarche (age at onset);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg20912593	chr19:45972316	FOSB	-0.56	-6.51	-0.47	1.04e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14019695	chr9:139328340	INPP5E	0.58	6.1	0.44	8.46e-9	Monocyte percentage of white cells;
PAAD	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg00122941	chr17:4613640	ARRB2	-0.81	-8.06	-0.55	2.07e-13	Lymphocyte counts;
PAAD	cis	rs507080	0.922	rs4474473	chr11:118553889	T/G	cg08498647	chr11:118550644	TREH	-0.38	-4.42	-0.34	1.87e-5	Serum metabolite levels;
PAAD	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.71	7.66	0.53	2e-12	Platelet distribution width;
PAAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg05785598	chr3:49045655	WDR6	0.44	5.18	0.39	6.9e-7	Parkinson's disease;
PAAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg23435118	chr5:141488016	NDFIP1	-0.53	-5.54	-0.41	1.32e-7	Asthma;
PAAD	cis	rs1400816	0.850	rs17581715	chr2:172921454	C/T	cg23624723	chr2:173292262	ITGA6	0.89	4.92	0.37	2.23e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07362569	chr17:61921086	SMARCD2	0.61	7.43	0.52	7.3e-12	Prudent dietary pattern;
PAAD	cis	rs6547631	0.595	rs34702373	chr2:85927404	C/T	cg24620635	chr2:85921963	GNLY	0.43	5.61	0.41	9.15e-8	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.45	-0.52	6.38e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.6	5.91	0.43	2.19e-8	Motion sickness;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.68	8.95	0.59	1.19e-15	Hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18641478	chr19:17970431	RPL18AP3;RPL18A	0.59	6.54	0.47	8.81e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.04	-0.55	2.4e-13	Brugada syndrome;
PAAD	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.93	6.15	0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.92	10.89	0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg21433313	chr16:3507492	NAT15	0.93	7.62	0.53	2.58e-12	Tuberculosis;
PAAD	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.68	7.48	0.52	5.43e-12	Colorectal cancer;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-6.85	-0.49	1.75e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13560548	chr3:10150139	C3orf24	0.52	4.47	0.34	1.49e-5	Alzheimer's disease;
PAAD	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-4.79	-0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg17541715	chr7:1216824	NA	-0.56	-6.4	-0.46	1.83e-9	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02834497	chr19:12405873	ZNF44	0.64	6.63	0.47	5.64e-10	Obesity-related traits;
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	5.79	0.42	3.95e-8	LDL cholesterol;
PAAD	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg23024343	chr7:107201750	COG5	0.54	4.5	0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.56	5.07	0.38	1.12e-6	Type 2 diabetes;
PAAD	cis	rs9467160	1.000	rs9467162	chr6:24442047	T/C	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.69	-8.42	-0.56	2.55e-14	Dupuytren's disease;
PAAD	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-7.87	-0.54	6.09e-13	Blood trace element (Cu levels);
PAAD	cis	rs72634501	0.517	rs6600289	chr1:39613812	C/T	cg11070191	chr1:39582205	MACF1	0.49	4.47	0.34	1.54e-5	HDL cholesterol;
PAAD	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.64	-6.8	-0.48	2.2e-10	Dilated cardiomyopathy;
PAAD	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.25	9.97	0.63	2.59e-18	Uric acid levels;
PAAD	cis	rs6141769	0.518	rs6058847	chr20:31324135	C/T	cg13636640	chr20:31349939	DNMT3B	-0.48	-4.6	-0.35	8.77e-6	Subjective well-being;
PAAD	cis	rs7551345	0.853	rs34563758	chr1:31765289	G/C	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-4.55	-0.35	1.1e-5	Electroencephalogram traits;
PAAD	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.99	12.86	0.72	4.44e-26	Heart rate;
PAAD	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.66	7.26	0.51	1.85e-11	Eye color traits;
PAAD	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg00531865	chr16:30841666	NA	-0.53	-4.82	-0.36	3.52e-6	Dementia with Lewy bodies;
PAAD	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.0	-0.67	4.65e-21	Coronary artery disease;
PAAD	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-5.07	-0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.41	-0.56	2.71e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.98	11.99	0.7	9.75e-24	Bone mineral density;
PAAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.67	6.43	0.46	1.58e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.43	-4.89	-0.37	2.59e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.63	5.45	0.4	1.99e-7	Primary sclerosing cholangitis;
PAAD	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.79	6.89	0.49	1.38e-10	Chronic kidney disease;
PAAD	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.86	-9.52	-0.61	3.82e-17	Coronary artery disease;
PAAD	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg00262122	chr8:11665843	FDFT1	-0.52	-4.42	-0.34	1.85e-5	Morning vs. evening chronotype;
PAAD	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.91	-11.55	-0.68	1.51e-22	Coronary artery disease;
PAAD	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg10495392	chr1:46806563	NSUN4	0.58	5.71	0.42	5.7e-8	Menopause (age at onset);
PAAD	cis	rs939584	1.000	rs10865549	chr2:631759	G/A	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.57	0.71	2.72e-25	Bone mineral density;
PAAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs6074578	0.541	rs6086539	chr20:145413	A/G	cg16931068	chr20:139680	DEFB127	-0.42	-5.77	-0.42	4.21e-8	Hirschsprung disease;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs7631605	0.846	rs60404305	chr3:36988221	G/T	cg17445812	chr3:36986805	TRANK1	0.34	4.57	0.35	1.01e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.71	-5.28	-0.39	4.34e-7	Vitiligo;
PAAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg10556349	chr10:835070	NA	0.68	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6746082	0.519	rs503594	chr2:25757803	C/T	cg23192403	chr2:25781496	DTNB	-0.29	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg22875332	chr1:76189707	ACADM	0.49	4.89	0.37	2.58e-6	Daytime sleep phenotypes;
PAAD	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.41	-5.79	-0.43	3.87e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg19318889	chr4:1322082	MAEA	-0.42	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs11990843	1.000	rs11990843	chr8:5655766	A/G	cg25956036	chr8:4854652	NA	0.6	5.11	0.38	9.67e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs8105895	0.935	rs28894669	chr19:22243264	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs2899832	0.866	rs7218	chr14:35743063	A/T	cg09327582	chr14:35236912	BAZ1A	-0.55	-4.43	-0.34	1.8e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs2882667	0.690	rs930062	chr5:138053623	G/A	cg09476006	chr5:138032270	NA	0.51	6.58	0.47	7e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1160297	0.609	rs12713232	chr2:53108308	A/T	cg07782112	chr2:53107842	NA	-0.38	-4.56	-0.35	1.03e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3734905	1.000	rs4716364	chr6:169949322	A/G	cg11181693	chr6:169825345	NA	0.81	4.81	0.36	3.6e-6	HIV-1 control;
PAAD	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg23167506	chr7:1303302	NA	0.37	6.42	0.46	1.62e-9	Menopause (age at onset);
PAAD	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.93	-7.96	-0.54	3.65e-13	Vitiligo;
PAAD	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-5.9	-0.43	2.32e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.29	0.45	3.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg04851639	chr8:1020857	NA	-0.58	-6.94	-0.49	1.04e-10	Schizophrenia;
PAAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.74	-7.2	-0.5	2.54e-11	DNA methylation (variation);
PAAD	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.11	6.82	0.48	1.99e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06057045	chr2:233562093	GIGYF2	0.62	7.0	0.49	7.75e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg21951975	chr1:209979733	IRF6	0.59	5.39	0.4	2.67e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.3	-0.33	3e-5	Breast cancer;
PAAD	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.53	5.84	0.43	3.03e-8	Heart rate;
PAAD	cis	rs1642645	0.872	rs642112	chr1:42453317	C/T	cg01990334	chr1:42801334	FOXJ3	-0.63	-5.58	-0.41	1.06e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg27129171	chr3:47204927	SETD2	0.6	6.05	0.44	1.08e-8	Birth weight;
PAAD	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11411865	chr7:2701802	TTYH3	0.65	4.65	0.35	7.23e-6	Bipolar disorder;
PAAD	cis	rs8005677	0.798	rs4982711	chr14:23398990	T/G	cg01529538	chr14:23388837	RBM23	0.48	4.79	0.36	3.88e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs13144136	0.647	rs12509884	chr4:10654043	C/T	cg10242279	chr4:10666415	CLNK	-0.48	-6.25	-0.45	3.97e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg26816564	chr1:7831052	VAMP3	0.63	5.06	0.38	1.21e-6	Inflammatory bowel disease;
PAAD	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.42	0.52	7.55e-12	Monocyte percentage of white cells;
PAAD	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.07	0.63	1.4e-18	Bladder cancer;
PAAD	cis	rs859767	0.812	rs842357	chr2:135345059	G/A	cg12500956	chr2:135428796	TMEM163	0.33	4.64	0.35	7.47e-6	Neuroticism;
PAAD	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg16386425	chr10:429943	DIP2C	0.49	4.77	0.36	4.22e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs41271473	0.687	rs35832347	chr1:228883738	G/C	cg10167378	chr1:228756711	NA	0.54	4.67	0.35	6.45e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs179429	0.898	rs179428	chr11:2550509	A/G	cg22366698	chr11:3400543	ZNF195	0.57	4.44	0.34	1.75e-5	Platelet aggregation;
PAAD	trans	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg18335740	chr13:41363409	SLC25A15	0.89	9.6	0.61	2.38e-17	Lewy body disease;
PAAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.74e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg15841412	chr13:111365552	ING1	0.53	4.41	0.34	1.91e-5	Coronary artery disease;
PAAD	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17323833	chr19:14117336	RFX1	0.58	6.4	0.46	1.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.69	7.3	0.51	1.48e-11	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	6.49	0.47	1.16e-9	Total body bone mineral density;
PAAD	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg19630374	chr17:18023558	MYO15A	-0.58	-6.09	-0.44	8.79e-9	Total body bone mineral density;
PAAD	cis	rs9469890	0.604	rs77186075	chr6:34504478	C/T	cg17674042	chr6:34482479	PACSIN1	-1.0	-6.81	-0.48	2.12e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.82	8.7	0.58	5.01e-15	Tuberculosis;
PAAD	cis	rs375066	0.869	rs379785	chr19:44428101	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	1.1	7.94	0.54	4.18e-13	IgG glycosylation;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	6.28	0.45	3.35e-9	Lung cancer in ever smokers;
PAAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg15448220	chr1:150897856	SETDB1	-0.66	-6.94	-0.49	1.04e-10	Tonsillectomy;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09221935	chr15:62709473	NA	-0.39	-4.65	-0.35	7.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs558003	0.826	rs606252	chr13:51199462	C/A	cg24585282	chr13:51257555	NA	-0.67	-4.53	-0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs5009270	0.553	rs11769472	chr7:112220214	A/C	cg23628563	chr7:112262597	NA	-0.64	-5.47	-0.41	1.77e-7	Osteoarthritis (hip);
PAAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26549601	chr10:134560360	INPP5A	-0.51	-5.08	-0.38	1.07e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg15595755	chr5:1867978	NA	0.43	4.53	0.35	1.17e-5	Cardiovascular disease risk factors;
PAAD	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.53e-9	Corneal astigmatism;
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg19337854	chr7:99768885	GPC2	-0.52	-4.9	-0.37	2.38e-6	Lung function (FEV1/FVC);
PAAD	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.81	9.38	0.61	9.06e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.72	7.0	0.49	7.87e-11	Recombination rate (males);
PAAD	cis	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs4987094	0.505	rs4938011	chr11:113247232	T/G	cg14632485	chr11:113216820	TTC12	0.55	4.56	0.35	1.03e-5	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.25	0.6	1.89e-16	Hemoglobin concentration;
PAAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19115630	chr4:76439549	RCHY1;THAP6	0.64	6.35	0.46	2.39e-9	Obesity-related traits;
PAAD	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	cis	rs655641	0.520	rs639012	chr11:85681583	A/G	cg07180834	chr11:85838833	NA	-0.43	-4.77	-0.36	4.36e-6	Platelet count;
PAAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.43	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1656368	0.700	rs73154304	chr3:158209239	T/G	cg16708174	chr3:158430962	RARRES1	0.62	5.68	0.42	6.81e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.89	7.92	0.54	4.72e-13	Diastolic blood pressure;
PAAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg20933634	chr6:27740509	NA	0.63	4.74	0.36	4.87e-6	Parkinson's disease;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg08869831	chr1:92764770	RPAP2;GLMN	-0.57	-6.46	-0.46	1.31e-9	Immature fraction of reticulocytes;
PAAD	cis	rs3096299	0.584	rs3114889	chr16:89415505	T/C	cg00750074	chr16:89608354	SPG7	-0.47	-4.51	-0.34	1.28e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs11606709	1	rs11606709	chr11:46730522	A/G	cg19486271	chr11:47235900	DDB2	-0.64	-6.41	-0.46	1.75e-9	Total body bone mineral density;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg27121462	chr16:89883253	FANCA	0.46	4.9	0.37	2.39e-6	Vitiligo;
PAAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.96	0.66	5.89e-21	Tonsillectomy;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.6	-6.0	-0.44	1.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg08390786	chr10:135334061	NA	0.47	4.53	0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg22777020	chr22:31556080	RNF185	-0.5	-4.28	-0.33	3.25e-5	Colorectal cancer;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.43	4.43	0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.7	6.83	0.48	1.91e-10	Blood metabolite levels;
PAAD	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.72	-8.33	-0.56	4.31e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.51e-6	Dermatomyositis;
PAAD	cis	rs4740619	0.619	rs1328276	chr9:16029036	A/G	cg14451791	chr9:16040625	NA	-0.46	-5.28	-0.39	4.32e-7	Body mass index;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg00988841	chr10:134556463	INPP5A	0.47	4.34	0.33	2.62e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00011284	chr16:53469344	RBL2	0.6	6.87	0.49	1.56e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3812111	0.525	rs2232472	chr6:116574455	G/A	cg18828861	chr6:116576566	TSPYL4	0.47	4.81	0.36	3.61e-6	Age-related macular degeneration;
PAAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-6.28	-0.45	3.38e-9	Personality dimensions;
PAAD	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.79	8.08	0.55	1.87e-13	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.18e-6	Prudent dietary pattern;
PAAD	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.7	6.71	0.48	3.53e-10	Anterior chamber depth;
PAAD	cis	rs16976116	0.951	rs11857087	chr15:55487181	T/A	cg11288833	chr15:55489084	RSL24D1	0.58	4.74	0.36	4.9100000000000004e-06	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg15117754	chr3:10150083	C3orf24	0.56	4.31	0.33	2.96e-5	Alzheimer's disease;
PAAD	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.27	0.39	4.67e-7	Lung cancer;
PAAD	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.33	-0.4	3.52e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20033079	chr15:55666362	MIR628;CCPG1	-0.63	-6.29	-0.45	3.23e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.48	-4.87	-0.37	2.79e-6	Type 2 diabetes;
PAAD	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.87	-9.89	-0.63	4.16e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.75	7.47	0.52	5.87e-12	Corneal astigmatism;
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13198984	chr17:80129470	CCDC57	-0.36	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.8	10.0	0.63	2.13e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg00999904	chr2:3704751	ALLC	0.62	6.65	0.47	4.97e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.4	-0.34	2.06e-5	Blood metabolite levels;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.69	-7.06	-0.5	5.54e-11	Menarche (age at onset);
PAAD	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9346353	0.737	rs6918407	chr6:70457024	A/C	cg03001484	chr6:70507230	LMBRD1	-0.3	-4.36	-0.33	2.35e-5	Sleep duration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06784576	chr3:113465925	ATP6V1A;NAA50	0.63	6.52	0.47	9.81e-10	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.57	5.37	0.4	2.89e-7	Mortality in heart failure;
PAAD	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	7.04	0.5	6.31e-11	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	5.76	0.42	4.6e-8	Personality dimensions;
PAAD	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.91	-0.54	4.96e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg00255919	chr5:131827918	IRF1	-0.47	-5.9	-0.43	2.29e-8	Breast cancer;Mosquito bite size;
PAAD	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.72	0.62	1.15e-17	Chronic sinus infection;
PAAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	5.26	0.39	4.81e-7	Mood instability;
PAAD	cis	rs4795519	0.845	rs8080725	chr17:22192732	G/T	cg22648282	chr17:21454238	C17orf51	-0.56	-5.33	-0.4	3.43e-7	Chronic myeloid leukemia;
PAAD	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.61	-4.69	-0.36	6.1e-6	Breast cancer;
PAAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg06375148	chr1:209958343	C1orf74	0.68	5.01	0.38	1.51e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs4834770	1.000	rs10034579	chr4:120244029	A/C	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.12	9.76	0.62	8.87e-18	Red blood cell traits;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.96	8.4	0.56	2.99e-14	Alzheimer's disease;
PAAD	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.73	0.42	5.19e-8	Blood protein levels;
PAAD	cis	rs9472414	0.510	rs227839	chr6:44685610	A/G	cg18551225	chr6:44695536	NA	0.52	5.14	0.38	8.24e-7	Height;
PAAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.87	-7.64	-0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs12286929	0.590	rs4936322	chr11:115061533	T/C	cg04055981	chr11:115044050	NA	0.43	4.45	0.34	1.68e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9928842	0.882	rs6564241	chr16:75263974	T/C	cg09066997	chr16:75300724	BCAR1	0.63	4.58	0.35	9.6e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.54	-5.28	-0.39	4.44e-7	Coronary artery disease;
PAAD	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.48	-0.47	1.23e-9	Mood instability;
PAAD	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg12623918	chr2:306882	NA	0.49	5.01	0.38	1.52e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.97	6.83	0.48	1.87e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.6	-6.46	-0.46	1.32e-9	Multiple myeloma (IgH translocation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12141179	chr2:172016663	TLK1	0.7	7.0	0.49	7.65e-11	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.95	8.45	0.57	2.15e-14	Alzheimer's disease;
PAAD	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.48	4.28	0.33	3.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg21584241	chr15:63341463	TPM1	0.7	5.2	0.39	6.3e-7	Orofacial clefts;
PAAD	cis	rs783540	1.000	rs698500	chr15:83237769	T/C	cg00614314	chr15:82944287	LOC80154	0.43	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.52	6.96	0.49	9.36e-11	Life satisfaction;
PAAD	cis	rs7631605	0.905	rs11717310	chr3:37175150	C/T	cg17445812	chr3:36986805	TRANK1	0.33	4.42	0.34	1.9e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	7.83	0.54	7.67e-13	Eosinophilic esophagitis;
PAAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg27478167	chr7:817139	HEATR2	-0.61	-4.78	-0.36	4.07e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs662064	0.963	rs636291	chr1:10556097	G/A	cg07384165	chr1:10488281	NA	-0.45	-4.26	-0.33	3.6e-5	Asthma;
PAAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.13	0.6	4e-16	Total body bone mineral density;
PAAD	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	5.94	0.43	1.9e-8	Total body bone mineral density;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg00450029	chr8:599525	NA	0.81	5.87	0.43	2.61e-8	IgG glycosylation;
PAAD	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.73	-6.95	-0.49	1.02e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4455778	0.580	rs6583501	chr7:49077636	A/T	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.44	-4.52	-0.34	1.24e-5	Vitiligo;
PAAD	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg20913747	chr6:44695427	NA	0.71	6.86	0.49	1.66e-10	Total body bone mineral density;
PAAD	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.56	-6.07	-0.44	9.86e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg06131755	chr6:160182447	ACAT2	0.53	4.46	0.34	1.57e-5	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19668597	chr12:46786365	NA	0.61	6.76	0.48	2.75e-10	Smoking initiation;
PAAD	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg20913747	chr6:44695427	NA	0.61	5.98	0.44	1.56e-8	Total body bone mineral density;
PAAD	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs7619427	0.544	rs9821661	chr3:44031551	G/A	cg12796028	chr3:44040206	NA	-0.56	-4.77	-0.36	4.22e-6	Schizophrenia;
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	4.7	0.36	5.89e-6	Electroencephalogram traits;
PAAD	cis	rs72901758	0.768	rs55782477	chr17:76250703	G/C	cg26068271	chr17:76253126	NA	0.53	5.07	0.38	1.13e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg14146966	chr2:61757674	XPO1	0.38	4.63	0.35	7.72e-6	Tuberculosis;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.73	5.53	0.41	1.35e-7	Initial pursuit acceleration;
PAAD	cis	rs91	0.624	rs10224276	chr7:24462842	G/A	cg13313214	chr7:23749942	STK31	0.45	4.34	0.33	2.54e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.83	9.33	0.6	1.2e-16	Total body bone mineral density;
PAAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-4.87	-0.37	2.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs877529	0.967	rs139406	chr22:39551798	T/C	cg13455509	chr22:39551605	NA	-0.45	-4.47	-0.34	1.55e-5	Multiple myeloma;
PAAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg01320130	chr1:67600311	NA	0.56	6.35	0.46	2.42e-9	Psoriasis;
PAAD	cis	rs9972944	0.651	rs9909246	chr17:63791547	C/G	cg07283582	chr17:63770753	CCDC46	-0.59	-6.87	-0.49	1.58e-10	Total body bone mineral density;
PAAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs778371	0.649	rs283465	chr2:233666787	G/A	cg08000102	chr2:233561755	GIGYF2	0.8	8.68	0.58	5.78e-15	Schizophrenia;
PAAD	cis	rs4343996	0.967	rs34608458	chr7:3357881	G/A	cg21248987	chr7:3385318	SDK1	-0.47	-5.14	-0.38	8.24e-7	Motion sickness;
PAAD	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg08779649	chr13:50194554	NA	0.39	5.42	0.4	2.24e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg18093559	chr17:18951025	GRAP	0.47	5.05	0.38	1.25e-6	Schizophrenia;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.65	-0.35	7.17e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21032013	chr22:50217662	BRD1	0.58	7.15	0.5	3.36e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19531713	chr17:41277059	BRCA1;NBR2	0.59	6.55	0.47	8.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg11833968	chr6:79620685	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.47	4.33	0.33	2.69e-5	Cognitive ability;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.56	6.38	0.46	2e-9	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-4.68	-0.35	6.44e-6	Blood pressure (smoking interaction);
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.98	13.14	0.73	7.86e-27	Menarche (age at onset);
PAAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg09222892	chr1:25734099	RHCE	-0.44	-4.33	-0.33	2.64e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.35e-13	Prostate cancer;
PAAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg19413350	chr8:57351067	NA	-0.51	-4.65	-0.35	7.19e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24785526	chr13:98929070	FARP1	-0.55	-6.68	-0.48	4.21e-10	Monocyte percentage of white cells;
PAAD	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg21483461	chr5:81570383	RPS23	0.52	4.93	0.37	2.09e-6	Breast cancer;
PAAD	cis	rs10774547	1.000	rs10774547	chr12:120862716	T/C	cg10072921	chr12:121022843	NA	-0.35	-4.26	-0.33	3.5e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05902531	chr12:58239324	CTDSP2	0.62	6.73	0.48	3.24e-10	Myopia (pathological);
PAAD	cis	rs7508	0.512	rs1057016	chr8:17887083	A/G	cg08627089	chr8:17753878	FGL1	-0.45	-4.48	-0.34	1.45e-5	Atrial fibrillation;
PAAD	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.53	8.0	0.54	2.95e-13	Hypertriglyceridemia;
PAAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.57	5.46	0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg17372223	chr3:52568218	NT5DC2	-0.55	-5.35	-0.4	3.18e-7	Bipolar disorder;
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg16083429	chr3:49237500	CCDC36	0.45	4.35	0.33	2.49e-5	Menarche (age at onset);
PAAD	cis	rs733175	0.830	rs10004571	chr4:10062965	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	4.34	0.33	2.63e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.84	10.21	0.64	5.89e-19	Menopause (age at onset);
PAAD	cis	rs72960926	0.590	rs7770639	chr6:75128400	G/A	cg03266952	chr6:74778945	NA	0.61	4.28	0.33	3.23e-5	Metabolite levels (MHPG);
PAAD	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs61876865	0.613	rs12419471	chr11:9793537	G/A	cg17999319	chr11:10396922	NA	0.5	4.35	0.33	2.47e-5	Tonsillectomy;
PAAD	cis	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg21546286	chr11:48923668	NA	-0.54	-5.54	-0.41	1.29e-7	HDL cholesterol;
PAAD	cis	rs831571	0.695	rs73120926	chr3:64036950	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.61	-4.67	-0.35	6.71e-6	Type 2 diabetes;
PAAD	cis	rs16975963	0.843	rs73041022	chr19:38272394	C/T	cg08679971	chr19:38281047	NA	0.51	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs59104589	0.583	rs12618809	chr2:242249122	G/A	cg04488487	chr2:242709673	NA	0.57	4.32	0.33	2.82e-5	Fibrinogen levels;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.42	-4.72	-0.36	5.41e-6	Mean arterial pressure;
PAAD	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg15181151	chr6:150070149	PCMT1	0.53	5.72	0.42	5.61e-8	Lung cancer;
PAAD	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.6	-0.35	8.86e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1371614	0.566	rs11902826	chr2:27177545	C/T	cg00617064	chr2:27272375	NA	0.45	4.68	0.35	6.38e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24729792	chr2:113192114	RGPD8;RGPD5	0.6	4.66	0.35	6.93e-6	Yeast infection;
PAAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg05110241	chr16:68378359	PRMT7	-1.11	-7.76	-0.53	1.15e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.14	-0.38	8.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.7	7.29	0.51	1.59e-11	Menarche (age at onset);
PAAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	0.96	8.91	0.59	1.44e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1419980	0.730	rs11534793	chr12:7752966	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.8	8.68	0.58	5.79e-15	Schizophrenia;
PAAD	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg20503657	chr10:835505	NA	0.47	4.96	0.37	1.85e-6	Survival in rectal cancer;
PAAD	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.51	-4.52	-0.34	1.23e-5	Mean corpuscular volume;
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9535307	0.929	rs9316474	chr13:50313345	C/A	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg20933634	chr6:27740509	NA	0.53	5.15	0.39	8.09e-7	Parkinson's disease;
PAAD	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17376030	chr22:41985996	PMM1	0.69	4.66	0.35	6.78e-6	Vitiligo;
PAAD	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	8.1	0.55	1.64e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.88	10.9	0.66	8.25e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.89	8.56	0.57	1.13e-14	Methadone dose in opioid dependence;
PAAD	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg06609049	chr19:2785107	THOP1	1.16	15.8	0.79	6.98e-34	Total cholesterol levels;
PAAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.55	0.52	3.66e-12	Menarche (age at onset);
PAAD	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg27236539	chr20:62289627	RTEL1	0.67	6.14	0.45	6.73e-9	Prostate cancer;
PAAD	cis	rs1535500	0.935	rs34247110	chr6:39282371	G/A	cg02883595	chr6:39281421	KCNK17	-0.45	-4.33	-0.33	2.69e-5	Type 2 diabetes;
PAAD	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	1.01	10.8	0.66	1.55e-20	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg21546286	chr11:48923668	NA	-0.44	-4.72	-0.36	5.42e-6	Height;
PAAD	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.74	-8.56	-0.57	1.14e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs62025270	0.522	rs338519	chr15:86214879	T/C	cg13263323	chr15:86062960	AKAP13	0.47	4.68	0.36	6.19e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg04721828	chr11:48285200	OR4X1	-0.52	-6.46	-0.46	1.36e-9	Migraine - clinic-based;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	9.21	0.6	2.39e-16	Lymphocyte counts;
PAAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19346786	chr7:2764209	NA	-0.38	-5.29	-0.39	4.12e-7	Height;
PAAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs112990264	0.892	rs76481348	chr1:213014365	C/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.63	7.07	0.5	5.41e-11	Colorectal cancer;
PAAD	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs427941	0.703	rs201458	chr7:101741439	T/C	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.93	-11.54	-0.68	1.65e-22	Refractive error;
PAAD	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-4.37	-0.33	2.26e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1878047	0.589	rs8110859	chr19:51776162	C/T	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	0.51	5.46	0.41	1.89e-7	Hypothyroidism;
PAAD	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.97	12.53	0.71	3.51e-25	Bone mineral density;
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.4	-4.27	-0.33	3.47e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.16	17.83	0.82	4.27e-39	Cognitive function;
PAAD	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg25649188	chr17:73499917	CASKIN2	0.51	4.76	0.36	4.46e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-4.74	-0.36	4.89e-6	Total body bone mineral density;
PAAD	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-5.61	-0.41	9.2e-8	Cognitive function;
PAAD	cis	rs9652601	0.719	rs12103174	chr16:11203730	A/G	cg04616529	chr16:11181986	CLEC16A	0.37	4.52	0.34	1.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.42	4.35	0.33	2.53e-5	Plateletcrit;
PAAD	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg20060109	chr17:81052770	NA	-0.44	-4.36	-0.33	2.35e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.73	0.36	5e-6	Major depressive disorder;
PAAD	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.57	-4.62	-0.35	8.19e-6	Corneal structure;
PAAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs12754538	0.777	rs12040568	chr1:8727944	G/T	cg06159269	chr1:8767347	RERE	0.4	4.7	0.36	5.76e-6	Subjective well-being;
PAAD	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg16586182	chr3:47516702	SCAP	-0.68	-7.72	-0.53	1.48e-12	Colorectal cancer;
PAAD	cis	rs11051970	0.625	rs2728709	chr12:32567716	C/T	cg24626660	chr12:32551988	NA	0.42	4.67	0.35	6.47e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.82	10.32	0.64	2.97e-19	Height;
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	5.72	0.42	5.61e-8	Vitiligo;
PAAD	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg12395012	chr8:11607386	GATA4	0.42	4.4	0.34	2.05e-5	Morning vs. evening chronotype;
PAAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg22800045	chr5:56110881	MAP3K1	0.63	5.19	0.39	6.74e-7	Coronary artery disease;
PAAD	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg19637330	chr1:19110922	NA	0.61	4.92	0.37	2.18e-6	Percentage gas trapping;
PAAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.96	0.54	3.71e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.68	7.08	0.5	4.95e-11	Height;
PAAD	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.84	-9.63	-0.62	2.03e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.08	0.38	1.07e-6	Restless legs syndrome;
PAAD	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	4.85	0.37	2.97e-6	Mean platelet volume;
PAAD	cis	rs6604026	0.656	rs2811591	chr1:93363951	C/A	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.4	-4.96	-0.37	1.84e-6	Electrocardiographic conduction measures;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	15.56	0.78	2.89e-33	Height;
PAAD	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg10137597	chr8:22132714	PIWIL2	0.5	5.96	0.44	1.68e-8	Hypertriglyceridemia;
PAAD	cis	rs9583531	0.714	rs76166228	chr13:111343774	T/C	cg07595035	chr13:111291582	CARKD	0.79	4.77	0.36	4.35e-6	Coronary artery disease;
PAAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.48	0.34	1.47e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7577696	0.785	rs2294179	chr2:32354005	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-4.67	-0.35	6.56e-6	Inflammatory biomarkers;
PAAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.51	-4.25	-0.33	3.73e-5	Gut microbiome composition (summer);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16418258	chr15:42840397	LRRC57;HAUS2	0.6	7.14	0.5	3.68e-11	Metabolite levels  (X-11787);
PAAD	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.76	8.81	0.58	2.7e-15	Colorectal cancer;
PAAD	cis	rs988913	1.000	rs1503134	chr6:54836224	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg03417191	chr3:183542750	MAP6D1	-0.61	-5.41	-0.4	2.38e-7	Menopause (age at onset);
PAAD	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	5.86	0.43	2.83e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	-0.46	-4.5	-0.34	1.37e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6604026	0.656	rs11164836	chr1:93381415	C/T	cg13858687	chr1:93297071	RPL5	0.48	4.36	0.33	2.34e-5	Multiple sclerosis;
PAAD	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.51	-4.51	-0.34	1.28e-5	Response to antidepressants in depression;
PAAD	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg18867708	chr6:26865862	GUSBL1	0.45	4.54	0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.61	7.2	0.5	2.52e-11	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg14926445	chr8:58193284	C8orf71	-0.71	-5.12	-0.38	9.33e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg08888203	chr3:10149979	C3orf24	0.7	6.26	0.45	3.8e-9	Alzheimer's disease;
PAAD	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.76e-8	Schizophrenia;
PAAD	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg12639453	chr1:2035780	PRKCZ	0.54	5.03	0.38	1.36e-6	Height;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg23034840	chr1:205782522	SLC41A1	0.73	7.34	0.51	1.23e-11	Monocyte percentage of white cells;
PAAD	cis	rs111342015	1.000	rs111342015	chr6:43227141	G/A	cg17076780	chr6:43251928	TTBK1	0.58	4.43	0.34	1.78e-5	Breast cancer;
PAAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg09873201	chr16:3507582	NAT15	0.6	5.61	0.41	9.38e-8	Tuberculosis;
PAAD	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.45e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10219575	chr19:59084223	MZF1;LOC100131691	0.6	6.65	0.47	4.93e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.76	-6.48	-0.47	1.2e-9	Vitiligo;
PAAD	cis	rs6688613	1.000	rs6682062	chr1:166949979	C/G	cg07049167	chr1:166818506	POGK	-0.48	-4.67	-0.35	6.52e-6	Refractive astigmatism;
PAAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	8.09	0.55	1.81e-13	Prudent dietary pattern;
PAAD	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.83	8.76	0.58	3.58e-15	Itch intensity from mosquito bite;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg10729496	chr3:10149963	C3orf24	0.94	7.95	0.54	3.95e-13	Alzheimer's disease;
PAAD	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.46	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg04197135	chr11:65769867	EIF1AD;BANF1	0.47	4.56	0.35	1.03e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7772697	0.635	rs1890612	chr6:149414461	G/A	cg21368479	chr6:149415018	NA	0.45	4.58	0.35	9.73e-6	Diabetic retinopathy;
PAAD	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs17032980	0.866	rs6546280	chr2:67314661	C/T	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.01e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs600626	0.945	rs499974	chr11:75455021	G/T	cg24262691	chr11:75473276	NA	0.5	4.77	0.36	4.29e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.56	-4.78	-0.36	4.16e-6	Myeloid white cell count;
PAAD	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.42	4.41	0.34	1.94e-5	Psoriasis;
PAAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.45	0.57	2.19e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs8005172	0.676	rs33990647	chr14:88405899	T/C	cg18078958	chr14:88630771	NA	0.46	5.53	0.41	1.35e-7	Parkinson's disease;
PAAD	cis	rs797680	0.856	rs1535699	chr1:93804952	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.46	0.34	1.56e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.46	-0.34	1.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg20893579	chr22:38215064	NA	-0.47	-4.91	-0.37	2.31e-6	Glioblastoma;Glioma;
PAAD	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg20913747	chr6:44695427	NA	0.69	6.86	0.49	1.62e-10	Total body bone mineral density;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03965827	chr15:50979356	TRPM7	0.58	6.5	0.47	1.1e-9	Metabolite levels  (X-11787);
PAAD	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.65	-5.71	-0.42	5.87e-8	Mean corpuscular volume;
PAAD	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.97	0.49	8.91e-11	Yeast infection;
PAAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02071572	chr4:1403502	NA	0.36	4.6	0.35	8.82e-6	Longevity;
PAAD	cis	rs2594989	0.895	rs2606741	chr3:11392426	G/A	cg01796438	chr3:11312864	ATG7	-0.52	-4.46	-0.34	1.59e-5	Circulating chemerin levels;
PAAD	cis	rs2010672	0.500	rs9888660	chr15:91160768	C/T	cg15547629	chr15:90437138	AP3S2	-0.51	-4.3	-0.33	3.03e-5	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.54	0.35	1.14e-5	Calcium levels;
PAAD	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg02696790	chr15:75250997	RPP25	-0.37	-4.53	-0.34	1.18e-5	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.52	-5.51	-0.41	1.51e-7	Male-pattern baldness;
PAAD	cis	rs2885056	0.891	rs2304161	chr19:10692117	T/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.34	0.6	1.12e-16	Red cell distribution width;
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.91e-6	Life satisfaction;
PAAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.46	5.03	0.38	1.34e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.7	5.75	0.42	4.71e-8	Alzheimer's disease;
PAAD	cis	rs3206736	0.548	rs1637676	chr7:35000559	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs733175	0.794	rs10033088	chr4:10057712	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.64	0.35	7.61e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.45	4.5	0.34	1.32e-5	Type 2 diabetes;
PAAD	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.74	-6.32	-0.46	2.76e-9	Exhaled nitric oxide output;
PAAD	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs11696501	0.688	rs8123346	chr20:44309987	A/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.62	-0.35	8.27e-6	Platelet count;
PAAD	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg21300403	chr2:198650112	BOLL	-0.53	-4.71	-0.36	5.64e-6	Dermatomyositis;
PAAD	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.46	4.88	0.37	2.61e-6	Age of smoking initiation;
PAAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.4	1.93e-7	Personality dimensions;
PAAD	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs73206853	0.614	rs12322130	chr12:110512408	C/T	cg12870014	chr12:110450643	ANKRD13A	0.87	4.77	0.36	4.28e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg11262906	chr1:85462892	MCOLN2	-0.67	-5.12	-0.38	9.02e-7	Serum sulfate level;
PAAD	trans	rs785830	0.558	rs2479326	chr9:258914	G/C	cg17093826	chr7:138458720	ATP6V0A4	0.51	6.7	0.48	3.88e-10	Platelet distribution width;
PAAD	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.43	4.28	0.33	3.32e-5	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg00571178	chr13:114841904	RASA3	-0.56	-4.65	-0.35	7.18e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.41e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.78	-7.98	-0.54	3.33e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs58521262	0.585	rs2927367	chr19:23230119	A/G	cg03433597	chr19:22806448	NA	0.24	4.28	0.33	3.34e-5	Testicular germ cell tumor;
PAAD	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.72	7.1	0.5	4.44e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9616064	0.704	rs41346347	chr22:46958507	A/C	cg03318428	chr22:46971703	NA	0.39	4.63	0.35	7.73e-6	Urate levels in obese individuals;
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.57	-5.68	-0.42	6.73e-8	Eye color traits;
PAAD	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg22532475	chr10:104410764	TRIM8	-0.38	-4.54	-0.35	1.15e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg11494091	chr17:61959527	GH2	0.5	4.28	0.33	3.27e-5	Height;
PAAD	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.08	-0.44	9.13e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.98	6.7	0.48	3.76e-10	IgG glycosylation;
PAAD	cis	rs3736485	0.934	rs8038203	chr15:51870683	G/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.28	-0.33	3.35e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.35	-0.82	6.99e-38	Height;
PAAD	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.45	-4.78	-0.36	4.02e-6	Pneumonia;
PAAD	cis	rs58521262	0.685	rs2935443	chr19:23214649	G/C	cg02350677	chr19:23254381	NA	0.27	4.7	0.36	5.73e-6	Testicular germ cell tumor;
PAAD	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.53	-5.64	-0.42	7.91e-8	Dupuytren's disease;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.89	10.97	0.66	5.59e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg27121462	chr16:89883253	FANCA	0.79	4.77	0.36	4.2e-6	Skin colour saturation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00374333	chr2:224702156	AP1S3	-0.65	-6.33	-0.46	2.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.29	0.45	3.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7009516	0.669	rs13280953	chr8:24250161	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.48	-5.56	-0.41	1.17e-7	Hair greying;
PAAD	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.68	6.17	0.45	5.93e-9	Birth weight;
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.78e-6	Lung cancer;
PAAD	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26687565	chr4:141072046	MAML3	0.59	6.89	0.49	1.38e-10	Immature fraction of reticulocytes;
PAAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg16147221	chr4:10020634	SLC2A9	0.47	4.34	0.33	2.54e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.95	-8.25	-0.56	7.21e-14	Alzheimer's disease;
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs877529	0.605	rs139381	chr22:39526296	T/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.82	-0.48	2.05e-10	Multiple myeloma;
PAAD	cis	rs7168592	1.000	rs35059326	chr15:101746312	G/A	cg24254196	chr15:101719523	CHSY1	-0.69	-4.88	-0.37	2.62e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.39	-0.4	2.63e-7	Total cholesterol levels;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.63	8.05	0.55	2.21e-13	Hypertriglyceridemia;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg16535667	chr11:65410126	SIPA1	-0.53	-5.02	-0.38	1.42e-6	Blood pressure (age interaction);
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg11843238	chr5:131593191	PDLIM4	0.52	4.95	0.37	1.91e-6	Acylcarnitine levels;
PAAD	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.58	-5.94	-0.43	1.82e-8	Pelvic organ prolapse;
PAAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg10556349	chr10:835070	NA	-0.49	-4.61	-0.35	8.45e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.95	7.99	0.54	3.19e-13	Dupuytren's disease;
PAAD	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg01851573	chr8:8652454	MFHAS1	0.55	4.76	0.36	4.51e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.8	5.7	0.42	6.09e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg00179576	chr16:74483694	GLG1	-0.42	-4.6	-0.35	8.76e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg07202610	chr7:1142643	C7orf50	-0.76	-5.38	-0.4	2.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.02	-0.44	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01790346	chr8:119634302	SAMD12	0.55	6.29	0.45	3.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11141652	chr22:24348549	GSTTP1	0.51	4.61	0.35	8.45e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.57	-6.51	-0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-4.37	-0.33	2.33e-5	Magnesium levels;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.86	7.17	0.5	3.11e-11	Alzheimer's disease;
PAAD	cis	rs6066835	1.000	rs6066815	chr20:47299870	T/C	cg18078177	chr20:47281410	PREX1	1.01	4.98	0.37	1.72e-6	Multiple myeloma;
PAAD	cis	rs13242816	1.000	rs987790	chr7:116134633	T/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22485171	chr5:169010600	CCDC99	0.61	6.52	0.47	9.82e-10	Myopia (pathological);
PAAD	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg09661984	chr15:25513376	HBII-52-46	1.04	6.4	0.46	1.81e-9	Major depressive disorder;
PAAD	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs5753618	0.539	rs695438	chr22:31811876	G/C	cg02404636	chr22:31891804	SFI1	0.61	6.12	0.44	7.6e-9	Colorectal cancer;
PAAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.39e-8	Tonsillectomy;
PAAD	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg12046867	chr14:103022105	NA	-0.63	-4.96	-0.37	1.85e-6	Platelet count;
PAAD	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg15440763	chr7:158190612	PTPRN2	0.49	5.0	0.38	1.55e-6	Obesity-related traits;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.46	-4.29	-0.33	3.18e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.4	-4.83	-0.37	3.24e-6	Blood metabolite levels;
PAAD	cis	rs2229238	1.000	rs2229238	chr1:154437896	T/C	cg21262032	chr1:154437693	IL6R	0.46	4.73	0.36	5.14e-6	Coronary heart disease;
PAAD	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg11143131	chr5:131608246	PDLIM4	-0.5	-4.92	-0.37	2.2e-6	Blood metabolite levels;
PAAD	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg15017067	chr4:17643749	FAM184B	0.44	4.86	0.37	2.91e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.67	-5.31	-0.4	3.79e-7	Vitiligo;
PAAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.66	-0.53	2.05e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	4.68	0.35	6.29e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.87	-10.24	-0.64	4.71e-19	Coronary artery disease;
PAAD	cis	rs5751901	0.688	rs2017869	chr22:24997309	C/G	cg08808123	chr22:24999002	GGT1	-0.45	-4.94	-0.37	2.06e-6	Protein quantitative trait loci;
PAAD	cis	rs8077577	0.945	rs9916193	chr17:18057215	C/G	cg16794390	chr17:18148240	FLII	0.67	5.58	0.41	1.08e-7	Obesity-related traits;
PAAD	cis	rs17032980	0.866	rs2222849	chr2:67306032	G/C	cg06994420	chr2:66672553	MEIS1	-0.5	-4.43	-0.34	1.79e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.7e-6	Cognitive function;
PAAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.58	5.1	0.38	9.81e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.61	-5.4	-0.4	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg00431813	chr7:1051703	C7orf50	-0.35	-4.48	-0.34	1.45e-5	Longevity;Endometriosis;
PAAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg15117754	chr3:10150083	C3orf24	0.68	5.87	0.43	2.66e-8	Alzheimer's disease;
PAAD	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg21181453	chr9:130700954	DPM2	0.42	4.86	0.37	2.9e-6	Glaucoma (primary angle closure);
PAAD	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg23346134	chr3:49453900	TCTA	0.44	4.83	0.36	3.29e-6	Menarche (age at onset);
PAAD	cis	rs7873102	0.653	rs12339915	chr9:37993508	G/A	cg03528946	chr9:38069800	SHB	-0.52	-5.21	-0.39	6.15e-7	Brain structure;
PAAD	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12812760	chr12:53645951	MFSD5	0.6	6.54	0.47	8.99e-10	Myopia (pathological);
PAAD	cis	rs7219021	0.926	rs7209437	chr17:46855267	A/G	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11739721	chr1:65532755	NA	0.63	7.63	0.53	2.4e-12	Immature fraction of reticulocytes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25764190	chr19:44037015	ZNF575	0.61	6.94	0.49	1.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs559928	0.692	rs915987	chr11:64027888	G/A	cg26898376	chr11:64110657	CCDC88B	0.54	4.54	0.35	1.16e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.54	4.82	0.36	3.47e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.78	6.73	0.48	3.25e-10	Response to amphetamines;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26549601	chr10:134560360	INPP5A	-0.49	-4.77	-0.36	4.33e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.75	9.23	0.6	2.14e-16	Alcohol dependence;
PAAD	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg00147160	chr1:26503991	CNKSR1	0.42	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs3112530	1.000	rs2927174	chr5:152651538	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs7752195	0.730	rs116418977	chr6:25365888	C/T	cg26336265	chr6:25042955	NA	0.86	4.82	0.36	3.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.33	0.33	2.75e-5	Asthma;
PAAD	cis	rs2562456	0.876	rs4638726	chr19:21592512	A/G	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.3	4.32	0.33	2.85e-5	Alopecia areata;
PAAD	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	1.05	9.45	0.61	5.94e-17	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05159043	chr1:43282594	ERMAP;CCDC23	0.66	6.45	0.46	1.39e-9	Obesity-related traits;
PAAD	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.59	-0.41	1.02e-7	Neuroticism;
PAAD	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg10223061	chr2:219282414	VIL1	-0.37	-4.44	-0.34	1.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13115616	chr1:17338059	ATP13A2	0.67	6.8	0.48	2.2e-10	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1723838	1.000	rs1792164	chr11:73548670	G/A	cg26954736	chr11:73693896	UCP2	1.14	4.82	0.36	3.46e-6	Obesity-related traits;
PAAD	cis	rs2964802	0.505	rs10513058	chr5:10804383	C/T	cg14521931	chr5:10832172	NA	-0.47	-4.76	-0.36	4.43e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs58521262	0.556	rs1645774	chr19:23216667	C/T	cg02350677	chr19:23254381	NA	0.26	4.57	0.35	1.01e-5	Testicular germ cell tumor;
PAAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs3753841	0.832	rs921416	chr1:103228579	C/T	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	1.01	5.65	0.42	7.67e-8	Parkinson's disease;
PAAD	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.97	-0.37	1.82e-6	Fibrinogen levels;
PAAD	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.48	-0.34	1.46e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.85	9.28	0.6	1.63e-16	Mortality in heart failure;
PAAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs7487075	0.619	rs7485599	chr12:46830479	A/G	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg18135206	chr14:102964638	TECPR2	0.55	4.42	0.34	1.87e-5	Blood protein levels;
PAAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg04106633	chr4:1044584	NA	0.65	5.62	0.41	8.78e-8	Recombination rate (females);
PAAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg13777783	chr17:79615861	NA	0.41	4.3	0.33	3.04e-5	Eye color traits;
PAAD	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.76	-0.53	1.14e-12	Hemoglobin concentration;
PAAD	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-1.1	-8.11	-0.55	1.61e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12802720	chr12:52467448	C12orf44	-0.74	-7.7	-0.53	1.6e-12	Obesity-related traits;
PAAD	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.52	0.41	1.4e-7	Coronary heart disease;
PAAD	cis	rs7957197	0.624	rs55805582	chr12:121486388	G/T	cg02419362	chr12:121203948	SPPL3	-0.6	-4.27	-0.33	3.42e-5	Type 2 diabetes;
PAAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.88	0.37	2.71e-6	Menopause (age at onset);
PAAD	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.84	-10.05	-0.63	1.5e-18	Body mass index;
PAAD	cis	rs73198271	0.515	rs79282666	chr8:8638225	T/C	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	1e-6	Electrocardiographic conduction measures;
PAAD	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.6	-5.58	-0.41	1.09e-7	Mosquito bite size;
PAAD	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.94	8.2	0.55	9.52e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.37	10.26	0.64	4.36e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.48	4.47	0.34	1.54e-5	Lewy body disease;
PAAD	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.49	4.34	0.33	2.55e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs7202877	0.561	rs8050662	chr16:75360734	A/G	cg03315344	chr16:75512273	CHST6	-0.63	-5.35	-0.4	3.11e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-6.82	-0.48	2.01e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.88	0.37	2.7e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16083429	chr3:49237500	CCDC36	-0.47	-5.32	-0.4	3.73e-7	Menarche (age at onset);
PAAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23158103	chr7:148848205	ZNF398	-0.52	-4.71	-0.36	5.55e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs2036225	1.000	rs2036225	chr12:99190372	C/T	cg03437318	chr12:56474175	ERBB3	0.63	6.32	0.46	2.72e-9	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	5.91	0.43	2.15e-8	Bipolar disorder;
PAAD	cis	rs1198430	0.714	rs1198437	chr1:23747424	G/C	cg19827787	chr1:23763612	ASAP3	0.55	4.74	0.36	4.89e-6	Total cholesterol levels;
PAAD	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.2	10.17	0.64	7.48e-19	Uric acid levels;
PAAD	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.51	-5.24	-0.39	5.37e-7	Total body bone mineral density;
PAAD	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg02696790	chr15:75250997	RPP25	-0.41	-4.84	-0.37	3.2e-6	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7246865	0.510	rs1551551	chr19:17170541	G/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.6	0.41	9.66e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg24634471	chr8:143751801	JRK	-0.51	-4.61	-0.35	8.59e-6	Urinary tract infection frequency;
PAAD	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs6504108	0.560	rs2072441	chr17:46185014	C/G	cg02219949	chr17:45927392	SP6	0.39	4.27	0.33	3.42e-5	Body mass index;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.64	7.97	0.54	3.41e-13	Lymphocyte counts;
PAAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.67	10.14	0.64	8.79e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg13540341	chr19:49222985	MAMSTR	0.44	5.13	0.38	8.68e-7	Dietary macronutrient intake;
PAAD	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg03909863	chr11:638404	DRD4	-0.6	-5.54	-0.41	1.29e-7	Systemic lupus erythematosus;
PAAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.7	-0.36	5.7e-6	Diastolic blood pressure;
PAAD	cis	rs2882667	0.690	rs311608	chr5:138043689	A/C	cg09476006	chr5:138032270	NA	0.52	6.55	0.47	8.31e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg23598562	chr12:53773812	SP1	0.45	4.28	0.33	3.34e-5	Height;
PAAD	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg19090574	chr1:205240910	TMCC2	-0.41	-4.47	-0.34	1.53e-5	Red blood cell count;
PAAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.28	0.51	1.65e-11	Eosinophil percentage of white cells;
PAAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Calcium levels;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04759335	chr10:21784250	C10orf114	0.46	5.07	0.38	1.14e-6	Monocyte percentage of white cells;
PAAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.51	-4.7	-0.36	5.85e-6	Urate levels;
PAAD	cis	rs12304921	1.000	rs73295896	chr12:51351846	G/C	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.17	18.93	0.84	8.23e-42	Platelet distribution width;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12871124	chr5:110848106	STARD4	-0.66	-7.04	-0.5	6.19e-11	Smoking initiation;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs11203032	0.831	rs4078488	chr10:90966546	C/T	cg16672925	chr10:90967113	CH25H	0.78	6.04	0.44	1.16e-8	Heart failure;
PAAD	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.48	4.96	0.37	1.9e-6	Social autistic-like traits;
PAAD	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-1.1	-11.79	-0.69	3.45e-23	Longevity;
PAAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.48	-4.77	-0.36	4.36e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.49	6.58	0.47	7.04e-10	Thyroid hormone levels;
PAAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg04450456	chr4:17643702	FAM184B	0.52	5.87	0.43	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.78	8.04	0.55	2.35e-13	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11295144	chr17:33447001	RAD51L3	0.66	6.81	0.48	2.16e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg07959490	chr17:80112427	CCDC57	0.36	4.26	0.33	3.53e-5	Life satisfaction;
PAAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.6	6.02	0.44	1.28e-8	Height;
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.7	8.21	0.55	8.81e-14	Height;
PAAD	cis	rs2882667	0.690	rs17031	chr5:138270542	A/T	cg09476006	chr5:138032270	NA	0.42	5.09	0.38	1.07e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg18370025	chr7:2749541	AMZ1	0.41	5.02	0.38	1.44e-6	Height;
PAAD	cis	rs354033	0.614	rs1965620	chr7:149193239	T/C	cg06920324	chr7:149264011	ZNF767	-0.62	-5.28	-0.39	4.45e-7	Multiple sclerosis;
PAAD	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16417436	chr16:28758564	NA	0.47	4.39	0.34	2.14e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6908034	0.607	rs78402429	chr6:19811690	C/A	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.75	8.35	0.56	4.04e-14	Menopause (age at onset);
PAAD	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs8014252	0.803	rs57339942	chr14:71083307	T/A	cg11204974	chr14:71022665	NA	-0.81	-4.91	-0.37	2.3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.52	-5.56	-0.41	1.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg20243544	chr17:37824526	PNMT	0.52	4.68	0.35	6.37e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs155346	0.901	rs265179	chr5:139365452	C/G	cg01090482	chr5:139365336	NRG2	-0.43	-4.25	-0.33	3.65e-5	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
PAAD	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg17366294	chr4:99064904	C4orf37	-0.47	-5.21	-0.39	5.97e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg27565382	chr3:53032988	SFMBT1	0.8	4.64	0.35	7.45e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.6	6.09	0.44	9.01e-9	Monocyte count;
PAAD	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg04156016	chr5:1868137	NA	0.43	4.38	0.33	2.2e-5	Cardiovascular disease risk factors;
PAAD	trans	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.64	6.03	0.44	1.17e-8	Parkinson's disease;
PAAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg19337854	chr7:99768885	GPC2	-0.45	-4.83	-0.36	3.33e-6	Coronary artery disease;
PAAD	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg24881330	chr22:46731750	TRMU	1.09	5.5	0.41	1.58e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.68	7.82	0.54	8.33e-13	Bladder cancer;
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.4	-4.35	-0.33	2.52e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.17	-0.45	5.78e-9	Hypospadias;
PAAD	cis	rs11871801	0.560	rs1905339	chr17:40582296	T/C	cg09776463	chr17:40836087	CNTNAP1	-0.55	-5.08	-0.38	1.07e-6	Crohn's disease;
PAAD	cis	rs4908768	0.579	rs11121237	chr1:8876392	A/G	cg25722041	chr1:8623473	RERE	0.52	4.56	0.35	1.04e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg09579323	chr1:150459698	TARS2	0.45	4.31	0.33	2.96e-5	Migraine;
PAAD	cis	rs9487051	0.621	rs351726	chr6:109548304	C/T	cg21918786	chr6:109611834	NA	-0.42	-4.37	-0.33	2.34e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.58	-6.5	-0.47	1.07e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08015590	chr7:2281924	NUDT1;FTSJ2	0.59	6.55	0.47	8.43e-10	Monocyte percentage of white cells;
PAAD	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-1.1	-16.3	-0.8	3.56e-35	Breast cancer;
PAAD	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg22705602	chr4:152727874	NA	-0.47	-5.06	-0.38	1.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.88	9.58	0.61	2.66e-17	Cognitive function;
PAAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.95	12.79	0.72	6.87e-26	Menopause (age at onset);
PAAD	cis	rs34156428	0.929	rs35925952	chr11:16600859	C/A	cg05607053	chr11:16424708	SOX6	0.51	4.25	0.33	3.76e-5	Coronary artery disease;
PAAD	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.9	-10.16	-0.64	7.68e-19	Obesity-related traits;
PAAD	cis	rs722599	0.501	rs2286912	chr14:75385437	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.63	-6.1	-0.44	8.24e-9	IgG glycosylation;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg03188948	chr7:1209495	NA	0.56	5.74	0.42	4.94e-8	Longevity;Endometriosis;
PAAD	cis	rs8133932	0.654	rs402039	chr21:47358809	A/G	cg11214348	chr21:47283868	PCBP3	-0.49	-4.45	-0.34	1.68e-5	Schizophrenia;
PAAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.58	0.61	2.63e-17	Menarche (age at onset);
PAAD	cis	rs7936247	1.000	rs7936247	chr11:92690032	G/T	cg26929280	chr11:92402250	FAT3	-0.42	-4.25	-0.33	3.78e-5	Glycemic traits (pregnancy);
PAAD	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg10072921	chr12:121022843	NA	0.46	5.5	0.41	1.61e-7	Type 1 diabetes nephropathy;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg12152193	chr5:175954583	RNF44	-0.64	-6.33	-0.46	2.66e-9	Primary biliary cholangitis;
PAAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.85	0.54	6.92e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11681884	0.786	rs11887249	chr2:113809266	C/T	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.95	-7.69	-0.53	1.75e-12	Blood protein levels;
PAAD	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.55	-7.07	-0.5	5.15e-11	Longevity;
PAAD	cis	rs1434579	0.798	rs12460231	chr19:44954688	A/T	cg08319238	chr19:45312525	BCAM	-0.37	-4.26	-0.33	3.52e-5	Tuberculosis;
PAAD	cis	rs13056815	1	rs13056815	chr22:31668250	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12438356	0.881	rs12440884	chr15:69575120	T/G	cg02375503	chr15:69591110	PAQR5	-0.52	-4.26	-0.33	3.53e-5	CTACK levels;
PAAD	cis	rs367943	0.698	rs10050530	chr5:112971042	A/C	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs4917833	0.816	rs4917834	chr10:100217879	C/T	cg19043522	chr10:100227446	HPSE2	0.45	4.29	0.33	3.11e-5	Pediatric bone mineral density (femoral neck);
PAAD	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.54	5.2	0.39	6.32e-7	Multiple myeloma;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.67	-6.27	-0.45	3.57e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14169450	chr9:139327907	INPP5E	0.75	9.07	0.59	5.61e-16	Monocyte percentage of white cells;
PAAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg07617317	chr6:118971624	C6orf204	0.52	4.41	0.34	1.95e-5	Diastolic blood pressure;
PAAD	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.17e-6	Schizophrenia;
PAAD	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg26597838	chr10:835615	NA	0.5	5.44	0.4	2.07e-7	Survival in rectal cancer;
PAAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs12304921	1.000	rs56402416	chr12:51357791	G/A	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.67	-0.42	6.89e-8	Type 2 diabetes;
PAAD	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.61	-6.05	-0.44	1.07e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs138918	0.967	rs105585	chr22:43557492	G/A	cg08909806	chr22:43548696	TSPO	0.45	4.45	0.34	1.66e-5	Monocyte count;
PAAD	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.28	0.33	3.24e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.63	4.61	0.35	8.52e-6	Alzheimer's disease (survival time);
PAAD	cis	rs4740619	0.689	rs1328283	chr9:15926469	T/G	cg14451791	chr9:16040625	NA	-0.4	-4.47	-0.34	1.49e-5	Body mass index;
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7719624	0.692	rs2237065	chr5:135367220	C/T	cg16684184	chr5:135415129	NA	-0.43	-5.37	-0.4	2.86e-7	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10887741	0.646	rs12257469	chr10:89437129	G/A	cg13926569	chr10:89418898	PAPSS2	0.5	5.14	0.38	8.38e-7	Exercise (leisure time);
PAAD	cis	rs73787773	0.799	rs7730334	chr5:111495150	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.75	-4.44	-0.34	1.74e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.36	-0.33	2.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.45	4.46	0.34	1.6e-5	Bipolar disorder;
PAAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.39	0.46	1.96e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.52	0.41	1.41e-7	Alcohol dependence;
PAAD	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.64	6.13	0.45	7.17e-9	Post bronchodilator FEV1;
PAAD	cis	rs6724465	0.929	rs77945941	chr2:219973745	G/C	cg25908985	chr2:219925065	IHH	0.66	4.3	0.33	2.99e-5	Height;
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.91	11.9	0.69	1.74e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg10856724	chr12:34555212	NA	0.41	4.29	0.33	3.2e-5	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.48	-0.34	1.46e-5	Neuroticism;
PAAD	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1642645	0.872	rs4660586	chr1:42407229	C/T	cg01990334	chr1:42801334	FOXJ3	-0.65	-5.79	-0.43	3.91e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.5	-0.34	1.32e-5	Platelet count;
PAAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.83	-0.43	3.23e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg18200150	chr17:30822561	MYO1D	0.57	7.34	0.51	1.24e-11	Schizophrenia;
PAAD	cis	rs28647808	1.000	rs2285482	chr9:136271792	G/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.57	5.63	0.42	8.5e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs11811982	0.793	rs79892036	chr1:227404012	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.44	7.26	0.51	1.82e-11	Mean corpuscular volume;
PAAD	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.08	0.63	1.31e-18	Smoking behavior;
PAAD	cis	rs151997	0.925	rs27579	chr5:50165147	G/A	cg06027927	chr5:50259733	NA	0.8	7.79	0.53	9.64e-13	Callous-unemotional behaviour;
PAAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg06740227	chr12:86229804	RASSF9	-0.54	-5.39	-0.4	2.59e-7	Major depressive disorder;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg11218175	chr11:495084	RNH1	0.77	4.44	0.34	1.69e-5	Body mass index;
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10870443	chr9:98270489	PTCH1	-0.63	-5.07	-0.38	1.14e-6	Neuroticism;
PAAD	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs4742903	0.935	rs1507507	chr9:106949429	A/G	cg14250997	chr9:106856677	SMC2	0.42	4.48	0.34	1.46e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg19630374	chr17:18023558	MYO15A	-0.55	-5.67	-0.42	7.05e-8	Total body bone mineral density;
PAAD	cis	rs6066835	1.000	rs6095249	chr20:47321045	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg00666640	chr1:248458726	OR2T12	0.65	5.57	0.41	1.15e-7	Common traits (Other);
PAAD	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.51	-5.17	-0.39	7.41e-7	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19300475	chr17:27230118	DHRS13	0.65	6.48	0.47	1.21e-9	Obesity-related traits;
PAAD	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.52	7.0	0.49	7.61e-11	Ewing sarcoma;
PAAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.9	0.37	2.42e-6	Breast cancer;
PAAD	cis	rs12144094	0.766	rs74984954	chr1:120234068	G/A	cg20995928	chr1:120229863	NA	0.52	4.68	0.36	6.25e-6	Height;
PAAD	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.46	4.94	0.37	2.05e-6	Educational attainment;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23397993	chr18:29598919	RNF125	-0.74	-6.49	-0.47	1.12e-9	Neuroticism;
PAAD	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02685945	chr6:22570146	HDGFL1	0.6	6.44	0.46	1.51e-9	Warfarin maintenance dose;
PAAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.41	-4.55	-0.35	1.08e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.59	-5.96	-0.44	1.68e-8	Hypospadias;
PAAD	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-7.01	-0.49	7.22e-11	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg02046226	chr10:121410475	BAG3	0.96	6.55	0.47	8.29e-10	Airflow obstruction;
PAAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.58	5.69	0.42	6.32e-8	Methadone dose in opioid dependence;
PAAD	trans	rs62179067	0.708	rs62175990	chr2:179883455	C/G	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.03	0.5	6.66e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62238980	0.831	rs62239006	chr22:32593663	C/T	cg02631450	chr22:32366979	NA	0.98	4.64	0.35	7.48e-6	Childhood ear infection;
PAAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.41	-0.34	1.98e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs115221473	chr3:128547136	T/G	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.44	4.3	0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs6867913	0.533	rs252152	chr5:141445774	A/G	cg23435118	chr5:141488016	NDFIP1	-0.52	-5.48	-0.41	1.72e-7	Asthma;
PAAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.55	-5.41	-0.4	2.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg02743256	chr7:2109353	MAD1L1	-0.72	-5.48	-0.41	1.76e-7	Bipolar disorder;
PAAD	cis	rs709400	0.633	rs10135868	chr14:104004147	T/C	cg26031613	chr14:104095156	KLC1	0.74	7.58	0.52	3.08e-12	Body mass index;
PAAD	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-9.08	-0.59	5.35e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.49	-4.62	-0.35	8.08e-6	Obesity-related traits;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg15117754	chr3:10150083	C3orf24	0.65	6.21	0.45	4.82e-9	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.85e-25	Prudent dietary pattern;
PAAD	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs41307935	0.596	rs34204245	chr1:27204183	T/C	cg12203394	chr1:27248618	NUDC	0.64	4.57	0.35	9.9e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs501120	0.810	rs541483	chr10:44746395	A/G	cg09554077	chr10:44749378	NA	0.49	6.49	0.47	1.17e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06850241	chr22:41845214	NA	-0.53	-4.88	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg06217245	chr20:33103252	DYNLRB1	0.44	4.97	0.37	1.81e-6	Height;
PAAD	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.79	6.12	0.44	7.44e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.88	5.83	0.43	3.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.6	5.44	0.4	2.13e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.55	-8.19	-0.55	1.02e-13	Social autistic-like traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10714403	chr17:55162284	AKAP1	-0.79	-6.86	-0.49	1.65e-10	Neuroticism;
PAAD	cis	rs2031532	0.544	rs9526563	chr13:50045749	C/T	cg03651054	chr13:50194643	NA	0.32	4.29	0.33	3.11e-5	Cardiac hypertrophy;
PAAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	trans	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg04154034	chr17:28927549	LRRC37B2	0.7	4.39	0.34	2.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.45	4.37	0.33	2.3e-5	Electroencephalogram traits;
PAAD	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.46	-5.0	-0.38	1.55e-6	HDL cholesterol;
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.45	0.34	1.66e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.71	5.83	0.43	3.22e-8	Alzheimer's disease;
PAAD	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.27	-0.39	4.5e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-4.67	-0.35	6.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.88	9.16	0.6	3.41e-16	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.32	7.87	0.54	6.32e-13	Body mass index;
PAAD	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.47	-4.31	-0.33	2.88e-5	Diastolic blood pressure;
PAAD	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.26	-0.33	3.52e-5	Triglycerides;
PAAD	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg00262122	chr8:11665843	FDFT1	-0.49	-4.31	-0.33	2.89e-5	Retinal vascular caliber;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg06815965	chr1:205818668	PM20D1	0.58	6.46	0.46	1.35e-9	Menarche (age at onset);
PAAD	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-4.27	-0.33	3.47e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg18302933	chr2:88491318	NA	-0.37	-4.33	-0.33	2.72e-5	Response to metformin (IC50);
PAAD	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.7	6.2	0.45	5.14e-9	Platelet count;
PAAD	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg06606381	chr12:133084897	FBRSL1	-1.48	-9.35	-0.6	1.09e-16	Urinary tract infection frequency;
PAAD	cis	rs4455778	0.658	rs111468777	chr7:49117642	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs10267417	0.603	rs6966428	chr7:19891587	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	4.75	0.36	4.71e-6	Night sleep phenotypes;
PAAD	trans	rs7137515	0.541	rs11115179	chr12:82466920	A/T	cg12623302	chr6:28058802	ZSCAN12L1	-0.54	-6.38	-0.46	2.08e-9	IgG glycosylation;
PAAD	cis	rs28785552	0.554	rs11084183	chr19:53213517	T/C	cg10871876	chr19:53194124	ZNF83	0.49	4.48	0.34	1.44e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.88	-11.93	-0.7	1.41e-23	Vitiligo;
PAAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.49	6.31	0.46	2.96e-9	Schizophrenia;
PAAD	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	9.27e-7	Motion sickness;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.9	12.65	0.72	1.61e-25	Age-related hearing impairment;
PAAD	cis	rs7168592	1.000	rs35050682	chr15:101737021	G/C	cg24254196	chr15:101719523	CHSY1	-0.68	-4.83	-0.37	3.24e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.6	7.36	0.51	1.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.72	-6.16	-0.45	6.33e-9	Cognitive test performance;
PAAD	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg16794390	chr17:18148240	FLII	0.57	4.83	0.36	3.35e-6	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.3e-5	Menopause (age at onset);
PAAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.85	-6.3	-0.46	3.05e-9	Prostate-specific antigen levels;
PAAD	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.97	-8.64	-0.57	7.11e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9657904	0.865	rs6437624	chr3:105590427	C/T	cg16975614	chr3:105601834	NA	-0.46	-4.42	-0.34	1.89e-5	Multiple sclerosis;
PAAD	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg01851573	chr8:8652454	MFHAS1	0.94	7.24	0.51	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.83	-7.75	-0.53	1.23e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.28	0.68	7.83e-22	Platelet count;
PAAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.42	-5.15	-0.39	8.02e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs4455778	0.580	rs6976152	chr7:49087711	A/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.75	7.47	0.52	5.87e-12	Corneal astigmatism;
PAAD	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-5.55	-0.41	1.23e-7	Cognitive function;
PAAD	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg16176600	chr6:116381609	FRK	0.28	4.27	0.33	3.4e-5	Total cholesterol levels;
PAAD	cis	rs793571	0.822	rs173214	chr15:59160188	A/G	cg05156742	chr15:59063176	FAM63B	0.59	4.56	0.35	1.04e-5	Schizophrenia;
PAAD	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.8	8.19	0.55	9.93e-14	Tuberculosis;
PAAD	cis	rs67133203	0.904	rs12809563	chr12:51356673	T/C	cg02675652	chr12:51477739	CSRNP2	0.49	4.3	0.33	2.99e-5	Urinary tract infection frequency;
PAAD	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg16512390	chr1:228756714	NA	0.58	4.55	0.35	1.11e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01283332	chr5:1856932	NA	-0.44	-4.54	-0.35	1.12e-5	Cardiovascular disease risk factors;
PAAD	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.06e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg11962587	chr1:145515913	GNRHR2;PEX11B	0.54	5.24	0.39	5.18e-7	HIV-1 control;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs2882667	0.690	rs7710288	chr5:138179738	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15451585	chr14:74444008	ENTPD5	-0.61	-7.06	-0.5	5.52e-11	Obesity-related traits;
PAAD	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.67e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	4.82	0.36	3.38e-6	Iron status biomarkers;
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.64	-8.08	-0.55	1.83e-13	Body mass index;
PAAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.93	-7.92	-0.54	4.63e-13	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.81	5.55	0.41	1.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs9398803	0.687	rs9491652	chr6:126943620	G/C	cg19875578	chr6:126661172	C6orf173	0.45	4.66	0.35	6.89e-6	Male-pattern baldness;
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	6.47	0.46	1.27e-9	Renal function-related traits (BUN);
PAAD	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.53	5.07	0.38	1.12e-6	Cognitive test performance;
PAAD	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.84	-7.69	-0.53	1.73e-12	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15990192	chr1:116915626	ATP1A1	0.67	7.38	0.51	9.71e-12	Myopia (pathological);
PAAD	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.57	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.84	0.43	2.99e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.27	0.56	6.12e-14	Schizophrenia;
PAAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-5.29	-0.39	4.12e-7	Total body bone mineral density;
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24549020	chr5:56110836	MAP3K1	-0.66	-4.78	-0.36	4.02e-6	Initial pursuit acceleration;
PAAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.27	0.64	4.11e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.99	-10.1	-0.63	1.17e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11643473	chr20:33872632	EIF6	0.58	6.42	0.46	1.64e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg22674798	chr1:3096360	PRDM16	0.61	9.23	0.6	2.2e-16	Migraine;
PAAD	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg09582351	chr12:29534625	ERGIC2	0.31	4.4	0.34	2.02e-5	QT interval;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.58	8.77	0.58	3.44e-15	Hypertriglyceridemia;
PAAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.05	0.5	5.8200000000000003e-11	Rheumatoid arthritis;
PAAD	cis	rs7804356	0.651	rs7802688	chr7:26785832	T/C	cg03456212	chr7:26904342	SKAP2	0.58	5.02	0.38	1.42e-6	Type 1 diabetes;
PAAD	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg27411982	chr8:10470053	RP1L1	-0.52	-5.71	-0.42	5.7e-8	Retinal vascular caliber;
PAAD	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.14	0.73	7.81e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04569364	chr19:57922590	ZNF17	0.61	6.78	0.48	2.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.49	4.91	0.37	2.37e-6	Parkinson's disease;
PAAD	cis	rs877529	0.932	rs139403	chr22:39547021	G/A	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.43e-5	Multiple myeloma;
PAAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	7.06	0.5	5.66e-11	Menarche (age at onset);
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.32	-4.34	-0.33	2.56e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	1.04	14.81	0.77	2.69e-31	Metabolite levels;
PAAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.52	-4.53	-0.34	1.2e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.68	9.91	0.63	3.66e-18	Height;
PAAD	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.51	-4.87	-0.37	2.83e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg05338066	chr1:7812865	CAMTA1	0.55	4.54	0.35	1.15e-5	Inflammatory bowel disease;
PAAD	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg24253500	chr15:84953950	NA	0.57	6.67	0.48	4.45e-10	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.57	5.34	0.4	3.3e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	7.28	0.51	1.65e-11	Eosinophil percentage of white cells;
PAAD	cis	rs802075	0.905	rs2396918	chr6:49636027	A/T	cg20364632	chr6:49636226	NA	-0.56	-6.7	-0.48	3.81e-10	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.32	-0.56	4.56e-14	Longevity;Endometriosis;
PAAD	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg21064579	chr19:49206444	FUT2	0.4	4.28	0.33	3.32e-5	Dietary macronutrient intake;
PAAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.59	5.7	0.42	5.97e-8	Lung cancer;
PAAD	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs228769	0.635	rs228754	chr17:42116056	C/A	cg19774624	chr17:42201019	HDAC5	0.62	4.27	0.33	3.48e-5	Bone mineral density (hip);Bone mineral density (spine);
PAAD	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.53	5.32	0.4	3.69e-7	Crohn's disease;
PAAD	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg00262122	chr8:11665843	FDFT1	0.48	4.62	0.35	8.08e-6	Neuroticism;
PAAD	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs35740288	0.731	rs12913556	chr15:86102196	C/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.59	-0.41	1.04e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2061333	0.557	rs10406335	chr19:44633953	G/A	cg18700516	chr19:44507157	ZNF230	-0.75	-5.15	-0.39	8.06e-7	Alzheimer's disease;
PAAD	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs300774	0.925	rs300735	chr2:167739	C/G	cg23649280	chr2:140451	NA	-0.47	-4.29	-0.33	3.22e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.66	6.33	0.46	2.67e-9	Platelet distribution width;
PAAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.43	5.18	0.39	7.09e-7	Tonsillectomy;
PAAD	cis	rs733175	0.830	rs714873	chr4:10059618	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	4.32	0.33	2.83e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg19630374	chr17:18023558	MYO15A	-0.49	-5.06	-0.38	1.22e-6	Total body bone mineral density;
PAAD	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.96	-0.54	3.69e-13	Neuroticism;
PAAD	cis	rs367943	0.603	rs1864066	chr5:112997865	C/T	cg12552261	chr5:112820674	MCC	0.62	6.67	0.48	4.36e-10	Type 2 diabetes;
PAAD	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.56	-5.67	-0.42	7.11e-8	Menarche (age at onset);
PAAD	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg02917321	chr22:38215204	NA	-0.41	-4.28	-0.33	3.25e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg10616300	chr11:66138557	SLC29A2	0.33	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.29	0.33	3.12e-5	Lung cancer in ever smokers;
PAAD	cis	rs1419980	0.556	rs11054516	chr12:7724875	C/T	cg10578777	chr12:7781093	NA	-0.85	-5.87	-0.43	2.68e-8	HDL cholesterol levels;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg12143784	chr7:64541923	NA	-0.33	-4.27	-0.33	3.39e-5	Aortic root size;
PAAD	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.98	-8.64	-0.57	7.1e-15	Blood protein levels;
PAAD	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg01426195	chr3:39028469	NA	-0.66	-6.23	-0.45	4.45e-9	Handedness;
PAAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.96	8.12	0.55	1.46e-13	Tuberculosis;
PAAD	cis	rs10426930	0.844	rs56386046	chr19:5037230	C/T	cg08036796	chr19:5034282	KDM4B	0.51	5.08	0.38	1.08e-6	Monocyte percentage of white cells;
PAAD	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg09659197	chr4:152720779	NA	0.36	5.2	0.39	6.48e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02351056	chr10:126480372	METTL10	0.61	6.63	0.47	5.49e-10	Myopia (pathological);
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.9	10.83	0.66	1.3e-20	Prudent dietary pattern;
PAAD	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg15654264	chr1:150340011	RPRD2	0.52	5.03	0.38	1.37e-6	Migraine;
PAAD	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg26174226	chr8:58114915	NA	-0.65	-5.74	-0.42	4.98e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.59	-7.86	-0.54	6.55e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.34e-13	Prostate cancer;
PAAD	cis	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.53	-0.35	1.18e-5	Triglycerides;
PAAD	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.71	7.63	0.53	2.44e-12	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.65	5.88	0.43	2.52e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.46	4.36	0.33	2.4e-5	Mean platelet volume;
PAAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg05484376	chr2:27715224	FNDC4	0.48	4.91	0.37	2.34e-6	Total body bone mineral density;
PAAD	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	1.01	10.75	0.66	2.11e-20	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.49	-0.41	1.63e-7	Mood instability;
PAAD	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg04218760	chr10:45406644	TMEM72	-0.29	-4.92	-0.37	2.26e-6	Mean corpuscular volume;
PAAD	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg23435118	chr5:141488016	NDFIP1	-0.53	-5.26	-0.39	4.86e-7	Crohn's disease;
PAAD	cis	rs58653258	0.667	rs2796164	chr1:234979708	A/G	cg03518729	chr1:235147744	NA	0.45	4.31	0.33	2.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.15	-0.39	8.06e-7	Cervical cancer;
PAAD	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.66	5.35	0.4	3.17e-7	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4774830	0.661	rs12443357	chr15:56305980	C/T	cg24530489	chr15:56299380	NA	-0.92	-4.39	-0.34	2.07e-5	Delta-5 desaturase activity;
PAAD	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.51	4.85	0.37	3.04e-6	Itch intensity from mosquito bite;
PAAD	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.36	-4.37	-0.33	2.31e-5	Electrocardiographic conduction measures;
PAAD	cis	rs8005172	0.750	rs11621530	chr14:88430294	C/T	cg18078958	chr14:88630771	NA	0.46	5.34	0.4	3.31e-7	Parkinson's disease;
PAAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	1.07	14.94	0.77	1.28e-31	Breast cancer;
PAAD	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.28	11.12	0.67	2.12e-21	Uric acid levels;
PAAD	cis	rs10483554	0.554	rs7149539	chr14:49870029	T/C	cg10380165	chr14:50360598	ARF6	0.48	4.5	0.34	1.37e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.65	-6.19	-0.45	5.37e-9	Rheumatoid arthritis;
PAAD	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg07810366	chr2:100720526	AFF3	0.36	4.6	0.35	8.67e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs59888335	0.964	rs13072898	chr3:80732016	C/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs12767760	0.669	rs10882963	chr10:99309958	C/T	cg25247692	chr10:99313390	UBTD1	0.5	4.83	0.37	3.24e-6	Obesity-related traits;
PAAD	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.84	9.07	0.59	5.76e-16	Corneal astigmatism;
PAAD	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	8.48	0.57	1.85e-14	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.53	-5.35	-0.4	3.21e-7	Monocyte count;
PAAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.69	6.59	0.47	6.78e-10	Blood metabolite levels;
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22601191	chr20:60968625	CABLES2	-0.54	-5.13	-0.38	8.82e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg00945038	chr17:61921165	SMARCD2	-0.48	-5.74	-0.42	5.05e-8	Prudent dietary pattern;
PAAD	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	5.12	0.38	9.11e-7	Uric acid clearance;
PAAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.59	-0.47	6.83e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs17032980	0.956	rs6546279	chr2:67311393	G/A	cg06994420	chr2:66672553	MEIS1	-0.51	-4.51	-0.34	1.3e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg19192590	chr2:178524533	PDE11A	0.39	4.34	0.33	2.55e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.94	8.62	0.57	7.91e-15	Mitochondrial DNA levels;
PAAD	cis	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.29	-0.33	3.21e-5	Schizophrenia;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01748193	chr11:64335575	SLC22A11	0.56	6.47	0.46	1.3e-9	Warfarin maintenance dose;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg01718231	chr17:29326311	RNF135	-0.63	-6.4	-0.46	1.81e-9	Primary biliary cholangitis;
PAAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.76	0.36	4.43e-6	Menopause (age at onset);
PAAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg01489032	chr8:143877656	NA	-0.39	-4.34	-0.33	2.59e-5	Urinary tract infection frequency;
PAAD	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg03938978	chr2:103052716	IL18RAP	0.6	5.56	0.41	1.16e-7	Blood protein levels;
PAAD	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.9	0.37	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg22027985	chr11:4115532	RRM1	0.48	4.4	0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs13144136	0.786	rs4309833	chr4:10666766	C/T	cg10242279	chr4:10666415	CLNK	0.37	4.63	0.35	7.73e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.72	7.21	0.51	2.41e-11	Obesity-related traits;
PAAD	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg24562669	chr7:97807699	LMTK2	-0.65	-9.09	-0.59	5.18e-16	Breast cancer;
PAAD	cis	rs10991814	0.688	rs76530346	chr9:94010298	G/A	cg14446406	chr9:93919335	NA	0.61	4.88	0.37	2.62e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg17509989	chr5:176798049	RGS14	0.77	7.25	0.51	1.99e-11	Urate levels in lean individuals;
PAAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.66	0.62	1.66e-17	Cognitive function;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.9	-0.49	1.34e-10	Life satisfaction;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.3	0.6	1.47e-16	Lymphocyte counts;
PAAD	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg03684893	chr10:554711	DIP2C	0.46	4.88	0.37	2.62e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.47	-4.53	-0.34	1.21e-5	Proinsulin levels;
PAAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg14515779	chr1:101123966	NA	0.55	6.39	0.46	1.96e-9	Monocyte count;
PAAD	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.86	9.08	0.59	5.33e-16	Body mass index;
PAAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.52	4.99	0.38	1.62e-6	Aortic root size;
PAAD	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-6.65	-0.47	4.94e-10	Morning vs. evening chronotype;
PAAD	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.62	-0.65	4.85e-20	Breast cancer;
PAAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.43	-4.6	-0.35	8.69e-6	Height;
PAAD	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.53	7.32	0.51	1.35e-11	Sitting height ratio;
PAAD	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg26904215	chr21:47823096	PCNT	0.83	4.26	0.33	3.55e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.47	-0.34	1.53e-5	Life satisfaction;
PAAD	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.6	5.83	0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-4.62	-0.35	8.08e-6	Joint mobility (Beighton score);
PAAD	cis	rs7568458	0.783	rs7591175	chr2:85738374	G/T	cg24330906	chr2:85765176	MAT2A	0.43	4.31	0.33	2.94e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.46	-0.41	1.88e-7	Glomerular filtration rate;
PAAD	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	8.02	0.55	2.58e-13	Menopause (age at onset);
PAAD	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.35	-4.35	-0.33	2.53e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg22162314	chr17:61951766	CSH2	0.51	4.33	0.33	2.69e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.48	4.58	0.35	9.75e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs12138061	0.954	rs4259707	chr1:50528591	C/T	cg09846084	chr1:50888024	DMRTA2	-0.51	-4.41	-0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.68	7.25	0.51	2.01e-11	Schizophrenia;
PAAD	cis	rs490234	0.783	rs7852065	chr9:128462023	T/C	cg14078157	chr9:128172775	NA	-0.44	-5.11	-0.38	9.53e-7	Mean arterial pressure;
PAAD	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-7.9	-0.54	5.14e-13	Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20169576	chr18:67070461	DOK6	-0.73	-7.51	-0.52	4.57e-12	Obesity-related traits;
PAAD	cis	rs4704187	0.687	rs1422699	chr5:74442410	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg23127183	chr11:57508653	C11orf31	-0.5	-4.39	-0.34	2.15e-5	Schizophrenia;
PAAD	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.9e-6	Lung cancer;
PAAD	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.81	-9.1	-0.59	4.73e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.56	5.37	0.4	2.86e-7	Body mass index;Social communication problems;
PAAD	cis	rs12612619	0.761	rs7606840	chr2:27243364	A/G	cg00617064	chr2:27272375	NA	-0.52	-5.39	-0.4	2.65e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg11062466	chr8:58055876	NA	0.7	4.78	0.36	4.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.69	5.59	0.41	1.02e-7	Coronary artery disease;
PAAD	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.65	5.48	0.41	1.72e-7	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00500681	chr6:42749811	NA	0.69	7.36	0.51	1.07e-11	Obesity-related traits;
PAAD	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.66	8.1	0.55	1.66e-13	Dupuytren's disease;
PAAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.52	-4.51	-0.34	1.29e-5	Tonsillectomy;
PAAD	cis	rs9604529	1.000	rs9604529	chr13:114622597	A/G	cg27119904	chr13:114814333	RASA3	0.38	4.28	0.33	3.33e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.49	5.23	0.39	5.58e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs12772102	chr10:46081101	G/A	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.33	6.0	0.44	1.37e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9472414	0.510	rs227853	chr6:44699746	T/C	cg18551225	chr6:44695536	NA	0.51	5.19	0.39	6.49e-7	Height;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3857067	1.000	rs6532454	chr4:95019067	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.66	-0.35	6.74e-6	QT interval;
PAAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg02487422	chr3:49467188	NICN1	0.41	4.26	0.33	3.63e-5	Menarche (age at onset);
PAAD	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.83	8.09	0.55	1.78e-13	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs9913156	0.841	rs4522461	chr17:4621773	T/G	cg23387401	chr17:4582204	PELP1	-0.48	-4.63	-0.35	7.69e-6	Lymphocyte counts;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26048897	chr10:51632982	NA	0.6	6.42	0.46	1.66e-9	Smoking initiation;
PAAD	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.36	0.33	2.4e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs61677309	0.964	rs112753655	chr11:118154795	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.47	-0.46	1.28e-9	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs58521262	0.556	rs289317	chr19:23161297	C/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	1.0	14.12	0.75	1.92e-29	Menarche (age at onset);
PAAD	cis	rs1620921	0.524	rs12214168	chr6:161195801	C/T	cg01280913	chr6:161186852	NA	-0.48	-5.31	-0.4	3.86e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs933117	0.892	rs112612973	chr21:31073320	G/A	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.29	-0.33	3.18e-5	Body mass index;
PAAD	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.54	0.41	1.33e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.4	-4.36	-0.33	2.36e-5	Triglycerides;
PAAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.36	0.6	1.01e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.66	7.18	0.5	2.87e-11	Resting heart rate;
PAAD	cis	rs5839475	1	rs5839475	chr2:234188015	A/AG	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	4.33	0.33	2.65e-5	Strep throat;
PAAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.41	4.88	0.37	2.65e-6	Tonsillectomy;
PAAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg24747557	chr10:131355152	MGMT	-0.47	-5.11	-0.38	9.74e-7	Response to temozolomide;
PAAD	cis	rs448720	0.811	rs383041	chr15:68184481	C/G	cg05925327	chr15:68127851	NA	-0.38	-4.33	-0.33	2.74e-5	Cognitive performance;
PAAD	cis	rs34375054	0.672	rs2291247	chr12:125618953	C/G	cg25124228	chr12:125621409	AACS	-0.63	-6.55	-0.47	8.17e-10	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.56	-6.71	-0.48	3.58e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9463078	0.605	rs9472411	chr6:44943183	T/C	cg25276700	chr6:44698697	NA	0.4	4.79	0.36	3.87e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg17201900	chr20:34330562	RBM39	-0.63	-4.4	-0.34	1.99e-5	Total cholesterol levels;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	6.29	0.45	3.26e-9	Initial pursuit acceleration;
PAAD	cis	rs35160687	0.712	rs9677502	chr2:86480938	A/C	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.75e-6	Night sleep phenotypes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16659246	chr4:18023725	LCORL	0.65	6.98	0.49	8.67e-11	Myopia (pathological);
PAAD	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.6	5.14	0.38	8.46e-7	Common traits (Other);
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20586607	chr14:50235780	KLHDC2	0.6	7.28	0.51	1.66e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs66530629	1.000	rs2153125	chr1:25070230	A/G	cg01905478	chr1:25040257	NA	-0.49	-5.26	-0.39	4.75e-7	Plateletcrit;
PAAD	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.8	-8.1	-0.55	1.62e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg27411982	chr8:10470053	RP1L1	0.48	4.94	0.37	2.05e-6	Retinal vascular caliber;
PAAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.53	5.21	0.39	5.94e-7	Sleep duration;
PAAD	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.29	-0.45	3.27e-9	Type 2 diabetes;
PAAD	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.57	4.73	0.36	5.1e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17407555	0.710	rs10489071	chr4:10273549	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-4.96	-0.37	1.9e-6	Schizophrenia (age at onset);
PAAD	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.88	-9.17	-0.6	3.05e-16	Obesity-related traits;
PAAD	cis	rs1144333	0.655	rs931506	chr1:76401349	T/C	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-4.32	-0.33	2.85e-5	Mean corpuscular volume;
PAAD	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg27411982	chr8:10470053	RP1L1	-0.49	-5.38	-0.4	2.74e-7	Neuroticism;
PAAD	cis	rs747650	0.504	rs61896133	chr11:47115719	G/C	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.45	3.07e-9	Acne (severe);
PAAD	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-5.31	-0.4	3.81e-7	Psoriasis;
PAAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg00786952	chr1:21763130	NA	0.52	5.13	0.38	8.58e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10924309	0.889	rs10924308	chr1:245858131	C/T	cg00036263	chr1:245852353	KIF26B	-0.7	-6.03	-0.44	1.2e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg17644776	chr2:200775616	C2orf69	-0.62	-4.79	-0.36	3.98e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13242816	1.000	rs4292624	chr7:116102724	A/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs9463078	0.691	rs6928753	chr6:45340070	T/C	cg25276700	chr6:44698697	NA	0.51	5.68	0.42	6.63e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-7.36	-0.51	1.09e-11	Neuroticism;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1891275	0.551	rs2027486	chr10:93413986	C/A	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.7	7.05	0.5	6e-11	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26944981	chr17:30469748	RHOT1	0.68	6.75	0.48	2.89e-10	Obesity-related traits;
PAAD	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg09760422	chr2:128146352	NA	-0.51	-9.23	-0.6	2.16e-16	Self-rated health;
PAAD	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.21	-0.39	5.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61931739	0.547	rs7966400	chr12:33703107	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.18	-0.5	2.9e-11	Morning vs. evening chronotype;
PAAD	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12956009	0.518	rs10163861	chr18:44820214	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.42	-0.34	1.86e-5	Educational attainment (years of education);
PAAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.55	-4.51	-0.34	1.3e-5	LDL cholesterol to HDL cholesterol ratio;
PAAD	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs59888335	0.825	rs991613	chr3:80527185	T/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs783540	0.967	rs783523	chr15:83283555	A/G	cg00614314	chr15:82944287	LOC80154	-0.43	-4.39	-0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg05083358	chr7:2394359	EIF3B	-0.77	-5.59	-0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3736485	0.966	rs11070855	chr15:51850283	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-4.28	-0.33	3.36e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg17885191	chr8:135476712	NA	-0.85	-8.91	-0.59	1.48e-15	Educational attainment;
PAAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.62	8.08	0.55	1.92e-13	Renal cell carcinoma;
PAAD	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.56	5.36	0.4	3.05e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-10.19	-0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.34	-6.3	-0.45	3.08e-9	Type 2 diabetes;
PAAD	cis	rs134594	0.844	rs134631	chr22:29480946	A/G	cg01361351	chr22:29467363	NA	-0.4	-4.47	-0.34	1.53e-5	Birth weight;
PAAD	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.48	0.57	1.89e-14	Rheumatoid arthritis;
PAAD	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs6681460	0.866	rs485521	chr1:67209562	T/C	cg02459107	chr1:67143332	SGIP1	-0.68	-6.26	-0.45	3.79e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.56	5.86	0.43	2.73e-8	Schizophrenia;
PAAD	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.5	-4.76	-0.36	4.4e-6	Eosinophilic esophagitis;
PAAD	cis	rs12935418	0.672	rs11150334	chr16:81042542	A/T	cg16651780	chr16:81037892	C16orf61	0.66	6.23	0.45	4.4e-9	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.49e-5	Life satisfaction;
PAAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.29	-0.39	4.14e-7	Breast cancer;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg27094323	chr7:1216898	NA	-0.46	-5.29	-0.39	4.19e-7	Longevity;Endometriosis;
PAAD	cis	rs12760731	0.565	rs116253445	chr1:178216962	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs7165102	1.000	rs11637431	chr15:65882251	T/C	cg22900193	chr15:65823441	PTPLAD1	0.46	4.41	0.34	1.96e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs11829119	1.000	rs76814118	chr12:19193317	G/A	cg24441383	chr12:19459574	PLEKHA5	0.92	4.26	0.33	3.62e-5	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.94	7.76	0.53	1.17e-12	Axial length;
PAAD	cis	rs501120	0.584	rs61855740	chr10:44679810	A/G	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg14906510	chr12:7781169	NA	0.62	4.52	0.34	1.22e-5	HDL cholesterol levels;
PAAD	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg04257695	chr17:30186438	C17orf79	-0.64	-5.02	-0.38	1.41e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.54	-5.84	-0.43	3.12e-8	Testicular germ cell tumor;
PAAD	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg21174375	chr14:64681225	SYNE2	0.32	4.44	0.34	1.73e-5	Atrial fibrillation;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs7582720	1.000	rs72932767	chr2:203679306	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.89	6.95	0.49	9.86e-11	Axial length;
PAAD	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.66	6.05	0.44	1.1e-8	Androgen levels;
PAAD	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	4.55	0.35	1.08e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04287289	chr16:89883240	FANCA	0.76	4.5	0.34	1.34e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs71496620	chr10:46074329	G/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.54	4.98	0.37	1.7e-6	Total body bone mineral density;
PAAD	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.75	8.88	0.58	1.79e-15	Obesity-related traits;
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg01299579	chr2:10830716	NOL10	-0.6	-6.11	-0.44	8.01e-9	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04483623	chr22:29949575	THOC5	0.66	6.89	0.49	1.36e-10	Myopia (pathological);
PAAD	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg04717802	chr22:42394638	WBP2NL	0.49	4.72	0.36	5.32e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23205231	chr4:139550400	NA	-0.56	-7.07	-0.5	5.4e-11	Monocyte percentage of white cells;
PAAD	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.82	8.37	0.56	3.52e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-7.07	-0.5	5.31e-11	Ulcerative colitis;
PAAD	cis	rs6545883	0.831	rs6733446	chr2:61806999	C/T	cg14146966	chr2:61757674	XPO1	0.36	4.35	0.33	2.47e-5	Tuberculosis;
PAAD	cis	rs7577696	0.853	rs212734	chr2:32472753	A/G	cg02381751	chr2:32503542	YIPF4	0.42	4.57	0.35	9.86e-6	Inflammatory biomarkers;
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05665937	chr4:1216051	CTBP1	0.4	4.37	0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.81	0.36	3.54e-6	Breast cancer;
PAAD	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-5.22	-0.39	5.78e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2147959	0.739	rs11587839	chr1:228630979	C/T	cg00655913	chr1:228633920	NA	0.51	4.65	0.35	7.14e-6	Adult asthma;
PAAD	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.46	4.34	0.33	2.57e-5	Endometrial cancer;
PAAD	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.44	-6.27	-0.45	3.53e-9	Breast cancer;
PAAD	cis	rs3126085	0.515	rs12029633	chr1:152347403	A/C	cg26876637	chr1:152193138	HRNR	-0.68	-5.16	-0.39	7.46e-7	Atopic dermatitis;
PAAD	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.39	-4.32	-0.33	2.78e-5	Platelet count;
PAAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs35084382	1.000	rs35084382	chr5:172197039	T/C	cg09799633	chr5:172199460	DUSP1	-0.95	-4.55	-0.35	1.1e-5	Optic cup area;
PAAD	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.92	6.26	0.45	3.74e-9	Thyroid stimulating hormone;
PAAD	cis	rs7608623	1.000	rs4665238	chr2:23942446	C/A	cg08917208	chr2:24149416	ATAD2B	-0.44	-4.34	-0.33	2.63e-5	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.43	-4.43	-0.34	1.82e-5	Obesity-related traits;
PAAD	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.7	-7.95	-0.54	3.9e-13	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs12044355	0.865	rs6691979	chr1:231860682	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	5.31	0.4	3.89e-7	Alzheimer's disease;
PAAD	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.31	0.64	3.22e-19	Smoking behavior;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12022895	chr7:149570992	ATP6V0E2;LOC401431	-0.82	-7.05	-0.5	5.86e-11	Neuroticism;
PAAD	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7897654	0.571	rs7920697	chr10:104633337	T/C	cg15744005	chr10:104629667	AS3MT	-0.5	-4.68	-0.36	6.24e-6	Schizophrenia;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.96	12.11	0.7	4.72e-24	Alcohol dependence;
PAAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs62045849	0.546	rs12933826	chr16:89165984	T/C	cg27661460	chr16:88844969	FAM38A	0.72	4.36	0.33	2.39e-5	Red blood cell count;
PAAD	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.6	6.41	0.46	1.71e-9	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04287289	chr16:89883240	FANCA	-0.97	-4.97	-0.37	1.8e-6	Skin colour saturation;
PAAD	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.81	-0.43	3.5e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9434723	0.841	rs12083129	chr1:9311323	G/A	cg04199779	chr1:9294473	H6PD	0.57	4.86	0.37	2.95e-6	Height;
PAAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.5	-5.9	-0.43	2.24e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg21665744	chr7:39171113	POU6F2	0.36	5.83	0.43	3.25e-8	IgG glycosylation;
PAAD	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg12623918	chr2:306882	NA	0.59	4.36	0.33	2.41e-5	Blood protein levels;
PAAD	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg18357526	chr6:26021779	HIST1H4A	0.58	4.87	0.37	2.76e-6	Height;
PAAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg03959625	chr15:84868606	LOC388152	0.45	4.59	0.35	9.3e-6	Schizophrenia;
PAAD	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg03180429	chr4:186128663	NA	-0.57	-4.33	-0.33	2.66e-5	Systemic lupus erythematosus;
PAAD	cis	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.45	5.02	0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.97	10.57	0.65	6.24e-20	Corneal astigmatism;
PAAD	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	6.8	0.48	2.28e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.94	12.37	0.71	9.36e-25	Prudent dietary pattern;
PAAD	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.61	-5.96	-0.44	1.69e-8	Subjective well-being;
PAAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.72	-7.62	-0.53	2.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	6.81	0.48	2.09e-10	Systemic lupus erythematosus;
PAAD	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.59e-7	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04094723	chr17:73717212	ITGB4	0.55	6.44	0.46	1.47e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2124910	0.689	rs2009362	chr19:52002729	A/G	cg14953197	chr19:52005651	SIGLEC12	-0.49	-5.35	-0.4	3.22e-7	Blood protein levels;
PAAD	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg06243866	chr13:111019493	COL4A2	0.58	5.47	0.41	1.8e-7	White matter hyperintensity burden;
PAAD	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.67	-0.48	4.55e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6963495	0.615	rs1728645	chr7:105205115	A/G	cg19920283	chr7:105172520	RINT1	0.68	5.52	0.41	1.45e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs58521262	0.530	rs289356	chr19:23144334	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.4	-0.4	2.47e-7	Schizophrenia;
PAAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg23587288	chr2:27483067	SLC30A3	-0.67	-6.01	-0.44	1.33e-8	Blood metabolite levels;
PAAD	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-5.37	-0.4	2.95e-7	Monocyte count;
PAAD	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.83	0.36	3.36e-6	Diastolic blood pressure;
PAAD	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-8.23	-0.56	7.73e-14	Lung function (FEV1);
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	7.88	0.54	5.73e-13	Alzheimer's disease;
PAAD	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg01953289	chr20:60874239	NA	0.65	4.72	0.36	5.33e-6	Obesity-related traits;
PAAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	7.14	0.5	3.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6066835	0.867	rs6063316	chr20:47358071	A/G	cg18078177	chr20:47281410	PREX1	1.02	4.82	0.36	3.45e-6	Multiple myeloma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15714329	chr1:154193618	C1orf43;UBAP2L	-0.88	-7.63	-0.53	2.33e-12	Neuroticism;
PAAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg11266682	chr4:10021025	SLC2A9	0.51	4.39	0.34	2.14e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.84	9.59	0.61	2.46e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.793	rs77071507	chr1:227407469	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	4.43	0.34	1.8e-5	Breast cancer;
PAAD	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg03255953	chr3:127056837	NA	-0.4	-4.5	-0.34	1.35e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs6460942	0.597	rs7811374	chr7:12517437	T/C	cg04557057	chr7:12151638	NA	-0.69	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg10556349	chr10:835070	NA	0.7	5.25	0.39	5.06e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9535307	0.929	rs2038608	chr13:50272027	A/C	cg04663916	chr13:50265991	EBPL	0.63	4.42	0.34	1.89e-5	Obesity-related traits;
PAAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-6.21	-0.45	4.71e-9	Bone mineral density;
PAAD	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg08888203	chr3:10149979	C3orf24	0.91	7.94	0.54	4.11e-13	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg14343924	chr8:8086146	FLJ10661	0.51	4.76	0.36	4.51e-6	Joint mobility (Beighton score);
PAAD	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.79	-0.43	3.88e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs17155006	0.664	rs448342	chr7:107739727	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-7.2	-0.5	2.64e-11	Pneumococcal bacteremia;
PAAD	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.03	-6.28	-0.45	3.36e-9	Mitochondrial DNA levels;
PAAD	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.52	-4.86	-0.37	2.84e-6	Mortality in heart failure;
PAAD	cis	rs12568771	0.505	rs2477134	chr1:17633572	A/C	cg08277548	chr1:17600880	PADI3	-0.48	-5.2	-0.39	6.33e-7	IgA nephropathy;
PAAD	cis	rs6991838	0.751	rs35553155	chr8:66463467	A/G	cg15971335	chr8:66515592	ARMC1	0.45	4.54	0.35	1.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg24110177	chr3:50126178	RBM5	-0.57	-4.47	-0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg10589385	chr1:150898437	SETDB1	-0.46	-5.69	-0.42	6.44e-8	Tonsillectomy;
PAAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.64	6.85	0.49	1.7e-10	Longevity;
PAAD	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.96	-12.45	-0.71	5.8e-25	Refractive error;
PAAD	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg10977910	chr1:84465055	TTLL7	0.49	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.72	7.17	0.5	2.99e-11	Coronary artery disease;
PAAD	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.51	-6.58	-0.47	7.31e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.63	4.35	0.33	2.5e-5	Carotid intima media thickness;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	4.96	0.37	1.84e-6	Iron status biomarkers;
PAAD	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.84	-9.32	-0.6	1.29e-16	Mortality in heart failure;
PAAD	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.82	-5.07	-0.38	1.13e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.48	-0.34	1.44e-5	Eotaxin levels;
PAAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg15691649	chr6:25882328	NA	0.49	4.51	0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	6.01	0.44	1.34e-8	Renal function-related traits (BUN);
PAAD	cis	rs10242455	0.702	rs59574285	chr7:99236151	C/T	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.74	-7.05	-0.5	5.78e-11	Height;
PAAD	cis	rs7823896	1.000	rs66850941	chr8:110187203	G/A	cg02458499	chr8:110280928	NUDCD1	0.73	4.55	0.35	1.1e-5	Myopia (pathological);
PAAD	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg08717414	chr16:71523259	ZNF19	-0.56	-4.5	-0.34	1.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.78	-0.42	4.2e-8	Schizophrenia;
PAAD	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.11	15.21	0.78	2.46e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.51	5.0	0.38	1.55e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.11	-0.77	4.46e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19346786	chr7:2764209	NA	-0.38	-5.29	-0.39	4.12e-7	Height;
PAAD	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.67	6.3	0.45	3.07e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14511498	chr3:115500667	NA	-0.67	-6.33	-0.46	2.68e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg23254163	chr1:152506842	NA	0.59	6.83	0.48	1.93e-10	Hair morphology;
PAAD	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.54	5.04	0.38	1.3e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1997066	0.831	rs73344325	chr10:106828753	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg05585544	chr11:47624801	NA	-0.49	-5.48	-0.41	1.69e-7	Subjective well-being;
PAAD	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.4	4.54	0.35	1.12e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg09324608	chr17:30823087	MYO1D	0.48	4.57	0.35	1.02e-5	Schizophrenia;
PAAD	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg05768032	chr16:30646687	NA	0.51	5.03	0.38	1.37e-6	Multiple myeloma;
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.77	8.51	0.57	1.54e-14	Lung cancer;
PAAD	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.69	-0.36	6.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.49	0.41	1.68e-7	HDL cholesterol;
PAAD	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	10.26	0.64	4.32e-19	Chronic sinus infection;
PAAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg05697835	chr1:2722811	NA	-0.43	-4.82	-0.36	3.45e-6	Ulcerative colitis;
PAAD	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg08856118	chr10:27389908	ANKRD26	-0.4	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.9	11.81	0.69	3.01e-23	Mean corpuscular volume;
PAAD	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg22764639	chr12:106532701	NUAK1	0.42	4.26	0.33	3.51e-5	Total body bone mineral density;
PAAD	cis	rs300774	0.925	rs300739	chr2:161605	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs500891	0.547	rs2152183	chr6:84102879	A/C	cg08257003	chr6:84140564	ME1	-0.38	-4.47	-0.34	1.5e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	1.0	13.28	0.73	3.31e-27	Menopause (age at onset);
PAAD	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg18323236	chr1:24743029	NIPAL3	0.44	4.78	0.36	4.16e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.82	-0.43	3.43e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15564428	chr3:101498201	FAM55C	-0.66	-6.79	-0.48	2.37e-10	Smoking initiation;
PAAD	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.69	6.85	0.49	1.74e-10	Obesity-related traits;
PAAD	cis	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg16898833	chr6:26189333	HIST1H4D	0.63	4.75	0.36	4.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11187837	1.000	rs3740360	chr10:96025491	A/C	cg07388132	chr10:96306137	HELLS	-0.67	-4.45	-0.34	1.64e-5	Sudden cardiac arrest;
PAAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg03959625	chr15:84868606	LOC388152	0.46	4.99	0.38	1.62e-6	Schizophrenia;
PAAD	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.95	7.92	0.54	4.7e-13	Triglycerides;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg19767477	chr5:127420684	SLC12A2	0.59	4.8	0.36	3.73e-6	Ileal carcinoids;
PAAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24229701	chr12:130821962	PIWIL1	0.41	4.29	0.33	3.21e-5	Menopause (age at onset);
PAAD	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00142150	chr22:38071001	LGALS1	0.52	4.57	0.35	1.02e-5	Fat distribution (HIV);
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.51	-5.35	-0.4	3.18e-7	Obesity-related traits;
PAAD	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.64	-6.8	-0.48	2.25e-10	Dilated cardiomyopathy;
PAAD	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.76	7.18	0.5	2.84e-11	Schizophrenia;
PAAD	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.47	5.1	0.38	1.01e-6	Age of smoking initiation;
PAAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg23601416	chr22:19950040	COMT	-0.29	-4.61	-0.35	8.63e-6	Blood metabolite levels;
PAAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.43	-0.4	2.2e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.46	5.41	0.4	2.43e-7	Coronary artery disease;
PAAD	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.97	-0.37	1.79e-6	Body mass index;
PAAD	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.7	-6.94	-0.49	1.09e-10	Platelet distribution width;
PAAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.79	-8.32	-0.56	4.67e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg18833306	chr6:118973337	C6orf204	0.53	5.89	0.43	2.44e-8	Electrocardiographic conduction measures;
PAAD	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.9	-13.01	-0.73	1.72e-26	Dental caries;
PAAD	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.39	5.11	0.38	9.53e-7	Educational attainment (years of education);
PAAD	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.56	-0.47	7.93e-10	Chronic sinus infection;
PAAD	cis	rs427943	0.750	rs2838807	chr21:46619001	A/G	cg06618935	chr21:46677482	NA	-0.38	-4.31	-0.33	2.88e-5	Body mass index;
PAAD	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.76	-0.42	4.63e-8	Retinal vascular caliber;
PAAD	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg11271282	chr2:238384023	NA	0.52	4.82	0.36	3.52e-6	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.51	5.0	0.38	1.58e-6	Red cell distribution width;
PAAD	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.51	4.86	0.37	2.9e-6	Blood metabolite levels;
PAAD	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.58	-0.47	7.03e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10100318	chr2:3504532	ADI1	-0.65	-6.45	-0.46	1.42e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06867916	chr14:69865653	SLC39A9;ERH	0.62	7.26	0.51	1.9e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10500871	0.622	rs12574088	chr11:20218827	G/A	cg02956962	chr6:161097311	NA	0.59	6.48	0.47	1.22e-9	Educational attainment;
PAAD	cis	rs16895831	0.549	rs3749900	chr6:42613379	A/G	cg10605015	chr6:42532144	UBR2	-0.62	-4.68	-0.35	6.28e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg09877947	chr5:131593287	PDLIM4	0.59	5.43	0.4	2.22e-7	Acylcarnitine levels;
PAAD	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9810890	0.850	rs73198884	chr3:128543424	T/C	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg18279126	chr7:2041391	MAD1L1	0.54	5.24	0.39	5.25e-7	Schizophrenia;
PAAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.46	-6.17	-0.45	5.91e-9	Myeloid white cell count;
PAAD	cis	rs2092319	0.649	rs2744773	chr1:26063043	G/A	cg12446045	chr1:25857419	NA	-0.47	-4.31	-0.33	2.96e-5	Nose morphology;
PAAD	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg02198044	chr15:56286336	NEDD4	-0.54	-5.51	-0.41	1.5e-7	Keloid;
PAAD	cis	rs838147	0.873	rs11667321	chr19:49250538	A/G	cg13540341	chr19:49222985	MAMSTR	0.38	4.48	0.34	1.45e-5	Dietary macronutrient intake;
PAAD	cis	rs8027181	0.583	rs11072384	chr15:73001314	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.66	5.63	0.42	8.6e-8	Triglyceride levels;
PAAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.77	-0.48	2.67e-10	Type 2 diabetes;
PAAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs28489187	0.706	rs2300634	chr1:85791257	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg16342193	chr10:102329863	NA	-0.76	-8.6	-0.57	9.13e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg26929925	chr5:138714136	SLC23A1	-0.53	-4.9	-0.37	2.46e-6	Schizophrenia;
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.95	10.41	0.65	1.73e-19	Blood metabolite levels;
PAAD	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg14631576	chr9:95140430	CENPP	0.43	4.31	0.33	2.97e-5	Height;
PAAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.71	7.85	0.54	6.77e-13	Melanoma;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.5	-4.9	-0.37	2.42e-6	Lung cancer;
PAAD	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.54	5.97	0.44	1.58e-8	Heart rate;
PAAD	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.86	10.64	0.65	4.04e-20	Heart rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21862903	chr15:40734369	BAHD1	0.65	6.81	0.48	2.1e-10	Myopia (pathological);
PAAD	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.66	6.64	0.47	5.16e-10	Coronary artery disease;
PAAD	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-5.64	-0.42	8.16e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg19760965	chr3:194868843	C3orf21	0.44	4.71	0.36	5.48e-6	Non-small cell lung cancer;
PAAD	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.54	-4.97	-0.37	1.81e-6	Obesity-related traits;
PAAD	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.45	-4.71	-0.36	5.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg20848291	chr7:100343083	ZAN	-0.58	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24349573	chr21:43430466	ZNF295	-0.7	-7.32	-0.51	1.33e-11	Smoking initiation;
PAAD	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.79	-9.2	-0.6	2.7e-16	Bipolar disorder;
PAAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs259964	0.526	rs259971	chr20:57810673	C/T	cg02081277	chr20:57875511	EDN3	0.41	4.41	0.34	1.94e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.75	8.99	0.59	9.29e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg14631576	chr9:95140430	CENPP	0.59	5.85	0.43	2.96e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.56	-5.21	-0.39	5.95e-7	Obesity-related traits;
PAAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg14416269	chr4:6271139	WFS1	0.68	6.65	0.47	4.88e-10	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-4.44	-0.34	1.72e-5	Height;
PAAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.23	0.45	4.3e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9857275	0.527	rs11708253	chr3:141191090	C/T	cg25967872	chr3:141205623	RASA2	0.51	4.42	0.34	1.87e-5	Prion diseases;
PAAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17188901	chr7:150672175	KCNH2	-0.66	-6.31	-0.46	2.83e-9	Primary biliary cholangitis;
PAAD	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg10011062	chr15:43941034	CATSPER2	0.74	4.31	0.33	2.87e-5	Lung cancer in ever smokers;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21155852	chr7:2048760	MAD1L1	-0.45	-4.56	-0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-4.6	-0.35	8.74e-6	DNA methylation (variation);
PAAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04297258	chr16:88772664	RNF166;CTU2	0.6	6.6	0.47	6.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.48	5.38	0.4	2.79e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02716147	chr3:126733173	PLXNA1	0.55	6.42	0.46	1.64e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-5.4	-0.4	2.55e-7	Alcohol dependence;
PAAD	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-1.01	-12.28	-0.71	1.67e-24	Monocyte percentage of white cells;
PAAD	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg11214348	chr21:47283868	PCBP3	0.48	4.28	0.33	3.35e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07362569	chr17:61921086	SMARCD2	-0.47	-5.39	-0.4	2.58e-7	Prudent dietary pattern;
PAAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg07153921	chr17:41440717	NA	0.45	4.8	0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.96	0.37	1.84e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg17347104	chr14:75034677	LTBP2	0.56	4.64	0.35	7.33e-6	Non-small cell lung cancer;
PAAD	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.66	-6.69	-0.48	3.99e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs73019876	0.869	rs7253518	chr19:22145667	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.66	6.34	0.46	2.52e-9	Pulse pressure;
PAAD	cis	rs35740288	0.753	rs4843095	chr15:86275131	T/G	cg07943548	chr15:86304357	KLHL25	-0.58	-4.88	-0.37	2.69e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.71	6.02e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.75	0.42	4.65e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.61	0.61	2.22e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12667521	chr19:29218732	NA	0.63	5.5	0.41	1.58e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.24	12.38	0.71	8.52e-25	Platelet count;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-1.08	-7.13	-0.5	3.75e-11	Mitochondrial DNA levels;
PAAD	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.63	-6.07	-0.44	9.99e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg16589663	chr20:23618590	CST3	0.79	6.85	0.49	1.69e-10	Chronic kidney disease;
PAAD	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.6	0.41	9.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.52	0.34	1.26e-5	Asthma;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.32	0.4	3.67e-7	Height;
PAAD	cis	rs2000999	0.514	rs17604676	chr16:72221984	C/T	cg04254540	chr16:71951199	KIAA0174	-0.77	-4.8	-0.36	3.76e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.95	0.43	1.82e-8	Eosinophil percentage of white cells;
PAAD	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.89	5.68	0.42	6.53e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Lymphocyte counts;
PAAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.82	-0.36	3.5e-6	Bipolar disorder;
PAAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.66	-0.35	6.9e-6	Joint mobility (Beighton score);
PAAD	cis	rs2281636	0.540	rs1057491	chr10:101466620	C/T	cg05149213	chr10:101381631	SLC25A28	-0.55	-5.4	-0.4	2.55e-7	Obesity-related traits;
PAAD	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg25902810	chr10:99078978	FRAT1	-0.64	-5.96	-0.44	1.68e-8	Monocyte count;
PAAD	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-4.78	-0.36	4.04e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg19980929	chr12:42632907	YAF2	0.53	5.97	0.44	1.63e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16083429	chr3:49237500	CCDC36	-0.47	-5.3	-0.39	4.04e-7	Menarche (age at onset);
PAAD	cis	rs5758659	0.789	rs2413684	chr22:42574830	C/T	cg05082376	chr22:42548792	NA	-0.52	-5.27	-0.39	4.6e-7	Cognitive function;
PAAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs16858210	0.657	rs73177515	chr3:183566825	T/A	cg25686905	chr3:183603175	PARL	-0.38	-4.38	-0.33	2.23e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59888335	0.895	rs6548725	chr3:80811252	T/C	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.87	7.55	0.52	3.81e-12	Recombination rate (females);
PAAD	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg14146966	chr2:61757674	XPO1	0.38	4.78	0.36	4.11e-6	Tuberculosis;
PAAD	trans	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	7.79	0.53	9.62e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.74	-7.77	-0.53	1.1e-12	Cognitive function;
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg00106254	chr7:1943704	MAD1L1	-0.64	-6.07	-0.44	9.63e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.08	-0.44	9.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.15	0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.75	-8.37	-0.56	3.4e-14	Colorectal cancer;
PAAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs7929679	0.521	rs7122506	chr11:34786853	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.7	-0.36	5.86e-6	Blood pressure;
PAAD	cis	rs6074578	0.517	rs6055888	chr20:144570	A/G	cg16931068	chr20:139680	DEFB127	-0.4	-5.45	-0.4	2.03e-7	Hirschsprung disease;
PAAD	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg00531865	chr16:30841666	NA	-0.5	-4.49	-0.34	1.41e-5	Dementia with Lewy bodies;
PAAD	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.17	0.73	6.67e-27	Platelet count;
PAAD	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg25204440	chr1:209979598	IRF6	0.62	4.95	0.37	1.92e-6	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.61	8.14	0.55	1.32e-13	Renal cell carcinoma;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.59	-0.41	1.04e-7	Monocyte count;
PAAD	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.33	-0.33	2.66e-5	Daytime sleep phenotypes;
PAAD	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.6	6.17	0.45	5.99e-9	Kawasaki disease;
PAAD	cis	rs1198430	0.562	rs504145	chr1:23788310	C/T	cg24580199	chr1:23763081	ASAP3	0.53	4.63	0.35	7.88e-6	Total cholesterol levels;
PAAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg03983476	chr2:10830698	NOL10	0.6	6.09	0.44	8.69e-9	Prostate cancer;
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.98	-0.37	1.68e-6	Longevity;Endometriosis;
PAAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.9	0.37	2.48e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.47	-5.46	-0.41	1.87e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.57	-5.47	-0.41	1.84e-7	Strep throat;
PAAD	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg27411982	chr8:10470053	RP1L1	0.47	5.12	0.38	9.32e-7	Triglycerides;
PAAD	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg12395012	chr8:11607386	GATA4	0.44	4.38	0.33	2.23e-5	Triglycerides;
PAAD	cis	rs367943	0.547	rs2081926	chr5:113004021	G/T	cg12552261	chr5:112820674	MCC	0.52	5.28	0.39	4.39e-7	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.74	0.62	1e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-4.54	-0.35	1.15e-5	Bipolar disorder;
PAAD	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.66	6.43	0.46	1.58e-9	White matter hyperintensity burden;
PAAD	cis	rs28795989	0.728	rs6811851	chr4:7911771	A/C	cg18538662	chr4:7941764	AFAP1	0.41	4.26	0.33	3.58e-5	Intraocular pressure;
PAAD	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.54	7.13	0.5	3.9e-11	Prostate cancer;
PAAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg03340356	chr1:67600835	NA	0.53	6.1	0.44	8.57e-9	Psoriasis;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs939584	0.877	rs35802221	chr2:632904	A/G	cg14515364	chr2:636606	NA	0.49	4.51	0.34	1.31e-5	Body mass index;
PAAD	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.47e-9	Hypospadias;
PAAD	cis	rs3806308	0.900	rs3820330	chr1:20142413	A/C	cg08917933	chr1:19615303	AKR7A3	-0.49	-4.33	-0.33	2.66e-5	Ulcerative colitis;
PAAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs1656368	0.770	rs6784511	chr3:158278606	A/G	cg16708174	chr3:158430962	RARRES1	0.54	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.51	-0.34	1.31e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10120829	chr14:74036418	ACOT2	-0.75	-6.35	-0.46	2.42e-9	Neuroticism;
PAAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.79	-0.36	3.9e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.58	-0.35	9.49e-6	Resting heart rate;
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13939156	chr17:80058883	NA	-0.41	-4.4	-0.34	1.99e-5	Blood metabolite levels;
PAAD	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.65	-6.86	-0.49	1.6e-10	Post bronchodilator FEV1;
PAAD	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.61	5.35	0.4	3.14e-7	Common traits (Other);
PAAD	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.6	-6.14	-0.45	6.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9503598	0.502	rs6923831	chr6:3430889	T/A	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.32	-0.33	2.77e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	4.76	0.36	4.38e-6	Menopause (age at onset);
PAAD	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg18436246	chr17:1640651	WDR81	0.86	7.97	0.54	3.59e-13	Serum albumin level;
PAAD	cis	rs1371614	0.523	rs12991124	chr2:27179492	G/A	cg00617064	chr2:27272375	NA	0.48	5.04	0.38	1.31e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.63	6.14	0.45	6.75e-9	Corneal astigmatism;
PAAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg07212818	chr11:638076	DRD4	-0.76	-7.24	-0.51	2.12e-11	Systemic lupus erythematosus;
PAAD	cis	rs6782025	0.837	rs9860056	chr3:120863730	T/G	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	1.11	9.4	0.61	7.77e-17	Vitiligo;
PAAD	cis	rs3818285	0.959	rs35712139	chr10:111642934	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.73	-7.06	-0.5	5.53e-11	Superior crus of antihelix expression;
PAAD	cis	rs55728055	0.661	rs7288051	chr22:32013816	C/T	cg01338084	chr22:32026380	PISD	1.6	8.55	0.57	1.25e-14	Age-related hearing impairment;
PAAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.53	5.09	0.38	1.05e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.75	-8.11	-0.55	1.54e-13	Schizophrenia;
PAAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.51	4.81	0.36	3.54e-6	Height;
PAAD	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	trans	rs901683	1.000	rs77204970	chr10:46034949	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg03094675	chr11:5960213	NA	-0.5	-4.33	-0.33	2.66e-5	DNA methylation (variation);
PAAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.23e-5	Life satisfaction;
PAAD	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg00257455	chr1:65530538	NA	-0.4	-4.34	-0.33	2.57e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	1.08	15.07	0.77	5.83e-32	Breast cancer;
PAAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs17095355	0.688	rs10884925	chr10:111822398	C/T	cg00817464	chr10:111662876	XPNPEP1	0.66	5.0	0.38	1.54e-6	Biliary atresia;
PAAD	cis	rs62247992	0.698	rs17075162	chr3:43117917	T/C	cg12239580	chr3:43073058	FAM198A	0.44	4.31	0.33	2.91e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2916733	0.530	rs2442518	chr8:6291485	C/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.51	-0.34	1.31e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs183266	0.736	rs112106863	chr14:77497103	C/T	cg01682506	chr14:77422843	NA	-0.98	-4.78	-0.36	4.02e-6	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.48	4.36	0.33	2.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12599982	chr1:44399894	ARTN	0.47	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.63	-0.35	7.79e-6	Eotaxin levels;
PAAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.44	5.8	0.43	3.69e-8	Ulcerative colitis;
PAAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.51	5.21	0.39	6.13e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.52	5.11	0.38	9.53e-7	Rheumatoid arthritis;
PAAD	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.1	-9.94	-0.63	2.96e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11579069	chr6:135502794	MYB	0.56	6.31	0.46	2.9e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26101560	chr11:118889209	TRAPPC4;RPS25	0.73	6.9	0.49	1.29e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13560548	chr3:10150139	C3orf24	0.59	5.26	0.39	4.83e-7	Alzheimer's disease;
PAAD	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.8	8.28	0.56	5.74e-14	Alzheimer's disease (late onset);
PAAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg13722127	chr7:150037890	RARRES2	0.55	5.4	0.4	2.52e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.6	5.36	0.4	2.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-6.14	-0.45	6.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2579500	0.848	rs2438712	chr2:97219710	C/T	cg09304357	chr2:97220596	NA	0.46	4.83	0.36	3.37e-6	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs3857067	0.578	rs2865339	chr4:95099605	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.61	-6.09	-0.44	8.73e-9	QT interval;
PAAD	cis	rs6445967	1.000	rs9847151	chr3:58285808	G/A	cg23715586	chr3:58305044	RPP14	0.5	4.45	0.34	1.65e-5	Platelet count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05062854	chr22:32435553	NA	0.56	6.36	0.46	2.21e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.81	-0.36	3.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg25838818	chr2:108905173	SULT1C2	0.36	4.49	0.34	1.41e-5	Blood pressure;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg09359103	chr1:154839909	KCNN3	-0.48	-4.68	-0.35	6.38e-6	Schizophrenia;
PAAD	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.84	-9.38	-0.61	8.99e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.71	-0.48	3.63e-10	Response to antipsychotic treatment;
PAAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19784903	chr17:45786737	TBKBP1	-0.56	-5.99	-0.44	1.49e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg01652476	chr7:809048	HEATR2	-0.65	-7.34	-0.51	1.21e-11	Subjective well-being;
PAAD	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.5	4.55	0.35	1.11e-5	Red blood cell count;
PAAD	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.65	-7.18	-0.5	2.83e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs4707930	0.666	rs2754051	chr6:72418574	G/A	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.65	0.35	7.04e-6	Height;
PAAD	cis	rs7487075	0.619	rs12314541	chr12:46794766	T/C	cg09447675	chr12:46877466	NA	-0.48	-4.43	-0.34	1.81e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7627468	1.000	rs9856914	chr3:121932854	G/A	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-1.08	-6.77	-0.48	2.68e-10	Skin colour saturation;
PAAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg15448220	chr1:150897856	SETDB1	0.61	6.52	0.47	9.99e-10	Tonsillectomy;
PAAD	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.87	9.3	0.6	1.42e-16	Corneal astigmatism;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.01	-0.54	2.78e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs62025270	0.632	rs7177107	chr15:86123364	G/A	cg13263323	chr15:86062960	AKAP13	0.53	4.65	0.35	7.03e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	1.21	13.88	0.75	8.01e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg22517653	chr1:2918612	NA	-0.65	-5.26	-0.39	4.9e-7	Plateletcrit;
PAAD	cis	rs829661	1.000	rs829661	chr2:30726691	T/C	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg19000871	chr14:103996768	TRMT61A	0.48	5.16	0.39	7.48e-7	Reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15011837	chr10:1071902	C10orf110;IDI2	-0.62	-6.57	-0.47	7.61e-10	Obesity-related traits;
PAAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg12658694	chr1:38397304	INPP5B	0.61	6.72	0.48	3.46e-10	Coronary artery disease;
PAAD	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg18551225	chr6:44695536	NA	-0.59	-6.33	-0.46	2.59e-9	Total body bone mineral density;
PAAD	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg23018236	chr17:30244563	NA	-0.52	-4.31	-0.33	2.9e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.78	-6.73	-0.48	3.23e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.41	-0.34	1.96e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg07162820	chr14:24837146	NFATC4	0.36	4.75	0.36	4.57e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs755249	0.567	rs76111861	chr1:39842690	G/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.43	5.5	0.41	1.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Mean corpuscular volume;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	1.11	7.59	0.52	2.99e-12	IgG glycosylation;
PAAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.66	5.45	0.4	2.01e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01510626	chr8:42396761	C8orf40;SLC20A2	-0.74	-6.64	-0.47	5.17e-10	Neuroticism;
PAAD	cis	rs501120	0.564	rs10899999	chr10:44690185	A/G	cg09554077	chr10:44749378	NA	0.44	5.71	0.42	5.72e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg03037974	chr15:76606532	NA	0.53	6.25	0.45	4e-9	Blood metabolite levels;
PAAD	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg07212818	chr11:638076	DRD4	-0.7	-7.03	-0.5	6.38e-11	Systemic lupus erythematosus;
PAAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg20761395	chr17:511517	VPS53	0.63	7.02	0.49	7.07e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.75	-8.72	-0.58	4.49e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6782228	0.565	rs11719239	chr3:128419054	A/G	cg16766828	chr3:128327626	NA	-0.45	-6.09	-0.44	8.8e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09826364	chr7:158789723	NA	-0.42	-5.57	-0.41	1.15e-7	Facial morphology (factor 20);
PAAD	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg02372037	chr12:42865986	PRICKLE1	0.73	6.41	0.46	1.76e-9	Anxiety disorder;
PAAD	cis	rs7925523	0.891	rs72918042	chr11:61451548	C/G	cg12472022	chr11:61462803	DAGLA	0.68	5.6	0.41	9.78e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg25902810	chr10:99078978	FRAT1	-0.61	-5.59	-0.41	1.04e-7	Monocyte count;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26726589	chr20:306364	SOX12	-0.69	-6.54	-0.47	8.69e-10	Blood protein levels;
PAAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	6.08e-7	Ulcerative colitis;
PAAD	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.62	8.09	0.55	1.79e-13	Crohn's disease;
PAAD	cis	rs7598759	0.617	rs6437017	chr2:232327584	C/A	cg10034588	chr2:232392055	NMUR1	-0.38	-4.53	-0.34	1.2e-5	Noise-induced hearing loss;
PAAD	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.76	7.84	0.54	7.34e-13	Breast cancer;
PAAD	cis	rs89107	0.531	rs1690662	chr6:118612354	A/G	cg21191810	chr6:118973309	C6orf204	0.46	6.47	0.46	1.26e-9	Cardiac structure and function;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg20302533	chr7:39170763	POU6F2	0.46	6.49	0.47	1.12e-9	IgG glycosylation;
PAAD	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.79	6.66	0.48	4.6e-10	Chronic kidney disease;
PAAD	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.57	-5.04	-0.38	1.29e-6	Life satisfaction;
PAAD	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.47	-4.36	-0.33	2.36e-5	Triglycerides;
PAAD	cis	rs6496932	0.663	rs2062238	chr15:85919233	G/T	cg19183879	chr15:85880815	NA	-0.58	-5.36	-0.4	2.97e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg05805236	chr11:65401703	PCNXL3	0.62	6.64	0.47	5.3e-10	Acne (severe);
PAAD	cis	rs4965359	0.533	rs2925203	chr15:101602558	G/T	cg02262866	chr15:101593693	LRRK1	-0.42	-4.5	-0.34	1.36e-5	Central corneal thickness;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	1.14	13.36	0.73	2.03e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.93	11.29	0.68	7.32e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.58	-5.42	-0.4	2.32e-7	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg27411982	chr8:10470053	RP1L1	0.44	4.67	0.35	6.66e-6	Retinal vascular caliber;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	9.39	0.61	8.28e-17	Height;
PAAD	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg14515779	chr1:101123966	NA	-0.52	-6.59	-0.47	6.75e-10	Monocyte count;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	14.97	0.77	1.04e-31	Height;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg16342193	chr10:102329863	NA	-0.65	-6.21	-0.45	4.85e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.61	-6.15	-0.45	6.51e-9	Post bronchodilator FEV1;
PAAD	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg25200586	chr1:148000763	NA	-0.61	-6.33	-0.46	2.62e-9	Hip geometry;
PAAD	cis	rs4711336	0.527	rs28651968	chr6:33717424	T/C	cg15676125	chr6:33679581	C6orf125	0.49	4.61	0.35	8.44e-6	Height;
PAAD	cis	rs79322592	0.865	rs12404622	chr1:248035778	C/T	cg00785941	chr1:248100591	OR2L13	-0.28	-4.29	-0.33	3.19e-5	Platelet distribution width;
PAAD	cis	rs41342147	0.660	rs77576057	chr2:242289843	A/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.59	-4.37	-0.33	2.25e-5	Vitiligo;
PAAD	cis	rs10750165	0.586	rs10892448	chr11:119624823	G/T	cg24085502	chr11:119066850	CCDC153	0.34	4.45	0.34	1.64e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05564831	chr3:52568323	NT5DC2	-0.46	-4.94	-0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg05132306	chr1:1846340	CALML6	-0.42	-4.92	-0.37	2.22e-6	Body mass index;
PAAD	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg17796960	chr10:135278976	LOC619207	-0.57	-6.36	-0.46	2.24e-9	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.95	-8.25	-0.56	7.13e-14	Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs829661	0.947	rs829634	chr2:30735763	T/C	cg12454169	chr2:30669597	LCLAT1	0.67	5.04	0.38	1.3e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Aortic root size;
PAAD	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-4.28	-0.33	3.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.959	rs2870509	chr11:48284109	T/C	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.68	-0.36	6.24e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7619427	0.507	rs6806526	chr3:44015285	T/C	cg12796028	chr3:44040206	NA	-0.56	-5.04	-0.38	1.33e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01212965	chr4:106630041	GSTCD;INTS12	0.6	6.66	0.48	4.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.7	-0.36	5.8e-6	Joint mobility (Beighton score);
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.47	-4.36	-0.33	2.37e-5	Tuberculosis;
PAAD	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-6.28	-0.45	3.44e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg00262122	chr8:11665843	FDFT1	0.53	5.04	0.38	1.32e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.55	5.02	0.38	1.44e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.4	5.88	0.43	2.54e-8	Educational attainment (years of education);
PAAD	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-5.17	-0.39	7.23e-7	Personality dimensions;
PAAD	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.53	0.65	8.4e-20	Bladder cancer;
PAAD	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.81	8.21	0.55	8.82e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs986417	1.000	rs8021347	chr14:60952773	G/C	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.42	-4.91	-0.37	2.34e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2576037	0.863	rs8097455	chr18:44593122	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	4.37	0.33	2.29e-5	Personality dimensions;
PAAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.5	0.52	4.9e-12	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05851813	chr8:146126851	ZNF250	-0.71	-6.39	-0.46	1.91e-9	Neuroticism;
PAAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.5	-0.34	1.34e-5	Glomerular filtration rate;
PAAD	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.75	6.99	0.49	8.19e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg26138144	chr22:38071188	LGALS1	0.41	4.61	0.35	8.54e-6	Fat distribution (HIV);
PAAD	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg01489256	chr8:11204017	TDH	0.45	4.34	0.33	2.58e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.91	-5.42	-0.4	2.26e-7	Hypertriglyceridemia;
PAAD	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg13918804	chr1:2043761	PRKCZ	-0.39	-5.24	-0.39	5.25e-7	Height;
PAAD	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.27	-0.39	4.5e-7	Bladder cancer;
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.66	-8.44	-0.56	2.37e-14	Body mass index;
PAAD	cis	rs507080	0.733	rs673547	chr11:118573339	G/A	cg08498647	chr11:118550644	TREH	-0.39	-4.46	-0.34	1.55e-5	Serum metabolite levels;
PAAD	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.84e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.5	-0.34	1.34e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs58521262	0.530	rs289346	chr19:23148000	T/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04535340	chr19:8454867	RAB11B	-0.73	-6.4	-0.46	1.85e-9	Neuroticism;
PAAD	cis	rs13034020	0.522	rs72809436	chr2:61251145	C/T	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs6594713	0.921	rs6870401	chr5:112738364	C/G	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.76	5.41	0.4	2.36e-7	Vitiligo;
PAAD	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-6.66	-0.48	4.62e-10	Coronary artery disease;
PAAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.83	8.15	0.55	1.28e-13	Cognitive function;
PAAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg05342682	chr7:94953680	PON1	-0.53	-4.57	-0.35	1.01e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.67	5.64	0.42	8.03e-8	Pubertal anthropometrics;
PAAD	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-8.33	-0.56	4.51e-14	Electrocardiographic conduction measures;
PAAD	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg10381502	chr11:71823885	C11orf51	1.11	5.04	0.38	1.3e-6	Severe influenza A (H1N1) infection;
PAAD	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.62	6.26	0.45	3.69e-9	Metabolic syndrome;
PAAD	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.62	6.87	0.49	1.53e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg08134877	chr2:44394819	PPM1B	0.44	4.35	0.33	2.49e-5	Height;
PAAD	cis	rs3781454	1	rs3781454	chr10:126348565	G/A	cg20435097	chr10:126320824	FAM53B	-0.52	-5.5	-0.41	1.61e-7	White blood cell count;
PAAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.01	-0.38	1.5e-6	Electroencephalogram traits;
PAAD	cis	rs9677476	0.657	rs9679430	chr2:232122482	C/T	cg07929768	chr2:232055508	NA	-0.36	-4.43	-0.34	1.79e-5	Food antigen IgG levels;
PAAD	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.96e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12432203	1.000	rs72622440	chr14:51737191	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs2030114	0.531	rs4783838	chr16:51594238	G/A	cg03758633	chr16:51611768	NA	0.51	4.95	0.37	1.96e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	1.18	6.81	0.48	2.09e-10	Inflammatory biomarkers;
PAAD	cis	rs9346649	0.967	rs6915427	chr6:168490000	A/T	cg09211372	chr6:168490623	NA	-0.39	-4.35	-0.33	2.45e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.65	-6.44	-0.46	1.48e-9	Blood protein levels;
PAAD	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.5	-4.74	-0.36	4.89e-6	Schizophrenia;
PAAD	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.59	-0.52	2.96e-12	Protein C levels;
PAAD	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg14784868	chr12:69753453	YEATS4	0.7	5.3	0.39	4.09e-7	Response to diuretic therapy;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.51	5.2	0.39	6.35e-7	Height;
PAAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs7551345	0.853	rs7517820	chr1:31760665	T/C	cg17086398	chr1:31896392	SERINC2	-0.49	-4.26	-0.33	3.5e-5	Schizophrenia;
PAAD	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26852971	chr16:4365424	NA	-0.44	-4.27	-0.33	3.44e-5	Body mass index (adult);
PAAD	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	7.79	0.53	9.91e-13	Eotaxin levels;
PAAD	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.84	9.39	0.61	8.19e-17	Mortality in heart failure;
PAAD	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.8e-6	Skin colour saturation;
PAAD	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.5	4.33	0.33	2.71e-5	Atopic dermatitis;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.68	4.47	0.34	1.52e-5	Glycated hemoglobin levels;
PAAD	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.84	-9.11	-0.59	4.42e-16	Mortality in heart failure;
PAAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.57	-6.1	-0.44	8.32e-9	Mean corpuscular volume;
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.94	-8.02	-0.55	2.69e-13	Other erythrocyte phenotypes;
PAAD	cis	rs28489187	0.577	rs729655	chr1:85844617	A/C	cg16011679	chr1:85725395	C1orf52	0.44	4.35	0.33	2.53e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.62	7.23	0.51	2.26e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.41	-4.56	-0.35	1.03e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.06	-0.38	1.2e-6	Personality dimensions;
PAAD	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs2885056	0.891	rs12460574	chr19:10689955	G/A	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs7172971	0.688	rs75615772	chr15:42386480	C/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6142102	0.502	rs58393429	chr20:32545802	C/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.79	0.36	3.87e-6	Skin pigmentation;
PAAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.63	6.36	0.46	2.23e-9	Cystic fibrosis severity;
PAAD	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs7127900	0.500	rs67798996	chr11:2233603	A/G	cg25635251	chr11:2234043	NA	0.8	7.71	0.53	1.57e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.38	4.4	0.34	2.02e-5	Fat distribution (HIV);
PAAD	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg18711553	chr6:27366782	ZNF391	-0.53	-4.6	-0.35	8.81e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg21775007	chr8:11205619	TDH	0.77	7.54	0.52	3.98e-12	Retinal vascular caliber;
PAAD	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.51	4.89	0.37	2.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.56	0.65	6.85e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	0.5	4.64	0.35	7.52e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg10290764	chr8:4849399	CSMD1	-0.38	-6.32	-0.46	2.78e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs215088	0.719	rs169985	chr16:16060881	C/T	cg08996506	chr16:16070868	ABCC1	0.4	4.76	0.36	4.54e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.44e-6	Life satisfaction;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09827440	chr7:112758744	LOC401397	-0.64	-6.48	-0.47	1.19e-9	Lung cancer in ever smokers;
PAAD	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	19.57	0.85	2.24e-43	Testicular germ cell tumor;
PAAD	cis	rs12913538	0.575	rs12437908	chr15:62889549	A/G	cg09983546	chr15:62884068	NA	0.6	5.94	0.43	1.87e-8	Sleep depth;
PAAD	cis	rs7474896	0.806	rs1779150	chr10:38038687	C/G	cg25427524	chr10:38739819	LOC399744	-0.79	-4.4	-0.34	2.02e-5	Obesity (extreme);
PAAD	cis	rs10821973	0.527	rs7092870	chr10:63971272	T/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.43	-0.34	1.79e-5	Hypothyroidism;
PAAD	cis	rs5756391	0.546	rs4821566	chr22:37314507	C/G	cg16356956	chr22:37317934	CSF2RB	0.4	4.81	0.36	3.62e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19800926	chr11:73087939	RELT	0.66	7.01	0.49	7.12e-11	Myopia (pathological);
PAAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg08029281	chr1:67600428	NA	0.45	5.24	0.39	5.21e-7	Psoriasis;
PAAD	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.88	-10.07	-0.63	1.33e-18	Morning vs. evening chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23974065	chr14:106235526	NA	-0.61	-6.31	-0.46	2.92e-9	Smoking initiation;
PAAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg05585544	chr11:47624801	NA	-0.49	-5.48	-0.41	1.69e-7	Subjective well-being;
PAAD	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02985541	chr2:219472218	PLCD4	-0.31	-4.91	-0.37	2.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.5	4.89	0.37	2.49e-6	Testicular germ cell tumor;
PAAD	cis	rs10992471	0.580	rs4744143	chr9:95438627	A/C	cg14631576	chr9:95140430	CENPP	-0.47	-4.41	-0.34	1.93e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.82	6.68	0.48	4.26e-10	Putamen volume;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.68	-0.53	1.85e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg26786172	chr16:88781646	CTU2	0.55	4.45	0.34	1.64e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs1190596	0.525	rs6575901	chr14:102691854	A/G	cg23289024	chr14:102554846	HSP90AA1	0.38	4.41	0.34	1.92e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2790216	0.951	rs2590325	chr10:60001130	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs76866386	0.892	rs79835740	chr2:44056148	A/T	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.31	-0.4	3.74e-7	Cholesterol, total;
PAAD	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.52	6.32	0.46	2.73e-9	Sitting height ratio;
PAAD	cis	rs9522267	0.737	rs9522276	chr13:112220208	C/T	cg10483660	chr13:112241077	NA	-0.5	-5.29	-0.39	4.27e-7	Hepatitis;
PAAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.78	-9.12	-0.59	4.3e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg19337854	chr7:99768885	GPC2	-0.41	-4.44	-0.34	1.69e-5	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.83	-0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26897989	chr16:1907736	C16orf73	0.58	5.02	0.38	1.41e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.87	10.66	0.65	3.7799999999999997e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg14847009	chr1:175162515	KIAA0040	-0.33	-5.13	-0.38	8.73e-7	Alcohol dependence;
PAAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.72	5.34	0.4	3.39e-7	Alzheimer's disease;
PAAD	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-4.37	-0.33	2.3e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs939584	1.000	rs35796073	chr2:636819	C/A	cg03610516	chr2:642275	NA	-0.6	-5.5	-0.41	1.57e-7	Body mass index;
PAAD	cis	rs9398803	0.624	rs1378579	chr6:126655243	A/C	cg19875578	chr6:126661172	C6orf173	-0.48	-4.69	-0.36	6.03e-6	Male-pattern baldness;
PAAD	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.66	7.43	0.52	7.3e-12	Body mass index (alcohol intake interaction);
PAAD	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01362455	chr6:29855490	HLA-H	0.54	4.65	0.35	7.08e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs797680	0.822	rs7541304	chr1:93757838	T/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.43	-0.34	1.76e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.63	-8.31	-0.56	4.89e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs59104589	0.617	rs60614486	chr2:242274998	C/G	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.79	8.36	0.56	3.61e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62247992	0.686	rs502399	chr3:43105018	G/A	cg12239580	chr3:43073058	FAM198A	-0.52	-4.55	-0.35	1.08e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.48	5.0	0.38	1.54e-6	Body mass index;
PAAD	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.67	6.9	0.49	1.32e-10	Response to antidepressants and depression;
PAAD	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg24565620	chr2:194026	NA	0.63	4.95	0.37	1.96e-6	Blood protein levels;
PAAD	cis	rs9810890	1.000	rs73210606	chr3:128617426	A/G	cg18531004	chr3:128564980	NA	-0.95	-5.38	-0.4	2.8e-7	Dental caries;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-4.37	-0.33	2.33e-5	Platelet count;
PAAD	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-10.25	-0.64	4.58e-19	Platelet distribution width;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12753518	chr1:28414763	EYA3	0.59	6.58	0.47	7.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.48	6.92	0.49	1.18e-10	Oropharynx cancer;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.76	5.85	0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03647317	chr4:187891568	NA	-0.54	-6.69	-0.48	4.09e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.5	4.86	0.37	2.84e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-7.26	-0.51	1.89e-11	Monocyte percentage of white cells;
PAAD	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.51	-0.34	1.29e-5	Glomerular filtration rate;
PAAD	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.46e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.54	5.63	0.42	8.59e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs66478310	0.590	rs55941868	chr12:108718451	G/A	cg04872675	chr12:108983234	NA	0.83	5.15	0.39	7.85e-7	Plasma clusterin levels;
PAAD	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.4	4.71	0.36	5.58e-6	Colorectal cancer;
PAAD	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs9346649	0.967	rs6907103	chr6:168490016	C/T	cg09211372	chr6:168490623	NA	0.39	4.35	0.33	2.45e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19910323	chr2:47168440	MCFD2;TTC7A	-0.69	-7.07	-0.5	5.26e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17429075	chr10:130492994	NA	0.58	6.52	0.47	9.76e-10	Warfarin maintenance dose;
PAAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.72	-0.36	5.32e-6	Aortic root size;
PAAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.38	0.4	2.81e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg01800442	chr17:74086473	EXOC7	0.53	4.25	0.33	3.67e-5	Psoriasis;
PAAD	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.97	10.29	0.64	3.57e-19	Corneal astigmatism;
PAAD	trans	rs144447022	1	rs144447022	chr6:29244219	G/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Intelligence (multi-trait analysis);Schizophrenia;
PAAD	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.87	10.87	0.66	9.92e-21	Body mass index;
PAAD	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-4.9	-0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg04738700	chr2:239367308	NA	0.4	4.32	0.33	2.76e-5	Multiple system atrophy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25873214	chr11:47587499	PTPMT1	0.64	7.32	0.51	1.31e-11	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg09796270	chr17:17721594	SREBF1	-0.49	-5.46	-0.41	1.88e-7	Total body bone mineral density;
PAAD	cis	rs7264396	0.887	rs4911502	chr20:34063034	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-4.33	-0.33	2.66e-5	Chronic sinus infection;
PAAD	cis	rs62264129	0.500	rs56008438	chr3:112034103	A/G	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.92	-0.37	2.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg08994789	chr17:28903642	LRRC37B2	0.66	4.98	0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.32	-0.33	2.76e-5	Lewy body disease;
PAAD	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.7	0.53	1.58e-12	Metabolite levels;
PAAD	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg14254433	chr6:34482411	PACSIN1	-1.14	-6.41	-0.46	1.76e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs116248771	0.739	rs76493374	chr3:158345639	G/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg23605961	chr7:751331	PRKAR1B	-0.28	-4.62	-0.35	8.23e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg08926642	chr1:7887455	PER3	0.49	4.39	0.34	2.07e-5	Inflammatory bowel disease;
PAAD	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06850241	chr22:41845214	NA	-0.52	-4.73	-0.36	5.06e-6	Vitiligo;
PAAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg16083429	chr3:49237500	CCDC36	-0.43	-4.52	-0.34	1.23e-5	Parkinson's disease;
PAAD	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.63	0.47	5.45e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.16	9.96	0.63	2.73e-18	Vitiligo;
PAAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-4.69	-0.36	6.03e-6	Skin colour saturation;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs28472312	0.648	rs115616784	chr16:29000446	G/A	cg16576597	chr16:28551801	NUPR1	-0.45	-4.59	-0.35	9.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg23587288	chr2:27483067	SLC30A3	0.81	7.13	0.5	3.77e-11	Blood metabolite levels;
PAAD	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	5.89	0.43	2.36e-8	LDL cholesterol;
PAAD	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5753037	0.809	rs740041	chr22:30200099	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-4.48	-0.34	1.47e-5	Type 1 diabetes;
PAAD	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg22771759	chr13:24902376	NA	-0.43	-4.36	-0.33	2.36e-5	Obesity-related traits;
PAAD	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.49	-4.62	-0.35	8.08e-6	Obesity-related traits;
PAAD	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.3	11.28	0.68	8.02e-22	Uric acid levels;
PAAD	cis	rs1144333	0.655	rs12402347	chr1:76447986	C/T	cg22875332	chr1:76189707	ACADM	0.76	4.46	0.34	1.59e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs4719841	0.662	rs6980357	chr7:25994009	A/G	cg24254488	chr7:25991654	NA	0.32	4.53	0.35	1.17e-5	Triglyceride levels;
PAAD	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.7	6.53	0.47	9.24e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.54e-12	Initial pursuit acceleration;
PAAD	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.58	-0.47	7.1e-10	HDL cholesterol;
PAAD	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.56	-7.22	-0.51	2.3e-11	Longevity;
PAAD	cis	rs7101378	0.577	rs7952458	chr11:108899235	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.05	0.55	2.26e-13	Morning vs. evening chronotype;
PAAD	cis	rs8133932	0.701	rs3788217	chr21:47287321	T/C	cg13695288	chr21:47294981	PCBP3	-0.47	-4.61	-0.35	8.65e-6	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.93	6.93	0.49	1.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs6700896	0.500	rs1938496	chr1:66100915	C/T	cg04111102	chr1:66153794	NA	0.47	4.42	0.34	1.88e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.85	10.76	0.66	1.98e-20	Menopause (age at onset);
PAAD	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	7.47	0.52	5.96e-12	Cognitive test performance;
PAAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.57	6.51	0.47	1.03e-9	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
PAAD	cis	rs7534824	0.625	rs61780285	chr1:101357627	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.58	0.35	9.48e-6	Refractive astigmatism;
PAAD	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.52	5.03	0.38	1.35e-6	Itch intensity from mosquito bite;
PAAD	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-1.1	-14.41	-0.76	3.15e-30	Height;
PAAD	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg03934478	chr11:495069	RNH1	1.01	5.35	0.4	3.17e-7	Body mass index;
PAAD	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg20169779	chr10:135381914	SYCE1	0.45	4.52	0.34	1.23e-5	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.82	6.75	0.48	2.86e-10	Alzheimer's disease;
PAAD	cis	rs2019216	0.631	rs12150287	chr17:21974265	C/G	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs61884328	0.866	rs12577969	chr11:46820788	G/A	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg06740227	chr12:86229804	RASSF9	0.51	5.05	0.38	1.26e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-6.82	-0.48	2.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.71	-9.11	-0.59	4.54e-16	Cancer;
PAAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.57	-5.96	-0.44	1.7e-8	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22756211	chr11:134118834	THYN1	0.67	7.47	0.52	5.88e-12	Smoking initiation;
PAAD	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg10072921	chr12:121022843	NA	-0.44	-5.46	-0.4	1.92e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.44	4.61	0.35	8.49e-6	Diastolic blood pressure;
PAAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg13259177	chr13:114761607	RASA3	-0.86	-6.88	-0.49	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg18323236	chr1:24743029	NIPAL3	0.44	4.78	0.36	4.12e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg27499820	chr13:21296301	IL17D	0.51	4.8	0.36	3.71e-6	Dental caries;
PAAD	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.43	-0.34	1.83e-5	Fear of minor pain;
PAAD	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg05784532	chr1:230284198	GALNT2	0.69	6.06	0.44	1.04e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs501120	0.657	rs494207	chr10:44741256	G/A	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9810890	1.000	rs73198849	chr3:128507879	G/C	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.54	-5.52	-0.41	1.4e-7	Lewy body disease;
PAAD	cis	rs8060686	0.920	rs56845922	chr16:67770828	T/C	cg09835421	chr16:68378352	PRMT7	-0.93	-5.32	-0.4	3.69e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1529711	0.636	rs11670365	chr19:11004833	A/G	cg16667279	chr19:11591998	ELAVL3	0.55	4.37	0.33	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs75757892	0.544	rs9505145	chr6:7318611	A/G	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.53	-5.76	-0.42	4.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.51	5.49	0.41	1.62e-7	Obesity-related traits;
PAAD	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.87	10.15	0.64	8.21e-19	Bladder cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08309311	chr7:99699557	MCM7;AP4M1	-0.76	-6.53	-0.47	9.52e-10	Neuroticism;
PAAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.47	-4.28	-0.33	3.29e-5	Obesity-related traits;
PAAD	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs728616	0.764	rs61545595	chr10:81853769	T/C	cg05935833	chr10:81318306	SFTPA2	-0.57	-4.47	-0.34	1.51e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg00206168	chr11:65308501	LTBP3	0.83	5.73	0.42	5.17e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2446066	0.872	rs11170532	chr12:53788335	G/A	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12311304	1.000	rs1479406	chr12:15387543	C/T	cg08258403	chr12:15378311	NA	0.37	4.66	0.35	6.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.52	-4.58	-0.35	9.78e-6	Cocaine dependence;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05025164	chr4:1340916	KIAA1530	0.95	11.22	0.67	1.19e-21	Longevity;
PAAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg02549819	chr16:58548995	SETD6	0.95	4.68	0.36	6.21e-6	Schizophrenia;
PAAD	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.52	-4.75	-0.36	4.65e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.76	6.84	0.49	1.79e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.34	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.67	7.2	0.5	2.61e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16292451	chr1:161954657	OLFML2B	-0.62	-6.41	-0.46	1.72e-9	Obesity-related traits;
PAAD	cis	rs28655083	0.552	rs76055145	chr16:77124905	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-4.6	-0.35	8.96e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs8040855	0.627	rs11632175	chr15:85611680	T/A	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7705042	0.865	rs166079	chr5:141528959	C/T	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.61	-0.35	8.47e-6	Asthma;
PAAD	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.35	4.61	0.35	8.5e-6	Vitiligo;
PAAD	cis	rs2997447	0.761	rs55960411	chr1:26437741	G/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-5.88	-0.43	2.48e-8	Breast cancer;
PAAD	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.44e-5	Hepatocellular carcinoma;
PAAD	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.06	9.87	0.62	4.68e-18	Red blood cell traits;
PAAD	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg02264943	chr11:130785842	SNX19	0.4	4.69	0.36	6.11e-6	Schizophrenia;
PAAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.69	-0.53	1.69e-12	Height;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.58	-6.39	-0.46	1.88e-9	Systemic lupus erythematosus;
PAAD	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.14	-0.38	8.34e-7	Pulmonary function;
PAAD	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-4.74	-0.36	4.94e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.73	7.58	0.52	3.18e-12	Height;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.27	-0.39	4.65e-7	Obesity-related traits;
PAAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.69	7.7	0.53	1.59e-12	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26335459	chr4:2845453	ADD1	0.56	6.37	0.46	2.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.62	-0.35	8.29e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.69	0.42	6.36e-8	Coronary artery disease;
PAAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-4.27	-0.33	3.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.35	-0.33	2.46e-5	Asthma;
PAAD	cis	rs2133450	0.780	rs13082785	chr3:7358711	G/A	cg19930620	chr3:7340148	GRM7	-0.43	-4.53	-0.34	1.18e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs12541635	1.000	rs4734897	chr8:107075518	G/A	cg10147462	chr8:107024639	NA	-0.44	-4.64	-0.35	7.54e-6	Age of smoking initiation;
PAAD	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.42	0.46	1.66e-9	Lung cancer in ever smokers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20603181	chr11:65337543	SSSCA1	-0.77	-6.78	-0.48	2.5e-10	Neuroticism;
PAAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.93	-6.63	-0.47	5.46e-10	Initial pursuit acceleration;
PAAD	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.42	-5.61	-0.41	9.17e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	4.74	0.36	4.95e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2286503	1.000	rs2286498	chr7:22857504	C/T	cg04907244	chr7:22894795	SNORD93	0.43	5.31	0.4	3.84e-7	Fibrinogen;
PAAD	cis	rs959260	0.925	rs9901434	chr17:73388770	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.71	7.9	0.54	5.33e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.75	8.2	0.55	9.35e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs873917	0.577	rs784612	chr1:40122939	T/C	cg06209491	chr1:40138402	NT5C1A	-0.64	-5.93	-0.43	1.95e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs28647808	1.000	rs4962141	chr9:136274478	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg03457528	chr8:128806865	MIR1204;PVT1	-0.72	-6.57	-0.47	7.66e-10	Blood protein levels;
PAAD	cis	rs35300120	0.757	rs12096351	chr1:233655610	G/A	cg23054119	chr1:233659267	NA	-0.54	-4.78	-0.36	4.05e-6	Cognitive function;
PAAD	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.37	5.36	0.4	2.98e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6494488	0.500	rs117686856	chr15:64885245	G/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	0.97	6.19	0.45	5.3e-9	IgG glycosylation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24495844	chr11:17411043	KCNJ11	-0.73	-6.75	-0.48	2.91e-10	Neuroticism;
PAAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.67	-0.42	6.98e-8	Gut microbiome composition (summer);
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.55	6.95	0.49	1.01e-10	Body mass index;
PAAD	cis	rs12760731	0.565	rs12047117	chr1:178132608	G/A	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs9287719	0.686	rs10174605	chr2:10725232	G/A	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.58	-8.38	-0.56	3.34e-14	Huntington's disease progression;
PAAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-1.04	-14.59	-0.76	1.02e-30	Breast cancer;
PAAD	cis	rs1797885	0.546	rs2454421	chr3:12601105	C/T	cg05638426	chr3:12878574	RPL32	-0.47	-4.42	-0.34	1.85e-5	Immature fraction of reticulocytes;
PAAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.92e-12	Height;
PAAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14895029	chr7:2775587	GNA12	-0.46	-4.68	-0.36	6.2e-6	Height;
PAAD	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg09754948	chr16:28834200	ATXN2L	-0.48	-4.42	-0.34	1.86e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.59	5.8	0.43	3.76e-8	Longevity;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.2	-0.39	6.29e-7	Life satisfaction;
PAAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg18279126	chr7:2041391	MAD1L1	0.58	5.98	0.44	1.54e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.65	7.02	0.49	7.02e-11	Morning vs. evening chronotype;
PAAD	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg09626299	chr10:82213104	TSPAN14	-0.44	-4.82	-0.36	3.45e-6	Post bronchodilator FEV1;
PAAD	cis	rs3809060	0.959	rs3858447	chr11:32451003	A/G	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.81e-8	Immature fraction of reticulocytes;
PAAD	cis	rs17221829	0.965	rs10830370	chr11:89461535	G/T	cg02982614	chr11:89391479	FOLH1B	-0.43	-4.39	-0.34	2.12e-5	Anxiety in major depressive disorder;
PAAD	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.64	7.15	0.5	3.47e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7904985	0.643	rs17323032	chr10:88099653	G/A	cg07322936	chr10:88137208	NA	-0.48	-4.37	-0.33	2.32e-5	Barrett's esophagus;
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg18612461	chr15:75251733	NA	0.58	7.27	0.51	1.81e-11	Breast cancer;
PAAD	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg08807101	chr21:30365312	RNF160	-0.65	-5.26	-0.39	4.78e-7	Cognitive test performance;
PAAD	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg05754148	chr16:3507555	NAT15	0.65	4.78	0.36	4.18e-6	Tuberculosis;
PAAD	cis	rs75920871	0.843	rs12099358	chr11:116726048	C/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.71	-0.36	5.52e-6	Subjective well-being;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg00837987	chr8:588849	NA	-0.86	-4.62	-0.35	8.01e-6	IgG glycosylation;
PAAD	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.51	5.67	0.42	6.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.37	-5.74	-0.42	5.06e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7260598	0.539	rs10412189	chr19:24080338	T/G	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg09659197	chr4:152720779	NA	-0.4	-5.54	-0.41	1.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg08198773	chr8:1697536	NA	0.47	5.17	0.39	7.37e-7	Systolic blood pressure;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg03407747	chr17:6899364	ALOX12	0.51	5.36	0.4	3.06e-7	Tonsillectomy;
PAAD	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg23153227	chr6:27725408	NA	0.42	4.44	0.34	1.75e-5	Pubertal anthropometrics;
PAAD	cis	rs7922314	0.571	rs61865722	chr10:64755548	G/A	cg08989932	chr10:65390526	NA	-0.95	-4.67	-0.35	6.48e-6	Cutaneous psoriasis;
PAAD	trans	rs901683	1.000	rs71499566	chr10:45996015	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.49	-0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg10382835	chr6:42185730	MRPS10	0.78	5.63	0.42	8.59e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.95	0.54	3.84e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.16	12.83	0.72	5.5e-26	Post bronchodilator FEV1;
PAAD	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	5.19	0.39	6.64e-7	Red blood cell count;
PAAD	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg11143131	chr5:131608246	PDLIM4	0.51	5.14	0.38	8.4e-7	Blood metabolite levels;
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs1190596	0.525	rs7157909	chr14:102734211	T/C	cg23904247	chr14:102554826	HSP90AA1	0.44	5.03	0.38	1.39e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs17162190	0.698	rs61692526	chr1:26849906	T/C	cg17456097	chr1:26900765	RPS6KA1	0.6	5.02	0.38	1.41e-6	Mean corpuscular volume;
PAAD	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-4.67	-0.35	6.61e-6	Primary sclerosing cholangitis;
PAAD	cis	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg27395922	chr11:50257633	LOC441601	0.42	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg12826209	chr6:26865740	GUSBL1	0.96	4.42	0.34	1.86e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg24905316	chr10:135186343	ECHS1	-0.72	-4.42	-0.34	1.85e-5	Lifespan;
PAAD	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg14146966	chr2:61757674	XPO1	0.34	4.32	0.33	2.85e-5	Tuberculosis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06414161	chr16:53534040	AKTIP	0.68	6.6	0.47	6.41e-10	Lung cancer in ever smokers;
PAAD	cis	rs6782025	0.837	rs56106401	chr3:120821221	A/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-8.83	-0.58	2.42e-15	Morning vs. evening chronotype;
PAAD	cis	rs743757	1.000	rs13087550	chr3:50455867	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.64	0.35	7.31e-6	Diastolic blood pressure;
PAAD	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.84	9.06	0.59	6.05e-16	Schizophrenia;
PAAD	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.48	-0.34	1.48e-5	Biliary atresia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03577460	chr14:24836084	NFATC4	0.74	7.42	0.52	7.58e-12	Obesity-related traits;
PAAD	cis	rs829661	0.894	rs2609960	chr2:30875332	A/C	cg12454169	chr2:30669597	LCLAT1	0.66	5.06	0.38	1.21e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00616447	chr15:41694635	NDUFAF1	0.56	6.39	0.46	1.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09597638	chr17:3907349	NA	0.73	7.63	0.53	2.37e-12	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.85	6.55	0.47	8.37e-10	Alzheimer's disease;
PAAD	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg19760965	chr3:194868843	C3orf21	0.51	4.77	0.36	4.21e-6	Non-small cell lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05302420	chr10:101419129	ENTPD7	-0.75	-6.44	-0.46	1.48e-9	Neuroticism;
PAAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	5.63	0.42	8.51e-8	Personality dimensions;
PAAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.58	6.81	0.48	2.16e-10	Aortic root size;
PAAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.95	10.42	0.65	1.64e-19	Diastolic blood pressure;
PAAD	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg00522288	chr12:125625016	AACS	-0.56	-6.19	-0.45	5.24e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg26516362	chr5:178986906	RUFY1	-0.45	-5.31	-0.4	3.75e-7	Lung cancer;
PAAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.13	15.63	0.79	1.9e-33	Cognitive function;
PAAD	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.68	-7.55	-0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs600626	0.529	rs59913369	chr11:75473265	A/G	cg24262691	chr11:75473276	NA	0.75	6.18	0.45	5.65e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg02580895	chr19:2754563	NA	-0.49	-4.29	-0.33	3.12e-5	Total cholesterol levels;
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.91	-6.15	-0.45	6.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.97	8.17	0.55	1.13e-13	Initial pursuit acceleration;
PAAD	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.15	-14.25	-0.76	8.41e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-5.79	-0.42	3.99e-8	Schizophrenia;
PAAD	cis	rs6785206	0.772	rs66460449	chr3:128538135	A/G	cg19205850	chr3:128446370	RAB7A	0.68	4.76	0.36	4.46e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.15	17.2	0.81	1.68e-37	Cognitive function;
PAAD	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg06307176	chr5:131281290	NA	0.51	4.47	0.34	1.52e-5	Life satisfaction;
PAAD	cis	rs2574704	0.532	rs2616553	chr3:11664812	T/C	cg07643000	chr3:11666825	VGLL4	-0.54	-4.31	-0.33	2.93e-5	Body mass index;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-5.05	-0.38	1.26e-6	Testicular germ cell tumor;
PAAD	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.55	6.88	0.49	1.5e-10	Crohn's disease;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg04415270	chr2:102091202	RFX8	-0.52	-6.52	-0.47	9.62e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.68	4.84	0.37	3.13e-6	Inflammatory bowel disease;
PAAD	cis	rs8060686	0.582	rs8182201	chr16:68091150	T/G	cg09835421	chr16:68378352	PRMT7	-0.75	-6.06	-0.44	1.02e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.81	6.87	0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.37	-4.28	-0.33	3.32e-5	Hemoglobin concentration;
PAAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.74	0.36	4.98e-6	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg03517284	chr6:25882590	NA	-0.58	-4.87	-0.37	2.77e-6	Iron status biomarkers;
PAAD	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.84	10.19	0.64	6.76e-19	Menopause (age at onset);
PAAD	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.63	-6.63	-0.47	5.47e-10	Adiposity;
PAAD	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.53e-8	Mean corpuscular volume;
PAAD	cis	rs5417	0.636	rs427784	chr17:7157516	C/T	cg14438174	chr17:7137923	DVL2	-0.46	-4.34	-0.33	2.54e-5	Diastolic blood pressure;
PAAD	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.55	5.63	0.42	8.57e-8	Schizophrenia;
PAAD	cis	rs354225	0.553	rs7564719	chr2:54829731	A/C	cg01766943	chr2:54829624	SPTBN1	0.54	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs9972944	0.756	rs8076925	chr17:63764616	A/C	cg07283582	chr17:63770753	CCDC46	-0.52	-6.06	-0.44	1.01e-8	Total body bone mineral density;
PAAD	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.42	-6.6	-0.47	6.29e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17077171	chr1:155658509	YY1AP1;DAP3	0.62	6.29	0.45	3.18e-9	Obesity-related traits;
PAAD	cis	rs2587695	0.904	rs2587686	chr2:120285695	G/T	cg05839767	chr2:119914248	C1QL2	-0.41	-4.25	-0.33	3.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1497828	0.956	rs2810779	chr1:217542866	G/A	cg04411442	chr1:217543379	NA	0.48	4.73	0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.19	0.45	5.37e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1075265	0.749	rs805434	chr2:54063333	T/C	cg04546899	chr2:54196757	PSME4	0.32	4.85	0.37	2.98e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.76	8.51	0.57	1.51e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05585810	chr3:152880101	RAP2B	0.65	6.66	0.48	4.71e-10	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.58	0.35	9.46e-6	Homoarginine levels;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.76	-7.92	-0.54	4.64e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.53	7.26	0.51	1.91e-11	Crohn's disease;
PAAD	cis	rs12920732	0.509	rs12598730	chr16:84795035	C/T	cg07647771	chr16:84786436	USP10	-0.31	-4.31	-0.33	2.97e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg14773178	chr5:1868261	NA	0.34	4.55	0.35	1.08e-5	Cardiovascular disease risk factors;
PAAD	cis	rs1358748	0.522	rs1321155	chr1:67589479	G/C	cg02640540	chr1:67518911	SLC35D1	0.7	4.68	0.35	6.27e-6	Tuberculosis;
PAAD	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.84	-7.15	-0.5	3.37e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg05785598	chr3:49045655	WDR6	0.41	4.9	0.37	2.38e-6	Parkinson's disease;
PAAD	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.55	5.27	0.39	4.57e-7	Corneal astigmatism;
PAAD	cis	rs8121916	1.000	rs6078570	chr20:12411720	C/T	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg17480646	chr11:65405466	SIPA1	0.9	4.28	0.33	3.29e-5	Height;
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.21	-0.39	5.93e-7	Lung cancer;
PAAD	cis	rs478222	1.000	rs478222	chr2:25301755	A/T	cg01884057	chr2:25150051	NA	-0.36	-4.38	-0.33	2.18e-5	Type 1 diabetes;
PAAD	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg00262122	chr8:11665843	FDFT1	0.5	4.72	0.36	5.32e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg19413350	chr8:57351067	NA	-0.45	-4.27	-0.33	3.44e-5	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.31e-8	Electroencephalogram traits;
PAAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.62	-4.93	-0.37	2.16e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9287719	0.649	rs9973374	chr2:10716384	C/T	cg00105475	chr2:10696890	NA	0.65	6.81	0.48	2.16e-10	Prostate cancer;
PAAD	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	4.3	0.33	3.01e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7567389	0.599	rs6430938	chr2:128162623	A/G	cg11380483	chr2:127933992	NA	-0.46	-4.32	-0.33	2.82e-5	Self-rated health;
PAAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg14092988	chr3:52407081	DNAH1	0.4	4.89	0.37	2.49e-6	Bipolar disorder;
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg05585544	chr11:47624801	NA	-0.48	-5.39	-0.4	2.63e-7	Subjective well-being;
PAAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.3	0.33	3.02e-5	Homoarginine levels;
PAAD	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	cis	rs7624766	0.555	rs4525912	chr3:160527149	C/T	cg22637730	chr3:160473554	PPM1L	0.51	4.38	0.34	2.16e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg08999081	chr20:33150536	PIGU	-0.6	-6.68	-0.48	4.13e-10	Height;
PAAD	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.09	8.53	0.57	1.37e-14	Diabetic kidney disease;
PAAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg17330251	chr7:94953956	PON1	-0.54	-4.52	-0.34	1.21e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11623869	0.695	rs3759579	chr14:103851272	A/G	cg10395934	chr14:104002654	TRMT61A	-0.46	-5.0	-0.38	1.57e-6	Bone mineral density;
PAAD	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.31	11.62	0.69	1e-22	Uric acid levels;
PAAD	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg19407955	chr1:165599744	MGST3	-0.75	-5.81	-0.43	3.51e-8	Total ventricular volume;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.84	7.26	0.51	1.9e-11	Alzheimer's disease;
PAAD	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.48	-4.67	-0.35	6.63e-6	Economic and political preferences (feminism/equality);
PAAD	trans	rs61931739	0.629	rs1842886	chr12:33704257	A/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg26031613	chr14:104095156	KLC1	-0.48	-5.2	-0.39	6.21e-7	Schizophrenia;
PAAD	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-4.32	-0.33	2.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.2e-7	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs75757892	0.621	rs1983851	chr6:7293542	A/C	cg02954307	chr6:7269328	NA	0.59	4.56	0.35	1.04e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg12395012	chr8:11607386	GATA4	0.42	4.33	0.33	2.69e-5	Triglycerides;
PAAD	cis	rs7319311	0.589	rs952358	chr13:111026738	T/A	cg05272587	chr13:111038400	COL4A2	0.62	5.56	0.41	1.21e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.62e-7	Life satisfaction;
PAAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg27094323	chr7:1216898	NA	-0.46	-5.43	-0.4	2.17e-7	Longevity;Endometriosis;
PAAD	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.59	5.06	0.38	1.22e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.13e-7	Obesity-related traits;
PAAD	cis	rs58521262	0.556	rs158693	chr19:23200807	C/T	cg02350677	chr19:23254381	NA	0.26	4.51	0.34	1.3e-5	Testicular germ cell tumor;
PAAD	cis	rs10838708	1.000	rs10838708	chr11:47441513	G/A	cg18512352	chr11:47633146	NA	-0.31	-4.7	-0.36	5.77e-6	Height;
PAAD	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg15192750	chr16:69999425	NA	0.75	5.81	0.43	3.61e-8	IgE levels;
PAAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.79	-9.83	-0.62	5.8e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs72759609	0.708	rs112237589	chr5:31962001	C/A	cg05687174	chr5:31382507	NA	0.55	4.31	0.33	2.97e-5	Vertical cup-disc ratio;
PAAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.97e-7	Monocyte percentage of white cells;
PAAD	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.85	-0.49	1.71e-10	Morning vs. evening chronotype;
PAAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.76	6.84	0.49	1.79e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg15443732	chr18:74961078	GALR1	0.57	5.25	0.39	5.11e-7	Obesity-related traits;
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg16988970	chr17:42248062	ASB16	-0.33	-4.55	-0.35	1.1e-5	Total body bone mineral density;
PAAD	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg06780032	chr1:8272277	NA	-0.33	-4.3	-0.33	3.06e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.62	0.35	8.01e-6	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08092965	chr16:71495883	ZNF23	-0.63	-6.65	-0.47	4.94e-10	Smoking initiation;
PAAD	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.42	-4.29	-0.33	3.11e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.7	-5.8	-0.43	3.66e-8	Exhaled nitric oxide output;
PAAD	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg06096015	chr1:231504339	EGLN1	-0.57	-6.17	-0.45	5.89e-9	Red blood cell count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08588455	chr17:40761604	FAM134C;TUBG1	0.59	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.05	0.38	1.25e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg25319279	chr11:5960081	NA	-0.6	-5.73	-0.42	5.17e-8	DNA methylation (variation);
PAAD	cis	rs7631605	0.905	rs11129748	chr3:37067050	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-5.31	-0.4	3.81e-7	Psoriasis;
PAAD	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg20913747	chr6:44695427	NA	-0.7	-6.96	-0.49	9.52e-11	Total body bone mineral density;
PAAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.6e-5	Renal cell carcinoma;
PAAD	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.69	7.44	0.52	6.74e-12	Menarche (age at onset);
PAAD	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.52	-5.04	-0.38	1.28e-6	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.56	-6.04	-0.44	1.11e-8	IgG glycosylation;
PAAD	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.58	-5.94	-0.43	1.85e-8	Hypospadias;
PAAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	10.77	0.66	1.86e-20	Smoking behavior;
PAAD	cis	rs1800469	0.598	rs8103493	chr19:41874339	T/G	cg08477640	chr19:41863820	B9D2	0.72	7.72	0.53	1.44e-12	Colorectal cancer;
PAAD	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg24053715	chr22:38214548	NA	-0.5	-4.86	-0.37	2.94e-6	Glioblastoma;Glioma;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg04154034	chr17:28927549	LRRC37B2	0.62	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6494488	0.500	rs72741348	chr15:64771044	A/T	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.96	9.56	0.61	2.95e-17	Corneal astigmatism;
PAAD	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg03989125	chr22:38214979	NA	0.66	6.65	0.47	4.97e-10	Glioblastoma;Glioma;
PAAD	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.36	-4.74	-0.36	4.92e-6	Primary biliary cholangitis;
PAAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg05785598	chr3:49045655	WDR6	0.42	4.9	0.37	2.44e-6	Parkinson's disease;
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg24112000	chr20:60950667	NA	-0.68	-8.66	-0.57	6.26e-15	Colorectal cancer;
PAAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.46	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.06	0.55	2.05e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	6.12	0.44	7.75e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.14	15.71	0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.84	8.34	0.56	4.17e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-6.73	-0.48	3.24e-10	Monocyte count;
PAAD	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.44	-4.95	-0.37	1.95e-6	Mean arterial pressure;
PAAD	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.13	0.6	3.94e-16	Morning vs. evening chronotype;
PAAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.45	4.29	0.33	3.12e-5	Multiple sclerosis;
PAAD	cis	rs2964802	0.505	rs2083232	chr5:10812811	G/A	cg14521931	chr5:10832172	NA	-0.48	-5.16	-0.39	7.75e-7	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.73	-7.52	-0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.8	9.09	0.59	5.12e-16	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.71	7.35	0.51	1.15e-11	Triglyceride levels;
PAAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.43	-4.35	-0.33	2.53e-5	Aortic root size;
PAAD	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-7.12	-0.5	4.04e-11	Morning vs. evening chronotype;
PAAD	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs300774	0.925	rs300722	chr2:134249	A/C	cg21211680	chr2:198530	NA	-0.59	-5.74	-0.42	5.05e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg09399716	chr2:46890238	NA	-0.5	-4.42	-0.34	1.85e-5	Height;
PAAD	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg11812906	chr14:75593930	NEK9	0.51	5.09	0.38	1.04e-6	Caffeine consumption;
PAAD	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg02631450	chr22:32366979	NA	1.03	5.42	0.4	2.24e-7	Childhood ear infection;
PAAD	cis	rs12136530	0.509	rs77930907	chr1:19724752	G/C	cg25104613	chr1:20649108	VWA5B1	-0.44	-4.79	-0.36	3.98e-6	Lead levels in blood;
PAAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.56	-5.31	-0.4	3.89e-7	Breast size;
PAAD	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.03	0.5	6.46e-11	Body mass index;
PAAD	cis	rs6960043	0.967	rs6978885	chr7:15053307	G/A	cg19272540	chr7:15055459	NA	-0.31	-5.84	-0.43	3.08e-8	Type 2 diabetes;
PAAD	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.75	8.19	0.55	1.01e-13	Psoriasis;
PAAD	cis	rs6132905	0.590	rs80091120	chr20:2617674	G/A	cg24848351	chr20:2622020	TMC2	-0.73	-5.33	-0.4	3.46e-7	Mumps;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	5.03	0.38	1.39e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.47	4.91	0.37	2.38e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.73	7.09	0.5	4.83e-11	Schizophrenia;
PAAD	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs1256061	0.624	rs944047	chr14:64700292	C/T	cg23250157	chr14:64679961	SYNE2	0.56	5.74	0.42	5.05e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.52	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7631605	0.935	rs9819025	chr3:37073287	T/G	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.21	-0.39	6.1e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg11783602	chr8:55087084	NA	0.52	5.46	0.41	1.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.59	-6.05	-0.44	1.06e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs12714314	0.718	rs1469645	chr2:1950140	C/A	cg22350835	chr2:1868857	MYT1L	0.48	4.57	0.35	1.01e-5	Type 2 diabetes (age of onset);
PAAD	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.57	6.58	0.47	7.03e-10	Mean corpuscular volume;
PAAD	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	8.94e-7	Motion sickness;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.17	0.55	1.13e-13	Alzheimer's disease;
PAAD	cis	rs12136530	0.577	rs4912002	chr1:19793402	G/T	cg12763668	chr1:19687257	CAPZB	0.49	4.47	0.34	1.51e-5	Lead levels in blood;
PAAD	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.42	-6.93	-0.49	1.14e-10	Paget's disease;
PAAD	trans	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg26939375	chr7:64535504	NA	0.75	9.02	0.59	7.72e-16	Aortic root size;
PAAD	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-0.45	-4.35	-0.33	2.48e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.36	0.46	2.3e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-7.99	-0.54	3.21e-13	Hemoglobin concentration;
PAAD	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.48	4.38	0.33	2.19e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1419980	0.730	rs1558533	chr12:7735848	A/G	cg25828445	chr12:7781288	NA	0.96	4.94	0.37	2e-6	HDL cholesterol levels;
PAAD	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg14703610	chr5:56206110	C5orf35	0.62	5.84	0.43	3.05e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs5756391	0.509	rs2075727	chr22:37310217	C/T	cg21209356	chr22:37319042	CSF2RB	0.34	4.35	0.33	2.45e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg18279126	chr7:2041391	MAD1L1	0.56	5.34	0.4	3.33e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03967431	chr4:99849653	EIF4E	0.56	6.29	0.45	3.23e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-8.21	-0.55	8.71e-14	Morning vs. evening chronotype;
PAAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.56	-6.12	-0.44	7.63e-9	Huntington's disease progression;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10663503	chr17:8126298	C17orf44	0.63	6.79	0.48	2.41e-10	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11542543	chr13:108017565	FAM155A	-0.61	-6.44	-0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.13	-0.5	3.72e-11	Neuroticism;
PAAD	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.76	-5.62	-0.41	8.94e-8	Mean platelet volume;
PAAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.73	6.77	0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg05341575	chr12:125625032	AACS	-0.47	-4.49	-0.34	1.41e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg21174375	chr14:64681225	SYNE2	0.32	4.45	0.34	1.68e-5	Atrial fibrillation;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.45e-6	Lung cancer;
PAAD	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg09659197	chr4:152720779	NA	-0.46	-6.15	-0.45	6.43e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs740474	0.768	rs6880745	chr5:140981247	C/A	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.43	5.23	0.39	5.62e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg10431340	chr1:161279108	MPZ	-0.62	-5.67	-0.42	7e-8	Rheumatoid arthritis;
PAAD	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	1.14	15.73	0.79	1.06e-33	Body mass index;
PAAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs7593730	0.636	rs6757491	chr2:161147743	G/C	cg22609984	chr2:161126801	NA	0.52	4.5	0.34	1.32e-5	Type 2 diabetes;
PAAD	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg05294307	chr14:35346193	BAZ1A	-0.63	-5.21	-0.39	6.17e-7	Psoriasis;
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-9.05	-0.59	6.52e-16	Total body bone mineral density;
PAAD	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg27205649	chr11:78285834	NARS2	0.64	4.95	0.37	1.98e-6	Alzheimer's disease (survival time);
PAAD	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg22437258	chr11:111473054	SIK2	-0.59	-5.44	-0.4	2.08e-7	Primary sclerosing cholangitis;
PAAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.47	4.7	0.36	5.75e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.73	-9.47	-0.61	5.05e-17	Height;
PAAD	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs3753841	0.832	rs7521799	chr1:103232517	T/G	cg24495344	chr1:103574097	COL11A1	0.4	4.6	0.35	8.71e-6	Glaucoma (primary angle closure);
PAAD	cis	rs1147246	0.764	rs10846882	chr12:125890152	C/T	cg26500143	chr12:125470770	DHX37	0.4	4.42	0.34	1.85e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6681460	1.000	rs6696927	chr1:67070381	A/G	cg02459107	chr1:67143332	SGIP1	0.78	8.16	0.55	1.2e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-13.12	-0.73	9.18e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17082373	chr17:57184450	TRIM37	0.67	6.79	0.48	2.31e-10	Obesity-related traits;
PAAD	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.45	0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg07148914	chr20:33460835	GGT7	0.5	4.85	0.37	3.06e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.63	3.93e-18	Vitiligo;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.07e-6	Testicular germ cell tumor;
PAAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg06740227	chr12:86229804	RASSF9	0.59	5.2	0.39	6.35e-7	Major depressive disorder;
PAAD	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg23241863	chr10:102295624	HIF1AN	0.48	4.35	0.33	2.48e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg27449745	chr7:23145252	KLHL7	-0.6	-5.41	-0.4	2.46e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.85	-0.37	3.05e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.62	5.3	0.39	4.01e-7	Response to diuretic therapy;
PAAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.07e-20	Total body bone mineral density;
PAAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.93	9.95	0.63	2.84e-18	Cognitive function;
PAAD	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg24296786	chr1:45957014	TESK2	0.49	4.44	0.34	1.7e-5	Homocysteine levels;
PAAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.59	-7.86	-0.54	6.55e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg05585544	chr11:47624801	NA	-0.47	-5.23	-0.39	5.63e-7	Neuroticism;
PAAD	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.52	-5.77	-0.42	4.39e-8	Migraine;
PAAD	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	5.14	0.38	8.3e-7	Lung cancer in ever smokers;
PAAD	cis	rs899997	1.000	rs1825086	chr15:79029492	A/G	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.66	-7.58	-0.52	3.2e-12	Huntington's disease progression;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.51	-5.54	-0.41	1.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.63	7.81	0.54	8.58e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg13614468	chr19:6393508	GTF2F1	0.58	6.51	0.47	1.02e-9	Smoking initiation;
PAAD	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg14515779	chr1:101123966	NA	0.39	4.31	0.33	2.88e-5	Monocyte count;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.37	0.4	2.96e-7	Schizophrenia;
PAAD	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs12304921	1.000	rs12317171	chr12:51337669	C/T	cg18059802	chr12:51347058	HIGD1C	0.74	6.11	0.44	7.97e-9	Type 2 diabetes;
PAAD	cis	rs7936247	1.000	rs10830958	chr11:92683955	T/G	cg26929280	chr11:92402250	FAT3	-0.42	-4.25	-0.33	3.78e-5	Glycemic traits (pregnancy);
PAAD	cis	rs1879734	0.636	rs1879732	chr1:54175909	C/T	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg19223190	chr17:80058835	NA	0.52	5.34	0.4	3.32e-7	Life satisfaction;
PAAD	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-5.24	-0.39	5.3e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.9	-10.06	-0.63	1.49e-18	Obesity-related traits;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.29	-0.33	3.13e-5	Longevity;Endometriosis;
PAAD	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.8	6.41	0.46	1.72e-9	Neutrophil percentage of white cells;
PAAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg14346243	chr4:90757452	SNCA	-0.54	-4.73	-0.36	5.09e-6	Neuroticism;
PAAD	cis	rs2882667	0.554	rs1368425	chr5:138280217	A/G	cg09476006	chr5:138032270	NA	0.44	5.55	0.41	1.27e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.67	-5.54	-0.41	1.29e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.62	5.38	0.4	2.71e-7	Plateletcrit;Platelet count;
PAAD	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.49	-4.34	-0.33	2.61e-5	P wave terminal force;
PAAD	cis	rs1359582	0.836	rs875050	chr10:90357105	A/C	cg15661332	chr10:90342814	RNLS	0.56	5.0	0.38	1.56e-6	Depressive and manic episodes in bipolar disorder;
PAAD	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.02e-11	Corneal astigmatism;
PAAD	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.72	-6.03	-0.44	1.2e-8	Inflammatory skin disease;
PAAD	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.25	-0.45	3.93e-9	Blood trace element (Zn levels);
PAAD	cis	rs490234	0.769	rs519812	chr9:128348790	T/G	cg14078157	chr9:128172775	NA	0.47	5.38	0.4	2.79e-7	Mean arterial pressure;
PAAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg21775007	chr8:11205619	TDH	-0.49	-4.4	-0.34	2.04e-5	Neuroticism;
PAAD	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.37	4.56	0.35	1.04e-5	Mosquito bite size;
PAAD	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg05579598	chr16:88989069	CBFA2T3	0.68	10.22	0.64	5.57e-19	Social autistic-like traits;
PAAD	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg17644776	chr2:200775616	C2orf69	-0.59	-5.33	-0.4	3.52e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.56	5.8	0.43	3.79e-8	Cognitive function;
PAAD	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.85	-9.5	-0.61	4.39e-17	Body mass index;
PAAD	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.62	-8.21	-0.55	8.8e-14	Systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.05	0.5	6.02e-11	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.23	9.84	0.62	5.51e-18	Alzheimer's disease (late onset);
PAAD	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.49	-4.4	-0.34	1.99e-5	Asthma;
PAAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.81	0.54	8.8e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.82	-0.36	3.39e-6	Mean corpuscular volume;
PAAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg09835421	chr16:68378352	PRMT7	-0.99	-6.44	-0.46	1.46e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.78	7.91	0.54	4.88e-13	Coronary artery disease;
PAAD	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.46	5.82	0.43	3.3e-8	Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg15181151	chr6:150070149	PCMT1	-0.56	-6.02	-0.44	1.25e-8	Lung cancer;
PAAD	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg20503657	chr10:835505	NA	0.52	5.7	0.42	6.05e-8	Survival in rectal cancer;
PAAD	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg04450456	chr4:17643702	FAM184B	0.47	4.89	0.37	2.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.56	-0.35	1.05e-5	Educational attainment;
PAAD	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9585327	0.714	rs8000973	chr13:100691367	C/T	cg11288260	chr13:100117058	NA	-0.22	-4.6	-0.35	8.99e-6	Myopia;
PAAD	cis	rs7714584	1.000	rs10078968	chr5:150244273	C/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg10864074	chr7:100318194	EPO	-0.47	-4.49	-0.34	1.43e-5	Other erythrocyte phenotypes;
PAAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.93	0.37	2.1e-6	Menarche (age at onset);
PAAD	trans	rs2880058	0.788	rs10800279	chr1:162038278	A/G	cg22816059	chr5:422114	AHRR	-0.62	-6.51	-0.47	1.02e-9	QT interval;
PAAD	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.96	13.89	0.75	7.82e-29	Intelligence (multi-trait analysis);
PAAD	cis	rs282587	0.569	rs428270	chr13:113411956	T/G	cg02820901	chr13:113351484	ATP11A	-0.65	-5.17	-0.39	7.26e-7	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg10631289	chr15:39006617	NA	0.47	4.6	0.35	8.78e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.43	0.46	1.59e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.932	rs11966360	chr6:26316982	A/G	cg14345882	chr6:26364793	BTN3A2	0.61	4.41	0.34	1.97e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg12395012	chr8:11607386	GATA4	0.42	4.27	0.33	3.47e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	0.88	4.47	0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.54	4.91	0.37	2.36e-6	Kawasaki disease;
PAAD	cis	rs4948102	0.686	rs7801467	chr7:56160977	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.32	0.4	3.68e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg18551225	chr6:44695536	NA	-0.69	-6.8	-0.48	2.26e-10	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10654165	chr8:105479705	DPYS	-0.62	-6.72	-0.48	3.49e-10	Obesity-related traits;
PAAD	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg09659197	chr4:152720779	NA	0.39	5.03	0.38	1.35e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5756391	0.606	rs5756408	chr22:37317848	T/C	cg21209356	chr22:37319042	CSF2RB	0.39	4.66	0.35	6.9e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg15478930	chr2:27652102	NRBP1	0.51	4.52	0.34	1.24e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs16975963	0.843	rs60731897	chr19:38269259	C/A	cg08679971	chr19:38281047	NA	0.51	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.77	4.34	0.33	2.61e-5	Coronary artery disease;
PAAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg23346134	chr3:49453900	TCTA	0.42	4.45	0.34	1.68e-5	Menarche (age at onset);
PAAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg21625146	chr5:486483	SLC9A3	0.38	5.56	0.41	1.2e-7	Cystic fibrosis severity;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.56	-5.59	-0.41	1.04e-7	Coronary artery disease;
PAAD	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26006440	chr19:4868007	PLIN3	0.55	6.36	0.46	2.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.78	-6.73	-0.48	3.23e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	4.31	0.33	2.93e-5	Coronary artery disease;
PAAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1;
PAAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg13047869	chr3:10149882	C3orf24	0.58	5.12	0.38	9.15e-7	Alzheimer's disease;
PAAD	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.84	5.25	0.39	4.95e-7	Sitting height ratio;
PAAD	cis	rs2137920	0.735	rs2175917	chr10:50224856	C/T	cg02657375	chr10:50863136	CHAT	0.54	4.37	0.33	2.29e-5	Migraine with aura;
PAAD	cis	rs1497828	0.956	rs2815232	chr1:217538336	A/G	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.78	-0.48	2.48e-10	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs1997066	0.831	rs57307057	chr10:106816462	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.52	0.34	1.24e-5	Diabetic kidney disease;
PAAD	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.35	-4.34	-0.33	2.55e-5	Pubertal anthropometrics;
PAAD	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.57	5.25	0.39	5.13e-7	RR interval (heart rate);
PAAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.49	5.14	0.38	8.45e-7	Menopause (age at onset);
PAAD	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.94	-0.43	1.82e-8	Schizophrenia;
PAAD	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.36	4.72	0.36	5.22e-6	Urate levels in overweight individuals;
PAAD	cis	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg21546286	chr11:48923668	NA	0.58	6.09	0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-4.99	-0.38	1.65e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg16898833	chr6:26189333	HIST1H4D	1.08	5.85	0.43	2.92e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8.13e-6	Life satisfaction;
PAAD	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.56	5.56	0.41	1.16e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02754494	chr5:78810199	HOMER1	0.57	6.4	0.46	1.84e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.66	-7.47	-0.52	5.7e-12	Sense of smell;
PAAD	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02711726	chr17:80685570	FN3KRP	-0.48	-4.38	-0.33	2.17e-5	Glycated hemoglobin levels;
PAAD	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.74	-0.36	4.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	11.15	0.67	1.78e-21	Smoking behavior;
PAAD	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg03225093	chr5:2008713	NA	0.36	4.43	0.34	1.79e-5	Lung cancer;
PAAD	cis	rs9503598	0.543	rs913536	chr6:3432608	G/A	cg00476032	chr6:3446245	SLC22A23	-0.42	-4.45	-0.34	1.68e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.91	-10.67	-0.65	3.38e-20	Refractive error;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17059624	chr11:85358760	TMEM126A	0.7	8.14	0.55	1.34e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.38	-4.42	-0.34	1.87e-5	Red blood cell traits;
PAAD	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-5.68	-0.42	6.69e-8	Subjective well-being;
PAAD	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.56	5.69	0.42	6.32e-8	Hemoglobin levels;
PAAD	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.47	5.14	0.38	8.51e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg24881330	chr22:46731750	TRMU	-1.07	-6.17	-0.45	6.02e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg00750074	chr16:89608354	SPG7	-0.61	-5.83	-0.43	3.26e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs62158211	0.565	rs2121243	chr2:114099346	C/T	cg17784749	chr2:114082611	LOC440839	0.58	5.65	0.42	7.6e-8	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg16745616	chr19:8428856	ANGPTL4	-0.54	-4.86	-0.37	2.94e-6	HDL cholesterol;
PAAD	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Bladder cancer;
PAAD	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs7264396	0.887	rs736031	chr20:34048625	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.43	-0.4	2.18e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.24e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg09835421	chr16:68378352	PRMT7	-1.1	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.37	-0.33	2.25e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.29e-8	Subjective well-being;
PAAD	cis	rs6596100	0.538	rs4705972	chr5:132179237	T/A	cg16419906	chr5:132167176	NA	-0.58	-4.41	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs58521262	0.519	rs55766474	chr19:22910850	T/C	cg07749055	chr19:23076870	NA	-0.57	-4.25	-0.33	3.78e-5	Testicular germ cell tumor;
PAAD	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.45	5.76	0.42	4.42e-8	Panic disorder;
PAAD	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg14515779	chr1:101123966	NA	-0.53	-6.63	-0.47	5.46e-10	Monocyte count;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	6.16	0.45	6.3e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14129169	chr19:12201983	ZNF788	-0.58	-6.47	-0.46	1.27e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg08994789	chr17:28903642	LRRC37B2	0.61	4.98	0.37	1.73e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.86	9.66	0.62	1.69e-17	Schizophrenia;
PAAD	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.75	-7.85	-0.54	6.97e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg17514665	chr17:1657533	SERPINF2	0.66	6.06	0.44	1.02e-8	Serum albumin level;
PAAD	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg07469887	chr10:131262384	NA	-0.43	-5.11	-0.38	9.74e-7	Response to temozolomide;
PAAD	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs71520386	0.632	rs12535331	chr7:22878104	G/T	cg04907244	chr7:22894795	SNORD93	-0.5	-5.24	-0.39	5.26e-7	Fibrinogen levels;
PAAD	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg07741184	chr6:167504864	NA	-0.38	-4.6	-0.35	8.69e-6	Crohn's disease;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.82	0.58	2.57e-15	Alzheimer's disease;
PAAD	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.82	-7.97	-0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Coronary artery disease;
PAAD	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg24253500	chr15:84953950	NA	0.57	6.51	0.47	1.04e-9	Schizophrenia;
PAAD	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.8	-5.81	-0.43	3.5e-8	Vitiligo;
PAAD	cis	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9810890	1.000	rs115639732	chr3:128555607	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.729	rs11667539	chr19:23062691	C/A	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs6494488	0.500	rs111858590	chr15:65063622	C/A	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.89	-12.94	-0.72	2.72e-26	Dental caries;
PAAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.69	-6.64	-0.47	5.29e-10	Neurofibrillary tangles;
PAAD	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.69	6.84	0.49	1.77e-10	Colorectal cancer;
PAAD	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg05134918	chr12:132603531	EP400NL	-0.65	-5.19	-0.39	6.64e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.62	5.55	0.41	1.24e-7	Lymphocyte counts;
PAAD	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-11.95	-0.7	1.23e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-0.93	-7.56	-0.52	3.48e-12	Dupuytren's disease;
PAAD	cis	rs9826463	0.757	rs73238202	chr3:142205344	C/T	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.67	-0.53	1.96e-12	Total cholesterol levels;
PAAD	cis	rs7752195	0.643	rs77951490	chr6:25236645	G/A	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09575269	chr17:41174397	VAT1	-0.57	-6.38	-0.46	2.01e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.49	-4.72	-0.36	5.23e-6	Obesity-related traits;
PAAD	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg18281939	chr5:77783895	LHFPL2	-0.52	-6.7	-0.48	3.9e-10	Triglycerides;
PAAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15128208	chr22:42549153	NA	0.42	4.28	0.33	3.26e-5	Cognitive function;
PAAD	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.56	5.37	0.4	2.9e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg09796270	chr17:17721594	SREBF1	0.44	4.91	0.37	2.34e-6	Total body bone mineral density;
PAAD	cis	rs78761021	0.824	rs55673552	chr17:9777593	G/A	cg26853458	chr17:9805074	RCVRN	0.7	8.2	0.55	9.42e-14	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08684551	chr19:56652453	ZNF444	0.62	6.31	0.46	2.83e-9	Myopia (pathological);
PAAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg00125455	chr20:44574271	PCIF1	0.43	4.39	0.34	2.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.57	-7.54	-0.52	3.91e-12	Height;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.84	4.95	0.37	1.96e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs4324798	1	rs4324798	chr6:28776117	G/A	cg06606381	chr12:133084897	FBRSL1	-1.41	-9.31	-0.6	1.38e-16	Lung adenocarcinoma;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05348668	chr2:190686969	PMS1	-0.72	-6.46	-0.46	1.31e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13126279	chr21:47581558	C21orf56	-0.4	-4.44	-0.34	1.7e-5	Testicular germ cell tumor;
PAAD	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg01329690	chr21:38580129	DSCR9	-0.34	-4.54	-0.35	1.14e-5	Eye color traits;
PAAD	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.79	8.52	0.57	1.47e-14	Cognitive function;
PAAD	cis	rs986417	1.000	rs8021348	chr14:60952777	G/T	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	8.82	0.58	2.46e-15	Total body bone mineral density;
PAAD	cis	rs8105895	0.935	rs2043316	chr19:22251204	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.26	-0.33	3.57e-5	Red blood cell count;
PAAD	cis	rs6604026	0.644	rs12069727	chr1:93399060	A/C	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg10820045	chr2:198174542	NA	0.44	4.37	0.33	2.31e-5	Dermatomyositis;
PAAD	cis	rs7577696	0.924	rs7601267	chr2:32272399	C/T	cg02381751	chr2:32503542	YIPF4	-0.4	-4.28	-0.33	3.3e-5	Inflammatory biomarkers;
PAAD	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg09060608	chr5:178986726	RUFY1	-0.43	-4.53	-0.34	1.2e-5	Lung cancer;
PAAD	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs2302729	0.860	rs7138079	chr12:2781304	G/A	cg19945202	chr12:2788847	CACNA1C	-0.62	-5.81	-0.43	3.48e-8	Sleep quality;
PAAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-4.47	-0.34	1.54e-5	Menarche (age at onset);
PAAD	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.42	-4.7	-0.36	5.89e-6	Coronary artery disease;
PAAD	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.17e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.63	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.56	0.41	1.21e-7	Ileal carcinoids;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg09473613	chr1:24152604	HMGCL	0.54	5.61	0.41	9.4e-8	Immature fraction of reticulocytes;
PAAD	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.68	-0.36	6.23e-6	Type 1 diabetes;
PAAD	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg16576597	chr16:28551801	NUPR1	0.63	6.97	0.49	9.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00855626	chr19:5690231	RPL36	0.74	8.31	0.56	4.85e-14	Myopia (pathological);
PAAD	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.71	-8.22	-0.55	8.56e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18825258	chr8:26435354	DPYSL2	0.63	7.23	0.51	2.17e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs863345	0.548	rs857687	chr1:158577998	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.99	-0.37	1.66e-6	Pneumococcal bacteremia;
PAAD	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00684032	chr4:1343700	KIAA1530	0.47	4.92	0.37	2.18e-6	Obesity-related traits;
PAAD	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg16341495	chr8:142228727	SLC45A4	-0.49	-4.72	-0.36	5.21e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg00277334	chr10:82204260	NA	0.54	6.19	0.45	5.45e-9	Sarcoidosis;
PAAD	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.98	-12.57	-0.71	2.69e-25	Coronary artery disease;
PAAD	cis	rs1656368	0.770	rs73154340	chr3:158276914	T/A	cg16708174	chr3:158430962	RARRES1	0.54	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1957429	0.614	rs1957416	chr14:65369329	C/T	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs4144027	0.967	rs10133399	chr14:104361843	A/T	cg19582115	chr14:103436037	CDC42BPB	-0.47	-4.55	-0.35	1.07e-5	Blood metabolite levels;
PAAD	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg01620082	chr3:125678407	NA	-1.08	-6.8	-0.48	2.19e-10	Depression;
PAAD	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg21466736	chr12:48725269	NA	-0.5	-4.65	-0.35	7.26e-6	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03004497	chr11:58874207	FAM111B	0.66	7.05	0.5	5.85e-11	Myopia (pathological);
PAAD	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg08198773	chr8:1697536	NA	0.47	5.2	0.39	6.43e-7	Systolic blood pressure;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.47	0.52	5.71e-12	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06854391	chr1:113499045	SLC16A1	0.63	6.29	0.45	3.24e-9	Myopia (pathological);
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg25811766	chr13:21894605	NA	0.82	8.98	0.59	9.87e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	7.59	0.52	3.06e-12	Height;
PAAD	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg07469887	chr10:131262384	NA	-0.43	-5.11	-0.38	9.74e-7	Response to temozolomide;
PAAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.66	6.3	0.46	3.02e-9	IgG glycosylation;
PAAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg00262122	chr8:11665843	FDFT1	-0.51	-4.49	-0.34	1.39e-5	Morning vs. evening chronotype;
PAAD	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg10495392	chr1:46806563	NSUN4	0.56	5.39	0.4	2.67e-7	Menopause (age at onset);
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.75	5.81	0.43	3.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg05085585	chr16:30420623	ZNF771	0.43	4.31	0.33	2.94e-5	Tonsillectomy;
PAAD	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg12215294	chr3:40350768	EIF1B	0.48	4.62	0.35	8.04e-6	Renal cell carcinoma;
PAAD	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.46	5.29	0.39	4.28e-7	Mean arterial pressure;
PAAD	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg14003231	chr6:33640908	ITPR3	0.48	5.67	0.42	6.86e-8	Platelet count;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.31e-6	Height;
PAAD	cis	rs9581857	0.547	rs9581877	chr13:28104321	T/A	cg22138327	chr13:27999177	GTF3A	0.79	5.31	0.4	3.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08677398	chr8:58056175	NA	0.67	4.63	0.35	7.95e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.97	-0.72	2.32e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs58653258	0.667	rs2796163	chr1:234978669	T/G	cg03518729	chr1:235147744	NA	0.45	4.31	0.33	2.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg15212455	chr7:39170539	POU6F2	0.49	6.84	0.48	1.84e-10	IgG glycosylation;
PAAD	cis	rs6580110	0.837	rs749777	chr5:154074270	T/C	cg17263206	chr5:154071247	NA	0.53	5.73	0.42	5.11e-8	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs12476592	0.543	rs262480	chr2:63873032	A/G	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs3125734	1.000	rs3125734	chr10:63958112	C/T	cg09941381	chr10:64027924	RTKN2	0.35	4.29	0.33	3.17e-5	Rheumatoid arthritis;
PAAD	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg14458575	chr2:238380390	NA	0.47	4.32	0.33	2.84e-5	Prostate cancer;
PAAD	cis	rs7524950	1	rs7524950	chr1:155272274	C/T	cg02153340	chr1:155202674	NA	-0.53	-4.8	-0.36	3.76e-6	Breast cancer;
PAAD	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.56	5.32	0.4	3.68e-7	Colorectal cancer;
PAAD	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.64	6.88	0.49	1.5e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.89	0.43	2.35e-8	Eosinophil percentage of white cells;
PAAD	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	5.0	0.38	1.59e-6	Depressive symptoms;
PAAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs370915	0.578	rs1367934	chr4:187776396	A/G	cg12892747	chr4:187813459	NA	-0.45	-4.73	-0.36	5.14e-6	Gout;
PAAD	cis	rs35164067	1.000	rs11879191	chr19:10512911	G/A	cg07306197	chr19:9546377	ZNF266	0.58	4.46	0.34	1.57e-5	Inflammatory bowel disease;
PAAD	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs2718812	1.000	rs2718815	chr3:133398786	A/G	cg12372414	chr3:134319805	KY	-0.41	-4.48	-0.34	1.44e-5	Iron status biomarkers;
PAAD	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01283332	chr5:1856932	NA	-0.43	-4.53	-0.34	1.2e-5	Cardiovascular disease risk factors;
PAAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.87	-0.43	2.6e-8	Type 2 diabetes;
PAAD	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.87	0.37	2.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg12454169	chr2:30669597	LCLAT1	0.73	5.94	0.43	1.83e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs7249921	0.802	rs62111399	chr19:35668771	C/T	cg11856182	chr19:35264148	ZNF599	-0.53	-4.59	-0.35	9.29e-6	Platelet count;
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.73	-0.48	3.34e-10	Life satisfaction;
PAAD	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-8.52	-0.57	1.47e-14	Neuroticism;
PAAD	cis	rs6604026	0.656	rs35367625	chr1:93399705	G/A	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.47	-4.68	-0.36	6.21e-6	Adiposity;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.61	4.5	0.34	1.36e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03333052	chr10:5683763	ASB13	0.58	6.47	0.46	1.28e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06753367	chr22:24256600	NA	-0.46	-4.87	-0.37	2.77e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	1.01	8.81	0.58	2.69e-15	Gut microbiome composition (summer);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21344215	chr2:27851972	GPN1;CCDC121	0.6	6.38	0.46	2.02e-9	Myopia (pathological);
PAAD	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.56	0.47	7.91e-10	Body mass index;
PAAD	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.73	8.63	0.57	7.85e-15	Hand grip strength;
PAAD	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs12612619	0.732	rs13020526	chr2:27204650	C/T	cg00617064	chr2:27272375	NA	-0.48	-5.11	-0.38	9.44e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12777893	chr7:139475765	HIPK2	0.6	6.45	0.46	1.39e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58521262	0.585	rs440580	chr19:23121679	T/C	cg02350677	chr19:23254381	NA	-0.27	-4.67	-0.35	6.63e-6	Testicular germ cell tumor;
PAAD	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.63	7.09	0.5	4.61e-11	Testicular germ cell tumor;
PAAD	cis	rs925642	0.700	rs7695274	chr4:187670410	T/A	cg20274950	chr4:187647402	NA	-0.38	-4.4	-0.34	2.01e-5	Obesity;
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.86	-9.78	-0.62	8.05e-18	Tonsillectomy;
PAAD	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg14092571	chr14:90743983	NA	0.58	5.58	0.41	1.09e-7	Mortality in heart failure;
PAAD	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	7.3	0.51	1.53e-11	Renal function-related traits (BUN);
PAAD	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg00990874	chr7:1149470	C7orf50	-0.76	-5.97	-0.44	1.64e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.66	-7.21	-0.5	2.44e-11	Diastolic blood pressure;
PAAD	cis	rs12136530	0.651	rs10753561	chr1:19711939	T/C	cg25104613	chr1:20649108	VWA5B1	-0.37	-4.45	-0.34	1.67e-5	Lead levels in blood;
PAAD	cis	rs112990264	0.568	rs3006239	chr1:212985840	A/G	cg01785514	chr1:212988523	TATDN3	-0.67	-5.01	-0.38	1.5e-6	Itch intensity from mosquito bite;
PAAD	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.52	5.21	0.39	6.19e-7	Schizophrenia;
PAAD	cis	rs2637266	0.807	rs2579762	chr10:78318879	A/C	cg18941641	chr10:78392320	NA	0.36	4.35	0.33	2.46e-5	Pulmonary function;
PAAD	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg07475973	chr22:42306951	NA	0.47	4.36	0.33	2.38e-5	Neuroticism;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.69	-7.86	-0.54	6.51e-13	Iron status biomarkers;
PAAD	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg11266682	chr4:10021025	SLC2A9	0.6	5.39	0.4	2.66e-7	Schizophrenia (age at onset);
PAAD	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.29	-0.39	4.24e-7	Subjective well-being;
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	7.42	0.52	7.67e-12	Renal function-related traits (BUN);
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.86	8.07	0.55	1.98e-13	Homoarginine levels;
PAAD	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg17380795	chr3:122379686	NA	0.51	5.45	0.4	1.95e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.51	5.0	0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.62	5.96	0.44	1.65e-8	Rheumatoid arthritis;
PAAD	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.97	-0.44	1.6e-8	Menarche (age at onset);
PAAD	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg16205897	chr5:131564050	P4HA2	-0.41	-4.47	-0.34	1.52e-5	Blood metabolite levels;
PAAD	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg18612461	chr15:75251733	NA	-0.54	-5.1	-0.38	9.85e-7	Blood trace element (Zn levels);
PAAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg14393609	chr7:65229607	NA	0.68	7.3	0.51	1.48e-11	Aortic root size;
PAAD	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	7.61	0.53	2.72e-12	HIV-1 control;
PAAD	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.3	4.91	0.37	2.3e-6	IgG glycosylation;
PAAD	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.84	-4.98	-0.37	1.68e-6	Cholesterol, total;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.77	7.84	0.54	7.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs732765	0.734	rs12891243	chr14:75208656	G/A	cg01090926	chr14:75137805	KIAA0317	0.49	4.5	0.34	1.35e-5	Non-small cell lung cancer;
PAAD	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.83	0.66	1.25e-20	Smoking behavior;
PAAD	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.64	-6.1	-0.44	8.24e-9	Asthma;
PAAD	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09695851	chr17:3907499	NA	0.67	6.77	0.48	2.67e-10	Type 2 diabetes;
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg26536354	chr8:144654954	C8orf73	0.63	4.26	0.33	3.52e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.38	-4.3	-0.33	3.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	0.680	rs73073290	chr3:42027684	T/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg20893579	chr22:38215064	NA	-0.57	-6.12	-0.44	7.53e-9	Glioblastoma;Glioma;
PAAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.35	0.4	3.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg10729496	chr3:10149963	C3orf24	0.84	6.62	0.47	5.76e-10	Alzheimer's disease;
PAAD	cis	rs11563648	0.553	rs2285338	chr7:127008430	A/C	cg21885361	chr7:127911034	NA	0.39	4.27	0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.53	8.14	0.55	1.34e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.35	-0.33	2.52e-5	Life satisfaction;
PAAD	cis	rs2204008	0.642	rs11169812	chr12:37995530	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-7.95	-0.54	4e-13	Bladder cancer;
PAAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.67	-0.42	6.98e-8	Gut microbiome composition (summer);
PAAD	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg00686598	chr14:53173677	PSMC6	-0.83	-5.01	-0.38	1.49e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.59	0.57	9.48e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.64	-6.68	-0.48	4.23e-10	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08235500	chr2:26467844	HADHA;HADHB	-0.74	-6.42	-0.46	1.64e-9	Neuroticism;
PAAD	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs427943	1.000	rs407133	chr21:46571889	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.43	4.33	0.33	2.67e-5	Body mass index;
PAAD	cis	rs901683	0.850	rs80021398	chr10:46039383	A/G	cg16908948	chr10:45500256	ZNF22	0.79	4.27	0.33	3.44e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.38	5.13	0.38	8.59e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg12757816	chr2:10669957	NA	0.44	4.44	0.34	1.72e-5	Prostate cancer;
PAAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.6	0.57	8.94e-15	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.87	11.81	0.69	2.99e-23	Prudent dietary pattern;
PAAD	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-14.97	-0.77	1.07e-31	Schizophrenia;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg03609598	chr5:56110824	MAP3K1	0.59	4.29	0.33	3.13e-5	Initial pursuit acceleration;
PAAD	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4455778	0.580	rs4291221	chr7:49114465	C/T	cg26309511	chr7:48887640	NA	-0.38	-4.55	-0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.79	6.78	0.48	2.48e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg20673091	chr1:2541236	MMEL1	0.74	7.83	0.54	7.64e-13	Ulcerative colitis;
PAAD	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.49	5.56	0.41	1.16e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	14.81	0.77	2.84e-31	Chronic sinus infection;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-4.27	-0.33	3.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.87e-13	Prostate cancer;
PAAD	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-4.98	-0.37	1.68e-6	Axial length;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.4	0.51	8.5e-12	Alzheimer's disease;
PAAD	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	0.97	7.1	0.5	4.56e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.44	4.89	0.37	2.5e-6	Testicular germ cell tumor;
PAAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg08079166	chr15:68083412	MAP2K5	0.61	4.59	0.35	9.35e-6	Restless legs syndrome;
PAAD	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.58	5.51	0.41	1.5e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.89	7.71	0.53	1.5e-12	Alzheimer's disease;
PAAD	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.5	4.54	0.35	1.16e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg01966878	chr4:90757139	SNCA	-0.6	-4.7	-0.36	5.88e-6	Neuroticism;
PAAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs4740619	0.905	rs10962098	chr9:15611407	G/C	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.1e-5	Body mass index;
PAAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg22325292	chr17:80708367	FN3K	-0.55	-4.54	-0.35	1.14e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg18402987	chr7:1209562	NA	1.11	5.59	0.41	1.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.79	6.36	0.46	2.25e-9	Monocyte percentage of white cells;
PAAD	cis	rs80346118	0.673	rs750085	chr20:47415898	T/C	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.59	-4.38	-0.33	2.19e-5	Diastolic blood pressure;
PAAD	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.61	-0.35	8.42e-6	Glomerular filtration rate;
PAAD	cis	rs2241685	0.850	rs3748989	chr2:1946968	C/T	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.83	-0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.82	9.17	0.6	3.05e-16	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-6.26	-0.45	3.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.66	5.0	0.38	1.54e-6	Hip geometry;
PAAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-5.34	-0.4	3.33e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.32	4.76	0.36	4.52e-6	Alopecia areata;
PAAD	cis	rs11252688	1.000	rs11252682	chr10:4769161	T/C	cg03822858	chr10:4066499	NA	0.69	4.27	0.33	3.42e-5	Major depressive disorder;
PAAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21963583	chr11:68658836	MRPL21	-0.37	-4.3	-0.33	3e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.03e-5	Systolic blood pressure;
PAAD	cis	rs863345	0.604	rs11265024	chr1:158513255	A/G	cg12129480	chr1:158549410	OR10X1	-0.42	-4.75	-0.36	4.75e-6	Pneumococcal bacteremia;
PAAD	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.44	4.62	0.35	8.13e-6	Coronary artery disease;
PAAD	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.53	0.34	1.2e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-6.66	-0.48	4.82e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.88	8.72	0.58	4.43e-15	Breast cancer;
PAAD	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg11519256	chr10:5708881	ASB13	0.59	4.63	0.35	7.85e-6	Childhood ear infection;
PAAD	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.44	0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg05895507	chr15:77155635	SCAPER	-0.36	-4.48	-0.34	1.46e-5	Blood metabolite levels;
PAAD	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.46	4.77	0.36	4.3e-6	Age of smoking initiation;
PAAD	cis	rs11264213	0.901	rs683622	chr1:36443569	C/T	cg27506609	chr1:36549197	TEKT2	-0.88	-5.26	-0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg04165759	chr1:150448943	RPRD2	-0.54	-5.69	-0.42	6.3e-8	Migraine;
PAAD	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg05212510	chr18:77623544	KCNG2	-0.44	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	0.99	6.6	0.47	6.34e-10	Sexual dysfunction (female);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11646757	chr7:128095699	C7orf68	0.6	6.89	0.49	1.39e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.76	8.59	0.57	9.54e-15	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02422812	chr5:154062204	NA	0.65	7.18	0.5	2.88e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.17	0.5	3.11e-11	Alzheimer's disease;
PAAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	1.1	11.19	0.67	1.39e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	4.71	0.36	5.66e-6	Schizophrenia;
PAAD	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.7	7.45	0.52	6.4e-12	Body mass index;
PAAD	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.49	0.41	1.64e-7	Alcohol dependence;
PAAD	cis	rs10768122	0.705	rs7110985	chr11:35343192	C/T	cg13971030	chr11:35366721	SLC1A2	-0.41	-4.7	-0.36	5.84e-6	Vitiligo;
PAAD	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.69	4.3	0.33	3e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.39	-0.4	2.59e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.94	9.55	0.61	3.12e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.87	-9.46	-0.61	5.41e-17	Tonsillectomy;
PAAD	cis	rs8112211	0.731	rs11673222	chr19:38824344	G/A	cg14299480	chr19:38876666	GGN	-0.65	-6.12	-0.44	7.52e-9	Blood protein levels;
PAAD	cis	rs34034104	0.501	rs16970660	chr15:40700767	G/A	cg25710630	chr15:40685225	C15orf23	0.66	4.42	0.34	1.84e-5	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
PAAD	cis	rs10267417	0.603	rs10950760	chr7:19912040	A/G	cg05791153	chr7:19748676	TWISTNB	-0.66	-4.72	-0.36	5.37e-6	Night sleep phenotypes;
PAAD	cis	rs282587	0.597	rs450351	chr13:113394987	C/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.96	-0.37	1.87e-6	Glycated hemoglobin levels;
PAAD	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg24220031	chr2:73402428	NA	-0.3	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.61	-5.97	-0.44	1.59e-8	Ear protrusion;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11277220	chr19:9271193	ZNF317	-0.64	-6.55	-0.47	8.56e-10	Obesity-related traits;
PAAD	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.5	5.41	0.4	2.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs714031	0.934	rs738315	chr22:40069245	T/C	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.51	-0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.79	8.14	0.55	1.33e-13	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg24733560	chr20:60626293	TAF4	0.45	5.58	0.41	1.05e-7	Body mass index;
PAAD	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.15	0.39	8.03e-7	Cognitive test performance;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-11.99	-0.7	9.9e-24	Prudent dietary pattern;
PAAD	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg16898833	chr6:26189333	HIST1H4D	0.98	5.04	0.38	1.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.504	rs11119458	chr1:210491097	T/A	cg22029157	chr1:209979665	IRF6	0.74	5.97	0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg22338127	chr1:209979572	IRF6	-0.52	-4.35	-0.33	2.53e-5	Coronary artery disease;
PAAD	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.1	-0.38	1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs4073221	0.654	rs34101648	chr3:18259998	A/G	cg07694806	chr3:18168406	NA	-0.67	-4.72	-0.36	5.2e-6	Parkinson's disease;
PAAD	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg00035074	chr7:2701567	TTYH3	-0.65	-4.47	-0.34	1.53e-5	Bipolar disorder;
PAAD	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg26220594	chr1:19110978	NA	0.58	4.54	0.35	1.13e-5	Percentage gas trapping;
PAAD	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-1.07	-15.54	-0.78	3.24e-33	Total body bone mineral density;
PAAD	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.66	6.89	0.49	1.41e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.48	8.52	0.57	1.46e-14	Multiple system atrophy;
PAAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.44	-5.02	-0.38	1.43e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.49	7.09	0.5	4.64e-11	Longevity;Endometriosis;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg25204440	chr1:209979598	IRF6	0.63	5.68	0.42	6.64e-8	Coronary artery disease;
PAAD	cis	rs9472414	0.566	rs72664272	chr6:44737467	A/C	cg20913747	chr6:44695427	NA	0.51	4.95	0.37	1.99e-6	Height;
PAAD	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23708337	chr7:1209742	NA	0.64	4.46	0.34	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.61	-4.75	-0.36	4.72e-6	Serum sulfate level;
PAAD	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.53	-6.38	-0.46	2.04e-9	Lewy body disease;
PAAD	cis	rs11563648	0.553	rs6973862	chr7:127015257	T/C	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.66	7.27	0.51	1.78e-11	Urate levels;
PAAD	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	7.65	0.53	2.15e-12	Lymphocyte counts;
PAAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.57	-5.3	-0.4	3.97e-7	Obesity-related traits;
PAAD	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.81	9.44	0.61	6.37e-17	Sudden cardiac arrest;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05978187	chr14:69864930	ERH;SLC39A9	0.62	7.69	0.53	1.69e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3126085	0.560	rs3120665	chr1:152316590	A/G	cg26876637	chr1:152193138	HRNR	-0.73	-5.56	-0.41	1.19e-7	Atopic dermatitis;
PAAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg22143856	chr6:28129313	ZNF389	0.5	4.64	0.35	7.49e-6	Parkinson's disease;
PAAD	cis	rs10899021	0.915	rs11236198	chr11:74372200	G/T	cg25880958	chr11:74394337	NA	-0.86	-5.38	-0.4	2.71e-7	Response to metformin (IC50);
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18084083	chr3:190232258	IL1RAP	-0.65	-6.73	-0.48	3.27e-10	Smoking initiation;
PAAD	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg12705353	chr12:122356852	WDR66	0.49	5.51	0.41	1.51e-7	Mean corpuscular volume;
PAAD	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	1.7	10.52	0.65	8.56e-20	Height;
PAAD	cis	rs7951870	0.617	rs12274785	chr11:46714279	T/C	cg19486271	chr11:47235900	DDB2	0.55	5.59	0.41	1.01e-7	Schizophrenia;
PAAD	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.61	5.06	0.38	1.22e-6	Red blood cell count;
PAAD	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16905586	chr3:49761211	GMPPB	0.64	6.32	0.46	2.73e-9	Myopia (pathological);
PAAD	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.59	-0.52	2.98e-12	Aortic root size;
PAAD	cis	rs4287000	0.802	rs10821184	chr9:96387905	A/G	cg13787134	chr9:96362102	PHF2	0.38	4.47	0.34	1.52e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6594713	0.921	rs6594714	chr5:112738620	C/G	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.72	-6.3	-0.46	3.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7219021	1.000	rs68012338	chr17:46856405	G/A	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.58	0.41	1.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.68	-0.48	4.28e-10	Body mass index;
PAAD	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg08390786	chr10:135334061	NA	0.64	5.24	0.39	5.23e-7	Gout;
PAAD	cis	rs7584330	0.504	rs61213635	chr2:238428132	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.15	0.39	7.92e-7	Prostate cancer;
PAAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg13770153	chr20:60521292	NA	-0.46	-4.52	-0.34	1.21e-5	Body mass index;
PAAD	cis	rs6066835	1.000	rs6066829	chr20:47351630	G/T	cg18078177	chr20:47281410	PREX1	-0.91	-5.35	-0.4	3.14e-7	Multiple myeloma;
PAAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.51	5.16	0.39	7.75e-7	Longevity;
PAAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg05110241	chr16:68378359	PRMT7	-0.85	-7.01	-0.49	7.35e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg03995555	chr7:121651992	PTPRZ1	-0.5	-6.29	-0.45	3.22e-9	Energy expenditure (24h);
PAAD	cis	rs863345	0.935	rs863363	chr1:158549511	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.93	-0.37	2.14e-6	Pneumococcal bacteremia;
PAAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.17	0.55	1.11e-13	Schizophrenia;
PAAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg15181151	chr6:150070149	PCMT1	0.54	5.88	0.43	2.51e-8	Lung cancer;
PAAD	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.25	18.2	0.83	5.1e-40	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02732134	chr10:101732382	DNMBP	0.56	6.64	0.47	5.35e-10	Body fat percentage;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg07212818	chr11:638076	DRD4	-0.73	-6.84	-0.49	1.83e-10	Systemic lupus erythematosus;
PAAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg18944383	chr4:111397179	ENPEP	-0.75	-8.17	-0.55	1.09e-13	Coronary artery disease;
PAAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg05785598	chr3:49045655	WDR6	0.42	4.81	0.36	3.57e-6	Parkinson's disease;
PAAD	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.58	-7.43	-0.52	7.22e-12	Lewy body disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21842262	chr14:103777909	NA	0.61	7.51	0.52	4.66e-12	Smoking initiation;
PAAD	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg23461800	chr14:103021989	NA	0.65	4.64	0.35	7.56e-6	Platelet count;
PAAD	cis	rs12220238	0.822	rs11000979	chr10:76067865	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.66	4.3	0.33	3.09e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9918079	0.542	rs1789	chr4:15664535	G/A	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.49	-0.34	1.41e-5	Obesity-related traits;
PAAD	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.5	5.43	0.4	2.2e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.46	4.85	0.37	3.04e-6	Longevity;Endometriosis;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.6	-6.7	-0.48	3.89e-10	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-4.82	-0.36	3.49e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.96	-11.83	-0.69	2.61e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.86	10.39	0.64	1.88e-19	Menarche (age at onset);
PAAD	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04146151	chr16:2155961	PKD1	-0.72	-7.24	-0.51	2.05e-11	Triglycerides;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg21951975	chr1:209979733	IRF6	0.57	5.74	0.42	4.93e-8	Coronary artery disease;
PAAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.75	-6.78	-0.48	2.44e-10	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg13406893	chr12:131568647	GPR133	-0.43	-4.28	-0.33	3.32e-5	Longevity;
PAAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.66	9.99	0.63	2.28e-18	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.5	4.52	0.34	1.26e-5	Mean corpuscular volume;
PAAD	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs900145	0.859	rs1481892	chr11:13301921	C/G	cg15603424	chr11:13300592	ARNTL	-0.53	-4.8	-0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.85	-0.43	2.88e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.56	5.01	0.38	1.51e-6	Type 2 diabetes;
PAAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.66	7.29	0.51	1.62e-11	Longevity;
PAAD	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.86	-9.1	-0.59	4.87e-16	Body mass index;
PAAD	cis	rs4150161	0.591	rs1056616	chr16:84211718	C/T	cg10106505	chr16:84220380	TAF1C	-0.91	-5.17	-0.39	7.39e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12698343	chr2:158485436	ACVR1C	0.63	7.17	0.5	3.14e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.93	-0.63	3.26e-18	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.87	-9.79	-0.62	7.3e-18	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01159004	chr20:48330681	B4GALT5	0.59	6.32	0.46	2.7e-9	Monocyte percentage of white cells;
PAAD	cis	rs2526932	0.625	rs8007165	chr14:73057396	G/A	cg13588403	chr14:73209128	DPF3	-0.41	-5.69	-0.42	6.21e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg20003494	chr4:90757398	SNCA	-0.67	-6.23	-0.45	4.38e-9	Neuroticism;
PAAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.72	7.39	0.51	9.29e-12	Caffeine consumption;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg14830002	chr1:247616686	OR2B11	0.58	4.97	0.37	1.79e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg21191810	chr6:118973309	C6orf204	0.4	4.81	0.36	3.55e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9810890	1.000	rs73198816	chr3:128474440	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2279817	0.908	rs12137775	chr1:18018927	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.72	6.71	0.48	3.57e-10	Neuroticism;
PAAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.56	-6.12	-0.44	7.74e-9	Total body bone mineral density;
PAAD	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.39	4.9	0.37	2.47e-6	Pulmonary function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.6	6.74	0.48	3.06e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6076960	0.741	rs2021702	chr20:6178954	T/A	cg24759859	chr6:86352639	SYNCRIP	0.67	6.6	0.47	6.51e-10	Smooth-surface caries;
PAAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.46	5.54	0.41	1.28e-7	Vitiligo;
PAAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg09796270	chr17:17721594	SREBF1	0.42	4.68	0.35	6.27e-6	Total body bone mineral density;
PAAD	cis	rs66530629	0.874	rs4648878	chr1:25164113	A/G	cg01905478	chr1:25040257	NA	-0.55	-6.1	-0.44	8.26e-9	Plateletcrit;
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg07873178	chr11:65307616	LTBP3	0.94	4.71	0.36	5.57e-6	Height;
PAAD	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg20487152	chr13:99095054	FARP1	0.6	5.26	0.39	4.78e-7	Neuroticism;
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg18357526	chr6:26021779	HIST1H4A	0.5	4.3	0.33	3.09e-5	Blood metabolite levels;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.7	5.41	0.4	2.4e-7	Alzheimer's disease;
PAAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06677660	chr19:49140777	SEC1;DBP	-0.68	-5.63	-0.42	8.37e-8	Myeloid white cell count;
PAAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.5	-6.07	-0.44	9.98e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.66	7.14	0.5	3.67e-11	Blood protein levels;
PAAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.46	-4.94	-0.37	2e-6	Facial morphology (factor 20);
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.71	6.84	0.49	1.78e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.58	5.09	0.38	1.04e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg08316699	chr6:150357289	NA	0.38	4.27	0.33	3.46e-5	Alopecia areata;
PAAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs1018697	1.000	rs7080587	chr10:104545274	C/T	cg14489801	chr10:103603810	KCNIP2	-0.31	-4.48	-0.34	1.47e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.57	-4.98	-0.37	1.68e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.82	9.84	0.62	5.57e-18	Blood metabolite ratios;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15559938	chr1:206837731	NA	0.63	7.42	0.52	7.76e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7897654	0.578	rs11191506	chr10:104768634	A/G	cg14737131	chr10:104680354	CNNM2	-0.43	-4.64	-0.35	7.48e-6	Schizophrenia;
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Body mass index;
PAAD	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07879399	chr17:73885626	TRIM65	-0.59	-6.3	-0.46	3.03e-9	Obesity-related traits;
PAAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg17724175	chr1:150552817	MCL1	0.41	4.55	0.35	1.08e-5	Melanoma;
PAAD	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.56	-7.34	-0.51	1.17e-11	Schizophrenia;
PAAD	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.91	8.09	0.55	1.72e-13	IgG glycosylation;
PAAD	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.48	-4.3	-0.33	3.06e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg14926445	chr8:58193284	C8orf71	0.68	4.63	0.35	7.82e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	6.59	0.47	6.66e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7688540	0.800	rs11731285	chr4:264941	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	4.81	0.36	3.64e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.03	-0.44	1.21e-8	Prostate cancer;
PAAD	cis	rs4073221	0.520	rs13067391	chr3:18191929	C/T	cg07694806	chr3:18168406	NA	-1.05	-6.51	-0.47	1.02e-9	Parkinson's disease;
PAAD	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.57	5.7	0.42	5.99e-8	Systolic blood pressure;
PAAD	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.43	-0.34	1.77e-5	Testicular germ cell tumor;
PAAD	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg05555928	chr11:63887634	MACROD1	-0.61	-4.55	-0.35	1.08e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg14343924	chr8:8086146	FLJ10661	-0.55	-5.25	-0.39	5.01e-7	Joint mobility (Beighton score);
PAAD	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	4.27	0.33	3.37e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg18898632	chr2:242989856	NA	-0.67	-5.21	-0.39	6e-7	Obesity-related traits;
PAAD	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.7	6.56	0.47	7.93e-10	Uric acid levels;
PAAD	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg24097872	chr10:5724021	NA	0.56	4.53	0.35	1.17e-5	Childhood ear infection;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.7	8.2	0.55	9.16e-14	Height;
PAAD	trans	rs17158483	1.000	rs17158483	chr7:29962524	C/T	cg13392957	chr1:147782279	NA	1.19	6.38	0.46	2.06e-9	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12738264	chr7:148725795	PDIA4	0.65	7.22	0.51	2.37e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg20913747	chr6:44695427	NA	-0.7	-7.01	-0.49	7.21e-11	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.79	8.39	0.56	3.09e-14	Schizophrenia;
PAAD	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg04520793	chr17:42248056	ASB16	0.41	4.76	0.36	4.44e-6	Total body bone mineral density;
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.65	5.28	0.39	4.38e-7	Plateletcrit;
PAAD	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.67	-6.43	-0.46	1.6e-9	Mean platelet volume;
PAAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.48	6.11	0.44	8.2e-9	Ulcerative colitis;
PAAD	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.08	0.59	5.32e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.87	8.77	0.58	3.4e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs375066	0.935	rs4803662	chr19:44359564	C/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.49e-6	Breast cancer;
PAAD	cis	rs1879734	0.595	rs7554636	chr1:54193023	T/C	cg14659662	chr1:54151053	GLIS1	-0.31	-4.48	-0.34	1.48e-5	Mitral valve prolapse;
PAAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.1	-0.38	1.01e-6	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.38	4.56	0.35	1.03e-5	Tonsillectomy;
PAAD	cis	rs4889855	0.556	rs4297763	chr17:78533626	G/C	cg16591659	chr17:78472290	NA	0.49	4.82	0.36	3.52e-6	Fractional excretion of uric acid;
PAAD	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.89	0.37	2.51e-6	Menopause (age at onset);
PAAD	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.5e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs7594645	1.000	rs17214441	chr2:207683777	A/G	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg25886479	chr11:50257625	LOC441601	0.4	4.25	0.33	3.74e-5	Coronary artery disease;
PAAD	cis	rs9314614	0.901	rs2978902	chr8:6690173	C/G	cg27319216	chr8:6693540	XKR5	0.34	4.59	0.35	9.09e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg02462569	chr6:150064036	NUP43	-0.49	-5.44	-0.4	2.1e-7	Lung cancer;
PAAD	cis	rs12586317	0.576	rs10143690	chr14:35651945	T/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.62	-0.35	8.05e-6	Psoriasis;
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg24747557	chr10:131355152	MGMT	-0.44	-4.72	-0.36	5.41e-6	Response to temozolomide;
PAAD	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg15309053	chr8:964076	NA	0.46	5.12	0.38	9.15e-7	Schizophrenia;
PAAD	cis	rs2036402	0.868	rs6866051	chr5:156409623	T/G	cg21915449	chr5:156456672	HAVCR1	-0.38	-4.4	-0.34	2.06e-5	Hypertriglyceridemia;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.72	7.1	0.5	4.44e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2318131	0.830	rs57900267	chr2:237927593	C/A	cg15867307	chr2:238110829	NA	0.26	4.27	0.33	3.41e-5	Motion sickness;
PAAD	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-6.08	-0.44	9.1e-9	Pancreatic cancer;
PAAD	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg14092571	chr14:90743983	NA	0.44	4.28	0.33	3.27e-5	Mortality in heart failure;
PAAD	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	1.000	rs2590335	chr10:60009389	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6748734	0.581	rs4675847	chr2:241865156	A/G	cg04034577	chr2:241836375	C2orf54	-0.31	-4.25	-0.33	3.73e-5	Urinary metabolites;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg02135003	chr7:105160482	PUS7	-0.8	-6.39	-0.46	1.92e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10887741	0.646	rs4934355	chr10:89425411	G/A	cg13926569	chr10:89418898	PAPSS2	0.49	5.05	0.38	1.26e-6	Exercise (leisure time);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00696756	chr4:152020723	RPS3A	0.57	6.69	0.48	4.03e-10	Monocyte percentage of white cells;
PAAD	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.19	13.11	0.73	9.3e-27	Eosinophil percentage of granulocytes;
PAAD	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21028142	chr17:79581711	NPLOC4	0.49	5.79	0.42	3.98e-8	Eye color traits;
PAAD	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg05347473	chr6:146136440	FBXO30	0.51	4.83	0.36	3.25e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	4.62	0.35	8.17e-6	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.57	6.36	0.46	2.2e-9	Bladder cancer;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.2	-0.45	5.06e-9	Lung cancer;
PAAD	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.65	7.38	0.51	9.6e-12	Verbal declarative memory;
PAAD	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.16	0.39	7.63e-7	Schizophrenia;
PAAD	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.45	4.27	0.33	3.48e-5	Mean platelet volume;
PAAD	cis	rs6541297	0.757	rs642235	chr1:230325027	C/G	cg22153407	chr1:230290089	GALNT2	-0.47	-4.29	-0.33	3.22e-5	Coronary artery disease;
PAAD	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.5	5.14	0.38	8.34e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.56	6.17	0.45	6.02e-9	Menopause (age at onset);
PAAD	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-5.86	-0.43	2.76e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1109114	0.714	rs9512	chr5:148639762	G/A	cg06539116	chr5:148597365	ABLIM3	-0.34	-4.34	-0.33	2.6e-5	Body mass index;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.79	9.98	0.63	2.4e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7219021	1.000	rs2032844	chr17:46847364	C/A	cg12314713	chr17:47074576	IGF2BP1	-0.37	-4.6	-0.35	8.74e-6	Schizophrenia or bipolar disorder;
PAAD	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	6.44	0.46	1.5e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.67	7.9	0.54	5.17e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.73	-7.7	-0.53	1.62e-12	Aortic root size;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-4.47	-0.34	1.55e-5	Type 2 diabetes;
PAAD	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.36	-0.51	1.06e-11	Mosquito bite size;
PAAD	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.49	5.04	0.38	1.29e-6	Bladder cancer;
PAAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.5	4.75	0.36	4.65e-6	Menarche (age at onset);
PAAD	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs899997	1.000	rs1814880	chr15:79021140	T/C	cg04896959	chr15:78267971	NA	0.68	6.91	0.49	1.25e-10	Coronary artery disease or large artery stroke;
PAAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg10518543	chr12:38710700	ALG10B	0.5	4.69	0.36	6.1e-6	Morning vs. evening chronotype;
PAAD	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.93	12.27	0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02372421	chr2:128284109	IWS1	-0.71	-6.37	-0.46	2.1e-9	Neuroticism;
PAAD	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.86	10.16	0.64	7.88e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs669446	0.591	rs617521	chr1:44114199	G/T	cg12908607	chr1:44402522	ARTN	-0.45	-4.76	-0.36	4.51e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.6	-6.09	-0.44	8.9e-9	Blood metabolite levels;
PAAD	cis	rs72960926	0.744	rs72964209	chr6:74861734	C/T	cg03266952	chr6:74778945	NA	-1.08	-6.87	-0.49	1.56e-10	Metabolite levels (MHPG);
PAAD	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.36	0.46	2.25e-9	Schizophrenia;
PAAD	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg20406979	chr6:167373233	NA	-0.32	-4.34	-0.33	2.63e-5	Graves' disease;
PAAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg27121462	chr16:89883253	FANCA	0.48	5.03	0.38	1.34e-6	Vitiligo;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg03655884	chr8:86230419	NA	-0.51	-6.37	-0.46	2.09e-9	Energy expenditure (24h);
PAAD	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg07541023	chr7:19748670	TWISTNB	0.65	4.83	0.36	3.3e-6	Thyroid stimulating hormone;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05972654	chr5:1076843	SLC12A7	0.67	8.52	0.57	1.44e-14	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10949834	0.642	rs2356530	chr7:73533221	T/A	cg07137043	chr7:73588983	EIF4H	-0.6	-4.51	-0.34	1.29e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs3018712	0.590	rs11228331	chr11:68485225	T/C	cg23009355	chr11:68451396	GAL	-0.47	-4.48	-0.34	1.48e-5	Total body bone mineral density;
PAAD	cis	rs904092	0.720	rs1229976	chr4:100202078	C/T	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.75	-8.64	-0.57	7.17e-15	Height;
PAAD	cis	rs2190422	0.677	rs2382694	chr7:103070983	A/G	cg04218035	chr7:103086829	SLC26A5	0.35	5.03	0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.58	-5.99	-0.44	1.49e-8	Testicular germ cell tumor;
PAAD	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	0.87	5.43	0.4	2.22e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs61884328	0.733	rs61897858	chr11:47235263	A/T	cg23433285	chr11:47201945	PACSIN3	0.85	4.36	0.33	2.43e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08359958	chr19:925900	ARID3A	0.58	6.61	0.47	6.16e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19626725	chr5:178986131	RUFY1	0.52	5.57	0.41	1.11e-7	Lung cancer;
PAAD	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.79e-14	Dupuytren's disease;
PAAD	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.75	5.39	0.4	2.67e-7	Vitiligo;
PAAD	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.4	-0.34	2.03e-5	Testicular germ cell tumor;
PAAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.88	8.91	0.59	1.5e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.72	7.65	0.53	2.13e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg03983715	chr16:68378420	PRMT7	-0.89	-6.32	-0.46	2.76e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.89	-8.92	-0.59	1.41e-15	Asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15354892	chr7:72935613	BAZ1B	0.65	6.49	0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06799790	chr17:61951754	CSH2	-0.47	-4.81	-0.36	3.62e-6	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14957639	chr3:128598318	ACAD9	0.53	6.34	0.46	2.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7264396	0.887	rs224364	chr20:34063865	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.3	0.33	3.08e-5	Total cholesterol levels;
PAAD	cis	rs7924197	0.518	rs913872	chr10:133916286	T/C	cg15338884	chr10:133913937	NA	0.59	5.91	0.43	2.21e-8	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.32	-0.4	3.68e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.68	6.03	0.44	1.22e-8	Inflammatory skin disease;
PAAD	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.59	8.96	0.59	1.08e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	7.53	0.52	4.22e-12	Educational attainment;
PAAD	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg01236616	chr12:121019343	POP5	0.46	4.26	0.33	3.63e-5	High light scatter reticulocyte count;
PAAD	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg13444538	chr7:158905317	VIPR2	-0.66	-5.89	-0.43	2.34e-8	Facial morphology (factor 20);
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs1864585	0.520	rs73209921	chr8:10707724	C/T	cg21775007	chr8:11205619	TDH	-0.61	-4.53	-0.35	1.17e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.87	9.94	0.63	3.05e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.46	4.52	0.34	1.22e-5	Breast cancer;
PAAD	cis	rs3826795	0.569	rs34128150	chr19:46795109	C/A	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg09211372	chr6:168490623	NA	-0.45	-4.75	-0.36	4.66e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.52	-4.94	-0.37	2.06e-6	P wave terminal force;
PAAD	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.79	9.41	0.61	7.23e-17	Eosinophil percentage of white cells;
PAAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg14709524	chr16:89940631	TCF25	0.99	4.6	0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-4.89	-0.37	2.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg04520793	chr17:42248056	ASB16	-0.47	-6.34	-0.46	2.44e-9	Total body bone mineral density;
PAAD	cis	rs807669	0.900	rs712964	chr22:19156117	T/C	cg02655711	chr22:19163373	SLC25A1	0.81	9.37	0.61	9.37e-17	Metabolite levels;
PAAD	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.53	5.45	0.4	1.99e-7	Resting heart rate;
PAAD	cis	rs10851478	0.558	rs17478694	chr15:49738542	C/G	cg08060515	chr15:49448048	GALK2;COPS2	0.55	5.12	0.38	9.24e-7	Oral cavity cancer;
PAAD	cis	rs2885056	0.843	rs1821279	chr19:10693008	G/C	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.63	7.07	0.5	5.34e-11	Emphysema distribution in smoking;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.38	4.79	0.36	3.85e-6	Metabolite levels (MHPG);
PAAD	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.77	7.91	0.54	4.79e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05025164	chr4:1340916	KIAA1530	0.52	5.0	0.38	1.56e-6	Obesity-related traits;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26418147	chr1:205743515	RAB7L1	-0.4	-4.65	-0.35	7.16e-6	Menarche (age at onset);
PAAD	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12636108	chr5:176036956	GPRIN1	0.6	6.7	0.48	3.73e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.67	-6.85	-0.49	1.72e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9657904	0.738	rs13085563	chr3:105509918	A/C	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.55e-5	Multiple sclerosis;
PAAD	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.66	-0.42	7.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.46	4.29	0.33	3.11e-5	Acne (severe);
PAAD	cis	rs4478858	0.735	rs12404861	chr1:31861271	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.95	-0.43	1.78e-8	Alcohol dependence;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11000221	chr17:57643293	DHX40	-0.57	-6.37	-0.46	2.11e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs11264799	0.731	rs7517149	chr1:157688641	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.49	5.06	0.38	1.19e-6	Longevity;
PAAD	cis	rs9472414	0.510	rs227852	chr6:44699559	A/G	cg18551225	chr6:44695536	NA	-0.5	-5.19	-0.39	6.76e-7	Height;
PAAD	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.44	-4.29	-0.33	3.22e-5	Prostate-specific antigen levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02145048	chr20:55926395	RAE1	0.69	6.81	0.48	2.09e-10	Obesity-related traits;
PAAD	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	4.95	0.37	1.96e-6	Mood instability;
PAAD	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.53	4.86	0.37	2.9e-6	Educational attainment;
PAAD	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg06131755	chr6:160182447	ACAT2	0.51	4.48	0.34	1.48e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-5.03	-0.38	1.36e-6	Lung cancer;
PAAD	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-4.64	-0.35	7.55e-6	Mean corpuscular volume;
PAAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.46	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	6.66	0.48	4.73e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12311304	1.000	rs12303992	chr12:15386448	A/G	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg05895507	chr15:77155635	SCAPER	-0.39	-4.29	-0.33	3.11e-5	Blood metabolite levels;
PAAD	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.92	-9.03	-0.59	7.24e-16	Exhaled nitric oxide output;
PAAD	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	6.86	0.49	1.65e-10	Neuroticism;
PAAD	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.34	0.33	2.63e-5	Cancer;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17960347	chr12:2457373	CACNA1C	0.57	6.83	0.48	1.96e-10	Body fat percentage;
PAAD	cis	rs10768122	1.000	rs17378105	chr11:35294891	C/G	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.36	-0.33	2.37e-5	Vitiligo;
PAAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg07395648	chr5:131743802	NA	-0.64	-6.62	-0.47	5.73e-10	Blood metabolite levels;
PAAD	cis	rs9857275	0.501	rs13084444	chr3:141277651	A/C	cg25967872	chr3:141205623	RASA2	0.5	4.31	0.33	2.9e-5	Prion diseases;
PAAD	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.62	-6.82	-0.48	2.07e-10	Tuberculosis;
PAAD	cis	rs6782228	0.606	rs4857861	chr3:128406767	T/C	cg16766828	chr3:128327626	NA	-0.47	-6.38	-0.46	2e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.38	0.56	3.27e-14	Dupuytren's disease;
PAAD	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg14348967	chr4:10160060	NA	-0.38	-4.59	-0.35	9.2e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.08	-0.5	5e-11	Reticulocyte fraction of red cells;
PAAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs9682041	0.597	rs13076319	chr3:170104630	T/G	cg11886554	chr3:170076028	SKIL	0.63	4.77	0.36	4.37e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg02196655	chr2:10830764	NOL10	-0.55	-5.68	-0.42	6.73e-8	Prostate cancer;
PAAD	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	5.01	0.38	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs66530629	0.917	rs7555134	chr1:25161662	C/T	cg01905478	chr1:25040257	NA	0.5	5.6	0.41	9.56e-8	Plateletcrit;
PAAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.64	-6.33	-0.46	2.67e-9	DNA methylation (variation);
PAAD	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.54	5.12	0.38	9.11e-7	Uric acid clearance;
PAAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.57	6.26	0.45	3.67e-9	Major depressive disorder;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.13	15.43	0.78	6.36e-33	Subjective well-being;
PAAD	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4865169	0.623	rs6838975	chr4:57739816	G/C	cg00922110	chr4:57842668	C4orf14	0.43	4.7	0.36	5.7e-6	Breast cancer;
PAAD	cis	rs7172689	0.908	rs11634869	chr15:81566613	A/T	cg05624577	chr15:81411055	NA	-0.55	-4.29	-0.33	3.18e-5	Inattentive symptoms;
PAAD	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.48	0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.6	5.18	0.39	6.93e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.64	6.51	0.47	1.05e-9	Colorectal cancer;
PAAD	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg00262122	chr8:11665843	FDFT1	-0.53	-4.8	-0.36	3.83e-6	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	6.0	0.44	1.4e-8	Prudent dietary pattern;
PAAD	cis	rs7092929	0.831	rs667943	chr10:3575417	C/T	cg14308648	chr10:3568949	NA	0.67	5.02	0.38	1.4e-6	Coronary artery calcification;
PAAD	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.54	0.35	1.12e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.59	-4.32	-0.33	2.78e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs16975963	0.644	rs12162238	chr19:38082385	A/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.56	-5.88	-0.43	2.53e-8	Paraoxonase activity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14116439	chr4:20852337	KCNIP4	-0.62	-6.53	-0.47	9.31e-10	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg18281939	chr5:77783895	LHFPL2	0.5	5.61	0.41	9.5e-8	Triglycerides;
PAAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg13798912	chr7:905769	UNC84A	0.59	4.48	0.34	1.44e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	trans	rs405795	1.000	rs314415	chr13:89784090	G/A	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Yeast infection;
PAAD	cis	rs76917914	0.589	rs7022455	chr9:100866872	C/T	cg21225548	chr9:100864335	TRIM14	0.53	6.01	0.44	1.35e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.7	8.95	0.59	1.18e-15	Eye color traits;
PAAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.35	-0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.5	5.09	0.38	1.04e-6	Testicular germ cell tumor;
PAAD	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.73	0.36	5.12e-6	Serum sulfate level;
PAAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.48	-0.34	1.43e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Alcohol dependence;
PAAD	cis	rs877529	0.625	rs139416	chr22:39554749	A/G	cg18708252	chr22:39545030	CBX7	-0.68	-7.42	-0.52	7.92e-12	Multiple myeloma;
PAAD	cis	rs300774	1.000	rs300799	chr2:105514	G/A	cg21211680	chr2:198530	NA	-0.58	-5.39	-0.4	2.61e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg14820908	chr5:178986412	RUFY1	-0.61	-6.39	-0.46	1.91e-9	Lung cancer;
PAAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg07689907	chr11:61582574	FADS1	0.46	4.58	0.35	9.65e-6	Trans fatty acid levels;
PAAD	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg06042504	chr8:55087323	NA	-0.77	-8.69	-0.58	5.29e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.73	6.29	0.45	3.17e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.58	-5.5	-0.41	1.56e-7	Height;
PAAD	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.91	11.72	0.69	5.22e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15815349	chr17:30334793	NA	0.6	6.7	0.48	3.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.73	-6.29	-0.45	3.17e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.69	8.81	0.58	2.66e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	9.35	0.6	1.05e-16	Platelet count;
PAAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs2950393	0.804	rs2290894	chr12:57108695	C/G	cg02954252	chr12:57119365	NACA	0.46	4.27	0.33	3.47e-5	Platelet distribution width;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg23346134	chr3:49453900	TCTA	-0.43	-4.5	-0.34	1.34e-5	Menarche (age at onset);
PAAD	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.84	9.98	0.63	2.32e-18	Selective IgA deficiency;
PAAD	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg22349387	chr12:9600060	DDX12	-0.41	-4.3	-0.33	3e-5	Breast size;
PAAD	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg11995313	chr8:8860691	ERI1	0.48	4.56	0.35	1.03e-5	Joint mobility (Beighton score);
PAAD	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.65	5.75	0.42	4.83e-8	Birth weight;
PAAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.55	-0.47	8.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg07813855	chr1:200183606	FAM58B	0.46	4.26	0.33	3.52e-5	Permanent tooth development;
PAAD	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.69	7.24	0.51	2.13e-11	Schizophrenia;
PAAD	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg02549819	chr16:58548995	SETD6	0.91	4.45	0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.61	-6.08	-0.44	9.31e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg11477892	chr4:106580295	NA	-0.54	-4.47	-0.34	1.53e-5	Post bronchodilator FEV1;
PAAD	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.86	-10.8	-0.66	1.59e-20	Lung cancer;
PAAD	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.5e-7	Restless legs syndrome;
PAAD	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.51	-6.14	-0.45	6.95e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg05156901	chr22:51016646	CPT1B;CHKB-CPT1B	0.41	4.62	0.35	8.24e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06002616	chr8:101225028	SPAG1	0.48	5.35	0.4	3.13e-7	Atrioventricular conduction;
PAAD	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.65	7.11	0.5	4.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs787274	0.867	rs6477959	chr9:115554296	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.61	5.9	0.43	2.24e-8	Systolic blood pressure;
PAAD	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.73	5.65	0.42	7.66e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	6.95	0.49	1.01e-10	Schizophrenia;
PAAD	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	5.04	0.38	1.33e-6	Blood metabolite levels;
PAAD	cis	rs7326068	0.595	rs2477164	chr13:21402388	A/C	cg27499820	chr13:21296301	IL17D	0.51	4.58	0.35	9.42e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-5.38	-0.4	2.81e-7	Breast cancer;
PAAD	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.54	-5.51	-0.41	1.51e-7	Hepatitis;
PAAD	cis	rs1144333	0.655	rs1146649	chr1:76268803	A/G	cg22875332	chr1:76189707	ACADM	-0.77	-4.73	-0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.44e-6	Depressive symptoms;
PAAD	cis	rs41419946	1.000	rs114251281	chr1:165408546	G/A	cg24428232	chr1:166124419	MIR921;FAM78B	0.88	4.57	0.35	9.87e-6	Gut microbiome composition (winter);
PAAD	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-4.45	-0.34	1.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11673344	0.504	rs4806408	chr19:37588777	C/T	cg23950597	chr19:37808831	NA	-0.5	-4.27	-0.33	3.48e-5	Obesity-related traits;
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.29	0.64	3.56e-19	Platelet count;
PAAD	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.85	-9.66	-0.62	1.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04731861	chr2:219085781	ARPC2	0.37	4.34	0.33	2.56e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.42	0.34	1.88e-5	Homoarginine levels;
PAAD	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21964637	chr7:150729118	ABCB8	-0.62	-6.45	-0.46	1.38e-9	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg06781209	chr11:61594997	FADS2	-0.52	-4.49	-0.34	1.39e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg19264203	chr11:92714893	MTNR1B	0.41	4.7	0.36	5.89e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.62	-5.97	-0.44	1.61e-8	Subjective well-being;
PAAD	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg09659197	chr4:152720779	NA	0.35	5.03	0.38	1.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs34638952	0.638	rs7209812	chr17:27536988	A/G	cg11956953	chr17:27347092	NA	0.44	4.49	0.34	1.42e-5	Sitting height ratio;
PAAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-5.76	-0.42	4.61e-8	Morning vs. evening chronotype;
PAAD	cis	rs8170	0.603	rs1544940	chr19:17414843	A/T	cg04749549	chr19:17459798	NA	-0.45	-4.85	-0.37	3.02e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.57	-4.99	-0.38	1.61e-6	Pursuit maintenance gain;
PAAD	cis	rs4743820	0.603	rs7045740	chr9:93926650	A/G	cg14446406	chr9:93919335	NA	0.36	4.87	0.37	2.75e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04836792	chr2:204192791	ABI2	0.57	6.47	0.46	1.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.79	-0.48	2.36e-10	Lung cancer;
PAAD	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg25809561	chr17:30822961	MYO1D	0.59	6.14	0.45	6.8e-9	Schizophrenia;
PAAD	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-4.33	-0.33	2.73e-5	Cognitive ability (multi-trait analysis);
PAAD	cis	rs672059	1.000	rs3118181	chr1:183166970	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	4.32	0.33	2.78e-5	Hypertriglyceridemia;
PAAD	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.1e-8	Electroencephalogram traits;
PAAD	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.68	4.66	0.35	6.92e-6	Major depressive disorder;
PAAD	cis	rs988913	0.629	rs34685175	chr6:54866737	G/C	cg03513858	chr6:54763001	FAM83B	-0.43	-4.65	-0.35	7.17e-6	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.84e-15	Coffee consumption (cups per day);
PAAD	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.61	6.13	0.45	7.21e-9	Mood instability;
PAAD	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.89	0.43	2.43e-8	HIV-1 control;
PAAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.65	8.33	0.56	4.49e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-11.05	-0.67	3.36e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-7.06	-0.5	5.71e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10821973	0.527	rs10740066	chr10:63976416	T/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs4534636	0.853	rs4304840	chr12:8667897	C/T	cg12193649	chr12:8324628	ZNF705A	-0.45	-4.6	-0.35	9e-6	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
PAAD	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.76	5.98	0.44	1.54e-8	Diisocyanate-induced asthma;
PAAD	cis	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.65	6.99	0.49	8.31e-11	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.88	5.56	0.41	1.17e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.37	-0.46	2.15e-9	Type 2 diabetes;
PAAD	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.9	-0.43	2.31e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.28	0.33	3.24e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.43	-4.41	-0.34	1.92e-5	Response to statin therapy;
PAAD	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2928148	0.522	rs11070318	chr15:41257854	A/T	cg18705301	chr15:41695430	NDUFAF1	0.63	5.78	0.42	4.03e-8	Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-6.63	-0.47	5.4e-10	Bipolar disorder;
PAAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.11	-0.38	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2271400	0.566	rs6474010	chr8:56655434	T/C	cg08894788	chr8:56792171	LYN	-0.53	-5.12	-0.38	9.18e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg05562828	chr17:3906858	NA	0.47	4.69	0.36	6.16e-6	Type 2 diabetes;
PAAD	cis	rs9815354	0.857	rs794902	chr3:42025939	T/C	cg03022575	chr3:42003672	ULK4	-0.71	-4.98	-0.37	1.68e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg02696790	chr15:75250997	RPP25	0.36	4.3	0.33	3.09e-5	Breast cancer;
PAAD	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs288342	0.832	rs184078	chr2:183590868	A/C	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs59888335	0.964	rs35261677	chr3:80781674	A/G	cg21735741	chr3:80819488	NA	0.55	4.75	0.36	4.68e-6	Schizophrenia;
PAAD	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03032247	chr17:46570338	NA	-0.61	-6.31	-0.46	2.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg21573476	chr21:45109991	RRP1B	0.47	4.3	0.33	3.03e-5	Mean corpuscular volume;
PAAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.91	0.49	1.22e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg06057569	chr22:50219754	BRD1	0.69	5.1	0.38	9.88e-7	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs747650	0.504	rs10769227	chr11:47002614	A/T	cg19486271	chr11:47235900	DDB2	-0.63	-6.12	-0.44	7.7e-9	Acne (severe);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26175815	chr3:129420294	TMCC1	-0.61	-6.44	-0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.55	6.25	0.45	3.88e-9	Mean corpuscular volume;
PAAD	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.43	0.34	1.8e-5	Axial length;
PAAD	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg14758556	chr20:62440591	NA	-0.51	-4.52	-0.34	1.25e-5	Atopic dermatitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13899293	chr4:79175365	FRAS1	0.67	8.24	0.56	7.34e-14	Smoking initiation;
PAAD	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.51	5.0	0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs9462027	0.628	rs998278	chr6:34765584	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.03	-0.38	1.39e-6	Systemic lupus erythematosus;
PAAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24813355	chr7:6388618	C7orf70	-0.77	-6.63	-0.47	5.39e-10	Neuroticism;
PAAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg23281280	chr6:28129359	ZNF389	0.54	4.87	0.37	2.79e-6	Parkinson's disease;
PAAD	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg27121462	chr16:89883253	FANCA	0.75	4.43	0.34	1.82e-5	Skin colour saturation;
PAAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-4.4	-0.34	2.01e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-6.66	-0.48	4.73e-10	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10016972	chr12:133370462	GOLGA3	-0.62	-6.44	-0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.98	10.72	0.66	2.62e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.72	-8.4	-0.56	2.94e-14	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs12044355	0.929	rs6693517	chr1:231852444	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.2	0.39	6.32e-7	Alzheimer's disease;
PAAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.78	-7.18	-0.5	2.92e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9346353	0.737	rs3752789	chr6:70507119	T/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.4	-0.34	2.05e-5	Sleep duration;
PAAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.38	-0.33	2.21e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.52	4.82	0.36	3.48e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00175980	chr12:120426618	CCDC64	0.57	6.57	0.47	7.75e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.68	9.14	0.6	3.75e-16	Hemoglobin concentration;
PAAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.71	7.69	0.53	1.72e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg04165759	chr1:150448943	RPRD2	0.5	5.19	0.39	6.58e-7	Migraine;
PAAD	cis	rs4698412	0.583	rs4257653	chr4:15711933	T/G	cg01353608	chr4:15656911	FBXL5	-0.48	-4.41	-0.34	1.93e-5	Parkinson's disease;
PAAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.62	6.37	0.46	2.09e-9	Testicular germ cell tumor;
PAAD	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1062753	0.527	rs6002560	chr22:42356886	C/T	cg01059385	chr22:42394853	WBP2NL	-0.48	-4.44	-0.34	1.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.56	6.33	0.46	2.6e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.26	-0.39	4.75e-7	Mood instability;
PAAD	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.64	6.32	0.46	2.77e-9	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	5.46	0.41	1.86e-7	Prudent dietary pattern;
PAAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg14092988	chr3:52407081	DNAH1	0.45	5.61	0.41	9.3e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14090374	chr1:85667233	SYDE2	0.57	6.35	0.46	2.42e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg05110241	chr16:68378359	PRMT7	-1.07	-8.1	-0.55	1.63e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg10705379	chr10:99080932	FRAT1	-0.38	-4.39	-0.34	2.1e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-1.27	-10.07	-0.63	1.32e-18	Obesity-related traits;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27297192	chr10:134578999	INPP5A	0.61	5.42	0.4	2.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18915197	chr5:32017214	PDZD2	-0.66	-7.09	-0.5	4.72e-11	Obesity-related traits;
PAAD	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.4	5.86	0.43	2.76e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.67	-7.04	-0.5	6.33e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.56	-0.35	1.04e-5	Resting heart rate;
PAAD	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.5	-4.63	-0.35	7.63e-6	Neuroticism;
PAAD	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.77	7.42	0.52	7.92e-12	Coronary artery disease;
PAAD	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.62	6.4	0.46	1.84e-9	Height;
PAAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg21300403	chr2:198650112	BOLL	-0.65	-4.33	-0.33	2.72e-5	Ulcerative colitis;
PAAD	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.57	6.75	0.48	2.93e-10	Total body bone mineral density;
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-5.09	-0.38	1.04e-6	Mean platelet volume;
PAAD	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Intracranial aneurysm;
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg12807937	chr2:240965920	NDUFA10	-0.45	-4.42	-0.34	1.85e-5	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.75	-0.58	3.75e-15	Morning vs. evening chronotype;
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg25566285	chr7:158114605	PTPRN2	0.75	6.42	0.46	1.63e-9	Response to amphetamines;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg01759136	chr6:27242945	NA	0.4	4.35	0.33	2.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2019960	0.759	rs2648844	chr8:129178530	T/C	cg15331705	chr8:129180010	NA	-0.44	-5.83	-0.43	3.28e-8	Hodgkin's lymphoma;Multiple sclerosis;
PAAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg02781088	chr2:113192302	RGPD8;RGPD5	0.94	6.84	0.48	1.85e-10	Yeast infection;
PAAD	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.11e-7	Prostate cancer;
PAAD	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg00262122	chr8:11665843	FDFT1	-0.51	-4.29	-0.33	3.14e-5	Retinal vascular caliber;
PAAD	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.98	10.41	0.65	1.71e-19	Platelet distribution width;
PAAD	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg24375607	chr4:120327624	NA	0.55	5.19	0.39	6.64e-7	Corneal astigmatism;
PAAD	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs732765	0.657	rs11849512	chr14:75237484	C/A	cg17347104	chr14:75034677	LTBP2	0.55	4.27	0.33	3.38e-5	Non-small cell lung cancer;
PAAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	1.01	13.62	0.74	3.95e-28	Total body bone mineral density;
PAAD	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.56	6.03	0.44	1.2e-8	Bladder cancer;
PAAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs73416724	0.925	rs2651201	chr6:43293366	G/A	cg26312998	chr6:43337775	ZNF318	-0.7	-5.83	-0.43	3.2e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.8	0.43	3.64e-8	Response to antipsychotic treatment;
PAAD	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.57	-5.59	-0.41	1.02e-7	Platelet count;
PAAD	cis	rs4919087	0.926	rs945189	chr10:99091766	C/G	cg25902810	chr10:99078978	FRAT1	0.61	5.98	0.44	1.52e-8	Monocyte count;
PAAD	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.54	-6.92	-0.49	1.2e-10	Schizophrenia;
PAAD	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.64	-0.35	7.4e-6	Lung cancer in ever smokers;
PAAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg13798912	chr7:905769	UNC84A	0.6	4.52	0.34	1.24e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs10044254	0.512	rs4701638	chr5:15692383	G/A	cg07238450	chr5:15720153	FBXL7	-0.53	-5.02	-0.38	1.45e-6	Asthma (corticosteroid response);
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00546594	chr21:35287829	ATP5O	0.56	6.32	0.46	2.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	9.07	0.59	5.75e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.93	-0.49	1.11e-10	Morning vs. evening chronotype;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.63	5.62	0.41	8.81e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07930192	chr7:1003750	NA	0.49	5.84	0.43	3.07e-8	Longevity;Endometriosis;
PAAD	cis	rs7873102	0.654	rs7874305	chr9:37969882	C/T	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.86	6.86	0.49	1.67e-10	Prostate cancer;
PAAD	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.6	-4.4	-0.34	2.06e-5	Diisocyanate-induced asthma;
PAAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	5.66	0.42	7.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7082209	0.646	rs12414744	chr10:44808313	C/A	cg13191911	chr10:44806660	NA	-0.94	-4.52	-0.34	1.22e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.35	0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.53	-5.21	-0.39	6.09e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.53	-7.71	-0.53	1.54e-12	Diastolic blood pressure;
PAAD	cis	rs4843185	0.763	rs9534	chr16:85711502	C/T	cg26571870	chr16:85723150	GINS2	0.48	5.94	0.43	1.82e-8	Platelet distribution width;
PAAD	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg03098721	chr1:84464084	TTLL7	0.47	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.93	6.2	0.45	5.15e-9	Systolic blood pressure;
PAAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.46e-5	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg15309053	chr8:964076	NA	0.5	5.67	0.42	7.06e-8	Schizophrenia;
PAAD	cis	rs11696501	0.688	rs714595	chr20:44330591	G/A	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs3771514	0.543	rs11126272	chr2:70692128	C/T	cg18150120	chr2:71134936	VAX2	-0.38	-4.55	-0.35	1.09e-5	Obesity-related traits;
PAAD	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs62460802	1	rs62460802	chr7:83052869	G/A	cg14519356	chr7:83097669	SEMA3E	-0.47	-4.87	-0.37	2.81e-6	Lobe attachment (rater scored);
PAAD	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.67	-5.66	-0.42	7.2e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs600550	0.588	rs7943848	chr11:60092590	T/C	cg05040360	chr11:60102449	MS4A6E	-0.43	-5.05	-0.38	1.26e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs4372836	0.543	rs3768665	chr2:29005602	G/A	cg09009506	chr2:28216851	BRE	0.43	4.7	0.36	5.86e-6	Body mass index;
PAAD	cis	rs300774	0.858	rs300718	chr2:136579	G/A	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.3	-0.4	3.95e-7	Height;
PAAD	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.44	-0.34	1.72e-5	Cholesterol, total;
PAAD	cis	rs9646944	0.501	rs10186052	chr2:103079608	G/A	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.78	9.36	0.6	9.95e-17	Emphysema distribution in smoking;
PAAD	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.53	-5.31	-0.4	3.83e-7	Obesity-related traits;
PAAD	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg18279126	chr7:2041391	MAD1L1	0.63	6.18	0.45	5.53e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs5009270	0.512	rs75795332	chr7:112241690	G/A	cg23628563	chr7:112262597	NA	0.64	5.71	0.42	5.87e-8	Osteoarthritis (hip);
PAAD	cis	rs9815354	1.000	rs939558	chr3:41976040	C/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.91	-0.43	2.21e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	1.05	14.83	0.77	2.46e-31	Metabolite levels;
PAAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.17e-20	Menopause (age at onset);
PAAD	cis	rs13424612	1.000	rs4149556	chr2:240915307	C/T	cg01812947	chr2:240904978	NDUFA10	0.58	5.01	0.38	1.46e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05665937	chr4:1216051	CTBP1	0.46	4.62	0.35	8.27e-6	Obesity-related traits;
PAAD	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.93	7.54	0.52	4.07e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs9287719	0.649	rs12618726	chr2:10728375	C/G	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.66	-0.42	7.16e-8	Primary biliary cholangitis;
PAAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	6.17	0.45	5.82e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21203562	chr5:6752456	POLS	-0.66	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg04824913	chr4:887549	GAK	0.82	8.61	0.57	8.69e-15	Systemic sclerosis;
PAAD	cis	rs73206853	0.841	rs11065663	chr12:110988886	G/T	cg12870014	chr12:110450643	ANKRD13A	0.64	4.55	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.76	9.25	0.6	1.9e-16	Bone mineral density;
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg05554000	chr7:158905015	VIPR2	0.57	5.07	0.38	1.15e-6	Facial morphology (factor 20);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27104822	chr19:10698084	AP1M2	0.46	6.72	0.48	3.4e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs786425	0.689	rs2222060	chr12:124194438	A/G	cg16237390	chr12:124156159	TCTN2	0.46	4.29	0.33	3.2e-5	Pubertal anthropometrics;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.7	-0.53	1.64e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg18721089	chr20:30220636	NA	0.63	5.08	0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-5.13	-0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs11264799	0.581	rs849815	chr1:157542162	A/G	cg18268488	chr1:157545234	FCRL4	0.48	5.36	0.4	3e-7	IgA nephropathy;
PAAD	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg20673841	chr7:107026890	COG5	0.48	4.33	0.33	2.69e-5	Coronary artery disease;
PAAD	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.39	4.25	0.33	3.73e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs2153904	0.702	rs1418549	chr1:205644848	G/C	cg23034840	chr1:205782522	SLC41A1	0.68	5.4	0.4	2.5e-7	Prostate-specific antigen levels;
PAAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	3.43e-18	Cognitive function;
PAAD	cis	rs7624766	0.714	rs897494	chr3:160529290	T/C	cg22637730	chr3:160473554	PPM1L	0.52	4.66	0.35	6.77e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-1.06	-14.93	-0.77	1.35e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs1419980	0.730	rs1946125	chr12:7760149	A/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2117029	0.586	rs10875928	chr12:49556303	A/G	cg05368762	chr12:50135785	TMBIM6	0.43	4.29	0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2944591	0.505	rs1083515	chr2:233789463	C/T	cg08000102	chr2:233561755	GIGYF2	-0.47	-4.52	-0.34	1.22e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00166722	chr3:10149974	C3orf24	0.93	7.97	0.54	3.57e-13	Alzheimer's disease;
PAAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.77	-0.48	2.63e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.07	-0.44	9.62e-9	Prostate cancer;
PAAD	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.52	5.79	0.43	3.88e-8	Cognitive function;
PAAD	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.89	8.84	0.58	2.28e-15	Exhaled nitric oxide output;
PAAD	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.63	5.36	0.4	3.09e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.16	0.39	7.57e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7580658	0.554	rs2069915	chr2:128178378	G/A	cg09760422	chr2:128146352	NA	-0.35	-5.99	-0.44	1.48e-8	Protein C levels;
PAAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg19257562	chr1:2043853	PRKCZ	0.46	5.56	0.41	1.16e-7	Height;
PAAD	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.53	4.94	0.37	2.03e-6	Airway imaging phenotypes;
PAAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.35	-0.4	3.11e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs965604	0.965	rs4299116	chr15:78766194	T/A	cg18825076	chr15:78729989	IREB2	-0.45	-4.38	-0.33	2.18e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.06	14.74	0.77	4.25e-31	Body mass index (adult);
PAAD	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.19	0.39	6.69e-7	Childhood ear infection;
PAAD	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.68	-6.78	-0.48	2.49e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.71	-6.74	-0.48	3.03e-10	Gout;
PAAD	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.88	0.43	2.49e-8	Lung cancer;
PAAD	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Androgen levels;
PAAD	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.54	0.65	7.59e-20	Electrocardiographic conduction measures;
PAAD	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg06569542	chr10:98946673	SLIT1	0.47	4.84	0.37	3.12e-6	Monocyte count;
PAAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg21033440	chr11:65409861	SIPA1	-0.41	-4.5	-0.34	1.37e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.79	-0.48	2.42e-10	Response to antipsychotic treatment;
PAAD	cis	rs375066	0.934	rs411803	chr19:44432840	C/T	cg08633290	chr19:44405433	NA	0.56	5.56	0.41	1.17e-7	Breast cancer;
PAAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs317865	0.867	rs73234625	chr4:16166206	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.01	6.81	0.48	2.11e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg18612461	chr15:75251733	NA	0.59	7.59	0.52	2.97e-12	Breast cancer;
PAAD	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg27234864	chr13:21295941	IL17D	0.61	5.29	0.39	4.28e-7	Dental caries;
PAAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.45	0.61	5.92e-17	Rheumatoid arthritis;
PAAD	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg15192750	chr16:69999425	NA	0.69	5.43	0.4	2.2e-7	IgE levels;
PAAD	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.15	-0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.39	-4.38	-0.33	2.22e-5	Lung cancer;
PAAD	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.68	6.36	0.46	2.3e-9	Corneal astigmatism;
PAAD	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs507080	0.663	rs523793	chr11:118570697	C/T	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg02440177	chr19:53496695	ZNF702P	-0.55	-5.6	-0.41	9.56e-8	Psoriasis;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.9	10.98	0.67	5.07e-21	Menarche (age at onset);
PAAD	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg14061069	chr19:46274453	DMPK	-0.6	-6.25	-0.45	3.94e-9	Coronary artery disease;
PAAD	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg12568669	chr8:11666485	FDFT1	0.26	4.3	0.33	3e-5	Neuroticism;
PAAD	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-4.93	-0.37	2.1e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg18944383	chr4:111397179	ENPEP	0.68	8.9	0.59	1.52e-15	Height;
PAAD	cis	rs7640424	0.680	rs68147515	chr3:107903216	T/A	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.7	-5.78	-0.42	4.19e-8	Neuroticism;
PAAD	cis	rs8067354	0.574	rs2526358	chr17:57942585	A/G	cg02344993	chr17:57696989	CLTC	0.57	4.58	0.35	9.47e-6	Hemoglobin concentration;
PAAD	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg02404636	chr22:31891804	SFI1	0.59	5.7	0.42	5.97e-8	Paclitaxel-induced neuropathy;
PAAD	cis	rs6066835	0.867	rs11698661	chr20:47360148	A/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg09579323	chr1:150459698	TARS2	-0.45	-4.29	-0.33	3.11e-5	Migraine;
PAAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.82	-6.96	-0.49	9.37e-11	Gut microbiome composition (summer);
PAAD	cis	rs1879734	0.731	rs4927026	chr1:54140843	C/T	cg14659662	chr1:54151053	GLIS1	0.41	5.52	0.41	1.42e-7	Mitral valve prolapse;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.57	-6.37	-0.46	2.13e-9	Cognitive function;
PAAD	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20740967	chr4:2252862	MXD4	-0.66	-6.35	-0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.6e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2004318	1.000	rs77024125	chr19:55077406	G/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.83	8.11	0.55	1.6e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2201728	0.967	rs12507573	chr4:100226324	A/C	cg12011299	chr4:100065546	ADH4	0.39	4.33	0.33	2.72e-5	Cardiac Troponin-T levels;
PAAD	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24276346	chr20:49626161	KCNG1	-0.63	-7.59	-0.52	2.99e-12	Monocyte percentage of white cells;
PAAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	7.26	0.51	1.82e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.49	-4.41	-0.34	1.97e-5	Mean corpuscular volume;
PAAD	cis	rs62025270	0.688	rs55957626	chr15:86316717	G/A	cg13263323	chr15:86062960	AKAP13	0.56	5.02	0.38	1.46e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-4.72	-0.36	5.25e-6	Schizophrenia;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs17601876	0.814	rs8029537	chr15:51557698	A/G	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.37	0.33	2.33e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07421368	chr2:67624930	ETAA1	0.61	7.04	0.5	6.09e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.65	8.42	0.56	2.57e-14	Hypertriglyceridemia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05647660	chr4:76439704	RCHY1;THAP6	0.58	6.69	0.48	4.12e-10	Metabolite levels  (X-11787);
PAAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.85	-8.85	-0.58	2.04e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.29	-0.51	1.55e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg14709524	chr16:89940631	TCF25	0.71	4.39	0.34	2.1e-5	Skin colour saturation;
PAAD	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.56	5.36	0.4	3.05e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg13722127	chr7:150037890	RARRES2	-0.6	-5.83	-0.43	3.27e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2278796	0.697	rs4951150	chr1:204952849	C/A	cg04862289	chr1:204966208	NFASC	0.48	5.34	0.4	3.33e-7	Mean platelet volume;
PAAD	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	6.67	0.48	4.46e-10	Height;
PAAD	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.57	6.09	0.44	8.69e-9	Mean corpuscular volume;
PAAD	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg00806126	chr19:22604979	ZNF98	-0.42	-5.35	-0.4	3.21e-7	Pain;
PAAD	trans	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg25214090	chr10:38739885	LOC399744	0.79	7.7	0.53	1.62e-12	Corneal astigmatism;
PAAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.5	-4.26	-0.33	3.6e-5	Vitiligo;
PAAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.32	13.91	0.75	6.93e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs10916814	0.632	rs10799646	chr1:20903985	G/T	cg04087271	chr1:20915334	CDA	0.37	4.69	0.36	5.94e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg25730555	chr22:47059586	GRAMD4	0.46	4.38	0.33	2.19e-5	Urate levels in obese individuals;
PAAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg11764359	chr7:65958608	NA	0.78	5.26	0.39	4.91e-7	Diabetic kidney disease;
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	4.65	0.35	7.19e-6	Educational attainment;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1105228	0.959	rs567344	chr6:165712338	C/G	cg20535254	chr6:165714960	C6orf118	-0.5	-4.93	-0.37	2.09e-6	Number of pregnancies;Number of children;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.7	5.73	0.42	5.17e-8	Alzheimer's disease;
PAAD	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.78	5.79	0.43	3.92e-8	Vitiligo;
PAAD	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6734238	0.739	rs1542176	chr2:113849837	A/G	cg06156847	chr2:113672199	IL1F7	0.42	4.27	0.33	3.48e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.87	-10.06	-0.63	1.45e-18	Coronary artery disease;
PAAD	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg11993925	chr19:44307056	LYPD5	0.5	6.66	0.48	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.59	5.43	0.4	2.15e-7	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21574429	chr6:143381827	AIG1	0.62	7.68	0.53	1.8e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg01851573	chr8:8652454	MFHAS1	0.6	5.08	0.38	1.08e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.64e-6	Breast cancer;
PAAD	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg09344028	chr17:70110421	NA	0.51	6.61	0.47	6.26e-10	Thyroid hormone levels;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg16083429	chr3:49237500	CCDC36	0.45	4.41	0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26418147	chr1:205743515	RAB7L1	-0.5	-6.0	-0.44	1.37e-8	Menarche (age at onset);
PAAD	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-6.98	-0.49	8.56e-11	Type 2 diabetes;
PAAD	cis	rs72960926	0.744	rs72967284	chr6:75024375	C/T	cg03266952	chr6:74778945	NA	-1.13	-6.3	-0.46	3.02e-9	Metabolite levels (MHPG);
PAAD	cis	rs4588572	0.561	rs7727592	chr5:77804547	G/A	cg18281939	chr5:77783895	LHFPL2	0.43	4.94	0.37	2.03e-6	Triglycerides;
PAAD	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.56	-5.93	-0.43	1.97e-8	Menarche (age at onset);
PAAD	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.67e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17641971	0.684	rs10957363	chr8:49999175	T/A	cg00325661	chr8:49890786	NA	0.61	6.05	0.44	1.07e-8	Blood metabolite levels;
PAAD	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg00576331	chr11:65640516	EFEMP2	-0.62	-5.46	-0.4	1.92e-7	DNA methylation (variation);
PAAD	cis	rs6494488	0.500	rs72742988	chr15:64994090	T/C	cg16425858	chr15:64791681	ZNF609	0.89	5.06	0.38	1.2e-6	Coronary artery disease;
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.72	0.36	5.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg01097406	chr16:89675127	NA	-0.38	-4.68	-0.35	6.41e-6	Vitiligo;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.75	-8.04	-0.55	2.35e-13	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03676636	chr4:99064102	C4orf37	0.33	6.1	0.44	8.48e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.37	5.86	0.43	2.82e-8	Alopecia areata;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.58	-6.31	-0.46	2.94e-9	IgG glycosylation;
PAAD	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-4.37	-0.33	2.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg14146966	chr2:61757674	XPO1	-0.38	-4.8	-0.36	3.84e-6	Tuberculosis;
PAAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.87	10.66	0.65	3.7799999999999997e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg19787841	chr12:53845606	PCBP2	0.44	4.37	0.33	2.33e-5	Height;
PAAD	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.73	-8.39	-0.56	3.15e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13198984	chr17:80129470	CCDC57	0.41	4.99	0.38	1.62e-6	Life satisfaction;
PAAD	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg15047889	chr8:124780837	FAM91A1	-0.65	-5.13	-0.38	8.87e-7	Pancreatic cancer;
PAAD	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.45	4.53	0.35	1.17e-5	Airway imaging phenotypes;
PAAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.07	0.5	5.14e-11	Systemic lupus erythematosus;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.47	5.55	0.41	1.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg07454742	chr17:42254645	ASB16;C17orf65	-0.4	-4.36	-0.33	2.41e-5	Total body bone mineral density;
PAAD	cis	rs6880778	0.505	rs10473183	chr5:40370251	T/C	cg05240017	chr5:40756081	TTC33	0.5	4.31	0.33	2.94e-5	Inflammatory bowel disease;
PAAD	cis	rs7925523	1.000	rs60399071	chr11:61443155	G/A	cg12472022	chr11:61462803	DAGLA	0.66	5.63	0.42	8.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.6	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs4843185	0.733	rs1049868	chr16:85706633	A/G	cg26571870	chr16:85723150	GINS2	-0.4	-4.52	-0.34	1.24e-5	Platelet distribution width;
PAAD	cis	rs9810890	0.850	rs115721474	chr3:128430370	G/A	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.92	11.27	0.67	8.6e-22	Prudent dietary pattern;
PAAD	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.6	5.62	0.41	8.91e-8	Monocyte count;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-8.01	-0.54	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.95	-0.54	4.02e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.22	-0.39	5.9e-7	Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09520126	chr7:158802720	LOC154822	-0.52	-6.31	-0.46	2.89e-9	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg12639453	chr1:2035780	PRKCZ	0.54	5.07	0.38	1.16e-6	Height;
PAAD	cis	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg27411982	chr8:10470053	RP1L1	0.45	5.32	0.4	3.65e-7	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08897759	chr5:178415944	GRM6	-0.68	-6.69	-0.48	3.92e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.7	6.06	0.44	1.03e-8	Diabetic retinopathy;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.7	-0.42	5.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.91e-7	Body mass index;
PAAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7250872	0.606	rs1078229	chr19:1826383	A/C	cg23684787	chr19:1848742	REXO1	-0.51	-4.29	-0.33	3.16e-5	Bipolar disorder;
PAAD	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg18402987	chr7:1209562	NA	0.94	5.07	0.38	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.74	0.36	4.78e-6	Testicular germ cell tumor;
PAAD	cis	rs7113874	0.802	rs10128597	chr11:8694830	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-4.39	-0.34	2.09e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.96	-10.65	-0.65	3.93e-20	Systemic lupus erythematosus;
PAAD	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.47	-5.2	-0.39	6.28e-7	Blood metabolite levels;
PAAD	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.45	-0.34	1.67e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.69	7.88	0.54	5.9e-13	Testicular germ cell tumor;
PAAD	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Myopia (pathological);
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.83	-5.71	-0.42	5.89e-8	Body mass index;
PAAD	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.8	8.26	0.56	6.6e-14	Coronary artery disease;
PAAD	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg23860436	chr12:58378763	NA	0.46	4.26	0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg23298862	chr7:158159286	PTPRN2	-0.62	-5.58	-0.41	1.06e-7	Calcium levels;
PAAD	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.71	0.69	5.53e-23	Lymphocyte percentage of white cells;
PAAD	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg01620082	chr3:125678407	NA	-1.12	-7.34	-0.51	1.19e-11	Depression;
PAAD	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg03417191	chr3:183542750	MAP6D1	-0.6	-5.36	-0.4	3.07e-7	Menopause (age at onset);
PAAD	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.67	-6.49	-0.47	1.15e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18204762	chr7:98741983	SMURF1	0.6	6.36	0.46	2.3e-9	Myopia (pathological);
PAAD	cis	rs9652601	0.959	rs11865121	chr16:11166688	C/A	cg04616529	chr16:11181986	CLEC16A	0.47	5.14	0.38	8.38e-7	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg00543991	chr22:32367038	NA	-1.18	-7.18	-0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg19223190	chr17:80058835	NA	-0.49	-5.18	-0.39	7.1e-7	Life satisfaction;
PAAD	cis	rs3112530	1.000	rs3101485	chr5:152639235	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs7737355	0.812	rs8180462	chr5:130907189	A/G	cg06307176	chr5:131281290	NA	0.49	4.3	0.33	3e-5	Life satisfaction;
PAAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.44	0.4	2.12e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.65	6.56	0.47	8.15e-10	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.78e-5	Life satisfaction;
PAAD	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.65	6.31	0.46	2.92e-9	Type 2 diabetes;
PAAD	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.35	0.33	2.51e-5	Schizophrenia;
PAAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.61	6.07	0.44	9.84e-9	Blood protein levels;
PAAD	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.64	-4.61	-0.35	8.47e-6	Smoking behavior;
PAAD	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg14348967	chr4:10160060	NA	-0.38	-4.49	-0.34	1.4e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7922314	0.571	rs61865710	chr10:64735714	T/C	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg05110241	chr16:68378359	PRMT7	-0.99	-5.88	-0.43	2.54e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg04415270	chr2:102091202	RFX8	-0.52	-6.54	-0.47	8.96e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.27	0.45	3.54e-9	Height;
PAAD	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg01851573	chr8:8652454	MFHAS1	0.58	4.98	0.37	1.71e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	cis	rs6921919	0.848	rs6903823	chr6:28322296	A/G	cg23153227	chr6:27725408	NA	0.54	4.6	0.35	8.98e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2274459	1.000	rs12211565	chr6:33725852	C/T	cg06253072	chr6:33679850	C6orf125	0.67	4.78	0.36	4.17e-6	Obesity (extreme);
PAAD	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.65	5.59	0.41	1.03e-7	Gut microbiome composition (summer);
PAAD	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.91	-10.97	-0.66	5.58e-21	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg23018236	chr17:30244563	NA	-0.52	-4.31	-0.33	2.98e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs8060686	0.641	rs3785108	chr16:68106846	C/T	cg03983715	chr16:68378420	PRMT7	-0.84	-4.94	-0.37	1.99e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg00262122	chr8:11665843	FDFT1	0.47	4.3	0.33	3.04e-5	Retinal vascular caliber;
PAAD	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.87	10.09	0.63	1.2e-18	Ulcerative colitis;
PAAD	cis	rs2790216	1.000	rs2590349	chr10:60014646	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.47	4.58	0.35	9.72e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg20283391	chr11:68216788	NA	-0.55	-5.3	-0.39	4.05e-7	Total body bone mineral density;
PAAD	cis	rs12136530	0.593	rs12404362	chr1:19739958	A/G	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	cis	rs9039	1.000	rs17652208	chr16:9196463	C/T	cg08831531	chr16:9218945	NA	-0.66	-6.44	-0.46	1.45e-9	Menopause (age at onset);
PAAD	cis	rs9815354	0.537	rs73073272	chr3:42022446	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.47	-0.34	1.49e-5	Glomerular filtration rate;
PAAD	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg14388049	chr10:71211838	TSPAN15	-0.52	-5.27	-0.39	4.63e-7	Venous thromboembolism;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs787274	1.000	rs7030795	chr9:115558962	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Birth weight;
PAAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.64	-8.37	-0.56	3.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8105895	0.935	rs1560717	chr19:22292247	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11912956	chr7:73588697	EIF4H	0.7	7.86	0.54	6.51e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg00238848	chr11:72408252	ARAP1	-0.44	-4.39	-0.34	2.1e-5	Body mass index;
PAAD	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg08898775	chr15:59042684	ADAM10	0.45	5.88	0.43	2.57e-8	Schizophrenia;
PAAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.83	0.48	1.89e-10	Personality dimensions;
PAAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg18279126	chr7:2041391	MAD1L1	0.59	6.15	0.45	6.54e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.11	-0.44	8.1e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.82	-9.44	-0.61	6.07e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg12193833	chr17:30244370	NA	-0.67	-5.15	-0.39	7.97e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.46e-12	Recombination rate (females);
PAAD	cis	rs10450586	0.932	rs7107790	chr11:27324730	G/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.56	-5.36	-0.4	3.08e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.68	-5.81	-0.43	3.55e-8	Blood protein levels;
PAAD	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.76	-7.0	-0.49	7.5e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.47	-0.41	1.81e-7	Common traits (Other);
PAAD	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.79	8.9	0.59	1.52e-15	Colorectal cancer;
PAAD	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.59	5.39	0.4	2.7e-7	Lymphocyte counts;
PAAD	cis	rs11811982	0.793	rs75948705	chr1:227510285	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg10664184	chr19:17420304	DDA1	0.61	4.29	0.33	3.13e-5	Systemic lupus erythematosus;
PAAD	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.6	-5.35	-0.4	3.17e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.6	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg10547527	chr2:198650123	BOLL	0.49	4.31	0.33	2.98e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.67	-6.21	-0.45	4.74e-9	Subjective well-being;
PAAD	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg13722127	chr7:150037890	RARRES2	0.51	5.25	0.39	5.09e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.52	-7.6	-0.52	2.81e-12	Diastolic blood pressure;
PAAD	cis	rs73198271	0.515	rs11780216	chr8:8625720	G/T	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	5.31	0.4	3.9e-7	Axial length;
PAAD	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.8	9.68	0.62	1.46e-17	Height;
PAAD	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.73	7.82	0.54	8.05e-13	Schizophrenia;
PAAD	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-0.88	-7.62	-0.53	2.56e-12	Blood protein levels;
PAAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	1.17	6.97	0.49	9.16e-11	Skin colour saturation;
PAAD	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.42	-0.34	1.86e-5	Tuberculosis;
PAAD	cis	rs2916733	0.530	rs2442520	chr8:6290914	A/G	cg02465761	chr8:6735510	DEFB1	-0.42	-4.33	-0.33	2.64e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.96	12.69	0.72	1.28e-25	Menarche (age at onset);
PAAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg16434002	chr17:42200994	HDAC5	0.52	5.36	0.4	2.97e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs72772090	1.000	rs56116814	chr5:96048714	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-5.88	-0.43	2.49e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs901683	0.850	rs117582049	chr10:46050228	C/A	cg16908948	chr10:45500256	ZNF22	0.79	4.26	0.33	3.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7631605	0.875	rs10154916	chr3:37185960	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg09699651	chr6:150184138	LRP11	0.4	4.26	0.33	3.62e-5	Lung cancer;
PAAD	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.49	4.38	0.33	2.23e-5	Sudden cardiac arrest;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1561176	0.830	rs11773280	chr7:154994990	G/A	cg25063631	chr7:155025500	NA	-0.52	-4.75	-0.36	4.65e-6	Personality dimensions;
PAAD	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-5.07	-0.38	1.13e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27626844	chr6:108615979	LACE1	0.62	6.9	0.49	1.3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	4.84	0.37	3.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.86	-11.0	-0.67	4.39e-21	Height;
PAAD	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	8.77	0.58	3.41e-15	Platelet count;
PAAD	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.16	0.55	1.18e-13	Height;
PAAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg16926213	chr1:1841314	NA	0.36	4.41	0.34	1.91e-5	Body mass index;
PAAD	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs134594	0.885	rs134676	chr22:29503191	C/T	cg01361351	chr22:29467363	NA	-0.39	-4.4	-0.34	2.02e-5	Birth weight;
PAAD	cis	rs12431939	0.779	rs3007081	chr14:51645492	G/A	cg23942311	chr14:51606299	NA	0.61	5.28	0.39	4.45e-7	Cancer;
PAAD	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg17812751	chr4:3478348	DOK7	0.45	4.94	0.37	2.01e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg18898632	chr2:242989856	NA	-0.73	-5.78	-0.42	4.16e-8	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03316107	chr7:5085477	RBAK	0.69	7.65	0.53	2.19e-12	Myopia (pathological);
PAAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	7.97	0.54	3.58e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs17157884	chr10:46015942	C/T	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6466055	0.661	rs6942483	chr7:104950161	T/A	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23708337	chr7:1209742	NA	0.64	4.46	0.34	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	5.04	0.38	1.31e-6	Educational attainment;
PAAD	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg06002616	chr8:101225028	SPAG1	0.48	5.69	0.42	6.48e-8	Atrioventricular conduction;
PAAD	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.47	-4.6	-0.35	8.94e-6	Birth weight;
PAAD	cis	rs593531	0.513	rs3867268	chr11:74033377	A/C	cg15670924	chr11:73669256	DNAJB13	0.45	4.94	0.37	2.01e-6	Neuroticism;
PAAD	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.62	6.55	0.47	8.42e-10	Mean platelet volume;
PAAD	cis	rs9810890	1.000	rs73198828	chr3:128489894	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.73	-7.01	-0.49	7.25e-11	QRS duration;
PAAD	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	8.65	0.57	6.99e-15	Multiple sclerosis;
PAAD	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.59	-8.2	-0.55	9.41e-14	Primary biliary cholangitis;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	8.64	0.57	7.38e-15	Lymphocyte counts;
PAAD	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.61	5.36	0.4	2.97e-7	Sudden cardiac arrest;
PAAD	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg25319279	chr11:5960081	NA	0.46	4.8	0.36	3.73e-6	DNA methylation (variation);
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.62	5.84	0.43	3.02e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.1	-0.38	1.02e-6	Life satisfaction;
PAAD	cis	rs6494488	0.500	rs72744715	chr15:65016145	G/C	cg16425858	chr15:64791681	ZNF609	1.01	4.73	0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.87	7.67	0.53	1.93e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs13242816	1.000	rs12669740	chr7:116138576	T/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs12760731	0.720	rs12048459	chr1:178412702	T/C	cg00404053	chr1:178313656	RASAL2	0.68	5.15	0.39	7.88e-7	Obesity-related traits;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg05341575	chr12:125625032	AACS	-0.57	-5.4	-0.4	2.49e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.5	4.85	0.37	2.99e-6	Parkinson's disease;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.8	-8.65	-0.57	6.84e-15	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18002905	chr4:8442565	ACOX3	0.59	6.41	0.46	1.74e-9	Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.25	0.33	3.65e-5	Iron status biomarkers;
PAAD	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.24	8.04	0.55	2.33e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1322639	0.550	rs9505943	chr6:169592919	C/T	cg04662567	chr6:169592167	NA	-0.45	-4.68	-0.35	6.32e-6	Pulse pressure;
PAAD	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg27565382	chr3:53032988	SFMBT1	0.72	4.31	0.33	2.96e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.82e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.08	16.71	0.8	3.03e-36	Height;
PAAD	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.71	7.31	0.51	1.43e-11	Alcohol dependence;
PAAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.4	-0.4	2.49e-7	Obesity-related traits;
PAAD	cis	rs13011075	0.535	rs13028971	chr2:68630038	A/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg22431228	chr1:16359049	CLCNKA	-0.44	-5.38	-0.4	2.76e-7	Dilated cardiomyopathy;
PAAD	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.58	0.35	9.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.83	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.35	-0.33	2.53e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg05697835	chr1:2722811	NA	0.37	4.29	0.33	3.14e-5	Ulcerative colitis;
PAAD	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.41	-0.34	1.98e-5	IgG glycosylation;
PAAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.72e-5	Skin colour saturation;
PAAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs89107	0.688	rs283082	chr6:118605441	A/C	cg21191810	chr6:118973309	C6orf204	0.44	6.29	0.45	3.13e-9	Cardiac structure and function;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18621852	chr3:10150065	C3orf24	0.7	5.93	0.43	1.99e-8	Alzheimer's disease;
PAAD	cis	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg16606324	chr3:10149918	C3orf24	0.61	4.68	0.35	6.29e-6	Alzheimer's disease;
PAAD	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg01620082	chr3:125678407	NA	-1.25	-7.51	-0.52	4.72e-12	Lung cancer in ever smokers;
PAAD	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg24747557	chr10:131355152	MGMT	0.57	5.52	0.41	1.44e-7	Response to temozolomide;
PAAD	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.7	-7.4	-0.51	8.83e-12	Leprosy;
PAAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.31	0.46	2.88e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg10621924	chr7:39171070	POU6F2	0.27	4.52	0.34	1.24e-5	IgG glycosylation;
PAAD	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.66	-0.42	7.26e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09068198	chr2:65357064	RAB1A	0.59	6.72	0.48	3.42e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.52	5.36	0.4	3.02e-7	Menopause (age at onset);
PAAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg23281280	chr6:28129359	ZNF389	0.52	4.63	0.35	7.7e-6	Parkinson's disease;
PAAD	cis	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.29	-0.33	3.17e-5	Eotaxin levels;
PAAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg20917491	chr3:195578259	NA	0.53	4.98	0.37	1.72e-6	Pancreatic cancer;
PAAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg06740227	chr12:86229804	RASSF9	0.49	4.44	0.34	1.73e-5	Major depressive disorder;
PAAD	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg04896959	chr15:78267971	NA	-0.5	-4.43	-0.34	1.82e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg06618935	chr21:46677482	NA	-0.54	-6.74	-0.48	3.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2657888	0.628	rs2638335	chr12:56880672	C/T	cg23002907	chr12:56915593	RBMS2	-0.46	-4.44	-0.34	1.72e-5	Adiponectin levels;
PAAD	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg07541023	chr7:19748670	TWISTNB	0.65	4.56	0.35	1.04e-5	Thyroid stimulating hormone;
PAAD	cis	rs1469170	0.571	rs1014463	chr11:110736616	T/C	cg10131836	chr11:111167086	C11orf92	0.52	4.27	0.33	3.42e-5	Malaria;
PAAD	cis	rs4704187	0.687	rs2161371	chr5:74520275	T/A	cg03227963	chr5:74354835	NA	0.52	5.0	0.38	1.59e-6	Response to amphetamines;
PAAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.86	0.66	1.1e-20	Smoking behavior;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02664216	chr12:19592651	AEBP2	0.67	7.49	0.52	5.19e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg07703079	chr11:430292	ANO9	0.77	4.43	0.34	1.82e-5	Body mass index;
PAAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00982548	chr2:198649783	BOLL	-0.82	-5.91	-0.43	2.16e-8	Ulcerative colitis;
PAAD	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg04545296	chr12:48745243	ZNF641	0.36	4.61	0.35	8.42e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg19949948	chr17:19361230	NA	0.45	4.6	0.35	8.66e-6	Schizophrenia;
PAAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	Trans fatty acid levels;
PAAD	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.93	-9.94	-0.63	2.96e-18	Cognitive test performance;
PAAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.02e-6	Diastolic blood pressure;
PAAD	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.26	-14.12	-0.75	1.85e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs2567992	1.000	rs11065497	chr12:121662370	A/C	cg26872792	chr12:120763815	PLA2G1B	-0.72	-4.42	-0.34	1.86e-5	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-5.77	-0.42	4.37e-8	Colorectal cancer;
PAAD	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05483131	chr10:327612	DIP2C	0.55	6.61	0.47	6.26e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04829746	chr11:58346531	LPXN;ZFP91-CNTF;ZFP91	0.6	7.33	0.51	1.24e-11	Monocyte percentage of white cells;
PAAD	cis	rs8027181	0.682	rs890354	chr15:73100924	C/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.54	5.06	0.38	1.22e-6	Triglyceride levels;
PAAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.28	0.45	3.38e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg08079166	chr15:68083412	MAP2K5	-0.55	-4.36	-0.33	2.4e-5	Motion sickness;
PAAD	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.83	-0.58	2.29e-15	Depression;
PAAD	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.58	4.66	0.35	6.86e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07355551	chr20:2489285	ZNF343	0.58	6.32	0.46	2.74e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-6.72	-0.48	3.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.76	-7.22	-0.51	2.3e-11	Breast cancer;
PAAD	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs965469	0.779	rs2236109	chr20:3286439	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs6750047	0.549	rs151096	chr2:38316571	A/C	cg19753864	chr2:38320028	NA	-0.44	-4.96	-0.37	1.87e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs2790216	0.950	rs2590316	chr10:59987439	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg00934597	chr7:893267	UNC84A	-0.48	-4.4	-0.34	2e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27141345	chr16:29816675	MAZ;KIF22	0.6	6.87	0.49	1.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.95	10.22	0.64	5.59e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.85	-9.18	-0.6	2.97e-16	Colorectal cancer;
PAAD	cis	rs73058052	0.531	rs3745475	chr19:50100295	A/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.54	-4.69	-0.36	5.99e-6	Fibrinogen levels;
PAAD	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs6715793	0.869	rs2061027	chr2:33434336	A/G	cg26672287	chr2:33391915	LTBP1	-0.4	-4.63	-0.35	7.9e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	trans	rs901683	1.000	rs12776336	chr10:46063911	G/C	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg02696790	chr15:75250997	RPP25	0.47	5.57	0.41	1.1e-7	Caffeine consumption;
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.76	4.41	0.34	1.95e-5	Body mass index;
PAAD	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.23	9.84	0.62	5.51e-18	Alzheimer's disease (late onset);
PAAD	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03627880	chr6:151815985	C6orf97	-0.51	-4.59	-0.35	9.15e-6	Menarche (age at onset);
PAAD	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg00105475	chr2:10696890	NA	0.64	6.71	0.48	3.57e-10	Prostate cancer;
PAAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.54	8.37	0.56	3.41e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.51	4.72	0.36	5.2e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.05	-0.44	1.06e-8	Diastolic blood pressure;
PAAD	cis	rs282587	0.597	rs408247	chr13:113405738	C/A	cg19217778	chr13:113420270	ATP11A	-0.54	-4.28	-0.33	3.26e-5	Glycated hemoglobin levels;
PAAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.67	-8.06	-0.55	2.08e-13	Huntington's disease progression;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg26279152	chr13:20356101	PSPC1	-0.63	-6.65	-0.47	5.05e-10	Educational attainment;Educational attainment (years of education);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg11748417	chr20:18548094	LOC388789	-0.64	-6.66	-0.48	4.6e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.26	0.39	4.79e-7	Schizophrenia;
PAAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.68	4.96	0.37	1.87e-6	Fat distribution (HIV);
PAAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg16928487	chr17:17741425	SREBF1	-0.31	-4.27	-0.33	3.44e-5	Total body bone mineral density;
PAAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg17633681	chr16:88106987	BANP	0.62	7.94	0.54	4.16e-13	Menopause (age at onset);
PAAD	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.45e-8	Prudent dietary pattern;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.17	0.5	3.09e-11	Renal function-related traits (BUN);
PAAD	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	5.98	0.44	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.62	-6.07	-0.44	9.74e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg18078305	chr2:65215753	SLC1A4	-0.64	-6.57	-0.47	7.48e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs929596	0.667	rs7567229	chr2:234612539	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-6.2	-0.45	5.19e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.4	0.46	1.83e-9	Lung cancer in ever smokers;
PAAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg17644776	chr2:200775616	C2orf69	0.64	5.85	0.43	2.88e-8	Schizophrenia;
PAAD	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.1	0.63	1.14e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.69	-4.64	-0.35	7.51e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.72	-8.45	-0.57	2.18e-14	Diastolic blood pressure;
PAAD	cis	rs860295	0.506	rs3020781	chr1:155269776	A/G	cg02153340	chr1:155202674	NA	-0.53	-4.81	-0.36	3.6e-6	Body mass index;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg00522288	chr12:125625016	AACS	-0.53	-5.52	-0.41	1.44e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.51	-4.59	-0.35	9.21e-6	Lung cancer;
PAAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg13468214	chr4:1046988	NA	-0.55	-5.96	-0.44	1.68e-8	Recombination rate (males);
PAAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.61	-6.88	-0.49	1.47e-10	Huntington's disease progression;
PAAD	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.67	6.78	0.48	2.46e-10	Coronary artery disease;
PAAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.55	6.7	0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-5.14	-0.38	8.47e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07908229	chr1:182353640	GLUL	-0.58	-6.5	-0.47	1.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg26497354	chr6:109612229	NA	-0.44	-4.48	-0.34	1.48e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg13468214	chr4:1046988	NA	0.53	5.73	0.42	5.34e-8	Recombination rate (males);
PAAD	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	1.04	13.89	0.75	7.87e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-6.17	-0.45	5.8e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg20673091	chr1:2541236	MMEL1	0.74	7.84	0.54	7.51e-13	Ulcerative colitis;
PAAD	cis	rs12311304	1.000	rs56232194	chr12:15383683	G/C	cg08258403	chr12:15378311	NA	0.37	4.69	0.36	6.08e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.46	5.69	0.42	6.35e-8	Body mass index in non-asthmatics;
PAAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg26939375	chr7:64535504	NA	0.53	5.89	0.43	2.44e-8	Aortic root size;
PAAD	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.86e-9	Lung cancer;
PAAD	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.6	5.83	0.43	3.19e-8	Coronary artery disease;
PAAD	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.56	6.08	0.44	9.47e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs62025270	0.688	rs62022941	chr15:86256055	G/A	cg13263323	chr15:86062960	AKAP13	0.48	4.38	0.33	2.21e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg06484146	chr7:12443880	VWDE	-0.64	-4.51	-0.34	1.28e-5	Coronary artery disease;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.65	-0.47	5.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.67	5.49	0.41	1.64e-7	Prostate cancer;
PAAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg12639453	chr1:2035780	PRKCZ	-0.55	-5.98	-0.44	1.54e-8	Height;
PAAD	trans	rs4864201	0.560	rs2952867	chr4:130766024	A/G	cg08471972	chr13:51844375	FAM124A	-0.55	-6.48	-0.47	1.23e-9	Obesity;
PAAD	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.88	7.16	0.5	3.19e-11	Chronic kidney disease;
PAAD	cis	rs288326	0.561	rs75848966	chr2:183878093	A/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.88	-0.43	2.5e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.27e-15	Emphysema distribution in smoking;
PAAD	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg02683114	chr2:24398427	C2orf84	-0.55	-5.65	-0.42	7.52e-8	Asthma;
PAAD	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg10483660	chr13:112241077	NA	0.67	6.83	0.48	1.87e-10	Menarche (age at onset);
PAAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.63e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7172971	0.688	rs7166789	chr15:42382778	T/C	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-8.47	-0.57	1.94e-14	Response to antipsychotic treatment;
PAAD	cis	rs787274	0.764	rs1891402	chr9:115567184	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.48	-0.34	1.48e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.92	11.03	0.67	3.86e-21	Longevity;
PAAD	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.79	-0.36	3.93e-6	Hirschsprung disease;
PAAD	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg08345082	chr10:99160200	RRP12	-0.31	-4.46	-0.34	1.58e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.52	5.28	0.39	4.45e-7	Bladder cancer;
PAAD	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.51	-4.49	-0.34	1.41e-5	Dental caries;
PAAD	cis	rs2885056	0.891	rs1821282	chr19:10692714	G/T	cg06392426	chr19:10676186	KRI1	0.53	5.22	0.39	5.74e-7	Red cell distribution width;
PAAD	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg06217245	chr20:33103252	DYNLRB1	0.43	4.37	0.33	2.25e-5	Skin pigmentation;
PAAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg21698718	chr17:80085957	CCDC57	0.41	4.44	0.34	1.74e-5	Life satisfaction;
PAAD	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	1.17	18.08	0.83	1.03e-39	Gut microbiome composition (winter);
PAAD	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	14.09	0.75	2.29e-29	Colorectal cancer;
PAAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	cis	rs9900972	1.000	rs9900972	chr17:76868614	A/G	cg00961940	chr17:76876995	TIMP2	0.54	5.1	0.38	9.94e-7	Obesity-related traits;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.98	6.74	0.48	3.02e-10	IgG glycosylation;
PAAD	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg04398451	chr17:18023971	MYO15A	0.51	4.76	0.36	4.41e-6	Lymphocyte counts;
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.75	0.48	2.99e-10	Systemic lupus erythematosus;
PAAD	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg21253087	chr9:139290292	SNAPC4	0.43	4.48	0.34	1.45e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg26205652	chr12:48591994	NA	0.93	9.13	0.6	4.03e-16	Longevity (90 years and older);
PAAD	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.41	0.46	1.77e-9	Leprosy;
PAAD	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg11266682	chr4:10021025	SLC2A9	0.63	5.29	0.39	4.16e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg01851573	chr8:8652454	MFHAS1	0.54	4.52	0.34	1.22e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-4.46	-0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs7567389	0.671	rs11692990	chr2:128112190	C/T	cg11380483	chr2:127933992	NA	0.45	4.52	0.34	1.24e-5	Self-rated health;
PAAD	cis	rs2834902	0.605	rs35080435	chr21:36683647	G/A	cg04915566	chr21:36421472	RUNX1	-0.33	-4.49	-0.34	1.38e-5	Corneal curvature;
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.19	0.39	6.71e-7	Obesity-related traits;
PAAD	cis	rs6539288	0.901	rs11113143	chr12:107303859	T/A	cg16260113	chr12:107380972	MTERFD3	0.43	4.64	0.35	7.32e-6	Total body bone mineral density;
PAAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg10018233	chr7:150070692	REPIN1	0.58	6.2	0.45	5e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.71	7.98	0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26094470	chr10:75187383	ZMYND17	-0.71	-6.85	-0.49	1.71e-10	Obesity-related traits;
PAAD	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.3	0.33	2.99e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.14	0.55	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.4e-10	Lung cancer;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg04520793	chr17:42248056	ASB16	0.46	6.04	0.44	1.13e-8	Total body bone mineral density;
PAAD	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	6.19	0.45	5.39e-9	Mean platelet volume;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-7.88	-0.54	5.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-4.94	-0.37	2e-6	Schizophrenia;
PAAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.74	7.08	0.5	5.11e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.66	-0.62	1.62e-17	Height;
PAAD	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.94	7.72	0.53	1.42e-12	Vitiligo;
PAAD	cis	rs151997	0.962	rs27476	chr5:50178160	A/T	cg06027927	chr5:50259733	NA	-0.79	-7.91	-0.54	4.96e-13	Callous-unemotional behaviour;
PAAD	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg15412446	chr2:106886593	NA	-0.66	-4.41	-0.34	1.92e-5	Facial morphology (factor 23);
PAAD	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg15017067	chr4:17643749	FAM184B	0.43	4.69	0.36	5.95e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7189233	1.000	rs62048520	chr16:53491095	C/A	cg00221382	chr16:54322308	NA	-0.28	-4.34	-0.33	2.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7567389	0.671	rs11692990	chr2:128112190	C/T	cg09760422	chr2:128146352	NA	0.38	5.96	0.44	1.65e-8	Self-rated health;
PAAD	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs4930776	0.808	rs416128	chr12:5752494	A/G	cg06629086	chr12:6715057	CHD4	0.51	4.71	0.36	5.45e-6	Plasma clusterin levels;
PAAD	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.55	4.43	0.34	1.8e-5	Bone mineral density (spine);
PAAD	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.67	-6.03	-0.44	1.21e-8	Mortality in heart failure;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01585852	chr22:24235823	MIF	-0.47	-5.01	-0.38	1.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-5.16	-0.39	7.56e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.76	0.42	4.57e-8	Eosinophil percentage of white cells;
PAAD	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.96	-9.59	-0.61	2.48e-17	Monocyte percentage of white cells;
PAAD	cis	rs12620999	0.887	rs6723783	chr2:237963572	C/A	cg23555395	chr2:238036564	NA	0.42	4.75	0.36	4.62e-6	Systemic lupus erythematosus;
PAAD	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.53	-5.33	-0.4	3.56e-7	Mortality in heart failure;
PAAD	cis	rs757081	0.648	rs1488933	chr11:17267029	C/T	cg04705435	chr11:17411270	KCNJ11	-0.54	-5.4	-0.4	2.5e-7	Systolic blood pressure;
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.68	-6.6	-0.47	6.6e-10	Total body bone mineral density;
PAAD	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.16	-0.39	7.46e-7	Blood metabolite levels;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg08926642	chr1:7887455	PER3	0.54	4.45	0.34	1.67e-5	Inflammatory bowel disease;
PAAD	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.56	-4.8	-0.36	3.8e-6	Obesity-related traits;
PAAD	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.76	-8.57	-0.57	1.06e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.31	0.4	3.78e-7	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.63	9.11	0.59	4.42e-16	Breast cancer;
PAAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs11264799	0.603	rs10489674	chr1:157566019	G/A	cg18268488	chr1:157545234	FCRL4	0.46	5.34	0.4	3.35e-7	IgA nephropathy;
PAAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs9888739	1.000	rs73534420	chr16:31311374	G/T	cg02256631	chr16:31342952	ITGAM	-0.53	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg20673091	chr1:2541236	MMEL1	0.73	7.75	0.53	1.24e-12	Ulcerative colitis;
PAAD	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.69	5.6	0.41	9.68e-8	Mammographic density (dense area);
PAAD	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	4.91	0.37	2.34e-6	Neuroticism;
PAAD	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.88	8.71	0.58	4.8e-15	Multiple myeloma;
PAAD	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.51	4.85	0.37	3.05e-6	Migraine;
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.27	0.45	3.64e-9	Lung cancer;
PAAD	cis	rs7552393	0.585	rs6676587	chr1:84276429	C/T	cg10977910	chr1:84465055	TTLL7	-0.6	-5.76	-0.42	4.48e-8	Select biomarker traits;
PAAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.68	7.45	0.52	6.37e-12	Aortic root size;
PAAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.7	6.72	0.48	3.42e-10	Parkinson's disease;
PAAD	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	7.37	0.51	1.02e-11	Chronic sinus infection;
PAAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.78	-0.36	4.17e-6	Parkinson's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15777910	chr17:3488907	TRPV1	0.53	6.41	0.46	1.74e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.86	8.44	0.56	2.37e-14	Vitamin D levels;
PAAD	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg07395648	chr5:131743802	NA	-0.53	-4.45	-0.34	1.68e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	4.93	0.37	2.17e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3734905	1.000	rs77336201	chr6:169942337	T/G	cg11181693	chr6:169825345	NA	-0.89	-5.32	-0.4	3.68e-7	HIV-1 control;
PAAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.41	5.54	0.41	1.32e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.44	4.78	0.36	4.15e-6	Post-traumatic stress disorder;
PAAD	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-10.46	-0.65	1.28e-19	Dental caries;
PAAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	5.7	0.42	6.14e-8	Lung cancer;
PAAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.62	8.09	0.55	1.71e-13	Renal cell carcinoma;
PAAD	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.28	-0.39	4.42e-7	Height;
PAAD	trans	rs687432	0.688	rs12788387	chr11:57893347	A/C	cg17345188	chr11:109964581	ZC3H12C	-0.62	-7.46	-0.52	6.15e-12	Parkinson's disease;
PAAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg03983715	chr16:68378420	PRMT7	-0.82	-6.1	-0.44	8.61e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28489187	0.706	rs233062	chr1:85800385	T/G	cg16011679	chr1:85725395	C1orf52	0.53	4.97	0.37	1.8e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-5.4	-0.4	2.48e-7	Bone mineral density;
PAAD	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg14146966	chr2:61757674	XPO1	0.36	4.61	0.35	8.35e-6	Tuberculosis;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-5.28	-0.39	4.44e-7	Obesity-related traits;
PAAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.67	-7.97	-0.54	3.51e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.44	0.65	1.42e-19	Cannabis dependence symptom count;
PAAD	cis	rs2662368	0.522	rs254392	chr5:77088594	A/G	cg16293892	chr5:77142620	NA	-0.5	-4.83	-0.37	3.25e-6	Platelet distribution width;
PAAD	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	6.02	0.44	1.29e-8	Hip circumference;
PAAD	cis	rs6893807	0.778	rs1501672	chr5:87963761	A/G	cg02225085	chr5:87975992	LOC645323	-0.71	-5.28	-0.39	4.44e-7	Body mass index;
PAAD	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.82	8.41	0.56	2.8e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-1.13	-16.98	-0.81	6.35e-37	Breast cancer;
PAAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	6.29	0.45	3.16e-9	Initial pursuit acceleration;
PAAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.84e-8	Personality dimensions;
PAAD	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.59	-5.95	-0.43	1.74e-8	Monocyte count;
PAAD	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg19192590	chr2:178524533	PDE11A	0.39	4.49	0.34	1.41e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	5.0	0.38	1.55e-6	Mean platelet volume;
PAAD	cis	rs11105468	0.660	rs10858946	chr12:90444042	A/C	cg16962463	chr12:89968675	NA	0.45	4.74	0.36	4.89e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg20893579	chr22:38215064	NA	0.51	5.08	0.38	1.08e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs654384	0.507	rs4723420	chr7:4174889	A/T	cg27574739	chr7:4176374	SDK1	-0.48	-4.56	-0.35	1.03e-5	Positive affect;
PAAD	cis	rs9810890	0.850	rs1466572	chr3:128543415	T/A	cg19129842	chr3:128565090	NA	-0.87	-5.16	-0.39	7.67e-7	Dental caries;
PAAD	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.75	-0.53	1.19e-12	Hemoglobin concentration;
PAAD	cis	rs939584	0.825	rs13028252	chr2:632529	T/C	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21564660	chr12:50236950	BCDIN3D	0.61	6.78	0.48	2.52e-10	Myopia (pathological);
PAAD	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.48	-4.37	-0.33	2.29e-5	Tuberculosis;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.38	0.76	3.75e-30	Headache;
PAAD	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg24296786	chr1:45957014	TESK2	0.54	5.06	0.38	1.22e-6	Homocysteine levels;
PAAD	cis	rs2734839	0.964	rs12364051	chr11:113305314	A/G	cg14159747	chr11:113255604	NA	0.45	6.73	0.48	3.29e-10	Information processing speed;
PAAD	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.87	-8.72	-0.58	4.65e-15	Breast cancer;
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.45	-0.34	1.65e-5	Tonsillectomy;
PAAD	cis	rs4787491	0.704	rs67218159	chr16:30050505	C/T	cg06015834	chr16:30021696	DOC2A	-0.41	-4.41	-0.34	1.92e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4388249	0.687	rs2301017	chr5:109199397	G/C	cg17395555	chr5:108820864	NA	0.3	4.28	0.33	3.35e-5	Schizophrenia;
PAAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.78	0.42	4.03e-8	Eosinophil percentage of white cells;
PAAD	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.6	5.4	0.4	2.5e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7547997	0.615	rs35752748	chr1:158321565	A/C	cg26014409	chr1:158324471	CD1E	0.35	4.39	0.34	2.11e-5	QRS duration;
PAAD	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.56	4.85	0.37	2.96e-6	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.94	0.49	1.03e-10	Triglycerides;
PAAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3026101	0.624	rs1806219	chr17:5288073	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.67	0.42	7.11e-8	Body mass index;
PAAD	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.5	-5.33	-0.4	3.55e-7	Menopause (age at onset);
PAAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.37	0.64	2.17e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11825064	0.774	rs2000861	chr11:134496258	A/G	cg06603561	chr11:134479413	NA	-0.89	-6.21	-0.45	4.92e-9	Seasonality;
PAAD	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.57	-0.41	1.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg04717802	chr22:42394638	WBP2NL	0.55	4.49	0.34	1.38e-5	Birth weight;
PAAD	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.07	-0.38	1.12e-6	Reticulocyte count;
PAAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.06	-0.44	1.01e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6676180	0.555	rs12060730	chr1:119770702	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-4.66	-0.35	6.88e-6	Monobrow;
PAAD	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	9.93	0.63	3.27e-18	Cognitive test performance;
PAAD	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.46	4.43	0.34	1.8e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.85	0.49	1.71e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6519955	0.755	rs8135712	chr22:46425388	T/C	cg05468064	chr22:46423449	NA	0.55	6.84	0.49	1.82e-10	Dupuytren's disease;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.86	7.41	0.51	8.38e-12	Alzheimer's disease;
PAAD	cis	rs642743	0.967	rs789208	chr10:105935096	A/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.43	0.34	1.81e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4513299	0.562	rs3105507	chr2:115004332	C/G	cg12978357	chr2:114426529	NA	-0.44	-4.34	-0.33	2.6e-5	Inflammatory biomarkers;
PAAD	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.68	7.45	0.52	6.55e-12	Menopause (age at onset);
PAAD	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs6499755	1.000	rs6499755	chr16:55341135	T/C	cg02859129	chr16:55357253	IRX6	0.34	4.55	0.35	1.07e-5	Hypospadias;
PAAD	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.97	-6.4	-0.46	1.85e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.78	0.58	3.1e-15	Colorectal cancer;
PAAD	cis	rs8005677	0.828	rs57822749	chr14:23409967	G/A	cg01529538	chr14:23388837	RBM23	0.48	4.72	0.36	5.29e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.41	-5.96	-0.44	1.7e-8	Subjective well-being;
PAAD	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-1.08	-6.88	-0.49	1.49e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs11208691	0.513	rs11208698	chr1:66131238	G/A	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg12623918	chr2:306882	NA	0.6	4.53	0.34	1.19e-5	Blood protein levels;
PAAD	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg16606324	chr3:10149918	C3orf24	0.62	4.27	0.33	3.39e-5	Alzheimer's disease;
PAAD	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg09127314	chr1:152161683	NA	-0.62	-4.29	-0.33	3.2e-5	Atopic dermatitis;
PAAD	cis	rs2652822	0.710	rs56208666	chr15:63451858	T/G	cg02713581	chr15:63449717	RPS27L	0.5	4.73	0.36	5.14e-6	Metabolic traits;
PAAD	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7243821	1.000	rs11661669	chr18:52642981	G/A	cg16669619	chr18:52630472	NA	-0.44	-4.49	-0.34	1.38e-5	Chin dimples;
PAAD	cis	rs7714584	1.000	rs80075680	chr5:150223737	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.85	9.94	0.63	3.06e-18	Metabolic syndrome;
PAAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.77	-8.58	-0.57	1.03e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.99	11.62	0.69	9.53e-23	Breast cancer;
PAAD	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg05555928	chr11:63887634	MACROD1	0.55	5.33	0.4	3.54e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg07978099	chr16:83986941	OSGIN1	-0.58	-5.02	-0.38	1.42e-6	Pursuit maintenance gain;
PAAD	cis	rs12935418	0.616	rs9931292	chr16:81009568	C/G	cg16651780	chr16:81037892	C16orf61	0.65	6.03	0.44	1.22e-8	Mean corpuscular volume;
PAAD	cis	rs1545257	0.550	rs66943245	chr2:24631075	G/A	cg06627628	chr2:24431161	ITSN2	-0.59	-5.76	-0.42	4.48e-8	Sjögren's syndrome;
PAAD	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg07469887	chr10:131262384	NA	-0.4	-4.34	-0.33	2.56e-5	Response to temozolomide;
PAAD	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.49	4.45	0.34	1.66e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg21419209	chr3:44054225	NA	-0.71	-7.28	-0.51	1.66e-11	Coronary artery disease;
PAAD	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg04775059	chr7:64541387	NA	0.57	5.92	0.43	2.08e-8	Calcium levels;
PAAD	cis	rs3736757	0.935	rs7523023	chr1:184675285	A/C	cg05045817	chr1:184633523	NA	0.42	4.55	0.35	1.1e-5	Obesity-related traits;
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg10207240	chr12:122356781	WDR66	-0.48	-4.98	-0.37	1.74e-6	Mean corpuscular volume;
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.39	0.4	2.68e-7	Total body bone mineral density;
PAAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.81	-0.36	3.63e-6	Fibrinogen levels;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.68	-7.72	-0.53	1.46e-12	Iron status biomarkers;
PAAD	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-5.65	-0.42	7.71e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg10437265	chr15:77819839	NA	-0.39	-4.52	-0.34	1.26e-5	Type 2 diabetes;
PAAD	cis	rs7582720	1.000	rs72934535	chr2:203968973	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.0	5.7	0.42	6.19e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.52	5.06	0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	10.46	0.65	1.26e-19	Nonalcoholic fatty liver disease;
PAAD	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.98	8.22	0.55	8.53e-14	Neutrophil percentage of white cells;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.54	-5.54	-0.41	1.28e-7	Testicular germ cell tumor;
PAAD	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.52	-6.08	-0.44	9.36e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	10.09	0.63	1.21e-18	IgG glycosylation;
PAAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg08934286	chr12:123463762	ARL6IP4;OGFOD2	-0.41	-4.26	-0.33	3.62e-5	Platelet count;
PAAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26850624	chr5:429559	AHRR	0.44	5.56	0.41	1.17e-7	Cystic fibrosis severity;
PAAD	cis	rs17155006	0.746	rs366690	chr7:107749880	T/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.12	0.5	4.09e-11	Lung cancer in ever smokers;
PAAD	trans	rs2817937	1.000	rs2789067	chr6:121100486	G/C	cg22125214	chr7:135612081	LUZP6;MTPN	-1.11	-6.59	-0.47	6.98e-10	Primary tooth development (number of teeth);
PAAD	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.62	6.24	0.45	4.21e-9	Schizophrenia;
PAAD	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.81	6.8	0.48	2.26e-10	Cancer;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02071572	chr4:1403502	NA	0.48	6.17	0.45	5.97e-9	Longevity;
PAAD	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	0.78	5.27	0.39	4.7e-7	Body mass index;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg10729496	chr3:10149963	C3orf24	0.83	7.14	0.5	3.57e-11	Alzheimer's disease;
PAAD	cis	rs1925576	0.905	rs1925587	chr10:68660105	C/T	cg04444303	chr10:69634106	NA	-0.45	-4.52	-0.34	1.23e-5	Educational attainment (years of education);
PAAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg14343924	chr8:8086146	FLJ10661	0.54	4.64	0.35	7.39e-6	Mood instability;
PAAD	cis	rs12304921	0.683	rs56335028	chr12:51441680	G/T	cg18059802	chr12:51347058	HIGD1C	-0.72	-5.59	-0.41	1.01e-7	Type 2 diabetes;
PAAD	cis	rs3736485	0.934	rs28410165	chr15:51875019	C/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.47	-4.26	-0.33	3.64e-5	Response to temozolomide;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06492813	chr6:56301992	NA	0.76	7.52	0.52	4.55e-12	Neuroticism;
PAAD	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg03037974	chr15:76606532	NA	0.51	5.56	0.41	1.21e-7	Blood metabolite levels;
PAAD	cis	rs1879734	0.689	rs6673378	chr1:54160812	G/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg14393609	chr7:65229607	NA	0.48	4.85	0.37	3e-6	Aortic root size;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05462328	chr2:172963910	NA	0.63	6.61	0.47	6.14e-10	Myopia (pathological);
PAAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg00988841	chr10:134556463	INPP5A	0.5	4.61	0.35	8.4e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg23887609	chr12:130822674	PIWIL1	-0.62	-6.77	-0.48	2.69e-10	Menopause (age at onset);
PAAD	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.27	-0.33	3.37e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25616573	chr4:156684300	GUCY1B3	-0.66	-6.65	-0.47	4.84e-10	Obesity-related traits;
PAAD	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05491587	chr18:77659695	KCNG2	-0.73	-4.25	-0.33	3.71e-5	Opioid sensitivity;
PAAD	cis	rs939584	1.000	rs35913461	chr2:653575	C/T	cg03610516	chr2:642275	NA	-0.62	-5.35	-0.4	3.18e-7	Body mass index;
PAAD	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg07741184	chr6:167504864	NA	-0.4	-4.86	-0.37	2.86e-6	Graves' disease;
PAAD	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Bladder cancer;
PAAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.99	9.36	0.6	1.01e-16	Corneal structure;
PAAD	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg26031613	chr14:104095156	KLC1	0.48	5.32	0.4	3.63e-7	Schizophrenia;
PAAD	cis	rs939584	0.867	rs74832795	chr2:632592	G/A	cg14515364	chr2:636606	NA	0.53	4.82	0.36	3.46e-6	Body mass index;
PAAD	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs7922314	0.571	rs16917961	chr10:64721008	C/G	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.75	5.31	0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs10850408	0.844	rs7972038	chr12:115352977	C/T	cg05726002	chr12:115341178	NA	-0.44	-5.36	-0.4	3.08e-7	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.42	5.56	0.41	1.2e-7	Ulcerative colitis;
PAAD	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg11262906	chr1:85462892	MCOLN2	0.66	4.93	0.37	2.18e-6	Serum sulfate level;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.71	-5.88	-0.43	2.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	5.4	0.4	2.46e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.42	-0.34	1.89e-5	Vitiligo;
PAAD	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.89	-0.58	1.65e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	1.0	12.79	0.72	6.97e-26	Breast cancer;
PAAD	cis	rs17152411	0.652	rs1036676	chr10:126654184	A/G	cg07081759	chr10:126330905	FAM53B	-0.4	-4.41	-0.34	1.96e-5	Height;
PAAD	trans	rs62179067	0.708	rs12475463	chr2:179881971	T/A	cg21380341	chr12:94543978	PLXNC1	-0.65	-6.32	-0.46	2.75e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9487051	0.646	rs4548045	chr6:109576135	C/T	cg21918786	chr6:109611834	NA	-0.48	-4.96	-0.37	1.89e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12620999	0.887	rs10929214	chr2:238037436	C/G	cg23555395	chr2:238036564	NA	-0.53	-6.0	-0.44	1.42e-8	Systemic lupus erythematosus;
PAAD	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00570391	chr7:815417	HEATR2	0.63	7.61	0.53	2.67e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg16576597	chr16:28551801	NUPR1	-0.54	-5.09	-0.38	1.05e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	6.03	0.44	1.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.66	9.59	0.61	2.54e-17	Airflow obstruction;
PAAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg12215294	chr3:40350768	EIF1B	0.45	4.42	0.34	1.84e-5	Renal cell carcinoma;
PAAD	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-1.3	-8.45	-0.57	2.26e-14	Depression;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24465787	chr1:22109848	USP48	0.58	6.79	0.48	2.36e-10	Monocyte percentage of white cells;
PAAD	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.04	0.38	1.31e-6	Restless legs syndrome;
PAAD	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg13160058	chr8:26243215	BNIP3L	-0.39	-4.71	-0.36	5.51e-6	Red cell distribution width;
PAAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.16	-0.5	3.3e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1413885	0.516	rs3818449	chr1:65844963	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.85	0.43	2.91e-8	Anticoagulant levels;
PAAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.92	-0.37	2.24e-6	Neuroticism;
PAAD	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.68	7.39	0.51	9.34e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.73	0.42	5.35e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg22875332	chr1:76189707	ACADM	-0.47	-4.7	-0.36	5.79e-6	Daytime sleep phenotypes;
PAAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9463078	0.546	rs1284987	chr6:45063721	C/T	cg18551225	chr6:44695536	NA	0.42	4.37	0.33	2.28e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg10356904	chr22:49881777	NA	-0.49	-4.71	-0.36	5.55e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11077019	chr1:52520979	TXNDC12;BTF3L4	-0.74	-7.47	-0.52	5.85e-12	Lung cancer in ever smokers;
PAAD	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06850241	chr22:41845214	NA	-0.6	-5.23	-0.39	5.53e-7	Vitiligo;
PAAD	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.19	0.55	1.01e-13	Height;
PAAD	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.54	5.09	0.38	1.05e-6	Aortic root size;
PAAD	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-6.58	-0.47	7.02e-10	Coffee consumption (cups per day);
PAAD	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.02	-0.49	6.78e-11	Menarche (age at onset);
PAAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	1.11	10.15	0.64	8.29e-19	Initial pursuit acceleration;
PAAD	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	6.28	0.45	3.36e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27297192	chr10:134578999	INPP5A	0.58	5.56	0.41	1.18e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10792830	0.741	rs519778	chr11:85764693	T/C	cg07180834	chr11:85838833	NA	-0.48	-5.36	-0.4	3.09e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.86	5.83	0.43	3.27e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs300774	0.800	rs300732	chr2:166725	A/G	cg23649280	chr2:140451	NA	-0.47	-4.35	-0.33	2.5e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.69e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3762637	0.941	rs9810996	chr3:122074387	G/A	cg24169773	chr3:122142474	KPNA1	-0.64	-4.33	-0.33	2.66e-5	LDL cholesterol levels;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg08529186	chr19:42807008	PAFAH1B3;PRR19	-0.57	-6.35	-0.46	2.39e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.41	-6.2	-0.45	5.06e-9	Subjective well-being;
PAAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg12072164	chr19:44306565	LYPD5	0.48	5.02	0.38	1.43e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.52e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088813	0.961	rs981818	chr20:33924130	C/A	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05179757	chr22:25591042	KIAA1671	0.6	6.65	0.47	4.93e-10	Smoking initiation;
PAAD	cis	rs2421770	0.796	rs10768124	chr11:35304064	T/C	cg13971030	chr11:35366721	SLC1A2	-0.47	-5.63	-0.42	8.33e-8	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg13870426	chr17:30244630	NA	-0.76	-5.7	-0.42	5.96e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg12193833	chr17:30244370	NA	-0.57	-4.72	-0.36	5.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg10819733	chr22:24237672	NA	-0.59	-5.0	-0.38	1.55e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg10685839	chr11:66611485	RCE1	0.45	4.4	0.34	1.99e-5	Educational attainment (years of education);
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.93	12.29	0.71	1.57e-24	Menarche (age at onset);
PAAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	1.1	16.59	0.8	6.3e-36	Menarche (age at onset);
PAAD	cis	rs1797885	0.763	rs299649	chr3:12538719	T/C	cg07775309	chr3:12595852	NA	0.41	4.43	0.34	1.82e-5	Immature fraction of reticulocytes;
PAAD	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.87	6.46	0.46	1.33e-9	Axial length;
PAAD	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.58	6.03	0.44	1.17e-8	Personality dimensions;
PAAD	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.54	0.47	8.78e-10	Morning vs. evening chronotype;
PAAD	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.2	0.39	6.48e-7	Educational attainment;
PAAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.78	9.52	0.61	3.89e-17	Bone mineral density;
PAAD	cis	rs2290416	0.688	rs34892354	chr8:144690648	G/C	cg08017634	chr8:144659831	NAPRT1	0.9	7.2	0.5	2.61e-11	Attention deficit hyperactivity disorder;
PAAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg24733560	chr20:60626293	TAF4	0.43	5.17	0.39	7.31e-7	Body mass index;
PAAD	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.44	4.68	0.35	6.37e-6	Age of smoking initiation;
PAAD	cis	rs797680	0.964	rs1060622	chr1:93620393	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.43	0.34	1.77e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg02404636	chr22:31891804	SFI1	-0.6	-5.45	-0.4	1.98e-7	Colorectal cancer;
PAAD	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg26528668	chr16:1614120	IFT140	0.51	4.81	0.36	3.62e-6	Coronary artery disease;
PAAD	cis	rs7804356	0.734	rs13229947	chr7:26767430	T/C	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.28e-5	Type 1 diabetes;
PAAD	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.57	0.35	9.98e-6	Morning vs. evening chronotype;
PAAD	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg12700464	chr11:78128424	GAB2	-0.57	-4.32	-0.33	2.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs67385638	1.000	rs11036474	chr11:5275178	T/C	cg12559170	chr11:5275217	HBG2	0.51	4.85	0.37	2.99e-6	Hemoglobin levels;
PAAD	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.63	7.24	0.51	2.13e-11	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13975362	chr6:46890512	GPR116	-0.7	-7.06	-0.5	5.66e-11	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.48	-0.34	1.48e-5	Pulmonary function;
PAAD	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.74	0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.51	5.57	0.41	1.13e-7	Life satisfaction;
PAAD	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.54	4.85	0.37	3.02e-6	Anterior chamber depth;
PAAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15128208	chr22:42549153	NA	-0.47	-4.57	-0.35	9.86e-6	Cognitive function;
PAAD	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	0.75	5.12	0.38	8.92e-7	Body mass index;
PAAD	trans	rs927821	0.680	rs11597058	chr10:104201995	A/G	cg03343063	chr1:16023706	PLEKHM2	-0.5	-6.42	-0.46	1.68e-9	Social autistic-like traits;
PAAD	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.72	-0.36	5.3e-6	Joint mobility (Beighton score);
PAAD	cis	rs6074578	0.541	rs1080148	chr20:161450	G/A	cg16931068	chr20:139680	DEFB127	-0.4	-5.3	-0.39	4.02e-7	Hirschsprung disease;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.65	5.52	0.41	1.45e-7	Morning vs. evening chronotype;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg07703079	chr11:430292	ANO9	1.0	6.3	0.45	3.07e-9	Body mass index;
PAAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.42	-4.38	-0.34	2.16e-5	Blood protein levels;
PAAD	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.49	-4.87	-0.37	2.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg02869306	chr7:64672164	INTS4L1	-0.51	-6.14	-0.45	6.85e-9	Calcium levels;
PAAD	cis	rs6070	0.933	rs1354774	chr19:51393118	A/G	cg11738530	chr19:51047879	LRRC4B	0.42	4.4	0.34	2.03e-5	Prostate-specific antigen levels;Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs4795519	0.667	rs12943303	chr17:22187772	G/A	cg22648282	chr17:21454238	C17orf51	-0.53	-4.71	-0.36	5.43e-6	Chronic myeloid leukemia;
PAAD	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.62	5.47	0.41	1.79e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06910254	chr16:3185002	ZNF213	0.64	6.39	0.46	1.87e-9	Obesity-related traits;
PAAD	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.73e-11	Asthma;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.74	10.39	0.64	1.87e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.46	-4.97	-0.37	1.81e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.51	-5.05	-0.38	1.22e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg19847866	chr10:1019161	NA	0.61	4.92	0.37	2.19e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.51	4.76	0.36	4.5e-6	Breast cancer;
PAAD	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg02071572	chr4:1403502	NA	0.37	4.3	0.33	2.99e-5	Obesity-related traits;
PAAD	cis	rs7737355	0.773	rs3756290	chr5:130951750	A/G	cg06307176	chr5:131281290	NA	0.51	4.35	0.33	2.53e-5	Life satisfaction;
PAAD	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.62	-4.89	-0.37	2.56e-6	Corneal structure;
PAAD	cis	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.8	-0.36	3.73e-6	Eotaxin levels;
PAAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.73	-7.77	-0.53	1.07e-12	Calcium levels;
PAAD	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg06484146	chr7:12443880	VWDE	-0.61	-4.39	-0.34	2.08e-5	Coronary artery disease;
PAAD	cis	rs1941184	0.759	rs724482	chr18:29024737	A/G	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs9815354	0.830	rs1716983	chr3:41964128	G/A	cg03022575	chr3:42003672	ULK4	-0.81	-5.75	-0.42	4.81e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1419980	0.730	rs11054555	chr12:7727755	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.58	4.64	0.35	7.33e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg11764359	chr7:65958608	NA	-0.72	-4.74	-0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs1015291	0.680	rs1352903	chr12:19994758	A/G	cg25401612	chr12:20009446	NA	-0.54	-5.3	-0.39	4.05e-7	Diastolic blood pressure;
PAAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg12193833	chr17:30244370	NA	-0.61	-4.84	-0.37	3.23e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.88	0.49	1.49e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs863345	0.604	rs1873511	chr1:158461366	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.77	-0.53	1.09e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5753037	0.838	rs140145	chr22:30178305	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-4.42	-0.34	1.87e-5	Type 1 diabetes;
PAAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-6.79	-0.48	2.31e-10	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26405583	chr21:43236218	PRDM15	0.61	6.57	0.47	7.48e-10	Smoking initiation;
PAAD	cis	rs863345	0.604	rs11264984	chr1:158464990	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.83	8.1	0.55	1.7e-13	Corneal astigmatism;
PAAD	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-6.25	-0.45	3.97e-9	Schizophrenia;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	4.79	0.36	3.9e-6	Body mass index;
PAAD	cis	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg24053715	chr22:38214548	NA	0.5	5.21	0.39	6.09e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg24296786	chr1:45957014	TESK2	0.49	4.44	0.34	1.7e-5	Homocysteine levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16995524	chr1:100504499	HIAT1	-0.58	-7.14	-0.5	3.59e-11	Body fat percentage;
PAAD	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.11	10.93	0.66	7.1e-21	Corneal structure;
PAAD	cis	rs2221894	0.922	rs4732894	chr8:28823051	C/T	cg20212339	chr8:28908912	HMBOX1	0.49	5.27	0.39	4.68e-7	Obesity-related traits;
PAAD	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.47	0.34	1.54e-5	Triglycerides;
PAAD	cis	rs35300120	0.757	rs7540816	chr1:233659142	A/G	cg23054119	chr1:233659267	NA	0.57	5.21	0.39	6.04e-7	Cognitive function;
PAAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.74	-6.99	-0.49	7.93e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.68	-6.53	-0.47	9.38e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.8e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.92	0.49	1.15e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	12.1	0.7	5.03e-24	Smoking behavior;
PAAD	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.72	0.42	5.37e-8	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-7.72	-0.53	1.44e-12	Total body bone mineral density;
PAAD	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.5	-0.34	1.32e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4272720	0.639	rs2137912	chr10:50257325	A/G	cg07637213	chr10:50820604	CHAT;SLC18A3	0.35	4.41	0.34	1.92e-5	Platelet count;Plateletcrit;
PAAD	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg24110177	chr3:50126178	RBM5	0.57	4.44	0.34	1.69e-5	Menarche (age at onset);
PAAD	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs375066	0.935	rs10414702	chr19:44380536	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.33e-7	Breast cancer;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg13248847	chr17:7137857	DVL2	0.67	6.34	0.46	2.52e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	6.86	0.49	1.59e-10	Fuchs's corneal dystrophy;
PAAD	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg16586182	chr3:47516702	SCAP	-0.46	-4.43	-0.34	1.76e-5	Birth weight;
PAAD	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg07617317	chr6:118971624	C6orf204	0.52	4.41	0.34	1.95e-5	Diastolic blood pressure;
PAAD	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	1.23	15.74	0.79	9.97e-34	IgG glycosylation;
PAAD	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.18	-0.5	2.9e-11	Personality dimensions;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg11335335	chr11:637885	DRD4	-0.38	-5.51	-0.41	1.52e-7	Systemic lupus erythematosus;
PAAD	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.5	4.61	0.35	8.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.54	-5.6	-0.41	9.63e-8	Daytime sleep phenotypes;
PAAD	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.54	-4.91	-0.37	2.35e-6	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs10750165	0.645	rs7926574	chr11:119641049	T/C	cg24085502	chr11:119066850	CCDC153	-0.36	-4.43	-0.34	1.76e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs1499972	0.817	rs62263118	chr3:117629053	C/T	cg07612923	chr3:117604196	NA	1.06	7.14	0.5	3.53e-11	Schizophrenia;
PAAD	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.52	-5.62	-0.41	8.86e-8	Non-response to antidepressants and depression;
PAAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.28	0.6	1.64e-16	Menopause (age at onset);
PAAD	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg10011062	chr15:43941034	CATSPER2	-0.76	-4.4	-0.34	2.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.82	8.55	0.57	1.21e-14	DNA methylation (variation);
PAAD	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.52	5.12	0.38	8.99e-7	Asthma;
PAAD	cis	rs6604026	0.656	rs12065253	chr1:93392309	G/A	cg17283838	chr1:93427260	FAM69A	0.61	5.59	0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg01489256	chr8:11204017	TDH	0.47	4.96	0.37	1.83e-6	Neuroticism;
PAAD	cis	rs4273100	0.646	rs4924990	chr17:19294824	G/T	cg19949948	chr17:19361230	NA	0.59	5.69	0.42	6.47e-8	Schizophrenia;
PAAD	cis	rs58521262	0.516	rs10408398	chr19:23095426	A/G	cg22640819	chr19:22990650	NA	-0.29	-4.28	-0.33	3.32e-5	Testicular germ cell tumor;
PAAD	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11871801	0.918	rs4633765	chr17:40682341	T/A	cg21692620	chr17:40835849	CNTNAP1	0.49	5.02	0.38	1.44e-6	Crohn's disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24053061	chr12:107168846	RIC8B	-0.66	-6.69	-0.48	4.06e-10	Lung cancer in ever smokers;
PAAD	cis	rs1539053	0.966	rs1524707	chr1:58102540	A/G	cg00026909	chr1:58089001	DAB1	0.64	7.5	0.52	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.42	-0.34	1.85e-5	Caffeine consumption;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9788682	0.694	rs3825845	chr15:78910258	C/T	cg24631222	chr15:78858424	CHRNA5	0.61	4.59	0.35	9.04e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg12645284	chr15:79092878	ADAMTS7	-0.46	-4.41	-0.34	1.95e-5	Diastolic blood pressure;
PAAD	cis	rs6577655	0.517	rs6999469	chr8:135577530	G/A	cg17885191	chr8:135476712	NA	0.52	4.31	0.33	2.98e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-6.63	-0.47	5.64e-10	Bipolar disorder;
PAAD	cis	rs6841948	0.764	rs4696927	chr4:7981873	C/T	cg14959746	chr4:7987834	ABLIM2	0.58	4.45	0.34	1.63e-5	Post bronchodilator FEV1 in COPD;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.56	-0.74	5.86e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17903627	chr1:10927190	NA	0.64	6.72	0.48	3.52e-10	Myopia (pathological);
PAAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg10589385	chr1:150898437	SETDB1	0.41	5.12	0.38	9.25e-7	Melanoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23020857	chr14:54980058	CGRRF1	-0.68	-6.72	-0.48	3.49e-10	Obesity-related traits;
PAAD	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.98	6.77	0.48	2.64e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4889855	0.556	rs4890043	chr17:78526831	C/T	cg16591659	chr17:78472290	NA	0.49	4.82	0.36	3.52e-6	Fractional excretion of uric acid;
PAAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.82e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.95	-12.35	-0.71	1.05e-24	Menopause (age at onset);
PAAD	cis	rs912784	1.000	rs912784	chr13:46785521	C/A	cg27068143	chr13:47471264	HTR2A	1.16	5.39	0.4	2.58e-7	Systemic lupus erythematosus;
PAAD	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.16	0.7	3.43e-24	Smoking behavior;
PAAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-0.84	-5.47	-0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.36	5.96e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4903604	0.581	rs11850485	chr14:78033863	A/G	cg18872420	chr14:78023429	SPTLC2	0.45	4.75	0.36	4.61e-6	Gut microbiome composition (winter);
PAAD	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.49	-0.34	1.4e-5	Prevalent atrial fibrillation;
PAAD	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Diabetic kidney disease;
PAAD	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.53	-6.0	-0.44	1.42e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.7	8.26	0.56	6.47e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.75	-6.7	-0.48	3.87e-10	Triglycerides;
PAAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.47e-6	Cognitive function;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg11335335	chr11:637885	DRD4	-0.38	-5.48	-0.41	1.76e-7	Systemic lupus erythematosus;
PAAD	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg13263323	chr15:86062960	AKAP13	-0.64	-7.27	-0.51	1.72e-11	Coronary artery disease;
PAAD	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.5	4.9	0.37	2.38e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.89	0.43	2.45e-8	Tonsillectomy;
PAAD	cis	rs7681440	0.669	rs7693616	chr4:90792230	G/T	cg20003494	chr4:90757398	SNCA	0.39	4.27	0.33	3.49e-5	Dementia with Lewy bodies;
PAAD	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.69	6.64	0.47	5.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg13859433	chr6:33739653	LEMD2	0.65	4.41	0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.51e-38	Height;
PAAD	cis	rs9826463	0.757	rs79576118	chr3:142244645	A/C	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs990171	0.538	rs12987295	chr2:103115838	G/A	cg13897122	chr2:103039542	IL18RAP	-0.48	-5.33	-0.4	3.53e-7	Lymphocyte counts;
PAAD	cis	rs11700980	0.551	rs2832031	chr21:30114680	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.84	10.04	0.63	1.63e-18	Menopause (age at onset);
PAAD	trans	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg02075570	chr1:205649849	SLC45A3	0.69	6.36	0.46	2.27e-9	Blood protein levels;
PAAD	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.7	-6.24	-0.45	4.08e-9	Blood trace element (Zn levels);
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.53	5.01	0.38	1.51e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.74	9.51	0.61	4.02e-17	Cardiovascular disease risk factors;
PAAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.79	7.94	0.54	4.25e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.81	-9.32	-0.6	1.24e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.46	-7.04	-0.5	6.27e-11	Cutaneous nevi;
PAAD	cis	rs10991814	1.000	rs78806746	chr9:93996269	G/A	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.56	0.61	3.02e-17	Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13326172	chr17:34122745	MMP28	-0.78	-6.89	-0.49	1.37e-10	Neuroticism;
PAAD	cis	rs965469	0.779	rs6037546	chr20:3298697	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs9287719	0.649	rs6717431	chr2:10726046	A/G	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.2e-10	Prostate cancer;
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.8	10.08	0.63	1.28e-18	Vitiligo;
PAAD	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg23752985	chr2:85803571	VAMP8	0.56	5.92	0.43	2.07e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9463078	0.546	rs7758031	chr6:45025836	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg21040360	chr2:3383326	TTC15	-0.42	-4.41	-0.34	1.91e-5	Obesity-related traits;
PAAD	cis	rs12325245	0.536	rs12931124	chr16:58620063	G/A	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg12661370	chr5:149340060	SLC26A2	-0.64	-5.49	-0.41	1.68e-7	HIV-1 control;
PAAD	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-4.75	-0.36	4.69e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26127025	chr5:2703138	NA	-0.66	-6.92	-0.49	1.21e-10	Obesity-related traits;
PAAD	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs4938096	1.000	rs7115460	chr11:114215021	T/C	cg00557402	chr11:114466517	FAM55D	0.71	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.12e-5	Breast cancer;
PAAD	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg15841412	chr13:111365552	ING1	0.52	4.4	0.34	2.01e-5	Coronary artery disease;
PAAD	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg25588787	chr5:154027256	NA	0.6	4.52	0.34	1.25e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9463078	0.774	rs1321081	chr6:45355609	T/C	cg25276700	chr6:44698697	NA	0.48	5.55	0.41	1.25e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11038280	chr7:92466132	CDK6	0.6	6.94	0.49	1.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7179456	0.567	rs72745027	chr15:59094329	A/G	cg05156742	chr15:59063176	FAM63B	-0.78	-8.38	-0.56	3.38e-14	Asperger disorder;
PAAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	4.98	0.37	1.73e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4692589	0.581	rs6821231	chr4:170959988	C/T	cg19918862	chr4:170955249	NA	0.5	4.42	0.34	1.85e-5	Anxiety disorder;
PAAD	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.18	0.45	5.5e-9	Electrocardiographic conduction measures;
PAAD	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.63	5.0	0.38	1.55e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	7.04	0.5	6.36e-11	Educational attainment;
PAAD	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg12700464	chr11:78128424	GAB2	-0.6	-4.51	-0.34	1.28e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.64	5.9	0.43	2.29e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs4742903	0.935	rs10820618	chr9:106960503	T/A	cg14250997	chr9:106856677	SMC2	0.43	4.51	0.34	1.28e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.65	-6.98	-0.49	8.43e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.63	-0.47	5.61e-10	Eye color traits;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg10729496	chr3:10149963	C3orf24	0.83	6.38	0.46	1.98e-9	Alzheimer's disease;
PAAD	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs11718455	0.503	rs2302351	chr3:44039889	G/A	cg21419209	chr3:44054225	NA	-0.61	-6.93	-0.49	1.12e-10	Coronary artery disease;
PAAD	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg10920065	chr6:169824652	NA	-0.45	-4.52	-0.34	1.21e-5	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10335659	chr2:99757356	C2orf15;TSGA10	0.59	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg20007245	chr22:24372913	LOC391322	0.75	6.91	0.49	1.22e-10	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs9463078	0.715	rs9357459	chr6:44782562	C/T	cg25276700	chr6:44698697	NA	-0.44	-4.85	-0.37	3e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.86	-11.0	-0.67	4.39e-21	Height;
PAAD	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.44	4.87	0.37	2.76e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs2562456	0.833	rs11666525	chr19:21599305	G/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.55	-4.86	-0.37	2.91e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.64	-0.57	7.05e-15	Exhaled nitric oxide output;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.86	10.69	0.66	2.97e-20	Menopause (age at onset);
PAAD	cis	rs11671005	0.779	rs35631681	chr19:58999840	C/T	cg25952890	chr19:58913133	NA	0.72	5.59	0.41	1.02e-7	Mean platelet volume;
PAAD	cis	rs59888335	0.964	rs67606111	chr3:80689470	C/T	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01753731	chr4:903032	GAK	0.73	7.49	0.52	5.34e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg15192750	chr16:69999425	NA	0.69	5.42	0.4	2.34e-7	IgE levels;
PAAD	cis	rs7301826	0.627	rs34103763	chr12:131290149	G/A	cg11011512	chr12:131303247	STX2	-0.43	-4.46	-0.34	1.57e-5	Plasma plasminogen activator levels;
PAAD	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.5e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.59	-0.52	3.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.52	6.34	0.46	2.55e-9	Psoriasis;
PAAD	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	1.57	8.95	0.59	1.18e-15	Cannabis dependence symptom count;
PAAD	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13424612	1.000	rs4149547	chr2:240933308	C/T	cg01812947	chr2:240904978	NDUFA10	0.57	4.98	0.37	1.68e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.5	5.19	0.39	6.59e-7	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.31	-4.45	-0.34	1.66e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.64	6.35	0.46	2.34e-9	Type 2 diabetes;
PAAD	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg14146966	chr2:61757674	XPO1	-0.39	-4.8	-0.36	3.74e-6	Tuberculosis;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.48	-4.3	-0.33	3.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg20558230	chr5:484149	SLC9A3	-0.38	-5.06	-0.38	1.21e-6	Cystic fibrosis severity;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	ch.14.35531994F	chr14:36462243	NA	-0.61	-7.32	-0.51	1.35e-11	Body fat percentage;
PAAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.79	-7.69	-0.53	1.71e-12	DNA methylation (variation);
PAAD	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.49	-4.6	-0.35	8.98e-6	Endometrial cancer;
PAAD	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.54	-5.59	-0.41	1.01e-7	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg08875078	chr22:50639485	SELO	0.48	4.48	0.34	1.48e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs4889855	0.530	rs4890048	chr17:78549602	G/A	cg16591659	chr17:78472290	NA	0.46	4.43	0.34	1.76e-5	Fractional excretion of uric acid;
PAAD	cis	rs78472555	1.000	rs11247124	chr15:100265725	C/T	cg23669855	chr15:100272142	LYSMD4	-0.62	-5.08	-0.38	1.11e-6	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.99	-0.38	1.63e-6	Obesity-related traits;
PAAD	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	0.6	5.44	0.4	2.08e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9322817	0.691	rs2486138	chr6:105290223	G/A	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.53	5.85	0.43	2.98e-8	Major depressive disorder;
PAAD	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.09	10.38	0.64	2.03e-19	Orofacial clefts;
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg15557168	chr22:42548783	NA	0.54	6.13	0.45	7.31e-9	Cognitive function;
PAAD	cis	rs4218	0.531	rs6494065	chr15:59345448	A/G	cg25595834	chr15:59156878	NA	-0.42	-4.34	-0.33	2.57e-5	Social communication problems;
PAAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.98	0.49	8.76e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg17514665	chr17:1657533	SERPINF2	0.66	6.06	0.44	1.02e-8	Serum albumin level;
PAAD	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.42	5.81	0.43	3.59e-8	Oropharynx cancer;
PAAD	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.14	11.26	0.67	9e-22	Cognitive test performance;
PAAD	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.75	0.53	1.2e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.25	0.39	5.04e-7	Lung cancer;
PAAD	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.7	-9.44	-0.61	6.1e-17	Hemoglobin concentration;
PAAD	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg21419209	chr3:44054225	NA	-0.69	-6.71	-0.48	3.7e-10	Coronary artery disease;
PAAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12963246	chr6:28129442	ZNF389	0.56	4.52	0.34	1.21e-5	Parkinson's disease;
PAAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg00484396	chr16:3507460	NAT15	0.89	7.03	0.5	6.68e-11	Tuberculosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18369979	chr2:27886535	SLC4A1AP;SUPT7L	0.63	6.31	0.46	2.88e-9	Obesity-related traits;
PAAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.84	10.21	0.64	5.89e-19	Menopause (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16308174	chr11:70049109	FADD	0.66	7.63	0.53	2.36e-12	Metabolite levels  (X-11787);
PAAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03676636	chr4:99064102	C4orf37	0.29	5.47	0.41	1.8e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10280299	chr10:35929920	FZD8	-0.64	-6.4	-0.46	1.78e-9	Smoking initiation;
PAAD	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	11.37	0.68	4.45e-22	Menopause (age at onset);
PAAD	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg02376097	chr19:46275166	DMPK	-0.4	-4.41	-0.34	1.91e-5	Coronary artery disease;
PAAD	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-4.94	-0.37	2.04e-6	Height;
PAAD	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.79	6.72	0.48	3.51e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs8067287	0.688	rs11078356	chr17:16846208	A/G	cg26910001	chr17:16838321	NA	0.5	4.82	0.36	3.49e-6	Diabetic kidney disease;
PAAD	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.94	-7.83	-0.54	7.82e-13	Dupuytren's disease;
PAAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg14703610	chr5:56206110	C5orf35	-0.56	-5.23	-0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs7561149	1.000	rs12464151	chr2:179690909	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.57	5.72	0.42	5.46e-8	QT interval;
PAAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg07648498	chr16:89883185	FANCA	-0.64	-6.49	-0.47	1.14e-9	Vitiligo;
PAAD	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	5.91	0.43	2.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.66	7.03	0.5	6.58e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.4	0.46	1.82e-9	IgG glycosylation;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg21832906	chr1:221785710	NA	0.64	6.91	0.49	1.28e-10	Alcohol dependence;
PAAD	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs2834902	0.633	rs6517290	chr21:36679257	C/G	cg04915566	chr21:36421472	RUNX1	0.31	4.26	0.33	3.56e-5	Corneal curvature;
PAAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.49	-4.95	-0.37	1.97e-6	Immature fraction of reticulocytes;
PAAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.72	-8.14	-0.55	1.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs12149202	0.627	rs393793	chr16:85728152	T/C	cg07784872	chr16:85687041	KIAA0182	0.51	4.51	0.34	1.27e-5	Blood pressure traits (multi-trait analysis);
PAAD	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs7713065	0.765	rs4540166	chr5:131779857	C/T	cg14196790	chr5:131705035	SLC22A5	-0.44	-4.36	-0.33	2.36e-5	Lung function (FEV1/FVC);
PAAD	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.6	6.33	0.46	2.59e-9	Coronary artery disease;
PAAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.44	-4.57	-0.35	1.01e-5	Testicular germ cell tumor;
PAAD	cis	rs2271400	0.521	rs6990961	chr8:56751154	G/C	cg08894788	chr8:56792171	LYN	-0.55	-5.0	-0.38	1.6e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs1903068	0.785	rs12331538	chr4:55998086	A/C	cg09978860	chr4:56023921	NA	0.41	4.41	0.34	1.95e-5	Endometriosis;
PAAD	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.53	-5.44	-0.4	2.06e-7	Resting heart rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03670164	chr3:178789707	ZMAT3	0.57	6.47	0.46	1.25e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.86	9.44	0.61	6.38e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.53	-0.47	9.44e-10	Bone mineral density;
PAAD	cis	rs11051970	0.636	rs325421	chr12:32571595	C/T	cg02745156	chr12:32552066	NA	0.43	4.44	0.34	1.7e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg23254163	chr1:152506842	NA	0.54	6.29	0.45	3.27e-9	Hair morphology;
PAAD	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-5.88	-0.43	2.55e-8	Longevity;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg17372657	chr7:1216933	NA	-0.39	-4.9	-0.37	2.44e-6	Longevity;Endometriosis;
PAAD	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg04398451	chr17:18023971	MYO15A	-1.11	-15.7	-0.79	1.29e-33	Total body bone mineral density;
PAAD	cis	rs787274	1.000	rs10739370	chr9:115556941	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.95	-10.13	-0.63	9.59e-19	Asthma;
PAAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.31	0.4	3.74e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.53	4.51	0.34	1.28e-5	Dementia with Lewy bodies;
PAAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-4.84	-0.37	3.16e-6	Breast cancer;
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg08886695	chr4:3369023	RGS12	0.43	4.29	0.33	3.13e-5	Parental longevity (mother's age at death);
PAAD	cis	rs62408225	1.000	rs62408224	chr6:90955995	A/G	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.43	5.33	0.4	3.52e-7	Ulcerative colitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22190774	chr12:112849407	NA	-0.61	-6.31	-0.46	2.83e-9	Lung cancer in ever smokers;
PAAD	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.65	6.5	0.47	1.07e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.92	-9.8	-0.62	7.02e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.53	6.82	0.48	2.02e-10	Body mass index;
PAAD	cis	rs2236918	0.643	rs1776141	chr1:242038907	G/A	cg17736920	chr1:242011382	EXO1	0.57	5.52	0.41	1.44e-7	Menopause (age at onset);
PAAD	cis	rs9463078	0.605	rs13216116	chr6:44936681	C/T	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.14	-0.64	9.12e-19	Response to antipsychotic treatment;
PAAD	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg08886695	chr4:3369023	RGS12	0.52	5.1	0.38	1.01e-6	Parental longevity (mother's age at death);
PAAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-1.02	-14.37	-0.76	4.12e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg20893579	chr22:38215064	NA	0.51	5.12	0.38	9.28e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.45	4.72	0.36	5.22e-6	Type 2 diabetes;
PAAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.55	6.06	0.44	1.04e-8	Menopause (age at onset);
PAAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.0	0.54	2.93e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10439651	chr1:161103008	DEDD	-0.64	-6.32	-0.46	2.7e-9	Lung cancer in ever smokers;
PAAD	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.48	-6.25	-0.45	3.86e-9	Renal cell carcinoma;
PAAD	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.52	-5.08	-0.38	1.09e-6	White matter hyperintensity burden;
PAAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.2	0.55	9.24e-14	Lipoprotein (a) levels;
PAAD	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.43	-5.07	-0.38	1.14e-6	Body mass index;
PAAD	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs3931020	0.745	rs10874274	chr1:75252134	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.57	5.8	0.43	3.77e-8	Resistin levels;
PAAD	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-4.68	-0.35	6.32e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	ch.22.909671F	chr22:46114168	ATXN10	0.62	6.35	0.46	2.31e-9	Obesity-related traits;
PAAD	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg12757816	chr2:10669957	NA	-0.44	-4.54	-0.35	1.12e-5	Prostate cancer;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg14440974	chr22:39074834	NA	-0.59	-6.73	-0.48	3.3e-10	Menopause (age at onset);
PAAD	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg23281280	chr6:28129359	ZNF389	0.51	4.55	0.35	1.11e-5	Parkinson's disease;
PAAD	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg17326555	chr1:119535693	NA	-0.36	-4.58	-0.35	9.62e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.49	4.62	0.35	8.11e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2718812	0.719	rs1867505	chr3:133411052	T/C	cg08048268	chr3:133502702	NA	0.48	5.93	0.43	1.95e-8	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14655649	chr8:30769870	NA	-0.66	-7.36	-0.51	1.05e-11	Smoking initiation;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.69	5.74	0.42	4.94e-8	Alzheimer's disease;
PAAD	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.56	5.92	0.43	2.03e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.731	rs12208523	chr6:45058828	C/T	cg18551225	chr6:44695536	NA	-0.66	-6.35	-0.46	2.32e-9	Total body bone mineral density;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.5	-4.49	-0.34	1.37e-5	Lung cancer;
PAAD	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg06131755	chr6:160182447	ACAT2	0.54	4.82	0.36	3.44e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg19090574	chr1:205240910	TMCC2	-0.41	-4.47	-0.34	1.54e-5	Red blood cell count;
PAAD	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.59	-4.32	-0.33	2.78e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	6.85	0.49	1.68e-10	Body mass index (adult);
PAAD	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.6	-4.61	-0.35	8.52e-6	Mosquito bite size;
PAAD	cis	rs2342371	0.756	rs28712197	chr3:196107214	T/C	cg09821211	chr3:195954098	OSTalpha	0.65	6.06	0.44	1.05e-8	Fat distribution (HIV);
PAAD	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.81	-0.79	6.49e-34	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.91	-0.37	2.37e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg18279126	chr7:2041391	MAD1L1	0.58	5.93	0.43	1.94e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg00806126	chr19:22604979	ZNF98	-0.39	-4.79	-0.36	3.95e-6	Pain;
PAAD	cis	rs8099014	1.000	rs12608175	chr18:56129976	T/C	cg12907477	chr18:56117327	MIR122	0.53	4.29	0.33	3.19e-5	Platelet count;
PAAD	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg19026207	chr17:26645466	TMEM97	-0.4	-4.38	-0.33	2.19e-5	Osteoprotegerin levels;
PAAD	cis	rs939584	1.000	rs939583	chr2:622531	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg05717871	chr11:638507	DRD4	-0.58	-5.5	-0.41	1.57e-7	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9486594	0.597	rs2500581	chr6:107646779	C/G	cg23052020	chr6:106960170	AIM1	0.61	4.28	0.33	3.3e-5	Airway responsiveness in chronic obstructive pulmonary disease;
PAAD	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	1.14	13.06	0.73	1.3e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.71	6.53	0.47	9.17e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs593531	0.513	rs7120394	chr11:74034473	G/T	cg15670924	chr11:73669256	DNAJB13	0.45	4.93	0.37	2.09e-6	Neuroticism;
PAAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.55	4.47	0.34	1.5e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs72960926	0.744	rs16884690	chr6:75046076	A/C	cg03266952	chr6:74778945	NA	-1.02	-6.32	-0.46	2.81e-9	Metabolite levels (MHPG);
PAAD	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.72	-7.38	-0.51	9.48e-12	Cognitive function;
PAAD	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg10534938	chr5:1868639	NA	0.47	6.05	0.44	1.06e-8	Cardiovascular disease risk factors;
PAAD	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.53	5.23	0.39	5.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9652601	0.779	rs12935413	chr16:11210447	C/T	cg04616529	chr16:11181986	CLEC16A	0.39	4.52	0.34	1.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.6	-5.58	-0.41	1.06e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg22162314	chr17:61951766	CSH2	0.53	5.08	0.38	1.1e-6	Height;
PAAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.1	-0.38	1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg02404636	chr22:31891804	SFI1	-0.6	-5.42	-0.4	2.28e-7	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26378453	chr18:8706260	NA	0.63	6.32	0.46	2.73e-9	Obesity-related traits;
PAAD	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg18551225	chr6:44695536	NA	-0.72	-7.2	-0.5	2.65e-11	Total body bone mineral density;
PAAD	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg24565620	chr2:194026	NA	-0.68	-5.19	-0.39	6.53e-7	Blood protein levels;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.53	-5.84	-0.43	3.08e-8	Testicular germ cell tumor;
PAAD	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-0.84	-8.02	-0.55	2.62e-13	Response to hepatitis C treatment;
PAAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.92	-0.37	2.19e-6	Thrombosis;
PAAD	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.74	7.52	0.52	4.41e-12	Mosquito bite size;
PAAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs17023223	0.537	rs1057991	chr1:119575170	C/A	cg17326555	chr1:119535693	NA	-0.41	-4.86	-0.37	2.94e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-1.13	-12.49	-0.71	4.56e-25	Hair shape;
PAAD	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.5	5.19	0.39	6.59e-7	Multiple sclerosis;
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg26939375	chr7:64535504	NA	0.75	8.92	0.59	1.36e-15	Aortic root size;
PAAD	cis	rs9411298	0.657	rs4880189	chr9:139923265	A/G	cg14024893	chr9:139943146	ENTPD2	0.64	7.2	0.5	2.6e-11	Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg27394845	chr17:28928406	LRRC37B2	-0.7	-4.42	-0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.48	6.0	0.44	1.4e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.02	-0.49	7.04e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.47	-4.83	-0.36	3.25e-6	Eosinophil percentage of white cells;
PAAD	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg06042504	chr8:55087323	NA	-0.77	-8.69	-0.58	5.29e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16417436	chr16:28758564	NA	0.47	4.37	0.33	2.32e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.61	5.31	0.4	3.74e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg22467129	chr15:76604101	ETFA	0.51	4.78	0.36	4.02e-6	Blood metabolite levels;
PAAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg26497354	chr6:109612229	NA	-0.44	-4.71	-0.36	5.61e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.63	-5.37	-0.4	2.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg05805236	chr11:65401703	PCNXL3	0.6	6.26	0.45	3.67e-9	Acne (severe);
PAAD	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.68	-7.82	-0.54	8.36e-13	Colorectal cancer;
PAAD	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.62	6.77	0.48	2.6200000000000003e-10	Leprosy;
PAAD	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.65	-5.46	-0.4	1.93e-7	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15629096	chr6:43967558	C6orf223	-0.61	-6.46	-0.46	1.31e-9	Obesity-related traits;
PAAD	cis	rs787274	1.000	rs787302	chr9:115543839	G/A	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14782991	chr12:6833168	COPS7A	0.64	6.44	0.46	1.48e-9	Obesity-related traits;
PAAD	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg15193198	chr20:60906057	LAMA5	-0.47	-5.22	-0.39	5.73e-7	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.67	7.49	0.52	5.13e-12	Systemic lupus erythematosus;
PAAD	cis	rs1723838	0.826	rs1792194	chr11:73560614	T/C	cg26954736	chr11:73693896	UCP2	1.04	4.62	0.35	8e-6	Obesity-related traits;
PAAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.94	-8.81	-0.58	2.69e-15	Asthma;
PAAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs9972944	0.651	rs9897920	chr17:63832286	C/T	cg07283582	chr17:63770753	CCDC46	-0.58	-6.87	-0.49	1.54e-10	Total body bone mineral density;
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.5	-5.74	-0.42	5.09e-8	Mean corpuscular volume;
PAAD	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg18764771	chr6:116381957	FRK	0.31	4.93	0.37	2.14e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs5417	0.751	rs1634381	chr17:7180007	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	0.64	7.02	0.49	6.86e-11	Diastolic blood pressure;
PAAD	cis	rs11264213	0.591	rs684594	chr1:36489977	G/A	cg27506609	chr1:36549197	TEKT2	-0.81	-5.96	-0.44	1.71e-8	Schizophrenia;
PAAD	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06481639	chr22:41940642	POLR3H	0.56	4.28	0.33	3.36e-5	Vitiligo;
PAAD	cis	rs59888335	1.000	rs35326234	chr3:80756017	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.73	-7.29	-0.51	1.6e-11	Itch intensity from mosquito bite;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04400540	chr1:44440242	ATP6V0B	0.57	6.48	0.47	1.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	1.04	7.08	0.5	5e-11	Mitochondrial DNA levels;
PAAD	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg27471124	chr11:109292789	C11orf87	0.26	4.57	0.35	1e-5	Schizophrenia;
PAAD	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.52	4.87	0.37	2.83e-6	Sjögren's syndrome;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.33	-0.33	2.69e-5	Life satisfaction;
PAAD	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-5.87	-0.43	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15450295	chr8:80696411	NA	0.61	6.6	0.47	6.4e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.81	-10.14	-0.64	8.82e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.86	-9.98	-0.63	2.36e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.69	7.92	0.54	4.56e-13	Height;
PAAD	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.8	5.73	0.42	5.25e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2282930	0.836	rs2237471	chr7:50740065	T/C	cg07379434	chr7:49814597	VWC2	0.26	4.54	0.35	1.14e-5	Bone mineral density;
PAAD	cis	rs1735151	0.915	rs4816654	chr21:41130620	G/C	cg25077654	chr21:40555395	PSMG1	-0.6	-4.26	-0.33	3.64e-5	Hypertension;
PAAD	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14764512	chr3:49058575	MIR191;DALRD3;NDUFAF3;MIR425	0.59	6.36	0.46	2.22e-9	Morning vs. evening chronotype;
PAAD	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg01388757	chr2:102091195	RFX8	0.53	6.54	0.47	8.88e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg23024343	chr7:107201750	COG5	0.58	4.8	0.36	3.68e-6	Coronary artery disease;
PAAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25809561	chr17:30822961	MYO1D	-0.56	-5.97	-0.44	1.63e-8	Schizophrenia;
PAAD	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.79	8.68	0.58	5.7e-15	Obesity-related traits;
PAAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg08284496	chr17:37894027	GRB7	0.25	4.35	0.33	2.45e-5	Asthma;
PAAD	cis	rs11264799	0.539	rs12125930	chr1:157577086	A/G	cg18268488	chr1:157545234	FCRL4	0.49	5.85	0.43	2.86e-8	IgA nephropathy;
PAAD	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg04520793	chr17:42248056	ASB16	0.42	4.67	0.35	6.45e-6	Total body bone mineral density;
PAAD	cis	rs6088813	1.000	rs6579234	chr20:33983485	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs7537660	0.636	rs10749635	chr1:248014615	C/T	cg08944170	chr1:248100614	OR2L13	0.54	5.4	0.4	2.56e-7	Platelet distribution width;
PAAD	cis	rs2302729	0.929	rs10744567	chr12:2780816	A/G	cg19945202	chr12:2788847	CACNA1C	-0.66	-6.26	-0.45	3.74e-9	Sleep quality;
PAAD	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg22143856	chr6:28129313	ZNF389	0.51	4.42	0.34	1.9e-5	Parkinson's disease;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-5.98	-0.44	1.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.9	-7.35	-0.51	1.13e-11	Initial pursuit acceleration;
PAAD	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg05294307	chr14:35346193	BAZ1A	-0.54	-5.25	-0.39	5.02e-7	Psoriasis;
PAAD	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.74	-6.82	-0.48	1.99e-10	Coronary artery disease;
PAAD	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg05555928	chr11:63887634	MACROD1	0.61	4.82	0.36	3.47e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16781439	chr22:29469035	KREMEN1	0.69	7.31	0.51	1.43e-11	Myopia (pathological);
PAAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg27494647	chr7:150038898	RARRES2	0.44	4.72	0.36	5.26e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.93	10.39	0.64	1.9e-19	Testicular germ cell tumor;
PAAD	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.71	6.45	0.46	1.41e-9	Asthma;
PAAD	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.58	-7.83	-0.54	7.88e-13	Primary biliary cholangitis;
PAAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01200585	chr1:228362443	C1orf69	-0.49	-5.47	-0.41	1.84e-7	Diastolic blood pressure;
PAAD	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.41	1.22e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2790457	0.958	rs1265829	chr10:28911303	T/C	cg05705492	chr10:28955341	NA	-0.43	-4.31	-0.33	2.97e-5	Multiple myeloma;
PAAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg15847926	chr7:2749597	AMZ1	-0.37	-4.57	-0.35	9.97e-6	Height;
PAAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.68	-7.65	-0.53	2.19e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11225569	0.540	rs10895423	chr11:103279762	A/C	cg13041032	chr11:102826090	MMP13	0.38	4.42	0.34	1.87e-5	Diisocyanate-induced asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23593537	chr11:72353580	PDE2A	0.62	6.83	0.48	1.89e-10	Monocyte percentage of white cells;
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg21665744	chr7:39171113	POU6F2	0.35	5.96	0.44	1.72e-8	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg09659197	chr4:152720779	NA	0.42	5.13	0.38	8.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.9	10.55	0.65	7.13e-20	Lewy body disease;
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.74e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6733011	0.622	rs12712036	chr2:99462711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.08	-0.38	1.1e-6	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.49	0.57	1.71e-14	Alzheimer's disease;
PAAD	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg18099408	chr3:52552593	STAB1	-0.49	-5.39	-0.4	2.62e-7	Electroencephalogram traits;
PAAD	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.94	8.56	0.57	1.15e-14	Platelet distribution width;
PAAD	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg21466736	chr12:48725269	NA	-0.49	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg25364880	chr3:44379878	C3orf23	0.59	5.43	0.4	2.17e-7	Depressive symptoms;
PAAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.71	-5.91	-0.43	2.16e-8	Coronary artery disease;
PAAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9659323	0.596	rs11589179	chr1:119497585	T/C	cg17326555	chr1:119535693	NA	-0.37	-4.59	-0.35	9.24e-6	Body mass index;
PAAD	cis	rs2882667	0.690	rs10043478	chr5:138188711	C/G	cg09476006	chr5:138032270	NA	0.46	5.89	0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg03808351	chr9:123631620	PHF19	0.45	4.87	0.37	2.76e-6	Rheumatoid arthritis;
PAAD	cis	rs4523957	0.854	rs404392	chr17:2191000	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.75	-0.42	4.67e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.7	10.0	0.63	2.03e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7243821	0.921	rs8097666	chr18:52632886	T/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg20406979	chr6:167373233	NA	0.4	5.59	0.41	1.04e-7	Crohn's disease;
PAAD	cis	rs732505	0.850	rs10412919	chr19:5586749	T/C	cg26242866	chr19:5711310	LONP1	1.05	5.76	0.42	4.49e-8	vWF and FVIII levels;
PAAD	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-7.13	-0.5	3.7e-11	Neuroticism;
PAAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.69	6.32	0.46	2.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17937497	chr19:55740727	TMEM86B	0.56	7.47	0.52	6e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.62	0.47	5.94e-10	Educational attainment;
PAAD	cis	rs72681920	0.618	rs12649136	chr4:100070816	A/G	cg12011299	chr4:100065546	ADH4	-0.83	-4.88	-0.37	2.71e-6	Alcohol dependence;
PAAD	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09597638	chr17:3907349	NA	0.74	7.88	0.54	5.85e-13	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.63	6.57	0.47	7.67e-10	Mean platelet volume;
PAAD	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg12395012	chr8:11607386	GATA4	0.45	4.57	0.35	1.01e-5	Morning vs. evening chronotype;
PAAD	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs58521262	0.519	rs11669364	chr19:22957316	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.29e-5	Testicular germ cell tumor;
PAAD	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.09	-0.38	1.06e-6	Subjective well-being;
PAAD	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-6.3	-0.45	3.1e-9	Dilated cardiomyopathy;
PAAD	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs2124910	0.873	rs10410468	chr19:52026600	G/T	cg12008991	chr19:52034861	SIGLEC6	-0.37	-4.72	-0.36	5.23e-6	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.76	-0.36	4.5e-6	Menarche (age at onset);
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18297960	chr7:1142765	C7orf50	-0.55	-4.35	-0.33	2.49e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg10845886	chr2:3471009	TTC15	-0.57	-5.37	-0.4	2.85e-7	Neurofibrillary tangles;
PAAD	trans	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.85	-9.27	-0.6	1.73e-16	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00405152	chr19:47217237	PRKD2	-0.71	-7.73	-0.53	1.34e-12	Smoking initiation;
PAAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	Trans fatty acid levels;
PAAD	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-4.57	-0.35	1.01e-5	Mean corpuscular volume;
PAAD	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.63	-0.47	5.61e-10	Eye color traits;
PAAD	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	4.54	0.35	1.12e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-5.18	-0.39	7.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-6.12	-0.44	7.46e-9	Coronary artery disease;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.52	-5.18	-0.39	7.05e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6442522	0.799	rs4395387	chr3:15503055	G/A	cg16303742	chr3:15540471	COLQ	0.45	4.74	0.36	4.93e-6	Uric acid levels;
PAAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg00758881	chr16:58534681	NDRG4	-0.89	-4.73	-0.36	5e-6	Schizophrenia;
PAAD	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg11288833	chr15:55489084	RSL24D1	0.57	4.53	0.34	1.21e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.41	-0.34	1.97e-5	Fibrinogen levels;
PAAD	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	7.02	0.5	6.72e-11	Lung cancer in ever smokers;
PAAD	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.82	-5.55	-0.41	1.23e-7	Red cell distribution width;
PAAD	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.65	0.47	5.06e-10	Multiple sclerosis;
PAAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.88	11.24	0.67	1.03e-21	Aortic root size;
PAAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg16147221	chr4:10020634	SLC2A9	0.51	4.59	0.35	9.21e-6	Bone mineral density;
PAAD	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.43	0.52	7.39e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-6.0	-0.44	1.41e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg18944383	chr4:111397179	ENPEP	0.73	7.98	0.54	3.24e-13	Height;
PAAD	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.62	-7.14	-0.5	3.66e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23071583	chr13:113951629	LAMP1	-0.73	-7.42	-0.52	7.55e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.39	-4.28	-0.33	3.35e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7084783	0.500	rs10883892	chr10:105397102	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.64	0.35	7.46e-6	Fear of pain;
PAAD	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.52	5.33	0.4	3.55e-7	Lymphocyte counts;
PAAD	cis	rs76917914	0.820	rs2281732	chr9:100845007	A/G	cg03040243	chr9:100819229	NANS	0.56	4.44	0.34	1.69e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2147904	0.933	rs783621	chr1:42368035	A/G	cg16685388	chr1:42384056	HIVEP3	0.4	4.72	0.36	5.4e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.23	-0.51	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs3026101	0.671	rs1071705	chr17:5290033	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs2806561	0.619	rs7543975	chr1:23381116	G/A	cg12483005	chr1:23474871	LUZP1	0.76	7.68	0.53	1.8e-12	Height;
PAAD	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14008862	chr17:28927542	LRRC37B2	0.86	5.81	0.43	3.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4588572	0.774	rs4072853	chr5:77656402	G/C	cg11547950	chr5:77652471	NA	0.95	8.35	0.56	3.84e-14	Triglycerides;
PAAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg20744362	chr22:50050164	C22orf34	0.69	7.8	0.53	8.97e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg09754948	chr16:28834200	ATXN2L	-0.48	-4.42	-0.34	1.86e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	5.14	0.38	8.33e-7	Colorectal cancer;
PAAD	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.78	9.52	0.61	3.74e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.7	9.23	0.6	2.16e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.76	-6.73	-0.48	3.25e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.57	6.23	0.45	4.42e-9	Birth weight;
PAAD	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.73	6.29	0.45	3.2e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs12246027	0.580	rs74332769	chr10:260044	T/C	cg11001780	chr10:623056	DIP2C	-0.41	-4.43	-0.34	1.76e-5	Blood metabolite levels;
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.72	8.52	0.57	1.47e-14	Height;
PAAD	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.47	-5.42	-0.4	2.26e-7	Platelet distribution width;
PAAD	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	5.01	0.38	1.49e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.45	-0.52	6.44e-12	Total body bone mineral density;
PAAD	cis	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg22101045	chr11:47927509	NA	0.53	4.25	0.33	3.67e-5	Axial length;
PAAD	cis	rs11669133	1.000	rs11669948	chr19:11097450	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.7	7.46	0.52	6.23e-12	Aortic root size;
PAAD	cis	rs11807834	0.522	rs12565365	chr1:230251507	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs346785	0.692	rs7225131	chr17:74290097	T/A	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs4722166	0.567	rs62449490	chr7:22748491	T/G	cg05472934	chr7:22766657	IL6	0.48	4.99	0.38	1.61e-6	Lung cancer;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.55	4.58	0.35	9.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-5.64	-0.42	8.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02071572	chr4:1403502	NA	0.43	5.7	0.42	6.17e-8	Obesity-related traits;
PAAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg04450456	chr4:17643702	FAM184B	0.46	4.7	0.36	5.79e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.7	-5.71	-0.42	5.79e-8	Blood protein levels;
PAAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs6908034	0.607	rs77791009	chr6:19812602	A/G	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.93	-10.72	-0.66	2.47e-20	Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23053782	chr3:47844291	DHX30	0.62	6.32	0.46	2.82e-9	Obesity-related traits;
PAAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.64	6.14	0.45	6.79e-9	Schizophrenia;
PAAD	cis	rs17095355	0.892	rs1571617	chr10:111732025	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.68	-0.35	6.4e-6	Biliary atresia;
PAAD	cis	rs1512829	0.578	rs4910072	chr11:9910958	C/T	cg06876053	chr11:9810051	SBF2	-0.38	-4.29	-0.33	3.15e-5	Lung adenocarcinoma;
PAAD	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08704250	chr15:31115839	NA	-0.6	-8.25	-0.56	7.04e-14	Huntington's disease progression;
PAAD	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg24879335	chr3:133465180	TF	0.4	4.39	0.34	2.13e-5	Iron status biomarkers;
PAAD	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.43	-5.2	-0.39	6.28e-7	Coronary artery disease;
PAAD	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg26441486	chr22:50317300	CRELD2	0.37	4.43	0.34	1.8e-5	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.91	7.82	0.54	8.38e-13	Alzheimer's disease;
PAAD	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.49	5.03	0.38	1.34e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg26685658	chr5:74633012	HMGCR	-0.51	-4.32	-0.33	2.79e-5	Age-related disease endophenotypes;
PAAD	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19737468	chr14:24701538	NEDD8;GMPR2	0.61	6.75	0.48	2.86e-10	Monocyte percentage of white cells;
PAAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6796502	0.500	rs7624422	chr3:46873667	C/T	cg23231268	chr3:46792462	NA	-0.65	-4.68	-0.35	6.35e-6	Breast cancer;
PAAD	cis	rs7172971	0.688	rs79813811	chr15:42379939	C/G	cg07013680	chr15:42186124	SPTBN5	0.53	4.27	0.33	3.4e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.72	-5.92	-0.43	2.08e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.55	-6.54	-0.47	8.88e-10	Lung cancer;
PAAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.55	4.73	0.36	5.01e-6	Urinary metabolites;
PAAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00300879	chr1:26503847	CNKSR1	0.3	4.69	0.36	5.93e-6	Height;
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg16909742	chr2:127635678	NA	0.87	5.26	0.39	4.84e-7	Heart failure;
PAAD	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.41	-4.51	-0.34	1.3e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.77	8.51	0.57	1.58e-14	Body mass index;
PAAD	cis	rs4731207	0.596	rs10081336	chr7:124575945	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.52	-0.34	1.22e-5	Cutaneous malignant melanoma;
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg07841815	chr7:100318223	EPO	-0.48	-4.39	-0.34	2.11e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7894051	0.764	rs11101725	chr10:135194608	A/G	cg19176072	chr10:135083742	ADAM8	-0.96	-4.65	-0.35	7.09e-6	Lifespan;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg00431813	chr7:1051703	C7orf50	-0.35	-4.33	-0.33	2.71e-5	Longevity;Endometriosis;
PAAD	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg14146966	chr2:61757674	XPO1	-0.39	-4.77	-0.36	4.21e-6	Tuberculosis;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	6.69	0.48	3.92e-10	Lymphocyte counts;
PAAD	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg00717180	chr2:96193071	NA	0.64	6.94	0.49	1.08e-10	HDL cholesterol;
PAAD	cis	rs59104589	0.521	rs2240482	chr2:242405021	C/T	cg19488206	chr2:242435732	STK25	0.47	4.62	0.35	8.05e-6	Fibrinogen levels;
PAAD	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.45	5.11	0.38	9.58e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.58	-0.41	1.09e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1014246	0.796	rs2420331	chr10:118471197	A/G	cg14471191	chr10:117818509	GFRA1	0.38	4.34	0.33	2.54e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.33	-0.4	3.44e-7	Mean platelet volume;
PAAD	cis	rs4919087	0.561	rs7101333	chr10:99083669	A/G	cg25902810	chr10:99078978	FRAT1	-0.57	-5.18	-0.39	6.98e-7	Monocyte count;
PAAD	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Red blood cell count;
PAAD	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.52	-5.63	-0.42	8.6e-8	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.54	-5.16	-0.39	7.71e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg06740227	chr12:86229804	RASSF9	0.49	4.29	0.33	3.19e-5	Major depressive disorder;
PAAD	cis	rs9810890	1.000	rs73207976	chr3:128569020	C/T	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15606819	chr19:49661083	TRPM4	0.54	6.45	0.46	1.38e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg21300403	chr2:198650112	BOLL	-0.65	-4.48	-0.34	1.44e-5	Ulcerative colitis;
PAAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.57	6.06	0.44	1.01e-8	Schizophrenia;
PAAD	cis	rs868943	0.582	rs9488861	chr6:116502405	A/G	cg26893134	chr6:116381904	FRK	0.3	4.58	0.35	9.5e-6	Total cholesterol levels;
PAAD	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00540400	chr15:79124168	NA	0.58	6.72	0.48	3.43e-10	Coronary artery disease;
PAAD	cis	rs5771040	0.521	rs5771039	chr22:50901534	A/G	cg03450049	chr22:50913555	SBF1	0.61	5.41	0.4	2.45e-7	IgG glycosylation;
PAAD	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.06	0.38	1.19e-6	Birth weight;
PAAD	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.08	11.53	0.68	1.73e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg00531865	chr16:30841666	NA	0.45	4.45	0.34	1.68e-5	Triglycerides;
PAAD	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg09659197	chr4:152720779	NA	0.44	5.93	0.43	1.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs2320952	0.874	rs7217021	chr17:10495245	A/G	cg19806995	chr17:9728972	GLP2R	0.37	4.25	0.33	3.77e-5	Gut microbiome composition (winter);
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg09211372	chr6:168490623	NA	-0.42	-4.45	-0.34	1.63e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7301826	0.651	rs2037789	chr12:131288292	C/T	cg11011512	chr12:131303247	STX2	-0.52	-5.38	-0.4	2.76e-7	Plasma plasminogen activator levels;
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs4740619	0.619	rs1410453	chr9:16042191	T/A	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg03188948	chr7:1209495	NA	0.94	5.16	0.39	7.58e-7	Longevity;Endometriosis;
PAAD	cis	rs3857067	0.530	rs72663744	chr4:94998544	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.06	-0.38	1.21e-6	QT interval;
PAAD	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.54	5.0	0.38	1.58e-6	Systemic lupus erythematosus;
PAAD	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.81	9.49	0.61	4.48e-17	Blood metabolite ratios;
PAAD	cis	rs12760731	0.641	rs12727289	chr1:178327027	T/C	cg00404053	chr1:178313656	RASAL2	0.74	5.77	0.42	4.3e-8	Obesity-related traits;
PAAD	cis	rs939584	0.778	rs6548239	chr2:635154	G/A	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg17810781	chr1:201082982	CACNA1S	0.5	5.95	0.43	1.79e-8	Permanent tooth development;
PAAD	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3736485	0.934	rs2899475	chr15:51883051	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.52	0.34	1.26e-5	Axial length;
PAAD	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.59	-6.78	-0.48	2.47e-10	Height;
PAAD	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs7172971	0.688	rs4924617	chr15:42369548	A/G	cg07013680	chr15:42186124	SPTBN5	-0.53	-4.43	-0.34	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg12310025	chr6:25882481	NA	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg26338869	chr17:61819248	STRADA	-0.7	-7.48	-0.52	5.58e-12	Prudent dietary pattern;
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.65	0.47	4.9e-10	Blood metabolite levels;
PAAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.54	-4.79	-0.36	4.01e-6	P wave terminal force;
PAAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.27	-0.33	3.42e-5	Pulse pressure;
PAAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00982548	chr2:198649783	BOLL	-0.79	-5.77	-0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg08390786	chr10:135334061	NA	0.48	4.64	0.35	7.5e-6	Obesity-related traits;
PAAD	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7873102	0.654	rs7023815	chr9:37967578	T/C	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.38	-0.33	2.18e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.53	-5.9	-0.43	2.31e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs8170	0.603	rs1544940	chr19:17414843	A/T	cg10664184	chr19:17420304	DDA1	0.48	4.38	0.33	2.18e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs7896729	0.941	rs7904154	chr10:5353209	T/G	cg07902545	chr10:6194255	PFKFB3	-0.43	-4.35	-0.33	2.49e-5	Intelligence;
PAAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg16205897	chr5:131564050	P4HA2	-0.49	-5.43	-0.4	2.16e-7	Blood metabolite levels;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg20966754	chr17:47091339	IGF2BP1	-0.43	-5.51	-0.41	1.51e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg14393609	chr7:65229607	NA	-0.46	-4.53	-0.35	1.17e-5	Aortic root size;
PAAD	cis	rs6681460	0.933	rs7554101	chr1:67156472	A/G	cg02459107	chr1:67143332	SGIP1	-0.67	-6.19	-0.45	5.35e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.81	-7.9	-0.54	5.34e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs859767	0.501	rs6705916	chr2:135397569	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.57	-0.35	9.89e-6	Neuroticism;
PAAD	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.66	-6.24	-0.45	4.08e-9	Subjective well-being;
PAAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-4.59	-0.35	9.41e-6	Height;
PAAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	1.0	13.85	0.75	1.02e-28	Rheumatoid arthritis;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg14893161	chr1:205819251	PM20D1	0.66	5.63	0.42	8.33e-8	Prostate-specific antigen levels;
PAAD	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.29	-9.19	-0.6	2.74e-16	Blood pressure (smoking interaction);
PAAD	cis	rs10916814	0.632	rs7524492	chr1:20902750	G/A	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs600626	0.588	rs10899112	chr11:75458518	T/C	cg24262691	chr11:75473276	NA	0.76	6.17	0.45	5.86e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	4.92	0.37	2.26e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.54	7.13	0.5	3.9e-11	Prostate cancer;
PAAD	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.65	0.47	4.92e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg11232448	chr19:2858854	NA	-0.45	-4.41	-0.34	1.96e-5	Total cholesterol levels;
PAAD	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs4253772	0.575	rs75097576	chr22:46763233	G/A	cg00784671	chr22:46762841	CELSR1	-0.78	-4.31	-0.33	2.88e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22601191	chr20:60968625	CABLES2	-0.56	-5.33	-0.4	3.41e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs73206853	0.697	rs16934006	chr12:110527907	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.29	0.33	3.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6681460	1.000	rs10789210	chr1:67066030	G/A	cg02459107	chr1:67143332	SGIP1	0.77	7.9	0.54	5.22e-13	Presence of antiphospholipid antibodies;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20084434	chr4:157999344	GLRB	-0.55	-6.49	-0.47	1.17e-9	Energy expenditure (24h);
PAAD	cis	rs367943	0.688	rs1464163	chr5:112691815	A/G	cg12552261	chr5:112820674	MCC	0.63	6.11	0.44	7.82e-9	Type 2 diabetes;
PAAD	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.97	8.93	0.59	1.31e-15	Resting heart rate;
PAAD	cis	rs77741769	0.571	rs11611087	chr12:121267126	C/T	cg02419362	chr12:121203948	SPPL3	0.54	5.98	0.44	1.51e-8	Mean corpuscular volume;
PAAD	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs3126085	1.000	rs12405278	chr1:152282267	G/A	cg26876637	chr1:152193138	HRNR	-0.8	-5.43	-0.4	2.19e-7	Atopic dermatitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23385388	chr11:107436500	ALKBH8	0.68	7.28	0.51	1.64e-11	Myopia (pathological);
PAAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	0.88	4.47	0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.25	18.04	0.83	1.32e-39	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs67385638	0.855	rs3759074	chr11:5257778	C/T	cg12559170	chr11:5275217	HBG2	0.58	5.86	0.43	2.83e-8	Hemoglobin levels;
PAAD	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.61	4.52	0.34	1.23e-5	Neuroblastoma;
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.96	8.04	0.55	2.4e-13	Initial pursuit acceleration;
PAAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.64e-6	Menarche (age at onset);
PAAD	cis	rs6690583	0.560	rs1542427	chr1:85554402	T/C	cg12037450	chr1:85513124	MCOLN3	-0.5	-4.49	-0.34	1.42e-5	Serum sulfate level;
PAAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs10905065	0.648	rs4237365	chr10:5821484	T/G	cg18989491	chr10:6185502	PFKFB3	0.48	4.4	0.34	2.03e-5	Menopause (age at onset);
PAAD	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Breast cancer;
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.78	9.22	0.6	2.39e-16	Systemic lupus erythematosus;
PAAD	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg10011062	chr15:43941034	CATSPER2	0.77	4.67	0.35	6.68e-6	Lung cancer in ever smokers;
PAAD	cis	rs72960926	0.744	rs67076726	chr6:74992577	A/G	cg03266952	chr6:74778945	NA	-1.08	-6.22	-0.45	4.56e-9	Metabolite levels (MHPG);
PAAD	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-7.5	-0.52	4.85e-12	Vitiligo;
PAAD	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.99	5.81	0.43	3.48e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.72	-7.94	-0.54	4.09e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg22029157	chr1:209979665	IRF6	0.69	6.07	0.44	9.79e-9	Coronary artery disease;
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.77	-7.45	-0.52	6.72e-12	Systemic lupus erythematosus;
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.67	-7.4	-0.51	8.85e-12	Facial morphology (factor 20);
PAAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.85	5.33	0.4	3.52e-7	Schizophrenia;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.64	6.85	0.49	1.72e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.5	4.48	0.34	1.49e-5	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs11794666	1.000	rs1838672	chr9:31705387	C/T	cg05628366	chr6:35744188	C6orf126	1.12	7.15	0.5	3.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.75	0.58	3.79e-15	Bipolar disorder;
PAAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	9.68	0.62	1.49e-17	Personality dimensions;
PAAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.94	-11.52	-0.68	1.81e-22	Longevity;
PAAD	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.96	-14.83	-0.77	2.5e-31	Height;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.55	-5.22	-0.39	5.69e-7	Monocyte count;
PAAD	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8016982	0.662	rs2288498	chr14:81660710	T/C	cg01989461	chr14:81687754	GTF2A1	0.57	4.56	0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15644539	chr6:139802112	NA	-0.58	-6.37	-0.46	2.11e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02071572	chr4:1403502	NA	-0.44	-5.96	-0.44	1.7e-8	Obesity-related traits;
PAAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.65	-6.65	-0.47	4.95e-10	Urate levels in lean individuals;
PAAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.73	-5.95	-0.43	1.81e-8	Schizophrenia;
PAAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.59	-5.79	-0.42	3.94e-8	Urate levels in lean individuals;
PAAD	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.58	-5.44	-0.4	2.05e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg15478930	chr2:27652102	NRBP1	0.53	4.36	0.33	2.41e-5	Blood metabolite levels;
PAAD	cis	rs6700896	0.500	rs1892535	chr1:66097181	G/A	cg04111102	chr1:66153794	NA	0.47	4.42	0.34	1.88e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs62408225	0.722	rs3734660	chr6:90916345	A/G	cg03795776	chr6:90687632	BACH2	0.41	4.33	0.33	2.72e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2036402	0.704	rs10070224	chr5:156345735	A/G	cg21915449	chr5:156456672	HAVCR1	-0.47	-5.02	-0.38	1.42e-6	Hypertriglyceridemia;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.27	0.33	3.44e-5	Bipolar disorder;
PAAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.69	-0.42	6.31e-8	Ulcerative colitis;
PAAD	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.55	5.99	0.44	1.49e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.61	-5.47	-0.41	1.83e-7	Total body bone mineral density;
PAAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.65	6.99	0.49	8.16e-11	Mean corpuscular volume;
PAAD	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.52	-10.61	-0.65	5.01e-20	Atopic dermatitis;
PAAD	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.66	0.48	4.81e-10	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.06	-0.5	5.47e-11	Life satisfaction;
PAAD	cis	rs9788721	0.775	rs8040868	chr15:78911181	C/T	cg18825076	chr15:78729989	IREB2	0.43	4.28	0.33	3.35e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61677309	1.000	rs1074459	chr11:118155997	T/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	trans	rs901683	1.000	rs78766622	chr10:46087519	A/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.31	4.48	0.34	1.46e-5	Body mass index;
PAAD	cis	rs1075265	0.756	rs809280	chr2:54148407	G/A	cg04546899	chr2:54196757	PSME4	0.33	4.93	0.37	2.15e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.57	-5.83	-0.43	3.14e-8	Systemic sclerosis;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg01759136	chr6:27242945	NA	0.37	4.29	0.33	3.22e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.63	-5.03	-0.38	1.39e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg14345882	chr6:26364793	BTN3A2	0.39	4.46	0.34	1.6e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.42	-5.17	-0.39	7.24e-7	Crohn's disease;
PAAD	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	5.52	0.41	1.42e-7	Mood instability;
PAAD	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.43	4.61	0.35	8.32e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.81	8.5	0.57	1.66e-14	Selective IgA deficiency;
PAAD	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.09	0.5	4.65e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.67	5.3	0.39	4.1e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.4	5.41	0.4	2.39e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs747650	0.504	rs11039080	chr11:47093084	T/C	cg19486271	chr11:47235900	DDB2	0.68	6.29	0.45	3.26e-9	Acne (severe);
PAAD	cis	rs62229266	0.654	rs62230787	chr21:37376480	A/G	cg08632701	chr21:37451849	NA	-0.59	-6.07	-0.44	9.77e-9	Mitral valve prolapse;
PAAD	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg21601837	chr3:125900065	ALDH1L1	-0.47	-5.18	-0.39	6.91e-7	Metabolite levels;
PAAD	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.59	4.96	0.37	1.85e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg22437258	chr11:111473054	SIK2	0.66	6.64	0.47	5.13e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.96	10.72	0.66	2.54e-20	Testicular germ cell tumor;
PAAD	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg07148914	chr20:33460835	GGT7	0.47	4.26	0.33	3.61e-5	Height;
PAAD	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.72e-5	Systolic blood pressure;
PAAD	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.42	-4.26	-0.33	3.64e-5	Ulcerative colitis;
PAAD	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.29e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.66	5.19	0.39	6.71e-7	Alzheimer's disease (survival time);
PAAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.84	-8.77	-0.58	3.4e-15	Total body bone mineral density;
PAAD	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	5.08	0.38	1.1e-6	Iron status biomarkers;
PAAD	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg10977910	chr1:84465055	TTLL7	0.51	4.6	0.35	8.87e-6	Obesity-related traits;
PAAD	cis	rs9646944	0.501	rs10166330	chr2:103050390	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	4.28	0.33	3.28e-5	Blood protein levels;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.51	5.36	0.4	3.06e-7	Menopause (age at onset);
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.51	-4.99	-0.38	1.6e-6	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs71636778	0.722	rs35650645	chr1:27169484	T/C	cg12203394	chr1:27248618	NUDC	0.63	4.55	0.35	1.08e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.78	8.46	0.57	2.07e-14	Menopause (age at onset);
PAAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	6.02	0.44	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.73	-7.67	-0.53	1.94e-12	DNA methylation (variation);
PAAD	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	5.55	0.41	1.25e-7	Lung cancer in ever smokers;
PAAD	cis	rs11735070	0.618	rs12152555	chr4:100712375	T/C	cg10031042	chr4:101090547	NA	0.38	4.46	0.34	1.6e-5	Response to antipsychotic treatment;
PAAD	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.69	-7.11	-0.5	4.28e-11	Coronary artery disease;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg02696790	chr15:75250997	RPP25	0.49	5.85	0.43	2.84e-8	Breast cancer;
PAAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.45	-4.29	-0.33	3.16e-5	Response to metformin (IC50);
PAAD	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.11e-9	Monobrow;
PAAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.93	-12.08	-0.7	5.75e-24	Coronary artery disease;
PAAD	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg09127314	chr1:152161683	NA	-0.75	-5.4	-0.4	2.53e-7	Atopic dermatitis;
PAAD	trans	rs901683	0.557	rs34663276	chr10:45971360	A/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg00750074	chr16:89608354	SPG7	-0.51	-4.32	-0.33	2.8e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs227425	0.596	rs227426	chr14:70456664	G/T	cg18302334	chr14:70454441	SMOC1	-0.39	-4.31	-0.33	2.94e-5	Bone mineral density;
PAAD	cis	rs8014252	0.803	rs74062743	chr14:71023411	G/T	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.47	6.14	0.45	6.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.2	-0.5	2.52e-11	Alcohol dependence;
PAAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.58	7.25	0.51	1.94e-11	Diastolic blood pressure;
PAAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.73e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs790110	1.000	rs790110	chr3:122384020	T/G	cg16054280	chr3:122517974	DIRC2	0.86	4.53	0.34	1.21e-5	Acoustic startle blink response;
PAAD	cis	rs3749237	1.000	rs9819511	chr3:49884261	C/T	cg03060546	chr3:49711283	APEH	0.61	6.04	0.44	1.11e-8	Resting heart rate;
PAAD	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.58	6.47	0.46	1.25e-9	Mean corpuscular volume;
PAAD	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.86	10.15	0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.69	-6.44	-0.46	1.48e-9	Paraoxonase activity;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.34	0.56	4.19e-14	Prudent dietary pattern;
PAAD	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.41	-5.24	-0.39	5.24e-7	Vitiligo;
PAAD	cis	rs7814319	0.838	rs6997073	chr8:97232117	T/G	cg20787634	chr8:97240163	UQCRB	-0.6	-6.11	-0.44	8.13e-9	Lung function (FVC);
PAAD	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.74	-0.36	4.92e-6	Morning vs. evening chronotype;
PAAD	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.45	-5.11	-0.38	9.58e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.62	-0.53	2.54e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs12044355	0.929	rs11122322	chr1:231843962	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-4.71	-0.36	5.64e-6	Alzheimer's disease;
PAAD	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg24687543	chr11:63912206	MACROD1	0.62	5.41	0.4	2.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.35	0.33	2.5e-5	Renal cell carcinoma;
PAAD	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.37	4.56	0.35	1.05e-5	Inflammatory bowel disease;
PAAD	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11297382	chr12:54070143	ATP5G2	0.61	6.7	0.48	3.81e-10	Monocyte percentage of white cells;
PAAD	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	5.28	0.39	4.38e-7	Joint mobility (Beighton score);
PAAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.72	-0.36	5.22e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.71	6.89	0.49	1.37e-10	Heart rate;
PAAD	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg20302533	chr7:39170763	POU6F2	-0.43	-5.8	-0.43	3.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	cis	rs375066	0.935	rs396874	chr19:44397225	G/C	cg08633290	chr19:44405433	NA	-0.58	-5.86	-0.43	2.76e-8	Breast cancer;
PAAD	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg15117754	chr3:10150083	C3orf24	0.68	5.73	0.42	5.29e-8	Alzheimer's disease;
PAAD	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.53	6.23	0.45	4.38e-9	Mean corpuscular volume;
PAAD	cis	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs6066835	1.000	rs6095247	chr20:47320835	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs6604026	0.656	rs7515257	chr1:93393718	G/A	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.42	0.34	1.87e-5	Tonsillectomy;
PAAD	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.65	7.31	0.51	1.39e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-6.59	-0.47	6.77e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.54	5.85	0.43	2.98e-8	Obesity-related traits;
PAAD	cis	rs13102973	0.640	rs11722290	chr4:135832268	C/T	cg14419869	chr4:135874104	NA	0.45	4.59	0.35	9.21e-6	Subjective well-being;
PAAD	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.32	11.26	0.67	8.95e-22	Uric acid levels;
PAAD	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg07099767	chr17:78039528	CCDC40	0.44	4.37	0.33	2.31e-5	Yeast infection;
PAAD	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-12.71	-0.72	1.14e-25	Schizophrenia;
PAAD	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.51	-5.06	-0.38	1.2e-6	Mean platelet volume;
PAAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg26497354	chr6:109612229	NA	-0.42	-4.34	-0.33	2.58e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs9677476	0.632	rs10198572	chr2:232096723	G/A	cg07929768	chr2:232055508	NA	0.37	4.41	0.34	1.91e-5	Food antigen IgG levels;
PAAD	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg03959625	chr15:84868606	LOC388152	0.5	5.52	0.41	1.45e-7	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg04154034	chr17:28927549	LRRC37B2	0.62	4.32	0.33	2.84e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg21132104	chr15:45694354	SPATA5L1	0.87	8.41	0.56	2.79e-14	Homoarginine levels;
PAAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.47	4.73	0.36	5.12e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg16419906	chr5:132167176	NA	-0.66	-5.23	-0.39	5.6e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg21351543	chr2:191399470	TMEM194B	-0.64	-4.67	-0.35	6.47e-6	Diastolic blood pressure;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.48	4.33	0.33	2.65e-5	Acylcarnitine levels;
PAAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.67	7.26	0.51	1.83e-11	Hemoglobin concentration;
PAAD	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg07810366	chr2:100720526	AFF3	-0.35	-4.4	-0.34	2.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.62	-6.26	-0.45	3.68e-9	Height;
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs72772787	1.000	rs74152846	chr1:248013318	G/T	cg00785941	chr1:248100591	OR2L13	0.43	4.32	0.33	2.81e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1800469	0.965	rs12983775	chr19:41857439	G/A	cg09537434	chr19:41945824	ATP5SL	-0.61	-5.76	-0.42	4.54e-8	Colorectal cancer;
PAAD	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg11783602	chr8:55087084	NA	-0.68	-7.87	-0.54	6.33e-13	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.98e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	7.09	0.5	4.82e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.75	-8.07	-0.55	2.01e-13	Lung cancer;
PAAD	cis	rs72960926	1.000	rs16884733	chr6:75064563	A/G	cg13997649	chr6:74171430	MTO1	0.83	4.63	0.35	7.84e-6	Metabolite levels (MHPG);
PAAD	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.29e-16	Asthma;
PAAD	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.56	4.64	0.35	7.43e-6	Schizophrenia;
PAAD	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-5.62	-0.41	8.84e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.77	-0.36	4.31e-6	Height;
PAAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg01320130	chr1:67600311	NA	0.54	5.69	0.42	6.41e-8	Psoriasis;
PAAD	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.57	5.62	0.41	8.86e-8	Coronary artery disease;
PAAD	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg23920097	chr1:209922102	NA	0.5	4.53	0.34	1.18e-5	Red blood cell count;
PAAD	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs354225	0.544	rs13423873	chr2:54786677	A/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.7	0.36	5.77e-6	Schizophrenia;
PAAD	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.7	-7.28	-0.51	1.64e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg10072921	chr12:121022843	NA	-0.42	-5.16	-0.39	7.51e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg19486271	chr11:47235900	DDB2	0.54	5.58	0.41	1.06e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs11811982	0.793	rs11808210	chr1:227515049	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg27615366	chr5:131592974	PDLIM4	0.41	4.25	0.33	3.69e-5	Acylcarnitine levels;
PAAD	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2882667	0.690	rs700629	chr5:138123994	T/G	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.5	5.5	0.41	1.55e-7	Electroencephalogram traits;
PAAD	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg09659197	chr4:152720779	NA	0.4	5.04	0.38	1.28e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16057532	chr1:112524901	KCND3	-0.71	-7.52	-0.52	4.48e-12	Obesity-related traits;
PAAD	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg00181669	chr3:44000978	NA	0.43	4.53	0.34	1.21e-5	Coronary artery disease;
PAAD	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg11663144	chr21:46675770	NA	-0.47	-5.66	-0.42	7.36e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg11619707	chr19:22235551	ZNF257	0.56	5.59	0.41	1.01e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.41	-0.46	1.74e-9	Response to antipsychotic treatment;
PAAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg03303774	chr4:1407052	NA	0.48	6.02	0.44	1.27e-8	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19343014	chr12:97611381	NA	0.63	6.99	0.49	7.97e-11	Smoking initiation;
PAAD	cis	rs730532	0.597	rs57847444	chr14:52504950	T/C	cg01781974	chr14:52535973	NID2	-0.58	-4.26	-0.33	3.51e-5	Pulmonary function;
PAAD	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-4.54	-0.35	1.13e-5	Type 1 diabetes;
PAAD	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.55	7.79	0.53	9.91e-13	Homoarginine levels;
PAAD	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.49	5.4	0.4	2.51e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.1	-0.38	9.81e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.63	-7.97	-0.54	3.51e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06998765	chr14:75389618	RPS6KL1	-0.29	-5.11	-0.38	9.61e-7	Caffeine consumption;
PAAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03676636	chr4:99064102	C4orf37	0.32	5.89	0.43	2.39e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.87	-8.91	-0.59	1.45e-15	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10476558	chr20:30326789	TPX2	0.56	7.12	0.5	4.03e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4343996	1.000	rs6966619	chr7:3359491	A/T	cg21248987	chr7:3385318	SDK1	0.47	5.17	0.39	7.13e-7	Motion sickness;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11677203	1.000	rs11685890	chr2:12564292	C/T	cg01444004	chr2:11726968	GREB1	0.45	4.31	0.33	2.88e-5	Electroencephalogram traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13366586	chr4:83265422	NA	-0.55	-6.73	-0.48	3.28e-10	Monocyte percentage of white cells;
PAAD	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.7	6.05	0.44	1.07e-8	Pubertal anthropometrics;
PAAD	cis	rs1468734	1.000	rs12919777	chr16:5004839	A/G	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs3206736	0.548	rs329234	chr7:35055880	A/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.4	-4.46	-0.34	1.61e-5	Inflammatory bowel disease;
PAAD	cis	rs508970	0.519	rs515855	chr11:60917983	A/G	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.88	-9.3	-0.6	1.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs9810890	1.000	rs116772388	chr3:128453215	A/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg25837213	chr17:80849375	TBCD	-0.56	-4.63	-0.35	7.9e-6	Breast cancer;
PAAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.67	5.62	0.41	8.91e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.58	-5.49	-0.41	1.64e-7	Primary biliary cholangitis;
PAAD	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-5.61	-0.41	9.34e-8	Mean corpuscular volume;
PAAD	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.57	-5.07	-0.38	1.14e-6	P wave terminal force;
PAAD	cis	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg21546286	chr11:48923668	NA	-0.44	-4.72	-0.36	5.42e-6	Height;
PAAD	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.04	0.59	6.69e-16	Hemoglobin concentration;
PAAD	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs72828912	0.831	rs4574616	chr6:24094037	C/G	cg27524988	chr6:24583477	KIAA0319	0.48	4.57	0.35	9.92e-6	Squamous cell lung carcinoma;
PAAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	7.11	0.5	4.19e-11	Personality dimensions;
PAAD	cis	rs7264396	0.887	rs6060434	chr20:34068382	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg00999904	chr2:3704751	ALLC	0.45	4.96	0.37	1.87e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.77	0.42	4.41e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs17162190	0.698	rs4659443	chr1:26823631	C/T	cg17456097	chr1:26900765	RPS6KA1	0.6	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.93	0.37	2.13e-6	Cognitive ability;
PAAD	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.5	-0.47	1.11e-9	HDL cholesterol;
PAAD	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg11271282	chr2:238384023	NA	0.56	4.37	0.33	2.29e-5	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27177954	chr22:41601126	L3MBTL2	-0.59	-6.66	-0.48	4.77e-10	Smoking initiation;
PAAD	cis	rs6669119	0.818	rs78431755	chr1:19078203	G/A	cg19637330	chr1:19110922	NA	0.76	4.75	0.36	4.72e-6	Percentage gas trapping;
PAAD	cis	rs3764400	0.507	rs16954324	chr17:46324584	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	0.87	8.4	0.56	2.99e-14	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-4.79	-0.36	3.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg09737314	chr17:6899359	ALOX12	0.53	5.56	0.41	1.2e-7	Tonsillectomy;
PAAD	cis	rs11264213	0.901	rs72661608	chr1:36333850	C/G	cg27506609	chr1:36549197	TEKT2	1.05	5.67	0.42	7e-8	Schizophrenia;
PAAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	9.94	0.63	3.09e-18	Ulcerative colitis;
PAAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg03983715	chr16:68378420	PRMT7	0.88	6.16	0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.72	7.77	0.53	1.07e-12	Cystic fibrosis severity;
PAAD	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg03538708	chr1:25844672	NA	-0.49	-4.97	-0.37	1.81e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.72e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-5.01	-0.38	1.5e-6	Schizophrenia;
PAAD	cis	rs59888335	0.964	rs2176028	chr3:80655077	G/A	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19630440	chr20:33146371	MAP1LC3A	0.57	6.64	0.47	5.21e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.54	5.03	0.38	1.35e-6	Airway imaging phenotypes;
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07163401	chr2:72376239	CYP26B1	-0.66	-6.5	-0.47	1.1e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg05110241	chr16:68378359	PRMT7	-1.11	-8.12	-0.55	1.47e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.56	5.36	0.4	2.97e-7	Blood metabolite levels;
PAAD	cis	rs17655565	0.581	rs12424634	chr12:52769186	C/T	cg22980804	chr12:52818037	KRT75	-0.48	-4.28	-0.33	3.27e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.57	-5.05	-0.38	1.24e-6	Obesity-related traits;
PAAD	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.81	5.72	0.42	5.56e-8	Anti-saccade response;
PAAD	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-5.91	-0.43	2.15e-8	Glomerular filtration rate;
PAAD	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg19486271	chr11:47235900	DDB2	-0.57	-5.8	-0.43	3.7e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs4074493	1.000	rs11122199	chr1:231172686	T/C	cg22172038	chr1:231176991	FAM89A	0.5	4.71	0.36	5.62e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.87	9.43	0.61	6.76e-17	Cognitive function;
PAAD	cis	rs7402982	0.647	rs4966007	chr15:99200056	G/A	cg03437748	chr15:99193247	IGF1R	0.65	5.7	0.42	5.95e-8	Birth weight;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26549601	chr10:134560360	INPP5A	-0.45	-4.72	-0.36	5.4e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.69	-0.36	6.11e-6	Diastolic blood pressure;
PAAD	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-1.12	-10.25	-0.64	4.43e-19	Blood trace element (Zn levels);
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg00791764	chr4:53727839	RASL11B	-0.65	-4.29	-0.33	3.18e-5	Optic nerve measurement (cup area);
PAAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.45	4.48	0.34	1.46e-5	Chronic sinus infection;
PAAD	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs74181299	0.684	rs9797989	chr2:65336529	T/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.37	-0.33	2.33e-5	Pulse pressure;
PAAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg26939375	chr7:64535504	NA	-0.76	-9.17	-0.6	3.06e-16	Corneal structure;
PAAD	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.47	4.37	0.33	2.26e-5	Airway imaging phenotypes;
PAAD	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-1.09	-15.43	-0.78	6.48e-33	Total body bone mineral density;
PAAD	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.63	6.76	0.48	2.74e-10	Longevity;
PAAD	cis	rs7619427	0.544	rs62252204	chr3:43965558	G/A	cg12796028	chr3:44040206	NA	-0.55	-4.77	-0.36	4.35e-6	Schizophrenia;
PAAD	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.71	7.32	0.51	1.36e-11	Colorectal cancer;
PAAD	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.73	-0.36	5.09e-6	Educational attainment (years of education);
PAAD	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.29	-0.39	4.27e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs116248771	0.739	rs12488447	chr3:158421824	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	5.04e-14	Prudent dietary pattern;
PAAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg23346134	chr3:49453900	TCTA	0.46	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs859767	0.741	rs4954155	chr2:135383504	T/C	cg12500956	chr2:135428796	TMEM163	-0.31	-4.38	-0.33	2.18e-5	Neuroticism;
PAAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.7	4.81	0.36	3.61e-6	Hip geometry;
PAAD	cis	rs7132746	0.553	rs7399276	chr12:86189219	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-4.71	-0.36	5.49e-6	Lewy body disease;
PAAD	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.72	7.37	0.51	1e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21775007	chr8:11205619	TDH	0.56	4.86	0.37	2.84e-6	Neuroticism;
PAAD	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg26384229	chr12:38710491	ALG10B	0.7	7.25	0.51	1.98e-11	Morning vs. evening chronotype;
PAAD	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.37	0.46	2.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	1.07	9.42	0.61	6.97e-17	Eosinophil percentage of granulocytes;
PAAD	cis	rs10159528	0.631	rs10788464	chr10:87461067	C/T	cg03356747	chr10:88126089	GRID1	-0.38	-4.34	-0.33	2.61e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3112530	1.000	rs2609665	chr5:152677967	G/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.88	5.27	0.39	4.65e-7	Prostate cancer;
PAAD	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.88	0.37	2.62e-6	Diastolic blood pressure;
PAAD	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs13253111	1.000	rs17411738	chr8:28060572	T/G	cg26534493	chr8:28060551	NA	0.44	4.89	0.37	2.54e-6	Childhood body mass index;
PAAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09099927	chr4:40045641	LOC344967	-0.7	-7.13	-0.5	3.72e-11	Obesity-related traits;
PAAD	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.79	7.08	0.5	5.06e-11	Response to diuretic therapy;
PAAD	cis	rs9816226	0.591	rs76880877	chr3:185802628	A/C	cg00760338	chr3:185826511	ETV5	-0.72	-5.55	-0.41	1.26e-7	Obesity;Body mass index;
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.99	-0.44	1.47e-8	Prostate cancer;
PAAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.32e-6	Mood instability;
PAAD	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.64	5.74	0.42	5.03e-8	Type 2 diabetes;
PAAD	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.76	-8.22	-0.55	8.26e-14	Colorectal cancer;
PAAD	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.53	-4.75	-0.36	4.63e-6	Lung cancer;
PAAD	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01086369	chr19:50885373	NR1H2	0.54	6.36	0.46	2.19e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12282928	0.959	rs2870509	chr11:48284109	T/C	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09597638	chr17:3907349	NA	-0.7	-7.52	-0.52	4.5e-12	Type 2 diabetes;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07157834	chr1:205819609	PM20D1	0.5	4.92	0.37	2.21e-6	Parkinson's disease;
PAAD	cis	rs758324	0.773	rs13183449	chr5:131116082	C/A	cg06307176	chr5:131281290	NA	0.49	4.31	0.33	2.88e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2415984	0.579	rs1389606	chr14:46964226	T/C	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.52	-4.98	-0.37	1.7e-6	Acylcarnitine levels;
PAAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg05207973	chr5:176823642	SLC34A1	0.4	4.87	0.37	2.71e-6	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.51	-5.31	-0.4	3.84e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.9	9.22	0.6	2.38e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.51	4.35	0.33	2.51e-5	Depression;
PAAD	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.54	-7.88	-0.54	5.94e-13	Diastolic blood pressure;
PAAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg25452165	chr22:42524984	CYP2D6	0.58	5.2	0.39	6.45e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.83	0.54	7.85e-13	Prudent dietary pattern;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs1437396	0.556	rs12621734	chr2:55566531	A/C	cg00883689	chr2:54802904	SPTBN1	0.28	4.28	0.33	3.3e-5	Alcohol dependence;
PAAD	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23158103	chr7:148848205	ZNF398	-0.59	-5.87	-0.43	2.7e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8112211	0.599	rs2302182	chr19:38827960	T/C	cg14299480	chr19:38876666	GGN	-0.57	-4.8	-0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.7	-6.06	-0.44	1.03e-8	Diabetic retinopathy;
PAAD	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg10820045	chr2:198174542	NA	0.44	4.37	0.33	2.31e-5	Intracranial aneurysm;
PAAD	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-5.03	-0.38	1.39e-6	Coronary artery disease;
PAAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.35	-0.4	3.14e-7	Blood metabolite levels;
PAAD	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg22517653	chr1:2918612	NA	-0.65	-5.51	-0.41	1.51e-7	Plateletcrit;
PAAD	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs12989701	0.877	rs13029812	chr2:127872622	A/G	cg08168897	chr2:127865431	BIN1	0.68	5.9	0.43	2.26e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.52	5.0	0.38	1.59e-6	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-5.24	-0.39	5.29e-7	Bladder cancer;
PAAD	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.4e-6	Diastolic blood pressure;
PAAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18099408	chr3:52552593	STAB1	-0.57	-6.23	-0.45	4.37e-9	Electroencephalogram traits;
PAAD	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	6.4	0.46	1.83e-9	Lung cancer in ever smokers;
PAAD	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.74	6.27	0.45	3.57e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	4.65	0.35	7.11e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7123876	0.587	rs61895588	chr11:72360986	A/G	cg03713592	chr11:72463424	ARAP1	0.64	4.3	0.33	3e-5	Body mass index;
PAAD	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg04896959	chr15:78267971	NA	0.63	6.26	0.45	3.68e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg15017067	chr4:17643749	FAM184B	0.38	4.25	0.33	3.65e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8025118	0.583	rs11856016	chr15:79545422	T/C	cg24739098	chr15:79297159	RASGRF1	-0.4	-4.5	-0.34	1.34e-5	Cognitive function;
PAAD	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.41	0.34	1.93e-5	Asthma;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01388144	chr15:43785382	TP53BP1	-0.46	-4.5	-0.34	1.33e-5	Lung cancer in ever smokers;
PAAD	cis	rs68170813	1.000	rs10953541	chr7:107244545	C/T	cg23024343	chr7:107201750	COG5	0.53	4.36	0.33	2.4e-5	Coronary artery disease;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.84	11.44	0.68	3.06e-22	Emphysema distribution in smoking;
PAAD	cis	rs216303	1.000	rs216303	chr12:6159045	C/T	cg12895370	chr12:6755816	ACRBP	-0.5	-4.27	-0.33	3.45e-5	Low vWF levels;
PAAD	cis	rs6785206	0.554	rs9841748	chr3:128480204	C/A	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.64	-5.27	-0.39	4.66e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19202786	chr6:166797286	BRP44L	0.63	6.85	0.49	1.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg21351543	chr2:191399470	TMEM194B	0.7	5.27	0.39	4.53e-7	Diastolic blood pressure;
PAAD	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.61	5.06	0.38	1.17e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs955333	0.641	rs7750564	chr6:154904363	C/A	cg20019720	chr6:154832845	CNKSR3	0.37	5.04	0.38	1.3e-6	Diabetic kidney disease;
PAAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.55	7.77	0.53	1.07e-12	Schizophrenia;
PAAD	cis	rs67257959	0.708	rs1979261	chr19:17193518	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.48	-4.87	-0.37	2.82e-6	Selective IgA deficiency;
PAAD	cis	rs11614333	1.000	rs12316046	chr12:15054415	A/G	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg00717180	chr2:96193071	NA	-0.61	-7.1	-0.5	4.56e-11	HDL cholesterol;
PAAD	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.94	7.04	0.5	6.19e-11	Dental caries;
PAAD	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg21775007	chr8:11205619	TDH	-0.46	-4.38	-0.33	2.18e-5	Systolic blood pressure;
PAAD	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.59	5.71	0.42	5.77e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02071572	chr4:1403502	NA	0.43	5.69	0.42	6.26e-8	Obesity-related traits;
PAAD	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg11130432	chr3:121712080	ILDR1	0.52	4.41	0.34	1.99e-5	Multiple sclerosis;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg01762785	chr22:42226837	NA	-0.44	-4.85	-0.37	3.01e-6	Intelligence;
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.52	-0.47	9.74e-10	Lung cancer;
PAAD	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.91	12.22	0.7	2.41e-24	Body mass index;
PAAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.71	-0.36	5.6e-6	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.77	-6.78	-0.48	2.54e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs11264985	chr1:158465166	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg23860436	chr12:58378763	NA	-0.46	-4.31	-0.33	2.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.93	10.34	0.64	2.61e-19	DNA methylation (variation);
PAAD	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.61	-4.26	-0.33	3.56e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg26031613	chr14:104095156	KLC1	0.79	8.1	0.55	1.62e-13	Body mass index;
PAAD	cis	rs2790216	1.000	rs2153282	chr10:59972416	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.89	11.02	0.67	4.05e-21	Prudent dietary pattern;
PAAD	cis	rs4908760	0.965	rs10864354	chr1:8549741	C/T	cg20416874	chr1:8611966	RERE	-0.48	-4.64	-0.35	7.53e-6	Vitiligo;
PAAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg24253500	chr15:84953950	NA	0.57	6.84	0.49	1.79e-10	Schizophrenia;
PAAD	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-4.26	-0.33	3.5e-5	Mean corpuscular volume;
PAAD	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg09491104	chr22:46646882	C22orf40	-0.96	-5.99	-0.44	1.43e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.72	0.66	2.6e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1519814	0.696	rs6985424	chr8:121062976	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-5.31	-0.4	3.91e-7	Breast cancer;
PAAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.55	5.21	0.39	6.02e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.48e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.63	-4.28	-0.33	3.32e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.53	5.2	0.39	6.25e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.79	9.07	0.59	5.65e-16	Diastolic blood pressure;
PAAD	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.99	11.61	0.69	1.04e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-4.77	-0.36	4.38e-6	Cystic fibrosis severity;
PAAD	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.46	-5.61	-0.41	9.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	1.08	15.42	0.78	6.9e-33	Breast cancer;
PAAD	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.56	-5.64	-0.42	8.17e-8	QT interval;
PAAD	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.34	-4.37	-0.33	2.25e-5	Educational attainment (years of education);
PAAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.56	6.11	0.44	7.84e-9	Menopause (age at onset);
PAAD	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.86	-0.37	2.92e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs16895831	0.519	rs62414629	chr6:42598898	G/A	cg10605015	chr6:42532144	UBR2	-0.66	-5.0	-0.38	1.59e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.79	8.11	0.55	1.53e-13	Prostate cancer;
PAAD	cis	rs894734	0.535	rs979013	chr12:54320805	C/A	cg17410650	chr12:54324560	NA	-0.47	-7.87	-0.54	6.24e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg25204440	chr1:209979598	IRF6	0.67	5.66	0.42	7.48e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg09491104	chr22:46646882	C22orf40	-0.97	-8.93	-0.59	1.29e-15	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.74	7.44	0.52	6.9e-12	Menopause (age at onset);
PAAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-5.82	-0.43	3.29e-8	IgG glycosylation;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg07648498	chr16:89883185	FANCA	0.48	4.56	0.35	1.05e-5	Vitiligo;
PAAD	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	5.03e-7	Pulmonary function;
PAAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-5.38	-0.4	2.79e-7	Schizophrenia;
PAAD	cis	rs7765175	0.524	rs2226244	chr6:113634490	C/A	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs1977584	0.725	rs79498729	chr10:45402161	C/T	cg04218760	chr10:45406644	TMEM72	0.36	4.48	0.34	1.46e-5	Selective IgA deficiency;
PAAD	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-6.2	-0.45	5.2e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.06e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2422052	0.729	rs967252	chr2:118643492	T/G	cg22545206	chr2:118617499	NA	0.53	5.48	0.41	1.7e-7	Mosquito bite size;
PAAD	cis	rs9826463	0.757	rs73240323	chr3:142294803	T/A	cg20824294	chr3:142316082	PLS1	0.43	4.87	0.37	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg07212818	chr11:638076	DRD4	-0.77	-6.68	-0.48	4.2e-10	Systemic lupus erythematosus;
PAAD	cis	rs4965359	0.665	rs8031193	chr15:101598964	A/G	cg02262866	chr15:101593693	LRRK1	0.44	4.41	0.34	1.93e-5	Central corneal thickness;
PAAD	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.67	0.53	1.91e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11811982	0.793	rs76859897	chr1:227365040	C/A	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg24253500	chr15:84953950	NA	0.59	6.66	0.48	4.72e-10	Schizophrenia;
PAAD	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.64	6.56	0.47	7.82e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg14092988	chr3:52407081	DNAH1	0.45	5.63	0.42	8.46e-8	Bipolar disorder;
PAAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.46	-4.4	-0.34	2.06e-5	Body mass index;
PAAD	cis	rs41311933	1.000	rs16910254	chr9:123751661	A/G	cg13567360	chr9:123745713	C5	-0.73	-4.64	-0.35	7.35e-6	Coronary artery disease;
PAAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19346786	chr7:2764209	NA	-0.38	-5.15	-0.39	8.13e-7	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07050602	chr15:85291082	ZNF592	0.62	7.22	0.51	2.37e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07039975	chr2:74592036	DCTN1	-0.66	-6.63	-0.47	5.4e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.56	-6.09	-0.44	8.66e-9	Electroencephalogram traits;
PAAD	cis	rs4919087	0.926	rs945189	chr10:99091766	C/G	cg06569542	chr10:98946673	SLIT1	-0.53	-5.76	-0.42	4.52e-8	Monocyte count;
PAAD	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.57	5.57	0.41	1.13e-7	Fibrinogen levels;
PAAD	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.83	7.85	0.54	6.94e-13	Corneal astigmatism;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.94	12.08	0.7	5.64e-24	Prudent dietary pattern;
PAAD	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.33	-0.51	1.3e-11	Chronic sinus infection;
PAAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg21890820	chr11:65308645	LTBP3	-0.65	-7.94	-0.54	4.21e-13	Bone mineral density;
PAAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07755735	chr2:20870362	GDF7	-0.53	-6.56	-0.47	8.14e-10	Abdominal aortic aneurysm;
PAAD	cis	rs6688613	1.000	rs7518155	chr1:166954896	G/T	cg07049167	chr1:166818506	POGK	-0.44	-4.41	-0.34	1.95e-5	Refractive astigmatism;
PAAD	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs10068717	1	rs10068717	chr5:141494934	C/T	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.26	-0.39	4.89e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs16975963	0.843	rs11083442	chr19:38427528	C/A	cg25793785	chr19:38281423	NA	0.57	4.66	0.35	6.88e-6	Longevity;
PAAD	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.19	-0.5	2.72e-11	Triglycerides;
PAAD	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.45	-4.35	-0.33	2.46e-5	Mean platelet volume;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18621852	chr3:10150065	C3orf24	0.74	6.57	0.47	7.73e-10	Alzheimer's disease;
PAAD	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg26138144	chr22:38071188	LGALS1	0.41	4.5	0.34	1.33e-5	Fat distribution (HIV);
PAAD	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.49	-5.91	-0.43	2.16e-8	Lewy body disease;
PAAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg05083358	chr7:2394359	EIF3B	-0.77	-5.59	-0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.61	5.99	0.44	1.48e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg06789500	chr7:2109450	MAD1L1	-0.44	-4.54	-0.35	1.14e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25423225	chr7:935108	C7orf20	0.54	6.5	0.47	1.06e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-4.32	-0.33	2.86e-5	Tonsillectomy;
PAAD	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs2080501	0.628	rs1861656	chr16:49663019	G/T	cg27618369	chr16:49636483	ZNF423	-0.54	-5.61	-0.41	9.15e-8	IgG glycosylation;
PAAD	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.6	-5.02	-0.38	1.44e-6	Atopic dermatitis;
PAAD	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg18031326	chr11:68079681	LRP5	-0.34	-4.35	-0.33	2.44e-5	Mean corpuscular volume;
PAAD	cis	rs6142102	0.602	rs4911402	chr20:32667645	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	5.11	0.38	9.75e-7	Skin pigmentation;
PAAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.63	-7.21	-0.5	2.46e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs6594713	0.533	rs4705562	chr5:112978482	C/G	cg12552261	chr5:112820674	MCC	0.7	4.39	0.34	2.1e-5	Brain cytoarchitecture;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.88	7.53	0.52	4.26e-12	Alzheimer's disease;
PAAD	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.61e-13	Motion sickness;
PAAD	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg08992911	chr2:238395768	MLPH	0.68	5.67	0.42	7.09e-8	Prostate cancer;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.83	9.47	0.61	5.17e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.72	-7.25	-0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.14	0.45	7.01e-9	Breast cancer;
PAAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg09796270	chr17:17721594	SREBF1	0.44	4.67	0.35	6.47e-6	Total body bone mineral density;
PAAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	7.98	0.54	3.22e-13	Mood instability;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-5.12	-0.38	8.99e-7	Longevity;Endometriosis;
PAAD	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.84	7.16	0.5	3.3e-11	Alzheimer's disease;
PAAD	cis	rs17776563	1.000	rs17776563	chr15:89119104	G/A	cg27664085	chr15:89157815	NA	0.32	4.31	0.33	2.97e-5	Thyroid hormone levels;
PAAD	cis	rs1144713	0.531	rs1716941	chr12:32255094	A/G	cg01321189	chr12:32259338	BICD1	0.48	5.05	0.38	1.28e-6	Obesity-related traits;
PAAD	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.48	5.33	0.4	3.53e-7	Total cholesterol levels;
PAAD	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg21479132	chr6:26055353	NA	0.89	5.29	0.39	4.28e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4742903	0.935	rs10991166	chr9:106974096	T/C	cg14250997	chr9:106856677	SMC2	0.43	4.54	0.35	1.12e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.17e-7	Ulcerative colitis;
PAAD	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.74	-0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.96	-9.09	-0.59	5.02e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg10856724	chr12:34555212	NA	0.42	4.44	0.34	1.74e-5	Morning vs. evening chronotype;
PAAD	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.76	-6.95	-0.49	1.01e-10	Blood protein levels;
PAAD	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.49	-0.78	4.55e-33	Schizophrenia;
PAAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg17366294	chr4:99064904	C4orf37	0.56	5.96	0.44	1.68e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20087221	chr10:98135160	TLL2	0.58	6.41	0.46	1.7e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10847915	chr10:131813485	NA	-0.54	-6.36	-0.46	2.22e-9	Morning vs. evening chronotype;
PAAD	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg02820901	chr13:113351484	ATP11A	0.72	4.78	0.36	4.04e-6	Glycated hemoglobin levels;
PAAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs893363	0.610	rs920252	chr3:53848672	G/C	cg15798837	chr3:54122146	NA	0.35	4.3	0.33	2.99e-5	Axial length;
PAAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.78	7.52	0.52	4.44e-12	Cognitive function;
PAAD	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs8010715	0.816	rs2332224	chr14:24598544	C/G	cg23112188	chr14:24563095	PCK2	-0.49	-5.3	-0.4	3.92e-7	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18856894	chr3:63850083	THOC7;ATXN7	-0.65	-6.67	-0.48	4.48e-10	Smoking initiation;
PAAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs12042938	0.622	rs11122318	chr1:231806852	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.39	0.34	2.12e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg19418318	chr19:17219073	MYO9B	0.48	5.72	0.42	5.53e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.67	5.45	0.4	1.97e-7	Coronary artery disease;
PAAD	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.74	-9.29	-0.6	1.57e-16	Educational attainment;
PAAD	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg24721873	chr10:135334122	NA	0.61	4.46	0.34	1.61e-5	Gout;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg24132523	chr1:145827062	GPR89A	-0.79	-6.6	-0.47	6.45e-10	Photic sneeze reflex;
PAAD	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.67	6.56	0.47	7.79e-10	Coronary artery disease;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg15181151	chr6:150070149	PCMT1	0.55	6.0	0.44	1.41e-8	Lung cancer;
PAAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.16	-0.5	3.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg26513180	chr16:89883248	FANCA	-0.44	-4.41	-0.34	1.98e-5	Vitiligo;
PAAD	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.54	4.39	0.34	2.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.34	-4.26	-0.33	3.57e-5	Longevity;Endometriosis;
PAAD	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.89	-0.37	2.5e-6	Bladder cancer;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.47	-0.34	1.51e-5	Joint mobility (Beighton score);
PAAD	cis	rs988913	1.000	rs1503136	chr6:54851965	A/C	cg03513858	chr6:54763001	FAM83B	-0.45	-4.97	-0.37	1.78e-6	Menarche (age at onset);
PAAD	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg14343924	chr8:8086146	FLJ10661	0.53	4.93	0.37	2.18e-6	Mood instability;
PAAD	cis	rs9463078	0.585	rs1290386	chr6:45168753	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.26	10.22	0.64	5.53e-19	Uric acid levels;
PAAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.69	6.79	0.48	2.36e-10	Lymphocyte counts;
PAAD	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.7	-0.36	5.71e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg26677194	chr12:130822605	PIWIL1	0.72	7.11	0.5	4.34e-11	Menopause (age at onset);
PAAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.71	7.14	0.5	3.55e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	1.12	17.94	0.82	2.28e-39	Menarche (age at onset);
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.74	0.42	5e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.83	-0.54	7.77e-13	Initial pursuit acceleration;
PAAD	cis	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg21546286	chr11:48923668	NA	0.6	6.34	0.46	2.5e-9	HDL cholesterol;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.72	-5.05	-0.38	1.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs795484	0.926	rs1726390	chr12:118645384	A/G	cg16572268	chr12:118583242	PEBP1	-0.44	-4.37	-0.33	2.31e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs282587	0.597	rs438116	chr13:113392149	G/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.96	-0.37	1.87e-6	Glycated hemoglobin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14420117	chr14:74724299	VSX2	0.67	6.65	0.47	5.04e-10	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg01957732	chr6:133561716	EYA4	-0.98	-7.15	-0.5	3.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.43	0.56	2.4e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.5	5.08	0.38	1.11e-6	Breast cancer;
PAAD	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10957961	0.586	rs7014791	chr8:81065580	A/G	cg10609868	chr8:81963379	PAG1	-0.37	-4.44	-0.34	1.75e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11264799	0.773	rs56273037	chr1:157680561	A/G	cg18268488	chr1:157545234	FCRL4	0.58	5.2	0.39	6.4e-7	IgA nephropathy;
PAAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.86	6.49	0.47	1.14e-9	Gut microbiome composition (summer);
PAAD	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.61	-6.62	-0.47	5.87e-10	HDL cholesterol;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03611598	chr17:48586076	MYCBPAP	0.67	6.57	0.47	7.69e-10	Visceral fat;
PAAD	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.25	6.16	0.45	6.34e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg15956490	chr3:53032818	SFMBT1	0.81	4.74	0.36	4.86e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs11264213	1.000	rs727005	chr1:36281336	A/G	cg27506609	chr1:36549197	TEKT2	0.69	4.74	0.36	4.89e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.58	-6.19	-0.45	5.47e-9	Cognitive function;
PAAD	cis	rs9467160	0.822	rs9461013	chr6:24443683	A/G	cg16211469	chr6:24423932	MRS2	0.42	4.38	0.33	2.24e-5	Liver enzyme levels;
PAAD	cis	rs59888335	0.830	rs35171311	chr3:80514191	T/C	cg21735741	chr3:80819488	NA	0.59	5.15	0.39	7.84e-7	Schizophrenia;
PAAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.94	-0.49	1.04e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
PAAD	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.67	0.48	4.53e-10	Response to antipsychotic treatment;
PAAD	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.81	-8.8	-0.58	2.76e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.4	-0.4	2.56e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg14196790	chr5:131705035	SLC22A5	0.46	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.71	-6.05	-0.44	1.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.54	-5.91	-0.43	2.2e-8	Longevity;
PAAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg14092988	chr3:52407081	DNAH1	0.45	5.71	0.42	5.85e-8	Bipolar disorder;
PAAD	cis	rs7119038	0.629	rs73001429	chr11:118603165	T/G	cg04176122	chr11:118779835	BCL9L	0.42	4.64	0.35	7.62e-6	Sjögren's syndrome;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-8.1	-0.55	1.62e-13	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg05318427	chr2:85199320	KCMF1	0.58	6.41	0.46	1.74e-9	Response to antipsychotic treatment;
PAAD	cis	rs35740288	0.822	rs4843090	chr15:86220629	T/C	cg07943548	chr15:86304357	KLHL25	-0.65	-5.57	-0.41	1.11e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs58653258	0.502	rs2802977	chr1:234987704	T/C	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg20243544	chr17:37824526	PNMT	0.5	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13870426	chr17:30244630	NA	-0.73	-7.24	-0.51	2.13e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.9	-0.43	2.28e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-4.69	-0.36	6.09e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.54	0.57	1.3e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.93	0.37	2.14e-6	Oropharynx cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24069935	chr14:74226554	C14orf43	0.71	6.98	0.49	8.46e-11	Obesity-related traits;
PAAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14119001	chr9:139324193	INPP5E	-0.59	-5.3	-0.39	4.07e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.18	-8.44	-0.56	2.34e-14	Schizophrenia;
PAAD	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.51	-4.69	-0.36	6.12e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.63	6.93	0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg06917634	chr15:78832804	PSMA4	-0.47	-4.6	-0.35	8.98e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-6.25	-0.45	3.98e-9	Blood protein levels;
PAAD	cis	rs13102973	0.682	rs7441468	chr4:135886736	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16583193	chr19:3652060	PIP5K1C	0.61	7.42	0.52	7.6e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.73e-11	Asthma;
PAAD	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.49	-4.67	-0.35	6.49e-6	Urinary tract infection frequency;
PAAD	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.1e-12	Colorectal cancer;
PAAD	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.49	4.83	0.36	3.28e-6	Eosinophil percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24527131	chr17:34869085	MYO19	-0.62	-6.43	-0.46	1.59e-9	Obesity-related traits;
PAAD	cis	rs12935418	0.579	rs2123627	chr16:81021816	C/A	cg16651780	chr16:81037892	C16orf61	-0.65	-5.98	-0.44	1.5e-8	Mean corpuscular volume;
PAAD	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.52	-5.15	-0.39	7.98e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.56	-4.38	-0.33	2.2e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6088813	0.883	rs1406948	chr20:33905619	G/A	cg14752227	chr20:34000481	UQCC	0.49	4.87	0.37	2.8e-6	Height;
PAAD	cis	rs912881	0.740	rs11962670	chr6:41412564	A/G	cg02404974	chr6:41376295	NA	0.56	4.37	0.33	2.34e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9815354	0.516	rs75047809	chr3:42033437	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3857067	0.550	rs28776332	chr4:95002429	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.64	6.25	0.45	3.84e-9	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27341045	chr15:75315928	PPCDC	0.57	6.34	0.46	2.44e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6442522	0.733	rs4143273	chr3:15501808	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-4.5	-0.34	1.37e-5	Uric acid levels;
PAAD	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg21479132	chr6:26055353	NA	1.0	6.44	0.46	1.5e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.34	0.33	2.56e-5	Schizophrenia;
PAAD	cis	rs17032980	0.910	rs7589620	chr2:67309662	T/G	cg06994420	chr2:66672553	MEIS1	-0.51	-4.51	-0.34	1.3e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.59	0.61	2.54e-17	Electrocardiographic conduction measures;
PAAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.53	5.44	0.4	2.06e-7	Major depressive disorder;
PAAD	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.58	5.64	0.42	8.19e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4462272	0.605	rs12265333	chr10:102011211	A/G	cg02250046	chr10:101825185	CPN1	-0.4	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.99	-11.73	-0.69	4.97e-23	Breast cancer;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.84	0.58	2.17e-15	Lung cancer;
PAAD	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.51	5.21	0.39	6.18e-7	Diastolic blood pressure;
PAAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.61	-7.44	-0.52	7.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	8.09	0.55	1.72e-13	Post bronchodilator FEV1;
PAAD	cis	rs6998277	0.553	rs6468837	chr8:103602767	A/G	cg10187029	chr8:103597600	NA	0.86	10.12	0.63	1.01e-18	Migraine;
PAAD	trans	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.64	-5.71	-0.42	5.63e-8	Serum sulfate level;
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.79	5.94	0.43	1.9e-8	Initial pursuit acceleration;
PAAD	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.67	-7.43	-0.52	7.21e-12	White blood cell count (basophil);
PAAD	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.92	-13.69	-0.74	2.63e-28	Height;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.89	10.23	0.64	5.1e-19	Tonsillectomy;
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.59e-7	Lung cancer;
PAAD	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg24110177	chr3:50126178	RBM5	-0.59	-5.77	-0.42	4.39e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.95	-16.15	-0.79	8.67e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg03959625	chr15:84868606	LOC388152	0.45	4.6	0.35	8.98e-6	Schizophrenia;
PAAD	cis	rs939584	0.935	rs73139123	chr2:630075	C/T	cg03610516	chr2:642275	NA	0.63	5.45	0.4	2.03e-7	Body mass index;
PAAD	cis	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.31	-0.4	3.83e-7	Neuroticism;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.93	7.71	0.53	1.49e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg09796270	chr17:17721594	SREBF1	-0.43	-4.62	-0.35	8.09e-6	Total body bone mineral density;
PAAD	cis	rs61759167	0.774	rs61759173	chr1:3097509	C/T	cg22396632	chr1:3079212	PRDM16	-0.55	-5.19	-0.39	6.65e-7	Motion sickness;
PAAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.9	-0.37	2.41e-6	Vitiligo;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.55	5.28	0.39	4.36e-7	Testicular germ cell tumor;
PAAD	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.63e-6	Renal cell carcinoma;
PAAD	cis	rs13424612	0.965	rs58652766	chr2:240904884	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.88	-0.37	2.63e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs4919087	0.590	rs1253400	chr10:99049566	G/A	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg19254793	chr6:44695348	NA	0.48	4.59	0.35	9.41e-6	Total body bone mineral density;
PAAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.6	-5.37	-0.4	2.83e-7	Myeloid white cell count;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.93	0.43	2e-8	Prudent dietary pattern;
PAAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs258892	0.895	rs10036866	chr5:72068932	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs375066	0.762	rs2284245	chr19:44422589	A/T	cg21496419	chr19:44306685	LYPD5	-0.4	-4.65	-0.35	7.04e-6	Breast cancer;
PAAD	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg09579323	chr1:150459698	TARS2	0.46	4.39	0.34	2.12e-5	Morning vs. evening chronotype;
PAAD	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg07166546	chr14:35805898	NA	-0.29	-4.26	-0.33	3.6e-5	Psoriasis;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg21565972	chr17:80109576	CCDC57	-0.6	-6.77	-0.48	2.69e-10	Life satisfaction;
PAAD	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg08501292	chr6:25962987	TRIM38	0.55	4.31	0.33	2.92e-5	Homocysteine levels;
PAAD	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.82	8.91	0.59	1.45e-15	Mortality in heart failure;
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	4.65	0.35	7.18e-6	Eosinophil percentage of white cells;
PAAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg05110241	chr16:68378359	PRMT7	-0.9	-7.19	-0.5	2.69e-11	Schizophrenia;
PAAD	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.58	5.42	0.4	2.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg09659197	chr4:152720779	NA	0.4	5.14	0.38	8.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2299587	0.710	rs62498203	chr8:17876574	T/A	cg08627089	chr8:17753878	FGL1	-0.47	-4.61	-0.35	8.32e-6	Economic and political preferences;
PAAD	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	7.04	0.5	6.26e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3736485	0.966	rs8028017	chr15:51912708	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.51	-4.64	-0.35	7.63e-6	Monocyte count;
PAAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.03	-0.44	1.19e-8	Personality dimensions;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25139619	chr13:91999408	MIR17HG	-0.61	-7.22	-0.51	2.37e-11	Body fat percentage;
PAAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.71	-8.78	-0.58	3.1e-15	Bone mineral density;
PAAD	cis	rs16975963	0.843	rs1056405	chr19:38313021	T/C	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg10356904	chr22:49881777	NA	-0.52	-5.51	-0.41	1.51e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.99	-13.23	-0.73	4.47e-27	Menopause (age at onset);
PAAD	cis	rs1639906	0.708	rs3779013	chr7:2210844	A/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-4.81	-0.36	3.56e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7765004	0.961	rs9372376	chr6:114074965	G/A	cg13100190	chr6:114053961	NA	0.35	4.37	0.33	2.26e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg23250157	chr14:64679961	SYNE2	-0.52	-5.6	-0.41	9.71e-8	Atrial fibrillation;
PAAD	cis	rs4713118	0.550	rs9368527	chr6:27679445	C/A	cg20933634	chr6:27740509	NA	0.46	4.35	0.33	2.5e-5	Parkinson's disease;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	14.29	0.76	6.76e-30	Height;
PAAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.99	0.38	1.62e-6	Parkinson's disease;
PAAD	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06850241	chr22:41845214	NA	-0.58	-5.13	-0.38	8.8e-7	Vitiligo;
PAAD	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.61	5.34	0.4	3.26e-7	Dialysis-related mortality;
PAAD	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg02527881	chr3:46936655	PTH1R	0.42	4.91	0.37	2.35e-6	Colorectal cancer;
PAAD	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg01851573	chr8:8652454	MFHAS1	-0.44	-4.44	-0.34	1.7e-5	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14153511	chr20:45034743	ELMO2	0.7	7.02	0.49	7.05e-11	Obesity-related traits;
PAAD	cis	rs4740619	0.604	rs9650685	chr9:15808994	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.47	-0.34	1.52e-5	Body mass index;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg15181151	chr6:150070149	PCMT1	0.59	6.58	0.47	7.27e-10	Lung cancer;
PAAD	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.67	8.59	0.57	9.71e-15	Hemoglobin concentration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23249239	chr20:48729561	UBE2V1;TMEM189-UBE2V1	-0.8	-7.07	-0.5	5.21e-11	Neuroticism;
PAAD	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.75	6.99	0.49	8.28e-11	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs7594192	0.511	rs7566830	chr2:199366511	T/G	cg01558212	chr2:200327336	NA	0.34	4.38	0.33	2.18e-5	Educational attainment;
PAAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	6.81	0.48	2.12e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7202877	0.706	rs4888375	chr16:75322356	T/C	cg03315344	chr16:75512273	CHST6	0.56	4.71	0.36	5.54e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.61	0.41	9.34e-8	Prudent dietary pattern;
PAAD	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg10207240	chr12:122356781	WDR66	-0.55	-5.8	-0.43	3.75e-8	Mean corpuscular volume;
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.92	-7.8	-0.53	8.97e-13	Alzheimer's disease;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.45	4.94	0.37	2.07e-6	Life satisfaction;
PAAD	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg10434728	chr15:90938212	IQGAP1	0.44	4.54	0.35	1.13e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.81	10.33	0.64	2.78e-19	Breast cancer;
PAAD	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.28	-0.39	4.47e-7	Fear of minor pain;
PAAD	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	6.45	0.46	1.42e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.63	6.34	0.46	2.46e-9	Multiple sclerosis;
PAAD	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.75	5.69	0.42	6.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs30380	0.690	rs2911139	chr5:96179593	C/G	cg17330273	chr5:96107758	CAST;ERAP1	0.52	5.32	0.4	3.71e-7	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04760602	chr4:54243733	FIP1L1	0.68	7.56	0.52	3.63e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg03989125	chr22:38214979	NA	0.61	5.86	0.43	2.81e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3736485	0.966	rs11070860	chr15:51892654	G/A	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	4.63	0.35	7.66e-6	Coffee consumption (cups per day);
PAAD	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.51	4.73	0.36	5.04e-6	Anterior chamber depth;
PAAD	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs3784262	0.565	rs12914414	chr15:58318757	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-5.35	-0.4	3.15e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg03268063	chr7:1337281	NA	-0.51	-4.43	-0.34	1.78e-5	Neuroticism;
PAAD	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg11439826	chr17:76250004	NA	0.46	4.58	0.35	9.59e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06665095	chr4:159573230	RXFP1	0.5	6.58	0.47	7.27e-10	Body fat percentage;
PAAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.23	-0.45	4.32e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2834256	0.847	rs11702148	chr21:35089712	G/T	cg14850771	chr21:34775459	IFNGR2	0.47	4.35	0.33	2.52e-5	Red cell distribution width;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.49	4.99	0.38	1.61e-6	Colorectal cancer;
PAAD	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg14541582	chr5:601475	NA	-0.28	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4605213	0.528	rs11079947	chr17:49301788	G/A	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.94	10.16	0.64	7.93e-19	Tonsillectomy;
PAAD	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg05043794	chr9:111880884	C9orf5	-0.37	-4.43	-0.34	1.82e-5	Menarche (age at onset);
PAAD	cis	rs62247992	0.698	rs7619872	chr3:43116170	C/T	cg12239580	chr3:43073058	FAM198A	0.42	4.29	0.33	3.17e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.45	0.61	5.91e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.64	5.2	0.39	6.21e-7	Neutrophil percentage of white cells;
PAAD	cis	rs13065560	0.594	rs4336049	chr3:38922068	G/A	cg01426195	chr3:39028469	NA	-0.57	-5.78	-0.42	4.2e-8	Interleukin-18 levels;
PAAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.65	-7.37	-0.51	1.02e-11	Iron status biomarkers;
PAAD	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.39	0.34	2.13e-5	Educational attainment (years of education);
PAAD	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg17644776	chr2:200775616	C2orf69	0.6	5.14	0.38	8.39e-7	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20545551	chr22:18560636	PEX26	-0.79	-6.74	-0.48	3.11e-10	Neuroticism;
PAAD	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-7.01	-0.49	7.19e-11	Vitamin D levels;
PAAD	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.96	-0.37	1.83e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.96	9.14	0.6	3.69e-16	Psoriasis;
PAAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.63	6.82	0.48	1.97e-10	Multiple sclerosis;
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg04369109	chr6:150039330	LATS1	-0.46	-4.63	-0.35	7.88e-6	Lung cancer;
PAAD	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.68	7.87	0.54	6.07e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6089829	0.723	rs747128	chr20:61656398	G/A	cg08045932	chr20:61659980	NA	-0.54	-5.76	-0.42	4.5e-8	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-4.37	-0.33	2.33e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg26727032	chr16:67993705	SLC12A4	0.7	4.86	0.37	2.84e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.74	-8.05	-0.55	2.22e-13	Obesity-related traits;
PAAD	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03168026	chr3:93692564	PROS1	-0.57	-6.45	-0.46	1.41e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.68	7.46	0.52	6.14e-12	Mean corpuscular volume;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg02951883	chr7:2050386	MAD1L1	0.58	5.67	0.42	6.96e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg18825076	chr15:78729989	IREB2	-0.57	-5.76	-0.42	4.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.33	4.51	0.34	1.27e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	7.34	0.51	1.21e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.45	0.4	2.01e-7	Obesity-related traits;
PAAD	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.42	0.4	2.26e-7	Life satisfaction;
PAAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.54	5.27	0.39	4.58e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.58	-7.2	-0.5	2.6e-11	Educational attainment;
PAAD	cis	rs11771526	0.681	rs1868775	chr7:32403793	C/T	cg13207630	chr7:32358064	NA	-0.86	-4.68	-0.35	6.26e-6	Body mass index;
PAAD	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.89	10.33	0.64	2.84e-19	Resting heart rate;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.44	4.34	0.33	2.63e-5	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg02877791	chr2:177005403	NA	0.44	4.33	0.33	2.64e-5	IgG glycosylation;
PAAD	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg14700524	chr10:3282231	NA	0.32	4.56	0.35	1.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.9	11.14	0.67	1.86e-21	Dental caries;
PAAD	cis	rs12767760	0.669	rs10882957	chr10:99299542	T/A	cg25247692	chr10:99313390	UBTD1	0.56	5.52	0.41	1.44e-7	Obesity-related traits;
PAAD	cis	rs7188861	0.861	rs2032933	chr16:11445040	G/A	cg01510278	chr16:11456238	NA	-0.43	-4.27	-0.33	3.38e-5	HDL cholesterol;
PAAD	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.24	0.51	2.03e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg01378222	chr16:28622494	SULT1A1	-0.77	-5.1	-0.38	1.02e-6	Platelet distribution width;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.52	5.11	0.38	9.67e-7	Acylcarnitine levels;
PAAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.04	0.38	1.32e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	1.000	rs6768542	chr3:41865474	G/A	cg03022575	chr3:42003672	ULK4	0.84	6.32	0.46	2.78e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.61	-5.91	-0.43	2.14e-8	Subjective well-being;
PAAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs12432203	1.000	rs59302370	chr14:51739943	A/C	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg27449745	chr7:23145252	KLHL7	-0.57	-5.28	-0.39	4.45e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13891985	chr10:13482679	BEND7	0.66	7.85	0.54	6.99e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.47	-5.01	-0.38	1.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	1.000	rs6783001	chr3:41862232	C/A	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4336470	0.504	rs62418774	chr6:105175132	G/A	cg02098413	chr6:105308735	HACE1	-0.46	-5.79	-0.43	3.93e-8	Neuroblastoma;
PAAD	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19882132	chr14:106167949	NA	-0.55	-4.87	-0.37	2.77e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-0.59	-5.73	-0.42	5.1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.87	-10.7	-0.66	2.83e-20	Bipolar disorder;
PAAD	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.39	4.26	0.33	3.59e-5	Schizophrenia;
PAAD	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.52	-0.78	3.82e-33	Schizophrenia;
PAAD	cis	rs603424	0.509	rs6584362	chr10:102087113	G/T	cg10365880	chr10:102089681	PKD2L1	-0.58	-4.5	-0.34	1.35e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs13242816	1.000	rs3801993	chr7:116190382	C/G	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-7.15	-0.5	3.41e-11	Colorectal cancer;
PAAD	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg18200150	chr17:30822561	MYO1D	0.79	12.38	0.71	8.75e-25	Schizophrenia;
PAAD	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg05338066	chr1:7812865	CAMTA1	0.7	5.21	0.39	6.11e-7	Inflammatory bowel disease;
PAAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.66	-6.22	-0.45	4.68e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs939584	0.935	rs7561556	chr2:638560	T/C	cg14515364	chr2:636606	NA	0.47	4.27	0.33	3.46e-5	Body mass index;
PAAD	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs7517847	0.567	rs7523955	chr1:67692132	G/C	cg16314899	chr1:68516101	DIRAS3	-0.45	-4.4	-0.34	2.02e-5	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.89	-11.54	-0.68	1.59e-22	Total body bone mineral density;
PAAD	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg11645453	chr3:52864694	ITIH4	0.31	4.49	0.34	1.41e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13533528	chr12:98992088	SLC25A3;SNORA53	-0.54	-6.52	-0.47	9.7e-10	Monocyte percentage of white cells;
PAAD	cis	rs1934953	0.544	rs7899661	chr10:96643950	G/A	cg09036531	chr10:96991505	NA	0.45	4.25	0.33	3.77e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs367943	0.501	rs960691	chr5:112971654	G/C	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.59	-7.84	-0.54	7.37e-13	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15505141	chr4:154388378	KIAA0922	0.74	7.44	0.52	6.85e-12	Obesity-related traits;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg08219700	chr8:58056026	NA	0.69	5.22	0.39	5.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg04160749	chr8:58172571	NA	-0.6	-4.38	-0.33	2.22e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs256277	0.657	rs255924	chr5:111378780	A/C	cg17919331	chr5:112312406	DCP2	-0.53	-4.49	-0.34	1.41e-5	Coronary artery disease;
PAAD	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.9	-11.13	-0.67	1.97e-21	Prudent dietary pattern;
PAAD	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg18357526	chr6:26021779	HIST1H4A	0.56	5.02	0.38	1.42e-6	Educational attainment;
PAAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20553930	chr7:120590671	ING3	-0.65	-6.46	-0.46	1.34e-9	Smoking initiation;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13560548	chr3:10150139	C3orf24	0.49	4.27	0.33	3.38e-5	Alzheimer's disease;
PAAD	trans	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg01620082	chr3:125678407	NA	-1.09	-6.33	-0.46	2.63e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.78	9.8	0.62	7.2e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6010044	0.680	rs6010042	chr22:51098764	G/A	cg07576525	chr22:51146088	SHANK3	0.52	4.51	0.34	1.26e-5	Fibrinogen levels;Fibrinogen;
PAAD	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.47	-4.91	-0.37	2.28e-6	Type 1 diabetes;
PAAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.68	0.69	6.9e-23	Smoking behavior;
PAAD	cis	rs10899021	1.000	rs10899025	chr11:74367040	G/A	cg25880958	chr11:74394337	NA	-0.88	-5.65	-0.42	7.87e-8	Response to metformin (IC50);
PAAD	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	7.03	0.5	6.67e-11	Neuroticism;
PAAD	cis	rs11252926	0.529	rs10904398	chr10:562805	G/A	cg05528280	chr10:464225	DIP2C	0.43	4.28	0.33	3.3e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg12908607	chr1:44402522	ARTN	-0.42	-4.64	-0.35	7.53e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7792596	0.514	rs71562850	chr7:94006979	T/A	cg20814616	chr7:94014465	NA	-0.57	-4.28	-0.33	3.25e-5	Intelligence;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.93	13.5	0.74	8.3e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.48	5.36	0.4	3.09e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg01982873	chr5:490308	SLC9A3	-0.43	-4.88	-0.37	2.68e-6	Cystic fibrosis severity;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	0.82	6.37	0.46	2.19e-9	Obesity-related traits;
PAAD	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-7.65	-0.53	2.16e-12	Body mass index;
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg09839279	chr12:125627357	AACS	-0.52	-5.17	-0.39	7.41e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.11	0.38	9.36e-7	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21123366	chr2:240960755	NDUFA10	-0.64	-6.86	-0.49	1.62e-10	Obesity-related traits;
PAAD	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.61	6.37	0.46	2.15e-9	Crohn's disease;
PAAD	cis	rs5015933	0.734	rs10126025	chr9:128146064	C/G	cg14078157	chr9:128172775	NA	-0.44	-5.12	-0.38	9.19e-7	Body mass index;
PAAD	cis	rs72827839	0.696	rs117974417	chr17:46156510	C/G	cg23391107	chr17:45924227	SP6	0.84	5.9	0.43	2.32e-8	Ease of getting up in the morning;
PAAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.19	-0.39	6.67e-7	Cognitive function;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-11.12	-0.67	2.12e-21	Height;
PAAD	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	5.15	0.39	8.11e-7	Thyroid stimulating hormone;
PAAD	cis	rs12935418	0.616	rs13336292	chr16:81005692	G/A	cg16651780	chr16:81037892	C16orf61	0.69	6.76	0.48	2.71e-10	Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00779328	chr1:33745989	ZNF362	0.61	7.21	0.5	2.44e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20036869	chr10:48355053	ZNF488	0.65	7.54	0.52	3.96e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg06217071	chr17:408420	NA	0.46	4.77	0.36	4.29e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09696465	chr17:70934769	SLC39A11	0.42	4.45	0.34	1.64e-5	Smoking initiation;
PAAD	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.82	-5.09	-0.38	1.05e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.45	4.54	0.35	1.16e-5	Pulmonary function;
PAAD	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.68	7.13	0.5	3.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.99	0.38	1.6e-6	Thyroid stimulating hormone;
PAAD	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg14092988	chr3:52407081	DNAH1	-0.46	-5.97	-0.44	1.64e-8	Bipolar disorder;
PAAD	trans	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg01620082	chr3:125678407	NA	-1.09	-6.34	-0.46	2.43e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs757081	0.658	rs190046	chr11:17293356	T/C	cg04705435	chr11:17411270	KCNJ11	-0.56	-6.0	-0.44	1.38e-8	Systolic blood pressure;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24741101	chr5:14508945	TRIO	-0.7	-6.42	-0.46	1.67e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg01426195	chr3:39028469	NA	-0.62	-6.12	-0.44	7.69e-9	Handedness;
PAAD	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg08558340	chr7:100472263	SRRT	0.51	4.5	0.34	1.34e-5	Resting heart rate;
PAAD	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg05585544	chr11:47624801	NA	-0.46	-5.13	-0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.4	0.46	1.83e-9	Personality dimensions;
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg03264133	chr6:25882463	NA	-0.54	-4.61	-0.35	8.34e-6	Iron status biomarkers;
PAAD	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.68	0.62	1.46e-17	Diabetic retinopathy;
PAAD	cis	rs7132746	0.553	rs56135828	chr12:86191269	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-4.71	-0.36	5.49e-6	Lewy body disease;
PAAD	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg15309053	chr8:964076	NA	0.62	7.11	0.5	4.24e-11	Schizophrenia;
PAAD	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg27234864	chr13:21295941	IL17D	0.61	5.28	0.39	4.48e-7	Dental caries;
PAAD	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg13535736	chr9:111863775	C9orf5	0.35	4.37	0.33	2.27e-5	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg19761014	chr17:28927070	LRRC37B2	0.94	6.43	0.46	1.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg25833597	chr17:30823145	MYO1D	0.55	5.33	0.4	3.44e-7	Schizophrenia;
PAAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14779627	chr7:6048715	PMS2;AIMP2	0.7	6.95	0.49	9.97e-11	Obesity-related traits;
PAAD	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.3	0.46	3.04e-9	Rheumatoid arthritis;
PAAD	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.15	-0.39	7.87e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2577720	0.935	rs13426684	chr2:23543325	C/A	cg09674093	chr2:23646462	KLHL29	0.38	4.32	0.33	2.78e-5	F-cell distribution;
PAAD	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-7.69	-0.53	1.71e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg15770106	chr1:208133116	NA	-0.65	-6.46	-0.46	1.37e-9	Corneal structure;
PAAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.59	-0.35	9.14e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.76	-10.16	-0.64	8.07e-19	Bone mineral density;
PAAD	cis	rs317865	0.737	rs73234651	chr4:16196651	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.67	0.48	4.54e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.65	-0.35	7.1e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.64	6.73	0.48	3.31e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.87	-6.78	-0.48	2.45e-10	Blood protein levels;
PAAD	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.3	-0.51	1.48e-11	Diastolic blood pressure;
PAAD	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.65	0.53	2.11e-12	Platelet count;
PAAD	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.8	7.84	0.54	7.21e-13	Coronary artery disease;
PAAD	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	4.71	0.36	5.66e-6	Schizophrenia;
PAAD	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg04374321	chr14:90722782	PSMC1	0.51	4.3	0.33	3.02e-5	Longevity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07107441	chr3:10157155	C3orf10	-0.63	-6.31	-0.46	2.9e-9	Smoking initiation;
PAAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs1468734	0.929	rs11645150	chr16:5005222	C/G	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.52	-4.32	-0.33	2.8e-5	Cancer;
PAAD	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg00922110	chr4:57842668	C4orf14	-0.45	-4.47	-0.34	1.49e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs7932354	0.528	rs10466478	chr11:47162604	A/C	cg19486271	chr11:47235900	DDB2	-0.53	-5.4	-0.4	2.49e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.66	7.45	0.52	6.47e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.48	5.98	0.44	1.53e-8	Menopause (age at onset);
PAAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.77	0.36	4.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23708337	chr7:1209742	NA	0.42	4.36	0.33	2.35e-5	Longevity;Endometriosis;
PAAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.44	6.19	0.45	5.27e-9	Vitiligo;
PAAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.69	-5.77	-0.42	4.3e-8	Gut microbiome composition (summer);
PAAD	cis	rs1359582	0.793	rs3980065	chr10:90398803	T/C	cg15661332	chr10:90342814	RNLS	0.57	5.03	0.38	1.38e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg26876637	chr1:152193138	HRNR	0.86	6.37	0.46	2.08e-9	Atopic dermatitis;
PAAD	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.49	5.11	0.38	9.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg10253484	chr15:75165896	SCAMP2	0.6	5.46	0.41	1.88e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.52	6.52	0.47	9.75e-10	Crohn's disease;
PAAD	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.46	0.4	1.93e-7	Obesity-related traits;
PAAD	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg12661370	chr5:149340060	SLC26A2	0.64	5.49	0.41	1.68e-7	HIV-1 control;
PAAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.22	-0.45	4.55e-9	Menarche (age at onset);
PAAD	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.9100000000000004e-06	Daytime sleep phenotypes;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg00999904	chr2:3704751	ALLC	-0.83	-8.12	-0.55	1.45e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs13102973	0.932	rs13112852	chr4:135838470	C/T	cg14419869	chr4:135874104	NA	0.55	5.82	0.43	3.29e-8	Subjective well-being;
PAAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22478328	chr22:32340140	C22orf24;YWHAH	0.66	7.32	0.51	1.34e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-13.99	-0.75	4.06e-29	Schizophrenia;
PAAD	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.87	10.93	0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.91	-0.43	2.15e-8	Bipolar disorder;
PAAD	cis	rs12311304	0.965	rs7302643	chr12:15394463	T/C	cg08258403	chr12:15378311	NA	0.35	4.5	0.34	1.34e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.31	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.6	0.47	6.52e-10	Personality dimensions;
PAAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg22143856	chr6:28129313	ZNF389	0.49	4.48	0.34	1.47e-5	Parkinson's disease;
PAAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.52	4.95	0.37	1.92e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg20731937	chr12:48336164	NA	0.51	4.26	0.33	3.51e-5	Longevity (90 years and older);
PAAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg21929781	chr1:2537748	MMEL1	0.51	5.31	0.4	3.78e-7	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.66	7.26	0.51	1.86e-11	Melanoma;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.58	6.8	0.48	2.22e-10	Calcium levels;
PAAD	cis	rs10883437	0.763	rs7090924	chr10:101776392	T/G	cg04359915	chr10:101825029	CPN1	-0.28	-4.36	-0.33	2.38e-5	Liver enzyme levels (alanine transaminase);
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.45	-5.89	-0.43	2.37e-8	Primary biliary cholangitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20832448	chr3:36418645	NA	0.64	6.91	0.49	1.28e-10	Smoking initiation;
PAAD	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.66	4.62	0.35	8.16e-6	Corneal structure;
PAAD	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.79	8.5	0.57	1.65e-14	Corneal astigmatism;
PAAD	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.33	-0.33	2.68e-5	Coronary artery disease;
PAAD	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.82	-0.43	3.37e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08677398	chr8:58056175	NA	0.69	5.05	0.38	1.25e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.63	-5.99	-0.44	1.44e-8	Schizophrenia;
PAAD	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs73416724	0.841	rs75782786	chr6:43320055	C/A	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12136530	0.636	rs4244001	chr1:19734368	C/T	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.47	5.88	0.43	2.47e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08219700	chr8:58056026	NA	0.67	5.38	0.4	2.71e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11615916	0.790	rs11612567	chr12:62817736	A/G	cg11441379	chr12:63026424	NA	-0.66	-4.34	-0.33	2.59e-5	Pulmonary function decline;
PAAD	cis	rs17169635	0.601	rs3778853	chr7:134545098	A/G	cg02516134	chr7:134575187	CALD1	-0.48	-4.6	-0.35	8.84e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.35	-0.33	2.52e-5	Breast cancer;
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27436995	chr16:743998	FBXL16	-0.36	-4.29	-0.33	3.17e-5	Height;
PAAD	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.32	-0.4	3.63e-7	Glomerular filtration rate;
PAAD	cis	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg04607699	chr11:48328132	OR4S1	-0.52	-4.99	-0.38	1.63e-6	Migraine - clinic-based;
PAAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.57	5.34	0.4	3.34e-7	Schizophrenia;
PAAD	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg05250797	chr16:70222502	NA	-0.53	-4.52	-0.34	1.25e-5	Sjögren's syndrome;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.69	7.06	0.5	5.54e-11	Menarche (age at onset);
PAAD	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.6	6.48	0.47	1.23e-9	Mean corpuscular volume;
PAAD	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg23127183	chr11:57508653	C11orf31	-0.51	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18621852	chr3:10150065	C3orf24	0.59	4.61	0.35	8.31e-6	Alzheimer's disease;
PAAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.46	4.75	0.36	4.59e-6	Longevity;
PAAD	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.43	-4.51	-0.34	1.3e-5	QRS complex (12-leadsum);
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg08992911	chr2:238395768	MLPH	0.58	5.6	0.41	9.97e-8	Prostate cancer;
PAAD	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-1.04	-6.8	-0.48	2.24e-10	Opioid sensitivity;
PAAD	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg14343924	chr8:8086146	FLJ10661	0.51	5.02	0.38	1.45e-6	Joint mobility (Beighton score);
PAAD	cis	rs6784615	0.744	rs13093555	chr3:52298171	T/C	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	1.0	9.68	0.62	1.47e-17	Dilated cardiomyopathy;
PAAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.49	5.3	0.39	4.08e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg21269045	chr12:125625041	AACS	0.49	4.96	0.37	1.89e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-4.65	-0.35	7.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.17e-6	Lung cancer;
PAAD	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.89	11.48	0.68	2.3e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg09168692	chr1:7887560	PER3	0.47	4.48	0.34	1.43e-5	Inflammatory bowel disease;
PAAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.51	5.02	0.38	1.4e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.36	-0.33	2.38e-5	Resting heart rate;
PAAD	cis	rs4478858	0.735	rs12408524	chr1:31835853	A/G	cg18939081	chr1:31884902	SERINC2	0.51	5.75	0.42	4.73e-8	Alcohol dependence;
PAAD	cis	rs1539053	1.000	rs57982718	chr1:58100694	T/C	cg20292791	chr1:58089357	DAB1	-0.54	-5.33	-0.4	3.52e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.36	4.39	0.34	2.09e-5	Height;
PAAD	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg06042504	chr8:55087323	NA	-0.75	-8.22	-0.55	8.35e-14	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs8049634	0.732	rs2875860	chr16:84231580	G/A	cg00961177	chr16:84213833	TAF1C	-0.45	-4.56	-0.35	1.04e-5	Small cell lung carcinoma;
PAAD	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	5.26	0.39	4.92e-7	Monocyte percentage of white cells;
PAAD	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg09399716	chr2:46890238	NA	-0.72	-5.72	-0.42	5.42e-8	Height;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg20302533	chr7:39170763	POU6F2	0.37	5.25	0.39	5.15e-7	IgG glycosylation;
PAAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.89	-10.37	-0.64	2.23e-19	Coronary artery disease;
PAAD	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg19442545	chr10:75533431	FUT11	-0.59	-6.19	-0.45	5.27e-9	Inflammatory bowel disease;
PAAD	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.47	-5.37	-0.4	2.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs735539	0.521	rs575063	chr13:21422911	A/C	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19517509	chr12:120933726	DYNLL1	0.62	7.1	0.5	4.46e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	6.46	0.46	1.31e-9	Obesity-related traits;
PAAD	cis	rs11220082	0.636	rs11220058	chr11:125287395	A/G	cg23156348	chr11:124981869	NA	0.44	4.27	0.33	3.48e-5	Schizophrenia;
PAAD	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.54e-17	White blood cell count (basophil);
PAAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg09945482	chr18:12777974	NA	0.6	5.38	0.4	2.79e-7	Inflammatory skin disease;
PAAD	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	7.37	0.51	1.05e-11	Verbal declarative memory;
PAAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.55e-15	Chronic sinus infection;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.85	6.99	0.49	8.17e-11	Alzheimer's disease;
PAAD	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs7567389	0.626	rs11683344	chr2:127956252	A/C	cg09760422	chr2:128146352	NA	0.47	7.17	0.5	3.01e-11	Self-rated health;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-6.29	-0.45	3.29e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7873102	0.630	rs2183128	chr9:38014322	T/C	cg03528946	chr9:38069800	SHB	-0.5	-4.98	-0.37	1.69e-6	Brain structure;
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg18888403	chr1:24152774	HMGCL	-0.38	-4.34	-0.33	2.64e-5	Immature fraction of reticulocytes;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg22868518	chr11:507468	RNH1	-0.92	-4.95	-0.37	1.93e-6	Body mass index;
PAAD	cis	rs7922314	0.571	rs16917958	chr10:64720114	A/C	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.82	-6.96	-0.49	9.37e-11	Gut microbiome composition (summer);
PAAD	cis	rs80346118	0.673	rs6095300	chr20:47422388	A/G	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.64	-4.57	-0.35	9.87e-6	Diastolic blood pressure;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-0.96	-6.59	-0.47	6.93e-10	Breast cancer;
PAAD	cis	rs4938330	0.608	rs2239012	chr11:117088362	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs35160687	0.666	rs36104799	chr2:86484123	C/G	cg10973622	chr2:86423274	IMMT	-0.44	-4.87	-0.37	2.81e-6	Night sleep phenotypes;
PAAD	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.91	6.97	0.49	9.24e-11	Axial length;
PAAD	cis	rs1545257	0.537	rs11125582	chr2:24646213	C/T	cg06627628	chr2:24431161	ITSN2	-0.59	-5.76	-0.42	4.48e-8	Sjögren's syndrome;
PAAD	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs59888335	0.964	rs2099563	chr3:80740366	C/T	cg21735741	chr3:80819488	NA	0.56	4.88	0.37	2.62e-6	Schizophrenia;
PAAD	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg00484396	chr16:3507460	NAT15	-0.45	-4.4	-0.34	2.05e-5	Body mass index (adult);
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg01831904	chr17:28903510	LRRC37B2	0.88	6.24	0.45	4.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10916814	0.610	rs4655222	chr1:20901418	C/T	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	1.81	10.44	0.65	1.46e-19	Cannabis dependence symptom count;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.01e-6	Electroencephalogram traits;
PAAD	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg01244601	chr4:120671846	NA	-0.51	-4.42	-0.34	1.84e-5	Corneal astigmatism;
PAAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg14847009	chr1:175162515	KIAA0040	0.33	5.26	0.39	4.74e-7	Alcohol dependence;
PAAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs1595825	0.732	rs114972685	chr2:198437829	G/A	cg00982548	chr2:198649783	BOLL	-0.64	-4.27	-0.33	3.42e-5	Ulcerative colitis;
PAAD	cis	rs959260	0.502	rs11658023	chr17:73308722	C/T	cg23244877	chr17:73518230	TSEN54	0.5	4.32	0.33	2.84e-5	Systemic lupus erythematosus;
PAAD	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs17428471	0.867	rs4722681	chr7:27320319	T/C	cg08483376	chr7:27285136	EVX1	-0.71	-4.29	-0.33	3.1e-5	Blood pressure;
PAAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg07943548	chr15:86304357	KLHL25	-0.56	-4.79	-0.36	3.87e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.6	-6.63	-0.47	5.42e-10	Hematocrit;
PAAD	cis	rs2286503	0.839	rs1054471	chr7:22852643	T/A	cg11367502	chr7:22862612	TOMM7	0.52	5.28	0.39	4.4e-7	Fibrinogen;
PAAD	cis	rs10795433	0.630	rs3858184	chr10:16968785	A/G	cg00939682	chr10:16933505	CUBN	0.61	5.77	0.42	4.37e-8	Urinary albumin-to-creatinine ratio;Microalbuminuria;
PAAD	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.48	4.32	0.33	2.84e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.68	-7.73	-0.53	1.33e-12	Motion sickness;
PAAD	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	1.04	12.41	0.71	7.41e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.69	5.72	0.42	5.58e-8	Schizophrenia;
PAAD	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg24220031	chr2:73402428	NA	-0.42	-6.28	-0.45	3.32e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg20356878	chr3:121714668	ILDR1	-0.53	-5.07	-0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.54	-5.04	-0.38	1.29e-6	Neurofibrillary tangles;
PAAD	cis	rs7083	0.716	rs574603	chr11:117177741	C/T	cg06114171	chr11:117561139	DSCAML1	-0.37	-4.36	-0.33	2.37e-5	Blood protein levels;
PAAD	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.63	6.25	0.45	3.89e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	1.09	6.01	0.44	1.3e-8	Body mass index;
PAAD	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.15	0.39	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.68e-7	Type 2 diabetes;
PAAD	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	1.1	8.61	0.57	8.58e-15	Iron status biomarkers;
PAAD	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.46	5.09	0.38	1.04e-6	Blood protein levels;
PAAD	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.83	6.76	0.48	2.83e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2016586	0.929	rs4821439	chr22:36114263	C/T	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Body mass index;
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.61	5.68	0.42	6.7e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19760648	chr10:131688745	EBF3	-0.62	-6.6	-0.47	6.5e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.73	-0.36	5e-6	Type 2 diabetes;
PAAD	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9409082	0.798	rs13300395	chr9:108926464	G/A	cg07010948	chr13:79181613	NA	-0.35	-6.47	-0.46	1.29e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.75	8.1	0.55	1.64e-13	Eye color traits;
PAAD	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg21951975	chr1:209979733	IRF6	0.59	5.44	0.4	2.09e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2286503	0.839	rs2270107	chr7:22862183	G/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.81	-8.56	-0.57	1.12e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.56	5.14	0.39	8.18e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.61	-0.41	9.53e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.89	-0.37	2.57e-6	Menopause (age at onset);
PAAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.45	5.4	0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.09	0.44	8.8e-9	Height;
PAAD	cis	rs11023332	0.650	rs2122942	chr11:14807375	T/G	cg19336497	chr11:14380999	RRAS2	-0.39	-4.3	-0.33	3.09e-5	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs2124969	0.548	rs7586751	chr2:160958145	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-5.55	-0.41	1.26e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.56	-6.5	-0.47	1.09e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	1.11	6.57	0.47	7.49e-10	Body mass index;
PAAD	cis	rs7715811	0.912	rs1502049	chr5:13779935	T/C	cg07548982	chr5:13769939	DNAH5	-0.54	-5.21	-0.39	6.18e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.5	2.45e-11	Schizophrenia;
PAAD	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.88	-10.75	-0.66	2.15e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6074578	0.517	rs28897484	chr20:158114	G/A	cg16931068	chr20:139680	DEFB127	-0.42	-5.58	-0.41	1.07e-7	Hirschsprung disease;
PAAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg21130718	chr4:1044621	NA	0.55	4.76	0.36	4.52e-6	Recombination rate (females);
PAAD	cis	rs12773846	0.537	rs34737775	chr10:126272883	A/G	cg04949429	chr10:126290192	LHPP	0.66	5.68	0.42	6.57e-8	Subcutaneous adipose tissue;
PAAD	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg27490568	chr2:178487706	NA	0.44	4.72	0.36	5.24e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg21281001	chr8:11725306	CTSB	0.51	4.59	0.35	9.42e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.6	-5.95	-0.43	1.78e-8	Red cell distribution width;
PAAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10311549	chr10:135272056	LOC619207	0.52	6.4	0.46	1.84e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.71	7.04	0.5	6.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-8.12	-0.55	1.46e-13	Eosinophil percentage of granulocytes;
PAAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-4.66	-0.35	6.8e-6	Blood metabolite levels;
PAAD	cis	rs2075671	0.818	rs10953303	chr7:100365613	G/T	cg20848291	chr7:100343083	ZAN	-0.74	-6.0	-0.44	1.4e-8	Other erythrocyte phenotypes;
PAAD	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg02250501	chr15:90694978	NA	-0.47	-4.44	-0.34	1.71e-5	Rheumatoid arthritis;
PAAD	cis	rs3790645	1.000	rs282176	chr1:26898956	T/C	cg17456097	chr1:26900765	RPS6KA1	0.52	4.44	0.34	1.73e-5	Glucose homeostasis traits;
PAAD	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.65	-6.58	-0.47	7.19e-10	White matter hyperintensity burden;
PAAD	cis	rs2171564	0.537	rs9815847	chr3:112439054	G/A	cg06685282	chr3:112453648	NA	0.54	5.35	0.4	3.25e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg15485101	chr11:133734466	NA	-0.41	-4.82	-0.36	3.48e-6	Childhood ear infection;
PAAD	cis	rs17135859	0.715	rs1871910	chr5:113054882	A/G	cg12552261	chr5:112820674	MCC	0.74	4.5	0.34	1.37e-5	F-cell distribution;
PAAD	cis	rs4073221	0.789	rs34901970	chr3:18264186	C/G	cg07694806	chr3:18168406	NA	-0.76	-5.04	-0.38	1.28e-6	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26703674	chr2:173292216	ITGA6	0.63	6.64	0.47	5.26e-10	Myopia (pathological);
PAAD	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg14343924	chr8:8086146	FLJ10661	-0.63	-5.53	-0.41	1.37e-7	Mood instability;
PAAD	cis	rs7074356	0.688	rs34894697	chr10:82169888	T/C	cg19423196	chr10:82049429	MAT1A	0.47	4.9	0.37	2.39e-6	Borderline personality disorder;
PAAD	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg21496419	chr19:44306685	LYPD5	0.37	4.66	0.35	6.86e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.52	-5.43	-0.4	2.22e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.95	6.9	0.49	1.29e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2279817	0.780	rs71644065	chr1:18001669	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-5.57	-0.41	1.1e-7	Neuroticism;
PAAD	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.56	-5.03	-0.38	1.36e-6	Breast cancer;
PAAD	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.73	7.32	0.51	1.36e-11	HIV-1 control;
PAAD	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg14758556	chr20:62440591	NA	0.51	4.5	0.34	1.34e-5	Atopic dermatitis;
PAAD	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg21951975	chr1:209979733	IRF6	0.58	5.88	0.43	2.52e-8	Coronary artery disease;
PAAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs73416724	1.000	rs112472472	chr6:43279276	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs432925	0.559	rs412243	chr16:339672	T/C	cg06233593	chr16:337645	AXIN1	0.48	5.34	0.4	3.28e-7	Morning vs. evening chronotype;
PAAD	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.87	-0.43	2.64e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs377457	0.623	rs4565	chr16:85711411	C/G	cg07784872	chr16:85687041	KIAA0182	-0.83	-8.97	-0.59	1.02e-15	Type 2 diabetes;
PAAD	cis	rs593531	0.513	rs7944333	chr11:74022429	C/T	cg15670924	chr11:73669256	DNAJB13	0.45	4.85	0.37	3.09e-6	Neuroticism;
PAAD	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1419980	0.730	rs7972470	chr12:7734978	A/G	cg25828445	chr12:7781288	NA	0.83	4.34	0.33	2.58e-5	HDL cholesterol levels;
PAAD	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.22	0.6	2.28e-16	Bipolar disorder;
PAAD	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg00147160	chr1:26503991	CNKSR1	-0.37	-4.28	-0.33	3.35e-5	QRS complex (12-leadsum);
PAAD	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg22325292	chr17:80708367	FN3K	0.6	4.25	0.33	3.64e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs922692	0.935	rs4886580	chr15:78969385	T/G	cg00540400	chr15:79124168	NA	-0.42	-4.83	-0.36	3.25e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.79	-5.95	-0.43	1.78e-8	Coronary artery calcification;
PAAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.54	4.87	0.37	2.82e-6	RR interval (heart rate);
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11245990	chr11:68621969	NA	-0.4	-5.48	-0.41	1.75e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.96	0.37	1.89e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.31	-4.73	-0.36	5.14e-6	Red cell distribution width;
PAAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs58521262	0.546	rs158691	chr19:23200053	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06033194	chr7:35079111	DPY19L1	0.69	6.48	0.47	1.19e-9	Neuroticism;
PAAD	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	5.8	0.43	3.79e-8	Rheumatoid arthritis;
PAAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs9826463	0.757	rs73240318	chr3:142277427	A/G	cg20824294	chr3:142316082	PLS1	0.43	4.87	0.37	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.39	-4.81	-0.36	3.55e-6	Pulmonary function;
PAAD	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.49	6.25	0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13732083	chr21:47605072	C21orf56	-0.49	-4.9	-0.37	2.45e-6	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.65	-7.19	-0.5	2.79e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.84	-8.08	-0.55	1.82e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg01448562	chr3:133502909	NA	-0.44	-4.35	-0.33	2.52e-5	Iron status biomarkers;
PAAD	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.44	-4.76	-0.36	4.42e-6	Sarcoidosis;
PAAD	cis	rs2120243	0.539	rs2124497	chr3:157120259	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.47	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs9659323	0.670	rs12095067	chr1:119635733	A/T	cg26570165	chr1:119541833	NA	-0.47	-5.08	-0.38	1.12e-6	Body mass index;
PAAD	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.7	7.49	0.52	5.19e-12	Colorectal cancer;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07157834	chr1:205819609	PM20D1	0.53	5.09	0.38	1.05e-6	Parkinson's disease;
PAAD	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.3	-0.33	3.03e-5	Joint mobility (Beighton score);
PAAD	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.78	7.23	0.51	2.15e-11	Breast cancer;
PAAD	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.47	4.6	0.35	8.81e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13560548	chr3:10150139	C3orf24	0.6	5.35	0.4	3.24e-7	Alzheimer's disease;
PAAD	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg14631576	chr9:95140430	CENPP	-0.54	-5.21	-0.39	5.94e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs3753841	0.832	rs1451042	chr1:103278710	T/C	cg24495344	chr1:103574097	COL11A1	0.39	4.53	0.35	1.17e-5	Glaucoma (primary angle closure);
PAAD	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg24851651	chr11:66362959	CCS	0.45	5.21	0.39	5.95e-7	HIV-1 susceptibility;
PAAD	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.56	-0.35	1.05e-5	Joint mobility (Beighton score);
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg20744362	chr22:50050164	C22orf34	0.68	8.27	0.56	6.29e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24110177	chr3:50126178	RBM5	0.6	6.4	0.46	1.81e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1015291	0.708	rs1586838	chr12:19998182	A/G	cg25401612	chr12:20009446	NA	-0.54	-5.27	-0.39	4.52e-7	Diastolic blood pressure;
PAAD	cis	rs2521295	1.000	rs2521295	chr11:2348860	T/A	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.45	-0.34	1.65e-5	Monocyte count;
PAAD	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.98	-14.18	-0.75	1.28e-29	Post bronchodilator FEV1;
PAAD	cis	rs7044106	0.655	rs1359329	chr9:123370985	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	4.99	0.38	1.62e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	1.09	9.01	0.59	8.05e-16	Height;
PAAD	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg01059385	chr22:42394853	WBP2NL	-0.46	-4.33	-0.33	2.69e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg24069376	chr3:38537580	EXOG	0.4	4.92	0.37	2.21e-6	Electrocardiographic conduction measures;
PAAD	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.78	6.97	0.49	9.17e-11	Blood pressure (smoking interaction);
PAAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg17333051	chr19:2783644	SGTA	0.47	5.17	0.39	7.34e-7	Total cholesterol levels;
PAAD	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.62	-5.32	-0.4	3.69e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg12458913	chr13:53173898	NA	0.48	4.83	0.37	3.25e-6	Lewy body disease;
PAAD	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.58	-6.02	-0.44	1.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg04398451	chr17:18023971	MYO15A	0.61	5.81	0.43	3.55e-8	Body mass index;
PAAD	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg20893579	chr22:38215064	NA	0.47	4.95	0.37	1.95e-6	Glioblastoma;Glioma;
PAAD	cis	rs11971779	0.838	rs4728468	chr7:139122978	G/A	cg07862535	chr7:139043722	LUC7L2	0.72	5.6	0.41	9.62e-8	Diisocyanate-induced asthma;
PAAD	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	0.98	12.49	0.71	4.42e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17572116	chr12:47473388	AMIGO2	-0.75	-6.47	-0.46	1.26e-9	Neuroticism;
PAAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.79	5.89	0.43	2.4e-8	Initial pursuit acceleration;
PAAD	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.56	5.95	0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg16205897	chr5:131564050	P4HA2	-0.49	-5.48	-0.41	1.76e-7	Blood metabolite levels;
PAAD	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg14003231	chr6:33640908	ITPR3	0.35	4.44	0.34	1.69e-5	Plateletcrit;
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg07068956	chr7:100330872	ZAN	-0.71	-5.37	-0.4	2.95e-7	Other erythrocyte phenotypes;
PAAD	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg09695851	chr17:3907499	NA	0.81	8.13	0.55	1.43e-13	Type 2 diabetes;
PAAD	cis	rs3829109	0.564	rs4307444	chr9:139279634	C/T	cg21253087	chr9:139290292	SNAPC4	0.52	4.62	0.35	8.14e-6	Peak insulin response;Acute insulin response;
PAAD	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg08390786	chr10:135334061	NA	0.49	4.64	0.35	7.34e-6	Obesity-related traits;
PAAD	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.91	-10.3	-0.64	3.37e-19	Obesity-related traits;
PAAD	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.74	-6.74	-0.48	3.09e-10	Obesity-related traits;
PAAD	cis	rs13102973	1.000	rs7439938	chr4:135897696	G/A	cg14419869	chr4:135874104	NA	-0.58	-6.07	-0.44	9.69e-9	Subjective well-being;
PAAD	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg20169779	chr10:135381914	SYCE1	0.46	4.45	0.34	1.66e-5	Obesity-related traits;
PAAD	cis	rs4150161	0.656	rs3743642	chr16:84212928	G/A	cg10106505	chr16:84220380	TAF1C	-1.08	-6.0	-0.44	1.37e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.44	4.55	0.35	1.08e-5	Longevity;Endometriosis;
PAAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs6597981	0.543	rs3901233	chr11:749452	T/A	cg08747591	chr11:789928	CEND1	-0.67	-6.42	-0.46	1.64e-9	Breast cancer;
PAAD	cis	rs2735413	0.914	rs1922608	chr16:78065139	A/G	cg04733911	chr16:78082701	NA	-0.51	-5.07	-0.38	1.16e-6	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg09127314	chr1:152161683	NA	0.74	5.45	0.4	1.95e-7	Atopic dermatitis;
PAAD	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg02527881	chr3:46936655	PTH1R	0.38	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.51	0.61	3.98e-17	Rheumatoid arthritis;
PAAD	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.92e-7	Ulcerative colitis;
PAAD	cis	rs7567389	0.719	rs4150471	chr2:128034539	A/G	cg09760422	chr2:128146352	NA	-0.38	-5.93	-0.43	1.97e-8	Self-rated health;
PAAD	cis	rs12138061	0.954	rs56184305	chr1:50379591	C/A	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.67	7.72	0.53	1.43e-12	Multiple sclerosis;
PAAD	cis	rs1532557	1.000	rs61827076	chr1:224796346	C/T	cg09988837	chr1:224811939	CNIH3	0.57	4.32	0.33	2.8e-5	Cancer;
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg10556349	chr10:835070	NA	0.7	5.49	0.41	1.61e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.1e-6	Asthma (childhood onset);
PAAD	cis	rs66731853	0.557	rs576968	chr1:20901246	A/G	cg24502330	chr1:20914028	CDA	0.35	4.3	0.33	3.03e-5	Mean corpuscular volume;
PAAD	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg00401753	chr5:405986	AHRR;LOC100310782	1.01	5.21	0.39	6.01e-7	Breast cancer;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg20744362	chr22:50050164	C22orf34	0.64	7.42	0.52	7.79e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-1.0	-6.86	-0.49	1.59e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.63	-7.06	-0.5	5.64e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg23463467	chr20:60627584	TAF4	0.46	4.99	0.38	1.64e-6	Body mass index;
PAAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg23346134	chr3:49453900	TCTA	0.44	4.44	0.34	1.75e-5	Menarche (age at onset);
PAAD	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.96	-6.7	-0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs367943	0.698	rs2195373	chr5:112998798	G/C	cg12552261	chr5:112820674	MCC	0.62	6.67	0.48	4.36e-10	Type 2 diabetes;
PAAD	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.45	-4.92	-0.37	2.24e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.63	-5.75	-0.42	4.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-0.74	-5.93	-0.43	1.93e-8	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg15117754	chr3:10150083	C3orf24	0.69	6.0	0.44	1.39e-8	Alzheimer's disease;
PAAD	cis	rs2252790	1.000	rs12212609	chr6:116614045	A/T	cg18764771	chr6:116381957	FRK	0.26	4.41	0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs9314614	0.872	rs2738060	chr8:6709933	G/C	cg27319216	chr8:6693540	XKR5	-0.35	-4.69	-0.36	5.97e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs3812111	0.525	rs1055814	chr6:116570597	T/C	cg18828861	chr6:116576566	TSPYL4	0.49	5.23	0.39	5.64e-7	Age-related macular degeneration;
PAAD	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.61	-5.77	-0.42	4.21e-8	IgG glycosylation;
PAAD	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg01305830	chr4:1604576	NA	-0.46	-4.57	-0.35	9.83e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	7.42	0.52	7.88e-12	HIV-1 control;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg15847926	chr7:2749597	AMZ1	-0.39	-4.6	-0.35	8.79e-6	Height;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs7144011	0.654	rs4899741	chr14:79848520	C/T	cg18311665	chr14:79483171	NRXN3	0.36	4.58	0.35	9.47e-6	Waist circumference;Hip circumference;
PAAD	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.53	-5.54	-0.41	1.33e-7	Daytime sleep phenotypes;
PAAD	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.73e-5	Aortic root size;
PAAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.93	11.21	0.67	1.24e-21	Diastolic blood pressure;
PAAD	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.81	8.44	0.56	2.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.92	-0.37	2.19e-6	Thrombosis;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11696501	0.738	rs6104294	chr20:44326850	T/C	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.48	-0.41	1.69e-7	Prevalent atrial fibrillation;
PAAD	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16320894	chr3:139398044	NMNAT3	-0.77	-8.08	-0.55	1.92e-13	Obesity-related traits;
PAAD	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.53	0.34	1.2e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg15226751	chr1:10001911	LZIC	-0.38	-4.3	-0.33	3.03e-5	Hepatocellular carcinoma;
PAAD	cis	rs2294693	0.891	rs9381024	chr6:40984262	A/C	cg14769373	chr6:40998127	UNC5CL	0.63	5.01	0.38	1.49e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35952432	1	rs35952432	chr6:28074901	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Lung cancer;
PAAD	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.4	-0.4	2.55e-7	Bladder cancer;
PAAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs2882667	0.690	rs13178601	chr5:138267377	G/A	cg09476006	chr5:138032270	NA	0.45	5.51	0.41	1.47e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	7.27	0.51	1.73e-11	Lymphocyte counts;
PAAD	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	4.37	0.33	2.27e-5	Eosinophil percentage of white cells;
PAAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	9.61	0.61	2.2e-17	Total body bone mineral density;
PAAD	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19904058	chr10:135279010	LOC619207	-0.53	-6.57	-0.47	7.64e-10	Systemic lupus erythematosus;
PAAD	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs804280	0.625	rs4840581	chr8:11635569	T/C	cg12395012	chr8:11607386	GATA4	0.67	8.33	0.56	4.48e-14	Myopia (pathological);
PAAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.51	5.39	0.4	2.59e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	4.93e-20	Heart rate;
PAAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg14703610	chr5:56206110	C5orf35	-0.56	-5.23	-0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs62400317	0.731	rs12208523	chr6:45058828	C/T	cg20913747	chr6:44695427	NA	-0.61	-5.78	-0.42	4.08e-8	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	7.43	0.52	7.11e-12	Alzheimer's disease;
PAAD	cis	rs17152411	0.652	rs1046373	chr10:126674689	A/C	cg04726013	chr10:126223236	LHPP	-0.34	-5.02	-0.38	1.41e-6	Height;
PAAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg11494091	chr17:61959527	GH2	0.53	4.4	0.34	2.03e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.58	-5.52	-0.41	1.43e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg14926445	chr8:58193284	C8orf71	-0.65	-4.55	-0.35	1.11e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg10729496	chr3:10149963	C3orf24	0.83	6.67	0.48	4.52e-10	Alzheimer's disease;
PAAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.86	-5.54	-0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.66	8.69	0.58	5.37e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2085601	0.542	rs2670624	chr4:89977728	A/G	cg17769793	chr4:89976368	FAM13A	0.44	5.48	0.41	1.71e-7	Hair greying;
PAAD	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.8	7.95	0.54	4.01e-13	Retinal vascular caliber;
PAAD	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.22	0.45	4.61e-9	Schizophrenia;
PAAD	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg21929781	chr1:2537748	MMEL1	0.48	5.08	0.38	1.1e-6	Ulcerative colitis;
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-15.83	-0.79	5.73e-34	Height;
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.77	9.38	0.61	8.81e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.01	0.49	7.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2555155	0.806	rs4758426	chr11:6544649	G/A	cg24637308	chr11:6592297	DNHD1	0.46	4.76	0.36	4.56e-6	DNA methylation (variation);
PAAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg21433313	chr16:3507492	NAT15	0.94	7.74	0.53	1.27e-12	Tuberculosis;
PAAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs12365397	0.530	rs1845824	chr11:43175559	T/G	cg03447554	chr11:43094025	NA	0.41	4.65	0.35	7.13e-6	Migraine;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04144333	chr10:3187835	PITRM1	0.68	7.45	0.52	6.48e-12	Lung cancer in ever smokers;
PAAD	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg05528293	chr18:74961138	GALR1	0.58	5.31	0.4	3.87e-7	Obesity-related traits;
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.75	8.78	0.58	3.24e-15	Age at first birth;
PAAD	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.57	-4.62	-0.35	8.25e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.2e-5	Schizophrenia;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg10467557	chr13:21893662	NA	-0.41	-4.72	-0.36	5.29e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg06287003	chr12:125626642	AACS	-0.51	-5.01	-0.38	1.46e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.26e-5	Height;
PAAD	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.5	-5.47	-0.41	1.82e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19671926	chr4:122722719	EXOSC9	0.52	5.1	0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg13468214	chr4:1046988	NA	-0.5	-4.85	-0.37	3e-6	Recombination rate (females);
PAAD	cis	rs2252790	1.000	rs910391	chr6:116575344	A/C	cg18764771	chr6:116381957	FRK	-0.26	-4.28	-0.33	3.28e-5	Fast beta electroencephalogram;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18621852	chr3:10150065	C3orf24	0.69	6.02	0.44	1.29e-8	Alzheimer's disease;
PAAD	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg20283391	chr11:68216788	NA	-0.52	-4.97	-0.37	1.76e-6	Bone mineral density (spine);
PAAD	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.38	9.43	0.61	6.68e-17	Prostate cancer;
PAAD	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.66	6.04	0.44	1.14e-8	Corneal astigmatism;
PAAD	cis	rs1015291	0.680	rs1388676	chr12:19993958	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.5	-0.41	1.57e-7	Diastolic blood pressure;
PAAD	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg15654264	chr1:150340011	RPRD2	-0.51	-4.88	-0.37	2.6e-6	Migraine;
PAAD	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.57	6.32	0.46	2.77e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2286503	0.533	rs1880239	chr7:22871684	C/A	cg04907244	chr7:22894795	SNORD93	-0.43	-4.42	-0.34	1.84e-5	Fibrinogen;
PAAD	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs11696501	0.739	rs6073784	chr20:44201931	T/A	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-6.75	-0.48	2.96e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg11657817	chr20:23433608	CST11	0.48	5.34	0.4	3.29e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10214930	0.697	rs2110526	chr7:27635680	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg16850897	chr7:100343110	ZAN	-0.58	-4.84	-0.37	3.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs4548	chr3:128525253	C/T	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg20578329	chr17:80767326	TBCD	-0.87	-5.62	-0.41	9.09e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs76419734	0.558	rs17035915	chr4:106520435	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	4.26	0.33	3.62e-5	Post bronchodilator FEV1;
PAAD	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.84	-10.22	-0.64	5.53e-19	Body mass index;
PAAD	cis	rs12148477	0.787	rs8031311	chr15:51654731	G/T	cg25905881	chr15:51634250	GLDN	0.41	4.29	0.33	3.14e-5	Follicule stimulating hormone;
PAAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00142150	chr22:38071001	LGALS1	0.81	9.09	0.59	5.15e-16	Fat distribution (HIV);
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.73	5.38	0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg13206674	chr6:150067644	NUP43	0.62	6.49	0.47	1.17e-9	Lung cancer;
PAAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-6.06	-0.44	1.04e-8	Schizophrenia;
PAAD	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-6.33	-0.46	2.66e-9	Ileal carcinoids;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg18279126	chr7:2041391	MAD1L1	0.6	6.05	0.44	1.11e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9657904	0.774	rs769315	chr3:105521025	A/G	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.89e-6	Multiple sclerosis;
PAAD	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.48	-5.37	-0.4	2.87e-7	Blood pressure (smoking interaction);
PAAD	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.64	6.17	0.45	6.05e-9	Hip circumference;
PAAD	cis	rs2342371	0.715	rs9846106	chr3:196126539	G/A	cg09821211	chr3:195954098	OSTalpha	0.64	6.01	0.44	1.34e-8	Fat distribution (HIV);
PAAD	cis	rs1879734	0.689	rs55786134	chr1:54171981	T/C	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.43	-4.38	-0.34	2.16e-5	Menarche (age at onset);
PAAD	cis	rs2555155	1.000	rs2256920	chr11:6508124	G/C	cg10208301	chr11:6592745	DNHD1	0.42	4.36	0.33	2.34e-5	DNA methylation (variation);
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.63	5.67	0.42	7.1e-8	Height;
PAAD	cis	rs7567389	0.719	rs6744237	chr2:128004045	C/G	cg11380483	chr2:127933992	NA	-0.47	-4.68	-0.36	6.22e-6	Self-rated health;
PAAD	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg08648136	chr8:956695	NA	0.49	5.18	0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg27411982	chr8:10470053	RP1L1	-0.48	-4.74	-0.36	4.78e-6	Neuroticism;
PAAD	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.59	-0.47	6.88e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.79	6.13	0.44	7.4e-9	Diisocyanate-induced asthma;
PAAD	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg00717180	chr2:96193071	NA	0.58	6.49	0.47	1.15e-9	HDL cholesterol;
PAAD	cis	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg21546286	chr11:48923668	NA	-0.44	-4.67	-0.35	6.5e-6	HDL cholesterol;
PAAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-5.95	-0.43	1.76e-8	Neuroticism;
PAAD	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2594989	0.943	rs7646500	chr3:11478000	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-4.57	-0.35	9.85e-6	Circulating chemerin levels;
PAAD	cis	rs804280	0.564	rs809202	chr8:11628659	T/C	cg12395012	chr8:11607386	GATA4	-0.64	-7.79	-0.53	9.71e-13	Myopia (pathological);
PAAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs8084125	0.938	rs62105163	chr18:74943673	C/T	cg15443732	chr18:74961078	GALR1	0.72	5.96	0.44	1.66e-8	Obesity-related traits;
PAAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.5	5.12	0.38	8.97e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.67	7.68	0.53	1.77e-12	High light scatter reticulocyte count;
PAAD	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.53	5.14	0.38	8.26e-7	Testicular germ cell tumor;
PAAD	cis	rs11203032	0.831	rs12570154	chr10:90951027	T/C	cg16672925	chr10:90967113	CH25H	0.8	5.94	0.43	1.83e-8	Heart failure;
PAAD	cis	rs13011075	0.535	rs6742200	chr2:68623302	A/G	cg06275642	chr2:68546038	CNRIP1	0.35	4.66	0.35	6.94e-6	Mean corpuscular volume;
PAAD	cis	rs7714584	1.000	rs6875011	chr5:150182710	G/A	cg22134413	chr5:150180641	NA	0.91	6.48	0.47	1.18e-9	Crohn's disease;
PAAD	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg06496078	chr12:107350075	C12orf23	-0.46	-4.63	-0.35	7.93e-6	Total body bone mineral density;
PAAD	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.25	-0.39	4.99e-7	Mood instability;
PAAD	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg21483461	chr5:81570383	RPS23	0.53	4.91	0.37	2.32e-6	Breast cancer;
PAAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.41e-10	Coronary artery disease;
PAAD	cis	rs438034	0.775	rs2070064	chr1:214787130	G/A	cg16144317	chr1:214725524	PTPN14	0.4	4.3	0.33	3.03e-5	Response to antineoplastic agents;
PAAD	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.91	-10.2	-0.64	6.22e-19	Obesity-related traits;
PAAD	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.64	6.15	0.45	6.5e-9	Cognitive test performance;
PAAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-4.47	-0.34	1.5e-5	Gut microbiome composition (summer);
PAAD	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.63	6.77	0.48	2.69e-10	Leprosy;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.84	8.37	0.56	3.56e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.97	10.36	0.64	2.38e-19	Corneal astigmatism;
PAAD	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.77	5.57	0.41	1.13e-7	White matter hyperintensity burden;
PAAD	cis	rs4795519	0.704	rs11870550	chr17:22175355	A/G	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.86	8.67	0.58	6.04e-15	DNA methylation (variation);
PAAD	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.6	5.37	0.4	2.86e-7	Retinal vascular caliber;
PAAD	cis	rs7713065	0.765	rs1012794	chr5:131781681	C/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.36	0.33	2.36e-5	Lung function (FEV1/FVC);
PAAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.56	-5.29	-0.39	4.21e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg20007245	chr22:24372913	LOC391322	-0.89	-9.64	-0.62	1.84e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg05868516	chr6:26286170	HIST1H4H	0.51	4.7	0.36	5.85e-6	Educational attainment;
PAAD	cis	rs2131877	0.830	rs62290329	chr3:194843634	G/A	cg16306870	chr3:194868790	C3orf21	0.55	5.3	0.4	3.94e-7	Non-small cell lung cancer;
PAAD	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.77	5.34	0.4	3.28e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg00738919	chr7:1100172	C7orf50	0.67	5.06	0.38	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26276294	chr10:30024803	SVIL	0.61	6.94	0.49	1.06e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg05697835	chr1:2722811	NA	0.41	4.65	0.35	7.07e-6	Ulcerative colitis;
PAAD	cis	rs6743376	0.556	rs12475161	chr2:113823626	T/C	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17973462	chr19:6279770	MLLT1	0.55	6.46	0.46	1.33e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs757081	0.648	rs214923	chr11:17237080	G/C	cg15432903	chr11:17409602	KCNJ11	-0.6	-6.11	-0.44	8.17e-9	Systolic blood pressure;
PAAD	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7539409	0.831	rs6682282	chr1:84223416	G/A	cg10977910	chr1:84465055	TTLL7	0.7	4.58	0.35	9.76e-6	Alzheimer's disease;
PAAD	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.42	0.52	7.92e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.59	0.35	9.27e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.61	5.06	0.38	1.17e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs728616	0.614	rs61859199	chr10:82118613	G/T	cg19423196	chr10:82049429	MAT1A	0.48	4.74	0.36	4.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.81	-0.43	3.5e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.65	7.29	0.51	1.55e-11	Aortic root size;
PAAD	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.610	rs73194020	chr12:111131366	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.4	0.34	1.99e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.55	-0.61	3.16e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.58	-5.03	-0.38	1.34e-6	Total ventricular volume;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg14840727	chr4:7783969	AFAP1	0.6	6.32	0.46	2.78e-9	Educational attainment (years of education);
PAAD	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.39	4.45	0.34	1.64e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.77	8.28	0.56	5.83e-14	Coronary artery disease;
PAAD	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.51	5.51	0.41	1.5e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs75920871	0.920	rs61905687	chr11:116862144	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.73	-4.38	-0.33	2.19e-5	Subjective well-being;
PAAD	cis	rs11807834	0.505	rs880328	chr1:230246806	T/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.47	-0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg23346134	chr3:49453900	TCTA	-0.54	-5.17	-0.39	7.11e-7	Menarche (age at onset);
PAAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.55	-0.41	1.22e-7	Schizophrenia;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26549601	chr10:134560360	INPP5A	-0.47	-4.6	-0.35	8.84e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13047869	chr3:10149882	C3orf24	0.84	7.0	0.49	7.6e-11	Alzheimer's disease;
PAAD	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.8	6.47	0.46	1.28e-9	Gastritis;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.54	5.76	0.42	4.46e-8	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14778608	chr10:60094189	UBE2D1	-0.57	-6.76	-0.48	2.78e-10	Obesity-related traits;
PAAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-1.37	-11.0	-0.67	4.65e-21	Schizophrenia;
PAAD	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.61	-5.42	-0.4	2.3e-7	Blood trace element (Cu levels);
PAAD	cis	rs11630290	0.736	rs4777239	chr15:64148098	T/A	cg12036633	chr15:63758958	NA	0.67	4.55	0.35	1.09e-5	Iris characteristics;
PAAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.54	5.76	0.42	4.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	5.2	0.39	6.24e-7	Longevity;
PAAD	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.66	-7.37	-0.51	1.02e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.46	-4.88	-0.37	2.61e-6	Dilated cardiomyopathy;
PAAD	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg23860436	chr12:58378763	NA	0.55	5.34	0.4	3.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.53	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs11825685	0.887	rs4359223	chr11:134563721	T/G	cg02089395	chr11:134479357	NA	-0.72	-4.54	-0.35	1.15e-5	IgG glycosylation;
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.76	7.33	0.51	1.25e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.74	6.11	0.44	8.13e-9	Glioblastoma;
PAAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs7818688	0.697	rs78802294	chr8:95977974	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.89	-15.17	-0.78	3.1e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6689305	0.545	rs12039637	chr1:100240070	A/G	cg22872634	chr1:100462710	SLC35A3	-0.44	-4.27	-0.33	3.47e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs7202877	0.656	rs3851736	chr16:75387332	T/C	cg03315344	chr16:75512273	CHST6	0.63	5.35	0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.62	6.87	0.49	1.53e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.87	11.49	0.68	2.22e-22	Subjective well-being (multi-trait analysis);
PAAD	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg08898775	chr15:59042684	ADAM10	0.37	4.98	0.37	1.67e-6	Schizophrenia;
PAAD	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.37	0.33	2.33e-5	Bipolar disorder;
PAAD	cis	rs42648	0.564	rs11563947	chr7:89808764	C/T	cg27367526	chr7:89841692	STEAP2	0.34	4.76	0.36	4.52e-6	Homocysteine levels;
PAAD	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg13010199	chr12:38710504	ALG10B	0.63	5.3	0.4	3.94e-7	Morning vs. evening chronotype;
PAAD	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg18093559	chr17:18951025	GRAP	0.48	4.75	0.36	4.67e-6	Schizophrenia;
PAAD	cis	rs2387326	0.818	rs2782862	chr10:129919825	A/G	cg16087940	chr10:129947807	NA	-0.53	-4.46	-0.34	1.56e-5	Select biomarker traits;
PAAD	cis	rs2031532	0.587	rs2077848	chr13:50035208	G/A	cg08779649	chr13:50194554	NA	0.36	4.77	0.36	4.2e-6	Cardiac hypertrophy;
PAAD	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	5.8	0.43	3.66e-8	Renal function-related traits (BUN);
PAAD	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17286258	chr2:198299746	SF3B1	0.66	6.63	0.47	5.38e-10	Obesity-related traits;
PAAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs630539	1.000	rs8071056	chr17:40822308	C/A	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs6442522	0.678	rs878946	chr3:15509212	T/C	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg10932868	chr11:921992	NA	0.43	4.48	0.34	1.46e-5	Alzheimer's disease (late onset);
PAAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs61931739	0.649	rs864614	chr12:33725409	C/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.66	-4.82	-0.36	3.43e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.58	4.66	0.35	7.01e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.44	4.53	0.35	1.17e-5	Height;
PAAD	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.57	6.5	0.47	1.09e-9	Educational attainment;
PAAD	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6743376	0.556	rs2251876	chr2:113818727	A/G	cg24553058	chr2:113831203	IL1F10	0.38	4.25	0.33	3.77e-5	Inflammatory biomarkers;
PAAD	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-10.66	-0.65	3.62e-20	Height;
PAAD	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.26	0.64	4.31e-19	Myeloid white cell count;
PAAD	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg05785598	chr3:49045655	WDR6	0.43	5.07	0.38	1.16e-6	Parkinson's disease;
PAAD	cis	rs8070740	0.559	rs12600578	chr17:5299950	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.76	0.36	4.4e-6	Menopause (age at onset);
PAAD	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg07023327	chr7:56019384	MRPS17	0.86	6.31	0.46	2.9e-9	Lung function (FEV1/FVC);
PAAD	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg20607287	chr7:12443886	VWDE	-0.62	-4.95	-0.37	1.91e-6	Coronary artery disease;
PAAD	cis	rs2016586	0.561	rs5755929	chr22:36118302	G/A	cg26342177	chr22:36113512	APOL5	-0.48	-4.94	-0.37	2.01e-6	Body mass index;
PAAD	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	0.98	12.46	0.71	5.28e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.43	-5.3	-0.39	4.08e-7	Lewy body disease;
PAAD	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.25e-5	Obesity-related traits;
PAAD	cis	rs7567389	0.677	rs72845997	chr2:128110082	T/C	cg11380483	chr2:127933992	NA	0.43	4.29	0.33	3.1e-5	Self-rated health;
PAAD	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.58	5.16	0.39	7.74e-7	Mean platelet volume;
PAAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.5	-5.32	-0.4	3.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg01426195	chr3:39028469	NA	0.64	6.4	0.46	1.8e-9	Handedness;
PAAD	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg20761395	chr17:511517	VPS53	0.53	5.62	0.41	8.83e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.94	-0.37	2.03e-6	Bipolar disorder;
PAAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.7	-5.76	-0.42	4.47e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg02463844	chr16:88152170	NA	0.29	4.82	0.36	3.48e-6	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06370795	chr19:33572183	GPATCH1	0.56	6.37	0.46	2.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.54	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.93	9.73	0.62	1.09e-17	Response to antineoplastic agents;
PAAD	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg26205652	chr12:48591994	NA	0.85	7.74	0.53	1.26e-12	Longevity (90 years and older);
PAAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.93	8.15	0.55	1.27e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-6.57	-0.47	7.63e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7188861	0.768	rs9939877	chr16:11396779	G/A	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.44	5.51	0.41	1.5e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2017305	0.749	rs118077372	chr10:70780683	G/C	cg25290552	chr10:70751067	KIAA1279	-0.88	-5.61	-0.41	9.27e-8	Depression (quantitative trait);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08907819	chr7:70255804	AUTS2	-0.66	-6.59	-0.47	6.81e-10	Obesity-related traits;
PAAD	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg06217071	chr17:408420	NA	0.65	7.05	0.5	5.76e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.89	-10.71	-0.66	2.64e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.65	6.74	0.48	3.13e-10	Resting heart rate;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02994291	chr16:1782905	MAPK8IP3	0.52	4.25	0.33	3.72e-5	Mean corpuscular volume;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.71	9.96	0.63	2.71e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.54e-15	Eye color traits;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.59	0.61	2.49e-17	Prudent dietary pattern;
PAAD	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.66	-5.11	-0.38	9.56e-7	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13101865	chr20:3154899	NA	0.59	6.49	0.47	1.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.87	-9.14	-0.6	3.72e-16	Body mass index;
PAAD	cis	rs988913	0.874	rs4712084	chr6:54861284	G/A	cg03513858	chr6:54763001	FAM83B	-0.46	-5.03	-0.38	1.39e-6	Menarche (age at onset);
PAAD	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.52	-0.71	3.58e-25	Ulcerative colitis;
PAAD	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.5	-0.47	1.11e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05612640	chr18:77748679	TXNL4A	-0.66	-6.61	-0.47	6e-10	Smoking initiation;
PAAD	cis	rs9918079	0.560	rs4698402	chr4:15629803	G/A	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.97	10.57	0.65	6.24e-20	Corneal astigmatism;
PAAD	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.94	5.83	0.43	3.24e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26484621	chr16:2816224	SRRM2	0.58	6.75	0.48	2.86e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	10.14	0.64	9.16e-19	Colorectal cancer;
PAAD	cis	rs258892	1.000	rs2253215	chr5:72247868	T/C	cg21869765	chr5:72125136	TNPO1	0.67	4.71	0.36	5.63e-6	Small cell lung carcinoma;
PAAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.68	-6.95	-0.49	1.02e-10	Monocyte count;
PAAD	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg03983715	chr16:68378420	PRMT7	-0.59	-4.47	-0.34	1.52e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg15838301	chr4:7719899	SORCS2	0.6	6.29	0.45	3.22e-9	Schizophrenia;
PAAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	6.91	0.49	1.28e-10	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg11946769	chr3:48343235	NME6	-0.52	-4.96	-0.37	1.87e-6	Educational attainment (years of education);
PAAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.72	9.03	0.59	7.17e-16	Body mass index;
PAAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.65	7.9	0.54	5.14e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.37	-0.33	2.31e-5	Joint mobility (Beighton score);
PAAD	cis	rs62264129	0.500	rs9816969	chr3:112037942	G/A	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.03	-0.38	1.36e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs6137287	0.813	rs11697462	chr20:21209026	C/T	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs818427	0.635	rs2229992	chr5:112162854	C/T	cg06941702	chr5:112196734	SRP19	0.46	4.32	0.33	2.81e-5	Total body bone mineral density;
PAAD	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	4e-27	Heart rate;
PAAD	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg05874882	chr4:1763078	NA	-0.39	-5.38	-0.4	2.74e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg23018236	chr17:30244563	NA	-0.59	-5.25	-0.39	5.05e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-6.1	-0.44	8.5e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg27411982	chr8:10470053	RP1L1	0.47	5.47	0.41	1.8e-7	Neuroticism;
PAAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.57	5.28	0.39	4.44e-7	Schizophrenia;
PAAD	cis	rs3857067	1.000	rs899133	chr4:95019609	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-5.42	-0.4	2.34e-7	QT interval;
PAAD	cis	rs4740619	0.619	rs4741560	chr9:16043170	C/T	cg14451791	chr9:16040625	NA	0.45	5.13	0.38	8.55e-7	Body mass index;
PAAD	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.48	4.44	0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-5.45	-0.4	1.94e-7	Neutrophil percentage of white cells;
PAAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg04844267	chr4:1394941	NA	0.39	4.25	0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs714031	0.934	rs2235342	chr22:40068853	T/C	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs35079168	0.625	rs3132295	chr9:137309645	C/T	cg00753924	chr9:137298813	RXRA	-0.51	-5.51	-0.41	1.52e-7	Intelligence;
PAAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.86	0.37	2.96e-6	Coronary artery disease;
PAAD	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.4	4.96	0.37	1.85e-6	Electrocardiographic conduction measures;
PAAD	cis	rs877529	0.934	rs139418	chr22:39557162	A/C	cg13455509	chr22:39551605	NA	-0.5	-4.9	-0.37	2.41e-6	Multiple myeloma;
PAAD	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg22437258	chr11:111473054	SIK2	-0.5	-4.82	-0.36	3.48e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-13.58	-0.74	5.25e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.67	-0.35	6.68e-6	Blood metabolite levels;
PAAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.53	-6.76	-0.48	2.77e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.65	7.45	0.52	6.65e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26549601	chr10:134560360	INPP5A	-0.47	-4.86	-0.37	2.87e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.58	0.61	2.62e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg16898833	chr6:26189333	HIST1H4D	1.06	5.72	0.42	5.54e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.68	7.82	0.54	8.25e-13	Multiple sclerosis;
PAAD	cis	rs6132905	0.590	rs76355228	chr20:2605980	C/T	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.52	-5.31	-0.4	3.85e-7	Height;
PAAD	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.5	4.61	0.35	8.38e-6	Breast cancer;
PAAD	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.18e-6	Type 2 diabetes;
PAAD	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.68	-7.07	-0.5	5.24e-11	Leprosy;
PAAD	cis	rs2790216	1.000	rs1339586	chr10:60017646	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1561176	0.943	rs12667735	chr7:155003753	G/C	cg25063631	chr7:155025500	NA	-0.51	-4.37	-0.33	2.25e-5	Personality dimensions;
PAAD	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Vitiligo;
PAAD	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.92	-9.83	-0.62	5.83e-18	Inhibitory control;
PAAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.56	6.05	0.44	1.06e-8	Major depressive disorder;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.83	-0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.36e-5	Dementia with Lewy bodies;
PAAD	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.92	12.14	0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.72	8.06	0.55	2.08e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.72	7.31	0.51	1.42e-11	Coronary artery disease;
PAAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg25487775	chr2:162093969	NA	0.75	8.66	0.57	6.35e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.25	0.39	4.95e-7	Parkinson's disease;
PAAD	cis	rs11696501	0.688	rs6065866	chr20:44323440	G/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs12134040	0.646	rs12734378	chr1:236511354	A/G	cg21399712	chr1:236511386	NA	0.52	4.87	0.37	2.83e-6	Urate levels (BMI interaction);
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.39	-0.4	2.7e-7	Psoriasis;
PAAD	cis	rs761746	0.705	rs10154390	chr22:32051089	C/T	cg01338084	chr22:32026380	PISD	0.62	5.35	0.4	3.21e-7	Intelligence;
PAAD	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.42	-0.4	2.26e-7	Schizophrenia;
PAAD	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-0.8	-4.89	-0.37	2.54e-6	Blood trace element (Zn levels);
PAAD	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg01270228	chr10:1369114	ADARB2	0.54	4.94	0.37	2.08e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2555155	0.935	rs2723655	chr11:6516755	C/A	cg24637308	chr11:6592297	DNHD1	0.48	4.93	0.37	2.13e-6	DNA methylation (variation);
PAAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.43	10.08	0.63	1.26e-18	Opioid sensitivity;
PAAD	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.56	5.68	0.42	6.75e-8	Systolic blood pressure;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg20295408	chr7:1910781	MAD1L1	-0.54	-5.04	-0.38	1.28e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.78	7.35	0.51	1.16e-11	Body mass index;
PAAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.6	-5.21	-0.39	6.17e-7	Type 2 diabetes;
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg21665744	chr7:39171113	POU6F2	0.36	6.11	0.44	8.12e-9	IgG glycosylation;
PAAD	cis	rs2239785	0.959	rs136159	chr22:36657023	T/C	cg15716373	chr22:36655542	APOL1	-0.46	-4.35	-0.33	2.46e-5	Glomerulosclerosis;
PAAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.83	-9.09	-0.59	4.97e-16	Prostate cancer;
PAAD	cis	rs11024102	1.000	rs10766368	chr11:17014882	G/C	cg15084286	chr11:17036142	PLEKHA7	0.5	4.6	0.35	8.84e-6	Glaucoma (primary angle closure);
PAAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.48	-4.74	-0.36	4.82e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs9810890	1.000	rs73198844	chr3:128503044	G/A	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14019695	chr9:139328340	INPP5E	0.58	6.13	0.45	7.23e-9	Monocyte percentage of white cells;
PAAD	trans	rs4707930	0.628	rs927277	chr6:72419055	T/C	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.53	-0.34	1.19e-5	Alcohol dependence;
PAAD	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.87	-8.72	-0.58	4.65e-15	Breast cancer;
PAAD	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg01851573	chr8:8652454	MFHAS1	0.58	5.01	0.38	1.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.42	-4.81	-0.36	3.62e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.62	-6.07	-0.44	9.98e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	4.5	0.34	1.35e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-5.91	-0.43	2.11e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2790216	1.000	rs1199107	chr10:59943709	T/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg27236539	chr20:62289627	RTEL1	0.58	4.69	0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.99	-12.16	-0.7	3.42e-24	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg08079166	chr15:68083412	MAP2K5	0.65	5.14	0.39	8.16e-7	Restless legs syndrome;
PAAD	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	7.67	0.53	1.91e-12	Electrocardiographic conduction measures;
PAAD	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.67	-6.47	-0.46	1.26e-9	Blood metabolite levels;
PAAD	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.73	6.8	0.48	2.29e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.28	0.45	3.37e-9	Schizophrenia;
PAAD	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-1.22	-5.68	-0.42	6.7e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18404041	chr3:52824283	ITIH1	0.41	4.41	0.34	1.96e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg26816564	chr1:7831052	VAMP3	0.81	6.17	0.45	5.96e-9	Inflammatory bowel disease;
PAAD	cis	rs13102973	0.867	rs12501608	chr4:135896365	T/C	cg14419869	chr4:135874104	NA	0.44	4.49	0.34	1.37e-5	Subjective well-being;
PAAD	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg00536532	chr6:33561449	C6orf227	-0.41	-4.43	-0.34	1.77e-5	Height;
PAAD	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.19	-0.64	6.54e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg14393609	chr7:65229607	NA	0.51	4.37	0.33	2.25e-5	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13465838	chr2:103235720	SLC9A2	0.62	6.37	0.46	2.09e-9	Obesity-related traits;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg11766577	chr21:47581405	C21orf56	-0.42	-4.81	-0.36	3.68e-6	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01292486	chr7:87848742	SRI	0.66	6.71	0.48	3.57e-10	Obesity-related traits;
PAAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.07	15.41	0.78	7.26e-33	Multiple system atrophy;
PAAD	cis	rs507080	0.501	rs637563	chr11:118575479	A/G	cg08498647	chr11:118550644	TREH	-0.42	-5.21	-0.39	6.01e-7	Serum metabolite levels;
PAAD	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.44	-0.34	1.73e-5	Height;
PAAD	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs787274	0.718	rs1711745	chr9:115452909	C/A	cg13803584	chr9:115635662	SNX30	0.83	5.43	0.4	2.19e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg16898833	chr6:26189333	HIST1H4D	0.86	4.74	0.36	4.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13198984	chr17:80129470	CCDC57	-0.36	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs501120	0.584	rs11238906	chr10:44685925	T/C	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg26935685	chr1:15502881	TMEM51	-0.5	-4.26	-0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg09626299	chr10:82213104	TSPAN14	-0.44	-4.82	-0.36	3.45e-6	Post bronchodilator FEV1;
PAAD	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.33	0.4	3.54e-7	Colorectal cancer;
PAAD	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-1.0	-12.89	-0.72	3.76e-26	Refractive error;
PAAD	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.28	7.24	0.51	2.12e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs75920871	0.925	rs61903426	chr11:116968268	C/T	cg04087571	chr11:116723030	SIK3	-0.43	-4.52	-0.34	1.24e-5	Subjective well-being;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27446566	chr2:99952965	EIF5B;TXNDC9	0.68	6.94	0.49	1.05e-10	Obesity-related traits;
PAAD	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg25664220	chr3:72788482	NA	-0.68	-6.88	-0.49	1.45e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs6499129	0.558	rs60626639	chr16:67625797	A/G	cg09835421	chr16:68378352	PRMT7	-0.66	-4.39	-0.34	2.07e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2229238	0.911	rs59838898	chr1:154466301	C/T	cg21262032	chr1:154437693	IL6R	-0.48	-5.0	-0.38	1.56e-6	Coronary heart disease;
PAAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg03094675	chr11:5960213	NA	-0.53	-5.13	-0.38	8.79e-7	DNA methylation (variation);
PAAD	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16576597	chr16:28551801	NUPR1	0.65	7.39	0.51	9.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs688181	0.621	rs596183	chr6:158100199	G/A	cg17310882	chr6:158066609	ZDHHC14	0.35	4.34	0.33	2.62e-5	Platelet distribution width;
PAAD	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	5.74	0.42	4.98e-8	Lung cancer in ever smokers;
PAAD	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg16205897	chr5:131564050	P4HA2	-0.47	-5.02	-0.38	1.44e-6	Blood metabolite levels;
PAAD	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.84	6.62	0.47	5.85e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05025164	chr4:1340916	KIAA1530	-0.55	-5.44	-0.4	2.09e-7	Obesity-related traits;
PAAD	trans	rs7172971	0.745	rs75068385	chr15:42382481	G/A	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22987389	chr8:22428557	SORBS3	0.55	6.34	0.46	2.49e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.69	-6.29	-0.45	3.14e-9	Diabetic retinopathy;
PAAD	cis	rs7580717	0.785	rs12622630	chr2:232152297	A/G	cg07929768	chr2:232055508	NA	0.48	5.42	0.4	2.32e-7	Multiple myeloma;
PAAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.71	-7.18	-0.5	2.89e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs113779084	0.632	rs10435044	chr7:11935228	G/A	cg15090509	chr7:11872073	THSD7A	0.39	5.04	0.38	1.31e-6	Educational attainment (years of education);
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-6.78	-0.48	2.45e-10	Bipolar disorder;
PAAD	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg16576597	chr16:28551801	NUPR1	0.63	7.01	0.49	7.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2327429	0.519	rs4895388	chr6:134150561	G/A	cg06643013	chr6:134217242	NA	0.4	4.43	0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.5	0.47	1.07e-9	Bladder cancer;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg08057985	chr22:42470123	FAM109B	-0.36	-4.42	-0.34	1.87e-5	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.64	6.35	0.46	2.38e-9	Platelet count;
PAAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs959260	1.000	rs2117562	chr17:73369000	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.39	0.34	2.14e-5	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs12195424	0.558	rs75574110	chr6:56299478	A/T	cg10030658	chr6:56298004	NA	-0.73	-4.27	-0.33	3.43e-5	Cerebrospinal fluid clusterin levels;
PAAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.65	7.29	0.51	1.63e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.65	6.44	0.46	1.47e-9	Capecitabine sensitivity;
PAAD	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg25364880	chr3:44379878	C3orf23	0.56	5.03	0.38	1.34e-6	Depressive symptoms;
PAAD	cis	rs58521262	0.685	rs289291	chr19:23177889	T/C	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs72772090	0.710	rs113710451	chr5:96060306	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.86	-6.52	-0.47	9.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	1.06	5.91	0.43	2.19e-8	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21930229	chr1:32758033	HDAC1	0.63	7.05	0.5	5.73e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.5	-5.24	-0.39	5.3e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.59	-6.15	-0.45	6.69e-9	Blood metabolite levels;
PAAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.81	-9.29	-0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs11235843	0.929	rs4944032	chr11:73413121	A/G	cg18195628	chr11:73498948	MRPL48	-0.78	-4.29	-0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg06496078	chr12:107350075	C12orf23	-0.46	-4.52	-0.34	1.23e-5	Total body bone mineral density;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.46	-4.4	-0.34	2.04e-5	Itch intensity from mosquito bite;
PAAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.86	0.37	2.95e-6	Breast cancer;
PAAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.04	-18.63	-0.83	4.37e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.67	6.35	0.46	2.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg12826209	chr6:26865740	GUSBL1	0.62	4.95	0.37	1.91e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs1018697	1.000	rs10748830	chr10:104548382	A/C	cg14489801	chr10:103603810	KCNIP2	-0.3	-4.33	-0.33	2.67e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg22027985	chr11:4115532	RRM1	-0.5	-4.48	-0.34	1.46e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.55	-6.97	-0.49	8.88e-11	Height;
PAAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs360071	0.528	rs360094	chr1:226064846	C/T	cg11967457	chr1:226128626	LEFTY2	-0.53	-5.01	-0.38	1.53e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	trans	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.54	5.49	0.41	1.65e-7	Lewy body disease;
PAAD	cis	rs7591163	1.000	rs6744308	chr2:228711816	T/G	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.57	-5.68	-0.42	6.77e-8	Parkinson's disease;
PAAD	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10186876	0.728	rs6759659	chr2:44143756	A/G	cg26828767	chr2:44457733	PPM1B	-0.46	-4.46	-0.34	1.62e-5	Hand grip strength;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14012826	chr19:58083387	ZNF416	-0.68	-6.99	-0.49	8.08e-11	Obesity-related traits;
PAAD	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg10932868	chr11:921992	NA	0.51	6.07	0.44	9.71e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.63	-5.86	-0.43	2.8e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6782228	0.848	rs6439141	chr3:128420534	T/C	cg15607142	chr3:128420513	NA	-0.43	-4.79	-0.36	3.85e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.59	5.93	0.43	2e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13868050	chr9:140671200	EHMT1	-0.68	-6.46	-0.46	1.36e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.91	0.37	2.32e-6	Menopause (age at onset);
PAAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.15	0.55	1.24e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.29	0.39	4.12e-7	Neuroticism;
PAAD	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.58	-5.18	-0.39	6.9e-7	Platelet count;
PAAD	cis	rs965513	1.000	rs7030256	chr9:100535203	C/G	cg13688889	chr9:100608707	NA	-0.51	-4.35	-0.33	2.49e-5	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
PAAD	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg01821656	chr2:2190118	MYT1L	-0.55	-6.73	-0.48	3.23e-10	Alzheimer's disease (survival time);
PAAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.84	-9.96	-0.63	2.66e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.32	0.4	3.58e-7	Ovarian reserve;
PAAD	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.73	5.82	0.43	3.29e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.78e-9	Diastolic blood pressure;
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs4979906	1.000	rs11813624	chr10:79453162	T/C	cg07817648	chr10:79422355	NA	-0.67	-5.99	-0.44	1.45e-8	Mortality in heart failure;
PAAD	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg08992911	chr2:238395768	MLPH	0.62	5.77	0.42	4.23e-8	Prostate cancer;
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg05564831	chr3:52568323	NT5DC2	-0.41	-4.38	-0.33	2.23e-5	Bipolar disorder;
PAAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-4.27	-0.33	3.43e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11166927	0.703	rs2126128	chr8:140788299	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.48	-5.27	-0.39	4.66e-7	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.9	5.89	0.43	2.45e-8	Diabetic kidney disease;
PAAD	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.62	-4.55	-0.35	1.07e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11411865	chr7:2701802	TTYH3	0.65	4.74	0.36	4.87e-6	Bipolar disorder;
PAAD	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.57	4.97	0.37	1.79e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.84e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7752195	0.643	rs77042011	chr6:25204583	A/G	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.58	-7.39	-0.51	8.91e-12	Atrioventricular conduction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27402805	chr16:30681996	FBRS	-0.61	-6.35	-0.46	2.42e-9	Obesity-related traits;
PAAD	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg16083429	chr3:49237500	CCDC36	0.44	4.44	0.34	1.74e-5	Menarche (age at onset);
PAAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.49	-4.82	-0.36	3.49e-6	Obesity-related traits;
PAAD	cis	rs6694270	0.529	rs11261065	chr1:19106254	A/C	cg19637330	chr1:19110922	NA	-0.6	-4.96	-0.37	1.87e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.72	-6.46	-0.46	1.32e-9	Body mass index (adult);
PAAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.68	-5.76	-0.42	4.47e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.51	5.06	0.38	1.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.68	-6.38	-0.46	2.07e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs2000999	0.573	rs34682685	chr16:72096227	G/A	cg16558253	chr16:72132732	DHX38	-0.7	-4.42	-0.34	1.84e-5	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09935461	chr17:76802152	USP36	0.63	6.34	0.46	2.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03813033	chr19:50380022	AKT1S1;TBC1D17	0.63	7.33	0.51	1.26e-11	Metabolite levels  (X-11787);
PAAD	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs28795989	0.731	rs6857814	chr4:7916540	A/G	cg18538662	chr4:7941764	AFAP1	0.43	4.51	0.34	1.27e-5	Intraocular pressure;
PAAD	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.01	8.52	0.57	1.42e-14	Dupuytren's disease;
PAAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg19257562	chr1:2043853	PRKCZ	-0.41	-4.7	-0.36	5.72e-6	Coronary artery disease;
PAAD	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05628381	chr19:982985	WDR18	-0.71	-6.39	-0.46	1.88e-9	Neuroticism;
PAAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-10.27	-0.64	4.04e-19	Height;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.42	4.6	0.35	9.01e-6	Dietary macronutrient intake;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09760836	chr7:140397266	LOC100134713;NDUFB2	0.6	6.4	0.46	1.8e-9	Myopia (pathological);
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.52e-6	Testicular germ cell tumor;
PAAD	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg08992911	chr2:238395768	MLPH	0.67	6.58	0.47	7.11e-10	Prostate cancer;
PAAD	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.68	5.87	0.43	2.64e-8	Schizophrenia;
PAAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22947322	chr17:47091978	IGF2BP1	0.38	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs2677744	0.657	rs11073961	chr15:91483392	A/G	cg23684204	chr15:91497937	RCCD1	0.54	4.69	0.36	6.05e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24868830	chr4:140374821	RAB33B	-0.66	-6.6	-0.47	6.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.61	0.47	6.15e-10	Platelet count;
PAAD	cis	rs899997	1.000	rs12901228	chr15:79030049	G/T	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs9341808	0.556	rs1474791	chr6:81033097	A/G	cg08355045	chr6:80787529	NA	0.43	5.33	0.4	3.5e-7	Sitting height ratio;
PAAD	cis	rs950881	0.562	rs11692335	chr2:103077893	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Allergy;
PAAD	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-5.55	-0.41	1.26e-7	Schizophrenia;
PAAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.71	7.12	0.5	4.01e-11	Platelet count;
PAAD	cis	rs3790455	0.560	rs1171558	chr1:156452093	G/A	cg14087168	chr1:156450669	MEF2D	-0.4	-4.33	-0.33	2.74e-5	Migraine;
PAAD	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.71	0.42	5.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.39	4.68	0.36	6.23e-6	Pulmonary function;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13047869	chr3:10149882	C3orf24	0.89	7.32	0.51	1.34e-11	Alzheimer's disease;
PAAD	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg09127314	chr1:152161683	NA	0.72	5.31	0.4	3.82e-7	Atopic dermatitis;
PAAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg18944383	chr4:111397179	ENPEP	-0.75	-8.17	-0.55	1.09e-13	Coronary artery disease;
PAAD	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.38	9.64	0.62	1.83e-17	Atopic dermatitis;
PAAD	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	6.37	0.46	2.17e-9	Blood protein levels;
PAAD	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.44	6.81	0.48	2.08e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4742903	0.935	rs7872170	chr9:106957103	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.72	0.36	5.36e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.87	9.26	0.6	1.84e-16	Cognitive function;
PAAD	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs9463078	0.845	rs1360196	chr6:44952642	G/A	cg25276700	chr6:44698697	NA	-0.5	-5.87	-0.43	2.62e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.49	4.56	0.35	1.03e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.58	5.65	0.42	7.82e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2034650	0.563	rs12914315	chr15:40713878	C/T	cg05276125	chr15:40653601	DISP2	-0.46	-4.46	-0.34	1.58e-5	Interstitial lung disease;
PAAD	cis	rs2555155	1.000	rs2250886	chr11:6529642	G/A	cg11185456	chr11:6592066	DNHD1	0.4	4.25	0.33	3.67e-5	DNA methylation (variation);
PAAD	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.47	0.41	1.79e-7	Orofacial clefts;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16476890	chr4:40631571	RBM47	-0.66	-6.4	-0.46	1.78e-9	Lung cancer in ever smokers;
PAAD	cis	rs114540395	0.858	rs3730478	chr10:103339142	G/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.46	-0.34	1.6e-5	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.75	8.45	0.57	2.17e-14	Lung cancer;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.55	-0.41	1.26e-7	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.0	-0.38	1.58e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.2	0.64	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.66	0.57	6.25e-15	Alzheimer's disease;
PAAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg12639453	chr1:2035780	PRKCZ	-0.59	-6.46	-0.46	1.31e-9	Height;
PAAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.73	6.86	0.49	1.61e-10	Coronary artery disease;
PAAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25833597	chr17:30823145	MYO1D	0.46	4.59	0.35	9.28e-6	Schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03643709	chr15:41186784	VPS18	0.6	6.79	0.48	2.37e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-9.83	-0.62	6.01e-18	Body mass index;
PAAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.66	0.57	6.59e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.95	0.37	1.98e-6	Colorectal cancer;
PAAD	cis	rs10878977	0.542	rs17225223	chr12:69810208	C/T	cg13322954	chr12:69198953	NA	0.7	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10611115	chr20:10655495	JAG1	0.66	6.71	0.48	3.59e-10	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	trans	rs877282	0.741	rs35865720	chr10:753022	G/A	cg22713356	chr15:30763199	NA	1.25	9.85	0.62	5.35e-18	Uric acid levels;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.47	4.63	0.35	7.77e-6	Longevity;Endometriosis;
PAAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.55	-6.36	-0.46	2.27e-9	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.14	-0.45	6.76e-9	Bone mineral density;
PAAD	trans	rs901683	1.000	rs35639934	chr10:46070627	T/A	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.24	0.45	4.11e-9	Bladder cancer;
PAAD	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg23435118	chr5:141488016	NDFIP1	-0.57	-5.52	-0.41	1.42e-7	Crohn's disease;
PAAD	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.57	0.41	1.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg02440177	chr19:53496695	ZNF702P	-0.62	-6.5	-0.47	1.1e-9	Psoriasis;
PAAD	cis	rs6076065	0.723	rs2253925	chr20:23388021	C/G	cg11657817	chr20:23433608	CST11	0.49	5.0	0.38	1.54e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9810890	1.000	rs115201118	chr3:128552140	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-4.85	-0.37	3e-6	Obesity-related traits;
PAAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.58	-8.23	-0.56	7.89e-14	Huntington's disease progression;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.81	-9.16	-0.6	3.35e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg15590007	chr10:45870220	ALOX5	-0.55	-5.32	-0.4	3.68e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs7631605	0.905	rs1558527	chr3:37115658	C/T	cg17445812	chr3:36986805	TRANK1	-0.35	-4.74	-0.36	4.83e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs939421	0.521	rs2139633	chr3:46602736	A/G	cg23009419	chr3:46618597	LRRC2;TDGF1	0.3	4.33	0.33	2.65e-5	Blood protein levels;
PAAD	cis	rs9810890	1.000	rs73198820	chr3:128476794	G/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg18944383	chr4:111397179	ENPEP	-0.75	-8.6	-0.57	9.19e-15	Height;
PAAD	cis	rs9815354	1.000	rs1716997	chr3:41924333	A/G	cg03022575	chr3:42003672	ULK4	-0.83	-5.94	-0.43	1.83e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.81	-6.14	-0.45	6.87e-9	Coronary artery calcification;
PAAD	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.62	6.52	0.47	9.61e-10	N-glycan levels;
PAAD	cis	rs9487051	0.646	rs7773490	chr6:109623048	T/C	cg21918786	chr6:109611834	NA	-0.52	-5.54	-0.41	1.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg00944433	chr1:107599041	PRMT6	0.4	4.49	0.34	1.42e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs75920871	1.000	rs61905691	chr11:116880703	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	8.05	0.55	2.26e-13	Eye color traits;
PAAD	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs91	0.575	rs2722396	chr7:24428217	C/T	cg13313214	chr7:23749942	STK31	0.47	4.79	0.36	3.93e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg09578614	chr16:68405406	SMPD3	-0.69	-6.42	-0.46	1.67e-9	Blood protein levels;
PAAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-5.95	-0.43	1.74e-8	Lymphocyte counts;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02536620	chr8:413240	FBXO25	0.66	7.27	0.51	1.79e-11	Smoking initiation;
PAAD	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg08099141	chr12:7053170	C12orf57	0.44	4.5	0.34	1.37e-5	IgG glycosylation;
PAAD	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg15282417	chr9:129245246	FAM125B	0.37	4.62	0.35	8.07e-6	Intraocular pressure;
PAAD	cis	rs7647973	0.583	rs55935606	chr3:49565505	A/G	cg07636037	chr3:49044803	WDR6	-0.88	-6.81	-0.48	2.14e-10	Menarche (age at onset);
PAAD	cis	rs4356203	0.905	rs2052188	chr11:17126670	C/T	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04873627	chr4:26832099	NA	0.58	6.61	0.47	6.09e-10	Smoking initiation;
PAAD	cis	rs7551345	0.806	rs12131153	chr1:31867655	C/T	cg17086398	chr1:31896392	SERINC2	-0.6	-4.49	-0.34	1.41e-5	Schizophrenia;
PAAD	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg08601574	chr20:25228251	PYGB	0.5	5.09	0.38	1.04e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12042503	chr14:103987728	CKB	0.58	6.3	0.46	3e-9	Myopia (pathological);
PAAD	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21545522	chr1:205238299	TMCC2	0.48	4.28	0.33	3.32e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.68	-7.46	-0.52	6.26e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.43	-4.59	-0.35	9.31e-6	Aortic root size;
PAAD	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg05555928	chr11:63887634	MACROD1	-0.6	-4.69	-0.36	6.12e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.34	-9.21	-0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg01966878	chr4:90757139	SNCA	-0.62	-4.87	-0.37	2.71e-6	Neuroticism;
PAAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg07701084	chr6:150067640	NUP43	-0.53	-4.59	-0.35	9.36e-6	Lung cancer;
PAAD	cis	rs4455778	0.579	rs4563839	chr7:49076344	T/A	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.48	4.7	0.36	5.66e-6	HDL cholesterol;
PAAD	cis	rs9905704	0.633	rs2680707	chr17:56455641	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.66e-5	Testicular germ cell tumor;
PAAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06217245	chr20:33103252	DYNLRB1	0.42	5.01	0.38	1.52e-6	Coronary artery disease;
PAAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.36	15.78	0.79	7.74e-34	Eosinophil percentage of granulocytes;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.88	8.78	0.58	3.26e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg10935138	chr17:73851978	WBP2	0.94	7.78	0.53	1.05e-12	Psoriasis;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.62	7.74	0.53	1.29e-12	Prudent dietary pattern;
PAAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.61	-7.2	-0.5	2.6e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.72	7.08	0.5	4.96e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9810890	0.850	rs73198884	chr3:128543424	T/C	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.2e-11	Life satisfaction;
PAAD	cis	rs755249	0.567	rs4660636	chr1:39770227	T/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.73	-0.36	5.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-5.64	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.67	5.96	0.44	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs7998202	0.720	rs2274773	chr13:113343171	A/G	cg02820901	chr13:113351484	ATP11A	-0.73	-4.76	-0.36	4.56e-6	Glycated hemoglobin levels;
PAAD	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg17552801	chr10:99332121	ANKRD2	-0.45	-4.65	-0.35	7.25e-6	Metabolite levels;
PAAD	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs4343996	0.837	rs10234204	chr7:3519885	A/G	cg21248987	chr7:3385318	SDK1	0.51	5.67	0.42	6.92e-8	Motion sickness;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	8.01	0.54	2.76e-13	Coffee consumption (cups per day);
PAAD	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.29	0.39	4.15e-7	Heart rate;
PAAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00982548	chr2:198649783	BOLL	-0.84	-5.92	-0.43	2.07e-8	Ulcerative colitis;
PAAD	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.71	-0.36	5.48e-6	Type 2 diabetes;
PAAD	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.94	0.37	2.04e-6	Post bronchodilator FEV1;
PAAD	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.56	5.73	0.42	5.24e-8	Diastolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24242082	chr20:61448325	COL9A3	-0.68	-6.76	-0.48	2.78e-10	Smoking initiation;
PAAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.55	-5.69	-0.42	6.34e-8	Tonsillectomy;
PAAD	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg26752888	chr8:11627280	NEIL2	1.12	10.1	0.63	1.13e-18	Alcohol dependence;Nicotine use;
PAAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.69	7.4	0.51	8.87e-12	Aortic root size;
PAAD	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.4	-5.1	-0.38	9.95e-7	Prostate cancer;
PAAD	cis	rs889122	0.959	rs62104260	chr19:9991637	A/C	cg03494634	chr19:9238958	OR7G3	0.38	4.25	0.33	3.65e-5	Menarche (age at onset);
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs2286379	0.714	rs2190556	chr12:1833912	G/A	cg05227549	chr12:1770782	NA	-0.41	-4.69	-0.36	5.93e-6	Blood pressure (smoking interaction);
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg07336987	chr11:625147	MUPCDH	-0.38	-4.72	-0.36	5.23e-6	Systemic lupus erythematosus;
PAAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6494488	0.500	rs72744788	chr15:65095235	C/T	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg22705602	chr4:152727874	NA	-0.48	-5.1	-0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22601191	chr20:60968625	CABLES2	0.82	7.66	0.53	2.04e-12	Colorectal cancer;
PAAD	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.46	4.52	0.34	1.26e-5	HDL cholesterol;
PAAD	cis	rs258892	0.894	rs155435	chr5:72200093	G/A	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12826209	chr6:26865740	GUSBL1	-0.51	-4.66	-0.35	6.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11671653	1.000	rs4334414	chr19:10831673	T/C	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.51	-4.95	-0.37	1.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.48	-5.51	-0.41	1.5e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg10011062	chr15:43941034	CATSPER2	-0.9	-5.56	-0.41	1.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs13191038	1	rs13191038	chr6:28482917	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.56	4.44	0.34	1.69e-5	Urinary tract infection frequency;
PAAD	cis	rs508970	0.556	rs536121	chr11:60923230	A/C	cg24692310	chr11:60915630	VPS37C	0.34	4.7	0.36	5.9e-6	Rheumatoid arthritis;
PAAD	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs73568641	0.583	rs4870224	chr6:154104380	A/G	cg15658985	chr6:154448740	OPRM1	-0.55	-4.68	-0.35	6.36e-6	Methadone dose in opioid dependence;
PAAD	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	6.93	0.49	1.12e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06530960	chr19:49140787	SEC1;DBP	-0.64	-5.34	-0.4	3.36e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.82	-9.69	-0.62	1.38e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17554472	chr22:41940697	POLR3H	0.61	4.44	0.34	1.73e-5	Vitiligo;
PAAD	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.87	-10.12	-0.63	1e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	5.69	0.42	6.24e-8	Renal function-related traits (BUN);
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.58	-5.5	-0.41	1.54e-7	Menarche (age at onset);
PAAD	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg15208524	chr1:10270712	KIF1B	0.45	4.27	0.33	3.44e-5	Hepatocellular carcinoma;
PAAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6864727	0.963	rs13358047	chr5:137403095	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.04	0.38	1.31e-6	Atrial fibrillation;
PAAD	cis	rs12753920	0.857	rs4658296	chr1:92673015	T/C	cg00856177	chr1:93645673	TMED5;CCDC18	-0.45	-4.3	-0.33	3.03e-5	Systemic lupus erythematosus;
PAAD	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.87	-9.85	-0.62	5.15e-18	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09882587	chr5:96143769	ERAP1	0.6	6.46	0.46	1.36e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.75	8.37	0.56	3.46e-14	Prostate cancer;
PAAD	cis	rs704	0.790	rs4795434	chr17:26716917	G/T	cg10342447	chr17:26645325	TMEM97	-0.35	-4.31	-0.33	2.97e-5	Osteoprotegerin levels;
PAAD	cis	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg27411982	chr8:10470053	RP1L1	0.47	5.47	0.41	1.8e-7	Neuroticism;
PAAD	cis	rs4834770	1.000	rs1397613	chr4:120242929	G/T	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20698069	chr12:122242495	SETD1B;LOC338799	0.67	6.69	0.48	4.06e-10	Obesity-related traits;
PAAD	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg11266682	chr4:10021025	SLC2A9	-0.67	-5.83	-0.43	3.22e-8	Schizophrenia (age at onset);
PAAD	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.71	-5.91	-0.43	2.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.31	4.75	0.36	4.65e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg25558440	chr8:11882962	NA	-0.44	-4.33	-0.33	2.74e-5	Retinal vascular caliber;
PAAD	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg14583973	chr4:3374767	RGS12	-0.38	-5.78	-0.42	4.13e-8	Parental longevity (mother's age at death);
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12516959	chr21:47718080	NA	0.44	4.34	0.33	2.58e-5	Testicular germ cell tumor;
PAAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg01075559	chr1:2537774	MMEL1	0.52	5.42	0.4	2.29e-7	Ulcerative colitis;
PAAD	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg10616300	chr11:66138557	SLC29A2	-0.32	-4.26	-0.33	3.52e-5	Educational attainment (years of education);
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.54	6.89	0.49	1.37e-10	Hypertriglyceridemia;
PAAD	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.86	-0.37	2.84e-6	Renal cell carcinoma;
PAAD	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.1	0.44	8.57e-9	Bladder cancer;
PAAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.66	-5.23	-0.39	5.47e-7	Gut microbiome composition (summer);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01783706	chr12:49739991	DNAJC22	0.61	6.37	0.46	2.12e-9	Myopia (pathological);
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg01422370	chr2:73384389	NA	0.35	4.7	0.36	5.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.5	-0.34	1.35e-5	Body mass index;
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg07841815	chr7:100318223	EPO	0.44	4.85	0.37	3.07e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.81	-0.62	6.5e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23281280	chr6:28129359	ZNF389	0.58	4.53	0.34	1.19e-5	Parkinson's disease;
PAAD	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.85	-9.8	-0.62	6.93e-18	Iron status biomarkers;
PAAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.57	-6.12	-0.44	7.65e-9	Huntington's disease progression;
PAAD	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg20673841	chr7:107026890	COG5	0.47	4.3	0.33	3.02e-5	Coronary artery disease;
PAAD	cis	rs13011075	0.535	rs34852232	chr2:68638599	C/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.39	0.34	2.08e-5	Mean corpuscular volume;
PAAD	cis	rs9944715	0.834	rs9949494	chr18:43811300	T/C	cg00381974	chr18:44260357	ST8SIA5	-0.47	-4.3	-0.33	3e-5	Red cell distribution width;Mean corpuscular volume;
PAAD	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.56	-5.33	-0.4	3.56e-7	Strep throat;
PAAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.96	0.54	3.65e-13	Parkinson's disease;
PAAD	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.81	-0.43	3.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-4.59	-0.35	9.25e-6	Neuroticism;
PAAD	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg19792802	chr11:65647270	CTSW	-0.44	-5.82	-0.43	3.33e-8	DNA methylation (variation);
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.7	5.41	0.4	2.4e-7	Alzheimer's disease;
PAAD	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	1.16	9.81	0.62	6.62e-18	Height;
PAAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04300632	chr17:6915671	RNASEK	0.61	6.43	0.46	1.59e-9	Obesity-related traits;
PAAD	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg24881330	chr22:46731750	TRMU	1.02	4.48	0.34	1.48e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.15	-0.39	7.83e-7	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	4.3	0.33	3.09e-5	Breast cancer;
PAAD	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg15585409	chr19:12750806	NA	-0.47	-4.27	-0.33	3.42e-5	Red blood cell traits;
PAAD	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.25	-0.51	1.93e-11	Diastolic blood pressure;
PAAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg16876255	chr19:9731953	ZNF561	0.94	4.42	0.34	1.85e-5	Pursuit maintenance gain;
PAAD	cis	rs2204008	0.642	rs11169812	chr12:37995530	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-5.51	-0.41	1.52e-7	Bladder cancer;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.68	0.58	5.58e-15	Alzheimer's disease;
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs73196965	chr3:128436709	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.74	8.56	0.57	1.14e-14	Height;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06015834	chr16:30021696	DOC2A	-0.41	-4.34	-0.33	2.54e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.64	6.07	0.44	9.72e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.58	-6.65	-0.47	4.9e-10	Post bronchodilator FEV1;
PAAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg00540400	chr15:79124168	NA	0.7	8.81	0.58	2.65e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.67	-8.35	-0.56	3.84e-14	Inflammatory bowel disease;
PAAD	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.46	-0.4	1.89e-7	Personality dimensions;
PAAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	5.05	0.38	1.23e-6	Lung cancer in ever smokers;
PAAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.45	4.29	0.33	3.12e-5	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11502736	chr1:179923845	CEP350	0.6	6.64	0.47	5.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.47	0.52	5.99e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.67	0.58	6.15e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg25173405	chr17:45401733	C17orf57	0.53	5.19	0.39	6.55e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg16926213	chr1:1841314	NA	0.39	4.75	0.36	4.74e-6	Body mass index;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.83	-7.97	-0.54	3.49e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3857067	0.736	rs2865333	chr4:95019964	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.67e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.76	9.14	0.6	3.84e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22857025	chr5:266934	NA	-1.1	-4.52	-0.34	1.26e-5	Asthma (childhood onset);
PAAD	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17341361	chr7:5414170	TNRC18	0.57	7.41	0.52	8.38e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2077654	0.822	rs12293228	chr11:17436951	C/T	cg25308976	chr11:17434268	ABCC8	0.78	5.27	0.39	4.61e-7	Gout;
PAAD	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2242420	0.920	rs829382	chr1:21957747	G/C	cg26362272	chr1:22108717	USP48	0.55	4.27	0.33	3.47e-5	Hematological and biochemical traits;
PAAD	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg17796960	chr10:135278976	LOC619207	-0.57	-6.36	-0.46	2.24e-9	Systemic lupus erythematosus;
PAAD	cis	rs8049634	0.869	rs3759975	chr16:84221085	A/C	cg26466773	chr16:84211947	TAF1C	0.58	5.18	0.39	6.89e-7	Small cell lung carcinoma;
PAAD	cis	rs4906332	0.966	rs34372508	chr14:103977515	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-4.67	-0.35	6.5e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg00166722	chr3:10149974	C3orf24	0.86	7.03	0.5	6.57e-11	Alzheimer's disease;
PAAD	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.55	-4.42	-0.34	1.85e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.39	-5.72	-0.42	5.39e-8	Cutaneous nevi;
PAAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	6.85	0.49	1.74e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg26876637	chr1:152193138	HRNR	-0.85	-6.18	-0.45	5.52e-9	Atopic dermatitis;
PAAD	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.25e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg07636037	chr3:49044803	WDR6	-0.81	-6.37	-0.46	2.13e-9	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04094829	chr7:101885409	CUX1	0.55	6.74	0.48	3.09e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	5.77	0.42	4.3e-8	Monocyte count;
PAAD	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.51	5.41	0.4	2.42e-7	Male-pattern baldness;
PAAD	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.53	5.85	0.43	2.98e-8	Major depressive disorder;
PAAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg02917321	chr22:38215204	NA	0.44	4.56	0.35	1.07e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg25452165	chr22:42524984	CYP2D6	0.61	5.8	0.43	3.75e-8	Schizophrenia;
PAAD	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg09709951	chr12:54017699	ATF7	0.54	4.77	0.36	4.37e-6	Height;
PAAD	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg19847866	chr10:1019161	NA	0.66	7.09	0.5	4.68e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs990171	1.000	rs12712145	chr2:103008710	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.49	0.34	1.38e-5	Lymphocyte counts;
PAAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9361491	0.608	rs4706728	chr6:79466811	G/T	cg05283184	chr6:79620031	NA	-0.39	-4.73	-0.36	5.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12282928	0.851	rs4980421	chr11:48301482	G/A	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg24253500	chr15:84953950	NA	0.58	6.83	0.48	1.96e-10	Schizophrenia;
PAAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-4.99	-0.38	1.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs7537605	0.513	rs78458460	chr1:108347599	G/T	cg19413693	chr1:108442921	VAV3	0.47	4.4	0.34	2.01e-5	Hashimoto thyroiditis versus Graves' disease;
PAAD	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg14515779	chr1:101123966	NA	-0.52	-6.29	-0.45	3.29e-9	Monocyte count;
PAAD	cis	rs7132746	0.553	rs11831936	chr12:86193148	C/T	cg18827107	chr12:86230957	RASSF9	0.49	4.77	0.36	4.32e-6	Lewy body disease;
PAAD	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.47	-4.57	-0.35	1e-5	HDL cholesterol;
PAAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.82	8.46	0.57	2.07e-14	Breast cancer;
PAAD	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.77	8.29	0.56	5.63e-14	Height;
PAAD	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.7	-0.72	1.18e-25	Primary sclerosing cholangitis;
PAAD	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.47	-4.93	-0.37	2.11e-6	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.66e-7	Lung cancer;
PAAD	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	1.12	8.77	0.58	3.27e-15	Iron status biomarkers;
PAAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg00579200	chr11:133705235	NA	-0.51	-5.74	-0.42	5.05e-8	Childhood ear infection;
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.52	0.34	1.22e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	1.07	6.75	0.48	2.95e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.7	-8.31	-0.56	5.07e-14	Huntington's disease progression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14653418	chr10:32217953	ARHGAP12	0.73	7.55	0.52	3.71e-12	Obesity-related traits;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.06	0.38	1.18e-6	Lung function (FEV1/FVC);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15009294	chr1:214813712	CENPF	-0.64	-6.96	-0.49	9.65e-11	Obesity-related traits;
PAAD	cis	rs6800768	0.516	rs1026407	chr3:23869469	G/C	cg10674438	chr3:24145617	LOC152024	0.46	4.39	0.34	2.15e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7638995	0.617	rs9842761	chr3:69194345	C/A	cg26574240	chr3:69171822	LMOD3	0.72	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg19486271	chr11:47235900	DDB2	0.59	6.05	0.44	1.1e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.68	7.45	0.52	6.51e-12	Longevity;
PAAD	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.63	-0.42	8.38e-8	Joint mobility (Beighton score);
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.96	0.54	3.64e-13	Prudent dietary pattern;
PAAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-1.09	-15.36	-0.78	9.89e-33	Total body bone mineral density;
PAAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg19337854	chr7:99768885	GPC2	0.4	4.56	0.35	1.05e-5	Coronary artery disease;
PAAD	cis	rs9314614	0.789	rs2980950	chr8:6712807	C/G	cg27319216	chr8:6693540	XKR5	-0.4	-5.34	-0.4	3.26e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg04415270	chr2:102091202	RFX8	-0.51	-6.35	-0.46	2.35e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.82	0.36	3.47e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs62264129	0.500	rs11923402	chr3:112050148	G/T	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.01	-0.38	1.5e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg07166546	chr14:35805898	NA	-0.3	-4.6	-0.35	8.9e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg09839279	chr12:125627357	AACS	-0.51	-5.07	-0.38	1.17e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg17470449	chr10:769945	NA	0.52	5.16	0.39	7.72e-7	Uric acid levels;
PAAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-1.12	-13.01	-0.73	1.79e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.43	-5.09	-0.38	1.04e-6	Type 2 diabetes;
PAAD	cis	rs7922314	0.571	rs61865691	chr10:64728320	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg05373962	chr22:49881684	NA	-0.45	-4.73	-0.36	5.18e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-6.23	-0.45	4.34e-9	Monocyte count;
PAAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg05304507	chr6:116381966	FRK	0.33	6.16	0.45	6.15e-9	Total cholesterol levels;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg03338584	chr11:507455	RNH1	0.54	4.29	0.33	3.23e-5	Systemic lupus erythematosus;
PAAD	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg08134877	chr2:44394819	PPM1B	0.46	4.48	0.34	1.48e-5	Height;
PAAD	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.61	-6.6	-0.47	6.4e-10	Coronary artery disease;
PAAD	cis	rs501120	0.657	rs11238908	chr10:44688080	T/G	cg09554077	chr10:44749378	NA	0.47	5.78	0.42	4.05e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg02459107	chr1:67143332	SGIP1	0.77	7.8	0.53	9.22e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.45	-0.34	1.66e-5	Body mass index;
PAAD	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	0.75	5.12	0.38	8.92e-7	Body mass index;
PAAD	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-4.77	-0.36	4.23e-6	Recombination measurement;
PAAD	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.0	0.38	1.56e-6	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.33	0.81	8.1e-38	Height;
PAAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg06375148	chr1:209958343	C1orf74	0.67	4.98	0.37	1.73e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs96067	0.643	rs274133	chr1:36581792	G/A	cg27506609	chr1:36549197	TEKT2	-0.68	-4.74	-0.36	4.93e-6	Corneal structure;
PAAD	cis	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg26856322	chr1:169076014	ATP1B1	-0.52	-5.15	-0.39	7.87e-7	Coronary artery disease;
PAAD	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.82	10.1	0.63	1.11e-18	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.65	6.35	0.46	2.39e-9	Schizophrenia;
PAAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.59	0.41	1.04e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7633770	0.735	rs11719679	chr3:46687684	A/G	cg11219411	chr3:46661640	NA	-0.58	-6.85	-0.49	1.73e-10	Coronary artery disease;
PAAD	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.76	-8.22	-0.55	8.29e-14	Schizophrenia;
PAAD	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.14e-5	Noise-induced hearing loss;
PAAD	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg04775059	chr7:64541387	NA	0.56	5.84	0.43	3.04e-8	Calcium levels;
PAAD	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.47	4.47	0.34	1.55e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8044868	0.893	rs3909543	chr16:72183543	G/A	cg16579770	chr16:72058938	DHODH	0.41	4.28	0.33	3.25e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs1371614	0.632	rs3739088	chr2:27167784	C/T	cg07507200	chr2:27712693	IFT172	0.49	4.32	0.33	2.86e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22162314	chr17:61951766	CSH2	-0.54	-5.52	-0.41	1.44e-7	Height;
PAAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08677398	chr8:58056175	NA	0.67	4.45	0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg14146966	chr2:61757674	XPO1	0.39	4.94	0.37	2.07e-6	Tuberculosis;
PAAD	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg18171855	chr10:2543474	NA	0.64	7.63	0.53	2.4e-12	Age-related hearing impairment;
PAAD	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.17	14.74	0.77	4.17e-31	Schizophrenia;
PAAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.81	5.91	0.43	2.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4638749	0.906	rs2219079	chr2:108879739	C/T	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.77	-0.36	4.23e-6	Blood pressure;
PAAD	cis	rs12432203	1.000	rs72622427	chr14:51731653	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.65	-0.35	7.08e-6	Cancer;
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13126279	chr21:47581558	C21orf56	-0.4	-4.43	-0.34	1.8e-5	Testicular germ cell tumor;
PAAD	cis	rs357618	1.000	rs357620	chr5:150847121	A/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs6693295	0.729	rs2185073	chr1:246213341	G/A	cg26013412	chr1:247094486	AHCTF1	-0.59	-4.38	-0.33	2.22e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-1.01	-13.76	-0.74	1.7e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg04450456	chr4:17643702	FAM184B	0.47	4.92	0.37	2.27e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs732765	0.734	rs10137800	chr14:75170286	C/T	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25589945	chr2:46429383	NA	-0.64	-6.66	-0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.8	0.66	1.52e-20	Platelet count;
PAAD	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	7.96e-6	Breast cancer;
PAAD	cis	rs10450586	0.932	rs10835153	chr11:27313863	A/T	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg04154034	chr17:28927549	LRRC37B2	0.78	4.64	0.35	7.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg14393609	chr7:65229607	NA	0.61	6.32	0.46	2.73e-9	Calcium levels;
PAAD	cis	rs6061231	0.630	rs62196294	chr20:60973432	T/G	cg22601191	chr20:60968625	CABLES2	0.49	4.77	0.36	4.29e-6	Colorectal cancer;
PAAD	trans	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg01620082	chr3:125678407	NA	-1.38	-8.02	-0.55	2.61e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.85	0.54	6.75e-13	Lung cancer in ever smokers;
PAAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.73	-7.38	-0.51	9.8e-12	Neurofibrillary tangles;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.15	15.69	0.79	1.38e-33	Body mass index;
PAAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg03115019	chr17:80708279	FN3K	0.5	4.49	0.34	1.41e-5	Glycated hemoglobin levels;
PAAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg06740227	chr12:86229804	RASSF9	-0.52	-5.1	-0.38	9.93e-7	Major depressive disorder;
PAAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg14393609	chr7:65229607	NA	-0.48	-4.86	-0.37	2.93e-6	Aortic root size;
PAAD	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.26e-5	Height;
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.28	0.39	4.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9503598	0.521	rs4959834	chr6:3436691	A/C	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.26	-0.33	3.56e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.89	11.15	0.67	1.84e-21	Coronary artery disease;
PAAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.62	-7.5	-0.52	5.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.95	0.43	1.78e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs7551222	0.714	rs930947	chr1:204541197	G/A	cg01064725	chr1:204461714	NA	-0.58	-5.03	-0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg00717180	chr2:96193071	NA	-0.65	-7.85	-0.54	6.83e-13	Height;
PAAD	cis	rs17152411	0.947	rs17152408	chr10:126649007	C/T	cg07906193	chr10:126599966	NA	0.7	5.82	0.43	3.44e-8	Height;
PAAD	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg06096015	chr1:231504339	EGLN1	0.59	6.46	0.46	1.34e-9	Red blood cell count;
PAAD	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg24053715	chr22:38214548	NA	-0.51	-5.05	-0.38	1.28e-6	Glioblastoma;Glioma;
PAAD	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.59	-0.41	1.04e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg03127898	chr11:62455098	LRRN4CL	-0.37	-4.33	-0.33	2.67e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06387028	chr7:72395397	POM121	0.55	6.29	0.45	3.29e-9	Metabolite levels  (X-11787);
PAAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.73	7.12	0.5	3.98e-11	Recombination rate (males);
PAAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg20913747	chr6:44695427	NA	-0.69	-6.9	-0.49	1.29e-10	Total body bone mineral density;
PAAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.97	0.63	2.55e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg14709524	chr16:89940631	TCF25	0.88	4.58	0.35	9.63e-6	Skin colour saturation;
PAAD	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.56	-5.33	-0.4	3.56e-7	Strep throat;
PAAD	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.9	-0.49	1.29e-10	Response to antipsychotic treatment;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7580658	0.711	rs12469035	chr2:127984917	A/G	cg21855830	chr2:127963489	CYP27C1	0.47	4.35	0.33	2.48e-5	Protein C levels;
PAAD	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-10.42	-0.65	1.5700000000000001e-19	Age at first birth;
PAAD	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.08	-11.57	-0.68	1.32e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs112990264	1.000	rs78100430	chr1:213017070	A/G	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg18279126	chr7:2041391	MAD1L1	-0.52	-5.11	-0.38	9.69e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg14146966	chr2:61757674	XPO1	0.38	4.56	0.35	1.03e-5	Tuberculosis;
PAAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-5.19	-0.39	6.57e-7	Schizophrenia;
PAAD	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.74	7.57	0.52	3.29e-12	Alcohol dependence;
PAAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.61	0.41	9.48e-8	Major depressive disorder;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg09654669	chr8:57350985	NA	0.54	5.16	0.39	7.54e-7	Obesity-related traits;
PAAD	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg09491104	chr22:46646882	C22orf40	-1.03	-6.06	-0.44	1.05e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9462027	0.585	rs2814976	chr6:34576237	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.25	-0.33	3.77e-5	Systemic lupus erythematosus;
PAAD	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg13736514	chr6:26305472	NA	-0.54	-5.89	-0.43	2.4e-8	Mosquito bite size;
PAAD	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-5.43	-0.4	2.21e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg13565585	chr5:132299512	AFF4	0.51	4.98	0.37	1.71e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.11	14.27	0.76	7.63e-30	Schizophrenia;
PAAD	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg23283495	chr1:209979779	IRF6	0.61	5.4	0.4	2.5e-7	Coronary artery disease;
PAAD	cis	rs2798269	0.604	rs7325693	chr13:22163211	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.51	-4.72	-0.36	5.31e-6	PR segment;
PAAD	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.5	6.17	0.45	6.03e-9	Sitting height ratio;
PAAD	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.73e-14	Triglycerides;
PAAD	cis	rs34375054	0.672	rs2291248	chr12:125619308	C/T	cg06287003	chr12:125626642	AACS	-0.48	-4.77	-0.36	4.22e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.68	4.77	0.36	4.3e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7000551	0.556	rs13258367	chr8:22235759	C/A	cg12081754	chr8:22256438	SLC39A14	0.75	8.14	0.55	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.92	-10.48	-0.65	1.08e-19	Prudent dietary pattern;
PAAD	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.73	-7.42	-0.52	7.54e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.08	0.38	1.11e-6	Vitamin D levels;
PAAD	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.38	0.33	2.22e-5	Self-reported allergy;
PAAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3753841	0.832	rs1599703	chr1:103310189	T/C	cg24495344	chr1:103574097	COL11A1	0.38	4.45	0.34	1.64e-5	Glaucoma (primary angle closure);
PAAD	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg19418318	chr19:17219073	MYO9B	0.41	5.01	0.38	1.47e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16699715	chr5:148961007	FLJ41603	0.55	6.59	0.47	6.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg18769074	chr3:133464867	TF	0.44	5.37	0.4	2.93e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.73	4.61	0.35	8.6e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06850241	chr22:41845214	NA	0.49	4.31	0.33	2.95e-5	Vitiligo;
PAAD	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg22674798	chr1:3096360	PRDM16	0.63	9.68	0.62	1.44e-17	Migraine;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.9	-11.36	-0.68	4.77e-22	Monocyte percentage of white cells;
PAAD	cis	rs6496932	0.802	rs6497006	chr15:85873537	T/C	cg19183879	chr15:85880815	NA	0.48	4.46	0.34	1.59e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.65	6.98	0.49	8.34e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg02462569	chr6:150064036	NUP43	-0.45	-4.95	-0.37	1.94e-6	Lung cancer;
PAAD	cis	rs28489187	0.617	rs233072	chr1:85807695	A/G	cg16011679	chr1:85725395	C1orf52	0.47	4.45	0.34	1.68e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg25833597	chr17:30823145	MYO1D	0.48	4.63	0.35	7.93e-6	Schizophrenia;
PAAD	cis	rs258892	0.895	rs13177678	chr5:72045646	G/T	cg21869765	chr5:72125136	TNPO1	-0.81	-5.46	-0.4	1.93e-7	Small cell lung carcinoma;
PAAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg21951975	chr1:209979733	IRF6	0.41	5.15	0.39	8e-7	Monobrow;
PAAD	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.81	-8.62	-0.57	8.37e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.1	0.55	1.7e-13	Alzheimer's disease;
PAAD	cis	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.89	-9.36	-0.6	9.91e-17	Inhibitory control;
PAAD	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.74	-6.81	-0.48	2.11e-10	Asthma;
PAAD	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg14686297	chr22:46650375	NA	-0.43	-4.39	-0.34	2.09e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9322817	0.691	rs6929746	chr6:105167548	G/C	cg02098413	chr6:105308735	HACE1	-0.42	-5.38	-0.4	2.75e-7	Thyroid stimulating hormone;
PAAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2244497	0.671	rs56011218	chr17:64510006	T/C	cg26726141	chr17:64612159	PRKCA	-0.46	-4.37	-0.33	2.34e-5	Neuroticism;
PAAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13126279	chr21:47581558	C21orf56	-0.4	-4.44	-0.34	1.7e-5	Testicular germ cell tumor;
PAAD	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-5.71	-0.42	5.79e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs11676855	0.893	rs6431329	chr2:235934338	C/T	cg14917874	chr2:235941519	SH3BP4	0.57	5.74	0.42	4.99e-8	Dialysis-related mortality;
PAAD	cis	rs2004318	1.000	rs77465355	chr19:55134215	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs6908034	0.607	rs80355837	chr6:19808343	C/G	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg24687543	chr11:63912206	MACROD1	0.61	5.38	0.4	2.7e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.09e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.89	8.51	0.57	1.58e-14	Homoarginine levels;
PAAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg01868782	chr6:126071099	HEY2	-0.36	-4.25	-0.33	3.75e-5	Brugada syndrome;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg12218747	chr21:37451666	NA	-0.51	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21016266	chr12:122356598	WDR66	-0.61	-6.6	-0.47	6.32e-10	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06154860	chr7:14029085	ETV1	0.64	7.45	0.52	6.44e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11252926	0.732	rs10904542	chr10:744013	G/A	cg03684893	chr10:554711	DIP2C	0.49	5.07	0.38	1.17e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs501120	1.000	rs1746048	chr10:44775824	A/G	cg09554077	chr10:44749378	NA	-0.49	-6.39	-0.46	1.95e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.54	4.67	0.35	6.57e-6	Red blood cell count;
PAAD	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg22356347	chr1:167427500	CD247	-0.56	-6.21	-0.45	4.77e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.15	0.45	6.43e-9	Rheumatoid arthritis;
PAAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.41	4.53	0.35	1.16e-5	Type 2 diabetes;
PAAD	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs76793172	1.000	rs16980059	chr19:46353634	C/T	cg13320842	chr19:46175254	GIPR	0.63	4.79	0.36	4e-6	Eosinophil counts;
PAAD	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.64	-9.21	-0.6	2.48e-16	Airflow obstruction;
PAAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.3	-0.33	3.02e-5	Prostate cancer;
PAAD	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg03004497	chr11:58874207	FAM111B	-0.52	-4.39	-0.34	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.51	2.4e-11	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22354234	chr2:40006543	THUMPD2	0.65	7.5	0.52	5.02e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.16	0.39	7.59e-7	Educational attainment;
PAAD	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg10985347	chr2:127963512	CYP27C1	0.46	4.27	0.33	3.44e-5	Protein C levels;
PAAD	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15556689	chr8:8085844	FLJ10661	-0.72	-6.7	-0.48	3.72e-10	Neuroticism;
PAAD	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.47	-4.7	-0.36	5.85e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6137287	0.751	rs4815028	chr20:21150633	T/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.74	0.36	4.92e-6	Height;
PAAD	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg09592244	chr17:37024020	NA	-0.45	-4.81	-0.36	3.59e-6	Height;
PAAD	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	4.49	0.34	1.43e-5	Red cell distribution width;Platelet distribution width;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.65	-6.94	-0.49	1.07e-10	Longevity;Endometriosis;
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg13191508	chr8:144600686	ZC3H3	-0.8	-4.56	-0.35	1.04e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.5	5.37	0.4	2.91e-7	Height;
PAAD	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg18964960	chr10:1102726	WDR37	0.92	4.46	0.34	1.57e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.15	-0.39	7.88e-7	Mood instability;
PAAD	cis	rs6466055	0.501	rs7776707	chr7:104605530	C/A	cg04380332	chr7:105027541	SRPK2	-0.66	-6.89	-0.49	1.39e-10	Schizophrenia;
PAAD	cis	rs557074	0.821	rs9502560	chr6:7177140	T/G	cg01785233	chr6:7260807	NA	0.48	4.42	0.34	1.9e-5	Monocyte count;
PAAD	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.53	4.55	0.35	1.09e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.72	-6.0	-0.44	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs61759167	0.710	rs12745073	chr1:3094672	A/G	cg22674798	chr1:3096360	PRDM16	0.47	5.67	0.42	7.09e-8	Motion sickness;
PAAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg22482690	chr17:47019901	SNF8	0.46	4.93	0.37	2.14e-6	Type 2 diabetes;
PAAD	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-6.59	-0.47	6.86e-10	Monocyte percentage of white cells;
PAAD	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	4.99	0.38	1.61e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2885056	0.824	rs2360747	chr19:10693753	T/C	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg16342193	chr10:102329863	NA	-0.76	-8.29	-0.56	5.6e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg05577437	chr8:1586825	DLGAP2	-0.41	-4.52	-0.34	1.25e-5	Systolic blood pressure;
PAAD	cis	rs76917914	0.780	rs16912622	chr9:100843660	A/C	cg03040243	chr9:100819229	NANS	-0.56	-4.52	-0.34	1.23e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.55	5.86	0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg20821713	chr7:1055600	C7orf50	-0.41	-4.6	-0.35	8.98e-6	Longevity;Endometriosis;
PAAD	cis	rs10768122	0.932	rs11524863	chr11:35318394	T/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.26	-0.33	3.59e-5	Vitiligo;
PAAD	cis	rs10929159	0.928	rs7565059	chr2:236926347	A/G	cg14226755	chr2:236923322	AGAP1	0.29	4.55	0.35	1.11e-5	Parkinson's disease;
PAAD	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.42	5.31	0.4	3.82e-7	Colorectal cancer;
PAAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg00701064	chr4:6280414	WFS1	0.78	6.75	0.48	2.97e-10	Cisplatin-induced ototoxicity;
PAAD	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.6	-5.94	-0.43	1.84e-8	Post bronchodilator FEV1;
PAAD	cis	rs2031532	0.569	rs7326345	chr13:50067443	G/A	cg03651054	chr13:50194643	NA	0.32	4.36	0.33	2.36e-5	Cardiac hypertrophy;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg13444538	chr7:158905317	VIPR2	0.52	4.79	0.36	4.01e-6	Facial morphology (factor 20);
PAAD	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg13446199	chr8:143762866	PSCA	0.38	4.53	0.34	1.19e-5	Urinary tract infection frequency;
PAAD	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.73	-8.92	-0.59	1.41e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.79	-0.81	1.95e-36	Myeloid white cell count;
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.86	11.36	0.68	4.93e-22	Vitiligo;
PAAD	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.84	-6.31	-0.46	2.96e-9	Alcohol consumption (maxi-drinks);
PAAD	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg03318428	chr22:46971703	NA	0.37	4.47	0.34	1.5e-5	Urate levels in obese individuals;
PAAD	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.82	0.48	2.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs3018712	0.522	rs1546309	chr11:68454682	C/T	cg23009355	chr11:68451396	GAL	-0.46	-4.5	-0.34	1.36e-5	Total body bone mineral density;
PAAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.5	-5.25	-0.39	4.99e-7	Huntington's disease progression;
PAAD	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.21	16.95	0.81	7.53e-37	Triglycerides;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05857825	chr20:31408213	MAPRE1	-0.57	-6.33	-0.46	2.68e-9	Body fat percentage;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21211053	chr19:49496578	GYS1;RUVBL2	-0.62	-7.09	-0.5	4.66e-11	Body fat percentage;
PAAD	trans	rs901683	1.000	rs17157898	chr10:46037209	C/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs6477998	1.000	rs6477998	chr9:115997249	A/C	ch.10.2633792F	chr10:123987885	TACC2	-0.61	-6.43	-0.46	1.56e-9	Hematology traits;
PAAD	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg05250797	chr16:70222502	NA	0.87	6.55	0.47	8.27e-10	IgE levels;
PAAD	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-5.14	-0.38	8.5e-7	Personality dimensions;
PAAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.49	-4.86	-0.37	2.93e-6	Type 2 diabetes;
PAAD	cis	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg21546286	chr11:48923668	NA	-0.45	-4.73	-0.36	4.99e-6	Height;
PAAD	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg18531004	chr3:128564980	NA	-0.89	-5.02	-0.38	1.43e-6	Dental caries;
PAAD	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.72	6.26	0.45	3.73e-9	Platelet count;
PAAD	cis	rs1891275	0.540	rs10732773	chr10:93416225	A/G	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.81	9.73	0.62	1.08e-17	Verbal declarative memory;
PAAD	trans	rs62179067	0.708	rs62176028	chr2:179919987	T/C	cg13380624	chr19:7735426	NA	-0.73	-6.69	-0.48	4.03e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs5756391	0.546	rs2899276	chr22:37312173	A/G	cg21209356	chr22:37319042	CSF2RB	0.37	4.51	0.34	1.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg19025524	chr12:109796872	NA	-0.55	-4.47	-0.34	1.51e-5	Neuroticism;
PAAD	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg05805236	chr11:65401703	PCNXL3	0.44	4.67	0.35	6.51e-6	Acne (severe);
PAAD	cis	rs11958404	0.517	rs35212858	chr5:157238942	T/C	cg05962755	chr5:157440814	NA	0.66	4.56	0.35	1.05e-5	IgG glycosylation;
PAAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.83	7.87	0.54	6.17e-13	Cleft lip with or without cleft palate;
PAAD	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.57	5.14	0.38	8.24e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.74	7.43	0.52	7.36e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg19875578	chr6:126661172	C6orf173	0.52	5.49	0.41	1.64e-7	Male-pattern baldness;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07661340	chr19:47354324	AP2S1	-0.75	-7.06	-0.5	5.5e-11	Lung cancer in ever smokers;
PAAD	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg23465465	chr6:26364728	BTN3A2	0.71	4.44	0.34	1.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.77	9.36	0.6	1.01e-16	Bladder cancer;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.68	-6.79	-0.48	2.42e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs75920871	0.858	rs17120197	chr11:116845104	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.8	5.27	0.39	4.61e-7	Subjective well-being;
PAAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	10.05	0.63	1.57e-18	Electrocardiographic conduction measures;
PAAD	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg01304814	chr3:48885189	PRKAR2A	0.64	4.35	0.33	2.53e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.5	5.9	0.43	2.27e-8	Height;
PAAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.96	-12.54	-0.71	3.32e-25	Height;
PAAD	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg10973622	chr2:86423274	IMMT	0.46	5.42	0.4	2.34e-7	Night sleep phenotypes;
PAAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg03538708	chr1:25844672	NA	-0.53	-5.51	-0.41	1.49e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs282587	0.542	rs914021	chr13:113375548	T/C	cg19217778	chr13:113420270	ATP11A	0.57	4.38	0.33	2.17e-5	Glycated hemoglobin levels;
PAAD	cis	rs6141769	0.518	rs28510728	chr20:31287891	G/A	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.63	-0.35	7.81e-6	Subjective well-being;
PAAD	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.51	-0.34	1.29e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg11282156	chr3:63428840	SYNPR	-0.58	-4.73	-0.36	5.13e-6	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs6681460	0.625	rs2312154	chr1:67072976	C/T	cg02459107	chr1:67143332	SGIP1	-0.52	-4.96	-0.37	1.91e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13198984	chr17:80129470	CCDC57	-0.43	-5.42	-0.4	2.3e-7	Life satisfaction;
PAAD	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg23093090	chr10:104574429	C10orf26	-0.43	-5.03	-0.38	1.36e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06437144	chr17:45973627	SP2	0.62	6.32	0.46	2.73e-9	Primary biliary cholangitis;
PAAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg18833306	chr6:118973337	C6orf204	-0.53	-4.35	-0.33	2.45e-5	Renal cell carcinoma;
PAAD	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.0	-0.38	1.6e-6	Fear of minor pain;
PAAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.39	0.64	1.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg16898833	chr6:26189333	HIST1H4D	0.83	4.53	0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11083475	0.654	rs11669249	chr19:39256808	A/T	cg26703956	chr19:39260304	NA	-0.41	-4.96	-0.37	1.88e-6	Heart rate;
PAAD	cis	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.73	-0.36	5.14e-6	Menarche (age at onset);
PAAD	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-7.25	-0.51	1.93e-11	Neuroticism;
PAAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	0.69	4.7	0.36	5.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.78	5.94	0.43	1.86e-8	Mean platelet volume;
PAAD	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.25	0.6	1.89e-16	Hemoglobin concentration;
PAAD	cis	rs939584	1.000	rs4429506	chr2:652576	C/A	cg03610516	chr2:642275	NA	0.61	5.65	0.42	7.71e-8	Body mass index;
PAAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.97	-9.8	-0.62	6.98e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg01262667	chr19:19385393	TM6SF2	0.45	5.04	0.38	1.33e-6	Tonsillectomy;
PAAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	-0.62	-5.91	-0.43	2.16e-8	Resistin levels;
PAAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg22189786	chr22:42395067	WBP2NL	0.66	5.49	0.41	1.68e-7	Birth weight;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08677398	chr8:58056175	NA	0.66	4.66	0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08439880	chr3:133502540	NA	-0.52	-5.7	-0.42	6.1e-8	Iron status biomarkers;
PAAD	cis	rs13253111	0.583	rs6993376	chr8:28096300	A/C	cg26534493	chr8:28060551	NA	0.41	4.58	0.35	9.62e-6	Childhood body mass index;
PAAD	trans	rs2982694	0.681	rs2982689	chr6:152285152	C/T	cg08544209	chr10:10837368	SFTA1P	-0.71	-6.43	-0.46	1.56e-9	Sudden cardiac arrest;
PAAD	cis	rs7567389	0.719	rs1504135	chr2:128003251	C/T	cg11380483	chr2:127933992	NA	-0.47	-4.68	-0.36	6.23e-6	Self-rated health;
PAAD	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.63	-6.19	-0.45	5.46e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs6681460	0.966	rs4655646	chr1:67094336	G/A	cg02459107	chr1:67143332	SGIP1	0.79	7.81	0.54	8.48e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.23	0.56	7.65e-14	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.52	5.25	0.39	4.95e-7	Resting heart rate;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.52	-0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.67	-6.54	-0.47	8.79e-10	Smoking initiation;
PAAD	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.73	-6.2	-0.45	5.18e-9	Bone mineral density;
PAAD	cis	rs783147	0.652	rs1782627	chr6:161196800	A/G	cg01280913	chr6:161186852	NA	0.45	4.94	0.37	2.05e-6	Lp (a) levels;
PAAD	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.37	0.61	9.4e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13732083	chr21:47605072	C21orf56	0.45	4.54	0.35	1.12e-5	Testicular germ cell tumor;
PAAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.64	8.8	0.58	2.75e-15	Height;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	0.43	4.25	0.33	3.74e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs9487051	0.621	rs351722	chr6:109550939	A/G	cg21918786	chr6:109611834	NA	-0.42	-4.37	-0.33	2.34e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12016809	chr21:47604291	C21orf56	0.5	5.02	0.38	1.46e-6	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10132104	chr4:8108443	ABLIM2	-0.56	-6.29	-0.45	3.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.22	16.9	0.81	1.01e-36	Schizophrenia;
PAAD	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-8.69	-0.58	5.27e-15	Height;
PAAD	cis	rs11811982	0.793	rs115128840	chr1:227422406	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.73e-7	Daytime sleep phenotypes;
PAAD	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg09659197	chr4:152720779	NA	-0.36	-5.21	-0.39	5.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg20406979	chr6:167373233	NA	-0.38	-5.14	-0.38	8.48e-7	Crohn's disease;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	5.97	0.44	1.58e-8	Renal function-related traits (BUN);
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg03188948	chr7:1209495	NA	1.0	5.8	0.43	3.75e-8	Longevity;Endometriosis;
PAAD	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.55	5.03	0.38	1.35e-6	Schizophrenia;
PAAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg01320130	chr1:67600311	NA	0.54	5.51	0.41	1.48e-7	Psoriasis;
PAAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg11663144	chr21:46675770	NA	-0.48	-5.44	-0.4	2.07e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08504310	chr19:36214022	MLL4	0.64	6.82	0.48	1.97e-10	Obesity-related traits;
PAAD	cis	rs35160687	0.862	rs17737955	chr2:86508014	C/T	cg10973622	chr2:86423274	IMMT	0.46	5.06	0.38	1.21e-6	Night sleep phenotypes;
PAAD	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-5.23	-0.39	5.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs507080	0.663	rs7926970	chr11:118559881	T/G	cg08498647	chr11:118550644	TREH	-0.37	-4.27	-0.33	3.49e-5	Serum metabolite levels;
PAAD	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg03289416	chr15:75166202	SCAMP2	0.51	4.88	0.37	2.7e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19152024	chr3:50374954	RASSF1	0.59	6.32	0.46	2.75e-9	Monocyte percentage of white cells;
PAAD	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg21625146	chr5:486483	SLC9A3	-0.41	-5.23	-0.39	5.59e-7	Cystic fibrosis severity;
PAAD	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.5	-5.02	-0.38	1.42e-6	Inflammatory bowel disease;
PAAD	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg11232448	chr19:2858854	NA	-0.48	-4.73	-0.36	5.05e-6	Total cholesterol levels;
PAAD	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg15193198	chr20:60906057	LAMA5	-0.53	-5.46	-0.41	1.88e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.22e-8	Lung cancer;
PAAD	cis	rs59888335	0.965	rs13069583	chr3:80719120	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-5.0	-0.38	1.58e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.4	-4.35	-0.33	2.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs56011263	0.532	rs4234853	chr4:735150	G/A	cg14024328	chr4:719362	PCGF3	-0.54	-5.24	-0.39	5.3e-7	White blood cell count;
PAAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.61	0.35	8.48e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.46	0.71	5.2e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	10.83	0.66	1.32e-20	Monocyte count;
PAAD	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-0.98	-6.54	-0.47	8.76e-10	Post bronchodilator FEV1;
PAAD	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.85	9.1	0.59	4.81e-16	Anterior chamber depth;
PAAD	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-7.06	-0.5	5.62e-11	Parkinson's disease;
PAAD	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg14019146	chr3:50243930	SLC38A3	0.49	5.14	0.38	8.26e-7	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23237097	chr1:160278129	COPA	0.61	6.6	0.47	6.41e-10	Smoking initiation;
PAAD	cis	rs9659323	0.632	rs6658479	chr1:119627856	C/T	cg26570165	chr1:119541833	NA	-0.52	-5.86	-0.43	2.74e-8	Body mass index;
PAAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	cis	rs7631605	0.905	rs11711937	chr3:37224838	C/G	cg17445812	chr3:36986805	TRANK1	-0.35	-4.64	-0.35	7.33e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-5.16	-0.39	7.53e-7	Schizophrenia;
PAAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg11608241	chr8:8085544	FLJ10661	0.45	4.27	0.33	3.38e-5	Mood instability;
PAAD	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.59	4.26	0.33	3.5e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.26	0.39	4.75e-7	Life satisfaction;
PAAD	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg05791153	chr7:19748676	TWISTNB	0.63	4.83	0.36	3.32e-6	Thyroid stimulating hormone;
PAAD	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg07395648	chr5:131743802	NA	-0.56	-4.84	-0.37	3.14e-6	Breast cancer;
PAAD	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.57	5.55	0.41	1.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg25533220	chr19:2328480	SPPL2B;LSM7	0.58	6.71	0.48	3.57e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.5	4.91	0.37	2.34e-6	Trans fatty acid levels;
PAAD	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.0	9.38	0.61	9e-17	Monocyte percentage of white cells;
PAAD	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18337363	chr3:52569053	NT5DC2	0.44	4.48	0.34	1.44e-5	Electroencephalogram traits;
PAAD	cis	rs17539620	0.808	rs62434163	chr6:154874692	G/C	cg20019720	chr6:154832845	CNKSR3	0.48	6.41	0.46	1.73e-9	Lipoprotein (a) levels;
PAAD	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.51	-5.39	-0.4	2.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7816613	1.000	rs10107483	chr8:102745291	C/T	cg20585841	chr8:102729926	NCALD	-0.57	-4.87	-0.37	2.73e-6	Age-related hearing impairment;
PAAD	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.61	-5.71	-0.42	5.77e-8	Height;
PAAD	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.76	8.05	0.55	2.24e-13	Hypertriglyceridemia;
PAAD	cis	rs786425	0.682	rs7979528	chr12:124181820	A/G	cg16237390	chr12:124156159	TCTN2	0.46	4.25	0.33	3.78e-5	Pubertal anthropometrics;
PAAD	cis	rs17739167	0.532	rs8035074	chr15:42239779	C/T	cg20935245	chr15:42234343	EHD4	0.57	6.43	0.46	1.6e-9	Monocyte count;
PAAD	cis	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13955432	chr7:117864720	ANKRD7	-0.52	-4.66	-0.35	6.89e-6	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.24	-0.39	5.29e-7	Blood metabolite levels;
PAAD	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.49	-5.11	-0.38	9.55e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.67	7.2	0.5	2.61e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	5.16	0.39	7.46e-7	Joint mobility (Beighton score);
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg15017067	chr4:17643749	FAM184B	0.42	4.98	0.37	1.73e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1413885	0.516	rs1591364	chr1:65842364	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.76	0.42	4.59e-8	Anticoagulant levels;
PAAD	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.43	-0.4	2.21e-7	Mood instability;
PAAD	cis	rs1539053	0.932	rs7548317	chr1:58106514	A/G	cg20292791	chr1:58089357	DAB1	-0.54	-5.49	-0.41	1.66e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg08601574	chr20:25228251	PYGB	0.62	6.47	0.46	1.24e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.0	0.63	2.11e-18	Prudent dietary pattern;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg03605463	chr16:89740564	NA	-0.57	-5.37	-0.4	2.87e-7	Vitiligo;
PAAD	cis	rs1126510	0.897	rs12459883	chr19:47126614	C/G	cg07844738	chr19:47129343	PTGIR	0.43	5.17	0.39	7.24e-7	Ulcerative colitis;
PAAD	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.39	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.33	-0.46	2.59e-9	Neuroticism;
PAAD	cis	rs7591163	1.000	rs7574255	chr2:228699884	C/G	cg22994281	chr2:228029448	COL4A3;COL4A4	-0.43	-4.38	-0.33	2.21e-5	Blood pressure;
PAAD	cis	rs2506028	1.000	rs788263	chr10:43437250	C/G	cg20628663	chr10:43360327	NA	-0.37	-4.44	-0.34	1.74e-5	Blood protein levels;
PAAD	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.83	-7.01	-0.49	7.43e-11	Body mass index;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.55	5.0	0.38	1.57e-6	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18732527	chr19:11669878	ELOF1	-0.73	-6.41	-0.46	1.71e-9	Neuroticism;
PAAD	cis	rs58653258	0.554	rs2674007	chr1:234968658	A/T	cg03518729	chr1:235147744	NA	-0.45	-4.26	-0.33	3.5e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18404041	chr3:52824283	ITIH1	0.42	4.49	0.34	1.39e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14125423	chr2:14782249	NA	-0.69	-7.3	-0.51	1.48e-11	Obesity-related traits;
PAAD	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.03	0.44	1.22e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg17156803	chr10:102416598	NA	0.42	4.3	0.33	3e-5	Body mass index;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	cis	rs7551345	0.853	rs12118473	chr1:31774802	C/G	cg17086398	chr1:31896392	SERINC2	-0.49	-4.55	-0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg21419209	chr3:44054225	NA	0.71	7.57	0.52	3.38e-12	Coronary artery disease;
PAAD	cis	rs8037137	0.915	rs3826033	chr15:91548601	G/A	cg23684204	chr15:91497937	RCCD1	0.81	4.98	0.37	1.72e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.67	0.42	7e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	4.53	0.34	1.19e-5	Total body bone mineral density;
PAAD	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg12473912	chr3:136751656	NA	0.38	4.29	0.33	3.17e-5	Gestational age at birth (child effect);
PAAD	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.44	-0.71	6.02e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.84	8.34	0.56	4.1e-14	Response to antineoplastic agents;
PAAD	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg15956490	chr3:53032818	SFMBT1	-0.7	-4.3	-0.33	3.01e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.98	-14.18	-0.75	1.28e-29	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg15117754	chr3:10150083	C3orf24	0.56	4.31	0.33	2.96e-5	Alzheimer's disease;
PAAD	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2858942	0.818	rs2685123	chr16:248418	T/C	cg16367168	chr16:231905	NA	-0.32	-4.51	-0.34	1.31e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg02071572	chr4:1403502	NA	0.37	4.39	0.34	2.15e-5	Obesity-related traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg09762563	chr11:110300584	FDX1	-0.66	-6.35	-0.46	2.32e-9	Primary biliary cholangitis;
PAAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.53	-4.79	-0.36	3.85e-6	Asthma;
PAAD	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg06156847	chr2:113672199	IL1F7	-0.52	-5.23	-0.39	5.42e-7	Pulmonary function;
PAAD	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.49	-0.34	1.39e-5	Biliary atresia;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg16342193	chr10:102329863	NA	-0.8	-8.56	-0.57	1.15e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18337363	chr3:52569053	NT5DC2	0.41	4.31	0.33	2.87e-5	Bipolar disorder;
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.28	0.45	3.31e-9	Rheumatoid arthritis;
PAAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.98	-12.42	-0.71	6.84e-25	Refractive error;
PAAD	cis	rs78472555	1.000	rs78472555	chr15:100267322	G/C	cg23669855	chr15:100272142	LYSMD4	-0.63	-5.17	-0.39	7.32e-7	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.87	10.24	0.64	4.71e-19	Coronary artery disease;
PAAD	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg10729496	chr3:10149963	C3orf24	0.83	7.01	0.49	7.43e-11	Alzheimer's disease;
PAAD	cis	rs9467603	0.566	rs10214468	chr6:25789390	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	5.41	0.4	2.42e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20095390	chr2:187373473	ZC3H15	0.6	7.35	0.51	1.14e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72960926	0.744	rs6914400	chr6:75018941	G/A	cg03266952	chr6:74778945	NA	-1.14	-6.47	-0.46	1.29e-9	Metabolite levels (MHPG);
PAAD	cis	rs4481887	0.538	rs10888328	chr1:248378777	G/A	cg00666640	chr1:248458726	OR2T12	0.54	4.29	0.33	3.12e-5	Common traits (Other);
PAAD	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.57	5.92	0.43	2.02e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg09659197	chr4:152720779	NA	0.46	6.27	0.45	3.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.45	5.72	0.42	5.51e-8	Prostate cancer;
PAAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs11811982	0.793	rs75790780	chr1:227569460	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-7.9	-0.54	5.07e-13	Total body bone mineral density;
PAAD	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs8040855	1.000	rs8040855	chr15:85699207	G/C	cg08123816	chr15:85640762	PDE8A	0.4	4.97	0.37	1.81e-6	Bulimia nervosa;
PAAD	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.18	0.45	5.7e-9	Hip circumference;
PAAD	cis	rs79146658	0.736	rs4894060	chr2:179751817	T/A	cg17765952	chr2:179737173	CCDC141	-0.6	-4.43	-0.34	1.8e-5	Diastolic blood pressure;
PAAD	cis	rs7707921	0.752	rs12108681	chr5:81278375	T/C	cg21483461	chr5:81570383	RPS23	-0.54	-4.53	-0.34	1.18e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20707764	chr2:42796178	MTA3	0.63	6.51	0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.21	0.39	5.99e-7	Migraine;
PAAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.22	-0.45	4.52e-9	Lung cancer;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg18783429	chr5:92414398	NA	0.3	4.3	0.33	2.99e-5	Migraine;
PAAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.61	7.28	0.51	1.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11235843	0.516	rs666839	chr11:73346041	A/G	cg15670924	chr11:73669256	DNAJB13	-0.5	-4.25	-0.33	3.68e-5	Hand grip strength;
PAAD	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.52	-5.03	-0.38	1.35e-6	Motion sickness;
PAAD	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg22143856	chr6:28129313	ZNF389	0.54	4.96	0.37	1.87e-6	Parkinson's disease;
PAAD	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.39	5.11	0.38	9.53e-7	Educational attainment (years of education);
PAAD	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg03264133	chr6:25882463	NA	0.44	4.32	0.33	2.75e-5	Schizophrenia;
PAAD	cis	rs4704187	0.663	rs28448485	chr5:74425775	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg23719950	chr11:63933701	MACROD1	-0.7	-4.95	-0.37	1.99e-6	Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs16910800	1.000	rs73479578	chr11:23197173	C/T	cg20040320	chr11:23191996	NA	-0.6	-5.12	-0.38	9.22e-7	Cancer;
PAAD	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-6.86	-0.49	1.65e-10	Total cholesterol levels;
PAAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.55	6.16	0.45	6.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs56011263	0.532	rs6845891	chr4:744233	T/C	cg05835009	chr4:710272	PCGF3	0.62	5.03	0.38	1.34e-6	White blood cell count;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.69	-0.36	6.13e-6	Testicular germ cell tumor;
PAAD	cis	rs17125944	0.686	rs1952090	chr14:53342992	A/G	cg00686598	chr14:53173677	PSMC6	-0.82	-4.97	-0.37	1.79e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.3	0.39	4.07e-7	Bipolar disorder;
PAAD	cis	rs375066	0.934	rs454813	chr19:44408973	A/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs4750440	0.706	rs1599414	chr10:14019519	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.74	-5.43	-0.4	2.15e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg15448220	chr1:150897856	SETDB1	0.58	6.07	0.44	1e-8	Melanoma;
PAAD	cis	rs6584202	0.589	rs10883094	chr10:100188106	C/T	cg26618903	chr10:100175079	PYROXD2	-0.42	-4.49	-0.34	1.39e-5	Obesity-related traits;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg03199926	chr20:60860733	OSBPL2	-0.37	-4.59	-0.35	9.34e-6	Pelvic organ prolapse;
PAAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.97	-9.49	-0.61	4.52e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.87	7.49	0.52	5.26e-12	Recombination rate (females);
PAAD	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg08079166	chr15:68083412	MAP2K5	0.6	4.59	0.35	9.14e-6	Obesity;
PAAD	cis	rs1419980	0.730	rs11054915	chr12:7777003	G/T	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.35	4.35	0.33	2.45e-5	Schizophrenia;
PAAD	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg25050447	chr17:78165522	CARD14	0.36	4.41	0.34	1.98e-5	Yeast infection;
PAAD	cis	rs1018697	1.000	rs11191397	chr10:104558274	C/A	cg04362960	chr10:104952993	NT5C2	0.59	6.07	0.44	9.66e-9	Colorectal adenoma (advanced);
PAAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg03795903	chr2:30669940	LCLAT1	1.01	5.42	0.4	2.33e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg03037974	chr15:76606532	NA	0.51	5.7	0.42	5.9e-8	Blood metabolite levels;
PAAD	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg18551225	chr6:44695536	NA	-0.73	-7.12	-0.5	3.94e-11	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27493885	chr12:95467123	NR2C1	0.64	7.51	0.52	4.64e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs61931739	0.577	rs7313428	chr12:33672325	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.53	-0.47	9.17e-10	Morning vs. evening chronotype;
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg19784903	chr17:45786737	TBKBP1	-0.52	-4.89	-0.37	2.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.55	-4.98	-0.37	1.74e-6	Multiple sclerosis;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.84	0.54	7.25e-13	Prudent dietary pattern;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27470027	chr11:63684601	RCOR2	0.51	6.39	0.46	1.96e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.6	6.08	0.44	9.11e-9	Monocyte count;
PAAD	cis	rs939584	0.932	rs2867111	chr2:651286	A/C	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.66	-0.42	7.41e-8	Mood instability;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21831937	chr15:57519802	TCF12	-0.53	-6.4	-0.46	1.86e-9	Energy expenditure (24h);
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04967530	chr3:99979613	TBC1D23	0.55	6.35	0.46	2.31e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-5.3	-0.39	4.08e-7	Longevity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07976390	chr1:154600456	ADAR	0.57	6.64	0.47	5.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	5.21	0.39	6.16e-7	Prudent dietary pattern;
PAAD	cis	rs9372498	0.505	rs62424204	chr6:118861642	G/A	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg14926445	chr8:58193284	C8orf71	-0.71	-5.73	-0.42	5.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs300774	0.925	rs300714	chr2:138106	G/A	cg23649280	chr2:140451	NA	-0.5	-4.8	-0.36	3.83e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs12044355	0.927	rs12043433	chr1:231843591	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.2	0.39	6.32e-7	Alzheimer's disease;
PAAD	cis	rs1256335	0.638	rs1256342	chr1:21876492	C/T	cg00786952	chr1:21763130	NA	-0.6	-4.27	-0.33	3.38e-5	Folate pathway vitamin levels;
PAAD	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.49	-0.34	1.43e-5	Mean corpuscular volume;
PAAD	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg19337854	chr7:99768885	GPC2	-0.44	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.61	-5.09	-0.38	1.02e-6	Neuroblastoma;
PAAD	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26031613	chr14:104095156	KLC1	1.17	16.06	0.79	1.43e-34	Body mass index;
PAAD	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-5.98	-0.44	1.55e-8	Menarche (age at onset);
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.71	-7.95	-0.54	3.88e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.67	6.6	0.47	6.35e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.58	5.48	0.41	1.7e-7	Schizophrenia;
PAAD	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.91	11.04	0.67	3.51e-21	Ulcerative colitis;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.7	8.19	0.55	9.79e-14	Lung cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06070291	chr15:44828899	EIF3J	0.58	6.54	0.47	8.89e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6142102	0.602	rs4911380	chr20:32546224	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.81	0.36	3.54e-6	Skin pigmentation;
PAAD	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg10006428	chr1:248814059	OR2T27	0.42	4.92	0.37	2.2e-6	Common traits (Other);
PAAD	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.54	4.39	0.34	2.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.65	7.36	0.51	1.07e-11	Longevity;Endometriosis;
PAAD	cis	rs7216064	0.773	rs11867618	chr17:65875587	G/A	cg12091567	chr17:66097778	LOC651250	-0.66	-4.33	-0.33	2.66e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.8	9.6	0.61	2.32e-17	Eosinophil percentage of white cells;
PAAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.68	6.23	0.45	4.33e-9	Monocyte count;
PAAD	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	0.86	11.29	0.68	7.55e-22	Vitiligo;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.88	9.67	0.62	1.52e-17	Cleft lip with or without cleft palate;
PAAD	trans	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg23024343	chr7:107201750	COG5	-0.57	-4.68	-0.36	6.17e-6	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg17633681	chr16:88106987	BANP	0.66	8.39	0.56	3.09e-14	Menopause (age at onset);
PAAD	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-5.25	-0.39	5.13e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.35	0.33	2.46e-5	Tonsillectomy;
PAAD	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-1.07	-7.69	-0.53	1.75e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg21565972	chr17:80109576	CCDC57	0.48	5.2	0.39	6.33e-7	Life satisfaction;
PAAD	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg01868782	chr6:126071099	HEY2	0.4	4.66	0.35	6.98e-6	High light scatter reticulocyte count;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14461349	chr14:76127409	C14orf1;TTLL5	-0.68	-7.09	-0.5	4.61e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.69	-0.36	6.11e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.54	7.46	0.52	6.23e-12	Crohn's disease;
PAAD	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg07150166	chr2:30669952	LCLAT1	0.7	5.29	0.39	4.24e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.13	-0.5	3.74e-11	Cognitive function;
PAAD	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg18898632	chr2:242989856	NA	-0.74	-5.28	-0.39	4.48e-7	Obesity-related traits;
PAAD	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg12183467	chr14:104352244	NA	0.35	4.33	0.33	2.72e-5	Blood metabolite levels;
PAAD	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.57	-6.35	-0.46	2.41e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	10.21	0.64	5.68e-19	Platelet count;
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.48	-4.7	-0.36	5.81e-6	Total body bone mineral density;
PAAD	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg24721873	chr10:135334122	NA	-0.61	-4.46	-0.34	1.61e-5	Gout;
PAAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.54	5.8	0.43	3.67e-8	Obesity-related traits;
PAAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.08	0.38	1.09e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-5.03	-0.38	1.39e-6	Type 2 diabetes;
PAAD	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13870426	chr17:30244630	NA	-0.75	-7.5	-0.52	5.08e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02617981	chr4:3449663	HGFAC	0.49	6.36	0.46	2.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs4908768	0.657	rs1353130	chr1:8822364	T/C	cg00590817	chr1:8272081	NA	-0.36	-4.37	-0.33	2.27e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.82	7.13	0.5	3.78e-11	Recombination rate (females);
PAAD	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.63	9.11	0.59	4.42e-16	Breast cancer;
PAAD	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.51	0.41	1.47e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.73	-5.18	-0.39	7.03e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.11	-9.6	-0.61	2.39e-17	Red blood cell traits;
PAAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg13468214	chr4:1046988	NA	-0.52	-4.96	-0.37	1.9e-6	Recombination rate (females);
PAAD	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.36	-0.4	3.05e-7	Bladder cancer;
PAAD	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg15309053	chr8:964076	NA	0.41	4.35	0.33	2.45e-5	Schizophrenia;
PAAD	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.3	7.97	0.54	3.46e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9467160	0.834	rs9467171	chr6:24455155	G/A	cg16211469	chr6:24423932	MRS2	0.48	4.44	0.34	1.71e-5	Liver enzyme levels;
PAAD	cis	rs11615916	0.790	rs1074957	chr12:62664266	G/A	cg11441379	chr12:63026424	NA	0.7	4.54	0.35	1.15e-5	Pulmonary function decline;
PAAD	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-6.93	-0.49	1.14e-10	Morning vs. evening chronotype;
PAAD	cis	rs11615916	0.790	rs73136830	chr12:62730962	A/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.49	-0.68	2.25e-22	Coronary artery disease;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg04877966	chr15:75135169	ULK3	0.55	4.65	0.35	7.07e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1144333	0.655	rs76794487	chr1:76384055	G/A	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-5.6	-0.41	9.65e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.19	-0.39	6.72e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11792649	chr11:68664631	MRPL21	0.64	7.8	0.53	9.16e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg07648498	chr16:89883185	FANCA	0.47	4.55	0.35	1.08e-5	Vitiligo;
PAAD	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.95	12.34	0.71	1.12e-24	Menarche (age at onset);
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.59	6.59	0.47	6.73e-10	Longevity;Endometriosis;
PAAD	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg06618935	chr21:46677482	NA	-0.46	-5.51	-0.41	1.5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.51e-9	Bipolar disorder;
PAAD	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.74	-7.08	-0.5	5.11e-11	Multiple sclerosis;
PAAD	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.88	-9.85	-0.62	5.24e-18	Cognitive function;
PAAD	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.61	-5.89	-0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.92	-5.66	-0.42	7.36e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs8258	1.000	rs8258	chr11:117283676	C/T	cg15227623	chr11:117232454	CEP164	-0.59	-5.65	-0.42	7.52e-8	Pulse pressure;
PAAD	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.41	-0.34	1.95e-5	Blood metabolite levels;
PAAD	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.58	6.46	0.46	1.31e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.73	-7.04	-0.5	6.32e-11	Alcohol dependence;
PAAD	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.81	9.26	0.6	1.85e-16	Heart rate;
PAAD	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05619639	chr19:53269486	ZNF600	-0.76	-6.99	-0.49	8.08e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs1015213	0.609	rs117118889	chr8:52873558	A/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.47	4.52	0.34	1.25e-5	Lung cancer;
PAAD	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg08886695	chr4:3369023	RGS12	0.53	4.97	0.37	1.8e-6	Parental longevity (mother's age at death);
PAAD	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg09163369	chr1:210001066	C1orf107	0.52	5.54	0.41	1.3e-7	Orofacial clefts;
PAAD	cis	rs9287604	0.953	rs4077980	chr2:237781193	A/G	cg15065627	chr2:237796583	NA	0.54	4.61	0.35	8.44e-6	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs76793172	0.557	rs6509234	chr19:46229711	T/G	cg13320842	chr19:46175254	GIPR	-0.55	-4.79	-0.36	3.89e-6	Eosinophil counts;
PAAD	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.34	0.33	2.58e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Acylcarnitine levels;
PAAD	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg19442545	chr10:75533431	FUT11	-0.54	-5.58	-0.41	1.06e-7	Inflammatory bowel disease;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.78	-7.52	-0.52	4.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg21855830	chr2:127963489	CYP27C1	0.46	4.49	0.34	1.38e-5	Protein C levels;
PAAD	cis	rs1463132	1.000	rs9926046	chr16:10183081	C/T	cg15027563	chr16:11038165	CLEC16A	-0.5	-4.25	-0.33	3.78e-5	HIV-1 control;
PAAD	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.48	4.86	0.37	2.95e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.57	4.63	0.35	7.63e-6	Platelet count;
PAAD	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.47	4.49	0.34	1.42e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.51	-5.67	-0.42	6.98e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-6.84	-0.49	1.77e-10	Glomerular filtration rate;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00083937	chr22:51039805	MAPK8IP2	0.44	4.35	0.33	2.47e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs78707713	0.836	rs77602872	chr10:71211734	G/A	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.73	-7.34	-0.51	1.18e-11	Paraoxonase activity;
PAAD	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg01304814	chr3:48885189	PRKAR2A	0.91	5.29	0.39	4.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-6.25	-0.45	3.95e-9	Lymphocyte counts;
PAAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.71	7.42	0.52	7.63e-12	Calcium levels;
PAAD	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.59	5.62	0.41	8.74e-8	Schizophrenia;
PAAD	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg18964960	chr10:1102726	WDR37	-0.74	-6.27	-0.45	3.53e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11811982	0.793	rs11805012	chr1:227221683	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.75	0.36	4.71e-6	Optic disc area;
PAAD	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.65	-0.35	7.23e-6	Testicular germ cell tumor;
PAAD	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.64	-0.35	7.62e-6	Total body bone mineral density;
PAAD	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg20900008	chr2:392811	NA	0.52	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.11e-8	Coronary artery disease;
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.72	7.17	0.5	3.12e-11	Prostate cancer;
PAAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.55	-5.18	-0.39	7.09e-7	Obesity-related traits;
PAAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.82	-9.53	-0.61	3.72e-17	DNA methylation (variation);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06500355	chr6:111804104	REV3L	0.76	8.72	0.58	4.58e-15	Myopia (pathological);
PAAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg16205897	chr5:131564050	P4HA2	-0.52	-5.59	-0.41	1.05e-7	Blood metabolite levels;
PAAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.61	-4.62	-0.35	8.05e-6	Breast cancer;
PAAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.74	-8.02	-0.55	2.68e-13	Eye color traits;
PAAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.63	-0.35	7.75e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg00262122	chr8:11665843	FDFT1	-0.48	-4.32	-0.33	2.8e-5	Retinal vascular caliber;
PAAD	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.93	-8.97	-0.59	1.03e-15	Psoriasis;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08120226	chr3:195531633	MUC4	-0.44	-4.96	-0.37	1.88e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8067287	1.000	rs55810902	chr17:16816421	A/G	cg26910001	chr17:16838321	NA	-0.74	-6.04	-0.44	1.15e-8	Diabetic kidney disease;
PAAD	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg16576597	chr16:28551801	NUPR1	-0.65	-6.51	-0.47	1.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg13468214	chr4:1046988	NA	-0.5	-4.85	-0.37	3e-6	Recombination rate (females);
PAAD	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg20805835	chr1:248005719	OR11L1	0.5	4.37	0.33	2.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs12136530	0.593	rs12404783	chr1:19735885	A/C	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.75	-0.36	4.68e-6	Lead levels in blood;
PAAD	cis	rs9677476	0.587	rs2053921	chr2:232158246	A/G	cg07929768	chr2:232055508	NA	0.36	4.33	0.33	2.68e-5	Food antigen IgG levels;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.6	6.98	0.49	8.57e-11	Lung cancer;
PAAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg19413350	chr8:57351067	NA	-0.48	-4.64	-0.35	7.59e-6	Obesity-related traits;
PAAD	cis	rs10905065	0.895	rs1567706	chr10:5853767	T/C	cg11519256	chr10:5708881	ASB13	-0.51	-4.43	-0.34	1.81e-5	Menopause (age at onset);
PAAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg08392591	chr16:89556376	ANKRD11	0.54	5.35	0.4	3.13e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.52	-5.49	-0.41	1.66e-7	Red blood cell count;
PAAD	cis	rs922692	0.715	rs11632102	chr15:79086057	G/A	cg00540400	chr15:79124168	NA	-0.59	-6.91	-0.49	1.23e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.65	6.44	0.46	1.46e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs7101378	0.599	rs7938927	chr11:108899180	A/G	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.49	-0.47	1.15e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.66	-4.6	-0.35	8.91e-6	Hypertriglyceridemia;
PAAD	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg20761395	chr17:511517	VPS53	-0.69	-7.79	-0.53	9.54e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.62	-6.49	-0.47	1.13e-9	Prostate cancer;
PAAD	cis	rs4739066	0.579	rs76538830	chr8:63862919	C/A	cg12194929	chr8:63776755	NKAIN3	0.72	4.51	0.34	1.28e-5	Myocardial infarction;
PAAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg26174226	chr8:58114915	NA	-0.6	-4.99	-0.38	1.64e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2421770	0.532	rs6484781	chr11:35349242	A/G	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.5	-0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.72	-4.26	-0.33	3.55e-5	Lung cancer in ever smokers;
PAAD	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-5.01	-0.38	1.49e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.91	-11.09	-0.67	2.56e-21	Menarche (age at onset);
PAAD	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.52	0.57	1.49e-14	Coffee consumption (cups per day);
PAAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.64	6.85	0.49	1.72e-10	IgG glycosylation;
PAAD	cis	rs2244613	0.882	rs7204940	chr16:55794983	C/G	cg27396498	chr16:55794478	CES4	0.69	5.37	0.4	2.83e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.51	5.02	0.38	1.43e-6	Schizophrenia;
PAAD	cis	rs13011075	0.535	rs6419644	chr2:68631823	A/G	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs3931020	0.772	rs1409785	chr1:75248122	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.57	5.73	0.42	5.19e-8	Resistin levels;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.13	-0.45	7.27e-9	Cystic fibrosis severity;
PAAD	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg02573091	chr5:74908125	NA	-0.54	-4.52	-0.34	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg09796270	chr17:17721594	SREBF1	-0.47	-5.0	-0.38	1.59e-6	Body mass index;
PAAD	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.67	7.26	0.51	1.85e-11	Resting heart rate;
PAAD	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg20435097	chr10:126320824	FAM53B	-0.48	-4.61	-0.35	8.41e-6	Cocaine dependence;
PAAD	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.38	0.33	2.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg13406893	chr12:131568647	GPR133	-0.44	-4.28	-0.33	3.26e-5	Longevity;
PAAD	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg25905881	chr15:51634250	GLDN	0.52	4.68	0.35	6.32e-6	Hormone measurements;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs55692468	0.570	rs12614608	chr2:153331546	G/A	cg22159341	chr2:152893963	CACNB4	0.45	4.39	0.34	2.14e-5	Intraocular pressure;
PAAD	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21659725	chr3:3221576	CRBN	0.76	7.99	0.54	3.13e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13198269	chr1:202927637	ADIPOR1	-0.74	-6.82	-0.48	2.02e-10	Neuroticism;
PAAD	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2073499	0.872	rs78671882	chr3:50411188	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	4.92	0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.51	4.31	0.33	2.97e-5	Height;
PAAD	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.34	-0.4	3.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg05768032	chr16:30646687	NA	0.52	5.09	0.38	1.07e-6	Multiple myeloma;
PAAD	cis	rs7960581	0.585	rs35274249	chr12:99170506	G/T	cg17109042	chr12:99139387	ANKS1B	-0.65	-4.39	-0.34	2.1e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs3733418	0.929	rs7656863	chr4:165883244	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.6	-5.47	-0.41	1.77e-7	Obesity-related traits;
PAAD	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.77	-7.91	-0.54	4.84e-13	Obesity-related traits;
PAAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.82	-10.18	-0.64	7.09e-19	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs894734	0.535	rs3847783	chr12:54320692	C/T	cg17410650	chr12:54324560	NA	-0.47	-7.74	-0.53	1.27e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
PAAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg23947450	chr7:900037	UNC84A	-0.53	-4.51	-0.34	1.28e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.31	-4.55	-0.35	1.09e-5	Body mass index;
PAAD	cis	rs11264799	0.639	rs61691958	chr1:157740789	G/C	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.89	10.37	0.64	2.17e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.47	-4.73	-0.36	5.04e-6	Eosinophil percentage of white cells;
PAAD	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs17054480	0.614	rs6842732	chr4:169618430	C/T	cg18174542	chr22:41956861	CSDC2	0.8	6.29	0.45	3.25e-9	Advanced glycation end-product levels;
PAAD	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.97	8.88	0.58	1.8e-15	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9913156	0.517	rs9893958	chr17:4611388	A/G	cg23387401	chr17:4582204	PELP1	0.42	4.6	0.35	8.75e-6	Lymphocyte counts;
PAAD	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-1.11	-15.7	-0.79	1.29e-33	Total body bone mineral density;
PAAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg01320130	chr1:67600311	NA	0.52	5.79	0.43	3.83e-8	Psoriasis;
PAAD	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-4.92	-0.37	2.26e-6	Total body bone mineral density;
PAAD	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.73	11.25	0.67	9.76e-22	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.41	6.01	0.44	1.3e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13095912	0.752	rs7613002	chr3:185353235	T/C	cg11274856	chr3:185301563	NA	0.6	5.88	0.43	2.48e-8	Systolic blood pressure;
PAAD	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.78	9.2	0.6	2.61e-16	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg19192590	chr2:178524533	PDE11A	0.4	4.39	0.34	2.1e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg15654264	chr1:150340011	RPRD2	-0.51	-4.95	-0.37	1.92e-6	Migraine;
PAAD	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg10253484	chr15:75165896	SCAMP2	0.49	4.6	0.35	8.69e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6494488	0.500	rs72742918	chr15:64852576	T/C	cg16425858	chr15:64791681	ZNF609	0.95	4.55	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.62	-0.35	8.04e-6	Breast cancer;
PAAD	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-8.21	-0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg21253087	chr9:139290292	SNAPC4	0.48	4.33	0.33	2.65e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.48	5.26	0.39	4.87e-7	Life satisfaction;
PAAD	cis	rs11168618	0.776	rs7955785	chr12:48862538	T/A	cg01881778	chr12:48919444	OR8S1	-0.49	-4.92	-0.37	2.19e-6	Adiponectin levels;
PAAD	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04915780	chr12:59989742	NA	-0.78	-6.73	-0.48	3.28e-10	Neuroticism;
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.48	0.61	4.86e-17	Platelet count;
PAAD	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg20891283	chr12:69753455	YEATS4	0.71	5.39	0.4	2.66e-7	Response to diuretic therapy;
PAAD	cis	rs965604	0.965	rs12899351	chr15:78792398	T/C	cg18825076	chr15:78729989	IREB2	-0.47	-4.56	-0.35	1.04e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs11997175	0.838	rs7836762	chr8:33667153	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.64	0.47	5.17e-10	Body mass index;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.54	5.54	0.41	1.28e-7	Longevity;Endometriosis;
PAAD	cis	rs5756391	0.509	rs4821559	chr22:37310269	T/C	cg16356956	chr22:37317934	CSF2RB	0.37	4.63	0.35	7.65e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.86	-5.78	-0.42	4e-8	Schizophrenia;
PAAD	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.5	-6.53	-0.47	9.35e-10	Primary biliary cholangitis;
PAAD	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.65	6.7	0.48	3.77e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.83	-9.68	-0.62	1.47e-17	Body mass index;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.87	0.72	4.07e-26	Platelet count;
PAAD	cis	rs9659323	0.700	rs2885226	chr1:119624163	A/G	cg26570165	chr1:119541833	NA	-0.5	-5.41	-0.4	2.43e-7	Body mass index;
PAAD	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26876637	chr1:152193138	HRNR	0.88	6.87	0.49	1.57e-10	Atopic dermatitis;
PAAD	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	6.52	0.47	9.71e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.92	-0.37	2.23e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.09	-10.03	-0.63	1.73e-18	Platelet count;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.8	-9.52	-0.61	3.87e-17	Monocyte percentage of white cells;
PAAD	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.65	-0.35	7.29e-6	Mean corpuscular volume;
PAAD	cis	rs2072732	0.904	rs1138513	chr1:2976816	T/C	cg22517653	chr1:2918612	NA	-0.62	-4.89	-0.37	2.55e-6	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11074378	chr7:5938227	C7orf28A	0.72	7.56	0.52	3.49e-12	Obesity-related traits;
PAAD	cis	rs6088813	1.000	rs6087705	chr20:34001250	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs10781543	0.845	rs10735662	chr9:139327869	A/T	cg14169450	chr9:139327907	INPP5E	0.75	9.18	0.6	2.88e-16	Monocyte percentage of white cells;
PAAD	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-11.26	-0.67	8.93e-22	Ulcerative colitis;
PAAD	cis	rs9649465	1.000	rs7805759	chr7:123318696	C/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg23682824	chr7:23144976	KLHL7	0.49	4.4	0.34	2.01e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs1359582	0.836	rs1409136	chr10:90356598	C/T	cg15661332	chr10:90342814	RNLS	-0.56	-5.04	-0.38	1.29e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-1.0	-9.78	-0.62	8.05e-18	Prostate cancer;
PAAD	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.79	-0.42	3.94e-8	Eye color traits;
PAAD	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.46	4.81	0.36	3.58e-6	Dementia with Lewy bodies;
PAAD	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.83	-9.23	-0.6	2.17e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.62	-0.41	8.77e-8	Vitiligo;
PAAD	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.94	-0.37	2.07e-6	Pulmonary function;
PAAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6066835	0.867	rs6066844	chr20:47375153	T/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs7786877	0.723	rs62482237	chr7:100213476	A/G	cg20848291	chr7:100343083	ZAN	-0.82	-6.7	-0.48	3.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.28	7.24	0.51	2.12e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg10862848	chr6:42927986	GNMT	0.37	5.38	0.4	2.81e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs800160	0.777	rs2651783	chr11:2345890	C/T	cg09785033	chr11:2336066	TSPAN32	-0.52	-4.35	-0.33	2.44e-5	Bacteremia;
PAAD	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.05e-7	Testicular germ cell tumor;
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-4.97	-0.37	1.81e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.7	-9.69	-0.62	1.34e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6850606	0.557	rs1450939	chr4:42894636	G/A	cg24533989	chr4:42659536	ATP8A1	0.47	4.27	0.33	3.43e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg22139774	chr2:100720529	AFF3	-0.35	-4.33	-0.33	2.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg14433983	chr11:636460	DRD4	-0.46	-4.74	-0.36	4.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs2300603	1.000	rs2359737	chr14:76002057	C/A	cg01624173	chr14:75981868	NA	0.6	6.21	0.45	4.92e-9	Multiple sclerosis;
PAAD	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.49	-5.77	-0.42	4.21e-8	Coronary artery disease;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg20007245	chr22:24372913	LOC391322	-0.76	-7.89	-0.54	5.67e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6679454	1.000	rs12145305	chr1:58361292	T/C	cg17491850	chr1:57888480	DAB1	-0.41	-4.7	-0.36	5.83e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.62	8.72	0.58	4.42e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg09658497	chr7:2847517	GNA12	-0.58	-5.82	-0.43	3.4e-8	Plateletcrit;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.54	5.66	0.42	7.28e-8	Lung cancer;
PAAD	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.43	-0.34	1.79e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg15571903	chr15:79123663	NA	-0.47	-6.08	-0.44	9.19e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.39	-4.79	-0.36	3.99e-6	Intraocular pressure;
PAAD	cis	rs17155006	0.702	rs446566	chr7:107730650	A/G	cg05962710	chr7:107745446	LAMB4	0.37	4.42	0.34	1.88e-5	Pneumococcal bacteremia;
PAAD	cis	rs11020478	0.600	rs4753485	chr11:93374276	T/C	cg10523193	chr11:93463762	SNORA25	0.46	4.6	0.35	8.85e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg25457927	chr22:38595422	NA	-0.39	-5.6	-0.41	9.96e-8	Breast cancer;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg13560548	chr3:10150139	C3orf24	0.52	4.52	0.34	1.21e-5	Alzheimer's disease;
PAAD	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg23024343	chr7:107201750	COG5	0.54	4.33	0.33	2.72e-5	Osteoarthritis;
PAAD	cis	rs73019876	0.839	rs1064170	chr19:22149044	T/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg21665744	chr7:39171113	POU6F2	0.3	4.67	0.35	6.59e-6	IgG glycosylation;
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.61	6.86	0.49	1.61e-10	Systemic lupus erythematosus;
PAAD	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.78	7.85	0.54	6.79e-13	Coronary artery disease;
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg09877947	chr5:131593287	PDLIM4	0.62	5.57	0.41	1.11e-7	Acylcarnitine levels;
PAAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.64	-6.9	-0.49	1.28e-10	Schizophrenia;
PAAD	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.66	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7072216	0.687	rs11189589	chr10:100154565	A/G	cg19567339	chr10:100142640	NA	0.42	4.41	0.34	1.93e-5	Metabolite levels;
PAAD	cis	rs12936587	0.633	rs35851484	chr17:17507905	A/G	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.45	-0.34	1.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	1.09	8.87	0.58	1.85e-15	Initial pursuit acceleration;
PAAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs969348	0.901	rs16973019	chr15:81867517	G/A	cg27388777	chr15:81616568	STARD5	-0.73	-4.62	-0.35	8.17e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.11	14.37	0.76	4.08e-30	Cognitive function;
PAAD	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.74	7.78	0.53	1.04e-12	Schizophrenia;
PAAD	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.56	-5.69	-0.42	6.24e-8	Testicular germ cell tumor;
PAAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.64	8.71	0.58	4.8e-15	Height;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg16362232	chr11:430036	ANO9	0.86	5.31	0.4	3.79e-7	Body mass index;
PAAD	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg18200150	chr17:30822561	MYO1D	0.81	11.68	0.69	6.6e-23	Schizophrenia;
PAAD	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.45	4.46	0.34	1.56e-5	Chronic sinus infection;
PAAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.81	8.63	0.57	7.48e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.6	4.79	0.36	3.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.91	0.49	1.23e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-4.82	-0.36	3.5e-6	Common traits (Other);
PAAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg15017067	chr4:17643749	FAM184B	0.43	5.11	0.38	9.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24952754	chr5:112768887	TSSK1B;MCC	0.64	6.61	0.47	6.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs73058052	0.597	rs56873913	chr19:50091199	T/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.59	-5.13	-0.38	8.75e-7	Fibrinogen levels;
PAAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg14393609	chr7:65229607	NA	-0.47	-4.77	-0.36	4.22e-6	Aortic root size;
PAAD	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs113779084	0.728	rs67823574	chr7:11949278	C/T	cg24676244	chr7:11872050	THSD7A	0.36	4.28	0.33	3.36e-5	Educational attainment (years of education);
PAAD	cis	rs829661	1.000	rs829671	chr2:30712152	C/T	cg12454169	chr2:30669597	LCLAT1	0.64	4.89	0.37	2.51e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs4427176	0.543	rs4413778	chr8:9586209	G/A	cg03024720	chr8:9765601	NA	0.48	4.61	0.35	8.54e-6	Mosquito bite size;
PAAD	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.34	-4.47	-0.34	1.53e-5	Vitiligo;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.54	-5.49	-0.41	1.61e-7	Iron status biomarkers;
PAAD	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.46	4.51	0.34	1.3e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.51	-4.43	-0.34	1.82e-5	Coronary artery disease;
PAAD	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg14393609	chr7:65229607	NA	0.63	6.99	0.49	8.26e-11	Aortic root size;
PAAD	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.87	-8.15	-0.55	1.25e-13	Menarche (age at onset);
PAAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21773710	chr5:180688230	TRIM52	0.61	6.55	0.47	8.46e-10	Myopia (pathological);
PAAD	cis	rs3125734	0.591	rs3125729	chr10:63940452	G/T	cg19640130	chr10:64028056	RTKN2	0.37	4.54	0.35	1.15e-5	Rheumatoid arthritis;
PAAD	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.69	-4.92	-0.37	2.25e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg15654264	chr1:150340011	RPRD2	0.49	4.71	0.36	5.48e-6	Migraine;
PAAD	cis	rs7098414	0.530	rs12220655	chr10:82219066	T/C	cg09626299	chr10:82213104	TSPAN14	-0.38	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14276488	chr9:4491114	SLC1A1	0.56	6.43	0.46	1.57e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-5.18	-0.39	6.97e-7	Body mass index;
PAAD	cis	rs2916733	0.838	rs2440400	chr8:6323309	T/G	cg01691696	chr8:6734962	DEFB1	-0.55	-4.35	-0.33	2.46e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs1497828	0.871	rs2815238	chr1:217543384	T/A	cg04411442	chr1:217543379	NA	0.51	4.93	0.37	2.12e-6	Dialysis-related mortality;
PAAD	cis	rs6442522	0.678	rs3773451	chr3:15510133	T/G	cg16303742	chr3:15540471	COLQ	0.48	5.1	0.38	9.96e-7	Uric acid levels;
PAAD	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg20406979	chr6:167373233	NA	-0.34	-4.4	-0.34	2.03e-5	Crohn's disease;
PAAD	cis	rs78773383	0.505	rs10033019	chr4:39391940	A/G	cg16714752	chr4:39368184	RFC1	0.5	5.15	0.39	8.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12153243	0.714	rs6895860	chr5:142913679	C/T	cg13907255	chr5:142895549	NA	-0.53	-4.87	-0.37	2.8e-6	Migraine;
PAAD	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.93	12.22	0.7	2.41e-24	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16433800	chr2:173420778	PDK1	-0.72	-7.88	-0.54	5.72e-13	Smoking initiation;
PAAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg20381115	chr15:45671148	LOC145663;GATM	0.4	4.39	0.34	2.11e-5	Glomerular filtration rate;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.51	-4.39	-0.34	2.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.79	6.72	0.48	3.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.79	-0.42	3.96e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	4.27	0.33	3.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-6.63	-0.47	5.47e-10	Gut microbiome composition (summer);
PAAD	cis	rs10276303	0.516	rs2705612	chr7:3619763	A/C	cg15231989	chr7:2742433	AMZ1	0.48	4.42	0.34	1.9e-5	Dupuytren's disease;
PAAD	cis	rs2271400	0.529	rs6988556	chr8:56745312	C/T	cg08894788	chr8:56792171	LYN	-0.54	-4.95	-0.37	1.94e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg12963246	chr6:28129442	ZNF389	0.58	4.59	0.35	9.06e-6	Cardiac Troponin-T levels;
PAAD	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26876637	chr1:152193138	HRNR	-0.87	-6.91	-0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.76	6.52	0.47	9.88e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.42	0.34	1.88e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21813473	chr20:40247231	CHD6	-0.63	-6.78	-0.48	2.44e-10	Smoking initiation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14567414	chr17:41910795	MPP3	0.6	6.83	0.48	1.89e-10	Monocyte percentage of white cells;
PAAD	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.35	4.92	0.37	2.24e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg14393609	chr7:65229607	NA	-0.64	-6.81	-0.48	2.18e-10	Calcium levels;
PAAD	cis	rs2278796	0.639	rs6697344	chr1:204971485	G/T	cg17947172	chr1:204966197	NFASC	0.43	4.7	0.36	5.86e-6	Mean platelet volume;
PAAD	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.68	5.69	0.42	6.22e-8	Pubertal anthropometrics;
PAAD	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.52	5.37	0.4	2.87e-7	Red blood cell count;
PAAD	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg24747557	chr10:131355152	MGMT	-0.43	-4.36	-0.33	2.39e-5	Response to temozolomide;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.39	4.3	0.33	3.09e-5	Bipolar disorder;
PAAD	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	8.31e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.48	6.16	0.45	6.28e-9	Primary biliary cholangitis;
PAAD	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg08648136	chr8:956695	NA	0.49	5.18	0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg21565972	chr17:80109576	CCDC57	-0.58	-6.77	-0.48	2.69e-10	Life satisfaction;
PAAD	cis	rs9888739	0.920	rs12102768	chr16:31303950	G/A	cg02256631	chr16:31342952	ITGAM	-0.53	-4.33	-0.33	2.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg14843632	chr5:14870594	ANKH	0.51	6.27	0.45	3.63e-9	Blood metabolite levels;
PAAD	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg21951975	chr1:209979733	IRF6	0.56	5.59	0.41	1.01e-7	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg07148914	chr20:33460835	GGT7	0.48	4.77	0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.6	-5.55	-0.41	1.25e-7	Mean corpuscular volume;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	11.93	0.7	1.44e-23	Cognitive ability;
PAAD	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg23534315	chr17:78082725	GAA	0.48	4.42	0.34	1.89e-5	Yeast infection;
PAAD	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.49	5.29	0.39	4.15e-7	Heart rate;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21055532	chr19:19030391	DDX49;COPE	-0.72	-7.1	-0.5	4.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.97	8.36	0.56	3.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	6.7	0.48	3.75e-10	Homoarginine levels;
PAAD	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.93	8.23	0.56	7.96e-14	Gut microbiome composition (summer);
PAAD	cis	rs35160687	0.509	rs35723061	chr2:86549088	G/A	cg10973622	chr2:86423274	IMMT	-0.44	-4.99	-0.38	1.63e-6	Night sleep phenotypes;
PAAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.37	-0.33	2.3e-5	Renal cell carcinoma;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg09197432	chr4:183729176	NA	0.62	5.29	0.39	4.2e-7	Pediatric autoimmune diseases;
PAAD	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-4.62	-0.35	8.08e-6	Blood pressure;
PAAD	cis	rs375066	0.935	rs423320	chr19:44422982	G/A	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs747650	0.504	rs10769225	chr11:46982481	G/A	cg19486271	chr11:47235900	DDB2	-0.64	-6.11	-0.44	7.9e-9	Acne (severe);
PAAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg09659197	chr4:152720779	NA	0.48	6.47	0.46	1.25e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs7173419	0.516	rs10852218	chr15:28231793	T/C	cg20906524	chr15:28200668	OCA2	-0.48	-4.36	-0.33	2.4e-5	Eye color;
PAAD	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.7	6.87	0.49	1.58e-10	Retinal vascular caliber;
PAAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3981351	0.797	rs12771452	chr10:115488331	G/A	cg24846397	chr10:115438155	CASP7	-0.5	-4.64	-0.35	7.61e-6	Obesity-related traits;
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.83	6.29	0.45	3.14e-9	Initial pursuit acceleration;
PAAD	cis	rs7894051	0.681	rs2185747	chr10:135191460	T/G	cg19176072	chr10:135083742	ADAM8	-0.96	-4.65	-0.35	7.09e-6	Lifespan;
PAAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.06	0.38	1.2e-6	Personality dimensions;
PAAD	cis	rs3779195	0.789	rs6965424	chr7:97991125	A/G	cg21770322	chr7:97807741	LMTK2	0.53	4.9	0.37	2.41e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.69	7.43	0.52	7.41e-12	Resting heart rate;
PAAD	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.31	0.6	1.38e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11700980	0.551	rs56166203	chr21:30109607	G/C	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7127900	1.000	rs4077456	chr11:2230152	A/G	cg25635251	chr11:2234043	NA	0.84	7.53	0.52	4.15e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.73	6.97	0.49	9.18e-11	Obesity-related traits;
PAAD	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.59	-6.12	-0.44	7.78e-9	Dental caries;
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg26939375	chr7:64535504	NA	-0.75	-9.06	-0.59	6.19e-16	Aortic root size;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.76	-0.48	2.74e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg24519413	chr1:26490540	NA	0.5	4.63	0.35	7.8e-6	Height;
PAAD	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.04	0.5	6.03e-11	Lung cancer in ever smokers;
PAAD	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.54	4.58	0.35	9.53e-6	Sudden cardiac arrest;
PAAD	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg14580859	chr9:123691850	NA	0.38	4.27	0.33	3.38e-5	Rheumatoid arthritis;
PAAD	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg16898833	chr6:26189333	HIST1H4D	0.48	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs7243821	1.000	rs11661245	chr18:52646385	C/G	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.91	-0.37	2.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg10395934	chr14:104002654	TRMT61A	0.55	5.63	0.42	8.41e-8	Body mass index;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.89	12.21	0.7	2.51e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg12935359	chr14:103987150	CKB	-0.66	-7.02	-0.49	6.96e-11	Body mass index;
PAAD	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.6	4.62	0.35	7.98e-6	Pancreatic cancer;
PAAD	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.59	-0.35	9.4e-6	Joint mobility (Beighton score);
PAAD	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.92	-0.72	3.09e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.42	-0.34	1.89e-5	Fear of minor pain;
PAAD	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.84	0.49	1.81e-10	Body mass index;
PAAD	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.35	-0.33	2.47e-5	Life satisfaction;
PAAD	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.7	6.87	0.49	1.55e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.86	-0.49	1.63e-10	Platelet distribution width;
PAAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg16205897	chr5:131564050	P4HA2	0.46	4.88	0.37	2.64e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03167275	chr21:18886093	CXADR	0.53	6.99	0.49	8.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.28	0.6	1.6e-16	Parkinson's disease;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18621852	chr3:10150065	C3orf24	0.62	5.33	0.4	3.5e-7	Alzheimer's disease;
PAAD	cis	rs1190596	0.830	rs2298877	chr14:102548224	T/C	cg23904247	chr14:102554826	HSP90AA1	-0.49	-5.41	-0.4	2.44e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs8062405	0.558	rs3743963	chr16:28604686	A/G	cg16576597	chr16:28551801	NUPR1	0.51	5.69	0.42	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02071572	chr4:1403502	NA	0.51	6.55	0.47	8.4e-10	Longevity;
PAAD	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.12	-0.67	2.09e-21	Rheumatoid arthritis;
PAAD	trans	rs6030712	0.948	rs1744765	chr20:35722830	A/G	cg17467750	chr11:10878933	ZBED5	-0.77	-6.3	-0.46	3.03e-9	Height;
PAAD	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg19930314	chr7:98593876	TRRAP	-0.49	-4.75	-0.36	4.62e-6	Breast cancer;
PAAD	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg22325292	chr17:80708367	FN3K	0.62	4.63	0.35	7.69e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-10.19	-0.64	6.38e-19	Height;
PAAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.57	-0.35	1.02e-5	Alcohol dependence;
PAAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg03983715	chr16:68378420	PRMT7	-0.74	-5.37	-0.4	2.84e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs11651753	0.561	rs1108833	chr17:45982797	G/A	cg24458315	chr17:46148407	CBX1	0.41	4.52	0.34	1.25e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.88	-0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9810890	1.000	rs76610941	chr3:128524526	G/A	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs7508679	0.769	rs12610987	chr19:7219697	T/C	cg09779027	chr19:7224513	INSR	0.59	6.1	0.44	8.41e-9	Hypothyroidism;
PAAD	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg23587288	chr2:27483067	SLC30A3	0.64	6.0	0.44	1.36e-8	Blood metabolite levels;
PAAD	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg12623918	chr2:306882	NA	0.48	5.03	0.38	1.36e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs939584	1.000	rs4854349	chr2:647861	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg16362232	chr11:430036	ANO9	0.86	5.31	0.4	3.79e-7	Body mass index;
PAAD	cis	rs1891275	0.551	rs2421628	chr10:93422169	A/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.25	-0.39	4.97e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.71	8.13	0.55	1.38e-13	Lung cancer;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.71	0.36	5.46e-6	Bipolar disorder;
PAAD	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.58	7.67	0.53	1.9e-12	Primary biliary cholangitis;
PAAD	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.6	-0.35	8.93e-6	Bipolar disorder;
PAAD	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.36	0.6	1.03e-16	Cognitive test performance;
PAAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.74	10.39	0.64	1.87e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17129141	chr2:47629949	MSH2	0.61	6.69	0.48	4.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2414095	0.527	rs35241865	chr15:51541301	C/T	cg21478137	chr15:51532386	CYP19A1	0.54	5.5	0.41	1.58e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	cis	rs4077515	0.839	rs1132005	chr9:139296927	T/C	cg14169450	chr9:139327907	INPP5E	0.55	5.59	0.41	1.04e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	5.85	0.43	2.87e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7009516	0.819	rs5012230	chr8:24208934	A/C	cg01759110	chr8:24241694	ADAMDEC1	0.42	5.12	0.38	9.01e-7	Hair greying;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.39	4.26	0.33	3.55e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-1.08	-12.5	-0.71	4.23e-25	Obesity-related traits;
PAAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-6.23	-0.45	4.34e-9	Monocyte count;
PAAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.57	0.57	1.1e-14	Hip circumference adjusted for BMI;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21539087	chr12:133346125	GOLGA3	-0.68	-6.74	-0.48	3.05e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1499972	0.938	rs1604060	chr3:117772036	A/G	cg07612923	chr3:117604196	NA	-1.06	-6.91	-0.49	1.28e-10	Schizophrenia;
PAAD	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.7	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.62	-0.41	8.77e-8	Vitiligo;
PAAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg20848291	chr7:100343083	ZAN	-0.76	-6.51	-0.47	1.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg19673125	chr6:150240577	RAET1G	0.43	6.07	0.44	9.59e-9	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg14829360	chr17:73884958	NA	-0.55	-5.68	-0.42	6.66e-8	White matter hyperintensity burden;
PAAD	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.79	9.3	0.6	1.42e-16	Colorectal cancer;
PAAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg04738700	chr2:239367308	NA	0.41	4.44	0.34	1.7e-5	Multiple system atrophy;
PAAD	cis	rs941898	0.836	rs8016001	chr14:100598691	A/G	cg26002632	chr14:100625216	DEGS2	-0.43	-5.32	-0.4	3.65e-7	White matter hyperintensity burden;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11921270	chr19:19051154	HOMER3	0.56	6.59	0.47	6.92e-10	Myopia (pathological);
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.79	-0.42	3.99e-8	Lung cancer;
PAAD	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.54	0.35	1.13e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.04	-0.38	1.28e-6	Schizophrenia;
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg20302533	chr7:39170763	POU6F2	0.5	7.0	0.49	7.65e-11	IgG glycosylation;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg21361702	chr7:150065534	REPIN1	0.58	4.78	0.36	4.02e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs58521262	0.519	rs4933033	chr19:22937148	G/A	cg07749055	chr19:23076870	NA	-0.57	-4.26	-0.33	3.53e-5	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.54	-0.41	1.3e-7	Total body bone mineral density;
PAAD	cis	rs77106637	0.932	rs1783598	chr11:72851463	C/T	cg03713592	chr11:72463424	ARAP1	-0.59	-5.0	-0.38	1.59e-6	Type 2 diabetes;
PAAD	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-1.01	-8.21	-0.55	8.99e-14	Smoking behavior;
PAAD	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09238162	chr7:137651542	CREB3L2	-0.76	-8.06	-0.55	2.13e-13	Obesity-related traits;
PAAD	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	3.98e-27	Heart rate;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg14664628	chr15:75095509	CSK	-0.48	-4.64	-0.35	7.53e-6	Caffeine consumption;
PAAD	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11807834	0.522	rs12564901	chr1:230244337	G/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.44	-0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.99	0.67	4.82e-21	Smoking behavior;
PAAD	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	10.78	0.66	1.73e-20	Smoking behavior;
PAAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/GT	cg05169160	chr2:178484487	TTC30A	-0.59	-4.42	-0.34	1.85e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.78	-9.22	-0.6	2.38e-16	White blood cell count (basophil);
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg11335335	chr11:637885	DRD4	-0.37	-5.08	-0.38	1.11e-6	Systemic lupus erythematosus;
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg16083429	chr3:49237500	CCDC36	-0.46	-5.17	-0.39	7.17e-7	Menarche (age at onset);
PAAD	cis	rs375066	0.935	rs108775	chr19:44405922	G/C	cg11993925	chr19:44307056	LYPD5	0.52	6.68	0.48	4.28e-10	Breast cancer;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg05313129	chr8:58192883	C8orf71	-0.65	-5.17	-0.39	7.27e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14579157	chr2:99061273	INPP4A	0.68	7.33	0.51	1.24e-11	Myopia (pathological);
PAAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg01831904	chr17:28903510	LRRC37B2	0.78	6.01	0.44	1.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.41	4.8	0.36	3.72e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01419164	chr10:131742167	EBF3	0.55	6.76	0.48	2.72e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg10820045	chr2:198174542	NA	0.48	4.88	0.37	2.66e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs804280	0.544	rs804270	chr8:11627621	G/C	cg00262122	chr8:11665843	FDFT1	0.47	4.41	0.34	1.97e-5	Myopia (pathological);
PAAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg21300403	chr2:198650112	BOLL	-0.65	-4.45	-0.34	1.63e-5	Ulcerative colitis;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.75	10.14	0.64	8.73e-19	Iron status biomarkers;
PAAD	cis	rs300774	0.925	rs300719	chr2:136203	C/T	cg21211680	chr2:198530	NA	-0.6	-5.69	-0.42	6.45e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.62	-4.45	-0.34	1.67e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg08390786	chr10:135334061	NA	-0.58	-4.85	-0.37	2.98e-6	Gout;
PAAD	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg05784532	chr1:230284198	GALNT2	0.69	6.02	0.44	1.26e-8	Coronary artery disease;
PAAD	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg14583973	chr4:3374767	RGS12	0.42	6.28	0.45	3.46e-9	Serum sulfate level;
PAAD	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.5	-4.72	-0.36	5.31e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10267417	0.603	rs10216149	chr7:19909093	A/T	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs17152411	1.000	rs17152448	chr10:126675645	C/G	cg07906193	chr10:126599966	NA	0.79	6.33	0.46	2.62e-9	Height;
PAAD	cis	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs4713118	1.000	rs4713118	chr6:27676794	A/G	cg20933634	chr6:27740509	NA	0.68	6.45	0.46	1.44e-9	Parkinson's disease;
PAAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14169450	chr9:139327907	INPP5E	0.65	6.0	0.44	1.38e-8	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs6499755	0.870	rs31074	chr16:55357170	A/C	cg02859129	chr16:55357253	IRX6	0.35	4.73	0.36	5.03e-6	Hypospadias;
PAAD	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg17366294	chr4:99064904	C4orf37	0.45	4.92	0.37	2.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg14393609	chr7:65229607	NA	-0.48	-4.63	-0.35	7.79e-6	Aortic root size;
PAAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-1.36	-9.67	-0.62	1.53e-17	Schizophrenia;
PAAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.37	-0.4	2.84e-7	HDL cholesterol;
PAAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg06375148	chr1:209958343	C1orf74	0.67	4.98	0.37	1.73e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.61	7.09	0.5	4.78e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg24147428	chr11:65409760	SIPA1	-0.34	-4.31	-0.33	2.88e-5	Urate levels;
PAAD	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg00738919	chr7:1100172	C7orf50	0.67	5.39	0.4	2.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	7.79	0.53	9.62e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.82	7.66	0.53	2.04e-12	Colorectal cancer;
PAAD	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.71	7.87	0.54	6.02e-13	Platelet distribution width;
PAAD	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.03	0.44	1.17e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg20628663	chr10:43360327	NA	0.66	4.78	0.36	4.15e-6	Pediatric bone mineral content (radius);
PAAD	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg20936604	chr3:58311152	NA	-0.78	-4.29	-0.33	3.18e-5	Cholesterol, total;
PAAD	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.65	7.0	0.49	7.78e-11	Crohn's disease;
PAAD	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.61	-0.35	8.44e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.57	6.05	0.44	1.06e-8	Obesity-related traits;
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg07212818	chr11:638076	DRD4	-0.77	-6.97	-0.49	8.85e-11	Systemic lupus erythematosus;
PAAD	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg15378786	chr11:17036137	PLEKHA7	0.5	4.3	0.33	3.1e-5	Systolic blood pressure;
PAAD	cis	rs2455826	0.521	rs1447649	chr3:15837784	A/G	cg13420985	chr3:16524424	RFTN1	0.47	4.44	0.34	1.74e-5	Inflammatory skin disease;
PAAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.42	0.34	1.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg00262122	chr8:11665843	FDFT1	-0.5	-4.33	-0.33	2.74e-5	Neuroticism;
PAAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.58	6.08	0.44	9.2e-9	Menopause (age at onset);
PAAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09695851	chr17:3907499	NA	0.66	6.95	0.49	1.01e-10	Type 2 diabetes;
PAAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg12215294	chr3:40350768	EIF1B	0.45	4.42	0.34	1.9e-5	Renal cell carcinoma;
PAAD	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg14343924	chr8:8086146	FLJ10661	0.49	4.69	0.36	6.16e-6	Joint mobility (Beighton score);
PAAD	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg19792802	chr11:65647270	CTSW	-0.53	-6.91	-0.49	1.22e-10	Crohn's disease;
PAAD	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg20283391	chr11:68216788	NA	-0.54	-5.21	-0.39	6.05e-7	Total body bone mineral density;
PAAD	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	1.17	10.97	0.66	5.35e-21	Colorectal cancer;
PAAD	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg01388757	chr2:102091195	RFX8	-0.59	-7.52	-0.52	4.55e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.68	6.5	0.47	1.11e-9	Hip circumference;
PAAD	cis	rs9314614	0.789	rs2978887	chr8:6710879	C/T	cg27319216	chr8:6693540	XKR5	-0.36	-4.84	-0.37	3.18e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg10006428	chr1:248814059	OR2T27	0.41	4.84	0.37	3.2e-6	Common traits (Other);
PAAD	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.22	0.45	4.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-7.1	-0.5	4.51e-11	Cognitive function;
PAAD	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	6.03	0.44	1.17e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3026101	0.671	rs3026125	chr17:5293627	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs73198271	0.632	rs477018	chr8:8600817	T/A	cg01851573	chr8:8652454	MFHAS1	0.51	4.4	0.34	2.06e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.18e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.64	-6.91	-0.49	1.22e-10	Systemic lupus erythematosus;
PAAD	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.04	0.44	1.14e-8	Rheumatoid arthritis;
PAAD	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg16586182	chr3:47516702	SCAP	-0.69	-7.85	-0.54	7.03e-13	Colorectal cancer;
PAAD	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg18551225	chr6:44695536	NA	-0.58	-5.18	-0.39	6.86e-7	Total body bone mineral density;
PAAD	cis	rs17152411	0.895	rs7914206	chr10:126585397	G/A	cg07906193	chr10:126599966	NA	0.75	5.79	0.43	3.88e-8	Height;
PAAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.74	7.97	0.54	3.5e-13	DNA methylation (variation);
PAAD	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.84	6.46	0.46	1.32e-9	Axial length;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg08888203	chr3:10149979	C3orf24	0.85	7.54	0.52	4.02e-12	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13560548	chr3:10150139	C3orf24	0.54	5.0	0.38	1.58e-6	Alzheimer's disease;
PAAD	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg00666640	chr1:248458726	OR2T12	0.6	4.88	0.37	2.63e-6	Common traits (Other);
PAAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.39	4.05e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.72	7.98	0.54	3.37e-13	Schizophrenia;
PAAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4731207	0.505	rs7791488	chr7:124578268	A/G	cg14311320	chr7:124405732	GPR37	-0.45	-4.7	-0.36	5.73e-6	Cutaneous malignant melanoma;
PAAD	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.2	-0.5	2.58e-11	Triglycerides;
PAAD	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg07384165	chr1:10488281	NA	-0.45	-4.61	-0.35	8.42e-6	Breast cancer;
PAAD	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs9826463	0.702	rs73228757	chr3:142320081	A/G	cg20824294	chr3:142316082	PLS1	0.44	4.99	0.38	1.6e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg23859931	chr19:22123797	NA	-0.45	-5.1	-0.38	1e-6	Telomere length;
PAAD	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.41	0.56	2.8e-14	Coffee consumption (cups per day);
PAAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg19680485	chr15:31195859	MTMR15	0.43	4.25	0.33	3.68e-5	Huntington's disease progression;
PAAD	trans	rs7746199	0.736	rs13217620	chr6:27653120	C/T	cg01620082	chr3:125678407	NA	-1.51	-8.22	-0.55	8.16e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg14631576	chr9:95140430	CENPP	-0.47	-4.59	-0.35	9.34e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.46	5.02	0.38	1.42e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs832187	0.813	rs704369	chr3:63868271	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.46	4.4	0.34	2.07e-5	Schizophrenia;
PAAD	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.9	6.07	0.44	9.83e-9	Thyroid stimulating hormone;
PAAD	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12568669	chr8:11666485	FDFT1	-0.25	-4.34	-0.33	2.58e-5	Myopia (pathological);
PAAD	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.2	0.39	6.32e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg14092571	chr14:90743983	NA	0.45	4.45	0.34	1.66e-5	Mortality in heart failure;
PAAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.7	-4.88	-0.37	2.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1642645	0.831	rs6698877	chr1:42500436	T/C	cg01990334	chr1:42801334	FOXJ3	-0.61	-5.73	-0.42	5.28e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6466055	0.777	rs2240463	chr7:104844328	C/T	cg04380332	chr7:105027541	SRPK2	-0.65	-7.33	-0.51	1.26e-11	Schizophrenia;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07362569	chr17:61921086	SMARCD2	0.6	7.15	0.5	3.47e-11	Prudent dietary pattern;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg02462569	chr6:150064036	NUP43	-0.53	-5.96	-0.43	1.73e-8	Lung cancer;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13939156	chr17:80058883	NA	-0.41	-4.42	-0.34	1.83e-5	Life satisfaction;
PAAD	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg05250797	chr16:70222502	NA	0.8	6.3	0.46	3.04e-9	IgE levels;
PAAD	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg27638815	chr19:15662578	CYP4F22	0.73	4.57	0.35	9.95e-6	Inflammatory biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17102069	chr6:37139542	PIM1	0.66	6.78	0.48	2.51e-10	Obesity-related traits;
PAAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg27494647	chr7:150038898	RARRES2	0.44	4.56	0.35	1.05e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg07148914	chr20:33460835	GGT7	0.5	4.86	0.37	2.87e-6	Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	9.73	0.62	1.1e-17	Platelet count;
PAAD	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.5	-4.84	-0.37	3.18e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.58	4.31	0.33	2.96e-5	Systolic blood pressure;
PAAD	cis	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg27411982	chr8:10470053	RP1L1	0.48	5.68	0.42	6.62e-8	Neuroticism;
PAAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg16850897	chr7:100343110	ZAN	-0.58	-4.84	-0.37	3.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.61	-7.17	-0.5	3.07e-11	Dementia with Lewy bodies;
PAAD	cis	rs4908768	0.594	rs11121228	chr1:8830642	T/C	cg25722041	chr1:8623473	RERE	0.51	4.38	0.33	2.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg05484376	chr2:27715224	FNDC4	0.48	4.66	0.35	6.77e-6	Oral cavity cancer;
PAAD	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.96	-5.49	-0.41	1.62e-7	Schizophrenia;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg11207081	chr8:145000968	PLEC1	-0.62	-7.45	-0.52	6.63e-12	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4919087	0.590	rs1253397	chr10:99045556	C/T	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	trans	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg14171944	chr9:126323477	DENND1A	0.54	6.43	0.46	1.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.96	8.0	0.54	3.01e-13	Gut microbiome composition (summer);
PAAD	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.3	-0.33	3.07e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg15117754	chr3:10150083	C3orf24	0.66	6.27	0.45	3.59e-9	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg05110241	chr16:68378359	PRMT7	-1.01	-6.53	-0.47	9.3e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.83	10.03	0.63	1.7e-18	Menopause (age at onset);
PAAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14180030	chr9:123475675	MEGF9	-0.45	-5.02	-0.38	1.45e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.76	8.76	0.58	3.65e-15	Noise-induced hearing loss;
PAAD	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-13.66	-0.74	3.27e-28	Dental caries;
PAAD	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.88	-0.37	2.62e-6	Vitiligo;
PAAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4787491	0.588	rs12924622	chr16:30084052	A/T	cg06015834	chr16:30021696	DOC2A	-0.44	-4.47	-0.34	1.5e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg08601574	chr20:25228251	PYGB	0.5	5.09	0.38	1.04e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.55	6.3	0.45	3.11e-9	Mean corpuscular volume;
PAAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.56	-5.56	-0.41	1.2e-7	Childhood ear infection;
PAAD	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg13722127	chr7:150037890	RARRES2	0.65	6.41	0.46	1.72e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg16447950	chr5:562315	NA	-0.67	-5.95	-0.43	1.77e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.53e-6	Bipolar disorder;
PAAD	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg09709951	chr12:54017699	ATF7	0.52	4.66	0.35	6.84e-6	Height;
PAAD	cis	rs6494488	0.500	rs67799896	chr15:64963776	C/T	cg16425858	chr15:64791681	ZNF609	0.97	5.18	0.39	6.8e-7	Coronary artery disease;
PAAD	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.76	8.58	0.57	1.01e-14	Neuroticism;
PAAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg21929781	chr1:2537748	MMEL1	0.51	5.31	0.4	3.78e-7	Ulcerative colitis;
PAAD	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.89	0.49	1.41e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg12143784	chr7:64541923	NA	-0.34	-4.38	-0.33	2.2e-5	Aortic root size;
PAAD	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg27449745	chr7:23145252	KLHL7	-0.57	-5.28	-0.39	4.45e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs5009270	0.597	rs10225077	chr7:112159448	G/A	cg25550468	chr7:112262557	NA	0.46	4.25	0.33	3.65e-5	Osteoarthritis (hip);
PAAD	cis	rs425535	0.757	rs240610	chr4:74792228	G/C	cg01447579	chr4:74847100	PF4	0.65	4.37	0.33	2.26e-5	Blood protein levels;
PAAD	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.7	7.38	0.51	9.63e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.47	-4.41	-0.34	1.91e-5	Coronary artery disease;
PAAD	cis	rs2117029	0.586	rs10783307	chr12:49529605	A/T	cg05368762	chr12:50135785	TMBIM6	0.45	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.57e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.79	0.36	4.01e-6	HDL cholesterol;
PAAD	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.97	0.49	8.8e-11	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20124547	chr2:175062978	OLA1	-0.67	-6.66	-0.48	4.79e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9810890	1.000	rs79217699	chr3:128445585	C/T	cg19129842	chr3:128565090	NA	-0.86	-5.4	-0.4	2.48e-7	Dental caries;
PAAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg11204139	chr17:3907470	NA	0.85	8.68	0.58	5.78e-15	Type 2 diabetes;
PAAD	cis	rs965604	1.000	rs12593229	chr15:78765290	T/G	cg18825076	chr15:78729989	IREB2	-0.45	-4.38	-0.33	2.18e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.42	-0.34	1.85e-5	Life satisfaction;
PAAD	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.05	-0.38	1.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06799790	chr17:61951754	CSH2	-0.46	-4.89	-0.37	2.56e-6	Height;
PAAD	cis	rs3784262	0.565	rs2642630	chr15:58316960	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-4.92	-0.37	2.18e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.44	6.54	0.47	8.9e-10	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.98	0.54	3.33e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs704	0.790	rs9913833	chr17:26718592	C/T	cg10342447	chr17:26645325	TMEM97	-0.35	-4.31	-0.33	2.96e-5	Osteoprotegerin levels;
PAAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg25319279	chr11:5960081	NA	-0.59	-5.67	-0.42	7.1e-8	DNA methylation (variation);
PAAD	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg10183150	chr4:120222239	C4orf3	0.37	5.18	0.39	7.06e-7	Corneal astigmatism;
PAAD	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.73	9.51	0.61	4.05e-17	Cancer;
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg13047869	chr3:10149882	C3orf24	0.54	4.77	0.36	4.24e-6	Alzheimer's disease;
PAAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg10556349	chr10:835070	NA	0.57	4.63	0.35	7.94e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9810890	0.850	rs73196995	chr3:128458070	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.6e-9	Childhood ear infection;
PAAD	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19757253	chr2:32853039	TTC27	0.68	7.34	0.51	1.24e-11	Myopia (pathological);
PAAD	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg09980403	chr19:12975529	MAST1	0.29	4.77	0.36	4.36e-6	Mean corpuscular volume;
PAAD	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06028605	chr16:24865363	SLC5A11	0.47	5.87	0.43	2.6e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs12778143	chr10:46063540	T/C	cg23720331	chr10:123873670	TACC2	-0.87	-6.53	-0.47	9.25e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.52	5.65	0.42	7.61e-8	Total body bone mineral density;
PAAD	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.92	-0.54	4.68e-13	Schizophrenia;
PAAD	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.8	-10.15	-0.64	8.27e-19	Height;
PAAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.16	0.39	7.76e-7	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02774070	chr7:66093889	KCTD7	0.65	7.49	0.52	5.14e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.57	-6.02	-0.44	1.24e-8	Subjective well-being;
PAAD	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.69	4.68	0.36	6.23e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs41341749	0.831	rs76190126	chr17:34310256	C/A	cg12096988	chr19:57702809	ZNF264	-1.33	-6.39	-0.46	1.96e-9	Blood protein levels;
PAAD	trans	rs11989843	0.666	rs11989353	chr8:118080721	A/G	cg24636944	chr5:92615296	NA	0.49	6.33	0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.47	5.87	0.43	2.62e-8	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg13271783	chr10:134563150	INPP5A	-0.42	-4.57	-0.35	9.99e-6	Migraine;
PAAD	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	7.11	0.5	4.31e-11	HIV-1 control;
PAAD	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	1.02	11.87	0.69	2.04e-23	Multiple myeloma;
PAAD	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg08562672	chr19:21860753	NA	0.45	4.67	0.35	6.44e-6	Pain;
PAAD	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg02027945	chr11:20618230	NA	0.34	4.87	0.37	2.77e-6	Pursuit maintenance gain;
PAAD	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.42	0.46	1.63e-9	Educational attainment;
PAAD	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg09695851	chr17:3907499	NA	-0.67	-6.99	-0.49	8.11e-11	Type 2 diabetes;
PAAD	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg15676125	chr6:33679581	C6orf125	0.49	4.83	0.36	3.34e-6	Plateletcrit;
PAAD	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.6	5.21	0.39	6.09e-7	QRS duration;
PAAD	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.54	5.11	0.38	9.62e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.57	7.22	0.51	2.27e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	6.71	0.48	3.54e-10	Response to antipsychotic treatment;
PAAD	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.64	6.21	0.45	4.72e-9	Breast cancer;
PAAD	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg07395648	chr5:131743802	NA	-0.57	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.49	-0.57	1.79e-14	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg01763666	chr17:80159506	CCDC57	0.43	4.37	0.33	2.32e-5	Life satisfaction;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05492660	chr2:71205564	ANKRD53	-0.64	-6.42	-0.46	1.67e-9	Lung cancer in ever smokers;
PAAD	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg19337854	chr7:99768885	GPC2	0.44	4.56	0.35	1.05e-5	Coronary artery disease;
PAAD	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.64	0.42	8.02e-8	Alzheimer's disease (late onset);
PAAD	cis	rs16975963	0.793	rs73034946	chr19:38460493	T/C	cg08679971	chr19:38281047	NA	0.55	5.24	0.39	5.4e-7	Longevity;
PAAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg01815783	chr4:1047043	NA	0.45	4.34	0.33	2.61e-5	Recombination rate (females);
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg09699651	chr6:150184138	LRP11	0.47	5.0	0.38	1.54e-6	Lung cancer;
PAAD	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.57	5.48	0.41	1.72e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg19767477	chr5:127420684	SLC12A2	-0.58	-4.69	-0.36	6.11e-6	Ileal carcinoids;
PAAD	cis	rs11264799	0.813	rs6694875	chr1:157709128	C/T	cg18268488	chr1:157545234	FCRL4	0.55	5.23	0.39	5.46e-7	IgA nephropathy;
PAAD	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg27411982	chr8:10470053	RP1L1	0.5	5.2	0.39	6.33e-7	Retinal vascular caliber;
PAAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.55	-0.41	1.22e-7	Immature fraction of reticulocytes;
PAAD	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.62	-5.21	-0.39	5.96e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-1.14	-11.64	-0.69	8.49e-23	Hair shape;
PAAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg16876255	chr19:9731953	ZNF561	0.96	4.27	0.33	3.38e-5	Pursuit maintenance gain;
PAAD	cis	rs7608623	0.810	rs7572949	chr2:24162018	T/C	cg08917208	chr2:24149416	ATAD2B	-0.45	-4.38	-0.33	2.22e-5	Obesity-related traits;
PAAD	cis	rs655641	0.539	rs609903	chr11:85740409	A/G	cg07180834	chr11:85838833	NA	-0.47	-5.15	-0.39	7.8e-7	Platelet count;
PAAD	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg00543991	chr22:32367038	NA	1.18	7.22	0.51	2.26e-11	Childhood ear infection;
PAAD	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.62	5.83	0.43	3.23e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.58	5.36	0.4	3.04e-7	Self-reported allergy;
PAAD	cis	rs4450131	0.522	rs876352	chr10:126337350	C/T	cg20435097	chr10:126320824	FAM53B	0.5	5.02	0.38	1.44e-6	White blood cell count (basophil);
PAAD	cis	rs900145	0.906	rs2279286	chr11:13298519	G/A	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.59	5.98	0.44	1.52e-8	Platelet count;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.93e-6	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14119137	chr6:24477147	GPLD1	-0.63	-7.4	-0.51	8.78e-12	Obesity-related traits;
PAAD	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.5	-4.54	-0.35	1.16e-5	Red blood cell count;
PAAD	cis	rs733175	0.953	rs4485819	chr4:10037393	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	5.37	0.4	2.95e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.5	5.47	0.41	1.81e-7	Major depressive disorder;
PAAD	cis	rs2292030	1	rs2292030	chr5:132161294	G/A	cg16419906	chr5:132167176	NA	-0.58	-4.38	-0.33	2.22e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.46	-0.52	6.31e-12	Testicular germ cell tumor;
PAAD	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.17	16.91	0.81	9.54e-37	Cognitive function;
PAAD	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg09127314	chr1:152161683	NA	0.73	5.23	0.39	5.44e-7	Atopic dermatitis;
PAAD	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Reticulocyte count;High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.76	5.45	0.4	2.03e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22962425	chr14:58891595	TIMM9	0.56	6.47	0.46	1.24e-9	Smoking initiation;
PAAD	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.64	-6.83	-0.48	1.89e-10	Dementia with Lewy bodies;
PAAD	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.45	-4.52	-0.34	1.23e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7594192	0.744	rs4356658	chr2:199369404	G/A	cg01558212	chr2:200327336	NA	0.36	4.73	0.36	5.17e-6	Educational attainment;
PAAD	cis	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg16898833	chr6:26189333	HIST1H4D	0.92	4.65	0.35	7.16e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.78	-8.89	-0.58	1.68e-15	Age at first birth;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10813610	chr7:150783881	AGAP3	0.64	7.33	0.51	1.25e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.6	5.66	0.42	7.17e-8	Restless legs syndrome;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22605799	chr17:65374541	PITPNC1	-0.62	-6.54	-0.47	8.8e-10	Smoking initiation;
PAAD	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.41	13.34	0.73	2.31e-27	Corneal structure;
PAAD	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06671706	chr8:8559999	CLDN23	-0.57	-5.19	-0.39	6.61e-7	Obesity-related traits;
PAAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg26893134	chr6:116381904	FRK	-0.44	-7.06	-0.5	5.44e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.53	6.41	0.46	1.78e-9	Sitting height ratio;
PAAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs564309	0.764	rs572442	chr1:228553651	T/C	cg01328119	chr1:228783545	DUSP5P	0.65	4.29	0.33	3.12e-5	Hip circumference (psychosocial stress interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08015590	chr7:2281924	NUDT1;FTSJ2	-0.75	-6.54	-0.47	8.73e-10	Neuroticism;
PAAD	cis	rs72827839	0.654	rs56104550	chr17:45941794	A/T	cg23391107	chr17:45924227	SP6	0.71	6.32	0.46	2.76e-9	Ease of getting up in the morning;
PAAD	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg26174226	chr8:58114915	NA	-0.61	-4.52	-0.34	1.22e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11411865	chr7:2701802	TTYH3	0.59	4.37	0.33	2.28e-5	Bipolar disorder;
PAAD	cis	rs8032158	0.963	rs56333939	chr15:56124535	T/C	cg02198044	chr15:56286336	NEDD4	-0.52	-5.49	-0.41	1.66e-7	Keloid;
PAAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.72	-6.64	-0.47	5.14e-10	DNA methylation (variation);
PAAD	cis	rs75920871	1.000	rs61905680	chr11:116836031	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9525927	0.570	rs9533797	chr13:44799368	A/C	cg19190762	chr13:44806055	NA	0.41	4.56	0.35	1.03e-5	Dupuytren's disease;
PAAD	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.95	0.43	1.79e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.68	9.72	0.62	1.14e-17	Breast size;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.63	7.41	0.52	8.18e-12	Lung cancer;
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.49	8.79	0.58	2.97e-15	Multiple system atrophy;
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg23985595	chr17:80112537	CCDC57	0.45	5.56	0.41	1.16e-7	Life satisfaction;
PAAD	cis	rs11811982	0.793	rs77755024	chr1:227357784	T/A	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs727479	0.545	rs12899068	chr15:51538810	A/G	cg21478137	chr15:51532386	CYP19A1	0.65	7.39	0.51	9.27e-12	Estradiol levels;
PAAD	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs597583	0.806	rs2276339	chr11:117395481	G/A	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.25	-0.45	4e-9	Putamen volume;
PAAD	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.85e-6	Personality dimensions;
PAAD	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	1.28	8.07	0.55	2e-13	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.33	0.4	3.46e-7	Lung cancer in ever smokers;
PAAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.11e-11	Coronary artery disease;
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.79	-5.94	-0.43	1.9e-8	Initial pursuit acceleration;
PAAD	cis	rs11235843	1.000	rs72974833	chr11:73375104	A/C	cg18195628	chr11:73498948	MRPL48	0.79	4.28	0.33	3.36e-5	Hand grip strength;
PAAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	6.21e-16	Menopause (age at onset);
PAAD	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg03252829	chr6:39282164	KCNK17	-0.54	-5.52	-0.41	1.45e-7	Type 2 diabetes;
PAAD	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-4.45	-0.34	1.64e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.55e-11	Chronic sinus infection;
PAAD	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.85	-6.02	-0.44	1.28e-8	Coronary artery disease;
PAAD	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg22467129	chr15:76604101	ETFA	-0.54	-5.13	-0.38	8.61e-7	Blood metabolite levels;
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.56	-5.23	-0.39	5.46e-7	Menarche (age at onset);
PAAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.61	-4.62	-0.35	7.97e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs28655083	0.509	rs664408	chr16:77104820	A/G	cg06128999	chr16:77247126	NA	-0.37	-4.38	-0.33	2.18e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04734688	chr11:17229674	NA	0.56	6.45	0.46	1.44e-9	Monocyte percentage of white cells;
PAAD	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.59	5.64	0.42	8.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.64	5.08	0.38	1.08e-6	Osteoarthritis;
PAAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	1.08	13.68	0.74	2.83e-28	Breast cancer;
PAAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg17366294	chr4:99064904	C4orf37	0.47	5.26	0.39	4.86e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs71520386	0.583	rs35322907	chr7:22846211	T/G	cg04907244	chr7:22894795	SNORD93	0.45	4.8	0.36	3.83e-6	Fibrinogen levels;
PAAD	cis	rs16975963	0.644	rs12459013	chr19:38129497	C/G	cg08679971	chr19:38281047	NA	0.47	4.61	0.35	8.3e-6	Longevity;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.54	5.14	0.39	8.15e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7818688	0.654	rs11783262	chr8:95979816	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07013032	chr16:23074005	USP31	0.59	6.39	0.46	1.91e-9	Smoking initiation;
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-0.8	-6.41	-0.46	1.75e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg26248373	chr2:1572462	NA	-1.09	-7.16	-0.5	3.22e-11	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3026101	0.671	rs739768	chr17:5290703	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg22325292	chr17:80708367	FN3K	0.6	4.27	0.33	3.38e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11239695	chr6:26458489	BTN2A1	0.61	6.44	0.46	1.5e-9	Myopia (pathological);
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.76	6.23	0.45	4.25e-9	Alzheimer's disease;
PAAD	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg23254163	chr1:152506842	NA	0.46	4.51	0.34	1.3e-5	Hair morphology;
PAAD	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg05805236	chr11:65401703	PCNXL3	-0.59	-6.36	-0.46	2.21e-9	Acne (severe);
PAAD	cis	rs28489187	0.706	rs233099	chr1:85826194	T/C	cg16011679	chr1:85725395	C1orf52	0.53	4.97	0.37	1.75e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg24330906	chr2:85765176	MAT2A	0.55	5.32	0.4	3.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9913156	0.517	rs9893958	chr17:4611388	A/G	cg19197139	chr17:4613644	ARRB2	0.61	6.48	0.47	1.23e-9	Lymphocyte counts;
PAAD	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.96	-8.55	-0.57	1.25e-14	Body mass index;
PAAD	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg21300403	chr2:198650112	BOLL	0.48	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.72	-10.37	-0.64	2.16e-19	Birth weight;
PAAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg14343924	chr8:8086146	FLJ10661	0.53	4.69	0.36	6.08e-6	Mood instability;
PAAD	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.02	12.88	0.72	3.92e-26	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg23719950	chr11:63933701	MACROD1	-0.5	-4.36	-0.33	2.35e-5	Platelet count;
PAAD	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.72	6.34	0.46	2.46e-9	Platelet count;
PAAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs2030114	0.848	rs11865992	chr16:51585139	A/C	cg03758633	chr16:51611768	NA	0.58	4.66	0.35	6.76e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	trans	rs9345521	1.000	rs9345520	chr6:65511155	T/C	cg26414000	chr1:85721327	C1orf52	0.54	6.48	0.47	1.21e-9	Iris color (a* coordinate);
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	5.17	0.39	7.39e-7	Menarche (age at onset);
PAAD	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.57	5.68	0.42	6.59e-8	Platelet count;
PAAD	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.38	-0.51	9.74e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg16322479	chr5:444228	EXOC3;C5orf55	0.46	5.3	0.4	3.96e-7	Cystic fibrosis severity;
PAAD	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg00277334	chr10:82204260	NA	0.57	4.5	0.34	1.35e-5	Post bronchodilator FEV1;
PAAD	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.49	5.11	0.38	9.33e-7	Plasma plasminogen activator levels;
PAAD	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.78	4.44	0.34	1.7e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.9	6.0	0.44	1.39e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.8	-9.25	-0.6	1.9e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs990171	0.538	rs4851599	chr2:103116020	C/T	cg13897122	chr2:103039542	IL18RAP	-0.47	-5.22	-0.39	5.67e-7	Lymphocyte counts;
PAAD	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.59	5.31	0.4	3.88e-7	Schizophrenia;
PAAD	cis	rs59888335	0.894	rs7628798	chr3:80779795	C/A	cg21735741	chr3:80819488	NA	0.54	4.73	0.36	5.03e-6	Schizophrenia;
PAAD	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.28	-0.71	1.6e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1075265	0.870	rs6724389	chr2:54212835	G/A	cg04546899	chr2:54196757	PSME4	0.33	4.82	0.36	3.46e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg26205652	chr12:48591994	NA	0.85	7.74	0.53	1.26e-12	Longevity (90 years and older);
PAAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg15061591	chr7:98625706	SMURF1	-0.49	-4.58	-0.35	9.45e-6	Breast cancer;
PAAD	cis	rs4774830	0.744	rs77377502	chr15:56307889	A/G	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs6662572	0.901	rs58692133	chr1:46067269	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	4.32	0.33	2.79e-5	Blood protein levels;
PAAD	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs9810890	1.000	rs73210622	chr3:128659748	A/G	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg23461800	chr14:103021989	NA	-0.58	-4.4	-0.34	1.99e-5	Platelet count;
PAAD	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs2033908	0.620	rs10765996	chr11:12853043	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-4.67	-0.35	6.58e-6	Sitting height ratio;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.58	7.38	0.51	9.87e-12	Longevity;
PAAD	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs8033133	0.706	rs12594112	chr15:25350127	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.44	-4.67	-0.35	6.63e-6	Blood osmolality (transformed sodium);
PAAD	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg04330084	chr7:123175371	IQUB	0.52	4.47	0.34	1.5e-5	Plateletcrit;Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03490545	chr3:187397549	NA	0.57	6.47	0.46	1.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	1e-6	Electrocardiographic conduction measures;
PAAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.71	-6.71	-0.48	3.64e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.53	5.33	0.4	3.54e-7	Blood metabolite levels;
PAAD	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.83	-0.43	3.14e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg16898833	chr6:26189333	HIST1H4D	0.74	4.59	0.35	9.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.59	-5.78	-0.42	4.05e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7077446	0.733	rs6584467	chr10:103748333	G/A	cg11685391	chr10:103594334	KCNIP2	-0.36	-4.37	-0.33	2.26e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2594989	0.943	rs9836824	chr3:11463517	G/A	cg01796438	chr3:11312864	ATG7	-0.58	-4.38	-0.34	2.16e-5	Circulating chemerin levels;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg01620082	chr3:125678407	NA	-1.48	-8.22	-0.55	8.15e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg00076195	chr5:140892677	NA	0.45	4.82	0.36	3.42e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs3993105	0.511	rs7941761	chr11:13351181	C/T	cg15603424	chr11:13300592	ARNTL	-0.53	-4.31	-0.33	2.93e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg19423196	chr10:82049429	MAT1A	0.33	4.55	0.35	1.1e-5	Sarcoidosis;
PAAD	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	4.39	0.34	2.09e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.64	-0.35	7.46e-6	Menarche (age at onset);
PAAD	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.68	7.02	0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs939584	0.935	rs73139123	chr2:630075	C/T	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.22e-6	Body mass index;
PAAD	cis	rs3018712	0.590	rs10896362	chr11:68493243	A/G	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.57	-0.41	1.13e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg13639937	chr1:92012655	NA	-0.42	-4.29	-0.33	3.12e-5	Breast cancer;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.66	7.15	0.5	3.37e-11	Leprosy;
PAAD	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg21351543	chr2:191399470	TMEM194B	-0.7	-5.29	-0.39	4.17e-7	Diastolic blood pressure;
PAAD	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.72	-7.76	-0.53	1.18e-12	Type 2 diabetes;
PAAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg22508957	chr16:3507546	NAT15	0.82	6.27	0.45	3.62e-9	Tuberculosis;
PAAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.44	0.56	2.32e-14	Menopause (age at onset);
PAAD	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg19630374	chr17:18023558	MYO15A	-0.56	-5.93	-0.43	1.99e-8	Total body bone mineral density;
PAAD	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg02415014	chr8:143852576	LYNX1	-0.52	-6.31	-0.46	2.89e-9	Urinary tract infection frequency;
PAAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.08e-5	Vitiligo;
PAAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-5.31	-0.4	3.88e-7	Daytime sleep phenotypes;
PAAD	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.7	5.39	0.4	2.68e-7	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4739066	0.579	rs16929963	chr8:63876244	A/G	cg25248160	chr8:63776642	NKAIN3	0.76	4.84	0.37	3.16e-6	Myocardial infarction;
PAAD	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16417436	chr16:28758564	NA	0.45	4.32	0.33	2.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6679454	0.843	rs61770278	chr1:58345890	C/T	cg17491850	chr1:57888480	DAB1	-0.39	-4.38	-0.33	2.17e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.98	0.37	1.74e-6	Menarche (age at onset);
PAAD	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.68	6.75	0.48	2.88e-10	Cancer;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg10621924	chr7:39171070	POU6F2	0.33	5.24	0.39	5.33e-7	IgG glycosylation;
PAAD	cis	rs911119	0.955	rs67997662	chr20:23592864	G/A	cg16589663	chr20:23618590	CST3	0.8	6.92	0.49	1.15e-10	Chronic kidney disease;
PAAD	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.28	-0.39	4.32e-7	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.5	-0.34	1.34e-5	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18576335	chr17:8110165	AURKB	0.61	7.06	0.5	5.59e-11	Body fat percentage;
PAAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.71	-0.36	5.6e-6	Type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.97	0.37	1.76e-6	Parkinson's disease;
PAAD	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.86	-8.62	-0.57	7.9e-15	Breast cancer;
PAAD	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.5	-4.86	-0.37	2.93e-6	Diastolic blood pressure;
PAAD	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-5.11	-0.38	9.38e-7	Mean platelet volume;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.68	6.06	0.44	1.04e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19183248	chr4:152364959	FAM160A1	-0.6	-6.37	-0.46	2.11e-9	Obesity-related traits;
PAAD	cis	rs73416724	0.688	rs113283188	chr6:43355266	A/C	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03404452	chr11:1674150	HCCA2	-0.56	-6.39	-0.46	1.93e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.97e-5	Schizophrenia;
PAAD	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.56	-4.88	-0.37	2.6e-6	Obesity-related traits;
PAAD	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg24737193	chr18:12778029	NA	0.63	5.32	0.4	3.62e-7	Inflammatory skin disease;
PAAD	cis	rs7202877	0.656	rs37596	chr16:75498320	C/A	cg03315344	chr16:75512273	CHST6	-0.59	-5.24	-0.39	5.32e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.61	7.08	0.5	5.09e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62264129	0.500	rs13316383	chr3:112039067	C/G	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.03	-0.38	1.36e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.9e-5	Rheumatoid arthritis;
PAAD	cis	rs1419980	0.730	rs11533525	chr12:7750251	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23659337	chr14:72983722	RGS6	-0.63	-6.46	-0.46	1.31e-9	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg19223190	chr17:80058835	NA	0.54	5.64	0.42	8.23e-8	Life satisfaction;
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.29	-0.33	3.14e-5	Tonsillectomy;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.93	-0.54	4.27e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg01852476	chr1:2232063	SKI	-0.28	-4.61	-0.35	8.3e-6	Ulcerative colitis;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	1.06	8.66	0.57	6.38e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs367943	0.576	rs10074024	chr5:112980820	G/A	cg12552261	chr5:112820674	MCC	0.56	5.85	0.43	2.9e-8	Type 2 diabetes;
PAAD	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg12193833	chr17:30244370	NA	-0.63	-4.39	-0.34	2.12e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.55	-0.35	1.08e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg14829360	chr17:73884958	NA	-0.68	-5.99	-0.44	1.49e-8	Psoriasis;
PAAD	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.11	0.44	8.09e-9	Rheumatoid arthritis;
PAAD	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	4.42	0.34	1.85e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10958605	0.761	rs724323	chr8:40038864	C/T	cg14545590	chr8:40388592	ZMAT4	0.43	4.77	0.36	4.23e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs7727544	0.545	rs17674015	chr5:131361778	C/A	cg14196790	chr5:131705035	SLC22A5	0.42	4.47	0.34	1.51e-5	Blood metabolite levels;
PAAD	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg22467129	chr15:76604101	ETFA	0.51	4.77	0.36	4.33e-6	Blood metabolite levels;
PAAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.73	-7.04	-0.5	6.25e-11	Monocyte count;
PAAD	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.07	0.38	1.15e-6	Common traits (Other);
PAAD	cis	rs6782025	0.837	rs1795421	chr3:120756057	G/A	cg16417163	chr3:121280760	NA	0.45	4.67	0.35	6.47e-6	Aging (facial);
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg17551891	chr7:1960795	MAD1L1	-0.41	-4.47	-0.34	1.5e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00149659	chr3:10157352	C3orf10	0.55	4.35	0.33	2.53e-5	Alzheimer's disease;
PAAD	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.15	-0.39	7.98e-7	Subjective well-being;
PAAD	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.39	0.51	9.29e-12	IgG glycosylation;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03644271	chr11:18415989	LDHA	0.55	6.39	0.46	1.94e-9	Monocyte percentage of white cells;
PAAD	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.49	-0.34	1.4e-5	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs4908768	0.501	rs6577502	chr1:8615577	T/C	cg20416874	chr1:8611966	RERE	-0.46	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs793571	0.915	rs11071400	chr15:59183646	T/C	cg08898775	chr15:59042684	ADAM10	-0.39	-4.47	-0.34	1.54e-5	Schizophrenia;
PAAD	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	8.34	0.56	4.18e-14	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.41	0.34	1.92e-5	Tonsillectomy;
PAAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg18833306	chr6:118973337	C6orf204	-0.58	-4.71	-0.36	5.46e-6	Diastolic blood pressure;
PAAD	cis	rs12826942	1.000	rs12826942	chr12:42796300	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	4.96	0.37	1.89e-6	Coronary artery disease;
PAAD	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-4.76	-0.36	4.55e-6	Mood instability;
PAAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.54	4.59	0.35	9.09e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg14348967	chr4:10160060	NA	-0.38	-4.47	-0.34	1.49e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.69	6.85	0.49	1.69e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.59	4.93	0.37	2.11e-6	Response to antidepressants in depression;
PAAD	cis	rs7192380	0.651	rs11643240	chr16:69635916	A/G	cg05250797	chr16:70222502	NA	0.64	5.54	0.41	1.29e-7	Sjögren's syndrome;
PAAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	ch.11.42038R	chr11:967971	AP2A2	0.64	6.25	0.45	3.96e-9	Alzheimer's disease (late onset);
PAAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg23346134	chr3:49453900	TCTA	0.42	4.26	0.33	3.53e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.47	5.18	0.39	7.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg10327424	chr1:202611933	SYT2	-0.43	-4.36	-0.33	2.4e-5	Mean platelet volume;
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09826364	chr7:158789723	NA	-0.4	-5.12	-0.38	9.15e-7	Facial morphology (factor 20);
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	1.04	13.89	0.75	7.52e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-6.78	-0.48	2.53e-10	Gut microbiome composition (summer);
PAAD	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	6.79	0.48	2.32e-10	Mean platelet volume;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.67	-7.7	-0.53	1.66e-12	Renal function-related traits (BUN);
PAAD	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg24253500	chr15:84953950	NA	0.42	4.45	0.34	1.68e-5	Schizophrenia;
PAAD	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.91	11.21	0.67	1.21e-21	Dental caries;
PAAD	cis	rs1800973	0.536	rs11177576	chr12:69671660	A/G	cg20891283	chr12:69753455	YEATS4	-0.84	-4.47	-0.34	1.52e-5	Monocyte percentage of white cells;Monocyte count;Blood protein levels;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.68	6.74	0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg12310025	chr6:25882481	NA	-0.46	-4.56	-0.35	1.04e-5	Schizophrenia;
PAAD	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.73	5.82	0.43	3.29e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs2790216	1.000	rs2019022	chr10:60024052	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.39	4.58	0.35	9.8e-6	Total body bone mineral density;
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	10.05	0.63	1.52e-18	Platelet count;
PAAD	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg04733989	chr22:42467013	NAGA	-0.68	-5.35	-0.4	3.2e-7	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg12963866	chr19:57752005	ZNF805	-0.46	-4.47	-0.34	1.51e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-6.86	-0.49	1.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2373794	0.583	rs6720270	chr2:40379861	T/C	cg12449404	chr2:40437698	SLC8A1	0.54	4.52	0.34	1.22e-5	Asthma;
PAAD	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.96	8.16	0.55	1.15e-13	Bipolar disorder;
PAAD	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-8.77	-0.58	3.39e-15	Body mass index;
PAAD	cis	rs11264213	0.901	rs794222	chr1:36369024	T/C	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.98	11.76	0.69	4.18e-23	Breast cancer;
PAAD	trans	rs901683	1.000	rs71499566	chr10:45996015	T/C	cg11747279	chr17:21096632	NA	0.81	6.41	0.46	1.69e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-0.82	-8.99	-0.59	9.28e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24782146	chr19:1021307	C19orf6	0.69	6.96	0.49	9.45e-11	Obesity-related traits;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg05341575	chr12:125625032	AACS	-0.52	-4.8	-0.36	3.7e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg27490568	chr2:178487706	NA	0.41	4.47	0.34	1.49e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.71	11.1	0.67	2.4e-21	Breast cancer;
PAAD	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.44	-4.9	-0.37	2.39e-6	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.58	5.95	0.43	1.76e-8	Testicular germ cell tumor;
PAAD	cis	rs35883536	1.000	rs4243810	chr1:101139914	T/C	cg14515779	chr1:101123966	NA	-0.54	-6.83	-0.48	1.94e-10	Monocyte count;
PAAD	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg19875578	chr6:126661172	C6orf173	0.51	5.35	0.4	3.24e-7	Male-pattern baldness;
PAAD	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.59	6.21	0.45	4.89e-9	Bladder cancer;
PAAD	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-7.05	-0.5	6e-11	Coffee consumption (cups per day);
PAAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00982548	chr2:198649783	BOLL	-0.82	-5.81	-0.43	3.5e-8	Ulcerative colitis;
PAAD	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.3	-0.46	3.03e-9	Schizophrenia;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	6.17	0.45	5.99e-9	Lung function (FEV1/FVC);
PAAD	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg23920097	chr1:209922102	NA	-0.45	-4.37	-0.33	2.25e-5	Red blood cell count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14312115	chr15:34630047	SLC12A6	0.59	6.48	0.47	1.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg23895963	chr12:117471115	NA	0.48	4.31	0.33	2.91e-5	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg24375607	chr4:120327624	NA	0.55	5.25	0.39	5.15e-7	Corneal astigmatism;
PAAD	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.21	18.88	0.84	1.06e-41	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-1.05	-14.01	-0.75	3.77e-29	Height;
PAAD	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.2	-0.39	6.31e-7	Pulmonary function;
PAAD	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg16219178	chr22:29784644	AP1B1	-0.57	-6.55	-0.47	8.56e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.68	6.93	0.49	1.14e-10	Lymphocyte counts;
PAAD	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg12654155	chr4:185238627	NA	-0.44	-4.38	-0.33	2.19e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06815965	chr1:205818668	PM20D1	0.71	8.14	0.55	1.3e-13	Menarche (age at onset);
PAAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	cis	rs2637266	0.628	rs846632	chr10:78535759	C/A	cg18941641	chr10:78392320	NA	0.39	4.68	0.35	6.34e-6	Pulmonary function;
PAAD	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg03060546	chr3:49711283	APEH	0.61	6.13	0.44	7.39e-9	Resting heart rate;
PAAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs73416724	1.000	rs74766084	chr6:43287804	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs9649465	1.000	rs608447	chr7:123395983	A/G	cg04330084	chr7:123175371	IQUB	0.49	4.61	0.35	8.46e-6	Migraine;
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg07747251	chr5:1868357	NA	0.59	6.6	0.47	6.3e-10	Cardiovascular disease risk factors;
PAAD	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.71	6.3	0.46	3.05e-9	Asthma;
PAAD	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.61	-0.35	8.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.82	8.98	0.59	9.92e-16	Schizophrenia;
PAAD	cis	rs9462027	0.583	rs2814949	chr6:34656722	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-4.38	-0.33	2.2e-5	Systemic lupus erythematosus;
PAAD	cis	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg27411982	chr8:10470053	RP1L1	0.43	4.6	0.35	8.86e-6	Neuroticism;
PAAD	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg08992911	chr2:238395768	MLPH	0.7	5.43	0.4	2.22e-7	Prostate cancer;
PAAD	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs11264799	0.564	rs6691569	chr1:157648098	G/A	cg18268488	chr1:157545234	FCRL4	0.45	4.75	0.36	4.58e-6	IgA nephropathy;
PAAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7094131	0.523	rs10764342	chr10:22882081	A/G	cg19500236	chr10:22911537	PIP4K2A	0.46	5.06	0.38	1.22e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20247102	chr3:141206102	RASA2	0.65	7.12	0.5	4.07e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7932354	0.517	rs7940441	chr11:46939027	G/A	cg19486271	chr11:47235900	DDB2	-0.59	-5.9	-0.43	2.29e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.49	5.22	0.39	5.79e-7	Life satisfaction;
PAAD	cis	rs8170	0.603	rs1544940	chr19:17414843	A/T	cg01047959	chr19:17666446	GLT25D1	0.51	4.68	0.36	6.21e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.51	5.5	0.41	1.57e-7	Lung cancer;
PAAD	cis	rs4938096	0.661	rs4938095	chr11:114216020	C/T	cg00557402	chr11:114466517	FAM55D	0.66	4.58	0.35	9.79e-6	Asthma;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	1.2	9.91	0.63	3.57e-18	Obesity-related traits;
PAAD	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs12136530	0.636	rs4244001	chr1:19734368	C/T	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.78	-0.36	4.18e-6	Lead levels in blood;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg06753227	chr18:9475508	RALBP1	0.62	6.34	0.46	2.5e-9	Primary biliary cholangitis;
PAAD	cis	rs868943	0.743	rs4628134	chr6:116360141	A/G	cg05304507	chr6:116381966	FRK	0.32	6.1	0.44	8.54e-9	Total cholesterol levels;
PAAD	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg27478167	chr7:817139	HEATR2	0.72	5.87	0.43	2.62e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg02683114	chr2:24398427	C2orf84	-0.47	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-6.11	-0.44	8.05e-9	Schizophrenia;
PAAD	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.57	-6.57	-0.47	7.7e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg15676125	chr6:33679581	C6orf125	0.46	4.46	0.34	1.6e-5	Height;
PAAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04180668	chr6:163148903	PARK2;PACRG	0.65	7.63	0.53	2.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.6	0.35	8.68e-6	White blood cell count;Multiple sclerosis;
PAAD	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.72	-8.42	-0.56	2.57e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.85	-10.39	-0.64	1.89e-19	Aortic root size;
PAAD	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	1.21	15.77	0.79	8.21e-34	Longevity;
PAAD	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.88	-10.02	-0.63	1.81e-18	Morning vs. evening chronotype;
PAAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg20821713	chr7:1055600	C7orf50	-0.54	-4.48	-0.34	1.48e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg25833597	chr17:30823145	MYO1D	0.51	4.9	0.37	2.38e-6	Schizophrenia;
PAAD	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.61	6.0	0.44	1.37e-8	Endometrial cancer;
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg27394845	chr17:28928406	LRRC37B2	0.63	4.51	0.34	1.28e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg08917208	chr2:24149416	ATAD2B	0.48	4.29	0.33	3.17e-5	Asthma;
PAAD	cis	rs2492906	0.600	rs2782340	chr10:28075809	G/A	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.77	6.36	0.46	2.25e-9	Type 2 diabetes;
PAAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg02734326	chr4:10020555	SLC2A9	0.51	5.25	0.39	5.14e-7	Bone mineral density;
PAAD	cis	rs11264213	0.591	rs4653158	chr1:36556187	G/A	cg27506609	chr1:36549197	TEKT2	-0.7	-4.7	-0.36	5.69e-6	Schizophrenia;
PAAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.6	-6.49	-0.47	1.12e-9	Coronary artery disease;
PAAD	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.58	4.65	0.35	7.03e-6	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.74	7.57	0.52	3.3e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.34	4.73	0.36	4.99e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.12	15.57	0.78	2.71e-33	Schizophrenia;
PAAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg26072250	chr5:443457	EXOC3;C5orf55	0.68	5.21	0.39	6.18e-7	Fat distribution (HIV);
PAAD	cis	rs2712184	0.756	rs715049	chr2:217657102	C/T	cg05032264	chr2:217675019	NA	-0.56	-6.32	-0.46	2.76e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg17346650	chr17:80929145	B3GNTL1	0.35	4.27	0.33	3.42e-5	Glycated hemoglobin levels;
PAAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg02376097	chr19:46275166	DMPK	-0.58	-5.88	-0.43	2.57e-8	Coronary artery disease;
PAAD	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-5.89	-0.43	2.35e-8	Obesity (extreme);
PAAD	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.76	8.21	0.55	8.61e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg10556349	chr10:835070	NA	0.58	5.21	0.39	5.98e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.54	-5.21	-0.39	6.04e-7	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16218377	chr11:34073324	CAPRIN1	-0.58	-6.63	-0.47	5.49e-10	Body fat percentage;
PAAD	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg22089800	chr15:90895588	ZNF774	-0.56	-5.36	-0.4	3.07e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.44	0.52	6.75e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.8	-7.37	-0.51	1.04e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg25620797	chr2:55921863	PNPT1	-0.47	-4.28	-0.33	3.33e-5	Metabolic syndrome;
PAAD	cis	rs1042026	0.813	rs10008281	chr4:100142302	C/A	cg09112717	chr4:100009950	ADH5	-0.57	-5.0	-0.38	1.58e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg01884057	chr2:25150051	NA	-0.38	-4.63	-0.35	7.79e-6	Body mass index in non-asthmatics;
PAAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.24	-6.68	-0.48	4.22e-10	Body mass index;
PAAD	cis	rs12999616	0.696	rs56035334	chr2:98329047	T/G	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs7631605	0.905	rs4647250	chr3:37049098	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.59	0.35	9.18e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-1.23	-9.43	-0.61	6.66e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg09399716	chr2:46890238	NA	-0.72	-5.95	-0.43	1.76e-8	Height;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg08219700	chr8:58056026	NA	0.7	5.58	0.41	1.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.39	4.8	0.36	3.75e-6	Sitting height ratio;
PAAD	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.69	7.64	0.53	2.29e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	1.03	11.97	0.7	1.13e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs10943724	0.679	rs10806194	chr6:81265682	C/T	cg19323245	chr6:80716898	TTK	-0.43	-4.43	-0.34	1.78e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colorectal cancer;
PAAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg24253500	chr15:84953950	NA	0.59	6.71	0.48	3.61e-10	Schizophrenia;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15574972	chr11:65265134	MALAT1	-0.55	-6.3	-0.46	3.04e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.59e-21	Breast cancer;
PAAD	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg06740227	chr12:86229804	RASSF9	-0.55	-5.26	-0.39	4.73e-7	Major depressive disorder;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg11965913	chr1:205819406	PM20D1	0.82	9.01	0.59	8.05e-16	Monocyte percentage of white cells;
PAAD	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs9942416	0.533	rs12109251	chr5:75024240	C/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.53	4.52	0.34	1.24e-5	Age-related disease endophenotypes;
PAAD	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.92	7.06	0.5	5.59e-11	Alzheimer's disease;
PAAD	cis	rs11166927	0.967	rs7834010	chr8:140791732	A/C	cg16909799	chr8:140841666	TRAPPC9	0.6	6.73	0.48	3.19e-10	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs7551222	0.680	rs2169137	chr1:204497913	G/C	cg01064725	chr1:204461714	NA	-0.56	-4.9	-0.37	2.42e-6	Schizophrenia;
PAAD	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02743256	chr7:2109353	MAD1L1	-0.73	-5.17	-0.39	7.21e-7	Neuroticism;
PAAD	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg18265118	chr7:2139243	MAD1L1	0.52	4.26	0.33	3.64e-5	Neuroticism;
PAAD	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg21269045	chr12:125625041	AACS	-0.47	-4.69	-0.36	6e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.73	-0.42	5.3e-8	Coronary artery disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24536410	chr11:82611753	C11orf82;PRCP	-0.6	-6.38	-0.46	2.02e-9	Lung cancer in ever smokers;
PAAD	cis	rs7715811	0.913	rs4368727	chr5:13770248	C/T	cg07548982	chr5:13769939	DNAH5	-0.56	-5.44	-0.4	2.06e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.39	0.46	1.91e-9	Lung cancer in ever smokers;
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.66	7.38	0.51	9.44e-12	Menarche (age at onset);
PAAD	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg26695010	chr11:65641043	EFEMP2	0.55	5.16	0.39	7.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.71	0.42	5.62e-8	Adiposity;
PAAD	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.84	-0.37	3.1e-6	High light scatter reticulocyte count;
PAAD	cis	rs950881	0.932	rs72823632	chr2:102931534	C/T	cg03938978	chr2:103052716	IL18RAP	0.54	4.39	0.34	2.14e-5	Allergy;
PAAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.67	0.53	1.9e-12	Menarche (age at onset);
PAAD	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg27449745	chr7:23145252	KLHL7	-0.57	-4.97	-0.37	1.77e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.89e-5	Height;
PAAD	cis	rs365132	0.702	rs2336718	chr5:176465099	A/T	cg25401027	chr5:176370377	UIMC1	0.53	5.04	0.38	1.32e-6	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.71	-0.36	5.43e-6	Tuberculosis;
PAAD	cis	rs9377188	0.618	rs9285516	chr6:149398516	A/G	cg21368479	chr6:149415018	NA	0.4	4.32	0.33	2.75e-5	Cancer;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.9	7.78	0.53	1.01e-12	Alzheimer's disease;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-4.84	-0.37	3.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs988913	0.957	rs7746965	chr6:54844432	G/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.94	-0.37	2.08e-6	Menarche (age at onset);
PAAD	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg09856410	chr20:34287384	ROMO1;NFS1	-0.66	-4.38	-0.33	2.19e-5	Neuroticism;
PAAD	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.89	-0.43	2.35e-8	Mood instability;
PAAD	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.55	5.79	0.43	3.85e-8	Dupuytren's disease;
PAAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.24	0.45	4.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-1.11	-4.95	-0.37	1.95e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs580384	0.786	rs580358	chr3:62732799	A/C	cg04570624	chr3:62673394	CADPS	0.49	4.48	0.34	1.49e-5	Breast size;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09597638	chr17:3907349	NA	0.65	6.13	0.45	7.2e-9	Type 2 diabetes;
PAAD	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg15192750	chr16:69999425	NA	-0.77	-6.06	-0.44	1.03e-8	IgE levels;
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg15691649	chr6:25882328	NA	-0.49	-4.44	-0.34	1.73e-5	Blood metabolite levels;
PAAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs2658782	1.000	rs2605585	chr11:93171862	C/T	cg15737290	chr11:93063684	CCDC67	0.81	6.45	0.46	1.39e-9	Pulmonary function decline;
PAAD	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.66	5.35	0.4	3.17e-7	Morning vs. evening chronotype;
PAAD	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.63	0.35	7.78e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg13880726	chr7:1868755	MAD1L1	-0.48	-4.59	-0.35	9.21e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.52	-4.96	-0.37	1.86e-6	Mortality in heart failure;
PAAD	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6594713	0.837	rs67693032	chr5:112708468	G/A	cg12552261	chr5:112820674	MCC	0.63	4.4	0.34	2.02e-5	Brain cytoarchitecture;
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.89	-9.85	-0.62	5.34e-18	Chronic sinus infection;
PAAD	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5995177	1.000	rs5995177	chr22:36309553	G/A	cg17345985	chr22:35950011	RASD2	0.7	4.49	0.34	1.42e-5	Reading disability or specific language impairment (pleiotropy);
PAAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.73	6.06	0.44	1.01e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.75	0.48	2.97e-10	IgG glycosylation;
PAAD	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg23920097	chr1:209922102	NA	-0.49	-4.39	-0.34	2.11e-5	Red blood cell count;
PAAD	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	6.75	0.48	2.93e-10	Height;
PAAD	cis	rs9888739	0.858	rs60312440	chr16:31340086	C/T	cg15817542	chr16:31343056	ITGAM	-0.46	-4.53	-0.35	1.17e-5	Systemic lupus erythematosus;
PAAD	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs600626	1.000	rs600626	chr11:75455309	A/G	cg24262691	chr11:75473276	NA	0.51	4.78	0.36	4.08e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16447950	chr5:562315	NA	-0.73	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.47	4.52	0.34	1.25e-5	Lung cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01525244	chr22:39548611	CBX7	0.57	6.78	0.48	2.52e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10031648	chr16:67210632	KIAA0895L	-0.66	-6.33	-0.46	2.65e-9	Smoking initiation;
PAAD	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.46	-5.77	-0.42	4.22e-8	Crohn's disease;
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-1.02	-11.13	-0.67	2.01e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-6.6	-0.47	6.57e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-4.36	-0.33	2.36e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.89	-0.49	1.42e-10	Migraine;Coronary artery disease;
PAAD	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-4.43	-0.34	1.79e-5	Menarche (age at onset);
PAAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.79	-9.19	-0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.92	7.04	0.5	6.13e-11	Initial pursuit acceleration;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.76	-9.11	-0.59	4.39e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.44	-4.25	-0.33	3.65e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	1.1	7.27	0.51	1.79e-11	Parkinson's disease;
PAAD	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg24626660	chr12:32551988	NA	0.39	4.33	0.33	2.7e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16982291	chr2:190715638	PMS1	-0.56	-6.47	-0.46	1.26e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.97	12.3	0.71	1.46e-24	Menopause (age at onset);
PAAD	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg09491104	chr22:46646882	C22orf40	-0.91	-5.77	-0.42	4.26e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg03199926	chr20:60860733	OSBPL2	-0.38	-4.34	-0.33	2.61e-5	Colorectal cancer;
PAAD	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg13266496	chr6:110720918	DDO	-0.46	-4.94	-0.37	2.06e-6	Platelet distribution width;
PAAD	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.9	-8.97	-0.59	1.06e-15	Neurofibrillary tangles;
PAAD	cis	rs7243821	1.000	rs11152105	chr18:52646575	A/G	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.66	5.81	0.43	3.61e-8	Neurocognitive impairment in HIV-1 infection (continuous);
PAAD	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	6.33	0.46	2.61e-9	Mean platelet volume;
PAAD	cis	rs288342	0.797	rs288258	chr2:183603236	T/C	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.93	-10.19	-0.64	6.63e-19	Parkinson's disease;
PAAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg14515779	chr1:101123966	NA	-0.48	-6.17	-0.45	6.05e-9	Monocyte count;
PAAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg11494091	chr17:61959527	GH2	-0.5	-4.31	-0.33	2.91e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.85	10.16	0.64	7.69e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.27	0.33	3.47e-5	Tonsillectomy;
PAAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.03	0.38	1.37e-6	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17886038	chr15:100273718	LYSMD4	-0.6	-6.31	-0.46	2.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg20936604	chr3:58311152	NA	-0.77	-4.39	-0.34	2.15e-5	Cholesterol, total;
PAAD	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.6	4.81	0.36	3.64e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.8	8.49	0.57	1.7e-14	DNA methylation (variation);
PAAD	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg01796438	chr3:11312864	ATG7	-0.67	-5.13	-0.38	8.85e-7	Circulating chemerin levels;
PAAD	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-4.61	-0.35	8.37e-6	Retinal vascular caliber;
PAAD	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg04705435	chr11:17411270	KCNJ11	0.64	6.65	0.47	5.06e-10	Type 2 diabetes;
PAAD	cis	rs58521262	0.649	rs464598	chr19:23131067	A/C	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs3764618	1.000	rs3764622	chr19:49506390	T/C	cg12515942	chr19:49552529	CGB8	-0.7	-4.25	-0.33	3.75e-5	Follicule stimulating hormone;
PAAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg12639453	chr1:2035780	PRKCZ	-0.59	-6.38	-0.46	2.03e-9	Height;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.79	5.66	0.42	7.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.82	5.93	0.43	2.01e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg06243866	chr13:111019493	COL4A2	-0.63	-5.95	-0.43	1.79e-8	White matter hyperintensity burden;
PAAD	cis	rs4378999	0.588	rs13061003	chr3:51077419	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.55	-4.31	-0.33	2.9e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.97	-9.68	-0.62	1.43e-17	Systemic lupus erythematosus;
PAAD	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.62	-7.64	-0.53	2.21e-12	Dementia with Lewy bodies;
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg11416102	chr8:651193	ERICH1	1.02	6.4	0.46	1.87e-9	IgG glycosylation;
PAAD	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.56	-5.03	-0.38	1.4e-6	P wave terminal force;
PAAD	cis	rs3026101	0.671	rs1806256	chr17:5314357	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.43	-4.89	-0.37	2.59e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.73	-7.25	-0.51	1.98e-11	Alcohol dependence;
PAAD	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.91	-5.78	-0.42	4.07e-8	Prostate cancer;
PAAD	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.92	-9.52	-0.61	3.73e-17	Response to antineoplastic agents;
PAAD	cis	rs73198271	0.628	rs11781258	chr8:8589758	A/G	cg01851573	chr8:8652454	MFHAS1	0.62	4.67	0.35	6.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.92	-0.37	2.23e-6	Initial pursuit acceleration;
PAAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02633599	chr2:62424849	B3GNT2	-0.6	-6.48	-0.47	1.2e-9	Smoking initiation;
PAAD	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.79	-9.29	-0.6	1.53e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.73	-7.43	-0.52	7.12e-12	Retinal vascular caliber;
PAAD	cis	rs2133450	0.526	rs12492754	chr3:7346656	A/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.1	-0.38	1.01e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg11874272	chr3:121773564	CD86	-0.42	-4.37	-0.33	2.29e-5	Multiple sclerosis;
PAAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.78	8.72	0.58	4.44e-15	Type 2 diabetes;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-7.49	-0.52	5.26e-12	Longevity;Endometriosis;
PAAD	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.73	0.36	5.03e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.67	-0.35	6.64e-6	Platelet count;
PAAD	cis	rs546131	0.600	rs7946699	chr11:34820069	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.48	4.47	0.34	1.52e-5	Lung disease severity in cystic fibrosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04326269	chr17:38219837	THRA	0.66	7.45	0.52	6.36e-12	Monocyte percentage of white cells;
PAAD	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.67	6.58	0.47	6.99e-10	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.5	4.93	0.37	2.12e-6	Pulse pressure;
PAAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.83	0.36	3.35e-6	Coronary artery disease;
PAAD	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.58	-5.47	-0.41	1.8e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.51	-0.52	4.59e-12	Chronic sinus infection;
PAAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18713168	chr3:45883381	LZTFL1	-0.65	-6.71	-0.48	3.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12580194	0.593	rs13377995	chr12:55757380	C/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.35	0.33	2.52e-5	Cancer;
PAAD	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.58	-5.71	-0.42	5.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs12936587	0.807	rs12602348	chr17:17547236	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-4.64	-0.35	7.53e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.73	7.39	0.51	9.04e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9409082	0.665	rs10156597	chr9:108941509	A/T	cg07010948	chr13:79181613	NA	-0.35	-6.63	-0.47	5.46e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs1642645	0.915	rs10890176	chr1:42503950	A/C	cg01990334	chr1:42801334	FOXJ3	-0.55	-4.96	-0.37	1.83e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-6.27	-0.45	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg20607287	chr7:12443886	VWDE	-0.75	-5.51	-0.41	1.53e-7	Coronary artery disease;
PAAD	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.48	0.34	1.44e-5	Mean corpuscular volume;
PAAD	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.46	-5.58	-0.41	1.08e-7	Colorectal cancer;
PAAD	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg11941060	chr3:133502564	NA	-0.52	-5.51	-0.41	1.51e-7	Iron status biomarkers;
PAAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	cis	rs3981351	0.833	rs2227309	chr10:115489167	G/A	cg24846397	chr10:115438155	CASP7	-0.5	-4.64	-0.35	7.61e-6	Obesity-related traits;
PAAD	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg26570165	chr1:119541833	NA	-0.48	-4.48	-0.34	1.45e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.89	8.39	0.56	3.08e-14	Response to diuretic therapy;
PAAD	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.46	-4.36	-0.33	2.39e-5	Obesity-related traits;
PAAD	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg00857998	chr1:205179979	DSTYK	0.47	4.56	0.35	1.05e-5	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
PAAD	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.18	0.55	1.06e-13	Morning vs. evening chronotype;
PAAD	trans	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.32	15.18	0.78	2.92e-32	IgG glycosylation;
PAAD	cis	rs6499755	0.712	rs31111	chr16:55378686	C/A	cg02859129	chr16:55357253	IRX6	0.36	5.04	0.38	1.29e-6	Hypospadias;
PAAD	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.6	-5.82	-0.43	3.31e-8	Coronary artery disease;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg09017928	chr7:158110068	PTPRN2	0.59	5.35	0.4	3.25e-7	Response to amphetamines;
PAAD	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	5.29	0.39	4.1e-7	LDL cholesterol;
PAAD	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs7771547	0.723	rs9394360	chr6:36550370	A/G	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs539096	0.602	rs2970610	chr1:44097530	T/C	cg12908607	chr1:44402522	ARTN	-0.4	-4.31	-0.33	2.9e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs863345	0.625	rs10752626	chr1:158528118	G/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.74	-0.36	4.78e-6	Pneumococcal bacteremia;
PAAD	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.59	4.48	0.34	1.44e-5	Vitiligo;
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg04204118	chr10:4194429	NA	0.86	4.88	0.37	2.65e-6	Major depressive disorder;
PAAD	cis	rs4356203	0.870	rs7937176	chr11:17279745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-4.74	-0.36	4.83e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg22143856	chr6:28129313	ZNF389	0.64	4.95	0.37	1.97e-6	Depression;
PAAD	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.52	4.86	0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs2882667	0.690	rs176382	chr5:138226767	A/G	cg09476006	chr5:138032270	NA	0.46	5.89	0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.67	7.09	0.5	4.71e-11	Dupuytren's disease;
PAAD	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.9	8.19	0.55	9.87e-14	Body mass index;
PAAD	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.47	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	6.29	0.45	3.19e-9	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.91	-0.49	1.23e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.41	1.1e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.11	0.55	1.6e-13	Prudent dietary pattern;
PAAD	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.72	9.3	0.6	1.42e-16	Weight;
PAAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.67	6.94	0.49	1.05e-10	Systemic lupus erythematosus;
PAAD	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg15628303	chr1:26608928	UBXN11	-0.63	-5.99	-0.44	1.46e-8	Obesity-related traits;
PAAD	trans	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.82	-9.34	-0.6	1.15e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.92	9.12	0.59	4.33e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.7	7.99	0.54	3.11e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg07979401	chr6:33739406	LEMD2	-0.54	-4.58	-0.35	9.54e-6	Schizophrenia;
PAAD	cis	rs74472562	0.661	rs4755280	chr11:44755562	A/G	cg18247223	chr11:44908673	TSPAN18	0.74	4.43	0.34	1.82e-5	Obstructive sleep apnea trait (average respiratory event duration);
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.86	10.21	0.64	5.84e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs62238980	1.000	rs62238980	chr22:32578912	C/T	cg00543991	chr22:32367038	NA	1.14	6.24	0.45	4.09e-9	Childhood ear infection;
PAAD	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.46	0.34	1.58e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg12395012	chr8:11607386	GATA4	-0.43	-4.63	-0.35	7.87e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.65	7.3	0.51	1.47e-11	Coronary artery disease;
PAAD	cis	rs6723108	0.603	rs6708336	chr2:135719132	T/A	cg26890182	chr2:135621176	ACMSD	0.32	4.51	0.34	1.29e-5	Type 2 diabetes;
PAAD	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14169450	chr9:139327907	INPP5E	0.65	6.88	0.49	1.44e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg12645284	chr15:79092878	ADAMTS7	0.5	4.39	0.34	2.14e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg00543991	chr22:32367038	NA	-1.18	-7.18	-0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.51	-4.49	-0.34	1.38e-5	IgG glycosylation;
PAAD	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.73	-0.42	5.16e-8	Menarche (age at onset);
PAAD	cis	rs7631605	0.647	rs59594366	chr3:37173774	A/C	cg17445812	chr3:36986805	TRANK1	0.33	4.39	0.34	2.15e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12044355	0.929	rs11122323	chr1:231848933	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	5.2	0.39	6.32e-7	Alzheimer's disease;
PAAD	cis	rs8181588	0.661	rs3852528	chr11:2826617	A/G	cg24047810	chr11:2162341	IGF2AS;INS-IGF2;IGF2	0.72	5.22	0.39	5.73e-7	Type 2 diabetes;
PAAD	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.74e-5	Morning vs. evening chronotype;
PAAD	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.53	-5.0	-0.38	1.58e-6	Red blood cell count;
PAAD	cis	rs528301	0.799	rs340496	chr2:45134871	G/C	cg15393275	chr2:45165193	NA	-0.48	-5.25	-0.39	5.01e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.65	7.36	0.51	1.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs11794666	1.000	rs80212294	chr9:31662620	A/C	cg05628366	chr6:35744188	C6orf126	1.04	6.63	0.47	5.44e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00845593	chr15:40857396	C15orf57	-0.64	-6.32	-0.46	2.81e-9	Lung cancer in ever smokers;
PAAD	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	5.55	0.41	1.26e-7	Blood protein levels;
PAAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.43	0.34	1.82e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.79	0.36	3.96e-6	Menopause (age at onset);
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg12705353	chr12:122356852	WDR66	-0.43	-4.35	-0.33	2.44e-5	Mean corpuscular volume;
PAAD	cis	rs8077889	0.750	rs231535	chr17:41944865	T/G	cg26893861	chr17:41843967	DUSP3	-0.82	-5.92	-0.43	2.03e-8	Triglycerides;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13631	0.728	rs10118245	chr9:139979592	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.45	4.84	0.37	3.14e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.77	8.35	0.56	4e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg15017067	chr4:17643749	FAM184B	0.43	5.11	0.38	9.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	7.55	0.52	3.85e-12	Prudent dietary pattern;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs863345	0.604	rs7549581	chr1:158489704	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	trans	rs61931739	0.613	rs61927732	chr12:33678166	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.56	-0.47	7.94e-10	Morning vs. evening chronotype;
PAAD	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	1.21	7.6	0.52	2.88e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.45	-4.47	-0.34	1.51e-5	Colorectal cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg16095767	chr12:122110467	NA	0.63	7.12	0.5	4.1e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1577917	0.687	rs13197828	chr6:86805630	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-8.87	-0.58	1.91e-15	Response to antipsychotic treatment;
PAAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.5	-5.07	-0.38	1.16e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg07617317	chr6:118971624	C6orf204	0.55	4.58	0.35	9.53e-6	Renal cell carcinoma;
PAAD	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.74	7.2	0.5	2.55e-11	Asthma;
PAAD	cis	rs3736485	0.966	rs4775961	chr15:51892959	A/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.43e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.51	-4.49	-0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.57	5.14	0.38	8.24e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.82	6.07	0.44	9.83e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs72843506	0.656	rs10459970	chr17:19937341	G/A	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg11859384	chr17:80120422	CCDC57	0.48	4.85	0.37	3.02e-6	Life satisfaction;
PAAD	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.67	7.22	0.51	2.37e-11	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs1413885	0.516	rs716592	chr1:65843982	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.81	-0.43	3.6e-8	Anticoagulant levels;
PAAD	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.96	-9.78	-0.62	7.8e-18	Systemic lupus erythematosus;
PAAD	cis	rs11892454	0.544	rs7582924	chr2:25997020	T/C	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs2555155	0.633	rs2723663	chr11:6483510	G/T	cg24637308	chr11:6592297	DNHD1	0.43	4.5	0.34	1.35e-5	DNA methylation (variation);
PAAD	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.76	6.78	0.48	2.55e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg07202610	chr7:1142643	C7orf50	-0.62	-4.9	-0.37	2.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.13	0.45	7.15e-9	Height;
PAAD	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	5.94e-6	Testicular germ cell tumor;
PAAD	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.67	4.73	0.36	5.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.73	5.8	0.43	3.65e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs863345	0.604	rs12118446	chr1:158496235	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.12	-0.38	9.15e-7	Pneumococcal bacteremia;
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg03396347	chr1:1875803	NA	-0.66	-8.23	-0.56	7.84e-14	Body mass index;
PAAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg23627948	chr7:2760692	NA	0.42	4.49	0.34	1.39e-5	Loneliness (linear analysis);
PAAD	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-5.55	-0.41	1.24e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3753841	0.832	rs11164603	chr1:103248978	A/T	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2952768	1.000	rs2709380	chr2:208496410	C/T	cg22329743	chr2:208688774	PLEKHM3	0.22	4.34	0.33	2.55e-5	Opioid sensitivity;
PAAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg15691649	chr6:25882328	NA	-0.52	-4.67	-0.35	6.48e-6	Blood metabolite levels;
PAAD	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.39	-4.46	-0.34	1.61e-5	Pubertal anthropometrics;
PAAD	cis	rs2180341	0.656	rs6569491	chr6:127769338	C/G	cg24812749	chr6:127587940	RNF146	0.92	9.98	0.63	2.38e-18	Breast cancer;
PAAD	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07837209	chr13:79184101	NA	-0.47	-4.84	-0.37	3.12e-6	Large artery stroke;
PAAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.55	-5.49	-0.41	1.61e-7	Obesity-related traits;
PAAD	cis	rs2075671	0.582	rs3891039	chr7:100346654	T/C	cg07841815	chr7:100318223	EPO	-0.5	-4.97	-0.37	1.75e-6	Other erythrocyte phenotypes;
PAAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg16147221	chr4:10020634	SLC2A9	0.46	4.26	0.33	3.62e-5	Bone mineral density;
PAAD	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.16	0.8	8.02e-35	Prudent dietary pattern;
PAAD	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg10253484	chr15:75165896	SCAMP2	0.58	5.37	0.4	2.83e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6733011	0.538	rs10175560	chr2:99465418	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.56	-0.35	1.04e-5	Bipolar disorder;
PAAD	cis	rs78761021	0.597	rs1402657	chr17:9789352	A/G	cg26853458	chr17:9805074	RCVRN	-0.43	-5.1	-0.38	9.84e-7	Type 2 diabetes;
PAAD	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs10905065	0.804	rs2380202	chr10:5823397	C/T	cg11519256	chr10:5708881	ASB13	-0.53	-4.61	-0.35	8.47e-6	Menopause (age at onset);
PAAD	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.33	0.4	3.42e-7	Male-pattern baldness;
PAAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.72	7.8	0.53	9.12e-13	Menarche (age at onset);
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg12705353	chr12:122356852	WDR66	0.44	4.49	0.34	1.38e-5	Mean corpuscular volume;
PAAD	cis	rs1883415	0.750	rs2076316	chr6:24489741	A/C	cg20631270	chr6:24437470	GPLD1	0.46	4.26	0.33	3.55e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg04002187	chr5:40835754	RPL37	0.81	4.31	0.33	2.89e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.5	6.64	0.47	5.1e-10	Life satisfaction;
PAAD	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs901683	0.867	rs71496625	chr10:46086649	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.64	6.07	0.44	9.85e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.5	-5.1	-0.38	1e-6	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14075211	chr2:23643295	KLHL29	0.55	6.34	0.46	2.54e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3136739	0.681	rs78427883	chr8:41991348	A/T	cg12054981	chr8:42037387	PLAT	0.7	5.05	0.38	1.27e-6	Plasma plasminogen activator levels;
PAAD	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg08704217	chr1:110036942	CYB561D1	-0.5	-4.26	-0.33	3.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg23188684	chr11:67383651	NA	0.42	4.31	0.33	2.92e-5	Mean corpuscular volume;
PAAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.49	-4.92	-0.37	2.18e-6	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.03e-5	Breast cancer;
PAAD	cis	rs8053891	0.756	rs28629271	chr16:72003732	C/T	cg04254540	chr16:71951199	KIAA0174	-0.51	-4.36	-0.33	2.38e-5	Coronary artery disease;
PAAD	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.52	6.54	0.47	8.82e-10	Sitting height ratio;
PAAD	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.99	0.75	4.06e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg11204139	chr17:3907470	NA	-0.67	-6.88	-0.49	1.49e-10	Type 2 diabetes;
PAAD	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg02696790	chr15:75250997	RPP25	-0.4	-4.69	-0.36	6.01e-6	Caffeine consumption;
PAAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.88	0.58	1.79e-15	Schizophrenia;
PAAD	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs4750440	0.706	rs4237437	chr10:14018711	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.6	-6.47	-0.46	1.26e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9535307	0.929	rs9535340	chr13:50357873	A/C	cg04663916	chr13:50265991	EBPL	0.59	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.62	-6.6	-0.47	6.35e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.37e-17	Response to antipsychotic treatment;
PAAD	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	7.6	0.52	2.86e-12	Body mass index;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.71	-6.97	-0.49	8.94e-11	Retinal vascular caliber;
PAAD	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-7.71	-0.53	1.52e-12	Morning vs. evening chronotype;
PAAD	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	7.85	0.54	6.91e-13	Response to antipsychotic treatment;
PAAD	cis	rs11811982	0.655	rs7547092	chr1:227413438	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg03209412	chr4:183728196	NA	0.92	7.7	0.53	1.61e-12	Pediatric autoimmune diseases;
PAAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.66e-5	Aortic root size;
PAAD	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.92	-10.59	-0.65	5.63e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg14926445	chr8:58193284	C8orf71	0.65	4.7	0.36	5.78e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg06740227	chr12:86229804	RASSF9	0.59	5.37	0.4	2.95e-7	Major depressive disorder;
PAAD	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03627880	chr6:151815985	C6orf97	-0.5	-4.35	-0.33	2.53e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13918628	chr9:35610380	CD72	-0.66	-6.75	-0.48	2.97e-10	Obesity-related traits;
PAAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg03999872	chr20:62272968	STMN3	-0.76	-7.06	-0.5	5.47e-11	Atopic dermatitis;
PAAD	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.75	-0.36	4.61e-6	Mean corpuscular volume;
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.55	-0.47	8.2e-10	Life satisfaction;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg11235426	chr6:292522	DUSP22	-0.74	-7.61	-0.53	2.75e-12	Menopause (age at onset);
PAAD	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg24881330	chr22:46731750	TRMU	1.07	5.57	0.41	1.13e-7	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18458431	chr19:19739060	LPAR2	0.65	6.82	0.48	2.03e-10	Pancreatic cancer;
PAAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg08992911	chr2:238395768	MLPH	0.64	5.35	0.4	3.16e-7	Prostate cancer;
PAAD	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg10072921	chr12:121022843	NA	-0.35	-4.57	-0.35	1.02e-5	High light scatter reticulocyte count;
PAAD	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg04257695	chr17:30186438	C17orf79	-0.53	-4.42	-0.34	1.86e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg16928487	chr17:17741425	SREBF1	0.36	4.88	0.37	2.65e-6	Total body bone mineral density;
PAAD	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.63	6.24	0.45	4.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg25319279	chr11:5960081	NA	-0.73	-7.17	-0.5	3.01e-11	DNA methylation (variation);
PAAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06217245	chr20:33103252	DYNLRB1	0.4	4.83	0.36	3.35e-6	Coronary artery disease;
PAAD	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.47	-4.83	-0.36	3.28e-6	Brain structure;
PAAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg17401720	chr7:158221031	PTPRN2	-0.48	-5.09	-0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg06484146	chr7:12443880	VWDE	-0.85	-5.63	-0.42	8.58e-8	Coronary artery disease;
PAAD	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-5.95	-0.43	1.75e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-10.02	-0.63	1.82e-18	Height;
PAAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg11057378	chr10:81107060	PPIF	0.51	5.99	0.44	1.46e-8	Height;
PAAD	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.54	-0.35	1.14e-5	Educational attainment;
PAAD	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.3	-4.58	-0.35	9.68e-6	Urate levels in overweight individuals;
PAAD	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.69	-0.48	4.04e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg23465465	chr6:26364728	BTN3A2	0.82	4.42	0.34	1.9e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4740619	0.905	rs4741517	chr9:15616281	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.36	-0.33	2.43e-5	Body mass index;
PAAD	cis	rs3779195	0.697	rs1688606	chr7:97974851	G/A	cg21770322	chr7:97807741	LMTK2	0.52	4.8	0.36	3.71e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs795544	0.564	rs61016840	chr5:13761321	C/A	cg07548982	chr5:13769939	DNAH5	-0.64	-4.77	-0.36	4.22e-6	Corneal astigmatism;
PAAD	cis	rs1362153	1.000	rs1362153	chr1:44469031	T/C	cg12908607	chr1:44402522	ARTN	0.65	4.71	0.36	5.58e-6	Alcohol dependence (age at onset);
PAAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg03871329	chr12:110338662	TCHP	-0.64	-4.66	-0.35	6.91e-6	Neuroticism;
PAAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.77	8.14	0.55	1.33e-13	Renal function-related traits (BUN);
PAAD	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20487152	chr13:99095054	FARP1	-0.63	-5.76	-0.42	4.53e-8	Neuroticism;
PAAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.5	-0.34	1.36e-5	Mood instability;
PAAD	cis	rs12620999	0.589	rs6753960	chr2:238105270	C/G	cg23555395	chr2:238036564	NA	-0.44	-5.02	-0.38	1.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.62	5.04	0.38	1.33e-6	Cognitive function;
PAAD	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.86	5.54	0.41	1.31e-7	Systolic blood pressure;
PAAD	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.68	-7.84	-0.54	7.22e-13	Educational attainment;
PAAD	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.42	-0.34	1.89e-5	Lung cancer in ever smokers;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.56	6.04	0.44	1.16e-8	Longevity;Endometriosis;
PAAD	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.56	5.18	0.39	6.88e-7	Mood instability;
PAAD	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.55e-15	Chronic sinus infection;
PAAD	cis	rs12138061	1.000	rs56252615	chr1:50531611	G/C	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.67	-0.35	6.46e-6	Schizophrenia;
PAAD	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.12	0.75	1.92e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.98	8.18	0.55	1.07e-13	Neutrophil percentage of white cells;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.93	-6.27	-0.45	3.47e-9	IgG glycosylation;
PAAD	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.74	8.32	0.56	4.59e-14	Colorectal cancer;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg17372657	chr7:1216933	NA	-0.38	-4.85	-0.37	3e-6	Longevity;Endometriosis;
PAAD	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.34	-0.4	3.27e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg03161606	chr19:29218774	NA	0.58	4.38	0.33	2.24e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.82	6.15	0.45	6.7e-9	Gut microbiome composition (summer);
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg16331281	chr10:4445958	NA	0.8	5.02	0.38	1.44e-6	Major depressive disorder;
PAAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6594713	0.724	rs6883102	chr5:112757982	A/G	cg12552261	chr5:112820674	MCC	0.6	4.34	0.33	2.64e-5	Brain cytoarchitecture;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13062821	chr12:121790146	ANAPC5	-0.74	-6.6	-0.47	6.56e-10	Neuroticism;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.58	6.53	0.47	9.52e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs76793172	1.000	rs74450753	chr19:46317709	G/C	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg04289385	chr6:36355825	ETV7	-0.45	-4.71	-0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.45	4.88	0.37	2.64e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3996993	0.724	rs2749010	chr6:52626572	A/G	cg00536792	chr6:53530503	KLHL31	-0.43	-4.44	-0.34	1.71e-5	Hemoglobin concentration;
PAAD	cis	rs4727443	0.769	rs12672695	chr7:99580426	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.88	0.37	2.63e-6	Interstitial lung disease;
PAAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.54	5.64	0.42	8.07e-8	Subjective well-being;
PAAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg09796270	chr17:17721594	SREBF1	-0.46	-5.29	-0.39	4.12e-7	Total body bone mineral density;
PAAD	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.42	-5.18	-0.39	6.95e-7	Colorectal cancer;
PAAD	cis	rs4455778	0.580	rs4270913	chr7:49112389	T/C	cg26309511	chr7:48887640	NA	0.37	4.49	0.34	1.42e-5	Lung cancer in never smokers;
PAAD	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.45	4.42	0.34	1.88e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.05	0.38	1.26e-6	Childhood ear infection;
PAAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg21487550	chr3:127056955	NA	-0.36	-4.61	-0.35	8.55e-6	Interleukin-10 levels;Interleukin-13 levels;
PAAD	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.64	6.43	0.46	1.6e-9	Lymphocyte counts;
PAAD	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2271001	0.955	rs7950603	chr11:19147562	A/C	cg00161556	chr11:19138045	ZDHHC13	0.5	5.38	0.4	2.77e-7	Gut microbiome composition (winter);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02053850	chr1:202612633	SYT2	0.69	7.39	0.51	9.04e-12	Obesity-related traits;
PAAD	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.63	5.17	0.39	7.25e-7	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00461901	chr19:49653797	PPFIA3	0.67	6.75	0.48	2.95e-10	Obesity-related traits;
PAAD	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26926768	chr12:34528122	NA	0.37	4.63	0.35	7.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.42	0.34	1.89e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17125944	0.686	rs6572869	chr14:53353454	C/T	cg00686598	chr14:53173677	PSMC6	0.87	5.46	0.41	1.87e-7	Alzheimer's disease (late onset);
PAAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.92	6.98	0.49	8.47e-11	Gut microbiome composition (summer);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20215148	chr11:69357396	NA	0.51	6.45	0.46	1.44e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.55e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs288326	0.561	rs79804181	chr2:183710898	T/C	cg09997497	chr2:183902928	NCKAP1	0.81	4.45	0.34	1.64e-5	Blood protein levels;
PAAD	cis	rs16944613	0.510	rs4932350	chr15:91143438	A/G	cg15547629	chr15:90437138	AP3S2	-0.5	-4.28	-0.33	3.23e-5	Colorectal cancer;
PAAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs6750047	0.573	rs149148	chr2:38318640	G/A	cg19753864	chr2:38320028	NA	0.44	4.94	0.37	2.02e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs507080	0.733	rs541631	chr11:118571023	A/G	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.67	-0.42	6.83e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.53	5.48	0.41	1.76e-7	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14728024	chr6:90543432	CASP8AP2	0.7	7.06	0.5	5.68e-11	Neuroticism;
PAAD	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.41e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9815354	1.000	rs9828398	chr3:41895893	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.94	12.51	0.71	3.95e-25	Menopause (age at onset);
PAAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.76	-0.42	4.48e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950881	0.932	rs72823632	chr2:102931534	C/T	cg20060108	chr2:102954350	IL1RL1	0.61	4.78	0.36	4.17e-6	Allergy;
PAAD	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.77	5.91	0.43	2.16e-8	Mean platelet volume;
PAAD	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.7	-0.42	5.99e-8	P wave terminal force;
PAAD	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12292205	chr6:26970375	C6orf41	-0.49	-4.63	-0.35	7.68e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.41	-0.4	2.44e-7	Monocyte count;
PAAD	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	1.01	6.01	0.44	1.29e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs10078545	0.823	rs10942313	chr5:82130700	C/A	cg20697188	chr5:82360356	TMEM167A;SCARNA18	-0.41	-4.32	-0.33	2.78e-5	Chin dimples;
PAAD	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	1.08	7.11	0.5	4.21e-11	Mitochondrial DNA levels;
PAAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.35	0.4	3.19e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1867631	0.585	rs9787219	chr1:67080159	G/C	cg02459107	chr1:67143332	SGIP1	0.44	4.33	0.33	2.72e-5	Menopause (age at onset);
PAAD	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.94	-0.43	1.82e-8	Schizophrenia;
PAAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-7.77	-0.53	1.08e-12	Total body bone mineral density;
PAAD	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-7.58	-0.52	3.11e-12	Menarche (age at onset);
PAAD	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.57	4.59	0.35	9.28e-6	Response to antidepressants in depression;
PAAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.9e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg10518543	chr12:38710700	ALG10B	0.51	4.87	0.37	2.75e-6	Morning vs. evening chronotype;
PAAD	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-4.92	-0.37	2.25e-6	Common traits (Other);
PAAD	cis	rs1499972	0.938	rs864199	chr3:117755612	T/C	cg07612923	chr3:117604196	NA	-1.05	-6.87	-0.49	1.55e-10	Schizophrenia;
PAAD	cis	rs4073221	0.654	rs67595197	chr3:18296884	A/G	cg07694806	chr3:18168406	NA	-0.64	-4.68	-0.35	6.33e-6	Parkinson's disease;
PAAD	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg09835421	chr16:68378352	PRMT7	-0.87	-6.82	-0.48	1.99e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.72	6.85	0.49	1.7e-10	Obesity-related traits;
PAAD	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.54	-4.41	-0.34	1.98e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	0.959	rs1354293	chr11:48264370	A/G	cg04721828	chr11:48285200	OR4X1	-0.48	-6.09	-0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.67	-5.96	-0.44	1.7e-8	Mean corpuscular volume;
PAAD	cis	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg03999872	chr20:62272968	STMN3	-0.74	-6.48	-0.47	1.18e-9	Atopic dermatitis;
PAAD	cis	rs8040855	0.627	rs17541051	chr15:85649353	C/G	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs2085601	0.567	rs6846926	chr4:89949707	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs2594989	0.943	rs6784861	chr3:11465568	T/C	cg01796438	chr3:11312864	ATG7	-0.58	-4.42	-0.34	1.87e-5	Circulating chemerin levels;
PAAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-8.65	-0.57	6.94e-15	Coronary artery disease;
PAAD	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg12568669	chr8:11666485	FDFT1	0.27	4.29	0.33	3.2e-5	Morning vs. evening chronotype;
PAAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg15478930	chr2:27652102	NRBP1	0.5	4.58	0.35	9.53e-6	Total body bone mineral density;
PAAD	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6466055	0.867	rs10241415	chr7:104948076	A/G	cg04380332	chr7:105027541	SRPK2	0.64	7.13	0.5	3.78e-11	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.51	0.57	1.51e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	5.22	0.39	5.67e-7	Neuroticism;
PAAD	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg11644478	chr21:40555479	PSMG1	-0.47	-4.71	-0.36	5.62e-6	Menarche (age at onset);
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.06	-18.46	-0.83	1.18e-40	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6074578	0.649	rs6086092	chr20:134539	A/T	cg16931068	chr20:139680	DEFB127	0.39	5.08	0.38	1.11e-6	Hirschsprung disease;
PAAD	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9810890	1.000	rs73196965	chr3:128436709	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.48	-0.47	1.21e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	7.91	0.54	5.03e-13	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs795943	0.527	rs7955321	chr12:78654311	C/T	cg00023351	chr12:79187938	NA	0.62	4.42	0.34	1.88e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.71	-0.36	5.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs9463078	0.546	rs1284988	chr6:45064772	G/A	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2051773	0.567	rs11024113	chr11:17042444	G/A	cg15378786	chr11:17036137	PLEKHA7	0.53	4.53	0.34	1.2e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01947862	chr2:86116624	ST3GAL5	0.58	6.31	0.46	2.87e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg02297831	chr4:17616191	MED28	0.6	5.86	0.43	2.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10155981	0.510	rs4722158	chr7:22584183	G/A	cg05062323	chr7:22590069	NA	-0.8	-4.51	-0.34	1.27e-5	Bilirubin levels;
PAAD	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.95	11.06	0.67	3.1e-21	Blood protein levels;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.97e-5	Bipolar disorder;
PAAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg22029157	chr1:209979665	IRF6	0.68	6.3	0.45	3.1e-9	Coronary artery disease;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.04	0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.1	-0.59	4.66e-16	Prostate cancer;
PAAD	cis	rs11885103	0.554	rs2724851	chr2:528929	T/C	cg25542745	chr2:497296	NA	-0.34	-4.3	-0.33	3.07e-5	Heschl's gyrus morphology;
PAAD	cis	rs13070279	0.786	rs11716884	chr3:71809397	A/C	cg03457142	chr3:71804859	EIF4E3	-0.59	-4.67	-0.35	6.46e-6	Monocyte count;
PAAD	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.78	-9.38	-0.61	8.92e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22476893	chr17:7210162	EIF5A	0.65	7.45	0.52	6.51e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10214930	0.697	rs11973492	chr7:27680389	C/T	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.1e-12	Colorectal cancer;
PAAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg15226751	chr1:10001911	LZIC	0.41	4.57	0.35	9.95e-6	Hepatocellular carcinoma;
PAAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.75	8.83	0.58	2.34e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12511749	chr12:75949788	NA	-0.54	-6.78	-0.48	2.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.42	5.24	0.39	5.36e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.78	-7.67	-0.53	1.91e-12	Primary sclerosing cholangitis;
PAAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg21351543	chr2:191399470	TMEM194B	-0.69	-5.15	-0.39	7.8e-7	Diastolic blood pressure;
PAAD	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06850241	chr22:41845214	NA	-0.52	-4.73	-0.36	5.06e-6	Vitiligo;
PAAD	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.41e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12667521	chr19:29218732	NA	0.77	7.06	0.5	5.41e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg05555928	chr11:63887634	MACROD1	-0.64	-4.85	-0.37	2.97e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg05684501	chr22:37415824	MPST;TST	0.56	6.31	0.46	2.86e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21385522	chr1:16154831	NA	0.55	4.83	0.36	3.32e-6	Dilated cardiomyopathy;
PAAD	cis	rs4713118	0.628	rs12179134	chr6:27675469	A/G	cg20933634	chr6:27740509	NA	0.74	6.38	0.46	2.04e-9	Parkinson's disease;
PAAD	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.38	-0.33	2.18e-5	Recombination measurement;
PAAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs12304921	1.000	rs61577980	chr12:51345370	G/C	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.4	-0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs322144	0.967	rs322146	chr19:11421239	T/C	cg22357700	chr19:11805638	NA	0.45	4.33	0.33	2.69e-5	Breast cancer;
PAAD	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.59	-5.31	-0.4	3.88e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-4.52	-0.34	1.22e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.29	-0.45	3.14e-9	Longevity;Endometriosis;
PAAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	trans	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg03168184	chr14:100071186	CCDC85C	0.63	6.36	0.46	2.19e-9	Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.67	-0.35	6.57e-6	Lung cancer;
PAAD	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	4.78	0.36	4.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.68	7.21	0.5	2.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.83	10.27	0.64	3.95e-19	Menopause (age at onset);
PAAD	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.97	8.89	0.58	1.68e-15	Migraine;
PAAD	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23992171	chr20:33460724	GGT7	-0.59	-6.87	-0.49	1.52e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9522267	1.000	rs9522265	chr13:112195182	A/G	cg10483660	chr13:112241077	NA	-0.51	-5.33	-0.4	3.51e-7	Hepatitis;
PAAD	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15644404	chr18:77186268	NFATC1	0.87	5.44	0.4	2.09e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.39	5.84	0.43	3.02e-8	Educational attainment (years of education);
PAAD	cis	rs12519773	0.597	rs10514370	chr5:92435481	G/T	cg18783429	chr5:92414398	NA	0.42	5.96	0.44	1.65e-8	Migraine;
PAAD	cis	rs4875857	0.551	rs664600	chr8:2855892	A/C	cg01466164	chr8:2481226	NA	-0.66	-4.42	-0.34	1.83e-5	IgG glycosylation;
PAAD	cis	rs10769945	0.730	rs217208	chr11:1974892	C/G	cg23202291	chr11:1979235	NA	-0.47	-4.35	-0.33	2.49e-5	DNA methylation (variation);
PAAD	cis	rs9217	1.000	rs9217	chr17:7363088	T/C	cg22637538	chr17:7348327	CHRNB1	-0.47	-5.2	-0.39	6.44e-7	Height;
PAAD	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg08079166	chr15:68083412	MAP2K5	0.62	4.91	0.37	2.31e-6	Restless legs syndrome;
PAAD	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-1.08	-7.77	-0.53	1.09e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.52	5.45	0.4	1.99e-7	Male-pattern baldness;
PAAD	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg27565382	chr3:53032988	SFMBT1	-0.73	-4.56	-0.35	1.05e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-4.53	-0.34	1.21e-5	Ulcerative colitis;
PAAD	cis	rs1519814	1.000	rs10087151	chr8:121172261	C/T	cg22335954	chr8:121166405	COL14A1	-0.62	-5.94	-0.43	1.85e-8	Breast cancer;
PAAD	cis	rs902774	1.000	rs115756021	chr12:53275701	A/G	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-4.38	-0.33	2.2e-5	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg15181151	chr6:150070149	PCMT1	0.58	6.28	0.45	3.42e-9	Lung cancer;
PAAD	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.61	-5.28	-0.39	4.46e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10950821	0.770	rs2893006	chr7:20687181	C/T	cg21202529	chr7:20656503	ABCB5	-0.51	-4.9	-0.37	2.44e-6	Response to statin therapy;
PAAD	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.57	4.98	0.37	1.74e-6	Common traits (Other);
PAAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs12780845	0.965	rs10795454	chr10:17214154	C/A	cg00857480	chr10:17188594	TRDMT1	-0.33	-4.25	-0.33	3.74e-5	Homocysteine levels;
PAAD	cis	rs1419980	0.730	rs11531089	chr12:7749855	G/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs73058052	0.531	rs3745475	chr19:50100295	A/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.57	-5.0	-0.38	1.59e-6	Fibrinogen levels;
PAAD	cis	rs10155981	0.510	rs28439106	chr7:22592349	T/C	cg05062323	chr7:22590069	NA	-0.9	-5.55	-0.41	1.24e-7	Bilirubin levels;
PAAD	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg20607287	chr7:12443886	VWDE	-0.72	-4.78	-0.36	4.05e-6	Coronary artery disease;
PAAD	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.42	-6.24	-0.45	4.23e-9	Subjective well-being;
PAAD	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.41	0.34	1.93e-5	Asthma;
PAAD	cis	rs12118280	0.512	rs11185301	chr1:108741228	G/A	cg11967332	chr1:108735228	SLC25A24	0.65	4.27	0.33	3.44e-5	Myeloid white cell count;
PAAD	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.71	-5.21	-0.39	5.98e-7	Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09517077	chr6:108880982	FOXO3	0.72	8.07	0.55	2.03e-13	Myopia (pathological);
PAAD	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-5.24	-0.39	5.39e-7	Vitiligo;
PAAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22601191	chr20:60968625	CABLES2	-0.51	-4.67	-0.35	6.44e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.45	-0.34	1.68e-5	Joint mobility (Beighton score);
PAAD	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg03289416	chr15:75166202	SCAMP2	0.51	4.96	0.37	1.9e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7651511	1.000	rs9808953	chr3:141249864	T/A	cg25967872	chr3:141205623	RASA2	0.51	4.6	0.35	8.69e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.48	5.02	0.38	1.46e-6	Longevity;Endometriosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02991799	chr19:35168510	ZNF302	0.67	7.24	0.51	2.05e-11	Myopia (pathological);
PAAD	cis	rs2019960	0.679	rs2648846	chr8:129179990	A/G	cg15331705	chr8:129180010	NA	-0.44	-5.9	-0.43	2.25e-8	Hodgkin's lymphoma;Multiple sclerosis;
PAAD	trans	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg21108553	chr6:28357838	ZSCAN12	-0.88	-6.43	-0.46	1.53e-9	Red blood cell count;
PAAD	cis	rs41005	0.967	rs6753101	chr2:8104849	G/T	cg03155496	chr2:8117019	LOC339788	-0.55	-5.63	-0.42	8.56e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs12138061	0.954	rs12128108	chr1:50293421	C/T	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.28	4.64	0.35	7.47e-6	Asthma;
PAAD	cis	rs9810890	1.000	rs73198855	chr3:128512664	G/A	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.38	-0.4	2.74e-7	Aortic root size;
PAAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg14703610	chr5:56206110	C5orf35	-0.57	-5.26	-0.39	4.79e-7	Initial pursuit acceleration;
PAAD	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.94	6.15	0.45	6.66e-9	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08260549	chr8:21777063	XPO7	0.58	6.31	0.46	2.94e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg24737193	chr18:12778029	NA	-0.65	-5.41	-0.4	2.36e-7	Inflammatory skin disease;
PAAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg17341477	chr12:133246679	POLE	0.73	4.97	0.37	1.81e-6	Urate levels in overweight individuals;
PAAD	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	1.25	8.42	0.56	2.62e-14	Prostate cancer;
PAAD	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.58	-0.35	9.76e-6	Daytime sleep phenotypes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11938120	chr5:56110761	MAP3K1	0.75	6.85	0.49	1.7e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.66	6.89	0.49	1.4e-10	Eye color traits;
PAAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.8	-5.42	-0.4	2.32e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6071524	0.818	rs4812317	chr20:37466529	G/A	cg09937324	chr20:37376998	ACTR5	-0.5	-4.37	-0.33	2.34e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg21546286	chr11:48923668	NA	-0.54	-5.5	-0.41	1.55e-7	HDL cholesterol;
PAAD	cis	rs3931020	0.772	rs1475396	chr1:75242396	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.57	5.76	0.42	4.46e-8	Resistin levels;
PAAD	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	cis	rs6142102	0.625	rs1883707	chr20:32552587	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-4.85	-0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.63	-6.42	-0.46	1.65e-9	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01221484	chr19:58920079	ZNF584	0.64	6.95	0.49	1.02e-10	Myopia (pathological);
PAAD	cis	rs1144333	1.000	rs1144333	chr1:76275100	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.69	7.35	0.51	1.12e-11	Blood metabolite levels;
PAAD	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.75	5.33	0.4	3.54e-7	Phospholipid levels (plasma);
PAAD	cis	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.86	-5.44	-0.4	2.05e-7	Mononucleosis;
PAAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.56	-5.83	-0.43	3.26e-8	Testicular germ cell tumor;
PAAD	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.64	-5.83	-0.43	3.24e-8	Cognitive test performance;
PAAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.7	4.88	0.37	2.6e-6	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08240335	chr3:50273314	GNAI2	0.66	6.42	0.46	1.67e-9	Obesity-related traits;
PAAD	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.54	5.95	0.43	1.8e-8	Eye color traits;
PAAD	cis	rs12410462	0.551	rs68046179	chr1:227897635	G/A	cg23173402	chr1:227635558	NA	0.55	4.27	0.33	3.48e-5	Major depressive disorder;
PAAD	cis	rs12286929	0.609	rs12791813	chr11:115091510	G/A	cg04055981	chr11:115044050	NA	0.45	4.46	0.34	1.61e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.95	-9.6	-0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.61	4.72	0.36	5.33e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.57	-6.42	-0.46	1.68e-9	Diastolic blood pressure;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg21724239	chr8:58056113	NA	0.67	5.31	0.4	3.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.56	-5.11	-0.38	9.36e-7	Diastolic blood pressure;
PAAD	cis	rs7598759	0.679	rs6437019	chr2:232327707	T/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.53	-0.34	1.2e-5	Noise-induced hearing loss;
PAAD	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.51	-5.56	-0.41	1.18e-7	Motion sickness;
PAAD	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.77	8.57	0.57	1.12e-14	Prostate cancer;
PAAD	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.36	-4.25	-0.33	3.72e-5	Colorectal cancer;
PAAD	cis	rs12533831	0.667	rs2257090	chr7:150883761	C/T	cg25403974	chr7:150105495	LOC728743	0.5	4.61	0.35	8.39e-6	Childhood ear infection;
PAAD	cis	rs9640161	0.789	rs68107602	chr7:150054146	C/T	cg10018233	chr7:150070692	REPIN1	0.65	6.92	0.49	1.18e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.51	-4.46	-0.34	1.6e-5	Vitiligo;
PAAD	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs7932354	0.583	rs7107778	chr11:46860855	C/T	cg19486271	chr11:47235900	DDB2	-0.57	-5.65	-0.42	7.55e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.47	7.01	0.49	7.33e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.12	0.38	9.3e-7	Coronary artery disease;
PAAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.93	10.87	0.66	1.03e-20	IgG glycosylation;
PAAD	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.49	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	4.98	0.37	1.73e-6	Height;
PAAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.64	9.98	0.63	2.31e-18	Diastolic blood pressure;
PAAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.7	7.33	0.51	1.28e-11	Menarche (age at onset);
PAAD	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg02404636	chr22:31891804	SFI1	-0.6	-5.45	-0.4	1.98e-7	Colorectal cancer;
PAAD	cis	rs16867321	0.671	rs1544848	chr2:181487422	A/G	cg23363182	chr2:181467187	NA	-0.66	-4.4	-0.34	2e-5	Obesity;
PAAD	cis	rs6604026	0.656	rs34084844	chr1:93387592	A/G	cg13858687	chr1:93297071	RPL5	0.5	4.56	0.35	1.06e-5	Multiple sclerosis;
PAAD	cis	rs9810890	1.000	rs41266497	chr3:128526207	A/G	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.64	-7.7	-0.53	1.62e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg20302533	chr7:39170763	POU6F2	0.38	5.45	0.4	2.03e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.65	6.53	0.47	9.11e-10	Depressive symptoms;
PAAD	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.99	12.93	0.72	2.97e-26	Menopause (age at onset);
PAAD	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg09491104	chr22:46646882	C22orf40	-0.96	-6.17	-0.45	5.95e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.61	6.42	0.46	1.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.76	5.89	0.43	2.35e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg15660573	chr17:549704	VPS53	-0.85	-8.61	-0.57	8.77e-15	Prostate cancer;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-7.29	-0.51	1.62e-11	Longevity;Endometriosis;
PAAD	cis	rs7187994	0.848	rs8051512	chr16:84781101	C/G	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.95	12.58	0.71	2.48e-25	Menopause (age at onset);
PAAD	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg06872176	chr1:68697386	GPR177	-0.63	-6.54	-0.47	9.02e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.97	0.44	1.58e-8	Schizophrenia;
PAAD	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.8	7.66	0.53	2.08e-12	Neuroticism;
PAAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.66	0.35	6.92e-6	Blood metabolite levels;
PAAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.82	-5.2	-0.39	6.45e-7	Tuberculosis;
PAAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.46	5.77	0.42	4.26e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.69	6.09	0.44	8.86e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.5	5.0	0.38	1.59e-6	Height;
PAAD	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs4668356	1.000	rs73013435	chr2:171990300	T/C	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.63	-0.35	7.79e-6	Breast cancer;
PAAD	cis	rs10947428	0.522	rs2967	chr6:33689534	C/T	cg13859433	chr6:33739653	LEMD2	0.52	4.69	0.36	5.93e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.67	7.73	0.53	1.34e-12	Motion sickness;
PAAD	cis	rs1497828	1.000	rs2810766	chr1:217565056	G/A	cg04411442	chr1:217543379	NA	0.5	4.89	0.37	2.51e-6	Dialysis-related mortality;
PAAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs3106136	0.678	rs7675615	chr4:95295352	T/G	cg11021082	chr4:95130006	SMARCAD1	0.48	4.58	0.35	9.69e-6	Capecitabine sensitivity;
PAAD	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg05294307	chr14:35346193	BAZ1A	-0.53	-5.27	-0.39	4.52e-7	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03122372	chr12:56651912	ANKRD52	0.66	6.49	0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.38	7.4	0.51	8.63e-12	Skin colour saturation;
PAAD	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg19090574	chr1:205240910	TMCC2	-0.41	-4.28	-0.33	3.3e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13063040	chr8:145669623	NFKBIL2	0.59	6.97	0.49	9.11e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03404566	chr17:6899310	ALOX12	0.45	4.71	0.36	5.62e-6	Tonsillectomy;
PAAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs375066	0.935	rs424729	chr19:44422802	G/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3026101	0.671	rs1806258	chr17:5314956	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs11250714	0.885	rs7071633	chr10:1699933	G/A	cg10435618	chr10:838112	NA	-0.49	-4.64	-0.35	7.37e-6	Gut microbiome composition (summer);
PAAD	cis	rs6681849	0.933	rs10399785	chr1:94877801	T/C	cg17801055	chr1:95285809	SLC44A3	-0.43	-4.26	-0.33	3.58e-5	Platelet distribution width;
PAAD	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.52	-4.98	-0.37	1.71e-6	Hypospadias;
PAAD	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.48	-0.41	1.76e-7	Neuroticism;
PAAD	cis	rs3112530	1.000	rs3101482	chr5:152641908	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg08501292	chr6:25962987	TRIM38	0.9	5.48	0.41	1.69e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.37	4.43	0.34	1.8e-5	Schizophrenia;
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-5.89	-0.43	2.37e-8	Prostate cancer;
PAAD	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.69	7.41	0.51	8.34e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25833597	chr17:30823145	MYO1D	0.6	5.95	0.43	1.74e-8	Schizophrenia;
PAAD	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.34	-0.33	2.58e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg21040360	chr2:3383326	TTC15	-0.42	-4.55	-0.35	1.11e-5	Obesity-related traits;
PAAD	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.81	10.19	0.64	6.72e-19	Breast cancer;
PAAD	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	4.81	0.36	3.55e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs13070279	0.786	rs11716884	chr3:71809397	A/C	cg02995710	chr3:71805022	EIF4E3	-0.62	-4.32	-0.33	2.75e-5	Monocyte count;
PAAD	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.53	-5.12	-0.38	9.01e-7	Obesity-related traits;
PAAD	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1371614	0.611	rs540490	chr2:27132822	A/T	cg00617064	chr2:27272375	NA	0.44	4.57	0.35	9.89e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	6.03	0.44	1.18e-8	Systolic blood pressure;
PAAD	cis	rs3779195	0.929	rs10953259	chr7:98013107	G/T	cg24562669	chr7:97807699	LMTK2	-0.52	-4.88	-0.37	2.61e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.7	8.27	0.56	6.4e-14	Eye color traits;
PAAD	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs1883415	0.534	rs760906	chr6:24479845	C/T	cg20631270	chr6:24437470	GPLD1	-0.44	-4.33	-0.33	2.68e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.74	7.36	0.51	1.06e-11	Mosquito bite size;
PAAD	cis	rs7707921	1.000	rs2407064	chr5:81457358	C/A	cg21483461	chr5:81570383	RPS23	0.51	4.32	0.33	2.83e-5	Breast cancer;
PAAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.54	-7.88	-0.54	5.94e-13	Diastolic blood pressure;
PAAD	trans	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-1.37	-11.0	-0.67	4.65e-21	Magnesium levels;
PAAD	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.51	-4.88	-0.37	2.62e-6	Pancreatic cancer;
PAAD	cis	rs1879734	0.953	rs3006905	chr1:54130119	G/C	cg14659662	chr1:54151053	GLIS1	0.37	5.99	0.44	1.43e-8	Mitral valve prolapse;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.49	4.88	0.37	2.7e-6	Lung cancer;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13894748	chr10:102107266	SCD	0.7	8.19	0.55	9.77e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg09659197	chr4:152720779	NA	-0.4	-5.77	-0.42	4.4e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg07166546	chr14:35805898	NA	-0.35	-5.32	-0.4	3.67e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.72	5.08	0.38	1.07e-6	Breast cancer;
PAAD	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	7.96	0.54	3.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26002253	chr1:26438845	PDIK1L	0.59	6.31	0.46	2.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.9	11.17	0.67	1.61e-21	Blood protein levels;
PAAD	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.23	-0.39	5.56e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg25547332	chr5:131281432	NA	-0.56	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.67	0.53	1.94e-12	Prudent dietary pattern;
PAAD	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg21565972	chr17:80109576	CCDC57	0.52	5.97	0.44	1.64e-8	Life satisfaction;
PAAD	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	1.000	rs62239001	chr22:32590150	T/C	cg00543991	chr22:32367038	NA	1.14	6.3	0.45	3.07e-9	Childhood ear infection;
PAAD	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	6.86	0.49	1.65e-10	Multiple sclerosis;
PAAD	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.58	6.02	0.44	1.24e-8	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.63	6.61	0.47	6.19e-10	Prostate cancer;
PAAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.87	11.11	0.67	2.29e-21	Total body bone mineral density;
PAAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg14343924	chr8:8086146	FLJ10661	0.52	4.58	0.35	9.52e-6	Mood instability;
PAAD	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg24881330	chr22:46731750	TRMU	1.08	5.57	0.41	1.12e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs73206853	0.841	rs3026456	chr12:110748735	G/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7551345	0.853	rs12145697	chr1:31714638	G/T	cg17086398	chr1:31896392	SERINC2	-0.52	-4.56	-0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.61	6.36	0.46	2.28e-9	Resting heart rate;
PAAD	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.72	7.52	0.52	4.32e-12	Body mass index;
PAAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.66	0.42	7.37e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.74	-7.49	-0.52	5.38e-12	Uric acid clearance;
PAAD	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg21037935	chr19:58911965	NA	0.55	4.39	0.34	2.12e-5	Mean platelet volume;
PAAD	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.48	4.74	0.36	4.79e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs66530629	0.874	rs4648876	chr1:25097392	A/G	cg22509179	chr1:25234806	RUNX3	-0.49	-4.54	-0.35	1.16e-5	Plateletcrit;
PAAD	cis	rs7188861	0.813	rs2867937	chr16:11398798	A/T	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.55e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg27494647	chr7:150038898	RARRES2	0.45	4.91	0.37	2.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg21823605	chr1:152486609	CRCT1	0.53	6.31	0.46	2.86e-9	Hair morphology;
PAAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg19592336	chr6:28129416	ZNF389	0.62	4.37	0.33	2.25e-5	Depression;
PAAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.6	8.12	0.55	1.49e-13	Renal cell carcinoma;
PAAD	cis	rs732765	0.734	rs12323392	chr14:75115673	A/G	cg17347104	chr14:75034677	LTBP2	0.63	5.15	0.39	7.82e-7	Non-small cell lung cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09007620	chr9:127532874	NR6A1	-0.69	-6.57	-0.47	7.46e-10	Lung cancer in ever smokers;
PAAD	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.47	0.46	1.25e-9	Morning vs. evening chronotype;
PAAD	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.89	0.58	1.65e-15	Bone mineral density;
PAAD	cis	rs12282928	0.885	rs1503176	chr11:48269191	C/T	cg04721828	chr11:48285200	OR4X1	-0.48	-6.07	-0.44	9.67e-9	Migraine - clinic-based;
PAAD	cis	rs12282928	1.000	rs10769339	chr11:48294296	T/A	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.57	6.18	0.45	5.58e-9	Blood metabolite levels;
PAAD	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.58	-5.33	-0.4	3.46e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs621942	0.718	rs664596	chr11:85751854	C/A	cg07180834	chr11:85838833	NA	-0.48	-4.69	-0.36	5.99e-6	Tourette syndrome;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.85	-9.5	-0.61	4.35e-17	Bipolar disorder and schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08146156	chr16:66918260	PDP2	-0.55	-7.09	-0.5	4.64e-11	Monocyte percentage of white cells;
PAAD	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	6.12	0.44	7.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.21	8.07	0.55	1.98e-13	Cognitive function;
PAAD	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg23112188	chr14:24563095	PCK2	-0.5	-5.49	-0.41	1.62e-7	IgG glycosylation;
PAAD	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.57e-7	Bladder cancer;
PAAD	cis	rs258892	0.895	rs155432	chr5:72138608	G/T	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs2555155	1.000	rs2555155	chr11:6522804	G/A	cg11185456	chr11:6592066	DNHD1	0.42	4.35	0.33	2.44e-5	DNA methylation (variation);
PAAD	cis	rs4759375	0.667	rs28646185	chr12:123849629	T/C	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11960001	chr19:59066599	CHMP2A	0.63	7.16	0.5	3.22e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.47	-6.02	-0.44	1.22e-8	Ulcerative colitis;
PAAD	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.51	-4.78	-0.36	4.12e-6	Response to antidepressants and depression;
PAAD	cis	rs6782025	0.837	rs2203079	chr3:121053656	G/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs4455778	0.500	rs7783586	chr7:49057244	C/A	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg03098721	chr1:84464084	TTLL7	0.47	4.43	0.34	1.76e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.54	-4.41	-0.34	1.98e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.51	5.08	0.38	1.11e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-4.99	-0.38	1.63e-6	Longevity;Endometriosis;
PAAD	cis	rs10276303	0.584	rs2614950	chr7:3581391	A/G	cg24872851	chr7:4265468	SDK1	0.43	4.43	0.34	1.78e-5	Dupuytren's disease;
PAAD	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.1	0.44	8.51e-9	Bladder cancer;
PAAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.43	4.51	0.34	1.31e-5	Obesity-related traits;
PAAD	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg05895507	chr15:77155635	SCAPER	-0.38	-4.68	-0.36	6.24e-6	Blood metabolite levels;
PAAD	cis	rs55893317	0.526	rs7107916	chr11:10012511	A/G	cg06876053	chr11:9810051	SBF2	-0.34	-4.47	-0.34	1.5e-5	Red blood cell count;
PAAD	cis	rs758324	0.773	rs2404776	chr5:131168937	C/T	cg06307176	chr5:131281290	NA	0.49	4.31	0.33	2.88e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.34	-0.33	2.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.61	-6.14	-0.45	6.87e-9	Height;
PAAD	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.95	5.59	0.41	1.04e-7	Obesity (early onset extreme);
PAAD	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.52e-10	Capecitabine sensitivity;
PAAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg05697835	chr1:2722811	NA	-0.43	-4.81	-0.36	3.54e-6	Multiple sclerosis;
PAAD	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.64	6.13	0.44	7.41e-9	Asthma;
PAAD	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.75	6.4	0.46	1.87e-9	Pulmonary function decline;
PAAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.79	-5.02	-0.38	1.46e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.6	-6.48	-0.47	1.23e-9	Eye color traits;
PAAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.72	7.53	0.52	4.18e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.99	-11.73	-0.69	5.06e-23	Cognitive function;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg25886479	chr11:50257625	LOC441601	-0.42	-4.53	-0.35	1.16e-5	Coronary artery disease;
PAAD	cis	rs78761021	0.829	rs55973554	chr17:9793756	G/A	cg26853458	chr17:9805074	RCVRN	0.72	8.44	0.56	2.31e-14	Type 2 diabetes;
PAAD	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.29	-0.33	3.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.57	-5.22	-0.39	5.91e-7	Diisocyanate-induced asthma;
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.48	-0.41	1.77e-7	Blood metabolite levels;
PAAD	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19882132	chr14:106167949	NA	-0.55	-4.91	-0.37	2.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg24699146	chr1:24152579	HMGCL	0.54	5.72	0.42	5.43e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.82	-0.48	2.06e-10	Post bronchodilator FEV1;
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09640425	chr7:158790006	NA	-0.47	-5.06	-0.38	1.2e-6	Facial morphology (factor 20);
PAAD	cis	rs6494488	0.500	rs113248293	chr15:64960751	T/G	cg16425858	chr15:64791681	ZNF609	0.93	4.94	0.37	2.08e-6	Coronary artery disease;
PAAD	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	5.45	0.4	2.03e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.84	0.54	7.24e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-4.77	-0.36	4.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09695851	chr17:3907499	NA	0.67	6.77	0.48	2.67e-10	Type 2 diabetes;
PAAD	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.57	-5.46	-0.4	1.9e-7	Rheumatoid arthritis;
PAAD	cis	rs1018697	1.000	rs7086400	chr10:104562097	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg21665744	chr7:39171113	POU6F2	0.3	4.58	0.35	9.42e-6	IgG glycosylation;
PAAD	cis	rs655641	0.539	rs561646	chr11:85746037	C/T	cg07180834	chr11:85838833	NA	-0.45	-4.91	-0.37	2.33e-6	Platelet count;
PAAD	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg20587970	chr11:113659929	NA	-1.2	-9.97	-0.63	2.51e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.67	-6.35	-0.46	2.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.53	5.05	0.38	1.25e-6	Menarche (age at onset);
PAAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg18402987	chr7:1209562	NA	1.11	5.61	0.41	9.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.8	-8.71	-0.58	4.74e-15	Prostate cancer;
PAAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.75	-6.96	-0.49	9.36e-11	Coronary artery disease;
PAAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.72	4.47	0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs4148191	1.000	rs4148191	chr2:44042904	C/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.73	-4.39	-0.34	2.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg05110241	chr16:68378359	PRMT7	-0.75	-5.89	-0.43	2.35e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg15890332	chr12:107067104	RFX4	0.41	4.48	0.34	1.48e-5	Total body bone mineral density;
PAAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.8e-9	Diastolic blood pressure;
PAAD	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg01489032	chr8:143877656	NA	0.43	4.58	0.35	9.43e-6	Urinary tract infection frequency;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17840343	chr10:93683703	BTAF1	0.57	6.31	0.46	2.89e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg27411982	chr8:10470053	RP1L1	-0.5	-5.37	-0.4	2.84e-7	Triglycerides;
PAAD	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.13	-0.5	3.79e-11	Neuroticism;
PAAD	cis	rs2410601	0.579	rs4921623	chr8:18923101	A/G	cg19414122	chr8:18896631	NA	0.41	4.86	0.37	2.85e-6	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-6.21	-0.45	4.76e-9	Blood trace element (Zn levels);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15737365	chr16:30217452	LOC613038;LOC388242	0.58	6.58	0.47	7.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg10596483	chr8:143751796	JRK	-0.48	-4.25	-0.33	3.75e-5	Urinary tract infection frequency;
PAAD	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-4.42	-0.34	1.89e-5	Morning vs. evening chronotype;
PAAD	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg11764359	chr7:65958608	NA	0.75	5.77	0.42	4.28e-8	Diabetic kidney disease;
PAAD	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg20893579	chr22:38215064	NA	-0.43	-4.79	-0.36	4.01e-6	Glioblastoma;Glioma;
PAAD	cis	rs2275565	0.872	rs11802532	chr1:237056601	C/T	cg17297354	chr1:237056641	MTR	-0.5	-4.41	-0.34	1.97e-5	Homocysteine levels;
PAAD	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14119001	chr9:139324193	INPP5E	-0.62	-5.55	-0.41	1.22e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg11859384	chr17:80120422	CCDC57	0.46	4.78	0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs2992756	0.663	rs1360919	chr1:18805844	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.58	-6.55	-0.47	8.54e-10	Breast cancer;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6604026	0.656	rs2811600	chr1:93334138	C/T	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs13273891	1.000	rs6997924	chr8:58986641	G/C	cg05901852	chr8:59757290	TOX	-0.53	-4.83	-0.36	3.37e-6	Pit-and-Fissure caries;
PAAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs732765	0.734	rs12891243	chr14:75208656	G/A	cg17347104	chr14:75034677	LTBP2	0.55	4.87	0.37	2.76e-6	Non-small cell lung cancer;
PAAD	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg26876637	chr1:152193138	HRNR	-0.83	-6.07	-0.44	9.8e-9	Atopic dermatitis;
PAAD	cis	rs4073221	0.585	rs7426729	chr3:18320922	G/A	cg07694806	chr3:18168406	NA	-0.62	-4.59	-0.35	9.18e-6	Parkinson's disease;
PAAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg18944383	chr4:111397179	ENPEP	-0.75	-8.17	-0.55	1.09e-13	Coronary artery disease;
PAAD	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-4.56	-0.35	1.06e-5	Mean corpuscular volume;
PAAD	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.44	4.34	0.33	2.57e-5	Chronic sinus infection;
PAAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.83	6.68	0.48	4.29e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10150615	chr22:24372951	LOC391322	-0.58	-5.43	-0.4	2.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	1e-10	Axial length;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg03351412	chr1:154909251	PMVK	0.45	4.28	0.33	3.36e-5	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs7093483	chr10:64001753	T/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.77	-8.11	-0.55	1.58e-13	Cognitive function;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs72960926	0.744	rs72957986	chr6:74969096	A/C	cg03266952	chr6:74778945	NA	-1.09	-6.19	-0.45	5.27e-9	Metabolite levels (MHPG);
PAAD	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.96	-6.65	-0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	0.49	4.44	0.34	1.73e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.51	5.1	0.38	9.96e-7	Parkinson's disease;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg16606324	chr3:10149918	C3orf24	0.75	6.11	0.44	7.9e-9	Alzheimer's disease;
PAAD	cis	rs8105895	0.935	rs10406551	chr19:22244520	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs941024	0.651	rs17117846	chr12:56039381	C/T	cg20737382	chr12:56040096	NA	-0.67	-4.41	-0.34	1.91e-5	Conotruncal heart defects (inherited effects);
PAAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.95	8.61	0.57	8.74e-15	Gut microbiome composition (summer);
PAAD	cis	rs12936587	0.601	rs7222423	chr17:17556707	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-5.33	-0.4	3.52e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg00631609	chr15:63340700	TPM1	-0.44	-4.8	-0.36	3.72e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.91	-0.43	2.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg13429435	chr10:81271195	EIF5AL1	-0.4	-4.39	-0.34	2.1e-5	Sarcoidosis;
PAAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.97	12.81	0.72	6.21e-26	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26365399	chr6:127587909	RNF146	-0.69	-6.3	-0.46	2.98e-9	Neuroticism;
PAAD	cis	rs2004318	1.000	rs4097296	chr19:55141019	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.68	9.05	0.59	6.5e-16	Hemoglobin concentration;
PAAD	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.67	5.23	0.39	5.48e-7	Alzheimer's disease (survival time);
PAAD	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.13	0.38	8.62e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.5	-4.41	-0.34	1.96e-5	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg08992911	chr2:238395768	MLPH	0.66	5.27	0.39	4.61e-7	Prostate cancer;
PAAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.27	-0.39	4.51e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19192649	chr2:99952969	EIF5B;TXNDC9	0.68	6.8	0.48	2.21e-10	Obesity-related traits;
PAAD	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.62	-4.53	-0.34	1.18e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.48	5.24	0.39	5.26e-7	Heart rate;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg13047869	chr3:10149882	C3orf24	0.71	5.85	0.43	2.89e-8	Alzheimer's disease;
PAAD	cis	rs12612619	0.732	rs6716275	chr2:27227707	C/T	cg00617064	chr2:27272375	NA	0.45	4.8	0.36	3.78e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs950027	0.967	rs3120975	chr15:45745125	T/C	cg26924012	chr15:45694286	SPATA5L1	0.61	5.7	0.42	6.12e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs6694270	1.000	rs6694270	chr1:19120377	A/G	cg13786083	chr1:19110734	NA	-0.63	-5.47	-0.41	1.82e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs1468734	0.929	rs12928442	chr16:5006781	G/C	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.53	-4.39	-0.34	2.12e-5	Cancer;
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.48	-0.41	1.76e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11264799	0.859	rs2317232	chr1:157688042	C/T	cg18268488	chr1:157545234	FCRL4	0.54	5.2	0.39	6.36e-7	IgA nephropathy;
PAAD	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.49	4.66	0.35	6.77e-6	Endometrial cancer;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs58521262	0.556	rs2927369	chr19:23191534	A/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-6.15	-0.45	6.64e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.08e-7	Atrioventricular conduction;
PAAD	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.54	4.57	0.35	9.89e-6	Sudden cardiac arrest;
PAAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg13722127	chr7:150037890	RARRES2	0.55	5.55	0.41	1.25e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.79	0.36	3.92e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6681460	0.649	rs7540195	chr1:67002406	C/T	cg02459107	chr1:67143332	SGIP1	-0.55	-4.96	-0.37	1.89e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg05083358	chr7:2394359	EIF3B	-0.76	-5.7	-0.42	6.12e-8	Multiple sclerosis;
PAAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs939584	0.935	rs5017302	chr2:631069	G/A	cg03610516	chr2:642275	NA	0.63	5.58	0.41	1.08e-7	Body mass index;
PAAD	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.67	6.96	0.49	9.74e-11	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.57	-0.57	1.07e-14	Body mass index;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg17333051	chr19:2783644	SGTA	0.42	4.7	0.36	5.9e-6	Total cholesterol levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22773219	chr4:618332	PDE6B	0.54	6.36	0.46	2.3e-9	Myopia (pathological);
PAAD	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	4.51	0.34	1.28e-5	Mood instability;
PAAD	cis	rs12523822	0.957	rs55717368	chr6:154955799	C/T	cg20019720	chr6:154832845	CNKSR3	0.3	4.32	0.33	2.77e-5	Diabetic kidney disease;
PAAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2e-27	Height;
PAAD	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.95	-9.86	-0.62	4.79e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg00280220	chr17:61926910	NA	0.45	4.73	0.36	5.15e-6	Prudent dietary pattern;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.76	9.85	0.62	5.29e-18	Iron status biomarkers (transferrin levels);
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.78	-9.64	-0.62	1.91e-17	Lymphocyte counts;
PAAD	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg10578777	chr12:7781093	NA	-0.9	-5.29	-0.39	4.14e-7	HDL cholesterol levels;
PAAD	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.33	4.9	0.37	2.39e-6	IgG glycosylation;
PAAD	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg15192750	chr16:69999425	NA	0.79	6.02	0.44	1.23e-8	IgE levels;
PAAD	cis	rs16867321	1.000	rs16867330	chr2:181446202	T/G	cg23363182	chr2:181467187	NA	-0.52	-4.64	-0.35	7.55e-6	Obesity;
PAAD	cis	rs59901009	0.517	rs7926141	chr11:10018430	A/C	cg06876053	chr11:9810051	SBF2	-0.34	-4.5	-0.34	1.34e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.43	-4.55	-0.35	1.07e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg26384229	chr12:38710491	ALG10B	0.6	6.82	0.48	2.01e-10	Morning vs. evening chronotype;
PAAD	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.9	10.76	0.66	1.98e-20	Sudden cardiac arrest;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	9.4	0.61	8.07e-17	Prudent dietary pattern;
PAAD	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs10044254	0.537	rs35719201	chr5:15693726	T/C	cg07238450	chr5:15720153	FBXL7	-0.49	-4.56	-0.35	1.03e-5	Asthma (corticosteroid response);
PAAD	cis	rs7487075	0.619	rs12824565	chr12:46834693	A/G	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.57e-5	Itch intensity from mosquito bite;
PAAD	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg10253484	chr15:75165896	SCAMP2	0.49	4.6	0.35	8.86e-6	Systemic lupus erythematosus;
PAAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12599982	chr1:44399894	ARTN	0.46	4.88	0.37	2.62e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg11088901	chr6:166572345	T	-0.49	-4.53	-0.34	1.19e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.41	4.32	0.33	2.76e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs939584	1.000	rs7559447	chr2:645646	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.47	4.29	0.33	3.17e-5	Red blood cell count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01181084	chr8:43059863	NA	0.58	6.85	0.49	1.69e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6700896	0.897	rs1938494	chr1:66117691	G/T	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg19630374	chr17:18023558	MYO15A	0.46	4.92	0.37	2.23e-6	Total body bone mineral density;
PAAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs2387326	1.000	rs2387328	chr10:129925986	C/T	cg16087940	chr10:129947807	NA	-0.51	-4.3	-0.33	3.05e-5	Select biomarker traits;
PAAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg24879335	chr3:133465180	TF	0.53	5.76	0.42	4.6e-8	Iron status biomarkers;
PAAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.19	0.6	2.74e-16	Menopause (age at onset);
PAAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg01815783	chr4:1047043	NA	-0.47	-4.42	-0.34	1.87e-5	Recombination rate (females);
PAAD	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg15676125	chr6:33679581	C6orf125	0.45	4.28	0.33	3.24e-5	Plateletcrit;
PAAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg15017067	chr4:17643749	FAM184B	0.43	5.17	0.39	7.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.72	8.36	0.56	3.73e-14	Alcohol dependence;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22442454	chr1:209979470	IRF6	0.57	5.14	0.38	8.52e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	9.96	0.63	2.69e-18	Colorectal cancer;
PAAD	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.38	0.56	3.27e-14	Dupuytren's disease;
PAAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.64	5.05	0.38	1.23e-6	Alzheimer's disease;
PAAD	cis	rs12042052	0.793	rs12036759	chr1:232925441	A/G	cg02191044	chr1:232940990	KIAA1383	0.91	4.48	0.34	1.44e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1419980	0.730	rs11054821	chr12:7766154	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs829661	0.793	rs829639	chr2:30703247	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	4.44	0.34	1.73e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17217603	chr1:150552017	MCL1	0.66	6.33	0.46	2.63e-9	Primary biliary cholangitis;
PAAD	cis	rs1144333	0.655	rs76532097	chr1:76320759	G/C	cg22875332	chr1:76189707	ACADM	0.6	4.31	0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7260598	0.539	rs73525884	chr19:24069701	C/T	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg01097406	chr16:89675127	NA	0.39	4.78	0.36	4.08e-6	Vitiligo;
PAAD	trans	rs1015213	0.609	rs17212845	chr8:52871913	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.51	-0.78	4.05e-33	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09895166	chr4:151615431	LRBA	0.56	6.69	0.48	3.97e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg09179987	chr1:167433047	CD247	0.5	5.85	0.43	2.89e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg04330084	chr7:123175371	IQUB	0.51	4.43	0.34	1.8e-5	Plateletcrit;Platelet count;
PAAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	6.14	0.45	6.84e-9	Bipolar disorder;
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg22764044	chr5:178986830	RUFY1	0.53	5.53	0.41	1.37e-7	Lung cancer;
PAAD	cis	rs7532866	0.885	rs7517224	chr1:26731029	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.53	-4.51	-0.34	1.28e-5	Height;
PAAD	cis	rs7554547	1.000	rs926271	chr1:11969917	A/G	cg07603449	chr1:11986842	KIAA2013	-0.28	-4.25	-0.33	3.69e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11112791	chr14:58619036	C14orf37	0.69	7.06	0.5	5.52e-11	Obesity-related traits;
PAAD	cis	rs72827839	1.000	rs72827877	chr17:46524904	G/A	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg21191810	chr6:118973309	C6orf204	-0.52	-5.16	-0.39	7.47e-7	Diastolic blood pressure;
PAAD	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg00792783	chr2:198669748	PLCL1	-0.48	-4.28	-0.33	3.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg11601000	chr22:42348013	LOC339674	0.44	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.8e-6	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14779627	chr7:6048715	PMS2;AIMP2	0.61	6.74	0.48	3.12e-10	Monocyte percentage of white cells;
PAAD	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg15890332	chr12:107067104	RFX4	0.41	4.35	0.33	2.46e-5	Total body bone mineral density;
PAAD	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.13	14.99	0.77	9.16e-32	Testicular germ cell tumor;
PAAD	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-6.31	-0.46	2.91e-9	Hypospadias;
PAAD	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.97	7.78	0.53	1.03e-12	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	5.44	0.4	2.06e-7	Educational attainment;
PAAD	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.43	6.24	0.45	4.12e-9	Information processing speed;
PAAD	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg10978503	chr1:24200527	CNR2	-0.39	-4.36	-0.33	2.42e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4740619	0.836	rs7027202	chr9:15894495	C/G	cg14451791	chr9:16040625	NA	0.38	4.57	0.35	9.9e-6	Body mass index;
PAAD	cis	rs66530629	0.917	rs3890756	chr1:25140825	A/G	cg01905478	chr1:25040257	NA	0.49	5.42	0.4	2.27e-7	Plateletcrit;
PAAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg13312174	chr5:178288687	ZNF354B	-0.6	-6.17	-0.45	5.81e-9	Sleep duration;
PAAD	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg10395934	chr14:104002654	TRMT61A	0.5	4.84	0.37	3.21e-6	Body mass index;
PAAD	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg09760422	chr2:128146352	NA	-0.33	-5.54	-0.41	1.33e-7	Protein C levels;
PAAD	cis	rs375066	0.967	rs436249	chr19:44399565	C/T	cg08633290	chr19:44405433	NA	-0.57	-5.75	-0.42	4.69e-8	Breast cancer;
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs61677309	1.000	rs56224295	chr11:118161891	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.32	-0.33	2.82e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg09980403	chr19:12975529	MAST1	-0.31	-4.67	-0.35	6.55e-6	Mean corpuscular volume;
PAAD	cis	rs58521262	0.585	rs289307	chr19:23166956	C/T	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.68	7.77	0.53	1.09e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.98	0.49	8.5e-11	Coffee consumption (cups per day);
PAAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs13102973	0.965	rs11735381	chr4:135850474	T/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.06e-8	Subjective well-being;
PAAD	cis	rs941207	0.756	rs2926743	chr12:57114100	A/G	cg02954252	chr12:57119365	NACA	0.53	4.33	0.33	2.68e-5	Platelet count;
PAAD	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg13660082	chr14:53194042	PSMC6	0.71	4.48	0.34	1.43e-5	Alzheimer's disease (late onset);
PAAD	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg17633681	chr16:88106987	BANP	0.62	7.9	0.54	5.08e-13	Menopause (age at onset);
PAAD	cis	rs904092	0.671	rs6532813	chr4:100167961	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-4.53	-0.34	1.21e-5	Alcohol dependence;
PAAD	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg16205897	chr5:131564050	P4HA2	-0.41	-4.46	-0.34	1.55e-5	Blood metabolite levels;
PAAD	cis	rs755249	0.517	rs66880209	chr1:39719812	G/A	cg14018543	chr1:39659967	MACF1	-0.56	-4.46	-0.34	1.61e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18337363	chr3:52569053	NT5DC2	0.44	4.46	0.34	1.58e-5	Electroencephalogram traits;
PAAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-4.64	-0.35	7.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.37	1.85e-6	Morning vs. evening chronotype;
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs58521262	0.729	rs62120834	chr19:23074115	G/T	cg07749055	chr19:23076870	NA	-0.68	-4.83	-0.36	3.28e-6	Testicular germ cell tumor;
PAAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.32	0.64	2.95e-19	Smoking behavior;
PAAD	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg21231944	chr12:82153410	PPFIA2	-0.55	-4.55	-0.35	1.11e-5	Resting heart rate;
PAAD	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.83	0.66	1.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.83	8.37	0.56	3.49e-14	Prostate cancer;
PAAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.37	0.33	2.29e-5	Melanoma;
PAAD	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.49	5.11	0.38	9.33e-7	Plasma plasminogen activator levels;
PAAD	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.62	5.52	0.41	1.46e-7	Red blood cell count;
PAAD	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.59	5.27	0.39	4.65e-7	Mean platelet volume;
PAAD	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg22467129	chr15:76604101	ETFA	0.54	4.98	0.37	1.7e-6	Blood metabolite levels;
PAAD	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.98	-12.42	-0.71	6.77e-25	Refractive error;
PAAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.56	6.2	0.45	5.04e-9	Major depressive disorder;
PAAD	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg27050936	chr6:887821	NA	-0.49	-5.01	-0.38	1.47e-6	Aging;
PAAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg14196790	chr5:131705035	SLC22A5	0.59	6.58	0.47	7.05e-10	Blood metabolite levels;
PAAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg10589385	chr1:150898437	SETDB1	-0.38	-4.57	-0.35	9.88e-6	Melanoma;
PAAD	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg21823605	chr1:152486609	CRCT1	0.5	6.19	0.45	5.3300000000000004e-09	Hair morphology;
PAAD	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.86	5.84	0.43	2.99e-8	Thyroid stimulating hormone;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.58	-0.41	1.07e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9361491	0.608	rs7747911	chr6:79437495	A/T	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.67	0.72	1.46e-25	Prudent dietary pattern;
PAAD	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg26031613	chr14:104095156	KLC1	0.53	5.54	0.41	1.28e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.92	-9.87	-0.62	4.73e-18	Height;
PAAD	cis	rs10044254	0.587	rs4484432	chr5:15739776	T/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.87	-8.52	-0.57	1.45e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.09	-0.38	1.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11825685	0.887	rs78560583	chr11:134571795	G/A	cg02089395	chr11:134479357	NA	-0.65	-4.51	-0.34	1.26e-5	IgG glycosylation;
PAAD	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	1.03	12.94	0.72	2.76e-26	Breast cancer;
PAAD	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-7.26	-0.51	1.9e-11	Morning vs. evening chronotype;
PAAD	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.67	-0.35	6.51e-6	Blood pressure (smoking interaction);
PAAD	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.97	9.12	0.59	4.21e-16	Psoriasis;
PAAD	cis	rs597480	0.963	rs556918	chr11:85486866	C/G	cg11817631	chr11:85522609	SYTL2	0.44	4.26	0.33	3.59e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-11.84	-0.69	2.44e-23	Cognitive function;
PAAD	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.73	7.47	0.52	5.87e-12	Prostate cancer;
PAAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7631605	0.905	rs6796088	chr3:37147572	G/T	cg17445812	chr3:36986805	TRANK1	0.35	4.68	0.35	6.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.91	0.37	2.36e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.86	11.94	0.7	1.35e-23	Bone mineral density;
PAAD	cis	rs75920871	0.925	rs61903418	chr11:116956665	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg24879335	chr3:133465180	TF	-0.55	-5.92	-0.43	2.11e-8	Iron status biomarkers;
PAAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.61	-6.27	-0.45	3.58e-9	Menopause (age at onset);
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.75	6.75	0.48	3.01e-10	Pediatric autoimmune diseases;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg17644776	chr2:200775616	C2orf69	-0.64	-4.76	-0.36	4.55e-6	Schizophrenia;
PAAD	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.49	4.87	0.37	2.73e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.04	-0.38	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18419694	chr6:143832440	FUCA2	0.55	6.42	0.46	1.63e-9	Monocyte percentage of white cells;
PAAD	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-6.03	-0.44	1.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	5.09	0.38	1.04e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.78	6.57	0.47	7.7e-10	Type 2 diabetes;
PAAD	cis	rs7668190	0.924	rs4864504	chr4:55097835	G/C	cg17187183	chr4:55093834	PDGFRA	0.45	4.4	0.34	2.07e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg16928487	chr17:17741425	SREBF1	-0.31	-4.26	-0.33	3.57e-5	Total body bone mineral density;
PAAD	cis	rs12044355	0.927	rs11122321	chr1:231835610	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.08	0.38	1.09e-6	Alzheimer's disease;
PAAD	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg00864860	chr1:7907996	UTS2	-0.5	-4.53	-0.34	1.21e-5	Crohn's disease;
PAAD	cis	rs6988985	0.530	rs57268571	chr8:143942602	A/G	cg10324643	chr8:143916377	GML	0.41	4.47	0.34	1.51e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg14393609	chr7:65229607	NA	-0.62	-6.66	-0.48	4.83e-10	Aortic root size;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.64	7.04	0.5	6.31e-11	Type 2 diabetes;
PAAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	6.13	0.45	7.15e-9	Calcium levels;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.74	7.89	0.54	5.41e-13	Height;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.69	7.58	0.52	3.09e-12	Calcium levels;
PAAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.1	0.67	2.47e-21	Parkinson's disease;
PAAD	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.52	-5.01	-0.38	1.46e-6	Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg16342193	chr10:102329863	NA	0.74	8.08	0.55	1.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg14440974	chr22:39074834	NA	-0.57	-6.62	-0.47	5.68e-10	Menopause (age at onset);
PAAD	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs508970	0.556	rs10792306	chr11:60910740	T/A	cg24692310	chr11:60915630	VPS37C	0.33	4.48	0.34	1.46e-5	Rheumatoid arthritis;
PAAD	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.94	10.02	0.63	1.8e-18	Alcohol dependence;
PAAD	cis	rs2410601	0.540	rs6586796	chr8:18927541	G/A	cg19414122	chr8:18896631	NA	-0.39	-4.55	-0.35	1.07e-5	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.57	5.02	0.38	1.46e-6	Schizophrenia;
PAAD	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.16	0.64	7.87e-19	Menopause (age at onset);
PAAD	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-5.04	-0.38	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg14795047	chr12:38710433	ALG10B	-0.67	-6.69	-0.48	3.95e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg07308232	chr7:1071921	C7orf50	-0.41	-4.36	-0.33	2.39e-5	Longevity;Endometriosis;
PAAD	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg00522288	chr12:125625016	AACS	0.45	4.8	0.36	3.83e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.83	-0.43	3.21e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.96	-16.51	-0.8	1.02e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11264799	0.731	rs7511680	chr1:157685212	A/G	cg18268488	chr1:157545234	FCRL4	0.64	5.63	0.42	8.38e-8	IgA nephropathy;
PAAD	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.44	4.32	0.33	2.77e-5	Red blood cell count;
PAAD	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.85	-9.86	-0.62	5.04e-18	Ulcerative colitis;
PAAD	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.9	11.01	0.67	4.19e-21	Menarche (age at onset);
PAAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.81	-9.15	-0.6	3.61e-16	Type 2 diabetes;
PAAD	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Height;
PAAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg00999904	chr2:3704751	ALLC	-0.84	-8.29	-0.56	5.66e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.37	2.6e-6	Breast cancer;
PAAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg14416269	chr4:6271139	WFS1	0.65	8.54	0.57	1.28e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.48	4.75	0.36	4.71e-6	Blood metabolite levels;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00815214	chr21:47717953	NA	0.42	4.29	0.33	3.16e-5	Testicular germ cell tumor;
PAAD	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	cis	rs939584	1.000	rs6760274	chr2:652272	G/A	cg03610516	chr2:642275	NA	-0.62	-5.58	-0.41	1.08e-7	Body mass index;
PAAD	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.76	6.06	0.44	1.03e-8	Weight;
PAAD	cis	rs9815354	1.000	rs9854838	chr3:41805670	C/A	cg03022575	chr3:42003672	ULK4	0.72	5.29	0.39	4.18e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg07959070	chr22:50026188	C22orf34	-0.36	-4.43	-0.34	1.77e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.52	-5.68	-0.42	6.53e-8	Migraine;
PAAD	cis	rs317865	0.867	rs10034143	chr4:16159734	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	5.96	0.44	1.71e-8	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg24737193	chr18:12778029	NA	0.63	5.42	0.4	2.31e-7	Inflammatory skin disease;
PAAD	cis	rs1697938	0.590	rs2455312	chr5:40946648	C/T	cg22359217	chr5:41925772	FBXO4	0.43	4.28	0.33	3.26e-5	Multiple system atrophy;
PAAD	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg20487152	chr13:99095054	FARP1	0.59	5.03	0.38	1.38e-6	Neuroticism;
PAAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.92	6.66	0.48	4.69e-10	Gut microbiome composition (summer);
PAAD	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.95e-5	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs12779005	chr10:46087374	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg01320130	chr1:67600311	NA	0.59	6.01	0.44	1.35e-8	Psoriasis;
PAAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg13821571	chr21:34406537	NA	-0.48	-4.62	-0.35	8.12e-6	Gastritis;
PAAD	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.48	0.57	1.86e-14	Coffee consumption (cups per day);
PAAD	cis	rs6537837	0.701	rs12021920	chr1:110147287	C/T	cg05049280	chr1:110155535	GNAT2	0.78	7.3	0.51	1.49e-11	Major depressive disorder;
PAAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg18944383	chr4:111397179	ENPEP	0.63	7.07	0.5	5.24e-11	Coronary artery disease;
PAAD	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-4.31	-0.33	2.96e-5	Height;
PAAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.18	-11.7	-0.69	6.05e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17677112	chr7:77428730	PHTF2;TMEM60	0.56	6.32	0.46	2.7e-9	Metabolite levels  (X-11787);
PAAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9326726	0.566	rs288145	chr5:107393190	T/C	cg19779370	chr5:108084990	FER	0.61	4.93	0.37	2.08e-6	Resting heart rate;
PAAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.64	-6.19	-0.45	5.39e-9	Schizophrenia;
PAAD	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg16745616	chr19:8428856	ANGPTL4	-0.52	-4.77	-0.36	4.23e-6	HDL cholesterol;
PAAD	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs9535307	0.929	rs4942863	chr13:50314408	T/C	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs17152411	0.652	rs2114834	chr10:126650186	A/G	cg07081759	chr10:126330905	FAM53B	-0.4	-4.41	-0.34	1.96e-5	Height;
PAAD	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.51	4.95	0.37	1.92e-6	Morning vs. evening chronotype;
PAAD	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.62	-6.55	-0.47	8.17e-10	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.65	-6.15	-0.45	6.44e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.53	5.27	0.39	4.69e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2421770	0.826	rs6484776	chr11:35317212	T/C	cg13971030	chr11:35366721	SLC1A2	-0.52	-5.19	-0.39	6.66e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs3026101	0.671	rs9789002	chr17:5298792	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.29	0.39	4.25e-7	Schizophrenia;
PAAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.57	6.0	0.44	1.4e-8	Dupuytren's disease;
PAAD	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.85	-6.46	-0.46	1.37e-9	Coronary artery calcification;
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.77	0.62	8.7e-18	Platelet count;
PAAD	cis	rs1451882	0.719	rs7014498	chr8:1052781	A/G	cg07395941	chr8:1078200	NA	-0.62	-4.62	-0.35	8.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.52	-4.76	-0.36	4.5e-6	Height;
PAAD	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.45	4.82	0.36	3.48e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg04389838	chr3:44770851	ZNF501	-0.58	-5.05	-0.38	1.24e-6	Depressive symptoms;
PAAD	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.88	-10.91	-0.66	7.68e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.15	0.5	3.34e-11	Longevity;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs360071	0.528	rs360098	chr1:226066690	C/G	cg01472176	chr1:226074946	LEFTY1	0.62	5.86	0.43	2.79e-8	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.8	-9.24	-0.6	2.05e-16	Breast cancer;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs1966248	0.656	rs11154745	chr6:134123832	G/A	cg17736819	chr6:133783020	EYA4	0.44	4.5	0.34	1.35e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg20007245	chr22:24372913	LOC391322	-0.8	-8.46	-0.57	2.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.62	-0.78	2.05e-33	Schizophrenia;
PAAD	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.56	-4.25	-0.33	3.76e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg24112000	chr20:60950667	NA	0.78	10.14	0.64	9.08e-19	Colorectal cancer;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.32	-0.33	2.82e-5	Longevity;Endometriosis;
PAAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.78	-9.4	-0.61	7.98e-17	Height;
PAAD	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg26898376	chr11:64110657	CCDC88B	0.45	4.74	0.36	4.77e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg05562828	chr17:3906858	NA	-0.43	-4.6	-0.35	8.73e-6	Type 2 diabetes;
PAAD	cis	rs6844506	0.706	rs34696522	chr4:185196417	G/A	cg12654155	chr4:185238627	NA	-0.49	-4.54	-0.35	1.12e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg14393609	chr7:65229607	NA	0.53	5.36	0.4	3e-7	Aortic root size;
PAAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg22143856	chr6:28129313	ZNF389	0.52	4.88	0.37	2.61e-6	Parkinson's disease;
PAAD	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.66	4.67	0.35	6.67e-6	Inflammatory bowel disease;
PAAD	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.81	9.88	0.63	4.43e-18	Monocyte percentage of white cells;
PAAD	cis	rs7818688	0.697	rs17665714	chr8:95982542	T/C	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10547527	chr2:198650123	BOLL	0.49	4.33	0.33	2.69e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.52	-4.73	-0.36	5.03e-6	Glycated hemoglobin levels;
PAAD	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.48	4.34	0.33	2.54e-5	Neuroticism;
PAAD	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.79	6.5	0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg10253484	chr15:75165896	SCAMP2	-0.49	-4.42	-0.34	1.89e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg23283495	chr1:209979779	IRF6	0.67	6.07	0.44	9.62e-9	Coronary artery disease;
PAAD	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg25902810	chr10:99078978	FRAT1	-0.55	-4.9	-0.37	2.47e-6	Monocyte count;
PAAD	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-1.02	-8.74	-0.58	4e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.66	-6.54	-0.47	8.94e-10	Dental caries;
PAAD	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.69	7.94	0.54	4.19e-13	Colorectal cancer;
PAAD	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg19025524	chr12:109796872	NA	-0.52	-4.75	-0.36	4.65e-6	Neuroticism;
PAAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.45e-7	Body mass index;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	1.07	9.67	0.62	1.59e-17	Initial pursuit acceleration;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg19337854	chr7:99768885	GPC2	0.53	4.95	0.37	1.95e-6	Platelet count;
PAAD	cis	rs1499972	0.941	rs55734908	chr3:117613268	A/T	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.39	-5.16	-0.39	7.44e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-7.07	-0.5	5.2e-11	Birth weight;
PAAD	cis	rs3007168	0.951	rs3007078	chr14:51612550	T/A	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs7729447	0.566	rs3828589	chr5:32713327	T/C	cg16267343	chr5:32710456	NPR3	0.49	4.91	0.37	2.29e-6	Blood pressure;
PAAD	cis	rs73416724	1.000	rs75782458	chr6:43340810	G/A	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.86	-5.57	-0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg17595323	chr11:93583763	C11orf90	-0.35	-4.46	-0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.91	-7.55	-0.52	3.83e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.62	6.61	0.47	6.16e-10	Crohn's disease;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.92	7.93	0.54	4.42e-13	Alzheimer's disease;
PAAD	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.94	-0.54	4.19e-13	Parkinson's disease;
PAAD	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.68	7.45	0.52	6.41e-12	Systemic lupus erythematosus;
PAAD	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.99	-0.38	1.61e-6	Height;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01588449	chr2:242682104	D2HGDH	-0.6	-6.38	-0.46	2.02e-9	Iris heterochromicity;
PAAD	cis	rs3010562	0.668	rs9457305	chr6:167760702	T/G	cg20481416	chr6:167803413	NA	0.44	4.64	0.35	7.32e-6	Gut microbiome composition (summer and winter);
PAAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.6	-7.1	-0.5	4.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg05251000	chr9:132935664	FREQ	0.55	4.55	0.35	1.11e-5	Alzheimer's disease (cognitive decline);
PAAD	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg01612440	chr4:3296283	NA	0.43	4.39	0.34	2.07e-5	Serum sulfate level;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01621420	chr11:74660152	XRRA1;SPCS2	-0.64	-6.41	-0.46	1.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9815354	1.000	rs10212536	chr3:41827026	A/G	cg03022575	chr3:42003672	ULK4	0.81	6.01	0.44	1.35e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg09659197	chr4:152720779	NA	0.36	5.29	0.39	4.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg03371404	chr2:241525653	CAPN10	-0.61	-4.98	-0.37	1.74e-6	Bipolar disorder;
PAAD	cis	rs2882667	0.690	rs995177	chr5:138169563	G/A	cg09476006	chr5:138032270	NA	-0.45	-5.72	-0.42	5.42e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.61	-5.89	-0.43	2.42e-8	Body mass index;
PAAD	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.57	4.97	0.37	1.79e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-5.01	-0.38	1.47e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-5.87	-0.43	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg02196655	chr2:10830764	NOL10	0.57	6.0	0.44	1.39e-8	Prostate cancer;
PAAD	cis	rs1322639	0.592	rs7743597	chr6:169591678	T/C	cg26074411	chr6:169568564	NA	0.47	4.67	0.35	6.55e-6	Pulse pressure;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	6.86	0.49	1.59e-10	Lymphocyte counts;
PAAD	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-7.27	-0.51	1.73e-11	Menarche (age at onset);
PAAD	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg17182837	chr8:41585554	ANK1	-0.41	-4.49	-0.34	1.41e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg14851346	chr12:38532713	NA	-0.45	-4.33	-0.33	2.7e-5	Bladder cancer;
PAAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg21699342	chr2:239360505	ASB1	-0.52	-5.37	-0.4	2.91e-7	Multiple system atrophy;
PAAD	cis	rs56346965	0.967	rs2159819	chr2:191532737	C/G	cg27211696	chr2:191398769	TMEM194B	-0.49	-4.3	-0.33	3.04e-5	Bone mineral density (Ward's triangle area);
PAAD	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	6.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs901683	0.850	rs79529960	chr10:46045315	C/T	cg16908948	chr10:45500256	ZNF22	0.79	4.26	0.33	3.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12431939	0.762	rs12435765	chr14:51702128	A/G	cg23942311	chr14:51606299	NA	-0.6	-5.0	-0.38	1.55e-6	Cancer;
PAAD	cis	rs4757319	0.515	rs7934026	chr11:15339942	A/G	cg03245590	chr11:15329459	NA	0.44	5.27	0.39	4.55e-7	Breast cancer;
PAAD	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.56	-5.42	-0.4	2.32e-7	Lymphocyte counts;
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.8	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-15.23	-0.78	2.22e-32	Ulcerative colitis;
PAAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg03225093	chr5:2008713	NA	0.35	4.35	0.33	2.45e-5	Lung cancer;
PAAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg07703079	chr11:430292	ANO9	0.8	4.59	0.35	9.08e-6	Body mass index;
PAAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	4.35	0.33	2.47e-5	Obesity-related traits;
PAAD	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg27395922	chr11:50257633	LOC441601	0.41	4.74	0.36	4.95e-6	Height;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19318450	chr21:34852305	TMEM50B	0.57	6.65	0.47	5.09e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27087555	chr16:88793112	FAM38A	-1.03	-5.79	-0.42	3.98e-8	Plateletcrit;
PAAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg26571870	chr16:85723150	GINS2	0.45	5.13	0.38	8.53e-7	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23037274	chr19:7968594	MAP2K7	0.72	7.26	0.51	1.89e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-1.2	-9.93	-0.63	3.18e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-7.39	-0.51	9.32e-12	Vitiligo;
PAAD	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.1	0.63	1.14e-18	Cognitive test performance;
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg10978503	chr1:24200527	CNR2	0.51	6.06	0.44	1.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.68	-5.8	-0.43	3.71e-8	Diabetic retinopathy;
PAAD	cis	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg02421172	chr7:1938701	MAD1L1	0.64	4.7	0.36	5.69e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6076065	0.963	rs6048797	chr20:23422621	G/A	cg11657817	chr20:23433608	CST11	0.45	4.71	0.36	5.57e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg02415014	chr8:143852576	LYNX1	0.39	4.52	0.34	1.24e-5	Urinary tract infection frequency;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	1.11	15.48	0.78	4.68e-33	Breast cancer;
PAAD	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-11.6	-0.69	1.09e-22	Chronic sinus infection;
PAAD	trans	rs9328321	0.580	rs9378431	chr6:5580951	C/G	cg20268689	chr2:20431435	NA	0.42	6.61	0.47	6.21e-10	Obesity (early onset extreme);
PAAD	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.76	-7.11	-0.5	4.22e-11	Breast cancer;
PAAD	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.66	-0.35	6.95e-6	Body mass index;
PAAD	cis	rs71520386	0.632	rs12532938	chr7:22860495	A/C	cg04907244	chr7:22894795	SNORD93	0.5	5.43	0.4	2.17e-7	Fibrinogen levels;
PAAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	7.48	0.52	5.53e-12	Menopause (age at onset);
PAAD	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.51	-5.95	-0.43	1.74e-8	Mean arterial pressure;
PAAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg26752003	chr8:145688521	CYHR1	0.6	7.11	0.5	4.25e-11	Age at first birth;
PAAD	cis	rs2004318	1.000	rs74727989	chr19:55139164	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.72	7.95	0.54	3.89e-13	Mood instability;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.74	9.96	0.63	2.59e-18	Lipoprotein (a) levels;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00982548	chr2:198649783	BOLL	-0.78	-5.62	-0.41	8.8e-8	Ulcerative colitis;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.51	5.44	0.4	2.04e-7	Menopause (age at onset);
PAAD	cis	rs1879734	0.731	rs72660679	chr1:54183531	C/G	cg14659662	chr1:54151053	GLIS1	-0.42	-5.59	-0.41	1.01e-7	Mitral valve prolapse;
PAAD	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg23506979	chr15:79090958	ADAMTS7	0.25	4.3	0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	4.4	0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.15	0.5	3.44e-11	Lung cancer in ever smokers;
PAAD	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.6	-5.56	-0.41	1.18e-7	White matter hyperintensity burden;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg18429911	chr11:64877380	C11orf2	-0.5	-5.0	-0.38	1.59e-6	Eosinophil percentage of white cells;
PAAD	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.48	7.67	0.53	1.87e-12	Neuroticism;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.2	0.39	6.36e-7	Life satisfaction;
PAAD	cis	rs35160687	0.644	rs4610056	chr2:86553250	T/C	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.02	0.49	6.87e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.09	0.38	1.04e-6	Breast cancer;
PAAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs76793172	1.000	rs3810328	chr19:46368222	G/T	cg13320842	chr19:46175254	GIPR	0.62	4.7	0.36	5.86e-6	Eosinophil counts;
PAAD	cis	rs12476592	0.602	rs4671065	chr2:63791131	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09065629	chr16:1709722	CRAMP1L	0.49	5.4	0.4	2.5e-7	Coronary artery disease;
PAAD	cis	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg21546286	chr11:48923668	NA	-0.54	-5.57	-0.41	1.14e-7	HDL cholesterol;
PAAD	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs55637147	0.553	rs879646	chr11:57124196	C/T	cg25492363	chr11:57319872	UBE2L6	-0.38	-4.31	-0.33	2.9e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg00614314	chr15:82944287	LOC80154	0.45	4.68	0.35	6.4e-6	Schizophrenia;
PAAD	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.15	-0.67	1.8e-21	Rheumatoid arthritis;
PAAD	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg09821211	chr3:195954098	OSTalpha	0.62	5.76	0.42	4.46e-8	Fat distribution (HIV);
PAAD	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.89	-0.49	1.41e-10	Atrioventricular conduction;
PAAD	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg16205897	chr5:131564050	P4HA2	-0.42	-4.57	-0.35	1e-5	Blood metabolite levels;
PAAD	trans	rs6490294	0.528	rs11066126	chr12:112444891	T/A	cg08332908	chr17:38465326	RARA	0.76	6.32	0.46	2.79e-9	Mean platelet volume;
PAAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.58	-7.97	-0.54	3.47e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs11264799	0.731	rs17676381	chr1:157681898	T/G	cg18268488	chr1:157545234	FCRL4	0.64	5.59	0.41	1.05e-7	IgA nephropathy;
PAAD	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.59	-8.63	-0.57	7.48e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.44	-0.4	2.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.77	-6.42	-0.46	1.67e-9	Pancreatic cancer;
PAAD	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.37	4.59	0.35	9.07e-6	Corneal astigmatism;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.62	6.79	0.48	2.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.27	-0.39	4.62e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	8.77	0.58	3.38e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg12908607	chr1:44402522	ARTN	-0.42	-4.64	-0.35	7.53e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.52	-7.06	-0.5	5.54e-11	Huntington's disease progression;
PAAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.57	-6.12	-0.44	7.64e-9	Menopause (age at onset);
PAAD	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	1.0	9.13	0.6	3.97e-16	Triglycerides;
PAAD	cis	rs3734905	1.000	rs16888119	chr6:169937237	C/T	cg11181693	chr6:169825345	NA	-0.88	-5.29	-0.39	4.24e-7	HIV-1 control;
PAAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.58	4.29	0.33	3.17e-5	Fat distribution (HIV);
PAAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.48	-5.05	-0.38	1.24e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg00262122	chr8:11665843	FDFT1	-0.62	-5.32	-0.4	3.61e-7	Neuroticism;
PAAD	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg20363699	chr7:23626180	CLK2P	0.41	5.0	0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-11.27	-0.67	8.31e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.75	-8.11	-0.55	1.59e-13	Prostate cancer;
PAAD	cis	rs1624802	0.967	rs1696432	chr12:130496976	A/G	cg15444478	chr12:130494697	NA	-0.36	-4.34	-0.33	2.56e-5	Obesity-related traits;
PAAD	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.64	5.92	0.43	2.05e-8	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00616603	chr17:71228383	C17orf80;FAM104A	0.57	6.45	0.46	1.41e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	1.49	8.53	0.57	1.36e-14	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.1	9.41	0.61	7.47e-17	Red blood cell traits;
PAAD	cis	rs3106136	0.843	rs7438414	chr4:95265822	T/C	cg11021082	chr4:95130006	SMARCAD1	0.6	5.92	0.43	2.07e-8	Capecitabine sensitivity;
PAAD	cis	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7922314	0.571	rs57110080	chr10:64736699	G/A	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.7	-5.9	-0.43	2.23e-8	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg26338869	chr17:61819248	STRADA	0.5	4.66	0.35	6.96e-6	Height;
PAAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.61	-7.3	-0.51	1.54e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg10972932	chr11:63215698	NA	-0.42	-4.46	-0.34	1.6e-5	Platelet count;
PAAD	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg10556349	chr10:835070	NA	0.6	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-1.17	-9.62	-0.62	2.05e-17	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.67	0.42	7.1e-8	Prudent dietary pattern;
PAAD	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg18357526	chr6:26021779	HIST1H4A	0.58	5.2	0.39	6.24e-7	Educational attainment;
PAAD	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.72	6.65	0.47	4.99e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.09	0.63	1.22e-18	Cognitive test performance;
PAAD	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	0.98	11.52	0.68	1.79e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.93	-8.14	-0.55	1.35e-13	Gut microbiome composition (summer);
PAAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.7	-0.42	5.99e-8	Tonsillectomy;
PAAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg02966332	chr20:62369605	LIME1	-0.5	-4.66	-0.35	6.88e-6	Prostate cancer;
PAAD	cis	rs251130	0.915	rs173821	chr5:110865365	C/T	cg11925263	chr5:110849104	STARD4	0.38	4.57	0.35	1.02e-5	Menarche (age at onset);
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.53	-0.41	1.34e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6076065	0.723	rs2281429	chr20:23399544	A/T	cg11657817	chr20:23433608	CST11	0.48	4.86	0.37	2.91e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1642645	0.597	rs702225	chr1:42373900	C/T	cg16685388	chr1:42384056	HIVEP3	-0.42	-4.26	-0.33	3.51e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg08316699	chr6:150357289	NA	-0.38	-4.49	-0.34	1.42e-5	Alopecia areata;
PAAD	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.62	6.33	0.46	2.6e-9	Monocyte count;
PAAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.48	6.37	0.46	2.08e-9	Ulcerative colitis;
PAAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	5.05	0.38	1.25e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.4	-0.4	2.55e-7	Waist circumference;Hip circumference;
PAAD	cis	rs7960581	0.673	rs61933595	chr12:99206718	G/C	cg17109042	chr12:99139387	ANKS1B	-0.76	-4.84	-0.37	3.2e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg16928487	chr17:17741425	SREBF1	0.38	5.03	0.38	1.38e-6	Total body bone mineral density;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12035827	chr1:10855226	CASZ1	0.56	6.37	0.46	2.18e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21908828	chr4:154386136	KIAA0922	0.54	6.35	0.46	2.41e-9	Smoking initiation;
PAAD	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	6.62	0.47	5.78e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg02230254	chr11:65586170	NA	-0.34	-4.75	-0.36	4.66e-6	Eosinophil percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09763514	chr7:2298050	SNX8	0.72	6.31	0.46	2.88e-9	Neuroticism;
PAAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg13939156	chr17:80058883	NA	0.49	5.38	0.4	2.75e-7	Life satisfaction;
PAAD	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.66	-0.35	6.9e-6	Neuroticism;
PAAD	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.71e-8	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs71499567	chr10:46083956	G/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.39	5.92	0.43	2.02e-8	Height;
PAAD	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.54	4.4	0.34	2.01e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.59e-7	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.44e-9	Lung cancer;
PAAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.32e-6	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs4802307	1.000	rs4802307	chr19:46849806	G/T	cg22304262	chr19:47287778	SLC1A5	-0.5	-4.58	-0.35	9.79e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23410386	chr6:56637189	DST	0.67	7.13	0.5	3.89e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs490234	0.932	rs506874	chr9:128319066	G/A	cg14078157	chr9:128172775	NA	0.39	4.25	0.33	3.65e-5	Mean arterial pressure;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs923375	0.632	rs227802	chr17:3342315	G/A	cg02458198	chr17:3375211	SPATA22	0.53	4.48	0.34	1.48e-5	Myopia (pathological);
PAAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.16	0.5	3.28e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg17842918	chr13:113540400	ATP11A	0.42	4.52	0.34	1.25e-5	Glycated hemoglobin levels;
PAAD	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.53	6.38	0.46	2.02e-9	Sitting height ratio;
PAAD	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3779195	0.860	rs12704986	chr7:97986430	T/C	cg24562669	chr7:97807699	LMTK2	0.51	4.86	0.37	2.91e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.49	4.66	0.35	6.87e-6	HDL cholesterol;
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.5	-0.83	9.12e-41	Ulcerative colitis;
PAAD	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Alcohol dependence;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.68	7.39	0.51	9.19e-12	Longevity;
PAAD	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.01	-0.38	1.5e-6	Joint mobility (Beighton score);
PAAD	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.86	9.94	0.63	3.04e-18	Ulcerative colitis;
PAAD	cis	rs7101378	0.577	rs1509708	chr11:108900875	A/C	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs2976388	0.507	rs13279795	chr8:143838669	G/A	cg06565975	chr8:143823917	SLURP1	0.21	4.88	0.37	2.67e-6	Urinary tract infection frequency;
PAAD	cis	rs11020478	0.562	rs9888134	chr11:93374972	G/A	cg10523193	chr11:93463762	SNORA25	0.45	4.65	0.35	7.27e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	0.98	10.81	0.66	1.5e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	6.14	0.45	7.03e-9	Mean platelet volume;
PAAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg16362232	chr11:430036	ANO9	0.84	5.21	0.39	6.16e-7	Body mass index;
PAAD	cis	rs2997447	0.688	rs17257100	chr1:26439586	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg16083429	chr3:49237500	CCDC36	-0.44	-4.56	-0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.69	6.28	0.45	3.33e-9	Blood metabolite levels;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg16898833	chr6:26189333	HIST1H4D	0.63	5.01	0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg14180030	chr9:123475675	MEGF9	-0.42	-4.75	-0.36	4.75e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6142102	0.961	rs4911411	chr20:32715842	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	4.29	0.33	3.22e-5	Skin pigmentation;
PAAD	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.28	0.33	3.27e-5	Diabetic retinopathy;
PAAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-1.05	-14.65	-0.77	7.23e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	4.36	0.33	2.41e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.92	-8.85	-0.58	2.06e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5771040	0.560	rs738683	chr22:50910875	A/G	cg03450049	chr22:50913555	SBF1	0.55	4.75	0.36	4.59e-6	IgG glycosylation;
PAAD	cis	rs4690686	0.760	rs1377838	chr4:177282547	G/T	cg17059388	chr4:177262070	NA	0.54	5.24	0.39	5.3e-7	Essential tremor;
PAAD	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.72	-6.29	-0.45	3.15e-9	Pulmonary function decline;
PAAD	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.51	5.28	0.39	4.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs988913	1.000	rs2221334	chr6:54834541	A/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs73419609	1.000	rs73419631	chr15:54722648	T/C	cg11288833	chr15:55489084	RSL24D1	-1.01	-4.38	-0.33	2.2e-5	Post-traumatic stress disorder;
PAAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs509477	0.738	rs1424452	chr18:32556816	G/C	cg23791764	chr18:32556832	MAPRE2	0.69	5.61	0.41	9.33e-8	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs8025118	0.583	rs7163859	chr15:79552585	A/G	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.25	-0.33	3.77e-5	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11407514	chr10:99094219	FRAT2	0.62	7.25	0.51	1.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.69	-0.36	6.03e-6	Height;
PAAD	cis	rs7577696	0.539	rs2280972	chr2:32377961	C/T	cg02381751	chr2:32503542	YIPF4	-0.46	-4.35	-0.33	2.52e-5	Inflammatory biomarkers;
PAAD	cis	rs9810890	1.000	rs73198844	chr3:128503044	G/A	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	1.07	15.25	0.78	1.87e-32	Metabolite levels;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg18769074	chr3:133464867	TF	0.39	4.4	0.34	2.02e-5	Iron status biomarkers;
PAAD	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg16898833	chr6:26189333	HIST1H4D	0.89	4.92	0.37	2.22e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.85	7.43	0.52	7.27e-12	Coronary artery disease;
PAAD	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	1.26	13.06	0.73	1.29e-26	Post bronchodilator FEV1;
PAAD	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg19949948	chr17:19361230	NA	-0.43	-4.44	-0.34	1.74e-5	Schizophrenia;
PAAD	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.94	6.62	0.47	5.86e-10	Opioid sensitivity;
PAAD	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg24737193	chr18:12778029	NA	0.64	5.47	0.41	1.84e-7	Inflammatory skin disease;
PAAD	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg05294307	chr14:35346193	BAZ1A	0.49	4.69	0.36	5.93e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.47	6.96	0.49	9.75e-11	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.82	-8.86	-0.58	1.93e-15	Parkinson's disease;
PAAD	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg12568669	chr8:11666485	FDFT1	0.31	5.25	0.39	5.14e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.69	0.62	1.34e-17	Prudent dietary pattern;
PAAD	cis	rs6681460	0.899	rs1280280	chr1:67173903	G/A	cg02459107	chr1:67143332	SGIP1	0.7	6.57	0.47	7.67e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.64	6.81	0.48	2.11e-10	Lung cancer;
PAAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg19592336	chr6:28129416	ZNF389	0.62	4.37	0.33	2.25e-5	Depression;
PAAD	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg09237302	chr4:906077	GAK	-0.44	-4.51	-0.34	1.29e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.46	4.59	0.35	9.26e-6	Selective IgA deficiency;
PAAD	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.36	-0.33	2.36e-5	Height;
PAAD	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	1.18	15.4	0.78	7.49e-33	Ewing sarcoma;
PAAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.32	6.03	0.44	1.2e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12967884	0.892	rs4799234	chr18:76606637	C/T	cg16859165	chr18:76601647	NA	-0.54	-4.37	-0.33	2.26e-5	Subcutaneous adipose tissue;
PAAD	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg23750338	chr8:142222470	SLC45A4	-0.49	-4.95	-0.37	1.95e-6	Birth weight;
PAAD	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-6.5	-0.47	1.08e-9	Mosquito bite size;
PAAD	cis	rs990171	0.955	rs2058658	chr2:103054803	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.64	0.47	5.13e-10	Lung function (FEV1/FVC);
PAAD	cis	rs7260598	0.539	rs7254143	chr19:24080537	C/T	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.56	5.59	0.41	1.02e-7	Lung cancer;
PAAD	trans	rs6694672	1.000	rs1576879	chr1:196992318	C/G	cg26994526	chr18:47719735	MYO5B	-0.81	-6.38	-0.46	2.04e-9	Asthma;
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	5.9	0.43	2.3e-8	Platelet count;
PAAD	cis	rs4356203	0.905	rs598946	chr11:17209087	C/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg25547332	chr5:131281432	NA	-0.56	-4.33	-0.33	2.74e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
PAAD	trans	rs4864201	0.560	rs2952869	chr4:130766339	A/G	cg08471972	chr13:51844375	FAM124A	-0.56	-6.66	-0.48	4.82e-10	Obesity;
PAAD	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.72	7.05	0.5	5.73e-11	Mean platelet volume;
PAAD	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-10.12	-0.63	1.01e-18	Platelet distribution width;
PAAD	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.5	-5.17	-0.39	7.2e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg00531865	chr16:30841666	NA	-0.51	-4.98	-0.37	1.74e-6	Dementia with Lewy bodies;
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.15	-0.6	3.49e-16	Prostate cancer;
PAAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg05392440	chr1:2478653	NA	0.56	6.05	0.44	1.09e-8	Ulcerative colitis;
PAAD	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05491587	chr18:77659695	KCNG2	-0.73	-4.25	-0.33	3.71e-5	Opioid sensitivity;
PAAD	cis	rs7631605	0.905	rs6808735	chr3:37104246	A/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg01299579	chr2:10830716	NOL10	0.59	6.13	0.45	7.13e-9	Prostate cancer;
PAAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg00717180	chr2:96193071	NA	-0.62	-7.71	-0.53	1.52e-12	HDL cholesterol;
PAAD	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.45	-4.41	-0.34	1.94e-5	QT interval;
PAAD	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.74	-0.42	5.06e-8	Mean corpuscular volume;
PAAD	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-4.72	-0.36	5.28e-6	Personality dimensions;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.91	11.08	0.67	2.8e-21	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2034650	0.525	rs11790	chr15:40712737	T/C	cg05276125	chr15:40653601	DISP2	0.46	4.43	0.34	1.81e-5	Interstitial lung disease;
PAAD	cis	rs11264799	0.520	rs861998	chr1:157543878	G/A	cg18268488	chr1:157545234	FCRL4	0.54	6.17	0.45	5.85e-9	IgA nephropathy;
PAAD	cis	rs62264129	0.500	rs62278843	chr3:112041382	T/C	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.28	-0.33	3.27e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.33	-0.51	1.3e-11	Chronic sinus infection;
PAAD	cis	rs1419980	0.730	rs7962586	chr12:7772315	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg20406979	chr6:167373233	NA	0.36	4.76	0.36	4.52e-6	Crohn's disease;
PAAD	cis	rs6460942	0.908	rs6978768	chr7:12232366	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg03983715	chr16:68378420	PRMT7	-0.97	-6.68	-0.48	4.26e-10	Schizophrenia;
PAAD	cis	rs501120	0.584	rs1746034	chr10:44714768	T/C	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9928842	0.824	rs889515	chr16:75251299	T/C	cg09066997	chr16:75300724	BCAR1	0.65	4.72	0.36	5.35e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.24	12.35	0.71	1.08e-24	Platelet count;
PAAD	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.44	0.34	1.71e-5	Neuroticism;
PAAD	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg02297831	chr4:17616191	MED28	-0.61	-5.93	-0.43	1.95e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12936587	0.633	rs12941217	chr17:17503206	G/A	cg03641529	chr17:17716218	SREBF1	-0.4	-4.31	-0.33	2.88e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-8.34	-0.56	4.17e-14	Gut microbiome composition (summer);
PAAD	cis	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.91	-12.22	-0.7	2.41e-24	Body mass index;
PAAD	cis	rs17102423	0.859	rs34184001	chr14:65596027	T/C	cg11161011	chr14:65562177	MAX	-0.49	-4.31	-0.33	2.87e-5	Obesity-related traits;
PAAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.39	-4.65	-0.35	7.2e-6	Tonsillectomy;
PAAD	cis	rs4900538	0.827	rs3742444	chr14:102971050	T/G	cg01761236	chr14:102990251	NA	0.38	4.43	0.34	1.82e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.45	-6.99	-0.49	8.12e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.63	6.8	0.48	2.23e-10	Heart rate;
PAAD	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.93	10.77	0.66	1.82e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs375066	0.935	rs388706	chr19:44418693	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg05896902	chr15:45671018	LOC145663;GATM	0.5	4.29	0.33	3.23e-5	Homoarginine levels;
PAAD	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.89	-0.49	1.39e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9857275	0.788	rs13066993	chr3:141129999	G/A	cg00789793	chr3:141329863	RASA2	0.49	4.29	0.33	3.16e-5	Prion diseases;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14628049	chr9:123943388	RAB14	-0.54	-6.55	-0.47	8.37e-10	Monocyte percentage of white cells;
PAAD	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22818913	chr6:37467785	C6orf129	-0.75	-6.7	-0.48	3.9e-10	Neuroticism;
PAAD	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.96	-0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.56	-5.24	-0.39	5.16e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg11204139	chr17:3907470	NA	0.7	7.08	0.5	5.12e-11	Type 2 diabetes;
PAAD	cis	rs2286379	0.596	rs10848563	chr12:1841543	T/C	cg05227549	chr12:1770782	NA	-0.44	-5.1	-0.38	9.95e-7	Blood pressure (smoking interaction);
PAAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg00206168	chr11:65308501	LTBP3	0.54	5.65	0.42	7.57e-8	Bone mineral density;
PAAD	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.85	8.89	0.58	1.67e-15	Corneal astigmatism;
PAAD	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.7	-7.63	-0.53	2.43e-12	Colorectal cancer;
PAAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.32	-0.6	1.28e-16	Pancreatic cancer;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.88	6.69	0.48	4.06e-10	Alzheimer's disease;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg23912435	chr1:150601613	ENSA	0.49	4.51	0.34	1.27e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg08648136	chr8:956695	NA	0.42	4.48	0.34	1.43e-5	Schizophrenia;
PAAD	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	4.78	0.36	4.06e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02706910	chr19:24269975	ZNF254	-0.66	-6.84	-0.49	1.8e-10	Smoking initiation;
PAAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg16664915	chr8:10907788	XKR6	-0.42	-4.41	-0.34	1.95e-5	Triglycerides;
PAAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-4.77	-0.36	4.37e-6	Testicular germ cell tumor;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10535786	chr2:159313397	CCDC148;PKP4	-0.73	-6.57	-0.47	7.67e-10	Neuroticism;
PAAD	cis	rs3112530	1.000	rs2964816	chr5:152660235	G/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9815354	1.000	rs6803652	chr3:41824556	A/G	cg03022575	chr3:42003672	ULK4	0.75	5.55	0.41	1.22e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.63	-6.33	-0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.57	6.0	0.44	1.4e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg09835421	chr16:68378352	PRMT7	-0.98	-5.97	-0.44	1.64e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs57244997	0.725	rs7754703	chr6:162440488	T/C	cg17173639	chr6:162384350	PARK2	-0.65	-5.07	-0.38	1.16e-6	Mosquito bite size;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.56	5.95	0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.71	6.45	0.46	1.42e-9	Body mass index;
PAAD	cis	rs4668356	0.892	rs7608813	chr2:171803906	C/A	cg13882835	chr2:172017928	TLK1	-0.86	-4.25	-0.33	3.73e-5	Cognitive performance;
PAAD	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.27	-0.71	1.72e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2790216	0.901	rs2590354	chr10:60016587	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg01840333	chr6:26225767	HIST1H3E	0.45	4.56	0.35	1.07e-5	Blood metabolite levels;
PAAD	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.38	0.56	3.29e-14	Homoarginine levels;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.88	0.37	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.88	11.28	0.68	7.95e-22	Body mass index;
PAAD	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.85	-0.37	3e-6	Mean corpuscular volume;
PAAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.59	5.65	0.42	7.76e-8	Schizophrenia;
PAAD	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.44	-0.34	1.74e-5	Ileal carcinoids;
PAAD	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12502441	chr20:56285530	PMEPA1	0.55	6.44	0.46	1.51e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7816613	0.920	rs10106317	chr8:102669701	C/G	cg20585841	chr8:102729926	NCALD	-0.7	-5.46	-0.41	1.88e-7	Age-related hearing impairment;
PAAD	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6782025	0.802	rs338958	chr3:120963502	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-8.06	-0.55	2.1e-13	Vitiligo;
PAAD	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26926768	chr12:34528122	NA	0.37	4.61	0.35	8.63e-6	Morning vs. evening chronotype;
PAAD	cis	rs9314614	0.763	rs2980947	chr8:6713941	C/T	cg27319216	chr8:6693540	XKR5	-0.38	-5.02	-0.38	1.42e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.78	9.08	0.59	5.25e-16	Heart rate;
PAAD	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs11807834	0.522	rs2057234	chr1:230233014	A/T	cg00566187	chr1:230250356	GALNT2	-0.61	-6.5	-0.47	1.07e-9	Schizophrenia;
PAAD	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg07384165	chr1:10488281	NA	-0.48	-5.13	-0.38	8.55e-7	Breast size;
PAAD	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg10621924	chr7:39171070	POU6F2	0.37	5.74	0.42	4.95e-8	IgG glycosylation;
PAAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.63	-8.68	-0.58	5.69e-15	Renal cell carcinoma;
PAAD	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg21366198	chr4:185655624	MLF1IP	-0.48	-4.27	-0.33	3.43e-5	Kawasaki disease;
PAAD	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.84	-4.56	-0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg24851651	chr11:66362959	CCS	0.53	5.02	0.38	1.44e-6	Airway imaging phenotypes;
PAAD	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.66	0.48	4.73e-10	Response to antipsychotic treatment;
PAAD	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.89	0.54	5.48e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.68	5.04	0.38	1.3e-6	Bipolar disorder;
PAAD	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg15956490	chr3:53032818	SFMBT1	0.82	4.85	0.37	3.01e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25236837	chr7:65959120	NA	0.56	6.58	0.47	7.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.75	-7.69	-0.53	1.73e-12	DNA methylation (variation);
PAAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.61	-5.74	-0.42	4.98e-8	Glaucoma (primary open-angle);
PAAD	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2790216	1.000	rs2590368	chr10:60043482	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.56	-5.11	-0.38	9.66e-7	Serum sulfate level;
PAAD	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.92	5.96	0.44	1.72e-8	Chronic kidney disease;
PAAD	cis	rs900145	0.775	rs7926712	chr11:13303085	A/G	cg15603424	chr11:13300592	ARNTL	0.51	4.51	0.34	1.3e-5	Menarche (age at onset);
PAAD	cis	rs67257959	0.586	rs111818766	chr19:17158092	G/A	cg19418318	chr19:17219073	MYO9B	0.35	4.92	0.37	2.25e-6	Selective IgA deficiency;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg04719420	chr1:183441464	SMG7	-0.63	-7.34	-0.51	1.19e-11	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18319916	chr18:54305957	TXNL1	0.73	7.97	0.54	3.48e-13	Myopia (pathological);
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.27	0.39	4.5e-7	Resting heart rate;
PAAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg05805236	chr11:65401703	PCNXL3	0.53	4.42	0.34	1.86e-5	Crohn's disease;
PAAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.62	6.22	0.45	4.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.93	8.96	0.59	1.08e-15	Psoriasis;
PAAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.55	-0.41	1.27e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs67257959	0.708	rs1979260	chr19:17193551	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.48	-4.81	-0.36	3.54e-6	Selective IgA deficiency;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.94	12.01	0.7	8.94e-24	Menarche (age at onset);
PAAD	cis	rs6142102	0.625	rs7263727	chr20:32540939	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	4.71	0.36	5.45e-6	Skin pigmentation;
PAAD	cis	rs9283706	0.594	rs7735834	chr5:66337444	A/G	cg11590213	chr5:66331682	MAST4	-0.63	-5.07	-0.38	1.16e-6	Coronary artery disease;
PAAD	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.76	-0.42	4.57e-8	Neuroticism;
PAAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs12714314	0.593	rs11690447	chr2:1967880	G/A	cg22350835	chr2:1868857	MYT1L	0.48	4.77	0.36	4.21e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg10556349	chr10:835070	NA	0.57	4.95	0.37	1.98e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg21400344	chr1:25870172	LDLRAP1	-0.72	-6.58	-0.47	7.01e-10	Blood protein levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11221657	chr2:173940432	ZAK	0.68	7.05	0.5	5.78e-11	Obesity-related traits;
PAAD	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.07	-0.38	1.16e-6	Reticulocyte count;
PAAD	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg01090926	chr14:75137805	KIAA0317	0.51	4.74	0.36	4.9e-6	Non-small cell lung cancer;
PAAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg09597638	chr17:3907349	NA	0.8	6.09	0.44	8.8e-9	Type 2 diabetes;
PAAD	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg07469887	chr10:131262384	NA	-0.4	-4.48	-0.34	1.44e-5	Response to temozolomide;
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18364779	chr6:26104403	HIST1H4C	0.45	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg21395723	chr22:39101663	GTPBP1	0.49	5.13	0.38	8.83e-7	Menopause (age at onset);
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.56	5.65	0.42	7.73e-8	Parkinson's disease;
PAAD	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.13	-0.38	8.77e-7	Mean corpuscular volume;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg03909863	chr11:638404	DRD4	-0.6	-5.45	-0.4	1.94e-7	Systemic lupus erythematosus;
PAAD	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.55	5.92	0.43	2.11e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26306683	chr17:18585705	ZNF286B	0.52	4.25	0.33	3.64e-5	Pancreatic cancer;
PAAD	cis	rs7830933	0.955	rs7002330	chr8:23590900	A/G	cg04349084	chr8:23602677	NA	0.41	4.41	0.34	1.95e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.6	-5.89	-0.43	2.42e-8	Itch intensity from mosquito bite;
PAAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.84	11.44	0.68	3.06e-22	Emphysema distribution in smoking;
PAAD	cis	rs2637266	0.783	rs860167	chr10:78532936	A/G	cg18941641	chr10:78392320	NA	0.4	4.85	0.37	2.97e-6	Pulmonary function;
PAAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.49	5.4	0.4	2.51e-7	Aortic root size;
PAAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.46	5.86	0.43	2.82e-8	Cystic fibrosis severity;
PAAD	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg21108841	chr4:24914750	CCDC149	-0.54	-4.48	-0.34	1.48e-5	Heschl's gyrus morphology;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.64	0.57	7.13e-15	Lung cancer;
PAAD	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.67	7.92	0.54	4.54e-13	Heart rate;
PAAD	cis	rs987237	0.892	rs2206277	chr6:50798526	C/T	cg24161652	chr6:50813859	TFAP2B	0.35	4.27	0.33	3.4e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Childhood body mass index;Adiposity;Body mass index in physically active individuals;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13813874	chr22:20849595	KLHL22	0.63	7.01	0.49	7.29e-11	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27470295	chr4:169401621	DDX60L	0.56	6.38	0.46	2.01e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.8	8.12	0.55	1.51e-13	Blood protein levels;
PAAD	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.97	11.52	0.68	1.76e-22	Breast cancer;
PAAD	cis	rs2384207	0.818	rs7299870	chr12:113708590	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.59	5.25	0.39	5.03e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-5.48	-0.41	1.73e-7	Initial pursuit acceleration;
PAAD	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.29	-0.6	1.53e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.63	6.18	0.45	5.66e-9	Pancreatic cancer;
PAAD	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg00546117	chr1:8445545	RERE	0.44	4.39	0.34	2.09e-5	Crohn's disease;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.79	-10.31	-0.64	3.13e-19	Vitiligo;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg01097406	chr16:89675127	NA	0.38	4.55	0.35	1.1e-5	Vitiligo;
PAAD	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.04	-7.72	-0.53	1.45e-12	Diabetic kidney disease;
PAAD	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.5	-6.15	-0.45	6.59e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06544989	chr22:39130855	UNC84B	-0.44	-4.47	-0.34	1.51e-5	Menopause (age at onset);
PAAD	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg06606381	chr12:133084897	FBRSL1	-1.38	-8.57	-0.57	1.09e-14	Depression;
PAAD	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg00179576	chr16:74483694	GLG1	-0.4	-4.46	-0.34	1.58e-5	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.45	0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.55	-5.18	-0.39	6.98e-7	Neurofibrillary tangles;
PAAD	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	4.92	0.37	2.25e-6	Childhood ear infection;
PAAD	cis	rs4605213	0.528	rs11079949	chr17:49320404	T/C	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.61	0.41	9.47e-8	Height;
PAAD	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.96	-13.66	-0.74	3.27e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3996993	0.597	rs62412900	chr6:52721568	C/T	cg00536792	chr6:53530503	KLHL31	-0.41	-4.5	-0.34	1.36e-5	Hemoglobin concentration;
PAAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	6.09	0.44	8.76e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg05697835	chr1:2722811	NA	0.42	4.69	0.36	6.16e-6	Ulcerative colitis;
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg06883089	chr1:45254480	BEST4	0.36	4.69	0.36	6.14e-6	High light scatter reticulocyte count;
PAAD	cis	rs41311933	1.000	rs12685289	chr9:123755383	T/A	cg13567360	chr9:123745713	C5	-0.73	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg00262122	chr8:11665843	FDFT1	0.56	5.02	0.38	1.45e-6	Neuroticism;
PAAD	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.5	5.52	0.41	1.43e-7	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg13468214	chr4:1046988	NA	-0.54	-5.02	-0.38	1.4e-6	Recombination rate (females);
PAAD	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.78	0.42	4.19e-8	Schizophrenia;
PAAD	cis	rs761746	0.739	rs131225	chr22:32113849	A/G	cg01338084	chr22:32026380	PISD	0.62	5.07	0.38	1.17e-6	Intelligence;
PAAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.87	12.37	0.71	9.36e-25	Bone mineral density;
PAAD	cis	rs9880406	0.833	rs938389	chr3:126058762	C/T	cg13708016	chr3:126007563	NA	-0.47	-4.51	-0.34	1.29e-5	Macular telangiectasia type 2;
PAAD	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg18279126	chr7:2041391	MAD1L1	-0.52	-5.11	-0.38	9.69e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.77	-11.07	-0.67	3.01e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15484161	chr1:234746568	IRF2BP2	0.76	8.07	0.55	1.94e-13	Obesity-related traits;
PAAD	cis	rs16910800	0.954	rs7123141	chr11:23203403	G/A	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.29e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9810890	0.850	rs7632015	chr3:128659244	G/T	cg15676455	chr3:128564943	NA	0.76	5.2	0.39	6.46e-7	Dental caries;
PAAD	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.68	5.03	0.38	1.35e-6	Thyroid stimulating hormone;
PAAD	cis	rs9660180	0.819	rs4648629	chr1:1695462	C/A	cg27541892	chr1:1571801	CDK11B	-0.53	-5.43	-0.4	2.14e-7	Body mass index;
PAAD	cis	rs6542838	0.646	rs2008648	chr2:99408323	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.09	-0.38	1.05e-6	Fear of minor pain;
PAAD	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg17372657	chr7:1216933	NA	-0.38	-5.05	-0.38	1.28e-6	Longevity;Endometriosis;
PAAD	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg08614441	chr13:113633676	MCF2L	-0.43	-4.32	-0.33	2.76e-5	Systolic blood pressure;
PAAD	trans	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg02569823	chr6:5851330	NA	0.63	6.72	0.48	3.52e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg05562828	chr17:3906858	NA	0.6	6.48	0.47	1.22e-9	Type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg16342193	chr10:102329863	NA	-0.83	-8.94	-0.59	1.25e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.67	7.13	0.5	3.81e-11	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18201392	chr1:185023741	RNF2	-0.74	-7.63	-0.53	2.35e-12	Obesity-related traits;
PAAD	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-4.99	-0.38	1.62e-6	P wave terminal force;
PAAD	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg06569542	chr10:98946673	SLIT1	0.5	5.06	0.38	1.19e-6	Monocyte count;
PAAD	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.0	0.49	7.53e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.64	4.64	0.35	7.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg00945038	chr17:61921165	SMARCD2	0.5	6.04	0.44	1.14e-8	Prudent dietary pattern;
PAAD	cis	rs11955175	0.702	rs74653842	chr5:40773178	C/T	cg17351974	chr5:40835760	RPL37	0.82	4.37	0.33	2.33e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	8.71	0.58	4.93e-15	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.56	-6.7	-0.48	3.75e-10	Total body bone mineral density;
PAAD	cis	rs988913	1.000	rs1503135	chr6:54841672	C/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.81	-0.36	3.62e-6	Menarche (age at onset);
PAAD	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19630440	chr20:33146371	MAP1LC3A	0.69	7.89	0.54	5.58e-13	Myopia (pathological);
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.39	-0.51	9.23e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.42	5.24	0.39	5.39e-7	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.63	0.35	7.78e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18631292	chr19:13875311	MRI1	-0.67	-6.63	-0.47	5.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.47	4.47	0.34	1.54e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg05110241	chr16:68378359	PRMT7	-1.21	-8.53	-0.57	1.37e-14	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.82	-8.05	-0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs6537837	1.000	rs2301229	chr1:110136678	C/T	cg05049280	chr1:110155535	GNAT2	0.46	4.6	0.35	8.69e-6	Major depressive disorder;
PAAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.82e-16	Parkinson's disease;
PAAD	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.95	11.59	0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg22467129	chr15:76604101	ETFA	0.51	4.79	0.36	4e-6	Blood metabolite levels;
PAAD	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg05341575	chr12:125625032	AACS	-0.5	-4.48	-0.34	1.46e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24722405	chr5:138677638	PAIP2	-0.63	-7.65	-0.53	2.09e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.81	-7.66	-0.53	1.98e-12	DNA methylation (variation);
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.23	-0.39	5.52e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7714584	0.590	rs4352593	chr5:150269332	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13732083	chr21:47605072	C21orf56	0.5	4.87	0.37	2.72e-6	Testicular germ cell tumor;
PAAD	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.56	6.1	0.44	8.31e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs8014252	0.803	rs12588723	chr14:70984951	C/T	cg11204974	chr14:71022665	NA	0.76	4.8	0.36	3.69e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.87	7.59	0.52	2.94e-12	Large artery stroke;
PAAD	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.56	5.92	0.43	2.06e-8	Subjective well-being;
PAAD	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.8	9.76	0.62	9.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs8133932	0.521	rs1625244	chr21:47364499	C/T	cg11214348	chr21:47283868	PCBP3	-0.51	-4.61	-0.35	8.6e-6	Schizophrenia;
PAAD	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.86	-0.37	2.85e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-12.08	-0.7	5.74e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs12282928	0.959	rs713325	chr11:48285301	A/G	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16528022	chr14:65438707	RAB15	-0.77	-8.29	-0.56	5.62e-14	Smoking initiation;
PAAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23130739	chr14:100563887	EVL	-0.74	-8.11	-0.55	1.6e-13	Obesity-related traits;
PAAD	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.17e-10	Life satisfaction;
PAAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18357526	chr6:26021779	HIST1H4A	0.73	7.74	0.53	1.29e-12	Height;
PAAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.43	0.4	2.23e-7	Personality dimensions;
PAAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.78	-7.14	-0.5	3.54e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg18939081	chr1:31884902	SERINC2	0.46	5.12	0.38	9.07e-7	Alcohol dependence;
PAAD	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.97	9.25	0.6	1.96e-16	Psoriasis;
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg00431813	chr7:1051703	C7orf50	0.75	4.78	0.36	4.17e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2137920	0.685	rs12764062	chr10:50239475	A/G	cg02657375	chr10:50863136	CHAT	0.54	4.39	0.34	2.15e-5	Migraine with aura;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21520050	chr4:6645756	NA	0.6	6.96	0.49	9.5e-11	Smoking initiation;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.41e-6	Lung cancer;
PAAD	cis	rs11105468	0.659	rs11105520	chr12:90550853	G/T	cg16962463	chr12:89968675	NA	0.44	4.62	0.35	8.29e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg09376583	chr16:88111425	NA	-0.49	-4.35	-0.33	2.46e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.23	0.39	5.57e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg02404636	chr22:31891804	SFI1	-0.55	-5.34	-0.4	3.26e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	1.25	6.55	0.47	8.43e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2070632	0.708	rs2248690	chr3:186330088	A/T	cg25162301	chr3:186330055	AHSG	-0.46	-4.57	-0.35	1e-5	Blood protein levels;
PAAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.56	7.34	0.51	1.17e-11	Schizophrenia;
PAAD	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.64	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-5.44	-0.4	2.09e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg10631289	chr15:39006617	NA	0.47	4.55	0.35	1.09e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.57e-5	Breast cancer;
PAAD	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.47	6.03	0.44	1.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4795519	0.736	rs1520021	chr17:22152965	A/G	cg22648282	chr17:21454238	C17orf51	-0.52	-4.86	-0.37	2.86e-6	Chronic myeloid leukemia;
PAAD	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.48	0.34	1.45e-5	Breast cancer;
PAAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9810890	1.000	rs73196988	chr3:128453467	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13919506	chr9:131535850	NA	-0.69	-7.16	-0.5	3.21e-11	Obesity-related traits;
PAAD	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg07384165	chr1:10488281	NA	-0.44	-4.5	-0.34	1.35e-5	Breast cancer;
PAAD	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs9815354	1.000	rs2683695	chr3:41914928	C/T	cg03022575	chr3:42003672	ULK4	0.84	6.12	0.44	7.66e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs72960926	1.000	rs72956962	chr6:75100904	T/C	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.44	0.65	1.45e-19	Platelet count;
PAAD	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.15	0.55	1.28e-13	Monocyte percentage of white cells;
PAAD	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg11995313	chr8:8860691	ERI1	0.52	5.41	0.4	2.43e-7	Joint mobility (Beighton score);
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.05	-0.5	5.9e-11	Life satisfaction;
PAAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs72901758	0.768	rs55782477	chr17:76250703	G/C	cg11439826	chr17:76250004	NA	0.46	4.58	0.35	9.59e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.83	0.48	1.95e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.96	0.37	1.89e-6	Post bronchodilator FEV1;
PAAD	cis	rs9283706	0.689	rs10041705	chr5:66317222	C/T	cg11590213	chr5:66331682	MAST4	-0.62	-5.07	-0.38	1.12e-6	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Breast cancer;
PAAD	cis	rs17095355	0.818	rs12571773	chr10:111776004	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.73	7.13	0.5	3.73e-11	Recombination rate (males);
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-4.88	-0.37	2.63e-6	Height;
PAAD	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-1.12	-4.68	-0.35	6.28e-6	Breast cancer;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg21620606	chr4:1342894	KIAA1530	0.45	4.25	0.33	3.77e-5	Obesity-related traits;
PAAD	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg11644478	chr21:40555479	PSMG1	0.86	9.08	0.59	5.35e-16	Cognitive function;
PAAD	cis	rs427941	0.632	rs201526	chr7:101774333	T/G	cg06246474	chr7:101738831	CUX1	0.43	4.28	0.33	3.35e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.56	5.77	0.42	4.26e-8	Menarche (age at onset);
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg18928584	chr10:104192519	CUEDC2	0.76	6.48	0.47	1.22e-9	Atopic dermatitis;
PAAD	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg02023728	chr11:77925099	USP35	-0.43	-4.35	-0.33	2.52e-5	Alzheimer's disease (survival time);
PAAD	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-6.69	-0.48	4.08e-10	Colorectal cancer;
PAAD	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg14343924	chr8:8086146	FLJ10661	-0.66	-5.47	-0.41	1.83e-7	Mood instability;
PAAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg02012338	chr4:187126139	CYP4V2	0.63	4.37	0.33	2.29e-5	Blood protein levels;
PAAD	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.61	-6.35	-0.46	2.31e-9	Motion sickness;
PAAD	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg02230254	chr11:65586170	NA	-0.34	-4.75	-0.36	4.66e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.69	7.4	0.51	8.86e-12	Obesity-related traits;
PAAD	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11644478	chr21:40555479	PSMG1	-0.48	-4.82	-0.36	3.39e-6	Menarche (age at onset);
PAAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.92	10.78	0.66	1.8e-20	Total body bone mineral density;
PAAD	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg12215294	chr3:40350768	EIF1B	-0.48	-4.86	-0.37	2.84e-6	Renal cell carcinoma;
PAAD	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.36	-0.46	2.22e-9	Menopause (age at onset);
PAAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg24733560	chr20:60626293	TAF4	0.53	6.62	0.47	5.87e-10	Body mass index;
PAAD	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.61	5.07	0.38	1.13e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10875595	0.732	rs62378370	chr5:140679460	T/C	cg24830062	chr5:140700576	TAF7	-0.53	-4.41	-0.34	1.94e-5	Pulmonary function decline;
PAAD	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg00543991	chr22:32367038	NA	1.17	7.35	0.51	1.12e-11	Childhood ear infection;
PAAD	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.19	0.64	6.41e-19	Cognitive test performance;
PAAD	cis	rs9810890	1.000	rs6768014	chr3:128592457	A/G	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.49	-4.62	-0.35	8.08e-6	Obesity-related traits;
PAAD	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg20607287	chr7:12443886	VWDE	-0.67	-5.18	-0.39	7.07e-7	Coronary artery disease;
PAAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg13918804	chr1:2043761	PRKCZ	0.43	5.87	0.43	2.62e-8	Height;
PAAD	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.23	0.6	2.15e-16	Rheumatoid arthritis;
PAAD	cis	rs6782228	0.848	rs3935016	chr3:128420434	C/T	cg15607142	chr3:128420513	NA	-0.43	-4.79	-0.36	3.85e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01835144	chr2:234763301	HJURP	-0.67	-6.67	-0.48	4.43e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1950626	0.699	rs12880424	chr14:101459660	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.03	12.6	0.71	2.23e-25	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs58521262	0.615	rs24833	chr19:23199700	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs7173419	0.516	rs1037208	chr15:28231357	G/T	cg20906524	chr15:28200668	OCA2	-0.48	-4.36	-0.33	2.4e-5	Eye color;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15540144	chr2:99553141	C2orf55	0.61	6.77	0.48	2.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg05347473	chr6:146136440	FBXO30	0.5	4.86	0.37	2.92e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.76	0.62	9.14e-18	Electrocardiographic conduction measures;
PAAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.67	-6.35	-0.46	2.38e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg18512352	chr11:47633146	NA	0.41	5.96	0.44	1.71e-8	Subjective well-being;
PAAD	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-5.23	-0.39	5.46e-7	Chronic sinus infection;
PAAD	cis	rs9547692	0.938	rs9547689	chr13:37451861	G/A	cg01493522	chr13:37497338	NA	-0.63	-6.05	-0.44	1.08e-8	Coronary artery disease;
PAAD	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.31	-0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs10821973	0.527	rs3852405	chr10:64012554	G/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg02376097	chr19:46275166	DMPK	-0.58	-5.84	-0.43	3.02e-8	Coronary artery disease;
PAAD	cis	rs7071247	0.915	rs3014183	chr10:105274270	C/T	cg06423925	chr10:105883847	C10orf78	-0.57	-4.57	-0.35	1.02e-5	Platelet aggregation;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15319206	chr6:159065938	DYNLT1	-0.58	-6.47	-0.46	1.29e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.71e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.83	0.36	3.3e-6	Breast cancer;
PAAD	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.3	8.51	0.57	1.56e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg05805236	chr11:65401703	PCNXL3	-0.46	-5.21	-0.39	6.11e-7	Systemic lupus erythematosus;
PAAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.44	-4.27	-0.33	3.36e-5	Renal cell carcinoma;
PAAD	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-11.21	-0.67	1.26e-21	Ulcerative colitis;
PAAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.45	-4.26	-0.33	3.53e-5	Schizophrenia;
PAAD	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg07154921	chr7:157260426	NA	-0.43	-4.32	-0.33	2.79e-5	Body mass index;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.54	-0.35	1.16e-5	Height;
PAAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-6.38	-0.46	2.02e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.09	-0.38	1.06e-6	Monocyte count;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-7.43	-0.52	7.29e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17450446	chr1:160002111	PIGM	-0.72	-6.3	-0.46	3.13e-9	Neuroticism;
PAAD	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.51	-4.32	-0.33	2.78e-5	QT interval (drug interaction);
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg14926445	chr8:58193284	C8orf71	-0.65	-5.11	-0.38	9.39e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg07525751	chr5:1416958	SLC6A3	0.58	6.29	0.45	3.29e-9	Educational attainment (years of education);
PAAD	cis	rs54211	0.808	rs137629	chr22:39717233	G/C	cg11247378	chr22:39784982	NA	-0.74	-4.3	-0.33	3.01e-5	Sudden cardiac arrest;
PAAD	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg05110241	chr16:68378359	PRMT7	0.71	5.5	0.41	1.6e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	1.03	8.86	0.58	1.97e-15	Vitiligo;
PAAD	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.84	-0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	1.05	7.37	0.51	9.98e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.75	5.57	0.41	1.14e-7	Initial pursuit acceleration;
PAAD	cis	rs732505	1.000	rs10417622	chr19:5592547	T/C	cg26242866	chr19:5711310	LONP1	1.05	5.76	0.42	4.49e-8	vWF and FVIII levels;
PAAD	cis	rs6782025	0.837	rs680233	chr3:120738007	A/G	cg16417163	chr3:121280760	NA	-0.48	-5.11	-0.38	9.42e-7	Aging (facial);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17336172	chr3:49377548	USP4	-0.57	-6.48	-0.47	1.2e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.0	-4.54	-0.35	1.16e-5	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
PAAD	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.81	-0.48	2.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4704187	0.687	rs4704179	chr5:74457273	C/T	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg20302342	chr1:156215951	PAQR6	0.62	6.81	0.48	2.1e-10	Tonsillectomy;
PAAD	cis	rs76866386	0.786	rs4507142	chr2:44086591	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.75	-4.64	-0.35	7.52e-6	Cholesterol, total;
PAAD	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.59	-4.89	-0.37	2.58e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.92	7.04	0.5	6.13e-11	Initial pursuit acceleration;
PAAD	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.62	-4.75	-0.36	4.75e-6	Serum sulfate level;
PAAD	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	1.01	7.68	0.53	1.83e-12	Dental caries;
PAAD	cis	rs1529711	0.500	rs17616023	chr19:10902794	A/C	cg18582342	chr19:11591989	ELAVL3	0.74	5.85	0.43	2.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs62179067	0.708	rs62175990	chr2:179883455	C/G	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg27087555	chr16:88793112	FAM38A	-1.27	-8.99	-0.59	8.97e-16	Plateletcrit;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.52	5.43	0.4	2.2e-7	Obesity-related traits;
PAAD	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.45	4.27	0.33	3.44e-5	Self-reported allergy;
PAAD	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-4.92	-0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-1.03	-7.1	-0.5	4.4e-11	Post bronchodilator FEV1;
PAAD	cis	rs4343996	0.967	rs7791820	chr7:3353180	T/G	cg21248987	chr7:3385318	SDK1	-0.46	-5.05	-0.38	1.26e-6	Motion sickness;
PAAD	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg10761708	chr20:43804764	PI3	0.55	4.42	0.34	1.87e-5	Blood protein levels;
PAAD	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg03465714	chr1:152285911	FLG	0.63	4.37	0.33	2.28e-5	Atopic dermatitis;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7904985	0.960	rs34731943	chr10:88125890	C/A	cg07322936	chr10:88137208	NA	-0.49	-4.42	-0.34	1.85e-5	Barrett's esophagus;
PAAD	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg26597838	chr10:835615	NA	0.49	5.28	0.39	4.34e-7	Survival in rectal cancer;
PAAD	cis	rs80346118	0.673	rs6019433	chr20:47422568	G/A	cg20907517	chr20:47894756	C20orf199;ZNFX1;SNORD12C	-0.59	-4.4	-0.34	2.04e-5	Diastolic blood pressure;
PAAD	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg23029597	chr12:123009494	RSRC2	0.98	4.39	0.34	2.08e-5	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
PAAD	cis	rs1345301	0.518	rs17689452	chr2:102864681	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.46	-0.34	1.58e-5	Waist circumference;
PAAD	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.69	-7.72	-0.53	1.43e-12	Motion sickness;
PAAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.41	5.38	0.4	2.82e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.66	6.74	0.48	3.05e-10	Blood protein levels;
PAAD	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.47	-6.35	-0.46	2.4e-9	Height;
PAAD	cis	rs6604026	0.656	rs2811589	chr1:93367643	C/T	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2291447	0.967	rs8069937	chr17:43208626	C/T	cg10701640	chr17:43249399	NA	0.37	4.54	0.35	1.13e-5	Economic and political preferences;
PAAD	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.58	6.16	0.45	6.34e-9	Mean corpuscular volume;
PAAD	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg12395012	chr8:11607386	GATA4	0.46	5.08	0.38	1.1e-6	Myopia (pathological);
PAAD	cis	rs802075	0.905	rs1321616	chr6:49651951	A/T	cg20364632	chr6:49636226	NA	-0.44	-5.1	-0.38	9.85e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.33	0.33	2.71e-5	Menarche (age at onset);
PAAD	cis	rs4908768	0.556	rs11121230	chr1:8834706	C/T	cg25722041	chr1:8623473	RERE	0.5	4.28	0.33	3.24e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	10.92	0.66	7.39e-21	Electrocardiographic conduction measures;
PAAD	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.55	0.65	7.17e-20	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-8.44	-0.56	2.32e-14	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs17135859	0.762	rs34397886	chr5:113049092	G/C	cg12552261	chr5:112820674	MCC	0.73	4.43	0.34	1.77e-5	F-cell distribution;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg27289501	chr12:77378460	NA	-0.7	-6.95	-0.49	9.98e-11	Primary biliary cholangitis;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23187101	chr19:1812290	ATP8B3	0.56	6.33	0.46	2.59e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6700896	0.864	rs6588153	chr1:66092017	T/A	cg04111102	chr1:66153794	NA	0.48	5.3	0.39	4.07e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9652601	0.626	rs887864	chr16:11158885	G/A	cg04616529	chr16:11181986	CLEC16A	-0.44	-4.75	-0.36	4.59e-6	Systemic lupus erythematosus;
PAAD	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	7.73	0.53	1.39e-12	Cognitive test performance;
PAAD	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg18809830	chr7:99032528	PTCD1	-1.04	-4.56	-0.35	1.06e-5	Blood metabolite levels;
PAAD	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg22755534	chr11:128796442	NA	-0.53	-4.36	-0.33	2.38e-5	Atopic dermatitis;
PAAD	cis	rs6496932	0.802	rs12441698	chr15:85853701	G/A	cg19183879	chr15:85880815	NA	0.48	4.46	0.34	1.56e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs2421770	0.532	rs10768129	chr11:35362489	C/T	cg13971030	chr11:35366721	SLC1A2	0.57	5.58	0.41	1.08e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4668356	0.542	rs57145113	chr2:172050413	G/A	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs6669119	1.000	rs9439746	chr1:19111857	T/C	cg26220594	chr1:19110978	NA	0.74	4.53	0.35	1.18e-5	Percentage gas trapping;
PAAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.47	4.52	0.34	1.23e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.52	-0.34	1.23e-5	Atopic dermatitis;
PAAD	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26897989	chr16:1907736	C16orf73	-0.6	-5.46	-0.41	1.89e-7	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs8113142	0.551	rs60227266	chr19:29213655	T/G	cg04546413	chr19:29218101	NA	0.38	4.37	0.33	2.29e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.64	6.35	0.46	2.38e-9	Platelet count;
PAAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.18	0.39	6.88e-7	Initial pursuit acceleration;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg07202610	chr7:1142643	C7orf50	-0.61	-4.25	-0.33	3.66e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg06697600	chr4:7070879	GRPEL1	0.89	5.17	0.39	7.36e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg21452805	chr1:244014465	NA	0.47	4.29	0.33	3.18e-5	RR interval (heart rate);
PAAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.92	-0.37	2.25e-6	Body mass index;
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.71	-0.42	5.64e-8	Bipolar disorder;
PAAD	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg18281939	chr5:77783895	LHFPL2	0.52	6.7	0.48	3.9e-10	Triglycerides;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21233275	chr2:136634095	MCM6	0.54	6.39	0.46	1.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.79	-0.48	2.36e-10	Lung cancer;
PAAD	cis	rs2275565	0.568	rs12407420	chr1:236960003	G/C	cg17297354	chr1:237056641	MTR	-0.55	-4.92	-0.37	2.25e-6	Homocysteine levels;
PAAD	cis	rs308971	0.563	rs394945	chr3:12075117	T/C	cg02700894	chr3:12045449	SYN2	0.63	4.6	0.35	8.71e-6	Fasting blood insulin (BMI interaction);
PAAD	cis	rs9715521	0.900	rs7440797	chr4:59809260	C/T	cg11281224	chr4:60001000	NA	0.52	5.12	0.38	9.02e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs30380	0.632	rs26489	chr5:96133427	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-5.25	-0.39	4.93e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.56	6.1	0.44	8.62e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg21427119	chr20:30132790	HM13	-0.58	-5.31	-0.4	3.87e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.65	6.55	0.47	8.42e-10	Diastolic blood pressure;
PAAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21233275	chr2:136634095	MCM6	-0.71	-6.55	-0.47	8.26e-10	Neuroticism;
PAAD	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg19131313	chr8:1704013	NA	-0.41	-4.45	-0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg01851573	chr8:8652454	MFHAS1	0.63	5.21	0.39	5.98e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.69	7.4	0.51	8.87e-12	Aortic root size;
PAAD	cis	rs4739066	0.579	rs16929963	chr8:63876244	A/G	cg20602954	chr8:63776762	NKAIN3	0.8	5.16	0.39	7.64e-7	Myocardial infarction;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.62	-6.07	-0.44	9.66e-9	Prudent dietary pattern;
PAAD	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg27121462	chr16:89883253	FANCA	0.48	4.99	0.38	1.61e-6	Vitiligo;
PAAD	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.57	4.38	0.33	2.2e-5	IgG glycosylation;
PAAD	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.6	5.72	0.42	5.53e-8	Lymphocyte counts;
PAAD	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs7260329	0.670	rs4803413	chr19:41485977	G/A	cg04530860	chr19:41870213	B9D2;TMEM91	-0.51	-4.37	-0.33	2.25e-5	Smoking behavior;
PAAD	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.6	6.2	0.45	5.04e-9	Bladder cancer;
PAAD	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.4	-0.34	2.03e-5	Educational attainment;
PAAD	cis	rs682748	0.755	rs2402349	chr5:17122819	T/C	cg23987134	chr5:17158319	LOC285696	-0.37	-4.69	-0.36	6.06e-6	Hippocampal atrophy;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.59	7.25	0.51	1.98e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.73	-7.85	-0.54	6.91e-13	Body mass index;
PAAD	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.6	6.71	0.48	3.69e-10	Coronary artery disease;
PAAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.77	-6.88	-0.49	1.49e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg15128208	chr22:42549153	NA	0.52	4.51	0.34	1.27e-5	Birth weight;
PAAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.47	-5.21	-0.39	6.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4073221	0.697	rs1464046	chr3:18226695	A/G	cg07694806	chr3:18168406	NA	-0.61	-4.4	-0.34	2e-5	Parkinson's disease;
PAAD	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg00631329	chr6:26305371	NA	-0.49	-4.94	-0.37	2.07e-6	Educational attainment;
PAAD	cis	rs9549328	0.837	rs7988967	chr13:113651160	A/G	cg20742385	chr13:113633654	MCF2L	-0.44	-4.46	-0.34	1.58e-5	Systolic blood pressure;
PAAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg21017887	chr14:105400489	NA	0.99	13.6	0.74	4.63e-28	Systemic lupus erythematosus;
PAAD	cis	rs11807834	0.522	rs56230791	chr1:230245015	T/C	cg00566187	chr1:230250356	GALNT2	-0.65	-6.88	-0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg01657329	chr11:68192670	LRP5	-0.67	-4.81	-0.36	3.67e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.51	5.29	0.39	4.1e-7	Plasma plasminogen activator levels;
PAAD	cis	rs4889855	0.516	rs4890041	chr17:78521114	A/T	cg16591659	chr17:78472290	NA	0.52	5.09	0.38	1.06e-6	Fractional excretion of uric acid;
PAAD	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg12700464	chr11:78128424	GAB2	-0.57	-4.32	-0.33	2.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.61	5.43	0.4	2.16e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.4	4.5	0.34	1.35e-5	High light scatter reticulocyte count;
PAAD	cis	rs17095355	0.605	rs7916801	chr10:111632445	A/G	cg00817464	chr10:111662876	XPNPEP1	0.63	4.48	0.34	1.47e-5	Biliary atresia;
PAAD	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	4.96	0.37	1.9e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs959260	0.528	rs4559942	chr17:73309269	G/A	cg14668889	chr17:73230827	NUP85	-0.55	-4.92	-0.37	2.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs3734905	1.000	rs1033458	chr6:169994794	A/G	cg11181693	chr6:169825345	NA	0.8	5.03	0.38	1.39e-6	HIV-1 control;
PAAD	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.96	0.37	1.83e-6	Ovarian reserve;
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg00253185	chr1:247542119	NA	-0.53	-4.39	-0.34	2.15e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg20761395	chr17:511517	VPS53	0.52	5.44	0.4	2.09e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg08886695	chr4:3369023	RGS12	-0.54	-5.29	-0.39	4.27e-7	Mean platelet volume;
PAAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.54	4.47	0.34	1.51e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.51	-0.47	1.01e-9	Hip circumference;
PAAD	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.57	-6.19	-0.45	5.34e-9	Platelet distribution width;
PAAD	cis	rs6681460	0.528	rs2031477	chr1:67158874	A/T	cg02459107	chr1:67143332	SGIP1	0.58	5.36	0.4	3.01e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.58	-6.51	-0.47	1.01e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6681460	1.000	rs6680944	chr1:67122565	A/T	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.85e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg01966878	chr4:90757139	SNCA	-0.68	-5.57	-0.41	1.13e-7	Neuroticism;
PAAD	cis	rs4906172	1.000	rs2169926	chr14:102425872	T/C	cg23904247	chr14:102554826	HSP90AA1	0.41	4.51	0.34	1.3e-5	Menopause (age at onset);
PAAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.73	-7.66	-0.53	2.08e-12	Neurofibrillary tangles;
PAAD	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-1.15	-14.3	-0.76	6.26e-30	Longevity;
PAAD	cis	rs2412208	1.000	rs2412208	chr1:7092782	T/G	cg26570804	chr1:6352357	ACOT7	0.49	4.62	0.35	8.19e-6	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs1144333	0.510	rs12408897	chr1:76448102	T/C	cg22875332	chr1:76189707	ACADM	0.76	4.46	0.34	1.59e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10214930	0.697	rs7783447	chr7:27626855	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs10998941	0.711	rs2616132	chr10:71469514	G/A	cg26770870	chr10:71561502	COL13A1	0.47	4.25	0.33	3.67e-5	CSF tryptophan concentration in tuberculous meningitis;
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.45	4.86	0.37	2.95e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00071950	chr4:10020882	SLC2A9	0.54	5.94	0.43	1.88e-8	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.56	0.57	1.18e-14	Bipolar disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27460534	chr17:80046302	FASN	0.58	6.68	0.48	4.31e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg00666640	chr1:248458726	OR2T12	0.51	5.11	0.38	9.42e-7	Common traits (Other);
PAAD	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.95	9.75	0.62	9.36e-18	Homoarginine levels;
PAAD	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg00484396	chr16:3507460	NAT15	0.91	7.93	0.54	4.41e-13	Tuberculosis;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs34311866	0.656	rs11736451	chr4:977022	A/G	cg07828340	chr4:882639	GAK	0.78	5.75	0.42	4.82e-8	Parkinson's disease;
PAAD	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.53	5.15	0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg24881330	chr22:46731750	TRMU	0.86	6.13	0.45	7.08e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7224737	1.000	rs8072215	chr17:40271970	A/G	cg00647820	chr17:40259828	DHX58	-0.44	-5.35	-0.4	3.23e-7	Fibrinogen levels;
PAAD	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6733011	0.519	rs12712034	chr2:99458933	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-4.82	-0.36	3.42e-6	Bipolar disorder;
PAAD	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.32	0.71	1.26e-24	Cognitive ability;
PAAD	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg05890377	chr2:74357713	NA	0.84	9.33	0.6	1.19e-16	Gestational age at birth (maternal effect);
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.8	-8.37	-0.56	3.45e-14	Urate levels;
PAAD	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.83	9.12	0.59	4.16e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00856157	chr4:115519920	UGT8	0.6	7.08	0.5	4.95e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg16606324	chr3:10149918	C3orf24	0.63	5.03	0.38	1.35e-6	Alzheimer's disease;
PAAD	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg02743256	chr7:2109353	MAD1L1	-0.67	-4.91	-0.37	2.31e-6	Bipolar disorder;
PAAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg16506815	chr2:162101123	NA	-0.59	-5.88	-0.43	2.5e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg02683114	chr2:24398427	C2orf84	-0.61	-6.55	-0.47	8.4e-10	Venous thromboembolism (SNP x SNP interaction);
PAAD	trans	rs10861342	0.892	rs3829297	chr12:105592823	G/C	cg11421182	chr20:36153479	BLCAP	-0.54	-6.36	-0.46	2.21e-9	IgG glycosylation;
PAAD	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg03805757	chr16:71968109	PKD1L3	-0.5	-4.37	-0.33	2.28e-5	Post bronchodilator FEV1;
PAAD	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.54	0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg18769074	chr3:133464867	TF	0.42	4.88	0.37	2.69e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs4273100	0.790	rs2048230	chr17:19276199	G/A	cg19949948	chr17:19361230	NA	-0.51	-4.33	-0.33	2.66e-5	Schizophrenia;
PAAD	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.7	6.1	0.44	8.32e-9	Radiation response;
PAAD	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.54	-6.75	-0.48	2.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.61	5.13	0.38	8.89e-7	QRS duration;
PAAD	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.98	-11.91	-0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg21823605	chr1:152486609	CRCT1	0.52	6.62	0.47	5.72e-10	Hair morphology;
PAAD	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.55	0.61	3.11e-17	Bladder cancer;
PAAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.7	-0.66	2.8e-20	Total body bone mineral density;
PAAD	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.47	5.12	0.38	9.19e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs900145	0.953	rs1384030	chr11:13292909	T/C	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.47	4.53	0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.35	0.51	1.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21646471	chr2:242523971	THAP4	0.66	5.29	0.39	4.21e-7	Prostate cancer;
PAAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.4	0.34	1.99e-5	Trans fatty acid levels;
PAAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.45	-5.72	-0.42	5.55e-8	Ulcerative colitis;
PAAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.6	7.32	0.51	1.33e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.38	-5.86	-0.43	2.8e-8	Educational attainment (years of education);
PAAD	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-5.33	-0.4	3.52e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs1371614	0.632	rs6547318	chr2:27153481	A/C	cg00617064	chr2:27272375	NA	-0.42	-4.49	-0.34	1.38e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.85	-7.49	-0.52	5.24e-12	Obesity;Body mass index;
PAAD	cis	rs6545883	0.831	rs6733446	chr2:61806999	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.34	-0.33	2.54e-5	Tuberculosis;
PAAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs4273100	0.790	rs60166680	chr17:19277544	C/G	cg19949948	chr17:19361230	NA	-0.51	-4.33	-0.33	2.66e-5	Schizophrenia;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.76	7.78	0.53	1.01e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg07153921	chr17:41440717	NA	-0.44	-4.62	-0.35	8e-6	Menopause (age at onset);
PAAD	cis	rs4699954	1	rs4699954	chr5:59634544	G/A	cg09712066	chr5:59783629	PART1;PDE4D	0.5	4.69	0.36	6.06e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.43	0.52	7.32e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.63	-5.55	-0.41	1.23e-7	Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26836413	chr4:55129115	PDGFRA	-0.56	-6.72	-0.48	3.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs11020478	0.574	rs7111796	chr11:93434313	C/T	cg10523193	chr11:93463762	SNORA25	0.43	4.47	0.34	1.53e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.69	-4.95	-0.37	1.92e-6	Post bronchodilator FEV1;
PAAD	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg19660806	chr8:588740	NA	-0.63	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	7.25	0.51	2.02e-11	Lung cancer in ever smokers;
PAAD	cis	rs12999616	0.602	rs35589428	chr2:98565743	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	5.5	0.41	1.6e-7	Colorectal cancer;
PAAD	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg00122941	chr17:4613640	ARRB2	-0.81	-8.03	-0.55	2.47e-13	Eosinophil percentage of white cells;
PAAD	cis	rs3812111	0.525	rs3749893	chr6:116571695	A/G	cg18764771	chr6:116381957	FRK	0.27	4.36	0.33	2.39e-5	Age-related macular degeneration;
PAAD	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg25364880	chr3:44379878	C3orf23	0.68	5.35	0.4	3.15e-7	IgG glycosylation;
PAAD	cis	rs10885582	0.754	rs10749167	chr10:116300041	G/C	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg14092988	chr3:52407081	DNAH1	0.36	4.56	0.35	1.05e-5	Electroencephalogram traits;
PAAD	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	5.83	0.43	3.24e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg18827107	chr12:86230957	RASSF9	-0.43	-4.57	-0.35	1.02e-5	Major depressive disorder;
PAAD	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.54	4.36	0.33	2.36e-5	Vitamin D levels;
PAAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.32	0.6	1.25e-16	Parkinson's disease;
PAAD	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.5	0.47	1.06e-9	Educational attainment;
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.71	7.66	0.53	2.02e-12	Mean corpuscular volume;
PAAD	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.63	6.38	0.46	1.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11892454	0.543	rs9941574	chr2:26055668	C/T	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10702170	chr19:58360436	ZNF587	-0.59	-6.84	-0.49	1.82e-10	Monocyte percentage of white cells;
PAAD	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg05562828	chr17:3906858	NA	0.61	6.83	0.48	1.91e-10	Type 2 diabetes;
PAAD	cis	rs7577696	0.962	rs6760105	chr2:32307386	A/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.01	14.26	0.76	7.88e-30	Heart rate;
PAAD	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	4.67	0.35	6.58e-6	Systemic lupus erythematosus;
PAAD	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.56	-6.11	-0.44	8.01e-9	Psychosis in Alzheimer's disease;
PAAD	cis	rs992157	0.932	rs1870125	chr2:219187901	C/T	cg00012203	chr2:219082015	ARPC2	0.59	6.05	0.44	1.08e-8	Colorectal cancer;
PAAD	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.64	7.02	0.49	6.93e-11	Colorectal cancer;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	6.68	0.48	4.22e-10	Systemic lupus erythematosus;
PAAD	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg17385448	chr1:15911702	AGMAT	0.35	4.31	0.33	2.88e-5	Systolic blood pressure;
PAAD	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.66	5.55	0.41	1.25e-7	Obesity (extreme);
PAAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	5.98	0.44	1.53e-8	Height;
PAAD	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.9	11.33	0.68	5.97e-22	Mean corpuscular volume;
PAAD	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs13175840	0.645	rs2098644	chr5:133214175	T/C	cg18514949	chr5:133563216	PPP2CA	-0.32	-4.41	-0.34	1.93e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.65	6.7	0.48	3.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.54	4.4	0.34	2.01e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg14349672	chr11:133703707	NA	-0.53	-6.0	-0.44	1.37e-8	Childhood ear infection;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg16826753	chr21:34915507	GART;SON	0.56	6.56	0.47	7.89e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs300703	0.719	rs378738	chr2:194039	A/G	cg21211680	chr2:198530	NA	0.89	7.77	0.53	1.07e-12	Blood protein levels;
PAAD	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.51	4.84	0.37	3.22e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg21483461	chr5:81570383	RPS23	0.53	4.91	0.37	2.32e-6	Breast cancer;
PAAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.61	-5.77	-0.42	4.32e-8	Glaucoma (primary open-angle);
PAAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.61	7.34	0.51	1.18e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.66	6.92	0.49	1.15e-10	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-6.36	-0.46	2.19e-9	Neuroticism;
PAAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.4	-0.34	2.05e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1625975	0.681	rs6480537	chr10:73391381	A/G	cg26005973	chr10:72643678	PCBD1	0.73	5.05	0.38	1.23e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.45	-4.62	-0.35	8.04e-6	Menarche (age at onset);
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06915872	chr16:87998081	BANP	-0.58	-5.59	-0.41	1.03e-7	Menopause (age at onset);
PAAD	cis	rs12311304	0.965	rs7980227	chr12:15367715	T/A	cg08258403	chr12:15378311	NA	0.37	4.69	0.36	6.06e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg08179530	chr6:36648295	CDKN1A	0.7	6.95	0.49	9.98e-11	QRS duration;
PAAD	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg00184732	chr15:51633821	GLDN	0.46	4.73	0.36	5.05e-6	Hormone measurements;
PAAD	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg08779649	chr13:50194554	NA	0.48	6.35	0.46	2.3e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.95	10.91	0.66	7.95e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.4	0.34	2.01e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.51	-0.41	1.51e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs77633900	0.772	rs283796	chr15:76774105	G/A	cg21673338	chr15:77095150	SCAPER	-0.85	-4.39	-0.34	2.14e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.52	6.75	0.48	2.86e-10	Schizophrenia;
PAAD	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	1.06	17.48	0.82	3.28e-38	Urate levels in lean individuals;
PAAD	cis	rs4073221	0.860	rs17403715	chr3:18254381	C/T	cg07694806	chr3:18168406	NA	-0.76	-5.05	-0.38	1.27e-6	Parkinson's disease;
PAAD	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.52	5.54	0.41	1.3e-7	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.81	6.68	0.48	4.18e-10	Alzheimer's disease;
PAAD	cis	rs564309	1.000	rs532465	chr1:228587492	T/C	cg01328119	chr1:228783545	DUSP5P	0.64	4.34	0.33	2.62e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs721399	0.539	rs10087857	chr8:18267461	G/C	cg18736775	chr8:18248649	NAT2	-0.62	-4.63	-0.35	7.76e-6	Blood metabolite levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg21844450	chr20:8112956	PLCB1	0.54	6.65	0.47	5.03e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.78	-9.23	-0.6	2.21e-16	Huntington's disease progression;
PAAD	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.46	-4.44	-0.34	1.69e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.62	5.74	0.42	4.9e-8	Refractive astigmatism;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.65	5.35	0.4	3.16e-7	Red blood cell count;
PAAD	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.76	4.98	0.37	1.67e-6	Lung cancer in ever smokers;
PAAD	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	10.14	0.64	8.65e-19	Testicular germ cell tumor;
PAAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg08132940	chr7:1081526	C7orf50	0.56	4.26	0.33	3.5e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.41	-0.34	1.92e-5	Resting heart rate;
PAAD	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.51	-5.87	-0.43	2.62e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01683593	chr17:54991473	TRIM25	-0.76	-6.81	-0.48	2.09e-10	Neuroticism;
PAAD	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.42	4.38	0.33	2.24e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.62	-5.37	-0.4	2.94e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg17541715	chr7:1216824	NA	-0.41	-4.58	-0.35	9.67e-6	Longevity;Endometriosis;
PAAD	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.65	7.84	0.54	7.3e-13	Dupuytren's disease;
PAAD	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.68	6.59	0.47	6.92e-10	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	1.02	6.73	0.48	3.28e-10	Mitochondrial DNA levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03208016	chr1:180124071	QSOX1	0.61	7.04	0.5	6.36e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.97	-0.37	1.82e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.67	-0.42	7e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10267417	0.603	rs34087364	chr7:19860293	A/C	cg05791153	chr7:19748676	TWISTNB	0.79	5.07	0.38	1.13e-6	Night sleep phenotypes;
PAAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.34	-4.85	-0.37	2.99e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	6.99	0.49	8.05e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg05084668	chr3:125655381	ALG1L	-0.53	-5.45	-0.4	1.98e-7	Blood pressure (smoking interaction);
PAAD	cis	rs2498796	0.727	rs3803307	chr14:105207134	C/T	cg07004394	chr14:106090750	NA	-0.34	-4.46	-0.34	1.61e-5	Endometrial cancer;Endometrial endometrioid carcinoma;
PAAD	cis	rs7326068	0.595	rs2762988	chr13:21370780	T/A	cg27499820	chr13:21296301	IL17D	0.55	5.13	0.38	8.63e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs2882667	0.654	rs10044432	chr5:138274896	C/T	cg09476006	chr5:138032270	NA	0.42	5.16	0.39	7.63e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1348850	0.526	rs4243391	chr2:178468089	A/T	cg03700679	chr2:178418002	TTC30B	-0.63	-5.16	-0.39	7.53e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.66	6.75	0.48	2.99e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.53	0.57	1.4e-14	Corneal astigmatism;
PAAD	trans	rs3905000	1.000	rs3847302	chr9:107648595	A/G	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.36	0.33	2.34e-5	Lung cancer in ever smokers;
PAAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20362242	chr5:692897	TPPP	-0.61	-7.17	-0.5	3.11e-11	Body fat percentage;
PAAD	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg23743573	chr11:89867420	NAALAD2	0.58	4.29	0.33	3.15e-5	Trans fatty acid levels;
PAAD	cis	rs7179456	0.517	rs7167872	chr15:59271375	T/C	cg05156742	chr15:59063176	FAM63B	0.48	4.62	0.35	8.01e-6	Asperger disorder;
PAAD	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.5	4.49	0.34	1.42e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg00383909	chr3:49044727	WDR6	1.08	6.18	0.45	5.55e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.77	-7.54	-0.52	3.94e-12	Mosquito bite size;
PAAD	cis	rs35160687	0.829	rs13017143	chr2:86466549	C/T	cg10973622	chr2:86423274	IMMT	-0.49	-5.58	-0.41	1.05e-7	Night sleep phenotypes;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.39	-5.61	-0.41	9.18e-8	Cutaneous nevi;
PAAD	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.69	-6.43	-0.46	1.57e-9	Diabetic retinopathy;
PAAD	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-7.84	-0.54	7.48e-13	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg19318889	chr4:1322082	MAEA	0.46	4.61	0.35	8.64e-6	Obesity-related traits;
PAAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.41e-10	Coronary artery disease;
PAAD	cis	rs59104589	0.521	rs62190404	chr2:242401422	C/T	cg04488487	chr2:242709673	NA	0.58	4.7	0.36	5.84e-6	Fibrinogen levels;
PAAD	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.74	-5.31	-0.4	3.77e-7	Major depressive disorder;
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.31	-0.33	2.92e-5	Fear of minor pain;
PAAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg23281280	chr6:28129359	ZNF389	0.48	4.25	0.33	3.68e-5	Parkinson's disease;
PAAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.62	-6.24	-0.45	4.11e-9	Obesity-related traits;
PAAD	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg25649188	chr17:73499917	CASKIN2	0.63	5.64	0.42	8.07e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs1816752	0.524	rs1965154	chr13:25072200	T/C	cg05820861	chr13:24882296	C1QTNF9	0.47	4.51	0.34	1.29e-5	Obesity-related traits;
PAAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.01	-0.44	1.31e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg14668889	chr17:73230827	NUP85	-0.55	-5.05	-0.38	1.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.61	-0.61	2.22e-17	Alzheimer's disease (late onset);
PAAD	cis	rs490608	0.581	rs12741350	chr1:155268425	C/T	cg02153340	chr1:155202674	NA	-0.53	-4.81	-0.36	3.6e-6	Inflammatory bowel disease;
PAAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs2637266	0.518	rs2579721	chr10:78250890	T/C	cg18941641	chr10:78392320	NA	0.36	4.26	0.33	3.57e-5	Pulmonary function;
PAAD	cis	rs77880822	0.562	rs74416343	chr20:1238488	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12315302	chr6:26189340	HIST1H4D	0.55	4.36	0.33	2.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg15571903	chr15:79123663	NA	0.39	4.67	0.35	6.52e-6	Coronary artery disease;
PAAD	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.66	-0.35	6.85e-6	Dupuytren's disease;
PAAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.71	10.05	0.63	1.58e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg05163071	chr3:108476540	RETNLB	0.96	6.83	0.48	1.88e-10	Dental caries;
PAAD	cis	rs4668356	0.773	rs57335774	chr2:172031967	T/G	cg13882835	chr2:172017928	TLK1	0.76	4.44	0.34	1.73e-5	Cognitive performance;
PAAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.61	7.2	0.5	2.54e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg23752985	chr2:85803571	VAMP8	0.58	6.29	0.45	3.17e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	7.8	0.53	9.16e-13	Height;
PAAD	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg13786083	chr1:19110734	NA	-0.74	-6.61	-0.47	6.25e-10	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.71	-0.8	3.03e-36	Height;
PAAD	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28795989	0.795	rs4696778	chr4:7919308	C/G	cg18538662	chr4:7941764	AFAP1	0.45	4.71	0.36	5.47e-6	Intraocular pressure;
PAAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	1.28	13.0	0.73	1.9e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.69	-5.89	-0.43	2.34e-8	Diabetic retinopathy;
PAAD	cis	rs593531	0.571	rs11236087	chr11:74094138	C/T	cg15670924	chr11:73669256	DNAJB13	0.43	4.57	0.35	1.01e-5	Neuroticism;
PAAD	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.47	-0.46	1.27e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg15764593	chr10:829463	NA	-0.74	-5.44	-0.4	2.12e-7	Uric acid levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09470230	chr10:72972137	UNC5B	0.74	8.14	0.55	1.35e-13	Myopia (pathological);
PAAD	cis	rs76866386	0.892	rs56132765	chr2:44078853	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.82	-5.16	-0.39	7.48e-7	Cholesterol, total;
PAAD	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.55	-4.76	-0.36	4.46e-6	Testicular germ cell tumor;
PAAD	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg02880119	chr16:3481970	NA	-0.52	-4.46	-0.34	1.62e-5	Body mass index (adult);
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.4	-5.12	-0.38	9.04e-7	Prostate cancer;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00166722	chr3:10149974	C3orf24	0.95	7.86	0.54	6.38e-13	Alzheimer's disease;
PAAD	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.87	-8.83	-0.58	2.32e-15	Obesity-related traits;
PAAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg10556349	chr10:835070	NA	0.71	5.25	0.39	5.05e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs1501550	0.596	rs61848992	chr1:211091849	C/T	cg06939061	chr1:211432106	RCOR3	-0.75	-4.78	-0.36	4.16e-6	Circulating vasoactive peptide levels;
PAAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.86	9.78	0.62	7.78e-18	Cognitive function;
PAAD	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.74	-0.42	5.08e-8	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	6.86e-11	Life satisfaction;
PAAD	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg17105886	chr17:28927953	LRRC37B2	0.81	4.35	0.33	2.53e-5	Body mass index;
PAAD	cis	rs6466055	0.565	rs12534381	chr7:104947195	T/C	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.66	4.41	0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg02745156	chr12:32552066	NA	0.42	4.36	0.33	2.35e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs859767	0.887	rs842362	chr2:135341120	C/T	cg12500956	chr2:135428796	TMEM163	0.33	4.83	0.36	3.34e-6	Neuroticism;
PAAD	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.78	6.23	0.45	4.32e-9	Neutrophil percentage of white cells;
PAAD	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	5.09	0.38	1.03e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs793571	0.915	rs12708456	chr15:59215835	T/A	cg08898775	chr15:59042684	ADAM10	-0.38	-4.4	-0.34	2.03e-5	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg21565972	chr17:80109576	CCDC57	0.57	6.69	0.48	4.09e-10	Life satisfaction;
PAAD	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.45	5.54	0.41	1.3e-7	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
PAAD	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.67	-6.84	-0.49	1.8e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg11657440	chr19:46296263	DMWD	-0.7	-6.05	-0.44	1.08e-8	Coronary artery disease;
PAAD	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.43	-0.4	2.2e-7	Mononucleosis;
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg19761014	chr17:28927070	LRRC37B2	0.95	6.45	0.46	1.42e-9	Body mass index;
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.67e-12	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2073300	1.000	rs6137975	chr20:23461778	A/G	cg12062639	chr20:23401060	NAPB	-0.93	-5.08	-0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg02887458	chr19:19495540	GATAD2A	-0.42	-4.3	-0.33	3.06e-5	Tonsillectomy;
PAAD	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.77	8.72	0.58	4.44e-15	Breast cancer;
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg04482110	chr17:41364121	TMEM106A	-0.39	-4.51	-0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs9810890	0.850	rs7632015	chr3:128659244	G/T	cg18531004	chr3:128564980	NA	0.79	5.19	0.39	6.77e-7	Dental caries;
PAAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.64	-7.26	-0.51	1.82e-11	Huntington's disease progression;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01967073	chr7:48147130	UPP1	0.58	6.66	0.48	4.8e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9815354	1.000	rs1717021	chr3:41983860	A/T	cg03022575	chr3:42003672	ULK4	-0.86	-6.11	-0.44	8.07e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.6	-5.32	-0.4	3.73e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.49	-6.16	-0.45	6.11e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs17169634	1.000	rs17169634	chr7:34093997	A/G	cg24927974	chr7:35078269	DPY19L1	-0.6	-5.06	-0.38	1.21e-6	Alzheimer's disease;
PAAD	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.86	-5.99	-0.44	1.49e-8	Coronary artery disease;
PAAD	cis	rs7081476	0.737	rs16916444	chr10:27491648	C/T	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.77	5.66	0.42	7.2e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1797885	0.714	rs1797880	chr3:12567677	C/A	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.01e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs498136	0.966	rs11601678	chr11:69366513	G/A	cg24388239	chr11:68438018	NA	-0.42	-4.4	-0.34	2.02e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.88	0.75	7.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg05373962	chr22:49881684	NA	-0.51	-5.06	-0.38	1.22e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg22189786	chr22:42395067	WBP2NL	0.56	4.85	0.37	2.97e-6	Birth weight;
PAAD	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg24747557	chr10:131355152	MGMT	0.56	5.66	0.42	7.4e-8	Response to temozolomide;
PAAD	cis	rs3736485	0.934	rs1902592	chr15:51881980	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1545257	0.505	rs11125570	chr2:24629577	G/A	cg06627628	chr2:24431161	ITSN2	-0.58	-5.72	-0.42	5.38e-8	Sjögren's syndrome;
PAAD	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-5.82	-0.43	3.43e-8	Personality dimensions;
PAAD	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg24733560	chr20:60626293	TAF4	0.45	5.42	0.4	2.31e-7	Body mass index;
PAAD	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.4	-4.94	-0.37	2.01e-6	Systolic blood pressure;
PAAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.74	0.36	4.97e-6	Total body bone mineral density;
PAAD	cis	rs10450586	0.932	rs10734389	chr11:27331452	C/T	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.46	-0.41	1.88e-7	Blood metabolite levels;
PAAD	cis	rs3136441	0.901	rs11039002	chr11:46857279	T/C	cg19486271	chr11:47235900	DDB2	0.67	5.25	0.39	4.99e-7	HDL cholesterol;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.95	12.74	0.72	9.67e-26	Menarche (age at onset);
PAAD	cis	rs8076220	1.000	rs7219307	chr17:11078947	G/T	cg00134787	chr17:10419499	MYH1	0.6	4.29	0.33	3.18e-5	Obesity-related traits;
PAAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.46	4.88	0.37	2.61e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.77	-0.36	4.24e-6	Mean platelet volume;
PAAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.83	-0.36	3.29e-6	Atopic dermatitis;
PAAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs11051970	0.918	rs76930558	chr12:32538839	A/C	cg02745156	chr12:32552066	NA	0.47	4.82	0.36	3.47e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00715988	chr14:96968640	PAPOLA	0.6	6.44	0.46	1.46e-9	Myopia (pathological);
PAAD	cis	rs7267005	0.661	rs41293084	chr20:34192340	C/G	cg17201900	chr20:34330562	RBM39	1.46	6.69	0.48	3.93e-10	Response to paliperidone in schizophrenia (Multivariate);
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.7	-5.09	-0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7132746	0.553	rs12829972	chr12:86174249	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-4.8	-0.36	3.83e-6	Lewy body disease;
PAAD	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.52	5.1	0.38	9.85e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.83	-0.48	1.89e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.85	-0.81	1.36e-36	Height;
PAAD	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.71	7.25	0.51	2.01e-11	Retinal vascular caliber;
PAAD	cis	rs4481887	0.861	rs6676061	chr1:248443887	G/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.44	-0.4	2.1e-7	Common traits (Other);
PAAD	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.81	-6.14	-0.45	6.87e-9	Coronary artery calcification;
PAAD	cis	rs1847202	0.859	rs13079651	chr3:72922181	C/T	cg25664220	chr3:72788482	NA	-0.48	-5.26	-0.39	4.91e-7	Motion sickness;
PAAD	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.84	9.07	0.59	5.76e-16	Corneal astigmatism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16059596	chr5:142150321	ARHGAP26	0.64	6.69	0.48	4.01e-10	Myopia (pathological);
PAAD	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-4.7	-0.36	5.67e-6	Schizophrenia;
PAAD	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.96	-8.33	-0.56	4.53e-14	Lymphocyte percentage of white cells;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.73	5.37	0.4	2.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4759375	0.667	rs28475177	chr12:123872037	A/G	cg05908960	chr12:123472150	PITPNM2	0.67	4.69	0.36	6.04e-6	HDL cholesterol;
PAAD	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs35084382	1.000	rs17714774	chr5:172189628	C/T	cg19801141	chr5:172198162	DUSP1	1.42	6.42	0.46	1.62e-9	Optic cup area;
PAAD	cis	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19671926	chr4:122722719	EXOSC9	-0.65	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.99	-10.27	-0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.61	-5.72	-0.42	5.58e-8	Mean corpuscular volume;
PAAD	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.47	-4.48	-0.34	1.49e-5	Stearic acid (18:0) levels;
PAAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg14416269	chr4:6271139	WFS1	0.62	7.08	0.5	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.91	-9.07	-0.59	5.77e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	0.89	8.84	0.58	2.28e-15	Exhaled nitric oxide output;
PAAD	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.58	5.14	0.38	8.47e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4908768	0.579	rs11121237	chr1:8876392	A/G	cg12700319	chr1:8272199	NA	-0.39	-4.28	-0.33	3.31e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-4.94	-0.37	2.03e-6	Glomerular filtration rate;
PAAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.5	6.67e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg20340250	chr2:86737593	VPS24	0.62	6.44	0.46	1.46e-9	Parkinson's disease;
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.33	-5.24	-0.39	5.34e-7	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs34112283	0.592	rs4430884	chr2:144225629	A/C	cg10530280	chr1:167759869	MPZL1	-0.66	-6.57	-0.47	7.47e-10	Neuroticism;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-4.57	-0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-5.37	-0.4	2.95e-7	Longevity;Endometriosis;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.5	-6.22	-0.45	4.59e-9	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.8e-6	Height;
PAAD	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-1.06	-5.65	-0.42	7.63e-8	Plateletcrit;
PAAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.49	-4.39	-0.34	2.15e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg12568669	chr8:11666485	FDFT1	-0.29	-4.55	-0.35	1.08e-5	Monocyte count;
PAAD	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg12870014	chr12:110450643	ANKRD13A	0.67	4.86	0.37	2.85e-6	Headache;
PAAD	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.99	11.43	0.68	3.24e-22	Breast cancer;
PAAD	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-10.83	-0.66	1.31e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.68	8.48	0.57	1.86e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	cis	rs9361491	0.614	rs4312941	chr6:79450201	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-7.3	-0.51	1.49e-11	Neuroticism;
PAAD	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	7.38	0.51	9.6e-12	Verbal declarative memory;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	5.12	0.38	9.13e-7	Urate levels in obese individuals;
PAAD	cis	rs900145	0.823	rs7928655	chr11:13300252	C/G	cg15603424	chr11:13300592	ARNTL	0.5	4.54	0.35	1.13e-5	Menarche (age at onset);
PAAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.67	7.91	0.54	4.83e-13	Multiple sclerosis;
PAAD	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.62	-5.41	-0.4	2.38e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	1.23	6.49	0.47	1.14e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.17	0.55	1.12e-13	Alzheimer's disease;
PAAD	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	8.93e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	4.5	0.34	1.35e-5	Iron status biomarkers;
PAAD	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs12304921	0.683	rs60910794	chr12:51507634	T/G	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.45	-0.4	2e-7	Type 2 diabetes;
PAAD	cis	rs27434	0.583	rs468130	chr5:96156029	A/G	cg16492584	chr5:96139282	ERAP1	-0.55	-5.36	-0.4	3.06e-7	Ankylosing spondylitis;
PAAD	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs1007738	0.542	rs4752970	chr11:47208982	A/G	cg19486271	chr11:47235900	DDB2	-0.61	-5.63	-0.42	8.37e-8	Bone mineral density (hip);
PAAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.71	5.5	0.41	1.54e-7	Crohn's disease;
PAAD	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.6	-6.26	-0.45	3.82e-9	Motion sickness;
PAAD	cis	rs11243437	1	rs11243437	chr9:134450073	G/C	cg14126884	chr9:134533116	RAPGEF1	-0.48	-4.52	-0.34	1.25e-5	Response to amphetamines;
PAAD	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15914589	chr3:10206523	IRAK2	-0.58	-6.96	-0.49	9.34e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs593531	0.571	rs10898983	chr11:74093992	C/T	cg23327896	chr11:73669290	DNAJB13	-0.37	-4.82	-0.36	3.47e-6	Neuroticism;
PAAD	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.57	6.84	0.49	1.83e-10	Aortic root size;
PAAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.56	7.49	0.52	5.31e-12	Renal cell carcinoma;
PAAD	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	5.0	0.38	1.56e-6	Height;
PAAD	cis	rs3809912	0.509	rs11661322	chr18:13012294	T/A	cg12848697	chr18:13133368	NA	0.48	4.46	0.34	1.61e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	4.34	0.33	2.57e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.75	-7.41	-0.51	8.38e-12	White matter hyperintensity burden;
PAAD	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.52	-5.32	-0.4	3.72e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.49	-0.52	5.11e-12	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg14019146	chr3:50243930	SLC38A3	-0.47	-4.97	-0.37	1.78e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20859525	chr6:80714300	TTK	0.62	7.16	0.5	3.2e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-11.13	-0.67	2.02e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg04717802	chr22:42394638	WBP2NL	0.55	4.72	0.36	5.25e-6	Birth weight;
PAAD	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.98	11.63	0.69	8.9e-23	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs12576326	1.000	rs35403813	chr11:44980322	G/A	cg01859616	chr11:44970771	TP53I11	-0.49	-4.63	-0.35	7.68e-6	Resting heart rate;
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.78	10.0	0.63	2.03e-18	Vitiligo;
PAAD	cis	rs6746082	0.519	rs637519	chr2:25760891	G/A	cg23192403	chr2:25781496	DTNB	-0.29	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.85e-5	Pubertal anthropometrics;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15772712	chr22:41843233	TOB2	0.67	6.78	0.48	2.52e-10	Obesity-related traits;
PAAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg13770153	chr20:60521292	NA	-0.47	-4.58	-0.35	9.68e-6	Body mass index;
PAAD	trans	rs17713676	0.510	rs75356863	chr16:79075475	A/G	cg05696950	chr2:8715754	NA	-0.88	-6.67	-0.48	4.38e-10	Response to amphetamines;
PAAD	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.85	8.47	0.57	1.99e-14	Vitamin D levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03381996	chr20:62496646	TPD52L2	0.69	7.07	0.5	5.39e-11	Obesity-related traits;
PAAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg03517284	chr6:25882590	NA	-0.58	-4.87	-0.37	2.77e-6	Iron status biomarkers;
PAAD	cis	rs1797885	0.714	rs1699362	chr3:12528583	A/G	cg07775309	chr3:12595852	NA	0.4	4.36	0.33	2.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.46	-4.33	-0.33	2.65e-5	Monocyte count;
PAAD	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.01	-0.49	7.12e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg12458913	chr13:53173898	NA	0.62	6.15	0.45	6.53e-9	Lewy body disease;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg13996209	chr9:33447594	SUGT1P1;AQP3	0.63	7.01	0.49	7.09e-11	Iris heterochromicity;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6689305	0.674	rs6670361	chr1:100200184	C/T	cg22872634	chr1:100462710	SLC35A3	-0.49	-4.33	-0.33	2.74e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs9907295	0.591	rs3817655	chr17:34199641	A/T	cg19411729	chr17:34207663	CCL5	0.53	4.48	0.34	1.48e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.45	4.82	0.36	3.48e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.93	0.37	2.16e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11170685	chr14:101005511	BEGAIN	0.55	6.29	0.45	3.15e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.52	-4.63	-0.35	7.87e-6	Mean corpuscular volume;
PAAD	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.58	6.66	0.48	4.74e-10	Schizophrenia;
PAAD	cis	rs6782228	0.606	rs2811490	chr3:128351755	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.73	-0.48	3.19e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs72772787	1.000	rs72772787	chr1:248016378	C/T	cg04028570	chr1:248100427	OR2L13	0.63	4.75	0.36	4.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs3745621	0.962	rs184290	chr19:47627065	G/A	cg24326880	chr19:47634349	SAE1	0.56	4.61	0.35	8.52e-6	Lymphocyte counts;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	6.17	0.45	5.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg04906043	chr13:21280425	IL17D	0.47	4.38	0.33	2.24e-5	Dental caries;
PAAD	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.76	7.69	0.53	1.74e-12	Coronary artery disease;
PAAD	cis	rs9913156	0.517	rs8069382	chr17:4612874	G/T	cg23387401	chr17:4582204	PELP1	0.42	4.61	0.35	8.62e-6	Lymphocyte counts;
PAAD	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.7	-7.11	-0.5	4.13e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	1.000	rs78020607	chr3:50254624	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	4.84	0.37	3.1e-6	Schizophrenia;
PAAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.49	4.75	0.36	4.67e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.6	-6.92	-0.49	1.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.78	-7.75	-0.53	1.22e-12	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.7	8.88	0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.13	-0.5	3.79e-11	Neuroticism;
PAAD	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs7849585	0.898	rs67827752	chr9:139137204	G/A	cg14147151	chr9:138948000	NACC2	-0.41	-4.53	-0.35	1.17e-5	Height;
PAAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.5	-4.82	-0.36	3.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.6	-5.63	-0.42	8.37e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg12568669	chr8:11666485	FDFT1	-0.28	-4.35	-0.33	2.46e-5	Monocyte count;
PAAD	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	6.67	0.48	4.39e-10	Response to antipsychotic treatment;
PAAD	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.91	5.83	0.43	3.27e-8	Prostate cancer;
PAAD	cis	rs288326	0.561	rs75936972	chr2:183756989	C/T	cg09997497	chr2:183902928	NCKAP1	1.02	5.36	0.4	3e-7	Blood protein levels;
PAAD	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.15	-0.55	1.26e-13	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.5	-5.23	-0.39	5.6e-7	Blood metabolite levels;
PAAD	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg21827317	chr3:136751795	NA	0.51	5.37	0.4	2.95e-7	Neuroticism;Schizophrenia;
PAAD	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	4.56	0.35	1.03e-5	Educational attainment (years of education);
PAAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg23262073	chr20:60523788	NA	-0.45	-4.42	-0.34	1.85e-5	Body mass index;
PAAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.51	-0.34	1.31e-5	Eosinophil percentage of white cells;
PAAD	cis	rs11811982	0.793	rs77168416	chr1:227321838	T/G	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs2017305	0.915	rs117058070	chr10:70696562	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01765077	chr12:122356316	WDR66	0.62	6.54	0.47	8.81e-10	Mean corpuscular volume;
PAAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.8	7.96	0.54	3.75e-13	Calcium levels;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg24699146	chr1:24152579	HMGCL	0.54	5.76	0.42	4.47e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2529218	0.551	rs2529204	chr7:101419102	A/G	cg09205156	chr7:101991189	SPDYE6	0.53	4.55	0.35	1.11e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9398803	0.687	rs9401897	chr6:126940641	A/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.79	9.76	0.62	8.74e-18	Gut microbiome composition (winter);
PAAD	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs2034650	0.544	rs600791	chr15:40721067	G/C	cg05276125	chr15:40653601	DISP2	0.51	4.82	0.36	3.43e-6	Interstitial lung disease;
PAAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.3	0.56	5.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg16259171	chr11:73660510	DNAJB13	-0.65	-4.31	-0.33	2.92e-5	Obesity-related traits;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg16898833	chr6:26189333	HIST1H4D	1.0	5.6	0.41	9.62e-8	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg04053776	chr11:6947353	ZNF215	0.49	4.29	0.33	3.15e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs2076222	1.000	rs2072939	chr1:209801058	C/T	cg00257659	chr1:209800214	LAMB3	-1.23	-4.86	-0.37	2.9e-6	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
PAAD	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-5.13	-0.38	8.88e-7	Joint mobility (Beighton score);
PAAD	cis	rs58653258	0.570	rs2673945	chr1:234987706	G/T	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13939156	chr17:80058883	NA	0.4	4.29	0.33	3.13e-5	Life satisfaction;
PAAD	cis	rs10916814	0.632	rs10799645	chr1:20903784	T/C	cg04087271	chr1:20915334	CDA	0.38	4.67	0.35	6.62e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg19264203	chr11:92714893	MTNR1B	0.42	4.85	0.37	2.97e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg01868782	chr6:126071099	HEY2	0.46	5.42	0.4	2.26e-7	Brugada syndrome;
PAAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.24	-0.51	2.07e-11	Coronary artery disease;
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg23281280	chr6:28129359	ZNF389	0.54	4.83	0.36	3.3e-6	Parkinson's disease;
PAAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.39	-0.34	2.14e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	11.24	0.67	1e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8133932	0.701	rs3788228	chr21:47307669	G/A	cg13695288	chr21:47294981	PCBP3	-0.46	-4.49	-0.34	1.41e-5	Schizophrenia;
PAAD	cis	rs13221852	0.714	rs34731314	chr7:3438362	T/C	cg21248987	chr7:3385318	SDK1	0.42	4.47	0.34	1.51e-5	Acute graft versus host disease in bone marrow transplantation (donor effect);
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.58	-8.04	-0.55	2.31e-13	Asthma (sex interaction);
PAAD	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.71	7.02	0.49	7.09e-11	Schizophrenia;
PAAD	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs642743	0.595	rs607069	chr10:105991003	T/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.26	4.3	0.33	3.01e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23041410	chr2:113884447	IL1RN	-0.62	-6.32	-0.46	2.79e-9	Obesity-related traits;
PAAD	cis	rs2952768	1.000	rs2551936	chr2:208497027	A/G	cg22329743	chr2:208688774	PLEKHM3	0.22	4.41	0.34	1.96e-5	Opioid sensitivity;
PAAD	cis	rs6963495	0.615	rs7384092	chr7:105203084	G/A	cg02135003	chr7:105160482	PUS7	0.59	4.89	0.37	2.5e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg07841815	chr7:100318223	EPO	-0.47	-4.42	-0.34	1.84e-5	Other erythrocyte phenotypes;
PAAD	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.69	6.4	0.46	1.85e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg12463550	chr7:65579703	CRCP	-0.47	-4.45	-0.34	1.66e-5	Calcium levels;
PAAD	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg06795125	chr2:108905320	SULT1C2	-0.44	-4.44	-0.34	1.7e-5	Lobe size;
PAAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.89	-10.37	-0.64	2.23e-19	Coronary artery disease;
PAAD	cis	rs7818688	0.697	rs57890591	chr8:95983130	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.44	7.48	0.52	5.39e-12	Multiple system atrophy;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27436995	chr16:743998	FBXL16	-0.37	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs7168592	1.000	rs67175901	chr15:101748227	C/T	cg24254196	chr15:101719523	CHSY1	-0.59	-4.33	-0.33	2.67e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-4.57	-0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.54	-5.02	-0.38	1.42e-6	Menarche (age at onset);
PAAD	cis	rs10991814	0.920	rs78978656	chr9:94090130	G/A	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg03676636	chr4:99064102	C4orf37	0.27	4.68	0.35	6.36e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.63	6.04	0.44	1.15e-8	Cystic fibrosis severity;
PAAD	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.35	-0.4	3.16e-7	Mean corpuscular volume;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	6.02	0.44	1.23e-8	Tonsillectomy;
PAAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs6604026	0.630	rs56193705	chr1:93455887	C/G	cg17283838	chr1:93427260	FAM69A	0.62	5.73	0.42	5.2e-8	Multiple sclerosis;
PAAD	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg02745156	chr12:32552066	NA	0.44	4.87	0.37	2.75e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs354033	0.800	rs62491927	chr7:149172894	C/A	cg06920324	chr7:149264011	ZNF767	-0.57	-4.87	-0.37	2.8e-6	Multiple sclerosis;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15851312	chr15:73076263	ADPGK	0.67	6.55	0.47	8.48e-10	Myopia (pathological);
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01585852	chr22:24235823	MIF	-0.47	-5.01	-0.38	1.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1468333	0.567	rs11567983	chr5:137647947	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg05697835	chr1:2722811	NA	0.42	4.68	0.36	6.21e-6	Ulcerative colitis;
PAAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.24e-17	Lymphocyte counts;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	14.65	0.77	7.34e-31	Prudent dietary pattern;
PAAD	cis	rs55637147	0.671	rs9667065	chr11:57116381	C/A	cg25492363	chr11:57319872	UBE2L6	-0.42	-4.57	-0.35	1.02e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6718203	1.000	rs56404075	chr2:60631365	T/C	cg10480506	chr2:60280451	NA	0.8	4.49	0.34	1.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.88e-5	Total body bone mineral density;
PAAD	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs2191566	0.887	rs55703004	chr19:44504781	T/G	cg20607764	chr19:44506953	ZNF230	-0.47	-4.36	-0.33	2.35e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11020478	0.600	rs1939568	chr11:93391559	C/T	cg10523193	chr11:93463762	SNORA25	-0.41	-4.27	-0.33	3.49e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.59	5.3	0.4	3.93e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg00522288	chr12:125625016	AACS	-0.44	-4.64	-0.35	7.51e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.64	-6.19	-0.45	5.26e-9	Asthma;
PAAD	cis	rs4668356	1.000	rs6746133	chr2:171937689	G/A	cg13882835	chr2:172017928	TLK1	0.91	4.84	0.37	3.18e-6	Cognitive performance;
PAAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.58	-7.93	-0.54	4.34e-13	Rheumatoid arthritis;
PAAD	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.56	6.53	0.47	9.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs727479	0.585	rs12911554	chr15:51542757	C/T	cg21478137	chr15:51532386	CYP19A1	0.42	4.4	0.34	2e-5	Estradiol levels;
PAAD	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	cis	rs7246657	0.508	rs1644702	chr19:37491907	C/T	cg23950597	chr19:37808831	NA	-0.81	-5.54	-0.41	1.32e-7	Coronary artery calcification;
PAAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg06632027	chr4:90757378	SNCA	-0.6	-5.39	-0.4	2.59e-7	Neuroticism;
PAAD	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.78	6.92	0.49	1.18e-10	Coronary artery disease;
PAAD	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.49	-5.21	-0.39	6.15e-7	Menarche (age at onset);
PAAD	cis	rs9372498	0.536	rs724868	chr6:118795152	C/T	cg07617317	chr6:118971624	C6orf204	0.56	4.67	0.35	6.65e-6	Diastolic blood pressure;
PAAD	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.57	-5.94	-0.43	1.84e-8	Pubertal anthropometrics;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg20761395	chr17:511517	VPS53	0.75	7.4	0.51	8.67e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.77	5.4	0.4	2.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.59	-6.22	-0.45	4.67e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23427998	chr5:54522784	NA	0.61	6.52	0.47	9.76e-10	Myopia (pathological);
PAAD	cis	rs12431939	0.948	rs12436158	chr14:51669891	G/A	cg23942311	chr14:51606299	NA	-0.71	-5.71	-0.42	5.75e-8	Cancer;
PAAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg01616529	chr11:638424	DRD4	-0.59	-5.75	-0.42	4.68e-8	Systemic lupus erythematosus;
PAAD	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg22134325	chr11:66188745	NPAS4	0.43	5.36	0.4	3.01e-7	Airway imaging phenotypes;
PAAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg09796270	chr17:17721594	SREBF1	-0.44	-4.65	-0.35	7.02e-6	Total body bone mineral density;
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg03037974	chr15:76606532	NA	0.51	6.01	0.44	1.32e-8	Blood metabolite levels;
PAAD	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-4.4	-0.34	2.04e-5	Self-reported allergy;
PAAD	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.97	-13.0	-0.73	1.85e-26	Body mass index (adult);
PAAD	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg02683114	chr2:24398427	C2orf84	-0.54	-5.11	-0.38	9.33e-7	Asthma;
PAAD	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-1.0	-12.89	-0.72	3.68e-26	Refractive error;
PAAD	cis	rs7582720	1.000	rs72932741	chr2:203661048	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.51	0.52	4.72e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs61884328	0.866	rs61593070	chr11:46836611	T/C	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.6	-7.04	-0.5	6.07e-11	Aortic root size;
PAAD	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg21823605	chr1:152486609	CRCT1	0.52	6.58	0.47	7.03e-10	Hair morphology;
PAAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.39	-5.77	-0.42	4.32e-8	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg02462569	chr6:150064036	NUP43	-0.48	-5.31	-0.4	3.84e-7	Lung cancer;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg24154853	chr7:158122151	PTPRN2	0.79	7.37	0.51	1.03e-11	Response to amphetamines;
PAAD	cis	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg23682824	chr7:23144976	KLHL7	0.5	4.64	0.35	7.46e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg04877966	chr15:75135169	ULK3	0.54	4.7	0.36	5.74e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg12826209	chr6:26865740	GUSBL1	0.76	4.47	0.34	1.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17407555	0.955	rs11734209	chr4:10170371	T/A	cg02734326	chr4:10020555	SLC2A9	-0.51	-4.35	-0.33	2.47e-5	Schizophrenia (age at onset);
PAAD	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.78	6.11	0.44	7.88e-9	IgE levels;
PAAD	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.44	4.31	0.33	2.91e-5	Red blood cell count;
PAAD	cis	rs793571	0.505	rs16940587	chr15:58898663	A/T	cg05156742	chr15:59063176	FAM63B	0.64	4.67	0.35	6.66e-6	Schizophrenia;
PAAD	cis	rs2579500	0.807	rs6576978	chr2:97285852	C/T	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.86	9.99	0.63	2.16e-18	Iron status biomarkers;
PAAD	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.87	-9.83	-0.62	5.94e-18	Cognitive function;
PAAD	cis	rs12600304	0.684	rs2405129	chr16:58015841	G/A	cg08699646	chr16:58019359	TEPP	0.39	4.51	0.34	1.3e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19552494	chr11:60674271	PRPF19	0.59	6.55	0.47	8.48e-10	Response to antipsychotic treatment;
PAAD	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.11	-16.27	-0.8	4.26e-35	Testicular germ cell tumor;
PAAD	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg23387401	chr17:4582204	PELP1	0.51	5.01	0.38	1.46e-6	Lymphocyte counts;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.36	-4.5	-0.34	1.37e-5	Iron status biomarkers;
PAAD	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	5.99	0.44	1.48e-8	Mean platelet volume;
PAAD	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg11530693	chr1:120165357	ZNF697	0.64	5.6	0.41	9.76e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24512311	chr12:2977833	FOXM1	-0.68	-6.83	-0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs12799264	0.841	rs2449500	chr11:19976564	T/C	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.49e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs757978	0.733	rs11689496	chr2:242426399	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.72	-4.58	-0.35	9.61e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg19784903	chr17:45786737	TBKBP1	-0.6	-6.57	-0.47	7.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9880406	1.000	rs9880406	chr3:126049305	C/T	cg11830761	chr3:126007485	NA	-0.51	-4.84	-0.37	3.2e-6	Macular telangiectasia type 2;
PAAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.34	16.32	0.8	3.13e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg15691649	chr6:25882328	NA	-0.5	-4.89	-0.37	2.5e-6	Blood metabolite levels;
PAAD	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg08807101	chr21:30365312	RNF160	-0.65	-5.31	-0.4	3.87e-7	Cognitive test performance;
PAAD	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg19510604	chr15:74901076	CLK3	0.56	4.32	0.33	2.81e-5	Blood trace element (Zn levels);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26126750	chr3:195809198	TFRC	0.7	7.55	0.52	3.67e-12	Myopia (pathological);
PAAD	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.54	5.22	0.39	5.81e-7	Multiple sclerosis;
PAAD	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-4.47	-0.34	1.55e-5	Type 2 diabetes;
PAAD	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.27	0.51	1.74e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-5.17	-0.39	7.39e-7	Type 2 diabetes;
PAAD	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg04287289	chr16:89883240	FANCA	0.87	4.31	0.33	2.97e-5	Skin colour saturation;
PAAD	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg13207630	chr7:32358064	NA	0.78	4.31	0.33	2.89e-5	Body mass index;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-0.6	-4.58	-0.35	9.61e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.32	-0.33	2.77e-5	Aortic root size;
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg09594475	chr20:60884601	LAMA5	-0.45	-4.25	-0.33	3.72e-5	Colorectal cancer;
PAAD	cis	rs16910800	0.953	rs73481422	chr11:23205174	T/C	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.76	-8.57	-0.57	1.1e-14	Basophil percentage of granulocytes;Basophil percentage of white cells;
PAAD	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	6.58	0.47	7.16e-10	LDL cholesterol;
PAAD	cis	rs17641971	0.783	rs2385127	chr8:49975746	C/T	cg00325661	chr8:49890786	NA	0.49	4.85	0.37	3.03e-6	Blood metabolite levels;
PAAD	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	0.84	5.7	0.42	6.09e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.74	-8.82	-0.58	2.52e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.23	0.39	5.59e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	1.000	rs9857175	chr3:41822054	T/G	cg03022575	chr3:42003672	ULK4	0.81	6.23	0.45	4.44e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.73	6.9	0.49	1.3e-10	Obesity-related traits;
PAAD	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg04995300	chr3:66848608	NA	0.4	4.31	0.33	2.97e-5	Type 2 diabetes;
PAAD	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs62264129	0.500	rs9829698	chr3:112028239	A/G	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.03	-0.38	1.36e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg13495574	chr1:173793781	CENPL;DARS2	-0.69	-6.33	-0.46	2.64e-9	Blood protein levels;
PAAD	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.12	0.67	2.17e-21	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg03037974	chr15:76606532	NA	0.55	6.71	0.48	3.6e-10	Blood metabolite levels;
PAAD	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.75	-0.48	2.85e-10	Glomerular filtration rate;
PAAD	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	8.53	0.57	1.35e-14	Alzheimer's disease;
PAAD	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.34	-0.56	4.22e-14	Hemoglobin concentration;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24678148	chr1:193227662	NA	0.59	6.62	0.47	5.67e-10	Smoking initiation;
PAAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg18281939	chr5:77783895	LHFPL2	0.49	5.59	0.41	1e-7	Triglycerides;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.46	-5.21	-0.39	6.03e-7	Breast size;
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.27	-0.39	4.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2885056	0.891	rs73018644	chr19:10689015	A/C	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg03676636	chr4:99064102	C4orf37	0.31	5.69	0.42	6.28e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4450131	0.618	rs3781452	chr10:126355129	A/G	cg20435097	chr10:126320824	FAM53B	0.52	5.48	0.41	1.75e-7	White blood cell count (basophil);
PAAD	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.56	5.5	0.41	1.59e-7	Systolic blood pressure;
PAAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg00753924	chr9:137298813	RXRA	-0.48	-5.28	-0.39	4.31e-7	Intelligence;
PAAD	trans	rs9409082	0.748	rs62576756	chr9:108936402	T/A	cg07010948	chr13:79181613	NA	-0.35	-6.54	-0.47	9.04e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg09699651	chr6:150184138	LRP11	0.52	5.41	0.4	2.45e-7	Lung cancer;
PAAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg08029281	chr1:67600428	NA	0.45	5.49	0.41	1.62e-7	Psoriasis;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07362569	chr17:61921086	SMARCD2	-0.49	-5.92	-0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs58521262	0.556	rs453743	chr19:23121640	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.64	-0.35	7.33e-6	Testicular germ cell tumor;
PAAD	cis	rs31872	0.678	rs702390	chr5:140442209	G/A	cg19650706	chr5:140594406	PCDHB13	-0.59	-5.22	-0.39	5.7e-7	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs6496044	0.507	rs2467096	chr15:86210678	G/A	cg10818794	chr15:86012489	AKAP13	0.42	4.4	0.34	2e-5	Interstitial lung disease;
PAAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.87	-8.52	-0.57	1.45e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.89	-13.48	-0.74	9.37e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6519955	0.755	rs8138989	chr22:46425432	C/T	cg00147172	chr22:46423604	NA	0.4	5.41	0.4	2.36e-7	Dupuytren's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24704182	chr1:155108583	RAG1AP1	-0.8	-6.71	-0.48	3.56e-10	Neuroticism;
PAAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	1.24	12.51	0.71	3.86e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11245990	chr11:68621969	NA	-0.36	-4.62	-0.35	8.13e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.91	10.44	0.65	1.43e-19	Cognitive function;
PAAD	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-5.05	-0.38	1.23e-6	Height;
PAAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11618113	0.633	rs11617579	chr13:111200970	T/C	cg11688093	chr13:111178359	RAB20	-0.83	-4.61	-0.35	8.54e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.51	-4.88	-0.37	2.62e-6	Psoriasis;
PAAD	cis	rs1879734	0.731	rs12405835	chr1:54129732	C/G	cg14659662	chr1:54151053	GLIS1	-0.38	-5.12	-0.38	9.2e-7	Mitral valve prolapse;
PAAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.96	-10.31	-0.64	3.17e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.43	4.79	0.36	3.99e-6	Dietary macronutrient intake;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.49	5.38	0.4	2.76e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.52	0.47	9.98e-10	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.49	5.68	0.42	6.82e-8	Platelet count;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg22663859	chr13:21900854	NA	0.56	6.41	0.46	1.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-10.57	-0.65	6.5e-20	Platelet distribution width;
PAAD	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.74	7.55	0.52	3.65e-12	Corneal astigmatism;
PAAD	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg04520793	chr17:42248056	ASB16	-0.37	-4.3	-0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs16958440	0.708	rs57468764	chr18:44624856	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-5.33	-0.4	3.47e-7	Sitting height ratio;
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.42	-5.13	-0.38	8.54e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	7.16	0.5	3.31e-11	Body mass index;
PAAD	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22792048	chr13:114911579	NA	-0.59	-6.44	-0.46	1.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.69	-0.48	4.07e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg05627522	chr15:75251581	NA	-0.52	-6.39	-0.46	1.94e-9	Caffeine consumption;
PAAD	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg27499820	chr13:21296301	IL17D	0.51	4.8	0.36	3.71e-6	Dental caries;
PAAD	cis	rs372883	0.509	rs1999322	chr21:30533959	A/T	cg24692254	chr21:30365293	RNF160	0.47	4.27	0.33	3.4e-5	Pancreatic cancer;
PAAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg15017067	chr4:17643749	FAM184B	0.45	5.3	0.39	4.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.73	-9.16	-0.6	3.25e-16	Educational attainment;
PAAD	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs11811982	0.793	rs79505001	chr1:227578302	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg14851346	chr12:38532713	NA	0.49	4.52	0.34	1.21e-5	Morning vs. evening chronotype;
PAAD	cis	rs797680	0.856	rs797672	chr1:93702119	A/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.43	-0.34	1.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg00684032	chr4:1343700	KIAA1530	0.42	4.27	0.33	3.48e-5	Longevity;
PAAD	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04731861	chr2:219085781	ARPC2	0.37	4.37	0.33	2.31e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-4.3	-0.33	3.1e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg18769074	chr3:133464867	TF	-0.4	-4.57	-0.35	9.9e-6	Iron status biomarkers;
PAAD	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.54	-5.1	-0.38	9.77e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.55	-7.15	-0.5	3.37e-11	Height;
PAAD	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	5.15	0.39	7.89e-7	Menarche (age at onset);
PAAD	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg25902810	chr10:99078978	FRAT1	-0.6	-5.44	-0.4	2.08e-7	Monocyte count;
PAAD	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.03	-0.5	6.65e-11	Total body bone mineral density;
PAAD	cis	rs4731207	0.596	rs1481330	chr7:124631363	C/T	cg14311320	chr7:124405732	GPR37	-0.43	-4.51	-0.34	1.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg07701084	chr6:150067640	NUP43	-0.64	-5.6	-0.41	9.81e-8	Lung cancer;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.91	6.84	0.49	1.77e-10	Alzheimer's disease;
PAAD	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09597638	chr17:3907349	NA	0.79	8.88	0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.98	0.44	1.52e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.27	0.39	4.56e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	5.38	0.4	2.78e-7	Mood instability;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.56	-5.46	-0.41	1.88e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.86	0.58	1.92e-15	Lung cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05747105	chr6:53224391	NA	0.55	6.35	0.46	2.39e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	cis	rs569214	0.648	rs576956	chr8:27513609	G/A	cg04264299	chr8:27491209	SCARA3	0.52	4.74	0.36	4.89e-6	Alzheimer's disease;
PAAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg22143856	chr6:28129313	ZNF389	-0.68	-5.58	-0.41	1.07e-7	Depression;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.76	-6.34	-0.46	2.51e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.51	4.89	0.37	2.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs1497828	0.956	rs1566178	chr1:217526431	G/A	cg04411442	chr1:217543379	NA	-0.46	-4.48	-0.34	1.43e-5	Dialysis-related mortality;
PAAD	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.74	8.98	0.59	9.5e-16	Bladder cancer;
PAAD	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.78	5.71	0.42	5.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.67	-8.74	-0.58	4e-15	Schizophrenia;
PAAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg00207856	chr7:1054120	C7orf50	-0.5	-4.48	-0.34	1.44e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg14349672	chr11:133703707	NA	-0.47	-5.02	-0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg26205652	chr12:48591994	NA	-0.86	-8.13	-0.55	1.42e-13	Longevity (90 years and older);
PAAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.1	-0.38	1.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.61	-4.96	-0.37	1.88e-6	Putamen volume;
PAAD	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-4.33	-0.33	2.68e-5	Joint mobility (Beighton score);
PAAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.68	-4.93	-0.37	2.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.722	rs4753525	chr11:93688134	A/G	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.15	-0.39	8.01e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	5.09	0.38	1.06e-6	Breast cancer;
PAAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.54	-5.75	-0.42	4.76e-8	Huntington's disease progression;
PAAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.98	10.62	0.65	4.58e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.72	7.32	0.51	1.36e-11	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg06521852	chr22:38141419	TRIOBP	0.44	4.42	0.34	1.9e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs893363	0.517	rs9836592	chr3:53855083	C/T	cg15798837	chr3:54122146	NA	0.34	4.31	0.33	2.95e-5	Axial length;
PAAD	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg14169450	chr9:139327907	INPP5E	0.52	4.43	0.34	1.78e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg20628663	chr10:43360327	NA	-0.69	-5.13	-0.38	8.59e-7	Blood protein levels;
PAAD	cis	rs859767	0.924	rs842349	chr2:135342452	G/T	cg12500956	chr2:135428796	TMEM163	0.32	4.69	0.36	5.98e-6	Neuroticism;
PAAD	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.64	0.35	7.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg23093090	chr10:104574429	C10orf26	-0.46	-4.87	-0.37	2.72e-6	Arsenic metabolism;
PAAD	cis	rs732765	0.734	rs888418	chr14:75119296	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.53	-0.35	1.17e-5	Non-small cell lung cancer;
PAAD	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.47	-4.85	-0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10936797	0.775	rs11718088	chr3:174214920	T/C	cg16219125	chr3:174043293	NA	-0.42	-4.29	-0.33	3.16e-5	Obesity-related traits;
PAAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.62	5.55	0.41	1.22e-7	Mean platelet volume;
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg10864074	chr7:100318194	EPO	-0.42	-4.25	-0.33	3.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg06740227	chr12:86229804	RASSF9	0.5	4.94	0.37	2.07e-6	Major depressive disorder;
PAAD	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg20487152	chr13:99095054	FARP1	0.45	4.74	0.36	4.79e-6	Longevity;
PAAD	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.55	5.96	0.44	1.66e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9810890	1.000	rs73196960	chr3:128432222	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23890158	chr1:154377807	IL6R	0.58	6.42	0.46	1.68e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.54	0.61	3.31e-17	Prudent dietary pattern;
PAAD	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs7705042	0.828	rs249638	chr5:141530696	G/C	cg08523384	chr5:141488047	NDFIP1	-0.49	-4.61	-0.35	8.47e-6	Asthma;
PAAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg21775979	chr11:780331	NA	-0.66	-6.5	-0.47	1.11e-9	Breast cancer;
PAAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.78	9.92	0.63	3.34e-18	Bone mineral density;
PAAD	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.62	6.08	0.44	9.28e-9	Lymphocyte counts;
PAAD	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg27449745	chr7:23145252	KLHL7	0.49	4.3	0.33	3.08e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-5.05	-0.38	1.27e-6	Vitiligo;
PAAD	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.82	7.0	0.49	7.71e-11	Alzheimer's disease;
PAAD	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg23153227	chr6:27725408	NA	0.42	4.58	0.35	9.57e-6	Pubertal anthropometrics;
PAAD	cis	rs1499972	0.941	rs56310214	chr3:117640127	G/A	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.77	-0.42	4.24e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs11264799	0.731	rs2095611	chr1:157686581	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.63	0.42	8.38e-8	IgA nephropathy;
PAAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg04165759	chr1:150448943	RPRD2	-0.49	-5.04	-0.38	1.33e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs643506	0.874	rs615642	chr11:111649421	G/A	cg09085632	chr11:111637200	PPP2R1B	0.51	4.6	0.35	8.91e-6	Breast cancer;
PAAD	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.14e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs2415984	0.579	rs113349829	chr14:46973973	C/A	cg14871534	chr14:47121158	RPL10L	-0.47	-4.81	-0.36	3.55e-6	Number of children ever born;
PAAD	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.63	6.0	0.44	1.41e-8	Mood instability;
PAAD	cis	rs9815354	1.000	rs6790732	chr3:41864872	C/T	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01738944	chr1:1677273	SLC35E2	0.63	7.13	0.5	3.9e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg08132940	chr7:1081526	C7orf50	0.6	4.42	0.34	1.89e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs10885582	0.781	rs7893570	chr10:116294295	G/A	cg17056676	chr10:116301354	ABLIM1	-0.4	-5.42	-0.4	2.26e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1420338	0.967	rs1014581	chr7:34164677	T/G	cg01275685	chr7:34179230	BMPER	-0.53	-5.02	-0.38	1.46e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-6.41	-0.46	1.69e-9	Morning vs. evening chronotype;
PAAD	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	5.63	0.42	8.46e-8	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.91	11.41	0.68	3.54e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.56	4.61	0.35	8.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg19761014	chr17:28927070	LRRC37B2	0.74	5.16	0.39	7.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7187365	1.000	rs7187365	chr16:86511915	C/T	cg06866187	chr16:86489453	NA	0.49	4.4	0.34	1.99e-5	Obesity (early onset extreme);
PAAD	cis	rs8060686	0.920	rs56047901	chr16:67742326	G/A	cg09835421	chr16:68378352	PRMT7	-0.93	-5.32	-0.4	3.69e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs282587	0.569	rs282564	chr13:113373953	G/T	cg02820901	chr13:113351484	ATP11A	0.65	4.73	0.36	5.11e-6	Glycated hemoglobin levels;
PAAD	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	7.4	0.51	8.83e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.11	-0.44	8.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4704187	0.617	rs6898134	chr5:74456731	T/C	cg03227963	chr5:74354835	NA	0.46	4.4	0.34	2.04e-5	Response to amphetamines;
PAAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.59	5.45	0.4	1.98e-7	IgG glycosylation;
PAAD	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.62	5.32	0.4	3.67e-7	Schizophrenia;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg26385993	chr17:80788710	TBCD;ZNF750	0.43	4.39	0.34	2.1e-5	Glycated hemoglobin levels;
PAAD	cis	rs13011075	0.535	rs1050181	chr2:68622952	G/C	cg06275642	chr2:68546038	CNRIP1	0.35	4.66	0.35	6.94e-6	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	6.75	0.48	2.94e-10	Neuroticism;
PAAD	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.27	0.45	3.64e-9	Lung cancer;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.87	-0.49	1.53e-10	Life satisfaction;
PAAD	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg18612461	chr15:75251733	NA	-0.58	-5.23	-0.39	5.53e-7	Blood trace element (Zn levels);
PAAD	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs12220238	0.915	rs7073139	chr10:76071189	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.66	4.3	0.33	3.09e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs8060686	0.641	rs3785108	chr16:68106846	C/T	cg05110241	chr16:68378359	PRMT7	-1.07	-5.98	-0.44	1.57e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg00431813	chr7:1051703	C7orf50	0.35	4.46	0.34	1.59e-5	Longevity;Endometriosis;
PAAD	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg25364880	chr3:44379878	C3orf23	0.54	5.34	0.4	3.35e-7	Depressive symptoms;
PAAD	cis	rs7816613	0.920	rs16868159	chr8:102672227	T/C	cg20585841	chr8:102729926	NCALD	-0.67	-5.46	-0.41	1.89e-7	Age-related hearing impairment;
PAAD	cis	rs75920871	0.925	rs61903418	chr11:116956665	G/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.77	9.8	0.62	7.03e-18	Iron status biomarkers (transferrin levels);
PAAD	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg20744362	chr22:50050164	C22orf34	0.63	7.23	0.51	2.18e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-4.54	-0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.35	0.71	1.04e-24	Chronic sinus infection;
PAAD	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg18612461	chr15:75251733	NA	0.69	8.91	0.59	1.49e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs42648	0.535	rs10952994	chr7:89753859	G/C	cg27367526	chr7:89841692	STEAP2	0.34	4.79	0.36	3.92e-6	Homocysteine levels;
PAAD	cis	rs2251260	0.685	rs1088673	chr14:62005648	A/G	cg23386212	chr14:62041363	NA	-0.54	-4.28	-0.33	3.25e-5	Yeast infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11877726	chr14:99637027	BCL11B	-0.59	-6.4	-0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	8.62	0.57	8.33e-15	Colorectal cancer;
PAAD	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.58	-0.35	9.52e-6	Pulmonary function;
PAAD	cis	rs3106136	0.609	rs72665612	chr4:95101183	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.68	-6.14	-0.45	6.81e-9	Capecitabine sensitivity;
PAAD	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg01620082	chr3:125678407	NA	-1.61	-9.73	-0.62	1.06e-17	Breast cancer;
PAAD	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.77	8.7	0.58	5.08e-15	Heart rate;
PAAD	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.38	-0.4	2.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01626895	chr12:116425790	MED13L	-0.55	-6.43	-0.46	1.58e-9	Monocyte percentage of white cells;
PAAD	cis	rs12754538	0.922	rs902356	chr1:8432653	G/A	cg06159269	chr1:8767347	RERE	0.39	4.75	0.36	4.72e-6	Subjective well-being;
PAAD	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25796963	chr3:52827657	ITIH3	-0.63	-6.92	-0.49	1.18e-10	Obesity-related traits;
PAAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.54	5.74	0.42	4.87e-8	Schizophrenia;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg05874882	chr4:1763078	NA	-0.36	-4.8	-0.36	3.84e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.64	0.35	7.45e-6	Neuroticism;
PAAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.77	8.98	0.59	9.71e-16	Lung cancer;
PAAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Menopause (age at onset);
PAAD	cis	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg22500703	chr18:23806247	TAF4B	-0.46	-4.25	-0.33	3.77e-5	Dental caries;
PAAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.72	7.7	0.53	1.57e-12	Morning vs. evening chronotype;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg08200582	chr11:442649	ANO9	0.54	4.43	0.34	1.8e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg19640130	chr10:64028056	RTKN2	-0.37	-4.42	-0.34	1.84e-5	Rheumatoid arthritis;
PAAD	cis	rs9324022	0.656	rs72698711	chr14:101167563	C/T	cg18089426	chr14:101175970	NA	0.73	5.34	0.4	3.39e-7	Plateletcrit;
PAAD	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg26205652	chr12:48591994	NA	0.92	9.2	0.6	2.63e-16	Longevity (90 years and older);
PAAD	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.78	-7.5	-0.52	5.08e-12	Urate levels in lean individuals;
PAAD	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg14146966	chr2:61757674	XPO1	0.37	4.49	0.34	1.41e-5	Tuberculosis;
PAAD	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.41	-0.34	1.98e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg10437265	chr15:77819839	NA	0.42	4.68	0.35	6.29e-6	Type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg14703610	chr5:56206110	C5orf35	0.61	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.56	6.08	0.44	9.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26926768	chr12:34528122	NA	0.4	4.92	0.37	2.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.92	11.26	0.67	9.14e-22	Blood protein levels;
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg13632729	chr17:80989170	B3GNTL1	0.42	4.25	0.33	3.65e-5	Glycated hemoglobin levels;
PAAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24549020	chr5:56110836	MAP3K1	-0.51	-4.29	-0.33	3.12e-5	Initial pursuit acceleration;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.65	-7.29	-0.51	1.58e-11	Renal function-related traits (BUN);
PAAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.96	5.98	0.44	1.56e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07685180	chr8:600429	NA	-0.83	-5.3	-0.4	3.98e-7	IgG glycosylation;
PAAD	cis	rs617219	0.765	rs10053349	chr5:78475423	T/C	cg24856658	chr5:78533917	JMY	-0.39	-4.44	-0.34	1.73e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg18939081	chr1:31884902	SERINC2	0.5	5.71	0.42	5.66e-8	Alcohol dependence;
PAAD	cis	rs12472274	0.591	rs11679528	chr2:239073506	C/A	cg17459225	chr2:239074497	NA	0.74	5.16	0.39	7.75e-7	Phospholipid levels (plasma);
PAAD	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.55	-5.76	-0.42	4.5e-8	Menopause (age at onset);
PAAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.53	-6.95	-0.49	9.98e-11	Height;
PAAD	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.45	5.09	0.38	1.02e-6	Testicular germ cell tumor;
PAAD	cis	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.71	-6.89	-0.49	1.37e-10	Cognitive function;
PAAD	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	Cognitive function;
PAAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg05110241	chr16:68378359	PRMT7	-0.82	-6.81	-0.48	2.14e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17095355	0.539	rs3890722	chr10:111925233	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.73	-0.36	5.14e-6	Biliary atresia;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.49	-4.9	-0.37	2.43e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00930706	chr16:88752925	MGC23284;SNAI3	0.6	6.63	0.47	5.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.53	6.03	0.44	1.21e-8	Personality dimensions;
PAAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23463467	chr20:60627584	TAF4	0.43	4.82	0.36	3.4e-6	Body mass index;
PAAD	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.62	-0.35	8.17e-6	Mood instability;
PAAD	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs877529	0.530	rs1005300	chr22:39547891	C/G	cg18708252	chr22:39545030	CBX7	-0.66	-6.91	-0.49	1.27e-10	Multiple myeloma;
PAAD	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.79	8.06	0.55	2.1e-13	Retinal vascular caliber;
PAAD	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-6.3	-0.45	3.1e-9	Vitamin D levels;
PAAD	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg22587600	chr2:46883368	NA	0.31	4.27	0.33	3.38e-5	Height;
PAAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.26	-0.33	3.64e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12956009	0.507	rs1560900	chr18:44866849	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-4.35	-0.33	2.45e-5	Educational attainment (years of education);
PAAD	cis	rs12580194	0.593	rs61957887	chr12:55721734	C/T	cg06899799	chr12:56650233	ANKRD52	0.33	4.29	0.33	3.12e-5	Cancer;
PAAD	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.6	-5.95	-0.43	1.75e-8	Glioblastoma;
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg21565972	chr17:80109576	CCDC57	0.49	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg21906852	chr1:75198582	TYW3;CRYZ	0.52	4.99	0.38	1.64e-6	Resistin levels;
PAAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg03060546	chr3:49711283	APEH	-0.53	-4.52	-0.34	1.22e-5	Menarche (age at onset);
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.64	-4.9	-0.37	2.43e-6	Initial pursuit acceleration;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.76	8.94	0.59	1.25e-15	White blood cell count (basophil);
PAAD	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.41	-6.16	-0.45	6.23e-9	Subjective well-being;
PAAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.47	4.83	0.36	3.32e-6	Height;
PAAD	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	4.88	0.37	2.69e-6	Cervical cancer;
PAAD	cis	rs3010562	0.668	rs9457305	chr6:167760702	T/G	cg22772386	chr6:167763320	NA	-0.41	-4.37	-0.33	2.28e-5	Gut microbiome composition (summer and winter);
PAAD	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.54	4.67	0.35	6.5e-6	Lymphocyte counts;
PAAD	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.89	9.91	0.63	3.55e-18	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg16205897	chr5:131564050	P4HA2	-0.42	-4.35	-0.33	2.49e-5	Acylcarnitine levels;
PAAD	cis	rs3112530	1.000	rs2061638	chr5:152638132	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.94	-5.25	-0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-4.47	-0.34	1.54e-5	Body mass index;
PAAD	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg23127183	chr11:57508653	C11orf31	-0.49	-4.25	-0.33	3.72e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.98	0.44	1.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.764	rs494982	chr6:44937255	C/T	cg25276700	chr6:44698697	NA	-0.49	-5.73	-0.42	5.26e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.83	-8.32	-0.56	4.76e-14	Prostate cancer;
PAAD	cis	rs10490913	0.583	rs853923	chr10:120153263	C/T	cg04126427	chr10:120840676	EIF3A	0.43	4.39	0.34	2.11e-5	Cancer;
PAAD	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.89	-13.56	-0.74	5.86e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.62	6.45	0.46	1.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.6	7.19	0.5	2.76e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.63	-0.57	7.49e-15	Type 2 diabetes;
PAAD	cis	rs7593730	0.666	rs10929973	chr2:161119907	A/G	cg22609984	chr2:161126801	NA	0.51	4.4	0.34	2.02e-5	Type 2 diabetes;
PAAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg05484376	chr2:27715224	FNDC4	0.51	5.13	0.38	8.71e-7	Total body bone mineral density;
PAAD	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg14458575	chr2:238380390	NA	0.54	4.62	0.35	8.09e-6	Prostate cancer;
PAAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.44	5.77	0.42	4.4e-8	Childhood ear infection;
PAAD	cis	rs11113894	0.901	rs58166649	chr12:108859278	A/G	cg06834313	chr12:108851556	NA	-0.75	-4.59	-0.35	9.14e-6	Obesity-related traits;
PAAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg06632027	chr4:90757378	SNCA	-0.5	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs1823874	0.720	rs1993296	chr15:100363588	T/A	cg16400843	chr15:100339927	C15orf51	0.4	5.13	0.38	8.85e-7	IgG glycosylation;
PAAD	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.39	-4.95	-0.37	1.98e-6	Prostate cancer;
PAAD	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-0.94	-10.76	-0.66	1.93e-20	Prostate cancer;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg03188948	chr7:1209495	NA	1.05	5.55	0.41	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1903068	0.853	rs10012589	chr4:56002689	A/T	cg20092376	chr4:56023423	NA	0.41	4.27	0.33	3.48e-5	Endometriosis;
PAAD	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg13798912	chr7:905769	UNC84A	0.61	4.64	0.35	7.42e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10214930	0.767	rs6957378	chr7:27696949	C/T	cg22168087	chr7:27702803	HIBADH	-0.49	-4.42	-0.34	1.85e-5	Hypospadias;
PAAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg15571903	chr15:79123663	NA	-0.49	-6.3	-0.45	3.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg01616529	chr11:638424	DRD4	-0.62	-5.34	-0.4	3.27e-7	Systemic lupus erythematosus;
PAAD	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.73	7.49	0.52	5.32e-12	Alcohol dependence;
PAAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21620608	chr2:139259466	SPOPL	0.74	7.83	0.54	7.77e-13	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.08	14.34	0.76	4.96e-30	Height;
PAAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.63	-5.63	-0.42	8.59e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg26893134	chr6:116381904	FRK	0.4	6.23	0.45	4.26e-9	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg13206674	chr6:150067644	NUP43	0.6	5.42	0.4	2.26e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10171557	chr20:34256821	NFS1	-0.65	-6.57	-0.47	7.42e-10	Obesity-related traits;
PAAD	cis	rs7264396	0.887	rs4911510	chr20:34093153	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg03676636	chr4:99064102	C4orf37	0.32	5.9	0.43	2.26e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.88	10.76	0.66	1.94e-20	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	4.56	0.35	1.05e-5	Menarche (age at onset);
PAAD	cis	rs375066	0.623	rs239949	chr19:44356627	C/T	cg11993925	chr19:44307056	LYPD5	0.41	4.37	0.33	2.33e-5	Breast cancer;
PAAD	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.34	4.36	0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs8112211	0.554	rs11673203	chr19:38851930	G/C	cg01275006	chr19:38876250	GGN	-0.95	-5.59	-0.41	1e-7	Blood protein levels;
PAAD	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.6	-8.01	-0.54	2.81e-13	Longevity;
PAAD	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.93	13.17	0.73	6.67e-27	Height;
PAAD	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.29	0.33	3.16e-5	Lung cancer;
PAAD	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs7219021	0.926	rs12150249	chr17:46852108	A/T	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg06569542	chr10:98946673	SLIT1	0.45	4.59	0.35	9.05e-6	Monocyte count;
PAAD	cis	rs7688540	0.610	rs6830496	chr4:215774	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.53	4.42	0.34	1.87e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg20503657	chr10:835505	NA	0.49	5.06	0.38	1.18e-6	Survival in rectal cancer;
PAAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16434002	chr17:42200994	HDAC5	-0.68	-7.57	-0.52	3.36e-12	Total body bone mineral density;
PAAD	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.42	-0.46	1.62e-9	Systolic blood pressure;
PAAD	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.74	10.13	0.63	9.38e-19	Glomerular filtration rate (creatinine);
PAAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.28	-0.56	6.04e-14	Gut microbiome composition (summer);
PAAD	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.86	9.79	0.62	7.42e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs586688	0.625	rs602668	chr1:201657709	A/G	cg27441486	chr1:201708522	NAV1	0.48	4.29	0.33	3.2e-5	Obesity-related traits;
PAAD	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.81	7.56	0.52	3.56e-12	Corneal astigmatism;
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs901683	1.000	rs35585999	chr10:46070159	C/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.94	4.78	0.36	4.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg08992911	chr2:238395768	MLPH	0.57	5.33	0.4	3.52e-7	Prostate cancer;
PAAD	cis	rs4148087	0.929	rs4148098	chr21:43639553	T/A	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.59	-6.57	-0.47	7.54e-10	Monocyte count;
PAAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg19052272	chr2:3704530	ALLC	-0.54	-5.94	-0.43	1.85e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05112574	chr17:76374542	PGS1	0.71	7.34	0.51	1.18e-11	Obesity-related traits;
PAAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs4356203	0.870	rs11024208	chr11:17259979	G/A	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.53	-0.34	1.18e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1032355	0.558	rs79606973	chr4:100517144	T/A	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.9	-10.18	-0.64	6.95e-19	Refractive error;
PAAD	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	4.79	0.36	3.97e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.69	8.06	0.55	2.08e-13	Colorectal cancer;
PAAD	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.77e-6	Mortality in heart failure;
PAAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.94	-9.81	-0.62	6.76e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.53e-6	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21047322	chr6:151666620	AKAP12	-0.59	-6.58	-0.47	7.1e-10	Obesity-related traits;
PAAD	cis	rs7873102	0.654	rs10732358	chr9:37954913	G/A	cg03528946	chr9:38069800	SHB	0.57	5.75	0.42	4.81e-8	Brain structure;
PAAD	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23158103	chr7:148848205	ZNF398	-0.6	-5.58	-0.41	1.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.86	-10.12	-0.63	1.01e-18	Tonsillectomy;
PAAD	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg19257562	chr1:2043853	PRKCZ	0.39	4.65	0.35	7.18e-6	Height;
PAAD	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.52	5.26	0.39	4.81e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.62	5.59	0.41	1.04e-7	Obesity-related traits;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.67	6.31	0.46	2.85e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	1.08	13.75	0.74	1.86e-28	Breast cancer;
PAAD	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4845552	1.000	rs4845552	chr1:153479998	G/A	cg15998505	chr1:153479701	NA	-0.49	-4.42	-0.34	1.88e-5	Hippocampal atrophy;
PAAD	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg04990556	chr1:26633338	UBXN11	0.66	4.96	0.37	1.87e-6	Obesity-related traits;
PAAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	6.82	0.48	2.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg13530377	chr2:235902088	SH3BP4	-0.4	-4.32	-0.33	2.79e-5	Dialysis-related mortality;
PAAD	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.77	-8.72	-0.58	4.39e-15	Eosinophil percentage of white cells;
PAAD	cis	rs2016586	0.894	rs5995155	chr22:36102700	A/G	cg26342177	chr22:36113512	APOL5	-0.41	-4.35	-0.33	2.48e-5	Body mass index;
PAAD	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.48	-4.89	-0.37	2.57e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4523957	0.890	rs432200	chr17:2191960	A/G	cg16513277	chr17:2031491	SMG6	0.51	5.01	0.38	1.47e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs375066	0.762	rs62114648	chr19:44414816	T/C	cg08633290	chr19:44405433	NA	0.54	5.16	0.39	7.61e-7	Breast cancer;
PAAD	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.57	-5.85	-0.43	2.88e-8	Hypospadias;
PAAD	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.72	4.39	0.34	2.15e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.53	-4.86	-0.37	2.89e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs8105895	0.935	rs16998834	chr19:22267037	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	5.92	0.43	2.07e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.78	-9.04	-0.59	6.63e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.66	0.42	7.29e-8	Alcohol dependence;
PAAD	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg08219700	chr8:58056026	NA	0.68	5.49	0.41	1.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.3	0.46	3.04e-9	Personality dimensions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27390207	chr19:44124298	ZNF428	0.62	6.98	0.49	8.55e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.86	-10.04	-0.63	1.66e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg18765565	chr5:669397	TPPP	-0.42	-4.52	-0.34	1.23e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.5	-5.04	-0.38	1.31e-6	Gout;
PAAD	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8005172	0.808	rs12878879	chr14:88479226	A/G	cg18078958	chr14:88630771	NA	0.5	5.88	0.43	2.55e-8	Parkinson's disease;
PAAD	cis	rs72772090	0.539	rs17484359	chr5:96197013	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.0	-0.44	1.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8060686	0.641	rs3785108	chr16:68106846	C/T	cg09835421	chr16:68378352	PRMT7	-1.09	-6.19	-0.45	5.23e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg11494091	chr17:61959527	GH2	-0.97	-14.28	-0.76	6.94e-30	Prudent dietary pattern;
PAAD	cis	rs1443512	0.947	rs894739	chr12:54346869	T/C	cg17410650	chr12:54324560	NA	-0.38	-5.54	-0.41	1.33e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.42	-5.48	-0.41	1.71e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.74	-8.02	-0.55	2.68e-13	Eye color traits;
PAAD	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	0.76	4.61	0.35	8.41e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.84	9.98	0.63	2.32e-18	Selective IgA deficiency;
PAAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.1	-0.38	1e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.42	-0.34	1.89e-5	Lung cancer in ever smokers;
PAAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.67	7.46	0.52	6.23e-12	Melanoma;
PAAD	cis	rs72480273	0.583	rs11578979	chr1:161658658	C/T	cg26156167	chr1:161582651	NA	0.55	4.39	0.34	2.1e-5	Birth weight;
PAAD	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.55	8.65	0.57	6.95e-15	IgG glycosylation;
PAAD	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.83	8.22	0.55	8.23e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	1.1	12.23	0.7	2.25e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg15654264	chr1:150340011	RPRD2	0.52	4.94	0.37	2e-6	Migraine;
PAAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg23711139	chr7:23627109	CLK2P	0.41	4.29	0.33	3.13e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs216303	0.642	rs216315	chr12:6136914	A/G	cg12895370	chr12:6755816	ACRBP	-0.59	-4.64	-0.35	7.53e-6	Low vWF levels;
PAAD	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.96	-8.86	-0.58	1.97e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-8.36	-0.56	3.64e-14	Hemoglobin concentration;
PAAD	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-4.84	-0.37	3.19e-6	Neuroticism;
PAAD	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.85	-6.13	-0.45	7.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13939156	chr17:80058883	NA	0.43	4.7	0.36	5.73e-6	Life satisfaction;
PAAD	cis	rs12913538	0.962	rs12437894	chr15:62896799	A/G	cg09983546	chr15:62884068	NA	0.71	8.05	0.55	2.2e-13	Sleep depth;
PAAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg10556349	chr10:835070	NA	0.57	4.96	0.37	1.86e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.5	-5.43	-0.4	2.17e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg00053292	chr17:61678300	TACO1	-0.57	-6.29	-0.45	3.25e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.3	-0.33	3.06e-5	Height;
PAAD	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg08917208	chr2:24149416	ATAD2B	0.52	4.53	0.34	1.2e-5	Lymphocyte counts;
PAAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.43	-0.46	1.59e-9	Height;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs716804	0.729	rs6484160	chr11:10308979	T/C	cg06875754	chr11:10328428	ADM	-0.33	-4.34	-0.33	2.62e-5	Neuroticism;
PAAD	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg23912435	chr1:150601613	ENSA	0.51	4.79	0.36	3.99e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	4.99	0.37	1.66e-6	Joint mobility (Beighton score);
PAAD	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs2718812	0.792	rs3772680	chr3:133371807	A/G	cg08048268	chr3:133502702	NA	-0.51	-6.37	-0.46	2.08e-9	Iron status biomarkers;
PAAD	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09286183	chr16:2042466	SYNGR3	0.46	4.35	0.33	2.46e-5	Insulin-like growth factors;
PAAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs939584	0.935	rs6725686	chr2:630436	C/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.55	5.17	0.39	7.15e-7	Resting heart rate;
PAAD	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg00383909	chr3:49044727	WDR6	0.79	5.75	0.42	4.81e-8	Cognitive function;
PAAD	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.75	-7.2	-0.5	2.55e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.78	-0.36	4.09e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs507080	0.733	rs489126	chr11:118572747	G/A	cg08498647	chr11:118550644	TREH	-0.4	-4.65	-0.35	7.05e-6	Serum metabolite levels;
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.47	-0.34	1.49e-5	Glomerular filtration rate;
PAAD	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.14	16.52	0.8	9.44e-36	Testicular germ cell tumor;
PAAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg07506560	chr2:240697449	NA	0.62	6.28	0.45	3.45e-9	Obesity-related traits;
PAAD	cis	rs6804624	0.676	rs2951498	chr3:99166060	G/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg01064725	chr1:204461714	NA	-0.48	-4.56	-0.35	1.03e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.48	-0.52	5.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7011192	0.793	rs7017953	chr8:10524054	G/A	cg25377605	chr8:10513717	RP1L1	-0.72	-4.85	-0.37	2.97e-6	Suicide;
PAAD	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.67	-7.41	-0.52	8.05e-12	Systemic lupus erythematosus;
PAAD	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	5.0	0.38	1.55e-6	Ileal carcinoids;
PAAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg10107264	chr6:52669712	GSTA1	0.76	6.44	0.46	1.5e-9	Atopic dermatitis;
PAAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg01701555	chr1:146544097	NA	0.39	4.29	0.33	3.12e-5	HIV-1 control;
PAAD	cis	rs1642645	0.831	rs1327711	chr1:42495949	A/G	cg01990334	chr1:42801334	FOXJ3	-0.61	-5.64	-0.42	7.92e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.32	-4.36	-0.33	2.39e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-5.87	-0.43	2.61e-8	Coffee consumption (cups per day);
PAAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg22663859	chr13:21900854	NA	0.59	6.4	0.46	1.82e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.56	6.92	0.49	1.17e-10	Monobrow;
PAAD	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.62	-5.89	-0.43	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.62	5.28	0.39	4.42e-7	Initial pursuit acceleration;
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.3	0.33	3.05e-5	Self-reported allergy;
PAAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3126085	0.515	rs11204984	chr1:152331987	T/C	cg26876637	chr1:152193138	HRNR	-0.72	-5.36	-0.4	3.06e-7	Atopic dermatitis;
PAAD	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24026388	chr12:48099519	RPAP3	0.74	8.38	0.56	3.39e-14	Myopia (pathological);
PAAD	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.43	-5.04	-0.38	1.3e-6	Body mass index;
PAAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg21856205	chr7:94953877	PON1	-0.53	-4.39	-0.34	2.13e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4702	0.611	rs11539637	chr15:91428290	C/T	cg04510874	chr15:91427884	FES	-0.39	-4.55	-0.35	1.09e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.8	-0.36	3.8e-6	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg27121462	chr16:89883253	FANCA	0.75	4.43	0.34	1.82e-5	Skin colour saturation;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02043585	chr18:59853978	PIGN;KIAA1468	0.69	8.24	0.56	7.56e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.71	7.86	0.54	6.46e-13	Leprosy;
PAAD	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg20913747	chr6:44695427	NA	-0.68	-6.83	-0.48	1.96e-10	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13507452	chr14:53658573	NA	0.53	6.37	0.46	2.13e-9	Smoking initiation;
PAAD	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg03093033	chr18:61089985	VPS4B	1.0	7.35	0.51	1.13e-11	Airflow obstruction;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.42	-4.51	-0.34	1.31e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg05803361	chr1:145727320	PDZK1	0.76	4.28	0.33	3.27e-5	Mitochondrial DNA levels;
PAAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.63	6.31	0.46	2.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23793263	chr12:132434133	EP400	0.66	7.04	0.5	6.22e-11	Myopia (pathological);
PAAD	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg15571903	chr15:79123663	NA	0.39	4.79	0.36	3.91e-6	Coronary artery disease;
PAAD	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.16	6.23	0.45	4.44e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.72	4.7	0.36	5.87e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2885056	0.891	rs3760648	chr19:10680103	A/G	cg04833646	chr19:10679720	CDKN2D	1.02	10.2	0.64	6.02e-19	Red cell distribution width;
PAAD	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.61	0.61	2.19e-17	Menopause (age at onset);
PAAD	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.7	-7.06	-0.5	5.43e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.48	0.52	5.44e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.66	-0.72	1.52e-25	Longevity;Endometriosis;
PAAD	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.77	-0.36	4.25e-6	Menarche (age at onset);
PAAD	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.75	-5.31	-0.4	3.83e-7	Lung cancer;
PAAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg03808351	chr9:123631620	PHF19	-0.46	-4.99	-0.37	1.65e-6	Rheumatoid arthritis;
PAAD	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.4	-0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.16	-0.5	3.25e-11	Colorectal cancer;
PAAD	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg04087571	chr11:116723030	SIK3	-0.39	-5.66	-0.42	7.33e-8	Subjective well-being;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg11619707	chr19:22235551	ZNF257	0.58	5.82	0.43	3.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg04106633	chr4:1044584	NA	0.54	5.01	0.38	1.47e-6	Recombination rate (males);
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg15117754	chr3:10150083	C3orf24	0.61	5.78	0.42	4.14e-8	Alzheimer's disease;
PAAD	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg12046867	chr14:103022105	NA	-0.71	-5.43	-0.4	2.16e-7	Platelet count;
PAAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg03808351	chr9:123631620	PHF19	0.45	4.99	0.38	1.64e-6	Rheumatoid arthritis;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg09343327	chr16:20912245	LYRM1;DCUN1D3	0.62	6.39	0.46	1.94e-9	Iris heterochromicity;
PAAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg02841227	chr6:26021843	HIST1H4A	0.54	5.45	0.4	2.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg05554000	chr7:158905015	VIPR2	0.57	5.07	0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13560548	chr3:10150139	C3orf24	0.57	5.14	0.38	8.25e-7	Alzheimer's disease;
PAAD	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg27449745	chr7:23145252	KLHL7	-0.5	-4.44	-0.34	1.7e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7932354	0.583	rs2306026	chr11:46889713	T/C	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs3026101	0.624	rs1058398	chr17:5288760	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.49	-5.34	-0.4	3.34e-7	Body mass index;
PAAD	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg20628663	chr10:43360327	NA	0.79	8.31	0.56	4.82e-14	Blood protein levels;
PAAD	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.51	4.97	0.37	1.82e-6	Asthma;
PAAD	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.72	-5.08	-0.38	1.07e-6	Obesity-related traits;
PAAD	cis	rs7594192	0.744	rs35332031	chr2:199364616	C/T	cg01558212	chr2:200327336	NA	-0.34	-4.36	-0.33	2.34e-5	Educational attainment;
PAAD	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs73086581	1.000	rs6107391	chr20:3983083	A/G	cg02187196	chr20:3869020	PANK2	0.61	5.21	0.39	6.13e-7	Response to antidepressants in depression;
PAAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs4751058	0.526	rs10829563	chr10:130859036	A/G	cg04854917	chr10:131378330	MGMT	-0.47	-4.74	-0.36	4.97e-6	Vitamin D levels;
PAAD	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg03315344	chr16:75512273	CHST6	-0.69	-5.65	-0.42	7.6e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs4240897	1.000	rs4240897	chr1:12042755	A/G	cg13216073	chr1:12042593	MFN2	-0.48	-5.55	-0.41	1.26e-7	Tuberculosis;
PAAD	cis	rs375066	0.935	rs376032	chr19:44407564	A/G	cg21496419	chr19:44306685	LYPD5	0.44	5.27	0.39	4.69e-7	Breast cancer;
PAAD	cis	rs490234	0.719	rs13296519	chr9:128471924	G/T	cg14078157	chr9:128172775	NA	-0.41	-4.66	-0.35	6.82e-6	Mean arterial pressure;
PAAD	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg09127314	chr1:152161683	NA	0.68	4.91	0.37	2.28e-6	Atopic dermatitis;
PAAD	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg14703610	chr5:56206110	C5orf35	0.61	5.54	0.41	1.3e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.14	0.5	3.65e-11	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14140629	chr6:127587906	RNF146	0.66	6.98	0.49	8.75e-11	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01012394	chr1:28416212	EYA3	-0.59	-6.67	-0.48	4.52e-10	Obesity-related traits;
PAAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6256	0.929	rs56272325	chr11:13508857	C/G	cg11976911	chr11:13509032	NA	-0.67	-5.2	-0.39	6.23e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19183433	chr2:180871780	CWC22	0.61	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg25664220	chr3:72788482	NA	-0.69	-6.74	-0.48	3.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-1.0	-9.31	-0.6	1.37e-16	Blood pressure (smoking interaction);
PAAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.38	4.57	0.35	9.91e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg09835421	chr16:68378352	PRMT7	-0.58	-4.31	-0.33	2.91e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1697938	0.590	rs2597738	chr5:40941071	T/C	cg22359217	chr5:41925772	FBXO4	-0.46	-4.58	-0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1468333	0.667	rs4835784	chr5:137730794	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.42	0.4	2.26e-7	Resting heart rate;
PAAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.07	-0.77	5.78e-32	Height;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21071512	chr6:135818740	AHI1;C6orf217	-0.61	-6.38	-0.46	2.02e-9	Warfarin maintenance dose;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.48	-4.88	-0.37	2.6e-6	Hirschsprung disease;
PAAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg12568669	chr8:11666485	FDFT1	-0.3	-4.78	-0.36	4.18e-6	Myopia (pathological);
PAAD	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg06740227	chr12:86229804	RASSF9	0.48	4.48	0.34	1.47e-5	Major depressive disorder;
PAAD	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg12046867	chr14:103022105	NA	-0.65	-5.13	-0.38	8.78e-7	Platelet count;
PAAD	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.79	-5.61	-0.41	9.27e-8	Coronary artery calcification;
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.48	4.88	0.37	2.69e-6	Menarche (age at onset);
PAAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.49	-0.41	1.62e-7	Prevalent atrial fibrillation;
PAAD	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.4	-0.34	2.03e-5	Joint mobility (Beighton score);
PAAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12963246	chr6:28129442	ZNF389	0.61	4.26	0.33	3.57e-5	Depression;
PAAD	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.41	-4.92	-0.37	2.24e-6	Uric acid levels;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.22	-0.39	5.76e-7	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.73	7.55	0.52	3.85e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.31e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs4144743	0.938	rs7225134	chr17:45326932	C/T	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs11811982	0.793	rs79773617	chr1:227238308	T/G	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23838434	chr22:17652388	NA	-0.75	-6.53	-0.47	9.24e-10	Neuroticism;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg09503522	chr19:53445286	ZNF321	-0.4	-4.25	-0.33	3.78e-5	Psoriasis;
PAAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.94	9.45	0.61	5.81e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9810890	1.000	rs73196987	chr3:128453382	A/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-5.0	-0.38	1.59e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.14	-0.55	1.31e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.56	-0.52	3.5e-12	Coronary artery disease;
PAAD	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg02404636	chr22:31891804	SFI1	0.64	6.17	0.45	5.91e-9	Colorectal cancer;
PAAD	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.53	-4.74	-0.36	4.97e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17463508	chr17:4737022	MINK1	-0.61	-7.42	-0.52	7.67e-12	Body fat percentage;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg26338869	chr17:61819248	STRADA	-0.51	-4.79	-0.36	3.87e-6	Height;
PAAD	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.68	7.04	0.5	6.35e-11	Morning vs. evening chronotype;
PAAD	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-4.34	-0.33	2.6e-5	Coronary artery disease;
PAAD	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.53	-5.29	-0.39	4.21e-7	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs883565	0.606	rs7650682	chr3:39079418	C/A	cg01426195	chr3:39028469	NA	-0.7	-7.83	-0.54	7.91e-13	Handedness;
PAAD	cis	rs1891275	0.551	rs1891271	chr10:93426323	C/T	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7537660	1.000	rs7537660	chr1:248006764	C/T	cg00785941	chr1:248100591	OR2L13	-0.4	-4.75	-0.36	4.62e-6	Platelet distribution width;
PAAD	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.46	5.73	0.42	5.28e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.74	8.19	0.55	1.01e-13	Breast cancer;
PAAD	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.67	-6.18	-0.45	5.58e-9	Primary sclerosing cholangitis;
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs77880822	0.562	rs79079125	chr20:1234333	T/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.36	4.28	0.33	3.3e-5	Schizophrenia;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22633769	chr20:60982531	CABLES2	0.54	5.18	0.39	7.03e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.3	-4.3	-0.33	2.98e-5	Urate levels in overweight individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18628493	chr13:101326339	TMTC4	0.57	6.48	0.47	1.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6445967	1.000	rs35495842	chr3:58310250	T/C	cg23715586	chr3:58305044	RPP14	0.5	4.35	0.33	2.51e-5	Platelet count;
PAAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-1.37	-9.93	-0.63	3.3e-18	Magnesium levels;
PAAD	cis	rs1443512	0.947	rs9804784	chr12:54343472	A/C	cg25382128	chr12:54346509	NA	-0.61	-6.31	-0.46	2.97e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.48	-4.28	-0.33	3.36e-5	Waist circumference;Body mass index;
PAAD	cis	rs2016586	0.719	rs5999971	chr22:36115349	C/T	cg26342177	chr22:36113512	APOL5	-0.49	-4.83	-0.37	3.23e-6	Body mass index;
PAAD	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.13e-9	Educational attainment;
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-5.91	-0.43	2.21e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-1.15	-9.59	-0.61	2.51e-17	Initial pursuit acceleration;
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs77880822	0.562	rs56211547	chr20:1254640	C/T	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.63	6.41	0.46	1.75e-9	Multiple sclerosis;
PAAD	cis	rs6929137	0.632	rs11155806	chr6:151956890	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.49	-0.34	1.4e-5	Bone mineral density (spine);
PAAD	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs11252926	0.529	rs10904398	chr10:562805	G/A	cg03684893	chr10:554711	DIP2C	-0.43	-4.47	-0.34	1.52e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.39	0.4	2.59e-7	Personality dimensions;
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.49	5.09	0.38	1.05e-6	Breast cancer;
PAAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.95	12.76	0.72	8.04e-26	Menarche (age at onset);
PAAD	cis	rs4752700	0.840	rs760338	chr10:124238997	C/T	cg20417071	chr10:124901456	NA	-0.3	-4.27	-0.33	3.43e-5	Coronary artery disease;
PAAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.81	7.56	0.52	3.49e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.87	0.49	1.5e-10	Systemic lupus erythematosus;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19998654	chr2:37458983	CEBPZ;C2orf56	0.56	6.57	0.47	7.71e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs138918	1.000	rs138914	chr22:43555921	G/A	cg08909806	chr22:43548696	TSPO	0.47	4.75	0.36	4.64e-6	Monocyte count;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	6.21	0.45	4.86e-9	Total body bone mineral density;
PAAD	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.78	0.53	1.05e-12	Coronary artery disease;
PAAD	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.66	4.95	0.37	1.98e-6	Exhaled nitric oxide output;
PAAD	cis	rs1015291	0.708	rs1466687	chr12:19996058	A/G	cg25401612	chr12:20009446	NA	-0.54	-5.3	-0.39	4.05e-7	Diastolic blood pressure;
PAAD	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.78	9.52	0.61	3.74e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs16882447	0.607	rs13435967	chr5:53490881	G/T	cg06461071	chr5:53490839	ARL15	-0.45	-4.79	-0.36	3.85e-6	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.46	5.85	0.43	2.98e-8	Childhood ear infection;
PAAD	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg17541715	chr7:1216824	NA	-0.41	-4.55	-0.35	1.1e-5	Longevity;Endometriosis;
PAAD	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.38	-0.56	3.29e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs35160687	0.644	rs10204589	chr2:86493223	A/G	cg10973622	chr2:86423274	IMMT	0.49	5.5	0.41	1.58e-7	Night sleep phenotypes;
PAAD	cis	rs2387326	0.761	rs3191122	chr10:129900858	C/T	cg16087940	chr10:129947807	NA	-0.5	-4.26	-0.33	3.52e-5	Select biomarker traits;
PAAD	cis	rs543686	1.000	rs543686	chr15:35068309	C/T	cg01471153	chr15:34876295	GOLGA8B	0.44	4.25	0.33	3.66e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.84	-9.57	-0.61	2.88e-17	Ulcerative colitis;
PAAD	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg10985347	chr2:127963512	CYP27C1	0.49	4.98	0.37	1.7e-6	Protein C levels;
PAAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.8	8.29	0.56	5.67e-14	Schizophrenia;
PAAD	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg04717802	chr22:42394638	WBP2NL	0.42	4.59	0.35	9.05e-6	Intelligence;
PAAD	cis	rs7572263	0.959	rs10804167	chr2:209049840	C/T	cg23998903	chr2:209048830	C2orf80	0.48	4.54	0.35	1.15e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.77	9.2	0.6	2.67e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.96	-9.88	-0.63	4.38e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs9287604	0.953	rs10084297	chr2:237777998	G/C	cg15065627	chr2:237796583	NA	-0.53	-4.38	-0.33	2.17e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs3820068	0.815	rs1042010	chr1:15793913	G/A	cg21004104	chr1:15954209	DDI2	0.56	4.63	0.35	7.76e-6	Systolic blood pressure;
PAAD	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs73416724	1.000	rs112336903	chr6:43338115	T/C	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.55	-5.37	-0.4	2.94e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg18402987	chr7:1209562	NA	0.79	6.79	0.48	2.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg24747557	chr10:131355152	MGMT	-0.45	-4.94	-0.37	2.01e-6	Response to temozolomide;
PAAD	cis	rs59888335	0.895	rs13077623	chr3:80798243	G/A	cg21735741	chr3:80819488	NA	0.55	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs10740065	chr10:63976415	A/C	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs847577	0.550	rs6465654	chr7:97786282	G/A	cg21770322	chr7:97807741	LMTK2	0.74	12.03	0.7	7.57e-24	Breast cancer;
PAAD	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.55	4.48	0.34	1.44e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs35000415	0.873	rs34748780	chr7:128700153	A/G	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs8016982	0.589	rs4640110	chr14:81692191	A/G	cg01989461	chr14:81687754	GTF2A1	-0.64	-5.75	-0.42	4.8e-8	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.86	0.54	6.65e-13	Menopause (age at onset);
PAAD	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Body mass index;
PAAD	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg09579323	chr1:150459698	TARS2	0.46	4.39	0.34	2.12e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.85	-0.37	3.07e-6	Depression;
PAAD	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg07836142	chr6:28411423	ZSCAN23	0.4	4.37	0.33	2.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.47	-4.59	-0.35	9.36e-6	Testicular germ cell tumor;
PAAD	cis	rs17428041	0.521	rs13255951	chr8:21722998	T/C	cg17168535	chr8:21777572	XPO7	-0.46	-4.58	-0.35	9.61e-6	Neuropathic pain in type 2 diabetes;
PAAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.4	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.79	8.34	0.56	4.09e-14	Coronary artery disease;
PAAD	cis	rs3018712	0.553	rs4432027	chr11:68451247	C/T	cg23009355	chr11:68451396	GAL	-0.52	-5.77	-0.42	4.36e-8	Total body bone mineral density;
PAAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	5.01	0.38	1.48e-6	Yeast infection;
PAAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg10547527	chr2:198650123	BOLL	-0.7	-4.7	-0.36	5.81e-6	Ulcerative colitis;
PAAD	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs2637030	0.559	rs2637024	chr5:52993453	A/G	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.3	0.33	3.05e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs13144136	0.687	rs11723949	chr4:10658093	G/T	cg10242279	chr4:10666415	CLNK	-0.47	-5.97	-0.44	1.57e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg14146966	chr2:61757674	XPO1	-0.37	-4.64	-0.35	7.39e-6	Tuberculosis;
PAAD	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.58	-5.86	-0.43	2.8e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.32	4.73	0.36	5.05e-6	Alopecia areata;
PAAD	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg10820045	chr2:198174542	NA	0.42	4.31	0.33	2.92e-5	Dermatomyositis;
PAAD	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11113894	0.901	rs11113902	chr12:108858635	C/T	cg25832824	chr12:108733253	CMKLR1	-0.65	-4.26	-0.33	3.57e-5	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.66	4.96	0.37	1.87e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.84	5.35	0.4	3.14e-7	Diabetic kidney disease;
PAAD	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg00277334	chr10:82204260	NA	0.58	5.89	0.43	2.36e-8	Post bronchodilator FEV1;
PAAD	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.62	5.98	0.44	1.52e-8	Coronary artery disease;
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-4.25	-0.33	3.64e-5	IFN-related cytopenia;
PAAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.35	-0.33	2.44e-5	Bone mineral density;
PAAD	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.76	7.9	0.54	5.17e-13	Schizophrenia;
PAAD	cis	rs7173419	0.607	rs11633338	chr15:28217011	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.31	-0.4	3.88e-7	Eye color;
PAAD	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg23093090	chr10:104574429	C10orf26	-0.43	-5.03	-0.38	1.36e-6	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs71496609	chr10:46021031	C/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.38e-5	Longevity (90 years and older);
PAAD	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg02287630	chr1:101361426	SLC30A7;EXTL2	-0.5	-4.41	-0.34	1.94e-5	Breast cancer;
PAAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs400736	0.562	rs10864331	chr1:8172178	A/G	cg25007680	chr1:8021821	PARK7	-0.46	-4.3	-0.33	3.05e-5	Response to antidepressants and depression;
PAAD	cis	rs61759167	1.000	rs7518255	chr1:3086464	G/A	cg22674798	chr1:3096360	PRDM16	0.38	4.4	0.34	2.05e-5	Motion sickness;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg13560548	chr3:10150139	C3orf24	0.56	5.13	0.38	8.56e-7	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.03	-0.5	6.52e-11	Morning vs. evening chronotype;
PAAD	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12753920	0.775	rs12729867	chr1:92681020	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	0.46	4.35	0.33	2.44e-5	Systemic lupus erythematosus;
PAAD	cis	rs10121009	0.565	rs10972468	chr9:35431471	T/C	cg11846315	chr9:35647073	NA	-0.48	-4.32	-0.33	2.81e-5	Parkinson's disease;
PAAD	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-4.44	-0.34	1.71e-5	Systemic lupus erythematosus;
PAAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.83	-8.95	-0.59	1.13e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9567406	0.660	rs55877010	chr13:44870604	G/A	cg08635097	chr13:44833857	NA	-0.54	-4.25	-0.33	3.68e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.78	-8.17	-0.55	1.11e-13	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25161386	chr17:27621177	NUFIP2	0.64	7.08	0.5	5.08e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg22437258	chr11:111473054	SIK2	-0.59	-5.58	-0.41	1.05e-7	Primary sclerosing cholangitis;
PAAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.68	8.48	0.57	1.86e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg04721828	chr11:48285200	OR4X1	0.49	6.11	0.44	7.98e-9	Migraine - clinic-based;
PAAD	cis	rs8099014	0.861	rs2277722	chr18:56121280	G/C	cg12907477	chr18:56117327	MIR122	0.59	4.65	0.35	7.27e-6	Platelet count;
PAAD	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.62	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.47	-0.34	1.51e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs317865	0.737	rs16893097	chr4:16156964	G/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.95	6.09	0.44	8.91e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.2	-0.39	6.42e-7	Cognitive function;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.87	0.62	4.71e-18	Prudent dietary pattern;
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg08888203	chr3:10149979	C3orf24	0.91	7.98	0.54	3.37e-13	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13581785	chr20:32274191	E2F1	-0.81	-6.62	-0.47	5.82e-10	Neuroticism;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	1.12	17.94	0.82	2.28e-39	Menarche (age at onset);
PAAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.51	5.13	0.38	8.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17123764	0.892	rs7136052	chr12:50110736	A/T	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.38	5.63	0.42	8.27e-8	Educational attainment (years of education);
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.6	5.83	0.43	3.24e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.61e-8	Migraine;
PAAD	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.57	5.76	0.42	4.57e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8105895	1.000	rs11881224	chr19:22220340	G/A	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.37e-17	Menopause (age at onset);
PAAD	cis	rs11955175	1.000	rs11956741	chr5:40677576	G/C	cg17351974	chr5:40835760	RPL37	0.77	4.52	0.34	1.23e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg04749549	chr19:17459798	NA	-0.51	-5.56	-0.41	1.18e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.5	-6.42	-0.46	1.62e-9	Height;
PAAD	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.48	-4.68	-0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.48	-0.57	1.86e-14	Venous thromboembolism;
PAAD	cis	rs7816613	0.920	rs10101770	chr8:102668312	A/T	cg20585841	chr8:102729926	NCALD	0.69	5.52	0.41	1.44e-7	Age-related hearing impairment;
PAAD	cis	rs10155981	0.510	rs4722157	chr7:22583941	G/A	cg05062323	chr7:22590069	NA	-0.85	-5.11	-0.38	9.69e-7	Bilirubin levels;
PAAD	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.11	-0.38	9.73e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.45e-6	Lung cancer;
PAAD	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg05228244	chr10:1102351	WDR37	0.86	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.58	6.02	0.44	1.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.5	-7.22	-0.51	2.31e-11	Diastolic blood pressure;
PAAD	cis	rs3774830	0.623	rs7661692	chr4:5471853	G/A	cg26943120	chr4:5472116	STK32B	0.4	4.95	0.37	1.93e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg04763273	chr20:55502381	NA	0.47	5.27	0.39	4.68e-7	Verbal memory performance (delayed recall level);
PAAD	cis	rs13006833	0.765	rs291431	chr2:191199530	G/A	cg27211696	chr2:191398769	TMEM194B	0.44	4.31	0.33	2.87e-5	Urinary metabolites;
PAAD	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg17771515	chr6:154831774	CNKSR3	0.6	4.26	0.33	3.63e-5	Lipoprotein (a) levels;
PAAD	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	1.06	6.63	0.47	5.59e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Gout;
PAAD	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.18	-0.5	2.85e-11	Diastolic blood pressure;
PAAD	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg09709951	chr12:54017699	ATF7	0.52	4.53	0.34	1.18e-5	Height;
PAAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	9.11	0.59	4.55e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.48	-0.47	1.21e-9	Neuroticism;
PAAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.52	0.52	4.39e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg07944420	chr16:89185293	ACSF3	0.48	4.41	0.34	1.91e-5	Multiple myeloma (IgH translocation);
PAAD	trans	rs901683	1.000	rs76422608	chr10:46041945	G/C	cg11747279	chr17:21096632	NA	0.88	6.71	0.48	3.53e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg14952266	chr13:112191215	NA	0.47	5.41	0.4	2.39e-7	Hepatitis;
PAAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.51	-0.34	1.29e-5	Tonsillectomy;
PAAD	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-4.36	-0.33	2.38e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7255045	0.788	rs10424001	chr19:12948462	A/G	cg09980403	chr19:12975529	MAST1	0.29	4.82	0.36	3.51e-6	Mean corpuscular volume;
PAAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.66	6.65	0.47	4.98e-10	Blood protein levels;
PAAD	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.86e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs332507	0.830	rs3772781	chr3:124387439	G/T	cg05980111	chr3:124395277	KALRN	0.46	4.49	0.34	1.42e-5	Plateletcrit;
PAAD	cis	rs3764400	0.567	rs1979897	chr17:46309546	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg16691477	chr11:64889790	FAU;MRPL49	-0.68	-6.63	-0.47	5.61e-10	Testicular germ cell tumor;
PAAD	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.44	-5.93	-0.43	2e-8	Type 1 diabetes;
PAAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg18944383	chr4:111397179	ENPEP	-0.63	-7.38	-0.51	9.81e-12	Coronary artery disease;
PAAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-5.61	-0.41	9.32e-8	Gut microbiome composition (summer);
PAAD	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.87	10.14	0.64	9.14e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-4.91	-0.37	2.35e-6	Neuroticism;
PAAD	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.66	5.77	0.42	4.28e-8	Coronary artery disease;
PAAD	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.98	6.92	0.49	1.18e-10	Menopause (age at onset);
PAAD	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.93	-12.05	-0.7	6.61e-24	Coronary artery disease;
PAAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.33e-7	Ulcerative colitis;
PAAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg05835009	chr4:710272	PCGF3	0.71	6.31	0.46	2.9e-9	White blood cell count;
PAAD	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.51	-5.28	-0.39	4.29e-7	Type 2 diabetes;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg19000871	chr14:103996768	TRMT61A	0.5	5.75	0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.45	4.68	0.35	6.32e-6	Corneal astigmatism;
PAAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.84	-9.16	-0.6	3.36e-16	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.52	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.57	4.99	0.38	1.65e-6	Common traits (Other);
PAAD	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg17842918	chr13:113540400	ATP11A	-0.37	-4.27	-0.33	3.4e-5	Interstitial lung disease;
PAAD	cis	rs11264213	0.901	rs11263830	chr1:36345798	C/T	cg27506609	chr1:36549197	TEKT2	0.72	5.25	0.39	5.11e-7	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.58	6.61	0.47	6.08e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.7	7.45	0.52	6.58e-12	Triglyceride levels;
PAAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg00253185	chr1:247542119	NA	0.54	4.39	0.34	2.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7260329	0.713	rs7254579	chr19:41494891	T/C	cg06653635	chr19:40910092	PRX	-0.48	-4.52	-0.34	1.25e-5	Smoking behavior;
PAAD	cis	rs863345	1.000	rs863356	chr1:158543739	G/T	cg12129480	chr1:158549410	OR10X1	-0.45	-4.93	-0.37	2.1e-6	Pneumococcal bacteremia;
PAAD	cis	rs1620921	0.505	rs13199812	chr6:161201960	T/C	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg11782729	chr17:576564	VPS53	-0.4	-4.4	-0.34	2.07e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2137920	0.735	rs3810954	chr10:50227129	C/T	cg02657375	chr10:50863136	CHAT	0.54	4.34	0.33	2.59e-5	Migraine with aura;
PAAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg20356878	chr3:121714668	ILDR1	0.53	5.01	0.38	1.51e-6	Cognitive performance;
PAAD	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.52	-4.63	-0.35	7.71e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.54	-7.13	-0.5	3.78e-11	Alcohol dependence;
PAAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg24565620	chr2:194026	NA	0.61	5.12	0.38	9.01e-7	Blood protein levels;
PAAD	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg20503657	chr10:835505	NA	0.51	5.35	0.4	3.23e-7	Survival in rectal cancer;
PAAD	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.83	6.5	0.47	1.1e-9	Gastritis;
PAAD	cis	rs881827	0.962	rs2839329	chr21:47984563	A/G	cg14789911	chr21:47582049	C21orf56	0.47	4.54	0.35	1.15e-5	Lymphocyte counts;
PAAD	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg20130138	chr11:64956067	CAPN1	0.6	4.27	0.33	3.43e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.55	-0.35	1.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.72	7.43	0.52	7.48e-12	Corneal astigmatism;
PAAD	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	0.81	5.43	0.4	2.17e-7	Body mass index;
PAAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.61	-0.53	2.61e-12	Mood instability;
PAAD	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg21535247	chr6:8435926	SLC35B3	-0.56	-5.47	-0.41	1.79e-7	Motion sickness;
PAAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.58	6.07	0.44	9.54e-9	Longevity;
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs7567389	0.502	rs2069919	chr2:128179553	G/A	cg09760422	chr2:128146352	NA	0.41	6.03	0.44	1.17e-8	Self-rated health;
PAAD	cis	rs3112530	1.000	rs2615173	chr5:152711947	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs185694	1.000	rs202082	chr13:30881026	G/A	cg07600127	chr13:30881527	KATNAL1	-0.68	-4.42	-0.34	1.9e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.48	-0.57	1.79e-14	Obesity-related traits;
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.52	6.69	0.48	3.92e-10	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.84	9.24	0.6	2.04e-16	Mortality in heart failure;
PAAD	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.46	0.4	1.94e-7	Educational attainment (years of education);
PAAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.67	6.66	0.48	4.64e-10	Coronary artery disease or large artery stroke;
PAAD	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs793571	0.866	rs11071401	chr15:59210935	T/C	cg05156742	chr15:59063176	FAM63B	0.59	4.8	0.36	3.68e-6	Schizophrenia;
PAAD	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.38	5.19	0.39	6.7e-7	Schizophrenia;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.69	-11.24	-0.67	1.05e-21	Longevity;Endometriosis;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	6.14e-7	Ulcerative colitis;
PAAD	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.23	0.45	4.41e-9	Body mass index;
PAAD	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg11266682	chr4:10021025	SLC2A9	0.45	4.41	0.34	1.94e-5	Blood metabolite levels;
PAAD	cis	rs4716602	0.898	rs1534001	chr7:156163283	A/G	cg04090468	chr7:156181990	NA	0.5	4.86	0.37	2.9e-6	Anti-saccade response;
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.52	-0.52	4.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	4.61	0.35	8.57e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06850241	chr22:41845214	NA	-0.57	-4.93	-0.37	2.17e-6	Vitiligo;
PAAD	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg21546286	chr11:48923668	NA	-0.53	-5.52	-0.41	1.42e-7	HDL cholesterol;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg15555402	chr12:19593456	AEBP2	-0.71	-6.8	-0.48	2.3e-10	Blood protein levels;
PAAD	cis	rs1007738	0.597	rs10838635	chr11:46945227	G/A	cg19486271	chr11:47235900	DDB2	-0.59	-5.81	-0.43	3.63e-8	Bone mineral density (hip);
PAAD	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs939584	1.000	rs13412194	chr2:653245	A/C	cg03610516	chr2:642275	NA	-0.65	-6.05	-0.44	1.08e-8	Body mass index;
PAAD	cis	rs778371	0.749	rs2675964	chr2:233793676	A/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-6.23	-0.45	4.33e-9	Schizophrenia;
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg21565972	chr17:80109576	CCDC57	0.58	6.74	0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs11668609	0.515	rs58278214	chr19:24071689	A/G	cg09235885	chr19:23456588	NA	-0.64	-4.47	-0.34	1.5e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs9398803	0.624	rs1591806	chr6:126641185	A/G	cg19875578	chr6:126661172	C6orf173	0.53	5.09	0.38	1.06e-6	Male-pattern baldness;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-8.39	-0.56	3.06e-14	Vitiligo;
PAAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.57	6.15	0.45	6.7e-9	Diastolic blood pressure;
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg18436246	chr17:1640651	WDR81	0.86	8.03	0.55	2.45e-13	Serum albumin level;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs593531	0.571	rs11236087	chr11:74094138	C/T	cg15851278	chr11:73669449	DNAJB13	0.4	4.86	0.37	2.92e-6	Neuroticism;
PAAD	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.29	0.45	3.25e-9	Body mass index;
PAAD	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.09	16.15	0.79	8.74e-35	Height;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs273573	0.600	rs7117074	chr11:30986087	A/C	cg21705394	chr11:30344510	C11orf46	0.45	4.3	0.33	3.1e-5	Total body bone mineral density;
PAAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14895029	chr7:2775587	GNA12	-0.47	-4.79	-0.36	3.87e-6	Height;
PAAD	cis	rs72772787	1.000	rs12096473	chr1:248016894	C/T	cg20507276	chr1:248100600	OR2L13	0.57	5.08	0.38	1.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.74	-5.66	-0.42	7.25e-8	Mean platelet volume;
PAAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.54	5.51	0.41	1.53e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.79	5.86	0.43	2.72e-8	Vitiligo;
PAAD	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.6	-4.36	-0.33	2.39e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03924805	chr2:242211663	HDLBP	-0.58	-6.3	-0.46	3.05e-9	Body fat percentage;
PAAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-5.01	-0.38	1.46e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs8099014	1.000	rs8092072	chr18:56129804	C/T	cg12907477	chr18:56117327	MIR122	0.59	4.85	0.37	2.96e-6	Platelet count;
PAAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg09237302	chr4:906077	GAK	-0.49	-6.37	-0.46	2.1e-9	Systemic sclerosis;
PAAD	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14953804	chr12:51021072	DIP2B	-0.55	-6.45	-0.46	1.42e-9	Monocyte percentage of white cells;
PAAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg09127314	chr1:152161683	NA	0.63	4.38	0.33	2.2e-5	Atopic dermatitis;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg11508406	chr4:1595515	NA	0.46	4.67	0.35	6.59e-6	Obesity-related traits;
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.54	-6.57	-0.47	7.64e-10	Iron status biomarkers;
PAAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	0.68	4.36	0.33	2.38e-5	Tonsillectomy;
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.78e-5	Life satisfaction;
PAAD	cis	rs7552393	0.636	rs4001466	chr1:84285240	A/G	cg10977910	chr1:84465055	TTLL7	0.59	5.61	0.41	9.41e-8	Select biomarker traits;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.84	-0.37	3.22e-6	Lung cancer;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.84	9.78	0.62	8.2e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.41	-0.4	2.43e-7	Daytime sleep phenotypes;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12483801	chr4:183727862	NA	0.75	5.89	0.43	2.35e-8	Pediatric autoimmune diseases;
PAAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg14393609	chr7:65229607	NA	-0.65	-7.12	-0.5	4.07e-11	Aortic root size;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27516732	chr6:161351879	NA	-0.81	-8.44	-0.56	2.39e-14	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00945038	chr17:61921165	SMARCD2	-0.47	-5.71	-0.42	5.75e-8	Prudent dietary pattern;
PAAD	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg17551891	chr7:1960795	MAD1L1	-0.48	-4.54	-0.35	1.12e-5	Neuroticism;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.71e-10	Life satisfaction;
PAAD	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-5.79	-0.42	3.94e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.91	-6.93	-0.49	1.12e-10	Initial pursuit acceleration;
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.59	-5.48	-0.41	1.75e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg01494348	chr8:144660395	NAPRT1	0.97	4.58	0.35	9.57e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.17	16.49	0.8	1.15e-35	Body mass index;
PAAD	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.66	6.55	0.47	8.35e-10	Coronary artery disease;
PAAD	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg00262122	chr8:11665843	FDFT1	-0.59	-5.44	-0.4	2.08e-7	Morning vs. evening chronotype;
PAAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.96	0.37	1.83e-6	Schizophrenia;
PAAD	cis	rs7264396	0.775	rs2296402	chr20:34054729	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.27	0.33	3.45e-5	Total cholesterol levels;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18621852	chr3:10150065	C3orf24	0.57	4.9	0.37	2.38e-6	Alzheimer's disease;
PAAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.53	-5.96	-0.44	1.72e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg15585409	chr19:12750806	NA	-0.47	-4.27	-0.33	3.42e-5	Red blood cell traits;
PAAD	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.3	-0.33	2.98e-5	Coronary artery disease;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg00178359	chr16:56659460	MT1E	-0.59	-6.31	-0.46	2.84e-9	Body mass index;
PAAD	trans	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg05163071	chr3:108476540	RETNLB	0.96	6.83	0.48	1.88e-10	Dental caries;
PAAD	cis	rs7744392	0.557	rs12211943	chr6:35306857	G/A	cg06656924	chr6:35228319	ZNF76	0.79	4.55	0.35	1.09e-5	Cataracts in type 2 diabetes;
PAAD	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.53	6.41	0.46	1.78e-9	Sitting height ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20579505	chr3:125680736	NA	-0.62	-6.67	-0.48	4.45e-10	Obesity-related traits;
PAAD	cis	rs4787491	0.729	rs4788215	chr16:30047930	G/A	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.88	0.37	2.69e-6	Blood metabolite levels;
PAAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.73	-7.32	-0.51	1.34e-11	Menopause (age at onset);
PAAD	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg25797454	chr6:150327115	RAET1K	0.31	4.58	0.35	9.73e-6	Alopecia areata;
PAAD	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01200585	chr1:228362443	C1orf69	-0.47	-5.3	-0.39	4.08e-7	Diastolic blood pressure;
PAAD	cis	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg21546286	chr11:48923668	NA	-0.43	-4.47	-0.34	1.51e-5	HDL cholesterol;
PAAD	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg08926642	chr1:7887455	PER3	0.52	4.56	0.35	1.03e-5	Inflammatory bowel disease;
PAAD	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.41	5.12	0.38	9.05e-7	Pulmonary function;
PAAD	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.66	-7.73	-0.53	1.37e-12	Coronary artery disease;
PAAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg19847866	chr10:1019161	NA	-0.59	-4.68	-0.35	6.34e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.61	4.48	0.34	1.44e-5	Exhaled nitric oxide output;
PAAD	cis	rs4919087	0.590	rs793519	chr10:99030554	C/G	cg25902810	chr10:99078978	FRAT1	0.49	4.37	0.33	2.25e-5	Monocyte count;
PAAD	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg10374248	chr10:99083645	NA	0.51	4.45	0.34	1.67e-5	Monocyte count;
PAAD	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.54	5.71	0.42	5.79e-8	Male-pattern baldness;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.49	4.85	0.37	2.96e-6	Vitiligo;
PAAD	cis	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.66	-0.35	6.9e-6	Neuroticism;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.52	5.01	0.38	1.52e-6	Resistin levels;
PAAD	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6679454	0.881	rs58020116	chr1:58370201	T/C	cg17491850	chr1:57888480	DAB1	-0.47	-5.07	-0.38	1.13e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	4.39	0.34	2.08e-5	Total body bone mineral density;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7172971	0.745	rs4923922	chr15:42333173	A/T	cg07013680	chr15:42186124	SPTBN5	0.55	4.39	0.34	2.13e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg01851573	chr8:8652454	MFHAS1	0.49	4.44	0.34	1.74e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.52	-5.08	-0.38	1.08e-6	Glomerular filtration rate;
PAAD	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.48	-4.43	-0.34	1.78e-5	Red blood cell count;
PAAD	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs10029851	0.645	rs893036	chr4:109623350	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	0.5	4.57	0.35	1e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.53	5.11	0.38	9.65e-7	Bladder cancer;
PAAD	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.59	4.75	0.36	4.76e-6	Body mass index;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg08562672	chr19:21860753	NA	0.45	4.67	0.35	6.44e-6	Pain;
PAAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.22e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11958404	0.615	rs7727924	chr5:157433736	A/G	cg05962755	chr5:157440814	NA	0.55	5.37	0.4	2.85e-7	IgG glycosylation;
PAAD	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg11062466	chr8:58055876	NA	0.68	5.11	0.38	9.73e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.3	-0.51	1.53e-11	Myopia (pathological);
PAAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.99	-0.38	1.63e-6	Diastolic blood pressure;
PAAD	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.6	-5.76	-0.42	4.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg26939375	chr7:64535504	NA	0.52	5.76	0.42	4.53e-8	Aortic root size;
PAAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.83	9.73	0.62	1.07e-17	Breast cancer;
PAAD	cis	rs9815354	1.000	rs6768563	chr3:41865541	G/A	cg03022575	chr3:42003672	ULK4	0.84	6.32	0.46	2.78e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.24	0.39	5.37e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-14.5	-0.76	1.8e-30	Ulcerative colitis;
PAAD	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.5	-0.34	1.35e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9810890	1.000	rs4548	chr3:128525253	C/T	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs3784262	0.765	rs8026952	chr15:58276950	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.51	-5.8	-0.43	3.78e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1419980	0.730	rs7969376	chr12:7759028	A/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.73	5.81	0.43	3.52e-8	Schizophrenia;
PAAD	cis	rs4662592	0.511	rs10496666	chr2:128913552	A/G	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.82	7.9	0.54	5.2e-13	Corneal astigmatism;
PAAD	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.65	-5.73	-0.42	5.22e-8	Coronary artery disease;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg02532672	chr7:808649	HEATR2	-0.58	-6.18	-0.45	5.62e-9	Subjective well-being;
PAAD	cis	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg02356786	chr1:243265016	LOC731275	1.2	8.05	0.55	2.23e-13	Obesity (early onset extreme);
PAAD	cis	rs7804356	0.651	rs1030648	chr7:26802672	T/C	cg03456212	chr7:26904342	SKAP2	-0.57	-4.94	-0.37	1.99e-6	Type 1 diabetes;
PAAD	cis	rs332507	0.830	rs13069961	chr3:124358715	A/G	cg05980111	chr3:124395277	KALRN	0.48	4.62	0.35	8.01e-6	Plateletcrit;
PAAD	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.34	-0.33	2.57e-5	Biliary atresia;
PAAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.36	-0.33	2.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.95	9.91	0.63	3.62e-18	Homoarginine levels;
PAAD	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.42	-0.34	1.88e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9659323	0.745	rs10923723	chr1:119544002	G/A	cg26570165	chr1:119541833	NA	-0.54	-5.68	-0.42	6.73e-8	Body mass index;
PAAD	cis	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg27395922	chr11:50257633	LOC441601	0.39	4.25	0.33	3.7e-5	Height;
PAAD	cis	rs77633900	0.772	rs2957613	chr15:76700589	C/T	cg21673338	chr15:77095150	SCAPER	-0.86	-4.45	-0.34	1.66e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs13253111	0.603	rs28605937	chr8:28099179	A/G	cg26534493	chr8:28060551	NA	0.4	4.4	0.34	2.04e-5	Childhood body mass index;
PAAD	cis	rs9650315	0.500	rs114625362	chr8:57060359	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	4.36	0.33	2.39e-5	Height;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg04522676	chr10:134968826	NA	-0.48	-4.56	-0.35	1.06e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg19000871	chr14:103996768	TRMT61A	0.5	5.72	0.42	5.62e-8	Coronary artery disease;
PAAD	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg03959625	chr15:84868606	LOC388152	0.45	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.85	0.43	2.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.71	6.35	0.46	2.35e-9	Menarche (age at onset);
PAAD	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.79	8.05	0.55	2.23e-13	Coronary artery disease;
PAAD	cis	rs5751901	0.614	rs2070477	chr22:24990916	G/A	cg15363607	chr22:24998974	GGT1	-0.44	-4.34	-0.33	2.63e-5	Protein quantitative trait loci;
PAAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg13482628	chr17:19912719	NA	0.51	4.99	0.38	1.61e-6	Schizophrenia;
PAAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg11995313	chr8:8860691	ERI1	0.49	4.91	0.37	2.33e-6	Joint mobility (Beighton score);
PAAD	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	12.46	0.71	5.48e-25	Colorectal cancer;
PAAD	cis	rs911119	0.955	rs7265178	chr20:23603382	C/G	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg27478167	chr7:817139	HEATR2	-0.64	-4.97	-0.37	1.79e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs59888335	0.929	rs34743396	chr3:80856409	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4908768	0.686	rs79644886	chr1:8803216	A/C	cg00590817	chr1:8272081	NA	-0.37	-4.37	-0.33	2.25e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.18	13.29	0.73	3.14e-27	Post bronchodilator FEV1;
PAAD	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.77	4.95	0.37	1.95e-6	HDL cholesterol;
PAAD	cis	rs508970	0.556	rs655807	chr11:60922055	G/A	cg24692310	chr11:60915630	VPS37C	0.33	4.6	0.35	8.86e-6	Rheumatoid arthritis;
PAAD	cis	rs1190545	0.588	rs4906213	chr14:102991021	C/T	cg18135206	chr14:102964638	TECPR2	0.59	4.92	0.37	2.23e-6	Platelet count;
PAAD	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.4	0.34	2.03e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.67	-7.67	-0.53	1.9e-12	Huntington's disease progression;
PAAD	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7819412	0.618	rs13276836	chr8:10981003	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-4.47	-0.34	1.55e-5	Triglycerides;
PAAD	cis	rs261532	0.906	rs355162	chr5:138956241	T/C	cg11459648	chr5:138714337	SLC23A1	-0.62	-5.67	-0.42	6.87e-8	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg09998033	chr7:158218633	PTPRN2	-0.77	-7.99	-0.54	3.15e-13	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.75	7.5	0.52	4.92e-12	Corneal astigmatism;
PAAD	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.53	4.75	0.36	4.63e-6	Lung cancer;
PAAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-1.14	-9.03	-0.59	7.06e-16	Type 2 diabetes;
PAAD	cis	rs28647808	0.867	rs28534766	chr9:136273381	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs2835872	0.758	rs1709821	chr21:39035622	T/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.41	0.4	2.4e-7	Body mass index;
PAAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.06	-0.44	1.01e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.68	7.51	0.52	4.63e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs12304921	0.625	rs17125369	chr12:51496659	T/C	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs6137287	0.847	rs6047268	chr20:21119108	C/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.45	0.34	1.64e-5	Height;
PAAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.89	-10.44	-0.65	1.39e-19	Multiple sclerosis;
PAAD	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.88	5.33	0.4	3.47e-7	Prostate cancer;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg02696790	chr15:75250997	RPP25	0.49	5.87	0.43	2.69e-8	Breast cancer;
PAAD	cis	rs11159840	0.573	rs7146550	chr14:88599886	G/A	cg18078958	chr14:88630771	NA	-0.42	-5.22	-0.39	5.78e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.27	0.39	4.51e-7	Ovarian reserve;
PAAD	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04282258	chr1:220250989	BPNT1	-0.54	-6.59	-0.47	6.73e-10	Energy expenditure (24h);
PAAD	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.49	0.34	1.41e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8042680	1.000	rs4544218	chr15:91520373	C/A	cg08919649	chr15:91565780	VPS33B	0.48	4.25	0.33	3.68e-5	Type 2 diabetes;
PAAD	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.7	-7.75	-0.53	1.24e-12	Motion sickness;
PAAD	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg27478167	chr7:817139	HEATR2	-0.6	-4.73	-0.36	4.99e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.75	6.96	0.49	9.5e-11	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs8103278	1.000	rs7250497	chr19:46358425	A/G	cg11657440	chr19:46296263	DMWD	-0.68	-5.91	-0.43	2.15e-8	Coronary artery disease;
PAAD	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.53	-0.34	1.18e-5	Testicular germ cell tumor;
PAAD	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg18512352	chr11:47633146	NA	-0.45	-6.59	-0.47	6.98e-10	Subjective well-being;
PAAD	cis	rs4936891	0.563	rs78294880	chr11:123890006	C/T	cg22125253	chr11:123886957	OR10G4	0.46	4.63	0.35	7.79e-6	Male fertility;
PAAD	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.56	-7.31	-0.51	1.4e-11	Longevity;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs12936587	0.601	rs7223430	chr17:17556490	T/C	cg04398451	chr17:18023971	MYO15A	0.46	4.29	0.33	3.13e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	5.13	0.38	8.83e-7	Blood metabolite levels;
PAAD	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg07395648	chr5:131743802	NA	0.54	4.55	0.35	1.1e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs2281636	0.540	rs1057490	chr10:101466606	G/T	cg05149213	chr10:101381631	SLC25A28	-0.55	-5.4	-0.4	2.55e-7	Obesity-related traits;
PAAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg14906510	chr12:7781169	NA	-0.86	-5.36	-0.4	3.04e-7	HDL cholesterol levels;
PAAD	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg02421172	chr7:1938701	MAD1L1	0.55	4.53	0.34	1.21e-5	Bipolar disorder;
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg09471204	chr22:42347991	LOC339674	0.33	4.32	0.33	2.76e-5	Cognitive function;
PAAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg23298862	chr7:158159286	PTPRN2	0.45	4.34	0.33	2.58e-5	Calcium levels;
PAAD	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.57	-4.93	-0.37	2.1e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs10865541	0.967	rs6755327	chr2:3397281	T/C	cg12447832	chr2:3383257	TTC15	-0.35	-4.33	-0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.67	5.96	0.44	1.65e-8	Radiation response;
PAAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.7	-0.42	6.06e-8	Mood instability;
PAAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.79	-9.19	-0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs787274	1.000	rs787285	chr9:115536743	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.45	-0.34	1.68e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs901683	1.000	rs12779976	chr10:46042932	C/T	cg14076390	chr17:34947837	DHRS11	-0.87	-6.65	-0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-8.34	-0.56	4.22e-14	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27066254	chr17:28443640	CCDC55;MIR423	-0.52	-6.33	-0.46	2.68e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.79	-7.69	-0.53	1.67e-12	DNA methylation (variation);
PAAD	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.46	0.41	1.86e-7	Birth weight;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.45	-4.82	-0.36	3.46e-6	Major depressive disorder;
PAAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.31	15.05	0.77	6.57e-32	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16452756	chr5:172483361	C5orf41	0.73	7.4	0.51	8.81e-12	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12637911	chr8:121628381	SNTB1	0.59	6.66	0.48	4.65e-10	Smoking initiation;
PAAD	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs72960926	1.000	rs72958987	chr6:75129721	T/G	cg13997649	chr6:74171430	MTO1	0.88	4.64	0.35	7.45e-6	Metabolite levels (MHPG);
PAAD	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.07e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs72960926	1.000	rs72956938	chr6:75092873	G/A	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.7	6.72	0.48	3.42e-10	Recombination rate (males);
PAAD	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-7.54	-0.52	3.88e-12	Colorectal cancer;
PAAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg04106633	chr4:1044584	NA	0.66	5.46	0.4	1.9e-7	Recombination rate (females);
PAAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24229701	chr12:130821962	PIWIL1	0.41	4.46	0.34	1.59e-5	Menopause (age at onset);
PAAD	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs227833	0.537	rs2817117	chr6:44646741	G/A	cg20913747	chr6:44695427	NA	0.41	4.28	0.33	3.31e-5	Monobrow;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg11601000	chr22:42348013	LOC339674	0.42	4.85	0.37	3e-6	Cognitive function;
PAAD	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg19744528	chr7:157553346	PTPRN2	0.4	4.27	0.33	3.46e-5	Body mass index;
PAAD	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-5.54	-0.41	1.3e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.67	-6.95	-0.49	1.02e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg13320842	chr19:46175254	GIPR	-0.57	-5.15	-0.39	7.98e-7	Eosinophil counts;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18337363	chr3:52569053	NT5DC2	0.41	4.29	0.33	3.12e-5	Bipolar disorder;
PAAD	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6604026	0.656	rs6698233	chr1:93397300	C/T	cg17283838	chr1:93427260	FAM69A	0.62	5.68	0.42	6.58e-8	Multiple sclerosis;
PAAD	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.7	7.18	0.5	2.85e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg24998770	chr7:37888106	TXNDC3	0.52	4.61	0.35	8.61e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.55	8.03	0.55	2.48e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13126279	chr21:47581558	C21orf56	0.38	4.25	0.33	3.75e-5	Testicular germ cell tumor;
PAAD	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.74	6.96	0.49	9.31e-11	Dilated cardiomyopathy;
PAAD	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.75	-0.48	2.95e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.71	-6.58	-0.47	7.05e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.74	-8.81	-0.58	2.6e-15	Body mass index;
PAAD	cis	rs7567389	0.677	rs61422716	chr2:128087651	C/T	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs4780401	0.933	rs8058003	chr16:11815178	C/T	cg01061890	chr16:11836724	TXNDC11	-0.54	-5.19	-0.39	6.58e-7	Rheumatoid arthritis;
PAAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.5	5.75	0.42	4.76e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-7.58	-0.52	3.14e-12	Morning vs. evening chronotype;
PAAD	cis	rs6137287	0.751	rs1569959	chr20:21223410	T/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.36	0.33	2.34e-5	Height;
PAAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.86	14.58	0.76	1.15e-30	Schizophrenia;
PAAD	cis	rs11613048	0.897	rs7306688	chr12:30347331	C/T	cg03476860	chr12:30948794	NA	-0.36	-4.42	-0.34	1.89e-5	Major depressive disorder;
PAAD	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.29	-17.67	-0.82	1.08e-38	Ulcerative colitis;
PAAD	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.65	6.92	0.49	1.17e-10	Testicular germ cell tumor;
PAAD	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg10915739	chr21:34405733	NA	0.33	4.48	0.34	1.48e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12671247	chr5:34905841	RAD1	0.6	6.98	0.49	8.47e-11	Smoking initiation;
PAAD	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg08632701	chr21:37451849	NA	-0.64	-6.56	-0.47	8.02e-10	Mitral valve prolapse;
PAAD	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg18833306	chr6:118973337	C6orf204	0.51	5.91	0.43	2.13e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	trans	rs9942416	0.715	rs10057967	chr5:74997756	C/T	cg03931927	chr7:65215969	CCT6P1	0.64	6.37	0.46	2.16e-9	Age-related disease endophenotypes;
PAAD	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg24747557	chr10:131355152	MGMT	0.42	4.35	0.33	2.51e-5	Response to temozolomide;
PAAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.85e-6	Type 2 diabetes;
PAAD	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg09366796	chr5:75012313	C5orf37	0.49	4.45	0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10865050	1	rs10865050	chr2:102941311	G/A	cg20060108	chr2:102954350	IL1RL1	0.56	4.44	0.34	1.73e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.87e-6	Bone mineral density;
PAAD	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.7	7.29	0.51	1.62e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.56	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.29	0.33	3.19e-5	Major depressive disorder;
PAAD	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.74	-8.68	-0.58	5.84e-15	Body mass index;
PAAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.17	16.8	0.81	1.75e-36	Cognitive function;
PAAD	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg08807101	chr21:30365312	RNF160	-0.64	-5.18	-0.39	6.9e-7	Cognitive test performance;
PAAD	cis	rs7084783	0.538	rs3781367	chr10:105337294	C/G	cg09754828	chr10:105363329	SH3PXD2A	0.45	4.34	0.33	2.55e-5	Fear of pain;
PAAD	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.87e-5	Life satisfaction;
PAAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.88	12.19	0.7	2.91e-24	Vitiligo;
PAAD	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.68	-6.88	-0.49	1.45e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5167	0.539	rs4803783	chr19:45470458	G/C	cg08436089	chr19:45594493	GEMIN7	0.25	4.31	0.33	2.94e-5	Blood protein levels;
PAAD	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.67	-0.48	4.4e-10	Systolic blood pressure;
PAAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-8.06	-0.55	2.14e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs62408225	0.722	rs1319433	chr6:90921988	G/A	cg03795776	chr6:90687632	BACH2	0.4	4.25	0.33	3.74e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs5756391	0.532	rs4820261	chr22:37316949	G/A	cg16356956	chr22:37317934	CSF2RB	0.39	4.77	0.36	4.22e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12760731	0.720	rs67857740	chr1:178402250	A/G	cg00404053	chr1:178313656	RASAL2	0.7	5.23	0.39	5.61e-7	Obesity-related traits;
PAAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.92	11.84	0.69	2.45e-23	Mean corpuscular volume;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg14433983	chr11:636460	DRD4	-0.45	-4.65	-0.35	7.06e-6	Systemic lupus erythematosus;
PAAD	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.26	-0.33	3.63e-5	Body mass index;
PAAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.7	-10.05	-0.63	1.5e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8018808	1.000	rs11844594	chr14:77843814	T/C	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.88e-7	Myeloid white cell count;
PAAD	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.73	0.36	5.16e-6	Serum sulfate level;
PAAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg20243544	chr17:37824526	PNMT	0.54	4.71	0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1555895	0.576	rs4881537	chr10:848059	A/T	cg26597838	chr10:835615	NA	0.46	4.9	0.37	2.44e-6	Survival in rectal cancer;
PAAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg22710661	chr11:17411071	KCNJ11	0.43	4.32	0.33	2.8e-5	Type 2 diabetes;
PAAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.6	5.42	0.4	2.34e-7	Initial pursuit acceleration;
PAAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg09579323	chr1:150459698	TARS2	-0.46	-4.46	-0.34	1.55e-5	Migraine;
PAAD	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.12	9.49	0.61	4.55e-17	Vitiligo;
PAAD	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	cis	rs1572438	0.868	rs9378518	chr6:861084	A/G	cg13447295	chr6:887704	NA	-0.45	-4.43	-0.34	1.79e-5	Aging;
PAAD	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10547527	chr2:198650123	BOLL	0.48	4.3	0.33	3.01e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2384207	0.818	rs2241544	chr12:113724945	A/G	cg22376712	chr12:113623594	C12orf52;DDX54	0.62	5.29	0.39	4.1e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.51	-6.57	-0.47	7.57e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26418147	chr1:205743515	RAB7L1	0.38	4.41	0.34	1.96e-5	Monocyte percentage of white cells;
PAAD	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.41	-0.4	2.45e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6710503	0.547	rs2304892	chr2:24714923	C/T	cg21011133	chr2:25142198	ADCY3	-0.39	-4.31	-0.33	2.94e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs7264396	0.778	rs6120959	chr20:34077848	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.65	-0.42	7.51e-8	Total cholesterol levels;
PAAD	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.62	-5.11	-0.38	9.69e-7	Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16098921	chr7:150026554	C7orf29;LRRC61	-0.65	-6.34	-0.46	2.55e-9	Obesity-related traits;
PAAD	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg04165759	chr1:150448943	RPRD2	0.53	5.62	0.41	9.05e-8	Migraine;
PAAD	cis	rs7119038	0.629	rs10892271	chr11:118598544	G/A	cg04176122	chr11:118779835	BCL9L	0.43	4.68	0.35	6.41e-6	Sjögren's syndrome;
PAAD	cis	rs7678296	1.000	rs73126364	chr4:37223531	G/A	cg06805348	chr4:37245195	KIAA1239	0.65	4.83	0.36	3.34e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.63	6.08	0.44	9.45e-9	Corneal astigmatism;
PAAD	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg24565620	chr2:194026	NA	-0.6	-4.7	-0.36	5.69e-6	Blood protein levels;
PAAD	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.45	-4.31	-0.33	2.93e-5	Mean platelet volume;
PAAD	cis	rs10861342	1.000	rs11112394	chr12:105551570	C/T	cg23923672	chr12:105501055	KIAA1033	-0.74	-4.35	-0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs10792830	0.778	rs604767	chr11:85789983	C/G	cg07180834	chr11:85838833	NA	-0.56	-6.28	-0.45	3.34e-9	Psychosis and Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs17451208	chr10:46051905	C/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.73	-6.21	-0.45	4.9e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg11802864	chr11:65308245	LTBP3	1.35	6.76	0.48	2.76e-10	Height;
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg00450029	chr8:599525	NA	0.75	4.88	0.37	2.63e-6	IgG glycosylation;
PAAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.57	0.65	6.52e-20	Menopause (age at onset);
PAAD	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.74	7.79	0.53	9.5e-13	Body mass index;
PAAD	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-4.82	-0.36	3.42e-6	Coronary artery disease;
PAAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-7.35	-0.51	1.12e-11	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26310240	chr20:30192190	ID1	-0.75	-6.42	-0.46	1.65e-9	Neuroticism;
PAAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.57	6.73	0.48	3.19e-10	Menopause (age at onset);
PAAD	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.64e-5	Life satisfaction;
PAAD	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.29	-0.33	3.1e-5	Tuberculosis;
PAAD	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.28	0.6	1.63e-16	Hemoglobin concentration;
PAAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg09796270	chr17:17721594	SREBF1	0.44	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	0.77	5.39	0.4	2.67e-7	Body mass index;
PAAD	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.72	5.46	0.41	1.88e-7	Electroencephalogram traits;
PAAD	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.69	-6.12	-0.44	7.78e-9	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg05754148	chr16:3507555	NAT15	0.72	5.16	0.39	7.44e-7	Tuberculosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24169248	chr11:66247869	DPP3	0.59	6.8	0.48	2.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg26597838	chr10:835615	NA	0.61	5.12	0.38	9.14e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg08134877	chr2:44394819	PPM1B	0.43	4.26	0.33	3.52e-5	Height;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3996993	0.809	rs6458879	chr6:52688783	G/C	cg20803780	chr6:52668592	GSTA1	-0.35	-4.48	-0.34	1.47e-5	Hemoglobin concentration;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.79	-0.36	3.91e-6	Eosinophil percentage of white cells;
PAAD	cis	rs35740288	0.703	rs10520598	chr15:86173381	T/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg19781863	chr12:62918364	MON2	0.73	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.94	9.73	0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12876333	chr18:55710995	NEDD4L	0.66	7.1	0.5	4.39e-11	Obesity-related traits;
PAAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.79	0.43	3.9e-8	Tonsillectomy;
PAAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.23e-6	Bipolar disorder;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	0.86	11.61	0.69	1.04e-22	Vitiligo;
PAAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.55	-4.81	-0.36	3.57e-6	Schizophrenia;
PAAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.37	-0.33	2.32e-5	Post bronchodilator FEV1;
PAAD	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg25319279	chr11:5960081	NA	-0.79	-7.69	-0.53	1.67e-12	DNA methylation (variation);
PAAD	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.75	8.15	0.55	1.22e-13	Red blood cell count;
PAAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg08085267	chr17:45401833	C17orf57	-0.85	-8.12	-0.55	1.48e-13	Coronary artery disease;
PAAD	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs1532557	1.000	rs1985338	chr1:224796045	G/A	cg09988837	chr1:224811939	CNIH3	0.57	4.32	0.33	2.8e-5	Cancer;
PAAD	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.66	-6.03	-0.44	1.19e-8	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08939942	chr2:202838362	NA	-0.61	-6.73	-0.48	3.18e-10	Obesity-related traits;
PAAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.59	0.35	9.39e-6	Height;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.0	0.79	2.04e-34	Prudent dietary pattern;
PAAD	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.47	4.58	0.35	9.75e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg11498726	chr8:26250323	BNIP3L	-0.55	-5.28	-0.39	4.39e-7	Red cell distribution width;
PAAD	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg25364880	chr3:44379878	C3orf23	0.53	5.16	0.39	7.65e-7	Depressive symptoms;
PAAD	cis	rs1419980	0.730	rs11054889	chr12:7773058	C/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs11811982	0.793	rs114398201	chr1:227493378	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10996014	chr3:49449848	RHOA;TCTA	0.66	6.65	0.47	4.89e-10	Obesity-related traits;
PAAD	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg23024343	chr7:107201750	COG5	0.53	4.42	0.34	1.84e-5	Coronary artery disease;
PAAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.73	5.81	0.43	3.51e-8	Cognitive function;
PAAD	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Vitiligo;
PAAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.42	-0.52	7.7e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11694441	0.590	rs1866408	chr2:119573528	C/T	cg14634534	chr2:119616825	NA	-0.43	-4.72	-0.36	5.37e-6	Monobrow;
PAAD	cis	rs7084783	0.519	rs4918025	chr10:105342866	T/C	cg09754828	chr10:105363329	SH3PXD2A	0.45	4.32	0.33	2.85e-5	Fear of pain;
PAAD	cis	rs6558174	0.965	rs2003908	chr8:22491518	T/C	cg03733263	chr8:22462867	KIAA1967	0.48	4.69	0.36	6.02e-6	Breast cancer;
PAAD	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.5	-4.71	-0.36	5.59e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2109514	0.902	rs1007751	chr7:116110055	A/T	cg19719915	chr7:115928094	NA	-0.45	-4.36	-0.33	2.37e-5	Prevalent atrial fibrillation;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg16937583	chr3:9997177	NA	0.46	4.28	0.33	3.35e-5	Alzheimer's disease;
PAAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg22710661	chr11:17411071	KCNJ11	0.45	4.53	0.35	1.18e-5	Type 2 diabetes;
PAAD	cis	rs13242816	1.000	rs13243017	chr7:116189371	G/A	cg16553024	chr7:116138462	CAV2	-0.64	-4.27	-0.33	3.49e-5	P wave duration;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26804004	chr15:77155428	SCAPER	-0.55	-6.36	-0.46	2.27e-9	Energy expenditure (24h);
PAAD	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.35e-10	Monocyte count;
PAAD	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.68	-8.62	-0.57	8.34e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg18888403	chr1:24152774	HMGCL	0.4	4.6	0.35	8.78e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	2.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg11518657	chr1:67396239	MIER1	0.69	5.2	0.39	6.48e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg17524265	chr8:144659883	NAPRT1	0.87	4.31	0.33	2.97e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg27121462	chr16:89883253	FANCA	-0.46	-4.82	-0.36	3.4e-6	Vitiligo;
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.61	-0.53	2.67e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	1.23	13.72	0.74	2.23e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1997066	0.831	rs73344308	chr10:106824851	G/A	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.52	-4.86	-0.37	2.86e-6	Red blood cell count;
PAAD	cis	rs4800452	0.956	rs4308051	chr18:20735461	T/G	cg26136497	chr18:20735537	CABLES1	-0.51	-4.66	-0.35	6.86e-6	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1075232	1.000	rs12437749	chr15:31649888	C/T	cg15751117	chr15:30700112	NA	0.94	5.0	0.38	1.57e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs4085154	1.000	rs4085154	chr1:216858013	G/A	cg20869501	chr1:216774677	ESRRG	-0.44	-4.52	-0.34	1.25e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.43	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1497828	0.956	rs1007737	chr1:217547872	G/C	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs7714584	1.000	rs11747270	chr5:150258867	C/T	cg22134413	chr5:150180641	NA	-0.7	-4.92	-0.37	2.18e-6	Crohn's disease;
PAAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.1	-0.44	8.6e-9	Prostate cancer;
PAAD	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.49	0.34	1.39e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.94	12.25	0.7	1.92e-24	Menopause (age at onset);
PAAD	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.93	-9.2	-0.6	2.57e-16	Asthma;
PAAD	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg18551225	chr6:44695536	NA	-0.74	-7.53	-0.52	4.09e-12	Total body bone mineral density;
PAAD	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.52	0.34	1.22e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs3764400	0.567	rs208012	chr17:46258017	G/A	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.51	5.39	0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.64	-5.73	-0.42	5.33e-8	Personality dimensions;
PAAD	trans	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg09127314	chr1:152161683	NA	-0.68	-4.59	-0.35	9.22e-6	Atopic dermatitis;
PAAD	cis	rs76917914	0.820	rs7020081	chr9:100823360	C/A	cg03040243	chr9:100819229	NANS	0.59	4.72	0.36	5.32e-6	Immature fraction of reticulocytes;
PAAD	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.94	7.71	0.53	1.52e-12	Tuberculosis;
PAAD	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs9815354	1.000	rs4973991	chr3:41927273	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.85	-0.43	2.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02743256	chr7:2109353	MAD1L1	-0.74	-6.08	-0.44	9.5e-9	Bipolar disorder;
PAAD	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg20849893	chr7:64541193	NA	0.54	5.28	0.39	4.44e-7	Calcium levels;
PAAD	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg23939001	chr4:940644	TMEM175	0.83	10.21	0.64	5.95e-19	Sjögren's syndrome;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.22	0.39	5.77e-7	Mean platelet volume;
PAAD	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.61	5.38	0.4	2.73e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-1.17	-6.08	-0.44	9.44e-9	Inflammatory biomarkers;
PAAD	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.23	-0.39	5.64e-7	Pulmonary function;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.52	-0.47	9.64e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.53	-6.11	-0.44	8e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.84e-6	Testicular germ cell tumor;
PAAD	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	6.87	0.49	1.51e-10	LDL cholesterol;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-5.72	-0.42	5.6e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs12153243	0.686	rs12152870	chr5:142898255	C/T	cg13907255	chr5:142895549	NA	-0.53	-4.91	-0.37	2.34e-6	Migraine;
PAAD	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00292662	chr22:38071168	LGALS1	0.53	5.54	0.41	1.31e-7	Fat distribution (HIV);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01219048	chr4:110623974	CASP6	-0.79	-7.26	-0.51	1.9e-11	Neuroticism;
PAAD	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg18854424	chr1:2615690	NA	-0.46	-5.84	-0.43	3.01e-8	Multiple sclerosis;
PAAD	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.97	-0.44	1.6e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	5.25	0.39	5.08e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.47	-0.34	1.52e-5	Response to amphetamines;
PAAD	cis	rs553086	0.527	rs664437	chr11:56918361	C/G	cg01427848	chr11:56972618	NA	-0.44	-4.55	-0.35	1.07e-5	Fear of severe pain;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02672962	chr16:3665541	NA	0.54	6.52	0.47	9.62e-10	Body fat percentage;
PAAD	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg15798862	chr7:76129360	DTX2	-0.42	-5.35	-0.4	3.14e-7	Multiple sclerosis;
PAAD	cis	rs4704187	0.687	rs6453111	chr5:74379926	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.64	6.18	0.45	5.53e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.51	-0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.84	-9.45	-0.61	5.71e-17	Prudent dietary pattern;
PAAD	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.87	10.21	0.64	5.78e-19	Height;
PAAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg24733560	chr20:60626293	TAF4	0.52	6.47	0.46	1.28e-9	Body mass index;
PAAD	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.12	-0.38	9.04e-7	Systemic lupus erythematosus;
PAAD	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.89	11.06	0.67	3.13e-21	Mean corpuscular volume;
PAAD	cis	rs11250714	0.845	rs7918604	chr10:1697448	G/T	cg10435618	chr10:838112	NA	-0.46	-4.4	-0.34	2.05e-5	Gut microbiome composition (summer);
PAAD	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.31	-0.33	2.97e-5	Ileal carcinoids;
PAAD	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg08975724	chr8:8085496	FLJ10661	-0.71	-6.97	-0.49	9.01e-11	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10660136	chr2:232379107	C2orf52	0.65	6.55	0.47	8.4e-10	Myopia (pathological);
PAAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg05725404	chr16:58534157	NDRG4	-0.79	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.84	-9.56	-0.61	3.03e-17	Ulcerative colitis;
PAAD	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs501120	0.584	rs11517251	chr10:44724052	A/G	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02982160	chr12:120971999	RNF10	-0.65	-6.32	-0.46	2.75e-9	Lung cancer in ever smokers;
PAAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.55	-5.59	-0.41	1.02e-7	Personality dimensions;
PAAD	cis	rs7678296	1.000	rs73140740	chr4:37173848	A/G	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs17824933	1.000	rs916813	chr11:60764028	A/G	cg16817237	chr11:60793675	NA	0.5	5.98	0.44	1.52e-8	Multiple sclerosis;
PAAD	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24249390	chr15:90295951	MESP1	-0.54	-5.79	-0.43	3.91e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.41	4.9	0.37	2.41e-6	Uric acid levels;
PAAD	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg23024343	chr7:107201750	COG5	0.54	4.5	0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.45	-4.6	-0.35	8.83e-6	Vitiligo;
PAAD	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.12	-0.38	9.06e-7	Personality dimensions;
PAAD	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.61	6.6	0.47	6.43e-10	Obesity-related traits;
PAAD	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.69	6.05	0.44	1.09e-8	Platelet count;
PAAD	cis	rs11124272	0.857	rs7587666	chr2:32055890	C/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.58	-0.35	9.79e-6	Interleukin-18 levels;
PAAD	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-5.06	-0.38	1.21e-6	Blood pressure;
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg23978390	chr7:1156363	C7orf50	0.54	4.31	0.33	2.91e-5	Bronchopulmonary dysplasia;
PAAD	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs747650	0.504	rs7126005	chr11:47041065	G/A	cg19486271	chr11:47235900	DDB2	-0.67	-6.28	-0.45	3.44e-9	Acne (severe);
PAAD	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	4.94	0.37	1.99e-6	Lung cancer in ever smokers;
PAAD	cis	rs73416724	0.688	rs113283188	chr6:43355266	A/C	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.84	10.11	0.63	1.05e-18	Menopause (age at onset);
PAAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-1.07	-14.11	-0.75	2.04e-29	Total body bone mineral density;
PAAD	cis	rs288342	0.796	rs11901549	chr2:183599110	T/G	cg02625481	chr2:183667124	NA	-0.44	-4.3	-0.33	3e-5	Recurrent major depressive disorder;
PAAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.48	-5.63	-0.42	8.3e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.53	5.21	0.39	5.94e-7	Sleep duration;
PAAD	cis	rs6142102	0.646	rs2223553	chr20:32709444	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.93	0.37	2.11e-6	Skin pigmentation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00926874	chr1:226309722	NA	0.66	6.89	0.49	1.38e-10	Myopia (pathological);
PAAD	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.99	7.58	0.52	3.18e-12	Eosinophilic esophagitis;
PAAD	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg14829155	chr15:31115871	NA	-0.66	-7.25	-0.51	1.92e-11	Huntington's disease progression;
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs12586317	0.653	rs4981287	chr14:35828198	G/A	cg05294307	chr14:35346193	BAZ1A	-0.73	-6.15	-0.45	6.67e-9	Psoriasis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17977474	chr19:14073064	RFX1	0.64	6.72	0.48	3.46e-10	Smoking initiation;
PAAD	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg27490568	chr2:178487706	NA	0.45	4.99	0.37	1.66e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.27	-0.6	1.71e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.09	0.44	8.94e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs61332075	0.504	rs7596847	chr2:239321118	T/A	cg18131467	chr2:239335373	ASB1	-0.6	-4.38	-0.33	2.22e-5	Lung function (FEV1/FVC);
PAAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg02841227	chr6:26021843	HIST1H4A	0.47	4.81	0.36	3.61e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs76849715	chr10:46080433	G/A	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	8.09e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18176509	chr1:94305707	NA	-0.66	-6.44	-0.46	1.48e-9	Obesity-related traits;
PAAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.85	9.69	0.62	1.41e-17	Multiple sclerosis;
PAAD	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.78	8.34	0.56	4.18e-14	Blood metabolite levels;
PAAD	cis	rs9287719	0.601	rs62128635	chr2:10725334	G/C	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.81	-0.43	3.57e-8	Monocyte count;
PAAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	6.38	0.46	1.99e-9	Initial pursuit acceleration;
PAAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg05038881	chr1:10490043	APITD1	0.45	5.25	0.39	5.02e-7	Prostate cancer;
PAAD	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.42	4.49	0.34	1.39e-5	Platelet count;
PAAD	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg05805236	chr11:65401703	PCNXL3	0.5	4.29	0.33	3.17e-5	Crohn's disease;
PAAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg09226986	chr6:160852328	SLC22A3	-0.48	-4.49	-0.34	1.41e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.5	-5.32	-0.4	3.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg15764593	chr10:829463	NA	0.9	4.7	0.36	5.69e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.69	4.78	0.36	4.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg03094675	chr11:5960213	NA	0.48	4.49	0.34	1.39e-5	DNA methylation (variation);
PAAD	cis	rs2885056	0.891	rs73018643	chr19:10688969	G/C	cg06392426	chr19:10676186	KRI1	0.56	5.42	0.4	2.25e-7	Red cell distribution width;
PAAD	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.58	4.78	0.36	4.09e-6	Red blood cell count;
PAAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.43	0.34	1.83e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11581903	0.929	rs34275176	chr1:53056063	A/G	cg18087326	chr1:53067637	GPX7	-0.56	-4.97	-0.37	1.82e-6	Joint mobility (Beighton score);
PAAD	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.48	-0.41	1.69e-7	Prevalent atrial fibrillation;
PAAD	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg16576597	chr16:28551801	NUPR1	0.67	7.2	0.5	2.66e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4478858	0.746	rs10798832	chr1:31688630	C/G	cg00250761	chr1:31883323	NA	0.4	4.46	0.34	1.61e-5	Alcohol dependence;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10111153	chr12:56622058	OBFC2B	0.65	6.88	0.49	1.49e-10	Smoking initiation;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01516881	chr6:292596	DUSP22	-0.73	-7.31	-0.51	1.45e-11	Menopause (age at onset);
PAAD	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9652601	0.691	rs9941107	chr16:11196041	C/T	cg04616529	chr16:11181986	CLEC16A	0.36	4.26	0.33	3.62e-5	Systemic lupus erythematosus;
PAAD	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg12568669	chr8:11666485	FDFT1	-0.28	-4.88	-0.37	2.66e-6	Myopia (pathological);
PAAD	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-5.86	-0.43	2.77e-8	Menopause (age at onset);
PAAD	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	6.58	0.47	7.25e-10	Neuroticism;
PAAD	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.88	-0.43	2.45e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs4787491	0.765	rs8054507	chr16:30046042	G/A	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.26	-0.39	4.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg05785598	chr3:49045655	WDR6	0.41	4.85	0.37	3.04e-6	Parkinson's disease;
PAAD	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.74	-0.36	4.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.48	4.61	0.35	8.59e-6	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.28	0.56	5.96e-14	Prudent dietary pattern;
PAAD	cis	rs9857275	0.501	rs13078872	chr3:141249961	C/G	cg25967872	chr3:141205623	RASA2	0.5	4.29	0.33	3.19e-5	Prion diseases;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg12143784	chr7:64541923	NA	0.44	5.75	0.42	4.7e-8	Calcium levels;
PAAD	cis	rs1413885	0.504	rs9436287	chr1:65863302	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-5.02	-0.38	1.46e-6	Anticoagulant levels;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.61	7.43	0.52	7.49e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.57	4.82	0.36	3.39e-6	Type 2 diabetes;
PAAD	cis	rs12760731	0.565	rs12044522	chr1:178190180	G/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.5	-4.95	-0.37	1.93e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.44	0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18663768	chr10:103546545	MGEA5	-0.64	-6.74	-0.48	3.07e-10	Obesity-related traits;
PAAD	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg21775007	chr8:11205619	TDH	0.59	5.56	0.41	1.21e-7	Neuroticism;
PAAD	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg16447950	chr5:562315	NA	-0.66	-5.84	-0.43	3.05e-8	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.95	-0.37	1.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04004882	chr2:215674386	BARD1	0.62	4.62	0.35	8.07e-6	Neuroblastoma;
PAAD	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg25828445	chr12:7781288	NA	0.8	5.69	0.42	6.26e-8	HDL cholesterol levels;
PAAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-7.54	-0.52	3.95e-12	Longevity;Endometriosis;
PAAD	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg04851639	chr8:1020857	NA	-0.59	-6.52	-0.47	9.68e-10	Schizophrenia;
PAAD	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.49	-0.34	1.41e-5	IgG glycosylation;
PAAD	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.55	-5.38	-0.4	2.74e-7	IgG glycosylation;
PAAD	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg03482866	chr13:111040579	COL4A2	0.48	4.78	0.36	4.19e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07636095	chr6:27759817	NA	0.7	7.3	0.51	1.52e-11	Obesity-related traits;
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.28	-0.45	3.4e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg20936604	chr3:58311152	NA	-0.74	-4.41	-0.34	1.95e-5	Cholesterol, total;
PAAD	cis	rs11203032	0.831	rs9651424	chr10:90932935	A/G	cg16672925	chr10:90967113	CH25H	0.72	5.57	0.41	1.13e-7	Heart failure;
PAAD	cis	rs3760982	0.747	rs62116990	chr19:44301608	G/A	cg11993925	chr19:44307056	LYPD5	-0.51	-6.71	-0.48	3.59e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.69	7.95	0.54	4.02e-13	Colorectal cancer;
PAAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg09127314	chr1:152161683	NA	-0.68	-5.09	-0.38	1.06e-6	Atopic dermatitis;
PAAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg00255919	chr5:131827918	IRF1	0.47	6.08	0.44	9.39e-9	Breast cancer;Mosquito bite size;
PAAD	cis	rs728616	0.614	rs17678737	chr10:82133985	A/G	cg19423196	chr10:82049429	MAT1A	0.5	4.91	0.37	2.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-5.88	-0.43	2.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6679454	0.843	rs61770279	chr1:58345943	T/C	cg17491850	chr1:57888480	DAB1	-0.39	-4.38	-0.33	2.17e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.38	5.53	0.41	1.37e-7	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs988913	0.957	rs9382405	chr6:54836613	T/C	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.65	-0.47	5.05e-10	Total body bone mineral density;
PAAD	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	0.97	12.48	0.71	4.64e-25	Menopause (age at onset);
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.4	-5.87	-0.43	2.58e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.27	-0.33	3.42e-5	Longevity;Endometriosis;
PAAD	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.63	6.33	0.46	2.6e-9	Triglyceride levels;
PAAD	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.55	4.86	0.37	2.86e-6	Height;
PAAD	cis	rs2342371	0.756	rs28712197	chr3:196107214	T/C	cg08209042	chr3:196295218	WDR53;FBXO45	-0.59	-4.68	-0.35	6.37e-6	Fat distribution (HIV);
PAAD	trans	rs62179067	1.000	rs62175450	chr2:180003056	G/A	cg23458843	chr12:58136445	AGAP2	0.96	6.39	0.46	1.94e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08893839	chr5:154027129	NA	-0.65	-4.96	-0.37	1.87e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg07362569	chr17:61921086	SMARCD2	0.43	4.79	0.36	3.98e-6	Height;
PAAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs3026101	0.723	rs1544400	chr17:5305924	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.96	0.44	1.71e-8	Body mass index;
PAAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.57	0.35	1.01e-5	Bone mineral density;
PAAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.45	-4.51	-0.34	1.3e-5	Vitiligo;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25276149	chr1:234509074	C1orf31	-0.73	-6.47	-0.46	1.25e-9	Neuroticism;
PAAD	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04731861	chr2:219085781	ARPC2	0.37	4.34	0.33	2.56e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18337363	chr3:52569053	NT5DC2	0.4	4.34	0.33	2.58e-5	Bipolar disorder;
PAAD	trans	rs901683	1.000	rs9422655	chr10:46051408	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	10.05	0.63	1.52e-18	Platelet count;
PAAD	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.23	0.51	2.19e-11	Obesity-related traits;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg08048268	chr3:133502702	NA	-0.51	-6.09	-0.44	8.93e-9	Iron status biomarkers (transferrin levels);
PAAD	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.7	7.24	0.51	2.12e-11	Morning vs. evening chronotype;
PAAD	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg01489256	chr8:11204017	TDH	-0.43	-4.28	-0.33	3.33e-5	Neuroticism;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.7	-7.06	-0.5	5.69e-11	Prudent dietary pattern;
PAAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20432680	chr17:19850460	AKAP10	-0.71	-7.55	-0.52	3.85e-12	Obesity-related traits;
PAAD	cis	rs1359582	0.793	rs750508	chr10:90400677	T/C	cg15661332	chr10:90342814	RNLS	0.55	4.8	0.36	3.76e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-6.08	-0.44	9.51e-9	Fibrinogen levels;
PAAD	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.44	4.77	0.36	4.28e-6	Menarche (age at onset);
PAAD	cis	rs1801239	1.000	rs45619139	chr10:16940846	C/G	cg00939682	chr10:16933505	CUBN	0.7	4.85	0.37	3.03e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg02869306	chr7:64672164	INTS4L1	-0.5	-5.86	-0.43	2.71e-8	Calcium levels;
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2017305	0.915	rs1539163	chr10:70739630	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.56	-5.33	-0.4	3.49e-7	Daytime sleep phenotypes;
PAAD	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg26939375	chr7:64535504	NA	0.52	5.73	0.42	5.2100000000000003e-08	Aortic root size;
PAAD	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	11.24	0.67	1.04e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06816875	chr1:6845440	CAMTA1	0.6	7.11	0.5	4.23e-11	Monocyte percentage of white cells;
PAAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg12568669	chr8:11666485	FDFT1	-0.3	-4.63	-0.35	7.87e-6	Retinal vascular caliber;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.83	0.36	3.28e-6	Breast cancer;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.66	7.51	0.52	4.69e-12	Iron status biomarkers;
PAAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.41	4.46	0.34	1.58e-5	Aortic root size;
PAAD	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg08917208	chr2:24149416	ATAD2B	0.5	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs1198872	0.892	rs1198869	chr2:10902445	C/T	cg07921008	chr2:10924176	ATP6V1C2;PDIA6	0.44	4.27	0.33	3.5e-5	Cardiac Troponin-T levels;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.78e-7	Lung cancer;
PAAD	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.68	-4.88	-0.37	2.66e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13560548	chr3:10150139	C3orf24	0.55	4.92	0.37	2.25e-6	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.89	12.21	0.7	2.57e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.43	4.73	0.36	5.16e-6	Axial length;
PAAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.03	0.44	1.2e-8	Platelet count;
PAAD	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.91	0.49	1.27e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.44	4.63	0.35	7.75e-6	Age of smoking initiation;
PAAD	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.29	-0.33	3.22e-5	Renal cell carcinoma;
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.99	-0.38	1.63e-6	Initial pursuit acceleration;
PAAD	cis	rs4926611	0.736	rs4927023	chr1:54121458	C/T	cg11411929	chr1:53679725	CPT2	0.42	4.25	0.33	3.76e-5	Hand grip strength;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.26	-0.33	3.56e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg00531865	chr16:30841666	NA	0.5	4.38	0.33	2.17e-5	Dementia with Lewy bodies;
PAAD	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.66	7.25	0.51	1.99e-11	Melanoma;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.1	-0.5	4.45e-11	Coffee consumption (cups per day);
PAAD	cis	rs364477	0.855	rs279894	chr9:968334	G/A	cg13952963	chr9:998547	NA	0.65	4.52	0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg02640540	chr1:67518911	SLC35D1	-0.5	-4.44	-0.34	1.73e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs72960926	0.744	rs2018820	chr6:74892329	T/C	cg03266952	chr6:74778945	NA	-1.04	-6.0	-0.44	1.38e-8	Metabolite levels (MHPG);
PAAD	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.52	6.19	0.45	5.43e-9	Sitting height ratio;
PAAD	cis	rs58521262	0.790	rs56103105	chr19:23120827	A/T	cg22640819	chr19:22990650	NA	0.36	4.3	0.33	2.99e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs3770081	1.000	rs61477982	chr2:86160532	G/T	cg16398094	chr2:86333206	PTCD3;POLR1A	0.79	4.28	0.33	3.34e-5	Facial emotion recognition (sad faces);
PAAD	cis	rs6132905	0.590	rs80091120	chr20:2617674	G/A	cg23469025	chr20:2645106	IDH3B	0.6	4.27	0.33	3.46e-5	Mumps;
PAAD	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.66	-6.96	-0.49	9.53e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs9472414	0.680	rs9463017	chr6:44710304	A/C	cg20913747	chr6:44695427	NA	-0.5	-4.8	-0.36	3.73e-6	Height;
PAAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.78	-9.09	-0.59	5.06e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6500602	1.000	rs4786491	chr16:4493612	C/G	cg08645402	chr16:4508243	NA	0.58	5.3	0.39	4.05e-7	Schizophrenia;
PAAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23158103	chr7:148848205	ZNF398	-0.51	-4.61	-0.35	8.32e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.86	10.16	0.64	7.88e-19	Blood protein levels;
PAAD	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.44	-0.34	1.7e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg04721828	chr11:48285200	OR4X1	-0.4	-5.13	-0.38	8.91e-7	Migraine - clinic-based;
PAAD	cis	rs17739167	0.550	rs17739125	chr15:42234424	T/C	cg20935245	chr15:42234343	EHD4	-0.57	-6.55	-0.47	8.31e-10	Monocyte count;
PAAD	cis	rs8067287	0.688	rs58928848	chr17:16844876	G/A	cg26910001	chr17:16838321	NA	-0.54	-5.13	-0.38	8.66e-7	Diabetic kidney disease;
PAAD	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs863345	0.604	rs1157525	chr1:158457253	T/C	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs4919087	0.715	rs793520	chr10:99032375	G/A	cg25902810	chr10:99078978	FRAT1	-0.63	-5.58	-0.41	1.09e-7	Monocyte count;
PAAD	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.58	-6.07	-0.44	9.94e-9	Total body bone mineral density;
PAAD	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.49	0.76	1.99e-30	Headache;
PAAD	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.61	-5.87	-0.43	2.68e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.86	-0.49	1.63e-10	Blood metabolite levels;
PAAD	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg07384165	chr1:10488281	NA	-0.47	-5.01	-0.38	1.53e-6	Breast size;
PAAD	cis	rs427941	0.703	rs201451	chr7:101739550	G/A	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-1.0	-8.61	-0.57	8.86e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs10821973	0.527	rs6479790	chr10:63980298	A/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17848003	chr1:3704513	LRRC47	0.4	4.32	0.33	2.84e-5	Red cell distribution width;
PAAD	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.51	-4.89	-0.37	2.57e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg02841227	chr6:26021843	HIST1H4A	0.53	5.18	0.39	6.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.85	5.75	0.42	4.66e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg15485101	chr11:133734466	NA	0.5	6.34	0.46	2.53e-9	Childhood ear infection;
PAAD	cis	rs227833	0.826	rs4714813	chr6:44709890	C/A	cg18551225	chr6:44695536	NA	0.44	4.5	0.34	1.37e-5	Monobrow;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.48	6.43	0.46	1.53e-9	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.62	-0.41	8.77e-8	Vitiligo;
PAAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14019695	chr9:139328340	INPP5E	0.58	5.07	0.38	1.14e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.75	-7.9	-0.54	5.15e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.86	11.07	0.67	2.95e-21	Methadone dose in opioid dependence;
PAAD	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg07943548	chr15:86304357	KLHL25	-0.74	-6.09	-0.44	8.64e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	1.04	12.65	0.72	1.64e-25	Breast cancer;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg02071572	chr4:1403502	NA	0.46	5.68	0.42	6.57e-8	Obesity-related traits;
PAAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.6	4.83	0.36	3.31e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg21466736	chr12:48725269	NA	-0.5	-4.65	-0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.84	9.23	0.6	2.15e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2120991	0.967	rs10783611	chr12:54258980	G/A	cg23795217	chr12:54812000	ITGA5	-0.3	-4.35	-0.33	2.51e-5	Biliary atresia;
PAAD	trans	rs6892884	0.807	rs1030677	chr5:170998981	C/G	cg25792990	chr1:229569965	ACTA1	-0.62	-6.42	-0.46	1.64e-9	Height;
PAAD	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.08	0.55	1.91e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.31	0.33	2.9e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	1.1	8.2	0.55	9.25e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.71	7.4	0.51	8.53e-12	Osteoporosis;
PAAD	cis	rs3026101	0.578	rs59605950	chr17:5303493	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.89	0.43	2.42e-8	Body mass index;
PAAD	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg15226275	chr6:116381976	FRK	0.27	4.42	0.34	1.86e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg24747557	chr10:131355152	MGMT	-0.45	-4.9	-0.37	2.43e-6	Response to temozolomide;
PAAD	cis	rs2275731	0.749	rs10795400	chr10:16535888	G/A	cg04254609	chr10:16479192	PTER	-0.6	-6.3	-0.46	3e-9	Bone fracture in osteoporosis;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23708337	chr7:1209742	NA	0.46	4.84	0.37	3.12e-6	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	0.744	rs72952257	chr6:74924073	A/G	cg03266952	chr6:74778945	NA	-1.17	-6.5	-0.47	1.1e-9	Metabolite levels (MHPG);
PAAD	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-12.3	-0.71	1.39e-24	Primary sclerosing cholangitis;
PAAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg18005901	chr6:33739558	LEMD2	-0.57	-4.57	-0.35	1e-5	Schizophrenia;
PAAD	cis	rs54211	0.731	rs137663	chr22:39734668	G/T	cg11247378	chr22:39784982	NA	-0.77	-4.47	-0.34	1.51e-5	Sudden cardiac arrest;
PAAD	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.51	5.39	0.4	2.65e-7	Bladder cancer;
PAAD	cis	rs2882667	0.690	rs9327826	chr5:138182007	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.06e-7	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg14580859	chr9:123691850	NA	0.38	4.32	0.33	2.76e-5	Rheumatoid arthritis;
PAAD	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-1.13	-12.51	-0.71	3.99e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs9810890	1.000	rs73198827	chr3:128489521	G/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.88	-11.1	-0.67	2.49e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58521262	0.556	rs289322	chr19:23157270	G/T	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	14.41	0.76	3.17e-30	Prudent dietary pattern;
PAAD	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.52	-0.34	1.24e-5	Arsenic metabolism;
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.75	7.78	0.53	1.01e-12	Height;
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg23463467	chr20:60627584	TAF4	0.46	5.0	0.38	1.56e-6	Body mass index;
PAAD	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.78	-0.36	4.05e-6	Biliary atresia;
PAAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg07701084	chr6:150067640	NUP43	0.75	8.43	0.56	2.5e-14	Lung cancer;
PAAD	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.67	-7.01	-0.49	7.2e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.69	-7.98	-0.54	3.31e-13	Educational attainment;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.56	5.69	0.42	6.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg24633833	chr3:10029261	TMEM111	0.58	4.27	0.33	3.41e-5	Alzheimer's disease;
PAAD	cis	rs11563648	0.517	rs2269729	chr7:127032663	A/T	cg21885361	chr7:127911034	NA	-0.42	-4.49	-0.34	1.41e-5	Resting heart rate;
PAAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.26	0.33	3.59e-5	Breast cancer;
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.73	0.62	1.08e-17	Menopause (age at onset);
PAAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg02117656	chr17:79614917	TSPAN10	0.54	5.43	0.4	2.17e-7	Eye color traits;
PAAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg19680485	chr15:31195859	MTMR15	-0.45	-4.34	-0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-4.25	-0.33	3.65e-5	Lung cancer;
PAAD	cis	rs7688540	0.511	rs61794965	chr4:171669	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.55	4.55	0.35	1.08e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.58	6.43	0.46	1.6e-9	Systemic lupus erythematosus;
PAAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	11.15	0.67	1.78e-21	Smoking behavior;
PAAD	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.01	0.54	2.85e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.92	-8.11	-0.55	1.54e-13	Ankle injury;
PAAD	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg05555928	chr11:63887634	MACROD1	-0.53	-4.28	-0.33	3.29e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.11	14.31	0.76	5.84e-30	Body mass index;
PAAD	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs79839061	0.636	rs76839318	chr4:837810	T/A	cg07828340	chr4:882639	GAK	1.29	6.79	0.48	2.37e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.88	5.98	0.44	1.55e-8	Thyroid stimulating hormone;
PAAD	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26378065	chr17:18585709	ZNF286B	0.46	4.43	0.34	1.8e-5	Educational attainment (years of education);
PAAD	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.56	5.71	0.42	5.71e-8	Testicular germ cell tumor;
PAAD	cis	rs6594713	0.851	rs13171482	chr5:112701966	G/A	cg12552261	chr5:112820674	MCC	0.65	5.22	0.39	5.9e-7	Brain cytoarchitecture;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.41	-4.56	-0.35	1.03e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	0.91	5.5	0.41	1.57e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.52	-5.38	-0.4	2.81e-7	Schizophrenia;
PAAD	cis	rs939584	0.935	rs10166979	chr2:640701	A/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.58	4.68	0.35	6.38e-6	Schizophrenia;
PAAD	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8077577	0.708	rs4450455	chr17:18140447	A/G	cg16794390	chr17:18148240	FLII	-0.53	-4.6	-0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.8	-7.81	-0.54	8.69e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs6494488	0.500	rs72741307	chr15:64700223	G/A	cg16425858	chr15:64791681	ZNF609	1.08	4.99	0.38	1.61e-6	Coronary artery disease;
PAAD	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs11638815	0.626	rs4779039	chr15:83317767	C/G	cg00614314	chr15:82944287	LOC80154	-0.48	-4.77	-0.36	4.28e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs4792901	0.802	rs28608935	chr17:41609470	G/A	cg05614735	chr17:40936078	WNK4	-0.37	-4.34	-0.33	2.6e-5	Dupuytren's disease;
PAAD	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.67	4.53	0.34	1.2e-5	Lung cancer in ever smokers;
PAAD	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg08501292	chr6:25962987	TRIM38	0.99	5.84	0.43	3e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.28	-4.3	-0.33	3.06e-5	Longevity;Endometriosis;
PAAD	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	1.18	6.93	0.49	1.1e-10	Cannabis dependence symptom count;
PAAD	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.75	-5.46	-0.41	1.86e-7	Mosquito bite size;
PAAD	cis	rs2278796	0.639	rs6697344	chr1:204971485	G/T	cg04862289	chr1:204966208	NFASC	0.5	5.18	0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.51	0.57	1.52e-14	Alzheimer's disease;
PAAD	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7301016	0.948	rs73141045	chr12:62931083	C/G	cg19781863	chr12:62918364	MON2	0.74	4.37	0.33	2.28e-5	IgG glycosylation;
PAAD	cis	rs8126001	0.573	rs6090043	chr20:62717930	C/T	cg14436426	chr20:62712394	OPRL1;RGS19	0.41	4.41	0.34	1.98e-5	Pulse pressure;Mean corpuscular volume;
PAAD	cis	rs6893807	0.778	rs7703782	chr5:87938557	A/T	cg02225085	chr5:87975992	LOC645323	-0.68	-5.07	-0.38	1.14e-6	Body mass index;
PAAD	cis	rs12760731	0.623	rs12045201	chr1:178399218	A/G	cg00404053	chr1:178313656	RASAL2	0.66	5.64	0.42	7.88e-8	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.69	-0.48	4.03e-10	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09804833	chr16:21964504	UQCRC2	-0.65	-7.02	-0.49	6.94e-11	Smoking initiation;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.65	7.07	0.5	5.18e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.55	5.9	0.43	2.29e-8	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg21479132	chr6:26055353	NA	0.92	5.2	0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg01304814	chr3:48885189	PRKAR2A	0.89	4.64	0.35	7.33e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.48	5.05	0.38	1.23e-6	Male-pattern baldness;
PAAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	5.01	0.38	1.48e-6	Yeast infection;
PAAD	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg19630374	chr17:18023558	MYO15A	-0.57	-5.92	-0.43	2.07e-8	Total body bone mineral density;
PAAD	cis	rs3736485	0.934	rs17609924	chr15:51911592	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.13e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1198430	0.562	rs7523811	chr1:23789567	C/T	cg27447006	chr1:23763279	ASAP3	-0.66	-5.81	-0.43	3.6e-8	Total cholesterol levels;
PAAD	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg10729496	chr3:10149963	C3orf24	-0.78	-6.3	-0.46	3e-9	Alzheimer's disease;
PAAD	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.27	-0.45	3.5e-9	Mood instability;
PAAD	trans	rs17073641	0.500	rs7227579	chr18:62458254	C/T	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.88	8.1	0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.61	6.34	0.46	2.47e-9	Testicular germ cell tumor;
PAAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.52	-5.64	-0.42	8.18e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-5.24	-0.39	5.39e-7	Vitiligo;
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.69	-6.83	-0.48	1.88e-10	Blood metabolite levels;
PAAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg19774624	chr17:42201019	HDAC5	0.87	10.8	0.66	1.58e-20	Total body bone mineral density;
PAAD	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.54	5.71	0.42	5.67e-8	Menopause (age at onset);
PAAD	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.71	6.02	0.44	1.25e-8	Bone mineral density;
PAAD	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	4.83	0.36	3.32e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg24220031	chr2:73402428	NA	-0.33	-4.54	-0.35	1.14e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1144333	0.655	rs76416835	chr1:76341511	G/T	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs7873102	0.654	rs10814642	chr9:38015037	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.01	-0.38	1.52e-6	Brain structure;
PAAD	cis	rs58521262	0.585	rs2645875	chr19:23192711	T/A	cg02350677	chr19:23254381	NA	0.26	4.51	0.34	1.3e-5	Testicular germ cell tumor;
PAAD	cis	rs2131877	0.701	rs61231387	chr3:194832120	G/T	cg24618514	chr3:194868507	C3orf21	0.5	4.75	0.36	4.58e-6	Non-small cell lung cancer;
PAAD	trans	rs9372498	1.000	rs17422275	chr6:118611041	A/G	cg15607664	chr12:57630422	NDUFA4L2	-0.78	-7.56	-0.52	3.64e-12	Diastolic blood pressure;
PAAD	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.74e-5	Bipolar disorder;
PAAD	cis	rs7213347	1.000	rs7213347	chr17:2153257	G/C	cg15816464	chr17:2026533	SMG6	0.47	5.23	0.39	5.51e-7	Total body bone mineral density;
PAAD	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.65	-4.64	-0.35	7.47e-6	Pulse pressure;
PAAD	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg25204440	chr1:209979598	IRF6	0.63	5.68	0.42	6.64e-8	Coronary artery disease;
PAAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-4.31	-0.33	2.96e-5	Educational attainment;
PAAD	cis	rs4676482	0.577	rs17038576	chr3:39261375	C/T	cg02254461	chr3:39195904	CSRNP1	-0.7	-5.17	-0.39	7.26e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01573938	chr5:131347556	ACSL6	-0.66	-6.61	-0.47	6.24e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.69	-6.36	-0.46	2.22e-9	DNA methylation (variation);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13205578	chr10:52382136	SGMS1	-0.67	-6.47	-0.46	1.26e-9	Neuroticism;
PAAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.62	5.79	0.43	3.86e-8	Prostate cancer;
PAAD	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-5.04	-0.38	1.29e-6	Schizophrenia;
PAAD	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.98	11.53	0.68	1.66e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.57	-5.83	-0.43	3.24e-8	Schizophrenia;
PAAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.77	7.07	0.5	5.27e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.48	4.61	0.35	8.6e-6	Type 2 diabetes;
PAAD	cis	rs990171	0.538	rs4851017	chr2:103120769	C/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg24253500	chr15:84953950	NA	-0.42	-4.42	-0.34	1.87e-5	Schizophrenia;
PAAD	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg12658694	chr1:38397304	INPP5B	-0.82	-9.69	-0.62	1.4e-17	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09220393	chr16:1703475	CRAMP1L	-0.68	-6.54	-0.47	8.98e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs12760731	0.565	rs34303391	chr1:178178126	T/A	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.32	-0.33	2.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62392365	0.615	rs80021880	chr6:25194261	T/C	cg26336265	chr6:25042955	NA	0.67	4.69	0.36	6.05e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09059670	chr5:79552137	SERINC5	0.56	6.67	0.48	4.44e-10	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.56	5.1	0.38	1.02e-6	Monocyte count;
PAAD	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.54	4.99	0.37	1.66e-6	Resting heart rate;
PAAD	cis	rs1620921	0.505	rs11756434	chr6:161201356	T/C	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.85	0.62	5.22e-18	Prudent dietary pattern;
PAAD	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg25452165	chr22:42524984	CYP2D6	0.54	5.1	0.38	1.01e-6	Schizophrenia;
PAAD	cis	rs3112530	1.000	rs2615178	chr5:152700033	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.84	4.46	0.34	1.59e-5	Aging (time to event);
PAAD	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	9.86	0.62	4.99e-18	Smoking behavior;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg08888203	chr3:10149979	C3orf24	-0.66	-5.98	-0.44	1.54e-8	Alzheimer's disease;
PAAD	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.74	5.59	0.41	1e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13560548	chr3:10150139	C3orf24	0.62	5.58	0.41	1.05e-7	Alzheimer's disease;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.62	6.68	0.48	4.17e-10	Lung cancer;
PAAD	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.93	7.34	0.51	1.22e-11	Bipolar disorder;
PAAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.64	6.8	0.48	2.22e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.37	0.33	2.25e-5	Cancer;
PAAD	cis	rs1334894	0.901	rs12528458	chr6:35505311	C/T	cg07213720	chr6:35227408	ZNF76	-0.8	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	1.25	7.74	0.53	1.32e-12	Skin colour saturation;
PAAD	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-1.13	-7.47	-0.52	5.81e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.18	0.45	5.74e-9	Coffee consumption (cups per day);
PAAD	cis	rs9903692	0.505	rs208008	chr17:46230838	C/T	cg10706073	chr17:46328419	SKAP1	0.97	5.93	0.43	1.98e-8	Pulse pressure;
PAAD	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.8	10.0	0.63	2.1e-18	Height;
PAAD	cis	rs3764400	0.567	rs36071506	chr17:46279772	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs72827839	0.793	rs72823527	chr17:46098810	G/T	cg23391107	chr17:45924227	SP6	0.62	5.43	0.4	2.22e-7	Ease of getting up in the morning;
PAAD	cis	rs716804	0.592	rs10770106	chr11:10312077	A/C	cg01453529	chr11:10209919	SBF2	-0.88	-4.68	-0.36	6.25e-6	Neuroticism;
PAAD	cis	rs28374715	0.510	rs28468975	chr15:41564592	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-6.91	-0.49	1.23e-10	Ulcerative colitis;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18297960	chr7:1142765	C7orf50	-0.58	-4.32	-0.33	2.75e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.51	0.71	3.99e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	5.1	0.38	9.85e-7	Prudent dietary pattern;
PAAD	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs1371614	0.566	rs10184824	chr2:27177952	C/A	cg00617064	chr2:27272375	NA	0.44	4.58	0.35	9.51e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg16576597	chr16:28551801	NUPR1	0.68	7.7	0.53	1.57e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.78	10.14	0.64	8.85e-19	Vitiligo;
PAAD	cis	rs3931020	0.720	rs1327090	chr1:75266479	G/A	cg26752657	chr1:75199075	CRYZ;TYW3	0.49	4.81	0.36	3.63e-6	Resistin levels;
PAAD	cis	rs829661	0.843	rs829617	chr2:30748039	T/C	cg12454169	chr2:30669597	LCLAT1	0.59	4.25	0.33	3.72e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs3112530	0.901	rs172569	chr5:152718705	T/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2839627	0.638	rs9974287	chr21:44317003	T/G	cg03543861	chr21:44258195	NA	0.66	4.81	0.36	3.65e-6	Information processing speed;
PAAD	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.64	0.47	5.29e-10	Lung cancer in ever smokers;
PAAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.58	6.66	0.48	4.71e-10	Major depressive disorder;
PAAD	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg16576597	chr16:28551801	NUPR1	-0.55	-5.23	-0.39	5.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.9	-10.44	-0.65	1.38e-19	Total body bone mineral density;
PAAD	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg15117754	chr3:10150083	C3orf24	0.69	6.02	0.44	1.26e-8	Alzheimer's disease;
PAAD	cis	rs2479106	0.791	rs4838083	chr9:126714308	A/C	cg16191174	chr9:126692580	DENND1A	-0.47	-4.38	-0.33	2.19e-5	Polycystic ovary syndrome;
PAAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg12215294	chr3:40350768	EIF1B	-0.47	-4.73	-0.36	4.98e-6	Renal cell carcinoma;
PAAD	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg10818794	chr15:86012489	AKAP13	-0.46	-5.01	-0.38	1.52e-6	Interstitial lung disease;
PAAD	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-7.98	-0.54	3.34e-13	Hemoglobin concentration;
PAAD	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg22153463	chr1:85462885	MCOLN2	0.72	5.34	0.4	3.27e-7	Serum sulfate level;
PAAD	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01616529	chr11:638424	DRD4	-0.62	-5.82	-0.43	3.39e-8	Systemic lupus erythematosus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07907998	chr16:27561398	GTF3C1;KIAA0556	-0.67	-6.7	-0.48	3.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7511006	0.893	rs2272854	chr22:50658274	C/G	cg16473166	chr22:50639996	SELO	0.65	6.31	0.46	2.97e-9	Obesity-related traits;
PAAD	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-9.58	-0.61	2.62e-17	Height;
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.58	6.25	0.45	3.85e-9	Lung cancer;
PAAD	cis	rs282587	0.569	rs282594	chr13:113379640	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-6.57	-0.47	7.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg19008133	chr3:123124015	ADCY5	0.67	4.76	0.36	4.54e-6	LDL cholesterol levels;
PAAD	cis	rs1468734	0.929	rs3890988	chr16:5006210	G/A	cg06510647	chr16:5006106	NA	0.61	5.69	0.42	6.3e-8	Cancer;
PAAD	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.4	-0.4	2.53e-7	Blood metabolite levels;
PAAD	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg07617317	chr6:118971624	C6orf204	0.55	4.56	0.35	1.05e-5	Diastolic blood pressure;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.52	0.52	4.55e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-4.75	-0.36	4.74e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs11252688	1.000	rs11252682	chr10:4769161	T/C	cg22861794	chr10:5032070	AKR1C2	0.79	4.45	0.34	1.64e-5	Major depressive disorder;
PAAD	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2754412	1	rs2754412	chr10:38627834	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-7.24	-0.51	2.05e-11	Breast cancer;
PAAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg15017067	chr4:17643749	FAM184B	-0.47	-5.66	-0.42	7.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg02997394	chr19:33096574	ANKRD27	-0.44	-4.85	-0.37	3e-6	Schizophrenia;
PAAD	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13198984	chr17:80129470	CCDC57	-0.43	-5.47	-0.41	1.82e-7	Life satisfaction;
PAAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.08	0.38	1.1e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg21419209	chr3:44054225	NA	0.69	6.83	0.48	1.87e-10	Coronary artery disease;
PAAD	cis	rs1178968	0.901	rs1178970	chr7:72750345	G/A	cg25889504	chr7:72793014	NA	0.58	4.26	0.33	3.59e-5	Triglyceride levels;
PAAD	cis	rs2080501	0.628	rs28542020	chr16:49660588	T/C	cg27618369	chr16:49636483	ZNF423	0.54	5.57	0.41	1.13e-7	IgG glycosylation;
PAAD	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.85	-9.29	-0.6	1.53e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs4742903	0.904	rs10123189	chr9:107000640	A/G	cg14250997	chr9:106856677	SMC2	0.45	4.83	0.37	3.24e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.3e-6	Height;
PAAD	cis	rs746265	0.818	rs11631702	chr15:39580746	A/G	cg10099207	chr15:39544144	C15orf54	0.57	4.37	0.33	2.3e-5	PR interval;
PAAD	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg07841815	chr7:100318223	EPO	0.45	4.46	0.34	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg00717180	chr2:96193071	NA	-0.62	-7.7	-0.53	1.63e-12	Coronary artery disease;
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg04154034	chr17:28927549	LRRC37B2	0.64	4.27	0.33	3.45e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2274459	0.722	rs9461896	chr6:33649697	C/T	cg06253072	chr6:33679850	C6orf125	0.6	4.98	0.37	1.74e-6	Obesity (extreme);
PAAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	4.47	0.34	1.53e-5	IgG glycosylation;
PAAD	cis	rs11105468	0.701	rs10858943	chr12:90418122	A/G	cg16962463	chr12:89968675	NA	-0.45	-4.36	-0.33	2.4e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs4455778	0.580	rs10257863	chr7:49092400	C/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs12431939	0.947	rs68180359	chr14:51672027	G/A	cg23942311	chr14:51606299	NA	-0.71	-5.71	-0.42	5.75e-8	Cancer;
PAAD	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.52	-5.3	-0.4	3.98e-7	IgG glycosylation;
PAAD	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg27499820	chr13:21296301	IL17D	0.55	5.13	0.38	8.62e-7	Dental caries;
PAAD	cis	rs13100165	1.000	rs4676909	chr3:73275145	A/G	cg07385778	chr3:72320634	NA	-0.28	-4.44	-0.34	1.7e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg13332499	chr17:408570	NA	0.54	5.03	0.38	1.35e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1358748	0.522	rs4655676	chr1:67580054	C/T	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.7	6.95	0.49	1.01e-10	Lymphocyte counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21415305	chr3:9851855	TTLL3	-0.77	-6.48	-0.47	1.23e-9	Neuroticism;
PAAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.74	-8.36	-0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs11958404	0.615	rs10475649	chr5:157447301	T/C	cg05962755	chr5:157440814	NA	0.56	5.37	0.4	2.87e-7	IgG glycosylation;
PAAD	cis	rs2415984	0.783	rs1353190	chr14:46952601	C/T	cg14871534	chr14:47121158	RPL10L	0.45	4.6	0.35	8.99e-6	Number of children ever born;
PAAD	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19671926	chr4:122722719	EXOSC9	0.61	5.87	0.43	2.58e-8	Type 2 diabetes;
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.19	0.5	2.75e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.3	-0.33	3.08e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04876069	chr12:132293656	NA	-0.5	-5.23	-0.39	5.5e-7	Migraine;
PAAD	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg05347473	chr6:146136440	FBXO30	0.53	5.09	0.38	1.03e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1941184	0.759	rs7236759	chr18:29025230	A/G	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.58	6.73	0.48	3.3e-10	Schizophrenia;
PAAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs12760731	0.623	rs16852708	chr1:178308249	T/G	cg00404053	chr1:178313656	RASAL2	0.65	5.2	0.39	6.41e-7	Obesity-related traits;
PAAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	6.7	0.48	3.89e-10	Monocyte count;
PAAD	cis	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs11958404	0.517	rs35714701	chr5:157302862	T/C	cg05962755	chr5:157440814	NA	0.78	5.08	0.38	1.09e-6	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs1006703	0.544	rs7220897	chr17:3837643	A/G	cg06463185	chr17:3833770	ATP2A3	-0.92	-7.52	-0.52	4.49e-12	Glucose homeostasis traits;
PAAD	cis	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg00614314	chr15:82944287	LOC80154	-0.41	-4.25	-0.33	3.74e-5	Schizophrenia;
PAAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.64	6.04	0.44	1.12e-8	Menopause (age at onset);
PAAD	cis	rs608114	0.793	rs73557975	chr6:96356655	T/C	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg07212818	chr11:638076	DRD4	-0.7	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.69	7.46	0.52	6.33e-12	Lung cancer;
PAAD	cis	rs4946900	0.925	rs9372181	chr6:108416483	A/G	cg15416877	chr6:108492769	NR2E1	0.42	4.82	0.36	3.48e-6	Major depressive disorder;
PAAD	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs377457	0.623	rs4565	chr16:85711411	C/G	cg02758499	chr16:85682440	KIAA0182	0.36	4.25	0.33	3.65e-5	Type 2 diabetes;
PAAD	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg26528668	chr16:1614120	IFT140	0.53	4.95	0.37	1.94e-6	Coronary artery disease;
PAAD	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.76	0.36	4.51e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.84	0.48	1.84e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg24846680	chr1:228362309	C1orf69	0.45	4.29	0.33	3.18e-5	Diastolic blood pressure;
PAAD	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07099627	chr19:11466020	LPPR2	-0.73	-6.29	-0.45	3.15e-9	Neuroticism;
PAAD	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1023500	1.000	rs1023500	chr22:42340844	C/T	cg25452165	chr22:42524984	CYP2D6	0.57	4.34	0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.37	0.4	2.84e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6681460	0.549	rs7537440	chr1:67031907	A/C	cg02459107	chr1:67143332	SGIP1	0.66	7.1	0.5	4.42e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs2290419	0.614	rs115322032	chr11:68943863	T/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.71	0.62	1.22e-17	Prudent dietary pattern;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg24053715	chr22:38214548	NA	-0.5	-5.09	-0.38	1.05e-6	Glioblastoma;Glioma;
PAAD	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00933542	chr6:150070202	PCMT1	0.59	6.15	0.45	6.65e-9	Lung cancer;
PAAD	cis	rs501120	1.000	rs670056	chr10:44753375	C/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.55	5.11	0.38	9.64e-7	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07961406	chr16:67193646	FBXL8;TRADD	0.67	6.58	0.47	7.01e-10	Obesity-related traits;
PAAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.56	-5.67	-0.42	7.11e-8	P wave terminal force;
PAAD	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-4.55	-0.35	1.1e-5	Tonsillectomy;
PAAD	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg11062466	chr8:58055876	NA	0.68	4.8	0.36	3.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.07e-8	Platelet count;
PAAD	trans	rs901683	1.000	rs71496622	chr10:46081588	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs375066	0.935	rs430308	chr19:44400375	C/G	cg08633290	chr19:44405433	NA	-0.54	-5.3	-0.4	3.92e-7	Breast cancer;
PAAD	cis	rs9682041	0.627	rs3772173	chr3:170078232	C/T	cg11886554	chr3:170076028	SKIL	0.65	4.84	0.37	3.21e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.89	-8.93	-0.59	1.34e-15	Asthma;
PAAD	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.66	-6.19	-0.45	5.23e-9	Platelet distribution width;
PAAD	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs75920871	0.925	rs11826651	chr11:116920693	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	1.2	13.21	0.73	4.96e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg23283495	chr1:209979779	IRF6	0.67	5.71	0.42	5.73e-8	Coronary artery disease;
PAAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg02135003	chr7:105160482	PUS7	-0.73	-5.79	-0.42	3.95e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.83	7.34	0.51	1.23e-11	Alzheimer's disease;
PAAD	cis	rs202065757	1	rs202065757	chr6:28766359	C/CAT	cg12740337	chr6:28058973	ZSCAN12L1	0.56	4.69	0.36	5.94e-6	Tuberculosis;
PAAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg23346134	chr3:49453900	TCTA	0.45	4.87	0.37	2.75e-6	Menarche (age at onset);
PAAD	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg00666640	chr1:248458726	OR2T12	0.6	4.88	0.37	2.63e-6	Common traits (Other);
PAAD	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.44	-0.34	1.74e-5	Lung cancer in ever smokers;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01874084	chr12:56320851	WIBG	-0.65	-6.32	-0.46	2.75e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.82	8.47	0.57	1.92e-14	Cognitive function;
PAAD	cis	rs2976388	0.507	rs13279795	chr8:143838669	G/A	cg02415014	chr8:143852576	LYNX1	-0.41	-5.11	-0.38	9.64e-7	Urinary tract infection frequency;
PAAD	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg02683114	chr2:24398427	C2orf84	-0.54	-5.15	-0.39	8.06e-7	Asthma;
PAAD	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.82	8.37	0.56	3.57e-14	Uric acid levels;
PAAD	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.64	5.31	0.4	3.77e-7	Prostate cancer;
PAAD	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.74	-4.84	-0.37	3.18e-6	Anti-saccade response;
PAAD	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-8.73	-0.58	4.37e-15	Chronic sinus infection;
PAAD	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	trans	rs72828912	0.634	rs9358743	chr6:24047987	C/T	cg10859177	chr4:189973211	NA	0.74	6.87	0.49	1.51e-10	Squamous cell lung carcinoma;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25589945	chr2:46429383	NA	0.63	6.51	0.47	1.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg19423196	chr10:82049429	MAT1A	0.61	4.69	0.36	6.03e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01806965	chr8:144378397	ZNF696	0.55	6.31	0.46	2.95e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg17507749	chr15:85114479	UBE2QP1	0.52	4.95	0.37	1.92e-6	P wave terminal force;
PAAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.45	0.34	1.64e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg01851573	chr8:8652454	MFHAS1	0.49	4.77	0.36	4.23e-6	Mood instability;
PAAD	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg16342193	chr10:102329863	NA	-0.77	-8.51	-0.57	1.55e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9815354	0.953	rs13088394	chr3:41951715	G/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.78	-0.42	4.13e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.54	6.01	0.44	1.33e-8	Heart rate;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.31	-0.46	2.88e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.52	-0.41	1.45e-7	Adiposity;
PAAD	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.63	6.12	0.44	7.66e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.79	8.94	0.59	1.24e-15	DNA methylation (variation);
PAAD	cis	rs7539409	0.831	rs6576940	chr1:84220236	C/T	cg10977910	chr1:84465055	TTLL7	-1.04	-6.15	-0.45	6.5e-9	Alzheimer's disease;
PAAD	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg02670123	chr2:173330395	ITGA6	0.22	4.28	0.33	3.31e-5	Myopia;
PAAD	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.45	-4.54	-0.35	1.12e-5	Dementia with Lewy bodies;
PAAD	cis	rs2061333	0.557	rs8104573	chr19:44603385	A/G	cg18700516	chr19:44507157	ZNF230	-0.8	-5.42	-0.4	2.25e-7	Alzheimer's disease;
PAAD	cis	rs7584330	0.554	rs57140815	chr2:238428330	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.15	0.39	7.92e-7	Prostate cancer;
PAAD	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg13722127	chr7:150037890	RARRES2	0.69	6.91	0.49	1.26e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4795519	0.845	rs34060970	chr17:22194839	A/G	cg22648282	chr17:21454238	C17orf51	-0.56	-5.64	-0.42	7.9e-8	Chronic myeloid leukemia;
PAAD	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-8.9	-0.59	1.53e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer;
PAAD	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.49	0.47	1.13e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg04632378	chr13:21900426	NA	0.7	8.01	0.54	2.82e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.39	-0.34	2.12e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2694528	0.544	rs6449481	chr5:59911179	G/C	cg11474532	chr5:59995715	DEPDC1B	0.95	5.28	0.39	4.42e-7	Parkinson's disease;
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.63	-5.85	-0.43	2.84e-8	Total body bone mineral density;
PAAD	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.4	0.34	2.02e-5	Asthma;
PAAD	cis	rs13242816	1.000	rs56275709	chr7:116108489	A/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.54e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg13565585	chr5:132299512	AFF4	0.6	4.36	0.33	2.38e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.73	8.56	0.57	1.18e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.1	0.44	8.58e-9	Coffee consumption (cups per day);
PAAD	cis	rs3764400	0.508	rs1473117	chr17:46092539	C/T	cg10706073	chr17:46328419	SKAP1	-0.86	-5.55	-0.41	1.23e-7	Body mass index;
PAAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg19630374	chr17:18023558	MYO15A	-0.46	-4.79	-0.36	4e-6	Total body bone mineral density;
PAAD	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg13385521	chr17:29058706	SUZ12P	-0.7	-4.82	-0.36	3.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	4.36	0.33	2.42e-5	Schizophrenia;
PAAD	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10090774	0.932	rs9644449	chr8:141947285	T/C	cg02508881	chr8:142216119	NA	-0.41	-4.28	-0.33	3.28e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25503001	chr13:21476923	XPO4	-0.62	-6.61	-0.47	5.99e-10	Warfarin maintenance dose;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.26	0.39	4.72e-7	Prudent dietary pattern;
PAAD	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg06217071	chr17:408420	NA	0.78	8.86	0.58	1.94e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg06917634	chr15:78832804	PSMA4	-0.47	-4.6	-0.35	8.98e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7301826	0.571	rs4759788	chr12:131296314	T/C	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09826364	chr7:158789723	NA	-0.4	-5.14	-0.38	8.25e-7	Facial morphology (factor 20);
PAAD	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.36	0.33	2.34e-5	Lung cancer in ever smokers;
PAAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg01075559	chr1:2537774	MMEL1	-0.5	-5.35	-0.4	3.18e-7	Ulcerative colitis;
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.76	0.48	2.76e-10	Schizophrenia;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	5.41	0.4	2.43e-7	Calcium levels;
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg13444538	chr7:158905317	VIPR2	0.53	4.99	0.38	1.65e-6	Facial morphology (factor 20);
PAAD	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.1	-0.38	9.81e-7	Systolic blood pressure;
PAAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.58	4.76	0.36	4.39e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs75920871	0.764	rs61903394	chr11:116931898	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg02462569	chr6:150064036	NUP43	-0.51	-5.68	-0.42	6.62e-8	Lung cancer;
PAAD	trans	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg00717180	chr2:96193071	NA	-0.62	-6.48	-0.47	1.19e-9	Migraine - clinic-based;
PAAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	4.86	0.37	2.84e-6	Menarche (age at onset);
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.68	7.38	0.51	9.78e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2448490	0.642	rs535111	chr11:65485337	A/G	cg01098237	chr11:65601417	SNX32	-0.39	-4.26	-0.33	3.52e-5	Platelet count;
PAAD	cis	rs67072384	0.688	rs66948758	chr11:72440074	A/G	cg04827223	chr11:72435913	ARAP1	-0.54	-4.25	-0.33	3.66e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
PAAD	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-4.49	-0.34	1.39e-5	Dental caries;
PAAD	cis	rs12935418	0.583	rs7206625	chr16:80964433	G/A	cg16651780	chr16:81037892	C16orf61	0.54	4.6	0.35	8.92e-6	Mean corpuscular volume;
PAAD	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.81	10.15	0.64	8.44e-19	Blood metabolite levels;
PAAD	cis	rs4845552	1.000	rs4845553	chr1:153480173	G/A	cg15998505	chr1:153479701	NA	-0.49	-4.39	-0.34	2.15e-5	Hippocampal atrophy;
PAAD	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg11367502	chr7:22862612	TOMM7	0.51	5.04	0.38	1.3e-6	Fibrinogen;
PAAD	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg27365978	chr10:106093659	ITPRIP	-0.5	-4.85	-0.37	3.08e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.9	-9.0	-0.59	8.47e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.97	12.47	0.71	5.08e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.78	8.76	0.58	3.54e-15	Heart rate;
PAAD	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg20045696	chr14:77926864	AHSA1	-0.76	-5.54	-0.41	1.33e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
PAAD	cis	rs7567389	0.637	rs4150421	chr2:128044930	A/G	cg11380483	chr2:127933992	NA	-0.47	-4.67	-0.35	6.58e-6	Self-rated health;
PAAD	cis	rs6141769	0.542	rs6057627	chr20:31306728	C/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs922692	0.967	rs11633351	chr15:79056815	C/T	cg00540400	chr15:79124168	NA	-0.43	-4.69	-0.36	5.92e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16993684	chr20:57466131	GNAS	-0.67	-6.75	-0.48	2.99e-10	Smoking initiation;
PAAD	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg12486944	chr17:80159399	CCDC57	-0.51	-4.52	-0.34	1.21e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg03808351	chr9:123631620	PHF19	0.46	4.91	0.37	2.29e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg02135003	chr7:105160482	PUS7	-0.7	-6.15	-0.45	6.59e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs35955747	0.714	rs5997989	chr22:31839950	T/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.03	-0.38	1.38e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09633973	chr17:1957365	HIC1	0.63	6.65	0.47	4.86e-10	Obesity-related traits;
PAAD	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg15192750	chr16:69999425	NA	0.77	5.93	0.43	1.96e-8	IgE levels;
PAAD	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9039	1.000	rs12924275	chr16:9191790	C/T	cg08831531	chr16:9218945	NA	-0.67	-6.63	-0.47	5.47e-10	Menopause (age at onset);
PAAD	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.95	-10.33	-0.64	2.85e-19	Corneal astigmatism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05424527	chr16:84485599	ATP2C2	0.52	6.4	0.46	1.79e-9	Smoking initiation;
PAAD	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.18	-0.39	6.82e-7	Monocyte percentage of white cells;
PAAD	cis	rs7095944	0.552	rs12764568	chr10:126544646	A/T	cg08799069	chr10:126477246	METTL10	-0.45	-4.27	-0.33	3.43e-5	Asthma;
PAAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.76	-8.52	-0.57	1.45e-14	Childhood ear infection;
PAAD	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.29	-0.33	3.15e-5	Joint mobility (Beighton score);
PAAD	cis	rs60154123	0.504	rs4844997	chr1:210486895	A/G	cg21951975	chr1:209979733	IRF6	0.53	4.85	0.37	3.04e-6	Coronary artery disease;
PAAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04362095	chr11:63592001	C11orf84	-0.51	-4.69	-0.36	6.06e-6	Platelet count;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.51	5.25	0.39	4.97e-7	Interleukin-18 levels;
PAAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.53	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs7916697	0.947	rs56238729	chr10:70001640	T/C	cg18338521	chr10:69995036	NA	-0.4	-5.15	-0.39	7.78e-7	Optic disc area;
PAAD	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6681460	0.546	rs4143025	chr1:67167548	A/G	cg02459107	chr1:67143332	SGIP1	-0.59	-5.65	-0.42	7.8e-8	Presence of antiphospholipid antibodies;
PAAD	cis	rs11825685	0.607	rs61327677	chr11:134552340	C/A	cg06603561	chr11:134479413	NA	-0.66	-4.97	-0.37	1.82e-6	IgG glycosylation;
PAAD	cis	rs75920871	0.920	rs7924318	chr11:116816630	C/G	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.75	-5.29	-0.39	4.24e-7	Carotid intima media thickness;
PAAD	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.48	-4.5	-0.34	1.34e-5	Triglycerides;
PAAD	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg09597638	chr17:3907349	NA	0.9	10.12	0.63	1.01e-18	Type 2 diabetes;
PAAD	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg24747557	chr10:131355152	MGMT	-0.44	-4.74	-0.36	4.78e-6	Response to temozolomide;
PAAD	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.55	-6.06	-0.44	1.04e-8	Body mass index;
PAAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.54	-4.63	-0.35	7.76e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.11	-0.38	9.39e-7	Systemic lupus erythematosus;
PAAD	cis	rs282587	0.502	rs282603	chr13:113393984	G/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs2153904	1.000	rs2153904	chr1:205642790	A/C	cg23034840	chr1:205782522	SLC41A1	0.58	4.77	0.36	4.24e-6	Prostate-specific antigen levels;
PAAD	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.5	5.97	0.44	1.59e-8	Sitting height ratio;
PAAD	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs7737355	0.704	rs984616	chr5:130891101	C/T	cg06307176	chr5:131281290	NA	0.51	4.35	0.33	2.53e-5	Life satisfaction;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27205941	chr6:2245854	GMDS	0.52	6.29	0.45	3.16e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg13444538	chr7:158905317	VIPR2	-0.59	-4.68	-0.35	6.26e-6	Facial morphology (factor 20);
PAAD	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.64	-6.79	-0.48	2.42e-10	Menarche (age at onset);
PAAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.28	-14.14	-0.75	1.61e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.87	7.33	0.51	1.3e-11	Recombination rate (females);
PAAD	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg23024343	chr7:107201750	COG5	0.56	4.42	0.34	1.84e-5	Coronary artery disease;
PAAD	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.77	9.07	0.59	5.59e-16	Lung function (FVC);
PAAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16447950	chr5:562315	NA	-0.73	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.94	11.42	0.68	3.29e-22	Longevity;
PAAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg18370025	chr7:2749541	AMZ1	-0.42	-4.91	-0.37	2.31e-6	Height;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.92	-0.54	4.68e-13	Schizophrenia;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.46	4.84	0.37	3.16e-6	Longevity;Endometriosis;
PAAD	cis	rs2526932	0.625	rs9671286	chr14:73062838	G/A	cg13588403	chr14:73209128	DPF3	-0.4	-5.41	-0.4	2.35e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.47	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.35	5.43	0.4	2.14e-7	Alzheimer's disease (late onset);
PAAD	cis	rs12098973	0.591	rs77206011	chr11:131799326	G/A	cg13055484	chr11:132662455	OPCML	0.52	4.38	0.34	2.16e-5	Cardiac Troponin-T levels;
PAAD	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.37	-0.33	2.25e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.72	7.95	0.54	3.86e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg24687543	chr11:63912206	MACROD1	0.57	4.61	0.35	8.49e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	0.52	4.58	0.35	9.53e-6	Testicular germ cell tumor;
PAAD	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg02580895	chr19:2754563	NA	-0.57	-4.82	-0.36	3.39e-6	Total cholesterol levels;
PAAD	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg24829409	chr8:58192753	C8orf71	-0.9	-8.06	-0.55	2.14e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.84	6.86	0.49	1.65e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10261878	0.826	rs11980825	chr7:26010003	C/T	cg01322214	chr7:25219198	C7orf31	1.03	4.29	0.33	3.2e-5	Body mass index;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg00945038	chr17:61921165	SMARCD2	-0.38	-4.64	-0.35	7.59e-6	Prudent dietary pattern;
PAAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.61	-6.33	-0.46	2.6e-9	Body mass index;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.67	6.36	0.46	2.2e-9	Tuberculosis;
PAAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-1.04	-14.15	-0.75	1.53e-29	Breast cancer;
PAAD	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.26	-0.39	4.9e-7	Reticulocyte count;
PAAD	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.72	6.59	0.47	6.84e-10	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg26338869	chr17:61819248	STRADA	0.48	4.66	0.35	6.86e-6	Height;
PAAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.71	-0.36	5.58e-6	Lung cancer;
PAAD	cis	rs6681460	0.934	rs4655631	chr1:67054907	C/G	cg02459107	chr1:67143332	SGIP1	0.75	7.62	0.53	2.5e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg01766943	chr2:54829624	SPTBN1	0.54	5.15	0.39	7.85e-7	Schizophrenia;
PAAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.54	5.51	0.41	1.52e-7	Longevity;
PAAD	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.48	-5.1	-0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.48	-6.57	-0.47	7.62e-10	Height;
PAAD	cis	rs375066	0.870	rs7258418	chr19:44383083	G/C	cg08633290	chr19:44405433	NA	-0.58	-5.86	-0.43	2.76e-8	Breast cancer;
PAAD	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.62e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs7737355	0.773	rs7720194	chr5:130837077	T/C	cg06307176	chr5:131281290	NA	0.49	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.34	-0.33	2.56e-5	Height;
PAAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.47	4.85	0.37	3.02e-6	Blood metabolite levels;
PAAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.22	0.45	4.69e-9	Personality dimensions;
PAAD	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.13	0.5	3.83e-11	Obesity-related traits;
PAAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.45	-0.52	6.5e-12	Body mass index;
PAAD	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.69	-6.61	-0.47	6.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.95	-11.33	-0.68	5.92e-22	Osteoporosis;
PAAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.63	7.12	0.5	4.1e-11	Emphysema distribution in smoking;
PAAD	cis	rs11235843	0.929	rs72974840	chr11:73380362	T/C	cg18195628	chr11:73498948	MRPL48	0.77	4.27	0.33	3.44e-5	Hand grip strength;
PAAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.23	-10.26	-0.64	4.2e-19	Breast cancer;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg20007245	chr22:24372913	LOC391322	-0.71	-7.02	-0.49	7.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.15	-0.39	7.97e-7	Daytime sleep phenotypes;
PAAD	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10915437	0.536	rs6663939	chr1:4197256	C/T	cg27165836	chr1:4193882	NA	0.59	6.13	0.45	7.07e-9	Migraine - clinic-based;
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	4.94	0.37	2.08e-6	Prostate cancer;
PAAD	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.58	-0.35	9.46e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg23995914	chr4:10459228	ZNF518B	-0.38	-4.36	-0.33	2.41e-5	Schizophrenia (age at onset);
PAAD	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg20406979	chr6:167373233	NA	-0.32	-4.34	-0.33	2.63e-5	Crohn's disease;
PAAD	cis	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	17.27	0.81	1.13e-37	Prudent dietary pattern;
PAAD	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg10356904	chr22:49881777	NA	-0.49	-5.41	-0.4	2.43e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.69	6.73	0.48	3.23e-10	Blood protein levels;
PAAD	cis	rs9876781	1.000	rs73074358	chr3:48427247	T/A	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.66	-6.6	-0.47	6.35e-10	Body mass index;
PAAD	cis	rs35160687	0.901	rs12478575	chr2:86535314	C/G	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs17428471	0.867	rs17502260	chr7:27325313	T/C	cg08483376	chr7:27285136	EVX1	-0.71	-4.29	-0.33	3.13e-5	Blood pressure;
PAAD	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg16898833	chr6:26189333	HIST1H4D	0.88	5.06	0.38	1.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.84	6.21	0.45	4.85e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.66	0.48	4.69e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.95	10.38	0.64	1.99e-19	Diastolic blood pressure;
PAAD	cis	rs12282928	1.000	rs7952009	chr11:48286845	A/G	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.67	7.2	0.5	2.61e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs3736757	0.934	rs2024765	chr1:184653541	A/G	cg05045817	chr1:184633523	NA	0.45	4.9	0.37	2.41e-6	Obesity-related traits;
PAAD	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.59	-5.43	-0.4	2.21e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6688613	0.840	rs6695609	chr1:166953866	A/C	cg07049167	chr1:166818506	POGK	-0.62	-6.09	-0.44	8.77e-9	Refractive astigmatism;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.77	0.36	4.22e-6	Resting heart rate;
PAAD	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	6.66	0.48	4.83e-10	Coronary artery disease;
PAAD	cis	rs300774	0.925	rs397911	chr2:147317	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.66	-7.5	-0.52	4.92e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs10189230	0.935	rs3770146	chr2:222344196	G/A	cg14652038	chr2:222343519	EPHA4	0.54	5.86	0.43	2.82e-8	Urate levels in lean individuals;
PAAD	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg13206674	chr6:150067644	NUP43	0.57	5.34	0.4	3.36e-7	Lung cancer;
PAAD	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07950158	chr19:45874032	ERCC2	0.69	8.29	0.56	5.42e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.62	-6.11	-0.44	7.98e-9	Aortic root size;
PAAD	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	1.0	15.15	0.78	3.47e-32	Height;
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.51	4.85	0.37	3.02e-6	Cognitive function;
PAAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.5	5.02	0.38	1.43e-6	Menopause (age at onset);
PAAD	cis	rs4332037	0.805	rs4721142	chr7:1918079	T/C	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.95	-0.37	1.95e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg03948781	chr1:205179583	DSTYK	0.47	4.32	0.33	2.86e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg13264159	chr8:625131	ERICH1	-0.71	-4.53	-0.34	1.19e-5	IgG glycosylation;
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.7	7.61	0.53	2.71e-12	Longevity;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.89	11.54	0.68	1.57e-22	Prudent dietary pattern;
PAAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg05484376	chr2:27715224	FNDC4	-0.48	-4.94	-0.37	2.06e-6	Total body bone mineral density;
PAAD	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21175976	chr8:11421337	BLK	-0.41	-4.63	-0.35	7.78e-6	Neuroticism;
PAAD	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.56	5.63	0.42	8.66e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6782228	0.651	rs9852825	chr3:128387357	C/G	cg16766828	chr3:128327626	NA	-0.46	-6.1	-0.44	8.4e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.35	-0.33	2.5e-5	Height;
PAAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg03340356	chr1:67600835	NA	0.56	6.49	0.47	1.17e-9	Psoriasis;
PAAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.2	0.45	5.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.68	6.59	0.47	6.91e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.32	-0.4	3.71e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2885056	0.891	rs1045361	chr19:10692000	T/C	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	cis	rs12476592	0.602	rs6736411	chr2:63674060	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.38	0.33	2.23e-5	Childhood ear infection;
PAAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	5.69	0.42	6.24e-8	Prudent dietary pattern;
PAAD	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg27499820	chr13:21296301	IL17D	0.52	4.96	0.37	1.84e-6	Dental caries;
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.54	-5.18	-0.39	6.88e-7	Aortic root size;
PAAD	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs4356203	0.792	rs620241	chr11:17196890	A/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.27	-0.33	3.45e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.74	-0.48	3.02e-10	Systolic blood pressure;
PAAD	cis	rs600626	0.636	rs10793125	chr11:75452364	C/T	cg24262691	chr11:75473276	NA	-0.69	-6.17	-0.45	5.87e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17347471	chr5:52405518	MOCS2	0.6	6.65	0.47	5.05e-10	Pancreatic cancer;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26418147	chr1:205743515	RAB7L1	-0.47	-5.5	-0.41	1.59e-7	Menarche (age at onset);
PAAD	cis	rs7259965	0.839	rs62109048	chr19:41503257	T/C	cg20630647	chr19:41531805	NA	0.47	4.28	0.33	3.25e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg01851573	chr8:8652454	MFHAS1	0.93	7.17	0.5	3.06e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs4242434	0.892	rs4872527	chr8:22496048	G/A	cg03733263	chr8:22462867	KIAA1967	1.05	13.25	0.73	3.87e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs773506	0.576	rs943502	chr9:93920745	G/A	cg14446406	chr9:93919335	NA	-0.38	-5.01	-0.38	1.48e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs12304921	0.748	rs12580097	chr12:51500886	G/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.45	-0.4	2e-7	Type 2 diabetes;
PAAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg14440974	chr22:39074834	NA	-0.59	-7.15	-0.5	3.46e-11	Menopause (age at onset);
PAAD	cis	rs9287719	0.674	rs12622551	chr2:10720443	G/A	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.77	6.75	0.48	2.9e-10	Cisplatin-induced ototoxicity;
PAAD	cis	rs258892	0.895	rs34302030	chr5:72059832	T/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg26818257	chr2:241905806	NA	0.47	4.9	0.37	2.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs1198430	0.683	rs1198440	chr1:23780861	C/A	cg19827787	chr1:23763612	ASAP3	0.58	4.79	0.36	4.01e-6	Total cholesterol levels;
PAAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	1.08	9.43	0.61	6.72e-17	Eosinophil percentage of granulocytes;
PAAD	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.44	0.34	1.73e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Cardiac Troponin-T levels;
PAAD	cis	rs730532	0.556	rs2173145	chr14:52518485	T/C	cg00766845	chr14:52536022	NID2	0.6	4.46	0.34	1.61e-5	Pulmonary function;
PAAD	cis	rs288342	0.763	rs3115425	chr2:183616748	G/C	cg02625481	chr2:183667124	NA	-0.44	-4.27	-0.33	3.4e-5	Recurrent major depressive disorder;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg21565972	chr17:80109576	CCDC57	0.55	6.48	0.47	1.21e-9	Life satisfaction;
PAAD	cis	rs7668190	0.924	rs6554162	chr4:55093955	G/A	cg17187183	chr4:55093834	PDGFRA	0.45	4.4	0.34	2.07e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg26816564	chr1:7831052	VAMP3	0.56	4.78	0.36	4.06e-6	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	5.05	0.38	1.25e-6	Mood instability;
PAAD	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg26338869	chr17:61819248	STRADA	0.57	4.44	0.34	1.73e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.841	rs118053970	chr12:110932820	C/G	cg12870014	chr12:110450643	ANKRD13A	0.77	4.32	0.33	2.75e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	5.35	0.4	3.12e-7	Mean platelet volume;
PAAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	4.61	0.35	8.5e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26552733	chr10:5542941	CALML5	0.6	6.44	0.46	1.46e-9	Smoking initiation;
PAAD	cis	rs959260	0.502	rs11658023	chr17:73308722	C/T	cg14668889	chr17:73230827	NUP85	-0.56	-4.98	-0.37	1.68e-6	Systemic lupus erythematosus;
PAAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg07384165	chr1:10488281	NA	-0.56	-5.56	-0.41	1.2e-7	Prostate cancer;
PAAD	cis	rs797680	0.856	rs10874764	chr1:93661342	C/A	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg26338869	chr17:61819248	STRADA	-0.62	-6.09	-0.44	8.94e-9	Prudent dietary pattern;
PAAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.05	14.88	0.77	1.79e-31	Multiple system atrophy;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.59	-0.35	9.06e-6	Testicular germ cell tumor;
PAAD	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.2	8.02	0.55	2.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4750440	0.671	rs10796149	chr10:14025859	C/T	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.36	-0.33	2.41e-5	Adiponectin levels;
PAAD	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.63	0.35	7.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7561149	1.000	rs12992014	chr2:179691285	G/A	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.49	4.71	0.36	5.6e-6	QT interval;
PAAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg04194840	chr16:58545502	NDRG4	0.72	4.29	0.33	3.11e-5	Schizophrenia;
PAAD	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2835872	0.758	rs1709833	chr21:39037805	C/T	cg06728970	chr21:39037746	KCNJ6	-0.51	-5.84	-0.43	3.01e-8	Electroencephalographic traits in alcoholism;
PAAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3774830	0.748	rs58854245	chr4:5466134	G/A	cg26943120	chr4:5472116	STK32B	0.34	4.25	0.33	3.76e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7824557	0.707	rs2572419	chr8:11137820	C/T	cg21775007	chr8:11205619	TDH	-0.59	-5.32	-0.4	3.7e-7	Retinal vascular caliber;
PAAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg08029281	chr1:67600428	NA	0.44	5.1	0.38	9.98e-7	Crohn's disease;
PAAD	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.42	-6.22	-0.45	4.53e-9	Subjective well-being;
PAAD	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.34	-0.46	2.53e-9	Chronic sinus infection;
PAAD	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.62	5.21	0.39	6.06e-7	Neutrophil percentage of white cells;
PAAD	cis	rs9463078	0.727	rs2396371	chr6:44946550	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.5	-0.41	1.57e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg15571903	chr15:79123663	NA	0.48	6.27	0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14930269	chr3:49142045	QARS	0.64	7.32	0.51	1.31e-11	Myopia (pathological);
PAAD	cis	rs13424612	1.000	rs10206993	chr2:240900919	C/A	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.76	-0.36	4.52e-6	Odorant perception (isobutyraldehyde);
PAAD	trans	rs6722456	1.000	rs75362784	chr2:134570239	T/C	cg06476693	chr11:130283454	ADAMTS8	0.81	6.4	0.46	1.85e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg18543610	chr13:100627929	NA	-0.64	-6.43	-0.46	1.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.88	-9.67	-0.62	1.55e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.5	5.5	0.41	1.54e-7	Schizophrenia;
PAAD	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.59	-5.76	-0.42	4.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.78	0.58	3.17e-15	Lung cancer;
PAAD	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10190329	chr10:126605450	NA	-0.65	-7.79	-0.53	9.77e-13	Body fat percentage;
PAAD	cis	rs7786896	1.000	rs7786896	chr7:39093928	C/T	cg13319711	chr7:39015544	NA	0.21	4.75	0.36	4.73e-6	Schizophrenia;
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.16	0.39	7.75e-7	Longevity;
PAAD	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.65	5.26	0.39	4.9e-7	Blood protein levels;
PAAD	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.91	9.14	0.6	3.74e-16	Post bronchodilator FEV1;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-7.7	-0.53	1.61e-12	Prudent dietary pattern;
PAAD	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.52	0.34	1.23e-5	Lung cancer;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg21153622	chr11:89784906	NA	-0.56	-6.39	-0.46	1.95e-9	HDL cholesterol;
PAAD	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg20503657	chr10:835505	NA	1.21	11.9	0.69	1.74e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg02421172	chr7:1938701	MAD1L1	0.57	4.26	0.33	3.58e-5	Bipolar disorder;
PAAD	cis	rs8127571	0.551	rs2838986	chr21:47145374	C/T	cg11214348	chr21:47283868	PCBP3	0.67	4.92	0.37	2.21e-6	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.55	4.71	0.36	5.5e-6	Prostate cancer;
PAAD	cis	rs4605213	0.528	rs8076039	chr17:49323807	T/A	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	trans	rs4915077	1.000	rs9787296	chr1:108382827	A/G	cg18565342	chr10:124714098	C10orf88	-1.2	-6.36	-0.46	2.19e-9	Hypothyroidism;
PAAD	cis	rs2421770	0.530	rs10836375	chr11:35353842	C/T	cg13971030	chr11:35366721	SLC1A2	-0.54	-6.33	-0.46	2.68e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-5.46	-0.41	1.86e-7	Monocyte count;
PAAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	1.31	14.93	0.77	1.29e-31	Eosinophil percentage of granulocytes;
PAAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg04450456	chr4:17643702	FAM184B	0.58	6.65	0.47	5.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7929679	0.521	rs11032852	chr11:34788308	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs6062788	0.811	rs11698110	chr20:61701531	T/C	cg01771885	chr20:60882801	ADRM1	-0.27	-4.35	-0.33	2.45e-5	Body mass index;
PAAD	cis	rs11811982	0.793	rs115823838	chr1:227303587	C/T	cg24860534	chr1:227506868	CDC42BPA	0.49	4.4	0.34	2.05e-5	Optic disc area;
PAAD	trans	rs901683	1.000	rs10508895	chr10:45967768	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.49	-4.39	-0.34	2.14e-5	Testicular germ cell tumor;
PAAD	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.94	-10.09	-0.63	1.19e-18	Gut microbiome composition (winter);
PAAD	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1075265	0.704	rs805402	chr2:54116349	T/C	cg04546899	chr2:54196757	PSME4	0.29	4.37	0.33	2.33e-5	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	0.95	8.79	0.58	2.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.55	-5.21	-0.39	6.19e-7	Red blood cell count;
PAAD	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.78	5.71	0.42	5.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23281280	chr6:28129359	ZNF389	0.69	5.28	0.39	4.32e-7	Depression;
PAAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg04106633	chr4:1044584	NA	0.7	5.74	0.42	4.9e-8	Recombination rate (females);
PAAD	cis	rs56046484	0.956	rs17541572	chr15:85665247	C/T	cg08123816	chr15:85640762	PDE8A	0.5	5.15	0.39	7.93e-7	Testicular germ cell tumor;
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	8.88	0.58	1.75e-15	Platelet count;
PAAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	5.74	0.42	4.91e-8	Schizophrenia;
PAAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	10.61	0.65	4.97e-20	Menopause (age at onset);
PAAD	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.61	-6.96	-0.49	9.77e-11	Melanoma;
PAAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg19636519	chr7:99541626	NA	0.4	4.45	0.34	1.66e-5	Coronary artery disease;
PAAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.53	0.34	1.18e-5	Personality dimensions;
PAAD	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.51	4.77	0.36	4.22e-6	Self-reported allergy;
PAAD	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.94	-0.37	2e-6	Neuroticism;
PAAD	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.38	4.34	0.33	2.58e-5	High light scatter reticulocyte count;
PAAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1497828	0.956	rs2132993	chr1:217547640	A/G	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg02743256	chr7:2109353	MAD1L1	-0.66	-4.98	-0.37	1.71e-6	Bipolar disorder;
PAAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.71	-8.7	-0.58	4.95e-15	Breast cancer;
PAAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.74	7.92	0.54	4.76e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15458637	chr13:23471766	NA	-0.64	-6.41	-0.46	1.7e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.84e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7591163	0.959	rs2396497	chr2:228724139	T/C	cg22994281	chr2:228029448	COL4A3;COL4A4	0.48	4.79	0.36	3.95e-6	Blood pressure;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.99	14.01	0.75	3.71e-29	Menarche (age at onset);
PAAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	6.31	0.46	2.84e-9	Neuroticism;
PAAD	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.23	20.44	0.86	1.87e-45	Testicular germ cell tumor;
PAAD	cis	rs7582720	0.731	rs934287	chr2:203708307	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.79	-5.88	-0.43	2.54e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg03909863	chr11:638404	DRD4	-0.69	-6.1	-0.44	8.42e-9	Systemic lupus erythematosus;
PAAD	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.87e-13	Prostate cancer;
PAAD	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02743256	chr7:2109353	MAD1L1	-0.65	-5.76	-0.42	4.42e-8	Neuroticism;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.23	-0.51	2.17e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.4	4.9	0.37	2.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs8102137	0.672	rs12460611	chr19:30326600	A/G	cg27475126	chr19:30303651	CCNE1	-0.5	-5.12	-0.38	8.94e-7	Bladder cancer;
PAAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg21483461	chr5:81570383	RPS23	-0.53	-4.91	-0.37	2.32e-6	Breast cancer;
PAAD	cis	rs4140564	0.730	rs964570	chr1:186684977	T/C	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.33	-0.51	1.27e-11	Body mass index;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg27394845	chr17:28928406	LRRC37B2	0.74	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6681460	0.634	rs994396	chr1:67012236	G/A	cg02459107	chr1:67143332	SGIP1	0.57	5.0	0.38	1.56e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24847757	chr3:32909493	TRIM71	-0.6	-7.32	-0.51	1.32e-11	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg26174226	chr8:58114915	NA	-0.68	-6.12	-0.44	7.66e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.85	-0.37	3.07e-6	Depression;
PAAD	trans	rs62179067	0.708	rs17363006	chr2:179915541	T/C	cg21380341	chr12:94543978	PLXNC1	-0.67	-6.3	-0.46	3.09e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg23250157	chr14:64679961	SYNE2	0.56	5.62	0.41	8.76e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs755249	0.567	rs4660214	chr1:39731550	T/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.71	-0.36	5.63e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-4.58	-0.35	9.76e-6	Glomerular filtration rate;
PAAD	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	1.0	8.24	0.56	7.46e-14	Blood protein levels;
PAAD	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-1.04	-6.79	-0.48	2.36e-10	Opioid sensitivity;
PAAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.46	4.26	0.33	3.58e-5	Uric acid levels;
PAAD	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.98	-0.44	1.57e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg14583973	chr4:3374767	RGS12	0.34	4.96	0.37	1.83e-6	Mean platelet volume;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs72634501	0.568	rs590214	chr1:39612493	A/G	cg11070191	chr1:39582205	MACF1	-0.48	-4.37	-0.33	2.29e-5	HDL cholesterol;
PAAD	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.79	-5.34	-0.4	3.4e-7	Coronary artery calcification;
PAAD	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs2061333	0.557	rs28539456	chr19:44607547	G/T	cg18700516	chr19:44507157	ZNF230	-0.77	-5.55	-0.41	1.24e-7	Alzheimer's disease;
PAAD	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-4.44	-0.34	1.75e-5	Personality dimensions;
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Body mass index;
PAAD	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg18281939	chr5:77783895	LHFPL2	-0.46	-5.1	-0.38	9.79e-7	Triglycerides;
PAAD	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-1.03	-6.98	-0.49	8.47e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg01868782	chr6:126071099	HEY2	0.46	5.48	0.41	1.77e-7	Brugada syndrome;
PAAD	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg27284194	chr4:1044797	NA	0.51	4.84	0.37	3.19e-6	Obesity-related traits;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg08088566	chr11:430123	ANO9	0.91	5.64	0.42	8.12e-8	Body mass index;
PAAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.81	7.74	0.53	1.26e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg27494647	chr7:150038898	RARRES2	0.53	5.5	0.41	1.6e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg25754956	chr12:51612065	POU6F1	1.05	11.5	0.68	2e-22	Cisplatin-induced ototoxicity;
PAAD	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg13476313	chr9:127244764	NR5A1	-0.32	-5.0	-0.38	1.59e-6	Menarche (age at onset);
PAAD	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg19442545	chr10:75533431	FUT11	-0.43	-4.36	-0.33	2.35e-5	Inflammatory bowel disease;
PAAD	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg14146966	chr2:61757674	XPO1	0.38	4.76	0.36	4.44e-6	Tuberculosis;
PAAD	cis	rs2286379	0.596	rs10848563	chr12:1841543	T/C	cg11558135	chr12:861715	WNK1	-0.46	-4.52	-0.34	1.23e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.05e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7873102	0.654	rs10973636	chr9:37997561	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.58	4.53	0.34	1.21e-5	Platelet count;
PAAD	cis	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.68	-4.59	-0.35	9.09e-6	Hypertriglyceridemia;
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.59	6.37	0.46	2.18e-9	Lung cancer;
PAAD	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg25364880	chr3:44379878	C3orf23	0.6	5.51	0.41	1.49e-7	Depressive symptoms;
PAAD	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-6.15	-0.45	6.6e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs17407555	0.909	rs56133633	chr4:10291351	G/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.53	-0.34	1.2e-5	Schizophrenia (age at onset);
PAAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg25204440	chr1:209979598	IRF6	0.64	5.34	0.4	3.37e-7	Coronary artery disease;
PAAD	cis	rs7737355	0.773	rs31589	chr5:131004646	G/A	cg06307176	chr5:131281290	NA	0.48	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.97e-5	Pain;
PAAD	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	1.06	8.67	0.58	5.96e-15	Corneal structure;
PAAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.17	0.5	3.02e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg25566285	chr7:158114605	PTPRN2	0.75	6.42	0.46	1.63e-9	Response to amphetamines;
PAAD	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs1359582	0.836	rs7917696	chr10:90378205	G/A	cg15661332	chr10:90342814	RNLS	0.55	4.96	0.37	1.83e-6	Depressive and manic episodes in bipolar disorder;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg07147234	chr12:56522077	ESYT1	-0.59	-6.33	-0.46	2.61e-9	Immature fraction of reticulocytes;
PAAD	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg23555395	chr2:238036564	NA	-0.46	-5.22	-0.39	5.77e-7	Systemic lupus erythematosus;
PAAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.97	9.96	0.63	2.74e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg18518183	chr2:172544446	DYNC1I2	0.48	4.28	0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.93	-9.78	-0.62	7.78e-18	Urate levels in obese individuals;
PAAD	cis	rs12767760	0.669	rs17108059	chr10:99308118	G/T	cg25247692	chr10:99313390	UBTD1	0.53	5.01	0.38	1.46e-6	Obesity-related traits;
PAAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.63	0.42	8.58e-8	Major depressive disorder;
PAAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs73086581	1.000	rs73086595	chr20:3983448	A/G	cg02187196	chr20:3869020	PANK2	0.61	5.21	0.39	6.13e-7	Response to antidepressants in depression;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg16031515	chr1:205743344	RAB7L1	0.4	4.67	0.35	6.52e-6	Monocyte percentage of white cells;
PAAD	cis	rs72843506	0.656	rs9911879	chr17:19990142	T/A	cg12246644	chr17:19995277	CYTSB	0.58	4.3	0.33	3.01e-5	Schizophrenia;
PAAD	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-5.31	-0.4	3.81e-7	Psoriasis;
PAAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.83	8.24	0.56	7.36e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg16147221	chr4:10020634	SLC2A9	0.48	4.42	0.34	1.84e-5	Bone mineral density;
PAAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.19	11.24	0.67	1.01e-21	Platelet count;
PAAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.51e-38	Height;
PAAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-4.92	-0.37	2.24e-6	Longevity;
PAAD	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.63	-0.42	8.55e-8	Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00606900	chr22:50175250	BRD1;LOC90834	0.63	7.38	0.51	9.61e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.73	-7.32	-0.51	1.31e-11	Prostate cancer;
PAAD	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-11.3	-0.68	7.02e-22	Schizophrenia;
PAAD	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg11232448	chr19:2858854	NA	-0.49	-4.78	-0.36	4.06e-6	Total cholesterol levels;
PAAD	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.13	-0.63	9.63e-19	Coronary artery disease;
PAAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.57	5.95	0.43	1.81e-8	Personality dimensions;
PAAD	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.7	-6.98	-0.49	8.51e-11	Uric acid levels;
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg10621924	chr7:39171070	POU6F2	0.33	5.05	0.38	1.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.53	-4.66	-0.35	6.88e-6	Glycated hemoglobin levels;
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.31	-0.33	2.87e-5	Platelet count;
PAAD	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.72	7.01	0.49	7.14e-11	Colorectal cancer;
PAAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-6.57	-0.47	7.52e-10	Bipolar disorder;
PAAD	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg04450456	chr4:17643702	FAM184B	0.53	5.74	0.42	5.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs863345	0.967	rs11265030	chr1:158529388	A/G	cg12129480	chr1:158549410	OR10X1	0.43	4.76	0.36	4.45e-6	Pneumococcal bacteremia;
PAAD	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12594348	chr12:51477468	CSRNP2	-0.72	-6.37	-0.46	2.12e-9	Neuroticism;
PAAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.46	4.25	0.33	3.71e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.99	-0.87	4.48e-49	Myeloid white cell count;
PAAD	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg00101154	chr16:420108	MRPL28	-0.86	-9.37	-0.61	9.29e-17	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.98	10.77	0.66	1.84e-20	Multiple myeloma;
PAAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.62	6.41	0.46	1.73e-9	Monocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25137365	chr4:10089904	WDR1	0.56	6.7	0.48	3.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.45	-0.34	1.62e-5	Tonsillectomy;
PAAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.46	0.46	1.34e-9	Tonsillectomy;
PAAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg14346243	chr4:90757452	SNCA	-0.46	-4.28	-0.33	3.36e-5	Neuroticism;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.84	-6.05	-0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.55	7.42	0.52	7.58e-12	Renal cell carcinoma;
PAAD	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.66	-6.34	-0.46	2.44e-9	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg14137381	chr5:502291	SLC9A3	-0.33	-4.34	-0.33	2.6e-5	Cystic fibrosis severity;
PAAD	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg02580895	chr19:2754563	NA	-0.51	-4.44	-0.34	1.69e-5	Total cholesterol levels;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.56	7.09	0.5	4.61e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11235843	0.929	rs4944028	chr11:73407570	A/G	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs12153243	0.686	rs72806733	chr5:142945025	C/T	cg13907255	chr5:142895549	NA	-0.54	-4.68	-0.35	6.27e-6	Migraine;
PAAD	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg07162820	chr14:24837146	NFATC4	0.36	4.78	0.36	4.15e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.7	7.32	0.51	1.32e-11	Body mass index;
PAAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.98	-14.08	-0.75	2.4e-29	Post bronchodilator FEV1;
PAAD	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.75	-5.45	-0.4	2.03e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.46	5.29	0.39	4.28e-7	Mean arterial pressure;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14159672	chr1:205819179	PM20D1	0.94	11.94	0.7	1.37e-23	Menarche (age at onset);
PAAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg13468214	chr4:1046988	NA	-0.52	-4.85	-0.37	3.04e-6	Recombination rate (females);
PAAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07416502	chr17:10440933	MYH2	-0.47	-6.59	-0.47	6.72e-10	Energy expenditure (24h);
PAAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs41342147	0.591	rs3771547	chr2:242296273	G/C	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.6	-4.45	-0.34	1.64e-5	Vitiligo;
PAAD	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg06627628	chr2:24431161	ITSN2	0.57	5.54	0.41	1.31e-7	Sjögren's syndrome;
PAAD	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1620921	0.505	rs66496533	chr6:161210741	T/C	cg01280913	chr6:161186852	NA	-0.46	-5.03	-0.38	1.39e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.29	-0.45	3.28e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg24733560	chr20:60626293	TAF4	0.45	5.69	0.42	6.22e-8	Body mass index;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.49	4.46	0.34	1.58e-5	Renal cell carcinoma;
PAAD	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.74	7.8	0.53	8.95e-13	Body mass index;
PAAD	cis	rs8112211	0.953	rs61160177	chr19:38819463	C/G	cg14299480	chr19:38876666	GGN	-0.56	-7.13	-0.5	3.85e-11	Blood protein levels;
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg04257695	chr17:30186438	C17orf79	-0.66	-4.37	-0.33	2.26e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.45	-0.34	1.67e-5	Tonsillectomy;
PAAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.79	-0.48	2.36e-10	Retinal vascular caliber;
PAAD	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg09796270	chr17:17721594	SREBF1	-0.49	-5.39	-0.4	2.66e-7	Total body bone mineral density;
PAAD	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.48	4.98	0.37	1.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	4.81	0.36	3.53e-6	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.62	6.46	0.46	1.32e-9	Caffeine consumption;
PAAD	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.55	7.63	0.53	2.39e-12	Thyroid hormone levels;
PAAD	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg00546117	chr1:8445545	RERE	-0.44	-4.45	-0.34	1.69e-5	Crohn's disease;
PAAD	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg22437258	chr11:111473054	SIK2	0.64	6.48	0.47	1.21e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg20673841	chr7:107026890	COG5	0.51	4.3	0.33	3e-5	Coronary artery disease;
PAAD	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.71	6.89	0.49	1.37e-10	Heart rate;
PAAD	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-7.42	-0.52	7.91e-12	Heart rate;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.88	-12.78	-0.72	7.31e-26	Cystic fibrosis severity;
PAAD	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.32e-7	Body mass index;
PAAD	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.54	4.91	0.37	2.36e-6	Mean platelet volume;
PAAD	cis	rs793571	0.822	rs11637077	chr15:59198396	A/C	cg05156742	chr15:59063176	FAM63B	0.59	4.73	0.36	5.17e-6	Schizophrenia;
PAAD	cis	rs28595532	0.841	rs115516095	chr4:119760096	A/C	cg21605333	chr4:119757512	SEC24D	2.0	10.54	0.65	7.83e-20	Cannabis dependence symptom count;
PAAD	cis	rs1497828	1.000	rs2818966	chr1:217569557	G/A	cg04411442	chr1:217543379	NA	0.5	4.89	0.37	2.51e-6	Dialysis-related mortality;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18715318	chr22:19420067	HIRA;MRPL40	0.75	8.32	0.56	4.78e-14	Myopia (pathological);
PAAD	cis	rs17095355	0.605	rs7075964	chr10:111631265	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.27	-0.33	3.49e-5	Biliary atresia;
PAAD	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg15443732	chr18:74961078	GALR1	0.6	5.54	0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.9	0.69	1.77e-23	Platelet count;
PAAD	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.78	6.56	0.47	8.05e-10	Colorectal cancer;
PAAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.66	0.35	6.78e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg08501292	chr6:25962987	TRIM38	0.87	4.69	0.36	6.07e-6	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs17407555	0.779	rs17250843	chr4:10127978	C/G	cg23995914	chr4:10459228	ZNF518B	-0.37	-4.28	-0.33	3.26e-5	Schizophrenia (age at onset);
PAAD	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.48	-0.52	5.68e-12	Height;
PAAD	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.53	-5.08	-0.38	1.08e-6	Psoriasis;
PAAD	cis	rs8105895	0.935	rs7254050	chr19:22286741	G/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.88	9.73	0.62	1.09e-17	Cognitive function;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-6.96	-0.49	9.6e-11	Prudent dietary pattern;
PAAD	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.62	0.35	8.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17221829	1.000	rs17221829	chr11:89466732	A/C	cg02982614	chr11:89391479	FOLH1B	0.45	4.43	0.34	1.76e-5	Anxiety in major depressive disorder;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg07703079	chr11:430292	ANO9	0.91	5.71	0.42	5.67e-8	Body mass index;
PAAD	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.55	5.2	0.39	6.29e-7	Endometrial cancer;
PAAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	4.56	0.35	1.03e-5	Iron status biomarkers;
PAAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.86	-10.33	-0.64	2.81e-19	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	0.69	6.9	0.49	1.28e-10	Obesity-related traits;
PAAD	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.77	0.36	4.26e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg03303774	chr4:1407052	NA	0.46	5.8	0.43	3.65e-8	Obesity-related traits;
PAAD	cis	rs1350666	0.608	rs1017735	chr4:75253136	G/T	cg19308222	chr4:75230391	EREG	0.49	4.57	0.35	9.87e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.61	6.11	0.44	7.95e-9	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7129556	0.954	rs10899387	chr11:77276188	C/T	cg24456632	chr11:77314957	AQP11	-0.5	-4.36	-0.33	2.4e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.59	-5.76	-0.42	4.61e-8	Mean corpuscular volume;
PAAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg05484376	chr2:27715224	FNDC4	0.47	4.78	0.36	4.1e-6	Menopause (age at onset);
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg15693483	chr7:1102177	C7orf50	0.41	4.93	0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg13010199	chr12:38710504	ALG10B	0.47	4.49	0.34	1.39e-5	Morning vs. evening chronotype;
PAAD	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg02244288	chr16:89573955	SPG7	-0.32	-4.27	-0.33	3.5e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.53	-4.65	-0.35	7.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.61	5.98	0.44	1.54e-8	Uric acid clearance;
PAAD	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.51	-5.35	-0.4	3.15e-7	Menopause (age at onset);
PAAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg12072164	chr19:44306565	LYPD5	0.47	4.99	0.37	1.65e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg14631576	chr9:95140430	CENPP	-0.46	-4.52	-0.34	1.23e-5	Height;
PAAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg00750074	chr16:89608354	SPG7	-0.6	-5.62	-0.41	8.83e-8	Multiple myeloma (IgH translocation);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15249106	chr17:27277861	PHF12	-0.62	-6.59	-0.47	6.9e-10	Smoking initiation;
PAAD	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.89	-10.41	-0.65	1.72e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	1.12	9.38	0.61	8.74e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04551154	chr10:95462393	C10orf4	-0.79	-7.06	-0.5	5.68e-11	Neuroticism;
PAAD	cis	rs3136441	1.000	rs4752933	chr11:46803785	G/A	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	cis	rs17169634	0.557	rs17169631	chr7:34088264	C/T	cg24927974	chr7:35078269	DPY19L1	-0.59	-4.61	-0.35	8.56e-6	Alzheimer's disease;
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.7	-7.17	-0.5	3.1e-11	Lung cancer;
PAAD	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg00207856	chr7:1054120	C7orf50	-0.5	-4.45	-0.34	1.69e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg10011062	chr15:43941034	CATSPER2	-0.79	-4.28	-0.33	3.35e-5	Lung cancer in ever smokers;
PAAD	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.71	7.08	0.5	4.86e-11	Cancer;
PAAD	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg09491104	chr22:46646882	C22orf40	-0.8	-5.08	-0.38	1.11e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.35e-5	Coronary artery disease;
PAAD	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.36	-5.08	-0.38	1.07e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.6	4.87	0.37	2.82e-6	Chronic sinus infection;
PAAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.1	-0.59	4.84e-16	Mean platelet volume;
PAAD	cis	rs2562456	0.833	rs2650801	chr19:21635355	C/T	cg00806126	chr19:22604979	ZNF98	-0.37	-5.15	-0.39	8.12e-7	Pain;
PAAD	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.47	-0.34	1.52e-5	Blood metabolite levels;
PAAD	cis	rs950881	0.932	rs10173081	chr2:102957348	C/T	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.8	-0.36	3.8e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22302626	chr19:10196930	C19orf66	0.58	6.64	0.47	5.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.47	5.04	0.38	1.28e-6	Age of smoking initiation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20321726	chr6:96025796	MANEA	0.59	6.57	0.47	7.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg03989125	chr22:38214979	NA	0.57	5.77	0.42	4.35e-8	Glioblastoma;Glioma;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.21	7.37	0.51	1.02e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.54	6.65	0.47	4.95e-10	Multiple sclerosis;
PAAD	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	1.26	15.59	0.78	2.46e-33	Ewing sarcoma;
PAAD	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.37	0.4	2.93e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.72	-8.77	-0.58	3.37e-15	Type 2 diabetes;
PAAD	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-4.96	-0.37	1.86e-6	Mean platelet volume;
PAAD	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.56	-5.19	-0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4747197	0.922	rs4747195	chr10:73558952	C/T	cg04506911	chr10:72937119	NA	0.4	4.36	0.33	2.35e-5	Progranulin levels;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9815354	0.812	rs73075234	chr3:42051801	G/A	cg03022575	chr3:42003672	ULK4	0.79	5.65	0.42	7.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.59	5.01	0.38	1.5e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.66	-7.93	-0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	7.33	0.51	1.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.98	8.17	0.55	1.11e-13	Blood protein levels;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg19337854	chr7:99768885	GPC2	0.48	4.42	0.34	1.86e-5	Platelet count;
PAAD	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.9	11.44	0.68	2.97e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7635838	0.819	rs2454476	chr3:11545442	G/A	cg00170343	chr3:11313890	ATG7	0.49	4.54	0.35	1.12e-5	HDL cholesterol;
PAAD	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg14146966	chr2:61757674	XPO1	-0.4	-5.08	-0.38	1.1e-6	Tuberculosis;
PAAD	cis	rs9463078	0.605	rs17339124	chr6:44942577	C/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22089736	chr6:36359367	PXT1	-0.66	-6.6	-0.47	6.32e-10	Obesity-related traits;
PAAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	7.25	0.51	2e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.94	12.81	0.72	5.9e-26	Superior crus of antihelix expression;
PAAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.1.543953R	chr1:15965817	DDI2	-0.62	-6.31	-0.46	2.85e-9	Lung cancer in ever smokers;
PAAD	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.36e-8	QT interval;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.73	8.24	0.56	7.25e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-5.88	-0.43	2.57e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.85	7.79	0.53	9.48e-13	Corneal astigmatism;
PAAD	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	1.02	11.44	0.68	2.92e-22	Primary sclerosing cholangitis;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs7705042	0.865	rs4912805	chr5:141493685	A/G	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.16	-0.39	7.64e-7	Asthma;
PAAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-5.1	-0.38	1e-6	Menarche (age at onset);
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.61	5.55	0.41	1.25e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.85	6.56	0.47	7.92e-10	Axial length;
PAAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.71	4.96	0.37	1.91e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.7	-5.84	-0.43	3.04e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.6	7.32	0.51	1.33e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7804356	0.871	rs6461962	chr7:26746304	A/T	cg03456212	chr7:26904342	SKAP2	0.55	4.5	0.34	1.32e-5	Type 1 diabetes;
PAAD	cis	rs76866386	0.536	rs6709904	chr2:44080324	C/T	cg26706238	chr2:44066206	ABCG5;ABCG8	0.76	5.91	0.43	2.17e-8	Cholesterol, total;
PAAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg09658497	chr7:2847517	GNA12	-0.41	-4.44	-0.34	1.72e-5	Height;
PAAD	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.3	-0.51	1.47e-11	Longevity;
PAAD	cis	rs59888335	0.929	rs12631230	chr3:80804828	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg23331303	chr5:5135948	NA	0.45	6.31	0.46	2.97e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.61	7.39	0.51	9.29e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14343924	chr8:8086146	FLJ10661	0.5	4.64	0.35	7.42e-6	Mood instability;
PAAD	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-4.97	-0.37	1.75e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.53	0.34	1.19e-5	Menopause (age at onset);
PAAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg17646820	chr3:66848679	NA	0.41	4.29	0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg13264159	chr8:625131	ERICH1	0.75	4.7	0.36	5.67e-6	IgG glycosylation;
PAAD	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg11547950	chr5:77652471	NA	0.91	7.75	0.53	1.24e-12	Triglycerides;
PAAD	cis	rs7633770	1.000	rs7633770	chr3:46688562	G/A	cg11219411	chr3:46661640	NA	0.63	7.45	0.52	6.53e-12	Coronary artery disease;
PAAD	cis	rs11203032	0.831	rs10887926	chr10:90940358	G/A	cg16672925	chr10:90967113	CH25H	0.72	5.62	0.41	8.85e-8	Heart failure;
PAAD	cis	rs4751006	0.543	rs61875505	chr10:128774635	A/G	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.22	8.49	0.57	1.69e-14	IgG glycosylation;
PAAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg25809561	chr17:30822961	MYO1D	0.58	6.01	0.44	1.32e-8	Schizophrenia;
PAAD	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg15192750	chr16:69999425	NA	-0.77	-5.95	-0.43	1.76e-8	IgE levels;
PAAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.64	7.15	0.5	3.44e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.48	-4.54	-0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs4140564	0.667	rs10911916	chr1:186698254	C/T	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-4.55	-0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.93	10.55	0.65	7.17e-20	Longevity;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg00579200	chr11:133705235	NA	-0.51	-5.72	-0.42	5.4e-8	Childhood ear infection;
PAAD	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.81	-8.12	-0.55	1.46e-13	Vitamin D levels;
PAAD	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22307297	chr20:60903441	LAMA5	-0.42	-4.4	-0.34	2.03e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2271404	0.506	rs10197366	chr2:111996785	C/T	cg23466623	chr2:111982296	NA	-0.5	-4.9	-0.37	2.42e-6	Atopic dermatitis;
PAAD	cis	rs9815354	0.597	rs73075211	chr3:42033424	G/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg08079166	chr15:68083412	MAP2K5	-0.54	-4.99	-0.38	1.61e-6	Restless legs syndrome;
PAAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg01966878	chr4:90757139	SNCA	-0.47	-4.39	-0.34	2.08e-5	Dementia with Lewy bodies;
PAAD	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.57	5.08	0.38	1.12e-6	Macular telangiectasia type 2;
PAAD	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.5	4.96	0.37	1.84e-6	Eotaxin levels;
PAAD	cis	rs4924935	0.543	rs1737939	chr17:18848023	A/G	cg26378065	chr17:18585709	ZNF286B	0.5	4.79	0.36	3.92e-6	Pancreatic cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23322531	chr2:8821658	ID2	0.56	6.76	0.48	2.77e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg05313129	chr8:58192883	C8orf71	-0.67	-5.68	-0.42	6.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4908768	0.686	rs79644886	chr1:8803216	A/C	cg25722041	chr1:8623473	RERE	0.51	4.29	0.33	3.13e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg27449745	chr7:23145252	KLHL7	-0.55	-4.92	-0.37	2.21e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.9	-8.93	-0.59	1.3e-15	Exhaled nitric oxide output;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.47	5.14	0.38	8.4e-7	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.72	-0.42	5.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7180079	1.000	rs8034610	chr15:64628917	G/A	cg18210365	chr15:65066710	RBPMS2	0.65	4.95	0.37	1.91e-6	Monocyte count;
PAAD	cis	rs6142102	0.602	rs2300209	chr20:32643100	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	5.08	0.38	1.09e-6	Skin pigmentation;
PAAD	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.56	6.1	0.44	8.31e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6494488	0.500	rs72741338	chr15:64761087	G/A	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.86e-9	Lung cancer;
PAAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg26138144	chr22:38071188	LGALS1	0.5	5.55	0.41	1.24e-7	Fat distribution (HIV);
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.68	7.42	0.52	7.7e-12	Resting heart rate;
PAAD	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	1.27	7.44	0.52	6.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.81	-9.95	-0.63	2.84e-18	Height;
PAAD	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.71	5.69	0.42	6.32e-8	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg04257695	chr17:30186438	C17orf79	-0.63	-4.98	-0.37	1.67e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.77	-0.42	4.29e-8	Monocyte count;
PAAD	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs2733310	1.000	rs2591068	chr15:57495687	C/G	cg13626582	chr15:57592083	LOC283663	-0.37	-4.38	-0.33	2.21e-5	Mean platelet volume;
PAAD	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-4.28	-0.33	3.31e-5	Diabetic retinopathy;
PAAD	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.22	-0.39	5.73e-7	Monocyte percentage of white cells;
PAAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.7	-6.91	-0.49	1.23e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.45	-0.34	1.68e-5	Height;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.57	5.63	0.42	8.59e-8	Parkinson's disease;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg03137908	chr10:81447366	LOC650623	0.38	4.27	0.33	3.38e-5	Height;
PAAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg06569542	chr10:98946673	SLIT1	-0.47	-4.98	-0.37	1.74e-6	Monocyte count;
PAAD	cis	rs1522232	0.967	rs2030510	chr12:24395202	A/G	cg17853504	chr12:24715538	SOX5	0.35	4.35	0.33	2.49e-5	AIDS;
PAAD	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg09945482	chr18:12777974	NA	-0.63	-5.47	-0.41	1.85e-7	Inflammatory skin disease;
PAAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.88	10.42	0.65	1.65e-19	Body mass index;
PAAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs6844506	1.000	rs6844506	chr4:185217148	C/T	cg12654155	chr4:185238627	NA	-0.5	-4.69	-0.36	6.04e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs3760982	0.776	rs62116991	chr19:44303447	G/C	cg12072164	chr19:44306565	LYPD5	-0.47	-4.78	-0.36	4.01e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.95	-13.51	-0.74	8.07e-28	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs279612	0.620	rs279620	chr8:122788225	A/G	cg15153412	chr8:121823462	SNTB1	-0.6	-4.31	-0.33	2.94e-5	Metabolite levels (5-HIAA);
PAAD	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg15595755	chr5:1867978	NA	0.43	4.47	0.34	1.52e-5	Cardiovascular disease risk factors;
PAAD	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg13160058	chr8:26243215	BNIP3L	-0.38	-4.69	-0.36	6.09e-6	Red cell distribution width;
PAAD	cis	rs4740619	0.653	rs4741553	chr9:15963999	C/T	cg14451791	chr9:16040625	NA	-0.44	-4.97	-0.37	1.8e-6	Body mass index;
PAAD	cis	rs8022179	0.580	rs6575977	chr14:103823348	G/T	cg12935359	chr14:103987150	CKB	0.5	4.35	0.33	2.5e-5	Monocyte count;
PAAD	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs2652834	1.000	rs2652840	chr15:63393220	T/C	cg05507819	chr15:63340323	TPM1	0.7	4.62	0.35	8.06e-6	HDL cholesterol;
PAAD	cis	rs2274459	0.915	rs6925337	chr6:33732219	G/T	cg06253072	chr6:33679850	C6orf125	0.68	5.21	0.39	6.13e-7	Obesity (extreme);
PAAD	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg10434728	chr15:90938212	IQGAP1	0.46	4.84	0.37	3.17e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs9815354	1.000	rs9840037	chr3:41827522	C/T	cg03022575	chr3:42003672	ULK4	0.81	6.07	0.44	9.94e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs561655	0.525	rs3851178	chr11:85858497	G/T	cg07180834	chr11:85838833	NA	-0.39	-4.3	-0.33	2.99e-5	Alzheimer's disease (late onset);
PAAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-4.71	-0.36	5.6e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs16958440	0.867	rs16948928	chr18:44675821	C/T	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.88	9.75	0.62	9.55e-18	Prudent dietary pattern;
PAAD	cis	rs1692580	0.807	rs260508	chr1:2187085	T/G	cg04315214	chr1:2043799	PRKCZ	-0.42	-4.82	-0.36	3.38e-6	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs2327429	0.858	rs7769954	chr6:134196381	A/G	cg06296503	chr6:134217401	NA	0.47	4.83	0.36	3.31e-6	Coronary artery disease;
PAAD	cis	rs1144333	0.655	rs1938321	chr1:76464302	T/C	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg23024343	chr7:107201750	COG5	0.53	4.49	0.34	1.38e-5	Coronary artery disease;
PAAD	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg22546130	chr22:19950026	COMT	0.27	4.36	0.33	2.37e-5	Blood metabolite levels;
PAAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.88	10.71	0.66	2.65e-20	Methadone dose in opioid dependence;
PAAD	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.67	-7.72	-0.53	1.44e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1572438	0.929	rs9406073	chr6:854451	T/C	cg13447295	chr6:887704	NA	-0.53	-4.73	-0.36	5.18e-6	Aging;
PAAD	cis	rs7828089	0.935	rs4872485	chr8:22255990	G/T	cg12081754	chr8:22256438	SLC39A14	0.44	4.51	0.34	1.31e-5	Verbal declarative memory;
PAAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.11e-20	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.83	9.39	0.61	8.39e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg07648498	chr16:89883185	FANCA	-0.53	-5.03	-0.38	1.36e-6	Vitiligo;
PAAD	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.57	7.15	0.5	3.47e-11	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs12432203	1.000	rs4444247	chr14:51740634	G/A	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs4676482	0.541	rs17735402	chr3:39205176	C/T	cg02254461	chr3:39195904	CSRNP1	0.77	5.46	0.4	1.9e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3736485	0.966	rs11070859	chr15:51890802	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg06740227	chr12:86229804	RASSF9	0.6	5.84	0.43	3.11e-8	Major depressive disorder;
PAAD	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.39	0.68	4.07e-22	Smoking behavior;
PAAD	cis	rs7795096	0.806	rs10261999	chr7:151540659	G/T	cg17008978	chr7:151542804	PRKAG2	0.41	4.84	0.37	3.11e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.5	-4.77	-0.36	4.33e-6	Hirschsprung disease;
PAAD	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg06787764	chr1:46668870	C1orf190;POMGNT1	-0.51	-5.57	-0.41	1.11e-7	Red blood cell count;Reticulocyte count;
PAAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.29	0.64	3.59e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg26513180	chr16:89883248	FANCA	0.64	7.27	0.51	1.77e-11	Vitiligo;
PAAD	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14019695	chr9:139328340	INPP5E	0.61	5.41	0.4	2.41e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4253772	0.575	rs75097576	chr22:46763233	G/A	cg24881330	chr22:46731750	TRMU	1.19	5.68	0.42	6.59e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg26818257	chr2:241905806	NA	0.44	4.64	0.35	7.54e-6	Urinary metabolites;
PAAD	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg01329153	chr1:8417399	RERE	-0.48	-4.27	-0.33	3.45e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7631605	0.905	rs6765395	chr3:37073579	T/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.43	-0.34	1.76e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06832331	chr3:125635186	LOC100125556	-0.7	-7.59	-0.52	2.99e-12	Smoking initiation;
PAAD	cis	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.63	6.31	0.46	2.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.29e-7	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.77	-0.36	4.26e-6	Aortic root size;
PAAD	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.59	-5.13	-0.38	8.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg18809830	chr7:99032528	PTCD1	-1.15	-5.12	-0.38	9.13e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.51	6.89	0.49	1.4e-10	Life satisfaction;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.56	-5.1	-0.38	9.79e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg13263323	chr15:86062960	AKAP13	-0.61	-6.9	-0.49	1.35e-10	Coronary artery disease;
PAAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg21395723	chr22:39101663	GTPBP1	0.46	4.79	0.36	3.96e-6	Menopause (age at onset);
PAAD	cis	rs4455778	0.580	rs4244231	chr7:49103406	G/A	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.99	10.42	0.65	1.61e-19	Pulmonary function decline;
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-6.07	-0.44	9.86e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.65	-6.64	-0.47	5.22e-10	Menarche (age at onset);
PAAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs10899021	1.000	rs11236186	chr11:74362865	G/A	cg25880958	chr11:74394337	NA	-0.86	-5.58	-0.41	1.08e-7	Response to metformin (IC50);
PAAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg11833968	chr6:79620685	NA	-0.43	-4.49	-0.34	1.42e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.67	5.12	0.38	9.28e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg06375148	chr1:209958343	C1orf74	0.63	5.42	0.4	2.25e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs7714584	1.000	rs61530785	chr5:150261364	A/G	cg22134413	chr5:150180641	NA	0.9	6.29	0.45	3.23e-9	Crohn's disease;
PAAD	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.98	-0.49	8.62e-11	Body mass index;
PAAD	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.66	-5.37	-0.4	2.94e-7	Obesity (extreme);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09062038	chr10:22825269	PIP4K2A	-0.65	-6.47	-0.46	1.27e-9	Obesity-related traits;
PAAD	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.47	-6.92	-0.49	1.2e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.53	-0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.08e-11	Life satisfaction;
PAAD	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg03030879	chr14:75389066	RPS6KL1	0.41	4.35	0.33	2.44e-5	Height;
PAAD	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.56	5.46	0.4	1.93e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.69	-7.8	-0.53	9.4e-13	Height;
PAAD	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.52	6.99	0.49	8.22e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05593479	chr2:233415006	TIGD1;EIF4E2	0.93	6.51	0.47	1.04e-9	Airflow obstruction;
PAAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.25	-0.39	5.14e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-5.8	-0.43	3.67e-8	Colorectal cancer;
PAAD	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.83	-7.88	-0.54	5.99e-13	Breast cancer;
PAAD	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.58	-7.66	-0.53	1.98e-12	Longevity;
PAAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03370490	chr11:1380305	NA	-0.54	-6.81	-0.48	2.09e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1879734	0.731	rs10888804	chr1:54160570	C/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-1.02	-17.22	-0.81	1.56e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26926768	chr12:34528122	NA	-0.38	-4.74	-0.36	4.82e-6	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	5.6	0.41	9.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13047869	chr3:10149882	C3orf24	0.82	6.86	0.49	1.64e-10	Alzheimer's disease;
PAAD	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.44	-6.99	-0.49	8.26e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg11288833	chr15:55489084	RSL24D1	0.58	4.77	0.36	4.21e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	4.83	0.36	3.31e-6	Lung cancer in ever smokers;
PAAD	cis	rs7577696	0.924	rs7561519	chr2:32312700	T/C	cg02381751	chr2:32503542	YIPF4	-0.44	-4.67	-0.35	6.53e-6	Inflammatory biomarkers;
PAAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs899997	1.000	rs1383634	chr15:79029396	T/C	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.25	-0.39	4.97e-7	Total body bone mineral density;
PAAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg14180030	chr9:123475675	MEGF9	-0.43	-4.75	-0.36	4.67e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs9900972	0.959	rs4789941	chr17:76877500	G/C	cg20937029	chr17:76870563	TIMP2	0.59	5.35	0.4	3.2e-7	Obesity-related traits;
PAAD	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg09298818	chr12:111181546	PPP1CC	-0.48	-4.25	-0.33	3.75e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg04087571	chr11:116723030	SIK3	-0.34	-4.4	-0.34	2.03e-5	Subjective well-being;
PAAD	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.81	-0.36	3.64e-6	Type 2 diabetes;
PAAD	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.5	-0.34	1.36e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg21361702	chr7:150065534	REPIN1	0.57	4.67	0.35	6.49e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.73	-7.9	-0.54	5.34e-13	Blood metabolite levels;
PAAD	cis	rs11696501	0.688	rs6104291	chr20:44323368	C/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg06375148	chr1:209958343	C1orf74	0.67	5.25	0.39	5.14e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6142102	0.590	rs6059691	chr20:32736967	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.45	-4.42	-0.34	1.9e-5	Skin pigmentation;
PAAD	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-4.67	-0.35	6.64e-6	Blood pressure;
PAAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.57	-5.73	-0.42	5.1e-8	Birth weight;
PAAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.7	-6.13	-0.45	7.21e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-4.79	-0.36	3.99e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.52	4.55	0.35	1.11e-5	Prudent dietary pattern;
PAAD	cis	rs1468333	0.538	rs13153017	chr5:137750669	C/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.79e-7	Alcohol dependence;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	9.57	0.61	2.88e-17	Response to antipsychotic treatment;
PAAD	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02368587	chr1:226735384	C1orf95	-0.63	-6.31	-0.46	2.92e-9	Lung cancer in ever smokers;
PAAD	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.56	-0.47	7.85e-10	Retinal vascular caliber;
PAAD	cis	rs7715811	0.913	rs10513154	chr5:13780601	T/C	cg07548982	chr5:13769939	DNAH5	-0.55	-4.93	-0.37	2.18e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.63	6.23	0.45	4.43e-9	Type 2 diabetes;
PAAD	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-6.98	-0.49	8.79e-11	Longevity;Endometriosis;
PAAD	cis	rs375066	0.762	rs17656688	chr19:44425077	T/C	cg21496419	chr19:44306685	LYPD5	-0.38	-4.39	-0.34	2.13e-5	Breast cancer;
PAAD	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.53	-4.79	-0.36	4e-6	HDL cholesterol;
PAAD	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.7	6.66	0.48	4.62e-10	Subjective well-being;
PAAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-5.01	-0.38	1.48e-6	Lung cancer;
PAAD	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.08	15.42	0.78	6.78e-33	Multiple system atrophy;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.34	0.46	2.45e-9	Platelet count;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.81	0.58	2.63e-15	Lung cancer;
PAAD	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.19	0.5	2.67e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.94	12.21	0.7	2.47e-24	Mean corpuscular volume;
PAAD	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg03277515	chr1:153321198	PGLYRP4	0.42	5.01	0.38	1.52e-6	Psoriasis;
PAAD	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.71	0.62	1.22e-17	Prudent dietary pattern;
PAAD	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.73	6.93	0.49	1.14e-10	Obesity-related traits;
PAAD	cis	rs11807834	0.522	rs6697219	chr1:230248266	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.47	-0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.7	6.55	0.47	8.22e-10	Parkinson's disease;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.47	-4.25	-0.33	3.75e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	6.27	0.45	3.62e-9	Body mass index;
PAAD	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	5.34	0.4	3.39e-7	Body mass index;
PAAD	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg17514665	chr17:1657533	SERPINF2	0.66	6.0	0.44	1.38e-8	Serum albumin level;
PAAD	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.32	11.4	0.68	3.77e-22	Uric acid levels;
PAAD	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.76	-0.62	8.83e-18	Blood trace element (Zn levels);
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.6	6.72	0.48	3.46e-10	Cardiovascular disease risk factors;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.65	-5.91	-0.43	2.19e-8	Renal function-related traits (BUN);
PAAD	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.55	5.56	0.41	1.15e-7	Menopause (age at onset);
PAAD	cis	rs10152831	1	rs10152831	chr15:91059190	C/T	cg22089800	chr15:90895588	ZNF774	0.6	4.43	0.34	1.78e-5	Neutrophil percentage of white cells;
PAAD	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.7	5.03	0.38	1.35e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05051118	chr16:50613529	NKD1	-0.55	-6.32	-0.46	2.72e-9	Monocyte percentage of white cells;
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.38	5.52	0.41	1.42e-7	Neuroticism;
PAAD	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg21479132	chr6:26055353	NA	0.87	4.35	0.33	2.45e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.94	10.58	0.65	5.87e-20	Parkinson's disease;
PAAD	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg17192377	chr18:44677553	HDHD2	0.62	4.37	0.33	2.28e-5	Sitting height ratio;
PAAD	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.79	5.8	0.43	3.66e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	6.72	0.48	3.38e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.37	-4.54	-0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.43	5.81	0.43	3.52e-8	Urate levels in overweight individuals;
PAAD	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-5.92	-0.43	2.11e-8	Cognitive test performance;
PAAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg13859433	chr6:33739653	LEMD2	-0.63	-4.87	-0.37	2.72e-6	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73196993	chr3:128456755	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.84	-9.45	-0.61	5.71e-17	Prudent dietary pattern;
PAAD	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.7	-0.53	1.58e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.34	0.4	3.27e-7	Lung cancer in ever smokers;
PAAD	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg17346650	chr17:80929145	B3GNTL1	0.43	5.18	0.39	7.1e-7	Glycated hemoglobin levels;
PAAD	cis	rs9314614	0.766	rs2978901	chr8:6690215	G/C	cg27319216	chr8:6693540	XKR5	-0.38	-5.04	-0.38	1.3e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs16910800	0.731	rs16910738	chr11:23189455	C/T	cg20040320	chr11:23191996	NA	-0.82	-6.89	-0.49	1.4e-10	Cancer;
PAAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.46	-5.13	-0.38	8.86e-7	Testicular germ cell tumor;
PAAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.47	4.41	0.34	1.96e-5	Height;
PAAD	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.77	7.4	0.51	8.43e-12	Obesity-related traits;
PAAD	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6028335	0.610	rs73110616	chr20:37552943	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.66	-4.94	-0.37	2.08e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.62	5.49	0.41	1.68e-7	Common traits (Other);
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.78	6.06	0.44	1.04e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.89	12.36	0.71	9.63e-25	Birth weight;
PAAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.6	7.01	0.49	7.28e-11	Immature fraction of reticulocytes;
PAAD	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.79	5.55	0.41	1.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs60154123	0.730	rs12030512	chr1:210466886	A/G	cg23283495	chr1:209979779	IRF6	0.63	5.54	0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg08132940	chr7:1081526	C7orf50	0.59	4.3	0.33	3.03e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg23024343	chr7:107201750	COG5	0.61	4.66	0.35	6.84e-6	Coronary artery disease;
PAAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.71	0.48	3.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.54	-5.54	-0.41	1.32e-7	Menarche (age at onset);
PAAD	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.17	-0.39	7.35e-7	Systolic blood pressure;
PAAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs13242816	1.000	rs7809755	chr7:116110732	C/T	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.89	-8.58	-0.57	1.02e-14	DNA methylation (variation);
PAAD	cis	rs11264799	0.603	rs12133056	chr1:157585751	G/T	cg18268488	chr1:157545234	FCRL4	0.47	5.41	0.4	2.44e-7	IgA nephropathy;
PAAD	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	0.66	5.93	0.43	2e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.67	5.75	0.42	4.86e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6460942	0.544	rs34644264	chr7:12536090	C/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.92	6.63	0.47	5.57e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg03923535	chr7:1197113	ZFAND2A	0.43	4.28	0.33	3.36e-5	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.88	0.37	2.62e-6	Myopia (pathological);
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg03909863	chr11:638404	DRD4	-0.59	-5.43	-0.4	2.14e-7	Systemic lupus erythematosus;
PAAD	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.68	-9.14	-0.6	3.75e-16	Hemoglobin concentration;
PAAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.46	-5.21	-0.39	6.1e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.53	-0.35	1.17e-5	Asthma;
PAAD	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.37	1.85e-6	Morning vs. evening chronotype;
PAAD	cis	rs3131085	1	rs3131085	chr6:29044701	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Blood protein levels;
PAAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.35	-0.33	2.51e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10546523	chr3:50310484	SEMA3B	0.65	6.86	0.49	1.62e-10	Myopia (pathological);
PAAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg24733560	chr20:60626293	TAF4	0.38	4.29	0.33	3.17e-5	Body mass index;
PAAD	cis	rs7737355	0.738	rs13174592	chr5:130963700	C/T	cg06307176	chr5:131281290	NA	0.51	4.35	0.33	2.53e-5	Life satisfaction;
PAAD	cis	rs12959570	1	rs12959570	chr18:54333584	G/A	cg18434998	chr18:54306185	TXNL1	0.57	4.63	0.35	7.82e-6	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.75	4.39	0.34	2.08e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.74	-8.56	-0.57	1.13e-14	Pulse pressure;
PAAD	cis	rs2562456	0.754	rs62109226	chr19:21536913	T/C	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs59104589	0.617	rs3771550	chr2:242302811	A/G	cg04488487	chr2:242709673	NA	0.55	4.26	0.33	3.64e-5	Fibrinogen levels;
PAAD	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs2882667	0.690	rs288017	chr5:138193515	A/T	cg09476006	chr5:138032270	NA	-0.43	-5.39	-0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg10556349	chr10:835070	NA	0.7	5.49	0.41	1.61e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	4.48	0.34	1.45e-5	Refractive astigmatism;
PAAD	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.49	-5.16	-0.39	7.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg14092571	chr14:90743983	NA	0.54	5.15	0.39	7.84e-7	Mortality in heart failure;
PAAD	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg12072164	chr19:44306565	LYPD5	-0.42	-4.66	-0.35	6.82e-6	Breast cancer;
PAAD	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs3126085	0.825	rs116321073	chr1:152240413	A/T	cg26876637	chr1:152193138	HRNR	0.87	6.51	0.47	1.04e-9	Atopic dermatitis;
PAAD	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.54	-4.97	-0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.5	2.62e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg12700464	chr11:78128424	GAB2	-0.61	-4.63	-0.35	7.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.83	-6.26	-0.45	3.73e-9	Alzheimer's disease;
PAAD	cis	rs863345	0.604	rs7555174	chr1:158487426	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.86	-0.37	2.84e-6	Pneumococcal bacteremia;
PAAD	cis	rs62025270	0.632	rs1807309	chr15:86211757	G/A	cg13263323	chr15:86062960	AKAP13	0.5	4.44	0.34	1.7e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.55	-4.92	-0.37	2.18e-6	Height;
PAAD	cis	rs59888335	0.895	rs17469810	chr3:80807568	C/T	cg21735741	chr3:80819488	NA	0.5	4.31	0.33	2.97e-5	Schizophrenia;
PAAD	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg06219351	chr7:158114137	PTPRN2	-0.83	-8.91	-0.59	1.45e-15	Calcium levels;
PAAD	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	4.65	0.35	7.15e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.55	-4.59	-0.35	9.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.51	4.42	0.34	1.83e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.57	-6.63	-0.47	5.44e-10	Type 2 diabetes;
PAAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs10214930	0.671	rs1009252	chr7:27621673	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs4908768	0.582	rs12410893	chr1:8878885	A/G	cg25722041	chr1:8623473	RERE	0.5	4.27	0.33	3.45e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg09796270	chr17:17721594	SREBF1	-0.49	-5.39	-0.4	2.66e-7	Total body bone mineral density;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg03983476	chr2:10830698	NOL10	-0.61	-6.07	-0.44	9.55e-9	Prostate cancer;
PAAD	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg21300403	chr2:198650112	BOLL	0.48	4.36	0.33	2.35e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3736485	0.966	rs6493510	chr15:51900651	T/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.66e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18364779	chr6:26104403	HIST1H4C	-0.48	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.55	6.61	0.47	5.97e-10	Multiple system atrophy;
PAAD	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11691635	chr17:35969582	SYNRG	0.64	6.3	0.46	3.1e-9	Obesity-related traits;
PAAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11133665	0.858	rs11750211	chr5:1183560	C/T	cg00080423	chr5:1144950	NA	0.48	4.62	0.35	8.1e-6	Urinary metabolites;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg02462569	chr6:150064036	NUP43	-0.45	-5.03	-0.38	1.36e-6	Lung cancer;
PAAD	cis	rs2131877	0.871	rs62290354	chr3:194867296	A/G	cg24618514	chr3:194868507	C3orf21	0.49	4.36	0.33	2.4e-5	Non-small cell lung cancer;
PAAD	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg06917634	chr15:78832804	PSMA4	-0.45	-4.43	-0.34	1.82e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.51	-0.47	1.01e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2908197	0.788	rs6465111	chr7:75991378	A/G	cg22830091	chr7:75961684	YWHAG	-0.61	-7.1	-0.5	4.37e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	5.03	0.38	1.34e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.61	6.47	0.46	1.27e-9	Crohn's disease;
PAAD	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.59	-0.35	9.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg04132472	chr17:19861366	AKAP10	0.42	4.25	0.33	3.77e-5	Platelet count;
PAAD	cis	rs569214	0.515	rs542876	chr8:27520745	C/T	cg04264299	chr8:27491209	SCARA3	0.53	5.09	0.38	1.04e-6	Alzheimer's disease;
PAAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.79	0.42	3.94e-8	Tonsillectomy;
PAAD	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.62	-5.61	-0.41	9.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.42	-4.3	-0.33	3.08e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.57	-5.21	-0.39	5.94e-7	Cancer;
PAAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg20003494	chr4:90757398	SNCA	-0.64	-5.86	-0.43	2.84e-8	Neuroticism;
PAAD	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.74	-4.71	-0.36	5.59e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg03959625	chr15:84868606	LOC388152	0.42	4.36	0.33	2.41e-5	Schizophrenia;
PAAD	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-10.39	-0.64	1.93e-19	Height;
PAAD	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	trans	rs6477998	1.000	rs6477998	chr9:115997249	A/C	cg10985086	chr5:153418668	MFAP3;FAM114A2	-0.62	-6.6	-0.47	6.4e-10	Hematology traits;
PAAD	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02985541	chr2:219472218	PLCD4	0.28	4.3	0.33	3e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg19767477	chr5:127420684	SLC12A2	-0.57	-4.6	-0.35	8.91e-6	Ileal carcinoids;
PAAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.66	-7.01	-0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22601191	chr20:60968625	CABLES2	0.62	5.78	0.42	4.14e-8	Colorectal cancer;
PAAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00166722	chr3:10149974	C3orf24	0.94	8.02	0.55	2.69e-13	Alzheimer's disease;
PAAD	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.49	-5.82	-0.43	3.29e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.29	0.6	1.5e-16	Bipolar disorder;
PAAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-4.25	-0.33	3.7e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10651537	chr2:177134737	MTX2	0.68	6.68	0.48	4.32e-10	Obesity-related traits;
PAAD	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.13	-14.09	-0.75	2.29e-29	Colorectal cancer;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg14092988	chr3:52407081	DNAH1	0.38	4.85	0.37	3.01e-6	Electroencephalogram traits;
PAAD	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg25251562	chr2:3704773	ALLC	-0.46	-5.18	-0.39	6.97e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg10253484	chr15:75165896	SCAMP2	0.52	4.66	0.35	6.82e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.44	-0.46	1.49e-9	Morning vs. evening chronotype;
PAAD	cis	rs375066	0.935	rs446674	chr19:44421007	G/A	cg11993925	chr19:44307056	LYPD5	0.5	6.36	0.46	2.2e-9	Breast cancer;
PAAD	cis	rs10875746	0.551	rs3751273	chr12:48739438	T/C	cg26205652	chr12:48591994	NA	0.76	7.05	0.5	6.02e-11	Longevity (90 years and older);
PAAD	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	trans	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.23	-0.39	5.41e-7	Systolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23960561	chr4:40058360	N4BP2;LOC344967	-0.77	-6.86	-0.49	1.63e-10	Neuroticism;
PAAD	cis	rs2718812	1.000	rs2718812	chr3:133399702	C/T	cg08439880	chr3:133502540	NA	0.41	4.62	0.35	8.2e-6	Iron status biomarkers;
PAAD	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg20607287	chr7:12443886	VWDE	-0.79	-5.74	-0.42	5.03e-8	Coronary artery disease;
PAAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.49	-5.69	-0.42	6.31e-8	Longevity;Endometriosis;
PAAD	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.76	-5.76	-0.42	4.62e-8	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08265790	chr5:141704696	SPRY4	0.58	6.34	0.46	2.43e-9	Myopia (pathological);
PAAD	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1570884	0.539	rs4942843	chr13:50109287	A/G	cg03651054	chr13:50194643	NA	0.35	4.28	0.33	3.26e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2249694	0.922	rs8192780	chr10:135354125	T/G	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.82	8.36	0.56	3.71e-14	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.66	6.53	0.47	9.27e-10	Gastritis;
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs858239	0.965	rs156429	chr7:23306020	A/G	cg27449745	chr7:23145252	KLHL7	-0.58	-5.37	-0.4	2.83e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.72	0.42	5.6e-8	Platelet count;
PAAD	trans	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg15770106	chr1:208133116	NA	-0.69	-6.34	-0.46	2.53e-9	Corneal structure;
PAAD	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.38e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg17182837	chr8:41585554	ANK1	-0.44	-4.85	-0.37	3.03e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.25	-0.39	4.94e-7	Pulmonary function;
PAAD	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs28489187	0.706	rs72724606	chr1:85850246	T/C	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.64	-6.26	-0.45	3.83e-9	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg07159951	chr1:45983175	PRDX1	0.44	4.74	0.36	4.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs818427	0.527	rs469886	chr5:112245147	G/T	cg06941702	chr5:112196734	SRP19	0.57	5.61	0.41	9.49e-8	Total body bone mineral density;
PAAD	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg20356878	chr3:121714668	ILDR1	0.49	4.64	0.35	7.5e-6	Cognitive performance;
PAAD	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg14349672	chr11:133703707	NA	0.56	6.32	0.46	2.71e-9	Childhood ear infection;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-5.69	-0.42	6.23e-8	Prudent dietary pattern;
PAAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.7	6.2	0.45	5.14e-9	Platelet count;
PAAD	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg08992911	chr2:238395768	MLPH	-0.71	-5.32	-0.4	3.65e-7	Prostate cancer;
PAAD	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg03999872	chr20:62272968	STMN3	0.68	6.38	0.46	2.07e-9	Atopic dermatitis;
PAAD	cis	rs2657888	0.628	rs2638334	chr12:56882528	A/C	cg23002907	chr12:56915593	RBMS2	0.45	4.42	0.34	1.86e-5	Adiponectin levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14915854	chr11:46722264	ZNF408;ARHGAP1	0.57	6.49	0.47	1.12e-9	Monocyte percentage of white cells;
PAAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg12757816	chr2:10669957	NA	-0.54	-5.88	-0.43	2.55e-8	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	4.76	0.36	4.47e-6	Menarche (age at onset);
PAAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.88	9.31	0.6	1.33e-16	Parkinson's disease;
PAAD	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	1.07	6.68	0.48	4.33e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs11638815	0.520	rs4779032	chr15:83245326	A/G	cg00614314	chr15:82944287	LOC80154	0.5	5.17	0.39	7.41e-7	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.46	-0.4	1.93e-7	Obesity-related traits;
PAAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg21231944	chr12:82153410	PPFIA2	-0.53	-4.57	-0.35	9.89e-6	Resting heart rate;
PAAD	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg21479132	chr6:26055353	NA	0.93	5.81	0.43	3.61e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.75e-6	Height;
PAAD	cis	rs372883	0.564	rs13051579	chr21:30589840	C/T	cg08807101	chr21:30365312	RNF160	0.47	4.6	0.35	8.74e-6	Pancreatic cancer;
PAAD	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg00717180	chr2:96193071	NA	-0.63	-7.63	-0.53	2.44e-12	HDL cholesterol;
PAAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg13264159	chr8:625131	ERICH1	0.74	4.63	0.35	7.65e-6	IgG glycosylation;
PAAD	cis	rs9462027	0.561	rs2235568	chr6:34570094	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.52	-0.34	1.22e-5	Systemic lupus erythematosus;
PAAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.45	-4.28	-0.33	3.3e-5	Renal cell carcinoma;
PAAD	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.06	9.94	0.63	2.98e-18	Red blood cell traits;
PAAD	cis	rs1823874	0.924	rs4965542	chr15:100356619	A/G	cg16400843	chr15:100339927	C15orf51	0.41	5.05	0.38	1.24e-6	IgG glycosylation;
PAAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.33	-0.4	3.45e-7	Blood metabolite levels;
PAAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.54	-5.16	-0.39	7.6e-7	Paraoxonase activity;
PAAD	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.62	6.29	0.45	3.2e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.54	-4.98	-0.37	1.68e-6	Strep throat;
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg25124228	chr12:125621409	AACS	-0.64	-6.12	-0.44	7.53e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.5	4.56	0.35	1.05e-5	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.79	0.36	3.88e-6	Menopause (age at onset);
PAAD	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.72	5.78	0.42	4.07e-8	Exhaled nitric oxide output;
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11512800	chr11:94822733	ENDOD1	-0.65	-6.34	-0.46	2.51e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg10356904	chr22:49881777	NA	-0.49	-4.87	-0.37	2.77e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.99	7.51	0.52	4.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.93	0.43	1.93e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.86e-6	Refractive error;
PAAD	cis	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg11196182	chr7:1989412	MAD1L1	0.41	4.37	0.33	2.33e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg20312557	chr2:97357134	FER1L5	-0.82	-4.35	-0.33	2.49e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg15956490	chr3:53032818	SFMBT1	0.73	4.31	0.33	2.97e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg06606381	chr12:133084897	FBRSL1	0.99	6.35	0.46	2.35e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-6.12	-0.44	7.46e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg16606324	chr3:10149918	C3orf24	0.82	6.37	0.46	2.11e-9	Alzheimer's disease;
PAAD	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.44	-6.09	-0.44	9e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg03538708	chr1:25844672	NA	0.53	5.42	0.4	2.32e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg12935359	chr14:103987150	CKB	-0.66	-7.02	-0.49	6.96e-11	Body mass index;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01942863	chr7:99769432	GPC2	0.54	4.39	0.34	2.1e-5	Platelet count;
PAAD	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-1.19	-13.25	-0.73	3.91e-27	Hair shape;
PAAD	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg02887458	chr19:19495540	GATAD2A	0.49	4.64	0.35	7.56e-6	Bipolar disorder;
PAAD	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.83	10.12	0.63	1.02e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.51	4.83	0.36	3.31e-6	Sjögren's syndrome;
PAAD	cis	rs2221894	0.960	rs4732893	chr8:28794678	A/G	cg20212339	chr8:28908912	HMBOX1	-0.51	-5.44	-0.4	2.13e-7	Obesity-related traits;
PAAD	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg14196790	chr5:131705035	SLC22A5	0.46	4.96	0.37	1.83e-6	Blood metabolite levels;
PAAD	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.8	9.78	0.62	8.15e-18	Breast cancer;
PAAD	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.96	5.62	0.42	8.68e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17376030	chr22:41985996	PMM1	0.63	4.41	0.34	1.98e-5	Vitiligo;
PAAD	cis	rs6076065	0.676	rs4813490	chr20:23325150	A/G	cg11657817	chr20:23433608	CST11	0.46	4.7	0.36	5.89e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs13242816	0.881	rs35062002	chr7:116142458	G/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.78	-0.36	4.11e-6	P wave duration;
PAAD	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	9.98	0.63	2.41e-18	Cognitive test performance;
PAAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.2e-14	Eye color traits;
PAAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.49	-5.38	-0.4	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg05768032	chr16:30646687	NA	0.53	5.22	0.39	5.66e-7	Multiple myeloma;
PAAD	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05347473	chr6:146136440	FBXO30	0.5	4.76	0.36	4.5e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.73	-0.36	5.12e-6	Cognitive function;
PAAD	trans	rs12545912	0.820	rs11779335	chr8:9587854	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10929159	0.928	rs6761121	chr2:236922541	T/C	cg14226755	chr2:236923322	AGAP1	0.29	4.55	0.35	1.08e-5	Parkinson's disease;
PAAD	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg12929805	chr1:2399054	NA	-0.39	-4.28	-0.33	3.24e-5	Non-obstructive azoospermia;
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg05861140	chr6:150128134	PCMT1	-0.57	-6.5	-0.47	1.07e-9	Lung cancer;
PAAD	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16686137	chr19:48837272	TMEM143	-0.77	-6.71	-0.48	3.64e-10	Neuroticism;
PAAD	cis	rs357618	1.000	rs441652	chr5:150847505	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-4.48	-0.34	1.44e-5	Basophil percentage of white cells;
PAAD	cis	rs12612619	0.704	rs2119026	chr2:27310393	A/G	cg00617064	chr2:27272375	NA	0.51	5.32	0.4	3.59e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.78	-7.8	-0.53	9.19e-13	Coronary artery disease;
PAAD	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg02887458	chr19:19495540	GATAD2A	0.55	5.13	0.38	8.7e-7	Bipolar disorder;
PAAD	cis	rs3917254	0.543	rs12470623	chr2:102744015	A/T	cg22835712	chr2:102737379	NA	-0.63	-4.9	-0.37	2.4e-6	Blood protein levels;
PAAD	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.63	-0.35	7.74e-6	Coronary artery disease;
PAAD	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg15309053	chr8:964076	NA	0.5	5.63	0.42	8.61e-8	Schizophrenia;
PAAD	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.8	-9.18	-0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.65	6.69	0.48	4.01e-10	Obesity-related traits;
PAAD	cis	rs12760731	0.623	rs12691482	chr1:178421901	T/G	cg00404053	chr1:178313656	RASAL2	0.64	5.46	0.41	1.89e-7	Obesity-related traits;
PAAD	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg23587288	chr2:27483067	SLC30A3	-0.8	-6.57	-0.47	7.55e-10	Blood metabolite levels;
PAAD	cis	rs863345	0.967	rs863355	chr1:158542595	T/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.89	-0.37	2.57e-6	Pneumococcal bacteremia;
PAAD	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.73	5.14	0.38	8.39e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg06815965	chr1:205818668	PM20D1	0.63	7.01	0.49	7.26e-11	Menarche (age at onset);
PAAD	cis	rs12464483	1.000	rs12464483	chr2:30888924	G/A	cg12454169	chr2:30669597	LCLAT1	0.87	5.71	0.42	5.9e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs740474	0.768	rs2530223	chr5:141014494	T/C	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.31	4.56	0.35	1.03e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.06	14.42	0.76	3.05e-30	Testicular germ cell tumor;
PAAD	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.47	4.97	0.37	1.81e-6	Morning vs. evening chronotype;
PAAD	cis	rs988913	0.515	rs11756299	chr6:54951016	A/G	cg03513858	chr6:54763001	FAM83B	-0.4	-4.54	-0.35	1.13e-5	Menarche (age at onset);
PAAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.72	7.47	0.52	5.99e-12	Morning vs. evening chronotype;
PAAD	cis	rs1499972	0.618	rs62264768	chr3:117642924	T/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs9810890	0.850	rs115970727	chr3:128559179	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	1.0	10.12	0.63	9.95e-19	Breast cancer;
PAAD	cis	rs939584	0.935	rs12714413	chr2:642253	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06737937	chr7:87849496	SRI	0.6	6.35	0.46	2.37e-9	Myopia (pathological);
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.53	5.14	0.38	8.37e-7	Testicular germ cell tumor;
PAAD	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.56	-5.9	-0.43	2.23e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-0.82	-8.99	-0.59	9.28e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg09386050	chr7:809078	HEATR2	-0.67	-7.14	-0.5	3.63e-11	Subjective well-being;
PAAD	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	6.75	0.48	2.9e-10	Body mass index;
PAAD	cis	rs6743376	0.509	rs3180234	chr2:113820655	A/T	cg12858261	chr2:113808755	IL1F8	0.43	4.34	0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-5.07	-0.38	1.12e-6	Personality dimensions;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg17372223	chr3:52568218	NT5DC2	-0.49	-5.02	-0.38	1.42e-6	Electroencephalogram traits;
PAAD	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-1.02	-10.22	-0.64	5.43e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg08992911	chr2:238395768	MLPH	0.59	5.17	0.39	7.21e-7	Prostate cancer;
PAAD	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6879260	0.682	rs12173080	chr5:179741411	A/C	cg02891314	chr5:179741120	GFPT2	-0.77	-7.84	-0.54	7.23e-13	Height;
PAAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg14343924	chr8:8086146	FLJ10661	0.53	4.65	0.35	7.29e-6	Mood instability;
PAAD	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs7547997	0.615	rs114657189	chr1:158318340	G/C	cg26014409	chr1:158324471	CD1E	0.37	4.63	0.35	7.65e-6	QRS duration;
PAAD	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.74	-6.32	-0.46	2.76e-9	Exhaled nitric oxide output;
PAAD	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg15309053	chr8:964076	NA	0.43	4.92	0.37	2.24e-6	Schizophrenia;
PAAD	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.78	-9.23	-0.6	2.21e-16	Huntington's disease progression;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.98	6.84	0.49	1.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-9.04	-0.59	6.6e-16	Bone mineral density;
PAAD	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg03538708	chr1:25844672	NA	-0.52	-5.31	-0.4	3.86e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs72781680	0.566	rs6714016	chr2:23899948	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	5.81	0.43	3.52e-8	Lymphocyte counts;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.59	-5.66	-0.42	7.43e-8	Resistin levels;
PAAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.52	5.09	0.38	1.06e-6	Mood instability;
PAAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.99	-0.38	1.61e-6	Initial pursuit acceleration;
PAAD	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg06241208	chr11:30344200	C11orf46	-0.51	-4.58	-0.35	9.68e-6	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg17105886	chr17:28927953	LRRC37B2	0.75	4.94	0.37	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.5	4.86	0.37	2.95e-6	Major depressive disorder;
PAAD	cis	rs12612619	0.732	rs12616092	chr2:27217228	G/A	cg00617064	chr2:27272375	NA	-0.48	-5.12	-0.38	8.92e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-1.01	-12.84	-0.72	4.95e-26	Refractive error;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21754773	chr3:58477622	KCTD6	0.65	7.15	0.5	3.46e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26690034	chr1:75198963	CRYZ;TYW3	0.52	4.77	0.36	4.35e-6	Resistin levels;
PAAD	cis	rs13092825	1.000	rs71319373	chr3:113306741	C/A	cg18753928	chr3:113234510	CCDC52	-0.46	-4.43	-0.34	1.81e-5	Dental caries;
PAAD	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg27565382	chr3:53032988	SFMBT1	0.74	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.74	5.31	0.4	3.91e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.83	-0.43	3.29e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg06386533	chr2:46925753	SOCS5	0.53	4.47	0.34	1.5e-5	Height;
PAAD	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.41	-5.65	-0.42	7.85e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.72	6.75	0.48	2.86e-10	Asthma;
PAAD	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	5.81	0.43	3.56e-8	Adiposity;
PAAD	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg19901468	chr14:105411992	AHNAK2	-0.95	-11.21	-0.67	1.27e-21	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg11764359	chr7:65958608	NA	0.78	5.24	0.39	5.25e-7	Diabetic kidney disease;
PAAD	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.77	-0.36	4.23e-6	Joint mobility (Beighton score);
PAAD	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg03098721	chr1:84464084	TTLL7	0.48	4.52	0.34	1.25e-5	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg10534938	chr5:1868639	NA	0.47	6.23	0.45	4.38e-9	Cardiovascular disease risk factors;
PAAD	cis	rs75920871	0.702	rs59511712	chr11:116945762	C/T	cg04087571	chr11:116723030	SIK3	-0.39	-4.75	-0.36	4.63e-6	Subjective well-being;
PAAD	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.59	-5.48	-0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1620921	0.505	rs34797199	chr6:161203769	C/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs901683	0.850	rs112997714	chr10:46097216	A/G	cg13065504	chr15:42448234	PLA2G4F	0.78	6.4	0.46	1.78e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.57	6.68	0.48	4.19e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04998419	chr1:40626967	RLF	-0.59	-6.84	-0.49	1.8e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.73	7.43	0.52	7.26e-12	Age at first birth;
PAAD	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs9535307	0.584	rs7996307	chr13:50408023	C/T	cg04663916	chr13:50265991	EBPL	-0.67	-4.8	-0.36	3.69e-6	Obesity-related traits;
PAAD	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg15676125	chr6:33679581	C6orf125	0.49	4.8	0.36	3.8e-6	Plateletcrit;
PAAD	cis	rs4668356	1.000	rs16859087	chr2:171855833	G/A	cg13882835	chr2:172017928	TLK1	0.95	5.03	0.38	1.36e-6	Cognitive performance;
PAAD	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.41	0.4	2.4e-7	HDL cholesterol;
PAAD	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.51	-8.04	-0.55	2.4e-13	Cutaneous nevi;
PAAD	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg04851639	chr8:1020857	NA	-0.58	-6.94	-0.49	1.04e-10	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13170934	chr1:156722147	HDGF	-0.75	-6.47	-0.46	1.24e-9	Neuroticism;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg04810063	chr16:88703634	IL17C	-0.56	-5.15	-0.39	7.94e-7	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.64	5.31	0.4	3.77e-7	Prostate cancer;
PAAD	cis	rs89107	0.688	rs281867	chr6:118575808	C/T	cg18833306	chr6:118973337	C6orf204	0.48	5.61	0.41	9.41e-8	Cardiac structure and function;
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.46	-0.76	2.31e-30	Headache;
PAAD	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.6	-0.41	9.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.88	-9.73	-0.62	1.08e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs8037137	0.915	rs112770790	chr15:91507495	G/A	cg23684204	chr15:91497937	RCCD1	0.81	5.03	0.38	1.38e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.89	-8.94	-0.59	1.24e-15	Asthma;
PAAD	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs151997	0.538	rs1345777	chr5:50263788	A/G	cg06027927	chr5:50259733	NA	-0.62	-5.5	-0.41	1.59e-7	Callous-unemotional behaviour;
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.76	7.25	0.51	1.97e-11	Pancreatic cancer;
PAAD	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.95	0.43	1.76e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.48	0.41	1.71e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg15798862	chr7:76129360	DTX2	-0.52	-6.87	-0.49	1.57e-10	Multiple sclerosis;
PAAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.47	-5.37	-0.4	2.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg01815783	chr4:1047043	NA	-0.49	-4.62	-0.35	8.21e-6	Recombination rate (females);
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg15181151	chr6:150070149	PCMT1	0.6	6.54	0.47	8.96e-10	Lung cancer;
PAAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.65	7.33	0.51	1.25e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.4	-4.79	-0.36	3.99e-6	Blood protein levels;
PAAD	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.79	0.36	4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-1.08	-8.49	-0.57	1.71e-14	Initial pursuit acceleration;
PAAD	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.54	-0.41	1.3e-7	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.59	-8.88	-0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs9535307	0.929	rs9526593	chr13:50288777	T/C	cg04663916	chr13:50265991	EBPL	0.61	4.69	0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg04106633	chr4:1044584	NA	0.66	5.57	0.41	1.11e-7	Recombination rate (females);
PAAD	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.15	0.5	3.44e-11	Lung cancer in ever smokers;
PAAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.53	-7.38	-0.51	9.87e-12	Rheumatoid arthritis;
PAAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.96	-11.15	-0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg00181669	chr3:44000978	NA	-0.43	-4.28	-0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg26220594	chr1:19110978	NA	0.7	5.96	0.44	1.68e-8	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs8105895	0.935	rs7253053	chr19:22245685	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17037329	chr17:73285700	SLC25A19	0.65	7.06	0.5	5.55e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.14e-9	Bladder cancer;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg23958373	chr8:599963	NA	-1.13	-7.22	-0.51	2.31e-11	IgG glycosylation;
PAAD	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.64	6.45	0.46	1.43e-9	Colorectal cancer;
PAAD	cis	rs9687846	1.000	rs9687846	chr5:55861894	G/A	cg15001016	chr5:55860904	NA	-0.51	-4.93	-0.37	2.15e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7668190	0.924	rs2114039	chr4:55092626	T/C	cg17187183	chr4:55093834	PDGFRA	0.46	4.47	0.34	1.53e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg01329690	chr21:38580129	DSCR9	0.31	4.25	0.33	3.75e-5	Eye color traits;
PAAD	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg22771759	chr13:24902376	NA	0.48	4.72	0.36	5.34e-6	Obesity-related traits;
PAAD	cis	rs9434723	0.920	rs2239560	chr1:9304731	C/T	cg04199779	chr1:9294473	H6PD	0.57	5.02	0.38	1.42e-6	Height;
PAAD	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.8	-9.34	-0.6	1.15e-16	Morning vs. evening chronotype;
PAAD	cis	rs4743820	0.620	rs7046632	chr9:93919341	C/T	cg14446406	chr9:93919335	NA	0.48	5.74	0.42	5.01e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs75920871	1.000	rs4938325	chr11:116898479	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.42e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs2286379	0.626	rs10848557	chr12:1827810	G/T	cg05227549	chr12:1770782	NA	-0.43	-4.99	-0.37	1.67e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-7.22	-0.51	2.33e-11	Body mass index;
PAAD	cis	rs2882667	0.690	rs4835708	chr5:138179893	C/T	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.91	-8.54	-0.57	1.31e-14	Gut microbiome composition (summer);
PAAD	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg19630374	chr17:18023558	MYO15A	-0.47	-4.88	-0.37	2.63e-6	Total body bone mineral density;
PAAD	cis	rs8005172	0.722	rs9671908	chr14:88470049	G/T	cg18078958	chr14:88630771	NA	0.48	5.65	0.42	7.78e-8	Parkinson's disease;
PAAD	cis	rs7070678	0.505	rs12775988	chr10:29784489	T/C	cg14001239	chr10:29771743	SVIL	0.45	4.83	0.36	3.33e-6	Platelet thrombus formation;
PAAD	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.84	0.49	1.81e-10	Coffee consumption (cups per day);
PAAD	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.75	8.03	0.55	2.47e-13	Menopause (age at onset);
PAAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	6.71	0.48	3.55e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg16557858	chr17:37879740	ERBB2	-0.45	-4.39	-0.34	2.07e-5	Asthma;
PAAD	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.45	7.26	0.51	1.91e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg03700679	chr2:178418002	TTC30B	-0.54	-4.38	-0.33	2.23e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-6.17	-0.45	6.02e-9	Schizophrenia;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg18279126	chr7:2041391	MAD1L1	0.57	5.78	0.42	4.06e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12144094	0.882	rs55806106	chr1:120232539	T/A	cg20995928	chr1:120229863	NA	0.53	4.79	0.36	3.96e-6	Height;
PAAD	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.76	5.41	0.4	2.36e-7	Vitiligo;
PAAD	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.7	6.62	0.47	5.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.22e-7	Vitamin D levels;
PAAD	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.75	8.13	0.55	1.38e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	1.04	9.09	0.59	4.93e-16	Neutrophil percentage of white cells;
PAAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg03983715	chr16:68378420	PRMT7	-0.73	-5.31	-0.4	3.77e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs448720	0.811	rs2458506	chr15:68182610	G/A	cg05925327	chr15:68127851	NA	-0.38	-4.31	-0.33	2.96e-5	Cognitive performance;
PAAD	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.8	7.55	0.52	3.74e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.59e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs11694441	0.618	rs4849725	chr2:119574890	C/G	cg14634534	chr2:119616825	NA	-0.43	-4.72	-0.36	5.37e-6	Monobrow;
PAAD	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg22920501	chr2:26401640	FAM59B	-0.91	-8.01	-0.54	2.84e-13	Gut microbiome composition (summer);
PAAD	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.85	-4.65	-0.35	7.26e-6	Toenail selenium levels;
PAAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.78e-5	Monobrow;
PAAD	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.42	4.81	0.36	3.55e-6	Breast cancer;
PAAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg11502198	chr6:26597334	ABT1	0.42	4.51	0.34	1.26e-5	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7615916	0.542	rs73134740	chr3:12384266	C/T	cg23514324	chr3:12329213	PPARG	0.66	4.53	0.34	1.2e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.7	-7.0	-0.49	7.84e-11	Retinal vascular caliber;
PAAD	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.55	-5.42	-0.4	2.27e-7	Inflammatory bowel disease;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.73	7.29	0.51	1.55e-11	Blood metabolite levels;
PAAD	cis	rs2252790	0.930	rs1204860	chr6:116588606	G/A	cg26893134	chr6:116381904	FRK	-0.29	-4.47	-0.34	1.53e-5	Fast beta electroencephalogram;
PAAD	cis	rs2171564	0.557	rs9831780	chr3:112442083	G/A	cg06685282	chr3:112453648	NA	0.53	5.22	0.39	5.86e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.94	-11.02	-0.67	4.11e-21	Coronary artery disease;
PAAD	cis	rs7558233	0.614	rs6544858	chr2:23676071	C/T	cg00747342	chr2:23700632	KLHL29	-0.67	-4.25	-0.33	3.7e-5	Cannabis use (initiation);
PAAD	cis	rs28785552	0.554	rs11084184	chr19:53213939	G/A	cg10871876	chr19:53194124	ZNF83	0.51	4.63	0.35	7.92e-6	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.59	-0.41	1.04e-7	Neuroticism;
PAAD	cis	rs990171	1.000	rs1465321	chr2:102986618	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.54	0.35	1.13e-5	Lymphocyte counts;
PAAD	cis	rs11651753	0.561	rs61422354	chr17:45969809	A/G	cg24458315	chr17:46148407	CBX1	0.41	4.54	0.35	1.11e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg26174226	chr8:58114915	NA	0.59	4.33	0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	10.87	0.66	9.86e-21	Ulcerative colitis;
PAAD	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.7	6.97	0.49	9.12e-11	Body mass index;
PAAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.66	6.75	0.48	2.91e-10	Testicular germ cell tumor;
PAAD	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg20848291	chr7:100343083	ZAN	-0.54	-4.55	-0.35	1.11e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs914615	0.529	rs11264338	chr1:155138557	A/G	cg20311333	chr1:155197753	GBAP1	0.44	4.26	0.33	3.61e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-5.79	-0.43	3.9e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.76	8.64	0.57	7.11e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18364779	chr6:26104403	HIST1H4C	0.44	4.43	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg23947450	chr7:900037	UNC84A	-0.53	-4.38	-0.33	2.2e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.33	-0.4	3.55e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	1.06	8.26	0.56	6.67e-14	Menopause (age at onset);
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	1.13	6.62	0.47	5.8e-10	Body mass index;
PAAD	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.71	8.19	0.55	9.66e-14	Corneal astigmatism;
PAAD	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.45	-4.58	-0.35	9.43e-6	Menopause (age at onset);
PAAD	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.87	8.63	0.57	7.84e-15	Response to hepatitis C treatment;
PAAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg03676636	chr4:99064102	C4orf37	0.29	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg21479132	chr6:26055353	NA	0.88	5.78	0.42	4.01e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg24733560	chr20:60626293	TAF4	0.45	5.67	0.42	7.14e-8	Body mass index;
PAAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.62	6.59	0.47	6.76e-10	Multiple sclerosis;
PAAD	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-5.33	-0.4	3.5e-7	Menarche (age at onset);
PAAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.91	-0.49	1.28e-10	Neuroticism;
PAAD	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg05484376	chr2:27715224	FNDC4	-0.43	-4.42	-0.34	1.86e-5	Oral cavity cancer;
PAAD	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-5.19	-0.39	6.59e-7	Systolic blood pressure;
PAAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09835421	chr16:68378352	PRMT7	-1.18	-8.67	-0.58	6.19e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg00262122	chr8:11665843	FDFT1	-0.6	-5.12	-0.38	9.03e-7	Neuroticism;
PAAD	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg12046867	chr14:103022105	NA	-0.62	-4.84	-0.37	3.14e-6	Platelet count;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg26071806	chr7:100318239	EPO	-0.51	-4.94	-0.37	1.99e-6	Other erythrocyte phenotypes;
PAAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg16434002	chr17:42200994	HDAC5	-0.68	-7.42	-0.52	7.56e-12	Total body bone mineral density;
PAAD	cis	rs939584	1.000	rs939581	chr2:623224	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.69	6.91	0.49	1.22e-10	Blood metabolite levels;
PAAD	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.53	-0.34	1.2e-5	Longevity;Endometriosis;
PAAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.03e-8	Blood metabolite levels;
PAAD	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.56	5.37	0.4	2.9e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.57	-0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg00228799	chr9:131580591	ENDOG	0.64	6.43	0.46	1.58e-9	Blood metabolite levels;
PAAD	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.75e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07648498	chr16:89883185	FANCA	0.69	7.12	0.5	4.07e-11	Vitiligo;
PAAD	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.96	-7.88	-0.54	5.69e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2882667	0.690	rs10067361	chr5:138240874	G/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.08	-0.38	1.08e-6	Bladder cancer;
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg04369109	chr6:150039330	LATS1	-0.5	-4.83	-0.36	3.31e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg00166722	chr3:10149974	C3orf24	0.73	6.69	0.48	4.11e-10	Alzheimer's disease;
PAAD	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.67	0.35	6.45e-6	Educational attainment;
PAAD	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.76	-8.12	-0.55	1.52e-13	Rheumatoid arthritis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05462360	chr17:18218585	TOP3A;SMCR8	0.64	6.8	0.48	2.28e-10	Myopia (pathological);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27619446	chr6:4955582	CDYL	-0.62	-6.36	-0.46	2.25e-9	Obesity-related traits;
PAAD	cis	rs727479	0.543	rs56097510	chr15:51533478	C/G	cg21478137	chr15:51532386	CYP19A1	0.54	5.25	0.39	4.93e-7	Estradiol levels;
PAAD	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg08213375	chr14:104286397	PPP1R13B	0.43	5.91	0.43	2.18e-8	Schizophrenia;
PAAD	cis	rs990171	1.000	rs3771170	chr2:102985980	T/A	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.49	-0.34	1.42e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35160687	0.842	rs10200526	chr2:86527599	G/A	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17167289	chr3:42846087	HIGD1A	-0.67	-6.89	-0.49	1.38e-10	Smoking initiation;
PAAD	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.41	0.34	1.95e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs4975616	0.686	rs37009	chr5:1350339	C/T	cg26209169	chr5:1316264	NA	0.37	4.26	0.33	3.61e-5	Lung cancer;
PAAD	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs621942	0.718	rs583463	chr11:85775828	G/C	cg07180834	chr11:85838833	NA	-0.5	-5.0	-0.38	1.54e-6	Tourette syndrome;
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.74	-6.55	-0.47	8.17e-10	Breast cancer;
PAAD	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.43	4.82	0.36	3.5e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg07159951	chr1:45983175	PRDX1	-0.41	-4.46	-0.34	1.56e-5	High light scatter reticulocyte count;
PAAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg13468214	chr4:1046988	NA	-0.58	-4.62	-0.35	8.1e-6	Recombination rate (females);
PAAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg06740227	chr12:86229804	RASSF9	0.54	4.96	0.37	1.83e-6	Major depressive disorder;
PAAD	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.23	-0.51	2.25e-11	Response to antipsychotic treatment;
PAAD	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.81	9.43	0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg23708337	chr7:1209742	NA	0.69	5.23	0.39	5.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.6	0.41	9.94e-8	Response to antipsychotic treatment;
PAAD	cis	rs2286379	0.597	rs9739162	chr12:1838008	G/T	cg11558135	chr12:861715	WNK1	-0.48	-4.68	-0.35	6.29e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.34	-0.4	3.36e-7	Subjective well-being;
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.84e-6	Monocyte percentage of white cells;
PAAD	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.55	-6.16	-0.45	6.2e-9	Longevity;
PAAD	cis	rs322458	0.550	rs662110	chr3:120636473	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.1	6.53	0.47	9.38e-10	Body mass index;
PAAD	cis	rs939584	1.000	rs7591067	chr2:642846	G/A	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg25558440	chr8:11882962	NA	-0.45	-4.31	-0.33	2.97e-5	Triglycerides;
PAAD	cis	rs28489187	0.683	rs1554597	chr1:85877098	C/T	cg16011679	chr1:85725395	C1orf52	-0.53	-5.08	-0.38	1.09e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.63	-7.47	-0.52	5.99e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-5.8	-0.43	3.64e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14422446	chr4:184858353	STOX2	-0.67	-6.89	-0.49	1.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6574988	0.514	rs751072	chr14:88562982	C/T	cg18078958	chr14:88630771	NA	0.48	4.39	0.34	2.14e-5	Bipolar disorder;
PAAD	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.55	-0.41	1.22e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06307176	chr5:131281290	NA	0.51	4.63	0.35	7.71e-6	Life satisfaction;
PAAD	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	5.11	0.38	9.5e-7	Birth weight;
PAAD	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg00614314	chr15:82944287	LOC80154	0.52	5.17	0.39	7.38e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.49	-4.84	-0.37	3.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2880058	0.958	rs10918593	chr1:162030654	C/T	cg23260004	chr1:161736072	ATF6	-0.5	-4.43	-0.34	1.8e-5	QT interval;
PAAD	cis	rs89107	1.000	rs9489327	chr6:118561889	T/C	cg21191810	chr6:118973309	C6orf204	0.4	5.17	0.39	7.17e-7	Cardiac structure and function;
PAAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.55	5.5	0.41	1.57e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.68	7.82	0.54	8.25e-13	Multiple sclerosis;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.77	9.22	0.6	2.33e-16	Lung cancer;
PAAD	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg14458575	chr2:238380390	NA	0.55	6.24	0.45	4.1e-9	Prostate cancer;
PAAD	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.19	5.87	0.43	2.6e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.62	-6.64	-0.47	5.29e-10	IgG glycosylation;
PAAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.5	-7.21	-0.51	2.4e-11	Diastolic blood pressure;
PAAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.52	5.16	0.39	7.53e-7	Menopause (age at onset);
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02359409	chr6:42947317	PEX6	-0.48	-4.91	-0.37	2.37e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg12935359	chr14:103987150	CKB	-0.57	-5.98	-0.44	1.54e-8	Body mass index;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.14e-8	Life satisfaction;
PAAD	cis	rs2730260	0.611	rs73169224	chr7:158850818	C/T	cg13444538	chr7:158905317	VIPR2	-0.69	-4.44	-0.34	1.7e-5	Myopia (pathological);
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.91	12.38	0.71	8.64e-25	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05332306	chr17:9548278	USP43	0.67	7.02	0.49	7.03e-11	Myopia (pathological);
PAAD	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg23995914	chr4:10459228	ZNF518B	0.36	4.33	0.33	2.73e-5	Schizophrenia (age at onset);
PAAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg27490568	chr2:178487706	NA	0.42	4.44	0.34	1.7e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg16230307	chr14:35515116	FAM177A1	0.41	4.34	0.33	2.62e-5	Psoriasis;
PAAD	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg06307176	chr5:131281290	NA	0.49	4.29	0.33	3.15e-5	Life satisfaction;
PAAD	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.68	5.11	0.38	9.49e-7	Initial pursuit acceleration;
PAAD	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg24220031	chr2:73402428	NA	-0.35	-5.39	-0.4	2.62e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.6	6.25	0.45	4.02e-9	Testicular germ cell tumor;
PAAD	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg20487152	chr13:99095054	FARP1	0.58	4.9	0.37	2.44e-6	Neuroticism;
PAAD	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	6.97	0.49	8.99e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg19052272	chr2:3704530	ALLC	-0.54	-6.44	-0.46	1.48e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg27426351	chr10:43362370	NA	0.55	4.44	0.34	1.76e-5	Blood protein levels;
PAAD	cis	rs501120	0.810	rs607592	chr10:44750215	A/G	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	trans	rs61677309	0.964	rs113145584	chr11:118154798	G/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.47	-0.46	1.28e-9	Lung cancer in ever smokers;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs4790333	0.539	rs67887169	chr17:2256828	G/A	cg02569219	chr17:2266849	SGSM2	0.49	4.74	0.36	4.84e-6	Proinsulin levels;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.58	0.8	6.69e-36	Prudent dietary pattern;
PAAD	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	4.74	0.36	4.94e-6	Thyroid stimulating hormone;
PAAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg26939375	chr7:64535504	NA	-0.75	-8.86	-0.58	1.96e-15	Aortic root size;
PAAD	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-4.67	-0.35	6.53e-6	Dementia with Lewy bodies;
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.41	-4.47	-0.34	1.53e-5	Mean platelet volume;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.67	-7.12	-0.5	4.02e-11	Longevity;Endometriosis;
PAAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.56	-6.38	-0.46	2.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00090800	chr16:27325237	IL4R	-0.59	-6.57	-0.47	7.58e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg11630242	chr17:19881632	AKAP10	-0.48	-4.42	-0.34	1.86e-5	Schizophrenia;
PAAD	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.51	-4.92	-0.37	2.27e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-1.03	-13.62	-0.74	4.14e-28	Refractive error;
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04497992	chr16:616212	NHLRC4	0.37	4.26	0.33	3.51e-5	Height;
PAAD	cis	rs6585424	1.000	rs34332933	chr10:81926750	G/C	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7771547	0.603	rs7344	chr6:36570366	A/G	cg07856975	chr6:36356162	ETV7	0.56	5.92	0.43	2.11e-8	Platelet distribution width;
PAAD	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19671926	chr4:122722719	EXOSC9	0.59	4.91	0.37	2.3e-6	Type 2 diabetes;
PAAD	cis	rs11951515	0.509	rs12521249	chr5:43558629	T/C	cg01983248	chr5:43482804	C5orf28	0.3	4.33	0.33	2.75e-5	Metabolite levels  (X-11787);
PAAD	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.5	4.63	0.35	7.75e-6	Hepatocellular carcinoma;
PAAD	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.59	5.33	0.4	3.54e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	1.01	7.11	0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs2790216	1.000	rs2790228	chr10:60014325	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.51	-5.04	-0.38	1.32e-6	Schizophrenia;
PAAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.45	4.55	0.35	1.08e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs144447022	1	rs144447022	chr6:29244219	G/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Intelligence (multi-trait analysis);Schizophrenia;
PAAD	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.19	-0.5	2.72e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.63	-0.42	8.45e-8	Life satisfaction;
PAAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.75	0.53	1.22e-12	Personality dimensions;
PAAD	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs16857609	0.564	rs6734808	chr2:218294571	C/T	cg15335768	chr2:218268053	DIRC3	-0.49	-5.09	-0.38	1.05e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg10437265	chr15:77819839	NA	0.43	4.75	0.36	4.74e-6	Type 2 diabetes;
PAAD	cis	rs12926503	0.502	rs36160302	chr16:84034500	G/T	cg05253165	chr16:84033146	NECAB2	-0.62	-4.29	-0.33	3.16e-5	Body mass index (change over time);
PAAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.59	6.48	0.47	1.22e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg03945807	chr20:60948434	NA	0.44	4.43	0.34	1.8e-5	Colorectal cancer;
PAAD	cis	rs35424364	1	rs35424364	chr6:109643605	A/AT	cg01475377	chr6:109611718	NA	-0.52	-4.37	-0.33	2.29e-5	Obstructive sleep apnea trait (average respiratory event duration);
PAAD	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg22189786	chr22:42395067	WBP2NL	0.52	4.4	0.34	2.05e-5	Birth weight;
PAAD	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg05250797	chr16:70222502	NA	0.87	6.72	0.48	3.39e-10	IgE levels;
PAAD	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.45	4.61	0.35	8.53e-6	Age of smoking initiation;
PAAD	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.87	-4.3	-0.33	3.02e-5	Toenail selenium levels;
PAAD	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg19640130	chr10:64028056	RTKN2	-0.39	-4.79	-0.36	3.88e-6	Rheumatoid arthritis;
PAAD	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.79	-5.84	-0.43	3.08e-8	Mean platelet volume;
PAAD	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20080590	chr4:24831413	CCDC149	0.63	7.19	0.5	2.67e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.68	-0.36	6.21e-6	Height;
PAAD	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9646944	0.501	rs13030675	chr2:103091618	C/A	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.85	-0.49	1.76e-10	Life satisfaction;
PAAD	cis	rs795484	0.856	rs431038	chr12:118657807	C/T	cg16572268	chr12:118583242	PEBP1	-0.47	-4.68	-0.35	6.28e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg01851573	chr8:8652454	MFHAS1	0.57	4.87	0.37	2.82e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2241685	0.621	rs7579818	chr2:1899145	G/T	cg22511877	chr2:1942942	MYT1L	-0.75	-5.13	-0.38	8.54e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.95	13.34	0.73	2.32e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2562456	0.833	rs7246339	chr19:21475297	T/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.59	-5.63	-0.42	8.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg18209359	chr17:80159595	CCDC57	0.43	4.3	0.33	3.02e-5	Life satisfaction;
PAAD	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg07943548	chr15:86304357	KLHL25	-0.74	-6.1	-0.44	8.31e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.1	-0.38	9.8e-7	Systemic lupus erythematosus;
PAAD	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-6.94	-0.49	1.07e-10	Personality dimensions;
PAAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.72	7.47	0.52	5.87e-12	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg08917208	chr2:24149416	ATAD2B	0.47	4.25	0.33	3.77e-5	Asthma;
PAAD	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	1.16	9.81	0.62	6.62e-18	Height;
PAAD	cis	rs2252790	1.000	rs2252790	chr6:116663323	G/A	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	trans	rs3905000	1.000	rs3847300	chr9:107648430	G/A	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs1190596	0.525	rs2236493	chr14:102695693	A/G	cg23904247	chr14:102554826	HSP90AA1	0.4	4.55	0.35	1.09e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg26248373	chr2:1572462	NA	-1.08	-7.56	-0.52	3.55e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg18788872	chr11:32605728	EIF3M	0.58	6.9	0.49	1.29e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs322458	0.573	rs660495	chr3:120621410	A/G	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.34e-6	Aging (facial);
PAAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.44	6.17	0.45	5.87e-9	Vitiligo;
PAAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg07841815	chr7:100318223	EPO	-0.47	-4.45	-0.34	1.68e-5	Other erythrocyte phenotypes;
PAAD	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.36	6.7	0.48	3.74e-10	Type 2 diabetes;
PAAD	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7823896	0.722	rs113820279	chr8:110301493	C/T	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg27234864	chr13:21295941	IL17D	0.61	5.32	0.4	3.67e-7	Dental caries;
PAAD	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.44	-4.46	-0.34	1.59e-5	Dementia with Lewy bodies;
PAAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg18230493	chr5:56204884	C5orf35	-0.57	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11811982	0.793	rs77218109	chr1:227469249	C/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.59	-5.55	-0.41	1.26e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg06609049	chr19:2785107	THOP1	0.89	10.08	0.63	1.32e-18	Total cholesterol levels;
PAAD	cis	rs16975963	0.843	rs11672257	chr19:38439362	A/G	cg25793785	chr19:38281423	NA	0.58	4.71	0.36	5.46e-6	Longevity;
PAAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17761864	0.555	rs11654642	chr17:2008938	G/A	cg16513277	chr17:2031491	SMG6	0.43	4.25	0.33	3.73e-5	Esophageal cancer (squamous cell);
PAAD	cis	rs17095355	0.818	rs7088861	chr10:111775544	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-4.75	-0.36	4.66e-6	Biliary atresia;
PAAD	cis	rs8067287	1.000	rs62065413	chr17:16813978	G/A	cg26910001	chr17:16838321	NA	-0.76	-5.99	-0.44	1.46e-8	Diabetic kidney disease;
PAAD	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.39	4.4	0.34	1.99e-5	IgG glycosylation;
PAAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.86	6.61	0.47	6.05e-10	Alzheimer's disease;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00149659	chr3:10157352	C3orf10	0.79	6.01	0.44	1.3e-8	Alzheimer's disease;
PAAD	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg08562672	chr19:21860753	NA	0.44	4.65	0.35	7.2e-6	Pain;
PAAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg04719120	chr6:96025338	MANEA	0.54	4.32	0.33	2.8e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs75920871	0.764	rs17120347	chr11:116996539	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.85	-4.25	-0.33	3.7e-5	Subjective well-being;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg14926445	chr8:58193284	C8orf71	-0.66	-5.48	-0.41	1.72e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg07777115	chr5:623756	CEP72	-0.47	-4.34	-0.33	2.64e-5	Cystic fibrosis severity;
PAAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.48	-4.86	-0.37	2.88e-6	Eosinophil percentage of white cells;
PAAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	1.19	6.43	0.46	1.59e-9	Skin colour saturation;
PAAD	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.74	-7.52	-0.52	4.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21028142	chr17:79581711	NPLOC4	0.51	5.94	0.43	1.89e-8	Eye color traits;
PAAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg06375148	chr1:209958343	C1orf74	0.61	4.65	0.35	7.24e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.57	5.6	0.41	9.85e-8	Lung cancer;
PAAD	cis	rs7255374	0.566	rs11666982	chr19:41531368	T/G	cg27089200	chr19:41531976	NA	0.43	4.85	0.37	2.98e-6	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs9502570	0.578	rs76831056	chr6:7269423	G/A	cg02954307	chr6:7269328	NA	0.53	4.25	0.33	3.67e-5	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg23555395	chr2:238036564	NA	0.49	5.7	0.42	6.12e-8	Systemic lupus erythematosus;
PAAD	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg19445457	chr11:5799446	OR52N5	-0.5	-4.57	-0.35	1.01e-5	DNA methylation (variation);
PAAD	cis	rs1879734	0.731	rs72660654	chr1:54157287	C/T	cg14659662	chr1:54151053	GLIS1	-0.42	-5.61	-0.41	9.3e-8	Mitral valve prolapse;
PAAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.63	8.24	0.56	7.48e-14	Renal cell carcinoma;
PAAD	cis	rs2457480	0.778	rs11238901	chr10:44681012	C/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;
PAAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00350441	chr16:57220262	FAM192A;RSPRY1	-0.71	-6.29	-0.45	3.16e-9	Neuroticism;
PAAD	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.55	-0.41	1.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs7122257	0.507	rs7110986	chr11:11161248	A/G	cg16931664	chr11:11169707	NA	-0.29	-4.25	-0.33	3.67e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.62	6.68	0.48	4.3e-10	N-glycan levels;
PAAD	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.76	7.92	0.54	4.59e-13	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.3	0.45	3.11e-9	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.08	0.81	3.45e-37	Prudent dietary pattern;
PAAD	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	0.89	6.37	0.46	2.16e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.98	0.37	1.72e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.42	0.46	1.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.44	4.37	0.33	2.31e-5	Crohn's disease;
PAAD	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.45	4.72	0.36	5.22e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.13	12.67	0.72	1.41e-25	Type 1 diabetes nephropathy;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg16850897	chr7:100343110	ZAN	-0.77	-6.38	-0.46	2.02e-9	Other erythrocyte phenotypes;
PAAD	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs73198271	0.628	rs11780486	chr8:8589494	C/T	cg01851573	chr8:8652454	MFHAS1	-0.63	-4.91	-0.37	2.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.99	10.93	0.66	6.96e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24895954	chr17:80988473	B3GNTL1	0.62	7.67	0.53	1.89e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-10.41	-0.65	1.73e-19	Blood trace element (Zn levels);
PAAD	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg27121462	chr16:89883253	FANCA	-0.43	-4.62	-0.35	8.27e-6	Multiple myeloma (IgH translocation);
PAAD	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-7.44	-0.52	6.86e-12	Leprosy;
PAAD	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg07212818	chr11:638076	DRD4	-0.7	-7.03	-0.5	6.38e-11	Systemic lupus erythematosus;
PAAD	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.98	11.99	0.7	9.75e-24	Bone mineral density;
PAAD	cis	rs7631605	0.905	rs2058476	chr3:37104896	G/T	cg17445812	chr3:36986805	TRANK1	0.35	4.63	0.35	7.93e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.52	0.41	1.43e-7	Depression;
PAAD	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.39	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.75	-0.48	3e-10	Type 2 diabetes;
PAAD	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.93	10.75	0.66	2.1e-20	IgG glycosylation;
PAAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6494488	0.500	rs118175183	chr15:64899341	A/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	6.35	0.46	2.42e-9	Hip circumference;
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.56	-7.14	-0.5	3.54e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg19792802	chr11:65647270	CTSW	0.36	4.62	0.35	8.13e-6	DNA methylation (variation);
PAAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6681460	0.546	rs12117649	chr1:67168606	G/A	cg02459107	chr1:67143332	SGIP1	0.61	5.85	0.43	2.89e-8	Presence of antiphospholipid antibodies;
PAAD	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.7	5.14	0.38	8.34e-7	Vitiligo;
PAAD	cis	rs6499244	0.552	rs7196917	chr16:69896527	A/G	cg05250797	chr16:70222502	NA	0.56	4.98	0.37	1.72e-6	Menarche (age at onset);
PAAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.76	-12.08	-0.7	5.8e-24	Body mass index;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg12525736	chr1:228269915	ARF1	0.65	6.4	0.46	1.8e-9	Primary biliary cholangitis;
PAAD	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.65	0.42	7.82e-8	Prostate cancer;
PAAD	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg07741184	chr6:167504864	NA	0.36	4.67	0.35	6.46e-6	Primary biliary cholangitis;
PAAD	cis	rs1345301	0.935	rs11691721	chr2:102876679	G/A	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.34	-0.33	2.57e-5	Waist circumference;
PAAD	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg09659197	chr4:152720779	NA	0.4	5.06	0.38	1.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.34	1.36e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.57	6.02	0.44	1.29e-8	Response to antidepressants and depression;
PAAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21646471	chr2:242523971	THAP4	0.66	5.29	0.39	4.21e-7	Prostate cancer;
PAAD	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg21665744	chr7:39171113	POU6F2	0.35	5.86	0.43	2.76e-8	IgG glycosylation;
PAAD	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg09127314	chr1:152161683	NA	-0.69	-4.83	-0.36	3.35e-6	Atopic dermatitis;
PAAD	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg01620082	chr3:125678407	NA	-1.13	-7.44	-0.52	6.91e-12	Depression;
PAAD	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-7.48	-0.52	5.5e-12	Total body bone mineral density;
PAAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg15117754	chr3:10150083	C3orf24	0.61	4.64	0.35	7.4e-6	Alzheimer's disease;
PAAD	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg23254163	chr1:152506842	NA	0.59	6.86	0.49	1.65e-10	Hair morphology;
PAAD	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.5	4.75	0.36	4.64e-6	Hepatocellular carcinoma;
PAAD	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-4.33	-0.33	2.69e-5	Multiple sclerosis;
PAAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-9.83	-0.62	5.78e-18	Bone mineral density;
PAAD	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg05925327	chr15:68127851	NA	-0.59	-5.19	-0.39	6.64e-7	Obesity;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12415761	chr2:210179077	NA	-0.51	-6.46	-0.46	1.35e-9	Energy expenditure (24h);
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.03	6.66	0.48	4.64e-10	Mitochondrial DNA levels;
PAAD	cis	rs59901009	0.532	rs7936461	chr11:10040886	C/T	cg06876053	chr11:9810051	SBF2	-0.33	-4.33	-0.33	2.74e-5	Hematocrit;Hemoglobin concentration;
PAAD	trans	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg16606324	chr3:10149918	C3orf24	0.52	4.44	0.34	1.73e-5	Alzheimer's disease;
PAAD	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.93	11.97	0.7	1.09e-23	Menarche (age at onset);
PAAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg14393609	chr7:65229607	NA	-0.48	-4.86	-0.37	2.93e-6	Aortic root size;
PAAD	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.58	6.32	0.46	2.72e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.72	7.17	0.5	3.12e-11	Prostate cancer;
PAAD	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.67	5.37	0.4	2.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.86	8.07	0.55	1.98e-13	Homoarginine levels;
PAAD	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8067287	0.724	rs35380019	chr17:16826904	G/A	cg26910001	chr17:16838321	NA	-0.68	-6.1	-0.44	8.35e-9	Diabetic kidney disease;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.82	-8.4	-0.56	3.01e-14	Prudent dietary pattern;
PAAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Height;
PAAD	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg23587288	chr2:27483067	SLC30A3	-0.79	-6.44	-0.46	1.49e-9	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg10547527	chr2:198650123	BOLL	0.49	4.31	0.33	2.98e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs713477	0.505	rs10131672	chr14:55905091	A/T	cg13175173	chr14:55914753	NA	-0.34	-4.51	-0.34	1.26e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs901683	1.000	rs71496613	chr10:46032573	A/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.64	-0.35	7.32e-6	Ulcerative colitis;
PAAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.06	-0.5	5.51e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg14092988	chr3:52407081	DNAH1	-0.55	-6.69	-0.48	4.08e-10	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21800906	chr11:32914818	QSER1	0.62	6.93	0.49	1.13e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg18833306	chr6:118973337	C6orf204	-0.56	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-6.72	-0.48	3.35e-10	Renal function-related traits (BUN);
PAAD	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.72	7.6	0.52	2.76e-12	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg14440974	chr22:39074834	NA	-0.53	-6.04	-0.44	1.13e-8	Menopause (age at onset);
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.86e-17	Platelet count;
PAAD	cis	rs17123764	0.605	rs6580719	chr12:50071092	C/A	cg14846292	chr12:49726500	C1QL4	-0.67	-4.35	-0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2109514	0.967	rs4730743	chr7:116145957	A/T	cg19719915	chr7:115928094	NA	-0.47	-4.42	-0.34	1.85e-5	Prevalent atrial fibrillation;
PAAD	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.01	0.59	8.14e-16	Menopause (age at onset);
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg17105886	chr17:28927953	LRRC37B2	0.76	4.88	0.37	2.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg01028140	chr2:1542097	TPO	-0.84	-6.22	-0.45	4.7e-9	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.89	11.11	0.67	2.35e-21	Prudent dietary pattern;
PAAD	cis	rs7264396	0.887	rs2236164	chr20:34097353	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.3	0.33	3.09e-5	Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.66	4.9	0.37	2.4e-6	Exhaled nitric oxide output;
PAAD	cis	rs11886999	0.812	rs12613263	chr2:96863677	G/C	cg16627346	chr2:96057706	NA	0.53	4.33	0.33	2.66e-5	Cardiac Troponin-T levels;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	10.22	0.64	5.44e-19	Cognitive test performance;
PAAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs7631605	0.905	rs2302505	chr3:37131404	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.98	-0.44	1.55e-8	Menarche (age at onset);
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.98	-13.03	-0.73	1.54e-26	Prudent dietary pattern;
PAAD	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.47	-7.81	-0.54	8.77e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg00982548	chr2:198649783	BOLL	-0.79	-5.64	-0.42	8.25e-8	Ulcerative colitis;
PAAD	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg01489032	chr8:143877656	NA	-0.38	-4.35	-0.33	2.53e-5	Urinary tract infection frequency;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg08219700	chr8:58056026	NA	0.72	5.73	0.42	5.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-6.96	-0.49	9.3e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.47	-4.94	-0.37	2.04e-6	Obesity-related traits;
PAAD	cis	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.78	-8.03	-0.55	2.45e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6687430	0.532	rs2150038	chr1:10609973	G/T	cg17425144	chr1:10567563	PEX14	-0.43	-4.71	-0.36	5.58e-6	Hand grip strength;
PAAD	cis	rs4478147	0.506	rs17409478	chr4:87244834	G/A	cg10685359	chr4:87814065	C4orf36	-0.52	-5.25	-0.39	5.09e-7	Migraine - clinic-based;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-7.42	-0.52	7.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1006703	0.544	rs8082265	chr17:3838761	C/T	cg06463185	chr17:3833770	ATP2A3	-0.87	-7.14	-0.5	3.55e-11	Glucose homeostasis traits;
PAAD	trans	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg11413142	chr17:80250339	NA	-0.68	-6.65	-0.47	4.92e-10	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Breast cancer;
PAAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.89	-9.28	-0.6	1.65e-16	Colorectal cancer;
PAAD	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.74	-6.75	-0.48	2.87e-10	Plateletcrit;Platelet count;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10497720	chr1:70876918	CTH	0.68	6.92	0.49	1.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7092929	0.941	rs590338	chr10:3557100	T/C	cg14308648	chr10:3568949	NA	0.67	4.95	0.37	1.98e-6	Coronary artery calcification;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03662217	chr21:35747882	FAM165B	0.6	6.74	0.48	3.09e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg08847533	chr14:75593920	NEK9	-0.52	-5.15	-0.39	7.95e-7	Caffeine consumption;
PAAD	cis	rs4594175	0.892	rs4572305	chr14:51592095	C/T	cg15942720	chr14:51706980	TMX1	0.53	4.39	0.34	2.07e-5	Cancer;
PAAD	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg19264203	chr11:92714893	MTNR1B	0.39	4.56	0.35	1.05e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs1146751	0.674	rs487539	chr3:84934198	T/A	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-7.38	-0.51	9.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.67	4.8	0.36	3.7e-6	Neuroticism;
PAAD	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs6688613	1.000	rs10918606	chr1:166957249	A/G	cg07049167	chr1:166818506	POGK	0.45	4.41	0.34	1.96e-5	Refractive astigmatism;
PAAD	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.85	-0.37	3.08e-6	Mean corpuscular volume;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.27	-0.33	3.43e-5	Breast cancer;
PAAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg10645314	chr2:3704589	ALLC	0.53	5.7	0.42	6.08e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2458413	0.771	rs7010076	chr8:105342827	C/G	cg04554929	chr8:105342491	NA	-0.39	-6.36	-0.46	2.26e-9	Paget's disease;
PAAD	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.61	-8.35	-0.56	4e-14	Asthma (sex interaction);
PAAD	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.71	-7.55	-0.52	3.81e-12	Response to antipsychotic treatment;
PAAD	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg06610559	chr17:74554360	SNORD1C	0.63	4.66	0.35	6.92e-6	Airflow obstruction;
PAAD	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.96	-14.83	-0.77	2.5e-31	Height;
PAAD	cis	rs9826463	0.757	rs60001529	chr3:142282717	G/A	cg20824294	chr3:142316082	PLS1	0.43	4.87	0.37	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg24101359	chr6:42928495	GNMT	0.55	5.59	0.41	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03909863	chr11:638404	DRD4	-0.78	-6.51	-0.47	1.01e-9	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.37	9.39	0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26926768	chr12:34528122	NA	0.39	4.58	0.35	9.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	5.37	0.4	2.92e-7	Breast cancer;
PAAD	cis	rs1561288	0.731	rs72852524	chr2:25346687	A/T	cg02492873	chr2:25193821	DNAJC27	0.49	4.25	0.33	3.75e-5	Body mass index;
PAAD	cis	rs75757892	0.544	rs4637687	chr6:7315986	A/T	cg02954307	chr6:7269328	NA	0.52	4.54	0.35	1.16e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.71	-6.12	-0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg13722127	chr7:150037890	RARRES2	0.61	5.96	0.44	1.69e-8	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24899292	chr19:41798372	HNRNPUL1	-0.58	-6.31	-0.46	2.89e-9	Immature fraction of reticulocytes;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.77	9.53	0.61	3.67e-17	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.48	-4.3	-0.33	3.06e-5	Testicular germ cell tumor;
PAAD	cis	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.54	-4.36	-0.33	2.4e-5	Diastolic blood pressure;
PAAD	cis	rs1529711	0.636	rs11673064	chr19:10955925	A/C	cg18582342	chr19:11591989	ELAVL3	-0.57	-4.87	-0.37	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.04e-5	Life satisfaction;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18297960	chr7:1142765	C7orf50	-0.55	-4.35	-0.33	2.49e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.9	9.58	0.61	2.75e-17	Bone mineral density;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27094323	chr7:1216898	NA	-0.52	-6.05	-0.44	1.1e-8	Longevity;Endometriosis;
PAAD	cis	rs27524	0.734	rs27037	chr5:96094694	T/G	cg17330273	chr5:96107758	CAST;ERAP1	0.6	5.86	0.43	2.74e-8	Psoriasis;Hodgkin's lymphoma;
PAAD	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	1.06	7.4	0.51	8.77e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7188861	0.724	rs12924957	chr16:11403766	C/T	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.14	-16.93	-0.81	8.47e-37	Cognitive function;
PAAD	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg02743256	chr7:2109353	MAD1L1	-0.71	-4.94	-0.37	1.99e-6	Neuroticism;
PAAD	cis	rs818427	0.896	rs9011	chr5:112212608	G/A	cg06941702	chr5:112196734	SRP19	-0.46	-4.28	-0.33	3.34e-5	Total body bone mineral density;
PAAD	cis	rs2635047	0.710	rs2684838	chr18:44748079	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.38	0.33	2.22e-5	Educational attainment;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg19223190	chr17:80058835	NA	0.47	4.79	0.36	3.92e-6	Life satisfaction;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14577476	chr17:49337432	MBTD1;UTP18	-0.61	-7.07	-0.5	5.4e-11	Body fat percentage;
PAAD	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08886695	chr4:3369023	RGS12	-0.48	-4.69	-0.36	6.15e-6	Serum sulfate level;
PAAD	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg01064725	chr1:204461714	NA	-0.48	-4.65	-0.35	7.11e-6	Schizophrenia;
PAAD	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	Trans fatty acid levels;
PAAD	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.43	-4.35	-0.33	2.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12165864	chr7:66369176	NA	-0.8	-5.34	-0.4	3.36e-7	Diabetic kidney disease;
PAAD	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.8	8.03	0.55	2.49e-13	Retinal vascular caliber;
PAAD	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-5.9	-0.43	2.28e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	13.49	0.74	9.17e-28	Platelet count;
PAAD	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.64	6.06	0.44	1.04e-8	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.62	5.48	0.41	1.73e-7	Diastolic blood pressure;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg07677032	chr17:61819896	STRADA	0.45	4.29	0.33	3.16e-5	Height;
PAAD	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.54	4.45	0.34	1.65e-5	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08677398	chr8:58056175	NA	0.68	4.77	0.36	4.24e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.86	0.43	2.79e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05174924	chr6:90062691	UBE2J1	0.56	6.59	0.47	6.83e-10	Immature fraction of reticulocytes;
PAAD	cis	rs11892454	0.565	rs13422139	chr2:26066570	C/A	cg25181710	chr2:26045287	ASXL2	0.38	4.28	0.33	3.34e-5	Heschl's gyrus morphology;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.48	-5.93	-0.43	1.93e-8	Monobrow;
PAAD	cis	rs11168618	0.740	rs11168617	chr12:48928708	G/A	cg01881778	chr12:48919444	OR8S1	-0.52	-5.62	-0.41	9.02e-8	Adiponectin levels;
PAAD	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.82	8.0	0.54	2.89e-13	Corneal astigmatism;
PAAD	cis	rs59888335	0.895	rs35545811	chr3:80535291	C/T	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.94	-0.49	1.06e-10	Neuroticism;
PAAD	trans	rs4272720	0.853	rs72785087	chr10:50360223	G/A	cg15329866	chr3:171455826	PLD1	0.77	6.3	0.46	2.99e-9	Platelet count;Plateletcrit;
PAAD	cis	rs2279817	0.731	rs11203435	chr1:18010233	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-6.18	-0.45	5.69e-9	Neuroticism;
PAAD	cis	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.67	-6.61	-0.47	5.97e-10	Multiple sclerosis;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.25e-10	Life satisfaction;
PAAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.24	0.6	2.03e-16	Parkinson's disease;
PAAD	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg14758556	chr20:62440591	NA	-0.51	-4.52	-0.34	1.25e-5	Ulcerative colitis;
PAAD	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.7	-7.17	-0.5	3.03e-11	Alcohol dependence;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.45e-8	Prudent dietary pattern;
PAAD	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg23912435	chr1:150601613	ENSA	0.5	4.65	0.35	7.24e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.79	-0.36	3.98e-6	Hirschsprung disease;
PAAD	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs9463078	0.585	rs1284969	chr6:45153881	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-7.93	-0.54	4.39e-13	Dental caries;
PAAD	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.63	-0.35	7.69e-6	Dupuytren's disease;
PAAD	cis	rs11997175	0.603	rs12156112	chr8:33791598	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	6.35	0.46	2.31e-9	Body mass index;
PAAD	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs901683	0.850	rs17157861	chr10:45990925	T/C	cg13065504	chr15:42448234	PLA2G4F	0.83	6.45	0.46	1.43e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg23920097	chr1:209922102	NA	-0.51	-4.86	-0.37	2.91e-6	Red blood cell count;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.82	-7.83	-0.54	7.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9913156	0.670	rs9894225	chr17:4546559	A/G	cg00122941	chr17:4613640	ARRB2	-0.79	-7.89	-0.54	5.5e-13	Lymphocyte counts;
PAAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.56	7.46	0.52	6.27e-12	Renal cell carcinoma;
PAAD	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.85	10.58	0.65	5.97e-20	Bladder cancer;
PAAD	cis	rs6141769	0.542	rs6058821	chr20:31304713	C/T	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-6.6	-0.47	6.5e-10	Menopause (age at onset);
PAAD	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.69	-7.31	-0.51	1.39e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.7	-7.81	-0.53	8.85e-13	Motion sickness;
PAAD	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg15309053	chr8:964076	NA	0.46	5.12	0.38	9.15e-7	Schizophrenia;
PAAD	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.18	8.15	0.55	1.21e-13	Schizophrenia;
PAAD	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-5.27	-0.39	4.55e-7	Electroencephalogram traits;
PAAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg09654669	chr8:57350985	NA	-0.55	-5.18	-0.39	7.09e-7	Obesity-related traits;
PAAD	cis	rs11563648	0.553	rs7777556	chr7:127042372	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.36	-0.33	2.35e-5	Resting heart rate;
PAAD	cis	rs643506	0.874	rs4936786	chr11:111727227	C/T	cg09085632	chr11:111637200	PPP2R1B	0.55	4.6	0.35	8.98e-6	Breast cancer;
PAAD	cis	rs778371	0.755	rs709935	chr2:233802585	A/G	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.87	-0.43	2.59e-8	Schizophrenia;
PAAD	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.49	5.65	0.42	7.67e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.85	0.43	2.9e-8	Eosinophil percentage of white cells;
PAAD	cis	rs6496932	0.663	rs7183764	chr15:85903051	A/G	cg19183879	chr15:85880815	NA	-0.54	-5.1	-0.38	1.01e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs2662368	0.542	rs6414974	chr5:77120477	G/A	cg02570643	chr5:77531473	AP3B1	0.43	4.66	0.35	6.96e-6	Platelet distribution width;
PAAD	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.97e-5	Age-related disease endophenotypes;
PAAD	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg16434002	chr17:42200994	HDAC5	0.61	5.77	0.42	4.39e-8	Total body bone mineral density;
PAAD	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.62	5.82	0.43	3.45e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10887741	0.542	rs1969823	chr10:89415425	T/C	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.13	-0.38	8.66e-7	Exercise (leisure time);
PAAD	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.4	-4.91	-0.37	2.37e-6	Uric acid levels;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs10450586	0.863	rs7119628	chr11:27302716	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.13e-5	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg05562828	chr17:3906858	NA	0.6	6.48	0.47	1.21e-9	Type 2 diabetes;
PAAD	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.53	5.3	0.4	3.93e-7	Red blood cell count;
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg01798341	chr17:80842262	TBCD	0.47	4.9	0.37	2.38e-6	Breast cancer;
PAAD	cis	rs8112211	0.689	rs11672219	chr19:38793596	G/C	cg14299480	chr19:38876666	GGN	-0.5	-4.35	-0.33	2.45e-5	Blood protein levels;
PAAD	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg20607287	chr7:12443886	VWDE	-0.79	-5.74	-0.42	5.03e-8	Coronary artery disease;
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg20295408	chr7:1910781	MAD1L1	-0.57	-5.61	-0.41	9.39e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	4.76	0.36	4.44e-6	Joint mobility (Beighton score);
PAAD	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.4	-0.46	1.79e-9	Leprosy;
PAAD	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.25	0.84	1.34e-42	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs116095464	1.000	rs116095464	chr5:345109	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.97	5.3	0.39	4.07e-7	Breast cancer;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs12780845	0.894	rs7099222	chr10:17251430	C/G	cg00857480	chr10:17188594	TRDMT1	-0.35	-4.41	-0.34	1.96e-5	Homocysteine levels;
PAAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.95	-12.34	-0.71	1.09e-24	Height;
PAAD	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	4.37	0.33	2.27e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00300879	chr1:26503847	CNKSR1	0.32	4.84	0.37	3.15e-6	Height;
PAAD	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.95	10.54	0.65	7.74e-20	Corneal astigmatism;
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	4.27	0.33	3.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1198430	0.639	rs2297841	chr1:23764149	C/G	cg27447006	chr1:23763279	ASAP3	0.68	5.44	0.4	2.13e-7	Total cholesterol levels;
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg08835956	chr7:39171034	POU6F2	0.32	4.91	0.37	2.32e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00862481	chr16:29998852	TAOK2	0.6	6.34	0.46	2.53e-9	Warfarin maintenance dose;
PAAD	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg00206168	chr11:65308501	LTBP3	0.85	5.91	0.43	2.22e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00043005	chr19:2227429	DOT1L	0.59	6.54	0.47	8.94e-10	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.52	-0.61	3.95e-17	Response to antipsychotic treatment;
PAAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.53	-0.52	4.1e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.58	-7.49	-0.52	5.1e-12	Longevity;
PAAD	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs3736757	1.000	rs1040666	chr1:184694583	C/A	cg05045817	chr1:184633523	NA	0.44	4.71	0.36	5.64e-6	Obesity-related traits;
PAAD	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.61	4.48	0.34	1.44e-5	Exhaled nitric oxide output;
PAAD	cis	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg21546286	chr11:48923668	NA	0.46	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.92	7.96	0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.76	-8.06	-0.55	2.14e-13	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13939156	chr17:80058883	NA	-0.42	-4.52	-0.34	1.23e-5	Life satisfaction;
PAAD	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-4.99	-0.38	1.64e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.46e-8	Life satisfaction;
PAAD	cis	rs7165102	0.895	rs1699937	chr15:65791579	T/C	cg22900193	chr15:65823441	PTPLAD1	-0.47	-4.51	-0.34	1.3e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg09127314	chr1:152161683	NA	0.69	4.98	0.37	1.74e-6	Atopic dermatitis;
PAAD	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.46	0.34	1.59e-5	Self-reported allergy;
PAAD	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-1.11	-7.69	-0.53	1.69e-12	Post bronchodilator FEV1;
PAAD	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	4.73	0.36	5.02e-6	Blood protein levels;
PAAD	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.84	0.49	1.78e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26623224	chr19:49661080	TRPM4	0.58	6.3	0.46	3.01e-9	Myopia (pathological);
PAAD	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.68	5.75	0.42	4.7e-8	Educational attainment;
PAAD	cis	rs1468333	0.667	rs113260319	chr5:137742713	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.42	0.4	2.26e-7	Resting heart rate;
PAAD	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.85	-7.86	-0.54	6.59e-13	Exhaled nitric oxide output;
PAAD	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21707521	chr2:238875814	UBE2F	0.66	6.29	0.45	3.16e-9	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.67	0.35	6.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs735539	0.521	rs2763000	chr13:21449692	C/G	cg27499820	chr13:21296301	IL17D	0.51	4.51	0.34	1.27e-5	Dental caries;
PAAD	cis	rs12681288	0.782	rs12544713	chr8:1026697	C/T	cg04851639	chr8:1020857	NA	-0.65	-8.1	-0.55	1.64e-13	Schizophrenia;
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.41	4.41	0.34	1.94e-5	Cystic fibrosis severity;
PAAD	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-6.79	-0.48	2.42e-10	Menarche (age at onset);
PAAD	cis	rs77633900	0.772	rs157775	chr15:76755641	A/G	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg26394196	chr10:1453818	ADARB2	-0.6	-6.75	-0.48	2.89e-10	Radiation response;
PAAD	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.73	8.65	0.57	6.72e-15	Colorectal cancer;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.53	5.4	0.4	2.49e-7	Longevity;Endometriosis;
PAAD	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg09654669	chr8:57350985	NA	-0.57	-5.19	-0.39	6.49e-7	Obesity-related traits;
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.54	-5.3	-0.39	4.03e-7	Blood metabolite levels;
PAAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg06728252	chr6:26598149	ABT1	-0.43	-4.99	-0.38	1.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.98	-0.37	1.68e-6	Reticulocyte count;
PAAD	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg27449745	chr7:23145252	KLHL7	-0.58	-5.45	-0.4	2.03e-7	Blood protein levels;
PAAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.63e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs802075	0.676	rs13204884	chr6:49791907	G/A	cg20364632	chr6:49636226	NA	0.46	5.14	0.38	8.24e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg13207630	chr7:32358064	NA	0.96	4.91	0.37	2.28e-6	Body mass index;
PAAD	cis	rs4343996	0.720	rs10250421	chr7:3458288	A/T	cg21248987	chr7:3385318	SDK1	0.47	5.01	0.38	1.51e-6	Motion sickness;
PAAD	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg08999081	chr20:33150536	PIGU	-0.54	-5.86	-0.43	2.83e-8	Height;
PAAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.62	6.57	0.47	7.46e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.62	-7.61	-0.53	2.64e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg07153921	chr17:41440717	NA	-0.42	-4.44	-0.34	1.69e-5	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9810890	1.000	rs6789094	chr3:128591267	G/C	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg18132916	chr6:79620363	NA	-0.47	-4.85	-0.37	2.96e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs245880	0.740	rs245883	chr7:29187946	G/A	cg17163760	chr7:29186267	CPVL	-0.5	-5.79	-0.42	3.95e-8	Warfarin maintenance dose;
PAAD	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7107174	0.688	rs7927923	chr11:77979414	C/T	cg02023728	chr11:77925099	USP35	-0.41	-4.59	-0.35	9.4e-6	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20959564	chr11:47448208	PSMC3	0.66	7.64	0.53	2.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.45	4.98	0.37	1.7e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg22903657	chr4:1355424	KIAA1530	0.42	4.48	0.34	1.46e-5	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.52	-0.41	1.41e-7	Total body bone mineral density;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.94	-15.68	-0.79	1.42e-33	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg02696790	chr15:75250997	RPP25	-0.37	-4.43	-0.34	1.82e-5	Systemic lupus erythematosus;
PAAD	cis	rs939584	0.866	rs13387090	chr2:650974	G/T	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.54	-7.88	-0.54	5.76e-13	Diastolic blood pressure;
PAAD	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.6	-5.81	-0.43	3.57e-8	Lymphocyte counts;
PAAD	cis	rs12753920	0.697	rs4414091	chr1:92672738	C/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.45	-4.3	-0.33	3.03e-5	Systemic lupus erythematosus;
PAAD	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	6.0	0.44	1.41e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15384640	chr17:6557720	NA	0.59	7.17	0.5	3.07e-11	Body fat percentage;
PAAD	cis	rs17407555	0.632	rs12510727	chr4:10271070	T/G	cg00071950	chr4:10020882	SLC2A9	0.48	5.21	0.39	6.17e-7	Schizophrenia (age at onset);
PAAD	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.01e-7	IgG glycosylation;
PAAD	cis	rs2414098	1	rs2414098	chr15:51537806	T/C	cg21478137	chr15:51532386	CYP19A1	0.58	6.53	0.47	9.09e-10	Total body bone mineral density;Endometrial endometrioid carcinoma;Endometrial cancer;
PAAD	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.82	9.85	0.62	5.19e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.68	5.98	0.44	1.51e-8	Breast cancer;
PAAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.64	-6.67	-0.48	4.44e-10	Multiple sclerosis;
PAAD	cis	rs6565180	1.000	rs68051857	chr16:30360011	A/G	cg17640201	chr16:30407289	ZNF48	-0.89	-10.15	-0.64	8.31e-19	Tonsillectomy;
PAAD	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.54	5.16	0.39	7.7e-7	Cancer;
PAAD	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg10856724	chr12:34555212	NA	-0.44	-4.49	-0.34	1.39e-5	Morning vs. evening chronotype;
PAAD	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg00717180	chr2:96193071	NA	-0.58	-6.5	-0.47	1.11e-9	HDL cholesterol;
PAAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.3	0.46	3.04e-9	Personality dimensions;
PAAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.7	9.13	0.59	4.08e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.84	6.82	0.48	1.97e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.52	-5.15	-0.39	8.02e-7	Longevity;
PAAD	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.55	7.4	0.51	8.48e-12	Primary biliary cholangitis;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg17541715	chr7:1216824	NA	-0.41	-4.58	-0.35	9.67e-6	Longevity;Endometriosis;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg16262614	chr3:133464971	TF	0.47	5.05	0.38	1.24e-6	Iron status biomarkers;
PAAD	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.67	-0.42	7.12e-8	Crohn's disease;
PAAD	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.89	10.33	0.64	2.84e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.71	-7.94	-0.54	4.26e-13	Temporomandibular joint disorder;
PAAD	cis	rs76533333	0.564	rs17751071	chr13:113392724	G/A	cg02820901	chr13:113351484	ATP11A	-0.75	-4.56	-0.35	1.04e-5	Red cell distribution width;
PAAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.63	4.73	0.36	5.02e-6	Breast cancer;
PAAD	cis	rs16976116	0.901	rs8030981	chr15:55499442	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg15123519	chr2:136567270	LCT	0.37	4.53	0.35	1.18e-5	Mosquito bite size;
PAAD	cis	rs35955747	0.934	rs5994397	chr22:31826150	G/C	cg02404636	chr22:31891804	SFI1	-0.58	-5.72	-0.42	5.44e-8	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.43	4.51	0.34	1.28e-5	Coronary artery disease;
PAAD	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-4.45	-0.34	1.64e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.53	-0.52	4.23e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-4.58	-0.35	9.76e-6	Bipolar disorder;
PAAD	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.38	0.56	3.25e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.96	-6.74	-0.48	3.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.62	-5.91	-0.43	2.12e-8	Height;
PAAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Iron status biomarkers;
PAAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.92	7.96	0.54	3.66e-13	Gut microbiome composition (summer);
PAAD	cis	rs1519814	0.956	rs4871040	chr8:121131611	A/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.54	5.13	0.38	8.7e-7	Uric acid clearance;
PAAD	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.76	6.54	0.47	8.72e-10	Schizophrenia;
PAAD	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg20312557	chr2:97357134	FER1L5	-0.83	-4.41	-0.34	1.92e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg09839279	chr12:125627357	AACS	-0.48	-4.74	-0.36	4.79e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.45	0.71	5.5e-25	Cognitive ability;
PAAD	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg13010199	chr12:38710504	ALG10B	0.6	5.26	0.39	4.8e-7	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg14092571	chr14:90743983	NA	0.59	5.73	0.42	5.1e-8	Mortality in heart failure;
PAAD	cis	rs1358748	0.522	rs7531589	chr1:67555366	A/G	cg02640540	chr1:67518911	SLC35D1	0.67	4.59	0.35	9.29e-6	Tuberculosis;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs818427	0.964	rs35726351	chr5:112217737	G/A	cg06941702	chr5:112196734	SRP19	0.46	4.25	0.33	3.74e-5	Total body bone mineral density;
PAAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.9e-7	Blood metabolite levels;
PAAD	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-6.3	-0.46	3.09e-9	Neuroticism;
PAAD	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg22916017	chr11:64110731	CCDC88B	0.39	4.6	0.35	8.69e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	4.95e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.53	-5.14	-0.38	8.26e-7	Hypertension (SNP x SNP interaction);
PAAD	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.27	-0.6	1.71e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg00982548	chr2:198649783	BOLL	-0.78	-5.54	-0.41	1.31e-7	Ulcerative colitis;
PAAD	cis	rs881375	0.502	rs4837811	chr9:123901594	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	5.42	0.4	2.26e-7	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-1.02	-8.51	-0.57	1.57e-14	Vitiligo;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg06740227	chr12:86229804	RASSF9	0.52	4.62	0.35	8.08e-6	Major depressive disorder;
PAAD	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.78	-9.25	-0.6	1.93e-16	Height;
PAAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.73	7.59	0.52	2.95e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1879734	0.731	rs7512093	chr1:54163207	T/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs12431939	1.000	rs12433445	chr14:51666091	G/A	cg23942311	chr14:51606299	NA	-0.71	-5.71	-0.42	5.75e-8	Cancer;
PAAD	cis	rs6442522	0.678	rs11128745	chr3:15498261	T/C	cg16303742	chr3:15540471	COLQ	0.46	4.82	0.36	3.5e-6	Uric acid levels;
PAAD	cis	rs8133932	0.736	rs2839020	chr21:47280001	A/G	cg13695288	chr21:47294981	PCBP3	-0.48	-4.76	-0.36	4.57e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11828509	chr1:26146223	FAM54B	0.62	7.15	0.5	3.43e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.85	8.46	0.57	2.08e-14	Cognitive function;
PAAD	cis	rs4906332	0.782	rs12147596	chr14:104006716	T/C	cg19000871	chr14:103996768	TRMT61A	-0.58	-6.16	-0.45	6.07e-9	Coronary artery disease;
PAAD	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.39	5.84	0.43	3.02e-8	Educational attainment (years of education);
PAAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.55	5.21	0.39	6.12e-7	Monocyte count;
PAAD	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.61	-5.71	-0.42	5.78e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs758324	0.773	rs2404777	chr5:131172803	C/A	cg06307176	chr5:131281290	NA	0.51	4.46	0.34	1.56e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-1.23	-9.18	-0.6	2.99e-16	Blood pressure (smoking interaction);
PAAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.98	13.29	0.73	3.18e-27	Menopause (age at onset);
PAAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.88	10.69	0.66	3.03e-20	Aortic root size;
PAAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.47	5.84	0.43	3e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.47	-4.7	-0.36	5.84e-6	Inflammatory skin disease;
PAAD	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.99	13.25	0.73	3.98e-27	Heart rate;
PAAD	cis	rs959260	0.925	rs8072449	chr17:73312184	G/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.29	-0.33	3.2e-5	Systemic lupus erythematosus;
PAAD	cis	rs2004318	1.000	rs74668532	chr19:55123155	C/T	cg03320607	chr19:54800032	LILRA3	-1.12	-6.3	-0.45	3.07e-9	Blood protein levels;
PAAD	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.68	-7.11	-0.5	4.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	7.02	0.49	7.04e-11	Response to antipsychotic treatment;
PAAD	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.4	-4.42	-0.34	1.86e-5	Barrett's esophagus  or Esophageal adenocarcinoma;
PAAD	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg02966332	chr20:62369605	LIME1	-0.46	-4.47	-0.34	1.52e-5	Prostate cancer;
PAAD	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.65	-5.79	-0.42	3.97e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.78e-5	Monobrow;
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg18612461	chr15:75251733	NA	0.59	7.09	0.5	4.81e-11	Caffeine consumption;
PAAD	cis	rs9463078	0.630	rs7775717	chr6:44967761	G/A	cg25276700	chr6:44698697	NA	-0.55	-6.35	-0.46	2.4e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7246865	0.510	rs3816549	chr19:17173937	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.72	0.42	5.37e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg17366294	chr4:99064904	C4orf37	0.44	4.9	0.37	2.4e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10885582	0.846	rs4752016	chr10:116348539	C/T	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.07	-0.38	1.12e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-6.72	-0.48	3.44e-10	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg15571903	chr15:79123663	NA	0.4	4.88	0.37	2.7e-6	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-5.68	-0.42	6.51e-8	Mean platelet volume;
PAAD	cis	rs10901513	0.932	rs2090248	chr10:127672759	C/T	cg22975853	chr10:127789788	ADAM12	0.43	4.59	0.35	9.37e-6	Visceral fat;
PAAD	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.39	0.34	2.11e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg01851573	chr8:8652454	MFHAS1	0.46	4.56	0.35	1.04e-5	Mood instability;
PAAD	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	8.22	0.55	8.38e-14	LDL cholesterol;
PAAD	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09658576	chr7:139477957	TBXAS1;HIPK2	0.6	6.44	0.46	1.46e-9	Myopia (pathological);
PAAD	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg10253484	chr15:75165896	SCAMP2	0.6	5.56	0.41	1.2e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24801087	chr17:76481729	DNAH17	-0.71	-7.16	-0.5	3.27e-11	Obesity-related traits;
PAAD	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs4455778	0.580	rs6583507	chr7:49122261	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.58	-6.64	-0.47	5.27e-10	Blood metabolite levels;
PAAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.52	4.74	0.36	4.94e-6	Height;
PAAD	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15929437	chr11:65101539	DPF2	-0.72	-6.35	-0.46	2.39e-9	Neuroticism;
PAAD	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.54	0.57	1.33e-14	Rheumatoid arthritis;
PAAD	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3779195	0.697	rs13232861	chr7:97929081	A/G	cg21770322	chr7:97807741	LMTK2	0.52	4.58	0.35	9.67e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.11	0.38	9.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	6.44	0.46	1.46e-9	Renal function-related traits (BUN);
PAAD	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.33	0.33	2.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	8.62	0.57	8.14e-15	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs6604026	0.656	rs6698179	chr1:93390714	G/C	cg17283838	chr1:93427260	FAM69A	0.62	5.68	0.42	6.58e-8	Multiple sclerosis;
PAAD	cis	rs8018808	0.905	rs11622359	chr14:77939449	C/T	cg20045696	chr14:77926864	AHSA1	-0.53	-5.15	-0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs258892	1.000	rs571646	chr5:72367339	A/G	cg21869765	chr5:72125136	TNPO1	0.66	4.65	0.35	7.09e-6	Small cell lung carcinoma;
PAAD	cis	rs9311474	0.775	rs352162	chr3:52252969	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.72	-0.36	5.37e-6	Electroencephalogram traits;
PAAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.26	-10.38	-0.64	2.06e-19	Breast cancer;
PAAD	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg10616300	chr11:66138557	SLC29A2	-0.35	-4.74	-0.36	4.81e-6	Educational attainment (years of education);
PAAD	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	6.73	0.48	3.26e-10	Renal function-related traits (BUN);
PAAD	cis	rs76419734	0.558	rs7698817	chr4:106532500	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.56	0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00706019	chr19:11546163	CCDC151;PRKCSH	-0.72	-6.46	-0.46	1.34e-9	Neuroticism;
PAAD	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg16341495	chr8:142228727	SLC45A4	-0.46	-4.3	-0.33	3.04e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs72960926	1.000	rs117827660	chr6:75159847	C/A	cg13435101	chr6:74171350	MTO1	1.01	4.91	0.37	2.35e-6	Metabolite levels (MHPG);
PAAD	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.56	5.58	0.41	1.05e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg03959625	chr15:84868606	LOC388152	0.43	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.6	-0.47	6.51e-10	Longevity;
PAAD	cis	rs1109501	0.700	rs28532597	chr4:71411512	A/C	cg25553522	chr4:71388589	AMTN	0.52	4.31	0.33	2.89e-5	Alcoholism (heaviness of drinking);
PAAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7799006	0.606	rs2286207	chr7:2303109	G/A	cg08027265	chr7:2291960	NA	-0.7	-7.1	-0.5	4.59e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1499972	0.941	rs62263112	chr3:117615515	T/C	cg07612923	chr3:117604196	NA	1.06	7.2	0.5	2.63e-11	Schizophrenia;
PAAD	cis	rs2117029	0.619	rs2753	chr12:49521672	C/T	cg05368762	chr12:50135785	TMBIM6	0.43	4.3	0.33	3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs6594713	0.921	rs13181534	chr5:112724641	A/G	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs6710503	0.574	rs17734650	chr2:24812163	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.3	-0.33	3.07e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-5.65	-0.42	7.7e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.46	4.32	0.33	2.77e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.61	-5.88	-0.43	2.54e-8	Subjective well-being;
PAAD	cis	rs6088813	1.000	rs6088815	chr20:33976474	G/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs12753920	0.775	rs17519385	chr1:92676309	A/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg23793686	chr15:68133972	NA	-0.54	-4.59	-0.35	9.36e-6	Obesity;
PAAD	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg14583973	chr4:3374767	RGS12	0.42	6.16	0.45	6.31e-9	Serum sulfate level;
PAAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg24110177	chr3:50126178	RBM5	-0.82	-9.14	-0.6	3.72e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs12042107	0.818	rs12568187	chr1:91193691	T/C	cg13456504	chr1:91191583	NA	0.41	4.52	0.34	1.23e-5	Educational attainment;
PAAD	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg18649319	chr8:144631768	NA	-0.3	-4.7	-0.36	5.85e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg02683114	chr2:24398427	C2orf84	0.55	5.76	0.42	4.55e-8	Asthma;
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg13374026	chr7:158955107	NA	-0.46	-4.3	-0.33	3.08e-5	Facial morphology (factor 20);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11578784	chr10:105005750	LOC729020	-0.69	-7.08	-0.5	5.04e-11	Obesity-related traits;
PAAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg06569542	chr10:98946673	SLIT1	-0.53	-5.97	-0.44	1.58e-8	Monocyte count;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg13896783	chr2:159313876	CCDC148;PKP4	-0.57	-6.39	-0.46	1.89e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.06	-0.38	1.18e-6	Height;
PAAD	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.44	-4.46	-0.34	1.6e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg05084668	chr3:125655381	ALG1L	-1.04	-8.6	-0.57	9.19e-15	Blood pressure (smoking interaction);
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.47	5.41	0.4	2.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.89	-10.18	-0.64	6.83e-19	Morning vs. evening chronotype;
PAAD	cis	rs9372498	0.536	rs55899435	chr6:118812099	C/T	cg18833306	chr6:118973337	C6orf204	-0.56	-4.51	-0.34	1.27e-5	Diastolic blood pressure;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.68	0.48	4.29e-10	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23355166	chr7:72610628	GTF2IP1;LOC100093631	0.58	6.32	0.46	2.74e-9	Smoking initiation;
PAAD	cis	rs9815354	0.680	rs73073285	chr3:42027566	T/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.54	-5.37	-0.4	2.92e-7	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg07099767	chr17:78039528	CCDC40	-0.48	-4.58	-0.35	9.54e-6	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.63	0.42	8.35e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg16576597	chr16:28551801	NUPR1	0.63	7.01	0.49	7.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.92	7.88	0.54	5.99e-13	Dupuytren's disease;
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg05373962	chr22:49881684	NA	-0.51	-5.05	-0.38	1.24e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.57	6.2	0.45	4.98e-9	Testicular germ cell tumor;
PAAD	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.5	0.47	1.1e-9	Schizophrenia;
PAAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg25364880	chr3:44379878	C3orf23	0.62	5.86	0.43	2.76e-8	Depressive symptoms;
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.87	-9.03	-0.59	7.27e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg09597638	chr17:3907349	NA	-0.62	-6.24	-0.45	4.18e-9	Type 2 diabetes;
PAAD	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.9	-10.16	-0.64	7.68e-19	Obesity-related traits;
PAAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.69	-6.73	-0.48	3.18e-10	Initial pursuit acceleration;
PAAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg03959625	chr15:84868606	LOC388152	0.45	4.57	0.35	9.92e-6	Schizophrenia;
PAAD	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12432903	chr7:1882776	MAD1L1	-0.59	-4.28	-0.33	3.36e-5	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg16680214	chr1:154839983	KCNN3	-0.4	-4.46	-0.34	1.55e-5	Schizophrenia;
PAAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.08	-0.5	5e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.55	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.41	-4.78	-0.36	4.04e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6500550	0.851	rs11646287	chr16:3719344	A/G	cg01678580	chr16:4674018	MGRN1	-0.46	-4.32	-0.33	2.82e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
PAAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23158103	chr7:148848205	ZNF398	-0.62	-6.11	-0.44	8e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.49	5.33	0.4	3.52e-7	Fibrinogen levels;
PAAD	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg05791153	chr7:19748676	TWISTNB	0.74	4.99	0.38	1.63e-6	Night sleep phenotypes;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.51e-6	Mood instability;
PAAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.76e-6	Menarche (age at onset);
PAAD	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19346786	chr7:2764209	NA	-0.38	-4.56	-0.35	1.03e-5	Height;
PAAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.69	0.42	6.19e-8	Tonsillectomy;
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg04522676	chr10:134968826	NA	0.46	5.17	0.39	7.14e-7	Gait speed in old age;
PAAD	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-4.4	-0.34	1.99e-5	Tuberculosis;
PAAD	cis	rs12286929	1.000	rs12286929	chr11:115022404	A/G	cg04055981	chr11:115044050	NA	0.44	4.48	0.34	1.49e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs308971	0.611	rs307598	chr3:12102273	T/C	cg15873301	chr3:12045459	SYN2	0.64	5.34	0.4	3.3e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.95	-11.58	-0.68	1.24e-22	Coronary artery disease;
PAAD	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg04289385	chr6:36355825	ETV7	0.44	4.35	0.33	2.53e-5	Platelet distribution width;
PAAD	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg10578991	chr7:12443926	VWDE	-0.57	-4.25	-0.33	3.72e-5	Coronary artery disease;
PAAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.26	0.56	6.58e-14	Parkinson's disease;
PAAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg01851573	chr8:8652454	MFHAS1	-0.48	-4.35	-0.33	2.47e-5	Obesity-related traits;
PAAD	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg03934865	chr2:198174659	NA	-0.44	-4.4	-0.34	2.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg15598662	chr11:61582890	MIR1908;FADS1	0.53	4.74	0.36	4.8e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs58521262	0.519	rs11085546	chr19:22993102	C/A	cg07749055	chr19:23076870	NA	-0.59	-4.66	-0.35	7e-6	Testicular germ cell tumor;
PAAD	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg13482628	chr17:19912719	NA	0.5	4.95	0.37	1.93e-6	Schizophrenia;
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg05717871	chr11:638507	DRD4	-0.59	-5.0	-0.38	1.6e-6	Systemic lupus erythematosus;
PAAD	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg12011299	chr4:100065546	ADH4	0.48	5.5	0.41	1.55e-7	Alcohol dependence;
PAAD	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs12935418	0.552	rs2549833	chr16:81022232	T/C	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.34e-8	Mean corpuscular volume;
PAAD	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-5.38	-0.4	2.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-5.25	-0.39	5.07e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs73787773	0.867	rs7731129	chr5:111495510	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.77	-4.56	-0.35	1.05e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.46	-4.96	-0.37	1.9e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4140564	0.667	rs2223332	chr1:186692733	G/A	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs7567389	0.677	rs72848616	chr2:128135097	T/C	cg09760422	chr2:128146352	NA	0.39	6.02	0.44	1.29e-8	Self-rated health;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg04990556	chr1:26633338	UBXN11	-0.82	-8.75	-0.58	3.77e-15	Obesity-related traits;
PAAD	cis	rs11997175	0.550	rs7463110	chr8:33837033	A/C	ch.8.33884649F	chr8:33765107	NA	0.63	6.16	0.45	6.09e-9	Body mass index;
PAAD	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg09579323	chr1:150459698	TARS2	-0.45	-4.25	-0.33	3.67e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg02966332	chr20:62369605	LIME1	-0.48	-4.48	-0.34	1.43e-5	Prostate cancer;
PAAD	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg15621731	chr19:5074616	KDM4B	0.3	4.51	0.34	1.3e-5	Monocyte percentage of white cells;
PAAD	cis	rs1570884	0.539	rs7983291	chr13:50111931	G/C	cg03651054	chr13:50194643	NA	0.34	4.34	0.33	2.58e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6804624	0.559	rs2670344	chr3:99163610	C/T	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg20607287	chr7:12443886	VWDE	-0.68	-6.15	-0.45	6.62e-9	Coronary artery disease;
PAAD	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.4	-5.75	-0.42	4.77e-8	Cutaneous nevi;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11556929	chr2:240323605	HDAC4	0.58	6.44	0.46	1.49e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-4.95	-0.37	1.97e-6	Schizophrenia;
PAAD	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.97e-10	Resting heart rate;
PAAD	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-1.08	-15.07	-0.77	5.77e-32	Total body bone mineral density;
PAAD	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs10768122	0.966	rs9633870	chr11:35268900	T/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.34	-0.33	2.59e-5	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04122601	chr12:10826785	STYK1	0.59	6.47	0.46	1.3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.53	4.98	0.37	1.73e-6	Monocyte count;
PAAD	cis	rs2271001	0.910	rs11025026	chr11:19140385	G/A	cg00161556	chr11:19138045	ZDHHC13	0.5	5.32	0.4	3.67e-7	Gut microbiome composition (winter);
PAAD	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.48	4.62	0.35	8.13e-6	Mean corpuscular volume;
PAAD	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.58	5.56	0.41	1.18e-7	Total body bone mineral density;
PAAD	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.84	-7.59	-0.52	2.93e-12	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.73	-7.7	-0.53	1.62e-12	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22933469	chr3:11888149	C3orf31	-0.75	-6.52	-0.47	9.56e-10	Neuroticism;
PAAD	cis	rs2133450	0.526	rs12485342	chr3:7349051	G/A	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-6.39	-0.46	1.94e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.66	-7.14	-0.5	3.65e-11	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.39	-5.39	-0.4	2.67e-7	Triglycerides;
PAAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs1879734	0.906	rs1615037	chr1:54165541	C/T	cg14659662	chr1:54151053	GLIS1	0.41	6.35	0.46	2.42e-9	Mitral valve prolapse;
PAAD	cis	rs12898370	0.561	rs8028830	chr15:77508046	A/G	cg17802220	chr15:77601643	NA	-0.61	-4.28	-0.33	3.24e-5	Risky sexual behaviors (alcohol dependence interaction);
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00166722	chr3:10149974	C3orf24	0.95	7.86	0.54	6.38e-13	Alzheimer's disease;
PAAD	cis	rs7951870	0.645	rs10769205	chr11:46723603	A/G	cg19486271	chr11:47235900	DDB2	0.57	5.76	0.42	4.46e-8	Schizophrenia;
PAAD	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.52	-5.01	-0.38	1.46e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg02795151	chr17:7402630	POLR2A	0.62	5.81	0.43	3.6e-8	Androgen levels;
PAAD	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.4	-4.42	-0.34	1.89e-5	Schizophrenia;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.95	-16.1	-0.79	1.17e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg15957291	chr4:170533587	NEK1	-0.57	-4.46	-0.34	1.58e-5	Anxiety disorder;
PAAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.87	8.46	0.57	2.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs847851	1.000	rs4646926	chr6:34852253	G/T	cg05379947	chr6:35436047	RPL10A	0.55	4.65	0.35	7.26e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg09165964	chr15:75287851	SCAMP5	-0.56	-4.47	-0.34	1.53e-5	Blood trace element (Zn levels);
PAAD	cis	rs2446066	0.872	rs7955418	chr12:53791630	G/A	cg20591337	chr12:53693442	C12orf10	-0.62	-4.39	-0.34	2.13e-5	Red blood cell count;
PAAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs3206736	0.520	rs1637674	chr7:34998087	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.73	-0.36	5.09e-6	Diastolic blood pressure;
PAAD	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg00864860	chr1:7907996	UTS2	-0.56	-4.81	-0.36	3.68e-6	Crohn's disease;
PAAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg07148914	chr20:33460835	GGT7	-0.48	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.62	-6.82	-0.48	2.01e-10	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-5.02	-0.38	1.42e-6	Type 2 diabetes;
PAAD	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg24747557	chr10:131355152	MGMT	-0.53	-5.87	-0.43	2.65e-8	Response to temozolomide;
PAAD	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.82	-0.48	2.06e-10	Post bronchodilator FEV1;
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.69	6.94	0.49	1.05e-10	Blood metabolite levels;
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.59	-6.15	-0.45	6.56e-9	Mean corpuscular volume;
PAAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.57	6.23	0.45	4.42e-9	Birth weight;
PAAD	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.35	5.39	0.4	2.59e-7	Schizophrenia;
PAAD	cis	rs258430	0.644	rs11049221	chr12:28064107	C/G	cg05632229	chr12:27924396	LOC100133893	0.58	4.86	0.37	2.92e-6	Fast beta electroencephalogram;
PAAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	1.09	15.75	0.79	9.53e-34	Systemic lupus erythematosus;
PAAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.64	5.86	0.43	2.75e-8	Methadone dose in opioid dependence;
PAAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.8	8.68	0.58	5.83e-15	Schizophrenia;
PAAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.65	-6.71	-0.48	3.65e-10	IgG glycosylation;
PAAD	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg13397359	chr6:42928475	GNMT	0.56	4.54	0.35	1.12e-5	Blood protein levels;
PAAD	cis	rs9287719	0.624	rs10172926	chr2:10733254	A/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.67	-4.7	-0.36	5.69e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg26546229	chr16:89385611	ANKRD11	-0.45	-4.26	-0.33	3.59e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.67e-13	Mean platelet volume;
PAAD	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg13002189	chr3:66846049	NA	0.53	5.11	0.38	9.6e-7	Type 2 diabetes;
PAAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.6	5.08	0.38	1.1e-6	QRS duration;
PAAD	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.57	-0.35	9.97e-6	Biliary atresia;
PAAD	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg02250501	chr15:90694978	NA	-0.47	-4.44	-0.34	1.71e-5	Rheumatoid arthritis;
PAAD	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.56	-5.78	-0.42	4.02e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg23283495	chr1:209979779	IRF6	0.64	5.71	0.42	5.74e-8	Coronary artery disease;
PAAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg02475695	chr16:616220	NHLRC4	0.49	5.77	0.42	4.22e-8	Height;
PAAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-4.74	-0.36	4.86e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05009141	chr3:48471233	PLXNB1	0.57	6.66	0.48	4.66e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2004318	0.702	rs61739175	chr19:55144710	A/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.87	0.37	2.81e-6	Bipolar disorder;
PAAD	cis	rs2031532	0.959	rs4942835	chr13:50090844	C/A	cg08779649	chr13:50194554	NA	0.36	4.34	0.33	2.63e-5	Cardiac hypertrophy;
PAAD	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.48	-4.49	-0.34	1.42e-5	Neutrophil percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05190752	chr4:113558509	LARP7;C4orf21	0.63	6.35	0.46	2.4e-9	Obesity-related traits;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.21e-5	Cognitive function;
PAAD	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16418163	chr3:140950828	ACPL2	-0.65	-6.47	-0.46	1.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg05784532	chr1:230284198	GALNT2	0.71	6.16	0.45	6.13e-9	Coronary artery disease;
PAAD	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg01119278	chr6:110721349	DDO	-0.64	-7.21	-0.5	2.5e-11	Platelet distribution width;
PAAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg13444538	chr7:158905317	VIPR2	-0.47	-4.3	-0.33	3.02e-5	Facial morphology (factor 20);
PAAD	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg08975724	chr8:8085496	FLJ10661	-0.67	-6.67	-0.48	4.43e-10	Morning vs. evening chronotype;
PAAD	cis	rs10899021	0.790	rs59958321	chr11:74354614	G/A	cg25880958	chr11:74394337	NA	-0.77	-4.88	-0.37	2.65e-6	Response to metformin (IC50);
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.64	-6.17	-0.45	5.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.64	6.96	0.49	9.68e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.93e-5	Total body bone mineral density;
PAAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.71	-6.75	-0.48	2.99e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.75	7.89	0.54	5.53e-13	Mean corpuscular volume;
PAAD	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	7.92e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	5.93	0.43	1.99e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg21918786	chr6:109611834	NA	-0.45	-4.8	-0.36	3.68e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.72	0.36	5.35e-6	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.51	4.44	0.34	1.74e-5	Breast cancer;
PAAD	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.95	11.15	0.67	1.83e-21	Blood protein levels;
PAAD	cis	rs9401295	0.546	rs1933717	chr6:98271019	A/G	cg00987395	chr6:98934664	NA	0.38	4.5	0.34	1.37e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.7	-7.68	-0.53	1.81e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.5	-4.64	-0.35	7.41e-6	Acylcarnitine levels;
PAAD	cis	rs8032158	0.702	rs12910830	chr15:56122664	T/C	cg02198044	chr15:56286336	NEDD4	-0.42	-4.38	-0.33	2.21e-5	Keloid;
PAAD	cis	rs793571	0.915	rs12708456	chr15:59215835	T/A	cg05156742	chr15:59063176	FAM63B	-0.6	-5.21	-0.39	6.03e-7	Schizophrenia;
PAAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.92	11.87	0.69	2.09e-23	Methadone dose in opioid dependence;
PAAD	cis	rs7101378	0.577	rs2136532	chr11:108900150	A/G	cg02420102	chr11:108338162	C11orf65	-0.45	-4.33	-0.33	2.68e-5	IgG glycosylation;
PAAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.41	-0.46	1.75e-9	Triglycerides;
PAAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.74	7.96	0.54	3.77e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg20761395	chr17:511517	VPS53	0.7	7.84	0.54	7.39e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.72	7.03	0.5	6.64e-11	Colorectal cancer;
PAAD	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.71	-7.19	-0.5	2.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.75	4.79	0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs4523957	0.583	rs7225168	chr17:2023089	T/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.71	-7.98	-0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10248584	chr11:86666552	FZD4	0.59	6.42	0.46	1.66e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.84	8.26	0.56	6.66e-14	Vitamin D levels;
PAAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24161838	chr10:2544339	NA	-0.59	-6.71	-0.48	3.6e-10	Obesity-related traits;
PAAD	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.66	-5.02	-0.38	1.4e-6	Exhaled nitric oxide output;
PAAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.5e-5	Systemic lupus erythematosus;
PAAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	6.96	0.49	9.3e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs73206853	0.841	rs73191840	chr12:110970457	A/G	cg12870014	chr12:110450643	ANKRD13A	0.77	4.88	0.37	2.66e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	trans	rs61677309	1.000	rs61706007	chr11:118167278	T/G	cg15548380	chr1:19984784	NBL1	-0.61	-6.39	-0.46	1.91e-9	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23169784	chr7:37947061	SFRP4	-0.62	-6.73	-0.48	3.3e-10	Obesity-related traits;
PAAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.83	-0.54	7.88e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.56	-0.35	1.05e-5	LDL cholesterol levels;
PAAD	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.49	5.66	0.42	7.46e-8	Coronary artery disease;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg26354017	chr1:205819088	PM20D1	0.59	5.46	0.41	1.88e-7	White blood cell types;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6681460	0.932	rs524114	chr1:67188335	C/T	cg02459107	chr1:67143332	SGIP1	-0.71	-6.46	-0.46	1.35e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07318088	chr6:90539243	CASP8AP2	0.42	4.36	0.33	2.42e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg08773314	chr2:239334832	ASB1	-0.42	-6.17	-0.45	6.01e-9	Multiple system atrophy;
PAAD	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.93	0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.62	4.38	0.33	2.24e-5	Alzheimer's disease;
PAAD	cis	rs2286503	0.839	rs1054471	chr7:22852643	T/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.7	-0.36	5.73e-6	Fibrinogen;
PAAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.45	0.52	6.45e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg15123519	chr2:136567270	LCT	-0.39	-4.68	-0.35	6.31e-6	Mosquito bite size;
PAAD	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg11779900	chr17:80519722	FOXK2	-0.48	-4.96	-0.37	1.85e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.63	5.36	0.4	3.06e-7	Initial pursuit acceleration;
PAAD	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.79	6.57	0.47	7.54e-10	HIV-1 control;
PAAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.79	7.86	0.54	6.36e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs58521262	0.530	rs462713	chr19:23140705	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg09796270	chr17:17721594	SREBF1	0.44	5.04	0.38	1.31e-6	Total body bone mineral density;
PAAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.87	10.36	0.64	2.33e-19	DNA methylation (variation);
PAAD	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.5	0.61	4.21e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.55	5.73	0.42	5.14e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.3e-6	Tuberculosis;
PAAD	cis	rs13326165	0.543	rs77020200	chr3:52312976	C/T	cg16977858	chr3:52567510	NT5DC2	0.69	4.32	0.33	2.78e-5	HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-9.04	-0.59	6.84e-16	Gut microbiome composition (summer);
PAAD	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.23	-14.94	-0.77	1.23e-31	Ulcerative colitis;
PAAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.67	5.7	0.42	6e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.7	5.23	0.39	5.5e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2271001	0.910	rs11604471	chr11:19144724	C/T	cg00161556	chr11:19138045	ZDHHC13	0.52	5.71	0.42	5.65e-8	Gut microbiome composition (winter);
PAAD	cis	rs939584	1.000	rs13401686	chr2:650519	A/G	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.67	-0.42	6.97e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4787491	0.765	rs4788216	chr16:30048077	C/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.41	-0.34	1.92e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg06096015	chr1:231504339	EGLN1	0.59	6.46	0.46	1.34e-9	Red blood cell count;
PAAD	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-5.43	-0.4	2.21e-7	Lung cancer;
PAAD	cis	rs78049276	0.688	rs75697049	chr4:148375242	C/T	cg00400743	chr4:148603008	PRMT10	-0.71	-4.48	-0.34	1.48e-5	Pulse pressure;
PAAD	cis	rs10929159	0.928	rs11890052	chr2:236918533	A/G	cg14226755	chr2:236923322	AGAP1	0.28	4.51	0.34	1.27e-5	Parkinson's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03588460	chr10:89623442	PTEN;KILLIN	-0.79	-7.04	-0.5	6.35e-11	Neuroticism;
PAAD	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg16928487	chr17:17741425	SREBF1	0.38	5.06	0.38	1.17e-6	Total body bone mineral density;
PAAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.34	0.56	4.26e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.7	-5.84	-0.43	3.13e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.36e-6	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.74	-6.64	-0.47	5.28e-10	Blood protein levels;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.68	7.51	0.52	4.63e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg00071950	chr4:10020882	SLC2A9	-0.72	-6.46	-0.46	1.33e-9	Schizophrenia (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22645421	chr5:6749246	POLS	-0.58	-6.46	-0.46	1.31e-9	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	0.89	6.1	0.44	8.44e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.49	4.9	0.37	2.41e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.52	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg20406979	chr6:167373233	NA	-0.38	-5.23	-0.39	5.45e-7	Crohn's disease;
PAAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg22903657	chr4:1355424	KIAA1530	0.4	4.35	0.33	2.46e-5	Obesity-related traits;
PAAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	8.47	0.57	1.94e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg09659197	chr4:152720779	NA	-0.37	-5.37	-0.4	2.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23158103	chr7:148848205	ZNF398	-0.57	-5.68	-0.42	6.58e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.88	-13.3	-0.73	2.9e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg22681709	chr2:178499509	PDE11A	-0.4	-5.01	-0.38	1.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.56e-6	Skin colour saturation;
PAAD	cis	rs7624766	0.555	rs1378657	chr3:160526759	G/A	cg22637730	chr3:160473554	PPM1L	0.5	4.27	0.33	3.5e-5	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.19e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.48	6.37	0.46	2.08e-9	Ulcerative colitis;
PAAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg20744362	chr22:50050164	C22orf34	0.67	8.12	0.55	1.51e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2882667	0.690	rs288031	chr5:138216066	T/C	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.63	-0.42	8.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg20936604	chr3:58311152	NA	-0.77	-4.39	-0.34	2.15e-5	Cholesterol, total;
PAAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg02734326	chr4:10020555	SLC2A9	0.43	4.5	0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg11204139	chr17:3907470	NA	0.83	8.28	0.56	5.8e-14	Type 2 diabetes;
PAAD	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg23127183	chr11:57508653	C11orf31	-0.52	-4.4	-0.34	2.02e-5	Schizophrenia;
PAAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.56	0.41	1.18e-7	Cognitive function;
PAAD	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg25124228	chr12:125621409	AACS	-0.61	-6.12	-0.44	7.62e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	9.91e-6	Renal cell carcinoma;
PAAD	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-7.29	-0.51	1.59e-11	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg10820045	chr2:198174542	NA	0.51	5.07	0.38	1.13e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4908768	0.657	rs1353130	chr1:8822364	T/C	cg25722041	chr1:8623473	RERE	0.51	4.38	0.33	2.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-1.43	-10.55	-0.65	7.32e-20	Magnesium levels;
PAAD	cis	rs7101378	0.577	rs4586113	chr11:108894798	C/A	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	IgG glycosylation;
PAAD	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.64	-6.03	-0.44	1.19e-8	DNA methylation (variation);
PAAD	cis	rs4880487	0.888	rs10794731	chr10:1251905	T/A	cg03183215	chr10:1252341	ADARB2	-0.48	-4.75	-0.36	4.77e-6	Migraine;
PAAD	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.97	-8.42	-0.56	2.63e-14	Dilated cardiomyopathy;
PAAD	cis	rs9815354	0.951	rs1617271	chr3:41914000	G/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg15691649	chr6:25882328	NA	-0.49	-4.45	-0.34	1.65e-5	Blood metabolite levels;
PAAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs57994353	0.568	rs3812581	chr9:139311471	C/T	cg21253087	chr9:139290292	SNAPC4	0.54	4.79	0.36	3.88e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.62	6.87	0.49	1.53e-10	Longevity;Endometriosis;
PAAD	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg02404636	chr22:31891804	SFI1	0.63	5.82	0.43	3.33e-8	Colorectal cancer;
PAAD	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.54	-5.37	-0.4	2.84e-7	Inflammatory bowel disease;
PAAD	cis	rs9346455	0.554	rs9346457	chr6:72009302	A/T	cg27238071	chr6:71998145	OGFRL1	0.75	4.38	0.33	2.18e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.54	4.85	0.37	3.03e-6	Blood metabolite levels;
PAAD	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.81	-8.11	-0.55	1.56e-13	Coronary artery disease;
PAAD	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.93	13.44	0.74	1.24e-27	Height;
PAAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg19488206	chr2:242435732	STK25	0.5	4.94	0.37	2.02e-6	Fibrinogen levels;
PAAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.14e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9982086	0.557	rs57126	chr21:27311825	A/G	cg04970570	chr5:87990145	NA	0.6	6.35	0.46	2.34e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs4791774	0.540	rs7218002	chr17:8923718	A/T	cg14181409	chr17:9802860	RCVRN	0.39	4.7	0.36	5.91e-6	Nonsyndromic cleft lip with or without cleft palate;
PAAD	cis	rs16958440	1.000	rs16952848	chr18:44597829	A/G	cg17192377	chr18:44677553	HDHD2	0.9	5.56	0.41	1.18e-7	Sitting height ratio;
PAAD	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-10.38	-0.64	2.09e-19	Cognitive function;
PAAD	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg09659197	chr4:152720779	NA	0.37	5.37	0.4	2.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	4.8	0.36	3.7e-6	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10774808	chr3:149181865	NA	0.58	6.58	0.47	7.35e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.55	5.7	0.42	6.03e-8	Interleukin-18 levels;
PAAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.53	-4.67	-0.35	6.62e-6	P wave terminal force;
PAAD	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.87	8.76	0.58	3.49e-15	Uric acid levels;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	15.6	0.78	2.26e-33	Height;
PAAD	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg03885332	chr11:832357	CD151	-0.45	-5.25	-0.39	4.96e-7	Mean platelet volume;
PAAD	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.57	7.09	0.5	4.83e-11	Crohn's disease;
PAAD	cis	rs10905065	0.931	rs6602240	chr10:5816751	C/A	cg11519256	chr10:5708881	ASB13	-0.53	-4.55	-0.35	1.09e-5	Menopause (age at onset);
PAAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.29	-0.33	3.19e-5	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg09017928	chr7:158110068	PTPRN2	0.46	4.68	0.35	6.41e-6	Calcium levels;
PAAD	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.37	4.58	0.35	9.5e-6	Response to Dalcetrapib treatment in acute coronary syndrome;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20941530	chr11:118992036	HINFP	-0.78	-6.86	-0.49	1.6e-10	Neuroticism;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.87	-10.7	-0.66	2.93e-20	Prudent dietary pattern;
PAAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Gout;
PAAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.87	-7.84	-0.54	7.13e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23881601	chr1:156698494	C1orf66;ISG20L2	-0.63	-7.26	-0.51	1.9e-11	Body fat percentage;
PAAD	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.42	-4.35	-0.33	2.52e-5	Schizophrenia;
PAAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg09835421	chr16:68378352	PRMT7	-1.16	-8.31	-0.56	4.96e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	0.76	5.85	0.43	2.92e-8	Blood protein levels;
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg08994789	chr17:28903642	LRRC37B2	0.53	4.37	0.33	2.27e-5	Body mass index;
PAAD	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.94	8.2	0.55	9.14e-14	Pediatric autoimmune diseases;
PAAD	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.48	0.34	1.45e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg15181151	chr6:150070149	PCMT1	0.56	5.97	0.44	1.58e-8	Lung cancer;
PAAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.13	0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs3206736	0.548	rs57315957	chr7:35062819	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.6	-0.35	8.84e-6	Diastolic blood pressure;
PAAD	cis	rs16854884	0.770	rs13091882	chr3:143818661	C/T	cg06585982	chr3:143692056	C3orf58	0.49	4.82	0.36	3.5e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg06483076	chr3:194406458	FAM43A	0.53	5.03	0.38	1.36e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs9395066	0.545	rs4714828	chr6:44846008	A/G	cg18551225	chr6:44695536	NA	-0.43	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.79	7.68	0.53	1.78e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04987827	chr17:66508605	PRKAR1A	0.59	6.8	0.48	2.21e-10	Monocyte percentage of white cells;
PAAD	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg05805236	chr11:65401703	PCNXL3	-0.43	-4.41	-0.34	1.93e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10450586	0.863	rs7123749	chr11:27303855	A/G	cg10370305	chr11:27303972	NA	0.38	4.51	0.34	1.31e-5	Total body bone mineral density;
PAAD	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.36	-0.4	3.01e-7	Number of children ever born;
PAAD	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.78	0.42	4.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.67	-6.24	-0.45	4.1e-9	White matter hyperintensity burden;
PAAD	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.68	6.79	0.48	2.34e-10	Blood protein levels;
PAAD	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs4455778	0.580	rs7796581	chr7:49124966	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.34	1.36e-5	Acylcarnitine levels;
PAAD	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4986172	0.539	rs12603813	chr17:43196584	T/C	cg10701640	chr17:43249399	NA	0.43	4.36	0.33	2.37e-5	Height;
PAAD	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg19019345	chr11:8888814	ST5	0.38	4.26	0.33	3.6e-5	Hemoglobin concentration;
PAAD	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg23995914	chr4:10459228	ZNF518B	-0.39	-4.65	-0.35	7.04e-6	Schizophrenia (age at onset);
PAAD	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-10.03	-0.63	1.75e-18	Brugada syndrome;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.82	-7.9	-0.54	5.33e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.7	-6.85	-0.49	1.74e-10	Retinal vascular caliber;
PAAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg02734326	chr4:10020555	SLC2A9	-0.45	-4.62	-0.35	8.12e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.58	-7.35	-0.51	1.14e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.85	-10.52	-0.65	8.57e-20	Aortic root size;
PAAD	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg14061069	chr19:46274453	DMPK	-0.64	-6.79	-0.48	2.42e-10	Coronary artery disease;
PAAD	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.46	0.61	5.63e-17	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.88	-0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	8.88	0.58	1.79e-15	Alzheimer's disease;
PAAD	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.53	-0.34	1.2e-5	Subjective well-being;
PAAD	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.92	6.29	0.45	3.27e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.55	-6.06	-0.44	1.01e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs11614333	0.920	rs10492151	chr12:15026065	A/C	cg00431549	chr12:15039025	MGP	0.39	4.75	0.36	4.67e-6	Hand grip strength;
PAAD	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.75	-10.14	-0.64	8.95e-19	Late-onset Alzheimer's disease;
PAAD	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg12610070	chr10:71211762	TSPAN15	-0.58	-7.92	-0.54	4.72e-13	Venous thromboembolism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26093790	chr2:62733166	TMEM17	-0.79	-6.77	-0.48	2.6200000000000003e-10	Neuroticism;
PAAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.46	5.08	0.38	1.12e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1864585	0.520	rs57348261	chr8:10669089	G/A	cg21775007	chr8:11205619	TDH	-0.56	-4.57	-0.35	1e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.45	4.42	0.34	1.88e-5	Dupuytren's disease;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.58	-5.3	-0.39	4.02e-7	Total body bone mineral density;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg03407747	chr17:6899364	ALOX12	0.52	5.41	0.4	2.44e-7	Tonsillectomy;
PAAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.45	0.46	1.41e-9	Rheumatoid arthritis;
PAAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.56	5.87	0.43	2.64e-8	Hepatitis;
PAAD	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.74	6.9	0.49	1.3100000000000001e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs929596	0.564	rs2602362	chr2:234516548	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.49	-0.34	1.4e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.9	-10.27	-0.64	4.11e-19	Refractive error;
PAAD	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.61	-6.94	-0.49	1.04e-10	Menarche (age at onset);
PAAD	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.69	0.42	6.36e-8	Coronary artery disease;
PAAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg19257562	chr1:2043853	PRKCZ	-0.38	-4.43	-0.34	1.76e-5	Height;
PAAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg02196655	chr2:10830764	NOL10	-0.43	-4.36	-0.33	2.42e-5	Prostate cancer;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.44	-5.54	-0.41	1.3e-7	Longevity;Endometriosis;
PAAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01585723	chr16:33734837	NA	0.44	4.76	0.36	4.39e-6	Menopause (age at onset);
PAAD	cis	rs1561176	0.830	rs4620236	chr7:154986897	C/T	cg25063631	chr7:155025500	NA	-0.49	-4.28	-0.33	3.33e-5	Personality dimensions;
PAAD	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.76	-7.5	-0.52	4.85e-12	Schizophrenia;
PAAD	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.66	-6.74	-0.48	3.04e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs11113894	0.901	rs17040591	chr12:108860695	A/T	cg03612522	chr12:108733261	CMKLR1	-0.66	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.45	-0.46	1.42e-9	Neuroticism;
PAAD	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg05784532	chr1:230284198	GALNT2	0.69	6.02	0.44	1.26e-8	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03676636	chr4:99064102	C4orf37	0.33	5.99	0.44	1.49e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.54	5.27	0.39	4.69e-7	Eosinophil percentage of white cells;
PAAD	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs12612619	0.591	rs12714092	chr2:27314882	G/A	cg00617064	chr2:27272375	NA	0.46	4.43	0.34	1.79e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.48	4.68	0.35	6.3e-6	Coronary artery disease;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.9	-0.37	2.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg03115019	chr17:80708279	FN3K	0.51	4.53	0.34	1.2e-5	Glycated hemoglobin levels;
PAAD	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg05341575	chr12:125625032	AACS	-0.48	-4.54	-0.35	1.15e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.65	-7.15	-0.5	3.42e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.34	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.52	0.65	8.52e-20	Bladder cancer;
PAAD	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg01620082	chr3:125678407	NA	-0.9	-6.7	-0.48	3.84e-10	Depression;
PAAD	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.92	-9.6	-0.61	2.34e-17	Urate levels in obese individuals;
PAAD	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	5.63	0.42	8.5e-8	Myopia (pathological);
PAAD	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg05627522	chr15:75251581	NA	0.41	5.01	0.38	1.47e-6	Systemic lupus erythematosus;
PAAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	8.01e-9	Schizophrenia;
PAAD	cis	rs11614333	1.000	rs12300129	chr12:15044354	C/T	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14495033	chr9:140707378	EHMT1	0.63	7.17	0.5	3.07e-11	Smoking initiation;
PAAD	cis	rs75920871	1.000	rs61905705	chr11:116883776	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.62e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.8	-0.36	3.72e-6	Neuroticism;
PAAD	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg10290764	chr8:4849399	CSMD1	-0.39	-6.47	-0.46	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg22467129	chr15:76604101	ETFA	0.51	4.79	0.36	4e-6	Blood metabolite levels;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg12647257	chr2:47043387	NA	0.47	4.97	0.37	1.8e-6	Height;
PAAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.58	6.49	0.47	1.12e-9	Blood metabolite levels;
PAAD	cis	rs76866386	1.000	rs41360247	chr2:44073656	C/T	cg21783355	chr2:44066198	ABCG5;ABCG8	0.77	4.91	0.37	2.34e-6	Cholesterol, total;
PAAD	cis	rs73198271	0.628	rs11783457	chr8:8588842	G/C	cg01851573	chr8:8652454	MFHAS1	0.65	4.9	0.37	2.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26853093	chr19:17448469	GTPBP3	0.62	7.22	0.51	2.32e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-5.71	-0.42	5.79e-8	Longevity;Endometriosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07609703	chr2:240032685	HDAC4	0.61	6.37	0.46	2.09e-9	Smoking initiation;
PAAD	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.92	-0.43	2.03e-8	Coronary artery disease;
PAAD	cis	rs11807834	0.522	rs12078342	chr1:230252950	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.58	6.51	0.47	1.02e-9	Platelet distribution width;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.95	5.91	0.43	2.14e-8	Body mass index;
PAAD	cis	rs290268	0.769	rs2562396	chr9:93567425	C/A	cg02608019	chr9:93564028	SYK	0.61	5.83	0.43	3.24e-8	Platelet count;
PAAD	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6604026	0.656	rs7550347	chr1:93401157	G/C	cg13858687	chr1:93297071	RPL5	0.47	4.28	0.33	3.28e-5	Multiple sclerosis;
PAAD	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.89	10.56	0.65	6.86e-20	Response to antipsychotic treatment;
PAAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.89	-0.49	1.43e-10	Menopause (age at onset);
PAAD	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg08662619	chr6:150070041	PCMT1	-0.44	-4.29	-0.33	3.19e-5	Lung cancer;
PAAD	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.57	-0.41	1.11e-7	Neuroticism;
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg16898833	chr6:26189333	HIST1H4D	0.69	5.34	0.4	3.31e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6669119	0.591	rs77152015	chr1:19104640	G/A	cg19637330	chr1:19110922	NA	0.92	5.62	0.41	8.88e-8	Percentage gas trapping;
PAAD	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg23489630	chr19:44645078	ZNF234	0.61	4.7	0.36	5.74e-6	Alzheimer's disease;
PAAD	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg26818257	chr2:241905806	NA	0.43	4.33	0.33	2.69e-5	Urinary metabolites;
PAAD	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08128228	chr1:167191360	POU2F1	-0.63	-7.47	-0.52	5.81e-12	Body fat percentage;
PAAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-4.57	-0.35	1e-5	Height;
PAAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.57	-5.94	-0.43	1.84e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg04990556	chr1:26633338	UBXN11	0.68	4.87	0.37	2.72e-6	Obesity-related traits;
PAAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.7	-7.94	-0.54	4.06e-13	Huntington's disease progression;
PAAD	cis	rs2119480	0.739	rs7998588	chr13:111351534	G/A	cg24331049	chr13:111365604	ING1	-0.49	-4.38	-0.33	2.18e-5	Diastolic blood pressure;
PAAD	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.95	8.24	0.56	7.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs9810890	1.000	rs73198816	chr3:128474440	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg14440974	chr22:39074834	NA	-0.55	-6.77	-0.48	2.7e-10	Menopause (age at onset);
PAAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-6.47	-0.46	1.25e-9	Morning vs. evening chronotype;
PAAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg22546130	chr22:19950026	COMT	-0.32	-5.08	-0.38	1.09e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.06	-0.38	1.17e-6	Educational attainment (years of education);
PAAD	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.62	5.31	0.4	3.79e-7	QRS duration;
PAAD	cis	rs1371614	0.545	rs13035643	chr2:27173341	G/A	cg07507200	chr2:27712693	IFT172	0.48	4.34	0.33	2.55e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.75	-8.17	-0.55	1.09e-13	Personality dimensions;
PAAD	cis	rs939584	0.735	rs13035713	chr2:633659	T/C	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.6	6.08	0.44	9.11e-9	Monocyte count;
PAAD	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg01214346	chr17:406501	NA	0.48	4.63	0.35	7.69e-6	Prostate cancer;
PAAD	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg02023728	chr11:77925099	USP35	-0.43	-4.25	-0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg02631450	chr22:32366979	NA	1.07	5.75	0.42	4.67e-8	Childhood ear infection;
PAAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-4.68	-0.35	6.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.61	6.22	0.45	4.63e-9	Resistin levels;
PAAD	cis	rs1075265	0.756	rs2542576	chr2:54048796	T/C	cg04546899	chr2:54196757	PSME4	0.3	4.54	0.35	1.14e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs863345	0.584	rs6427438	chr1:158454730	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.83	-0.36	3.33e-6	Pneumococcal bacteremia;
PAAD	cis	rs11235843	0.929	rs112650783	chr11:73389928	G/A	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.32	7.54	0.52	3.86e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.44	0.4	2.12e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs6466055	0.589	rs6980244	chr7:104636940	T/C	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.77e-6	Schizophrenia;
PAAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg23281280	chr6:28129359	ZNF389	-0.48	-4.25	-0.33	3.71e-5	Parkinson's disease;
PAAD	cis	rs12282928	0.959	rs1393788	chr11:48279416	A/G	cg04721828	chr11:48285200	OR4X1	0.45	5.65	0.42	7.52e-8	Migraine - clinic-based;
PAAD	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg07148914	chr20:33460835	GGT7	-0.49	-4.79	-0.36	4.01e-6	Coronary artery disease;
PAAD	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.51	-6.9	-0.49	1.3100000000000001e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.61	-6.32	-0.46	2.75e-9	Menopause (age at onset);
PAAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.4	-0.4	2.53e-7	Glomerular filtration rate;
PAAD	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.4	-0.34	2.01e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg05627522	chr15:75251581	NA	-0.51	-6.23	-0.45	4.39e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14572895	chr18:61368902	SERPINB11	-0.61	-6.61	-0.47	6.28e-10	Obesity-related traits;
PAAD	cis	rs4742903	0.935	rs7024069	chr9:107008176	A/G	cg14250997	chr9:106856677	SMC2	0.42	4.47	0.34	1.51e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.47	4.88	0.37	2.68e-6	Longevity;
PAAD	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.75	-7.67	-0.53	1.89e-12	Parkinson's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26272417	chr14:72148982	SIPA1L1	0.61	7.05	0.5	5.97e-11	Smoking initiation;
PAAD	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.49	4.55	0.35	1.11e-5	Malaria;
PAAD	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	1.23	6.34	0.46	2.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg02799478	chr19:58090259	ZNF416	-0.48	-4.32	-0.33	2.75e-5	Uric acid clearance;
PAAD	cis	rs4792901	0.802	rs9894910	chr17:41574306	T/A	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.95e-5	Dupuytren's disease;
PAAD	trans	rs17213965	1.000	rs17213965	chr16:15881967	C/T	cg13673563	chr14:21738473	HNRNPC	-0.88	-6.36	-0.46	2.26e-9	Waist-hip ratio;
PAAD	cis	rs524281	0.814	rs2270448	chr11:65835931	G/T	cg16950941	chr11:66035639	RAB1B	-0.58	-4.29	-0.33	3.17e-5	Electroencephalogram traits;
PAAD	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.63	-0.35	7.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.67	6.25	0.45	3.99e-9	Corneal astigmatism;
PAAD	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.59	-0.41	1.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg22691776	chr3:15032403	NR2C2	0.3	4.35	0.33	2.51e-5	Mean platelet volume;
PAAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.69	-6.03	-0.44	1.18e-8	Neuroticism;
PAAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.01	-0.49	7.19e-11	Gut microbiome composition (summer);
PAAD	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	5.58	0.41	1.1e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg08088566	chr11:430123	ANO9	0.94	5.75	0.42	4.71e-8	Body mass index;
PAAD	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.53	5.52	0.41	1.45e-7	Red blood cell count;
PAAD	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg26031613	chr14:104095156	KLC1	1.16	16.25	0.8	4.79e-35	Body mass index;
PAAD	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.43e-7	Type 2 diabetes;
PAAD	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg14349672	chr11:133703707	NA	-0.47	-5.08	-0.38	1.09e-6	Childhood ear infection;
PAAD	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.23	19.21	0.84	1.71e-42	IgG glycosylation;
PAAD	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.56	6.35	0.46	2.38e-9	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12230010	chr10:72163718	EIF4EBP2	0.62	7.2	0.5	2.59e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.45	5.36	0.4	2.97e-7	Tonsillectomy;
PAAD	cis	rs11563648	0.553	rs1419421	chr7:127017694	A/T	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08550205	chr17:45786854	TBKBP1	-0.41	-4.48	-0.34	1.48e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.58	5.85	0.43	2.91e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.62	-6.81	-0.48	2.18e-10	Longevity;Endometriosis;
PAAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.6	6.15	0.45	6.63e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10847980	0.702	rs11060708	chr12:123397136	G/C	cg25930673	chr12:123319894	HIP1R	1.11	4.71	0.36	5.57e-6	Adiponectin levels;
PAAD	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.63	5.48	0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs7631605	0.935	rs3774334	chr3:37072705	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg16342193	chr10:102329863	NA	-0.8	-8.85	-0.58	2.12e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg07549590	chr16:15018862	NA	-0.48	-4.99	-0.38	1.63e-6	Triglycerides;
PAAD	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.85	10.27	0.64	4.06e-19	Body mass index;
PAAD	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg03999872	chr20:62272968	STMN3	0.65	5.7	0.42	6.02e-8	Atopic dermatitis;
PAAD	cis	rs2274459	0.841	rs2281918	chr6:33663055	G/A	cg06253072	chr6:33679850	C6orf125	0.63	4.8	0.36	3.69e-6	Obesity (extreme);
PAAD	cis	rs4742903	1.000	rs4742906	chr9:106857078	A/G	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.14	0.38	8.48e-7	Mood instability;
PAAD	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg14181355	chr19:12984996	MAST1	0.48	4.72	0.36	5.37e-6	Mean corpuscular volume;
PAAD	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.6	-5.92	-0.43	2.04e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs939584	1.000	rs4854349	chr2:647861	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg00431813	chr7:1051703	C7orf50	0.75	4.54	0.35	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2051773	0.510	rs11024129	chr11:17056417	C/A	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-5.42	-0.4	2.31e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.68	-0.35	6.39e-6	Bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15352185	chr13:77601313	FBXL3	0.64	7.44	0.52	6.85e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs61861422	0.516	rs12767762	chr10:134443032	A/G	cg09421083	chr10:134358535	INPP5A	-0.53	-4.82	-0.36	3.49e-6	Primary sclerosing cholangitis;
PAAD	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	2.97e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.63	-0.35	7.78e-6	Mood instability;
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.89	7.74	0.53	1.28e-12	Alzheimer's disease;
PAAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs728616	0.681	rs35420115	chr10:81908188	A/G	cg19423196	chr10:82049429	MAT1A	0.46	4.32	0.33	2.79e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg05110241	chr16:68378359	PRMT7	-1.11	-7.76	-0.53	1.15e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg21191810	chr6:118973309	C6orf204	0.42	5.08	0.38	1.1e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.49	4.82	0.36	3.41e-6	Airway imaging phenotypes;
PAAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	5.44	0.4	2.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2017305	0.748	rs76382335	chr10:70714945	C/G	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.8	-6.98	-0.49	8.72e-11	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg10818794	chr15:86012489	AKAP13	-0.57	-4.67	-0.35	6.53e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.55	5.96	0.44	1.66e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.83	0.43	3.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	1.03	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg02527881	chr3:46936655	PTH1R	0.38	4.4	0.34	2.07e-5	Colorectal cancer;
PAAD	cis	rs931127	0.554	rs34007146	chr11:65477954	G/A	cg06492744	chr11:65406254	SIPA1	-0.32	-4.43	-0.34	1.78e-5	Systemic lupus erythematosus;
PAAD	cis	rs4287000	0.740	rs10761244	chr9:96387592	C/T	cg13787134	chr9:96362102	PHF2	0.38	4.47	0.34	1.52e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg14393609	chr7:65229607	NA	-0.66	-7.28	-0.51	1.69e-11	Aortic root size;
PAAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.92	-11.5	-0.68	2.1e-22	Rheumatoid arthritis;
PAAD	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.5	-4.91	-0.37	2.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.49	-5.05	-0.38	1.24e-6	Type 2 diabetes;
PAAD	cis	rs3774830	0.649	rs10000998	chr4:5467983	C/T	cg26943120	chr4:5472116	STK32B	0.34	4.36	0.33	2.4e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	0.56	4.77	0.36	4.22e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.71	6.58	0.47	7.13e-10	Response to bleomycin (chromatid breaks);
PAAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg21890820	chr11:65308645	LTBP3	0.63	7.56	0.52	3.6e-12	Bone mineral density;
PAAD	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-5.62	-0.41	9.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.5	4.86	0.37	2.93e-6	Common traits (Other);
PAAD	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.88	-8.44	-0.56	2.39e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg21496419	chr19:44306685	LYPD5	0.37	4.65	0.35	7.05e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg08315770	chr6:39281885	KCNK17	-0.61	-6.47	-0.46	1.29e-9	Type 2 diabetes;
PAAD	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg18551225	chr6:44695536	NA	-0.62	-5.72	-0.42	5.39e-8	Total body bone mineral density;
PAAD	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.71	8.93	0.59	1.32e-15	Dupuytren's disease;
PAAD	cis	rs773506	0.628	rs10820836	chr9:93928329	A/G	cg14446406	chr9:93919335	NA	-0.4	-5.45	-0.4	2.03e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg21351543	chr2:191399470	TMEM194B	-0.58	-4.5	-0.34	1.32e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg03162506	chr22:38580953	NA	-0.39	-4.4	-0.34	2.02e-5	Cutaneous nevi;
PAAD	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg06740227	chr12:86229804	RASSF9	0.48	4.5	0.34	1.34e-5	Major depressive disorder;
PAAD	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.39	-0.34	2.15e-5	Coronary artery disease;
PAAD	cis	rs787274	1.000	rs1418410	chr9:115465282	A/G	cg13803584	chr9:115635662	SNX30	0.96	6.47	0.46	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.56	0.35	1.07e-5	Self-reported allergy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20588892	chr5:87565114	TMEM161B	0.71	8.33	0.56	4.44e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg22467129	chr15:76604101	ETFA	0.45	4.32	0.33	2.85e-5	Blood metabolite levels;
PAAD	cis	rs7178572	0.633	rs12901130	chr15:77848806	C/T	cg22256960	chr15:77711686	NA	-0.55	-4.26	-0.33	3.5e-5	Type 2 diabetes;
PAAD	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg23860436	chr12:58378763	NA	0.46	4.34	0.33	2.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.84	7.3	0.51	1.52e-11	Alzheimer's disease;
PAAD	cis	rs4356203	0.870	rs214915	chr11:17241773	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg08917208	chr2:24149416	ATAD2B	0.5	4.47	0.34	1.5e-5	Asthma;
PAAD	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg02869306	chr7:64672164	INTS4L1	0.43	4.91	0.37	2.37e-6	Calcium levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20706482	chr19:54641315	CNOT3	0.61	6.81	0.48	2.17e-10	Monocyte percentage of white cells;
PAAD	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.56	5.36	0.4	3.04e-7	Body mass index;Social communication problems;
PAAD	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg11952622	chr19:58962976	ZNF324B	0.45	4.39	0.34	2.1e-5	Uric acid clearance;
PAAD	trans	rs901683	0.850	rs78999882	chr10:46076813	A/T	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.61	6.49	0.47	1.13e-9	Caffeine consumption;
PAAD	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.49	4.48	0.34	1.45e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-5.03	-0.38	1.34e-6	Glycated hemoglobin levels;
PAAD	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg14345882	chr6:26364793	BTN3A2	0.71	4.26	0.33	3.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	ch.11.42038R	chr11:967971	AP2A2	0.61	6.2	0.45	5.2e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.43	0.46	1.59e-9	Educational attainment;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08354388	chr11:121526264	NA	-0.74	-6.38	-0.46	2e-9	Neuroticism;
PAAD	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.81	-6.55	-0.47	8.4e-10	Vitiligo;
PAAD	cis	rs16975963	0.644	rs73031326	chr19:38043022	G/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-8.54	-0.57	1.28e-14	Chronic sinus infection;
PAAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.4	-5.43	-0.4	2.23e-7	Height;
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	5.38	0.4	2.79e-7	Menarche (age at onset);
PAAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.72	6.63	0.47	5.51e-10	Obesity-related traits;
PAAD	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	1.03	9.15	0.6	3.43e-16	Neutrophil percentage of white cells;
PAAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg05562828	chr17:3906858	NA	0.55	6.43	0.46	1.55e-9	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.24	12.35	0.71	1.08e-24	Platelet count;
PAAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.16	-9.23	-0.6	2.17e-16	Breast cancer;
PAAD	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.94	-11.04	-0.67	3.44e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.15	0.39	8e-7	HIV-1 control;
PAAD	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-5.39	-0.4	2.6e-7	Coronary artery disease;
PAAD	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg02683114	chr2:24398427	C2orf84	-0.57	-5.5	-0.41	1.57e-7	Asthma;
PAAD	cis	rs5756391	0.568	rs4821570	chr22:37317177	C/G	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.55	-5.72	-0.42	5.6e-8	Resting heart rate;
PAAD	cis	rs617219	0.737	rs1275103	chr5:78448105	C/G	cg24856658	chr5:78533917	JMY	-0.39	-4.39	-0.34	2.14e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	trans	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs10885582	0.781	rs10885578	chr10:116303554	G/C	cg17056676	chr10:116301354	ABLIM1	-0.39	-5.28	-0.39	4.32e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs899997	1.000	rs12901228	chr15:79030049	G/T	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs9649465	0.967	rs1005568	chr7:123306470	G/A	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.14.1452150F	chr14:91751397	CCDC88C	-0.75	-7.42	-0.52	7.76e-12	Lung cancer in ever smokers;
PAAD	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.54	-4.52	-0.34	1.22e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg19257562	chr1:2043853	PRKCZ	-0.39	-4.58	-0.35	9.44e-6	Height;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg15181151	chr6:150070149	PCMT1	0.59	6.47	0.46	1.25e-9	Lung cancer;
PAAD	cis	rs642743	0.967	rs591784	chr10:105936290	G/T	cg23130731	chr10:105978651	MIR609;C10orf79	0.24	4.58	0.35	9.68e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.69	-4.57	-0.35	9.93e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg08898775	chr15:59042684	ADAM10	0.35	4.46	0.34	1.58e-5	Schizophrenia;
PAAD	cis	rs6761276	0.932	rs10186133	chr2:113836944	G/T	cg24553058	chr2:113831203	IL1F10	0.44	4.58	0.35	9.57e-6	Protein quantitative trait loci;
PAAD	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.91	11.04	0.67	3.46e-21	Dental caries;
PAAD	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.97	-0.63	2.58e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg19500098	chr13:21900506	NA	0.59	6.5	0.47	1.09e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.68	-7.21	-0.5	2.49e-11	Ulcerative colitis;
PAAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-6.98	-0.49	8.47e-11	Educational attainment;
PAAD	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	5.52	0.41	1.44e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10905065	0.569	rs4750553	chr10:5728174	C/T	cg09234995	chr10:5726438	C10orf18	-0.51	-4.67	-0.35	6.61e-6	Menopause (age at onset);
PAAD	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-7.54	-0.52	4.04e-12	Colorectal cancer;
PAAD	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.63	-0.35	7.89e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.03	-10.87	-0.66	9.99e-21	Ulcerative colitis;
PAAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.98e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.74	-7.52	-0.52	4.35e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12315302	chr6:26189340	HIST1H4D	0.57	4.55	0.35	1.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.81	5.61	0.41	9.4e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg27499820	chr13:21296301	IL17D	-0.56	-5.26	-0.39	4.79e-7	Dental caries;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.21	-0.7	2.55e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.48	-5.4	-0.4	2.57e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7567389	0.719	rs4662718	chr2:128015367	C/T	cg11380483	chr2:127933992	NA	-0.44	-4.35	-0.33	2.46e-5	Self-rated health;
PAAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.84	-6.77	-0.48	2.68e-10	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs6694672	0.850	rs857027	chr1:197013464	T/C	cg26994526	chr18:47719735	MYO5B	-0.81	-6.47	-0.46	1.28e-9	Asthma;
PAAD	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg26149184	chr10:133730230	NA	0.78	6.87	0.49	1.52e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-4.7	-0.36	5.73e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.56	6.12	0.44	7.71e-9	Cognitive function;
PAAD	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-5.52	-0.41	1.44e-7	Fibrinogen levels;
PAAD	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg01426195	chr3:39028469	NA	-0.69	-6.5	-0.47	1.07e-9	Handedness;
PAAD	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg03417191	chr3:183542750	MAP6D1	-0.58	-5.13	-0.38	8.67e-7	Menopause (age at onset);
PAAD	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.42	-0.34	1.86e-5	Resting heart rate;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.8	-9.04	-0.59	6.6e-16	Monocyte percentage of white cells;
PAAD	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg27411982	chr8:10470053	RP1L1	-0.5	-5.51	-0.41	1.48e-7	Retinal vascular caliber;
PAAD	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.77	7.22	0.51	2.36e-11	Vitamin D levels;
PAAD	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.58	-5.46	-0.41	1.86e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.36	0.33	2.35e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.54	6.04	0.44	1.12e-8	Major depressive disorder;
PAAD	cis	rs10750165	0.716	rs11217503	chr11:119652847	T/G	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.46e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.6	-0.35	8.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.51	-4.36	-0.33	2.43e-5	Cocaine dependence;
PAAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.69	5.8	0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg07959070	chr22:50026188	C22orf34	-0.37	-4.56	-0.35	1.06e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.46	4.87	0.37	2.8e-6	QRS complex (12-leadsum);
PAAD	cis	rs1050846	0.564	rs1050863	chr16:87440895	C/T	cg00512563	chr16:87398040	FBXO31	-0.36	-4.76	-0.36	4.41e-6	Neuroticism;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16266579	chr12:48591673	NA	0.7	6.38	0.46	2.03e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg13798912	chr7:905769	UNC84A	0.58	4.39	0.34	2.08e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7250872	0.578	rs1609761	chr19:1847698	A/C	cg10370574	chr19:1840461	REXO1	-0.49	-4.58	-0.35	9.58e-6	Bipolar disorder;
PAAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.53	5.42	0.4	2.32e-7	Platelet count;
PAAD	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.96	10.69	0.66	3.02e-20	Systemic lupus erythematosus;
PAAD	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.82	6.34	0.46	2.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-6.25	-0.45	3.86e-9	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.78	6.79	0.48	2.38e-10	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.38	7.55	0.52	3.78e-12	Skin colour saturation;
PAAD	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.16	0.39	7.67e-7	Tonsillectomy;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.71e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.51	-4.64	-0.35	7.5e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	1.01	11.05	0.67	3.24e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12431939	1.000	rs66806841	chr14:51670524	G/C	cg23942311	chr14:51606299	NA	-0.6	-4.88	-0.37	2.67e-6	Cancer;
PAAD	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.32	-0.4	3.71e-7	Educational attainment (years of education);
PAAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.59	-5.56	-0.41	1.21e-7	Facial morphology (factor 20);
PAAD	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.55	-0.41	1.27e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.62	8.57	0.57	1.07e-14	Airflow obstruction;
PAAD	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.18	-0.6	2.97e-16	Response to antipsychotic treatment;
PAAD	cis	rs6076065	0.723	rs6083104	chr20:23366038	C/T	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2997447	0.723	rs868551	chr1:26475521	C/T	cg24519413	chr1:26490540	NA	-0.52	-4.73	-0.36	5.1e-6	QRS complex (12-leadsum);
PAAD	cis	rs7156960	0.862	rs35545196	chr14:76723013	G/A	cg13981132	chr14:76734493	NA	-0.52	-5.08	-0.38	1.11e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.6	-6.75	-0.48	2.87e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs357618	0.965	rs357621	chr5:150847554	T/C	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg18833306	chr6:118973337	C6orf204	-0.54	-4.44	-0.34	1.69e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.67	6.82	0.48	1.97e-10	Menarche (age at onset);
PAAD	cis	rs7627468	0.770	rs1463892	chr3:121970386	C/T	cg17240004	chr3:121949083	CASR	-0.5	-4.76	-0.36	4.44e-6	Kidney stones;
PAAD	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg09796270	chr17:17721594	SREBF1	0.46	5.14	0.38	8.28e-7	Total body bone mineral density;
PAAD	cis	rs73195822	0.649	rs56159960	chr12:110994068	T/C	cg12870014	chr12:110450643	ANKRD13A	0.99	5.17	0.39	7.36e-7	Itch intensity from mosquito bite;
PAAD	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	4.26	0.33	3.53e-5	Educational attainment;
PAAD	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.17	-0.55	1.14e-13	Exhaled nitric oxide output;
PAAD	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs72681920	0.881	rs2156731	chr4:100072567	C/T	cg12011299	chr4:100065546	ADH4	-0.74	-4.41	-0.34	1.96e-5	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25540579	chr19:1653193	TCF3	0.66	6.5	0.47	1.08e-9	Obesity-related traits;
PAAD	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11446398	chr5:77624930	NA	0.48	5.36	0.4	3.04e-7	Hippocampal atrophy;
PAAD	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.53	-0.47	9.14e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.72	5.26	0.39	4.85e-7	Plateletcrit;
PAAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.6	5.46	0.4	1.94e-7	Blood protein levels;
PAAD	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.44	0.46	1.47e-9	Lung cancer in ever smokers;
PAAD	cis	rs7688540	0.800	rs10028482	chr4:247825	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	4.7	0.36	5.85e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.48	0.57	1.79e-14	Menarche (age at onset);
PAAD	cis	rs12760731	0.582	rs9803679	chr1:178410425	T/C	cg00404053	chr1:178313656	RASAL2	0.65	5.43	0.4	2.17e-7	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10768122	0.966	rs7946149	chr11:35316846	A/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.29	-0.33	3.17e-5	Vitiligo;
PAAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg11949866	chr1:10754891	CASZ1	0.52	4.32	0.33	2.76e-5	Ewing sarcoma;
PAAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg16928487	chr17:17741425	SREBF1	0.33	4.36	0.33	2.38e-5	Total body bone mineral density;
PAAD	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs76419734	0.558	rs11735330	chr4:106521870	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.43	0.34	1.8e-5	Post bronchodilator FEV1;
PAAD	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg05082376	chr22:42548792	NA	-0.52	-5.6	-0.41	9.67e-8	Cognitive function;
PAAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.89	0.63	4.19e-18	Total body bone mineral density;
PAAD	cis	rs61861422	0.516	rs11814062	chr10:134439823	C/T	cg27286337	chr10:134555280	INPP5A	0.67	5.82	0.43	3.31e-8	Primary sclerosing cholangitis;
PAAD	cis	rs2051773	0.567	rs6486346	chr11:17049890	A/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	7.66	0.53	2.03e-12	Prudent dietary pattern;
PAAD	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.74	8.81	0.58	2.72e-15	Bladder cancer;
PAAD	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.01e-6	Lung cancer;
PAAD	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg10064339	chr11:73693792	UCP2	1.52	6.62	0.47	5.86e-10	Obesity-related traits;
PAAD	cis	rs16958440	1.000	rs62096476	chr18:44658621	T/C	cg17192377	chr18:44677553	HDHD2	0.93	5.73	0.42	5.16e-8	Sitting height ratio;
PAAD	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.72	-8.65	-0.57	6.99e-15	Body mass index;
PAAD	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.56	5.66	0.42	7.34e-8	Yeast infection;
PAAD	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	6.84	0.49	1.81e-10	Body mass index (adult);
PAAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg01503450	chr10:980765	NA	-0.54	-4.43	-0.34	1.8e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.13	0.38	8.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg10935138	chr17:73851978	WBP2	0.86	5.63	0.42	8.6e-8	Psoriasis;
PAAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12599982	chr1:44399894	ARTN	-0.42	-4.5	-0.34	1.35e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.37	5.52	0.41	1.46e-7	Educational attainment (years of education);
PAAD	cis	rs3136739	0.681	rs80098805	chr8:41995314	G/A	cg12054981	chr8:42037387	PLAT	0.66	4.78	0.36	4.08e-6	Plasma plasminogen activator levels;
PAAD	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-1.1	-11.79	-0.69	3.45e-23	Longevity;
PAAD	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs2415984	0.579	rs12185007	chr14:46976217	G/A	cg14871534	chr14:47121158	RPL10L	-0.49	-5.13	-0.38	8.71e-7	Number of children ever born;
PAAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	0.744	rs6933439	chr6:75006170	T/C	cg03266952	chr6:74778945	NA	-1.04	-5.95	-0.43	1.77e-8	Metabolite levels (MHPG);
PAAD	cis	rs13144136	0.748	rs11933682	chr4:10670911	C/G	cg10242279	chr4:10666415	CLNK	0.4	5.02	0.38	1.45e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.87	0.37	2.76e-6	Motion sickness;
PAAD	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg09839279	chr12:125627357	AACS	-0.48	-4.41	-0.34	1.94e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26926768	chr12:34528122	NA	0.39	4.81	0.36	3.67e-6	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg18279126	chr7:2041391	MAD1L1	0.62	6.2	0.45	4.98e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.35	-0.33	2.5e-5	Life satisfaction;
PAAD	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.44	4.28	0.33	3.36e-5	Bipolar disorder;
PAAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg03999872	chr20:62272968	STMN3	0.49	4.41	0.34	1.98e-5	Prostate cancer;
PAAD	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg14329783	chr7:75779857	NA	0.77	4.64	0.35	7.32e-6	Mononucleosis;
PAAD	cis	rs58521262	0.585	rs289302	chr19:23169954	G/A	cg02350677	chr19:23254381	NA	0.26	4.61	0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.49e-11	Retinal vascular caliber;
PAAD	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg21496419	chr19:44306685	LYPD5	0.37	4.66	0.35	6.98e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Alcohol dependence;
PAAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.49	-0.61	4.51e-17	Tonsillectomy;
PAAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg17346650	chr17:80929145	B3GNTL1	0.51	6.64	0.47	5.12e-10	Glycated hemoglobin levels;
PAAD	cis	rs11235843	0.929	rs67167213	chr11:73422208	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs3736485	0.844	rs6493501	chr15:51815643	C/G	cg08986416	chr15:51914746	DMXL2	0.44	4.27	0.33	3.44e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.63	5.51	0.41	1.5e-7	Lymphocyte counts;
PAAD	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.71	-0.36	5.46e-6	Breast cancer;
PAAD	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.94	-0.43	1.89e-8	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.79	7.99	0.54	3.08e-13	Vitiligo;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17722469	chr8:146077906	COMMD5	0.6	6.45	0.46	1.43e-9	Primary biliary cholangitis;
PAAD	cis	rs4838594	0.563	rs730509	chr10:49679153	C/A	cg17291251	chr10:49678358	ARHGAP22	0.48	4.54	0.35	1.12e-5	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26558591	chr16:27829801	GSG1L	-0.56	-6.5	-0.47	1.11e-9	Obesity-related traits;
PAAD	cis	rs863345	0.527	rs10797019	chr1:158490221	A/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg07202610	chr7:1142643	C7orf50	-0.69	-4.85	-0.37	3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.58	7.38	0.51	9.75e-12	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.54	5.74	0.42	4.98e-8	Menopause (age at onset);
PAAD	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.63	-6.38	-0.46	2.01e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Birth weight;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs6585424	1.000	rs34148644	chr10:81923456	G/C	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1198430	0.759	rs1198427	chr1:23752898	G/C	cg27447006	chr1:23763279	ASAP3	0.59	4.67	0.35	6.52e-6	Total cholesterol levels;
PAAD	cis	rs7771547	0.603	rs10947614	chr6:36573822	G/C	cg07856975	chr6:36356162	ETV7	0.55	5.86	0.43	2.83e-8	Platelet distribution width;
PAAD	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.54	-4.52	-0.34	1.24e-5	Heschl's gyrus morphology;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19235966	chr1:16173721	SPEN;FLJ37453	-0.56	-6.63	-0.47	5.41e-10	Body fat percentage;
PAAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.43	-4.51	-0.34	1.31e-5	Parkinson's disease;
PAAD	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.62	5.65	0.42	7.74e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9677476	0.587	rs12623587	chr2:232160554	C/A	cg07929768	chr2:232055508	NA	0.45	5.24	0.39	5.18e-7	Food antigen IgG levels;
PAAD	cis	rs1358748	0.555	rs10736408	chr1:67590877	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	4.28	0.33	3.34e-5	Tuberculosis;
PAAD	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14019695	chr9:139328340	INPP5E	0.58	4.91	0.37	2.35e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs17209837	1.000	rs6465116	chr7:87113001	G/A	cg00919237	chr7:87102261	ABCB4	-0.76	-5.01	-0.38	1.47e-6	Gallbladder cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14329045	chr2:106694419	C2orf40	-0.66	-6.66	-0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.76	-8.87	-0.58	1.85e-15	White blood cell count (basophil);
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16863796	chr2:37458781	CEBPZ;C2orf56	0.7	7.0	0.49	7.66e-11	Obesity-related traits;
PAAD	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg11204139	chr17:3907470	NA	-0.66	-6.25	-0.45	3.88e-9	Type 2 diabetes;
PAAD	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg04153130	chr7:4456396	NA	0.67	5.03	0.38	1.37e-6	Borderline personality disorder;
PAAD	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg18551225	chr6:44695536	NA	-0.7	-6.97	-0.49	9.26e-11	Total body bone mineral density;
PAAD	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg01620082	chr3:125678407	NA	-1.09	-6.91	-0.49	1.24e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg00428638	chr19:7224713	INSR	0.51	5.59	0.41	1.04e-7	Hypothyroidism;
PAAD	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg20487152	chr13:99095054	FARP1	0.58	5.0	0.38	1.59e-6	Neuroticism;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg27313501	chr16:2034198	GFER	0.56	6.5	0.47	1.08e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.73	-0.42	5.12e-8	Total cholesterol levels;
PAAD	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.49	5.54	0.41	1.33e-7	Coronary artery disease;
PAAD	cis	rs12304921	1.000	rs66744607	chr12:51336491	T/C	cg04427360	chr12:51347099	HIGD1C	-0.59	-4.32	-0.33	2.81e-5	Type 2 diabetes;
PAAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.37	0.46	2.18e-9	Bladder cancer;
PAAD	cis	rs12760731	0.720	rs10913557	chr1:178442190	C/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.54e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg22143635	chr11:980567	AP2A2	0.52	5.6	0.41	9.62e-8	Alzheimer's disease (late onset);
PAAD	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg06074448	chr4:187884817	NA	-0.63	-8.1	-0.55	1.64e-13	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs7156960	0.866	rs935331	chr14:76699532	A/G	cg13981132	chr14:76734493	NA	0.52	4.72	0.36	5.26e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs12999616	0.550	rs35358137	chr2:98502201	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	5.35	0.4	3.19e-7	Colorectal cancer;
PAAD	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11161846	chr1:160990452	F11R	-0.61	-6.26	-0.45	3.8e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg08698997	chr16:88989212	CBFA2T3	0.4	5.0	0.38	1.59e-6	Social autistic-like traits;
PAAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26209169	chr5:1316264	NA	0.38	4.57	0.35	1.02e-5	Lung cancer;
PAAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.8	-9.49	-0.61	4.61e-17	Menopause (age at onset);
PAAD	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	trans	rs1015213	0.609	rs79440584	chr8:52870614	C/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.6	5.21	0.39	6.01e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg09796270	chr17:17721594	SREBF1	0.48	4.6	0.35	8.93e-6	Total body bone mineral density;
PAAD	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.56	4.37	0.33	2.27e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg05299278	chr17:33885742	SLFN14	-0.43	-5.16	-0.39	7.5e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.1	-0.38	9.81e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Urinary tract infection frequency;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg23985595	chr17:80112537	CCDC57	-0.5	-6.54	-0.47	8.61e-10	Life satisfaction;
PAAD	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg04705435	chr11:17411270	KCNJ11	0.7	8.0	0.54	2.9e-13	Type 2 diabetes;
PAAD	cis	rs16975963	0.793	rs1807157	chr19:38465523	G/T	cg25793785	chr19:38281423	NA	0.57	4.67	0.35	6.72e-6	Longevity;
PAAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs9487051	0.621	rs449736	chr6:109524342	A/T	cg21918786	chr6:109611834	NA	-0.43	-4.47	-0.34	1.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.96	0.37	1.9e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01998682	chr6:151712546	ZBTB2	0.58	6.6	0.47	6.5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.08	7.97	0.54	3.48e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs10214930	0.671	rs2391452	chr7:27686152	T/C	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg10211485	chr17:655108	ELP2P;GEMIN4	-0.68	-6.7	-0.48	3.74e-10	Primary biliary cholangitis;
PAAD	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg14593290	chr7:50529359	DDC	-0.51	-5.47	-0.41	1.81e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.09	0.5	4.73e-11	Body mass index;
PAAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.23e-9	Height;
PAAD	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs10214930	0.752	rs2391448	chr7:27678185	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.81	6.36	0.46	2.25e-9	Mean platelet volume;
PAAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.75	7.76	0.53	1.15e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.59	-5.53	-0.41	1.36e-7	Cognitive function;
PAAD	cis	rs4332037	0.805	rs4721142	chr7:1918079	T/C	cg02421172	chr7:1938701	MAD1L1	0.65	5.01	0.38	1.49e-6	Bipolar disorder;
PAAD	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg09659197	chr4:152720779	NA	0.46	6.13	0.45	7.23e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg19423196	chr10:82049429	MAT1A	0.57	4.39	0.34	2.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs73206853	0.620	rs17682644	chr12:111156008	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	4.45	0.34	1.66e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.84	10.33	0.64	2.79e-19	Platelet distribution width;
PAAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.04	0.55	2.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg27394845	chr17:28928406	LRRC37B2	-0.59	-4.31	-0.33	2.87e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12760731	0.565	rs57247289	chr1:178090138	G/A	cg00404053	chr1:178313656	RASAL2	0.63	4.78	0.36	4.03e-6	Obesity-related traits;
PAAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.87	9.96	0.63	2.65e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4148087	0.929	rs915845	chr21:43635438	T/G	cg08841829	chr21:43638893	ABCG1	-0.73	-4.81	-0.36	3.58e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs9815354	1.000	rs1716651	chr3:41975099	A/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.91	-0.43	2.21e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.51	4.6	0.35	9e-6	Total body bone mineral density;
PAAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.56	-5.65	-0.42	7.59e-8	Childhood ear infection;
PAAD	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg10729496	chr3:10149963	C3orf24	0.76	6.23	0.45	4.33e-9	Alzheimer's disease;
PAAD	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.85	-5.92	-0.43	2.03e-8	Coronary artery disease;
PAAD	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg04398451	chr17:18023971	MYO15A	-0.83	-9.55	-0.61	3.19e-17	Total body bone mineral density;
PAAD	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.92	-10.49	-0.65	1.05e-19	Refractive error;
PAAD	cis	rs72827839	1.000	rs72827887	chr17:46537636	A/G	cg23391107	chr17:45924227	SP6	0.58	4.9	0.37	2.44e-6	Ease of getting up in the morning;
PAAD	cis	rs9857275	0.788	rs13069734	chr3:141148419	G/A	cg00789793	chr3:141329863	RASA2	0.5	4.32	0.33	2.8e-5	Prion diseases;
PAAD	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.34	-4.45	-0.34	1.62e-5	Schizophrenia;
PAAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg06521852	chr22:38141419	TRIOBP	0.42	4.26	0.33	3.61e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	5.87	0.43	2.67e-8	Total cholesterol levels;
PAAD	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg10621924	chr7:39171070	POU6F2	0.26	4.46	0.34	1.57e-5	IgG glycosylation;
PAAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-4.67	-0.35	6.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.95	-11.38	-0.68	4.38e-22	Height;
PAAD	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.26	-0.51	1.83e-11	Neuroticism;
PAAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.36	0.64	2.36e-19	Smoking behavior;
PAAD	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg18551225	chr6:44695536	NA	-0.7	-7.03	-0.5	6.65e-11	Total body bone mineral density;
PAAD	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.47	-6.56	-0.47	8.09e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.97	-6.7	-0.48	3.76e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs12760731	0.623	rs10913539	chr1:178336682	T/C	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg06207120	chr15:45996521	NA	0.31	4.47	0.34	1.55e-5	Waist circumference;Weight;
PAAD	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg00717180	chr2:96193071	NA	-0.58	-6.5	-0.47	1.11e-9	HDL cholesterol;
PAAD	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.64	6.68	0.48	4.13e-10	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-4.5	-0.34	1.35e-5	Interleukin-18 levels;
PAAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg03999872	chr20:62272968	STMN3	0.49	4.35	0.33	2.44e-5	Prostate cancer;
PAAD	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.53	5.27	0.39	4.6e-7	Multiple sclerosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13577493	chr3:50541078	CACNA2D2	0.61	6.64	0.47	5.18e-10	Monocyte percentage of white cells;
PAAD	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.6	4.47	0.34	1.53e-5	Neuroblastoma;
PAAD	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg02398342	chr17:80708632	TBCD;FN3K	0.67	4.53	0.35	1.18e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.66	-5.69	-0.42	6.43e-8	Menarche (age at onset);
PAAD	cis	rs2637030	0.542	rs429384	chr5:52908205	A/G	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.63	6.4	0.46	1.81e-9	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.48	5.02	0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg11601000	chr22:42348013	LOC339674	-0.5	-4.3	-0.33	3.01e-5	Birth weight;
PAAD	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.62	5.63	0.42	8.49e-8	Obesity-related traits;
PAAD	cis	rs6693295	0.536	rs55912974	chr1:246225155	C/T	cg11798871	chr1:246315928	SMYD3	-0.79	-5.71	-0.42	5.86e-8	Migraine - clinic-based;Migraine with aura;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13445938	chr9:93840773	NA	0.55	6.41	0.46	1.75e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.97	5.89	0.43	2.43e-8	Type 2 diabetes nephropathy;
PAAD	cis	rs7219021	0.886	rs9915337	chr17:46857421	T/A	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.36	-0.33	2.43e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.94	10.02	0.63	1.8e-18	Alcohol dependence;
PAAD	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.54	-6.32	-0.46	2.82e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.6	7.14	0.5	3.53e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg19847866	chr10:1019161	NA	-0.54	-4.34	-0.33	2.56e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.08	0.38	1.07e-6	Childhood ear infection;
PAAD	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	7.64	0.53	2.33e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.28	-0.51	1.71e-11	Longevity;
PAAD	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.68	9.05	0.59	6.42e-16	Hemoglobin concentration;
PAAD	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg03989125	chr22:38214979	NA	0.63	5.68	0.42	6.6e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4460629	0.901	rs4745	chr1:155106227	A/T	cg22049894	chr1:155113146	DPM3	-0.44	-4.27	-0.33	3.47e-5	Serum magnesium levels;
PAAD	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.54	6.4	0.46	1.8e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.5	-5.24	-0.39	5.16e-7	Breast cancer;
PAAD	cis	rs41271473	0.687	rs2295256	chr1:228874049	C/T	cg10167378	chr1:228756711	NA	0.53	4.58	0.35	9.59e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7591163	1.000	rs4300818	chr2:228713255	G/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.91	-10.68	-0.65	3.19e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	1.03	8.0	0.54	2.98e-13	IgG glycosylation;
PAAD	cis	rs7916410	0.512	rs1900003	chr10:70004551	A/C	cg18338521	chr10:69995036	NA	-0.39	-5.07	-0.38	1.16e-6	Optic disc area;
PAAD	cis	rs438465	1.000	rs452888	chr6:169816416	C/T	cg11181693	chr6:169825345	NA	-0.55	-4.3	-0.33	2.98e-5	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07362569	chr17:61921086	SMARCD2	0.62	7.85	0.54	6.9e-13	Prudent dietary pattern;
PAAD	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.58	-0.35	9.52e-6	Body mass index;
PAAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.44	4.5	0.34	1.36e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9287719	0.649	rs10929683	chr2:10732208	C/T	cg00105475	chr2:10696890	NA	-0.63	-6.56	-0.47	8.07e-10	Prostate cancer;
PAAD	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-5.76	-0.42	4.6e-8	Bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19292062	chr20:524344	CSNK2A1	0.49	6.35	0.46	2.4e-9	Myopia (pathological);
PAAD	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.99e-17	Electrocardiographic conduction measures;
PAAD	cis	rs1879734	0.731	rs7555711	chr1:54158220	A/G	cg14659662	chr1:54151053	GLIS1	-0.45	-6.03	-0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg12615879	chr12:58013172	SLC26A10	-0.51	-5.64	-0.42	8.17e-8	Multiple sclerosis;
PAAD	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg19748678	chr4:122722346	EXOSC9	0.69	6.0	0.44	1.36e-8	Type 2 diabetes;
PAAD	cis	rs743757	1.000	rs2236953	chr3:50424182	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	4.64	0.35	7.31e-6	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08810106	chr16:18936940	SMG1	0.64	7.4	0.51	8.57e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg20652954	chr20:61716293	NA	0.41	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	1.02	6.71	0.48	3.57e-10	Mitochondrial DNA levels;
PAAD	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.55	4.71	0.36	5.5e-6	Prostate cancer;
PAAD	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg14343924	chr8:8086146	FLJ10661	-0.64	-5.48	-0.41	1.72e-7	Mood instability;
PAAD	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-4.73	-0.36	5.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg12463550	chr7:65579703	CRCP	0.86	4.68	0.35	6.34e-6	Diabetic kidney disease;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26652484	chr3:57582327	ARF4	0.54	6.3	0.46	2.98e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.61	4.72	0.36	5.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.61	5.93	0.43	1.94e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.82	-9.55	-0.61	3.17e-17	Type 2 diabetes;
PAAD	cis	rs10046574	0.561	rs7781454	chr7:135205422	A/G	cg27474649	chr7:135195673	CNOT4	0.69	4.91	0.37	2.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1891275	0.516	rs10881935	chr10:93397701	G/A	cg07889827	chr10:93443413	NA	-0.41	-4.37	-0.33	2.26e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.84	8.03	0.55	2.55e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.52	-4.89	-0.37	2.5e-6	Neurofibrillary tangles;
PAAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg00206168	chr11:65308501	LTBP3	0.51	5.21	0.39	5.93e-7	Bone mineral density;
PAAD	cis	rs7727544	0.505	rs721121	chr5:131406433	T/G	cg16205897	chr5:131564050	P4HA2	-0.45	-4.85	-0.37	3e-6	Blood metabolite levels;
PAAD	cis	rs4704187	0.687	rs10462513	chr5:74422607	C/T	cg03227963	chr5:74354835	NA	0.49	4.83	0.37	3.25e-6	Response to amphetamines;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23093116	chr1:117489843	PTGFRN	0.62	6.77	0.48	2.69e-10	Smoking initiation;
PAAD	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-5.02	-0.38	1.4e-6	Schizophrenia;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg02869306	chr7:64672164	INTS4L1	0.41	4.83	0.36	3.31e-6	Corneal structure;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg01097406	chr16:89675127	NA	-0.37	-4.39	-0.34	2.12e-5	Vitiligo;
PAAD	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.84	8.49	0.57	1.78e-14	Methadone dose in opioid dependence;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.72	8.92	0.59	1.41e-15	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs1413885	1.000	rs1536174	chr1:65813709	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	4.75	0.36	4.61e-6	Anticoagulant levels;
PAAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.6	-7.08	-0.5	4.98e-11	Monobrow;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18621852	chr3:10150065	C3orf24	0.54	5.15	0.39	7.87e-7	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21815047	chr1:156182617	PMF1	0.74	7.75	0.53	1.2e-12	Obesity-related traits;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06753367	chr22:24256600	NA	-0.45	-4.86	-0.37	2.93e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12893428	chr3:195717962	SDHAP1	0.47	4.99	0.38	1.63e-6	Pancreatic cancer;
PAAD	cis	rs748802	0.704	rs59205434	chr9:35916448	G/A	cg24444059	chr9:35909412	LOC158376	0.45	4.57	0.35	1.02e-5	Resting heart rate;
PAAD	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.43	-0.34	1.77e-5	Testicular germ cell tumor;
PAAD	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.42	4.28	0.33	3.31e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg00049323	chr5:472564	LOC25845	-0.47	-4.94	-0.37	2.03e-6	Cystic fibrosis severity;
PAAD	cis	rs7781977	0.554	rs7797255	chr7:50351604	C/T	cg01139861	chr7:50343298	IKZF1	-0.28	-4.25	-0.33	3.67e-5	IgG glycosylation;
PAAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg23887609	chr12:130822674	PIWIL1	0.68	6.96	0.49	9.41e-11	Menopause (age at onset);
PAAD	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg09066997	chr16:75300724	BCAR1	0.63	4.58	0.35	9.76e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs4356203	0.905	rs615358	chr11:17210432	T/C	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.63	-0.35	7.75e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg19930314	chr7:98593876	TRRAP	0.47	4.32	0.33	2.82e-5	Breast cancer;
PAAD	cis	rs4740619	0.619	rs10756741	chr9:16041911	A/G	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.77	7.76	0.53	1.17e-12	Anterior chamber depth;
PAAD	cis	rs6466055	0.661	rs12532201	chr7:104922944	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.03	-0.38	1.37e-6	HDL cholesterol;
PAAD	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg03929089	chr4:120376271	NA	-0.85	-6.66	-0.48	4.6e-10	Axial length;
PAAD	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg19882132	chr14:106167949	NA	-0.55	-4.75	-0.36	4.73e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg20243544	chr17:37824526	PNMT	0.5	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.59	5.33	0.4	3.54e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.46	-4.41	-0.34	1.98e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13870426	chr17:30244630	NA	-0.59	-5.72	-0.42	5.47e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.95	-10.59	-0.65	5.64e-20	Headache;
PAAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg11008003	chr7:157255264	NA	0.34	4.59	0.35	9.16e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.73	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg25753631	chr6:25732923	NA	-0.5	-5.67	-0.42	6.85e-8	Iron status biomarkers;
PAAD	cis	rs6604026	0.656	rs2811591	chr1:93363951	C/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs9657904	0.704	rs6788366	chr3:105573324	T/A	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.77	6.2	0.45	5.08e-9	Alzheimer's disease;
PAAD	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.68	-7.96	-0.54	3.66e-13	Body mass index;
PAAD	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg08648136	chr8:956695	NA	0.41	4.4	0.34	2.05e-5	Schizophrenia;
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg04520793	chr17:42248056	ASB16	-0.48	-6.07	-0.44	9.55e-9	Total body bone mineral density;
PAAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.48	0.41	1.7e-7	Tonsillectomy;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18550509	chr15:100273145	LYSMD4	0.56	6.46	0.46	1.35e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1891275	0.527	rs35812291	chr10:93402341	G/C	cg07889827	chr10:93443413	NA	-0.4	-4.31	-0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg05627522	chr15:75251581	NA	0.59	7.21	0.5	2.45e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.38	-4.26	-0.33	3.6e-5	High light scatter reticulocyte count;
PAAD	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg07395648	chr5:131743802	NA	0.6	5.48	0.41	1.73e-7	Breast cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17407411	chr12:1800083	ADIPOR2	-0.74	-6.34	-0.46	2.47e-9	Neuroticism;
PAAD	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.79	6.83	0.48	1.88e-10	Morning vs. evening chronotype;
PAAD	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7577696	0.814	rs435572	chr2:32488081	A/G	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.68e-6	Inflammatory biomarkers;
PAAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	5.62	0.41	9.04e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3925075	0.553	rs9888907	chr16:31349040	A/G	cg02846316	chr16:31340340	ITGAM	0.43	5.09	0.38	1.04e-6	IgA nephropathy;
PAAD	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.58	5.12	0.38	9.17e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.9	4.89	0.37	2.56e-6	Childhood ear infection;
PAAD	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.42	4.37	0.33	2.32e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2115386	0.648	rs1896639	chr19:7203846	C/T	cg09779027	chr19:7224513	INSR	0.47	4.77	0.36	4.28e-6	Diabetic retinopathy;
PAAD	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.78	-7.15	-0.5	3.43e-11	Vitamin D levels;
PAAD	cis	rs1376877	0.519	rs12466364	chr2:204226331	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.6	4.91	0.37	2.37e-6	Subclinical atherosclerosis traits (other);
PAAD	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.65	-0.35	7.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg24375607	chr4:120327624	NA	0.55	5.19	0.39	6.64e-7	Corneal astigmatism;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.65	-7.46	-0.52	6.22e-12	Vitamin D levels;
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg27449745	chr7:23145252	KLHL7	0.47	4.44	0.34	1.7e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg08562672	chr19:21860753	NA	0.45	4.67	0.35	6.44e-6	Pain;
PAAD	cis	rs7172971	0.688	rs76996351	chr15:42382689	T/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.65	0.47	5.08e-10	Blood protein levels;
PAAD	cis	rs965469	0.603	rs6051861	chr20:3415566	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.51	-0.34	1.27e-5	IFN-related cytopenia;
PAAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg10547527	chr2:198650123	BOLL	-0.83	-5.75	-0.42	4.64e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.89	-0.37	2.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26331164	chr11:68860000	NA	-0.66	-6.78	-0.48	2.51e-10	Obesity-related traits;
PAAD	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1497828	0.871	rs2047401	chr1:217544107	T/A	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg13446199	chr8:143762866	PSCA	0.39	4.63	0.35	7.8e-6	Urinary tract infection frequency;
PAAD	cis	rs35160687	0.712	rs11127020	chr2:86474544	G/A	cg10973622	chr2:86423274	IMMT	-0.43	-4.78	-0.36	4.04e-6	Night sleep phenotypes;
PAAD	cis	rs2252790	0.859	rs1204824	chr6:116563825	T/C	cg26893134	chr6:116381904	FRK	-0.29	-4.53	-0.35	1.17e-5	Fast beta electroencephalogram;
PAAD	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.63	-6.33	-0.46	2.62e-9	Ear protrusion;
PAAD	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.29e-8	Colorectal cancer;
PAAD	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg00262122	chr8:11665843	FDFT1	-0.59	-5.45	-0.4	2e-7	Morning vs. evening chronotype;
PAAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.45	-0.34	1.66e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg04450456	chr4:17643702	FAM184B	0.49	5.36	0.4	2.97e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg15226275	chr6:116381976	FRK	0.4	7.49	0.52	5.38e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg02404636	chr22:31891804	SFI1	0.64	6.19	0.45	5.36e-9	Colorectal cancer;
PAAD	cis	rs2415984	0.579	rs1389608	chr14:46957777	C/A	cg14871534	chr14:47121158	RPL10L	-0.52	-5.32	-0.4	3.71e-7	Number of children ever born;
PAAD	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg21951975	chr1:209979733	IRF6	0.55	5.1	0.38	1.02e-6	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.69	-0.42	6.28e-8	Schizophrenia;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7260329	0.670	rs4802103	chr19:41503245	C/T	cg06653635	chr19:40910092	PRX	-0.48	-4.54	-0.35	1.16e-5	Smoking behavior;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01893041	chr5:67583972	PIK3R1	0.59	6.56	0.47	8.08e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.7	-7.03	-0.5	6.61e-11	Alcohol dependence;
PAAD	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.52	4.8	0.36	3.78e-6	Uric acid clearance;
PAAD	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg16558253	chr16:72132732	DHX38	-0.69	-4.58	-0.35	9.67e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.45	4.28	0.33	3.3e-5	Mean corpuscular volume;
PAAD	cis	rs12610836	1.000	rs753948	chr19:412730	C/T	cg12817436	chr19:1068561	HMHA1	-0.69	-4.8	-0.36	3.72e-6	Hepatitis A;
PAAD	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg02153855	chr1:11041070	C1orf127	-0.34	-4.26	-0.33	3.53e-5	Hepatocellular carcinoma;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.6	-0.47	6.3e-10	Lung cancer;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.74	6.5	0.47	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00871917	chr3:53164423	RFT1	0.6	7.04	0.5	6.16e-11	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs28472312	0.685	rs11642638	chr16:28984945	A/C	cg16576597	chr16:28551801	NUPR1	-0.46	-4.76	-0.36	4.55e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.75	8.27	0.56	6.38e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.58	4.3	0.33	3.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs860295	0.557	rs10796941	chr1:155284261	C/T	cg02153340	chr1:155202674	NA	-0.52	-4.62	-0.35	7.98e-6	Body mass index;
PAAD	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-1.35	-12.6	-0.71	2.22e-25	Obesity-related traits;
PAAD	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg20761395	chr17:511517	VPS53	-0.51	-4.7	-0.36	5.7e-6	Prostate cancer;
PAAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	6.19	0.45	5.21e-9	Mood instability;
PAAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.35	-0.33	2.51e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg27449745	chr7:23145252	KLHL7	-0.61	-5.7	-0.42	6.08e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	5.69	0.42	6.35e-8	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.18e-6	Prudent dietary pattern;
PAAD	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.47	-4.27	-0.33	3.39e-5	Lung cancer (smoking interaction);
PAAD	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.62	6.52	0.47	9.98e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.66	8.7	0.58	4.98e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.85	-9.93	-0.63	3.26e-18	Sudden cardiac arrest;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg07234876	chr8:600039	NA	-1.06	-6.79	-0.48	2.31e-10	IgG glycosylation;
PAAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg16083429	chr3:49237500	CCDC36	0.46	4.48	0.34	1.43e-5	Menarche (age at onset);
PAAD	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg09035930	chr12:129282057	SLC15A4	0.79	4.84	0.37	3.21e-6	Systemic lupus erythematosus;
PAAD	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-4.35	-0.33	2.49e-5	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.64	-6.32	-0.46	2.74e-9	Lung cancer;
PAAD	cis	rs1497828	0.956	rs1497835	chr1:217562287	C/T	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.84	-0.66	1.2e-20	Systemic lupus erythematosus;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg20025656	chr1:229570230	ACTA1	0.54	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.51e-5	Dental caries;
PAAD	cis	rs16976116	0.901	rs16976177	chr15:55509260	C/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.63	0.35	7.77e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10915437	0.516	rs10915445	chr1:4197642	G/A	cg27165836	chr1:4193882	NA	0.59	6.13	0.45	7.07e-9	Migraine - clinic-based;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-6.6	-0.47	6.51e-10	Lymphocyte counts;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.54	5.41	0.4	2.36e-7	Height;
PAAD	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.8	-9.91	-0.63	3.64e-18	Height;
PAAD	cis	rs3812111	0.727	rs471766	chr6:116461477	C/T	cg18828861	chr6:116576566	TSPYL4	0.41	4.41	0.34	1.92e-5	Age-related macular degeneration;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15482168	chr19:53970942	ZNF813	-0.63	-6.42	-0.46	1.69e-9	Lung cancer in ever smokers;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	10.13	0.63	9.44e-19	Platelet count;
PAAD	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.71	8.47	0.57	1.98e-14	Lewy body disease;
PAAD	cis	rs939584	0.932	rs2867108	chr2:650143	T/C	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	5.44	0.4	2.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg24253500	chr15:84953950	NA	0.46	5.01	0.38	1.5e-6	P wave terminal force;
PAAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg11802864	chr11:65308245	LTBP3	0.45	4.57	0.35	1.01e-5	Bone mineral density;
PAAD	cis	rs9810890	1.000	rs114366529	chr3:128564604	A/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14878009	chr2:242122380	PPP1R7	0.65	6.49	0.47	1.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.91	9.11	0.59	4.58e-16	Orofacial clefts;
PAAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg17410650	chr12:54324560	NA	-0.44	-6.98	-0.49	8.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.57	6.06	0.44	1.01e-8	Schizophrenia;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26418147	chr1:205743515	RAB7L1	-0.5	-5.98	-0.44	1.55e-8	Menarche (age at onset);
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26926768	chr12:34528122	NA	0.37	4.47	0.34	1.52e-5	Morning vs. evening chronotype;
PAAD	cis	rs432925	0.559	rs412243	chr16:339672	T/C	cg08823186	chr16:347294	AXIN1	0.5	4.54	0.35	1.16e-5	Morning vs. evening chronotype;
PAAD	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg07813855	chr1:200183606	FAM58B	0.48	4.58	0.35	9.76e-6	Permanent tooth development;
PAAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg10556349	chr10:835070	NA	0.57	4.96	0.37	1.86e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.1	-10.14	-0.64	8.98e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.45	-0.34	1.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs6964492	0.576	rs2347716	chr7:134416085	G/A	cg22430036	chr7:134592620	CALD1	-0.51	-4.66	-0.35	6.79e-6	Tonsillectomy;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.58	6.04	0.44	1.14e-8	Tonsillectomy;
PAAD	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.41	-4.57	-0.35	1.01e-5	Metabolite levels;
PAAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg08992911	chr2:238395768	MLPH	0.59	5.58	0.41	1.08e-7	Prostate cancer;
PAAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.71	8.79	0.58	2.94e-15	Bone mineral density;
PAAD	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.67	7.67	0.53	1.92e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4972806	0.814	rs966801	chr2:177037827	G/A	cg02877791	chr2:177005403	NA	0.43	4.25	0.33	3.74e-5	IgG glycosylation;
PAAD	cis	rs6547631	0.670	rs4832181	chr2:85916005	A/G	cg24620635	chr2:85921963	GNLY	0.42	5.17	0.39	7.33e-7	Blood protein levels;
PAAD	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg23254163	chr1:152506842	NA	0.6	7.08	0.5	4.96e-11	Hair morphology;
PAAD	cis	rs116248771	0.690	rs73156490	chr3:158416484	G/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7631605	0.935	rs6550447	chr3:37078280	G/C	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.29e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.13e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.84	-6.52	-0.47	1e-9	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.93	-8.82	-0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg03188948	chr7:1209495	NA	0.91	4.83	0.36	3.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.67	9.74	0.62	1e-17	Airflow obstruction;
PAAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.4	0.34	2.03e-5	Aortic root size;
PAAD	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.65	0.42	7.85e-8	Major depressive disorder;
PAAD	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.41	-0.34	1.98e-5	Recombination measurement;
PAAD	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs8181588	0.661	rs3852528	chr11:2826617	A/G	cg10890346	chr11:2207660	NA	0.67	4.64	0.35	7.55e-6	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg15510373	chr7:100224934	TFR2	-0.56	-4.81	-0.36	3.63e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg22627940	chr8:49390241	NA	0.55	6.39	0.46	1.88e-9	Body fat percentage;
PAAD	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.76e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg21573476	chr21:45109991	RRP1B	-0.51	-4.51	-0.34	1.27e-5	Mean corpuscular volume;
PAAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.62	-6.42	-0.46	1.64e-9	Body mass index;
PAAD	cis	rs2327429	0.858	rs2105092	chr6:134184972	G/A	cg06296503	chr6:134217401	NA	0.48	4.91	0.37	2.37e-6	Coronary artery disease;
PAAD	cis	rs12599426	1.000	rs34472980	chr16:34768098	G/A	cg08331635	chr16:34430078	NA	-0.63	-4.25	-0.33	3.7e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs3126085	0.560	rs2525	chr1:152339064	A/G	cg26876637	chr1:152193138	HRNR	-0.68	-5.15	-0.39	8.05e-7	Atopic dermatitis;
PAAD	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.47	-4.32	-0.33	2.78e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.6	5.69	0.42	6.37e-8	Systolic blood pressure;
PAAD	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg21775007	chr8:11205619	TDH	0.48	4.33	0.33	2.72e-5	Neuroticism;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.68	6.88	0.49	1.48e-10	Menarche (age at onset);
PAAD	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-4.47	-0.34	1.52e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-9.16	-0.6	3.35e-16	Gut microbiome composition (summer);
PAAD	cis	rs12304921	0.935	rs4768941	chr12:51355601	A/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.77	-0.48	2.67e-10	Type 2 diabetes;
PAAD	cis	rs6466055	0.612	rs67421818	chr7:104860671	T/G	cg04380332	chr7:105027541	SRPK2	0.48	4.62	0.35	8.13e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg20607287	chr7:12443886	VWDE	-0.6	-4.85	-0.37	3.09e-6	Coronary artery disease;
PAAD	cis	rs6787172	0.644	rs67286798	chr3:158214203	G/A	cg16708174	chr3:158430962	RARRES1	0.42	4.5	0.34	1.36e-5	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.65	7.43	0.52	7.3e-12	Coronary artery disease;
PAAD	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.55	5.95	0.43	1.74e-8	Hepatitis;
PAAD	cis	rs1891275	0.551	rs7908678	chr10:93419010	A/G	cg07889827	chr10:93443413	NA	0.41	4.41	0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.76	6.23	0.45	4.25e-9	Alzheimer's disease;
PAAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg00933542	chr6:150070202	PCMT1	0.58	6.16	0.45	6.15e-9	Lung cancer;
PAAD	cis	rs1144333	0.655	rs76735776	chr1:76455211	A/G	cg22875332	chr1:76189707	ACADM	0.76	4.46	0.34	1.59e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.56	-5.73	-0.42	5.34e-8	Multiple myeloma;
PAAD	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg14055004	chr2:241860995	NA	0.28	4.45	0.34	1.63e-5	Joint mobility (Beighton score);
PAAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.44	5.6	0.41	9.97e-8	Multiple sclerosis;
PAAD	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.31	-0.4	3.75e-7	Schizophrenia;
PAAD	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg01620082	chr3:125678407	NA	-1.42	-7.85	-0.54	6.89e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs2716882	1.000	rs2716882	chr17:5582334	A/G	cg06213360	chr17:6462302	NA	-0.71	-4.36	-0.33	2.42e-5	Gut microbiome composition (summer);
PAAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.72	7.35	0.51	1.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg19423196	chr10:82049429	MAT1A	0.61	4.72	0.36	5.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-1.35	-10.59	-0.65	5.58e-20	Obesity-related traits;
PAAD	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.61	6.26	0.45	3.8e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.59	-0.41	1.02e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg13736514	chr6:26305472	NA	-0.44	-4.78	-0.36	4.06e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg02156692	chr7:2749751	AMZ1	-0.33	-4.4	-0.34	2.01e-5	Height;
PAAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.02	0.59	7.54e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg27511599	chr7:32358540	NA	0.9	4.73	0.36	5.09e-6	Body mass index;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg05785598	chr3:49045655	WDR6	0.41	4.88	0.37	2.62e-6	Parkinson's disease;
PAAD	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs74544699	1.000	rs353028	chr4:74777223	C/T	cg06834998	chr4:74847824	PF4	1.1	4.3	0.33	3.08e-5	Growth-regulated protein alpha levels;
PAAD	trans	rs4427176	0.507	rs6983608	chr8:9581327	C/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg16083429	chr3:49237500	CCDC36	-0.43	-4.32	-0.33	2.78e-5	Menarche (age at onset);
PAAD	cis	rs8084125	0.938	rs62105163	chr18:74943673	C/T	cg05528293	chr18:74961138	GALR1	0.61	5.04	0.38	1.32e-6	Obesity-related traits;
PAAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.64	-5.26	-0.39	4.89e-7	Diastolic blood pressure;
PAAD	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.9	7.11	0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs61884328	0.789	rs61884327	chr11:46766890	T/C	cg23433285	chr11:47201945	PACSIN3	0.84	4.31	0.33	2.89e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09311052	chr1:154531418	UBE2Q1	0.6	6.61	0.47	6.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.92	0.49	1.15e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	10.61	0.65	4.97e-20	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.81	-5.78	-0.42	4.07e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00166722	chr3:10149974	C3orf24	-0.69	-6.2	-0.45	5.12e-9	Alzheimer's disease;
PAAD	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.54	5.46	0.4	1.9e-7	Plateletcrit;Platelet count;
PAAD	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	5.96	0.44	1.66e-8	Neuroticism;
PAAD	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.68	-7.75	-0.53	1.23e-12	Alcohol dependence;
PAAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg04450456	chr4:17643702	FAM184B	0.54	6.01	0.44	1.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20195957	chr2:68694673	APLF;FBXO48	0.68	7.06	0.5	5.62e-11	Obesity-related traits;
PAAD	cis	rs1997066	0.831	rs73344320	chr10:106828512	A/T	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.51	-6.52	-0.47	9.77e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg21546286	chr11:48923668	NA	-0.48	-4.99	-0.38	1.61e-6	HDL cholesterol;
PAAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.47	5.67	0.42	7.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-1.0	-10.8	-0.66	1.52e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26549601	chr10:134560360	INPP5A	-0.5	-4.88	-0.37	2.65e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg05861140	chr6:150128134	PCMT1	-0.51	-5.83	-0.43	3.2e-8	Lung cancer;
PAAD	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.62	6.0	0.44	1.4e-8	Height;
PAAD	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12997796	0.556	rs12477737	chr2:86930966	G/T	cg25203885	chr2:87302643	LOC285074	-0.82	-6.19	-0.45	5.43e-9	Schizophrenia;
PAAD	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.32	-0.33	2.85e-5	Tuberculosis;
PAAD	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.55	4.72	0.36	5.37e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs73416724	0.688	rs75966707	chr6:43356743	A/C	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg16342193	chr10:102329863	NA	-0.77	-8.5	-0.57	1.65e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.56	-5.26	-0.39	4.82e-7	Obesity-related traits;
PAAD	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.52	-0.34	1.26e-5	Biliary atresia;
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.47	5.34	0.4	3.33e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg02770688	chr6:168491649	NA	0.48	4.95	0.37	1.91e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs832187	0.776	rs854622	chr3:63862842	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.44	-4.26	-0.33	3.6e-5	Schizophrenia;
PAAD	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg00717180	chr2:96193071	NA	-0.61	-6.83	-0.48	1.96e-10	HDL cholesterol;
PAAD	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg11143131	chr5:131608246	PDLIM4	-0.51	-4.79	-0.36	3.92e-6	Breast cancer;
PAAD	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.62	-6.29	-0.45	3.23e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg06714761	chr1:201096289	NA	0.28	4.25	0.33	3.73e-5	Permanent tooth development;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27119415	chr17:38137936	PSMD3	0.65	6.44	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs7539409	1.000	rs7539409	chr1:84254735	A/G	cg10977910	chr1:84465055	TTLL7	-1.0	-5.33	-0.4	3.55e-7	Alzheimer's disease;
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.98	-7.67	-0.53	1.88e-12	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.87	-8.01	-0.55	2.72e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs8113142	0.614	rs4805257	chr19:29130465	A/G	cg04546413	chr19:29218101	NA	-0.42	-4.25	-0.33	3.77e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.42	4.37	0.33	2.29e-5	Bulimia nervosa;
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-6.28	-0.45	3.38e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02779467	chr17:18761289	PRPSAP2	-0.7	-6.65	-0.47	5.09e-10	Neuroticism;
PAAD	cis	rs12580194	0.593	rs61957884	chr12:55720177	A/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.29	0.33	3.13e-5	Cancer;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.41	-5.9	-0.43	2.32e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg13374026	chr7:158955107	NA	0.47	4.36	0.33	2.4e-5	Facial morphology (factor 20);
PAAD	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg21890820	chr11:65308645	LTBP3	0.94	7.6	0.52	2.88e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs1532557	1.000	rs1532557	chr1:224805112	C/T	cg09988837	chr1:224811939	CNIH3	0.57	4.37	0.33	2.32e-5	Cancer;
PAAD	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg20487152	chr13:99095054	FARP1	0.58	4.91	0.37	2.34e-6	Neuroticism;
PAAD	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.6	-5.86	-0.43	2.75e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-11.1	-0.67	2.5e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.26e-13	Alzheimer's disease;
PAAD	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.78	-9.22	-0.6	2.35e-16	Eye color traits;
PAAD	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.31	-0.33	2.93e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs863345	0.967	rs5009954	chr1:158530417	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg13332499	chr17:408570	NA	0.55	5.88	0.43	2.56e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.65	-5.77	-0.42	4.35e-8	Obesity-related traits;
PAAD	cis	rs1497828	0.956	rs2646831	chr1:217544521	C/T	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.47	0.41	1.84e-7	Obesity-related traits;
PAAD	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	4.5	0.34	1.32e-5	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05537360	chr6:70506940	LMBRD1	0.61	6.71	0.48	3.65e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.15	-0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.61	-8.8	-0.58	2.76e-15	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.7	-4.39	-0.34	2.14e-5	IgG glycosylation;
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03885332	chr11:832357	CD151	-0.45	-5.19	-0.39	6.55e-7	Mean platelet volume;
PAAD	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.46	4.76	0.36	4.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1997066	0.831	rs61309696	chr10:106798781	T/G	cg17321814	chr10:106440892	SORCS3	0.61	4.26	0.33	3.56e-5	Diabetic kidney disease;
PAAD	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs300774	0.800	rs300716	chr2:136844	G/A	cg23649280	chr2:140451	NA	-0.47	-4.53	-0.34	1.18e-5	Suicide attempts in bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03462940	chr10:132877288	NA	0.65	7.01	0.49	7.19e-11	Smoking initiation;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs735539	0.645	rs9550662	chr13:21141552	C/T	cg27234864	chr13:21295941	IL17D	0.63	5.49	0.41	1.61e-7	Dental caries;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05013783	chr12:56652058	ANKRD52	0.58	6.43	0.46	1.55e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.55	7.37	0.51	1.03e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs7567389	0.677	rs72845976	chr2:128086440	T/A	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.8	-7.09	-0.5	4.81e-11	Diastolic blood pressure;
PAAD	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05671241	chr3:126373822	NA	0.66	6.69	0.48	4e-10	Myopia (pathological);
PAAD	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.94	-6.66	-0.48	4.64e-10	Body mass index;
PAAD	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.83	-0.43	3.13e-8	Height;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.95	0.43	1.77e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg15571903	chr15:79123663	NA	-0.36	-4.3	-0.33	3.05e-5	Coronary artery disease;
PAAD	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.63	-7.07	-0.5	5.35e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs908922	0.961	rs574749	chr1:152460672	T/G	cg21823605	chr1:152486609	CRCT1	0.54	5.97	0.44	1.65e-8	Hair morphology;
PAAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg11764359	chr7:65958608	NA	0.8	5.1	0.38	1.01e-6	Diabetic kidney disease;
PAAD	trans	rs9810890	1.000	rs116641256	chr3:128587572	G/A	cg05163071	chr3:108476540	RETNLB	1.06	6.68	0.48	4.31e-10	Dental caries;
PAAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	trans	rs901683	1.000	rs9422655	chr10:46051408	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.78	5.94	0.43	1.86e-8	Mean platelet volume;
PAAD	cis	rs2302729	0.625	rs12228313	chr12:2831297	C/T	cg19945202	chr12:2788847	CACNA1C	0.59	4.64	0.35	7.32e-6	Sleep quality;
PAAD	cis	rs2790216	1.000	rs2590313	chr10:59986383	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg05643964	chr20:62369504	LIME1	-0.46	-4.43	-0.34	1.83e-5	Prostate cancer;
PAAD	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.52	-6.07	-0.44	9.71e-9	Blood pressure (smoking interaction);
PAAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.61	6.14	0.45	7.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	1.1	12.1	0.7	4.92e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.74	-10.19	-0.64	6.63e-19	Iron status biomarkers;
PAAD	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.71	8.3	0.56	5.12e-14	Colorectal cancer;
PAAD	cis	rs7598759	0.679	rs6437018	chr2:232327691	A/C	cg19187155	chr2:232395269	NMUR1	0.53	5.81	0.43	3.59e-8	Noise-induced hearing loss;
PAAD	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.7	0.36	5.9e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2999052	1.000	rs13434079	chr3:127963448	A/G	cg18206867	chr2:62422351	B3GNT2	-0.46	-6.41	-0.46	1.74e-9	Hypospadias;
PAAD	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.75	-11.92	-0.69	1.55e-23	Body mass index;
PAAD	cis	rs1075265	0.783	rs805450	chr2:54178909	T/C	cg04546899	chr2:54196757	PSME4	0.33	5.0	0.38	1.56e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.65	-0.53	2.08e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg03209412	chr4:183728196	NA	0.92	7.72	0.53	1.41e-12	Pediatric autoimmune diseases;
PAAD	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.38	-0.64	2.05e-19	Response to antipsychotic treatment;
PAAD	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg11062466	chr8:58055876	NA	0.66	4.67	0.35	6.5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg02353165	chr6:42928485	GNMT	0.6	4.81	0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.82	0.58	2.46e-15	Menopause (age at onset);
PAAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.47	8.37	0.56	3.41e-14	Multiple system atrophy;
PAAD	cis	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg11619707	chr19:22235551	ZNF257	0.58	5.82	0.43	3.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.42e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.62	5.29	0.39	4.29e-7	Coronary artery disease;
PAAD	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-4.9	-0.37	2.48e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg11271282	chr2:238384023	NA	0.57	4.47	0.34	1.53e-5	Prostate cancer;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.34	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	6.39	0.46	1.96e-9	Lymphocyte percentage of white cells;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19997181	chr10:2699357	NA	-0.5	-6.6	-0.47	6.36e-10	Energy expenditure (24h);
PAAD	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.74	-5.24	-0.39	5.17e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.76	-5.39	-0.4	2.63e-7	Vitiligo;
PAAD	cis	rs12304921	1.000	rs73092531	chr12:51357987	C/T	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.37	-0.33	2.33e-5	Type 2 diabetes;
PAAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.62	5.25	0.39	4.96e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9921192	1.000	rs251736	chr16:4318455	A/G	cg00021532	chr16:4324280	TFAP4	0.9	12.73	0.72	1.01e-25	Prostate-specific antigen levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10955293	chr1:24117561	LYPLA2	0.64	7.12	0.5	3.99e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12450239	0.514	rs7217700	chr17:77452372	C/T	cg09567646	chr17:76962761	NA	-0.41	-4.56	-0.35	1.05e-5	Body mass index;
PAAD	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg19336497	chr11:14380999	RRAS2	-0.48	-5.09	-0.38	1.03e-6	Vitamin D levels;
PAAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.77	8.05	0.55	2.19e-13	Alzheimer's disease (late onset);
PAAD	cis	rs7853377	0.723	rs13296528	chr9:86522550	C/T	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg26138144	chr22:38071188	LGALS1	0.42	4.67	0.35	6.56e-6	Fat distribution (HIV);
PAAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	5.61	0.41	9.28e-8	Mood instability;
PAAD	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg05585544	chr11:47624801	NA	-0.52	-5.87	-0.43	2.7e-8	Subjective well-being;
PAAD	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78761021	0.867	rs62066056	chr17:9782864	G/A	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.12e-13	Type 2 diabetes;
PAAD	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs375066	0.935	rs371875	chr19:44393257	A/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg01090926	chr14:75137805	KIAA0317	0.53	4.68	0.35	6.27e-6	Non-small cell lung cancer;
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.78	8.11	0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.12	0.67	2.13e-21	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08393086	chr7:100081535	C7orf51	-0.55	-6.45	-0.46	1.39e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg22832135	chr15:78370102	TBC1D2B	0.55	4.76	0.36	4.56e-6	Breast cancer;
PAAD	trans	rs901683	1.000	rs768673	chr10:45966749	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.46	0.57	2.04e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs375066	0.901	rs438517	chr19:44419658	G/A	cg11993925	chr19:44307056	LYPD5	0.5	6.36	0.46	2.2e-9	Breast cancer;
PAAD	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.61	-0.35	8.48e-6	Total body bone mineral density;
PAAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg14440974	chr22:39074834	NA	-0.58	-7.0	-0.49	7.79e-11	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg16419906	chr5:132167176	NA	-0.43	-4.42	-0.34	1.87e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.76	-7.27	-0.51	1.73e-11	Systemic lupus erythematosus;
PAAD	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs4889855	0.556	rs4506961	chr17:78543182	G/A	cg16591659	chr17:78472290	NA	0.52	4.94	0.37	2.01e-6	Fractional excretion of uric acid;
PAAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.83	11.38	0.68	4.42e-22	Emphysema distribution in smoking;
PAAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.81	8.78	0.58	3.22e-15	Schizophrenia;
PAAD	cis	rs4740619	0.689	rs10810503	chr9:15953051	C/T	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.47	-4.83	-0.36	3.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg15604389	chr3:122379662	NA	0.43	4.31	0.33	2.91e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.62	6.67	0.48	4.37e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-6.32	-0.46	2.7e-9	Bipolar disorder;
PAAD	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.72	-8.15	-0.55	1.26e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg19445457	chr11:5799446	OR52N5	-0.48	-4.27	-0.33	3.37e-5	DNA methylation (variation);
PAAD	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.7	-7.16	-0.5	3.2e-11	Primary sclerosing cholangitis;
PAAD	cis	rs12449964	0.524	rs7224756	chr17:17572342	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-5.26	-0.39	4.92e-7	Coronary artery disease or ischemic stroke;
PAAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.74	7.04	0.5	6.15e-11	Methadone dose in opioid dependence;
PAAD	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs2229238	0.911	rs41313910	chr1:154514203	C/G	cg21262032	chr1:154437693	IL6R	-0.47	-4.91	-0.37	2.37e-6	Coronary heart disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06562184	chr8:19319451	CSGALNACT1	-0.56	-6.47	-0.46	1.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-7.66	-0.53	1.97e-12	Vitiligo;
PAAD	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	7.93	0.54	4.42e-13	Hemoglobin concentration;
PAAD	cis	rs8049634	1.000	rs8049634	chr16:84225679	A/G	cg26466773	chr16:84211947	TAF1C	0.5	4.39	0.34	2.11e-5	Small cell lung carcinoma;
PAAD	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4141404	0.748	rs2232170	chr22:31537122	A/G	cg02404636	chr22:31891804	SFI1	-0.59	-4.83	-0.36	3.28e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07914959	chr6:91006321	BACH2	0.42	4.52	0.34	1.23e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg09491104	chr22:46646882	C22orf40	-1.02	-6.84	-0.49	1.84e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4072705	0.615	rs10986355	chr9:127248299	G/A	cg13476313	chr9:127244764	NR5A1	0.3	4.77	0.36	4.34e-6	Menarche (age at onset);
PAAD	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.56	-0.52	3.62e-12	Neuroticism;
PAAD	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.59	-0.35	9.33e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01755369	chr19:10764728	ILF3;LOC147727	0.62	7.04	0.5	6.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11078597	0.731	rs2287322	chr17:1641035	A/G	cg17514665	chr17:1657533	SERPINF2	0.66	6.07	0.44	9.82e-9	Serum albumin level;
PAAD	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.77	-0.53	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	1.08	16.23	0.8	5.29e-35	Height;
PAAD	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg12568669	chr8:11666485	FDFT1	0.29	4.91	0.37	2.31e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg01762785	chr22:42226837	NA	-0.41	-4.54	-0.35	1.13e-5	Intelligence;
PAAD	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg00262122	chr8:11665843	FDFT1	0.53	5.1	0.38	1.02e-6	Neuroticism;
PAAD	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.39	-4.36	-0.33	2.41e-5	Mean platelet volume;
PAAD	cis	rs747650	0.504	rs10838641	chr11:47003304	G/A	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg17541715	chr7:1216824	NA	-0.4	-4.4	-0.34	2.04e-5	Longevity;Endometriosis;
PAAD	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg23387468	chr7:139079360	LUC7L2	0.38	4.57	0.35	9.96e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6594713	0.533	rs71577455	chr5:112953197	C/T	cg12552261	chr5:112820674	MCC	0.74	4.72	0.36	5.27e-6	Brain cytoarchitecture;
PAAD	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	5.28	0.39	4.3e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg02683114	chr2:24398427	C2orf84	-0.63	-7.14	-0.5	3.61e-11	Asthma;
PAAD	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.99	0.44	1.49e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg27411982	chr8:10470053	RP1L1	0.47	5.45	0.4	1.95e-7	Neuroticism;
PAAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg03037974	chr15:76606532	NA	0.41	4.59	0.35	9.42e-6	Blood metabolite levels;
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg07168214	chr17:7380112	ZBTB4	-0.65	-6.06	-0.44	1e-8	Androgen levels;
PAAD	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.09	14.97	0.77	1.01e-31	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24260218	chr8:29208126	DUSP4	0.62	6.72	0.48	3.46e-10	Myopia (pathological);
PAAD	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg18489755	chr3:183533873	MAP6D1	0.34	4.27	0.33	3.42e-5	Anterior chamber depth;
PAAD	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg08390786	chr10:135334061	NA	-0.48	-4.52	-0.34	1.23e-5	Obesity-related traits;
PAAD	cis	rs80346118	0.636	rs6012533	chr20:47416665	T/A	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.59	-4.48	-0.34	1.45e-5	Diastolic blood pressure;
PAAD	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg10818794	chr15:86012489	AKAP13	-0.43	-4.66	-0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.76	9.25	0.6	1.97e-16	Alcohol dependence;
PAAD	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.81	0.48	2.08e-10	Exhaled nitric oxide levels;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	10.77	0.66	1.87e-20	Menopause (age at onset);
PAAD	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.62	-5.99	-0.44	1.44e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.08	-0.38	1.08e-6	Educational attainment;
PAAD	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg01798341	chr17:80842262	TBCD	0.42	4.65	0.35	7.17e-6	Breast cancer;
PAAD	cis	rs4077468	1.000	rs9661504	chr1:205915667	A/T	cg21828629	chr1:205913422	SLC26A9	-0.42	-4.58	-0.35	9.53e-6	Cystic fibrosis-related diabetes;
PAAD	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.77e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.71	7.96	0.54	3.69e-13	Colorectal cancer;
PAAD	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.62	5.35	0.4	3.22e-7	Corneal structure;
PAAD	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.52	4.77	0.36	4.3e-6	Optic cup area;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg00631329	chr6:26305371	NA	-0.48	-4.84	-0.37	3.21e-6	Educational attainment;
PAAD	trans	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg25482853	chr8:67687455	SGK3	0.99	6.31	0.46	2.89e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs10073892	0.703	rs60647834	chr5:101623780	T/A	cg17280723	chr5:101634495	NA	0.41	4.45	0.34	1.63e-5	Cognitive decline (age-related);
PAAD	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg03651054	chr13:50194643	NA	-0.36	-4.48	-0.34	1.45e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.6	-5.72	-0.42	5.45e-8	Colorectal cancer;
PAAD	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg18265118	chr7:2139243	MAD1L1	0.52	4.34	0.33	2.6e-5	Neuroticism;
PAAD	cis	rs7191751	1.000	rs717482	chr16:86304997	T/C	cg27499105	chr16:86337823	NA	-0.48	-4.49	-0.34	1.38e-5	Response to platinum-based chemotherapy (cisplatin);
PAAD	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.76	5.09	0.38	1.03e-6	Anti-saccade response;
PAAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.83	-8.16	-0.55	1.17e-13	Birth weight;
PAAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.54	5.5	0.41	1.57e-7	Longevity;
PAAD	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg03959625	chr15:84868606	LOC388152	-0.46	-4.54	-0.35	1.14e-5	P wave terminal force;
PAAD	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	4.35	0.33	2.44e-5	Bone mineral density;
PAAD	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.57	5.07	0.38	1.14e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-6.41	-0.46	1.74e-9	Body mass index;
PAAD	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs134594	0.885	rs134577	chr22:29464223	T/C	cg25916307	chr22:29467684	KREMEN1	-0.48	-4.46	-0.34	1.58e-5	Birth weight;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23970758	chr19:38893547	FAM98C	-0.66	-6.39	-0.46	1.88e-9	Smoking initiation;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.76	-7.51	-0.52	4.8e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.89	10.2	0.64	6.35e-19	Adiposity;
PAAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-7.88	-0.54	5.96e-13	Total body bone mineral density;
PAAD	cis	rs8049634	0.869	rs3759975	chr16:84221085	A/C	cg00961177	chr16:84213833	TAF1C	-0.46	-4.6	-0.35	8.99e-6	Small cell lung carcinoma;
PAAD	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg03938978	chr2:103052716	IL18RAP	0.63	4.4	0.34	1.99e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs893363	0.594	rs12676	chr3:53857803	A/C	cg15798837	chr3:54122146	NA	0.36	4.36	0.33	2.39e-5	Axial length;
PAAD	cis	rs732765	0.734	rs17183139	chr14:75153950	G/A	cg17347104	chr14:75034677	LTBP2	0.63	5.38	0.4	2.78e-7	Non-small cell lung cancer;
PAAD	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg27565382	chr3:53032988	SFMBT1	-0.73	-4.56	-0.35	1.05e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.67	7.09	0.5	4.71e-11	Dupuytren's disease;
PAAD	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	9.03	0.59	7.05e-16	Chronic sinus infection;
PAAD	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.98	8.02	0.55	2.59e-13	Blood trace element (Zn levels);
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11382291	chr4:160024674	NA	-0.62	-6.38	-0.46	2.07e-9	Warfarin maintenance dose;
PAAD	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg06714761	chr1:201096289	NA	0.31	4.67	0.35	6.66e-6	Permanent tooth development;
PAAD	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	1.2	13.21	0.73	4.96e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.54	-5.28	-0.39	4.34e-7	Hypospadias;
PAAD	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.91	0.54	4.85e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.75	7.8	0.53	8.99e-13	Height;
PAAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg09659197	chr4:152720779	NA	0.4	5.1	0.38	9.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs11671653	1.000	rs58380026	chr19:10832506	C/T	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.82	0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg07954423	chr9:130741881	FAM102A	-0.6	-5.73	-0.42	5.13e-8	Glaucoma (primary angle closure);
PAAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs5756391	0.568	rs10222238	chr22:37318014	G/T	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg13012494	chr21:47604986	C21orf56	0.44	4.67	0.35	6.45e-6	Testicular germ cell tumor;
PAAD	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg20587970	chr11:113659929	NA	-1.06	-10.07	-0.63	1.35e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg04160749	chr8:58172571	NA	-0.6	-4.32	-0.33	2.79e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.68	0.58	5.69e-15	Bipolar disorder;
PAAD	cis	rs9462027	0.628	rs6929567	chr6:34692735	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.37	0.4	2.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg24881330	chr22:46731750	TRMU	0.59	4.32	0.33	2.75e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg01181863	chr3:195395398	SDHAP2	-0.79	-7.6	-0.52	2.77e-12	Pancreatic cancer;
PAAD	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.41	5.01	0.38	1.47e-6	Electrocardiographic conduction measures;
PAAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00292662	chr22:38071168	LGALS1	0.65	6.94	0.49	1.08e-10	Fat distribution (HIV);
PAAD	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg25753631	chr6:25732923	NA	-0.48	-4.45	-0.34	1.68e-5	Iron status biomarkers;
PAAD	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.93	-10.23	-0.64	4.99e-19	Parkinson's disease;
PAAD	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.51	-4.45	-0.34	1.63e-5	Acne (severe);
PAAD	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.15	-0.39	7.87e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.43	4.41	0.34	1.95e-5	Breast cancer;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.39	4.25	0.33	3.69e-5	Life satisfaction;
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	4.97	0.37	1.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.53	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2253017	0.767	rs4770070	chr13:21330776	G/A	cg27234864	chr13:21295941	IL17D	0.57	4.71	0.36	5.43e-6	PR segment;
PAAD	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs11700980	0.551	rs2832030	chr21:30114620	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs4478858	0.746	rs10914328	chr1:31688406	A/G	cg00250761	chr1:31883323	NA	0.41	4.53	0.35	1.16e-5	Alcohol dependence;
PAAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs2137920	0.636	rs2175916	chr10:50225754	C/T	cg02657375	chr10:50863136	CHAT	0.54	4.34	0.33	2.59e-5	Migraine with aura;
PAAD	trans	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg26939375	chr7:64535504	NA	-0.72	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs1975974	0.539	rs58796614	chr17:21733767	C/T	cg18423549	chr17:21743878	NA	-0.56	-5.3	-0.39	4.08e-7	Psoriasis;
PAAD	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7594192	0.744	rs12998934	chr2:199366955	T/C	cg03163783	chr2:200326591	SATB2	-0.33	-4.51	-0.34	1.27e-5	Educational attainment;
PAAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.47	4.88	0.37	2.68e-6	Longevity;
PAAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	1.08	15.2	0.78	2.63e-32	Breast cancer;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	0.71	4.81	0.36	3.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg03948781	chr1:205179583	DSTYK	0.48	4.47	0.34	1.51e-5	Red blood cell count;
PAAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg10729496	chr3:10149963	C3orf24	0.86	6.27	0.45	3.62e-9	Alzheimer's disease;
PAAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.63e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.52	-0.47	9.71e-10	Longevity;
PAAD	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.93	13.8	0.75	1.38e-28	Age-related hearing impairment;
PAAD	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.67	6.71	0.48	3.64e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.09	7.4	0.51	8.55e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21238619	chr17:78079768	GAA	-0.48	-5.88	-0.43	2.47e-8	Yeast infection;
PAAD	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26926768	chr12:34528122	NA	0.39	4.66	0.35	6.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.38	-4.57	-0.35	9.85e-6	Coronary artery disease;
PAAD	cis	rs2124910	1.000	rs4146202	chr19:52032668	T/C	cg12008991	chr19:52034861	SIGLEC6	0.38	5.07	0.38	1.12e-6	Blood protein levels;
PAAD	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.42	5.18	0.39	6.87e-7	Thyroid stimulating hormone;
PAAD	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-4.28	-0.33	3.24e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs79839061	0.636	rs73207778	chr4:836762	C/T	cg07828340	chr4:882639	GAK	1.31	6.7	0.48	3.85e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.59	6.07	0.44	9.68e-9	Coronary artery disease;
PAAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.85	-9.89	-0.63	4.12e-18	Coronary artery disease;
PAAD	cis	rs6011674	1.000	rs11908424	chr20:61863955	C/T	cg22476268	chr20:62715760	OPRL1;C20orf201	-0.69	-4.33	-0.33	2.7e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.75	8.6	0.57	9.19e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg10374248	chr10:99083645	NA	0.47	4.32	0.33	2.79e-5	Monocyte count;
PAAD	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.8	8.96	0.59	1.07e-15	Birth weight;
PAAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.7	7.8	0.53	9.12e-13	Melanoma;
PAAD	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg11779900	chr17:80519722	FOXK2	-0.49	-5.02	-0.38	1.41e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.53	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs3764400	0.517	rs7209042	chr17:46207792	G/C	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg13010199	chr12:38710504	ALG10B	0.41	4.28	0.33	3.24e-5	Heart rate;
PAAD	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.51	5.17	0.39	7.16e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03274021	chr8:130952480	FAM49B	0.58	6.62	0.47	5.83e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.67	-8.25	-0.56	7.18e-14	Schizophrenia;
PAAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.56	6.34	0.46	2.53e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11211309	1.000	rs11211309	chr1:47045213	A/T	cg06911238	chr1:46859671	FAAH	0.47	4.25	0.33	3.65e-5	Schizophrenia;
PAAD	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg02683114	chr2:24398427	C2orf84	-0.59	-6.3	-0.46	3e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.26	-0.39	4.8e-7	Life satisfaction;
PAAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg17987982	chr7:158820591	NA	-0.42	-4.78	-0.36	4.07e-6	Facial morphology (factor 20);
PAAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg27490568	chr2:178487706	NA	0.41	4.39	0.34	2.14e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.65	-7.47	-0.52	5.75e-12	Mosquito bite size;
PAAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg00579200	chr11:133705235	NA	-0.5	-5.75	-0.42	4.7e-8	Childhood ear infection;
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16937126	chr8:38088972	DDHD2	0.66	7.63	0.53	2.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.75	8.68	0.58	5.79e-15	Body mass index;
PAAD	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg11204139	chr17:3907470	NA	0.7	7.08	0.5	5.12e-11	Type 2 diabetes;
PAAD	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg20607287	chr7:12443886	VWDE	-0.67	-5.18	-0.39	7.07e-7	Coronary artery disease;
PAAD	cis	rs4668356	1.000	rs56382502	chr2:171951831	A/G	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.07e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.72	8.55	0.57	1.23e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.7	-7.74	-0.53	1.27e-12	Motion sickness;
PAAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg03808351	chr9:123631620	PHF19	0.47	5.08	0.38	1.07e-6	Rheumatoid arthritis;
PAAD	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs8112211	0.608	rs112827305	chr19:38811275	G/T	cg01275006	chr19:38876250	GGN	-0.83	-5.17	-0.39	7.35e-7	Blood protein levels;
PAAD	cis	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs8040855	0.627	rs11632899	chr15:85600840	A/G	cg08123816	chr15:85640762	PDE8A	-0.41	-4.93	-0.37	2.15e-6	Bulimia nervosa;
PAAD	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.53	-0.41	1.35e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9815354	0.857	rs7634985	chr3:42019565	C/T	cg03022575	chr3:42003672	ULK4	-0.72	-5.22	-0.39	5.67e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4280164	0.560	rs11626191	chr14:24736574	A/C	cg07162820	chr14:24837146	NFATC4	0.43	4.82	0.36	3.4e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.73	-6.0	-0.44	1.37e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7853377	0.723	rs7047907	chr9:86368660	G/A	cg03531853	chr9:86535572	KIF27	-0.44	-4.46	-0.34	1.56e-5	Height;
PAAD	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-6.69	-0.48	4.05e-10	Blood pressure (smoking interaction);
PAAD	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.51	-4.49	-0.34	1.41e-5	Dental caries;
PAAD	cis	rs72960926	1.000	rs11751231	chr6:75138811	T/C	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	cis	rs6141769	0.518	rs6057620	chr20:31265165	A/G	cg13636640	chr20:31349939	DNMT3B	-0.54	-5.06	-0.38	1.2e-6	Subjective well-being;
PAAD	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs375066	0.901	rs1050054	chr19:44376681	G/T	cg11993925	chr19:44307056	LYPD5	0.52	6.66	0.48	4.8e-10	Breast cancer;
PAAD	cis	rs4523957	0.651	rs1002136	chr17:2098006	C/A	cg16513277	chr17:2031491	SMG6	-0.55	-5.72	-0.42	5.59e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg04111102	chr1:66153794	NA	0.5	5.73	0.42	5.28e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.88	5.8	0.43	3.69e-8	Diabetic kidney disease;
PAAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg00540400	chr15:79124168	NA	0.7	8.87	0.58	1.84e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00049323	chr5:472564	LOC25845	0.42	4.9	0.37	2.42e-6	Cystic fibrosis severity;
PAAD	cis	rs990171	1.000	rs10197284	chr2:102982703	G/A	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.88e-5	Lymphocyte counts;
PAAD	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg10523679	chr1:76189770	ACADM	-0.56	-5.32	-0.4	3.68e-7	Daytime sleep phenotypes;
PAAD	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.46	-5.71	-0.42	5.87e-8	Lewy body disease;
PAAD	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.25	0.56	6.97e-14	Lung cancer;
PAAD	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.74	8.15	0.55	1.27e-13	Bipolar disorder;
PAAD	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.51	4.9	0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.56	4.94	0.37	2.01e-6	Systolic blood pressure;
PAAD	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg04370829	chr17:406249	NA	-0.46	-4.95	-0.37	1.95e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-1.04	-5.69	-0.42	6.49e-8	Inflammatory biomarkers;
PAAD	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	0.85	4.99	0.38	1.62e-6	Alzheimer's disease (late onset);
PAAD	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg13256891	chr4:100009986	ADH5	0.42	4.27	0.33	3.37e-5	Alcohol dependence;
PAAD	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	9.49	0.61	4.65e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg19337854	chr7:99768885	GPC2	0.59	5.45	0.4	2e-7	Lung function (FEV1/FVC);
PAAD	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs2835872	0.758	rs7278101	chr21:39035873	T/C	cg06728970	chr21:39037746	KCNJ6	-0.46	-5.12	-0.38	9e-7	Electroencephalographic traits in alcoholism;
PAAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	9.14	0.6	3.65e-16	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	0.92	6.5	0.47	1.08e-9	Pulse pressure;
PAAD	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.68	-0.35	6.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.55	6.87	0.49	1.56e-10	Atrioventricular conduction;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg07202610	chr7:1142643	C7orf50	-0.78	-5.49	-0.41	1.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2016586	0.929	rs5755921	chr22:36104730	A/G	cg26342177	chr22:36113512	APOL5	0.49	4.94	0.37	2.07e-6	Body mass index;
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.74	8.51	0.57	1.54e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs7792596	0.565	rs10464587	chr7:93982039	G/A	cg20814616	chr7:94014465	NA	-0.62	-5.92	-0.43	2.1e-8	Intelligence;
PAAD	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.73	6.19	0.45	5.3e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.46	5.04	0.38	1.3e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg00031303	chr3:195681400	NA	-0.56	-5.88	-0.43	2.47e-8	Pancreatic cancer;
PAAD	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.78	9.01	0.59	8.05e-16	Heart rate;
PAAD	cis	rs2286379	1.000	rs2286379	chr12:1902164	C/T	cg05227549	chr12:1770782	NA	-0.38	-4.36	-0.33	2.41e-5	Blood pressure (smoking interaction);
PAAD	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg23461800	chr14:103021989	NA	-0.58	-4.4	-0.34	1.99e-5	Platelet count;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.68	6.76	0.48	2.82e-10	Menarche (age at onset);
PAAD	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-14.97	-0.77	1.07e-31	Schizophrenia;
PAAD	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.72	7.17	0.5	3.02e-11	Obesity-related traits;
PAAD	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	6.0	0.44	1.38e-8	Blood metabolite levels;
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.72	-6.45	-0.46	1.4e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2241685	0.764	rs12471967	chr2:1941173	G/A	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs12257961	0.579	rs4748160	chr10:15360718	T/A	cg10616319	chr10:15468812	NA	-0.45	-4.35	-0.33	2.49e-5	Selective IgA deficiency;
PAAD	cis	rs4321325	0.733	rs78516281	chr2:127944564	G/C	cg11380483	chr2:127933992	NA	0.68	5.06	0.38	1.18e-6	Protein C levels;
PAAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs7236492	0.748	rs73494235	chr18:77208509	T/C	cg15644404	chr18:77186268	NFATC1	-0.85	-5.88	-0.43	2.47e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.51	-5.22	-0.39	5.67e-7	Breast size;
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg03909863	chr11:638404	DRD4	-0.6	-5.44	-0.4	2.05e-7	Systemic lupus erythematosus;
PAAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg27494647	chr7:150038898	RARRES2	0.5	4.89	0.37	2.59e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.38	-0.4	2.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2279817	0.818	rs883379	chr1:17983789	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.62	-5.73	-0.42	5.14e-8	Neuroticism;
PAAD	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.41	-4.78	-0.36	4.05e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.4	0.34	2e-5	Tonsillectomy;
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg20090690	chr10:134436459	INPP5A	0.51	4.31	0.33	2.89e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21028142	chr17:79581711	NPLOC4	0.58	7.15	0.5	3.45e-11	Myopia;
PAAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg03037974	chr15:76606532	NA	0.52	5.94	0.43	1.91e-8	Blood metabolite levels;
PAAD	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg06609049	chr19:2785107	THOP1	0.88	9.92	0.63	3.5e-18	Total cholesterol levels;
PAAD	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg00042356	chr1:8021962	PARK7	0.72	4.98	0.37	1.74e-6	Inflammatory bowel disease;
PAAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg04450456	chr4:17643702	FAM184B	0.47	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.4	-0.4	2.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7729447	0.813	rs7715279	chr5:32689875	T/A	cg16267343	chr5:32710456	NPR3	0.48	4.57	0.35	9.9e-6	Blood pressure;
PAAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.35	0.33	2.46e-5	Tonsillectomy;
PAAD	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	cis	rs2882667	0.654	rs160406	chr5:138083721	T/C	cg09476006	chr5:138032270	NA	-0.46	-5.92	-0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.54	4.48	0.34	1.44e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7771547	0.723	rs9368940	chr6:36558700	T/A	cg07856975	chr6:36356162	ETV7	0.44	4.58	0.35	9.54e-6	Platelet distribution width;
PAAD	cis	rs747650	0.504	rs4394802	chr11:46990587	C/T	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg02023728	chr11:77925099	USP35	-0.44	-4.39	-0.34	2.08e-5	Alzheimer's disease (survival time);
PAAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg10356904	chr22:49881777	NA	-0.52	-5.35	-0.4	3.11e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.83	10.44	0.65	1.42e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.39	0.68	4.07e-22	Smoking behavior;
PAAD	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.8	4.77	0.36	4.32e-6	Childhood ear infection;
PAAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg03983715	chr16:68378420	PRMT7	-0.95	-7.14	-0.5	3.61e-11	Magnesium levels;
PAAD	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs71499566	chr10:45996015	T/C	cg14076390	chr17:34947837	DHRS11	0.92	6.81	0.48	2.15e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.42	-6.5	-0.47	1.07e-9	Cutaneous nevi;
PAAD	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.47	5.19	0.39	6.69e-7	Heart rate;
PAAD	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg07954423	chr9:130741881	FAM102A	0.57	5.46	0.41	1.86e-7	Glaucoma (primary angle closure);
PAAD	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.82	5.91	0.43	2.18e-8	Height;
PAAD	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.81	8.27	0.56	6.11e-14	Breast cancer;
PAAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09597638	chr17:3907349	NA	0.86	9.29	0.6	1.53e-16	Type 2 diabetes;
PAAD	cis	rs7786877	0.679	rs10953301	chr7:100264893	A/G	cg20848291	chr7:100343083	ZAN	-0.87	-7.69	-0.53	1.73e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.52	-5.77	-0.42	4.4e-8	Testicular germ cell tumor;
PAAD	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg16342193	chr10:102329863	NA	-0.79	-8.63	-0.57	7.59e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	5.42	0.4	2.29e-7	Mean platelet volume;
PAAD	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.55	-5.41	-0.4	2.43e-7	Educational attainment (years of education);
PAAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.45	4.72	0.36	5.25e-6	Longevity;Endometriosis;
PAAD	cis	rs6256	1.000	rs11022876	chr11:13572708	A/G	cg11976911	chr11:13509032	NA	-0.67	-5.07	-0.38	1.13e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2562456	0.833	rs62109229	chr19:21537182	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs9810089	1.000	rs1279831	chr3:135933264	A/G	cg21827317	chr3:136751795	NA	0.44	4.39	0.34	2.11e-5	Gestational age at birth (child effect);
PAAD	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg27335600	chr3:53528857	CACNA1D	-0.39	-4.34	-0.33	2.63e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.72	5.25	0.39	5.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.53	-5.38	-0.4	2.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10065203	0.527	rs181927	chr5:14351946	G/T	cg26595256	chr5:14380529	TRIO	-0.55	-6.08	-0.44	9.46e-9	Paclitaxel-induced neuropathy;
PAAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg12395012	chr8:11607386	GATA4	-0.43	-4.65	-0.35	7.13e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.84	-0.37	3.15e-6	Eotaxin levels;
PAAD	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.91	7.82	0.54	8.34e-13	Lymphocyte percentage of white cells;
PAAD	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.85	-0.43	2.91e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.8	-8.46	-0.57	2.04e-14	DNA methylation (variation);
PAAD	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg10183150	chr4:120222239	C4orf3	-0.38	-5.4	-0.4	2.49e-7	Corneal astigmatism;
PAAD	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg06740227	chr12:86229804	RASSF9	-0.49	-4.9	-0.37	2.48e-6	Major depressive disorder;
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.67	7.71	0.53	1.52e-12	High light scatter reticulocyte count;
PAAD	cis	rs755249	0.567	rs3754346	chr1:39814960	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg02135003	chr7:105160482	PUS7	-0.78	-5.85	-0.43	2.94e-8	Bipolar disorder (body mass index interaction);
PAAD	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.87	6.46	0.46	1.33e-9	Axial length;
PAAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.67	-6.84	-0.48	1.85e-10	Schizophrenia;
PAAD	cis	rs6028335	0.610	rs67621213	chr20:37582553	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.62	-4.69	-0.36	6.02e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.96	-0.44	1.69e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-1.14	-16.15	-0.79	8.74e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6142102	0.961	rs6059649	chr20:32643877	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	4.33	0.33	2.7e-5	Skin pigmentation;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg07212818	chr11:638076	DRD4	-0.7	-6.99	-0.49	8.26e-11	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8099014	0.954	rs28393850	chr18:56129141	T/C	cg12907477	chr18:56117327	MIR122	0.55	4.48	0.34	1.46e-5	Platelet count;
PAAD	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg16579770	chr16:72058938	DHODH	0.37	4.27	0.33	3.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg19567339	chr10:100142640	NA	0.43	4.56	0.35	1.05e-5	Metabolite levels;
PAAD	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg05085585	chr16:30420623	ZNF771	0.43	4.46	0.34	1.61e-5	Tonsillectomy;
PAAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-4.69	-0.36	6.16e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11696501	0.843	rs6130846	chr20:44115129	A/G	cg11783356	chr20:44313418	WFDC10B	-0.63	-5.38	-0.4	2.74e-7	Brain structure;
PAAD	cis	rs8067287	0.696	rs62065422	chr17:16828570	G/A	cg26910001	chr17:16838321	NA	-0.67	-6.08	-0.44	9.52e-9	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.84	0.49	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.55	-4.53	-0.35	1.17e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.86	6.16	0.45	6.27e-9	Iron status biomarkers;
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.52	-5.15	-0.39	8.02e-7	Longevity;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg26174226	chr8:58114915	NA	-0.56	-4.41	-0.34	1.97e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.08	-0.5	4.96e-11	Colorectal cancer;
PAAD	cis	rs2425143	0.908	rs6088889	chr20:34175417	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	4.56	0.35	1.05e-5	Blood protein levels;
PAAD	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.29	8.05	0.55	2.16e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs35955747	0.902	rs7288735	chr22:31679546	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.51	4.54	0.35	1.12e-5	Anterior chamber depth;
PAAD	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.45	4.27	0.33	3.38e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.56	4.62	0.35	7.99e-6	Interleukin-17 levels;
PAAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.82	9.23	0.6	2.16e-16	Total body bone mineral density;
PAAD	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.84	-0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.59	4.81	0.36	3.59e-6	Mammographic density (dense area);
PAAD	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.57	-0.47	7.72e-10	Total body bone mineral density;
PAAD	trans	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.73	11.29	0.68	7.75e-22	Breast cancer;
PAAD	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19623624	chr10:135278901	LOC619207	-0.47	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.76	0.48	2.85e-10	Eye color traits;
PAAD	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.93	8.54	0.57	1.28e-14	Vitiligo;
PAAD	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg00536532	chr6:33561449	C6orf227	-0.41	-4.28	-0.33	3.3e-5	Height;
PAAD	cis	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg15792487	chr17:7348316	CHRNB1	0.49	5.54	0.41	1.31e-7	Height;
PAAD	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.46	4.56	0.35	1.06e-5	Birth weight;
PAAD	cis	rs7219021	0.926	rs68169424	chr17:46851676	T/C	cg12314713	chr17:47074576	IGF2BP1	-0.34	-4.33	-0.33	2.73e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg04482110	chr17:41364121	TMEM106A	0.39	4.43	0.34	1.81e-5	Menopause (age at onset);
PAAD	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg09667013	chr22:42394590	WBP2NL	-0.54	-5.41	-0.4	2.43e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.49	5.61	0.41	9.37e-8	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.91	0.43	2.12e-8	Alzheimer's disease;
PAAD	cis	rs73416724	1.000	rs79329802	chr6:43387332	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.47	0.34	1.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.09	-0.38	1.06e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.64	-7.33	-0.51	1.27e-11	Platelet distribution width;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06808430	chr7:102984880	DNAJC2	0.62	6.43	0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs6908034	0.607	rs112659166	chr6:19807409	C/T	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg27094323	chr7:1216898	NA	-0.45	-5.38	-0.4	2.8e-7	Longevity;Endometriosis;
PAAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.49	-4.4	-0.34	1.99e-5	Asthma;
PAAD	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg20607287	chr7:12443886	VWDE	-0.48	-4.3	-0.33	3.08e-5	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07134240	chr4:186435954	PDLIM3	0.57	6.38	0.46	2e-9	Smoking initiation;
PAAD	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.97	-8.67	-0.58	6.22e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.57	6.18	0.45	5.53e-9	Cardiovascular disease risk factors;
PAAD	cis	rs877529	0.566	rs139393	chr22:39537932	T/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.89	-0.49	1.35e-10	Multiple myeloma;
PAAD	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.02	0.5	6.74e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.14	-15.88	-0.79	4.24e-34	Exhaled nitric oxide output;
PAAD	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-6.45	-0.46	1.4e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2797685	0.606	rs72632043	chr1:7809383	C/T	cg06712362	chr1:7811235	CAMTA1	0.5	4.39	0.34	2.08e-5	Crohn's disease;
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg09699651	chr6:150184138	LRP11	0.5	5.32	0.4	3.64e-7	Lung cancer;
PAAD	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.62	5.22	0.39	5.71e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1903068	0.925	rs1551641	chr4:55993915	C/T	cg01777861	chr4:56023843	NA	0.36	4.26	0.33	3.54e-5	Endometriosis;
PAAD	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg17595323	chr11:93583763	C11orf90	-0.36	-4.51	-0.34	1.27e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs3007168	1.000	rs2999356	chr14:51606543	A/G	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg05552183	chr6:42928497	GNMT	0.85	10.09	0.63	1.24e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9377188	0.810	rs2340802	chr6:149348504	C/T	cg21368479	chr6:149415018	NA	0.43	4.54	0.35	1.15e-5	Cancer;
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2147959	0.700	rs12725863	chr1:228630986	C/T	cg02753203	chr1:228287806	NA	-0.6	-4.84	-0.37	3.16e-6	Adult asthma;
PAAD	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg24053715	chr22:38214548	NA	0.57	5.25	0.39	4.95e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.07	-0.38	1.13e-6	Testicular germ cell tumor;
PAAD	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	0.81	5.46	0.4	1.93e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.69	7.41	0.51	8.39e-12	Cognitive function;
PAAD	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.67	-0.53	1.94e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg07153921	chr17:41440717	NA	0.41	4.38	0.33	2.21e-5	Menopause (age at onset);
PAAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3996993	0.702	rs2749035	chr6:52633933	G/A	cg00536792	chr6:53530503	KLHL31	0.4	4.29	0.33	3.13e-5	Hemoglobin concentration;
PAAD	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.61	-5.73	-0.42	5.32e-8	Total body bone mineral density;
PAAD	cis	rs4513299	0.601	rs13009847	chr2:115012818	C/T	cg12978357	chr2:114426529	NA	-0.44	-4.4	-0.34	2.03e-5	Inflammatory biomarkers;
PAAD	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg03315344	chr16:75512273	CHST6	-0.68	-5.66	-0.42	7.43e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25632853	chr15:73088954	NA	0.38	4.26	0.33	3.51e-5	Triglyceride levels;
PAAD	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg10820045	chr2:198174542	NA	-0.48	-4.83	-0.36	3.35e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg05717871	chr11:638507	DRD4	-0.57	-5.47	-0.41	1.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.71	-0.36	5.57e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.79	8.36	0.56	3.61e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8060686	0.920	rs73597582	chr16:67683626	G/A	cg09835421	chr16:68378352	PRMT7	-0.95	-4.88	-0.37	2.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10501293	1.000	rs7111028	chr11:43060516	C/T	cg03447554	chr11:43094025	NA	0.52	5.16	0.39	7.62e-7	Cognitive performance;
PAAD	trans	rs12137025	1.000	rs12137025	chr1:223872051	T/C	cg18879828	chr11:46942432	NA	-0.77	-6.46	-0.46	1.33e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.01	0.38	1.47e-6	Body mass index;
PAAD	cis	rs7711186	0.881	rs721142	chr5:178019208	C/A	cg07427642	chr5:177944298	COL23A1	0.68	4.41	0.34	1.93e-5	Urate levels in obese individuals;
PAAD	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.64	-5.81	-0.43	3.58e-8	Diabetic retinopathy;
PAAD	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg05207973	chr5:176823642	SLC34A1	0.41	4.66	0.35	6.75e-6	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.5	5.17	0.39	7.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.75	-8.89	-0.58	1.7e-15	Colorectal cancer;
PAAD	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6597981	0.543	rs3901233	chr11:749452	T/A	cg21775979	chr11:780331	NA	-0.72	-6.73	-0.48	3.24e-10	Breast cancer;
PAAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg14003231	chr6:33640908	ITPR3	0.35	4.41	0.34	1.95e-5	Plateletcrit;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg22947322	chr17:47091978	IGF2BP1	0.38	4.45	0.34	1.65e-5	Type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg20893579	chr22:38215064	NA	0.49	4.59	0.35	9.21e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs72634258	0.786	rs7539807	chr1:8183789	C/T	cg09168692	chr1:7887560	PER3	0.48	4.65	0.35	7.08e-6	Inflammatory bowel disease;
PAAD	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.53	-5.57	-0.41	1.13e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.96e-5	Total body bone mineral density;
PAAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs735539	0.598	rs745680	chr13:21269314	T/G	cg27234864	chr13:21295941	IL17D	0.62	5.56	0.41	1.16e-7	Dental caries;
PAAD	cis	rs11677416	1.000	rs1516789	chr2:113531024	C/T	cg27083787	chr2:113543245	IL1A	0.47	4.7	0.36	5.85e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.0	-0.49	7.56e-11	Life satisfaction;
PAAD	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg02380750	chr20:61661411	NA	0.36	4.31	0.33	2.95e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.59	6.93	0.49	1.09e-10	Mean corpuscular volume;
PAAD	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-5.2	-0.39	6.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.42	-10.28	-0.64	3.88e-19	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9633402	0.526	rs10788726	chr1:247997114	T/C	cg08944170	chr1:248100614	OR2L13	0.65	4.72	0.36	5.37e-6	Systemic juvenile idiopathic arthritis;
PAAD	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg08316699	chr6:150357289	NA	0.39	4.27	0.33	3.38e-5	Alopecia areata;
PAAD	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs1497828	0.913	rs2646836	chr1:217550020	A/T	cg04411442	chr1:217543379	NA	0.5	4.93	0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.89	-10.56	-0.65	6.94e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	6.49	0.47	1.12e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.54	-4.88	-0.37	2.65e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	5e-7	Type 2 diabetes nephropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18749629	chr8:144566769	ZC3H3	-0.65	-6.45	-0.46	1.38e-9	Obesity-related traits;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.59	6.33	0.46	2.61e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.52	7.06	0.5	5.48e-11	Ewing sarcoma;
PAAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-5.18	-0.39	6.87e-7	Mean platelet volume;
PAAD	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.93	8.96	0.59	1.08e-15	Psoriasis;
PAAD	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.56	5.26	0.39	4.71e-7	Red blood cell count;
PAAD	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.5	5.1	0.38	1.01e-6	Colorectal cancer;
PAAD	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg22467129	chr15:76604101	ETFA	0.53	5.02	0.38	1.4e-6	Blood metabolite levels;
PAAD	cis	rs2980439	0.517	rs793753	chr8:8105359	T/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.09	-0.44	8.83e-9	Neuroticism;
PAAD	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.75	0.58	3.79e-15	Bipolar disorder;
PAAD	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02985541	chr2:219472218	PLCD4	-0.31	-4.79	-0.36	3.84e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05482832	chr17:74734106	MIR636;SFRS2;MFSD11	0.63	6.94	0.49	1.06e-10	Myopia (pathological);
PAAD	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.89	6.86	0.49	1.63e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs755249	0.567	rs905381	chr1:39688552	T/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.48	5.16	0.39	7.76e-7	Monocyte percentage of white cells;
PAAD	cis	rs9863706	0.556	rs7628338	chr3:72432888	C/T	cg14612785	chr3:71774842	EIF4E3	-0.52	-4.35	-0.33	2.46e-5	Height;
PAAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg01852476	chr1:2232063	SKI	-0.27	-4.46	-0.34	1.56e-5	Ulcerative colitis;
PAAD	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.47	0.52	5.69e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg04738700	chr2:239367308	NA	0.39	4.41	0.34	1.98e-5	Multiple system atrophy;
PAAD	cis	rs7009516	0.749	rs7012863	chr8:24218225	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.41	4.85	0.37	2.99e-6	Hair greying;
PAAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs61759167	0.954	rs28594467	chr1:3097051	C/T	cg22396632	chr1:3079212	PRDM16	-0.55	-5.19	-0.39	6.65e-7	Motion sickness;
PAAD	cis	rs11585357	0.501	rs72646770	chr1:17580767	T/C	cg08277548	chr1:17600880	PADI3	-0.8	-5.99	-0.44	1.49e-8	Hair shape;
PAAD	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.63	-5.53	-0.41	1.39e-7	Mean platelet volume;
PAAD	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23994702	chr19:12833615	TNPO2	-0.69	-6.83	-0.48	1.95e-10	Lung cancer in ever smokers;
PAAD	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg07395648	chr5:131743802	NA	-0.57	-5.02	-0.38	1.41e-6	Acylcarnitine levels;
PAAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg05038881	chr1:10490043	APITD1	0.42	5.03	0.38	1.38e-6	Prostate cancer;
PAAD	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.22	0.64	5.39e-19	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.65	-5.07	-0.38	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.56	6.03	0.44	1.17e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.56	4.96	0.37	1.84e-6	Testicular germ cell tumor;
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg08057985	chr22:42470123	FAM109B	-0.36	-4.33	-0.33	2.68e-5	Schizophrenia;
PAAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg27494647	chr7:150038898	RARRES2	0.45	4.73	0.36	5.11e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.47	4.7	0.36	5.86e-6	Schizophrenia;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg15192750	chr16:69999425	NA	0.67	5.1	0.38	9.85e-7	IgE levels;
PAAD	cis	rs7631605	0.905	rs6806861	chr3:37121293	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07701084	chr6:150067640	NUP43	0.6	6.04	0.44	1.11e-8	Testicular germ cell tumor;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12923728	chr3:195709715	SDHAP1	-0.87	-9.15	-0.6	3.59e-16	Pancreatic cancer;
PAAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-4.32	-0.33	2.84e-5	Renal cell carcinoma;
PAAD	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs746265	0.818	rs62002277	chr15:39588609	G/C	cg10099207	chr15:39544144	C15orf54	0.56	4.29	0.33	3.23e-5	PR interval;
PAAD	cis	rs2281636	0.540	rs12249652	chr10:101478721	G/A	cg05149213	chr10:101381631	SLC25A28	-0.53	-5.05	-0.38	1.25e-6	Obesity-related traits;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg24543097	chr20:388556	RBCK1	0.97	7.21	0.5	2.44e-11	Lung function (FEV1/FVC);
PAAD	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.72	-5.98	-0.44	1.56e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.49	5.74	0.42	5.07e-8	Electroencephalogram traits;
PAAD	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg00647317	chr7:50633725	DDC	0.41	4.31	0.33	2.93e-5	Systemic sclerosis;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg09877947	chr5:131593287	PDLIM4	0.59	5.43	0.4	2.22e-7	Acylcarnitine levels;
PAAD	cis	rs1570884	0.539	rs7982445	chr13:50111622	C/T	cg08779649	chr13:50194554	NA	0.34	4.25	0.33	3.65e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.67	-6.88	-0.49	1.47e-10	Urate levels in lean individuals;
PAAD	cis	rs7092929	0.680	rs24401	chr10:3584829	A/G	cg14308648	chr10:3568949	NA	-0.66	-4.96	-0.37	1.83e-6	Coronary artery calcification;
PAAD	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.42	-0.52	7.73e-12	Neuroticism;
PAAD	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg21892295	chr12:121157589	UNC119B	-0.44	-4.31	-0.33	2.91e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs55728055	0.661	rs58365021	chr22:32060838	G/C	cg01338084	chr22:32026380	PISD	1.54	8.3	0.56	5.33e-14	Age-related hearing impairment;
PAAD	cis	rs6909752	0.629	rs4712695	chr6:22556680	C/T	cg13666174	chr6:22585274	NA	0.41	4.6	0.35	8.7e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	6.32	0.46	2.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs16975963	0.843	rs73041045	chr19:38296026	C/T	cg14218481	chr19:38281219	NA	0.47	4.78	0.36	4.1e-6	Longevity;
PAAD	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs34599045	0.708	rs10888519	chr1:152901858	A/T	cg02855850	chr1:152882420	IVL	-0.7	-4.42	-0.34	1.9e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg21433313	chr16:3507492	NAT15	0.92	7.36	0.51	1.08e-11	Tuberculosis;
PAAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.63	-6.42	-0.46	1.66e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6710503	0.574	rs62140850	chr2:24746900	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.57	-5.68	-0.42	6.76e-8	Height;
PAAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg25811867	chr2:3488468	NA	0.42	4.38	0.33	2.18e-5	Neurofibrillary tangles;
PAAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.9	-8.67	-0.58	5.89e-15	Asthma;
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	9.36	0.6	9.8e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00982548	chr2:198649783	BOLL	-0.8	-5.79	-0.43	3.82e-8	Ulcerative colitis;
PAAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg21951975	chr1:209979733	IRF6	0.59	5.39	0.4	2.63e-7	Coronary artery disease;
PAAD	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg06697600	chr4:7070879	GRPEL1	1.0	6.31	0.46	2.95e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.86	10.28	0.64	3.9e-19	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.39	4.05e-7	Corneal astigmatism;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg21724239	chr8:58056113	NA	0.67	5.33	0.4	3.5e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.67	6.26	0.45	3.71e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.57	4.98	0.37	1.73e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.83	8.06	0.55	2.09e-13	Vitamin D levels;
PAAD	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.9e-6	Bone mineral density;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	6.09	0.44	8.67e-9	Renal function-related traits (BUN);
PAAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	10.6	0.65	5.31e-20	Tonsillectomy;
PAAD	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.73	-6.88	-0.49	1.45e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs1883415	0.552	rs2328824	chr6:24507761	G/A	cg20631270	chr6:24437470	GPLD1	-0.51	-4.52	-0.34	1.22e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg01631408	chr1:248437212	OR2T33	-0.54	-4.85	-0.37	3.06e-6	Common traits (Other);
PAAD	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.78	-0.36	4.07e-6	Atopic dermatitis;
PAAD	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.62	7.72	0.53	1.46e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs6137287	0.924	rs6047275	chr20:21135726	A/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.53	0.35	1.16e-5	Height;
PAAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	cis	rs6700896	0.966	rs7516341	chr1:66088143	T/C	cg04111102	chr1:66153794	NA	0.43	4.65	0.35	7.2e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg20965017	chr5:231967	SDHA	-0.63	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg15447662	chr7:55979688	ZNF713	-0.56	-6.46	-0.46	1.35e-9	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11972327	chr1:8419796	RERE	-0.65	-6.56	-0.47	8.14e-10	Obesity-related traits;
PAAD	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.27e-20	Electrocardiographic conduction measures;
PAAD	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.59	-6.79	-0.48	2.32e-10	Prostate cancer;
PAAD	cis	rs507080	0.922	rs638805	chr11:118558889	G/T	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.89	-11.1	-0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.28	-4.78	-0.36	4.1e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs72627123	1.000	rs72627117	chr14:74355233	T/C	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.16	-19.25	-0.84	1.37e-42	Platelet distribution width;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.62	6.6	0.47	6.46e-10	Menarche (age at onset);
PAAD	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.5	-4.98	-0.37	1.72e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs354033	0.837	rs4727075	chr7:149187738	G/T	cg06920324	chr7:149264011	ZNF767	-0.58	-4.99	-0.38	1.61e-6	Multiple sclerosis;
PAAD	cis	rs7580658	0.588	rs2069920	chr2:128179646	T/C	cg09760422	chr2:128146352	NA	-0.35	-5.99	-0.44	1.48e-8	Protein C levels;
PAAD	cis	rs3106136	0.678	rs28437833	chr4:95280510	A/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs11105468	0.695	rs10858959	chr12:90522149	C/T	cg16962463	chr12:89968675	NA	0.45	4.66	0.35	6.84e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg14820908	chr5:178986412	RUFY1	-0.55	-5.76	-0.42	4.6e-8	Lung cancer;
PAAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.01	0.44	1.33e-8	Rheumatoid arthritis;
PAAD	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg11143131	chr5:131608246	PDLIM4	0.5	5.09	0.38	1.02e-6	Blood metabolite levels;
PAAD	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg06728252	chr6:26598149	ABT1	0.39	4.56	0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs6579837	0.656	rs59926079	chr5:150447743	A/G	cg13897374	chr5:150004783	SYNPO	0.71	4.47	0.34	1.55e-5	Sjögren's syndrome;
PAAD	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	ch.19.931598F	chr19:24232204	NA	-0.69	-6.5	-0.47	1.1e-9	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-6.05	-0.44	1.11e-8	Lymphocyte counts;
PAAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.39	0.34	2.09e-5	Bipolar disorder;
PAAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs6490294	0.571	rs35662477	chr12:112313208	A/T	cg08332908	chr17:38465326	RARA	0.77	6.34	0.46	2.53e-9	Mean platelet volume;
PAAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg19680485	chr15:31195859	MTMR15	-0.42	-4.42	-0.34	1.87e-5	Huntington's disease progression;
PAAD	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg19630374	chr17:18023558	MYO15A	-0.55	-6.11	-0.44	7.85e-9	Total body bone mineral density;
PAAD	cis	rs9659323	0.632	rs12045138	chr1:119619448	G/T	cg26570165	chr1:119541833	NA	-0.51	-5.71	-0.42	5.85e-8	Body mass index;
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16988970	chr17:42248062	ASB16	-0.33	-4.65	-0.35	7.12e-6	Total body bone mineral density;
PAAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs75920871	1.000	rs7130531	chr11:116863833	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.73	-4.38	-0.33	2.19e-5	Subjective well-being;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10827090	chr21:17252050	USP25	-0.57	-6.89	-0.49	1.42e-10	Energy expenditure (24h);
PAAD	cis	rs10490913	1.000	rs10787820	chr10:120149459	G/T	cg04126427	chr10:120840676	EIF3A	-0.47	-4.98	-0.37	1.71e-6	Cancer;
PAAD	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.56	6.58	0.47	7.16e-10	QRS complex (12-leadsum);
PAAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg09835421	chr16:68378352	PRMT7	-0.91	-7.24	-0.51	2.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.99	7.83	0.54	7.67e-13	Eosinophilic esophagitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04691540	chr1:179198414	ABL2	0.63	7.19	0.5	2.68e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.7	4.7	0.36	5.81e-6	Major depressive disorder;
PAAD	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2514805	0.892	rs2251996	chr8:95160288	G/C	cg25183890	chr8:94929275	PDP1	0.72	4.59	0.35	9.16e-6	Diisocyanate-induced asthma;
PAAD	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	0.89	8.84	0.58	2.28e-15	Exhaled nitric oxide output;
PAAD	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg06606381	chr12:133084897	FBRSL1	-1.4	-8.93	-0.59	1.3e-15	Depression;
PAAD	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26926768	chr12:34528122	NA	-0.38	-4.72	-0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs4442500	chr10:46082498	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg27394845	chr17:28928406	LRRC37B2	0.63	4.33	0.33	2.64e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.75	0.36	4.59e-6	Height;
PAAD	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	5.13	0.38	8.78e-7	Motion sickness;
PAAD	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.04	-0.38	1.29e-6	Bipolar disorder;
PAAD	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.62	-7.28	-0.51	1.64e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2421770	0.927	rs3794096	chr11:35310649	A/C	cg13971030	chr11:35366721	SLC1A2	-0.55	-6.63	-0.47	5.41e-10	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-5.79	-0.43	3.87e-8	Longevity;Endometriosis;
PAAD	cis	rs932287	0.544	rs10769986	chr11:9066100	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.49	4.66	0.35	6.97e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.56	5.38	0.4	2.8e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs7631605	0.576	rs6806158	chr3:36966067	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.69	0.36	6.14e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.7	-0.48	3.86e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03311606	chr2:173292277	ITGA6	0.61	6.8	0.48	2.19e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3745621	0.962	rs466477	chr19:47679798	T/C	cg24326880	chr19:47634349	SAE1	0.56	4.64	0.35	7.47e-6	Lymphocyte counts;
PAAD	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-6.57	-0.47	7.66e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg20283391	chr11:68216788	NA	0.55	5.28	0.39	4.29e-7	Total body bone mineral density;
PAAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg22143856	chr6:28129313	ZNF389	0.48	4.4	0.34	2.06e-5	Parkinson's disease;
PAAD	cis	rs1035491	0.715	rs2366903	chr5:63923711	G/C	cg01791865	chr5:63954708	NA	0.51	5.47	0.41	1.79e-7	Body mass index;
PAAD	cis	rs12597422	0.522	rs55835063	chr16:53881184	G/A	cg16085531	chr16:54322938	NA	-0.33	-4.5	-0.34	1.34e-5	Eyebrow thickness;
PAAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg07068956	chr7:100330872	ZAN	0.52	4.69	0.36	6.01e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7627468	0.837	rs9811123	chr3:121949292	G/A	cg03198317	chr3:121949109	CASR	0.51	4.59	0.35	9.19e-6	Kidney stones;
PAAD	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg20542592	chr8:11973495	FAM66D	0.48	4.65	0.35	7.28e-6	Retinal vascular caliber;
PAAD	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.67	-0.48	4.55e-10	Eye color traits;
PAAD	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg04501334	chr8:10513686	RP1L1	0.63	4.85	0.37	3.06e-6	Suicide;
PAAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.72	9.51	0.61	3.96e-17	Bone mineral density;
PAAD	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs12773846	0.587	rs7908284	chr10:126250069	A/G	cg04949429	chr10:126290192	LHPP	-0.53	-4.61	-0.35	8.32e-6	Subcutaneous adipose tissue;
PAAD	cis	rs1143633	1.000	rs1143633	chr2:113590467	A/G	cg06771106	chr2:113671356	IL1F7	-0.49	-4.83	-0.36	3.29e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.55	-0.52	3.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1620921	0.505	rs1991598	chr6:161204488	G/A	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-4.71	-0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs9652601	0.879	rs8062322	chr16:11092319	C/A	cg04616529	chr16:11181986	CLEC16A	0.45	4.67	0.35	6.66e-6	Systemic lupus erythematosus;
PAAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg02841227	chr6:26021843	HIST1H4A	0.51	5.14	0.38	8.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.66	-4.89	-0.37	2.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	0.98	6.9	0.49	1.29e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs55728055	1.000	rs55728055	chr22:32093268	G/C	cg01338084	chr22:32026380	PISD	1.53	8.44	0.57	2.27e-14	Age-related hearing impairment;
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-4.54	-0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.09e-11	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15714321	chr21:38739180	DYRK1A	0.58	6.68	0.48	4.29e-10	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.9	11.51	0.68	1.93e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg16205897	chr5:131564050	P4HA2	-0.43	-4.66	-0.35	6.78e-6	Blood metabolite levels;
PAAD	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg14458575	chr2:238380390	NA	0.69	7.37	0.51	1.02e-11	Prostate cancer;
PAAD	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-8.85	-0.58	2.13e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg08717414	chr16:71523259	ZNF19	-0.51	-4.69	-0.36	6.16e-6	Blood protein levels;
PAAD	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg21479132	chr6:26055353	NA	1.0	6.44	0.46	1.5e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.99	0.38	1.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.41	0.61	7.34e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7894051	1.000	rs2185746	chr10:135195332	A/G	cg24905316	chr10:135186343	ECHS1	-0.73	-4.45	-0.34	1.65e-5	Lifespan;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.23	-0.39	5.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4740619	1.000	rs4740619	chr9:15634326	T/C	cg14451791	chr9:16040625	NA	-0.37	-4.34	-0.33	2.63e-5	Body mass index;
PAAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg11380483	chr2:127933992	NA	-0.48	-4.96	-0.37	1.9e-6	Self-rated health;
PAAD	cis	rs7979473	1	rs7979473	chr12:121420260	A/G	cg02403541	chr12:121454288	C12orf43	-0.47	-4.92	-0.37	2.2e-6	C-reactive protein;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	5.91	0.43	2.14e-8	Height;
PAAD	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg03999872	chr20:62272968	STMN3	0.69	6.13	0.45	7.25e-9	Atopic dermatitis;
PAAD	cis	rs863345	0.967	rs10797017	chr1:158468485	G/A	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg12560992	chr17:57184187	TRIM37	0.68	5.1	0.38	1e-6	Vitamin D levels;
PAAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg09324608	chr17:30823087	MYO1D	0.47	4.67	0.35	6.48e-6	Schizophrenia;
PAAD	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.42	-6.38	-0.46	2e-9	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs75920871	0.702	rs11216162	chr11:116728277	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.75	5.04	0.38	1.33e-6	Subjective well-being;
PAAD	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-4.79	-0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13944286	chr17:73201579	NUP85	0.64	6.52	0.47	9.88e-10	Obesity-related traits;
PAAD	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2017305	0.915	rs77659857	chr10:70684361	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-8.58	-0.57	1.01e-14	Alzheimer's disease;
PAAD	cis	rs6787391	0.545	rs7645905	chr3:4758244	T/G	cg11584376	chr3:4789075	ITPR1	-0.47	-5.16	-0.39	7.54e-7	Breast cancer;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8016982	0.662	rs1864169	chr14:81670033	G/T	cg01989461	chr14:81687754	GTF2A1	0.56	4.37	0.33	2.3e-5	Schizophrenia;
PAAD	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.72	-7.46	-0.52	6.06e-12	Type 2 diabetes;
PAAD	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16579770	chr16:72058938	DHODH	0.38	4.41	0.34	1.94e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs9815354	1.000	rs7648357	chr3:41849670	A/G	cg03022575	chr3:42003672	ULK4	0.81	6.13	0.45	7.34e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg24220031	chr2:73402428	NA	-0.3	-4.4	-0.34	2.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.46	-4.53	-0.34	1.18e-5	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs7264396	0.887	rs224347	chr20:34037523	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11781344	chr5:133706657	UBE2B	0.59	6.29	0.45	3.18e-9	Pancreatic cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06445428	chr5:176433245	UIMC1	0.57	6.46	0.46	1.37e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.98	12.95	0.72	2.56e-26	Menarche (age at onset);
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg16040993	chr19:53496440	ZNF702P	-0.46	-4.61	-0.35	8.53e-6	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02945294	chr17:2206979	SRR;SMG6	0.63	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.66	-0.35	6.89e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.92	10.79	0.66	1.61e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.83	-0.48	1.95e-10	Capecitabine sensitivity;
PAAD	cis	rs9283706	0.950	rs10053810	chr5:66281898	C/G	cg11590213	chr5:66331682	MAST4	-0.46	-4.28	-0.33	3.3e-5	Coronary artery disease;
PAAD	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.55	7.24	0.51	2.1e-11	IgA nephropathy;
PAAD	trans	rs8177376	0.727	rs651034	chr11:126201458	A/G	cg02219016	chr2:44222742	LRPPRC	0.72	6.32	0.46	2.82e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg13256891	chr4:100009986	ADH5	0.53	5.25	0.39	5.15e-7	Alcohol dependence;
PAAD	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	0.93	6.03	0.44	1.22e-8	Fat distribution (HIV);
PAAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.82	7.4	0.51	8.6e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.04	-0.67	3.48e-21	Ulcerative colitis;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.53	4.84	0.37	3.11e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12043302	0.945	rs2898914	chr1:7063696	G/T	cg05591769	chr1:6197050	CHD5	-0.55	-4.32	-0.33	2.86e-5	Gestational age at birth in labor-initiated deliveries (child effect);
PAAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg19257562	chr1:2043853	PRKCZ	0.49	5.99	0.44	1.49e-8	Height;
PAAD	cis	rs988913	0.581	rs3125269	chr6:54858449	G/C	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17524151	chr16:475494	RAB11FIP3	-0.58	-6.65	-0.47	4.86e-10	Body fat percentage;
PAAD	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg00531865	chr16:30841666	NA	-0.56	-4.26	-0.33	3.62e-5	Dementia with Lewy bodies;
PAAD	cis	rs7561149	1.000	rs7591782	chr2:179693013	C/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.54	5.26	0.39	4.84e-7	QT interval;
PAAD	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.57	-6.6	-0.47	6.5e-10	Coronary artery disease;
PAAD	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.78	8.04	0.55	2.35e-13	Body mass index;
PAAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.98e-13	Rheumatoid arthritis;
PAAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg07153921	chr17:41440717	NA	-0.42	-4.46	-0.34	1.57e-5	Menopause (age at onset);
PAAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.96	0.63	2.65e-18	Cognitive function;
PAAD	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg24623649	chr8:11872141	NA	-0.45	-4.41	-0.34	1.97e-5	Monocyte count;
PAAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.59	-7.24	-0.51	2.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg10616300	chr11:66138557	SLC29A2	-0.33	-4.36	-0.33	2.43e-5	Educational attainment (years of education);
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13560548	chr3:10150139	C3orf24	0.61	5.56	0.41	1.19e-7	Alzheimer's disease;
PAAD	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	1.1	8.76	0.58	3.66e-15	Iron status biomarkers;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg21395723	chr22:39101663	GTPBP1	-0.41	-4.34	-0.33	2.54e-5	Menopause (age at onset);
PAAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.71	0.36	5.44e-6	Melanoma;
PAAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.96	-10.82	-0.66	1.34e-20	Tonsillectomy;
PAAD	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg20487152	chr13:99095054	FARP1	-0.49	-4.83	-0.36	3.32e-6	Longevity;
PAAD	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.84	-6.46	-0.46	1.35e-9	Lung adenocarcinoma;
PAAD	cis	rs4668356	0.730	rs73027271	chr2:171910256	T/C	cg13882835	chr2:172017928	TLK1	0.92	5.37	0.4	2.83e-7	Cognitive performance;
PAAD	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.48	-5.02	-0.38	1.44e-6	Menopause (age at onset);
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.47	4.73	0.36	5.14e-6	Lymphocyte counts;
PAAD	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-4.27	-0.33	3.43e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02711726	chr17:80685570	FN3KRP	0.49	4.86	0.37	2.88e-6	Glycated hemoglobin levels;
PAAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.27	0.56	6.12e-14	Schizophrenia;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.69	7.66	0.53	2.02e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg03983715	chr16:68378420	PRMT7	0.91	6.37	0.46	2.19e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.58	-5.54	-0.41	1.33e-7	Schizophrenia;
PAAD	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.92	-0.59	1.37e-15	Morning vs. evening chronotype;
PAAD	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg04907244	chr7:22894795	SNORD93	-0.38	-4.37	-0.33	2.31e-5	Fibrinogen;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg12310025	chr6:25882481	NA	0.43	4.26	0.33	3.6e-5	Schizophrenia;
PAAD	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg15571903	chr15:79123663	NA	0.43	5.28	0.39	4.43e-7	Coronary artery disease;
PAAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.69	8.12	0.55	1.51e-13	Multiple sclerosis;
PAAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-1.39	-10.36	-0.64	2.35e-19	Schizophrenia;
PAAD	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06074314	chr2:70475575	TIA1	0.64	7.29	0.51	1.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6594713	0.643	rs59195845	chr5:112738011	C/T	cg12552261	chr5:112820674	MCC	0.67	5.29	0.39	4.11e-7	Brain cytoarchitecture;
PAAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	9.68	0.62	1.46e-17	Platelet count;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.58	-6.03	-0.44	1.21e-8	Body mass index;
PAAD	cis	rs7172971	0.688	rs4924616	chr15:42369256	A/C	cg07013680	chr15:42186124	SPTBN5	0.53	4.4	0.34	2.01e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.47	-0.34	1.52e-5	Bipolar disorder;
PAAD	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.71	7.8	0.53	8.96e-13	Schizophrenia;
PAAD	cis	rs2271316	0.587	rs11078659	chr17:6903944	G/A	cg02493798	chr17:6899577	ALOX12	0.49	5.17	0.39	7.29e-7	Blood metabolite levels;
PAAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.31	0.56	4.82e-14	Homoarginine levels;
PAAD	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg16964102	chr10:135390573	NA	0.41	4.46	0.34	1.58e-5	Obesity-related traits;
PAAD	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.43	5.58	0.41	1.07e-7	Ulcerative colitis;
PAAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.35	-0.33	2.47e-5	Post bronchodilator FEV1;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.52e-6	Testicular germ cell tumor;
PAAD	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16576597	chr16:28551801	NUPR1	0.65	7.05	0.5	6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.61	0.41	9.48e-8	Major depressive disorder;
PAAD	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.2	13.77	0.75	1.57e-28	Post bronchodilator FEV1;
PAAD	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.31	-0.33	2.88e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs300774	1.000	rs300773	chr2:115035	C/T	cg21211680	chr2:198530	NA	-0.6	-5.55	-0.41	1.27e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg01329690	chr21:38580129	DSCR9	0.37	5.02	0.38	1.46e-6	Eye color traits;
PAAD	cis	rs4765663	1.000	rs11062103	chr12:2178165	A/G	cg24952640	chr12:3108225	TEAD4	-0.59	-4.48	-0.34	1.44e-5	Aortic root size;
PAAD	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21561701	chr13:114193150	TMCO3	0.57	6.67	0.48	4.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.92	8.31	0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs56046484	0.956	rs35885781	chr15:85591083	A/T	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.65	0.57	6.75e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.71	9.25	0.6	1.91e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.63	-4.7	-0.36	5.71e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.89	-0.37	2.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.73	8.45	0.57	2.19e-14	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.72	-5.31	-0.4	3.77e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg23958373	chr8:599963	NA	-1.2	-8.07	-0.55	1.99e-13	IgG glycosylation;
PAAD	cis	rs7009110	0.706	rs13253128	chr8:81265092	A/T	cg21158561	chr8:81178149	NA	0.44	4.59	0.35	9.17e-6	Asthma and hay fever;
PAAD	cis	rs8016982	0.520	rs17111601	chr14:81717808	C/T	cg01989461	chr14:81687754	GTF2A1	-0.62	-4.63	-0.35	7.71e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.1	-0.55	1.71e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2004318	1.000	rs77583653	chr19:55134747	T/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.76	0.36	4.46e-6	Electroencephalogram traits;
PAAD	cis	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg27411982	chr8:10470053	RP1L1	0.48	5.62	0.41	8.82e-8	Neuroticism;
PAAD	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.68	6.57	0.47	7.39e-10	Coronary artery disease;
PAAD	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg00540400	chr15:79124168	NA	-0.62	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg23752985	chr2:85803571	VAMP8	0.6	6.4	0.46	1.82e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14169450	chr9:139327907	INPP5E	0.56	5.61	0.41	9.41e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.43	4.75	0.36	4.67e-6	Refractive error;
PAAD	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.87	4.71	0.36	5.5e-6	Childhood ear infection;
PAAD	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs621942	0.718	rs568755	chr11:85806262	C/T	cg07180834	chr11:85838833	NA	0.47	4.88	0.37	2.68e-6	Tourette syndrome;
PAAD	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-8.48	-0.57	1.89e-14	Vitiligo;
PAAD	cis	rs1595825	0.732	rs4589750	chr2:198426003	C/T	cg00982548	chr2:198649783	BOLL	-0.66	-4.3	-0.33	3.04e-5	Ulcerative colitis;
PAAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.89e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.55	-6.99	-0.49	7.95e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.76	7.99	0.54	3.19e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs2882667	0.690	rs288025	chr5:138223633	A/G	cg09476006	chr5:138032270	NA	0.46	5.66	0.42	7.43e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	4.34	0.33	2.57e-5	Refractive astigmatism;
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.83	7.33	0.51	1.3e-11	Recombination rate (females);
PAAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	7.19	0.5	2.71e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.69	7.31	0.51	1.39e-11	Type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11587315	chr1:223254976	NA	0.6	6.43	0.46	1.59e-9	Myopia (pathological);
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg11995313	chr8:8860691	ERI1	0.43	4.3	0.33	3e-5	Mood instability;
PAAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.52	5.11	0.38	9.68e-7	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-6.63	-0.47	5.66e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4751058	0.526	rs10764842	chr10:130861658	A/C	cg09559163	chr10:130298860	NA	0.39	4.55	0.35	1.07e-5	Vitamin D levels;
PAAD	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.66	-6.8	-0.48	2.29e-10	Height;
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs8077577	0.747	rs35738574	chr17:18151424	C/G	cg16794390	chr17:18148240	FLII	0.53	4.56	0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	4.62	0.35	8.11e-6	Bipolar disorder;
PAAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg14343924	chr8:8086146	FLJ10661	0.53	4.67	0.35	6.52e-6	Mood instability;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.53	-5.98	-0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-1.1	-10.56	-0.65	7e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.6	5.44	0.4	2.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs4938096	1.000	rs11214959	chr11:114214433	T/C	cg00557402	chr11:114466517	FAM55D	0.71	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.32	14.28	0.76	7.04e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	4.88	0.37	2.69e-6	Iron status biomarkers;
PAAD	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02543470	chr2:105862877	NA	-0.54	-5.24	-0.39	5.32e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.81	5.62	0.41	8.94e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.76	0.58	3.63e-15	Lung cancer;
PAAD	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg25208724	chr1:156163844	SLC25A44	1.03	12.95	0.72	2.57e-26	Testicular germ cell tumor;
PAAD	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	1.05	12.98	0.73	2.15e-26	Breast cancer;
PAAD	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.93	11.64	0.69	8.52e-23	Height;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.43	-6.55	-0.47	8.18e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg04415270	chr2:102091202	RFX8	-0.58	-7.38	-0.51	9.84e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6066835	1.000	rs6066820	chr20:47318444	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.75	0.36	4.71e-6	Multiple myeloma;
PAAD	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.73	6.58	0.47	7.28e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-1.14	-11.03	-0.67	3.66e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.583	rs2760737	chr17:2024647	C/T	cg16513277	chr17:2031491	SMG6	-0.65	-6.79	-0.48	2.31e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.69	7.26	0.51	1.89e-11	Menopause (age at onset);
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.69	7.86	0.54	6.48e-13	Longevity;Endometriosis;
PAAD	cis	rs2481665	0.775	rs2476201	chr1:62619960	C/T	cg18591186	chr1:62594603	INADL	0.64	5.56	0.41	1.17e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg10544611	chr16:67998164	SLC12A4	-0.75	-4.4	-0.34	2.07e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.47	-4.54	-0.35	1.12e-5	Coronary artery disease;
PAAD	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	1.01	13.3	0.73	3.02e-27	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.31	8.91	0.59	1.43e-15	Diabetic retinopathy;
PAAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg07883600	chr3:53528162	CACNA1D	-0.4	-4.31	-0.33	2.94e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21535655	chr11:58601627	GLYATL2	-0.62	-6.81	-0.48	2.12e-10	Obesity-related traits;
PAAD	cis	rs2016586	0.802	rs5999972	chr22:36115542	A/C	cg26342177	chr22:36113512	APOL5	-0.49	-4.83	-0.37	3.23e-6	Body mass index;
PAAD	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg12193833	chr17:30244370	NA	-0.65	-5.41	-0.4	2.42e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg20965017	chr5:231967	SDHA	-0.6	-4.41	-0.34	1.93e-5	Breast cancer;
PAAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg21565972	chr17:80109576	CCDC57	0.48	5.2	0.39	6.31e-7	Life satisfaction;
PAAD	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-7.16	-0.5	3.25e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.54e-6	Bipolar disorder;
PAAD	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.79	-5.48	-0.41	1.72e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.37	0.4	2.84e-7	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12875760	chr11:126935684	NA	-0.58	-6.33	-0.46	2.64e-9	Obesity-related traits;
PAAD	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.65	5.94	0.43	1.84e-8	Obesity-related traits;
PAAD	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.62	6.02	0.44	1.25e-8	White matter hyperintensity burden;
PAAD	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.08	-0.44	9.13e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs1692120	0.669	rs61898510	chr11:61425464	T/C	cg23038520	chr11:61406508	RPLP0P2	0.49	5.64	0.42	8.17e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.4	5.01	0.38	1.5e-6	Pulmonary function;
PAAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg17372223	chr3:52568218	NT5DC2	0.55	5.72	0.42	5.42e-8	Electroencephalogram traits;
PAAD	cis	rs818427	0.593	rs448613	chr5:112210966	T/C	cg06941702	chr5:112196734	SRP19	-0.53	-5.05	-0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	1.01	6.51	0.47	1.05e-9	Type 2 diabetes;
PAAD	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.8	9.76	0.62	9.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.43	4.75	0.36	4.76e-6	Life satisfaction;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.24	-0.39	5.38e-7	Pulmonary function;
PAAD	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.6	6.3	0.46	3.01e-9	Lewy body disease;
PAAD	cis	rs7577696	0.888	rs494569	chr2:32469622	A/T	cg02381751	chr2:32503542	YIPF4	0.43	4.74	0.36	4.98e-6	Inflammatory biomarkers;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg16898833	chr6:26189333	HIST1H4D	0.87	4.7	0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.59	-0.47	6.64e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.74	-8.75	-0.58	3.7e-15	Body mass index;
PAAD	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9308433	0.733	rs11120300	chr1:214509499	A/T	cg06198575	chr1:214491504	SMYD2	-0.48	-4.77	-0.36	4.34e-6	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13939156	chr17:80058883	NA	-0.4	-4.34	-0.33	2.63e-5	Life satisfaction;
PAAD	cis	rs7487075	0.619	rs7488450	chr12:46821038	T/C	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg05132306	chr1:1846340	CALML6	-0.42	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-5.94	-0.43	1.87e-8	Obesity (extreme);
PAAD	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9488822	0.585	rs529574	chr6:116268158	T/A	cg18764771	chr6:116381957	FRK	-0.26	-4.25	-0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs73206853	0.841	rs56076213	chr12:110572913	G/A	cg12870014	chr12:110450643	ANKRD13A	0.71	4.47	0.34	1.55e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.5	-4.41	-0.34	1.94e-5	Blood metabolite levels;
PAAD	cis	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.47	0.41	1.78e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.86	-0.49	1.64e-10	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.58	-7.51	-0.52	4.77e-12	Lewy body disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25064910	chr4:39408416	KLB	-0.41	-6.56	-0.47	7.77e-10	Obesity-related traits;
PAAD	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08484944	chr1:222817468	MIA3	0.56	6.36	0.46	2.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12431939	0.626	rs7350715	chr14:51717060	C/A	cg23942311	chr14:51606299	NA	0.53	4.71	0.36	5.44e-6	Cancer;
PAAD	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg22517653	chr1:2918612	NA	-0.66	-5.37	-0.4	2.9e-7	Plateletcrit;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg26174226	chr8:58114915	NA	-0.56	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.48	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.82	-9.8	-0.62	7.24e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06586915	chr7:65958596	NA	0.59	6.52	0.47	9.65e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7132746	0.620	rs61928910	chr12:86195948	A/G	cg18827107	chr12:86230957	RASSF9	-0.55	-4.57	-0.35	1.02e-5	Lewy body disease;
PAAD	cis	rs28655083	0.879	rs1502444	chr16:77059172	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-4.28	-0.33	3.26e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg26929247	chr19:58907184	NA	0.4	4.52	0.34	1.21e-5	Uric acid clearance;
PAAD	cis	rs4234284	1.000	rs732410	chr3:126946339	G/A	cg27326032	chr3:127006922	NA	-0.47	-4.7	-0.36	5.77e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs78761021	0.867	rs17743194	chr17:9788251	A/G	cg26853458	chr17:9805074	RCVRN	-0.7	-7.96	-0.54	3.72e-13	Type 2 diabetes;
PAAD	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.89	7.34	0.51	1.22e-11	Gastritis;
PAAD	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg02841227	chr6:26021843	HIST1H4A	0.44	4.34	0.33	2.64e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg05342682	chr7:94953680	PON1	0.53	4.71	0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg02353165	chr6:42928485	GNMT	0.61	4.81	0.36	3.59e-6	Blood protein levels;
PAAD	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.53	4.27	0.33	3.4e-5	HDL cholesterol;
PAAD	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.43	0.34	1.79e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3764400	0.567	rs208011	chr17:46258345	A/G	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	5.15	0.39	8.14e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg26904215	chr21:47823096	PCNT	-0.91	-4.98	-0.37	1.74e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg19442545	chr10:75533431	FUT11	-0.43	-4.37	-0.33	2.33e-5	Inflammatory bowel disease;
PAAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.65	-6.11	-0.44	8.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs501916	1.000	rs501916	chr15:48053229	C/A	cg16110827	chr15:48056943	SEMA6D	-0.41	-4.51	-0.34	1.3e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.83	0.36	3.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.38	-7.44	-0.52	6.74e-12	Mean corpuscular volume;
PAAD	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	trans	rs901683	1.000	rs71496619	chr10:46068095	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	7.28	0.51	1.65e-11	Response to antipsychotic treatment;
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.48	0.47	1.2e-9	Platelet count;
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.56	7.41	0.52	8.07e-12	Hypertriglyceridemia;
PAAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3177980	0.560	rs73026243	chr1:169880031	G/T	cg18229820	chr1:169693534	SELE	0.51	4.48	0.34	1.45e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	1.04	15.52	0.78	3.68e-33	Height;
PAAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.74	0.58	4.03e-15	Homoarginine levels;
PAAD	cis	rs2005	0.686	rs58707510	chr6:35044746	C/T	cg05235151	chr6:35108114	TCP11	0.65	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg17372223	chr3:52568218	NT5DC2	0.46	4.43	0.34	1.78e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	5.75	0.42	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.55	6.92	0.49	1.21e-10	Renal cell carcinoma;
PAAD	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.52	-4.85	-0.37	3.03e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.51	-6.63	-0.47	5.49e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.75	-8.44	-0.56	2.31e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg08677398	chr8:58056175	NA	0.61	4.35	0.33	2.45e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.46	-4.43	-0.34	1.78e-5	Inflammatory bowel disease;
PAAD	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.79	7.26	0.51	1.84e-11	Gout;
PAAD	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.51	-5.06	-0.38	1.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	4.97	0.37	1.81e-6	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13560548	chr3:10150139	C3orf24	-0.57	-5.04	-0.38	1.29e-6	Alzheimer's disease;
PAAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.86	-9.1	-0.59	4.63e-16	Menopause (age at onset);
PAAD	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.77	9.25	0.6	1.98e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.96	-11.42	-0.68	3.34e-22	Chronic sinus infection;
PAAD	cis	rs10991814	0.920	rs7856555	chr9:94001263	A/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.41	-4.67	-0.35	6.51e-6	Refractive error;
PAAD	cis	rs6494488	0.500	rs72744725	chr15:65023953	T/C	cg16425858	chr15:64791681	ZNF609	0.94	5.05	0.38	1.28e-6	Coronary artery disease;
PAAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg15847926	chr7:2749597	AMZ1	-0.38	-4.67	-0.35	6.59e-6	Height;
PAAD	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.86	9.96	0.63	2.7e-18	Resting heart rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01244034	chr16:25078253	NA	0.69	7.24	0.51	2.03e-11	Myopia (pathological);
PAAD	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.74	6.78	0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg18944383	chr4:111397179	ENPEP	0.73	8.43	0.56	2.52e-14	Height;
PAAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.59	6.17	0.45	5.83e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.62	-6.67	-0.48	4.4e-10	High light scatter reticulocyte count;
PAAD	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	4.85	0.37	3.01e-6	Parkinson's disease;
PAAD	cis	rs3736485	0.966	rs2414113	chr15:51903896	C/T	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.51e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.86	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs56379725	1	rs56379725	chr7:43859415	A/AT	cg26645494	chr7:44153500	AEBP1	-0.67	-4.34	-0.33	2.59e-5	Peak insulin response;
PAAD	cis	rs17023223	0.537	rs2794313	chr1:119587440	T/C	cg17326555	chr1:119535693	NA	-0.42	-5.14	-0.38	8.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.13	0.5	3.81e-11	Eye color traits;
PAAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.18	0.39	7e-7	Tonsillectomy;
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg11941060	chr3:133502564	NA	-0.49	-5.03	-0.38	1.34e-6	Iron status biomarkers;
PAAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.23	-0.56	7.92e-14	Height;
PAAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.62	6.6	0.47	6.4e-10	Multiple sclerosis;
PAAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.58e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs12148477	0.787	rs35463563	chr15:51654961	G/A	cg25905881	chr15:51634250	GLDN	0.41	4.29	0.33	3.19e-5	Follicule stimulating hormone;
PAAD	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.86	10.09	0.63	1.24e-18	Resting heart rate;
PAAD	cis	rs2885056	0.891	rs892081	chr19:10680684	G/T	cg06392426	chr19:10676186	KRI1	0.6	5.94	0.43	1.85e-8	Red cell distribution width;
PAAD	cis	rs11051970	0.879	rs2733682	chr12:32574608	G/A	cg24626660	chr12:32551988	NA	0.38	4.29	0.33	3.2e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.52	4.83	0.36	3.31e-6	Height;
PAAD	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	trans	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	4.29	0.33	3.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2421770	0.594	rs10836357	chr11:35285048	G/T	cg13971030	chr11:35366721	SLC1A2	-0.43	-5.29	-0.39	4.27e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs4538187	0.660	rs67615384	chr2:64133432	T/C	cg08613950	chr2:64719184	NA	0.71	4.27	0.33	3.43e-5	Systolic blood pressure;
PAAD	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs3126085	0.560	rs11204987	chr1:152342869	G/A	cg26876637	chr1:152193138	HRNR	-0.67	-5.02	-0.38	1.44e-6	Atopic dermatitis;
PAAD	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.11	0.63	1.04e-18	Cognitive test performance;
PAAD	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.3	-0.33	3.08e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.67	-6.35	-0.46	2.38e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.46	0.52	6.17e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg18769074	chr3:133464867	TF	-0.41	-4.76	-0.36	4.48e-6	Iron status biomarkers;
PAAD	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.62	6.03	0.44	1.21e-8	White matter hyperintensity burden;
PAAD	cis	rs17681684	0.521	rs12150554	chr17:9753370	T/C	cg26853458	chr17:9805074	RCVRN	0.74	7.68	0.53	1.77e-12	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg21479132	chr6:26055353	NA	0.92	5.2	0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.83	8.62	0.57	8.18e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs1032355	0.558	rs41275715	chr4:100533913	C/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.64	-6.34	-0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg05373962	chr22:49881684	NA	-0.55	-5.17	-0.39	7.35e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.9	-0.37	2.45e-6	Schizophrenia;
PAAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.75	8.66	0.57	6.3e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.47	4.55	0.35	1.1e-5	Blood pressure;
PAAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg06714761	chr1:201096289	NA	-0.29	-4.53	-0.34	1.19e-5	Permanent tooth development;
PAAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs1419980	0.730	rs11054868	chr12:7770601	A/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4130590	0.966	rs6478770	chr9:130112231	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.54	4.95	0.37	1.96e-6	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18621852	chr3:10150065	C3orf24	0.67	5.83	0.43	3.14e-8	Alzheimer's disease;
PAAD	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg01631408	chr1:248437212	OR2T33	0.56	5.08	0.38	1.11e-6	Common traits (Other);
PAAD	trans	rs10500871	0.622	rs11025430	chr11:20213955	C/T	cg02956962	chr6:161097311	NA	0.56	6.29	0.45	3.22e-9	Educational attainment;
PAAD	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.32e-14	Hemoglobin concentration;
PAAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs859767	0.741	rs1516991	chr2:135370052	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.48	-0.34	1.47e-5	Neuroticism;
PAAD	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.56	-5.19	-0.39	6.55e-7	Mosquito bite size;
PAAD	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.36	3.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs111342015	0.803	rs45448395	chr6:43189645	G/A	cg17076780	chr6:43251928	TTBK1	0.64	4.55	0.35	1.1e-5	Breast cancer;
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs12304921	0.683	rs73103154	chr12:51468512	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.87	-0.37	2.76e-6	Type 2 diabetes;
PAAD	cis	rs1434579	0.897	rs2037904	chr19:44945091	A/G	cg23218533	chr19:44645662	ZNF234	-0.51	-4.3	-0.33	2.99e-5	Tuberculosis;
PAAD	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg14664628	chr15:75095509	CSK	0.48	4.63	0.35	7.77e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1198872	0.563	rs1686497	chr2:10961184	A/G	cg15705551	chr2:10952987	PDIA6	0.47	4.26	0.33	3.55e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.95	9.94	0.63	2.94e-18	Blood metabolite levels;
PAAD	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.64	-6.57	-0.47	7.63e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs16857609	0.529	rs74723351	chr2:218288217	G/A	cg15335768	chr2:218268053	DIRC3	-0.49	-5.01	-0.38	1.47e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.52	-4.99	-0.38	1.65e-6	Mortality in heart failure;
PAAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg12215294	chr3:40350768	EIF1B	0.47	4.7	0.36	5.89e-6	Renal cell carcinoma;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.88	11.0	0.67	4.62e-21	Prudent dietary pattern;
PAAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14074830	chr2:3224552	TSSC1	0.64	6.3	0.46	3.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg22403471	chr8:68256159	ARFGEF1	0.62	6.32	0.46	2.74e-9	Primary biliary cholangitis;
PAAD	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs7567389	0.719	rs6733478	chr2:127995989	C/A	cg09760422	chr2:128146352	NA	-0.38	-5.94	-0.43	1.84e-8	Self-rated health;
PAAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-4.66	-0.35	7e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg09163369	chr1:210001066	C1orf107	-0.7	-6.64	-0.47	5.11e-10	Orofacial clefts;
PAAD	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs863345	0.967	rs1857251	chr1:158512801	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-4.99	-0.38	1.65e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.21	-8.92	-0.59	1.41e-15	Alzheimer's disease;
PAAD	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.69	7.37	0.51	1.02e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.05	-0.38	1.26e-6	Neuroticism;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs8102137	0.637	rs7250406	chr19:30325379	G/A	cg27475126	chr19:30303651	CCNE1	-0.49	-5.05	-0.38	1.24e-6	Bladder cancer;
PAAD	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg20913747	chr6:44695427	NA	-0.7	-6.86	-0.49	1.62e-10	Total body bone mineral density;
PAAD	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	1.12	10.11	0.63	1.08e-18	Colorectal cancer;
PAAD	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.97	-0.44	1.63e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs1957429	0.614	rs17883073	chr14:65404059	G/A	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.5	-5.41	-0.4	2.39e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.9	-0.37	2.46e-6	Recombination rate (females);
PAAD	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg09835421	chr16:68378352	PRMT7	-0.74	-4.69	-0.36	5.98e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.44	-0.34	1.73e-5	Breast cancer;
PAAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6256	0.790	rs11607062	chr11:13591741	G/A	cg11976911	chr11:13509032	NA	-0.65	-5.06	-0.38	1.22e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs4663866	0.505	rs3739064	chr2:239176386	A/G	cg01753270	chr2:239240285	TRAF3IP1	0.44	4.28	0.33	3.29e-5	Irritable bowel syndrome;
PAAD	cis	rs2882667	0.690	rs495638	chr5:138200942	C/T	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8121916	1.000	rs6033406	chr20:12397045	A/G	cg16404259	chr20:12988931	SPTLC3	0.46	4.68	0.35	6.26e-6	Tumor necrosis factor alpha levels;
PAAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.66	7.06	0.5	5.6e-11	Blood protein levels;
PAAD	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.56	0.47	7.77e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.72	5.25	0.39	5.07e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00405494	chr9:7797524	C9orf123	-0.6	-6.61	-0.47	6.19e-10	Myopia (pathological);
PAAD	cis	rs76419734	0.558	rs72669984	chr4:106544702	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.61	0.35	8.4e-6	Post bronchodilator FEV1;
PAAD	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	1.25	10.27	0.64	3.96e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.47	-0.52	5.93e-12	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.6	6.54	0.47	8.72e-10	Morning vs. evening chronotype;
PAAD	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg21823605	chr1:152486609	CRCT1	0.53	6.0	0.44	1.36e-8	Hair morphology;
PAAD	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.84	-0.49	1.8e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs58521262	0.585	rs291772	chr19:23207386	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs13380717	0.657	rs4335778	chr16:86914742	A/G	cg00721125	chr16:87417448	FBXO31	-0.51	-4.25	-0.33	3.68e-5	Sepsis in extremely premature infants;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.58	5.29	0.39	4.22e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.69	7.39	0.51	8.98e-12	Diastolic blood pressure;
PAAD	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.53	-4.59	-0.35	9.31e-6	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg08648136	chr8:956695	NA	0.41	4.4	0.34	2.05e-5	Schizophrenia;
PAAD	cis	rs2252790	0.859	rs1204822	chr6:116563547	A/G	cg26893134	chr6:116381904	FRK	-0.29	-4.53	-0.35	1.17e-5	Fast beta electroencephalogram;
PAAD	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-4.43	-0.34	1.83e-5	Morning vs. evening chronotype;
PAAD	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.5	7.21	0.5	2.47e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4751006	0.543	rs76245329	chr10:128773697	T/C	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.44	0.65	1.42e-19	Menopause (age at onset);
PAAD	cis	rs12714314	0.756	rs11687068	chr2:1948949	A/G	cg22350835	chr2:1868857	MYT1L	0.48	4.69	0.36	6.02e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.55	5.18	0.39	6.96e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4077468	0.963	rs4951271	chr1:205913848	A/G	cg21828629	chr1:205913422	SLC26A9	-0.44	-4.78	-0.36	4.12e-6	Cystic fibrosis-related diabetes;
PAAD	cis	rs2011503	0.509	rs11668721	chr19:19760916	G/A	cg11584989	chr19:19387371	SF4	0.87	6.48	0.47	1.21e-9	Bipolar disorder;
PAAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-10.06	-0.63	1.43e-18	Coronary artery disease;
PAAD	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg08994789	chr17:28903642	LRRC37B2	0.67	5.3	0.4	3.93e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	cis	rs12967884	1.000	rs7236474	chr18:76590725	A/G	cg16859165	chr18:76601647	NA	-0.54	-4.37	-0.33	2.26e-5	Subcutaneous adipose tissue;
PAAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.78	8.98	0.59	9.5e-16	Morning vs. evening chronotype;
PAAD	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg06569542	chr10:98946673	SLIT1	0.48	4.84	0.37	3.18e-6	Monocyte count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04547205	chr19:4535357	PLIN5	0.6	6.39	0.46	1.94e-9	Myopia (pathological);
PAAD	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	6.83	0.48	1.88e-10	Eosinophil percentage of white cells;
PAAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.58	5.34	0.4	3.27e-7	Urate levels;
PAAD	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.48	-5.06	-0.38	1.18e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03276167	chr6:86388360	SNHG5;SNORD50B;SNORD50A	0.63	7.41	0.52	8.29e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6496932	0.663	rs7182814	chr15:85906071	C/T	cg19183879	chr15:85880815	NA	-0.5	-4.71	-0.36	5.6e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.7	7.83	0.54	7.69e-13	Facial morphology (factor 20);
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.72	0.42	5.56e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.5	-4.89	-0.37	2.58e-6	Red cell distribution width;
PAAD	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.4	4.46	0.34	1.56e-5	Height;
PAAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.65	-5.92	-0.43	2.1e-8	Blood metabolite levels;
PAAD	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.66	7.34	0.51	1.21e-11	Corneal astigmatism;
PAAD	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02743256	chr7:2109353	MAD1L1	-0.73	-5.13	-0.38	8.74e-7	Neuroticism;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.19	9.02	0.59	7.58e-16	Alzheimer's disease;
PAAD	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26926768	chr12:34528122	NA	0.37	4.51	0.34	1.28e-5	Morning vs. evening chronotype;
PAAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.77	8.27	0.56	6.15e-14	Mean corpuscular volume;
PAAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.93e-10	Bipolar disorder;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.07	-0.38	1.17e-6	Platelet count;
PAAD	cis	rs4291556	1.000	rs34961776	chr1:203363574	C/T	cg03511671	chr1:203019520	PPFIA4	0.85	4.4	0.34	2.05e-5	Facial morphology (factor 5, width of mouth relative to central midface);
PAAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg26695010	chr11:65641043	EFEMP2	-0.44	-4.27	-0.33	3.45e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg21906605	chr1:21766650	NBPF3	0.44	4.29	0.33	3.16e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.88	11.14	0.67	1.88e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-5.51	-0.41	1.5e-7	Personality dimensions;
PAAD	cis	rs13053817	0.950	rs12484045	chr22:29828751	A/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.14	-0.39	8.18e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.49	-5.78	-0.42	4.1e-8	Iron status biomarkers;
PAAD	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.8	7.17	0.5	3.1e-11	Exhaled nitric oxide levels;
PAAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.48	4.91	0.37	2.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.18e-8	Lung cancer;
PAAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2073300	1.000	rs6048826	chr20:23458050	C/A	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.7	7.53	0.52	4.15e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.42	-0.34	1.89e-5	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00945038	chr17:61921165	SMARCD2	-0.48	-5.73	-0.42	5.33e-8	Prudent dietary pattern;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.95	-9.76	-0.62	9.26e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.29e-6	Height;
PAAD	cis	rs2997447	0.846	rs3008226	chr1:26394997	A/C	cg24519413	chr1:26490540	NA	0.47	4.4	0.34	2.04e-5	QRS complex (12-leadsum);
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg00945038	chr17:61921165	SMARCD2	0.46	5.55	0.41	1.22e-7	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20274790	chr1:157111560	NA	-0.62	-6.49	-0.47	1.12e-9	Obesity-related traits;
PAAD	cis	rs16975963	0.843	rs73025630	chr19:38351284	G/A	cg14218481	chr19:38281219	NA	0.47	4.78	0.36	4.1e-6	Longevity;
PAAD	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.77	6.13	0.45	7.31e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg04717802	chr22:42394638	WBP2NL	-0.52	-4.44	-0.34	1.69e-5	Birth weight;
PAAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs13102973	0.899	rs7438900	chr4:135909921	T/A	cg14419869	chr4:135874104	NA	0.48	4.86	0.37	2.84e-6	Subjective well-being;
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.69	-5.34	-0.4	3.28e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08219700	chr8:58056026	NA	0.71	5.26	0.39	4.78e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg10556349	chr10:835070	NA	0.6	4.97	0.37	1.77e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.64	-0.35	7.39e-6	Resting heart rate;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs6782228	1.000	rs12495411	chr3:128395695	G/A	cg15607142	chr3:128420513	NA	-0.41	-4.41	-0.34	1.94e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-8.46	-0.57	2.11e-14	Exhaled nitric oxide output;
PAAD	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.05	-0.38	1.26e-6	Bipolar disorder;
PAAD	cis	rs4253772	0.530	rs2007791	chr22:46803469	C/A	cg09491104	chr22:46646882	C22orf40	-0.79	-4.35	-0.33	2.51e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.63	-0.79	1.93e-33	Ulcerative colitis;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10819733	chr22:24237672	NA	-0.62	-6.97	-0.49	8.94e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.94	-8.27	-0.56	6.39e-14	Alopecia areata;
PAAD	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.72	-6.89	-0.49	1.38e-10	Platelet distribution width;
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg15691649	chr6:25882328	NA	-0.55	-5.14	-0.38	8.44e-7	Blood metabolite levels;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg18209359	chr17:80159595	CCDC57	0.48	4.87	0.37	2.81e-6	Life satisfaction;
PAAD	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.46	-4.78	-0.36	4.08e-6	Motion sickness;
PAAD	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.92	0.49	1.15e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7132746	0.553	rs61928907	chr12:86194084	C/T	cg18827107	chr12:86230957	RASSF9	-0.51	-4.95	-0.37	1.92e-6	Lewy body disease;
PAAD	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg20435097	chr10:126320824	FAM53B	-0.48	-4.66	-0.35	6.97e-6	Cocaine dependence;
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg00576331	chr11:65640516	EFEMP2	0.44	4.26	0.33	3.54e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-5.23	-0.39	5.48e-7	Vitiligo;
PAAD	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.99	-0.49	8.18e-11	Hip circumference;
PAAD	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6690583	0.560	rs7522046	chr1:85544410	A/G	cg12037450	chr1:85513124	MCOLN3	-0.51	-4.62	-0.35	8.06e-6	Serum sulfate level;
PAAD	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11838688	chr11:133907229	LOC100128239	0.71	7.06	0.5	5.45e-11	Obesity-related traits;
PAAD	cis	rs9992101	0.547	rs10032549	chr4:77398015	A/G	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs7647973	0.601	rs59357103	chr3:49890967	G/A	cg24110177	chr3:50126178	RBM5	-0.63	-4.76	-0.36	4.56e-6	Menarche (age at onset);
PAAD	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.42	-5.38	-0.4	2.75e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-9.82	-0.62	6.18e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.58	6.55	0.47	8.43e-10	Testicular germ cell tumor;
PAAD	trans	rs901683	0.681	rs71494795	chr10:45987745	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.6	6.11	0.44	8.07e-9	White matter hyperintensity burden;
PAAD	cis	rs13011075	0.553	rs6546397	chr2:68630367	G/A	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.62	-6.11	-0.44	7.81e-9	Longevity;Endometriosis;
PAAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.02	-6.08	-0.44	9.51e-9	Mitochondrial DNA levels;
PAAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.72	-0.48	3.48e-10	Retinal vascular caliber;
PAAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	0.98	11.19	0.67	1.37e-21	Testicular germ cell tumor;
PAAD	cis	rs6748734	0.625	rs4563218	chr2:241820035	G/A	cg04034577	chr2:241836375	C2orf54	-0.34	-5.04	-0.38	1.3e-6	Urinary metabolites;
PAAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.73	8.34	0.56	4.24e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.63	-0.35	7.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.82	-0.43	3.37e-8	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.3	-0.4	3.96e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7729447	0.841	rs10941021	chr5:32691144	C/T	cg16267343	chr5:32710456	NPR3	0.44	4.33	0.33	2.69e-5	Blood pressure;
PAAD	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg21269045	chr12:125625041	AACS	0.47	4.75	0.36	4.73e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.66	6.34	0.46	2.54e-9	Corneal astigmatism;
PAAD	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.69	7.22	0.51	2.32e-11	Prostate cancer;
PAAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-6.8	-0.48	2.22e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.77	7.0	0.49	7.66e-11	Obesity-related traits;
PAAD	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.65	7.44	0.52	7.01e-12	Height;
PAAD	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.68	9.08	0.59	5.47e-16	Hemoglobin concentration;
PAAD	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.67	6.98	0.49	8.37e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs1075265	0.756	rs2160931	chr2:53939548	C/T	cg04546899	chr2:54196757	PSME4	0.31	4.59	0.35	9.16e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.63	6.25	0.45	3.91e-9	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22621528	chr10:118855542	NA	-0.53	-6.49	-0.47	1.15e-9	Obesity-related traits;
PAAD	cis	rs4938330	0.608	rs3882897	chr11:117091227	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg23461800	chr14:103021989	NA	-0.58	-4.39	-0.34	2.14e-5	Platelet count;
PAAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Bipolar disorder;
PAAD	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-5.19	-0.39	6.7e-7	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs66696671	0.542	rs3847488	chr10:121388960	A/T	cg26070865	chr5:959141	NA	0.35	6.29	0.45	3.18e-9	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
PAAD	cis	rs597480	0.687	rs2044392	chr11:85522332	G/A	cg11817631	chr11:85522609	SYTL2	0.51	4.47	0.34	1.55e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.08	-0.44	9.33e-9	Schizophrenia;
PAAD	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.63	6.78	0.48	2.54e-10	Neuroticism;
PAAD	cis	rs7714584	0.590	rs115823027	chr5:150265951	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs911555	0.755	rs2756128	chr14:103974964	C/T	cg12935359	chr14:103987150	CKB	0.63	6.37	0.46	2.1e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.61	-6.34	-0.46	2.47e-9	Testicular germ cell tumor;
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg23752985	chr2:85803571	VAMP8	-0.54	-6.47	-0.46	1.29e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6604026	0.656	rs2811597	chr1:93341153	G/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg07747251	chr5:1868357	NA	0.56	6.34	0.46	2.47e-9	Cardiovascular disease risk factors;
PAAD	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg05658771	chr16:89884179	FANCA	-0.89	-4.25	-0.33	3.68e-5	Skin colour saturation;
PAAD	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.85	6.89	0.49	1.36e-10	Chronic kidney disease;
PAAD	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.63	-6.11	-0.44	7.99e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.79	-8.61	-0.57	8.8e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg21546286	chr11:48923668	NA	0.56	5.92	0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg25886479	chr11:50257625	LOC441601	-0.43	-5.16	-0.39	7.61e-7	Height;
PAAD	cis	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg22926526	chr14:31028192	G2E3	0.69	6.91	0.49	1.27e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.55	-4.8	-0.36	3.8e-6	Itch intensity from mosquito bite;
PAAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg07362569	chr17:61921086	SMARCD2	0.44	4.97	0.37	1.81e-6	Height;
PAAD	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs939584	1.000	rs6755502	chr2:635721	A/G	cg03610516	chr2:642275	NA	0.59	5.37	0.4	2.89e-7	Body mass index;
PAAD	cis	rs9914578	0.573	rs7213049	chr17:2001657	C/T	cg16513277	chr17:2031491	SMG6	-0.66	-4.72	-0.36	5.34e-6	Body mass index;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.74	8.65	0.57	6.91e-15	Lung cancer;
PAAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.0	-12.14	-0.7	3.97e-24	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.43	7.34	0.51	1.17e-11	Psoriasis vulgaris;
PAAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg03909863	chr11:638404	DRD4	-0.6	-5.5	-0.41	1.58e-7	Systemic lupus erythematosus;
PAAD	cis	rs9888739	0.841	rs11864503	chr16:31331137	T/C	cg02256631	chr16:31342952	ITGAM	-0.53	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.39	-4.75	-0.36	4.61e-6	Systolic blood pressure;
PAAD	cis	rs11615916	0.790	rs73137519	chr12:62711935	A/C	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23332817	chr15:43425462	TMEM62	-0.47	-4.3	-0.33	3.1e-5	Lung cancer in ever smokers;
PAAD	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.81	8.44	0.56	2.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.63	5.57	0.41	1.15e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.59	-7.34	-0.51	1.2e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-4.5	-0.34	1.33e-5	Mean corpuscular volume;
PAAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg23346134	chr3:49453900	TCTA	0.41	4.32	0.33	2.82e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.66	-5.84	-0.43	3.03e-8	Response to diuretic therapy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19642189	chr7:86974847	TP53TG1;CROT	0.65	6.55	0.47	8.34e-10	Obesity-related traits;
PAAD	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.64	6.17	0.45	5.97e-9	Schizophrenia;
PAAD	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	1.49	8.53	0.57	1.36e-14	Cannabis dependence symptom count;
PAAD	cis	rs4704187	0.663	rs12523187	chr5:74379625	A/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg04362960	chr10:104952993	NT5C2	0.5	4.55	0.35	1.1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02985541	chr2:219472218	PLCD4	-0.31	-4.76	-0.36	4.43e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.6	-8.12	-0.55	1.49e-13	Renal cell carcinoma;
PAAD	cis	rs7619427	0.908	rs62254360	chr3:44082313	G/A	cg12796028	chr3:44040206	NA	-0.59	-4.26	-0.33	3.5e-5	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05790073	chr1:151299784	PI4KB	-0.73	-6.6	-0.47	6.41e-10	Neuroticism;
PAAD	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg26695010	chr11:65641043	EFEMP2	0.49	4.81	0.36	3.56e-6	Eosinophil percentage of white cells;
PAAD	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.75	-8.23	-0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs10736390	0.538	rs12410550	chr1:55107306	A/G	cg06007645	chr1:55107421	C1orf175	0.47	4.92	0.37	2.22e-6	Survival in pancreatic cancer;
PAAD	cis	rs12580740	0.867	rs78173461	chr12:119258478	G/A	cg13810723	chr12:119592343	SRRM4	-0.58	-4.52	-0.34	1.23e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.66	-5.52	-0.41	1.44e-7	Coronary artery disease;
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.49	4.48	0.34	1.43e-5	Total body bone mineral density;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg00166722	chr3:10149974	C3orf24	0.89	6.66	0.48	4.62e-10	Alzheimer's disease;
PAAD	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.74	10.39	0.64	1.87e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg20673841	chr7:107026890	COG5	0.5	4.34	0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.19	0.5	2.69e-11	Eosinophil percentage of white cells;
PAAD	trans	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.31	-0.46	2.96e-9	Mean corpuscular volume;
PAAD	cis	rs13248545	0.529	rs7462737	chr8:17615456	T/C	cg13252206	chr8:16970768	EFHA2	-0.57	-4.32	-0.33	2.8e-5	Yeast infection;
PAAD	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.35	0.33	2.53e-5	Height;
PAAD	cis	rs11997175	0.603	rs7016580	chr8:33824135	G/A	ch.8.33884649F	chr8:33765107	NA	0.64	6.58	0.47	7.18e-10	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11856189	chr19:16308750	AP1M1	0.66	7.03	0.5	6.58e-11	Myopia (pathological);
PAAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.95	-0.37	1.93e-6	Bipolar disorder;
PAAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.93	8.15	0.55	1.27e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.8	8.29	0.56	5.5e-14	Tuberculosis;
PAAD	cis	rs7250872	0.647	rs7259484	chr19:1813207	A/G	cg10370574	chr19:1840461	REXO1	-0.5	-4.65	-0.35	7.04e-6	Bipolar disorder;
PAAD	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.57	6.87	0.49	1.56e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg25952890	chr19:58913133	NA	0.68	5.58	0.41	1.06e-7	Mean platelet volume;
PAAD	cis	rs62025270	0.632	rs62022920	chr15:86223390	T/G	cg13263323	chr15:86062960	AKAP13	0.5	4.46	0.34	1.6e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08219700	chr8:58056026	NA	0.72	5.73	0.42	5.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg14438174	chr17:7137923	DVL2	-0.44	-4.41	-0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs7823896	1.000	rs67131445	chr8:110207419	C/T	cg02458499	chr8:110280928	NUDCD1	0.66	4.32	0.33	2.86e-5	Myopia (pathological);
PAAD	cis	rs7011049	1.000	rs72643586	chr8:53847859	A/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg11198734	chr3:53381585	DCP1A	0.61	6.7	0.48	3.79e-10	Morning vs. evening chronotype;
PAAD	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.37	-0.46	2.13e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.21	0.39	6.02e-7	Bipolar disorder;
PAAD	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg26954736	chr11:73693896	UCP2	1.25	5.29	0.39	4.23e-7	Obesity-related traits;
PAAD	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg27234864	chr13:21295941	IL17D	-0.53	-4.62	-0.35	8.21e-6	Dental caries;
PAAD	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.71	5.38	0.4	2.73e-7	Diastolic blood pressure;
PAAD	cis	rs34226255	0.957	rs6512096	chr19:16427607	A/G	cg26918011	chr19:16634068	CHERP	0.52	4.5	0.34	1.35e-5	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.77	9.16	0.6	3.36e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2004318	1.000	rs74468741	chr19:55137836	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg14171486	chr1:155139557	NA	0.33	4.46	0.34	1.61e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12614435	0.510	rs12693167	chr2:179628517	G/A	cg26153162	chr2:179751100	CCDC141	0.46	4.28	0.33	3.31e-5	Atrial fibrillation;
PAAD	cis	rs10450586	0.932	rs10767632	chr11:27318465	C/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg01489032	chr8:143877656	NA	-0.48	-5.06	-0.38	1.18e-6	Urinary tract infection frequency;
PAAD	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg00262122	chr8:11665843	FDFT1	0.53	5.0	0.38	1.57e-6	Neuroticism;
PAAD	cis	rs11700980	0.551	rs2832034	chr21:30114927	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.5	-4.72	-0.36	5.4e-6	Hypospadias;
PAAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.52	-0.47	9.83e-10	Longevity;
PAAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	0.88	4.47	0.34	1.49e-5	Schizophrenia;
PAAD	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg00684032	chr4:1343700	KIAA1530	0.59	5.88	0.43	2.46e-8	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.8	-6.82	-0.48	2.01e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11825685	0.887	rs76149265	chr11:134571697	T/C	cg06603561	chr11:134479413	NA	-0.7	-4.75	-0.36	4.59e-6	IgG glycosylation;
PAAD	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg17380795	chr3:122379686	NA	0.54	5.73	0.42	5.26e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4547160	0.821	rs949824	chr12:63482910	C/T	cg26727693	chr12:63544175	AVPR1A	-0.36	-4.27	-0.33	3.4e-5	Morning vs. evening chronotype;
PAAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.47	4.7	0.36	5.88e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.12	-0.38	9.31e-7	Mood instability;
PAAD	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg21918786	chr6:109611834	NA	-0.45	-4.91	-0.37	2.31e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg00750074	chr16:89608354	SPG7	-0.56	-5.74	-0.42	4.93e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs375066	0.935	rs423752	chr19:44423195	G/A	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.59	0.61	2.49e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.43	-0.61	6.43e-17	Response to antipsychotic treatment;
PAAD	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	6.14	0.45	6.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.73	-6.19	-0.45	5.4e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg04717802	chr22:42394638	WBP2NL	0.52	4.44	0.34	1.69e-5	Birth weight;
PAAD	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-1.19	-17.15	-0.81	2.33e-37	Gut microbiome composition (winter);
PAAD	cis	rs6494488	0.500	rs72741315	chr15:64713525	T/C	cg16425858	chr15:64791681	ZNF609	1.08	4.48	0.34	1.46e-5	Coronary artery disease;
PAAD	cis	rs6679454	0.763	rs852789	chr1:58306389	C/A	cg17491850	chr1:57888480	DAB1	-0.41	-4.38	-0.33	2.21e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-1.06	-13.71	-0.74	2.33e-28	Headache;
PAAD	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.67	8.79	0.58	2.92e-15	Birth weight;
PAAD	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.92	0.54	4.66e-13	Mean platelet volume;
PAAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg23346134	chr3:49453900	TCTA	0.4	4.28	0.33	3.26e-5	Menarche (age at onset);
PAAD	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.88e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.43	-4.41	-0.34	1.91e-5	Systemic lupus erythematosus;
PAAD	cis	rs939584	1.000	rs6744653	chr2:628524	A/G	cg03610516	chr2:642275	NA	0.63	5.78	0.42	4.08e-8	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12587386	chr11:119020099	ABCG4	-0.76	-6.32	-0.46	2.81e-9	Neuroticism;
PAAD	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.87	5.86	0.43	2.79e-8	Thyroid stimulating hormone;
PAAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg01176363	chr20:62369445	LIME1	-0.58	-5.53	-0.41	1.38e-7	Prostate cancer;
PAAD	cis	rs7129556	0.954	rs10793255	chr11:77267611	A/G	cg24456632	chr11:77314957	AQP11	-0.5	-4.36	-0.33	2.43e-5	Weight loss (gastric bypass surgery);
PAAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg18944383	chr4:111397179	ENPEP	0.77	8.47	0.57	1.99e-14	Coronary artery disease;
PAAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-4.93	-0.37	2.11e-6	Neurofibrillary tangles;
PAAD	cis	rs2274459	1.000	rs12662447	chr6:33714673	C/T	cg06253072	chr6:33679850	C6orf125	0.63	4.66	0.35	6.98e-6	Obesity (extreme);
PAAD	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.52	0.34	1.23e-5	Lung cancer;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg06815965	chr1:205818668	PM20D1	0.49	5.26	0.39	4.88e-7	Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25125898	chr5:5422196	KIAA0947	0.65	7.07	0.5	5.41e-11	Myopia (pathological);
PAAD	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg03733263	chr8:22462867	KIAA1967	-0.79	-9.33	-0.6	1.2e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13870426	chr17:30244630	NA	-0.73	-6.89	-0.49	1.41e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs131777	0.563	rs5770927	chr22:51028945	C/T	cg25309564	chr22:51001381	C22orf41	0.54	4.89	0.37	2.57e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.47	4.6	0.35	9.03e-6	Dupuytren's disease;
PAAD	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.77	9.05	0.59	6.29e-16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	10.59	0.65	5.64e-20	Cognitive test performance;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19864851	chr10:75503847	SEC24C	0.59	6.66	0.48	4.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.42	-5.59	-0.41	1.03e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.81	-6.08	-0.44	9.48e-9	Atopic dermatitis;
PAAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg18898632	chr2:242989856	NA	-0.81	-5.84	-0.43	3.11e-8	Obesity-related traits;
PAAD	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg00277334	chr10:82204260	NA	-0.58	-5.68	-0.42	6.59e-8	Post bronchodilator FEV1;
PAAD	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.56	-6.5	-0.47	1.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7714584	1.000	rs79780973	chr5:150174810	T/C	cg22134413	chr5:150180641	NA	0.95	6.39	0.46	1.92e-9	Crohn's disease;
PAAD	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09682311	chr7:23053758	FAM126A	-0.4	-4.36	-0.33	2.41e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12667521	chr19:29218732	NA	0.63	5.5	0.41	1.58e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs943466	0.955	rs2281819	chr6:33771673	T/A	cg04704449	chr6:33738291	NA	-0.53	-5.29	-0.39	4.11e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs2051773	0.567	rs7929927	chr11:17044358	T/A	cg15084286	chr11:17036142	PLEKHA7	0.56	5.03	0.38	1.37e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.65	-0.35	7.3e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.62	-6.74	-0.48	3.01e-10	Longevity;Endometriosis;
PAAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg22029157	chr1:209979665	IRF6	0.71	6.64	0.47	5.22e-10	Coronary artery disease;
PAAD	cis	rs58521262	0.585	rs2927366	chr19:23229962	A/G	cg03433597	chr19:22806448	NA	0.25	4.49	0.34	1.38e-5	Testicular germ cell tumor;
PAAD	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg10985347	chr2:127963512	CYP27C1	0.48	4.81	0.36	3.56e-6	Protein C levels;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-6.27	-0.45	3.59e-9	Lymphocyte counts;
PAAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.63	-5.47	-0.41	1.78e-7	Coronary artery disease;
PAAD	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.47	-4.29	-0.33	3.18e-5	Height;
PAAD	cis	rs7246865	0.510	rs11086051	chr19:17168590	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.69	0.42	6.35e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4356203	0.543	rs214088	chr11:17298125	C/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.5	-0.34	1.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2120019	0.786	rs12911421	chr15:75287822	C/A	cg09165964	chr15:75287851	SCAMP5	1.16	12.7	0.72	1.2e-25	Blood trace element (Zn levels);
PAAD	cis	rs7727544	0.545	rs743564	chr5:131410879	T/C	cg16205897	chr5:131564050	P4HA2	-0.46	-4.83	-0.36	3.32e-6	Blood metabolite levels;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg23708337	chr7:1209742	NA	0.57	4.37	0.33	2.26e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-8.45	-0.57	2.2e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.76	-8.07	-0.55	1.94e-13	Cognitive function;
PAAD	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.65	-7.35	-0.51	1.13e-11	Atrial fibrillation;
PAAD	cis	rs4481887	0.861	rs6676061	chr1:248443887	G/C	cg00666640	chr1:248458726	OR2T12	0.6	5.08	0.38	1.1e-6	Common traits (Other);
PAAD	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-7.68	-0.53	1.85e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg06102954	chr21:42741788	MX2	0.48	4.77	0.36	4.35e-6	Melanoma;
PAAD	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	6.34	0.46	2.49e-9	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg13047869	chr3:10149882	C3orf24	0.72	5.93	0.43	1.96e-8	Alzheimer's disease;
PAAD	cis	rs8016982	0.662	rs7144005	chr14:81656437	C/T	cg01989461	chr14:81687754	GTF2A1	0.57	4.57	0.35	9.92e-6	Schizophrenia;
PAAD	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg00786952	chr1:21763130	NA	0.56	5.56	0.41	1.19e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg19192590	chr2:178524533	PDE11A	0.43	4.45	0.34	1.68e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.63	5.04	0.38	1.33e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.27e-7	Electroencephalogram traits;
PAAD	trans	rs901683	1.000	rs4442500	chr10:46082498	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.61	-6.73	-0.48	3.23e-10	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.77	-8.14	-0.55	1.34e-13	Uric acid clearance;
PAAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.43	4.45	0.34	1.66e-5	HDL cholesterol;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.76	0.42	4.55e-8	Alzheimer's disease;
PAAD	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.79	9.04	0.59	6.74e-16	Breast cancer;
PAAD	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6922632	1.000	rs28921123	chr6:24126112	G/A	cg26194775	chr6:24126114	NRSN1	-0.74	-5.19	-0.39	6.5e-7	Information processing speed;
PAAD	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg08495239	chr10:135273341	LOC619207	-0.42	-4.36	-0.33	2.38e-5	Systemic lupus erythematosus;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.31	-0.33	2.92e-5	Aortic root size;
PAAD	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	4.28	0.33	3.24e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.67	7.52	0.52	4.48e-12	Total body bone mineral density;
PAAD	cis	rs863345	0.584	rs10797024	chr1:158497163	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg01966878	chr4:90757139	SNCA	-0.67	-5.27	-0.39	4.58e-7	Neuroticism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22351924	chr1:27994914	IFI6	0.58	6.56	0.47	7.77e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9472414	0.510	rs609699	chr6:44705266	G/A	cg18551225	chr6:44695536	NA	0.48	4.88	0.37	2.61e-6	Height;
PAAD	cis	rs17032980	0.956	rs55719437	chr2:67309787	G/A	cg02551743	chr2:66673428	MEIS1	-0.5	-4.49	-0.34	1.39e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7760535	0.597	rs9320368	chr6:111904737	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.01	-0.38	1.47e-6	Metabolic traits;
PAAD	cis	rs5498	0.809	rs1056538	chr19:10402938	G/A	cg10604476	chr19:10403908	ICAM5	0.35	4.43	0.34	1.78e-5	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-5.2	-0.39	6.45e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.84	0.54	7.21e-13	Mean platelet volume;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.65	7.27	0.51	1.77e-11	Menarche (age at onset);
PAAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.43	6.66	0.48	4.72e-10	Height;
PAAD	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.7	-6.18	-0.45	5.5e-9	Personality dimensions;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.92	11.37	0.68	4.67e-22	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22509189	chr2:225307070	NA	-0.47	-4.68	-0.36	6.17e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-1.4	-10.47	-0.65	1.2e-19	Schizophrenia;
PAAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.81	-7.58	-0.52	3.22e-12	DNA methylation (variation);
PAAD	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.44	4.95	0.37	1.99e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18252515	chr7:66147081	NA	-0.51	-4.9	-0.37	2.48e-6	Corneal structure;
PAAD	cis	rs17209837	1.000	rs66869391	chr7:87119069	G/A	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.62	-6.16	-0.45	6.09e-9	Hip circumference;
PAAD	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.6	8.57	0.57	1.09e-14	Asthma (sex interaction);
PAAD	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.99	-0.67	4.7e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.4	-5.1	-0.38	9.95e-7	Prostate cancer;
PAAD	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg25600027	chr14:23388339	RBM23	-0.47	-4.44	-0.34	1.74e-5	Cognitive ability (multi-trait analysis);
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-5.63	-0.42	8.56e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.51	-4.7	-0.36	5.91e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12753920	0.735	rs12734478	chr1:92678875	G/T	cg00856177	chr1:93645673	TMED5;CCDC18	-0.46	-4.39	-0.34	2.09e-5	Systemic lupus erythematosus;
PAAD	cis	rs3112530	1.000	rs12655396	chr5:152710988	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.83	-4.37	-0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.55	6.81	0.48	2.1e-10	Crohn's disease;
PAAD	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.72	5.22	0.39	5.8e-7	Carotid intima media thickness;
PAAD	cis	rs950881	0.932	rs13431828	chr2:102954653	C/T	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	11.94	0.7	1.33e-23	Platelet count;
PAAD	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg21929781	chr1:2537748	MMEL1	-0.5	-5.24	-0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs9287719	0.601	rs759401	chr2:10709922	G/A	cg12757816	chr2:10669957	NA	-0.43	-4.42	-0.34	1.87e-5	Prostate cancer;
PAAD	cis	rs9674544	0.556	rs9890278	chr17:47073949	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.65	-9.12	-0.59	4.27e-16	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg00253185	chr1:247542119	NA	0.56	4.64	0.35	7.63e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs76793172	1.000	rs10406609	chr19:46345208	T/G	cg13320842	chr19:46175254	GIPR	0.63	4.84	0.37	3.21e-6	Eosinophil counts;
PAAD	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.46	4.92	0.37	2.23e-6	Monocyte percentage of white cells;
PAAD	cis	rs308971	0.656	rs307558	chr3:12095130	G/A	cg02700894	chr3:12045449	SYN2	0.62	5.27	0.39	4.49e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.75	-8.66	-0.57	6.42e-15	Height;
PAAD	cis	rs2834256	0.924	rs2834244	chr21:35035012	T/A	cg14850771	chr21:34775459	IFNGR2	0.48	4.36	0.33	2.39e-5	Red cell distribution width;
PAAD	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg15654264	chr1:150340011	RPRD2	-0.49	-4.77	-0.36	4.31e-6	Migraine;
PAAD	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.36	4.5	0.34	1.34e-5	Calcium levels;
PAAD	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg19257562	chr1:2043853	PRKCZ	-0.39	-4.61	-0.35	8.51e-6	Height;
PAAD	cis	rs5751901	0.575	rs2154611	chr22:24989920	C/T	cg15363607	chr22:24998974	GGT1	-0.45	-4.51	-0.34	1.26e-5	Protein quantitative trait loci;
PAAD	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.78	6.35	0.46	2.38e-9	Gallbladder cancer;
PAAD	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.65	9.13	0.59	4.07e-16	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg05234568	chr11:5960015	NA	-0.83	-8.81	-0.58	2.59e-15	DNA methylation (variation);
PAAD	cis	rs4149423	1.000	rs13410305	chr2:108912673	C/A	cg06795125	chr2:108905320	SULT1C2	-0.47	-4.66	-0.35	6.86e-6	Lobe size;
PAAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg13722127	chr7:150037890	RARRES2	0.61	6.54	0.47	8.73e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.17	-0.45	5.96e-9	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.8	0.62	7.21e-18	Prudent dietary pattern;
PAAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.95	-9.08	-0.59	5.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.7	-5.07	-0.38	1.12e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.58	-4.34	-0.33	2.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg07930192	chr7:1003750	NA	0.6	7.85	0.54	6.87e-13	Longevity;Endometriosis;
PAAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Calcium levels;
PAAD	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.55e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.78	0.42	4.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07752472	chr3:136471634	STAG1	0.76	8.11	0.55	1.54e-13	Obesity-related traits;
PAAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07362569	chr17:61921086	SMARCD2	-0.44	-5.03	-0.38	1.34e-6	Prudent dietary pattern;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.89	-13.39	-0.74	1.69e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.54	5.85	0.43	2.95e-8	Menopause (age at onset);
PAAD	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.3	4.47	0.34	1.52e-5	Alopecia areata;
PAAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.51	5.11	0.38	9.54e-7	IgG glycosylation;
PAAD	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.93	-0.49	1.11e-10	Neuroticism;
PAAD	cis	rs9361491	0.608	rs7383685	chr6:79455982	T/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg23127183	chr11:57508653	C11orf31	-0.53	-4.55	-0.35	1.07e-5	Schizophrenia;
PAAD	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.43	0.34	1.83e-5	Breast cancer;
PAAD	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.7	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs9463078	0.625	rs3799986	chr6:44900253	C/T	cg25276700	chr6:44698697	NA	0.53	5.93	0.43	1.99e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg08057985	chr22:42470123	FAM109B	0.36	4.26	0.33	3.57e-5	Schizophrenia;
PAAD	cis	rs6142102	0.961	rs4911393	chr20:32570926	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.38	0.33	2.2e-5	Skin pigmentation;
PAAD	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg26876637	chr1:152193138	HRNR	0.79	5.83	0.43	3.24e-8	Atopic dermatitis;
PAAD	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.61	6.34	0.46	2.47e-9	Testicular germ cell tumor;
PAAD	cis	rs1499972	0.517	rs1456183	chr3:117639441	C/T	cg07612923	chr3:117604196	NA	-0.63	-5.0	-0.38	1.55e-6	Schizophrenia;
PAAD	trans	rs901683	1.000	rs77651228	chr10:46056129	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs5769765	0.720	rs9628127	chr22:50166092	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11264213	0.901	rs620956	chr1:36362162	T/C	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg21191810	chr6:118973309	C6orf204	0.48	6.06	0.44	1.02e-8	Electrocardiographic conduction measures;
PAAD	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg27211696	chr2:191398769	TMEM194B	0.44	4.4	0.34	2.02e-5	Urinary metabolites;
PAAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg12705353	chr12:122356852	WDR66	0.47	5.42	0.4	2.34e-7	Mean corpuscular volume;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.61	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.39	-5.78	-0.42	4.13e-8	Educational attainment (years of education);
PAAD	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.39	0.71	8.03e-25	Cognitive ability;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21016266	chr12:122356598	WDR66	0.56	6.15	0.45	6.67e-9	Mean corpuscular volume;
PAAD	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg02887458	chr19:19495540	GATAD2A	0.56	5.17	0.39	7.43e-7	Bipolar disorder;
PAAD	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	4.95	0.37	1.99e-6	Breast cancer;
PAAD	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-9.18	-0.6	2.98e-16	Colorectal cancer;
PAAD	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.62	-6.1	-0.44	8.43e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-4.47	-0.34	1.55e-5	Vitiligo;
PAAD	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.25	0.45	3.84e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.64	6.56	0.47	7.87e-10	Resting heart rate;
PAAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.56	0.41	1.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14211415	chr2:98612370	TMEM131	0.6	6.79	0.48	2.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.53	4.98	0.37	1.72e-6	Height;
PAAD	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.59	6.98	0.49	8.74e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs11828289	0.660	rs76421899	chr11:23242594	G/A	cg20040320	chr11:23191996	NA	-0.71	-4.7	-0.36	5.89e-6	Cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21530045	chr6:150263035	ULBP2	-0.74	-6.67	-0.48	4.55e-10	Neuroticism;
PAAD	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.27	0.56	6.4e-14	Bladder cancer;
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.21	0.39	6.04e-7	Life satisfaction;
PAAD	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg19192590	chr2:178524533	PDE11A	0.42	4.28	0.33	3.32e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.79	-7.38	-0.51	9.81e-12	Asthma;
PAAD	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.59	-4.52	-0.34	1.24e-5	Osteoarthritis;
PAAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.61	-0.35	8.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.25	-0.39	5.1e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs35160687	0.644	rs11676515	chr2:86496057	A/G	cg10973622	chr2:86423274	IMMT	-0.45	-5.0	-0.38	1.55e-6	Night sleep phenotypes;
PAAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg16257655	chr7:1659720	NA	0.43	4.33	0.33	2.72e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs9646944	0.501	rs10166330	chr2:103050390	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.53	0.34	1.19e-5	Blood protein levels;
PAAD	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg01685242	chr11:65405760	SIPA1	0.56	4.48	0.34	1.45e-5	Blood pressure (age interaction);
PAAD	cis	rs758324	0.738	rs648304	chr5:131286708	T/C	cg06307176	chr5:131281290	NA	-0.53	-4.59	-0.35	9.27e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.67	4.58	0.35	9.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.67	8.05	0.55	2.17e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg12568669	chr8:11666485	FDFT1	0.35	4.81	0.36	3.67e-6	Myopia (pathological);
PAAD	cis	rs6076065	0.723	rs4815199	chr20:23347169	G/A	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs73394838	0.590	rs5997519	chr22:30170217	G/A	cg14926439	chr22:29999402	NF2	-0.88	-4.37	-0.33	2.25e-5	Telomere length;
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.38	4.28	0.33	3.33e-5	High light scatter reticulocyte count;
PAAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7715811	1.000	rs7446025	chr5:13773800	T/A	cg07548982	chr5:13769939	DNAH5	-0.57	-5.46	-0.4	1.9e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.59	6.78	0.48	2.55e-10	HDL cholesterol levels;
PAAD	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.44	-4.46	-0.34	1.57e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.63	0.42	8.39e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.85	0.49	1.71e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg19636519	chr7:99541626	NA	0.48	5.17	0.39	7.34e-7	Coronary artery disease;
PAAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25833597	chr17:30823145	MYO1D	0.52	5.07	0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs56390503	0.832	rs10030346	chr4:187533258	C/T	cg01483139	chr4:187549458	FAT1	-0.4	-4.29	-0.33	3.15e-5	Major depressive disorder;
PAAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.88	9.54	0.61	3.39e-17	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23427998	chr5:54522784	NA	0.72	8.76	0.58	3.59e-15	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.57	-0.35	9.93e-6	Breast cancer;
PAAD	cis	rs131777	0.532	rs131747	chr22:51025074	C/T	cg00083937	chr22:51039805	MAPK8IP2	0.45	4.7	0.36	5.89e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg10556349	chr10:835070	NA	0.71	5.32	0.4	3.6e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.58	-0.35	9.79e-6	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg01503450	chr10:980765	NA	-0.54	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg18279126	chr7:2041391	MAD1L1	0.51	4.75	0.36	4.69e-6	Schizophrenia;
PAAD	cis	rs9463078	0.585	rs1284961	chr6:45172621	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg16898833	chr6:26189333	HIST1H4D	0.92	5.15	0.39	8.05e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25032375	chr2:61293268	KIAA1841	0.65	6.48	0.47	1.23e-9	Obesity-related traits;
PAAD	cis	rs939584	0.825	rs7579971	chr2:631603	C/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs508970	0.556	rs676821	chr11:60924621	C/A	cg24692310	chr11:60915630	VPS37C	0.34	4.68	0.35	6.32e-6	Rheumatoid arthritis;
PAAD	cis	rs2964802	0.505	rs7737359	chr5:10832104	A/G	cg14521931	chr5:10832172	NA	-0.48	-5.06	-0.38	1.17e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs2668423	0.922	rs2668418	chr19:1366422	C/G	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.73	-0.48	3.32e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs12282928	0.959	rs1566736	chr11:48238179	A/G	cg22827986	chr11:48284249	OR4X1	0.41	5.22	0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	11.4	0.68	3.91e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.59	-6.01	-0.44	1.35e-8	Height;
PAAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg11062466	chr8:58055876	NA	0.68	5.09	0.38	1.02e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg26031613	chr14:104095156	KLC1	0.8	8.19	0.55	9.83e-14	Body mass index;
PAAD	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg12046867	chr14:103022105	NA	-0.63	-4.98	-0.37	1.73e-6	Platelet count;
PAAD	cis	rs7772697	0.632	rs2340800	chr6:149423044	C/T	cg21368479	chr6:149415018	NA	0.41	4.3	0.33	3.01e-5	Diabetic retinopathy;
PAAD	cis	rs1345301	0.587	rs12464251	chr2:102867208	C/G	cg03938978	chr2:103052716	IL18RAP	-0.44	-4.83	-0.36	3.29e-6	Waist circumference;
PAAD	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03115019	chr17:80708279	FN3K	0.5	4.45	0.34	1.62e-5	Glycated hemoglobin levels;
PAAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17848003	chr1:3704513	LRRC47	0.41	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.5	4.81	0.36	3.55e-6	Hepatocellular carcinoma;
PAAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg06131755	chr6:160182447	ACAT2	0.54	4.81	0.36	3.6e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.73	5.39	0.4	2.61e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-7.72	-0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	trans	rs901683	1.000	rs12779637	chr10:46081096	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg24296786	chr1:45957014	TESK2	0.54	5.12	0.38	8.92e-7	Homocysteine levels;
PAAD	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.5	0.41	1.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg03094675	chr11:5960213	NA	-0.5	-4.25	-0.33	3.66e-5	DNA methylation (variation);
PAAD	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.67	-8.74	-0.58	4e-15	Schizophrenia;
PAAD	cis	rs990171	1.000	rs2110735	chr2:103050925	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg00166722	chr3:10149974	C3orf24	0.86	7.13	0.5	3.76e-11	Alzheimer's disease;
PAAD	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.65	7.1	0.5	4.37e-11	Alcohol dependence;
PAAD	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.74	-12.57	-0.71	2.72e-25	Urate levels in overweight individuals;
PAAD	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	6.9	0.49	1.3100000000000001e-10	Hip circumference;
PAAD	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg18093559	chr17:18951025	GRAP	-0.47	-4.98	-0.37	1.7e-6	Schizophrenia;
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg08835956	chr7:39171034	POU6F2	0.32	4.89	0.37	2.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.47	-5.34	-0.4	3.25e-7	Testicular germ cell tumor;
PAAD	cis	rs9810890	0.867	rs68127468	chr3:128583514	G/T	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg03983715	chr16:68378420	PRMT7	-0.72	-5.23	-0.39	5.43e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35955747	0.870	rs4820969	chr22:31773573	C/G	cg02404636	chr22:31891804	SFI1	-0.55	-5.44	-0.4	2.1e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg06606381	chr12:133084897	FBRSL1	1.26	8.03	0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.73	-0.36	5.1e-6	Lung cancer;
PAAD	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.42	-4.65	-0.35	7.06e-6	Aortic root size;
PAAD	cis	rs11122272	0.735	rs2790878	chr1:231534390	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.23	0.6	2.18e-16	Hemoglobin concentration;
PAAD	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.7	-0.36	5.82e-6	Menarche (age at onset);
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg16040993	chr19:53496440	ZNF702P	0.46	4.57	0.35	9.88e-6	Psoriasis;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	5.99	0.44	1.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.51	4.43	0.34	1.81e-5	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25550546	chr5:139682720	PFDN1	0.58	6.75	0.48	2.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg05313129	chr8:58192883	C8orf71	0.72	5.89	0.43	2.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	1.05	6.94	0.49	1.08e-10	Plateletcrit;
PAAD	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.62	5.5	0.41	1.6e-7	Eosinophil counts;
PAAD	cis	rs13102973	0.863	rs13129178	chr4:135858219	A/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg15847926	chr7:2749597	AMZ1	-0.39	-4.78	-0.36	4.07e-6	Height;
PAAD	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.45	4.27	0.33	3.47e-5	Prostate-specific antigen levels;
PAAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.38	5.24	0.39	5.24e-7	Age at first birth;
PAAD	cis	rs9815354	0.951	rs6781529	chr3:41751333	C/T	cg03022575	chr3:42003672	ULK4	0.8	5.73	0.42	5.28e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.56	-4.89	-0.37	2.58e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.6	-5.85	-0.43	2.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.7	-9.85	-0.62	5.17e-18	Breast cancer;
PAAD	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.45	-0.4	1.94e-7	Height;
PAAD	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.75	-0.48	3.01e-10	Response to antipsychotic treatment;
PAAD	trans	rs62179067	1.000	rs62177281	chr2:180025012	C/T	cg23458843	chr12:58136445	AGAP2	0.96	6.39	0.46	1.94e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23158103	chr7:148848205	ZNF398	-0.6	-5.9	-0.43	2.3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	1.01	8.33	0.56	4.51e-14	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.91	-8.53	-0.57	1.37e-14	Body mass index;
PAAD	cis	rs2073300	1.000	rs6048835	chr20:23462343	G/C	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs73206853	0.841	rs56017468	chr12:110653857	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.34e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.39	-0.34	2.14e-5	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20411547	chr4:148502509	NA	-0.59	-6.79	-0.48	2.42e-10	Obesity-related traits;
PAAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg21929781	chr1:2537748	MMEL1	0.54	5.65	0.42	7.85e-8	Ulcerative colitis;
PAAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg07148914	chr20:33460835	GGT7	-0.5	-4.75	-0.36	4.65e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.87	-9.32	-0.6	1.29e-16	Schizophrenia;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg19477001	chr10:104192319	CUEDC2	-0.82	-7.59	-0.52	2.93e-12	Blood protein levels;
PAAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg23205692	chr1:25664452	TMEM50A	-0.5	-4.9	-0.37	2.45e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg15590007	chr10:45870220	ALOX5	0.53	5.49	0.41	1.64e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.52	5.17	0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg02795151	chr17:7402630	POLR2A	0.62	5.38	0.4	2.73e-7	Androgen levels;
PAAD	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.54	-5.14	-0.39	8.16e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.41	4.97	0.37	1.8e-6	Iron status biomarkers;
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg15691649	chr6:25882328	NA	0.48	4.37	0.33	2.27e-5	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.13	0.55	1.41e-13	Menopause (age at onset);
PAAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.7	6.35	0.46	2.33e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg12615879	chr12:58013172	SLC26A10	0.51	5.58	0.41	1.08e-7	Multiple sclerosis;
PAAD	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg16447950	chr5:562315	NA	-0.52	-4.92	-0.37	2.23e-6	Obesity-related traits;
PAAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.93	-7.96	-0.54	3.61e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.45	5.0	0.38	1.57e-6	Menarche (age at onset);
PAAD	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.8	9.56	0.61	3.01e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7180079	1.000	rs1533378	chr15:64646777	A/G	cg18210365	chr15:65066710	RBPMS2	-0.64	-4.92	-0.37	2.24e-6	Monocyte count;
PAAD	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg00531865	chr16:30841666	NA	-0.49	-4.34	-0.33	2.54e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18621852	chr3:10150065	C3orf24	0.71	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.55	-6.01	-0.44	1.33e-8	Hepatitis;
PAAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.75	-9.04	-0.59	6.95e-16	Huntington's disease progression;
PAAD	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4748857	0.891	rs4747456	chr10:23571136	A/T	cg18853376	chr10:23633759	C10orf67	0.51	4.53	0.34	1.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs6988985	0.589	rs13252628	chr8:143994944	T/G	cg10324643	chr8:143916377	GML	-0.42	-4.42	-0.34	1.86e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg14343924	chr8:8086146	FLJ10661	0.54	4.6	0.35	8.78e-6	Neuroticism;
PAAD	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs507080	0.501	rs494459	chr11:118574675	A/G	cg08498647	chr11:118550644	TREH	0.42	5.21	0.39	6.01e-7	Serum metabolite levels;
PAAD	cis	rs4448343	0.892	rs28496034	chr9:98278332	C/G	cg13428213	chr9:98267529	PTCH1	0.46	4.29	0.33	3.14e-5	Height;
PAAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	10.57	0.65	6.59e-20	Cognitive test performance;
PAAD	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-5.83	-0.43	3.15e-8	Menopause (age at onset);
PAAD	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	1.25	6.02	0.44	1.23e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3736485	0.966	rs8040538	chr15:51904584	G/A	cg19558802	chr15:51695713	GLDN	-0.43	-4.28	-0.33	3.28e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.47e-16	Motion sickness;
PAAD	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.34	-0.4	3.36e-7	P wave terminal force;
PAAD	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.76	4.98	0.37	1.67e-6	Lung cancer in ever smokers;
PAAD	cis	rs7577696	0.853	rs430759	chr2:32447868	C/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.59	-0.35	9.17e-6	Inflammatory biomarkers;
PAAD	cis	rs6496667	0.642	rs12148876	chr15:91065208	G/A	cg22089800	chr15:90895588	ZNF774	0.61	4.76	0.36	4.4e-6	Rheumatoid arthritis;
PAAD	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg26116260	chr4:7069785	GRPEL1	-1.0	-5.77	-0.42	4.29e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1678618	0.559	rs1245532	chr10:73790774	G/A	cg20897136	chr10:74034667	DDIT4	0.37	4.39	0.34	2.13e-5	Smoking behavior;
PAAD	cis	rs7650267	0.572	rs78879443	chr3:43563334	T/C	cg07997066	chr3:44154910	MIR138-1	0.55	4.32	0.33	2.83e-5	Obesity-related traits;
PAAD	cis	rs1018836	0.700	rs4735201	chr8:91528313	C/T	cg16814680	chr8:91681699	NA	-0.87	-10.72	-0.66	2.56e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.99	10.71	0.66	2.73e-20	Ulcerative colitis;
PAAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.5	-0.41	1.55e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.68	-6.16	-0.45	6.1e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03079208	chr4:87855937	AFF1	0.7	6.94	0.49	1.06e-10	Obesity-related traits;
PAAD	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.78	7.83	0.54	7.64e-13	Uric acid levels;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08439880	chr3:133502540	NA	-0.46	-5.09	-0.38	1.06e-6	Iron status biomarkers;
PAAD	cis	rs7236492	0.630	rs8086439	chr18:77173038	A/G	cg15644404	chr18:77186268	NFATC1	-0.9	-5.35	-0.4	3.25e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6688613	1.000	rs1327866	chr1:166952910	C/T	cg07049167	chr1:166818506	POGK	-0.46	-4.58	-0.35	9.65e-6	Refractive astigmatism;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.43	4.33	0.33	2.72e-5	Myopia (pathological);
PAAD	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg26597838	chr10:835615	NA	0.55	5.98	0.44	1.54e-8	Survival in rectal cancer;
PAAD	cis	rs12136530	0.593	rs2314145	chr1:19736843	C/G	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs28647808	1.000	rs28709650	chr9:136276699	G/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg15956490	chr3:53032818	SFMBT1	0.79	4.49	0.34	1.42e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-4.65	-0.35	7.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.81	9.56	0.61	3.03e-17	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.43	4.58	0.35	9.62e-6	Aortic root size;
PAAD	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs35740288	0.770	rs12898597	chr15:86189919	T/C	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	4.98e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg25753631	chr6:25732923	NA	0.35	4.4	0.34	2.01e-5	Blood metabolite levels;
PAAD	cis	rs2124910	0.779	rs8100330	chr19:52039135	A/T	cg12008991	chr19:52034861	SIGLEC6	-0.35	-4.59	-0.35	9.22e-6	Blood protein levels;
PAAD	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.68	-7.38	-0.51	9.79e-12	Post bronchodilator FEV1;
PAAD	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.53	4.74	0.36	4.9100000000000004e-06	Mortality in heart failure;
PAAD	cis	rs10450586	0.932	rs10767636	chr11:27334061	T/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.68	7.82	0.54	8.03e-13	High light scatter reticulocyte count;
PAAD	cis	rs35740288	0.770	rs745191	chr15:86123170	G/T	cg07943548	chr15:86304357	KLHL25	-0.66	-5.81	-0.43	3.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.66	-7.42	-0.52	7.86e-12	Platelet distribution width;
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00684032	chr4:1343700	KIAA1530	0.46	4.82	0.36	3.39e-6	Obesity-related traits;
PAAD	cis	rs6466055	0.666	rs4730081	chr7:105006850	C/T	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.47	4.38	0.33	2.17e-5	Obesity-related traits;
PAAD	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.48	4.42	0.34	1.87e-5	Airway imaging phenotypes;
PAAD	cis	rs28595532	0.748	rs72670246	chr4:119335061	G/A	cg21605333	chr4:119757512	SEC24D	1.54	7.94	0.54	4.05e-13	Cannabis dependence symptom count;
PAAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.62	-7.08	-0.5	4.99e-11	Eye color traits;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-5.26	-0.39	4.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4478147	0.506	rs17451111	chr4:87274174	C/G	cg10685359	chr4:87814065	C4orf36	-0.52	-5.36	-0.4	2.98e-7	Migraine - clinic-based;
PAAD	cis	rs73019876	0.502	rs6511318	chr19:22245745	A/C	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs6066835	1.000	rs6066830	chr20:47353897	C/T	cg18078177	chr20:47281410	PREX1	0.98	4.93	0.37	2.11e-6	Multiple myeloma;
PAAD	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06850241	chr22:41845214	NA	-0.43	-4.27	-0.33	3.49e-5	Vitiligo;
PAAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg20243544	chr17:37824526	PNMT	0.5	4.29	0.33	3.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs72960926	0.744	rs56365866	chr6:74910810	T/C	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.55	6.88	0.49	1.49e-10	Crohn's disease;
PAAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.59	6.5	0.47	1.11e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg20628663	chr10:43360327	NA	0.81	5.72	0.42	5.41e-8	Blood protein levels;
PAAD	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19904058	chr10:135279010	LOC619207	-0.63	-7.61	-0.53	2.62e-12	Systemic lupus erythematosus;
PAAD	cis	rs12450239	0.700	rs12452149	chr17:77434840	G/A	cg09567646	chr17:76962761	NA	-0.47	-4.41	-0.34	1.96e-5	Body mass index;
PAAD	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg05283184	chr6:79620031	NA	-0.5	-5.89	-0.43	2.41e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.68	-6.67	-0.48	4.43e-10	Uric acid levels;
PAAD	cis	rs12282928	1.000	rs4980423	chr11:48258607	C/G	cg26585981	chr11:48327164	OR4S1	0.51	4.39	0.34	2.08e-5	Migraine - clinic-based;
PAAD	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.81e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.556	rs424913	chr19:23122426	G/A	cg03433597	chr19:22806448	NA	-0.25	-4.48	-0.34	1.46e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-8.95	-0.59	1.17e-15	Vitiligo;
PAAD	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg24594292	chr6:111179867	NA	0.59	7.03	0.5	6.56e-11	Body fat percentage;
PAAD	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg18551225	chr6:44695536	NA	-0.75	-7.33	-0.51	1.24e-11	Total body bone mineral density;
PAAD	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.61	-5.88	-0.43	2.56e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg24053715	chr22:38214548	NA	-0.49	-5.02	-0.38	1.4e-6	Glioblastoma;Glioma;
PAAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.89	-0.43	2.34e-8	Menarche (age at onset);
PAAD	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.9	11.74	0.69	4.54e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	5.97e-7	Ulcerative colitis;
PAAD	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1950357	0.589	rs2180090	chr14:37212140	A/T	cg14479910	chr14:36975263	SFTA3	-0.33	-4.61	-0.35	8.6e-6	Lobe attachment (rater scored);Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.49	0.41	1.64e-7	Alcohol dependence;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.39	-4.6	-0.35	8.88e-6	Lewy body disease;
PAAD	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg03938978	chr2:103052716	IL18RAP	-0.65	-8.16	-0.55	1.17e-13	Asthma;
PAAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.53	5.27	0.39	4.69e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.82	6.21	0.45	4.77e-9	Alzheimer's disease;
PAAD	trans	rs901683	0.850	rs112297763	chr10:46069436	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.36	0.46	2.23e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-10.43	-0.65	1.51e-19	Age at first birth;
PAAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg21361702	chr7:150065534	REPIN1	0.58	4.78	0.36	4.16e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	7.97	0.54	3.44e-13	Electrocardiographic conduction measures;
PAAD	cis	rs66530629	1.000	rs16829945	chr1:25040315	C/T	cg01905478	chr1:25040257	NA	0.56	5.94	0.43	1.91e-8	Plateletcrit;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg15117754	chr3:10150083	C3orf24	0.56	4.98	0.37	1.68e-6	Alzheimer's disease;
PAAD	cis	rs34156428	0.657	rs4757428	chr11:16762666	T/C	cg15111638	chr11:16631993	NA	-0.43	-4.37	-0.33	2.29e-5	Coronary artery disease;
PAAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.79	-6.88	-0.49	1.48e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.82	8.42	0.56	2.55e-14	Corneal astigmatism;
PAAD	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.67	-7.25	-0.51	2.02e-11	Blood protein levels;
PAAD	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.8	-8.73	-0.58	4.26e-15	Caffeine consumption;
PAAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.51	0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg10494973	chr17:80897199	TBCD	0.57	4.73	0.36	5.02e-6	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.67	7.64	0.53	2.29e-12	Height;
PAAD	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.92	-9.2	-0.6	2.69e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.87	-9.07	-0.59	5.81e-16	Corneal astigmatism;
PAAD	cis	rs357618	0.897	rs165362	chr5:150863087	T/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-4.51	-0.34	1.27e-5	Basophil percentage of white cells;
PAAD	cis	rs2120991	0.967	rs10876510	chr12:54266738	C/T	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.25	-0.33	3.76e-5	Biliary atresia;
PAAD	cis	rs9512730	0.906	rs4771136	chr13:28070769	C/G	cg22138327	chr13:27999177	GTF3A	0.78	5.43	0.4	2.18e-7	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.67	5.51	0.41	1.47e-7	Prostate cancer;
PAAD	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg02498382	chr2:70120550	SNRNP27	-0.47	-4.89	-0.37	2.5e-6	Breast cancer;Platelet count;
PAAD	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs6137287	0.883	rs2236178	chr20:21142813	T/C	cg04219410	chr20:21106687	PLK1S1	0.44	5.06	0.38	1.19e-6	Height;
PAAD	cis	rs294958	0.777	rs294950	chr5:151538849	T/C	cg04453665	chr5:151504455	NA	0.44	4.97	0.37	1.78e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.67	-6.59	-0.47	6.94e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs910873	0.505	rs6058099	chr20:33249134	C/T	cg16810054	chr20:33298113	TP53INP2	-0.56	-4.27	-0.33	3.45e-5	Melanoma;
PAAD	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.61	-0.35	8.57e-6	Triglycerides;
PAAD	cis	rs7188861	0.768	rs181694	chr16:11384829	C/T	cg01510278	chr16:11456238	NA	0.43	4.46	0.34	1.58e-5	HDL cholesterol;
PAAD	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.85	5.47	0.41	1.78e-7	Body mass index;
PAAD	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg27565382	chr3:53032988	SFMBT1	0.7	4.35	0.33	2.44e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06684987	chr19:45567721	SFRS16	-0.66	-7.16	-0.5	3.18e-11	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg00484396	chr16:3507460	NAT15	0.88	6.83	0.48	1.87e-10	Tuberculosis;
PAAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.68	7.89	0.54	5.64e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg00409905	chr10:38381863	ZNF37A	0.51	5.17	0.39	7.24e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	6.31	0.46	2.88e-9	Breast cancer;
PAAD	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg14388049	chr10:71211838	TSPAN15	-0.55	-5.49	-0.41	1.65e-7	Venous thromboembolism;
PAAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.92	9.12	0.59	4.33e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg18551225	chr6:44695536	NA	-0.69	-6.93	-0.49	1.1e-10	Total body bone mineral density;
PAAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.55	5.14	0.38	8.25e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13102973	0.932	rs13112935	chr4:135829379	T/C	cg14419869	chr4:135874104	NA	0.55	5.85	0.43	2.96e-8	Subjective well-being;
PAAD	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.69	-6.96	-0.49	9.67e-11	White matter hyperintensity burden;
PAAD	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.79	6.01	0.44	1.32e-8	Mean platelet volume;
PAAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	6.83	0.48	1.93e-10	Platelet count;
PAAD	cis	rs1925576	0.935	rs1916382	chr10:68656486	G/T	cg04444303	chr10:69634106	NA	-0.44	-4.41	-0.34	1.97e-5	Educational attainment (years of education);
PAAD	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg03277515	chr1:153321198	PGLYRP4	0.38	4.49	0.34	1.42e-5	Psoriasis;
PAAD	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg08027265	chr7:2291960	NA	-0.6	-5.81	-0.43	3.61e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.57	0.35	1.01e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02828054	chr19:8478160	MARCH2	-0.76	-6.51	-0.47	1.02e-9	Neuroticism;
PAAD	cis	rs322458	0.550	rs590436	chr3:120633305	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg03264133	chr6:25882463	NA	-0.54	-4.61	-0.35	8.34e-6	Iron status biomarkers;
PAAD	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.62	8.23	0.56	7.96e-14	Crohn's disease;
PAAD	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg25838818	chr2:108905173	SULT1C2	-0.48	-4.63	-0.35	7.79e-6	Blood pressure;
PAAD	cis	rs7092929	0.941	rs1890583	chr10:3590269	T/C	cg14308648	chr10:3568949	NA	0.65	4.76	0.36	4.44e-6	Coronary artery calcification;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg11062466	chr8:58055876	NA	0.66	4.56	0.35	1.06e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.57	0.35	1.02e-5	Height;
PAAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Calcium levels;
PAAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-9.92	-0.63	3.31e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.49	0.34	1.4e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	9.65	0.62	1.72e-17	Cognitive test performance;
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg05717871	chr11:638507	DRD4	-0.6	-5.38	-0.4	2.78e-7	Systemic lupus erythematosus;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-6.59	-0.47	6.81e-10	Lymphocyte counts;
PAAD	cis	rs7081476	0.737	rs7919198	chr10:27497485	G/A	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.63	8.28	0.56	5.88e-14	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21714849	chr6:126413224	NA	-0.61	-6.6	-0.47	6.32e-10	Obesity-related traits;
PAAD	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg24110177	chr3:50126178	RBM5	-0.49	-4.87	-0.37	2.75e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17866680	chr15:82338403	MEX3B	-0.68	-7.53	-0.52	4.2e-12	Smoking initiation;
PAAD	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.6	5.48	0.41	1.7e-7	Interstitial lung disease;
PAAD	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg08698997	chr16:88989212	CBFA2T3	0.48	5.71	0.42	5.68e-8	Social autistic-like traits;
PAAD	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7873102	0.654	rs2244712	chr9:37983442	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.54e-10	Total body bone mineral density;
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg05283184	chr6:79620031	NA	-0.58	-7.5	-0.52	4.84e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.16e-5	Breast cancer;
PAAD	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.57	-5.51	-0.41	1.5e-7	Primary sclerosing cholangitis;
PAAD	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	5.58	0.41	1.1e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.51	4.55	0.35	1.1e-5	Height;
PAAD	cis	rs2252790	0.640	rs1128261	chr6:116598853	A/G	cg18764771	chr6:116381957	FRK	-0.29	-4.67	-0.35	6.61e-6	Fast beta electroencephalogram;
PAAD	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	8.13	0.55	1.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.61	6.4	0.46	1.84e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.44	-0.61	6.12e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.08	0.38	1.08e-6	Restless legs syndrome;
PAAD	cis	rs6460942	0.511	rs13245890	chr7:12543134	A/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17265576	chr5:1509299	LPCAT1	0.55	6.3	0.46	3.01e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg10518543	chr12:38710700	ALG10B	0.5	4.79	0.36	3.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.77	-9.0	-0.59	8.39e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs9463078	0.625	rs1891412	chr6:44760642	T/C	cg25276700	chr6:44698697	NA	0.44	5.13	0.38	8.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs1376303	1.000	rs3801335	chr7:32956338	C/G	cg19007141	chr4:140808552	MAML3	-0.59	-6.45	-0.46	1.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.51	-0.34	1.27e-5	Fear of minor pain;
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg00576331	chr11:65640516	EFEMP2	-0.47	-4.37	-0.33	2.32e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.61	5.43	0.4	2.16e-7	Phospholipid levels (plasma);
PAAD	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.91	-0.37	2.33e-6	Type 1 diabetes;
PAAD	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.09	-6.95	-0.49	1.02e-10	Gout;
PAAD	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-5.31	-0.4	3.9e-7	Axial length;
PAAD	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg27490568	chr2:178487706	NA	-0.44	-4.85	-0.37	3.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7577696	0.962	rs11124275	chr2:32303762	T/A	cg02381751	chr2:32503542	YIPF4	-0.41	-4.37	-0.33	2.33e-5	Inflammatory biomarkers;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.91	7.95	0.54	3.99e-13	Alzheimer's disease;
PAAD	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg07884673	chr3:53033167	SFMBT1	0.74	4.5	0.34	1.33e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	-0.49	-4.35	-0.33	2.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12148477	0.787	rs35754161	chr15:51655048	G/T	cg25905881	chr15:51634250	GLDN	0.41	4.29	0.33	3.19e-5	Follicule stimulating hormone;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03358980	chr10:102770406	NA	-0.67	-6.59	-0.47	6.76e-10	Obesity-related traits;
PAAD	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.06	12.74	0.72	9.31e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg26668713	chr11:65405903	SIPA1	0.59	5.53	0.41	1.34e-7	Blood pressure (age interaction);
PAAD	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg01657329	chr11:68192670	LRP5	-0.74	-6.79	-0.48	2.39e-10	Bone mineral density;
PAAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.69	7.49	0.52	5.29e-12	Melanoma;
PAAD	cis	rs4908768	0.501	rs7518608	chr1:8557320	C/G	cg20416874	chr1:8611966	RERE	-0.45	-4.27	-0.33	3.48e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.52	-5.16	-0.39	7.76e-7	Iron status biomarkers;
PAAD	cis	rs11807834	0.522	rs754665	chr1:230250297	T/C	cg00566187	chr1:230250356	GALNT2	-0.68	-7.37	-0.51	9.97e-12	Schizophrenia;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg06332512	chr16:670800	RAB40C	-0.37	-4.33	-0.33	2.73e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21558508	chr5:133968566	SAR1B	0.64	7.16	0.5	3.16e-11	Myopia (pathological);
PAAD	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.68	-6.74	-0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.84	-0.58	2.29e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs7688540	0.511	rs11731927	chr4:174105	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.55	4.55	0.35	1.08e-5	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs773506	1.000	rs773513	chr9:93980843	G/A	cg14446406	chr9:93919335	NA	-0.31	-4.38	-0.33	2.2e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.0	-0.44	1.4e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg11802864	chr11:65308245	LTBP3	0.48	4.98	0.37	1.74e-6	Bone mineral density;
PAAD	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.37	4.33	0.33	2.69e-5	Total body bone mineral density;
PAAD	cis	rs988913	0.513	rs2134538	chr6:54858157	G/A	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg14515779	chr1:101123966	NA	0.39	4.25	0.33	3.74e-5	Monocyte count;
PAAD	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.48	-4.37	-0.33	2.32e-5	Systemic sclerosis;
PAAD	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.21	21.92	0.87	6.38e-49	Myeloid white cell count;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.4	-4.31	-0.33	2.88e-5	Longevity;Endometriosis;
PAAD	cis	rs62045844	0.536	rs9940965	chr16:89180664	C/G	cg03605463	chr16:89740564	NA	-0.9	-4.83	-0.36	3.35e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg00147160	chr1:26503991	CNKSR1	0.37	4.3	0.33	3.09e-5	QRS complex (12-leadsum);
PAAD	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg20913747	chr6:44695427	NA	-0.7	-7.01	-0.49	7.21e-11	Total body bone mineral density;
PAAD	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.69	7.34	0.51	1.18e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg27411982	chr8:10470053	RP1L1	0.49	5.39	0.4	2.67e-7	Neuroticism;
PAAD	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs790123	0.692	rs790118	chr3:122380614	C/A	cg15604389	chr3:122379662	NA	0.51	4.56	0.35	1.05e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg19847866	chr10:1019161	NA	-0.59	-4.65	-0.35	7.21e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.62	6.65	0.47	5.09e-10	Testicular germ cell tumor;
PAAD	cis	rs10929159	0.928	rs6749436	chr2:236919992	A/G	cg14226755	chr2:236923322	AGAP1	0.28	4.55	0.35	1.09e-5	Parkinson's disease;
PAAD	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg27411982	chr8:10470053	RP1L1	-0.5	-5.51	-0.41	1.5e-7	Retinal vascular caliber;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg21951975	chr1:209979733	IRF6	0.55	4.8	0.36	3.77e-6	Coronary artery disease;
PAAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg15181151	chr6:150070149	PCMT1	0.56	6.02	0.44	1.24e-8	Lung cancer;
PAAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05789608	chr1:205180802	DSTYK	-0.63	-6.31	-0.46	2.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg18367735	chr17:79674897	NA	0.85	6.89	0.49	1.42e-10	Dental caries;
PAAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg07617317	chr6:118971624	C6orf204	0.54	4.56	0.35	1.04e-5	Diastolic blood pressure;
PAAD	cis	rs7092929	0.941	rs611726	chr10:3572073	T/C	cg14308648	chr10:3568949	NA	0.69	5.04	0.38	1.32e-6	Coronary artery calcification;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg00934597	chr7:893267	UNC84A	-0.48	-4.4	-0.34	2e-5	Subjective well-being;
PAAD	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg14631576	chr9:95140430	CENPP	0.58	5.62	0.41	8.86e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11264799	0.639	rs2065883	chr1:157753573	A/C	cg18268488	chr1:157545234	FCRL4	0.55	4.99	0.37	1.66e-6	IgA nephropathy;
PAAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.18	-0.39	7.05e-7	Recombination rate (females);
PAAD	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.48	-4.47	-0.34	1.5e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.1	-0.44	8.27e-9	Prostate cancer;
PAAD	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg25952890	chr19:58913133	NA	0.65	5.45	0.4	1.95e-7	Mean platelet volume;
PAAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.2	-0.39	6.2e-7	Initial pursuit acceleration;
PAAD	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	0.96	7.2	0.5	2.61e-11	Prostate cancer;
PAAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.17	17.66	0.82	1.14e-38	Cognitive function;
PAAD	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	8.35	0.56	3.84e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.53	5.89	0.43	2.4e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-5.4	-0.4	2.51e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08219700	chr8:58056026	NA	0.67	5.21	0.39	6.13e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6594713	0.570	rs35933960	chr5:112841469	T/C	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.53	-0.34	1.2e-5	Mood instability;
PAAD	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.48	-4.78	-0.36	4.16e-6	Hirschsprung disease;
PAAD	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15177315	chr10:102046452	BLOC1S2	0.65	7.3	0.51	1.46e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23641677	chr1:63989251	ITGB3BP;EFCAB7	0.64	6.48	0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg01942863	chr7:99769432	GPC2	-0.47	-4.49	-0.34	1.38e-5	Coronary artery disease;
PAAD	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.64	9.25	0.6	1.93e-16	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-1.04	-10.32	-0.64	3.02e-19	Cognitive test performance;
PAAD	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.59	4.26	0.33	3.5e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs12931792	0.840	rs8050401	chr16:30163157	A/G	cg17640201	chr16:30407289	ZNF48	0.58	6.12	0.44	7.44e-9	Tonsillectomy;
PAAD	cis	rs639012	0.594	rs543293	chr11:85820077	C/T	cg07180834	chr11:85838833	NA	0.42	4.37	0.33	2.31e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg02951883	chr7:2050386	MAD1L1	-0.55	-5.11	-0.38	9.54e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg17372223	chr3:52568218	NT5DC2	0.48	4.56	0.35	1.06e-5	Bipolar disorder;
PAAD	cis	rs2252790	0.859	rs3053	chr6:116679751	A/T	cg18764771	chr6:116381957	FRK	-0.26	-4.29	-0.33	3.22e-5	Fast beta electroencephalogram;
PAAD	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	1.02	6.4	0.46	1.85e-9	Alzheimer's disease;
PAAD	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg14583973	chr4:3374767	RGS12	0.38	5.63	0.42	8.5e-8	Parental longevity (mother's age at death);
PAAD	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.49	4.61	0.35	8.64e-6	Hepatocellular carcinoma;
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-4.82	-0.36	3.38e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.5	6.01	0.44	1.33e-8	Height;
PAAD	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs2077654	0.822	rs1805036	chr11:17434284	G/A	cg25308976	chr11:17434268	ABCC8	0.92	6.22	0.45	4.51e-9	Gout;
PAAD	cis	rs6137287	0.722	rs6137297	chr20:21218023	C/T	cg04219410	chr20:21106687	PLK1S1	0.39	4.39	0.34	2.1e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08917092	chr7:16566261	NA	0.61	6.59	0.47	6.92e-10	Myopia (pathological);
PAAD	cis	rs12431939	0.571	rs7493931	chr14:51736401	T/C	cg23942311	chr14:51606299	NA	0.57	5.34	0.4	3.26e-7	Cancer;
PAAD	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.09	10.27	0.64	4.14e-19	Night sleep phenotypes;
PAAD	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.51	-4.64	-0.35	7.5e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg17749961	chr2:30669863	LCLAT1	-0.64	-5.03	-0.38	1.37e-6	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs8005172	0.750	rs2165568	chr14:88453833	T/C	cg18078958	chr14:88630771	NA	0.47	5.45	0.4	1.99e-7	Parkinson's disease;
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.81	-8.67	-0.58	6.05e-15	Prostate cancer;
PAAD	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	trans	rs10829156	0.629	rs7069955	chr10:18977139	A/G	cg16048803	chr17:38956837	KRT28	0.68	6.46	0.46	1.34e-9	Sudden cardiac arrest;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-8.11	-0.55	1.5700000000000001e-13	Longevity;Endometriosis;
PAAD	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.36	-0.33	2.37e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12042938	0.579	rs6692440	chr1:231760047	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.35	-0.33	2.5e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs8113142	0.614	rs73028023	chr19:29134072	C/T	cg04546413	chr19:29218101	NA	0.42	4.25	0.33	3.77e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs58521262	0.660	rs57042530	chr19:23034580	G/A	cg07749055	chr19:23076870	NA	-0.66	-4.76	-0.36	4.53e-6	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.53	-0.57	1.41e-14	Vitiligo;
PAAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg05785598	chr3:49045655	WDR6	0.43	4.93	0.37	2.16e-6	Parkinson's disease;
PAAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg27511599	chr7:32358540	NA	0.73	4.33	0.33	2.72e-5	Body mass index;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg25664220	chr3:72788482	NA	-0.46	-4.95	-0.37	1.96e-6	Motion sickness;
PAAD	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	trans	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg17712092	chr4:129076599	LARP1B	-0.74	-7.84	-0.54	7.31e-13	Eosinophil percentage of white cells;
PAAD	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg02056144	chr12:54070517	ATP5G2	-0.5	-5.47	-0.41	1.8e-7	Height;
PAAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.48	-0.41	1.69e-7	Triglycerides;
PAAD	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg14686297	chr22:46650375	NA	-0.46	-4.63	-0.35	7.66e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.53	-4.88	-0.37	2.71e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg06740227	chr12:86229804	RASSF9	0.52	4.61	0.35	8.57e-6	Major depressive disorder;
PAAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14169450	chr9:139327907	INPP5E	-0.56	-5.11	-0.38	9.45e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4664293	0.585	rs35081473	chr2:160536481	G/C	cg04215213	chr2:159602169	NA	0.4	4.42	0.34	1.84e-5	Monocyte percentage of white cells;
PAAD	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg11657440	chr19:46296263	DMWD	-0.57	-5.68	-0.42	6.62e-8	Coronary artery disease;
PAAD	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.92	0.54	4.59e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1570884	0.539	rs7982964	chr13:50111762	G/A	cg03651054	chr13:50194643	NA	0.34	4.34	0.33	2.58e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	trans	rs6694672	0.702	rs6685259	chr1:197093098	A/T	cg18235662	chr6:164975487	NA	-0.96	-6.33	-0.46	2.59e-9	Asthma;
PAAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.65	7.24	0.51	2.12e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg09597638	chr17:3907349	NA	-0.73	-7.88	-0.54	5.9e-13	Type 2 diabetes;
PAAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.46	6.32	0.46	2.69e-9	Cardiovascular disease risk factors;
PAAD	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.97	-0.63	2.52e-18	Monocyte percentage of white cells;
PAAD	cis	rs7916697	0.891	rs4746748	chr10:70009388	G/A	cg18338521	chr10:69995036	NA	0.33	4.3	0.33	3.01e-5	Optic disc area;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.65	6.21	0.45	4.78e-9	Prostate cancer;
PAAD	cis	rs3753841	0.832	rs10782909	chr1:103309862	A/C	cg24495344	chr1:103574097	COL11A1	0.38	4.45	0.34	1.64e-5	Glaucoma (primary angle closure);
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.59	-8.07	-0.55	1.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg17595323	chr11:93583763	C11orf90	-0.36	-4.49	-0.34	1.41e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg05338066	chr1:7812865	CAMTA1	0.69	5.05	0.38	1.23e-6	Inflammatory bowel disease;
PAAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-9.26	-0.6	1.84e-16	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6142102	0.961	rs6059587	chr20:32542926	C/G	cg08999081	chr20:33150536	PIGU	0.46	4.31	0.33	2.98e-5	Skin pigmentation;
PAAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06634786	chr22:41940651	POLR3H	-0.65	-5.14	-0.38	8.28e-7	Vitiligo;
PAAD	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg21479132	chr6:26055353	NA	0.84	5.3	0.4	3.93e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.73	-7.66	-0.53	2.08e-12	Neurofibrillary tangles;
PAAD	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg05372495	chr19:1063624	ABCA7	-0.51	-4.49	-0.34	1.39e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.84	9.77	0.62	8.57e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.6	-5.97	-0.44	1.58e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.81	-8.77	-0.58	3.37e-15	Colorectal cancer;
PAAD	cis	rs8105895	0.935	rs62112921	chr19:22227577	T/C	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs6908034	0.547	rs79963847	chr6:19756203	C/T	cg02682789	chr6:19804855	NA	0.79	4.35	0.33	2.46e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03647317	chr4:187891568	NA	-0.54	-6.75	-0.48	2.87e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4523957	0.890	rs12941836	chr17:2194874	C/G	cg16513277	chr17:2031491	SMG6	0.47	4.72	0.36	5.21e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	6.93	0.49	1.15e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.85	0.37	3.04e-6	Pancreatic cancer;
PAAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.76	8.71	0.58	4.91e-15	Prostate cancer;
PAAD	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.52	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg21546286	chr11:48923668	NA	-0.42	-4.58	-0.35	9.44e-6	Coronary artery disease;
PAAD	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.47	7.55	0.52	3.69e-12	Mean corpuscular volume;
PAAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg16928487	chr17:17741425	SREBF1	-0.34	-4.48	-0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg10589385	chr1:150898437	SETDB1	0.4	4.85	0.37	3.01e-6	Melanoma;
PAAD	cis	rs10274279	0.614	rs12669148	chr7:157404930	T/C	cg26886268	chr7:157387156	PTPRN2	-0.62	-4.59	-0.35	9.26e-6	Myopia (pathological);
PAAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg22903657	chr4:1355424	KIAA1530	0.41	4.43	0.34	1.79e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs7011049	1.000	rs72643588	chr8:53849335	C/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.65	6.59	0.47	6.86e-10	Colorectal cancer;
PAAD	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.36	0.33	2.34e-5	Lung cancer in ever smokers;
PAAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.58	5.94	0.43	1.87e-8	Huntington's disease progression;
PAAD	cis	rs4417704	0.577	rs7591322	chr2:241900403	T/C	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.69e-7	Joint mobility (Beighton score);
PAAD	cis	rs757081	0.648	rs12276859	chr11:17276965	C/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.78	-0.42	4.15e-8	Systolic blood pressure;
PAAD	cis	rs2580764	0.566	rs2920900	chr2:55280083	T/C	cg09592903	chr2:55203963	RTN4	0.56	6.05	0.44	1.07e-8	Mean platelet volume;
PAAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12963246	chr6:28129442	ZNF389	0.63	4.49	0.34	1.38e-5	Parkinson's disease;
PAAD	cis	rs7101378	0.577	rs1912234	chr11:108898314	T/C	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-6.26	-0.45	3.79e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.47e-6	Lung cancer;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	1.01	14.47	0.76	2.2e-30	Menarche (age at onset);
PAAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg09835421	chr16:68378352	PRMT7	-1.1	-8.13	-0.55	1.41e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg20673841	chr7:107026890	COG5	0.51	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.83	-9.48	-0.61	4.9e-17	Ulcerative colitis;
PAAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.97	9.43	0.61	6.69e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg05861140	chr6:150128134	PCMT1	-0.56	-6.07	-0.44	9.92e-9	Lung cancer;
PAAD	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.75	8.14	0.55	1.35e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-5.96	-0.44	1.66e-8	Parkinson's disease;
PAAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg22495480	chr3:40350820	EIF1B	-0.46	-4.48	-0.34	1.45e-5	Renal cell carcinoma;
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.42	-0.34	1.85e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-4.67	-0.35	6.55e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg00750074	chr16:89608354	SPG7	-0.48	-4.39	-0.34	2.08e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.87	-10.8	-0.66	1.54e-20	Body mass index;
PAAD	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.1	0.5	4.51e-11	Renal function-related traits (BUN);
PAAD	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	10.02	0.63	1.85e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs1345301	0.518	rs1558624	chr2:102862233	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.46	-0.34	1.57e-5	Waist circumference;
PAAD	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg23400002	chr11:75917724	WNT11	-0.55	-6.32	-0.46	2.71e-9	Energy expenditure (24h);
PAAD	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg26850624	chr5:429559	AHRR	-0.76	-9.02	-0.59	7.84e-16	Cystic fibrosis severity;
PAAD	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.34	0.46	2.46e-9	Alzheimer's disease;
PAAD	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.8	-6.04	-0.44	1.12e-8	Coronary artery disease;
PAAD	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.25	0.51	1.92e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs528301	0.705	rs173076	chr2:45175585	G/A	cg15393275	chr2:45165193	NA	-0.53	-5.94	-0.43	1.91e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg06115741	chr20:33292138	TP53INP2	-0.69	-4.35	-0.33	2.46e-5	Neuroticism;
PAAD	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-5.28	-0.39	4.41e-7	Common traits (Other);
PAAD	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg15654264	chr1:150340011	RPRD2	0.49	4.77	0.36	4.31e-6	Morning vs. evening chronotype;
PAAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15128208	chr22:42549153	NA	-0.47	-4.58	-0.35	9.56e-6	Cognitive function;
PAAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.48	-5.45	-0.4	2.04e-7	Major depressive disorder;
PAAD	cis	rs11825685	0.607	rs1893869	chr11:134553300	C/T	cg06603561	chr11:134479413	NA	-0.57	-4.9	-0.37	2.46e-6	IgG glycosylation;
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05740668	chr2:132203203	LOC401010	-0.57	-6.49	-0.47	1.13e-9	Smoking initiation;
PAAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.66	-4.84	-0.37	3.19e-6	Initial pursuit acceleration;
PAAD	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	10.71	0.66	2.77e-20	Electrocardiographic conduction measures;
PAAD	cis	rs17221829	0.965	rs12278734	chr11:89461172	G/A	cg02982614	chr11:89391479	FOLH1B	-0.43	-4.39	-0.34	2.12e-5	Anxiety in major depressive disorder;
PAAD	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.63	6.05	0.44	1.05e-8	Monocyte count;
PAAD	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.58	-5.33	-0.4	3.46e-7	Total body bone mineral density;
PAAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg14346243	chr4:90757452	SNCA	-0.46	-4.28	-0.33	3.36e-5	Neuroticism;
PAAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.68	7.79	0.53	9.7e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg22089800	chr15:90895588	ZNF774	0.57	5.41	0.4	2.41e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.7	5.44	0.4	2.09e-7	Initial pursuit acceleration;
PAAD	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.07	0.38	1.15e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.89	10.86	0.66	1.07e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	cis	rs7551222	0.646	rs10900590	chr1:204451086	C/T	cg01064725	chr1:204461714	NA	-0.54	-4.82	-0.36	3.52e-6	Schizophrenia;
PAAD	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg25251562	chr2:3704773	ALLC	-0.81	-7.7	-0.53	1.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.49	-5.1	-0.38	9.84e-7	IgG glycosylation;
PAAD	cis	rs11264213	0.786	rs72659692	chr1:36292258	A/G	cg27506609	chr1:36549197	TEKT2	0.84	4.29	0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg04201373	chr6:33551533	GGNBP1	0.62	4.98	0.37	1.71e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs12304921	1.000	rs66518563	chr12:51358252	T/C	cg04427360	chr12:51347099	HIGD1C	-0.64	-4.97	-0.37	1.79e-6	Type 2 diabetes;
PAAD	cis	rs4234284	0.900	rs12491804	chr3:126983124	G/T	cg03987639	chr3:127174481	NA	0.45	4.8	0.36	3.83e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs3787159	0.573	rs551988	chr20:56888641	T/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.38	-0.33	2.2e-5	Systolic blood pressure;
PAAD	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.6	4.32	0.33	2.82e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00152838	chr16:24741724	TNRC6A	0.52	4.38	0.33	2.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.53	5.96	0.44	1.69e-8	Prostate cancer;
PAAD	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.91	-7.81	-0.54	8.68e-13	Obesity-related traits;
PAAD	cis	rs1035491	0.753	rs6888159	chr5:63932234	C/G	cg01791865	chr5:63954708	NA	-0.45	-4.69	-0.36	6.04e-6	Body mass index;
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.63	5.71	0.42	5.79e-8	Schizophrenia;
PAAD	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg08213375	chr14:104286397	PPP1R13B	0.48	6.54	0.47	9e-10	Schizophrenia;
PAAD	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.78	7.23	0.51	2.22e-11	Breast cancer;
PAAD	cis	rs4740619	0.810	rs10756714	chr9:15885041	A/G	cg14451791	chr9:16040625	NA	-0.38	-4.35	-0.33	2.52e-5	Body mass index;
PAAD	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg26876637	chr1:152193138	HRNR	-0.86	-6.38	-0.46	1.98e-9	Atopic dermatitis;
PAAD	cis	rs6494488	0.500	rs113037933	chr15:64898614	T/C	cg16425858	chr15:64791681	ZNF609	0.82	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.72	-6.96	-0.49	9.36e-11	Platelet distribution width;
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg16316162	chr8:144660157	NAPRT1	0.94	6.86	0.49	1.63e-10	Attention deficit hyperactivity disorder;
PAAD	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.18	-0.5	2.86e-11	Neuroticism;
PAAD	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.56	-5.64	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg11266682	chr4:10021025	SLC2A9	0.62	5.09	0.38	1.04e-6	Blood metabolite levels;
PAAD	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.46	5.41	0.4	2.46e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.22	0.55	8.55e-14	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg03037974	chr15:76606532	NA	-0.55	-6.7	-0.48	3.72e-10	Blood metabolite levels;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.76	-8.02	-0.55	2.65e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07395648	chr5:131743802	NA	-0.5	-4.54	-0.35	1.14e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.62	8.54	0.57	1.33e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	8.29	0.56	5.72e-14	Bone mineral density;
PAAD	cis	rs1539053	0.934	rs1524708	chr1:58102590	T/A	cg20292791	chr1:58089357	DAB1	-0.55	-5.41	-0.4	2.41e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.52	-4.99	-0.38	1.65e-6	Mortality in heart failure;
PAAD	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	1.09	10.97	0.66	5.4e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.85	-10.12	-0.63	1.03e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs73198271	1.000	rs4841031	chr8:8607395	G/A	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.32e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.23	-0.51	2.14e-11	Aortic root size;
PAAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	trans	rs11794666	1.000	rs11794635	chr9:31661858	A/G	cg05628366	chr6:35744188	C6orf126	0.99	6.56	0.47	7.98e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.73	6.41	0.46	1.71e-9	Obesity-related traits;
PAAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.15	-0.39	8.06e-7	Asthma;
PAAD	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.64	-5.89	-0.43	2.34e-8	Breast cancer;
PAAD	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.61	-6.44	-0.46	1.52e-9	Breast cancer;
PAAD	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.73	-5.36	-0.4	3.05e-7	Iron status biomarkers;
PAAD	cis	rs75757892	0.544	rs75962093	chr6:7315055	G/A	cg02954307	chr6:7269328	NA	0.58	4.6	0.35	8.68e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.77	-0.36	4.37e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs863345	0.967	rs4528114	chr1:158467713	T/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg24565620	chr2:194026	NA	0.55	4.52	0.34	1.22e-5	Blood protein levels;
PAAD	cis	rs7577696	0.524	rs212696	chr2:32441685	A/G	cg02381751	chr2:32503542	YIPF4	0.51	4.9	0.37	2.4e-6	Inflammatory biomarkers;
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-4.99	-0.37	1.66e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14318489	chr14:100759310	SLC25A29	-0.56	-6.39	-0.46	1.89e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	5.96	0.44	1.69e-8	Mean platelet volume;
PAAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs12935418	0.616	rs2602446	chr16:81017915	G/C	cg16651780	chr16:81037892	C16orf61	-0.64	-6.01	-0.44	1.33e-8	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17012575	chr11:125757631	HYLS1	0.64	6.54	0.47	8.64e-10	Obesity-related traits;
PAAD	trans	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.46	-0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.47	0.41	1.85e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg08975724	chr8:8085496	FLJ10661	-0.69	-6.59	-0.47	6.7e-10	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27238026	chr3:107941463	IFT57	0.65	6.83	0.48	1.93e-10	Obesity-related traits;
PAAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.65	7.23	0.51	2.18e-11	Hemoglobin concentration;
PAAD	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.57	5.74	0.42	4.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.35	0.46	2.4e-9	Platelet count;
PAAD	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.51	4.53	0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg02462569	chr6:150064036	NUP43	-0.48	-5.33	-0.4	3.52e-7	Lung cancer;
PAAD	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg06243866	chr13:111019493	COL4A2	-0.58	-5.52	-0.41	1.41e-7	White matter hyperintensity burden;
PAAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.38	-0.74	1.76e-27	Height;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.93	12.98	0.73	2.12e-26	Prudent dietary pattern;
PAAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.89	-9.29	-0.6	1.5e-16	Obesity-related traits;
PAAD	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.27	7.18	0.5	2.9100000000000002e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-6.18	-0.45	5.51e-9	Gallbladder cancer;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg07362569	chr17:61921086	SMARCD2	0.44	5.01	0.38	1.48e-6	Height;
PAAD	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.8	6.53	0.47	9.24e-10	Schizophrenia;
PAAD	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.63	-6.96	-0.49	9.41e-11	Schizophrenia;
PAAD	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg01953289	chr20:60874239	NA	0.72	5.49	0.41	1.65e-7	Obesity-related traits;
PAAD	cis	rs988913	0.678	rs9349753	chr6:54981922	A/T	cg03513858	chr6:54763001	FAM83B	-0.39	-4.3	-0.33	3.06e-5	Menarche (age at onset);
PAAD	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.85e-6	Prudent dietary pattern;
PAAD	cis	rs7804356	0.651	rs10227898	chr7:26764618	C/T	cg03456212	chr7:26904342	SKAP2	0.54	4.78	0.36	4.1e-6	Type 1 diabetes;
PAAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14580859	chr9:123691850	NA	0.38	4.28	0.33	3.3e-5	Rheumatoid arthritis;
PAAD	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.49	-6.16	-0.45	6.18e-9	Menopause (age at onset);
PAAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg09873201	chr16:3507582	NAT15	0.56	5.35	0.4	3.17e-7	Tuberculosis;
PAAD	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.48	-4.35	-0.33	2.46e-5	Mean corpuscular volume;
PAAD	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.92	8.22	0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs733175	0.599	rs6856396	chr4:10031163	A/T	cg00071950	chr4:10020882	SLC2A9	0.58	4.66	0.35	6.93e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.55	5.19	0.39	6.49e-7	Red blood cell count;
PAAD	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg00543991	chr22:32367038	NA	1.13	7.03	0.5	6.63e-11	Childhood ear infection;
PAAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs78761021	0.867	rs17810453	chr17:9789466	A/G	cg26853458	chr17:9805074	RCVRN	0.72	8.28	0.56	5.96e-14	Type 2 diabetes;
PAAD	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.51	-5.16	-0.39	7.52e-7	Schizophrenia;
PAAD	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.45	5.24	0.39	5.2e-7	Coronary artery disease;
PAAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.39	-0.34	2.11e-5	Glomerular filtration rate;
PAAD	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.52	5.4	0.4	2.55e-7	Red blood cell count;
PAAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.83	7.23	0.51	2.21e-11	Recombination rate (females);
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.81	-0.36	3.63e-6	Hirschsprung disease;
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs931555	0.577	rs12186656	chr5:35948187	C/T	cg05512756	chr5:35991735	UGT3A1	-0.39	-4.25	-0.33	3.73e-5	Multiple sclerosis;
PAAD	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.27	0.33	3.37e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.71	-6.39	-0.46	1.95e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-6.12	-0.44	7.46e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4880487	0.853	rs883490	chr10:1249567	G/C	cg03183215	chr10:1252341	ADARB2	-0.5	-4.94	-0.37	2.03e-6	Migraine;
PAAD	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-5.26	-0.39	4.86e-7	Menarche (age at onset);
PAAD	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.63	-6.07	-0.44	9.76e-9	Itch intensity from mosquito bite;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.68	0.48	4.29e-10	Height;
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.93	-9.11	-0.59	4.48e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	1.0	8.81	0.58	2.72e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg16850897	chr7:100343110	ZAN	-0.6	-4.93	-0.37	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs9527	0.518	rs11191487	chr10:104734623	A/G	cg14737131	chr10:104680354	CNNM2	0.68	5.98	0.44	1.57e-8	Arsenic metabolism;
PAAD	trans	rs17100498	1.000	rs17100506	chr5:143005388	C/T	cg01299369	chr10:103113776	BTRC	1.15	6.3	0.46	3.04e-9	Response to antipsychotic treatment;
PAAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg14349672	chr11:133703707	NA	-0.53	-6.04	-0.44	1.14e-8	Childhood ear infection;
PAAD	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.51e-6	Vitiligo;
PAAD	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg00409905	chr10:38381863	ZNF37A	0.6	5.83	0.43	3.27e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg27449745	chr7:23145252	KLHL7	-0.61	-5.54	-0.41	1.28e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.63	-0.35	7.67e-6	Iron status biomarkers;
PAAD	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19671926	chr4:122722719	EXOSC9	-0.7	-6.88	-0.49	1.47e-10	Type 2 diabetes;
PAAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12895977	chr3:73441232	PDZRN3	-0.65	-6.46	-0.46	1.35e-9	Obesity-related traits;
PAAD	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg13266496	chr6:110720918	DDO	-0.46	-4.87	-0.37	2.78e-6	Platelet distribution width;
PAAD	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg21269045	chr12:125625041	AACS	-0.46	-4.67	-0.35	6.46e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.46	4.42	0.34	1.9e-5	Renal cell carcinoma;
PAAD	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.53	4.68	0.35	6.26e-6	Atopic dermatitis;
PAAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.4	0.34	2e-5	Tonsillectomy;
PAAD	cis	rs2968864	0.917	rs74819531	chr7:150610935	G/C	cg06221570	chr7:150558377	ABP1	0.42	5.05	0.38	1.27e-6	QT interval;
PAAD	cis	rs73416724	0.688	rs77915916	chr6:43287722	A/T	cg26312998	chr6:43337775	ZNF318	0.64	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4144027	0.791	rs11160770	chr14:104362291	A/C	cg12183467	chr14:104352244	NA	0.36	4.52	0.34	1.21e-5	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.49	0.57	1.71e-14	Alzheimer's disease;
PAAD	cis	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg27395922	chr11:50257633	LOC441601	-0.42	-4.58	-0.35	9.55e-6	Coronary artery disease;
PAAD	cis	rs2562456	0.793	rs62109212	chr19:21526518	T/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs10450586	0.932	rs10082611	chr11:27320108	C/G	cg10370305	chr11:27303972	NA	0.38	4.57	0.35	9.9e-6	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg05484376	chr2:27715224	FNDC4	0.46	4.68	0.36	6.23e-6	Total body bone mineral density;
PAAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg17775713	chr3:133465469	TF	0.5	5.56	0.41	1.19e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs58521262	0.516	rs290587	chr19:23203361	A/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	trans	rs1800562	1	rs1800562	chr6:26093141	C/T	cg21435394	chr14:105648024	NUDT14	0.96	7.16	0.5	3.31e-11	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
PAAD	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.84	9.9	0.63	3.91e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg07153921	chr17:41440717	NA	-0.41	-4.29	-0.33	3.14e-5	Menopause (age at onset);
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.46e-5	Testicular germ cell tumor;
PAAD	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg06287003	chr12:125626642	AACS	-0.53	-5.1	-0.38	1.01e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg13047869	chr3:10149882	C3orf24	-0.56	-4.97	-0.37	1.77e-6	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06622737	chr1:171750501	METTL13	0.62	6.64	0.47	5.23e-10	Myopia (pathological);
PAAD	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.5	4.48	0.34	1.45e-5	Ovarian reserve;
PAAD	cis	rs4237845	0.611	rs4583019	chr12:58316745	T/C	cg00677455	chr12:58241039	CTDSP2	0.51	5.16	0.39	7.69e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.68	-5.4	-0.4	2.57e-7	Smoking behavior;
PAAD	trans	rs13089920	1.000	rs1444481	chr3:78553323	A/G	cg07996532	chr1:21620812	ECE1	-0.57	-6.3	-0.46	3.02e-9	Craniofacial microsomia;
PAAD	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs329648	0.534	rs4937850	chr11:133764891	G/C	cg12362517	chr11:133800685	IGSF9B	0.61	6.59	0.47	6.95e-10	Parkinson's disease;
PAAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg02038168	chr22:39784481	NA	-0.51	-4.42	-0.34	1.87e-5	Post bronchodilator FEV1;
PAAD	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg09796270	chr17:17721594	SREBF1	0.39	4.26	0.33	3.55e-5	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg23465465	chr6:26364728	BTN3A2	0.8	4.72	0.36	5.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19346786	chr7:2764209	NA	0.35	4.62	0.35	8.2e-6	Height;
PAAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg03684893	chr10:554711	DIP2C	0.43	4.4	0.34	2.02e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.79	7.37	0.51	1e-11	Gout;
PAAD	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.81	-5.48	-0.41	1.71e-7	Red cell distribution width;
PAAD	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7818345	0.845	rs4625053	chr8:19317270	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.48	4.89	0.37	2.52e-6	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg07810366	chr2:100720526	AFF3	-0.38	-4.84	-0.37	3.21e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	trans	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08418111	chr11:18433745	LDHC	0.6	6.32	0.46	2.75e-9	Calcium levels;
PAAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg11766577	chr21:47581405	C21orf56	-0.38	-4.35	-0.33	2.45e-5	Testicular germ cell tumor;
PAAD	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	10.44	0.65	1.42e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs901683	1.000	rs35632234	chr10:45983379	G/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1468734	1.000	rs11642379	chr16:5003326	C/T	cg06510647	chr16:5006106	NA	0.56	5.02	0.38	1.45e-6	Cancer;
PAAD	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.72	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.59	6.23	0.45	4.46e-9	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.1	-0.5	4.46e-11	Neuroticism;
PAAD	cis	rs617219	0.737	rs13158309	chr5:78463395	C/T	cg24856658	chr5:78533917	JMY	0.38	4.3	0.33	3.01e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.51	-5.17	-0.39	7.41e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs755249	0.567	rs61779274	chr1:39816941	C/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1519814	1.000	rs4871037	chr8:121124042	A/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.7	7.12	0.5	3.97e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467603	0.920	rs13213957	chr6:25786226	T/C	cg01620082	chr3:125678407	NA	-1.41	-7.8	-0.53	9.33e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg26205652	chr12:48591994	NA	0.86	7.78	0.53	1.04e-12	Longevity (90 years and older);
PAAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	4.62	0.35	7.98e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.73	-0.36	5.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.48	-4.6	-0.35	8.86e-6	Hepatocellular carcinoma;
PAAD	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-5.24	-0.39	5.28e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs57709857	0.957	rs6981405	chr8:38120276	C/A	cg16625770	chr8:38300134	FGFR1	-0.47	-4.33	-0.33	2.71e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.58	-5.75	-0.42	4.69e-8	Motion sickness;
PAAD	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.31	0.46	2.92e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.46	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs6796031	chr3:128593259	G/A	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg00945038	chr17:61921165	SMARCD2	0.51	6.02	0.44	1.26e-8	Prudent dietary pattern;
PAAD	cis	rs3764400	0.517	rs7209042	chr17:46207792	G/C	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg08390786	chr10:135334061	NA	0.47	4.58	0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9815354	0.953	rs1717034	chr3:41955913	A/G	cg03022575	chr3:42003672	ULK4	-0.82	-5.78	-0.42	4.13e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs933117	0.892	rs79487314	chr21:31076991	T/C	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.31	-0.33	2.91e-5	Body mass index;
PAAD	cis	rs4450131	0.522	rs2272005	chr10:126402100	C/T	cg20435097	chr10:126320824	FAM53B	0.49	4.94	0.37	2.01e-6	White blood cell count (basophil);
PAAD	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg23985595	chr17:80112537	CCDC57	0.44	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs3733418	0.799	rs2280327	chr4:165928581	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-4.94	-0.37	2.01e-6	Obesity-related traits;
PAAD	cis	rs8067287	0.802	rs62065417	chr17:16820679	T/C	cg26910001	chr17:16838321	NA	-0.73	-6.44	-0.46	1.45e-9	Diabetic kidney disease;
PAAD	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg16928487	chr17:17741425	SREBF1	0.32	4.45	0.34	1.63e-5	Total body bone mineral density;
PAAD	trans	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg06606381	chr12:133084897	FBRSL1	1.06	6.53	0.47	9.19e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.27	0.51	1.75e-11	Rheumatoid arthritis;
PAAD	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs5757949	0.529	rs5758018	chr22:40987730	T/G	cg14701072	chr22:41075428	MCHR1	-0.44	-4.3	-0.33	3.03e-5	Height;
PAAD	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.85	-9.95	-0.63	2.76e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.61	0.57	8.37e-15	Lung cancer;
PAAD	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg08315770	chr6:39281885	KCNK17	-0.61	-6.46	-0.46	1.33e-9	Type 2 diabetes;
PAAD	cis	rs1419980	0.730	rs7958896	chr12:7774118	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.22	-19.35	-0.84	7.42e-43	Exhaled nitric oxide output;
PAAD	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.45	-5.08	-0.38	1.1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.38	-5.56	-0.41	1.18e-7	Glomerular filtration rate;
PAAD	cis	rs12620999	0.941	rs58678188	chr2:237971036	C/A	cg23555395	chr2:238036564	NA	0.49	5.61	0.41	9.41e-8	Systemic lupus erythematosus;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg10621924	chr7:39171070	POU6F2	0.28	4.49	0.34	1.39e-5	IgG glycosylation;
PAAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	4.64	0.35	7.37e-6	Multiple sclerosis;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs9815354	0.951	rs6768438	chr3:41865355	G/A	cg03022575	chr3:42003672	ULK4	0.78	5.66	0.42	7.17e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg00310523	chr12:86230176	RASSF9	0.39	4.32	0.33	2.81e-5	Major depressive disorder;
PAAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg10645314	chr2:3704589	ALLC	-0.55	-5.49	-0.41	1.65e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.88	9.67	0.62	1.52e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-12.21	-0.7	2.58e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.46	-0.4	1.89e-7	Personality dimensions;
PAAD	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg12092346	chr18:77659572	KCNG2	-0.6	-4.32	-0.33	2.77e-5	Opioid sensitivity;
PAAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg10589385	chr1:150898437	SETDB1	-0.44	-5.42	-0.4	2.32e-7	Tonsillectomy;
PAAD	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.76	-0.42	4.6e-8	QT interval;
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg16434002	chr17:42200994	HDAC5	0.65	6.39	0.46	1.92e-9	Total body bone mineral density;
PAAD	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.51	-4.53	-0.34	1.21e-5	Mean corpuscular volume;
PAAD	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.76	7.92	0.54	4.64e-13	Blood protein levels;
PAAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18436758	chr1:21113190	HP1BP3	0.56	6.76	0.48	2.74e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs12476592	0.602	rs262477	chr2:63870959	A/C	cg10828910	chr2:63850056	LOC388955	0.52	4.52	0.34	1.26e-5	Childhood ear infection;
PAAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg21395723	chr22:39101663	GTPBP1	0.45	4.76	0.36	4.52e-6	Menopause (age at onset);
PAAD	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.58	-5.56	-0.41	1.18e-7	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
PAAD	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg19090574	chr1:205240910	TMCC2	0.46	5.46	0.4	1.94e-7	Red blood cell count;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg03909863	chr11:638404	DRD4	-0.66	-5.37	-0.4	2.87e-7	Systemic lupus erythematosus;
PAAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs227833	0.537	rs2817117	chr6:44646741	G/A	cg18551225	chr6:44695536	NA	0.41	4.28	0.33	3.34e-5	Monobrow;
PAAD	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg19192590	chr2:178524533	PDE11A	0.42	4.27	0.33	3.43e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	4.54	0.35	1.15e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg10556349	chr10:835070	NA	0.57	4.96	0.37	1.9e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg19223190	chr17:80058835	NA	0.53	5.52	0.41	1.4e-7	Life satisfaction;
PAAD	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs375066	0.935	rs10414702	chr19:44380536	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.85	-0.43	2.88e-8	Breast cancer;
PAAD	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.97	-12.19	-0.7	2.85e-24	Coronary artery disease;
PAAD	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg16810054	chr20:33298113	TP53INP2	0.59	4.87	0.37	2.77e-6	Neuroticism;
PAAD	cis	rs4704187	0.687	rs28376290	chr5:74454706	C/T	cg03227963	chr5:74354835	NA	0.47	4.61	0.35	8.47e-6	Response to amphetamines;
PAAD	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg01631408	chr1:248437212	OR2T33	-0.56	-5.26	-0.39	4.86e-7	Common traits (Other);
PAAD	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg02531859	chr7:37888154	TXNDC3	-0.55	-4.43	-0.34	1.78e-5	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06320134	chr1:6663664	KLHL21	0.63	6.41	0.46	1.75e-9	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20612964	chr1:1668511	SLC35E2	0.56	6.41	0.46	1.69e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3749237	1.000	rs13316065	chr3:49884913	C/T	cg21659725	chr3:3221576	CRBN	0.72	6.57	0.47	7.62e-10	Resting heart rate;
PAAD	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg04717802	chr22:42394638	WBP2NL	-0.51	-4.37	-0.33	2.25e-5	Birth weight;
PAAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-6.94	-0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09120960	chr11:115427472	NA	-0.63	-6.72	-0.48	3.49e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.12	0.38	9.11e-7	Rheumatoid arthritis;
PAAD	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.94	-8.27	-0.56	6.39e-14	Alopecia areata;
PAAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.99	0.54	3.04e-13	Prudent dietary pattern;
PAAD	cis	rs1559473	0.572	rs2042470	chr2:222908391	A/G	cg15825116	chr2:223169586	CCDC140	0.3	4.36	0.33	2.37e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-5.81	-0.43	3.51e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs9346455	0.764	rs9354996	chr6:72035192	C/T	cg25737224	chr6:72926121	RIMS1	-0.51	-4.33	-0.33	2.68e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg13266496	chr6:110720918	DDO	-0.46	-4.87	-0.37	2.78e-6	Platelet distribution width;
PAAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.47	-6.13	-0.45	7.21e-9	Renal cell carcinoma;
PAAD	cis	rs17592366	0.517	rs11845027	chr14:35315574	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	5.38	0.4	2.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01409793	chr4:106394821	PPA2	0.58	6.45	0.46	1.38e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.38	7.39	0.51	9.08e-12	Skin colour saturation;
PAAD	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg07159951	chr1:45983175	PRDX1	-0.43	-4.77	-0.36	4.23e-6	High light scatter reticulocyte count;
PAAD	cis	rs9487051	0.621	rs830554	chr6:109543226	C/T	cg21918786	chr6:109611834	NA	0.42	4.44	0.34	1.7e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08109568	chr15:31115862	NA	-0.68	-7.49	-0.52	5.13e-12	Huntington's disease progression;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7101378	0.599	rs7927428	chr11:108899634	C/A	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.6	6.95	0.49	9.85e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1359582	0.736	rs7899358	chr10:90373845	C/T	cg15661332	chr10:90342814	RNLS	0.53	4.71	0.36	5.45e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.98	-0.37	1.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.82	9.74	0.62	9.96e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs5758659	0.810	rs5758623	chr22:42566314	G/C	cg15128208	chr22:42549153	NA	-0.56	-5.69	-0.42	6.45e-8	Cognitive function;
PAAD	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02419362	chr12:121203948	SPPL3	0.54	6.01	0.44	1.34e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01880540	chr11:118977881	C2CD2L	0.6	6.54	0.47	9e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.56	-5.9	-0.43	2.22e-8	Subjective well-being;
PAAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-4.36	-0.33	2.36e-5	Life satisfaction;
PAAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg04450456	chr4:17643702	FAM184B	0.52	5.87	0.43	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.46	-0.46	1.36e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6991838	0.778	rs11779602	chr8:66462482	T/C	cg15971335	chr8:66515592	ARMC1	0.44	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8042680	0.522	rs8026678	chr15:91562005	A/G	cg08919649	chr15:91565780	VPS33B	0.48	4.34	0.33	2.62e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.81	7.85	0.54	7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9395066	0.545	rs35357222	chr6:44940552	C/G	cg25276700	chr6:44698697	NA	0.48	5.45	0.4	2.02e-7	Height;
PAAD	cis	rs9372498	0.536	rs17080302	chr6:118854037	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.85	10.41	0.65	1.74e-19	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-1.2	-10.38	-0.64	2.11e-19	Obesity-related traits;
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg22105103	chr4:187893119	NA	0.6	7.43	0.52	7.28e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.55	-4.98	-0.37	1.7e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg05457628	chr5:178986728	RUFY1	-0.67	-7.06	-0.5	5.68e-11	Lung cancer;
PAAD	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14019695	chr9:139328340	INPP5E	0.49	4.58	0.35	9.68e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.5	-0.41	1.54e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg18842474	chr6:3356384	SLC22A23	-0.78	-6.78	-0.48	2.54e-10	Photic sneeze reflex;
PAAD	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.51	4.71	0.36	5.49e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8005677	0.828	rs712486	chr14:23425041	A/G	cg01529538	chr14:23388837	RBM23	0.49	4.98	0.37	1.74e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.93	0.49	1.13e-10	Rheumatoid arthritis;
PAAD	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.25	0.51	2.02e-11	Dupuytren's disease;
PAAD	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.56	0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19388017	chr19:15285100	NOTCH3	-0.56	-6.62	-0.47	5.8e-10	Monocyte percentage of white cells;
PAAD	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	1.08	10.95	0.66	6.3e-21	Corneal structure;
PAAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.76	-7.09	-0.5	4.73e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg17372223	chr3:52568218	NT5DC2	0.47	4.4	0.34	2.05e-5	Bipolar disorder;
PAAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.76	8.26	0.56	6.73e-14	Lung cancer in ever smokers;
PAAD	trans	rs901683	1.000	rs75595592	chr10:46039930	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.92e-6	Skin colour saturation;
PAAD	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.64	-5.94	-0.43	1.87e-8	Diisocyanate-induced asthma;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.61	5.55	0.41	1.24e-7	Bipolar disorder;
PAAD	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.78	-6.8	-0.48	2.26e-10	Large artery stroke;
PAAD	cis	rs507080	0.922	rs654792	chr11:118552996	A/C	cg08498647	chr11:118550644	TREH	0.4	4.9	0.37	2.4e-6	Serum metabolite levels;
PAAD	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	trans	rs901683	1.000	rs35424022	chr10:45976540	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg02624704	chr1:173446429	PRDX6	-0.72	-6.83	-0.48	1.89e-10	Blood protein levels;
PAAD	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.79	9.16	0.6	3.38e-16	Heart rate;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.75	5.39	0.4	2.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	4.92	0.37	2.27e-6	Coronary artery disease;
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg04522676	chr10:134968826	NA	0.47	4.4	0.34	2.03e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.72	0.48	3.36e-10	Resting heart rate;
PAAD	cis	rs1867631	0.565	rs10749764	chr1:67149706	G/C	cg02459107	chr1:67143332	SGIP1	0.47	4.48	0.34	1.45e-5	Menopause (age at onset);
PAAD	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg06883089	chr1:45254480	BEST4	0.34	4.28	0.33	3.28e-5	High light scatter reticulocyte count;
PAAD	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.39	4.45	0.34	1.68e-5	Longevity;
PAAD	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg08999081	chr20:33150536	PIGU	0.6	6.65	0.47	4.88e-10	Height;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.74	7.45	0.52	6.38e-12	Prostate cancer;
PAAD	cis	rs77688320	1.000	rs80273648	chr2:202311155	G/A	cg02738983	chr2:202315807	TRAK2;STRADB	-0.6	-4.3	-0.33	3.04e-5	Breast cancer;
PAAD	cis	rs4144027	0.967	rs4900601	chr14:104358076	C/T	cg12183467	chr14:104352244	NA	0.35	4.31	0.33	2.94e-5	Blood metabolite levels;
PAAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.6	-0.47	6.34e-10	Obesity-related traits;
PAAD	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.65	-7.39	-0.51	9.1e-12	Atrial fibrillation;
PAAD	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	7.32	0.51	1.37e-11	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00861411	chr19:2115611	AP3D1	0.53	6.59	0.47	6.71e-10	Body fat percentage;
PAAD	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs72960926	1.000	rs72956936	chr6:75092837	G/A	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	cis	rs4343996	0.902	rs4722710	chr7:3388254	C/A	cg21248987	chr7:3385318	SDK1	-0.46	-4.9	-0.37	2.39e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg12193833	chr17:30244370	NA	-0.63	-4.38	-0.33	2.19e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.78e-13	Blood protein levels;
PAAD	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg10523679	chr1:76189770	ACADM	-0.51	-4.86	-0.37	2.95e-6	Daytime sleep phenotypes;
PAAD	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.12e-23	Smoking behavior;
PAAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.62	6.55	0.47	8.44e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.47	-5.41	-0.4	2.45e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2190422	0.505	rs2711846	chr7:103152497	G/T	cg04218035	chr7:103086829	SLC26A5	0.37	5.16	0.39	7.64e-7	Morning vs. evening chronotype;
PAAD	trans	rs11795343	0.503	rs11791921	chr9:32493027	A/G	cg27623451	chr3:171965350	FNDC3B	0.68	6.44	0.46	1.51e-9	Psoriasis vulgaris;Psoriasis;Inflammatory skin disease;
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.89	10.81	0.66	1.5e-20	Metabolic syndrome;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg05717871	chr11:638507	DRD4	-0.6	-5.49	-0.41	1.67e-7	Systemic lupus erythematosus;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.47	-5.82	-0.43	3.43e-8	Orofacial clefts;
PAAD	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.54	-6.01	-0.44	1.33e-8	Total body bone mineral density;
PAAD	cis	rs3760982	0.776	rs62116991	chr19:44303447	G/C	cg21496419	chr19:44306685	LYPD5	-0.38	-4.56	-0.35	1.03e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg11802864	chr11:65308245	LTBP3	0.48	4.89	0.37	2.52e-6	Bone mineral density;
PAAD	cis	rs10214930	0.697	rs4722724	chr7:27654933	A/G	cg22168087	chr7:27702803	HIBADH	-0.45	-4.27	-0.33	3.47e-5	Hypospadias;
PAAD	cis	rs12760731	0.565	rs12026482	chr1:178155861	G/A	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	5.45	0.4	1.95e-7	Menarche (age at onset);
PAAD	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.68	7.73	0.53	1.34e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.65	6.48	0.47	1.19e-9	Cognitive test performance;
PAAD	cis	rs3736485	0.932	rs4775946	chr15:51775930	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1400816	0.850	rs2028670	chr2:172853809	C/T	cg23624723	chr2:173292262	ITGA6	-0.76	-4.38	-0.33	2.2e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.98	11.81	0.69	3.08e-23	Breast cancer;
PAAD	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg24565620	chr2:194026	NA	0.63	4.95	0.37	1.96e-6	Blood protein levels;
PAAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-4.95	-0.37	1.94e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs71520386	0.607	rs11767419	chr7:22878983	T/G	cg04907244	chr7:22894795	SNORD93	0.5	5.39	0.4	2.59e-7	Fibrinogen levels;
PAAD	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-7.63	-0.53	2.45e-12	Migraine;Coronary artery disease;
PAAD	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg08017634	chr8:144659831	NAPRT1	-0.8	-4.28	-0.33	3.29e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Coronary artery disease;
PAAD	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	1.07	11.08	0.67	2.82e-21	Post bronchodilator FEV1;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.7	-0.48	3.89e-10	Life satisfaction;
PAAD	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.04	0.5	6.2e-11	Lung cancer in ever smokers;
PAAD	cis	rs9810890	1.000	rs73196961	chr3:128436383	T/C	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg23573114	chr20:34634400	LOC647979	-0.54	-4.34	-0.33	2.59e-5	Blood protein levels;
PAAD	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.74	8.33	0.56	4.35e-14	Prostate cancer;
PAAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14169450	chr9:139327907	INPP5E	0.51	4.42	0.34	1.9e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.62	-6.1	-0.44	8.6e-9	Itch intensity from mosquito bite;
PAAD	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	4.59	0.35	9.14e-6	Height;
PAAD	cis	rs12044355	0.858	rs1538975	chr1:231828372	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	5.55	0.41	1.26e-7	Alzheimer's disease;
PAAD	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.43	0.56	2.48e-14	Rheumatoid arthritis;
PAAD	cis	rs9463078	0.932	rs1324538	chr6:45080144	T/A	cg25276700	chr6:44698697	NA	-0.49	-5.81	-0.43	3.48e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-4.75	-0.36	4.58e-6	Parkinson's disease;
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs2885056	0.891	rs3760648	chr19:10680103	A/G	cg06392426	chr19:10676186	KRI1	0.6	5.94	0.43	1.85e-8	Red cell distribution width;
PAAD	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg02795151	chr17:7402630	POLR2A	0.58	5.34	0.4	3.35e-7	Androgen levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00108222	chr15:49268046	NA	0.58	6.35	0.46	2.36e-9	Monocyte percentage of white cells;
PAAD	cis	rs12484776	0.729	rs8136149	chr22:40532484	C/T	cg07138101	chr22:40742427	ADSL	0.6	4.42	0.34	1.84e-5	Uterine fibroids;
PAAD	cis	rs8112211	0.689	rs112311840	chr19:38796572	G/A	cg01275006	chr19:38876250	GGN	-0.88	-5.81	-0.43	3.5e-8	Blood protein levels;
PAAD	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	1.18	18.71	0.84	2.82e-41	Gut microbiome composition (winter);
PAAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.69	-0.36	6.11e-6	HDL cholesterol;
PAAD	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg05872129	chr22:39784769	NA	-0.67	-5.98	-0.44	1.52e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.7	5.18	0.39	6.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12042938	0.622	rs61707606	chr1:231813446	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.59	0.35	9.19e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg14343924	chr8:8086146	FLJ10661	0.54	4.88	0.37	2.69e-6	Mood instability;
PAAD	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg01299579	chr2:10830716	NOL10	0.52	5.33	0.4	3.51e-7	Prostate cancer;
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00933542	chr6:150070202	PCMT1	0.53	5.63	0.42	8.64e-8	Lung cancer;
PAAD	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	5.6	0.41	9.7e-8	Itch intensity from mosquito bite;
PAAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	7.52	0.52	4.48e-12	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01092528	chr4:76861103	NAAA	0.62	7.06	0.5	5.67e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.39	0.4	2.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs61931739	0.620	rs11829476	chr12:33699285	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.48	-0.52	5.62e-12	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.65	-8.12	-0.55	1.52e-13	Schizophrenia;
PAAD	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.98	-13.22	-0.73	4.88e-27	Menarche (age at onset);
PAAD	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs5758659	0.810	rs5758623	chr22:42566314	G/C	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.38	-0.33	2.19e-5	Cognitive function;
PAAD	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	4.91	0.37	2.34e-6	Blood metabolite levels;
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg15674680	chr20:60982522	CABLES2	0.49	4.7	0.36	5.87e-6	Colorectal cancer;
PAAD	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.52	0.34	1.24e-5	Colorectal cancer;
PAAD	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg01990334	chr1:42801334	FOXJ3	-0.58	-5.46	-0.41	1.88e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-10.19	-0.64	6.47e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-5.26	-0.39	4.87e-7	Body mass index;
PAAD	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg14631576	chr9:95140430	CENPP	0.59	5.75	0.42	4.77e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs116248771	0.739	rs73156426	chr3:158346289	G/A	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg14349672	chr11:133703707	NA	-0.47	-5.01	-0.38	1.48e-6	Childhood ear infection;
PAAD	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg23241863	chr10:102295624	HIF1AN	-0.5	-4.38	-0.33	2.24e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.46	-0.4	1.89e-7	Fear of minor pain;
PAAD	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg14515779	chr1:101123966	NA	-0.53	-6.52	-0.47	9.75e-10	Monocyte count;
PAAD	cis	rs728616	0.867	rs17096197	chr10:81808184	T/C	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.81	-0.43	3.56e-8	Monocyte count;
PAAD	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.49	-0.34	1.42e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2275731	0.723	rs12220247	chr10:16540310	A/G	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg20406979	chr6:167373233	NA	0.33	4.43	0.34	1.76e-5	Crohn's disease;
PAAD	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg22143635	chr11:980567	AP2A2	0.52	5.51	0.41	1.51e-7	Alzheimer's disease (late onset);
PAAD	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.98	-0.59	9.92e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs35955747	0.902	rs5997929	chr22:31664032	C/T	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.43	-4.29	-0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4743820	0.651	rs10114465	chr9:93936592	C/T	cg14446406	chr9:93919335	NA	0.52	6.24	0.45	4.06e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1941184	0.526	rs9956575	chr18:29030497	A/G	cg03238162	chr18:29027701	DSG3	0.42	4.81	0.36	3.56e-6	Parkinson's disease (age of onset);
PAAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg05697835	chr1:2722811	NA	0.43	4.87	0.37	2.76e-6	Ulcerative colitis;
PAAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.44	-0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs2286503	1.000	rs2286503	chr7:22856606	C/T	cg04907244	chr7:22894795	SNORD93	-0.43	-5.33	-0.4	3.51e-7	Fibrinogen;
PAAD	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	1.04	13.92	0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.75	0.48	2.86e-10	Coronary artery disease;
PAAD	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.44	-4.75	-0.36	4.62e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg24053715	chr22:38214548	NA	-0.5	-5.19	-0.39	6.73e-7	Glioblastoma;Glioma;
PAAD	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg17328665	chr1:7887199	PER3	-0.47	-4.42	-0.34	1.88e-5	Crohn's disease;
PAAD	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-7.37	-0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.58	5.14	0.38	8.47e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.49	5.0	0.38	1.54e-6	Schizophrenia;
PAAD	cis	rs16958440	0.867	rs79712753	chr18:44676727	C/A	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	cis	rs8103278	1.000	rs7250497	chr19:46358425	A/G	cg14061069	chr19:46274453	DMPK	-0.64	-6.87	-0.49	1.55e-10	Coronary artery disease;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg04160749	chr8:58172571	NA	-0.65	-4.68	-0.36	6.21e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.87	5.36	0.4	3e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.67	7.44	0.52	6.87e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.67	5.74	0.42	5.07e-8	Exhaled nitric oxide output;
PAAD	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.75	8.9	0.59	1.61e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.32	-0.4	3.65e-7	Systemic lupus erythematosus;
PAAD	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.87	-9.46	-0.61	5.41e-17	Tonsillectomy;
PAAD	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs793571	0.915	rs2270664	chr15:59181985	G/A	cg08898775	chr15:59042684	ADAM10	-0.39	-4.49	-0.34	1.38e-5	Schizophrenia;
PAAD	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.57	5.92	0.43	2.09e-8	Dupuytren's disease;
PAAD	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs332507	0.830	rs3772789	chr3:124395607	A/G	cg05980111	chr3:124395277	KALRN	0.43	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.74	-7.45	-0.52	6.46e-12	Retinal vascular caliber;
PAAD	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg10932868	chr11:921992	NA	0.45	4.81	0.36	3.62e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.41	13.34	0.73	2.31e-27	Corneal structure;
PAAD	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.36	-4.73	-0.36	5.19e-6	Dupuytren's disease;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.16	-0.45	6.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs54211	0.908	rs137665	chr22:39735047	T/A	cg24399712	chr22:39784796	NA	-0.77	-4.35	-0.33	2.47e-5	Sudden cardiac arrest;
PAAD	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-5.15	-0.39	7.94e-7	Chronic sinus infection;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.94e-7	Alzheimer's disease;
PAAD	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26926768	chr12:34528122	NA	0.38	4.69	0.36	6.03e-6	Morning vs. evening chronotype;
PAAD	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg26205652	chr12:48591994	NA	0.93	9.64	0.62	1.89e-17	Longevity (90 years and older);
PAAD	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.6	5.12	0.38	9.06e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs8105895	0.935	rs10420019	chr19:22251905	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg24375607	chr4:120327624	NA	0.54	5.1	0.38	1e-6	Corneal astigmatism;
PAAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.86	10.94	0.66	6.5e-21	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg27182935	chr16:89790473	ZNF276	-0.68	-4.28	-0.33	3.3e-5	Skin colour saturation;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.5	-0.34	1.36e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs1519814	0.654	rs11986190	chr8:121013325	G/A	cg22335954	chr8:121166405	COL14A1	-0.64	-4.95	-0.37	1.98e-6	Breast cancer;
PAAD	cis	rs7631605	0.905	rs4678931	chr3:37093748	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.5	0.34	1.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs73019876	0.869	rs10416159	chr19:22168802	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.64	5.6	0.41	9.81e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7593730	0.551	rs6706685	chr2:161151559	T/C	cg22609984	chr2:161126801	NA	0.53	4.45	0.34	1.67e-5	Type 2 diabetes;
PAAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13047869	chr3:10149882	C3orf24	0.67	5.55	0.41	1.26e-7	Alzheimer's disease;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg24794623	chr5:52853787	NA	-0.54	-6.56	-0.47	7.88e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg26752003	chr8:145688521	CYHR1	0.57	6.35	0.46	2.35e-9	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25072359	chr17:41440525	NA	0.6	6.5	0.47	1.11e-9	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	6.83	0.48	1.89e-10	Lung function (FEV1/FVC);
PAAD	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.93e-11	Mosquito bite size;
PAAD	cis	rs501916	0.605	rs11632156	chr15:48082099	A/G	cg16110827	chr15:48056943	SEMA6D	-0.49	-5.27	-0.39	4.65e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.86	9.64	0.62	1.91e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.19	0.39	6.66e-7	Birth weight;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21607453	chr9:98783545	NCRNA00092	0.61	6.69	0.48	3.92e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-6.89	-0.49	1.36e-10	Morning vs. evening chronotype;
PAAD	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg26752888	chr8:11627280	NEIL2	-0.43	-4.48	-0.34	1.47e-5	Myopia (pathological);
PAAD	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16600432	chr14:64970085	ZBTB1;ZBTB25	0.54	6.54	0.47	8.65e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11123610	0.698	rs72769388	chr2:3725964	C/T	cg19052272	chr2:3704530	ALLC	-0.48	-4.95	-0.37	1.96e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg20913747	chr6:44695427	NA	-0.66	-6.62	-0.47	5.8e-10	Total body bone mineral density;
PAAD	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg00262122	chr8:11665843	FDFT1	-0.53	-4.58	-0.35	9.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.65	7.49	0.52	5.13e-12	Testicular germ cell tumor;
PAAD	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg05392440	chr1:2478653	NA	0.56	6.06	0.44	1.01e-8	Ulcerative colitis;
PAAD	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.59	-5.48	-0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	8.01e-9	Schizophrenia;
PAAD	cis	rs375066	0.935	rs396973	chr19:44399306	C/T	cg21496419	chr19:44306685	LYPD5	-0.43	-5.22	-0.39	5.71e-7	Breast cancer;
PAAD	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.67	0.65	3.35e-20	Bladder cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19028357	chr3:121468552	GOLGB1	0.65	6.51	0.47	1.02e-9	Obesity-related traits;
PAAD	trans	rs1146751	0.674	rs1694924	chr3:84896964	A/G	cg21856205	chr7:94953877	PON1	0.69	6.5	0.47	1.12e-9	Photic sneeze reflex;
PAAD	cis	rs13082711	0.680	rs7647818	chr3:27418896	T/C	cg02860705	chr3:27208620	NA	0.61	5.49	0.41	1.68e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-4.37	-0.33	2.28e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6074578	0.740	rs1865432	chr20:146951	A/G	cg16931068	chr20:139680	DEFB127	0.41	5.55	0.41	1.22e-7	Hirschsprung disease;
PAAD	cis	rs3736485	0.966	rs7174435	chr15:51895065	G/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.43e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg15117754	chr3:10150083	C3orf24	0.7	6.01	0.44	1.34e-8	Alzheimer's disease;
PAAD	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.96	-10.78	-0.66	1.75e-20	Coronary artery disease;
PAAD	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg27411982	chr8:10470053	RP1L1	-0.5	-5.58	-0.41	1.08e-7	Neuroticism;
PAAD	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg11464842	chr2:97427975	CNNM4	0.72	4.42	0.34	1.85e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs797680	0.856	rs7512911	chr1:93715818	C/G	cg04535902	chr1:92947332	GFI1	-0.45	-4.32	-0.33	2.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs776905	0.598	rs569557	chr13:113769917	G/A	cg09069900	chr13:113776964	F10	-0.56	-4.57	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.68	-7.4	-0.51	8.52e-12	Menarche (age at onset);
PAAD	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.88	-0.37	2.66e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg13385521	chr17:29058706	SUZ12P	-0.64	-4.44	-0.34	1.73e-5	Body mass index;
PAAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg25319279	chr11:5960081	NA	-0.66	-6.21	-0.45	4.79e-9	DNA methylation (variation);
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	1.05	7.27	0.51	1.73e-11	IgG glycosylation;
PAAD	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg02230254	chr11:65586170	NA	-0.32	-4.7	-0.36	5.71e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg00206168	chr11:65308501	LTBP3	0.53	5.48	0.41	1.75e-7	Bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22156735	chr22:43506786	BIK	-0.72	-6.45	-0.46	1.43e-9	Neuroticism;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07930192	chr7:1003750	NA	0.39	4.82	0.36	3.49e-6	Longevity;Endometriosis;
PAAD	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.98	8.77	0.58	3.34e-15	Bipolar disorder;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.92	11.98	0.7	1.03e-23	Menarche (age at onset);
PAAD	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg06740227	chr12:86229804	RASSF9	-0.6	-5.84	-0.43	3.12e-8	Major depressive disorder;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg10253484	chr15:75165896	SCAMP2	0.48	4.6	0.35	9.01e-6	Systemic lupus erythematosus;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20601919	chr2:219646831	CYP27A1	0.62	6.96	0.49	9.44e-11	Monocyte percentage of white cells;
PAAD	trans	rs9409082	0.715	rs997068	chr9:108984477	C/T	cg07010948	chr13:79181613	NA	0.34	6.31	0.46	2.95e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.77e-7	Life satisfaction;
PAAD	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg13256891	chr4:100009986	ADH5	-0.5	-4.93	-0.37	2.09e-6	Alcohol dependence;
PAAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.8	7.48	0.52	5.6e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12935418	0.672	rs3784814	chr16:81041257	C/G	cg16651780	chr16:81037892	C16orf61	0.66	6.23	0.45	4.4e-9	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg04369109	chr6:150039330	LATS1	0.49	4.69	0.36	5.92e-6	Lung cancer;
PAAD	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg05083358	chr7:2394359	EIF3B	-0.77	-5.59	-0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs5769707	0.967	rs739241	chr22:50052921	G/A	cg20744362	chr22:50050164	C22orf34	0.6	7.69	0.53	1.75e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14159971	chr2:239228995	TRAF3IP1	0.62	6.38	0.46	1.97e-9	Obesity-related traits;
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.44e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.68	-4.99	-0.38	1.65e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg11262906	chr1:85462892	MCOLN2	-0.62	-4.51	-0.34	1.3e-5	Serum sulfate level;
PAAD	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.71	-6.6	-0.47	6.36e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.54	5.76	0.42	4.59e-8	Menopause (age at onset);
PAAD	cis	rs9467160	0.834	rs17247566	chr6:24450404	A/C	cg16211469	chr6:24423932	MRS2	-0.46	-4.25	-0.33	3.77e-5	Liver enzyme levels;
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.61	5.43	0.4	2.14e-7	Obesity-related traits;
PAAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg25753631	chr6:25732923	NA	-0.48	-4.45	-0.34	1.68e-5	Iron status biomarkers;
PAAD	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg06217071	chr17:408420	NA	0.74	8.26	0.56	6.68e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg16606324	chr3:10149918	C3orf24	-0.6	-4.67	-0.35	6.51e-6	Alzheimer's disease;
PAAD	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg04717802	chr22:42394638	WBP2NL	0.56	4.86	0.37	2.86e-6	Birth weight;
PAAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs10037758	0.522	rs6888634	chr5:128298437	G/T	cg25555059	chr5:128301488	SLC27A6	0.29	5.12	0.38	9.14e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	5.91	0.43	2.14e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.39	-0.34	2.09e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg01075559	chr1:2537774	MMEL1	0.51	5.53	0.41	1.38e-7	Multiple sclerosis;
PAAD	cis	rs8064299	0.503	rs11653346	chr17:72773333	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.53	4.69	0.36	6.06e-6	Monocyte count;
PAAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.74	-6.27	-0.45	3.53e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.75	-6.88	-0.49	1.43e-10	Coronary artery disease;
PAAD	cis	rs2982694	1.000	rs1884052	chr6:152291366	G/C	cg26219152	chr6:152443475	SYNE1	-0.65	-4.34	-0.33	2.6e-5	Sudden cardiac arrest;
PAAD	cis	rs9287719	0.649	rs6722126	chr2:10721642	A/G	cg00105475	chr2:10696890	NA	0.61	6.47	0.46	1.27e-9	Prostate cancer;
PAAD	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.73	-4.88	-0.37	2.67e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.47	4.94	0.37	2.05e-6	Corneal astigmatism;
PAAD	cis	rs12304921	0.622	rs67466786	chr12:51505336	C/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.45	-0.4	2e-7	Type 2 diabetes;
PAAD	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.29	0.6	1.55e-16	Cognitive test performance;
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Body mass index;
PAAD	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg16584676	chr17:46985605	UBE2Z	-0.64	-6.54	-0.47	8.97e-10	Type 2 diabetes;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20015535	chr1:231556123	EGLN1	-0.64	-6.29	-0.45	3.21e-9	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.3	0.46	3.04e-9	Alzheimer's disease;
PAAD	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.53	-0.47	9.2e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6782025	0.837	rs338959	chr3:120964940	T/C	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.34e-6	Aging (facial);
PAAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs17023223	0.537	rs2794312	chr1:119591046	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.11	-0.38	9.62e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03891330	chr8:27491259	SCARA3	0.57	6.29	0.45	3.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7101378	0.577	rs6589047	chr11:108902062	T/C	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg24112000	chr20:60950667	NA	-0.69	-8.74	-0.58	3.91e-15	Colorectal cancer;
PAAD	cis	rs9467603	0.920	rs13213957	chr6:25786226	T/C	cg16898833	chr6:26189333	HIST1H4D	0.96	4.81	0.36	3.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.14	0.5	3.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.81	9.73	0.62	1.08e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg22705602	chr4:152727874	NA	0.49	5.24	0.39	5.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	7.78	0.53	1.02e-12	Total body bone mineral density;
PAAD	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.41	4.53	0.35	1.16e-5	Red cell distribution width;
PAAD	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-4.64	-0.35	7.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.81	-9.1	-0.59	4.69e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.18	-14.43	-0.76	2.82e-30	Type 1 diabetes nephropathy;
PAAD	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg19254793	chr6:44695348	NA	-0.41	-4.54	-0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.97	13.06	0.73	1.3e-26	Menopause (age at onset);
PAAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	1.09	13.74	0.74	1.96e-28	Breast cancer;
PAAD	cis	rs728616	0.681	rs55855057	chr10:82034729	G/A	cg19423196	chr10:82049429	MAT1A	0.5	4.92	0.37	2.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.49	4.84	0.37	3.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.57	-6.32	-0.46	2.81e-9	Cognitive function;
PAAD	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.8	6.06	0.44	1.04e-8	Diisocyanate-induced asthma;
PAAD	cis	rs216303	0.570	rs216321	chr12:6143984	T/C	cg12895370	chr12:6755816	ACRBP	-0.59	-4.66	-0.35	6.8e-6	Low vWF levels;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22550330	chr3:50336343	HYAL3;NAT6	0.66	6.88	0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.71	-7.19	-0.5	2.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg05785598	chr3:49045655	WDR6	0.42	4.88	0.37	2.6e-6	Parkinson's disease;
PAAD	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs9467711	0.651	rs55912630	chr6:25866935	T/C	cg21479132	chr6:26055353	NA	0.86	4.3	0.33	3.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	14.98	0.77	1e-31	Prudent dietary pattern;
PAAD	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4294134	0.608	rs12707239	chr7:135247183	C/T	cg04619859	chr7:134855396	C7orf49	0.56	4.36	0.33	2.35e-5	Paget's disease;
PAAD	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07151155	chr5:1473589	LPCAT1	-0.48	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.81	10.17	0.64	7.24e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-4.93	-0.37	2.1e-6	Pancreatic cancer;
PAAD	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.29	0.33	3.11e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg05083358	chr7:2394359	EIF3B	-0.75	-5.61	-0.41	9.31e-8	Multiple sclerosis;
PAAD	cis	rs2412208	0.796	rs6693136	chr1:7066567	G/A	cg26570804	chr1:6352357	ACOT7	0.56	5.28	0.39	4.48e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg23387468	chr7:139079360	LUC7L2	0.38	4.29	0.33	3.17e-5	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.28e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4748857	0.782	rs4748848	chr10:23531244	C/T	cg18853376	chr10:23633759	C10orf67	0.53	4.69	0.36	6.1e-6	Systemic lupus erythematosus;
PAAD	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.88	10.39	0.64	1.89e-19	Metabolic syndrome;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14625425	chr6:164012034	NA	0.65	6.73	0.48	3.24e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.76	0.36	4.52e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11718455	0.563	rs6809096	chr3:43902494	G/C	cg00181669	chr3:44000978	NA	-0.54	-5.85	-0.43	2.96e-8	Coronary artery disease;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.49	-4.91	-0.37	2.32e-6	Testicular germ cell tumor;
PAAD	trans	rs61677309	1.000	rs12577820	chr11:118164233	C/T	cg15548380	chr1:19984784	NBL1	-0.64	-6.6	-0.47	6.4e-10	Lung cancer in ever smokers;
PAAD	cis	rs7071247	0.915	rs10883875	chr10:105259917	T/C	cg20028483	chr10:104949090	NT5C2	0.66	4.72	0.36	5.32e-6	Platelet aggregation;
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-4.88	-0.37	2.69e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7707921	0.846	rs4293895	chr5:81425592	T/C	cg21483461	chr5:81570383	RPS23	-0.52	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16975963	0.644	rs12151280	chr19:38067890	A/C	cg08679971	chr19:38281047	NA	0.45	4.43	0.34	1.83e-5	Longevity;
PAAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg25452165	chr22:42524984	CYP2D6	0.6	5.77	0.42	4.33e-8	Schizophrenia;
PAAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.88	-8.59	-0.57	9.8e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3736485	0.934	rs1902593	chr15:51882080	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs883565	0.740	rs6763016	chr3:39098964	G/A	cg01426195	chr3:39028469	NA	-0.68	-7.18	-0.5	2.87e-11	Handedness;
PAAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs375066	0.762	rs10424336	chr19:44392100	C/T	cg11993925	chr19:44307056	LYPD5	0.52	6.31	0.46	2.83e-9	Breast cancer;
PAAD	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.6	-5.36	-0.4	3.08e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1419980	0.643	rs12229762	chr12:7776621	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26084319	chr14:21905280	CHD8	0.65	7.32	0.51	1.32e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-1.02	-13.99	-0.75	4.1e-29	Breast cancer;
PAAD	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14019695	chr9:139328340	INPP5E	0.45	4.28	0.33	3.34e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.89	0.37	2.52e-6	Lung cancer in ever smokers;
PAAD	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.6	5.44	0.4	2.06e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.51	-5.06	-0.38	1.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.96e-6	Vitiligo;
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.78	-8.35	-0.56	3.85e-14	Prostate cancer;
PAAD	cis	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg27411982	chr8:10470053	RP1L1	0.47	5.45	0.4	1.95e-7	Neuroticism;
PAAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.56	5.51	0.41	1.49e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18621852	chr3:10150065	C3orf24	0.6	4.57	0.35	1e-5	Alzheimer's disease;
PAAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12997796	0.556	rs7558827	chr2:86923178	A/G	cg25203885	chr2:87302643	LOC285074	-0.84	-6.18	-0.45	5.5e-9	Schizophrenia;
PAAD	cis	rs7631605	0.783	rs67385735	chr3:37138751	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11203032	1.000	rs11203032	chr10:90964614	T/G	cg16672925	chr10:90967113	CH25H	0.78	5.94	0.43	1.84e-8	Heart failure;
PAAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg03676636	chr4:99064102	C4orf37	0.32	5.69	0.42	6.28e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	High light scatter reticulocyte count;
PAAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.98	0.37	1.73e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg15278734	chr4:147443742	SLC10A7	-0.61	-6.46	-0.46	1.32e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs3206736	0.583	rs1649233	chr7:35000459	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs8031584	0.752	rs2001686	chr15:31185772	G/A	cg14829155	chr15:31115871	NA	-0.68	-7.39	-0.51	9.37e-12	Huntington's disease progression;
PAAD	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg18084798	chr19:33555255	RHPN2	-0.45	-4.7	-0.36	5.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2034650	0.563	rs2412523	chr15:40709686	C/G	cg05276125	chr15:40653601	DISP2	0.45	4.39	0.34	2.15e-5	Interstitial lung disease;
PAAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs1730008	0.778	rs827121	chr3:157947046	T/C	cg01557547	chr3:157823089	SHOX2	0.41	4.26	0.33	3.63e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-4.46	-0.34	1.58e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg14773178	chr5:1868261	NA	0.35	4.68	0.35	6.43e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.43	4.38	0.33	2.17e-5	Height;
PAAD	cis	rs877426	0.681	rs61973920	chr13:114836067	C/A	cg00571178	chr13:114841904	RASA3	-0.57	-4.77	-0.36	4.29e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg27246729	chr12:121163418	ACADS	0.4	4.36	0.33	2.41e-5	Mean corpuscular volume;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.21	0.39	6.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg10591111	chr5:226296	SDHA	0.61	4.88	0.37	2.68e-6	Breast cancer;
PAAD	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.67e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg21724239	chr8:58056113	NA	0.65	5.0	0.38	1.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-7.67	-0.53	1.93e-12	Colorectal cancer;
PAAD	cis	rs8105895	0.935	rs62111028	chr19:22272397	A/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-4.98	-0.37	1.73e-6	Diastolic blood pressure;
PAAD	cis	rs2282930	0.836	rs76602404	chr7:50737835	C/T	cg07379434	chr7:49814597	VWC2	0.25	4.44	0.34	1.75e-5	Bone mineral density;
PAAD	cis	rs377457	1.000	rs377457	chr16:85735652	A/G	cg07784872	chr16:85687041	KIAA0182	0.76	7.76	0.53	1.14e-12	Type 2 diabetes;
PAAD	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg22437258	chr11:111473054	SIK2	-0.51	-4.79	-0.36	3.97e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6844506	0.933	rs6841399	chr4:185221748	A/G	cg12654155	chr4:185238627	NA	-0.5	-4.76	-0.36	4.44e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.9	9.14	0.6	3.67e-16	Methadone dose in opioid dependence;
PAAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg14092988	chr3:52407081	DNAH1	0.4	5.11	0.38	9.72e-7	Electroencephalogram traits;
PAAD	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg20129853	chr10:51489980	NA	-0.47	-4.57	-0.35	9.94e-6	Prostate-specific antigen levels;
PAAD	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg10705379	chr10:99080932	FRAT1	-0.45	-5.22	-0.39	5.72e-7	Monocyte count;
PAAD	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	6.93	0.49	1.13e-10	Breast cancer;
PAAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.54	-7.46	-0.52	6.21e-12	Huntington's disease progression;
PAAD	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.78	4.83	0.36	3.34e-6	IgG glycosylation;
PAAD	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.72	7.57	0.52	3.44e-12	Blood protein levels;
PAAD	cis	rs3796727	0.609	rs3822198	chr4:8617255	C/T	cg05284713	chr4:8621361	CPZ	-0.42	-4.27	-0.33	3.46e-5	Sporadic neuroblastoma;
PAAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg11062466	chr8:58055876	NA	0.73	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.53	-5.4	-0.4	2.55e-7	Gout;
PAAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.68	6.54	0.47	9.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.41	4.71	0.36	5.44e-6	Height;
PAAD	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg03959625	chr15:84868606	LOC388152	0.49	5.37	0.4	2.96e-7	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-4.91	-0.37	2.34e-6	Personality dimensions;
PAAD	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs12936587	0.576	rs8073975	chr17:17555631	G/T	cg04398451	chr17:18023971	MYO15A	0.48	4.46	0.34	1.57e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3126085	0.515	rs12033221	chr1:152356113	A/G	cg26876637	chr1:152193138	HRNR	-0.6	-4.42	-0.34	1.85e-5	Atopic dermatitis;
PAAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.78	-0.36	4.08e-6	Bone mineral density;
PAAD	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.89	-8.46	-0.57	2.1e-14	Asthma;
PAAD	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19671926	chr4:122722719	EXOSC9	0.51	5.01	0.38	1.48e-6	Type 2 diabetes;
PAAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.79	7.59	0.52	3.08e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs17095355	1.000	rs17126877	chr10:111672786	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.34	-0.33	2.61e-5	Biliary atresia;
PAAD	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.95	-0.37	1.96e-6	Type 2 diabetes;
PAAD	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg21483461	chr5:81570383	RPS23	0.53	4.91	0.37	2.32e-6	Breast cancer;
PAAD	cis	rs1443512	0.588	rs1838173	chr12:54342822	C/T	cg25382128	chr12:54346509	NA	0.6	5.36	0.4	3.05e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.53	-0.47	9.4e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23281280	chr6:28129359	ZNF389	0.68	5.23	0.39	5.59e-7	Depression;
PAAD	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg04257695	chr17:30186438	C17orf79	-0.63	-5.12	-0.38	9.08e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.26	-0.39	4.89e-7	Ulcerative colitis;
PAAD	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.53	5.45	0.4	2e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs3206736	0.548	rs73110545	chr7:35063794	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.54	-0.35	1.12e-5	Diastolic blood pressure;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.99	8.49	0.57	1.77e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.47e-7	Total body bone mineral density;
PAAD	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.71	7.97	0.54	3.5e-13	Parkinson's disease;
PAAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg03959625	chr15:84868606	LOC388152	-0.48	-5.32	-0.4	3.61e-7	Schizophrenia;
PAAD	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.56	4.52	0.34	1.21e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.07	-0.38	1.16e-6	Obesity-related traits;
PAAD	cis	rs28795989	0.613	rs4627847	chr4:7922624	G/T	cg18538662	chr4:7941764	AFAP1	0.43	4.51	0.34	1.31e-5	Intraocular pressure;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.71	7.58	0.52	3.18e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.58	7.32	0.51	1.31e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.52	5.12	0.38	9.1e-7	Trans fatty acid levels;
PAAD	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.04	0.44	1.12e-8	Lung cancer in ever smokers;
PAAD	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.64	5.98	0.44	1.52e-8	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25753720	chr2:200904751	NA	0.57	6.35	0.46	2.31e-9	Smoking initiation;
PAAD	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg15322876	chr12:52910980	KRT5	-0.65	-4.4	-0.34	2.03e-5	Red blood cell count;
PAAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg11764359	chr7:65958608	NA	0.78	5.14	0.38	8.4e-7	Diabetic kidney disease;
PAAD	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	9.72	0.62	1.17e-17	Total body bone mineral density;
PAAD	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.93	-10.23	-0.64	4.99e-19	Parkinson's disease;
PAAD	cis	rs939584	0.825	rs2867124	chr2:622857	A/G	cg03610516	chr2:642275	NA	0.63	5.71	0.42	5.85e-8	Body mass index;
PAAD	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00864171	chr11:67383662	NA	0.55	5.71	0.42	5.68e-8	Mean corpuscular volume;
PAAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.54	-5.99	-0.44	1.47e-8	Total body bone mineral density;
PAAD	cis	rs73019876	0.502	rs632709	chr19:22233096	T/C	cg08394602	chr19:22123885	NA	0.46	4.82	0.36	3.49e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg07202610	chr7:1142643	C7orf50	-0.6	-4.55	-0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7567389	0.510	rs1473623	chr2:128196220	T/C	cg09760422	chr2:128146352	NA	-0.45	-7.5	-0.52	4.83e-12	Self-rated health;
PAAD	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg06745378	chr2:55841452	SMEK2	-0.49	-5.05	-0.38	1.27e-6	Alcohol dependence;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.49	-4.41	-0.34	1.93e-5	Acylcarnitine levels;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.94	-0.43	1.84e-8	Total cholesterol levels;
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.66	4.94	0.37	2.07e-6	Hip geometry;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-5.95	-0.43	1.8e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.5	4.71	0.36	5.47e-6	Longevity;Endometriosis;
PAAD	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-5.3	-0.39	4.09e-7	Educational attainment;
PAAD	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.97	14.68	0.77	6.23e-31	Dental caries;
PAAD	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.81	6.84	0.49	1.78e-10	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.52	4.35	0.33	2.47e-5	Depression;
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.54	5.27	0.39	4.64e-7	Prostate cancer;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.48	-5.42	-0.4	2.28e-7	Cardiovascular disease risk factors;
PAAD	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg16434002	chr17:42200994	HDAC5	0.62	5.56	0.41	1.16e-7	Total body bone mineral density;
PAAD	cis	rs757081	0.676	rs677042	chr11:17207080	A/T	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.73	-0.42	5.15e-8	Systolic blood pressure;
PAAD	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00526397	chr5:32228442	MTMR12	-0.64	-6.52	-0.47	9.6e-10	Obesity-related traits;
PAAD	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg18898632	chr2:242989856	NA	-0.81	-6.4	-0.46	1.84e-9	Obesity-related traits;
PAAD	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1519814	1.000	rs4871041	chr8:121136584	C/T	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs939584	1.000	rs6731688	chr2:630662	A/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg05376267	chr1:226075388	LEFTY1	-0.43	-5.11	-0.38	9.47e-7	Preschool internalizing problems;
PAAD	cis	rs2492906	0.515	rs2815560	chr10:27978030	C/T	cg25523538	chr10:28031957	MKX	0.51	4.35	0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.84	0.66	1.24e-20	Homoarginine levels;
PAAD	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	4.93	0.37	2.1e-6	Mean platelet volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27037103	chr6:37666346	MDGA1	-0.63	-6.36	-0.46	2.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-4.74	-0.36	4.89e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.03e-5	Breast cancer;
PAAD	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs1355223	0.701	rs745377	chr11:34858413	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.68	-7.17	-0.5	3.05e-11	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.16	0.6	3.41e-16	Bipolar disorder;
PAAD	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.6	0.47	6.42e-10	Total body bone mineral density;
PAAD	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.88e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08418111	chr11:18433745	LDHC	0.6	6.42	0.46	1.62e-9	Calcium levels;
PAAD	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg00579200	chr11:133705235	NA	-0.51	-5.77	-0.42	4.26e-8	Childhood ear infection;
PAAD	cis	rs539096	0.624	rs603542	chr1:44079411	T/C	cg12908607	chr1:44402522	ARTN	-0.42	-4.5	-0.34	1.34e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6784615	0.744	rs353548	chr3:52269491	A/G	cg27565382	chr3:53032988	SFMBT1	-1.03	-4.58	-0.35	9.68e-6	Waist-hip ratio;
PAAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.74	-0.48	3.05e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg08601574	chr20:25228251	PYGB	0.66	7.31	0.51	1.44e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.98	12.92	0.72	3.08e-26	Menarche (age at onset);
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02071572	chr4:1403502	NA	0.46	5.74	0.42	4.88e-8	Obesity-related traits;
PAAD	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.63	-6.72	-0.48	3.41e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs78761021	0.867	rs62067563	chr17:9786520	C/T	cg26853458	chr17:9805074	RCVRN	0.69	8.01	0.54	2.84e-13	Type 2 diabetes;
PAAD	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	0.81	6.32	0.46	2.71e-9	Obesity-related traits;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg25204440	chr1:209979598	IRF6	0.69	6.74	0.48	3.05e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs939584	0.935	rs13022164	chr2:632536	A/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.7	8.01	0.55	2.71e-13	Height;
PAAD	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.47	-5.2	-0.39	6.41e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.67	-6.87	-0.49	1.56e-10	Longevity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03938353	chr16:87740479	LOC100129637	-0.55	-6.72	-0.48	3.4e-10	Monocyte percentage of white cells;
PAAD	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg00129232	chr17:37814104	STARD3	-0.52	-4.59	-0.35	9.21e-6	Self-reported allergy;
PAAD	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg08562672	chr19:21860753	NA	0.42	4.4	0.34	2.03e-5	Pain;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-5.84	-0.43	3.03e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.73	-6.84	-0.49	1.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs939584	1.000	rs4854339	chr2:623212	T/C	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs5742933	0.744	rs13009889	chr2:190628568	G/A	cg04003228	chr2:190539410	ANKAR	-0.52	-4.32	-0.33	2.83e-5	Ferritin levels;
PAAD	cis	rs6987853	0.563	rs2974302	chr8:42443119	C/G	cg09913449	chr8:42400586	C8orf40	0.52	5.85	0.43	2.84e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs990171	0.506	rs4141631	chr2:102757216	A/G	cg22835712	chr2:102737379	NA	0.53	5.43	0.4	2.22e-7	Lymphocyte counts;
PAAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.53	-5.44	-0.4	2.07e-7	Body mass index;
PAAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.51	-4.56	-0.35	1.04e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg03983715	chr16:68378420	PRMT7	-0.96	-6.81	-0.48	2.1e-10	Magnesium levels;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.77	5.15	0.39	8.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.53	4.96	0.37	1.85e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg22189786	chr22:42395067	WBP2NL	0.42	4.42	0.34	1.91e-5	Cognitive function;
PAAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2013441	0.613	rs9901125	chr17:20008929	A/G	cg25070565	chr17:20044324	CYTSB	-0.41	-4.25	-0.33	3.77e-5	Obesity-related traits;
PAAD	cis	rs55788414	0.725	rs7184704	chr16:81188620	T/C	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.55	-0.57	1.23e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	4.25	0.33	3.69e-5	Longevity;
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.69	-6.67	-0.48	4.54e-10	Total body bone mineral density;
PAAD	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.57	5.28	0.39	4.49e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12044355	0.927	rs66909551	chr1:231834942	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	5.02	0.38	1.4e-6	Alzheimer's disease;
PAAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg24846680	chr1:228362309	C1orf69	0.46	4.4	0.34	2.04e-5	Diastolic blood pressure;
PAAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg10356904	chr22:49881777	NA	-0.47	-4.67	-0.35	6.62e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18902795	chr6:166124436	NA	-0.76	-7.65	-0.53	2.09e-12	Obesity-related traits;
PAAD	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.2	0.45	5.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.49	5.26	0.39	4.93e-7	Neuroticism;
PAAD	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.62	-5.11	-0.38	9.47e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.64	-6.72	-0.48	3.44e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11853189	0.938	rs77185764	chr15:78556076	G/A	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg16447950	chr5:562315	NA	-0.51	-4.86	-0.37	2.85e-6	Obesity-related traits;
PAAD	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.41	-4.56	-0.35	1.04e-5	Metabolite levels;
PAAD	cis	rs2652822	0.710	rs55862039	chr15:63451563	C/T	cg02713581	chr15:63449717	RPS27L	0.5	4.74	0.36	4.93e-6	Metabolic traits;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.32	0.33	2.79e-5	Platelet count;
PAAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.32	-0.33	2.8e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.37	0.71	9.36e-25	Prudent dietary pattern;
PAAD	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-5.22	-0.39	5.8e-7	Diastolic blood pressure;
PAAD	cis	rs2562456	0.833	rs55899865	chr19:21481735	G/A	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.69	-0.42	6.39e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7567389	0.719	rs11890243	chr2:127958041	C/A	cg11380483	chr2:127933992	NA	-0.51	-4.92	-0.37	2.25e-6	Self-rated health;
PAAD	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01230929	chr5:133706738	UBE2B	0.59	6.39	0.46	1.89e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18337363	chr3:52569053	NT5DC2	0.42	4.6	0.35	8.79e-6	Electroencephalogram traits;
PAAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25072359	chr17:41440525	NA	0.57	5.45	0.4	1.97e-7	Menopause (age at onset);
PAAD	cis	rs10943724	0.679	rs683706	chr6:81245203	A/G	cg19323245	chr6:80716898	TTK	-0.45	-4.78	-0.36	4.17e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg12700464	chr11:78128424	GAB2	0.59	4.45	0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8102137	0.962	rs62104480	chr19:30298800	A/G	cg27475126	chr19:30303651	CCNE1	-0.46	-5.13	-0.38	8.6e-7	Bladder cancer;
PAAD	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	4.92	0.37	2.23e-6	Neuroticism;
PAAD	cis	rs10090774	0.965	rs55967138	chr8:141954426	C/A	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.79	-7.27	-0.51	1.77e-11	Body mass index;
PAAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.44	5.01	0.38	1.5e-6	Height;
PAAD	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-6.1	-0.44	8.45e-9	Monocyte percentage of white cells;
PAAD	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.68	0.48	4.33e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg20243544	chr17:37824526	PNMT	0.54	4.6	0.35	8.71e-6	Self-reported allergy;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13939156	chr17:80058883	NA	-0.41	-4.4	-0.34	1.99e-5	Life satisfaction;
PAAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.32	0.6	1.31e-16	Gut microbiome composition (summer);
PAAD	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg27246729	chr12:121163418	ACADS	0.4	4.25	0.33	3.72e-5	Mean corpuscular volume;
PAAD	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.68	0.35	6.35e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.31	-0.4	3.83e-7	Breast cancer;
PAAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg10547527	chr2:198650123	BOLL	-0.74	-5.14	-0.38	8.5e-7	Ulcerative colitis;
PAAD	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg25833597	chr17:30823145	MYO1D	0.47	4.31	0.33	2.93e-5	Schizophrenia;
PAAD	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs73206853	0.764	rs55823622	chr12:110781628	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-4.53	-0.35	1.17e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg04717802	chr22:42394638	WBP2NL	0.6	4.31	0.33	2.98e-5	Birth weight;
PAAD	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg23719950	chr11:63933701	MACROD1	-0.72	-5.28	-0.39	4.3e-7	Mean platelet volume;
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.52	-0.47	9.74e-10	Lung cancer;
PAAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	10.67	0.65	3.46e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg24331049	chr13:111365604	ING1	-0.83	-4.5	-0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	5.74	0.42	5.02e-8	Mood instability;
PAAD	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg13870426	chr17:30244630	NA	-0.72	-5.71	-0.42	5.74e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs11700980	0.551	rs2832028	chr21:30114431	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg16147221	chr4:10020634	SLC2A9	0.46	4.25	0.33	3.66e-5	Bone mineral density;
PAAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.73	-5.02	-0.38	1.4e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	6.37	0.46	2.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.57e-7	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.68	-7.73	-0.53	1.35e-12	Motion sickness;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09791681	chr13:114144567	DCUN1D2;TMCO3	0.76	7.23	0.51	2.2e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs859767	0.704	rs1818614	chr2:135356351	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-4.44	-0.34	1.71e-5	Neuroticism;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg00738919	chr7:1100172	C7orf50	0.74	5.57	0.41	1.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-5.51	-0.41	1.53e-7	Electroencephalogram traits;
PAAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg02421172	chr7:1938701	MAD1L1	0.57	4.27	0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.69	5.58	0.41	1.1e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.62	7.09	0.5	4.76e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg00579200	chr11:133705235	NA	-0.49	-5.5	-0.41	1.58e-7	Childhood ear infection;
PAAD	cis	rs35084382	1.000	rs114503346	chr5:172192350	C/T	cg19801141	chr5:172198162	DUSP1	1.42	6.58	0.47	7.35e-10	Optic cup area;
PAAD	cis	rs2834188	1.000	rs9982088	chr21:34686841	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	4.44	0.34	1.71e-5	Narcolepsy;
PAAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg18833306	chr6:118973337	C6orf204	-0.54	-4.39	-0.34	2.08e-5	Diastolic blood pressure;
PAAD	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-0.44	-4.26	-0.33	3.54e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs7072216	0.587	rs2296435	chr10:100182285	C/T	cg17552801	chr10:99332121	ANKRD2	0.48	4.75	0.36	4.71e-6	Metabolite levels;
PAAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	trans	rs9409082	0.798	rs34703797	chr9:108926190	T/C	cg07010948	chr13:79181613	NA	-0.35	-6.47	-0.46	1.29e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-5.25	-0.39	5.03e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg15691649	chr6:25882328	NA	-0.52	-4.78	-0.36	4.08e-6	Blood metabolite levels;
PAAD	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.82e-6	Biliary atresia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20609493	chr15:60420227	NA	0.65	7.39	0.51	8.94e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	4.98	0.37	1.68e-6	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.71e-15	Lung cancer;
PAAD	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg21890820	chr11:65308645	LTBP3	0.94	7.59	0.52	2.97e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.6	0.35	8.89e-6	Hepatocellular carcinoma;
PAAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.6	-8.21	-0.55	8.8e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.46	-4.88	-0.37	2.61e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.55	-5.11	-0.38	9.45e-7	Strep throat;
PAAD	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2051773	0.567	rs77545208	chr11:17047747	G/T	cg15084286	chr11:17036142	PLEKHA7	0.56	4.87	0.37	2.8e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs17023223	0.537	rs12072768	chr1:119593918	A/G	cg26570165	chr1:119541833	NA	-0.45	-4.3	-0.33	3.09e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs7823896	0.722	rs61245151	chr8:110303556	T/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs9659323	0.612	rs10923721	chr1:119542187	A/G	cg26570165	chr1:119541833	NA	-0.54	-5.66	-0.42	7.3900000000000007e-08	Body mass index;
PAAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.73	8.68	0.58	5.56e-15	Lung cancer;
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00933542	chr6:150070202	PCMT1	0.58	6.08	0.44	9.16e-9	Lung cancer;
PAAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg23346134	chr3:49453900	TCTA	0.4	4.25	0.33	3.73e-5	Menarche (age at onset);
PAAD	cis	rs6976053	0.846	rs314375	chr7:100457344	G/A	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.8	0.58	2.77e-15	Colorectal cancer;
PAAD	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg24253500	chr15:84953950	NA	0.59	6.65	0.47	4.97e-10	Schizophrenia;
PAAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg03808351	chr9:123631620	PHF19	0.45	4.85	0.37	3.02e-6	Rheumatoid arthritis;
PAAD	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.57	0.35	1.02e-5	Lung cancer in ever smokers;
PAAD	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg23684787	chr19:1848742	REXO1	-0.51	-4.37	-0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-5.76	-0.42	4.59e-8	Colorectal cancer;
PAAD	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.6	5.66	0.42	7.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs308971	0.563	rs307611	chr3:12063344	G/C	cg15873301	chr3:12045459	SYN2	0.62	4.37	0.33	2.31e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.63	6.05	0.44	1.1e-8	Schizophrenia;
PAAD	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.25	0.56	7e-14	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.82	-9.03	-0.59	7.16e-16	Tuberculosis;
PAAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7873102	0.702	rs4878734	chr9:38010085	A/T	cg03528946	chr9:38069800	SHB	0.54	5.53	0.41	1.39e-7	Brain structure;
PAAD	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.84	5.47	0.41	1.83e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg01620082	chr3:125678407	NA	-1.21	-7.4	-0.51	8.57e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.79	9.14	0.6	3.8e-16	Hemoglobin concentration;
PAAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	7.11	0.5	4.14e-11	Menarche (age at onset);
PAAD	cis	rs990171	1.000	rs2058623	chr2:102986170	C/T	cg03938978	chr2:103052716	IL18RAP	0.44	4.42	0.34	1.84e-5	Lymphocyte counts;
PAAD	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.36	-0.4	3.1e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22035320	chr15:42170125	SPTBN5	0.61	6.5	0.47	1.06e-9	Smoking initiation;
PAAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg25952890	chr19:58913133	NA	0.58	5.12	0.38	9.31e-7	Mean platelet volume;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg22105103	chr4:187893119	NA	0.61	7.47	0.52	5.78e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	0.521	rs2762989	chr13:21392521	C/G	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.61	-8.6	-0.57	9.37e-15	Huntington's disease progression;
PAAD	cis	rs7873102	0.608	rs4342708	chr9:38006757	C/T	cg03528946	chr9:38069800	SHB	-0.5	-5.0	-0.38	1.58e-6	Brain structure;
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.44	6.54	0.47	8.9e-10	Mean corpuscular volume;
PAAD	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg08992911	chr2:238395768	MLPH	0.61	5.64	0.42	7.95e-8	Prostate cancer;
PAAD	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg11779900	chr17:80519722	FOXK2	-0.49	-5.15	-0.39	8.1e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg10547527	chr2:198650123	BOLL	-0.63	-4.33	-0.33	2.71e-5	Ulcerative colitis;
PAAD	cis	rs9857275	0.501	rs13083593	chr3:141198568	A/G	cg25967872	chr3:141205623	RASA2	0.49	4.3	0.33	3.05e-5	Prion diseases;
PAAD	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.77	-9.17	-0.6	3.1e-16	White blood cell count (basophil);
PAAD	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma;
PAAD	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-4.85	-0.37	2.97e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs4074493	0.963	rs6660782	chr1:231173904	A/G	cg22172038	chr1:231176991	FAM89A	0.49	4.47	0.34	1.52e-5	Carotid plaque burden (smoking interaction);
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.51	5.4	0.4	2.49e-7	Longevity;Endometriosis;
PAAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	1.07	12.41	0.71	7.28e-25	Eosinophil percentage of granulocytes;
PAAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-5.32	-0.4	3.68e-7	Mean corpuscular volume;
PAAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg14393609	chr7:65229607	NA	0.46	4.7	0.36	5.72e-6	Aortic root size;
PAAD	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg22578926	chr7:157437844	PTPRN2	-0.52	-4.32	-0.33	2.82e-5	Colorectal cancer;
PAAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.5	5.19	0.39	6.73e-7	Blood metabolite levels;
PAAD	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.59	6.01	0.44	1.31e-8	Migraine;
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.78	-0.36	4.14e-6	Lung cancer;
PAAD	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.63	-5.85	-0.43	2.88e-8	Diisocyanate-induced asthma;
PAAD	cis	rs6545883	0.825	rs4672426	chr2:61457148	G/A	cg14146966	chr2:61757674	XPO1	-0.4	-4.99	-0.38	1.63e-6	Tuberculosis;
PAAD	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07677032	chr17:61819896	STRADA	-0.56	-5.49	-0.41	1.69e-7	Prudent dietary pattern;
PAAD	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg10587741	chr22:38071170	LGALS1	0.43	4.88	0.37	2.7e-6	Fat distribution (HIV);
PAAD	cis	rs3106136	0.778	rs1593554	chr4:95278501	C/T	cg11021082	chr4:95130006	SMARCAD1	0.63	6.05	0.44	1.08e-8	Capecitabine sensitivity;
PAAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg04844267	chr4:1394941	NA	0.53	5.79	0.43	3.91e-8	Obesity-related traits;
PAAD	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg25952890	chr19:58913133	NA	0.67	5.7	0.42	5.94e-8	Mean platelet volume;
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.41	-5.72	-0.42	5.61e-8	Vitiligo;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg20090690	chr10:134436459	INPP5A	0.51	4.32	0.33	2.75e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.63	6.6	0.47	6.38e-10	Mood instability;
PAAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.95	10.87	0.66	1.04e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.81	-0.43	3.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg04352962	chr1:209979756	IRF6	0.53	4.62	0.35	8.26e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-6.71	-0.48	3.56e-10	Personality dimensions;
PAAD	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.7	-7.91	-0.54	4.81e-13	Temporomandibular joint disorder;
PAAD	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9535307	0.719	rs1198319	chr13:50376858	T/C	cg04663916	chr13:50265991	EBPL	-0.57	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg06917634	chr15:78832804	PSMA4	0.52	4.95	0.37	1.97e-6	Sudden cardiac arrest;
PAAD	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.49	-0.41	1.64e-7	Mean corpuscular volume;
PAAD	cis	rs7765175	0.598	rs9384862	chr6:113656446	C/T	cg19037598	chr6:113666021	NA	-0.41	-4.4	-0.34	2.05e-5	Coronary artery calcification;
PAAD	cis	rs6565189	0.865	rs4500746	chr16:30504344	T/C	cg17640201	chr16:30407289	ZNF48	0.47	4.43	0.34	1.79e-5	Tonsillectomy;
PAAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.08	-0.44	9.2e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7113874	0.802	rs1502317	chr11:8682018	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.84	-0.37	3.15e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26714650	chr12:56694279	CS	-1.29	-6.05	-0.44	1.08e-8	Psoriasis vulgaris;
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg04257695	chr17:30186438	C17orf79	-0.6	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-4.62	-0.35	7.97e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.15	-0.5	3.34e-11	Systemic lupus erythematosus;
PAAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.28e-10	Coronary artery disease;
PAAD	cis	rs6782228	1.000	rs11711038	chr3:128394310	T/G	cg15607142	chr3:128420513	NA	-0.41	-4.33	-0.33	2.72e-5	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.45	7.14	0.5	3.62e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg03989125	chr22:38214979	NA	-0.54	-5.45	-0.4	1.95e-7	Glioblastoma;Glioma;
PAAD	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-4.45	-0.34	1.68e-5	Plateletcrit;
PAAD	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-5.71	-0.42	5.77e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs901683	0.850	rs17157931	chr10:46054359	T/C	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13126279	chr21:47581558	C21orf56	-0.4	-4.45	-0.34	1.62e-5	Testicular germ cell tumor;
PAAD	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-4.34	-0.33	2.62e-5	IFN-related cytopenia;
PAAD	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.76	8.4	0.56	2.99e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15874270	chr4:123161078	KIAA1109	0.55	6.39	0.46	1.95e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg00106254	chr7:1943704	MAD1L1	0.49	4.44	0.34	1.75e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	4.3	0.33	3.08e-5	Total cholesterol levels;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.98	10.83	0.66	1.3e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.48	5.97	0.44	1.65e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11681884	0.786	rs28928270	chr2:113826223	C/G	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.17	-9.64	-0.62	1.85e-17	Post bronchodilator FEV1;
PAAD	cis	rs7588746	0.621	rs11691757	chr2:201148951	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.38	-0.4	2.72e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-6.74	-0.48	3.1e-10	Glomerular filtration rate;
PAAD	cis	rs427943	0.864	rs4819034	chr21:46628591	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.45	4.43	0.34	1.82e-5	Body mass index;
PAAD	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.55	-5.58	-0.41	1.08e-7	IgG glycosylation;
PAAD	cis	rs6494488	0.500	rs72744730	chr15:65040065	C/G	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.42	5.23	0.39	5.61e-7	Sitting height ratio;
PAAD	cis	rs3781663	0.526	rs6592468	chr11:70019047	G/A	cg06393558	chr11:69982916	ANO1	-0.58	-6.02	-0.44	1.28e-8	Survival in rectal cancer;
PAAD	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.83	-8.15	-0.55	1.24e-13	Breast cancer;
PAAD	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34891900	0.508	rs734297	chr22:18225684	T/C	cg13346441	chr22:18231586	BID	0.44	4.29	0.33	3.21e-5	Sum neutrophil eosinophil counts;
PAAD	cis	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg12568669	chr8:11666485	FDFT1	-0.32	-5.39	-0.4	2.59e-7	Monocyte count;
PAAD	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.69	-0.36	6.02e-6	Educational attainment;
PAAD	cis	rs6754311	0.589	rs749873	chr2:136817088	C/T	cg07169764	chr2:136633963	MCM6	-0.63	-6.01	-0.44	1.32e-8	Mosquito bite size;
PAAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg25197388	chr11:66278006	BBS1	-0.43	-4.3	-0.33	3.04e-5	Mean corpuscular volume;
PAAD	cis	rs8005677	0.828	rs2295682	chr14:23374862	C/T	cg01529538	chr14:23388837	RBM23	0.47	4.8	0.36	3.81e-6	Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16348316	chr2:128181325	PROC	0.67	6.64	0.47	5.19e-10	Obesity-related traits;
PAAD	cis	rs533581	0.816	rs8058234	chr16:88975447	C/G	cg08698997	chr16:88989212	CBFA2T3	0.49	5.92	0.43	2.11e-8	Social autistic-like traits;
PAAD	cis	rs59104589	0.617	rs3755395	chr2:242294116	A/G	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.73	-7.45	-0.52	6.62e-12	Cognitive function;
PAAD	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs10814247	1.000	rs10758308	chr9:35509782	G/C	cg18130437	chr9:35658183	CCDC107;RMRP	-0.42	-4.33	-0.33	2.74e-5	Psoriasis;
PAAD	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs735539	0.521	rs7984503	chr13:21448486	T/C	cg27499820	chr13:21296301	IL17D	0.56	5.16	0.39	7.69e-7	Dental caries;
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg10621924	chr7:39171070	POU6F2	0.28	4.45	0.34	1.66e-5	IgG glycosylation;
PAAD	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.39	-4.36	-0.33	2.37e-5	Prostate cancer;
PAAD	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg05338066	chr1:7812865	CAMTA1	0.62	4.55	0.35	1.11e-5	Inflammatory bowel disease;
PAAD	cis	rs8077059	0.959	rs8074377	chr17:55810287	T/G	cg12582317	chr17:55822272	NA	0.51	4.64	0.35	7.42e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg27395922	chr11:50257633	LOC441601	0.4	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19784903	chr17:45786737	TBKBP1	-0.55	-5.8	-0.43	3.76e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg22223119	chr13:99095684	FARP1	-0.73	-7.59	-0.52	3.05e-12	Obesity-related traits;
PAAD	cis	rs58521262	0.592	rs62123860	chr19:23021844	C/T	cg07749055	chr19:23076870	NA	-0.67	-4.82	-0.36	3.52e-6	Testicular germ cell tumor;
PAAD	cis	rs863345	0.604	rs12078065	chr1:158465063	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs16958440	1.000	rs76594057	chr18:44637272	A/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.18	15.67	0.79	1.55e-33	Type 1 diabetes nephropathy;
PAAD	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg26898376	chr11:64110657	CCDC88B	0.54	4.54	0.35	1.16e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.73	-7.37	-0.51	1.04e-11	Height;
PAAD	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-5.08	-0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.75	8.84	0.58	2.17e-15	Lung cancer;
PAAD	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.61	4.47	0.34	1.49e-5	Prostate cancer;
PAAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg24739098	chr15:79297159	RASGRF1	-0.33	-4.26	-0.33	3.63e-5	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.59	7.03	0.5	6.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.16	-0.39	7.68e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-1.07	-11.35	-0.68	5.34e-22	Longevity;
PAAD	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.45	4.59	0.35	9.21e-6	Airway imaging phenotypes;
PAAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg02574844	chr11:5959923	NA	-0.68	-6.24	-0.45	4.12e-9	DNA methylation (variation);
PAAD	cis	rs72960926	1.000	rs72950596	chr6:74921364	C/T	cg03266952	chr6:74778945	NA	-1.26	-6.39	-0.46	1.93e-9	Metabolite levels (MHPG);
PAAD	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg04907244	chr7:22894795	SNORD93	-0.38	-4.37	-0.33	2.31e-5	Fibrinogen;
PAAD	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.6	-0.41	9.92e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.84	0.49	1.81e-10	Body mass index;
PAAD	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg10985347	chr2:127963512	CYP27C1	-0.44	-4.41	-0.34	1.95e-5	Protein C levels;
PAAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.79	-7.86	-0.54	6.6e-13	Coronary artery disease;
PAAD	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.54	-0.35	1.16e-5	Height;
PAAD	cis	rs73198271	0.515	rs11779327	chr8:8624955	G/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg01759136	chr6:27242945	NA	-0.41	-4.49	-0.34	1.38e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg16447950	chr5:562315	NA	-0.67	-6.0	-0.44	1.39e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs713587	0.571	rs475868	chr2:25318059	A/G	cg01884057	chr2:25150051	NA	-0.37	-4.48	-0.34	1.43e-5	Body mass index in non-asthmatics;
PAAD	cis	rs4740619	0.619	rs10810521	chr9:16031471	C/G	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.92	12.2	0.7	2.66e-24	Methadone dose in opioid dependence;
PAAD	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-4.65	-0.35	7.1e-6	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.49	-0.68	2.25e-22	Coronary artery disease;
PAAD	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg02917321	chr22:38215204	NA	-0.45	-4.79	-0.36	3.85e-6	Glioblastoma;Glioma;
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.68	6.5	0.47	1.07e-9	Blood metabolite levels;
PAAD	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.64	7.48	0.52	5.58e-12	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.64	-6.72	-0.48	3.44e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4795519	0.922	rs8080557	chr17:22172228	G/A	cg22648282	chr17:21454238	C17orf51	-0.55	-5.59	-0.41	1.03e-7	Chronic myeloid leukemia;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.79	9.78	0.62	8.14e-18	Lymphocyte counts;
PAAD	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.53	4.93	0.37	2.12e-6	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.6	7.35	0.51	1.16e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-1.01	-12.75	-0.72	9.04e-26	Refractive error;
PAAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.07	-0.38	1.17e-6	Mean corpuscular volume;
PAAD	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.44	5.63	0.42	8.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06544989	chr22:39130855	UNC84B	0.45	4.33	0.33	2.7e-5	Menopause (age at onset);
PAAD	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.75	-8.14	-0.55	1.33e-13	Body mass index;
PAAD	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.61	0.57	8.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg05935833	chr10:81318306	SFTPA2	-0.5	-4.26	-0.33	3.5e-5	Borderline personality disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02467765	chr4:78978708	FRAS1	0.57	6.47	0.46	1.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2017305	0.833	rs2262239	chr10:70773553	T/C	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.0	-0.38	1.59e-6	Depression (quantitative trait);
PAAD	cis	rs939584	0.877	rs7559547	chr2:615627	C/T	cg14515364	chr2:636606	NA	0.47	4.28	0.33	3.34e-5	Body mass index;
PAAD	cis	rs939584	0.877	rs35802221	chr2:632904	A/G	cg03610516	chr2:642275	NA	0.59	5.24	0.39	5.32e-7	Body mass index;
PAAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.85	9.45	0.61	5.69e-17	Mortality in heart failure;
PAAD	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg10208897	chr5:178548229	ADAMTS2	-0.54	-4.79	-0.36	3.96e-6	Pubertal anthropometrics;
PAAD	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.49	5.14	0.39	8.18e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	4.35	0.33	2.5e-5	Iron status biomarkers;
PAAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-4.68	-0.35	6.39e-6	Personality dimensions;
PAAD	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.21	-0.39	6.18e-7	Personality dimensions;
PAAD	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Alcohol dependence;
PAAD	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.16	-0.39	7.74e-7	Body mass index;
PAAD	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg15017067	chr4:17643749	FAM184B	0.45	5.14	0.38	8.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10861661	0.963	rs3782707	chr12:107185187	G/A	cg15890332	chr12:107067104	RFX4	0.47	4.42	0.34	1.9e-5	Triglyceride levels;
PAAD	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11245990	chr11:68621969	NA	0.4	5.33	0.4	3.45e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1532557	1.000	rs1499289	chr1:224772665	A/G	cg09988837	chr1:224811939	CNIH3	-0.65	-4.84	-0.37	3.19e-6	Cancer;
PAAD	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg00450029	chr8:599525	NA	0.92	6.47	0.46	1.25e-9	IgG glycosylation;
PAAD	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.98	11.35	0.68	5.09e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg26816564	chr1:7831052	VAMP3	-0.6	-4.87	-0.37	2.75e-6	Inflammatory bowel disease;
PAAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg19784903	chr17:45786737	TBKBP1	0.53	5.66	0.42	7.43e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2455601	1.000	rs2455601	chr11:8899400	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.74	-6.14	-0.45	6.87e-9	Schizophrenia;
PAAD	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg20283391	chr11:68216788	NA	-0.54	-5.17	-0.39	7.25e-7	Total body bone mineral density;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg26516362	chr5:178986906	RUFY1	0.41	4.54	0.35	1.12e-5	Lung cancer;
PAAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09597638	chr17:3907349	NA	0.73	6.79	0.48	2.36e-10	Type 2 diabetes;
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.62	-8.9	-0.59	1.58e-15	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg00262122	chr8:11665843	FDFT1	-0.6	-5.1	-0.38	9.77e-7	Neuroticism;
PAAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs2790216	1.000	rs2590357	chr10:60019964	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.37	0.4	2.94e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.7	-7.7	-0.53	1.66e-12	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg18279126	chr7:2041391	MAD1L1	0.6	6.22	0.45	4.7e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.41	-8.6	-0.57	9.03e-15	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10943724	0.704	rs28360539	chr6:81275996	A/T	cg19323245	chr6:80716898	TTK	-0.42	-4.39	-0.34	2.11e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs959260	1.000	rs4788892	chr17:73391277	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.91	11.32	0.68	6.18e-22	Methadone dose in opioid dependence;
PAAD	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg23173402	chr1:227635558	NA	0.64	4.3	0.33	3.01e-5	Major depressive disorder;
PAAD	cis	rs10895140	0.756	rs4312036	chr11:101519352	C/T	cg17707274	chr11:102401523	MMP7	-0.55	-4.57	-0.35	1.02e-5	Menarche (age at onset);
PAAD	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.17	-0.39	7.34e-7	Reticulocyte count;
PAAD	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.47	-5.11	-0.38	9.52e-7	Educational attainment;
PAAD	cis	rs6782025	0.914	rs488636	chr3:121234327	C/T	cg16417163	chr3:121280760	NA	-0.49	-4.87	-0.37	2.78e-6	Aging (facial);
PAAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg02734326	chr4:10020555	SLC2A9	0.45	4.68	0.35	6.31e-6	Bone mineral density;
PAAD	cis	rs2051773	0.538	rs4468326	chr11:17041034	A/G	cg15084286	chr11:17036142	PLEKHA7	0.55	4.98	0.37	1.73e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg10932868	chr11:921992	NA	0.47	5.06	0.38	1.2e-6	Alzheimer's disease (late onset);
PAAD	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.55	-5.45	-0.4	1.96e-7	Capecitabine sensitivity;
PAAD	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs16944613	0.510	rs7163773	chr15:91144486	G/C	cg15547629	chr15:90437138	AP3S2	-0.51	-4.42	-0.34	1.9e-5	Colorectal cancer;
PAAD	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg21775007	chr8:11205619	TDH	-0.52	-4.65	-0.35	7.17e-6	Triglycerides;
PAAD	cis	rs2004318	1.000	rs79274890	chr19:55078044	G/A	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.54	-4.56	-0.35	1.02e-5	IgG glycosylation;
PAAD	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.57	-0.47	7.59e-10	Crohn's disease;
PAAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs78707713	0.841	rs77784890	chr10:71199295	G/C	cg12610070	chr10:71211762	TSPAN15	-0.57	-5.37	-0.4	2.92e-7	Venous thromboembolism;
PAAD	cis	rs7873102	0.568	rs7037465	chr9:38085678	C/G	cg03528946	chr9:38069800	SHB	-0.45	-4.32	-0.33	2.8e-5	Brain structure;
PAAD	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg19254793	chr6:44695348	NA	-0.46	-4.48	-0.34	1.46e-5	Total body bone mineral density;
PAAD	cis	rs11951515	0.508	rs6898866	chr5:43586375	G/A	cg01983248	chr5:43482804	C5orf28	-0.3	-4.29	-0.33	3.14e-5	Metabolite levels  (X-11787);
PAAD	cis	rs7561149	1.000	rs12464151	chr2:179690909	C/T	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.48	4.6	0.35	8.83e-6	QT interval;
PAAD	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.99	0.54	3.12e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg08729031	chr10:102416179	NA	0.43	4.33	0.33	2.68e-5	Body mass index;
PAAD	cis	rs7572733	0.792	rs1440089	chr2:198944947	C/T	cg10820045	chr2:198174542	NA	0.43	4.29	0.33	3.18e-5	Dermatomyositis;
PAAD	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg09998033	chr7:158218633	PTPRN2	0.67	7.0	0.49	7.89e-11	Obesity-related traits;
PAAD	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.57	-7.54	-0.52	4.04e-12	Endometriosis;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg14433983	chr11:636460	DRD4	-0.43	-4.29	-0.33	3.15e-5	Systemic lupus erythematosus;
PAAD	cis	rs593531	0.504	rs4944041	chr11:74029859	C/T	cg15670924	chr11:73669256	DNAJB13	0.45	4.92	0.37	2.27e-6	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18334848	chr8:42306711	SLC20A2	-0.56	-6.29	-0.45	3.15e-9	Monocyte percentage of white cells;
PAAD	cis	rs847851	0.958	rs847850	chr6:34904968	T/C	cg13196216	chr6:34231128	NA	-0.61	-5.02	-0.38	1.44e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-1.1	-11.79	-0.69	3.45e-23	Longevity;
PAAD	cis	rs12136530	0.593	rs9287047	chr1:19736534	T/C	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.58	7.77	0.53	1.09e-12	IgA nephropathy;
PAAD	cis	rs16975963	0.843	rs241935	chr19:38293963	A/C	cg08679971	chr19:38281047	NA	-0.45	-4.49	-0.34	1.42e-5	Longevity;
PAAD	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26926768	chr12:34528122	NA	0.38	4.61	0.35	8.66e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs62392365	0.649	rs215011	chr6:25384361	C/T	cg26336265	chr6:25042955	NA	0.86	4.81	0.36	3.68e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg10011062	chr15:43941034	CATSPER2	-0.75	-4.34	-0.33	2.57e-5	Lung cancer in ever smokers;
PAAD	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg14393609	chr7:65229607	NA	0.64	7.17	0.5	3.1e-11	Aortic root size;
PAAD	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg20130138	chr11:64956067	CAPN1	0.62	4.47	0.34	1.5e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17370718	chr7:154632540	DPP6	-0.64	-6.45	-0.46	1.4e-9	Obesity-related traits;
PAAD	cis	rs76866386	0.536	rs6709904	chr2:44080324	C/T	cg21783355	chr2:44066198	ABCG5;ABCG8	0.63	5.21	0.39	6.04e-7	Cholesterol, total;
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22168489	chr12:122356033	WDR66	-0.3	-4.4	-0.34	2.03e-5	Mean corpuscular volume;
PAAD	cis	rs282587	0.502	rs416703	chr13:113399219	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-5.02	-0.38	1.4e-6	Glycated hemoglobin levels;
PAAD	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg11779900	chr17:80519722	FOXK2	-0.49	-5.13	-0.38	8.78e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.23	-0.64	5.29e-19	Response to antipsychotic treatment;
PAAD	cis	rs793571	0.915	rs3145	chr15:59212111	G/A	cg05156742	chr15:59063176	FAM63B	-0.59	-5.09	-0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs2275731	0.525	rs7922050	chr10:16479007	C/G	cg04254609	chr10:16479192	PTER	-0.55	-6.03	-0.44	1.22e-8	Bone fracture in osteoporosis;
PAAD	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.6	6.55	0.47	8.53e-10	Testicular germ cell tumor;
PAAD	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.75	11.38	0.68	4.43e-22	Breast cancer;
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03605463	chr16:89740564	NA	0.49	4.62	0.35	8.23e-6	Vitiligo;
PAAD	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.77	-0.36	4.35e-6	Smoking behavior;
PAAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.5	-6.28	-0.45	3.33e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs3812762	0.871	rs11042068	chr11:8815599	C/G	cg11156914	chr11:8892616	ST5	0.52	4.62	0.35	8.2e-6	Hypospadias;
PAAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg01815783	chr4:1047043	NA	-0.4	-4.31	-0.33	2.93e-5	Recombination rate (males);
PAAD	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.63	-0.42	8.48e-8	Vitiligo;
PAAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.55	-6.38	-0.46	2.03e-9	Immature fraction of reticulocytes;
PAAD	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg23283495	chr1:209979779	IRF6	0.6	5.65	0.42	7.66e-8	Coronary artery disease;
PAAD	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg03684893	chr10:554711	DIP2C	-0.42	-4.51	-0.34	1.28e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	7.06	0.5	5.51e-11	Schizophrenia;
PAAD	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.55	0.61	3.11e-17	Bladder cancer;
PAAD	cis	rs7567389	0.719	rs1504135	chr2:128003251	C/T	cg09760422	chr2:128146352	NA	-0.38	-5.94	-0.43	1.84e-8	Self-rated health;
PAAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.88e-10	Lymphocyte counts;
PAAD	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.72	5.96	0.44	1.69e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg10547527	chr2:198650123	BOLL	-0.63	-4.33	-0.33	2.65e-5	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.54	4.42	0.34	1.85e-5	Iron status biomarkers;
PAAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.66	-5.76	-0.42	4.57e-8	Serum sulfate level;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	8.49	0.57	1.71e-14	Alzheimer's disease;
PAAD	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.16	16.63	0.8	4.95e-36	Body mass index;
PAAD	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9652601	0.959	rs9931397	chr16:11177394	G/C	cg04616529	chr16:11181986	CLEC16A	0.48	5.11	0.38	9.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.18	0.5	2.82e-11	Colorectal cancer;
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.0	-0.38	1.57e-6	Platelet count;
PAAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg12886188	chr2:28547016	BRE	-0.58	-6.34	-0.46	2.47e-9	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	0.67	6.59	0.47	6.97e-10	Obesity-related traits;
PAAD	cis	rs8063761	0.568	rs4350572	chr16:90043840	A/G	cg25193494	chr16:90016004	DEF8	0.49	4.83	0.37	3.24e-6	Squamous cell carcinoma;
PAAD	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	5.34	0.4	3.26e-7	Multiple sclerosis;
PAAD	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.38	-0.46	2.05e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.69	-5.03	-0.38	1.35e-6	Type 2 diabetes;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.87	9.45	0.61	5.97e-17	Prudent dietary pattern;
PAAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg21479132	chr6:26055353	NA	0.98	5.48	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11825685	0.945	rs77292504	chr11:134572985	G/A	cg02089395	chr11:134479357	NA	-0.67	-4.39	-0.34	2.08e-5	IgG glycosylation;
PAAD	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.5	-5.24	-0.39	5.33e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2278796	0.789	rs12136572	chr1:204962660	G/A	cg04862289	chr1:204966208	NFASC	0.45	4.58	0.35	9.75e-6	Mean platelet volume;
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12315302	chr6:26189340	HIST1H4D	0.56	4.3	0.33	2.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	1.2	13.21	0.73	4.96e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.32	-0.6	1.31e-16	Gut microbiome composition (summer);
PAAD	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-4.31	-0.33	2.94e-5	Mean corpuscular volume;
PAAD	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg11952622	chr19:58962976	ZNF324B	0.44	4.26	0.33	3.63e-5	Uric acid clearance;
PAAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg05697835	chr1:2722811	NA	0.43	4.85	0.37	2.99e-6	Ulcerative colitis;
PAAD	cis	rs728616	0.867	rs79904324	chr10:81804688	A/G	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.77	9.74	0.62	1.02e-17	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg14829360	chr17:73884958	NA	-0.64	-6.14	-0.45	6.86e-9	Psoriasis;
PAAD	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg20607287	chr7:12443886	VWDE	-0.74	-5.74	-0.42	4.97e-8	Coronary artery disease;
PAAD	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.45	4.81	0.36	3.53e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.57	-5.47	-0.41	1.78e-7	Neuroticism;
PAAD	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-1.04	-12.92	-0.72	3.13e-26	Total body bone mineral density;
PAAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg00988841	chr10:134556463	INPP5A	0.51	4.72	0.36	5.36e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26953293	chr16:85684108	KIAA0182	0.57	6.77	0.48	2.68e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.7	9.44	0.61	6.14e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg24354784	chr6:26059952	NA	-0.39	-4.26	-0.33	3.58e-5	Schizophrenia;
PAAD	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.85	9.18	0.6	3.01e-16	Schizophrenia;
PAAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg21351543	chr2:191399470	TMEM194B	-0.58	-4.5	-0.34	1.32e-5	Diastolic blood pressure;
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg26554054	chr8:600488	NA	0.91	6.02	0.44	1.27e-8	IgG glycosylation;
PAAD	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.61	-5.5	-0.41	1.61e-7	Mean corpuscular volume;
PAAD	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg02887458	chr19:19495540	GATAD2A	-0.54	-5.2	-0.39	6.48e-7	Bipolar disorder;
PAAD	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4239252	0.696	rs4795087	chr17:34091078	C/G	cg19411729	chr17:34207663	CCL5	-0.52	-4.62	-0.35	8.05e-6	Blood protein levels;
PAAD	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.44	-0.34	1.73e-5	Arsenic metabolism;
PAAD	cis	rs507080	0.922	rs644867	chr11:118567545	A/G	cg08498647	chr11:118550644	TREH	-0.39	-4.47	-0.34	1.52e-5	Serum metabolite levels;
PAAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.55	6.06	0.44	1.04e-8	Menopause (age at onset);
PAAD	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.75e-5	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27479418	chr10:126107594	OAT	0.62	6.49	0.47	1.17e-9	Myopia (pathological);
PAAD	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.35	-0.33	2.52e-5	Breast cancer;
PAAD	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.56	-5.03	-0.38	1.36e-6	Breast cancer;
PAAD	cis	rs2301888	0.830	rs2240336	chr1:17674402	C/T	cg01790353	chr1:17674483	PADI4	0.42	5.32	0.4	3.64e-7	Rheumatoid arthritis;
PAAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg09835421	chr16:68378352	PRMT7	-0.97	-5.8	-0.43	3.78e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.28	12.46	0.71	5.46e-25	Corneal structure;
PAAD	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.28	-0.51	1.7e-11	Neuroticism;
PAAD	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg20893579	chr22:38215064	NA	-0.45	-4.83	-0.36	3.32e-6	Glioblastoma;Glioma;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg19626725	chr5:178986131	RUFY1	-0.52	-5.53	-0.41	1.34e-7	Lung cancer;
PAAD	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.87	4.44	0.34	1.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.58	0.35	9.51e-6	P wave terminal force;
PAAD	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	7.48	0.52	5.65e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg18279126	chr7:2041391	MAD1L1	0.65	6.48	0.47	1.19e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.7	4.79	0.36	3.85e-6	Major depressive disorder;
PAAD	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.32	0.33	2.83e-5	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.65	5.06	0.38	1.18e-6	Alzheimer's disease;
PAAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.82	8.85	0.58	2.16e-15	Colorectal cancer;
PAAD	cis	rs17095355	0.605	rs2274979	chr10:111631781	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.48	-0.34	1.47e-5	Biliary atresia;
PAAD	cis	rs7927771	0.507	rs3740699	chr11:47504075	G/T	cg20307385	chr11:47447363	PSMC3	0.69	6.46	0.46	1.37e-9	Subjective well-being;
PAAD	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg20406979	chr6:167373233	NA	0.33	4.52	0.34	1.22e-5	Crohn's disease;
PAAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.52	-7.03	-0.5	6.61e-11	Height;
PAAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg10589385	chr1:150898437	SETDB1	0.39	4.74	0.36	4.88e-6	Melanoma;
PAAD	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.31	-0.33	2.88e-5	Morning vs. evening chronotype;
PAAD	cis	rs3764563	1.000	rs681417	chr19:15694802	G/T	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.25	-0.51	1.95e-11	Longevity;
PAAD	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.75e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg23254163	chr1:152506842	NA	0.61	7.03	0.5	6.38e-11	Hair morphology;
PAAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.86	-11.0	-0.67	4.39e-21	Height;
PAAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.56	-6.13	-0.45	7.06e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.32	0.46	2.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.75	-0.36	4.59e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-6.6	-0.47	6.44e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg07725925	chr16:89976287	TCF25	0.68	4.46	0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs1419980	0.730	rs11054565	chr12:7729433	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.08	-0.63	1.31e-18	Idiopathic membranous nephropathy;
PAAD	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.76	0.69	4e-23	Intelligence (multi-trait analysis);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg03380347	chr4:4107978	NA	0.57	6.3	0.46	3.03e-9	Body mass index;
PAAD	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg20936604	chr3:58311152	NA	-0.79	-4.27	-0.33	3.4e-5	Cholesterol, total;
PAAD	cis	rs9918079	0.560	rs7662032	chr4:15635414	C/G	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs2594989	0.887	rs4684071	chr3:11443084	C/G	cg01796438	chr3:11312864	ATG7	-0.58	-4.38	-0.34	2.16e-5	Circulating chemerin levels;
PAAD	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.6	5.6	0.41	9.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.19	-0.64	6.54e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.61	-6.93	-0.49	1.11e-10	Longevity;Endometriosis;
PAAD	cis	rs4727443	0.769	rs2301806	chr7:99580907	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.86	0.37	2.94e-6	Interstitial lung disease;
PAAD	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.27	-0.33	3.44e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs73019876	0.901	rs1848999	chr19:22135273	T/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.95	-13.17	-0.73	6.71e-27	Height;
PAAD	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg20636351	chr8:55087400	NA	-0.79	-8.85	-0.58	2.09e-15	Pelvic organ prolapse (moderate/severe);
PAAD	trans	rs7824557	0.527	rs4841495	chr8:10958824	T/C	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.25	-0.51	1.93e-11	Retinal vascular caliber;
PAAD	cis	rs1642645	0.757	rs3845574	chr1:42476574	C/A	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13482236	chr15:59062977	FAM63B	0.57	6.29	0.45	3.17e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg06057569	chr22:50219754	BRD1	0.67	4.99	0.38	1.61e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.86	9.39	0.61	8.2e-17	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-6.92	-0.49	1.19e-10	Gout;
PAAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.38	-0.33	2.19e-5	Skin colour saturation;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00131618	chr5:37248984	C5orf42	-0.61	-7.16	-0.5	3.21e-11	Body fat percentage;
PAAD	cis	rs1499972	0.941	rs56077465	chr3:117540517	C/T	cg07612923	chr3:117604196	NA	1.05	6.84	0.49	1.8e-10	Schizophrenia;
PAAD	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg15212455	chr7:39170539	POU6F2	0.33	4.58	0.35	9.53e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.25	-0.39	5e-7	Tonsillectomy;
PAAD	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.61	-6.29	-0.45	3.24e-9	IgG glycosylation;
PAAD	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg03517284	chr6:25882590	NA	0.55	4.98	0.37	1.74e-6	Iron status biomarkers;
PAAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs2882667	0.690	rs10054682	chr5:138259443	C/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs258892	0.843	rs11954478	chr5:72019275	A/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-6.8	-0.48	2.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.98e-7	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.19	10.08	0.63	1.26e-18	Uric acid levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24967142	chr12:112280161	C12orf47;MAPKAPK5	-0.83	-7.33	-0.51	1.24e-11	Neuroticism;
PAAD	cis	rs288326	0.561	rs78177114	chr2:183730429	A/G	cg09997497	chr2:183902928	NCKAP1	0.85	4.8	0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24741873	chr10:82223998	TSPAN14	0.45	4.91	0.37	2.33e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.55	4.77	0.36	4.26e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.63	4.75	0.36	4.69e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6689263	0.649	rs12074493	chr1:20875189	A/G	cg25104613	chr1:20649108	VWA5B1	0.51	4.28	0.33	3.33e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26743569	chr2:25194997	DNAJC27	0.59	6.84	0.49	1.78e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.6	-6.35	-0.46	2.4e-9	Lung cancer;
PAAD	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.49	-0.41	1.66e-7	Glomerular filtration rate;
PAAD	cis	rs728616	0.681	rs55899456	chr10:82050646	G/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-4.47	-0.34	1.54e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg02683114	chr2:24398427	C2orf84	-0.57	-5.49	-0.41	1.66e-7	Asthma;
PAAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg02910952	chr12:132569714	EP400NL	0.63	4.75	0.36	4.58e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.61	-6.05	-0.44	1.06e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	5.11	0.38	9.72e-7	Iron status biomarkers;
PAAD	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.73	0.58	4.24e-15	Corneal astigmatism;
PAAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.58	-5.25	-0.39	4.97e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16083429	chr3:49237500	CCDC36	-0.47	-5.13	-0.38	8.61e-7	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.58	0.47	7.33e-10	Lung cancer in ever smokers;
PAAD	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg09491104	chr22:46646882	C22orf40	-0.94	-5.75	-0.42	4.68e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02725872	chr8:58115012	NA	-0.78	-5.6	-0.41	9.91e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Diastolic blood pressure;
PAAD	cis	rs9463078	0.715	rs1891411	chr6:44760903	G/C	cg25276700	chr6:44698697	NA	0.52	6.03	0.44	1.19e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13560548	chr3:10150139	C3orf24	0.63	5.51	0.41	1.53e-7	Alzheimer's disease;
PAAD	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg04398451	chr17:18023971	MYO15A	0.75	8.38	0.56	3.35e-14	Total body bone mineral density;
PAAD	cis	rs7487075	0.619	rs4768723	chr12:46845724	C/T	cg14671384	chr12:47219920	SLC38A4	0.44	4.33	0.33	2.66e-5	Itch intensity from mosquito bite;
PAAD	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg02500806	chr16:89349976	ANKRD11	-0.78	-4.36	-0.33	2.43e-5	Red blood cell count;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.69	7.78	0.53	1.05e-12	Height;
PAAD	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg07701084	chr6:150067640	NUP43	0.56	4.77	0.36	4.36e-6	Lung cancer;
PAAD	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	1.14	8.31	0.56	4.82e-14	Type 2 diabetes;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.54	4.49	0.34	1.39e-5	Neutrophil percentage of white cells;
PAAD	cis	rs731174	0.840	rs525379	chr1:38151705	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.76	11.84	0.69	2.56e-23	Breast cancer;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.93	9.77	0.62	8.36e-18	Parkinson's disease;
PAAD	cis	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg27395922	chr11:50257633	LOC441601	-0.41	-4.47	-0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.86	7.52	0.52	4.31e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.37	0.33	2.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs731174	0.802	rs12123842	chr1:38187989	T/C	cg06917450	chr1:38156652	C1orf109	-0.51	-4.34	-0.33	2.61e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg10168330	chr8:27262164	PTK2B	0.37	4.4	0.34	2.03e-5	Neuroticism;
PAAD	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.73	0.58	4.25e-15	Corneal astigmatism;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	cis	rs2036402	0.955	rs6882177	chr5:156410136	C/T	cg21915449	chr5:156456672	HAVCR1	-0.38	-4.4	-0.34	2.06e-5	Hypertriglyceridemia;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16800975	chr8:17434541	PDGFRL	0.63	6.36	0.46	2.3e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4740619	0.803	rs1984246	chr9:15898553	A/C	cg14451791	chr9:16040625	NA	0.39	4.47	0.34	1.53e-5	Body mass index;
PAAD	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg14825688	chr5:132208181	LEAP2	-0.7	-5.06	-0.38	1.19e-6	Breast cancer;
PAAD	cis	rs9907295	0.591	rs8080959	chr17:34140454	G/A	cg19411729	chr17:34207663	CCL5	-0.52	-4.62	-0.35	8.2e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg10756475	chr4:1757242	NA	-0.49	-4.38	-0.33	2.21e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9463078	0.653	rs6910974	chr6:45082169	A/T	cg25276700	chr6:44698697	NA	-0.52	-5.74	-0.42	4.94e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs593531	0.513	rs3867268	chr11:74033377	A/C	cg23327896	chr11:73669290	DNAJB13	0.33	4.45	0.34	1.65e-5	Neuroticism;
PAAD	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.47	4.86	0.37	2.95e-6	Resting heart rate;
PAAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02658657	chr17:8339255	NDEL1	-0.77	-7.11	-0.5	4.26e-11	Neuroticism;
PAAD	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg01866162	chr16:67596514	CTCF	0.58	4.36	0.33	2.39e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.95	9.55	0.61	3.18e-17	Coronary artery disease;
PAAD	cis	rs1925576	0.935	rs7077924	chr10:68677437	T/C	cg04444303	chr10:69634106	NA	-0.44	-4.3	-0.33	3.04e-5	Educational attainment (years of education);
PAAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.68	7.65	0.53	2.19e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.53	0.41	1.37e-7	Total body bone mineral density;
PAAD	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg20913747	chr6:44695427	NA	-0.66	-6.63	-0.47	5.65e-10	Total body bone mineral density;
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.93	-8.28	-0.56	5.98e-14	Other erythrocyte phenotypes;
PAAD	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg08835956	chr7:39171034	POU6F2	0.27	4.49	0.34	1.4e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-4.58	-0.35	9.51e-6	Lung cancer;
PAAD	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.51	-0.47	1.02e-9	Coffee consumption (cups per day);
PAAD	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg05484376	chr2:27715224	FNDC4	0.44	4.54	0.35	1.15e-5	Oral cavity cancer;
PAAD	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.69	-0.53	1.73e-12	Brugada syndrome;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg08676812	chr11:65308423	LTBP3	1.55	8.0	0.54	2.88e-13	Height;
PAAD	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg08501292	chr6:25962987	TRIM38	0.9	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2492906	0.515	rs2637303	chr10:27980318	G/T	cg25523538	chr10:28031957	MKX	-0.51	-4.35	-0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg25324976	chr17:61989376	CSHL1	0.54	4.28	0.33	3.28e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.71	-5.94	-0.43	1.89e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.55	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg03983715	chr16:68378420	PRMT7	-0.81	-5.7	-0.42	6.17e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.45	4.53	0.34	1.2e-5	Menopause (age at onset);
PAAD	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg21427119	chr20:30132790	HM13	-0.56	-4.56	-0.35	1.05e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.57	-5.61	-0.41	9.54e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg19025524	chr12:109796872	NA	-0.56	-4.75	-0.36	4.76e-6	Neuroticism;
PAAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs7631605	0.905	rs9823428	chr3:37111130	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg02734326	chr4:10020555	SLC2A9	-0.52	-5.22	-0.39	5.91e-7	Bone mineral density;
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg01815783	chr4:1047043	NA	-0.47	-4.43	-0.34	1.76e-5	Recombination rate (females);
PAAD	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05367846	chr22:18507520	MICAL3	0.7	7.35	0.51	1.14e-11	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	8.8	0.58	2.86e-15	Homoarginine levels;
PAAD	cis	rs56677333	1.000	rs56677333	chr8:6750801	A/C	cg02606480	chr8:6366994	ANGPT2;MCPH1	-0.72	-4.35	-0.33	2.53e-5	Psoriatic arthritis;
PAAD	cis	rs2051773	0.510	rs11024130	chr11:17056425	G/A	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs300774	1.000	rs300797	chr2:107140	G/A	cg21211680	chr2:198530	NA	-0.58	-5.39	-0.4	2.61e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-8.02	-0.55	2.66e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.54	6.25	0.45	3.85e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.43	6.24	0.45	4.12e-9	Information processing speed;
PAAD	cis	rs7119038	0.629	rs11216995	chr11:118603526	G/A	cg04176122	chr11:118779835	BCL9L	0.43	4.62	0.35	8.08e-6	Sjögren's syndrome;
PAAD	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg21253087	chr9:139290292	SNAPC4	0.49	4.31	0.33	2.96e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.91	7.82	0.54	8.38e-13	Alzheimer's disease;
PAAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs3026101	0.671	rs28437236	chr17:5319214	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.16	0.45	6.36e-9	Body mass index;
PAAD	cis	rs73568641	0.583	rs73570642	chr6:154069117	C/A	cg15658985	chr6:154448740	OPRM1	0.55	4.57	0.35	1.01e-5	Methadone dose in opioid dependence;
PAAD	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-4.26	-0.33	3.58e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs1015291	0.708	rs1388692	chr12:20008682	A/G	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs9361491	0.608	rs4706725	chr6:79466391	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.73	-0.36	5.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	7.12	0.5	4.1e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	5.1	0.38	9.81e-7	Height;
PAAD	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg15128208	chr22:42549153	NA	0.52	4.58	0.35	9.76e-6	Birth weight;
PAAD	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.35	4.59	0.35	9.26e-6	Educational attainment (years of education);
PAAD	cis	rs6908034	0.660	rs74457659	chr6:19760725	C/T	cg02682789	chr6:19804855	NA	0.8	4.57	0.35	9.8200000000000008e-06	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs3733418	0.799	rs13110766	chr4:165956628	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.46	-4.44	-0.34	1.72e-5	Obesity-related traits;
PAAD	cis	rs7127900	0.950	rs11603101	chr11:2232814	C/T	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.41	0.46	1.71e-9	Bladder cancer;
PAAD	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Obesity-related traits;
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg10729496	chr3:10149963	C3orf24	0.83	6.13	0.45	7.3e-9	Alzheimer's disease;
PAAD	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.42	4.81	0.36	3.59e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10046574	0.656	rs76799185	chr7:135194266	G/C	cg27474649	chr7:135195673	CNOT4	0.72	5.0	0.38	1.56e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.42	-5.42	-0.4	2.33e-7	Ulcerative colitis;
PAAD	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.77	-0.42	4.39e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.92	-10.28	-0.64	3.81e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg12935359	chr14:103987150	CKB	-0.55	-5.56	-0.41	1.2e-7	Body mass index;
PAAD	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg23093090	chr10:104574429	C10orf26	-0.46	-4.91	-0.37	2.29e-6	Arsenic metabolism;
PAAD	cis	rs4548095	1	rs4548095	chr7:100226665	C/T	cg20848291	chr7:100343083	ZAN	0.51	4.92	0.37	2.28e-6	Plateletcrit;
PAAD	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.93	-8.31	-0.56	4.83e-14	Breast cancer;
PAAD	trans	rs9372498	1.000	rs62421489	chr6:118601980	G/A	cg15607664	chr12:57630422	NDUFA4L2	-0.78	-7.6	-0.52	2.81e-12	Diastolic blood pressure;
PAAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg07703079	chr11:430292	ANO9	0.79	4.51	0.34	1.3e-5	Body mass index;
PAAD	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.66	-7.43	-0.52	7.13e-12	Schizophrenia;
PAAD	cis	rs7619833	0.620	rs1445111	chr3:27253971	C/T	cg02860705	chr3:27208620	NA	0.4	4.3	0.33	3.06e-5	Breast cancer;
PAAD	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.57	-0.47	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.65	6.05	0.44	1.08e-8	Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1144	0.537	rs2470942	chr7:104583772	G/A	cg04380332	chr7:105027541	SRPK2	-0.65	-6.93	-0.49	1.1e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	4.35	0.33	2.46e-5	Height;
PAAD	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	11.01	0.67	4.14e-21	Electrocardiographic conduction measures;
PAAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.63	5.86	0.43	2.8e-8	Urate levels;
PAAD	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	5.85	0.43	2.86e-8	Blood protein levels;
PAAD	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg11498726	chr8:26250323	BNIP3L	-0.49	-4.81	-0.36	3.57e-6	Red cell distribution width;
PAAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.68e-5	Parkinson's disease;
PAAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05214679	chr19:36630902	CAPNS1	0.57	6.4	0.46	1.83e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-1.15	-11.78	-0.69	3.73e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg21269045	chr12:125625041	AACS	-0.48	-4.65	-0.35	7.06e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	1.13	6.15	0.45	6.49e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.64	6.67	0.48	4.56e-10	Parkinson's disease;
PAAD	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg20636351	chr8:55087400	NA	-0.69	-6.43	-0.46	1.59e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg10434728	chr15:90938212	IQGAP1	0.44	4.61	0.35	8.34e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg25204440	chr1:209979598	IRF6	0.67	5.73	0.42	5.33e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.83	0.43	3.17e-8	Lung cancer;
PAAD	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.51e-5	Life satisfaction;
PAAD	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26926768	chr12:34528122	NA	0.37	4.31	0.33	2.95e-5	Morning vs. evening chronotype;
PAAD	cis	rs8016982	0.662	rs1957546	chr14:81639984	C/T	cg01989461	chr14:81687754	GTF2A1	0.6	4.75	0.36	4.61e-6	Schizophrenia;
PAAD	cis	rs7260538	0.808	rs1552219	chr19:41525374	A/G	cg13322449	chr19:42300200	CEACAM3	0.38	4.38	0.33	2.18e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.69	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.86	7.79	0.53	9.77e-13	Coronary artery disease;
PAAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.47	4.9	0.37	2.44e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-4.8	-0.36	3.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-1.41	-10.2	-0.64	6.03e-19	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08623091	chr2:209224999	NA	0.61	6.29	0.45	3.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg07870213	chr5:140052090	DND1	-0.73	-7.02	-0.49	7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17554472	chr22:41940697	POLR3H	0.57	4.42	0.34	1.86e-5	Vitiligo;
PAAD	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.71	-11.15	-0.67	1.83e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.77	8.41	0.56	2.78e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1075265	0.901	rs1058320	chr2:54312153	A/T	cg04546899	chr2:54196757	PSME4	0.31	4.37	0.33	2.25e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.5	-0.41	1.54e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04569837	chr5:60921535	NA	0.81	7.77	0.53	1.07e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12379764	chr21:47803548	PCNT	0.45	4.27	0.33	3.49e-5	Testicular germ cell tumor;
PAAD	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg12935359	chr14:103987150	CKB	-0.58	-6.09	-0.44	8.8e-9	Body mass index;
PAAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.65	-7.02	-0.49	6.95e-11	Mean corpuscular volume;
PAAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs16958440	0.708	rs62096477	chr18:44662310	G/A	cg17192377	chr18:44677553	HDHD2	0.61	4.26	0.33	3.51e-5	Sitting height ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21881364	chr11:72438004	ARAP1	0.57	6.66	0.48	4.76e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.61	0.35	8.63e-6	Electroencephalogram traits;
PAAD	cis	rs1697938	0.634	rs1450656	chr5:40949997	C/T	cg17351974	chr5:40835760	RPL37	0.41	4.26	0.33	3.52e-5	Multiple system atrophy;
PAAD	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25131503	chr6:90529529	MDN1	0.57	6.49	0.47	1.15e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.72	0.58	4.63e-15	Lung cancer;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01585852	chr22:24235823	MIF	-0.43	-4.63	-0.35	7.64e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	4.44	0.34	1.76e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg10729496	chr3:10149963	C3orf24	-0.83	-7.01	-0.49	7.43e-11	Alzheimer's disease;
PAAD	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.49	5.6	0.41	1e-7	Coronary artery disease;
PAAD	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.85	-8.05	-0.55	2.21e-13	Neurofibrillary tangles;
PAAD	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.43	-6.67	-0.48	4.53e-10	Mean corpuscular volume;
PAAD	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs13053817	1.000	rs13057815	chr22:29853526	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-4.93	-0.37	2.09e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	cis	rs73198271	0.729	rs11786474	chr8:8605492	T/C	cg01851573	chr8:8652454	MFHAS1	0.56	4.33	0.33	2.67e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.71	-7.01	-0.49	7.19e-11	Retinal vascular caliber;
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.46	-4.32	-0.33	2.85e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.61	-6.62	-0.47	5.88e-10	Calcium levels;
PAAD	trans	rs901683	1.000	rs71494787	chr10:45972247	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs2221894	0.770	rs10088428	chr8:28909523	C/T	cg20212339	chr8:28908912	HMBOX1	-0.48	-4.71	-0.36	5.47e-6	Obesity-related traits;
PAAD	cis	rs28595532	0.841	rs116093021	chr4:119763872	C/G	cg21605333	chr4:119757512	SEC24D	2.0	10.54	0.65	7.83e-20	Cannabis dependence symptom count;
PAAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.99	-13.25	-0.73	3.94e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg17366294	chr4:99064904	C4orf37	0.45	5.01	0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg08888203	chr3:10149979	C3orf24	0.83	7.0	0.49	7.76e-11	Alzheimer's disease;
PAAD	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-8.06	-0.55	2.12e-13	Exhaled nitric oxide output;
PAAD	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg14393609	chr7:65229607	NA	0.6	6.29	0.45	3.29e-9	Aortic root size;
PAAD	cis	rs933117	0.786	rs112628083	chr21:31074627	T/A	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.29	-0.33	3.18e-5	Body mass index;
PAAD	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs6988985	0.617	rs7016924	chr8:144006073	A/G	cg10324643	chr8:143916377	GML	-0.41	-4.41	-0.34	1.95e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg24296786	chr1:45957014	TESK2	0.52	4.85	0.37	3.05e-6	Homocysteine levels;
PAAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs3026101	0.554	rs1806259	chr17:5315502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.84	0.43	3.05e-8	Body mass index;
PAAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.81	7.86	0.54	6.56e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.65	-5.5	-0.41	1.55e-7	Neuroticism;
PAAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg06569542	chr10:98946673	SLIT1	0.51	5.68	0.42	6.62e-8	Monocyte count;
PAAD	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.53	5.54	0.41	1.27e-7	Red blood cell count;
PAAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.43	0.34	1.83e-5	Breast cancer;
PAAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-6.42	-0.46	1.66e-9	Total cholesterol levels;
PAAD	trans	rs901683	1.000	rs71496620	chr10:46074329	G/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg05082376	chr22:42548792	NA	-0.53	-5.83	-0.43	3.25e-8	Cognitive function;
PAAD	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg01305830	chr4:1604576	NA	0.46	4.57	0.35	1.01e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-0.91	-9.82	-0.62	6.14e-18	Body mass index;
PAAD	cis	rs3736485	0.966	rs7176044	chr15:51895343	T/C	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2.03e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs16975963	0.843	rs73031215	chr19:38433555	G/A	cg08679971	chr19:38281047	NA	0.55	5.29	0.39	4.1e-7	Longevity;
PAAD	cis	rs9739640	1	rs9739640	chr12:53783174	A/G	cg20591337	chr12:53693442	C12orf10	-0.63	-4.48	-0.34	1.48e-5	Reticulocyte count;
PAAD	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.45	-0.34	1.68e-5	Joint mobility (Beighton score);
PAAD	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.06	-0.38	1.22e-6	Breast cancer;
PAAD	cis	rs12681288	0.695	rs6559205	chr8:973607	G/A	cg15309053	chr8:964076	NA	0.51	5.65	0.42	7.59e-8	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.42	-4.56	-0.35	1.05e-5	Motion sickness;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797685	0.786	rs72632093	chr1:7897988	G/A	cg17328665	chr1:7887199	PER3	-0.55	-4.72	-0.36	5.37e-6	Crohn's disease;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg15674680	chr20:60982522	CABLES2	-0.63	-5.96	-0.44	1.68e-8	Colorectal cancer;
PAAD	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg01631684	chr10:65280961	REEP3	-0.46	-4.66	-0.35	6.86e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.33	-0.46	2.68e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.87	10.96	0.66	5.73e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.43	4.64	0.35	7.41e-6	Depression;
PAAD	cis	rs16910800	0.953	rs73481416	chr11:23204663	T/A	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12776158	1.000	rs12776158	chr10:71218094	T/C	cg12610070	chr10:71211762	TSPAN15	-0.5	-4.73	-0.36	5.1e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	4.98	0.37	1.68e-6	Mean platelet volume;
PAAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg21929781	chr1:2537748	MMEL1	0.51	5.38	0.4	2.8e-7	Ulcerative colitis;
PAAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.65	7.58	0.52	3.09e-12	Platelet distribution width;
PAAD	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.75e-5	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.65	0.53	2.19e-12	Motion sickness;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	9.35	0.6	1.05e-16	Platelet count;
PAAD	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg23018236	chr17:30244563	NA	-0.6	-4.78	-0.36	4.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.42	-4.32	-0.33	2.83e-5	Response to statin therapy;
PAAD	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg14515779	chr1:101123966	NA	-0.55	-6.44	-0.46	1.49e-9	Monocyte count;
PAAD	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.27	0.56	6.28e-14	Corneal astigmatism;
PAAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.74	-7.98	-0.54	3.27e-13	DNA methylation (variation);
PAAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-4.58	-0.35	9.63e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg01329690	chr21:38580129	DSCR9	0.33	4.42	0.34	1.89e-5	Eye color traits;
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.38	-4.99	-0.38	1.65e-6	Age at first birth;
PAAD	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.68	7.07	0.5	5.14e-11	Response to antidepressants and depression;
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	5.93	0.43	1.99e-8	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.65	6.43	0.46	1.57e-9	Primary sclerosing cholangitis;
PAAD	cis	rs76866386	1.000	rs115445558	chr2:44063098	G/C	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.83	-5.25	-0.39	5.15e-7	Cholesterol, total;
PAAD	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.61	5.89	0.43	2.38e-8	Subjective well-being;
PAAD	cis	rs3762637	0.882	rs9818537	chr3:122086457	G/T	cg24169773	chr3:122142474	KPNA1	-0.65	-4.45	-0.34	1.69e-5	LDL cholesterol levels;
PAAD	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs2594989	0.837	rs7642031	chr3:11453754	G/A	cg01796438	chr3:11312864	ATG7	-0.58	-4.42	-0.34	1.87e-5	Circulating chemerin levels;
PAAD	cis	rs1678542	1.000	rs1678542	chr12:57968715	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.32	-0.4	3.67e-7	Rheumatoid arthritis;
PAAD	cis	rs1419980	0.730	rs7978534	chr12:7773878	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.55	6.31	0.46	2.87e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.65	5.28	0.39	4.46e-7	Gut microbiome composition (summer);
PAAD	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg24112000	chr20:60950667	NA	-0.7	-8.66	-0.57	6.34e-15	Colorectal cancer;
PAAD	cis	rs6585424	1.000	rs61860025	chr10:81925554	G/T	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9309711	0.961	rs6739269	chr2:3470995	C/T	cg25811867	chr2:3488468	NA	0.47	4.36	0.33	2.4e-5	Neurofibrillary tangles;
PAAD	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.35	-5.01	-0.38	1.52e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.92	0.37	2.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2562456	0.833	rs2154302	chr19:21490411	G/A	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.42	-0.4	2.3e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.58	-0.41	1.07e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.86	9.86	0.62	4.97e-18	Gout;
PAAD	cis	rs13065560	0.505	rs4396821	chr3:38917641	A/C	cg01426195	chr3:39028469	NA	-0.46	-4.39	-0.34	2.14e-5	Interleukin-18 levels;
PAAD	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg23985595	chr17:80112537	CCDC57	0.44	5.58	0.41	1.07e-7	Life satisfaction;
PAAD	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	11.79	0.69	3.44e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1639906	1.000	rs1639906	chr7:2219966	T/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-5.28	-0.39	4.32e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.05e-6	Diisocyanate-induced asthma;
PAAD	cis	rs863345	0.967	rs1418846	chr1:158484285	A/C	cg12129480	chr1:158549410	OR10X1	-0.45	-5.26	-0.39	4.78e-7	Pneumococcal bacteremia;
PAAD	cis	rs6784615	0.744	rs10865972	chr3:52491447	G/T	cg27565382	chr3:53032988	SFMBT1	-1.21	-5.44	-0.4	2.06e-7	Waist-hip ratio;
PAAD	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.87	-7.09	-0.5	4.82e-11	Gut microbiome composition (summer);
PAAD	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.83	-9.09	-0.59	5.2e-16	Caffeine consumption;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17360299	chr2:16082032	MYCNOS;MYCN	0.7	6.98	0.49	8.73e-11	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg09796270	chr17:17721594	SREBF1	-0.49	-5.15	-0.39	7.94e-7	Body mass index;
PAAD	cis	rs116248771	0.739	rs73156428	chr3:158346471	T/C	cg16708174	chr3:158430962	RARRES1	0.72	5.43	0.4	2.24e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg03315344	chr16:75512273	CHST6	0.58	4.83	0.36	3.34e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.51	-4.75	-0.36	4.72e-6	Hypospadias;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.81	-9.59	-0.61	2.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.67e-6	Breast cancer;
PAAD	cis	rs8014252	0.803	rs17108201	chr14:70988931	A/G	cg11204974	chr14:71022665	NA	-0.77	-5.04	-0.38	1.3e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9463078	0.509	rs1300126	chr6:45084861	G/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg07671805	chr5:74907694	NA	0.53	4.33	0.33	2.72e-5	Coronary artery disease;
PAAD	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.53	-5.29	-0.39	4.2e-7	Blood metabolite levels;
PAAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.78	-7.6	-0.52	2.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.66	-0.72	1.52e-25	Longevity;Endometriosis;
PAAD	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg00531865	chr16:30841666	NA	-0.5	-4.44	-0.34	1.74e-5	Dementia with Lewy bodies;
PAAD	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg02404636	chr22:31891804	SFI1	-0.62	-5.94	-0.43	1.85e-8	Colorectal cancer;
PAAD	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-1.0	-10.91	-0.66	8.04e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.49	-0.34	1.42e-5	Daytime sleep phenotypes;
PAAD	cis	rs9913156	0.748	rs56124631	chr17:4561378	A/G	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs2016586	0.895	rs5995156	chr22:36105236	A/C	cg26342177	chr22:36113512	APOL5	-0.46	-4.75	-0.36	4.58e-6	Body mass index;
PAAD	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	trans	rs9409082	0.798	rs12684045	chr9:108924287	T/G	cg07010948	chr13:79181613	NA	-0.34	-6.32	-0.46	2.71e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.84	10.29	0.64	3.64e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.79	6.31	0.46	2.88e-9	Weight;
PAAD	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.75	4.76	0.36	4.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6688613	1.000	rs6665341	chr1:166947018	A/G	cg07049167	chr1:166818506	POGK	0.48	4.79	0.36	3.92e-6	Refractive astigmatism;
PAAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.71	8.13	0.55	1.4e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.24	-0.45	4.18e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.83	-0.54	7.86e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6032067	0.527	rs6017490	chr20:43736369	C/A	cg10761708	chr20:43804764	PI3	0.47	4.3	0.33	3.05e-5	Blood protein levels;
PAAD	cis	rs1468333	1.000	rs34927605	chr5:137580418	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.46	0.46	1.31e-9	Resting heart rate;
PAAD	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16727027	chr4:57844010	C4orf14;POLR2B	0.6	6.29	0.45	3.17e-9	Pancreatic cancer;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18955060	chr12:57030799	BAZ2A	0.58	6.39	0.46	1.94e-9	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21194723	chr11:60681294	TMEM109	0.59	6.43	0.46	1.56e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.49	0.76	1.99e-30	Headache;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.68	-8.61	-0.57	8.54e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11166927	0.594	rs4736007	chr8:140817192	A/G	cg16909799	chr8:140841666	TRAPPC9	0.49	5.29	0.39	4.29e-7	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg05627522	chr15:75251581	NA	0.47	5.63	0.42	8.46e-8	Breast cancer;
PAAD	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.65	6.78	0.48	2.51e-10	Homocysteine levels;
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg06629702	chr1:2706960	NA	-0.36	-4.26	-0.33	3.55e-5	Ulcerative colitis;
PAAD	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-1.35	-12.57	-0.71	2.67e-25	Obesity-related traits;
PAAD	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.67	5.3	0.39	4.1e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.6	-6.32	-0.46	2.75e-9	Corneal astigmatism;
PAAD	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.96	0.37	1.89e-6	Depressive symptoms;
PAAD	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.56	-4.98	-0.37	1.7e-6	P wave terminal force;
PAAD	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg01620082	chr3:125678407	NA	-1.17	-7.79	-0.53	9.59e-13	Depression;
PAAD	cis	rs10821973	0.527	rs10733771	chr10:63982434	A/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.51	-5.26	-0.39	4.83e-7	Obesity-related traits;
PAAD	cis	rs8105895	0.935	rs62111030	chr19:22279375	C/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.81	0.54	8.51e-13	Prudent dietary pattern;
PAAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.56	4.81	0.36	3.64e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.65	-6.01	-0.44	1.31e-8	Diisocyanate-induced asthma;
PAAD	cis	rs1468333	0.567	rs6861656	chr5:137667512	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.1	0.38	9.8e-7	Resting heart rate;
PAAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.57	7.0	0.49	7.76e-11	Multiple system atrophy;
PAAD	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.46	4.81	0.36	3.59e-6	Menopause (age at onset);
PAAD	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.61	-4.94	-0.37	2.06e-6	Platelet count;
PAAD	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01872447	chr12:96336980	AMDHD1;CCDC38	0.77	7.92	0.54	4.73e-13	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23291754	chr4:71767977	MOBKL1A	0.7	7.02	0.49	6.87e-11	Obesity-related traits;
PAAD	cis	rs62025270	0.688	rs55738258	chr15:86316231	A/G	cg13263323	chr15:86062960	AKAP13	0.56	5.02	0.38	1.46e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg04315214	chr1:2043799	PRKCZ	0.6	7.81	0.54	8.67e-13	Height;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.58	6.36	0.46	2.28e-9	Cardiovascular disease risk factors;
PAAD	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg11232448	chr19:2858854	NA	-0.46	-4.49	-0.34	1.38e-5	Total cholesterol levels;
PAAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg03538708	chr1:25844672	NA	-0.53	-5.44	-0.4	2.12e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	7.66	0.53	1.97e-12	Menarche (age at onset);
PAAD	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	6.3	0.46	2.98e-9	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.9	0.66	8.13e-21	Homoarginine levels;
PAAD	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.79	7.22	0.51	2.34e-11	Breast cancer;
PAAD	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24958916	chr17:28257155	EFCAB5;SSH2	-0.62	-6.4	-0.46	1.79e-9	Smoking initiation;
PAAD	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	1.19	7.0	0.49	7.76e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.68	9.91	0.63	3.53e-18	Huntington's disease progression;
PAAD	cis	rs77831929	0.739	rs1906609	chr4:111666451	T/G	cg18064927	chr4:111531975	NA	-0.49	-4.47	-0.34	1.51e-5	Atrial fibrillation;
PAAD	cis	rs16958440	0.581	rs60726022	chr18:44679813	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-4.67	-0.35	6.47e-6	Sitting height ratio;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14781041	chr1:232649623	SIPA1L2	-0.73	-7.34	-0.51	1.18e-11	Obesity-related traits;
PAAD	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.84	9.76	0.62	8.82e-18	Ulcerative colitis;
PAAD	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.99	-0.38	1.63e-6	Height;
PAAD	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.67	0.48	4.54e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg22143856	chr6:28129313	ZNF389	0.51	4.72	0.36	5.42e-6	Parkinson's disease;
PAAD	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs5753618	0.504	rs9609296	chr22:31891784	T/G	cg02404636	chr22:31891804	SFI1	0.63	6.12	0.44	7.56e-9	Colorectal cancer;
PAAD	cis	rs9463078	0.653	rs6899378	chr6:45080368	C/T	cg25276700	chr6:44698697	NA	-0.53	-5.94	-0.43	1.91e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.24	0.39	5.37e-7	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09744435	chr15:43425949	TMEM62	0.65	6.94	0.49	1.06e-10	Myopia (pathological);
PAAD	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg25664220	chr3:72788482	NA	-0.49	-5.23	-0.39	5.57e-7	Motion sickness;
PAAD	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.65	7.48	0.52	5.44e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.63	0.35	7.73e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.73	-7.51	-0.52	4.76e-12	Blood metabolite levels;
PAAD	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg11673840	chr17:47092156	IGF2BP1	0.38	4.37	0.33	2.31e-5	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08741833	chr4:190769280	NA	-0.7	-7.44	-0.52	6.9e-12	Obesity-related traits;
PAAD	cis	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg24053715	chr22:38214548	NA	-0.5	-5.13	-0.38	8.55e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.16e-13	Prostate cancer;
PAAD	cis	rs7081476	0.737	rs7919198	chr10:27497485	G/A	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs8044995	0.636	rs12596500	chr16:68299771	G/A	cg09835421	chr16:68378352	PRMT7	-1.31	-7.81	-0.54	8.67e-13	Schizophrenia;
PAAD	cis	rs7804356	0.871	rs6951065	chr7:26756162	G/A	cg03456212	chr7:26904342	SKAP2	0.54	4.36	0.33	2.36e-5	Type 1 diabetes;
PAAD	cis	rs3812762	0.912	rs4929936	chr11:8792622	C/T	cg11156914	chr11:8892616	ST5	0.52	4.51	0.34	1.31e-5	Hypospadias;
PAAD	cis	rs1730008	0.865	rs827090	chr3:157986788	A/T	cg01557547	chr3:157823089	SHOX2	0.41	4.33	0.33	2.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.75	8.77	0.58	3.29e-15	Morning vs. evening chronotype;
PAAD	cis	rs1023500	1.000	rs1023500	chr22:42340844	C/T	cg04733989	chr22:42467013	NAGA	0.64	5.12	0.38	9.15e-7	Schizophrenia;
PAAD	cis	rs7580658	0.963	rs62160261	chr2:128152661	G/T	cg10985347	chr2:127963512	CYP27C1	0.5	4.54	0.35	1.12e-5	Protein C levels;
PAAD	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09065629	chr16:1709722	CRAMP1L	0.44	4.55	0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.52	-5.1	-0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	1.0	8.28	0.56	5.99e-14	Neutrophil percentage of white cells;
PAAD	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg14393609	chr7:65229607	NA	0.54	4.6	0.35	8.87e-6	Aortic root size;
PAAD	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.5	-0.57	1.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	4.98	0.37	1.68e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8077577	0.747	rs11872031	chr17:18150814	G/A	cg16794390	chr17:18148240	FLII	0.54	4.65	0.35	7.15e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116248771	0.549	rs9825140	chr3:158435374	C/T	cg16708174	chr3:158430962	RARRES1	0.82	6.11	0.44	8.16e-9	diarrhoeal disease at age 2;
PAAD	trans	rs12137025	1.000	rs72747974	chr1:223849696	A/T	cg18879828	chr11:46942432	NA	-0.77	-6.46	-0.46	1.33e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs89107	1.000	rs283077	chr6:118569679	T/G	cg18833306	chr6:118973337	C6orf204	0.49	5.52	0.41	1.44e-7	Cardiac structure and function;
PAAD	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.77	-0.53	1.07e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg02100629	chr10:71892760	AIFM2	-0.41	-4.73	-0.36	4.99e-6	Blood protein levels;
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.91	-0.37	2.32e-6	Personality dimensions;
PAAD	cis	rs59888335	0.830	rs13066260	chr3:80524726	G/A	cg21735741	chr3:80819488	NA	0.59	5.06	0.38	1.2e-6	Schizophrenia;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.62	-6.49	-0.47	1.17e-9	Lung cancer;
PAAD	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg16591659	chr17:78472290	NA	-0.5	-4.71	-0.36	5.62e-6	Schizophrenia;
PAAD	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg01426195	chr3:39028469	NA	0.71	6.56	0.47	7.76e-10	Handedness;
PAAD	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg03115019	chr17:80708279	FN3K	0.51	4.53	0.34	1.18e-5	Glycated hemoglobin levels;
PAAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg00758881	chr16:58534681	NDRG4	-0.96	-5.13	-0.38	8.71e-7	Schizophrenia;
PAAD	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.41	4.27	0.33	3.39e-5	Breast cancer;
PAAD	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg26174226	chr8:58114915	NA	-0.67	-5.42	-0.4	2.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67385638	0.962	rs2071348	chr11:5264146	T/G	cg12559170	chr11:5275217	HBG2	0.57	5.6	0.41	9.87e-8	Hemoglobin levels;
PAAD	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	4.64	0.35	7.4e-6	Mood instability;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-4.58	-0.35	9.72e-6	Obesity-related traits;
PAAD	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	4.6	0.35	8.82e-6	Thyroid stimulating hormone;
PAAD	cis	rs4513299	0.601	rs1110899	chr2:115011700	A/G	cg12978357	chr2:114426529	NA	-0.44	-4.4	-0.34	2.03e-5	Inflammatory biomarkers;
PAAD	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.97	-0.37	1.78e-6	Menopause (age at onset);
PAAD	cis	rs78761021	0.688	rs55811931	chr17:9796537	G/A	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.8	-8.05	-0.55	2.23e-13	Obesity-related traits;
PAAD	cis	rs12586317	0.557	rs4488360	chr14:35656211	G/C	cg05294307	chr14:35346193	BAZ1A	-0.49	-4.62	-0.35	8.05e-6	Psoriasis;
PAAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.63	8.95	0.59	1.17e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.64	-5.56	-0.41	1.18e-7	Cognitive test performance;
PAAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs6804624	0.597	rs2700617	chr3:99163611	A/G	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg21960279	chr19:17905606	B3GNT3	0.41	4.5	0.34	1.35e-5	Tumor biomarkers;
PAAD	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-4.52	-0.34	1.23e-5	Red blood cell count;
PAAD	cis	rs6028335	0.610	rs67882716	chr20:37573239	T/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.89	-0.37	2.59e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.65	7.16	0.5	3.28e-11	Menopause (age at onset);
PAAD	cis	rs4455778	0.580	rs6952911	chr7:49092794	C/T	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.7	6.78	0.48	2.49e-10	Recombination rate (males);
PAAD	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg24747557	chr10:131355152	MGMT	0.47	4.92	0.37	2.18e-6	Response to temozolomide;
PAAD	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg04717802	chr22:42394638	WBP2NL	0.59	4.26	0.33	3.62e-5	Birth weight;
PAAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.63	-5.34	-0.4	3.27e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-4.47	-0.34	1.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.68	7.4	0.51	8.68e-12	Hemoglobin concentration;
PAAD	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	1.14	7.69	0.53	1.69e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg05342682	chr7:94953680	PON1	-0.5	-4.49	-0.34	1.37e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg27411982	chr8:10470053	RP1L1	0.42	4.43	0.34	1.79e-5	Neuroticism;
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1488564	1.000	rs1488564	chr3:173453868	A/G	cg19643252	chr7:151264653	PRKAG2	-0.52	-6.46	-0.46	1.36e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-4.7	-0.36	5.66e-6	Height;
PAAD	cis	rs17407555	1.000	rs73224414	chr4:10297679	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.46	-0.34	1.56e-5	Schizophrenia (age at onset);
PAAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg04287289	chr16:89883240	FANCA	0.63	6.81	0.48	2.13e-10	Vitiligo;
PAAD	cis	rs61841072	0.961	rs12131267	chr1:243138336	G/A	cg02356786	chr1:243265016	LOC731275	0.51	4.35	0.33	2.52e-5	Schizophrenia;
PAAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.53	4.69	0.36	5.96e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.75	0.36	4.76e-6	Height;
PAAD	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	4.29	0.33	3.13e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg16898833	chr6:26189333	HIST1H4D	0.97	4.83	0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.97	-0.37	1.8e-6	Cognitive function;
PAAD	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.86	7.32	0.51	1.36e-11	Alzheimer's disease;
PAAD	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg22482690	chr17:47019901	SNF8	0.5	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs2281636	1.000	rs10883409	chr10:101517865	T/C	cg05149213	chr10:101381631	SLC25A28	0.49	4.73	0.36	5.14e-6	Obesity-related traits;
PAAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg09796270	chr17:17721594	SREBF1	0.45	5.1	0.38	9.8e-7	Total body bone mineral density;
PAAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg02734326	chr4:10020555	SLC2A9	0.46	4.74	0.36	4.9e-6	Bone mineral density;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12359697	chr3:187456323	BCL6	0.45	4.44	0.34	1.69e-5	Myopia (pathological);
PAAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.53	-4.6	-0.35	8.83e-6	Parkinson's disease;
PAAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg06883089	chr1:45254480	BEST4	0.33	4.26	0.33	3.51e-5	High light scatter reticulocyte count;
PAAD	cis	rs6076065	0.723	rs2424541	chr20:23386776	T/C	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.15e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.56	5.13	0.38	8.68e-7	Type 2 diabetes;
PAAD	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.44e-6	Type 2 diabetes;
PAAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.63	-5.63	-0.42	8.42e-8	Lung cancer;
PAAD	cis	rs8077577	0.708	rs2290502	chr17:18133495	G/A	cg16794390	chr17:18148240	FLII	-0.52	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.43	-4.37	-0.33	2.26e-5	Breast cancer;
PAAD	cis	rs2929278	0.617	rs533143	chr15:44188854	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	4.62	0.35	8.24e-6	Schizophrenia;
PAAD	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.38	4.88	0.37	2.71e-6	Mean corpuscular volume;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg19761014	chr17:28927070	LRRC37B2	-0.73	-5.33	-0.4	3.5e-7	Body mass index;
PAAD	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-5.62	-0.42	8.69e-8	Response to antipsychotic treatment;
PAAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs2133450	0.508	rs9825942	chr3:7350426	C/G	cg19930620	chr3:7340148	GRM7	-0.56	-6.21	-0.45	4.8e-9	Early response to risperidone in schizophrenia;
PAAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.74	6.39	0.46	1.89e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.4	-0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg13357408	chr7:157437802	PTPRN2	1.14	10.36	0.64	2.3e-19	Colorectal cancer;
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg06026331	chr20:60912101	LAMA5	0.52	4.47	0.34	1.53e-5	Colorectal cancer;
PAAD	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	trans	rs12545912	0.789	rs56369100	chr8:9593607	G/A	cg01912921	chr6:1611712	FOXC1	0.8	6.41	0.46	1.7e-9	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.87	6.98	0.49	8.42e-11	Axial length;
PAAD	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-6.54	-0.47	8.94e-10	Coronary artery disease;
PAAD	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.56	-5.3	-0.39	4.02e-7	Self-reported allergy;
PAAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg01028140	chr2:1542097	TPO	-1.02	-8.95	-0.59	1.18e-15	IgG glycosylation;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg13736514	chr6:26305472	NA	-0.6	-7.45	-0.52	6.65e-12	Educational attainment;
PAAD	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.46	0.65	1.26e-19	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.32e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.64	-0.35	7.32e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg20487152	chr13:99095054	FARP1	-0.46	-4.91	-0.37	2.33e-6	Longevity;
PAAD	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.72	9.29	0.6	1.5e-16	Asthma;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18621852	chr3:10150065	C3orf24	0.61	5.36	0.4	3.09e-7	Alzheimer's disease;
PAAD	cis	rs354033	0.580	rs1965619	chr7:149193240	G/A	cg06920324	chr7:149264011	ZNF767	-0.62	-5.28	-0.39	4.45e-7	Multiple sclerosis;
PAAD	cis	rs258892	0.895	rs10042574	chr5:72085684	C/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg15478930	chr2:27652102	NRBP1	0.54	4.44	0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg23719950	chr11:63933701	MACROD1	-0.7	-4.95	-0.37	1.99e-6	Mean platelet volume;
PAAD	cis	rs10901513	0.861	rs10794049	chr10:127671377	C/T	cg22975853	chr10:127789788	ADAM12	0.43	4.63	0.35	7.88e-6	Visceral fat;
PAAD	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.64	6.44	0.46	1.52e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-7.0	-0.49	7.59e-11	Gut microbiome composition (summer);
PAAD	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.18	0.7	3e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg06632027	chr4:90757378	SNCA	-0.53	-4.7	-0.36	5.85e-6	Neuroticism;
PAAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs10037055	0.853	rs10077929	chr5:176697844	C/T	cg03567656	chr5:176764267	LMAN2	-0.49	-4.5	-0.34	1.34e-5	Migraine without aura;
PAAD	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg26816564	chr1:7831052	VAMP3	0.75	5.78	0.42	4.14e-8	Inflammatory bowel disease;
PAAD	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg08999081	chr20:33150536	PIGU	-0.49	-5.43	-0.4	2.21e-7	Height;
PAAD	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.62	5.89	0.43	2.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.64	6.25	0.45	3.84e-9	Multiple sclerosis;
PAAD	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.74	7.95	0.54	3.86e-13	Melanoma;
PAAD	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.48	6.19	0.45	5.26e-9	Primary biliary cholangitis;
PAAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	4.61	0.35	8.62e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	Cognitive function;
PAAD	cis	rs4356203	0.678	rs1125737	chr11:17263933	T/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.4	-0.34	2.05e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7627468	0.770	rs1979869	chr3:121963285	T/C	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.79e-5	Kidney stones;
PAAD	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.54	5.56	0.41	1.19e-7	Red blood cell count;
PAAD	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.89	10.83	0.66	1.29e-20	Metabolic syndrome;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03495059	chr16:30913719	CTF1	-0.65	-6.76	-0.48	2.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg15117754	chr3:10150083	C3orf24	0.62	5.61	0.41	9.4e-8	Alzheimer's disease;
PAAD	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.54	7.34	0.51	1.17e-11	Renal cell carcinoma;
PAAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg13918804	chr1:2043761	PRKCZ	0.43	5.85	0.43	2.98e-8	Height;
PAAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	4.77	0.36	4.28e-6	Mood instability;
PAAD	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.17	-15.11	-0.77	4.42e-32	IgG glycosylation;
PAAD	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12432903	chr7:1882776	MAD1L1	-0.62	-4.5	-0.34	1.33e-5	Bipolar disorder;
PAAD	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg22875332	chr1:76189707	ACADM	-0.51	-5.05	-0.38	1.27e-6	Daytime sleep phenotypes;
PAAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs258892	0.793	rs13168325	chr5:72021520	T/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs4740619	0.803	rs2382554	chr9:15897372	C/T	cg14451791	chr9:16040625	NA	-0.42	-4.72	-0.36	5.3e-6	Body mass index;
PAAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	1.19	6.34	0.46	2.47e-9	Skin colour saturation;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs501120	0.810	rs474281	chr10:44749120	T/C	cg09554077	chr10:44749378	NA	0.51	6.81	0.48	2.16e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg02696790	chr15:75250997	RPP25	0.42	4.98	0.37	1.68e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06850241	chr22:41845214	NA	0.57	4.99	0.38	1.64e-6	Vitiligo;
PAAD	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.66	-0.48	4.7e-10	Total body bone mineral density;
PAAD	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs9815354	0.903	rs11705749	chr3:41947294	C/T	cg03022575	chr3:42003672	ULK4	-0.82	-5.79	-0.42	3.97e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.73	-11.1	-0.67	2.4e-21	Body mass index;
PAAD	cis	rs80346118	0.673	rs2869676	chr20:47424026	C/T	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.63	-4.66	-0.35	6.97e-6	Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg17385448	chr1:15911702	AGMAT	0.39	4.6	0.35	8.89e-6	Systolic blood pressure;
PAAD	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg03098721	chr1:84464084	TTLL7	0.48	4.52	0.34	1.25e-5	Obesity-related traits;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.65	4.65	0.35	7.18e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.55	5.51	0.41	1.48e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.71	7.56	0.52	3.48e-12	Response to antipsychotic treatment;
PAAD	cis	rs59888335	0.964	rs34868871	chr3:80735390	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg25418670	chr11:30344373	C11orf46	0.59	5.79	0.43	3.82e-8	Morning vs. evening chronotype;
PAAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg10356904	chr22:49881777	NA	-0.47	-4.67	-0.35	6.62e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.49	4.89	0.37	2.52e-6	Testicular germ cell tumor;
PAAD	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.98	7.83	0.54	7.84e-13	Eosinophilic esophagitis;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg11062466	chr8:58055876	NA	0.7	4.78	0.36	4.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.91	-0.49	1.26e-10	Psoriasis;
PAAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg17845761	chr1:175162550	KIAA0040	0.32	4.66	0.35	6.94e-6	Alcohol dependence;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-11.01	-0.67	4.25e-21	Cognitive function;
PAAD	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.13e-5	Noise-induced hearing loss;
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg24690094	chr11:67383802	NA	0.45	4.25	0.33	3.65e-5	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	5.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg10885151	chr13:24270087	NA	0.39	4.38	0.33	2.18e-5	Obesity-related traits;
PAAD	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	5.4	0.4	2.55e-7	Personality dimensions;
PAAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14895029	chr7:2775587	GNA12	-0.48	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.57	6.83	0.48	1.95e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg14725641	chr11:61582763	MIR1908;FADS1	0.5	4.43	0.34	1.76e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21497602	chr12:12715811	DUSP16	-0.78	-6.57	-0.47	7.45e-10	Neuroticism;
PAAD	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-1.15	-4.5	-0.34	1.37e-5	Asthma (childhood onset);
PAAD	cis	rs7818688	0.697	rs11782818	chr8:95978221	A/G	cg16049864	chr8:95962084	TP53INP1	0.54	4.41	0.34	1.92e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg00083206	chr6:110721305	DDO	-0.48	-5.06	-0.38	1.17e-6	Platelet distribution width;
PAAD	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	5.71	0.42	5.89e-8	Lung cancer in ever smokers;
PAAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-4.72	-0.36	5.25e-6	Schizophrenia;
PAAD	cis	rs55692468	0.570	rs12623070	chr2:153318339	T/C	cg22159341	chr2:152893963	CACNB4	0.46	4.49	0.34	1.41e-5	Intraocular pressure;
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.83	8.9	0.59	1.59e-15	Prostate cancer;
PAAD	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg00864860	chr1:7907996	UTS2	-0.56	-4.92	-0.37	2.22e-6	Crohn's disease;
PAAD	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg12560992	chr17:57184187	TRIM37	0.68	5.13	0.38	8.83e-7	Vitamin D levels;
PAAD	cis	rs1015291	0.836	rs7297605	chr12:19989121	T/G	cg25401612	chr12:20009446	NA	-0.5	-4.94	-0.37	2.06e-6	Diastolic blood pressure;
PAAD	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg10518543	chr12:38710700	ALG10B	0.51	4.82	0.36	3.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs9913156	0.748	rs72835626	chr17:4560326	C/A	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.0	0.7	9.28e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6466055	0.661	rs6466050	chr7:104897059	T/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.51	-0.68	1.96e-22	Height;
PAAD	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.42	-4.38	-0.33	2.18e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.52	-4.87	-0.37	2.81e-6	Acylcarnitine levels;
PAAD	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.5	-5.33	-0.4	3.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6684428	0.706	rs10888941	chr1:56333935	T/G	cg11651538	chr1:56320950	NA	-0.52	-4.5	-0.34	1.32e-5	Airflow obstruction;
PAAD	trans	rs9942416	0.715	rs4704230	chr5:74986481	T/C	cg03931927	chr7:65215969	CCT6P1	-0.64	-6.37	-0.46	2.16e-9	Age-related disease endophenotypes;
PAAD	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-1.2	-10.22	-0.64	5.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27167413	chr1:209957652	C1orf74	0.63	7.29	0.51	1.6e-11	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg21565972	chr17:80109576	CCDC57	-0.56	-6.54	-0.47	8.74e-10	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.42	0.4	2.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg02780029	chr10:43622663	RET	-0.48	-4.78	-0.36	4.02e-6	Hirschsprung disease;
PAAD	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg12486944	chr17:80159399	CCDC57	0.52	4.64	0.35	7.45e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12681288	0.782	rs2600498	chr8:1026520	A/G	cg08648136	chr8:956695	NA	0.41	4.34	0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.51	-6.89	-0.49	1.42e-10	Primary biliary cholangitis;
PAAD	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg13798912	chr7:905769	UNC84A	0.64	4.5	0.34	1.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg08742575	chr21:47604166	C21orf56	0.47	4.63	0.35	7.66e-6	Testicular germ cell tumor;
PAAD	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.9	8.53	0.57	1.36e-14	Response to diuretic therapy;
PAAD	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg09399716	chr2:46890238	NA	-0.51	-4.54	-0.35	1.12e-5	Height;
PAAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg06740227	chr12:86229804	RASSF9	0.59	5.37	0.4	2.95e-7	Major depressive disorder;
PAAD	cis	rs76917914	0.589	rs6478563	chr9:100864919	T/C	cg21225548	chr9:100864335	TRIM14	-0.52	-6.02	-0.44	1.28e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Graves' disease;
PAAD	cis	rs2997447	0.601	rs61776577	chr1:26431931	T/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs11811982	0.557	rs76599385	chr1:227318924	A/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs74181299	0.684	rs6756585	chr2:65340070	G/A	cg20592124	chr2:65290738	CEP68	-0.47	-4.41	-0.34	1.91e-5	Pulse pressure;
PAAD	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-4.74	-0.36	4.9100000000000004e-06	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.56	0.35	1.06e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	4.96	0.37	1.85e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.88	7.29	0.51	1.58e-11	Triglycerides;
PAAD	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg21523564	chr15:75251491	NA	0.5	4.29	0.33	3.14e-5	Blood trace element (Zn levels);
PAAD	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.7	7.67	0.53	1.89e-12	Longevity;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg04844267	chr4:1394941	NA	0.42	4.71	0.36	5.61e-6	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg18721089	chr20:30220636	NA	-0.8	-6.07	-0.44	9.66e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.29	-0.39	4.18e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.41	-4.79	-0.36	3.96e-6	Sarcoidosis;
PAAD	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-6.82	-0.48	1.97e-10	Hemoglobin concentration;
PAAD	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.99	9.6	0.61	2.37e-17	Cognitive ability;
PAAD	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	5.38	0.4	2.76e-7	Cognitive test performance;
PAAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.62	0.65	4.73e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-5.0	-0.38	1.53e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	4.27	0.33	3.43e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs55962025	0.842	rs362306	chr4:3242100	C/T	cg08886695	chr4:3369023	RGS12	0.48	4.63	0.35	7.67e-6	Parental longevity (mother's age at death);
PAAD	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.46	5.1	0.38	1.01e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg18084798	chr19:33555255	RHPN2	0.45	4.68	0.35	6.28e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	trans	rs350729	0.649	rs62140320	chr2:53173252	G/A	cg24639469	chr1:4837462	AJAP1	0.63	6.37	0.46	2.14e-9	Bronchodilator response in asthma;
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07685180	chr8:600429	NA	0.88	5.47	0.41	1.83e-7	IgG glycosylation;
PAAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.82	9.5	0.61	4.31e-17	Methadone dose in opioid dependence;
PAAD	cis	rs7765175	0.698	rs9488153	chr6:113664384	C/T	cg19037598	chr6:113666021	NA	0.45	4.77	0.36	4.31e-6	Coronary artery calcification;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02819828	chr13:37453855	SMAD9	0.6	6.29	0.45	3.22e-9	Warfarin maintenance dose;
PAAD	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.5	5.25	0.39	4.93e-7	Male-pattern baldness;
PAAD	cis	rs12476592	0.571	rs112194	chr2:63876872	T/G	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.79	-7.28	-0.51	1.64e-11	Multiple system atrophy;
PAAD	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.58	6.65	0.47	5.01e-10	Schizophrenia;
PAAD	cis	rs9472414	0.510	rs3997503	chr6:44708416	G/A	cg18551225	chr6:44695536	NA	0.48	4.88	0.37	2.61e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10201874	chr2:220412606	TMEM198	-0.53	-6.53	-0.47	9.09e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg14146966	chr2:61757674	XPO1	-0.38	-4.81	-0.36	3.55e-6	Tuberculosis;
PAAD	cis	rs501916	1.000	rs565627	chr15:48056735	A/C	cg16110827	chr15:48056943	SEMA6D	-0.43	-4.68	-0.35	6.34e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg02887458	chr19:19495540	GATAD2A	0.61	5.56	0.41	1.16e-7	Bipolar disorder;
PAAD	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg05393297	chr12:53359155	NA	-1.05	-6.28	-0.45	3.33e-9	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.57	-6.75	-0.48	2.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.48	4.66	0.35	6.78e-6	Blood pressure;
PAAD	cis	rs375066	0.935	rs429027	chr19:44395489	G/A	cg11993925	chr19:44307056	LYPD5	0.55	6.95	0.49	9.87e-11	Breast cancer;
PAAD	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.66	-6.03	-0.44	1.19e-8	Crohn's disease;
PAAD	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg27455613	chr17:80820699	TBCD	-0.46	-4.59	-0.35	9.39e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs17169635	0.819	rs1452915	chr7:134492292	A/C	cg02516134	chr7:134575187	CALD1	-0.44	-4.47	-0.34	1.53e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.53	-5.25	-0.39	5.14e-7	Adiposity;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.5	0.41	1.6e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.5	-4.87	-0.37	2.74e-6	Menarche (age at onset);
PAAD	cis	rs2916733	0.752	rs2442490	chr8:6330806	A/T	cg01691696	chr8:6734962	DEFB1	-0.54	-4.33	-0.33	2.71e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.64	7.09	0.5	4.64e-11	Height;
PAAD	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.52	-4.96	-0.37	1.9e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.48	0.41	1.7e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg07725925	chr16:89976287	TCF25	0.75	4.63	0.35	7.83e-6	Skin colour saturation;
PAAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.48	4.8	0.36	3.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg04415270	chr2:102091202	RFX8	-0.58	-7.57	-0.52	3.39e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.53	5.64	0.42	7.99e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4621152	0.738	rs6723019	chr2:217880831	A/C	cg21875423	chr2:217559867	IGFBP5	-0.44	-4.36	-0.33	2.37e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.64	0.53	2.21e-12	Platelet count;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg05791153	chr7:19748676	TWISTNB	0.66	5.12	0.38	8.99e-7	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-6.31	-0.46	2.96e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.92	-0.37	2.21e-6	Bipolar disorder;
PAAD	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.86	-7.3	-0.51	1.49e-11	Blood protein levels;
PAAD	cis	rs732765	0.644	rs10483860	chr14:75119507	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.53	-0.35	1.17e-5	Non-small cell lung cancer;
PAAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.01e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.81	-0.43	3.5e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg22907277	chr7:1156413	C7orf50	0.48	5.14	0.38	8.37e-7	Longevity;Endometriosis;
PAAD	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg24562669	chr7:97807699	LMTK2	-0.45	-4.98	-0.37	1.74e-6	Breast cancer;
PAAD	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs2238823	1.000	rs2238823	chr22:45936320	A/G	cg17791035	chr22:45705866	FAM118A	-0.54	-4.5	-0.34	1.33e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs4513299	0.540	rs1505437	chr2:114999705	A/G	cg12978357	chr2:114426529	NA	-0.45	-4.3	-0.33	3.1e-5	Inflammatory biomarkers;
PAAD	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.83	-0.36	3.35e-6	Body mass index;
PAAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.99	9.71	0.62	1.23e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.51	-4.55	-0.35	1.08e-5	Total body bone mineral density;
PAAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg10547527	chr2:198650123	BOLL	-0.73	-5.16	-0.39	7.65e-7	Ulcerative colitis;
PAAD	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.99	13.75	0.74	1.87e-28	Heart rate;
PAAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.88	8.25	0.56	6.84e-14	Gestational age at birth (maternal effect);
PAAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.95	-9.09	-0.59	4.91e-16	Bronchopulmonary dysplasia;
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.75e-6	Bipolar disorder;
PAAD	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.65	-9.08	-0.59	5.29e-16	Breast cancer;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.53	4.72	0.36	5.24e-6	Depression;
PAAD	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs17085007	1.000	rs17085007	chr13:27531267	T/C	cg02869929	chr13:28527832	NA	-0.48	-4.61	-0.35	8.49e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs17123764	0.786	rs58446833	chr12:50116733	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.33	-0.33	2.69e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-1.0	-15.14	-0.78	3.62e-32	Height;
PAAD	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.7e-7	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.92	-0.37	2.2e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg05914723	chr15:78953907	NA	0.55	4.32	0.33	2.86e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg01631408	chr1:248437212	OR2T33	-0.57	-5.55	-0.41	1.23e-7	Common traits (Other);
PAAD	cis	rs883565	0.740	rs6780772	chr3:39087764	A/G	cg01426195	chr3:39028469	NA	-0.68	-7.23	-0.51	2.18e-11	Handedness;
PAAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14119001	chr9:139324193	INPP5E	-0.61	-5.51	-0.41	1.51e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg18323236	chr1:24743029	NIPAL3	0.44	4.78	0.36	4.16e-6	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg19337854	chr7:99768885	GPC2	0.53	4.99	0.37	1.66e-6	Platelet count;
PAAD	cis	rs714515	0.586	rs4916263	chr1:172450689	A/C	cg13446689	chr1:172328377	DNM3	-0.43	-5.3	-0.4	3.98e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19908028	chr2:65538635	SPRED2	-0.57	-6.6	-0.47	6.55e-10	Obesity-related traits;
PAAD	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg08048268	chr3:133502702	NA	0.48	6.04	0.44	1.12e-8	Iron status biomarkers;
PAAD	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.88	8.53	0.57	1.37e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs818427	1.000	rs151977	chr5:112234549	A/T	cg06941702	chr5:112196734	SRP19	0.47	4.45	0.34	1.66e-5	Total body bone mineral density;
PAAD	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.54	5.59	0.41	1.02e-7	Mean corpuscular volume;
PAAD	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-9.37	-0.61	9.27e-17	Gut microbiome composition (summer);
PAAD	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.47	-4.87	-0.37	2.78e-6	Motion sickness;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs9401295	0.613	rs1343667	chr6:98293830	C/T	cg00987395	chr6:98934664	NA	0.38	4.57	0.35	1.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17155006	0.651	rs416811	chr7:107724047	G/C	cg05962710	chr7:107745446	LAMB4	-0.38	-4.5	-0.34	1.35e-5	Pneumococcal bacteremia;
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.9	-11.49	-0.68	2.14e-22	Age at first birth;
PAAD	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg20673841	chr7:107026890	COG5	-0.49	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.66	-7.15	-0.5	3.45e-11	Colorectal cancer;
PAAD	cis	rs7539542	0.529	rs57756744	chr1:202859028	G/A	cg03161476	chr1:203596940	ATP2B4	0.57	4.35	0.33	2.44e-5	Mean platelet volume;
PAAD	cis	rs1178968	0.901	rs757937	chr7:72750159	C/T	cg25889504	chr7:72793014	NA	0.58	4.26	0.33	3.59e-5	Triglyceride levels;
PAAD	cis	rs7582720	1.000	rs72932765	chr2:203679183	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	7.36	0.51	1.1e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs79146658	0.736	rs6707222	chr2:179743923	C/T	cg17765952	chr2:179737173	CCDC141	-0.6	-4.5	-0.34	1.37e-5	Diastolic blood pressure;
PAAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.08	15.38	0.78	8.7e-33	Multiple system atrophy;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25422665	chr17:16485103	NA	-0.51	-6.4	-0.46	1.79e-9	Energy expenditure (24h);
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939584	0.935	rs12997450	chr2:630113	C/T	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.22e-6	Body mass index;
PAAD	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg03277515	chr1:153321198	PGLYRP4	0.39	4.51	0.34	1.3e-5	Psoriasis;
PAAD	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs863345	0.535	rs12064570	chr1:158499631	T/C	cg12129480	chr1:158549410	OR10X1	-0.41	-4.66	-0.35	6.74e-6	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10348543	chr7:100209640	MOSPD3	0.67	6.47	0.46	1.28e-9	Obesity-related traits;
PAAD	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-5.08	-0.38	1.09e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg11464842	chr2:97427975	CNNM4	-0.66	-4.41	-0.34	1.91e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg17662387	chr10:116286880	ABLIM1	0.41	4.25	0.33	3.69e-5	Obesity-related traits;
PAAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.72	-6.47	-0.46	1.29e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.87	-0.49	1.57e-10	Life satisfaction;
PAAD	cis	rs3106136	0.586	rs72663785	chr4:95069794	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.94	-0.37	2.01e-6	Capecitabine sensitivity;
PAAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.51	-4.51	-0.34	1.31e-5	Parkinson's disease;
PAAD	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg13736514	chr6:26305472	NA	-0.44	-4.78	-0.36	4.06e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.55	-6.18	-0.45	5.69e-9	Lung function (FVC);
PAAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.31	-0.33	2.9e-5	Tuberculosis;
PAAD	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.43	-0.34	1.83e-5	Neuroticism;
PAAD	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11044724	chr2:7005733	CMPK2	0.59	6.76	0.48	2.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs6850606	0.537	rs961150	chr4:42883094	C/G	cg24533989	chr4:42659536	ATP8A1	0.49	4.28	0.33	3.32e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.43	5.68	0.42	6.63e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.39	13.37	0.74	1.88e-27	Uric acid levels;
PAAD	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-1.0	-11.18	-0.67	1.49e-21	Multiple myeloma;
PAAD	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.66	-7.73	-0.53	1.37e-12	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	trans	rs41264869	1.000	rs2242001	chr1:205031744	G/A	cg08840230	chr19:15622718	CYP4F22	0.49	6.41	0.46	1.7e-9	Blood protein levels;
PAAD	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg20503657	chr10:835505	NA	0.48	4.92	0.37	2.25e-6	Survival in rectal cancer;
PAAD	cis	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.61	-5.81	-0.43	3.61e-8	Total body bone mineral density;
PAAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.52	4.72	0.36	5.21e-6	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.62	-5.08	-0.38	1.08e-6	Body mass index;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.73	9.72	0.62	1.15e-17	Iron status biomarkers;
PAAD	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	2.04e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-6.0	-0.44	1.42e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9815354	0.953	rs6795797	chr3:41862250	A/G	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.92	-7.91	-0.54	4.97e-13	Dupuytren's disease;
PAAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs900145	0.906	rs2279287	chr11:13298485	T/C	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.23	0.39	5.53e-7	Lung cancer;
PAAD	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.08	-0.44	9.5e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg09366796	chr5:75012313	C5orf37	0.49	4.45	0.34	1.66e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.62	-0.35	8.25e-6	Calcium levels;
PAAD	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	5.01	0.38	1.47e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.34	-0.33	2.58e-5	Total body bone mineral density;
PAAD	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26933691	chr19:36139020	COX6B1	0.62	6.39	0.46	1.93e-9	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.48	4.68	0.35	6.41e-6	HDL cholesterol;
PAAD	cis	rs12410462	0.551	rs2819513	chr1:227630987	G/A	cg23173402	chr1:227635558	NA	-0.55	-4.56	-0.35	1.06e-5	Major depressive disorder;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.71	0.48	3.55e-10	Height;
PAAD	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11697226	chr18:59992385	TNFRSF11A	-0.65	-6.53	-0.47	9.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg15412446	chr2:106886593	NA	-0.82	-8.5	-0.57	1.66e-14	Facial morphology (factor 23);
PAAD	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs61759167	0.774	rs61759173	chr1:3097509	C/T	cg22674798	chr1:3096360	PRDM16	0.4	4.65	0.35	7.29e-6	Motion sickness;
PAAD	trans	rs901683	1.000	rs12768131	chr10:45986448	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.47	-0.46	1.29e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs9832740	1.000	rs9815886	chr3:72393312	A/C	cg07881171	chr3:72988159	GXYLT2	0.45	4.49	0.34	1.43e-5	Height;
PAAD	cis	rs354225	0.544	rs28581481	chr2:54812372	T/G	cg01766943	chr2:54829624	SPTBN1	0.53	4.99	0.37	1.67e-6	Schizophrenia;
PAAD	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.68	-6.99	-0.49	8.23e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.34	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9652601	0.959	rs12919083	chr16:11188930	G/T	cg04616529	chr16:11181986	CLEC16A	-0.46	-5.1	-0.38	9.87e-7	Systemic lupus erythematosus;
PAAD	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2952768	0.802	rs11904814	chr2:208426798	G/T	cg22329743	chr2:208688774	PLEKHM3	-0.26	-4.91	-0.37	2.32e-6	Opioid sensitivity;
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.74	-7.67	-0.53	1.93e-12	Prostate cancer;
PAAD	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-6.51	-0.47	1.01e-9	Schizophrenia;
PAAD	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.74	0.58	4.1e-15	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs901683	0.850	rs12765244	chr10:46032041	A/T	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18404041	chr3:52824283	ITIH1	0.42	4.41	0.34	1.98e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9535307	0.929	rs7984061	chr13:50337340	G/A	cg04663916	chr13:50265991	EBPL	0.59	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg09597638	chr17:3907349	NA	0.67	6.77	0.48	2.68e-10	Type 2 diabetes;
PAAD	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.53	5.32	0.4	3.62e-7	Resting heart rate;
PAAD	cis	rs8044868	0.886	rs12325266	chr16:72214858	C/T	cg14768367	chr16:72042858	DHODH	-0.46	-4.39	-0.34	2.09e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-8.64	-0.57	7.14e-15	Bone mineral density;
PAAD	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.69	-6.5	-0.47	1.11e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.63	7.2	0.5	2.57e-11	Emphysema distribution in smoking;
PAAD	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg14440974	chr22:39074834	NA	0.5	5.95	0.43	1.76e-8	Menopause (age at onset);
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.48	-0.47	1.21e-9	Bipolar disorder;
PAAD	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.52	6.16	0.45	6.35e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.8	-8.5	-0.57	1.64e-14	Glaucoma (primary open-angle);
PAAD	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.01	-0.38	1.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg17524180	chr13:113633600	MCF2L	-0.52	-5.68	-0.42	6.79e-8	Systolic blood pressure;
PAAD	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs2657888	0.628	rs3809122	chr12:56882710	A/T	cg23002907	chr12:56915593	RBMS2	-0.43	-4.38	-0.33	2.22e-5	Adiponectin levels;
PAAD	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.72	4.25	0.33	3.75e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.06	-0.38	1.2e-6	Reticulocyte count;
PAAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.8	-7.53	-0.52	4.22e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.82	0.62	6.1e-18	Cognitive function;
PAAD	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.99	5.79	0.42	4e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2236267	0.693	rs11626612	chr14:88610244	C/T	cg18078958	chr14:88630771	NA	-0.5	-6.37	-0.46	2.09e-9	Food antigen IgG levels;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10819733	chr22:24237672	NA	-0.61	-6.8	-0.48	2.28e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9862730	0.519	rs349567	chr3:140242814	A/C	cg01966470	chr11:70258111	CTTN	0.74	6.31	0.46	2.85e-9	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
PAAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-5.8	-0.43	3.63e-8	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs294958	0.777	rs71588038	chr5:151532349	A/T	cg04453665	chr5:151504455	NA	0.45	4.68	0.36	6.18e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg14146966	chr2:61757674	XPO1	0.35	4.48	0.34	1.48e-5	Tuberculosis;
PAAD	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.63	0.47	5.6e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.23e-6	Bipolar disorder;
PAAD	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs375066	0.762	rs2284245	chr19:44422589	A/T	cg11993925	chr19:44307056	LYPD5	-0.49	-5.98	-0.44	1.57e-8	Breast cancer;
PAAD	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs28472312	0.823	rs62037373	chr16:28893295	C/G	cg16576597	chr16:28551801	NUPR1	0.49	5.17	0.39	7.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6894268	0.722	rs6601058	chr5:179032187	A/G	cg26135573	chr5:179059668	NA	0.73	6.2	0.45	5.13e-9	Eating disorders;
PAAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.45	-4.92	-0.37	2.24e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.7	4.99	0.37	1.67e-6	Breast cancer;
PAAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-4.4	-0.34	2.07e-5	Coronary artery disease;
PAAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.65	-6.82	-0.48	2.07e-10	Body mass index;
PAAD	cis	rs7071247	0.915	rs3014183	chr10:105274270	C/T	cg20028483	chr10:104949090	NT5C2	-0.58	-4.28	-0.33	3.31e-5	Platelet aggregation;
PAAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.3e-22	Coronary artery disease;
PAAD	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.16	0.39	7.7300000000000005e-07	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg13397359	chr6:42928475	GNMT	0.77	8.38	0.56	3.32e-14	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.8	-8.36	-0.56	3.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.71	7.18	0.5	2.96e-11	Retinal vascular caliber;
PAAD	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg10591111	chr5:226296	SDHA	-0.74	-5.7	-0.42	5.93e-8	Breast cancer;
PAAD	cis	rs6028335	0.877	rs67829021	chr20:37748452	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.52	-4.29	-0.33	3.12e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07615839	chr2:231921515	PSMD1	0.7	7.7	0.53	1.62e-12	Myopia (pathological);
PAAD	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.89	-7.76	-0.53	1.13e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18862610	chr10:6019621	IL15RA	0.62	6.31	0.46	2.85e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.52	6.68	0.48	4.33e-10	Diastolic blood pressure;
PAAD	trans	rs901683	1.000	rs12781506	chr10:46038702	T/C	cg14076390	chr17:34947837	DHRS11	0.88	6.62	0.47	5.87e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.79	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.86	11.18	0.67	1.49e-21	Subjective well-being (multi-trait analysis);
PAAD	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.09	-0.59	5.15e-16	Blood trace element (Zn levels);
PAAD	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg17644776	chr2:200775616	C2orf69	-0.5	-4.37	-0.33	2.29e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11106836	chr11:117852822	NA	-0.63	-6.74	-0.48	3.04e-10	Obesity-related traits;
PAAD	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	8.19	0.55	9.88e-14	Lung cancer in ever smokers;
PAAD	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs7719624	0.545	rs2215012	chr5:135414464	C/T	cg16684184	chr5:135415129	NA	-0.47	-6.08	-0.44	9.51e-9	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg01320130	chr1:67600311	NA	-0.61	-6.4	-0.46	1.79e-9	Psoriasis;
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.93	0.37	2.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.17	-0.5	3.1e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.6	-6.74	-0.48	3.12e-10	Obesity-related traits;
PAAD	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7823896	0.722	rs1993593	chr8:110289581	C/T	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4454254	0.796	rs6578060	chr8:141045683	C/G	cg06693505	chr8:141057453	TRAPPC9	-0.34	-4.67	-0.35	6.51e-6	Pulse pressure;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg10490147	chr1:11120546	SRM	0.56	6.5	0.47	1.06e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.59	5.92	0.43	2.02e-8	Systolic blood pressure;
PAAD	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg01631408	chr1:248437212	OR2T33	0.58	5.45	0.4	2.01e-7	Common traits (Other);
PAAD	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg02951883	chr7:2050386	MAD1L1	-0.88	-9.11	-0.59	4.53e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg20125331	chr7:66768030	STAG3L4;PMS2L4	-0.42	-4.3	-0.33	3.06e-5	Aortic root size;
PAAD	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.22	-0.51	2.33e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg10483660	chr13:112241077	NA	0.53	4.87	0.37	2.82e-6	Menarche (age at onset);
PAAD	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs2615061	0.580	rs943759	chr1:225886318	C/T	cg22789900	chr1:226411715	MIXL1	0.53	4.28	0.33	3.34e-5	Monocyte count;
PAAD	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	5.54	0.41	1.32e-7	Monocyte count;
PAAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.55	7.27	0.51	1.76e-11	Height;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.75	8.74	0.58	3.99e-15	Lung cancer;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.94	-7.79	-0.53	9.76e-13	Alopecia areata;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15356195	chr7:5569741	ACTB	-0.63	-7.4	-0.51	8.7e-12	Body fat percentage;
PAAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.54	-5.49	-0.41	1.61e-7	Iron status biomarkers;
PAAD	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.6	6.18	0.45	5.62e-9	Crohn's disease;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs10073892	0.830	rs11746537	chr5:101593522	C/T	cg17280723	chr5:101634495	NA	0.41	4.29	0.33	3.21e-5	Cognitive decline (age-related);
PAAD	cis	rs7640424	0.649	rs13082569	chr3:107870835	A/C	cg09227934	chr3:107805635	CD47	0.44	5.24	0.39	5.24e-7	Body mass index;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg14926445	chr8:58193284	C8orf71	-0.65	-5.29	-0.39	4.21e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10804591	0.848	rs6782700	chr3:129309147	G/A	cg21885638	chr3:129306552	PLXND1	-0.56	-4.82	-0.36	3.52e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.64	-0.35	7.32e-6	Mood instability;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.77	-0.48	2.68e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-10.92	-0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs10792830	0.741	rs541674	chr11:85737502	A/G	cg07180834	chr11:85838833	NA	-0.51	-6.03	-0.44	1.17e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2555155	0.602	rs2555143	chr11:6541580	G/T	cg11185456	chr11:6592066	DNHD1	-0.49	-4.84	-0.37	3.1e-6	DNA methylation (variation);
PAAD	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.8	-7.72	-0.53	1.41e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.72	6.9	0.49	1.33e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.29	-0.33	3.16e-5	Longevity;Endometriosis;
PAAD	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg12935359	chr14:103987150	CKB	-0.55	-5.75	-0.42	4.66e-8	Body mass index;
PAAD	cis	rs308971	0.563	rs454615	chr3:12077010	A/G	cg15873301	chr3:12045459	SYN2	0.63	4.46	0.34	1.56e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs9652601	0.691	rs3862468	chr16:11194018	C/G	cg04616529	chr16:11181986	CLEC16A	-0.37	-4.49	-0.34	1.41e-5	Systemic lupus erythematosus;
PAAD	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.92	-10.57	-0.65	6.36e-20	Refractive error;
PAAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-4.87	-0.37	2.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.81	0.36	3.67e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1358748	0.522	rs6658185	chr1:67553733	C/G	cg02640540	chr1:67518911	SLC35D1	-0.62	-4.25	-0.33	3.67e-5	Tuberculosis;
PAAD	cis	rs10736390	0.813	rs6687894	chr1:55105038	A/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.84	-10.38	-0.64	2.08e-19	Survival in pancreatic cancer;
PAAD	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.47	4.53	0.35	1.18e-5	Fractional excretion of uric acid;
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg16898833	chr6:26189333	HIST1H4D	1.02	5.73	0.42	5.27e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.86	0.43	2.79e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	7.18	0.5	2.85e-11	Body mass index (adult);
PAAD	cis	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.47	-6.84	-0.49	1.82e-10	Diastolic blood pressure;
PAAD	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.65	-6.52	-0.47	9.65e-10	Morning vs. evening chronotype;
PAAD	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.72	-5.88	-0.43	2.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.52	0.47	9.96e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.51	4.98	0.37	1.71e-6	Menopause (age at onset);
PAAD	cis	rs818427	0.634	rs818428	chr5:112220613	A/T	cg06941702	chr5:112196734	SRP19	0.53	5.05	0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs9467160	0.520	rs793671	chr6:24438662	C/T	cg20631270	chr6:24437470	GPLD1	-0.44	-4.31	-0.33	2.88e-5	Liver enzyme levels;
PAAD	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg21625146	chr5:486483	SLC9A3	-0.36	-4.59	-0.35	9.29e-6	Cystic fibrosis severity;
PAAD	cis	rs89107	0.688	rs283088	chr6:118592191	T/C	cg18833306	chr6:118973337	C6orf204	0.49	5.7	0.42	6.01e-8	Cardiac structure and function;
PAAD	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.57	-5.26	-0.39	4.87e-7	Corneal structure;
PAAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg06618935	chr21:46677482	NA	-0.53	-6.59	-0.47	6.8e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs990171	0.687	rs6739301	chr2:103125457	A/G	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.7	5.73	0.42	5.13e-8	Exhaled nitric oxide output;
PAAD	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs251130	0.915	rs251136	chr5:110858565	T/C	cg11925263	chr5:110849104	STARD4	0.37	4.66	0.35	6.79e-6	Menarche (age at onset);
PAAD	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg18551225	chr6:44695536	NA	-0.75	-7.58	-0.52	3.1e-12	Total body bone mineral density;
PAAD	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.03	-0.44	1.18e-8	Joint mobility (Beighton score);
PAAD	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.91	-0.43	2.15e-8	Bipolar disorder;
PAAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-4.27	-0.33	3.43e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11264213	0.591	rs3754076	chr1:36549157	A/G	cg27506609	chr1:36549197	TEKT2	-0.82	-6.06	-0.44	1.01e-8	Schizophrenia;
PAAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs17125944	0.686	rs7155860	chr14:53335229	G/C	cg13660082	chr14:53194042	PSMC6	0.71	4.44	0.34	1.72e-5	Alzheimer's disease (late onset);
PAAD	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.8	6.47	0.46	1.28e-9	Gastritis;
PAAD	cis	rs17124318	1.000	rs17124318	chr1:63480730	C/G	cg01067151	chr1:63792863	NA	0.75	4.25	0.33	3.68e-5	Weight;Body mass index;
PAAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-4.63	-0.35	7.79e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2278796	0.789	rs12136572	chr1:204962660	G/A	cg17947172	chr1:204966197	NFASC	0.41	4.51	0.34	1.28e-5	Mean platelet volume;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg09324608	chr17:30823087	MYO1D	0.46	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.58	4.52	0.34	1.25e-5	Breast cancer;
PAAD	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg23855989	chr12:50355821	AQP5	0.67	5.85	0.43	2.91e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.92	11.54	0.68	1.58e-22	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10715637	chr10:90751534	FAS;ACTA2	-0.56	-6.53	-0.47	9.33e-10	Body fat percentage;
PAAD	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg05895507	chr15:77155635	SCAPER	-0.38	-4.25	-0.33	3.76e-5	Blood metabolite levels;
PAAD	cis	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg21546286	chr11:48923668	NA	-0.46	-4.84	-0.37	3.12e-6	Height;
PAAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg03983715	chr16:68378420	PRMT7	-0.83	-5.95	-0.43	1.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	0.77	5.39	0.4	2.67e-7	Body mass index;
PAAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg09324608	chr17:30823087	MYO1D	-0.49	-4.99	-0.38	1.62e-6	Schizophrenia;
PAAD	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.66	4.94	0.37	2.07e-6	Hip geometry;
PAAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-9.74	-0.62	1.01e-17	Total body bone mineral density;
PAAD	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg09659197	chr4:152720779	NA	0.36	5.07	0.38	1.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.82	-10.12	-0.63	1.02e-18	Blood metabolite ratios;
PAAD	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.63	6.19	0.45	5.36e-9	Schizophrenia;
PAAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.48	-4.56	-0.35	1.04e-5	Height;
PAAD	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg17178900	chr1:205818956	PM20D1	-0.5	-4.81	-0.36	3.65e-6	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs3096644	1.000	rs3096644	chr17:46757575	A/C	cg10864433	chr17:46724237	NA	0.46	4.35	0.33	2.52e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.61	-7.53	-0.52	4.14e-12	Renal function-related traits (BUN);
PAAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.49	-0.34	1.43e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.79	7.34	0.51	1.19e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07362569	chr17:61921086	SMARCD2	0.61	7.2	0.5	2.53e-11	Prudent dietary pattern;
PAAD	cis	rs4742903	0.740	rs4596709	chr9:106978756	G/C	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg00262122	chr8:11665843	FDFT1	-0.52	-4.73	-0.36	5.07e-6	Neuroticism;
PAAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.09	0.44	8.72e-9	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20643444	chr12:49061475	SNORA2B;C12orf41	-0.68	-7.21	-0.5	2.39e-11	Obesity-related traits;
PAAD	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1;
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg01631408	chr1:248437212	OR2T33	-0.6	-5.24	-0.39	5.34e-7	Common traits (Other);
PAAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg03351412	chr1:154909251	PMVK	0.48	4.6	0.35	8.89e-6	Prostate cancer;
PAAD	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg14752227	chr20:34000481	UQCC	0.53	5.35	0.4	3.14e-7	Height;
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg07873178	chr11:65307616	LTBP3	0.95	4.88	0.37	2.67e-6	Height;
PAAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg26060667	chr1:247681242	NA	-0.43	-5.04	-0.38	1.31e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-6.13	-0.45	7.37e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs1561176	1.000	rs12719684	chr7:155005458	T/C	cg08570118	chr7:155025533	NA	0.51	4.42	0.34	1.89e-5	Personality dimensions;
PAAD	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg14159304	chr10:105212236	CALHM2	0.49	4.34	0.33	2.58e-5	Colorectal cancer;
PAAD	cis	rs282587	0.569	rs166865	chr13:113384879	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.01e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.43	-0.34	1.83e-5	Body mass index;
PAAD	cis	rs8060686	0.920	rs76841123	chr16:67683564	C/G	cg27539214	chr16:67997921	SLC12A4	-0.74	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4702	0.591	rs7183988	chr15:91428589	T/G	cg04510874	chr15:91427884	FES	-0.37	-4.34	-0.33	2.62e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-8.6	-0.57	8.92e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg23860436	chr12:58378763	NA	-0.49	-4.81	-0.36	3.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.75	8.7	0.58	4.95e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs6066835	1.000	rs4516495	chr20:47316482	A/G	cg18078177	chr20:47281410	PREX1	1.01	5.25	0.39	5.14e-7	Multiple myeloma;
PAAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.53	-5.37	-0.4	2.95e-7	Glycated hemoglobin levels;
PAAD	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg10818794	chr15:86012489	AKAP13	-0.6	-4.77	-0.36	4.23e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs55728055	0.661	rs9680589	chr22:31853484	G/A	cg01338084	chr22:32026380	PISD	1.38	6.71	0.48	3.61e-10	Age-related hearing impairment;
PAAD	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.55	0.41	1.26e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1878047	0.665	rs8111393	chr19:51775876	T/C	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.54	-8.0	-0.54	2.98e-13	Diastolic blood pressure;
PAAD	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-1.19	-9.98	-0.63	2.39e-18	Obesity-related traits;
PAAD	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.65	-0.35	7.23e-6	Testicular germ cell tumor;
PAAD	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-9.33	-0.6	1.23e-16	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.82e-6	Biliary atresia;
PAAD	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.82	9.64	0.62	1.91e-17	Bladder cancer;
PAAD	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg00181669	chr3:44000978	NA	-0.55	-5.85	-0.43	2.9e-8	Coronary artery disease;
PAAD	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	5.86	0.43	2.75e-8	Lung cancer;
PAAD	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg02683114	chr2:24398427	C2orf84	0.62	6.99	0.49	8.3e-11	Asthma;
PAAD	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs11159086	0.793	rs8015894	chr14:74958620	C/T	cg10195687	chr14:74926396	NA	-0.46	-5.21	-0.39	5.99e-7	Advanced glycation end-product levels;
PAAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.84	5.65	0.42	7.71e-8	Psoriasis;
PAAD	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.78	8.33	0.56	4.32e-14	Body mass index;
PAAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg24253500	chr15:84953950	NA	0.43	4.52	0.34	1.22e-5	Schizophrenia;
PAAD	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg23254163	chr1:152506842	NA	0.57	6.58	0.47	7.34e-10	Hair morphology;
PAAD	cis	rs11615916	0.790	rs73135253	chr12:62665772	T/A	cg11441379	chr12:63026424	NA	0.7	4.54	0.35	1.15e-5	Pulmonary function decline;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.54	5.33	0.4	3.54e-7	Prudent dietary pattern;
PAAD	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.63	6.62	0.47	5.8e-10	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.76	8.1	0.55	1.67e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg27205649	chr11:78285834	NARS2	0.62	4.62	0.35	8.29e-6	Alzheimer's disease (survival time);
PAAD	cis	rs11690935	0.632	rs12987931	chr2:172900948	C/T	cg13550731	chr2:172543902	DYNC1I2	0.7	7.71	0.53	1.56e-12	Schizophrenia;
PAAD	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.62	-0.47	5.77e-10	Eye color traits;
PAAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg06632027	chr4:90757378	SNCA	-0.61	-5.5	-0.41	1.59e-7	Neuroticism;
PAAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.69	7.6	0.52	2.89e-12	Melanoma;
PAAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.76	-7.96	-0.54	3.65e-13	Menarche (age at onset);
PAAD	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs375066	0.901	rs376069	chr19:44417295	T/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-6.2	-0.45	5.14e-9	Eye color traits;
PAAD	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg09579323	chr1:150459698	TARS2	-0.47	-4.45	-0.34	1.66e-5	Migraine;
PAAD	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.77	-8.78	-0.58	3.13e-15	Mean platelet volume;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12074093	chr17:16256568	CENPV	0.59	6.44	0.46	1.51e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.27	19.14	0.84	2.42e-42	IgG glycosylation;
PAAD	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7081476	0.737	rs4747594	chr10:27511043	C/G	cg25705717	chr10:27608719	NA	0.87	4.38	0.33	2.18e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.95	-9.65	-0.62	1.79e-17	Parkinson's disease;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.95	12.47	0.71	5.04e-25	Menarche (age at onset);
PAAD	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.81	-8.61	-0.57	8.55e-15	Breast cancer;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.88	-13.3	-0.73	2.9e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg02404636	chr22:31891804	SFI1	0.66	6.15	0.45	6.57e-9	Colorectal cancer;
PAAD	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00455402	chr19:21769736	NA	-0.46	-4.29	-0.33	3.11e-5	Pain;
PAAD	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.6	5.25	0.39	5.02e-7	Response to diuretic therapy;
PAAD	trans	rs62179067	0.708	rs12475463	chr2:179881971	T/A	cg13380624	chr19:7735426	NA	-0.75	-7.46	-0.52	6.07e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.53	4.77	0.36	4.36e-6	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01685689	chr11:126081170	FAM118B;RPUSD4	0.62	7.06	0.5	5.64e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg05025164	chr4:1340916	KIAA1530	-0.63	-6.74	-0.48	3.15e-10	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg21724239	chr8:58056113	NA	0.67	5.16	0.39	7.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.73	0.72	9.85e-26	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.23	0.51	2.17e-11	Body mass index;
PAAD	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	11.83	0.69	2.7e-23	Metabolite levels;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.61	-6.49	-0.47	1.14e-9	Lymphocyte counts;
PAAD	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.38	0.4	2.75e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs73198271	0.628	rs11777908	chr8:8590437	C/T	cg01851573	chr8:8652454	MFHAS1	0.63	4.69	0.36	6.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.66	8.02	0.55	2.56e-13	Platelet count;
PAAD	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.61	-5.5	-0.41	1.61e-7	Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg01305830	chr4:1604576	NA	0.47	4.26	0.33	3.57e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.97	-0.44	1.65e-8	Alcohol dependence;
PAAD	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs62025270	0.632	rs6496109	chr15:86132008	C/G	cg13263323	chr15:86062960	AKAP13	0.49	4.3	0.33	3.02e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.02	0.49	6.8e-11	Rheumatoid arthritis;
PAAD	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04733989	chr22:42467013	NAGA	-0.48	-4.89	-0.37	2.57e-6	Cognitive function;
PAAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.41	-4.33	-0.33	2.69e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs757081	0.658	rs214069	chr11:17305600	G/A	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.88	-0.43	2.55e-8	Systolic blood pressure;
PAAD	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.67	6.44	0.46	1.45e-9	Coronary artery disease;
PAAD	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-4.33	-0.33	2.7e-5	Monocyte percentage of white cells;
PAAD	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.76	-0.53	1.17e-12	Morning vs. evening chronotype;
PAAD	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.61	-6.55	-0.47	8.33e-10	Coronary artery disease;
PAAD	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.49	5.75	0.42	4.7e-8	Systemic lupus erythematosus;
PAAD	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs30380	0.632	rs26500	chr5:96133712	A/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.25	-0.39	4.93e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg05562828	chr17:3906858	NA	-0.54	-6.05	-0.44	1.09e-8	Type 2 diabetes;
PAAD	cis	rs1358748	0.573	rs7529446	chr1:67581576	A/C	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03676636	chr4:99064102	C4orf37	0.33	5.98	0.44	1.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg00982548	chr2:198649783	BOLL	0.65	4.53	0.34	1.2e-5	Ulcerative colitis;
PAAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg01176363	chr20:62369445	LIME1	-0.58	-5.67	-0.42	6.97e-8	Prostate cancer;
PAAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.83	9.45	0.61	5.99e-17	Total body bone mineral density;
PAAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.73	8.53	0.57	1.35e-14	Childhood ear infection;
PAAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.06	0.38	1.18e-6	Parkinson's disease;
PAAD	cis	rs73058052	0.530	rs10421333	chr19:50086080	A/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.52	-4.45	-0.34	1.63e-5	Fibrinogen levels;
PAAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg01075559	chr1:2537774	MMEL1	0.52	5.46	0.4	1.89e-7	Ulcerative colitis;
PAAD	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.72	7.45	0.52	6.5e-12	Brugada syndrome;
PAAD	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.59	6.07	0.44	9.68e-9	Coronary artery disease;
PAAD	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9463078	0.585	rs1285004	chr6:45098201	A/T	cg18551225	chr6:44695536	NA	-0.41	-4.33	-0.33	2.72e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3106136	0.843	rs1426575	chr4:95260069	G/C	cg11021082	chr4:95130006	SMARCAD1	0.63	6.07	0.44	9.71e-9	Capecitabine sensitivity;
PAAD	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.78	-0.53	1e-12	Neuroticism;
PAAD	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.61	-0.41	9.53e-8	Coronary artery disease;
PAAD	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.85	-6.13	-0.45	7.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	16.97	0.81	6.47e-37	Height;
PAAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.79	-8.87	-0.58	1.88e-15	Iron status biomarkers;
PAAD	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-4.41	-0.34	1.93e-5	Immature fraction of reticulocytes;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.42	4.29	0.33	3.22e-5	Longevity;Endometriosis;
PAAD	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.7	-6.83	-0.48	1.87e-10	Platelet distribution width;
PAAD	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs965469	0.779	rs6133031	chr20:3300857	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg26896255	chr1:171887300	DNM3	-0.52	-6.38	-0.46	1.99e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21028142	chr17:79581711	NPLOC4	0.49	5.83	0.43	3.23e-8	Eye color traits;
PAAD	cis	rs412050	0.547	rs61757982	chr22:22113740	A/G	cg17089214	chr22:22089827	YPEL1	0.68	4.66	0.35	6.88e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.69	-5.88	-0.43	2.49e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs375066	0.577	rs12462476	chr19:44310520	A/C	cg11993925	chr19:44307056	LYPD5	-0.44	-4.71	-0.36	5.46e-6	Breast cancer;
PAAD	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.48	5.32	0.4	3.72e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.57	8.89	0.58	1.63e-15	IgG glycosylation;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.63	6.59	0.47	6.86e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.41	-5.99	-0.44	1.49e-8	Subjective well-being;
PAAD	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.71	-8.19	-0.55	1e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.47	4.87	0.37	2.83e-6	Longevity;
PAAD	cis	rs4253772	0.515	rs6008784	chr22:46774317	T/C	cg24881330	chr22:46731750	TRMU	1.03	5.0	0.38	1.55e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.34	0.33	2.63e-5	Cancer;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10819733	chr22:24237672	NA	-0.54	-5.46	-0.4	1.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg03948781	chr1:205179583	DSTYK	0.47	4.32	0.33	2.86e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg05304507	chr6:116381966	FRK	0.27	4.39	0.34	2.1e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg04990556	chr1:26633338	UBXN11	0.68	4.87	0.37	2.72e-6	Obesity-related traits;
PAAD	cis	rs6594713	0.603	rs13170435	chr5:112636466	C/T	cg12552261	chr5:112820674	MCC	0.7	4.51	0.34	1.29e-5	Brain cytoarchitecture;
PAAD	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.5	-4.68	-0.35	6.33e-6	Multiple sclerosis;
PAAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.46	-4.36	-0.33	2.38e-5	Urate levels;
PAAD	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	0.91	4.33	0.33	2.67e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg25204440	chr1:209979598	IRF6	0.62	5.41	0.4	2.39e-7	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs682748	0.846	rs13175997	chr5:17160258	A/G	cg23987134	chr5:17158319	LOC285696	-0.35	-4.41	-0.34	1.94e-5	Hippocampal atrophy;
PAAD	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs6594713	0.837	rs71577447	chr5:112753957	T/C	cg12552261	chr5:112820674	MCC	0.6	4.34	0.33	2.64e-5	Brain cytoarchitecture;
PAAD	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.19	-0.5	2.68e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12893428	chr3:195717962	SDHAP1	0.47	4.96	0.37	1.88e-6	Pancreatic cancer;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.4	-0.34	2.03e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs9982086	0.557	rs1783020	chr21:27314080	T/C	cg04970570	chr5:87990145	NA	0.66	6.88	0.49	1.44e-10	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg15117754	chr3:10150083	C3orf24	0.73	6.3	0.46	3.02e-9	Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.45	0.34	1.67e-5	P wave terminal force;
PAAD	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15510118	chr2:174774395	SP3	0.63	7.29	0.51	1.6e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.57	-5.98	-0.44	1.53e-8	Hepatitis;
PAAD	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.67	6.52	0.47	9.91e-10	Smoking initiation;
PAAD	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.43	4.75	0.36	4.73e-6	HDL cholesterol levels;
PAAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.74	-6.05	-0.44	1.08e-8	Alzheimer's disease;
PAAD	cis	rs17155006	0.664	rs448833	chr7:107739181	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6066835	0.867	rs28404239	chr20:47361176	T/C	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.89	9.7	0.62	1.27e-17	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.87	-8.97	-0.59	1.03e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.71	-8.26	-0.56	6.45e-14	Huntington's disease progression;
PAAD	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.78	7.37	0.51	9.94e-12	Breast cancer;
PAAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26850624	chr5:429559	AHRR	0.47	5.9	0.43	2.29e-8	Cystic fibrosis severity;
PAAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg18612461	chr15:75251733	NA	0.59	7.19	0.5	2.72e-11	Breast cancer;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.84	-9.58	-0.61	2.63e-17	Idiopathic membranous nephropathy;
PAAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg26174226	chr8:58114915	NA	-0.63	-5.07	-0.38	1.13e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.49	4.52	0.34	1.23e-5	Neutrophil percentage of white cells;
PAAD	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-1.03	-10.8	-0.66	1.51e-20	Platelet distribution width;
PAAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.59	4.3	0.33	3.01e-5	Depression;
PAAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.74	-6.99	-0.49	8.09e-11	Pancreatic cancer;
PAAD	cis	rs1572438	1.000	rs873559	chr6:875336	G/A	cg13447295	chr6:887704	NA	0.52	4.82	0.36	3.48e-6	Aging;
PAAD	trans	rs61677309	0.964	rs12576118	chr11:118158440	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.62	0.41	8.91e-8	Mean corpuscular volume;
PAAD	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.6	-6.89	-0.49	1.38e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2637266	0.627	rs2013238	chr10:78476272	A/C	cg18941641	chr10:78392320	NA	0.36	4.28	0.33	3.32e-5	Pulmonary function;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07666984	chr4:153858209	NA	-0.57	-6.45	-0.46	1.4e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs965604	1.000	rs8043227	chr15:78768871	C/G	cg18825076	chr15:78729989	IREB2	-0.46	-4.44	-0.34	1.75e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.41	-0.56	2.72e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.57	5.07	0.38	1.14e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	trans	rs901683	0.850	rs117668126	chr10:46062952	G/C	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg25972092	chr12:117363249	FBXW8	-0.82	-6.35	-0.46	2.38e-9	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.81	-7.23	-0.51	2.23e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	1.04	17.03	0.81	4.78e-37	Height;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23463467	chr20:60627584	TAF4	0.41	4.31	0.33	2.92e-5	Body mass index;
PAAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs34043524	1.000	rs11724737	chr4:118018508	A/G	cg14562394	chr4:117851367	NA	0.79	4.28	0.33	3.26e-5	Lateral ventricle volume in trauma-exposed individuals;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-1.1	-8.27	-0.56	6.41e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.45	5.03	0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.48	-5.12	-0.38	8.99e-7	Monocyte count;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08677398	chr8:58056175	NA	0.66	4.94	0.37	2.03e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.66	7.26	0.51	1.84e-11	Prostate cancer;
PAAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.4	-0.46	1.79e-9	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14291549	chr6:135818752	AHI1;C6orf217	0.72	7.59	0.52	3.04e-12	Obesity-related traits;
PAAD	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.72	-5.51	-0.41	1.53e-7	Diastolic blood pressure;
PAAD	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.86	-7.03	-0.5	6.57e-11	Menopause (age at onset);
PAAD	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg01176363	chr20:62369445	LIME1	-0.54	-5.48	-0.41	1.71e-7	Prostate cancer;
PAAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg05895507	chr15:77155635	SCAPER	0.36	4.39	0.34	2.15e-5	Blood metabolite levels;
PAAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	4.98	0.37	1.73e-6	Tonsillectomy;
PAAD	cis	rs3126085	0.667	rs12747821	chr1:152240424	G/A	cg09127314	chr1:152161683	NA	0.69	4.87	0.37	2.81e-6	Atopic dermatitis;
PAAD	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.58	5.51	0.41	1.5e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.83	9.14	0.6	3.79e-16	Mortality in heart failure;
PAAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg13012494	chr21:47604986	C21orf56	-0.44	-4.86	-0.37	2.95e-6	Testicular germ cell tumor;
PAAD	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	8.18	0.55	1.07e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg19254793	chr6:44695348	NA	0.47	4.44	0.34	1.73e-5	Total body bone mineral density;
PAAD	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	1.14	17.77	0.82	6.14e-39	Menarche (age at onset);
PAAD	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	6.1	0.44	8.58e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg16584676	chr17:46985605	UBE2Z	-0.5	-4.97	-0.37	1.76e-6	Type 2 diabetes;
PAAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.51	5.17	0.39	7.11e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg01422370	chr2:73384389	NA	0.35	4.79	0.36	4.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.72	8.15	0.55	1.22e-13	Colorectal cancer;
PAAD	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.48	5.15	0.39	8.1e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg06026331	chr20:60912101	LAMA5	0.5	4.7	0.36	5.81e-6	Colorectal cancer;
PAAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg16602846	chr15:78114278	NA	0.42	4.59	0.35	9.33e-6	Coronary artery disease or large artery stroke;
PAAD	cis	rs9549260	0.564	rs4943804	chr13:41269994	A/G	cg21288729	chr13:41239152	FOXO1	0.53	4.46	0.34	1.55e-5	Red blood cell count;
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00117825	chr1:57004017	PPAP2B	-0.6	-6.43	-0.46	1.59e-9	Obesity-related traits;
PAAD	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.66	-0.42	7.45e-8	Coronary artery disease;
PAAD	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.73	-9.44	-0.61	6.15e-17	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	6.63	0.47	5.38e-10	Height;
PAAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	trans	rs12596233	0.611	rs67114359	chr16:78659693	A/C	cg03237845	chr15:57377660	TCF12	0.67	6.37	0.46	2.09e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.55	-4.53	-0.34	1.21e-5	Corneal structure;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg08501292	chr6:25962987	TRIM38	0.8	4.34	0.33	2.57e-5	Urinary tract infection frequency;
PAAD	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.54	4.6	0.35	8.87e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg08898775	chr15:59042684	ADAM10	0.37	4.54	0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.34	-0.4	3.34e-7	Daytime sleep phenotypes;
PAAD	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg21855830	chr2:127963489	CYP27C1	0.47	4.35	0.33	2.48e-5	Protein C levels;
PAAD	cis	rs8005172	0.663	rs7146799	chr14:88522003	C/T	cg18078958	chr14:88630771	NA	0.35	4.38	0.33	2.18e-5	Parkinson's disease;
PAAD	trans	rs12545912	0.908	rs10465002	chr8:9582217	G/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.18	-0.45	5.52e-9	Schizophrenia;
PAAD	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07741184	chr6:167504864	NA	-0.35	-4.52	-0.34	1.22e-5	Primary biliary cholangitis;
PAAD	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.53	5.4	0.4	2.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg18993626	chr8:74463939	STAU2	-0.59	-6.29	-0.45	3.14e-9	Alcohol dependence;
PAAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-1.0	-7.8	-0.53	9.1e-13	Initial pursuit acceleration;
PAAD	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.78	-8.23	-0.56	7.9e-14	Type 2 diabetes;
PAAD	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg09357268	chr20:43379437	KCNK15	-0.44	-4.71	-0.36	5.5e-6	Obesity-related traits;
PAAD	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.31	0.6	1.32e-16	Bipolar disorder;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.54	4.48	0.34	1.47e-5	Platelet count;
PAAD	cis	rs16975963	0.594	rs73039018	chr19:38217894	C/A	cg14218481	chr19:38281219	NA	0.42	4.5	0.34	1.32e-5	Longevity;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05398940	chr16:89351098	ANKRD11	0.64	6.68	0.48	4.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs76793172	1.000	rs16980027	chr19:46313105	C/T	cg13320842	chr19:46175254	GIPR	0.59	4.49	0.34	1.4e-5	Eosinophil counts;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.4	5.02	0.38	1.43e-6	Sitting height ratio;
PAAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg03517284	chr6:25882590	NA	0.54	4.44	0.34	1.69e-5	Iron status biomarkers;
PAAD	cis	rs89107	0.651	rs447193	chr6:118607662	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.64	0.42	8.26e-8	Cardiac structure and function;
PAAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.27	-0.39	4.7e-7	Monocyte count;
PAAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.12	0.67	2.13e-21	Menopause (age at onset);
PAAD	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs829661	0.948	rs2609954	chr2:30871808	G/A	cg12454169	chr2:30669597	LCLAT1	0.63	4.69	0.36	6e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.98	-11.48	-0.68	2.32e-22	Cognitive function;
PAAD	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg09980403	chr19:12975529	MAST1	-0.3	-4.81	-0.36	3.58e-6	Mean corpuscular volume;
PAAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.75	-0.42	4.82e-8	Bipolar disorder;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.86	-0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.61	5.78	0.42	4.16e-8	Corneal astigmatism;
PAAD	cis	rs58521262	0.556	rs289333	chr19:23153042	C/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.71	6.59	0.47	6.73e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02788857	chr8:22132959	PIWIL2	0.61	8.01	0.54	2.86e-13	Hypertriglyceridemia;
PAAD	cis	rs4704187	0.687	rs9654429	chr5:74466925	C/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.53	0.34	1.19e-5	Chronic sinus infection;
PAAD	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.44	-0.65	1.42e-19	Systemic lupus erythematosus;
PAAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.76	0.36	4.52e-6	Schizophrenia;
PAAD	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.64	-6.92	-0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg22467129	chr15:76604101	ETFA	0.44	4.54	0.35	1.14e-5	Blood metabolite levels;
PAAD	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.88	7.29	0.51	1.58e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-1.2	-11.28	-0.68	7.81e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.86	-8.85	-0.58	2.07e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs3733418	0.860	rs35449092	chr4:165949676	C/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-4.97	-0.37	1.75e-6	Obesity-related traits;
PAAD	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.35	-0.4	3.17e-7	Testicular germ cell tumor;
PAAD	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs7084921	0.526	rs11591518	chr10:101775611	C/T	cg04359915	chr10:101825029	CPN1	-0.33	-4.99	-0.38	1.61e-6	Bone mineral density;
PAAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.96	-11.1	-0.67	2.39e-21	Tonsillectomy;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.96	7.05	0.5	6.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.6	6.42	0.46	1.61e-9	Testicular germ cell tumor;
PAAD	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-1.16	-8.17	-0.55	1.11e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.84	0.58	2.17e-15	Schizophrenia;
PAAD	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.69	-0.36	6.14e-6	Breast cancer;
PAAD	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.74	8.0	0.54	2.92e-13	Lewy body disease;
PAAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg11833968	chr6:79620685	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.81	9.44	0.61	6.37e-17	Sudden cardiac arrest;
PAAD	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.52	-5.48	-0.41	1.69e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs8112211	0.689	rs2304177	chr19:38795159	G/A	cg01275006	chr19:38876250	GGN	-0.86	-5.53	-0.41	1.37e-7	Blood protein levels;
PAAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs17155006	0.655	rs433534	chr7:107727440	A/G	cg05962710	chr7:107745446	LAMB4	-0.44	-5.39	-0.4	2.61e-7	Pneumococcal bacteremia;
PAAD	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.7	-8.28	-0.56	5.76e-14	Educational attainment;
PAAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs73198271	0.515	rs78890841	chr8:8637018	G/A	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.46	5.06	0.38	1.22e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3018712	0.605	rs2513297	chr11:68446144	T/C	cg23009355	chr11:68451396	GAL	-0.54	-4.88	-0.37	2.64e-6	Total body bone mineral density;
PAAD	cis	rs12949688	0.654	rs4793914	chr17:55834581	T/G	cg12582317	chr17:55822272	NA	0.5	5.9	0.43	2.28e-8	Schizophrenia;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25726414	chr10:21785708	C10orf114;MIR1915	0.45	4.9	0.37	2.38e-6	Monocyte percentage of white cells;
PAAD	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.57	5.97	0.44	1.62e-8	Testicular germ cell tumor;
PAAD	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.57	4.95	0.37	1.94e-6	Common traits (Other);
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.62	-5.93	-0.43	1.98e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-7.8	-0.53	9.15e-13	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg10518543	chr12:38710700	ALG10B	0.53	5.0	0.38	1.57e-6	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.64	-6.16	-0.45	6.24e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9826463	0.757	rs73238195	chr3:142171525	A/C	cg20824294	chr3:142316082	PLS1	0.46	5.3	0.39	4.1e-7	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs16910800	1.000	rs2468648	chr11:23201494	C/G	cg20040320	chr11:23191996	NA	0.6	5.13	0.38	8.79e-7	Cancer;
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.88	6.78	0.48	2.56e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.08	0.59	5.29e-16	Cognitive test performance;
PAAD	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.29	-0.39	4.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12767760	0.714	rs4919109	chr10:99297954	A/T	cg25247692	chr10:99313390	UBTD1	-0.5	-4.82	-0.36	3.47e-6	Obesity-related traits;
PAAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.51	-5.24	-0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.4	5.37	0.4	2.84e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7714584	1.000	rs10053750	chr5:150270051	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.89	-0.63	4.16e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg12661370	chr5:149340060	SLC26A2	-0.8	-7.59	-0.52	3e-12	HIV-1 control;
PAAD	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.6	-4.92	-0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.93	5.14	0.38	8.3e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.36	7.97	0.54	3.53e-13	Corneal curvature;
PAAD	cis	rs988712	0.536	rs11030016	chr11:27487992	C/T	cg10635145	chr11:27742435	BDNF	0.36	4.56	0.35	1.04e-5	Obesity;
PAAD	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs9463078	0.899	rs9395069	chr6:45128521	A/G	cg25276700	chr6:44698697	NA	-0.49	-5.78	-0.42	4e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10466107	chr6:144607399	NA	0.6	6.54	0.47	9.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg14092988	chr3:52407081	DNAH1	0.44	5.47	0.41	1.77e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg20913747	chr6:44695427	NA	-0.6	-6.73	-0.48	3.33e-10	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.59	6.33	0.46	2.59e-9	Lung cancer;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16138775	chr2:241907643	NA	0.6	6.31	0.46	2.86e-9	Warfarin maintenance dose;
PAAD	cis	rs11563648	0.511	rs1419405	chr7:127057758	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-7.28	-0.51	1.66e-11	Neuroticism;
PAAD	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs6991838	0.778	rs13261559	chr8:66462043	G/A	cg15971335	chr8:66515592	ARMC1	0.45	4.6	0.35	8.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg00071950	chr4:10020882	SLC2A9	-0.67	-6.28	-0.45	3.42e-9	Schizophrenia (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02690648	chr8:10683044	PINX1;MIR1322	0.55	6.31	0.46	2.94e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.39	4.99	0.38	1.62e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg10932868	chr11:921992	NA	0.52	6.13	0.45	7.3e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs10901513	1.000	rs10901514	chr10:127700066	T/C	cg22975853	chr10:127789788	ADAM12	0.41	4.31	0.33	2.95e-5	Visceral fat;
PAAD	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg24117442	chr12:93963504	SOCS2	-0.56	-6.71	-0.48	3.6e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.1e-8	Electroencephalogram traits;
PAAD	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.19	-0.39	6.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.6	-6.09	-0.44	8.79e-9	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22772771	chr6:159420466	RSPH3	0.6	6.83	0.48	1.94e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07177430	chr11:3400574	ZNF195	0.56	6.41	0.46	1.77e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.34	-0.4	3.29e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13674574	chr14:64971270	ZBTB25;ZBTB1	0.58	6.46	0.46	1.33e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.39	5.03	0.38	1.36e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	4.45	0.34	1.64e-5	Red cell distribution width;Platelet distribution width;
PAAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.07e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07701084	chr6:150067640	NUP43	0.57	5.7	0.42	6.14e-8	Testicular germ cell tumor;
PAAD	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg23331303	chr5:5135948	NA	0.47	6.64	0.47	5.19e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg00717180	chr2:96193071	NA	0.59	6.49	0.47	1.12e-9	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13236315	chr12:53645720	MFSD5	0.59	6.55	0.47	8.36e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	5.29	0.39	4.2e-7	Menarche (age at onset);
PAAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.89	6.62	0.47	5.75e-10	Alzheimer's disease;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.89e-5	Bipolar disorder;
PAAD	cis	rs6460942	0.597	rs4721105	chr7:12534881	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg04106633	chr4:1044584	NA	0.62	5.3	0.4	3.97e-7	Recombination rate (females);
PAAD	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.93	-0.43	2.01e-8	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.86	9.87	0.62	4.75e-18	Prudent dietary pattern;
PAAD	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.52	5.22	0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9463078	0.585	rs1748234	chr6:45140853	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg18721089	chr20:30220636	NA	-0.82	-6.18	-0.45	5.75e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs6142102	0.812	rs6059574	chr20:32523172	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.36	-0.33	2.35e-5	Skin pigmentation;
PAAD	cis	rs4742903	1.000	rs2274724	chr9:106860568	C/T	cg14250997	chr9:106856677	SMC2	0.48	5.21	0.39	6.01e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.51	-5.44	-0.4	2.04e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg18765565	chr5:669397	TPPP	0.43	4.56	0.35	1.06e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.56	-0.57	1.15e-14	Longevity;Endometriosis;
PAAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.48	4.48	0.34	1.44e-5	Type 2 diabetes;
PAAD	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg00277334	chr10:82204260	NA	-0.64	-6.7	-0.48	3.83e-10	Post bronchodilator FEV1;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs9472414	0.680	rs9463020	chr6:44713432	G/A	cg20913747	chr6:44695427	NA	0.53	5.24	0.39	5.17e-7	Height;
PAAD	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg18551225	chr6:44695536	NA	-0.69	-8.07	-0.55	1.97e-13	Total body bone mineral density;
PAAD	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.42	4.71	0.36	5.49e-6	Breast cancer;
PAAD	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg26248373	chr2:1572462	NA	-1.02	-7.83	-0.54	7.72e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4343996	0.869	rs6974577	chr7:3511350	G/T	cg21248987	chr7:3385318	SDK1	0.49	5.54	0.41	1.29e-7	Motion sickness;
PAAD	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-7.91	-0.54	4.83e-13	Body mass index;
PAAD	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg18721089	chr20:30220636	NA	-0.6	-5.01	-0.38	1.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.61	7.12	0.5	4e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg02196655	chr2:10830764	NOL10	0.54	5.52	0.41	1.45e-7	Prostate cancer;
PAAD	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg10183150	chr4:120222239	C4orf3	-0.31	-4.44	-0.34	1.73e-5	Educational attainment;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg20076718	chr12:11754972	NA	0.73	6.33	0.46	2.59e-9	Photic sneeze reflex;
PAAD	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.59	5.84	0.43	3.12e-8	Eye color traits;
PAAD	cis	rs6679454	1.000	rs11582953	chr1:58364333	C/A	cg17491850	chr1:57888480	DAB1	-0.39	-4.36	-0.33	2.41e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	4.91	0.37	2.34e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.6	0.35	8.74e-6	Coronary artery disease;
PAAD	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg21951975	chr1:209979733	IRF6	0.55	5.29	0.39	4.28e-7	Coronary artery disease;
PAAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04713951	chr22:38966166	DMC1	0.6	6.56	0.47	8.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.71	6.7	0.48	3.9e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.9	5.63	0.42	8.51e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.62	5.53	0.41	1.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21077069	chr7:99063506	ATP5J2	0.57	6.36	0.46	2.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.6	-8.48	-0.57	1.85e-14	Venous thromboembolism;
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.52	6.44	0.46	1.45e-9	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12226111	chr12:123320057	HIP1R	0.56	6.56	0.47	7.95e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.8	-7.74	-0.53	1.26e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg11874272	chr3:121773564	CD86	0.43	4.53	0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs10044254	0.563	rs16867538	chr5:15680744	A/G	cg07238450	chr5:15720153	FBXL7	-0.61	-6.32	-0.46	2.73e-9	Asthma (corticosteroid response);
PAAD	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg08853572	chr16:1843915	IGFALS	-0.25	-4.28	-0.33	3.26e-5	Blood metabolite levels;
PAAD	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.56	5.24	0.39	5.31e-7	Night sleep phenotypes;
PAAD	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.48	-4.42	-0.34	1.88e-5	Red blood cell count;
PAAD	cis	rs4595586	0.505	rs11609838	chr12:39413277	C/T	cg26384229	chr12:38710491	ALG10B	0.76	6.49	0.47	1.15e-9	Morning vs. evening chronotype;
PAAD	cis	rs7975161	0.630	rs4964732	chr12:104652705	A/T	cg25273343	chr12:104657179	TXNRD1	-0.9	-4.52	-0.34	1.22e-5	Toenail selenium levels;
PAAD	cis	rs800160	0.844	rs2651784	chr11:2347549	C/T	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.52	-0.34	1.24e-5	Bacteremia;
PAAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg15448220	chr1:150897856	SETDB1	-0.66	-6.96	-0.49	9.64e-11	Tonsillectomy;
PAAD	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg21535247	chr6:8435926	SLC35B3	-0.56	-5.47	-0.41	1.79e-7	Motion sickness;
PAAD	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.49	-4.28	-0.33	3.25e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.4	4.55	0.35	1.09e-5	Tonsillectomy;
PAAD	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	0.98	5.95	0.43	1.75e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.48	5.84	0.43	3.11e-8	Sitting height ratio;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.94	10.34	0.64	2.58e-19	Breast cancer;
PAAD	cis	rs9913156	0.748	rs7219787	chr17:4562257	A/T	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.56	-5.3	-0.39	4.01e-7	Total body bone mineral density;
PAAD	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg23920097	chr1:209922102	NA	-0.46	-4.5	-0.34	1.37e-5	Red blood cell count;
PAAD	cis	rs7301826	1.000	rs10773819	chr12:131279022	G/A	cg11011512	chr12:131303247	STX2	0.42	4.41	0.34	1.94e-5	Plasma plasminogen activator levels;
PAAD	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg21775007	chr8:11205619	TDH	-0.49	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-1.1	-16.57	-0.8	6.98e-36	Height;
PAAD	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg10556349	chr10:835070	NA	0.57	4.94	0.37	2.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.61	-6.39	-0.46	1.88e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	5.07	0.38	1.14e-6	Iron status biomarkers;
PAAD	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	4.42	0.34	1.86e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1045902	0.967	rs10207625	chr2:73464808	T/C	cg24220031	chr2:73402428	NA	-0.43	-6.36	-0.46	2.25e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg03983715	chr16:68378420	PRMT7	-0.72	-5.23	-0.39	5.43e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.8	-9.96	-0.63	2.71e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.08	-0.5	4.96e-11	Colorectal cancer;
PAAD	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg15432903	chr11:17409602	KCNJ11	0.75	8.94	0.59	1.23e-15	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10049880	chr9:130213948	LRSAM1;RPL12	0.63	7.01	0.49	7.47e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	0.94	6.01	0.44	1.32e-8	Crohn's disease;
PAAD	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs7180079	0.925	rs4776447	chr15:64643067	C/T	cg18210365	chr15:65066710	RBPMS2	0.64	4.92	0.37	2.24e-6	Monocyte count;
PAAD	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.39	0.4	2.6e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.63	6.44	0.46	1.45e-9	Testicular germ cell tumor;
PAAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.47	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.39	-4.42	-0.34	1.9e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-11.4	-0.68	3.75e-22	Chronic sinus infection;
PAAD	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.81	-10.04	-0.63	1.62e-18	Bone mineral density;
PAAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg18888403	chr1:24152774	HMGCL	0.39	4.5	0.34	1.36e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4919087	0.590	rs1253400	chr10:99049566	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.69	-0.48	4.02e-10	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.64	5.74	0.42	5.01e-8	Platelet count;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg19760965	chr3:194868843	C3orf21	0.44	4.71	0.36	5.48e-6	Non-small cell lung cancer;
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02071572	chr4:1403502	NA	0.51	6.73	0.48	3.2e-10	Longevity;
PAAD	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08817983	chr4:3391423	RGS12	0.39	4.36	0.33	2.41e-5	Mean platelet volume;
PAAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg20503657	chr10:835505	NA	0.72	6.6	0.47	6.62e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.62	7.23	0.51	2.23e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs965469	1.000	rs6051715	chr20:3266548	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs11165354	0.687	rs2391027	chr1:92172097	G/A	cg00730172	chr1:91176405	NA	0.37	4.69	0.36	6.16e-6	Type 2 diabetes;
PAAD	cis	rs11811982	0.793	rs11810440	chr1:227267402	T/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.57	-0.47	7.48e-10	Glomerular filtration rate;
PAAD	cis	rs863345	0.967	rs10489835	chr1:158521392	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.96e-6	Pneumococcal bacteremia;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.97e-5	Bipolar disorder;
PAAD	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07930192	chr7:1003750	NA	0.35	4.28	0.33	3.35e-5	Longevity;Endometriosis;
PAAD	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg06115741	chr20:33292138	TP53INP2	-0.69	-4.27	-0.33	3.47e-5	Neuroticism;
PAAD	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg13736514	chr6:26305472	NA	-0.59	-6.27	-0.45	3.63e-9	Educational attainment;
PAAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22624253	chr6:90539556	CASP8AP2	0.42	4.51	0.34	1.26e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-6.85	-0.49	1.74e-10	Menarche (age at onset);
PAAD	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.61	6.75	0.48	2.86e-10	Testicular germ cell tumor;
PAAD	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.89	10.36	0.64	2.27e-19	White blood cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21060784	chr13:99460097	DOCK9	-0.56	-6.61	-0.47	6.24e-10	Monocyte percentage of white cells;
PAAD	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	1.06	5.91	0.43	2.19e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.81	7.56	0.52	3.6e-12	Blood metabolite levels;
PAAD	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.35	5.42	0.4	2.31e-7	IgG glycosylation;
PAAD	cis	rs7172971	0.745	rs75068385	chr15:42382481	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg01616529	chr11:638424	DRD4	-0.61	-5.26	-0.39	4.74e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18796438	chr2:242845662	NA	-0.69	-6.97	-0.49	9.21e-11	Obesity-related traits;
PAAD	cis	rs16975963	0.843	rs77895245	chr19:38419780	G/C	cg25793785	chr19:38281423	NA	0.57	4.66	0.35	6.88e-6	Longevity;
PAAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg27417659	chr7:98567827	TRRAP	-0.48	-4.5	-0.34	1.35e-5	Breast cancer;
PAAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	8.47	0.57	1.96e-14	Lymphocyte counts;
PAAD	cis	rs3996993	0.839	rs9382146	chr6:52702085	G/A	cg20803780	chr6:52668592	GSTA1	-0.36	-4.62	-0.35	8.2e-6	Hemoglobin concentration;
PAAD	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.31	0.64	3.18e-19	White blood cell count;
PAAD	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08677398	chr8:58056175	NA	0.66	4.94	0.37	2.01e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.54	5.79	0.42	3.96e-8	Sitting height ratio;
PAAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.26	-0.6	1.79e-16	Exhaled nitric oxide output;
PAAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.53	4.65	0.35	7.06e-6	Facial morphology (factor 20);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25750363	chr12:133156565	FBRSL1	-0.58	-6.67	-0.48	4.56e-10	Monocyte percentage of white cells;
PAAD	cis	rs9346353	0.627	rs1457500	chr6:70417920	A/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.93e-5	Sleep duration;
PAAD	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.69	4.84	0.37	3.22e-6	Inflammatory bowel disease;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.54	0.57	1.29e-14	Platelet count;
PAAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs8113142	0.614	rs60001754	chr19:29190250	C/T	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.08e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.78e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2278796	0.639	rs6661381	chr1:204971553	A/G	cg04862289	chr1:204966208	NFASC	0.49	5.12	0.38	9.02e-7	Mean platelet volume;
PAAD	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.91	-11.01	-0.67	4.26e-21	Eosinophil percentage of white cells;
PAAD	cis	rs1007738	0.580	rs10501319	chr11:47174062	C/T	cg19486271	chr11:47235900	DDB2	0.62	5.82	0.43	3.36e-8	Bone mineral density (hip);
PAAD	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.43	5.53	0.41	1.35e-7	Schizophrenia;
PAAD	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg22143856	chr6:28129313	ZNF389	0.56	4.57	0.35	1.01e-5	Depression;
PAAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.4	4.52	0.34	1.22e-5	Tonsillectomy;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	4.77	0.36	4.29e-6	Vitiligo;
PAAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg01503450	chr10:980765	NA	-0.56	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.31	0.33	2.92e-5	Mean corpuscular volume;
PAAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg10167378	chr1:228756711	NA	0.43	4.26	0.33	3.57e-5	Diastolic blood pressure;
PAAD	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs72634258	0.945	rs2641116	chr1:8029494	T/G	cg09168692	chr1:7887560	PER3	0.48	4.34	0.33	2.54e-5	Inflammatory bowel disease;
PAAD	cis	rs643506	0.874	rs10789849	chr11:111716070	A/C	cg09085632	chr11:111637200	PPP2R1B	0.5	4.26	0.33	3.62e-5	Breast cancer;
PAAD	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.53e-9	Bladder cancer;
PAAD	cis	rs876084	0.505	rs7834024	chr8:121103053	T/C	cg06265175	chr8:121136014	COL14A1	0.48	4.75	0.36	4.73e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.57	-6.57	-0.47	7.72e-10	Lung cancer;
PAAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs72827839	0.846	rs72825517	chr17:46171824	G/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-5.36	-0.4	3.06e-7	Atrioventricular conduction;
PAAD	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.8	0.48	2.27e-10	Lung cancer in ever smokers;
PAAD	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg13662851	chr12:48723821	H1FNT	-0.62	-6.77	-0.48	2.67e-10	Morning vs. evening chronotype;
PAAD	cis	rs965469	0.779	rs6051752	chr20:3310452	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-4.27	-0.33	3.49e-5	IFN-related cytopenia;
PAAD	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg25547332	chr5:131281432	NA	0.53	4.26	0.33	3.5e-5	Life satisfaction;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg26174226	chr8:58114915	NA	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg16205897	chr5:131564050	P4HA2	-0.42	-4.57	-0.35	9.95e-6	Breast cancer;
PAAD	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg04315214	chr1:2043799	PRKCZ	0.6	7.65	0.53	2.15e-12	Height;
PAAD	cis	rs1468333	1.000	rs2906127	chr5:137539466	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.25	0.45	3.84e-9	Schizophrenia;
PAAD	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg19192590	chr2:178524533	PDE11A	0.4	4.56	0.35	1.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2718812	1.000	rs2718812	chr3:133399702	C/T	cg11941060	chr3:133502564	NA	0.47	4.98	0.37	1.73e-6	Iron status biomarkers;
PAAD	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.68	8.54	0.57	1.29e-14	Asthma;
PAAD	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg26816564	chr1:7831052	VAMP3	0.86	7.05	0.5	5.76e-11	Inflammatory bowel disease;
PAAD	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.6	-7.08	-0.5	4.9e-11	Blood pressure (smoking interaction);
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.72	8.39	0.56	3.18e-14	Height;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.58	6.97	0.49	9.06e-11	Mean corpuscular volume;
PAAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.51	5.13	0.38	8.6e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9409082	0.531	rs2008393	chr9:108914057	A/G	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.6	-5.87	-0.43	2.63e-8	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.68	5.77	0.42	4.33e-8	Common traits (Other);
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg00280220	chr17:61926910	NA	0.46	4.78	0.36	4.04e-6	Prudent dietary pattern;
PAAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.71	-8.26	-0.56	6.45e-14	Huntington's disease progression;
PAAD	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.98	6.19	0.45	5.21e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.74	-7.97	-0.54	3.51e-13	Colorectal cancer;
PAAD	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.72	-0.53	1.46e-12	Brugada syndrome;
PAAD	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs17655565	1.000	rs76413558	chr12:52694156	A/G	cg02645295	chr12:52705424	NA	-0.49	-4.53	-0.34	1.19e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs12760731	0.720	rs10913544	chr1:178350980	C/T	cg00404053	chr1:178313656	RASAL2	0.67	5.04	0.38	1.33e-6	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.48	-4.25	-0.33	3.66e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.48	-6.36	-0.46	2.2e-9	Height;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.5	-5.66	-0.42	7.3900000000000007e-08	Blood pressure (age interaction);
PAAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg14092988	chr3:52407081	DNAH1	-0.4	-5.15	-0.39	7.89e-7	Electroencephalogram traits;
PAAD	cis	rs13401620	0.555	rs2018962	chr2:120974602	C/A	cg15425061	chr2:121036351	RALB	0.49	4.37	0.33	2.31e-5	Breast size;
PAAD	cis	rs2882667	0.587	rs6596450	chr5:138146520	G/A	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.77	9.74	0.62	9.87e-18	Bone mineral density;
PAAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.57	-0.35	1.02e-5	Major depressive disorder;
PAAD	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.58	-4.31	-0.33	2.96e-5	HDL cholesterol;
PAAD	cis	rs507080	0.733	rs544452	chr11:118571357	G/T	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs896623	0.672	rs17051321	chr4:122119449	A/G	cg19463078	chr4:122099598	TNIP3	0.51	4.42	0.34	1.89e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.42	-5.53	-0.41	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs877529	0.605	rs139397	chr22:39543371	T/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.89	-0.49	1.38e-10	Multiple myeloma;
PAAD	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22857025	chr5:266934	NA	-1.23	-5.34	-0.4	3.26e-7	Breast cancer;
PAAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.56	-6.48	-0.47	1.18e-9	Coronary artery disease;
PAAD	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg10395934	chr14:104002654	TRMT61A	0.54	5.62	0.41	8.94e-8	Body mass index;
PAAD	cis	rs988913	0.723	rs75537920	chr6:54999717	T/C	cg03513858	chr6:54763001	FAM83B	0.41	4.39	0.34	2.09e-5	Menarche (age at onset);
PAAD	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.91	-0.43	2.13e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg15017067	chr4:17643749	FAM184B	0.39	4.37	0.33	2.3e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3857067	0.550	rs2865331	chr4:95004722	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg13446199	chr8:143762866	PSCA	0.37	4.38	0.33	2.23e-5	Urinary tract infection frequency;
PAAD	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.59	-0.41	1.05e-7	Urate levels in overweight individuals;
PAAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.09	14.42	0.76	2.89e-30	Cognitive function;
PAAD	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg10072921	chr12:121022843	NA	0.44	5.34	0.4	3.33e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.74	-7.56	-0.52	3.46e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6774494	0.802	rs7617754	chr3:169081584	G/A	cg01324963	chr3:169781717	GPR160	-0.45	-4.36	-0.33	2.4e-5	Nasopharyngeal carcinoma;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.59	5.77	0.42	4.21e-8	Resistin levels;
PAAD	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.42e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.73	8.56	0.57	1.15e-14	Methadone dose in opioid dependence;
PAAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.76	6.78	0.48	2.55e-10	Total body bone mineral density;
PAAD	cis	rs34734847	0.715	rs695952	chr12:121178644	G/A	cg21892295	chr12:121157589	UNC119B	-0.4	-4.65	-0.35	7.03e-6	Mean corpuscular volume;
PAAD	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.5	4.42	0.34	1.87e-5	Corneal astigmatism;
PAAD	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg22467129	chr15:76604101	ETFA	0.54	4.97	0.37	1.81e-6	Blood metabolite levels;
PAAD	cis	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.35	0.33	2.44e-5	Breast cancer;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-4.92	-0.37	2.25e-6	Longevity;Endometriosis;
PAAD	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.71	6.4	0.46	1.79e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg10818794	chr15:86012489	AKAP13	-0.45	-4.98	-0.37	1.71e-6	Interstitial lung disease;
PAAD	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.52	4.88	0.37	2.65e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg16558253	chr16:72132732	DHX38	-0.62	-5.26	-0.39	4.89e-7	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25623604	chr8:99837491	STK3	-0.65	-6.93	-0.49	1.12e-10	Smoking initiation;
PAAD	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.77	8.55	0.57	1.21e-14	Caffeine consumption;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.86	11.94	0.7	1.37e-23	Vitiligo;
PAAD	cis	rs10767942	0.525	rs10835913	chr11:32473981	G/A	cg27259320	chr11:32460587	WIT1	0.5	4.73	0.36	5.14e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16101101	chr1:153643504	ILF2	-0.67	-7.27	-0.51	1.77e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs56046484	0.871	rs34493704	chr15:85558770	A/G	cg08123816	chr15:85640762	PDE8A	-0.43	-4.34	-0.33	2.6e-5	Testicular germ cell tumor;
PAAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.44	0.46	1.52e-9	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15769689	chr21:47167601	NA	-0.65	-6.79	-0.48	2.35e-10	Obesity-related traits;
PAAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.53	-4.6	-0.35	8.83e-6	Parkinson's disease;
PAAD	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs12127944	0.867	rs17347117	chr1:205478285	G/A	cg08473693	chr1:205342340	NA	-0.71	-4.61	-0.35	8.37e-6	IgG glycosylation;
PAAD	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.89	-9.72	-0.62	1.14e-17	Obesity-related traits;
PAAD	cis	rs863345	0.967	rs4411130	chr1:158530665	C/T	cg12129480	chr1:158549410	OR10X1	0.44	4.95	0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.73	7.32	0.51	1.35e-11	Asperger disorder;
PAAD	cis	rs859767	0.501	rs10193171	chr2:135403199	C/T	cg12500956	chr2:135428796	TMEM163	0.32	4.56	0.35	1.03e-5	Neuroticism;
PAAD	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.72	5.22	0.39	5.72e-7	Major depressive disorder;
PAAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.74	-6.41	-0.46	1.76e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg12935359	chr14:103987150	CKB	-0.66	-7.04	-0.5	6.36e-11	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23011194	chr10:97197631	SORBS1	0.61	6.74	0.48	3.15e-10	Myopia (pathological);
PAAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg25319279	chr11:5960081	NA	-0.6	-6.04	-0.44	1.12e-8	DNA methylation (variation);
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.46	4.45	0.34	1.68e-5	Lung cancer;
PAAD	cis	rs10792830	0.815	rs666682	chr11:85739838	T/C	cg07180834	chr11:85838833	NA	-0.52	-6.03	-0.44	1.21e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.15	0.5	3.48e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-4.82	-0.36	3.42e-6	Coronary artery disease;
PAAD	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.01	-0.44	1.34e-8	Dilated cardiomyopathy;
PAAD	cis	rs6424115	0.691	rs4341315	chr1:24204683	C/G	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-1.33	-12.56	-0.71	2.91e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg02640540	chr1:67518911	SLC35D1	0.61	4.83	0.37	3.24e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg02230254	chr11:65586170	NA	-0.34	-4.75	-0.36	4.66e-6	Eosinophil percentage of white cells;
PAAD	cis	rs12620999	0.941	rs62183344	chr2:237979165	T/C	cg23555395	chr2:238036564	NA	0.49	5.83	0.43	3.27e-8	Systemic lupus erythematosus;
PAAD	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.69	-6.85	-0.49	1.75e-10	Post bronchodilator FEV1;
PAAD	cis	rs7301016	1.000	rs73141014	chr12:62891412	T/G	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-9.98	-0.63	2.43e-18	Total body bone mineral density;
PAAD	cis	rs67257959	0.586	rs111818766	chr19:17158092	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	4.76	0.36	4.56e-6	Selective IgA deficiency;
PAAD	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.62	-0.35	7.97e-6	Mean corpuscular volume;
PAAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.07	0.38	1.16e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.37	5.42	0.4	2.29e-7	Neuroticism;
PAAD	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs4950322	0.576	rs11240015	chr1:146852534	A/G	cg22381352	chr1:146742008	CHD1L	-0.4	-4.26	-0.33	3.54e-5	Protein quantitative trait loci;
PAAD	cis	rs11264799	0.813	rs1999793	chr1:157695412	G/A	cg18268488	chr1:157545234	FCRL4	0.54	5.09	0.38	1.04e-6	IgA nephropathy;
PAAD	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.57	5.59	0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.54e-8	Migraine;
PAAD	cis	rs11945232	0.790	rs6816224	chr4:88346510	G/A	cg23841344	chr4:88312519	HSD17B11	-0.57	-5.4	-0.4	2.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.43	4.63	0.35	7.74e-6	Schizophrenia;
PAAD	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09065629	chr16:1709722	CRAMP1L	0.47	4.82	0.36	3.46e-6	Coronary artery disease;
PAAD	cis	rs10821973	0.527	rs4420157	chr10:63979105	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.32	-0.33	2.75e-5	Hypothyroidism;
PAAD	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.52	5.39	0.4	2.7e-7	Electroencephalogram traits;
PAAD	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg23024343	chr7:107201750	COG5	0.57	4.69	0.36	6.08e-6	Coronary artery disease;
PAAD	cis	rs55728055	0.661	rs12168645	chr22:32061014	G/A	cg01338084	chr22:32026380	PISD	1.45	8.25	0.56	7.05e-14	Age-related hearing impairment;
PAAD	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9815354	0.680	rs73075204	chr3:42030392	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12984174	1.000	rs12984174	chr19:18132540	T/C	cg21649277	chr19:18117794	ARRDC2	0.9	6.39	0.46	1.95e-9	Pulmonary function in asthmatics;
PAAD	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.88	-8.47	-0.57	1.91e-14	Bone mineral density;
PAAD	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs9916302	0.560	rs3764352	chr17:37790939	C/T	cg00129232	chr17:37814104	STARD3	-0.77	-6.61	-0.47	6.22e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.17	-0.5	3.13e-11	Body mass index;
PAAD	cis	rs17032980	0.910	rs6712923	chr2:67313799	A/T	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.61e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.49	-5.86	-0.43	2.8e-8	Reticulocyte fraction of red cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19089033	chr1:51434335	CDKN2C	-0.56	-6.42	-0.46	1.68e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.84	-0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.49	-0.34	1.38e-5	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18458131	chr8:98288616	TSPYL5	-0.61	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	1.07	6.71	0.48	3.68e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.51	4.8	0.36	3.82e-6	Educational attainment;
PAAD	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs9825741	chr3:41761828	A/T	cg03022575	chr3:42003672	ULK4	-0.76	-5.54	-0.41	1.32e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3764400	0.567	rs2325784	chr17:46212309	A/G	cg10706073	chr17:46328419	SKAP1	1.05	6.3	0.46	3e-9	Body mass index;
PAAD	cis	rs17641971	0.708	rs1511363	chr8:49901023	C/T	cg00325661	chr8:49890786	NA	0.48	4.72	0.36	5.26e-6	Blood metabolite levels;
PAAD	cis	rs1144	0.536	rs2428162	chr7:104595664	T/C	cg04380332	chr7:105027541	SRPK2	-0.58	-5.86	-0.43	2.72e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.62	5.83	0.43	3.19e-8	Corneal astigmatism;
PAAD	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.79	6.25	0.45	3.86e-9	Neutrophil percentage of white cells;
PAAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.59	-0.35	9.27e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.68	6.82	0.48	1.98e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.84e-6	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg10820045	chr2:198174542	NA	-0.43	-4.36	-0.33	2.35e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.64	-6.01	-0.44	1.34e-8	DNA methylation (variation);
PAAD	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.77	-7.94	-0.54	4.17e-13	Obesity-related traits;
PAAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.98	8.68	0.58	5.8e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.86	10.51	0.65	9.41e-20	Type 2 diabetes;
PAAD	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	1.01	7.68	0.53	1.83e-12	Dental caries;
PAAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.54	-8.35	-0.56	4.04e-14	Urinary metabolites;
PAAD	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.95	-0.37	1.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg00579200	chr11:133705235	NA	-0.51	-5.72	-0.42	5.4e-8	Childhood ear infection;
PAAD	cis	rs9810890	1.000	rs59065735	chr3:128595566	C/T	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs4704187	0.687	rs2216638	chr5:74512987	A/G	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.63	7.24	0.51	2.13e-11	Testicular germ cell tumor;
PAAD	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10342447	chr17:26645325	TMEM97	-0.42	-5.68	-0.42	6.71e-8	Osteoprotegerin levels;
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27099511	chr16:88729703	MGC23284;MVD	-0.89	-4.55	-0.35	1.1e-5	Plateletcrit;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.72	-0.36	5.42e-6	Asthma;
PAAD	cis	rs10885582	0.904	rs11196797	chr10:116354236	C/T	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.04	-0.38	1.29e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.5e-8	Lung cancer;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.88	7.07	0.5	5.34e-11	Alzheimer's disease;
PAAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg05895507	chr15:77155635	SCAPER	0.41	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs3126085	0.515	rs12407319	chr1:152365929	T/C	cg26876637	chr1:152193138	HRNR	-0.6	-4.48	-0.34	1.43e-5	Atopic dermatitis;
PAAD	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.63	-4.63	-0.35	7.91e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.09	5.13	0.38	8.9e-7	Breast cancer;
PAAD	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.64	8.84	0.58	2.26e-15	Airflow obstruction;
PAAD	cis	rs8133932	0.520	rs380120	chr21:47364511	C/A	cg11214348	chr21:47283868	PCBP3	-0.51	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs10073892	0.830	rs10078945	chr5:101623086	T/A	cg17280723	chr5:101634495	NA	0.41	4.33	0.33	2.66e-5	Cognitive decline (age-related);
PAAD	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg00173435	chr12:106696525	TCP11L2	0.48	4.66	0.35	6.94e-6	Tourette syndrome;
PAAD	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.89	-9.29	-0.6	1.5e-16	Parkinson's disease;
PAAD	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6942407	0.592	rs6964225	chr7:86775235	A/G	cg02420886	chr7:86849541	C7orf23	0.61	4.93	0.37	2.12e-6	Food allergy;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg01585852	chr22:24235823	MIF	-0.42	-4.58	-0.35	9.73e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg10578991	chr7:12443926	VWDE	-0.66	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.94	-0.43	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467160	1.000	rs9467158	chr6:24441215	G/A	cg16211469	chr6:24423932	MRS2	0.56	5.26	0.39	4.91e-7	Liver enzyme levels;
PAAD	cis	rs73198271	0.595	rs55874147	chr8:8591954	T/C	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-4.83	-0.37	3.24e-6	Mean platelet volume;
PAAD	cis	rs6681460	0.966	rs2025595	chr1:67152499	G/A	cg02459107	chr1:67143332	SGIP1	0.77	7.57	0.52	3.42e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.54	5.1	0.38	9.97e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20325479	chr7:100271106	GNB2	-0.79	-6.74	-0.48	3.12e-10	Neuroticism;
PAAD	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.63	6.31	0.46	2.93e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs66530629	1.000	rs66530629	chr1:25032168	G/A	cg22509179	chr1:25234806	RUNX3	0.51	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg11416102	chr8:651193	ERICH1	-0.97	-5.84	-0.43	3.05e-8	IgG glycosylation;
PAAD	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg01022228	chr5:132202151	UQCRQ	0.99	6.57	0.47	7.55e-10	Myocardial infarction;
PAAD	cis	rs12935418	0.616	rs8060438	chr16:80963655	A/C	cg16651780	chr16:81037892	C16orf61	0.56	4.61	0.35	8.3e-6	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg07725925	chr16:89976287	TCF25	0.76	4.29	0.33	3.17e-5	Skin colour saturation;
PAAD	cis	rs797680	0.927	rs797675	chr1:93674226	A/T	cg04535902	chr1:92947332	GFI1	0.46	4.41	0.34	1.97e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.75	-9.25	-0.6	1.92e-16	Educational attainment;
PAAD	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24323328	chr12:1099998	ERC1	0.56	6.41	0.46	1.76e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	1.06	6.88	0.49	1.49e-10	IgG glycosylation;
PAAD	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.37	2.41e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1620921	0.505	rs9458031	chr6:161210119	G/A	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14933899	chr2:242041835	MTERFD2	-0.65	-6.67	-0.48	4.41e-10	Smoking initiation;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.9	9.39	0.61	8.61e-17	Nonalcoholic fatty liver disease;
PAAD	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg22437258	chr11:111473054	SIK2	-0.51	-5.01	-0.38	1.52e-6	Primary sclerosing cholangitis;
PAAD	cis	rs7714584	1.000	rs7732643	chr5:150261436	A/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	9.07	0.59	5.64e-16	Platelet count;
PAAD	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.96	-0.44	1.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06671706	chr8:8559999	CLDN23	0.73	7.14	0.5	3.68e-11	Obesity-related traits;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.33	-5.04	-0.38	1.32e-6	Cystic fibrosis severity;
PAAD	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.75	4.95	0.37	1.93e-6	Major depressive disorder;
PAAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.74	6.81	0.48	2.09e-10	Coronary artery disease;
PAAD	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.51	-6.04	-0.44	1.12e-8	Mean arterial pressure;
PAAD	cis	rs34421088	0.532	rs4515509	chr8:11172123	A/T	cg12568669	chr8:11666485	FDFT1	-0.28	-4.27	-0.33	3.48e-5	Neuroticism;
PAAD	cis	rs151997	0.962	rs28676922	chr5:50247221	C/T	cg06027927	chr5:50259733	NA	0.65	6.5	0.47	1.1e-9	Callous-unemotional behaviour;
PAAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.66	7.5	0.52	5.06e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs7814319	0.838	rs4537274	chr8:97232665	A/G	cg20787634	chr8:97240163	UQCRB	-0.61	-6.3	-0.45	3.08e-9	Lung function (FVC);
PAAD	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.46e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6466055	0.604	rs1204078	chr7:104986644	A/T	cg04380332	chr7:105027541	SRPK2	0.65	7.44	0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs2834902	0.605	rs35251029	chr21:36683728	T/C	cg04915566	chr21:36421472	RUNX1	-0.33	-4.49	-0.34	1.38e-5	Corneal curvature;
PAAD	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.53	0.68	1.69e-22	Menopause (age at onset);
PAAD	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.95	12.32	0.71	1.24e-24	Menopause (age at onset);
PAAD	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14169450	chr9:139327907	INPP5E	0.53	4.69	0.36	5.92e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.73	-7.44	-0.52	6.74e-12	Retinal vascular caliber;
PAAD	cis	rs1018697	0.966	rs11191396	chr10:104552865	A/G	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs4743820	0.651	rs10820838	chr9:93930913	G/A	cg14446406	chr9:93919335	NA	-0.51	-6.24	-0.45	4.07e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs4273100	0.850	rs11204306	chr17:19267371	A/G	cg19949948	chr17:19361230	NA	-0.51	-4.33	-0.33	2.66e-5	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.52	-5.32	-0.4	3.57e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg24253500	chr15:84953950	NA	-0.56	-6.53	-0.47	9.33e-10	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25103979	chr14:103148246	RCOR1	-0.64	-6.4	-0.46	1.82e-9	Obesity-related traits;
PAAD	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs60154123	0.730	rs12034871	chr1:210475701	T/C	cg22029157	chr1:209979665	IRF6	0.7	6.06	0.44	1.05e-8	Coronary artery disease;
PAAD	cis	rs2834188	0.557	rs2834186	chr21:34686753	C/T	cg04842828	chr21:34696676	IFNAR1	0.48	5.15	0.39	7.97e-7	Narcolepsy;
PAAD	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.49	-0.34	1.42e-5	Daytime sleep phenotypes;
PAAD	cis	rs8105895	0.935	rs7252023	chr19:22245646	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.54	-6.9	-0.49	1.35e-10	Height;
PAAD	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Birth weight;
PAAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg22189786	chr22:42395067	WBP2NL	0.65	4.72	0.36	5.24e-6	Birth weight;
PAAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.78	-0.48	2.52e-10	Aortic root size;
PAAD	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs55871839	0.533	rs1375193	chr8:59846943	T/C	cg07426533	chr8:59803705	TOX	0.46	4.67	0.35	6.62e-6	Pneumonia;
PAAD	cis	rs55692468	0.606	rs6759772	chr2:153322724	C/T	cg24749089	chr2:153322823	FMNL2	0.28	4.91	0.37	2.34e-6	Intraocular pressure;
PAAD	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.79	7.86	0.54	6.66e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.42	-0.52	7.88e-12	Heart rate;
PAAD	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg03805757	chr16:71968109	PKD1L3	-0.54	-4.79	-0.36	3.98e-6	Post bronchodilator FEV1;
PAAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	5.53	0.41	1.39e-7	Personality dimensions;
PAAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.16e-5	Breast cancer;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.69	7.89	0.54	5.49e-13	Height;
PAAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-1.13	-14.42	-0.76	2.98e-30	Urate levels;
PAAD	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.83	8.56	0.57	1.18e-14	Corneal astigmatism;
PAAD	cis	rs959260	0.557	rs55762977	chr17:73309338	A/G	cg14668889	chr17:73230827	NUP85	0.56	4.99	0.38	1.61e-6	Systemic lupus erythematosus;
PAAD	cis	rs4740619	0.774	rs4741548	chr9:15921622	G/A	cg14451791	chr9:16040625	NA	-0.42	-4.8	-0.36	3.69e-6	Body mass index;
PAAD	cis	rs3737883	1.000	rs2270543	chr1:203030685	T/C	cg03900565	chr1:203031815	PPFIA4	0.34	5.76	0.42	4.54e-8	Early onset atrial fibrillation;
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.31e-9	Lung cancer;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg22535103	chr8:58192502	C8orf71	-1.22	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-9.45	-0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs597583	0.775	rs12806865	chr11:117404769	C/T	cg27161313	chr11:117392002	DSCAML1	0.54	4.96	0.37	1.87e-6	Putamen volume;
PAAD	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-0.47	-4.44	-0.34	1.75e-5	Stearic acid (18:0) levels;
PAAD	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg08886695	chr4:3369023	RGS12	0.52	5.1	0.38	1e-6	Parental longevity (mother's age at death);
PAAD	cis	rs2221894	1.000	rs13280242	chr8:28756738	G/A	cg20212339	chr8:28908912	HMBOX1	0.5	5.22	0.39	5.75e-7	Obesity-related traits;
PAAD	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.18	-0.75	1.3e-29	Primary sclerosing cholangitis;
PAAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.71	9.82	0.62	6.23e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	8.9	0.59	1.54e-15	Lymphocyte counts;
PAAD	cis	rs35123781	0.518	rs72790986	chr5:138973081	A/G	cg26929925	chr5:138714136	SLC23A1	-0.54	-4.76	-0.36	4.45e-6	Schizophrenia;
PAAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg05484376	chr2:27715224	FNDC4	0.45	4.6	0.35	8.87e-6	Total body bone mineral density;
PAAD	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9472414	0.510	rs227857	chr6:44704392	A/T	cg18551225	chr6:44695536	NA	0.47	4.66	0.35	6.89e-6	Height;
PAAD	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg10290764	chr8:4849399	CSMD1	-0.39	-6.56	-0.47	7.79e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.47	4.79	0.36	3.85e-6	Airway imaging phenotypes;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.79	5.9	0.43	2.3e-8	White matter hyperintensity burden;
PAAD	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.83	-0.48	1.94e-10	Systolic blood pressure;
PAAD	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg06606381	chr12:133084897	FBRSL1	-1.18	-7.43	-0.52	7.22e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs6532374	0.872	rs1971197	chr4:93452467	A/G	cg01163837	chr2:31457287	EHD3	-0.77	-6.42	-0.46	1.68e-9	Interleukin-12p70 levels;
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.45	-0.4	1.95e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	5.19	0.39	6.56e-7	Tonsillectomy;
PAAD	cis	rs1997066	0.831	rs73340279	chr10:106809263	C/T	cg17321814	chr10:106440892	SORCS3	0.64	4.42	0.34	1.87e-5	Diabetic kidney disease;
PAAD	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.43	0.4	2.22e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.74	-7.47	-0.52	5.83e-12	DNA methylation (variation);
PAAD	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.88	7.1	0.5	4.38e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg21605333	chr4:119757512	SEC24D	1.25	7.8	0.53	9.22e-13	Cannabis dependence symptom count;
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg24699146	chr1:24152579	HMGCL	-0.55	-5.92	-0.43	2.05e-8	Immature fraction of reticulocytes;
PAAD	cis	rs77880822	0.562	rs74558331	chr20:1238619	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01765077	chr12:122356316	WDR66	0.7	7.21	0.51	2.4e-11	Mean corpuscular volume;
PAAD	cis	rs36093844	0.948	rs56271770	chr11:85548400	C/T	cg25872744	chr11:85566296	CCDC83	-0.57	-4.44	-0.34	1.71e-5	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
PAAD	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.53	5.85	0.43	2.94e-8	Heart rate;
PAAD	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.27	19.39	0.84	6.17e-43	IgG glycosylation;
PAAD	cis	rs73416724	1.000	rs76823934	chr6:43359424	G/A	cg17076780	chr6:43251928	TTBK1	0.58	4.59	0.35	9.27e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.02e-5	Platelet count;
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	5.75	0.42	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.35e-29	Rheumatoid arthritis;
PAAD	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg06484146	chr7:12443880	VWDE	-0.63	-4.53	-0.34	1.18e-5	Coronary artery disease;
PAAD	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.54	-4.87	-0.37	2.71e-6	Myeloid white cell count;
PAAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg23346134	chr3:49453900	TCTA	-0.47	-5.01	-0.38	1.46e-6	Menarche (age at onset);
PAAD	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.88	10.08	0.63	1.32e-18	Gout;
PAAD	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs5753037	0.653	rs131273	chr22:30153721	T/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.43	-0.4	2.2e-7	Total cholesterol levels;
PAAD	cis	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg21546286	chr11:48923668	NA	-0.52	-5.37	-0.4	2.89e-7	HDL cholesterol;
PAAD	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.04	0.44	1.13e-8	Colorectal cancer;
PAAD	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.55	7.45	0.52	6.44e-12	IgA nephropathy;
PAAD	cis	rs16975963	0.793	rs73027418	chr19:38361020	C/T	cg14218481	chr19:38281219	NA	0.47	4.78	0.36	4.1e-6	Longevity;
PAAD	cis	rs2764208	0.576	rs2764199	chr6:34706982	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.31	-0.33	2.86e-5	Systemic lupus erythematosus;
PAAD	cis	rs501120	0.564	rs11238905	chr10:44685136	T/A	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg03264133	chr6:25882463	NA	0.44	4.32	0.33	2.75e-5	Schizophrenia;
PAAD	cis	rs2115386	0.932	rs4804092	chr19:7196247	C/G	cg09779027	chr19:7224513	INSR	0.44	4.41	0.34	1.95e-5	Diabetic retinopathy;
PAAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.27	0.45	3.54e-9	Height;
PAAD	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-5.06	-0.38	1.18e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-0.87	-9.41	-0.61	7.63e-17	Body mass index;
PAAD	cis	rs76793172	0.623	rs10775546	chr19:46267534	C/T	cg13320842	chr19:46175254	GIPR	-0.55	-4.76	-0.36	4.52e-6	Eosinophil counts;
PAAD	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs78761021	0.867	rs74701139	chr17:9788360	A/C	cg26853458	chr17:9805074	RCVRN	0.72	8.37	0.56	3.53e-14	Type 2 diabetes;
PAAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg05110241	chr16:68378359	PRMT7	-0.86	-7.0	-0.49	7.63e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg27094323	chr7:1216898	NA	-0.52	-6.27	-0.45	3.49e-9	Longevity;Endometriosis;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.39	-5.34	-0.4	3.34e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-0.48	-4.85	-0.37	3.03e-6	Heart rate variability traits (SDNN);
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg26039829	chr8:22132926	PIWIL2	0.62	7.93	0.54	4.42e-13	Hypertriglyceridemia;
PAAD	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.4	5.46	0.41	1.87e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19403339	chr2:183580841	DNAJC10	0.62	6.3	0.46	3.04e-9	Primary biliary cholangitis;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.63	6.56	0.47	8.05e-10	Lung cancer;
PAAD	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.99	-8.3	-0.56	5.13e-14	Vitiligo;
PAAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.47	5.89	0.43	2.43e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9866391	0.679	rs726838	chr3:141072666	A/T	cg00789793	chr3:141329863	RASA2	0.52	4.4	0.34	2.06e-5	Myopia;
PAAD	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.45	-0.34	1.63e-5	Breast cancer;
PAAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	4.48	0.34	1.46e-5	Crohn's disease;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg03188948	chr7:1209495	NA	0.44	4.43	0.34	1.8e-5	Longevity;Endometriosis;
PAAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.8	0.36	3.73e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.57	5.06	0.38	1.18e-6	Dialysis-related mortality;
PAAD	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.4	-4.51	-0.34	1.29e-5	Refractive error;
PAAD	cis	rs758324	0.812	rs4705840	chr5:131206624	C/T	cg06307176	chr5:131281290	NA	0.54	4.62	0.35	8.22e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg26939375	chr7:64535504	NA	0.52	5.77	0.42	4.21e-8	Aortic root size;
PAAD	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	4.49	0.34	1.39e-5	Height;
PAAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg10589385	chr1:150898437	SETDB1	0.37	4.41	0.34	1.91e-5	Melanoma;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04156016	chr5:1868137	NA	0.47	4.77	0.36	4.33e-6	Cardiovascular disease risk factors;
PAAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.68	6.01	0.44	1.32e-8	Breast cancer;
PAAD	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.53	5.27	0.39	4.5e-7	Resting heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23809917	chr2:10953293	PDIA6	0.69	6.86	0.49	1.61e-10	Obesity-related traits;
PAAD	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.6	-5.42	-0.4	2.34e-7	Neutrophil percentage of white cells;
PAAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg06618935	chr21:46677482	NA	-0.59	-6.88	-0.49	1.49e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.36	3.3e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg25790453	chr13:113633590	MCF2L	-0.38	-4.45	-0.34	1.64e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.54	4.37	0.33	2.33e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2415984	0.622	rs1761025	chr14:46930439	T/C	cg14871534	chr14:47121158	RPL10L	0.53	5.55	0.41	1.24e-7	Number of children ever born;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06924355	chr4:79860764	PAQR3	0.74	7.23	0.51	2.16e-11	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs7487075	0.619	rs4768717	chr12:46831561	C/T	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg13752114	chr3:195489708	MUC4	0.75	5.78	0.42	4.01e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg02997394	chr19:33096574	ANKRD27	-0.41	-4.48	-0.34	1.45e-5	Schizophrenia;
PAAD	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.69	-0.53	1.74e-12	Coronary artery disease;
PAAD	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.0	0.59	8.83e-16	Airflow obstruction;
PAAD	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.52	4.72	0.36	5.27e-6	Anxiety disorder;
PAAD	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.76	7.91	0.54	4.88e-13	Neuroticism;
PAAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.77	7.79	0.53	9.61e-13	Body mass index;
PAAD	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.45	5.09	0.38	1.02e-6	Testicular germ cell tumor;
PAAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg26138144	chr22:38071188	LGALS1	0.51	5.57	0.41	1.12e-7	Fat distribution (HIV);
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.71	-6.11	-0.44	8.15e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg18551225	chr6:44695536	NA	-0.73	-7.44	-0.52	7.09e-12	Total body bone mineral density;
PAAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.74	7.93	0.54	4.32e-13	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	1.92e-13	Alzheimer's disease;
PAAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg07202610	chr7:1142643	C7orf50	-0.73	-5.07	-0.38	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.61	-5.15	-0.39	7.91e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs6028335	0.610	rs10392	chr20:37550935	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.94	-0.37	2.02e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.49	-5.57	-0.41	1.14e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2415984	0.622	rs2415998	chr14:46930712	A/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.46	-0.4	1.89e-7	Number of children ever born;
PAAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg03983476	chr2:10830698	NOL10	-0.52	-5.14	-0.39	8.17e-7	Prostate cancer;
PAAD	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg08975724	chr8:8085496	FLJ10661	0.72	7.34	0.51	1.17e-11	Morning vs. evening chronotype;
PAAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg11993925	chr19:44307056	LYPD5	0.51	6.89	0.49	1.36e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10500715	0.715	rs10160515	chr11:10001536	T/G	cg06875754	chr11:10328428	ADM	0.35	4.75	0.36	4.73e-6	Pancreatic cancer;
PAAD	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg24053715	chr22:38214548	NA	-0.58	-5.94	-0.43	1.89e-8	Glioblastoma;Glioma;
PAAD	cis	rs3787159	0.523	rs522214	chr20:56878569	C/T	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-6.82	-0.48	1.97e-10	Hemoglobin concentration;
PAAD	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg20435097	chr10:126320824	FAM53B	0.45	4.35	0.33	2.48e-5	Cocaine dependence;
PAAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.95	8.34	0.56	4.17e-14	Gut microbiome composition (summer);
PAAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.95	13.41	0.74	1.48e-27	Rheumatoid arthritis;
PAAD	cis	rs7554547	1.000	rs2336378	chr1:11975683	T/C	cg07603449	chr1:11986842	KIAA2013	-0.28	-4.25	-0.33	3.72e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs863345	0.967	rs1418847	chr1:158484378	A/T	cg12129480	chr1:158549410	OR10X1	-0.45	-5.22	-0.39	5.82e-7	Pneumococcal bacteremia;
PAAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.6	7.14	0.5	3.53e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	7.42	0.52	7.67e-12	Coffee consumption (cups per day);
PAAD	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	5.05	0.38	1.25e-6	Cognitive ability;
PAAD	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.64	5.42	0.4	2.29e-7	Schizophrenia;
PAAD	cis	rs2377058	0.924	rs7203947	chr16:89722511	T/C	cg03605463	chr16:89740564	NA	-0.62	-5.83	-0.43	3.15e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs66530629	0.874	rs7528154	chr1:25130083	T/C	cg22509179	chr1:25234806	RUNX3	-0.5	-4.69	-0.36	6.16e-6	Plateletcrit;
PAAD	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg10820045	chr2:198174542	NA	0.51	5.16	0.39	7.46e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.5	4.97	0.37	1.8e-6	Parkinson's disease;
PAAD	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.47	-4.31	-0.33	2.94e-5	Red blood cell count;
PAAD	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg13444538	chr7:158905317	VIPR2	-0.7	-5.21	-0.39	6.16e-7	Myopia (pathological);
PAAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	9.14	0.6	3.77e-16	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17410431	chr2:240012681	HDAC4	-0.64	-6.51	-0.47	1.02e-9	Obesity-related traits;
PAAD	cis	rs9469913	0.799	rs9462007	chr6:34715341	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18364779	chr6:26104403	HIST1H4C	0.51	4.75	0.36	4.7e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6076065	0.723	rs2424550	chr20:23394669	C/T	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	6.64	0.47	5.11e-10	Neuroticism;
PAAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.46	4.88	0.37	2.67e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03676636	chr4:99064102	C4orf37	0.29	5.47	0.41	1.8e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg05083358	chr7:2394359	EIF3B	-0.71	-5.27	-0.39	4.65e-7	Multiple sclerosis;
PAAD	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.66	-6.22	-0.45	4.68e-9	Neuroticism;
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg08088566	chr11:430123	ANO9	0.85	5.39	0.4	2.7e-7	Body mass index;
PAAD	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.4	-0.78	7.66e-33	Height;
PAAD	cis	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg07168214	chr17:7380112	ZBTB4	-0.68	-6.12	-0.44	7.42e-9	Androgen levels;
PAAD	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.71	-6.43	-0.46	1.54e-9	Blood pressure (smoking interaction);
PAAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs4343996	0.565	rs13246563	chr7:3438243	C/G	cg21248987	chr7:3385318	SDK1	0.42	4.47	0.34	1.51e-5	Motion sickness;
PAAD	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs501120	0.810	rs513391	chr10:44749708	A/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs8113142	0.540	rs56149853	chr19:29056578	A/G	cg04546413	chr19:29218101	NA	0.43	4.36	0.33	2.38e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.43	4.68	0.35	6.38e-6	HDL cholesterol levels;
PAAD	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.12	0.7	4.51e-24	Heart rate;
PAAD	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06771106	chr2:113671356	IL1F7	0.6	6.44	0.46	1.52e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg12140854	chr5:148520817	ABLIM3	0.4	4.26	0.33	3.57e-5	Breast cancer;
PAAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg02430305	chr4:183839170	DCTD	0.6	6.77	0.48	2.66e-10	Height;
PAAD	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.26	-0.33	3.62e-5	Neuroticism;
PAAD	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.55	-0.47	8.31e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.4	-5.21	-0.39	6.08e-7	Colorectal cancer;
PAAD	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs58521262	0.505	rs428612	chr19:23122604	A/G	cg02350677	chr19:23254381	NA	-0.27	-4.71	-0.36	5.63e-6	Testicular germ cell tumor;
PAAD	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg18135555	chr8:22132992	PIWIL2	0.57	8.51	0.57	1.57e-14	Hypertriglyceridemia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15172729	chr11:67056446	ANKRD13D	0.68	7.67	0.53	1.91e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs76917914	0.589	rs12552242	chr9:100866201	A/C	cg03040243	chr9:100819229	NANS	0.51	4.31	0.33	2.92e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg13468214	chr4:1046988	NA	-0.51	-4.58	-0.35	9.53e-6	Recombination rate (females);
PAAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs9463078	0.585	rs10807320	chr6:45238442	A/G	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-1.09	-15.35	-0.78	1.02e-32	Breast cancer;
PAAD	cis	rs7627468	0.837	rs7618100	chr3:121950120	G/C	cg17240004	chr3:121949083	CASR	0.53	4.83	0.36	3.26e-6	Kidney stones;
PAAD	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg05250797	chr16:70222502	NA	0.83	6.25	0.45	4e-9	IgE levels;
PAAD	cis	rs12711490	0.559	rs8045825	chr16:85970478	C/G	cg05709598	chr16:85699621	KIAA0182	0.42	4.44	0.34	1.76e-5	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;
PAAD	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs939584	0.877	rs11127484	chr2:623798	T/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.29	-0.33	3.14e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	6.28	0.45	3.33e-9	Alzheimer's disease;
PAAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.71	-7.92	-0.54	4.65e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs42648	0.596	rs6465251	chr7:89847881	C/G	cg27367526	chr7:89841692	STEAP2	-0.3	-4.25	-0.33	3.67e-5	Homocysteine levels;
PAAD	cis	rs4679121	0.642	rs76826102	chr3:126185964	C/T	cg05485589	chr3:126194908	ZXDC	-0.88	-4.39	-0.34	2.09e-5	Pursuit maintenance gain;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18635645	chr1:85667791	SYDE2	0.62	6.99	0.49	8.09e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-4.86	-0.37	2.84e-6	Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.83e-7	Motion sickness;
PAAD	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.61	-4.99	-0.38	1.65e-6	Personality dimensions;
PAAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.42	0.4	2.25e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs10500715	0.715	rs2403228	chr11:9987028	G/T	cg06875754	chr11:10328428	ADM	-0.32	-4.37	-0.33	2.25e-5	Pancreatic cancer;
PAAD	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.82	4.29	0.33	3.16e-5	Coronary artery disease;
PAAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.53	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg01075559	chr1:2537774	MMEL1	-0.52	-5.47	-0.41	1.77e-7	Ulcerative colitis;
PAAD	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg00181669	chr3:44000978	NA	-0.42	-4.25	-0.33	3.69e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14602982	chr11:119599176	PVRL1	0.63	7.15	0.5	3.33e-11	Myopia (pathological);
PAAD	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.83	-7.97	-0.54	3.58e-13	Body mass index;
PAAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.79	-8.14	-0.55	1.32e-13	Prostate cancer;
PAAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.97	-0.44	1.64e-8	Menarche (age at onset);
PAAD	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.58	6.79	0.48	2.36e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg11995313	chr8:8860691	ERI1	0.5	5.11	0.38	9.53e-7	Joint mobility (Beighton score);
PAAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs17155006	0.655	rs424978	chr7:107724747	C/G	cg05962710	chr7:107745446	LAMB4	-0.44	-5.46	-0.41	1.89e-7	Pneumococcal bacteremia;
PAAD	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg04261877	chr17:18218829	SMCR8;TOP3A	0.6	5.61	0.41	9.27e-8	Multiple sclerosis;
PAAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.47	4.91	0.37	2.29e-6	Longevity;Endometriosis;
PAAD	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.61	0.35	8.37e-6	Free thyroxine concentration;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.54	4.37	0.33	2.31e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.5	5.41	0.4	2.43e-7	Age at first birth;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg02462569	chr6:150064036	NUP43	0.49	5.5	0.41	1.58e-7	Lung cancer;
PAAD	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg03094675	chr11:5960213	NA	-0.48	-4.49	-0.34	1.39e-5	DNA methylation (variation);
PAAD	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.8	9.17	0.6	3.22e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.75	-6.76	-0.48	2.77e-10	Schizophrenia;
PAAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.62	-5.53	-0.41	1.35e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.73	7.62	0.53	2.56e-12	Prostate cancer;
PAAD	cis	rs16910800	1.000	rs16910794	chr11:23202631	A/T	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-5.01	-0.38	1.48e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.56	-6.34	-0.46	2.45e-9	Educational attainment;
PAAD	cis	rs56011263	0.532	rs4234853	chr4:735150	G/A	cg17689763	chr4:710664	PCGF3	-0.58	-5.73	-0.42	5.27e-8	White blood cell count;
PAAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.71	-8.13	-0.55	1.4e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.7	5.84	0.43	3.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13939156	chr17:80058883	NA	0.45	4.98	0.37	1.67e-6	Life satisfaction;
PAAD	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.6	-5.99	-0.44	1.46e-8	Aortic root size;
PAAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg21395723	chr22:39101663	GTPBP1	0.42	4.41	0.34	1.94e-5	Menopause (age at onset);
PAAD	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.38	-0.56	3.23e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	5.12	0.38	9.02e-7	Mean platelet volume;
PAAD	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.72	-7.4	-0.51	8.86e-12	Cognitive function;
PAAD	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.64	6.45	0.46	1.43e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg03989125	chr22:38214979	NA	-0.52	-5.38	-0.4	2.81e-7	Glioblastoma;Glioma;
PAAD	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg17971929	chr21:40555470	PSMG1	0.81	7.02	0.49	6.98e-11	Cognitive function;
PAAD	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	11.5	0.68	2.03e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.45e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.77	9.23	0.6	2.21e-16	Lung cancer;
PAAD	cis	rs73206853	0.534	rs7131996	chr12:111073276	C/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.73	0.36	5.16e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg08888203	chr3:10149979	C3orf24	0.73	6.56	0.47	7.83e-10	Alzheimer's disease;
PAAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg24253500	chr15:84953950	NA	0.43	4.59	0.35	9.09e-6	Schizophrenia;
PAAD	cis	rs10901513	0.932	rs10901494	chr10:127671071	G/A	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.52	4.83	0.36	3.3e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9646944	0.501	rs10174323	chr2:103012781	C/A	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.8	7.35	0.51	1.12e-11	Obesity-related traits;
PAAD	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.56	-5.62	-0.41	8.76e-8	Crohn's disease;
PAAD	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg00792783	chr2:198669748	PLCL1	-0.47	-4.33	-0.33	2.7e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.6	6.72	0.48	3.48e-10	Longevity;Endometriosis;
PAAD	cis	rs3996993	0.686	rs1009064	chr6:52623490	G/C	cg00536792	chr6:53530503	KLHL31	0.47	4.93	0.37	2.15e-6	Hemoglobin concentration;
PAAD	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.16	-0.5	3.28e-11	Blood pressure (smoking interaction);
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.51	-5.74	-0.42	5.06e-8	Mean corpuscular volume;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.94	-10.59	-0.65	5.6e-20	Height;
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.84	9.43	0.61	6.69e-17	Prostate cancer;
PAAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-5.63	-0.42	8.29e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-5.36	-0.4	3.07e-7	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.26e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03251615	chr12:6862186	MLF2	-0.57	-6.62	-0.47	5.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.59	5.71	0.42	5.79e-8	Height;
PAAD	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.09e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs595018	0.505	rs56401304	chr11:60595396	T/G	cg23904249	chr11:60608951	CCDC86	0.69	5.11	0.38	9.35e-7	Wegener's granulomatosis;
PAAD	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg00806126	chr19:22604979	ZNF98	-0.37	-4.72	-0.36	5.4e-6	Pain;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	8.85	0.58	2.08e-15	Alzheimer's disease;
PAAD	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.76	7.64	0.53	2.32e-12	Resting heart rate;
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.71	-7.05	-0.5	5.99e-11	Height;
PAAD	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg22105103	chr4:187893119	NA	0.62	7.73	0.53	1.35e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs863345	0.604	rs10797018	chr1:158490112	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg01426195	chr3:39028469	NA	-0.74	-7.68	-0.53	1.79e-12	Handedness;
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.5	4.51	0.34	1.28e-5	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.84	0.54	7.49e-13	Prudent dietary pattern;
PAAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25833597	chr17:30823145	MYO1D	0.55	5.33	0.4	3.44e-7	Schizophrenia;
PAAD	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.55	4.47	0.34	1.55e-5	Red blood cell count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06851336	chr10:104678166	CNNM2	0.67	7.41	0.52	8.38e-12	Myopia (pathological);
PAAD	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.12	-0.59	4.34e-16	Schizophrenia;
PAAD	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg04520793	chr17:42248056	ASB16	0.43	4.81	0.36	3.63e-6	Total body bone mineral density;
PAAD	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.51	-6.34	-0.46	2.43e-9	Crohn's disease;
PAAD	cis	rs863345	0.604	rs10908665	chr1:158499889	T/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs72960926	1.000	rs56168999	chr6:75121136	A/G	cg13997649	chr6:74171430	MTO1	0.82	4.49	0.34	1.38e-5	Metabolite levels (MHPG);
PAAD	cis	rs16867321	0.951	rs9989767	chr2:181429886	C/T	cg23363182	chr2:181467187	NA	-0.53	-4.59	-0.35	9.28e-6	Obesity;
PAAD	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg07469887	chr10:131262384	NA	-0.38	-4.28	-0.33	3.29e-5	Response to temozolomide;
PAAD	cis	rs2445762	0.659	rs12441170	chr15:51653898	G/A	cg00184732	chr15:51633821	GLDN	0.44	4.31	0.33	2.86e-5	Hormone measurements;
PAAD	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg18833306	chr6:118973337	C6orf204	0.43	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	cis	rs3749237	0.964	rs2276864	chr3:49894030	T/C	cg03060546	chr3:49711283	APEH	0.63	6.28	0.45	3.3e-9	Resting heart rate;
PAAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.27	-0.39	4.51e-7	Height;
PAAD	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg04165759	chr1:150448943	RPRD2	0.49	5.04	0.38	1.33e-6	Migraine;
PAAD	cis	rs6028335	0.877	rs2235769	chr20:37779569	C/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.53	-4.37	-0.33	2.29e-5	Alcohol and nicotine co-dependence;
PAAD	trans	rs901683	1.000	rs12779005	chr10:46087374	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.73	7.11	0.5	4.14e-11	Neuroticism;
PAAD	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg08648136	chr8:956695	NA	0.48	5.11	0.38	9.7e-7	Schizophrenia;
PAAD	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.88	5.88	0.43	2.49e-8	Tonometry;
PAAD	cis	rs1008126	0.600	rs4727570	chr7:103134675	A/G	cg04218035	chr7:103086829	SLC26A5	-0.33	-4.6	-0.35	8.91e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26209169	chr5:1316264	NA	0.37	4.3	0.33	3.02e-5	Lung cancer;
PAAD	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg14709524	chr16:89940631	TCF25	-0.95	-4.48	-0.34	1.48e-5	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19056537	chr2:132415749	NA	0.58	6.45	0.46	1.38e-9	Smoking initiation;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg06204629	chr1:72753076	NA	-0.54	-6.37	-0.46	2.1e-9	Energy expenditure (24h);
PAAD	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.89	9.6	0.61	2.38e-17	Lewy body disease;
PAAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.63	6.96	0.49	9.32e-11	Prostate cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24545687	chr12:132537711	EP400	-0.73	-6.83	-0.48	1.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7631605	0.905	rs3774321	chr3:37158567	T/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs783147	0.652	rs1782629	chr6:161195866	C/A	cg01280913	chr6:161186852	NA	0.44	4.9	0.37	2.47e-6	Lp (a) levels;
PAAD	cis	rs8010715	0.816	rs6573573	chr14:24599257	T/C	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.97	11.33	0.68	5.74e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.74	8.44	0.57	2.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Body mass index;
PAAD	trans	rs225245	0.782	rs321618	chr17:33912404	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.47	-0.46	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Electroencephalogram traits;
PAAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg03983715	chr16:68378420	PRMT7	-0.94	-7.11	-0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.5	5.13	0.38	8.65e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.56	4.28	0.33	3.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg08648136	chr8:956695	NA	0.51	5.37	0.4	2.9e-7	Schizophrenia;
PAAD	cis	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26926768	chr12:34528122	NA	0.39	4.76	0.36	4.47e-6	Morning vs. evening chronotype;
PAAD	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.48	4.55	0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-4.61	-0.35	8.5e-6	Self-reported allergy;
PAAD	cis	rs12484776	0.786	rs73165040	chr22:40538602	C/T	cg07138101	chr22:40742427	ADSL	0.6	4.47	0.34	1.51e-5	Uterine fibroids;
PAAD	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg10556349	chr10:835070	NA	0.56	4.84	0.37	3.14e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.76	8.83	0.58	2.37e-15	Blood metabolite ratios;
PAAD	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.49	4.51	0.34	1.29e-5	Airway imaging phenotypes;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg24829409	chr8:58192753	C8orf71	-0.9	-7.99	-0.54	3.21e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs360071	0.528	rs360100	chr1:226067382	G/A	cg01472176	chr1:226074946	LEFTY1	0.6	5.74	0.42	4.86e-8	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.73	-8.93	-0.59	1.27e-15	Body mass index;
PAAD	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg20344442	chr15:51633704	GLDN	0.52	4.87	0.37	2.82e-6	Hormone measurements;
PAAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.53	-5.81	-0.43	3.61e-8	Longevity;
PAAD	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.18	0.45	5.65e-9	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg11764359	chr7:65958608	NA	0.77	5.07	0.38	1.14e-6	Diabetic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23625086	chr17:78836339	RPTOR	0.67	7.41	0.52	8.08e-12	Smoking initiation;
PAAD	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg21108841	chr4:24914750	CCDC149	-0.54	-4.38	-0.33	2.23e-5	Heschl's gyrus morphology;
PAAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.05	-0.38	1.24e-6	Schizophrenia;
PAAD	cis	rs2180341	0.656	rs6569491	chr6:127769338	C/G	cg27446573	chr6:127587934	RNF146	0.88	9.43	0.61	6.69e-17	Breast cancer;
PAAD	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.54	9.47	0.61	5.18e-17	Age-related hearing impairment;
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.8	0.43	3.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.47	-0.46	1.3e-9	HDL cholesterol;
PAAD	cis	rs12773846	0.666	rs35422383	chr10:126267528	C/T	cg04949429	chr10:126290192	LHPP	0.5	4.73	0.36	5.02e-6	Subcutaneous adipose tissue;
PAAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.4	-0.68	3.74e-22	Coronary artery disease;
PAAD	cis	rs617219	0.726	rs1275105	chr5:78444148	T/C	cg24856658	chr5:78533917	JMY	-0.39	-4.44	-0.34	1.73e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.45e-6	Bipolar disorder;
PAAD	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg01267373	chr18:77410094	NA	0.42	4.34	0.33	2.54e-5	Monocyte count;
PAAD	cis	rs4656940	0.574	rs6427545	chr1:160770515	A/G	cg23981150	chr1:161111090	NA	-0.45	-4.34	-0.33	2.64e-5	Crohn's disease;
PAAD	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.74	-0.58	3.96e-15	Eye color traits;
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg26557270	chr6:116382179	FRK	0.31	5.51	0.41	1.49e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
PAAD	cis	rs12144094	0.882	rs12127451	chr1:120227630	C/A	cg20995928	chr1:120229863	NA	0.53	4.88	0.37	2.71e-6	Height;
PAAD	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.63	8.91	0.59	1.43e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.96	-6.7	-0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.56	5.69	0.42	6.49e-8	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.32e-6	Lung cancer;
PAAD	cis	rs990171	0.506	rs2041748	chr2:102756295	A/G	cg22835712	chr2:102737379	NA	0.53	5.43	0.4	2.22e-7	Lymphocyte counts;
PAAD	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs7577696	0.889	rs455060	chr2:32475109	G/A	cg02381751	chr2:32503542	YIPF4	0.43	4.7	0.36	5.68e-6	Inflammatory biomarkers;
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.51	0.34	1.29e-5	IgG glycosylation;
PAAD	cis	rs988913	0.581	rs3125267	chr6:54857921	A/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.72	-0.36	5.28e-6	Menarche (age at onset);
PAAD	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.82	9.55	0.61	3.25e-17	Blood metabolite ratios;
PAAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.28	-0.45	3.31e-9	IgG glycosylation;
PAAD	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs16852403	0.861	rs6662255	chr1:178040083	C/T	cg00404053	chr1:178313656	RASAL2	0.42	4.32	0.33	2.76e-5	Childhood ear infection;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.92	7.76	0.53	1.15e-12	Alzheimer's disease;
PAAD	cis	rs10894294	0.589	rs7933085	chr11:130796248	A/G	cg12179176	chr11:130786555	SNX19	0.79	8.88	0.58	1.73e-15	Schizophrenia;
PAAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.6	-5.9	-0.43	2.28e-8	Calcium levels;
PAAD	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs56379725	1	rs56379725	chr7:43859415	A/AT	cg06314643	chr7:44039612	SPDYE1;POLR2J4	-0.64	-4.49	-0.34	1.38e-5	Peak insulin response;
PAAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.72	6.4	0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.24	-0.39	5.22e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg00982548	chr2:198649783	BOLL	-0.71	-4.71	-0.36	5.45e-6	Ulcerative colitis;
PAAD	cis	rs12760731	0.720	rs7537811	chr1:178276421	A/T	cg00404053	chr1:178313656	RASAL2	0.72	5.5	0.41	1.55e-7	Obesity-related traits;
PAAD	cis	rs12760731	0.623	rs1342849	chr1:178296692	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.2	0.39	6.41e-7	Obesity-related traits;
PAAD	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.7	8.06	0.55	2.09e-13	Colorectal cancer;
PAAD	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	5.86	0.43	2.75e-8	Blood metabolite levels;
PAAD	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-6.75	-0.48	2.91e-10	Eye color traits;
PAAD	cis	rs1879734	0.731	rs7544346	chr1:54158475	C/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.61	7.21	0.51	2.4e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.9	8.85	0.58	2.1e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.97	14.71	0.77	5.05e-31	Dental caries;
PAAD	cis	rs10540	0.915	rs35333170	chr11:526478	A/G	cg07703079	chr11:430292	ANO9	0.79	4.36	0.33	2.37e-5	Body mass index;
PAAD	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.49	-5.69	-0.42	6.34e-8	Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20314438	chr6:126661369	C6orf173	0.6	7.07	0.5	5.37e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.58	0.57	1.02e-14	Exhaled nitric oxide output;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	1.09	8.49	0.57	1.78e-14	IgG glycosylation;
PAAD	cis	rs9659323	0.670	rs12096179	chr1:119635723	T/C	cg17326555	chr1:119535693	NA	-0.37	-5.02	-0.38	1.44e-6	Body mass index;
PAAD	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.62	6.16	0.45	6.08e-9	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg22029157	chr1:209979665	IRF6	0.7	6.87	0.49	1.55e-10	Coronary artery disease;
PAAD	cis	rs1833219	0.561	rs1420365	chr2:67294779	A/G	cg02624836	chr2:67312537	NA	-0.4	-4.25	-0.33	3.65e-5	Periodontitis (CDC/AAP);
PAAD	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg06521852	chr22:38141419	TRIOBP	0.44	4.35	0.33	2.47e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.12	-0.38	8.98e-7	Life satisfaction;
PAAD	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.47	-0.46	1.3e-9	HDL cholesterol;
PAAD	cis	rs68170813	1.000	rs35024078	chr7:107245468	A/G	cg23024343	chr7:107201750	COG5	0.53	4.32	0.33	2.77e-5	Coronary artery disease;
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Body mass index;
PAAD	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.13	14.62	0.76	8.91e-31	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.14	0.45	6.91e-9	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01555791	chr17:1012288	ABR	0.59	6.61	0.47	6.09e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.6	-7.98	-0.54	3.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg01090926	chr14:75137805	KIAA0317	0.54	4.84	0.37	3.17e-6	Non-small cell lung cancer;
PAAD	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.71	7.75	0.53	1.22e-12	Melanoma;
PAAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs6594713	0.800	rs67320720	chr5:112761449	A/C	cg12552261	chr5:112820674	MCC	0.6	4.34	0.33	2.64e-5	Brain cytoarchitecture;
PAAD	cis	rs863345	0.967	rs1592255	chr1:158470556	G/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs2882667	0.690	rs11750163	chr5:138041609	T/C	cg09476006	chr5:138032270	NA	0.52	6.71	0.48	3.55e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2286379	0.565	rs7962394	chr12:1787173	A/G	cg05227549	chr12:1770782	NA	-0.39	-4.4	-0.34	2.02e-5	Blood pressure (smoking interaction);
PAAD	cis	rs6137287	0.924	rs8120377	chr20:21168361	G/T	cg04219410	chr20:21106687	PLK1S1	-0.4	-4.61	-0.35	8.35e-6	Height;
PAAD	cis	rs6715793	0.869	rs6705772	chr2:33430048	A/C	cg26672287	chr2:33391915	LTBP1	-0.4	-4.64	-0.35	7.57e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01953134	chr6:90348409	LYRM2	0.42	4.31	0.33	2.91e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.38	-0.33	2.22e-5	Educational attainment;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg20295408	chr7:1910781	MAD1L1	-0.55	-5.08	-0.38	1.11e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4662750	0.650	rs1083297	chr2:128356997	C/T	cg09760422	chr2:128146352	NA	0.33	5.0	0.38	1.57e-6	Renal cell carcinoma;
PAAD	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.74	9.14	0.6	3.65e-16	Bladder cancer;
PAAD	cis	rs9584850	0.874	rs9168	chr13:99101583	C/A	cg20487152	chr13:99095054	FARP1	0.58	5.0	0.38	1.59e-6	Neuroticism;
PAAD	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg10090792	chr1:38198142	EPHA10	-0.41	-4.43	-0.34	1.81e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1642645	0.831	rs348128	chr1:42488361	T/C	cg01990334	chr1:42801334	FOXJ3	-0.64	-5.74	-0.42	5.02e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10887741	0.532	rs2038680	chr10:89415755	A/G	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.12	-0.38	8.95e-7	Exercise (leisure time);
PAAD	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13126279	chr21:47581558	C21orf56	-0.41	-4.57	-0.35	1.01e-5	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.61	5.87	0.43	2.7e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	trans	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg18187862	chr3:45730750	SACM1L	0.68	6.29	0.45	3.23e-9	Primary sclerosing cholangitis;
PAAD	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	5.61	0.41	9.37e-8	Blood protein levels;
PAAD	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.47	-4.71	-0.36	5.61e-6	Hirschsprung disease;
PAAD	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg25837213	chr17:80849375	TBCD	-0.46	-4.34	-0.33	2.62e-5	Breast cancer;
PAAD	cis	rs2204008	0.526	rs2320448	chr12:38224180	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.32	-0.4	3.71e-7	Bladder cancer;
PAAD	cis	rs9674544	0.556	rs9890278	chr17:47073949	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.56	-7.01	-0.49	7.31e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.64	5.3	0.39	4.07e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg16205897	chr5:131564050	P4HA2	-0.49	-5.42	-0.4	2.28e-7	Blood metabolite levels;
PAAD	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20307385	chr11:47447363	PSMC3	-0.48	-4.27	-0.33	3.43e-5	Subjective well-being;
PAAD	cis	rs1075232	1.000	rs72722847	chr15:31682346	C/T	cg06530883	chr15:30699977	NA	1.04	4.63	0.35	7.74e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs4708832	0.564	rs240854	chr6:159923334	C/T	cg04088182	chr6:159188303	EZR	-0.59	-4.25	-0.33	3.69e-5	QRS duration;
PAAD	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.2	10.6	0.65	5.23e-20	Uric acid levels;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-4.63	-0.35	7.73e-6	Menarche (age at onset);
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.89	-9.6	-0.61	2.35e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.64	5.75	0.42	4.75e-8	Corneal astigmatism;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	4.44	0.34	1.74e-5	Obesity-related traits;
PAAD	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs7765175	0.698	rs3851200	chr6:113674422	C/T	cg19037598	chr6:113666021	NA	-0.44	-4.78	-0.36	4.11e-6	Coronary artery calcification;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01635475	chr3:167813467	GOLIM4	0.65	6.52	0.47	9.62e-10	Obesity-related traits;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg09386050	chr7:809078	HEATR2	-0.68	-7.32	-0.51	1.37e-11	Subjective well-being;
PAAD	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-5.63	-0.42	8.62e-8	QRS duration;
PAAD	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.57	4.63	0.35	7.88e-6	Alzheimer's disease (cognitive decline);
PAAD	trans	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.46	-0.46	1.34e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-14.83	-0.77	2.5e-31	Height;
PAAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg10207240	chr12:122356781	WDR66	0.53	5.6	0.41	9.88e-8	Mean corpuscular volume;
PAAD	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.5	5.52	0.41	1.46e-7	Heart rate;
PAAD	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.54	-4.9	-0.37	2.39e-6	Diastolic blood pressure;
PAAD	cis	rs3753841	0.832	rs12132471	chr1:103221544	G/A	cg24495344	chr1:103574097	COL11A1	0.4	4.64	0.35	7.59e-6	Glaucoma (primary angle closure);
PAAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.77	8.37	0.56	3.56e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.58	5.19	0.39	6.51e-7	Mean platelet volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19914751	chr3:49142572	QARS	-0.56	-6.6	-0.47	6.49e-10	Body fat percentage;
PAAD	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.63	-6.62	-0.47	5.86e-10	Body mass index;
PAAD	cis	rs6960043	0.584	rs992823	chr7:15041187	C/T	cg19272540	chr7:15055459	NA	0.32	5.52	0.41	1.41e-7	Type 2 diabetes;
PAAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg08029281	chr1:67600428	NA	-0.46	-5.26	-0.39	4.83e-7	Psoriasis;
PAAD	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg19090574	chr1:205240910	TMCC2	-0.42	-4.55	-0.35	1.1e-5	Red blood cell count;
PAAD	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	1.12	9.16	0.6	3.34e-16	Blood trace element (Cu levels);
PAAD	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.96	13.22	0.73	4.75e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.8	0.58	2.86e-15	Homoarginine levels;
PAAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.09	-0.44	8.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs939584	1.000	rs7570198	chr2:648198	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs6191	0.874	rs852976	chr5:142685438	T/C	cg08845721	chr5:142780693	NR3C1	-0.4	-4.41	-0.34	1.93e-5	Night sleep phenotypes;
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.74e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg13468214	chr4:1046988	NA	-0.52	-5.59	-0.41	1.03e-7	Recombination rate (males);
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.78	7.86	0.54	6.54e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.49	-5.25	-0.39	4.97e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06281716	chr2:61293359	KIAA1841	0.64	6.62	0.47	5.94e-10	Obesity-related traits;
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg26557270	chr6:116382179	FRK	0.28	5.03	0.38	1.34e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.63	5.96	0.44	1.7e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs643506	0.874	rs648544	chr11:111666128	C/T	cg09085632	chr11:111637200	PPP2R1B	0.56	4.87	0.37	2.71e-6	Breast cancer;
PAAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg21130718	chr4:1044621	NA	0.5	4.89	0.37	2.56e-6	Recombination rate (males);
PAAD	cis	rs795484	0.889	rs708868	chr12:118629769	C/T	cg16572268	chr12:118583242	PEBP1	-0.45	-4.41	-0.34	1.95e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.72	-0.42	5.39e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg00944433	chr1:107599041	PRMT6	0.41	4.63	0.35	7.93e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.1	-17.17	-0.81	2.05e-37	Myeloid white cell count;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.93	-6.9	-0.49	1.33e-10	Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs12771275	chr10:45959652	C/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.83	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs6804624	0.676	rs2464149	chr3:99157687	G/T	cg02646433	chr3:99218170	NA	0.42	4.31	0.33	2.97e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23996123	chr1:59369444	NA	-0.54	-6.31	-0.46	2.92e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8112211	0.689	rs11669230	chr19:38802989	C/G	cg14299480	chr19:38876666	GGN	-0.54	-4.68	-0.35	6.4e-6	Blood protein levels;
PAAD	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.59	6.49	0.47	1.15e-9	Testicular germ cell tumor;
PAAD	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.68	6.18	0.45	5.64e-9	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19882132	chr14:106167949	NA	-0.56	-4.83	-0.36	3.26e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs4144743	1.000	rs55827077	chr17:45331083	G/C	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08677398	chr8:58056175	NA	0.69	4.25	0.33	3.74e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3736485	0.903	rs11070863	chr15:51904590	A/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.21e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.74	7.62	0.53	2.49e-12	Menarche (age at onset);
PAAD	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.61	0.57	8.87e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs11264213	0.901	rs72661605	chr1:36326227	A/G	cg27506609	chr1:36549197	TEKT2	1.04	5.66	0.42	7.21e-8	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-0.91	-15.81	-0.79	6.66e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.2	0.39	6.46e-7	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26031613	chr14:104095156	KLC1	1.16	15.6	0.78	2.35e-33	Body mass index;
PAAD	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.17e-8	Height;
PAAD	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.28	0.68	7.83e-22	Platelet count;
PAAD	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-4.42	-0.34	1.88e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs12826942	0.959	rs12820881	chr12:42726978	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	4.99	0.38	1.65e-6	Coronary artery disease;
PAAD	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg07167872	chr1:205819463	PM20D1	0.62	4.98	0.37	1.69e-6	Parkinson's disease;
PAAD	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.24	0.67	1.05e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.86	8.47	0.57	1.95e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg27631724	chr1:11040367	C1orf127	0.52	6.43	0.46	1.54e-9	Ewing sarcoma;
PAAD	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	4.92	0.37	2.2e-6	Oropharynx cancer;
PAAD	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg05895507	chr15:77155635	SCAPER	0.41	4.63	0.35	7.86e-6	Blood metabolite levels;
PAAD	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6445967	1.000	rs3796215	chr3:58316657	A/G	cg23715586	chr3:58305044	RPP14	0.5	4.28	0.33	3.24e-5	Platelet count;
PAAD	cis	rs11811982	0.793	rs76742911	chr1:227509018	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg21918786	chr6:109611834	NA	-0.39	-4.26	-0.33	3.57e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.64	6.98	0.49	8.54e-11	Colorectal cancer;
PAAD	cis	rs10982213	1.000	rs10982213	chr9:117189193	C/T	cg00078025	chr9:117159975	NA	0.6	4.44	0.34	1.76e-5	Interleukin-6 levels;
PAAD	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.62	-5.69	-0.42	6.28e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg10818794	chr15:86012489	AKAP13	-0.46	-5.06	-0.38	1.22e-6	Interstitial lung disease;
PAAD	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg07150166	chr2:30669952	LCLAT1	-0.7	-5.29	-0.39	4.24e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.45	4.64	0.35	7.62e-6	IgG glycosylation;
PAAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.31	-0.4	3.74e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.94	11.03	0.67	3.82e-21	Adiposity;
PAAD	cis	rs58521262	0.556	rs396653	chr19:23121284	A/C	cg02350677	chr19:23254381	NA	-0.26	-4.57	-0.35	9.83e-6	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.94	12.78	0.72	7.23e-26	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg07884673	chr3:53033167	SFMBT1	0.7	4.48	0.34	1.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7795096	0.806	rs10277655	chr7:151540697	T/C	cg17008978	chr7:151542804	PRKAG2	0.41	4.74	0.36	4.9e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.73	-8.37	-0.56	3.48e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs508970	0.534	rs483398	chr11:60924920	T/C	cg24692310	chr11:60915630	VPS37C	0.34	4.46	0.34	1.56e-5	Rheumatoid arthritis;
PAAD	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.64	-5.75	-0.42	4.8e-8	Psoriasis;
PAAD	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-8.09	-0.55	1.75e-13	Platelet distribution width;
PAAD	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10328875	chr14:32031012	NUBPL	0.53	6.37	0.46	2.12e-9	Energy expenditure (24h);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23712314	chr7:4721836	FOXK1	0.63	6.97	0.49	8.87e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.82	9.15	0.6	3.46e-16	IgG glycosylation;
PAAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.91	11.79	0.69	3.39e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.69	-6.84	-0.48	1.84e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17507749	chr15:85114479	UBE2QP1	0.65	5.66	0.42	7.47e-8	Schizophrenia;
PAAD	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	5.79	0.43	3.85e-8	Blood protein levels;
PAAD	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg08975724	chr8:8085496	FLJ10661	0.51	5.11	0.38	9.69e-7	Joint mobility (Beighton score);
PAAD	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.74	0.48	3.02e-10	Blood metabolite levels;
PAAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.71	7.19	0.5	2.71e-11	Platelet distribution width;
PAAD	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.72	7.29	0.51	1.56e-11	Coronary artery disease;
PAAD	cis	rs597480	0.783	rs667275	chr11:85484416	G/A	cg11817631	chr11:85522609	SYTL2	-0.52	-5.09	-0.38	1.03e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.51	-5.4	-0.4	2.46e-7	Type 2 diabetes;
PAAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg10518543	chr12:38710700	ALG10B	0.51	4.96	0.37	1.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.4	4.99	0.38	1.6e-6	Electrocardiographic conduction measures;
PAAD	cis	rs6694672	0.867	rs7554802	chr1:197148599	T/C	cg13682187	chr1:196946512	CFHR5	0.66	4.27	0.33	3.39e-5	Asthma;
PAAD	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.18	0.45	5.69e-9	Lymphocyte percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17082953	chr2:12856844	TRIB2	-0.64	-6.46	-0.46	1.31e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.48	-0.34	1.46e-5	Height;
PAAD	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg07930192	chr7:1003750	NA	0.61	7.9	0.54	5.12e-13	Longevity;Endometriosis;
PAAD	cis	rs6141769	0.542	rs6119939	chr20:31315153	T/C	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6964492	0.576	rs10273053	chr7:134408767	A/C	cg22430036	chr7:134592620	CALD1	0.51	4.66	0.35	6.79e-6	Tonsillectomy;
PAAD	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.61	-5.72	-0.42	5.57e-8	Adiposity;
PAAD	trans	rs4707930	0.666	rs2754049	chr6:72414808	G/A	cg17580045	chr12:4384890	CCND2	0.77	6.35	0.46	2.42e-9	Response to anti-TNF alpha therapy in inflammatory bowel disease;
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.89	10.8	0.66	1.57e-20	Ulcerative colitis;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.48	5.02	0.38	1.4e-6	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.812	rs7629767	chr3:42043509	T/G	cg03022575	chr3:42003672	ULK4	0.8	5.56	0.41	1.17e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	4.37	0.33	2.26e-5	Thyroid stimulating hormone;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.47	4.91	0.37	2.37e-6	Lymphocyte counts;
PAAD	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.73	7.23	0.51	2.25e-11	Corneal astigmatism;
PAAD	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg05250797	chr16:70222502	NA	0.8	6.3	0.46	3.04e-9	IgE levels;
PAAD	cis	rs7580658	0.895	rs7589451	chr2:128128775	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.82	4.6	0.35	8.73e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.75	5.42	0.4	2.28e-7	Major depressive disorder;
PAAD	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg09211372	chr6:168490623	NA	-0.42	-4.45	-0.34	1.63e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg22143856	chr6:28129313	ZNF389	-0.65	-5.11	-0.38	9.57e-7	Depression;
PAAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14119001	chr9:139324193	INPP5E	-0.58	-5.25	-0.39	5.11e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg24053715	chr22:38214548	NA	0.57	5.25	0.39	4.95e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg25124228	chr12:125621409	AACS	-0.61	-5.89	-0.43	2.34e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg18827107	chr12:86230957	RASSF9	0.41	4.42	0.34	1.85e-5	Major depressive disorder;
PAAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03676636	chr4:99064102	C4orf37	0.31	5.78	0.42	4.11e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7084783	0.967	rs7068081	chr10:105332617	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.43	4.39	0.34	2.13e-5	Fear of pain;
PAAD	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.57	-5.9	-0.43	2.26e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.4	5.07	0.38	1.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13244592	chr8:101158264	FBXO43	-0.56	-6.56	-0.47	7.91e-10	Body fat percentage;
PAAD	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg02404636	chr22:31891804	SFI1	0.64	5.88	0.43	2.57e-8	Colorectal cancer;
PAAD	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.85	-7.01	-0.49	7.26e-11	Triglycerides;
PAAD	cis	rs9487051	0.724	rs11751953	chr6:109635986	G/A	cg21918786	chr6:109611834	NA	-0.55	-5.9	-0.43	2.23e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg03989125	chr22:38214979	NA	0.6	5.48	0.41	1.76e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg11367502	chr7:22862612	TOMM7	0.52	5.09	0.38	1.07e-6	Fibrinogen;
PAAD	cis	rs9435341	0.929	rs3108681	chr1:107556493	C/A	cg09367891	chr1:107599246	PRMT6	-0.44	-4.38	-0.33	2.21e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs375066	0.935	rs10421518	chr19:44381286	A/G	cg08633290	chr19:44405433	NA	-0.58	-5.85	-0.43	2.88e-8	Breast cancer;
PAAD	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.91	10.93	0.66	6.96e-21	Morning vs. evening chronotype;
PAAD	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-7.71	-0.53	1.55e-12	White blood cell count;
PAAD	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg10208897	chr5:178548229	ADAMTS2	0.51	4.57	0.35	9.89e-6	Pubertal anthropometrics;
PAAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.38e-12	Calcium levels;
PAAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.97	14.67	0.77	6.33e-31	Dental caries;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg03877680	chr5:178157825	ZNF354A	0.83	6.89	0.49	1.35e-10	Neutrophil percentage of white cells;
PAAD	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.15	-12.66	-0.72	1.54e-25	Hip circumference adjusted for BMI;
PAAD	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-4.53	-0.34	1.19e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.61	7.47	0.52	5.91e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs714515	0.609	rs1009803	chr1:172452422	C/T	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.64	-9.11	-0.59	4.51e-16	Breast cancer;
PAAD	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.49	-5.04	-0.38	1.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.79	-5.34	-0.4	3.4e-7	Coronary artery calcification;
PAAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.6	7.31	0.51	1.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.68	7.48	0.52	5.62e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs10450586	0.863	rs7937389	chr11:27298451	C/T	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19839149	chr2:192542877	OBFC2A	0.66	6.4	0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Corneal structure;
PAAD	cis	rs1075265	0.749	rs2692518	chr2:54031883	G/A	cg04546899	chr2:54196757	PSME4	0.3	4.55	0.35	1.1e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9810890	0.850	rs73196977	chr3:128450224	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.76	-6.5	-0.47	1.08e-9	HIV-1 control;
PAAD	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7216064	0.817	rs12603589	chr17:65825248	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-5.66	-0.42	7.48e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg06899799	chr12:56650233	ANKRD52	0.33	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs868943	0.582	rs12210252	chr6:116477493	G/T	cg18764771	chr6:116381957	FRK	-0.26	-4.44	-0.34	1.76e-5	Total cholesterol levels;
PAAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg00310523	chr12:86230176	RASSF9	0.38	4.29	0.33	3.16e-5	Major depressive disorder;
PAAD	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-7.39	-0.51	8.89e-12	Total body bone mineral density;
PAAD	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2798269	0.763	rs11148172	chr13:22170275	C/T	cg17543804	chr13:22179073	EFHA1	0.54	5.07	0.38	1.13e-6	PR segment;
PAAD	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.57	5.69	0.42	6.48e-8	Systolic blood pressure;
PAAD	cis	rs7131987	0.644	rs1436323	chr12:29554741	A/G	cg09582351	chr12:29534625	ERGIC2	0.35	5.0	0.38	1.58e-6	QT interval;
PAAD	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.88	11.07	0.67	2.89e-21	Mean corpuscular volume;
PAAD	cis	rs35955747	0.902	rs12166373	chr22:31700508	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.67	4.47	0.34	1.55e-5	Lung cancer in ever smokers;
PAAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg25204440	chr1:209979598	IRF6	0.65	5.5	0.41	1.59e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.65e-7	Inflammatory bowel disease;
PAAD	cis	rs2271400	0.529	rs6997351	chr8:56651746	C/T	cg08894788	chr8:56792171	LYN	-0.49	-4.55	-0.35	1.1e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-4.43	-0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-4.45	-0.34	1.67e-5	Lung cancer;
PAAD	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.69	6.87	0.49	1.51e-10	Schizophrenia;
PAAD	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16447950	chr5:562315	NA	-0.67	-5.93	-0.43	1.99e-8	Obesity-related traits;
PAAD	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10820045	chr2:198174542	NA	-0.47	-4.73	-0.36	5.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.54	4.84	0.37	3.15e-6	Testicular germ cell tumor;
PAAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.56	6.04	0.44	1.15e-8	Menopause (age at onset);
PAAD	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.83	-0.48	1.96e-10	Psoriasis;
PAAD	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg23752985	chr2:85803571	VAMP8	0.62	6.6	0.47	6.39e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.41e-7	Cognitive function;
PAAD	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.64	-5.83	-0.43	3.24e-8	Cognitive test performance;
PAAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg04719120	chr6:96025338	MANEA	0.52	4.27	0.33	3.48e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.09	8.6	0.57	8.91e-15	Vitiligo;
PAAD	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.19	-0.45	5.23e-9	Blood trace element (Zn levels);
PAAD	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg07701084	chr6:150067640	NUP43	0.56	4.86	0.37	2.94e-6	Lung cancer;
PAAD	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg16989086	chr20:62203971	PRIC285	0.55	4.28	0.33	3.24e-5	Atopic dermatitis;
PAAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.51	-4.45	-0.34	1.63e-5	Coronary artery disease;
PAAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.71	8.18	0.55	1.07e-13	Menopause (age at onset);
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.31	-0.46	2.85e-9	Longevity;Endometriosis;
PAAD	cis	rs2017305	0.831	rs78475561	chr10:70686119	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs6782025	0.837	rs7635903	chr3:120841607	C/T	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.35	6.3e-6	Aging (facial);
PAAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.42e-6	Self-reported allergy;
PAAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22386646	chr1:112524496	KCND3	0.56	6.56	0.47	7.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg02344993	chr17:57696989	CLTC	-0.58	-5.42	-0.4	2.3e-7	Hemoglobin concentration;
PAAD	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.49	4.75	0.36	4.74e-6	Morning vs. evening chronotype;
PAAD	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg20607287	chr7:12443886	VWDE	-0.71	-5.49	-0.41	1.62e-7	Coronary artery disease;
PAAD	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.48	-5.6	-0.41	9.58e-8	Blood pressure (smoking interaction);
PAAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.51	-4.86	-0.37	2.95e-6	Vitiligo;
PAAD	cis	rs2694528	0.844	rs1031744	chr5:60052569	C/A	cg11474532	chr5:59995715	DEPDC1B	0.87	4.95	0.37	1.99e-6	Parkinson's disease;
PAAD	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.53	-4.65	-0.35	7.25e-6	Testicular germ cell tumor;
PAAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14119001	chr9:139324193	INPP5E	0.64	6.01	0.44	1.32e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.52	-5.9	-0.43	2.33e-8	Cardiovascular disease risk factors;
PAAD	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.47	4.58	0.35	9.58e-6	Schizophrenia;
PAAD	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.54	-6.6	-0.47	6.32e-10	Rheumatoid arthritis;
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.62	10.22	0.64	5.57e-19	IgG glycosylation;
PAAD	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.57	4.84	0.37	3.18e-6	Common traits (Other);
PAAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.72	-7.54	-0.52	4.06e-12	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.86e-6	Refractive error;
PAAD	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.41	0.4	2.4e-7	HDL cholesterol;
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.7	-7.77	-0.53	1.07e-12	Aortic root size;
PAAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.52	4.93	0.37	2.12e-6	Height;
PAAD	cis	rs10916814	1.000	rs12145351	chr1:20901181	C/A	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.77	7.44	0.52	6.76e-12	Prostate cancer;
PAAD	cis	rs1941184	0.759	rs10048305	chr18:29025949	A/G	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg11995313	chr8:8860691	ERI1	0.5	5.03	0.38	1.35e-6	Joint mobility (Beighton score);
PAAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg01075559	chr1:2537774	MMEL1	0.51	5.48	0.41	1.71e-7	Ulcerative colitis;
PAAD	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg14219918	chr9:127249562	NR5A1	-0.35	-4.62	-0.35	8.19e-6	Menarche (age at onset);
PAAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg19413350	chr8:57351067	NA	-0.44	-4.28	-0.33	3.31e-5	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17456842	chr15:35280510	ZNF770	-0.58	-6.57	-0.47	7.47e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.76	-7.96	-0.54	3.65e-13	Menarche (age at onset);
PAAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.31	0.4	3.87e-7	Eosinophil percentage of white cells;
PAAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.1	-0.55	1.69e-13	Height;
PAAD	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg19592336	chr6:28129416	ZNF389	-0.58	-4.26	-0.33	3.62e-5	Depression;
PAAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.74	-4.84	-0.37	3.18e-6	Anti-saccade response;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.68	7.96	0.54	3.76e-13	Height;
PAAD	cis	rs12476592	0.602	rs262488	chr2:63882179	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.08e-5	Childhood ear infection;
PAAD	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.48	6.2	0.45	5.2e-9	Primary biliary cholangitis;
PAAD	cis	rs5742933	0.817	rs11679767	chr2:190546300	A/G	cg04003228	chr2:190539410	ANKAR	-0.52	-4.28	-0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs11651753	0.561	rs4794261	chr17:45982346	C/G	cg24458315	chr17:46148407	CBX1	0.41	4.52	0.34	1.25e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23158103	chr7:148848205	ZNF398	-0.6	-5.86	-0.43	2.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12431939	1.000	rs67065973	chr14:51656225	T/C	cg23942311	chr14:51606299	NA	-0.75	-6.13	-0.44	7.41e-9	Cancer;
PAAD	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg21918786	chr6:109611834	NA	0.44	4.91	0.37	2.34e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg00184732	chr15:51633821	GLDN	0.47	4.73	0.36	5.03e-6	Hormone measurements;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.66	-6.08	-0.44	9.36e-9	White matter hyperintensity burden;
PAAD	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.96	-0.37	1.83e-6	Fibrinogen levels;
PAAD	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.49	6.25	0.45	3.93e-9	Sitting height ratio;
PAAD	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.68	7.68	0.53	1.79e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	0.951	rs1199106	chr10:59944924	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs73206853	0.841	rs7956963	chr12:110947783	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.44	0.34	1.73e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.55	5.68	0.42	6.76e-8	Testicular germ cell tumor;
PAAD	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-4.35	-0.33	2.45e-5	Coronary artery disease;
PAAD	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs10865541	0.571	rs12992865	chr2:3383741	G/A	cg21040360	chr2:3383326	TTC15	0.44	4.91	0.37	2.32e-6	Obesity-related traits;
PAAD	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg00750074	chr16:89608354	SPG7	-0.52	-5.05	-0.38	1.27e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	1.15	16.89	0.81	1.04e-36	Menarche (age at onset);
PAAD	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg21770322	chr7:97807741	LMTK2	0.49	6.77	0.48	2.66e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs6142102	0.581	rs4911148	chr20:32668244	A/G	cg06115741	chr20:33292138	TP53INP2	0.56	5.03	0.38	1.39e-6	Skin pigmentation;
PAAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.7	7.96	0.54	3.81e-13	Multiple sclerosis;
PAAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg06784991	chr1:53308768	ZYG11A	0.27	4.25	0.33	3.66e-5	Monocyte count;
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18323251	chr7:100484622	SRRT	-0.61	-6.57	-0.47	7.38e-10	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg09796270	chr17:17721594	SREBF1	0.45	4.85	0.37	3.04e-6	Total body bone mineral density;
PAAD	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19859290	chr11:20618399	NA	0.32	4.65	0.35	7.06e-6	Pursuit maintenance gain;
PAAD	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-5.62	-0.41	9.06e-8	Personality dimensions;
PAAD	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg00806126	chr19:22604979	ZNF98	0.41	5.22	0.39	5.7e-7	Pain;
PAAD	cis	rs6445967	1.000	rs62258069	chr3:58315263	A/T	cg23715586	chr3:58305044	RPP14	0.5	4.31	0.33	2.92e-5	Platelet count;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.86	9.9	0.63	3.78e-18	Resting heart rate;
PAAD	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03771185	chr4:775700	NA	0.58	6.58	0.47	7.18e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	1.23	11.56	0.68	1.42e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg20913747	chr6:44695427	NA	-0.7	-7.01	-0.49	7.21e-11	Total body bone mineral density;
PAAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.71	-5.91	-0.43	2.16e-8	Coronary artery disease;
PAAD	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	0.66	4.62	0.35	8.19e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs1941184	0.526	rs8085523	chr18:29027757	C/T	cg03238162	chr18:29027701	DSG3	0.42	4.68	0.35	6.32e-6	Parkinson's disease (age of onset);
PAAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg10290764	chr8:4849399	CSMD1	0.4	6.64	0.47	5.27e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.52	-0.41	1.46e-7	Obesity-related traits;
PAAD	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg02820901	chr13:113351484	ATP11A	0.7	4.78	0.36	4.05e-6	Glycated hemoglobin levels;
PAAD	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.75	7.67	0.53	1.87e-12	Coronary artery disease;
PAAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs7180079	1.000	rs4777181	chr15:64670566	T/C	cg18210365	chr15:65066710	RBPMS2	0.65	4.93	0.37	2.14e-6	Monocyte count;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.58	-5.42	-0.4	2.24e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg10621924	chr7:39171070	POU6F2	0.33	5.01	0.38	1.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.64	6.53	0.47	9.16e-10	Monocyte count;
PAAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.55	0.35	1.08e-5	Breast cancer;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.9	6.62	0.47	5.94e-10	Opioid sensitivity;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16015395	chr10:79789430	POLR3A	-0.67	-6.4	-0.46	1.79e-9	Lung cancer in ever smokers;
PAAD	cis	rs17293817	0.589	rs2805511	chr10:1427710	G/T	cg02408697	chr10:1416920	ADARB2	0.5	4.58	0.35	9.64e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	1.01	8.26	0.56	6.69e-14	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02575159	chr20:25176220	ENTPD6	0.66	6.5	0.47	1.1e-9	Obesity-related traits;
PAAD	cis	rs12541635	0.639	rs6415444	chr8:107043797	G/A	cg10147462	chr8:107024639	NA	0.45	4.76	0.36	4.44e-6	Age of smoking initiation;
PAAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg17845761	chr1:175162550	KIAA0040	-0.28	-4.28	-0.33	3.35e-5	Alcohol dependence;
PAAD	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg00982548	chr2:198649783	BOLL	-0.79	-5.64	-0.42	8.25e-8	Ulcerative colitis;
PAAD	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg00147160	chr1:26503991	CNKSR1	0.42	4.56	0.35	1.05e-5	Height;
PAAD	trans	rs1997066	0.834	rs78797151	chr10:106574428	A/T	cg20244273	chr11:7597349	PPFIBP2	-0.76	-6.33	-0.46	2.6e-9	Diabetic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19744122	chr7:105752980	SYPL1	-0.81	-7.17	-0.5	3.09e-11	Neuroticism;
PAAD	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	4.73	0.36	4.99e-6	Neuroticism;
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg05564831	chr3:52568323	NT5DC2	-0.49	-5.33	-0.4	3.54e-7	Electroencephalogram traits;
PAAD	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg15660573	chr17:549704	VPS53	0.53	5.97	0.44	1.59e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4343996	0.869	rs10256740	chr7:3481667	G/A	cg21248987	chr7:3385318	SDK1	0.47	5.22	0.39	5.69e-7	Motion sickness;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06139343	chr16:15188232	RRN3	0.66	6.91	0.49	1.28e-10	Myopia (pathological);
PAAD	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.93	0.43	1.98e-8	Rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.64	5.49	0.41	1.65e-7	Mean platelet volume;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02265379	chr5:87898506	LOC645323	0.53	6.82	0.48	2.01e-10	Body fat percentage;
PAAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg23461800	chr14:103021989	NA	-0.65	-5.19	-0.39	6.73e-7	Platelet count;
PAAD	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.65	6.44	0.46	1.46e-9	Primary sclerosing cholangitis;
PAAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.61	-6.05	-0.44	1.06e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25443234	chr5:95993897	NA	0.55	6.41	0.46	1.75e-9	Smoking initiation;
PAAD	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.49	5.11	0.38	9.63e-7	Body mass index;
PAAD	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.5	-0.83	9.42e-41	Ulcerative colitis;
PAAD	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.64	5.98	0.44	1.5e-8	Obesity-related traits;
PAAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg24739098	chr15:79297159	RASGRF1	0.36	4.67	0.35	6.63e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19671926	chr4:122722719	EXOSC9	0.52	5.11	0.38	9.59e-7	Type 2 diabetes;
PAAD	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.75	7.86	0.54	6.69e-13	Lung cancer;
PAAD	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg08999081	chr20:33150536	PIGU	0.54	5.85	0.43	2.9e-8	Height;
PAAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.56	5.13	0.38	8.52e-7	Schizophrenia;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.57	-6.87	-0.49	1.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-0.65	-6.64	-0.47	5.2e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.76	-0.48	2.73e-10	Life satisfaction;
PAAD	cis	rs2492906	0.644	rs2815494	chr10:28080558	T/A	cg25523538	chr10:28031957	MKX	0.46	4.26	0.33	3.57e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	6.49	0.47	1.17e-9	Resting heart rate;
PAAD	cis	rs3106136	0.649	rs28463907	chr4:95302595	A/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg24642844	chr7:1081250	C7orf50	0.53	4.36	0.33	2.42e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6460942	0.597	rs6977059	chr7:12535157	T/G	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg13699009	chr12:122356056	WDR66	-0.46	-6.61	-0.47	6.08e-10	Mean corpuscular volume;
PAAD	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg23387401	chr17:4582204	PELP1	-0.47	-4.7	-0.36	5.75e-6	Lymphocyte counts;
PAAD	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.78	-6.46	-0.46	1.36e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.43	4.26	0.33	3.51e-5	Red blood cell count;
PAAD	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.08	-0.63	1.25e-18	Response to antipsychotic treatment;
PAAD	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	4.89	0.37	2.56e-6	Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg19445457	chr11:5799446	OR52N5	-0.51	-4.57	-0.35	9.84e-6	DNA methylation (variation);
PAAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.4	-0.34	2.04e-5	Magnesium levels;
PAAD	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.63	6.02	0.44	1.25e-8	Height;
PAAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.54	0.57	1.28e-14	Homoarginine levels;
PAAD	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-1.2	-7.36	-0.51	1.09e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs904092	0.678	rs1230020	chr4:100175407	G/A	cg12011299	chr4:100065546	ADH4	0.58	5.43	0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg07648498	chr16:89883185	FANCA	0.5	4.79	0.36	3.85e-6	Vitiligo;
PAAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7651511	1.000	rs9850416	chr3:141272216	C/T	cg25967872	chr3:141205623	RASA2	0.49	4.43	0.34	1.77e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg02696790	chr15:75250997	RPP25	0.39	4.61	0.35	8.38e-6	Breast cancer;
PAAD	cis	rs818427	0.896	rs712663	chr5:112223594	T/C	cg06941702	chr5:112196734	SRP19	0.51	4.73	0.36	5.18e-6	Total body bone mineral density;
PAAD	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.25	-0.33	3.65e-5	Aortic root size;
PAAD	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg20913747	chr6:44695427	NA	-0.59	-5.46	-0.4	1.9e-7	Total body bone mineral density;
PAAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.6	6.2	0.45	5.04e-9	Bladder cancer;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg10453019	chr3:16216215	GALNTL2	0.39	4.35	0.33	2.44e-5	Mean platelet volume;
PAAD	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs10958605	0.761	rs2929122	chr8:40036316	C/T	cg14545590	chr8:40388592	ZMAT4	0.42	4.75	0.36	4.73e-6	Parkinson's disease (motor and cognition);
PAAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01498655	chr16:67694768	PARD6A;ACD	0.6	6.69	0.48	4.07e-10	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.51	0.34	1.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg23461800	chr14:103021989	NA	-0.65	-5.05	-0.38	1.23e-6	Platelet count;
PAAD	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.48	-5.27	-0.39	4.62e-7	Vitiligo;
PAAD	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.6	6.3	0.45	3.09e-9	Hyperactive-impulsive symptoms;
PAAD	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.54	-5.07	-0.38	1.14e-6	Obesity-related traits;
PAAD	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.68	6.37	0.46	2.11e-9	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2281636	0.540	rs2300980	chr10:101444365	G/C	cg05149213	chr10:101381631	SLC25A28	-0.55	-5.39	-0.4	2.64e-7	Obesity-related traits;
PAAD	cis	rs42648	0.564	rs13224065	chr7:89802363	G/A	cg27367526	chr7:89841692	STEAP2	-0.34	-4.76	-0.36	4.52e-6	Homocysteine levels;
PAAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.48	-4.37	-0.33	2.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.65	-5.73	-0.42	5.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.56	-5.65	-0.42	7.57e-8	Obesity-related traits;
PAAD	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg23752985	chr2:85803571	VAMP8	-0.58	-6.23	-0.45	4.3e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg17347104	chr14:75034677	LTBP2	-0.47	-4.65	-0.35	7.04e-6	Caffeine consumption;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg00280220	chr17:61926910	NA	0.44	4.66	0.35	6.91e-6	Prudent dietary pattern;
PAAD	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-0.75	-4.47	-0.34	1.53e-5	Lung cancer;
PAAD	cis	rs4787491	0.704	rs9928448	chr16:30072530	T/C	cg06015834	chr16:30021696	DOC2A	-0.45	-4.54	-0.35	1.13e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18519450	chr2:121746027	GLI2	0.69	6.99	0.49	8.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.73	6.76	0.48	2.81e-10	Obesity-related traits;
PAAD	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.37	5.04	0.38	1.28e-6	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.96	5.14	0.38	8.25e-7	Childhood ear infection;
PAAD	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-7.48	-0.52	5.67e-12	Schizophrenia;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.63	7.28	0.51	1.71e-11	Testicular germ cell tumor;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.63	6.72	0.48	3.36e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.64	5.39	0.4	2.67e-7	Lymphocyte counts;
PAAD	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.41	6.2	0.45	5.06e-9	Subjective well-being;
PAAD	cis	rs731174	0.592	rs12121777	chr1:38188841	C/T	cg06917450	chr1:38156652	C1orf109	-0.55	-4.66	-0.35	6.96e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.65	-0.53	2.12e-12	Total cholesterol levels;
PAAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.62	5.76	0.42	4.6e-8	Coronary artery disease;
PAAD	cis	rs2599510	1.000	rs2599510	chr2:32826002	A/G	cg02381751	chr2:32503542	YIPF4	0.56	5.36	0.4	3.1e-7	Interleukin-18 levels;
PAAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.55	4.31	0.33	2.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg24130564	chr14:104152367	KLC1	0.46	4.5	0.34	1.33e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73416724	0.544	rs732691	chr6:43240390	C/T	cg17076780	chr6:43251928	TTBK1	0.66	5.55	0.41	1.22e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg02071572	chr4:1403502	NA	0.38	4.52	0.34	1.26e-5	Longevity;
PAAD	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-7.72	-0.53	1.47e-12	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21994174	chr19:51870364	CLDND2;ETFB	0.65	6.36	0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12599982	chr1:44399894	ARTN	0.46	4.84	0.37	3.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs74544699	1.000	rs353028	chr4:74777223	C/T	cg02530824	chr4:74847766	PF4	1.18	4.39	0.34	2.11e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7539409	0.584	rs11163814	chr1:84198623	T/A	cg10977910	chr1:84465055	TTLL7	0.76	4.35	0.33	2.46e-5	Alzheimer's disease;
PAAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.51	-4.68	-0.36	6.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg26876637	chr1:152193138	HRNR	0.88	6.76	0.48	2.75e-10	Atopic dermatitis;
PAAD	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg08390786	chr10:135334061	NA	-0.62	-4.96	-0.37	1.86e-6	Gout;
PAAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.73	-6.77	-0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg06217071	chr17:408420	NA	-0.46	-4.73	-0.36	5.09e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6669119	0.818	rs115552960	chr1:19114301	G/T	cg19637330	chr1:19110922	NA	0.79	4.79	0.36	3.92e-6	Percentage gas trapping;
PAAD	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.26	-0.39	4.74e-7	Blood metabolite levels;
PAAD	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.54	-0.52	3.87e-12	Neuroticism;
PAAD	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-6.61	-0.47	6.25e-10	Vitiligo;
PAAD	cis	rs733175	0.830	rs6812851	chr4:10058703	G/C	cg00071950	chr4:10020882	SLC2A9	0.49	4.32	0.33	2.83e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.47	4.46	0.34	1.61e-5	Urinary tract infection frequency;
PAAD	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg19980929	chr12:42632907	YAF2	0.54	6.13	0.45	7.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.4	-0.46	1.79e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.93	-8.86	-0.58	1.98e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg04482110	chr17:41364121	TMEM106A	0.37	4.3	0.33	3.06e-5	Menopause (age at onset);
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-4.56	-0.35	1.07e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.52	-5.34	-0.4	3.31e-7	Number of children ever born;
PAAD	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.9	-0.37	2.43e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.56	0.35	1.06e-5	Personality dimensions;
PAAD	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.49	-4.75	-0.36	4.74e-6	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.51	5.38	0.4	2.81e-7	Red blood cell count;
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg13047869	chr3:10149882	C3orf24	0.72	5.18	0.39	6.79e-7	Alzheimer's disease;
PAAD	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.74	-8.78	-0.58	3.12e-15	Motion sickness;
PAAD	cis	rs797680	0.856	rs2031226	chr1:93786764	G/T	cg04535902	chr1:92947332	GFI1	0.47	4.56	0.35	1.05e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.39	0.64	1.94e-19	Myeloid white cell count;
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13939156	chr17:80058883	NA	-0.4	-4.39	-0.34	2.11e-5	Life satisfaction;
PAAD	cis	rs16867321	1.000	rs1358521	chr2:181444628	T/C	cg23363182	chr2:181467187	NA	-0.52	-4.64	-0.35	7.55e-6	Obesity;
PAAD	cis	rs6988985	0.678	rs4072020	chr8:143997415	T/C	cg10324643	chr8:143916377	GML	0.4	4.44	0.34	1.74e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg14196790	chr5:131705035	SLC22A5	0.43	4.59	0.35	9.33e-6	Blood metabolite levels;
PAAD	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	1.27	7.44	0.52	6.78e-12	Cannabis dependence symptom count;
PAAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg20965017	chr5:231967	SDHA	-0.63	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	cis	rs7680126	0.671	rs7663044	chr4:10023939	C/G	cg11266682	chr4:10021025	SLC2A9	0.56	4.35	0.33	2.48e-5	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.34	-0.4	3.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.61	4.89	0.37	2.51e-6	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.61	7.18	0.5	2.85e-11	Neuroticism;
PAAD	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.78	8.53	0.57	1.42e-14	Caffeine consumption;
PAAD	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.47	-4.49	-0.34	1.39e-5	Endometrial cancer;
PAAD	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg02640540	chr1:67518911	SLC35D1	0.52	4.61	0.35	8.34e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs798766	0.868	rs4507432	chr4:1748200	A/G	cg23460851	chr4:1604456	NA	-0.4	-4.37	-0.33	2.29e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.55	0.61	3.11e-17	Bladder cancer;
PAAD	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg05555928	chr11:63887634	MACROD1	-0.59	-5.71	-0.42	5.84e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg07841815	chr7:100318223	EPO	0.46	5.28	0.39	4.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg00700412	chr12:58011837	NA	0.42	4.4	0.34	2.06e-5	Multiple sclerosis;
PAAD	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.76	9.24	0.6	2.11e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg23947450	chr7:900037	UNC84A	-0.56	-4.54	-0.35	1.13e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09256448	chr16:638327	NA	0.41	4.28	0.33	3.28e-5	Height;
PAAD	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.86	10.64	0.65	4.04e-20	Heart rate;
PAAD	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg05791153	chr7:19748676	TWISTNB	0.62	5.47	0.41	1.82e-7	Thyroid stimulating hormone;
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	5.66	0.42	7.37e-8	Breast cancer;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06753367	chr22:24256600	NA	-0.42	-4.4	-0.34	2.03e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.23	5.52	0.41	1.43e-7	Urinary tract infection frequency;
PAAD	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	1.01	7.68	0.53	1.83e-12	Dental caries;
PAAD	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.4	4.9	0.37	2.41e-6	Pulmonary function;
PAAD	cis	rs863345	0.584	rs1342949	chr1:158463295	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.92	-0.37	2.25e-6	Pneumococcal bacteremia;
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.52	-5.35	-0.4	3.23e-7	Mean corpuscular volume;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16401346	chr18:48724009	MEX3C	0.64	6.7	0.48	3.83e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg15193198	chr20:60906057	LAMA5	-0.46	-5.06	-0.38	1.2e-6	Colorectal cancer;
PAAD	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	5.6	0.41	9.55e-8	Eye color traits;
PAAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.7	5.98	0.44	1.51e-8	Height;
PAAD	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.44	-0.46	1.48e-9	Triglycerides;
PAAD	cis	rs6782025	1.000	rs524026	chr3:121184913	G/A	cg16417163	chr3:121280760	NA	-0.48	-4.85	-0.37	3e-6	Aging (facial);
PAAD	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.14	9.91	0.63	3.67e-18	Vitiligo;
PAAD	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.75	8.63	0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs55788414	1.000	rs35769936	chr16:81180101	A/G	cg06400318	chr16:81190750	PKD1L2	-1.03	-6.35	-0.46	2.37e-9	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg14686297	chr22:46650375	NA	-0.48	-4.89	-0.37	2.55e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg24101359	chr6:42928495	GNMT	0.56	5.71	0.42	5.65e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.79	-8.98	-0.59	9.91e-16	Total body bone mineral density;
PAAD	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg02071572	chr4:1403502	NA	0.38	4.34	0.33	2.57e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59888335	0.964	rs34370299	chr3:80661667	C/T	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg08029281	chr1:67600428	NA	0.46	5.2	0.39	6.29e-7	Psoriasis;
PAAD	trans	rs61931739	0.564	rs7304271	chr12:33757011	G/T	cg26384229	chr12:38710491	ALG10B	0.69	7.28	0.51	1.66e-11	Morning vs. evening chronotype;
PAAD	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg01620082	chr3:125678407	NA	1.38	8.29	0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55946907	1.000	rs61828288	chr1:180128044	T/G	cg21538511	chr1:179335216	C1orf125	-0.89	-4.35	-0.33	2.53e-5	Anorexia nervosa;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg00988841	chr10:134556463	INPP5A	0.48	4.33	0.33	2.71e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26549601	chr10:134560360	INPP5A	-0.48	-4.6	-0.35	8.79e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.86	10.01	0.63	1.93e-18	Iron status biomarkers;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	1.0	13.83	0.75	1.11e-28	Menarche (age at onset);
PAAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.82	-5.83	-0.43	3.19e-8	Yeast infection;
PAAD	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.61	5.85	0.43	2.96e-8	Eye color traits;
PAAD	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs72772787	1.000	rs72772787	chr1:248016378	C/T	cg03748376	chr1:248100585	OR2L13	0.61	4.73	0.36	5.19e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.51	4.55	0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.48	0.61	4.76e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg20302533	chr7:39170763	POU6F2	0.5	7.0	0.49	7.65e-11	IgG glycosylation;
PAAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.72	10.29	0.64	3.62e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-4.82	-0.36	3.51e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.87	-11.05	-0.67	3.28e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.58	5.57	0.41	1.12e-7	Uric acid clearance;
PAAD	cis	rs71520386	0.632	rs9692432	chr7:22868863	G/A	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6750047	0.573	rs162331	chr2:38319594	C/T	cg19753864	chr2:38320028	NA	0.44	4.93	0.37	2.11e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg14343924	chr8:8086146	FLJ10661	0.55	4.97	0.37	1.77e-6	Mood instability;
PAAD	cis	rs1468734	0.929	rs759197	chr16:5006076	C/T	cg06510647	chr16:5006106	NA	0.58	5.44	0.4	2.06e-7	Cancer;
PAAD	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.66	-7.15	-0.5	3.35e-11	Menarche (age at onset);
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg27094323	chr7:1216898	NA	-0.56	-7.04	-0.5	6.08e-11	Longevity;Endometriosis;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.54	-0.35	1.16e-5	Height;
PAAD	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.36	-0.46	2.22e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4750440	0.702	rs7917812	chr10:14030067	G/A	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.25	-0.33	3.75e-5	Adiponectin levels;
PAAD	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06481639	chr22:41940642	POLR3H	-0.58	-4.27	-0.33	3.42e-5	Vitiligo;
PAAD	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.81	0.48	2.11e-10	Systemic lupus erythematosus;
PAAD	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.42	9.9	0.63	3.83e-18	Opioid sensitivity;
PAAD	cis	rs8179	0.593	rs7804722	chr7:92288106	C/T	cg03496780	chr7:92466842	CDK6	-0.49	-4.67	-0.35	6.61e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg13057898	chr1:3703894	LRRC47	0.48	4.75	0.36	4.72e-6	Red cell distribution width;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-5.04	-0.38	1.31e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.9	6.57	0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg18721089	chr20:30220636	NA	-0.6	-4.55	-0.35	1.11e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs10776612	0.565	rs11101359	chr10:49723939	C/T	cg08348173	chr10:49687869	ARHGAP22	-0.4	-4.27	-0.33	3.43e-5	Conduct disorder;
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.76	8.18	0.55	1.06e-13	Eye color traits;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.99	10.14	0.64	9.01e-19	Post bronchodilator FEV1;
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.25	-0.45	3.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4343996	0.901	rs1112428	chr7:3352512	T/C	cg21248987	chr7:3385318	SDK1	-0.48	-5.28	-0.39	4.36e-7	Motion sickness;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg10589385	chr1:150898437	SETDB1	0.39	4.89	0.37	2.51e-6	Melanoma;
PAAD	cis	rs722864	0.744	rs1809139	chr2:173982876	C/T	cg09210666	chr2:173941575	ZAK	0.54	4.72	0.36	5.4e-6	Lung cancer;
PAAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.75	7.14	0.5	3.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59888335	0.858	rs4856199	chr3:81006557	A/G	cg21735741	chr3:80819488	NA	-0.53	-4.62	-0.35	8e-6	Schizophrenia;
PAAD	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg15017067	chr4:17643749	FAM184B	0.41	4.39	0.34	2.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17401966	0.898	rs6670208	chr1:10252667	C/T	cg15208524	chr1:10270712	KIF1B	0.46	4.28	0.33	3.28e-5	Hepatocellular carcinoma;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.33	-5.91	-0.43	2.19e-8	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.58	5.67	0.42	7.15e-8	Prudent dietary pattern;
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg10534938	chr5:1868639	NA	0.49	6.37	0.46	2.18e-9	Cardiovascular disease risk factors;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22294755	chr7:16685683	BZW2;ANKMY2	0.57	6.29	0.45	3.26e-9	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.41	4.29	0.33	3.13e-5	Obesity-related traits;
PAAD	cis	rs1992660	0.523	rs10043093	chr5:40324220	C/A	cg05240017	chr5:40756081	TTC33	0.56	4.91	0.37	2.33e-6	Crohn's disease;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg20045696	chr14:77926864	AHSA1	-0.51	-4.96	-0.37	1.85e-6	Myeloid white cell count;
PAAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg15571903	chr15:79123663	NA	0.49	6.33	0.46	2.63e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg04257695	chr17:30186438	C17orf79	-0.64	-5.26	-0.39	4.74e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-5.11	-0.38	9.63e-7	Immature fraction of reticulocytes;
PAAD	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	4.55	0.35	1.07e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg00105475	chr2:10696890	NA	0.72	7.72	0.53	1.47e-12	Prostate cancer;
PAAD	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4690686	0.964	rs1840270	chr4:177246288	G/C	cg17059388	chr4:177262070	NA	0.5	4.96	0.37	1.84e-6	Essential tremor;
PAAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.84	7.26	0.51	1.9e-11	Alzheimer's disease;
PAAD	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.52	-4.48	-0.34	1.47e-5	Lung cancer (smoking interaction);
PAAD	cis	rs1499972	0.941	rs62263122	chr3:117630669	T/C	cg07612923	chr3:117604196	NA	1.08	7.1	0.5	4.55e-11	Schizophrenia;
PAAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg06740227	chr12:86229804	RASSF9	0.5	4.94	0.37	2.07e-6	Major depressive disorder;
PAAD	cis	rs3018712	0.700	rs2510386	chr11:68448058	T/C	cg02340541	chr11:68451699	GAL	-0.57	-4.52	-0.34	1.23e-5	Total body bone mineral density;
PAAD	cis	rs1371614	0.523	rs11904656	chr2:27173249	G/A	cg00617064	chr2:27272375	NA	-0.43	-4.45	-0.34	1.64e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-6.7	-0.48	3.91e-10	Mood instability;
PAAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg21859623	chr20:33103246	DYNLRB1	-0.45	-4.53	-0.35	1.17e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4372836	0.543	rs6742291	chr2:29007349	T/C	cg09009506	chr2:28216851	BRE	0.42	4.66	0.35	6.88e-6	Body mass index;
PAAD	cis	rs11966931	0.948	rs1607399	chr6:108089007	A/G	cg10566610	chr6:108093680	SCML4	-0.48	-4.52	-0.34	1.24e-5	Neutrophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22779765	chr14:103369786	TRAF3	0.61	6.77	0.48	2.59e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	1.15	12.81	0.72	6.19e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.14	17.58	0.82	1.82e-38	Cognitive function;
PAAD	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.86	6.57	0.47	7.58e-10	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	4.5	0.34	1.35e-5	Vitiligo;
PAAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.43	4.28	0.33	3.24e-5	Immature fraction of reticulocytes;
PAAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg08897044	chr19:12950850	MAST1	-0.35	-4.45	-0.34	1.62e-5	Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg00531865	chr16:30841666	NA	-0.62	-5.39	-0.4	2.67e-7	Multiple myeloma;
PAAD	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.77	-5.8	-0.43	3.75e-8	Mean platelet volume;
PAAD	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.58	5.64	0.42	7.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg24220031	chr2:73402428	NA	-0.34	-4.87	-0.37	2.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg03983498	chr1:55107291	C1orf175	0.49	5.19	0.39	6.63e-7	Survival in pancreatic cancer;
PAAD	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg25287198	chr4:183728479	NA	0.5	4.32	0.33	2.79e-5	Pediatric autoimmune diseases;
PAAD	cis	rs80346118	0.673	rs6095300	chr20:47422388	A/G	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.61	-4.52	-0.34	1.26e-5	Diastolic blood pressure;
PAAD	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg10705379	chr10:99080932	FRAT1	-0.47	-5.5	-0.41	1.59e-7	Monocyte count;
PAAD	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-6.5	-0.47	1.09e-9	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.93	-0.63	3.13e-18	Vitiligo;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg11802864	chr11:65308245	LTBP3	1.35	6.78	0.48	2.45e-10	Height;
PAAD	cis	rs10901513	0.896	rs11528564	chr10:127665932	G/A	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg09471204	chr22:42347991	LOC339674	0.37	4.3	0.33	3.01e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	4.73	0.36	5.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	6.98	0.49	8.59e-11	Alzheimer's disease;
PAAD	cis	rs11807834	0.505	rs11806744	chr1:230246454	C/T	cg00566187	chr1:230250356	GALNT2	-0.66	-7.05	-0.5	5.72e-11	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01942863	chr7:99769432	GPC2	0.51	4.26	0.33	3.62e-5	Platelet count;
PAAD	cis	rs9907295	0.748	rs4251719	chr17:34142362	C/T	cg16983627	chr17:34238386	NA	-0.54	-4.25	-0.33	3.68e-5	Fibroblast growth factor basic levels;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg22199361	chr20:5081567	C20orf30	0.59	6.6	0.47	6.41e-10	Iris heterochromicity;
PAAD	cis	rs859767	0.741	rs2176341	chr2:135371421	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-4.38	-0.33	2.18e-5	Neuroticism;
PAAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-5.33	-0.4	3.46e-7	Monocyte count;
PAAD	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.43	-5.29	-0.39	4.14e-7	Blood pressure;
PAAD	cis	rs2446066	0.872	rs12582170	chr12:53757831	A/G	cg20591337	chr12:53693442	C12orf10	0.61	4.31	0.33	2.93e-5	Red blood cell count;
PAAD	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.69	6.31	0.46	2.87e-9	Birth weight;
PAAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	4.8	0.36	3.83e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20843052	chr2:61293725	KIAA1841	0.57	7.22	0.51	2.26e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3790455	0.610	rs3790461	chr1:156469364	A/G	cg14087168	chr1:156450669	MEF2D	0.45	5.57	0.41	1.15e-7	Migraine;
PAAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.62	-5.74	-0.42	5.05e-8	Monocyte count;
PAAD	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.67	-5.17	-0.39	7.23e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg25837213	chr17:80849375	TBCD	-0.46	-4.44	-0.34	1.71e-5	Breast cancer;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs61861422	0.516	rs12767762	chr10:134443032	A/G	cg24416232	chr10:134405482	INPP5A	-0.45	-4.78	-0.36	4.06e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs4704187	0.687	rs10064409	chr5:74527134	A/G	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.44	5.28	0.39	4.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.48	4.7	0.36	5.7e-6	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg00945038	chr17:61921165	SMARCD2	-0.48	-5.9	-0.43	2.32e-8	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23683528	chr2:235860449	SH3BP4	-0.62	-6.47	-0.46	1.26e-9	Smoking initiation;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.08e-5	Renal cell carcinoma;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09796094	chr14:105350432	KIAA0284	-0.74	-6.69	-0.48	3.93e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg14393609	chr7:65229607	NA	0.5	5.01	0.38	1.46e-6	Aortic root size;
PAAD	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-1.26	-7.72	-0.53	1.47e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.1	0.38	1.02e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.58	-4.95	-0.37	1.97e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7224685	0.608	rs12602456	chr17:4273483	C/T	cg09597638	chr17:3907349	NA	0.61	5.31	0.4	3.81e-7	Type 2 diabetes;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.21	0.39	6.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg03804128	chr16:635623	NA	0.31	4.33	0.33	2.75e-5	Height;
PAAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg27478167	chr7:817139	HEATR2	-0.57	-4.56	-0.35	1.03e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.81	-9.22	-0.6	2.36e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-13.88	-0.75	8.43e-29	Primary sclerosing cholangitis;
PAAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.42	5.33	0.4	3.47e-7	Ulcerative colitis;
PAAD	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.62	-6.1	-0.44	8.6e-9	Itch intensity from mosquito bite;
PAAD	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10105259	chr15:23049020	NIPA1	0.62	7.3	0.51	1.51e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	11.18	0.67	1.52e-21	Monocyte count;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06799790	chr17:61951754	CSH2	-0.46	-4.77	-0.36	4.29e-6	Height;
PAAD	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17710535	chr19:10819994	QTRT1	0.49	4.31	0.33	2.88e-5	Inflammatory skin disease;
PAAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg05484376	chr2:27715224	FNDC4	0.5	5.14	0.38	8.42e-7	Total body bone mineral density;
PAAD	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.74	-7.13	-0.5	3.7e-11	Schizophrenia;
PAAD	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	7.57	0.52	3.29e-12	Eotaxin levels;
PAAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.92	9.42	0.61	6.87e-17	Alcohol dependence;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01503640	chr19:18963027	UPF1	0.6	6.85	0.49	1.71e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04415236	chr6:134158299	MGC34034	-0.66	-6.7	-0.48	3.79e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-8.24	-0.56	7.41e-14	Longevity;Endometriosis;
PAAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14343924	chr8:8086146	FLJ10661	0.5	4.63	0.35	7.8e-6	Mood instability;
PAAD	cis	rs35740288	1.000	rs11637212	chr15:86293097	C/G	cg07943548	chr15:86304357	KLHL25	0.55	4.74	0.36	4.8e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs28493229	0.708	rs78900506	chr19:41160096	T/C	cg21869046	chr19:41225005	ITPKC	0.51	5.22	0.39	5.82e-7	Kawasaki disease;
PAAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.7	-7.61	-0.53	2.62e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.91	10.01	0.63	1.95e-18	Cognitive function;
PAAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg23463467	chr20:60627584	TAF4	0.46	4.96	0.37	1.85e-6	Body mass index;
PAAD	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg08888203	chr3:10149979	C3orf24	0.68	6.22	0.45	4.5e-9	Alzheimer's disease;
PAAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-5.38	-0.4	2.82e-7	Monocyte count;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.58	6.0	0.44	1.36e-8	Personality dimensions;
PAAD	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.97	6.76	0.48	2.73e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09312254	chr12:112450979	ERP29;TMEM116	0.61	6.6	0.47	6.56e-10	Myopia (pathological);
PAAD	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg11143131	chr5:131608246	PDLIM4	0.48	4.51	0.34	1.27e-5	Acylcarnitine levels;
PAAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg17178900	chr1:205818956	PM20D1	0.45	4.37	0.33	2.3e-5	Parkinson's disease;
PAAD	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01942863	chr7:99769432	GPC2	0.53	4.39	0.34	2.08e-5	Platelet count;
PAAD	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.81	6.09	0.44	8.91e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.9	-7.72	-0.53	1.43e-12	Gut microbiome composition (summer);
PAAD	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.44	-4.29	-0.33	3.21e-5	Prostate-specific antigen levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16086579	chr12:132562626	EP400	0.6	6.34	0.46	2.48e-9	Smoking initiation;
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.59	-6.74	-0.48	3.09e-10	Lung cancer;
PAAD	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg14146966	chr2:61757674	XPO1	-0.37	-4.56	-0.35	1.03e-5	Tuberculosis;
PAAD	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-6.72	-0.48	3.43e-10	Menarche (age at onset);
PAAD	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg17326555	chr1:119535693	NA	-0.36	-4.58	-0.35	9.62e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7650267	0.572	rs6795944	chr3:43580243	C/T	cg07997066	chr3:44154910	MIR138-1	0.55	4.32	0.33	2.83e-5	Obesity-related traits;
PAAD	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.94	0.54	4.09e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.56	-5.12	-0.38	9.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg16558253	chr16:72132732	DHX38	-0.61	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs59888335	0.862	rs13061012	chr3:80546936	G/C	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-6.01	-0.44	1.33e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs5769765	0.720	rs138821	chr22:50166564	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.03	0.38	1.38e-6	Schizophrenia;
PAAD	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-4.57	-0.35	1.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.73	7.21	0.5	2.51e-11	Schizophrenia;
PAAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg00944433	chr1:107599041	PRMT6	0.39	4.45	0.34	1.67e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg14019146	chr3:50243930	SLC38A3	-0.55	-5.06	-0.38	1.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.76	8.1	0.55	1.67e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	1.1	11.26	0.67	8.92e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.44	-6.78	-0.48	2.5e-10	Subjective well-being;
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.12	0.5	3.95e-11	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.5	5.75	0.42	4.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.6	5.08	0.38	1.09e-6	Response to diuretic therapy;
PAAD	cis	rs11696501	0.591	rs6065854	chr20:44288816	T/C	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs7598759	0.712	rs6735961	chr2:232334414	T/C	cg19187155	chr2:232395269	NMUR1	0.52	5.59	0.41	1.04e-7	Noise-induced hearing loss;
PAAD	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg26818257	chr2:241905806	NA	0.44	4.46	0.34	1.61e-5	Urinary metabolites;
PAAD	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-5.76	-0.42	4.61e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg25062951	chr7:817576	HEATR2	0.37	4.28	0.33	3.26e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.94	9.07	0.59	5.78e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12044355	0.927	rs11577035	chr1:231835941	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	5.21	0.39	6.19e-7	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg14343924	chr8:8086146	FLJ10661	-0.46	-4.3	-0.33	3.02e-5	Mood instability;
PAAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs6499129	0.702	rs8044843	chr16:67318242	A/G	cg09395969	chr16:67918001	EDC4;NRN1L	0.63	4.49	0.34	1.38e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg25319279	chr11:5960081	NA	-0.6	-6.03	-0.44	1.21e-8	DNA methylation (variation);
PAAD	cis	rs6594713	0.533	rs12189067	chr5:112981528	C/A	cg12552261	chr5:112820674	MCC	0.71	4.42	0.34	1.84e-5	Brain cytoarchitecture;
PAAD	cis	rs73416724	0.688	rs77915916	chr6:43287722	A/T	cg17502394	chr6:43251710	TTBK1	0.71	4.46	0.34	1.59e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.4	7.48	0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.62	4.51	0.34	1.3e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.44	-4.48	-0.34	1.49e-5	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05970398	chr4:95129288	SMARCAD1	0.64	7.29	0.51	1.59e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.51	5.22	0.39	5.73e-7	Schizophrenia;
PAAD	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs116248771	0.549	rs9811858	chr3:158443093	T/C	cg16708174	chr3:158430962	RARRES1	0.81	5.97	0.44	1.63e-8	diarrhoeal disease at age 2;
PAAD	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.8	9.18	0.6	2.99e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-5.92	-0.43	2.09e-8	High light scatter reticulocyte count;
PAAD	cis	rs7729447	0.566	rs1421811	chr5:32714270	C/G	cg16267343	chr5:32710456	NPR3	0.49	4.91	0.37	2.32e-6	Blood pressure;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.05	-0.7	6.63e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.64	5.72e-19	Morning vs. evening chronotype;
PAAD	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.43	4.48	0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.17e-10	Life satisfaction;
PAAD	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22509189	chr2:225307070	NA	-0.44	-4.38	-0.33	2.21e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.49	-4.62	-0.35	7.99e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25173010	chr1:145438031	TXNIP	0.57	6.44	0.46	1.47e-9	Metabolite levels  (X-11787);
PAAD	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.44	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.83	0.48	1.94e-10	Longevity;Endometriosis;
PAAD	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.61	-5.83	-0.43	3.14e-8	Subjective well-being;
PAAD	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	5.82	0.43	3.43e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg16586182	chr3:47516702	SCAP	-0.69	-7.79	-0.53	9.53e-13	Colorectal cancer;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.69	-7.44	-0.52	6.83e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08677398	chr8:58056175	NA	0.71	4.93	0.37	2.14e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs332507	0.830	rs4678144	chr3:124404399	C/T	cg05980111	chr3:124395277	KALRN	-0.45	-4.49	-0.34	1.38e-5	Plateletcrit;
PAAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-5.15	-0.39	7.88e-7	Gut microbiome composition (summer);
PAAD	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.71	7.15	0.5	3.43e-11	Anterior chamber depth;
PAAD	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.35	0.33	2.46e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs12476592	0.571	rs2176415	chr2:63636568	A/C	cg10828910	chr2:63850056	LOC388955	0.51	4.43	0.34	1.79e-5	Childhood ear infection;
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg23119463	chr10:134592391	INPP5A	-0.49	-4.55	-0.35	1.08e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.15	0.5	3.47e-11	Response to antipsychotic treatment;
PAAD	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.39	4.51	0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.52	5.93	0.43	1.99e-8	Schizophrenia;
PAAD	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg10820045	chr2:198174542	NA	0.48	4.96	0.37	1.85e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg12935359	chr14:103987150	CKB	-0.63	-7.07	-0.5	5.21e-11	Body mass index;
PAAD	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-6.5	-0.47	1.07e-9	Crohn's disease;
PAAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.65	-6.86	-0.49	1.62e-10	Childhood ear infection;
PAAD	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs2694528	0.764	rs78620886	chr5:60087336	G/A	cg11474532	chr5:59995715	DEPDC1B	0.93	4.71	0.36	5.56e-6	Parkinson's disease;
PAAD	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg25902810	chr10:99078978	FRAT1	-0.52	-4.74	-0.36	4.82e-6	Monocyte count;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg00976097	chr5:421733	AHRR	-0.44	-4.39	-0.34	2.09e-5	Cystic fibrosis severity;
PAAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	1.07	14.87	0.77	1.86e-31	Breast cancer;
PAAD	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.58	4.79	0.36	3.87e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.99	0.44	1.47e-8	Prudent dietary pattern;
PAAD	cis	rs6547631	0.682	rs4832187	chr2:85929675	A/G	cg24620635	chr2:85921963	GNLY	0.41	5.54	0.41	1.27e-7	Blood protein levels;
PAAD	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.8	8.91	0.59	1.49e-15	Iron status biomarkers;
PAAD	cis	rs1371614	0.523	rs2891534	chr2:27184446	A/G	cg00617064	chr2:27272375	NA	-0.45	-4.76	-0.36	4.55e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg05805236	chr11:65401703	PCNXL3	-0.47	-4.95	-0.37	1.96e-6	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.66	-6.69	-0.48	4.06e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1865721	0.755	rs3213875	chr18:73184048	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-5.1	-0.38	9.79e-7	Intelligence;
PAAD	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg05202720	chr20:44486028	ACOT8;ZSWIM3	0.52	5.43	0.4	2.22e-7	Positive affect;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.8	-8.93	-0.59	1.3e-15	Iron status biomarkers;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.57	6.19	0.45	5.3e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg06217245	chr20:33103252	DYNLRB1	0.41	4.61	0.35	8.46e-6	Height;
PAAD	cis	rs9831894	0.668	rs4308217	chr3:121793187	A/C	cg03315247	chr3:122399498	PARP14	-0.55	-4.94	-0.37	2.04e-6	Selective IgA deficiency;
PAAD	cis	rs1412115	0.501	rs10827289	chr10:34091492	C/T	cg11147278	chr10:34062234	NA	0.36	4.25	0.33	3.71e-5	Schizophrenia;
PAAD	cis	rs16975963	0.644	rs11666738	chr19:38130319	C/G	cg08679971	chr19:38281047	NA	0.46	4.52	0.34	1.22e-5	Longevity;
PAAD	cis	rs11992162	0.636	rs113416335	chr8:11809421	C/T	cg12395012	chr8:11607386	GATA4	0.43	4.53	0.34	1.21e-5	Monocyte count;
PAAD	cis	rs73019876	0.869	rs6511306	chr19:22163848	A/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg15117754	chr3:10150083	C3orf24	0.67	5.54	0.41	1.32e-7	Alzheimer's disease;
PAAD	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.65	6.38	0.46	2.03e-9	Corneal astigmatism;
PAAD	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.65	5.59	0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.66	-8.31	-0.56	4.95e-14	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs258892	0.895	rs114748070	chr5:72024794	C/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs12230513	0.732	rs61957765	chr12:55868561	T/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.25	0.33	3.76e-5	Contrast sensitivity;
PAAD	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg10208897	chr5:178548229	ADAMTS2	0.52	4.68	0.35	6.42e-6	Pubertal anthropometrics;
PAAD	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.91e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.74	-0.48	3.16e-10	Aortic root size;
PAAD	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.37	-0.78	9.21e-33	Schizophrenia;
PAAD	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Visceral adipose tissue adjusted for BMI;
PAAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16036305	chr1:115053835	TRIM33	0.69	8.04	0.55	2.39e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6733011	0.600	rs1568213	chr2:99432063	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-4.93	-0.37	2.12e-6	Bipolar disorder;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs2275565	0.872	rs4659741	chr1:237051026	C/G	cg17297354	chr1:237056641	MTR	-0.51	-4.51	-0.34	1.28e-5	Homocysteine levels;
PAAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.97	-0.37	1.8e-6	Bipolar disorder;
PAAD	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.59	-5.42	-0.4	2.33e-7	Breast cancer;
PAAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg04106633	chr4:1044584	NA	0.7	5.92	0.43	2.01e-8	Recombination rate (females);
PAAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-4.98	-0.37	1.73e-6	Diastolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14312018	chr17:8151491	C17orf68;PFAS	-0.71	-7.08	-0.5	5.1e-11	Neuroticism;
PAAD	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.72	7.21	0.5	2.46e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02466008	chr5:14508414	TRIO	0.59	6.69	0.48	3.98e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.52	4.5	0.34	1.35e-5	Serum parathyroid hormone levels;
PAAD	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg00536532	chr6:33561449	C6orf227	-0.42	-4.45	-0.34	1.63e-5	Plateletcrit;
PAAD	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.58	-4.95	-0.37	1.97e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg25722041	chr1:8623473	RERE	0.48	4.3	0.33	2.99e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg04287289	chr16:89883240	FANCA	0.83	4.36	0.33	2.34e-5	Skin colour saturation;
PAAD	cis	rs360071	0.528	rs360094	chr1:226064846	C/T	cg25552768	chr1:226077287	LEFTY1	-0.45	-4.75	-0.36	4.71e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-4.74	-0.36	4.79e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.63	-0.35	7.73e-6	Obesity-related traits;
PAAD	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs41311933	0.710	rs4271038	chr9:123719014	C/A	cg21241889	chr9:123690658	TRAF1	-0.76	-4.42	-0.34	1.87e-5	Coronary artery disease;
PAAD	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.63	6.7	0.48	3.82e-10	Longevity;
PAAD	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg20129853	chr10:51489980	NA	-0.46	-4.58	-0.35	9.47e-6	Prostate-specific antigen levels;
PAAD	cis	rs6563842	0.572	rs9549263	chr13:41264784	G/T	cg21288729	chr13:41239152	FOXO1	0.56	4.51	0.34	1.3e-5	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.58	6.7	0.48	3.83e-10	Blood metabolite levels;
PAAD	cis	rs346785	0.965	rs164009	chr17:74283669	C/T	cg09812376	chr17:74270190	QRICH2	0.42	5.94	0.43	1.91e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg21625146	chr5:486483	SLC9A3	-0.43	-5.21	-0.39	6.15e-7	Cystic fibrosis severity;
PAAD	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.5	5.7	0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.59	0.61	2.45e-17	Diabetic retinopathy;
PAAD	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.05	0.55	2.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.39	-5.51	-0.41	1.51e-7	Cutaneous nevi;
PAAD	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg10616300	chr11:66138557	SLC29A2	0.34	4.58	0.35	9.8e-6	Educational attainment (years of education);
PAAD	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	9.57	0.61	2.88e-17	Ulcerative colitis;
PAAD	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.46	4.49	0.34	1.42e-5	Trans fatty acid levels;
PAAD	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs41271473	0.718	rs4500282	chr1:228878375	T/A	cg10167378	chr1:228756711	NA	0.54	4.61	0.35	8.42e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg18809830	chr7:99032528	PTCD1	-1.22	-5.29	-0.39	4.25e-7	Blood metabolite levels;
PAAD	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs12936587	0.807	rs9900673	chr17:17548633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-4.63	-0.35	7.86e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs4668356	1.000	rs56155163	chr2:172001690	C/T	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.58	6.93	0.49	1.15e-10	Prostate cancer;
PAAD	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.63	-5.68	-0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05049329	chr1:226924846	ITPKB	0.54	7.51	0.52	4.64e-12	Parkinson's disease;
PAAD	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg06217245	chr20:33103252	DYNLRB1	0.44	4.47	0.34	1.5e-5	Skin pigmentation;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.79	-6.14	-0.45	6.82e-9	Schizophrenia;
PAAD	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg19337854	chr7:99768885	GPC2	0.44	4.59	0.35	9.38e-6	Coronary artery disease;
PAAD	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg10351095	chr21:47802916	PCNT	-0.5	-4.83	-0.36	3.3e-6	Testicular germ cell tumor;
PAAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	1.97e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-6.36	-0.46	2.27e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7577696	0.554	rs3769605	chr2:32322456	A/G	cg02381751	chr2:32503542	YIPF4	-0.5	-4.79	-0.36	3.87e-6	Inflammatory biomarkers;
PAAD	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg21419209	chr3:44054225	NA	-0.74	-7.67	-0.53	1.91e-12	Coronary artery disease;
PAAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.05e-6	Resting heart rate;
PAAD	cis	rs859767	1.000	rs842361	chr2:135340840	C/G	cg12500956	chr2:135428796	TMEM163	0.31	4.63	0.35	7.76e-6	Neuroticism;
PAAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.78	-8.16	-0.55	1.21e-13	Prostate cancer;
PAAD	cis	rs6466055	0.661	rs66790006	chr7:104882025	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-6.66	-0.48	4.69e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.76	8.04	0.55	2.31e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.11	0.44	7.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24514230	chr11:3688722	CHRNA10	0.59	6.8	0.48	2.21e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-5.48	-0.41	1.74e-7	Gut microbiome composition (summer);
PAAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02359409	chr6:42947317	PEX6	-0.49	-4.97	-0.37	1.77e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs6694672	0.867	rs4915337	chr1:197091537	A/T	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.95	-10.41	-0.65	1.74e-19	Headache;
PAAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-5.08	-0.38	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg01304814	chr3:48885189	PRKAR2A	1.0	5.49	0.41	1.63e-7	Cognitive function;
PAAD	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.7	-0.36	5.67e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2790216	1.000	rs2790145	chr10:59976277	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs901683	1.000	rs34383275	chr10:46072877	C/T	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs73072330	0.643	rs56298666	chr3:47667218	A/G	cg04507495	chr3:47563649	NA	1.15	5.41	0.4	2.44e-7	Stem cell growth factor beta levels;
PAAD	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.75	-9.92	-0.63	3.32e-18	Birth weight;
PAAD	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.45	-5.1	-0.38	9.92e-7	Pneumonia;
PAAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.6	-6.88	-0.49	1.5e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-5.33	-0.4	3.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.15	-14.25	-0.76	8.41e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs12906542	0.544	rs35472584	chr15:78266727	C/T	cg26201283	chr15:79056434	ADAMTS7	-0.51	-4.71	-0.36	5.52e-6	Breast cancer;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.75	7.04	0.5	6.17e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg16766828	chr3:128327626	NA	-0.49	-6.73	-0.48	3.19e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00079375	chr15:79125835	NA	0.41	4.31	0.33	2.92e-5	Coronary artery disease;
PAAD	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.37	-5.39	-0.4	2.65e-7	Cutaneous nevi;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg23708337	chr7:1209742	NA	0.66	5.26	0.39	4.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.88	-10.58	-0.65	6.14e-20	Total body bone mineral density;
PAAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.5	4.77	0.36	4.27e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.59	5.34	0.4	3.34e-7	Retinal vascular caliber;
PAAD	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-6.73	-0.48	3.21e-10	Cognitive function;
PAAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg00945038	chr17:61921165	SMARCD2	0.49	6.08	0.44	9.17e-9	Prudent dietary pattern;
PAAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.59	7.05	0.5	5.91e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9535307	0.727	rs7983303	chr13:50358053	T/A	cg04663916	chr13:50265991	EBPL	0.59	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg17524180	chr13:113633600	MCF2L	-0.39	-4.36	-0.33	2.41e-5	Systolic blood pressure;
PAAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.53	-4.79	-0.36	3.88e-6	Schizophrenia;
PAAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg19680485	chr15:31195859	MTMR15	-0.43	-4.43	-0.34	1.78e-5	Huntington's disease progression;
PAAD	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg17552801	chr10:99332121	ANKRD2	-0.46	-4.64	-0.35	7.39e-6	Metabolite levels;
PAAD	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00292662	chr22:38071168	LGALS1	0.52	5.48	0.41	1.7e-7	Fat distribution (HIV);
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs761746	0.577	rs131244	chr22:32126563	T/C	cg01338084	chr22:32026380	PISD	0.61	5.44	0.4	2.05e-7	Intelligence;
PAAD	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs4460308	0.967	rs4304268	chr7:104415434	C/G	cg10575219	chr7:105313992	ATXN7L1	-0.41	-4.33	-0.33	2.65e-5	Social communication problems;
PAAD	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.4	3.92e-7	Male-pattern baldness;
PAAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.69	-10.11	-0.63	1.05e-18	Huntington's disease progression;
PAAD	cis	rs2120243	0.782	rs7609926	chr3:157149160	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	5.5	0.41	1.54e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs275456	0.614	rs275460	chr5:6806216	A/G	cg10857441	chr5:6722123	POLS	-0.39	-4.66	-0.35	6.77e-6	Paclitaxel-induced neuropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24904935	chr17:58740978	PPM1D	-0.59	-6.29	-0.45	3.14e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-6.08	-0.44	9.47e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.585	rs2548887	chr19:23211317	T/C	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.64	7.49	0.52	5.09e-12	Endometriosis;
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.65	0.47	5.08e-10	Lung cancer;
PAAD	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.4	-4.65	-0.35	7.29e-6	Intelligence;
PAAD	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.7	6.96	0.49	9.63e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.6	-5.7	-0.42	5.92e-8	Total body bone mineral density;
PAAD	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.39	4.71	0.36	5.56e-6	Sitting height ratio;
PAAD	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.7e-5	Bone mineral density;
PAAD	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.49	-4.28	-0.33	3.24e-5	Common traits (Other);
PAAD	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.94	-11.15	-0.67	1.81e-21	IgG glycosylation;
PAAD	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.74	7.55	0.52	3.65e-12	Corneal astigmatism;
PAAD	cis	rs7608623	0.840	rs12475813	chr2:24139520	T/C	cg08917208	chr2:24149416	ATAD2B	-0.47	-4.54	-0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs11807834	0.505	rs7537621	chr1:230236401	C/T	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.49e-13	Schizophrenia;
PAAD	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.46	4.87	0.37	2.82e-6	Age of smoking initiation;
PAAD	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg01299579	chr2:10830716	NOL10	-0.61	-6.18	-0.45	5.6e-9	Prostate cancer;
PAAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.5	0.41	1.56e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.96	-14.83	-0.77	2.5e-31	Height;
PAAD	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.5	-5.43	-0.4	2.16e-7	Menarche (age at onset);
PAAD	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.53	-0.41	1.34e-7	Blood protein levels;
PAAD	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.79	-9.43	-0.61	6.41e-17	White blood cell count (basophil);
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg05697835	chr1:2722811	NA	0.38	4.31	0.33	2.91e-5	Ulcerative colitis;
PAAD	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10342447	chr17:26645325	TMEM97	0.5	6.51	0.47	1.01e-9	Blood protein levels;
PAAD	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.78	-7.88	-0.54	5.95e-13	Coronary artery disease;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg26554054	chr8:600488	NA	0.94	6.06	0.44	1.03e-8	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	0.91	5.88	0.43	2.45e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg21951975	chr1:209979733	IRF6	0.51	4.95	0.37	1.98e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26251401	chr19:36236539	PSENEN;U2AF1L4	0.65	6.29	0.45	3.17e-9	Obesity-related traits;
PAAD	cis	rs941024	0.790	rs55644943	chr12:56051058	G/A	cg20737382	chr12:56040096	NA	-0.78	-4.82	-0.36	3.51e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg24747557	chr10:131355152	MGMT	-0.45	-4.9	-0.37	2.45e-6	Response to temozolomide;
PAAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs847851	0.710	rs111868030	chr6:34651306	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-4.55	-0.35	1.07e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.65	-7.46	-0.52	6.22e-12	Sense of smell;
PAAD	cis	rs12984174	0.752	rs388159	chr19:18141996	C/T	cg21649277	chr19:18117794	ARRDC2	0.72	5.26	0.39	4.87e-7	Pulmonary function in asthmatics;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg03983715	chr16:68378420	PRMT7	-0.74	-5.5	-0.41	1.54e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12523822	0.957	rs11970674	chr6:154955611	T/C	cg20019720	chr6:154832845	CNKSR3	0.3	4.45	0.34	1.68e-5	Diabetic kidney disease;
PAAD	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5756391	0.524	rs2413436	chr22:37312561	A/G	cg16356956	chr22:37317934	CSF2RB	0.39	4.73	0.36	5.02e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.42	5.11	0.38	9.52e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.61	-0.35	8.38e-6	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12350342	chr11:46558181	AMBRA1	-0.64	-6.86	-0.49	1.6e-10	Obesity-related traits;
PAAD	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs7829975	0.627	rs2979172	chr8:8310508	G/C	cg08975724	chr8:8085496	FLJ10661	0.62	6.12	0.44	7.48e-9	Mood instability;
PAAD	cis	rs6867913	0.951	rs4912799	chr5:141453720	G/C	cg23435118	chr5:141488016	NDFIP1	0.47	4.4	0.34	2.04e-5	Asthma;
PAAD	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.86	-9.61	-0.61	2.29e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12760731	0.720	rs12035174	chr1:178314311	A/T	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg21546286	chr11:48923668	NA	0.55	5.79	0.43	3.86e-8	HDL cholesterol;
PAAD	cis	rs7771547	0.723	rs9357219	chr6:36557683	C/G	cg07856975	chr6:36356162	ETV7	-0.45	-4.67	-0.35	6.69e-6	Platelet distribution width;
PAAD	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.79	9.18	0.6	3.01e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.45	4.51	0.34	1.28e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4979906	1.000	rs7070550	chr10:79459419	T/C	cg07817648	chr10:79422355	NA	-0.5	-4.64	-0.35	7.58e-6	Mortality in heart failure;
PAAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.75	0.36	4.73e-6	Bone mineral density;
PAAD	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.64	6.42	0.46	1.65e-9	Type 2 diabetes;
PAAD	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.28	-7.15	-0.5	3.37e-11	Body mass index;
PAAD	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.45	0.57	2.25e-14	Rheumatoid arthritis;
PAAD	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs11563648	0.553	rs1361938	chr7:126998282	A/C	cg13381984	chr7:127881344	LEP	0.29	4.32	0.33	2.77e-5	Resting heart rate;
PAAD	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs4273100	0.790	rs60606605	chr17:19277144	G/A	cg19949948	chr17:19361230	NA	-0.51	-4.33	-0.33	2.66e-5	Schizophrenia;
PAAD	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.63	6.57	0.47	7.72e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02071572	chr4:1403502	NA	0.35	4.35	0.33	2.5e-5	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15553848	chr2:39664346	MAP4K3	0.64	6.4	0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg03735013	chr11:61582769	MIR1908;FADS1	-0.45	-4.54	-0.35	1.15e-5	Trans fatty acid levels;
PAAD	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	4.6	0.35	8.88e-6	Height;
PAAD	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.6e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs559928	0.692	rs12146487	chr11:64026639	G/A	cg22916017	chr11:64110731	CCDC88B	0.49	4.64	0.35	7.55e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.93e-6	Skin colour saturation;
PAAD	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.58	6.08	0.44	9.31e-9	Selective IgA deficiency;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.51e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs2147959	0.941	rs4653960	chr1:228631719	T/C	cg02753203	chr1:228287806	NA	-0.53	-4.36	-0.33	2.38e-5	Adult asthma;
PAAD	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg17215666	chr7:56131930	SUMF2	0.46	4.26	0.33	3.57e-5	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs11614333	1.000	rs12311463	chr12:15050238	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg24253500	chr15:84953950	NA	0.57	6.67	0.48	4.45e-10	Schizophrenia;
PAAD	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.4	5.05	0.38	1.24e-6	Corneal astigmatism;
PAAD	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.61	5.84	0.43	3.09e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs746265	0.818	rs16968662	chr15:39580264	A/G	cg10099207	chr15:39544144	C15orf54	0.57	4.37	0.33	2.3e-5	PR interval;
PAAD	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.48	5.59	0.41	1.03e-7	Coronary artery disease;
PAAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg16083429	chr3:49237500	CCDC36	0.44	4.29	0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.49	5.72	0.42	5.47e-8	Inattentive symptoms;
PAAD	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.76	6.06	0.44	1.01e-8	Neutrophil percentage of white cells;
PAAD	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-7.02	-0.49	6.8e-11	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs11264799	0.539	rs2777968	chr1:157549325	T/G	cg18268488	chr1:157545234	FCRL4	0.57	6.46	0.46	1.32e-9	IgA nephropathy;
PAAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg20344442	chr15:51633704	GLDN	0.52	4.9	0.37	2.41e-6	Hormone measurements;
PAAD	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.27	0.33	3.38e-5	Lung cancer;
PAAD	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.46	4.75	0.36	4.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs847577	0.550	rs6465654	chr7:97786282	G/A	cg24562669	chr7:97807699	LMTK2	0.68	10.93	0.66	6.89e-21	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.59	6.36	0.46	2.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg16230307	chr14:35515116	FAM177A1	0.41	4.34	0.33	2.54e-5	Psoriasis;
PAAD	trans	rs3935740	0.649	rs11073003	chr15:81619566	A/C	cg27605748	chr5:42951711	NA	-0.81	-6.31	-0.46	2.91e-9	Parkinson's disease;
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.7	0.62	1.3e-17	Platelet count;
PAAD	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg22467129	chr15:76604101	ETFA	-0.53	-4.98	-0.37	1.74e-6	Blood metabolite levels;
PAAD	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.73	-6.58	-0.47	7e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.4	0.64	1.82e-19	Smoking behavior;
PAAD	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	4.98	0.37	1.68e-6	Mean platelet volume;
PAAD	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.67	0.53	1.91e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.32	0.33	2.86e-5	IgG glycosylation;
PAAD	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.57	5.88	0.43	2.46e-8	Daytime sleep phenotypes;
PAAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg16606324	chr3:10149918	C3orf24	0.54	4.63	0.35	7.74e-6	Alzheimer's disease;
PAAD	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Systemic lupus erythematosus;
PAAD	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26926768	chr12:34528122	NA	0.39	4.72	0.36	5.28e-6	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.36	-0.33	2.42e-5	Vitiligo;
PAAD	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.36	0.33	2.36e-5	Lung cancer;
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00933542	chr6:150070202	PCMT1	0.54	5.81	0.43	3.51e-8	Lung cancer;
PAAD	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.46	5.16	0.39	7.67e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12153243	0.714	rs17401682	chr5:142896049	A/G	cg13907255	chr5:142895549	NA	-0.52	-4.81	-0.36	3.59e-6	Migraine;
PAAD	cis	rs2278796	0.639	rs4951152	chr1:204970495	G/T	cg04862289	chr1:204966208	NFASC	0.5	5.18	0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs12986413	0.624	rs2238599	chr19:2140009	C/T	cg09261902	chr19:2140048	AP3D1	0.6	5.97	0.44	1.62e-8	Height;
PAAD	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.78	8.12	0.55	1.44e-13	Corneal astigmatism;
PAAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24729792	chr2:113192114	RGPD8;RGPD5	0.55	4.27	0.33	3.48e-5	Yeast infection;
PAAD	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg06060754	chr5:176797920	RGS14	0.66	6.56	0.47	7.92e-10	Urate levels in lean individuals;
PAAD	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg22134325	chr11:66188745	NPAS4	-0.29	-4.25	-0.33	3.77e-5	Airway imaging phenotypes;
PAAD	cis	rs10851478	0.500	rs36023246	chr15:49699311	A/G	cg14549078	chr15:48752032	FBN1	0.32	4.25	0.33	3.76e-5	Oral cavity cancer;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg26690034	chr1:75198963	CRYZ;TYW3	0.51	4.68	0.36	6.25e-6	Resistin levels;
PAAD	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg13660082	chr14:53194042	PSMC6	0.73	4.49	0.34	1.38e-5	Alzheimer's disease (late onset);
PAAD	cis	rs6141769	0.542	rs28612490	chr20:31297568	G/A	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.7	-0.36	5.7e-6	Subjective well-being;
PAAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.48	-4.83	-0.36	3.26e-6	Schizophrenia;
PAAD	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.46	4.97	0.37	1.79e-6	Age of smoking initiation;
PAAD	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg13045555	chr8:105342365	NA	-0.26	-4.49	-0.34	1.38e-5	Paget's disease;
PAAD	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.62	6.92	0.49	1.18e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4605213	0.528	rs11079950	chr17:49332866	A/G	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.58	0.41	1.06e-7	Height;
PAAD	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.66	-4.82	-0.36	3.43e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.96	9.79	0.62	7.59e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.79e-10	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12222525	chr1:109506178	CLCC1	-0.65	-7.04	-0.5	6.17e-11	Smoking initiation;
PAAD	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg00484396	chr16:3507460	NAT15	0.89	6.93	0.49	1.15e-10	Tuberculosis;
PAAD	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg23153227	chr6:27725408	NA	0.49	4.67	0.35	6.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9326248	0.530	rs511676	chr11:116824884	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.7	4.3	0.33	3.07e-5	Blood protein levels;
PAAD	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.75	6.52	0.47	9.93e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg05803361	chr1:145727320	PDZK1	0.69	4.32	0.33	2.81e-5	Mitochondrial DNA levels;
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg20302533	chr7:39170763	POU6F2	0.37	5.26	0.39	4.85e-7	IgG glycosylation;
PAAD	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.51	4.61	0.35	8.47e-6	Lung cancer;
PAAD	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg19337854	chr7:99768885	GPC2	0.55	5.08	0.38	1.1e-6	Platelet count;
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg10729496	chr3:10149963	C3orf24	0.79	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.21	0.5	2.44e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08677398	chr8:58056175	NA	0.67	4.53	0.34	1.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-8.34	-0.56	4.11e-14	Morning vs. evening chronotype;
PAAD	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Breast cancer;
PAAD	cis	rs375066	0.935	rs385321	chr19:44405287	C/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.64	6.16	0.45	6.28e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-7.97	-0.54	3.42e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg18769074	chr3:133464867	TF	0.41	4.79	0.36	3.99e-6	Iron status biomarkers;
PAAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.44	-5.86	-0.43	2.81e-8	Ulcerative colitis;
PAAD	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg24634471	chr8:143751801	JRK	-0.47	-4.66	-0.35	6.75e-6	Schizophrenia;
PAAD	cis	rs2446066	0.872	rs11170525	chr12:53782628	G/T	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.46	-4.52	-0.34	1.24e-5	Breast cancer;
PAAD	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.57	5.56	0.41	1.19e-7	Neuroticism;
PAAD	cis	rs12257961	0.646	rs10752365	chr10:15355625	C/T	cg10616319	chr10:15468812	NA	-0.44	-4.28	-0.33	3.3e-5	Selective IgA deficiency;
PAAD	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.51	-5.91	-0.43	2.17e-8	Alcohol dependence;
PAAD	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.74	-0.36	4.86e-6	Mood instability;
PAAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.59	4.79	0.36	4.01e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.93	12.67	0.72	1.46e-25	Prudent dietary pattern;
PAAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.71	7.06	0.5	5.62e-11	Menarche (age at onset);
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07308232	chr7:1071921	C7orf50	-0.64	-7.63	-0.53	2.33e-12	Longevity;Endometriosis;
PAAD	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.35	0.33	2.52e-5	Self-reported allergy;
PAAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	11.16	0.67	1.67e-21	IgG glycosylation;
PAAD	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.96	-0.44	1.67e-8	QT interval;
PAAD	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.73	8.25	0.56	7.15e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-6.95	-0.49	1.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.92	11.98	0.7	1.07e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14008862	chr17:28927542	LRRC37B2	0.77	5.72	0.42	5.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.59	-6.05	-0.44	1.11e-8	Lung function (FVC);
PAAD	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-7.03	-0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.54	-5.37	-0.4	2.91e-7	Schizophrenia;
PAAD	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.5	5.09	0.38	1.03e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24649771	chr6:4892044	CDYL	-0.7	-6.77	-0.48	2.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg22448304	chr2:130323509	NA	0.37	4.36	0.33	2.43e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs35000415	0.938	rs13236009	chr7:128663173	T/G	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs9398803	0.673	rs1262556	chr6:127054435	G/C	cg19875578	chr6:126661172	C6orf173	-0.46	-4.85	-0.37	3.07e-6	Male-pattern baldness;
PAAD	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.71	-7.66	-0.53	2.04e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.07	-0.44	9.58e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs66731853	0.845	rs1253904	chr1:20913519	C/T	cg04087271	chr1:20915334	CDA	-0.56	-6.35	-0.46	2.36e-9	Mean corpuscular volume;
PAAD	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.82	9.56	0.61	2.99e-17	Ulcerative colitis;
PAAD	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	1.03	6.84	0.49	1.8e-10	Gout;Renal underexcretion gout;
PAAD	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.88	10.51	0.65	8.99e-20	Metabolic syndrome;
PAAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.65e-13	Eye color traits;
PAAD	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg27211696	chr2:191398769	TMEM194B	-0.75	-6.65	-0.47	5.06e-10	Diastolic blood pressure;
PAAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.53	-5.44	-0.4	2.07e-7	Body mass index;
PAAD	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs11615916	0.656	rs73139025	chr12:62820569	G/A	cg11441379	chr12:63026424	NA	0.74	4.69	0.36	6.13e-6	Pulmonary function decline;
PAAD	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.45	-0.4	1.95e-7	Blood metabolite levels;
PAAD	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18364779	chr6:26104403	HIST1H4C	0.45	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg14343924	chr8:8086146	FLJ10661	0.55	5.26	0.39	4.91e-7	Joint mobility (Beighton score);
PAAD	cis	rs4356203	0.870	rs214916	chr11:17241649	A/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.65	-0.35	7.3e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg09184832	chr6:79620586	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26549601	chr10:134560360	INPP5A	-0.51	-4.92	-0.37	2.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.99	-0.38	1.62e-6	Bipolar disorder;
PAAD	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs2718812	1.000	rs7626210	chr3:133398099	G/A	cg08439880	chr3:133502540	NA	0.41	4.62	0.35	8.2e-6	Iron status biomarkers;
PAAD	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.57	-0.35	9.87e-6	Type 2 diabetes;
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.38	-5.03	-0.38	1.34e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.51	-4.73	-0.36	4.99e-6	Neuroticism;
PAAD	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg14146966	chr2:61757674	XPO1	0.37	4.47	0.34	1.49e-5	Tuberculosis;
PAAD	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg08886695	chr4:3369023	RGS12	0.47	4.51	0.34	1.27e-5	Parental longevity (mother's age at death);
PAAD	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg03651054	chr13:50194643	NA	0.4	5.42	0.4	2.28e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.08	0.38	1.1e-6	Colorectal cancer;
PAAD	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.49	-4.61	-0.35	8.45e-6	Coronary artery disease;
PAAD	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.4	0.34	2.02e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-7.25	-0.51	1.96e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9810890	1.000	rs73207976	chr3:128569020	C/T	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.99	12.76	0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs4389656	0.857	rs274680	chr5:6749085	T/G	cg10857441	chr5:6722123	POLS	-0.41	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.34	0.51	1.2e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.48	7.04	0.5	6.05e-11	Oropharynx cancer;
PAAD	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg05717871	chr11:638507	DRD4	-0.6	-5.17	-0.39	7.22e-7	Systemic lupus erythematosus;
PAAD	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg25204440	chr1:209979598	IRF6	0.56	4.6	0.35	8.73e-6	Coronary artery disease;
PAAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.61	0.65	4.86e-20	Platelet count;
PAAD	cis	rs818427	0.508	rs10076641	chr5:112057100	T/C	cg06941702	chr5:112196734	SRP19	-0.47	-4.35	-0.33	2.47e-5	Total body bone mineral density;
PAAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg11766577	chr21:47581405	C21orf56	-0.41	-4.66	-0.35	6.75e-6	Testicular germ cell tumor;
PAAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.59	5.36	0.4	3.02e-7	Breast cancer;
PAAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg14709524	chr16:89940631	TCF25	0.73	4.34	0.33	2.6e-5	Skin colour saturation;
PAAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.57	6.61	0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs11833313	1	rs11833313	chr12:110510470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.84	5.03	0.38	1.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6604026	0.656	rs12066638	chr1:93375391	C/G	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs4899260	0.779	rs4899261	chr14:69283375	C/T	cg03189333	chr14:69283534	NA	-0.58	-4.88	-0.37	2.64e-6	Celiac disease;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16167782	chr18:72925371	TSHZ1	-0.53	-5.45	-0.4	1.96e-7	Obesity-related traits;
PAAD	cis	rs71520386	0.632	rs2286500	chr7:22856804	T/C	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.74e-7	Fibrinogen levels;
PAAD	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg24253500	chr15:84953950	NA	0.55	6.52	0.47	9.64e-10	Schizophrenia;
PAAD	cis	rs78707713	1.000	rs78707713	chr10:71245276	T/C	cg12610070	chr10:71211762	TSPAN15	-0.6	-5.58	-0.41	1.05e-7	Venous thromboembolism;
PAAD	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs3206736	0.548	rs328925	chr7:35037327	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.53	-5.02	-0.38	1.42e-6	Mean platelet volume;
PAAD	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.47	4.76	0.36	4.46e-6	Total body bone mineral density;
PAAD	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-4.87	-0.37	2.81e-6	Metabolite levels;
PAAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02725872	chr8:58115012	NA	-0.75	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6681460	0.899	rs502690	chr1:67182403	A/T	cg02459107	chr1:67143332	SGIP1	0.71	6.78	0.48	2.5e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.89	10.08	0.63	1.29e-18	Parkinson's disease;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg13611204	chr9:139324423	INPP5E	-0.56	-4.77	-0.36	4.3e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-5.25	-0.39	4.97e-7	Mean corpuscular volume;
PAAD	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.58	-5.54	-0.41	1.33e-7	Prostate cancer;
PAAD	cis	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs7188861	0.813	rs1974882	chr16:11446480	T/G	cg01510278	chr16:11456238	NA	-0.43	-4.27	-0.33	3.38e-5	HDL cholesterol;
PAAD	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-11.26	-0.67	8.93e-22	Ulcerative colitis;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg25401027	chr5:176370377	UIMC1	0.54	5.39	0.4	2.61e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg18279126	chr7:2041391	MAD1L1	0.56	5.57	0.41	1.11e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.54e-17	White blood cell count (basophil);
PAAD	cis	rs4538187	1.000	rs4671073	chr2:64087270	T/A	cg08613950	chr2:64719184	NA	-0.67	-4.39	-0.34	2.12e-5	Systolic blood pressure;
PAAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg10556349	chr10:835070	NA	0.69	5.25	0.39	5.13e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.69	7.93	0.54	4.36e-13	Height;
PAAD	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13384512	chr1:203602040	ATP2B4	-0.56	-6.29	-0.45	3.25e-9	Monocyte percentage of white cells;
PAAD	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs58521262	0.556	rs771354	chr19:23187905	C/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg04545296	chr12:48745243	ZNF641	0.35	4.33	0.33	2.65e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.55	7.1	0.5	4.38e-11	Childhood ear infection;
PAAD	cis	rs112990264	0.892	rs77836406	chr1:212950410	A/C	cg01785514	chr1:212988523	TATDN3	1.33	8.63	0.57	7.55e-15	Itch intensity from mosquito bite;
PAAD	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.58	5.96	0.44	1.71e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.46	4.76	0.36	4.39e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.55	6.08	0.44	9.51e-9	Type 2 diabetes;
PAAD	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	1.17	17.06	0.81	4e-37	Gut microbiome composition (winter);
PAAD	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23288653	chr1:155145780	TRIM46;KRTCAP2	-0.64	-6.53	-0.47	9.32e-10	Smoking initiation;
PAAD	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg05585544	chr11:47624801	NA	-0.47	-5.16	-0.39	7.52e-7	Subjective well-being;
PAAD	cis	rs10121009	0.587	rs723877	chr9:35407431	A/G	cg11846315	chr9:35647073	NA	-0.49	-4.52	-0.34	1.24e-5	Parkinson's disease;
PAAD	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.69	-4.77	-0.36	4.3e-6	Vitiligo;
PAAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08886695	chr4:3369023	RGS12	-0.49	-4.83	-0.36	3.32e-6	Parental longevity (mother's age at death);
PAAD	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16417436	chr16:28758564	NA	0.45	4.32	0.33	2.79e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.82	5.35	0.4	3.24e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.51	4.6	0.35	8.97e-6	Acylcarnitine levels;
PAAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg23298862	chr7:158159286	PTPRN2	-0.46	-4.26	-0.33	3.56e-5	Calcium levels;
PAAD	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.42	-4.73	-0.36	5.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.78	6.92	0.49	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.71	7.7	0.53	1.59e-12	Lung cancer;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg08219700	chr8:58056026	NA	0.73	5.34	0.4	3.29e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs61861422	0.516	rs12416102	chr10:134456648	G/T	cg27286337	chr10:134555280	INPP5A	0.67	5.87	0.43	2.65e-8	Primary sclerosing cholangitis;
PAAD	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg02135003	chr7:105160482	PUS7	-0.85	-6.68	-0.48	4.22e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.34	5.02	0.38	1.44e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.53	-5.78	-0.42	4.09e-8	Metabolite levels;
PAAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg09065629	chr16:1709722	CRAMP1L	0.47	4.94	0.37	2.07e-6	Coronary artery disease;
PAAD	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.6	-6.35	-0.46	2.42e-9	Coronary artery disease;
PAAD	cis	rs990171	1.000	rs2160232	chr2:103046880	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.8e-5	Lymphocyte counts;
PAAD	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg13010199	chr12:38710504	ALG10B	0.56	5.69	0.42	6.24e-8	Bladder cancer;
PAAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.64	0.42	8.03e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs757081	0.658	rs190046	chr11:17293356	T/C	cg22710661	chr11:17411071	KCNJ11	-0.45	-4.73	-0.36	5.19e-6	Systolic blood pressure;
PAAD	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg14515779	chr1:101123966	NA	0.52	6.59	0.47	6.63e-10	Monocyte count;
PAAD	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg11266682	chr4:10021025	SLC2A9	0.62	5.09	0.38	1.04e-6	Blood metabolite levels;
PAAD	cis	rs59104589	0.583	rs57576464	chr2:242240697	C/T	cg04488487	chr2:242709673	NA	0.57	4.31	0.33	2.9e-5	Fibrinogen levels;
PAAD	cis	rs7260598	0.539	rs13345286	chr19:24069413	T/A	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	5.83	0.43	3.17e-8	Lung cancer in ever smokers;
PAAD	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.5	4.73	0.36	5.09e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.42	0.4	2.33e-7	Height;
PAAD	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.59	-4.56	-0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.58	6.68	0.48	4.3e-10	Major depressive disorder;
PAAD	cis	rs17407555	0.657	rs4698001	chr4:10279413	A/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.14	0.38	8.48e-7	Schizophrenia (age at onset);
PAAD	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.53	5.44	0.4	2.06e-7	Major depressive disorder;
PAAD	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.73	-7.75	-0.53	1.22e-12	Morning vs. evening chronotype;
PAAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14180030	chr9:123475675	MEGF9	-0.46	-5.07	-0.38	1.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs61884328	0.777	rs61897776	chr11:47133419	C/G	cg23433285	chr11:47201945	PACSIN3	0.8	4.27	0.33	3.49e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs1499972	0.591	rs817493	chr3:117696951	G/T	cg07612923	chr3:117604196	NA	-0.97	-5.35	-0.4	3.15e-7	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.28	-0.39	4.3e-7	Lung cancer;
PAAD	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.49	-5.43	-0.4	2.18e-7	Menarche (age at onset);
PAAD	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.85	-8.64	-0.57	7.27e-15	Bipolar disorder;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs62408225	0.748	rs7744528	chr6:90916931	C/G	cg03795776	chr6:90687632	BACH2	0.4	4.32	0.33	2.84e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.2	17.44	0.82	4.33e-38	Total cholesterol levels;
PAAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.01	0.49	7.42e-11	Life satisfaction;
PAAD	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg18132916	chr6:79620363	NA	-0.45	-4.46	-0.34	1.61e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg05110241	chr16:68378359	PRMT7	-0.96	-5.3	-0.39	4.04e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg11204139	chr17:3907470	NA	-0.67	-6.82	-0.48	2.01e-10	Type 2 diabetes;
PAAD	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.64	5.39	0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.67	6.98	0.49	8.58e-11	Mood instability;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.83	0.62	5.96e-18	Prudent dietary pattern;
PAAD	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.56	-5.33	-0.4	3.47e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9640161	0.789	rs68107602	chr7:150054146	C/T	cg27494647	chr7:150038898	RARRES2	0.43	4.44	0.34	1.7e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.71	-7.32	-0.51	1.35e-11	Colorectal cancer;
PAAD	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06850241	chr22:41845214	NA	-0.56	-4.88	-0.37	2.65e-6	Vitiligo;
PAAD	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs7561149	1.000	rs7600330	chr2:179689985	C/G	cg03283842	chr2:179343803	FKBP7;PLEKHA3;MIR548N	0.43	4.29	0.33	3.21e-5	QT interval;
PAAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	1.01	12.81	0.72	5.99e-26	Gestational age at birth (maternal effect);
PAAD	cis	rs10073892	0.830	rs13356480	chr5:101603504	T/A	cg17280723	chr5:101634495	NA	0.44	4.55	0.35	1.1e-5	Cognitive decline (age-related);
PAAD	cis	rs4740619	1.000	rs10756686	chr9:15634646	A/T	cg14451791	chr9:16040625	NA	-0.41	-4.89	-0.37	2.59e-6	Body mass index;
PAAD	cis	rs2455826	0.521	rs4685265	chr3:15896139	T/C	cg13420985	chr3:16524424	RFTN1	-0.45	-4.31	-0.33	2.87e-5	Inflammatory skin disease;
PAAD	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-7.51	-0.52	4.58e-12	Axial length;
PAAD	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.57	-5.81	-0.43	3.56e-8	Pelvic organ prolapse;
PAAD	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.46	4.26	0.33	3.56e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.87	7.42	0.52	7.65e-12	Gastritis;
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg04154034	chr17:28927549	LRRC37B2	0.69	4.34	0.33	2.6e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	14.97	0.77	1.04e-31	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18273818	chr5:5422589	KIAA0947	-0.69	-7.0	-0.49	7.58e-11	Smoking initiation;
PAAD	cis	rs1358748	0.522	rs4655516	chr1:67579882	A/C	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.19	-0.39	6.77e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9646944	0.501	rs3732127	chr2:103013750	G/C	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.44	4.54	0.35	1.15e-5	Response to statin therapy;
PAAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg26513180	chr16:89883248	FANCA	-0.45	-4.59	-0.35	9.23e-6	Vitiligo;
PAAD	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.52	6.89	0.49	1.4e-10	Life satisfaction;
PAAD	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Vitiligo;
PAAD	cis	rs6700896	0.500	rs12024269	chr1:66103674	G/T	cg04111102	chr1:66153794	NA	0.48	4.55	0.35	1.09e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20495540	chr11:30431965	MPPED2	-0.58	-6.4	-0.46	1.78e-9	Obesity-related traits;
PAAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg19413350	chr8:57351067	NA	-0.46	-4.36	-0.33	2.43e-5	Obesity-related traits;
PAAD	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.71e-7	Vitiligo;
PAAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Calcium levels;
PAAD	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.19	0.64	6.57e-19	Monocyte percentage of white cells;
PAAD	cis	rs11105468	0.701	rs7964216	chr12:90396480	C/T	cg16962463	chr12:89968675	NA	-0.48	-4.57	-0.35	1.02e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.59	-0.41	1.05e-7	Urate levels in overweight individuals;
PAAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	cis	rs3784262	0.740	rs1372369	chr15:58294381	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.51	-5.95	-0.43	1.78e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.6	6.34	0.46	2.43e-9	Caffeine consumption;
PAAD	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15369054	chr17:80825471	TBCD	-0.62	-5.24	-0.39	5.36e-7	Breast cancer;
PAAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg15181151	chr6:150070149	PCMT1	0.61	6.78	0.48	2.47e-10	Lung cancer;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg26513180	chr16:89883248	FANCA	-0.58	-6.61	-0.47	6.08e-10	Vitiligo;
PAAD	cis	rs427691	0.536	rs25916	chr5:108992465	A/G	cg17395555	chr5:108820864	NA	0.39	4.5	0.34	1.36e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg04089426	chr11:65307791	LTBP3	1.08	5.14	0.38	8.45e-7	Height;
PAAD	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-6.36	-0.46	2.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs367943	0.666	rs10051834	chr5:112693803	C/T	cg12552261	chr5:112820674	MCC	0.64	6.36	0.46	2.23e-9	Type 2 diabetes;
PAAD	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg22587600	chr2:46883368	NA	0.34	4.6	0.35	8.66e-6	Height;
PAAD	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14180030	chr9:123475675	MEGF9	-0.44	-4.99	-0.38	1.65e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg25837213	chr17:80849375	TBCD	-0.56	-4.6	-0.35	8.94e-6	Breast cancer;
PAAD	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.43	-6.36	-0.46	2.23e-9	Subjective well-being;
PAAD	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg12395012	chr8:11607386	GATA4	-0.42	-4.61	-0.35	8.55e-6	Myopia (pathological);
PAAD	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-11.37	-0.68	4.54e-22	Cognitive function;
PAAD	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02266452	chr11:82905235	ANKRD42	-0.72	-6.3	-0.46	3.09e-9	Neuroticism;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg16590910	chr6:42928470	GNMT	0.5	5.14	0.38	8.22e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.85	8.84	0.58	2.27e-15	Lymphocyte counts;
PAAD	cis	rs55823223	0.648	rs9894383	chr17:73865657	T/G	cg10935138	chr17:73851978	WBP2	0.91	7.6	0.52	2.9e-12	Psoriasis;
PAAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.76	-7.87	-0.54	6.34e-13	Prostate cancer;
PAAD	cis	rs76866386	0.892	rs114938914	chr2:44055510	C/T	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.31	-0.4	3.74e-7	Cholesterol, total;
PAAD	cis	rs58521262	0.556	rs396653	chr19:23121284	A/C	cg22640819	chr19:22990650	NA	-0.29	-4.4	-0.34	2.02e-5	Testicular germ cell tumor;
PAAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg18769074	chr3:133464867	TF	0.42	4.88	0.37	2.69e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg20169779	chr10:135381914	SYCE1	-0.46	-4.77	-0.36	4.24e-6	Obesity-related traits;
PAAD	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.6	-6.29	-0.45	3.24e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.97	-11.66	-0.69	7.46e-23	Cognitive function;
PAAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg14631576	chr9:95140430	CENPP	-0.53	-5.22	-0.39	5.77e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg11900509	chr10:81946545	ANXA11	-0.61	-4.27	-0.33	3.38e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs11794666	0.929	rs113129703	chr9:31657407	T/C	cg05628366	chr6:35744188	C6orf126	1.0	6.36	0.46	2.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg00750074	chr16:89608354	SPG7	-0.47	-4.58	-0.35	9.77e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-4.45	-0.34	1.63e-5	Monocyte count;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.58	-5.15	-0.39	7.98e-7	Mean corpuscular volume;
PAAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.91e-13	Response to antipsychotic treatment;
PAAD	cis	rs2526932	1.000	rs2526933	chr14:73080440	C/G	cg13588403	chr14:73209128	DPF3	0.45	5.62	0.41	8.98e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.1	0.59	4.79e-16	Motion sickness;
PAAD	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.65	6.39	0.46	1.93e-9	Corneal astigmatism;
PAAD	cis	rs2555155	0.697	rs10839566	chr11:6484487	G/A	cg24637308	chr11:6592297	DNHD1	0.43	4.58	0.35	9.73e-6	DNA methylation (variation);
PAAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg05861140	chr6:150128134	PCMT1	-0.54	-6.19	-0.45	5.21e-9	Lung cancer;
PAAD	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	1.04	14.81	0.77	2.69e-31	Metabolite levels;
PAAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.85	4.37	0.33	2.31e-5	Plasma clusterin levels;
PAAD	cis	rs12138061	0.859	rs12407318	chr1:50380088	C/T	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.48	-0.34	1.48e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg02463844	chr16:88152170	NA	0.29	4.8	0.36	3.76e-6	Menopause (age at onset);
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.19e-10	Lymphocyte counts;
PAAD	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg14784868	chr12:69753453	YEATS4	0.53	4.47	0.34	1.51e-5	Response to diuretic therapy;
PAAD	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.49	5.86	0.43	2.75e-8	Sitting height ratio;
PAAD	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg20893579	chr22:38215064	NA	0.5	4.68	0.35	6.26e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg20913747	chr6:44695427	NA	-0.72	-7.25	-0.51	1.93e-11	Total body bone mineral density;
PAAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	6.75	0.48	2.97e-10	Lymphocyte counts;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.9	-10.59	-0.65	5.48e-20	Menarche (age at onset);
PAAD	cis	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg21546286	chr11:48923668	NA	0.59	6.14	0.45	7.05e-9	HDL cholesterol;
PAAD	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-9.13	-0.6	3.88e-16	Dental caries;
PAAD	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg06057569	chr22:50219754	BRD1	0.59	4.3	0.33	3.1e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9346353	0.737	rs3947930	chr6:70508320	C/T	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.36	-0.33	2.4e-5	Sleep duration;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12539128	chr2:71222296	TEX261	-0.79	-6.72	-0.48	3.35e-10	Neuroticism;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.25	-0.45	3.9e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs17155006	0.601	rs382131	chr7:107733289	G/C	cg05962710	chr7:107745446	LAMB4	-0.45	-5.58	-0.41	1.09e-7	Pneumococcal bacteremia;
PAAD	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.78e-6	Lung cancer;
PAAD	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.59	5.89	0.43	2.39e-8	Red blood cell count;
PAAD	cis	rs1359582	0.767	rs10749593	chr10:90374057	A/G	cg15661332	chr10:90342814	RNLS	-0.55	-4.86	-0.37	2.95e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00982548	chr2:198649783	BOLL	-0.73	-5.15	-0.39	8.11e-7	Ulcerative colitis;
PAAD	cis	rs8037137	1.000	rs8037137	chr15:91506637	T/C	cg23684204	chr15:91497937	RCCD1	0.69	4.57	0.35	1e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs72843506	0.586	rs75721433	chr17:19882060	C/G	cg05625806	chr17:19284432	MAPK7	0.66	4.29	0.33	3.13e-5	Schizophrenia;
PAAD	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.57	-6.24	-0.45	4.04e-9	Longevity;
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.98	-0.44	1.57e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.72	-4.35	-0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg11619707	chr19:22235551	ZNF257	0.59	5.89	0.43	2.34e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg15440763	chr7:158190612	PTPRN2	0.47	4.63	0.35	7.86e-6	Obesity-related traits;
PAAD	cis	rs10073892	0.703	rs9327823	chr5:101638067	G/A	cg17280723	chr5:101634495	NA	0.41	4.41	0.34	1.98e-5	Cognitive decline (age-related);
PAAD	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg19949948	chr17:19361230	NA	-0.43	-4.54	-0.35	1.13e-5	Schizophrenia;
PAAD	cis	rs3743832	1.000	rs7185995	chr16:9214831	G/T	cg08831531	chr16:9218945	NA	-0.4	-4.25	-0.33	3.68e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg26935685	chr1:15502881	TMEM51	-0.53	-4.46	-0.34	1.58e-5	Systolic blood pressure;
PAAD	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.43	10.05	0.63	1.57e-18	Atopic dermatitis;
PAAD	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1318772	1.000	rs67344014	chr5:112687127	A/C	cg12552261	chr5:112820674	MCC	0.61	4.48	0.34	1.44e-5	F-cell distribution;
PAAD	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	1.2	11.77	0.69	3.74e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg07148914	chr20:33460835	GGT7	-0.5	-4.71	-0.36	5.58e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.49	-0.47	1.16e-9	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.86	-7.89	-0.54	5.62e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.77	0.53	1.12e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12550646	0.600	rs10089948	chr8:41672453	C/T	cg12180191	chr8:41686706	ANK1	0.46	4.52	0.34	1.21e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg10137597	chr8:22132714	PIWIL2	0.5	5.97	0.44	1.6e-8	Hypertriglyceridemia;
PAAD	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs72627123	1.000	rs2302139	chr14:74362935	A/C	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.89	10.87	0.66	1.01e-20	Prudent dietary pattern;
PAAD	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.54	-0.35	1.13e-5	Height;
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.92	-7.05	-0.5	5.83e-11	Initial pursuit acceleration;
PAAD	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	1.35	7.93	0.54	4.29e-13	Corneal curvature;
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11638815	0.626	rs1367841	chr15:83310625	A/G	cg00614314	chr15:82944287	LOC80154	-0.45	-4.52	-0.34	1.24e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg22437258	chr11:111473054	SIK2	-0.51	-4.97	-0.37	1.79e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.86	-5.99	-0.44	1.49e-8	Coronary artery disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15921797	chr8:133797018	PHF20L1	-0.71	-6.46	-0.46	1.33e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4704187	0.687	rs10035303	chr5:74505495	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	7.49	0.52	5.3e-12	Personality dimensions;
PAAD	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg24585817	chr7:64895279	NA	0.44	4.47	0.34	1.49e-5	Aortic root size;
PAAD	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg02250501	chr15:90694978	NA	0.49	4.28	0.33	3.34e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg06484146	chr7:12443880	VWDE	-0.85	-5.63	-0.42	8.58e-8	Coronary artery disease;
PAAD	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.21e-7	Mean platelet volume;
PAAD	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.6	5.23	0.39	5.5e-7	Obesity-related traits;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.42	4.34	0.33	2.59e-5	Breast cancer;
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg04267008	chr7:1944627	MAD1L1	0.76	7.91	0.54	4.93e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs593531	0.513	rs7944333	chr11:74022429	C/T	cg23327896	chr11:73669290	DNAJB13	0.33	4.37	0.33	2.32e-5	Neuroticism;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.73	-7.23	-0.51	2.19e-11	Retinal vascular caliber;
PAAD	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.25	0.33	3.67e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7084783	0.967	rs10786758	chr10:105326081	T/A	cg00126946	chr10:105363258	SH3PXD2A	0.45	4.72	0.36	5.33e-6	Fear of pain;
PAAD	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.41	-4.69	-0.36	5.94e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs55986470	0.763	rs6713788	chr2:239456932	T/A	cg18131467	chr2:239335373	ASB1	-0.64	-4.58	-0.35	9.72e-6	Chronotype;
PAAD	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.76	6.02	0.44	1.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg17646820	chr3:66848679	NA	0.42	4.4	0.34	1.99e-5	Type 2 diabetes;
PAAD	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg27205649	chr11:78285834	NARS2	0.58	4.42	0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.73e-9	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23306295	chr11:64684703	ATG2A	-0.54	-6.32	-0.46	2.75e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg16898833	chr6:26189333	HIST1H4D	0.9	6.25	0.45	3.93e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-7.55	-0.52	3.85e-12	Neuroticism;
PAAD	cis	rs11807834	0.522	rs880329	chr1:230246886	G/A	cg00566187	chr1:230250356	GALNT2	-0.66	-7.05	-0.5	5.72e-11	Schizophrenia;
PAAD	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.78	-7.15	-0.5	3.39e-11	Homoarginine levels;
PAAD	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-5.67	-0.42	7.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.63	7.38	0.51	9.54e-12	Lung cancer;
PAAD	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg09796270	chr17:17721594	SREBF1	0.46	5.02	0.38	1.4e-6	Total body bone mineral density;
PAAD	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.75	7.49	0.52	5.37e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg01426195	chr3:39028469	NA	0.6	5.87	0.43	2.6e-8	Handedness;
PAAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22482690	chr17:47019901	SNF8	0.49	5.25	0.39	5.01e-7	Type 2 diabetes;
PAAD	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.43	-4.59	-0.35	9.35e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg24154853	chr7:158122151	PTPRN2	0.71	7.43	0.52	7.43e-12	Calcium levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20241567	chr6:52529024	LOC730101	0.6	6.69	0.48	4.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-6.72	-0.48	3.52e-10	Testicular germ cell tumor;
PAAD	cis	rs6750047	0.516	rs458704	chr2:38318134	G/A	cg19753864	chr2:38320028	NA	0.44	4.94	0.37	2.02e-6	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.47	-0.34	1.51e-5	Systemic lupus erythematosus;
PAAD	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs11958404	0.929	rs80162289	chr5:157354639	T/C	cg05962755	chr5:157440814	NA	1.0	6.3	0.45	3.13e-9	IgG glycosylation;
PAAD	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.35	4.45	0.34	1.65e-5	Body mass index in non-asthmatics;
PAAD	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.24	-0.51	2.06e-11	Triglycerides;
PAAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.78	10.25	0.64	4.69e-19	Breast cancer;
PAAD	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.91	4.6	0.35	8.95e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19346786	chr7:2764209	NA	-0.32	-4.37	-0.33	2.33e-5	Height;
PAAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.21	12.3	0.71	1.45e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.73	7.27	0.51	1.75e-11	Schizophrenia;
PAAD	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.75	0.48	2.87e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs17169634	0.557	rs80053578	chr7:34085632	C/T	cg24927974	chr7:35078269	DPY19L1	-0.64	-4.81	-0.36	3.62e-6	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-5.58	-0.41	1.06e-7	Prudent dietary pattern;
PAAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.52	5.1	0.38	9.77e-7	Mean corpuscular volume;
PAAD	cis	rs12799172	0.688	rs3116383	chr11:6840063	G/A	cg23386594	chr11:6866523	OR10A5	0.41	4.25	0.33	3.71e-5	Periodontal disease-related phenotypes;
PAAD	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg14356550	chr1:18808102	KLHDC7A	-0.56	-6.11	-0.44	7.81e-9	Breast cancer;
PAAD	cis	rs66530629	0.874	rs4562565	chr1:25121874	A/G	cg01905478	chr1:25040257	NA	-0.48	-5.2	-0.39	6.4e-7	Plateletcrit;
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.62	-5.82	-0.43	3.41e-8	Blood metabolite levels;
PAAD	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg00540400	chr15:79124168	NA	-0.59	-6.94	-0.49	1.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg00738919	chr7:1100172	C7orf50	0.75	5.71	0.42	5.64e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.24	0.7	2.14e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11811982	0.793	rs78944317	chr1:227307861	A/T	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.53	5.85	0.43	2.98e-8	Major depressive disorder;
PAAD	cis	rs59191668	0.594	rs2165559	chr15:62832775	G/T	cg12918536	chr15:62891943	NA	0.36	4.97	0.37	1.79e-6	Immature fraction of reticulocytes;
PAAD	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.84	8.22	0.55	8.17e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs16975963	0.644	rs73033145	chr19:38097313	T/G	cg08679971	chr19:38281047	NA	0.47	4.6	0.35	8.98e-6	Longevity;
PAAD	cis	rs1419980	0.730	rs57772215	chr12:7746385	A/G	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.61	-5.66	-0.42	7.16e-8	Primary biliary cholangitis;
PAAD	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg15764593	chr10:829463	NA	-0.82	-4.54	-0.35	1.13e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.57	-6.51	-0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.54	4.65	0.35	7.24e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.8	8.58	0.57	1.05e-14	Caffeine consumption;
PAAD	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.94	10.34	0.64	2.58e-19	Breast cancer;
PAAD	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.47	-4.74	-0.36	4.88e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.96	12.51	0.71	3.94e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-11.54	-0.68	1.58e-22	Cognitive function;
PAAD	cis	rs7187994	0.848	rs12920732	chr16:84780613	C/T	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs876084	0.545	rs10096311	chr8:121102031	A/G	cg06265175	chr8:121136014	COL14A1	0.48	4.69	0.36	6.02e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg02153855	chr1:11041070	C1orf127	-0.34	-4.3	-0.33	3.05e-5	Hepatocellular carcinoma;
PAAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	8.85	0.58	2.13e-15	Monocyte percentage of white cells;
PAAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.8	8.09	0.55	1.8e-13	Blood protein levels;
PAAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-5.32	-0.4	3.66e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14180030	chr9:123475675	MEGF9	-0.4	-4.38	-0.33	2.22e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.68	5.82	0.43	3.38e-8	Diabetic retinopathy;
PAAD	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.57	5.68	0.42	6.69e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg05110241	chr16:68378359	PRMT7	-1.16	-8.17	-0.55	1.14e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.98	-0.44	1.54e-8	Cystic fibrosis severity;
PAAD	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.6	6.32	0.46	2.71e-9	Testicular germ cell tumor;
PAAD	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg08036796	chr19:5034282	KDM4B	0.46	4.44	0.34	1.7e-5	Monocyte percentage of white cells;
PAAD	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg21269045	chr12:125625041	AACS	-0.47	-4.72	-0.36	5.24e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.66	6.44	0.46	1.48e-9	Morning vs. evening chronotype;
PAAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.97	8.48	0.57	1.85e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.66	-5.22	-0.39	5.72e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2092319	0.649	rs2786875	chr1:26061266	C/A	cg02327719	chr1:26185386	C1orf135	-0.85	-4.9	-0.37	2.4e-6	Nose morphology;
PAAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.42e-17	Longevity (90 years and older);
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg23096020	chr7:158799433	NA	-0.45	-4.29	-0.33	3.2e-5	Facial morphology (factor 20);
PAAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.52	-5.35	-0.4	3.23e-7	Number of children ever born;
PAAD	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg24098013	chr12:12878779	APOLD1	-0.54	-5.42	-0.4	2.25e-7	Birth weight;
PAAD	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.65	7.05	0.5	5.8e-11	Obesity-related traits;
PAAD	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg24110177	chr3:50126178	RBM5	-0.57	-4.54	-0.35	1.15e-5	Menarche (age at onset);
PAAD	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg10820045	chr2:198174542	NA	0.51	5.08	0.38	1.1e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.58	5.84	0.43	3.01e-8	Menopause (age at onset);
PAAD	cis	rs758324	0.812	rs2133706	chr5:131165216	T/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.75	8.4	0.56	2.94e-14	Breast cancer;
PAAD	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.46	4.77	0.36	4.32e-6	Hirschsprung disease;
PAAD	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs1879734	0.731	rs11206197	chr1:54165831	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg14146966	chr2:61757674	XPO1	0.39	4.8	0.36	3.72e-6	Tuberculosis;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg13047869	chr3:10149882	C3orf24	0.63	5.52	0.41	1.44e-7	Alzheimer's disease;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.63	0.82	1.42e-38	Height;
PAAD	trans	rs9372498	0.908	rs3851206	chr6:118579100	C/T	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs7953249	0.773	rs7979478	chr12:121420263	A/G	cg02403541	chr12:121454288	C12orf43	-0.47	-4.92	-0.37	2.2e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg16558253	chr16:72132732	DHX38	-0.69	-4.58	-0.35	9.67e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.01	-0.44	1.33e-8	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05064645	chr7:55086868	EGFR	-0.63	-7.31	-0.51	1.41e-11	Body fat percentage;
PAAD	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg08897044	chr19:12950850	MAST1	0.36	4.77	0.36	4.23e-6	Mean corpuscular volume;
PAAD	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs469727	0.554	rs153561	chr5:112253133	A/G	cg06941702	chr5:112196734	SRP19	0.5	4.7	0.36	5.79e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.47	4.36	0.33	2.39e-5	Airway imaging phenotypes;
PAAD	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-8.16	-0.55	1.19e-13	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19889017	chr2:162095095	NA	0.65	7.41	0.52	8.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.64	6.88	0.49	1.5e-10	N-glycan levels;
PAAD	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.22	21.24	0.86	2.36e-47	Testicular germ cell tumor;
PAAD	cis	rs2124910	1.000	rs7249285	chr19:52025948	G/A	cg12008991	chr19:52034861	SIGLEC6	0.35	4.58	0.35	9.47e-6	Blood protein levels;
PAAD	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.75	-8.87	-0.58	1.89e-15	Body mass index;
PAAD	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg09659197	chr4:152720779	NA	0.42	5.51	0.41	1.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.65	5.66	0.42	7.35e-8	Resistin levels;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.8	-9.24	-0.6	2e-16	Sudden cardiac arrest;
PAAD	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.78e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg19254793	chr6:44695348	NA	-0.46	-4.41	-0.34	1.94e-5	Total body bone mineral density;
PAAD	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.27e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07415687	chr6:7910841	TXNDC5	0.69	7.31	0.51	1.38e-11	Obesity-related traits;
PAAD	cis	rs6066835	0.702	rs6095229	chr20:47283774	C/T	cg18078177	chr20:47281410	PREX1	1.16	5.48	0.41	1.72e-7	Multiple myeloma;
PAAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg04632378	chr13:21900426	NA	0.69	7.63	0.53	2.37e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.65	-7.25	-0.51	2.02e-11	Longevity;Endometriosis;
PAAD	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.47	4.78	0.36	4.18e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs11677416	0.601	rs12469600	chr2:113572357	T/C	cg27083787	chr2:113543245	IL1A	0.47	4.36	0.33	2.38e-5	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.83	7.52	0.52	4.51e-12	Homoarginine levels;
PAAD	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg27511599	chr7:32358540	NA	-0.76	-4.41	-0.34	1.92e-5	Body mass index;
PAAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg24733560	chr20:60626293	TAF4	0.45	5.5	0.41	1.58e-7	Body mass index;
PAAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.17	-16.7	-0.8	3.33e-36	Cognitive function;
PAAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2456568	0.808	rs2008041	chr11:93686002	C/T	cg19264203	chr11:92714893	MTNR1B	0.38	4.44	0.34	1.73e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg20487152	chr13:99095054	FARP1	0.6	5.26	0.39	4.78e-7	Neuroticism;
PAAD	cis	rs3764400	0.508	rs72823528	chr17:46098944	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.2	0.39	6.4e-7	Body mass index;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-5.27	-0.39	4.6e-7	Height;
PAAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.53	5.66	0.42	7.18e-8	Tumor biomarkers;
PAAD	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.53	-4.85	-0.37	3.01e-6	DNA methylation (variation);
PAAD	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg17509989	chr5:176798049	RGS14	0.79	7.61	0.53	2.71e-12	Urate levels in lean individuals;
PAAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.07e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs911119	0.955	rs8116859	chr20:23590703	A/T	cg16589663	chr20:23618590	CST3	0.79	6.91	0.49	1.26e-10	Chronic kidney disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12463100	chr10:71906585	TYSND1	-0.71	-6.41	-0.46	1.77e-9	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06786424	chr6:4021316	PRPF4B	-0.64	-6.34	-0.46	2.43e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01616529	chr11:638424	DRD4	-0.59	-5.84	-0.43	3.06e-8	Systemic lupus erythematosus;
PAAD	cis	rs6499755	0.965	rs2042448	chr16:55352063	G/A	cg02859129	chr16:55357253	IRX6	0.34	4.55	0.35	1.07e-5	Hypospadias;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.76	-8.45	-0.57	2.15e-14	Monocyte percentage of white cells;
PAAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-5.89	-0.43	2.36e-8	Menarche (age at onset);
PAAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.44	0.4	2.05e-7	Total body bone mineral density;
PAAD	cis	rs6594713	0.851	rs10038521	chr5:112693668	T/A	cg12552261	chr5:112820674	MCC	0.64	5.15	0.39	7.93e-7	Brain cytoarchitecture;
PAAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg09654669	chr8:57350985	NA	-0.57	-5.13	-0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-4.76	-0.36	4.39e-6	Total body bone mineral density;
PAAD	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.64	7.05	0.5	5.74e-11	Corneal astigmatism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26790818	chr3:187786456	NA	0.56	6.32	0.46	2.7e-9	Smoking initiation;
PAAD	cis	rs12304921	0.748	rs56847302	chr12:51506876	G/A	cg18059802	chr12:51347058	HIGD1C	-0.64	-5.03	-0.38	1.34e-6	Type 2 diabetes;
PAAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.58	7.41	0.51	8.31e-12	Hypertriglyceridemia;
PAAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.56	-5.48	-0.41	1.76e-7	Obesity-related traits;
PAAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.81	8.46	0.57	2.05e-14	Cognitive function;
PAAD	cis	rs757081	0.648	rs7108315	chr11:17267164	C/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.77	-0.42	4.21e-8	Systolic blood pressure;
PAAD	cis	rs2073300	1.000	rs2073300	chr20:23471681	T/G	cg12062639	chr20:23401060	NAPB	0.92	4.39	0.34	2.12e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2147904	0.866	rs1886729	chr1:42363966	G/A	cg16685388	chr1:42384056	HIVEP3	0.4	4.75	0.36	4.64e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.98	6.65	0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.55	4.38	0.33	2.23e-5	Schizophrenia;
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg02841227	chr6:26021843	HIST1H4A	0.54	5.51	0.41	1.51e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg23241863	chr10:102295624	HIF1AN	0.48	4.37	0.33	2.33e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs951266	0.505	rs12902602	chr15:78967401	A/G	cg00540400	chr15:79124168	NA	-0.45	-5.12	-0.38	9.28e-7	Post bronchodilator FEV1/FVC ratio in COPD;Pre bronchodilator FEV1;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.4	4.49	0.34	1.39e-5	Breast cancer;
PAAD	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	1.05	6.7	0.48	3.87e-10	Obesity (early onset extreme);
PAAD	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.79	9.32	0.6	1.29e-16	Eye color traits;
PAAD	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs863345	0.967	rs11264990	chr1:158469359	T/C	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.74	7.57	0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.52	4.77	0.36	4.27e-6	Schizophrenia;
PAAD	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg21253087	chr9:139290292	SNAPC4	0.45	4.38	0.33	2.2e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.56	6.25	0.45	3.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1075265	0.783	rs805359	chr2:54162454	A/T	cg04546899	chr2:54196757	PSME4	0.33	4.85	0.37	2.97e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.92	-7.91	-0.54	4.97e-13	Dupuytren's disease;
PAAD	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-4.25	-0.33	3.65e-5	IFN-related cytopenia;
PAAD	trans	rs62179067	0.708	rs62175986	chr2:179876509	A/G	cg22159514	chr19:11591185	ELAVL3	-0.74	-6.3	-0.46	3.12e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.03	9.29	0.6	1.49e-16	Gut microbiome composition (summer);
PAAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.83	-0.69	2.61e-23	Blood pressure (smoking interaction);
PAAD	cis	rs9462027	0.607	rs205259	chr6:34564066	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.38	-4.53	-0.35	1.18e-5	Systemic lupus erythematosus;
PAAD	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	6.14	0.45	6.86e-9	Menopause (age at onset);
PAAD	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.15	-0.64	8.2e-19	Response to antipsychotic treatment;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.45e-8	Prudent dietary pattern;
PAAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.65	-0.35	7.05e-6	Type 2 diabetes;
PAAD	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.53	-5.47	-0.41	1.77e-7	Schizophrenia;
PAAD	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg15130565	chr3:61546275	PTPRG	0.56	6.57	0.47	7.36e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1113500	0.541	rs9803640	chr1:108576267	A/C	cg06207961	chr1:108661230	NA	-0.47	-4.92	-0.37	2.25e-6	Growth-regulated protein alpha levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07955088	chr16:3073752	HCFC1R1;THOC6	0.67	6.77	0.48	2.6e-10	Obesity-related traits;
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg17346650	chr17:80929145	B3GNTL1	0.35	4.68	0.35	6.43e-6	Glycated hemoglobin levels;
PAAD	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.76	-0.36	4.56e-6	Daytime sleep phenotypes;
PAAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg07559730	chr19:53497048	ZNF702P	-0.47	-4.87	-0.37	2.8e-6	Psoriasis;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.56	5.46	0.41	1.86e-7	Menarche (age at onset);
PAAD	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg20129853	chr10:51489980	NA	-0.44	-4.5	-0.34	1.34e-5	Prostate-specific antigen levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18025976	chr4:74124864	ANKRD17	-0.59	-6.69	-0.48	4.07e-10	Body fat percentage;
PAAD	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.97	11.58	0.68	1.27e-22	Breast cancer;
PAAD	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-4.76	-0.36	4.38e-6	IgG glycosylation;
PAAD	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs12431939	1.000	rs57212982	chr14:51656464	A/G	cg23942311	chr14:51606299	NA	-0.62	-5.13	-0.38	8.55e-7	Cancer;
PAAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.63	-7.73	-0.53	1.38e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.81	0.48	2.08e-10	Exhaled nitric oxide levels;
PAAD	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	6.88	0.49	1.48e-10	Hip circumference;
PAAD	cis	rs885814	1.000	rs17455136	chr1:21862253	T/G	cg11834658	chr1:21611224	ECE1	-0.51	-4.33	-0.33	2.67e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
PAAD	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.99	-10.33	-0.64	2.87e-19	Platelet distribution width;
PAAD	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg22153407	chr1:230290089	GALNT2	0.49	5.0	0.38	1.55e-6	Coronary artery disease;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21016266	chr12:122356598	WDR66	0.65	6.91	0.49	1.24e-10	Mean corpuscular volume;
PAAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.47	-0.34	1.49e-5	Glomerular filtration rate;
PAAD	cis	rs12122100	0.651	rs12127461	chr1:146551888	C/G	cg19022274	chr1:146715514	CHD1L	-0.56	-4.29	-0.33	3.22e-5	HIV-1 control;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.82	0.58	2.54e-15	Lung cancer;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.72	8.06	0.55	2.08e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.84	-9.49	-0.61	4.54e-17	Body mass index;
PAAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-4.84	-0.37	3.15e-6	Subjective well-being;
PAAD	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg15764593	chr10:829463	NA	0.74	5.94	0.43	1.89e-8	Uric acid levels;
PAAD	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg15956490	chr3:53032818	SFMBT1	-0.71	-4.45	-0.34	1.67e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.93	6.82	0.48	2e-10	Schizophrenia;
PAAD	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg11779900	chr17:80519722	FOXK2	-0.49	-5.02	-0.38	1.41e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	0.98	9.07	0.59	5.78e-16	Monocyte percentage of white cells;
PAAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg02696790	chr15:75250997	RPP25	0.44	5.05	0.38	1.25e-6	Breast cancer;
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.15	0.39	7.96e-7	Prostate cancer;
PAAD	cis	rs2415984	0.579	rs2255935	chr14:46964271	A/G	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24984301	chr12:120032790	TMEM233	0.56	6.38	0.46	1.98e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.84	-9.57	-0.61	2.85e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs818427	0.795	rs454968	chr5:112188456	T/C	cg07820702	chr5:112228657	REEP5	0.51	4.64	0.35	7.36e-6	Total body bone mineral density;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.57	-5.98	-0.44	1.51e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.74	4.71	0.36	5.5e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs11167764	0.623	rs62384602	chr5:141477685	T/G	cg23435118	chr5:141488016	NDFIP1	0.52	4.48	0.34	1.48e-5	Crohn's disease;
PAAD	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	1.17	13.57	0.74	5.41e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.9	6.4	0.46	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.47	4.45	0.34	1.62e-5	Breast cancer;
PAAD	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-7.8	-0.53	9.01e-13	Coffee consumption (cups per day);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08679808	chr17:79886116	LOC92659;MAFG	0.56	6.32	0.46	2.81e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.64	5.42	0.4	2.26e-7	Gut microbiome composition (summer);
PAAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs41563	0.609	rs4727614	chr7:104600854	C/A	cg04380332	chr7:105027541	SRPK2	-0.63	-6.5	-0.47	1.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7523050	0.908	rs72697202	chr1:109398704	A/G	cg08274380	chr1:109419600	GPSM2	0.76	5.38	0.4	2.72e-7	Fat distribution (HIV);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03861593	chr6:108881876	FOXO3	0.64	6.55	0.47	8.35e-10	Obesity-related traits;
PAAD	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.53	-5.58	-0.41	1.1e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.75	-8.28	-0.56	5.79e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.67	7.02	0.49	6.86e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg23127183	chr11:57508653	C11orf31	-0.51	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs787274	1.000	rs7038684	chr9:115601431	A/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.73	6.49	0.47	1.15e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg06360820	chr2:242988706	NA	-1.36	-10.26	-0.64	4.41e-19	Obesity-related traits;
PAAD	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.65	5.45	0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.43	0.68	3.16e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19201894	chr2:27439765	C2orf28;CAD	-0.71	-7.47	-0.52	5.83e-12	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs4660306	0.677	rs11211110	chr1:45904815	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-4.66	-0.35	6.8e-6	Homocysteine levels;
PAAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg22338127	chr1:209979572	IRF6	0.53	4.34	0.33	2.55e-5	Coronary artery disease;
PAAD	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.79	0.42	3.98e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9900972	0.549	rs11077399	chr17:76864175	C/T	cg20937029	chr17:76870563	TIMP2	-0.4	-4.3	-0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.56	-5.84	-0.43	3.04e-8	IgG glycosylation;
PAAD	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.65	-0.35	7.21e-6	Neuroticism;
PAAD	cis	rs6708413	0.501	rs2075189	chr2:103118689	C/G	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06850241	chr22:41845214	NA	-0.45	-4.27	-0.33	3.48e-5	Vitiligo;
PAAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg14709524	chr16:89940631	TCF25	0.75	4.36	0.33	2.42e-5	Skin colour saturation;
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg27121462	chr16:89883253	FANCA	0.47	5.06	0.38	1.18e-6	Vitiligo;
PAAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.8	0.43	3.71e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14258857	chr14:105612971	JAG2	-0.68	-6.66	-0.48	4.66e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.69	-8.1	-0.55	1.69e-13	Coronary artery disease;
PAAD	cis	rs976337	0.609	rs10831330	chr11:95023580	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	4.34	0.33	2.6e-5	Positive affect;
PAAD	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.02	-0.38	1.41e-6	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg23024343	chr7:107201750	COG5	-0.55	-4.62	-0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.07	-0.5	5.22e-11	Life satisfaction;
PAAD	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg12568669	chr8:11666485	FDFT1	-0.3	-5.08	-0.38	1.09e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.52	0.34	1.24e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.74	6.23	0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2717559	0.515	rs55720963	chr8:143895957	T/A	cg02415014	chr8:143852576	LYNX1	0.43	5.65	0.42	7.65e-8	Urinary tract infection frequency;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20064151	chr1:145438865	TXNIP	-0.67	-6.55	-0.47	8.34e-10	Lung cancer in ever smokers;
PAAD	cis	rs1561176	0.830	rs11762624	chr7:154990360	C/T	cg08570118	chr7:155025533	NA	-0.47	-4.42	-0.34	1.86e-5	Personality dimensions;
PAAD	trans	rs9393777	0.920	rs34196306	chr6:27425644	G/C	cg06606381	chr12:133084897	FBRSL1	-1.41	-8.56	-0.57	1.14e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs10214930	0.697	rs12665991	chr7:27659771	A/G	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.85	9.07	0.59	5.81e-16	Calcium levels;
PAAD	cis	rs6466055	0.552	rs4727618	chr7:104662862	G/A	cg04380332	chr7:105027541	SRPK2	-0.48	-4.58	-0.35	9.79e-6	Schizophrenia;
PAAD	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.4	3.02e-7	Vitiligo;
PAAD	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.87	-9.08	-0.59	5.3e-16	DNA methylation (variation);
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.89	11.23	0.67	1.07e-21	Prudent dietary pattern;
PAAD	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-6.09	-0.44	9.05e-9	Hypospadias;
PAAD	cis	rs7818688	0.697	rs77055525	chr8:95980583	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.72	8.05	0.55	2.16e-13	Colorectal cancer;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23158103	chr7:148848205	ZNF398	-0.62	-6.12	-0.44	7.47e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg16590910	chr6:42928470	GNMT	0.54	5.34	0.4	3.29e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.6	-0.52	2.82e-12	Calcium levels;
PAAD	cis	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg27395922	chr11:50257633	LOC441601	-0.42	-4.58	-0.35	9.55e-6	Coronary artery disease;
PAAD	cis	rs1345301	0.518	rs1035131	chr2:102862641	A/C	cg03938978	chr2:103052716	IL18RAP	-0.43	-4.65	-0.35	7.08e-6	Waist circumference;
PAAD	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.87	-11.89	-0.69	1.79e-23	Height;
PAAD	cis	rs17669535	0.551	rs17747701	chr8:1248400	G/A	cg22761795	chr8:1265118	NA	0.71	4.73	0.36	5.06e-6	Menarche (age at onset);
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg26338869	chr17:61819248	STRADA	0.5	4.74	0.36	4.82e-6	Height;
PAAD	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.96	6.5	0.47	1.07e-9	Thyroid stimulating hormone;
PAAD	cis	rs152528	0.603	rs249916	chr5:142008388	A/G	cg01162549	chr5:141367464	RNF14	-0.45	-4.69	-0.36	6.03e-6	Cardiac hypertrophy;
PAAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-5.22	-0.39	5.85e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.28e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.73	8.54	0.57	1.3e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg11189052	chr15:85197271	WDR73	-0.54	-4.35	-0.33	2.45e-5	P wave terminal force;
PAAD	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.94	13.05	0.73	1.37e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.51	4.99	0.38	1.61e-6	Height;
PAAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg14393609	chr7:65229607	NA	-0.5	-4.31	-0.33	2.92e-5	Aortic root size;
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.76	-0.62	9.27e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs7615916	0.542	rs4135249	chr3:12396779	C/T	cg23514324	chr3:12329213	PPARG	0.64	4.32	0.33	2.86e-5	Eosinophil percentage of white cells;
PAAD	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg01871581	chr19:12707946	ZNF490	-0.83	-9.49	-0.61	4.73e-17	Bipolar disorder;
PAAD	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.79	-0.36	3.93e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg19673125	chr6:150240577	RAET1G	0.43	5.97	0.44	1.65e-8	Lung cancer;
PAAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg05785598	chr3:49045655	WDR6	0.44	5.13	0.38	8.86e-7	Parkinson's disease;
PAAD	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.91	-0.37	2.3e-6	Mean platelet volume;
PAAD	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.96	-7.58	-0.52	3.19e-12	Blood protein levels;
PAAD	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs564309	0.764	rs9787095	chr1:228527970	C/G	cg01328119	chr1:228783545	DUSP5P	0.71	4.41	0.34	1.98e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	1.26	6.07	0.44	9.9e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21646471	chr2:242523971	THAP4	0.64	5.07	0.38	1.15e-6	Prostate cancer;
PAAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.69	6.02	0.44	1.25e-8	Primary sclerosing cholangitis;
PAAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.51	-5.24	-0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg25837213	chr17:80849375	TBCD	0.44	4.32	0.33	2.78e-5	Breast cancer;
PAAD	cis	rs12311304	1.000	rs12580168	chr12:15387773	T/C	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.54	5.14	0.39	8.2e-7	Obesity-related traits;
PAAD	cis	rs89107	0.651	rs283084	chr6:118603999	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.82	0.43	3.36e-8	Cardiac structure and function;
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg16434002	chr17:42200994	HDAC5	-0.67	-6.64	-0.47	5.23e-10	Total body bone mineral density;
PAAD	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.96	-10.13	-0.63	9.44e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs738144	0.542	rs4303811	chr22:39157755	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-4.6	-0.35	8.86e-6	IgG glycosylation;
PAAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.5	8.42	0.56	2.67e-14	Mean corpuscular volume;
PAAD	cis	rs3784262	0.528	rs10518961	chr15:58334345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.38	-0.33	2.18e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg21625146	chr5:486483	SLC9A3	0.37	5.43	0.4	2.19e-7	Cystic fibrosis severity;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	6.13	0.45	7.27e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg18281939	chr5:77783895	LHFPL2	0.5	6.47	0.46	1.26e-9	Triglycerides;
PAAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg15017067	chr4:17643749	FAM184B	0.47	5.48	0.41	1.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.51	5.51	0.41	1.51e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg08355456	chr11:67383691	NA	0.44	4.46	0.34	1.56e-5	Mean corpuscular volume;
PAAD	trans	rs901683	0.850	rs74914325	chr10:46097648	A/C	cg07567308	chr20:3149320	ProSAPiP1	0.76	6.45	0.46	1.41e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2147959	0.941	rs10916317	chr1:228645063	A/G	cg18477163	chr1:228402036	OBSCN	-0.44	-4.57	-0.35	9.94e-6	Adult asthma;
PAAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.79	8.94	0.59	1.22e-15	Lung cancer;
PAAD	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg16290904	chr8:77912348	PXMP3	-0.7	-6.31	-0.46	2.83e-9	Blood protein levels;
PAAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.72	8.39	0.56	3.08e-14	Height;
PAAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.51	4.62	0.35	8.02e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg05342682	chr7:94953680	PON1	-0.52	-4.65	-0.35	7.15e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg19357499	chr8:144660631	NAPRT1	-0.77	-5.64	-0.42	8.18e-8	Attention deficit hyperactivity disorder;
PAAD	cis	rs375066	0.935	rs398193	chr19:44420420	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg26031613	chr14:104095156	KLC1	-0.51	-4.98	-0.37	1.68e-6	Reticulocyte count;
PAAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.46	-5.21	-0.39	6e-7	Breast cancer;
PAAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.51	0.47	1.06e-9	Tonsillectomy;
PAAD	cis	rs2526932	0.967	rs2803957	chr14:73079751	T/C	cg13588403	chr14:73209128	DPF3	0.41	4.95	0.37	1.99e-6	C-reactive protein and white blood cell count;
PAAD	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg18551225	chr6:44695536	NA	-0.69	-6.91	-0.49	1.25e-10	Total body bone mineral density;
PAAD	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.05	-0.38	1.27e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg15047889	chr8:124780837	FAM91A1	0.66	4.56	0.35	1.03e-5	Pancreatic cancer;
PAAD	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg20893579	chr22:38215064	NA	-0.46	-4.62	-0.35	7.98e-6	Glioblastoma;Glioma;
PAAD	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg04530666	chr10:3759553	NA	0.75	4.31	0.33	2.94e-5	Major depressive disorder;
PAAD	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.71	-7.51	-0.52	4.75e-12	Type 2 diabetes;
PAAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs2839627	0.638	rs60342559	chr21:44310051	T/C	cg03543861	chr21:44258195	NA	0.65	4.75	0.36	4.7e-6	Information processing speed;
PAAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.77	8.96	0.59	1.12e-15	Heart rate;
PAAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg19163074	chr7:65112434	INTS4L2	0.45	4.25	0.33	3.77e-5	Aortic root size;
PAAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.7	7.88	0.54	5.89e-13	Bone mineral density;
PAAD	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-8.62	-0.57	8.37e-15	Total body bone mineral density;
PAAD	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg09344028	chr17:70110421	NA	-0.55	-6.99	-0.49	8.21e-11	Thyroid hormone levels;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.61	6.5	0.47	1.06e-9	Menarche (age at onset);
PAAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.72	-0.48	3.48e-10	Retinal vascular caliber;
PAAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs17407555	0.609	rs10032742	chr4:10278893	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	5.04	0.38	1.28e-6	Schizophrenia (age at onset);
PAAD	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs72772787	1.000	rs74152845	chr1:248013317	T/G	cg00785941	chr1:248100591	OR2L13	0.43	4.32	0.33	2.81e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg21479132	chr6:26055353	NA	0.85	4.27	0.33	3.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs864537	1.000	rs840015	chr1:167409114	G/A	cg12184421	chr1:167409136	CD247	0.38	4.28	0.33	3.3e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.92	-10.21	-0.64	5.83e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs12044355	0.865	rs1340983	chr1:231861359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	4.64	0.35	7.47e-6	Alzheimer's disease;
PAAD	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08138807	chr3:195164060	ACAP2	0.68	6.78	0.48	2.55e-10	Obesity-related traits;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.86	10.21	0.64	5.84e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.6	7.35	0.51	1.16e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-5.66	-0.42	7.27e-8	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.75e-5	Aortic root size;
PAAD	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg20291162	chr17:40259547	DHX58	-0.6	-5.94	-0.43	1.9e-8	Fibrinogen levels;
PAAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.95	-9.88	-0.63	4.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.61	-6.32	-0.46	2.69e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs41311933	0.831	rs12685344	chr9:123764991	G/A	cg13567360	chr9:123745713	C5	-0.72	-4.59	-0.35	9.12e-6	Coronary artery disease;
PAAD	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.42	-6.6	-0.47	6.29e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-4.43	-0.34	1.76e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg05347473	chr6:146136440	FBXO30	0.52	4.92	0.37	2.21e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.34	0.4	3.31e-7	Bipolar disorder;
PAAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg18827107	chr12:86230957	RASSF9	-0.44	-4.6	-0.35	8.75e-6	Major depressive disorder;
PAAD	cis	rs939584	1.000	rs10190052	chr2:646674	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.08	9.64	0.62	1.91e-17	Red blood cell traits;
PAAD	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.5	-5.37	-0.4	2.87e-7	Calcium levels;
PAAD	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.58	4.84	0.37	3.11e-6	Atopic dermatitis;
PAAD	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.56	-5.73	-0.42	5.34e-8	Multiple myeloma;
PAAD	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.46	-4.43	-0.34	1.81e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg21929781	chr1:2537748	MMEL1	-0.53	-5.58	-0.41	1.08e-7	Multiple sclerosis;
PAAD	cis	rs12760731	0.720	rs12048790	chr1:178407906	T/C	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg11993925	chr19:44307056	LYPD5	0.5	6.7	0.48	3.8e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.6	-8.43	-0.56	2.49e-14	Thrombosis;
PAAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.68	-6.68	-0.48	4.25e-10	Urate levels in lean individuals;
PAAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-6.63	-0.47	5.5e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.8	-5.03	-0.38	1.39e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg11335335	chr11:637885	DRD4	-0.31	-4.43	-0.34	1.76e-5	Systemic lupus erythematosus;
PAAD	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-13.77	-0.74	1.63e-28	Schizophrenia;
PAAD	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.47	-5.03	-0.38	1.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.81	8.6	0.57	9.4e-15	Uric acid levels;
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.84	-9.94	-0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg09915433	chr19:53449742	NA	-0.82	-11.79	-0.69	3.42e-23	Psoriasis;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg11062466	chr8:58055876	NA	0.65	4.7	0.36	5.83e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-5.29	-0.39	4.16e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg09654669	chr8:57350985	NA	-0.56	-5.26	-0.39	4.73e-7	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg00988841	chr10:134556463	INPP5A	0.49	4.52	0.34	1.22e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08677398	chr8:58056175	NA	0.68	4.76	0.36	4.45e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.59	-6.98	-0.49	8.35e-11	Coronary artery disease;
PAAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg03037974	chr15:76606532	NA	0.58	6.97	0.49	8.97e-11	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs795484	0.963	rs1277442	chr12:118605571	G/T	cg16572268	chr12:118583242	PEBP1	0.51	5.15	0.39	7.79e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs2030114	0.898	rs11646442	chr16:51585667	A/C	cg03758633	chr16:51611768	NA	-0.59	-4.85	-0.37	2.96e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.07	0.5	5.28e-11	Eye color traits;
PAAD	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.85e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.4	4.49	0.34	1.42e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg15676125	chr6:33679581	C6orf125	0.47	4.49	0.34	1.38e-5	Plateletcrit;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	0.88	5.65	0.42	7.59e-8	IgG glycosylation;
PAAD	cis	rs17824933	0.943	rs11230562	chr11:60776186	C/T	cg16817237	chr11:60793675	NA	0.53	6.24	0.45	4.2e-9	Multiple sclerosis;
PAAD	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.45	-0.4	2e-7	Coronary artery calcification;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg01200585	chr1:228362443	C1orf69	0.57	6.29	0.45	3.15e-9	Diastolic blood pressure;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg23119463	chr10:134592391	INPP5A	-0.52	-4.85	-0.37	3.03e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	10.8	0.66	1.56e-20	Platelet count;
PAAD	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg13512537	chr8:22265999	SLC39A14	-0.43	-4.36	-0.33	2.41e-5	Verbal declarative memory;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.92	7.91	0.54	4.8e-13	Alzheimer's disease;
PAAD	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg04398451	chr17:18023971	MYO15A	0.51	4.76	0.36	4.41e-6	Lymphocyte counts;
PAAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	10.74	0.66	2.19e-20	Smoking behavior;
PAAD	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg02421172	chr7:1938701	MAD1L1	0.63	5.06	0.38	1.22e-6	Bipolar disorder;
PAAD	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.4	-0.51	8.75e-12	Diastolic blood pressure;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.7	-7.74	-0.53	1.32e-12	Idiopathic membranous nephropathy;
PAAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg26893134	chr6:116381904	FRK	0.45	7.33	0.51	1.29e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg02743256	chr7:2109353	MAD1L1	-0.62	-4.73	-0.36	5.01e-6	Bipolar disorder;
PAAD	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.49	4.96	0.37	1.85e-6	Height;
PAAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.99	-0.38	1.61e-6	Initial pursuit acceleration;
PAAD	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg12560992	chr17:57184187	TRIM37	0.65	4.98	0.37	1.67e-6	Vitamin D levels;
PAAD	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.46	-4.53	-0.34	1.21e-5	Primary biliary cholangitis;
PAAD	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg13870426	chr17:30244630	NA	-0.75	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.17	0.39	7.14e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.45	6.86	0.49	1.64e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg07153921	chr17:41440717	NA	-0.4	-4.28	-0.33	3.32e-5	Menopause (age at onset);
PAAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.98	8.24	0.56	7.62e-14	Dupuytren's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20032723	chr11:126174041	DCPS	0.57	6.36	0.46	2.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs7172677	1.000	rs2415159	chr15:75430715	T/A	cg10253484	chr15:75165896	SCAMP2	-0.5	-4.72	-0.36	5.36e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	6.46	0.46	1.33e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4455778	0.580	rs4336559	chr7:49125213	G/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.5	5.17	0.39	7.13e-7	Monocyte percentage of white cells;
PAAD	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.59	5.64	0.42	7.95e-8	Neurofibrillary tangles;
PAAD	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.78	-0.53	1.02e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg17674042	chr6:34482479	PACSIN1	-0.97	-6.68	-0.48	4.16e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	1.03	13.71	0.74	2.39e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs10950821	0.770	rs2285559	chr7:20692637	A/C	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg00614314	chr15:82944287	LOC80154	0.56	5.85	0.43	2.96e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg04165759	chr1:150448943	RPRD2	0.51	5.28	0.39	4.29e-7	Migraine;
PAAD	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15145965	chr22:50218605	BRD1	-0.58	-5.21	-0.39	6.11e-7	Schizophrenia;
PAAD	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg06484146	chr7:12443880	VWDE	-0.61	-4.97	-0.37	1.75e-6	Coronary artery disease;
PAAD	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.77	-9.36	-0.6	1.02e-16	White blood cell count (basophil);
PAAD	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.99	11.96	0.7	1.21e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg11657440	chr19:46296263	DMWD	0.67	4.91	0.37	2.33e-6	Eosinophil counts;
PAAD	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg14703610	chr5:56206110	C5orf35	0.61	5.56	0.41	1.21e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs642743	0.967	rs479879	chr10:105945985	A/C	cg03775802	chr10:105978702	MIR609;C10orf79	0.32	4.37	0.33	2.25e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.42	-4.82	-0.36	3.52e-6	Height;
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.3	-0.56	5.33e-14	Prostate cancer;
PAAD	cis	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg23465465	chr6:26364728	BTN3A2	-0.82	-4.84	-0.37	3.12e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs10695717	1	rs10695717	chr22:39558761	A/ATTC	cg18708252	chr22:39545030	CBX7	-0.7	-7.29	-0.51	1.57e-11	Breast cancer;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18364779	chr6:26104403	HIST1H4C	0.52	5.02	0.38	1.41e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs875971	0.638	rs801205	chr7:66022144	C/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-1.37	-11.03	-0.67	3.71e-21	Schizophrenia;
PAAD	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg18057887	chr11:133800913	IGSF9B	-0.71	-6.93	-0.49	1.1e-10	Parkinson's disease;
PAAD	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs4780401	0.901	rs34774904	chr16:11817107	G/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-5.19	-0.39	6.58e-7	Rheumatoid arthritis;
PAAD	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg03233332	chr7:66118400	NA	0.4	4.3	0.33	3.08e-5	Aortic root size;
PAAD	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.02	0.38	1.44e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9463078	0.585	rs1285014	chr6:45165225	A/G	cg25276700	chr6:44698697	NA	0.46	5.3	0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.47	4.64	0.35	7.39e-6	Educational attainment;
PAAD	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.53	4.53	0.34	1.19e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02359409	chr6:42947317	PEX6	-0.5	-5.07	-0.38	1.12e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.9	7.73	0.53	1.38e-12	Alzheimer's disease;
PAAD	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg09021430	chr5:549028	NA	-0.89	-6.49	-0.47	1.13e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22396632	chr1:3079212	PRDM16	-0.44	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-6.66	-0.48	4.8e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.17	-9.64	-0.62	1.85e-17	Post bronchodilator FEV1;
PAAD	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.74	0.53	1.28e-12	Personality dimensions;
PAAD	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.98	0.37	1.74e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.76e-14	Triglycerides;
PAAD	cis	rs12044355	0.964	rs12045144	chr1:231844248	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.94	0.37	2.05e-6	Alzheimer's disease;
PAAD	cis	rs55728055	0.661	rs16989274	chr22:31955908	G/A	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs2885056	0.891	rs1821281	chr19:10692860	C/T	cg06392426	chr19:10676186	KRI1	0.53	5.22	0.39	5.74e-7	Red cell distribution width;
PAAD	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.53	-4.92	-0.37	2.19e-6	Kawasaki disease;
PAAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.9	-6.03	-0.44	1.19e-8	Chronic kidney disease;
PAAD	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.73	7.34	0.51	1.18e-11	Tonsillectomy;
PAAD	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg16306870	chr3:194868790	C3orf21	0.42	4.46	0.34	1.56e-5	Non-small cell lung cancer;
PAAD	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-5.85	-0.43	2.91e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7731390	0.681	rs60934439	chr5:131639843	A/G	cg07395648	chr5:131743802	NA	-0.71	-4.56	-0.35	1.03e-5	IgG glycosylation;
PAAD	cis	rs8060686	0.764	rs73597575	chr16:67677001	C/T	cg09835421	chr16:68378352	PRMT7	-0.91	-4.42	-0.34	1.88e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.91e-10	Lung cancer;
PAAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.82	-10.34	-0.64	2.65e-19	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13357455	chr5:134240501	PCBD2	0.58	6.4	0.46	1.86e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.67	0.42	7.01e-8	Prudent dietary pattern;
PAAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01017895	chr20:388559	RBCK1	-0.57	-6.77	-0.48	2.64e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26240231	chr7:1148101	C7orf50	-0.48	-4.25	-0.33	3.7e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.88	-9.42	-0.61	6.88e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	6.1	0.44	8.26e-9	Blood protein levels;
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.48	-5.16	-0.39	7.45e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10450586	0.831	rs10835161	chr11:27338689	A/C	cg10370305	chr11:27303972	NA	-0.37	-4.47	-0.34	1.53e-5	Total body bone mineral density;
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.9	-0.43	2.23e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg02376097	chr19:46275166	DMPK	-0.6	-6.09	-0.44	9.04e-9	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20080590	chr4:24831413	CCDC149	-0.68	-6.56	-0.47	8.04e-10	Obesity-related traits;
PAAD	cis	rs28489187	0.706	rs233071	chr1:85806005	C/T	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.75	8.18	0.55	1.06e-13	Total body bone mineral density;
PAAD	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.48	6.31	0.46	2.88e-9	Renal cell carcinoma;
PAAD	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.58	5.66	0.42	7.21e-8	Platelet count;
PAAD	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.43	-6.4	-0.46	1.85e-9	Breast cancer;
PAAD	cis	rs11191270	1.000	rs4919626	chr10:104079818	T/C	cg15320455	chr10:103880129	LDB1	0.56	4.83	0.36	3.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-4.54	-0.35	1.14e-5	Tonsillectomy;
PAAD	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-6.43	-0.46	1.6e-9	Colorectal cancer;
PAAD	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.96	6.23	0.45	4.41e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg09796270	chr17:17721594	SREBF1	0.46	4.91	0.37	2.33e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.73	0.42	5.17e-8	Prudent dietary pattern;
PAAD	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg08632701	chr21:37451849	NA	-0.63	-6.94	-0.49	1.08e-10	Mitral valve prolapse;
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11000057	chr3:160580264	PPM1L	-0.69	-7.35	-0.51	1.15e-11	Obesity-related traits;
PAAD	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.5	-0.34	1.35e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs3112530	0.892	rs1363499	chr5:152605860	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	-1.09	-5.49	-0.41	1.67e-7	Aging (time to event);
PAAD	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.14	-0.45	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg17120908	chr11:65337727	SSSCA1	-0.71	-7.8	-0.53	9.19e-13	Bone mineral density;
PAAD	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.71	-0.53	1.54e-12	Sense of smell;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg20887711	chr4:1340912	KIAA1530	0.5	5.12	0.38	8.96e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.58	-6.19	-0.45	5.25e-9	Blood metabolite levels;
PAAD	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg02683114	chr2:24398427	C2orf84	0.61	6.81	0.48	2.19e-10	Asthma;
PAAD	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25632853	chr15:73088954	NA	0.42	4.84	0.37	3.1e-6	Triglyceride levels;
PAAD	cis	rs735539	0.521	rs575063	chr13:21422911	A/C	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.02e-6	Lung cancer;
PAAD	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.82	-7.37	-0.51	1.01e-11	Homoarginine levels;
PAAD	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.46	-4.65	-0.35	7.07e-6	Inflammatory skin disease;
PAAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.04	0.55	2.37e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.13	-0.38	8.53e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7319311	0.589	rs9588150	chr13:111025042	T/C	cg05272587	chr13:111038400	COL4A2	0.62	5.56	0.41	1.21e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.85	8.42	0.56	2.56e-14	Vitamin D levels;
PAAD	cis	rs9487051	0.621	rs830552	chr6:109549914	A/G	cg21918786	chr6:109611834	NA	-0.42	-4.37	-0.33	2.34e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	7.47	0.52	6.01e-12	Mean platelet volume;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.83	0.66	1.29e-20	Prudent dietary pattern;
PAAD	cis	rs9372498	0.536	rs77435770	chr6:118819467	G/A	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.16e-6	Diastolic blood pressure;
PAAD	cis	rs608114	0.623	rs57900371	chr6:96359864	C/G	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Body mass index;
PAAD	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg00262122	chr8:11665843	FDFT1	-0.57	-5.63	-0.42	8.37e-8	Morning vs. evening chronotype;
PAAD	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	14.53	0.76	1.54e-30	IgG glycosylation;
PAAD	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg00035074	chr7:2701567	TTYH3	0.63	4.25	0.33	3.76e-5	Bipolar disorder;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.46	4.95	0.37	1.95e-6	Longevity;Endometriosis;
PAAD	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.58	-5.83	-0.43	3.21e-8	Depression and alcohol dependence;
PAAD	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg24634471	chr8:143751801	JRK	-0.52	-4.72	-0.36	5.23e-6	Urinary tract infection frequency;
PAAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.31	0.46	2.96e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg11062466	chr8:58055876	NA	0.68	4.79	0.36	3.97e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.36e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs375066	0.551	rs1565057	chr19:44333192	G/C	cg11993925	chr19:44307056	LYPD5	-0.41	-4.56	-0.35	1.06e-5	Breast cancer;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg02869306	chr7:64672164	INTS4L1	0.42	4.89	0.37	2.52e-6	Aortic root size;
PAAD	cis	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg27411982	chr8:10470053	RP1L1	0.48	5.68	0.42	6.54e-8	Neuroticism;
PAAD	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02592214	chr2:128284498	IWS1	0.62	6.42	0.46	1.69e-9	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.57	5.48	0.41	1.76e-7	Uric acid clearance;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.55	5.45	0.4	2.01e-7	Prudent dietary pattern;
PAAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.34	-0.46	2.51e-9	Height;
PAAD	cis	rs2171564	0.557	rs9831780	chr3:112442083	G/A	cg18194305	chr3:113160637	WDR52	0.44	4.33	0.33	2.74e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg14481604	chr15:25334117	SNORD116-22	-0.47	-4.75	-0.36	4.68e-6	Blood osmolality (transformed sodium);
PAAD	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs4704187	0.687	rs10036527	chr5:74481837	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs2587695	0.901	rs2244213	chr2:120282026	T/G	cg05839767	chr2:119914248	C1QL2	-0.43	-4.62	-0.35	8.29e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs11638352	0.661	rs2464692	chr15:44480301	T/C	cg10011062	chr15:43941034	CATSPER2	-1.21	-4.31	-0.33	2.93e-5	Lipoprotein phospholipase A2 activity in cardiovascular disease;
PAAD	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg01426195	chr3:39028469	NA	0.6	5.78	0.42	4.2e-8	Handedness;
PAAD	cis	rs2730245	0.594	rs2657343	chr7:158745472	G/A	cg24397884	chr7:158709396	WDR60	-0.98	-11.03	-0.67	3.87e-21	Height;
PAAD	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.61	6.5	0.47	1.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-4.31	-0.33	2.87e-5	Fat distribution (HIV);
PAAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.4	5.01	0.38	1.52e-6	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73196993	chr3:128456755	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.66	6.66	0.48	4.64e-10	Type 2 diabetes;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg10395934	chr14:104002654	TRMT61A	0.54	5.45	0.4	2.02e-7	Body mass index;
PAAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.28	-0.33	3.35e-5	Tonsillectomy;
PAAD	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.73	-5.11	-0.38	9.71e-7	Schizophrenia;
PAAD	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.33	-0.33	2.69e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7804356	0.651	rs55959127	chr7:26810146	C/T	cg03456212	chr7:26904342	SKAP2	-0.58	-4.95	-0.37	1.92e-6	Type 1 diabetes;
PAAD	cis	rs7688540	0.800	rs61792060	chr4:256450	C/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	4.68	0.35	6.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.79	7.26	0.51	1.84e-11	Gout;
PAAD	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.62	5.63	0.42	8.3e-8	Height;
PAAD	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.67	5.42	0.4	2.3e-7	Morning vs. evening chronotype;
PAAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.53	5.9	0.43	2.26e-8	Coronary artery disease;
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Body mass index;
PAAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg04862289	chr1:204966208	NFASC	0.48	4.98	0.37	1.71e-6	Mean platelet volume;
PAAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg03037974	chr15:76606532	NA	-0.53	-6.36	-0.46	2.26e-9	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24361212	chr14:51298003	NIN	0.61	6.92	0.49	1.16e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg19761014	chr17:28927070	LRRC37B2	0.74	5.16	0.39	7.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg21419209	chr3:44054225	NA	-0.69	-7.15	-0.5	3.37e-11	Coronary artery disease;
PAAD	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg12395012	chr8:11607386	GATA4	0.55	4.25	0.33	3.65e-5	Alcohol dependence;Nicotine use;
PAAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg27494647	chr7:150038898	RARRES2	0.43	4.63	0.35	7.72e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6011002	0.636	rs1758199	chr20:62352827	T/C	cg01176363	chr20:62369445	LIME1	-0.92	-4.28	-0.33	3.28e-5	Dental caries;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26788616	chr16:11219021	CLEC16A	0.54	6.32	0.46	2.69e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	7.21	0.5	2.49e-11	Renal function-related traits (BUN);
PAAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.68	0.65	3.29e-20	Total body bone mineral density;
PAAD	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg14416269	chr4:6271139	WFS1	0.69	9.23	0.6	2.18e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01200585	chr1:228362443	C1orf69	-0.49	-5.54	-0.41	1.31e-7	Diastolic blood pressure;
PAAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.64	6.61	0.47	6.26e-10	Urate levels in lean individuals;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg02725872	chr8:58115012	NA	-0.63	-4.99	-0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.44	-5.89	-0.43	2.39e-8	Huntington's disease progression;
PAAD	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg12508331	chr16:3208203	NA	0.47	4.35	0.33	2.51e-5	Body mass index (adult);
PAAD	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg08501292	chr6:25962987	TRIM38	0.84	4.76	0.36	4.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.82	-8.81	-0.58	2.72e-15	Mortality in heart failure;
PAAD	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	4.53	0.35	1.17e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs28493229	0.708	rs10407650	chr19:41160970	T/C	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs1075232	0.826	rs16956738	chr15:31736231	C/T	cg01030201	chr15:31746330	NA	1.15	4.69	0.36	6.03e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.72	7.97	0.54	3.47e-13	Melanoma;
PAAD	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.82	-0.43	3.43e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg21929781	chr1:2537748	MMEL1	0.49	5.25	0.39	4.98e-7	Ulcerative colitis;
PAAD	cis	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg08112188	chr17:47440006	ZNF652	1.43	8.68	0.58	5.76e-15	Prostate cancer;
PAAD	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.9	0.54	5.35e-13	Parkinson's disease;
PAAD	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg14196790	chr5:131705035	SLC22A5	0.42	4.54	0.35	1.16e-5	Asthma;
PAAD	cis	rs1891275	0.515	rs7358148	chr10:93418532	C/T	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.49	4.39	0.34	2.13e-5	Anterior chamber depth;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14497348	chr9:6757781	KDM4C	-0.75	-6.83	-0.48	1.93e-10	Neuroticism;
PAAD	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg11143131	chr5:131608246	PDLIM4	0.49	4.97	0.37	1.8e-6	Blood metabolite levels;
PAAD	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg01329690	chr21:38580129	DSCR9	0.33	4.42	0.34	1.89e-5	Eye color traits;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	5.1	0.38	1e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg02071572	chr4:1403502	NA	-0.34	-4.36	-0.33	2.4e-5	Obesity-related traits;
PAAD	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg20167471	chr1:16528984	ARHGEF19	0.47	4.57	0.35	1.01e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.31	-0.4	3.75e-7	Schizophrenia;
PAAD	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.53	-5.49	-0.41	1.67e-7	Social autistic-like traits;
PAAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.63	-0.42	8.67e-8	HDL cholesterol;
PAAD	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13047869	chr3:10149882	C3orf24	0.71	5.83	0.43	3.16e-8	Alzheimer's disease;
PAAD	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.68	10.41	0.65	1.67e-19	Airflow obstruction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02467054	chr16:4664854	FAM100A	0.68	7.25	0.51	2e-11	Obesity-related traits;
PAAD	cis	rs258892	0.793	rs61141607	chr5:72056883	T/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg09399716	chr2:46890238	NA	-0.72	-5.69	-0.42	6.25e-8	Height;
PAAD	cis	rs7527798	1.000	rs12745818	chr1:207819401	C/T	cg05831823	chr1:207627978	CR2	-0.53	-4.33	-0.33	2.7e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	1.01	8.62	0.57	8e-15	Blood protein levels;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-5.99	-0.44	1.45e-8	Glioma;Non-glioblastoma glioma;Glioblastoma;
PAAD	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	0.79	7.79	0.53	9.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.4	-0.34	1.99e-5	Height;
PAAD	cis	rs12148477	0.583	rs930921	chr15:51658631	A/G	cg25905881	chr15:51634250	GLDN	0.43	4.83	0.36	3.29e-6	Follicule stimulating hormone;
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	4.48	0.34	1.44e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg00944433	chr1:107599041	PRMT6	-0.43	-5.0	-0.38	1.55e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-1.06	-19.01	-0.84	5.08e-42	Urate levels in lean individuals;
PAAD	cis	rs7216064	1.000	rs9915591	chr17:65826090	C/G	cg12091567	chr17:66097778	LOC651250	-0.69	-5.39	-0.4	2.59e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.48	5.02	0.38	1.42e-6	Longevity;Endometriosis;
PAAD	cis	rs7127900	0.821	rs10840603	chr11:2233797	A/G	cg25635251	chr11:2234043	NA	0.84	7.57	0.52	3.38e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06657217	chr20:50140011	NFATC2	0.59	7.03	0.5	6.68e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	7.91	0.54	5e-13	Schizophrenia;
PAAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.84	-9.82	-0.62	6.07e-18	Prostate cancer;
PAAD	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.67	-6.84	-0.49	1.84e-10	Colorectal cancer;
PAAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.76	-6.04	-0.44	1.12e-8	Initial pursuit acceleration;
PAAD	trans	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg16973527	chr15:70767570	NA	0.4	6.36	0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18404041	chr3:52824283	ITIH1	0.42	4.5	0.34	1.32e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg04756594	chr16:24857601	SLC5A11	0.47	4.42	0.34	1.83e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg08315770	chr6:39281885	KCNK17	-0.61	-6.44	-0.46	1.49e-9	Type 2 diabetes;
PAAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg13606994	chr1:44402422	ARTN	-0.43	-4.67	-0.35	6.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.9e-6	Life satisfaction;
PAAD	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.67	-6.44	-0.46	1.52e-9	Breast cancer;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs2422052	0.530	rs11683225	chr2:118644135	C/A	cg22545206	chr2:118617499	NA	0.44	4.35	0.33	2.5e-5	Mosquito bite size;
PAAD	cis	rs507080	0.733	rs657769	chr11:118571316	C/T	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.64	6.16	0.45	6.27e-9	Bone properties (heel);
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg13902645	chr11:5959945	NA	-0.62	-6.4	-0.46	1.81e-9	DNA methylation (variation);
PAAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19784903	chr17:45786737	TBKBP1	0.58	6.34	0.46	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg08601574	chr20:25228251	PYGB	0.6	6.68	0.48	4.13e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.64	7.42	0.52	7.54e-12	Dupuytren's disease;
PAAD	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.7	6.95	0.49	1.01e-10	Lymphocyte counts;
PAAD	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.97	-10.02	-0.63	1.81e-18	Prostate cancer;
PAAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs2712184	0.846	rs7598172	chr2:217677999	G/T	cg05032264	chr2:217675019	NA	-0.59	-6.54	-0.47	8.71e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg10168330	chr8:27262164	PTK2B	0.38	4.42	0.34	1.86e-5	Neuroticism;
PAAD	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.46	4.34	0.33	2.55e-5	RR interval (heart rate);
PAAD	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.45	5.02	0.38	1.41e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.57	-6.19	-0.45	5.34e-9	Platelet distribution width;
PAAD	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg13047869	chr3:10149882	C3orf24	0.75	5.71	0.42	5.71e-8	Alzheimer's disease;
PAAD	cis	rs10044254	0.774	rs12515897	chr5:15734898	A/T	cg07238450	chr5:15720153	FBXL7	-0.51	-4.29	-0.33	3.15e-5	Asthma (corticosteroid response);
PAAD	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-5.4	-0.4	2.56e-7	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs4834770	0.718	rs4833618	chr4:120309500	T/C	cg09307838	chr4:120376055	NA	-0.58	-5.68	-0.42	6.65e-8	Blood protein levels;
PAAD	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg12756303	chr2:74692479	MOGS	-0.51	-4.54	-0.35	1.16e-5	Metabolite levels;
PAAD	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg21905437	chr5:178450457	ZNF879	0.68	5.95	0.43	1.81e-8	Pubertal anthropometrics;
PAAD	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.54	6.58	0.47	7.08e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18364779	chr6:26104403	HIST1H4C	0.5	4.86	0.37	2.88e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.49	-0.34	1.42e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.52	-0.41	1.43e-7	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs7833787	1.000	rs7844500	chr8:18703343	A/G	cg17701159	chr8:18705777	PSD3	-0.46	-5.39	-0.4	2.63e-7	Obesity-related traits;
PAAD	cis	rs7561149	0.902	rs6715406	chr2:179650701	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.48	4.79	0.36	3.96e-6	QT interval;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.64	-7.0	-0.49	7.52e-11	Lung cancer;
PAAD	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.78	8.34	0.56	4.16e-14	Obesity-related traits;
PAAD	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg03700679	chr2:178418002	TTC30B	0.59	4.7	0.36	5.73e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9463078	0.585	rs12529946	chr6:45255294	G/A	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.3e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4343996	1.000	rs13230698	chr7:3361125	T/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08592527	chr10:98740981	C10orf12	-0.7	-7.58	-0.52	3.2e-12	Obesity-related traits;
PAAD	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg06917634	chr15:78832804	PSMA4	0.51	4.56	0.35	1.05e-5	Sudden cardiac arrest;
PAAD	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	6.82	0.48	2.07e-10	Electrocardiographic conduction measures;
PAAD	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-5.35	-0.4	3.22e-7	Atrioventricular conduction;
PAAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg16928487	chr17:17741425	SREBF1	-0.32	-4.42	-0.34	1.83e-5	Total body bone mineral density;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.05	-0.55	2.16e-13	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	8.14	0.55	1.31e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg04154034	chr17:28927549	LRRC37B2	-0.73	-4.29	-0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00142150	chr22:38071001	LGALS1	0.53	4.64	0.35	7.52e-6	Fat distribution (HIV);
PAAD	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg09491104	chr22:46646882	C22orf40	-1.02	-5.87	-0.43	2.63e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-4.4	-0.34	2.02e-5	Vitamin D levels;
PAAD	cis	rs6141769	0.542	rs6057628	chr20:31308684	C/T	cg13636640	chr20:31349939	DNMT3B	-0.46	-4.37	-0.33	2.3e-5	Subjective well-being;
PAAD	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.23	-0.39	5.64e-7	Migraine - clinic-based;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg08132940	chr7:1081526	C7orf50	-0.54	-4.25	-0.33	3.74e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4697263	0.552	rs10938876	chr4:22131609	C/T	cg26230338	chr4:22389934	GPR125	0.45	4.26	0.33	3.51e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg10018233	chr7:150070692	REPIN1	0.64	6.55	0.47	8.32e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9944275	0.799	rs12905290	chr15:97207544	C/T	cg23969200	chr15:97326567	SPATA8	0.69	4.75	0.36	4.64e-6	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs5756391	0.568	rs4821567	chr22:37316388	T/G	cg21209356	chr22:37319042	CSF2RB	0.39	4.75	0.36	4.63e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg19429281	chr19:53496738	ZNF702P	-0.58	-6.1	-0.44	8.57e-9	Psoriasis;
PAAD	cis	rs859767	0.779	rs6430528	chr2:135395348	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-4.44	-0.34	1.73e-5	Neuroticism;
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg11416102	chr8:651193	ERICH1	0.75	4.83	0.36	3.31e-6	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs4742903	0.935	rs4743694	chr9:106933163	C/G	cg14250997	chr9:106856677	SMC2	0.46	4.94	0.37	2.06e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	4.51	0.34	1.29e-5	Schizophrenia;
PAAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-0.96	-10.78	-0.66	1.74e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.62	8.2	0.55	9.48e-14	Renal cell carcinoma;
PAAD	cis	rs4742903	1.000	rs10820603	chr9:106877939	G/A	cg14250997	chr9:106856677	SMC2	0.48	5.22	0.39	5.92e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.68	7.04	0.5	6.08e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs4356203	0.870	rs214926	chr11:17231802	T/C	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.64	-0.35	7.48e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.61	-6.15	-0.45	6.56e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs7264396	0.887	rs224354	chr20:34054609	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.23	9.69	0.62	1.42e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13732083	chr21:47605072	C21orf56	0.44	4.26	0.33	3.54e-5	Testicular germ cell tumor;
PAAD	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02987984	chr7:101457447	NA	0.71	8.28	0.56	5.95e-14	Vitiligo;Type 1 diabetes;
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg07332563	chr6:291687	DUSP22	-0.78	-8.4	-0.56	2.94e-14	Menopause (age at onset);
PAAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg14349672	chr11:133703707	NA	-0.52	-6.0	-0.44	1.41e-8	Childhood ear infection;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg27057461	chr7:158136379	PTPRN2	-0.47	-4.3	-0.33	3.06e-5	Response to amphetamines;
PAAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.52	6.67	0.48	4.36e-10	Childhood ear infection;
PAAD	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.57	5.56	0.41	1.18e-7	Mortality in heart failure;
PAAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs2133450	0.742	rs1508707	chr3:7263955	T/C	cg19930620	chr3:7340148	GRM7	-0.43	-4.38	-0.34	2.17e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	4.25	0.33	3.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg01075559	chr1:2537774	MMEL1	-0.54	-5.6	-0.41	9.83e-8	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.41	0.82	5.02e-38	Prudent dietary pattern;
PAAD	cis	rs2526932	1.000	rs2526932	chr14:73081068	A/G	cg13588403	chr14:73209128	DPF3	0.45	5.62	0.41	8.98e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.3	0.45	3.08e-9	Rheumatoid arthritis;
PAAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.23e-9	Height;
PAAD	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.69	7.94	0.54	4.19e-13	Colorectal cancer;
PAAD	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.91	-0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11958404	0.929	rs6890364	chr5:157380519	T/G	cg05962755	chr5:157440814	NA	1.03	6.48	0.47	1.23e-9	IgG glycosylation;
PAAD	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.76	-9.05	-0.59	6.59e-16	Personality dimensions;
PAAD	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs9395066	0.545	rs4714830	chr6:44955528	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.41	-0.34	1.96e-5	Height;
PAAD	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.54	4.99	0.38	1.65e-6	Resting heart rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22193559	chr5:43065115	NA	0.57	6.34	0.46	2.46e-9	Monocyte percentage of white cells;
PAAD	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.7	-0.36	5.79e-6	Asthma;
PAAD	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg11380483	chr2:127933992	NA	0.48	4.68	0.36	6.21e-6	Self-rated health;
PAAD	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.92	-0.37	2.23e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.72	-8.12	-0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	1.05	14.27	0.76	7.45e-30	Headache;
PAAD	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs11696501	0.694	rs4812943	chr20:44260966	G/C	cg11783356	chr20:44313418	WFDC10B	-0.62	-5.37	-0.4	2.83e-7	Brain structure;
PAAD	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.61	7.12	0.5	4e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8102137	0.781	rs56285422	chr19:30319892	C/T	cg27475126	chr19:30303651	CCNE1	-0.46	-4.8	-0.36	3.76e-6	Bladder cancer;
PAAD	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg00717180	chr2:96193071	NA	-0.6	-6.55	-0.47	8.25e-10	HDL cholesterol;
PAAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.98	-7.74	-0.53	1.31e-12	Initial pursuit acceleration;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.55	-4.86	-0.37	2.91e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7236492	0.935	rs9960080	chr18:77227293	T/C	cg15644404	chr18:77186268	NFATC1	-0.88	-6.32	-0.46	2.81e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg10072921	chr12:121022843	NA	0.43	5.22	0.39	5.7e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs12773846	0.843	rs57330369	chr10:126273034	T/C	cg04949429	chr10:126290192	LHPP	0.49	4.93	0.37	2.17e-6	Subcutaneous adipose tissue;
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.73	-5.99	-0.44	1.46e-8	Gallbladder cancer;
PAAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.54	-5.34	-0.4	3.32e-7	Educational attainment (years of education);
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.9	-0.37	2.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1007738	0.542	rs7937410	chr11:47206082	C/G	cg19486271	chr11:47235900	DDB2	0.6	5.52	0.41	1.42e-7	Bone mineral density (hip);
PAAD	cis	rs35160687	0.842	rs10200619	chr2:86548848	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-4.52	-0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg10885151	chr13:24270087	NA	0.38	4.31	0.33	2.95e-5	Obesity-related traits;
PAAD	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.52	-4.9	-0.37	2.39e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs35740288	0.929	rs11630585	chr15:86306004	C/A	cg07943548	chr15:86304357	KLHL25	-0.6	-5.16	-0.39	7.7e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.59	-0.35	9.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs6499755	0.712	rs31109	chr16:55378226	G/C	cg02859129	chr16:55357253	IRX6	0.34	4.77	0.36	4.21e-6	Hypospadias;
PAAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.78	6.92	0.49	1.15e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	1.11	16.5	0.8	1.09e-35	Breast cancer;
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.58	6.3	0.46	3.03e-9	Lung cancer;
PAAD	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.16	0.39	7.71e-7	Educational attainment;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.97	12.64	0.72	1.77e-25	Menarche (age at onset);
PAAD	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.91	5.5	0.41	1.57e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs16966142	0.534	rs12447806	chr16:89662837	C/T	cg02628002	chr16:89649608	CPNE7	0.93	6.15	0.45	6.69e-9	Caffeine consumption;
PAAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg09324608	chr17:30823087	MYO1D	0.55	5.72	0.42	5.4e-8	Schizophrenia;
PAAD	cis	rs2290416	0.710	rs61005957	chr8:144669512	T/G	cg16316162	chr8:144660157	NAPRT1	0.82	4.33	0.33	2.66e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs863345	0.604	rs6670343	chr1:158497258	A/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.9	8.3	0.56	5.16e-14	Obesity-related traits;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg10072921	chr12:121022843	NA	-0.36	-4.78	-0.36	4.1e-6	High light scatter reticulocyte count;
PAAD	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg02780029	chr10:43622663	RET	-0.45	-4.52	-0.34	1.22e-5	Hirschsprung disease;
PAAD	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.53	5.13	0.38	8.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.97	-0.37	1.8e-6	Monocyte percentage of white cells;
PAAD	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg15660573	chr17:549704	VPS53	-0.6	-5.53	-0.41	1.36e-7	Prostate cancer;
PAAD	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs501916	1.000	rs648627	chr15:48055738	C/T	cg16110827	chr15:48056943	SEMA6D	-0.41	-4.46	-0.34	1.55e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	5.53	0.41	1.37e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.83	9.09	0.59	5.17e-16	Height;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg14893161	chr1:205819251	PM20D1	0.58	5.34	0.4	3.28e-7	White blood cell types;
PAAD	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs2290419	0.730	rs114820467	chr11:68944052	T/C	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.66	-5.25	-0.39	5.14e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs901683	1.000	rs35824277	chr10:46030477	C/T	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.46	-0.4	1.9e-7	Obesity-related traits;
PAAD	cis	rs28595532	0.764	rs17259257	chr4:119778889	C/T	cg21605333	chr4:119757512	SEC24D	2.0	10.54	0.65	7.83e-20	Cannabis dependence symptom count;
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05025164	chr4:1340916	KIAA1530	0.53	5.05	0.38	1.26e-6	Obesity-related traits;
PAAD	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs113779084	0.660	rs10464273	chr7:11968798	C/A	cg15090509	chr7:11872073	THSD7A	0.37	4.5	0.34	1.36e-5	Educational attainment (years of education);
PAAD	cis	rs7255	0.509	rs3072	chr2:20878406	T/C	cg07755735	chr2:20870362	GDF7	-0.44	-4.86	-0.37	2.88e-6	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.66	0.42	7.17e-8	Restless legs syndrome;
PAAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.66	7.08	0.5	4.95e-11	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.47	4.87	0.37	2.76e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	6.65	0.47	5.07e-10	Body mass index;
PAAD	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg14055004	chr2:241860995	NA	0.28	4.46	0.34	1.62e-5	Joint mobility (Beighton score);
PAAD	cis	rs8005962	0.717	rs911687	chr14:96048480	A/G	cg06625934	chr14:95238988	NA	0.4	4.46	0.34	1.57e-5	Tuberculosis;
PAAD	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-4.96	-0.37	1.85e-6	Reticulocyte count;
PAAD	cis	rs6964492	0.576	rs17168006	chr7:134406000	A/G	cg22430036	chr7:134592620	CALD1	0.52	4.72	0.36	5.33e-6	Tonsillectomy;
PAAD	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg04450456	chr4:17643702	FAM184B	0.48	5.27	0.39	4.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg15226751	chr1:10001911	LZIC	0.39	4.47	0.34	1.51e-5	Hepatocellular carcinoma;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg13604132	chr4:75023629	MTHFD2L	0.68	6.87	0.49	1.53e-10	Primary biliary cholangitis;
PAAD	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg06287003	chr12:125626642	AACS	-0.49	-4.82	-0.36	3.39e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.84	-0.49	1.8e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg05564831	chr3:52568323	NT5DC2	0.41	4.5	0.34	1.36e-5	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-4.46	-0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.57	6.54	0.47	8.74e-10	Aortic root size;
PAAD	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.02	7.54	0.52	4.07e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.55	-5.38	-0.4	2.82e-7	Coronary artery disease;
PAAD	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.93	-0.49	1.11e-10	Triglycerides;
PAAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.82	9.39	0.61	8.34e-17	Methadone dose in opioid dependence;
PAAD	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.08	-0.5	4.96e-11	Colorectal cancer;
PAAD	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg01489032	chr8:143877656	NA	-0.48	-5.06	-0.38	1.18e-6	Urinary tract infection frequency;
PAAD	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg07725925	chr16:89976287	TCF25	0.66	4.29	0.33	3.19e-5	Skin colour saturation;
PAAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.63	4.66	0.35	6.72e-6	Fat distribution (HIV);
PAAD	cis	rs55728055	0.661	rs16989278	chr22:31957167	A/G	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg25452165	chr22:42524984	CYP2D6	0.61	5.83	0.43	3.21e-8	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17255085	chr7:157193359	DNAJB6	0.57	6.61	0.47	6.08e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23489390	chr2:36712570	CRIM1	0.63	6.46	0.46	1.34e-9	Smoking initiation;
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-7.64	-0.53	2.24e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs2134046	0.555	rs11854483	chr15:82559558	T/C	cg00614314	chr15:82944287	LOC80154	0.55	5.21	0.39	6.07e-7	Cognitive ability;
PAAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs728616	0.764	rs61859016	chr10:81852500	C/A	cg05935833	chr10:81318306	SFTPA2	-0.63	-4.7	-0.36	5.78e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg24881330	chr22:46731750	TRMU	1.11	5.32	0.4	3.71e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.52	-5.65	-0.42	7.59e-8	Mitral valve prolapse;
PAAD	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.75	5.5	0.41	1.57e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs732765	0.734	rs17183139	chr14:75153950	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.5	-0.34	1.34e-5	Non-small cell lung cancer;
PAAD	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg15309053	chr8:964076	NA	0.63	7.22	0.51	2.31e-11	Schizophrenia;
PAAD	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg23912435	chr1:150601613	ENSA	0.51	4.71	0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00933542	chr6:150070202	PCMT1	0.58	5.91	0.43	2.2e-8	Lung cancer;
PAAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.46	0.82	3.82e-38	Height;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	5.06	0.38	1.21e-6	Renal function-related traits (BUN);
PAAD	cis	rs10899021	0.920	rs10899014	chr11:74325109	A/G	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.94	13.0	0.73	1.91e-26	Prudent dietary pattern;
PAAD	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.43	-4.83	-0.36	3.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.19	11.46	0.68	2.56e-22	Corneal structure;
PAAD	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs914615	0.508	rs4390169	chr1:155106054	A/G	cg22049894	chr1:155113146	DPM3	-0.45	-4.3	-0.33	3.02e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs282587	0.569	rs390657	chr13:113415085	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.97	-0.37	1.82e-6	Glycated hemoglobin levels;
PAAD	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg15654264	chr1:150340011	RPRD2	0.5	5.01	0.38	1.49e-6	Migraine;
PAAD	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs34845616	0.551	rs4936209	chr11:133686106	C/G	cg06067394	chr11:133789110	IGSF9B	0.43	4.54	0.35	1.14e-5	Hand grip strength;
PAAD	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg11657817	chr20:23433608	CST11	0.41	4.49	0.34	1.38e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04156016	chr5:1868137	NA	0.44	4.43	0.34	1.82e-5	Cardiovascular disease risk factors;
PAAD	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.48	4.44	0.34	1.7e-5	Lung cancer;
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.58	-0.35	9.54e-6	Lung cancer;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10750165	0.692	rs7933823	chr11:119651462	G/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.37	-0.33	2.26e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg15117754	chr3:10150083	C3orf24	-0.63	-5.21	-0.39	5.96e-7	Alzheimer's disease;
PAAD	cis	rs705471	0.762	rs555978	chr10:3662558	G/A	cg14308648	chr10:3568949	NA	0.54	5.58	0.41	1.09e-7	Capecitabine sensitivity;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.32e-7	Protein quantitative trait loci;
PAAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.44	6.82	0.48	2.01e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs4343996	0.967	rs1525556	chr7:3351304	G/C	cg21248987	chr7:3385318	SDK1	-0.47	-5.16	-0.39	7.64e-7	Motion sickness;
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.41	-0.34	1.96e-5	Educational attainment;
PAAD	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.64	6.48	0.47	1.24e-9	Morning vs. evening chronotype;
PAAD	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.12	-0.7	4.33e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-6.8	-0.48	2.29e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.63	4.31	0.33	2.88e-5	Skin colour saturation;
PAAD	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.62	6.01	0.44	1.33e-8	Lymphocyte counts;
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13939156	chr17:80058883	NA	-0.41	-4.46	-0.34	1.59e-5	Life satisfaction;
PAAD	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg26205652	chr12:48591994	NA	0.79	7.32	0.51	1.32e-11	Longevity (90 years and older);
PAAD	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.63	4.49	0.34	1.41e-5	Vitiligo;
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.55	0.41	1.23e-7	Total body bone mineral density;
PAAD	cis	rs11892454	0.515	rs4063544	chr2:26042515	A/C	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.44	5.28	0.39	4.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg21395723	chr22:39101663	GTPBP1	0.48	4.91	0.37	2.32e-6	Menopause (age at onset);
PAAD	cis	rs1499972	0.941	rs6807173	chr3:117642281	T/G	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.59	6.5	0.47	1.08e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9815354	0.680	rs73073296	chr3:42028074	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.47	4.98	0.37	1.7e-6	Monocyte percentage of white cells;
PAAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	cis	rs57994353	0.536	rs4298601	chr9:139303290	G/C	cg21253087	chr9:139290292	SNAPC4	0.48	4.41	0.34	1.97e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg15654264	chr1:150340011	RPRD2	0.5	4.91	0.37	2.35e-6	Migraine;
PAAD	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.77	-9.19	-0.6	2.72e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.72	0.66	2.5e-20	Prudent dietary pattern;
PAAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14895029	chr7:2775587	GNA12	-0.46	-4.36	-0.33	2.39e-5	Height;
PAAD	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	5.81	0.43	3.49e-8	Rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.81	-8.57	-0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10207060	0.500	rs10177457	chr2:240708067	G/A	cg07506560	chr2:240697449	NA	0.55	5.76	0.42	4.62e-8	Obesity-related traits;
PAAD	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.08	0.38	1.11e-6	Lung cancer in ever smokers;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.65	7.04	0.5	6.21e-11	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22103183	chr6:83667130	UBE2CBP	-0.59	-6.37	-0.46	2.13e-9	Obesity-related traits;
PAAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21028142	chr17:79581711	NPLOC4	0.51	5.94	0.43	1.89e-8	Eye color traits;
PAAD	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg23417306	chr2:180868811	CWC22	0.48	4.49	0.34	1.39e-5	Schizophrenia;
PAAD	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	1.01	6.33	0.46	2.6e-9	Skin colour saturation;
PAAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.51	-5.02	-0.38	1.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.57	4.55	0.35	1.09e-5	Type 2 diabetes;
PAAD	trans	rs3905000	1.000	rs3847301	chr9:107648519	T/C	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg06697600	chr4:7070879	GRPEL1	0.82	4.28	0.33	3.35e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2070677	0.673	rs3020503	chr10:135381766	C/T	cg18984983	chr10:135342936	CYP2E1	-0.49	-4.53	-0.34	1.18e-5	Gout;
PAAD	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-5.99	-0.44	1.48e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.54	-4.92	-0.37	2.18e-6	Menopause (age at onset);
PAAD	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.91	-0.37	2.34e-6	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22144486	chr17:8529207	MYH10	-0.69	-7.76	-0.53	1.12e-12	Obesity-related traits;
PAAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.4	0.4	2.54e-7	Mean corpuscular volume;
PAAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.03	-0.5	6.66e-11	Mood instability;
PAAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	5.53	0.41	1.34e-7	Eosinophil percentage of white cells;
PAAD	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.54	-4.87	-0.37	2.82e-6	Colorectal cancer;
PAAD	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.71	0.42	5.67e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.73	0.48	3.22e-10	Total body bone mineral density;
PAAD	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg02527881	chr3:46936655	PTH1R	0.41	5.0	0.38	1.55e-6	Colorectal cancer;
PAAD	cis	rs10121009	0.635	rs661712	chr9:35295984	T/C	cg11846315	chr9:35647073	NA	0.49	4.43	0.34	1.78e-5	Parkinson's disease;
PAAD	cis	rs863345	0.604	rs12044288	chr1:158463863	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.9	-0.37	2.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	6.38	0.46	2.02e-9	Personality dimensions;
PAAD	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg16083429	chr3:49237500	CCDC36	-0.44	-4.56	-0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.75e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.55	-5.01	-0.38	1.52e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-4.92	-0.37	2.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs354033	0.800	rs4725816	chr7:149174265	G/A	cg06920324	chr7:149264011	ZNF767	-0.53	-4.39	-0.34	2.07e-5	Multiple sclerosis;
PAAD	cis	rs6810498	0.932	rs10155365	chr4:26056021	G/A	cg02513547	chr4:26029960	NA	-0.48	-4.39	-0.34	2.08e-5	Alcohol dependence;
PAAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg23346134	chr3:49453900	TCTA	0.46	4.88	0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs1359582	0.793	rs701824	chr10:90417712	A/G	cg15661332	chr10:90342814	RNLS	0.55	4.84	0.37	3.16e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg26597838	chr10:835615	NA	0.45	4.83	0.36	3.36e-6	Survival in rectal cancer;
PAAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.74	11.46	0.68	2.62e-22	Schizophrenia;
PAAD	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg03989125	chr22:38214979	NA	0.64	5.84	0.43	3.03e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-1.01	-11.05	-0.67	3.28e-21	IgG glycosylation;
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg16850897	chr7:100343110	ZAN	0.6	5.82	0.43	3.37e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs10214930	0.813	rs2391451	chr7:27685822	C/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.83	-9.64	-0.62	1.88e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12442242	0.522	rs16966212	chr15:38360289	T/C	cg19084031	chr15:38361362	NA	0.94	5.7	0.42	6.05e-8	Total body bone mineral density;
PAAD	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg26816564	chr1:7831052	VAMP3	0.75	5.78	0.42	4.14e-8	Inflammatory bowel disease;
PAAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg06917634	chr15:78832804	PSMA4	0.52	4.95	0.37	1.97e-6	Sudden cardiac arrest;
PAAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.11	0.55	1.6e-13	Prudent dietary pattern;
PAAD	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg13402656	chr8:1511478	DLGAP2	-0.6	-6.32	-0.46	2.7e-9	Lung cancer;
PAAD	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg21191810	chr6:118973309	C6orf204	-0.4	-4.94	-0.37	2.01e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.8	5.84	0.43	3.02e-8	Vitiligo;
PAAD	cis	rs1499972	0.878	rs59470461	chr3:117616314	A/C	cg07612923	chr3:117604196	NA	1.05	7.22	0.51	2.36e-11	Schizophrenia;
PAAD	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.49	4.61	0.35	8.6e-6	Hepatocellular carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17371621	chr15:61264283	RORA	-0.62	-6.32	-0.46	2.81e-9	Obesity-related traits;
PAAD	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs3096299	0.506	rs3114863	chr16:89438667	G/C	cg00750074	chr16:89608354	SPG7	-0.55	-4.96	-0.37	1.9e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg17182837	chr8:41585554	ANK1	-0.45	-4.74	-0.36	4.84e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg05484376	chr2:27715224	FNDC4	0.5	5.07	0.38	1.17e-6	Total body bone mineral density;
PAAD	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.44	-0.34	1.7e-5	Dupuytren's disease;
PAAD	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.89	-11.29	-0.68	7.54e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.09	0.38	1.06e-6	Body mass index;
PAAD	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg10395934	chr14:104002654	TRMT61A	0.57	5.68	0.42	6.61e-8	Body mass index;
PAAD	cis	rs7766436	0.614	rs16886454	chr6:22562975	T/A	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.63	-5.96	-0.44	1.72e-8	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13000004	chr4:149074093	NR3C2	0.53	6.3	0.46	3.12e-9	Smoking initiation;
PAAD	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg24848339	chr3:12840334	CAND2	-0.45	-4.54	-0.35	1.11e-5	P wave duration;
PAAD	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	1.04	12.41	0.71	7.1e-25	Primary sclerosing cholangitis;
PAAD	cis	rs6558530	0.666	rs4242539	chr8:1694236	A/G	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.7e-5	Systolic blood pressure;
PAAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg17031739	chr1:67600172	NA	0.38	4.25	0.33	3.78e-5	Psoriasis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22464883	chr20:31407537	MAPRE1	0.62	6.63	0.47	5.64e-10	Obesity-related traits;
PAAD	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.73	5.75	0.42	4.66e-8	Schizophrenia;
PAAD	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-1.97	-11.23	-0.67	1.06e-21	Cannabis dependence symptom count;
PAAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12935418	0.616	rs2549853	chr16:81026455	G/A	cg16651780	chr16:81037892	C16orf61	-0.61	-5.68	-0.42	6.8e-8	Mean corpuscular volume;
PAAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.48	-4.99	-0.37	1.66e-6	Height;
PAAD	cis	rs6662572	0.585	rs12042481	chr1:45964766	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	4.62	0.35	8.02e-6	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01750051	chr2:178087938	HNRNPA3	-0.54	-6.54	-0.47	8.92e-10	Monocyte percentage of white cells;
PAAD	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.48	4.75	0.36	4.76e-6	Lewy body disease;
PAAD	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.55	4.68	0.36	6.23e-6	Height;
PAAD	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg08999081	chr20:33150536	PIGU	0.5	4.41	0.34	1.95e-5	Protein C levels;
PAAD	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg22827986	chr11:48284249	OR4X1	0.42	5.09	0.38	1.06e-6	Migraine - clinic-based;
PAAD	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.63	-4.7	-0.36	5.82e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.86	8.44	0.56	2.37e-14	Vitamin D levels;
PAAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg23957660	chr17:17878224	LRRC48	0.4	4.64	0.35	7.58e-6	Total body bone mineral density;
PAAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.57	0.35	1.01e-5	Iron status biomarkers;
PAAD	cis	rs4704187	0.687	rs10051040	chr5:74501976	G/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.96	6.95	0.49	9.98e-11	Dental caries;
PAAD	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.96	-6.42	-0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	5.0	0.38	1.54e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg06639496	chr22:50749598	NA	0.69	4.32	0.33	2.82e-5	Acne (severe);
PAAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.45	0.34	1.66e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg24154853	chr7:158122151	PTPRN2	-0.6	-5.42	-0.4	2.29e-7	Calcium levels;
PAAD	cis	rs11671653	1.000	rs60755785	chr19:10839494	T/G	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.79	-9.88	-0.63	4.23e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.45	-4.82	-0.36	3.46e-6	Major depressive disorder;
PAAD	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg21478137	chr15:51532386	CYP19A1	-0.42	-4.32	-0.33	2.77e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Birth weight;
PAAD	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.51	-5.95	-0.43	1.74e-8	Mean arterial pressure;
PAAD	cis	rs7953508	0.741	rs1498707	chr12:93997128	G/A	cg18151635	chr12:93972918	NA	-0.58	-6.22	-0.45	4.64e-9	Pubertal anthropometrics;
PAAD	cis	rs7180079	0.620	rs11071803	chr15:64965815	G/T	cg18210365	chr15:65066710	RBPMS2	-0.5	-4.52	-0.34	1.22e-5	Monocyte count;
PAAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg01840575	chr2:38977957	SFRS7	-0.65	-6.56	-0.47	8.05e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg25886479	chr11:50257625	LOC441601	-0.42	-4.53	-0.35	1.16e-5	Coronary artery disease;
PAAD	cis	rs3764400	0.567	rs12939334	chr17:46302669	A/G	cg24322968	chr17:46507895	SKAP1	0.86	5.27	0.39	4.65e-7	Body mass index;
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs564309	0.681	rs1188489	chr1:228621772	G/A	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.69	7.1	0.5	4.51e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	8.07	0.55	1.98e-13	Eotaxin levels;
PAAD	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.77	8.0	0.54	2.87e-13	Body mass index;
PAAD	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.57	5.39	0.4	2.62e-7	Height;
PAAD	cis	rs735539	0.521	rs7997062	chr13:21368822	A/G	cg27234864	chr13:21295941	IL17D	0.56	4.6	0.35	8.68e-6	Dental caries;
PAAD	cis	rs6585424	1.000	rs34749786	chr10:81924390	C/A	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.63	6.52	0.47	9.68e-10	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.59	-6.59	-0.47	6.81e-10	Lymphocyte counts;
PAAD	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.62	5.68	0.42	6.52e-8	Corneal astigmatism;
PAAD	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.54	-4.93	-0.37	2.13e-6	Glycated hemoglobin levels;
PAAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg18964960	chr10:1102726	WDR37	0.6	4.25	0.33	3.75e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7873102	0.654	rs7857446	chr9:37965641	C/T	cg03528946	chr9:38069800	SHB	0.55	5.62	0.41	8.88e-8	Brain structure;
PAAD	cis	rs8070740	0.559	rs16954604	chr17:5294450	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	4.62	0.35	8.21e-6	Menopause (age at onset);
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg17105886	chr17:28927953	LRRC37B2	0.7	4.71	0.36	5.6e-6	Body mass index;
PAAD	cis	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg21605333	chr4:119757512	SEC24D	1.25	7.8	0.53	9.22e-13	Cannabis dependence symptom count;
PAAD	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.8	8.04	0.55	2.41e-13	Testicular germ cell tumor;
PAAD	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg18165381	chr3:44552316	NA	-0.47	-4.29	-0.33	3.14e-5	Depressive symptoms;
PAAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	4.64	0.35	7.41e-6	Body mass index;
PAAD	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg14703610	chr5:56206110	C5orf35	0.61	5.56	0.41	1.21e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs10078	0.660	rs11746538	chr5:427466	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.43	-5.16	-0.39	7.67e-7	Fat distribution (HIV);
PAAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.19	0.39	6.49e-7	Menarche (age at onset);
PAAD	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.32	-0.46	2.7e-9	Bipolar disorder;
PAAD	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.53	-5.58	-0.41	1.06e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.47	4.59	0.35	9.25e-6	HDL cholesterol;
PAAD	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-4.7	-0.36	5.84e-6	Axial length;
PAAD	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.15	0.55	1.22e-13	Menarche (age at onset);
PAAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.71	-6.38	-0.46	2.06e-9	Coronary artery disease;
PAAD	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.51	-5.94	-0.43	1.91e-8	Mean arterial pressure;
PAAD	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.67	-7.62	-0.53	2.55e-12	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27100511	chr14:105927968	MTA1	0.57	6.5	0.47	1.09e-9	Smoking initiation;
PAAD	trans	rs901683	0.702	rs34176769	chr10:46071027	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12156277	0.513	rs894333	chr8:3174707	C/T	cg23564432	chr8:3253958	CSMD1	0.38	4.4	0.34	2.01e-5	Loneliness;
PAAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2421770	1.000	rs2273689	chr11:35323200	A/G	cg13971030	chr11:35366721	SLC1A2	-0.54	-6.46	-0.46	1.36e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.65	7.43	0.52	7.3e-12	Coronary artery disease;
PAAD	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06307176	chr5:131281290	NA	0.57	4.92	0.37	2.2e-6	Life satisfaction;
PAAD	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	9.68	0.62	1.48e-17	Cognitive test performance;
PAAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.74	6.46	0.46	1.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.66	6.65	0.47	5.07e-10	Platelet count;
PAAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs73206853	0.841	rs73191826	chr12:110943001	G/T	cg12870014	chr12:110450643	ANKRD13A	0.65	4.44	0.34	1.73e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2997447	0.669	rs61776624	chr1:26474580	A/C	cg24519413	chr1:26490540	NA	0.56	4.97	0.37	1.82e-6	QRS complex (12-leadsum);
PAAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.85	-8.08	-0.55	1.83e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg15598662	chr11:61582890	MIR1908;FADS1	0.42	4.27	0.33	3.42e-5	Trans fatty acid levels;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.44	4.53	0.34	1.21e-5	Longevity;Endometriosis;
PAAD	cis	rs12913538	0.619	rs12908357	chr15:62899904	A/G	cg09983546	chr15:62884068	NA	0.59	5.74	0.42	5.04e-8	Sleep depth;
PAAD	cis	rs7638995	0.878	rs1995665	chr3:69183140	A/C	cg26574240	chr3:69171822	LMOD3	-0.72	-5.35	-0.4	3.23e-7	Alzheimer's disease (late onset);
PAAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg05373962	chr22:49881684	NA	-0.46	-4.45	-0.34	1.64e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg17372223	chr3:52568218	NT5DC2	-0.54	-5.36	-0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs7127900	0.561	rs7109219	chr11:2233041	G/A	cg25635251	chr11:2234043	NA	0.8	7.71	0.53	1.57e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.83	-6.81	-0.48	2.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs12044355	0.927	rs11585981	chr1:231833962	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.6	0.35	9e-6	Alzheimer's disease;
PAAD	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg09941381	chr10:64027924	RTKN2	-0.38	-4.52	-0.34	1.23e-5	Rheumatoid arthritis;
PAAD	cis	rs1419980	0.730	rs11054852	chr12:7768918	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.53	-4.78	-0.36	4.19e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	1.32	8.39	0.56	3.11e-14	Diabetic retinopathy;
PAAD	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs61863818	0.557	rs7919862	chr10:99149964	C/T	cg10705379	chr10:99080932	FRAT1	-0.42	-5.17	-0.39	7.26e-7	Monocyte percentage of white cells;
PAAD	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs5742933	0.857	rs1437891	chr2:190562708	C/T	cg04003228	chr2:190539410	ANKAR	0.52	4.28	0.33	3.29e-5	Ferritin levels;
PAAD	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-5.16	-0.39	7.74e-7	Body mass index;
PAAD	cis	rs6499755	0.734	rs31117	chr16:55380843	A/G	cg02859129	chr16:55357253	IRX6	0.34	4.75	0.36	4.71e-6	Hypospadias;
PAAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg25050447	chr17:78165522	CARD14	-0.36	-4.48	-0.34	1.48e-5	Yeast infection;
PAAD	cis	rs1997066	0.831	rs73344313	chr10:106825666	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.45	0.34	1.68e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.89	11.24	0.67	1.04e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.63	5.87	0.43	2.61e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg08390786	chr10:135334061	NA	0.48	4.65	0.35	7.11e-6	Obesity-related traits;
PAAD	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg03907174	chr19:50030461	RCN3	-0.54	-4.41	-0.34	1.91e-5	Fibrinogen levels;
PAAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs7260598	0.539	rs115199376	chr19:24064990	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.48	-5.67	-0.42	6.93e-8	Graves' disease;
PAAD	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.64	-0.42	8.1e-8	Response to antipsychotic treatment;
PAAD	cis	rs243505	0.732	rs10255478	chr7:148501985	C/G	cg09806900	chr7:148480153	CUL1	0.52	4.89	0.37	2.6e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.72	6.39	0.46	1.94e-9	Menarche (age at onset);
PAAD	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.9	7.11	0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg24330906	chr2:85765176	MAT2A	-0.58	-5.75	-0.42	4.67e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7809615	0.748	rs66509940	chr7:99101503	C/T	cg12290671	chr7:99195819	NA	-0.89	-5.1	-0.38	1.01e-6	Blood metabolite ratios;
PAAD	cis	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg15590007	chr10:45870220	ALOX5	0.62	5.63	0.42	8.35e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.65	-8.05	-0.55	2.23e-13	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg16898833	chr6:26189333	HIST1H4D	0.8	4.52	0.34	1.21e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs59888335	1.000	rs13074302	chr3:80749667	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg05927578	chr16:4029543	ADCY9	-0.68	-5.63	-0.42	8.27e-8	Waist circumference;
PAAD	cis	rs9463078	0.746	rs3749863	chr6:45345248	A/C	cg25276700	chr6:44698697	NA	0.47	5.49	0.41	1.61e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.61	6.61	0.47	6.06e-10	Tumor biomarkers;
PAAD	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-5.76	-0.42	4.6e-8	Fear of minor pain;
PAAD	cis	rs3206736	0.520	rs329244	chr7:35060312	C/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.49	-4.44	-0.34	1.74e-5	Diastolic blood pressure;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.35	-0.51	1.14e-11	Longevity;
PAAD	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs2124910	0.689	rs10420457	chr19:52003089	C/T	cg14953197	chr19:52005651	SIGLEC12	0.47	4.97	0.37	1.82e-6	Blood protein levels;
PAAD	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.7	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.88	7.55	0.52	3.74e-12	Triglycerides;
PAAD	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.6	0.35	8.67e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs375066	0.935	rs367741	chr19:44429180	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.59	5.68	0.42	6.73e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4843185	0.764	rs12149202	chr16:85700360	G/A	cg07784872	chr16:85687041	KIAA0182	0.56	4.77	0.36	4.27e-6	Platelet distribution width;
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.73	0.42	5.33e-8	Prudent dietary pattern;
PAAD	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-6.0	-0.44	1.35e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.46	5.84	0.43	3.07e-8	Renal cell carcinoma;
PAAD	cis	rs4942783	0.647	rs9526167	chr13:31580145	T/C	cg22761482	chr13:31579400	NA	-0.45	-4.48	-0.34	1.47e-5	Subjective well-being;
PAAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.15	-8.62	-0.57	7.92e-15	Diabetic kidney disease;
PAAD	cis	rs4742903	0.839	rs10761016	chr9:107007721	A/T	cg14250997	chr9:106856677	SMC2	0.41	4.39	0.34	2.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg08213375	chr14:104286397	PPP1R13B	0.46	6.04	0.44	1.11e-8	Schizophrenia;
PAAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.61	-7.25	-0.51	2.01e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.75	8.88	0.58	1.72e-15	Schizophrenia;
PAAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.91	-11.03	-0.67	3.69e-21	IgG glycosylation;
PAAD	cis	rs9815354	0.761	rs1851149	chr3:42021708	T/C	cg03022575	chr3:42003672	ULK4	-0.71	-4.98	-0.37	1.68e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11771526	0.681	rs1868773	chr7:32401341	C/T	cg13207630	chr7:32358064	NA	0.89	4.47	0.34	1.54e-5	Body mass index;
PAAD	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.59	6.54	0.47	9.04e-10	Testicular germ cell tumor;
PAAD	cis	rs4450131	0.522	rs17152232	chr10:126398927	A/G	cg20435097	chr10:126320824	FAM53B	0.5	4.99	0.37	1.66e-6	White blood cell count (basophil);
PAAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.48	-5.08	-0.38	1.1e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.16	0.39	7.74e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.03e-5	Breast cancer;
PAAD	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.76	0.36	4.52e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.91	7.81	0.54	8.73e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.64	7.18	0.5	2.82e-11	Menopause (age at onset);
PAAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.77	9.02	0.59	7.44e-16	Huntington's disease progression;
PAAD	cis	rs6494488	0.500	rs72741328	chr15:64734339	C/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg08200582	chr11:442649	ANO9	0.51	4.46	0.34	1.59e-5	Systemic lupus erythematosus;
PAAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.86	0.37	2.85e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.89	11.05	0.67	3.41e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4950322	0.512	rs12409455	chr1:146850284	A/G	cg22381352	chr1:146742008	CHD1L	-0.4	-4.26	-0.33	3.54e-5	Protein quantitative trait loci;
PAAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg27455613	chr17:80820699	TBCD	-0.47	-4.64	-0.35	7.52e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg16342193	chr10:102329863	NA	-0.81	-8.84	-0.58	2.18e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.66	-7.22	-0.51	2.37e-11	Colorectal cancer;
PAAD	cis	rs2249694	0.878	rs2480256	chr10:135352514	A/G	cg20169779	chr10:135381914	SYCE1	0.46	4.53	0.34	1.21e-5	Obesity-related traits;
PAAD	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg05484376	chr2:27715224	FNDC4	-0.47	-4.79	-0.36	3.96e-6	Oral cavity cancer;
PAAD	trans	rs6065325	0.515	rs8122094	chr20:39681683	C/G	cg05904605	chr2:31161143	GALNT14	0.7	6.61	0.47	6.06e-10	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.32	0.33	2.8e-5	Mean corpuscular volume;
PAAD	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-6.57	-0.47	7.7e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Bladder cancer;
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21862992	chr11:68658383	NA	0.43	4.85	0.37	2.99e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05584675	chr12:56211824	SARNP;ORMDL2	0.59	6.5	0.47	1.1e-9	Myopia (pathological);
PAAD	cis	rs54211	0.908	rs137666	chr22:39735378	C/T	cg11247378	chr22:39784982	NA	-0.77	-4.47	-0.34	1.51e-5	Sudden cardiac arrest;
PAAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	ch.8.33884649F	chr8:33765107	NA	0.6	6.06	0.44	1.01e-8	Body mass index;
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.57	-5.47	-0.41	1.78e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.41	-0.4	2.44e-7	Obesity-related traits;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-5.74	-0.42	5.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.95	-9.9	-0.63	3.88e-18	Blood pressure (smoking interaction);
PAAD	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg09760422	chr2:128146352	NA	-0.35	-6.21	-0.45	4.76e-9	Protein C levels;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	8.11	0.55	1.56e-13	Prudent dietary pattern;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26556492	chr5:68431589	NA	-0.68	-6.37	-0.46	2.08e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.27	-0.39	4.65e-7	Glomerular filtration rate;
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13732083	chr21:47605072	C21orf56	0.44	4.32	0.33	2.84e-5	Testicular germ cell tumor;
PAAD	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.48	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.69	8.9	0.59	1.56e-15	Coronary artery disease;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.87	-6.44	-0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.6	6.9	0.49	1.3100000000000001e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs10140922	1.000	rs4981288	chr14:35828438	G/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.47	-0.34	1.55e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs41563	0.557	rs17777642	chr7:104599208	G/A	cg04380332	chr7:105027541	SRPK2	-0.53	-5.3	-0.39	4.09e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.62	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.85	4.29	0.33	3.12e-5	Plasma clusterin levels;
PAAD	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.72	0.77	4.64e-31	Chronic sinus infection;
PAAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg20003494	chr4:90757398	SNCA	-0.64	-5.92	-0.43	2.08e-8	Neuroticism;
PAAD	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	1.07	7.55	0.52	3.76e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14648190	chr10:525733	DIP2C	-0.64	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg00035074	chr7:2701567	TTYH3	0.64	4.56	0.35	1.06e-5	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	5.75	0.42	4.72e-8	Non-small cell lung cancer;
PAAD	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg00147160	chr1:26503991	CNKSR1	-0.41	-4.45	-0.34	1.68e-5	Height;
PAAD	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg04330084	chr7:123175371	IQUB	0.5	4.27	0.33	3.37e-5	Plateletcrit;Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10057631	chr1:204380960	PPP1R15B	0.69	7.47	0.52	5.94e-12	Myopia (pathological);
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.69	-0.36	5.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.93e-13	Response to antipsychotic treatment;
PAAD	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.4	5.14	0.38	8.27e-7	Sitting height ratio;
PAAD	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.96	0.49	9.79e-11	Rheumatoid arthritis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14047339	chr6:45345544	RUNX2;SUPT3H	-0.54	-6.38	-0.46	2.01e-9	Body fat percentage;
PAAD	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs7932354	0.550	rs10734549	chr11:46822686	C/A	cg19486271	chr11:47235900	DDB2	-0.57	-5.75	-0.42	4.78e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2073300	1.000	rs6114144	chr20:23462022	A/T	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8064299	0.503	rs11653346	chr17:72773333	A/G	cg21922841	chr17:72744131	SLC9A3R1	0.39	4.65	0.35	7.01e-6	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08618981	chr16:15744397	NDE1	0.55	6.32	0.46	2.82e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	7.51	0.52	4.69e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8018808	0.935	rs958463	chr14:77886721	G/T	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs4692589	0.581	rs62344678	chr4:170961308	G/A	cg19918862	chr4:170955249	NA	0.5	4.44	0.34	1.71e-5	Anxiety disorder;
PAAD	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	9.7	0.62	1.32e-17	Total body bone mineral density;
PAAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.11	-0.55	1.6e-13	Height;
PAAD	cis	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.3	-4.35	-0.33	2.5e-5	Body mass index;
PAAD	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.52	8.75	0.58	3.83e-15	IgG glycosylation;
PAAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.84	7.44	0.52	6.79e-12	Schizophrenia;
PAAD	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	4.54	0.35	1.13e-5	IgG glycosylation;
PAAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Male-pattern baldness;
PAAD	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg18198730	chr1:247681584	NA	0.51	4.75	0.36	4.6e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg01528321	chr10:82214614	TSPAN14	-1.11	-8.71	-0.58	4.83e-15	Post bronchodilator FEV1;
PAAD	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.74	-0.42	5.04e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg04154034	chr17:28927549	LRRC37B2	0.69	4.35	0.33	2.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg18721089	chr20:30220636	NA	-0.56	-5.01	-0.38	1.51e-6	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12282928	0.670	rs12576395	chr11:48355132	A/G	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	7.0	0.49	7.67e-11	Cognitive ability;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg10729496	chr3:10149963	C3orf24	0.63	5.46	0.4	1.89e-7	Alzheimer's disease;
PAAD	cis	rs75920871	0.513	rs113560866	chr11:117015189	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.84	-4.82	-0.36	3.41e-6	Subjective well-being;
PAAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.7	-6.3	-0.46	3.05e-9	Interleukin-10 levels;Interleukin-13 levels;
PAAD	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.79	8.28	0.56	6.01e-14	Gout;
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.19	0.45	5.45e-9	Vitiligo;
PAAD	cis	rs16958440	0.867	rs76558586	chr18:44737613	C/T	cg17192377	chr18:44677553	HDHD2	1.02	5.67	0.42	7.11e-8	Sitting height ratio;
PAAD	cis	rs2790216	1.000	rs1698392	chr10:59967089	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-4.39	-0.34	2.08e-5	Schizophrenia;
PAAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.92	11.54	0.68	1.63e-22	Coronary artery disease;
PAAD	cis	rs78761021	0.594	rs7207209	chr17:9767285	T/C	cg26853458	chr17:9805074	RCVRN	0.45	5.29	0.39	4.25e-7	Type 2 diabetes;
PAAD	cis	rs9659323	0.632	rs10923744	chr1:119613941	G/A	cg26570165	chr1:119541833	NA	-0.52	-5.9	-0.43	2.28e-8	Body mass index;
PAAD	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.66	-7.5	-0.52	4.89e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.24e-5	Coronary artery disease;
PAAD	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg03658251	chr13:50265850	EBPL	0.77	5.62	0.41	8.85e-8	Obesity-related traits;
PAAD	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg20243544	chr17:37824526	PNMT	0.51	4.38	0.34	2.17e-5	Self-reported allergy;
PAAD	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.61	5.38	0.4	2.73e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs2859741	0.587	rs510969	chr1:37475061	T/C	cg09363841	chr1:37513479	NA	-0.57	-6.85	-0.49	1.7e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg26554054	chr8:600488	NA	1.05	7.23	0.51	2.16e-11	IgG glycosylation;
PAAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16024904	chr19:17905718	B3GNT3	0.45	4.49	0.34	1.42e-5	Tumor biomarkers;
PAAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23463467	chr20:60627584	TAF4	0.42	4.37	0.33	2.33e-5	Body mass index;
PAAD	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.14	-0.5	3.61e-11	Blood pressure (smoking interaction);
PAAD	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg20917491	chr3:195578259	NA	0.45	4.49	0.34	1.39e-5	Pancreatic cancer;
PAAD	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.61	0.61	2.21e-17	Electrocardiographic conduction measures;
PAAD	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.61	5.79	0.43	3.88e-8	Lymphocyte counts;
PAAD	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.95	13.23	0.73	4.46e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg11519256	chr10:5708881	ASB13	0.58	5.15	0.39	7.82e-7	Childhood ear infection;
PAAD	cis	rs7210086	0.768	rs72849444	chr17:70637805	G/A	cg04206342	chr17:70636940	NA	-0.44	-5.42	-0.4	2.26e-7	Ulcerative colitis;
PAAD	cis	rs11807834	0.505	rs7512794	chr1:230253247	C/T	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg26727032	chr16:67993705	SLC12A4	-0.65	-4.39	-0.34	2.08e-5	Magnesium levels;
PAAD	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	5.05	0.38	1.23e-6	Monocyte percentage of white cells;
PAAD	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17554472	chr22:41940697	POLR3H	0.59	4.25	0.33	3.65e-5	Vitiligo;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg08779779	chr2:200322566	SATB2	0.63	6.31	0.46	2.96e-9	Primary biliary cholangitis;
PAAD	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg22189786	chr22:42395067	WBP2NL	0.66	4.78	0.36	4.08e-6	Birth weight;
PAAD	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.59	-6.01	-0.44	1.32e-8	Glioblastoma;
PAAD	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.71	-0.36	5.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.84	-0.43	3.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3112530	1.000	rs1462123	chr5:152658668	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg10820045	chr2:198174542	NA	0.45	4.42	0.34	1.87e-5	Dermatomyositis;
PAAD	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.81	5.2	0.39	6.29e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs8133932	0.667	rs760436	chr21:47278055	C/T	cg13695288	chr21:47294981	PCBP3	-0.5	-4.83	-0.36	3.36e-6	Schizophrenia;
PAAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.85	9.05	0.59	6.28e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg19827787	chr1:23763612	ASAP3	0.5	4.64	0.35	7.47e-6	Total cholesterol levels;
PAAD	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.58	-0.35	9.77e-6	Testicular germ cell tumor;
PAAD	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs910187	0.571	rs3827049	chr20:45801319	T/A	cg27589058	chr20:45804311	EYA2	-0.47	-4.97	-0.37	1.78e-6	Migraine;
PAAD	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.73e-10	Total body bone mineral density;
PAAD	trans	rs901683	1.000	rs9422657	chr10:46053061	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.81	6.17	0.45	5.88e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.94	-10.15	-0.64	8.22e-19	Parkinson's disease;
PAAD	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.28	-0.33	3.3e-5	Ileal carcinoids;
PAAD	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.89e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg16606324	chr3:10149918	C3orf24	0.79	6.28	0.45	3.4e-9	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg00543991	chr22:32367038	NA	1.13	6.91	0.49	1.23e-10	Childhood ear infection;
PAAD	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.6	5.99	0.44	1.45e-8	Blood metabolite levels;
PAAD	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.49	-4.36	-0.33	2.38e-5	Triglycerides;
PAAD	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.84	11.44	0.68	3.06e-22	Emphysema distribution in smoking;
PAAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg05185573	chr6:26598237	ABT1	-0.48	-4.88	-0.37	2.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg02487422	chr3:49467188	NICN1	0.46	4.68	0.35	6.43e-6	Resting heart rate;
PAAD	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.62	-5.99	-0.44	1.44e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.58	-6.27	-0.45	3.62e-9	Pelvic organ prolapse;
PAAD	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	1.02	5.0	0.38	1.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7932354	0.583	rs11039014	chr11:46895378	C/T	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2124910	0.779	rs8100538	chr19:52039101	G/C	cg12008991	chr19:52034861	SIGLEC6	0.33	4.33	0.33	2.71e-5	Blood protein levels;
PAAD	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg18518183	chr2:172544446	DYNC1I2	-0.47	-4.27	-0.33	3.43e-5	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.73	-5.95	-0.43	1.81e-8	Schizophrenia;
PAAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-5.67	-0.42	6.91e-8	Gut microbiome composition (summer);
PAAD	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.69	7.31	0.51	1.42e-11	Body mass index;
PAAD	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.38	4.54	0.35	1.12e-5	Rheumatoid arthritis;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg11809123	chr19:1584870	MBD3	-0.68	-6.99	-0.49	7.92e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg12661370	chr5:149340060	SLC26A2	-0.64	-5.49	-0.41	1.68e-7	HIV-1 control;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.17	-0.39	7.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1144	0.505	rs2252074	chr7:104594253	T/G	cg04380332	chr7:105027541	SRPK2	-0.58	-5.86	-0.43	2.72e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs8077577	0.708	rs3829590	chr17:18134265	C/A	cg16794390	chr17:18148240	FLII	-0.52	-4.45	-0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs77741769	0.571	rs1696357	chr12:121348649	A/G	cg02419362	chr12:121203948	SPPL3	0.54	6.23	0.45	4.45e-9	Mean corpuscular volume;
PAAD	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg20952532	chr13:20207656	MPHOSPH8	0.6	6.71	0.48	3.61e-10	Iris heterochromicity;
PAAD	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.65	-8.29	-0.56	5.42e-14	Schizophrenia;
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.66	6.48	0.47	1.19e-9	Blood metabolite levels;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	1.2	7.99	0.54	3.15e-13	IgG glycosylation;
PAAD	cis	rs6025261	0.761	rs6099359	chr20:55509896	G/T	cg11868041	chr20:55503363	NA	-0.43	-4.8	-0.36	3.8e-6	Verbal memory performance (delayed recall level);
PAAD	cis	rs4273100	0.688	rs1533034	chr17:19153175	G/C	cg18093559	chr17:18951025	GRAP	-0.47	-4.78	-0.36	4.17e-6	Schizophrenia;
PAAD	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.05	0.38	1.24e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.66	9.61	0.61	2.2e-17	Huntington's disease progression;
PAAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.02	0.5	6.72e-11	Hip circumference adjusted for BMI;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26260819	chr11:45869049	CRY2	0.6	6.78	0.48	2.46e-10	Monocyte percentage of white cells;
PAAD	cis	rs7707921	0.957	rs2059891	chr5:81508792	G/C	cg21483461	chr5:81570383	RPS23	0.57	4.74	0.36	4.94e-6	Breast cancer;
PAAD	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg02660097	chr11:68866761	NA	0.46	5.32	0.4	3.7e-7	Blond vs. brown hair color;
PAAD	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.81	0.48	2.09e-10	IgG glycosylation;
PAAD	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	7.14	0.5	3.58e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	4.46	0.34	1.6e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg04877966	chr15:75135169	ULK3	0.54	4.67	0.35	6.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.98	-15.31	-0.78	1.3e-32	Height;
PAAD	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg22029157	chr1:209979665	IRF6	-0.68	-6.43	-0.46	1.59e-9	Coronary artery disease;
PAAD	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg16584676	chr17:46985605	UBE2Z	0.51	5.01	0.38	1.47e-6	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05789608	chr1:205180802	DSTYK	0.7	7.17	0.5	3.11e-11	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09492354	chr11:27720709	BDNF	0.57	6.31	0.46	2.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.63	6.85	0.49	1.73e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	4.64	0.35	7.56e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06098346	chr12:48499667	PFKM;SENP1	-0.58	-6.83	-0.48	1.89e-10	Body fat percentage;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg00738919	chr7:1100172	C7orf50	0.67	5.39	0.4	2.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg14703610	chr5:56206110	C5orf35	-0.55	-5.21	-0.39	6.15e-7	Initial pursuit acceleration;
PAAD	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.17	12.88	0.72	3.95e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06850241	chr22:41845214	NA	0.56	4.87	0.37	2.73e-6	Vitiligo;
PAAD	cis	rs1879734	0.953	rs2948043	chr1:54156443	A/C	cg14659662	chr1:54151053	GLIS1	0.42	6.76	0.48	2.72e-10	Mitral valve prolapse;
PAAD	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.53	-5.88	-0.43	2.56e-8	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg24747557	chr10:131355152	MGMT	0.42	4.41	0.34	1.91e-5	Response to temozolomide;
PAAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs643506	0.874	rs582465	chr11:111668585	C/T	cg09085632	chr11:111637200	PPP2R1B	0.57	4.91	0.37	2.29e-6	Breast cancer;
PAAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg18551225	chr6:44695536	NA	-0.73	-7.29	-0.51	1.54e-11	Total body bone mineral density;
PAAD	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.93	-0.49	1.12e-10	Type 2 diabetes;
PAAD	cis	rs12799264	1.000	rs2585777	chr11:19975193	T/C	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.36	-0.4	3.06e-7	Diastolic blood pressure;
PAAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11242200	chr8:22857399	RHOBTB2	0.63	6.76	0.48	2.74e-10	Myopia (pathological);
PAAD	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.73	0.48	3.2e-10	Coffee consumption (cups per day);
PAAD	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	6.62	0.47	5.78e-10	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04205664	chr7:139209511	CLEC2L	0.58	7.04	0.5	6.13e-11	Body fat percentage;
PAAD	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.65	6.95	0.49	9.99e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg03983715	chr16:68378420	PRMT7	-0.74	-5.5	-0.41	1.54e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2790216	1.000	rs2790240	chr10:59982139	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-6.44	-0.46	1.52e-9	Lymphocyte counts;
PAAD	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.43	-5.09	-0.38	1.04e-6	Type 2 diabetes;
PAAD	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs6663390	0.510	rs73072979	chr1:208072057	G/A	cg00387621	chr1:208086895	NA	0.76	4.44	0.34	1.69e-5	Facial morphology (factor 18);
PAAD	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06850241	chr22:41845214	NA	-0.6	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg22800045	chr5:56110881	MAP3K1	0.59	5.31	0.4	3.78e-7	Initial pursuit acceleration;
PAAD	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.01	-17.56	-0.82	2.09e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg24253500	chr15:84953950	NA	0.54	5.23	0.39	5.43e-7	Schizophrenia;
PAAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.26	0.6	1.85e-16	Rheumatoid arthritis;
PAAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg06740227	chr12:86229804	RASSF9	0.5	4.94	0.37	2.07e-6	Major depressive disorder;
PAAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.55	-5.22	-0.39	5.8e-7	Resistin levels;
PAAD	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-5.63	-0.42	8.33e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.56	6.29	0.45	3.23e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs1292059	1	rs1292059	chr17:57957888	T/A	cg02344993	chr17:57696989	CLTC	0.52	4.26	0.33	3.63e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-4.39	-0.34	2.09e-5	Retinal vascular caliber;
PAAD	cis	rs10512697	0.655	rs13156164	chr5:3509083	C/T	cg19473799	chr5:3511975	NA	-1.07	-4.57	-0.35	1.02e-5	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs901683	1.000	rs12773463	chr10:46003631	A/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4774830	0.744	rs62046381	chr15:56300281	T/G	cg24530489	chr15:56299380	NA	-0.91	-4.48	-0.34	1.44e-5	Delta-5 desaturase activity;
PAAD	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg18087520	chr14:90862618	CALM1	0.41	4.31	0.33	2.89e-5	Mortality in heart failure;
PAAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.59	6.5	0.47	1.09e-9	Blood metabolite levels;
PAAD	cis	rs728616	0.867	rs17098720	chr10:81840236	A/G	cg05935833	chr10:81318306	SFTPA2	-0.58	-4.55	-0.35	1.09e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg00990874	chr7:1149470	C7orf50	-0.86	-8.69	-0.58	5.41e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs189798	0.845	rs330904	chr8:8991825	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.38	-0.46	2.01e-9	Myopia (pathological);
PAAD	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs9532580	0.614	rs2180961	chr13:41140044	T/A	cg21288729	chr13:41239152	FOXO1	0.59	4.62	0.35	8.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg02725872	chr8:58115012	NA	-0.6	-5.16	-0.39	7.46e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00149659	chr3:10157352	C3orf10	0.82	6.18	0.45	5.65e-9	Alzheimer's disease;
PAAD	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg01388757	chr2:102091195	RFX8	0.6	7.66	0.53	1.98e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09070503	chr1:36107132	PSMB2	0.58	6.62	0.47	5.88e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.87	10.09	0.63	1.19e-18	Coronary artery disease;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg11196182	chr7:1989412	MAD1L1	0.4	4.27	0.33	3.46e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg06375148	chr1:209958343	C1orf74	0.68	5.27	0.39	4.57e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.52	-5.01	-0.38	1.53e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.68	6.26	0.45	3.7e-9	Plateletcrit;Platelet count;
PAAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg03989125	chr22:38214979	NA	0.64	6.33	0.46	2.6e-9	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.91	10.35	0.64	2.53e-19	Obesity-related traits;
PAAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.58	6.8	0.48	2.22e-10	Aortic root size;
PAAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.55	-6.97	-0.49	9.19e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.38	-4.29	-0.33	3.11e-5	Type 2 diabetes;
PAAD	cis	rs7818688	0.697	rs11784212	chr8:95976995	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10512697	0.772	rs35155570	chr5:3518273	C/T	cg19473799	chr5:3511975	NA	-1.03	-4.6	-0.35	8.95e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.48	-4.8	-0.36	3.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs732765	0.646	rs4508370	chr14:75115887	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-4.52	-0.34	1.25e-5	Non-small cell lung cancer;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.53	-0.57	1.38e-14	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg16606324	chr3:10149918	C3orf24	0.81	6.31	0.46	2.95e-9	Alzheimer's disease;
PAAD	cis	rs9595066	1.000	rs66786230	chr13:44711625	T/C	cg04068111	chr13:44716778	NA	-0.59	-6.3	-0.46	3.04e-9	Schizophrenia;
PAAD	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.57	5.14	0.38	8.28e-7	Mean platelet volume;
PAAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg23283495	chr1:209979779	IRF6	-0.67	-5.6	-0.41	9.72e-8	Coronary artery disease;
PAAD	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.5	5.06	0.38	1.22e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg05874882	chr4:1763078	NA	-0.37	-5.19	-0.39	6.75e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg14393609	chr7:65229607	NA	-0.64	-7.0	-0.49	7.83e-11	Aortic root size;
PAAD	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	1.01	9.86	0.62	4.99e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg21937377	chr3:194868750	C3orf21	0.47	4.91	0.37	2.32e-6	Non-small cell lung cancer;
PAAD	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.79	-5.88	-0.43	2.57e-8	Coronary artery calcification;
PAAD	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg05914723	chr15:78953907	NA	0.57	4.43	0.34	1.8e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs656900	0.647	rs1615963	chr15:80115826	C/T	cg02196730	chr15:80188777	MTHFS	-0.42	-4.55	-0.35	1.08e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg15571903	chr15:79123663	NA	0.39	4.79	0.36	3.99e-6	Coronary artery disease;
PAAD	cis	rs9921192	0.967	rs251737	chr16:4318305	C/T	cg00021532	chr16:4324280	TFAP4	0.91	12.65	0.72	1.66e-25	Prostate-specific antigen levels;
PAAD	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.61	6.46	0.46	1.32e-9	Crohn's disease;
PAAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.66	-6.57	-0.47	7.69e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg00738919	chr7:1100172	C7orf50	0.59	4.51	0.34	1.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	7.92	0.54	4.65e-13	Coronary artery disease;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.46	5.87	0.43	2.63e-8	Cystic fibrosis severity;
PAAD	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg08807892	chr2:162101083	NA	-0.5	-5.03	-0.38	1.37e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.2	-0.5	2.52e-11	Alcohol dependence;
PAAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.95	-13.16	-0.73	6.97e-27	Height;
PAAD	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg09127314	chr1:152161683	NA	-0.63	-4.58	-0.35	9.45e-6	Atopic dermatitis;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg03098721	chr1:84464084	TTLL7	0.49	4.67	0.35	6.57e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg02196655	chr2:10830764	NOL10	0.54	5.62	0.41	9.03e-8	Prostate cancer;
PAAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg11143131	chr5:131608246	PDLIM4	-0.46	-4.7	-0.36	5.89e-6	Blood metabolite levels;
PAAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.43e-7	Bone mineral density;
PAAD	cis	rs12986413	0.781	rs2864419	chr19:2183175	A/C	cg09261902	chr19:2140048	AP3D1	-0.44	-4.34	-0.33	2.57e-5	Height;
PAAD	cis	rs4481887	0.538	rs10888328	chr1:248378777	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-4.67	-0.35	6.55e-6	Common traits (Other);
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg02869306	chr7:64672164	INTS4L1	-0.45	-5.2	-0.39	6.47e-7	Calcium levels;
PAAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg01075559	chr1:2537774	MMEL1	0.53	5.56	0.41	1.17e-7	Ulcerative colitis;
PAAD	cis	rs9463078	0.585	rs964452	chr6:45128742	G/A	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg00484396	chr16:3507460	NAT15	0.87	5.14	0.38	8.48e-7	Tuberculosis;
PAAD	cis	rs12311304	0.965	rs11056399	chr12:15365510	C/T	cg08258403	chr12:15378311	NA	0.36	4.53	0.34	1.2e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-7.86	-0.54	6.46e-13	Migraine;Coronary artery disease;
PAAD	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg01064725	chr1:204461714	NA	-0.51	-4.93	-0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.48	-4.35	-0.33	2.5e-5	Acne (severe);
PAAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	10.13	0.63	9.35e-19	Platelet count;
PAAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.32	0.4	3.59e-7	Prostate cancer;
PAAD	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.78	7.12	0.5	4.06e-11	Obesity-related traits;
PAAD	cis	rs4150161	0.656	rs2230131	chr16:84212779	G/A	cg10106505	chr16:84220380	TAF1C	-1.03	-5.85	-0.43	2.84e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs2421770	0.532	rs7110991	chr11:35343239	A/G	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs743757	1.000	rs12490042	chr3:50434984	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	4.58	0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs2790216	0.950	rs2790155	chr10:59974744	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg21929781	chr1:2537748	MMEL1	0.5	5.31	0.4	3.86e-7	Ulcerative colitis;
PAAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg02876276	chr17:77834299	NA	0.6	4.31	0.33	2.94e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	4.57	0.35	9.87e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs11871801	1.000	rs35261210	chr17:40588316	C/T	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg21859623	chr20:33103246	DYNLRB1	0.48	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.82	6.67	0.48	4.54e-10	Alzheimer's disease;
PAAD	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs17162190	0.698	rs6675469	chr1:26789813	G/A	cg17456097	chr1:26900765	RPS6KA1	0.57	4.56	0.35	1.06e-5	Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13595904	chr3:137834489	DZIP1L	-0.74	-6.47	-0.46	1.29e-9	Neuroticism;
PAAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.69	6.22	0.45	4.68e-9	Vitiligo;
PAAD	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.48	-5.88	-0.43	2.48e-8	Mean corpuscular volume;
PAAD	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs3112530	0.901	rs300326	chr5:152704461	T/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg00919237	chr7:87102261	ABCB4	-0.75	-6.18	-0.45	5.51e-9	Gallbladder cancer;
PAAD	cis	rs4588572	0.706	rs72760906	chr5:77652457	T/C	cg11547950	chr5:77652471	NA	0.92	8.59	0.57	9.45e-15	Triglycerides;
PAAD	cis	rs2882667	0.690	rs288040	chr5:138204894	A/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.44	5.65	0.42	7.78e-8	Panic disorder;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.49	7.63	0.53	2.39e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg08992911	chr2:238395768	MLPH	0.66	6.35	0.46	2.4e-9	Prostate cancer;
PAAD	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.61	5.87	0.43	2.66e-8	Subjective well-being;
PAAD	cis	rs1476670	0.661	rs10157253	chr1:44505646	C/G	cg09470012	chr1:44509516	NA	0.46	4.5	0.34	1.33e-5	Eotaxin levels;
PAAD	cis	rs10924309	0.737	rs4658797	chr1:245854862	G/A	cg00036263	chr1:245852353	KIF26B	-0.64	-6.15	-0.45	6.68e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.56	-0.35	1.06e-5	Breast cancer;
PAAD	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.71	4.63	0.35	7.92e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs1420338	0.867	rs7795950	chr7:34161715	A/G	cg01275685	chr7:34179230	BMPER	-0.53	-5.02	-0.38	1.46e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.8	-0.36	3.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.28	11.68	0.69	6.88e-23	Uric acid levels;
PAAD	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg20607287	chr7:12443886	VWDE	-0.65	-5.91	-0.43	2.14e-8	Coronary artery disease;
PAAD	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.97	12.59	0.71	2.33e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.12	-0.38	9.03e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.51	-6.17	-0.45	5.86e-9	Sitting height ratio;
PAAD	cis	rs6547631	0.592	rs13408224	chr2:85923936	C/T	cg24620635	chr2:85921963	GNLY	0.43	5.58	0.41	1.08e-7	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22933807	chr19:47925425	NA	0.57	6.43	0.46	1.58e-9	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.65	-0.62	1.77e-17	Alzheimer's disease (late onset);
PAAD	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.6	6.53	0.47	9.39e-10	Urate levels;
PAAD	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.64	5.81	0.43	3.62e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.73	-8.62	-0.57	7.94e-15	Height;
PAAD	cis	rs797680	0.856	rs693737	chr1:93724924	G/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.3	-0.33	3.1e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs2279817	0.863	rs6679957	chr1:18011361	T/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.71	-8.41	-0.56	2.78e-14	Huntington's disease progression;
PAAD	cis	rs734999	0.967	rs10910089	chr1:2498618	G/T	cg05392440	chr1:2478653	NA	0.56	6.15	0.45	6.52e-9	Ulcerative colitis;
PAAD	cis	rs7172971	0.688	rs7165460	chr15:42382873	A/G	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2137920	0.685	rs1877806	chr10:50238117	G/A	cg02657375	chr10:50863136	CHAT	0.54	4.39	0.34	2.15e-5	Migraine with aura;
PAAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg10167378	chr1:228756711	NA	0.6	4.49	0.34	1.43e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg09127314	chr1:152161683	NA	0.69	5.1	0.38	1e-6	Atopic dermatitis;
PAAD	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.72	6.06	0.44	1.05e-8	Schizophrenia;
PAAD	cis	rs1879734	0.731	rs61184814	chr1:54160709	G/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.76	-0.58	3.67e-15	Exhaled nitric oxide output;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20526654	chr3:72495865	RYBP	-0.64	-6.41	-0.46	1.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.42	-0.4	2.26e-7	Response to temozolomide;
PAAD	cis	rs7550636	0.797	rs10921283	chr1:192870469	A/G	cg05576974	chr1:193028138	TROVE2;UCHL5	0.45	4.34	0.33	2.58e-5	Coronary artery calcification;
PAAD	cis	rs75920871	0.589	rs56061158	chr11:117087118	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.44	-0.34	1.72e-5	Subjective well-being;
PAAD	cis	rs2810114	0.834	rs36559	chr14:71354949	A/T	cg15910301	chr14:71632612	NA	0.38	4.36	0.33	2.35e-5	Alcohol dependence;
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg04257695	chr17:30186438	C17orf79	-0.62	-4.89	-0.37	2.53e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.68	6.88	0.49	1.48e-10	Renal function-related traits (BUN);
PAAD	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg12963866	chr19:57752005	ZNF805	-0.47	-4.56	-0.35	1.06e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17407555	0.657	rs56346932	chr4:10377032	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.38	-0.4	2.75e-7	Schizophrenia (age at onset);
PAAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg03989125	chr22:38214979	NA	0.61	5.65	0.42	7.82e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.58	4.29	0.33	3.19e-5	Systolic blood pressure;
PAAD	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.54	5.9	0.43	2.24e-8	Bladder cancer;
PAAD	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg01851573	chr8:8652454	MFHAS1	0.6	5.08	0.38	1.08e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg06958535	chr1:203734478	LAX1	-0.34	-4.38	-0.33	2.17e-5	Schizophrenia;
PAAD	cis	rs282587	0.569	rs9604421	chr13:113410493	C/G	cg19217778	chr13:113420270	ATP11A	-0.54	-4.3	-0.33	3.03e-5	Glycated hemoglobin levels;
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Body mass index;
PAAD	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-0.95	-8.33	-0.56	4.3e-14	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24477899	chr19:10305780	DNMT1	0.62	7.04	0.5	6.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.06e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg12623918	chr2:306882	NA	0.45	4.64	0.35	7.42e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg14686297	chr22:46650375	NA	-0.46	-4.53	-0.35	1.16e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.42	4.97	0.37	1.8e-6	Uric acid levels;
PAAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2016586	0.894	rs1997883	chr22:36103709	C/T	cg26342177	chr22:36113512	APOL5	0.49	4.97	0.37	1.77e-6	Body mass index;
PAAD	cis	rs375066	0.935	rs397346	chr19:44399115	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.11e-7	Breast cancer;
PAAD	cis	rs748404	0.518	rs2927085	chr15:43989530	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.29	0.39	4.11e-7	Lung cancer;
PAAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.46	5.12	0.38	9.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.92	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.65	-4.52	-0.34	1.24e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.41	5.07	0.38	1.14e-6	Systolic blood pressure;
PAAD	trans	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg00717180	chr2:96193071	NA	-0.62	-6.61	-0.47	6.2e-10	Migraine - clinic-based;
PAAD	cis	rs12760731	0.623	rs3791026	chr1:178343890	G/A	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs9381040	0.692	rs4714430	chr6:41157054	T/G	cg03526776	chr6:41159608	TREML2	0.45	4.98	0.37	1.73e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.69	7.05	0.5	5.9e-11	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.84	-0.43	3.09e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-9.16	-0.6	3.34e-16	Mean platelet volume;
PAAD	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Colorectal cancer;
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-5.9	-0.43	2.32e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.36	0.4	3.02e-7	Rheumatoid arthritis;
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-4.51	-0.34	1.29e-5	Lung cancer;
PAAD	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.26	11.05	0.67	3.25e-21	Uric acid levels;
PAAD	cis	rs17095355	1.000	rs7067604	chr10:111734665	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.29	-0.33	3.11e-5	Biliary atresia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03734501	chr13:114838102	RASA3	-0.65	-6.57	-0.47	7.46e-10	Obesity-related traits;
PAAD	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg16606324	chr3:10149918	C3orf24	0.77	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.58	5.52	0.41	1.44e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12712270	chr4:3519929	LRPAP1	-0.59	-6.36	-0.46	2.21e-9	Monocyte percentage of white cells;
PAAD	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	1.0	9.23	0.6	2.24e-16	Migraine;
PAAD	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.65	6.28	0.45	3.38e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs2712184	0.875	rs7586692	chr2:217674703	G/T	cg05032264	chr2:217675019	NA	-0.61	-6.75	-0.48	2.93e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.94	0.49	1.03e-10	Triglycerides;
PAAD	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.41	-6.2	-0.45	5.06e-9	Subjective well-being;
PAAD	cis	rs2003620	1	rs2003620	chr7:134479484	C/T	cg19086309	chr7:134513289	CALD1	-0.86	-4.54	-0.35	1.14e-5	Hepatocyte growth factor levels;
PAAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.14	0.45	6.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs757081	0.648	rs11024223	chr11:17277693	A/T	cg04705435	chr11:17411270	KCNJ11	0.53	5.33	0.4	3.43e-7	Systolic blood pressure;
PAAD	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.79	7.52	0.52	4.55e-12	Neuroticism;
PAAD	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.68	6.44	0.46	1.49e-9	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.58	-6.8	-0.48	2.29e-10	Bipolar disorder;
PAAD	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.56	0.35	1.05e-5	Calcium levels;
PAAD	cis	rs9652601	0.959	rs12708715	chr16:11177824	C/T	cg04616529	chr16:11181986	CLEC16A	0.48	5.11	0.38	9.4e-7	Systemic lupus erythematosus;
PAAD	cis	rs7092929	0.883	rs651750	chr10:3577178	A/G	cg14308648	chr10:3568949	NA	0.67	5.02	0.38	1.4e-6	Coronary artery calcification;
PAAD	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg14343924	chr8:8086146	FLJ10661	-0.61	-5.25	-0.39	5.04e-7	Mood instability;
PAAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.54	-5.71	-0.42	5.73e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3136441	1.000	rs11604876	chr11:46768041	A/G	cg19486271	chr11:47235900	DDB2	0.66	5.12	0.38	9.17e-7	HDL cholesterol;
PAAD	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-4.79	-0.36	3.98e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg20159608	chr7:32802032	NA	-0.53	-5.23	-0.39	5.55e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	7.52	0.52	4.33e-12	Renal function-related traits (BUN);
PAAD	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg26597838	chr10:835615	NA	0.49	5.3	0.39	4e-7	Survival in rectal cancer;
PAAD	trans	rs34599045	0.522	rs3885994	chr1:152937926	A/C	cg17345985	chr22:35950011	RASD2	1.07	6.35	0.46	2.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.15	7.81	0.54	8.7e-13	Lung cancer in ever smokers;
PAAD	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Schizophrenia;
PAAD	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg10885151	chr13:24270087	NA	0.38	4.31	0.33	2.95e-5	Obesity-related traits;
PAAD	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg10856724	chr12:34555212	NA	-0.44	-4.49	-0.34	1.39e-5	Morning vs. evening chronotype;
PAAD	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg01620082	chr3:125678407	NA	-1.44	-8.11	-0.55	1.61e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs13424612	0.896	rs12466838	chr2:240893427	G/A	cg01812947	chr2:240904978	NDUFA10	0.6	5.29	0.39	4.13e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs2882667	0.690	rs7709789	chr5:138274451	C/T	cg09476006	chr5:138032270	NA	0.46	5.82	0.43	3.33e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.17	0.39	7.17e-7	Lung function (FEV1/FVC);
PAAD	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs346785	0.692	rs2279056	chr17:74309474	C/T	cg09812376	chr17:74270190	QRICH2	0.43	5.65	0.42	7.65e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9810890	1.000	rs115284166	chr3:128492511	A/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs1539053	0.966	rs11207081	chr1:58101851	A/C	cg00026909	chr1:58089001	DAB1	-0.7	-8.09	-0.55	1.72e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg05342682	chr7:94953680	PON1	-0.49	-4.44	-0.34	1.74e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.61	-0.41	9.48e-8	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.41	4.38	0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg02071572	chr4:1403502	NA	0.36	4.54	0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18364779	chr6:26104403	HIST1H4C	0.46	4.62	0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg27449745	chr7:23145252	KLHL7	-0.55	-4.93	-0.37	2.14e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.67	6.56	0.47	7.79e-10	Coronary artery disease;
PAAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg19930314	chr7:98593876	TRRAP	-0.48	-4.69	-0.36	5.93e-6	Breast cancer;
PAAD	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.65	-6.44	-0.46	1.48e-9	Post bronchodilator FEV1;
PAAD	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	7.7	0.53	1.65e-12	Response to antipsychotic treatment;
PAAD	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.47	5.67	0.42	6.87e-8	Crohn's disease;
PAAD	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.57	-6.51	-0.47	1.03e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg24253500	chr15:84953950	NA	0.55	6.5	0.47	1.07e-9	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.49	-5.01	-0.38	1.48e-6	Adult asthma;
PAAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.74	5.73	0.42	5.33e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	5.56	0.41	1.18e-7	Systolic blood pressure;
PAAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.78	8.63	0.57	7.78e-15	Longevity;
PAAD	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg11204139	chr17:3907470	NA	0.68	6.78	0.48	2.47e-10	Type 2 diabetes;
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.51	-6.52	-0.47	9.77e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.44	-4.58	-0.35	9.56e-6	Coronary heart disease;
PAAD	cis	rs6669119	0.591	rs9439748	chr1:19112836	A/G	cg19637330	chr1:19110922	NA	0.83	5.13	0.38	8.63e-7	Percentage gas trapping;
PAAD	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.84	-10.14	-0.64	9.15e-19	Brugada syndrome;
PAAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.51	-6.57	-0.47	7.57e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg10377582	chr12:51612794	POU6F1	-0.37	-4.38	-0.34	2.16e-5	Cisplatin-induced ototoxicity;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12417720	chr6:108878861	NA	0.58	6.62	0.47	5.84e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6466055	0.612	rs12154942	chr7:104859435	T/C	cg04380332	chr7:105027541	SRPK2	0.47	4.53	0.35	1.17e-5	Schizophrenia;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg00976097	chr5:421733	AHRR	-0.53	-5.05	-0.38	1.23e-6	Cystic fibrosis severity;
PAAD	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs11630290	0.736	rs6494440	chr15:64145709	C/T	cg12036633	chr15:63758958	NA	0.68	4.75	0.36	4.73e-6	Iris characteristics;
PAAD	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.55	6.91	0.49	1.23e-10	Atrioventricular conduction;
PAAD	cis	rs1620921	0.524	rs4440440	chr6:161183424	A/C	cg01280913	chr6:161186852	NA	-0.49	-5.44	-0.4	2.09e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs34285816	chr10:45976851	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2384550	0.581	rs7958534	chr12:115353100	A/G	cg05726002	chr12:115341178	NA	-0.39	-4.75	-0.36	4.6e-6	Blood pressure;Diastolic blood pressure;
PAAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.38	0.56	3.26e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.62	-7.54	-0.52	3.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.49	-4.52	-0.34	1.22e-5	Lung cancer;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.34	-0.33	2.55e-5	Lung cancer;
PAAD	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.69	8.15	0.55	1.27e-13	Lung cancer;
PAAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.48	4.99	0.38	1.6e-6	Type 2 diabetes;
PAAD	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.6	5.77	0.42	4.29e-8	Prudent dietary pattern;
PAAD	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.96	9.63	0.62	2.01e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-5.64	-0.42	8.17e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.47	-4.49	-0.34	1.38e-5	Urinary tract infection frequency;
PAAD	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18898632	chr2:242989856	NA	-0.85	-6.83	-0.48	1.92e-10	Obesity-related traits;
PAAD	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg09122158	chr11:57436238	ZDHHC5	-0.52	-4.36	-0.33	2.36e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.12	-7.83	-0.54	7.91e-13	Schizophrenia;
PAAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12599982	chr1:44399894	ARTN	0.44	4.34	0.33	2.61e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1561176	1.000	rs1561176	chr7:155008713	T/G	cg25063631	chr7:155025500	NA	-0.51	-4.28	-0.33	3.26e-5	Personality dimensions;
PAAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg23708337	chr7:1209742	NA	0.75	4.35	0.33	2.45e-5	Longevity;Endometriosis;
PAAD	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg13171406	chr11:92712998	MTNR1B	-0.5	-4.46	-0.34	1.62e-5	Pulmonary function decline;
PAAD	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg20607287	chr7:12443886	VWDE	-0.72	-6.58	-0.47	7.34e-10	Coronary artery disease;
PAAD	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.75	8.63	0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.93	12.16	0.7	3.46e-24	Menopause (age at onset);
PAAD	trans	rs3758141	0.858	rs6984859	chr8:18730946	C/G	cg02479022	chr8:22250005	SLC39A14	-1.04	-6.47	-0.46	1.3e-9	Body mass index (change over time) in gastrointestinal cancer;
PAAD	cis	rs17032980	0.910	rs1921280	chr2:67329905	A/C	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.03e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.71	6.18	0.45	5.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.6	6.12	0.44	7.71e-9	Monocyte count;
PAAD	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.48	4.57	0.35	1.01e-5	Fractional excretion of uric acid;
PAAD	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.53	-4.68	-0.35	6.35e-6	Myopia (pathological);
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	5.47	0.41	1.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg23281280	chr6:28129359	ZNF389	-0.48	-4.3	-0.33	3.08e-5	Parkinson's disease;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.64	0.62	1.91e-17	Lymphocyte counts;
PAAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg03650551	chr16:1797383	MAPK8IP3	-0.46	-4.25	-0.33	3.74e-5	Coronary artery disease;
PAAD	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg00717180	chr2:96193071	NA	0.6	6.72	0.48	3.42e-10	HDL cholesterol;
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg16040993	chr19:53496440	ZNF702P	-0.47	-4.66	-0.35	6.78e-6	Psoriasis;
PAAD	cis	rs12799172	0.566	rs2741742	chr11:6817328	A/T	cg23386594	chr11:6866523	OR10A5	0.4	4.29	0.33	3.21e-5	Periodontal disease-related phenotypes;
PAAD	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.54	4.39	0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs1499972	0.529	rs10212155	chr3:117785505	G/A	cg07612923	chr3:117604196	NA	-0.72	-5.11	-0.38	9.73e-7	Schizophrenia;
PAAD	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18364779	chr6:26104403	HIST1H4C	0.45	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.77	8.57	0.57	1.11e-14	Monocyte percentage of white cells;
PAAD	cis	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.83	10.29	0.64	3.64e-19	Bladder cancer;
PAAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.73e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.7	5.18	0.39	6.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.98	0.63	2.31e-18	Prudent dietary pattern;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	trans	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg10616974	chr17:74511719	NA	0.41	6.3	0.46	3.01e-9	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs35123781	0.502	rs2336901	chr5:138919078	A/G	cg11459648	chr5:138714337	SLC23A1	-0.66	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs12913538	0.962	rs10851714	chr15:62897029	A/G	cg09983546	chr15:62884068	NA	-0.71	-8.05	-0.55	2.2e-13	Sleep depth;
PAAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.52	4.63	0.35	7.77e-6	Mean corpuscular volume;
PAAD	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg10705379	chr10:99080932	FRAT1	-0.43	-5.03	-0.38	1.36e-6	Monocyte count;
PAAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.94	10.72	0.66	2.54e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs7129556	1.000	rs7129556	chr11:77300048	A/G	cg24456632	chr11:77314957	AQP11	0.5	4.29	0.33	3.14e-5	Weight loss (gastric bypass surgery);
PAAD	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	5.19	0.39	6.66e-7	Schizophrenia;
PAAD	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg22139774	chr2:100720529	AFF3	-0.35	-4.33	-0.33	2.71e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg00576331	chr11:65640516	EFEMP2	-0.45	-4.3	-0.33	3.1e-5	Eosinophil percentage of white cells;
PAAD	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg18370025	chr7:2749541	AMZ1	-0.37	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.88	4.63	0.35	7.77e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9462846	0.959	rs9462843	chr6:42856499	T/G	cg02353165	chr6:42928485	GNMT	0.61	4.72	0.36	5.38e-6	Blood protein levels;
PAAD	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.79	8.45	0.57	2.21e-14	Mean corpuscular volume;
PAAD	cis	rs8014252	0.803	rs74938470	chr14:71040022	T/C	cg11204974	chr14:71022665	NA	-0.78	-5.02	-0.38	1.42e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.4	-0.34	2.04e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13891985	chr10:13482679	BEND7	0.67	7.44	0.52	6.73e-12	Myopia (pathological);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03381515	chr2:20251148	LAPTM4A	-0.65	-6.68	-0.48	4.15e-10	Lung cancer in ever smokers;
PAAD	cis	rs10901513	0.826	rs56132121	chr10:127668056	T/C	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	7.32	0.51	1.34e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.99	13.74	0.74	2e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs621559	0.636	rs612626	chr1:43681184	C/T	cg14851383	chr1:43888477	KIAA0467	0.55	4.33	0.33	2.66e-5	Telomere length;
PAAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg03959625	chr15:84868606	LOC388152	0.41	4.26	0.33	3.62e-5	Schizophrenia;
PAAD	trans	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg08648136	chr8:956695	NA	0.49	5.18	0.39	6.99e-7	Schizophrenia;
PAAD	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.52e-6	Migraine;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03404566	chr17:6899310	ALOX12	0.44	4.59	0.35	9.2e-6	Tonsillectomy;
PAAD	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg16205897	chr5:131564050	P4HA2	-0.39	-4.36	-0.33	2.39e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.18	-0.39	6.83e-7	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.67	4.62	0.35	7.99e-6	Mean platelet volume;
PAAD	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.75	7.89	0.54	5.53e-13	Mean corpuscular volume;
PAAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg10534938	chr5:1868639	NA	0.5	6.56	0.47	7.84e-10	Cardiovascular disease risk factors;
PAAD	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-4.29	-0.33	3.11e-5	Coronary artery disease;
PAAD	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2133450	0.967	rs17697014	chr3:7342273	T/G	cg19930620	chr3:7340148	GRM7	-0.44	-4.6	-0.35	8.85e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs9534288	0.552	rs2840241	chr13:46658903	T/G	cg15192986	chr13:46630673	CPB2	-0.71	-6.0	-0.44	1.39e-8	Blood protein levels;
PAAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs7243821	1.000	rs58924585	chr18:52642611	C/T	cg16669619	chr18:52630472	NA	-0.44	-4.49	-0.34	1.38e-5	Chin dimples;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.61	6.67	0.48	4.57e-10	Lung cancer;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9826463	0.757	rs73238200	chr3:142204634	C/T	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.38	-0.33	2.18e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.65	7.26	0.51	1.86e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.26	0.73	3.74e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg12290671	chr7:99195819	NA	-0.92	-5.23	-0.39	5.51e-7	Blood metabolite ratios;
PAAD	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.69	5.67	0.42	7.11e-8	Menarche (age at onset);
PAAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Coronary artery disease;
PAAD	cis	rs799165	0.540	rs17145813	chr7:73046758	A/C	cg14087351	chr7:73037990	MLXIPL	0.44	4.35	0.33	2.49e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg03264133	chr6:25882463	NA	-0.54	-4.59	-0.35	9.09e-6	Iron status biomarkers;
PAAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.47	5.05	0.38	1.28e-6	Lung cancer;
PAAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.64	0.65	4.1e-20	Menopause (age at onset);
PAAD	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg20356878	chr3:121714668	ILDR1	0.48	4.53	0.34	1.2e-5	Cognitive performance;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.09	0.44	8.88e-9	Height;
PAAD	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.71	8.93	0.59	1.32e-15	Dupuytren's disease;
PAAD	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg01362358	chr17:58117360	NA	0.4	4.7	0.36	5.82e-6	Hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01225541	chr5:122110639	SNX2	0.62	6.76	0.48	2.82e-10	Myopia (pathological);
PAAD	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.88	-13.34	-0.73	2.28e-27	Colorectal cancer;
PAAD	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg10072921	chr12:121022843	NA	-0.36	-4.73	-0.36	5.13e-6	High light scatter reticulocyte count;
PAAD	cis	rs6102074	0.967	rs6072084	chr20:39271400	A/C	cg22477343	chr20:39312069	NA	-0.3	-4.29	-0.33	3.19e-5	White blood cell count;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-6.62	-0.47	5.72e-10	Lymphocyte counts;
PAAD	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	10.69	0.66	3.03e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.71	4.38	0.33	2.21e-5	Lung cancer (smoking interaction);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg21547190	chr19:33793141	CEBPA;LOC80054	0.58	6.46	0.46	1.35e-9	Immature fraction of reticulocytes;
PAAD	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.6	0.41	9.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4879913	0.801	rs7849006	chr9:35592324	C/A	cg18130437	chr9:35658183	CCDC107;RMRP	-0.45	-4.38	-0.33	2.2e-5	Electroencephalogram traits;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg01305625	chr5:131593812	PDLIM4	-0.45	-4.34	-0.33	2.6e-5	Acylcarnitine levels;
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.56	4.74	0.36	4.87e-6	Bronchopulmonary dysplasia;
PAAD	trans	rs11794666	0.746	rs35508661	chr9:31632697	A/C	cg05628366	chr6:35744188	C6orf126	1.05	6.39	0.46	1.88e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17641971	0.619	rs7013425	chr8:49953085	G/A	cg00325661	chr8:49890786	NA	0.53	5.33	0.4	3.47e-7	Blood metabolite levels;
PAAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.62	-6.61	-0.47	6.14e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg16584676	chr17:46985605	UBE2Z	0.58	5.73	0.42	5.2100000000000003e-08	Type 2 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24861191	chr19:2740086	SLC39A3	0.59	6.47	0.46	1.3e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg18402987	chr7:1209562	NA	1.04	5.47	0.41	1.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500395	0.888	rs8057165	chr16:48563467	A/C	cg04672837	chr16:48644449	N4BP1	0.57	5.39	0.4	2.65e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	6.05	0.44	1.08e-8	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.01e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.59	6.35	0.46	2.35e-9	Schizophrenia;
PAAD	cis	rs7945718	0.621	rs10831896	chr11:12693361	G/A	cg25843174	chr11:12811716	TEAD1	0.33	4.79	0.36	3.92e-6	Educational attainment (years of education);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14425843	chr7:92729833	SAMD9	-0.66	-6.73	-0.48	3.3e-10	Obesity-related traits;
PAAD	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.17	0.45	6.02e-9	Mean platelet volume;
PAAD	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.04	-0.38	1.29e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.94	-9.35	-0.6	1.04e-16	Obesity-related traits;
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs12455924	1.000	rs12455924	chr18:11064409	C/T	cg22543291	chr18:10451640	NA	0.76	4.28	0.33	3.27e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	7.38	0.51	9.69e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.84	0.43	3.03e-8	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs5015933	0.703	rs7037034	chr9:128144637	T/C	cg14078157	chr9:128172775	NA	-0.41	-4.68	-0.35	6.37e-6	Body mass index;
PAAD	cis	rs11771526	0.681	rs1868773	chr7:32401341	C/T	cg27511599	chr7:32358540	NA	0.9	4.88	0.37	2.62e-6	Body mass index;
PAAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.25	-0.45	3.87e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.68	-7.02	-0.49	6.79e-11	Schizophrenia;
PAAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19825600	chr2:3704501	ALLC	-0.51	-4.4	-0.34	2.03e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs868036	0.561	rs28376697	chr15:68140315	A/G	cg08079166	chr15:68083412	MAP2K5	0.59	4.57	0.35	1e-5	Restless legs syndrome;
PAAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.47e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.29	-0.45	3.13e-9	Alcohol dependence;
PAAD	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.53	4.48	0.34	1.43e-5	Myopia;
PAAD	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6669119	0.591	rs77152015	chr1:19104640	G/A	cg13786083	chr1:19110734	NA	0.71	4.31	0.33	2.93e-5	Percentage gas trapping;
PAAD	cis	rs2004318	1.000	rs73610580	chr19:55067183	G/A	cg03320607	chr19:54800032	LILRA3	-1.06	-5.77	-0.42	4.21e-8	Blood protein levels;
PAAD	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg21145140	chr5:110409467	TSLP	0.45	4.42	0.34	1.9e-5	Eosinophilic esophagitis;
PAAD	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.32	0.4	3.66e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg16205897	chr5:131564050	P4HA2	-0.55	-6.06	-0.44	1.04e-8	Blood metabolite levels;
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.44e-7	Life satisfaction;
PAAD	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg21253087	chr9:139290292	SNAPC4	0.49	4.31	0.33	2.96e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.23	5.55	0.41	1.25e-7	Urinary tract infection frequency;
PAAD	trans	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg22670128	chr1:1210100	UBE2J2	-0.58	-6.46	-0.46	1.33e-9	Menopause (age at onset);
PAAD	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.44	-0.34	1.72e-5	Coronary artery disease;
PAAD	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	0.95	8.33	0.56	4.3e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg24110177	chr3:50126178	RBM5	-0.56	-4.42	-0.34	1.91e-5	Menarche (age at onset);
PAAD	cis	rs10981012	0.554	rs4978464	chr9:114581117	C/T	cg14428669	chr9:114659192	UGCG	-0.61	-4.62	-0.35	8.09e-6	Coronary artery disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg13152082	chr4:100010005	ADH5	0.56	6.37	0.46	2.11e-9	Metabolite levels  (X-11787);
PAAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg08088566	chr11:430123	ANO9	0.94	5.81	0.43	3.51e-8	Body mass index;
PAAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg01616529	chr11:638424	DRD4	-0.61	-6.22	-0.45	4.52e-9	Systemic lupus erythematosus;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-6.4	-0.46	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	6.23	0.45	4.33e-9	Lung cancer in ever smokers;
PAAD	cis	rs8121916	1.000	rs6078572	chr20:12413317	G/A	cg16404259	chr20:12988931	SPTLC3	-0.45	-4.69	-0.36	5.98e-6	Tumor necrosis factor alpha levels;
PAAD	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.47e-21	Blood protein levels;
PAAD	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.89	11.64	0.69	8.62e-23	Age at first birth;
PAAD	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg21775007	chr8:11205619	TDH	-0.58	-4.93	-0.37	2.16e-6	Neuroticism;
PAAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg06565975	chr8:143823917	SLURP1	-0.22	-4.9	-0.37	2.42e-6	Urinary tract infection frequency;
PAAD	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.67	6.88	0.49	1.46e-10	Schizophrenia;
PAAD	cis	rs72960926	0.744	rs11753898	chr6:74861057	C/T	cg03266952	chr6:74778945	NA	-1.08	-6.87	-0.49	1.56e-10	Metabolite levels (MHPG);
PAAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.94	9.8	0.62	7.16e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9581857	0.685	rs79699519	chr13:28023241	C/T	cg22138327	chr13:27999177	GTF3A	0.66	4.45	0.34	1.69e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg08498647	chr11:118550644	TREH	0.4	4.28	0.33	3.24e-5	Sjögren's syndrome;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12441184	chr1:213224450	RPS6KC1	-0.77	-6.93	-0.49	1.13e-10	Neuroticism;
PAAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.27	0.64	4.1e-19	Platelet count;
PAAD	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg15571903	chr15:79123663	NA	0.39	4.75	0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.841	rs7185308	chr16:67767060	A/G	cg05110241	chr16:68378359	PRMT7	-0.71	-4.95	-0.37	1.91e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg05250797	chr16:70222502	NA	-0.51	-4.39	-0.34	2.12e-5	Sjögren's syndrome;
PAAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.54	6.02	0.44	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.52	-0.41	1.46e-7	Mood instability;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg09699651	chr6:150184138	LRP11	0.4	4.27	0.33	3.47e-5	Lung cancer;
PAAD	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14396892	chr9:96623032	NA	-0.4	-4.4	-0.34	2.02e-5	DNA methylation (variation);
PAAD	cis	rs7487075	0.619	rs7486495	chr12:46826336	A/G	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	7.65	0.53	2.2e-12	Total body bone mineral density;
PAAD	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.44	-0.4	2.12e-7	Mean corpuscular volume;
PAAD	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg17842918	chr13:113540400	ATP11A	-0.42	-4.71	-0.36	5.6e-6	Interstitial lung disease;
PAAD	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg01119278	chr6:110721349	DDO	-0.64	-7.21	-0.5	2.5e-11	Platelet distribution width;
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.88	10.39	0.64	1.91e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.86	11.0	0.67	4.58e-21	Body mass index;
PAAD	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.48	-4.51	-0.34	1.27e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	1.11	12.66	0.72	1.55e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs977987	1.000	rs977985	chr16:75506947	C/G	cg03315344	chr16:75512273	CHST6	0.67	7.92	0.54	4.63e-13	Dupuytren's disease;
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg13271783	chr10:134563150	INPP5A	-0.52	-5.69	-0.42	6.43e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.93	-10.56	-0.65	6.94e-20	Cancer (pleiotropy);
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.46	4.8	0.36	3.78e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg12486944	chr17:80159399	CCDC57	-0.52	-4.72	-0.36	5.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.79	9.32	0.6	1.3e-16	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.62	-6.67	-0.48	4.43e-10	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.83e-13	Motion sickness;
PAAD	cis	rs5756391	0.568	rs2280976	chr22:37318426	C/T	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.74	8.54	0.57	1.33e-14	Height;
PAAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg26516362	chr5:178986906	RUFY1	0.53	6.15	0.45	6.55e-9	Lung cancer;
PAAD	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.44	-0.46	1.51e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs96067	0.528	rs274131	chr1:36582925	C/T	cg27506609	chr1:36549197	TEKT2	-0.73	-4.78	-0.36	4.14e-6	Corneal structure;
PAAD	cis	rs10500715	0.715	rs10840332	chr11:9980501	T/C	cg06875754	chr11:10328428	ADM	-0.33	-4.48	-0.34	1.48e-5	Pancreatic cancer;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.57	-5.61	-0.41	9.17e-8	Reticulocyte count;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg19536664	chr17:6899085	ALOX12	0.56	6.22	0.45	4.66e-9	Tonsillectomy;
PAAD	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs478222	1.000	rs551573	chr2:25305504	A/G	cg01884057	chr2:25150051	NA	0.37	4.44	0.34	1.72e-5	Type 1 diabetes;
PAAD	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.57	-5.59	-0.41	1.01e-7	Reticulocyte count;
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs4704187	0.687	rs4324655	chr5:74373360	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02250241	chr15:75648987	MAN2C1	0.51	6.3	0.46	3.08e-9	Body fat percentage;
PAAD	cis	rs12712135	0.706	rs6543114	chr2:102925994	A/AC	cg23450938	chr2:102972792	NA	0.44	4.77	0.36	4.36e-6	Blood protein levels;
PAAD	cis	rs7554547	0.526	rs4846078	chr1:11967356	C/T	cg13216073	chr1:12042593	MFN2	0.39	4.27	0.33	3.38e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	5.13	0.38	8.59e-7	Mood instability;
PAAD	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg22431228	chr1:16359049	CLCNKA	0.46	5.44	0.4	2.13e-7	Systolic blood pressure;
PAAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg13468214	chr4:1046988	NA	-0.52	-4.95	-0.37	1.98e-6	Recombination rate (females);
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg23153227	chr6:27725408	NA	0.49	4.67	0.35	6.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.62	-6.88	-0.49	1.45e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs6693295	0.729	rs10802325	chr1:246213454	C/A	cg26013412	chr1:247094486	AHCTF1	-0.59	-4.38	-0.33	2.22e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.4	-4.94	-0.37	2.01e-6	Systolic blood pressure;
PAAD	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06850241	chr22:41845214	NA	-0.6	-5.26	-0.39	4.71e-7	Vitiligo;
PAAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.13	-0.38	8.69e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg27411982	chr8:10470053	RP1L1	0.48	5.58	0.41	1.07e-7	Neuroticism;
PAAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.48	4.66	0.35	6.73e-6	Pulse pressure;
PAAD	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.93	-9.71	-0.62	1.18e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01200585	chr1:228362443	C1orf69	-0.52	-5.81	-0.43	3.5e-8	Diastolic blood pressure;
PAAD	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.52	0.34	1.21e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.56	-7.09	-0.5	4.79e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg23254163	chr1:152506842	NA	0.57	6.59	0.47	6.92e-10	Hair morphology;
PAAD	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.64	6.87	0.49	1.56e-10	Colorectal cancer;
PAAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.9e-6	Schizophrenia;
PAAD	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21747090	chr2:27597821	SNX17	-0.44	-4.3	-0.33	3.08e-5	Total body bone mineral density;
PAAD	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.88	-11.08	-0.67	2.77e-21	Heart rate;
PAAD	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.76	7.86	0.54	6.52e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1371614	0.632	rs7599286	chr2:27152398	T/C	cg00617064	chr2:27272375	NA	-0.42	-4.45	-0.34	1.62e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg14393609	chr7:65229607	NA	-0.47	-4.53	-0.35	1.16e-5	Aortic root size;
PAAD	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.35	4.29	0.33	3.13e-5	Body mass index in non-asthmatics;
PAAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.76	7.77	0.53	1.07e-12	Menarche (age at onset);
PAAD	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.54	-4.55	-0.35	1.09e-5	Corneal structure;
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg10207240	chr12:122356781	WDR66	-0.56	-6.02	-0.44	1.26e-8	Mean corpuscular volume;
PAAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.1	0.59	4.77e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	9.21	0.6	2.47e-16	Cognitive test performance;
PAAD	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.35	-0.56	3.86e-14	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg24296786	chr1:45957014	TESK2	-0.52	-4.82	-0.36	3.5e-6	Homocysteine levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10878531	chr6:27721064	NA	0.69	7.59	0.52	3.01e-12	Obesity-related traits;
PAAD	cis	rs593531	0.592	rs3168173	chr11:74042787	A/G	cg23327896	chr11:73669290	DNAJB13	-0.37	-4.73	-0.36	5.12e-6	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17322444	chr19:33572249	GPATCH1	0.57	6.29	0.45	3.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2721811	0.782	rs2237307	chr7:24757660	G/A	cg17569154	chr7:24781545	DFNA5	0.45	4.6	0.35	8.77e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11835265	chr1:2011913	PRKCZ	0.6	6.61	0.47	6.19e-10	Smoking initiation;
PAAD	cis	rs9503598	0.644	rs4959240	chr6:3430674	C/T	cg00476032	chr6:3446245	SLC22A23	0.49	5.54	0.41	1.3e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	4.6	0.35	8.93e-6	Educational attainment;
PAAD	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg04132472	chr17:19861366	AKAP10	0.47	5.29	0.39	4.21e-7	Schizophrenia;
PAAD	cis	rs4742903	0.904	rs1333941	chr9:106996386	C/G	cg14250997	chr9:106856677	SMC2	0.42	4.61	0.35	8.51e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.6	5.79	0.42	3.95e-8	Prudent dietary pattern;
PAAD	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.53	4.58	0.35	9.8e-6	Menopause (age at onset);
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14867121	chr4:146297077	NA	0.53	6.45	0.46	1.41e-9	Smoking initiation;
PAAD	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.53	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.54	5.52	0.41	1.43e-7	Eosinophil percentage of white cells;
PAAD	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg05709478	chr1:6581295	PLEKHG5	0.74	4.63	0.35	7.87e-6	Body mass index;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	6.67	0.48	4.43e-10	Height;
PAAD	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg05313129	chr8:58192883	C8orf71	0.69	5.82	0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg01763666	chr17:80159506	CCDC57	0.43	4.37	0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.37	0.33	2.32e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7582720	0.945	rs72932716	chr2:203642244	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.05	7.3	0.51	1.52e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.27	-0.33	3.39e-5	Longevity;Endometriosis;
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.54	5.78	0.42	4.08e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06846441	chr7:4780516	FOXK1	-0.61	-6.87	-0.49	1.57e-10	Monocyte percentage of white cells;
PAAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.73	0.48	3.18e-10	Schizophrenia;
PAAD	cis	rs76793172	1.000	rs10420834	chr19:46347542	G/T	cg13320842	chr19:46175254	GIPR	0.63	4.84	0.37	3.21e-6	Eosinophil counts;
PAAD	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.11e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	4.54	0.35	1.12e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.45	0.46	1.41e-9	IgG glycosylation;
PAAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg16362232	chr11:430036	ANO9	0.84	5.21	0.39	6.16e-7	Body mass index;
PAAD	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs4144027	0.791	rs67727470	chr14:104361996	A/G	cg12183467	chr14:104352244	NA	0.35	4.43	0.34	1.77e-5	Blood metabolite levels;
PAAD	cis	rs11563648	0.500	rs6467124	chr7:127052187	T/C	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg27121462	chr16:89883253	FANCA	0.84	10.21	0.64	5.73e-19	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09184378	chr6:126698055	NA	-0.61	-6.47	-0.46	1.26e-9	Obesity-related traits;
PAAD	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.19	-8.47	-0.57	2.01e-14	Schizophrenia;
PAAD	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-1.09	-9.7	-0.62	1.27e-17	Orofacial clefts;
PAAD	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	11.88	0.69	2.01e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7247513	0.892	rs2861407	chr19:12711495	T/C	cg01871581	chr19:12707946	ZNF490	-0.9	-11.29	-0.68	7.62e-22	Bipolar disorder;
PAAD	cis	rs1539053	1.000	rs12079319	chr1:58101205	C/T	cg00026909	chr1:58089001	DAB1	-0.69	-8.06	-0.55	2.05e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs4731207	0.565	rs7776744	chr7:124599749	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.44	-0.34	1.7e-5	Cutaneous malignant melanoma;
PAAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg22710661	chr11:17411071	KCNJ11	0.45	4.45	0.34	1.62e-5	Type 2 diabetes;
PAAD	cis	rs6028335	0.577	rs16987738	chr20:37625015	G/T	cg09744151	chr20:37058415	LOC388796;SNORA71C	0.62	4.64	0.35	7.6e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.46	-0.46	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.68e-6	Pain;
PAAD	cis	rs8396	0.960	rs17843902	chr4:159641148	T/C	cg11637968	chr4:159732036	FNIP2	-0.27	-4.33	-0.33	2.7e-5	Acylcarnitine levels;Blood metabolite levels;Blood protein levels;Metabolic traits;Metabolite levels;
PAAD	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.45	5.13	0.38	8.87e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	1.08	15.19	0.78	2.67e-32	Breast cancer;
PAAD	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs116248771	0.739	rs116045655	chr3:158335368	G/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.81	-9.28	-0.6	1.67e-16	Schizophrenia;
PAAD	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.9	-0.37	2.43e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg24241305	chr13:114826075	RASA3	-0.56	-4.44	-0.34	1.69e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.8	7.15	0.5	3.4e-11	Exhaled nitric oxide levels;
PAAD	cis	rs9652601	0.881	rs11860603	chr16:11165017	T/C	cg04616529	chr16:11181986	CLEC16A	0.47	5.03	0.38	1.39e-6	Systemic lupus erythematosus;
PAAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.7	8.4	0.56	2.86e-14	Multiple sclerosis;
PAAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.66	5.46	0.4	1.9e-7	Gut microbiome composition (summer);
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.13e-6	Lung cancer;
PAAD	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg24011408	chr12:48396354	COL2A1	-0.41	-4.39	-0.34	2.13e-5	Plateletcrit;
PAAD	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16575025	chr1:112281790	C1orf183	0.57	6.52	0.47	1.01e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-5.94	-0.43	1.87e-8	Obesity (extreme);
PAAD	cis	rs11951515	0.508	rs10065689	chr5:43604258	T/C	cg01983248	chr5:43482804	C5orf28	-0.3	-4.29	-0.33	3.21e-5	Metabolite levels  (X-11787);
PAAD	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.71	-0.8	3.03e-36	Height;
PAAD	cis	rs501120	0.657	rs649192	chr10:44741179	G/C	cg09554077	chr10:44749378	NA	0.49	6.22	0.45	4.63e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.5	-5.06	-0.38	1.21e-6	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08610687	chr19:4246850	CCDC94	0.64	6.75	0.48	2.86e-10	Obesity-related traits;
PAAD	cis	rs8025118	0.559	rs1865365	chr15:79553571	C/T	cg11862246	chr15:78730200	IREB2	-0.56	-4.8	-0.36	3.69e-6	Cognitive function;
PAAD	cis	rs6433205	0.602	rs6753558	chr2:171353552	A/G	cg23399426	chr2:171627790	NA	-0.48	-4.33	-0.33	2.73e-5	Lobe attachment (rater scored);
PAAD	cis	rs2252790	1.000	rs12204234	chr6:116647587	T/C	cg18764771	chr6:116381957	FRK	0.26	4.36	0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs7301016	1.000	rs11174494	chr12:62864877	A/T	cg11441379	chr12:63026424	NA	0.85	6.11	0.44	8.06e-9	IgG glycosylation;
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.51	5.4	0.4	2.47e-7	Menopause (age at onset);
PAAD	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg23093090	chr10:104574429	C10orf26	-0.42	-4.39	-0.34	2.13e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12935418	0.523	rs2549840	chr16:81023422	G/T	cg16651780	chr16:81037892	C16orf61	-0.65	-6.17	-0.45	5.93e-9	Mean corpuscular volume;
PAAD	cis	rs2718812	0.719	rs1867505	chr3:133411052	T/C	cg08439880	chr3:133502540	NA	0.42	4.64	0.35	7.47e-6	Iron status biomarkers;
PAAD	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs76866386	0.892	rs56132765	chr2:44078853	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.96	-5.59	-0.41	1.01e-7	Cholesterol, total;
PAAD	cis	rs2790216	1.000	rs2790146	chr10:59975743	A/T	cg20442379	chr10:60024634	IPMK	-0.57	-4.3	-0.33	3.07e-5	Inflammatory bowel disease;
PAAD	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg00277334	chr10:82204260	NA	-0.58	-5.85	-0.43	2.96e-8	Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	4.51	0.34	1.27e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1345301	0.587	rs10186746	chr2:102866377	G/A	cg03938978	chr2:103052716	IL18RAP	-0.4	-4.39	-0.34	2.11e-5	Waist circumference;
PAAD	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	8.98	0.59	9.75e-16	Cognitive test performance;
PAAD	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	10.67	0.65	3.48e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.51	-6.04	-0.44	1.12e-8	Mean arterial pressure;
PAAD	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg07741184	chr6:167504864	NA	0.39	4.77	0.36	4.25e-6	Crohn's disease;
PAAD	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg01620082	chr3:125678407	NA	-1.51	-8.87	-0.58	1.83e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.75	-0.36	4.74e-6	Alcohol dependence;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.88	5.78	0.42	4.05e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg26873644	chr16:2260806	C16orf79	-0.44	-4.36	-0.33	2.42e-5	Height;
PAAD	cis	rs2718812	0.607	rs12497433	chr3:133388584	C/G	cg08048268	chr3:133502702	NA	-0.51	-6.3	-0.45	3.11e-9	Iron status biomarkers;
PAAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg04705435	chr11:17411270	KCNJ11	0.6	6.31	0.46	2.85e-9	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.75	0.48	2.93e-10	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22918914	chr5:6378597	MED10	-0.71	-7.62	-0.53	2.52e-12	Smoking initiation;
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg20295408	chr7:1910781	MAD1L1	-0.54	-4.99	-0.38	1.61e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs16958440	1.000	rs62096470	chr18:44641466	G/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg05305434	chr11:1874049	LSP1	0.46	5.2	0.39	6.32e-7	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17155006	0.664	rs440938	chr7:107741092	C/G	cg05962710	chr7:107745446	LAMB4	-0.54	-7.13	-0.5	3.73e-11	Pneumococcal bacteremia;
PAAD	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.86	6.58	0.47	7e-10	Axial length;
PAAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg06632027	chr4:90757378	SNCA	-0.5	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.75	8.03	0.55	2.47e-13	Menopause (age at onset);
PAAD	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.33	0.46	2.61e-9	Schizophrenia;
PAAD	trans	rs9345521	0.967	rs4710495	chr6:65488026	A/G	cg26414000	chr1:85721327	C1orf52	0.53	6.69	0.48	3.93e-10	Iris color (a* coordinate);
PAAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14282180	chr2:47630433	MSH2	0.64	6.86	0.49	1.64e-10	Myopia (pathological);
PAAD	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.69	-5.94	-0.43	1.87e-8	Obesity (extreme);
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.98	-8.61	-0.57	8.67e-15	Alzheimer's disease;
PAAD	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.76	-6.69	-0.48	4.05e-10	Blood pressure (smoking interaction);
PAAD	cis	rs9361491	0.608	rs2321770	chr6:79445408	T/C	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06233455	chr11:94474371	NA	-0.63	-6.31	-0.46	2.89e-9	Lung cancer in ever smokers;
PAAD	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-4.69	-0.36	6.13e-6	Menarche (age at onset);
PAAD	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg23024343	chr7:107201750	COG5	0.56	4.61	0.35	8.46e-6	Coronary artery disease;
PAAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.55	4.45	0.34	1.68e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.77e-7	Carotid intima media thickness;
PAAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.93	0.43	1.92e-8	Coronary artery disease;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11644478	chr21:40555479	PSMG1	-0.51	-5.27	-0.39	4.65e-7	Menarche (age at onset);
PAAD	cis	rs4748857	0.947	rs4237360	chr10:23547519	T/C	cg18853376	chr10:23633759	C10orf67	0.5	4.46	0.34	1.58e-5	Systemic lupus erythematosus;
PAAD	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.86	6.11	0.44	7.9e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.85	0.66	1.16e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs950881	0.932	rs13408569	chr2:102955056	G/C	cg20060108	chr2:102954350	IL1RL1	0.58	4.59	0.35	9.23e-6	Allergy;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg02071572	chr4:1403502	NA	0.35	4.5	0.34	1.33e-5	Obesity-related traits;
PAAD	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.38	-5.1	-0.38	1e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-8.32	-0.56	4.66e-14	Morning vs. evening chronotype;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg14820908	chr5:178986412	RUFY1	0.49	4.84	0.37	3.13e-6	Lung cancer;
PAAD	cis	rs2275731	0.723	rs7917489	chr10:16542650	G/T	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.42	-4.25	-0.33	3.72e-5	Aortic root size;
PAAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.55	5.88	0.43	2.48e-8	Menopause (age at onset);
PAAD	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.69	-7.58	-0.52	3.1e-12	Aortic root size;
PAAD	cis	rs10392	0.706	rs72623596	chr20:37585212	T/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.86	-0.37	2.86e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs11700980	0.551	rs4999007	chr21:30109259	C/T	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs7165102	1.000	rs627804	chr15:65734040	A/C	cg22900193	chr15:65823441	PTPLAD1	0.47	4.45	0.34	1.67e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.92	-10.43	-0.65	1.53e-19	Prudent dietary pattern;
PAAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.46	-4.64	-0.35	7.62e-6	Menarche (age at onset);
PAAD	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.51	-8.56	-0.57	1.15e-14	Cutaneous nevi;
PAAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg16083429	chr3:49237500	CCDC36	0.42	4.45	0.34	1.67e-5	Parkinson's disease;
PAAD	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.87	7.15	0.5	3.32e-11	Schizophrenia;
PAAD	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg15556689	chr8:8085844	FLJ10661	0.75	7.43	0.52	7.39e-12	Neuroticism;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg17967426	chr5:168006763	PANK3	0.57	6.34	0.46	2.52e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7624766	0.555	rs7618832	chr3:160488395	A/C	cg22637730	chr3:160473554	PPM1L	0.56	4.86	0.37	2.85e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs11563648	0.535	rs986584	chr7:127049231	T/C	cg21885361	chr7:127911034	NA	-0.4	-4.42	-0.34	1.85e-5	Resting heart rate;
PAAD	cis	rs12042107	0.818	rs12046000	chr1:91192396	G/T	cg13456504	chr1:91191583	NA	0.42	4.6	0.35	8.67e-6	Educational attainment;
PAAD	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg25204440	chr1:209979598	IRF6	0.59	4.9	0.37	2.47e-6	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	4.34	0.33	2.56e-5	Platelet count;
PAAD	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.85	8.04	0.55	2.29e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg15181151	chr6:150070149	PCMT1	0.58	6.27	0.45	3.64e-9	Lung cancer;
PAAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs4733117	0.551	rs17624997	chr8:32137649	A/G	cg00324366	chr8:32199183	NRG1	-0.62	-4.32	-0.33	2.83e-5	Interleukin-2 receptor antagonist levels;
PAAD	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19346786	chr7:2764209	NA	-0.4	-5.49	-0.41	1.64e-7	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13944275	chr9:140024112	NA	-0.75	-6.58	-0.47	7.31e-10	Neuroticism;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.63	-6.05	-0.44	1.08e-8	Acylcarnitine levels;
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.24e-5	Cognitive function;
PAAD	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs2440012	0.543	rs73167583	chr13:19421095	G/A	cg08120511	chr13:19412184	LOC284232	-0.66	-4.36	-0.33	2.37e-5	Longevity;
PAAD	cis	rs3796727	0.633	rs4696866	chr4:8618322	A/G	cg05284713	chr4:8621361	CPZ	-0.43	-4.3	-0.33	2.98e-5	Sporadic neuroblastoma;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	1.09	15.75	0.79	9.53e-34	Systemic lupus erythematosus;
PAAD	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13896604	chr17:73043189	ATP5H;KCTD2	0.57	6.29	0.45	3.16e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20703523	chr1:16302590	ZBTB17	-0.68	-7.25	-0.51	1.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.78	-8.09	-0.55	1.78e-13	Cognitive function;
PAAD	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.89	-4.88	-0.37	2.71e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.19	-0.45	5.37e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg20019720	chr6:154832845	CNKSR3	0.64	8.2	0.55	9.32e-14	Lipoprotein (a) levels;
PAAD	cis	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg13821571	chr21:34406537	NA	-0.45	-4.29	-0.33	3.21e-5	Gastritis;
PAAD	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.53	4.52	0.34	1.22e-5	Diastolic blood pressure;
PAAD	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs558003	0.826	rs549058	chr13:51201045	G/T	cg24585282	chr13:51257555	NA	-0.67	-4.53	-0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.7	-4.77	-0.36	4.37e-6	Coronary artery disease;
PAAD	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.53	-4.89	-0.37	2.54e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.88	7.72	0.53	1.46e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.52	-6.07	-0.44	9.71e-9	Blood pressure (smoking interaction);
PAAD	cis	rs793571	0.505	rs9920042	chr15:58901396	C/T	cg05156742	chr15:59063176	FAM63B	0.62	4.58	0.35	9.47e-6	Schizophrenia;
PAAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.63	-7.28	-0.51	1.65e-11	Huntington's disease progression;
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg14008862	chr17:28927542	LRRC37B2	0.81	5.42	0.4	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.81	-7.88	-0.54	6.01e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg00590817	chr1:8272081	NA	-0.39	-4.82	-0.36	3.38e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.51	-0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.82	-10.26	-0.64	4.22e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.75	9.54	0.61	3.41e-17	Cardiovascular disease risk factors;
PAAD	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01516881	chr6:292596	DUSP22	-0.74	-7.32	-0.51	1.34e-11	Menopause (age at onset);
PAAD	cis	rs72772787	1.000	rs12096473	chr1:248016894	C/T	cg00785941	chr1:248100591	OR2L13	0.53	5.31	0.4	3.84e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.67	6.05	0.44	1.1e-8	Platelet count;
PAAD	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.57	4.94	0.37	2.05e-6	Life satisfaction;
PAAD	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg24330906	chr2:85765176	MAT2A	0.44	4.46	0.34	1.6e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1371614	0.545	rs12105356	chr2:27175570	T/C	cg00617064	chr2:27272375	NA	-0.43	-4.45	-0.34	1.64e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Body mass index;
PAAD	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.55	-6.01	-0.44	1.31e-8	Educational attainment;
PAAD	cis	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs11264213	0.901	rs716926	chr1:36424476	A/G	cg27506609	chr1:36549197	TEKT2	0.7	5.15	0.39	8.1e-7	Schizophrenia;
PAAD	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.77	7.78	0.53	1.05e-12	Coronary artery disease;
PAAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.82	6.43	0.46	1.58e-9	Gut microbiome composition (summer);
PAAD	cis	rs7202877	0.561	rs4888369	chr16:75307277	T/C	cg03315344	chr16:75512273	CHST6	0.56	4.75	0.36	4.67e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg20283391	chr11:68216788	NA	0.54	5.12	0.38	9.07e-7	Total body bone mineral density;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-5.96	-0.44	1.72e-8	Body mass index;
PAAD	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.86	8.93	0.59	1.34e-15	Height;
PAAD	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.9	10.24	0.64	4.74e-19	Gout;
PAAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-5.12	-0.38	9.18e-7	Lung cancer;
PAAD	cis	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24168798	chr11:92577553	FAT3	-0.63	-6.33	-0.46	2.66e-9	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13523232	chr17:20905685	USP22	-0.62	-6.43	-0.46	1.6e-9	Obesity-related traits;
PAAD	cis	rs7072216	0.555	rs7921146	chr10:100186601	G/A	cg26618903	chr10:100175079	PYROXD2	-0.5	-5.51	-0.41	1.49e-7	Metabolite levels;
PAAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg18281939	chr5:77783895	LHFPL2	0.51	5.92	0.43	2.09e-8	Triglycerides;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13683282	chr1:40723560	ZMPSTE24	-0.76	-6.71	-0.48	3.61e-10	Neuroticism;
PAAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.51	-6.84	-0.48	1.84e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs1499972	0.938	rs1499971	chr3:117719537	A/C	cg07612923	chr3:117604196	NA	-0.98	-6.67	-0.48	4.45e-10	Schizophrenia;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.61	6.54	0.47	8.89e-10	Menarche (age at onset);
PAAD	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg01942863	chr7:99769432	GPC2	0.49	4.57	0.35	9.92e-6	Coronary artery disease;
PAAD	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.59	-5.81	-0.43	3.57e-8	Myopia;
PAAD	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.48	-5.07	-0.38	1.15e-6	Kawasaki disease;
PAAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs2229238	0.911	rs73023339	chr1:154510852	C/T	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg15117754	chr3:10150083	C3orf24	-0.7	-5.94	-0.43	1.9e-8	Alzheimer's disease;
PAAD	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.71	7.58	0.52	3.13e-12	Platelet distribution width;
PAAD	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	1.36	6.28	0.45	3.3e-9	Skin colour saturation;
PAAD	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.13e-5	Noise-induced hearing loss;
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs315934	0.769	rs315946	chr2:113893864	G/A	cg24553058	chr2:113831203	IL1F10	-0.64	-4.82	-0.36	3.46e-6	Dysmenorrheic pain;
PAAD	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs2004318	1.000	rs10403406	chr19:55120555	C/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg03909863	chr11:638404	DRD4	-0.67	-5.62	-0.42	8.71e-8	Systemic lupus erythematosus;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.0	-8.6	-0.57	9.31e-15	Vitiligo;
PAAD	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.03	-0.38	1.34e-6	Blood metabolite levels;
PAAD	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.6	-0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.14	16.6	0.8	5.7e-36	Primary sclerosing cholangitis;
PAAD	cis	rs1443512	0.541	rs1443510	chr12:54340841	C/T	cg25382128	chr12:54346509	NA	-0.63	-5.31	-0.4	3.9e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.63	5.0	0.38	1.55e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2033732	1.000	rs1465809	chr8:85080457	G/A	cg05716166	chr8:85095498	RALYL	0.51	4.62	0.35	8e-6	Body mass index;
PAAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12165864	chr7:66369176	NA	0.75	4.79	0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.63	-6.72	-0.48	3.47e-10	Lung cancer;
PAAD	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8077577	0.895	rs16960990	chr17:18108601	A/G	cg16794390	chr17:18148240	FLII	0.52	4.29	0.33	3.21e-5	Obesity-related traits;
PAAD	cis	rs2051773	0.539	rs34902253	chr11:17049380	T/A	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.9	7.46	0.52	6.27e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg01657329	chr11:68192670	LRP5	0.52	4.6	0.35	8.9e-6	Bone mineral density (spine);
PAAD	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.82	6.17	0.45	5.77e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.38	0.46	2.07e-9	Mean platelet volume;
PAAD	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.56	-5.51	-0.41	1.48e-7	Immature fraction of reticulocytes;
PAAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	4.44	0.34	1.7e-5	Longevity;
PAAD	cis	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2506028	0.619	rs788267	chr10:43435438	C/T	cg20628663	chr10:43360327	NA	-0.39	-4.67	-0.35	6.5e-6	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21263890	chr20:42839731	C20orf111	-0.8	-9.02	-0.59	7.65e-16	Smoking initiation;
PAAD	cis	rs543686	1.000	rs594880	chr15:35068085	G/T	cg01471153	chr15:34876295	GOLGA8B	0.44	4.33	0.33	2.73e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs939584	1.000	rs939584	chr2:621558	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-5.21	-0.39	6.02e-7	Vitiligo;
PAAD	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.26	0.39	4.81e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.37	-0.33	2.28e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg17796960	chr10:135278976	LOC619207	-0.38	-4.8	-0.36	3.81e-6	Systemic lupus erythematosus;
PAAD	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.51e-6	Vitiligo;
PAAD	cis	rs8064299	0.503	rs62084914	chr17:72773110	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.39	4.65	0.35	7.01e-6	Monocyte count;
PAAD	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.8	-0.53	9.08e-13	Body mass index;
PAAD	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.7	7.14	0.5	3.64e-11	Schizophrenia;
PAAD	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg21995147	chr19:1064017	ABCA7	-0.6	-5.27	-0.39	4.64e-7	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg09835421	chr16:68378352	PRMT7	-1.14	-8.37	-0.56	3.47e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-9.35	-0.6	1.08e-16	Mortality in heart failure;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.86	-10.88	-0.66	9.28e-21	Bipolar disorder;
PAAD	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg09163369	chr1:210001066	C1orf107	0.67	6.34	0.46	2.55e-9	Orofacial clefts;
PAAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs1413885	0.526	rs4325172	chr1:65858145	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.99	0.38	1.65e-6	Anticoagulant levels;
PAAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs5753037	0.838	rs1894474	chr22:30238074	A/G	cg01021169	chr22:30184971	ASCC2	-0.43	-4.48	-0.34	1.44e-5	Type 1 diabetes;
PAAD	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7631605	0.905	rs3774339	chr3:37062854	A/G	cg17445812	chr3:36986805	TRANK1	-0.34	-4.63	-0.35	7.87e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13424612	1.000	rs10193610	chr2:240940618	A/G	cg12807937	chr2:240965920	NDUFA10	-0.48	-4.95	-0.37	1.97e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.59	6.36	0.46	2.25e-9	QT interval;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.81	5.6	0.41	9.55e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26466856	chr7:16461077	ISPD	0.63	6.74	0.48	3.14e-10	Myopia (pathological);
PAAD	cis	rs1507153	0.673	rs9361414	chr6:79345448	G/T	cg05283184	chr6:79620031	NA	-0.38	-4.55	-0.35	1.1e-5	Sjögren's syndrome;
PAAD	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.18	0.45	5.5e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-6.83	-0.48	1.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19535980	chr5:159519152	PWWP2A	-0.57	-6.66	-0.48	4.67e-10	Energy expenditure (24h);
PAAD	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.14	5.41	0.4	2.45e-7	Breast cancer;
PAAD	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.47	4.43	0.34	1.83e-5	Childhood ear infection;
PAAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	4.42	0.34	1.89e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg09760422	chr2:128146352	NA	-0.41	-7.09	-0.5	4.8e-11	Protein C levels;
PAAD	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs939584	1.000	rs13412197	chr2:653250	A/G	cg03610516	chr2:642275	NA	-0.65	-6.05	-0.44	1.08e-8	Body mass index;
PAAD	cis	rs6132905	0.590	rs7270022	chr20:2615108	T/C	cg24848351	chr20:2622020	TMC2	-0.7	-5.06	-0.38	1.18e-6	Mumps;
PAAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	1.13	13.06	0.73	1.32e-26	Cognitive function;
PAAD	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-4.29	-0.33	3.19e-5	Crohn's disease;
PAAD	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-6.52	-0.47	9.82e-10	Lymphocyte counts;
PAAD	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs3126085	0.515	rs7534951	chr1:152362972	C/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	4.4	0.34	2.01e-5	Iron status biomarkers;
PAAD	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.95	-6.67	-0.48	4.51e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1126510	0.860	rs3760758	chr19:47129573	T/C	cg07844738	chr19:47129343	PTGIR	0.43	5.05	0.38	1.27e-6	Ulcerative colitis;
PAAD	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.44	-4.88	-0.37	2.71e-6	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.8	9.03	0.59	7.24e-16	Corneal astigmatism;
PAAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.33e-12	Recombination rate (females);
PAAD	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.49	-4.97	-0.37	1.81e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs747650	0.504	rs7108822	chr11:47044355	G/A	cg19486271	chr11:47235900	DDB2	-0.67	-6.2	-0.45	5.16e-9	Acne (severe);
PAAD	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.37	4.75	0.36	4.71e-6	Abdominal aortic aneurysm;
PAAD	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.58	-5.61	-0.41	9.14e-8	Coronary artery disease or large artery stroke;
PAAD	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.64	6.6	0.47	6.35e-10	Testicular germ cell tumor;
PAAD	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg00147172	chr22:46423604	NA	0.38	5.64	0.42	8.11e-8	Dupuytren's disease;
PAAD	cis	rs4750440	0.702	rs11258775	chr10:14029742	T/C	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.4	-0.34	2.01e-5	Adiponectin levels;
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7873102	0.654	rs2243893	chr9:37989893	C/T	cg03528946	chr9:38069800	SHB	-0.52	-5.23	-0.39	5.5e-7	Brain structure;
PAAD	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.63	6.73	0.48	3.34e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg23573114	chr20:34634400	LOC647979	-0.54	-4.36	-0.33	2.4e-5	Blood protein levels;
PAAD	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.95	-0.54	3.95e-13	Height;
PAAD	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.91	10.53	0.65	7.94e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg00933542	chr6:150070202	PCMT1	0.54	5.59	0.41	1.05e-7	Lung cancer;
PAAD	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.44	-4.42	-0.34	1.88e-5	Primary biliary cholangitis;
PAAD	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-5.7	-0.42	6.18e-8	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg19008133	chr3:123124015	ADCY5	-0.61	-4.44	-0.34	1.72e-5	LDL cholesterol levels;
PAAD	cis	rs990171	0.913	rs6729638	chr2:102996022	C/T	cg03938978	chr2:103052716	IL18RAP	0.44	4.37	0.33	2.31e-5	Lymphocyte counts;
PAAD	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.44	6.29	0.45	3.16e-9	Information processing speed;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	8.02	0.55	2.59e-13	Prudent dietary pattern;
PAAD	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.760	rs11150596	chr16:30850242	C/T	cg00531865	chr16:30841666	NA	-0.63	-6.35	-0.46	2.32e-9	Dementia with Lewy bodies;
PAAD	cis	rs2548003	0.518	rs967080	chr5:28755831	T/C	cg22863700	chr5:28928346	NA	0.52	5.09	0.38	1.04e-6	Hip geometry;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03032247	chr17:46570338	NA	-0.68	-7.28	-0.51	1.64e-11	Smoking initiation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07755173	chr10:35930525	FZD8	-0.72	-6.35	-0.46	2.32e-9	Neuroticism;
PAAD	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.59	6.27	0.45	3.55e-9	Bladder cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13571388	chr1:26947729	NA	0.61	6.58	0.47	7e-10	Myopia (pathological);
PAAD	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.45	4.33	0.33	2.7e-5	Mean corpuscular volume;
PAAD	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.82	7.37	0.51	1.01e-11	Homoarginine levels;
PAAD	cis	rs939584	1.000	rs7604609	chr2:643303	C/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs9322817	0.617	rs9404574	chr6:105162372	T/C	cg02098413	chr6:105308735	HACE1	-0.42	-5.26	-0.39	4.8e-7	Thyroid stimulating hormone;
PAAD	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.66	-0.42	7.26e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.95	-0.43	1.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg06697600	chr4:7070879	GRPEL1	0.95	5.72	0.42	5.52e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.63	6.08	0.44	9.45e-9	Corneal astigmatism;
PAAD	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg14146966	chr2:61757674	XPO1	0.42	5.17	0.39	7.42e-7	Tuberculosis;
PAAD	cis	rs7808424	0.651	rs17139625	chr7:116935478	A/G	cg00307073	chr7:116502428	CAPZA2	-0.7	-4.48	-0.34	1.44e-5	Coronary heart disease;
PAAD	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg00277334	chr10:82204260	NA	-0.52	-5.26	-0.39	4.92e-7	Post bronchodilator FEV1;
PAAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.57	-6.89	-0.49	1.37e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.35	0.33	2.49e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.39	4.02e-7	Male-pattern baldness;
PAAD	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9888739	1.000	rs11860650	chr16:31326706	C/T	cg02256631	chr16:31342952	ITGAM	-0.53	-4.32	-0.33	2.78e-5	Systemic lupus erythematosus;
PAAD	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.7	-0.48	3.81e-10	Neuroticism;
PAAD	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03348901	chr8:41436158	AGPAT6	-0.65	-6.58	-0.47	7.2e-10	Smoking initiation;
PAAD	cis	rs9287719	0.649	rs10183359	chr2:10733044	G/A	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.3	11.22	0.67	1.17e-21	Uric acid levels;
PAAD	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.98	-10.38	-0.64	2.11e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.77	9.21	0.6	2.41e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7572733	0.792	rs1036333	chr2:198943787	G/T	cg10820045	chr2:198174542	NA	0.43	4.29	0.33	3.18e-5	Dermatomyositis;
PAAD	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-5.4	-0.4	2.47e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.76	6.74	0.48	3.08e-10	Obesity-related traits;
PAAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg21625146	chr5:486483	SLC9A3	0.37	5.43	0.4	2.19e-7	Cystic fibrosis severity;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11927951	chr10:22638314	SPAG6	-0.43	-5.15	-0.39	7.88e-7	Monocyte percentage of white cells;
PAAD	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg21605333	chr4:119757512	SEC24D	1.84	9.3	0.6	1.4e-16	Cannabis dependence symptom count;
PAAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00864171	chr11:67383662	NA	-0.55	-5.47	-0.41	1.77e-7	Mean corpuscular volume;
PAAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-4.9	-0.37	2.46e-6	Height;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg02696790	chr15:75250997	RPP25	0.49	5.85	0.43	2.84e-8	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23436918	chr7:16685595	BZW2;ANKMY2	0.58	6.51	0.47	1.02e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9715521	0.746	rs62301192	chr4:59843340	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.76	7.5	0.52	4.99e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg02462569	chr6:150064036	NUP43	-0.51	-5.71	-0.42	5.84e-8	Lung cancer;
PAAD	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg18643199	chr10:82363313	SH2D4B	0.65	5.32	0.4	3.67e-7	Post bronchodilator FEV1;
PAAD	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.76e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs12600053	0.658	rs4783076	chr16:84848220	T/C	cg09249803	chr16:84846936	NA	0.52	4.34	0.33	2.64e-5	Asthma (childhood onset);
PAAD	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg23465465	chr6:26364728	BTN3A2	0.73	5.06	0.38	1.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.35e-8	Alzheimer's disease (late onset);
PAAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg12623918	chr2:306882	NA	0.49	5.07	0.38	1.16e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.2	0.45	5.19e-9	Coffee consumption (cups per day);
PAAD	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs55692468	1.000	rs55692468	chr2:153361375	T/G	cg04681845	chr2:153283485	FMNL2	0.39	4.33	0.33	2.64e-5	Intraocular pressure;
PAAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg14343924	chr8:8086146	FLJ10661	-0.69	-6.2	-0.45	4.98e-9	Mood instability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10180127	chr14:73806948	NUMB	-0.63	-6.35	-0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13424612	1.000	rs34849118	chr2:240919912	T/C	cg12807937	chr2:240965920	NDUFA10	-0.48	-4.72	-0.36	5.37e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg13560548	chr3:10150139	C3orf24	0.53	4.92	0.37	2.23e-6	Alzheimer's disease;
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs776905	0.598	rs491098	chr13:113769346	C/G	cg09069900	chr13:113776964	F10	0.57	4.79	0.36	3.95e-6	Blood protein levels;
PAAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-1.11	-9.19	-0.6	2.81e-16	Post bronchodilator FEV1;
PAAD	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.66	-6.93	-0.49	1.11e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg04362960	chr10:104952993	NT5C2	-0.51	-4.66	-0.35	6.92e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3134353	0.675	rs3019261	chr8:101978163	A/G	cg04962480	chr8:101962118	YWHAZ	-0.38	-4.43	-0.34	1.79e-5	Body mass index;
PAAD	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.88	0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.52	-5.38	-0.4	2.77e-7	Monocyte count;
PAAD	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg05250797	chr16:70222502	NA	0.84	6.39	0.46	1.89e-9	IgE levels;
PAAD	cis	rs282587	0.569	rs192530	chr13:113388303	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.21	0.39	6.17e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.74	8.1	0.55	1.71e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg12288994	chr5:1860383	NA	0.75	9.69	0.62	1.34e-17	Cardiovascular disease risk factors;
PAAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.47	4.85	0.37	3.06e-6	Longevity;
PAAD	cis	rs6693295	0.536	rs6656404	chr1:246255288	A/T	cg11798871	chr1:246315928	SMYD3	-0.74	-5.5	-0.41	1.6e-7	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.62	-6.98	-0.49	8.6e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.95	0.43	1.8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg09324608	chr17:30823087	MYO1D	0.56	5.71	0.42	5.71e-8	Schizophrenia;
PAAD	cis	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg03989125	chr22:38214979	NA	-0.52	-4.9	-0.37	2.42e-6	Glioblastoma;Glioma;
PAAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.42	4.43	0.34	1.78e-5	Obesity-related traits;
PAAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs2834188	0.924	rs6517160	chr21:34683512	A/G	cg04842828	chr21:34696676	IFNAR1	0.49	4.63	0.35	7.89e-6	Narcolepsy;
PAAD	cis	rs13242816	1.000	rs13233553	chr7:116182232	C/G	cg16553024	chr7:116138462	CAV2	-0.64	-4.47	-0.34	1.55e-5	P wave duration;
PAAD	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.58	-6.75	-0.48	2.9e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.7	6.5	0.47	1.08e-9	Primary sclerosing cholangitis;
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-5.94	-0.43	1.87e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.45	4.77	0.36	4.21e-6	Coronary artery disease;
PAAD	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg09455208	chr3:40491958	NA	0.45	5.8	0.43	3.7e-8	Renal cell carcinoma;
PAAD	trans	rs12714314	0.749	rs10185662	chr2:1964906	A/G	cg17170872	chr1:91487911	ZNF644	0.76	6.33	0.46	2.58e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs4073221	0.654	rs66497815	chr3:18305719	G/T	cg07694806	chr3:18168406	NA	-0.63	-4.49	-0.34	1.43e-5	Parkinson's disease;
PAAD	cis	rs790123	0.692	rs796892	chr3:122385402	C/T	cg15604389	chr3:122379662	NA	-0.56	-5.33	-0.4	3.57e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg21546286	chr11:48923668	NA	-0.52	-5.4	-0.4	2.52e-7	HDL cholesterol;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	1.01	16.08	0.79	1.31e-34	Recombination rate (males);
PAAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.65	-7.15	-0.5	3.36e-11	Bone mineral density;
PAAD	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.66	4.71	0.36	5.44e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg16316162	chr8:144660157	NAPRT1	0.84	4.38	0.34	2.16e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg23283495	chr1:209979779	IRF6	-0.8	-7.02	-0.49	6.95e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg05185573	chr6:26598237	ABT1	-0.41	-4.26	-0.33	3.64e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.66	-5.5	-0.41	1.54e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13151140	chr3:10290897	TATDN2	0.65	6.52	0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.59	-0.35	9.29e-6	Longevity;Endometriosis;
PAAD	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.6	5.43	0.4	2.15e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.52	4.89	0.37	2.55e-6	Night sleep phenotypes;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.67	7.15	0.5	3.41e-11	Iron status biomarkers;
PAAD	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.87	-6.8	-0.48	2.3e-10	Blood protein levels;
PAAD	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.83	8.72	0.58	4.47e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg14092988	chr3:52407081	DNAH1	0.45	5.34	0.4	3.32e-7	Bipolar disorder;
PAAD	cis	rs73787773	0.867	rs73787782	chr5:111494104	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.75	-4.48	-0.34	1.49e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.43	4.8	0.36	3.82e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg12568669	chr8:11666485	FDFT1	-0.27	-4.39	-0.34	2.09e-5	Neuroticism;
PAAD	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	6.06	0.44	1.02e-8	Tonsillectomy;
PAAD	cis	rs1957429	0.520	rs72625637	chr14:65307705	G/A	cg23373153	chr14:65346875	NA	-1.14	-5.79	-0.43	3.89e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	6.31	0.46	2.94e-9	Initial pursuit acceleration;
PAAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14580859	chr9:123691850	NA	0.38	4.37	0.33	2.3e-5	Rheumatoid arthritis;
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg26516362	chr5:178986906	RUFY1	0.47	5.21	0.39	6.09e-7	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01517273	chr1:154599968	ADAR	0.57	6.34	0.46	2.42e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.58	-5.61	-0.41	9.51e-8	Cancer;
PAAD	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.01	8.16	0.55	1.21e-13	Vitiligo;
PAAD	cis	rs1903068	0.853	rs12331471	chr4:56001509	T/C	cg09978860	chr4:56023921	NA	0.42	4.71	0.36	5.6e-6	Endometriosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18024801	chr6:24403143	MRS2	0.61	7.13	0.5	3.77e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6466055	0.566	rs10252714	chr7:104694071	T/G	cg04380332	chr7:105027541	SRPK2	-0.51	-4.98	-0.37	1.73e-6	Schizophrenia;
PAAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.5e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13939156	chr17:80058883	NA	-0.41	-4.37	-0.33	2.29e-5	Life satisfaction;
PAAD	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg19980929	chr12:42632907	YAF2	0.64	7.56	0.52	3.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg10523679	chr1:76189770	ACADM	-0.52	-4.9	-0.37	2.45e-6	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05742294	chr8:124169368	NA	0.67	7.37	0.51	1.01e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	4.73	0.36	5.16e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg09582351	chr12:29534625	ERGIC2	-0.38	-5.44	-0.4	2.11e-7	QT interval;
PAAD	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg21479132	chr6:26055353	NA	0.95	5.74	0.42	5.06e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.68	-6.77	-0.48	2.66e-10	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg13264159	chr8:625131	ERICH1	0.78	5.03	0.38	1.36e-6	IgG glycosylation;
PAAD	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	1.18	9.49	0.61	4.47e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2902440	0.502	rs7556198	chr1:67665543	A/G	cg01320130	chr1:67600311	NA	0.44	4.4	0.34	2e-5	Crohn's disease;
PAAD	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg26924012	chr15:45694286	SPATA5L1	0.46	4.32	0.33	2.81e-5	Uric acid levels;
PAAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs9398803	0.624	rs1455737	chr6:126647204	T/G	cg19875578	chr6:126661172	C6orf173	0.49	4.62	0.35	8.18e-6	Male-pattern baldness;
PAAD	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg08219700	chr8:58056026	NA	0.7	5.29	0.39	4.12e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-5.63	-0.42	8.29e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2952768	1.000	rs2709397	chr2:208492569	C/T	cg22329743	chr2:208688774	PLEKHM3	0.23	4.46	0.34	1.59e-5	Opioid sensitivity;
PAAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.47	-4.68	-0.35	6.42e-6	Subjective well-being;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.58	5.78	0.42	4.06e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-8.82	-0.58	2.45e-15	Lung function (FVC);
PAAD	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.72	-0.36	5.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-4.79	-0.36	4.01e-6	Cognitive test performance;
PAAD	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.8	9.51	0.61	4.09e-17	Crohn's disease;
PAAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	5.5	0.41	1.59e-7	Gut microbiome composition (summer);
PAAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.34	-6.67	-0.48	4.49e-10	Mean corpuscular volume;
PAAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.33	-10.29	-0.64	3.53e-19	Breast cancer;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.61	0.41	9.26e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg16444942	chr12:129309117	SLC15A4	-0.7	-4.26	-0.33	3.53e-5	Systemic lupus erythematosus;
PAAD	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.7	6.98	0.49	8.64e-11	Mosquito bite size;
PAAD	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg25547332	chr5:131281432	NA	0.53	4.25	0.33	3.71e-5	Life satisfaction;
PAAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.74	7.11	0.5	4.33e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg24699146	chr1:24152579	HMGCL	0.54	5.71	0.42	5.62e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.43	-5.28	-0.39	4.48e-7	Blood pressure;
PAAD	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg00531865	chr16:30841666	NA	0.56	4.26	0.33	3.62e-5	Dementia with Lewy bodies;
PAAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.49	0.34	1.41e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.69	-7.59	-0.52	3.02e-12	Longevity;
PAAD	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.87	0.63	4.54e-18	Smoking behavior;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14764512	chr3:49058575	MIR191;DALRD3;NDUFAF3;MIR425	0.62	6.87	0.49	1.53e-10	Monocyte percentage of white cells;
PAAD	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs10274279	0.623	rs221305	chr7:157371513	C/T	cg09270525	chr7:157391030	PTPRN2	-0.69	-6.43	-0.46	1.6e-9	Myopia (pathological);
PAAD	cis	rs75757892	0.500	rs2714312	chr6:7228462	A/C	cg15365232	chr6:7261319	NA	0.4	4.7	0.36	5.75e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.64	-0.35	7.32e-6	Ulcerative colitis;
PAAD	cis	rs17123764	0.818	rs4045193	chr12:50003980	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.25	-0.33	3.76e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg07559730	chr19:53497048	ZNF702P	-0.56	-6.04	-0.44	1.15e-8	Psoriasis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05986831	chr13:20135998	NA	-0.65	-6.38	-0.46	2.01e-9	Smoking initiation;
PAAD	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg26898376	chr11:64110657	CCDC88B	0.46	4.74	0.36	4.94e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.75	-8.89	-0.59	1.62e-15	Diastolic blood pressure;
PAAD	cis	rs227833	0.955	rs227836	chr6:44682740	C/G	cg18551225	chr6:44695536	NA	0.5	4.91	0.37	2.33e-6	Monobrow;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.68	6.92	0.49	1.16e-10	Resistin levels;
PAAD	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.46	4.87	0.37	2.82e-6	Age of smoking initiation;
PAAD	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg20487152	chr13:99095054	FARP1	-0.48	-4.98	-0.37	1.7e-6	Longevity;
PAAD	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.51	7.02	0.5	6.76e-11	Dupuytren's disease;
PAAD	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2120243	0.592	rs7618502	chr3:157095544	C/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	4.66	0.35	6.84e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs11581903	0.866	rs11591099	chr1:53056597	A/G	cg18087326	chr1:53067637	GPX7	-0.55	-4.98	-0.37	1.72e-6	Joint mobility (Beighton score);
PAAD	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.61	4.88	0.37	2.62e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.26	-0.39	4.76e-7	Vitamin D levels;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.05	-8.95	-0.59	1.16e-15	Alzheimer's disease;
PAAD	cis	rs6066835	0.867	rs4384849	chr20:47376185	A/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.1	0.55	1.71e-13	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15432510	chr17:78939670	RPTOR	0.5	6.8	0.48	2.23e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.56	-5.01	-0.38	1.48e-6	P wave terminal force;
PAAD	cis	rs8099014	0.954	rs4294895	chr18:56126867	T/C	cg12907477	chr18:56117327	MIR122	0.55	4.48	0.34	1.46e-5	Platelet count;
PAAD	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.37	0.33	2.26e-5	Tonsillectomy;
PAAD	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.64	-0.42	8.24e-8	Glomerular filtration rate;
PAAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.35e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg14926445	chr8:58193284	C8orf71	-0.66	-4.83	-0.36	3.25e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.7	-0.48	3.8e-10	Body mass index;
PAAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.82	-8.84	-0.58	2.29e-15	Body mass index;
PAAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.79	-0.48	2.33e-10	Calcium levels;
PAAD	cis	rs12431939	0.762	rs60225624	chr14:51704366	C/T	cg23942311	chr14:51606299	NA	-0.6	-5.0	-0.38	1.55e-6	Cancer;
PAAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.64	-6.1	-0.44	8.46e-9	Blood metabolite levels;
PAAD	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.51	6.39	0.46	1.89e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.53	-0.34	1.19e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.72	-5.8	-0.43	3.67e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs2299587	0.698	rs2283113	chr8:17880243	C/A	cg08627089	chr8:17753878	FGL1	-0.53	-5.22	-0.39	5.83e-7	Economic and political preferences;
PAAD	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20090482	chr10:135113191	TUBGCP2	0.56	6.87	0.49	1.55e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg08501292	chr6:25962987	TRIM38	0.84	4.31	0.33	2.88e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg27490568	chr2:178487706	NA	-0.4	-4.43	-0.34	1.76e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg02524346	chr8:600233	NA	-1.16	-7.71	-0.53	1.51e-12	IgG glycosylation;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14201459	chr13:114285638	TFDP1	-0.73	-7.12	-0.5	3.99e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	1.08	12.49	0.71	4.56e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.48	-4.26	-0.33	3.52e-5	Parkinson's disease;
PAAD	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.79	-6.1	-0.44	8.52e-9	Uric acid levels;
PAAD	cis	rs1075265	0.811	rs805308	chr2:54194934	C/G	cg04546899	chr2:54196757	PSME4	0.37	5.67	0.42	7.08e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs75920871	0.925	rs61903417	chr11:116956157	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg07061783	chr6:25882402	NA	-0.51	-4.92	-0.37	2.21e-6	Blood metabolite levels;
PAAD	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.6	5.14	0.38	8.3e-7	QRS duration;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07362569	chr17:61921086	SMARCD2	0.48	5.91	0.43	2.14e-8	Prudent dietary pattern;
PAAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg06307176	chr5:131281290	NA	0.45	4.28	0.33	3.3e-5	Blood metabolite levels;
PAAD	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.68	-7.43	-0.52	7.46e-12	Neuroticism;
PAAD	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg04022379	chr5:110408740	TSLP	0.54	4.97	0.37	1.8e-6	Eosinophilic esophagitis;
PAAD	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.5	-5.98	-0.44	1.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg13919466	chr1:32135498	COL16A1	-0.4	-4.51	-0.34	1.28e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25781202	chr8:33424350	RNF122	0.66	8.05	0.55	2.28e-13	Myopia (pathological);
PAAD	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg14583973	chr4:3374767	RGS12	0.33	4.71	0.36	5.58e-6	Mean platelet volume;
PAAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.61	-6.29	-0.45	3.24e-9	IgG glycosylation;
PAAD	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.59	-5.38	-0.4	2.8e-7	Primary biliary cholangitis;
PAAD	cis	rs12311304	1.000	rs1120565	chr12:15401796	A/T	cg08258403	chr12:15378311	NA	0.34	4.36	0.33	2.4e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg21775007	chr8:11205619	TDH	-0.51	-4.48	-0.34	1.45e-5	Triglycerides;
PAAD	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.97	-0.37	1.82e-6	Total cholesterol levels;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.82	8.97	0.59	1.02e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1539053	0.966	rs11207081	chr1:58101851	A/C	cg20292791	chr1:58089357	DAB1	-0.53	-5.2	-0.39	6.35e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg01171360	chr6:293285	DUSP22	-0.63	-6.4	-0.46	1.79e-9	Menopause (age at onset);
PAAD	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.76	-7.6	-0.52	2.88e-12	Mosquito bite size;
PAAD	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.88	-11.15	-0.67	1.74e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.92e-17	Electrocardiographic conduction measures;
PAAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.78	0.62	7.97e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg15131784	chr3:139108705	COPB2	-0.52	-4.49	-0.34	1.38e-5	Obesity-related traits;
PAAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	4.59	0.35	9.15e-6	Menopause (age at onset);
PAAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	trans	rs3905000	1.000	rs7043081	chr9:107649611	A/T	cg25813864	chr17:38334176	RAPGEFL1	0.86	6.44	0.46	1.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.76	-8.64	-0.57	7.31e-15	Renal function-related traits (BUN);
PAAD	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.66	-6.28	-0.45	3.45e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.48	-7.14	-0.5	3.65e-11	Mean corpuscular volume;
PAAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.5	5.26	0.39	4.76e-7	Life satisfaction;
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.7	0.62	1.28e-17	Platelet count;
PAAD	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.35	-0.33	2.45e-5	Fibrinogen levels;
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg18279126	chr7:2041391	MAD1L1	0.57	5.26	0.39	4.71e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.91	-11.33	-0.68	5.88e-22	Coronary artery disease;
PAAD	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg12935359	chr14:103987150	CKB	-0.57	-6.02	-0.44	1.25e-8	Body mass index;
PAAD	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-1.0	-10.91	-0.66	8.04e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	6.12	0.44	7.43e-9	Menarche (age at onset);
PAAD	cis	rs2229238	0.866	rs59741504	chr1:154504601	T/C	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.86e-6	Coronary heart disease;
PAAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.64	0.35	7.34e-6	Height;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.76	6.47	0.46	1.28e-9	Alzheimer's disease;
PAAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.74	-6.42	-0.46	1.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Migraine;
PAAD	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs3996993	0.809	rs2894805	chr6:52680600	C/T	cg20803780	chr6:52668592	GSTA1	-0.35	-4.48	-0.34	1.47e-5	Hemoglobin concentration;
PAAD	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.49	4.91	0.37	2.35e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg00912467	chr1:161369970	NA	0.48	4.42	0.34	1.88e-5	IgG glycosylation;
PAAD	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg16586182	chr3:47516702	SCAP	0.61	6.44	0.46	1.5e-9	Colorectal cancer;
PAAD	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg19257562	chr1:2043853	PRKCZ	-0.41	-4.7	-0.36	5.72e-6	Coronary artery disease;
PAAD	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	cis	rs8113142	0.614	rs55647098	chr19:29148429	T/G	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.08e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.58	5.67	0.42	7.11e-8	Systolic blood pressure;
PAAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.48	-4.55	-0.35	1.11e-5	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18527268	chr2:24270447	C2orf44	0.64	6.29	0.45	3.21e-9	Obesity-related traits;
PAAD	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.47	-4.27	-0.33	3.43e-5	Schizophrenia;
PAAD	cis	rs7319311	0.748	rs9515198	chr13:111029065	C/T	cg05272587	chr13:111038400	COL4A2	0.6	5.58	0.41	1.08e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.11	0.63	1.08e-18	Platelet count;
PAAD	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs251130	0.874	rs251135	chr5:110858691	A/G	cg11925263	chr5:110849104	STARD4	0.37	4.66	0.35	6.79e-6	Menarche (age at onset);
PAAD	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.64	5.26	0.39	4.93e-7	Prostate cancer;
PAAD	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.72	-6.95	-0.49	1.03e-10	Schizophrenia;
PAAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.8	8.31	0.56	4.9e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.77	8.71	0.58	4.92e-15	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13198984	chr17:80129470	CCDC57	0.43	5.28	0.39	4.34e-7	Life satisfaction;
PAAD	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg12615879	chr12:58013172	SLC26A10	0.44	4.68	0.35	6.37e-6	Multiple sclerosis;
PAAD	cis	rs3748682	0.821	rs12751325	chr1:38289383	T/C	cg12658694	chr1:38397304	INPP5B	0.47	4.45	0.34	1.63e-5	Hypothyroidism;
PAAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg01075559	chr1:2537774	MMEL1	0.46	4.97	0.37	1.75e-6	Ulcerative colitis;
PAAD	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.92	12.88	0.72	3.97e-26	Height;
PAAD	cis	rs9880406	0.876	rs1399712	chr3:126048439	C/T	cg11830761	chr3:126007485	NA	-0.5	-4.62	-0.35	8.2e-6	Macular telangiectasia type 2;
PAAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.57	-5.75	-0.42	4.66e-8	White blood cell count;
PAAD	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg12935359	chr14:103987150	CKB	-0.56	-5.92	-0.43	2.05e-8	Body mass index;
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22633769	chr20:60982531	CABLES2	0.42	4.34	0.33	2.62e-5	Colorectal cancer;
PAAD	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg17958577	chr5:488589	SLC9A3	-0.41	-6.34	-0.46	2.48e-9	Serum protein levels (sST2);
PAAD	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg18721089	chr20:30220636	NA	-0.81	-6.64	-0.47	5.17e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-5.84	-0.43	3.1e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.94	0.37	2.02e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs76419734	0.614	rs17036097	chr4:106597295	G/C	cg05309399	chr4:106552544	FLJ20184	-0.57	-4.41	-0.34	1.98e-5	Post bronchodilator FEV1;
PAAD	cis	rs4757319	0.515	rs58697209	chr11:15431540	C/T	cg03245590	chr11:15329459	NA	0.43	5.19	0.39	6.66e-7	Breast cancer;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.48	4.86	0.37	2.85e-6	Lymphocyte counts;
PAAD	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.61	6.14	0.45	7e-9	Triglyceride levels;
PAAD	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg24296786	chr1:45957014	TESK2	0.5	4.57	0.35	1.02e-5	Homocysteine levels;
PAAD	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-5.61	-0.41	9.49e-8	Response to antipsychotic treatment;
PAAD	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.98	9.65	0.62	1.78e-17	Blood protein levels;
PAAD	cis	rs6088813	1.000	rs1540927	chr20:33931344	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.92	9.57	0.61	2.91e-17	Corneal astigmatism;
PAAD	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.88	0.43	2.48e-8	Prudent dietary pattern;
PAAD	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg20283391	chr11:68216788	NA	0.54	5.2	0.39	6.21e-7	Total body bone mineral density;
PAAD	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs965469	1.000	rs6037532	chr20:3267911	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg27234864	chr13:21295941	IL17D	0.6	5.24	0.39	5.3e-7	Dental caries;
PAAD	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg23950597	chr19:37808831	NA	-0.77	-5.21	-0.39	6.09e-7	Coronary artery calcification;
PAAD	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	5.92	0.43	2.06e-8	Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22544376	chr2:74154016	DGUOK	0.62	6.42	0.46	1.69e-9	Myopia (pathological);
PAAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.63	7.66	0.53	2.03e-12	Iron status biomarkers (transferrin levels);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14054357	chr17:2607986	KIAA0664	0.54	6.5	0.47	1.1e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg04106633	chr4:1044584	NA	0.66	5.57	0.41	1.11e-7	Recombination rate (females);
PAAD	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.59	6.01	0.44	1.31e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg22143856	chr6:28129313	ZNF389	-0.49	-4.49	-0.34	1.4e-5	Parkinson's disease;
PAAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.92	9.54	0.61	3.48e-17	Cognitive function;
PAAD	cis	rs1539053	0.932	rs7544337	chr1:58108645	T/C	cg00026909	chr1:58089001	DAB1	-0.64	-7.21	-0.5	2.43e-11	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs10875746	0.768	rs4760676	chr12:48421663	G/A	cg26205652	chr12:48591994	NA	0.84	8.04	0.55	2.31e-13	Longevity (90 years and older);
PAAD	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.6	6.43	0.46	1.56e-9	Bladder cancer;
PAAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg19192590	chr2:178524533	PDE11A	-0.39	-4.43	-0.34	1.8e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18153137	chr3:71114771	FOXP1	-0.69	-6.64	-0.47	5.35e-10	Lung cancer in ever smokers;
PAAD	cis	rs1075265	0.588	rs1477258	chr2:54227168	T/A	cg04546899	chr2:54196757	PSME4	0.32	4.75	0.36	4.64e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	1.1	5.88	0.43	2.47e-8	Plasma clusterin levels;
PAAD	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.62	5.94	0.43	1.91e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	6.01	0.44	1.32e-8	Breast cancer;
PAAD	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-6.9	-0.49	1.34e-10	Parkinson's disease;
PAAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.22	-0.51	2.37e-11	Cognitive function;
PAAD	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.48	5.18	0.39	6.82e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-1.23	-11.9	-0.69	1.76e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.57	-6.24	-0.45	4.14e-9	Electroencephalogram traits;
PAAD	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.45	-4.59	-0.35	9.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.83	-0.48	1.9e-10	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.25	-0.39	4.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-4.39	-0.34	2.16e-5	Personality dimensions;
PAAD	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg05338066	chr1:7812865	CAMTA1	-0.55	-4.64	-0.35	7.4e-6	Inflammatory bowel disease;
PAAD	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.65	6.11	0.44	7.9e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg06496078	chr12:107350075	C12orf23	-0.46	-4.58	-0.35	9.61e-6	Total body bone mineral density;
PAAD	cis	rs73416724	1.000	rs75320251	chr6:43395101	G/A	cg26312998	chr6:43337775	ZNF318	0.65	5.45	0.4	1.98e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2004318	1.000	rs73612487	chr19:55119265	G/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg15211996	chr1:2936768	ACTRT2	0.44	4.25	0.33	3.74e-5	Plateletcrit;
PAAD	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.41	4.5	0.34	1.37e-5	Mean platelet volume;
PAAD	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg12046867	chr14:103022105	NA	-0.66	-5.39	-0.4	2.69e-7	Platelet count;
PAAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs863345	0.604	rs12075228	chr1:158502256	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.88	0.58	1.77e-15	Lung cancer;
PAAD	cis	rs790110	1.000	rs60226894	chr3:122384152	C/T	cg22468055	chr3:122334227	PARP15	0.84	4.67	0.35	6.47e-6	Acoustic startle blink response;
PAAD	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs4588572	0.643	rs9293752	chr5:77798432	A/G	cg11547950	chr5:77652471	NA	0.86	7.74	0.53	1.28e-12	Triglycerides;
PAAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.69	8.89	0.58	1.66e-15	Atrioventricular conduction;
PAAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.08	0.38	1.1e-6	Rheumatoid arthritis;
PAAD	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.41	5.2	0.39	6.32e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2583612	0.643	rs55876624	chr4:120629576	A/C	cg05550861	chr4:120222222	C4orf3	-0.72	-5.07	-0.38	1.13e-6	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs62158211	0.565	rs62158212	chr2:114106326	A/G	cg17784749	chr2:114082611	LOC440839	0.53	5.24	0.39	5.37e-7	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.58	-0.35	9.46e-6	Recombination measurement;
PAAD	cis	rs7577696	0.512	rs212691	chr2:32438075	G/A	cg02381751	chr2:32503542	YIPF4	0.51	4.91	0.37	2.37e-6	Inflammatory biomarkers;
PAAD	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.39	-0.4	2.65e-7	Daytime sleep phenotypes;
PAAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg03676636	chr4:99064102	C4orf37	0.25	4.4	0.34	2.05e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.59	-0.41	1.02e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.4	-0.4	2.48e-7	Personality dimensions;
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs71403859	0.570	rs77809998	chr16:71430687	C/T	cg08717414	chr16:71523259	ZNF19	-0.96	-5.85	-0.43	2.94e-8	Post bronchodilator FEV1;
PAAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg02404636	chr22:31891804	SFI1	-0.57	-5.19	-0.39	6.76e-7	Colorectal cancer;
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.91	-6.29	-0.45	3.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs6867032	1.000	rs4254943	chr5:2009878	C/T	cg26168224	chr5:2018326	NA	1.16	15.73	0.79	1.07e-33	Gut microbiome composition (winter);
PAAD	cis	rs6796502	0.541	rs28440083	chr3:46881986	A/G	cg23231268	chr3:46792462	NA	-0.64	-4.9	-0.37	2.48e-6	Breast cancer;
PAAD	cis	rs911119	1.000	rs6515375	chr20:23610841	G/A	cg16589663	chr20:23618590	CST3	0.8	6.53	0.47	9.29e-10	Chronic kidney disease;
PAAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg26727032	chr16:67993705	SLC12A4	-0.6	-4.37	-0.33	2.33e-5	Schizophrenia;
PAAD	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg02254774	chr11:50257496	LOC441601	-0.44	-4.53	-0.35	1.17e-5	Height;
PAAD	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.93	-9.01	-0.59	8.23e-16	Asthma;
PAAD	cis	rs77741769	1.000	rs77741769	chr12:121363835	C/T	cg02403541	chr12:121454288	C12orf43	0.49	5.1	0.38	1e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg09127314	chr1:152161683	NA	-0.68	-4.59	-0.35	9.22e-6	Atopic dermatitis;
PAAD	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg15128208	chr22:42549153	NA	0.51	4.39	0.34	2.09e-5	Birth weight;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.48e-13	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23978513	chr4:39979310	PDS5A	0.65	6.96	0.49	9.44e-11	Obesity-related traits;
PAAD	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.87	7.97	0.54	3.51e-13	Homoarginine levels;
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg10621924	chr7:39171070	POU6F2	0.27	4.51	0.34	1.29e-5	IgG glycosylation;
PAAD	cis	rs7766436	0.648	rs7757111	chr6:22591154	C/A	cg13666174	chr6:22585274	NA	-0.51	-5.45	-0.4	1.99e-7	Coronary artery disease;
PAAD	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	7.63	0.53	2.43e-12	Eotaxin levels;
PAAD	cis	rs258892	0.843	rs13190547	chr5:72035753	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.86	-0.54	6.6e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg09491104	chr22:46646882	C22orf40	-1.01	-6.08	-0.44	9.17e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.39	4.99	0.38	1.62e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.53	-0.41	1.38e-7	Personality dimensions;
PAAD	cis	rs10849004	1.000	rs7308094	chr12:4294769	C/T	cg03803796	chr12:3575061	NA	0.53	4.41	0.34	1.96e-5	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18760317	chr7:117864927	ANKRD7	-0.53	-4.62	-0.35	8.22e-6	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.54	-6.88	-0.49	1.43e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24902490	chr1:21502579	EIF4G3	-0.74	-6.32	-0.46	2.72e-9	Neuroticism;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs375066	0.551	rs11880651	chr19:44331798	T/C	cg11993925	chr19:44307056	LYPD5	-0.4	-4.36	-0.33	2.35e-5	Breast cancer;
PAAD	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg08027265	chr7:2291960	NA	-0.53	-5.28	-0.39	4.4e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.93	13.54	0.74	6.83e-28	Dental caries;
PAAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.41	-4.83	-0.36	3.34e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.31	-0.33	2.97e-5	Resting heart rate;
PAAD	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	6.78	0.48	2.49e-10	Resting heart rate;
PAAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs2637266	0.783	rs4980006	chr10:78477993	G/C	cg18941641	chr10:78392320	NA	0.37	4.37	0.33	2.31e-5	Pulmonary function;
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-4.75	-0.36	4.65e-6	Testicular germ cell tumor;
PAAD	cis	rs13024765	0.527	rs35707987	chr2:225176193	T/G	cg22455342	chr2:225449267	CUL3	0.47	4.4	0.34	2e-5	Platelet-derived growth factor BB levels;
PAAD	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	6.77	0.48	2.69e-10	Leprosy;
PAAD	cis	rs1468333	0.567	rs2240334	chr5:137763615	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.09	0.38	1.03e-6	Resting heart rate;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11506907	chr11:118972568	DPAGT1	-0.62	-6.38	-0.46	2.08e-9	Lung cancer in ever smokers;
PAAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg23298862	chr7:158159286	PTPRN2	-0.45	-4.28	-0.33	3.33e-5	Calcium levels;
PAAD	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.75	-0.48	3e-10	Life satisfaction;
PAAD	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.6	-4.77	-0.36	4.29e-6	Metabolite levels;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-5.27	-0.39	4.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.4	-5.41	-0.4	2.41e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg20850873	chr3:10149803	C3orf24	0.55	4.44	0.34	1.75e-5	Alzheimer's disease;
PAAD	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.42	-4.71	-0.36	5.62e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.47	-5.84	-0.43	3.09e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg15847926	chr7:2749597	AMZ1	-0.38	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.31	-0.4	3.83e-7	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10355708	chr8:145618298	ADCK5	0.62	6.37	0.46	2.16e-9	Myopia (pathological);
PAAD	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.66	-0.35	7e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	1.23	7.58	0.52	3.24e-12	Severe influenza A (H1N1) infection;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg14926445	chr8:58193284	C8orf71	-0.78	-6.0	-0.44	1.38e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.65	7.12	0.5	4.01e-11	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.49	-5.97	-0.44	1.58e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.63	5.91	0.43	2.13e-8	Height;
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.95	-0.43	1.77e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.61	7.2	0.5	2.63e-11	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg04705435	chr11:17411270	KCNJ11	0.61	6.34	0.46	2.43e-9	Type 2 diabetes;
PAAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.54	-6.54	-0.47	8.92e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.73	5.14	0.38	8.39e-7	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8077577	0.789	rs62072546	chr17:18253839	C/T	cg16794390	chr17:18148240	FLII	0.6	4.91	0.37	2.36e-6	Obesity-related traits;
PAAD	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.44	0.34	1.7e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.36	4.25	0.33	3.66e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.8	-6.91	-0.49	1.24e-10	Tuberculosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19394101	chr15:90645875	IDH2	-0.75	-6.31	-0.46	2.85e-9	Neuroticism;
PAAD	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.7	-6.7	-0.48	3.8e-10	White matter hyperintensity burden;
PAAD	cis	rs2562456	0.833	rs11666540	chr19:21539352	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16306731	chr3:118959850	B4GALT4	-0.79	-7.03	-0.5	6.7e-11	Neuroticism;
PAAD	cis	rs6804624	0.676	rs2670346	chr3:99163961	A/G	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs136211	1.000	rs136213	chr22:36759815	A/G	cg11153328	chr22:36877737	TXN2	-0.49	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73416724	0.614	rs78882866	chr6:43263473	T/G	cg17076780	chr6:43251928	TTBK1	0.74	5.19	0.39	6.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg08345082	chr10:99160200	RRP12	-0.31	-4.43	-0.34	1.82e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg10600917	chr12:121163489	ACADS	0.52	4.25	0.33	3.67e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.71	-6.49	-0.47	1.17e-9	Total body bone mineral density;
PAAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg18944383	chr4:111397179	ENPEP	-0.68	-8.71	-0.58	4.71e-15	Coronary artery disease;
PAAD	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg26850624	chr5:429559	AHRR	0.71	7.31	0.51	1.44e-11	Cystic fibrosis severity;
PAAD	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.57	4.77	0.36	4.36e-6	Height;
PAAD	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg21589280	chr1:85930151	DDAH1	-0.57	-4.36	-0.33	2.37e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.48	-4.38	-0.34	2.16e-5	Tonsillectomy;
PAAD	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.68	7.23	0.51	2.22e-11	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.78e-10	Bipolar disorder;
PAAD	cis	rs2718812	0.719	rs1867505	chr3:133411052	T/C	cg11941060	chr3:133502564	NA	0.48	5.0	0.38	1.56e-6	Iron status biomarkers;
PAAD	trans	rs4986811	0.500	rs72893557	chr11:32462873	A/C	cg16078836	chr3:185081374	MAP3K13	-0.94	-6.48	-0.47	1.22e-9	Rubella-specific interleukin-6 secretion;
PAAD	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.52	-4.57	-0.35	1.01e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07362569	chr17:61921086	SMARCD2	0.64	8.14	0.55	1.33e-13	Prudent dietary pattern;
PAAD	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.44	4.72	0.36	5.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.38	-4.52	-0.34	1.24e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg04106633	chr4:1044584	NA	0.66	5.37	0.4	2.9e-7	Recombination rate (females);
PAAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.02	0.5	6.74e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.5	5.16	0.39	7.75e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18573244	chr12:10956452	TAS2R7	-0.49	-6.43	-0.46	1.57e-9	Energy expenditure (24h);
PAAD	cis	rs1879734	0.731	rs4927032	chr1:54186489	C/T	cg14659662	chr1:54151053	GLIS1	-0.39	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.61	-0.41	9.22e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg07362569	chr17:61921086	SMARCD2	0.44	5.01	0.38	1.48e-6	Height;
PAAD	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg21191810	chr6:118973309	C6orf204	0.48	6.16	0.45	6.36e-9	Electrocardiographic conduction measures;
PAAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07135408	chr1:236908002	ACTN2	0.62	6.38	0.46	2.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13242816	1.000	rs987791	chr7:116134701	A/G	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.9e-24	Platelet count;
PAAD	cis	rs300774	0.800	rs300701	chr2:187396	C/G	cg21211680	chr2:198530	NA	-0.64	-5.74	-0.42	4.86e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-1.08	-15.07	-0.77	5.77e-32	Total body bone mineral density;
PAAD	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.39	5.77	0.42	4.34e-8	Educational attainment (years of education);
PAAD	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg10820045	chr2:198174542	NA	0.49	4.99	0.38	1.65e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs901683	1.000	rs34195613	chr10:46030374	G/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg22256960	chr15:77711686	NA	-0.53	-4.36	-0.33	2.42e-5	Type 2 diabetes;
PAAD	cis	rs17601876	0.814	rs8042086	chr15:51561478	C/T	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs72843506	0.656	rs79773274	chr17:19905931	C/T	cg05625806	chr17:19284432	MAPK7	0.69	4.53	0.34	1.19e-5	Schizophrenia;
PAAD	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	7.46	0.52	6.33e-12	Lymphocyte counts;
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg01942863	chr7:99769432	GPC2	0.51	4.67	0.35	6.62e-6	Coronary artery disease;
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg04520793	chr17:42248056	ASB16	-0.43	-5.18	-0.39	6.88e-7	Total body bone mineral density;
PAAD	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg05342945	chr12:48394962	COL2A1	0.66	4.28	0.33	3.29e-5	Lung cancer;
PAAD	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.49	-4.68	-0.35	6.33e-6	Hip circumference;
PAAD	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg08992911	chr2:238395768	MLPH	0.52	4.73	0.36	5.16e-6	Prostate cancer;
PAAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.67	5.79	0.42	3.99e-8	Inflammatory skin disease;
PAAD	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11378840	chr10:94449797	HHEX	-0.69	-6.31	-0.46	2.9e-9	Neuroticism;
PAAD	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg08200582	chr11:442649	ANO9	0.51	4.42	0.34	1.83e-5	Systemic lupus erythematosus;
PAAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg09222892	chr1:25734099	RHCE	-0.44	-4.26	-0.33	3.62e-5	Erythrocyte sedimentation rate;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10892866	chr1:154934115	PYGO2	0.61	6.61	0.47	6.01e-10	Myopia (pathological);
PAAD	cis	rs10929159	0.964	rs10170434	chr2:236937578	G/A	cg14226755	chr2:236923322	AGAP1	0.28	4.56	0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.63	-5.74	-0.42	4.88e-8	Restless legs syndrome;
PAAD	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.7	8.52	0.57	1.45e-14	Alcohol dependence;
PAAD	cis	rs3931020	0.772	rs1475396	chr1:75242396	C/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.47	4.58	0.35	9.56e-6	Resistin levels;
PAAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.51	-5.32	-0.4	3.69e-7	Breast cancer;
PAAD	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg15193198	chr20:60906057	LAMA5	-0.51	-4.63	-0.35	7.75e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	1.07	14.45	0.76	2.48e-30	Metabolite levels;
PAAD	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg23465465	chr6:26364728	BTN3A2	-0.8	-4.69	-0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6594713	0.533	rs13180357	chr5:112969041	A/C	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.47	5.46	0.4	1.94e-7	Cystic fibrosis severity;
PAAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs55728055	0.661	rs8142821	chr22:31941240	A/C	cg15823100	chr22:32027580	PISD	-0.8	-4.3	-0.33	3.06e-5	Age-related hearing impairment;
PAAD	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.38	-0.4	2.81e-7	Schizophrenia (age at onset);
PAAD	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-8.48	-0.57	1.89e-14	Vitiligo;
PAAD	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-6.15	-0.45	6.51e-9	Hypospadias;
PAAD	cis	rs62264129	0.500	rs56008438	chr3:112034103	A/G	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.03	-0.38	1.36e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg20813462	chr7:2646259	IQCE	0.66	4.71	0.36	5.6e-6	Urate levels in lean individuals;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.32	-0.33	2.79e-5	Alcohol dependence;
PAAD	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.71	0.58	4.7e-15	Personality dimensions;
PAAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	7.38	0.51	9.78e-12	Obesity-related traits;
PAAD	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.59	6.22	0.45	4.65e-9	Schizophrenia;
PAAD	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.66	6.51	0.47	1.05e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg23461800	chr14:103021989	NA	-0.58	-4.38	-0.33	2.23e-5	Platelet count;
PAAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg00933542	chr6:150070202	PCMT1	0.53	5.25	0.39	5.09e-7	Lung cancer;
PAAD	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.81	-0.36	3.53e-6	Prevalent atrial fibrillation;
PAAD	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg27234864	chr13:21295941	IL17D	0.54	4.75	0.36	4.67e-6	Dental caries;
PAAD	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.29	-0.33	3.21e-5	Schizophrenia;
PAAD	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.4	4.38	0.33	2.21e-5	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg13175981	chr1:150552382	MCL1	0.76	7.67	0.53	1.89e-12	Tonsillectomy;
PAAD	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg12046867	chr14:103022105	NA	-0.71	-5.29	-0.39	4.11e-7	Platelet count;
PAAD	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25832795	chr20:10019010	ANKRD5	-0.68	-6.75	-0.48	2.93e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg23033748	chr14:75592666	NEK9	-0.42	-5.17	-0.39	7.22e-7	Height;
PAAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.51e-38	Height;
PAAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.06	-0.38	1.21e-6	Blood metabolite levels;
PAAD	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg15226751	chr1:10001911	LZIC	0.38	4.29	0.33	3.19e-5	Hepatocellular carcinoma;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03207436	chr5:125937141	PHAX	0.56	6.3	0.46	3.12e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.47	5.41	0.4	2.41e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.77	-7.92	-0.54	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs9649465	0.967	rs13230230	chr7:123329603	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.75	-0.36	4.76e-6	Migraine;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.74	8.25	0.56	6.91e-14	Total body bone mineral density;
PAAD	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25403298	chr7:129251373	NRF1	0.72	8.23	0.56	7.69e-14	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg10547527	chr2:198650123	BOLL	-0.7	-4.93	-0.37	2.1e-6	Ulcerative colitis;
PAAD	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.6	5.26	0.39	4.72e-7	Retinal vascular caliber;
PAAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.93	0.63	3.26e-18	Total body bone mineral density;
PAAD	cis	rs258892	0.895	rs10473898	chr5:72037813	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg03959625	chr15:84868606	LOC388152	-0.49	-5.37	-0.4	2.88e-7	Schizophrenia;
PAAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.72	0.42	5.61e-8	Tonsillectomy;
PAAD	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg21427119	chr20:30132790	HM13	-0.58	-5.31	-0.4	3.87e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.48	5.75	0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16417436	chr16:28758564	NA	0.43	4.43	0.34	1.78e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26303175	chr10:102295141	HIF1AN	-0.65	-6.85	-0.49	1.77e-10	Obesity-related traits;
PAAD	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	4.71	0.36	5.45e-6	Iron status biomarkers;
PAAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg14343924	chr8:8086146	FLJ10661	-0.67	-5.68	-0.42	6.81e-8	Mood instability;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.13	-0.38	8.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg17633681	chr16:88106987	BANP	0.62	8.03	0.55	2.55e-13	Menopause (age at onset);
PAAD	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.28	0.51	1.69e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg00086871	chr4:6988644	TBC1D14	1.12	4.98	0.37	1.74e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg27411982	chr8:10470053	RP1L1	0.48	4.87	0.37	2.81e-6	Neuroticism;
PAAD	cis	rs9903692	0.505	rs208008	chr17:46230838	C/T	cg24322968	chr17:46507895	SKAP1	-0.91	-5.85	-0.43	2.85e-8	Pulse pressure;
PAAD	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.65	-8.63	-0.57	7.86e-15	Monocyte percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20407116	chr11:65029650	POLA2	-0.73	-6.51	-0.47	1.04e-9	Neuroticism;
PAAD	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs6688613	0.685	rs2142615	chr1:166922731	G/C	cg07049167	chr1:166818506	POGK	0.66	6.38	0.46	2.03e-9	Refractive astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14615195	chr2:2335088	MYT1L	-0.59	-6.97	-0.49	8.88e-11	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.24	-0.39	5.38e-7	Pulmonary function;
PAAD	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.43	4.83	0.36	3.27e-6	Breast cancer;
PAAD	cis	rs10073892	0.711	rs10074392	chr5:101596412	A/G	cg17280723	chr5:101634495	NA	0.43	4.49	0.34	1.42e-5	Cognitive decline (age-related);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19056833	chr13:114749079	RASA3	0.61	6.76	0.48	2.74e-10	Smoking initiation;
PAAD	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.79	6.62	0.47	5.88e-10	Brain cytoarchitecture;
PAAD	cis	rs3026101	0.671	rs13341936	chr17:5298858	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.96	0.44	1.71e-8	Body mass index;
PAAD	cis	rs9287719	0.624	rs10199831	chr2:10726863	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.74	8.54	0.57	1.33e-14	Height;
PAAD	cis	rs308971	0.803	rs2471469	chr3:12238077	A/G	cg03310376	chr3:12229001	SYN2	0.53	4.62	0.35	8.17e-6	Fasting blood insulin (BMI interaction);
PAAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs4704187	0.640	rs1600073	chr5:74436737	C/T	cg03227963	chr5:74354835	NA	0.49	4.71	0.36	5.55e-6	Response to amphetamines;
PAAD	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg00717180	chr2:96193071	NA	0.59	6.65	0.47	5.03e-10	HDL cholesterol;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg23759393	chr7:158110405	PTPRN2	0.37	4.48	0.34	1.48e-5	Response to amphetamines;
PAAD	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-7.0	-0.49	7.71e-11	Coffee consumption (cups per day);
PAAD	cis	rs12760731	0.720	rs10798606	chr1:178372965	G/A	cg00404053	chr1:178313656	RASAL2	0.72	5.64	0.42	8.21e-8	Obesity-related traits;
PAAD	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.86	9.11	0.59	4.38e-16	Anterior chamber depth;
PAAD	cis	rs7897654	0.571	rs12771681	chr10:104635620	T/C	cg03417317	chr10:104221000	TMEM180	0.55	4.44	0.34	1.75e-5	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.05	-0.5	5.9e-11	Life satisfaction;
PAAD	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg00999904	chr2:3704751	ALLC	-0.55	-5.25	-0.39	4.95e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg15571903	chr15:79123663	NA	0.48	6.25	0.45	4.03e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	10.61	0.65	4.86e-20	Platelet count;
PAAD	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.81	6.62	0.47	5.74e-10	Pulmonary function decline;
PAAD	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.26	0.39	4.82e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.85	9.96	0.63	2.67e-18	Menarche (age at onset);
PAAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-7.62	-0.53	2.47e-12	Total body bone mineral density;
PAAD	cis	rs9926296	0.632	rs4785590	chr16:89790167	G/C	cg26513180	chr16:89883248	FANCA	-0.61	-6.7	-0.48	3.87e-10	Vitiligo;
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.73	7.39	0.51	9.21e-12	Prostate cancer;
PAAD	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg24053715	chr22:38214548	NA	-0.57	-5.79	-0.42	3.95e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg22587600	chr2:46883368	NA	0.33	4.45	0.34	1.66e-5	Height;
PAAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-5.33	-0.4	3.54e-7	Total body bone mineral density;
PAAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.81	-0.36	3.63e-6	Recombination rate (females);
PAAD	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.21	17.47	0.82	3.59e-38	Total cholesterol levels;
PAAD	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.11	10.93	0.66	7.1e-21	Corneal structure;
PAAD	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.52	-5.56	-0.41	1.19e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg14926445	chr8:58193284	C8orf71	-0.71	-5.57	-0.41	1.11e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.47	5.42	0.4	2.28e-7	Height;
PAAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	1.08	12.5	0.71	4.23e-25	Obesity-related traits;
PAAD	cis	rs28595532	0.920	rs114667001	chr4:119786974	T/C	cg21605333	chr4:119757512	SEC24D	2.01	10.1	0.63	1.14e-18	Cannabis dependence symptom count;
PAAD	cis	rs6604026	0.740	rs6604031	chr1:93400766	T/G	cg17283838	chr1:93427260	FAM69A	-0.63	-5.79	-0.43	3.88e-8	Multiple sclerosis;
PAAD	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.68	10.06	0.63	1.43e-18	Airflow obstruction;
PAAD	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.5	5.83	0.43	3.24e-8	Platelet count;
PAAD	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg08501292	chr6:25962987	TRIM38	0.72	4.73	0.36	5.14e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13885842	chr22:41973319	PMM1	-0.67	-6.43	-0.46	1.56e-9	Obesity-related traits;
PAAD	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.78	8.37	0.56	3.52e-14	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2288884	0.943	rs11084132	chr19:52514580	C/T	cg24368865	chr19:51538134	KLK12	0.49	4.43	0.34	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
PAAD	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg01299579	chr2:10830716	NOL10	-0.51	-5.18	-0.39	6.83e-7	Prostate cancer;
PAAD	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-4.6	-0.35	8.7e-6	Body mass index;
PAAD	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs8077577	0.945	rs11654146	chr17:18076141	A/C	cg16794390	chr17:18148240	FLII	0.58	4.88	0.37	2.68e-6	Obesity-related traits;
PAAD	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.54	-6.01	-0.44	1.31e-8	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2278170	0.670	rs2641405	chr11:4576079	A/G	cg08325124	chr11:4565475	OR52M1	-0.44	-4.8	-0.36	3.68e-6	Amyotrophic lateral sclerosis;
PAAD	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg22467129	chr15:76604101	ETFA	0.52	4.85	0.37	3.07e-6	Blood metabolite levels;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.48	5.01	0.38	1.48e-6	Bipolar disorder;
PAAD	cis	rs151997	0.925	rs27624	chr5:50167662	C/T	cg06027927	chr5:50259733	NA	0.8	7.83	0.54	7.94e-13	Callous-unemotional behaviour;
PAAD	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.25	-0.39	5.02e-7	Neuroticism;
PAAD	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.17	16.16	0.79	8.23e-35	Body mass index;
PAAD	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.8	0.48	2.2e-10	Obesity-related traits;
PAAD	cis	rs4927850	0.794	rs4927849	chr3:195738482	A/G	cg00031303	chr3:195681400	NA	0.83	7.94	0.54	4.26e-13	Pancreatic cancer;
PAAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.14	15.14	0.78	3.65e-32	Cognitive function;
PAAD	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.58	4.41	0.34	1.96e-5	Obesity-related traits;
PAAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.07	-0.44	9.81e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.69	7.13	0.5	3.83e-11	Permanent tooth development;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07930192	chr7:1003750	NA	0.39	4.83	0.36	3.3e-6	Longevity;Endometriosis;
PAAD	cis	rs357618	1.000	rs357618	chr5:150846612	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-4.45	-0.34	1.62e-5	Basophil percentage of white cells;
PAAD	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg20731937	chr12:48336164	NA	0.52	4.41	0.34	1.95e-5	Longevity (90 years and older);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09441348	chr3:126290635	TXNRD3IT1	-0.57	-6.39	-0.46	1.9e-9	Obesity-related traits;
PAAD	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg01613454	chr2:70366299	NA	0.42	4.49	0.34	1.4e-5	Obesity-related traits;
PAAD	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.47	4.57	0.35	1e-5	Prostate-specific antigen levels;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.72	7.23	0.51	2.22e-11	Lung cancer;
PAAD	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.61e-7	Monocyte count;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.75	5.32	0.4	3.72e-7	Cancer;
PAAD	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.5	5.31	0.4	3.74e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.66	5.64	0.42	8.14e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs11651753	0.636	rs35280206	chr17:46035011	C/G	cg24458315	chr17:46148407	CBX1	0.42	4.44	0.34	1.75e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.63	6.25	0.45	3.95e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.74	-0.36	4.96e-6	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1358748	0.555	rs2815389	chr1:67536583	C/G	cg02640540	chr1:67518911	SLC35D1	0.69	4.59	0.35	9.37e-6	Tuberculosis;
PAAD	cis	rs2070729	0.523	rs743562	chr5:131872383	C/T	cg00255919	chr5:131827918	IRF1	-0.34	-4.53	-0.35	1.17e-5	Platelet count;
PAAD	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2790216	0.950	rs2790244	chr10:59979245	G/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.46	0.46	1.31e-9	Lung cancer;
PAAD	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg20673091	chr1:2541236	MMEL1	0.86	10.2	0.64	6.2800000000000005e-19	Ulcerative colitis;
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs897984	0.920	rs12926295	chr16:30890538	C/T	cg00531865	chr16:30841666	NA	0.59	5.74	0.42	5.04e-8	Dementia with Lewy bodies;
PAAD	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.52	5.45	0.4	1.99e-7	Male-pattern baldness;
PAAD	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	4.98	0.37	1.67e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs35785195	0.593	rs35746281	chr12:114236586	C/T	cg11070030	chr12:114232702	NA	0.56	4.35	0.33	2.46e-5	Daytime sleep phenotypes;
PAAD	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.65	-4.88	-0.37	2.65e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.79	-9.42	-0.61	6.81e-17	White blood cell count (basophil);
PAAD	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg02487422	chr3:49467188	NICN1	0.45	4.6	0.35	9e-6	Resting heart rate;
PAAD	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.52	6.96	0.49	9.36e-11	Life satisfaction;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs59888335	0.964	rs966618	chr3:80737297	C/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs245880	0.740	rs245892	chr7:29191273	T/C	cg17163760	chr7:29186267	CPVL	-0.52	-6.18	-0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.78	-8.24	-0.56	7.24e-14	Neurofibrillary tangles;
PAAD	cis	rs12906542	0.516	rs76398134	chr15:78288727	G/A	cg23683012	chr15:78369302	TBC1D2B	0.7	5.18	0.39	7.05e-7	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25535317	chr19:12833478	TNPO2	0.68	7.66	0.53	2.05e-12	Monocyte percentage of white cells;
PAAD	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs10794720	0.529	rs75145373	chr10:1184625	A/C	cg05228244	chr10:1102351	WDR37	1.0	4.38	0.33	2.18e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
PAAD	cis	rs4742903	1.000	rs4742903	chr9:106856793	G/C	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.68	-4.97	-0.37	1.75e-6	Menarche (age at onset);
PAAD	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	8.99	0.59	9.31e-16	Cognitive test performance;
PAAD	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.79	-0.43	3.88e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-11.02	-0.67	4.11e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs3790455	0.560	rs1171551	chr1:156472214	C/T	cg14087168	chr1:156450669	MEF2D	0.45	5.0	0.38	1.56e-6	Migraine;
PAAD	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg12560992	chr17:57184187	TRIM37	0.53	4.7	0.36	5.88e-6	Testicular germ cell tumor;
PAAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.62	-6.55	-0.47	8.51e-10	Obesity-related traits;
PAAD	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.9	10.26	0.64	4.26e-19	Breast cancer;
PAAD	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.27	-0.39	4.65e-7	Glomerular filtration rate;
PAAD	cis	rs1255143	0.764	rs2799395	chr10:130055731	A/C	cg17972361	chr10:130010134	NA	0.43	4.27	0.33	3.44e-5	Interleukin-16 levels;
PAAD	cis	rs9463078	0.683	rs6458412	chr6:44735834	A/G	cg25276700	chr6:44698697	NA	0.53	6.17	0.45	6.06e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg26939375	chr7:64535504	NA	0.74	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.54	-5.33	-0.4	3.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.64	4.96	0.37	1.88e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.49	4.66	0.35	6.93e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg09980403	chr19:12975529	MAST1	0.29	4.76	0.36	4.46e-6	Mean corpuscular volume;
PAAD	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.48	-5.82	-0.43	3.39e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-8.01	-0.54	2.76e-13	Coffee consumption (cups per day);
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.2	0.45	5.04e-9	Height;
PAAD	cis	rs1539053	0.932	rs12718425	chr1:58105213	G/A	cg00026909	chr1:58089001	DAB1	-0.66	-7.61	-0.53	2.66e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.94	7.52	0.52	4.52e-12	Lymphocyte counts;
PAAD	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.39	-0.4	2.59e-7	Coronary artery disease;
PAAD	cis	rs6466055	0.625	rs17707802	chr7:104866472	T/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs939584	1.000	rs6739303	chr2:628749	C/T	cg03610516	chr2:642275	NA	0.64	5.77	0.42	4.37e-8	Body mass index;
PAAD	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-1.18	-18.4	-0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs6088813	0.961	rs6060369	chr20:33907161	A/G	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg23708337	chr7:1209742	NA	0.67	4.98	0.37	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3136441	1.000	rs2290883	chr11:46890197	A/G	cg19486271	chr11:47235900	DDB2	-0.63	-4.83	-0.36	3.31e-6	HDL cholesterol;
PAAD	cis	rs6929137	0.568	rs12203668	chr6:151956625	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.49	-0.34	1.4e-5	Bone mineral density (spine);
PAAD	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.61e-8	Migraine;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.67	5.49	0.41	1.65e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.64	5.48	0.41	1.73e-7	Red blood cell count;
PAAD	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9462027	0.597	rs6940215	chr6:34706358	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.47	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs7932354	0.583	rs3829940	chr11:46879973	A/G	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	6.77	0.48	2.65e-10	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22558474	chr17:78388905	FLJ35220;LOC100294362	-0.58	-6.76	-0.48	2.8e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.05	-13.0	-0.73	1.83e-26	Schizophrenia;
PAAD	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.79	-9.29	-0.6	1.54e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6137287	0.924	rs6047279	chr20:21142353	C/T	cg04219410	chr20:21106687	PLK1S1	-0.42	-4.91	-0.37	2.3e-6	Height;
PAAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	1.0	9.13	0.6	3.97e-16	Triglycerides;
PAAD	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06998765	chr14:75389618	RPS6KL1	0.29	4.92	0.37	2.23e-6	Caffeine consumption;
PAAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.47	0.41	1.85e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.94	0.43	1.89e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7246657	0.508	rs10419845	chr19:37491192	G/T	cg23950597	chr19:37808831	NA	-0.77	-5.06	-0.38	1.22e-6	Coronary artery calcification;
PAAD	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs10044254	0.614	rs4318779	chr5:15738930	A/G	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg03808351	chr9:123631620	PHF19	0.46	4.88	0.37	2.7e-6	Rheumatoid arthritis;
PAAD	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.57	6.67	0.48	4.38e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg02376097	chr19:46275166	DMPK	-0.59	-5.79	-0.43	3.86e-8	Coronary artery disease;
PAAD	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg19000871	chr14:103996768	TRMT61A	0.48	5.33	0.4	3.45e-7	Reticulocyte count;
PAAD	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.91e-5	Total body bone mineral density;
PAAD	cis	rs8112211	0.648	rs77914289	chr19:38815372	G/A	cg01275006	chr19:38876250	GGN	-0.89	-5.72	-0.42	5.58e-8	Blood protein levels;
PAAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs308971	0.656	rs307606	chr3:12067126	A/T	cg15873301	chr3:12045459	SYN2	0.64	5.3	0.4	3.95e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.72	5.76	0.42	4.48e-8	Methadone dose in opioid dependence;
PAAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.49	4.61	0.35	8.59e-6	Pancreatic cancer;
PAAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Aortic root size;
PAAD	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg21253087	chr9:139290292	SNAPC4	0.43	4.39	0.34	2.15e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs832187	0.679	rs9879045	chr3:64001925	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.47	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.54	-4.79	-0.36	3.87e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg24503407	chr1:205819492	PM20D1	0.62	5.14	0.38	8.24e-7	Parkinson's disease;
PAAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.68e-6	Pain;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.66e-6	Life satisfaction;
PAAD	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.17	0.5	3.02e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16136290	chr1:112280233	C1orf183	0.6	6.3	0.46	2.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs394563	0.690	rs372205	chr6:149775267	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.33	-4.25	-0.33	3.7e-5	Dupuytren's disease;
PAAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26909864	chr16:21390421	NA	-0.72	-6.74	-0.48	3.02e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.45	-0.82	4.04e-38	Height;
PAAD	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg14343924	chr8:8086146	FLJ10661	0.52	5.08	0.38	1.07e-6	Joint mobility (Beighton score);
PAAD	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.69	4.96	0.37	1.88e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.21e-6	Skin colour saturation;
PAAD	cis	rs829661	0.947	rs829574	chr2:30682360	G/A	cg12454169	chr2:30669597	LCLAT1	0.66	4.98	0.37	1.7e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2555155	0.967	rs2555161	chr11:6515853	C/T	cg11185456	chr11:6592066	DNHD1	0.41	4.33	0.33	2.65e-5	DNA methylation (variation);
PAAD	cis	rs62392365	0.536	rs77078042	chr6:25148056	C/T	cg19882886	chr6:25043046	NA	1.0	4.41	0.34	1.95e-5	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8077577	0.747	rs57490980	chr17:18160753	T/A	cg16794390	chr17:18148240	FLII	0.53	4.63	0.35	7.76e-6	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.96	-7.61	-0.53	2.74e-12	Initial pursuit acceleration;
PAAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.95	-0.49	9.97e-11	Eye color traits;
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.9	-0.37	2.4e-6	Bipolar disorder;
PAAD	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg03989125	chr22:38214979	NA	-0.66	-6.79	-0.48	2.33e-10	Glioblastoma;Glioma;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg18721089	chr20:30220636	NA	-0.64	-5.15	-0.39	7.83e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.46	-5.42	-0.4	2.26e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.6	6.3	0.46	3.01e-9	Lewy body disease;
PAAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg19337854	chr7:99768885	GPC2	-0.44	-4.72	-0.36	5.2e-6	Coronary artery disease;
PAAD	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.87e-5	Self-reported allergy;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.66	0.35	6.96e-6	Height;
PAAD	cis	rs1665050	0.598	rs8041221	chr15:59334808	C/T	cg25595834	chr15:59156878	NA	0.44	4.55	0.35	1.08e-5	Atopic dermatitis;
PAAD	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.68	6.7	0.48	3.73e-10	Lymphocyte counts;
PAAD	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg05562828	chr17:3906858	NA	0.53	5.83	0.43	3.27e-8	Type 2 diabetes;
PAAD	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg12395012	chr8:11607386	GATA4	-0.4	-4.37	-0.33	2.29e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Bipolar disorder;
PAAD	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-5.7	-0.42	6.01e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs501120	0.929	rs528668	chr10:44762584	G/A	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.77	-6.03	-0.44	1.22e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.28	0.33	3.32e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11051970	0.594	rs325418	chr12:32572517	T/C	cg02745156	chr12:32552066	NA	0.43	4.45	0.34	1.64e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10490913	1.000	rs10787821	chr10:120154649	A/T	cg04126427	chr10:120840676	EIF3A	-0.47	-4.99	-0.37	1.66e-6	Cancer;
PAAD	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs4621152	0.708	rs4255939	chr2:217867889	T/G	cg21875423	chr2:217559867	IGFBP5	-0.42	-4.26	-0.33	3.61e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.31	-0.33	2.96e-5	Prostate cancer;
PAAD	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg23649088	chr2:200775458	C2orf69	-0.75	-4.86	-0.37	2.87e-6	Schizophrenia;
PAAD	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.04	0.38	1.31e-6	Colorectal cancer;
PAAD	cis	rs9649465	0.967	rs6966470	chr7:123299855	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.79	0.36	3.92e-6	Migraine;
PAAD	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.77	8.57	0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg06585982	chr3:143692056	C3orf58	0.71	7.73	0.53	1.37e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21797500	chr13:84406289	NA	-0.52	-6.47	-0.46	1.25e-9	Energy expenditure (24h);
PAAD	cis	rs2342371	0.539	rs35959625	chr3:196131941	C/T	cg09821211	chr3:195954098	OSTalpha	0.48	5.03	0.38	1.39e-6	Fat distribution (HIV);
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20066602	chr14:58619033	C14orf37	0.7	6.32	0.46	2.79e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs712046	0.568	rs854645	chr17:34364758	A/C	cg24399406	chr17:33895357	NA	0.47	4.36	0.33	2.34e-5	Pulmonary function;
PAAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.95	8.49	0.57	1.71e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs111342015	0.892	rs75591122	chr6:43205363	C/T	cg17076780	chr6:43251928	TTBK1	0.7	4.7	0.36	5.75e-6	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10754315	chr17:36413510	NA	0.63	6.85	0.49	1.74e-10	Myopia (pathological);
PAAD	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.78	9.44	0.61	6.15e-17	Height;
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.77	8.89	0.58	1.69e-15	Lung cancer;
PAAD	cis	rs9810890	1.000	rs116772388	chr3:128453215	A/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs13111989	0.895	rs11938037	chr4:177550246	G/A	cg11287292	chr4:178277261	NEIL3	-0.53	-4.27	-0.33	3.45e-5	HIV-1 viral setpoint;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03605463	chr16:89740564	NA	-0.49	-4.47	-0.34	1.52e-5	Vitiligo;
PAAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-1.34	-10.75	-0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.93	6.19	0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.94	10.05	0.63	1.56e-18	Cognitive function;
PAAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg05643964	chr20:62369504	LIME1	-0.53	-4.91	-0.37	2.31e-6	Prostate cancer;
PAAD	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.47	-0.41	1.84e-7	Reticulocyte count;
PAAD	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs253959	0.545	rs10072350	chr5:115433526	G/T	cg05931423	chr5:115697214	NA	0.49	4.35	0.33	2.45e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.5	4.98	0.37	1.71e-6	Schizophrenia;
PAAD	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	cis	rs10274279	1.000	rs73163814	chr7:157388012	A/G	cg26886268	chr7:157387156	PTPRN2	-0.73	-5.79	-0.43	3.87e-8	Myopia (pathological);
PAAD	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.27	-0.33	3.47e-5	Dupuytren's disease;
PAAD	cis	rs7696796	0.662	rs13115826	chr4:183178440	C/T	cg03209412	chr4:183728196	NA	0.57	5.01	0.38	1.48e-6	Neuroticism;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg06815965	chr1:205818668	PM20D1	-0.51	-5.26	-0.39	4.75e-7	Menarche (age at onset);
PAAD	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.59	-5.17	-0.39	7.27e-7	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10772210	chr14:24605565	PSME1	0.64	6.44	0.46	1.46e-9	Obesity-related traits;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08938475	chr2:70313833	PCBP1	0.61	6.96	0.49	9.76e-11	Metabolite levels  (X-11787);
PAAD	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.01	11.84	0.69	2.45e-23	Breast cancer;
PAAD	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg02225085	chr5:87975992	LOC645323	-0.63	-4.53	-0.34	1.18e-5	Body mass index;
PAAD	cis	rs11264213	0.901	rs72661632	chr1:36420715	G/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.65	-7.41	-0.52	8.19e-12	Iron status biomarkers;
PAAD	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg00383909	chr3:49044727	WDR6	0.52	4.42	0.34	1.87e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg19418458	chr7:158789849	NA	-0.71	-8.04	-0.55	2.3e-13	Facial morphology (factor 20);
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg20742385	chr13:113633654	MCF2L	-0.43	-4.33	-0.33	2.71e-5	Systolic blood pressure;
PAAD	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.15	10.01	0.63	2.02e-18	Vitiligo;
PAAD	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs30380	1.000	rs30380	chr5:96122281	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg19980929	chr12:42632907	YAF2	0.55	6.43	0.46	1.58e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.67	-5.36	-0.4	2.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.98	-0.37	1.7e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.64	5.41	0.4	2.37e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg09737314	chr17:6899359	ALOX12	0.53	5.54	0.41	1.29e-7	Tonsillectomy;
PAAD	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.63	5.75	0.42	4.75e-8	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13319757	chr6:75840675	COL12A1	-0.65	-6.92	-0.49	1.2e-10	Obesity-related traits;
PAAD	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11235843	0.929	rs7939193	chr11:73446369	T/C	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10500218	chr1:181058063	IER5	-0.65	-7.89	-0.54	5.36e-13	Body fat percentage;
PAAD	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.75	-8.48	-0.57	1.89e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.88	-0.37	2.7e-6	Mean corpuscular volume;
PAAD	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg08888203	chr3:10149979	C3orf24	0.87	6.52	0.47	9.84e-10	Alzheimer's disease;
PAAD	cis	rs12042938	0.902	rs1094658	chr1:231773397	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	4.97	0.37	1.77e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg13736514	chr6:26305472	NA	-0.58	-6.17	-0.45	5.77e-9	Educational attainment;
PAAD	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.84	-7.61	-0.53	2.64e-12	Neurofibrillary tangles;
PAAD	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs4711350	0.906	rs943463	chr6:33719877	A/G	cg13859433	chr6:33739653	LEMD2	-0.57	-4.26	-0.33	3.55e-5	Schizophrenia;
PAAD	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg15443732	chr18:74961078	GALR1	0.7	5.79	0.43	3.85e-8	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08796640	chr8:119123054	EXT1	0.59	6.77	0.48	2.6e-10	Monocyte percentage of white cells;
PAAD	cis	rs1075265	0.749	rs805430	chr2:54075416	A/C	cg04546899	chr2:54196757	PSME4	0.3	4.53	0.34	1.19e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.52	5.32	0.4	3.57e-7	Longevity;Endometriosis;
PAAD	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.47	-5.19	-0.39	6.5e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg18551225	chr6:44695536	NA	-0.74	-7.55	-0.52	3.72e-12	Total body bone mineral density;
PAAD	cis	rs89107	0.641	rs376875	chr6:118611592	C/T	cg18833306	chr6:118973337	C6orf204	0.46	5.38	0.4	2.72e-7	Cardiac structure and function;
PAAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg03340356	chr1:67600835	NA	0.53	6.49	0.47	1.12e-9	Psoriasis;
PAAD	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.63	6.82	0.48	1.99e-10	Mean platelet volume;
PAAD	trans	rs61931739	0.613	rs6488174	chr12:33756569	T/C	cg26384229	chr12:38710491	ALG10B	0.69	7.28	0.51	1.66e-11	Morning vs. evening chronotype;
PAAD	cis	rs12550646	0.652	rs13438989	chr8:41685845	T/G	cg12180191	chr8:41686706	ANK1	-0.52	-5.22	-0.39	5.88e-7	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.68	6.71	0.48	3.53e-10	Coronary artery disease;
PAAD	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.46	5.43	0.4	2.22e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.5	-5.78	-0.42	4.16e-8	Mean corpuscular volume;
PAAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg12463550	chr7:65579703	CRCP	0.87	5.63	0.42	8.56e-8	Diabetic kidney disease;
PAAD	cis	rs35740288	0.857	rs11630274	chr15:86288387	C/T	cg07943548	chr15:86304357	KLHL25	-0.53	-4.51	-0.34	1.26e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.6	0.61	2.3e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg03808351	chr9:123631620	PHF19	-0.45	-4.91	-0.37	2.3e-6	Rheumatoid arthritis;
PAAD	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12963246	chr6:28129442	ZNF389	0.64	4.49	0.34	1.42e-5	Depression;
PAAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	12.27	0.71	1.7e-24	Chronic sinus infection;
PAAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.69	6.78	0.48	2.5e-10	Blood metabolite levels;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.57	-7.81	-0.54	8.62e-13	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg12568669	chr8:11666485	FDFT1	-0.31	-5.24	-0.39	5.37e-7	Monocyte count;
PAAD	cis	rs3931020	0.616	rs277380	chr1:75263088	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.66	-5.78	-0.42	4.08e-8	Resistin levels;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-5.19	-0.39	6.78e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-4.89	-0.37	2.55e-6	Blood metabolite levels;
PAAD	cis	rs2092319	0.571	rs2744767	chr1:26055799	A/T	cg02327719	chr1:26185386	C1orf135	-0.79	-4.69	-0.36	6.11e-6	Nose morphology;
PAAD	cis	rs939584	0.935	rs6731872	chr2:624205	T/G	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	0.932	rs2903490	chr2:651290	A/G	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs2016586	0.802	rs5999974	chr22:36115897	C/A	cg26342177	chr22:36113512	APOL5	-0.47	-4.68	-0.35	6.41e-6	Body mass index;
PAAD	cis	rs7554547	0.667	rs7525521	chr1:11975166	G/A	cg07603449	chr1:11986842	KIAA2013	-0.37	-5.66	-0.42	7.19e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg05895507	chr15:77155635	SCAPER	0.37	4.51	0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.65	6.73	0.48	3.19e-10	Resting heart rate;
PAAD	cis	rs7894051	0.557	rs56305006	chr10:135107948	G/A	cg19176072	chr10:135083742	ADAM8	1.11	5.31	0.4	3.83e-7	Lifespan;
PAAD	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.84	0.43	3.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs12523822	0.912	rs56404066	chr6:154957617	G/A	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs10078	0.559	rs6893791	chr5:430413	T/C	cg24955955	chr5:415729	AHRR	0.6	4.38	0.33	2.19e-5	Fat distribution (HIV);
PAAD	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.07	0.38	1.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg20243544	chr17:37824526	PNMT	-0.52	-4.57	-0.35	1.02e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20630207	chr19:14640235	TECR;MIR639	0.57	6.31	0.46	2.92e-9	Metabolite levels  (X-11787);
PAAD	cis	rs6494488	0.500	rs72742913	chr15:64846710	G/A	cg16425858	chr15:64791681	ZNF609	1.0	4.69	0.36	6e-6	Coronary artery disease;
PAAD	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.82	9.3	0.6	1.47e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs488248	0.540	rs17514375	chr13:106593392	T/C	cg03898952	chr13:107069935	NA	0.68	4.43	0.34	1.8e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.52	4.73	0.36	5.16e-6	Height;
PAAD	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.77	8.09	0.55	1.78e-13	Gout;
PAAD	trans	rs11794666	0.929	rs11793573	chr9:31788145	G/A	cg05628366	chr6:35744188	C6orf126	1.11	7.4	0.51	8.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.71	-7.44	-0.52	6.8e-12	Neurofibrillary tangles;
PAAD	cis	rs7945718	0.621	rs4370915	chr11:12664998	C/T	cg25843174	chr11:12811716	TEAD1	0.32	4.62	0.35	7.96e-6	Educational attainment (years of education);
PAAD	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	8.27	0.56	6.41e-14	LDL cholesterol;
PAAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	0.92	6.22	0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.05	0.38	1.25e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-1.08	-9.66	-0.62	1.63e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg16898833	chr6:26189333	HIST1H4D	0.59	4.45	0.34	1.67e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05005422	chr7:101650989	CUX1	0.62	6.57	0.47	7.74e-10	Smoking initiation;
PAAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-4.86	-0.37	2.91e-6	Aortic root size;
PAAD	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.63	-4.93	-0.37	2.1e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11615916	0.790	rs17661264	chr12:62804079	A/G	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs11209002	0.956	rs10749772	chr1:67586231	A/G	cg02640540	chr1:67518911	SLC35D1	0.6	4.32	0.33	2.82e-5	Crohn's disease;
PAAD	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg16735072	chr8:11994639	FAM66D	0.45	4.44	0.34	1.69e-5	Neuroticism;
PAAD	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.33	10.95	0.66	6.13e-21	Uric acid levels;
PAAD	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	1.18	7.14	0.5	3.53e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.45	-0.34	1.64e-5	Response to amphetamines;
PAAD	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.5	-0.61	4.27e-17	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg24253500	chr15:84953950	NA	0.44	4.59	0.35	9.13e-6	Schizophrenia;
PAAD	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.63	-5.54	-0.41	1.32e-7	Type 2 diabetes;
PAAD	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.24	0.39	5.35e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.69	6.73	0.48	3.27e-10	Prostate cancer;
PAAD	cis	rs13217239	0.534	rs9379968	chr6:27244590	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.31	-4.49	-0.34	1.42e-5	Schizophrenia;
PAAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.48	0.41	1.76e-7	Bipolar disorder;
PAAD	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-7.43	-0.52	7.36e-12	Neuroticism;
PAAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.52	7.27	0.51	1.75e-11	Diastolic blood pressure;
PAAD	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg23465465	chr6:26364728	BTN3A2	0.56	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	8.14	0.55	1.33e-13	Cognitive test performance;
PAAD	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.24e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.6	-6.08	-0.44	9.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg04106633	chr4:1044584	NA	-0.65	-5.46	-0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-11.79	-0.69	3.38e-23	Cognitive function;
PAAD	cis	rs904092	0.786	rs2646011	chr4:100161381	A/G	cg12011299	chr4:100065546	ADH4	0.6	5.53	0.41	1.35e-7	Alcohol dependence;
PAAD	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.61	6.47	0.46	1.27e-9	Crohn's disease;
PAAD	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.58	-5.57	-0.41	1.11e-7	Gut microbiome composition (summer);
PAAD	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg12623918	chr2:306882	NA	0.46	4.8	0.36	3.7e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.82	8.72	0.58	4.41e-15	Height;
PAAD	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs17641971	0.899	rs341804	chr8:49991553	G/C	cg00325661	chr8:49890786	NA	-0.55	-5.34	-0.4	3.39e-7	Blood metabolite levels;
PAAD	cis	rs6995541	0.810	rs11993903	chr8:10674418	A/G	cg14855657	chr8:10587604	SOX7	0.46	4.41	0.34	1.91e-5	Triglyceride levels;
PAAD	cis	rs2908197	0.806	rs2961047	chr7:75935056	A/G	cg15798862	chr7:76129360	DTX2	-0.34	-4.31	-0.33	2.95e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs9888739	1.000	rs7190018	chr16:31301478	G/A	cg02256631	chr16:31342952	ITGAM	-0.54	-4.4	-0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16886468	chr17:27507505	MYO18A	-0.73	-6.51	-0.47	1.04e-9	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24209194	chr3:40518798	ZNF619	0.65	6.36	0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs1966248	0.656	rs4895387	chr6:134123317	A/T	cg17736819	chr6:133783020	EYA4	0.44	4.5	0.34	1.35e-5	Coronary artery disease;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.93	-0.37	2.09e-6	Obesity-related traits;
PAAD	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	1.01	11.07	0.67	2.86e-21	Gestational age at birth (maternal effect);
PAAD	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.66	9.16	0.6	3.28e-16	Airflow obstruction;
PAAD	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg23461800	chr14:103021989	NA	-0.63	-4.84	-0.37	3.17e-6	Platelet count;
PAAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23158103	chr7:148848205	ZNF398	-0.62	-6.3	-0.46	2.99e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg09760422	chr2:128146352	NA	-0.4	-6.02	-0.44	1.26e-8	Self-rated health;
PAAD	cis	rs4704187	0.663	rs6889760	chr5:74503704	A/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.17	-0.39	7.13e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11718455	1.000	rs1012410	chr3:44053516	G/C	cg08738300	chr3:44038990	NA	0.72	7.14	0.5	3.58e-11	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20683223	chr3:183893065	AP2M1	0.63	6.97	0.49	8.79e-11	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-4.86	-0.37	2.92e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	7.63	0.53	2.39e-12	Menarche (age at onset);
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.53	5.19	0.39	6.56e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.92	-12.44	-0.71	6.18e-25	Superior crus of antihelix expression;
PAAD	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg06060754	chr5:176797920	RGS14	0.67	6.56	0.47	7.78e-10	Urate levels in lean individuals;
PAAD	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.61	-6.27	-0.45	3.58e-9	Coronary artery disease;
PAAD	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.69	5.45	0.4	2.02e-7	Neuroticism;
PAAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-5.1	-0.38	1.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.75	6.89	0.49	1.4e-10	Post bronchodilator FEV1;
PAAD	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.99	11.57	0.68	1.29e-22	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg00334542	chr7:100209784	MOSPD3	-0.7	-5.3	-0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg26750617	chr12:132293702	NA	-0.46	-4.78	-0.36	4.19e-6	Migraine;
PAAD	cis	rs354033	0.959	rs354041	chr7:149297035	A/C	cg06920324	chr7:149264011	ZNF767	-0.6	-5.0	-0.38	1.6e-6	Multiple sclerosis;
PAAD	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg23465465	chr6:26364728	BTN3A2	0.86	4.99	0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.44	0.61	6.25e-17	Rheumatoid arthritis;
PAAD	cis	rs72772787	1.000	rs12096473	chr1:248016894	C/T	cg03748376	chr1:248100585	OR2L13	0.64	5.24	0.39	5.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.72	7.25	0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.7	0.48	3.81e-10	Life satisfaction;
PAAD	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg21361702	chr7:150065534	REPIN1	0.59	5.17	0.39	7.36e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.6	-0.47	6.48e-10	Neuroticism;
PAAD	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs3736485	0.934	rs7170330	chr15:51859313	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-7.54	-0.52	3.96e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24843246	chr19:7621952	PNPLA6	-0.69	-6.34	-0.46	2.5e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	17.81	0.82	4.98e-39	IgG glycosylation;
PAAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23463467	chr20:60627584	TAF4	0.41	4.39	0.34	2.13e-5	Body mass index;
PAAD	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-6.66	-0.48	4.73e-10	Menarche (age at onset);
PAAD	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.64	6.98	0.49	8.54e-11	Colorectal cancer;
PAAD	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7081476	0.737	rs111833489	chr10:27506479	C/T	cg20349793	chr10:26911186	NA	0.78	4.36	0.33	2.4e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg00086871	chr4:6988644	TBC1D14	0.88	4.71	0.36	5.59e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg24881330	chr22:46731750	TRMU	1.22	6.61	0.47	6.1e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg24675658	chr1:53192096	ZYG11B	0.72	7.21	0.5	2.41e-11	Monocyte count;
PAAD	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.47	7.45	0.52	6.55e-12	Neuroticism;
PAAD	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg08992911	chr2:238395768	MLPH	0.53	5.46	0.4	1.92e-7	Prostate cancer;
PAAD	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg03004497	chr11:58874207	FAM111B	0.51	4.27	0.33	3.45e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.53	5.34	0.4	3.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs682748	0.846	rs12656050	chr5:17142224	C/T	cg23987134	chr5:17158319	LOC285696	-0.35	-4.48	-0.34	1.44e-5	Hippocampal atrophy;
PAAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.56	-5.51	-0.41	1.53e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg02476566	chr12:106696527	TCP11L2	0.57	5.24	0.39	5.37e-7	Tourette syndrome;
PAAD	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Birth weight;
PAAD	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-4.82	-0.36	3.39e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.52	-4.96	-0.37	1.87e-6	Acylcarnitine levels;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.31	0.71	1.32e-24	Prudent dietary pattern;
PAAD	cis	rs5753037	0.653	rs131285	chr22:30157940	T/C	cg01021169	chr22:30184971	ASCC2	-0.47	-4.78	-0.36	4.02e-6	Type 1 diabetes;
PAAD	cis	rs2004318	0.702	rs61739176	chr19:55144711	G/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg19781863	chr12:62918364	MON2	0.73	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs12304921	0.938	rs73090631	chr12:51336006	T/C	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.15	-0.39	7.85e-7	Type 2 diabetes;
PAAD	cis	rs76866386	0.892	rs3923912	chr2:44057570	A/C	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.85	-5.04	-0.38	1.32e-6	Cholesterol, total;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.41	-4.97	-0.37	1.8e-6	Iron status biomarkers;
PAAD	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-1.23	-5.37	-0.4	2.85e-7	Breast cancer;
PAAD	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.56	5.12	0.38	9.02e-7	Multiple sclerosis;
PAAD	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	8.12	0.55	1.46e-13	Coronary artery disease;
PAAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg05110241	chr16:68378359	PRMT7	-0.95	-7.52	-0.52	4.45e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg23018236	chr17:30244563	NA	-0.6	-4.77	-0.36	4.19e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs13144136	0.643	rs4339204	chr4:10661011	A/T	cg10242279	chr4:10666415	CLNK	-0.47	-5.84	-0.43	3.02e-8	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg01851573	chr8:8652454	MFHAS1	0.44	4.54	0.35	1.15e-5	Mood instability;
PAAD	cis	rs11039131	0.929	rs1685404	chr11:47243665	C/G	cg20307385	chr11:47447363	PSMC3	-0.53	-4.89	-0.37	2.56e-6	Schizophrenia;
PAAD	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg01304814	chr3:48885189	PRKAR2A	1.0	5.49	0.41	1.63e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs12282928	0.959	rs1566736	chr11:48238179	A/G	cg04721828	chr11:48285200	OR4X1	0.48	6.09	0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.71	7.27	0.51	1.78e-11	Schizophrenia;
PAAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1144333	0.655	rs1146647	chr1:76265712	C/T	cg22875332	chr1:76189707	ACADM	-0.78	-4.89	-0.37	2.54e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs12286929	0.609	rs12417740	chr11:115098436	A/G	cg04055981	chr11:115044050	NA	-0.45	-4.52	-0.34	1.21e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.94	-0.87	5.95e-49	Myeloid white cell count;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.78	-8.25	-0.56	7.13e-14	Menopause (age at onset);
PAAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.86	11.26	0.67	9.12e-22	Vitiligo;
PAAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	0.83	6.99	0.49	8.18e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.76	-7.83	-0.54	7.59e-13	Body mass index;
PAAD	cis	rs593531	0.614	rs10736795	chr11:74039546	A/G	cg15851278	chr11:73669449	DNAJB13	-0.43	-5.1	-0.38	9.89e-7	Neuroticism;
PAAD	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg13002189	chr3:66846049	NA	0.53	5.16	0.39	7.69e-7	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21577007	chr18:55315848	ATP8B1	0.53	6.69	0.48	4.03e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg14926445	chr8:58193284	C8orf71	-0.65	-4.55	-0.35	1.11e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15557168	chr22:42548783	NA	-0.44	-4.49	-0.34	1.37e-5	Cognitive function;
PAAD	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs959260	0.614	rs8065441	chr17:73410447	C/G	cg14668889	chr17:73230827	NUP85	-0.69	-4.32	-0.33	2.83e-5	Systemic lupus erythematosus;
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg07648498	chr16:89883185	FANCA	0.46	4.47	0.34	1.52e-5	Vitiligo;
PAAD	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg15670924	chr11:73669256	DNAJB13	0.73	5.36	0.4	3.07e-7	Hand grip strength;
PAAD	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9287719	0.601	rs10177062	chr2:10713698	C/T	cg00105475	chr2:10696890	NA	0.65	6.78	0.48	2.5e-10	Prostate cancer;
PAAD	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.55	4.6	0.35	8.93e-6	Red blood cell count;
PAAD	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg08079166	chr15:68083412	MAP2K5	0.64	4.88	0.37	2.68e-6	Restless legs syndrome;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00166722	chr3:10149974	C3orf24	0.93	7.66	0.53	2.02e-12	Alzheimer's disease;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02359409	chr6:42947317	PEX6	-0.47	-4.67	-0.35	6.47e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg08317243	chr16:87101592	NA	-0.51	-4.84	-0.37	3.2e-6	Menopause (age at onset);
PAAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.47	-4.94	-0.37	2.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.68	6.2	0.45	5.09e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.48	-8.1	-0.55	1.63e-13	Mean corpuscular volume;
PAAD	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.26	-0.39	4.78e-7	Mood instability;
PAAD	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs508970	0.556	rs616346	chr11:60913600	C/T	cg24692310	chr11:60915630	VPS37C	0.35	4.92	0.37	2.19e-6	Rheumatoid arthritis;
PAAD	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.97	-8.18	-0.55	1.05e-13	Bipolar disorder;
PAAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.25	-0.51	1.99e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.75	0.53	1.24e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.6	6.58	0.47	7.1e-10	Tonsillectomy;
PAAD	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg01426195	chr3:39028469	NA	0.55	5.76	0.42	4.53e-8	Interleukin-18 levels;
PAAD	cis	rs1198430	0.925	rs487859	chr1:23801101	T/C	cg22040403	chr1:23858016	E2F2	0.79	4.94	0.37	2e-6	Total cholesterol levels;
PAAD	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.17	-0.67	1.63e-21	Rheumatoid arthritis;
PAAD	cis	rs7929679	0.521	rs1509667	chr11:34791303	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.39	0.34	2.13e-5	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
PAAD	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-10.1	-0.63	1.11e-18	Height;
PAAD	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03295096	chr2:173292268	ITGA6	-0.69	-7.18	-0.5	2.83e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs761746	0.921	rs761747	chr22:32001835	C/A	cg01338084	chr22:32026380	PISD	0.5	4.44	0.34	1.7e-5	Intelligence;
PAAD	cis	rs6604026	0.883	rs10874745	chr1:93321541	G/A	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.86	-5.97	-0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs73384572	0.571	rs4751054	chr10:130863603	A/G	cg27413539	chr10:131576096	NA	-0.73	-4.68	-0.35	6.3e-6	Neuroticism;
PAAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs6681460	0.837	rs6669023	chr1:67171868	G/T	cg02459107	chr1:67143332	SGIP1	0.7	6.54	0.47	8.97e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs11051970	0.918	rs7309115	chr12:32541241	A/G	cg02745156	chr12:32552066	NA	0.47	4.82	0.36	3.47e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	7.02	0.49	6.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.67	-7.06	-0.5	5.68e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs2221894	0.922	rs4407834	chr8:28841821	C/T	cg20212339	chr8:28908912	HMBOX1	0.53	5.69	0.42	6.42e-8	Obesity-related traits;
PAAD	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.4	5.0	0.38	1.57e-6	Blood protein levels;
PAAD	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.52	5.53	0.41	1.34e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg21194808	chr1:2205498	SKI	0.44	4.34	0.33	2.54e-5	Coronary artery disease;
PAAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg19337854	chr7:99768885	GPC2	0.46	5.02	0.38	1.42e-6	Coronary artery disease;
PAAD	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.48	4.67	0.35	6.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	5.49	0.41	1.64e-7	Personality dimensions;
PAAD	cis	rs4899554	0.509	rs78368951	chr14:75730348	A/G	cg18117039	chr14:75741733	NA	0.4	4.65	0.35	7.23e-6	Inflammatory bowel disease;
PAAD	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.55	7.3	0.51	1.51e-11	Hypertriglyceridemia;
PAAD	cis	rs9372149	0.532	rs9486548	chr6:107497830	C/G	cg26808436	chr6:108492696	NR2E1	0.31	4.55	0.35	1.09e-5	Childhood and early adolescence aggressive behavior;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.87	9.41	0.61	7.33e-17	Prudent dietary pattern;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23155118	chr7:32983012	RP9P	-0.68	-6.52	-0.47	9.66e-10	Lung cancer in ever smokers;
PAAD	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-7.5	-0.52	4.98e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs3812111	0.506	rs17582201	chr6:116567048	T/C	cg18828861	chr6:116576566	TSPYL4	0.49	5.25	0.39	5.12e-7	Age-related macular degeneration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11234017	chr17:42767172	CCDC43	0.62	6.84	0.49	1.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-4.47	-0.34	1.54e-5	Morning vs. evening chronotype;
PAAD	cis	rs939584	1.000	rs2867109	chr2:651030	A/C	cg03610516	chr2:642275	NA	-0.64	-6.01	-0.44	1.33e-8	Body mass index;
PAAD	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Systolic blood pressure;
PAAD	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.57	-6.21	-0.45	4.77e-9	High light scatter reticulocyte count;
PAAD	cis	rs1419980	0.730	rs11054858	chr12:7769597	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	8.05	0.55	2.25e-13	Eotaxin levels;
PAAD	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.52	4.83	0.36	3.31e-6	Height;
PAAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg02462569	chr6:150064036	NUP43	-0.48	-5.39	-0.4	2.66e-7	Lung cancer;
PAAD	cis	rs877529	0.625	rs713841	chr22:39529029	A/G	cg18708252	chr22:39545030	CBX7	-0.68	-7.25	-0.51	1.99e-11	Multiple myeloma;
PAAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.91	-7.96	-0.54	3.63e-13	Alzheimer's disease;
PAAD	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.9	7.2	0.5	2.65e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.85	0.37	3.08e-6	Menopause (age at onset);
PAAD	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.39	0.4	2.64e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg24253500	chr15:84953950	NA	0.59	6.51	0.47	1.03e-9	Schizophrenia;
PAAD	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.8	6.07	0.44	9.96e-9	Alzheimer's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01577865	chr5:176854009	GRK6	0.62	6.81	0.48	2.12e-10	Myopia (pathological);
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.5	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.28	0.33	3.29e-5	Asthma;
PAAD	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg14952266	chr13:112191215	NA	0.47	5.42	0.4	2.33e-7	Hepatitis;
PAAD	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	-0.7	-4.63	-0.35	7.95e-6	Lung cancer in ever smokers;
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.51e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.64	-7.41	-0.51	8.3e-12	Platelet distribution width;
PAAD	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg01097406	chr16:89675127	NA	0.38	4.71	0.36	5.48e-6	Vitiligo;
PAAD	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.32	-0.51	1.35e-11	Heart rate;
PAAD	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.58	-7.94	-0.54	4.1e-13	Rheumatoid arthritis;
PAAD	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg05585544	chr11:47624801	NA	-0.48	-5.3	-0.39	4.01e-7	Subjective well-being;
PAAD	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.72	7.57	0.52	3.44e-12	Blood protein levels;
PAAD	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.13	-0.7	4.01e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs6141769	0.542	rs28456361	chr20:31299597	T/C	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-4.81	-0.36	3.6e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg02683114	chr2:24398427	C2orf84	0.57	5.82	0.43	3.33e-8	Asthma;
PAAD	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.63	6.62	0.47	5.97e-10	Mean corpuscular volume;
PAAD	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.48	6.27	0.45	3.59e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg02297831	chr4:17616191	MED28	0.6	5.66	0.42	7.3900000000000007e-08	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.45	4.64	0.35	7.52e-6	Corneal astigmatism;
PAAD	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.71	0.48	3.55e-10	Resting heart rate;
PAAD	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg17764715	chr19:33622953	WDR88	-0.68	-6.46	-0.46	1.33e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.41	5.32	0.4	3.7e-7	Alcohol dependence;
PAAD	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.39	-5.74	-0.42	5.08e-8	Educational attainment (years of education);
PAAD	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.37	0.4	2.85e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1007738	0.580	rs61897844	chr11:47190860	G/A	cg19486271	chr11:47235900	DDB2	0.68	6.32	0.46	2.8e-9	Bone mineral density (hip);
PAAD	cis	rs9788721	0.504	rs1996371	chr15:78956806	T/C	cg00540400	chr15:79124168	NA	-0.45	-5.05	-0.38	1.27e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15245749	chr3:189547778	MIR944;TP63	-0.61	-6.54	-0.47	8.61e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.7	-7.41	-0.52	8.12e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg23346134	chr3:49453900	TCTA	0.41	4.37	0.33	2.28e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg20821713	chr7:1055600	C7orf50	-0.54	-4.41	-0.34	1.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6708331	0.517	rs2028879	chr2:70354637	C/T	cg01613454	chr2:70366299	NA	0.41	4.38	0.33	2.2e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7953508	0.700	rs10083107	chr12:93996035	T/A	cg18151635	chr12:93972918	NA	-0.61	-6.37	-0.46	2.12e-9	Pubertal anthropometrics;
PAAD	cis	rs863345	0.526	rs857723	chr1:158604000	C/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.72	-0.36	5.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg02404636	chr22:31891804	SFI1	-0.54	-5.01	-0.38	1.53e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.59	7.11	0.5	4.35e-11	Pubertal anthropometrics;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17397135	chr2:28789816	PLB1	-0.64	-6.33	-0.46	2.61e-9	Smoking initiation;
PAAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.63	-6.98	-0.49	8.53e-11	Lymphocyte counts;
PAAD	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.68	7.59	0.52	3.03e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg27398640	chr15:77910606	LINGO1	0.5	4.72	0.36	5.2e-6	Type 2 diabetes;
PAAD	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.02	-0.44	1.24e-8	Fibrinogen levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26188679	chr2:132919375	NCRNA00164	-0.58	-7.35	-0.51	1.13e-11	Myopia (pathological);
PAAD	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.78	-5.83	-0.43	3.15e-8	Obesity (extreme);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23634478	chr14:75348573	DLST	0.67	7.28	0.51	1.71e-11	Myopia (pathological);
PAAD	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.39	-0.51	8.99e-12	Neuroticism;
PAAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.74	-7.44	-0.52	6.75e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06873352	chr17:61820015	STRADA	-0.68	-7.61	-0.53	2.75e-12	Prudent dietary pattern;
PAAD	cis	rs735539	0.521	rs8001074	chr13:21448053	A/G	cg27234864	chr13:21295941	IL17D	0.59	4.81	0.36	3.65e-6	Dental caries;
PAAD	cis	rs2898681	0.874	rs4864688	chr4:53742636	A/G	cg00791764	chr4:53727839	RASL11B	0.53	4.42	0.34	1.89e-5	Optic nerve measurement (cup area);
PAAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.8	-6.72	-0.48	3.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs66530629	1.000	rs72654647	chr1:25022314	G/A	cg01905478	chr1:25040257	NA	0.46	4.75	0.36	4.57e-6	Plateletcrit;
PAAD	cis	rs16975963	0.793	rs12460735	chr19:38313550	C/T	cg14218481	chr19:38281219	NA	0.46	4.72	0.36	5.24e-6	Longevity;
PAAD	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-0.91	-15.06	-0.77	6.04e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.46	-4.7	-0.36	5.78e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.35	5.46	0.4	1.9e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs80346118	0.673	rs6012535	chr20:47423191	G/A	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.63	-4.58	-0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.43	-4.4	-0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.37	0.82	6.52e-38	Height;
PAAD	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg13010199	chr12:38710504	ALG10B	0.59	5.15	0.39	7.9e-7	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.99	13.6	0.74	4.51e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17095355	1.000	rs2122517	chr10:111754787	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-4.84	-0.37	3.12e-6	Biliary atresia;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.17	0.73	6.67e-27	Platelet count;
PAAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs2885056	0.891	rs4804509	chr19:10681641	A/G	cg04833646	chr19:10679720	CDKN2D	1.02	10.28	0.64	3.77e-19	Red cell distribution width;
PAAD	cis	rs2221894	1.000	rs2221894	chr8:28791159	G/A	cg20212339	chr8:28908912	HMBOX1	0.53	5.58	0.41	1.09e-7	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.27	0.45	3.55e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1334894	1.000	rs72913417	chr6:35546866	C/T	cg07213720	chr6:35227408	ZNF76	-0.84	-4.63	-0.35	7.78e-6	Coronary artery disease;
PAAD	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs4739066	0.579	rs4739028	chr8:63862646	C/A	cg12194929	chr8:63776755	NKAIN3	0.72	4.51	0.34	1.28e-5	Myocardial infarction;
PAAD	cis	rs9907295	0.818	rs4251737	chr17:34146818	C/A	cg16983627	chr17:34238386	NA	-0.55	-4.25	-0.33	3.74e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg27478167	chr7:817139	HEATR2	-0.6	-4.74	-0.36	4.85e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9595066	1.000	rs4942282	chr13:44708416	G/A	cg04068111	chr13:44716778	NA	-0.56	-5.96	-0.44	1.7e-8	Schizophrenia;
PAAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.3	-0.45	3.08e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10691809	chr22:31892045	SFI1	0.67	7.26	0.51	1.85e-11	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.56	-6.12	-0.44	7.74e-9	Total body bone mineral density;
PAAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg00758881	chr16:58534681	NDRG4	-0.91	-4.9	-0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs2882667	0.690	rs288035	chr5:138212417	A/T	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1468734	1.000	rs1468733	chr16:5001481	G/C	cg06510647	chr16:5006106	NA	0.54	4.84	0.37	3.13e-6	Cancer;
PAAD	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01493318	chr18:8705700	NA	0.66	6.54	0.47	8.8e-10	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	1.02	8.47	0.57	1.94e-14	Initial pursuit acceleration;
PAAD	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg05998816	chr21:47859926	PCNT	-0.54	-4.34	-0.33	2.63e-5	Lymphocyte counts;
PAAD	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg06609049	chr19:2785107	THOP1	0.87	9.52	0.61	3.88e-17	Total cholesterol levels;
PAAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs375066	0.901	rs1050054	chr19:44376681	G/T	cg08633290	chr19:44405433	NA	-0.57	-5.75	-0.42	4.82e-8	Breast cancer;
PAAD	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.66	-7.14	-0.5	3.5e-11	Schizophrenia;
PAAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.97e-6	Type 2 diabetes;
PAAD	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	7.86	0.54	6.7e-13	Lipoprotein (a) levels;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg02734326	chr4:10020555	SLC2A9	-0.52	-4.88	-0.37	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs16852403	0.619	rs6701497	chr1:178114644	G/C	cg00404053	chr1:178313656	RASAL2	0.45	4.36	0.33	2.38e-5	Childhood ear infection;
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	1.04	8.67	0.58	5.95e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg15660573	chr17:549704	VPS53	0.5	4.84	0.37	3.2e-6	Prostate cancer;
PAAD	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.23	0.39	5.53e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs16966142	0.786	rs2238533	chr16:89871344	T/C	cg04287289	chr16:89883240	FANCA	0.74	5.05	0.38	1.26e-6	Caffeine consumption;
PAAD	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs58521262	0.519	rs11085548	chr19:22998655	T/C	cg07749055	chr19:23076870	NA	-0.57	-4.55	-0.35	1.11e-5	Testicular germ cell tumor;
PAAD	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg26618903	chr10:100175079	PYROXD2	-0.43	-4.89	-0.37	2.5e-6	Metabolite levels;
PAAD	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.8e-10	Response to antipsychotic treatment;
PAAD	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.71	4.69	0.36	6.12e-6	HDL cholesterol;
PAAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.81	-0.43	3.57e-8	Monocyte count;
PAAD	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.45	-0.34	1.63e-5	Plateletcrit;
PAAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12760731	0.641	rs10047148	chr1:178250266	T/C	cg00404053	chr1:178313656	RASAL2	0.67	5.22	0.39	5.81e-7	Obesity-related traits;
PAAD	cis	rs3925075	0.525	rs2011491	chr16:31280255	G/A	cg02846316	chr16:31340340	ITGAM	0.49	5.84	0.43	2.98e-8	IgA nephropathy;
PAAD	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg22437258	chr11:111473054	SIK2	0.62	6.03	0.44	1.17e-8	Primary sclerosing cholangitis;
PAAD	cis	rs3781458	0.806	rs3781466	chr10:126328689	A/G	cg20435097	chr10:126320824	FAM53B	-0.54	-5.64	-0.42	8.08e-8	Male-pattern baldness;
PAAD	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.33	0.4	3.55e-7	Lung cancer;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg27094323	chr7:1216898	NA	0.41	4.79	0.36	3.96e-6	Longevity;Endometriosis;
PAAD	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.43e-5	Calcium levels;
PAAD	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.62	6.63	0.47	5.48e-10	Leprosy;
PAAD	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	cis	rs12311304	0.965	rs7965989	chr12:15361715	G/T	cg08258403	chr12:15378311	NA	0.37	4.72	0.36	5.32e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.76	5.54	0.41	1.31e-7	Major depressive disorder;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg17372223	chr3:52568218	NT5DC2	0.53	5.34	0.4	3.33e-7	Bipolar disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21574429	chr6:143381827	AIG1	0.57	6.38	0.46	2.03e-9	Myopia (pathological);
PAAD	cis	rs863345	0.967	rs10908680	chr1:158521961	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.98e-6	Pneumococcal bacteremia;
PAAD	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.81	6.06	0.44	1.02e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.32	-16.36	-0.8	2.41e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs2275565	0.872	rs10802568	chr1:237028085	C/G	cg17297354	chr1:237056641	MTR	0.51	4.81	0.36	3.63e-6	Homocysteine levels;
PAAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.62	6.65	0.47	5.09e-10	Testicular germ cell tumor;
PAAD	cis	rs2013441	0.579	rs34370440	chr17:20003430	A/G	cg25070565	chr17:20044324	CYTSB	-0.46	-4.74	-0.36	4.96e-6	Obesity-related traits;
PAAD	cis	rs13102973	0.710	rs4428340	chr4:135886451	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-6.02	-0.44	1.25e-8	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	1.05	13.07	0.73	1.23e-26	Breast cancer;
PAAD	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.56	7.36	0.51	1.08e-11	Ewing sarcoma;
PAAD	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	6.69	0.48	4.12e-10	Mood instability;
PAAD	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.4	-5.46	-0.41	1.87e-7	Educational attainment (years of education);
PAAD	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.73	-0.36	5.06e-6	Type 2 diabetes;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg03373091	chr22:38902403	DDX17	0.81	6.64	0.47	5.12e-10	Photic sneeze reflex;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24660030	chr5:34656560	RAI14	-0.54	-6.52	-0.47	9.97e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2158799	0.602	rs177459	chr7:28299722	A/G	cg21004899	chr7:28452131	CREB5	0.44	4.3	0.33	3e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Neutrophil count;White blood cell count;Granulocyte count;Sum basophil neutrophil counts;Lymphocyte percentage of white cells;Myeloid white cell count;Sum neutrophil eosinophil counts;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10878977	0.542	rs58786840	chr12:69799163	C/T	cg13322954	chr12:69198953	NA	0.67	4.34	0.33	2.59e-5	Colorectal cancer;
PAAD	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg00086871	chr4:6988644	TBC1D14	1.18	5.55	0.41	1.23e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-5.63	-0.42	8.34e-8	Schizophrenia (age at onset);
PAAD	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14169450	chr9:139327907	INPP5E	0.77	9.19	0.6	2.84e-16	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg20893579	chr22:38215064	NA	0.49	4.8	0.36	3.72e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg17326555	chr1:119535693	NA	-0.36	-4.58	-0.35	9.62e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.68	-7.03	-0.5	6.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg09699651	chr6:150184138	LRP11	0.43	4.59	0.35	9.17e-6	Lung cancer;
PAAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg10356904	chr22:49881777	NA	-0.5	-5.42	-0.4	2.28e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7017914	0.967	rs13257800	chr8:71714133	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-4.3	-0.33	3.08e-5	Bone mineral density;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.43	4.59	0.35	9.05e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19882132	chr14:106167949	NA	-0.55	-4.93	-0.37	2.14e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.77	6.48	0.47	1.18e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.38	5.21	0.39	6.1e-7	Blood protein levels;
PAAD	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.54	4.9	0.37	2.42e-6	Liver enzyme levels;
PAAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg00999904	chr2:3704751	ALLC	-0.39	-4.61	-0.35	8.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14458626	chr2:63834284	MDH1	0.6	6.68	0.48	4.32e-10	Smoking initiation;
PAAD	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-5.76	-0.42	4.54e-8	Alzheimer's disease (late onset);
PAAD	cis	rs55788414	0.818	rs56314716	chr16:81188747	T/C	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.55	-0.57	1.24e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09144098	chr16:56518581	BBS2	-0.6	-6.37	-0.46	2.14e-9	Obesity-related traits;
PAAD	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.91	5.5	0.41	1.57e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.43	-0.4	2.2e-7	Common traits (Other);
PAAD	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.62	-5.99	-0.44	1.44e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs59888335	0.964	rs11715019	chr3:80666257	C/A	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg12935359	chr14:103987150	CKB	-0.62	-5.79	-0.42	3.95e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09676606	chr12:102132872	SYCP3	0.6	6.68	0.48	4.2e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2518049	0.539	rs7921327	chr10:5159453	G/A	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.9	5.84	0.43	3e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.51	0.34	1.28e-5	Tonsillectomy;
PAAD	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg00546117	chr1:8445545	RERE	-0.5	-4.97	-0.37	1.76e-6	Crohn's disease;
PAAD	cis	rs899997	1.000	rs1825086	chr15:79029492	A/G	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.69	7.91	0.54	4.92e-13	Alcohol dependence;
PAAD	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs4388249	0.687	rs10041575	chr5:109104277	T/G	cg17395555	chr5:108820864	NA	0.32	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.67	-0.35	6.7e-6	Parkinson's disease;
PAAD	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.41	0.56	2.8e-14	Menopause (age at onset);
PAAD	cis	rs740474	0.707	rs251019	chr5:140899784	G/C	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.32	4.51	0.34	1.28e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.93	8.05	0.55	2.16e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.91	11.58	0.68	1.27e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.66	7.68	0.53	1.83e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35955747	0.838	rs28716	chr22:31730189	A/C	cg02404636	chr22:31891804	SFI1	0.49	4.9	0.37	2.43e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	trans	rs901683	1.000	rs71494800	chr10:46002954	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.32	-0.4	3.69e-7	Schizophrenia;
PAAD	cis	rs7567389	0.677	rs72845976	chr2:128086440	T/A	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.52	-0.34	1.22e-5	Coronary artery disease;
PAAD	cis	rs2137920	0.685	rs2102686	chr10:50233977	C/T	cg02657375	chr10:50863136	CHAT	0.52	4.26	0.33	3.6e-5	Migraine with aura;
PAAD	cis	rs7765175	0.598	rs2842842	chr6:113632998	G/A	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.48	5.34	0.4	3.29e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Vitiligo;
PAAD	cis	rs7562790	0.500	rs3821160	chr2:36644228	C/G	cg01206211	chr2:36825736	FEZ2	0.43	4.38	0.33	2.18e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg09222892	chr1:25734099	RHCE	-0.44	-4.27	-0.33	3.44e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.4	-5.04	-0.38	1.33e-6	Childhood ear infection;
PAAD	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.75	7.81	0.54	8.53e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.56	5.47	0.41	1.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.37	12.75	0.72	8.67e-26	Corneal structure;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg09252528	chr19:42901252	NA	-0.58	-6.6	-0.47	6.46e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.73	-0.36	5.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4072705	0.586	rs7855380	chr9:127246763	T/C	cg13476313	chr9:127244764	NR5A1	-0.3	-4.82	-0.36	3.49e-6	Menarche (age at onset);
PAAD	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.45	-0.34	1.68e-5	Obesity (extreme);
PAAD	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	5.75	0.42	4.75e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	1.08	8.25	0.56	7.16e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.54	-0.76	1.43e-30	Primary sclerosing cholangitis;
PAAD	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	5.27	0.39	4.6e-7	Eosinophil percentage of white cells;
PAAD	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.68	7.91	0.54	5.02e-13	Height;
PAAD	cis	rs1903068	0.785	rs28584303	chr4:55997622	C/T	cg09978860	chr4:56023921	NA	0.41	4.41	0.34	1.95e-5	Endometriosis;
PAAD	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.73	7.28	0.51	1.71e-11	Resting heart rate;
PAAD	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg05785598	chr3:49045655	WDR6	0.44	5.15	0.39	8.08e-7	Parkinson's disease;
PAAD	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs58521262	0.585	rs2935440	chr19:23211171	G/A	cg02350677	chr19:23254381	NA	0.26	4.61	0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.51	-0.34	1.28e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09835421	chr16:68378352	PRMT7	-1.19	-8.53	-0.57	1.34e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs735539	0.521	rs2762998	chr13:21375752	A/G	cg27234864	chr13:21295941	IL17D	0.59	4.92	0.37	2.26e-6	Dental caries;
PAAD	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.47	-5.42	-0.4	2.26e-7	Platelet distribution width;
PAAD	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.74	-7.32	-0.51	1.36e-11	Neuroticism;
PAAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-6.51	-0.47	1.02e-9	Mood instability;
PAAD	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg08345082	chr10:99160200	RRP12	-0.31	-4.37	-0.33	2.28e-5	Monocyte percentage of white cells;
PAAD	cis	rs7301016	0.895	rs11174514	chr12:62895074	G/C	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.79	9.55	0.61	3.11e-17	Height;
PAAD	cis	rs354033	1.000	rs58026905	chr7:149224358	G/A	cg06920324	chr7:149264011	ZNF767	-0.61	-5.08	-0.38	1.11e-6	Multiple sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17759595	chr8:26481696	DPYSL2	-0.7	-7.12	-0.5	4.02e-11	Obesity-related traits;
PAAD	cis	rs13242816	1.000	rs2402078	chr7:116128648	A/C	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.3	-0.46	3.03e-9	Prudent dietary pattern;
PAAD	cis	rs10958605	0.731	rs6985919	chr8:40043071	G/A	cg14545590	chr8:40388592	ZMAT4	-0.41	-4.53	-0.35	1.17e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg27535305	chr1:53392650	SCP2	-0.4	-4.26	-0.33	3.55e-5	Monocyte count;
PAAD	cis	rs4774830	0.744	rs62046390	chr15:56308506	G/A	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.39	4.31	0.33	2.91e-5	High light scatter reticulocyte count;
PAAD	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.58	5.5	0.41	1.59e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14911189	chr18:73140200	C18orf62	-0.48	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.87	10.29	0.64	3.47e-19	Ulcerative colitis;
PAAD	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	8.46	0.57	2.09e-14	Bone mineral density;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.79	8.82	0.58	2.46e-15	Menarche (age at onset);
PAAD	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.45	-5.77	-0.42	4.37e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs858239	1.000	rs199357	chr7:23288309	A/G	cg23682824	chr7:23144976	KLHL7	-0.47	-4.31	-0.33	2.94e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	1.21	12.74	0.72	9.32e-26	Eosinophil percentage of granulocytes;
PAAD	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.6e-12	Obesity-related traits;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06753367	chr22:24256600	NA	0.42	4.39	0.34	2.1e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.75	-0.66	2.15e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9463078	0.702	rs929614	chr6:44771934	C/A	cg25276700	chr6:44698697	NA	-0.48	-5.47	-0.41	1.85e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02071572	chr4:1403502	NA	0.43	5.46	0.4	1.89e-7	Obesity-related traits;
PAAD	cis	rs8105895	1.000	rs57912102	chr19:22136043	T/C	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg21929781	chr1:2537748	MMEL1	-0.5	-5.33	-0.4	3.47e-7	Ulcerative colitis;
PAAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.11	-9.02	-0.59	7.44e-16	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13560548	chr3:10150139	C3orf24	0.61	5.45	0.4	2.01e-7	Alzheimer's disease;
PAAD	cis	rs3736485	0.934	rs4775955	chr15:51873449	C/T	cg19558802	chr15:51695713	GLDN	0.45	4.56	0.35	1.05e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.68	7.17	0.5	3.07e-11	Menopause (age at onset);
PAAD	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.62	8.09	0.55	1.79e-13	Crohn's disease;
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.51	-4.81	-0.36	3.66e-6	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.16	0.5	3.19e-11	Corneal astigmatism;
PAAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.63	7.12	0.5	4.1e-11	Emphysema distribution in smoking;
PAAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg03209412	chr4:183728196	NA	0.9	7.92	0.54	4.71e-13	Pediatric autoimmune diseases;
PAAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg17644776	chr2:200775616	C2orf69	-0.69	-6.31	-0.46	2.83e-9	Schizophrenia;
PAAD	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	5.04	0.38	1.29e-6	Colorectal cancer;
PAAD	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg10932868	chr11:921992	NA	0.49	5.92	0.43	2.1e-8	Alzheimer's disease (late onset);
PAAD	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg18551225	chr6:44695536	NA	-0.69	-7.08	-0.5	4.95e-11	Total body bone mineral density;
PAAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.6	0.41	9.93e-8	Bipolar disorder;
PAAD	cis	rs13102973	0.867	rs11722699	chr4:135907871	G/T	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.77	9.68	0.62	1.48e-17	Bone mineral density;
PAAD	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg17595323	chr11:93583763	C11orf90	0.35	4.31	0.33	2.91e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.71	-7.67	-0.53	1.93e-12	Blood metabolite levels;
PAAD	cis	rs9810890	0.764	rs4927895	chr3:128555639	A/G	cg18531004	chr3:128564980	NA	-0.67	-4.36	-0.33	2.37e-5	Dental caries;
PAAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.55	4.87	0.37	2.78e-6	Type 2 diabetes;
PAAD	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.79	-8.71	-0.58	4.83e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.41	0.34	1.96e-5	Hepatocellular carcinoma;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.09	0.5	4.75e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.59	5.65	0.42	7.76e-8	Uric acid clearance;
PAAD	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.38	-4.34	-0.33	2.64e-5	Pubertal anthropometrics;
PAAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs11614333	1.000	rs11056233	chr12:15051203	G/A	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.63	6.34	0.46	2.46e-9	Multiple sclerosis;
PAAD	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.88	-9.3	-0.6	1.47e-16	Parkinson's disease;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05025164	chr4:1340916	KIAA1530	0.56	5.73	0.42	5.22e-8	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03647317	chr4:187891568	NA	0.51	5.7	0.42	5.94e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg25828445	chr12:7781288	NA	-0.74	-5.26	-0.39	4.71e-7	HDL cholesterol levels;
PAAD	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-1.04	-14.11	-0.75	1.96e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.76	9.07	0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs12956009	0.558	rs12960592	chr18:44857203	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.82	-0.36	3.47e-6	Educational attainment (years of education);
PAAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.58	5.78	0.42	4.05e-8	Tonsillectomy;
PAAD	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.71	-0.36	5.52e-6	Joint mobility (Beighton score);
PAAD	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.72	-6.79	-0.48	2.32e-10	Body mass index;
PAAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.54	0.41	1.27e-7	Bipolar disorder;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6841258	0.572	rs16852326	chr4:40553304	A/T	cg25639566	chr4:40539823	RBM47	-0.7	-4.55	-0.35	1.11e-5	Mosquito bite size;
PAAD	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.49	5.11	0.38	9.51e-7	Diastolic blood pressure;
PAAD	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.78	12.81	0.72	6.14e-26	Breast cancer;
PAAD	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.64	-5.48	-0.41	1.71e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.65	-7.74	-0.53	1.29e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24050671	chr11:124823775	CCDC15	-0.74	-6.89	-0.49	1.39e-10	Neuroticism;
PAAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	9.21	0.6	2.51e-16	Personality dimensions;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg15691649	chr6:25882328	NA	-0.48	-4.4	-0.34	1.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.73	-5.93	-0.43	1.99e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02788857	chr8:22132959	PIWIL2	0.55	7.32	0.51	1.32e-11	Hypertriglyceridemia;
PAAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.52	4.8	0.36	3.75e-6	Monocyte count;
PAAD	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg05895507	chr15:77155635	SCAPER	-0.41	-4.55	-0.35	1.07e-5	Blood metabolite levels;
PAAD	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.54	6.7	0.48	3.83e-10	Atrioventricular conduction;
PAAD	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg09754948	chr16:28834200	ATXN2L	0.5	4.53	0.34	1.19e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.18	0.39	7.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.84	7.47	0.52	5.81e-12	Phospholipid levels (plasma);
PAAD	cis	rs6433857	0.536	rs1971134	chr2:181351532	G/A	cg23363182	chr2:181467187	NA	-0.52	-5.26	-0.39	4.78e-7	Body mass index;
PAAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg17366294	chr4:99064904	C4orf37	-0.46	-5.14	-0.38	8.47e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.94	10.66	0.65	3.7e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.55	0.35	1.07e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-5.5	-0.41	1.55e-7	Reticulocyte count;
PAAD	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg12568669	chr8:11666485	FDFT1	0.32	5.24	0.39	5.39e-7	Monocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22007633	chr17:80887386	TBCD	0.56	6.47	0.46	1.3e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2073300	1.000	rs6036422	chr20:23456962	A/T	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.97	9.65	0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg13722127	chr7:150037890	RARRES2	0.61	6.0	0.44	1.38e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6864727	1.000	rs217259	chr5:137412963	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.04	0.38	1.31e-6	Atrial fibrillation;
PAAD	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.36	-0.71	9.7e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg03983715	chr16:68378420	PRMT7	-0.72	-5.23	-0.39	5.43e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.84e-11	Interstitial lung disease;
PAAD	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg06217245	chr20:33103252	DYNLRB1	0.42	4.29	0.33	3.18e-5	Skin pigmentation;
PAAD	cis	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs1879734	0.731	rs910298	chr1:54193701	T/C	cg14659662	chr1:54151053	GLIS1	-0.34	-4.52	-0.34	1.22e-5	Mitral valve prolapse;
PAAD	cis	rs74367352	0.831	rs7687817	chr4:109974121	C/T	cg06981781	chr4:110842888	EGF	-0.7	-4.38	-0.33	2.21e-5	Carotid plaque burden;
PAAD	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg19628046	chr18:33552617	C18orf21	0.52	4.38	0.34	2.16e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	4.42	0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.44	0.34	1.71e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-1.01	-11.34	-0.68	5.64e-22	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg02135003	chr7:105160482	PUS7	-0.7	-5.77	-0.42	4.23e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.57	5.99	0.44	1.48e-8	Menopause (age at onset);
PAAD	cis	rs8105895	0.935	rs8110975	chr19:22240233	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	trans	rs34112283	0.592	rs5025201	chr2:144206076	T/G	cg10530280	chr1:167759869	MPZL1	-0.66	-6.53	-0.47	9.53e-10	Neuroticism;
PAAD	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg22153407	chr1:230290089	GALNT2	0.49	5.04	0.38	1.33e-6	Coronary artery disease;
PAAD	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.47	-0.41	1.77e-7	Colorectal cancer;
PAAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg14393609	chr7:65229607	NA	-0.48	-4.63	-0.35	7.79e-6	Aortic root size;
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07701084	chr6:150067640	NUP43	0.61	6.11	0.44	7.91e-9	Testicular germ cell tumor;
PAAD	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg10932868	chr11:921992	NA	0.44	4.61	0.35	8.48e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.63	5.48	0.41	1.7e-7	Diastolic blood pressure;
PAAD	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	5.04	0.38	1.33e-6	Menarche (age at onset);
PAAD	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.47	4.53	0.34	1.2e-5	Blood pressure;
PAAD	cis	rs2147959	0.941	rs10916317	chr1:228645063	A/G	cg00655913	chr1:228633920	NA	0.51	4.59	0.35	9.17e-6	Adult asthma;
PAAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs4427176	0.507	rs11249942	chr8:9593749	C/G	cg01912921	chr6:1611712	FOXC1	0.8	6.41	0.46	1.7e-9	Mosquito bite size;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs3737883	1.000	rs4590732	chr1:203028711	C/G	cg03900565	chr1:203031815	PPFIA4	0.34	5.75	0.42	4.64e-8	Early onset atrial fibrillation;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2544527	0.586	rs1477253	chr2:15910457	T/C	cg26669897	chr2:15909070	NA	0.45	4.47	0.34	1.55e-5	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.95	11.07	0.67	2.93e-21	Coronary artery disease;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22338127	chr1:209979572	IRF6	0.52	4.29	0.33	3.14e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg15425427	chr11:65406154	SIPA1	0.48	4.28	0.33	3.31e-5	Blood pressure (age interaction);
PAAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.4	-5.17	-0.39	7.36e-7	Alcohol dependence;
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg14092988	chr3:52407081	DNAH1	0.44	5.31	0.4	3.9e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.04	-0.38	1.29e-6	Mortality in heart failure;
PAAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.45	5.3	0.39	4e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6076065	1.000	rs2424538	chr20:23382076	A/G	cg12633918	chr20:23549525	CST9L	-0.4	-4.43	-0.34	1.78e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.5	4.75	0.36	4.66e-6	HDL cholesterol;
PAAD	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.5	5.13	0.38	8.84e-7	Plasma plasminogen activator levels;
PAAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg01075559	chr1:2537774	MMEL1	-0.49	-5.2	-0.39	6.37e-7	Ulcerative colitis;
PAAD	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-5.64	-0.42	8.15e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.87	10.94	0.66	6.6e-21	Prudent dietary pattern;
PAAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg06970076	chr16:1560791	IFT140	0.5	4.45	0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg16031515	chr1:205743344	RAB7L1	-0.43	-5.03	-0.38	1.36e-6	Menarche (age at onset);
PAAD	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg03910582	chr17:19030146	GRAPL	-0.49	-4.72	-0.36	5.38e-6	Schizophrenia;
PAAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.57	6.16	0.45	6.17e-9	Lung cancer;
PAAD	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg02780029	chr10:43622663	RET	-0.48	-4.78	-0.36	4.02e-6	Hirschsprung disease;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.46e-5	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.7	-0.42	6.17e-8	Mood instability;
PAAD	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.6	6.94	0.49	1.06e-10	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11192808	chr8:101170185	SPAG1	0.58	6.69	0.48	4.07e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg25547332	chr5:131281432	NA	-0.57	-4.43	-0.34	1.82e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.65	8.76	0.58	3.58e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg18279126	chr7:2041391	MAD1L1	0.62	6.2	0.45	5.1e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.7	7.4	0.51	8.53e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.67	7.54	0.52	3.86e-12	Motion sickness;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg02725872	chr8:58115012	NA	-0.6	-4.93	-0.37	2.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.83	0.43	3.15e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14180030	chr9:123475675	MEGF9	-0.44	-4.94	-0.37	2e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.94	12.32	0.71	1.25e-24	Menopause (age at onset);
PAAD	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg13327785	chr12:132219529	SFRS8	-0.46	-4.49	-0.34	1.39e-5	Migraine;
PAAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg21395723	chr22:39101663	GTPBP1	-0.43	-4.45	-0.34	1.66e-5	Menopause (age at onset);
PAAD	cis	rs11892454	0.515	rs6741640	chr2:26068509	C/T	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.52e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.77	-5.54	-0.41	1.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.79	-7.08	-0.5	4.87e-11	Pancreatic cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21196628	chr14:93175350	LGMN	0.6	6.29	0.45	3.17e-9	Smoking initiation;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg07202610	chr7:1142643	C7orf50	-0.72	-5.24	-0.39	5.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	7.76	0.53	1.12e-12	Alzheimer's disease;
PAAD	cis	rs375066	0.935	rs4803662	chr19:44359564	C/G	cg11993925	chr19:44307056	LYPD5	0.52	6.66	0.48	4.8e-10	Breast cancer;
PAAD	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21545522	chr1:205238299	TMCC2	0.48	4.39	0.34	2.09e-5	Red blood cell count;
PAAD	cis	rs709400	0.663	rs10133035	chr14:103979127	C/T	cg10395934	chr14:104002654	TRMT61A	0.55	5.52	0.41	1.45e-7	Body mass index;
PAAD	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-6.73	-0.48	3.34e-10	Personality dimensions;
PAAD	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.67	5.57	0.41	1.12e-7	Obesity (extreme);
PAAD	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	18.49	0.83	9.86e-41	Schizophrenia;
PAAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg20933634	chr6:27740509	NA	0.8	7.31	0.51	1.4e-11	Depression;
PAAD	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg12935359	chr14:103987150	CKB	-0.5	-4.35	-0.33	2.48e-5	Monocyte count;
PAAD	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs35639934	chr10:46070627	T/A	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg04034577	chr2:241836375	C2orf54	-0.34	-5.15	-0.39	7.79e-7	Urinary metabolites;
PAAD	cis	rs367943	0.665	rs2115210	chr5:112966125	T/C	cg12552261	chr5:112820674	MCC	0.49	4.99	0.38	1.62e-6	Type 2 diabetes;
PAAD	cis	rs4740619	0.905	rs10756678	chr9:15615932	C/T	cg14451791	chr9:16040625	NA	-0.39	-4.44	-0.34	1.73e-5	Body mass index;
PAAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-5.5	-0.41	1.56e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs533581	0.873	rs529900	chr16:88976968	G/C	cg08698997	chr16:88989212	CBFA2T3	0.48	5.72	0.42	5.56e-8	Social autistic-like traits;
PAAD	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg08098950	chr16:4033226	ADCY9	-0.56	-5.43	-0.4	2.15e-7	Body mass index;
PAAD	cis	rs11235843	0.866	rs72974869	chr11:73414846	G/A	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.52	5.02	0.38	1.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.55	0.35	1.07e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs900145	0.861	rs11022743	chr11:13297800	G/A	cg15603424	chr11:13300592	ARNTL	-0.54	-4.63	-0.35	7.91e-6	Menarche (age at onset);
PAAD	cis	rs9283706	0.641	rs1990894	chr5:66331685	C/T	cg11590213	chr5:66331682	MAST4	0.58	4.77	0.36	4.2e-6	Coronary artery disease;
PAAD	cis	rs354225	0.544	rs13386146	chr2:54802514	G/C	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	1.09	15.35	0.78	1.02e-32	Breast cancer;
PAAD	cis	rs834811	0.563	rs834801	chr7:135871355	A/G	cg01726295	chr7:135938950	NA	0.41	4.32	0.33	2.8e-5	Post-traumatic stress disorder;
PAAD	cis	rs10484434	1.000	rs17596719	chr6:26097194	A/G	cg10704923	chr6:26108404	HIST1H1T	0.73	4.26	0.33	3.62e-5	HIV-1 viral setpoint;
PAAD	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11940518	chr11:65339797	FAM89B	-0.77	-6.99	-0.49	7.92e-11	Neuroticism;
PAAD	cis	rs1519814	0.616	rs2326428	chr8:121011363	A/G	cg22335954	chr8:121166405	COL14A1	-0.64	-4.95	-0.37	1.98e-6	Breast cancer;
PAAD	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg14851346	chr12:38532713	NA	-0.44	-4.29	-0.33	3.18e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06544989	chr22:39130855	UNC84B	0.5	5.16	0.39	7.62e-7	Menopause (age at onset);
PAAD	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.34	-0.33	2.61e-5	Lung cancer in ever smokers;
PAAD	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.51	0.34	1.28e-5	Resting heart rate;
PAAD	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.84	0.49	1.81e-10	Body mass index;
PAAD	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg01796438	chr3:11312864	ATG7	0.65	4.98	0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.68	-6.27	-0.45	3.55e-9	IgG glycosylation;
PAAD	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.52	-6.29	-0.45	3.27e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1015213	0.609	rs75473483	chr8:52877577	A/C	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg18898632	chr2:242989856	NA	-0.61	-4.63	-0.35	7.9e-6	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.53	-5.79	-0.42	3.97e-8	Carotid intima media thickness;
PAAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21028142	chr17:79581711	NPLOC4	0.46	5.49	0.41	1.66e-7	Eye color traits;
PAAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.46	-4.77	-0.36	4.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs9397240	0.689	rs1048587	chr6:155578684	G/A	cg26934881	chr6:155569291	TIAM2	-0.54	-4.46	-0.34	1.56e-5	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-5.2	-0.39	6.25e-7	Lung function (FEV1);
PAAD	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg23346134	chr3:49453900	TCTA	0.4	4.27	0.33	3.4e-5	Menarche (age at onset);
PAAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.54	5.55	0.41	1.22e-7	Caffeine consumption;
PAAD	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1472147	1.000	rs13226115	chr7:128504575	G/C	cg10778310	chr7:128509080	NA	-0.41	-4.76	-0.36	4.46e-6	Calcium levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12276228	chr11:62648277	SLC3A2	0.7	7.03	0.5	6.39e-11	Obesity-related traits;
PAAD	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.59	6.37	0.46	2.18e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs228916	1.000	rs228928	chr22:37509844	A/G	cg14326991	chr6:46889760	GPR116	-0.65	-6.55	-0.47	8.42e-10	Iron status biomarkers (iron levels);
PAAD	trans	rs901683	1.000	rs78766622	chr10:46087519	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg15017067	chr4:17643749	FAM184B	0.42	4.78	0.36	4.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4356203	0.870	rs10766381	chr11:17257045	A/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.6	-0.35	8.72e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg03676636	chr4:99064102	C4orf37	0.31	5.77	0.42	4.28e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg17076780	chr6:43251928	TTBK1	0.55	4.25	0.33	3.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	8.73	0.58	4.21e-15	Lymphocyte counts;
PAAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg10356904	chr22:49881777	NA	-0.5	-5.5	-0.41	1.56e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs877426	0.555	rs7988568	chr13:114826751	C/G	cg07437657	chr13:114220436	NA	-0.7	-4.38	-0.33	2.23e-5	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs2271001	0.955	rs10833064	chr11:19142375	C/T	cg00161556	chr11:19138045	ZDHHC13	0.55	5.57	0.41	1.1e-7	Gut microbiome composition (winter);
PAAD	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.28	-0.39	4.49e-7	Neuroticism;
PAAD	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11807834	0.522	rs4412597	chr1:230242755	G/A	cg00566187	chr1:230250356	GALNT2	-0.65	-6.88	-0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg24733560	chr20:60626293	TAF4	0.46	5.56	0.41	1.18e-7	Body mass index;
PAAD	cis	rs9900972	0.918	rs8082515	chr17:76876769	C/A	cg00961940	chr17:76876995	TIMP2	0.58	5.24	0.39	5.27e-7	Obesity-related traits;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14987222	chr20:18123352	CSRP2BP;PET117	-0.66	-6.31	-0.46	2.86e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.91	-12.22	-0.7	2.41e-24	Body mass index;
PAAD	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.59	-5.69	-0.42	6.29e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.71	5.76	0.42	4.49e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg07469887	chr10:131262384	NA	-0.38	-4.27	-0.33	3.4e-5	Response to temozolomide;
PAAD	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.52	4.64	0.35	7.54e-6	Systemic lupus erythematosus;
PAAD	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.79	-10.13	-0.64	9.19e-19	Height;
PAAD	cis	rs1797885	0.714	rs299657	chr3:12551491	C/G	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.53	-4.98	-0.37	1.69e-6	Coronary artery disease;
PAAD	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.67	6.35	0.46	2.37e-9	Uric acid levels;
PAAD	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg20913747	chr6:44695427	NA	-0.67	-6.65	-0.47	5.03e-10	Total body bone mineral density;
PAAD	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.55	5.65	0.42	7.62e-8	Schizophrenia;
PAAD	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.77	5.42	0.4	2.26e-7	Vitiligo;
PAAD	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.88	11.27	0.67	8.75e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4757319	0.515	rs7125389	chr11:15438571	A/G	cg03245590	chr11:15329459	NA	0.44	5.19	0.39	6.53e-7	Breast cancer;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.66	-4.97	-0.37	1.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.23e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg00901687	chr17:48585270	MYCBPAP	0.55	5.38	0.4	2.77e-7	Visceral fat;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.88	7.51	0.52	4.58e-12	Alzheimer's disease;
PAAD	cis	rs35955747	0.870	rs7289189	chr22:31657182	C/T	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14019695	chr9:139328340	INPP5E	0.58	4.96	0.37	1.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-1.02	-6.3	-0.46	3.05e-9	Type 2 diabetes;
PAAD	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg23920097	chr1:209922102	NA	-0.51	-4.59	-0.35	9.35e-6	Red blood cell count;
PAAD	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.74	0.36	4.85e-6	Plateletcrit;
PAAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg12463550	chr7:65579703	CRCP	0.48	4.45	0.34	1.68e-5	Aortic root size;
PAAD	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.58	6.03	0.44	1.19e-8	Huntington's disease progression;
PAAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.72	7.87	0.54	6.13e-13	Age at first birth;
PAAD	cis	rs113779084	0.623	rs13238659	chr7:11993974	A/C	cg15090509	chr7:11872073	THSD7A	0.43	5.12	0.38	9.15e-7	Educational attainment (years of education);
PAAD	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.05	0.38	1.27e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.82	-0.48	2.07e-10	Depression;
PAAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.62	-4.89	-0.37	2.58e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.48	0.41	1.75e-7	Prostate cancer;
PAAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.69	-8.46	-0.57	2.09e-14	Bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26475306	chr20:33999876	UQCC	0.74	8.31	0.56	5.08e-14	Myopia (pathological);
PAAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.8	-0.58	2.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.29	-0.33	3.21e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg05970768	chr5:171682616	UBTD2	0.62	6.35	0.46	2.34e-9	Body mass index;
PAAD	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.39e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9913156	0.748	rs7219787	chr17:4562257	A/T	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05863116	chr5:133562407	PPP2CA	0.71	8.2	0.55	9.55e-14	Myopia (pathological);
PAAD	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.92	7.78	0.53	1.01e-12	Dupuytren's disease;
PAAD	cis	rs9910055	0.550	rs377963	chr17:42158310	T/G	cg19774624	chr17:42201019	HDAC5	0.68	5.57	0.41	1.13e-7	Total body bone mineral density;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg08219700	chr8:58056026	NA	0.79	5.44	0.4	2.11e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg20090143	chr19:45452003	APOC2	0.4	4.94	0.37	2.06e-6	Blood protein levels;
PAAD	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg20893579	chr22:38215064	NA	-0.55	-5.88	-0.43	2.53e-8	Glioblastoma;Glioma;
PAAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.85	-7.16	-0.5	3.27e-11	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.76	5.45	0.4	2.03e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11892454	0.515	rs7609004	chr2:25969050	T/C	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.05e-6	Heschl's gyrus morphology;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.51	-7.55	-0.52	3.73e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.86	-9.55	-0.61	3.13e-17	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16083429	chr3:49237500	CCDC36	0.48	5.34	0.4	3.28e-7	Menarche (age at onset);
PAAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.58	5.13	0.38	8.88e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01616529	chr11:638424	DRD4	-0.6	-5.55	-0.41	1.24e-7	Systemic lupus erythematosus;
PAAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.64	-7.16	-0.5	3.17e-11	Type 2 diabetes;
PAAD	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.67	-5.81	-0.43	3.6e-8	Menarche (age at onset);
PAAD	cis	rs8179	0.593	rs17164683	chr7:92286980	C/T	cg03496780	chr7:92466842	CDK6	0.49	4.7	0.36	5.9e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.81	-6.0	-0.44	1.36e-8	Coronary artery calcification;
PAAD	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg03417191	chr3:183542750	MAP6D1	-0.58	-5.06	-0.38	1.21e-6	Menopause (age at onset);
PAAD	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	6.23	0.45	4.42e-9	Lung cancer in ever smokers;
PAAD	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.62	6.36	0.46	2.3e-9	Testicular germ cell tumor;
PAAD	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.81	10.31	0.64	3.17e-19	Alcohol dependence;
PAAD	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.51	-4.97	-0.37	1.75e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20181482	chr8:94929834	PDP1	0.61	6.32	0.46	2.71e-9	Myopia (pathological);
PAAD	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24979348	chr12:15374303	RERG	-0.77	-6.7	-0.48	3.83e-10	Neuroticism;
PAAD	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-1.07	-5.67	-0.42	7.1e-8	Plateletcrit;
PAAD	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg23033748	chr14:75592666	NEK9	0.43	5.28	0.39	4.46e-7	Height;
PAAD	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.83	10.55	0.65	7.09e-20	Cannabis dependence symptom count;
PAAD	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.53	13.24	0.73	4.14e-27	Atopic dermatitis;
PAAD	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-4.94	-0.37	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs939584	0.877	rs6731225	chr2:630224	A/T	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.52	4.28	0.33	3.24e-5	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12413365	chr12:12510412	LOH12CR1;LOH12CR2	0.65	7.23	0.51	2.22e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg05156742	chr15:59063176	FAM63B	0.77	8.01	0.54	2.73e-13	Schizophrenia;
PAAD	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-1.11	-7.92	-0.54	4.57e-13	Post bronchodilator FEV1;
PAAD	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.94	0.37	1.99e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.58	4.96	0.37	1.87e-6	Lymphocyte counts;
PAAD	cis	rs66530629	1.000	rs7520844	chr1:25054223	C/G	cg01905478	chr1:25040257	NA	-0.55	-5.93	-0.43	2e-8	Plateletcrit;
PAAD	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg10432947	chr4:2062441	NAT8L	0.48	4.33	0.33	2.71e-5	Systolic blood pressure;
PAAD	cis	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.82	-0.48	2.07e-10	Morning vs. evening chronotype;
PAAD	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.36	-0.4	3.01e-7	Daytime sleep phenotypes;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.66	7.22	0.51	2.34e-11	Lung cancer;
PAAD	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.45	4.58	0.35	9.6e-6	Asthma;
PAAD	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.78	7.99	0.54	3.06e-13	Retinal vascular caliber;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23468137	chr10:133784769	BNIP3	-0.68	-6.68	-0.48	4.27e-10	Obesity-related traits;
PAAD	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-5.67	-0.42	7.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.41	-4.92	-0.37	2.23e-6	Menarche (age at onset);
PAAD	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg17325771	chr7:75508891	RHBDD2	-0.37	-5.28	-0.39	4.31e-7	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg17541715	chr7:1216824	NA	-0.56	-6.77	-0.48	2.69e-10	Longevity;Endometriosis;
PAAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg01831904	chr17:28903510	LRRC37B2	0.93	6.47	0.46	1.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.19	-0.39	6.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3764563	0.935	rs643442	chr19:15684087	T/C	cg20725493	chr19:15740067	CYP4F8	0.95	5.23	0.39	5.42e-7	Inflammatory biomarkers;
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.54	-5.22	-0.39	5.8e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.93	10.06	0.63	1.49e-18	Cognitive function;
PAAD	cis	rs9857275	0.501	rs13072100	chr3:141196647	G/A	cg25967872	chr3:141205623	RASA2	0.51	4.35	0.33	2.47e-5	Prion diseases;
PAAD	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.49	5.65	0.42	7.7e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10214930	0.697	rs1608664	chr7:27623928	C/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg04717802	chr22:42394638	WBP2NL	0.52	4.9	0.37	2.48e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.28	-0.39	4.34e-7	Daytime sleep phenotypes;
PAAD	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs73019876	0.869	rs2522093	chr19:22125596	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.53	-6.39	-0.46	1.91e-9	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg00531865	chr16:30841666	NA	-0.61	-4.59	-0.35	9.06e-6	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24725933	chr2:98999128	CNGA3	-0.62	-6.32	-0.46	2.73e-9	Obesity-related traits;
PAAD	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg12935359	chr14:103987150	CKB	-0.55	-5.7	-0.42	5.9e-8	Body mass index;
PAAD	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg06042504	chr8:55087323	NA	-0.72	-7.57	-0.52	3.27e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.46	-7.55	-0.52	3.73e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.52	0.61	3.85e-17	Rheumatoid arthritis;
PAAD	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg16434002	chr17:42200994	HDAC5	0.6	5.67	0.42	7.15e-8	Total body bone mineral density;
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.58	0.47	7.3e-10	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06059318	chr7:72936700	BAZ1B	0.58	6.32	0.46	2.69e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.58	5.09	0.38	1.04e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg16342193	chr10:102329863	NA	0.75	8.21	0.55	8.93e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09042952	chr12:122237463	LOC338799	-0.64	-6.32	-0.46	2.74e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.68	6.51	0.47	1.06e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08677398	chr8:58056175	NA	0.59	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2020921	0.510	rs12544318	chr8:41983076	A/G	cg12054981	chr8:42037387	PLAT	0.79	5.37	0.4	2.89e-7	Plasma plasminogen activator levels;
PAAD	cis	rs17032980	0.956	rs10200196	chr2:67308410	T/C	cg06994420	chr2:66672553	MEIS1	-0.51	-4.49	-0.34	1.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.66	-7.01	-0.49	7.16e-11	Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.48	4.64	0.35	7.44e-6	Airway imaging phenotypes;
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg07559730	chr19:53497048	ZNF702P	-0.57	-6.16	-0.45	6.32e-9	Psoriasis;
PAAD	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs115356727	chr3:128558380	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09826364	chr7:158789723	NA	-0.45	-5.48	-0.41	1.72e-7	Facial morphology (factor 20);
PAAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.92	-0.37	2.27e-6	Breast cancer;
PAAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs12144049	0.662	rs2146118	chr1:152412196	G/A	cg25605289	chr1:151974222	NA	-0.35	-4.36	-0.33	2.42e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.6	-5.76	-0.42	4.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.88	6.31	0.46	2.88e-9	Initial pursuit acceleration;
PAAD	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg07220939	chr11:64358617	SLC22A12	-0.44	-4.71	-0.36	5.47e-6	Urate levels in obese individuals;
PAAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.47	5.05	0.38	1.23e-6	Calcium levels;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.36	0.56	3.61e-14	Prudent dietary pattern;
PAAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.51	0.34	1.31e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg14664628	chr15:75095509	CSK	0.51	4.91	0.37	2.35e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.51	5.13	0.38	8.81e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs59888335	0.929	rs36178213	chr3:80869304	C/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs11168618	0.846	rs11168577	chr12:48842592	C/T	cg01881778	chr12:48919444	OR8S1	-0.5	-4.97	-0.37	1.8e-6	Adiponectin levels;
PAAD	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg11232448	chr19:2858854	NA	-0.49	-4.79	-0.36	3.91e-6	Total cholesterol levels;
PAAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg18279126	chr7:2041391	MAD1L1	0.65	6.61	0.47	5.98e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.63	-5.58	-0.41	1.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-4.81	-0.36	3.61e-6	Menarche (age at onset);
PAAD	cis	rs7011049	1.000	rs78977297	chr8:53858902	T/C	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.47	5.64	0.42	8.01e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.86	-6.08	-0.44	9.53e-9	Night sleep phenotypes;
PAAD	cis	rs9463078	0.585	rs12205274	chr6:45245026	G/A	cg18551225	chr6:44695536	NA	-0.41	-4.29	-0.33	3.11e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7713065	0.765	rs4371745	chr5:131779955	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.49	0.34	1.39e-5	Lung function (FEV1/FVC);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05676377	chr6:26383673	BTN2A2	0.64	6.37	0.46	2.18e-9	Obesity-related traits;
PAAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg08493051	chr2:3487164	NA	-0.69	-6.46	-0.46	1.36e-9	Neurofibrillary tangles;
PAAD	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.61	-0.41	9.1e-8	Schizophrenia (age at onset);
PAAD	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.64	6.61	0.47	6.26e-10	Dupuytren's disease;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13560548	chr3:10150139	C3orf24	0.6	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.43	-0.34	1.81e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.99	6.7	0.48	3.75e-10	Prostate cancer;
PAAD	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg21238619	chr17:78079768	GAA	-0.6	-6.11	-0.44	7.96e-9	Yeast infection;
PAAD	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.62	5.95	0.43	1.74e-8	Uric acid clearance;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg00945038	chr17:61921165	SMARCD2	0.52	6.08	0.44	9.13e-9	Prudent dietary pattern;
PAAD	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs8038465	0.615	rs62004616	chr15:73961176	C/T	cg15420318	chr15:73925796	NPTN	0.51	5.19	0.39	6.72e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.59	6.34	0.46	2.51e-9	Body mass index;
PAAD	cis	rs608114	0.623	rs17055666	chr6:96357386	A/G	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.73	5.52	0.41	1.43e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.63	6.5	0.47	1.06e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14180030	chr9:123475675	MEGF9	-0.46	-5.13	-0.38	8.88e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs16958440	0.867	rs79285649	chr18:44699019	A/T	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg06740227	chr12:86229804	RASSF9	0.51	5.05	0.38	1.26e-6	Major depressive disorder;
PAAD	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.04	0.5	6.3e-11	Coffee consumption (cups per day);
PAAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs797680	0.856	rs569414	chr1:93784901	G/A	cg04535902	chr1:92947332	GFI1	0.47	4.57	0.35	9.93e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.86	0.66	1.09e-20	Smoking behavior;
PAAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs941408	0.515	rs1736192	chr19:2784678	G/A	cg17333051	chr19:2783644	SGTA	0.47	5.09	0.38	1.05e-6	Total cholesterol levels;
PAAD	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg21191810	chr6:118973309	C6orf204	0.47	6.02	0.44	1.26e-8	Electrocardiographic conduction measures;
PAAD	cis	rs332507	0.830	rs1846892	chr3:124399293	A/G	cg05980111	chr3:124395277	KALRN	0.42	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12459491	chr1:154955793	FLAD1	0.55	6.31	0.46	2.91e-9	Metabolite levels  (X-11787);
PAAD	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg08999081	chr20:33150536	PIGU	0.54	5.83	0.43	3.24e-8	Height;
PAAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.63	6.27	0.45	3.61e-9	Multiple sclerosis;
PAAD	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.67	-7.06	-0.5	5.55e-11	Multiple myeloma (IgH translocation);
PAAD	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg27029450	chr22:50098074	NA	0.72	4.78	0.36	4.05e-6	Natriuretic peptide levels;
PAAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.73	-9.54	-0.61	3.48e-17	Asthma;
PAAD	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg24687543	chr11:63912206	MACROD1	0.58	5.42	0.4	2.33e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02570171	chr17:39822195	NA	-0.58	-6.68	-0.48	4.35e-10	Body fat percentage;
PAAD	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg09796270	chr17:17721594	SREBF1	-0.44	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs427941	0.668	rs201459	chr7:101741502	G/A	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg10950924	chr17:47092072	IGF2BP1	-0.38	-4.41	-0.34	1.97e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.77	7.55	0.52	3.84e-12	Testicular germ cell tumor;
PAAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.73	0.36	5.04e-6	Menopause (age at onset);
PAAD	cis	rs7714584	1.000	rs11743488	chr5:150279218	A/G	cg22134413	chr5:150180641	NA	1.01	6.45	0.46	1.42e-9	Crohn's disease;
PAAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13560548	chr3:10150139	C3orf24	-0.59	-5.29	-0.39	4.15e-7	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs35955747	0.633	rs7287937	chr22:32020745	G/A	cg02404636	chr22:31891804	SFI1	-0.54	-5.27	-0.39	4.56e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.1	10.17	0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs11811982	0.793	rs11807425	chr1:227511793	A/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.54	5.93	0.43	1.94e-8	Heart rate;
PAAD	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg08992911	chr2:238395768	MLPH	0.63	5.52	0.41	1.45e-7	Prostate cancer;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg00450029	chr8:599525	NA	0.92	6.26	0.45	3.8e-9	IgG glycosylation;
PAAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.44	-6.01	-0.44	1.34e-8	Schizophrenia;
PAAD	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg23127183	chr11:57508653	C11orf31	-0.49	-4.27	-0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.52	0.65	8.52e-20	Bladder cancer;
PAAD	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.72	7.06	0.5	5.58e-11	Uric acid levels;
PAAD	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.98	0.54	3.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7833986	1.000	rs61690651	chr8:57096661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	4.26	0.33	3.62e-5	Height;
PAAD	cis	rs11203032	0.831	rs11203014	chr10:90940333	C/G	cg16672925	chr10:90967113	CH25H	0.74	5.72	0.42	5.54e-8	Heart failure;
PAAD	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg01620082	chr3:125678407	NA	-1.09	-6.33	-0.46	2.63e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.52	-4.6	-0.35	8.66e-6	Testicular germ cell tumor;
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.56	-0.41	1.17e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.55	-5.86	-0.43	2.74e-8	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.62	7.37	0.51	1.01e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg20045696	chr14:77926864	AHSA1	0.47	4.61	0.35	8.51e-6	Myeloid white cell count;
PAAD	cis	rs4740619	0.684	rs1887669	chr9:16035428	G/A	cg14451791	chr9:16040625	NA	-0.48	-5.59	-0.41	1.03e-7	Body mass index;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs7518708	chr1:158504274	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.87	10.63	0.65	4.44e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	0.97	4.67	0.35	6.45e-6	Economic and political preferences (immigration/crime);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16813087	chr1:147400848	GPR89B	-0.8	-6.72	-0.48	3.42e-10	Neuroticism;
PAAD	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.37	0.46	2.18e-9	Cognitive ability;
PAAD	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.53	-4.9	-0.37	2.42e-6	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs59888335	0.858	rs9813728	chr3:81006317	A/C	cg21735741	chr3:80819488	NA	-0.53	-4.62	-0.35	8e-6	Schizophrenia;
PAAD	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.67	-6.57	-0.47	7.59e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs78456975	0.766	rs13400150	chr2:1514901	G/A	cg26248373	chr2:1572462	NA	-0.96	-5.91	-0.43	2.12e-8	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2814982	0.605	rs73405697	chr6:34470396	T/C	cg17674042	chr6:34482479	PACSIN1	-1.21	-7.25	-0.51	1.96e-11	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	7.84	0.54	7.18e-13	Personality dimensions;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.17	0.55	1.09e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.77	8.54	0.57	1.27e-14	Lung cancer;
PAAD	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	1.14	7.61	0.53	2.74e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs13395090	1.000	rs13395090	chr2:3715015	C/T	cg19052272	chr2:3704530	ALLC	-0.47	-5.37	-0.4	2.84e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.01	14.4	0.76	3.4e-30	Heart rate;
PAAD	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.74e-13	Morning vs. evening chronotype;
PAAD	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.8	-0.58	2.74e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.07	0.55	1.99e-13	Homoarginine levels;
PAAD	cis	rs12541635	0.701	rs2029878	chr8:107025283	A/G	cg10147462	chr8:107024639	NA	0.48	5.3	0.39	3.99e-7	Age of smoking initiation;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	1.08	7.41	0.51	8.32e-12	IgG glycosylation;
PAAD	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.65	6.33	0.46	2.62e-9	Obesity-related traits;
PAAD	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.85	-0.54	7.03e-13	Mosquito bite size;
PAAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.71	-6.39	-0.46	1.95e-9	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18940113	chr2:161264053	RBMS1	0.58	6.65	0.47	4.85e-10	Monocyte percentage of white cells;
PAAD	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.47	-4.49	-0.34	1.39e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18621852	chr3:10150065	C3orf24	-0.58	-4.55	-0.35	1.08e-5	Alzheimer's disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10536076	chr5:83017921	HAPLN1	-0.57	-6.52	-0.47	1e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.93	-16.11	-0.79	1.08e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.68	-0.35	6.27e-6	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16579770	chr16:72058938	DHODH	0.38	4.41	0.34	1.94e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs35785195	0.593	rs35304519	chr12:114236677	C/T	cg11070030	chr12:114232702	NA	0.59	4.55	0.35	1.08e-5	Daytime sleep phenotypes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04990724	chr3:46735154	ALS2CL	0.63	6.54	0.47	8.62e-10	Myopia (pathological);
PAAD	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs790123	0.666	rs790124	chr3:122388605	A/G	cg15604389	chr3:122379662	NA	0.54	5.19	0.39	6.78e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs9652601	0.691	rs9921287	chr16:11209739	T/C	cg04616529	chr16:11181986	CLEC16A	0.35	4.32	0.33	2.77e-5	Systemic lupus erythematosus;
PAAD	cis	rs367943	0.698	rs2900074	chr5:113000374	A/C	cg12552261	chr5:112820674	MCC	0.62	6.71	0.48	3.65e-10	Type 2 diabetes;
PAAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg06618935	chr21:46677482	NA	-0.53	-6.43	-0.46	1.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.87	-0.37	2.71e-6	Body mass index;
PAAD	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.72	-8.3	-0.56	5.14e-14	Alcohol dependence;
PAAD	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg18904891	chr8:8559673	CLDN23	0.73	6.53	0.47	9.27e-10	Obesity-related traits;
PAAD	cis	rs7156960	0.835	rs4903390	chr14:76699220	G/A	cg13981132	chr14:76734493	NA	-0.54	-4.87	-0.37	2.81e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.58	6.66	0.48	4.71e-10	Major depressive disorder;
PAAD	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02743256	chr7:2109353	MAD1L1	-0.72	-5.06	-0.38	1.19e-6	Neuroticism;
PAAD	cis	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.52	0.34	1.21e-5	Neuroticism;
PAAD	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs10768122	0.642	rs11033079	chr11:35362050	G/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-5.33	-0.4	3.48e-7	Vitiligo;
PAAD	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.58	5.11	0.38	9.41e-7	Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg19413350	chr8:57351067	NA	-0.56	-5.67	-0.42	6.97e-8	Obesity-related traits;
PAAD	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.51	-4.77	-0.36	4.23e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.01	0.73	1.79e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6107516	0.645	rs6116471	chr20:4669534	C/T	cg02413285	chr20:4668134	PRNP	-0.64	-6.23	-0.45	4.36e-9	Creutzfeldt-Jakob disease (variant);Creutzfeldt-Jakob disease (sporadic);
PAAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg15847926	chr7:2749597	AMZ1	-0.38	-4.46	-0.34	1.56e-5	Height;
PAAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg14725641	chr11:61582763	MIR1908;FADS1	0.52	4.62	0.35	7.99e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.48	0.52	5.44e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-4.65	-0.35	7.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.66	0.42	7.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06679143	chr4:77871370	SEPT11	0.66	6.62	0.47	5.66e-10	Obesity-related traits;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.54	4.84	0.37	3.14e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.58	-0.47	7.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	9.34	0.6	1.16e-16	Electrocardiographic conduction measures;
PAAD	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.5	5.16	0.39	7.78e-7	Schizophrenia;
PAAD	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.79	-9.29	-0.6	1.54e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6496667	0.600	rs7174198	chr15:91083186	C/T	cg22089800	chr15:90895588	ZNF774	0.59	4.53	0.34	1.18e-5	Rheumatoid arthritis;
PAAD	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg08601574	chr20:25228251	PYGB	0.57	5.71	0.42	5.9e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.56	0.61	3.03e-17	Prudent dietary pattern;
PAAD	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg20129853	chr10:51489980	NA	-0.47	-4.69	-0.36	6.06e-6	Prostate-specific antigen levels;
PAAD	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-1.32	-8.78	-0.58	3.11e-15	Depression;
PAAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg22143856	chr6:28129313	ZNF389	0.49	4.48	0.34	1.47e-5	Parkinson's disease;
PAAD	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs7092929	0.824	rs11251951	chr10:3622867	C/T	cg14308648	chr10:3568949	NA	-0.63	-4.55	-0.35	1.08e-5	Coronary artery calcification;
PAAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg03983715	chr16:68378420	PRMT7	-0.72	-4.97	-0.37	1.77e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.59	-6.25	-0.45	3.94e-9	Body mass index;
PAAD	cis	rs8112211	0.554	rs11666449	chr19:38853659	C/T	cg14299480	chr19:38876666	GGN	-0.53	-5.26	-0.39	4.92e-7	Blood protein levels;
PAAD	cis	rs3736485	0.934	rs2414106	chr15:51868741	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.92	-0.37	2.27e-6	Mean corpuscular volume;
PAAD	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs4938330	0.608	rs2238006	chr11:117087792	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.861	rs57314710	chr8:58196051	T/C	cg14926445	chr8:58193284	C8orf71	-0.71	-5.57	-0.41	1.11e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-6.14	-0.45	6.77e-9	Longevity;
PAAD	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg02415014	chr8:143852576	LYNX1	-0.5	-6.22	-0.45	4.47e-9	Urinary tract infection frequency;
PAAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.62	-0.41	8.97e-8	Life satisfaction;
PAAD	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08817983	chr4:3391423	RGS12	0.39	4.36	0.33	2.41e-5	Mean platelet volume;
PAAD	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.7	7.01	0.49	7.42e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6547631	0.622	rs12845	chr2:85925848	C/G	cg24620635	chr2:85921963	GNLY	0.42	5.55	0.41	1.23e-7	Blood protein levels;
PAAD	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.84	8.17	0.55	1.13e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg05585630	chr7:157510462	PTPRN2	0.49	4.79	0.36	3.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.74	7.73	0.53	1.37e-12	Height;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25359924	chr5:134240787	PCBD2	0.74	6.64	0.47	5.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.12	0.38	9.32e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-5.14	-0.39	8.18e-7	Total cholesterol levels;
PAAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.69	-7.97	-0.54	3.49e-13	Diastolic blood pressure;
PAAD	cis	rs601339	0.592	rs3922628	chr12:123209295	T/A	cg18578876	chr12:123200353	GPR109B	0.53	4.34	0.33	2.56e-5	Adiponectin levels;
PAAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.63	6.17	0.45	5.79e-9	Ovarian reserve;
PAAD	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.52	-5.16	-0.39	7.59e-7	Mortality in heart failure;
PAAD	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.74	-8.05	-0.55	2.27e-13	Migraine;Coronary artery disease;
PAAD	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	4.41	0.34	1.93e-5	Mood instability;
PAAD	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	6.22	0.45	4.53e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.52	4.56	0.35	1.04e-5	Interleukin-17 levels;
PAAD	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.56	5.04	0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-6.71	-0.48	3.71e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.98e-8	Lymphocyte counts;
PAAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.89	-0.49	1.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.75	0.36	4.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.7	6.64	0.47	5.2400000000000005e-10	Asthma;
PAAD	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05665937	chr4:1216051	CTBP1	0.53	5.82	0.43	3.43e-8	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15969277	chr19:2757823	SGTA	-0.69	-6.93	-0.49	1.12e-10	Obesity-related traits;
PAAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.89	10.77	0.66	1.88e-20	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg17385448	chr1:15911702	AGMAT	0.35	4.36	0.33	2.37e-5	Systolic blood pressure;
PAAD	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg01426195	chr3:39028469	NA	-0.45	-4.73	-0.36	5e-6	Verbal declarative memory;
PAAD	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg27373749	chr11:63775612	MACROD1	0.42	4.79	0.36	3.86e-6	Pulse pressure;
PAAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.47	0.57	1.97e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg11494091	chr17:61959527	GH2	-0.51	-4.36	-0.33	2.34e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.1	14.45	0.76	2.45e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs79839061	0.764	rs12646225	chr4:696848	C/T	cg10902566	chr4:727664	PCGF3	0.6	4.3	0.33	2.99e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00303548	chr13:96742413	HS6ST3	-0.63	-6.33	-0.46	2.67e-9	Smoking initiation;
PAAD	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24110177	chr3:50126178	RBM5	-0.6	-6.75	-0.48	2.95e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg03948781	chr1:205179583	DSTYK	0.46	4.33	0.33	2.73e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.75	5.84	0.43	3.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.52	5.38	0.4	2.74e-7	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.04	-0.38	1.32e-6	Blood metabolite levels;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.57	-6.21	-0.45	4.89e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg00919237	chr7:87102261	ABCB4	-0.78	-6.35	-0.46	2.38e-9	Gallbladder cancer;
PAAD	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.93	0.43	1.92e-8	Coffee consumption (cups per day);
PAAD	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.77	4.95	0.37	1.98e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.76	6.41	0.46	1.76e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.91	-0.43	2.14e-8	Prostate cancer;
PAAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg20007245	chr22:24372913	LOC391322	0.67	5.66	0.42	7.36e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.72	-0.36	5.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs761746	0.960	rs9956	chr22:32015450	T/G	cg01338084	chr22:32026380	PISD	0.5	4.41	0.34	1.96e-5	Intelligence;
PAAD	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-1.1	-8.7	-0.58	5.06e-15	Post bronchodilator FEV1;
PAAD	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg03264133	chr6:25882463	NA	0.5	4.86	0.37	2.87e-6	Blood metabolite levels;
PAAD	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs7072216	0.691	rs10786419	chr10:100180940	T/C	cg26618903	chr10:100175079	PYROXD2	-0.4	-4.41	-0.34	1.93e-5	Metabolite levels;
PAAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	11.31	0.68	6.68e-22	Menopause (age at onset);
PAAD	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.37e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.39	-0.4	2.63e-7	Total cholesterol levels;
PAAD	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg26248373	chr2:1572462	NA	-1.04	-9.19	-0.6	2.7e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06634786	chr22:41940651	POLR3H	-0.58	-4.34	-0.33	2.61e-5	Vitiligo;
PAAD	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.62	-6.47	-0.46	1.24e-9	Menopause (age at onset);
PAAD	cis	rs1043763	0.826	rs11043307	chr12:122494845	A/G	cg26218692	chr12:122497826	BCL7A	0.65	6.36	0.46	2.3e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs2279817	0.863	rs6672069	chr1:18013835	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.83	-0.43	3.26e-8	Neuroticism;
PAAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg18944383	chr4:111397179	ENPEP	0.64	7.49	0.52	5.24e-12	Coronary artery disease;
PAAD	cis	rs75757892	0.588	rs77454875	chr6:7294355	G/A	cg02954307	chr6:7269328	NA	0.59	4.56	0.35	1.04e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-5.97	-0.44	1.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg01612440	chr4:3296283	NA	0.43	4.25	0.33	3.69e-5	Serum sulfate level;
PAAD	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.64	-5.61	-0.41	9.44e-8	White matter hyperintensity burden;
PAAD	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06850241	chr22:41845214	NA	-0.53	-4.88	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg07689907	chr11:61582574	FADS1	0.53	4.77	0.36	4.26e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14516517	chr7:128096174	C7orf68	-0.76	-6.38	-0.46	1.98e-9	Neuroticism;
PAAD	cis	rs3106136	0.681	rs62321981	chr4:95310408	A/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.01	0.38	1.53e-6	Capecitabine sensitivity;
PAAD	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg10090792	chr1:38198142	EPHA10	-0.43	-4.53	-0.34	1.21e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg10374813	chr17:38183790	MED24;SNORD124	-0.42	-4.31	-0.33	2.89e-5	Myeloid white cell count;
PAAD	cis	rs877529	0.605	rs79505	chr22:39551567	A/G	cg18708252	chr22:39545030	CBX7	-0.66	-6.91	-0.49	1.27e-10	Multiple myeloma;
PAAD	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.69	6.3	0.46	2.98e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2117029	0.521	rs10875925	chr12:49536358	G/A	cg05368762	chr12:50135785	TMBIM6	0.46	4.63	0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.57	6.19	0.45	5.36e-9	Longevity;Endometriosis;
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	5.33	0.4	3.54e-7	Total body bone mineral density;
PAAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg10729496	chr3:10149963	C3orf24	0.67	5.99	0.44	1.49e-8	Alzheimer's disease;
PAAD	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg02135003	chr7:105160482	PUS7	-0.69	-6.34	-0.46	2.44e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.16e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.08	0.5	4.91e-11	Body mass index;
PAAD	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	6.81	0.48	2.15e-10	Neuroticism;
PAAD	cis	rs6782025	1.000	rs541818	chr3:121188124	A/G	cg16417163	chr3:121280760	NA	-0.48	-4.89	-0.37	2.54e-6	Aging (facial);
PAAD	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg21823605	chr1:152486609	CRCT1	-0.49	-6.29	-0.45	3.14e-9	Hair morphology;
PAAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.91	-0.54	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.58	5.49	0.41	1.68e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.32	0.33	2.76e-5	Educational attainment;
PAAD	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg07943548	chr15:86304357	KLHL25	-0.73	-5.94	-0.43	1.91e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg12458913	chr13:53173898	NA	0.55	5.34	0.4	3.4e-7	Lewy body disease;
PAAD	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs988913	0.723	rs6936015	chr6:54991809	G/A	cg03513858	chr6:54763001	FAM83B	-0.4	-4.35	-0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg14346243	chr4:90757452	SNCA	-0.55	-5.07	-0.38	1.14e-6	Neuroticism;
PAAD	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg15192750	chr16:69999425	NA	0.77	5.95	0.43	1.76e-8	IgE levels;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.74	-0.42	5.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.74e-7	Motion sickness;
PAAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26850624	chr5:429559	AHRR	0.47	5.85	0.43	2.91e-8	Cystic fibrosis severity;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.08	0.44	9.44e-9	Obesity-related traits;
PAAD	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.63	5.81	0.43	3.5e-8	Obesity-related traits;
PAAD	cis	rs73416724	0.688	rs113247464	chr6:43261781	T/A	cg17076780	chr6:43251928	TTBK1	0.74	5.19	0.39	6.7e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.69	7.09	0.5	4.85e-11	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg22903657	chr4:1355424	KIAA1530	-0.4	-4.37	-0.33	2.29e-5	Obesity-related traits;
PAAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.48	4.27	0.33	3.46e-5	Renal cell carcinoma;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Diastolic blood pressure;
PAAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.71	0.58	4.83e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg10547527	chr2:198650123	BOLL	-0.73	-4.98	-0.37	1.74e-6	Ulcerative colitis;
PAAD	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.58	-5.31	-0.4	3.75e-7	Total body bone mineral density;
PAAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	5.18	0.39	6.88e-7	Mood instability;
PAAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg26513180	chr16:89883248	FANCA	0.65	7.49	0.52	5.15e-12	Vitiligo;
PAAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.52	4.43	0.34	1.82e-5	Aortic root size;
PAAD	cis	rs375066	0.935	rs408549	chr19:44425619	T/A	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg23465465	chr6:26364728	BTN3A2	0.91	5.23	0.39	5.47e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09538031	chr5:41072796	HEATR7B2	-0.56	-6.63	-0.47	5.58e-10	Obesity-related traits;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-5.42	-0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13102973	0.720	rs13122251	chr4:135887466	C/T	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-4.64	-0.35	7.52e-6	Joint mobility (Beighton score);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23679333	chr2:53995338	LOC100302652;ASB3;CHAC2	0.61	6.47	0.46	1.3e-9	Obesity-related traits;
PAAD	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.87	7.0	0.49	7.8e-11	Chronic kidney disease;
PAAD	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg26557270	chr6:116382179	FRK	0.31	5.49	0.41	1.63e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg19486271	chr11:47235900	DDB2	-0.6	-6.06	-0.44	1.02e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.5	-4.3	-0.33	3.04e-5	Triglycerides;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02139853	chr2:236867685	AGAP1	0.66	8.04	0.55	2.34e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg15847926	chr7:2749597	AMZ1	-0.38	-4.82	-0.36	3.43e-6	Height;
PAAD	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.47	4.38	0.33	2.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.62	-5.78	-0.42	4.08e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11168618	0.875	rs11458	chr12:48888594	C/T	cg01881778	chr12:48919444	OR8S1	-0.49	-4.94	-0.37	2.04e-6	Adiponectin levels;
PAAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.96	11.06	0.67	3.15e-21	Menopause (age at onset);
PAAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.71	-5.97	-0.44	1.64e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.89	-10.14	-0.64	9.07e-19	Obesity-related traits;
PAAD	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg08676812	chr11:65308423	LTBP3	0.79	5.32	0.4	3.7e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	7.19	0.5	2.8e-11	Mean platelet volume;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg24615749	chr5:102611933	C5orf30	-0.63	-6.62	-0.47	5.95e-10	Alcohol dependence;
PAAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg08029281	chr1:67600428	NA	0.43	5.18	0.39	6.8e-7	Psoriasis;
PAAD	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.57	6.69	0.48	4.08e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.66	-7.01	-0.49	7.24e-11	Capecitabine sensitivity;
PAAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg19257562	chr1:2043853	PRKCZ	0.48	5.97	0.44	1.62e-8	Height;
PAAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg16300553	chr8:8131077	NA	-0.37	-4.45	-0.34	1.65e-5	Joint mobility (Beighton score);
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.57	5.41	0.4	2.38e-7	Electroencephalogram traits;
PAAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg03340356	chr1:67600835	NA	0.52	5.74	0.42	5.05e-8	Psoriasis;
PAAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg27417659	chr7:98567827	TRRAP	-0.48	-4.49	-0.34	1.42e-5	Breast cancer;
PAAD	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg23254163	chr1:152506842	NA	-0.48	-4.74	-0.36	4.96e-6	Hair morphology;
PAAD	cis	rs1385374	0.920	rs11059910	chr12:129271719	G/A	cg09035930	chr12:129282057	SLC15A4	-0.78	-4.5	-0.34	1.33e-5	Systemic lupus erythematosus;
PAAD	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.59	-6.12	-0.44	7.7e-9	Menarche (age at onset);
PAAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.83	8.13	0.55	1.38e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.63	6.57	0.47	7.72e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Bladder cancer;
PAAD	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg26897989	chr16:1907736	C16orf73	-0.56	-4.92	-0.37	2.23e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg11877270	chr2:65658583	SPRED2	-0.64	-6.71	-0.48	3.58e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.34	-0.4	3.28e-7	Fibrinogen levels;
PAAD	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg10167378	chr1:228756711	NA	0.85	5.77	0.42	4.31e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.53	-0.34	1.19e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1334894	1.000	rs1334894	chr6:35615130	C/T	cg07213720	chr6:35227408	ZNF76	-0.89	-4.77	-0.36	4.25e-6	Coronary artery disease;
PAAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg06156847	chr2:113672199	IL1F7	-0.52	-5.23	-0.39	5.42e-7	Pulmonary function;
PAAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.19e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	5.18	0.39	6.87e-7	Personality dimensions;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg04520793	chr17:42248056	ASB16	-0.48	-6.7	-0.48	3.86e-10	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	7.66	0.53	2.03e-12	Alzheimer's disease;
PAAD	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg16447950	chr5:562315	NA	-0.65	-5.08	-0.38	1.11e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8060686	0.920	rs4474673	chr16:67758778	C/T	cg09835421	chr16:68378352	PRMT7	-0.93	-5.32	-0.4	3.69e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg10193763	chr2:225306901	NA	-0.5	-4.37	-0.33	2.27e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.38	1.21e-6	Menarche (age at onset);
PAAD	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-1.11	-15.84	-0.79	5.4400000000000004e-34	Total body bone mineral density;
PAAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.92	-8.93	-0.59	1.3e-15	Asthma;
PAAD	cis	rs60617249	0.560	rs12718972	chr7:50928058	G/A	cg15805451	chr7:51135775	COBL	-0.43	-4.59	-0.35	9.24e-6	Major depression and alcohol dependence;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg14789911	chr21:47582049	C21orf56	-0.43	-4.36	-0.33	2.35e-5	Testicular germ cell tumor;
PAAD	cis	rs6545883	0.931	rs778756	chr2:61781994	A/G	cg14146966	chr2:61757674	XPO1	0.38	4.58	0.35	9.75e-6	Tuberculosis;
PAAD	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg22153407	chr1:230290089	GALNT2	0.48	4.77	0.36	4.25e-6	Coronary artery disease;
PAAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.74	-6.08	-0.44	9.42e-9	Neuroticism;
PAAD	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.41	-4.5	-0.34	1.37e-5	Aortic root size;
PAAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	4.99	0.37	1.66e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg11204139	chr17:3907470	NA	-0.7	-7.09	-0.5	4.73e-11	Type 2 diabetes;
PAAD	cis	rs8113142	0.551	rs4130819	chr19:29211026	A/T	cg04546413	chr19:29218101	NA	0.38	4.26	0.33	3.63e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg00262122	chr8:11665843	FDFT1	0.5	4.41	0.34	1.95e-5	Retinal vascular caliber;
PAAD	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.6	-4.43	-0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.7	8.21	0.55	8.81e-14	Height;
PAAD	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.5	-0.41	1.59e-7	IgG glycosylation;
PAAD	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.6	0.35	8.87e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.75	0.36	4.63e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.09	0.38	1.06e-6	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg22800045	chr5:56110881	MAP3K1	-0.58	-4.81	-0.36	3.61e-6	Coronary artery disease;
PAAD	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.08	0.38	1.11e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09018852	chr2:239229201	TRAF3IP1	0.58	6.73	0.48	3.32e-10	Monocyte percentage of white cells;
PAAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.4e-6	Depressive symptoms;
PAAD	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.74	6.77	0.48	2.61e-10	Obesity-related traits;
PAAD	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.63	6.81	0.48	2.08e-10	Colorectal cancer;
PAAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg14440974	chr22:39074834	NA	-0.6	-7.39	-0.51	8.9e-12	Menopause (age at onset);
PAAD	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.42	4.39	0.34	2.15e-5	Facial morphology (factor 20);
PAAD	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.49	5.02	0.38	1.42e-6	Corneal astigmatism;
PAAD	cis	rs432925	0.625	rs2685119	chr16:341476	T/C	cg06233593	chr16:337645	AXIN1	0.47	5.42	0.4	2.3e-7	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg21361702	chr7:150065534	REPIN1	0.59	4.86	0.37	2.93e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs78472555	0.789	rs2603229	chr15:100263499	T/C	cg18869061	chr15:100272053	LYSMD4	0.73	6.11	0.44	7.98e-9	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg23465465	chr6:26364728	BTN3A2	0.77	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.76	0.36	4.45e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.46	4.55	0.35	1.08e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.72	10.25	0.64	4.68e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.56	5.56	0.41	1.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs3134353	0.769	rs7817485	chr8:101969528	T/C	cg04962480	chr8:101962118	YWHAZ	-0.38	-4.3	-0.33	2.99e-5	Body mass index;
PAAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-4.67	-0.35	6.68e-6	Blood metabolite levels;
PAAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.74	-0.36	4.96e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs253959	0.739	rs37181	chr5:115630004	A/C	cg05931423	chr5:115697214	NA	-0.46	-4.34	-0.33	2.57e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs76866386	1.000	rs4953023	chr2:44074000	C/T	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.78	-5.07	-0.38	1.13e-6	Cholesterol, total;
PAAD	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.8	9.23	0.6	2.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg23815491	chr16:72088622	HP	0.49	5.13	0.38	8.86e-7	Fibrinogen levels;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.79	7.61	0.53	2.72e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3785309	0.519	rs55689276	chr16:237453	A/G	cg27201940	chr16:1219628	CACNA1H	0.81	4.45	0.34	1.64e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	1.06	10.64	0.65	4.2e-20	Post bronchodilator FEV1;
PAAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Schizophrenia;
PAAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg13880726	chr7:1868755	MAD1L1	0.45	4.3	0.33	3.03e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg19980929	chr12:42632907	YAF2	0.55	6.37	0.46	2.15e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23671600	chr1:11724392	FBXO6	0.7	7.6	0.52	2.87e-12	Myopia (pathological);
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs6537837	0.838	rs12023950	chr1:110099858	T/C	cg05049280	chr1:110155535	GNAT2	0.46	4.76	0.36	4.51e-6	Major depressive disorder;
PAAD	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg22875332	chr1:76189707	ACADM	-0.47	-4.7	-0.36	5.79e-6	Daytime sleep phenotypes;
PAAD	cis	rs2479106	1.000	rs2479106	chr9:126525212	A/G	cg16191174	chr9:126692580	DENND1A	0.51	4.65	0.35	7.14e-6	Polycystic ovary syndrome;
PAAD	cis	rs350729	0.523	rs62140323	chr2:53176256	T/A	cg07782112	chr2:53107842	NA	-0.39	-4.83	-0.36	3.3e-6	Bronchodilator response in asthma;
PAAD	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.649	rs12617968	chr2:10721945	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	trans	rs9982086	0.557	rs1787440	chr21:27280653	A/C	cg04970570	chr5:87990145	NA	0.66	6.88	0.49	1.44e-10	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.49	4.64	0.35	7.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs2004318	1.000	rs113056067	chr19:55087702	C/T	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs72945132	0.507	rs34612166	chr11:70244400	C/T	cg14191688	chr11:70257035	CTTN	0.55	4.62	0.35	8.24e-6	Coronary artery disease;
PAAD	cis	rs9463078	0.585	rs1285014	chr6:45165225	A/G	cg18551225	chr6:44695536	NA	-0.4	-4.27	-0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.72	6.44	0.46	1.49e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.72	7.13	0.5	3.9e-11	Blood metabolite levels;
PAAD	cis	rs9535307	0.860	rs1127021	chr13:50296115	C/T	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg23306229	chr2:178417860	TTC30B	-0.63	-4.45	-0.34	1.62e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg18612461	chr15:75251733	NA	-0.45	-4.71	-0.36	5.61e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.49	-5.02	-0.38	1.4e-6	Schizophrenia;
PAAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03676636	chr4:99064102	C4orf37	0.33	5.83	0.43	3.14e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.78	-8.72	-0.58	4.62e-15	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15851274	chr15:75748063	SIN3A	-0.63	-6.56	-0.47	8.07e-10	Smoking initiation;
PAAD	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg06217245	chr20:33103252	DYNLRB1	0.44	4.94	0.37	2.04e-6	Height;
PAAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09946346	chr11:65244890	NA	0.66	7.41	0.52	7.95e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.82	8.95	0.59	1.19e-15	Height;
PAAD	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg01620082	chr3:125678407	NA	-1.41	-8.46	-0.57	2.05e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs11668609	0.515	rs61308481	chr19:24065347	C/T	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (docetaxel);
PAAD	cis	rs3736485	0.966	rs7170217	chr15:51890678	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.84e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16104869	chr1:111980075	NA	-0.57	-6.9	-0.49	1.29e-10	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.3	-0.39	4.08e-7	Lung cancer;
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg13263323	chr15:86062960	AKAP13	-0.6	-7.0	-0.49	7.66e-11	Interstitial lung disease;
PAAD	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg04034577	chr2:241836375	C2orf54	-0.34	-5.1	-0.38	1.02e-6	Urinary metabolites;
PAAD	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.53	5.94	0.43	1.9e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.64	-4.65	-0.35	7.04e-6	Blood protein levels;
PAAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.82	7.13	0.5	3.78e-11	Recombination rate (females);
PAAD	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs863345	0.604	rs1578763	chr1:158497414	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	6.58	0.47	7.08e-10	Cognitive test performance;
PAAD	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	11.28	0.68	8.01e-22	Primary sclerosing cholangitis;
PAAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.53	0.34	1.19e-5	Personality dimensions;
PAAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-5.82	-0.43	3.41e-8	Neuroticism;
PAAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.92	11.39	0.68	4.01e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.42	0.34	1.86e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.65	-0.35	7.04e-6	Bipolar disorder;
PAAD	cis	rs2992756	0.663	rs3007734	chr1:18803022	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.39	-4.66	-0.35	6.72e-6	Breast cancer;
PAAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg05484376	chr2:27715224	FNDC4	0.5	5.18	0.39	7.08e-7	Total body bone mineral density;
PAAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.41	0.46	1.78e-9	Personality dimensions;
PAAD	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs9899728	0.539	rs35928207	chr17:73033629	T/G	cg27626185	chr17:73056755	KCTD2	-1.15	-7.74	-0.53	1.31e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.2	0.39	6.38e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg02776659	chr21:47717406	C21orf57	-0.45	-4.92	-0.37	2.27e-6	Testicular germ cell tumor;
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.27	-0.67	8.44e-22	Total body bone mineral density;
PAAD	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.56	-5.42	-0.4	2.33e-7	Red cell distribution width;
PAAD	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg25122841	chr14:24911839	SDR39U1	0.5	4.27	0.33	3.46e-5	IgG glycosylation;
PAAD	cis	rs7210086	0.730	rs76126194	chr17:70638724	G/A	cg04206342	chr17:70636940	NA	-0.44	-5.42	-0.4	2.3e-7	Ulcerative colitis;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs7243821	0.921	rs1944360	chr18:52623560	C/T	cg16669619	chr18:52630472	NA	-0.59	-6.08	-0.44	9.36e-9	Chin dimples;
PAAD	cis	rs2275731	0.505	rs7894216	chr10:16479251	C/G	cg04254609	chr10:16479192	PTER	-0.55	-6.03	-0.44	1.22e-8	Bone fracture in osteoporosis;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg26939375	chr7:64535504	NA	-0.75	-9.06	-0.59	6.19e-16	Aortic root size;
PAAD	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg03983476	chr2:10830698	NOL10	0.54	5.39	0.4	2.68e-7	Prostate cancer;
PAAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs16975963	0.644	rs2290999	chr19:38138887	T/C	cg14218481	chr19:38281219	NA	0.43	4.62	0.35	8.22e-6	Longevity;
PAAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.11	-0.63	1.1e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.56	5.82	0.43	3.36e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg27449745	chr7:23145252	KLHL7	-0.54	-4.86	-0.37	2.9e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs78761021	0.898	rs62066046	chr17:9767181	A/G	cg26853458	chr17:9805074	RCVRN	0.7	8.14	0.55	1.31e-13	Type 2 diabetes;
PAAD	cis	rs6921919	0.789	rs6456814	chr6:28305812	C/A	cg23153227	chr6:27725408	NA	0.5	4.35	0.33	2.45e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs11669133	1.000	rs11669133	chr19:11092139	A/G	cg25243385	chr19:11167475	SMARCA4	-1.04	-5.34	-0.4	3.35e-7	LDL cholesterol;
PAAD	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.2	0.6	2.57e-16	Hemoglobin concentration;
PAAD	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg09473613	chr1:24152604	HMGCL	-0.55	-5.66	-0.42	7.32e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg23311950	chr12:74931760	LOC552889	-0.56	-6.44	-0.46	1.46e-9	Body fat percentage;
PAAD	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	5.81	0.43	3.62e-8	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs73019876	0.869	rs1987974	chr19:22158402	T/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-6.7	-0.48	3.77e-10	Morning vs. evening chronotype;
PAAD	cis	rs35740288	0.770	rs11635587	chr15:86173633	C/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg19980929	chr12:42632907	YAF2	-0.58	-6.86	-0.49	1.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg05785598	chr3:49045655	WDR6	0.43	5.03	0.38	1.4e-6	Parkinson's disease;
PAAD	cis	rs17155006	0.655	rs380046	chr7:107728315	A/G	cg05962710	chr7:107745446	LAMB4	-0.45	-5.52	-0.41	1.42e-7	Pneumococcal bacteremia;
PAAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.64	-6.51	-0.47	1.02e-9	Menopause (age at onset);
PAAD	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	1.08	15.2	0.78	2.63e-32	Breast cancer;
PAAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.74	9.05	0.59	6.5e-16	Methadone dose in opioid dependence;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.51	-4.85	-0.37	3.08e-6	Mean platelet volume;
PAAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23158103	chr7:148848205	ZNF398	-0.51	-4.62	-0.35	8.13e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs11807834	0.522	rs6697219	chr1:230248266	G/A	cg00566187	chr1:230250356	GALNT2	-0.66	-7.05	-0.5	5.72e-11	Schizophrenia;
PAAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.71	-0.48	3.53e-10	IgG glycosylation;
PAAD	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg15654264	chr1:150340011	RPRD2	-0.5	-4.81	-0.36	3.55e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7539542	0.556	rs1042990	chr1:202861566	C/T	cg19681188	chr1:202830198	LOC148709	-0.47	-4.65	-0.35	7.08e-6	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03737984	chr11:33280157	HIPK3	0.59	6.71	0.48	3.71e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs57244997	0.725	rs7746243	chr6:162436437	G/C	cg17173639	chr6:162384350	PARK2	-0.66	-5.17	-0.39	7.29e-7	Mosquito bite size;
PAAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.72	0.36	5.23e-6	Breast cancer;
PAAD	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.19	-0.45	5.27e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg10434728	chr15:90938212	IQGAP1	-0.5	-5.1	-0.38	1.02e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg14191688	chr11:70257035	CTTN	0.67	5.67	0.42	7.08e-8	Coronary artery disease;
PAAD	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg23306229	chr2:178417860	TTC30B	-0.65	-4.48	-0.34	1.45e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-5.13	-0.38	8.54e-7	Menarche (age at onset);
PAAD	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.89	-7.36	-0.51	1.08e-11	Eotaxin levels;
PAAD	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.62	8.09	0.55	1.79e-13	Crohn's disease;
PAAD	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.49	5.2	0.39	6.46e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs258892	0.841	rs1598010	chr5:72075374	G/A	cg21869765	chr5:72125136	TNPO1	-0.79	-5.3	-0.39	4.01e-7	Small cell lung carcinoma;
PAAD	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.31	-0.51	1.42e-11	Neuroticism;
PAAD	trans	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg05163071	chr3:108476540	RETNLB	0.96	6.84	0.49	1.86e-10	Dental caries;
PAAD	cis	rs10267417	0.584	rs10247789	chr7:19863570	G/C	cg05791153	chr7:19748676	TWISTNB	0.74	5.0	0.38	1.55e-6	Night sleep phenotypes;
PAAD	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.68	6.9	0.49	1.33e-10	Platelet distribution width;
PAAD	cis	rs9558996	0.638	rs78710634	chr13:107937264	T/C	cg09252360	chr13:107220595	ARGLU1	0.56	4.55	0.35	1.11e-5	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.69	7.3	0.51	1.53e-11	Triglyceride levels;
PAAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.44e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg00280220	chr17:61926910	NA	0.44	4.65	0.35	7.23e-6	Prudent dietary pattern;
PAAD	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9341808	0.556	rs1535075	chr6:81034806	A/G	cg08355045	chr6:80787529	NA	0.43	5.33	0.4	3.5e-7	Sitting height ratio;
PAAD	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-8.3	-0.56	5.15e-14	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.84	-10.29	-0.64	3.47e-19	Height;
PAAD	cis	rs11134654	0.627	rs4868033	chr5:170234264	A/T	cg01579024	chr5:170288757	RANBP17	0.6	4.76	0.36	4.48e-6	Smooth-surface caries;
PAAD	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg22705602	chr4:152727874	NA	-0.48	-5.18	-0.39	7.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.96	10.87	0.66	9.9e-21	Myeloid white cell count;
PAAD	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-4.29	-0.33	3.14e-5	Tonsillectomy;
PAAD	cis	rs478222	1.000	rs567359	chr2:25304574	C/T	cg01884057	chr2:25150051	NA	0.39	4.65	0.35	7.21e-6	Type 1 diabetes;
PAAD	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17467752	chr17:38218738	THRA	0.53	4.7	0.36	5.76e-6	Asthma;
PAAD	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05025164	chr4:1340916	KIAA1530	0.57	5.56	0.41	1.19e-7	Obesity-related traits;
PAAD	cis	rs151997	0.671	rs493507	chr5:50219675	G/T	cg06027927	chr5:50259733	NA	-0.66	-6.61	-0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16106770	chr11:120206550	ARHGEF12	0.7	7.6	0.52	2.78e-12	Myopia (pathological);
PAAD	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.46	4.56	0.35	1.06e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg15309053	chr8:964076	NA	0.49	5.48	0.41	1.72e-7	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.55	5.88	0.43	2.52e-8	Menopause (age at onset);
PAAD	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.94	0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg17127132	chr2:85788382	GGCX	0.46	4.47	0.34	1.53e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.45	-0.34	1.63e-5	Breast cancer;
PAAD	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.67	5.56	0.41	1.2e-7	Common traits (Other);
PAAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg25811867	chr2:3488468	NA	0.42	4.32	0.33	2.85e-5	Neurofibrillary tangles;
PAAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.6	-7.2	-0.5	2.62e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4823006	0.901	rs12321	chr22:29453193	G/C	cg23896685	chr22:29451551	ZNRF3	0.57	5.9	0.43	2.29e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.07	-0.44	9.92e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg10621924	chr7:39171070	POU6F2	0.28	4.44	0.34	1.7e-5	IgG glycosylation;
PAAD	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.51	4.92	0.37	2.22e-6	Malaria;
PAAD	cis	rs3737883	1.000	rs4950913	chr1:203032153	A/G	cg03900565	chr1:203031815	PPFIA4	0.34	5.59	0.41	1.04e-7	Early onset atrial fibrillation;
PAAD	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	1.0	13.51	0.74	7.81e-28	Heart rate;
PAAD	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.02	0.5	6.74e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.55	0.57	1.2e-14	Alzheimer's disease;
PAAD	cis	rs6142102	0.651	rs6119463	chr20:32737218	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.47	-4.64	-0.35	7.47e-6	Skin pigmentation;
PAAD	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.2	0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.69	0.42	6.33e-8	Prudent dietary pattern;
PAAD	cis	rs990171	0.687	rs9989842	chr2:103123633	C/G	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.88	-11.01	-0.67	4.14e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg16386425	chr10:429943	DIP2C	-0.41	-4.31	-0.33	2.96e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.52	-5.14	-0.38	8.46e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.46	0.34	1.56e-5	Menarche (age at onset);
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.16e-6	Life satisfaction;
PAAD	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2278796	0.639	rs11240330	chr1:204968258	C/A	cg17947172	chr1:204966197	NFASC	0.41	4.4	0.34	2.01e-5	Mean platelet volume;
PAAD	cis	rs17601876	0.814	rs11636639	chr15:51563092	T/G	cg19946085	chr15:51559439	CYP19A1	-0.46	-4.29	-0.33	3.19e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.38	-0.4	2.72e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs2085601	0.542	rs938266	chr4:89991395	C/T	cg17769793	chr4:89976368	FAM13A	-0.45	-5.63	-0.42	8.41e-8	Hair greying;
PAAD	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg18005901	chr6:33739558	LEMD2	0.53	4.35	0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.78	11.11	0.67	2.23e-21	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg03732007	chr1:2071316	PRKCZ	-0.47	-5.02	-0.38	1.45e-6	Height;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg10351095	chr21:47802916	PCNT	0.5	4.88	0.37	2.65e-6	Testicular germ cell tumor;
PAAD	cis	rs4352210	0.610	rs6712065	chr2:37775964	T/A	cg12040278	chr2:37572396	QPCT	0.51	4.41	0.34	1.97e-5	RR interval (heart rate);
PAAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.44	0.52	6.9e-12	IgG glycosylation;
PAAD	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.63	-7.59	-0.52	3.01e-12	HDL cholesterol;
PAAD	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.59	5.68	0.42	6.64e-8	Graves' disease;
PAAD	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.37	-0.4	2.84e-7	Daytime sleep phenotypes;
PAAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg23463467	chr20:60627584	TAF4	0.4	4.36	0.33	2.37e-5	Body mass index;
PAAD	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.52	4.58	0.35	9.47e-6	Lymphocyte counts;
PAAD	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	4.68	0.35	6.43e-6	Iron status biomarkers;
PAAD	cis	rs1075265	0.749	rs10203095	chr2:53964287	T/C	cg04546899	chr2:54196757	PSME4	0.3	4.53	0.34	1.2e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.74	7.48	0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.34	0.33	2.64e-5	Self-reported allergy;
PAAD	cis	rs10267417	0.657	rs28833898	chr7:19861022	G/A	cg05791153	chr7:19748676	TWISTNB	0.79	5.02	0.38	1.44e-6	Night sleep phenotypes;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs831571	1.000	rs166230	chr3:64053207	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.6	5.02	0.38	1.43e-6	Type 2 diabetes;
PAAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	5.44	0.4	2.06e-7	Monocyte count;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg11062466	chr8:58055876	NA	0.65	4.67	0.35	6.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12304921	0.935	rs11169627	chr12:51348450	G/A	cg04427360	chr12:51347099	HIGD1C	-0.68	-5.19	-0.39	6.77e-7	Type 2 diabetes;
PAAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.78	8.56	0.57	1.19e-14	Total body bone mineral density;
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs988913	0.647	rs4715519	chr6:54988593	T/A	cg03513858	chr6:54763001	FAM83B	0.4	4.35	0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.94	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.97	11.14	0.67	1.9e-21	Parkinson's disease;
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg02869306	chr7:64672164	INTS4L1	-0.5	-6.06	-0.44	1.05e-8	Calcium levels;
PAAD	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	6.66	0.48	4.62e-10	Body mass index;
PAAD	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	6.34	0.46	2.43e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.76	5.35	0.4	3.16e-7	Cannabis dependence symptom count;
PAAD	cis	rs79146658	0.736	rs4637162	chr2:179736012	T/C	cg17765952	chr2:179737173	CCDC141	0.63	4.72	0.36	5.37e-6	Diastolic blood pressure;
PAAD	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg19875578	chr6:126661172	C6orf173	0.52	5.44	0.4	2.1e-7	Male-pattern baldness;
PAAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg05725404	chr16:58534157	NDRG4	-0.77	-4.67	-0.35	6.52e-6	Schizophrenia;
PAAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	8.38	0.56	3.26e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs617219	0.710	rs6874525	chr5:78574237	C/T	cg24856658	chr5:78533917	JMY	0.4	4.38	0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.8	5.67	0.42	7.12e-8	Coronary artery calcification;
PAAD	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg23719950	chr11:63933701	MACROD1	-0.7	-4.91	-0.37	2.28e-6	Mean platelet volume;
PAAD	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.61	5.9	0.43	2.24e-8	Menopause (age at onset);
PAAD	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.64	6.16	0.45	6.16e-9	Coronary artery disease;
PAAD	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.9	-10.49	-0.65	1.06e-19	Refractive error;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.55e-7	Prudent dietary pattern;
PAAD	cis	rs6782025	0.737	rs787851	chr3:120936915	T/C	cg16417163	chr3:121280760	NA	-0.46	-4.73	-0.36	5.08e-6	Aging (facial);
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg14008862	chr17:28927542	LRRC37B2	0.83	5.48	0.41	1.71e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs59888335	0.862	rs6781254	chr3:80649139	A/G	cg21735741	chr3:80819488	NA	-0.59	-5.02	-0.38	1.44e-6	Schizophrenia;
PAAD	cis	rs6142102	0.625	rs1883706	chr20:32552877	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg10223061	chr2:219282414	VIL1	-0.44	-4.7	-0.36	5.74e-6	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs795484	0.856	rs1699160	chr12:118756336	C/A	cg16572268	chr12:118583242	PEBP1	-0.48	-4.66	-0.35	6.95e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs11235843	0.929	rs66481935	chr11:73380323	A/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-4.46	-0.34	1.57e-5	Major depressive disorder;
PAAD	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.73	-5.65	-0.42	7.57e-8	Bone mineral density (spine);
PAAD	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-6.67	-0.48	4.41e-10	Glomerular filtration rate;
PAAD	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-1.26	-11.2	-0.67	1.31e-21	Obesity-related traits;
PAAD	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg08632701	chr21:37451849	NA	-0.63	-6.91	-0.49	1.23e-10	Mitral valve prolapse;
PAAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.93	-8.28	-0.56	5.9e-14	Diastolic blood pressure;
PAAD	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.57	4.62	0.35	8.03e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.41	-4.46	-0.34	1.61e-5	Aortic root size;
PAAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	trans	rs12127679	0.614	rs12062118	chr1:244171363	A/G	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.66	7.7	0.53	1.64e-12	Colorectal cancer;
PAAD	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4668356	1.000	rs73013436	chr2:171990335	A/T	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	cis	rs2120243	0.538	rs4680360	chr3:157094479	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.45	-4.61	-0.35	8.35e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg16031515	chr1:205743344	RAB7L1	-0.42	-5.0	-0.38	1.57e-6	Menarche (age at onset);
PAAD	cis	rs2645694	0.569	rs11097584	chr4:77836059	C/T	cg03477792	chr4:77819574	ANKRD56	0.71	5.93	0.43	1.98e-8	Emphysema distribution in smoking;
PAAD	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.4	3.93e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25685456	chr6:143269881	NA	0.56	6.54	0.47	9.06e-10	Body fat percentage;
PAAD	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg05250797	chr16:70222502	NA	0.87	6.69	0.48	4.06e-10	IgE levels;
PAAD	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg06917450	chr1:38156652	C1orf109	-0.51	-4.48	-0.34	1.49e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.4	0.34	2.01e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2440012	0.543	rs73167586	chr13:19426433	A/C	cg08120511	chr13:19412184	LOC284232	-0.69	-4.25	-0.33	3.78e-5	Longevity;
PAAD	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.61	4.53	0.35	1.16e-5	Thyroid stimulating hormone;
PAAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.8	-10.07	-0.63	1.38e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00806126	chr19:22604979	ZNF98	-0.39	-4.94	-0.37	2e-6	Pain;
PAAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.59	-0.41	1.02e-7	Coronary artery disease;
PAAD	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06634786	chr22:41940651	POLR3H	-0.62	-4.99	-0.38	1.62e-6	Vitiligo;
PAAD	cis	rs743757	0.557	rs2236950	chr3:50420554	C/A	cg27149285	chr3:50375164	RASSF1	0.63	4.61	0.35	8.51e-6	Diastolic blood pressure;
PAAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	1.17	6.97	0.49	9.16e-11	Skin colour saturation;
PAAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	8.9	0.59	1.53e-15	Lymphocyte counts;
PAAD	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.71	5.8	0.43	3.73e-8	Mammographic density (dense area);
PAAD	cis	rs7107174	0.901	rs7937277	chr11:78114977	C/G	cg02023728	chr11:77925099	USP35	0.52	4.71	0.36	5.49e-6	Testicular germ cell tumor;
PAAD	cis	rs1015291	0.828	rs2638436	chr12:20003805	A/G	cg25401612	chr12:20009446	NA	0.51	4.98	0.37	1.68e-6	Diastolic blood pressure;
PAAD	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.27	7.91	0.54	4.92e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02344857	chr2:242448155	STK25	0.56	6.44	0.46	1.48e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.59	5.51	0.41	1.5e-7	Sudden cardiac arrest;
PAAD	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	1.2	10.22	0.64	5.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.86	-9.51	-0.61	4.03e-17	Morning vs. evening chronotype;
PAAD	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.6e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg16606324	chr3:10149918	C3orf24	0.68	5.34	0.4	3.4e-7	Alzheimer's disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03797305	chr16:30209202	SULT1A3;SULT1A4	0.58	6.35	0.46	2.32e-9	Pancreatic cancer;
PAAD	cis	rs797680	0.856	rs9432681	chr1:93761896	A/G	cg04535902	chr1:92947332	GFI1	-0.45	-4.46	-0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg08975724	chr8:8085496	FLJ10661	0.74	7.26	0.51	1.82e-11	Mood instability;
PAAD	cis	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg19129842	chr3:128565090	NA	-0.71	-4.26	-0.33	3.51e-5	Dental caries;
PAAD	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26926768	chr12:34528122	NA	0.39	4.63	0.35	7.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.6	0.52	2.84e-12	Platelet distribution width;
PAAD	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.48	-4.28	-0.33	3.23e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-6.28	-0.45	3.34e-9	Crohn's disease;
PAAD	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.7	-5.8	-0.43	3.66e-8	Exhaled nitric oxide output;
PAAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg10207240	chr12:122356781	WDR66	-0.48	-4.95	-0.37	1.91e-6	Mean corpuscular volume;
PAAD	cis	rs11191270	0.784	rs11191264	chr10:104096732	A/T	cg15320455	chr10:103880129	LDB1	0.56	4.83	0.36	3.37e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18108499	chr4:106629741	INTS12;GSTCD	0.63	6.6	0.47	6.46e-10	Myopia (pathological);
PAAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg19445457	chr11:5799446	OR52N5	-0.51	-4.55	-0.35	1.08e-5	DNA methylation (variation);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12104764	chr12:110011362	MMAB;MVK	0.62	7.02	0.49	6.84e-11	Monocyte percentage of white cells;
PAAD	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.69	7.26	0.51	1.91e-11	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20541120	chr2:33151749	LOC100271832;LOC285045	-0.65	-6.8	-0.48	2.24e-10	Obesity-related traits;
PAAD	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.86	0.62	4.87e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.5	-4.99	-0.38	1.61e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-1.08	-9.51	-0.61	3.98e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg13377237	chr1:149899427	SF3B4	0.47	4.29	0.33	3.14e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25930340	chr5:179160251	MAML1	-0.79	-7.07	-0.5	5.31e-11	Neuroticism;
PAAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.76	9.73	0.62	1.06e-17	Urinary electrolytes (magnesium/calcium ratio);
PAAD	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.93	-9.31	-0.6	1.34e-16	Obesity-related traits;
PAAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg10645314	chr2:3704589	ALLC	-0.43	-4.55	-0.35	1.08e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00250524	chr16:85722685	GINS2	0.57	6.35	0.46	2.4e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg20913747	chr6:44695427	NA	-0.54	-4.77	-0.36	4.2e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.1	-0.38	9.92e-7	Subjective well-being;
PAAD	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.52	-4.61	-0.35	8.52e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg23887609	chr12:130822674	PIWIL1	-0.6	-6.59	-0.47	6.68e-10	Menopause (age at onset);
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	11.34	0.68	5.65e-22	Primary sclerosing cholangitis;
PAAD	cis	rs12431939	0.598	rs4268678	chr14:51736185	G/T	cg23942311	chr14:51606299	NA	0.53	5.0	0.38	1.58e-6	Cancer;
PAAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.61	6.28	0.45	3.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg18451016	chr1:38461880	NA	0.52	6.2	0.45	5.2e-9	Coronary artery disease;
PAAD	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.11e-13	Dupuytren's disease;
PAAD	trans	rs901683	0.850	rs76395348	chr10:46082064	T/C	cg11747279	chr17:21096632	NA	0.9	6.5	0.47	1.08e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg11630242	chr17:19881632	AKAP10	-0.49	-4.52	-0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	1.05	8.69	0.58	5.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4851870	0.581	rs3754802	chr2:106489395	C/T	cg21551182	chr2:106399873	NCK2	-0.43	-4.35	-0.33	2.53e-5	Addiction;
PAAD	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.87e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-4.74	-0.36	4.95e-6	Bipolar disorder;
PAAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.63	6.73	0.48	3.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs66530629	0.874	rs4562565	chr1:25121874	A/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.6	-0.35	8.8e-6	Plateletcrit;
PAAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11191193	0.935	rs3740422	chr10:103565960	G/C	cg11685391	chr10:103594334	KCNIP2	-0.33	-4.32	-0.33	2.78e-5	Educational attainment;
PAAD	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg00717180	chr2:96193071	NA	-0.63	-7.62	-0.53	2.56e-12	Height;
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg23387401	chr17:4582204	PELP1	0.51	5.03	0.38	1.37e-6	Lymphocyte counts;
PAAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	6.77	0.48	2.63e-10	Body mass index;
PAAD	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.7	7.0	0.49	7.68e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.64	0.53	2.23e-12	Renal function-related traits (BUN);
PAAD	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.53	-6.96	-0.49	9.75e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg09754948	chr16:28834200	ATXN2L	0.53	5.19	0.39	6.73e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.39	-4.53	-0.34	1.19e-5	Intelligence;
PAAD	cis	rs13102973	0.720	rs7672296	chr4:135890056	C/G	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.48	-6.1	-0.44	8.49e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.66	-6.12	-0.44	7.8e-9	Diisocyanate-induced asthma;
PAAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg12639453	chr1:2035780	PRKCZ	0.52	5.52	0.41	1.44e-7	Height;
PAAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg18016565	chr1:150552671	MCL1	-0.55	-5.54	-0.41	1.29e-7	Urate levels;
PAAD	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg26898376	chr11:64110657	CCDC88B	0.43	4.49	0.34	1.41e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg19337854	chr7:99768885	GPC2	0.52	4.91	0.37	2.36e-6	Platelet count;
PAAD	cis	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg05134918	chr12:132603531	EP400NL	-0.61	-4.98	-0.37	1.68e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.52	5.19	0.39	6.51e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs7301826	0.610	rs9668291	chr12:131296908	C/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	1.02	6.73	0.48	3.17e-10	Fat distribution (HIV);
PAAD	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg20913747	chr6:44695427	NA	-0.64	-5.99	-0.44	1.46e-8	Total body bone mineral density;
PAAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.44	4.67	0.35	6.47e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.45	0.4	1.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg09796270	chr17:17721594	SREBF1	-0.42	-4.51	-0.34	1.26e-5	Total body bone mineral density;
PAAD	cis	rs1894633	0.582	rs9425627	chr1:172451408	G/A	cg13446689	chr1:172328377	DNM3	-0.44	-5.36	-0.4	3.01e-7	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.59	-5.33	-0.4	3.57e-7	Lung cancer;
PAAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	7.9	0.54	5.25e-13	Eotaxin levels;
PAAD	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.11e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.89	10.89	0.66	9.12e-21	Prudent dietary pattern;
PAAD	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.44	-0.46	1.46e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg24147428	chr11:65409760	SIPA1	-0.49	-5.11	-0.38	9.42e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg04359915	chr10:101825029	CPN1	-0.33	-5.32	-0.4	3.61e-7	Bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26682510	chr14:32546457	ARHGAP5;C14orf128	-0.67	-7.03	-0.5	6.67e-11	Smoking initiation;
PAAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg00450029	chr8:599525	NA	0.88	5.56	0.41	1.19e-7	IgG glycosylation;
PAAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg00262122	chr8:11665843	FDFT1	0.5	4.41	0.34	1.95e-5	Retinal vascular caliber;
PAAD	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.71	-8.5	-0.57	1.62e-14	Hand grip strength;
PAAD	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.44	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.48	5.34	0.4	3.29e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	7.69	0.53	1.68e-12	Alzheimer's disease;
PAAD	cis	rs939584	1.000	rs7574359	chr2:652542	T/C	cg03610516	chr2:642275	NA	-0.61	-5.65	-0.42	7.71e-8	Body mass index;
PAAD	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.57	6.06	0.44	1.03e-8	Bone mineral density;
PAAD	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11320690	chr20:17550474	DSTN	0.68	6.56	0.47	7.98e-10	Obesity-related traits;
PAAD	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.33	-0.33	2.67e-5	Educational attainment;
PAAD	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.83	5.36	0.4	2.97e-7	Systolic blood pressure;
PAAD	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.83	9.14	0.6	3.79e-16	Mortality in heart failure;
PAAD	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.74	-0.48	3.06e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	1.05	6.41	0.46	1.75e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	10.37	0.64	2.24e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs72960926	1.000	rs72969274	chr6:75089862	G/A	cg03266952	chr6:74778945	NA	-0.99	-5.26	-0.39	4.8e-7	Metabolite levels (MHPG);
PAAD	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.53	4.84	0.37	3.11e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13983578	chr8:29208153	DUSP4	0.59	6.49	0.47	1.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8102137	1.000	rs59868991	chr19:30297577	G/A	cg27475126	chr19:30303651	CCNE1	-0.46	-5.1	-0.38	1e-6	Bladder cancer;
PAAD	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg19767477	chr5:127420684	SLC12A2	-0.55	-4.44	-0.34	1.7e-5	Ileal carcinoids;
PAAD	cis	rs727479	0.502	rs7180552	chr15:51506768	T/G	cg21478137	chr15:51532386	CYP19A1	0.43	4.32	0.33	2.85e-5	Estradiol levels;
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.58	-0.47	7.23e-10	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13341536	chr3:56590940	CCDC66	0.63	6.3	0.46	3.01e-9	Obesity-related traits;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.6	5.55	0.41	1.25e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg02683114	chr2:24398427	C2orf84	0.63	7.05	0.5	5.94e-11	Asthma;
PAAD	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.5	0.47	1.11e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.75	7.97	0.54	3.54e-13	Uric acid levels;
PAAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14180030	chr9:123475675	MEGF9	-0.44	-4.91	-0.37	2.38e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	1.15	12.81	0.72	6.19e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26926768	chr12:34528122	NA	-0.38	-4.68	-0.35	6.34e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.58	6.18	0.45	5.64e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.67	7.0	0.49	7.62e-11	Multiple sclerosis;
PAAD	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg12568669	chr8:11666485	FDFT1	-0.3	-5.15	-0.39	7.85e-7	Myopia (pathological);
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.13e-7	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-5.69	-0.42	6.41e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1413885	1.000	rs1536173	chr1:65813477	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.48	-4.41	-0.34	1.93e-5	Anticoagulant levels;
PAAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.56	-5.14	-0.38	8.49e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg07169764	chr2:136633963	MCM6	0.74	7.31	0.51	1.38e-11	Mosquito bite size;
PAAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.73	-11.1	-0.67	2.4e-21	Body mass index;
PAAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg09654669	chr8:57350985	NA	-0.57	-5.12	-0.38	9.01e-7	Obesity-related traits;
PAAD	cis	rs939584	0.778	rs12992154	chr2:632300	G/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.73	-7.39	-0.51	8.87e-12	Colorectal cancer;
PAAD	cis	rs11588062	0.745	rs5019033	chr1:46735072	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.48	4.32	0.33	2.81e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.8	-0.53	9.03e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg14709524	chr16:89940631	TCF25	0.76	4.34	0.33	2.6e-5	Skin colour saturation;
PAAD	cis	rs5758511	0.573	rs1883205	chr22:42243020	A/G	cg03131358	chr22:42195972	CCDC134	-0.45	-4.75	-0.36	4.63e-6	Birth weight;
PAAD	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-4.46	-0.34	1.56e-5	Height;
PAAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05564831	chr3:52568323	NT5DC2	0.46	5.05	0.38	1.24e-6	Bipolar disorder;
PAAD	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.79	-0.53	9.64e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg08888203	chr3:10149979	C3orf24	0.72	6.34	0.46	2.52e-9	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01221207	chr20:33680493	TRPC4AP	0.64	7.09	0.5	4.66e-11	Monocyte percentage of white cells;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	6.06	0.44	1.03e-8	Renal function-related traits (BUN);
PAAD	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.03	0.38	1.34e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.42	-4.35	-0.33	2.53e-5	Plateletcrit;
PAAD	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19386159	chr12:109125243	CORO1C	-0.72	-6.31	-0.46	2.91e-9	Neuroticism;
PAAD	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.58	-6.03	-0.44	1.2e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.65	-7.03	-0.5	6.42e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.58	-6.21	-0.45	4.76e-9	Pelvic organ prolapse;
PAAD	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.4	0.34	2.04e-5	Educational attainment (years of education);
PAAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs58521262	0.556	rs2101921	chr19:23194587	T/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.94	8.08	0.55	1.82e-13	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.38	-4.85	-0.37	3.06e-6	Colorectal cancer;
PAAD	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg05925327	chr15:68127851	NA	-0.56	-5.05	-0.38	1.26e-6	Restless legs syndrome;
PAAD	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.87	0.49	1.54e-10	Resting heart rate;
PAAD	cis	rs593531	0.513	rs7944333	chr11:74022429	C/T	cg15851278	chr11:73669449	DNAJB13	0.39	4.86	0.37	2.93e-6	Neuroticism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07202532	chr17:29814621	RAB11FIP4	-0.67	-6.38	-0.46	2.04e-9	Lung cancer in ever smokers;
PAAD	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9463078	0.546	rs1284982	chr6:45081821	C/T	cg18551225	chr6:44695536	NA	0.44	4.58	0.35	9.62e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.54	-6.21	-0.45	4.89e-9	Vitiligo;
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	10.17	0.64	7.24e-19	Platelet count;
PAAD	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.84	-5.95	-0.43	1.82e-8	Gallbladder cancer;
PAAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg23188684	chr11:67383651	NA	0.48	4.97	0.37	1.75e-6	Mean corpuscular volume;
PAAD	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg19744528	chr7:157553346	PTPRN2	0.4	4.27	0.33	3.46e-5	Body mass index;
PAAD	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg06606381	chr12:133084897	FBRSL1	-1.31	-8.17	-0.55	1.09e-13	Depression;
PAAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg19423196	chr10:82049429	MAT1A	0.61	4.69	0.36	6.03e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.69	-0.36	6.05e-6	Mean corpuscular volume;
PAAD	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.58	-6.78	-0.48	2.49e-10	Coronary artery disease;
PAAD	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg22153407	chr1:230290089	GALNT2	0.5	5.19	0.39	6.61e-7	Coronary artery disease;
PAAD	cis	rs2327429	0.858	rs2209042	chr6:134188439	A/T	cg06296503	chr6:134217401	NA	0.48	4.93	0.37	2.16e-6	Coronary artery disease;
PAAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	6.12	0.44	7.72e-9	Mood instability;
PAAD	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.32	0.51	1.31e-11	Obesity-related traits;
PAAD	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.95	-0.49	9.97e-11	Eye color traits;
PAAD	cis	rs507080	0.922	rs533646	chr11:118566746	C/G	cg08498647	chr11:118550644	TREH	-0.38	-4.31	-0.33	2.96e-5	Serum metabolite levels;
PAAD	cis	rs6908034	0.607	rs112824001	chr6:19804691	C/T	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.75	-0.42	4.65e-8	Tonsillectomy;
PAAD	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-5.09	-0.38	1.04e-6	Height;
PAAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2730260	0.734	rs3793217	chr7:158848821	C/T	cg02254261	chr7:158964346	NA	0.57	4.56	0.35	1.04e-5	Myopia (pathological);
PAAD	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.54	-7.42	-0.52	7.7e-12	Electrocardiographic conduction measures;
PAAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.13	-0.38	8.88e-7	Schizophrenia;
PAAD	cis	rs131777	0.508	rs140518	chr22:50999182	C/T	cg05418105	chr22:50981406	NA	-0.8	-7.45	-0.52	6.69e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-1.05	-11.57	-0.68	1.3e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.86	-5.12	-0.38	9.07e-7	Cholesterol, total;
PAAD	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.28	-0.71	1.6e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg15733309	chr7:157513707	PTPRN2	0.64	8.01	0.54	2.76e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.02	-17.58	-0.82	1.85e-38	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00761861	chr14:68141669	VTI1B	0.67	6.56	0.47	7.88e-10	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07973140	chr15:75495174	C15orf39	-0.68	-6.73	-0.48	3.33e-10	Smoking initiation;
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03605463	chr16:89740564	NA	-0.49	-4.62	-0.35	8.23e-6	Vitiligo;
PAAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg14340114	chr7:124570081	POT1	-0.61	-6.29	-0.45	3.13e-9	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg20893579	chr22:38215064	NA	-0.48	-4.88	-0.37	2.66e-6	Glioblastoma;Glioma;
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.54	-0.41	1.31e-7	Mood instability;
PAAD	cis	rs6594713	0.879	rs13189910	chr5:112740153	G/A	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs3112530	1.000	rs304862	chr5:152719722	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2718812	0.792	rs1867504	chr3:133410661	C/T	cg11941060	chr3:133502564	NA	-0.48	-5.0	-0.38	1.56e-6	Iron status biomarkers;
PAAD	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7765175	0.698	rs6905600	chr6:113668457	G/T	cg19037598	chr6:113666021	NA	-0.41	-4.38	-0.33	2.24e-5	Coronary artery calcification;
PAAD	cis	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26926768	chr12:34528122	NA	0.36	4.26	0.33	3.51e-5	Morning vs. evening chronotype;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15529290	chr4:75480864	AREG	-0.56	-6.46	-0.46	1.33e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10186876	0.833	rs4953040	chr2:44178034	T/C	cg09541576	chr2:44873248	C2orf34	-0.47	-4.99	-0.38	1.65e-6	Hand grip strength;
PAAD	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg15764593	chr10:829463	NA	-0.88	-4.56	-0.35	1.06e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25202662	chr11:61106844	DAK	0.57	6.94	0.49	1.09e-10	Body fat percentage;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-5.02	-0.38	1.43e-6	Mean corpuscular volume;
PAAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.56	0.47	7.9e-10	Personality dimensions;
PAAD	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09065629	chr16:1709722	CRAMP1L	0.49	5.27	0.39	4.67e-7	Coronary artery disease;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg10729496	chr3:10149963	C3orf24	0.66	5.55	0.41	1.25e-7	Alzheimer's disease;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg01966878	chr4:90757139	SNCA	0.6	4.55	0.35	1.09e-5	Neuroticism;
PAAD	cis	rs7714584	1.000	rs79442859	chr5:150171210	T/C	cg22134413	chr5:150180641	NA	0.96	6.38	0.46	2.03e-9	Crohn's disease;
PAAD	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.47	4.55	0.35	1.11e-5	HDL cholesterol;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23039201	chr2:27851887	GPN1;CCDC121	0.54	6.47	0.46	1.24e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.84	7.5	0.52	5.07e-12	Cleft lip with or without cleft palate;
PAAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.59	-5.63	-0.42	8.36e-8	Obesity;
PAAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-0.96	-6.5	-0.47	1.09e-9	Breast cancer;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	1.02	6.73	0.48	3.24e-10	Fat distribution (HIV);
PAAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.55	7.34	0.51	1.19e-11	Renal cell carcinoma;
PAAD	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg10589385	chr1:150898437	SETDB1	0.36	4.28	0.33	3.33e-5	Melanoma;
PAAD	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.94	-0.49	1.08e-10	Triglycerides;
PAAD	cis	rs11264213	0.901	rs663163	chr1:36390527	A/G	cg27506609	chr1:36549197	TEKT2	0.73	5.07	0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg14500267	chr11:67383377	NA	0.43	4.3	0.33	2.99e-5	Mean corpuscular volume;
PAAD	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-9.32	-0.6	1.24e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.78	-0.72	7.34e-26	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.4	10.89	0.66	8.85e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-4.5	-0.34	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg15117754	chr3:10150083	C3orf24	0.74	6.19	0.45	5.47e-9	Alzheimer's disease;
PAAD	cis	rs7255045	0.702	rs2293682	chr19:12989560	G/A	cg09980403	chr19:12975529	MAST1	0.31	4.72	0.36	5.38e-6	Mean corpuscular volume;
PAAD	cis	rs6132905	0.590	rs75298178	chr20:2603683	G/A	cg24848351	chr20:2622020	TMC2	-0.68	-4.77	-0.36	4.29e-6	Mumps;
PAAD	cis	rs6762644	0.507	rs9311401	chr3:4764177	A/G	cg11584376	chr3:4789075	ITPR1	-0.41	-4.55	-0.35	1.09e-5	Breast cancer;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.9	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.46	-5.25	-0.39	5.03e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.71	7.11	0.5	4.22e-11	Alcohol dependence;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.5	-0.34	1.36e-5	Life satisfaction;
PAAD	cis	rs1075265	0.756	rs3821081	chr2:53965389	A/G	cg04546899	chr2:54196757	PSME4	-0.31	-4.56	-0.35	1.06e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg05555928	chr11:63887634	MACROD1	0.48	5.35	0.4	3.16e-7	Platelet count;
PAAD	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21028142	chr17:79581711	NPLOC4	-0.5	-5.8	-0.43	3.7e-8	Eye color traits;
PAAD	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.24	0.51	2.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.26	0.33	3.59e-5	Personality dimensions;
PAAD	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.61	8.26	0.56	6.64e-14	Systemic lupus erythematosus;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.86	10.69	0.66	3.09e-20	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12926720	chr3:30647773	TGFBR2	0.52	6.5	0.47	1.06e-9	Metabolite levels  (X-11787);
PAAD	cis	rs1600249	0.562	rs11250144	chr8:11386276	G/C	cg12568669	chr8:11666485	FDFT1	-0.28	-4.42	-0.34	1.91e-5	Rheumatoid arthritis;
PAAD	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17347941	chr15:79387269	NA	0.38	4.34	0.33	2.64e-5	Refractive error;
PAAD	cis	rs870825	0.932	rs13136635	chr4:185574807	C/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-5.49	-0.41	1.64e-7	Blood protein levels;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.66	7.47	0.52	5.93e-12	Height;
PAAD	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg14092571	chr14:90743983	NA	-0.58	-5.73	-0.42	5.23e-8	Mortality in heart failure;
PAAD	cis	rs6834538	0.867	rs12506894	chr4:113580912	T/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	4.37	0.33	2.27e-5	Free thyroxine concentration;
PAAD	cis	rs3736485	0.966	rs4775965	chr15:51908251	A/G	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.39	-0.34	2.09e-5	Mean corpuscular volume;
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.71	-8.06	-0.55	2.08e-13	Prudent dietary pattern;
PAAD	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.79	-8.84	-0.58	2.23e-15	Iron status biomarkers;
PAAD	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg21775007	chr8:11205619	TDH	0.46	4.28	0.33	3.25e-5	Neuroticism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13407446	chr9:123698965	NA	0.6	6.59	0.47	6.72e-10	Monocyte percentage of white cells;
PAAD	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg10820045	chr2:198174542	NA	0.49	5.0	0.38	1.59e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.09	0.44	8.86e-9	Schizophrenia;
PAAD	cis	rs829661	0.688	rs10175399	chr2:30798133	T/G	cg12454169	chr2:30669597	LCLAT1	0.61	4.86	0.37	2.87e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg26516362	chr5:178986906	RUFY1	0.41	4.54	0.35	1.13e-5	Lung cancer;
PAAD	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg24476569	chr13:95954382	ABCC4	-0.44	-4.29	-0.33	3.21e-5	Blood metabolite levels;
PAAD	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg26373071	chr5:1325741	CLPTM1L	0.5	5.26	0.39	4.92e-7	Lung cancer;
PAAD	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg21775007	chr8:11205619	TDH	-0.48	-4.54	-0.35	1.13e-5	Systolic blood pressure;
PAAD	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.46	-4.64	-0.35	7.34e-6	Dementia with Lewy bodies;
PAAD	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg22290704	chr6:144167951	LTV1	-0.52	-6.32	-0.46	2.8e-9	Energy expenditure (24h);
PAAD	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg10437265	chr15:77819839	NA	0.41	4.32	0.33	2.76e-5	Type 2 diabetes;
PAAD	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.65	4.88	0.37	2.65e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg02532672	chr7:808649	HEATR2	-0.59	-6.26	-0.45	3.68e-9	Subjective well-being;
PAAD	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.18	13.13	0.73	8.16e-27	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.08	-0.44	9.2e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-5.88	-0.43	2.48e-8	Schizophrenia;
PAAD	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	4.76	0.36	4.49e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-4.29	-0.33	3.12e-5	Coronary artery disease;
PAAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.83	7.43	0.52	7.43e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.5	4.93	0.37	2.13e-6	Mean corpuscular volume;
PAAD	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.13	8.89	0.58	1.7e-15	Vitiligo;
PAAD	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.74	-8.85	-0.58	2.05e-15	Colorectal cancer;
PAAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.55	4.44	0.34	1.74e-5	Bone mineral density (spine);
PAAD	cis	rs13253111	0.624	rs1979329	chr8:28096772	C/G	cg26534493	chr8:28060551	NA	0.41	4.57	0.35	9.87e-6	Childhood body mass index;
PAAD	cis	rs790123	0.581	rs2877628	chr3:122352678	A/G	cg17380795	chr3:122379686	NA	0.46	4.81	0.36	3.65e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.46	7.49	0.52	5.29e-12	Neuroticism;
PAAD	cis	rs11811982	0.793	rs79655227	chr1:227285708	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	15.0	0.77	8.67e-32	Schizophrenia;
PAAD	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg23995914	chr4:10459228	ZNF518B	-0.38	-4.36	-0.33	2.36e-5	Schizophrenia (age at onset);
PAAD	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs755249	0.567	rs112672438	chr1:39646787	C/T	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.95	-0.37	1.94e-6	Blood metabolite levels;
PAAD	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg23254163	chr1:152506842	NA	0.59	6.97	0.49	9.26e-11	Hair morphology;
PAAD	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg13047869	chr3:10149882	C3orf24	0.81	6.65	0.47	4.94e-10	Alzheimer's disease;
PAAD	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.53	-5.58	-0.41	1.06e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2916733	0.818	rs2916746	chr8:6317267	C/G	cg02465761	chr8:6735510	DEFB1	-0.46	-4.4	-0.34	2.03e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-4.99	-0.37	1.67e-6	Eosinophil percentage of white cells;
PAAD	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	9.59	0.61	2.51e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg09471204	chr22:42347991	LOC339674	0.34	4.47	0.34	1.51e-5	Cognitive function;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00564598	chr19:10216860	SNORD105;PPAN-P2RY11;PPAN	0.59	6.89	0.49	1.42e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs951266	0.505	rs4886579	chr15:78969256	C/T	cg00540400	chr15:79124168	NA	-0.45	-5.08	-0.38	1.1e-6	Post bronchodilator FEV1/FVC ratio in COPD;Pre bronchodilator FEV1;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.63	-5.27	-0.39	4.64e-7	Coronary artery disease;
PAAD	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.45	4.27	0.33	3.48e-5	Prostate-specific antigen levels;
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9361491	0.608	rs9350775	chr6:79463785	A/G	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	4.59	0.35	9.08e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3784262	0.565	rs1899355	chr15:58286989	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-4.56	-0.35	1.06e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.47	8.37	0.56	3.5e-14	Multiple system atrophy;
PAAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg03517284	chr6:25882590	NA	-0.55	-4.65	-0.35	7.18e-6	Iron status biomarkers;
PAAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg21951975	chr1:209979733	IRF6	0.59	5.4	0.4	2.56e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.93e-10	Bipolar disorder;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.67	0.35	6.6e-6	Electroencephalogram traits;
PAAD	cis	rs730570	1.000	rs10141733	chr14:101142651	A/G	cg05281145	chr14:100530975	EVL	-0.57	-4.35	-0.33	2.5e-5	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.88	9.75	0.62	9.55e-18	Prudent dietary pattern;
PAAD	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-5.43	-0.4	2.17e-7	Retinal vascular caliber;
PAAD	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	10.55	0.65	7.03e-20	Response to antipsychotic treatment;
PAAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg00988841	chr10:134556463	INPP5A	-0.47	-4.37	-0.33	2.32e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-5.04	-0.38	1.31e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008126	0.600	rs2711881	chr7:103135431	C/T	cg04218035	chr7:103086829	SLC26A5	0.33	4.63	0.35	7.91e-6	Metabolite levels (Pyroglutamine);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02619805	chr19:5623015	SAFB2;SAFB	0.6	6.55	0.47	8.3e-10	Myopia (pathological);
PAAD	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.45	4.52	0.34	1.25e-5	Educational attainment;
PAAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21171335	chr12:122356390	WDR66	0.58	6.22	0.45	4.51e-9	Mean corpuscular volume;
PAAD	cis	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.75	7.48	0.52	5.41e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs11696501	0.688	rs6073788	chr20:44213773	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.47	-5.3	-0.39	4.02e-7	Migraine;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg10207240	chr12:122356781	WDR66	0.62	6.69	0.48	3.97e-10	Mean corpuscular volume;
PAAD	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.52	-6.52	-0.47	9.67e-10	Lewy body disease;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.59	5.39	0.4	2.68e-7	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07774478	chr2:127865245	BIN1	0.53	6.36	0.46	2.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.56	-6.23	-0.45	4.38e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs11159086	0.793	rs4903229	chr14:74956568	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.21	-0.39	5.99e-7	Advanced glycation end-product levels;
PAAD	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg02683114	chr2:24398427	C2orf84	-0.48	-4.98	-0.37	1.69e-6	Sjögren's syndrome;
PAAD	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.81	9.09	0.59	4.95e-16	Metabolic syndrome;
PAAD	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	9.93	0.63	3.25e-18	Cognitive test performance;
PAAD	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	10.16	0.64	7.84e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.16	9.92	0.63	3.46e-18	Vitiligo;
PAAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.44	4.9	0.37	2.39e-6	Testicular germ cell tumor;
PAAD	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg00631329	chr6:26305371	NA	-0.49	-4.92	-0.37	2.21e-6	Educational attainment;
PAAD	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.38	4.36	0.33	2.39e-5	Immature fraction of reticulocytes;
PAAD	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-5.04	-0.38	1.29e-6	Reticulocyte count;
PAAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.61	5.81	0.43	3.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.68	7.1	0.5	4.4e-11	Pulse pressure;
PAAD	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	trans	rs225245	0.817	rs225297	chr17:33924587	G/A	cg19694781	chr19:47549865	TMEM160	-0.57	-6.47	-0.46	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.66	6.54	0.47	8.76e-10	Schizophrenia;
PAAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03526776	chr6:41159608	TREML2	0.63	7.57	0.52	3.37e-12	Alzheimer's disease (late onset);
PAAD	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-1.14	-7.71	-0.53	1.53e-12	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.54	-6.35	-0.46	2.4e-9	Tonsillectomy;
PAAD	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg25173405	chr17:45401733	C17orf57	0.5	5.1	0.38	1.02e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-1.5	-8.89	-0.58	1.66e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.42	-5.21	-0.39	6.06e-7	Rheumatoid arthritis;
PAAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.61	7.28	0.51	1.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1355223	0.872	rs913204	chr11:34706224	C/G	cg18508148	chr11:34937573	PDHX;APIP	0.44	4.34	0.33	2.6e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-6.9	-0.49	1.29e-10	Total cholesterol levels;
PAAD	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg26850624	chr5:429559	AHRR	1.0	4.58	0.35	9.8200000000000008e-06	Asthma (childhood onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17609600	chr2:97535892	SEMA4C	0.73	8.02	0.55	2.57e-13	Myopia (pathological);
PAAD	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.52	-5.92	-0.43	2.09e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.35	-0.4	3.24e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.35	0.6	1.07e-16	Platelet count;
PAAD	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.76	-6.99	-0.49	8.22e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-5.91	-0.43	2.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18774692	chr12:89033280	NA	-0.65	-6.65	-0.47	4.85e-10	Obesity-related traits;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.7	5.56	0.41	1.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs798766	0.909	rs744658	chr4:1755074	C/T	cg23460851	chr4:1604456	NA	-0.43	-4.32	-0.33	2.78e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	4.68	0.35	6.37e-6	Height;
PAAD	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.82	10.3	0.64	3.36e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.58	6.16	0.45	6.2e-9	Diastolic blood pressure;
PAAD	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg17848003	chr1:3704513	LRRC47	0.43	4.51	0.34	1.28e-5	Red cell distribution width;
PAAD	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.71	-0.42	5.76e-8	Schizophrenia;
PAAD	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg00147172	chr22:46423604	NA	0.38	5.66	0.42	7.45e-8	Dupuytren's disease;
PAAD	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	1.09	9.21	0.6	2.41e-16	Blood trace element (Zn levels);
PAAD	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.29	0.39	4.27e-7	Body mass index;
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.65	-5.93	-0.43	1.93e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19784903	chr17:45786737	TBKBP1	0.53	5.65	0.42	7.59e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.57	-7.73	-0.53	1.38e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2637266	0.783	rs2395434	chr10:78476161	T/C	cg18941641	chr10:78392320	NA	0.36	4.38	0.33	2.2e-5	Pulmonary function;
PAAD	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.54	5.8	0.43	3.67e-8	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs6604026	0.666	rs11164830	chr1:93356823	C/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs2124910	1.000	rs2124910	chr19:52025247	T/C	cg12008991	chr19:52034861	SIGLEC6	0.35	4.58	0.35	9.47e-6	Blood protein levels;
PAAD	cis	rs9287719	0.649	rs10190673	chr2:10718618	T/C	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	cis	rs7551345	0.853	rs61780094	chr1:31774306	A/G	cg17086398	chr1:31896392	SERINC2	-0.49	-4.36	-0.33	2.39e-5	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg01620082	chr3:125678407	NA	1.49	9.07	0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs8077059	1.000	rs9303396	chr17:55825118	A/G	cg12582317	chr17:55822272	NA	0.5	4.88	0.37	2.7e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.34	-0.33	2.61e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.4	4.49	0.34	1.39e-5	Breast cancer;
PAAD	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.97e-5	Pain;
PAAD	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg05925327	chr15:68127851	NA	-0.58	-5.23	-0.39	5.48e-7	Restless legs syndrome;
PAAD	cis	rs3764400	0.567	rs12936369	chr17:46270696	C/T	cg24322968	chr17:46507895	SKAP1	0.86	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.58	5.22	0.39	5.83e-7	Retinal vascular caliber;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.77	0.58	3.36e-15	Corneal astigmatism;
PAAD	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.92	-7.85	-0.54	6.95e-13	Body mass index;
PAAD	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.39	0.51	8.98e-12	Multiple sclerosis;
PAAD	cis	rs11129295	0.599	rs9872851	chr3:27802302	T/C	cg21473142	chr3:27762095	EOMES	0.28	4.65	0.35	7.13e-6	Multiple sclerosis;
PAAD	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg12623918	chr2:306882	NA	0.48	5.02	0.38	1.4e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-4.74	-0.36	4.93e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.49	-5.69	-0.42	6.32e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg27587063	chr1:1912065	KIAA1751	-0.39	-4.66	-0.35	6.75e-6	Severe influenza A (H1N1) infection;
PAAD	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg04450003	chr12:50355995	AQP5	0.64	5.27	0.39	4.65e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9463078	0.838	rs2396373	chr6:44983134	G/A	cg25276700	chr6:44698697	NA	-0.49	-5.7	-0.42	6.08e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs939584	1.000	rs6711254	chr2:624210	G/A	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.84	-8.26	-0.56	6.53e-14	Body mass index;
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg21226059	chr5:178986404	RUFY1	0.52	5.71	0.42	5.75e-8	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08367703	chr9:139304491	SDCCAG3;PMPCA	0.62	7.0	0.49	7.67e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs901683	1.000	rs71494789	chr10:45972481	C/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.86	9.56	0.61	2.99e-17	Multiple sclerosis;
PAAD	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06850241	chr22:41845214	NA	-0.6	-5.25	-0.39	5.05e-7	Vitiligo;
PAAD	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg19980929	chr12:42632907	YAF2	0.53	6.03	0.44	1.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.71	-5.68	-0.42	6.5e-8	Menopause (age at onset);
PAAD	cis	rs10991814	0.688	rs17501728	chr9:93946219	A/G	cg14446406	chr9:93919335	NA	0.59	4.63	0.35	7.91e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.3	0.6	1.47e-16	Lymphocyte counts;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg00945038	chr17:61921165	SMARCD2	0.51	6.11	0.44	7.99e-9	Prudent dietary pattern;
PAAD	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.91	-0.43	2.13e-8	Schizophrenia;
PAAD	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.54	5.67	0.42	6.93e-8	Mean corpuscular volume;
PAAD	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.86	-9.0	-0.59	8.45e-16	Body mass index;
PAAD	cis	rs5009270	0.512	rs1024410	chr7:112247542	A/T	cg25550468	chr7:112262557	NA	0.5	4.55	0.35	1.09e-5	Osteoarthritis (hip);
PAAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16576597	chr16:28551801	NUPR1	0.68	7.71	0.53	1.54e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23281280	chr6:28129359	ZNF389	0.68	5.2	0.39	6.28e-7	Parkinson's disease;
PAAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.72	7.71	0.53	1.5e-12	Longevity;
PAAD	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.49	4.82	0.36	3.46e-6	Mean corpuscular volume;
PAAD	cis	rs11825685	0.836	rs56100135	chr11:134588756	G/T	cg06603561	chr11:134479413	NA	-0.73	-5.19	-0.39	6.69e-7	IgG glycosylation;
PAAD	trans	rs17213965	0.852	rs4781691	chr16:15877655	A/G	cg13673563	chr14:21738473	HNRNPC	-0.82	-6.49	-0.47	1.16e-9	Waist-hip ratio;
PAAD	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.2	-10.35	-0.64	2.53e-19	Vitiligo;
PAAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg23033748	chr14:75592666	NEK9	-0.43	-5.26	-0.39	4.83e-7	Height;
PAAD	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg06026331	chr20:60912101	LAMA5	0.57	4.62	0.35	8.09e-6	Colorectal cancer;
PAAD	cis	rs1801239	0.786	rs62619939	chr10:16967586	C/G	cg00939682	chr10:16933505	CUBN	0.6	4.6	0.35	8.71e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.59	6.18	0.45	5.51e-9	Obesity-related traits;
PAAD	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.47	4.52	0.34	1.25e-5	Red cell distribution width;
PAAD	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg08853572	chr16:1843915	IGFALS	-0.25	-4.28	-0.33	3.26e-5	Blood metabolite levels;
PAAD	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.59	5.71	0.42	5.77e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs6681460	1.000	rs6656912	chr1:67083671	A/G	cg02459107	chr1:67143332	SGIP1	0.78	7.3	0.51	1.49e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-4.54	-0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.73	-6.44	-0.46	1.48e-9	Blood protein levels;
PAAD	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.35	4.34	0.33	2.63e-5	Body mass index in non-asthmatics;
PAAD	cis	rs8105895	0.935	rs7247228	chr19:22250136	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.3	-0.33	3.04e-5	Body mass index (change over time);
PAAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.58	5.5	0.41	1.61e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9584805	0.561	rs7329493	chr13:98999109	A/G	ch.13.1524792R	chr13:99552827	DOCK9	0.41	4.3	0.33	2.99e-5	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg12082025	chr19:1064218	ABCA7	-0.74	-7.18	-0.5	2.85e-11	Alzheimer's disease (late onset);
PAAD	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.4	5.25	0.39	5.09e-7	Monocyte count;
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg11601000	chr22:42348013	LOC339674	0.44	5.08	0.38	1.1e-6	Cognitive function;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.63	-0.35	7.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7945705	0.935	rs2568064	chr11:8852685	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.47	4.83	0.37	3.25e-6	Hemoglobin concentration;
PAAD	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16083429	chr3:49237500	CCDC36	-0.42	-4.5	-0.34	1.36e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.77	4.3	0.33	3.09e-5	Childhood ear infection;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg00280220	chr17:61926910	NA	0.42	4.31	0.33	2.86e-5	Prudent dietary pattern;
PAAD	cis	rs8005172	0.663	rs4259983	chr14:88523482	C/G	cg18078958	chr14:88630771	NA	0.35	4.38	0.33	2.18e-5	Parkinson's disease;
PAAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.26	-0.33	3.51e-5	Magnesium levels;
PAAD	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.37	-0.33	2.26e-5	Dupuytren's disease;
PAAD	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg14826516	chr22:50639351	SELO	0.91	6.45	0.46	1.38e-9	Lung function (FEV1/FVC);
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg05313129	chr8:58192883	C8orf71	-0.63	-5.13	-0.38	8.88e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs10908657	chr1:158465243	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.2e-6	Pneumococcal bacteremia;
PAAD	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.47	-5.22	-0.39	5.81e-7	Prevalent atrial fibrillation;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg24879335	chr3:133465180	TF	-0.54	-5.7	-0.42	6.08e-8	Iron status biomarkers;
PAAD	cis	rs863345	0.604	rs10797020	chr1:158490324	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg26174226	chr8:58114915	NA	-0.61	-4.71	-0.36	5.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Gout;
PAAD	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.81	0.36	3.67e-6	Cholesterol, total;
PAAD	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg25930673	chr12:123319894	HIP1R	1.23	6.4	0.46	1.87e-9	Adiponectin levels;
PAAD	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg01028140	chr2:1542097	TPO	-0.9	-8.23	-0.56	7.86e-14	IgG glycosylation;
PAAD	cis	rs58521262	0.556	rs289299	chr19:23175751	A/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2457480	0.543	rs1905150	chr10:44713311	G/A	cg09554077	chr10:44749378	NA	0.34	4.92	0.37	2.23e-6	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21826442	chr4:62935918	LPHN3	0.53	6.29	0.45	3.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg09796270	chr17:17721594	SREBF1	0.43	4.88	0.37	2.62e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.44e-6	Life satisfaction;
PAAD	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.52	-0.47	9.66e-10	Morning vs. evening chronotype;
PAAD	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	6.86	0.49	1.6e-10	Blood protein levels;
PAAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.69	0.58	5.5e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.73	4.53	0.35	1.17e-5	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.88	-6.61	-0.47	6.27e-10	Alzheimer's disease;
PAAD	cis	rs7714584	1.000	rs6579806	chr5:150271084	C/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg00579200	chr11:133705235	NA	-0.49	-5.53	-0.41	1.37e-7	Childhood ear infection;
PAAD	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.69	6.84	0.49	1.8e-10	Smoking initiation;
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.88	6.99	0.49	8.17e-11	Alzheimer's disease;
PAAD	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg02264943	chr11:130785842	SNX19	0.41	4.89	0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg12092346	chr18:77659572	KCNG2	-0.64	-4.51	-0.34	1.29e-5	Opioid sensitivity;
PAAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.87	9.7	0.62	1.3e-17	Prudent dietary pattern;
PAAD	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	4.53	0.35	1.16e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7081476	0.737	rs16916444	chr10:27491648	C/T	cg25705717	chr10:27608719	NA	0.91	4.69	0.36	6.07e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.52	-0.47	9.93e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.62	-0.35	8.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.58	6.27	0.45	3.64e-9	Mean corpuscular volume;
PAAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.59	-5.05	-0.38	1.23e-6	Coronary artery disease;
PAAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.31	0.33	2.98e-5	Breast cancer;
PAAD	cis	rs2765041	1	rs2765041	chr14:103991478	T/A	cg19000871	chr14:103996768	TRMT61A	0.56	6.03	0.44	1.19e-8	High light scatter reticulocyte count;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.42	0.46	1.67e-9	Rheumatoid arthritis;
PAAD	cis	rs17152411	0.652	rs1046373	chr10:126674689	A/C	cg07081759	chr10:126330905	FAM53B	-0.4	-4.32	-0.33	2.83e-5	Height;
PAAD	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.24	-9.14	-0.6	3.67e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.59	6.53	0.47	9.22e-10	Cardiovascular disease risk factors;
PAAD	cis	rs7168592	1.000	rs7168592	chr15:101723499	C/T	cg24254196	chr15:101719523	CHSY1	-0.63	-4.39	-0.34	2.15e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.53	4.78	0.36	4.14e-6	Anxiety disorder;
PAAD	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg18939081	chr1:31884902	SERINC2	0.49	5.67	0.42	6.93e-8	Alcohol dependence;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs59104589	0.617	rs111937035	chr2:242212177	C/T	cg04488487	chr2:242709673	NA	0.56	4.26	0.33	3.54e-5	Fibrinogen levels;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Body mass index;
PAAD	cis	rs7107174	0.688	rs10793294	chr11:77996403	G/T	cg02023728	chr11:77925099	USP35	-0.42	-4.83	-0.36	3.31e-6	Testicular germ cell tumor;
PAAD	cis	rs7176527	0.784	rs62021162	chr15:85108833	C/T	cg24253500	chr15:84953950	NA	-0.57	-4.7	-0.36	5.85e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.59	-6.19	-0.45	5.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.75	8.05	0.55	2.22e-13	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.56	-5.47	-0.41	1.81e-7	Height;
PAAD	cis	rs11264799	0.639	rs3811026	chr1:157766446	A/G	cg18268488	chr1:157545234	FCRL4	-0.56	-4.95	-0.37	1.96e-6	IgA nephropathy;
PAAD	cis	rs77774742	0.887	rs2069128	chr6:145342763	G/A	cg11675148	chr6:146285568	SHPRH	-0.71	-4.47	-0.34	1.49e-5	Loneliness (multivariate analysis);
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg00024416	chr22:24240387	NA	-0.45	-4.32	-0.33	2.85e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2685295	0.585	rs960472	chr1:237901370	C/T	cg13968398	chr1:236958353	MTR	0.56	4.4	0.34	2.02e-5	Bipolar disorder and eating disorder;
PAAD	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	1.08	5.65	0.42	7.73e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg20356878	chr3:121714668	ILDR1	0.48	4.58	0.35	9.72e-6	Cognitive performance;
PAAD	cis	rs1559473	0.659	rs7603435	chr2:222895598	C/T	cg15825116	chr2:223169586	CCDC140	-0.31	-4.26	-0.33	3.64e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.56	-5.85	-0.43	2.91e-8	Testicular germ cell tumor;
PAAD	cis	rs2288327	0.508	rs17076	chr2:179595117	C/G	cg26153162	chr2:179751100	CCDC141	0.48	4.98	0.37	1.69e-6	Atrial fibrillation;
PAAD	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.68	8.84	0.58	2.27e-15	Hemoglobin concentration;
PAAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00982548	chr2:198649783	BOLL	-0.85	-5.88	-0.43	2.48e-8	Ulcerative colitis;
PAAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.68	-8.65	-0.57	7.01e-15	Coronary artery disease;
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg20821713	chr7:1055600	C7orf50	-0.45	-4.95	-0.37	1.92e-6	Longevity;Endometriosis;
PAAD	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs7180079	1.000	rs8028184	chr15:64515543	G/A	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.58e-5	Monocyte count;
PAAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg11440486	chr17:48585216	MYCBPAP	-0.44	-4.43	-0.34	1.8e-5	Visceral fat;
PAAD	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg06483076	chr3:194406458	FAM43A	-0.52	-5.1	-0.38	9.84e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.86	-7.28	-0.51	1.64e-11	Body mass index;
PAAD	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-4.67	-0.35	6.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.53	-5.88	-0.43	2.54e-8	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg19680485	chr15:31195859	MTMR15	-0.43	-4.35	-0.33	2.49e-5	Huntington's disease progression;
PAAD	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	6.52	0.47	9.77e-10	Initial pursuit acceleration;
PAAD	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.59	6.11	0.44	8.11e-9	Pancreatic cancer;
PAAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.77	0.36	4.25e-6	Menopause (age at onset);
PAAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.88	-8.44	-0.56	2.31e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	1.05	12.98	0.73	2.15e-26	Breast cancer;
PAAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.59	5.44	0.4	2.09e-7	Coronary artery disease;
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.77	-9.27	-0.6	1.72e-16	Cystic fibrosis severity;
PAAD	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.6	0.47	6.47e-10	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	10.49	0.65	1.03e-19	Tonsillectomy;
PAAD	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-11.05	-0.67	3.28e-21	Height;
PAAD	cis	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11990443	chr7:23454952	IGF2BP3	0.41	4.33	0.33	2.66e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg07469887	chr10:131262384	NA	-0.44	-5.35	-0.4	3.1e-7	Response to temozolomide;
PAAD	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.9	9.31	0.6	1.35e-16	Educational attainment;
PAAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg21130718	chr4:1044621	NA	0.55	4.82	0.36	3.39e-6	Recombination rate (females);
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg26554054	chr8:600488	NA	-0.92	-6.35	-0.46	2.34e-9	IgG glycosylation;
PAAD	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.45	-0.46	1.38e-9	Coffee consumption (cups per day);
PAAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg19052272	chr2:3704530	ALLC	-0.58	-6.71	-0.48	3.63e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6691722	0.583	rs7537875	chr1:24695151	A/T	cg18323236	chr1:24743029	NIPAL3	0.41	4.38	0.33	2.24e-5	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.34	4.85	0.37	3.07e-6	Asthma;
PAAD	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg19413350	chr8:57351067	NA	-0.47	-4.43	-0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14411929	chr21:37500450	NA	-0.66	-6.61	-0.47	6.01e-10	Obesity-related traits;
PAAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.89	7.03	0.5	6.68e-11	Tuberculosis;
PAAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.77	0.53	1.08e-12	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs62025270	0.688	rs62022939	chr15:86250882	C/G	cg13263323	chr15:86062960	AKAP13	0.49	4.46	0.34	1.61e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg17372223	chr3:52568218	NT5DC2	0.46	4.43	0.34	1.78e-5	Bipolar disorder;
PAAD	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg10820045	chr2:198174542	NA	0.45	4.4	0.34	1.99e-5	Dermatomyositis;
PAAD	cis	rs11264213	0.786	rs72659702	chr1:36317471	G/C	cg27506609	chr1:36549197	TEKT2	0.84	4.32	0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs17824933	0.848	rs11230559	chr11:60769534	T/C	cg16817237	chr11:60793675	NA	0.51	6.04	0.44	1.13e-8	Multiple sclerosis;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1419980	0.730	rs11537450	chr12:7762480	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19627864	chr1:16940181	NBPF1	0.58	6.81	0.48	2.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.43	-4.89	-0.37	2.58e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg00666640	chr1:248458726	OR2T12	0.52	4.29	0.33	3.12e-5	Common traits (Other);
PAAD	cis	rs6496932	1.000	rs6496932	chr15:85825567	G/T	cg19183879	chr15:85880815	NA	0.5	4.4	0.34	2.06e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs59888335	0.798	rs7609816	chr3:80623589	T/C	cg21735741	chr3:80819488	NA	0.58	5.0	0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.63	-6.17	-0.45	5.79e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs1539053	1.000	rs11207076	chr1:58097024	G/A	cg00026909	chr1:58089001	DAB1	-0.69	-8.01	-0.54	2.75e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18302933	chr2:88491318	NA	-0.43	-5.16	-0.39	7.52e-7	Response to metformin (IC50);
PAAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.51	-5.7	-0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg04362960	chr10:104952993	NT5C2	-0.5	-4.57	-0.35	9.87e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.45	-5.59	-0.41	1.03e-7	Childhood ear infection;
PAAD	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.32	-0.4	3.68e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.55	6.36	0.46	2.25e-9	Total body bone mineral density;
PAAD	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-6.38	-0.46	2.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg15676125	chr6:33679581	C6orf125	0.48	4.71	0.36	5.61e-6	Plateletcrit;
PAAD	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.85	-8.08	-0.55	1.85e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.27	-0.33	3.39e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.71	-7.23	-0.51	2.2e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs7922314	0.571	rs16917963	chr10:64721827	A/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.37	-0.33	2.3e-5	Post bronchodilator FEV1;
PAAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Depression;
PAAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.89	-0.43	2.42e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-4.85	-0.37	3.04e-6	Total body bone mineral density;
PAAD	cis	rs1190596	0.525	rs3783372	chr14:102719620	A/G	cg23904247	chr14:102554826	HSP90AA1	0.43	4.97	0.37	1.81e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg08132940	chr7:1081526	C7orf50	0.57	4.37	0.33	2.25e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.81	-7.97	-0.54	3.53e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-6.75	-0.48	2.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.58	8.79	0.58	3.01e-15	Hypertriglyceridemia;
PAAD	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.8	-11.35	-0.68	5.16e-22	Emphysema distribution in smoking;
PAAD	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.74	-6.32	-0.46	2.76e-9	Exhaled nitric oxide output;
PAAD	cis	rs12760731	0.668	rs73037529	chr1:178410203	A/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-5.7	-0.42	6.08e-8	Pulmonary function;
PAAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg14847009	chr1:175162515	KIAA0040	0.33	5.26	0.39	4.72e-7	Alcohol dependence;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	8.66	0.57	6.32e-15	Lymphocyte counts;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22943243	chr1:26232311	STMN1	-0.75	-7.87	-0.54	6.32e-13	Smoking initiation;
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00166722	chr3:10149974	C3orf24	0.89	7.39	0.51	9.16e-12	Alzheimer's disease;
PAAD	cis	rs4740619	0.619	rs1887668	chr9:16033321	G/C	cg14451791	chr9:16040625	NA	-0.46	-5.33	-0.4	3.42e-7	Body mass index;
PAAD	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg24053715	chr22:38214548	NA	0.64	5.98	0.44	1.55e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg14631576	chr9:95140430	CENPP	-0.53	-5.22	-0.39	5.77e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.95	12.27	0.71	1.74e-24	Menopause (age at onset);
PAAD	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.77e-7	Carotid intima media thickness;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.8	5.76	0.42	4.43e-8	Alzheimer's disease;
PAAD	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.45	4.57	0.35	9.95e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7264396	0.887	rs736031	chr20:34048625	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs55986470	0.763	rs6739251	chr2:239419603	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-4.82	-0.36	3.52e-6	Chronotype;
PAAD	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.67e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-9.31	-0.6	1.4e-16	Colorectal cancer;
PAAD	cis	rs1535500	0.935	rs34247110	chr6:39282371	G/A	cg03252829	chr6:39282164	KCNK17	-0.56	-5.8	-0.43	3.74e-8	Type 2 diabetes;
PAAD	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.84	0.54	7.4e-13	Metabolite levels;
PAAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.98	-12.08	-0.7	5.65e-24	Coronary artery disease;
PAAD	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg14666354	chr17:73996423	CDK3;C17orf106	0.63	4.27	0.33	3.38e-5	Psoriasis;
PAAD	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.59	4.75	0.36	4.65e-6	Type 2 diabetes;
PAAD	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.76	9.41	0.61	7.33e-17	Lymphocyte counts;
PAAD	cis	rs7922314	0.571	rs4746751	chr10:64703334	G/A	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.75e-5	Cutaneous psoriasis;
PAAD	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg03115019	chr17:80708279	FN3K	0.55	5.12	0.38	9.15e-7	Glycated hemoglobin levels;
PAAD	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02985541	chr2:219472218	PLCD4	0.28	4.35	0.33	2.45e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11264799	0.731	rs7514353	chr1:157700437	C/T	cg18268488	chr1:157545234	FCRL4	0.65	5.75	0.42	4.79e-8	IgA nephropathy;
PAAD	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg20159608	chr7:32802032	NA	-0.6	-6.19	-0.45	5.36e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs7172971	0.688	rs4923928	chr15:42379194	G/A	cg07013680	chr15:42186124	SPTBN5	0.53	4.25	0.33	3.65e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg23024343	chr7:107201750	COG5	0.58	4.72	0.36	5.36e-6	Coronary artery disease;
PAAD	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg26585981	chr11:48327164	OR4S1	-0.5	-4.44	-0.34	1.72e-5	Migraine - clinic-based;
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1529711	0.500	rs77357022	chr19:10899942	G/A	cg18543610	chr13:100627929	NA	-0.61	-6.5	-0.47	1.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26255649	chr14:50778895	L2HGDH;ATP5S	0.57	6.33	0.46	2.68e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.95	12.75	0.72	8.87e-26	Methadone dose in opioid dependence;
PAAD	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.82	7.98	0.54	3.39e-13	Corneal astigmatism;
PAAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg19930314	chr7:98593876	TRRAP	-0.48	-4.57	-0.35	9.83e-6	Breast cancer;
PAAD	cis	rs2790216	1.000	rs1416764	chr10:60040351	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.6	6.07	0.44	9.81e-9	Essential tremor;
PAAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18404041	chr3:52824283	ITIH1	0.41	4.35	0.33	2.47e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.73	-9.72	-0.62	1.18e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.77	8.85	0.58	2.04e-15	Heart rate;
PAAD	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.7	-8.0	-0.54	2.87e-13	Metabolic syndrome;
PAAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs322144	0.967	rs322143	chr19:11425097	A/G	cg22357700	chr19:11805638	NA	0.47	4.55	0.35	1.08e-5	Breast cancer;
PAAD	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg24881330	chr22:46731750	TRMU	0.6	4.45	0.34	1.68e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.87	10.77	0.66	1.83e-20	Menopause (age at onset);
PAAD	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.76	9.35	0.6	1.09e-16	Bladder cancer;
PAAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02071572	chr4:1403502	NA	0.49	6.34	0.46	2.47e-9	Longevity;
PAAD	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.68	6.34	0.46	2.46e-9	Corneal astigmatism;
PAAD	cis	rs4638749	1.000	rs13388627	chr2:108883866	A/C	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.93	-0.37	2.14e-6	Blood pressure;
PAAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-7.77	-0.53	1.09e-12	Bone mineral density;
PAAD	cis	rs12913538	0.552	rs8037466	chr15:62910862	C/T	cg09983546	chr15:62884068	NA	-0.57	-6.4	-0.46	1.83e-9	Sleep depth;
PAAD	cis	rs10821973	0.527	rs1432414	chr10:63977069	A/T	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs6585424	1.000	rs11202031	chr10:81944043	G/C	cg19423196	chr10:82049429	MAT1A	0.46	4.51	0.34	1.31e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.64	6.26	0.45	3.74e-9	Ovarian reserve;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15048948	chr3:196158458	UBXN7	0.72	7.44	0.52	6.8e-12	Obesity-related traits;
PAAD	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg12568669	chr8:11666485	FDFT1	0.32	5.41	0.4	2.4e-7	Monocyte count;
PAAD	cis	rs2275731	0.723	rs12784829	chr10:16540564	G/A	cg04254609	chr10:16479192	PTER	-0.41	-4.31	-0.33	2.92e-5	Bone fracture in osteoporosis;
PAAD	cis	rs6681460	0.649	rs1856315	chr1:67005229	A/G	cg02459107	chr1:67143332	SGIP1	0.56	5.0	0.38	1.53e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg20673091	chr1:2541236	MMEL1	0.88	10.33	0.64	2.78e-19	Ulcerative colitis;
PAAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15128208	chr22:42549153	NA	-0.46	-4.61	-0.35	8.65e-6	Cognitive function;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-4.27	-0.33	3.49e-5	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	8.17	0.55	1.13e-13	Alzheimer's disease;
PAAD	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg05555928	chr11:63887634	MACROD1	-0.64	-4.86	-0.37	2.86e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs3857067	1.000	rs1397026	chr4:95013729	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.37	-4.81	-0.36	3.62e-6	Age at first birth;
PAAD	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.57	-5.64	-0.42	7.89e-8	Inflammatory bowel disease;
PAAD	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.42	-4.65	-0.35	7.06e-6	Aortic root size;
PAAD	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg15193198	chr20:60906057	LAMA5	0.54	6.09	0.44	8.98e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.53	5.27	0.39	4.5e-7	Resting heart rate;
PAAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg01305830	chr4:1604576	NA	-0.46	-4.55	-0.35	1.1e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-5.11	-0.38	9.52e-7	Menarche (age at onset);
PAAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.73	5.55	0.41	1.25e-7	Alzheimer's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg07638871	chr5:56247860	MIER3	-0.57	-6.33	-0.46	2.62e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10861661	0.963	rs10444533	chr12:107229705	A/G	cg15890332	chr12:107067104	RFX4	-0.48	-4.61	-0.35	8.33e-6	Triglyceride levels;
PAAD	cis	rs2286503	0.839	rs4722189	chr7:22860474	G/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21826946	chr3:169755748	GPR160	-0.81	-7.23	-0.51	2.24e-11	Neuroticism;
PAAD	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.42	-4.93	-0.37	2.1e-6	Mean arterial pressure;
PAAD	cis	rs6681460	1.000	rs6697088	chr1:67044724	C/G	cg02459107	chr1:67143332	SGIP1	-0.73	-7.15	-0.5	3.44e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.52	5.06	0.38	1.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs16910800	0.953	rs77585463	chr11:23205379	T/C	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	trans	rs785830	0.558	rs557716	chr9:263321	A/G	cg17093826	chr7:138458720	ATP6V0A4	0.51	6.49	0.47	1.15e-9	Platelet distribution width;
PAAD	cis	rs8040855	0.658	rs11634877	chr15:85611477	G/A	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10411590	chr13:21900810	NA	0.63	7.01	0.49	7.24e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.68	-7.04	-0.5	6.05e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04667246	chr5:5423192	KIAA0947	0.6	6.77	0.48	2.69e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	7.88	0.54	5.86e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.59	4.76	0.36	4.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.51	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.89e-7	HDL cholesterol;
PAAD	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.87	9.91	0.63	3.57e-18	Obesity-related traits;
PAAD	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.45	-5.53	-0.41	1.35e-7	Permanent tooth development;
PAAD	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.65	8.1	0.55	1.63e-13	Coronary artery disease;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg26014466	chr7:809109	HEATR2	-0.67	-7.42	-0.52	7.59e-12	Subjective well-being;
PAAD	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg07395648	chr5:131743802	NA	0.51	4.36	0.33	2.34e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.51	-0.34	1.29e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	4.64	0.35	7.4e-6	Depressive symptoms;
PAAD	cis	rs9463078	0.605	rs9472409	chr6:44926431	A/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.66	6.34	0.46	2.54e-9	Corneal astigmatism;
PAAD	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	6.38	0.46	2.03e-9	Hip circumference;
PAAD	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs8060686	0.858	rs7187476	chr16:67699948	T/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-4.85	-0.37	2.96e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.66	6.04	0.44	1.16e-8	Red blood cell count;
PAAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs55720021	1	rs55720021	chr19:49144241	G/T	cg06530960	chr19:49140787	SEC1;DBP	0.6	4.97	0.37	1.75e-6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
PAAD	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs901683	1.000	rs35670420	chr10:46088052	T/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.11	0.59	4.57e-16	Parkinson's disease;
PAAD	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	7.35	0.51	1.12e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02354107	chr4:77135186	SCARB2	0.71	6.81	0.48	2.17e-10	Obesity-related traits;
PAAD	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.0	-12.06	-0.7	6.44e-24	Dilated cardiomyopathy;
PAAD	cis	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg27395922	chr11:50257633	LOC441601	-0.42	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.54	-5.29	-0.39	4.27e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg22467129	chr15:76604101	ETFA	0.52	4.84	0.37	3.13e-6	Blood metabolite levels;
PAAD	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.61	0.35	8.66e-6	Educational attainment;
PAAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg12193833	chr17:30244370	NA	0.62	4.72	0.36	5.38e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8077577	0.895	rs62072468	chr17:18118179	A/G	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg19254793	chr6:44695348	NA	-0.44	-4.31	-0.33	2.87e-5	Total body bone mineral density;
PAAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg04106633	chr4:1044584	NA	-0.68	-5.79	-0.42	3.94e-8	Recombination rate (females);
PAAD	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.97	10.22	0.64	5.45e-19	Primary sclerosing cholangitis;
PAAD	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.71	5.04	0.38	1.32e-6	Type 2 diabetes;
PAAD	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.53	-5.02	-0.38	1.45e-6	Red blood cell count;
PAAD	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26545983	chr19:18632784	ELL	-0.74	-6.44	-0.46	1.46e-9	Neuroticism;
PAAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.6	9.23	0.6	2.23e-16	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs17539620	0.702	rs58590026	chr6:154877613	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	7.29	0.51	1.58e-11	Lipoprotein (a) levels;
PAAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs7945718	0.533	rs10765987	chr11:12705743	C/T	cg25843174	chr11:12811716	TEAD1	0.31	4.5	0.34	1.35e-5	Educational attainment (years of education);
PAAD	cis	rs4740619	0.901	rs2136355	chr9:15718989	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.38	-0.33	2.22e-5	Body mass index;
PAAD	cis	rs10958605	0.761	rs7818390	chr8:40034287	A/T	cg14545590	chr8:40388592	ZMAT4	-0.39	-4.41	-0.34	1.94e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg02117656	chr17:79614917	TSPAN10	0.57	5.74	0.42	4.93e-8	Eye color traits;
PAAD	trans	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.39	8.21e-7	Serum sulfate level;
PAAD	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-5.82	-0.43	3.43e-8	Personality dimensions;
PAAD	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg07167872	chr1:205819463	PM20D1	0.64	4.97	0.37	1.82e-6	Basophil percentage of granulocytes;
PAAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.45	7.27	0.51	1.73e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg03983715	chr16:68378420	PRMT7	-0.83	-5.83	-0.43	3.21e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.36	-0.33	2.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg01601518	chr4:2404284	ZFYVE28	-0.44	-4.6	-0.35	8.84e-6	Cognitive function;
PAAD	cis	rs4750440	0.702	rs7917296	chr10:14029639	G/A	cg27542038	chr10:14027202	FRMD4A	-0.43	-4.25	-0.33	3.75e-5	Adiponectin levels;
PAAD	cis	rs3787159	0.523	rs567515	chr20:56877437	G/A	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg10645314	chr2:3704589	ALLC	-0.52	-5.34	-0.4	3.4e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs564309	0.541	rs1188474	chr1:228613052	T/C	cg00655913	chr1:228633920	NA	0.62	4.69	0.36	6.05e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.78	-5.82	-0.43	3.37e-8	Initial pursuit acceleration;
PAAD	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.79	-8.58	-0.57	1.02e-14	Obesity-related traits;
PAAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg04025307	chr7:1156635	C7orf50	0.64	4.66	0.35	6.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg14583973	chr4:3374767	RGS12	0.41	6.4	0.46	1.84e-9	Parental longevity (mother's age at death);
PAAD	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.67	6.48	0.47	1.19e-9	Type 2 diabetes;
PAAD	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg26876637	chr1:152193138	HRNR	-0.82	-6.13	-0.45	7.36e-9	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03645265	chr16:87991496	BANP	0.53	6.37	0.46	2.16e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg21479132	chr6:26055353	NA	0.65	4.32	0.33	2.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.76	7.84	0.54	7.34e-13	Breast cancer;
PAAD	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg10193763	chr2:225306901	NA	-0.49	-4.29	-0.33	3.22e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg10845886	chr2:3471009	TTC15	-0.54	-4.88	-0.37	2.66e-6	Neurofibrillary tangles;
PAAD	cis	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg16558253	chr16:72132732	DHX38	-0.69	-4.58	-0.35	9.67e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	6.94	0.49	1.08e-10	Resting heart rate;
PAAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.45	-5.64	-0.42	8.03e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18658096	chr17:41116483	AARSD1	0.58	6.32	0.46	2.77e-9	Myopia (pathological);
PAAD	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.63	0.47	5.59e-10	Blood protein levels;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg11196182	chr7:1989412	MAD1L1	0.4	4.27	0.33	3.46e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg21951975	chr1:209979733	IRF6	0.6	5.37	0.4	2.9e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.33e-7	Ulcerative colitis;
PAAD	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg27094323	chr7:1216898	NA	-0.51	-6.01	-0.44	1.32e-8	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-1.14	-11.03	-0.67	3.66e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.7	7.95	0.54	3.98e-13	Colorectal cancer;
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg26557270	chr6:116382179	FRK	-0.31	-5.52	-0.41	1.44e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9896052	0.580	rs6416846	chr17:73462573	A/G	cg25649188	chr17:73499917	CASKIN2	0.62	4.71	0.36	5.5e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-5.23	-0.39	5.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs939584	1.000	rs2867122	chr2:624581	A/C	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.37	-0.51	1.01e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7621025	0.542	rs13075615	chr3:136505832	C/T	cg15507776	chr3:136538369	TMEM22	-0.64	-4.45	-0.34	1.62e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs58653258	0.667	rs2802978	chr1:234979353	T/C	cg03518729	chr1:235147744	NA	-0.45	-4.31	-0.33	2.87e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg04738700	chr2:239367308	NA	0.38	4.32	0.33	2.8e-5	Multiple system atrophy;
PAAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.64	-8.38	-0.56	3.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2415984	0.622	rs1761026	chr14:46930139	T/C	cg14871534	chr14:47121158	RPL10L	0.53	5.53	0.41	1.4e-7	Number of children ever born;
PAAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg05373962	chr22:49881684	NA	-0.5	-4.88	-0.37	2.68e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg10616300	chr11:66138557	SLC29A2	0.35	4.74	0.36	4.81e-6	Educational attainment (years of education);
PAAD	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg01305830	chr4:1604576	NA	-0.49	-4.73	-0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg23920097	chr1:209922102	NA	-0.46	-4.48	-0.34	1.44e-5	Red blood cell count;
PAAD	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.48	9.75	0.62	9.68e-18	Atopic dermatitis;
PAAD	cis	rs302972	0.826	rs303010	chr6:25082105	C/T	cg09546929	chr6:25930894	SLC17A2	-0.73	-4.29	-0.33	3.13e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg21175976	chr8:11421337	BLK	0.49	5.16	0.39	7.59e-7	Systemic lupus erythematosus;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08034535	chr4:140375469	RAB33B	0.56	6.29	0.45	3.16e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.5	-0.47	1.07e-9	Monocyte count;
PAAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.91	0.43	2.17e-8	Personality dimensions;
PAAD	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg02353165	chr6:42928485	GNMT	0.6	4.81	0.36	3.64e-6	Blood protein levels;
PAAD	cis	rs4676482	0.588	rs17729892	chr3:39234170	A/G	cg02254461	chr3:39195904	CSRNP1	-0.7	-4.47	-0.34	1.53e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.74	0.36	4.81e-6	Breast cancer;
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg09509183	chr1:209979624	IRF6	0.5	4.59	0.35	9.25e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.92	-9.74	-0.62	1.01e-17	Systemic lupus erythematosus;
PAAD	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg21922841	chr17:72744131	SLC9A3R1	0.41	5.33	0.4	3.55e-7	Monocyte count;
PAAD	cis	rs4740619	0.587	rs4740632	chr9:16030208	T/G	cg14451791	chr9:16040625	NA	-0.46	-5.29	-0.39	4.16e-7	Body mass index;
PAAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.58	-5.45	-0.4	1.97e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14551251	chr3:15901281	ANKRD28	-0.54	-6.49	-0.47	1.12e-9	Body fat percentage;
PAAD	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.8	6.83	0.48	1.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.66	6.75	0.48	2.91e-10	Testicular germ cell tumor;
PAAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	2.02e-13	Melanoma;
PAAD	cis	rs4742903	1.000	rs3818625	chr9:106856452	G/A	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg26528668	chr16:1614120	IFT140	0.53	5.06	0.38	1.21e-6	Coronary artery disease;
PAAD	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.72	-8.36	-0.56	3.69e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.81	-9.64	-0.62	1.83e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4455778	0.519	rs10227532	chr7:49048208	A/G	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27417294	chr10:81904244	PLAC9	0.46	4.97	0.37	1.79e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7172971	0.745	rs4924611	chr15:42334871	C/T	cg07013680	chr15:42186124	SPTBN5	0.53	4.28	0.33	3.27e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg19486271	chr11:47235900	DDB2	-0.54	-5.65	-0.42	7.83e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg07701084	chr6:150067640	NUP43	0.73	7.52	0.52	4.38e-12	Lung cancer;
PAAD	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.69	10.58	0.65	6.07e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg07665718	chr19:16244068	HSH2D;RAB8A	0.68	4.7	0.36	5.73e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2446066	0.524	rs2947337	chr12:53796998	G/A	cg20591337	chr12:53693442	C12orf10	-0.64	-4.43	-0.34	1.79e-5	Red blood cell count;
PAAD	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg11380483	chr2:127933992	NA	0.48	4.61	0.35	8.38e-6	Self-rated health;
PAAD	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.86	6.65	0.47	4.92e-10	Chronic kidney disease;
PAAD	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25650185	chr19:21324782	ZNF431	-0.47	-4.28	-0.33	3.29e-5	Pain;
PAAD	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.53	-4.8	-0.36	3.76e-6	Height;
PAAD	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-5.69	-0.42	6.4e-8	Systemic lupus erythematosus;
PAAD	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.63	6.04	0.44	1.12e-8	Itch intensity from mosquito bite;
PAAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6547631	0.622	rs1437745	chr2:85928283	A/G	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.65	7.27	0.51	1.77e-11	Menarche (age at onset);
PAAD	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg22189786	chr22:42395067	WBP2NL	0.6	5.25	0.39	5.03e-7	Birth weight;
PAAD	cis	rs3857067	0.967	rs1904096	chr4:95012684	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-0.75	-4.86	-0.37	2.89e-6	Lung cancer;
PAAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.75	7.26	0.51	1.88e-11	Breast cancer;
PAAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06209217	chr17:18575184	ZNF286B;FOXO3B	0.56	7.17	0.5	3.11e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-10.44	-0.65	1.45e-19	Electrocardiographic conduction measures;
PAAD	cis	rs6782025	0.794	rs6807604	chr3:120781289	T/C	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.23	-0.51	2.22e-11	Response to antipsychotic treatment;
PAAD	cis	rs2030114	1.000	rs11076047	chr16:51613402	G/C	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.01	-17.67	-0.82	1.1e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs282587	0.569	rs914012	chr13:113386715	C/T	cg02820901	chr13:113351484	ATP11A	-0.66	-4.9	-0.37	2.43e-6	Glycated hemoglobin levels;
PAAD	cis	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg12486944	chr17:80159399	CCDC57	-0.52	-4.69	-0.36	6.15e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg20003494	chr4:90757398	SNCA	-0.44	-4.74	-0.36	4.83e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.88	5.78	0.42	4.05e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21232476	chr9:125667249	RC3H2	0.57	6.63	0.47	5.56e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	5.32	0.4	3.68e-7	HIV-1 control;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg18902035	chr2:134949357	NA	0.57	6.64	0.47	5.33e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg05110241	chr16:68378359	PRMT7	-0.95	-7.52	-0.52	4.45e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.55	5.63	0.42	8.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7936247	1.000	rs10830960	chr11:92688012	A/T	cg26929280	chr11:92402250	FAT3	-0.42	-4.25	-0.33	3.78e-5	Glycemic traits (pregnancy);
PAAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg23947450	chr7:900037	UNC84A	-0.52	-4.33	-0.33	2.71e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg17105886	chr17:28927953	LRRC37B2	0.76	4.84	0.37	3.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg27121462	chr16:89883253	FANCA	0.46	4.94	0.37	2.01e-6	Vitiligo;
PAAD	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.8	-4.71	-0.36	5.48e-6	Skin colour saturation;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.46	0.4	1.92e-7	Total body bone mineral density;
PAAD	cis	rs17641971	0.708	rs1567555	chr8:49900154	G/A	cg00325661	chr8:49890786	NA	0.48	4.72	0.36	5.26e-6	Blood metabolite levels;
PAAD	cis	rs4072705	0.967	rs4838200	chr9:127451057	A/G	cg13476313	chr9:127244764	NR5A1	-0.27	-4.31	-0.33	2.91e-5	Menarche (age at onset);
PAAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20211422	chr11:66059599	TMEM151A	0.5	6.32	0.46	2.76e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.67	4.84	0.37	3.14e-6	Obesity-related traits;
PAAD	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg00206168	chr11:65308501	LTBP3	0.51	5.36	0.4	2.96e-7	Bone mineral density;
PAAD	cis	rs54211	0.536	rs470081	chr22:39713105	C/T	cg11247378	chr22:39784982	NA	-0.71	-5.28	-0.39	4.45e-7	Sudden cardiac arrest;
PAAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	6.26	0.45	3.73e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17670436	chr10:3374199	NA	-0.65	-6.35	-0.46	2.36e-9	Obesity-related traits;
PAAD	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.71	5.36	0.4	3.03e-7	Diastolic blood pressure;
PAAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.97	12.4	0.71	7.73e-25	Menopause (age at onset);
PAAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg18833306	chr6:118973337	C6orf204	0.44	4.56	0.35	1.06e-5	Electrocardiographic conduction measures;
PAAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg10589385	chr1:150898437	SETDB1	0.39	4.87	0.37	2.79e-6	Melanoma;
PAAD	cis	rs11816922	0.655	rs17309788	chr10:6908358	T/C	cg10119075	chr10:7709738	ITIH5	-0.57	-4.36	-0.33	2.39e-5	Migraine;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.79	-0.36	3.89e-6	Longevity;Endometriosis;
PAAD	cis	rs10943724	0.679	rs4410688	chr6:81264712	A/G	cg19323245	chr6:80716898	TTK	-0.44	-4.65	-0.35	7.11e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17092148	0.848	rs6060030	chr20:33340313	C/T	cg16810054	chr20:33298113	TP53INP2	-0.55	-4.68	-0.35	6.38e-6	Neuroticism;
PAAD	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg05555928	chr11:63887634	MACROD1	-0.72	-5.58	-0.41	1.1e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.93	6.87	0.49	1.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.24	-0.39	5.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.59	-6.76	-0.48	2.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.57	-4.43	-0.34	1.76e-5	Thyroid stimulating hormone;
PAAD	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs35001302	chr10:46068936	G/A	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg15676455	chr3:128564943	NA	-0.8	-4.62	-0.35	8.2e-6	Dental caries;
PAAD	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.76	-8.18	-0.55	1.05e-13	Lung cancer;
PAAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs3826795	0.530	rs11667159	chr19:46795246	C/A	cg15229275	chr19:46800054	HIF3A	0.59	4.36	0.33	2.39e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs2278796	0.918	rs2290138	chr1:204956325	C/G	cg04862289	chr1:204966208	NFASC	-0.42	-4.31	-0.33	2.98e-5	Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.43	4.64	0.35	7.48e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19964273	chr6:168745827	NA	0.53	6.36	0.46	2.26e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.68	6.97	0.49	8.99e-11	Breast cancer;
PAAD	cis	rs4478858	0.611	rs1007012	chr1:31710068	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.16	0.39	7.44e-7	Alcohol dependence;
PAAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.52	4.99	0.37	1.66e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.9	-9.7	-0.62	1.3e-17	Pulse pressure;
PAAD	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.46	4.7	0.36	5.83e-6	Type 2 diabetes;
PAAD	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs4722166	0.598	rs4722179	chr7:22803861	C/A	cg05472934	chr7:22766657	IL6	0.64	7.41	0.52	7.99e-12	Lung cancer;
PAAD	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.5	4.86	0.37	2.93e-6	Common traits (Other);
PAAD	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.49	-5.21	-0.39	6.05e-7	Menarche (age at onset);
PAAD	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.83	-0.36	3.35e-6	Body mass index;
PAAD	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg01305830	chr4:1604576	NA	0.49	4.73	0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.61	7.46	0.52	6.31e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.56	-5.83	-0.43	3.26e-8	Testicular germ cell tumor;
PAAD	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	trans	rs320203	0.741	rs2995194	chr9:104780950	G/C	cg27499259	chr13:28400924	NA	0.97	6.35	0.46	2.4e-9	Mucinous ovarian carcinoma;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.68	0.58	5.8e-15	Platelet count;
PAAD	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.53	-0.34	1.18e-5	Height;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.6	5.68	0.42	6.81e-8	Prudent dietary pattern;
PAAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.46	-4.37	-0.33	2.31e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22827501	chr12:132637734	NA	0.52	6.3	0.46	3.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02743256	chr7:2109353	MAD1L1	-0.73	-5.17	-0.39	7.21e-7	Neuroticism;
PAAD	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10438487	chr15:99640813	NA	0.62	6.99	0.49	7.94e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6693295	0.729	rs12022431	chr1:246216636	A/T	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.93	6.81	0.48	2.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.94	8.86	0.58	1.95e-15	Psoriasis;
PAAD	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.95	0.43	1.77e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg14926445	chr8:58193284	C8orf71	-0.65	-4.79	-0.36	3.87e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.81	8.46	0.57	2.05e-14	Cognitive function;
PAAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.1	0.59	4.77e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7192724	0.576	rs16955980	chr16:81957303	T/G	cg07397481	chr16:81927366	PLCG2	-0.43	-4.29	-0.33	3.23e-5	Breast cancer (menopausal hormone therapy interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22535921	chr3:58419709	PDHB	-0.76	-8.22	-0.55	8.54e-14	Smoking initiation;
PAAD	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.32	-0.33	2.75e-5	Menopause (age at onset);
PAAD	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.51	4.98	0.37	1.74e-6	Schizophrenia;
PAAD	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.88e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.22	0.55	8.12e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.51	6.6	0.47	6.36e-10	Renal cell carcinoma;
PAAD	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.84	-0.49	1.8e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg26752657	chr1:75199075	CRYZ;TYW3	0.54	5.2	0.39	6.46e-7	Resistin levels;
PAAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.92	8.3	0.56	5.27e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.23	0.39	5.44e-7	Migraine;
PAAD	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.28	-0.33	3.3e-5	Blood metabolite levels;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.21e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21862992	chr11:68658383	NA	0.4	4.26	0.33	3.59e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.57	-6.08	-0.44	9.42e-9	Carotid intima media thickness;
PAAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.76	-8.59	-0.57	9.89e-15	Childhood ear infection;
PAAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.55	-7.48	-0.52	5.45e-12	Height;
PAAD	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.18	11.74	0.69	4.59e-23	Corneal structure;
PAAD	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11563648	0.553	rs4731358	chr7:127054787	A/T	cg21885361	chr7:127911034	NA	-0.42	-4.49	-0.34	1.42e-5	Resting heart rate;
PAAD	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-8.37	-0.56	3.59e-14	Bladder cancer;
PAAD	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.65	0.42	7.53e-8	Ileal carcinoids;
PAAD	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs728616	1.000	rs12768613	chr10:81916566	C/T	cg11900509	chr10:81946545	ANXA11	-0.64	-4.54	-0.35	1.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13939156	chr17:80058883	NA	-0.41	-4.43	-0.34	1.79e-5	Life satisfaction;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.45	-0.34	1.64e-5	Chronic sinus infection;
PAAD	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs1012068	0.921	rs5994442	chr22:32271932	C/T	cg01338084	chr22:32026380	PISD	0.6	5.48	0.41	1.72e-7	Chronic hepatitis C infection;
PAAD	cis	rs11235843	0.778	rs4944861	chr11:73430505	G/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg20573242	chr4:122745356	CCNA2	0.64	5.2	0.39	6.25e-7	Type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14524337	chr9:100459217	XPA	-0.77	-7.18	-0.5	2.92e-11	Neuroticism;
PAAD	cis	rs12936587	0.633	rs12949039	chr17:17509721	A/C	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.45	-0.34	1.68e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15584630	chr3:150126560	TSC22D2	0.72	7.96	0.54	3.61e-13	Myopia (pathological);
PAAD	cis	rs78761021	0.755	rs75458334	chr17:9795535	C/T	cg26853458	chr17:9805074	RCVRN	0.73	8.61	0.57	8.62e-15	Type 2 diabetes;
PAAD	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg08648136	chr8:956695	NA	-0.42	-4.6	-0.35	8.76e-6	Schizophrenia;
PAAD	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.65	5.39	0.4	2.68e-7	Schizophrenia;
PAAD	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg26818257	chr2:241905806	NA	0.45	4.68	0.35	6.43e-6	Joint mobility (Beighton score);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12045531	chr12:49259487	RND1	-0.67	-6.69	-0.48	3.96e-10	Smoking initiation;
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.5	0.41	1.6e-7	Total body bone mineral density;
PAAD	cis	rs2017305	0.915	rs111712394	chr10:70660873	C/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.08	-0.38	1.08e-6	Depression (quantitative trait);
PAAD	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg10705379	chr10:99080932	FRAT1	0.39	4.48	0.34	1.46e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.48	-4.83	-0.36	3.26e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.46	-0.4	1.89e-7	Bipolar disorder;
PAAD	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	4.45	0.34	1.65e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6604026	0.740	rs6700585	chr1:93364156	T/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs9463078	0.546	rs12190261	chr6:45029019	T/A	cg25276700	chr6:44698697	NA	0.45	5.04	0.38	1.31e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14180030	chr9:123475675	MEGF9	-0.48	-5.2	-0.39	6.26e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10875658	chr9:73034460	NA	0.65	7.33	0.51	1.28e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	6.78	0.48	2.51e-10	Lung function (FEV1/FVC);
PAAD	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs735539	0.555	rs2253017	chr13:21300909	C/T	cg27234864	chr13:21295941	IL17D	0.61	5.02	0.38	1.4e-6	Dental caries;
PAAD	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg26876637	chr1:152193138	HRNR	-0.85	-6.33	-0.46	2.58e-9	Atopic dermatitis;
PAAD	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.78	10.39	0.64	1.9e-19	Coronary artery disease;
PAAD	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg27471124	chr11:109292789	C11orf87	0.28	5.14	0.38	8.47e-7	Schizophrenia;
PAAD	cis	rs4455778	0.538	rs4326333	chr7:49125565	A/T	cg26309511	chr7:48887640	NA	0.36	4.42	0.34	1.85e-5	Lung cancer in never smokers;
PAAD	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.87	6.95	0.49	9.82e-11	Axial length;
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg12193833	chr17:30244370	NA	-0.64	-5.41	-0.4	2.39e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg24739098	chr15:79297159	RASGRF1	0.34	4.35	0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.63	4.63	0.35	7.69e-6	Alzheimer's disease (survival time);
PAAD	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg07930552	chr6:133119739	C6orf192	0.81	4.47	0.34	1.51e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.68	6.94	0.49	1.04e-10	Platelet distribution width;
PAAD	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	1.03	7.04	0.5	6.03e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg12705353	chr12:122356852	WDR66	0.43	4.49	0.34	1.38e-5	Mean corpuscular volume;
PAAD	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.47	-4.55	-0.35	1.1e-5	Mean platelet volume;
PAAD	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.77	7.35	0.51	1.11e-11	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2131877	0.830	rs952586	chr3:194842322	G/A	cg16306870	chr3:194868790	C3orf21	0.5	5.09	0.38	1.04e-6	Non-small cell lung cancer;
PAAD	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg24238205	chr11:58912174	FAM111A	-0.5	-4.27	-0.33	3.47e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.12	14.96	0.77	1.09e-31	Cognitive function;
PAAD	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg04450456	chr4:17643702	FAM184B	-0.47	-5.13	-0.38	8.74e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.73	5.71	0.42	5.68e-8	Diisocyanate-induced asthma;
PAAD	cis	rs4704187	0.687	rs10462354	chr5:74453027	T/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.55	4.88	0.37	2.71e-6	Type 2 diabetes;
PAAD	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg27411982	chr8:10470053	RP1L1	0.48	5.27	0.39	4.57e-7	Retinal vascular caliber;
PAAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.42	0.46	1.66e-9	Lung cancer in ever smokers;
PAAD	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg17182837	chr8:41585554	ANK1	-0.46	-4.32	-0.33	2.84e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17155006	0.621	rs436573	chr7:107739906	A/T	cg05962710	chr7:107745446	LAMB4	-0.58	-7.84	-0.54	7.21e-13	Pneumococcal bacteremia;
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg00684032	chr4:1343700	KIAA1530	-0.52	-4.35	-0.33	2.52e-5	Systolic blood pressure;
PAAD	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.8	7.88	0.54	5.82e-13	Corneal astigmatism;
PAAD	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	4.68	0.35	6.42e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs567508	0.584	rs584037	chr11:126012987	T/C	cg08415973	chr6:40346114	TDRG1	-0.72	-6.51	-0.47	1.03e-9	Lung function (FEV1);
PAAD	cis	rs10065203	0.527	rs152177	chr5:14354270	G/A	cg26595256	chr5:14380529	TRIO	-0.54	-5.9	-0.43	2.28e-8	Paclitaxel-induced neuropathy;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.78	8.64	0.57	7.13e-15	Lung cancer;
PAAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.52	5.42	0.4	2.26e-7	Personality dimensions;
PAAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.42	5.31	0.4	3.76e-7	Ulcerative colitis;
PAAD	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg01075559	chr1:2537774	MMEL1	0.51	5.44	0.4	2.12e-7	Ulcerative colitis;
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.78	-6.94	-0.49	1.08e-10	Calcium levels;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg23205692	chr1:25664452	TMEM50A	0.48	4.58	0.35	9.75e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.52	-5.95	-0.43	1.82e-8	Systemic lupus erythematosus;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.46e-8	Electroencephalogram traits;
PAAD	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Gout;
PAAD	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg19701658	chr3:160286309	NA	-0.47	-4.39	-0.34	2.07e-5	Primary biliary cholangitis;
PAAD	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.65	-0.35	7.1e-6	Total body bone mineral density;
PAAD	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	cis	rs9896052	0.580	rs6501809	chr17:73467274	C/T	cg25649188	chr17:73499917	CASKIN2	0.61	4.66	0.35	6.77e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs490234	0.841	rs2793135	chr9:128338620	A/G	cg14078157	chr9:128172775	NA	0.44	4.94	0.37	2.03e-6	Mean arterial pressure;
PAAD	cis	rs4764124	0.592	rs12818627	chr12:14923522	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	5.51	0.41	1.52e-7	Pubertal anthropometrics;
PAAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.48	4.63	0.35	7.64e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg22777020	chr22:31556080	RNF185	0.55	4.51	0.34	1.29e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.81	-8.79	-0.58	3.06e-15	Urate levels in obese individuals;
PAAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.32	-0.51	1.36e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs4748857	0.947	rs7084042	chr10:23509719	T/C	cg18853376	chr10:23633759	C10orf67	0.54	4.93	0.37	2.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg16898833	chr6:26189333	HIST1H4D	0.63	4.67	0.35	6.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.71	11.13	0.67	2e-21	Breast cancer;
PAAD	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Bladder cancer;
PAAD	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg25025879	chr12:53359317	NA	-0.81	-9.17	-0.6	3.09e-16	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs6604026	0.656	rs11578986	chr1:93402823	G/T	cg17283838	chr1:93427260	FAM69A	0.61	5.71	0.42	5.64e-8	Multiple sclerosis;
PAAD	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg10578991	chr7:12443926	VWDE	-0.66	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.74	0.36	4.83e-6	Bipolar disorder;
PAAD	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.85	-9.02	-0.59	7.63e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4668356	1.000	rs16859167	chr2:171983407	T/C	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.5	5.23	0.39	5.49e-7	Testicular germ cell tumor;
PAAD	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.55	5.25	0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg12215294	chr3:40350768	EIF1B	0.45	4.26	0.33	3.52e-5	Renal cell carcinoma;
PAAD	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg10223061	chr2:219282414	VIL1	-0.39	-4.67	-0.35	6.56e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	5.85	0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg20060109	chr17:81052770	NA	-0.45	-4.4	-0.34	2e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07685180	chr8:600429	NA	-0.87	-4.9	-0.37	2.4e-6	IgG glycosylation;
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.66	-7.85	-0.54	6.81e-13	Vitiligo;
PAAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.79	5.14	0.38	8.39e-7	Yeast infection;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23427859	chr5:128430169	ISOC1	0.62	6.47	0.46	1.28e-9	Myopia (pathological);
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05025164	chr4:1340916	KIAA1530	0.58	6.23	0.45	4.3e-9	Obesity-related traits;
PAAD	cis	rs13053817	0.948	rs13058415	chr22:29848481	G/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.53	-4.59	-0.35	9.37e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs797680	0.964	rs4847398	chr1:93578402	C/T	cg04535902	chr1:92947332	GFI1	0.45	4.35	0.33	2.48e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.81	6.5	0.47	1.09e-9	Mean platelet volume;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.28	-4.29	-0.33	3.2e-5	Longevity;Endometriosis;
PAAD	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg13263323	chr15:86062960	AKAP13	-0.6	-7.0	-0.49	7.66e-11	Interstitial lung disease;
PAAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.75	-8.15	-0.55	1.21e-13	Lung function (FVC);
PAAD	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.49	-4.55	-0.35	1.11e-5	Response to antidepressants and depression;
PAAD	cis	rs10506621	0.764	rs7302994	chr12:71399128	C/T	cg14337085	chr12:72233324	TBC1D15	-0.64	-4.41	-0.34	1.93e-5	Gut microbiome composition (winter);
PAAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26796135	chr15:45671001	LOC145663;GATM	0.48	4.3	0.33	2.99e-5	Homoarginine levels;
PAAD	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-4.59	-0.35	9.28e-6	Morning vs. evening chronotype;
PAAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17264618	chr3:40429014	ENTPD3	0.35	4.31	0.33	2.95e-5	Renal cell carcinoma;
PAAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg04717802	chr22:42394638	WBP2NL	0.56	4.59	0.35	9.04e-6	Birth weight;
PAAD	cis	rs10121009	0.610	rs10972437	chr9:35330824	A/G	cg11846315	chr9:35647073	NA	-0.5	-4.55	-0.35	1.09e-5	Parkinson's disease;
PAAD	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.54	7.19	0.5	2.76e-11	Primary biliary cholangitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09655100	chr10:114709926	TCF7L2	-0.67	-6.5	-0.47	1.06e-9	Neuroticism;
PAAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.63e-11	Eye color traits;
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.46	4.45	0.34	1.68e-5	Lung cancer;
PAAD	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.79	9.11	0.59	4.54e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.48	4.39	0.34	2.1e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-5.61	-0.41	9.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.89	10.8	0.66	1.54e-20	Cannabis dependence symptom count;
PAAD	cis	rs9532580	0.524	rs79703116	chr13:41136442	C/T	cg21288729	chr13:41239152	FOXO1	0.54	4.32	0.33	2.81e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.86	-10.36	-0.64	2.34e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2133450	0.967	rs17697287	chr3:7349755	G/A	cg19930620	chr3:7340148	GRM7	-0.44	-4.58	-0.35	9.48e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.44	-5.06	-0.38	1.18e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg20607798	chr8:58055168	NA	-0.57	-4.6	-0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.69	7.37	0.51	1.02e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	1.08	13.64	0.74	3.49e-28	Gut microbiome composition (winter);
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.62	-7.9	-0.54	5.25e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg02071572	chr4:1403502	NA	0.39	4.84	0.37	3.2e-6	Obesity-related traits;
PAAD	cis	rs1190596	0.830	rs4947	chr14:102550803	G/A	cg23289024	chr14:102554846	HSP90AA1	-0.44	-4.72	-0.36	5.4e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs13242816	1.000	rs12706090	chr7:116104045	A/G	cg16553024	chr7:116138462	CAV2	0.71	5.03	0.38	1.37e-6	P wave duration;
PAAD	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.63	0.57	7.56e-15	Bladder cancer;
PAAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg11995313	chr8:8860691	ERI1	0.43	4.3	0.33	2.99e-5	Mood instability;
PAAD	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.73	8.43	0.56	2.44e-14	Metabolic syndrome;
PAAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	9.12	0.59	4.26e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.64	4.5	0.34	1.36e-5	White matter hyperintensity burden;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.15	-0.39	8.14e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs11761408	0.585	rs7800499	chr7:5257287	G/A	cg02820836	chr7:4652842	NA	-0.72	-4.35	-0.33	2.52e-5	Mean corpuscular volume;
PAAD	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	4.86	0.37	2.95e-6	Hirschsprung disease;
PAAD	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.37	0.51	1.04e-11	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg03676636	chr4:99064102	C4orf37	0.31	5.61	0.41	9.29e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg07395648	chr5:131743802	NA	-0.62	-6.4	-0.46	1.83e-9	Blood metabolite levels;
PAAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.54	5.69	0.42	6.37e-8	Blood metabolite levels;
PAAD	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.85	7.72	0.53	1.46e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.9	-6.2	-0.45	5.1e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.55	4.71	0.36	5.5e-6	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg17868515	chr10:100992068	HPSE2	-0.39	-4.48	-0.34	1.49e-5	Metabolite levels;
PAAD	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs790123	0.565	rs112785037	chr3:122386128	A/T	cg15604389	chr3:122379662	NA	0.55	4.53	0.34	1.21e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.44	0.4	2.06e-7	Height;
PAAD	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.79	-5.11	-0.38	9.66e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg20933634	chr6:27740509	NA	0.65	6.15	0.45	6.6e-9	Parkinson's disease;
PAAD	cis	rs10921219	0.966	rs6701996	chr1:192586687	C/T	cg12725760	chr1:192873912	NA	-0.4	-4.33	-0.33	2.74e-5	Survival in colon cancer;
PAAD	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.69	6.53	0.47	9.49e-10	Uric acid levels;
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.67	-7.94	-0.54	4.27e-13	Vitiligo;
PAAD	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.65	-0.79	1.66e-33	Schizophrenia;
PAAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.87	10.21	0.64	5.7e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.69	-7.71	-0.53	1.52e-12	Motion sickness;
PAAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.62	6.36	0.46	2.2e-9	Electroencephalogram traits;
PAAD	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	5.04	0.38	1.33e-6	Thyroid stimulating hormone;
PAAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.53	-4.49	-0.34	1.38e-5	Menarche (age at onset);
PAAD	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs11172134	0.508	rs1800191	chr12:57590758	C/T	cg01515074	chr12:57585135	LRP1	0.46	4.35	0.33	2.46e-5	Urate levels in overweight individuals;
PAAD	cis	rs73416724	0.688	rs77688577	chr6:43328629	A/G	cg17076780	chr6:43251928	TTBK1	0.74	5.22	0.39	5.85e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs11651753	0.613	rs3096	chr17:46029432	T/G	cg24458315	chr17:46148407	CBX1	0.45	4.7	0.36	5.87e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs1847202	0.859	rs11923247	chr3:72923306	A/G	cg25664220	chr3:72788482	NA	-0.48	-5.18	-0.39	6.8e-7	Motion sickness;
PAAD	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.85	10.16	0.64	8.02e-19	Urate levels in overweight individuals;
PAAD	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.76	5.81	0.43	3.53e-8	Mean platelet volume;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.57	5.68	0.42	6.77e-8	Parkinson's disease;
PAAD	cis	rs17407555	0.683	rs6852641	chr4:10275746	G/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.24	0.39	5.18e-7	Schizophrenia (age at onset);
PAAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs9810890	0.850	rs72977135	chr3:128661260	G/T	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.54	0.41	1.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.77	0.48	2.57e-10	Menarche (age at onset);
PAAD	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.79	-6.1	-0.44	8.52e-9	Uric acid levels;
PAAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.53	-0.34	1.2e-5	Breast cancer;
PAAD	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs112591243	0.685	rs78463142	chr21:47964481	A/G	cg26904215	chr21:47823096	PCNT	-0.82	-4.37	-0.33	2.29e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg02780029	chr10:43622663	RET	-0.48	-4.75	-0.36	4.73e-6	Hirschsprung disease;
PAAD	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg18551225	chr6:44695536	NA	-0.73	-7.31	-0.51	1.45e-11	Total body bone mineral density;
PAAD	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg18551225	chr6:44695536	NA	-0.6	-6.43	-0.46	1.53e-9	Total body bone mineral density;
PAAD	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.61	-6.23	-0.45	4.41e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	6.18	0.45	5.61e-9	Lymphocyte counts;
PAAD	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20361267	chr4:751205	PCGF3	-0.65	-6.71	-0.48	3.59e-10	Obesity-related traits;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Body mass index;
PAAD	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.79	-6.24	-0.45	4.22e-9	Schizophrenia;
PAAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg00049323	chr5:472564	LOC25845	-0.46	-4.74	-0.36	4.93e-6	Cystic fibrosis severity;
PAAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg07873178	chr11:65307616	LTBP3	0.72	4.62	0.35	8.14e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs58521262	0.556	rs289294	chr19:23176773	A/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg09455208	chr3:40491958	NA	0.45	5.77	0.42	4.3e-8	Renal cell carcinoma;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg08888203	chr3:10149979	C3orf24	0.69	6.27	0.45	3.58e-9	Alzheimer's disease;
PAAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.6	5.14	0.39	8.2e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs7172971	0.688	rs112413693	chr15:42383864	C/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg24642844	chr7:1081250	C7orf50	0.56	4.61	0.35	8.43e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.44	5.47	0.41	1.79e-7	Prostate cancer;
PAAD	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.75	-7.82	-0.54	8.19e-13	Blood metabolite levels;
PAAD	cis	rs11690935	0.959	rs6738445	chr2:172599615	T/C	cg13550731	chr2:172543902	DYNC1I2	1.1	14.96	0.77	1.1e-31	Schizophrenia;
PAAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7577696	0.785	rs11689817	chr2:32364241	T/A	cg02381751	chr2:32503542	YIPF4	-0.48	-4.81	-0.36	3.53e-6	Inflammatory biomarkers;
PAAD	cis	rs346785	0.692	rs4789273	chr17:74286082	A/G	cg09812376	chr17:74270190	QRICH2	0.47	5.72	0.42	5.6e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.65	6.19	0.45	5.22e-9	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg00579200	chr11:133705235	NA	0.5	5.51	0.41	1.54e-7	Childhood ear infection;
PAAD	cis	rs4757319	0.515	rs7109366	chr11:15438964	T/C	cg03245590	chr11:15329459	NA	0.44	5.19	0.39	6.53e-7	Breast cancer;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.62	0.57	8.35e-15	Alzheimer's disease;
PAAD	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.69	7.57	0.52	3.27e-12	Menarche (age at onset);
PAAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.7	6.74	0.48	3.01e-10	Parkinson's disease;
PAAD	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.44	0.61	6.39e-17	Cognitive test performance;
PAAD	cis	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg27411982	chr8:10470053	RP1L1	0.47	5.47	0.41	1.8e-7	Neuroticism;
PAAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.93e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg21565972	chr17:80109576	CCDC57	0.58	6.72	0.48	3.39e-10	Life satisfaction;
PAAD	cis	rs9810890	0.850	rs62265295	chr3:128654636	C/T	cg18531004	chr3:128564980	NA	-0.79	-4.72	-0.36	5.36e-6	Dental caries;
PAAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06544989	chr22:39130855	UNC84B	0.52	5.42	0.4	2.3e-7	Menopause (age at onset);
PAAD	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	1.11	14.59	0.76	1.03e-30	Migraine;
PAAD	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.49	5.66	0.42	7.25e-8	Dilated cardiomyopathy;
PAAD	cis	rs13144136	0.687	rs12499294	chr4:10654086	T/C	cg10242279	chr4:10666415	CLNK	-0.49	-6.44	-0.46	1.52e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14169450	chr9:139327907	INPP5E	0.61	5.58	0.41	1.07e-7	White blood cell count;
PAAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.96	10.64	0.65	4.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.61	6.4	0.46	1.79e-9	Loneliness (linear analysis);
PAAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.88	0.54	5.91e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.47e-9	Hypospadias;
PAAD	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg11062466	chr8:58055876	NA	0.71	4.86	0.37	2.86e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.45	0.34	1.66e-5	Tonsillectomy;
PAAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.82	11.11	0.67	2.31e-21	Emphysema distribution in smoking;
PAAD	cis	rs802075	0.806	rs12215136	chr6:49645869	A/G	cg20364632	chr6:49636226	NA	-0.46	-5.2	-0.39	6.45e-7	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26321464	chr19:7968588	MAP2K7	0.57	6.46	0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.81	9.39	0.61	8.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.85	9.1	0.59	4.79e-16	Body mass index;
PAAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.16	16.6	0.8	5.87e-36	Cognitive function;
PAAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-5.58	-0.41	1.09e-7	Gut microbiome composition (summer);
PAAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.66	0.53	2.04e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg23920097	chr1:209922102	NA	-0.48	-4.67	-0.35	6.6e-6	Red blood cell count;
PAAD	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.37	-7.12	-0.5	3.96e-11	Mean corpuscular volume;
PAAD	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg02135003	chr7:105160482	PUS7	-0.92	-6.7	-0.48	3.84e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg14686297	chr22:46650375	NA	-0.45	-4.58	-0.35	9.67e-6	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-6.67	-0.48	4.58e-10	Blood pressure (smoking interaction);
PAAD	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21659725	chr3:3221576	CRBN	0.83	9.58	0.61	2.71e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg14393609	chr7:65229607	NA	-0.49	-4.32	-0.33	2.83e-5	Aortic root size;
PAAD	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	6.61	0.47	6.03e-10	Coronary artery disease;
PAAD	cis	rs4281086	0.930	rs4240647	chr8:10354561	A/C	cg01072821	chr8:10382165	T-SP1	-0.45	-4.4	-0.34	2.06e-5	Obesity-related traits;
PAAD	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-1.27	-10.12	-0.63	1.02e-18	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-10.04	-0.63	1.68e-18	Response to antipsychotic treatment;
PAAD	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg05338066	chr1:7812865	CAMTA1	0.64	4.86	0.37	2.88e-6	Inflammatory bowel disease;
PAAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.62	-6.61	-0.47	6.1e-10	Longevity;
PAAD	cis	rs7568458	0.783	rs7591175	chr2:85738374	G/T	cg23752985	chr2:85803571	VAMP8	0.55	6.26	0.45	3.75e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.75	-5.15	-0.39	7.86e-7	Coronary artery calcification;
PAAD	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.59	5.53	0.41	1.37e-7	Height;
PAAD	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs2302729	0.578	rs7315556	chr12:2773855	G/A	cg19945202	chr12:2788847	CACNA1C	-0.76	-7.94	-0.54	4.15e-13	Sleep quality;
PAAD	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-5.36	-0.4	3.1e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02717618	chr18:42258984	SETBP1	0.59	6.3	0.46	2.98e-9	Obesity-related traits;
PAAD	cis	rs6494488	0.500	rs55990268	chr15:64854304	A/G	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.65	6.99	0.49	8.04e-11	Body mass index;
PAAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg01444801	chr10:135216882	MTG1	-0.61	-5.43	-0.4	2.14e-7	Systemic lupus erythematosus;
PAAD	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.21	0.39	5.93e-7	Schizophrenia;
PAAD	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.2	-0.5	2.52e-11	Alcohol dependence;
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg02462569	chr6:150064036	NUP43	-0.43	-4.87	-0.37	2.83e-6	Lung cancer;
PAAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.63	4.26	0.33	3.58e-5	Lung cancer in ever smokers;
PAAD	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.17	0.39	7.38e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-5.04	-0.38	1.28e-6	Neuroticism;
PAAD	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.85	9.0	0.59	8.87e-16	Corneal astigmatism;
PAAD	cis	rs11971779	0.715	rs6467854	chr7:139127083	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs9361491	0.608	rs9352620	chr6:79443547	T/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs375066	0.967	rs417400	chr19:44410846	A/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	4.04e-10	Atopic dermatitis;
PAAD	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.61	6.73	0.48	3.33e-10	Tonsillectomy;
PAAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.75	6.42	0.46	1.61e-9	Pediatric autoimmune diseases;
PAAD	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.55	6.0	0.44	1.36e-8	Tonsillectomy;
PAAD	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.8	7.94	0.54	4.25e-13	Corneal astigmatism;
PAAD	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-5.93	-0.43	2e-8	Homocysteine levels;
PAAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02071572	chr4:1403502	NA	0.52	6.84	0.49	1.77e-10	Longevity;
PAAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg24846680	chr1:228362309	C1orf69	0.45	4.35	0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs4713675	0.709	rs542441	chr6:33675851	A/C	cg25922239	chr6:33757077	LEMD2	-0.45	-4.44	-0.34	1.69e-5	Plateletcrit;
PAAD	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.7e-6	Plateletcrit;
PAAD	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.76	-0.62	8.83e-18	Blood trace element (Zn levels);
PAAD	cis	rs6500550	0.599	rs2379220	chr16:3694299	G/C	cg01678580	chr16:4674018	MGRN1	0.48	4.54	0.35	1.14e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17583526	chr6:139695867	CITED2	0.61	6.45	0.46	1.42e-9	Myopia (pathological);
PAAD	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.37e-7	Life satisfaction;
PAAD	cis	rs96067	0.652	rs274124	chr1:36591554	A/G	cg27506609	chr1:36549197	TEKT2	-0.85	-4.95	-0.37	1.91e-6	Corneal structure;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07167872	chr1:205819463	PM20D1	0.45	4.26	0.33	3.62e-5	Parkinson's disease;
PAAD	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.61	-5.83	-0.43	3.14e-8	Subjective well-being;
PAAD	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.8	-5.6	-0.41	9.74e-8	Coronary artery calcification;
PAAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs12900413	0.687	rs12902809	chr15:90305617	C/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.81	-0.43	3.51e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg07395648	chr5:131743802	NA	0.51	4.28	0.33	3.26e-5	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.53	-4.91	-0.37	2.34e-6	Corneal structure;
PAAD	cis	rs58521262	0.585	rs1645768	chr19:23199441	G/A	cg02350677	chr19:23254381	NA	0.25	4.35	0.33	2.53e-5	Testicular germ cell tumor;
PAAD	cis	rs12044355	0.827	rs16854783	chr1:231827371	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.61	-0.41	9.28e-8	Alzheimer's disease;
PAAD	cis	rs12311304	0.965	rs11056400	chr12:15365558	A/G	cg08258403	chr12:15378311	NA	-0.35	-4.6	-0.35	8.86e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.09	9.44	0.61	6.32e-17	Platelet count;
PAAD	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06307176	chr5:131281290	NA	-0.51	-4.7	-0.36	5.85e-6	Life satisfaction;
PAAD	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.58	-5.68	-0.42	6.72e-8	Coronary artery disease or large artery stroke;
PAAD	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.62	5.44	0.4	2.07e-7	Response to diuretic therapy;
PAAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.51	6.53	0.47	9.19e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13047869	chr3:10149882	C3orf24	0.72	5.93	0.43	1.95e-8	Alzheimer's disease;
PAAD	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.5	-4.76	-0.36	4.44e-6	Hepatocellular carcinoma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06775644	chr17:54991465	TRIM25	-0.76	-6.53	-0.47	9.51e-10	Neuroticism;
PAAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7904985	0.813	rs724862	chr10:88100542	C/G	cg07322936	chr10:88137208	NA	-0.47	-4.34	-0.33	2.59e-5	Barrett's esophagus;
PAAD	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg01378222	chr16:28622494	SULT1A1	-0.8	-5.26	-0.39	4.81e-7	Platelet distribution width;
PAAD	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.51	-4.45	-0.34	1.62e-5	Airflow obstruction;
PAAD	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-4.58	-0.35	9.76e-6	Menarche (age at onset);
PAAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.95	11.62	0.69	9.83e-23	Cognitive function;
PAAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg04370829	chr17:406249	NA	-0.49	-5.03	-0.38	1.38e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.77	-8.24	-0.56	7.34e-14	Cognitive function;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg25204440	chr1:209979598	IRF6	0.63	5.62	0.41	8.78e-8	Coronary artery disease;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg16898833	chr6:26189333	HIST1H4D	0.59	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	0.941	rs4721825	chr7:19823427	A/C	cg07541023	chr7:19748670	TWISTNB	0.56	4.52	0.34	1.24e-5	Thyroid stimulating hormone;
PAAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg16576597	chr16:28551801	NUPR1	0.64	7.03	0.5	6.46e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.48	-4.62	-0.35	8.25e-6	Monocyte count;
PAAD	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colorectal cancer;
PAAD	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.73	7.82	0.54	8.33e-13	Morning vs. evening chronotype;
PAAD	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.71	7.01	0.49	7.32e-11	Coronary artery disease;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	1.07	6.43	0.46	1.56e-9	Body mass index;
PAAD	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.55	6.25	0.45	3.88e-9	Mean corpuscular volume;
PAAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.61	-0.35	8.51e-6	Height;
PAAD	trans	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.56	6.29	0.45	3.14e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.61	-6.09	-0.44	8.76e-9	Red cell distribution width;
PAAD	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06109238	chr13:99017232	FARP1	0.64	6.87	0.49	1.57e-10	Smoking initiation;
PAAD	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	1.02	8.22	0.55	8.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg09127314	chr1:152161683	NA	-0.6	-4.34	-0.33	2.6e-5	Atopic dermatitis;
PAAD	cis	rs112990264	1.000	rs58746017	chr1:213028559	A/G	cg01785514	chr1:212988523	TATDN3	1.22	8.27	0.56	6.24e-14	Itch intensity from mosquito bite;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.73	0.48	3.31e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs4740619	0.935	rs4741519	chr9:15623961	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.11e-5	Body mass index;
PAAD	cis	rs7714584	1.000	rs10041072	chr5:150259642	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	4.6	0.35	8.68e-6	Mood instability;
PAAD	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg23024343	chr7:107201750	COG5	0.54	4.32	0.33	2.79e-5	Osteoarthritis;
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.65	5.12	0.38	8.93e-7	Alzheimer's disease;
PAAD	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	1.09	11.02	0.67	3.96e-21	Eosinophil percentage of granulocytes;
PAAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.83	0.36	3.34e-6	Depression;
PAAD	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	trans	rs901683	0.702	rs4418752	chr10:46102971	A/G	cg13039199	chr15:92455658	SLCO3A1	1.29	6.46	0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13092825	0.794	rs35452897	chr3:113282075	C/T	cg08171471	chr3:113771720	KIAA1407	0.56	5.06	0.38	1.22e-6	Dental caries;
PAAD	cis	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs8063160	0.756	rs71396951	chr16:89726593	G/C	cg07984980	chr16:89898383	SPIRE2	0.89	4.99	0.38	1.63e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	1.02	5.25	0.39	5.1e-7	Plasma clusterin levels;
PAAD	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.08	0.38	1.11e-6	Educational attainment;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.66	-0.42	7.41e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.75	6.57	0.47	7.54e-10	Coronary artery disease;
PAAD	cis	rs9646944	0.501	rs2110736	chr2:103050855	T/C	cg03938978	chr2:103052716	IL18RAP	0.5	4.28	0.33	3.28e-5	Blood protein levels;
PAAD	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.77	8.51	0.57	1.58e-14	Body mass index;
PAAD	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.26	-0.39	4.87e-7	Testicular germ cell tumor;
PAAD	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15506890	chr2:3487001	NA	-0.75	-7.34	-0.51	1.19e-11	Neurofibrillary tangles;
PAAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg06740227	chr12:86229804	RASSF9	0.52	5.22	0.39	5.85e-7	Major depressive disorder;
PAAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs9810890	1.000	rs116772388	chr3:128453215	A/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg20302533	chr7:39170763	POU6F2	-0.46	-7.49	-0.52	5.14e-12	IgG glycosylation;
PAAD	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg22705602	chr4:152727874	NA	-0.43	-4.3	-0.33	3.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12767760	0.651	rs12243136	chr10:99321661	C/G	cg25247692	chr10:99313390	UBTD1	-0.57	-5.57	-0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.68	6.92	0.49	1.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.82	9.92	0.63	3.49e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs597480	0.853	rs652615	chr11:85485450	T/C	cg11817631	chr11:85522609	SYTL2	-0.53	-5.03	-0.38	1.34e-6	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs4740619	0.619	rs1328298	chr9:16046417	T/C	cg14451791	chr9:16040625	NA	-0.46	-5.19	-0.39	6.54e-7	Body mass index;
PAAD	cis	rs10512697	0.772	rs6874923	chr5:3533998	G/A	cg19473799	chr5:3511975	NA	-0.92	-4.28	-0.33	3.27e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg03684893	chr10:554711	DIP2C	0.47	5.23	0.39	5.43e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	12.46	0.71	5.37e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	5.99e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1497828	0.956	rs2815242	chr1:217552998	C/T	cg04411442	chr1:217543379	NA	0.5	4.94	0.37	2.06e-6	Dialysis-related mortality;
PAAD	cis	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg03989125	chr22:38214979	NA	0.62	5.77	0.42	4.28e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.43	5.21	0.39	6.06e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	10.97	0.66	5.49e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg12218747	chr21:37451666	NA	0.48	5.34	0.4	3.3e-7	Mitral valve prolapse;
PAAD	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.77	8.66	0.57	6.34e-15	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07362569	chr17:61921086	SMARCD2	0.63	8.0	0.54	2.94e-13	Prudent dietary pattern;
PAAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg06740227	chr12:86229804	RASSF9	0.49	4.29	0.33	3.19e-5	Major depressive disorder;
PAAD	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.79	9.33	0.6	1.21e-16	Bladder cancer;
PAAD	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.87	10.87	0.66	1.03e-20	Prudent dietary pattern;
PAAD	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg10395934	chr14:104002654	TRMT61A	0.53	5.28	0.39	4.37e-7	Body mass index;
PAAD	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg08824895	chr13:115047677	UPF3A	0.51	4.71	0.36	5.6e-6	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg21130718	chr4:1044621	NA	-0.53	-4.53	-0.35	1.18e-5	Recombination rate (females);
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.56	-4.44	-0.34	1.71e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg20406979	chr6:167373233	NA	-0.34	-4.63	-0.35	7.65e-6	Crohn's disease;
PAAD	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-4.25	-0.33	3.76e-5	Menarche (age at onset);
PAAD	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.58	5.75	0.42	4.73e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.48	6.7	0.48	3.77e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-1.02	-6.3	-0.46	3.05e-9	Type 2 diabetes;
PAAD	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-13.92	-0.75	6.4e-29	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25861660	chr7:28145849	JAZF1	0.53	6.29	0.45	3.22e-9	Smoking initiation;
PAAD	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.96	-0.44	1.65e-8	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24712417	chr20:33543845	GSS	0.66	7.27	0.51	1.72e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7765175	0.598	rs2801419	chr6:113658814	C/T	cg19037598	chr6:113666021	NA	-0.41	-4.38	-0.34	2.17e-5	Coronary artery calcification;
PAAD	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.81	9.61	0.61	2.19e-17	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6964492	0.576	rs10488453	chr7:134405602	A/T	cg22430036	chr7:134592620	CALD1	0.51	4.68	0.36	6.25e-6	Tonsillectomy;
PAAD	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	1.06	10.78	0.66	1.81e-20	Post bronchodilator FEV1;
PAAD	cis	rs73416724	0.544	rs45564136	chr6:43251880	C/G	cg17076780	chr6:43251928	TTBK1	0.74	5.99	0.44	1.44e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg20312557	chr2:97357134	FER1L5	-0.87	-4.42	-0.34	1.85e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg18769074	chr3:133464867	TF	0.43	4.96	0.37	1.9e-6	Iron status biomarkers;
PAAD	cis	rs7247513	0.930	rs1864082	chr19:12707904	T/C	cg01871581	chr19:12707946	ZNF490	-0.86	-10.76	-0.66	1.99e-20	Bipolar disorder;
PAAD	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg01000188	chr9:133769184	QRFP	0.55	4.74	0.36	4.94e-6	Response to amphetamines;
PAAD	cis	rs8133932	0.701	rs7280054	chr21:47301246	T/G	cg13695288	chr21:47294981	PCBP3	-0.47	-4.61	-0.35	8.65e-6	Schizophrenia;
PAAD	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg10820045	chr2:198174542	NA	-0.44	-4.41	-0.34	1.92e-5	Dermatomyositis;
PAAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.47	0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs73416724	0.841	rs78415183	chr6:43394041	T/G	cg17076780	chr6:43251928	TTBK1	0.56	4.47	0.34	1.49e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg21419209	chr3:44054225	NA	-0.7	-6.83	-0.48	1.9e-10	Coronary artery disease;
PAAD	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.95	0.37	1.98e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg24733560	chr20:60626293	TAF4	0.52	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.82	-10.34	-0.64	2.65e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg20406979	chr6:167373233	NA	0.37	4.95	0.37	1.96e-6	Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02358165	chr17:78388892	FLJ35220;LOC100294362	-0.74	-6.5	-0.47	1.07e-9	Neuroticism;
PAAD	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.63	-5.48	-0.41	1.76e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.44	4.84	0.37	3.2e-6	HDL cholesterol levels;
PAAD	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.06e-7	Testicular germ cell tumor;
PAAD	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.61	-7.33	-0.51	1.3e-11	Schizophrenia;
PAAD	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg15211996	chr1:2936768	ACTRT2	0.45	4.34	0.33	2.55e-5	Plateletcrit;
PAAD	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg01422370	chr2:73384389	NA	0.39	5.13	0.38	8.8e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg00277334	chr10:82204260	NA	-0.54	-5.78	-0.42	4.08e-8	Sarcoidosis;
PAAD	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.61	-6.06	-0.44	1.02e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg13814708	chr10:81144099	ZCCHC24	-0.4	-4.43	-0.34	1.79e-5	Height;
PAAD	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	4.37	0.33	2.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.98	-8.52	-0.57	1.47e-14	Platelet count;
PAAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg08493051	chr2:3487164	NA	-0.76	-7.3	-0.51	1.48e-11	Neurofibrillary tangles;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18621852	chr3:10150065	C3orf24	-0.69	-6.08	-0.44	9.51e-9	Alzheimer's disease;
PAAD	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg23461800	chr14:103021989	NA	-0.64	-4.59	-0.35	9.35e-6	Platelet count;
PAAD	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg13611204	chr9:139324423	INPP5E	-0.55	-4.6	-0.35	8.82e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.71	11.1	0.67	2.4e-21	Breast cancer;
PAAD	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.84	10.02	0.63	1.88e-18	Selective IgA deficiency;
PAAD	cis	rs2075671	0.818	rs10953302	chr7:100365567	C/T	cg03098644	chr7:100410630	EPHB4	0.62	4.57	0.35	9.83e-6	Other erythrocyte phenotypes;
PAAD	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.6	0.57	9.29e-15	Schizophrenia;
PAAD	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg13263323	chr15:86062960	AKAP13	-0.62	-7.16	-0.5	3.21e-11	Interstitial lung disease;
PAAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.62	-6.91	-0.49	1.27e-10	Longevity;Endometriosis;
PAAD	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.56	-7.31	-0.51	1.4e-11	Longevity;
PAAD	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.85	9.87	0.62	4.62e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs797680	0.964	rs1932314	chr1:93638400	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.38	0.33	2.17e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.71	8.99	0.59	8.99e-16	Dupuytren's disease;
PAAD	cis	rs4740619	0.619	rs1328279	chr9:16030606	A/G	cg14451791	chr9:16040625	NA	-0.46	-5.41	-0.4	2.36e-7	Body mass index;
PAAD	cis	rs3812111	0.525	rs6914038	chr6:116549029	A/G	cg18828861	chr6:116576566	TSPYL4	0.43	4.6	0.35	8.83e-6	Age-related macular degeneration;
PAAD	cis	rs2688419	0.545	rs6550719	chr3:23072185	C/G	cg00327796	chr3:23032191	NA	-0.47	-4.65	-0.35	7.16e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00531307	chr14:50998683	MAP4K5;ATL1	0.64	7.26	0.51	1.82e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.63	5.97	0.44	1.65e-8	Refractive astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26887273	chr8:120845229	TAF2	0.58	6.57	0.47	7.63e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.87	7.8	0.53	9.09e-13	Coronary artery disease;
PAAD	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.31	0.4	3.83e-7	Rheumatoid arthritis;
PAAD	cis	rs11669133	1.000	rs45618443	chr19:11107295	G/A	cg25243385	chr19:11167475	SMARCA4	0.96	4.61	0.35	8.33e-6	LDL cholesterol;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.89	5.83	0.43	3.19e-8	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13442152	chr1:168044891	DCAF6	-0.62	-6.62	-0.47	5.78e-10	Obesity-related traits;
PAAD	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg06217071	chr17:408420	NA	0.48	5.01	0.38	1.52e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.73	7.49	0.52	5.32e-12	Alcohol dependence;
PAAD	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-4.92	-0.37	2.27e-6	Mean corpuscular volume;
PAAD	cis	rs300774	0.925	rs300708	chr2:140449	A/G	cg21211680	chr2:198530	NA	-0.6	-5.72	-0.42	5.44e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.58	6.0	0.44	1.41e-8	Mean corpuscular volume;
PAAD	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.85	-0.54	7.01e-13	Neuroticism;
PAAD	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.43	5.38	0.4	2.76e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.7	-7.75	-0.53	1.25e-12	Magnesium levels;
PAAD	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.49	4.6	0.35	8.69e-6	Hirschsprung disease;
PAAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.78	-6.98	-0.49	8.47e-11	Obesity-related traits;
PAAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.78	-7.76	-0.53	1.16e-12	Urate levels in lean individuals;
PAAD	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.01	-0.49	7.12e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.73	-4.64	-0.35	7.46e-6	White matter integrity;
PAAD	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.6	-6.15	-0.45	6.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-6.55	-0.47	8.27e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg20487152	chr13:99095054	FARP1	-0.5	-4.85	-0.37	3.07e-6	Longevity;
PAAD	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.24	0.51	2.05e-11	Lung cancer in ever smokers;
PAAD	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.68	9.65	0.62	1.72e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14460953	chr17:7835493	TRAPPC1;CNTROB	-0.6	-6.32	-0.46	2.74e-9	Smoking initiation;
PAAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23158103	chr7:148848205	ZNF398	-0.61	-5.94	-0.43	1.87e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg22875332	chr1:76189707	ACADM	-0.51	-5.12	-0.38	9.13e-7	Daytime sleep phenotypes;
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg04154034	chr17:28927549	LRRC37B2	0.63	4.41	0.34	1.91e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09835421	chr16:68378352	PRMT7	-1.07	-7.73	-0.53	1.36e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.37	9.8	0.62	7.1e-18	Prostate cancer;
PAAD	cis	rs2085601	0.542	rs1533291	chr4:89964456	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg09579323	chr1:150459698	TARS2	0.45	4.28	0.33	3.25e-5	Migraine;
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Body mass index;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg07703079	chr11:430292	ANO9	1.02	6.16	0.45	6.12e-9	Body mass index;
PAAD	cis	rs10981012	0.504	rs4978465	chr9:114585634	A/G	cg14428669	chr9:114659192	UGCG	-0.59	-4.35	-0.33	2.51e-5	Coronary artery disease;
PAAD	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7804356	0.834	rs10281261	chr7:26789472	T/C	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.45	-4.37	-0.33	2.3e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.36e-7	Fear of minor pain;
PAAD	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.49	6.54	0.47	8.79e-10	Thyroid hormone levels;
PAAD	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg25173405	chr17:45401733	C17orf57	-0.54	-4.92	-0.37	2.19e-6	Coronary artery disease;
PAAD	cis	rs7631605	0.905	rs11708049	chr3:37261396	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.37	0.33	2.31e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.65	5.56	0.41	1.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4938330	0.608	rs2277287	chr11:117096652	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.79	-5.83	-0.43	3.14e-8	Blood protein levels;
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.12	0.44	7.56e-9	Lung cancer;
PAAD	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.64	6.19	0.45	5.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.27	0.51	1.73e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.09	13.97	0.75	4.86e-29	Body mass index;
PAAD	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.56	-6.41	-0.46	1.76e-9	Mean corpuscular volume;
PAAD	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg15443732	chr18:74961078	GALR1	0.73	5.99	0.44	1.48e-8	Obesity-related traits;
PAAD	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.48	4.59	0.35	9.07e-6	HDL cholesterol;
PAAD	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg16558253	chr16:72132732	DHX38	0.48	4.99	0.38	1.65e-6	Prostate cancer;
PAAD	cis	rs8083432	0.668	rs34122643	chr18:22712555	G/A	cg13981356	chr18:22006370	IMPACT	0.62	4.56	0.35	1.05e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.67	6.36	0.46	2.22e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6074578	0.541	rs1469782	chr20:170589	T/C	cg16931068	chr20:139680	DEFB127	-0.41	-5.49	-0.41	1.63e-7	Hirschsprung disease;
PAAD	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.84	8.18	0.55	1.06e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.61	-4.89	-0.37	2.6e-6	Information processing speed;
PAAD	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.68	6.54	0.47	8.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.58	-0.35	9.58e-6	Bipolar disorder;
PAAD	cis	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg27395922	chr11:50257633	LOC441601	0.41	4.36	0.33	2.43e-5	Coronary artery disease;
PAAD	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.5	-4.76	-0.36	4.54e-6	Corneal structure;
PAAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	6.08	0.44	9.33e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.99	0.38	1.64e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.53	6.22	0.45	4.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.59	5.77	0.42	4.25e-8	Asthma;
PAAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg10193763	chr2:225306901	NA	-0.49	-4.34	-0.33	2.57e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.45	-4.59	-0.35	9.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-4.81	-0.36	3.66e-6	Lung cancer in ever smokers;
PAAD	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg20913747	chr6:44695427	NA	-0.66	-6.26	-0.45	3.67e-9	Total body bone mineral density;
PAAD	cis	rs17407555	0.683	rs4697998	chr4:10274626	G/T	cg11266682	chr4:10021025	SLC2A9	0.44	4.48	0.34	1.44e-5	Schizophrenia (age at onset);
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.53	5.08	0.38	1.08e-6	Prudent dietary pattern;
PAAD	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	5.02	0.38	1.44e-6	Ovarian reserve;
PAAD	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg09168692	chr1:7887560	PER3	0.5	4.27	0.33	3.42e-5	Inflammatory bowel disease;
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg04160749	chr8:58172571	NA	-0.66	-4.69	-0.36	5.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.82	8.66	0.57	6.3e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs12935418	0.552	rs2602448	chr16:81022672	G/A	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.34e-8	Mean corpuscular volume;
PAAD	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07741184	chr6:167504864	NA	-0.35	-4.53	-0.34	1.2e-5	Primary biliary cholangitis;
PAAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.43	4.29	0.33	3.12e-5	Aortic root size;
PAAD	cis	rs11696845	0.761	rs11698203	chr20:43357899	C/T	cg25301532	chr20:43378953	KCNK15	-0.52	-5.8	-0.43	3.8e-8	Obesity-related traits;
PAAD	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.75	-8.11	-0.55	1.56e-13	Height;
PAAD	cis	rs11997175	0.713	rs4733455	chr8:33651290	C/T	ch.8.33884649F	chr8:33765107	NA	-0.52	-5.92	-0.43	2.07e-8	Body mass index;
PAAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.88	6.73	0.48	3.32e-10	Tuberculosis;
PAAD	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.32	-0.46	2.76e-9	Aortic root size;
PAAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg00738919	chr7:1100172	C7orf50	0.67	5.39	0.4	2.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs593531	0.592	rs3168173	chr11:74042787	A/G	cg15670924	chr11:73669256	DNAJB13	-0.45	-4.63	-0.35	7.8e-6	Neuroticism;
PAAD	trans	rs4864201	0.560	rs2952865	chr4:130765170	C/T	cg08471972	chr13:51844375	FAM124A	-0.55	-6.48	-0.47	1.23e-9	Obesity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05722872	chr3:19989128	RAB5A	0.67	6.55	0.47	8.57e-10	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.94	-10.93	-0.66	7.01e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9581857	0.512	rs9652092	chr13:28074855	T/C	cg22138327	chr13:27999177	GTF3A	0.75	5.28	0.39	4.32e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs13174863	1.000	rs13174863	chr5:139080745	C/T	cg10513866	chr5:139070639	NA	-0.82	-5.19	-0.39	6.56e-7	Body mass index;
PAAD	cis	rs35000415	0.938	rs35234849	chr7:128648953	T/C	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.75	9.15	0.6	3.56e-16	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.81	6.31	0.46	2.85e-9	Mean platelet volume;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.61	6.52	0.47	9.69e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.64	6.35	0.46	2.33e-9	Height;
PAAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.45	0.61	5.79e-17	Parkinson's disease;
PAAD	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs28489187	0.730	rs12140103	chr1:85849489	G/A	cg16011679	chr1:85725395	C1orf52	0.54	5.16	0.39	7.53e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs9857275	0.788	rs13099193	chr3:141128804	G/A	cg00789793	chr3:141329863	RASA2	0.49	4.29	0.33	3.16e-5	Prion diseases;
PAAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg22549504	chr19:17448937	GTPBP3	0.54	4.29	0.33	3.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7631605	0.905	rs17204801	chr3:37143434	A/G	cg17445812	chr3:36986805	TRANK1	-0.35	-4.68	-0.35	6.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg16606324	chr3:10149918	C3orf24	0.77	6.1	0.44	8.51e-9	Alzheimer's disease;
PAAD	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	0.97	6.29	0.45	3.28e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.61	-7.74	-0.53	1.26e-12	Hypertriglyceridemia;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg18557215	chr3:108633926	GUCA1C	0.58	6.36	0.46	2.28e-9	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs735539	0.521	rs2762991	chr13:21394071	T/A	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	cis	rs5009270	0.553	rs765506	chr7:112213760	A/G	cg23628563	chr7:112262597	NA	-0.56	-4.65	-0.35	7.29e-6	Osteoarthritis (hip);
PAAD	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06771106	chr2:113671356	IL1F7	-0.62	-6.84	-0.49	1.77e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs617219	0.698	rs10055956	chr5:78479678	G/A	cg24856658	chr5:78533917	JMY	-0.4	-4.5	-0.34	1.36e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-5.85	-0.43	2.9e-8	Total cholesterol levels;
PAAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19346786	chr7:2764209	NA	-0.37	-5.15	-0.39	8.07e-7	Height;
PAAD	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16447950	chr5:562315	NA	-0.63	-5.53	-0.41	1.36e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11681884	0.786	rs11898158	chr2:113823572	A/G	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs3026101	0.671	rs56300366	chr17:5297839	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg06565975	chr8:143823917	SLURP1	0.19	4.57	0.35	1.01e-5	Urinary tract infection frequency;
PAAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.87	10.22	0.64	5.36e-19	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.72	0.66	2.5e-20	Prudent dietary pattern;
PAAD	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-13.92	-0.75	6.4e-29	Coronary artery disease;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.87	9.83	0.62	5.96e-18	Prudent dietary pattern;
PAAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg26939375	chr7:64535504	NA	0.53	5.89	0.43	2.38e-8	Aortic root size;
PAAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.52	4.94	0.37	2.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2834902	0.633	rs9974868	chr21:36680632	G/C	cg04915566	chr21:36421472	RUNX1	-0.32	-4.37	-0.33	2.3e-5	Corneal curvature;
PAAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.54	5.27	0.39	4.62e-7	Trans fatty acid levels;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg00631329	chr6:26305371	NA	-0.49	-4.94	-0.37	2.07e-6	Educational attainment;
PAAD	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.63	6.07	0.44	9.61e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.56	-0.41	1.21e-7	Immature fraction of reticulocytes;
PAAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22176353	chr13:114897925	RASA3	-0.78	-6.8	-0.48	2.2e-10	Neuroticism;
PAAD	cis	rs28489187	0.558	rs12044537	chr1:85846385	T/A	cg16011679	chr1:85725395	C1orf52	0.51	4.85	0.37	3.04e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs793571	0.505	rs9635351	chr15:58917961	T/C	cg05156742	chr15:59063176	FAM63B	0.64	4.5	0.34	1.33e-5	Schizophrenia;
PAAD	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg19623624	chr10:135278901	LOC619207	0.42	4.44	0.34	1.73e-5	Systemic lupus erythematosus;
PAAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.4	4.89	0.37	2.51e-6	Sitting height ratio;
PAAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.38	-0.56	3.34e-14	Bone mineral density;
PAAD	cis	rs7792596	0.861	rs2374718	chr7:94013502	T/A	cg20814616	chr7:94014465	NA	-0.63	-6.1	-0.44	8.22e-9	Intelligence;
PAAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.22	-9.75	-0.62	9.44e-18	Breast cancer;
PAAD	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.29	-0.39	4.17e-7	Electroencephalogram traits;
PAAD	cis	rs597480	0.963	rs290190	chr11:85427450	G/A	cg11817631	chr11:85522609	SYTL2	-0.46	-4.3	-0.33	3.06e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg18477163	chr1:228402036	OBSCN	0.43	4.43	0.34	1.83e-5	Adult asthma;
PAAD	cis	rs863345	0.604	rs2054991	chr1:158506083	A/G	cg12129480	chr1:158549410	OR10X1	0.43	5.05	0.38	1.27e-6	Pneumococcal bacteremia;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.86	-10.63	-0.65	4.34e-20	Body mass index;
PAAD	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-4.55	-0.35	1.07e-5	Metabolite levels;
PAAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg17541715	chr7:1216824	NA	-0.4	-4.49	-0.34	1.43e-5	Longevity;Endometriosis;
PAAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg02478829	chr6:26598070	ABT1	-0.47	-4.67	-0.35	6.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.58	-5.13	-0.38	8.55e-7	Life satisfaction;
PAAD	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	1.05	14.15	0.75	1.55e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg04833646	chr19:10679720	CDKN2D	1.12	10.9	0.66	8.31e-21	Red cell distribution width;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-0.56	-4.25	-0.33	3.65e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02725872	chr8:58115012	NA	-0.61	-5.08	-0.38	1.08e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9409082	0.798	rs12682937	chr9:108924249	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.46	-0.46	1.35e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02945294	chr17:2206979	SRR;SMG6	0.56	6.32	0.46	2.72e-9	Monocyte percentage of white cells;
PAAD	cis	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg21546286	chr11:48923668	NA	0.58	6.09	0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg14343924	chr8:8086146	FLJ10661	-0.59	-5.04	-0.38	1.34e-6	Mood instability;
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	1.28	13.0	0.73	1.9e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.41e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg10589385	chr1:150898437	SETDB1	0.37	4.55	0.35	1.11e-5	Melanoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07912181	chr11:43702277	HSD17B12	0.61	6.74	0.48	3.17e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.74	0.36	4.93e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.46	4.7	0.36	5.8e-6	Electroencephalogram traits;
PAAD	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg00359181	chr2:38893519	GALM	0.57	4.29	0.33	3.19e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-5.26	-0.39	4.72e-7	Inflammatory bowel disease;
PAAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-5.64	-0.42	8.04e-8	Gut microbiome composition (summer);
PAAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.72	-0.36	5.23e-6	Breast cancer;
PAAD	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.71	8.39	0.56	3.2e-14	Morning vs. evening chronotype;
PAAD	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg18612461	chr15:75251733	NA	-0.53	-4.99	-0.38	1.63e-6	Blood trace element (Zn levels);
PAAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-4.61	-0.35	8.4e-6	Acylcarnitine levels;
PAAD	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.7	-8.16	-0.55	1.2e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.64	5.32	0.4	3.64e-7	Hypertension (SNP x SNP interaction);
PAAD	cis	rs3857067	0.578	rs2865341	chr4:95099607	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.61	-6.09	-0.44	8.73e-9	QT interval;
PAAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg05925327	chr15:68127851	NA	-0.62	-5.7	-0.42	6.14e-8	Restless legs syndrome;
PAAD	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-4.61	-0.35	8.54e-6	Menarche (age at onset);
PAAD	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg06740227	chr12:86229804	RASSF9	0.55	4.97	0.37	1.75e-6	Major depressive disorder;
PAAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.03e-9	Monobrow;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15303472	chr22:38668914	TMEM184B	0.59	6.78	0.48	2.49e-10	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.41e-7	Prudent dietary pattern;
PAAD	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.71	7.11	0.5	4.13e-11	Platelet count;
PAAD	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg25650185	chr19:21324782	ZNF431	-0.5	-4.45	-0.34	1.64e-5	Pain;
PAAD	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg15309053	chr8:964076	NA	0.38	4.25	0.33	3.71e-5	Schizophrenia;
PAAD	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg05082376	chr22:42548792	NA	-0.47	-5.1	-0.38	9.83e-7	Cognitive function;
PAAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg01320130	chr1:67600311	NA	0.56	6.25	0.45	3.91e-9	Psoriasis;
PAAD	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg04450456	chr4:17643702	FAM184B	-0.42	-4.27	-0.33	3.41e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Colorectal cancer;
PAAD	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.7	6.49	0.47	1.12e-9	Cognitive test performance;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04479860	chr4:190767364	NA	0.54	6.46	0.46	1.37e-9	Body fat percentage;
PAAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg07153921	chr17:41440717	NA	0.41	4.38	0.33	2.21e-5	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26891329	chr6:43597837	MAD2L1BP;GTPBP2	-0.78	-6.73	-0.48	3.28e-10	Neuroticism;
PAAD	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg03538708	chr1:25844672	NA	0.52	5.39	0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.85	0.37	3.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg06632027	chr4:90757378	SNCA	-0.59	-5.49	-0.41	1.64e-7	Neuroticism;
PAAD	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.0	-8.6	-0.57	9.31e-15	Vitiligo;
PAAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.85	7.94	0.54	4.18e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.78	-0.36	4.09e-6	Aortic root size;
PAAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.53	-0.47	9.44e-10	Bone mineral density;
PAAD	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.64	5.04	0.38	1.33e-6	Serum sulfate level;
PAAD	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-5.28	-0.39	4.34e-7	Vitiligo;
PAAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02071572	chr4:1403502	NA	0.4	5.02	0.38	1.44e-6	Obesity-related traits;
PAAD	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.88	7.29	0.51	1.58e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.52	-5.0	-0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg10137597	chr8:22132714	PIWIL2	0.5	5.71	0.42	5.77e-8	Hypertriglyceridemia;
PAAD	cis	rs4742903	0.935	rs7853727	chr9:106990048	T/G	cg14250997	chr9:106856677	SMC2	0.44	4.7	0.36	5.89e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs3206736	0.521	rs2057819	chr7:34944871	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.74	-0.36	4.8e-6	Diastolic blood pressure;
PAAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.7	0.48	3.72e-10	Rheumatoid arthritis;
PAAD	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg10072921	chr12:121022843	NA	0.39	4.56	0.35	1.03e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs35160687	0.623	rs7569654	chr2:86478022	C/T	cg10973622	chr2:86423274	IMMT	-0.49	-5.55	-0.41	1.22e-7	Night sleep phenotypes;
PAAD	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.35	0.6	1.06e-16	Response to antipsychotic treatment;
PAAD	cis	rs13111989	1.000	rs13105175	chr4:177545743	G/A	cg11287292	chr4:178277261	NEIL3	-0.54	-4.39	-0.34	2.13e-5	HIV-1 viral setpoint;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.51	-5.03	-0.38	1.36e-6	Paraoxonase activity;
PAAD	cis	rs12712073	0.588	rs11123804	chr2:100643443	T/G	cg07810366	chr2:100720526	AFF3	-0.35	-4.35	-0.33	2.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-6.73	-0.48	3.18e-10	Morning vs. evening chronotype;
PAAD	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg00531865	chr16:30841666	NA	0.5	4.8	0.36	3.82e-6	Dementia with Lewy bodies;
PAAD	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg24253500	chr15:84953950	NA	0.42	4.34	0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.18	17.8	0.82	5.17e-39	Cognitive function;
PAAD	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg24966363	chr8:8932588	NA	-0.37	-4.49	-0.34	1.41e-5	Cervical cancer;
PAAD	cis	rs9463078	0.509	rs1300126	chr6:45084861	G/C	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.59	0.61	2.5e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.91	-0.43	2.15e-8	Fear of minor pain;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14163229	chr11:6440707	APBB1	0.64	7.06	0.5	5.65e-11	Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3790455	0.610	rs1185700	chr1:156450719	G/A	cg14087168	chr1:156450669	MEF2D	-0.42	-5.0	-0.38	1.55e-6	Migraine;
PAAD	cis	rs60154123	1.000	rs60154123	chr1:210468999	C/T	cg22029157	chr1:209979665	IRF6	0.69	5.88	0.43	2.52e-8	Coronary artery disease;
PAAD	cis	rs6066835	0.572	rs12329434	chr20:47260191	T/C	cg18078177	chr20:47281410	PREX1	1.03	5.37	0.4	2.95e-7	Multiple myeloma;
PAAD	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.42	4.3	0.33	3.07e-5	Coronary artery disease;
PAAD	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.72	-7.4	-0.51	8.86e-12	Cognitive function;
PAAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg12927641	chr6:109611667	NA	0.41	4.49	0.34	1.37e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24375607	chr4:120327624	NA	0.64	5.92	0.43	2.05e-8	Corneal astigmatism;
PAAD	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.32	5.16	0.39	7.65e-7	Non-small cell lung cancer (survival);
PAAD	cis	rs10413329	1.000	rs10403210	chr19:13103638	C/T	cg13338734	chr19:13113668	NFIX	-0.35	-4.58	-0.35	9.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg16083429	chr3:49237500	CCDC36	-0.42	-4.44	-0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.61	-6.82	-0.48	2.01e-10	Monocyte count;
PAAD	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	5.69	0.42	6.3e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs990171	0.538	rs12995030	chr2:103116466	C/G	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	trans	rs901683	1.000	rs12781186	chr10:46013438	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg04342483	chr1:7259290	CAMTA1	-0.41	-4.42	-0.34	1.85e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20493885	chr17:4607678	PELP1	0.67	7.51	0.52	4.62e-12	Obesity-related traits;
PAAD	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.75	-0.36	4.6e-6	Bipolar disorder;
PAAD	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs901683	1.000	rs78661209	chr10:46074939	G/A	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.48	4.53	0.34	1.18e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.58	-5.77	-0.42	4.27e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg08632701	chr21:37451849	NA	-0.58	-5.88	-0.43	2.54e-8	Mitral valve prolapse;
PAAD	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.05	0.38	1.26e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.63	4.95	0.37	1.97e-6	Glucocorticoid-induced osteonecrosis (age 10 years and older);
PAAD	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg14515779	chr1:101123966	NA	0.49	6.26	0.45	3.73e-9	Monocyte count;
PAAD	cis	rs73384572	0.541	rs12244401	chr10:130861851	C/T	cg27413539	chr10:131576096	NA	-0.68	-4.62	-0.35	8.07e-6	Neuroticism;
PAAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg17264618	chr3:40429014	ENTPD3	0.35	4.33	0.33	2.65e-5	Renal cell carcinoma;
PAAD	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.12	0.59	4.24e-16	Total body bone mineral density;
PAAD	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.58	0.47	7.08e-10	Body mass index;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg24435679	chr13:100314414	CLYBL	-0.54	-6.49	-0.47	1.16e-9	Energy expenditure (24h);
PAAD	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.98	-10.77	-0.66	1.84e-20	Headache;
PAAD	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.8	-0.36	3.8e-6	Pulmonary function;
PAAD	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.49	-4.39	-0.34	2.1e-5	Testicular germ cell tumor;
PAAD	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg07159951	chr1:45983175	PRDX1	-0.4	-4.32	-0.33	2.79e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg20744362	chr22:50050164	C22orf34	0.68	8.41	0.56	2.82e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.48	4.48	0.34	1.44e-5	Coronary artery disease;
PAAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg24737193	chr18:12778029	NA	-0.68	-5.72	-0.42	5.48e-8	Inflammatory skin disease;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-7.37	-0.51	1.04e-11	Colorectal cancer;
PAAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs6442522	0.678	rs12634346	chr3:15500295	C/T	cg16303742	chr3:15540471	COLQ	0.48	5.25	0.39	4.98e-7	Uric acid levels;
PAAD	cis	rs10857712	0.504	rs2265907	chr10:135218844	G/T	cg19904058	chr10:135279010	LOC619207	0.39	5.26	0.39	4.71e-7	Systemic lupus erythematosus;
PAAD	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.32e-7	Body mass index;
PAAD	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.87	-0.37	2.74e-6	Height;
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22605364	chr20:33330679	NCOA6	-0.58	-6.5	-0.47	1.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.7	6.0	0.44	1.4e-8	Common traits (Other);
PAAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg20936604	chr3:58311152	NA	-0.8	-4.38	-0.33	2.2e-5	Cholesterol, total;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.92	-8.04	-0.55	2.32e-13	Gut microbiome composition (summer);
PAAD	cis	rs7082209	0.941	rs67379075	chr10:44811968	A/C	cg13191911	chr10:44806660	NA	-0.84	-4.96	-0.37	1.83e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.58	6.67	0.48	4.51e-10	Schizophrenia;
PAAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.89	-13.76	-0.74	1.74e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7646881	0.812	rs73017541	chr3:158460796	T/G	cg19483011	chr3:158453295	NA	-0.64	-5.1	-0.38	9.78e-7	Tetralogy of Fallot;
PAAD	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg04121983	chr17:73511085	CASKIN2	0.74	4.64	0.35	7.56e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.13	-0.38	8.65e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs1144333	0.655	rs1938323	chr1:76464492	G/A	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.48	-0.57	1.88e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.33	-0.33	2.68e-5	Educational attainment;
PAAD	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg11441379	chr12:63026424	NA	0.88	6.41	0.46	1.78e-9	IgG glycosylation;
PAAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs643506	0.715	rs11214031	chr11:111766039	C/A	cg09085632	chr11:111637200	PPP2R1B	0.53	4.45	0.34	1.66e-5	Breast cancer;
PAAD	cis	rs72960926	0.590	rs72959617	chr6:74993963	G/A	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.72e-10	Metabolite levels (MHPG);
PAAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.73	7.58	0.52	3.18e-12	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05573182	chr20:39318437	MAFB	0.61	6.96	0.49	9.56e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg08345082	chr10:99160200	RRP12	-0.31	-4.43	-0.34	1.79e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg18711553	chr6:27366782	ZNF391	0.53	4.56	0.35	1.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-5.18	-0.39	6.82e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-6.16	-0.45	6.2e-9	Coronary artery disease;
PAAD	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs7631605	0.905	rs9829683	chr3:37217622	C/A	cg17445812	chr3:36986805	TRANK1	0.35	4.65	0.35	7.28e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg10518543	chr12:38710700	ALG10B	0.5	4.78	0.36	4.11e-6	Morning vs. evening chronotype;
PAAD	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg13565585	chr5:132299512	AFF4	0.6	4.36	0.33	2.38e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg13468214	chr4:1046988	NA	0.52	4.89	0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06026331	chr20:60912101	LAMA5	0.5	4.66	0.35	6.97e-6	Colorectal cancer;
PAAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.65	7.38	0.51	9.6e-12	Verbal declarative memory;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.8	0.62	6.96e-18	Prudent dietary pattern;
PAAD	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18357526	chr6:26021779	HIST1H4A	0.53	4.64	0.35	7.61e-6	Height;
PAAD	cis	rs10073892	0.703	rs10038081	chr5:101638266	T/C	cg17280723	chr5:101634495	NA	0.42	4.47	0.34	1.5e-5	Cognitive decline (age-related);
PAAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.44	0.46	1.51e-9	Coffee consumption (cups per day);
PAAD	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg00122941	chr17:4613640	ARRB2	0.81	8.04	0.55	2.32e-13	Lymphocyte counts;
PAAD	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.36	3.33e-6	Colorectal cancer;
PAAD	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg01448562	chr3:133502909	NA	0.47	4.82	0.36	3.4e-6	Iron status biomarkers;
PAAD	cis	rs3734905	1.000	rs78099962	chr6:169934984	T/C	cg11181693	chr6:169825345	NA	-0.89	-5.36	-0.4	3e-7	HIV-1 control;
PAAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.48	-4.46	-0.34	1.61e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-4.41	-0.34	1.95e-5	Type 2 diabetes;
PAAD	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg10168330	chr8:27262164	PTK2B	0.36	4.28	0.33	3.24e-5	Neuroticism;
PAAD	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.45	4.38	0.33	2.24e-5	Mean corpuscular volume;
PAAD	cis	rs2073300	1.000	rs6114141	chr20:23460620	T/G	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.39	-4.34	-0.33	2.61e-5	Mean platelet volume;
PAAD	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg23752985	chr2:85803571	VAMP8	0.55	6.18	0.45	5.58e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg00086871	chr4:6988644	TBC1D14	1.06	5.09	0.38	1.05e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-6.37	-0.46	2.12e-9	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg13722127	chr7:150037890	RARRES2	0.56	5.57	0.41	1.12e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs593531	0.571	rs6592557	chr11:74086642	T/C	cg23327896	chr11:73669290	DNAJB13	-0.35	-4.48	-0.34	1.47e-5	Neuroticism;
PAAD	cis	rs10421328	1.000	rs10421328	chr19:19776814	C/T	cg11584989	chr19:19387371	SF4	0.77	6.32	0.46	2.7e-9	Parental longevity (combined parental age at death);
PAAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.85	-0.49	1.73e-10	Breast cancer;
PAAD	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19859290	chr11:20618399	NA	0.31	4.46	0.34	1.58e-5	Pursuit maintenance gain;
PAAD	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg00630237	chr15:91433507	FES	0.48	4.66	0.35	6.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg20295408	chr7:1910781	MAD1L1	0.55	5.36	0.4	3.04e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.64	-0.42	7.88e-8	Personality dimensions;
PAAD	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs793571	0.688	rs7179399	chr15:59165527	T/C	cg05156742	chr15:59063176	FAM63B	-0.66	-6.3	-0.45	3.08e-9	Schizophrenia;
PAAD	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.68	6.69	0.48	3.99e-10	Lymphocyte counts;
PAAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.4	-0.4	2.49e-7	Alcohol dependence;
PAAD	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.42	-6.38	-0.46	2.03e-9	Body mass index;
PAAD	cis	rs11853189	0.938	rs75886457	chr15:78597701	G/A	cg22935921	chr15:78556834	DNAJA4	0.76	5.13	0.38	8.54e-7	Red cell distribution width;
PAAD	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-9.73	-0.62	1.05e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12582317	chr17:55822272	NA	-0.69	-8.71	-0.58	4.7e-15	Schizophrenia;
PAAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.66	-9.98	-0.63	2.4e-18	Asthma (sex interaction);
PAAD	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg02225085	chr5:87975992	LOC645323	0.63	4.69	0.36	5.97e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16736242	chr8:11660109	FDFT1	0.58	6.32	0.46	2.8e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.57	5.26	0.39	4.73e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg04944784	chr2:26401820	FAM59B	0.95	7.64	0.53	2.27e-12	Gut microbiome composition (summer);
PAAD	cis	rs56011263	0.532	rs17164964	chr4:745053	T/C	cg14024328	chr4:719362	PCGF3	-0.54	-5.13	-0.38	8.87e-7	White blood cell count;
PAAD	cis	rs892877	0.518	rs1432214	chr2:137878523	A/G	cg07757007	chr2:138734074	HNMT	-0.3	-4.35	-0.33	2.51e-5	Liver enzyme levels (aspartate transaminase);
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg18209359	chr17:80159595	CCDC57	0.47	4.73	0.36	5.09e-6	Life satisfaction;
PAAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg23463467	chr20:60627584	TAF4	0.4	4.35	0.33	2.52e-5	Body mass index;
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13126279	chr21:47581558	C21orf56	-0.41	-4.65	-0.35	7.03e-6	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.48	6.06	0.44	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.77	-0.36	4.2e-6	Schizophrenia;
PAAD	cis	rs11650494	0.516	rs9907942	chr17:47513891	C/T	cg08112188	chr17:47440006	ZNF652	1.06	5.38	0.4	2.79e-7	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19859290	chr11:20618399	NA	0.32	4.65	0.35	7.06e-6	Pursuit maintenance gain;
PAAD	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.59	5.33	0.4	3.54e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.76	0.53	1.18e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg01320130	chr1:67600311	NA	0.53	5.6	0.41	9.61e-8	Psoriasis;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15541040	chr2:3486749	NA	-0.78	-8.23	-0.56	8.03e-14	Neurofibrillary tangles;
PAAD	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1555399	0.901	rs12887115	chr14:67990648	C/T	cg25006823	chr14:67982456	TMEM229B	0.4	4.41	0.34	1.93e-5	Parkinson's disease;
PAAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg05373962	chr22:49881684	NA	-0.47	-4.56	-0.35	1.05e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.6	5.36	0.4	2.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.53	5.68	0.42	6.5e-8	Menopause (age at onset);
PAAD	cis	rs35300120	0.757	rs73101509	chr1:233655461	A/G	cg23054119	chr1:233659267	NA	-0.54	-4.88	-0.37	2.61e-6	Cognitive function;
PAAD	cis	rs11069062	0.642	rs12306018	chr12:119065663	A/G	cg10654373	chr12:118293336	KSR2	-0.5	-4.35	-0.33	2.51e-5	Obesity-related traits;
PAAD	cis	rs4742903	0.935	rs4742907	chr9:106968226	G/A	cg14250997	chr9:106856677	SMC2	0.44	4.69	0.36	5.96e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.89	6.49	0.47	1.12e-9	Prostate cancer;
PAAD	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs256277	0.853	rs255920	chr5:111384439	C/A	cg00938619	chr5:111753803	EPB41L4A;FLJ11235	0.49	4.34	0.33	2.56e-5	Coronary artery disease;
PAAD	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg04705435	chr11:17411270	KCNJ11	0.6	6.35	0.46	2.41e-9	Type 2 diabetes;
PAAD	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg18939081	chr1:31884902	SERINC2	0.47	5.23	0.39	5.48e-7	Alcohol dependence;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18621852	chr3:10150065	C3orf24	0.67	5.93	0.43	2.01e-8	Alzheimer's disease;
PAAD	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.74	7.02	0.49	6.87e-11	Obesity-related traits;
PAAD	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg08079166	chr15:68083412	MAP2K5	0.59	4.39	0.34	2.1e-5	Obesity;
PAAD	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg00277334	chr10:82204260	NA	-0.5	-5.07	-0.38	1.13e-6	Post bronchodilator FEV1;
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.51	5.36	0.4	3.06e-7	Menopause (age at onset);
PAAD	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-4.39	-0.34	2.09e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.77	4.43	0.34	1.77e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg07153921	chr17:41440717	NA	-0.42	-4.41	-0.34	1.94e-5	Menopause (age at onset);
PAAD	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg23346134	chr3:49453900	TCTA	0.5	4.75	0.36	4.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.74	0.48	3.03e-10	Rheumatoid arthritis;
PAAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.62	6.21	0.45	4.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.71	7.91	0.54	4.88e-13	Corneal astigmatism;
PAAD	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.72	6.94	0.49	1.04e-10	Anterior chamber depth;
PAAD	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg26149184	chr10:133730230	NA	0.78	6.71	0.48	3.54e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.64	0.42	7.89e-8	Alzheimer's disease;
PAAD	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-4.54	-0.35	1.13e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.71	-0.42	5.73e-8	Total cholesterol levels;
PAAD	cis	rs7616330	0.836	rs17008114	chr3:71045000	A/C	cg01511742	chr3:71112437	FOXP1	-0.7	-5.63	-0.42	8.53e-8	QT interval;
PAAD	cis	rs2279817	0.780	rs77072467	chr1:17979675	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.62e-8	Neuroticism;
PAAD	cis	rs282587	0.569	rs9604421	chr13:113410493	C/G	cg04656015	chr13:113407548	ATP11A	0.54	4.29	0.33	3.1e-5	Glycated hemoglobin levels;
PAAD	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg06970076	chr16:1560791	IFT140	0.54	4.88	0.37	2.71e-6	Coronary artery disease;
PAAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.6	0.35	8.67e-6	Asthma;
PAAD	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.54	-6.89	-0.49	1.41e-10	Renal cell carcinoma;
PAAD	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.89	10.08	0.63	1.29e-18	Parkinson's disease;
PAAD	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.85	8.62	0.57	8.28e-15	Corneal astigmatism;
PAAD	cis	rs75920871	0.925	rs11826651	chr11:116920693	T/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs7932354	0.617	rs7118170	chr11:46908721	C/G	cg19486271	chr11:47235900	DDB2	-0.61	-5.92	-0.43	2.11e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.76e-8	Eye color traits;
PAAD	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg13870426	chr17:30244630	NA	-0.72	-5.74	-0.42	4.92e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs4427176	0.507	rs4305907	chr8:9586468	G/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.11	8.21	0.55	8.91e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg01982873	chr5:490308	SLC9A3	-0.43	-4.87	-0.37	2.8e-6	Cystic fibrosis severity;
PAAD	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.71	6.92	0.49	1.21e-10	Renal function-related traits (BUN);
PAAD	cis	rs10982213	0.904	rs4979378	chr9:117163048	T/G	cg00078025	chr9:117159975	NA	0.59	4.33	0.33	2.68e-5	Interleukin-6 levels;
PAAD	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-7.95	-0.54	3.96e-13	Coffee consumption (cups per day);
PAAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.56	7.63	0.53	2.35e-12	Height;
PAAD	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.8	-9.17	-0.6	3.18e-16	Sudden cardiac arrest;
PAAD	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.72	0.36	5.21e-6	Cognitive ability;
PAAD	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.49	0.65	1.05e-19	Cognitive test performance;
PAAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-5.27	-0.39	4.64e-7	Coronary artery disease;
PAAD	cis	rs2790457	0.958	rs2772432	chr10:28894295	G/A	cg05705492	chr10:28955341	NA	-0.43	-4.3	-0.33	3.06e-5	Multiple myeloma;
PAAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.68	0.53	1.82e-12	Prudent dietary pattern;
PAAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.69	7.7	0.53	1.62e-12	Melanoma;
PAAD	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02527881	chr3:46936655	PTH1R	0.39	4.53	0.34	1.19e-5	Colorectal cancer;
PAAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.51	5.5	0.41	1.57e-7	Lung cancer;
PAAD	cis	rs6076065	0.723	rs6137924	chr20:23366171	C/G	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg01942863	chr7:99769432	GPC2	0.53	4.37	0.33	2.28e-5	Lung function (FEV1/FVC);
PAAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.55	5.86	0.43	2.78e-8	Height;
PAAD	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-4.96	-0.37	1.84e-6	Metabolite levels;
PAAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.46e-5	Blood metabolite levels;
PAAD	cis	rs11892454	0.544	rs35404220	chr2:26004120	T/C	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs800160	0.777	rs11022291	chr11:2345621	T/C	cg09785033	chr11:2336066	TSPAN32	-0.5	-4.29	-0.33	3.2e-5	Bacteremia;
PAAD	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.55	-0.52	3.83e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.61	-6.07	-0.44	9.9e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.53	5.69	0.42	6.49e-8	Major depressive disorder;
PAAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg02117656	chr17:79614917	TSPAN10	0.49	4.82	0.36	3.4e-6	Eye color traits;
PAAD	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.72	-0.36	5.32e-6	Body mass index;
PAAD	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.44	0.34	1.72e-5	IgG glycosylation;
PAAD	cis	rs58521262	0.932	rs55774410	chr19:23203496	A/G	cg22640819	chr19:22990650	NA	0.36	4.3	0.33	2.99e-5	Testicular germ cell tumor;
PAAD	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.3	-0.51	1.47e-11	Blood metabolite levels;
PAAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg16928487	chr17:17741425	SREBF1	0.37	5.01	0.38	1.49e-6	Total body bone mineral density;
PAAD	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.75	-5.47	-0.41	1.8e-7	Coronary artery disease;
PAAD	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.68	7.48	0.52	5.62e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.89	-0.37	2.5e-6	Venous thromboembolism;
PAAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.07e-10	Breast cancer;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg00631329	chr6:26305371	NA	-0.46	-4.75	-0.36	4.62e-6	Educational attainment;
PAAD	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12449964	0.524	rs7224619	chr17:17572384	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-4.97	-0.37	1.77e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.86	-8.89	-0.59	1.62e-15	Lymphocyte counts;
PAAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.38	-4.76	-0.36	4.5e-6	Prostate cancer;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.94	-7.95	-0.54	3.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.72	7.21	0.5	2.46e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg00431813	chr7:1051703	C7orf50	-0.36	-4.55	-0.35	1.09e-5	Longevity;Endometriosis;
PAAD	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg12623918	chr2:306882	NA	0.45	4.64	0.35	7.42e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.45	4.26	0.33	3.63e-5	HDL cholesterol;
PAAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg04520793	chr17:42248056	ASB16	-0.38	-4.66	-0.35	6.84e-6	Total body bone mineral density;
PAAD	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.13	14.93	0.77	1.33e-31	Schizophrenia;
PAAD	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg16230307	chr14:35515116	FAM177A1	0.43	4.45	0.34	1.66e-5	Psoriasis;
PAAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.53	-7.13	-0.5	3.85e-11	Height;
PAAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-5.41	-0.4	2.38e-7	Alcohol dependence;
PAAD	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg18700516	chr19:44507157	ZNF230	-0.47	-4.36	-0.33	2.39e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.53	-5.73	-0.42	5.17e-8	Mitral valve prolapse;
PAAD	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-6.27	-0.45	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.59	-6.05	-0.44	1.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16988970	chr17:42248062	ASB16	-0.37	-5.42	-0.4	2.32e-7	Total body bone mineral density;
PAAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13126279	chr21:47581558	C21orf56	-0.4	-4.42	-0.34	1.88e-5	Testicular germ cell tumor;
PAAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.03	0.38	1.36e-6	Personality dimensions;
PAAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	5.57	0.41	1.15e-7	Schizophrenia;
PAAD	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg05805236	chr11:65401703	PCNXL3	0.41	4.38	0.33	2.21e-5	Acne (severe);
PAAD	cis	rs8060686	0.920	rs60769312	chr16:67732186	C/T	cg27539214	chr16:67997921	SLC12A4	-0.67	-4.5	-0.34	1.34e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg26497354	chr6:109612229	NA	0.45	4.87	0.37	2.79e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2147959	1.000	rs2147959	chr1:228644232	A/T	cg02753203	chr1:228287806	NA	-0.58	-4.63	-0.35	7.91e-6	Adult asthma;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-4.32	-0.33	2.83e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg11508406	chr4:1595515	NA	0.43	4.28	0.33	3.26e-5	Obesity-related traits;
PAAD	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.64	6.06	0.44	1.01e-8	Aortic root size;
PAAD	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.5	-5.34	-0.4	3.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.76	6.63	0.47	5.38e-10	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11694441	0.618	rs11684772	chr2:119580473	T/C	cg14634534	chr2:119616825	NA	-0.41	-4.48	-0.34	1.46e-5	Monobrow;
PAAD	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.51	-5.98	-0.44	1.51e-8	Alcohol dependence;
PAAD	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-6.56	-0.47	7.92e-10	Colorectal cancer;
PAAD	trans	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.77	-6.43	-0.46	1.59e-9	Pancreatic cancer;
PAAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.87	10.48	0.65	1.11e-19	Menopause (age at onset);
PAAD	cis	rs1015291	0.708	rs10743340	chr12:19994777	G/A	cg25401612	chr12:20009446	NA	0.53	5.0	0.38	1.56e-6	Diastolic blood pressure;
PAAD	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7009516	0.669	rs4872231	chr8:24247556	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.74	-0.42	5.05e-8	Hair greying;
PAAD	trans	rs901683	0.867	rs71496625	chr10:46086649	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3935740	0.649	rs9920579	chr15:81631526	G/A	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.35e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs7577696	0.813	rs212723	chr2:32467148	C/A	cg02381751	chr2:32503542	YIPF4	0.43	4.76	0.36	4.53e-6	Inflammatory biomarkers;
PAAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.53	4.85	0.37	3.09e-6	Monocyte count;
PAAD	cis	rs7156960	1.000	rs10143886	chr14:76710551	C/T	cg13981132	chr14:76734493	NA	-0.47	-4.6	-0.35	8.99e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	4.88	0.37	2.71e-6	Non-small cell lung cancer;
PAAD	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs11168618	0.567	rs56354789	chr12:48803943	C/A	cg01881778	chr12:48919444	OR8S1	-0.46	-4.66	-0.35	6.83e-6	Adiponectin levels;
PAAD	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.77	4.31	0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.82	5.46	0.4	1.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.46	-7.37	-0.51	1e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs2882877	0.610	rs1123109	chr2:190444392	C/T	cg10752008	chr2:190445175	SLC40A1	-0.54	-4.56	-0.35	1.04e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.86e-7	Personality dimensions;
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.88	-10.59	-0.65	5.52e-20	Schizophrenia;
PAAD	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg25401027	chr5:176370377	UIMC1	0.44	4.42	0.34	1.86e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.52	8.08	0.55	1.85e-13	Neuroticism;
PAAD	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg11619707	chr19:22235551	ZNF257	-0.58	-5.7	-0.42	5.93e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs27434	0.583	rs34762	chr5:96153966	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.53	-0.41	1.38e-7	Ankylosing spondylitis;
PAAD	cis	rs2579500	0.807	rs11891926	chr2:97339781	A/G	cg09304357	chr2:97220596	NA	-0.47	-4.91	-0.37	2.37e-6	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.59	5.33	0.4	3.55e-7	Cognitive test performance;
PAAD	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.58	5.12	0.38	9.11e-7	Depressive symptoms;
PAAD	cis	rs2415984	0.570	rs28674745	chr14:46924415	G/C	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.42e-7	Number of children ever born;
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	6.69	0.48	4e-10	Schizophrenia;
PAAD	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.41	4.57	0.35	9.94e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.84	11.12	0.67	2.13e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg08135965	chr6:41755394	TOMM6	0.49	4.94	0.37	2e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	1.0	11.73	0.69	4.98e-23	Bone mineral density;
PAAD	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.78	-7.84	-0.54	7.37e-13	Menarche (age at onset);
PAAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg06375148	chr1:209958343	C1orf74	0.67	4.94	0.37	2.04e-6	Coronary artery disease;
PAAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.62	-4.6	-0.35	8.77e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-1.0	-8.01	-0.55	2.72e-13	Blood protein levels;
PAAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.75	8.5	0.57	1.64e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg03037974	chr15:76606532	NA	0.5	5.63	0.42	8.36e-8	Blood metabolite levels;
PAAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg16322479	chr5:444228	EXOC3;C5orf55	0.42	4.6	0.35	8.91e-6	Cystic fibrosis severity;
PAAD	cis	rs79349575	0.691	rs11079847	chr17:47037024	A/T	cg22947322	chr17:47091978	IGF2BP1	-0.42	-4.9	-0.37	2.46e-6	Type 2 diabetes;
PAAD	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.11	-0.44	7.8e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg07630564	chr3:128445061	RAB7A	0.69	6.89	0.49	1.39e-10	Primary biliary cholangitis;
PAAD	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.13	-0.38	8.53e-7	Myopia (pathological);
PAAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.88	9.92	0.63	3.32e-18	Parkinson's disease;
PAAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.15e-12	Calcium levels;
PAAD	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg27490568	chr2:178487706	NA	0.44	4.77	0.36	4.23e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs75920871	0.925	rs61905716	chr11:116919067	C/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	8.13	0.55	1.42e-13	Lymphocyte counts;
PAAD	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.52	5.28	0.39	4.47e-7	Myeloid white cell count;
PAAD	cis	rs6689305	0.545	rs12039676	chr1:100242497	G/T	cg22872634	chr1:100462710	SLC35A3	-0.45	-4.38	-0.33	2.2e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs4740619	0.745	rs4472620	chr9:15941439	A/G	cg14451791	chr9:16040625	NA	-0.41	-4.7	-0.36	5.72e-6	Body mass index;
PAAD	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.66	-5.39	-0.4	2.6e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.45	-4.82	-0.36	3.46e-6	Major depressive disorder;
PAAD	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.55	5.12	0.38	9.28e-7	Pulse pressure;
PAAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.83	-9.24	-0.6	2e-16	Aortic root size;
PAAD	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.61	-6.44	-0.46	1.5e-9	Post bronchodilator FEV1;
PAAD	cis	rs2992756	0.663	rs1360915	chr1:18801804	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs2229238	0.866	rs112231452	chr1:154504900	G/A	cg21262032	chr1:154437693	IL6R	-0.45	-4.77	-0.36	4.26e-6	Coronary heart disease;
PAAD	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14878009	chr2:242122380	PPP1R7	-0.67	-6.68	-0.48	4.2e-10	Obesity-related traits;
PAAD	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.49	-5.55	-0.41	1.27e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg00129232	chr17:37814104	STARD3	-0.6	-4.31	-0.33	2.93e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.53	-5.15	-0.39	8.02e-7	Body mass index;
PAAD	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.6	5.46	0.4	1.91e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.28	-0.51	1.7e-11	Personality dimensions;
PAAD	cis	rs6142102	0.961	rs6120519	chr20:32688113	A/G	cg06115741	chr20:33292138	TP53INP2	0.53	4.47	0.34	1.52e-5	Skin pigmentation;
PAAD	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.9	-0.43	2.27e-8	Rheumatoid arthritis;
PAAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg25173405	chr17:45401733	C17orf57	-0.53	-5.36	-0.4	3.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08957018	chr22:42487540	NDUFA6	0.6	6.5	0.47	1.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.52	-6.27	-0.45	3.64e-9	Lewy body disease;
PAAD	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg02683114	chr2:24398427	C2orf84	-0.47	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg13446199	chr8:143762866	PSCA	0.36	4.32	0.33	2.78e-5	Urinary tract infection frequency;
PAAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg14847009	chr1:175162515	KIAA0040	0.32	4.99	0.37	1.66e-6	Diastolic blood pressure;
PAAD	trans	rs405795	1.000	rs2251713	chr13:89779520	A/T	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Yeast infection;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.9	10.76	0.66	1.95e-20	Prudent dietary pattern;
PAAD	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20887711	chr4:1340912	KIAA1530	-0.47	-4.69	-0.36	5.95e-6	Obesity-related traits;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg00049323	chr5:472564	LOC25845	-0.46	-4.74	-0.36	4.93e-6	Cystic fibrosis severity;
PAAD	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.43	5.5	0.41	1.54e-7	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.29	-0.39	4.21e-7	Life satisfaction;
PAAD	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.87	-0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.6	5.01	0.38	1.5e-6	Neutrophil percentage of white cells;
PAAD	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.62	7.39	0.51	9.13e-12	Lung cancer;
PAAD	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.34	-4.63	-0.35	7.76e-6	Mean corpuscular volume;
PAAD	cis	rs609418	1.000	rs9315450	chr13:37408734	C/T	cg14962159	chr13:37441585	SMAD9	0.48	4.31	0.33	2.97e-5	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7671900	0.932	rs6531978	chr4:88277927	G/A	cg23841344	chr4:88312519	HSD17B11	-0.49	-4.59	-0.35	9.18e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.5	5.66	0.42	7.41e-8	Coronary artery disease;
PAAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.98	6.71	0.48	3.68e-10	Depression;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25506325	chr7:2093962	MAD1L1	0.59	6.66	0.48	4.67e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.95	12.44	0.71	6.02e-25	Menarche (age at onset);
PAAD	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.37	-0.46	2.09e-9	Mood instability;
PAAD	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.42	6.26	0.45	3.79e-9	Subjective well-being;
PAAD	cis	rs66530629	0.797	rs12758422	chr1:25078061	T/C	cg22509179	chr1:25234806	RUNX3	-0.5	-4.59	-0.35	9.29e-6	Plateletcrit;
PAAD	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.89	0.43	2.36e-8	Ileal carcinoids;
PAAD	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-6.03	-0.44	1.2e-8	Neuroticism;
PAAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs12304921	1.000	rs12318464	chr12:51357346	G/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-5.05	-0.38	1.24e-6	Type 2 diabetes;
PAAD	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.69	6.52	0.47	9.77e-10	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7688540	0.800	rs28531997	chr4:242787	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.57	0.35	9.83e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs9535307	0.522	rs9596200	chr13:50416370	G/A	cg04663916	chr13:50265991	EBPL	-0.59	-4.26	-0.33	3.63e-5	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.99e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg15510373	chr7:100224934	TFR2	-0.53	-4.3	-0.33	3.02e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs746265	0.818	rs8037961	chr15:39582384	T/C	cg10099207	chr15:39544144	C15orf54	0.56	4.29	0.33	3.23e-5	PR interval;
PAAD	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.5	0.41	1.59e-7	Neuroticism;
PAAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.57	5.45	0.4	2e-7	Platelet count;
PAAD	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	1.2	13.21	0.73	4.96e-27	Eosinophil percentage of granulocytes;
PAAD	trans	rs1838564	0.778	rs11049260	chr12:28145898	A/T	cg21416529	chr22:49795435	NA	1.2	6.55	0.47	8.43e-10	Breast size;
PAAD	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg02250501	chr15:90694978	NA	-0.45	-4.26	-0.33	3.55e-5	Rheumatoid arthritis;
PAAD	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg03517284	chr6:25882590	NA	0.49	4.61	0.35	8.38e-6	Blood metabolite levels;
PAAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg19847866	chr10:1019161	NA	-0.54	-4.42	-0.34	1.86e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg05250797	chr16:70222502	NA	0.68	5.5	0.41	1.56e-7	IgE levels;
PAAD	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.52	-5.04	-0.38	1.28e-6	Red blood cell count;
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg14343924	chr8:8086146	FLJ10661	0.52	5.04	0.38	1.3e-6	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08677398	chr8:58056175	NA	0.66	4.66	0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.79	5.63	0.42	8.35e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs35160687	0.712	rs6745235	chr2:86487083	A/G	cg10973622	chr2:86423274	IMMT	-0.43	-4.65	-0.35	7.2e-6	Night sleep phenotypes;
PAAD	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs1864585	0.520	rs73208778	chr8:10670154	A/T	cg21775007	chr8:11205619	TDH	-0.56	-4.59	-0.35	9.24e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.99	14.06	0.75	2.68e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10793968	0.688	rs2791742	chr9:133635695	G/A	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.53	-0.47	9.13e-10	Total body bone mineral density;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16320894	chr3:139398044	NMNAT3	0.66	6.54	0.47	8.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg17644776	chr2:200775616	C2orf69	0.66	5.2	0.39	6.27e-7	Schizophrenia;
PAAD	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.28	0.33	3.31e-5	Height;
PAAD	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.31e-7	Noise-induced hearing loss;
PAAD	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.76	7.95	0.54	3.92e-13	Neuroticism;
PAAD	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg12756303	chr2:74692479	MOGS	-0.49	-4.42	-0.34	1.9e-5	Metabolite levels;
PAAD	cis	rs75757892	0.621	rs76345703	chr6:7282374	A/G	cg02954307	chr6:7269328	NA	0.6	4.65	0.35	7.11e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs6782025	1.000	rs693403	chr3:121227392	C/T	cg16417163	chr3:121280760	NA	-0.52	-5.1	-0.38	1.02e-6	Aging (facial);
PAAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.68	-5.33	-0.4	3.55e-7	Coronary artery disease;
PAAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.18	-0.39	6.81e-7	Glomerular filtration rate;
PAAD	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.47	-4.86	-0.37	2.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg05896524	chr21:47604654	C21orf56	0.46	4.64	0.35	7.42e-6	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.64	5.8	0.43	3.77e-8	Blood metabolite levels;
PAAD	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg01489032	chr8:143877656	NA	-0.4	-4.56	-0.35	1.05e-5	Urinary tract infection frequency;
PAAD	cis	rs9907295	0.591	rs6505496	chr17:34129067	A/G	cg24325790	chr17:34345392	CCL23	-0.47	-4.34	-0.33	2.64e-5	Fibroblast growth factor basic levels;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg26338869	chr17:61819248	STRADA	-0.69	-7.35	-0.51	1.14e-11	Prudent dietary pattern;
PAAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.98e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg13789015	chr9:136890014	NCRNA00094	0.65	6.82	0.48	2.03e-10	Platelet distribution width;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	7.67	0.53	1.9e-12	Alzheimer's disease;
PAAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg09796270	chr17:17721594	SREBF1	0.43	4.64	0.35	7.42e-6	Total body bone mineral density;
PAAD	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-6.03	-0.44	1.2e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg26248373	chr2:1572462	NA	-1.08	-7.69	-0.53	1.7e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.14	16.61	0.8	5.6e-36	Cognitive function;
PAAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.78	0.48	2.47e-10	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.5	-5.1	-0.38	9.97e-7	Body mass index;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg00522288	chr12:125625016	AACS	-0.56	-5.9	-0.43	2.27e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg08999081	chr20:33150536	PIGU	0.49	5.16	0.39	7.64e-7	Height;
PAAD	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs886774	0.615	rs881176	chr7:107573254	G/T	cg00019997	chr7:108025567	NRCAM	0.4	4.36	0.33	2.36e-5	Ulcerative colitis;
PAAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.45	4.57	0.35	1e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg10645314	chr2:3704589	ALLC	0.6	5.5	0.41	1.54e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3857067	1.000	rs2219755	chr4:95015684	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-1.01	-12.84	-0.72	4.95e-26	Refractive error;
PAAD	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg00800038	chr16:89945340	TCF25	-0.7	-4.31	-0.33	2.87e-5	Skin colour saturation;
PAAD	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.09	-14.99	-0.77	9.18e-32	Schizophrenia;
PAAD	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.12	-0.5	4.04e-11	Morning vs. evening chronotype;
PAAD	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06156847	chr2:113672199	IL1F7	0.6	6.32	0.46	2.78e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.69	-0.58	5.49e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.81	-0.48	2.16e-10	Corneal structure;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.45	0.34	1.68e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.46	0.46	1.31e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.58	5.63	0.42	8.33e-8	Acylcarnitine levels;
PAAD	cis	rs11597390	0.865	rs12781812	chr10:101891222	G/T	cg04359915	chr10:101825029	CPN1	-0.3	-4.39	-0.34	2.11e-5	Liver enzyme levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11414945	chr2:190719470	PMS1	0.59	6.54	0.47	8.66e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.63	0.35	7.81e-6	Obesity-related traits;
PAAD	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.75	-7.71	-0.53	1.52e-12	Mosquito bite size;
PAAD	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02527881	chr3:46936655	PTH1R	0.39	4.51	0.34	1.28e-5	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12244544	chr17:26684744	TMEM199;POLDIP2	0.69	6.73	0.48	3.33e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg18209359	chr17:80159595	CCDC57	0.44	4.56	0.35	1.05e-5	Life satisfaction;
PAAD	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg10395934	chr14:104002654	TRMT61A	-0.55	-5.89	-0.43	2.4e-8	Body mass index;
PAAD	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.55	-0.78	3.13e-33	Height;
PAAD	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.66	0.35	6.97e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.72	7.91	0.54	5.03e-13	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21704448	chr6:132410188	NA	-0.6	-6.32	-0.46	2.76e-9	Obesity-related traits;
PAAD	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.67	7.01	0.49	7.39e-11	Height;
PAAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.73	0.53	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg19623624	chr10:135278901	LOC619207	-0.43	-4.45	-0.34	1.64e-5	Systemic lupus erythematosus;
PAAD	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.51	6.21	0.45	4.85e-9	Sitting height ratio;
PAAD	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-12.3	-0.71	1.39e-24	Primary sclerosing cholangitis;
PAAD	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.82	8.1	0.55	1.65e-13	Callous-unemotional behaviour;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.79	8.67	0.58	5.96e-15	Menopause (age at onset);
PAAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-5.86	-0.43	2.79e-8	Body mass index;
PAAD	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.48	-4.69	-0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-6.68	-0.48	4.23e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24549020	chr5:56110836	MAP3K1	0.71	5.21	0.39	6.13e-7	Initial pursuit acceleration;
PAAD	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg08495239	chr10:135273341	LOC619207	-0.42	-4.36	-0.33	2.38e-5	Systemic lupus erythematosus;
PAAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.6	-6.4	-0.46	1.86e-9	HDL cholesterol;
PAAD	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	trans	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg03161606	chr19:29218774	NA	0.59	4.36	0.33	2.36e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4917300	0.586	rs1352949	chr8:143096253	G/C	cg26003909	chr8:143102224	NA	-0.35	-5.77	-0.42	4.24e-8	Amyotrophic lateral sclerosis;
PAAD	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.5	0.57	1.61e-14	Corneal astigmatism;
PAAD	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.62	6.5	0.47	1.06e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.65	6.92	0.49	1.19e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.57	4.86	0.37	2.92e-6	Height;
PAAD	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg19217778	chr13:113420270	ATP11A	0.63	4.37	0.33	2.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.67	5.53	0.41	1.35e-7	Gut microbiome composition (summer);
PAAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg14349672	chr11:133703707	NA	-0.55	-6.06	-0.44	1.01e-8	Childhood ear infection;
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.81	-0.48	2.16e-10	Lung cancer;
PAAD	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.69	-0.36	6.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg16736954	chr20:23401023	NAPB	0.76	4.33	0.33	2.71e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg24747557	chr10:131355152	MGMT	0.48	4.56	0.35	1.06e-5	Response to temozolomide;
PAAD	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.53	4.45	0.34	1.62e-5	Fat distribution (HIV);
PAAD	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg16342193	chr10:102329863	NA	-0.79	-8.55	-0.57	1.25e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs55637147	0.703	rs3741090	chr11:57118467	A/C	cg25492363	chr11:57319872	UBE2L6	-0.42	-4.64	-0.35	7.31e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.53e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8040855	0.627	rs1532776	chr15:85624614	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg05313129	chr8:58192883	C8orf71	-0.44	-4.31	-0.33	2.95e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg19418458	chr7:158789849	NA	0.66	6.39	0.46	1.95e-9	Facial morphology (factor 20);
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.58	6.38	0.46	2.08e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	5.08	0.38	1.1e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	cis	rs7646881	0.812	rs7636023	chr3:158460059	T/C	cg19483011	chr3:158453295	NA	-0.62	-4.96	-0.37	1.9e-6	Tetralogy of Fallot;
PAAD	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg09659197	chr4:152720779	NA	0.36	5.28	0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.18	-0.39	6.84e-7	Pulmonary function;
PAAD	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg04826882	chr13:114838756	RASA3	-0.67	-5.65	-0.42	7.79e-8	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00720190	chr3:38537749	EXOG	0.57	6.45	0.46	1.4e-9	Metabolite levels  (X-11787);
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.79	-0.48	2.33e-10	Calcium levels;
PAAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	9.18e-15	Homoarginine levels;
PAAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.57	6.01	0.44	1.33e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.94	-9.6	-0.61	2.4e-17	Strep throat;
PAAD	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	5.4	0.4	2.47e-7	Response to antipsychotic treatment;
PAAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.65	-5.27	-0.39	4.66e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg05110241	chr16:68378359	PRMT7	-1.08	-8.13	-0.55	1.42e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	6.97	0.49	9.09e-11	Lymphocyte counts;
PAAD	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg00262122	chr8:11665843	FDFT1	-0.47	-4.29	-0.33	3.17e-5	Systolic blood pressure;
PAAD	cis	rs11696501	0.895	rs6065823	chr20:44114873	C/T	cg11783356	chr20:44313418	WFDC10B	0.67	5.97	0.44	1.63e-8	Brain structure;
PAAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.36	-0.33	2.39e-5	Height;
PAAD	cis	rs2286379	0.536	rs7316218	chr12:1788424	C/T	cg05227549	chr12:1770782	NA	-0.4	-4.48	-0.34	1.48e-5	Blood pressure (smoking interaction);
PAAD	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs13418717	0.793	rs4663053	chr2:127638990	A/G	cg25501666	chr2:127640322	NA	-0.9	-4.76	-0.36	4.39e-6	Heart failure;
PAAD	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.38	4.72	0.36	5.3e-6	Intraocular pressure;
PAAD	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.71	7.08	0.5	5.03e-11	Alcohol dependence;
PAAD	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26876637	chr1:152193138	HRNR	0.84	6.44	0.46	1.5e-9	Atopic dermatitis;
PAAD	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg20406979	chr6:167373233	NA	0.39	5.1	0.38	1.02e-6	Crohn's disease;
PAAD	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.6	-5.66	-0.42	7.46e-8	Mean corpuscular volume;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg01200585	chr1:228362443	C1orf69	0.63	6.31	0.46	2.89e-9	Diastolic blood pressure;
PAAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs9810890	1.000	rs13323787	chr3:128602135	G/T	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs2131877	0.913	rs12634646	chr3:194842911	A/G	cg19760965	chr3:194868843	C3orf21	0.41	4.45	0.34	1.66e-5	Non-small cell lung cancer;
PAAD	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.6	-6.85	-0.49	1.7e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg21951975	chr1:209979733	IRF6	0.58	5.88	0.43	2.52e-8	Coronary artery disease;
PAAD	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg11952622	chr19:58962976	ZNF324B	0.44	4.31	0.33	2.87e-5	Uric acid clearance;
PAAD	cis	rs9333029	0.524	rs3890011	chr1:47398743	C/G	cg08644498	chr1:46502608	NA	0.47	4.26	0.33	3.57e-5	Blood metabolite levels;
PAAD	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.75	7.29	0.51	1.61e-11	Neuroticism;
PAAD	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.58	5.1	0.38	1.01e-6	Interleukin-17 levels;
PAAD	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	9.65	0.62	1.72e-17	Prudent dietary pattern;
PAAD	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg03808351	chr9:123631620	PHF19	0.44	4.79	0.36	3.98e-6	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02985541	chr2:219472218	PLCD4	0.31	4.85	0.37	3e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs17213078	0.602	rs4851926	chr2:106742660	A/G	cg15412446	chr2:106886593	NA	0.59	5.83	0.43	3.15e-8	Facial morphology (factor 23);
PAAD	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs621942	0.718	rs1941375	chr11:85757133	T/C	cg07180834	chr11:85838833	NA	-0.5	-5.0	-0.38	1.59e-6	Tourette syndrome;
PAAD	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-6.99	-0.49	8.12e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg06781209	chr11:61594997	FADS2	-0.52	-4.52	-0.34	1.24e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs1529711	0.500	rs115016167	chr19:10917799	A/G	cg16667279	chr19:11591998	ELAVL3	-0.58	-4.6	-0.35	8.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg09796270	chr17:17721594	SREBF1	0.46	5.14	0.38	8.28e-7	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.76	9.34	0.6	1.14e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg17644776	chr2:200775616	C2orf69	0.46	4.44	0.34	1.74e-5	Asthma (bronchodilator response);
PAAD	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.59	-5.34	-0.4	3.34e-7	Corneal astigmatism;
PAAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-4.32	-0.33	2.77e-5	Aortic root size;
PAAD	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.49	4.44	0.34	1.73e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.31	0.56	5.04e-14	Prudent dietary pattern;
PAAD	cis	rs5009270	0.553	rs6947690	chr7:112233386	C/G	cg23628563	chr7:112262597	NA	0.64	5.61	0.41	9.32e-8	Osteoarthritis (hip);
PAAD	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.68e-6	Oral cavity cancer;
PAAD	cis	rs73206853	0.841	rs73191836	chr12:110966177	G/T	cg12870014	chr12:110450643	ANKRD13A	0.73	4.54	0.35	1.12e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	7.82	0.54	8.11e-13	Menarche (age at onset);
PAAD	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	7.35	0.51	1.11e-11	Lung cancer in ever smokers;
PAAD	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.65	-0.35	7.3e-6	Ulcerative colitis;
PAAD	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg00531865	chr16:30841666	NA	-0.56	-4.26	-0.33	3.57e-5	Multiple myeloma;
PAAD	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs9660180	0.819	rs4648629	chr1:1695462	C/A	cg17747265	chr1:1875780	NA	0.63	9.12	0.59	4.13e-16	Body mass index;
PAAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs3931020	0.616	rs277380	chr1:75263088	T/C	cg26752657	chr1:75199075	CRYZ;TYW3	-0.55	-4.61	-0.35	8.37e-6	Resistin levels;
PAAD	cis	rs2862774	1.000	rs2862774	chr2:113797677	A/C	cg06156847	chr2:113672199	IL1F7	-0.6	-5.3	-0.39	4.06e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.48	-0.47	1.22e-9	Leprosy;
PAAD	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.89	0.37	2.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02985541	chr2:219472218	PLCD4	-0.29	-4.43	-0.34	1.77e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.79	8.72	0.58	4.41e-15	Lewy body disease;
PAAD	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.55	4.61	0.35	8.42e-6	Neutrophil percentage of white cells;
PAAD	trans	rs2275606	0.920	rs13206260	chr6:146914151	G/A	cg02825511	chr16:69344779	VPS4A	0.81	6.34	0.46	2.51e-9	Leprosy;
PAAD	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg02743256	chr7:2109353	MAD1L1	0.55	4.36	0.33	2.42e-5	Bipolar disorder;
PAAD	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg06092702	chr1:163392909	NA	-0.52	-5.52	-0.41	1.43e-7	Motion sickness;
PAAD	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg08523384	chr5:141488047	NDFIP1	-0.66	-6.03	-0.44	1.2e-8	Crohn's disease;
PAAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.7	7.4	0.51	8.53e-12	Colorectal cancer;
PAAD	cis	rs6594713	0.642	rs17389165	chr5:112796598	A/C	cg12552261	chr5:112820674	MCC	-0.74	-5.34	-0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-1.06	-10.2	-0.64	6.15e-19	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7729723	0.508	rs2240331	chr5:137780368	C/A	cg26069252	chr5:137800343	EGR1	-0.47	-4.43	-0.34	1.81e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs367943	0.604	rs10477502	chr5:113007126	C/T	cg12552261	chr5:112820674	MCC	0.62	6.32	0.46	2.71e-9	Type 2 diabetes;
PAAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs1015291	0.700	rs2220683	chr12:19995503	G/A	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	9.9e-6	Renal cell carcinoma;
PAAD	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-5.24	-0.39	5.32e-7	Monocyte percentage of white cells;
PAAD	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.45	-4.7	-0.36	5.69e-6	Dementia with Lewy bodies;
PAAD	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.89	-8.7	-0.58	4.99e-15	Bone mineral density;
PAAD	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.59	5.37	0.4	2.84e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.4	4.74	0.36	4.96e-6	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27347727	chr19:12886506	HOOK2	0.56	6.46	0.46	1.33e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.06	6.75	0.48	2.96e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg14773178	chr5:1868261	NA	0.47	6.37	0.46	2.15e-9	Cardiovascular disease risk factors;
PAAD	cis	rs3806308	0.966	rs3806306	chr1:20143100	A/G	cg13843611	chr1:20143089	RNF186	0.51	5.26	0.39	4.85e-7	Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.81	9.72	0.62	1.13e-17	Bladder cancer;
PAAD	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.71	0.74	2.29e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs17154702	0.506	rs78790499	chr8:8628827	T/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Neurocognitive impairment in HIV-1 infection (continuous);
PAAD	trans	rs1146751	0.674	rs649851	chr3:84934492	G/T	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.9	9.48	0.61	4.88e-17	Breast cancer;
PAAD	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.83	10.12	0.63	1.02e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg01489032	chr8:143877656	NA	0.39	4.33	0.33	2.65e-5	Urinary tract infection frequency;
PAAD	cis	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.89e-7	HDL cholesterol;
PAAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	5.85	0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs4766646	0.542	rs4766635	chr12:110276914	A/G	cg10794374	chr12:110278745	NA	0.24	4.39	0.34	2.12e-5	Metabolite levels (MHPG);
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg26338869	chr17:61819248	STRADA	-0.62	-6.2	-0.45	5.04e-9	Prudent dietary pattern;
PAAD	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-5.21	-0.39	6.04e-7	Schizophrenia (age at onset);
PAAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	cis	rs58521262	0.556	rs918644	chr19:23224492	G/A	cg02350677	chr19:23254381	NA	0.26	4.46	0.34	1.57e-5	Testicular germ cell tumor;
PAAD	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.5	-5.26	-0.39	4.9e-7	Colorectal cancer;
PAAD	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	7.47	0.52	6e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg23119463	chr10:134592391	INPP5A	-0.47	-4.41	-0.34	1.98e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs901683	1.000	rs35303148	chr10:45989254	G/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.06	0.55	2.1e-13	Lung cancer;
PAAD	cis	rs6466055	0.669	rs7797912	chr7:104769415	C/T	cg04380332	chr7:105027541	SRPK2	0.63	7.08	0.5	5.05e-11	Schizophrenia;
PAAD	cis	rs7101378	0.500	rs1912236	chr11:108897971	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.37	0.6	9.71e-17	Lymphocyte counts;
PAAD	cis	rs2882667	0.690	rs2693963	chr5:138106326	T/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.46	0.34	1.58e-5	Anterior chamber depth;
PAAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg18370025	chr7:2749541	AMZ1	-0.39	-4.73	-0.36	5e-6	Height;
PAAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.76	6.77	0.48	2.64e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.8	-10.31	-0.64	3.17e-19	Menopause (age at onset);
PAAD	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.39	4.9	0.37	2.42e-6	Pulmonary function;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg08088566	chr11:430123	ANO9	0.85	5.43	0.4	2.22e-7	Body mass index;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs9506514	0.509	rs9509279	chr13:21133719	C/G	cg27234864	chr13:21295941	IL17D	0.47	4.49	0.34	1.38e-5	Coronary artery calcification;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg18209359	chr17:80159595	CCDC57	-0.46	-4.67	-0.35	6.44e-6	Life satisfaction;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg20295408	chr7:1910781	MAD1L1	0.55	5.49	0.41	1.68e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.3	0.56	5.37e-14	Coffee consumption (cups per day);
PAAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.97e-10	Platelet distribution width;
PAAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg03676636	chr4:99064102	C4orf37	-0.25	-4.36	-0.33	2.42e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.75	8.01	0.54	2.77e-13	Mosquito bite size;
PAAD	cis	rs1419980	0.643	rs11559835	chr12:7762615	T/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.84	7.02	0.49	6.85e-11	Alzheimer's disease;
PAAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg26169700	chr22:42538906	CYP2D7P1	0.6	4.64	0.35	7.61e-6	Birth weight;
PAAD	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.46	-4.62	-0.35	8.18e-6	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs9659323	1.000	rs9659323	chr1:119504361	A/G	cg17326555	chr1:119535693	NA	-0.42	-5.5	-0.41	1.55e-7	Body mass index;
PAAD	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.45	0.52	6.45e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.66	-0.53	2.07e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.77	-8.61	-0.57	8.61e-15	Ulcerative colitis;
PAAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.89	-11.03	-0.67	3.8e-21	Coronary artery disease;
PAAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.51	6.73	0.48	3.3e-10	Life satisfaction;
PAAD	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02985541	chr2:219472218	PLCD4	0.28	4.29	0.33	3.12e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.68	-5.4	-0.4	2.57e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg05785598	chr3:49045655	WDR6	0.43	4.93	0.37	2.16e-6	Parkinson's disease;
PAAD	cis	rs16838233	1.000	rs716325	chr1:29758457	A/G	cg12609322	chr1:29490924	SFRS4	-0.54	-4.48	-0.34	1.48e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs4764487	0.735	rs1990384	chr12:6342921	G/T	cg08284733	chr12:6341482	CD9	0.4	4.33	0.33	2.74e-5	Mean platelet volume;
PAAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.61	6.88	0.49	1.48e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg03989125	chr22:38214979	NA	0.62	5.69	0.42	6.46e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10750165	0.716	rs10892461	chr11:119654807	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg03538708	chr1:25844672	NA	-0.54	-5.46	-0.4	1.94e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.59	0.35	9.38e-6	Menopause (age at onset);
PAAD	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.8	9.4	0.61	8.11e-17	Morning vs. evening chronotype;
PAAD	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.87	9.63	0.62	2.03e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.63	0.47	5.46e-10	Coffee consumption (cups per day);
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18621852	chr3:10150065	C3orf24	0.67	5.93	0.43	2.01e-8	Alzheimer's disease;
PAAD	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg14345882	chr6:26364793	BTN3A2	-0.66	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.29	-0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.54	5.4	0.4	2.55e-7	Personality dimensions;
PAAD	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.5	4.77	0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.66	0.35	6.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.64	5.96	0.44	1.68e-8	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg24519413	chr1:26490540	NA	0.5	4.68	0.35	6.42e-6	QRS complex (12-leadsum);
PAAD	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.78e-7	White blood cell count;
PAAD	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.78	-7.65	-0.53	2.09e-12	Gout;
PAAD	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs904092	0.608	rs6532810	chr4:100152312	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-4.53	-0.34	1.21e-5	Alcohol dependence;
PAAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.35	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.56	5.98	0.44	1.5e-8	Schizophrenia;
PAAD	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg06883089	chr1:45254480	BEST4	0.35	4.5	0.34	1.36e-5	High light scatter reticulocyte count;
PAAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.44	-6.01	-0.44	1.31e-8	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08952239	chr16:85952285	IRF8	0.54	6.31	0.46	2.97e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1992660	0.523	rs12697408	chr5:40348573	T/A	cg05240017	chr5:40756081	TTC33	0.49	4.26	0.33	3.55e-5	Crohn's disease;
PAAD	cis	rs10768122	1.000	rs4756205	chr11:35292359	A/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.29	-0.33	3.13e-5	Vitiligo;
PAAD	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	6.33	0.46	2.62e-9	Post bronchodilator FEV1;
PAAD	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.55	-4.49	-0.34	1.4e-5	Corneal structure;
PAAD	cis	rs11168618	0.509	rs2731099	chr12:48883926	C/T	cg01881778	chr12:48919444	OR8S1	0.45	4.54	0.35	1.15e-5	Adiponectin levels;
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg19636519	chr7:99541626	NA	0.38	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs360071	0.528	rs360100	chr1:226067382	G/A	cg11967457	chr1:226128626	LEFTY2	0.51	4.83	0.36	3.35e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs728616	1.000	rs728615	chr10:81848089	G/A	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.54	-0.35	1.15e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7224685	0.731	rs35514092	chr17:4183041	G/A	cg09695851	chr17:3907499	NA	0.63	5.25	0.39	5.07e-7	Type 2 diabetes;
PAAD	cis	rs11807834	0.522	rs7549029	chr1:230253406	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.76	7.52	0.52	4.41e-12	Psoriasis;
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg26597838	chr10:835615	NA	0.49	5.28	0.39	4.34e-7	Survival in rectal cancer;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7172971	0.688	rs77356331	chr15:42387272	C/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg23018236	chr17:30244563	NA	-0.6	-4.55	-0.35	1.07e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg07212818	chr11:638076	DRD4	-0.77	-6.94	-0.49	1.09e-10	Systemic lupus erythematosus;
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg13206674	chr6:150067644	NUP43	0.66	6.91	0.49	1.26e-10	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06963648	chr14:23340939	LRP10	0.65	6.38	0.46	2e-9	Obesity-related traits;
PAAD	cis	rs642743	0.967	rs601019	chr10:105976452	C/T	cg23130731	chr10:105978651	MIR609;C10orf79	-0.25	-4.89	-0.37	2.56e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.49	8.01	0.54	2.74e-13	IgG glycosylation;
PAAD	cis	rs300774	1.000	rs146562	chr2:119663	T/G	cg23649280	chr2:140451	NA	-0.52	-4.65	-0.35	7.1e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg06740227	chr12:86229804	RASSF9	0.54	4.93	0.37	2.15e-6	Major depressive disorder;
PAAD	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg24553058	chr2:113831203	IL1F10	0.73	8.26	0.56	6.6e-14	Protein quantitative trait loci;
PAAD	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.89	10.15	0.64	8.59e-19	Gout;
PAAD	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.47	4.46	0.34	1.57e-5	Birth weight;
PAAD	cis	rs12754538	0.715	rs12028347	chr1:8708925	A/G	cg06159269	chr1:8767347	RERE	0.42	4.95	0.37	1.99e-6	Subjective well-being;
PAAD	cis	rs10792830	1.000	rs7114331	chr11:85839719	G/A	cg07180834	chr11:85838833	NA	-0.62	-7.52	-0.52	4.42e-12	Psychosis and Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.84	0.37	3.22e-6	Breast cancer;
PAAD	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.64	6.41	0.46	1.74e-9	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.63	-0.42	8.67e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.8	8.75	0.58	3.76e-15	Morning vs. evening chronotype;
PAAD	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg17595323	chr11:93583763	C11orf90	0.34	4.37	0.33	2.31e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	11.2	0.67	1.34e-21	Cognitive test performance;
PAAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.36	-0.4	2.99e-7	Diastolic blood pressure;
PAAD	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.6	-4.77	-0.36	4.36e-6	QRS complex (12-leadsum);
PAAD	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.53	5.17	0.39	7.23e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.54	-0.41	1.3e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2834188	1.000	rs2834190	chr21:34693011	A/T	cg04842828	chr21:34696676	IFNAR1	-0.43	-4.25	-0.33	3.73e-5	Narcolepsy;
PAAD	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-1.0	-8.01	-0.55	2.72e-13	Blood protein levels;
PAAD	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs7132746	0.553	rs7399277	chr12:86189246	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-4.71	-0.36	5.49e-6	Lewy body disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17310428	chr7:129777263	NA	-0.68	-6.82	-0.48	2.04e-10	Obesity-related traits;
PAAD	trans	rs61931739	0.649	rs1093031	chr12:33722730	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.78	9.08	0.59	5.36e-16	Eosinophil percentage of white cells;
PAAD	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	6.54	0.47	8.94e-10	Body mass index (adult);
PAAD	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg06697600	chr4:7070879	GRPEL1	0.79	5.16	0.39	7.63e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.63	5.59	0.41	1.04e-7	Mean platelet volume;
PAAD	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.78	-9.62	-0.62	2.11e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	1.28	8.37	0.56	3.45e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.42	5.03	0.38	1.36e-6	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	1.06	6.0	0.44	1.36e-8	Body mass index;
PAAD	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.99	-10.14	-0.64	9.15e-19	Menarche (age at onset);
PAAD	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-6.9	-0.49	1.29e-10	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs11676676	1.000	rs11681808	chr2:109770857	G/C	cg23046629	chr2:109745841	LOC100287216;SH3RF3	0.54	4.46	0.34	1.59e-5	Pediatric bone mineral density (spine);
PAAD	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.58	-5.51	-0.41	1.47e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.21e-7	IgG glycosylation;
PAAD	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.37	-0.33	2.32e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.06	12.09	0.7	5.4e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.76	8.64	0.57	7.19e-15	Schizophrenia;
PAAD	cis	rs1358748	0.522	rs1321152	chr1:67583666	A/T	cg02640540	chr1:67518911	SLC35D1	0.67	4.51	0.34	1.29e-5	Tuberculosis;
PAAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg04106633	chr4:1044584	NA	0.53	4.96	0.37	1.85e-6	Recombination rate (males);
PAAD	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg08758996	chr17:66097529	LOC651250	-0.53	-4.92	-0.37	2.23e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg23250157	chr14:64679961	SYNE2	-0.52	-5.5	-0.41	1.57e-7	Atrial fibrillation;
PAAD	cis	rs13418717	1.000	rs13418717	chr2:127662897	A/T	cg16909742	chr2:127635678	NA	-0.86	-4.29	-0.33	3.15e-5	Heart failure;
PAAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg21238619	chr17:78079768	GAA	-0.48	-5.85	-0.43	2.92e-8	Yeast infection;
PAAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.67	-10.02	-0.63	1.82e-18	Social autistic-like traits;
PAAD	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.59	-5.12	-0.38	9.18e-7	Blood metabolite levels;
PAAD	cis	rs3743102	0.591	rs8040152	chr15:83356728	C/T	cg00614314	chr15:82944287	LOC80154	-0.71	-5.3	-0.39	4.08e-7	Colorectal adenoma (advanced);
PAAD	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.75	7.5	0.52	4.82e-12	Corneal astigmatism;
PAAD	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.69	-7.94	-0.54	4.12e-13	White blood cell count (basophil);
PAAD	cis	rs4668356	0.773	rs60091560	chr2:172031406	T/C	cg13882835	chr2:172017928	TLK1	0.76	4.44	0.34	1.73e-5	Cognitive performance;
PAAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.57	-4.91	-0.37	2.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.6	6.09	0.44	8.79e-9	Platelet count;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23158103	chr7:148848205	ZNF398	0.59	5.42	0.4	2.26e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg23346134	chr3:49453900	TCTA	0.43	4.25	0.33	3.76e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08827079	chr19:35225142	ZNF181	0.66	6.95	0.49	9.91e-11	Myopia (pathological);
PAAD	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.2	0.64	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.53	-5.25	-0.39	5.14e-7	Adiposity;
PAAD	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg05341575	chr12:125625032	AACS	0.49	4.73	0.36	5.18e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-6.29	-0.45	3.14e-9	Coronary heart disease;
PAAD	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.19	0.55	9.96e-14	Morning vs. evening chronotype;
PAAD	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.46	4.99	0.38	1.62e-6	Age of smoking initiation;
PAAD	cis	rs57786342	0.806	rs55885232	chr14:69282512	G/T	cg03189333	chr14:69283534	NA	-0.61	-4.44	-0.34	1.73e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs7595037	0.663	rs11126185	chr2:68652580	G/A	cg12452813	chr2:68675892	NA	-0.53	-4.28	-0.33	3.27e-5	Multiple sclerosis;
PAAD	cis	rs7631605	0.935	rs1558528	chr3:37056990	C/A	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.54	-0.41	1.3e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6445967	1.000	rs6445967	chr3:58282576	T/C	cg23715586	chr3:58305044	RPP14	0.49	4.36	0.33	2.34e-5	Platelet count;
PAAD	cis	rs75920871	0.841	rs61905709	chr11:116897834	C/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg19682013	chr15:45996608	NA	-0.32	-4.25	-0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.99	14.03	0.75	3.28e-29	Rheumatoid arthritis;
PAAD	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00700412	chr12:58011837	NA	-0.46	-5.06	-0.38	1.2e-6	Multiple sclerosis;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.75	8.77	0.58	3.41e-15	Lung cancer;
PAAD	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs2147904	0.934	rs812487	chr1:42366198	G/A	cg16685388	chr1:42384056	HIVEP3	0.38	4.57	0.35	9.91e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.04	0.63	1.65e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6700896	0.500	rs12043254	chr1:66131707	A/G	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.87	10.71	0.66	2.67e-20	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13830646	chr11:65668067	FOSL1	0.68	7.38	0.51	9.5e-12	Myopia (pathological);
PAAD	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13198984	chr17:80129470	CCDC57	0.43	5.42	0.4	2.34e-7	Life satisfaction;
PAAD	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-5.51	-0.41	1.51e-7	Red cell distribution width;
PAAD	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	4.64	0.35	7.51e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg11494091	chr17:61959527	GH2	-0.6	-6.2	-0.45	5.02e-9	Height;
PAAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.5	-6.39	-0.46	1.9e-9	Height;
PAAD	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.74	7.1	0.5	4.51e-11	Breast cancer;
PAAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.25	-0.81	1.27e-37	Height;
PAAD	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06850241	chr22:41845214	NA	-0.56	-4.89	-0.37	2.51e-6	Vitiligo;
PAAD	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg01631408	chr1:248437212	OR2T33	-0.57	-5.19	-0.39	6.69e-7	Common traits (Other);
PAAD	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-4.95	-0.37	1.92e-6	Mean platelet volume;
PAAD	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-1.08	-15.07	-0.77	5.77e-32	Total body bone mineral density;
PAAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.76	6.13	0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg15145965	chr22:50218605	BRD1	0.57	4.7	0.36	5.78e-6	Schizophrenia;
PAAD	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.9	9.48	0.61	4.88e-17	Breast cancer;
PAAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.62	-6.69	-0.48	4.1e-10	Schizophrenia;
PAAD	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg11157765	chr11:69982996	ANO1	0.62	4.86	0.37	2.86e-6	Survival in rectal cancer;
PAAD	cis	rs59372292	0.597	rs17160491	chr19:8512940	T/G	cg03219694	chr19:9416667	ZNF699	0.45	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.78	0.36	4.18e-6	Breast cancer;
PAAD	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	4.9	0.37	2.47e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.71	0.62	1.22e-17	Prudent dietary pattern;
PAAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg15145965	chr22:50218605	BRD1	0.56	4.88	0.37	2.64e-6	Schizophrenia;
PAAD	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.85	9.44	0.61	6.18e-17	Resting heart rate;
PAAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26143326	chr5:218493	SDHA;CCDC127	0.66	7.74	0.53	1.3e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.0	5.45	0.4	2.02e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-1.09	-11.66	-0.69	7.79e-23	Longevity;
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg15691649	chr6:25882328	NA	-0.49	-4.51	-0.34	1.29e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.95	0.49	1.03e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg08835956	chr7:39171034	POU6F2	0.32	5.0	0.38	1.56e-6	IgG glycosylation;
PAAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.52	-5.74	-0.42	5.02e-8	Facial morphology (factor 20);
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.6	4.63	0.35	7.68e-6	Information processing speed;
PAAD	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.48	5.06	0.38	1.22e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1420338	0.967	rs9655014	chr7:34148632	T/C	cg01275685	chr7:34179230	BMPER	-0.54	-5.11	-0.38	9.73e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg03989125	chr22:38214979	NA	-0.52	-4.9	-0.37	2.42e-6	Glioblastoma;Glioma;
PAAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.54	5.02	0.38	1.46e-6	Type 2 diabetes;
PAAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-5.46	-0.41	1.86e-7	Monocyte count;
PAAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg09888920	chr5:474111	LOC25845;SLC9A3	0.48	4.31	0.33	2.96e-5	Cystic fibrosis severity;
PAAD	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.85	9.89	0.63	4e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-5.88	-0.43	2.46e-8	Bipolar disorder;
PAAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.42	4.6	0.35	8.9e-6	Lung cancer;
PAAD	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.55	-0.35	1.07e-5	Blood metabolite levels;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg27121462	chr16:89883253	FANCA	-0.46	-4.93	-0.37	2.13e-6	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05414835	chr15:59225898	SLTM	-0.64	-6.88	-0.49	1.45e-10	Smoking initiation;
PAAD	trans	rs3020418	0.928	rs926779	chr6:152355920	G/A	cg09520904	chr11:69462943	CCND1	-0.54	-6.62	-0.47	5.7e-10	Height;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.79	-8.4	-0.56	2.96e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	5.0	0.38	1.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.88	-9.4	-0.61	7.97e-17	Pancreatic cancer;
PAAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.86	-0.43	2.8e-8	Diabetic kidney disease;
PAAD	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.83	-5.52	-0.41	1.43e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.75	-8.61	-0.57	8.76e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.6	6.38	0.46	2e-9	Bladder cancer;
PAAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.9	8.79	0.58	3.07e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs1878047	0.665	rs8111074	chr19:51776117	G/T	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs1371614	0.523	rs4233714	chr2:27181454	A/G	cg00617064	chr2:27272375	NA	0.49	5.01	0.38	1.47e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19882132	chr14:106167949	NA	-0.54	-4.77	-0.36	4.25e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.97	-9.94	-0.63	3.07e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.55	-5.83	-0.43	3.29e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.39	0.34	2.07e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.64	6.21	0.45	4.92e-9	Coronary artery disease;
PAAD	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg10864074	chr7:100318194	EPO	-0.47	-4.49	-0.34	1.43e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.98	13.68	0.74	2.74e-28	Multiple system atrophy;
PAAD	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-5.09	-0.38	1.07e-6	Asthma;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.54	5.41	0.4	2.39e-7	Menarche (age at onset);
PAAD	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.54	-4.66	-0.35	6.9e-6	Fibrinogen levels;
PAAD	trans	rs61931739	0.649	rs815045	chr12:33722057	C/G	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs3112530	1.000	rs1026615	chr5:152699649	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.42	-4.36	-0.33	2.36e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.69	5.2	0.39	6.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.71	0.36	5.49e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.55	-4.31	-0.33	2.93e-5	IFN-related cytopenia;
PAAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg24053715	chr22:38214548	NA	-0.5	-4.86	-0.37	2.94e-6	Glioblastoma;Glioma;
PAAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.87	0.49	1.52e-10	Rheumatoid arthritis;
PAAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg16680214	chr1:154839983	KCNN3	-0.4	-4.63	-0.35	7.91e-6	Schizophrenia;
PAAD	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.96	11.34	0.68	5.42e-22	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.19	-0.5	2.8e-11	Gut microbiome composition (summer);
PAAD	cis	rs16975963	0.843	rs73041047	chr19:38299289	T/C	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg02071572	chr4:1403502	NA	0.39	4.84	0.37	3.2e-6	Obesity-related traits;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.57	5.79	0.43	3.81e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.87	-0.37	2.71e-6	Height;
PAAD	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.51	-5.34	-0.4	3.26e-7	Morning vs. evening chronotype;
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.72	8.56	0.57	1.14e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg12623918	chr2:306882	NA	0.6	4.66	0.35	6.85e-6	Blood protein levels;
PAAD	cis	rs1865721	0.804	rs35653478	chr18:73212546	C/T	cg26385618	chr18:73139727	C18orf62	-0.46	-5.37	-0.4	2.95e-7	Intelligence;
PAAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg21951975	chr1:209979733	IRF6	0.59	5.4	0.4	2.56e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02556042	chr12:117471086	NA	0.48	4.89	0.37	2.5e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.78	4.83	0.36	3.37e-6	Obesity-related traits;
PAAD	cis	rs11637339	0.503	rs7171291	chr15:100007996	G/A	cg03300787	chr15:100533202	ADAMTS17	-0.43	-4.31	-0.33	2.9e-5	Cervical cancer;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.54	5.33	0.4	3.5e-7	Prudent dietary pattern;
PAAD	cis	rs5417	0.627	rs62059170	chr17:7155056	T/C	cg25256661	chr17:7137939	DVL2	-0.95	-10.12	-0.63	1.04e-18	Diastolic blood pressure;
PAAD	cis	rs730532	0.556	rs72680315	chr14:52511539	T/C	cg10149976	chr14:52535953	NID2	-0.53	-4.34	-0.33	2.62e-5	Pulmonary function;
PAAD	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.37	0.46	2.18e-9	Cognitive ability;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.08	14.58	0.76	1.12e-30	Height;
PAAD	cis	rs8050755	0.536	rs78160478	chr16:2107322	G/T	cg04515572	chr16:2107413	TSC2	-1.15	-7.62	-0.53	2.47e-12	Major depressive disorder;
PAAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.2	0.64	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.9	10.76	0.66	1.98e-20	Sudden cardiac arrest;
PAAD	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.49	-4.46	-0.34	1.58e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09992883	chr1:41827373	NA	0.59	6.64	0.47	5.2e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg09127314	chr1:152161683	NA	-0.64	-4.27	-0.33	3.45e-5	Atopic dermatitis;
PAAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	4.6	0.35	8.79e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.68	-6.82	-0.48	1.98e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs58521262	0.615	rs1645772	chr19:23190990	A/G	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.52	4.97	0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-1.03	-14.28	-0.76	7.24e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.55	5.08	0.38	1.08e-6	Uric acid levels;
PAAD	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.1e-9	Crohn's disease;
PAAD	cis	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg27411982	chr8:10470053	RP1L1	0.41	4.33	0.33	2.72e-5	Neuroticism;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.72	-7.95	-0.54	3.89e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-9.71	-0.62	1.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.75	6.73	0.48	3.27e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10490913	0.966	rs10886229	chr10:120145292	T/C	cg04126427	chr10:120840676	EIF3A	-0.47	-4.98	-0.37	1.68e-6	Cancer;
PAAD	cis	rs728616	0.867	rs55835350	chr10:81801728	A/T	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.62	0.47	5.68e-10	Systemic lupus erythematosus;
PAAD	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg13647721	chr17:30228624	UTP6	0.59	4.81	0.36	3.57e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.65	-7.41	-0.52	8.21e-12	Iron status biomarkers;
PAAD	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.97	-7.64	-0.53	2.23e-12	Multiple sclerosis;
PAAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs1355223	0.867	rs7944030	chr11:34691738	A/T	cg18508148	chr11:34937573	PDHX;APIP	-0.44	-4.48	-0.34	1.45e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-7.23	-0.51	2.2e-11	Blood protein levels;
PAAD	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg09654669	chr8:57350985	NA	0.5	4.31	0.33	2.91e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-9.09	-0.59	4.97e-16	Prostate cancer;
PAAD	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg11251234	chr10:101825055	CPN1	-0.32	-4.77	-0.36	4.37e-6	Bone mineral density;
PAAD	cis	rs1514658	0.903	rs1113677	chr4:119280513	T/C	cg23709618	chr4:119273073	PRSS12	0.31	4.38	0.33	2.22e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.59	-4.31	-0.33	2.94e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.42	-0.46	1.66e-9	Neuroticism;
PAAD	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg01338084	chr22:32026380	PISD	1.54	9.51	0.61	4.03e-17	Age-related hearing impairment;
PAAD	cis	rs116248771	0.690	rs73156491	chr3:158416572	A/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg01942863	chr7:99769432	GPC2	0.51	4.71	0.36	5.61e-6	Coronary artery disease;
PAAD	cis	rs3736757	1.000	rs1046239	chr1:184660205	T/A	cg05045817	chr1:184633523	NA	0.42	4.55	0.35	1.07e-5	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.63	-0.42	8.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.44	-5.02	-0.38	1.41e-6	Testicular germ cell tumor;
PAAD	cis	rs12920732	0.509	rs1541696	chr16:84794844	A/G	cg07647771	chr16:84786436	USP10	-0.31	-4.39	-0.34	2.08e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg08079166	chr15:68083412	MAP2K5	0.61	4.74	0.36	4.9e-6	Restless legs syndrome;
PAAD	cis	rs7180079	1.000	rs6494475	chr15:64634884	C/A	cg18210365	chr15:65066710	RBPMS2	0.64	4.92	0.37	2.24e-6	Monocyte count;
PAAD	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Colorectal cancer;
PAAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg15478930	chr2:27652102	NRBP1	0.49	4.41	0.34	1.95e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.57	4.83	0.36	3.33e-6	Response to diuretic therapy;
PAAD	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg26816564	chr1:7831052	VAMP3	0.77	5.74	0.42	4.98e-8	Inflammatory bowel disease;
PAAD	cis	rs3931020	0.679	rs28671241	chr1:75181881	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.56	5.55	0.41	1.23e-7	Resistin levels;
PAAD	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg25114630	chr15:101792522	CHSY1	0.54	4.82	0.36	3.42e-6	Corneal structure;
PAAD	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.33	-7.78	-0.53	1.05e-12	Psoriasis vulgaris;
PAAD	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg02117656	chr17:79614917	TSPAN10	-0.59	-6.43	-0.46	1.59e-9	Eye color traits;
PAAD	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.56	-0.41	1.2e-7	Personality dimensions;
PAAD	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.44	-0.34	1.71e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.33	-0.4	3.41e-7	Blood metabolite levels;
PAAD	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs6494488	0.500	rs72744726	chr15:65030995	C/T	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.79	8.1	0.55	1.67e-13	Uric acid levels;
PAAD	cis	rs76917914	0.820	rs58427887	chr9:100820671	C/T	cg03040243	chr9:100819229	NANS	0.59	4.72	0.36	5.32e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg23465465	chr6:26364728	BTN3A2	0.75	5.13	0.38	8.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6496932	0.635	rs12900455	chr15:85905576	G/A	cg19183879	chr15:85880815	NA	-0.54	-5.1	-0.38	1.01e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg00536532	chr6:33561449	C6orf227	-0.42	-4.46	-0.34	1.57e-5	Plateletcrit;
PAAD	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.62	6.29	0.45	3.24e-9	Migraine;
PAAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.27	-0.45	3.63e-9	IgG glycosylation;
PAAD	cis	rs929596	0.564	rs2741030	chr2:234536152	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg00450029	chr8:599525	NA	0.88	6.03	0.44	1.19e-8	IgG glycosylation;
PAAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.37	4.3	0.33	3e-5	Depression;
PAAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.4	5.18	0.39	7.05e-7	Educational attainment (years of education);
PAAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg11421182	chr20:36153479	BLCAP	-0.54	-6.55	-0.47	8.45e-10	IgG glycosylation;
PAAD	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.07	-0.38	1.17e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Neutrophil percentage of white cells;
PAAD	cis	rs62025270	0.688	rs62025298	chr15:86317152	T/C	cg13263323	chr15:86062960	AKAP13	0.56	5.02	0.38	1.46e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.78	10.88	0.66	9.47e-21	Iron status biomarkers;
PAAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.26	-0.33	3.51e-5	Skin colour saturation;
PAAD	cis	rs6782228	0.509	rs4481172	chr3:128372657	C/A	cg16766828	chr3:128327626	NA	-0.48	-6.42	-0.46	1.66e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1413885	0.526	rs4554758	chr1:65857403	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.41	4.25	0.33	3.67e-5	Anticoagulant levels;
PAAD	cis	rs9815354	0.680	rs61646756	chr3:42029352	A/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.83	6.5	0.47	1.09e-9	Weight;
PAAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24729792	chr2:113192114	RGPD8;RGPD5	-0.61	-5.06	-0.38	1.17e-6	Yeast infection;
PAAD	cis	rs9715521	0.645	rs7687986	chr4:59844521	A/T	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.48	-0.34	1.46e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.44e-7	Restless legs syndrome;
PAAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18404041	chr3:52824283	ITIH1	0.41	4.35	0.33	2.47e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.55	4.5	0.34	1.33e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9469913	0.542	rs114543162	chr6:34696793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.34	-0.33	2.6e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.49	4.46	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.52	-6.54	-0.47	8.87e-10	Renal cell carcinoma;
PAAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.53	-6.14	-0.45	7e-9	Breast cancer;
PAAD	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00336071	chr15:63449943	RPS27L	-0.62	-6.45	-0.46	1.4e-9	Warfarin maintenance dose;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	4.76	0.36	4.56e-6	Bipolar disorder;
PAAD	cis	rs61884328	0.866	rs61897307	chr11:46832158	C/A	cg23433285	chr11:47201945	PACSIN3	0.79	4.51	0.34	1.3e-5	Total body bone mineral density (age over 60);
PAAD	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg10072921	chr12:121022843	NA	0.4	4.88	0.37	2.63e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	4.58	0.35	9.6e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg14926445	chr8:58193284	C8orf71	-0.59	-4.37	-0.33	2.26e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.51	-4.93	-0.37	2.1e-6	Chronic sinus infection;
PAAD	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.89e-6	Coronary artery disease;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg27615366	chr5:131592974	PDLIM4	0.4	4.28	0.33	3.36e-5	Acylcarnitine levels;
PAAD	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.59	6.43	0.46	1.56e-9	Testicular germ cell tumor;
PAAD	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.55	-0.47	8.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg10483660	chr13:112241077	NA	0.54	5.88	0.43	2.49e-8	Hepatitis;
PAAD	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs7094131	0.549	rs10764341	chr10:22880313	C/T	cg19500236	chr10:22911537	PIP4K2A	0.45	4.82	0.36	3.38e-6	Obesity-related traits;
PAAD	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.58	5.85	0.43	2.85e-8	Systolic blood pressure;
PAAD	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.63	5.1	0.38	1.01e-6	Bipolar disorder;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.06	-0.55	2.05e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.49	4.98	0.37	1.67e-6	Testicular germ cell tumor;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.57	-5.76	-0.42	4.52e-8	Parkinson's disease;
PAAD	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs7301016	1.000	rs7301016	chr12:62886123	A/G	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.59	5.9	0.43	2.31e-8	Schizophrenia;
PAAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Schizophrenia;
PAAD	cis	rs6785206	0.554	rs9831813	chr3:128478542	G/A	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03253314	chr19:17445711	ANO8	0.53	6.32	0.46	2.8e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.69	-5.2	-0.39	6.36e-7	Initial pursuit acceleration;
PAAD	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	4.94	0.37	2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1816752	0.875	rs59686377	chr13:25050007	C/T	cg01628528	chr13:24882594	C1QTNF9	-0.46	-4.31	-0.33	2.97e-5	Obesity-related traits;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg01759136	chr6:27242945	NA	0.4	4.35	0.33	2.54e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1723838	0.510	rs2471904	chr11:73690599	G/A	cg26954736	chr11:73693896	UCP2	1.05	4.68	0.36	6.19e-6	Obesity-related traits;
PAAD	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.74	-8.07	-0.55	2.02e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg00864171	chr11:67383662	NA	-0.49	-5.12	-0.38	9.15e-7	Mean corpuscular volume;
PAAD	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg11189052	chr15:85197271	WDR73	-0.53	-4.46	-0.34	1.6e-5	P wave terminal force;
PAAD	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.82	-9.19	-0.6	2.83e-16	Ulcerative colitis;
PAAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22601191	chr20:60968625	CABLES2	0.63	5.63	0.42	8.45e-8	Colorectal cancer;
PAAD	cis	rs6604026	0.656	rs2774952	chr1:93355246	A/C	cg17283838	chr1:93427260	FAM69A	-0.62	-5.71	-0.42	5.71e-8	Multiple sclerosis;
PAAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.53	5.23	0.39	5.49e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.53	5.11	0.38	9.69e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.35	4.96	0.37	1.9e-6	Schizophrenia;
PAAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.58	-5.47	-0.41	1.8e-7	Obesity-related traits;
PAAD	cis	rs1015291	0.836	rs2049614	chr12:19989625	G/C	cg25401612	chr12:20009446	NA	-0.5	-4.94	-0.37	2.06e-6	Diastolic blood pressure;
PAAD	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg19673125	chr6:150240577	RAET1G	0.42	5.86	0.43	2.73e-8	Testicular germ cell tumor;
PAAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg19630374	chr17:18023558	MYO15A	-0.45	-4.77	-0.36	4.34e-6	Total body bone mineral density;
PAAD	cis	rs4704187	0.687	rs7735937	chr5:74441700	G/A	cg03227963	chr5:74354835	NA	0.5	4.86	0.37	2.94e-6	Response to amphetamines;
PAAD	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.47	-4.55	-0.35	1.08e-5	Rheumatoid arthritis;
PAAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.67	-0.42	6.96e-8	Personality dimensions;
PAAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.56	6.0	0.44	1.42e-8	Lung cancer;
PAAD	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg00717180	chr2:96193071	NA	0.59	6.46	0.46	1.32e-9	HDL cholesterol;
PAAD	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg26876637	chr1:152193138	HRNR	-0.8	-5.6	-0.41	9.89e-8	Atopic dermatitis;
PAAD	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg01426195	chr3:39028469	NA	-0.74	-8.5	-0.57	1.68e-14	Handedness;
PAAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg01299579	chr2:10830716	NOL10	-0.61	-6.18	-0.45	5.64e-9	Prostate cancer;
PAAD	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.66	6.44	0.46	1.48e-9	White matter hyperintensity burden;
PAAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs9287719	0.649	rs2884232	chr2:10719679	C/A	cg00105475	chr2:10696890	NA	0.62	6.56	0.47	8.06e-10	Prostate cancer;
PAAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	trans	rs320203	0.741	rs1165881	chr9:104805596	A/G	cg27499259	chr13:28400924	NA	0.99	6.4	0.46	1.84e-9	Mucinous ovarian carcinoma;
PAAD	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg14132834	chr19:41945861	ATP5SL	0.5	4.82	0.36	3.51e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23213016	chr3:152880098	RAP2B	0.64	6.51	0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg04415270	chr2:102091202	RFX8	0.7	8.99	0.59	9.24e-16	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	4.48	0.34	1.48e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.97	-7.26	-0.51	1.83e-11	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02091366	chr17:16342131	NCRNA00188;SNORD49B;SNORD49A	0.59	6.79	0.48	2.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg09357268	chr20:43379437	KCNK15	-0.44	-4.71	-0.36	5.55e-6	Obesity-related traits;
PAAD	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.12	-0.38	9.25e-7	Pulmonary function;
PAAD	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs9473924	0.542	rs55648125	chr6:50816718	A/G	cg14470998	chr6:50812995	TFAP2B	0.81	5.0	0.38	1.59e-6	Body mass index;
PAAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.64	7.14	0.5	3.59e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg17644776	chr2:200775616	C2orf69	-0.7	-5.37	-0.4	2.92e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.71	7.78	0.53	1.02e-12	Alcohol dependence;
PAAD	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg16591659	chr17:78472290	NA	0.49	4.6	0.35	8.76e-6	Fractional excretion of uric acid;
PAAD	cis	rs7136716	0.541	rs74528383	chr12:7774981	G/A	cg25757697	chr12:8220002	C3AR1	-0.85	-4.28	-0.33	3.27e-5	Hematological and biochemical traits;
PAAD	cis	rs2421770	0.701	rs7105037	chr11:35259191	G/T	cg13971030	chr11:35366721	SLC1A2	0.49	4.96	0.37	1.85e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg02841227	chr6:26021843	HIST1H4A	0.55	5.36	0.4	3.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg00666640	chr1:248458726	OR2T12	0.53	5.19	0.39	6.65e-7	Common traits (Other);
PAAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg05697835	chr1:2722811	NA	0.43	4.85	0.37	2.99e-6	Ulcerative colitis;
PAAD	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg16691251	chr5:66510806	NA	0.73	7.84	0.54	7.47e-13	Breast cancer;
PAAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	1.01	7.93	0.54	4.36e-13	Lymphocyte counts;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.56	5.09	0.38	1.04e-6	Dilated cardiomyopathy;
PAAD	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg15192750	chr16:69999425	NA	0.72	5.5	0.41	1.59e-7	IgE levels;
PAAD	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg21466736	chr12:48725269	NA	0.5	4.65	0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg01511742	chr3:71112437	FOXP1	-0.83	-6.36	-0.46	2.23e-9	QT interval;
PAAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.64	6.41	0.46	1.77e-9	Blood protein levels;
PAAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.8	-0.43	3.75e-8	Lung cancer;
PAAD	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.6	-6.26	-0.45	3.82e-9	Motion sickness;
PAAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.53	-4.95	-0.37	1.93e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6604026	0.740	rs2893225	chr1:93368496	G/C	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs877426	0.681	rs58312371	chr13:114837577	C/T	cg00571178	chr13:114841904	RASA3	-0.57	-4.78	-0.36	4.04e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	cis	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg11619707	chr19:22235551	ZNF257	0.59	5.89	0.43	2.34e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9435732	0.578	rs55779591	chr1:17306948	C/T	cg22045253	chr1:17337346	ATP13A2	0.44	4.56	0.35	1.04e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg02027945	chr11:20618230	NA	0.31	4.3	0.33	3.02e-5	Pursuit maintenance gain;
PAAD	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg22601191	chr20:60968625	CABLES2	-0.71	-6.21	-0.45	4.83e-9	Colorectal cancer;
PAAD	cis	rs3753841	0.832	rs10735776	chr1:103218185	C/T	cg24495344	chr1:103574097	COL11A1	-0.39	-4.54	-0.35	1.12e-5	Glaucoma (primary angle closure);
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.74	0.48	3.02e-10	Blood metabolite levels;
PAAD	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.37	0.56	3.42e-14	Corneal astigmatism;
PAAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.47	4.45	0.34	1.62e-5	Renal cell carcinoma;
PAAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg01798341	chr17:80842262	TBCD	0.47	4.94	0.37	2.04e-6	Breast cancer;
PAAD	cis	rs7165102	1.000	rs8035639	chr15:65944548	C/T	cg22900193	chr15:65823441	PTPLAD1	0.46	4.28	0.33	3.35e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.3	4.32	0.33	2.85e-5	Alopecia areata;
PAAD	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.52	0.41	1.41e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.74	-5.39	-0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.64	6.39	0.46	1.88e-9	Retinal vascular caliber;
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg18279126	chr7:2041391	MAD1L1	0.67	6.85	0.49	1.72e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg24747557	chr10:131355152	MGMT	0.46	4.69	0.36	6.07e-6	Response to temozolomide;
PAAD	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	4.54	0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.91	-8.62	-0.57	8.13e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26259181	chr19:14247518	ASF1B	0.57	6.52	0.47	9.75e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.9	10.95	0.66	6.02e-21	Metabolic syndrome;
PAAD	cis	rs8077577	0.895	rs62072500	chr17:18126918	A/C	cg16794390	chr17:18148240	FLII	0.65	5.07	0.38	1.15e-6	Obesity-related traits;
PAAD	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.48	-4.51	-0.34	1.26e-5	Type 2 diabetes;
PAAD	cis	rs11159086	1.000	rs4899514	chr14:74940170	C/G	cg10195687	chr14:74926396	NA	0.45	4.86	0.37	2.85e-6	Advanced glycation end-product levels;
PAAD	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg20503657	chr10:835505	NA	0.49	4.96	0.37	1.88e-6	Survival in rectal cancer;
PAAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg18612461	chr15:75251733	NA	0.61	7.7	0.53	1.66e-12	Breast cancer;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg11416102	chr8:651193	ERICH1	-0.94	-5.9	-0.43	2.25e-8	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.46	5.4	0.4	2.53e-7	QRS complex (12-leadsum);
PAAD	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg15181151	chr6:150070149	PCMT1	0.59	6.4	0.46	1.81e-9	Lung cancer;
PAAD	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.61	5.85	0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.98	6.47	0.46	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.85	9.3	0.6	1.46e-16	Corneal astigmatism;
PAAD	cis	rs7646881	0.951	rs6441222	chr3:158449767	A/G	cg19483011	chr3:158453295	NA	-0.63	-5.43	-0.4	2.22e-7	Tetralogy of Fallot;
PAAD	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.64	7.19	0.5	2.74e-11	Menopause (age at onset);
PAAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-5.14	-0.39	8.21e-7	Height;
PAAD	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg15145965	chr22:50218605	BRD1	-0.55	-4.59	-0.35	9.29e-6	Schizophrenia;
PAAD	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.04	0.5	6.03e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.6	5.76	0.42	4.5e-8	Tourette syndrome;
PAAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.62	5.97	0.44	1.58e-8	Menopause (age at onset);
PAAD	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.14	0.38	8.45e-7	Menarche (age at onset);
PAAD	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.7	7.18	0.5	2.93e-11	Morning vs. evening chronotype;
PAAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg01320130	chr1:67600311	NA	0.53	5.6	0.41	9.61e-8	Psoriasis;
PAAD	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg24721873	chr10:135334122	NA	0.58	4.39	0.34	2.08e-5	Gout;
PAAD	cis	rs859767	0.741	rs7602801	chr2:135363870	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg01403660	chr11:68851641	TPCN2	-0.48	-4.25	-0.33	3.72e-5	Hair color;
PAAD	cis	rs7487075	0.619	rs7486532	chr12:46843255	T/G	cg14671384	chr12:47219920	SLC38A4	0.44	4.33	0.33	2.66e-5	Itch intensity from mosquito bite;
PAAD	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27297192	chr10:134578999	INPP5A	0.59	5.18	0.39	6.8e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.8	9.52	0.61	3.91e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.45	-4.99	-0.38	1.65e-6	Body mass index;
PAAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg25204440	chr1:209979598	IRF6	0.64	5.61	0.41	9.43e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs7714584	1.000	rs4579248	chr5:150268151	C/T	cg22134413	chr5:150180641	NA	0.99	6.35	0.46	2.33e-9	Crohn's disease;
PAAD	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-4.99	-0.37	1.66e-6	Fear of minor pain;
PAAD	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.23	-18.82	-0.84	1.55e-41	Ulcerative colitis;
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.74	-9.57	-0.61	2.83e-17	Educational attainment;
PAAD	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg00431813	chr7:1051703	C7orf50	0.51	4.54	0.35	1.14e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12153243	0.714	rs2895168	chr5:142895518	A/G	cg13907255	chr5:142895549	NA	-0.49	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.55	5.0	0.38	1.58e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.43	5.33	0.4	3.53e-7	Ulcerative colitis;
PAAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	7.84	0.54	7.42e-13	Bone mineral density;
PAAD	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg14403583	chr14:105418241	AHNAK2	-0.79	-8.35	-0.56	3.97e-14	Systemic lupus erythematosus;
PAAD	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.71	6.8	0.48	2.22e-10	Psoriasis;
PAAD	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg01657329	chr11:68192670	LRP5	-0.57	-4.7	-0.36	5.89e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.59	6.71	0.48	3.6e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.44	-7.01	-0.49	7.47e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg16596103	chr2:233749413	NGEF	-0.43	-4.67	-0.35	6.55e-6	Schizophrenia;
PAAD	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg15609812	chr20:47281632	PREX1	0.65	4.5	0.34	1.36e-5	Tonometry;
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg01097406	chr16:89675127	NA	0.35	4.26	0.33	3.63e-5	Vitiligo;
PAAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.83	-0.36	3.29e-6	Atopic dermatitis;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg12784172	chr15:43661957	TUBGCP4;ZSCAN29	0.64	6.67	0.48	4.36e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg25204440	chr1:209979598	IRF6	0.61	5.3	0.4	3.92e-7	Coronary artery disease;
PAAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.87	10.23	0.64	5.11e-19	Blood protein levels;
PAAD	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.46	4.8	0.36	3.82e-6	Menopause (age at onset);
PAAD	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.67	6.65	0.47	5.07e-10	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	1.04	13.94	0.75	5.78e-29	Menarche (age at onset);
PAAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.5	5.12	0.38	9.24e-7	Major depressive disorder;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs75920871	1.000	rs11216221	chr11:116868137	A/C	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs3809060	0.959	rs2301252	chr11:32457927	C/A	cg27259320	chr11:32460587	WIT1	0.36	4.58	0.35	9.81e-6	Inguinal hernia;
PAAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg18370025	chr7:2749541	AMZ1	-0.37	-4.51	-0.34	1.29e-5	Height;
PAAD	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.4	-0.4	2.57e-7	Neuroticism;
PAAD	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.77	7.37	0.51	1.04e-11	Gout;
PAAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg03735013	chr11:61582769	MIR1908;FADS1	0.47	4.61	0.35	8.48e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.81	6.31	0.46	2.85e-9	Mean platelet volume;
PAAD	cis	rs59104589	0.521	rs7618	chr2:242434602	A/G	cg04488487	chr2:242709673	NA	0.57	4.49	0.34	1.38e-5	Fibrinogen levels;
PAAD	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	1.94e-8	Alcohol dependence;
PAAD	cis	rs17209837	1.000	rs17275514	chr7:87122030	A/G	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.45	4.75	0.36	4.77e-6	Red blood cell count;Reticulocyte count;
PAAD	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-6.32	-0.46	2.79e-9	Colorectal cancer;
PAAD	cis	rs73416724	1.000	rs75473868	chr6:43352623	A/G	cg17076780	chr6:43251928	TTBK1	0.58	4.63	0.35	7.74e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2004318	1.000	rs113758310	chr19:55129509	T/C	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg03684893	chr10:554711	DIP2C	-0.47	-4.92	-0.37	2.2e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.73	5.1	0.38	1.01e-6	HDL cholesterol levels;
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.34e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.51	4.42	0.34	1.83e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.2	-0.39	6.31e-7	Pulmonary function;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5.07e-7	Life satisfaction;
PAAD	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.55	4.85	0.37	3.05e-6	Type 2 diabetes;
PAAD	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.62	-6.43	-0.46	1.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.74	-7.9	-0.54	5.17e-13	Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.92	10.78	0.66	1.8e-20	Total body bone mineral density;
PAAD	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg04415270	chr2:102091202	RFX8	0.74	9.35	0.6	1.07e-16	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg23920097	chr1:209922102	NA	-0.49	-4.46	-0.34	1.6e-5	Red blood cell count;
PAAD	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.29	0.56	5.54e-14	Coffee consumption (cups per day);
PAAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.63	8.05	0.55	2.28e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	10.1	0.63	1.11e-18	Smoking behavior;
PAAD	cis	rs73206853	0.764	rs7312939	chr12:110564108	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.69	0.36	5.93e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg15117754	chr3:10150083	C3orf24	0.67	5.6	0.41	9.66e-8	Alzheimer's disease;
PAAD	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg04450456	chr4:17643702	FAM184B	-0.49	-4.92	-0.37	2.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.63	6.12	0.44	7.58e-9	Total body bone mineral density;
PAAD	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.63	-4.84	-0.37	3.1e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg11459648	chr5:138714337	SLC23A1	0.65	6.19	0.45	5.36e-9	Esophageal squamous cell carcinoma;
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-1.03	-8.28	-0.56	5.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.63	7.35	0.51	1.13e-11	Dupuytren's disease;
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.95	-16.05	-0.79	1.54e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg01942863	chr7:99769432	GPC2	-0.48	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.1	-11.01	-0.67	4.21e-21	Blood pressure (smoking interaction);
PAAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02838143	chr10:126606107	NA	0.74	8.0	0.54	3.02e-13	Myopia (pathological);
PAAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.56	4.95	0.37	1.96e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.58	5.06	0.38	1.18e-6	Neutrophil percentage of white cells;
PAAD	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs2671540	0.501	rs7901413	chr10:65637387	A/C	cg19573236	chr10:65733388	NA	-0.57	-4.51	-0.34	1.29e-5	Coronary artery disease;
PAAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg19680485	chr15:31195859	MTMR15	0.45	4.34	0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.64	-7.04	-0.5	6.14e-11	Height;
PAAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs1997066	0.831	rs73340211	chr10:106804507	T/G	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.51	6.16	0.45	6.2e-9	Sitting height ratio;
PAAD	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.54	5.06	0.38	1.18e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.58	7.18	0.5	2.92e-11	Blood pressure (smoking interaction);
PAAD	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.68	-5.47	-0.41	1.79e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs6585424	1.000	rs34386571	chr10:81939432	C/T	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2124910	1.000	rs4802800	chr19:52021247	C/G	cg12008991	chr19:52034861	SIGLEC6	0.34	4.47	0.34	1.5e-5	Blood protein levels;
PAAD	trans	rs901683	1.000	rs76422608	chr10:46041945	G/C	cg13065504	chr15:42448234	PLA2G4F	0.81	6.49	0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14169450	chr9:139327907	INPP5E	0.55	5.49	0.41	1.64e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.38	4.4	0.34	2.02e-5	Fat distribution (HIV);
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.31	-0.51	1.44e-11	Longevity;
PAAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg01075559	chr1:2537774	MMEL1	-0.47	-4.99	-0.38	1.63e-6	Ulcerative colitis;
PAAD	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21175976	chr8:11421337	BLK	-0.39	-4.31	-0.33	2.94e-5	Triglycerides;
PAAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.88	7.24	0.51	2.13e-11	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.83	-9.9	-0.63	3.82e-18	Menopause (age at onset);
PAAD	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-5.44	-0.4	2.09e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.73	-0.48	3.3e-10	Gut microbiome composition (summer);
PAAD	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.36	-0.33	2.35e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19365166	chr12:52695623	KRT86	-0.61	-6.66	-0.48	4.6e-10	Obesity-related traits;
PAAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.55	4.98	0.37	1.74e-6	Multiple sclerosis;
PAAD	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-13.5	-0.74	8.59e-28	Schizophrenia;
PAAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.03	-0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg19760965	chr3:194868843	C3orf21	0.44	4.76	0.36	4.54e-6	Non-small cell lung cancer;
PAAD	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg14926445	chr8:58193284	C8orf71	-0.59	-4.54	-0.35	1.13e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg18281939	chr5:77783895	LHFPL2	0.51	6.57	0.47	7.42e-10	Triglycerides;
PAAD	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs6547631	0.622	rs10187164	chr2:85928209	G/C	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	cis	rs863345	0.604	rs923664	chr1:158507691	A/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.4	4.56	0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg23127183	chr11:57508653	C11orf31	-0.51	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.32	-0.6	1.31e-16	Gut microbiome composition (summer);
PAAD	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-7.02	-0.49	6.93e-11	Colorectal cancer;
PAAD	cis	rs2882667	0.690	rs6884198	chr5:138164307	C/T	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg26071806	chr7:100318239	EPO	-0.49	-4.88	-0.37	2.62e-6	Other erythrocyte phenotypes;
PAAD	trans	rs970548	0.954	rs2291429	chr10:45958881	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs4792901	0.802	rs9908559	chr17:41603161	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.28	-0.33	3.28e-5	Dupuytren's disease;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg16405210	chr4:1374714	KIAA1530	-0.7	-7.32	-0.51	1.34e-11	Longevity;
PAAD	cis	rs17293817	0.618	rs56117517	chr10:1430552	A/C	cg02408697	chr10:1416920	ADARB2	0.48	4.27	0.33	3.47e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1723838	0.826	rs1670571	chr11:73550026	C/T	cg26954736	chr11:73693896	UCP2	1.14	4.82	0.36	3.46e-6	Obesity-related traits;
PAAD	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.79	-10.33	-0.64	2.87e-19	Endometriosis;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.51	6.04	0.44	1.16e-8	Lung cancer;
PAAD	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	7.87	0.54	6.11e-13	Schizophrenia;
PAAD	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs57786342	0.569	rs10139199	chr14:69277800	G/T	cg03189333	chr14:69283534	NA	-0.6	-5.24	-0.39	5.2e-7	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg23188684	chr11:67383651	NA	0.42	4.32	0.33	2.78e-5	Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs488248	0.574	rs61972598	chr13:106591645	G/A	cg03898952	chr13:107069935	NA	0.71	4.55	0.35	1.09e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs740474	0.533	rs3844598	chr5:140992235	A/G	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.36	4.44	0.34	1.74e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6782025	0.802	rs1191296	chr3:120924204	G/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs863345	0.604	rs10797013	chr1:158465506	G/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.01	-0.38	1.46e-6	Pneumococcal bacteremia;
PAAD	cis	rs28655083	0.529	rs285019	chr16:77099450	G/A	cg06128999	chr16:77247126	NA	-0.39	-4.68	-0.35	6.28e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26926768	chr12:34528122	NA	0.38	4.48	0.34	1.46e-5	Morning vs. evening chronotype;
PAAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg19413350	chr8:57351067	NA	-0.47	-4.43	-0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg24220031	chr2:73402428	NA	-0.42	-6.28	-0.45	3.32e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs498136	0.842	rs12417865	chr11:69361386	T/G	cg24388239	chr11:68438018	NA	-0.43	-4.38	-0.33	2.24e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.89	-0.49	1.35e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7101378	0.577	rs1509708	chr11:108900875	A/C	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18364779	chr6:26104403	HIST1H4C	0.46	4.62	0.35	8.08e-6	Schizophrenia;
PAAD	cis	rs925946	0.666	rs10835211	chr11:27701365	G/A	cg01418645	chr11:27679469	BDNF;BDNFOS	-0.52	-4.61	-0.35	8.39e-6	Body mass index;Weight;
PAAD	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.92	-0.37	2.21e-6	Resting heart rate;
PAAD	cis	rs1908814	0.510	rs7819276	chr8:11755804	T/C	cg12568669	chr8:11666485	FDFT1	0.32	4.98	0.37	1.68e-6	Neuroticism;
PAAD	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.94	7.85	0.54	6.81e-13	Eotaxin levels;
PAAD	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.72	-0.62	1.13e-17	Response to antipsychotic treatment;
PAAD	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs2221894	0.881	rs2035644	chr8:28899697	C/G	cg20212339	chr8:28908912	HMBOX1	-0.51	-5.52	-0.41	1.41e-7	Obesity-related traits;
PAAD	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.63	-5.85	-0.43	2.85e-8	Breast size;
PAAD	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.5	4.67	0.35	6.53e-6	Hepatocellular carcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12577610	chr17:61920423	SMARCD2	0.6	6.57	0.47	7.56e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs55894132	1	rs55894132	chr14:23408837	C/G	cg01529538	chr14:23388837	RBM23	0.49	4.92	0.37	2.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg00601450	chr5:74908170	NA	-0.48	-4.34	-0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23053723	chr17:63133521	RGS9	0.65	6.4	0.46	1.8e-9	Obesity-related traits;
PAAD	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.3	-0.33	3.06e-5	Blood protein levels;
PAAD	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg11214348	chr21:47283868	PCBP3	-0.48	-4.36	-0.33	2.43e-5	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	4.98e-7	Pulmonary function;
PAAD	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.48	-4.31	-0.33	2.9e-5	Tuberculosis;
PAAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.58	-6.19	-0.45	5.25e-9	Blood metabolite levels;
PAAD	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.81	-6.8	-0.48	2.26e-10	Cancer;
PAAD	cis	rs4679121	0.642	rs75265687	chr3:126199475	A/C	cg05485589	chr3:126194908	ZXDC	-0.88	-4.39	-0.34	2.09e-5	Pursuit maintenance gain;
PAAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.53	4.85	0.37	3.09e-6	Monocyte count;
PAAD	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.15	-0.39	7.94e-7	Lung cancer in ever smokers;
PAAD	cis	rs73019876	0.502	rs7258080	chr19:22257625	A/T	cg08394602	chr19:22123885	NA	-0.46	-4.81	-0.36	3.61e-6	Testicular germ cell tumor;
PAAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00982548	chr2:198649783	BOLL	-0.81	-5.96	-0.44	1.69e-8	Ulcerative colitis;
PAAD	cis	rs73568641	0.583	rs73572625	chr6:154089464	T/C	cg15658985	chr6:154448740	OPRM1	0.56	4.62	0.35	8e-6	Methadone dose in opioid dependence;
PAAD	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg02683114	chr2:24398427	C2orf84	-0.47	-4.89	-0.37	2.51e-6	Sjögren's syndrome;
PAAD	cis	rs10792830	0.741	rs475639	chr11:85689785	A/G	cg07180834	chr11:85838833	NA	-0.49	-5.75	-0.42	4.67e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	12.54	0.71	3.28e-25	Colorectal cancer;
PAAD	cis	rs6494488	0.500	rs72741334	chr15:64754990	A/G	cg16425858	chr15:64791681	ZNF609	1.01	4.55	0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.97e-5	Pain;
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7577696	0.752	rs12618002	chr2:32347715	A/T	cg02381751	chr2:32503542	YIPF4	-0.46	-4.51	-0.34	1.31e-5	Inflammatory biomarkers;
PAAD	cis	rs282587	0.569	rs7987238	chr13:113409944	G/A	cg02820901	chr13:113351484	ATP11A	-0.64	-4.85	-0.37	3.06e-6	Glycated hemoglobin levels;
PAAD	cis	rs7000734	0.504	rs1441399	chr8:96154565	G/A	cg02171725	chr8:95564335	KIAA1429	-0.23	-4.35	-0.33	2.5e-5	Radiation response;
PAAD	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg04450456	chr4:17643702	FAM184B	0.46	4.89	0.37	2.58e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.86	-9.37	-0.6	9.69e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg10356904	chr22:49881777	NA	-0.5	-4.86	-0.37	2.87e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12476592	0.571	rs7584404	chr2:63794342	C/T	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.81	8.98	0.59	9.86e-16	Iron status biomarkers;
PAAD	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.39	9.44	0.61	6.37e-17	Prostate cancer;
PAAD	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.92	-10.21	-0.64	5.83e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg05895507	chr15:77155635	SCAPER	0.37	4.52	0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.52	5.37	0.4	2.83e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.07	0.38	1.13e-6	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.05e-5	Life satisfaction;
PAAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.61	7.1	0.5	4.38e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	4.54	0.35	1.14e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.8	6.15	0.45	6.5e-9	IgE levels;
PAAD	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs7172971	0.688	rs4924619	chr15:42379594	G/A	cg07013680	chr15:42186124	SPTBN5	0.53	4.29	0.33	3.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6681460	0.932	rs536410	chr1:67191084	C/T	cg02459107	chr1:67143332	SGIP1	0.71	6.78	0.48	2.51e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs4727443	0.866	rs13243708	chr7:99616291	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.61	0.35	8.59e-6	Interstitial lung disease;
PAAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg03676636	chr4:99064102	C4orf37	0.32	5.36	0.4	2.99e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg06558623	chr16:89946397	TCF25	1.12	6.53	0.47	9.34e-10	Skin colour saturation;
PAAD	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.44	5.76	0.42	4.46e-8	Ulcerative colitis;
PAAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg00982548	chr2:198649783	BOLL	-0.92	-6.35	-0.46	2.4e-9	Ulcerative colitis;
PAAD	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.48	-5.01	-0.38	1.49e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg00944433	chr1:107599041	PRMT6	-0.38	-4.35	-0.33	2.46e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.56	6.03	0.44	1.2e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11867934	0.861	rs9893911	chr17:16972998	G/A	cg05552144	chr17:17942551	ATPAF2;C17orf39	-0.56	-4.25	-0.33	3.69e-5	Diabetic retinopathy;
PAAD	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg01304814	chr3:48885189	PRKAR2A	0.97	5.51	0.41	1.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg25620797	chr2:55921863	PNPT1	-0.47	-4.28	-0.33	3.33e-5	Metabolic syndrome;
PAAD	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.53	4.34	0.33	2.6e-5	Metabolite levels;
PAAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.23	0.39	5.41e-7	Bipolar disorder;
PAAD	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg05315796	chr3:52349193	DNAH1	0.39	4.26	0.33	3.52e-5	Bipolar disorder;
PAAD	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.57	-5.76	-0.42	4.42e-8	Educational attainment (years of education);
PAAD	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.77	4.42	0.34	1.89e-5	Influenza A (H1N1) severity;
PAAD	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg08316699	chr6:150357289	NA	0.39	4.27	0.33	3.38e-5	Alopecia areata;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg01262667	chr19:19385393	TM6SF2	0.46	5.2	0.39	6.2e-7	Tonsillectomy;
PAAD	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-4.77	-0.36	4.35e-6	Blood pressure (smoking interaction);
PAAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg02734326	chr4:10020555	SLC2A9	0.43	4.5	0.34	1.34e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs6782228	0.675	rs6806687	chr3:128391789	C/T	cg16766828	chr3:128327626	NA	0.45	6.13	0.45	7.33e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.53	-0.34	1.18e-5	Mood instability;
PAAD	cis	rs183266	0.736	rs1106847	chr14:77499459	T/C	cg01682506	chr14:77422843	NA	-0.98	-4.78	-0.36	4.02e-6	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs41271473	0.687	rs35637401	chr1:228883578	T/C	cg16512390	chr1:228756714	NA	0.56	4.82	0.36	3.47e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs12612619	0.696	rs11678188	chr2:27247832	T/C	cg00617064	chr2:27272375	NA	-0.5	-5.3	-0.39	4.09e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.18	10.18	0.64	6.86e-19	Vitiligo;
PAAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg05373962	chr22:49881684	NA	-0.46	-4.45	-0.34	1.64e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.61	0.41	9.38e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.83	-0.54	7.77e-13	Initial pursuit acceleration;
PAAD	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.7	7.73	0.53	1.4e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg09127314	chr1:152161683	NA	0.55	5.51	0.41	1.51e-7	Inflammatory skin disease;
PAAD	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.45	-4.42	-0.34	1.86e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg10932868	chr11:921992	NA	0.45	4.88	0.37	2.71e-6	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg10183150	chr4:120222239	C4orf3	-0.39	-5.42	-0.4	2.26e-7	Corneal astigmatism;
PAAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg19761014	chr17:28927070	LRRC37B2	-0.73	-5.41	-0.4	2.4e-7	Body mass index;
PAAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.72	8.07	0.55	2.02e-13	Melanoma;
PAAD	cis	rs7752195	0.730	rs2744301	chr6:25323143	G/T	cg26336265	chr6:25042955	NA	0.86	4.83	0.36	3.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.74	0.74	1.93e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13126279	chr21:47581558	C21orf56	-0.41	-4.57	-0.35	1.02e-5	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs12913538	1.000	rs4569205	chr15:62894319	A/G	cg09983546	chr15:62884068	NA	0.71	7.95	0.54	3.96e-13	Sleep depth;
PAAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs965604	1.000	rs12910910	chr15:78767850	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-4.4	-0.34	2.05e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.01	-0.49	7.38e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.24	-0.39	5.18e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg27449745	chr7:23145252	KLHL7	-0.49	-4.31	-0.33	2.94e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.61	7.22	0.51	2.29e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg06375148	chr1:209958343	C1orf74	0.66	4.89	0.37	2.52e-6	Coronary artery disease;
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.53	0.65	8.22e-20	Platelet count;
PAAD	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.53	5.63	0.42	8.35e-8	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.68	-6.89	-0.49	1.42e-10	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.39	-0.4	2.61e-7	Personality dimensions;
PAAD	cis	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	6.52	0.47	1.01e-9	Body mass index;
PAAD	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	6.22	0.45	4.63e-9	Body mass index;
PAAD	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.67	-0.58	6.12e-15	Exhaled nitric oxide output;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.91	-7.31	-0.51	1.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.81	5.91	0.43	2.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg00666640	chr1:248458726	OR2T12	0.47	4.81	0.36	3.63e-6	Common traits (Other);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12350342	chr11:46558181	AMBRA1	-0.56	-6.65	-0.47	5.04e-10	Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02035330	chr19:36036387	TMEM147	0.64	6.84	0.49	1.78e-10	Myopia (pathological);
PAAD	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.1	-9.19	-0.6	2.82e-16	Vitiligo;
PAAD	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.86	-0.43	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1198430	0.759	rs1198438	chr1:23749557	C/G	cg27447006	chr1:23763279	ASAP3	0.59	4.67	0.35	6.52e-6	Total cholesterol levels;
PAAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.64	-6.61	-0.47	6e-10	Schizophrenia;
PAAD	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg17595323	chr11:93583763	C11orf90	-0.37	-4.64	-0.35	7.49e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-1.05	-14.69	-0.77	5.67e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19671926	chr4:122722719	EXOSC9	-0.61	-5.92	-0.43	2.02e-8	Type 2 diabetes;
PAAD	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.81	9.58	0.61	2.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	0.66	5.93	0.43	2e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg17551891	chr7:1960795	MAD1L1	-0.41	-4.46	-0.34	1.56e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs12530845	0.725	rs74873522	chr7:135339632	A/C	cg23117316	chr7:135346802	PL-5283	-0.46	-4.8	-0.36	3.82e-6	Red blood cell traits;
PAAD	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg14146966	chr2:61757674	XPO1	0.4	4.86	0.37	2.89e-6	Tuberculosis;
PAAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-6.07	-0.44	9.67e-9	Gut microbiome composition (summer);
PAAD	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.76	-0.53	1.18e-12	Response to antipsychotic treatment;
PAAD	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.98	-12.5	-0.71	4.24e-25	Headache;
PAAD	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.58	5.49	0.41	1.62e-7	HDL cholesterol;
PAAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg25204440	chr1:209979598	IRF6	0.55	4.77	0.36	4.22e-6	Coronary artery disease;
PAAD	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.69	-4.55	-0.35	1.11e-5	Body mass index;
PAAD	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.6	-6.92	-0.49	1.17e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg14349672	chr11:133703707	NA	-0.56	-6.28	-0.45	3.36e-9	Childhood ear infection;
PAAD	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.72	8.05	0.55	2.16e-13	Colorectal cancer;
PAAD	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg13976799	chr6:71469523	SMAP1	-0.63	-6.29	-0.45	3.21e-9	Alcohol dependence;
PAAD	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg12935359	chr14:103987150	CKB	-0.59	-6.19	-0.45	5.4e-9	Body mass index;
PAAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg08132940	chr7:1081526	C7orf50	-0.66	-4.74	-0.36	4.88e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.85	9.66	0.62	1.69e-17	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14039463	chr1:212004169	LPGAT1	0.58	6.65	0.47	5.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg14583973	chr4:3374767	RGS12	0.43	6.32	0.46	2.76e-9	Serum sulfate level;
PAAD	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg07701084	chr6:150067640	NUP43	-0.53	-4.58	-0.35	9.79e-6	Lung cancer;
PAAD	trans	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg26876637	chr1:152193138	HRNR	0.83	6.18	0.45	5.53e-9	Atopic dermatitis;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg08677398	chr8:58056175	NA	0.6	4.47	0.34	1.52e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg16342193	chr10:102329863	NA	-0.78	-8.5	-0.57	1.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.49	-5.11	-0.38	9.55e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.68	-6.93	-0.49	1.14e-10	Uric acid levels;
PAAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.5	-5.05	-0.38	1.27e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg21859623	chr20:33103246	DYNLRB1	-0.44	-4.33	-0.33	2.69e-5	Height;
PAAD	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.45	5.02	0.38	1.45e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs4679121	0.642	rs16837507	chr3:126189395	A/G	cg05485589	chr3:126194908	ZXDC	-0.88	-4.39	-0.34	2.09e-5	Pursuit maintenance gain;
PAAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.58	-5.34	-0.4	3.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-6.92	-0.49	1.16e-10	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-15.36	-0.78	9.76e-33	Prudent dietary pattern;
PAAD	cis	rs367943	0.666	rs7703503	chr5:112962334	A/C	cg12552261	chr5:112820674	MCC	0.53	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.37	12.83	0.72	5.37e-26	Corneal structure;
PAAD	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.72	8.11	0.55	1.61e-13	Morning vs. evening chronotype;
PAAD	cis	rs6137287	0.924	rs6035804	chr20:21154272	G/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.21e-6	Skin colour saturation;
PAAD	cis	rs258892	1.000	rs686233	chr5:72398895	C/T	cg21869765	chr5:72125136	TNPO1	-0.66	-4.92	-0.37	2.21e-6	Small cell lung carcinoma;
PAAD	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.8	8.17	0.55	1.13e-13	Corneal astigmatism;
PAAD	cis	rs3753841	0.752	rs4908272	chr1:103379548	A/G	cg24495344	chr1:103574097	COL11A1	0.4	4.43	0.34	1.82e-5	Glaucoma (primary angle closure);
PAAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.8	0.48	2.23e-10	Coronary artery disease;
PAAD	cis	rs75757892	0.544	rs78945098	chr6:7319338	G/A	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7188861	0.768	rs1690500	chr16:11389986	C/T	cg16532467	chr16:11454386	NA	-0.54	-4.33	-0.33	2.69e-5	HDL cholesterol;
PAAD	trans	rs901683	1.000	rs12769244	chr10:45959385	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs939584	0.696	rs62105306	chr2:633660	C/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs12912251	0.591	rs12912235	chr15:39000074	C/T	cg10631289	chr15:39006617	NA	0.54	4.82	0.36	3.48e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs12753569	0.837	rs1251490	chr1:76518693	T/C	cg00791851	chr1:76518896	NA	-0.44	-4.64	-0.35	7.49e-6	Personality dimensions;
PAAD	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.52	-0.78	3.82e-33	Schizophrenia;
PAAD	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg00576331	chr11:65640516	EFEMP2	-0.61	-5.32	-0.4	3.72e-7	DNA methylation (variation);
PAAD	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.63	6.05	0.44	1.07e-8	Height;
PAAD	cis	rs1075232	1.000	rs4450360	chr15:31682030	G/A	cg15751117	chr15:30700112	NA	0.94	4.75	0.36	4.59e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs8077577	0.747	rs62072509	chr17:18182393	G/A	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.77	-5.14	-0.38	8.3e-7	Coronary artery calcification;
PAAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-5.32	-0.4	3.67e-7	Longevity;Endometriosis;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg15557168	chr22:42548783	NA	0.42	4.51	0.34	1.31e-5	Intelligence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07956936	chr16:72127419	TXNL4B;DHX38	0.65	7.25	0.51	1.97e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg11518657	chr1:67396239	MIER1	-0.68	-5.11	-0.38	9.43e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.62	0.62	2.08e-17	Electrocardiographic conduction measures;
PAAD	cis	rs3126085	0.515	rs1923503	chr1:152360820	G/A	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.28	0.6	1.65e-16	Schizophrenia;
PAAD	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.57	5.8	0.43	3.72e-8	Testicular germ cell tumor;
PAAD	cis	rs7562790	0.624	rs2160366	chr2:36661672	C/T	cg01206211	chr2:36825736	FEZ2	0.46	4.42	0.34	1.9e-5	QRS duration;QRS complex (Cornell);
PAAD	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.43	-5.33	-0.4	3.49e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20887711	chr4:1340912	KIAA1530	-0.44	-4.42	-0.34	1.86e-5	Obesity-related traits;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg00945038	chr17:61921165	SMARCD2	0.48	5.78	0.42	4.03e-8	Prudent dietary pattern;
PAAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg10356904	chr22:49881777	NA	-0.53	-5.55	-0.41	1.26e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2004318	1.000	rs77391213	chr19:55125769	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg21479132	chr6:26055353	NA	0.8	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg14055004	chr2:241860995	NA	0.29	4.51	0.34	1.29e-5	Joint mobility (Beighton score);
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.66	-6.98	-0.49	8.36e-11	Schizophrenia;
PAAD	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.81	0.58	2.67e-15	Dupuytren's disease;
PAAD	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg04721828	chr11:48285200	OR4X1	-0.41	-5.41	-0.4	2.4e-7	Migraine - clinic-based;
PAAD	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16447950	chr5:562315	NA	-0.73	-6.45	-0.46	1.4e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.85	11.36	0.68	4.94e-22	Vitiligo;
PAAD	cis	rs7705042	0.865	rs6580223	chr5:141489027	G/T	cg08523384	chr5:141488047	NDFIP1	-0.55	-5.25	-0.39	5.02e-7	Asthma;
PAAD	cis	rs6909229	1.000	rs6909229	chr6:158572379	C/G	cg02332782	chr6:157801523	ZDHHC14	-0.52	-4.34	-0.33	2.61e-5	Lipoprotein (a) levels;
PAAD	cis	rs1930961	1.000	rs997872	chr22:25878614	G/A	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg12963866	chr19:57752005	ZNF805	-0.47	-4.56	-0.35	1.06e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.98	13.22	0.73	4.88e-27	Menarche (age at onset);
PAAD	cis	rs12425451	0.588	rs10848768	chr12:3142646	A/C	cg05389053	chr12:3131226	TEAD4	0.73	6.12	0.44	7.78e-9	Narcolepsy with cataplexy;
PAAD	cis	rs7631605	0.935	rs2302503	chr3:37107470	G/A	cg17445812	chr3:36986805	TRANK1	0.32	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16339185	chr3:20227809	SGOL1	-0.55	-6.8	-0.48	2.24e-10	Body fat percentage;
PAAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg16205897	chr5:131564050	P4HA2	-0.42	-4.35	-0.33	2.49e-5	Acylcarnitine levels;
PAAD	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.55	-0.35	1.11e-5	Lung cancer in ever smokers;
PAAD	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.37	-9.5	-0.61	4.32e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.55	-5.48	-0.41	1.7e-7	Coronary artery disease;
PAAD	cis	rs4708832	0.564	rs240833	chr6:159922284	G/A	cg04088182	chr6:159188303	EZR	-0.61	-4.4	-0.34	1.99e-5	QRS duration;
PAAD	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-4.6	-0.35	8.87e-6	Coronary artery disease;
PAAD	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.59	4.45	0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg04087571	chr11:116723030	SIK3	0.33	4.36	0.33	2.43e-5	Subjective well-being;
PAAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg14343924	chr8:8086146	FLJ10661	0.51	4.28	0.33	3.33e-5	Neuroticism;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09841898	chr14:50886416	MAP4K5	-0.51	-6.69	-0.48	4.13e-10	Energy expenditure (24h);
PAAD	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg06217245	chr20:33103252	DYNLRB1	0.41	4.64	0.35	7.53e-6	Height;
PAAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.82	0.58	2.57e-15	Menopause (age at onset);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.76	8.55	0.57	1.26e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.72	-0.36	5.2e-6	Mean platelet volume;
PAAD	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs2882667	0.690	rs700616	chr5:138087873	A/C	cg09476006	chr5:138032270	NA	-0.46	-5.92	-0.43	2.1e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.4	-0.34	2.01e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16386425	chr10:429943	DIP2C	0.5	4.71	0.36	5.62e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.63	0.82	1.42e-38	Height;
PAAD	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg05643964	chr20:62369504	LIME1	-0.47	-4.53	-0.34	1.21e-5	Prostate cancer;
PAAD	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	4.5	0.34	1.34e-5	High light scatter reticulocyte count;
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.67	-7.03	-0.5	6.62e-11	Longevity;
PAAD	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-6.16	-0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10929159	0.928	rs3738994	chr2:236918539	T/C	cg14226755	chr2:236923322	AGAP1	0.28	4.56	0.35	1.03e-5	Parkinson's disease;
PAAD	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg08632701	chr21:37451849	NA	0.61	6.38	0.46	1.98e-9	Mitral valve prolapse;
PAAD	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg24739098	chr15:79297159	RASGRF1	0.36	4.82	0.36	3.39e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.75	10.26	0.64	4.16e-19	Lipoprotein (a) levels;
PAAD	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.9	7.66	0.53	2.01e-12	Triglycerides;
PAAD	cis	rs6669119	0.591	rs77152015	chr1:19104640	G/A	cg26220594	chr1:19110978	NA	0.85	5.09	0.38	1.02e-6	Percentage gas trapping;
PAAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg06740227	chr12:86229804	RASSF9	-0.52	-4.64	-0.35	7.44e-6	Major depressive disorder;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg00334542	chr7:100209784	MOSPD3	-0.77	-5.74	-0.42	4.99e-8	Other erythrocyte phenotypes;
PAAD	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg10547527	chr2:198650123	BOLL	-0.66	-4.49	-0.34	1.4e-5	Ulcerative colitis;
PAAD	cis	rs4742903	0.904	rs1507514	chr9:106986114	T/C	cg14250997	chr9:106856677	SMC2	0.46	4.87	0.37	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.69	6.75	0.48	2.97e-10	Coronary artery disease;
PAAD	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg02023728	chr11:77925099	USP35	-0.43	-4.25	-0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg03674076	chr20:524243	CSNK2A1	-0.58	-6.42	-0.46	1.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg09876464	chr15:85330779	ZNF592	0.44	4.38	0.33	2.2e-5	P wave terminal force;
PAAD	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-5.06	-0.38	1.17e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs7009516	0.692	rs9650409	chr8:24240704	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.47	5.46	0.41	1.87e-7	Hair greying;
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-7.3	-0.51	1.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.95	9.96	0.63	2.65e-18	Cognitive function;
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.59	5.97	0.44	1.62e-8	Eosinophil percentage of white cells;
PAAD	cis	rs1891275	0.515	rs7908980	chr10:93419302	A/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.59	-6.04	-0.44	1.14e-8	Motion sickness;
PAAD	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.14	-13.79	-0.75	1.47e-28	Type 1 diabetes nephropathy;
PAAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26549601	chr10:134560360	INPP5A	-0.43	-4.36	-0.33	2.36e-5	Migraine;
PAAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.5	0.34	1.33e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.45	-5.33	-0.4	3.54e-7	Intelligence;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.86	-8.1	-0.55	1.71e-13	Colorectal adenoma (advanced);
PAAD	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg01422370	chr2:73384389	NA	0.35	4.69	0.36	6.09e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.9	0.43	2.22e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1075265	0.870	rs1421617	chr2:54260132	A/G	cg04546899	chr2:54196757	PSME4	0.37	5.44	0.4	2.11e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.62	-4.99	-0.38	1.63e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26298942	chr17:58603427	APPBP2	-0.56	-6.54	-0.47	8.77e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs76866386	0.892	rs56266464	chr2:44054991	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.97	-5.31	-0.4	3.74e-7	Cholesterol, total;
PAAD	cis	rs859767	0.501	rs6745983	chr2:135430709	C/T	cg12500956	chr2:135428796	TMEM163	-0.32	-4.66	-0.35	6.75e-6	Neuroticism;
PAAD	cis	rs7714584	1.000	rs7734928	chr5:150256613	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg17830980	chr10:43048298	ZNF37B	0.69	8.08	0.55	1.84e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs113835537	0.877	rs57127845	chr11:66318325	C/T	cg22134325	chr11:66188745	NPAS4	0.45	5.31	0.4	3.89e-7	Airway imaging phenotypes;
PAAD	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.8	7.86	0.54	6.7e-13	Callous-unemotional behaviour;
PAAD	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.52	4.81	0.36	3.55e-6	Dental caries;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17192681	chr2:10953115	PDIA6	0.68	6.42	0.46	1.61e-9	Obesity-related traits;
PAAD	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.0	8.99	0.59	8.92e-16	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6547631	0.622	rs2118402	chr2:85931078	A/G	cg24620635	chr2:85921963	GNLY	0.42	5.49	0.41	1.63e-7	Blood protein levels;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg02733842	chr7:1102375	C7orf50	-0.63	-4.88	-0.37	2.61e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs642743	0.967	rs591784	chr10:105936290	G/T	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.26	0.33	3.54e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-12.35	-0.71	1.08e-24	Corneal structure;
PAAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs72827839	0.846	rs72823599	chr17:46132424	C/G	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-8.49	-0.57	1.73e-14	Vitiligo;
PAAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.62	0.35	8.22e-6	Breast cancer;
PAAD	cis	rs17095355	0.818	rs1009532	chr10:111840725	C/T	cg00817464	chr10:111662876	XPNPEP1	0.69	5.49	0.41	1.61e-7	Biliary atresia;
PAAD	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg02640540	chr1:67518911	SLC35D1	-0.54	-4.68	-0.35	6.37e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11264799	0.603	rs12744410	chr1:157566211	A/G	cg18268488	chr1:157545234	FCRL4	0.46	5.34	0.4	3.35e-7	IgA nephropathy;
PAAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.45	6.09	0.44	8.97e-9	Height;
PAAD	cis	rs10768122	0.705	rs10836372	chr11:35341086	G/A	cg13971030	chr11:35366721	SLC1A2	-0.41	-4.64	-0.35	7.49e-6	Vitiligo;
PAAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.57	-5.34	-0.4	3.26e-7	Obesity-related traits;
PAAD	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg04254540	chr16:71951199	KIAA0174	0.42	4.34	0.33	2.54e-5	Fibrinogen levels;
PAAD	cis	rs11165354	0.796	rs4650271	chr1:92168758	C/T	cg00730172	chr1:91176405	NA	0.36	4.48	0.34	1.45e-5	Type 2 diabetes;
PAAD	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg06217245	chr20:33103252	DYNLRB1	0.38	4.37	0.33	2.33e-5	Height;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.63	-0.35	7.67e-6	Mood instability;
PAAD	cis	rs77633900	0.772	rs182253	chr15:76800755	C/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.58	-4.94	-0.37	2.05e-6	Gut microbiome composition (summer);
PAAD	cis	rs10875746	0.624	rs7297298	chr12:48672306	C/G	cg26205652	chr12:48591994	NA	0.86	7.87	0.54	6.02e-13	Longevity (90 years and older);
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg20295408	chr7:1910781	MAD1L1	0.55	5.36	0.4	3.04e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs8040855	0.627	rs11632658	chr15:85606213	C/T	cg08123816	chr15:85640762	PDE8A	0.47	5.59	0.41	1.01e-7	Bulimia nervosa;
PAAD	cis	rs4629180	1.000	rs4629180	chr2:102088370	G/A	cg04415270	chr2:102091202	RFX8	-0.64	-7.98	-0.54	3.28e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.49	5.24	0.39	5.33e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg25833597	chr17:30823145	MYO1D	0.53	5.15	0.39	7.8e-7	Schizophrenia;
PAAD	cis	rs7264396	0.887	rs2236161	chr20:34101631	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.34	0.33	2.6e-5	Total cholesterol levels;
PAAD	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09065629	chr16:1709722	CRAMP1L	0.48	5.04	0.38	1.28e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.73	0.53	1.38e-12	Prudent dietary pattern;
PAAD	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.89	0.37	2.58e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-4.68	-0.35	6.4e-6	Systemic lupus erythematosus;
PAAD	cis	rs2077654	0.822	rs4148634	chr11:17429872	G/A	cg25308976	chr11:17434268	ABCC8	0.75	5.22	0.39	5.89e-7	Gout;
PAAD	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg21724239	chr8:58056113	NA	0.68	5.25	0.39	4.96e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg05717871	chr11:638507	DRD4	-0.58	-4.77	-0.36	4.21e-6	Systemic lupus erythematosus;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.64	-7.6	-0.52	2.79e-12	Renal function-related traits (BUN);
PAAD	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.84	5.73	0.42	5.35e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7202877	0.572	rs8051611	chr16:75388933	C/T	cg03315344	chr16:75512273	CHST6	0.63	5.35	0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.47	-4.78	-0.36	4.12e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.32	-0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs3764618	0.901	rs79502742	chr19:49500366	G/A	cg12515942	chr19:49552529	CGB8	-0.73	-4.34	-0.33	2.63e-5	Follicule stimulating hormone;
PAAD	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.57	-6.21	-0.45	4.9e-9	Obesity-related traits;
PAAD	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.6	5.44	0.4	2.13e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06496078	chr12:107350075	C12orf23	0.62	6.69	0.48	3.94e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.58	-6.45	-0.46	1.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	1.1	11.97	0.7	1.11e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.62	6.53	0.47	9.23e-10	Blood protein levels;
PAAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.79	0.36	3.91e-6	Schizophrenia;
PAAD	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.53	-0.34	1.19e-5	Neuroticism;
PAAD	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg10431340	chr1:161279108	MPZ	0.62	5.64	0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.56	6.17	0.45	6.02e-9	Menopause (age at onset);
PAAD	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.38	-0.61	8.92e-17	Electrocardiographic conduction measures;
PAAD	cis	rs59104589	0.570	rs73006397	chr2:242415523	C/T	cg19488206	chr2:242435732	STK25	0.46	4.55	0.35	1.1e-5	Fibrinogen levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05984320	chr8:144373269	ZNF696	0.61	6.58	0.47	7.27e-10	Myopia (pathological);
PAAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg09491104	chr22:46646882	C22orf40	-0.93	-8.66	-0.57	6.58e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.93	7.22	0.51	2.27e-11	Initial pursuit acceleration;
PAAD	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	5.93	0.43	2.01e-8	LDL cholesterol;
PAAD	cis	rs1572438	0.931	rs13215634	chr6:866545	C/T	cg21062780	chr6:887772	NA	0.48	5.06	0.38	1.22e-6	Aging;
PAAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.68	8.48	0.57	1.86e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10385251	chr1:247679636	NA	-0.61	-7.08	-0.5	4.86e-11	Obesity-related traits;
PAAD	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg06565975	chr8:143823917	SLURP1	0.22	5.16	0.39	7.64e-7	Urinary tract infection frequency;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.58	6.83	0.48	1.88e-10	Lung cancer;
PAAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12599982	chr1:44399894	ARTN	-0.44	-4.82	-0.36	3.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.71	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18023558	chr4:10118459	WDR1	0.63	7.34	0.51	1.2e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg27449745	chr7:23145252	KLHL7	-0.57	-5.2	-0.39	6.22e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.89	6.73	0.48	3.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg25173405	chr17:45401733	C17orf57	-0.61	-5.36	-0.4	3.03e-7	Coronary artery disease;
PAAD	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1371614	0.577	rs877274	chr2:27140099	A/C	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.79	-7.86	-0.54	6.6e-13	Coronary artery disease;
PAAD	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg10377582	chr12:51612794	POU6F1	-0.39	-4.66	-0.35	6.72e-6	Cisplatin-induced ototoxicity;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.61	7.34	0.51	1.18e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02342257	chr1:3535872	NA	0.55	6.48	0.47	1.24e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg10437265	chr15:77819839	NA	-0.4	-4.62	-0.35	8.28e-6	Type 2 diabetes;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.45	5.11	0.38	9.42e-7	Electroencephalogram traits;
PAAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg05554000	chr7:158905015	VIPR2	-0.51	-4.52	-0.34	1.26e-5	Facial morphology (factor 20);
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg21784768	chr11:537496	LRRC56	-0.87	-4.57	-0.35	1e-5	Body mass index;
PAAD	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-6.12	-0.44	7.44e-9	Longevity;
PAAD	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.5	-4.88	-0.37	2.7e-6	Longevity;
PAAD	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg05791153	chr7:19748676	TWISTNB	-0.59	-5.04	-0.38	1.33e-6	Thyroid stimulating hormone;
PAAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.49	4.82	0.36	3.43e-6	Trans fatty acid levels;
PAAD	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs427941	0.668	rs201438	chr7:101735236	G/A	cg06246474	chr7:101738831	CUX1	0.44	4.47	0.34	1.54e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.46	4.26	0.33	3.56e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.78	8.17	0.55	1.13e-13	Gout;
PAAD	cis	rs2916733	0.887	rs2515583	chr8:6321865	C/G	cg01691696	chr8:6734962	DEFB1	-0.57	-4.43	-0.34	1.81e-5	Epirubicin-induced leukopenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21755257	chr18:23806431	TAF4B	0.64	6.29	0.45	3.15e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg14348967	chr4:10160060	NA	-0.38	-4.48	-0.34	1.45e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.53	5.78	0.42	4.03e-8	Urate levels in lean individuals;
PAAD	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.48	-4.42	-0.34	1.88e-5	Red blood cell count;
PAAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.43	4.79	0.36	3.92e-6	Refractive error;
PAAD	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.47	4.55	0.35	1.1e-5	Blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09725962	chr7:75268827	HIP1	0.69	6.71	0.48	3.56e-10	Obesity-related traits;
PAAD	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.71	-0.36	5.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.65	4.39	0.34	2.11e-5	Vitiligo;
PAAD	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	1.26	6.07	0.44	9.9e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg20246863	chr2:73402720	NA	-0.4	-4.27	-0.33	3.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.78	-0.42	4.14e-8	Airway imaging phenotypes;
PAAD	cis	rs939584	1.000	rs74676797	chr2:633063	G/A	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.65	-0.35	7.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1419980	0.730	rs11054877	chr12:7771545	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.56	-0.61	3.07e-17	Total body bone mineral density;
PAAD	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.65	-0.42	7.54e-8	Metabolite levels;
PAAD	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.56	6.03	0.44	1.2e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01402448	chr6:136571605	FAM54A	0.57	6.35	0.46	2.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-5.91	-0.43	2.19e-8	Prostate cancer;
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.72	-0.42	5.39e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.45	5.23	0.39	5.56e-7	Major depressive disorder;
PAAD	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.45	-0.34	1.66e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs427941	0.703	rs201445	chr7:101737921	G/T	cg06246474	chr7:101738831	CUX1	0.45	4.64	0.35	7.48e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.98e-8	Lymphocyte counts;
PAAD	cis	rs73019876	0.869	rs2522101	chr19:22144310	T/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01773951	chr1:247094386	AHCTF1	0.59	6.33	0.46	2.58e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2286379	0.745	rs2108642	chr12:1866799	A/C	cg05227549	chr12:1770782	NA	-0.39	-4.66	-0.35	6.83e-6	Blood pressure (smoking interaction);
PAAD	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.69	5.69	0.42	6.24e-8	Menarche (age at onset);
PAAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg19163074	chr7:65112434	INTS4L2	0.48	4.47	0.34	1.53e-5	Aortic root size;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08903089	chr10:22614276	BMI1	0.51	5.72	0.42	5.61e-8	Monocyte percentage of white cells;
PAAD	cis	rs757110	0.524	rs214067	chr11:17305831	A/C	cg04705435	chr11:17411270	KCNJ11	-0.57	-6.08	-0.44	9.35e-9	Type 2 diabetes;
PAAD	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg24147428	chr11:65409760	SIPA1	0.47	5.01	0.38	1.47e-6	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
PAAD	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.38	5.39	0.4	2.61e-7	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.89	11.57	0.68	1.35e-22	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg18944383	chr4:111397179	ENPEP	-0.72	-7.86	-0.54	6.63e-13	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	4.18e-17	IgG glycosylation;
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-8.09	-0.55	1.78e-13	Mean platelet volume;
PAAD	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg14311320	chr7:124405732	GPR37	-0.45	-4.48	-0.34	1.48e-5	Lewy body disease;
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.49	-0.61	4.57e-17	Tonsillectomy;
PAAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.66	-6.51	-0.47	1.05e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
PAAD	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.52	5.14	0.38	8.25e-7	Resting heart rate;
PAAD	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg03392386	chr11:133800800	IGSF9B	0.5	5.05	0.38	1.24e-6	Hand grip strength;
PAAD	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg07703079	chr11:430292	ANO9	0.8	4.47	0.34	1.53e-5	Body mass index;
PAAD	cis	rs6604026	0.922	rs12746956	chr1:93312142	A/G	cg17283838	chr1:93427260	FAM69A	0.51	4.3	0.33	3.05e-5	Multiple sclerosis;
PAAD	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.75	6.45	0.46	1.43e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.75	6.49	0.47	1.15e-9	Pulmonary function decline;
PAAD	cis	rs9810890	1.000	rs9847759	chr3:128594373	C/T	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg20744362	chr22:50050164	C22orf34	0.59	7.58	0.52	3.14e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.39	4.48	0.34	1.44e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.36	0.82	6.68e-38	Prudent dietary pattern;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18879646	chr1:89990278	LRRC8B	0.7	7.01	0.49	7.23e-11	Obesity-related traits;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.47	4.82	0.36	3.39e-6	Height;
PAAD	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.65	-6.26	-0.45	3.75e-9	Obesity-related traits;
PAAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.41	4.82	0.36	3.38e-6	Melanoma;
PAAD	cis	rs8105895	0.935	rs62110987	chr19:22257295	A/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08677398	chr8:58056175	NA	0.58	4.5	0.34	1.36e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11811982	0.655	rs114221628	chr1:227530286	A/G	cg24860534	chr1:227506868	CDC42BPA	0.53	5.09	0.38	1.04e-6	Optic disc area;
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg09473613	chr1:24152604	HMGCL	-0.48	-4.8	-0.36	3.73e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.39	0.4	2.59e-7	Educational attainment;
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.6	6.44	0.46	1.46e-9	Lung cancer;
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23708337	chr7:1209742	NA	0.5	5.56	0.41	1.21e-7	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.52	-5.62	-0.41	8.86e-8	Life satisfaction;
PAAD	cis	rs1499972	0.529	rs58533135	chr3:117655311	T/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs6801605	0.743	rs1025689	chr3:53883722	C/G	cg15798837	chr3:54122146	NA	0.33	4.3	0.33	3.01e-5	Blood protein levels;
PAAD	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-1.05	-9.14	-0.6	3.73e-16	Blood trace element (Zn levels);
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.96	6.96	0.49	9.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4523957	0.820	rs2209073	chr17:2205664	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.44	0.4	2.13e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.86	9.08	0.59	5.26e-16	Corneal astigmatism;
PAAD	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg09760422	chr2:128146352	NA	0.4	6.04	0.44	1.15e-8	Self-rated health;
PAAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.03	0.38	1.38e-6	Testicular germ cell tumor;
PAAD	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.48	4.61	0.35	8.53e-6	Prostate-specific antigen levels;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.51	-5.98	-0.44	1.5e-8	Testicular germ cell tumor;
PAAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg23346134	chr3:49453900	TCTA	-0.46	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.62	0.35	8.23e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13053817	1.000	rs71329486	chr22:29831208	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.12	-0.38	8.97e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.7	5.03	0.38	1.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7084783	0.519	rs4917395	chr10:105351382	G/A	cg09754828	chr10:105363329	SH3PXD2A	0.44	4.32	0.33	2.83e-5	Fear of pain;
PAAD	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.38	-4.28	-0.33	3.35e-5	Hemoglobin concentration;
PAAD	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	5.74	0.42	4.9e-8	Lung cancer in ever smokers;
PAAD	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.85	10.25	0.64	4.54e-19	Lung cancer;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.73	6.44	0.46	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.53	0.41	1.36e-7	Electroencephalogram traits;
PAAD	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-1.26	-11.2	-0.67	1.31e-21	Obesity-related traits;
PAAD	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11547950	chr5:77652471	NA	-0.68	-5.93	-0.43	1.94e-8	Triglycerides;
PAAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg14349672	chr11:133703707	NA	0.65	7.41	0.52	7.96e-12	Childhood ear infection;
PAAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	1.13	10.67	0.65	3.51e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10819733	chr22:24237672	NA	-0.61	-6.84	-0.48	1.86e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.54	6.23	0.45	4.27e-9	Lymphocyte counts;
PAAD	cis	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg21546286	chr11:48923668	NA	0.6	6.34	0.46	2.5e-9	HDL cholesterol;
PAAD	cis	rs1499972	0.941	rs55779525	chr3:117651483	A/C	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs258892	0.895	rs10059897	chr5:72080538	C/T	cg21869765	chr5:72125136	TNPO1	-0.81	-5.44	-0.4	2.07e-7	Small cell lung carcinoma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06399839	chr12:54674003	HNRNPA1;HNRPA1L-2;CBX5	0.54	6.46	0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	1.33	6.91	0.49	1.27e-10	Prostate cancer;
PAAD	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.66	4.66	0.35	6.72e-6	Neuroticism;
PAAD	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.51	-6.0	-0.44	1.38e-8	Mean arterial pressure;
PAAD	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.34	-0.4	3.35e-7	Blood metabolite levels;
PAAD	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg18612461	chr15:75251733	NA	-0.39	-4.31	-0.33	2.89e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.49	-4.74	-0.36	4.89e-6	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs58521262	0.530	rs289310	chr19:23165414	C/T	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs728616	0.764	rs12413678	chr10:81687099	G/A	cg19423196	chr10:82049429	MAT1A	0.58	4.51	0.34	1.26e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.48	5.49	0.41	1.62e-7	Morning vs. evening chronotype;
PAAD	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.0	-8.58	-0.57	1.03e-14	Vitiligo;
PAAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs877529	0.683	rs79501	chr22:39522940	A/G	cg13455509	chr22:39551605	NA	0.46	4.31	0.33	2.87e-5	Multiple myeloma;
PAAD	trans	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-7.37	-0.51	1.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs863345	0.604	rs7514968	chr1:158493852	A/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg27499820	chr13:21296301	IL17D	0.52	4.93	0.37	2.12e-6	Dental caries;
PAAD	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.62	5.74	0.42	5.04e-8	Obesity-related traits;
PAAD	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg15192750	chr16:69999425	NA	-0.53	-4.45	-0.34	1.66e-5	Sjögren's syndrome;
PAAD	cis	rs2016586	0.684	rs5750169	chr22:36129851	A/T	cg26342177	chr22:36113512	APOL5	0.47	4.94	0.37	2.04e-6	Body mass index;
PAAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg25251562	chr2:3704773	ALLC	-0.57	-6.53	-0.47	9.2e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.52	4.93	0.37	2.15e-6	Lung cancer;
PAAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg13057898	chr1:3703894	LRRC47	0.41	4.27	0.33	3.38e-5	Red cell distribution width;
PAAD	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma (childhood onset);
PAAD	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg21665744	chr7:39171113	POU6F2	0.34	4.95	0.37	1.91e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.6	-5.76	-0.42	4.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg12633918	chr20:23549525	CST9L	-0.42	-4.63	-0.35	7.63e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.08e-9	Life satisfaction;
PAAD	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.21	-9.28	-0.6	1.65e-16	Plateletcrit;
PAAD	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.15	-14.25	-0.76	8.41e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23708337	chr7:1209742	NA	0.43	4.34	0.33	2.55e-5	Longevity;Endometriosis;
PAAD	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.57	5.46	0.4	1.92e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.62	0.35	8.1e-6	Breast cancer;
PAAD	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.57	-5.15	-0.39	8.13e-7	Total body bone mineral density;
PAAD	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.26	-0.39	4.85e-7	Common traits (Other);
PAAD	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.2	0.39	6.3e-7	Monocyte percentage of white cells;
PAAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.56	-4.54	-0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs910187	1.000	rs4555399	chr20:45837896	G/A	cg27589058	chr20:45804311	EYA2	-0.49	-4.91	-0.37	2.33e-6	Migraine;
PAAD	cis	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.66	-4.6	-0.35	8.91e-6	Hypertriglyceridemia;
PAAD	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.29	14.27	0.76	7.5e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs795544	0.580	rs7709692	chr5:13789420	T/C	cg07548982	chr5:13769939	DNAH5	-0.51	-4.49	-0.34	1.42e-5	Corneal astigmatism;
PAAD	cis	rs5756391	0.568	rs7410682	chr22:37317258	A/G	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg11439826	chr17:76250004	NA	0.48	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg02683114	chr2:24398427	C2orf84	0.45	4.69	0.36	6.09e-6	Sjögren's syndrome;
PAAD	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg16950941	chr11:66035639	RAB1B	-0.6	-4.72	-0.36	5.38e-6	Electroencephalogram traits;
PAAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.63	6.98	0.49	8.7e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2882667	0.690	rs288033	chr5:138214094	A/G	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.78	-7.18	-0.5	2.93e-11	Blood protein levels;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-5.67	-0.42	6.99e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.93	11.49	0.68	2.17e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9900972	0.720	rs6501257	chr17:76877655	G/A	cg20937029	chr17:76870563	TIMP2	0.59	5.34	0.4	3.39e-7	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.55e-5	Parkinson's disease;
PAAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.74	-7.86	-0.54	6.43e-13	Prudent dietary pattern;
PAAD	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.49	-4.47	-0.34	1.55e-5	Diastolic blood pressure;
PAAD	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg14003231	chr6:33640908	ITPR3	0.35	4.45	0.34	1.62e-5	Plateletcrit;
PAAD	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg22482690	chr17:47019901	SNF8	0.49	5.34	0.4	3.29e-7	Type 2 diabetes;
PAAD	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg26174226	chr8:58114915	NA	-0.44	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.68	7.47	0.52	5.8e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs7594645	1.000	rs12478819	chr2:207645078	C/T	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg15764593	chr10:829463	NA	-0.74	-5.44	-0.4	2.12e-7	Uric acid levels;
PAAD	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg02917321	chr22:38215204	NA	0.44	4.49	0.34	1.42e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	1.0	14.02	0.75	3.48e-29	Heart rate;
PAAD	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-7.54	-0.52	3.88e-12	Colorectal cancer;
PAAD	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01116966	chr5:133450017	TCF7	0.59	6.6	0.47	6.29e-10	Metabolite levels  (X-11787);
PAAD	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.77	8.67	0.58	6.11e-15	Hemoglobin concentration;
PAAD	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg23387468	chr7:139079360	LUC7L2	0.4	4.76	0.36	4.47e-6	Diisocyanate-induced asthma;
PAAD	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04206499	chr1:228284292	ARF1	0.6	6.67	0.48	4.38e-10	Smoking initiation;
PAAD	cis	rs2016586	0.802	rs2009168	chr22:36117854	A/G	cg26342177	chr22:36113512	APOL5	0.46	4.49	0.34	1.42e-5	Body mass index;
PAAD	cis	rs79146658	0.736	rs1565287	chr2:179735946	C/T	cg17765952	chr2:179737173	CCDC141	0.59	4.41	0.34	1.95e-5	Diastolic blood pressure;
PAAD	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-4.43	-0.34	1.82e-5	Morning vs. evening chronotype;
PAAD	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	0.91	5.57	0.41	1.12e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg13160058	chr8:26243215	BNIP3L	-0.4	-4.98	-0.37	1.69e-6	Red cell distribution width;
PAAD	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.66	-5.09	-0.38	1.06e-6	Vitiligo;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg26086607	chr7:44084030	DBNL	0.58	7.21	0.5	2.44e-11	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg14709524	chr16:89940631	TCF25	0.95	4.37	0.33	2.27e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.68	-5.69	-0.42	6.45e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6137287	0.533	rs61139213	chr20:21221353	C/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	1.12	9.34	0.6	1.14e-16	Height;
PAAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg10934807	chr2:113191815	RGPD8;RGPD5	0.91	6.51	0.47	1.01e-9	Yeast infection;
PAAD	cis	rs2286379	0.595	rs10773988	chr12:1856181	A/G	cg11558135	chr12:861715	WNK1	-0.49	-4.87	-0.37	2.82e-6	Blood pressure (smoking interaction);
PAAD	cis	rs288342	0.734	rs288265	chr2:183581331	G/T	cg02625481	chr2:183667124	NA	-0.44	-4.38	-0.33	2.19e-5	Recurrent major depressive disorder;
PAAD	cis	rs28489187	0.706	rs233057	chr1:85798855	T/C	cg16011679	chr1:85725395	C1orf52	0.52	4.88	0.37	2.71e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.73	8.38	0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07157834	chr1:205819609	PM20D1	0.56	5.45	0.4	2e-7	Parkinson's disease;
PAAD	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg15145965	chr22:50218605	BRD1	0.57	4.72	0.36	5.37e-6	Schizophrenia;
PAAD	cis	rs11051970	0.879	rs2088807	chr12:32592101	C/G	cg24626660	chr12:32551988	NA	0.38	4.27	0.33	3.45e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.57	4.36	0.33	2.37e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1045902	0.583	rs2303904	chr2:73447775	C/T	cg24220031	chr2:73402428	NA	0.4	5.69	0.42	6.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-5.69	-0.42	6.36e-8	Mood instability;
PAAD	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.81	-8.67	-0.58	5.97e-15	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17336577	chr11:125932083	CDON	0.59	7.11	0.5	4.2e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25244628	chr11:65381814	MAP3K11	0.57	6.39	0.46	1.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg18825076	chr15:78729989	IREB2	0.56	5.56	0.41	1.17e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.54	-5.5	-0.41	1.56e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg22143856	chr6:28129313	ZNF389	-0.65	-5.06	-0.38	1.17e-6	Depression;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg01766943	chr2:54829624	SPTBN1	0.54	5.0	0.38	1.56e-6	Schizophrenia;
PAAD	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.51	-5.62	-0.41	8.84e-8	Coronary artery disease;
PAAD	cis	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg11619707	chr19:22235551	ZNF257	-0.56	-5.57	-0.41	1.15e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.58	6.02	0.44	1.24e-8	Personality dimensions;
PAAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg23602478	chr1:26503979	CNKSR1	0.32	4.27	0.33	3.41e-5	Height;
PAAD	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg15764593	chr10:829463	NA	-0.93	-4.8	-0.36	3.74e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.72	-8.14	-0.55	1.33e-13	Height;
PAAD	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs11264799	0.603	rs12118837	chr1:157561302	G/A	cg18268488	chr1:157545234	FCRL4	0.46	5.31	0.4	3.82e-7	IgA nephropathy;
PAAD	cis	rs4478858	0.775	rs6685868	chr1:31706956	C/T	cg18939081	chr1:31884902	SERINC2	0.46	5.12	0.38	9.32e-7	Alcohol dependence;
PAAD	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.25	0.39	5.06e-7	Ovarian reserve;
PAAD	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.71	-6.77	-0.48	2.61e-10	Lung cancer;
PAAD	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19878733	chr11:65264897	MALAT1	-0.79	-7.14	-0.5	3.51e-11	Neuroticism;
PAAD	cis	rs2439831	0.681	rs884704	chr15:43691150	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	6.4	0.46	1.85e-9	Lung cancer in ever smokers;
PAAD	cis	rs7246760	0.500	rs66490745	chr19:9999841	G/A	cg07515324	chr19:10461336	TYK2	-0.89	-4.62	-0.35	8.13e-6	Pursuit maintenance gain;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16725264	chr8:145582147	FBXL6;GPR172A	-0.66	-6.6	-0.47	6.3e-10	Smoking initiation;
PAAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.98	0.54	3.3e-13	Prudent dietary pattern;
PAAD	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.3	0.51	1.5e-11	Monocyte percentage of white cells;
PAAD	cis	rs6137287	0.889	rs4815024	chr20:21138367	C/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg25251562	chr2:3704773	ALLC	-0.52	-5.65	-0.42	7.59e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.75	7.62	0.53	2.58e-12	Obesity-related traits;
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.74	-4.82	-0.36	3.5e-6	IgG glycosylation;
PAAD	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.74	6.36	0.46	2.28e-9	Pulmonary function decline;
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16988970	chr17:42248062	ASB16	0.36	5.11	0.38	9.56e-7	Total body bone mineral density;
PAAD	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg01064725	chr1:204461714	NA	-0.49	-4.63	-0.35	7.67e-6	Schizophrenia;
PAAD	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg05110241	chr16:68378359	PRMT7	-0.71	-5.36	-0.4	3.07e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-4.39	-0.34	2.11e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.54	5.69	0.42	6.38e-8	Menopause (age at onset);
PAAD	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs3741151	0.686	rs7927344	chr11:73207517	T/C	cg17517138	chr11:73019481	ARHGEF17	0.73	4.34	0.33	2.62e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.87	0.49	1.55e-10	Renal function-related traits (BUN);
PAAD	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.56	-0.35	1.04e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.37	-4.45	-0.34	1.64e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg13047869	chr3:10149882	C3orf24	0.68	5.78	0.42	4.12e-8	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs1678618	0.585	rs1245520	chr10:73785176	A/C	cg20897136	chr10:74034667	DDIT4	-0.38	-4.56	-0.35	1.06e-5	Smoking behavior;
PAAD	cis	rs10090774	0.965	rs9324540	chr8:141990421	T/G	cg02508881	chr8:142216119	NA	-0.41	-4.32	-0.33	2.76e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs516243	0.703	rs284262	chr1:10743363	T/C	cg02903756	chr1:10750680	CASZ1	-0.49	-5.45	-0.4	2.03e-7	Migraine - clinic-based;
PAAD	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-5.33	-0.4	3.55e-7	Chronic sinus infection;
PAAD	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.9	5.88	0.43	2.57e-8	Major depressive disorder;
PAAD	cis	rs13424612	1.000	rs4149551	chr2:240921463	C/T	cg01812947	chr2:240904978	NDUFA10	0.58	5.02	0.38	1.43e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-4.7	-0.36	5.71e-6	Height;
PAAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.68	7.13	0.5	3.78e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.62	5.43	0.4	2.2e-7	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.48	5.97	0.44	1.6e-8	Longevity;Endometriosis;
PAAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.81	6.94	0.49	1.07e-10	Gut microbiome composition (summer);
PAAD	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02985541	chr2:219472218	PLCD4	0.29	4.45	0.34	1.68e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.79	8.6	0.57	9.21e-15	Schizophrenia;
PAAD	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg20744362	chr22:50050164	C22orf34	0.6	7.69	0.53	1.75e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.56	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs9473924	0.505	rs28360639	chr6:50783501	G/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.33	0.4	3.46e-7	Body mass index;
PAAD	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg21823605	chr1:152486609	CRCT1	0.49	6.28	0.45	3.43e-9	Hair morphology;
PAAD	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	0.66	4.59	0.35	9.05e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs71636778	0.722	rs17162315	chr1:27176431	A/T	cg12203394	chr1:27248618	NUDC	0.58	4.25	0.33	3.71e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.36	-0.4	3.08e-7	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs9810890	1.000	rs73198899	chr3:128566430	A/G	cg19129842	chr3:128565090	NA	-0.9	-5.32	-0.4	3.64e-7	Dental caries;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20239099	chr1:233464033	KIAA1804	0.62	6.5	0.47	1.07e-9	Myopia (pathological);
PAAD	cis	rs282587	0.569	rs395246	chr13:113415392	C/A	cg19217778	chr13:113420270	ATP11A	-0.56	-4.49	-0.34	1.42e-5	Glycated hemoglobin levels;
PAAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg20821713	chr7:1055600	C7orf50	-0.4	-4.5	-0.34	1.36e-5	Longevity;Endometriosis;
PAAD	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg19192590	chr2:178524533	PDE11A	0.43	5.09	0.38	1.06e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg25952890	chr19:58913133	NA	0.66	5.56	0.41	1.16e-7	Mean platelet volume;
PAAD	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.6	-4.82	-0.36	3.48e-6	QRS complex (12-leadsum);
PAAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.21	-18.92	-0.84	8.69e-42	Exhaled nitric oxide output;
PAAD	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	6.76	0.48	2.7e-10	Schizophrenia;
PAAD	trans	rs228916	1.000	rs228916	chr22:37505552	C/T	cg14326991	chr6:46889760	GPR116	-0.66	-6.57	-0.47	7.53e-10	Iron status biomarkers (iron levels);
PAAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.71	5.27	0.39	4.51e-7	Fat distribution (HIV);
PAAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07930192	chr7:1003750	NA	0.39	4.78	0.36	4.17e-6	Longevity;Endometriosis;
PAAD	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	5.36	0.4	3.04e-7	Total body bone mineral density;
PAAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10958369	0.871	rs2126793	chr8:54399039	C/A	cg12485204	chr8:54507357	NA	0.45	4.4	0.34	2.03e-5	Response to antineoplastic agents;
PAAD	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.71	-7.04	-0.5	6.04e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.84	10.52	0.65	8.52e-20	Bladder cancer;
PAAD	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs11853189	0.938	rs76053575	chr15:78603021	A/C	cg22935921	chr15:78556834	DNAJA4	0.76	5.1	0.38	1.01e-6	Red cell distribution width;
PAAD	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.62	6.68	0.48	4.31e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs72627123	1.000	rs72627138	chr14:74401900	G/T	cg19860245	chr14:74300557	NA	-0.72	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs89107	1.000	rs89107	chr6:118578043	G/A	cg21191810	chr6:118973309	C6orf204	0.4	5.21	0.39	6.09e-7	Cardiac structure and function;
PAAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.44	-4.95	-0.37	1.92e-6	Height;
PAAD	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.66	5.86	0.43	2.75e-8	Mean platelet volume;
PAAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.5	6.4	0.46	1.8e-9	Prostate cancer;
PAAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg13206674	chr6:150067644	NUP43	-0.55	-5.05	-0.38	1.26e-6	Lung cancer;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg14926445	chr8:58193284	C8orf71	-0.75	-6.06	-0.44	1.02e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg01320130	chr1:67600311	NA	0.53	5.33	0.4	3.42e-7	Psoriasis;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg27094323	chr7:1216898	NA	-0.56	-6.68	-0.48	4.13e-10	Longevity;Endometriosis;
PAAD	cis	rs9976767	0.932	rs7283281	chr21:43825519	C/G	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.56	-0.35	1.02e-5	Type 1 diabetes;
PAAD	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-9.96	-0.63	2.73e-18	Headache;
PAAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg09796270	chr17:17721594	SREBF1	0.45	4.86	0.37	2.85e-6	Total body bone mineral density;
PAAD	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.73	0.42	5.24e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.7	5.68	0.42	6.79e-8	Schizophrenia;
PAAD	cis	rs2574704	0.651	rs2616552	chr3:11666798	G/T	cg07643000	chr3:11666825	VGLL4	-0.63	-5.44	-0.4	2.11e-7	Body mass index;
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.94	12.08	0.7	5.62e-24	Prudent dietary pattern;
PAAD	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.12	14.74	0.77	4.32e-31	Primary sclerosing cholangitis;
PAAD	cis	rs7011049	1.000	rs72643590	chr8:53849595	A/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.73	0.58	4.16e-15	Lung cancer;
PAAD	cis	rs8060686	0.920	rs56047901	chr16:67742326	G/A	cg05110241	chr16:68378359	PRMT7	-0.96	-5.45	-0.4	1.99e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg18892244	chr7:807596	HEATR2	-0.68	-5.1	-0.38	1.02e-6	Initial pursuit acceleration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20738202	chr11:16759965	C11orf58	0.68	7.09	0.5	4.71e-11	Obesity-related traits;
PAAD	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.6	-5.39	-0.4	2.61e-7	Diastolic blood pressure;
PAAD	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	0.52	4.45	0.34	1.67e-5	Testicular germ cell tumor;
PAAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg05110241	chr16:68378359	PRMT7	-1.08	-7.75	-0.53	1.19e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.7	-6.99	-0.49	8.07e-11	Retinal vascular caliber;
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.7	0.82	9.33e-39	Height;
PAAD	cis	rs2882667	0.690	rs700627	chr5:138119400	A/T	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4704187	0.617	rs1477936	chr5:74448502	T/A	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.64	-7.48	-0.52	5.67e-12	Schizophrenia;
PAAD	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg22705602	chr4:152727874	NA	-0.49	-5.15	-0.39	7.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.81	6.84	0.49	1.78e-10	Morning vs. evening chronotype;
PAAD	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.51	5.52	0.41	1.41e-7	Bladder cancer;
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.27	0.45	3.64e-9	Platelet count;
PAAD	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.75	0.42	4.64e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.62	5.05	0.38	1.23e-6	Birth weight;
PAAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.82	-6.48	-0.47	1.19e-9	Gut microbiome composition (summer);
PAAD	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.64	-0.35	7.45e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27524515	chr8:38239417	WHSC1L1	-0.6	-7.09	-0.5	4.66e-11	Body fat percentage;
PAAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg01503450	chr10:980765	NA	-0.53	-4.83	-0.36	3.27e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg26816564	chr1:7831052	VAMP3	0.75	5.4	0.4	2.53e-7	Inflammatory bowel disease;
PAAD	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.45	5.76	0.42	4.55e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.52	4.99	0.38	1.64e-6	Cancer;
PAAD	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.66	7.09	0.5	4.68e-11	Type 2 diabetes;
PAAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg23463467	chr20:60627584	TAF4	0.47	4.96	0.37	1.84e-6	Body mass index;
PAAD	cis	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2555155	0.870	rs2723644	chr11:6543017	T/C	cg24637308	chr11:6592297	DNHD1	0.5	5.15	0.39	7.89e-7	DNA methylation (variation);
PAAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23009387	chr5:135468634	SMAD5;SMAD5OS	0.64	7.39	0.51	9.23e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg01631408	chr1:248437212	OR2T33	-0.58	-5.55	-0.41	1.21e-7	Common traits (Other);
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.7	-6.8	-0.48	2.28e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4523957	0.786	rs59428454	chr17:2114063	T/A	cg16513277	chr17:2031491	SMG6	-0.51	-5.26	-0.39	4.76e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9345521	0.967	rs6942336	chr6:65499982	C/T	cg26414000	chr1:85721327	C1orf52	0.54	6.6	0.47	6.51e-10	Iris color (a* coordinate);
PAAD	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.47	0.65	1.21e-19	Bladder cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19737468	chr14:24701538	NEDD8;GMPR2	-0.76	-6.55	-0.47	8.43e-10	Neuroticism;
PAAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg20512303	chr5:131592959	PDLIM4	0.4	4.27	0.33	3.4e-5	Blood metabolite levels;
PAAD	cis	rs6137287	0.924	rs879064	chr20:21175550	A/G	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.66	-0.35	6.92e-6	Height;
PAAD	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.59	-5.33	-0.4	3.41e-7	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14133339	chr19:54641332	CNOT3	0.68	6.56	0.47	8.14e-10	Obesity-related traits;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg11301795	chr4:187892539	NA	-0.92	-14.67	-0.77	6.47e-31	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.51	6.2	0.45	5.08e-9	Alcohol dependence;
PAAD	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg14356550	chr1:18808102	KLHDC7A	0.57	6.37	0.46	2.15e-9	Breast cancer;
PAAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg19761014	chr17:28927070	LRRC37B2	0.8	5.36	0.4	3.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.04	0.67	3.47e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.77	7.66	0.53	2.07e-12	Resting heart rate;
PAAD	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.77	-6.86	-0.49	1.66e-10	Obesity-related traits;
PAAD	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.66	-6.08	-0.44	9.11e-9	Platelet count;
PAAD	cis	rs4742903	1.000	rs4742905	chr9:106856972	G/C	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg12290671	chr7:99195819	NA	0.84	4.91	0.37	2.36e-6	Blood metabolite ratios;
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.0	-0.59	8.8e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.7	7.72	0.53	1.42e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21545522	chr1:205238299	TMCC2	0.47	4.34	0.33	2.6e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.5	-4.93	-0.37	2.11e-6	Fibrinogen levels;
PAAD	cis	rs11955175	1.000	rs113120818	chr5:40642896	T/A	cg17351974	chr5:40835760	RPL37	0.81	4.66	0.35	6.91e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.73	8.59	0.57	9.8e-15	Emphysema distribution in smoking;
PAAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg21130718	chr4:1044621	NA	0.53	4.53	0.35	1.18e-5	Recombination rate (females);
PAAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg12193833	chr17:30244370	NA	-0.57	-4.72	-0.36	5.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.67e-7	Personality dimensions;
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.59	4.72	0.36	5.26e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg06521852	chr22:38141419	TRIOBP	0.42	4.42	0.34	1.84e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	4.06e-10	Total body bone mineral density;
PAAD	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.77	-0.48	2.63e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.32	-0.6	1.31e-16	Gut microbiome composition (summer);
PAAD	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	7.33	0.51	1.25e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.55	-4.41	-0.34	1.95e-5	Iron status biomarkers;
PAAD	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10274279	0.660	rs9638055	chr7:157379914	A/G	cg09270525	chr7:157391030	PTPRN2	0.59	5.43	0.4	2.14e-7	Myopia (pathological);
PAAD	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.65	6.54	0.47	8.88e-10	Testicular germ cell tumor;
PAAD	cis	rs6539267	0.516	rs17218455	chr12:106716441	C/T	cg02476566	chr12:106696527	TCP11L2	0.7	5.25	0.39	5.15e-7	Tourette syndrome;
PAAD	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.55	5.74	0.42	5.03e-8	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.65	0.65	3.91e-20	Prudent dietary pattern;
PAAD	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.52	4.84	0.37	3.2e-6	Self-reported allergy;
PAAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg09796270	chr17:17721594	SREBF1	0.43	4.59	0.35	9.07e-6	Total body bone mineral density;
PAAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05585630	chr7:157510462	PTPRN2	-0.66	-6.26	-0.45	3.67e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.56	-5.27	-0.39	4.56e-7	Cancer;
PAAD	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg01448562	chr3:133502909	NA	0.42	4.27	0.33	3.39e-5	Iron status biomarkers;
PAAD	cis	rs7804356	0.834	rs212856	chr7:26729205	T/C	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.63	-0.35	7.81e-6	Height;
PAAD	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.17	9.72	0.62	1.17e-17	Mitochondrial DNA levels;
PAAD	cis	rs454510	1.000	rs377033	chr1:120196652	C/G	cg11530693	chr1:120165357	ZNF697	0.6	4.72	0.36	5.41e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg19217778	chr13:113420270	ATP11A	0.63	4.34	0.33	2.55e-5	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02985541	chr2:219472218	PLCD4	-0.31	-4.87	-0.37	2.78e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9557207	0.540	rs4605009	chr13:100064765	G/A	cg19304063	chr13:99101488	FARP1	-0.51	-4.25	-0.33	3.64e-5	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
PAAD	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg24397884	chr7:158709396	WDR60	-1.14	-9.75	-0.62	9.32e-18	Height;
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg18884388	chr7:190334	NA	0.57	4.48	0.34	1.43e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg08773314	chr2:239334832	ASB1	0.46	8.25	0.56	7.01e-14	Multiple system atrophy;
PAAD	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg09163369	chr1:210001066	C1orf107	0.52	5.47	0.41	1.8e-7	Orofacial clefts;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22394521	chr20:61569754	DIDO1;C20orf11	0.64	6.55	0.47	8.4e-10	Myopia (pathological);
PAAD	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.4	-4.9	-0.37	2.41e-6	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73196996	chr3:128458416	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg04160749	chr8:58172571	NA	-0.64	-4.47	-0.34	1.54e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs6076065	0.723	rs2251145	chr20:23399998	G/A	cg11657817	chr20:23433608	CST11	0.49	5.07	0.38	1.14e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg15604389	chr3:122379662	NA	0.54	5.74	0.42	4.88e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.81	-9.58	-0.61	2.6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.45	6.08	0.44	9.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2120243	0.592	rs28638274	chr3:157124479	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	4.71	0.36	5.53e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.63	7.92	0.54	4.65e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg18370025	chr7:2749541	AMZ1	-0.4	-4.76	-0.36	4.49e-6	Height;
PAAD	cis	rs1075232	1.000	rs9672214	chr15:31677775	A/T	cg15751117	chr15:30700112	NA	0.97	4.85	0.37	3e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.81	5.65	0.42	7.78e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.65	-6.28	-0.45	3.39e-9	White matter hyperintensity burden;
PAAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.59	7.03	0.5	6.4e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.81	0.36	3.64e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17762328	chr6:126965162	NA	0.56	6.38	0.46	1.97e-9	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg07173049	chr1:7289937	CAMTA1	0.58	8.05	0.55	2.22e-13	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg12290671	chr7:99195819	NA	-0.91	-5.3	-0.4	3.96e-7	Blood metabolite ratios;
PAAD	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg24562669	chr7:97807699	LMTK2	0.47	6.76	0.48	2.75e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg02580895	chr19:2754563	NA	-0.52	-4.59	-0.35	9.17e-6	Total cholesterol levels;
PAAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-1.06	-15.01	-0.77	8.35e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.83	-0.48	1.87e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs829661	1.000	rs1447193	chr2:30864980	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	4.83	0.36	3.35e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11284414	chr2:232573146	PTMA	-0.57	-6.62	-0.47	5.87e-10	Body fat percentage;
PAAD	cis	rs757081	0.658	rs214076	chr11:17300257	T/C	cg15432903	chr11:17409602	KCNJ11	-0.53	-5.65	-0.42	7.58e-8	Systolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14021555	chr22:43485536	TTLL1	0.66	7.37	0.51	9.92e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4796354	0.570	rs8081510	chr17:6716385	T/C	cg12642237	chr17:6703447	TEKT1	-0.36	-4.33	-0.33	2.71e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.57	-0.35	1.02e-5	Height;
PAAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.01	0.67	4.34e-21	Height;
PAAD	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.66	6.32	0.46	2.74e-9	Mood instability;
PAAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Myopia (pathological);
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.73	8.53	0.57	1.36e-14	Vitiligo;
PAAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-5.79	-0.42	3.99e-8	Personality dimensions;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	9.21	0.6	2.39e-16	Lymphocyte counts;
PAAD	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg21466736	chr12:48725269	NA	0.41	4.33	0.33	2.71e-5	Plateletcrit;
PAAD	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs11264213	0.901	rs661233	chr1:36364716	A/G	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.13	0.5	3.83e-11	Coffee consumption (cups per day);
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Body mass index;
PAAD	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04645421	chr5:108064041	NA	0.58	6.72	0.48	3.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg23598562	chr12:53773812	SP1	0.45	4.28	0.33	3.34e-5	Height;
PAAD	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg25401027	chr5:176370377	UIMC1	0.53	5.28	0.39	4.36e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs11615916	0.790	rs73137528	chr12:62725394	C/T	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs58521262	0.729	rs11669667	chr19:23064398	A/G	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs757081	0.514	rs214087	chr11:17298365	G/C	cg22710661	chr11:17411071	KCNJ11	-0.42	-4.36	-0.33	2.35e-5	Systolic blood pressure;
PAAD	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.79	7.26	0.51	1.84e-11	Gout;
PAAD	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.53	5.54	0.41	1.32e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-4.47	-0.34	1.52e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg07212818	chr11:638076	DRD4	-0.7	-7.03	-0.5	6.38e-11	Systemic lupus erythematosus;
PAAD	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg21929781	chr1:2537748	MMEL1	0.44	4.7	0.36	5.69e-6	Ulcerative colitis;
PAAD	cis	rs35000415	0.938	rs80086012	chr7:128711874	C/T	cg19972273	chr7:128594194	NA	0.96	5.33	0.4	3.55e-7	Systemic lupus erythematosus;
PAAD	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.62	-0.53	2.49e-12	Monocyte percentage of white cells;
PAAD	cis	rs1723838	0.826	rs17244671	chr11:73574422	A/C	cg26954736	chr11:73693896	UCP2	1.04	4.61	0.35	8.51e-6	Obesity-related traits;
PAAD	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg03894339	chr8:19674705	INTS10	-0.46	-4.4	-0.34	2.04e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.64	-6.16	-0.45	6.26e-9	Corneal astigmatism;
PAAD	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg23024343	chr7:107201750	COG5	0.56	4.59	0.35	9.35e-6	Coronary artery disease;
PAAD	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg01942863	chr7:99769432	GPC2	0.53	4.34	0.33	2.59e-5	Lung function (FEV1/FVC);
PAAD	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	1.08	5.65	0.42	7.74e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.68	0.82	1.04e-38	Height;
PAAD	cis	rs783540	0.934	rs4779053	chr15:83371598	T/C	cg00614314	chr15:82944287	LOC80154	-0.42	-4.29	-0.33	3.16e-5	Schizophrenia;
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg27005118	chr17:13972210	COX10	-0.39	-5.16	-0.39	7.52e-7	Temperament;
PAAD	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-1.17	-9.62	-0.62	2.05e-17	Obesity-related traits;
PAAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.74	-8.75	-0.58	3.76e-15	Childhood ear infection;
PAAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg15017067	chr4:17643749	FAM184B	0.4	4.63	0.35	7.93e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.61	-7.6	-0.52	2.9e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-14.69	-0.77	5.77e-31	Height;
PAAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.54	4.9	0.37	2.45e-6	Height;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02071572	chr4:1403502	NA	0.46	5.75	0.42	4.79e-8	Obesity-related traits;
PAAD	trans	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg14393609	chr7:65229607	NA	0.65	6.98	0.49	8.52e-11	Aortic root size;
PAAD	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg00369613	chr2:3483100	TTC15	0.56	4.31	0.33	2.98e-5	Type 2 diabetes;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg13903179	chr13:21900392	NA	0.62	6.85	0.49	1.68e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.66	5.16	0.39	7.45e-7	Alzheimer's disease;
PAAD	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27297192	chr10:134578999	INPP5A	0.56	5.42	0.4	2.26e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24742571	chr15:62531933	NA	0.71	7.13	0.5	3.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	0.75	5.12	0.38	8.92e-7	Body mass index;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.9	-8.35	-0.56	4.02e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.28	-0.45	3.31e-9	IgG glycosylation;
PAAD	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.93	-0.37	2.17e-6	Schizophrenia;
PAAD	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	1.04	8.39	0.56	3.1e-14	Inflammatory bowel disease;
PAAD	cis	rs11585357	0.501	rs58620951	chr1:17573965	G/A	cg08277548	chr1:17600880	PADI3	-0.8	-5.91	-0.43	2.12e-8	Hair shape;
PAAD	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg04374321	chr14:90722782	PSMC1	0.53	4.33	0.33	2.66e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.55	-5.7	-0.42	6.14e-8	Urate levels;
PAAD	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.58	6.83	0.48	1.92e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.77	-7.87	-0.54	6.26e-13	Body mass index;
PAAD	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs295140	0.710	rs1729421	chr2:201080113	G/C	cg23649088	chr2:200775458	C2orf69	0.47	4.81	0.36	3.58e-6	QT interval;
PAAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.54	5.76	0.42	4.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg17372657	chr7:1216933	NA	-0.36	-4.63	-0.35	7.77e-6	Longevity;Endometriosis;
PAAD	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.01	0.38	1.47e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.57	6.93	0.49	1.13e-10	Multiple system atrophy;
PAAD	cis	rs3177980	0.522	rs73026245	chr1:169881461	T/A	cg18229820	chr1:169693534	SELE	0.51	4.51	0.34	1.31e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.4	-0.56	2.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04013166	chr16:89971882	TCF25	0.66	4.41	0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg21698718	chr17:80085957	CCDC57	0.39	4.33	0.33	2.69e-5	Life satisfaction;
PAAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.76	-5.62	-0.41	8.94e-8	Mean platelet volume;
PAAD	cis	rs1867485	0.612	rs300029	chr16:86678875	A/G	cg01302649	chr16:86530623	NA	0.4	4.56	0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.68	7.02	0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	7.77	0.53	1.1e-12	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.77	6.0	0.44	1.37e-8	White matter hyperintensity burden;
PAAD	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg11713064	chr6:33730089	NA	0.35	4.25	0.33	3.73e-5	Platelet count;
PAAD	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg24253500	chr15:84953950	NA	0.53	6.15	0.45	6.53e-9	Schizophrenia;
PAAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2131877	0.913	rs1874099	chr3:194848766	G/T	cg16306870	chr3:194868790	C3orf21	0.42	4.35	0.33	2.46e-5	Non-small cell lung cancer;
PAAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.45	-4.69	-0.36	6.02e-6	Blood protein levels;
PAAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.42	4.52	0.34	1.25e-5	Obesity-related traits;
PAAD	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.74	-6.64	-0.47	5.28e-10	Blood protein levels;
PAAD	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.96	10.02	0.63	1.9e-18	Corneal astigmatism;
PAAD	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.17	-0.39	7.24e-7	Daytime sleep phenotypes;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.1	0.5	4.51e-11	Renal function-related traits (BUN);
PAAD	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.79	8.33	0.56	4.37e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.78	-5.95	-0.43	1.8e-8	Coronary artery disease;
PAAD	cis	rs11696501	0.739	rs6104257	chr20:44262100	G/T	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	cis	rs3931020	0.745	rs1980851	chr1:75268971	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.48	4.6	0.35	8.84e-6	Resistin levels;
PAAD	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.46	-0.46	1.34e-9	Crohn's disease;
PAAD	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs7631605	0.623	rs7619703	chr3:36981411	T/A	cg17445812	chr3:36986805	TRANK1	0.32	4.32	0.33	2.77e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15450734	chr14:103541957	NA	-0.6	-6.55	-0.47	8.57e-10	Height;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.62	-6.5	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.55	-6.13	-0.45	7.07e-9	Total body bone mineral density;
PAAD	cis	rs7719624	0.545	rs2215012	chr5:135414464	C/T	cg00308130	chr5:135415190	NA	-0.29	-4.32	-0.33	2.86e-5	Response to cytidine analogues (gemcitabine);
PAAD	trans	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.95	-0.49	9.94e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg24699146	chr1:24152579	HMGCL	-0.53	-5.58	-0.41	1.08e-7	Immature fraction of reticulocytes;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs72960926	1.000	rs72958945	chr6:75109509	G/C	cg03266952	chr6:74778945	NA	-1.04	-5.63	-0.42	8.51e-8	Metabolite levels (MHPG);
PAAD	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg10356904	chr22:49881777	NA	-0.48	-4.73	-0.36	5.16e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.56	-4.4	-0.34	2.05e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg03983715	chr16:68378420	PRMT7	-0.83	-5.95	-0.43	1.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg12564285	chr5:131593104	PDLIM4	0.54	5.37	0.4	2.85e-7	Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.61	-7.46	-0.52	6.17e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.65	7.3	0.51	1.51e-11	Coronary artery disease;
PAAD	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg00122941	chr17:4613640	ARRB2	-0.82	-8.41	-0.56	2.7e-14	Lymphocyte counts;
PAAD	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.77	8.85	0.58	2.04e-15	Heart rate;
PAAD	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.11e-6	Motion sickness;
PAAD	cis	rs988913	0.781	rs1963697	chr6:54772814	G/T	cg03513858	chr6:54763001	FAM83B	-0.44	-5.17	-0.39	7.23e-7	Menarche (age at onset);
PAAD	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg26205652	chr12:48591994	NA	0.84	7.63	0.53	2.4e-12	Longevity (90 years and older);
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg03289416	chr15:75166202	SCAMP2	-0.54	-5.64	-0.42	8.18e-8	Breast cancer;
PAAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg08099141	chr12:7053170	C12orf57	0.43	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	cis	rs10413329	0.810	rs10401950	chr19:13101197	C/G	cg13338734	chr19:13113668	NFIX	0.37	4.83	0.36	3.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8077577	1.000	rs7207276	chr17:18065737	G/C	cg16794390	chr17:18148240	FLII	0.59	4.96	0.37	1.89e-6	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs7009110	0.706	rs11786685	chr8:81275835	A/G	cg21158561	chr8:81178149	NA	0.44	4.78	0.36	4.18e-6	Asthma and hay fever;
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.76	8.6	0.57	9.21e-15	Lung cancer;
PAAD	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.67	7.3	0.51	1.49e-11	Alcohol dependence;
PAAD	cis	rs2109514	0.967	rs10271007	chr7:116145849	A/G	cg19719915	chr7:115928094	NA	-0.47	-4.42	-0.34	1.85e-5	Prevalent atrial fibrillation;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.8	-5.39	-0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.85	4.48	0.34	1.47e-5	Plasma clusterin levels;
PAAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.48	6.14	0.45	7.02e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.82	10.42	0.65	1.6e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.59	6.0	0.44	1.4e-8	Vitiligo;
PAAD	trans	rs901683	1.000	rs768673	chr10:45966749	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.46	4.59	0.35	9.23e-6	Aortic root size;
PAAD	cis	rs1941184	0.759	rs10048329	chr18:29023625	T/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.77	-8.99	-0.59	8.9e-16	Hemoglobin concentration;
PAAD	cis	rs1345301	0.609	rs56389410	chr2:102867663	C/T	cg03938978	chr2:103052716	IL18RAP	-0.44	-4.83	-0.36	3.29e-6	Waist circumference;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17510320	chr11:66360559	CCS;CCDC87	0.65	6.34	0.46	2.54e-9	Primary biliary cholangitis;
PAAD	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.53	5.14	0.38	8.25e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.93	11.29	0.68	7.32e-22	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35740288	0.822	rs10520599	chr15:86223097	C/T	cg07943548	chr15:86304357	KLHL25	-0.67	-5.75	-0.42	4.8e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg08898775	chr15:59042684	ADAM10	0.41	5.33	0.4	3.48e-7	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20049727	chr4:1981032	WHSC1	0.58	6.72	0.48	3.35e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8105895	0.935	rs8110969	chr19:22240222	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.39	-0.34	2.08e-5	Body mass index (change over time);
PAAD	cis	rs7627468	0.770	rs2134221	chr3:121962246	A/G	cg03198317	chr3:121949109	CASR	-0.48	-4.38	-0.33	2.18e-5	Kidney stones;
PAAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.71	5.85	0.43	2.85e-8	Schizophrenia;
PAAD	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.71	7.18	0.5	2.93e-11	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09597638	chr17:3907349	NA	-0.71	-7.58	-0.52	3.21e-12	Type 2 diabetes;
PAAD	cis	rs654950	1.000	rs600401	chr1:41984658	C/T	cg06885757	chr1:42089581	HIVEP3	0.6	7.09	0.5	4.72e-11	Airway imaging phenotypes;
PAAD	cis	rs11997175	0.597	rs4472473	chr8:33610255	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	6.52	0.47	9.66e-10	Body mass index;
PAAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.69	8.69	0.58	5.27e-15	Coronary artery disease;
PAAD	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg00122941	chr17:4613640	ARRB2	0.82	8.08	0.55	1.83e-13	Lymphocyte counts;
PAAD	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.54	5.06	0.38	1.19e-6	Malaria;
PAAD	cis	rs73198271	0.632	rs57687880	chr8:8602910	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	4.58	0.35	9.67e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26946534	chr17:54978923	TRIM25	-0.65	-7.22	-0.51	2.31e-11	Obesity-related traits;
PAAD	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.45	4.81	0.36	3.59e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs507080	0.733	rs4393358	chr11:118569097	C/T	cg08498647	chr11:118550644	TREH	-0.38	-4.33	-0.33	2.71e-5	Serum metabolite levels;
PAAD	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.65	7.38	0.51	9.42e-12	Hyperactive-impulsive symptoms;
PAAD	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.36	0.51	1.11e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg14393609	chr7:65229607	NA	0.62	6.66	0.48	4.83e-10	Aortic root size;
PAAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.8	7.26	0.51	1.86e-11	Blood protein levels;
PAAD	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg10818794	chr15:86012489	AKAP13	-0.47	-5.16	-0.39	7.54e-7	Interstitial lung disease;
PAAD	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg08558340	chr7:100472263	SRRT	0.52	4.6	0.35	8.71e-6	Resting heart rate;
PAAD	cis	rs9522267	0.643	rs9522279	chr13:112221296	C/T	cg10483660	chr13:112241077	NA	-0.5	-5.33	-0.4	3.56e-7	Hepatitis;
PAAD	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.71	6.12	0.44	7.43e-9	Pubertal anthropometrics;
PAAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg02734326	chr4:10020555	SLC2A9	0.48	4.77	0.36	4.36e-6	Bone mineral density;
PAAD	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg04450456	chr4:17643702	FAM184B	-0.43	-4.45	-0.34	1.63e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg22771759	chr13:24902376	NA	0.49	4.91	0.37	2.33e-6	Obesity-related traits;
PAAD	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.54	4.55	0.35	1.08e-5	RR interval (heart rate);
PAAD	cis	rs6442925	1.000	rs6442925	chr3:5013876	C/T	cg01815263	chr3:5237478	EDEM1	-0.5	-4.48	-0.34	1.44e-5	Corneal structure;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.72	7.07	0.5	5.28e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs988712	0.705	rs4923457	chr11:27648580	A/T	cg10635145	chr11:27742435	BDNF	-0.37	-4.44	-0.34	1.7e-5	Obesity;
PAAD	cis	rs1478897	0.898	rs2249040	chr8:11390779	A/T	cg08224773	chr8:11311868	FAM167A	-0.36	-4.32	-0.33	2.8e-5	Systemic lupus erythematosus;
PAAD	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09826364	chr7:158789723	NA	-0.43	-5.62	-0.41	8.86e-8	Facial morphology (factor 20);
PAAD	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.66	-0.42	7.5e-8	Morning vs. evening chronotype;
PAAD	cis	rs367943	0.634	rs6891281	chr5:112960014	G/A	cg12552261	chr5:112820674	MCC	0.49	4.94	0.37	2.07e-6	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.24	0.39	5.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1376303	0.555	rs57769699	chr7:32862288	G/T	cg22974337	chr7:33830608	NA	0.55	4.3	0.33	3.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26926768	chr12:34528122	NA	0.37	4.52	0.34	1.22e-5	Morning vs. evening chronotype;
PAAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg05562828	chr17:3906858	NA	-0.54	-6.05	-0.44	1.09e-8	Type 2 diabetes;
PAAD	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg08079166	chr15:68083412	MAP2K5	0.68	5.15	0.39	8.12e-7	Restless legs syndrome;
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.64	6.09	0.44	9.02e-9	Blood metabolite levels;
PAAD	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-7.84	-0.54	7.24e-13	Bladder cancer;
PAAD	cis	rs6976053	0.846	rs6465776	chr7:100462004	A/G	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg14092988	chr3:52407081	DNAH1	0.45	5.64	0.42	8.12e-8	Electroencephalogram traits;
PAAD	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs6681460	0.901	rs1373911	chr1:67041065	T/C	cg02459107	chr1:67143332	SGIP1	0.74	6.98	0.49	8.73e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2904967	0.778	rs603286	chr11:65095801	G/A	cg05057976	chr11:65779667	CST6	0.53	4.44	0.34	1.73e-5	Mean corpuscular volume;
PAAD	trans	rs9409082	0.798	rs72734746	chr9:108919167	A/C	cg07010948	chr13:79181613	NA	-0.34	-6.36	-0.46	2.28e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.52	-5.23	-0.39	5.56e-7	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17203840	chr5:134209212	TXNDC15	-0.69	-6.9	-0.49	1.33e-10	Obesity-related traits;
PAAD	cis	rs227833	1.000	rs227832	chr6:44681257	T/C	cg20913747	chr6:44695427	NA	0.57	5.91	0.43	2.17e-8	Monobrow;
PAAD	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.52	4.64	0.35	7.5e-6	Alzheimer's disease biomarkers;
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs757978	0.585	rs34227388	chr2:242443829	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.71	-4.61	-0.35	8.45e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.73	6.31	0.46	2.94e-9	Dilated cardiomyopathy;
PAAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg00229809	chr22:46761622	CELSR1	-0.61	-4.33	-0.33	2.67e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg01815783	chr4:1047043	NA	-0.4	-4.37	-0.33	2.31e-5	Recombination rate (males);
PAAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-5.26	-0.39	4.75e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg02038168	chr22:39784481	NA	-0.51	-4.95	-0.37	1.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-4.27	-0.33	3.48e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26418147	chr1:205743515	RAB7L1	0.4	4.68	0.36	6.23e-6	Monocyte percentage of white cells;
PAAD	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.26	0.64	4.29e-19	Platelet count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12053136	chr19:10252751	DNMT1	0.62	7.92	0.54	4.74e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.49	-5.23	-0.39	5.6e-7	Ulcerative colitis;
PAAD	cis	rs1421334	0.679	rs2160935	chr8:30840651	C/T	cg00964221	chr8:30240029	NA	0.46	4.27	0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6977660	1.000	rs10240227	chr7:19823188	T/C	cg05791153	chr7:19748676	TWISTNB	0.55	4.52	0.34	1.25e-5	Thyroid stimulating hormone;
PAAD	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs12760731	0.565	rs12406779	chr1:178088936	C/G	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs904092	0.720	rs931635	chr4:100210847	A/G	cg12011299	chr4:100065546	ADH4	-0.58	-5.43	-0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg15693483	chr7:1102177	C7orf50	0.46	5.08	0.38	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-5.76	-0.42	4.43e-8	Total cholesterol levels;
PAAD	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-7.72	-0.53	1.44e-12	Educational attainment;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.64e-14	Prudent dietary pattern;
PAAD	cis	rs6909229	0.625	rs1212038	chr6:158621014	G/A	cg02332782	chr6:157801523	ZDHHC14	0.54	4.31	0.33	2.97e-5	Lipoprotein (a) levels;
PAAD	cis	rs4668356	1.000	rs2883940	chr2:171853359	G/A	cg13882835	chr2:172017928	TLK1	0.95	5.06	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.98	-6.37	-0.46	2.09e-9	Lung cancer in ever smokers;
PAAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.37	0.46	2.15e-9	Personality dimensions;
PAAD	cis	rs7873102	0.654	rs56405143	chr9:37995099	G/A	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.87	6.43	0.46	1.57e-9	Alzheimer's disease;
PAAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-5.2	-0.39	6.39e-7	Personality dimensions;
PAAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.57	-6.18	-0.45	5.5e-9	IgG glycosylation;
PAAD	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.07	0.38	1.13e-6	Morning vs. evening chronotype;
PAAD	cis	rs1476670	0.565	rs2108201	chr1:44514883	G/C	cg09470012	chr1:44509516	NA	0.42	4.28	0.33	3.34e-5	Eotaxin levels;
PAAD	cis	rs7833986	1.000	rs34480844	chr8:57092973	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	4.26	0.33	3.55e-5	Height;
PAAD	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-13.37	-0.74	1.9e-27	Chronic sinus infection;
PAAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03226425	chr6:170151538	C6orf70;TCTE3	0.65	7.29	0.51	1.56e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09820084	chr6:18387507	RNF144B	0.58	6.65	0.47	5e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.35	-0.33	2.49e-5	Mood instability;
PAAD	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.7	6.65	0.47	5.05e-10	Coronary artery disease;
PAAD	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg05552183	chr6:42928497	GNMT	-0.45	-4.46	-0.34	1.59e-5	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19784903	chr17:45786737	TBKBP1	-0.55	-5.8	-0.43	3.76e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.8	-6.47	-0.46	1.26e-9	Total cholesterol levels;
PAAD	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.18	0.5	2.82e-11	Colorectal cancer;
PAAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg27411982	chr8:10470053	RP1L1	0.48	4.94	0.37	2.05e-6	Retinal vascular caliber;
PAAD	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.51	0.41	1.5e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	4.48	0.34	1.44e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-5.25	-0.39	5.14e-7	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.97	-6.58	-0.47	7.2e-10	Blood protein levels;
PAAD	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.85	-7.01	-0.49	7.26e-11	Triglycerides;
PAAD	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg25753631	chr6:25732923	NA	-0.49	-5.56	-0.41	1.19e-7	Iron status biomarkers;
PAAD	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.52	5.41	0.4	2.4e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.91	-10.1	-0.63	1.13e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs10046574	0.731	rs10270842	chr7:135163062	A/G	cg27474649	chr7:135195673	CNOT4	0.8	4.3	0.33	3e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.91	0.66	7.77e-21	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs7818688	0.697	rs11779698	chr8:95979764	C/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs72960926	1.000	rs72969247	chr6:75071533	G/T	cg03266952	chr6:74778945	NA	-1.02	-5.53	-0.41	1.39e-7	Metabolite levels (MHPG);
PAAD	cis	rs1385374	0.920	rs11059911	chr12:129271936	T/A	cg09035930	chr12:129282057	SLC15A4	-0.77	-4.48	-0.34	1.47e-5	Systemic lupus erythematosus;
PAAD	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.18	0.39	6.91e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09597638	chr17:3907349	NA	0.71	7.8	0.53	9e-13	Type 2 diabetes;
PAAD	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg27449745	chr7:23145252	KLHL7	0.5	4.37	0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs939584	1.000	rs2903492	chr2:624678	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.61	-6.32	-0.46	2.76e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.17	10.1	0.63	1.16e-18	Vitiligo;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.51	7.65	0.53	2.17e-12	Mean corpuscular volume;
PAAD	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	5.27	0.39	4.57e-7	Height;
PAAD	cis	rs4074493	0.928	rs4310430	chr1:231172881	T/G	cg22172038	chr1:231176991	FAM89A	0.53	4.83	0.36	3.25e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	4.96	0.37	1.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg15733309	chr7:157513707	PTPRN2	0.63	7.83	0.54	7.84e-13	Bipolar disorder and schizophrenia;
PAAD	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.96	-0.49	9.44e-11	Triglycerides;
PAAD	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Body mass index;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.68	7.16	0.5	3.25e-11	Mean corpuscular volume;
PAAD	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg08632701	chr21:37451849	NA	-0.59	-6.18	-0.45	5.75e-9	Mitral valve prolapse;
PAAD	cis	rs7534824	0.543	rs61780300	chr1:101403601	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.63	0.35	7.93e-6	Refractive astigmatism;
PAAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.8	-0.43	3.79e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg01620082	chr3:125678407	NA	-1.06	-7.26	-0.51	1.91e-11	Depression;
PAAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.46	5.8	0.43	3.73e-8	Childhood ear infection;
PAAD	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs7624766	0.555	rs2049214	chr3:160512501	C/T	cg22637730	chr3:160473554	PPM1L	0.53	4.58	0.35	9.59e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.41	-0.46	1.74e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg08886695	chr4:3369023	RGS12	-0.49	-4.72	-0.36	5.41e-6	Serum sulfate level;
PAAD	cis	rs114540395	0.858	rs117416511	chr10:103351588	G/A	cg21381511	chr10:104264849	SUFU	-0.81	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.42	-0.34	1.85e-5	Testicular germ cell tumor;
PAAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.68	-0.42	6.75e-8	Schizophrenia;
PAAD	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg06565975	chr8:143823917	SLURP1	0.18	4.3	0.33	3.06e-5	Urinary tract infection frequency;
PAAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg17031739	chr1:67600172	NA	0.38	4.25	0.33	3.78e-5	Psoriasis;
PAAD	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs7853377	0.723	rs10114889	chr9:86553106	G/C	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.67	5.81	0.43	3.59e-8	Breast cancer;
PAAD	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg03684893	chr10:554711	DIP2C	-0.41	-4.32	-0.33	2.78e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.48	6.94	0.49	1.09e-10	Mean corpuscular volume;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg17480646	chr11:65405466	SIPA1	0.9	4.28	0.33	3.29e-5	Height;
PAAD	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg08501292	chr6:25962987	TRIM38	0.74	4.51	0.34	1.29e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20007245	chr22:24372913	LOC391322	-0.77	-8.18	-0.55	1.05e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25345360	chr19:7600413	PNPLA6	-0.74	-6.36	-0.46	2.29e-9	Neuroticism;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.64	-6.91	-0.49	1.24e-10	Longevity;
PAAD	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.75	8.63	0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.73	0.62	1.07e-17	Lymphocyte counts;
PAAD	cis	rs17641971	0.708	rs4873303	chr8:49922675	G/A	cg00325661	chr8:49890786	NA	0.48	4.72	0.36	5.26e-6	Blood metabolite levels;
PAAD	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	4.66	0.35	6.78e-6	Menopause (age at onset);
PAAD	cis	rs4338575	1.000	rs7961187	chr12:77673046	A/C	cg08610361	chr12:77459885	E2F7	0.48	4.25	0.33	3.76e-5	Methadone dose in opioid dependence;
PAAD	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg04034577	chr2:241836375	C2orf54	-0.34	-5.15	-0.39	7.79e-7	Urinary metabolites;
PAAD	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.44	-5.86	-0.43	2.81e-8	Ulcerative colitis;
PAAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg16434002	chr17:42200994	HDAC5	0.62	5.83	0.43	3.19e-8	Total body bone mineral density;
PAAD	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.43	-4.45	-0.34	1.67e-5	Corneal structure;
PAAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg19980929	chr12:42632907	YAF2	0.51	5.89	0.43	2.36e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg08501292	chr6:25962987	TRIM38	0.77	4.59	0.35	9.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs939584	0.935	rs12993295	chr2:632808	G/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.67	4.9	0.37	2.48e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.75	-7.06	-0.5	5.49e-11	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.8	7.7	0.53	1.64e-12	Glomerular filtration rate (creatinine);
PAAD	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.41	4.57	0.35	9.98e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg10396713	chr8:602097	NA	0.67	4.43	0.34	1.78e-5	IgG glycosylation;
PAAD	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg04851639	chr8:1020857	NA	-0.64	-7.97	-0.54	3.56e-13	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.82	0.36	3.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.34	-0.33	2.59e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.28	0.39	4.32e-7	Ovarian reserve;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05665937	chr4:1216051	CTBP1	0.4	4.37	0.33	2.27e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg14393609	chr7:65229607	NA	-0.66	-6.88	-0.49	1.44e-10	Aortic root size;
PAAD	trans	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.49	5.0	0.38	1.59e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.77	-8.0	-0.54	2.89e-13	Blood metabolite levels;
PAAD	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1997066	0.831	rs7916764	chr10:106823773	G/A	cg17321814	chr10:106440892	SORCS3	0.63	4.42	0.34	1.9e-5	Diabetic kidney disease;
PAAD	cis	rs11807834	0.522	rs7529009	chr1:230232080	C/T	cg09847368	chr1:230250326	GALNT2	0.7	8.74	0.58	3.94e-15	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.01e-9	Life satisfaction;
PAAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg17366294	chr4:99064904	C4orf37	0.59	6.25	0.45	3.93e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.68	6.31	0.46	2.95e-9	Endometrial cancer;
PAAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.94	9.15	0.6	3.56e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4668356	0.730	rs57173242	chr2:171898070	A/C	cg13882835	chr2:172017928	TLK1	0.92	5.31	0.4	3.81e-7	Cognitive performance;
PAAD	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06002616	chr8:101225028	SPAG1	0.46	5.35	0.4	3.13e-7	Atrioventricular conduction;
PAAD	cis	rs7594192	0.744	rs6736652	chr2:199368000	C/T	cg01558212	chr2:200327336	NA	-0.34	-4.39	-0.34	2.14e-5	Educational attainment;
PAAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.65	-6.81	-0.48	2.14e-10	Height;
PAAD	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg00750074	chr16:89608354	SPG7	-0.57	-5.42	-0.4	2.34e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg15443732	chr18:74961078	GALR1	0.6	5.54	0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-1.05	-5.87	-0.43	2.66e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	5.02	0.38	1.42e-6	Urate levels in obese individuals;
PAAD	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg18078177	chr20:47281410	PREX1	0.99	5.41	0.4	2.36e-7	Multiple myeloma;
PAAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.03	-0.38	1.38e-6	Bipolar disorder;
PAAD	cis	rs12799264	1.000	rs12799264	chr11:19980232	A/G	cg17303119	chr11:19974895	NAV2	0.69	4.71	0.36	5.53e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.29e-8	Alcohol dependence;
PAAD	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.59	0.65	5.67e-20	Morning vs. evening chronotype;
PAAD	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg07943548	chr15:86304357	KLHL25	-0.61	-5.24	-0.39	5.34e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg16898833	chr6:26189333	HIST1H4D	0.55	4.47	0.34	1.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2303319	0.585	rs62194214	chr2:162041674	C/A	cg08807892	chr2:162101083	NA	-0.67	-4.54	-0.35	1.13e-5	Cognitive function;
PAAD	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.74	-6.64	-0.47	5.28e-10	Blood protein levels;
PAAD	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs12286929	0.839	rs12803174	chr11:115023159	T/C	cg04055981	chr11:115044050	NA	0.45	4.36	0.33	2.36e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.76	-0.53	1.18e-12	Blood metabolite levels;
PAAD	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.18	20.2	0.85	6.81e-45	Multiple myeloma;
PAAD	trans	rs17054480	0.614	rs61021568	chr4:169619772	C/T	cg18174542	chr22:41956861	CSDC2	0.8	6.35	0.46	2.37e-9	Advanced glycation end-product levels;
PAAD	cis	rs2029362	0.967	rs10835189	chr11:27541995	G/T	cg10635145	chr11:27742435	BDNF	0.3	4.26	0.33	3.64e-5	Total body bone mineral density;
PAAD	cis	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.55	5.44	0.4	2.04e-7	Resistin levels;
PAAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg08898775	chr15:59042684	ADAM10	0.37	4.73	0.36	5.15e-6	Asperger disorder;
PAAD	cis	rs6942407	0.592	rs6966613	chr7:86793494	C/T	cg02420886	chr7:86849541	C7orf23	0.55	4.58	0.35	9.44e-6	Food allergy;
PAAD	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-4.4	-0.34	2.04e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.08	13.41	0.74	1.52e-27	Type 1 diabetes nephropathy;
PAAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14180030	chr9:123475675	MEGF9	0.39	4.36	0.33	2.35e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs73058052	0.597	rs56873913	chr19:50091199	T/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.59	-5.09	-0.38	1.04e-6	Fibrinogen levels;
PAAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg03188948	chr7:1209495	NA	1.06	5.41	0.4	2.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.5	-5.14	-0.39	8.21e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.92	-9.88	-0.63	4.46e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.56	-5.33	-0.4	3.41e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.55	-6.5	-0.47	1.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg07648498	chr16:89883185	FANCA	0.48	4.64	0.35	7.37e-6	Vitiligo;
PAAD	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg14825688	chr5:132208181	LEAP2	0.61	6.23	0.45	4.32e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs2885056	0.713	rs58573889	chr19:10679733	A/G	cg06392426	chr19:10676186	KRI1	0.58	5.78	0.42	4.1e-8	Red cell distribution width;
PAAD	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.61	5.85	0.43	2.85e-8	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.83	9.88	0.63	4.34e-18	Coronary artery disease;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.61	-0.35	8.31e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.37	0.56	3.52e-14	Corneal astigmatism;
PAAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs73072330	0.643	rs56298666	chr3:47667218	A/G	cg09665691	chr3:47563885	NA	1.12	4.96	0.37	1.9e-6	Stem cell growth factor beta levels;
PAAD	cis	rs2070433	0.799	rs7279002	chr21:47910523	C/T	cg12379764	chr21:47803548	PCNT	-0.55	-4.84	-0.37	3.15e-6	Lymphocyte counts;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg19337854	chr7:99768885	GPC2	0.53	4.95	0.37	1.98e-6	Lung function (FEV1/FVC);
PAAD	trans	rs11989843	0.579	rs1910895	chr8:118073305	T/C	cg24636944	chr5:92615296	NA	0.49	6.31	0.46	2.91e-9	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg19784903	chr17:45786737	TBKBP1	-0.45	-4.62	-0.35	8e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg25790453	chr13:113633590	MCF2L	-0.38	-4.45	-0.34	1.64e-5	Systolic blood pressure;
PAAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.7	-8.31	-0.56	5.07e-14	Huntington's disease progression;
PAAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-6.47	-0.46	1.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg19254793	chr6:44695348	NA	-0.44	-4.34	-0.33	2.57e-5	Total body bone mineral density;
PAAD	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.97	-0.59	1e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4938330	0.723	rs7931398	chr11:116879676	T/C	cg04087571	chr11:116723030	SIK3	-0.34	-5.03	-0.38	1.4e-6	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Gout;
PAAD	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.44	-5.95	-0.43	1.75e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-6.04	-0.44	1.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.74	-5.73	-0.42	5.28e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg05082376	chr22:42548792	NA	-0.5	-5.36	-0.4	3e-7	Cognitive function;
PAAD	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.14	0.64	8.72e-19	Cognitive test performance;
PAAD	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.94	-8.36	-0.56	3.71e-14	Bipolar disorder;
PAAD	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.49	-5.82	-0.43	3.29e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.66	-8.08	-0.55	1.85e-13	Coronary artery disease;
PAAD	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.67	5.39	0.4	2.58e-7	Obesity (extreme);
PAAD	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.9	6.37	0.46	2.1e-9	Height;
PAAD	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.68	7.22	0.51	2.29e-11	Schizophrenia;
PAAD	cis	rs16975963	0.843	rs1056405	chr19:38313021	T/C	cg14218481	chr19:38281219	NA	0.46	4.72	0.36	5.24e-6	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14482292	chr2:132384714	NA	-0.59	-7.01	-0.49	7.27e-11	Obesity-related traits;
PAAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	0.93	4.41	0.34	1.96e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.54	4.73	0.36	4.98e-6	Coronary artery disease;
PAAD	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg05927578	chr16:4029543	ADCY9	0.71	5.93	0.43	1.98e-8	Waist circumference;
PAAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.77	9.17	0.6	3.19e-16	Emphysema distribution in smoking;
PAAD	cis	rs17655565	0.581	rs17657609	chr12:52763601	C/T	cg22980804	chr12:52818037	KRT75	-0.49	-4.35	-0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.31	4.43	0.34	1.76e-5	Migraine;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.59	7.1	0.5	4.43e-11	Pubertal anthropometrics;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12639763	chr10:97321104	SORBS1	0.57	6.3	0.46	3e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.1	-0.5	4.41e-11	Heart rate;
PAAD	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01061425	chr19:12273957	ZNF136	0.6	6.77	0.48	2.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-4.41	-0.34	1.93e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs17095355	1.000	rs2419313	chr10:111750851	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.78	9.51	0.61	4.03e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.72	7.98	0.54	3.39e-13	Prostate cancer;
PAAD	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.75	4.79	0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.27	0.64	3.95e-19	Cognitive test performance;
PAAD	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Body mass index;
PAAD	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg23860436	chr12:58378763	NA	0.48	4.53	0.34	1.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.3	4.58	0.35	9.68e-6	Menarche (age at onset);
PAAD	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.74	0.42	5.08e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.97	-5.1	-0.38	1e-6	Childhood ear infection;
PAAD	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg09168692	chr1:7887560	PER3	-0.53	-5.13	-0.38	8.53e-7	Inflammatory bowel disease;
PAAD	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg02640540	chr1:67518911	SLC35D1	-0.51	-4.48	-0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00147160	chr1:26503991	CNKSR1	0.44	6.9	0.49	1.3100000000000001e-10	Height;
PAAD	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.56	-5.13	-0.38	8.62e-7	Diastolic blood pressure;
PAAD	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.49	4.73	0.36	5.07e-6	Pancreatic cancer;
PAAD	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.76	-0.36	4.43e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1042026	0.848	rs7673323	chr4:100173103	G/C	cg09112717	chr4:100009950	ADH5	-0.53	-4.8	-0.36	3.69e-6	Esophageal cancer  (alcohol interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03786418	chr2:242681827	D2HGDH	0.63	7.46	0.52	6.11e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2286503	0.839	rs10276099	chr7:22862950	G/A	cg04907244	chr7:22894795	SNORD93	-0.39	-4.68	-0.36	6.19e-6	Fibrinogen;
PAAD	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.6	-5.89	-0.43	2.36e-8	Menopause (age at onset);
PAAD	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.26	10.56	0.65	6.98e-20	Corneal structure;
PAAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg00579200	chr11:133705235	NA	-0.46	-5.0	-0.38	1.58e-6	Childhood ear infection;
PAAD	cis	rs6782228	0.876	rs34198449	chr3:128381270	G/A	cg15607142	chr3:128420513	NA	-0.44	-4.75	-0.36	4.75e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.56	-0.41	1.17e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.66	4.65	0.35	7.14e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg22325292	chr17:80708367	FN3K	0.65	4.67	0.35	6.48e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg03037974	chr15:76606532	NA	0.49	5.71	0.42	5.77e-8	Blood metabolite levels;
PAAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.65	-6.08	-0.44	9.47e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg13263323	chr15:86062960	AKAP13	0.6	6.99	0.49	8.1e-11	Interstitial lung disease;
PAAD	cis	rs17601876	0.651	rs12907866	chr15:51545454	A/G	cg21478137	chr15:51532386	CYP19A1	0.49	4.9	0.37	2.39e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.67	6.52	0.47	9.81e-10	Blood metabolite levels;
PAAD	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.76	0.36	4.43e-6	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22035320	chr15:42170125	SPTBN5	-0.63	-6.63	-0.47	5.51e-10	Obesity-related traits;
PAAD	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.45	-4.94	-0.37	2e-6	Neuroticism;
PAAD	cis	rs6066835	0.764	rs2426103	chr20:47394490	A/C	cg18078177	chr20:47281410	PREX1	-0.88	-4.38	-0.33	2.23e-5	Multiple myeloma;
PAAD	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs10746514	0.833	rs2356925	chr1:232261769	G/A	cg09506761	chr1:232265262	NA	-0.44	-4.51	-0.34	1.28e-5	Response to statin therapy;
PAAD	cis	rs10792830	0.714	rs501505	chr11:85667916	C/A	cg07180834	chr11:85838833	NA	-0.48	-5.8	-0.43	3.65e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg25753631	chr6:25732923	NA	-0.44	-4.81	-0.36	3.59e-6	Iron status biomarkers;
PAAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg00035074	chr7:2701567	TTYH3	0.61	4.34	0.33	2.55e-5	Bipolar disorder;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.15	0.39	7.89e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.4	-8.48	-0.57	1.86e-14	Mean corpuscular volume;
PAAD	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.31	0.4	3.91e-7	Mammographic density (dense area);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.64	-5.79	-0.43	3.91e-8	Renal function-related traits (BUN);
PAAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.26	-0.56	6.67e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02985541	chr2:219472218	PLCD4	0.3	4.71	0.36	5.59e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs375066	0.935	rs407731	chr19:44418077	A/G	cg21496419	chr19:44306685	LYPD5	-0.39	-4.79	-0.36	3.89e-6	Breast cancer;
PAAD	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.71	5.5	0.41	1.54e-7	Crohn's disease;
PAAD	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.72	-7.51	-0.52	4.62e-12	Monocyte percentage of white cells;
PAAD	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.38e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.52	5.06	0.38	1.17e-6	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs847851	1.000	rs2473615	chr6:34893910	C/G	cg13196216	chr6:34231128	NA	-0.61	-4.94	-0.37	2.07e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-4.64	-0.35	7.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.01	0.49	7.41e-11	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	9.52	0.61	3.83e-17	Cognitive test performance;
PAAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	10.88	0.66	9.59e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1012068	0.581	rs5749339	chr22:32315735	A/G	cg01338084	chr22:32026380	PISD	-0.52	-4.35	-0.33	2.53e-5	Chronic hepatitis C infection;
PAAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.81	10.33	0.64	2.78e-19	Breast cancer;
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.71	-0.36	5.64e-6	Cognitive function;
PAAD	cis	rs11264213	0.591	rs1967782	chr1:36543783	C/T	cg27506609	chr1:36549197	TEKT2	-0.8	-5.99	-0.44	1.44e-8	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	cis	rs28795989	0.613	rs2385901	chr4:7921718	G/C	cg18538662	chr4:7941764	AFAP1	0.43	4.45	0.34	1.62e-5	Intraocular pressure;
PAAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.65	-5.18	-0.39	7e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs11700980	0.551	rs2251447	chr21:30109202	C/G	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.8	-8.91	-0.59	1.49e-15	Height;
PAAD	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg11995313	chr8:8860691	ERI1	0.48	4.82	0.36	3.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20887711	chr4:1340912	KIAA1530	-0.48	-4.84	-0.37	3.14e-6	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.43	0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.61	-5.07	-0.38	1.17e-6	Platelet count;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00166722	chr3:10149974	C3orf24	0.85	7.27	0.51	1.76e-11	Alzheimer's disease;
PAAD	cis	rs2688419	0.565	rs1094607	chr3:23062581	C/A	cg00327796	chr3:23032191	NA	-0.47	-4.65	-0.35	7.16e-6	Type 2 diabetes;
PAAD	cis	rs7180079	1.000	rs59190688	chr15:64516669	G/A	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	1.02	8.17	0.55	1.13e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-4.77	-0.36	4.26e-6	Educational attainment (years of education);
PAAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg22710661	chr11:17411071	KCNJ11	0.44	4.37	0.33	2.3e-5	Type 2 diabetes;
PAAD	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.08	-11.53	-0.68	1.69e-22	Ulcerative colitis;
PAAD	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-6.12	-0.44	7.46e-9	Coronary artery disease;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.84	0.69	2.49e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.83	-9.98	-0.63	2.37e-18	Menopause (age at onset);
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.47	4.93	0.37	2.11e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.7	7.9	0.54	5.09e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.59	-0.35	9.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.86	10.39	0.64	1.98e-19	Lung cancer;
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16262614	chr3:133464971	TF	-0.41	-4.54	-0.35	1.16e-5	Iron status biomarkers;
PAAD	cis	rs6710503	0.574	rs62142276	chr2:24771048	C/T	cg21151432	chr2:25142229	ADCY3	-0.36	-4.33	-0.33	2.72e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.8	6.25	0.45	4.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-5.69	-0.42	6.28e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.53	4.47	0.34	1.54e-5	Pursuit maintenance gain;
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg07153921	chr17:41440717	NA	-0.44	-4.62	-0.35	8.1e-6	Menopause (age at onset);
PAAD	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg00999904	chr2:3704751	ALLC	-0.81	-8.13	-0.55	1.39e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.6	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg10072921	chr12:121022843	NA	-0.35	-4.48	-0.34	1.44e-5	High light scatter reticulocyte count;
PAAD	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg16810054	chr20:33298113	TP53INP2	0.59	4.62	0.35	8.17e-6	Neuroticism;
PAAD	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.54	-5.79	-0.43	3.9e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.68	7.74	0.53	1.3e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg20291162	chr17:40259547	DHX58	-0.59	-5.94	-0.43	1.9e-8	Fibrinogen levels;
PAAD	cis	rs4924935	0.887	rs2428380	chr17:18843089	C/A	cg26306683	chr17:18585705	ZNF286B	-0.56	-4.25	-0.33	3.78e-5	Pancreatic cancer;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.08	-19.24	-0.84	1.44e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.48	5.03	0.38	1.38e-6	Longevity;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.59e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.7	8.49	0.57	1.69e-14	Dupuytren's disease;
PAAD	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg02574844	chr11:5959923	NA	-0.59	-6.14	-0.45	6.82e-9	DNA methylation (variation);
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.27	-0.45	3.47e-9	Bipolar disorder and schizophrenia;
PAAD	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.78	9.2	0.6	2.61e-16	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.32	-0.4	3.57e-7	Mononucleosis;
PAAD	cis	rs1697938	0.590	rs2597739	chr5:40940815	G/A	cg22359217	chr5:41925772	FBXO4	-0.46	-4.58	-0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs600626	0.529	rs10899115	chr11:75471849	A/G	cg24262691	chr11:75473276	NA	0.73	5.98	0.44	1.57e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.64	-5.69	-0.42	6.4e-8	Coronary artery disease;
PAAD	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.5	-0.34	1.35e-5	Asthma;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-1.04	-5.69	-0.42	6.49e-8	Inflammatory biomarkers;
PAAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.72	6.65	0.47	5.03e-10	Asthma;
PAAD	trans	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg01620082	chr3:125678407	NA	-1.17	-6.77	-0.48	2.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs778371	0.755	rs778347	chr2:233801356	A/G	cg08000102	chr2:233561755	GIGYF2	-0.62	-5.87	-0.43	2.59e-8	Schizophrenia;
PAAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.88	8.3	0.56	5.29e-14	Gestational age at birth (maternal effect);
PAAD	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg05085585	chr16:30420623	ZNF771	-0.43	-4.48	-0.34	1.47e-5	Tonsillectomy;
PAAD	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.6	-6.26	-0.45	3.82e-9	Motion sickness;
PAAD	cis	rs8037137	0.915	rs2301825	chr15:91528070	C/G	cg23684204	chr15:91497937	RCCD1	0.8	4.83	0.36	3.35e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.59	-6.24	-0.45	4.14e-9	Pulmonary function;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg19761014	chr17:28927070	LRRC37B2	0.75	5.17	0.39	7.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.36	4.32	0.33	2.79e-5	Pulmonary function;
PAAD	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.31	4.87	0.37	2.76e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	8.89	0.59	1.61e-15	Cognitive test performance;
PAAD	cis	rs7523050	0.554	rs34086470	chr1:109485991	C/A	cg08274380	chr1:109419600	GPSM2	0.88	5.29	0.39	4.1e-7	Fat distribution (HIV);
PAAD	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.94	6.17	0.45	6.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-5.21	-0.39	6.05e-7	QT interval;
PAAD	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.74	5.27	0.39	4.67e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs501120	0.925	rs559469	chr10:44752118	C/T	cg09554077	chr10:44749378	NA	-0.51	-6.74	-0.48	3.12e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.18	-0.39	6.91e-7	Other erythrocyte phenotypes;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.59	4.35	0.33	2.47e-5	Initial pursuit acceleration;
PAAD	cis	rs41311933	0.710	rs12377743	chr9:123710450	G/A	cg21241889	chr9:123690658	TRAF1	-0.68	-4.32	-0.33	2.75e-5	Coronary artery disease;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg08200582	chr11:442649	ANO9	0.51	4.37	0.33	2.31e-5	Systemic lupus erythematosus;
PAAD	cis	rs375066	0.935	rs365556	chr19:44408199	A/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13211287	chr8:144700128	TSTA3	0.65	6.76	0.48	2.72e-10	Myopia (pathological);
PAAD	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16447950	chr5:562315	NA	-0.71	-6.38	-0.46	2e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.26e-8	Sitting height ratio;
PAAD	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.06	0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.68	8.44	0.56	2.36e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.35	-0.33	2.49e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.43	5.13	0.38	8.81e-7	Monocyte count;
PAAD	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs11264799	0.765	rs2152710	chr1:157626964	A/G	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg20893579	chr22:38215064	NA	0.52	4.91	0.37	2.29e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.86	6.83	0.48	1.87e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.51	4.71	0.36	5.52e-6	Height;
PAAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.59	4.82	0.36	3.41e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg20913747	chr6:44695427	NA	-0.7	-7.02	-0.49	7.04e-11	Total body bone mineral density;
PAAD	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg02753203	chr1:228287806	NA	-0.58	-4.63	-0.35	7.91e-6	Adult asthma;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs67383251	0.881	rs7874131	chr9:137169720	A/G	cg14524403	chr9:136325208	C9orf7	0.88	4.29	0.33	3.21e-5	Response to Homoharringtonine (cytotoxicity);
PAAD	cis	rs7631605	0.846	rs68159333	chr3:37259739	G/A	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.46e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg11903854	chr6:3292969	SLC22A23	0.83	4.58	0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14180030	chr9:123475675	MEGF9	-0.43	-5.13	-0.38	8.7e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.95e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg22875332	chr1:76189707	ACADM	0.51	5.07	0.38	1.15e-6	Daytime sleep phenotypes;
PAAD	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.19	0.55	9.82e-14	Menopause (age at onset);
PAAD	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.98	13.62	0.74	4.05e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19882132	chr14:106167949	NA	-0.55	-4.87	-0.37	2.77e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs11264213	0.892	rs7530222	chr1:36200778	T/C	cg27506609	chr1:36549197	TEKT2	0.63	4.6	0.35	8.9e-6	Schizophrenia;
PAAD	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.59	4.32	0.33	2.85e-5	Vitiligo;
PAAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg14343924	chr8:8086146	FLJ10661	0.53	4.48	0.34	1.43e-5	Mood instability;
PAAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.59	-0.41	1.04e-7	Monocyte count;
PAAD	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.53	-4.65	-0.35	7.25e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9409082	0.578	rs1516883	chr9:108907267	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.51	5.8	0.43	3.69e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg20850873	chr3:10149803	C3orf24	0.53	4.26	0.33	3.59e-5	Alzheimer's disease;
PAAD	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.66	-6.63	-0.47	5.47e-10	Uric acid levels;
PAAD	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.43	-0.4	2.15e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3784262	0.740	rs4646598	chr15:58300328	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.78	-0.42	4.05e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.48	-0.34	1.49e-5	Dupuytren's disease;
PAAD	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg19337854	chr7:99768885	GPC2	-0.44	-4.47	-0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.46	4.78	0.36	4.15e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg14440974	chr22:39074834	NA	-0.6	-7.33	-0.51	1.27e-11	Menopause (age at onset);
PAAD	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20167471	chr1:16528984	ARHGEF19	0.48	4.9	0.37	2.39e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg04842828	chr21:34696676	IFNAR1	-0.43	-4.25	-0.33	3.73e-5	Narcolepsy;
PAAD	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.35	-0.33	2.52e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs10044254	0.563	rs6554897	chr5:15695253	A/G	cg07238450	chr5:15720153	FBXL7	-0.52	-4.79	-0.36	3.9e-6	Asthma (corticosteroid response);
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs9682041	0.627	rs11917188	chr3:170088607	C/T	cg11886554	chr3:170076028	SKIL	0.65	4.84	0.37	3.21e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	12.12	0.7	4.52e-24	Body mass index (adult);
PAAD	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg08079166	chr15:68083412	MAP2K5	0.59	4.48	0.34	1.46e-5	Obesity;
PAAD	cis	rs2421770	0.594	rs10768119	chr11:35268423	G/C	cg13971030	chr11:35366721	SLC1A2	-0.44	-5.32	-0.4	3.73e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.89	9.75	0.62	9.46e-18	Cognitive function;
PAAD	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10476473	chr2:170681531	METTL5	0.61	6.33	0.46	2.67e-9	Obesity-related traits;
PAAD	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg26703956	chr19:39260304	NA	-0.47	-5.64	-0.42	7.91e-8	Heart rate;
PAAD	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.43	4.9	0.37	2.4e-6	P wave duration;
PAAD	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.35	-0.4	3.2e-7	P wave terminal force;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg27094323	chr7:1216898	NA	-0.56	-6.78	-0.48	2.51e-10	Longevity;Endometriosis;
PAAD	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.89	-11.32	-0.68	6.2e-22	Metabolic syndrome;
PAAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.83	9.78	0.62	7.74e-18	Blood protein levels;
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	8.08	0.55	1.85e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg12463550	chr7:65579703	CRCP	0.85	5.6	0.41	9.73e-8	Diabetic kidney disease;
PAAD	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.59	-4.31	-0.33	2.94e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs477692	0.648	rs10829603	chr10:131327351	T/G	cg24747557	chr10:131355152	MGMT	-0.44	-4.75	-0.36	4.63e-6	Response to temozolomide;
PAAD	cis	rs4787951	0.698	rs12933283	chr16:27319378	C/T	cg08008352	chr16:27322356	NA	0.54	4.6	0.35	8.87e-6	Eosinophil percentage of white cells;
PAAD	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.88	-9.14	-0.6	3.76e-16	Cognitive test performance;
PAAD	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.65	6.5	0.47	1.07e-9	Coronary artery disease;
PAAD	cis	rs9913156	0.517	rs2326118	chr17:4611851	C/T	cg23387401	chr17:4582204	PELP1	0.42	4.6	0.35	8.75e-6	Lymphocyte counts;
PAAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.72	-7.78	-0.53	1.03e-12	Lung cancer;
PAAD	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.56	5.77	0.42	4.33e-8	Ulcerative colitis;
PAAD	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.93e-5	Pain;
PAAD	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.87	-8.21	-0.55	8.98e-14	Neurofibrillary tangles;
PAAD	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09065629	chr16:1709722	CRAMP1L	0.46	4.82	0.36	3.4e-6	Coronary artery disease;
PAAD	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.18	9.33	0.6	1.18e-16	Alzheimer's disease (late onset);
PAAD	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg22587600	chr2:46883368	NA	0.33	4.51	0.34	1.28e-5	Height;
PAAD	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21646471	chr2:242523971	THAP4	0.65	5.02	0.38	1.44e-6	Prostate cancer;
PAAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg12564285	chr5:131593104	PDLIM4	0.47	4.86	0.37	2.89e-6	Blood metabolite levels;
PAAD	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-1.0	-5.76	-0.42	4.5e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Tonsillectomy;
PAAD	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg15478930	chr2:27652102	NRBP1	0.54	4.47	0.34	1.53e-5	Blood metabolite levels;
PAAD	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.78	4.52	0.34	1.25e-5	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.03	0.55	2.44e-13	Prudent dietary pattern;
PAAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.53	5.23	0.39	5.49e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.57	-5.33	-0.4	3.55e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.81	-0.48	2.09e-10	Mood instability;
PAAD	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.46	-5.94	-0.43	1.89e-8	Ulcerative colitis;
PAAD	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	0.77	5.79	0.43	3.81e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg02569219	chr17:2266849	SGSM2	0.53	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.84	-9.09	-0.59	4.95e-16	Breast cancer;
PAAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg05484376	chr2:27715224	FNDC4	0.5	5.13	0.38	8.63e-7	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs7255045	0.913	rs10419408	chr19:12942750	C/T	cg14181355	chr19:12984996	MAST1	0.53	5.16	0.39	7.69e-7	Mean corpuscular volume;
PAAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.62	-0.35	8.18e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg22508957	chr16:3507546	NAT15	0.82	5.96	0.44	1.72e-8	Tuberculosis;
PAAD	cis	rs2834902	0.605	rs34169846	chr21:36683285	T/G	cg04915566	chr21:36421472	RUNX1	-0.33	-4.47	-0.34	1.53e-5	Corneal curvature;
PAAD	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg21479132	chr6:26055353	NA	0.93	5.86	0.43	2.75e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10117958	chr1:161719605	DUSP12	0.55	6.35	0.46	2.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.98e-10	Lung cancer;
PAAD	cis	rs1371614	0.610	rs6547317	chr2:27151919	A/G	cg00617064	chr2:27272375	NA	-0.41	-4.41	-0.34	1.91e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.49	-4.55	-0.35	1.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg21546286	chr11:48923668	NA	-0.53	-5.37	-0.4	2.94e-7	HDL cholesterol;
PAAD	cis	rs7260329	0.629	rs2873265	chr19:41505653	G/A	cg06653635	chr19:40910092	PRX	-0.49	-4.56	-0.35	1.05e-5	Smoking behavior;
PAAD	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.54	-5.63	-0.42	8.38e-8	Daytime sleep phenotypes;
PAAD	cis	rs7705042	0.759	rs3765011	chr5:141517665	G/C	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	7.02	0.49	6.83e-11	Educational attainment;
PAAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.67	5.85	0.43	2.86e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg14703610	chr5:56206110	C5orf35	0.61	5.54	0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4906332	1.000	rs35771849	chr14:103981942	A/G	cg26031613	chr14:104095156	KLC1	-0.46	-4.56	-0.35	1.03e-5	Coronary artery disease;
PAAD	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.86	8.85	0.58	2.14e-15	Prostate cancer;
PAAD	trans	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg24842760	chr6:133561719	EYA4	-0.9	-6.81	-0.48	2.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.28e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg27411982	chr8:10470053	RP1L1	0.47	4.91	0.37	2.35e-6	Retinal vascular caliber;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	5.17	0.39	7.2e-7	Prudent dietary pattern;
PAAD	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	4.53	0.34	1.21e-5	IgG glycosylation;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11276388	chr6:12064975	HIVEP1	-0.63	-6.99	-0.49	8.22e-11	Alcohol dependence;
PAAD	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.96	-8.34	-0.56	4.09e-14	Lymphocyte percentage of white cells;
PAAD	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg08648136	chr8:956695	NA	0.43	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs2422052	0.614	rs13004599	chr2:118647505	G/A	cg16911810	chr2:119596346	NA	0.34	4.25	0.33	3.78e-5	Mosquito bite size;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg07777115	chr5:623756	CEP72	-0.51	-4.49	-0.34	1.39e-5	Cystic fibrosis severity;
PAAD	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg18436246	chr17:1640651	WDR81	0.86	8.03	0.55	2.45e-13	Serum albumin level;
PAAD	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.27	19.7	0.85	1.09e-43	IgG glycosylation;
PAAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg24733560	chr20:60626293	TAF4	0.52	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	trans	rs785830	0.558	rs517616	chr9:258376	A/C	cg17093826	chr7:138458720	ATP6V0A4	0.51	6.7	0.48	3.88e-10	Platelet distribution width;
PAAD	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-6.24	-0.45	4.24e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg10518543	chr12:38710700	ALG10B	-0.48	-4.44	-0.34	1.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs2414095	0.527	rs11633715	chr15:51539843	A/G	cg21478137	chr15:51532386	CYP19A1	0.53	5.36	0.4	3.01e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.65	6.94	0.49	1.05e-10	Crohn's disease;
PAAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.18e-14	Bone mineral density;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg05025164	chr4:1340916	KIAA1530	0.5	4.39	0.34	2.09e-5	Obesity-related traits;
PAAD	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg26384229	chr12:38710491	ALG10B	0.72	7.39	0.51	9.12e-12	Morning vs. evening chronotype;
PAAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.54	5.52	0.41	1.41e-7	Caffeine consumption;
PAAD	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.16	14.88	0.77	1.75e-31	IgG glycosylation;
PAAD	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg18898632	chr2:242989856	NA	-0.74	-5.78	-0.42	4.02e-8	Obesity-related traits;
PAAD	cis	rs1062753	0.527	rs6002560	chr22:42356886	C/T	cg04717802	chr22:42394638	WBP2NL	-0.5	-4.87	-0.37	2.8e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs8060686	0.920	rs72556537	chr16:67691477	A/T	cg09835421	chr16:68378352	PRMT7	-1.12	-5.63	-0.42	8.5e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5753037	0.653	rs140121	chr22:30138689	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.79	-0.36	4e-6	Type 1 diabetes;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.94	12.57	0.71	2.64e-25	Prudent dietary pattern;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	1.07	5.11	0.38	9.72e-7	Breast cancer;
PAAD	cis	rs3764618	0.892	rs3764616	chr19:49497022	A/C	cg12515942	chr19:49552529	CGB8	-0.72	-4.39	-0.34	2.07e-5	Follicule stimulating hormone;
PAAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.56	-5.21	-0.39	5.98e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg26816564	chr1:7831052	VAMP3	-0.61	-5.27	-0.39	4.54e-7	Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	trans	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg01620082	chr3:125678407	NA	-1.09	-6.3	-0.46	3.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.67	6.44	0.46	1.5e-9	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.84	7.2	0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs654384	0.933	rs588123	chr7:4164277	G/A	cg27574739	chr7:4176374	SDK1	0.45	4.44	0.34	1.76e-5	Positive affect;
PAAD	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.44	-7.03	-0.5	6.64e-11	Mean corpuscular volume;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg09737314	chr17:6899359	ALOX12	0.52	5.55	0.41	1.23e-7	Tonsillectomy;
PAAD	cis	rs1912528	0.783	rs769663	chr4:140868446	G/A	cg11128457	chr4:140864437	MAML3	-0.32	-4.32	-0.33	2.81e-5	Educational attainment (years of education);
PAAD	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.55	-4.88	-0.37	2.61e-6	P wave terminal force;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.05e-7	Prudent dietary pattern;
PAAD	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg07168214	chr17:7380112	ZBTB4	-0.68	-6.12	-0.44	7.42e-9	Androgen levels;
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.77	0.58	3.32e-15	Lung cancer;
PAAD	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg12218747	chr21:37451666	NA	-0.48	-5.33	-0.4	3.44e-7	Mitral valve prolapse;
PAAD	cis	rs11700980	0.551	rs2832023	chr21:30112996	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27297192	chr10:134578999	INPP5A	0.56	5.44	0.4	2.1e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2030114	0.531	rs8062350	chr16:51597037	C/T	cg03758633	chr16:51611768	NA	-0.51	-4.98	-0.37	1.68e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg03233332	chr7:66118400	NA	0.41	4.53	0.34	1.2e-5	Aortic root size;
PAAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg19254793	chr6:44695348	NA	-0.45	-4.69	-0.36	6.15e-6	Total body bone mineral density;
PAAD	cis	rs59888335	0.929	rs13080156	chr3:80898613	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs6539267	0.775	rs11112997	chr12:106842558	T/C	cg00173435	chr12:106696525	TCP11L2	0.46	4.4	0.34	2.07e-5	Tourette syndrome;
PAAD	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.78	5.96	0.44	1.65e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.98	8.47	0.57	1.9e-14	Alzheimer's disease;
PAAD	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06850241	chr22:41845214	NA	0.55	5.06	0.38	1.21e-6	Vitiligo;
PAAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg16339924	chr4:17578868	LAP3	0.55	5.33	0.4	3.47e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.64	7.19	0.5	2.7e-11	Smoking initiation;
PAAD	cis	rs4748857	0.947	rs7089898	chr10:23591365	C/T	cg18853376	chr10:23633759	C10orf67	0.5	4.37	0.33	2.28e-5	Systemic lupus erythematosus;
PAAD	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg07117364	chr1:16154769	NA	-0.45	-4.35	-0.33	2.51e-5	Dilated cardiomyopathy;
PAAD	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg01812947	chr2:240904978	NDUFA10	-0.61	-5.51	-0.41	1.5e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs731174	0.759	rs575254	chr1:38149692	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.91	7.4	0.51	8.67e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.55	5.47	0.41	1.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.54	-4.74	-0.36	4.86e-6	Fibrinogen levels;
PAAD	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.71	6.74	0.48	3.12e-10	Anterior chamber depth;
PAAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.39	-0.34	2.11e-5	Blood metabolite levels;
PAAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.66	7.45	0.52	6.47e-12	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs4815879	1.000	rs7272705	chr20:5944790	A/G	cg22510814	chr11:68773285	MRGPRF	-1.08	-6.39	-0.46	1.89e-9	Preeclampsia;
PAAD	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.72	7.33	0.51	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg02404636	chr22:31891804	SFI1	0.64	6.19	0.45	5.36e-9	Colorectal cancer;
PAAD	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg05874882	chr4:1763078	NA	-0.39	-5.39	-0.4	2.6e-7	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs12681288	0.821	rs35134698	chr8:1035439	A/G	cg04851639	chr8:1020857	NA	-0.65	-7.84	-0.54	7.45e-13	Schizophrenia;
PAAD	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.89	5.76	0.42	4.42e-8	Severe influenza A (H1N1) infection;
PAAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs7714584	0.793	rs2161363	chr5:150182079	G/C	cg22134413	chr5:150180641	NA	0.91	6.48	0.47	1.18e-9	Crohn's disease;
PAAD	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.78	-0.58	3.08e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs7189233	0.910	rs3809634	chr16:53538157	A/G	cg00221382	chr16:54322308	NA	-0.28	-4.39	-0.34	2.09e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.43	-6.43	-0.46	1.59e-9	Subjective well-being;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg11218175	chr11:495084	RNH1	0.8	4.53	0.35	1.17e-5	Body mass index;
PAAD	cis	rs7608623	0.967	rs4665637	chr2:23954797	C/T	cg08917208	chr2:24149416	ATAD2B	-0.48	-4.62	-0.35	8.25e-6	Obesity-related traits;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.59e-11	Life satisfaction;
PAAD	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.73	6.37	0.46	2.12e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg08856118	chr10:27389908	ANKRD26	0.4	4.33	0.33	2.69e-5	Breast cancer;
PAAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg00250761	chr1:31883323	NA	-0.54	-6.24	-0.45	4.14e-9	Alcohol dependence;
PAAD	cis	rs16854884	0.770	rs7653331	chr3:143810909	G/A	cg06585982	chr3:143692056	C3orf58	0.55	5.41	0.4	2.37e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.58	6.66	0.48	4.71e-10	Schizophrenia;
PAAD	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg00806126	chr19:22604979	ZNF98	0.4	4.98	0.37	1.74e-6	Pain;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22820285	chr1:55008241	NA	-0.74	-6.56	-0.47	7.86e-10	Neuroticism;
PAAD	cis	rs10864907	0.806	rs11123152	chr2:113707112	G/C	cg06156847	chr2:113672199	IL1F7	-0.42	-4.34	-0.33	2.62e-5	Pulmonary function;
PAAD	trans	rs7915414	0.951	rs2094296	chr10:96423405	C/T	cg00735080	chr21:47285121	PCBP3	0.51	6.4	0.46	1.84e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	0.91	6.25	0.45	4.01e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11669133	1.000	rs11667377	chr19:11076192	A/G	cg18582342	chr19:11591989	ELAVL3	-0.66	-4.43	-0.34	1.81e-5	LDL cholesterol;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg15226275	chr6:116381976	FRK	-0.39	-7.28	-0.51	1.7e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.53	5.82	0.43	3.35e-8	Coronary artery disease;
PAAD	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.58	-7.08	-0.5	5.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11235843	0.853	rs55910552	chr11:73525917	A/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.18e-5	Hand grip strength;
PAAD	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.98	10.77	0.66	1.9e-20	Corneal astigmatism;
PAAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg03098721	chr1:84464084	TTLL7	0.47	4.4	0.34	1.99e-5	Obesity-related traits;
PAAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	4.37	0.33	2.27e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07685180	chr8:600429	NA	0.83	5.32	0.4	3.71e-7	IgG glycosylation;
PAAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12165864	chr7:66369176	NA	-0.7	-4.47	-0.34	1.51e-5	Diabetic kidney disease;
PAAD	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg11993925	chr19:44307056	LYPD5	0.51	6.9	0.49	1.3100000000000001e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22804418	chr4:1982702	WHSC1	-0.62	-6.39	-0.46	1.92e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs2412459	1.000	rs3816899	chr15:40314526	G/A	cg10636054	chr15:40330586	SRP14	0.86	4.93	0.37	2.17e-6	Response to haloperidol in psychosis;
PAAD	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.57	-5.71	-0.42	5.64e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.3	0.6	1.48e-16	Cognitive test performance;
PAAD	cis	rs1359582	0.793	rs2057641	chr10:90400148	G/C	cg15661332	chr10:90342814	RNLS	0.57	5.03	0.38	1.38e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19346786	chr7:2764209	NA	-0.38	-5.27	-0.39	4.51e-7	Height;
PAAD	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2051773	0.567	rs6486348	chr11:17057774	T/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs55728055	0.661	rs16989617	chr22:31839151	T/C	cg01338084	chr22:32026380	PISD	1.51	7.67	0.53	1.9e-12	Age-related hearing impairment;
PAAD	cis	rs9900972	0.877	rs8082025	chr17:76876464	C/T	cg00961940	chr17:76876995	TIMP2	0.58	5.37	0.4	2.91e-7	Obesity-related traits;
PAAD	cis	rs6782025	0.837	rs7432332	chr3:121053289	C/A	cg16417163	chr3:121280760	NA	-0.44	-4.59	-0.35	9.41e-6	Aging (facial);
PAAD	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-13.8	-0.75	1.36e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.98	13.55	0.74	6.3e-28	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs899997	1.000	rs755998	chr15:79032469	C/T	cg04896959	chr15:78267971	NA	0.64	6.14	0.45	6.79e-9	Coronary artery disease or large artery stroke;
PAAD	cis	rs2899832	0.866	rs73239030	chr14:35720720	A/G	cg09327582	chr14:35236912	BAZ1A	0.58	4.76	0.36	4.55e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.58	-7.21	-0.51	2.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-5.25	-0.39	4.97e-7	Reticulocyte count;
PAAD	cis	rs7631605	0.905	rs7651903	chr3:37006686	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.59e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.98	-8.84	-0.58	2.26e-15	Vitiligo;
PAAD	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.65	-7.78	-0.53	1.04e-12	Sense of smell;
PAAD	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg12165864	chr7:66369176	NA	-0.85	-4.68	-0.35	6.43e-6	Diabetic kidney disease;
PAAD	cis	rs11811982	0.793	rs111996994	chr1:227567209	A/G	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.15	-13.64	-0.74	3.68e-28	Type 1 diabetes nephropathy;
PAAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.73	-0.53	1.4e-12	Exhaled nitric oxide output;
PAAD	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.82	12.21	0.7	2.46e-24	Endometriosis;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3126085	0.560	rs45541239	chr1:152346391	T/G	cg26876637	chr1:152193138	HRNR	-0.64	-4.63	-0.35	7.78e-6	Atopic dermatitis;
PAAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg03315344	chr16:75512273	CHST6	-0.68	-5.61	-0.41	9.42e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.49	0.41	1.67e-7	Electroencephalogram traits;
PAAD	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14442939	chr10:27389572	ANKRD26	0.57	5.23	0.39	5.42e-7	Breast cancer;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg14515779	chr1:101123966	NA	-0.54	-6.62	-0.47	5.69e-10	Monocyte count;
PAAD	cis	rs7382539	1.000	rs4078087	chr6:169665885	T/C	cg16479247	chr6:168716332	DACT2	-0.58	-5.43	-0.4	2.21e-7	Liver disease severity in Alagille syndrome;
PAAD	trans	rs901683	1.000	rs78913745	chr10:46019911	A/T	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.76	-8.14	-0.55	1.31e-13	Cognitive function;
PAAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.56	-5.48	-0.41	1.76e-7	Obesity-related traits;
PAAD	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg01620082	chr3:125678407	NA	-1.43	-8.54	-0.57	1.33e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.09	14.37	0.76	4.08e-30	Primary sclerosing cholangitis;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.58	6.25	0.45	3.85e-9	Lung cancer;
PAAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg09945482	chr18:12777974	NA	-0.61	-5.2	-0.39	6.37e-7	Inflammatory skin disease;
PAAD	cis	rs367943	0.698	rs13167361	chr5:112961789	C/G	cg12552261	chr5:112820674	MCC	0.53	5.48	0.41	1.71e-7	Type 2 diabetes;
PAAD	cis	rs669446	0.591	rs483679	chr1:44108119	T/A	cg12908607	chr1:44402522	ARTN	-0.41	-4.38	-0.33	2.22e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.79	-7.91	-0.54	4.79e-13	Tuberculosis;
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.49	-5.05	-0.38	1.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9976767	0.792	rs883869	chr21:43844840	T/C	cg23042151	chr21:43824109	UBASH3A	-0.38	-4.75	-0.36	4.69e-6	Type 1 diabetes;
PAAD	cis	rs6540	0.744	rs75256197	chr11:211841	T/C	cg18011064	chr11:394289	PKP3	0.68	4.35	0.33	2.49e-5	Endometriosis;
PAAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.53	-7.56	-0.52	3.57e-12	Diastolic blood pressure;
PAAD	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg20406979	chr6:167373233	NA	0.37	4.84	0.37	3.12e-6	Crohn's disease;
PAAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6545977	0.527	rs2710647	chr2:63213970	T/C	cg17519650	chr2:63277830	OTX1	0.46	4.26	0.33	3.59e-5	Prostate cancer;
PAAD	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.51	-0.34	1.31e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.57	-6.37	-0.46	2.1e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.72	8.17	0.55	1.11e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12311346	chr5:56204834	C5orf35	-0.54	-4.35	-0.33	2.46e-5	Coronary artery disease;
PAAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.88	-9.02	-0.59	7.51e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-7.23	-0.51	2.2e-11	Rheumatoid arthritis;
PAAD	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg18084798	chr19:33555255	RHPN2	0.48	5.01	0.38	1.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.45	4.25	0.33	3.77e-5	Red blood cell count;
PAAD	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.58	6.7	0.48	3.8e-10	Testicular germ cell tumor;
PAAD	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.43	-4.41	-0.34	1.96e-5	Sarcoidosis;
PAAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg10518543	chr12:38710700	ALG10B	0.52	4.97	0.37	1.81e-6	Morning vs. evening chronotype;
PAAD	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg04106633	chr4:1044584	NA	0.65	5.46	0.4	1.94e-7	Recombination rate (females);
PAAD	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg21300403	chr2:198650112	BOLL	-0.69	-4.5	-0.34	1.35e-5	Ulcerative colitis;
PAAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg05785598	chr3:49045655	WDR6	0.4	4.76	0.36	4.52e-6	Parkinson's disease;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg15025200	chr1:152161237	NA	0.46	4.35	0.33	2.52e-5	Inflammatory skin disease;
PAAD	trans	rs75583333	0.502	rs888917	chr5:159628759	T/C	cg14222307	chr15:61097246	RORA	-0.75	-6.37	-0.46	2.18e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.67	-5.66	-0.42	7.2e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.7	4.54	0.35	1.13e-5	Glycated hemoglobin levels;
PAAD	cis	rs1322639	0.592	rs7743597	chr6:169591678	T/C	cg04662567	chr6:169592167	NA	-0.45	-4.77	-0.36	4.33e-6	Pulse pressure;
PAAD	cis	rs3764400	0.508	rs55696440	chr17:46271146	G/A	cg24322968	chr17:46507895	SKAP1	0.86	5.26	0.39	4.76e-7	Body mass index;
PAAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	1.02	13.99	0.75	4.1e-29	Breast cancer;
PAAD	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.82	9.14	0.6	3.84e-16	Body mass index;
PAAD	trans	rs405795	1.000	rs673029	chr13:89771451	C/T	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Yeast infection;
PAAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.11	-0.5	4.21e-11	Neuroticism;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09141939	chr4:139798470	NA	0.56	6.29	0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs757081	0.738	rs1073443	chr11:17350394	C/T	cg15432903	chr11:17409602	KCNJ11	-0.64	-6.16	-0.45	6.14e-9	Systolic blood pressure;
PAAD	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.35	9.45	0.61	5.97e-17	Diabetic retinopathy;
PAAD	cis	rs73206853	0.534	rs73205059	chr12:110509947	G/A	cg12870014	chr12:110450643	ANKRD13A	0.85	5.06	0.38	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg00181669	chr3:44000978	NA	-0.54	-5.74	-0.42	4.88e-8	Coronary artery disease;
PAAD	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.83	9.71	0.62	1.19e-17	Ulcerative colitis;
PAAD	cis	rs4690686	0.500	rs17062801	chr4:177262381	G/A	cg17059388	chr4:177262070	NA	0.61	6.01	0.44	1.31e-8	Essential tremor;
PAAD	cis	rs3106136	0.678	rs7685514	chr4:95292089	T/C	cg11021082	chr4:95130006	SMARCAD1	0.53	5.11	0.38	9.74e-7	Capecitabine sensitivity;
PAAD	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg08999081	chr20:33150536	PIGU	0.54	5.92	0.43	2.02e-8	Height;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.87	6.58	0.47	7.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.92e-16	Motion sickness;
PAAD	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	5.92e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-5.94	-0.43	1.89e-8	Monocyte percentage of white cells;
PAAD	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.53	-5.13	-0.38	8.65e-7	Cognitive ability;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18250212	chr7:90032604	CLDN12	-0.66	-6.37	-0.46	2.15e-9	Neuroticism;
PAAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	12.22	0.7	2.33e-24	Menopause (age at onset);
PAAD	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg05484376	chr2:27715224	FNDC4	0.48	4.7	0.36	5.9e-6	Oral cavity cancer;
PAAD	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg16386425	chr10:429943	DIP2C	-0.45	-4.66	-0.35	6.75e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs10214930	0.813	rs961724	chr7:27658035	A/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	1.08	7.15	0.5	3.38e-11	IgG glycosylation;
PAAD	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.75	9.35	0.6	1.08e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6787391	0.527	rs9816936	chr3:4757029	A/C	cg11584376	chr3:4789075	ITPR1	-0.48	-5.31	-0.4	3.8e-7	Breast cancer;
PAAD	cis	rs35740288	0.787	rs11635418	chr15:86244178	C/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.45	-0.4	1.95e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	cis	rs743757	0.762	rs12491425	chr3:50575312	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.66	-4.8	-0.36	3.71e-6	Diastolic blood pressure;
PAAD	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.78	-0.53	1.02e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg14348967	chr4:10160060	NA	-0.38	-4.47	-0.34	1.49e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.82	8.37	0.56	3.52e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	5.89	0.43	2.43e-8	Initial pursuit acceleration;
PAAD	cis	rs17155006	0.664	rs371024	chr7:107741055	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-7.13	-0.5	3.73e-11	Pneumococcal bacteremia;
PAAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.55	5.08	0.38	1.1e-6	Schizophrenia;
PAAD	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.1	-16.7	-0.8	3.28e-36	Myeloid white cell count;
PAAD	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.12	-0.55	1.44e-13	Brugada syndrome;
PAAD	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.68	-7.34	-0.51	1.21e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.78	0.62	8.13e-18	Platelet count;
PAAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.73	-0.36	5.07e-6	Alcohol dependence;
PAAD	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.48	4.59	0.35	9.28e-6	Depression;
PAAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.71	-7.61	-0.53	2.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22442454	chr1:209979470	IRF6	0.61	5.77	0.42	4.41e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.64	6.54	0.47	8.94e-10	Colorectal cancer;
PAAD	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.68	7.37	0.51	1.04e-11	Prostate cancer;
PAAD	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.97	-0.37	1.79e-6	Primary sclerosing cholangitis;
PAAD	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.94	-8.98	-0.59	9.59e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.41	-0.34	1.95e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4478858	0.684	rs12403136	chr1:31728920	A/G	cg00250761	chr1:31883323	NA	-0.53	-5.92	-0.43	2.07e-8	Alcohol dependence;
PAAD	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.63	6.12	0.44	7.67e-9	Mood instability;
PAAD	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.6	5.87	0.43	2.7e-8	Cognitive test performance;
PAAD	cis	rs6707813	0.518	rs3769213	chr2:173910787	C/A	cg00471696	chr2:173955214	ZAK	-0.42	-4.45	-0.34	1.66e-5	Parental longevity (mother's age at death);
PAAD	cis	rs490234	1.000	rs490234	chr9:128303734	T/C	cg14078157	chr9:128172775	NA	0.39	4.25	0.33	3.65e-5	Mean arterial pressure;
PAAD	cis	rs62264129	0.500	rs4507229	chr3:112023442	C/G	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.8	-0.36	3.83e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs73019876	0.502	rs7254363	chr19:22257048	C/T	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs6700896	0.931	rs12035753	chr1:66116691	T/G	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.53	5.54	0.41	1.31e-7	Longevity;Endometriosis;
PAAD	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg04995300	chr3:66848608	NA	0.42	4.45	0.34	1.67e-5	Type 2 diabetes;
PAAD	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg25150519	chr12:98850993	NA	0.55	5.48	0.41	1.71e-7	Colorectal adenoma (advanced);
PAAD	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-6.73	-0.48	3.24e-10	Breast cancer;
PAAD	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg26935685	chr1:15502881	TMEM51	-0.51	-4.32	-0.33	2.8e-5	Systolic blood pressure;
PAAD	cis	rs2072732	0.904	rs2993481	chr1:2973433	A/T	cg15211996	chr1:2936768	ACTRT2	0.46	4.39	0.34	2.14e-5	Plateletcrit;
PAAD	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg10631289	chr15:39006617	NA	0.47	4.55	0.35	1.09e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.7	8.11	0.55	1.61e-13	Colorectal cancer;
PAAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.54	-6.62	-0.47	5.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.49	5.09	0.38	1.03e-6	Life satisfaction;
PAAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26808779	chr11:119487753	NA	-0.63	-6.46	-0.46	1.31e-9	Obesity-related traits;
PAAD	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.54	-0.41	1.33e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23648919	chr2:156787418	NA	0.54	6.32	0.46	2.77e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.89	0.43	2.35e-8	Eosinophil percentage of white cells;
PAAD	cis	rs9913156	0.696	rs9905711	chr17:4558662	G/A	cg23387401	chr17:4582204	PELP1	-0.49	-4.87	-0.37	2.8e-6	Lymphocyte counts;
PAAD	cis	rs9372498	0.536	rs62421536	chr6:118727972	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-4.29	-0.33	3.12e-5	Diastolic blood pressure;
PAAD	cis	rs6540	0.744	rs879872	chr11:256714	C/T	cg04492369	chr11:491289	PTDSS2	-1.06	-4.47	-0.34	1.51e-5	Endometriosis;
PAAD	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg27373749	chr11:63775612	MACROD1	0.44	5.03	0.38	1.35e-6	Pulse pressure;
PAAD	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.49	-4.8	-0.36	3.71e-6	Hip circumference;
PAAD	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.31	-0.51	1.45e-11	Neuroticism;
PAAD	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.72	7.45	0.52	6.51e-12	Body mass index;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.97e-5	Life satisfaction;
PAAD	cis	rs1823874	1.000	rs1823874	chr15:100357435	T/C	cg16400843	chr15:100339927	C15orf51	0.41	5.05	0.38	1.24e-6	IgG glycosylation;
PAAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.7	6.93	0.49	1.12e-10	Blood metabolite levels;
PAAD	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.37	-0.33	2.32e-5	Height;
PAAD	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.48	5.04	0.38	1.29e-6	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06090383	chr4:174292579	SAP30	0.57	6.6	0.47	6.54e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-5.72	-0.42	5.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg17347104	chr14:75034677	LTBP2	-0.49	-4.83	-0.36	3.28e-6	Caffeine consumption;
PAAD	cis	rs146671954	1	rs146671954	chr9:136934203	G/A	cg13789015	chr9:136890014	NCRNA00094	0.55	4.41	0.34	1.98e-5	Red cell distribution width;
PAAD	cis	rs2016586	0.931	rs4821435	chr22:36113039	T/C	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.58	-0.35	9.77e-6	Reticulocyte count;
PAAD	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.52	-5.43	-0.4	2.19e-7	Interleukin-18 levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24862550	chr20:36661640	RPRD1B;KIAA0406	0.7	6.93	0.49	1.13e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18402987	chr7:1209562	NA	0.56	5.6	0.41	9.59e-8	Longevity;Endometriosis;
PAAD	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04731861	chr2:219085781	ARPC2	0.37	4.34	0.33	2.56e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs3779195	0.627	rs6950023	chr7:97915635	T/G	cg24562669	chr7:97807699	LMTK2	0.52	4.6	0.35	8.73e-6	Sex hormone-binding globulin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20424398	chr19:4182802	SIRT6;ANKRD24	0.68	7.93	0.54	4.29e-13	Vitiligo;Type 1 diabetes;
PAAD	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	7.04	0.5	6.09e-11	Leprosy;
PAAD	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.99	7.53	0.52	4.18e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.59	0.52	2.96e-12	Body mass index;
PAAD	cis	rs508970	0.518	rs614168	chr11:60913148	T/C	cg24692310	chr11:60915630	VPS37C	0.35	4.89	0.37	2.53e-6	Rheumatoid arthritis;
PAAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg23939001	chr4:940644	TMEM175	0.82	10.29	0.64	3.52e-19	Sjögren's syndrome;
PAAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg15440763	chr7:158190612	PTPRN2	0.48	4.73	0.36	5.18e-6	Obesity-related traits;
PAAD	cis	rs7608623	0.840	rs7369458	chr2:24183805	G/A	cg08917208	chr2:24149416	ATAD2B	-0.46	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs12780845	1.000	rs45615636	chr10:17210591	C/G	cg00857480	chr10:17188594	TRDMT1	0.37	4.72	0.36	5.32e-6	Homocysteine levels;
PAAD	cis	rs787274	0.764	rs1693411	chr9:115452665	G/C	cg13803584	chr9:115635662	SNX30	0.79	4.71	0.36	5.45e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.73	-0.58	4.25e-15	Eye color traits;
PAAD	cis	rs2278796	0.639	rs4950977	chr1:204970777	T/A	cg17947172	chr1:204966197	NFASC	0.43	4.7	0.36	5.86e-6	Mean platelet volume;
PAAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.52	-5.3	-0.4	3.98e-7	Blood metabolite levels;
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27297192	chr10:134578999	INPP5A	0.61	5.87	0.43	2.66e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.59	-6.51	-0.47	1.04e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg25620797	chr2:55921863	PNPT1	-0.47	-4.28	-0.33	3.33e-5	Metabolic syndrome;
PAAD	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs910039	0.556	rs4716146	chr6:17513954	T/C	cg22959611	chr6:18122991	NHLRC1	-0.45	-4.35	-0.33	2.49e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-6.52	-0.47	9.97e-10	Longevity;Endometriosis;
PAAD	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.19	12.1	0.7	4.87e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7678555	0.540	rs13119564	chr4:120847097	A/T	cg09307838	chr4:120376055	NA	0.47	4.3	0.33	3.1e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.66	7.79	0.53	1e-12	Mean corpuscular volume;
PAAD	cis	rs7572733	0.935	rs11690205	chr2:198933948	C/T	cg10820045	chr2:198174542	NA	0.44	4.37	0.33	2.28e-5	Dermatomyositis;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg00450029	chr8:599525	NA	-0.82	-5.04	-0.38	1.33e-6	IgG glycosylation;
PAAD	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg21016266	chr12:122356598	WDR66	-0.47	-4.75	-0.36	4.6e-6	Mean corpuscular volume;
PAAD	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.48	4.61	0.35	8.37e-6	Depression;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.89e-9	Lung cancer;
PAAD	cis	rs89107	0.543	rs72952795	chr6:118894271	G/T	cg21191810	chr6:118973309	C6orf204	0.38	4.46	0.34	1.56e-5	Cardiac structure and function;
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.19	0.39	6.66e-7	Birth weight;
PAAD	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-1.0	-10.22	-0.64	5.59e-19	Menarche (age at onset);
PAAD	cis	rs2051773	0.567	rs7924495	chr11:17038728	G/T	cg15084286	chr11:17036142	PLEKHA7	-0.57	-5.17	-0.39	7.25e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.63	0.53	2.43e-12	Resting heart rate;
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg11601000	chr22:42348013	LOC339674	-0.45	-5.46	-0.41	1.89e-7	Intelligence;
PAAD	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-4.44	-0.34	1.7e-5	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.86	10.72	0.66	2.55e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.69	4.99	0.38	1.64e-6	Anti-saccade response;
PAAD	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg18357526	chr6:26021779	HIST1H4A	0.5	4.47	0.34	1.5e-5	Height;
PAAD	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.04	0.5	6.19e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg23018236	chr17:30244563	NA	-0.57	-4.33	-0.33	2.7e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg04068111	chr13:44716778	NA	-0.46	-5.02	-0.38	1.41e-6	Schizophrenia;
PAAD	cis	rs2016586	0.802	rs5755925	chr22:36114994	A/G	cg26342177	chr22:36113512	APOL5	-0.48	-4.79	-0.36	3.91e-6	Body mass index;
PAAD	cis	rs1468734	1.000	rs34122066	chr16:5003288	G/A	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg05697835	chr1:2722811	NA	0.42	4.64	0.35	7.38e-6	Ulcerative colitis;
PAAD	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.32	-0.33	2.82e-5	Ulcerative colitis;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.21	0.73	5.09e-27	Platelet count;
PAAD	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-5.13	-0.38	8.89e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	9.01	0.59	8.18e-16	Motion sickness;
PAAD	cis	rs939584	0.932	rs1320336	chr2:650012	G/A	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.73	8.48	0.57	1.8e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg03233332	chr7:66118400	NA	-0.41	-4.3	-0.33	3.02e-5	Aortic root size;
PAAD	cis	rs10755723	1	rs10755723	chr6:42593718	T/A	cg10605015	chr6:42532144	UBR2	0.68	5.14	0.38	8.5e-7	Lung cancer in never smokers;
PAAD	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.76	0.36	4.38e-6	Menopause (age at onset);
PAAD	cis	rs13053817	1.000	rs12485237	chr22:29837286	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.54	-4.62	-0.35	8.18e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.69	6.62	0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs75920871	1.000	rs59294170	chr11:116841446	A/T	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg11508081	chr17:41442227	NA	0.41	4.31	0.33	2.95e-5	Menopause (age at onset);
PAAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.83	7.89	0.54	5.59e-13	Vitiligo;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14630369	chr13:100803190	PCCA	0.58	6.69	0.48	3.95e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg03948781	chr1:205179583	DSTYK	-0.46	-4.34	-0.33	2.61e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6604026	0.656	rs2774945	chr1:93346239	T/C	cg13858687	chr1:93297071	RPL5	-0.48	-4.4	-0.34	2e-5	Multiple sclerosis;
PAAD	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.64	-6.4	-0.46	1.85e-9	Fibrinogen levels;
PAAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.93	10.78	0.66	1.74e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.63	0.57	7.63e-15	Lung cancer;
PAAD	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.49	-0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.65	5.72	0.42	5.56e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.5	4.44	0.34	1.72e-5	Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25535317	chr19:12833478	TNPO2	-0.81	-7.04	-0.5	6.04e-11	Neuroticism;
PAAD	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-5.99	-0.44	1.47e-8	Hypospadias;
PAAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.37	-0.4	2.86e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.79	-7.95	-0.54	3.94e-13	Itch intensity from mosquito bite;
PAAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.71	0.53	1.57e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg06307176	chr5:131281290	NA	-0.65	-5.45	-0.4	2.01e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs804292	0.724	rs8191518	chr8:11627261	C/G	cg26752888	chr8:11627280	NEIL2	1.16	9.84	0.62	5.44e-18	Alcohol dependence;Nicotine use;
PAAD	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg06268327	chr11:63885740	FLRT1;MACROD1	-0.41	-4.29	-0.33	3.15e-5	Platelet count;
PAAD	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.2	-0.39	6.39e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg16362232	chr11:430036	ANO9	0.84	5.23	0.39	5.43e-7	Body mass index;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg17650747	chr5:1873721	NA	0.46	4.7	0.36	5.78e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.76	-12.08	-0.7	5.8e-24	Body mass index;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.74	7.95	0.54	4.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.94e-8	Tonsillectomy;
PAAD	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.48	-0.41	1.7e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6681460	1.000	rs6656550	chr1:67122552	C/T	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.85e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs75757892	0.544	rs9505143	chr6:7318554	T/C	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg21191810	chr6:118973309	C6orf204	0.49	6.19	0.45	5.3300000000000004e-09	Electrocardiographic conduction measures;
PAAD	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.64	-5.94	-0.43	1.86e-8	Multiple myeloma;
PAAD	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.37	12.7	0.72	1.17e-25	Uric acid levels;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs35661897	0.512	rs35025897	chr2:227360822	G/A	cg27243623	chr2:228093069	COL4A3	0.34	4.46	0.34	1.61e-5	Urinary tract infection frequency;
PAAD	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.8	7.65	0.53	2.12e-12	Neuroticism;
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-4.51	-0.34	1.3e-5	Acylcarnitine levels;
PAAD	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.52	-5.07	-0.38	1.12e-6	Menarche (age at onset);
PAAD	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.44	-5.0	-0.38	1.58e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.32e-14	Hemoglobin concentration;
PAAD	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23455341	chr17:54991409	TRIM25	-0.63	-6.63	-0.47	5.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg02524346	chr8:600233	NA	-1.07	-7.14	-0.5	3.5e-11	IgG glycosylation;
PAAD	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.62	5.68	0.42	6.73e-8	Late-onset Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00721125	chr16:87417448	FBXO31	-0.74	-6.41	-0.46	1.75e-9	Neuroticism;
PAAD	cis	rs709400	0.633	rs2296484	chr14:104003094	C/T	cg12935359	chr14:103987150	CKB	-0.72	-8.3	-0.56	5.33e-14	Body mass index;
PAAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg04497992	chr16:616212	NHLRC4	0.37	4.25	0.33	3.67e-5	Height;
PAAD	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.81	-9.26	-0.6	1.84e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.09	-0.44	9.02e-9	Total body bone mineral density;
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.81	-5.92	-0.43	2.03e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.68	8.39	0.56	3.1e-14	Dupuytren's disease;
PAAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	5.43	0.4	2.22e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.26	0.6	1.87e-16	Post bronchodilator FEV1;
PAAD	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg19000871	chr14:103996768	TRMT61A	0.48	5.55	0.41	1.24e-7	Coronary artery disease;
PAAD	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.25	0.33	3.68e-5	Cancer;
PAAD	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.47	4.59	0.35	9.12e-6	Dupuytren's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14443694	chr20:5107453	CDS2;PCNA	-0.67	-7.16	-0.5	3.21e-11	Smoking initiation;
PAAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.6	7.09	0.5	4.69e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg20487152	chr13:99095054	FARP1	0.61	5.38	0.4	2.71e-7	Neuroticism;
PAAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.95	10.42	0.65	1.64e-19	Diastolic blood pressure;
PAAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg03255953	chr3:127056837	NA	-0.4	-4.51	-0.34	1.31e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.76	8.63	0.57	7.45e-15	Lung cancer;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	0.86	11.12	0.67	2.17e-21	Eosinophil percentage of white cells;
PAAD	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.83	-7.44	-0.52	6.89e-12	Pancreatic cancer;
PAAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg01866162	chr16:67596514	CTCF	0.57	4.27	0.33	3.42e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs732765	0.734	rs11844127	chr14:75139936	C/G	cg01090926	chr14:75137805	KIAA0317	0.52	4.76	0.36	4.52e-6	Non-small cell lung cancer;
PAAD	cis	rs714515	0.569	rs2032529	chr1:172451999	T/G	cg13446689	chr1:172328377	DNM3	-0.44	-5.42	-0.4	2.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg09659197	chr4:152720779	NA	0.37	5.37	0.4	2.87e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.6	-5.21	-0.39	6.17e-7	Type 2 diabetes;
PAAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg17644776	chr2:200775616	C2orf69	0.65	5.96	0.43	1.73e-8	Schizophrenia;
PAAD	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg07541023	chr7:19748670	TWISTNB	-0.53	-4.43	-0.34	1.77e-5	Thyroid stimulating hormone;
PAAD	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg20085588	chr10:81316188	SFTPA2	0.38	4.29	0.33	3.22e-5	Post bronchodilator FEV1;
PAAD	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg15654264	chr1:150340011	RPRD2	-0.49	-4.77	-0.36	4.31e-6	Migraine;
PAAD	cis	rs6466055	0.639	rs11760317	chr7:104711711	T/C	cg04380332	chr7:105027541	SRPK2	-0.65	-7.15	-0.5	3.38e-11	Schizophrenia;
PAAD	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs13102973	0.899	rs13127659	chr4:135900604	G/A	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.54	-5.32	-0.4	3.66e-7	Metabolic syndrome;
PAAD	cis	rs797680	0.856	rs531358	chr1:93676011	C/T	cg04535902	chr1:92947332	GFI1	0.46	4.42	0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg16434002	chr17:42200994	HDAC5	0.57	5.24	0.39	5.34e-7	Total body bone mineral density;
PAAD	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.83	9.42	0.61	7.16e-17	Gout;
PAAD	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.6	5.37	0.4	2.86e-7	Retinal vascular caliber;
PAAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.62	-6.94	-0.49	1.05e-10	Huntington's disease progression;
PAAD	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-5.69	-0.42	6.23e-8	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.75	8.77	0.58	3.29e-15	Morning vs. evening chronotype;
PAAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.87	-8.52	-0.57	1.45e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.68	4.79	0.36	3.99e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.81	7.53	0.52	4.24e-12	Neurofibrillary tangles;
PAAD	cis	rs508970	0.578	rs677385	chr11:60915234	A/T	cg24692310	chr11:60915630	VPS37C	0.33	4.55	0.35	1.11e-5	Rheumatoid arthritis;
PAAD	cis	rs6540	0.744	rs75256197	chr11:211841	T/C	cg23856257	chr11:719828	EPS8L2	-1.1	-4.62	-0.35	8.01e-6	Endometriosis;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.31	0.46	2.85e-9	Platelet count;
PAAD	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg27490568	chr2:178487706	NA	0.43	4.8	0.36	3.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg00359181	chr2:38893519	GALM	-0.59	-4.45	-0.34	1.67e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.68	7.23	0.51	2.17e-11	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17343184	chr2:189834269	NA	0.55	6.62	0.47	5.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8076220	1.000	rs11869278	chr17:11080021	C/T	cg18156845	chr17:11985185	MIR744;MAP2K4	0.64	4.35	0.33	2.46e-5	Obesity-related traits;
PAAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.52	-5.18	-0.39	7.08e-7	IgG glycosylation;
PAAD	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.67	6.24	0.45	4.22e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1075265	0.933	rs2287642	chr2:54335584	C/T	cg04546899	chr2:54196757	PSME4	0.33	4.58	0.35	9.48e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23472261	chr7:142560422	EPHB6	-0.58	-6.55	-0.47	8.22e-10	Obesity-related traits;
PAAD	cis	rs11825064	0.562	rs80265266	chr11:134509727	A/G	cg06603561	chr11:134479413	NA	-0.94	-5.82	-0.43	3.39e-8	Seasonality;
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.52	5.55	0.41	1.26e-7	Menarche (age at onset);
PAAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.5	5.05	0.38	1.26e-6	Menopause (age at onset);
PAAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7824557	0.736	rs6601578	chr8:11136604	A/G	cg20542592	chr8:11973495	FAM66D	0.47	4.29	0.33	3.15e-5	Retinal vascular caliber;
PAAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg12757816	chr2:10669957	NA	0.46	4.96	0.37	1.88e-6	Prostate cancer;
PAAD	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg24220031	chr2:73402428	NA	-0.34	-4.86	-0.37	2.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.7	-4.31	-0.33	2.87e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.38	-0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-1.05	-15.13	-0.78	4e-32	Total body bone mineral density;
PAAD	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21028142	chr17:79581711	NPLOC4	0.58	7.86	0.54	6.41e-13	Eye color traits;
PAAD	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.55	-6.39	-0.46	1.95e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg13374026	chr7:158955107	NA	-0.53	-5.19	-0.39	6.52e-7	Facial morphology (factor 20);
PAAD	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.34	0.33	2.63e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.63	-0.42	8.49e-8	Total cholesterol levels;
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.7	7.75	0.53	1.25e-12	Longevity;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.67	6.58	0.47	7.16e-10	Prudent dietary pattern;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07362569	chr17:61921086	SMARCD2	-0.55	-6.33	-0.46	2.68e-9	Prudent dietary pattern;
PAAD	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg12757816	chr2:10669957	NA	0.45	4.6	0.35	8.69e-6	Prostate cancer;
PAAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.42	4.49	0.34	1.4e-5	Aortic root size;
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.64	-5.67	-0.42	7.08e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4742903	0.875	rs10991192	chr9:107008496	C/T	cg14250997	chr9:106856677	SMC2	0.44	4.78	0.36	4.18e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-6.81	-0.48	2.13e-10	Mitochondrial DNA levels;
PAAD	cis	rs939584	0.877	rs13028737	chr2:630782	G/A	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs732765	0.734	rs35461658	chr14:75207264	T/C	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs12935418	0.616	rs2549855	chr16:81026852	C/G	cg16651780	chr16:81037892	C16orf61	0.64	6.0	0.44	1.37e-8	Mean corpuscular volume;
PAAD	cis	rs7180079	1.000	rs3784381	chr15:64449839	G/T	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.57e-5	Monocyte count;
PAAD	cis	rs7326068	0.595	rs9552284	chr13:21378344	A/G	cg27234864	chr13:21295941	IL17D	0.59	4.9	0.37	2.45e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg22532475	chr10:104410764	TRIM8	0.4	4.56	0.35	1.03e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.23	0.45	4.27e-9	Personality dimensions;
PAAD	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.58	6.23	0.45	4.45e-9	HDL cholesterol;
PAAD	cis	rs2290416	0.710	rs61005957	chr8:144669512	T/G	cg01494348	chr8:144660395	NAPRT1	0.85	4.43	0.34	1.77e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.92	-9.71	-0.62	1.23e-17	Response to antineoplastic agents;
PAAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.5	4.92	0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs4742903	1.000	rs3739736	chr9:106857908	G/A	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.11e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-1.03	-11.43	-0.68	3.14e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg24110177	chr3:50126178	RBM5	-0.46	-4.6	-0.35	8.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-5.59	-0.41	1.05e-7	Mean corpuscular volume;
PAAD	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.3	-0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.98	-11.26	-0.67	9.22e-22	Parkinson's disease;
PAAD	cis	rs939584	1.000	rs2867114	chr2:651380	C/T	cg03610516	chr2:642275	NA	-0.6	-5.54	-0.41	1.33e-7	Body mass index;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs9810890	1.000	rs28694035	chr3:128575365	G/A	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-1.06	-14.84	-0.77	2.32e-31	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg04154034	chr17:28927549	LRRC37B2	0.71	4.39	0.34	2.15e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs427941	0.703	rs201457	chr7:101741338	C/A	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg27182935	chr16:89790473	ZNF276	-0.86	-4.26	-0.33	3.63e-5	Skin colour saturation;
PAAD	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg18436246	chr17:1640651	WDR81	0.85	7.82	0.54	8.01e-13	Serum albumin level;
PAAD	trans	rs834603	0.569	rs834602	chr7:47446215	A/C	cg00876541	chr19:10515578	MIR1181;CDC37	0.66	6.53	0.47	9.23e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.74	5.24	0.39	5.25e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.63	6.51	0.47	1.05e-9	Multiple sclerosis;
PAAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg07703079	chr11:430292	ANO9	0.78	4.45	0.34	1.66e-5	Body mass index;
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.56	5.37	0.4	2.86e-7	Body mass index;Social communication problems;
PAAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.79	-8.69	-0.58	5.37e-15	Height;
PAAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.65	-5.94	-0.43	1.89e-8	Psoriasis;
PAAD	cis	rs12311304	1.000	rs12309172	chr12:15403226	C/T	cg08258403	chr12:15378311	NA	0.35	4.52	0.34	1.26e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.72	7.25	0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.42	0.56	2.68e-14	Bone mineral density;
PAAD	cis	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16397071	chr2:15731827	DDX1	0.64	6.64	0.47	5.13e-10	Obesity-related traits;
PAAD	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	6.7	0.48	3.9e-10	Blood protein levels;
PAAD	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.73	-0.48	3.21e-10	HDL cholesterol;
PAAD	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-5.68	-0.42	6.51e-8	Crohn's disease;
PAAD	cis	rs12044355	0.827	rs7536118	chr1:231822189	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.87	0.43	2.59e-8	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs76419734	0.510	rs961473	chr4:106535402	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.69	4.61	0.35	8.4e-6	Post bronchodilator FEV1;
PAAD	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg07166546	chr14:35805898	NA	-0.29	-4.38	-0.33	2.19e-5	Psoriasis;
PAAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg14440974	chr22:39074834	NA	-0.57	-6.64	-0.47	5.26e-10	Menopause (age at onset);
PAAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg07362569	chr17:61921086	SMARCD2	0.44	4.89	0.37	2.52e-6	Height;
PAAD	cis	rs6025261	0.761	rs6092390	chr20:55510339	C/T	cg04763273	chr20:55502381	NA	0.47	5.34	0.4	3.27e-7	Verbal memory performance (delayed recall level);
PAAD	cis	rs367943	0.666	rs1850412	chr5:112696768	A/G	cg12552261	chr5:112820674	MCC	0.64	6.36	0.46	2.23e-9	Type 2 diabetes;
PAAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg04844267	chr4:1394941	NA	0.52	5.64	0.42	8e-8	Obesity-related traits;
PAAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg18964960	chr10:1102726	WDR37	0.74	6.29	0.45	3.18e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs564309	0.764	rs12031395	chr1:228538470	C/G	cg01328119	chr1:228783545	DUSP5P	0.71	4.6	0.35	9.02e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs16958440	0.867	rs16949275	chr18:44700703	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.7	4.81	0.36	3.61e-6	Hip geometry;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.62e-7	Bipolar disorder;
PAAD	cis	rs2240255	0.710	rs4999690	chr16:74778006	A/G	cg01733217	chr16:74700730	RFWD3	0.45	4.28	0.33	3.27e-5	White matter lesion progression (adjusted for white matter lesion burden at baseline);
PAAD	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.48	-6.61	-0.47	6.27e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	1.14	8.93	0.59	1.29e-15	Inflammatory bowel disease;
PAAD	cis	rs10924309	0.889	rs10802248	chr1:245858554	A/C	cg00036263	chr1:245852353	KIF26B	-0.67	-5.9	-0.43	2.26e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg07312716	chr22:50439227	IL17REL	-0.4	-4.27	-0.33	3.47e-5	Ulcerative colitis;
PAAD	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.57	5.04	0.38	1.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.49	4.45	0.34	1.66e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg11789530	chr4:8429930	ACOX3	0.78	7.69	0.53	1.7e-12	Response to antineoplastic agents;
PAAD	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-7.8	-0.53	9.19e-13	Body mass index;
PAAD	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.39	0.61	8.36e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1419980	0.730	rs6416274	chr12:7766631	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs12767760	0.714	rs11189270	chr10:99299480	A/G	cg25247692	chr10:99313390	UBTD1	-0.54	-5.44	-0.4	2.1e-7	Obesity-related traits;
PAAD	cis	rs17209837	1.000	rs4148805	chr7:87106365	G/A	cg00919237	chr7:87102261	ABCB4	-0.78	-5.23	-0.39	5.52e-7	Gallbladder cancer;
PAAD	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg00262122	chr8:11665843	FDFT1	0.48	4.6	0.35	8.91e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.49	-5.86	-0.43	2.71e-8	Lewy body disease;
PAAD	cis	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg22101045	chr11:47927509	NA	0.54	4.25	0.33	3.76e-5	Axial length;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-13.25	-0.73	4.03e-27	Dental caries;
PAAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.51	-7.17	-0.5	3.04e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11811982	0.793	rs11799389	chr1:227323787	G/A	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.35	6.24	0.45	4.2e-9	Skin colour saturation;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	1.08	14.88	0.77	1.76e-31	Menarche (age at onset);
PAAD	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.34	0.46	2.51e-9	Body mass index;
PAAD	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg15192750	chr16:69999425	NA	0.75	6.0	0.44	1.39e-8	IgE levels;
PAAD	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.15	-0.45	6.39e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.82	6.15	0.45	6.38e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.06	-11.41	-0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.48	-4.66	-0.35	6.94e-6	Mean platelet volume;
PAAD	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg13931752	chr15:40660718	DISP2	0.51	4.29	0.33	3.13e-5	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.39	0.34	2.08e-5	Bipolar disorder;
PAAD	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.56	5.85	0.43	2.94e-8	Caffeine consumption;
PAAD	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg24618514	chr3:194868507	C3orf21	0.49	4.43	0.34	1.82e-5	Non-small cell lung cancer;
PAAD	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.84	9.32	0.6	1.27e-16	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg24879335	chr3:133465180	TF	-0.6	-6.86	-0.49	1.62e-10	Iron status biomarkers;
PAAD	trans	rs901683	1.000	rs12766764	chr10:46079513	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg05110241	chr16:68378359	PRMT7	-0.99	-5.88	-0.43	2.54e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg24519413	chr1:26490540	NA	0.51	4.53	0.34	1.19e-5	QRS complex (12-leadsum);
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.11	0.44	7.86e-9	Lung cancer;
PAAD	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg14926445	chr8:58193284	C8orf71	-0.6	-4.65	-0.35	7.16e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4455778	0.501	rs10250970	chr7:49052491	T/C	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.26	0.56	6.47e-14	Rheumatoid arthritis;
PAAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg05110241	chr16:68378359	PRMT7	-1.18	-8.58	-0.57	1e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.56	5.77	0.42	4.36e-8	High light scatter reticulocyte count;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.55e-9	Lymphocyte counts;
PAAD	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg11266682	chr4:10021025	SLC2A9	0.59	4.99	0.38	1.62e-6	Psychosis and Alzheimer's disease;
PAAD	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	7.63	0.53	2.41e-12	Cognitive test performance;
PAAD	cis	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg21775007	chr8:11205619	TDH	-0.48	-4.41	-0.34	1.93e-5	Neuroticism;
PAAD	cis	rs1497828	1.000	rs1497828	chr1:217527024	C/G	cg04411442	chr1:217543379	NA	0.46	4.48	0.34	1.43e-5	Dialysis-related mortality;
PAAD	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.49	-4.94	-0.37	2.05e-6	Plasma plasminogen activator levels;
PAAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.6	6.28	0.45	3.37e-9	Body mass index;
PAAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.7	8.09	0.55	1.73e-13	Melanoma;
PAAD	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg06565975	chr8:143823917	SLURP1	-0.23	-4.89	-0.37	2.49e-6	Urinary tract infection frequency;
PAAD	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.5	4.46	0.34	1.6e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg19567339	chr10:100142640	NA	0.5	4.85	0.37	3.05e-6	Metabolite levels;
PAAD	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.27	0.33	3.39e-5	Bipolar disorder;
PAAD	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg27411982	chr8:10470053	RP1L1	0.5	5.53	0.41	1.34e-7	Neuroticism;
PAAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.34	16.32	0.8	3.13e-35	Eosinophil percentage of granulocytes;
PAAD	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.58	5.73	0.42	5.19e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-5.32	-0.4	3.61e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.85	8.64	0.57	7.25e-15	Anterior chamber depth;
PAAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.59	0.35	9.41e-6	Depression;
PAAD	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg21605333	chr4:119757512	SEC24D	1.56	8.89	0.58	1.69e-15	Cannabis dependence symptom count;
PAAD	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-1.05	-5.87	-0.43	2.66e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.53	5.42	0.4	2.32e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg08847533	chr14:75593920	NEK9	0.59	6.07	0.44	9.67e-9	IgG glycosylation;
PAAD	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.71	-6.43	-0.46	1.57e-9	Blood protein levels;
PAAD	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	4.63	0.35	7.85e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.29	0.39	4.29e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.77	-6.97	-0.49	9.23e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.48	-6.11	-0.44	8.19e-9	Menopause (age at onset);
PAAD	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg23127183	chr11:57508653	C11orf31	-0.49	-4.27	-0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg27411982	chr8:10470053	RP1L1	0.44	4.65	0.35	7.27e-6	Triglycerides;
PAAD	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg20813462	chr7:2646259	IQCE	0.66	4.71	0.36	5.6e-6	Urate levels in lean individuals;
PAAD	cis	rs113123495	0.609	rs806702	chr19:5624290	G/T	cg26242866	chr19:5711310	LONP1	1.07	5.28	0.39	4.42e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26789053	chr19:49141115	DBP;SEC1	0.62	6.88	0.49	1.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.55	-4.5	-0.34	1.34e-5	Coronary artery disease;
PAAD	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg26205652	chr12:48591994	NA	0.77	6.98	0.49	8.36e-11	Longevity (90 years and older);
PAAD	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg09998033	chr7:158218633	PTPRN2	-0.76	-7.88	-0.54	5.88e-13	Obesity-related traits;
PAAD	cis	rs16944613	0.510	rs7165476	chr15:91151948	C/T	cg15547629	chr15:90437138	AP3S2	-0.53	-4.5	-0.34	1.37e-5	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19232748	chr6:351361	NA	-0.63	-6.65	-0.47	4.84e-10	Obesity-related traits;
PAAD	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg08601574	chr20:25228251	PYGB	0.59	6.31	0.46	2.87e-9	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9462027	0.628	rs10807141	chr6:34693111	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.37	0.4	2.86e-7	Systemic lupus erythematosus;
PAAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.84	7.71	0.53	1.53e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg20435097	chr10:126320824	FAM53B	-0.48	-4.63	-0.35	7.72e-6	Cocaine dependence;
PAAD	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg05250797	chr16:70222502	NA	0.81	6.11	0.44	8.15e-9	IgE levels;
PAAD	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.75	7.96	0.54	3.64e-13	Mean corpuscular volume;
PAAD	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-4.49	-0.34	1.43e-5	Ulcerative colitis;
PAAD	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.82	8.72	0.58	4.41e-15	Height;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg24044776	chr19:53454761	ZNF816A	-0.52	-5.76	-0.42	4.54e-8	Psoriasis;
PAAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.52	-4.65	-0.35	7.09e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.65	-5.92	-0.43	2.11e-8	Corneal astigmatism;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg11416102	chr8:651193	ERICH1	0.91	5.71	0.42	5.75e-8	IgG glycosylation;
PAAD	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.2	12.33	0.71	1.17e-24	Corneal structure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07046399	chr14:105940820	CRIP2	-0.65	-6.81	-0.48	2.16e-10	Smoking initiation;
PAAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg06740227	chr12:86229804	RASSF9	0.61	5.2	0.39	6.34e-7	Major depressive disorder;
PAAD	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg06307176	chr5:131281290	NA	-0.5	-4.29	-0.33	3.14e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2274459	1.000	rs34139049	chr6:33716784	G/A	cg06253072	chr6:33679850	C6orf125	0.67	4.7	0.36	5.7e-6	Obesity (extreme);
PAAD	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg04257695	chr17:30186438	C17orf79	0.7	5.32	0.4	3.58e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.51	-4.59	-0.35	9.28e-6	IgG glycosylation;
PAAD	cis	rs7081476	0.737	rs12415447	chr10:27488884	A/G	cg20349793	chr10:26911186	NA	0.89	4.82	0.36	3.44e-6	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7180079	0.620	rs620171	chr15:64804862	T/A	cg18210365	chr15:65066710	RBPMS2	0.5	4.32	0.33	2.82e-5	Monocyte count;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg19429281	chr19:53496738	ZNF702P	-0.6	-6.36	-0.46	2.27e-9	Psoriasis;
PAAD	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg19000871	chr14:103996768	TRMT61A	-0.46	-4.99	-0.37	1.66e-6	Reticulocyte count;
PAAD	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg18357526	chr6:26021779	HIST1H4A	0.56	5.02	0.38	1.42e-6	Educational attainment;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg27565382	chr3:53032988	SFMBT1	0.73	4.36	0.33	2.36e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg20381115	chr15:45671148	LOC145663;GATM	-0.4	-4.27	-0.33	3.42e-5	Glomerular filtration rate;
PAAD	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.57	-5.94	-0.43	1.88e-8	Response to antidepressants and depression;
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.83	-7.97	-0.54	3.49e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg15448220	chr1:150897856	SETDB1	-0.64	-6.66	-0.48	4.7e-10	Tonsillectomy;
PAAD	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.48	4.64	0.35	7.44e-6	Airway imaging phenotypes;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-5.32	-0.4	3.67e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg04738700	chr2:239367308	NA	0.4	4.32	0.33	2.79e-5	Multiple system atrophy;
PAAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg15181151	chr6:150070149	PCMT1	0.59	6.47	0.46	1.25e-9	Lung cancer;
PAAD	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.74	-0.42	4.89e-8	YKL-40 levels;
PAAD	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07930192	chr7:1003750	NA	0.39	4.8	0.36	3.76e-6	Longevity;Endometriosis;
PAAD	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg20060109	chr17:81052770	NA	-0.45	-4.46	-0.34	1.61e-5	Reticulocyte fraction of red cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00384577	chr19:41223078	ITPKC;ADCK4	-0.69	-7.11	-0.5	4.27e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg20821713	chr7:1055600	C7orf50	-0.38	-4.4	-0.34	2.06e-5	Longevity;Endometriosis;
PAAD	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.51	0.34	1.31e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4740619	0.682	rs3824502	chr9:16016557	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.44	-0.34	1.75e-5	Body mass index;
PAAD	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.85	10.9	0.66	8.25e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2274459	0.749	rs12190155	chr6:33663241	G/A	cg06253072	chr6:33679850	C6orf125	0.6	4.78	0.36	4.08e-6	Obesity (extreme);
PAAD	trans	rs10198628	0.623	rs779339	chr2:13043884	A/G	cg10688514	chr10:48354852	ZNF488	-0.66	-6.45	-0.46	1.38e-9	Pericardial adipose tissue adjusted for height and weight;Pericardial fat;
PAAD	cis	rs9469913	0.604	rs2764203	chr6:34708901	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.91	9.83	0.62	5.95e-18	Corneal astigmatism;
PAAD	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.54	-4.79	-0.36	4.01e-6	P wave terminal force;
PAAD	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.33	0.46	2.68e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs757978	0.777	rs12475607	chr2:242189231	T/C	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-4.72	-0.36	5.34e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.81	6.18	0.45	5.7e-9	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.65	-0.35	7.24e-6	Colorectal cancer;
PAAD	cis	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg26552638	chr8:10875534	XKR6	-0.37	-4.29	-0.33	3.2e-5	Myopia (pathological);
PAAD	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.56	-6.52	-0.47	9.64e-10	Blood pressure (smoking interaction);
PAAD	cis	rs786425	0.770	rs7958693	chr12:124162750	C/T	cg16237390	chr12:124156159	TCTN2	0.44	4.25	0.33	3.78e-5	Pubertal anthropometrics;
PAAD	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg23024343	chr7:107201750	COG5	0.62	4.74	0.36	4.84e-6	Coronary artery disease;
PAAD	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg14003231	chr6:33640908	ITPR3	0.38	5.05	0.38	1.23e-6	Plateletcrit;
PAAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.53	-0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.36	6.14e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg00912467	chr1:161369970	NA	0.49	4.44	0.34	1.69e-5	IgG glycosylation;
PAAD	cis	rs970548	0.779	rs3891524	chr10:45971689	C/A	cg15590007	chr10:45870220	ALOX5	0.46	4.81	0.36	3.6e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.77	-7.15	-0.5	3.34e-11	Systemic lupus erythematosus;
PAAD	cis	rs7162310	1.000	rs7162310	chr15:63571234	C/T	cg05375668	chr15:63796746	USP3	0.57	4.29	0.33	3.19e-5	Myopia;
PAAD	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.58	-4.95	-0.37	1.93e-6	Total body bone mineral density;
PAAD	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.54	5.07	0.38	1.16e-6	Uric acid clearance;
PAAD	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.8	7.9	0.54	5.08e-13	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.49	4.62	0.35	8.27e-6	Monocyte count;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg24112000	chr20:60950667	NA	-0.5	-5.63	-0.42	8.43e-8	Pelvic organ prolapse;
PAAD	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg14003231	chr6:33640908	ITPR3	0.37	4.77	0.36	4.29e-6	Plateletcrit;
PAAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.76	7.93	0.54	4.43e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59888335	0.964	rs34283181	chr3:80780890	A/T	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.7	6.24	0.45	4.23e-9	Breast cancer;
PAAD	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.77	0.62	8.47e-18	Bladder cancer;
PAAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg05785598	chr3:49045655	WDR6	0.42	4.94	0.37	2.01e-6	Parkinson's disease;
PAAD	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg03909863	chr11:638404	DRD4	-0.6	-5.37	-0.4	2.89e-7	Systemic lupus erythematosus;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.69	7.87	0.54	6.15e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.19	0.7	2.86e-24	Platelet count;
PAAD	trans	rs1015213	0.609	rs80348021	chr8:52866992	C/A	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg11630242	chr17:19881632	AKAP10	-0.49	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs748404	0.578	rs2012467	chr15:43690565	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.41	0.4	2.35e-7	Lung cancer;
PAAD	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.58	5.18	0.39	6.91e-7	Common traits (Other);
PAAD	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	1.39	7.45	0.52	6.38e-12	Skin colour saturation;
PAAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.74	-6.65	-0.47	4.96e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs1499972	0.529	rs1499976	chr3:117801330	C/T	cg07612923	chr3:117604196	NA	0.74	5.3	0.39	4e-7	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6466055	0.661	rs7790653	chr7:104931545	A/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.86	0.37	2.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.89	-0.49	1.41e-10	Gut microbiome composition (summer);
PAAD	cis	rs8121916	0.865	rs912086	chr20:12391974	G/A	cg16404259	chr20:12988931	SPTLC3	-0.45	-4.57	-0.35	1e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg23684787	chr19:1848742	REXO1	-0.51	-4.29	-0.33	3.16e-5	Bipolar disorder;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07677032	chr17:61819896	STRADA	0.54	5.18	0.39	6.81e-7	Prudent dietary pattern;
PAAD	cis	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg27411982	chr8:10470053	RP1L1	0.46	5.38	0.4	2.78e-7	Neuroticism;
PAAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs901683	1.000	rs17157898	chr10:46037209	C/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg06781209	chr11:61594997	FADS2	0.37	4.28	0.33	3.25e-5	Sphingolipid levels;
PAAD	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	1.04	12.41	0.71	7.41e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.39	-0.56	3.11e-14	Urate levels in overweight individuals;
PAAD	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.49	-5.72	-0.42	5.49e-8	Platelet distribution width;
PAAD	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.47	-4.77	-0.36	4.36e-6	PR interval;
PAAD	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.66	6.45	0.46	1.44e-9	Pulse pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15794252	chr8:121824419	SNTB1	-0.78	-6.9	-0.49	1.33e-10	Neuroticism;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03647317	chr4:187891568	NA	-0.6	-7.62	-0.53	2.59e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.79	8.96	0.59	1.07e-15	Lung cancer;
PAAD	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg06636001	chr8:8085503	FLJ10661	0.88	9.5	0.61	4.45e-17	Schizophrenia;
PAAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.41	-4.47	-0.34	1.49e-5	Non-obstructive azoospermia;
PAAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs73416724	1.000	rs17209400	chr6:43328062	A/G	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.52	4.65	0.35	7.2e-6	IFN-related cytopenia;
PAAD	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg01064725	chr1:204461714	NA	0.51	4.87	0.37	2.76e-6	Schizophrenia;
PAAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23066280	chr7:158032496	PTPRN2	0.37	5.55	0.41	1.22e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg19223190	chr17:80058835	NA	0.52	5.35	0.4	3.25e-7	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15511401	chr20:13798846	C20orf7	0.66	7.42	0.52	7.77e-12	Smoking initiation;
PAAD	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.6	5.4	0.4	2.5e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.82	9.25	0.6	1.92e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.35e-10	Monocyte count;
PAAD	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.75	-7.53	-0.52	4.16e-12	Superior crus of antihelix expression;
PAAD	cis	rs12681963	0.614	rs73234781	chr8:30059758	T/C	cg23406830	chr8:30012838	DCTN6	-0.77	-4.41	-0.34	1.95e-5	Migraine;
PAAD	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs2109514	1.000	rs2270189	chr7:116140616	A/G	cg19719915	chr7:115928094	NA	-0.47	-4.42	-0.34	1.85e-5	Prevalent atrial fibrillation;
PAAD	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.47	0.41	1.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg21479132	chr6:26055353	NA	0.89	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg01759136	chr6:27242945	NA	0.41	4.48	0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.5	-0.34	1.32e-5	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg05791153	chr7:19748676	TWISTNB	0.54	4.39	0.34	2.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.46	-4.89	-0.37	2.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs12760731	0.623	rs7547158	chr1:178309399	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.2	0.39	6.41e-7	Obesity-related traits;
PAAD	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.78	-5.88	-0.43	2.56e-8	Coronary artery calcification;
PAAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.51	-4.71	-0.36	5.43e-6	Total body bone mineral density;
PAAD	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg20913747	chr6:44695427	NA	-0.7	-6.82	-0.48	1.97e-10	Total body bone mineral density;
PAAD	cis	rs72827839	0.846	rs74992250	chr17:46272986	G/C	cg23391107	chr17:45924227	SP6	0.61	5.18	0.39	6.88e-7	Ease of getting up in the morning;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	6.59	0.47	6.9e-10	Lung function (FEV1/FVC);
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.5	-4.95	-0.37	1.95e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.69	-8.85	-0.58	2.05e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.52	6.29	0.45	3.27e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs72753537	0.679	rs7860766	chr9:100576006	C/T	cg13688889	chr9:100608707	NA	-0.59	-4.27	-0.33	3.49e-5	Papillary thyroid cancer;Differentiated thyroid cancer;
PAAD	cis	rs3779195	0.929	rs10953259	chr7:98013107	G/T	cg21770322	chr7:97807741	LMTK2	-0.53	-4.85	-0.37	2.96e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg14458575	chr2:238380390	NA	0.49	5.68	0.42	6.7e-8	Prostate cancer;
PAAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg14440974	chr22:39074834	NA	-0.57	-6.73	-0.48	3.2e-10	Menopause (age at onset);
PAAD	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg13191508	chr8:144600686	ZC3H3	-0.97	-5.07	-0.38	1.15e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg14631576	chr9:95140430	CENPP	-0.53	-5.31	-0.4	3.75e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13896783	chr2:159313876	CCDC148;PKP4	0.54	6.37	0.46	2.15e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.39	-5.51	-0.41	1.51e-7	Cutaneous nevi;
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.77	8.58	0.57	1.01e-14	Lung cancer;
PAAD	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.62	5.4	0.4	2.54e-7	Red blood cell count;
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg16590910	chr6:42928470	GNMT	0.5	5.09	0.38	1.06e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3857067	0.806	rs1585651	chr4:95058755	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.46	-0.41	1.87e-7	QT interval;
PAAD	cis	rs35160687	0.814	rs4392258	chr2:86552577	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-4.52	-0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg05621596	chr22:47072043	GRAMD4	-0.93	-9.5	-0.61	4.32e-17	Urate levels in obese individuals;
PAAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.77	8.61	0.57	8.54e-15	Lung cancer;
PAAD	cis	rs5985	0.583	rs7758057	chr6:6307578	C/G	cg22185065	chr6:6318785	F13A1	-0.47	-5.06	-0.38	1.21e-6	End-stage coagulation;
PAAD	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg26695010	chr11:65641043	EFEMP2	0.55	5.16	0.39	7.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg01426195	chr3:39028469	NA	0.64	6.4	0.46	1.8e-9	Handedness;
PAAD	cis	rs7580717	0.785	rs10169399	chr2:232173111	C/A	cg07929768	chr2:232055508	NA	0.52	5.83	0.43	3.26e-8	Multiple myeloma;
PAAD	cis	rs6804624	0.892	rs6770131	chr3:99165973	G/C	cg02646433	chr3:99218170	NA	0.45	4.52	0.34	1.25e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.53	-4.51	-0.34	1.31e-5	Atopic dermatitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15001364	chr5:137688694	KDM3B	-0.76	-6.3	-0.46	3.12e-9	Neuroticism;
PAAD	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.65	9.15	0.6	3.55e-16	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.84	10.39	0.64	1.91e-19	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.71	-4.93	-0.37	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.67	9.15	0.6	3.47e-16	Breast size;
PAAD	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg13494126	chr7:1908745	MAD1L1	0.47	4.35	0.33	2.48e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs761746	0.705	rs5994415	chr22:32004588	G/A	cg01338084	chr22:32026380	PISD	0.54	4.45	0.34	1.67e-5	Intelligence;
PAAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg27490568	chr2:178487706	NA	0.43	4.51	0.34	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg15017067	chr4:17643749	FAM184B	0.42	4.5	0.34	1.35e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg20742385	chr13:113633654	MCF2L	-0.43	-4.33	-0.33	2.71e-5	Systolic blood pressure;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.86	11.8	0.69	3.15e-23	Vitiligo;
PAAD	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg11802864	chr11:65308245	LTBP3	-0.52	-5.18	-0.39	6.83e-7	Plateletcrit;
PAAD	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.75	5.61	0.41	9.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.33	4.97	0.37	1.75e-6	Blood metabolite levels;
PAAD	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg04254540	chr16:71951199	KIAA0174	-0.61	-5.18	-0.39	7.02e-7	Coronary artery disease;
PAAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg01942863	chr7:99769432	GPC2	-0.47	-4.5	-0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.5	-7.33	-0.51	1.3e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03426194	chr16:27500918	GTF3C1	0.56	6.38	0.46	2.06e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	5.68	0.42	6.73e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.6	8.25	0.56	6.82e-14	Eye color traits;
PAAD	cis	rs2790216	1.000	rs2486486	chr10:60046654	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.74	-8.68	-0.58	5.75e-15	Dental caries;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17012575	chr11:125757631	HYLS1	-0.62	-6.4	-0.46	1.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg20607287	chr7:12443886	VWDE	-0.65	-5.18	-0.39	6.85e-7	Coronary artery disease;
PAAD	cis	rs6929137	0.632	rs10872677	chr6:151959249	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.53	-0.34	1.21e-5	Bone mineral density (spine);
PAAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.91	-0.59	1.44e-15	Total body bone mineral density;
PAAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.56	6.17	0.45	6.02e-9	Menopause (age at onset);
PAAD	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.68	-0.36	6.18e-6	Eotaxin levels;
PAAD	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg21724239	chr8:58056113	NA	0.71	5.19	0.39	6.56e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13442495	chr12:25404467	KRAS	-0.76	-6.5	-0.47	1.07e-9	Neuroticism;
PAAD	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00540400	chr15:79124168	NA	0.59	6.62	0.47	5.85e-10	Coronary artery disease;
PAAD	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.24	0.64	4.74e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg25155006	chr6:37138205	PIM1	-0.52	-4.62	-0.35	8.24e-6	QRS duration;
PAAD	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.82	7.11	0.5	4.24e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6594713	0.533	rs2416322	chr5:112966663	T/C	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.49	0.57	1.72e-14	Homoarginine levels;
PAAD	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.54	-4.92	-0.37	2.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg10183150	chr4:120222239	C4orf3	-0.38	-5.33	-0.4	3.44e-7	Corneal astigmatism;
PAAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.59	-0.52	2.98e-12	Corneal structure;
PAAD	cis	rs2320952	0.903	rs8077773	chr17:10487345	C/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.27e-5	Gut microbiome composition (winter);
PAAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.56	-5.72	-0.42	5.39e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg03303774	chr4:1407052	NA	0.34	4.33	0.33	2.7e-5	Obesity-related traits;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10162958	chr13:113673671	MCF2L	0.63	6.84	0.49	1.83e-10	Warfarin maintenance dose;
PAAD	cis	rs6957745	1	rs6957745	chr7:73056750	T/C	cg07467649	chr7:72856462	BAZ1B	0.51	4.55	0.35	1.07e-5	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;
PAAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.75	7.5	0.52	4.9e-12	Tonsillectomy;
PAAD	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.59	5.36	0.4	2.99e-7	Total body bone mineral density;
PAAD	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg19640130	chr10:64028056	RTKN2	0.38	4.51	0.34	1.29e-5	Rheumatoid arthritis;
PAAD	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.7	5.83	0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.67	7.3	0.51	1.52e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.59	-0.41	1.04e-7	Sjögren's syndrome;
PAAD	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03009478	chr14:72134237	SIPA1L1	0.64	6.46	0.46	1.37e-9	Smoking initiation;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate;
PAAD	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.72	8.95	0.59	1.14e-15	Obesity (extreme);
PAAD	cis	rs1879734	0.737	rs2694594	chr1:54174846	G/C	cg14659662	chr1:54151053	GLIS1	0.37	6.03	0.44	1.17e-8	Mitral valve prolapse;
PAAD	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.57	5.45	0.4	1.99e-7	Corneal astigmatism;
PAAD	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.6	-6.41	-0.46	1.77e-9	Mitral valve prolapse;
PAAD	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24729792	chr2:113192114	RGPD8;RGPD5	0.6	4.69	0.36	5.95e-6	Yeast infection;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	6.51	0.47	1.01e-9	Menarche (age at onset);
PAAD	cis	rs6942407	0.546	rs2286268	chr7:86848385	C/T	cg02420886	chr7:86849541	C7orf23	0.69	5.33	0.4	3.47e-7	Food allergy;
PAAD	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg01338255	chr20:30176054	NA	-0.48	-4.37	-0.33	2.34e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.66	6.41	0.46	1.7e-9	Coronary artery disease;
PAAD	cis	rs113779084	0.728	rs11981990	chr7:11963553	A/G	cg15090509	chr7:11872073	THSD7A	0.4	5.09	0.38	1.03e-6	Educational attainment (years of education);
PAAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg23281280	chr6:28129359	ZNF389	0.51	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs2061333	0.842	rs8099869	chr19:44623376	C/T	cg23489630	chr19:44645078	ZNF234	-0.59	-4.4	-0.34	2.02e-5	Alzheimer's disease;
PAAD	cis	rs6715793	0.901	rs6720405	chr2:33408371	A/C	cg26672287	chr2:33391915	LTBP1	-0.43	-4.98	-0.37	1.69e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.73	8.68	0.58	5.56e-15	Lung cancer;
PAAD	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-1.27	-5.69	-0.42	6.25e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg05083358	chr7:2394359	EIF3B	-0.77	-5.62	-0.42	8.71e-8	Multiple sclerosis;
PAAD	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-9.08	-0.59	5.35e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.93	12.92	0.72	3.16e-26	Superior crus of antihelix expression;
PAAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.45	10.15	0.64	8.49e-19	Opioid sensitivity;
PAAD	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.58	5.68	0.42	6.75e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.75	-0.36	4.59e-6	Atopic dermatitis;
PAAD	cis	rs2085601	0.542	rs1708682	chr4:89965285	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-5.57	-0.41	1.13e-7	Hair greying;
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg24687543	chr11:63912206	MACROD1	0.58	4.65	0.35	7.22e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2514805	0.803	rs2514795	chr8:95156137	G/C	cg25183890	chr8:94929275	PDP1	0.7	4.52	0.34	1.24e-5	Diisocyanate-induced asthma;
PAAD	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg04178011	chr8:6876155	DEFA3;DEFA1B;DEFA1	0.44	4.6	0.35	9.03e-6	IgA nephropathy;
PAAD	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.85	6.85	0.49	1.72e-10	Axial length;
PAAD	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-11.92	-0.7	1.48e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.62	-4.28	-0.33	3.26e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg05528293	chr18:74961138	GALR1	0.61	4.93	0.37	2.1e-6	Obesity-related traits;
PAAD	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.45	0.34	1.68e-5	Axial length;
PAAD	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.93	6.55	0.47	8.2e-10	Body mass index;
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.72	-0.36	5.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17281638	chr2:33952673	MYADML	0.62	6.41	0.46	1.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.11	9.29	0.6	1.5e-16	Mitochondrial DNA levels;
PAAD	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-11.51	-0.68	1.91e-22	Height;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg19337854	chr7:99768885	GPC2	0.53	4.98	0.37	1.71e-6	Platelet count;
PAAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg08807892	chr2:162101083	NA	-0.62	-6.25	-0.45	3.88e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg23281280	chr6:28129359	ZNF389	-0.54	-4.86	-0.37	2.88e-6	Parkinson's disease;
PAAD	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.84	-9.84	-0.62	5.67e-18	Prostate cancer;
PAAD	cis	rs1190596	0.525	rs28565231	chr14:102663248	C/T	cg23904247	chr14:102554826	HSP90AA1	0.42	5.03	0.38	1.38e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.41	-8.6	-0.57	9.03e-15	Mean corpuscular volume;
PAAD	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg12870014	chr12:110450643	ANKRD13A	0.67	4.86	0.37	2.85e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14004477	chr1:27719043	GPR3	0.62	6.96	0.49	9.36e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.83e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg01353569	chr7:106810328	HBP1	0.61	6.8	0.48	2.25e-10	Hemostatic factors and hematological phenotypes;
PAAD	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.39	-0.51	9.18e-12	Body mass index;
PAAD	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.66	4.88	0.37	2.69e-6	Exhaled nitric oxide output;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg27094323	chr7:1216898	NA	-0.41	-4.63	-0.35	7.88e-6	Longevity;Endometriosis;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.69	0.36	6.04e-6	Obesity-related traits;
PAAD	cis	rs4074493	1.000	rs6700792	chr1:231170013	C/T	cg22172038	chr1:231176991	FAM89A	-0.5	-4.64	-0.35	7.37e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.81	7.84	0.54	7.32e-13	Coronary artery disease;
PAAD	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg24565620	chr2:194026	NA	-0.69	-5.28	-0.39	4.4e-7	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17114847	chr11:47736795	AGBL2	0.66	7.25	0.51	1.95e-11	Myopia (pathological);
PAAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg05342682	chr7:94953680	PON1	-0.5	-4.33	-0.33	2.66e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.71	6.33	0.46	2.55e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.75	5.32	0.4	3.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2885056	0.891	rs11085739	chr19:10694239	A/G	cg04833646	chr19:10679720	CDKN2D	0.95	9.15	0.6	3.63e-16	Red cell distribution width;
PAAD	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.59	-4.27	-0.33	3.37e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.27e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.48	5.1	0.38	1.02e-6	Dementia with Lewy bodies;
PAAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.7	8.41	0.56	2.79e-14	Vitiligo;
PAAD	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg12046867	chr14:103022105	NA	-0.66	-5.32	-0.4	3.71e-7	Platelet count;
PAAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.53	5.73	0.42	5.33e-8	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs7119038	0.629	rs10892273	chr11:118602809	G/A	cg04176122	chr11:118779835	BCL9L	0.43	4.75	0.36	4.75e-6	Sjögren's syndrome;
PAAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.78	9.93	0.63	3.26e-18	Bone mineral density;
PAAD	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg18898632	chr2:242989856	NA	-0.73	-5.71	-0.42	5.65e-8	Obesity-related traits;
PAAD	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg20003494	chr4:90757398	SNCA	0.43	4.82	0.36	3.43e-6	Dementia with Lewy bodies;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.4	-5.42	-0.4	2.32e-7	Age at first birth;
PAAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg25070565	chr17:20044324	CYTSB	0.45	4.29	0.33	3.15e-5	Obesity-related traits;
PAAD	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs516243	0.807	rs578554	chr1:10741669	A/C	cg02903756	chr1:10750680	CASZ1	-0.48	-5.27	-0.39	4.6e-7	Migraine - clinic-based;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.55	-6.79	-0.48	2.34e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg16205897	chr5:131564050	P4HA2	-0.43	-4.7	-0.36	5.76e-6	Breast cancer;
PAAD	cis	rs58521262	1.000	rs11670032	chr19:23166913	T/C	cg22640819	chr19:22990650	NA	0.36	4.4	0.34	2.06e-5	Testicular germ cell tumor;
PAAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.46	10.37	0.64	2.21e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.44	-0.4	2.11e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.82	0.58	2.46e-15	Menopause (age at onset);
PAAD	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	4.98	0.37	1.72e-6	Tonsillectomy;
PAAD	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7873102	0.534	rs2243887	chr9:37990199	C/T	cg03528946	chr9:38069800	SHB	0.52	5.21	0.39	6.15e-7	Brain structure;
PAAD	cis	rs55823223	0.504	rs2034946	chr17:73863589	T/G	cg08125733	chr17:73851984	WBP2	0.9	8.38	0.56	3.26e-14	Psoriasis;
PAAD	cis	rs1642645	0.831	rs12042133	chr1:42499365	A/C	cg01990334	chr1:42801334	FOXJ3	0.47	4.25	0.33	3.7e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs3996993	0.809	rs9474334	chr6:52733458	A/G	cg20803780	chr6:52668592	GSTA1	-0.36	-4.59	-0.35	9.2e-6	Hemoglobin concentration;
PAAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.79	-0.53	9.79e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg26338869	chr17:61819248	STRADA	0.87	9.65	0.62	1.76e-17	Prudent dietary pattern;
PAAD	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.8	9.4	0.61	8.11e-17	Morning vs. evening chronotype;
PAAD	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs2213920	0.749	rs4637918	chr9:118258247	G/T	cg13918206	chr9:118159781	DEC1	0.93	5.98	0.44	1.54e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-4.35	-0.33	2.5e-5	Height;
PAAD	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg09517075	chr8:22133004	PIWIL2	0.58	7.46	0.52	6.16e-12	Hypertriglyceridemia;
PAAD	cis	rs2281636	1.000	rs2281636	chr10:101492403	T/G	cg05149213	chr10:101381631	SLC25A28	-0.48	-4.58	-0.35	9.47e-6	Obesity-related traits;
PAAD	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.56	5.73	0.42	5.29e-8	Systolic blood pressure;
PAAD	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02985541	chr2:219472218	PLCD4	0.29	4.47	0.34	1.54e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg13695288	chr21:47294981	PCBP3	-0.49	-4.54	-0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.45	0.57	2.24e-14	Coffee consumption (cups per day);
PAAD	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.11	15.52	0.78	3.78e-33	Cognitive function;
PAAD	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.49	5.68	0.42	6.56e-8	Coronary artery disease;
PAAD	cis	rs2662368	0.542	rs13170774	chr5:77117759	A/G	cg02570643	chr5:77531473	AP3B1	0.4	4.32	0.33	2.8e-5	Platelet distribution width;
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg19337854	chr7:99768885	GPC2	0.55	5.08	0.38	1.1e-6	Platelet count;
PAAD	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg13798912	chr7:905769	UNC84A	0.58	4.4	0.34	2.05e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.45	4.59	0.35	9.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg06637938	chr14:75390232	RPS6KL1	0.45	4.37	0.33	2.31e-5	Height;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg07153921	chr17:41440717	NA	0.41	4.46	0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	11.33	0.68	5.94e-22	Menopause (age at onset);
PAAD	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.79	0.36	3.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs4658101	0.906	rs2136115	chr1:92073707	T/C	cg06318676	chr1:92077357	NA	-0.38	-4.29	-0.33	3.19e-5	Optic disc area;Vertical cup-disc ratio;
PAAD	cis	rs7998202	0.614	rs394369	chr13:113370228	A/G	cg19217778	chr13:113420270	ATP11A	0.6	4.31	0.33	2.89e-5	Glycated hemoglobin levels;
PAAD	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-4.55	-0.35	1.08e-5	Menopause (age at onset);
PAAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs16958440	0.867	rs74346439	chr18:44677467	G/C	cg17192377	chr18:44677553	HDHD2	0.98	5.75	0.42	4.73e-8	Sitting height ratio;
PAAD	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg23346134	chr3:49453900	TCTA	0.42	4.45	0.34	1.68e-5	Menarche (age at onset);
PAAD	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg17105886	chr17:28927953	LRRC37B2	0.86	5.17	0.39	7.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.59	4.93	0.37	2.09e-6	Schizophrenia;
PAAD	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.45	-4.91	-0.37	2.32e-6	Prevalent atrial fibrillation;
PAAD	cis	rs17407555	0.789	rs4348091	chr4:10115363	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.17	-0.39	7.29e-7	Schizophrenia (age at onset);
PAAD	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.68	4.84	0.37	3.13e-6	Inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11024027	chr15:43029242	CDAN1	-0.8	-6.7	-0.48	3.9e-10	Neuroticism;
PAAD	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg05294307	chr14:35346193	BAZ1A	0.53	5.2	0.39	6.28e-7	Psoriasis;
PAAD	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.59	-6.64	-0.47	5.37e-10	Colorectal cancer;
PAAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.75	9.18	0.6	2.97e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.44	-5.24	-0.39	5.3e-7	Height;
PAAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg11266682	chr4:10021025	SLC2A9	0.57	4.73	0.36	5.09e-6	Blood metabolite levels;
PAAD	cis	rs2637266	0.599	rs846574	chr10:78503082	G/A	cg18941641	chr10:78392320	NA	0.37	4.37	0.33	2.28e-5	Pulmonary function;
PAAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg02781088	chr2:113192302	RGPD8;RGPD5	-0.87	-6.25	-0.45	3.91e-9	Yeast infection;
PAAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg14196790	chr5:131705035	SLC22A5	0.51	5.46	0.4	1.91e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg10467557	chr13:21893662	NA	-0.38	-4.3	-0.33	3.08e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-5.91	-0.43	2.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.51	4.85	0.37	3.09e-6	Systemic lupus erythematosus;
PAAD	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-1.05	-14.98	-0.77	9.56e-32	Metabolite levels;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.92	-7.8	-0.53	9.11e-13	Alzheimer's disease;
PAAD	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg10950924	chr17:47092072	IGF2BP1	0.55	7.13	0.5	3.83e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11348338	chr1:85774063	NA	0.64	6.8	0.48	2.22e-10	Obesity-related traits;
PAAD	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.53	0.41	1.34e-7	Mean corpuscular volume;
PAAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.19	-0.39	6.67e-7	Personality dimensions;
PAAD	cis	rs6942407	0.546	rs10228392	chr7:86799673	A/T	cg02420886	chr7:86849541	C7orf23	0.64	4.88	0.37	2.6e-6	Food allergy;
PAAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.66	8.8	0.58	2.84e-15	Eye color traits;
PAAD	cis	rs4919087	0.590	rs78376466	chr10:99034835	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.48	5.02	0.38	1.41e-6	Tonsillectomy;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.82	-9.09	-0.59	4.95e-16	Prostate cancer;
PAAD	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09695851	chr17:3907499	NA	0.68	6.94	0.49	1.05e-10	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.82	6.05	0.44	1.06e-8	Alzheimer's disease;
PAAD	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.11	-0.38	9.73e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs58749629	1.000	rs58749629	chr20:44571317	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.64	-4.28	-0.33	3.25e-5	Abdominal aortic aneurysm;
PAAD	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.87e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg20821713	chr7:1055600	C7orf50	-0.54	-4.41	-0.34	1.93e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.58	0.35	9.68e-6	Pancreatic cancer;
PAAD	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg20933634	chr6:27740509	NA	-0.88	-6.24	-0.45	4.13e-9	Depression;
PAAD	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.42	-4.62	-0.35	8.3e-6	Blood metabolite levels;
PAAD	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg01305830	chr4:1604576	NA	-0.49	-4.73	-0.36	5.18e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg06131755	chr6:160182447	ACAT2	0.54	4.81	0.36	3.58e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg08923669	chr16:420230	MRPL28	-0.68	-6.48	-0.47	1.18e-9	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.65	-7.19	-0.5	2.79e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26056348	chr7:75932317	HSPB1	0.57	6.55	0.47	8.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	7.84	0.54	7.38e-13	Alzheimer's disease;
PAAD	trans	rs11212737	0.765	rs2640764	chr11:108511063	G/A	cg13462821	chr8:86214814	NA	-0.57	-6.62	-0.47	5.78e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg15061591	chr7:98625706	SMURF1	-0.48	-4.34	-0.33	2.54e-5	Breast cancer;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3781458	0.765	rs12571573	chr10:126323011	G/A	cg20435097	chr10:126320824	FAM53B	0.49	4.64	0.35	7.5e-6	Male-pattern baldness;
PAAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16417436	chr16:28758564	NA	0.43	4.45	0.34	1.66e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg20761395	chr17:511517	VPS53	0.49	5.24	0.39	5.3e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg19337854	chr7:99768885	GPC2	0.53	4.95	0.37	1.95e-6	Platelet count;
PAAD	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.46	0.34	1.57e-5	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.81	0.54	8.68e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-4.55	-0.35	1.1e-5	Morning vs. evening chronotype;
PAAD	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg23649088	chr2:200775458	C2orf69	0.66	5.64	0.42	8.13e-8	Schizophrenia;
PAAD	cis	rs12940923	0.507	rs12942443	chr17:56368393	T/C	cg26072851	chr17:56296444	MKS1	-0.58	-4.89	-0.37	2.56e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs4605213	0.649	rs8077566	chr17:49333241	T/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.57	-5.01	-0.38	1.52e-6	Height;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg04287289	chr16:89883240	FANCA	0.68	7.67	0.53	1.92e-12	Vitiligo;
PAAD	cis	rs4742903	0.904	rs4743691	chr9:106931541	G/A	cg14250997	chr9:106856677	SMC2	0.46	4.94	0.37	1.99e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.8	6.08	0.44	9.12e-9	Gut microbiome composition (summer);
PAAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.82	-8.01	-0.54	2.77e-13	Breast cancer;
PAAD	cis	rs11078597	0.767	rs874424	chr17:1640034	G/A	cg18436246	chr17:1640651	WDR81	0.85	7.73	0.53	1.4e-12	Serum albumin level;
PAAD	cis	rs6460942	0.511	rs13245890	chr7:12543134	A/C	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.34	-0.51	1.2e-11	Coronary artery disease;
PAAD	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.11	-0.5	4.17e-11	Life satisfaction;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22442454	chr1:209979470	IRF6	0.59	5.33	0.4	3.51e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.33	0.33	2.68e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.82	10.5	0.65	9.89e-20	Bone mineral density;
PAAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg10621924	chr7:39171070	POU6F2	0.28	4.73	0.36	5.16e-6	IgG glycosylation;
PAAD	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-5.94	-0.43	1.9e-8	Menarche (age at onset);
PAAD	cis	rs2562456	0.833	rs1781872	chr19:21477403	T/G	cg21994712	chr19:21861136	NA	-0.44	-4.26	-0.33	3.53e-5	Pain;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg09202227	chr16:68482715	SMPD3	-0.69	-6.37	-0.46	2.14e-9	Blood protein levels;
PAAD	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs9463078	0.691	rs9381361	chr6:45011417	A/C	cg25276700	chr6:44698697	NA	-0.54	-6.05	-0.44	1.07e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.56	5.57	0.41	1.14e-7	Breast cancer;
PAAD	cis	rs12444156	1	rs12444156	chr16:71841257	C/T	cg08717414	chr16:71523259	ZNF19	-1.04	-6.87	-0.49	1.54e-10	Post bronchodilator FEV1;
PAAD	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.37e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.56	-5.05	-0.38	1.25e-6	Mean platelet volume;
PAAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg05896902	chr15:45671018	LOC145663;GATM	0.49	4.26	0.33	3.57e-5	Homoarginine levels;
PAAD	cis	rs6594713	0.533	rs13183014	chr5:112964664	A/G	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.43	4.39	0.34	2.14e-5	Red cell distribution width;
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg04160749	chr8:58172571	NA	-0.71	-4.89	-0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg15654264	chr1:150340011	RPRD2	-0.5	-4.84	-0.37	3.19e-6	Migraine;
PAAD	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.54	7.46	0.52	6.08e-12	IgA nephropathy;
PAAD	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg10395934	chr14:104002654	TRMT61A	0.52	4.91	0.37	2.3e-6	Body mass index;
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.71	7.7	0.53	1.65e-12	Lung cancer;
PAAD	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-7.85	-0.54	6.83e-13	Chronic sinus infection;
PAAD	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15664640	chr17:80829946	TBCD	0.7	6.42	0.46	1.62e-9	Breast cancer;
PAAD	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-7.14	-0.5	3.67e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.48	-4.81	-0.36	3.61e-6	Hirschsprung disease;
PAAD	cis	rs6988985	0.678	rs9643358	chr8:144003138	G/C	cg10324643	chr8:143916377	GML	0.4	4.48	0.34	1.46e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.8	9.51	0.61	3.97e-17	Methadone dose in opioid dependence;
PAAD	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.46	4.77	0.36	4.27e-6	Educational attainment;
PAAD	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.24e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.4	3.95e-7	Prostate cancer;
PAAD	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg06569542	chr10:98946673	SLIT1	0.49	4.9	0.37	2.44e-6	Monocyte count;
PAAD	cis	rs317865	0.748	rs73234656	chr4:16212702	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.99	6.5	0.47	1.06e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.6	5.75	0.42	4.75e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	1.21	15.96	0.79	2.71e-34	Longevity;
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg26174226	chr8:58114915	NA	-0.59	-4.42	-0.34	1.85e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.52	-4.32	-0.33	2.83e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4343996	0.934	rs4722655	chr7:3342895	C/A	cg21248987	chr7:3385318	SDK1	0.49	5.42	0.4	2.29e-7	Motion sickness;
PAAD	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.25	0.45	3.86e-9	Personality dimensions;
PAAD	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.66	9.18	0.6	2.95e-16	Height;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.4	-0.4	2.48e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	5.4	0.4	2.46e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs7172971	0.688	rs7166789	chr15:42382778	T/C	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.58	5.6	0.41	9.89e-8	Breast cancer;
PAAD	cis	rs13253111	0.967	rs11136036	chr8:28061310	C/T	cg26534493	chr8:28060551	NA	0.44	4.88	0.37	2.65e-6	Childhood body mass index;
PAAD	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg02900213	chr11:20385756	HTATIP2	-0.46	-4.38	-0.33	2.18e-5	Pursuit maintenance gain;
PAAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.89e-5	Height;
PAAD	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg02415014	chr8:143852576	LYNX1	0.49	5.78	0.42	4.04e-8	Urinary tract infection frequency;
PAAD	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	1.07	17.95	0.82	2.16e-39	Colorectal adenoma (advanced);
PAAD	cis	rs6923462	0.867	rs17143141	chr6:7801217	G/A	cg20969151	chr6:7787925	BMP6	-0.57	-4.39	-0.34	2.1e-5	Lung function (forced vital capacity);
PAAD	cis	rs7172677	1.000	rs7178784	chr15:75425444	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.78	-0.36	4.14e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs62025270	0.688	rs17577869	chr15:86314373	C/A	cg13263323	chr15:86062960	AKAP13	0.56	5.03	0.38	1.39e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs16867321	0.671	rs4666665	chr2:181463705	A/G	cg23363182	chr2:181467187	NA	-0.67	-4.52	-0.34	1.23e-5	Obesity;
PAAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.02	0.49	7.02e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4455778	0.600	rs4404870	chr7:49078959	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.44	-0.34	1.75e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6734238	0.739	rs11687782	chr2:113841782	T/A	cg06156847	chr2:113672199	IL1F7	-0.43	-4.35	-0.33	2.51e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.8	-7.59	-0.52	3.04e-12	Breast cancer;
PAAD	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg05338066	chr1:7812865	CAMTA1	0.68	4.96	0.37	1.89e-6	Inflammatory bowel disease;
PAAD	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.78	6.11	0.44	8.09e-9	IgE levels;
PAAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02463440	chr8:22132932	PIWIL2	0.68	8.49	0.57	1.75e-14	Hypertriglyceridemia;
PAAD	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg01620082	chr3:125678407	NA	-0.92	-6.64	-0.47	5.21e-10	Depression;
PAAD	cis	rs2882667	0.654	rs6863054	chr5:138188855	C/T	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	7.62	0.53	2.56e-12	Obesity-related traits;
PAAD	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg05585544	chr11:47624801	NA	-0.49	-5.45	-0.4	2.03e-7	Subjective well-being;
PAAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12165864	chr7:66369176	NA	-0.81	-5.35	-0.4	3.23e-7	Diabetic kidney disease;
PAAD	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.42	0.4	2.29e-7	Systemic lupus erythematosus;
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.7e-6	Testicular germ cell tumor;
PAAD	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-4.26	-0.33	3.55e-5	Putamen volume;
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.13	-0.45	7.35e-9	Lung cancer;
PAAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-14.95	-0.77	1.16e-31	Coronary artery disease;
PAAD	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg13057898	chr1:3703894	LRRC47	0.4	4.25	0.33	3.69e-5	Red cell distribution width;
PAAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.71	7.59	0.52	2.97e-12	Colorectal cancer;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg14159672	chr1:205819179	PM20D1	0.62	6.03	0.44	1.17e-8	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg03538708	chr1:25844672	NA	-0.53	-5.44	-0.4	2.12e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.64	-5.62	-0.41	8.84e-8	Lung cancer;
PAAD	cis	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15216925	chr5:179921655	CNOT6	0.64	6.34	0.46	2.49e-9	Primary biliary cholangitis;
PAAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg03808351	chr9:123631620	PHF19	0.47	5.15	0.39	8.09e-7	Rheumatoid arthritis;
PAAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.09	-0.59	5.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17223645	chr10:465844	DIP2C	-0.64	-6.64	-0.47	5.15e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.76	8.84	0.58	2.21e-15	Lung cancer;
PAAD	cis	rs761746	0.921	rs7291918	chr22:32008039	A/G	cg01338084	chr22:32026380	PISD	0.53	4.6	0.35	8.72e-6	Intelligence;
PAAD	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.75	8.28	0.56	6.03e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.74	6.92	0.49	1.19e-10	Obesity-related traits;
PAAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.51	0.41	1.48e-7	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9217	1.000	rs7209131	chr17:7376411	C/T	cg24479590	chr17:7348322	CHRNB1	0.43	4.81	0.36	3.6e-6	Height;
PAAD	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg09127314	chr1:152161683	NA	-0.73	-4.74	-0.36	4.79e-6	Atopic dermatitis;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.55	-6.8	-0.48	2.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg11218175	chr11:495084	RNH1	0.76	4.42	0.34	1.87e-5	Body mass index;
PAAD	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg00250761	chr1:31883323	NA	-0.54	-6.24	-0.45	4.14e-9	Alcohol dependence;
PAAD	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.59	6.01	0.44	1.34e-8	Inflammatory bowel disease;
PAAD	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	7.36	0.51	1.1e-11	IgG glycosylation;
PAAD	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.48	-0.34	1.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.63	-0.35	7.79e-6	Mean corpuscular volume;
PAAD	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg04389838	chr3:44770851	ZNF501	-0.51	-4.4	-0.34	2.06e-5	Depressive symptoms;
PAAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.4	-0.34	2.04e-5	Skin colour saturation;
PAAD	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.19	0.45	5.3300000000000004e-09	Aortic root size;
PAAD	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1075265	0.729	rs10201364	chr2:54217357	T/C	cg04546899	chr2:54196757	PSME4	0.38	5.62	0.41	8.94e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg21823605	chr1:152486609	CRCT1	0.52	6.62	0.47	5.72e-10	Hair morphology;
PAAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg21395723	chr22:39101663	GTPBP1	-0.45	-4.85	-0.37	2.96e-6	Menopause (age at onset);
PAAD	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.49	-4.33	-0.33	2.71e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.41	0.46	1.72e-9	Lung cancer;
PAAD	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.42	-4.33	-0.33	2.72e-5	Mean corpuscular volume;
PAAD	cis	rs6976053	0.935	rs13226043	chr7:100475838	C/T	cg22425096	chr7:100417404	EPHB4	0.5	4.31	0.33	2.91e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs5009270	0.553	rs2188548	chr7:112235267	C/T	cg23628563	chr7:112262597	NA	0.64	5.61	0.41	9.32e-8	Osteoarthritis (hip);
PAAD	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-9.96	-0.63	2.73e-18	Headache;
PAAD	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.76	6.16	0.45	6.11e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg20913747	chr6:44695427	NA	-0.7	-6.98	-0.49	8.49e-11	Total body bone mineral density;
PAAD	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-4.49	-0.34	1.42e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs939584	1.000	rs6743060	chr2:629510	C/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00603274	chr11:61596626	FADS2	-0.59	-4.59	-0.35	9.09e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.68	-9.11	-0.59	4.48e-16	Hemoglobin concentration;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg19567339	chr10:100142640	NA	0.51	5.07	0.38	1.15e-6	Metabolite levels;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	5.3	0.39	4.08e-7	Prostate cancer;
PAAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg12564285	chr5:131593104	PDLIM4	0.47	4.86	0.37	2.92e-6	Blood metabolite levels;
PAAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.07	15.17	0.78	3.19e-32	Multiple system atrophy;
PAAD	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.42	-5.04	-0.38	1.33e-6	Blood pressure (smoking interaction);
PAAD	cis	rs11892454	0.515	rs11898327	chr2:26090249	T/C	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13560548	chr3:10150139	C3orf24	0.59	5.21	0.39	5.93e-7	Alzheimer's disease;
PAAD	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	4.62	0.35	7.96e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7627468	0.770	rs13326577	chr3:121965246	A/T	cg03198317	chr3:121949109	CASR	0.48	4.42	0.34	1.86e-5	Kidney stones;
PAAD	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.43	-5.64	-0.42	8.17e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs2817937	1.000	rs74478257	chr6:121107136	G/A	cg22125214	chr7:135612081	LUZP6;MTPN	1.11	6.51	0.47	1.01e-9	Primary tooth development (number of teeth);
PAAD	cis	rs3136441	1.000	rs61337452	chr11:46728966	T/C	cg19486271	chr11:47235900	DDB2	0.64	4.83	0.36	3.37e-6	HDL cholesterol;
PAAD	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.48	-4.68	-0.35	6.33e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-5.31	-0.4	3.8e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.98	-6.94	-0.49	1.07e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg18833306	chr6:118973337	C6orf204	0.41	4.3	0.33	3.07e-5	Electrocardiographic conduction measures;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	1.03	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.41	-0.61	7.36e-17	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7551222	0.681	rs10900595	chr1:204511602	C/A	cg01064725	chr1:204461714	NA	-0.52	-4.92	-0.37	2.22e-6	Schizophrenia;
PAAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.13	0.55	1.36e-13	Alzheimer's disease;
PAAD	cis	rs9866391	0.537	rs11714208	chr3:141295050	C/T	cg25967872	chr3:141205623	RASA2	-0.47	-4.26	-0.33	3.51e-5	Myopia;
PAAD	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.28	0.51	1.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7260598	0.539	rs116780835	chr19:24063516	G/A	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg07148914	chr20:33460835	GGT7	0.56	5.61	0.41	9.28e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10792830	0.706	rs565031	chr11:85671501	A/T	cg07180834	chr11:85838833	NA	-0.5	-6.06	-0.44	1.05e-8	Psychosis and Alzheimer's disease;
PAAD	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.84	7.8	0.53	9e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs73058052	0.597	rs2890072	chr19:50087876	T/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.52	-4.45	-0.34	1.66e-5	Fibrinogen levels;
PAAD	cis	rs3749237	0.964	rs10049413	chr3:49892896	A/G	cg02487422	chr3:49467188	NICN1	0.45	4.45	0.34	1.66e-5	Resting heart rate;
PAAD	trans	rs901683	1.000	rs71496611	chr10:46021732	G/A	cg11747279	chr17:21096632	NA	0.78	6.35	0.46	2.41e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15198493	chr7:6626877	ZDHHC4	-0.56	-6.37	-0.46	2.16e-9	Monocyte percentage of white cells;
PAAD	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11412766	chr2:55276306	RTN4	-0.46	-4.29	-0.33	3.22e-5	Alcohol dependence;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27111970	chr5:139492957	PURA	-0.77	-6.47	-0.46	1.29e-9	Neuroticism;
PAAD	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg01798341	chr17:80842262	TBCD	-0.41	-4.53	-0.35	1.17e-5	Breast cancer;
PAAD	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.63	5.24	0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25185536	chr2:37642493	NA	-0.67	-6.58	-0.47	7.05e-10	Obesity-related traits;
PAAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	4.74	0.36	4.93e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25347362	chr19:9938857	UBL5	-0.68	-6.87	-0.49	1.56e-10	Lung cancer in ever smokers;
PAAD	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	0.52	4.58	0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.82	-8.08	-0.55	1.89e-13	Breast cancer;
PAAD	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg20406979	chr6:167373233	NA	0.38	5.1	0.38	1.02e-6	Crohn's disease;
PAAD	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg09796270	chr17:17721594	SREBF1	0.43	4.61	0.35	8.56e-6	Total body bone mineral density;
PAAD	cis	rs1109501	0.666	rs4146575	chr4:71407324	T/C	cg25553522	chr4:71388589	AMTN	0.53	4.51	0.34	1.29e-5	Alcoholism (heaviness of drinking);
PAAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.55	5.3	0.39	4.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.44	4.72	0.36	5.36e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.77	-8.22	-0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg26668713	chr11:65405903	SIPA1	0.63	5.85	0.43	2.93e-8	Blood pressure (age interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01300410	chr10:95653653	TMEM20	0.67	7.55	0.52	3.75e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26856871	chr21:45363775	AGPAT3	0.64	6.5	0.47	1.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg23281280	chr6:28129359	ZNF389	0.54	4.81	0.36	3.53e-6	Parkinson's disease;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.46	5.29	0.39	4.28e-7	Mean arterial pressure;
PAAD	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	0.91	4.35	0.33	2.46e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg06026331	chr20:60912101	LAMA5	0.57	4.62	0.35	8.09e-6	Colorectal cancer;
PAAD	cis	rs2085601	0.542	rs2464513	chr4:89945728	T/C	cg17769793	chr4:89976368	FAM13A	-0.44	-5.46	-0.4	1.91e-7	Hair greying;
PAAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6604026	0.656	rs949915	chr1:93369774	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.98	14.59	0.76	1.03e-30	Dental caries;
PAAD	cis	rs6466055	0.661	rs12532134	chr7:104922603	G/A	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.16	14.55	0.76	1.36e-30	Type 1 diabetes nephropathy;
PAAD	cis	rs4704187	0.640	rs7707246	chr5:74354875	G/T	cg03227963	chr5:74354835	NA	0.5	4.83	0.36	3.36e-6	Response to amphetamines;
PAAD	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs9907295	0.636	rs4251724	chr17:34143645	T/A	cg19411729	chr17:34207663	CCL5	-0.53	-4.74	-0.36	4.92e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg22437258	chr11:111473054	SIK2	-0.65	-5.87	-0.43	2.64e-8	Primary sclerosing cholangitis;
PAAD	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg24565620	chr2:194026	NA	-0.61	-4.47	-0.34	1.53e-5	Blood protein levels;
PAAD	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg02487422	chr3:49467188	NICN1	0.46	4.77	0.36	4.22e-6	Resting heart rate;
PAAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.81	8.09	0.55	1.77e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg18827107	chr12:86230957	RASSF9	0.4	4.26	0.33	3.52e-5	Major depressive disorder;
PAAD	cis	rs2133450	0.712	rs1546235	chr3:7366864	T/A	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23991263	chr11:46958558	C11orf49	0.58	6.4	0.46	1.86e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.14	0.45	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.7	-7.71	-0.53	1.51e-12	Colorectal cancer;
PAAD	cis	rs2030114	0.580	rs1498778	chr16:51615886	C/T	cg03758633	chr16:51611768	NA	0.51	5.04	0.38	1.29e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	0.89	6.1	0.44	8.44e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08274821	chr1:214557901	PTPN14	0.56	6.52	0.47	9.96e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg22617819	chr1:44378782	ST3GAL3	-0.47	-4.36	-0.33	2.36e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.71	7.01	0.49	7.32e-11	Coronary artery disease;
PAAD	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21646471	chr2:242523971	THAP4	0.65	5.09	0.38	1.04e-6	Prostate cancer;
PAAD	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	11.3	0.68	6.9e-22	Primary sclerosing cholangitis;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.55	-7.44	-0.52	6.86e-12	Longevity;Endometriosis;
PAAD	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg16205897	chr5:131564050	P4HA2	-0.49	-5.37	-0.4	2.88e-7	Blood metabolite levels;
PAAD	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.69	-5.54	-0.41	1.33e-7	Mammographic density (dense area);
PAAD	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.84	8.73	0.58	4.37e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10929159	0.928	rs6431419	chr2:236919669	C/A	cg14226755	chr2:236923322	AGAP1	0.28	4.5	0.34	1.33e-5	Parkinson's disease;
PAAD	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-5.57	-0.41	1.12e-7	Reticulocyte count;
PAAD	cis	rs8170	0.603	rs4808622	chr19:17415457	C/G	cg01047959	chr19:17666446	GLT25D1	0.51	4.68	0.36	6.21e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3736485	0.966	rs7177720	chr15:51890282	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.84e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2300603	0.800	rs117882885	chr14:76025603	C/T	cg01624173	chr14:75981868	NA	0.55	5.5	0.41	1.57e-7	Multiple sclerosis;
PAAD	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs1144333	1.000	rs5745392	chr1:76306809	C/T	cg22875332	chr1:76189707	ACADM	0.6	4.31	0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs8005172	0.750	rs3844023	chr14:88424275	T/A	cg18078958	chr14:88630771	NA	0.46	5.34	0.4	3.31e-7	Parkinson's disease;
PAAD	cis	rs8014252	0.803	rs56922268	chr14:71052171	A/C	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-4.63	-0.35	7.83e-6	Resting heart rate;
PAAD	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.39	0.51	9.13e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13985252	chr19:43918371	TEX101	-0.61	-6.57	-0.47	7.62e-10	Obesity-related traits;
PAAD	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg04450456	chr4:17643702	FAM184B	0.48	4.95	0.37	1.97e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6782228	0.606	rs7650156	chr3:128361555	T/A	cg16766828	chr3:128327626	NA	-0.49	-6.51	-0.47	1.02e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00791764	chr4:53727839	RASL11B	0.75	4.77	0.36	4.28e-6	Optic nerve measurement (cup area);
PAAD	cis	rs4455778	0.580	rs4292637	chr7:49121114	C/T	cg26309511	chr7:48887640	NA	-0.38	-4.55	-0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Body mass index;
PAAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.29	0.39	4.14e-7	Bipolar disorder;
PAAD	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg02135003	chr7:105160482	PUS7	0.69	6.34	0.46	2.44e-9	Bipolar disorder (body mass index interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10462751	chr12:107168330	RIC8B	0.7	6.8	0.48	2.28e-10	Obesity-related traits;
PAAD	cis	rs4343996	0.967	rs10250444	chr7:3350027	A/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.21	-0.39	6.18e-7	Motion sickness;
PAAD	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg24375607	chr4:120327624	NA	0.44	4.56	0.35	1.03e-5	Diastolic blood pressure;
PAAD	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg08888203	chr3:10149979	C3orf24	0.66	5.95	0.43	1.77e-8	Alzheimer's disease;
PAAD	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.86	10.94	0.66	6.39e-21	Body mass index;
PAAD	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs72828912	0.764	rs10946669	chr6:24095059	T/C	cg27524988	chr6:24583477	KIAA0319	-0.49	-4.38	-0.33	2.19e-5	Squamous cell lung carcinoma;
PAAD	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.61	4.5	0.34	1.32e-5	Exhaled nitric oxide output;
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg14664628	chr15:75095509	CSK	-0.46	-4.47	-0.34	1.55e-5	Caffeine consumption;
PAAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs1878047	0.640	rs8111217	chr19:51776229	G/A	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs2074409	0.571	rs67499664	chr17:35893645	T/A	cg16670864	chr17:35848621	DUSP14	0.51	4.28	0.33	3.31e-5	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg24739098	chr15:79297159	RASGRF1	-0.34	-4.32	-0.33	2.84e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-7.06	-0.5	5.67e-11	Vitiligo;
PAAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg17052926	chr7:915758	C7orf20	-0.45	-4.53	-0.34	1.21e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.71	7.67	0.53	1.95e-12	Prostate cancer;
PAAD	cis	rs790123	0.749	rs1355562	chr3:122397064	G/T	cg17380795	chr3:122379686	NA	0.52	5.34	0.4	3.26e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs2147904	0.934	rs783622	chr1:42366988	C/T	cg16685388	chr1:42384056	HIVEP3	-0.38	-4.5	-0.34	1.35e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs501120	1.000	rs665855	chr10:44757751	T/C	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-5.18	-0.39	6.88e-7	Coronary artery disease;
PAAD	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.06	12.95	0.72	2.6e-26	Testicular germ cell tumor;
PAAD	cis	rs939584	1.000	rs1320332	chr2:621954	T/C	cg14515364	chr2:636606	NA	0.47	4.26	0.33	3.59e-5	Body mass index;
PAAD	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg05925327	chr15:68127851	NA	-0.5	-4.43	-0.34	1.76e-5	Obesity;
PAAD	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.53	-5.23	-0.39	5.53e-7	Systolic blood pressure;
PAAD	cis	rs7631605	0.875	rs67401825	chr3:37085970	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.63	-5.27	-0.39	4.64e-7	Coronary artery disease;
PAAD	cis	rs593531	0.614	rs655719	chr11:74042241	A/G	cg23327896	chr11:73669290	DNAJB13	-0.37	-4.66	-0.35	6.91e-6	Neuroticism;
PAAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg19680485	chr15:31195859	MTMR15	-0.43	-4.35	-0.33	2.49e-5	Huntington's disease progression;
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs11168618	0.904	rs12366459	chr12:48930900	C/T	cg01881778	chr12:48919444	OR8S1	-0.45	-4.46	-0.34	1.61e-5	Adiponectin levels;
PAAD	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7707921	0.881	rs73134709	chr5:81268499	G/A	cg21483461	chr5:81570383	RPS23	-0.52	-4.41	-0.34	1.93e-5	Breast cancer;
PAAD	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.53	4.56	0.35	1.07e-5	Aortic root size;
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs9815354	0.680	rs73075231	chr3:42051694	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.15	0.45	6.49e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.54	-6.17	-0.45	5.99e-9	Systemic lupus erythematosus;
PAAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.68	7.07	0.5	5.36e-11	Retinal vascular caliber;
PAAD	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.59	-7.77	-0.53	1.09e-12	Longevity;
PAAD	cis	rs3768617	0.903	rs1413386	chr1:183104811	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	7.46	0.52	6.26e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg17644776	chr2:200775616	C2orf69	-0.61	-4.72	-0.36	5.24e-6	Schizophrenia;
PAAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.7	0.36	5.84e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg07164556	chr1:145727247	PDZK1	0.79	4.31	0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.61	5.57	0.41	1.11e-7	Red blood cell count;
PAAD	cis	rs11892454	0.533	rs13392329	chr2:26065592	G/T	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs654950	0.967	rs621727	chr1:41984612	C/T	cg06885757	chr1:42089581	HIVEP3	-0.61	-7.14	-0.5	3.55e-11	Airway imaging phenotypes;
PAAD	cis	rs9398803	0.687	rs6911485	chr6:126975115	A/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg16898833	chr6:26189333	HIST1H4D	0.91	5.09	0.38	1.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12979813	1.000	rs17001244	chr19:11340057	C/T	cg08405405	chr19:11485325	C19orf39	0.64	4.62	0.35	8.28e-6	HDL cholesterol;
PAAD	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg03277515	chr1:153321198	PGLYRP4	0.4	4.74	0.36	4.79e-6	Psoriasis;
PAAD	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.47	0.34	1.51e-5	Menarche (age at onset);
PAAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg07148914	chr20:33460835	GGT7	0.49	4.88	0.37	2.64e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.76	-6.87	-0.49	1.58e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.29e-6	Airway imaging phenotypes;
PAAD	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.6	-0.57	8.89e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.99	7.46	0.52	6.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.94	-0.49	1.04e-10	Glomerular filtration rate (creatinine);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18707867	chr19:3971272	DAPK3	0.55	6.36	0.46	2.22e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg22382021	chr8:145755756	MGC70857;KIAA1688	0.33	4.4	0.34	2.03e-5	Age at first birth;
PAAD	cis	rs4757319	0.532	rs7350480	chr11:15431408	A/G	cg03245590	chr11:15329459	NA	-0.38	-4.54	-0.35	1.14e-5	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15889003	chr4:6925288	TBC1D14	-0.66	-6.33	-0.46	2.63e-9	Obesity-related traits;
PAAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.0	11.93	0.7	1.44e-23	Cognitive ability;
PAAD	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	0.9	6.22	0.45	4.68e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10819733	chr22:24237672	NA	0.61	6.59	0.47	6.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.61	-6.13	-0.45	7.17e-9	Coronary artery disease;
PAAD	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.44	-5.17	-0.39	7.29e-7	Mean arterial pressure;
PAAD	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.44	0.56	2.31e-14	Bipolar disorder;
PAAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	6.98	0.49	8.47e-11	Eosinophil percentage of white cells;
PAAD	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15659409	chr10:134161996	LRRC27	0.61	6.33	0.46	2.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	6.21	0.45	4.72e-9	Height;
PAAD	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01516440	chr12:9102261	M6PR	0.57	6.45	0.46	1.4e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21230317	chr9:116240607	RGS3	0.62	6.73	0.48	3.31e-10	Smoking initiation;
PAAD	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12304921	1.000	rs73092531	chr12:51357987	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.43	-0.4	2.22e-7	Type 2 diabetes;
PAAD	cis	rs2290419	0.730	rs75885625	chr11:68941870	G/T	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.87	0.37	2.73e-6	Major depressive disorder;
PAAD	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.67	-0.35	6.71e-6	Breast cancer;
PAAD	cis	rs2764208	0.535	rs7751664	chr6:34681188	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.4	4.25	0.33	3.72e-5	Systemic lupus erythematosus;
PAAD	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09597638	chr17:3907349	NA	0.64	6.03	0.44	1.18e-8	Type 2 diabetes;
PAAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-9.76	-0.62	8.82e-18	Total body bone mineral density;
PAAD	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.46	-5.21	-0.39	6.1e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg24737193	chr18:12778029	NA	0.66	5.81	0.43	3.55e-8	Inflammatory skin disease;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	6.63	0.47	5.38e-10	Height;
PAAD	cis	rs6547631	0.622	rs1837115	chr2:85928411	C/A	cg24620635	chr2:85921963	GNLY	0.43	5.61	0.41	9.15e-8	Blood protein levels;
PAAD	cis	rs863345	0.604	rs12025831	chr1:158496282	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg19980929	chr12:42632907	YAF2	0.58	6.92	0.49	1.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7715811	1.000	rs13436952	chr5:13773993	A/G	cg09526469	chr5:14277668	TRIO	-0.39	-4.26	-0.33	3.61e-5	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs58653258	0.554	rs822840	chr1:234971854	T/G	cg03518729	chr1:235147744	NA	0.45	4.26	0.33	3.5e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.49	5.49	0.41	1.63e-7	Lung cancer;
PAAD	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02706205	chr15:49447933	GALK2;COPS2	0.62	6.82	0.48	2.04e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs761746	0.739	rs140078	chr22:32110163	A/G	cg01338084	chr22:32026380	PISD	-0.66	-5.74	-0.42	4.94e-8	Intelligence;
PAAD	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg09366796	chr5:75012313	C5orf37	0.52	4.81	0.36	3.58e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg08477640	chr19:41863820	B9D2	0.69	7.23	0.51	2.26e-11	Colorectal cancer;
PAAD	cis	rs55788414	0.932	rs35852981	chr16:81180897	G/A	cg06400318	chr16:81190750	PKD1L2	-1.08	-7.18	-0.5	2.9e-11	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-5.7	-0.42	5.92e-8	Prostate cancer;
PAAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9525927	0.570	rs9316074	chr13:44803181	A/G	cg19190762	chr13:44806055	NA	0.4	4.36	0.33	2.4e-5	Dupuytren's disease;
PAAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.57	6.61	0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.57	6.75	0.48	2.93e-10	Total body bone mineral density;
PAAD	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg00717180	chr2:96193071	NA	-0.6	-6.79	-0.48	2.41e-10	HDL cholesterol;
PAAD	cis	rs656900	0.715	rs1870576	chr15:80107128	T/C	cg02196730	chr15:80188777	MTHFS	0.49	5.33	0.4	3.49e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.36	4.67	0.35	6.57e-6	Calcium levels;
PAAD	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13647721	chr17:30228624	UTP6	0.57	4.37	0.33	2.27e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	trans	rs621559	0.535	rs841383	chr1:43557465	C/A	cg08853571	chr5:121305621	SRFBP1	0.6	6.36	0.46	2.23e-9	Telomere length;
PAAD	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg04374321	chr14:90722782	PSMC1	-0.82	-8.81	-0.58	2.72e-15	Mortality in heart failure;
PAAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.92	-11.53	-0.68	1.7e-22	Pulse pressure;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Electroencephalogram traits;
PAAD	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.66	-4.97	-0.37	1.75e-6	Lung function (FEV1/FVC);
PAAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.74	-0.42	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	cis	rs2004318	1.000	rs45479893	chr19:55086169	A/G	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs7264396	0.887	rs1570841	chr20:34048161	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.65	6.67	0.48	4.53e-10	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18514344	chr10:95242156	MYOF	0.69	6.8	0.48	2.24e-10	Obesity-related traits;
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg11941060	chr3:133502564	NA	-0.52	-5.2	-0.39	6.21e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.42	4.54	0.35	1.13e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-5.14	-0.38	8.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10950821	0.843	rs73684577	chr7:20665781	A/G	cg21202529	chr7:20656503	ABCB5	-0.51	-4.79	-0.36	3.87e-6	Response to statin therapy;
PAAD	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.17	-6.09	-0.44	8.64e-9	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
PAAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.2	0.45	4.95e-9	Ileal carcinoids;
PAAD	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.64	-7.41	-0.52	8.23e-12	Breast cancer;
PAAD	cis	rs9463078	0.874	rs2093901	chr6:45177315	C/G	cg25276700	chr6:44698697	NA	-0.49	-5.63	-0.42	8.57e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg15443732	chr18:74961078	GALR1	0.72	5.91	0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs7714584	0.793	rs11958146	chr5:150254158	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs4740619	0.616	rs10756734	chr9:16026444	T/C	cg14451791	chr9:16040625	NA	-0.46	-5.27	-0.39	4.5e-7	Body mass index;
PAAD	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.58	-4.92	-0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs16944613	0.510	rs7165429	chr15:91151881	C/T	cg15547629	chr15:90437138	AP3S2	-0.52	-4.42	-0.34	1.87e-5	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16997989	chr18:9136565	ANKRD12	0.56	6.41	0.46	1.75e-9	Monocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.43	0.56	2.49e-14	Menopause (age at onset);
PAAD	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.76	7.44	0.52	6.75e-12	Corneal astigmatism;
PAAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.59	6.29	0.45	3.27e-9	Lung cancer;
PAAD	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.61	-5.09	-0.38	1.02e-6	Neuroblastoma;
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg09473613	chr1:24152604	HMGCL	0.54	5.62	0.41	8.87e-8	Immature fraction of reticulocytes;
PAAD	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.8	7.89	0.54	5.38e-13	Callous-unemotional behaviour;
PAAD	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-5.58	-0.41	1.06e-7	Schizophrenia;
PAAD	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12748367	chr2:216301062	FN1	0.67	7.25	0.51	1.94e-11	Obesity-related traits;
PAAD	cis	rs9900972	0.918	rs8065102	chr17:76876735	T/C	cg20937029	chr17:76870563	TIMP2	0.58	5.08	0.38	1.08e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03208010	chr4:103940950	NHEDC1	0.62	6.84	0.49	1.81e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11933116	chr6:139349681	C6orf115	0.58	6.34	0.46	2.54e-9	Metabolite levels  (X-11787);
PAAD	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-4.58	-0.35	9.75e-6	Testicular germ cell tumor;
PAAD	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg08514558	chr10:81106712	PPIF	0.53	6.45	0.46	1.41e-9	Height;
PAAD	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg08345082	chr10:99160200	RRP12	-0.29	-4.25	-0.33	3.64e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg03808351	chr9:123631620	PHF19	0.46	5.01	0.38	1.51e-6	Rheumatoid arthritis;
PAAD	cis	rs6496932	0.635	rs2200214	chr15:85926976	C/A	cg19183879	chr15:85880815	NA	-0.61	-5.55	-0.41	1.24e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.45	-4.55	-0.35	1.08e-5	Calcium levels;
PAAD	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg20503657	chr10:835505	NA	0.5	5.25	0.39	5.04e-7	Survival in rectal cancer;
PAAD	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.72	-4.41	-0.34	1.93e-5	White matter integrity;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg01800442	chr17:74086473	EXOC7	0.54	4.33	0.33	2.68e-5	Psoriasis;
PAAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.44	-6.11	-0.44	7.9e-9	Height;
PAAD	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs8077577	0.848	rs12600694	chr17:18091019	C/T	cg16794390	chr17:18148240	FLII	0.57	4.83	0.36	3.32e-6	Obesity-related traits;
PAAD	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg04920474	chr2:44395004	PPM1B	0.45	4.41	0.34	1.95e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.82	0.36	3.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.55	5.32	0.4	3.66e-7	Anterior chamber depth;
PAAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.79	0.42	3.98e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.86e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg23173402	chr1:227635558	NA	0.73	4.78	0.36	4.04e-6	Major depressive disorder;
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.88	-9.89	-0.63	3.97e-18	Bipolar disorder and schizophrenia;
PAAD	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12165864	chr7:66369176	NA	0.82	5.23	0.39	5.52e-7	Diabetic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22605936	chr7:75296038	HIP1	-0.66	-6.54	-0.47	8.95e-10	Obesity-related traits;
PAAD	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-6.14	-0.45	7.05e-9	Neuroticism;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.64	7.23	0.51	2.21e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.57	7.73	0.53	1.36e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	10.91	0.66	7.88e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.43	-4.5	-0.34	1.36e-5	Ulcerative colitis;
PAAD	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg07537917	chr2:241836409	C2orf54	-0.27	-5.29	-0.39	4.17e-7	Urinary metabolites;
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.52	5.46	0.4	1.89e-7	Longevity;Endometriosis;
PAAD	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.93	12.69	0.72	1.3e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg15571903	chr15:79123663	NA	0.48	6.17	0.45	5.97e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.45	4.44	0.34	1.72e-5	Chronic sinus infection;
PAAD	cis	rs8025118	0.583	rs35664583	chr15:79546165	C/T	cg24739098	chr15:79297159	RASGRF1	-0.38	-4.3	-0.33	3.07e-5	Cognitive function;
PAAD	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.53	-5.49	-0.41	1.65e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7173743	0.525	rs8027870	chr15:79134045	A/G	cg00540400	chr15:79124168	NA	0.45	4.69	0.36	6.06e-6	Coronary artery disease;
PAAD	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg02683114	chr2:24398427	C2orf84	-0.44	-4.77	-0.36	4.37e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.69	0.58	5.35e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.73	-5.55	-0.41	1.22e-7	Mean platelet volume;
PAAD	cis	rs1419980	0.730	rs74058423	chr12:7728396	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-5.63	-0.42	8.58e-8	Coronary artery disease;
PAAD	cis	rs6804624	0.676	rs2670321	chr3:99167107	A/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14300568	chr18:57567149	PMAIP1	0.63	6.56	0.47	7.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6679454	0.920	rs17579464	chr1:58369662	A/G	cg17491850	chr1:57888480	DAB1	0.47	5.12	0.38	9.28e-7	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-5.22	-0.39	5.77e-7	Personality dimensions;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.88	-10.53	-0.65	8.17e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.47	4.63	0.35	7.74e-6	Electroencephalogram traits;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg07527105	chr16:88053339	BANP	-0.49	-4.85	-0.37	3e-6	Menopause (age at onset);
PAAD	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg21994822	chr11:66741747	C11orf86	0.39	4.33	0.33	2.72e-5	HIV-1 susceptibility;
PAAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.74	-7.05	-0.5	5.88e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg13722127	chr7:150037890	RARRES2	0.6	5.79	0.43	3.92e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.88	-10.59	-0.65	5.62e-20	Total body bone mineral density;
PAAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg07153921	chr17:41440717	NA	-0.42	-4.41	-0.34	1.91e-5	Menopause (age at onset);
PAAD	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg15145965	chr22:50218605	BRD1	0.62	5.39	0.4	2.58e-7	Schizophrenia;
PAAD	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	1.07	9.78	0.62	7.97e-18	Monocyte percentage of white cells;
PAAD	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.22	0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg16591659	chr17:78472290	NA	0.47	4.45	0.34	1.62e-5	Fractional excretion of uric acid;
PAAD	cis	rs2410601	0.562	rs7846416	chr8:18913273	C/G	cg19414122	chr8:18896631	NA	0.47	5.78	0.42	4.13e-8	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.03	-0.55	2.48e-13	Longevity;Endometriosis;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.62	5.65	0.42	7.51e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs3112530	1.000	rs1462109	chr5:152652626	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.92	5.07	0.38	1.13e-6	Aging (time to event);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18941211	chr1:179266761	SOAT1	-0.72	-7.15	-0.5	3.44e-11	Obesity-related traits;
PAAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21028142	chr17:79581711	NPLOC4	-0.5	-5.8	-0.43	3.7e-8	Eye color traits;
PAAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.64	0.47	5.14e-10	Systemic lupus erythematosus;
PAAD	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg22691776	chr3:15032403	NR2C2	0.29	4.3	0.33	3e-5	Mean platelet volume;
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.27	-0.33	3.42e-5	Prostate cancer;
PAAD	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	trans	rs901683	1.000	rs34383275	chr10:46072877	C/T	cg06308084	chr22:50493570	TTLL8	0.88	6.49	0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg09835421	chr16:68378352	PRMT7	0.64	4.26	0.33	3.51e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.66	7.23	0.51	2.17e-11	Lung cancer;
PAAD	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.3	0.56	5.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg15693483	chr7:1102177	C7orf50	0.36	4.54	0.35	1.12e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.61	-6.23	-0.45	4.46e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.49	-0.41	1.68e-7	Subjective well-being;
PAAD	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.5	5.44	0.4	2.12e-7	Testicular germ cell tumor;
PAAD	cis	rs2279817	0.865	rs35255680	chr1:17981184	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.63	-5.86	-0.43	2.83e-8	Neuroticism;
PAAD	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-4.52	-0.34	1.24e-5	Primary biliary cholangitis;
PAAD	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03188526	chr2:55556201	CCDC88A	-0.48	-5.07	-0.38	1.15e-6	Alcohol dependence;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.67	5.34	0.4	3.34e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9616064	1.000	rs5768991	chr22:46983018	A/G	cg05621596	chr22:47072043	GRAMD4	0.54	5.04	0.38	1.28e-6	Urate levels in obese individuals;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06406300	chr17:40828394	PLEKHH3	0.62	6.88	0.49	1.5e-10	Monocyte percentage of white cells;
PAAD	cis	rs8084125	1.000	rs1944560	chr18:74939705	G/T	cg05528293	chr18:74961138	GALR1	0.58	5.07	0.38	1.12e-6	Obesity-related traits;
PAAD	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.35	6.3e-6	Vitiligo;
PAAD	cis	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.31	0.33	2.87e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.8	8.45	0.57	2.23e-14	Corneal astigmatism;
PAAD	cis	rs4740619	0.688	rs4582646	chr9:15935502	C/T	cg14451791	chr9:16040625	NA	-0.42	-4.77	-0.36	4.23e-6	Body mass index;
PAAD	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.76	-0.58	3.48e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs13082711	0.954	rs35523848	chr3:27552800	A/C	cg02860705	chr3:27208620	NA	0.71	6.4	0.46	1.79e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg07162820	chr14:24837146	NFATC4	-0.37	-4.82	-0.36	3.43e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg13263323	chr15:86062960	AKAP13	-0.62	-7.16	-0.5	3.21e-11	Interstitial lung disease;
PAAD	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg07883600	chr3:53528162	CACNA1D	-0.41	-4.36	-0.33	2.42e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	1.05	17.31	0.81	8.94e-38	Height;
PAAD	cis	rs4668356	0.543	rs73017295	chr2:172049743	A/T	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06544989	chr22:39130855	UNC84B	-0.52	-5.07	-0.38	1.13e-6	Menopause (age at onset);
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.69	0.48	4.13e-10	Height;
PAAD	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1190552	1.000	rs1190552	chr14:102911907	A/G	cg18135206	chr14:102964638	TECPR2	-0.68	-5.36	-0.4	3.02e-7	Blood protein levels;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.58	-5.6	-0.41	9.92e-8	Height;
PAAD	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.47	4.4	0.34	2.05e-5	Mean corpuscular volume;
PAAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.34	-0.4	3.39e-7	Diastolic blood pressure;
PAAD	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.2	0.5	2.53e-11	Coffee consumption (cups per day);
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-6.29	-0.45	3.17e-9	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21486913	chr19:37046582	ZNF529	-0.61	-6.46	-0.46	1.32e-9	Obesity-related traits;
PAAD	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.49	5.25	0.39	4.94e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.64	-7.4	-0.51	8.7e-12	Coronary artery disease;
PAAD	cis	rs6724465	0.852	rs7561119	chr2:219986253	A/G	cg25908985	chr2:219925065	IHH	0.64	4.41	0.34	1.92e-5	Height;
PAAD	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.85	-0.37	3.04e-6	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg15399174	chr15:28349794	NA	-0.65	-6.42	-0.46	1.67e-9	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.553	rs9909515	chr17:2039733	T/C	cg16513277	chr17:2031491	SMG6	-0.66	-6.96	-0.49	9.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.7	8.82	0.58	2.44e-15	Chronic obstructive pulmonary disease;
PAAD	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg08999081	chr20:33150536	PIGU	0.46	5.02	0.38	1.45e-6	Height;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg13483984	chr1:224580455	WDR26	-0.6	-6.43	-0.46	1.54e-9	Alcohol dependence;
PAAD	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg12046867	chr14:103022105	NA	-0.66	-5.44	-0.4	2.13e-7	Platelet count;
PAAD	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.6	-5.94	-0.43	1.88e-8	Primary sclerosing cholangitis;
PAAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg15948785	chr7:158030626	PTPRN2	-0.43	-4.28	-0.33	3.34e-5	Calcium levels;
PAAD	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	1.05	12.98	0.73	2.15e-26	Breast cancer;
PAAD	cis	rs3764400	0.567	rs16951519	chr17:46152291	G/A	cg24322968	chr17:46507895	SKAP1	0.87	5.3	0.39	4.06e-7	Body mass index;
PAAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.49	0.41	1.65e-7	Tonsillectomy;
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	1.07	15.55	0.78	3.07e-33	Systemic lupus erythematosus;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01136335	chr5:68629714	NA	0.64	6.47	0.46	1.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg14500267	chr11:67383377	NA	0.42	4.25	0.33	3.66e-5	Mean corpuscular volume;
PAAD	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.74	-10.02	-0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg01631408	chr1:248437212	OR2T33	-0.56	-5.08	-0.38	1.1e-6	Common traits (Other);
PAAD	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg08999081	chr20:33150536	PIGU	0.51	5.59	0.41	1e-7	Height;
PAAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11807834	0.522	rs11585739	chr1:230245900	C/T	cg00566187	chr1:230250356	GALNT2	0.69	7.26	0.51	1.83e-11	Schizophrenia;
PAAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.44	0.34	1.7e-5	Tonsillectomy;
PAAD	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.63	-0.35	7.83e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.04	0.81	4.32e-37	Prudent dietary pattern;
PAAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	4.94	0.37	2.01e-6	Height;
PAAD	cis	rs261532	0.861	rs2434576	chr5:138917674	A/G	cg11459648	chr5:138714337	SLC23A1	-0.66	-5.93	-0.43	1.93e-8	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg10640731	chr10:70092995	PBLD;HNRNPH3	-0.67	-6.77	-0.48	2.65e-10	Dental caries;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22079685	chr18:74175082	ZNF516	-0.43	-4.43	-0.34	1.78e-5	Obesity-related traits;
PAAD	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.6	5.43	0.4	2.22e-7	Breast cancer;
PAAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.49	-0.41	1.68e-7	Psoriasis;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.58	5.21	0.39	6.19e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.47e-11	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.54e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.64	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.91	10.01	0.63	1.95e-18	Cognitive function;
PAAD	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg05925327	chr15:68127851	NA	-0.56	-4.87	-0.37	2.72e-6	Obesity;
PAAD	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	4.46	0.34	1.6e-5	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.93	12.67	0.72	1.46e-25	Prudent dietary pattern;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg19761014	chr17:28927070	LRRC37B2	0.75	4.68	0.36	6.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.23	0.45	4.43e-9	Coffee consumption (cups per day);
PAAD	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg22153463	chr1:85462885	MCOLN2	0.64	4.86	0.37	2.91e-6	Serum sulfate level;
PAAD	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.29	-0.39	4.26e-7	Tonsillectomy;
PAAD	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.79	9.55	0.61	3.11e-17	Height;
PAAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg19429281	chr19:53496738	ZNF702P	-0.49	-4.91	-0.37	2.29e-6	Psoriasis;
PAAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.5	-0.34	1.33e-5	Diastolic blood pressure;
PAAD	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg00121533	chr1:75199117	CRYZ;TYW3	0.54	5.33	0.4	3.42e-7	Resistin levels;
PAAD	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg05925327	chr15:68127851	NA	-0.62	-5.61	-0.41	9.35e-8	Obesity;
PAAD	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05585630	chr7:157510462	PTPRN2	-0.8	-9.24	-0.6	2.09e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-1.01	-10.44	-0.65	1.43e-19	Blood pressure (smoking interaction);
PAAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.68	9.9	0.63	3.89e-18	Height;
PAAD	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10992471	0.564	rs10491804	chr9:95487407	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-4.5	-0.34	1.33e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.5	-5.38	-0.4	2.82e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.78	-6.56	-0.47	7.95e-10	Coronary artery disease;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02071572	chr4:1403502	NA	0.44	5.93	0.43	1.98e-8	Obesity-related traits;
PAAD	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-4.33	-0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs11921456	chr3:128581001	A/T	cg18531004	chr3:128564980	NA	0.79	5.01	0.38	1.47e-6	Dental caries;
PAAD	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.79	-8.16	-0.55	1.15e-13	Blood protein levels;
PAAD	cis	rs4356203	0.905	rs651513	chr11:17199328	C/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-4.28	-0.33	3.25e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.66	-6.4	-0.46	1.79e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.34	0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.53	-0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.52	4.76	0.36	4.47e-6	Mean corpuscular volume;
PAAD	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	4.89	0.37	2.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02244288	chr16:89573955	SPG7	-0.33	-4.33	-0.33	2.67e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	7.71	0.53	1.55e-12	Migraine;Coronary artery disease;
PAAD	cis	rs939584	0.778	rs62105304	chr2:632925	A/G	cg03610516	chr2:642275	NA	0.59	5.24	0.39	5.32e-7	Body mass index;
PAAD	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.51	5.29	0.39	4.21e-7	Coronary artery disease;
PAAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs496547	1.000	rs496547	chr11:118576463	A/T	cg08498647	chr11:118550644	TREH	-0.39	-4.65	-0.35	7.27e-6	Hip minimal joint space width;
PAAD	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg06636372	chr16:89349979	ANKRD11	-0.76	-4.8	-0.36	3.84e-6	Red blood cell count;
PAAD	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.58	-0.35	9.55e-6	Post bronchodilator FEV1;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05764240	chr1:205425468	NA	-0.67	-6.86	-0.49	1.64e-10	Smoking initiation;
PAAD	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-5.1	-0.38	9.77e-7	Body mass index;
PAAD	cis	rs5997397	0.933	rs5762783	chr22:29165525	T/G	cg02153584	chr22:29168773	CCDC117	0.51	4.62	0.35	8.28e-6	Red cell distribution width;
PAAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg09197432	chr4:183729176	NA	0.46	4.32	0.33	2.82e-5	Pediatric autoimmune diseases;
PAAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	7.0	0.49	7.81e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.49	-0.65	1.06e-19	Breast cancer;
PAAD	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-4.78	-0.36	4.18e-6	Common traits (Other);
PAAD	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-7.34	-0.51	1.19e-11	Asthma;
PAAD	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.39	12.47	0.71	5.13e-25	Uric acid levels;
PAAD	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg14664628	chr15:75095509	CSK	0.51	4.85	0.37	3.06e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.73	-7.6	-0.52	2.84e-12	Coronary artery disease;
PAAD	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg27565382	chr3:53032988	SFMBT1	0.73	4.29	0.33	3.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.52	4.87	0.37	2.76e-6	Monocyte count;
PAAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27297192	chr10:134578999	INPP5A	0.57	5.45	0.4	2.03e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08842232	chr2:226265447	KIAA1486	-0.6	-6.53	-0.47	9.3e-10	Obesity-related traits;
PAAD	cis	rs11892454	0.515	rs3731638	chr2:26046845	T/C	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg09835421	chr16:68378352	PRMT7	-0.61	-4.53	-0.35	1.17e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg00599163	chr2:162100495	NA	0.38	4.63	0.35	7.78e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9549260	0.876	rs9549258	chr13:41248026	T/C	cg21288729	chr13:41239152	FOXO1	0.62	4.6	0.35	9.02e-6	Red blood cell count;
PAAD	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg15440763	chr7:158190612	PTPRN2	0.47	4.6	0.35	8.8e-6	Obesity-related traits;
PAAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.72	0.42	5.46e-8	Tonsillectomy;
PAAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg22868518	chr11:507468	RNH1	-0.98	-5.16	-0.39	7.72e-7	Body mass index;
PAAD	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.7	0.42	6.01e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.64	-6.75	-0.48	2.99e-10	Ankylosing spondylitis;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08045932	chr20:61659980	NA	0.72	9.36	0.6	1.01e-16	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13535231	chr9:125003777	RBM18	-0.64	-6.95	-0.49	9.87e-11	Obesity-related traits;
PAAD	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.51	0.57	1.54e-14	Dupuytren's disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg24488506	chr11:65667952	FOSL1	0.68	6.95	0.49	1.02e-10	Primary biliary cholangitis;
PAAD	cis	rs8049634	0.732	rs11149631	chr16:84228770	G/C	cg00961177	chr16:84213833	TAF1C	-0.42	-4.27	-0.33	3.36e-5	Small cell lung carcinoma;
PAAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.6	6.7	0.48	3.83e-10	Vitiligo;
PAAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17819702	chr2:180128907	SESTD1	0.67	7.12	0.5	3.93e-11	Myopia (pathological);
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.71	-4.84	-0.37	3.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.78	-9.54	-0.61	3.3e-17	Bone mineral density;
PAAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.74	-0.42	4.95e-8	Tonsillectomy;
PAAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.53	5.68	0.42	6.5e-8	Menopause (age at onset);
PAAD	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.65	-5.95	-0.43	1.81e-8	Crohn's disease;
PAAD	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26897989	chr16:1907736	C16orf73	-0.57	-5.03	-0.38	1.39e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg25801113	chr15:45476975	SHF	0.4	4.79	0.36	3.85e-6	Uric acid levels;
PAAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.4	0.4	2.49e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.65	4.98	0.37	1.72e-6	Coronary artery disease;
PAAD	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.85	9.91	0.63	3.63e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.53	-0.34	1.2e-5	Ulcerative colitis;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.71	8.87	0.58	1.89e-15	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.79	8.36	0.56	3.68e-14	Schizophrenia;
PAAD	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg18867708	chr6:26865862	GUSBL1	-0.44	-4.48	-0.34	1.48e-5	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10161685	chr10:25239957	PRTFDC1	-0.64	-6.62	-0.47	5.82e-10	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.24	0.67	1.05e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.63	8.18	0.55	1.05e-13	Hypertriglyceridemia;
PAAD	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-1.03	-13.44	-0.74	1.27e-27	Refractive error;
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.63	-7.99	-0.54	3.13e-13	Body mass index;
PAAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg26060667	chr1:247681242	NA	0.44	5.25	0.39	5.06e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7577696	0.850	rs11124276	chr2:32318428	C/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	4.42	0.34	1.84e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	-0.44	-4.97	-0.37	1.75e-6	Electroencephalogram traits;
PAAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg24733560	chr20:60626293	TAF4	0.6	7.97	0.54	3.48e-13	Body mass index;
PAAD	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Breast cancer;
PAAD	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg05373962	chr22:49881684	NA	-0.5	-4.87	-0.37	2.73e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.27	-7.77	-0.53	1.09e-12	Body mass index;
PAAD	trans	rs61677309	1.000	rs12576100	chr11:118158281	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	7.39	0.51	9.02e-12	Lymphocyte counts;
PAAD	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg15443732	chr18:74961078	GALR1	0.73	5.99	0.44	1.48e-8	Obesity-related traits;
PAAD	cis	rs9463078	0.625	rs500773	chr6:44888464	C/T	cg25276700	chr6:44698697	NA	-0.54	-6.1	-0.44	8.24e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4907240	0.961	rs7580048	chr2:97304180	G/C	cg26665480	chr2:98280029	ACTR1B	-0.51	-4.63	-0.35	7.79e-6	Event-related brain oscillations;
PAAD	cis	rs13053817	1.000	rs13054354	chr22:29840180	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.14	-0.38	8.27e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.8	9.04	0.59	6.85e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.6	-4.43	-0.34	1.76e-5	LDL cholesterol levels;
PAAD	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg00792783	chr2:198669748	PLCL1	-0.48	-4.34	-0.33	2.6e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.55	5.5	0.41	1.57e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3753841	0.832	rs12410008	chr1:103241798	G/A	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21179051	chr10:99894758	C10orf28	0.58	6.71	0.48	3.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.87	8.15	0.55	1.23e-13	Menarche (age at onset);
PAAD	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.61	5.06	0.38	1.22e-6	Red blood cell count;
PAAD	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.7	-8.26	-0.56	6.68e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-5.43	-0.4	2.22e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22029157	chr1:209979665	IRF6	0.73	6.61	0.47	6.08e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1507153	0.775	rs9361413	chr6:79345249	A/G	cg05283184	chr6:79620031	NA	-0.38	-4.56	-0.35	1.04e-5	Sjögren's syndrome;
PAAD	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.96	7.91	0.54	4.98e-13	Eotaxin levels;
PAAD	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	10.57	0.65	6.59e-20	Cognitive test performance;
PAAD	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.76	0.42	4.49e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.42	4.52	0.34	1.25e-5	Prevalent atrial fibrillation;
PAAD	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-7.88	-0.54	5.87e-13	Body mass index;
PAAD	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26306683	chr17:18585705	ZNF286B	0.58	5.89	0.43	2.37e-8	Educational attainment (years of education);
PAAD	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.95	0.49	9.82e-11	Neuroticism;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg12143784	chr7:64541923	NA	-0.41	-5.31	-0.4	3.75e-7	Calcium levels;
PAAD	cis	rs11853189	0.938	rs11854322	chr15:78590414	G/C	cg22935921	chr15:78556834	DNAJA4	0.77	5.21	0.39	6.04e-7	Red cell distribution width;
PAAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg23947450	chr7:900037	UNC84A	-0.55	-4.47	-0.34	1.51e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg23033748	chr14:75592666	NEK9	-0.45	-5.58	-0.41	1.07e-7	Height;
PAAD	cis	rs9928842	0.679	rs4888361	chr16:75267676	A/G	cg09066997	chr16:75300724	BCAR1	0.61	4.51	0.34	1.28e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.22	-10.64	-0.65	4.27e-20	Breast cancer;
PAAD	cis	rs2131877	0.645	rs11721261	chr3:194876993	C/T	cg11177333	chr3:195857752	NA	0.45	4.81	0.36	3.67e-6	Non-small cell lung cancer;
PAAD	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg11204139	chr17:3907470	NA	0.68	6.71	0.48	3.53e-10	Type 2 diabetes;
PAAD	cis	rs881952	0.791	rs2577646	chr2:60877171	T/A	cg02739593	chr2:60880222	NA	-0.47	-4.33	-0.33	2.7e-5	Glucose homeostasis traits;
PAAD	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg11266682	chr4:10021025	SLC2A9	-0.63	-5.59	-0.41	1e-7	Schizophrenia (age at onset);
PAAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs2070677	0.627	rs2987797	chr10:135379934	G/A	cg20169779	chr10:135381914	SYCE1	0.8	7.66	0.53	2.07e-12	Gout;
PAAD	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.7	-7.38	-0.51	9.8e-12	Bone mineral density;
PAAD	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.5	5.24	0.39	5.18e-7	Male-pattern baldness;
PAAD	cis	rs11892454	0.515	rs11898327	chr2:26090249	T/C	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs6024905	0.715	rs6014745	chr20:36957604	A/G	cg07053727	chr20:36965646	BPI	0.5	5.24	0.39	5.39e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.3	0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg06599209	chr2:1746509	PXDN	0.27	4.44	0.34	1.72e-5	Response to antipsychotic treatment;
PAAD	cis	rs883565	0.655	rs9837975	chr3:39064293	T/C	cg01426195	chr3:39028469	NA	-0.7	-7.8	-0.53	8.94e-13	Handedness;
PAAD	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.74	8.81	0.58	2.72e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs17407555	0.683	rs6833035	chr4:10272269	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	4.46	0.34	1.59e-5	Schizophrenia (age at onset);
PAAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.89	-0.37	2.52e-6	Bone mineral density;
PAAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg09473613	chr1:24152604	HMGCL	0.42	4.29	0.33	3.15e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.82	9.58	0.61	2.71e-17	Breast cancer;
PAAD	cis	rs11825685	0.887	rs76377465	chr11:134569562	T/G	cg06603561	chr11:134479413	NA	-0.81	-5.31	-0.4	3.8e-7	IgG glycosylation;
PAAD	trans	rs9467711	1.000	rs9467713	chr6:26338128	T/C	cg01620082	chr3:125678407	NA	-1.09	-6.3	-0.46	3.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	0.8	5.87	0.43	2.62e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.75	6.56	0.47	7.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2236521	0.632	rs35265388	chr20:60894278	C/T	cg24112000	chr20:60950667	NA	-0.51	-5.74	-0.42	4.88e-8	Pelvic organ prolapse;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.88	-0.43	2.57e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.03	-0.5	6.65e-11	Alcohol dependence;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.65	-5.72	-0.42	5.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7932354	0.583	rs2070851	chr11:46744528	T/C	cg19486271	chr11:47235900	DDB2	0.69	6.46	0.46	1.32e-9	Bone mineral density (hip);Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13935558	chr7:138144067	TRIM24	-0.63	-6.53	-0.47	9.15e-10	Obesity-related traits;
PAAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19346786	chr7:2764209	NA	-0.37	-5.02	-0.38	1.4e-6	Height;
PAAD	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.58	-5.44	-0.4	2.05e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-4.25	-0.33	3.72e-5	Renal cell carcinoma;
PAAD	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.91	9.83	0.62	5.95e-18	Corneal astigmatism;
PAAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs7243821	0.921	rs1944377	chr18:52641362	G/C	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs75757892	0.544	rs9505141	chr6:7318367	T/C	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.26	0.6	1.88e-16	Parkinson's disease;
PAAD	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.43	-5.41	-0.4	2.39e-7	Thyroid stimulating hormone;
PAAD	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.36e-8	QT interval;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23225415	chr2:80278200	CTNNA2	0.65	7.0	0.49	7.75e-11	Smoking initiation;
PAAD	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs11700980	0.551	rs16983159	chr21:30118326	C/G	cg24692254	chr21:30365293	RNF160	-0.71	-4.97	-0.37	1.76e-6	QRS complex (12-leadsum);
PAAD	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.53	-0.47	9.49e-10	Neuroticism;
PAAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg24733560	chr20:60626293	TAF4	-0.39	-4.38	-0.33	2.2e-5	Body mass index;
PAAD	cis	rs7264396	0.887	rs6060438	chr20:34077403	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.65	-0.42	7.51e-8	Total cholesterol levels;
PAAD	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.46	5.78	0.42	4.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg01851573	chr8:8652454	MFHAS1	-0.39	-4.29	-0.33	3.2e-5	Joint mobility (Beighton score);
PAAD	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg07862535	chr7:139043722	LUC7L2	-0.55	-4.37	-0.33	2.33e-5	Diisocyanate-induced asthma;
PAAD	cis	rs9928842	0.770	rs4888364	chr16:75279510	A/G	cg09066997	chr16:75300724	BCAR1	0.58	4.33	0.33	2.72e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.41	4.54	0.35	1.14e-5	Calcium levels;
PAAD	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg14709524	chr16:89940631	TCF25	0.95	4.37	0.33	2.27e-5	Skin colour saturation;
PAAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.7	-0.36	5.9e-6	Lung cancer;
PAAD	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1365505	0.600	rs4238381	chr15:50484714	A/T	cg26188685	chr15:50540269	HDC	0.44	4.78	0.36	4.04e-6	Blood metabolite ratios;
PAAD	cis	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.55	6.15	0.45	6.7e-9	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.44	0.46	1.52e-9	Blood protein levels;
PAAD	cis	rs9659323	0.670	rs61808898	chr1:119638855	T/C	cg26570165	chr1:119541833	NA	-0.48	-5.23	-0.39	5.45e-7	Body mass index;
PAAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.51	-0.61	3.99e-17	Total body bone mineral density;
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.75	0.42	4.72e-8	Eosinophil percentage of white cells;
PAAD	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs6547631	0.622	rs1561285	chr2:85924384	C/G	cg24620635	chr2:85921963	GNLY	0.42	5.44	0.4	2.05e-7	Blood protein levels;
PAAD	cis	rs11811982	0.793	rs115769147	chr1:227488343	G/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.02	0.38	1.44e-6	Breast cancer;
PAAD	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg11993925	chr19:44307056	LYPD5	-0.46	-6.17	-0.45	5.99e-9	Breast cancer;
PAAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg26695010	chr11:65641043	EFEMP2	-0.44	-4.27	-0.33	3.46e-5	Eosinophil percentage of white cells;
PAAD	cis	rs62264129	0.500	rs62278771	chr3:112030789	G/A	cg01411366	chr3:112012867	SLC9A10	-0.3	-4.82	-0.36	3.44e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9434723	0.844	rs9435148	chr1:9300962	G/C	cg04199779	chr1:9294473	H6PD	0.57	4.99	0.38	1.61e-6	Height;
PAAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.31	-4.62	-0.35	7.98e-6	Urate levels in overweight individuals;
PAAD	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.51	5.75	0.42	4.84e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.44	4.34	0.33	2.57e-5	Chronic sinus infection;
PAAD	cis	rs558003	0.826	rs1262720	chr13:51184425	C/T	cg24585282	chr13:51257555	NA	-0.67	-4.53	-0.34	1.18e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs11009175	0.615	rs6481818	chr10:33299356	C/A	cg00146027	chr10:33299147	NA	-0.4	-4.87	-0.37	2.81e-6	Depression (quantitative trait);
PAAD	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.48	-0.34	1.47e-5	Body mass index;
PAAD	cis	rs17428471	0.867	rs17473424	chr7:27324369	G/A	cg08483376	chr7:27285136	EVX1	-0.71	-4.29	-0.33	3.13e-5	Blood pressure;
PAAD	cis	rs17407555	0.865	rs2241464	chr4:10158961	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.91	-0.37	2.34e-6	Schizophrenia (age at onset);
PAAD	cis	rs35785195	0.593	rs35304519	chr12:114236677	C/T	cg24771877	chr12:114234123	NA	0.67	5.3	0.4	3.98e-7	Daytime sleep phenotypes;
PAAD	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.7	5.86	0.43	2.84e-8	Coronary artery disease;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg01857591	chr8:81083836	TPD52	0.67	7.39	0.51	8.97e-12	Iris heterochromicity;
PAAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg25251562	chr2:3704773	ALLC	0.47	5.15	0.39	7.99e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19090637	chr4:111119052	ELOVL6	-0.72	-6.38	-0.46	1.98e-9	Neuroticism;
PAAD	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg16540259	chr10:75572220	NDST2	0.43	4.31	0.33	2.93e-5	Inflammatory bowel disease;
PAAD	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.36	4.64e-6	Common traits (Other);
PAAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg14703610	chr5:56206110	C5orf35	-0.55	-5.16	-0.39	7.64e-7	Initial pursuit acceleration;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.51	0.61	4.02e-17	Post bronchodilator FEV1;
PAAD	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.96	-8.36	-0.56	3.65e-14	Body mass index;
PAAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.46	5.75	0.42	4.66e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7249921	0.833	rs7255878	chr19:35667192	C/T	cg11856182	chr19:35264148	ZNF599	-0.56	-5.05	-0.38	1.26e-6	Platelet count;
PAAD	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.65	0.42	7.66e-8	Height;
PAAD	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.47	-4.93	-0.37	2.14e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11123056	chr17:74553845	SNORD1C	0.61	6.84	0.49	1.81e-10	Myopia (pathological);
PAAD	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg08698997	chr16:88989212	CBFA2T3	0.5	5.85	0.43	2.91e-8	Social autistic-like traits;
PAAD	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg05528293	chr18:74961138	GALR1	0.55	5.04	0.38	1.31e-6	Obesity-related traits;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.43	4.31	0.33	2.92e-5	Longevity;Endometriosis;
PAAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.7	0.66	2.9e-20	Smoking behavior;
PAAD	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg27234864	chr13:21295941	IL17D	0.64	5.48	0.41	1.71e-7	PR segment;
PAAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.51	4.54	0.35	1.12e-5	Anterior chamber depth;
PAAD	cis	rs4144027	0.740	rs8015761	chr14:104353308	T/C	cg26031613	chr14:104095156	KLC1	0.44	4.37	0.33	2.29e-5	Blood metabolite levels;
PAAD	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.71	-7.35	-0.51	1.16e-11	Body mass index;
PAAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg15448220	chr1:150897856	SETDB1	-0.64	-6.62	-0.47	5.69e-10	Tonsillectomy;
PAAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.77	-9.25	-0.6	1.89e-16	Height;
PAAD	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2662368	0.522	rs35547081	chr5:77118549	T/C	cg02570643	chr5:77531473	AP3B1	-0.43	-4.64	-0.35	7.35e-6	Platelet distribution width;
PAAD	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.61	-7.57	-0.52	3.33e-12	Schizophrenia;
PAAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg00576331	chr11:65640516	EFEMP2	0.46	4.36	0.33	2.34e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.63	6.25	0.45	3.98e-9	Coronary artery disease;
PAAD	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	4.87	0.37	2.81e-6	Parkinson's disease;
PAAD	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.79	5.31	0.4	3.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	4.67	0.35	6.51e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.63	8.91	0.59	1.43e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7260598	0.539	rs73525888	chr19:24069841	G/T	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-1.0	-10.39	-0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg18338521	chr10:69995036	NA	-0.34	-4.43	-0.34	1.76e-5	Optic disc area;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.74	0.42	5.01e-8	Alzheimer's disease;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg23708337	chr7:1209742	NA	0.65	5.16	0.39	7.62e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.98	-10.57	-0.65	6.35e-20	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.51	0.57	1.55e-14	Colorectal cancer;
PAAD	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg08501292	chr6:25962987	TRIM38	0.9	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11811982	0.793	rs80297171	chr1:227516320	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1043763	0.826	rs11061153	chr12:122615033	G/A	cg26218692	chr12:122497826	BCL7A	-0.56	-5.15	-0.39	8.12e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.85	10.71	0.66	2.73e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.87	0.37	2.83e-6	Breast cancer;
PAAD	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg06217071	chr17:408420	NA	0.77	9.45	0.61	5.83e-17	Hip circumference adjusted for BMI;
PAAD	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	1.08	14.67	0.77	6.6e-31	Headache;
PAAD	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	1.04	7.11	0.5	4.15e-11	Mitochondrial DNA levels;
PAAD	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.2	10.6	0.65	5.23e-20	Uric acid levels;
PAAD	trans	rs785830	0.558	rs9408082	chr9:262207	G/C	cg17093826	chr7:138458720	ATP6V0A4	0.5	6.47	0.46	1.27e-9	Platelet distribution width;
PAAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg21951975	chr1:209979733	IRF6	-0.55	-4.78	-0.36	4.17e-6	Coronary artery disease;
PAAD	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg05585544	chr11:47624801	NA	-0.48	-5.35	-0.4	3.16e-7	Subjective well-being;
PAAD	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg11204139	chr17:3907470	NA	0.71	6.35	0.46	2.37e-9	Type 2 diabetes;
PAAD	cis	rs73198271	0.628	rs76079102	chr8:8591553	A/T	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12379764	chr21:47803548	PCNT	-0.47	-4.45	-0.34	1.64e-5	Testicular germ cell tumor;
PAAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06544989	chr22:39130855	UNC84B	0.51	5.03	0.38	1.38e-6	Menopause (age at onset);
PAAD	cis	rs10465746	0.545	rs12145516	chr1:84480376	A/G	cg10977910	chr1:84465055	TTLL7	0.48	4.35	0.33	2.52e-5	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg15017067	chr4:17643749	FAM184B	0.42	4.81	0.36	3.67e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs7567389	0.638	rs12105051	chr2:127990177	T/G	cg11380483	chr2:127933992	NA	-0.48	-4.7	-0.36	5.87e-6	Self-rated health;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.52	0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs13242816	1.000	rs13235720	chr7:116113663	T/C	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg02683114	chr2:24398427	C2orf84	0.57	5.84	0.43	3.02e-8	Asthma;
PAAD	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg13263323	chr15:86062960	AKAP13	0.64	7.31	0.51	1.44e-11	Coronary artery disease;
PAAD	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06850241	chr22:41845214	NA	-0.61	-5.3	-0.39	4.03e-7	Vitiligo;
PAAD	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg27130406	chr16:89901659	SPIRE2	-0.62	-5.13	-0.38	8.77e-7	Skin aging (microtopography measurement);
PAAD	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.81	-0.53	8.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	0.97	6.82	0.48	2.06e-10	IgG glycosylation;
PAAD	cis	rs6426833	0.715	rs6670226	chr1:20194702	A/T	cg11186344	chr1:19253694	IFFO2	0.33	4.28	0.33	3.33e-5	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.13	-0.6	3.91e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs12935418	0.616	rs8045512	chr16:80986307	A/G	cg16651780	chr16:81037892	C16orf61	0.58	4.76	0.36	4.51e-6	Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg23024343	chr7:107201750	COG5	-0.56	-4.61	-0.35	8.37e-6	Coronary artery disease;
PAAD	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.61	7.98	0.54	3.3e-13	Breast cancer;
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.5	4.98	0.37	1.69e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18297960	chr7:1142765	C7orf50	-0.56	-4.3	-0.33	3.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.33	-0.33	2.75e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg00700412	chr12:58011837	NA	0.44	4.7	0.36	5.74e-6	Multiple sclerosis;
PAAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg14851346	chr12:38532713	NA	0.49	4.52	0.34	1.25e-5	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.62	5.64	0.42	8.23e-8	Retinal vascular caliber;
PAAD	cis	rs9447004	1.000	rs9442968	chr6:74508564	A/G	cg22208108	chr6:74363775	SLC17A5	-0.45	-4.34	-0.33	2.56e-5	Blood protein levels;Calcium levels;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	6.07	0.44	9.99e-9	Height;
PAAD	cis	rs758324	0.812	rs1875176	chr5:131202457	A/G	cg06307176	chr5:131281290	NA	-0.49	-4.32	-0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.75	9.13	0.6	3.92e-16	Huntington's disease progression;
PAAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs10214930	0.723	rs1524529	chr7:27620415	C/G	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.61	-5.43	-0.4	2.14e-7	Systemic lupus erythematosus;
PAAD	cis	rs300774	0.925	rs6732024	chr2:148410	A/G	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.71	7.12	0.5	4.04e-11	Obesity-related traits;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.64	4.43	0.34	1.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4280164	0.945	rs3181384	chr14:24786976	C/T	cg07162820	chr14:24837146	NFATC4	0.38	4.38	0.33	2.24e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs4845552	0.767	rs16835366	chr1:153468106	A/G	cg15998505	chr1:153479701	NA	0.5	4.53	0.34	1.2e-5	Hippocampal atrophy;
PAAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg03983476	chr2:10830698	NOL10	-0.59	-5.77	-0.42	4.28e-8	Prostate cancer;
PAAD	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.48	7.67	0.53	1.97e-12	IgG glycosylation;
PAAD	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.75	0.53	1.24e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.01	17.79	0.82	5.53e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-6.48	-0.47	1.23e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.67	0.53	1.9e-12	Cognitive test performance;
PAAD	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	4.86	0.37	2.87e-6	Lung cancer;
PAAD	trans	rs6532374	0.872	rs62307845	chr4:93469959	C/T	cg01163837	chr2:31457287	EHD3	-0.71	-6.3	-0.46	3.1e-9	Interleukin-12p70 levels;
PAAD	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs1198430	0.599	rs946269	chr1:23769359	T/C	cg19827787	chr1:23763612	ASAP3	0.58	4.79	0.36	3.84e-6	Total cholesterol levels;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.38	4.38	0.34	2.16e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.84	9.53	0.61	3.61e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Depression;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.56	0.52	3.52e-12	Prudent dietary pattern;
PAAD	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.85	-0.37	3.08e-6	Hirschsprung disease;
PAAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.37	0.4	2.96e-7	Lung function (FEV1/FVC);
PAAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-4.88	-0.37	2.63e-6	Height;
PAAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.77	0.53	1.11e-12	HIV-1 control;
PAAD	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg24399712	chr22:39784796	NA	-0.62	-5.8	-0.43	3.7e-8	IgG glycosylation;
PAAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.57	-7.31	-0.51	1.4e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4273100	0.512	rs1355128	chr17:19299144	G/A	cg18093559	chr17:18951025	GRAP	0.45	4.7	0.36	5.84e-6	Schizophrenia;
PAAD	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg09399716	chr2:46890238	NA	-0.51	-4.49	-0.34	1.42e-5	Height;
PAAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs2020921	0.510	rs11784813	chr8:41979431	A/G	cg12054981	chr8:42037387	PLAT	-0.75	-5.25	-0.39	5.12e-7	Plasma plasminogen activator levels;
PAAD	cis	rs2492906	0.600	rs2815489	chr10:28061420	A/G	cg25523538	chr10:28031957	MKX	0.46	4.25	0.33	3.66e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs10792830	0.706	rs545592	chr11:85762118	T/C	cg07180834	chr11:85838833	NA	-0.48	-5.36	-0.4	3.09e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	1.0	11.86	0.69	2.23e-23	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4765663	0.872	rs11062105	chr12:2180596	C/T	cg24952640	chr12:3108225	TEAD4	-0.66	-4.88	-0.37	2.7e-6	Aortic root size;
PAAD	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.34	0.4	3.31e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-6.16	-0.45	6.11e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-1.04	-14.59	-0.76	1.02e-30	Breast cancer;
PAAD	cis	rs7792596	0.861	rs7788014	chr7:94012278	C/T	cg20814616	chr7:94014465	NA	0.51	5.39	0.4	2.64e-7	Intelligence;
PAAD	cis	rs7552393	0.636	rs6696585	chr1:84287850	T/A	cg10977910	chr1:84465055	TTLL7	0.58	5.51	0.41	1.48e-7	Select biomarker traits;
PAAD	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08978859	chr3:49066699	IMPDH2	0.72	7.56	0.52	3.52e-12	Obesity-related traits;
PAAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.74	8.81	0.58	2.6e-15	Lung cancer;
PAAD	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg08992911	chr2:238395768	MLPH	0.53	5.4	0.4	2.54e-7	Prostate cancer;
PAAD	cis	rs8067354	0.574	rs1292043	chr17:57934169	A/G	cg02344993	chr17:57696989	CLTC	0.58	4.71	0.36	5.5e-6	Hemoglobin concentration;
PAAD	cis	rs9361491	0.608	rs9352619	chr6:79442714	G/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.49	6.51	0.47	1.06e-9	Life satisfaction;
PAAD	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg07841815	chr7:100318223	EPO	-0.48	-4.4	-0.34	2.05e-5	Other erythrocyte phenotypes;
PAAD	cis	rs1075265	1.000	rs1075265	chr2:54354927	C/G	cg04546899	chr2:54196757	PSME4	0.33	4.66	0.35	6.85e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.66	9.16	0.6	3.28e-16	Airflow obstruction;
PAAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.76	-8.72	-0.58	4.44e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.31e-17	Cognitive function;
PAAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg08132940	chr7:1081526	C7orf50	0.63	4.91	0.37	2.35e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.63	-5.96	-0.44	1.72e-8	Body mass index;
PAAD	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg25730555	chr22:47059586	GRAMD4	0.46	4.38	0.33	2.19e-5	Urate levels in obese individuals;
PAAD	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.44	4.28	0.33	3.27e-5	Mortality in heart failure;
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.72	8.11	0.55	1.5700000000000001e-13	Height;
PAAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg04257695	chr17:30186438	C17orf79	0.69	5.02	0.38	1.41e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.67	6.32	0.46	2.82e-9	Initial pursuit acceleration;
PAAD	trans	rs11890236	0.579	rs12622008	chr2:104730389	A/G	cg08715231	chr8:25906064	NA	0.61	6.46	0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.66	-6.77	-0.48	2.6200000000000003e-10	Testicular germ cell tumor;
PAAD	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs6074578	0.679	rs12626088	chr20:139154	A/G	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.65	-0.62	1.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.6	-5.87	-0.43	2.59e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.76	6.77	0.48	2.69e-10	Quantitative traits;
PAAD	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.44	-5.24	-0.39	5.24e-7	Body mass index;
PAAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.59	5.43	0.4	2.2e-7	Monocyte count;
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs6076065	0.511	rs2424560	chr20:23431665	C/T	cg11657817	chr20:23433608	CST11	0.59	6.14	0.45	6.73e-9	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.86	-9.89	-0.63	4.16e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg15117754	chr3:10150083	C3orf24	0.68	6.38	0.46	2.07e-9	Alzheimer's disease;
PAAD	cis	rs8077577	0.708	rs3829589	chr17:18134266	T/C	cg03916694	chr17:18150707	FLII	-0.39	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs2414095	0.527	rs11636667	chr15:51542193	C/T	cg21478137	chr15:51532386	CYP19A1	0.54	5.5	0.41	1.58e-7	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
PAAD	cis	rs2882667	0.690	rs288039	chr5:138206200	G/T	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1043763	0.826	rs4758689	chr12:122611004	A/T	cg26218692	chr12:122497826	BCL7A	-0.66	-6.65	-0.47	4.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs731174	0.559	rs10908376	chr1:38196026	G/A	cg06917450	chr1:38156652	C1orf109	-0.59	-5.05	-0.38	1.24e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62238980	0.614	rs9609388	chr22:32334739	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.81	4.43	0.34	1.8e-5	Childhood ear infection;
PAAD	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.89	8.94	0.59	1.22e-15	Corneal astigmatism;
PAAD	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg14515779	chr1:101123966	NA	-0.54	-6.67	-0.48	4.53e-10	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27638778	chr16:788935	NARFL	-0.65	-6.5	-0.47	1.06e-9	Obesity-related traits;
PAAD	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.79	8.94	0.59	1.26e-15	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.8	5.76	0.42	4.49e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.08	-11.29	-0.68	7.68e-22	Blood pressure (smoking interaction);
PAAD	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.39	-5.57	-0.41	1.15e-7	Breast cancer;
PAAD	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg10705379	chr10:99080932	FRAT1	0.39	4.58	0.35	9.56e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.63	-0.35	7.69e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01426354	chr20:33999881	UQCC	0.62	6.62	0.47	5.93e-10	Myopia (pathological);
PAAD	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs7766436	0.583	rs7757926	chr6:22561611	C/A	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg22442454	chr1:209979470	IRF6	0.5	4.28	0.33	3.33e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.31	4.78	0.36	4.12e-6	Menarche (age at onset);
PAAD	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.68	7.14	0.5	3.69e-11	Schizophrenia;
PAAD	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06850241	chr22:41845214	NA	-0.61	-5.41	-0.4	2.39e-7	Vitiligo;
PAAD	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg18551225	chr6:44695536	NA	-0.67	-6.59	-0.47	6.81e-10	Total body bone mineral density;
PAAD	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg20356878	chr3:121714668	ILDR1	0.51	4.88	0.37	2.71e-6	Cognitive performance;
PAAD	cis	rs10515457	0.848	rs2162767	chr5:132652976	C/T	cg00557469	chr5:133562427	PPP2CA	-0.53	-4.35	-0.33	2.48e-5	Eyebrow thickness;
PAAD	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs35160687	0.901	rs12472676	chr2:86510815	T/C	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.58	-5.9	-0.43	2.22e-8	Coronary artery disease;
PAAD	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg26338869	chr17:61819248	STRADA	-0.8	-8.35	-0.56	3.87e-14	Prudent dietary pattern;
PAAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg00579200	chr11:133705235	NA	-0.48	-5.55	-0.41	1.23e-7	Childhood ear infection;
PAAD	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.5	5.76	0.42	4.48e-8	Coronary artery disease;
PAAD	cis	rs11264799	0.520	rs849817	chr1:157542045	G/A	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs4478858	0.746	rs12136121	chr1:31689743	G/C	cg00250761	chr1:31883323	NA	0.4	4.45	0.34	1.68e-5	Alcohol dependence;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.92	0.43	2.09e-8	Prudent dietary pattern;
PAAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg13468214	chr4:1046988	NA	-0.53	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.64	-5.51	-0.41	1.47e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg20487152	chr13:99095054	FARP1	0.46	4.7	0.36	5.73e-6	Longevity;
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.52	-0.57	1.48e-14	Initial pursuit acceleration;
PAAD	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg15956490	chr3:53032818	SFMBT1	-0.71	-4.43	-0.34	1.76e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.49	4.7	0.36	5.86e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs10894604	0.520	rs10894605	chr11:132654027	A/G	cg03590420	chr11:132662963	OPCML	-0.41	-4.58	-0.35	9.56e-6	Waist-hip ratio;
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg03094675	chr11:5960213	NA	-0.46	-4.32	-0.33	2.84e-5	DNA methylation (variation);
PAAD	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.54	0.57	1.28e-14	Homoarginine levels;
PAAD	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg02683114	chr2:24398427	C2orf84	-0.54	-5.15	-0.39	8.06e-7	Asthma;
PAAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg19337854	chr7:99768885	GPC2	0.48	4.43	0.34	1.77e-5	Platelet count;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.93	-0.37	2.16e-6	Platelet count;
PAAD	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	4.38	0.33	2.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1.02e-7	Alzheimer's disease;
PAAD	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.92	9.2	0.6	2.68e-16	Orofacial clefts;
PAAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg12215294	chr3:40350768	EIF1B	0.47	4.67	0.35	6.44e-6	Renal cell carcinoma;
PAAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.73	-11.1	-0.67	2.4e-21	Body mass index;
PAAD	cis	rs354033	0.837	rs60206402	chr7:149189637	G/A	cg06920324	chr7:149264011	ZNF767	-0.56	-4.75	-0.36	4.6e-6	Multiple sclerosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12744888	chr3:108248186	MYH15	0.61	6.43	0.46	1.58e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13348293	chr10:28821714	WAC	0.68	7.17	0.5	3.01e-11	Myopia (pathological);
PAAD	cis	rs7808424	0.562	rs3779545	chr7:116935563	A/G	cg00307073	chr7:116502428	CAPZA2	0.7	4.48	0.34	1.44e-5	Coronary heart disease;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg08835956	chr7:39171034	POU6F2	0.33	5.8	0.43	3.74e-8	IgG glycosylation;
PAAD	cis	rs7727544	0.625	rs3864277	chr5:131420249	G/A	cg14196790	chr5:131705035	SLC22A5	0.48	5.13	0.38	8.83e-7	Blood metabolite levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12428298	chr2:71206811	ANKRD53	0.61	6.3	0.46	3.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11966931	0.948	rs112065868	chr6:108088207	C/T	cg10566610	chr6:108093680	SCML4	0.48	4.51	0.34	1.26e-5	Neutrophil percentage of white cells;
PAAD	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.58	5.36	0.4	3.07e-7	Malaria;
PAAD	cis	rs9913156	0.748	rs72835635	chr17:4563127	A/G	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg09659197	chr4:152720779	NA	0.35	5.13	0.38	8.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.65	6.3	0.46	3.04e-9	Obesity-related traits;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs10943724	0.679	rs471335	chr6:81226896	G/A	cg19323245	chr6:80716898	TTK	-0.46	-4.7	-0.36	5.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	5.01	0.38	1.48e-6	Yeast infection;
PAAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg16606324	chr3:10149918	C3orf24	0.77	6.2	0.45	5.08e-9	Alzheimer's disease;
PAAD	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg14631576	chr9:95140430	CENPP	-0.62	-5.96	-0.44	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10242455	0.571	rs79694709	chr7:99214711	C/G	cg18809830	chr7:99032528	PTCD1	-1.1	-4.81	-0.36	3.66e-6	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.54	5.31	0.4	3.85e-7	Multiple sclerosis;
PAAD	cis	rs3867498	0.943	rs17178787	chr15:25071780	C/T	cg08194505	chr15:25684383	UBE3A	0.7	4.82	0.36	3.49e-6	Pulmonary function;
PAAD	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs7551222	0.752	rs12133735	chr1:204556836	G/T	cg01064725	chr1:204461714	NA	-0.54	-5.18	-0.39	6.93e-7	Schizophrenia;
PAAD	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.68	-6.3	-0.46	3.1e-9	Endometrial cancer;
PAAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.15	16.73	0.8	2.77e-36	Cognitive function;
PAAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.38	-0.4	2.73e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21595737	chr14:54955895	GMFB	0.57	6.46	0.46	1.37e-9	Monocyte percentage of white cells;
PAAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.43	4.79	0.36	3.92e-6	Type 2 diabetes;
PAAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.68	7.13	0.5	3.75e-11	Colorectal cancer;
PAAD	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.5	-4.45	-0.34	1.66e-5	Atopic dermatitis;
PAAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.6	0.41	9.98e-8	Bipolar disorder;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg05373962	chr22:49881684	NA	-0.54	-5.24	-0.39	5.21e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs60154123	0.730	rs12040684	chr1:210472053	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.5	0.41	1.56e-7	Coronary artery disease;
PAAD	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.76	6.54	0.47	8.72e-10	Schizophrenia;
PAAD	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.57	0.47	7.66e-10	High light scatter reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15750611	chr11:68191055	LRP5	-0.64	-6.32	-0.46	2.75e-9	Obesity-related traits;
PAAD	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.22	-0.51	2.33e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.34	-0.46	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.42	4.41	0.34	1.96e-5	Schizophrenia;
PAAD	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.58	6.26	0.45	3.76e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg01831904	chr17:28903510	LRRC37B2	0.83	6.24	0.45	4.05e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72960926	0.744	rs56077244	chr6:74920700	A/G	cg03266952	chr6:74778945	NA	-1.11	-6.29	-0.45	3.21e-9	Metabolite levels (MHPG);
PAAD	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.41	-6.07	-0.44	9.84e-9	Subjective well-being;
PAAD	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg14440974	chr22:39074834	NA	-0.57	-6.54	-0.47	8.76e-10	Menopause (age at onset);
PAAD	cis	rs4427176	0.765	rs10100914	chr8:9616425	C/A	cg03024720	chr8:9765601	NA	-0.47	-4.44	-0.34	1.75e-5	Mosquito bite size;
PAAD	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg20542592	chr8:11973495	FAM66D	0.46	4.38	0.33	2.2e-5	Retinal vascular caliber;
PAAD	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg21130718	chr4:1044621	NA	0.48	4.71	0.36	5.61e-6	Recombination rate (males);
PAAD	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.44	-4.84	-0.37	3.2e-6	Breast cancer;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.57	4.7	0.36	5.67e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.54	-0.41	1.27e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.55	-0.35	1.1e-5	Breast cancer;
PAAD	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg00035074	chr7:2701567	TTYH3	0.68	4.69	0.36	6.11e-6	Bipolar disorder;
PAAD	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.55	-0.35	1.09e-5	Retinal vascular caliber;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	0.850	rs35081812	chr10:45995789	C/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.63	0.42	8.67e-8	HDL cholesterol;
PAAD	cis	rs8040855	0.965	rs1961276	chr15:85714217	C/T	cg08123816	chr15:85640762	PDE8A	-0.38	-4.37	-0.33	2.32e-5	Bulimia nervosa;
PAAD	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg00908766	chr1:109817496	CELSR2	0.58	6.36	0.46	2.26e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
PAAD	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg02250501	chr15:90694978	NA	-0.47	-4.44	-0.34	1.71e-5	Rheumatoid arthritis;
PAAD	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.06	-0.55	2.13e-13	Brugada syndrome;
PAAD	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.73	7.31	0.51	1.45e-11	Schizophrenia;
PAAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.97	-13.25	-0.73	3.92e-27	Height;
PAAD	cis	rs11129295	0.618	rs9816235	chr3:27803017	A/C	cg21473142	chr3:27762095	EOMES	0.29	4.75	0.36	4.74e-6	Multiple sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22233152	chr17:62833729	PLEKHM1P	0.63	6.51	0.47	1.05e-9	Obesity-related traits;
PAAD	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg14061069	chr19:46274453	DMPK	0.61	5.61	0.41	9.47e-8	Eosinophil counts;
PAAD	cis	rs354033	0.959	rs4727091	chr7:149267704	G/A	cg06920324	chr7:149264011	ZNF767	-0.62	-5.16	-0.39	7.75e-7	Multiple sclerosis;
PAAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.5	4.54	0.35	1.15e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.62	9.68	0.62	1.48e-17	Migraine;
PAAD	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.6	-5.37	-0.4	2.85e-7	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.39	-0.46	1.88e-9	Breast cancer;
PAAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.78	-8.23	-0.56	7.92e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.87	-7.28	-0.51	1.72e-11	Blood protein levels;
PAAD	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.45	4.74	0.36	4.96e-6	QRS complex (12-leadsum);
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.9	7.85	0.54	6.93e-13	Alzheimer's disease;
PAAD	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.49	-0.34	1.38e-5	Height;
PAAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg13918804	chr1:2043761	PRKCZ	0.4	5.4	0.4	2.57e-7	Height;
PAAD	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.79	-9.02	-0.59	7.67e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.98	0.37	1.74e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.49e-6	Tonsillectomy;
PAAD	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	5.56	0.41	1.19e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg17470449	chr10:769945	NA	0.5	4.97	0.37	1.75e-6	Uric acid levels;
PAAD	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs8042680	1.000	rs12593261	chr15:91520319	T/C	cg08919649	chr15:91565780	VPS33B	0.48	4.28	0.33	3.29e-5	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg15117754	chr3:10150083	C3orf24	0.61	5.33	0.4	3.53e-7	Alzheimer's disease;
PAAD	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964492	0.898	rs10155941	chr7:134422732	T/C	cg22430036	chr7:134592620	CALD1	-0.43	-4.43	-0.34	1.77e-5	Tonsillectomy;
PAAD	cis	rs7216064	0.954	rs12602556	chr17:65826861	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-5.66	-0.42	7.48e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-5.55	-0.41	1.25e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	trans	rs10511378	1.000	rs1520115	chr3:118182377	C/T	cg19885331	chr19:12512166	ZNF799	-0.7	-6.37	-0.46	2.08e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg15017067	chr4:17643749	FAM184B	0.43	4.72	0.36	5.38e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.85e-10	Neurofibrillary tangles;
PAAD	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg14583973	chr4:3374767	RGS12	0.42	6.1	0.44	8.3e-9	Serum sulfate level;
PAAD	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.81	6.65	0.47	5.08e-10	Type 2 diabetes;
PAAD	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.46	-5.74	-0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.72	7.98	0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs6142102	0.924	rs6059662	chr20:32675727	C/T	cg06115741	chr20:33292138	TP53INP2	-0.53	-4.43	-0.34	1.82e-5	Skin pigmentation;
PAAD	cis	rs794728	0.502	rs62394137	chr5:173864038	T/C	cg20434911	chr5:173954559	NA	-0.49	-4.59	-0.35	9.08e-6	Depressive symptoms (SSRI exposure interaction);
PAAD	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.57	-6.18	-0.45	5.57e-9	Birth weight;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.8	-0.48	2.2e-10	Mitochondrial DNA levels;
PAAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.5	4.81	0.36	3.53e-6	Longevity;
PAAD	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.71e-5	Ulcerative colitis;
PAAD	cis	rs9287719	0.593	rs13009015	chr2:10763118	T/A	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs11129295	0.618	rs55998928	chr3:27807730	A/G	cg21473142	chr3:27762095	EOMES	0.27	4.47	0.34	1.53e-5	Multiple sclerosis;
PAAD	cis	rs10929159	0.928	rs7557693	chr2:236920713	G/A	cg14226755	chr2:236923322	AGAP1	0.28	4.5	0.34	1.33e-5	Parkinson's disease;
PAAD	trans	rs17073641	0.500	rs113884146	chr18:62456176	C/T	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg03568305	chr17:38183559	MED24;SNORD124	0.36	4.75	0.36	4.66e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.51	0.34	1.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11615916	0.790	rs73135299	chr12:62698859	G/A	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg14458575	chr2:238380390	NA	0.57	4.85	0.37	3.03e-6	Prostate cancer;
PAAD	cis	rs7897654	0.571	rs12767543	chr10:104631663	G/A	cg15744005	chr10:104629667	AS3MT	-0.5	-4.68	-0.36	6.24e-6	Schizophrenia;
PAAD	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.0	-0.49	7.81e-11	Triglycerides;
PAAD	cis	rs112990264	1.000	rs113951608	chr1:213019672	A/T	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.02	0.55	2.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.47	4.27	0.33	3.39e-5	Self-reported allergy;
PAAD	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-4.69	-0.36	5.93e-6	Vitiligo;
PAAD	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.77	7.94	0.54	4.06e-13	Body mass index;
PAAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.1	0.38	9.76e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg00280220	chr17:61926910	NA	0.45	4.67	0.35	6.51e-6	Prudent dietary pattern;
PAAD	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.49	4.39	0.34	2.14e-5	Lung cancer;
PAAD	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs72827839	1.000	rs72827830	chr17:46397502	T/C	cg23391107	chr17:45924227	SP6	0.61	5.19	0.39	6.75e-7	Ease of getting up in the morning;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg15590007	chr10:45870220	ALOX5	0.6	6.01	0.44	1.3e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.48	-0.34	1.45e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.12	0.55	1.45e-13	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.84	0.54	7.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg20913747	chr6:44695427	NA	-0.69	-6.93	-0.49	1.11e-10	Total body bone mineral density;
PAAD	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg14146966	chr2:61757674	XPO1	0.39	4.81	0.36	3.55e-6	Tuberculosis;
PAAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.08	-0.59	5.22e-16	Type 2 diabetes;
PAAD	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.64	7.71	0.53	1.54e-12	Sense of smell;
PAAD	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg19418458	chr7:158789849	NA	0.53	4.44	0.34	1.73e-5	Facial morphology (factor 20);
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.73	-0.48	3.17e-10	Lymphocyte counts;
PAAD	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.58	0.35	9.52e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg02841227	chr6:26021843	HIST1H4A	-0.44	-4.35	-0.33	2.53e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.31	-0.46	2.88e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.72	-6.45	-0.46	1.41e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.43	4.58	0.35	9.62e-6	Aortic root size;
PAAD	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.54	5.08	0.38	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4787951	0.568	rs12933581	chr16:27304848	G/A	cg08008352	chr16:27322356	NA	0.5	4.63	0.35	7.85e-6	Eosinophil percentage of white cells;
PAAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22530822	chr17:61905144	FTSJ3;PSMC5	-0.72	-6.31	-0.46	2.97e-9	Neuroticism;
PAAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.13	0.55	1.36e-13	Coffee consumption (cups per day);
PAAD	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg22089800	chr15:90895588	ZNF774	-0.57	-5.23	-0.39	5.64e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	6.23	0.45	4.35e-9	Hip circumference;
PAAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.82	-0.36	3.49e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455799	0.927	rs7624256	chr3:15843274	G/A	cg13420985	chr3:16524424	RFTN1	-0.46	-4.33	-0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.3	-0.33	3.05e-5	Body mass index;
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg02776659	chr21:47717406	C21orf57	-0.46	-5.07	-0.38	1.14e-6	Testicular germ cell tumor;
PAAD	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg00179576	chr16:74483694	GLG1	-0.4	-4.46	-0.34	1.56e-5	Testicular germ cell tumor;
PAAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.81	-0.36	3.55e-6	Blood metabolite levels;
PAAD	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	1.01	7.68	0.53	1.83e-12	Dental caries;
PAAD	cis	rs55728055	0.661	rs12160763	chr22:31794754	A/G	cg01338084	chr22:32026380	PISD	1.4	7.05	0.5	5.87e-11	Age-related hearing impairment;
PAAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg16928487	chr17:17741425	SREBF1	0.36	4.79	0.36	3.9e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.52	5.51	0.41	1.53e-7	Life satisfaction;
PAAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.67	7.17	0.5	3.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs914615	0.508	rs4971079	chr1:155130391	C/T	cg18645493	chr1:154167437	MIR190B	0.45	4.34	0.33	2.57e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.54	6.11	0.44	7.8e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg10556349	chr10:835070	NA	0.58	4.92	0.37	2.26e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.55	7.23	0.51	2.18e-11	Primary biliary cholangitis;
PAAD	cis	rs939584	1.000	rs7561317	chr2:644953	A/G	cg03610516	chr2:642275	NA	0.66	5.82	0.43	3.34e-8	Body mass index;
PAAD	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.42	-0.4	2.33e-7	Total cholesterol levels;
PAAD	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13476313	chr9:127244764	NR5A1	-0.32	-5.18	-0.39	6.97e-7	Menarche (age at onset);
PAAD	cis	rs11681884	0.786	rs1992761	chr2:113810286	C/T	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg18551225	chr6:44695536	NA	-0.68	-7.91	-0.54	5e-13	Total body bone mineral density;
PAAD	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-4.34	-0.33	2.63e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.46	6.38	0.46	2.06e-9	Cardiovascular disease risk factors;
PAAD	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.16	-0.55	1.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.65	6.34	0.46	2.51e-9	Menarche (age at onset);
PAAD	cis	rs2013441	0.613	rs11204422	chr17:19996429	A/T	cg25070565	chr17:20044324	CYTSB	0.46	4.86	0.37	2.93e-6	Obesity-related traits;
PAAD	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.69	7.21	0.51	2.4e-11	Monocyte count;
PAAD	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.44	-5.93	-0.43	2e-8	Type 1 diabetes;
PAAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-5.59	-0.41	1.01e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.71	-6.57	-0.47	7.59e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	trans	rs11794666	1.000	rs2375604	chr9:31668430	T/A	cg05628366	chr6:35744188	C6orf126	1.0	6.41	0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs733175	0.951	rs6826764	chr4:10030794	C/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.59	-0.41	1.03e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-5.61	-0.41	9.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.32	0.33	2.86e-5	IgG glycosylation;
PAAD	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-13.98	-0.75	4.56e-29	Schizophrenia;
PAAD	cis	rs357618	1.000	rs193299	chr5:150847655	G/C	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	9.13	0.6	3.99e-16	Ulcerative colitis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00512374	chr17:38599682	IGFBP4	-0.58	-6.68	-0.48	4.26e-10	Body fat percentage;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08677398	chr8:58056175	NA	0.68	4.66	0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.8	-0.36	3.76e-6	Lung cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26726589	chr20:306364	SOX12	0.54	6.54	0.47	8.89e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9810890	1.000	rs116641256	chr3:128587572	G/A	cg15676455	chr3:128564943	NA	-0.86	-4.43	-0.34	1.81e-5	Dental caries;
PAAD	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.54	4.59	0.35	9.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6782025	0.813	rs2126139	chr3:121145506	A/G	cg16417163	chr3:121280760	NA	-0.48	-4.88	-0.37	2.61e-6	Aging (facial);
PAAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.22	-0.39	5.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg25902810	chr10:99078978	FRAT1	-0.59	-5.28	-0.39	4.49e-7	Monocyte count;
PAAD	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.11	-0.44	8.13e-9	Coronary artery disease;
PAAD	cis	rs939584	0.877	rs13027828	chr2:632379	T/G	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.57	-7.58	-0.52	3.24e-12	Renal cell carcinoma;
PAAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-5.11	-0.38	9.64e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.86e-6	Refractive error;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21205803	chr2:211346899	CPS1	0.59	6.7	0.48	3.8e-10	Smoking initiation;
PAAD	cis	rs2339219	0.929	rs2082098	chr18:24383970	A/C	cg15671181	chr18:24443849	AQP4;C18orf16	0.38	4.29	0.33	3.16e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.25	0.45	3.9e-9	Skin colour saturation;
PAAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09256448	chr16:638327	NA	0.43	4.43	0.34	1.78e-5	Height;
PAAD	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.67	-5.93	-0.43	1.95e-8	Body mass index;
PAAD	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs12826942	0.879	rs7312066	chr12:42766380	G/C	cg19980929	chr12:42632907	YAF2	0.56	5.12	0.38	9.02e-7	Coronary artery disease;
PAAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.78	-7.35	-0.51	1.12e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01139808	chr6:170549344	NA	-0.52	-6.47	-0.46	1.29e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.25	-0.33	3.71e-5	Lung cancer;
PAAD	cis	rs35300120	0.719	rs58437968	chr1:233662301	A/G	cg23054119	chr1:233659267	NA	-0.58	-5.24	-0.39	5.26e-7	Cognitive function;
PAAD	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.84e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs58521262	0.556	rs10410470	chr19:23216991	T/C	cg02350677	chr19:23254381	NA	0.26	4.43	0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.66	-0.42	7.26e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs1557351	1.000	rs55892810	chr18:54747982	A/G	cg00016439	chr18:55018650	ST8SIA3	0.51	4.53	0.34	1.21e-5	Multiple sclerosis (age of onset);
PAAD	cis	rs6501435	0.875	rs2080540	chr17:69076979	T/C	cg00193521	chr17:68133597	NA	0.48	4.71	0.36	5.64e-6	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg14737131	chr10:104680354	CNNM2	0.44	4.31	0.33	2.93e-5	Arsenic metabolism;
PAAD	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.47	5.0	0.38	1.57e-6	Diastolic blood pressure;
PAAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.92	-8.69	-0.58	5.44e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.7	-6.13	-0.45	7.21e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1.01e-5	Renal cell carcinoma;
PAAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-4.41	-0.34	1.97e-5	Renal cell carcinoma;
PAAD	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg09165964	chr15:75287851	SCAMP5	0.43	4.38	0.33	2.17e-5	Caffeine consumption;
PAAD	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.5	-5.68	-0.42	6.65e-8	Airway imaging phenotypes;
PAAD	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.51	-4.53	-0.35	1.16e-5	Red blood cell traits;
PAAD	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.49	5.12	0.38	9.07e-7	Type 2 diabetes;
PAAD	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7547997	0.615	rs716221	chr1:158303872	C/T	cg26014409	chr1:158324471	CD1E	0.36	4.48	0.34	1.48e-5	QRS duration;
PAAD	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	5.87	0.43	2.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.82	0.48	2.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Body mass index;
PAAD	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.75	-0.36	4.69e-6	Height;
PAAD	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.56	-6.47	-0.46	1.27e-9	Aortic root size;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg04520793	chr17:42248056	ASB16	0.47	6.43	0.46	1.56e-9	Total body bone mineral density;
PAAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.51	6.56	0.47	8.1e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg00122941	chr17:4613640	ARRB2	-0.64	-6.5	-0.47	1.07e-9	Lymphocyte counts;
PAAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.61	-6.44	-0.46	1.47e-9	Menopause (age at onset);
PAAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-5.22	-0.39	5.72e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2271001	0.567	rs1393957	chr11:19172911	C/T	cg00161556	chr11:19138045	ZDHHC13	0.44	4.67	0.35	6.53e-6	Gut microbiome composition (winter);
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19860154	chr18:72999596	TSHZ1	-0.65	-6.5	-0.47	1.11e-9	Obesity-related traits;
PAAD	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg10864074	chr7:100318194	EPO	-0.47	-4.49	-0.34	1.43e-5	Other erythrocyte phenotypes;
PAAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.45	-0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2033711	0.936	rs893185	chr19:58989495	A/C	cg26874164	chr19:58962979	ZNF324B	0.48	4.5	0.34	1.32e-5	Uric acid clearance;
PAAD	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs3169166	0.500	rs12909123	chr15:78559843	A/G	cg09214398	chr15:78556534	DNAJA4	-0.29	-5.02	-0.38	1.46e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs12432203	1.000	rs72622438	chr14:51735903	C/T	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs11638815	0.603	rs783520	chr15:83279505	G/A	cg00614314	chr15:82944287	LOC80154	0.44	4.42	0.34	1.86e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg21724239	chr8:58056113	NA	0.67	5.14	0.38	8.41e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.67	6.76	0.48	2.82e-10	Morning vs. evening chronotype;
PAAD	cis	rs13223928	0.572	rs16870744	chr7:3135781	G/A	cg19214707	chr7:3157722	NA	-0.62	-5.79	-0.43	3.93e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.54	-5.1	-0.38	1.02e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08677398	chr8:58056175	NA	0.62	4.69	0.36	6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.72	7.53	0.52	4.18e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	5.12	0.38	9.32e-7	Height;
PAAD	cis	rs1345301	0.518	rs56238602	chr2:102863095	G/T	cg03938978	chr2:103052716	IL18RAP	-0.41	-4.42	-0.34	1.88e-5	Waist circumference;
PAAD	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	4.31	0.33	2.96e-5	Neuroticism;
PAAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.74	-0.48	3.04e-10	Glomerular filtration rate;
PAAD	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.16	-0.39	7.49e-7	Vitiligo;
PAAD	cis	rs10044254	0.563	rs4235555	chr5:15730368	C/T	cg07238450	chr5:15720153	FBXL7	-0.51	-4.84	-0.37	3.17e-6	Asthma (corticosteroid response);
PAAD	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg17514665	chr17:1657533	SERPINF2	0.66	6.06	0.44	1.02e-8	Serum albumin level;
PAAD	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg10395934	chr14:104002654	TRMT61A	0.58	5.97	0.44	1.57e-8	Body mass index;
PAAD	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.61	-5.53	-0.41	1.33e-7	Diisocyanate-induced asthma;
PAAD	cis	rs7631605	0.905	rs4579	chr3:37094679	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15541040	chr2:3486749	NA	0.59	5.73	0.42	5.2100000000000003e-08	Neurofibrillary tangles;
PAAD	cis	rs7264396	0.573	rs58355182	chr20:34075687	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.65	-0.42	7.51e-8	Total cholesterol levels;
PAAD	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.94	-0.43	1.89e-8	Rheumatoid arthritis;
PAAD	cis	rs12144049	0.662	rs1951523	chr1:152408461	C/T	cg25605289	chr1:151974222	NA	-0.35	-4.36	-0.33	2.42e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.51	-4.47	-0.34	1.52e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.26	-0.39	4.87e-7	Life satisfaction;
PAAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.35e-6	Parkinson's disease;
PAAD	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-4.96	-0.37	1.87e-6	Schizophrenia;
PAAD	cis	rs909341	0.909	rs2253823	chr20:62372956	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.59	-4.98	-0.37	1.7e-6	Atopic dermatitis;
PAAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs7763441	0.567	rs13196905	chr6:2429573	T/C	cg18740289	chr6:2437142	NA	-0.72	-7.37	-0.51	1.03e-11	Monobrow;
PAAD	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.65	-6.81	-0.48	2.13e-10	Capecitabine sensitivity;
PAAD	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.45	4.4	0.34	2e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg09659197	chr4:152720779	NA	-0.36	-5.35	-0.4	3.22e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs9463078	0.585	rs1748234	chr6:45140853	C/T	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11235843	0.853	rs1043234	chr11:73471761	C/A	cg18195628	chr11:73498948	MRPL48	0.78	4.33	0.33	2.73e-5	Hand grip strength;
PAAD	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.83	10.44	0.65	1.46e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.15	0.45	6.51e-9	Mean platelet volume;
PAAD	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.82	-0.62	6.17e-18	Response to antipsychotic treatment;
PAAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.73	10.16	0.64	7.76e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00292662	chr22:38071168	LGALS1	0.53	5.59	0.41	1.01e-7	Fat distribution (HIV);
PAAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.61	6.19	0.45	5.28e-9	Parkinson's disease;
PAAD	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg22089800	chr15:90895588	ZNF774	-0.55	-5.27	-0.39	4.54e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.79	5.61	0.41	9.47e-8	Monocyte percentage of white cells;
PAAD	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.97	-0.49	9.07e-11	Morning vs. evening chronotype;
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18364779	chr6:26104403	HIST1H4C	0.52	4.87	0.37	2.82e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.67e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.69	4.91	0.37	2.34e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs4427176	0.507	rs11785987	chr8:9587894	G/A	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg04844267	chr4:1394941	NA	0.45	4.87	0.37	2.78e-6	Longevity;
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.53	5.16	0.39	7.6e-7	Schizophrenia;
PAAD	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg13660082	chr14:53194042	PSMC6	0.74	4.59	0.35	9.33e-6	Alzheimer's disease (late onset);
PAAD	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs7588746	0.621	rs4672726	chr2:201149413	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.54	-5.05	-0.38	1.26e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.85e-17	Cognitive function;
PAAD	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs7517847	0.629	rs7518660	chr1:67685443	G/A	cg16314899	chr1:68516101	DIRAS3	-0.46	-4.58	-0.35	9.64e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.67	-6.23	-0.45	4.41e-9	White matter hyperintensity burden;
PAAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.51	-5.67	-0.42	6.88e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.61	-5.82	-0.43	3.45e-8	Cognitive test performance;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-5.2	-0.39	6.47e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12527284	chr5:75013342	C5orf37	0.71	6.58	0.47	7.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.83	9.46	0.61	5.67e-17	Total body bone mineral density;
PAAD	cis	rs6681460	0.549	rs7547794	chr1:67031878	A/G	cg02459107	chr1:67143332	SGIP1	0.62	6.66	0.48	4.68e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	trans	rs6076960	0.741	rs2021702	chr20:6178954	T/A	cg17788362	chr6:86352627	SYNCRIP	0.65	6.46	0.46	1.31e-9	Smooth-surface caries;
PAAD	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs10901513	0.932	rs2138275	chr10:127668610	C/T	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.16	15.17	0.78	3.09e-32	Type 1 diabetes nephropathy;
PAAD	cis	rs2006771	0.810	rs4820988	chr22:32065807	G/A	cg02404636	chr22:31891804	SFI1	-0.5	-5.19	-0.39	6.78e-7	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg08498647	chr11:118550644	TREH	0.4	4.28	0.33	3.24e-5	Sjögren's syndrome;
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18297960	chr7:1142765	C7orf50	-0.56	-4.42	-0.34	1.89e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.26e-10	Hair morphology;
PAAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27323780	chr13:28024626	MTIF3	0.6	6.96	0.49	9.58e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.69	7.46	0.52	6.19e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1075265	0.568	rs2542577	chr2:54049248	G/A	cg04546899	chr2:54196757	PSME4	0.3	4.4	0.34	1.99e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg04289385	chr6:36355825	ETV7	-0.45	-4.74	-0.36	4.85e-6	Platelet distribution width;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26456999	chr2:236900867	AGAP1	0.56	6.66	0.48	4.65e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.54	0.41	1.31e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2271400	0.556	rs7000249	chr8:56658213	T/C	cg08894788	chr8:56792171	LYN	-0.55	-5.28	-0.39	4.37e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg01868782	chr6:126071099	HEY2	0.45	5.35	0.4	3.14e-7	Brugada syndrome;
PAAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.86	0.37	2.89e-6	Schizophrenia;
PAAD	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.24	0.39	5.28e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.75	-0.36	4.6e-6	Bipolar disorder;
PAAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.58	5.87	0.43	2.62e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.2	0.45	4.99e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs3126085	0.515	rs12032854	chr1:152347361	G/A	cg26876637	chr1:152193138	HRNR	-0.68	-5.25	-0.39	4.95e-7	Atopic dermatitis;
PAAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.89	-0.43	2.44e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.41	5.11	0.38	9.55e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg05392440	chr1:2478653	NA	0.56	6.06	0.44	1.01e-8	Ulcerative colitis;
PAAD	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.7	6.52	0.47	9.77e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.7	-5.25	-0.39	5.02e-7	Initial pursuit acceleration;
PAAD	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-4.56	-0.35	1.06e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.78	7.59	0.52	2.92e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9715521	0.775	rs62301193	chr4:59844120	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.56	-6.19	-0.45	5.48e-9	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.62	-5.65	-0.42	7.6e-8	White blood cell count;
PAAD	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.12	-0.44	7.44e-9	Schizophrenia;
PAAD	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg18612461	chr15:75251733	NA	-0.39	-4.46	-0.34	1.62e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs793571	0.744	rs12901551	chr15:59160069	A/T	cg05156742	chr15:59063176	FAM63B	-0.65	-6.1	-0.44	8.52e-9	Schizophrenia;
PAAD	cis	rs12044355	1.000	rs12044355	chr1:231844347	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	5.17	0.39	7.44e-7	Alzheimer's disease;
PAAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.76	0.36	4.53e-6	Menopause (age at onset);
PAAD	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-4.66	-0.35	6.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.46	5.33	0.4	3.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.38e-7	Monocyte count;
PAAD	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.64	5.45	0.4	1.97e-7	Common traits (Other);
PAAD	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.59	-8.33	-0.56	4.48e-14	Venous thromboembolism;
PAAD	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg01304814	chr3:48885189	PRKAR2A	0.71	4.55	0.35	1.07e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg19486271	chr11:47235900	DDB2	-0.61	-5.97	-0.44	1.58e-8	Acne (severe);
PAAD	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.59	6.39	0.46	1.89e-9	Eye color traits;
PAAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	5.37	0.4	2.95e-7	Rheumatoid arthritis;
PAAD	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.66	6.75	0.48	2.91e-10	Testicular germ cell tumor;
PAAD	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg18612461	chr15:75251733	NA	-0.53	-5.01	-0.38	1.49e-6	Blood trace element (Zn levels);
PAAD	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-0.79	-5.34	-0.4	3.28e-7	Body mass index;
PAAD	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-6.16	-0.45	6.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs61759167	0.863	rs1393064	chr1:3099138	G/C	cg22674798	chr1:3096360	PRDM16	0.45	5.12	0.38	8.92e-7	Motion sickness;
PAAD	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10342447	chr17:26645325	TMEM97	-0.42	-5.68	-0.42	6.71e-8	Osteoprotegerin levels;
PAAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.81	7.34	0.51	1.21e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.57	5.45	0.4	2e-7	Platelet count;
PAAD	cis	rs564309	0.618	rs12061733	chr1:228523412	G/A	cg01328119	chr1:228783545	DUSP5P	0.74	4.52	0.34	1.26e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg09796270	chr17:17721594	SREBF1	-0.41	-4.52	-0.34	1.26e-5	Total body bone mineral density;
PAAD	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26592208	chr11:61477833	DAGLA	-0.65	-6.5	-0.47	1.06e-9	Obesity-related traits;
PAAD	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg00717180	chr2:96193071	NA	0.59	6.58	0.47	7.28e-10	HDL cholesterol;
PAAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg25833597	chr17:30823145	MYO1D	0.51	4.87	0.37	2.77e-6	Schizophrenia;
PAAD	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.93	-0.37	2.17e-6	QT interval;
PAAD	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.51	-4.51	-0.34	1.31e-5	Parkinson's disease;
PAAD	trans	rs3129682	1	rs3129682	chr6:29283672	C/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Blood protein levels;
PAAD	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-5.49	-0.41	1.62e-7	Resistin levels;
PAAD	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.77	5.96	0.44	1.68e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.5	5.34	0.4	3.29e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.12	-0.38	9.25e-7	Pulmonary function;
PAAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.11	-0.38	9.44e-7	Mean corpuscular volume;
PAAD	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg12215294	chr3:40350768	EIF1B	-0.48	-4.91	-0.37	2.37e-6	Renal cell carcinoma;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15340644	chr19:13262082	IER2;STX10	-0.66	-6.53	-0.47	9.39e-10	Lung cancer in ever smokers;
PAAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.28	0.56	5.94e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2594989	0.778	rs6801721	chr3:11470267	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.44	-0.34	1.7e-5	Circulating chemerin levels;
PAAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs59888335	0.929	rs13090674	chr3:80896557	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.98	-7.67	-0.53	1.88e-12	Initial pursuit acceleration;
PAAD	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-4.55	-0.35	1.11e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.26	0.64	4.21e-19	Menopause (age at onset);
PAAD	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.54	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.59	6.1	0.44	8.56e-9	Temperament;
PAAD	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	6.6	0.47	6.61e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	0.96	7.02	0.49	7.04e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg02580895	chr19:2754563	NA	-0.5	-4.3	-0.33	3.09e-5	Total cholesterol levels;
PAAD	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg16586182	chr3:47516702	SCAP	-0.68	-7.74	-0.53	1.31e-12	Colorectal cancer;
PAAD	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.42	6.25	0.45	3.89e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs73419609	0.867	rs73419633	chr15:54723018	G/A	cg11288833	chr15:55489084	RSL24D1	-1.01	-4.38	-0.33	2.2e-5	Post-traumatic stress disorder;
PAAD	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.46	-0.34	1.55e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.46	0.41	1.88e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2834256	1.000	rs2244966	chr21:35127360	C/T	cg14850771	chr21:34775459	IFNGR2	-0.48	-4.43	-0.34	1.76e-5	Red cell distribution width;
PAAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.47	4.98	0.37	1.7e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg20406979	chr6:167373233	NA	-0.38	-5.24	-0.39	5.29e-7	Crohn's disease;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.42	0.56	2.69e-14	Prudent dietary pattern;
PAAD	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg08992911	chr2:238395768	MLPH	0.61	5.2	0.39	6.48e-7	Prostate cancer;
PAAD	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-5.97	-0.44	1.64e-8	Obesity (extreme);
PAAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg21395723	chr22:39101663	GTPBP1	0.44	4.64	0.35	7.51e-6	Menopause (age at onset);
PAAD	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg16584676	chr17:46985605	UBE2Z	0.55	5.58	0.41	1.09e-7	Type 2 diabetes;
PAAD	cis	rs6076065	0.723	rs2424536	chr20:23381601	C/T	cg11657817	chr20:23433608	CST11	0.49	5.0	0.38	1.54e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.57	-6.72	-0.48	3.35e-10	Menopause (age at onset);
PAAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.97	-5.22	-0.39	5.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg08992911	chr2:238395768	MLPH	0.6	5.03	0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg06287003	chr12:125626642	AACS	-0.49	-4.67	-0.35	6.5e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.3	-0.46	3e-9	Triglycerides;
PAAD	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg05791153	chr7:19748676	TWISTNB	0.63	4.83	0.36	3.32e-6	Thyroid stimulating hormone;
PAAD	cis	rs10865541	0.571	rs12992865	chr2:3383741	G/A	cg12447832	chr2:3383257	TTC15	0.36	4.46	0.34	1.6e-5	Obesity-related traits;
PAAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	4.84	0.37	3.22e-6	Mood instability;
PAAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.28	0.33	3.29e-5	Depression;
PAAD	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg24110177	chr3:50126178	RBM5	0.57	4.44	0.34	1.69e-5	Menarche (age at onset);
PAAD	cis	rs3745672	0.590	rs10411299	chr19:12169163	A/C	cg11321965	chr19:12780562	MORG1;C19orf56	-1.03	-4.66	-0.35	6.79e-6	Multiple sclerosis;
PAAD	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.3	4.28	0.33	3.34e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	1.02	7.59	0.52	2.96e-12	IgG glycosylation;
PAAD	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.57	-4.58	-0.35	9.54e-6	Personality dimensions;
PAAD	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-6.53	-0.47	9.49e-10	Response to antipsychotic treatment;
PAAD	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg23995914	chr4:10459228	ZNF518B	-0.38	-4.58	-0.35	9.69e-6	Schizophrenia (age at onset);
PAAD	cis	rs1499972	0.941	rs62263120	chr3:117630253	A/G	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26926768	chr12:34528122	NA	0.37	4.52	0.34	1.22e-5	Morning vs. evening chronotype;
PAAD	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.85	-5.48	-0.41	1.74e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg26174226	chr8:58114915	NA	-0.68	-6.12	-0.44	7.66e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.75	-7.77	-0.53	1.08e-12	DNA methylation (variation);
PAAD	cis	rs7577696	0.962	rs7600173	chr2:32268410	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.75e-6	Inflammatory biomarkers;
PAAD	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.84	0.49	1.81e-10	Body mass index;
PAAD	cis	rs1359582	0.801	rs7068639	chr10:90369699	T/C	cg15661332	chr10:90342814	RNLS	0.55	4.89	0.37	2.5e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.74	-0.36	4.94e-6	Tuberculosis;
PAAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.44	0.61	6.17e-17	Cognitive function;
PAAD	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.77e-7	Vitiligo;
PAAD	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs12586317	0.728	rs2415288	chr14:35807508	T/C	cg05294307	chr14:35346193	BAZ1A	-0.64	-5.4	-0.4	2.57e-7	Psoriasis;
PAAD	cis	rs2077654	0.556	rs2299640	chr11:17441228	A/G	cg25308976	chr11:17434268	ABCC8	0.72	5.16	0.39	7.77e-7	Gout;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg14926445	chr8:58193284	C8orf71	-0.72	-5.85	-0.43	2.91e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg10932868	chr11:921992	NA	-0.49	-5.98	-0.44	1.51e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg01489032	chr8:143877656	NA	0.46	4.83	0.36	3.36e-6	Urinary tract infection frequency;
PAAD	cis	rs1419980	0.730	rs11054567	chr12:7729600	A/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.83	7.85	0.54	7.02e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.45	-4.35	-0.33	2.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.68	-0.48	4.28e-10	Body mass index;
PAAD	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.48	-4.82	-0.36	3.48e-6	Red blood cell count;
PAAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06199750	chr1:1510566	SSU72	-0.54	-6.36	-0.46	2.23e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.62	4.49	0.34	1.39e-5	Bipolar disorder;
PAAD	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	1.04	12.41	0.71	7.41e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.95	0.37	1.94e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.39	0.34	2.12e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.55	6.0	0.44	1.38e-8	Bladder cancer;
PAAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.64	6.76	0.48	2.74e-10	Testicular germ cell tumor;
PAAD	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	1.05	6.63	0.47	5.61e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs4142041	0.500	rs6480230	chr10:68636135	A/T	cg04444303	chr10:69634106	NA	-0.42	-4.26	-0.33	3.58e-5	Nicotine dependence;
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.77	5.85	0.43	2.87e-8	Platelet count;
PAAD	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13870426	chr17:30244630	NA	-0.64	-6.17	-0.45	5.94e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.45	-0.46	1.38e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.52	4.99	0.38	1.65e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10479542	0.614	rs10041685	chr5:178973259	C/T	cg09060608	chr5:178986726	RUFY1	0.47	4.56	0.35	1.04e-5	Lung cancer;
PAAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.38	4.82	0.36	3.5e-6	Prostate cancer;
PAAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs501120	0.584	rs680091	chr10:44738932	G/A	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.1e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg08992911	chr2:238395768	MLPH	0.94	7.32	0.51	1.36e-11	Prostate cancer;
PAAD	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.64	-6.93	-0.49	1.15e-10	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.47	-5.87	-0.43	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg04160749	chr8:58172571	NA	-0.7	-4.95	-0.37	1.91e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11638815	0.603	rs2678448	chr15:83263405	G/A	cg00614314	chr15:82944287	LOC80154	0.46	4.52	0.34	1.25e-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.25	-0.33	3.74e-5	Menarche (age at onset);
PAAD	cis	rs12313068	0.709	rs73404675	chr12:110504102	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.17	0.45	6.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7804356	0.651	rs7782621	chr7:26790937	G/A	cg03456212	chr7:26904342	SKAP2	0.57	4.94	0.37	1.99e-6	Type 1 diabetes;
PAAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.95	10.37	0.64	2.19e-19	Parkinson's disease;
PAAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.51	-9.5	-0.61	4.39e-17	Self-rated health;
PAAD	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.64	-5.51	-0.41	1.47e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg02016764	chr4:38805732	TLR1	-0.55	-4.35	-0.33	2.53e-5	Breast cancer;
PAAD	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21545522	chr1:205238299	TMCC2	0.48	4.38	0.33	2.17e-5	Red blood cell count;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.4	0.34	1.99e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs300774	0.925	rs6735974	chr2:179581	A/G	cg21211680	chr2:198530	NA	-0.66	-6.01	-0.44	1.31e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs6137287	0.924	rs721785	chr20:21140171	G/A	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.8	-6.65	-0.47	4.93e-10	Pancreatic cancer;
PAAD	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-1.15	-11.06	-0.67	3.17e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.26e-6	Lung cancer;
PAAD	cis	rs4356203	0.818	rs214927	chr11:17231245	T/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.65	-0.35	7.17e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4713675	0.525	rs622917	chr6:33702869	C/T	cg14003231	chr6:33640908	ITPR3	-0.36	-4.6	-0.35	8.66e-6	Plateletcrit;
PAAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.94	-7.68	-0.53	1.8e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-8.14	-0.55	1.32e-13	Bladder cancer;
PAAD	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19671926	chr4:122722719	EXOSC9	-0.58	-5.23	-0.39	5.43e-7	Type 2 diabetes;
PAAD	cis	rs9463078	0.510	rs11964325	chr6:45053617	G/A	cg25276700	chr6:44698697	NA	0.46	5.2	0.39	6.36e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-7.58	-0.52	3.18e-12	Monocyte percentage of white cells;
PAAD	cis	rs116248771	0.549	rs1548013	chr3:158431070	C/T	cg16708174	chr3:158430962	RARRES1	0.81	6.09	0.44	8.99e-9	diarrhoeal disease at age 2;
PAAD	cis	rs3814231	0.531	rs17090904	chr10:115476138	C/T	cg24846397	chr10:115438155	CASP7	-0.52	-5.17	-0.39	7.16e-7	Vitiligo;
PAAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.12	17.27	0.81	1.15e-37	Menarche (age at onset);
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01805784	chr5:176873808	PRR7	0.68	6.49	0.47	1.17e-9	Myopia (pathological);
PAAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.58	-0.57	1.02e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs12620464	1.000	rs12620464	chr2:102029646	A/G	cg13027851	chr2:102433793	MAP4K4	0.65	4.53	0.34	1.2e-5	Estradiol plasma levels (breast cancer);
PAAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15441629	chr19:16582551	EPS15L1	0.66	7.89	0.54	5.46e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg13736514	chr6:26305472	NA	-0.44	-4.78	-0.36	4.06e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.51	-5.14	-0.38	8.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg07617317	chr6:118971624	C6orf204	0.57	4.63	0.35	7.76e-6	Diastolic blood pressure;
PAAD	cis	rs12799264	1.000	rs2018644	chr11:19971439	T/C	cg17303119	chr11:19974895	NAV2	0.72	4.42	0.34	1.85e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg16205897	chr5:131564050	P4HA2	-0.44	-4.7	-0.36	5.83e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.51	5.64	0.42	8.02e-8	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg14393609	chr7:65229607	NA	0.5	4.99	0.38	1.63e-6	Aortic root size;
PAAD	cis	rs3764400	0.567	rs4995899	chr17:46150730	G/A	cg10706073	chr17:46328419	SKAP1	-1.08	-6.38	-0.46	2.02e-9	Body mass index;
PAAD	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.44	-6.73	-0.48	3.25e-10	Subjective well-being;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11104443	chr15:45021117	NA	0.59	6.74	0.48	3.01e-10	Metabolite levels  (X-11787);
PAAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.45	0.61	5.79e-17	Parkinson's disease;
PAAD	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg27170260	chr1:38156575	C1orf109	-0.45	-4.28	-0.33	3.25e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12165864	chr7:66369176	NA	-0.79	-5.04	-0.38	1.28e-6	Diabetic kidney disease;
PAAD	cis	rs9443645	0.507	rs2208518	chr6:79430465	T/G	cg05283184	chr6:79620031	NA	-0.49	-6.03	-0.44	1.22e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg00080972	chr5:178986291	RUFY1	-0.52	-5.03	-0.38	1.37e-6	Lung cancer;
PAAD	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13870426	chr17:30244630	NA	0.59	5.65	0.42	7.62e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02475777	chr4:1388615	CRIPAK	0.51	4.89	0.37	2.49e-6	Longevity;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.38	-4.29	-0.33	3.11e-5	Type 2 diabetes;
PAAD	cis	rs1499972	0.941	rs55704727	chr3:117616431	C/T	cg07612923	chr3:117604196	NA	1.05	7.22	0.51	2.36e-11	Schizophrenia;
PAAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.81	-7.22	-0.51	2.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.32	0.56	4.56e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs4594175	0.926	rs10498421	chr14:51586412	A/G	cg23942311	chr14:51606299	NA	-0.68	-5.92	-0.43	2.08e-8	Cancer;
PAAD	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.91	-6.91	-0.49	1.24e-10	Monocyte percentage of white cells;
PAAD	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.62	4.9	0.37	2.43e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg10729496	chr3:10149963	C3orf24	0.89	7.46	0.52	6.35e-12	Alzheimer's disease;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-5.27	-0.39	4.59e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg20243544	chr17:37824526	PNMT	0.54	4.71	0.36	5.6e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.48	-5.4	-0.4	2.56e-7	Platelet distribution width;
PAAD	cis	rs11264213	0.901	rs636832	chr1:36363475	G/A	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.23	-9.91	-0.63	3.55e-18	Breast cancer;
PAAD	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.58	4.49	0.34	1.39e-5	Pancreatic cancer;
PAAD	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.6	-5.54	-0.41	1.27e-7	Total body bone mineral density;
PAAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.36	-0.46	2.22e-9	Menarche (age at onset);
PAAD	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.68e-8	Schizophrenia;
PAAD	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.39	4.46	0.34	1.56e-5	Blood protein levels;
PAAD	cis	rs798766	0.859	rs798727	chr4:1685137	C/T	cg11461875	chr4:1768568	NA	-0.37	-4.33	-0.33	2.66e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.82	5.34	0.4	3.38e-7	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.47e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12541635	1.000	rs1896918	chr8:107090500	G/A	cg10147462	chr8:107024639	NA	-0.44	-4.71	-0.36	5.54e-6	Age of smoking initiation;
PAAD	cis	rs35740288	0.929	rs3858927	chr15:86301616	C/G	cg07943548	chr15:86304357	KLHL25	-0.58	-4.96	-0.37	1.89e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg22947322	chr17:47091978	IGF2BP1	0.46	5.82	0.43	3.31e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.62	6.77	0.48	2.6200000000000003e-10	Leprosy;
PAAD	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.74	-6.18	-0.45	5.52e-9	Schizophrenia;
PAAD	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	4.52	0.34	1.23e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.78	8.8	0.58	2.82e-15	Lung cancer;
PAAD	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-4.31	-0.33	2.92e-5	Educational attainment;
PAAD	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-7.16	-0.5	3.25e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg10978503	chr1:24200527	CNR2	0.47	5.52	0.41	1.41e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-6.02	-0.44	1.25e-8	Blood trace element (Zn levels);
PAAD	cis	rs797680	0.856	rs2765545	chr1:93677269	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.42	0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20517742	chr7:123453915	HYALP1	-0.55	-6.68	-0.48	4.2e-10	Energy expenditure (24h);
PAAD	cis	rs9398803	0.723	rs853971	chr6:127066190	T/C	cg19875578	chr6:126661172	C6orf173	-0.46	-4.82	-0.36	3.44e-6	Male-pattern baldness;
PAAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	7.29	0.51	1.59e-11	Height;
PAAD	cis	rs9810890	1.000	rs73207973	chr3:128568365	A/G	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-7.99	-0.54	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.26e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10214930	0.705	rs12700824	chr7:27661754	T/C	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.71	7.27	0.51	1.73e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.87	-0.43	2.6e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg23033748	chr14:75592666	NEK9	-0.41	-5.03	-0.38	1.34e-6	Height;
PAAD	trans	rs901683	1.000	rs71499567	chr10:46083956	G/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.61	6.18	0.45	5.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.57	-4.89	-0.37	2.56e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs71520386	0.632	rs28526185	chr7:22871318	T/C	cg04907244	chr7:22894795	SNORD93	0.51	5.48	0.41	1.7e-7	Fibrinogen levels;
PAAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg08439880	chr3:133502540	NA	-0.48	-5.32	-0.4	3.59e-7	Iron status biomarkers;
PAAD	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.72	6.01	0.44	1.32e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg27411982	chr8:10470053	RP1L1	-0.41	-4.67	-0.35	6.45e-6	Neuroticism;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-5.49	-0.41	1.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg19169023	chr15:41853346	TYRO3	0.69	7.08	0.5	5e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs319204	0.659	rs9686807	chr5:146235633	C/G	cg02760293	chr5:146258785	PPP2R2B	0.5	4.28	0.33	3.29e-5	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.57	-0.41	1.14e-7	Alzheimer's disease (late onset);
PAAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	4.62	0.35	8.15e-6	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.8	10.07	0.63	1.34e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg18944383	chr4:111397179	ENPEP	-0.68	-8.1	-0.55	1.66e-13	Coronary artery disease;
PAAD	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	4.73	0.36	5.12e-6	Height;
PAAD	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.54	0.47	8.89e-10	High light scatter reticulocyte count;
PAAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.62	-7.34	-0.51	1.19e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.49	5.24	0.39	5.36e-7	Red blood cell count;
PAAD	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg06569542	chr10:98946673	SLIT1	0.45	4.59	0.35	9.05e-6	Monocyte count;
PAAD	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9463078	0.746	rs9395095	chr6:45273877	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.32	-0.4	3.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.66	-4.63	-0.35	7.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.45	-4.58	-0.35	9.43e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg15393565	chr14:53162558	ERO1L	-0.55	-6.33	-0.46	2.66e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.01	-0.38	1.51e-6	Reticulocyte count;
PAAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.53	-4.43	-0.34	1.77e-5	Platelet count;
PAAD	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg08523384	chr5:141488047	NDFIP1	-0.51	-5.09	-0.38	1.02e-6	Asthma;
PAAD	cis	rs617219	0.726	rs1962002	chr5:78430689	T/C	cg24856658	chr5:78533917	JMY	-0.4	-4.47	-0.34	1.5e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.62	-7.77	-0.53	1.07e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.45	4.68	0.35	6.32e-6	Corneal astigmatism;
PAAD	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.47	-4.36	-0.33	2.39e-5	Coronary artery disease;
PAAD	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg10761708	chr20:43804764	PI3	0.5	4.31	0.33	2.94e-5	Blood protein levels;
PAAD	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg02421172	chr7:1938701	MAD1L1	0.59	4.63	0.35	7.93e-6	Bipolar disorder;
PAAD	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg08523384	chr5:141488047	NDFIP1	-0.61	-5.63	-0.42	8.38e-8	Crohn's disease;
PAAD	cis	rs7873102	0.597	rs56198718	chr9:37980898	T/A	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.84	-0.49	1.84e-10	Retinal vascular caliber;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19700746	chr14:105553234	NA	-0.62	-6.42	-0.46	1.67e-9	Smoking initiation;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg07061783	chr6:25882402	NA	-0.46	-4.39	-0.34	2.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.9	-0.37	2.43e-6	Erythrocyte sedimentation rate;
PAAD	trans	rs12137025	1.000	rs72747975	chr1:223849807	C/T	cg18879828	chr11:46942432	NA	-0.77	-6.46	-0.46	1.33e-9	Carotenoid levels (alpha-carotene);
PAAD	cis	rs7765175	0.631	rs9488152	chr6:113664302	A/G	cg19037598	chr6:113666021	NA	-0.44	-4.63	-0.35	7.87e-6	Coronary artery calcification;
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg01262667	chr19:19385393	TM6SF2	0.45	4.99	0.38	1.65e-6	Tonsillectomy;
PAAD	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.44	4.68	0.35	6.37e-6	Age of smoking initiation;
PAAD	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-5.34	-0.4	3.34e-7	Vitiligo;
PAAD	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg00277334	chr10:82204260	NA	0.54	4.29	0.33	3.13e-5	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.55	-4.49	-0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-4.87	-0.37	2.73e-6	Oropharynx cancer;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18621852	chr3:10150065	C3orf24	0.66	5.68	0.42	6.69e-8	Alzheimer's disease;
PAAD	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.64	7.36	0.51	1.09e-11	Carotid intima media thickness;
PAAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2688419	0.527	rs2171030	chr3:23083720	A/G	cg00327796	chr3:23032191	NA	-0.51	-4.87	-0.37	2.82e-6	Type 2 diabetes;
PAAD	cis	rs736801	0.538	rs2548998	chr5:131832514	G/A	cg21138405	chr5:131827807	IRF1	-0.46	-6.06	-0.44	1.01e-8	Breast cancer;Mosquito bite size;
PAAD	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.57	-6.02	-0.44	1.28e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.42	-5.32	-0.4	3.69e-7	Ulcerative colitis;
PAAD	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.7	6.73	0.48	3.31e-10	Coronary artery disease;
PAAD	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg10978503	chr1:24200527	CNR2	-0.47	-5.49	-0.41	1.65e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg21238619	chr17:78079768	GAA	-0.51	-5.0	-0.38	1.55e-6	Yeast infection;
PAAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg14851346	chr12:38532713	NA	0.49	4.47	0.34	1.5e-5	Morning vs. evening chronotype;
PAAD	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.66	5.68	0.42	6.58e-8	Breast cancer;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-4.65	-0.35	7.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.79	6.35	0.46	2.41e-9	Alzheimer's disease;
PAAD	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg15212455	chr7:39170539	POU6F2	0.43	6.2	0.45	4.95e-9	IgG glycosylation;
PAAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.91	-8.65	-0.57	6.92e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg25886479	chr11:50257625	LOC441601	0.41	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs496300	0.691	rs535024	chr21:44794374	A/G	cg18342814	chr21:45755740	C21orf2	-0.47	-4.42	-0.34	1.87e-5	Metabolic syndrome;
PAAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs375066	0.868	rs368079	chr19:44393356	C/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Urate levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24700663	chr4:77172643	FAM47E	0.65	6.81	0.48	2.1e-10	Obesity-related traits;
PAAD	cis	rs1570155	1.000	rs1998223	chr6:20383649	C/T	cg03881924	chr6:20404342	E2F3	0.44	4.48	0.34	1.48e-5	Obesity-related traits;
PAAD	cis	rs6494488	0.500	rs16948170	chr15:64967654	C/T	cg16425858	chr15:64791681	ZNF609	0.9	4.8	0.36	3.77e-6	Coronary artery disease;
PAAD	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	1.01	12.29	0.71	1.51e-24	Longevity;
PAAD	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-6.47	-0.46	1.25e-9	Morning vs. evening chronotype;
PAAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.78	-8.09	-0.55	1.73e-13	DNA methylation (variation);
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.75	8.79	0.58	2.93e-15	Emphysema distribution in smoking;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08457315	chr6:151673369	AKAP12	-0.63	-6.69	-0.48	3.95e-10	Obesity-related traits;
PAAD	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.01	0.54	2.8e-13	Colorectal cancer;
PAAD	cis	rs2290416	0.688	rs62522171	chr8:144690832	C/A	cg08017634	chr8:144659831	NAPRT1	0.9	7.2	0.5	2.61e-11	Attention deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg17105886	chr17:28927953	LRRC37B2	0.76	4.89	0.37	2.57e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.53e-25	Bone mineral density;
PAAD	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg09796270	chr17:17721594	SREBF1	-0.48	-5.16	-0.39	7.44e-7	Total body bone mineral density;
PAAD	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.89	-0.43	2.38e-8	QT interval;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.59	6.43	0.46	1.56e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs35955747	0.934	rs4820045	chr22:31785969	G/A	cg02404636	chr22:31891804	SFI1	-0.55	-5.42	-0.4	2.26e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08076807	chr17:80255910	NA	0.62	6.87	0.49	1.58e-10	Myopia (pathological);
PAAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.77	7.35	0.51	1.14e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs6669119	0.759	rs116404531	chr1:19112851	T/C	cg26220594	chr1:19110978	NA	0.72	4.32	0.33	2.78e-5	Percentage gas trapping;
PAAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7113874	0.802	rs10769938	chr11:8671547	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-4.99	-0.38	1.62e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07648498	chr16:89883185	FANCA	0.69	7.06	0.5	5.65e-11	Vitiligo;
PAAD	cis	rs959260	1.000	rs7211915	chr17:73379872	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.89	0.43	2.39e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07677032	chr17:61819896	STRADA	0.55	5.28	0.39	4.33e-7	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.7	-6.45	-0.46	1.43e-9	Total body bone mineral density;
PAAD	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg01270228	chr10:1369114	ADARB2	0.5	4.26	0.33	3.53e-5	Radiation response;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg15226275	chr6:116381976	FRK	0.36	6.58	0.47	7.12e-10	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs2415984	0.579	rs754962	chr14:46962719	T/C	cg14871534	chr14:47121158	RPL10L	0.5	5.09	0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.49	-5.07	-0.38	1.16e-6	Pancreatic cancer;
PAAD	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.42	5.03	0.38	1.36e-6	Colorectal cancer;
PAAD	cis	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.46	4.36	0.33	2.38e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26343512	chr14:77413728	NA	0.56	6.37	0.46	2.09e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg07813855	chr1:200183606	FAM58B	0.48	4.58	0.35	9.76e-6	Permanent tooth development;
PAAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.43	-5.09	-0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs262150	0.566	rs2247275	chr7:158765812	A/G	cg13374026	chr7:158955107	NA	-0.52	-4.28	-0.33	3.33e-5	Facial morphology (factor 20);
PAAD	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	4.79	0.36	3.98e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-5.6	-0.41	9.78e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg07371521	chr5:154026371	NA	-0.5	-6.62	-0.47	5.91e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.75	-8.59	-0.57	9.66e-15	White blood cell count (basophil);
PAAD	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg22431228	chr1:16359049	CLCNKA	0.44	5.36	0.4	3.07e-7	Systolic blood pressure;
PAAD	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg18551225	chr6:44695536	NA	-0.69	-6.52	-0.47	9.66e-10	Total body bone mineral density;
PAAD	cis	rs8053891	0.756	rs9928413	chr16:72001110	C/T	cg16558253	chr16:72132732	DHX38	-0.57	-5.09	-0.38	1.03e-6	Coronary artery disease;
PAAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.73	6.93	0.49	1.09e-10	Breast cancer;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.63	7.72	0.53	1.47e-12	Lung cancer;
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.74	8.5	0.57	1.61e-14	Height;
PAAD	cis	rs59888335	0.858	rs7645003	chr3:80951903	T/G	cg21735741	chr3:80819488	NA	-0.53	-4.55	-0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.52	4.41	0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs829661	0.793	rs829653	chr2:30714906	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	4.44	0.34	1.73e-5	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9810890	0.557	rs78115835	chr3:128583226	C/T	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-5.98	-0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg02743256	chr7:2109353	MAD1L1	-0.51	-4.29	-0.33	3.11e-5	Bipolar disorder;
PAAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.48	-4.74	-0.36	4.9e-6	Breast size;
PAAD	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-8.04	-0.55	2.33e-13	Lung cancer;Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs9422442	chr10:46048078	C/A	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15128208	chr22:42549153	NA	0.42	4.35	0.33	2.53e-5	Cognitive function;
PAAD	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg09044154	chr16:88155775	NA	-0.52	-4.26	-0.33	3.6e-5	Menopause (age at onset);
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg18209359	chr17:80159595	CCDC57	0.44	4.47	0.34	1.51e-5	Life satisfaction;
PAAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg19052272	chr2:3704530	ALLC	-0.59	-6.7	-0.48	3.74e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7101378	0.577	rs10749932	chr11:108898886	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	10.13	0.63	9.39e-19	Smoking behavior;
PAAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-5.54	-0.41	1.3e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.47	7.01	0.49	7.33e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg05484376	chr2:27715224	FNDC4	0.48	4.9	0.37	2.44e-6	Total body bone mineral density;
PAAD	cis	rs112721625	1	rs112721625	chr17:57927426	AT/A	cg02344993	chr17:57696989	CLTC	0.48	4.59	0.35	9.37e-6	Monocyte count;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.7	5.18	0.39	6.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.54	4.78	0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.47	0.41	1.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.21	0.67	1.23e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.72	0.36	5.42e-6	Total body bone mineral density;
PAAD	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.52	-0.34	1.22e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.53	-0.34	1.19e-5	Alcohol dependence;
PAAD	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.37	5.1	0.38	9.96e-7	Schizophrenia;
PAAD	cis	rs73206853	0.764	rs73206878	chr12:110835015	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.37	5.13	0.38	8.56e-7	Educational attainment (years of education);
PAAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg14146966	chr2:61757674	XPO1	0.43	5.33	0.4	3.49e-7	Tuberculosis;
PAAD	cis	rs72827839	0.739	rs16953235	chr17:46244948	A/G	cg23391107	chr17:45924227	SP6	0.62	5.31	0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.76	7.92	0.54	4.7e-13	Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs820218	0.687	rs820150	chr17:73615962	T/C	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.28	-0.33	3.24e-5	Rotator cuff tears;
PAAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	1.19	6.34	0.46	2.47e-9	Interleukin-17 levels;
PAAD	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.69	-7.46	-0.52	6.19e-12	Heart rate;
PAAD	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.66e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05472934	chr7:22766657	IL6	0.89	9.77	0.62	8.68e-18	Lung cancer;
PAAD	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-1.03	-7.34	-0.51	1.22e-11	Dupuytren's disease;
PAAD	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg13590414	chr9:128173245	NA	-0.47	-4.69	-0.36	5.95e-6	Resting heart rate;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg15017067	chr4:17643749	FAM184B	0.46	5.3	0.39	4.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Coronary artery disease;
PAAD	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-1.14	-13.24	-0.73	4.28e-27	Longevity;
PAAD	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg01191920	chr7:158217561	PTPRN2	-0.79	-7.82	-0.54	8.39e-13	Obesity-related traits;
PAAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18404041	chr3:52824283	ITIH1	0.42	4.43	0.34	1.8e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.47e-10	Lung cancer;
PAAD	cis	rs7224685	0.689	rs67831913	chr17:4184856	T/C	cg11204139	chr17:3907470	NA	0.69	5.76	0.42	4.54e-8	Type 2 diabetes;
PAAD	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.53	-5.19	-0.39	6.56e-7	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.6	-4.71	-0.36	5.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg02917321	chr22:38215204	NA	0.47	4.81	0.36	3.55e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.52	5.7	0.42	6.05e-8	Longevity;Endometriosis;
PAAD	cis	rs2288912	0.620	rs875255	chr19:45493635	C/G	cg13119609	chr19:45449297	APOC2	-0.42	-4.88	-0.37	2.63e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.65	7.39	0.51	9.05e-12	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs8112449	0.893	rs12983665	chr19:10538373	A/G	cg03722295	chr19:10519375	NA	0.32	4.41	0.34	1.96e-5	Multiple sclerosis;Gastritis;
PAAD	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	1.14	7.95	0.54	3.88e-13	Major depressive disorder;
PAAD	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.77	-0.53	1.11e-12	Hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.27	0.45	3.63e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.41	-5.19	-0.39	6.66e-7	Colorectal cancer;
PAAD	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.52	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.91	11.32	0.68	6.18e-22	Methadone dose in opioid dependence;
PAAD	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.1	0.5	4.42e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	5.83	0.43	3.26e-8	Personality dimensions;
PAAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.48	-4.61	-0.35	8.63e-6	Coronary artery disease;
PAAD	cis	rs11126435	0.641	rs6709863	chr2:74746080	C/T	cg05490924	chr2:74730755	LOC151534;LBX2	-0.43	-4.32	-0.33	2.8e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.77	9.27	0.6	1.73e-16	Metabolite levels;
PAAD	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.91	-8.95	-0.59	1.15e-15	Asthma;
PAAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.63	-5.6	-0.41	9.67e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs959260	1.000	rs4788891	chr17:73391145	A/G	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.97	0.49	8.8e-11	Rheumatoid arthritis;
PAAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg02117656	chr17:79614917	TSPAN10	-0.55	-5.56	-0.41	1.2e-7	Eye color traits;
PAAD	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.98	9.67	0.62	1.55e-17	Blood protein levels;
PAAD	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.14	-0.7	3.96e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.77	0.36	4.31e-6	Bone mineral density;
PAAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.38	-0.33	2.18e-5	Life satisfaction;
PAAD	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	6.96	0.49	9.71e-11	Response to antipsychotic treatment;
PAAD	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.69	7.71	0.53	1.53e-12	Prostate cancer;
PAAD	cis	rs7631605	0.875	rs4678937	chr3:37145174	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.72	0.36	5.42e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.34	1.6e-5	Breast cancer;
PAAD	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs4697263	0.515	rs16872408	chr4:22114968	C/T	cg26230338	chr4:22389934	GPR125	0.44	4.25	0.33	3.78e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2562456	0.793	rs11667103	chr19:21486641	G/C	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.49e-5	Pain;
PAAD	cis	rs9810890	1.000	rs73198892	chr3:128559117	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg07617317	chr6:118971624	C6orf204	0.51	4.29	0.33	3.14e-5	Diastolic blood pressure;
PAAD	cis	rs3935685	0.874	rs4477663	chr15:78007254	A/G	cg25212270	chr15:78015279	NA	-0.39	-4.3	-0.33	3.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.49	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3771570	0.748	rs62186361	chr2:242168518	G/A	cg21646471	chr2:242523971	THAP4	0.68	5.09	0.38	1.04e-6	Prostate cancer;
PAAD	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg17796960	chr10:135278976	LOC619207	-0.4	-4.52	-0.34	1.24e-5	Systemic lupus erythematosus;
PAAD	cis	rs12484776	0.677	rs6001795	chr22:40530922	G/A	cg07138101	chr22:40742427	ADSL	0.6	4.47	0.34	1.49e-5	Uterine fibroids;
PAAD	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg04717802	chr22:42394638	WBP2NL	0.53	4.51	0.34	1.3e-5	Birth weight;
PAAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.51	4.99	0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg12315302	chr6:26189340	HIST1H4D	0.86	4.58	0.35	9.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Blood metabolite levels;
PAAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.39	-0.34	2.11e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09133386	chr6:20404188	E2F3	0.64	7.18	0.5	2.94e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg15448220	chr1:150897856	SETDB1	-0.69	-6.63	-0.47	5.43e-10	Urate levels;
PAAD	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg01884057	chr2:25150051	NA	0.35	4.3	0.33	3.1e-5	Body mass index in non-asthmatics;
PAAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	1.23	11.9	0.69	1.76e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg18531004	chr3:128564980	NA	-0.89	-5.0	-0.38	1.54e-6	Dental caries;
PAAD	cis	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.89	-0.37	2.55e-6	HDL cholesterol;
PAAD	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.65	-4.35	-0.33	2.44e-5	Skin colour saturation;
PAAD	cis	rs1032355	0.558	rs17533517	chr4:100521637	C/T	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg20243544	chr17:37824526	PNMT	0.7	6.25	0.45	3.93e-9	Asthma;
PAAD	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	1.0	5.49	0.41	1.63e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg11271282	chr2:238384023	NA	0.52	4.96	0.37	1.87e-6	Prostate cancer;
PAAD	cis	rs2730260	0.800	rs73169218	chr7:158836906	T/A	cg13444538	chr7:158905317	VIPR2	-0.62	-4.47	-0.34	1.55e-5	Myopia (pathological);
PAAD	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs4853525	0.923	rs7578618	chr2:191733357	A/T	cg11065262	chr2:191878861	STAT1	-0.5	-4.26	-0.33	3.6e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.78	-8.15	-0.55	1.21e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9381107	0.505	rs9394957	chr6:9484928	C/G	cg14735645	chr6:9486422	NA	-0.59	-4.95	-0.37	1.95e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-7.1	-0.5	4.54e-11	Airway imaging phenotypes;
PAAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg06131755	chr6:160182447	ACAT2	0.55	4.86	0.37	2.89e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg07202610	chr7:1142643	C7orf50	-0.67	-5.56	-0.41	1.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Aortic root size;
PAAD	cis	rs4919087	0.590	rs1088187	chr10:99027581	T/C	cg10374248	chr10:99083645	NA	0.5	4.57	0.35	1e-5	Monocyte count;
PAAD	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.68	-6.99	-0.49	7.92e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg14458575	chr2:238380390	NA	0.71	7.84	0.54	7.47e-13	Prostate cancer;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22264975	chr6:90121670	RRAGD	0.4	4.27	0.33	3.5e-5	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.41	0.65	1.69e-19	Electrocardiographic conduction measures;
PAAD	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg05338066	chr1:7812865	CAMTA1	0.48	4.33	0.33	2.7e-5	Inflammatory bowel disease;
PAAD	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.66	-4.84	-0.37	3.19e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg05392440	chr1:2478653	NA	0.55	5.87	0.43	2.62e-8	Ulcerative colitis;
PAAD	cis	rs11811982	0.793	rs7524967	chr1:227370823	G/C	cg24860534	chr1:227506868	CDC42BPA	0.51	5.0	0.38	1.54e-6	Optic disc area;
PAAD	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.69	6.84	0.48	1.85e-10	Uric acid levels;
PAAD	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.6	5.79	0.43	3.83e-8	Adiposity;
PAAD	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.46	-5.03	-0.38	1.36e-6	Triglycerides;
PAAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.45	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9913156	0.748	rs56364707	chr17:4562579	A/T	cg19197139	chr17:4613644	ARRB2	0.83	8.7	0.58	5.14e-15	Lymphocyte counts;
PAAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.64	9.47	0.61	5.23e-17	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.62	-9.34	-0.6	1.15e-16	Asthma (sex interaction);
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.88e-10	Lymphocyte counts;
PAAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.69	-0.36	6.14e-6	Breast cancer;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.44e-6	Life satisfaction;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03452623	chr4:187889614	NA	-0.97	-17.29	-0.81	1.01e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg14343924	chr8:8086146	FLJ10661	-0.62	-5.17	-0.39	7.24e-7	Mood instability;
PAAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	4.35	0.33	2.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.92	9.47	0.61	5.06e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.61	-6.29	-0.45	3.15e-9	Motion sickness;
PAAD	cis	rs7945718	0.650	rs10831889	chr11:12665834	A/T	cg25843174	chr11:12811716	TEAD1	0.32	4.71	0.36	5.44e-6	Educational attainment (years of education);
PAAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.84	6.12	0.44	7.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.48	6.2	0.45	5.08e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg22029157	chr1:209979665	IRF6	0.74	6.7	0.48	3.75e-10	Coronary artery disease;
PAAD	cis	rs7765175	0.775	rs9398341	chr6:113682160	A/C	cg19037598	chr6:113666021	NA	-0.4	-4.63	-0.35	7.69e-6	Coronary artery calcification;
PAAD	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg10006428	chr1:248814059	OR2T27	0.37	4.46	0.34	1.61e-5	Common traits (Other);
PAAD	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg26248373	chr2:1572462	NA	-1.07	-7.45	-0.52	6.56e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.88	-8.24	-0.56	7.27e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.49	5.41	0.4	2.38e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2882667	0.690	rs1039788	chr5:138171501	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg03289416	chr15:75166202	SCAMP2	0.57	6.03	0.44	1.18e-8	Breast cancer;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.61	0.47	6.15e-10	Platelet count;
PAAD	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.5	4.88	0.37	2.68e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs35123781	0.502	rs2336901	chr5:138919078	A/G	cg26929925	chr5:138714136	SLC23A1	-0.57	-5.15	-0.39	7.89e-7	Schizophrenia;
PAAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.89	-0.37	2.53e-6	Tuberculosis;
PAAD	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.47	6.25	0.45	3.96e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	6.04	0.44	1.15e-8	Cognitive test performance;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg13012494	chr21:47604986	C21orf56	-0.49	-5.26	-0.39	4.75e-7	Testicular germ cell tumor;
PAAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg04450456	chr4:17643702	FAM184B	0.47	5.0	0.38	1.6e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7804356	0.871	rs117217399	chr7:26805212	T/C	cg03456212	chr7:26904342	SKAP2	-0.55	-4.51	-0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.46	-0.52	6.31e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8060686	0.858	rs28563117	chr16:67782130	C/T	cg05110241	chr16:68378359	PRMT7	-0.71	-4.95	-0.37	1.91e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	7.0	0.49	7.83e-11	Mean platelet volume;
PAAD	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.67	5.64	0.42	8.02e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs7804356	0.871	rs212857	chr7:26730200	A/C	cg03456212	chr7:26904342	SKAP2	-0.55	-4.51	-0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.78	-9.66	-0.62	1.64e-17	Hemoglobin concentration;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg22087367	chr20:34242979	CPNE1;RBM12	-0.62	-6.45	-0.46	1.37e-9	Alcohol dependence;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg17644776	chr2:200775616	C2orf69	0.53	4.3	0.33	3.03e-5	Schizophrenia;
PAAD	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.46	0.41	1.87e-7	Ileal carcinoids;
PAAD	cis	rs17266958	1.000	rs76175331	chr9:83248894	C/G	cg13911576	chr9:84174038	NA	0.8	4.26	0.33	3.63e-5	Preschool internalizing problems;
PAAD	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	8.27	0.56	6.3e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg06740227	chr12:86229804	RASSF9	0.6	5.33	0.4	3.46e-7	Major depressive disorder;
PAAD	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.51	6.94	0.49	1.07e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.58	-4.42	-0.34	1.84e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg14146966	chr2:61757674	XPO1	-0.41	-5.11	-0.38	9.58e-7	Tuberculosis;
PAAD	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg15192750	chr16:69999425	NA	0.61	4.97	0.37	1.82e-6	IgE levels;
PAAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	1.02	11.08	0.67	2.82e-21	Eosinophil percentage of granulocytes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg12196473	chr3:99536614	MIR548G;C3orf26	0.62	7.36	0.51	1.09e-11	Metabolite levels  (X-11787);
PAAD	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.82	5.35	0.4	3.24e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg06565975	chr8:143823917	SLURP1	0.22	5.29	0.39	4.25e-7	Urinary tract infection frequency;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.75	-8.24	-0.56	7.47e-14	Menopause (age at onset);
PAAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.35	-0.4	3.12e-7	Fibrinogen levels;
PAAD	cis	rs7594192	0.736	rs4850457	chr2:199428387	C/T	cg03163783	chr2:200326591	SATB2	-0.34	-4.74	-0.36	4.97e-6	Educational attainment;
PAAD	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.6	-8.26	-0.56	6.57e-14	Eye color traits;
PAAD	cis	rs608114	0.623	rs73557987	chr6:96360482	A/G	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07216348	chr8:22213245	PIWIL2	0.62	7.23	0.51	2.2e-11	Smoking initiation;
PAAD	cis	rs12365397	0.549	rs11037285	chr11:43177129	A/G	cg03447554	chr11:43094025	NA	0.42	4.82	0.36	3.5e-6	Migraine;
PAAD	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.57e-8	Obesity-related traits;
PAAD	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.64	6.34	0.46	2.44e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg01244601	chr4:120671846	NA	-0.52	-4.45	-0.34	1.67e-5	Corneal astigmatism;
PAAD	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.92	0.37	2.24e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs714515	0.502	rs4916254	chr1:172364012	G/A	cg13446689	chr1:172328377	DNM3	-0.39	-4.6	-0.35	8.97e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.7	7.86	0.54	6.49e-13	Height;
PAAD	cis	rs1519814	0.696	rs7012522	chr8:121038044	A/G	cg22335954	chr8:121166405	COL14A1	-0.66	-5.16	-0.39	7.5e-7	Breast cancer;
PAAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg21395723	chr22:39101663	GTPBP1	-0.42	-4.48	-0.34	1.43e-5	Menopause (age at onset);
PAAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg07703079	chr11:430292	ANO9	0.79	4.4	0.34	1.99e-5	Body mass index;
PAAD	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.29	-0.45	3.21e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.95	0.37	1.92e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg02135003	chr7:105160482	PUS7	-0.91	-6.73	-0.48	3.28e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.61	-5.66	-0.42	7.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2247341	0.515	rs35313041	chr4:1696103	C/T	cg05874882	chr4:1763078	NA	-0.27	-4.65	-0.35	7.29e-6	Hip circumference adjusted for BMI;Height;
PAAD	cis	rs9346455	0.614	rs9294899	chr6:72016302	G/T	cg27238071	chr6:71998145	OGFRL1	0.75	4.41	0.34	1.97e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02617837	chr12:107349530	C12orf23	0.69	6.83	0.48	1.96e-10	Obesity-related traits;
PAAD	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	11.31	0.68	6.76e-22	Cognitive ability;
PAAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg05643964	chr20:62369504	LIME1	-0.5	-4.61	-0.35	8.44e-6	Prostate cancer;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.75	7.64	0.53	2.25e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs3753841	0.832	rs1599706	chr1:103311915	C/T	cg24495344	chr1:103574097	COL11A1	0.38	4.45	0.34	1.64e-5	Glaucoma (primary angle closure);
PAAD	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Body mass index;
PAAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg14440974	chr22:39074834	NA	-0.63	-7.56	-0.52	3.52e-12	Menopause (age at onset);
PAAD	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.94	-0.43	1.84e-8	Schizophrenia;
PAAD	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	5.05	0.38	1.27e-6	Diastolic blood pressure;
PAAD	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.62	6.68	0.48	4.31e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.25	0.39	4.93e-7	Bipolar disorder;
PAAD	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs11825685	0.887	rs78806216	chr11:134568320	C/T	cg02089395	chr11:134479357	NA	-0.68	-4.38	-0.34	2.17e-5	IgG glycosylation;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.41	0.56	2.71e-14	Prudent dietary pattern;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg11062466	chr8:58055876	NA	0.69	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.44	4.87	0.37	2.72e-6	Refractive error;
PAAD	cis	rs6540	1.000	rs7131679	chr11:260925	A/G	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg23119463	chr10:134592391	INPP5A	-0.51	-4.69	-0.36	5.92e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02781704	chr3:194033517	NA	-0.58	-6.65	-0.47	5.04e-10	Body fat percentage;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00174252	chr21:27096915	ATP5J	0.57	6.43	0.46	1.53e-9	Smoking initiation;
PAAD	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg05425664	chr17:57184151	TRIM37	-0.55	-4.69	-0.36	5.98e-6	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.81	-0.36	3.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.81	-8.41	-0.56	2.8e-14	Sleep quality;
PAAD	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	1.05	8.87	0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg18833306	chr6:118973337	C6orf204	0.44	4.64	0.35	7.61e-6	Electrocardiographic conduction measures;
PAAD	cis	rs986417	0.892	rs78026410	chr14:60801142	G/A	cg27398547	chr14:60952738	C14orf39	-0.81	-4.83	-0.36	3.37e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg26138144	chr22:38071188	LGALS1	0.5	5.55	0.41	1.24e-7	Fat distribution (HIV);
PAAD	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.65	0.47	4.91e-10	Joint mobility (Beighton score);
PAAD	cis	rs7101378	0.577	rs10749933	chr11:108898964	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.46	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.76	5.26	0.39	4.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg21724239	chr8:58056113	NA	0.67	5.16	0.39	7.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg14851346	chr12:38532713	NA	0.44	4.31	0.33	2.95e-5	Bladder cancer;
PAAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00982548	chr2:198649783	BOLL	0.8	5.67	0.42	7.04e-8	Ulcerative colitis;
PAAD	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.65	-6.22	-0.45	4.6e-9	Cognitive function;
PAAD	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg08807892	chr2:162101083	NA	-0.53	-5.63	-0.42	8.4e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.63	-5.9	-0.43	2.25e-8	Cognitive test performance;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.61	-6.48	-0.47	1.22e-9	Brugada syndrome;
PAAD	cis	rs7624766	0.743	rs9883862	chr3:160527265	C/A	cg22637730	chr3:160473554	PPM1L	0.52	4.66	0.35	6.77e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs965604	1.000	rs4362358	chr15:78796104	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-4.56	-0.35	1.04e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg21659725	chr3:3221576	CRBN	0.73	7.08	0.5	4.96e-11	Resting heart rate;
PAAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.57	-5.65	-0.42	7.65e-8	Coronary artery disease;
PAAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg03808351	chr9:123631620	PHF19	0.47	5.15	0.39	8.09e-7	Rheumatoid arthritis;
PAAD	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-6.97	-0.49	9.21e-11	Migraine;Coronary artery disease;
PAAD	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	9.84	0.62	5.64e-18	Total body bone mineral density;
PAAD	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.26	-4.47	-0.34	1.5e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.56	6.15	0.45	6.44e-9	Lung cancer;
PAAD	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.77	7.79	0.53	9.95e-13	Schizophrenia;
PAAD	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs17286411	0.814	rs12708918	chr16:71984941	C/G	cg16558253	chr16:72132732	DHX38	-0.42	-4.61	-0.35	8.62e-6	Blood protein levels;
PAAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg25319279	chr11:5960081	NA	-0.78	-7.96	-0.54	3.67e-13	DNA methylation (variation);
PAAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03350042	chr15:40733177	BAHD1	0.55	6.53	0.47	9.34e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11700980	0.551	rs62223678	chr21:30118656	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.53	5.73	0.42	5.25e-8	Schizophrenia;
PAAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.84	10.01	0.63	1.91e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg14092988	chr3:52407081	DNAH1	0.51	6.59	0.47	6.8e-10	Bipolar disorder;
PAAD	cis	rs4146653	0.513	rs10795196	chr10:4740290	T/A	cg10503599	chr10:4193868	NA	-0.51	-4.37	-0.33	2.25e-5	Major depressive disorder;
PAAD	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.64	-6.19	-0.45	5.43e-9	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16139491	chr7:141463169	TAS2R3	-0.65	-6.67	-0.48	4.58e-10	Obesity-related traits;
PAAD	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	6.57	0.47	7.52e-10	Menarche (age at onset);
PAAD	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.61	-6.09	-0.44	8.76e-9	Red cell distribution width;
PAAD	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs3812111	0.608	rs576791	chr6:116427814	G/A	cg05304507	chr6:116381966	FRK	0.23	4.27	0.33	3.48e-5	Age-related macular degeneration;
PAAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg23463467	chr20:60627584	TAF4	0.47	4.96	0.37	1.84e-6	Body mass index;
PAAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	6.25	0.45	3.9e-9	Schizophrenia;
PAAD	cis	rs1539053	0.932	rs12038397	chr1:58108237	C/G	cg00026909	chr1:58089001	DAB1	-0.63	-7.01	-0.49	7.33e-11	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.44	-4.53	-0.34	1.2e-5	Resting heart rate;
PAAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.44	-4.52	-0.34	1.26e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.13	-0.45	7.06e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg14393609	chr7:65229607	NA	0.5	4.34	0.33	2.57e-5	Aortic root size;
PAAD	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	4.75	0.36	4.76e-6	Height;
PAAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.61	-5.65	-0.42	7.81e-8	IgG glycosylation;
PAAD	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.34	-0.4	3.37e-7	Plateletcrit;
PAAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.53	4.97	0.37	1.8e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.24	0.64	4.85e-19	Menopause (age at onset);
PAAD	cis	rs2562456	0.833	rs2061916	chr19:21541708	A/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.61	0.35	8.39e-6	Breast cancer;
PAAD	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg04370829	chr17:406249	NA	0.58	5.37	0.4	2.86e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg03983715	chr16:68378420	PRMT7	-1.0	-7.03	-0.5	6.52e-11	Magnesium levels;
PAAD	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.7	0.72	1.19e-25	Chronic sinus infection;
PAAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23288078	chr8:124268173	ZHX1	-0.63	-6.6	-0.47	6.61e-10	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.88e-25	Prudent dietary pattern;
PAAD	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.58	-4.73	-0.36	5.03e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg04721828	chr11:48285200	OR4X1	0.47	5.73	0.42	5.35e-8	Migraine - clinic-based;
PAAD	cis	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00358220	chr18:3247473	MYL12A	0.44	5.04	0.38	1.3e-6	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs2712184	0.655	rs1003622	chr2:217653608	A/G	cg05032264	chr2:217675019	NA	-0.56	-6.3	-0.45	3.06e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.37	0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg27234864	chr13:21295941	IL17D	0.6	5.11	0.38	9.46e-7	Dental caries;
PAAD	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.79	6.5	0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.56	-5.4	-0.4	2.46e-7	Reticulocyte count;
PAAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.68	6.42	0.46	1.64e-9	Initial pursuit acceleration;
PAAD	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	5.85	0.43	2.92e-8	Ileal carcinoids;
PAAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08219700	chr8:58056026	NA	0.7	5.64	0.42	8.24e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.51	-4.58	-0.35	9.46e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8053891	0.673	rs10492824	chr16:72018771	A/C	cg16558253	chr16:72132732	DHX38	-0.53	-4.75	-0.36	4.6e-6	Coronary artery disease;
PAAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg19413350	chr8:57351067	NA	-0.45	-4.36	-0.33	2.37e-5	Obesity-related traits;
PAAD	cis	rs1126510	0.752	rs11666367	chr19:47120381	A/G	cg07844738	chr19:47129343	PTGIR	0.46	5.49	0.41	1.68e-7	Ulcerative colitis;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.69	7.58	0.52	3.09e-12	Calcium levels;
PAAD	cis	rs7940866	0.678	rs11222395	chr11:130794355	A/C	cg12179176	chr11:130786555	SNX19	0.82	9.31	0.6	1.32e-16	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.85	0.37	3.09e-6	Bone mineral density;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs9535307	0.719	rs1198322	chr13:50380404	G/A	cg04663916	chr13:50265991	EBPL	-0.57	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18621852	chr3:10150065	C3orf24	0.61	5.3	0.39	4.02e-7	Alzheimer's disease;
PAAD	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.72	8.44	0.57	2.29e-14	Bladder cancer;
PAAD	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.44	-0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9640161	0.750	rs61421252	chr7:150037972	T/C	cg21361702	chr7:150065534	REPIN1	0.54	4.35	0.33	2.52e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.28e-11	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs911119	0.908	rs6048949	chr20:23603199	C/T	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.5	4.69	0.36	6.09e-6	Uric acid clearance;
PAAD	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg01620082	chr3:125678407	NA	-1.6	-9.61	-0.61	2.17e-17	Depression;
PAAD	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.62	5.32	0.4	3.67e-7	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.79	-8.66	-0.57	6.54e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs988913	1.000	rs6941291	chr6:54837376	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.93	-0.37	2.16e-6	Menarche (age at onset);
PAAD	cis	rs10411161	0.721	rs1433082	chr19:52390726	A/C	cg24886414	chr19:53290126	ZNF600	-0.48	-4.29	-0.33	3.2e-5	Breast cancer;
PAAD	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.48	4.7	0.36	5.66e-6	HDL cholesterol;
PAAD	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-5.16	-0.39	7.69e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	4.47	0.34	1.55e-5	Resting heart rate;
PAAD	cis	rs62025270	0.547	rs338536	chr15:86197240	G/A	cg13263323	chr15:86062960	AKAP13	0.48	4.65	0.35	7.27e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-4.38	-0.33	2.22e-5	Monocyte count;
PAAD	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg13397359	chr6:42928475	GNMT	0.57	4.51	0.34	1.3e-5	Blood protein levels;
PAAD	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.66	6.65	0.47	5.07e-10	Platelet count;
PAAD	cis	rs732765	0.734	rs9323602	chr14:75182008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg25204440	chr1:209979598	IRF6	0.61	5.12	0.38	9.13e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg17372657	chr7:1216933	NA	-0.35	-4.41	-0.34	1.99e-5	Longevity;Endometriosis;
PAAD	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg00129232	chr17:37814104	STARD3	-0.53	-4.81	-0.36	3.54e-6	Self-reported allergy;
PAAD	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.77	-0.36	4.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg01631408	chr1:248437212	OR2T33	-0.59	-5.15	-0.39	8.09e-7	Common traits (Other);
PAAD	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.86	-11.91	-0.69	1.6e-23	Cystic fibrosis severity;
PAAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.74	-8.71	-0.58	4.72e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.81	-7.89	-0.54	5.6e-13	Response to hepatitis C treatment;
PAAD	cis	rs4455778	0.580	rs4304291	chr7:49116983	T/C	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11809443	1.000	rs11809443	chr1:228326492	T/C	cg18477163	chr1:228402036	OBSCN	0.48	5.07	0.38	1.15e-6	Coronary artery disease;
PAAD	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.59e-8	Coronary artery calcification;
PAAD	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.61	-5.96	-0.44	1.69e-8	Subjective well-being;
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg26516362	chr5:178986906	RUFY1	0.53	6.22	0.45	4.6e-9	Lung cancer;
PAAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.46	4.44	0.34	1.69e-5	Pulse pressure;
PAAD	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	5.93	0.43	2.01e-8	Cognitive test performance;
PAAD	cis	rs117623576	0.941	rs72778716	chr10:32370541	G/A	cg03047570	chr10:32398778	NA	-0.87	-5.35	-0.4	3.15e-7	Anti-saccade response;
PAAD	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg25558440	chr8:11882962	NA	-0.44	-4.25	-0.33	3.76e-5	Neuroticism;
PAAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg03037974	chr15:76606532	NA	0.51	5.7	0.42	5.9e-8	Blood metabolite levels;
PAAD	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.41	10.3	0.64	3.25e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.49	-5.2	-0.39	6.38e-7	Type 2 diabetes;
PAAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.56	-5.14	-0.39	8.19e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg00814883	chr7:100076585	TSC22D4	-0.64	-5.28	-0.39	4.45e-7	Platelet count;
PAAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.24	-0.45	4.18e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg01796438	chr3:11312864	ATG7	-0.55	-4.29	-0.33	3.18e-5	Circulating chemerin levels;
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.41	5.68	0.42	6.52e-8	Vitiligo;
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg04154034	chr17:28927549	LRRC37B2	0.62	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.88	4.76	0.36	4.4e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs7631605	0.623	rs9857252	chr3:36985232	C/A	cg17445812	chr3:36986805	TRANK1	0.31	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg02734326	chr4:10020555	SLC2A9	-0.49	-4.82	-0.36	3.43e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg00012203	chr2:219082015	ARPC2	0.58	5.89	0.43	2.44e-8	Ulcerative colitis;
PAAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.63	-6.59	-0.47	6.87e-10	Body mass index;
PAAD	trans	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13560548	chr3:10150139	C3orf24	0.52	4.73	0.36	5e-6	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg16606324	chr3:10149918	C3orf24	0.73	5.9	0.43	2.29e-8	Alzheimer's disease;
PAAD	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.16	0.39	7.67e-7	Tonsillectomy;
PAAD	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg20811857	chr17:78079795	GAA	-0.46	-4.41	-0.34	1.95e-5	Yeast infection;
PAAD	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	4.7	0.36	5.72e-6	Homocysteine levels;
PAAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg03983715	chr16:68378420	PRMT7	-0.56	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02985541	chr2:219472218	PLCD4	-0.31	-4.91	-0.37	2.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35079168	0.701	rs3132296	chr9:137302631	C/T	cg00753924	chr9:137298813	RXRA	-0.48	-5.19	-0.39	6.51e-7	Intelligence;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.71	7.69	0.53	1.72e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg10395934	chr14:104002654	TRMT61A	0.54	5.4	0.4	2.5e-7	Body mass index;
PAAD	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.63	8.45	0.57	2.18e-14	Renal cell carcinoma;
PAAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.52	4.74	0.36	4.94e-6	Total body bone mineral density;
PAAD	cis	rs7127900	0.561	rs7125026	chr11:2233617	C/T	cg25635251	chr11:2234043	NA	0.8	7.68	0.53	1.81e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	7.49	0.52	5.1e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.44	-4.92	-0.37	2.23e-6	Mean arterial pressure;
PAAD	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg20731937	chr12:48336164	NA	0.58	4.97	0.37	1.79e-6	Longevity (90 years and older);
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.45	-4.51	-0.34	1.3e-5	Iron status biomarkers;
PAAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-5.25	-0.39	4.95e-7	Schizophrenia;
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg03289416	chr15:75166202	SCAMP2	0.56	5.7	0.42	5.95e-8	Breast cancer;
PAAD	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.06	0.38	1.21e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.27	0.39	4.61e-7	Hemoglobin concentration;
PAAD	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.56	-7.45	-0.52	6.53e-12	Height;
PAAD	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.95	8.34	0.56	4.17e-14	Gut microbiome composition (summer);
PAAD	cis	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.5	-0.34	1.34e-5	Eotaxin levels;
PAAD	cis	rs6723108	0.626	rs1530559	chr2:135755629	C/T	cg26890182	chr2:135621176	ACMSD	-0.32	-4.49	-0.34	1.42e-5	Type 2 diabetes;
PAAD	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-5.62	-0.41	8.97e-8	Height;
PAAD	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.64	-6.52	-0.47	9.79e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.09e-6	Life satisfaction;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg12705353	chr12:122356852	WDR66	0.47	5.42	0.4	2.34e-7	Mean corpuscular volume;
PAAD	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-4.76	-0.36	4.43e-6	Testicular germ cell tumor;
PAAD	cis	rs3206736	0.548	rs1559959	chr7:35074367	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.59	-0.35	9.27e-6	Diastolic blood pressure;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18918831	chr3:195489782	MUC4	0.76	5.75	0.42	4.72e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-8.43	-0.56	2.48e-14	Total body bone mineral density;
PAAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.51e-14	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.45	-4.88	-0.37	2.64e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg02297831	chr4:17616191	MED28	-0.58	-5.35	-0.4	3.13e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.5	0.47	1.07e-9	Lung cancer in ever smokers;
PAAD	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.83	0.36	3.33e-6	Blood metabolite levels;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg25036197	chr15:72876508	ARIH1	-0.54	-6.29	-0.45	3.28e-9	Immature fraction of reticulocytes;
PAAD	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.66	6.03	0.44	1.19e-8	Platelet count;
PAAD	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg03371404	chr2:241525653	CAPN10	0.54	4.81	0.36	3.55e-6	Bipolar disorder;
PAAD	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs959260	1.000	rs2053157	chr17:73378595	A/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25967505	chr3:50606708	HEMK1	-0.68	-6.42	-0.46	1.65e-9	Lung cancer in ever smokers;
PAAD	cis	rs6584283	0.744	rs1332099	chr10:101298451	T/C	cg24926711	chr10:100993662	HPSE2	-0.31	-4.32	-0.33	2.78e-5	Ulcerative colitis;
PAAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	1.14	10.42	0.65	1.5700000000000001e-19	Initial pursuit acceleration;
PAAD	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs4679121	0.642	rs16837500	chr3:126183460	G/A	cg05485589	chr3:126194908	ZXDC	-0.88	-4.4	-0.34	2.02e-5	Pursuit maintenance gain;
PAAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.55	5.89	0.43	2.39e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.32	-0.4	3.71e-7	Educational attainment (years of education);
PAAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg19630374	chr17:18023558	MYO15A	0.47	4.86	0.37	2.86e-6	Total body bone mineral density;
PAAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.61	5.83	0.43	3.13e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.94	9.45	0.61	5.81e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.57	-5.3	-0.4	3.96e-7	Gut microbiome composition (summer);
PAAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs17135859	1.000	rs17135859	chr5:112996654	T/C	cg12552261	chr5:112820674	MCC	0.7	4.42	0.34	1.89e-5	F-cell distribution;
PAAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.48	4.51	0.34	1.27e-5	Renal cell carcinoma;
PAAD	cis	rs7577696	0.925	rs212695	chr2:32440868	G/T	cg02381751	chr2:32503542	YIPF4	0.43	4.66	0.35	6.86e-6	Inflammatory biomarkers;
PAAD	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24213567	chr19:53496664	ZNF702P	-0.43	-4.46	-0.34	1.6e-5	Psoriasis;
PAAD	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg04330084	chr7:123175371	IQUB	-0.53	-5.02	-0.38	1.45e-6	Migraine;
PAAD	cis	rs6446731	1.000	rs6446731	chr4:3284751	G/A	cg14583973	chr4:3374767	RGS12	0.37	5.0	0.38	1.56e-6	Mean platelet volume;
PAAD	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.58	6.1	0.44	8.59e-9	Hepatitis;
PAAD	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.82	8.37	0.56	3.52e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg14393609	chr7:65229607	NA	0.48	4.81	0.36	3.61e-6	Aortic root size;
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg26939375	chr7:64535504	NA	0.75	8.92	0.59	1.36e-15	Aortic root size;
PAAD	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg17595323	chr11:93583763	C11orf90	-0.36	-4.52	-0.34	1.26e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg04520793	chr17:42248056	ASB16	-0.47	-6.34	-0.46	2.44e-9	Total body bone mineral density;
PAAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg27121462	chr16:89883253	FANCA	0.47	5.05	0.38	1.26e-6	Vitiligo;
PAAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.86	9.23	0.6	2.24e-16	Cognitive function;
PAAD	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs9283706	0.689	rs12517976	chr5:66321579	G/A	cg11590213	chr5:66331682	MAST4	0.58	4.77	0.36	4.22e-6	Coronary artery disease;
PAAD	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.44	4.6	0.35	8.92e-6	Menopause (age at onset);
PAAD	trans	rs3733631	0.947	rs2189220	chr4:104598099	T/A	cg21490444	chr5:171095097	NA	0.77	6.29	0.45	3.16e-9	Menarche (age at onset);
PAAD	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.54	5.61	0.41	9.29e-8	Diastolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10231126	chr17:73753800	ITGB4	0.56	6.42	0.46	1.68e-9	Smoking initiation;
PAAD	cis	rs11676348	0.935	rs4674248	chr2:218960131	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.64	-0.35	7.33e-6	Ulcerative colitis;
PAAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg16083429	chr3:49237500	CCDC36	-0.44	-4.29	-0.33	3.18e-5	Menarche (age at onset);
PAAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19167755	chr6:53667257	LRRC1	-0.67	-7.39	-0.51	9.16e-12	Obesity-related traits;
PAAD	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	6.05	0.44	1.07e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26876637	chr1:152193138	HRNR	0.84	6.44	0.46	1.5e-9	Atopic dermatitis;
PAAD	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.59	-5.69	-0.42	6.38e-8	Blood protein levels;
PAAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.36	-0.4	2.99e-7	Diastolic blood pressure;
PAAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.78	-7.78	-0.53	1.03e-12	Tuberculosis;
PAAD	cis	rs10274279	1.000	rs10274279	chr7:157387441	C/T	cg26886268	chr7:157387156	PTPRN2	0.71	5.69	0.42	6.48e-8	Myopia (pathological);
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	4.99e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	5.85	0.43	2.92e-8	Eye color traits;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-8.24	-0.56	7.26e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.99	-0.49	8.33e-11	Psoriasis;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg05457628	chr5:178986728	RUFY1	-0.74	-8.06	-0.55	2.12e-13	Lung cancer;
PAAD	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.57	0.41	1.12e-7	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15923408	chr8:8750314	MFHAS1	0.62	6.85	0.49	1.73e-10	Myopia (pathological);
PAAD	cis	rs747650	0.504	rs4315028	chr11:47099125	A/C	cg19486271	chr11:47235900	DDB2	0.68	6.28	0.45	3.31e-9	Acne (severe);
PAAD	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.73	-0.36	5.06e-6	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.58	6.82	0.48	2.03e-10	Lung cancer;
PAAD	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg14181355	chr19:12984996	MAST1	-0.47	-4.34	-0.33	2.62e-5	Mean corpuscular volume;
PAAD	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg23254163	chr1:152506842	NA	0.58	6.76	0.48	2.78e-10	Plantar warts;
PAAD	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.86	9.3	0.6	1.41e-16	Corneal astigmatism;
PAAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.45	-4.68	-0.35	6.26e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2645694	1.000	rs2645694	chr4:77833947	C/T	cg18351406	chr4:77819688	ANKRD56	0.73	7.64	0.53	2.27e-12	Emphysema distribution in smoking;
PAAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-1.07	-15.15	-0.78	3.4e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs806321	0.538	rs2066689	chr13:50878604	G/A	cg03369344	chr13:50705024	NA	0.43	4.34	0.33	2.59e-5	Multiple sclerosis;
PAAD	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	8.2	0.55	9.22e-14	Neuroticism;
PAAD	trans	rs4678145	0.908	rs17282078	chr3:124481760	T/A	cg03983498	chr1:55107291	C1orf175	1.0	6.39	0.46	1.94e-9	Coronary artery disease;
PAAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-5.49	-0.41	1.61e-7	Joint mobility (Beighton score);
PAAD	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg03315344	chr16:75512273	CHST6	-0.63	-5.35	-0.4	3.24e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-4.94	-0.37	2.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg07153588	chr17:77290851	HRNBP3	0.4	4.41	0.34	1.96e-5	HDL cholesterol levels;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg10207240	chr12:122356781	WDR66	0.58	6.15	0.45	6.51e-9	Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.78	-8.43	-0.56	2.54e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg14393609	chr7:65229607	NA	-0.65	-7.17	-0.5	3.02e-11	Aortic root size;
PAAD	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.6	5.67	0.42	6.98e-8	Lymphocyte counts;
PAAD	cis	rs78707713	0.841	rs2033372	chr10:71212333	C/G	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg02250501	chr15:90694978	NA	-0.46	-4.32	-0.33	2.76e-5	Rheumatoid arthritis;
PAAD	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.72	-7.19	-0.5	2.73e-11	Uric acid clearance;
PAAD	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg12633918	chr20:23549525	CST9L	-0.42	-4.61	-0.35	8.64e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.92	0.37	2.21e-6	Blood metabolite levels;
PAAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg01942863	chr7:99769432	GPC2	-0.44	-4.26	-0.33	3.62e-5	Coronary artery disease;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg23119463	chr10:134592391	INPP5A	-0.49	-4.55	-0.35	1.08e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.57	-4.92	-0.37	2.19e-6	Type 2 diabetes;
PAAD	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg26068271	chr17:76253126	NA	0.56	5.57	0.41	1.15e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06483802	chr13:43169237	TNFSF11	-0.77	-6.99	-0.49	8.11e-11	Neuroticism;
PAAD	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.83	0.62	5.78e-18	Post bronchodilator FEV1;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.85	-9.86	-0.62	4.91e-18	Iron status biomarkers;
PAAD	cis	rs10932679	0.532	rs2712162	chr2:217661788	C/T	cg05032264	chr2:217675019	NA	-0.52	-4.95	-0.37	1.92e-6	Pulse pressure;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.8	9.0	0.59	8.64e-16	Lung cancer;
PAAD	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg18196295	chr10:418757	DIP2C	0.44	4.82	0.36	3.41e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg10578991	chr7:12443926	VWDE	-0.5	-4.33	-0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	1.08	8.66	0.57	6.29e-15	IgG glycosylation;
PAAD	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.61	6.1	0.44	8.58e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.57	5.57	0.41	1.15e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.62	-0.41	8.96e-8	Bipolar disorder;
PAAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg24699146	chr1:24152579	HMGCL	0.55	5.79	0.43	3.87e-8	Immature fraction of reticulocytes;
PAAD	cis	rs863345	0.547	rs10908675	chr1:158504129	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.13	-0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs78761021	0.829	rs55789050	chr17:9793417	A/T	cg26853458	chr17:9805074	RCVRN	0.72	8.32	0.56	4.57e-14	Type 2 diabetes;
PAAD	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.65	-5.45	-0.4	2.01e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.77	8.29	0.56	5.54e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.6	0.65	5.28e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.55	6.05	0.44	1.07e-8	Height;
PAAD	trans	rs901683	1.000	rs71496623	chr10:46085866	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	7.15	0.5	3.45e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs3857067	0.967	rs7668980	chr4:95037320	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-4.47	-0.34	1.5e-5	QT interval;
PAAD	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.32	0.56	4.57e-14	Menarche (age at onset);
PAAD	cis	rs11264213	0.901	rs55762724	chr1:36382702	C/T	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs13135934	0.503	rs1988252	chr4:95004279	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.24	-0.39	5.39e-7	Menarche (age at onset);
PAAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06449653	chr1:23670777	HNRNPR	0.63	6.91	0.49	1.27e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.57	-0.41	1.14e-7	Mean platelet volume;
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg00450029	chr8:599525	NA	0.82	5.38	0.4	2.79e-7	IgG glycosylation;
PAAD	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.59	-5.9	-0.43	2.24e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.91	5.18	0.39	6.81e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	0.92	5.47	0.41	1.79e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg07148914	chr20:33460835	GGT7	0.54	5.1	0.38	9.89e-7	Coronary artery disease;
PAAD	cis	rs2555155	0.775	rs10769696	chr11:6547114	T/A	cg11185456	chr11:6592066	DNHD1	-0.45	-4.8	-0.36	3.72e-6	DNA methylation (variation);
PAAD	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg27490568	chr2:178487706	NA	0.48	5.0	0.38	1.56e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	6.19	0.45	5.39e-9	Renal function-related traits (BUN);
PAAD	cis	rs4662592	0.566	rs7587813	chr2:128840881	T/C	cg17144508	chr2:128283727	IWS1	-0.55	-4.39	-0.34	2.08e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04733989	chr22:42467013	NAGA	0.47	4.76	0.36	4.47e-6	Cognitive function;
PAAD	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg27398640	chr15:77910606	LINGO1	0.45	4.26	0.33	3.5e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.81e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59888335	0.862	rs67063167	chr3:80848632	T/C	cg21735741	chr3:80819488	NA	0.55	4.89	0.37	2.57e-6	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19802241	chr11:14402761	NA	-0.81	-7.2	-0.5	2.57e-11	Neuroticism;
PAAD	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.03	-10.86	-0.66	1.06e-20	Ulcerative colitis;
PAAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	6.99	0.49	7.94e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.66	-4.85	-0.37	3.07e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg00898013	chr13:113819073	PROZ	-0.79	-6.81	-0.48	2.18e-10	Blood protein levels;
PAAD	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg10985347	chr2:127963512	CYP27C1	0.49	4.76	0.36	4.55e-6	Protein C levels;
PAAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.24	0.39	5.33e-7	Rheumatoid arthritis;
PAAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg17372223	chr3:52568218	NT5DC2	0.48	4.64	0.35	7.5e-6	Bipolar disorder;
PAAD	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.62	-4.52	-0.34	1.23e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg19197139	chr17:4613644	ARRB2	0.86	8.89	0.59	1.62e-15	Lymphocyte counts;
PAAD	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.76	7.6	0.52	2.86e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs17232800	0.866	rs12232701	chr18:66309392	C/A	cg03686067	chr18:66504389	CCDC102B	0.73	4.25	0.33	3.76e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.71	8.38	0.56	3.39e-14	Lung cancer;
PAAD	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg06643849	chr19:57742421	AURKC	0.45	4.54	0.35	1.13e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.83	0.62	5.78e-18	Post bronchodilator FEV1;
PAAD	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.66	-6.25	-0.45	3.84e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.64	-5.8	-0.43	3.65e-8	Response to antineoplastic agents;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26549601	chr10:134560360	INPP5A	-0.51	-4.87	-0.37	2.74e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.07	-0.44	9.59e-9	Menarche (age at onset);
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04156016	chr5:1868137	NA	0.45	4.6	0.35	8.94e-6	Cardiovascular disease risk factors;
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.63	5.12	0.38	8.96e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.38	0.33	2.23e-5	Tonsillectomy;
PAAD	cis	rs7119038	0.629	rs10892271	chr11:118598544	G/A	cg08498647	chr11:118550644	TREH	0.41	4.29	0.33	3.19e-5	Sjögren's syndrome;
PAAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.4	0.4	2.57e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	4.49	0.34	1.39e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.6	-6.7	-0.48	3.76e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs62025270	0.747	rs12324721	chr15:86310972	C/T	cg13263323	chr15:86062960	AKAP13	0.57	5.27	0.39	4.69e-7	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.92	10.86	0.66	1.1e-20	Coronary artery disease;
PAAD	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	10.26	0.64	4.38e-19	Nonalcoholic fatty liver disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01705458	chr11:27384997	CCDC34	0.58	6.4	0.46	1.86e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.9	7.06	0.5	5.43e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.11	-0.5	4.12e-11	Life satisfaction;
PAAD	cis	rs6466055	0.661	rs6466048	chr7:104896865	C/T	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg04018474	chr16:31008003	STX1B	-0.29	-4.48	-0.34	1.47e-5	Dementia with Lewy bodies;
PAAD	trans	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.6e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg22827986	chr11:48284249	OR4X1	-0.43	-5.27	-0.39	4.56e-7	Migraine - clinic-based;
PAAD	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg11766577	chr21:47581405	C21orf56	-0.4	-4.46	-0.34	1.59e-5	Testicular germ cell tumor;
PAAD	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07234876	chr8:600039	NA	-1.09	-7.6	-0.52	2.8e-12	IgG glycosylation;
PAAD	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg00564555	chr16:1970112	NA	0.37	4.27	0.33	3.47e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg20607287	chr7:12443886	VWDE	-0.92	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.99	6.65	0.47	4.94e-10	Depression;
PAAD	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.7	7.19	0.5	2.71e-11	Platelet count;
PAAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7619833	0.607	rs7634878	chr3:27241219	C/T	cg02860705	chr3:27208620	NA	0.4	4.45	0.34	1.64e-5	Breast cancer;
PAAD	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg06812019	chr5:1143331	NA	0.46	4.25	0.33	3.74e-5	Gut microbiome composition (winter);
PAAD	cis	rs654384	0.866	rs13224870	chr7:4172006	C/T	cg27574739	chr7:4176374	SDK1	-0.5	-5.03	-0.38	1.36e-6	Positive affect;
PAAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.57	-7.31	-0.51	1.44e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg14515779	chr1:101123966	NA	0.39	4.26	0.33	3.54e-5	Monocyte count;
PAAD	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.6	6.86	0.49	1.67e-10	Dupuytren's disease;
PAAD	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg00717180	chr2:96193071	NA	0.59	6.49	0.47	1.17e-9	HDL cholesterol;
PAAD	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.7	6.6	0.47	6.31e-10	Primary sclerosing cholangitis;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14573099	chr2:101761014	TBC1D8	-0.6	-7.05	-0.5	5.94e-11	Immature fraction of reticulocytes;
PAAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg05785598	chr3:49045655	WDR6	0.4	4.76	0.36	4.52e-6	Parkinson's disease;
PAAD	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.1	0.44	8.51e-9	Bladder cancer;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.63	6.1	0.44	8.5e-9	Subjective well-being;
PAAD	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.58	-5.35	-0.4	3.11e-7	White blood cell count;
PAAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.57	-5.59	-0.41	1.03e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.49	5.68	0.42	6.65e-8	Night sleep phenotypes;
PAAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg01489256	chr8:11204017	TDH	-0.45	-4.76	-0.36	4.54e-6	Retinal vascular caliber;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg27539214	chr16:67997921	SLC12A4	-0.67	-5.14	-0.39	8.15e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1879734	0.731	rs11206187	chr1:54127969	A/G	cg14659662	chr1:54151053	GLIS1	0.39	5.23	0.39	5.6e-7	Mitral valve prolapse;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs35504302	chr10:46010505	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.78	0.48	2.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02985541	chr2:219472218	PLCD4	-0.31	-4.91	-0.37	2.37e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	8.06	0.55	2.06e-13	Platelet count;
PAAD	cis	rs7674212	0.581	rs13150953	chr4:103942498	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-4.4	-0.34	2.03e-5	Type 2 diabetes;
PAAD	cis	rs116175783	0.557	rs72876083	chr2:162184038	C/T	cg08807892	chr2:162101083	NA	-0.67	-4.93	-0.37	2.13e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.68	4.98	0.37	1.69e-6	Bipolar disorder;
PAAD	cis	rs12767760	0.714	rs11189274	chr10:99311629	A/G	cg25247692	chr10:99313390	UBTD1	-0.51	-4.96	-0.37	1.85e-6	Obesity-related traits;
PAAD	cis	rs11615916	0.790	rs55938311	chr12:62680747	A/G	cg11441379	chr12:63026424	NA	0.65	4.41	0.34	1.93e-5	Pulmonary function decline;
PAAD	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.5	-5.72	-0.42	5.36e-8	Personality dimensions;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg15181151	chr6:150070149	PCMT1	0.56	6.07	0.44	9.86e-9	Lung cancer;
PAAD	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg06138931	chr13:21896616	NA	0.74	5.58	0.41	1.08e-7	White matter hyperintensity burden;
PAAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.68	7.39	0.51	9.19e-12	Longevity;
PAAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg16417436	chr16:28758564	NA	0.42	4.26	0.33	3.64e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.7	-0.36	5.89e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.42	5.5	0.41	1.58e-7	Alcohol dependence;
PAAD	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.44	-4.98	-0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.7e-8	Eye color traits;
PAAD	cis	rs16895831	0.549	rs12198323	chr6:42611872	A/G	cg10605015	chr6:42532144	UBR2	-0.62	-4.68	-0.35	6.28e-6	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.51	-5.58	-0.41	1.07e-7	Vitamin D levels;
PAAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.89	9.59	0.61	2.56e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.62	-0.47	5.68e-10	Hip circumference;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg15117754	chr3:10150083	C3orf24	0.58	5.4	0.4	2.48e-7	Alzheimer's disease;
PAAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.3	-4.35	-0.33	2.51e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55788414	0.932	rs11649028	chr16:81185326	G/A	cg06400318	chr16:81190750	PKD1L2	1.06	7.94	0.54	4.04e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.87	9.82	0.62	6.22e-18	Parkinson's disease;
PAAD	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.51	4.97	0.37	1.82e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg02462569	chr6:150064036	NUP43	-0.45	-5.0	-0.38	1.58e-6	Lung cancer;
PAAD	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.63	6.3	0.46	3.05e-9	Type 2 diabetes;
PAAD	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-11.26	-0.67	8.93e-22	Ulcerative colitis;
PAAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.85	9.89	0.63	4.12e-18	Coronary artery disease;
PAAD	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.55	-5.84	-0.43	3.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs642743	0.967	rs527154	chr10:105943683	C/G	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.7	0.36	5.82e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg05313129	chr8:58192883	C8orf71	-0.62	-5.26	-0.39	4.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs904092	0.816	rs1693458	chr4:100225992	T/C	cg12011299	chr4:100065546	ADH4	-0.54	-4.58	-0.35	9.66e-6	Alcohol dependence;
PAAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg21191810	chr6:118973309	C6orf204	-0.51	-4.9	-0.37	2.45e-6	Diastolic blood pressure;
PAAD	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.6	6.12	0.44	7.79e-9	Morning vs. evening chronotype;
PAAD	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.54	4.35	0.33	2.51e-5	HDL cholesterol;
PAAD	cis	rs6494488	0.500	rs72742925	chr15:64863303	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.59	6.61	0.47	6.05e-10	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg16303742	chr3:15540471	COLQ	-0.51	-4.96	-0.37	1.86e-6	Mean platelet volume;
PAAD	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.86	10.77	0.66	1.9e-20	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg10215110	chr6:44225450	SLC35B2	-0.55	-6.3	-0.46	3.05e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.82	5.38	0.4	2.81e-7	Severe influenza A (H1N1) infection;
PAAD	trans	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	6.4	0.46	1.84e-9	Resting heart rate;
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.8	-0.43	3.65e-8	Prostate cancer;
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg10864074	chr7:100318194	EPO	-0.48	-4.79	-0.36	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.53	-5.42	-0.4	2.3e-7	Number of children ever born;
PAAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg14345882	chr6:26364793	BTN3A2	0.73	5.29	0.39	4.19e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.45	4.29	0.33	3.16e-5	Heart rate;
PAAD	cis	rs346785	1.000	rs164106	chr17:74290566	C/A	cg09812376	chr17:74270190	QRICH2	-0.43	-5.98	-0.44	1.52e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg08704217	chr1:110036942	CYB561D1	-0.47	-4.35	-0.33	2.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg23254163	chr1:152506842	NA	0.48	4.7	0.36	5.75e-6	Hair morphology;
PAAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs7631605	0.518	rs11706926	chr3:36978647	A/G	cg10333520	chr3:36987040	TRANK1	0.41	5.65	0.42	7.69e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.7	-7.33	-0.51	1.27e-11	Morning vs. evening chronotype;
PAAD	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.61	-4.49	-0.34	1.37e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg22089800	chr15:90895588	ZNF774	0.53	5.2	0.39	6.38e-7	Rheumatoid arthritis;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.6	6.85	0.49	1.71e-10	Dupuytren's disease;
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.9	12.77	0.72	7.97e-26	Vitiligo;
PAAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg13870426	chr17:30244630	NA	-0.74	-6.54	-0.47	8.96e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.55	5.01	0.38	1.52e-6	Type 2 diabetes;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.95	12.68	0.72	1.38e-25	Menarche (age at onset);
PAAD	cis	rs6976053	0.804	rs314371	chr7:100455700	C/T	cg22425096	chr7:100417404	EPHB4	0.51	4.44	0.34	1.69e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.68	-7.68	-0.53	1.82e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg26174226	chr8:58114915	NA	-0.61	-4.71	-0.36	5.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.48	-7.75	-0.53	1.23e-12	Urinary metabolites;
PAAD	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.37	4.85	0.37	3.08e-6	Calcium levels;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg26354017	chr1:205819088	PM20D1	0.69	5.93	0.43	1.96e-8	Prostate-specific antigen levels;
PAAD	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.52	-0.34	1.22e-5	Retinal vascular caliber;
PAAD	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.82	10.32	0.64	3.05e-19	Morning vs. evening chronotype;
PAAD	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.79	8.42	0.56	2.66e-14	Mean corpuscular volume;
PAAD	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.86	-10.02	-0.63	1.82e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6604026	0.630	rs2481711	chr1:93346572	C/T	cg13858687	chr1:93297071	RPL5	-0.48	-4.4	-0.34	2e-5	Multiple sclerosis;
PAAD	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.55	4.86	0.37	2.93e-6	Dilated cardiomyopathy;
PAAD	cis	rs630539	1.000	rs4306571	chr17:40814207	A/T	cg20669292	chr17:40823420	PLEKHH3	-0.49	-4.43	-0.34	1.8e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs564309	0.681	rs1150918	chr1:228608689	T/C	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.87	6.87	0.49	1.54e-10	Axial length;
PAAD	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.42	4.68	0.35	6.32e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg07828024	chr6:149772892	ZC3H12D	0.32	4.27	0.33	3.4e-5	Dupuytren's disease;
PAAD	cis	rs7260598	0.539	rs59175483	chr19:24065542	T/C	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.7	5.37	0.4	2.86e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17464271	chr1:1447047	ATAD3A	0.71	7.96	0.54	3.68e-13	Myopia (pathological);
PAAD	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg18888403	chr1:24152774	HMGCL	0.41	4.66	0.35	6.94e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7705042	0.826	rs13184323	chr5:141494719	T/G	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.16	-0.39	7.64e-7	Asthma;
PAAD	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.49	-4.82	-0.36	3.43e-6	Depression;
PAAD	cis	rs3112530	1.000	rs2560243	chr5:152701346	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	1.08	5.15	0.39	8.03e-7	Breast cancer;
PAAD	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg27398640	chr15:77910606	LINGO1	0.48	4.72	0.36	5.35e-6	Type 2 diabetes;
PAAD	cis	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg26205652	chr12:48591994	NA	-0.93	-10.33	-0.64	2.76e-19	Longevity (90 years and older);
PAAD	cis	rs7631605	0.870	rs6775008	chr3:37179031	A/G	cg17445812	chr3:36986805	TRANK1	0.33	4.42	0.34	1.9e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.68	-6.53	-0.47	9.07e-10	QRS duration;
PAAD	cis	rs6763768	0.563	rs2930176	chr3:53487279	G/A	cg20929811	chr3:52516414	NISCH	-0.47	-4.71	-0.36	5.51e-6	Bacterial meningitis;
PAAD	cis	rs4085154	1.000	rs3862956	chr1:216858315	C/T	cg20869501	chr1:216774677	ESRRG	-0.43	-4.47	-0.34	1.5e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.98	-11.3	-0.68	6.94e-22	Tonsillectomy;
PAAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.7	7.33	0.51	1.24e-11	Pulse pressure;
PAAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9815354	1.000	rs1717009	chr3:41946308	T/C	cg03022575	chr3:42003672	ULK4	-0.82	-5.94	-0.43	1.86e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg07202610	chr7:1142643	C7orf50	-0.67	-5.56	-0.41	1.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs448720	0.811	rs399408	chr15:68183851	G/A	cg05925327	chr15:68127851	NA	-0.38	-4.31	-0.33	2.96e-5	Cognitive performance;
PAAD	cis	rs7814319	0.838	rs951194	chr8:97230489	T/A	cg20787634	chr8:97240163	UQCRB	-0.6	-6.15	-0.45	6.46e-9	Lung function (FVC);
PAAD	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.54	-5.79	-0.43	3.84e-8	Hepatitis;
PAAD	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs507080	0.733	rs611733	chr11:118572760	C/T	cg08498647	chr11:118550644	TREH	-0.39	-4.46	-0.34	1.55e-5	Serum metabolite levels;
PAAD	cis	rs10789285	0.650	rs2245330	chr1:69690808	G/A	cg04447890	chr1:68697988	GPR177	-0.53	-4.29	-0.33	3.13e-5	Psoriasis;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20887711	chr4:1340912	KIAA1530	0.5	5.14	0.38	8.34e-7	Obesity-related traits;
PAAD	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.73	-0.48	3.32e-10	Neuroticism;
PAAD	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg26205652	chr12:48591994	NA	0.72	6.49	0.47	1.15e-9	Longevity (90 years and older);
PAAD	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg12046867	chr14:103022105	NA	-0.66	-5.39	-0.4	2.69e-7	Platelet count;
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg00809820	chr17:80708513	TBCD;FN3K	0.48	4.79	0.36	4e-6	Glycated hemoglobin levels;
PAAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.7	7.69	0.53	1.69e-12	Prostate cancer;
PAAD	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.14	-0.64	8.97e-19	Response to antipsychotic treatment;
PAAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	8.49	0.57	1.73e-14	Alzheimer's disease;
PAAD	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg02743256	chr7:2109353	MAD1L1	-0.67	-5.27	-0.39	4.65e-7	Bipolar disorder;
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.92	-15.16	-0.78	3.34e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.36	5.66	0.42	7.46e-8	Alopecia areata;
PAAD	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg12730826	chr1:205179972	DSTYK	-0.42	-4.4	-0.34	1.99e-5	Red blood cell count;
PAAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.57	7.09	0.5	4.82e-11	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.76	-8.52	-0.57	1.47e-14	Height;
PAAD	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.61	-6.71	-0.48	3.67e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06400595	chr12:56551642	MYL6B;MYL6	0.58	6.32	0.46	2.8e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.03	0.38	1.36e-6	Mean platelet volume;
PAAD	cis	rs617219	0.698	rs7706045	chr5:78507910	T/G	cg24856658	chr5:78533917	JMY	-0.4	-4.51	-0.34	1.31e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg06131755	chr6:160182447	ACAT2	0.52	4.41	0.34	1.91e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.73	-0.36	4.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs747650	0.504	rs7128193	chr11:46988983	A/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.72e-5	Systolic blood pressure;
PAAD	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.4	-0.4	2.57e-7	Morning vs. evening chronotype;
PAAD	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.8	-0.36	3.75e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00603274	chr11:61596626	FADS2	-0.59	-4.6	-0.35	8.7e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg16596103	chr2:233749413	NGEF	0.41	4.47	0.34	1.55e-5	Schizophrenia;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.58	-6.23	-0.45	4.41e-9	Menopause (age at onset);
PAAD	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.41	0.61	7.63e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.66	6.1	0.44	8.46e-9	White matter hyperintensity burden;
PAAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.37	-0.56	3.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg02580895	chr19:2754563	NA	-0.52	-4.37	-0.33	2.3e-5	Total cholesterol levels;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	7.3	0.51	1.53e-11	Renal function-related traits (BUN);
PAAD	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg26950739	chr16:89183275	ACSF3	0.72	5.21	0.39	6.15e-7	Red blood cell count;
PAAD	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.44	-4.43	-0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs714031	0.934	rs4820387	chr22:40070446	A/G	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.51	-0.34	1.3e-5	Schizophrenia;
PAAD	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.63	6.28	0.45	3.34e-9	Blood protein levels;
PAAD	cis	rs4417704	0.551	rs7585067	chr2:241893465	T/C	cg26818257	chr2:241905806	NA	0.51	5.25	0.39	4.97e-7	Joint mobility (Beighton score);
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.45	-4.32	-0.33	2.78e-5	Breast cancer;
PAAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.7	-6.28	-0.45	3.4e-9	Menarche (age at onset);
PAAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.01	-0.54	2.72e-13	Rheumatoid arthritis;
PAAD	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.18	0.6	3.02e-16	Hemoglobin concentration;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg00809820	chr17:80708513	TBCD;FN3K	-0.46	-4.53	-0.34	1.21e-5	Glycated hemoglobin levels;
PAAD	cis	rs1413885	0.516	rs6588138	chr1:65838366	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.88	0.43	2.57e-8	Anticoagulant levels;
PAAD	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.7	5.03	0.38	1.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.63	8.16	0.55	1.17e-13	Hypertriglyceridemia;
PAAD	cis	rs855965	0.527	rs4752095	chr10:119468305	T/C	cg17249170	chr10:119305798	EMX2;EMX2OS	0.32	4.29	0.33	3.2e-5	Ovarian disease with few adhesions;
PAAD	cis	rs7243821	0.921	rs35440774	chr18:52633644	C/T	cg16669619	chr18:52630472	NA	-0.5	-5.15	-0.39	8.06e-7	Chin dimples;
PAAD	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg14254433	chr6:34482411	PACSIN1	-0.96	-6.09	-0.44	8.83e-9	Chronic lymphocytic leukemia;
PAAD	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-5.62	-0.41	8.89e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg19847866	chr10:1019161	NA	-0.58	-4.48	-0.34	1.43e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.64	6.59	0.47	6.87e-10	Blood protein levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12157281	chr2:8168246	NA	0.65	6.76	0.48	2.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg07164556	chr1:145727247	PDZK1	-0.68	-4.62	-0.35	8.15e-6	Mitochondrial DNA levels;
PAAD	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.46	-5.15	-0.39	8.05e-7	Menarche (age at onset);
PAAD	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.67	-0.35	6.71e-6	Migraine;
PAAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.75	0.58	3.75e-15	Parkinson's disease;
PAAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18337363	chr3:52569053	NT5DC2	-0.42	-4.35	-0.33	2.45e-5	Bipolar disorder;
PAAD	cis	rs75920871	0.925	rs17120237	chr11:116891046	T/C	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.95	9.94	0.63	2.94e-18	Blood metabolite levels;
PAAD	cis	rs12986413	0.874	rs4806832	chr19:2184652	C/T	cg09261902	chr19:2140048	AP3D1	0.51	5.05	0.38	1.28e-6	Height;
PAAD	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg22027985	chr11:4115532	RRM1	0.48	4.4	0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg13565585	chr5:132299512	AFF4	0.68	4.97	0.37	1.78e-6	Breast cancer;
PAAD	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg06496078	chr12:107350075	C12orf23	-0.46	-4.58	-0.35	9.61e-6	Total body bone mineral density;
PAAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg09796270	chr17:17721594	SREBF1	-0.47	-5.24	-0.39	5.32e-7	Strep throat;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23513784	chr8:22550797	EGR3	-0.68	-6.87	-0.49	1.52e-10	Smoking initiation;
PAAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.09	15.92	0.79	3.28e-34	Chronic sinus infection;
PAAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg21890820	chr11:65308645	LTBP3	0.66	7.91	0.54	4.86e-13	Bone mineral density;
PAAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-4.39	-0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs9395066	0.545	rs10948192	chr6:44947321	G/A	cg25276700	chr6:44698697	NA	0.48	5.53	0.41	1.38e-7	Height;
PAAD	cis	rs4740619	0.967	rs7036674	chr9:15653882	C/T	cg14451791	chr9:16040625	NA	-0.37	-4.25	-0.33	3.68e-5	Body mass index;
PAAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.52	6.02	0.44	1.25e-8	Bipolar disorder;
PAAD	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.99	-15.48	-0.78	4.61e-33	Height;
PAAD	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.06	-0.38	1.17e-6	Bipolar disorder;
PAAD	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	1.11	7.04	0.5	6.03e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg23216685	chr1:86174607	ZNHIT6	0.3	4.49	0.34	1.4e-5	Urate levels in overweight individuals;
PAAD	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24249390	chr15:90295951	MESP1	-0.55	-5.96	-0.44	1.66e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs1642645	0.597	rs702225	chr1:42373900	C/T	cg01990334	chr1:42801334	FOXJ3	0.67	5.76	0.42	4.58e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	5.01	0.38	1.5e-6	Neuroticism;
PAAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.49	-0.34	1.4e-5	Cognitive function;
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg04520793	chr17:42248056	ASB16	-0.47	-6.34	-0.46	2.44e-9	Total body bone mineral density;
PAAD	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.71	7.41	0.52	8.19e-12	Body mass index;
PAAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.48	6.02	0.44	1.24e-8	Childhood ear infection;
PAAD	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs72960926	1.000	rs72960912	chr6:75144719	C/T	cg03266952	chr6:74778945	NA	-1.28	-6.69	-0.48	4.01e-10	Metabolite levels (MHPG);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11524642	chr7:1191861	NA	0.51	6.34	0.46	2.45e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.45	4.68	0.36	6.22e-6	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.89	11.17	0.67	1.59e-21	Prudent dietary pattern;
PAAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.57	6.08	0.44	9.14e-9	Lung cancer;
PAAD	cis	rs12145833	0.748	rs11807162	chr1:243454680	C/T	cg02356786	chr1:243265016	LOC731275	0.78	5.09	0.38	1.03e-6	Obesity (early onset extreme);
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-4.86	-0.37	2.91e-6	Morning vs. evening chronotype;
PAAD	cis	rs6433857	0.536	rs12474658	chr2:181352992	G/T	cg23363182	chr2:181467187	NA	-0.51	-5.15	-0.39	7.85e-7	Body mass index;
PAAD	cis	rs8044476	0.887	rs34889159	chr16:72747685	T/A	cg00207534	chr16:71929512	KIAA0174	0.65	4.27	0.33	3.43e-5	Blood protein levels;
PAAD	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs12136530	0.593	rs9287046	chr1:19736395	C/G	cg01468656	chr1:19991678	HTR6	0.5	4.46	0.34	1.58e-5	Lead levels in blood;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg04165759	chr1:150448943	RPRD2	0.51	5.28	0.39	4.29e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.63e-5	Life satisfaction;
PAAD	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.35	0.4	3.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.76	7.14	0.5	3.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.66	6.71	0.48	3.7e-10	Eosinophil percentage of white cells;
PAAD	cis	rs1015291	0.708	rs1352901	chr12:20005347	A/G	cg25401612	chr12:20009446	NA	-0.54	-5.29	-0.39	4.29e-7	Diastolic blood pressure;
PAAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg14847009	chr1:175162515	KIAA0040	0.41	6.25	0.45	3.85e-9	Alcohol dependence;
PAAD	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-1.0	-12.73	-0.72	1.01e-25	Refractive error;
PAAD	cis	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06634786	chr22:41940651	POLR3H	0.64	4.89	0.37	2.54e-6	Vitiligo;
PAAD	cis	rs375066	0.901	rs438517	chr19:44419658	G/A	cg21496419	chr19:44306685	LYPD5	0.41	4.95	0.37	1.97e-6	Breast cancer;
PAAD	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.55e-5	Menopause (age at onset);
PAAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Electroencephalogram traits;
PAAD	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg00086871	chr4:6988644	TBC1D14	1.1	5.03	0.38	1.39e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2013441	0.606	rs12942179	chr17:19999781	G/A	cg13482628	chr17:19912719	NA	0.48	4.59	0.35	9.4e-6	Obesity-related traits;
PAAD	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	5.43	0.4	2.22e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.83	9.44	0.61	6.1e-17	Blood metabolite ratios;
PAAD	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.18e-14	Colorectal cancer;
PAAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg10556349	chr10:835070	NA	0.59	4.99	0.38	1.61e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.74	-8.06	-0.55	2.12e-13	Lung cancer;
PAAD	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.08	0.44	9.51e-9	Colorectal cancer;
PAAD	cis	rs59888335	0.895	rs34390769	chr3:80805371	T/C	cg21735741	chr3:80819488	NA	0.55	4.8	0.36	3.79e-6	Schizophrenia;
PAAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.74	7.98	0.54	3.38e-13	Sjögren's syndrome;
PAAD	cis	rs3847687	1.000	rs11061290	chr12:131518747	C/T	cg13406893	chr12:131568647	GPR133	-0.47	-4.65	-0.35	7.18e-6	Longevity;
PAAD	cis	rs7517847	0.540	rs7543633	chr1:67691772	A/G	cg22500004	chr1:68516272	DIRAS3	-0.48	-4.81	-0.36	3.67e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4953404	0.588	rs1319499	chr2:46894846	T/A	cg12784625	chr2:46524557	EPAS1	-0.48	-4.3	-0.33	3.1e-5	Pulse pressure (alcohol consumption interaction);
PAAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.95	-10.18	-0.64	7.11e-19	Alcohol dependence;
PAAD	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs3741798	1.000	rs3825259	chr12:12496635	A/G	cg08615371	chr12:12503544	MANSC1	1.06	7.4	0.51	8.77e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg06632027	chr4:90757378	SNCA	-0.52	-4.91	-0.37	2.28e-6	Neuroticism;
PAAD	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs12431939	1.000	rs11845886	chr14:51635873	G/A	cg23942311	chr14:51606299	NA	-0.72	-5.71	-0.42	5.85e-8	Cancer;
PAAD	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.77	9.44	0.61	6.06e-17	Metabolite levels;
PAAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg26174226	chr8:58114915	NA	-0.57	-4.45	-0.34	1.62e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.78	0.42	4.09e-8	Response to antipsychotic treatment;
PAAD	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg25547332	chr5:131281432	NA	0.54	4.28	0.33	3.24e-5	Life satisfaction;
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.75	8.4	0.56	2.96e-14	Longevity;
PAAD	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg00350942	chr9:140034073	GRIN1	-0.34	-4.42	-0.34	1.88e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.27	-0.45	3.6e-9	Bone mineral density;
PAAD	cis	rs10450586	0.863	rs10767625	chr11:27304965	A/C	cg10370305	chr11:27303972	NA	0.38	4.5	0.34	1.34e-5	Total body bone mineral density;
PAAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg13918804	chr1:2043761	PRKCZ	0.42	5.47	0.41	1.81e-7	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15403654	chr17:7747012	KDM6B	0.67	6.83	0.48	1.87e-10	Obesity-related traits;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.88	-9.79	-0.62	7.29e-18	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15129097	chr10:7376699	SFMBT2	-0.63	-6.38	-0.46	2.03e-9	Obesity-related traits;
PAAD	cis	rs797680	0.856	rs6688230	chr1:93641124	C/T	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg00717180	chr2:96193071	NA	-0.58	-6.38	-0.46	1.99e-9	HDL cholesterol;
PAAD	cis	rs12906542	0.544	rs35472584	chr15:78266727	C/T	cg27637606	chr15:78420039	CIB2	0.54	4.91	0.37	2.3e-6	Breast cancer;
PAAD	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-5.74	-0.42	4.89e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs3026445	1.000	rs3026445	chr12:110723203	T/C	cg19752449	chr12:109915316	UBE3B;KCTD10	-0.47	-4.26	-0.33	3.55e-5	QT interval;
PAAD	cis	rs2834288	0.500	rs881230	chr21:35322824	C/A	cg22542663	chr21:34915757	GART;SON	0.43	4.27	0.33	3.42e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25632300	chr5:174905618	SFXN1	-0.56	-6.32	-0.46	2.74e-9	Body fat percentage;
PAAD	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg03885332	chr11:832357	CD151	-0.45	-5.14	-0.38	8.22e-7	Mean platelet volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09325174	chr14:50154983	POLE2	0.57	6.5	0.47	1.07e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.72	5.87	0.43	2.68e-8	White matter hyperintensity burden;
PAAD	trans	rs2839627	0.568	rs73235419	chr21:44463406	G/A	cg24637261	chr10:75410817	SYNPO2L	1.28	6.45	0.46	1.37e-9	Information processing speed;
PAAD	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-5.9	-0.43	2.25e-8	Gut microbiome composition (summer);
PAAD	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.15	17.64	0.82	1.3e-38	Multiple myeloma;
PAAD	cis	rs9361491	0.608	rs9448553	chr6:79463645	T/G	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7771547	0.603	rs6913530	chr6:36598209	A/G	cg07856975	chr6:36356162	ETV7	-0.56	-5.96	-0.44	1.67e-8	Platelet distribution width;
PAAD	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.58	6.74	0.48	3.13e-10	Schizophrenia;
PAAD	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.56	5.48	0.41	1.72e-7	Breast cancer;
PAAD	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	6.04	0.44	1.16e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg16898833	chr6:26189333	HIST1H4D	0.78	4.55	0.35	1.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	4.78	0.36	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.47	4.66	0.35	6.92e-6	Mean corpuscular volume;
PAAD	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg14146966	chr2:61757674	XPO1	0.44	5.39	0.4	2.66e-7	Tuberculosis;
PAAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs7301826	0.651	rs4514465	chr12:131313669	T/A	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.01e-7	Plasma plasminogen activator levels;
PAAD	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs7976059	0.895	rs73109568	chr12:52249003	A/C	cg13698196	chr12:52257893	NA	0.59	7.14	0.5	3.53e-11	Urate levels;
PAAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	1.07	12.41	0.71	7.28e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	4.25	0.33	3.75e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg09455208	chr3:40491958	NA	0.45	5.8	0.43	3.7e-8	Renal cell carcinoma;
PAAD	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-4.9	-0.37	2.45e-6	Mood instability;
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg24642844	chr7:1081250	C7orf50	-0.84	-4.8	-0.36	3.71e-6	Longevity;Endometriosis;
PAAD	cis	rs652260	0.603	rs553205	chr19:7909255	C/T	cg26014689	chr19:7917955	EVI5L	-0.63	-6.22	-0.45	4.58e-9	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12398261	chr7:158217002	PTPRN2	0.56	6.32	0.46	2.82e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg05041596	chr11:89867385	NAALAD2	-0.57	-4.3	-0.33	3.07e-5	White blood cell types;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg14092988	chr3:52407081	DNAH1	0.37	4.78	0.36	4.17e-6	Electroencephalogram traits;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg07068956	chr7:100330872	ZAN	-0.69	-5.34	-0.4	3.37e-7	Other erythrocyte phenotypes;
PAAD	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22590775	chr19:49891494	CCDC155	0.66	5.25	0.39	5.05e-7	Multiple sclerosis;
PAAD	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.5	-4.58	-0.35	9.73e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs3857067	1.000	rs1397027	chr4:95013562	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-4.53	-0.34	1.2e-5	QT interval;
PAAD	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg02711726	chr17:80685570	FN3KRP	-0.64	-6.13	-0.45	7.16e-9	Glycated hemoglobin levels;
PAAD	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg04257695	chr17:30186438	C17orf79	-0.54	-4.41	-0.34	1.97e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	4.93e-20	Heart rate;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	8.39	0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.72	-5.64	-0.42	8.16e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.49	4.76	0.36	4.54e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16548348	chr22:19842481	GNB1L;C22orf29	0.62	7.18	0.5	2.84e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-1.39	-10.33	-0.64	2.81e-19	Schizophrenia;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.34e-6	Prudent dietary pattern;
PAAD	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-11.13	-0.67	2.06e-21	Ulcerative colitis;
PAAD	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg22777020	chr22:31556080	RNF185	0.51	4.27	0.33	3.44e-5	Paclitaxel-induced neuropathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16010827	chr1:200708413	CAMSAP1L1	0.68	7.23	0.51	2.21e-11	Obesity-related traits;
PAAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18110333	chr6:292329	DUSP22	-0.63	-6.47	-0.46	1.28e-9	Menopause (age at onset);
PAAD	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.64	-6.11	-0.44	8.2e-9	Schizophrenia;
PAAD	cis	rs1190596	0.549	rs11621083	chr14:102559538	T/A	cg23289024	chr14:102554846	HSP90AA1	-0.45	-4.93	-0.37	2.11e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7727544	0.526	rs17516457	chr5:131590387	T/C	cg14196790	chr5:131705035	SLC22A5	0.48	4.89	0.37	2.49e-6	Blood metabolite levels;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.86	9.24	0.6	2.06e-16	Cognitive function;
PAAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.59	-5.57	-0.41	1.14e-7	Monocyte count;
PAAD	cis	rs13092825	1.000	rs35871806	chr3:113307671	A/C	cg18753928	chr3:113234510	CCDC52	-0.46	-4.43	-0.34	1.81e-5	Dental caries;
PAAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg00206168	chr11:65308501	LTBP3	0.52	5.4	0.4	2.5e-7	Bone mineral density;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03635649	chr5:41510801	PLCXD3	0.57	6.94	0.49	1.04e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.2	0.6	2.65e-16	Parkinson's disease;
PAAD	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.91	-0.72	3.24e-26	Obesity-related traits;
PAAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4792901	0.802	rs9915326	chr17:41588602	A/G	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.48	-5.1	-0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.36	-0.51	1.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.55	6.06	0.44	1.04e-8	Menopause (age at onset);
PAAD	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.45	-4.78	-0.36	4.14e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg20893579	chr22:38215064	NA	-0.53	-5.66	-0.42	7.3e-8	Glioblastoma;Glioma;
PAAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.6	-4.89	-0.37	2.52e-6	Gut microbiome composition (summer);
PAAD	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	7.92	0.54	4.59e-13	Coffee consumption (cups per day);
PAAD	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg18171855	chr10:2543474	NA	0.66	7.83	0.54	7.59e-13	Age-related hearing impairment;
PAAD	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg26816564	chr1:7831052	VAMP3	0.75	5.75	0.42	4.86e-8	Inflammatory bowel disease;
PAAD	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.75	0.85	8.4e-44	IgG glycosylation;
PAAD	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.7	-8.82	-0.58	2.49e-15	Coronary artery disease;
PAAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg25204440	chr1:209979598	IRF6	0.67	5.73	0.42	5.33e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs5997397	0.933	rs5762783	chr22:29165525	T/G	cg15103426	chr22:29168792	CCDC117	0.48	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.67	-6.27	-0.45	3.57e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs71496605	chr10:46009818	C/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.62	-0.47	5.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.57	-5.96	-0.44	1.72e-8	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26930584	chr1:225616198	LBR	0.64	6.38	0.46	2.04e-9	Obesity-related traits;
PAAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs1075265	0.584	rs34769118	chr2:54329310	C/T	cg04546899	chr2:54196757	PSME4	0.31	4.54	0.35	1.12e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.47	4.59	0.35	9.1e-6	Longevity;
PAAD	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24141078	chr1:32671127	IQCC	0.59	6.39	0.46	1.88e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg15798862	chr7:76129360	DTX2	-0.37	-4.31	-0.33	2.9e-5	Eotaxin levels;
PAAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs89107	0.575	rs11153768	chr6:118988152	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.42	-0.34	1.84e-5	Cardiac structure and function;
PAAD	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9815354	1.000	rs57479675	chr3:41798038	C/T	cg03022575	chr3:42003672	ULK4	0.66	4.68	0.36	6.2e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23627620	chr6:134273564	TBPL1	0.68	7.25	0.51	2.01e-11	Obesity-related traits;
PAAD	cis	rs12304921	1.000	rs73090666	chr12:51356502	T/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg21300742	chr4:120133583	USP53	0.65	6.42	0.46	1.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs3764400	0.567	rs8071199	chr17:46195335	A/T	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs939584	0.799	rs2683992	chr2:600575	G/T	cg03610516	chr2:642275	NA	0.52	4.51	0.34	1.27e-5	Body mass index;
PAAD	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.63	-0.79	1.93e-33	Ulcerative colitis;
PAAD	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-5.09	-0.38	1.02e-6	Mean platelet volume;
PAAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	4.27	0.33	3.38e-5	Schizophrenia;
PAAD	cis	rs3733346	0.510	rs6815138	chr4:941290	A/C	cg23939001	chr4:940644	TMEM175	0.76	9.4	0.61	7.95e-17	Sjögren's syndrome;
PAAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.47	-4.62	-0.35	8.2e-6	Multiple sclerosis;
PAAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg21351543	chr2:191399470	TMEM194B	-0.57	-4.39	-0.34	2.12e-5	Diastolic blood pressure;
PAAD	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg16596103	chr2:233749413	NGEF	0.41	4.27	0.33	3.47e-5	Schizophrenia;
PAAD	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.73	7.19	0.5	2.72e-11	Asperger disorder;
PAAD	cis	rs3206736	0.548	rs328936	chr7:35047579	T/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs9527	0.518	rs7899608	chr10:104727304	C/T	cg14737131	chr10:104680354	CNNM2	0.64	5.65	0.42	7.63e-8	Arsenic metabolism;
PAAD	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs6089829	0.692	rs62197304	chr20:61656064	C/T	cg08045932	chr20:61659980	NA	-0.54	-5.76	-0.42	4.5e-8	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.8	-8.55	-0.57	1.19e-14	Prostate cancer;
PAAD	cis	rs4739066	0.579	rs78867188	chr8:63870128	A/G	cg20602954	chr8:63776762	NKAIN3	0.8	5.16	0.39	7.64e-7	Myocardial infarction;
PAAD	cis	rs4523957	0.818	rs4790887	chr17:2130592	C/A	cg16513277	chr17:2031491	SMG6	0.49	4.96	0.37	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9640161	0.750	rs17173617	chr7:150038023	G/C	cg27494647	chr7:150038898	RARRES2	0.53	5.38	0.4	2.77e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.47	-11.1	-0.67	2.46e-21	Atopic dermatitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06388871	chr9:132388425	METTL11A	-0.7	-6.83	-0.48	1.92e-10	Lung cancer in ever smokers;
PAAD	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.98	6.65	0.47	4.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.88	6.25	0.45	3.96e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs12059669	chr1:158501480	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs3781458	0.803	rs10901793	chr10:126324209	G/A	cg20435097	chr10:126320824	FAM53B	0.54	5.69	0.42	6.26e-8	Male-pattern baldness;
PAAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3787159	0.523	rs480143	chr20:56879555	G/T	cg15032960	chr20:56888536	RAB22A	-0.41	-4.4	-0.34	2.02e-5	Systolic blood pressure;
PAAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.64	5.29	0.39	4.17e-7	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg03371404	chr2:241525653	CAPN10	-0.59	-4.63	-0.35	7.82e-6	Bipolar disorder;
PAAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg12315302	chr6:26189340	HIST1H4D	0.86	4.58	0.35	9.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.13	-0.38	8.53e-7	Myopia (pathological);
PAAD	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg17771515	chr6:154831774	CNKSR3	0.61	4.34	0.33	2.59e-5	Lipoprotein (a) levels;
PAAD	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.35	0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs868036	0.681	rs745213	chr15:68060389	T/G	cg05925327	chr15:68127851	NA	0.61	5.33	0.4	3.47e-7	Restless legs syndrome;
PAAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs16910800	1.000	rs2468647	chr11:23202054	C/T	cg20040320	chr11:23191996	NA	0.58	4.92	0.37	2.27e-6	Cancer;
PAAD	cis	rs2120243	0.565	rs13087207	chr3:157099638	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.53	0.35	1.16e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs2072732	0.706	rs112690788	chr1:2954055	A/G	cg22517653	chr1:2918612	NA	-0.61	-4.88	-0.37	2.6e-6	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17350441	chr10:88389642	NA	-0.62	-6.68	-0.48	4.25e-10	Obesity-related traits;
PAAD	cis	rs7631605	0.518	rs6777094	chr3:36976926	A/T	cg17445812	chr3:36986805	TRANK1	-0.33	-4.69	-0.36	6.11e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg06824641	chr8:22298455	PPP3CC	-0.43	-4.27	-0.33	3.42e-5	Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21330094	chr4:8418132	ACOX3	0.57	6.59	0.47	6.68e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg20295408	chr7:1910781	MAD1L1	-0.51	-4.71	-0.36	5.48e-6	Schizophrenia;
PAAD	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.08	0.55	1.84e-13	Corneal astigmatism;
PAAD	cis	rs17152411	0.652	rs3845	chr10:126674093	T/C	cg07081759	chr10:126330905	FAM53B	-0.4	-4.28	-0.33	3.23e-5	Height;
PAAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg14343924	chr8:8086146	FLJ10661	0.51	4.54	0.35	1.13e-5	Mood instability;
PAAD	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.38	4.36	0.33	2.39e-5	Immature fraction of reticulocytes;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.62	5.62	0.41	8.85e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.71	-5.28	-0.39	4.34e-7	Vitiligo;
PAAD	cis	rs41271473	0.687	rs2295256	chr1:228874049	C/T	cg16512390	chr1:228756714	NA	0.56	4.78	0.36	4.02e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg14092988	chr3:52407081	DNAH1	0.46	5.42	0.4	2.3e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.2	-0.39	6.27e-7	Life satisfaction;
PAAD	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.74	-8.16	-0.55	1.19e-13	Schizophrenia;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.18e-6	Bipolar disorder;
PAAD	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg27182935	chr16:89790473	ZNF276	-0.68	-4.28	-0.33	3.3e-5	Skin colour saturation;
PAAD	cis	rs4356203	0.905	rs7939750	chr11:17079755	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.37	-5.22	-0.39	5.67e-7	QT interval;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22803821	chr14:75304111	NA	0.65	7.1	0.5	4.45e-11	Smoking initiation;
PAAD	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.33	-0.33	2.69e-5	Educational attainment;
PAAD	cis	rs950881	0.867	rs56179005	chr2:102974328	G/A	cg20060108	chr2:102954350	IL1RL1	0.59	4.64	0.35	7.5e-6	Allergy;
PAAD	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.91	-7.16	-0.5	3.22e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.47	4.25	0.33	3.66e-5	Arsenic metabolism;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg14737905	chr2:128186178	PROC	-0.65	-6.62	-0.47	5.96e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.85	-9.38	-0.61	9.06e-17	Prostate cancer;
PAAD	cis	rs59888335	0.858	rs13059676	chr3:80780332	T/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs17789174	0.951	rs12445079	chr16:85105296	C/A	cg00921722	chr16:85061575	KIAA0513	0.71	4.27	0.33	3.41e-5	Dysphagia;
PAAD	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.3	-0.33	3.08e-5	Schizophrenia;
PAAD	cis	rs2415984	0.558	rs10220566	chr14:46965511	A/T	cg14871534	chr14:47121158	RPL10L	-0.49	-5.06	-0.38	1.21e-6	Number of children ever born;
PAAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg09945482	chr18:12777974	NA	0.6	5.38	0.4	2.79e-7	Inflammatory skin disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14711475	chr6:133757084	EYA4	-0.58	-6.4	-0.46	1.81e-9	Obesity-related traits;
PAAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg14393609	chr7:65229607	NA	-0.65	-6.96	-0.49	9.6e-11	Calcium levels;
PAAD	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.58	-5.13	-0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.37	4.27	0.33	3.49e-5	Blood protein levels;
PAAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-1.01	-10.52	-0.65	8.74e-20	Platelet distribution width;
PAAD	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-7.16	-0.5	3.2e-11	Axial length;
PAAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	trans	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg26939375	chr7:64535504	NA	-0.74	-8.56	-0.57	1.17e-14	Aortic root size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17685115	chr5:1483868	LPCAT1	0.55	6.88	0.49	1.46e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.45	5.24	0.39	5.19e-7	Immature fraction of reticulocytes;
PAAD	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg21775007	chr8:11205619	TDH	-0.58	-4.93	-0.37	2.16e-6	Neuroticism;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.87	-9.48	-0.61	4.91e-17	Schizophrenia;
PAAD	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.32	-0.33	2.76e-5	Platelet count;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06820907	chr2:242122206	PPP1R7	0.61	6.32	0.46	2.71e-9	Warfarin maintenance dose;
PAAD	cis	rs7577696	0.962	rs13017189	chr2:32281280	A/G	cg02381751	chr2:32503542	YIPF4	-0.43	-4.58	-0.35	9.62e-6	Inflammatory biomarkers;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.76	6.72	0.48	3.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13102973	0.720	rs13129730	chr4:135888329	G/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.23	5.52	0.41	1.43e-7	Urinary tract infection frequency;
PAAD	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs375066	0.901	rs1978723	chr19:44383800	C/T	cg11993925	chr19:44307056	LYPD5	-0.51	-6.61	-0.47	6.18e-10	Breast cancer;
PAAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.87	10.77	0.66	1.83e-20	Menopause (age at onset);
PAAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.42	-5.33	-0.4	3.46e-7	Height;
PAAD	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg12315302	chr6:26189340	HIST1H4D	0.86	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3112530	0.818	rs2964813	chr5:152648708	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs59888335	0.929	rs67507470	chr3:80788251	C/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs4474465	0.573	rs7101478	chr11:78272517	C/A	cg27205649	chr11:78285834	NARS2	0.65	5.18	0.39	6.81e-7	Alzheimer's disease (survival time);
PAAD	cis	rs4740619	0.933	rs6474954	chr9:15714811	C/G	cg14451791	chr9:16040625	NA	0.38	4.49	0.34	1.41e-5	Body mass index;
PAAD	cis	rs4740619	0.905	rs4146291	chr9:15783266	C/T	cg14451791	chr9:16040625	NA	-0.38	-4.44	-0.34	1.71e-5	Body mass index;
PAAD	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.55	5.06	0.38	1.17e-6	Homocysteine levels;
PAAD	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.46	-4.41	-0.34	1.96e-5	Body mass index;
PAAD	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.79	-6.05	-0.44	1.07e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9896933	0.895	rs6416854	chr17:80899811	T/A	cg22325292	chr17:80708367	FN3K	-0.7	-4.77	-0.36	4.35e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.31e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	8.8	0.58	2.86e-15	Homoarginine levels;
PAAD	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.86	7.95	0.54	3.98e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13126279	chr21:47581558	C21orf56	-0.41	-4.6	-0.35	8.9e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.45	5.02	0.38	1.46e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs1499972	0.941	rs62264782	chr3:117655445	C/A	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.45	4.62	0.35	8.21e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg18939081	chr1:31884902	SERINC2	0.48	5.17	0.39	7.29e-7	Alcohol dependence;
PAAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg03732007	chr1:2071316	PRKCZ	-0.51	-5.57	-0.41	1.1e-7	Height;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.3	0.45	3.09e-9	Lung cancer;
PAAD	cis	rs41271473	0.687	rs13349	chr1:228881129	A/G	cg10167378	chr1:228756711	NA	0.54	4.67	0.35	6.45e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg25124228	chr12:125621409	AACS	-0.63	-6.38	-0.46	1.98e-9	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10339200	chr11:74660161	XRRA1;SPCS2	-0.68	-7.01	-0.49	7.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg09835421	chr16:68378352	PRMT7	-1.04	-7.81	-0.53	8.83e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.32	0.51	1.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.53	-4.64	-0.35	7.45e-6	Waist circumference;Body mass index;
PAAD	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.55	5.99	0.44	1.49e-8	Bladder cancer;
PAAD	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-10.73	-0.66	2.42e-20	Longevity;Endometriosis;
PAAD	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.79	-6.96	-0.49	9.73e-11	Blood protein levels;
PAAD	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs11129295	0.618	rs4680851	chr3:27805177	G/A	cg21473142	chr3:27762095	EOMES	0.27	4.55	0.35	1.07e-5	Multiple sclerosis;
PAAD	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.52	-6.59	-0.47	6.84e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.57	0.57	1.1e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.74	8.1	0.55	1.71e-13	Schizophrenia;
PAAD	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.49	-5.18	-0.39	6.97e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3931020	0.745	rs10874274	chr1:75252134	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.44	4.27	0.33	3.48e-5	Resistin levels;
PAAD	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-4.26	-0.33	3.61e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7771547	0.632	rs79102826	chr6:36555814	C/T	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02563922	chr16:920048	LMF1	-0.64	-6.92	-0.49	1.18e-10	Myopia (pathological);
PAAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09835421	chr16:68378352	PRMT7	-1.1	-8.13	-0.55	1.41e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-8.57	-0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.66	7.08	0.5	5.1e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.49	7.86	0.54	6.41e-13	Neuroticism;
PAAD	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg16417436	chr16:28758564	NA	0.43	4.39	0.34	2.08e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	12.54	0.71	3.32e-25	Testicular germ cell tumor;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg10729496	chr3:10149963	C3orf24	0.67	5.99	0.44	1.49e-8	Alzheimer's disease;
PAAD	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-5.27	-0.39	4.68e-7	Common traits (Other);
PAAD	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.5	4.85	0.37	2.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.24	0.45	4.04e-9	Vitiligo;
PAAD	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg11995313	chr8:8860691	ERI1	0.48	4.81	0.36	3.68e-6	Joint mobility (Beighton score);
PAAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.1	9.41	0.61	7.47e-17	Red blood cell traits;
PAAD	cis	rs9652601	0.696	rs12917656	chr16:11187862	T/C	cg04616529	chr16:11181986	CLEC16A	0.38	4.65	0.35	7.07e-6	Systemic lupus erythematosus;
PAAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.78	8.63	0.57	7.46e-15	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22082745	chr15:101169751	ASB7	-0.71	-7.39	-0.51	8.99e-12	Obesity-related traits;
PAAD	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.7	7.38	0.51	9.44e-12	Menarche (age at onset);
PAAD	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-9.22	-0.6	2.28e-16	Vitiligo;
PAAD	cis	rs939584	1.000	rs10169736	chr2:641082	A/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	8.81	0.58	2.67e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.81	-6.78	-0.48	2.5e-10	Alzheimer's disease;
PAAD	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.54	-5.24	-0.39	5.27e-7	P wave terminal force;
PAAD	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	6.03	0.44	1.22e-8	Lung cancer in ever smokers;
PAAD	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg14346243	chr4:90757452	SNCA	0.51	4.38	0.33	2.21e-5	Neuroticism;
PAAD	cis	rs300774	1.000	rs2015419	chr2:118385	A/G	cg23649280	chr2:140451	NA	-0.52	-4.86	-0.37	2.85e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs508970	0.874	rs10792304	chr11:60910591	C/T	cg06482904	chr11:61537000	C11orf9	0.38	4.27	0.33	3.48e-5	Rheumatoid arthritis;
PAAD	cis	rs58521262	0.556	rs465723	chr19:23131463	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs755249	0.567	rs2296175	chr1:39924398	G/A	cg14018543	chr1:39659967	MACF1	-0.54	-4.54	-0.35	1.15e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.73	8.58	0.57	1.05e-14	Type 2 diabetes;
PAAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs755249	0.567	rs61779300	chr1:39885763	G/A	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.69	-8.16	-0.55	1.17e-13	Huntington's disease progression;
PAAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg06766960	chr11:133703094	NA	-0.57	-5.68	-0.42	6.61e-8	Childhood ear infection;
PAAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-1.02	-13.83	-0.75	1.14e-28	Breast cancer;
PAAD	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg01884057	chr2:25150051	NA	-0.37	-4.48	-0.34	1.43e-5	Body mass index in non-asthmatics;
PAAD	cis	rs6960043	0.738	rs9639218	chr7:15045619	T/C	cg19272540	chr7:15055459	NA	-0.3	-5.46	-0.4	1.91e-7	Type 2 diabetes;
PAAD	cis	rs12940923	0.507	rs10853005	chr17:56371149	C/T	cg26072851	chr17:56296444	MKS1	-0.58	-4.94	-0.37	2.02e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	4.59	0.35	9.33e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-6.83	-0.48	1.96e-10	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.42	-0.34	1.86e-5	Obesity-related traits;
PAAD	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.51	-4.33	-0.33	2.73e-5	Neuroticism;
PAAD	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg03938978	chr2:103052716	IL18RAP	0.5	5.05	0.38	1.27e-6	Blood protein levels;
PAAD	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4834770	1.000	rs6857641	chr4:120243511	T/C	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.48	4.48	0.34	1.43e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.67	-0.42	7.01e-8	Coronary artery disease;
PAAD	cis	rs282587	0.569	rs419334	chr13:113415346	G/A	cg04656015	chr13:113407548	ATP11A	0.56	4.48	0.34	1.44e-5	Glycated hemoglobin levels;
PAAD	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg26876637	chr1:152193138	HRNR	-0.8	-5.32	-0.4	3.6e-7	Atopic dermatitis;
PAAD	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7246865	0.510	rs7254154	chr19:17178119	A/C	cg19418318	chr19:17219073	MYO9B	0.35	4.98	0.37	1.7e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	6.1	0.44	8.62e-9	Lung function (FEV1/FVC);
PAAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg17470449	chr10:769945	NA	0.47	4.81	0.36	3.59e-6	Uric acid levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05608716	chr16:3096484	MMP25	-0.65	-6.34	-0.46	2.53e-9	Smoking initiation;
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.69	-8.05	-0.55	2.24e-13	Bipolar disorder and schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06836338	chr17:17942007	ATPAF2;C17orf39	0.54	6.32	0.46	2.7e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg18867708	chr6:26865862	GUSBL1	-0.45	-4.39	-0.34	2.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6995541	0.776	rs10105487	chr8:10668751	T/A	cg14855657	chr8:10587604	SOX7	0.46	4.4	0.34	2.02e-5	Triglyceride levels;
PAAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.8	9.12	0.59	4.33e-16	Schizophrenia;
PAAD	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.27	-0.33	3.4e-5	Depression;
PAAD	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.52	4.44	0.34	1.69e-5	Cocaine dependence;
PAAD	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-5.33	-0.4	3.55e-7	Chronic sinus infection;
PAAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.84	-7.9	-0.54	5.36e-13	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs722864	0.789	rs6759847	chr2:173968996	C/A	cg09210666	chr2:173941575	ZAK	-0.47	-4.45	-0.34	1.64e-5	Lung cancer;
PAAD	cis	rs7771547	0.723	rs12153820	chr6:36554030	A/G	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg27136344	chr17:80606911	WDR45L	0.65	6.97	0.49	9.18e-11	Breast cancer;
PAAD	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.73	-5.18	-0.39	6.81e-7	Carotid intima media thickness;
PAAD	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.91	-9.69	-0.62	1.34e-17	Obesity-related traits;
PAAD	cis	rs1545257	0.505	rs894466	chr2:24633771	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.41	-0.4	2.43e-7	Sjögren's syndrome;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg07313626	chr1:247681931	NA	0.44	4.53	0.35	1.18e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3812111	0.525	rs3749893	chr6:116571695	A/G	cg05304507	chr6:116381966	FRK	0.27	4.65	0.35	7.16e-6	Age-related macular degeneration;
PAAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24229701	chr12:130821962	PIWIL1	0.42	4.44	0.34	1.71e-5	Menopause (age at onset);
PAAD	cis	rs4589502	0.841	rs75991095	chr15:67123224	C/G	cg12317470	chr15:67143691	NA	0.92	5.13	0.38	8.69e-7	Lung cancer (smoking interaction);
PAAD	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.5	4.32	0.33	2.85e-5	Atopic dermatitis;
PAAD	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg17541715	chr7:1216824	NA	-0.4	-4.49	-0.34	1.43e-5	Longevity;Endometriosis;
PAAD	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.5	-4.99	-0.38	1.62e-6	Pancreatic cancer;
PAAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.01	0.38	1.48e-6	Erythrocyte sedimentation rate;
PAAD	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.63	-7.06	-0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.71	4.51	0.34	1.26e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg04160749	chr8:58172571	NA	-0.64	-4.65	-0.35	7.07e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.9	5.83	0.43	3.17e-8	Prostate cancer;
PAAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	6.82	0.48	2e-10	Schizophrenia;
PAAD	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.55	5.9	0.43	2.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg07841815	chr7:100318223	EPO	-0.48	-4.39	-0.34	2.11e-5	Other erythrocyte phenotypes;
PAAD	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs354225	0.554	rs10166844	chr2:54798272	T/C	cg01766943	chr2:54829624	SPTBN1	0.52	4.79	0.36	3.97e-6	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.93	-8.71	-0.58	4.65e-15	Gut microbiome composition (summer);
PAAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.32	-10.19	-0.64	6.7e-19	Breast cancer;
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-5.05	-0.38	1.26e-6	Triglycerides;
PAAD	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.65	7.25	0.51	1.95e-11	Body mass index;
PAAD	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg21775007	chr8:11205619	TDH	-0.56	-4.89	-0.37	2.53e-6	Neuroticism;
PAAD	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.71	7.19	0.5	2.74e-11	Schizophrenia;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.35	6.29e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.24	0.56	7.54e-14	Hypertriglyceridemia;
PAAD	cis	rs12432203	0.915	rs76084602	chr14:51743859	A/T	cg23942311	chr14:51606299	NA	-0.75	-4.98	-0.37	1.67e-6	Cancer;
PAAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	1.09	15.2	0.78	2.56e-32	Breast cancer;
PAAD	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.79	-7.38	-0.51	9.81e-12	Asthma;
PAAD	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.84	-9.56	-0.61	3.01e-17	Height;
PAAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.2	10.78	0.66	1.79e-20	Breast cancer;
PAAD	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.62	-0.35	7.96e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08327378	chr16:69796558	WWP2	0.57	6.43	0.46	1.53e-9	Monocyte percentage of white cells;
PAAD	cis	rs597480	0.765	rs2008890	chr11:85513470	A/G	cg11817631	chr11:85522609	SYTL2	0.45	4.56	0.35	1.04e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.35	0.46	2.37e-9	Height;
PAAD	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg10818794	chr15:86012489	AKAP13	-0.44	-4.7	-0.36	5.88e-6	Interstitial lung disease;
PAAD	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.89	-0.37	2.5e-6	Body mass index;
PAAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg08992911	chr2:238395768	MLPH	0.66	6.53	0.47	9.29e-10	Prostate cancer;
PAAD	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02743256	chr7:2109353	MAD1L1	-0.68	-5.9	-0.43	2.3e-8	Neuroticism;
PAAD	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.57	-6.61	-0.47	6.15e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6540	1.000	rs474787	chr11:258397	C/T	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.84	0.43	3.11e-8	Platelet count;
PAAD	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.62	0.57	8.17e-15	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.34e-6	Lung cancer;
PAAD	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg02493740	chr2:85810744	VAMP5	-0.41	-4.51	-0.34	1.31e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs77880822	0.562	rs10485821	chr20:1234390	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.73	-7.22	-0.51	2.36e-11	Hip circumference;
PAAD	cis	rs1329189	1.000	rs1335015	chr10:130006561	G/T	cg17972361	chr10:130010134	NA	0.48	4.89	0.37	2.52e-6	Orofacial clefts;
PAAD	cis	rs6964492	0.576	rs10229310	chr7:134417742	C/T	cg22430036	chr7:134592620	CALD1	-0.51	-4.63	-0.35	7.76e-6	Tonsillectomy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16311334	chr11:926082	AP2A2	0.68	7.78	0.53	1e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7554547	0.765	rs6541010	chr1:11973842	A/G	cg07603449	chr1:11986842	KIAA2013	-0.38	-6.05	-0.44	1.08e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	4.76	0.36	4.47e-6	Menarche (age at onset);
PAAD	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.69	6.17	0.45	5.9e-9	Response to diuretic therapy;
PAAD	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.63	-0.35	7.89e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.59	5.41	0.4	2.41e-7	Prostate cancer;
PAAD	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.65	6.73	0.48	3.28e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs317865	0.737	rs73234648	chr4:16193602	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.67	0.48	4.54e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	7.05e-7	Tuberculosis;
PAAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.6	-5.83	-0.43	3.29e-8	Schizophrenia;
PAAD	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.79	9.45	0.61	5.89e-17	Metabolite levels;
PAAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.77	-7.38	-0.51	9.78e-12	Neurofibrillary tangles;
PAAD	cis	rs1419980	0.730	rs11054558	chr12:7728518	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23990949	chr1:43282943	CCDC23;ERMAP	-0.61	-6.7	-0.48	3.8e-10	Smoking initiation;
PAAD	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	15.91	0.79	3.6e-34	Chronic sinus infection;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28489187	0.643	rs1884139	chr1:85845998	G/T	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs11807834	0.522	rs10864690	chr1:230237540	A/T	cg00566187	chr1:230250356	GALNT2	0.64	6.81	0.48	2.18e-10	Schizophrenia;
PAAD	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.58	6.67	0.48	4.51e-10	Schizophrenia;
PAAD	trans	rs901683	0.867	rs17157885	chr10:46020094	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.17	-0.39	7.18e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.72	0.36	5.32e-6	Neuroticism;
PAAD	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06850241	chr22:41845214	NA	0.57	4.92	0.37	2.22e-6	Vitiligo;
PAAD	cis	rs262147	0.592	rs2527212	chr7:158747040	G/A	cg24397884	chr7:158709396	WDR60	-1.03	-9.06	-0.59	6.13e-16	Hippocampal volume;
PAAD	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.4	-5.99	-0.44	1.47e-8	Subjective well-being;
PAAD	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg10631289	chr15:39006617	NA	0.46	4.48	0.34	1.47e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14190943	chr14:105957502	C14orf80	-0.63	-6.83	-0.48	1.94e-10	Smoking initiation;
PAAD	cis	rs9283706	0.676	rs6449842	chr5:66323159	C/G	cg11590213	chr5:66331682	MAST4	0.55	4.48	0.34	1.45e-5	Coronary artery disease;
PAAD	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-7.83	-0.54	7.67e-13	Body mass index;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.66	-7.05	-0.5	5.99e-11	Iron status biomarkers;
PAAD	cis	rs3206736	0.548	rs1649238	chr7:35004517	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	0.47	4.52	0.34	1.22e-5	Diastolic blood pressure;
PAAD	cis	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.74	-7.82	-0.54	8.23e-13	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg23024343	chr7:107201750	COG5	0.56	4.54	0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg07486100	chr7:132562508	CHCHD3	0.39	4.32	0.33	2.83e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02902124	chr2:70121106	SNRNP27	-0.59	-6.65	-0.47	4.97e-10	Smoking initiation;
PAAD	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.97	10.23	0.64	5.25e-19	Platelet distribution width;
PAAD	cis	rs116248771	0.739	rs73156423	chr3:158345628	C/A	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs7561149	1.000	rs12469367	chr2:179691670	T/C	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.55	5.6	0.41	9.63e-8	QT interval;
PAAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg11416102	chr8:651193	ERICH1	-0.8	-5.03	-0.38	1.39e-6	IgG glycosylation;
PAAD	cis	rs1595825	0.786	rs1902247	chr2:198492826	C/T	cg00982548	chr2:198649783	BOLL	-0.72	-5.17	-0.39	7.4e-7	Ulcerative colitis;
PAAD	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.68	-8.54	-0.57	1.33e-14	Educational attainment;
PAAD	cis	rs593531	0.614	rs486758	chr11:74058932	C/T	cg15670924	chr11:73669256	DNAJB13	-0.43	-4.46	-0.34	1.56e-5	Neuroticism;
PAAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.43	-4.37	-0.33	2.31e-5	Body mass index;
PAAD	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.94	10.94	0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.964	rs463229	chr5:112201284	G/A	cg06941702	chr5:112196734	SRP19	-0.45	-4.25	-0.33	3.65e-5	Total body bone mineral density;
PAAD	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg14458575	chr2:238380390	NA	0.54	4.68	0.35	6.31e-6	Prostate cancer;
PAAD	cis	rs12220238	0.908	rs10824133	chr10:76020585	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.34	0.33	2.6e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.62	6.82	0.48	2.04e-10	Mean platelet volume;
PAAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14180030	chr9:123475675	MEGF9	-0.43	-4.79	-0.36	3.93e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.77e-11	Asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08084218	chr2:20850887	HS1BP3	0.61	7.15	0.5	3.33e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.56	-0.35	1.06e-5	Cognitive function;
PAAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.47	5.88	0.43	2.55e-8	Vitiligo;
PAAD	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.57	7.23	0.51	2.23e-11	Crohn's disease;
PAAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg19623624	chr10:135278901	LOC619207	-0.43	-4.5	-0.34	1.34e-5	Systemic lupus erythematosus;
PAAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg26497354	chr6:109612229	NA	-0.43	-4.56	-0.35	1.02e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-5.29	-0.39	4.27e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.68	7.86	0.54	6.71e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.55	-5.25	-0.39	5.05e-7	Monocyte count;
PAAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg27539214	chr16:67997921	SLC12A4	0.62	4.58	0.35	9.76e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.88	-5.66	-0.42	7.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.68	7.44	0.52	6.84e-12	Longevity;
PAAD	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs2051773	0.510	rs11024130	chr11:17056425	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg26898376	chr11:64110657	CCDC88B	0.52	5.54	0.41	1.31e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs12989701	0.877	rs34745987	chr2:127875384	C/T	cg08168897	chr2:127865431	BIN1	0.69	5.9	0.43	2.23e-8	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs16975963	0.843	rs73025630	chr19:38351284	G/A	cg08679971	chr19:38281047	NA	0.55	5.18	0.39	6.92e-7	Longevity;
PAAD	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.72	5.0	0.38	1.55e-6	HDL cholesterol levels;
PAAD	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg26205652	chr12:48591994	NA	0.75	6.69	0.48	3.93e-10	Longevity (90 years and older);
PAAD	cis	rs3540	0.960	rs7167704	chr15:90956801	G/T	cg22089800	chr15:90895588	ZNF774	0.57	5.37	0.4	2.83e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg21775007	chr8:11205619	TDH	-0.47	-4.31	-0.33	2.97e-5	Neuroticism;
PAAD	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.43	-4.35	-0.33	2.5e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.68	-6.94	-0.49	1.03e-10	Ear protrusion;
PAAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9463078	0.585	rs1797147	chr6:45162159	T/C	cg25276700	chr6:44698697	NA	-0.45	-5.09	-0.38	1.03e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.47	-0.41	1.77e-7	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg10011062	chr15:43941034	CATSPER2	-0.82	-5.03	-0.38	1.38e-6	Lung cancer in ever smokers;
PAAD	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	7.18	0.5	2.96e-11	IgG glycosylation;
PAAD	cis	rs6681460	1.000	rs4655647	chr1:67106077	C/G	cg02459107	chr1:67143332	SGIP1	0.78	7.81	0.53	8.87e-13	Presence of antiphospholipid antibodies;
PAAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.74	-8.28	-0.56	5.91e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg04482110	chr17:41364121	TMEM106A	0.38	4.28	0.33	3.26e-5	Menopause (age at onset);
PAAD	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.6	5.01	0.38	1.5e-6	Neutrophil percentage of white cells;
PAAD	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.76	10.17	0.64	7.3e-19	Bone mineral density;
PAAD	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.74	-0.36	4.78e-6	High light scatter reticulocyte count;
PAAD	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.7	-7.78	-0.53	1e-12	Colorectal cancer;
PAAD	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs9463078	0.715	rs9395049	chr6:44792718	C/T	cg25276700	chr6:44698697	NA	0.52	6.38	0.46	2e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg17551891	chr7:1960795	MAD1L1	-0.4	-4.31	-0.33	2.95e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.87	-7.83	-0.54	7.73e-13	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Body mass index;
PAAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.61	-0.35	8.51e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg09491104	chr22:46646882	C22orf40	-0.93	-8.95	-0.59	1.16e-15	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.52	-4.88	-0.37	2.68e-6	Daytime sleep phenotypes;
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.7	-6.13	-0.45	7.21e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-1.23	-6.72	-0.48	3.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03760483	chr17:6899297	ALOX12	0.43	4.5	0.34	1.32e-5	Tonsillectomy;
PAAD	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.68	0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg12062639	chr20:23401060	NAPB	1.02	5.03	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.64	0.47	5.32e-10	Alzheimer's disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18014789	chr12:123717788	C12orf65	0.7	6.29	0.45	3.23e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3106136	0.678	rs13146089	chr4:95281388	C/T	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs8084125	1.000	rs62105170	chr18:74945570	A/G	cg05528293	chr18:74961138	GALR1	0.61	5.04	0.38	1.32e-6	Obesity-related traits;
PAAD	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg01798341	chr17:80842262	TBCD	0.41	4.57	0.35	9.89e-6	Breast cancer;
PAAD	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.54	-5.35	-0.4	3.17e-7	Mean platelet volume;
PAAD	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.93e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg20913747	chr6:44695427	NA	-0.63	-7.35	-0.51	1.14e-11	Total body bone mineral density;
PAAD	cis	rs8040855	0.965	rs11073990	chr15:85711301	C/T	cg08123816	chr15:85640762	PDE8A	-0.39	-4.9	-0.37	2.48e-6	Bulimia nervosa;
PAAD	cis	rs10501293	1.000	rs1425850	chr11:43109833	T/C	cg03447554	chr11:43094025	NA	-0.51	-5.09	-0.38	1.04e-6	Cognitive performance;
PAAD	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.13	0.38	8.67e-7	HIV-1 control;
PAAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.8e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.8	-0.66	1.6e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.74	4.71	0.36	5.5e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.83	-5.9	-0.43	2.31e-8	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.8	8.43	0.56	2.41e-14	Schizophrenia;
PAAD	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.64	4.45	0.34	1.66e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.85	-10.61	-0.65	5e-20	Heart rate;
PAAD	cis	rs7165102	1.000	rs352476	chr15:65805389	T/C	cg22900193	chr15:65823441	PTPLAD1	-0.49	-4.63	-0.35	7.84e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.54	-4.88	-0.37	2.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-5.53	-0.41	1.33e-7	Renal function-related traits (BUN);
PAAD	cis	rs10450586	0.932	rs931080	chr11:27324312	T/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13560548	chr3:10150139	C3orf24	0.6	5.44	0.4	2.04e-7	Alzheimer's disease;
PAAD	cis	rs7752195	0.730	rs79249301	chr6:25260918	T/C	cg26336265	chr6:25042955	NA	0.87	4.84	0.37	3.15e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg16928487	chr17:17741425	SREBF1	0.31	4.25	0.33	3.69e-5	Total body bone mineral density;
PAAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.69	9.23	0.6	2.24e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.82	-9.36	-0.6	9.79e-17	Lung cancer;
PAAD	cis	rs2030114	0.904	rs11862291	chr16:51613697	C/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg10110957	chr16:89460751	ANKRD11	-0.47	-4.38	-0.33	2.19e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.31e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15602053	chr3:138635064	NA	0.64	6.6	0.47	6.31e-10	Obesity-related traits;
PAAD	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.22	6.95	0.49	1.03e-10	Type 2 diabetes nephropathy;
PAAD	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg04717802	chr22:42394638	WBP2NL	0.49	4.65	0.35	7.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs8053891	0.673	rs12444854	chr16:72024490	G/A	cg16558253	chr16:72132732	DHX38	-0.57	-5.08	-0.38	1.08e-6	Coronary artery disease;
PAAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.82	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9826463	0.757	rs113288103	chr3:142175321	C/T	cg20824294	chr3:142316082	PLS1	0.48	5.6	0.41	9.77e-8	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg25204440	chr1:209979598	IRF6	0.57	4.54	0.35	1.15e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2235573	0.662	rs6000991	chr22:38460484	T/C	cg24053715	chr22:38214548	NA	-0.51	-4.94	-0.37	2.06e-6	Glioblastoma;Glioma;
PAAD	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg03060546	chr3:49711283	APEH	-0.59	-4.4	-0.34	2e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.62	5.99	0.44	1.46e-8	Coronary artery disease or large artery stroke;
PAAD	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.34	-0.33	2.58e-5	Total body bone mineral density;
PAAD	cis	rs6782025	0.579	rs2331708	chr3:121030327	A/T	cg16417163	chr3:121280760	NA	-0.45	-4.64	-0.35	7.33e-6	Aging (facial);
PAAD	cis	rs12913538	1.000	rs12913538	chr15:62899160	G/A	cg09983546	chr15:62884068	NA	0.7	7.75	0.53	1.19e-12	Sleep depth;
PAAD	cis	rs8067287	0.645	rs55770108	chr17:16841424	A/G	cg26910001	chr17:16838321	NA	-0.58	-5.19	-0.39	6.79e-7	Diabetic kidney disease;
PAAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.53	-0.47	9.4e-10	Aortic root size;
PAAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg09835421	chr16:68378352	PRMT7	-0.95	-6.86	-0.49	1.67e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.81	-7.83	-0.54	7.68e-13	Breast cancer;
PAAD	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14024823	chr9:72131026	APBA1	-0.63	-6.44	-0.46	1.48e-9	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-5.9	-0.43	2.25e-8	Gut microbiome composition (summer);
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.63	5.29	0.39	4.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-1.39	-10.33	-0.64	2.81e-19	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs58521262	0.556	rs289342	chr19:23150389	T/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11736903	chr11:67262185	PITPNM1	-0.67	-6.47	-0.46	1.3e-9	Lung cancer in ever smokers;
PAAD	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.68	8.35	0.56	3.83e-14	Dupuytren's disease;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.59	6.07	0.44	9.93e-9	Lung cancer;
PAAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.8	-5.97	-0.44	1.59e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	6.18	0.45	5.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11696501	0.739	rs4812933	chr20:44230792	C/A	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.39	-0.46	1.93e-9	Brain structure;
PAAD	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.64	-4.33	-0.33	2.66e-5	LDL cholesterol levels;
PAAD	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.77	-5.98	-0.44	1.56e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	9.73	0.62	1.05e-17	Breast cancer;
PAAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14751398	chr6:20402153	E2F3	0.57	6.43	0.46	1.6e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.5	-0.34	1.37e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.56	7.77	0.53	1.12e-12	IgG glycosylation;
PAAD	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.45	-5.0	-0.38	1.54e-6	Testicular germ cell tumor;
PAAD	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg19223190	chr17:80058835	NA	0.56	5.76	0.42	4.62e-8	Life satisfaction;
PAAD	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg03732007	chr1:2071316	PRKCZ	0.45	4.29	0.33	3.17e-5	Height;
PAAD	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.37	-5.24	-0.39	5.18e-7	Cutaneous nevi;
PAAD	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.34	-0.64	2.6e-19	Cognitive function;
PAAD	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.5	-5.4	-0.4	2.52e-7	Coronary artery disease;
PAAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06695338	chr4:187518024	FAT1	-0.63	-6.66	-0.48	4.65e-10	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.6	-0.41	9.92e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg10729496	chr3:10149963	C3orf24	0.92	7.98	0.54	3.25e-13	Alzheimer's disease;
PAAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg05895507	chr15:77155635	SCAPER	0.39	4.77	0.36	4.29e-6	Blood metabolite levels;
PAAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs11168618	0.626	rs11514105	chr12:48820934	G/C	cg01881778	chr12:48919444	OR8S1	-0.43	-4.38	-0.33	2.22e-5	Adiponectin levels;
PAAD	cis	rs733175	0.951	rs6826764	chr4:10030794	C/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-5.17	-0.39	7.34e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.75	9.37	0.6	9.7e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11264799	0.639	rs17677855	chr1:157761888	T/G	cg18268488	chr1:157545234	FCRL4	0.57	5.05	0.38	1.23e-6	IgA nephropathy;
PAAD	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.47	4.54	0.35	1.15e-5	Crohn's disease;
PAAD	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.85	0.54	6.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11168618	0.509	rs2731108	chr12:48887361	G/A	cg01881778	chr12:48919444	OR8S1	0.44	4.55	0.35	1.09e-5	Adiponectin levels;
PAAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg05785598	chr3:49045655	WDR6	0.42	5.17	0.39	7.39e-7	Parkinson's disease;
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg08501292	chr6:25962987	TRIM38	0.8	4.34	0.33	2.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17655565	0.581	rs949384	chr12:52767548	T/C	cg15701111	chr12:52685334	KRT81	0.5	4.39	0.34	2.1e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.78	9.04	0.59	6.68e-16	Hemoglobin concentration;
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.66	6.5	0.47	1.09e-9	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg21698718	chr17:80085957	CCDC57	-0.45	-4.96	-0.37	1.88e-6	Life satisfaction;
PAAD	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.66	0.53	1.98e-12	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg10578991	chr7:12443926	VWDE	-0.66	-4.75	-0.36	4.65e-6	Coronary artery disease;
PAAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.53	-5.04	-0.38	1.32e-6	Vitiligo;
PAAD	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.88	-0.58	1.75e-15	Exhaled nitric oxide output;
PAAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.93	0.59	1.34e-15	Menopause (age at onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg23460551	chr7:66325901	NA	-0.48	-6.59	-0.47	6.92e-10	Energy expenditure (24h);
PAAD	cis	rs3136441	1.000	rs57704144	chr11:46770359	C/T	cg19486271	chr11:47235900	DDB2	0.66	4.98	0.37	1.73e-6	HDL cholesterol;
PAAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.39	-4.25	-0.33	3.66e-5	Rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.62	8.42	0.56	2.62e-14	Renal cell carcinoma;
PAAD	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.63	6.7	0.48	3.73e-10	Obesity-related traits;
PAAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg24324837	chr19:49891574	CCDC155	-0.48	-4.25	-0.33	3.73e-5	Multiple sclerosis;
PAAD	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.07	-8.28	-0.56	5.92e-14	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22439777	chr2:200776285	C2orf69	-0.56	-6.41	-0.46	1.74e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17293817	0.650	rs12778422	chr10:1413776	A/G	cg02408697	chr10:1416920	ADARB2	0.47	4.41	0.34	1.92e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11563648	0.553	rs9791825	chr7:127018596	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.86	10.64	0.65	4.04e-20	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.47	0.34	1.55e-5	Menarche (age at onset);
PAAD	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg07157834	chr1:205819609	PM20D1	0.57	4.44	0.34	1.73e-5	Parkinson's disease;
PAAD	cis	rs2235573	0.657	rs760973	chr22:38447266	C/A	cg24053715	chr22:38214548	NA	-0.51	-5.24	-0.39	5.21e-7	Glioblastoma;Glioma;
PAAD	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg00383909	chr3:49044727	WDR6	0.54	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg25753631	chr6:25732923	NA	-0.44	-4.75	-0.36	4.76e-6	Iron status biomarkers;
PAAD	cis	rs74161807	0.561	rs12247177	chr10:118398353	C/T	cg10511988	chr10:118891706	VAX1	0.39	4.64	0.35	7.51e-6	Loneliness (multivariate analysis);Loneliness;
PAAD	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.19e-7	Red blood cell count;
PAAD	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg05998816	chr21:47859926	PCNT	0.48	4.28	0.33	3.29e-5	Lymphocyte counts;
PAAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.63	6.35	0.46	2.4e-9	Multiple sclerosis;
PAAD	cis	rs17407555	0.909	rs56240429	chr4:10327589	G/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-4.39	-0.34	2.14e-5	Schizophrenia (age at onset);
PAAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs227833	1.000	rs227832	chr6:44681257	T/C	cg18551225	chr6:44695536	NA	0.48	4.87	0.37	2.77e-6	Monobrow;
PAAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.88	-11.06	-0.67	3.09e-21	Menopause (age at onset);
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-7.15	-0.5	3.45e-11	Life satisfaction;
PAAD	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-4.47	-0.34	1.51e-5	Non-alcoholic fatty liver disease histology (lobular);
PAAD	cis	rs2120991	0.967	rs10783611	chr12:54258980	G/A	cg25640699	chr12:54070114	ATP5G2	-0.41	-4.25	-0.33	3.71e-5	Biliary atresia;
PAAD	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-4.74	-0.36	4.79e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg11335335	chr11:637885	DRD4	-0.37	-5.08	-0.38	1.11e-6	Systemic lupus erythematosus;
PAAD	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.51	-5.15	-0.39	8.08e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg19761014	chr17:28927070	LRRC37B2	0.95	6.45	0.46	1.42e-9	Body mass index;
PAAD	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.6	6.25	0.45	4e-9	Blood protein levels;
PAAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	4.76	0.36	4.47e-6	Personality dimensions;
PAAD	trans	rs901683	0.702	rs113478021	chr10:46063563	C/T	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.51	4.98	0.37	1.75e-6	Rheumatoid arthritis;
PAAD	cis	rs76533333	0.646	rs71446911	chr13:113377528	G/T	cg02820901	chr13:113351484	ATP11A	-0.8	-4.68	-0.36	6.2e-6	Red cell distribution width;
PAAD	cis	rs4917300	0.669	rs4917294	chr8:143119767	C/A	cg26003909	chr8:143102224	NA	-0.32	-5.3	-0.39	3.99e-7	Amyotrophic lateral sclerosis;
PAAD	cis	rs900145	0.863	rs1384026	chr11:13296401	T/A	cg15603424	chr11:13300592	ARNTL	0.53	4.8	0.36	3.77e-6	Menarche (age at onset);
PAAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg10018233	chr7:150070692	REPIN1	0.57	6.03	0.44	1.17e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.53	5.67	0.42	7e-8	Menopause (age at onset);
PAAD	cis	rs332507	0.830	rs3772787	chr3:124395368	G/C	cg05980111	chr3:124395277	KALRN	0.45	4.35	0.33	2.48e-5	Plateletcrit;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03000156	chr6:79577260	IRAK1BP1	0.58	6.56	0.47	7.88e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg25833597	chr17:30823145	MYO1D	0.55	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.56	0.41	1.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg05347473	chr6:146136440	FBXO30	0.53	5.18	0.39	7.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg12092346	chr18:77659572	KCNG2	-0.63	-4.43	-0.34	1.78e-5	Opioid sensitivity;
PAAD	cis	rs59901009	0.577	rs7932484	chr11:10024883	T/C	cg06876053	chr11:9810051	SBF2	-0.34	-4.47	-0.34	1.52e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs375066	0.935	rs396973	chr19:44399306	C/T	cg08633290	chr19:44405433	NA	0.56	5.54	0.41	1.3e-7	Breast cancer;
PAAD	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.4	-0.34	2.05e-5	Fibrinogen levels;
PAAD	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg03309721	chr19:2236316	PLEKHJ1;SF3A2	-0.57	-4.46	-0.34	1.58e-5	Bipolar disorder;
PAAD	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.5	-5.39	-0.4	2.58e-7	Educational attainment;
PAAD	cis	rs7260329	0.507	rs1552222	chr19:41525904	T/A	cg06653635	chr19:40910092	PRX	-0.65	-5.02	-0.38	1.43e-6	Smoking behavior;
PAAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg22771759	chr13:24902376	NA	0.48	4.72	0.36	5.34e-6	Obesity-related traits;
PAAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg00334542	chr7:100209784	MOSPD3	-0.76	-5.61	-0.41	9.31e-8	Other erythrocyte phenotypes;
PAAD	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg01028140	chr2:1542097	TPO	-1.01	-8.92	-0.59	1.4e-15	IgG glycosylation;
PAAD	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-7.3	-0.51	1.5e-11	Morning vs. evening chronotype;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg02821500	chr4:54931072	CHIC2	0.54	6.35	0.46	2.32e-9	Metabolite levels  (X-11787);
PAAD	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03117416	chr13:78271876	SLAIN1	-0.72	-6.54	-0.47	8.84e-10	Lung cancer in ever smokers;
PAAD	cis	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-1.22	-6.67	-0.48	4.46e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-6.39	-0.46	1.93e-9	Total cholesterol levels;
PAAD	cis	rs2885056	0.891	rs12978228	chr19:10691323	G/T	cg06392426	chr19:10676186	KRI1	0.56	5.47	0.41	1.85e-7	Red cell distribution width;
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6912958	0.703	rs4365903	chr6:88282653	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.42	-0.4	2.25e-7	Monocyte percentage of white cells;
PAAD	cis	rs9815354	1.000	rs9875083	chr3:41775786	T/A	cg03022575	chr3:42003672	ULK4	0.84	5.87	0.43	2.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.31	0.64	3.11e-19	Monocyte percentage of white cells;
PAAD	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.69	7.16	0.5	3.16e-11	Monocyte count;
PAAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg24846680	chr1:228362309	C1orf69	0.45	4.31	0.33	2.96e-5	Diastolic blood pressure;
PAAD	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.53	-4.55	-0.35	1.1e-5	Total body bone mineral density (age 0-15);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20409466	chr11:9635889	NA	-0.71	-6.3	-0.46	3.03e-9	Neuroticism;
PAAD	cis	rs1519814	0.956	rs11774123	chr8:121119274	C/T	cg22335954	chr8:121166405	COL14A1	0.63	5.5	0.41	1.58e-7	Breast cancer;
PAAD	cis	rs722599	0.501	rs2286914	chr14:75387012	T/C	cg08847533	chr14:75593920	NEK9	-0.58	-5.86	-0.43	2.76e-8	IgG glycosylation;
PAAD	cis	rs7582720	0.559	rs4675290	chr2:203639839	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.62	-5.08	-0.38	1.09e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2229238	0.868	rs73018293	chr1:154465577	C/T	cg21262032	chr1:154437693	IL6R	-0.48	-5.0	-0.38	1.56e-6	Coronary heart disease;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg13207630	chr7:32358064	NA	0.97	4.97	0.37	1.81e-6	Body mass index;
PAAD	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg17674042	chr6:34482479	PACSIN1	-1.26	-7.44	-0.52	6.8e-12	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs59888335	0.895	rs2372451	chr3:80856453	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.7	0.62	1.25e-17	Prudent dietary pattern;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.55	0.35	1.08e-5	Electrocardiographic conduction measures;
PAAD	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.53	5.21	0.39	6.17e-7	Parkinson's disease;
PAAD	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg00629941	chr15:75287862	SCAMP5	0.58	4.43	0.34	1.77e-5	Blood trace element (Zn levels);
PAAD	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.19e-7	Red blood cell count;
PAAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25717658	chr6:169540677	NA	-0.58	-6.6	-0.47	6.44e-10	Obesity-related traits;
PAAD	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg09226986	chr6:160852328	SLC22A3	-0.45	-4.3	-0.33	3.09e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	6.02	0.44	1.25e-8	Lung cancer in ever smokers;
PAAD	cis	rs4443100	0.958	rs9608066	chr22:23387172	A/G	cg14186256	chr22:23484241	RTDR1	0.51	4.47	0.34	1.49e-5	Serum parathyroid hormone levels;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-5.29	-0.39	4.29e-7	Renal function-related traits (BUN);
PAAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg06815965	chr1:205818668	PM20D1	0.53	5.51	0.41	1.49e-7	Monocyte percentage of white cells;
PAAD	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.61	5.62	0.41	9.07e-8	Fibrinogen levels;
PAAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.62	6.92	0.49	1.18e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg21479132	chr6:26055353	NA	0.7	4.49	0.34	1.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.12e-6	Tuberculosis;
PAAD	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg02135003	chr7:105160482	PUS7	0.67	5.46	0.41	1.86e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.73	-7.96	-0.54	3.72e-13	Blood metabolite levels;
PAAD	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.55	-0.52	3.83e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09256448	chr16:638327	NA	0.41	4.27	0.33	3.4e-5	Height;
PAAD	cis	rs59888335	0.862	rs893163	chr3:80628555	C/G	cg21735741	chr3:80819488	NA	0.58	5.01	0.38	1.46e-6	Schizophrenia;
PAAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.39	-0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.6	7.01	0.49	7.28e-11	Immature fraction of reticulocytes;
PAAD	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	0.97	12.51	0.71	3.88e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg11335335	chr11:637885	DRD4	-0.36	-5.01	-0.38	1.5e-6	Systemic lupus erythematosus;
PAAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.72	-0.42	5.47e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg25174290	chr11:3078921	CARS	0.5	5.05	0.38	1.23e-6	Longevity;
PAAD	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11484403	chr4:755143	PCGF3	0.59	7.07	0.5	5.39e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs1497828	0.956	rs1013386	chr1:217566215	C/T	cg04411442	chr1:217543379	NA	0.52	5.09	0.38	1.02e-6	Dialysis-related mortality;
PAAD	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg18612461	chr15:75251733	NA	-0.4	-4.39	-0.34	2.09e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-6.06	-0.44	1.04e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg00035074	chr7:2701567	TTYH3	0.63	4.34	0.33	2.63e-5	Bipolar disorder;
PAAD	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16988970	chr17:42248062	ASB16	-0.37	-5.29	-0.39	4.28e-7	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg15674680	chr20:60982522	CABLES2	0.48	4.66	0.35	7e-6	Colorectal cancer;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06753367	chr22:24256600	NA	-0.4	-4.29	-0.33	3.1e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs962856	0.693	rs2902005	chr2:67623081	A/C	cg09028215	chr2:67624308	ETAA1	-0.6	-5.06	-0.38	1.18e-6	Pancreatic cancer;
PAAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg22482690	chr17:47019901	SNF8	0.49	5.14	0.38	8.39e-7	Type 2 diabetes;
PAAD	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.76	-8.75	-0.58	3.8e-15	Handedness;
PAAD	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.37	-13.09	-0.73	1.06e-26	Corneal structure;
PAAD	cis	rs3736485	0.966	rs6493498	chr15:51754451	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.3	-0.33	3.08e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-9.27	-0.6	1.71e-16	Gut microbiome composition (summer);
PAAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.28	0.39	4.41e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg11088901	chr6:166572345	T	-0.49	-4.48	-0.34	1.48e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2268241	0.938	rs2300373	chr21:34788739	A/T	cg14850771	chr21:34775459	IFNGR2	0.92	7.19	0.5	2.8e-11	Obesity-related traits;
PAAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg02117656	chr17:79614917	TSPAN10	-0.59	-6.36	-0.46	2.27e-9	Eye color traits;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.57	-5.48	-0.41	1.69e-7	Rheumatoid arthritis;
PAAD	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.79e-13	Response to antipsychotic treatment;
PAAD	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg16434002	chr17:42200994	HDAC5	-0.6	-5.81	-0.43	3.53e-8	Total body bone mineral density;
PAAD	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.52	0.65	8.66e-20	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg05313129	chr8:58192883	C8orf71	-0.63	-5.28	-0.39	4.36e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg10973622	chr2:86423274	IMMT	-0.42	-4.84	-0.37	3.1e-6	Night sleep phenotypes;
PAAD	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.96	-0.44	1.67e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19742111	chr11:66460113	SPTBN2	0.61	6.78	0.48	2.54e-10	Warfarin maintenance dose;
PAAD	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.61	5.97	0.44	1.62e-8	Primary sclerosing cholangitis;
PAAD	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.72	9.68	0.62	1.46e-17	Eosinophil percentage of white cells;
PAAD	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00292662	chr22:38071168	LGALS1	0.5	5.39	0.4	2.6e-7	Fat distribution (HIV);
PAAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.59	6.55	0.47	8.44e-10	Emphysema distribution in smoking;
PAAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	5.13	0.38	8.66e-7	Free thyroxine concentration;
PAAD	cis	rs9972944	0.589	rs11870559	chr17:63772633	G/A	cg07283582	chr17:63770753	CCDC46	0.5	5.51	0.41	1.53e-7	Total body bone mineral density;
PAAD	cis	rs258892	0.793	rs16900954	chr5:72021191	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs10783615	0.719	rs1975471	chr12:54336981	A/G	cg08974225	chr12:53574518	CSAD;ZNF740	0.59	4.62	0.35	8.07e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.49	-5.57	-0.41	1.13e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.56	5.82	0.43	3.33e-8	Schizophrenia;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	cis	rs6604026	0.666	rs11164830	chr1:93356823	C/A	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.3	-0.33	3.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.43	-4.68	-0.35	6.36e-6	Pneumonia;
PAAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg03098721	chr1:84464084	TTLL7	0.46	4.4	0.34	2.04e-5	Obesity-related traits;
PAAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	0.56	4.77	0.36	4.22e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24489237	chr1:164529170	PBX1	-0.64	-6.77	-0.48	2.7e-10	Myopia (pathological);
PAAD	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg00750074	chr16:89608354	SPG7	-0.56	-5.57	-0.41	1.13e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg00262122	chr8:11665843	FDFT1	-0.51	-4.79	-0.36	4.01e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg25364880	chr3:44379878	C3orf23	0.56	5.05	0.38	1.26e-6	Depressive symptoms;
PAAD	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg07288347	chr16:12145724	SNX29;RUNDC2A	-0.51	-4.78	-0.36	4.17e-6	Testicular germ cell tumor;
PAAD	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2279817	0.780	rs79923328	chr1:18008116	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-5.24	-0.39	5.16e-7	Neuroticism;
PAAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.72	-6.45	-0.46	1.4e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.66	-7.18	-0.5	2.87e-11	Childhood ear infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01062786	chr14:20929651	TMEM55B	0.65	6.49	0.47	1.13e-9	Smoking initiation;
PAAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.7	-9.08	-0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg18850127	chr7:39170497	POU6F2	0.44	6.0	0.44	1.36e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.22	15.17	0.78	3.04e-32	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03676636	chr4:99064102	C4orf37	0.33	6.02	0.44	1.24e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg14709524	chr16:89940631	TCF25	0.99	4.64	0.35	7.5e-6	Skin colour saturation;
PAAD	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.62	6.4	0.46	1.83e-9	Adiposity;
PAAD	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.67	-6.61	-0.47	6.28e-10	Pubertal anthropometrics;
PAAD	cis	rs7301016	1.000	rs11174494	chr12:62864877	A/T	cg19781863	chr12:62918364	MON2	0.75	4.44	0.34	1.7e-5	IgG glycosylation;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11141652	chr22:24348549	GSTTP1	0.48	4.27	0.33	3.44e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.7	6.76	0.48	2.82e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	6.85	0.49	1.7e-10	Mean platelet volume;
PAAD	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg01620082	chr3:125678407	NA	-1.49	-8.75	-0.58	3.73e-15	Depression;
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	5.75	0.42	4.75e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.7	-6.78	-0.48	2.54e-10	Platelet distribution width;
PAAD	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg26384229	chr12:38710491	ALG10B	0.7	7.11	0.5	4.2e-11	Morning vs. evening chronotype;
PAAD	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.34	4.32	0.33	2.85e-5	Prostate cancer;
PAAD	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.48	4.49	0.34	1.42e-5	Endometrial cancer;
PAAD	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.43	0.34	1.78e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22330165	chr2:70781302	TGFA	-0.77	-6.76	-0.48	2.73e-10	Neuroticism;
PAAD	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg07784872	chr16:85687041	KIAA0182	0.53	4.32	0.33	2.79e-5	Platelet distribution width;
PAAD	trans	rs901683	1.000	rs34516867	chr10:46081737	T/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.55	0.35	1.1e-5	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.6	-0.35	8.92e-6	Obesity-related traits;
PAAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.79	-0.43	3.89e-8	Total body bone mineral density;
PAAD	cis	rs501120	0.584	rs11592445	chr10:44732945	G/T	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg09659197	chr4:152720779	NA	0.45	5.97	0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25307277	chr6:26124601	HIST1H2AC;HIST1H2BC	0.6	6.31	0.46	2.89e-9	Myopia (pathological);
PAAD	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06671706	chr8:8559999	CLDN23	0.56	5.11	0.38	9.54e-7	Obesity-related traits;
PAAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.34	-0.33	2.61e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4908768	0.501	rs1463050	chr1:8597042	G/A	cg20416874	chr1:8611966	RERE	-0.46	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg08888203	chr3:10149979	C3orf24	0.85	6.11	0.44	7.86e-9	Alzheimer's disease;
PAAD	cis	rs28489187	0.617	rs2840319	chr1:85886224	C/T	cg16011679	chr1:85725395	C1orf52	-0.45	-4.49	-0.34	1.38e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg04289385	chr6:36355825	ETV7	0.44	4.38	0.33	2.18e-5	Platelet distribution width;
PAAD	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.63	-4.59	-0.35	9.34e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72827839	0.790	rs116944299	chr17:46267765	C/A	cg23391107	chr17:45924227	SP6	0.62	5.31	0.4	3.84e-7	Ease of getting up in the morning;
PAAD	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-5.01	-0.38	1.48e-6	Axial length;
PAAD	cis	rs8005172	0.663	rs1545227	chr14:88512454	T/C	cg18078958	chr14:88630771	NA	0.35	4.43	0.34	1.78e-5	Parkinson's disease;
PAAD	cis	rs58521262	0.556	rs388507	chr19:23122614	C/A	cg02350677	chr19:23254381	NA	-0.27	-4.71	-0.36	5.63e-6	Testicular germ cell tumor;
PAAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.67	-6.82	-0.48	2.04e-10	Longevity;
PAAD	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-7.14	-0.5	3.56e-11	Cognitive function;
PAAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.59	-6.24	-0.45	4.08e-9	Hyperactive-impulsive symptoms;
PAAD	cis	rs6841948	0.698	rs12644791	chr4:7977611	A/T	cg14959746	chr4:7987834	ABLIM2	-0.59	-4.57	-0.35	1.01e-5	Post bronchodilator FEV1 in COPD;
PAAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07648498	chr16:89883185	FANCA	0.69	7.16	0.5	3.21e-11	Vitiligo;
PAAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.54	5.33	0.4	3.52e-7	Pulmonary function;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20704793	chr12:124858407	NCOR2	0.73	8.03	0.55	2.5e-13	Smoking initiation;
PAAD	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.11	15.09	0.77	5.02e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.55	4.94	0.37	2.02e-6	RR interval (heart rate);
PAAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	5.45	0.4	2e-7	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08753403	chr12:10007156	CLEC2B	0.48	6.3	0.46	3.01e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06028808	chr11:68637592	NA	0.48	5.33	0.4	3.47e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.58	-5.64	-0.42	8.2e-8	Anterior chamber depth;
PAAD	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	7.83	0.54	7.73e-13	Monocyte percentage of white cells;
PAAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.41	4.38	0.33	2.18e-5	Aortic root size;
PAAD	cis	rs728616	0.867	rs56235549	chr10:81834948	G/A	cg05935833	chr10:81318306	SFTPA2	-0.62	-4.73	-0.36	5.07e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs72960926	1.000	rs55775775	chr6:75133634	A/G	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.55	6.1	0.44	8.4e-9	Testicular germ cell tumor;
PAAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18337363	chr3:52569053	NT5DC2	0.42	4.52	0.34	1.26e-5	Electroencephalogram traits;
PAAD	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg11630242	chr17:19881632	AKAP10	-0.49	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.52	-5.08	-0.38	1.09e-6	Crohn's disease;
PAAD	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.75	-0.62	9.83e-18	Total body bone mineral density;
PAAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.87	0.69	2.08e-23	Smoking behavior;
PAAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10064575	chr17:40610771	ATP6V0A1	0.61	7.12	0.5	3.94e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8037137	0.915	rs76119208	chr15:91535329	G/T	cg23684204	chr15:91497937	RCCD1	0.8	4.85	0.37	3.06e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10373958	chr11:17801276	KCNC1	0.58	6.7	0.48	3.77e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Coronary artery disease;
PAAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg19630374	chr17:18023558	MYO15A	-0.56	-5.74	-0.42	4.88e-8	Total body bone mineral density;
PAAD	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	11.05	0.67	3.31e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.68	5.61	0.41	9.29e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.82	-0.36	3.41e-6	Mean corpuscular volume;
PAAD	cis	rs1190596	0.594	rs33997362	chr14:102719890	A/T	cg23904247	chr14:102554826	HSP90AA1	0.44	5.03	0.38	1.39e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.51	6.33	0.46	2.68e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.5	-6.54	-0.47	8.62e-10	Height;
PAAD	cis	rs35740288	0.770	rs62022909	chr15:86207481	A/G	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-6.78	-0.48	2.49e-10	Lymphocyte counts;
PAAD	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-5.24	-0.39	5.33e-7	Vitamin D levels;
PAAD	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05585630	chr7:157510462	PTPRN2	-0.78	-9.09	-0.59	5.14e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.56	5.53	0.41	1.39e-7	Menarche (age at onset);
PAAD	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.67	-9.26	-0.6	1.88e-16	Venous thromboembolism;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	trans	rs12714314	0.957	rs2060196	chr2:1955972	T/A	cg17170872	chr1:91487911	ZNF644	-0.76	-6.3	-0.46	3.12e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.46	-0.34	1.56e-5	Triglycerides;
PAAD	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.09e-9	Morning vs. evening chronotype;
PAAD	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg11204139	chr17:3907470	NA	0.58	5.14	0.39	8.17e-7	Type 2 diabetes;
PAAD	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.11	0.38	9.36e-7	Educational attainment;
PAAD	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg06569542	chr10:98946673	SLIT1	-0.54	-5.93	-0.43	1.93e-8	Monocyte count;
PAAD	cis	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg06360820	chr2:242988706	NA	-1.07	-8.43	-0.56	2.54e-14	Obesity-related traits;
PAAD	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.4	-0.34	2.02e-5	Metabolite levels;
PAAD	cis	rs8099014	0.861	rs4940706	chr18:56121803	C/T	cg12907477	chr18:56117327	MIR122	-0.61	-4.7	-0.36	5.74e-6	Platelet count;
PAAD	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.98	-11.75	-0.69	4.31e-23	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg14440974	chr22:39074834	NA	-0.63	-7.55	-0.52	3.76e-12	Menopause (age at onset);
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2491441	1.000	rs3010061	chr1:183824869	C/T	cg08905629	chr1:183188297	LAMC2	-0.46	-4.32	-0.33	2.83e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02419362	chr12:121203948	SPPL3	0.51	5.61	0.41	9.2e-8	Systemic lupus erythematosus;
PAAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.73	0.62	1.09e-17	Cognitive function;
PAAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-7.35	-0.51	1.14e-11	Longevity;
PAAD	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.21	-0.67	1.25e-21	Lymphocyte percentage of white cells;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg22442454	chr1:209979470	IRF6	0.51	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs5009270	0.513	rs4478510	chr7:112220494	C/A	cg25550468	chr7:112262557	NA	0.49	4.28	0.33	3.26e-5	Osteoarthritis (hip);
PAAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-5.15	-0.39	8.01e-7	Personality dimensions;
PAAD	cis	rs9506514	0.509	rs9509294	chr13:21174645	T/A	cg27499820	chr13:21296301	IL17D	-0.43	-4.47	-0.34	1.5e-5	Coronary artery calcification;
PAAD	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg24253500	chr15:84953950	NA	0.56	6.57	0.47	7.64e-10	Schizophrenia;
PAAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg06671706	chr8:8559999	CLDN23	0.75	7.36	0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs59888335	0.793	rs7623802	chr3:81009014	C/T	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.49	5.9	0.43	2.25e-8	Coronary artery disease;
PAAD	cis	rs17824933	0.848	rs11230560	chr11:60771077	G/A	cg27098804	chr11:60776124	CD6	0.44	4.35	0.33	2.44e-5	Multiple sclerosis;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.63	6.17	0.45	5.99e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7594192	0.744	rs11898801	chr2:199361421	T/C	cg03163783	chr2:200326591	SATB2	-0.33	-4.51	-0.34	1.3e-5	Educational attainment;
PAAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.87e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.8	6.07	0.44	9.98e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1007738	0.507	rs10742797	chr11:47240490	A/T	cg19486271	chr11:47235900	DDB2	0.63	5.64	0.42	8.22e-8	Bone mineral density (hip);
PAAD	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs73019876	0.836	rs2666438	chr19:22144259	A/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.4	-0.34	2.04e-5	Testicular germ cell tumor;
PAAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.49	7.69	0.53	1.75e-12	Mean corpuscular volume;
PAAD	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.68	6.82	0.48	2.04e-10	Cancer;
PAAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.91	0.43	2.21e-8	Prudent dietary pattern;
PAAD	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs8077577	1.000	rs8077577	chr17:18064730	C/T	cg16794390	chr17:18148240	FLII	0.62	5.13	0.38	8.8e-7	Obesity-related traits;
PAAD	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.56	-5.63	-0.42	8.37e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.65	-9.12	-0.59	4.26e-16	Breast cancer;
PAAD	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg21546286	chr11:48923668	NA	-0.54	-5.57	-0.41	1.15e-7	HDL cholesterol;
PAAD	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg00614314	chr15:82944287	LOC80154	0.53	5.26	0.39	4.71e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-4.76	-0.36	4.56e-6	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.72	-7.01	-0.49	7.27e-11	Morning vs. evening chronotype;
PAAD	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04492929	chr16:2155436	PKD1	-0.65	-6.58	-0.47	7.01e-10	Triglycerides;
PAAD	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21775007	chr8:11205619	TDH	-0.49	-4.64	-0.35	7.51e-6	Systolic blood pressure;
PAAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg22134325	chr11:66188745	NPAS4	0.45	5.31	0.4	3.89e-7	Airway imaging phenotypes;
PAAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg05697835	chr1:2722811	NA	-0.42	-4.71	-0.36	5.45e-6	Ulcerative colitis;
PAAD	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg26924012	chr15:45694286	SPATA5L1	0.48	4.55	0.35	1.09e-5	Uric acid levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23002658	chr20:52824474	PFDN4	0.57	6.29	0.45	3.2e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-1.2	-11.64	-0.69	8.8e-23	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2790216	1.000	rs2790167	chr10:60024470	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.66	5.36	0.4	3.08e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs17095355	0.642	rs7918758	chr10:111919866	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.63	-0.35	7.72e-6	Biliary atresia;
PAAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.66	7.29	0.51	1.62e-11	Longevity;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.56	-5.29	-0.39	4.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-0.96	-6.41	-0.46	1.71e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.73	8.13	0.55	1.37e-13	Colorectal cancer;
PAAD	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.85	-0.37	2.97e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.45	-4.5	-0.34	1.33e-5	Mean platelet volume;
PAAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.76	-8.61	-0.57	8.49e-15	Childhood ear infection;
PAAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.54	5.92	0.43	2.09e-8	Major depressive disorder;
PAAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.56	-8.14	-0.55	1.35e-13	Huntington's disease progression;
PAAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08893839	chr5:154027129	NA	-0.77	-6.22	-0.45	4.57e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6782228	1.000	rs6782407	chr3:128338748	T/C	cg15607142	chr3:128420513	NA	-0.43	-4.58	-0.35	9.63e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24639069	chr1:42955247	NA	-0.64	-6.36	-0.46	2.29e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg03909863	chr11:638404	DRD4	-0.69	-6.1	-0.44	8.42e-9	Systemic lupus erythematosus;
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg19673125	chr6:150240577	RAET1G	0.42	5.94	0.43	1.85e-8	Testicular germ cell tumor;
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.57	0.41	1.14e-7	Total body bone mineral density;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.5	-4.94	-0.37	2.08e-6	Parkinson's disease;
PAAD	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.08	0.38	1.08e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg18850127	chr7:39170497	POU6F2	0.44	6.11	0.44	8.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.92	-0.37	2.27e-6	QT interval;
PAAD	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg20893579	chr22:38215064	NA	-0.45	-4.74	-0.36	4.88e-6	Glioblastoma;Glioma;
PAAD	cis	rs1941184	0.759	rs16961919	chr18:29026915	T/C	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	7.34	0.51	1.18e-11	Prudent dietary pattern;
PAAD	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.43	4.46	0.34	1.55e-5	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00533393	chr11:747458	TALDO1	-0.78	-6.59	-0.47	6.69e-10	Neuroticism;
PAAD	cis	rs1620921	0.505	rs11758404	chr6:161210455	A/G	cg01280913	chr6:161186852	NA	-0.46	-5.03	-0.38	1.39e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs1015213	0.609	rs77456701	chr8:52870680	G/A	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs1015291	0.708	rs12310169	chr12:20005949	C/T	cg25401612	chr12:20009446	NA	-0.54	-5.42	-0.4	2.27e-7	Diastolic blood pressure;
PAAD	cis	rs9397240	0.789	rs9383751	chr6:155615791	C/T	cg06694381	chr6:155569200	TIAM2	-0.48	-4.35	-0.33	2.51e-5	Life satisfaction;
PAAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg08514558	chr10:81106712	PPIF	0.54	6.47	0.46	1.27e-9	Height;
PAAD	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.03	-0.5	6.38e-11	Life satisfaction;
PAAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg13770153	chr20:60521292	NA	-0.45	-4.4	-0.34	2e-5	Body mass index;
PAAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.51	6.02	0.44	1.24e-8	Testicular germ cell tumor;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14241138	chr9:82188393	TLE4	0.7	6.29	0.45	3.15e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.69	5.97	0.44	1.58e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-4.98	-0.37	1.69e-6	Mood instability;
PAAD	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02901728	chr18:8704722	NA	0.58	6.41	0.46	1.74e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.48	-4.96	-0.37	1.89e-6	Iron status biomarkers;
PAAD	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.6	5.57	0.41	1.12e-7	Acylcarnitine levels;
PAAD	cis	rs3736485	0.966	rs2414110	chr15:51901302	T/C	cg19558802	chr15:51695713	GLDN	-0.45	-4.5	-0.34	1.36e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.65	7.11	0.5	4.34e-11	Testicular germ cell tumor;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07930192	chr7:1003750	NA	0.36	4.36	0.33	2.43e-5	Longevity;Endometriosis;
PAAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.84	9.88	0.63	4.3e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.75	-5.11	-0.38	9.46e-7	Monocyte percentage of white cells;
PAAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.59	-0.41	1.03e-7	Tonsillectomy;
PAAD	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.45	5.61	0.41	9.34e-8	Stem cell growth factor beta levels;
PAAD	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05898123	chr13:21549161	LATS2	0.6	6.96	0.49	9.45e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg00253185	chr1:247542119	NA	0.49	4.4	0.34	2.06e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs3779195	0.860	rs12704986	chr7:97986430	T/C	cg21770322	chr7:97807741	LMTK2	0.53	4.9	0.37	2.41e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg19163074	chr7:65112434	INTS4L2	0.47	4.44	0.34	1.7e-5	Aortic root size;
PAAD	cis	rs4906332	0.966	rs12885786	chr14:103972503	C/T	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.35	-0.4	3.15e-7	Coronary artery disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04787413	chr13:111358532	CARS2	-0.75	-6.65	-0.47	5.03e-10	Neuroticism;
PAAD	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.55	-7.03	-0.5	6.67e-11	Longevity;
PAAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs12311304	0.965	rs7303854	chr12:15359241	A/T	cg08258403	chr12:15378311	NA	0.34	4.41	0.34	1.97e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00166722	chr3:10149974	C3orf24	0.98	8.08	0.55	1.82e-13	Alzheimer's disease;
PAAD	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.63	5.74	0.42	5.06e-8	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg24375607	chr4:120327624	NA	0.54	4.71	0.36	5.64e-6	Corneal astigmatism;
PAAD	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg23920097	chr1:209922102	NA	-0.45	-4.35	-0.33	2.45e-5	Red blood cell count;
PAAD	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg13263323	chr15:86062960	AKAP13	0.63	7.28	0.51	1.66e-11	Interstitial lung disease;
PAAD	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.49	5.77	0.42	4.28e-8	Alcohol dependence;
PAAD	cis	rs2278796	0.752	rs6677763	chr1:204951540	A/G	cg04862289	chr1:204966208	NFASC	0.48	5.34	0.4	3.33e-7	Mean platelet volume;
PAAD	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.07	5.19	0.39	6.52e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06998765	chr14:75389618	RPS6KL1	0.28	4.87	0.37	2.72e-6	Caffeine consumption;
PAAD	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-4.45	-0.34	1.65e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6987853	0.563	rs2923408	chr8:42451526	A/G	cg09913449	chr8:42400586	C8orf40	0.52	5.85	0.43	2.9e-8	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21825625	chr3:194393329	LSG1	0.62	6.53	0.47	9.23e-10	Myopia (pathological);
PAAD	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg04896959	chr15:78267971	NA	-0.6	-4.56	-0.35	1.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs78761021	0.685	rs62064483	chr17:9796862	C/T	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg13482628	chr17:19912719	NA	0.55	5.12	0.38	8.99e-7	Schizophrenia;
PAAD	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg00791764	chr4:53727839	RASL11B	0.54	4.55	0.35	1.1e-5	Optic nerve measurement (cup area);
PAAD	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.41	-0.4	2.45e-7	Mood instability;
PAAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.64	-0.47	5.33e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs874460	1.000	rs874460	chr19:47176752	C/A	cg13467550	chr19:47212573	PRKD2	-0.73	-4.35	-0.33	2.44e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.85	10.96	0.66	5.76e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg11288833	chr15:55489084	RSL24D1	0.58	4.69	0.36	6.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.3	4.25	0.33	3.65e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg18939081	chr1:31884902	SERINC2	0.49	5.52	0.41	1.42e-7	Alcohol dependence;
PAAD	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs55637647	0.515	rs7206699	chr16:88523815	A/G	cg01690119	chr16:88511822	NA	-0.41	-4.99	-0.38	1.6e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.83	-0.43	3.23e-8	Height;
PAAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg22143856	chr6:28129313	ZNF389	0.52	4.51	0.34	1.27e-5	Breast cancer;
PAAD	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg02404636	chr22:31891804	SFI1	-0.59	-5.28	-0.39	4.36e-7	Colorectal cancer;
PAAD	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	6.58	0.47	7.08e-10	Body mass index;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.86	9.66	0.62	1.68e-17	Multiple system atrophy;
PAAD	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.29e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.85	0.54	6.92e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1160297	0.539	rs12469781	chr2:53136539	C/T	cg07782112	chr2:53107842	NA	-0.36	-4.39	-0.34	2.13e-5	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.41	-4.31	-0.33	2.9e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg00262122	chr8:11665843	FDFT1	-0.55	-4.84	-0.37	3.13e-6	Morning vs. evening chronotype;
PAAD	cis	rs11700980	0.551	rs2832037	chr21:30115246	A/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg15654264	chr1:150340011	RPRD2	0.52	4.99	0.37	1.66e-6	Migraine;
PAAD	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.51	4.92	0.37	2.2e-6	White matter hyperintensity burden;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23711139	chr7:23627109	CLK2P	-0.59	-6.41	-0.46	1.77e-9	Monocyte percentage of white cells;
PAAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg05342682	chr7:94953680	PON1	-0.51	-4.55	-0.35	1.07e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.46	5.9	0.43	2.31e-8	Psoriasis;
PAAD	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg16342193	chr10:102329863	NA	-0.76	-8.17	-0.55	1.1e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.13	10.78	0.66	1.72e-20	Cognitive test performance;
PAAD	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.95	12.49	0.71	4.5e-25	Menopause (age at onset);
PAAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-11.05	-0.67	3.24e-21	Coronary artery disease;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg09873201	chr16:3507582	NAT15	0.59	5.53	0.41	1.38e-7	Tuberculosis;
PAAD	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs4450131	0.522	rs4962683	chr10:126371957	C/T	cg20435097	chr10:126320824	FAM53B	0.51	5.12	0.38	9.3e-7	White blood cell count (basophil);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02637302	chr17:79670369	MRPL12	0.65	6.34	0.46	2.48e-9	Obesity-related traits;
PAAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.25	0.51	1.95e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg02230254	chr11:65586170	NA	-0.34	-4.75	-0.36	4.66e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.89	6.34	0.46	2.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-5.17	-0.39	7.32e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.57	-5.39	-0.4	2.64e-7	Corneal astigmatism;
PAAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg19337854	chr7:99768885	GPC2	0.52	4.74	0.36	4.8e-6	Lung function (FEV1/FVC);
PAAD	cis	rs1468734	0.963	rs35051265	chr16:5002903	T/C	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs897200	0.536	rs12327969	chr2:192010771	C/G	cg23477168	chr2:192750645	NA	-0.47	-4.27	-0.33	3.46e-5	Behcet's disease;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18621852	chr3:10150065	C3orf24	0.66	5.8	0.43	3.65e-8	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg18209359	chr17:80159595	CCDC57	-0.46	-4.68	-0.35	6.32e-6	Life satisfaction;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.32	0.46	2.78e-9	Height;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg22442454	chr1:209979470	IRF6	0.51	4.49	0.34	1.43e-5	Coronary artery disease;
PAAD	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-6.07	-0.44	9.85e-9	Schizophrenia;
PAAD	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg05309399	chr4:106552544	FLJ20184	-0.53	-4.25	-0.33	3.7e-5	Post bronchodilator FEV1;
PAAD	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.36	-5.36	-0.4	3.05e-7	Cutaneous nevi;
PAAD	cis	rs939584	1.000	rs2867112	chr2:651349	T/G	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg26174226	chr8:58114915	NA	-0.44	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7188861	0.681	rs12935137	chr16:11422015	T/C	cg16532467	chr16:11454386	NA	-0.56	-4.46	-0.34	1.58e-5	HDL cholesterol;
PAAD	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.68	8.36	0.56	3.72e-14	Dupuytren's disease;
PAAD	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs4835937	0.551	rs4836344	chr5:127263443	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.52	-4.25	-0.33	3.73e-5	Cancer;
PAAD	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.43	-5.2	-0.39	6.28e-7	Coronary artery disease;
PAAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg26312998	chr6:43337775	ZNF318	0.66	5.29	0.39	4.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00521551	chr11:64646313	EHD1	-0.57	-6.64	-0.47	5.33e-10	Body fat percentage;
PAAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg19673125	chr6:150240577	RAET1G	0.45	6.2	0.45	5.16e-9	Testicular germ cell tumor;
PAAD	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.6	-5.94	-0.43	1.86e-8	Coronary artery disease;
PAAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg14686297	chr22:46650375	NA	-0.49	-4.97	-0.37	1.8e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6701037	0.522	rs12094153	chr1:175094025	G/A	cg00321850	chr1:175162397	KIAA0040	-0.39	-5.16	-0.39	7.5e-7	Alcohol dependence;
PAAD	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg10495392	chr1:46806563	NSUN4	0.57	5.4	0.4	2.51e-7	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.56	5.49	0.41	1.64e-7	Prudent dietary pattern;
PAAD	cis	rs3794271	0.646	rs4430560	chr12:20809889	G/T	cg03618715	chr12:21590536	PYROXD1	-0.49	-4.28	-0.33	3.35e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
PAAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.95	5.59	0.41	1.04e-7	Obesity (early onset extreme);
PAAD	cis	rs66530629	0.958	rs55965563	chr1:25050829	G/A	cg01905478	chr1:25040257	NA	0.54	5.85	0.43	2.84e-8	Plateletcrit;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-7.87	-0.54	6.14e-13	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17318943	chr17:74446266	UBE2O	-0.67	-7.11	-0.5	4.2e-11	Obesity-related traits;
PAAD	cis	rs28493229	0.881	rs73931345	chr19:41180347	G/A	cg21869046	chr19:41225005	ITPKC	0.61	6.21	0.45	4.95e-9	Kawasaki disease;
PAAD	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.61	-5.29	-0.39	4.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.77	8.92	0.59	1.4e-15	Blood metabolite ratios;
PAAD	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.87	7.02	0.5	6.75e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.47	6.72	0.48	3.4e-10	Oropharynx cancer;
PAAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs3806308	1.000	rs10917547	chr1:20143142	A/T	cg13843611	chr1:20143089	RNF186	-0.52	-5.39	-0.4	2.6e-7	Ulcerative colitis;
PAAD	cis	rs10078	0.559	rs6893791	chr5:430413	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-4.92	-0.37	2.24e-6	Fat distribution (HIV);
PAAD	cis	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg03315344	chr16:75512273	CHST6	-0.63	-5.31	-0.4	3.86e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg12163867	chr12:51592794	POU6F1	-0.64	-6.41	-0.46	1.71e-9	Cisplatin-induced ototoxicity;
PAAD	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.72	4.7	0.36	5.87e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26616078	chr7:138552825	KIAA1549	0.61	7.24	0.51	2.05e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs75920871	0.920	rs61907594	chr11:116801811	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.93	7.13	0.5	3.89e-11	Alzheimer's disease;
PAAD	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.77	-6.24	-0.45	4.21e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
PAAD	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.29	0.39	4.18e-7	Colorectal cancer;
PAAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.82	0.62	6.33e-18	Intelligence (multi-trait analysis);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg00433081	chr5:179719502	MAPK9	0.62	6.46	0.46	1.33e-9	Iris heterochromicity;
PAAD	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.9	5.92	0.43	2.11e-8	Major depressive disorder;
PAAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.63	5.48	0.41	1.73e-7	Initial pursuit acceleration;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20041257	chr19:10828819	DNM2;MIR638	-0.53	-6.33	-0.46	2.68e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.69	-6.67	-0.48	4.54e-10	Total body bone mineral density;
PAAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.9	13.02	0.73	1.66e-26	Bone mineral density;
PAAD	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg13919466	chr1:32135498	COL16A1	-0.45	-5.23	-0.39	5.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.7	5.36	0.4	3.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18621852	chr3:10150065	C3orf24	0.7	6.28	0.45	3.31e-9	Alzheimer's disease;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg05940881	chr5:139726074	HBEGF	0.62	6.29	0.45	3.13e-9	Iris heterochromicity;
PAAD	cis	rs6011674	1.000	rs11908424	chr20:61863955	C/T	cg08263991	chr20:62715781	OPRL1;C20orf201	-0.75	-4.56	-0.35	1.03e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.79	-8.16	-0.55	1.2e-13	Menopause (age at onset);
PAAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	8.02	0.55	2.68e-13	Eye color traits;
PAAD	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg02421172	chr7:1938701	MAD1L1	0.61	4.65	0.35	7.27e-6	Bipolar disorder;
PAAD	cis	rs9926296	0.632	rs8048331	chr16:89793042	G/T	cg03605463	chr16:89740564	NA	0.55	5.19	0.39	6.67e-7	Vitiligo;
PAAD	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg14851346	chr12:38532713	NA	-0.48	-4.29	-0.33	3.12e-5	Morning vs. evening chronotype;
PAAD	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62408225	1.000	rs55881869	chr6:90968025	C/A	cg03795776	chr6:90687632	BACH2	0.43	4.29	0.33	3.23e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07777156	chr17:22022000	NA	-0.66	-6.35	-0.46	2.4e-9	Smoking initiation;
PAAD	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg09594475	chr20:60884601	LAMA5	0.51	4.52	0.34	1.23e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10214930	0.752	rs7808275	chr7:27661504	C/T	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.87	-5.89	-0.43	2.36e-8	Schizophrenia;
PAAD	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg03098721	chr1:84464084	TTLL7	0.49	4.76	0.36	4.53e-6	Obesity-related traits;
PAAD	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.49	-0.41	1.66e-7	Mortality in heart failure;
PAAD	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.49	5.47	0.41	1.85e-7	Educational attainment;
PAAD	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg24220031	chr2:73402428	NA	-0.3	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg09796270	chr17:17721594	SREBF1	0.43	5.03	0.38	1.37e-6	Total body bone mineral density;
PAAD	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.67	7.91	0.54	5.04e-13	Extrinsic epigenetic age acceleration;
PAAD	trans	rs901683	1.000	rs12764693	chr10:46023327	A/G	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg08758996	chr17:66097529	LOC651250	0.52	4.34	0.33	2.6e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg09597638	chr17:3907349	NA	0.89	10.08	0.63	1.27e-18	Type 2 diabetes;
PAAD	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-4.46	-0.34	1.6e-5	Resting heart rate;
PAAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.75	8.0	0.54	2.91e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.66	7.26	0.51	1.83e-11	Coronary artery disease;
PAAD	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.41	1.1e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.91	8.1	0.55	1.64e-13	Cognitive function;
PAAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg08436684	chr16:88034427	BANP	-0.5	-4.34	-0.33	2.59e-5	Menopause (age at onset);
PAAD	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs2479106	0.892	rs2768819	chr9:126593370	A/G	cg16191174	chr9:126692580	DENND1A	0.57	5.25	0.39	5.04e-7	Polycystic ovary syndrome;
PAAD	cis	rs4074493	0.928	rs11122197	chr1:231168477	A/G	cg22172038	chr1:231176991	FAM89A	-0.47	-4.33	-0.33	2.72e-5	Carotid plaque burden (smoking interaction);
PAAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.73	9.0	0.59	8.84e-16	Bone mineral density;
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	7.01	0.49	7.14e-11	Menarche (age at onset);
PAAD	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.31	0.76	5.77e-30	Headache;
PAAD	cis	rs7009516	0.745	rs1492414	chr8:24224911	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.42	5.04	0.38	1.29e-6	Hair greying;
PAAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.97	11.02	0.67	3.94e-21	Parkinson's disease;
PAAD	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg01064725	chr1:204461714	NA	-0.52	-4.89	-0.37	2.58e-6	Schizophrenia;
PAAD	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.54	6.16	0.45	6.26e-9	Mean corpuscular volume;
PAAD	cis	rs10851478	0.529	rs9920722	chr15:49735112	C/T	cg08060515	chr15:49448048	GALK2;COPS2	-0.52	-4.98	-0.37	1.7e-6	Oral cavity cancer;
PAAD	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	7.97	0.54	3.58e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg00717180	chr2:96193071	NA	-0.64	-7.91	-0.54	5e-13	HDL cholesterol;
PAAD	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.62	8.26	0.56	6.62e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2020921	0.510	rs12545129	chr8:41981118	G/T	cg17828057	chr8:42037527	PLAT	0.78	4.97	0.37	1.75e-6	Plasma plasminogen activator levels;
PAAD	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg20913747	chr6:44695427	NA	-0.66	-6.72	-0.48	3.45e-10	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01722343	chr4:25235437	PI4K2B	-0.63	-6.41	-0.46	1.73e-9	Smoking initiation;
PAAD	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	8.11	0.55	1.6e-13	Cognitive test performance;
PAAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg14393609	chr7:65229607	NA	-0.47	-4.47	-0.34	1.51e-5	Aortic root size;
PAAD	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.75	0.48	2.88e-10	Schizophrenia;
PAAD	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.67	-5.97	-0.44	1.64e-8	Blood trace element (Zn levels);
PAAD	cis	rs76866386	1.000	rs6756629	chr2:44065090	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.83	-5.25	-0.39	5.15e-7	Cholesterol, total;
PAAD	cis	rs6804624	0.636	rs2700645	chr3:99159460	T/C	cg02646433	chr3:99218170	NA	0.42	4.31	0.33	2.97e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs10821973	0.527	rs4979775	chr10:63981847	G/A	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg17771515	chr6:154831774	CNKSR3	0.61	4.49	0.34	1.38e-5	Lipoprotein (a) levels;
PAAD	cis	rs9810890	1.000	rs73196970	chr3:128443193	A/G	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg02462569	chr6:150064036	NUP43	-0.54	-5.93	-0.43	1.95e-8	Lung cancer;
PAAD	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.99	13.26	0.73	3.71e-27	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.49e-5	Life satisfaction;
PAAD	cis	rs2553268	1.000	rs2553268	chr8:30936356	G/T	cg00964221	chr8:30240029	NA	0.51	4.3	0.33	3.09e-5	Exercise treadmill test traits;
PAAD	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.18	-14.43	-0.76	2.82e-30	Type 1 diabetes nephropathy;
PAAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.23e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs621559	0.636	rs632866	chr1:43670624	C/A	cg14851383	chr1:43888477	KIAA0467	0.56	4.35	0.33	2.47e-5	Telomere length;
PAAD	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.79	-7.91	-0.54	4.94e-13	Anterior chamber depth;
PAAD	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.77	-0.53	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.69	-6.86	-0.49	1.63e-10	Pubertal anthropometrics;
PAAD	cis	rs2070677	0.673	rs3020503	chr10:135381766	C/T	cg20169779	chr10:135381914	SYCE1	0.75	7.43	0.52	7.32e-12	Gout;
PAAD	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04055981	chr11:115044050	NA	0.46	4.91	0.37	2.34e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.66	6.89	0.49	1.37e-10	Systemic lupus erythematosus;
PAAD	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.58	-5.77	-0.42	4.31e-8	Obesity-related traits;
PAAD	cis	rs7896691	0.925	rs17132175	chr10:3150814	G/C	cg15228268	chr10:3146741	PFKP	0.9	4.75	0.36	4.72e-6	Disc degeneration (lumbar);
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.67	5.81	0.43	3.53e-8	Inflammatory skin disease;
PAAD	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.9	6.34	0.46	2.53e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-6.43	-0.46	1.55e-9	Lymphocyte counts;
PAAD	cis	rs11051970	0.592	rs11052002	chr12:32590854	T/A	cg24626660	chr12:32551988	NA	0.41	4.32	0.33	2.84e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs262150	0.566	rs2247275	chr7:158765812	A/G	cg13444538	chr7:158905317	VIPR2	-0.73	-6.29	-0.45	3.18e-9	Facial morphology (factor 20);
PAAD	cis	rs6929137	0.666	rs6914432	chr6:151936214	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-4.48	-0.34	1.46e-5	Bone mineral density (spine);
PAAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.59	-5.55	-0.41	1.26e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.52	-4.83	-0.36	3.29e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.62	-6.38	-0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.89e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg13722127	chr7:150037890	RARRES2	0.66	6.94	0.49	1.08e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1997066	0.831	rs73340296	chr10:106815142	C/T	cg17321814	chr10:106440892	SORCS3	0.65	4.47	0.34	1.54e-5	Diabetic kidney disease;
PAAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.68	4.85	0.37	3e-6	Facial morphology (factor 23);
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.72	5.92	0.43	2.1e-8	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11965514	chr8:124253535	C8orf76	0.69	6.75	0.48	2.9e-10	Obesity-related traits;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg21784768	chr11:537496	LRRC56	-0.86	-4.43	-0.34	1.82e-5	Body mass index;
PAAD	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.62	0.53	2.59e-12	Schizophrenia;
PAAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg03037974	chr15:76606532	NA	-0.5	-5.86	-0.43	2.79e-8	Blood metabolite levels;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4740619	0.967	rs7025669	chr9:15654254	T/A	cg14451791	chr9:16040625	NA	-0.39	-4.5	-0.34	1.33e-5	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02838143	chr10:126606107	NA	0.65	7.33	0.51	1.26e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.97	11.67	0.69	7.2e-23	Osteoporosis;
PAAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.16	-0.5	3.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.74	8.23	0.56	7.82e-14	Prostate cancer;
PAAD	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg08436089	chr19:45594493	GEMIN7	-0.27	-4.3	-0.33	3.02e-5	Blood protein levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03033930	chr19:50905585	POLD1	0.64	6.47	0.46	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	7.63	0.53	2.42e-12	Mean platelet volume;
PAAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg03808351	chr9:123631620	PHF19	0.41	4.35	0.33	2.51e-5	Rheumatoid arthritis;
PAAD	cis	rs3112530	0.901	rs2973151	chr5:152656309	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.78	4.33	0.33	2.66e-5	Aging (time to event);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21403771	chr7:131241396	PODXL	0.57	6.68	0.48	4.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.55	5.55	0.41	1.23e-7	Coronary artery disease;
PAAD	cis	rs3996993	0.809	rs4715353	chr6:52703766	A/G	cg20803780	chr6:52668592	GSTA1	-0.35	-4.54	-0.35	1.12e-5	Hemoglobin concentration;
PAAD	cis	rs1142	0.507	rs2428161	chr7:104592567	A/G	cg04380332	chr7:105027541	SRPK2	-0.52	-5.23	-0.39	5.57e-7	Advanced age-related macular degeneration;
PAAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.37	-4.31	-0.33	2.88e-5	Type 2 diabetes;
PAAD	cis	rs988913	0.736	rs4588693	chr6:54878219	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-4.27	-0.33	3.49e-5	Menarche (age at onset);
PAAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg09760422	chr2:128146352	NA	-0.26	-4.29	-0.33	3.18e-5	Protein C levels;
PAAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.1	0.67	2.39e-21	Tonsillectomy;
PAAD	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg21937377	chr3:194868750	C3orf21	0.46	4.9	0.37	2.42e-6	Non-small cell lung cancer;
PAAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.96	0.63	2.65e-18	Cognitive function;
PAAD	cis	rs2236267	0.693	rs8008120	chr14:88622367	A/C	cg18078958	chr14:88630771	NA	-0.46	-5.94	-0.43	1.88e-8	Food antigen IgG levels;
PAAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.53	5.53	0.41	1.36e-7	Menopause (age at onset);
PAAD	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg20893717	chr7:100318190	EPO	0.46	5.2	0.39	6.42e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg14709524	chr16:89940631	TCF25	1.0	4.66	0.35	6.75e-6	Skin colour saturation;
PAAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.82	7.65	0.53	2.08e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.76	7.15	0.5	3.34e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg00543991	chr22:32367038	NA	1.17	7.35	0.51	1.12e-11	Childhood ear infection;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg04522676	chr10:134968826	NA	0.47	4.46	0.34	1.56e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.35	6.34e-6	Vitiligo;
PAAD	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg10011062	chr15:43941034	CATSPER2	-0.84	-4.83	-0.36	3.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.54	-5.63	-0.42	8.38e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg15604389	chr3:122379662	NA	0.55	5.79	0.43	3.92e-8	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04483336	chr17:5323402	RPAIN;NUP88	0.72	7.58	0.52	3.2e-12	Obesity-related traits;
PAAD	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.47	-4.65	-0.35	7.06e-6	Malaria;
PAAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs2286503	1.000	rs2286499	chr7:22857477	A/G	cg04907244	chr7:22894795	SNORD93	-0.43	-5.31	-0.4	3.84e-7	Fibrinogen;
PAAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.81	-0.43	3.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14169450	chr9:139327907	INPP5E	0.53	4.67	0.35	6.48e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs66530629	0.874	rs3120831	chr1:25094344	A/T	cg22509179	chr1:25234806	RUNX3	-0.49	-4.58	-0.35	9.76e-6	Plateletcrit;
PAAD	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	6.36	0.46	2.29e-9	Hip circumference;
PAAD	cis	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg21546286	chr11:48923668	NA	-0.57	-5.98	-0.44	1.5e-8	HDL cholesterol;
PAAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.61	-6.19	-0.45	5.25e-9	Schizophrenia;
PAAD	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.78	8.95	0.59	1.15e-15	Heart rate;
PAAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg17775713	chr3:133465469	TF	0.5	5.56	0.41	1.19e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.92	-9.04	-0.59	6.69e-16	Monocyte percentage of white cells;
PAAD	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.31	0.46	2.94e-9	IgG glycosylation;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.99	8.56	0.57	1.17e-14	Alzheimer's disease;
PAAD	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.97	10.71	0.66	2.69e-20	Corneal astigmatism;
PAAD	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.71	7.98	0.54	3.3e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg00012203	chr2:219082015	ARPC2	0.6	5.77	0.42	4.39e-8	Colorectal cancer;
PAAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	0.850	rs17157861	chr10:45990925	T/C	cg12869334	chr8:37699360	GPR124	0.98	6.53	0.47	9.52e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18397137	chr19:59055873	TRIM28	-0.63	-6.35	-0.46	2.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.79	4.84	0.37	3.19e-6	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg17796960	chr10:135278976	LOC619207	-0.42	-4.7	-0.36	5.79e-6	Systemic lupus erythematosus;
PAAD	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg13741927	chr9:139327495	INPP5E	0.44	4.4	0.34	2.02e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18621852	chr3:10150065	C3orf24	0.54	5.15	0.39	7.87e-7	Alzheimer's disease;
PAAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg10645314	chr2:3704589	ALLC	0.51	5.31	0.4	3.87e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.69	-6.82	-0.48	1.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-9.0	-0.59	8.45e-16	Morning vs. evening chronotype;
PAAD	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	5.33	0.4	3.5e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg15331088	chr8:600555	NA	0.74	4.77	0.36	4.37e-6	IgG glycosylation;
PAAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.56	6.2	0.45	5.04e-9	Major depressive disorder;
PAAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.98	-14.04	-0.75	2.98e-29	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs4740619	0.661	rs13297383	chr9:15944400	T/C	cg14451791	chr9:16040625	NA	-0.44	-5.06	-0.38	1.18e-6	Body mass index;
PAAD	cis	rs1983170	0.673	rs61798836	chr1:92013622	T/C	cg07011357	chr1:92949813	GFI1	-0.54	-4.3	-0.33	2.99e-5	Eosinophil percentage of white cells;
PAAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-4.33	-0.33	2.7e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.68	6.84	0.49	1.79e-10	Menarche (age at onset);
PAAD	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	7.25	0.51	1.97e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg08898775	chr15:59042684	ADAM10	0.39	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.55	-6.77	-0.48	2.57e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-4.81	-0.36	3.59e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.63	7.89	0.54	5.64e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.48	5.3	0.4	3.92e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg00035636	chr13:21900591	NA	0.63	6.68	0.48	4.29e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11664809	chr8:146126282	ZNF250	0.72	6.67	0.48	4.55e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10819733	chr22:24237672	NA	0.58	6.32	0.46	2.73e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.45	6.13	0.45	7.3e-9	Vitiligo;
PAAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg17346650	chr17:80929145	B3GNTL1	0.43	5.38	0.4	2.82e-7	Glycated hemoglobin levels;
PAAD	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg12633918	chr20:23549525	CST9L	-0.4	-4.43	-0.34	1.78e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1982963	0.627	rs61971552	chr14:52481524	G/T	cg20550154	chr14:52487779	NID2	0.57	4.62	0.35	8.07e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07706515	chr7:4830907	KIAA0415	0.58	6.92	0.49	1.21e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04102734	chr1:209406725	NA	0.58	6.67	0.48	4.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.81	-0.48	2.15e-10	Mood instability;
PAAD	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1008375	0.762	rs17499929	chr4:17590671	G/A	cg16339924	chr4:17578868	LAP3	0.62	6.26	0.45	3.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.47	-0.46	1.27e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.29	-5.48	-0.41	1.71e-7	Urinary metabolites;
PAAD	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-4.3	-0.33	3.05e-5	Tuberculosis;
PAAD	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-1.03	-13.62	-0.74	4.14e-28	Refractive error;
PAAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg09127314	chr1:152161683	NA	0.74	5.45	0.4	1.95e-7	Atopic dermatitis;
PAAD	cis	rs9287719	0.600	rs10197187	chr2:10726639	A/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg13444538	chr7:158905317	VIPR2	-0.71	-6.45	-0.46	1.45e-9	Facial morphology (factor 20);
PAAD	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.81	7.24	0.51	2.08e-11	Response to diuretic therapy;
PAAD	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.67	8.59	0.57	9.5e-15	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-4.8	-0.36	3.71e-6	Schizophrenia;
PAAD	cis	rs7567389	0.677	rs72846002	chr2:128118147	G/A	cg11380483	chr2:127933992	NA	0.47	4.68	0.36	6.18e-6	Self-rated health;
PAAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.84	9.57	0.61	2.78e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.46	4.61	0.35	8.4e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.7	-5.84	-0.43	3e-8	Type 2 diabetes;
PAAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.73	8.6	0.57	9.25e-15	Height;
PAAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-7.09	-0.5	4.66e-11	Gut microbiome composition (summer);
PAAD	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.47	-4.53	-0.34	1.19e-5	Breast cancer;
PAAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs7678296	1.000	rs59175692	chr4:37195539	C/T	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs329648	0.553	rs329653	chr11:133771179	G/A	cg12362517	chr11:133800685	IGSF9B	0.61	6.6	0.47	6.48e-10	Parkinson's disease;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg01762785	chr22:42226837	NA	-0.42	-4.63	-0.35	7.85e-6	Intelligence;
PAAD	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.42	0.4	2.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg19223190	chr17:80058835	NA	-0.54	-5.44	-0.4	2.1e-7	Life satisfaction;
PAAD	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-4.51	-0.34	1.31e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.49	-0.34	1.41e-5	Coronary artery disease;
PAAD	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.81	9.44	0.61	6.31e-17	Coronary artery disease;
PAAD	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.56	-5.97	-0.44	1.6e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs732765	0.734	rs12323392	chr14:75115673	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-4.52	-0.34	1.25e-5	Non-small cell lung cancer;
PAAD	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg00383909	chr3:49044727	WDR6	0.53	4.43	0.34	1.77e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.73	-0.36	5.09e-6	Type 2 diabetes;
PAAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.95	0.43	1.74e-8	Blood metabolite levels;
PAAD	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.85	9.68	0.62	1.49e-17	Body mass index;
PAAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg27511599	chr7:32358540	NA	0.72	4.38	0.33	2.23e-5	Body mass index;
PAAD	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1434579	0.865	rs12978546	chr19:44945947	C/A	cg23218533	chr19:44645662	ZNF234	-0.51	-4.3	-0.33	2.99e-5	Tuberculosis;
PAAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.7	7.57	0.52	3.42e-12	Blood metabolite levels;
PAAD	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.81	6.09	0.44	8.67e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg01831904	chr17:28903510	LRRC37B2	0.8	6.03	0.44	1.18e-8	Body mass index;
PAAD	cis	rs11828289	0.660	rs12099049	chr11:23219311	A/G	cg20040320	chr11:23191996	NA	-0.77	-5.48	-0.41	1.75e-7	Cancer;
PAAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg03264133	chr6:25882463	NA	-0.52	-4.46	-0.34	1.57e-5	Iron status biomarkers;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg21665744	chr7:39171113	POU6F2	0.39	5.88	0.43	2.53e-8	IgG glycosylation;
PAAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.59	-5.62	-0.41	9.07e-8	Monocyte count;
PAAD	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg20821713	chr7:1055600	C7orf50	-0.42	-4.56	-0.35	1.03e-5	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.92	0.43	2.06e-8	Prudent dietary pattern;
PAAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg21300403	chr2:198650112	BOLL	-0.64	-4.35	-0.33	2.49e-5	Ulcerative colitis;
PAAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.64	-5.8	-0.43	3.79e-8	Response to metformin (IC50);
PAAD	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.92	10.44	0.65	1.42e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.56	7.23	0.51	2.25e-11	Schizophrenia;
PAAD	cis	rs7101378	0.538	rs1509710	chr11:108900583	G/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.58	-5.32	-0.4	3.62e-7	Diisocyanate-induced asthma;
PAAD	cis	rs1497828	0.956	rs2646808	chr1:217523045	G/C	cg04411442	chr1:217543379	NA	-0.48	-4.76	-0.36	4.46e-6	Dialysis-related mortality;
PAAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.56	-5.41	-0.4	2.35e-7	Obesity-related traits;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	4.87	0.37	2.81e-6	Bipolar disorder;
PAAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02244288	chr16:89573955	SPG7	0.34	4.45	0.34	1.64e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.49	7.16	0.5	3.18e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	6.18	0.45	5.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs13102973	0.897	rs10434068	chr4:135840331	A/G	cg14419869	chr4:135874104	NA	0.56	5.9	0.43	2.31e-8	Subjective well-being;
PAAD	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg08807892	chr2:162101083	NA	-0.53	-4.75	-0.36	4.65e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24229701	chr12:130821962	PIWIL1	-0.42	-4.44	-0.34	1.71e-5	Menopause (age at onset);
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.56	-5.39	-0.4	2.61e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs4073221	0.585	rs7429106	chr3:18321125	A/G	cg07694806	chr3:18168406	NA	-0.62	-4.59	-0.35	9.18e-6	Parkinson's disease;
PAAD	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-5.17	-0.39	7.18e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02128981	chr11:58904901	NA	0.56	6.36	0.46	2.26e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg16576597	chr16:28551801	NUPR1	-0.71	-7.39	-0.51	9.04e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.77	6.11	0.44	7.91e-9	Diisocyanate-induced asthma;
PAAD	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg10223061	chr2:219282414	VIL1	0.36	4.36	0.33	2.43e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs370915	0.607	rs28548850	chr4:187786716	G/A	cg12892747	chr4:187813459	NA	-0.45	-4.6	-0.35	8.82e-6	Gout;
PAAD	cis	rs1497828	1.000	rs2646846	chr1:217564117	G/A	cg04411442	chr1:217543379	NA	0.51	5.06	0.38	1.21e-6	Dialysis-related mortality;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22269913	chr19:49956353	PIH1D1;ALDH16A1	-0.71	-7.26	-0.51	1.89e-11	Smoking initiation;
PAAD	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.22e-11	Life satisfaction;
PAAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15128208	chr22:42549153	NA	-0.47	-4.69	-0.36	6.11e-6	Cognitive function;
PAAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg05022225	chr19:49866942	DKKL1;TEAD2	0.62	6.16	0.45	6.29e-9	Multiple sclerosis;
PAAD	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.85	0.43	2.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg22517653	chr1:2918612	NA	-0.66	-5.37	-0.4	2.9e-7	Plateletcrit;
PAAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.49	-0.34	1.4e-5	Mean platelet volume;
PAAD	cis	rs9616064	0.778	rs73181048	chr22:46965493	C/T	cg03318428	chr22:46971703	NA	0.41	4.62	0.35	8.11e-6	Urate levels in obese individuals;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg17148978	chr1:151584446	SNX27	-0.58	-6.31	-0.46	2.9e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-7.74	-0.53	1.25e-12	Alcohol dependence;
PAAD	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.6	4.8	0.36	3.82e-6	Information processing speed;
PAAD	cis	rs12908161	0.650	rs182517	chr15:85389631	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	5.98	0.44	1.56e-8	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.91	12.38	0.71	8.64e-25	Prudent dietary pattern;
PAAD	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.21	0.39	6.15e-7	Myeloid white cell count;
PAAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.63	-6.18	-0.45	5.55e-9	Menopause (age at onset);
PAAD	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg05585544	chr11:47624801	NA	-0.51	-5.61	-0.41	9.22e-8	Subjective well-being;
PAAD	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg12963866	chr19:57752005	ZNF805	-0.46	-4.47	-0.34	1.51e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	8.01	0.54	2.77e-13	Lymphocyte counts;
PAAD	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	6.33	0.46	2.6e-9	Schizophrenia;
PAAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	4.6	0.35	8.82e-6	Iron status biomarkers;
PAAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.42	-0.34	1.88e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7623687	0.786	rs34290943	chr3:49161660	T/C	cg19401529	chr3:49056140	DALRD3	1.04	6.53	0.47	9.4e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.77	-5.52	-0.41	1.46e-7	Coronary artery disease;
PAAD	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-7.19	-0.5	2.73e-11	Monocyte count;
PAAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.29	-0.56	5.62e-14	Eye color traits;
PAAD	cis	rs16958440	1.000	rs2289131	chr18:44602864	G/A	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs16910800	1.000	rs16910800	chr11:23202785	C/T	cg20040320	chr11:23191996	NA	-0.61	-5.16	-0.39	7.57e-7	Cancer;
PAAD	cis	rs55788414	0.932	rs8059559	chr16:81185684	G/A	cg06400318	chr16:81190750	PKD1L2	1.06	7.94	0.54	4.04e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-8.91	-0.59	1.45e-15	Vitiligo;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25181236	chr4:56387275	CLOCK	-0.54	-6.6	-0.47	6.62e-10	Energy expenditure (24h);
PAAD	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg00922110	chr4:57842668	C4orf14	0.41	4.62	0.35	7.98e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg25204440	chr1:209979598	IRF6	0.62	5.39	0.4	2.64e-7	Coronary artery disease;
PAAD	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs4702	0.611	rs7177338	chr15:91428636	G/A	cg04510874	chr15:91427884	FES	-0.37	-4.34	-0.33	2.62e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2790216	1.000	rs1199099	chr10:59948335	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg21191810	chr6:118973309	C6orf204	0.47	5.99	0.44	1.44e-8	Electrocardiographic conduction measures;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.92	-0.49	1.21e-10	Neuroticism;
PAAD	cis	rs1642645	0.872	rs689277	chr1:42450371	C/T	cg01990334	chr1:42801334	FOXJ3	0.63	5.6	0.41	9.94e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg14393609	chr7:65229607	NA	0.63	6.69	0.48	4.08e-10	Calcium levels;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg21565972	chr17:80109576	CCDC57	0.56	6.47	0.46	1.26e-9	Life satisfaction;
PAAD	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	trans	rs6694672	1.000	rs1888991	chr1:197110822	A/G	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	8.19	0.55	1.01e-13	Exhaled nitric oxide output;
PAAD	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.84	8.69	0.58	5.39e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg24220031	chr2:73402428	NA	-0.35	-5.39	-0.4	2.7e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg27478167	chr7:817139	HEATR2	-0.77	-6.05	-0.44	1.1e-8	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	8.66	0.57	6.32e-15	Lymphocyte counts;
PAAD	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg23793686	chr15:68133972	NA	-0.51	-4.31	-0.33	2.92e-5	Obesity;
PAAD	cis	rs59888335	0.964	rs11127705	chr3:80665977	C/T	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg19847866	chr10:1019161	NA	-0.6	-4.69	-0.36	6.02e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.34	-0.33	2.56e-5	Educational attainment;
PAAD	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-5.14	-0.39	8.19e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	1.01	13.87	0.75	8.91e-29	Menarche (age at onset);
PAAD	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg22139774	chr2:100720529	AFF3	-0.37	-4.46	-0.34	1.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8040855	0.694	rs12908400	chr15:85573176	T/G	cg08123816	chr15:85640762	PDE8A	-0.41	-4.93	-0.37	2.15e-6	Bulimia nervosa;
PAAD	cis	rs12138061	0.954	rs11205658	chr1:50365194	A/G	cg09846084	chr1:50888024	DMRTA2	-0.54	-4.55	-0.35	1.1e-5	Schizophrenia;
PAAD	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.62	-5.91	-0.43	2.14e-8	Hip circumference;
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.56	-5.74	-0.42	5.02e-8	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9649465	0.967	rs3757505	chr7:123391641	C/T	cg04330084	chr7:123175371	IQUB	-0.49	-4.62	-0.35	8.05e-6	Migraine;
PAAD	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg16342193	chr10:102329863	NA	-0.74	-8.06	-0.55	2.15e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs10419226	0.604	rs12976741	chr19:18767477	G/A	cg14292368	chr19:18793705	CRTC1	-0.47	-4.94	-0.37	2.07e-6	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08583059	chr17:37887002	C17orf37	-0.68	-6.37	-0.46	2.11e-9	Lung cancer in ever smokers;
PAAD	cis	rs7534824	0.625	rs61780332	chr1:101484733	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg09835421	chr16:68378352	PRMT7	-1.16	-8.2	-0.55	9.36e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18621852	chr3:10150065	C3orf24	0.68	5.85	0.43	2.86e-8	Alzheimer's disease;
PAAD	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg13798912	chr7:905769	UNC84A	-0.6	-4.28	-0.33	3.31e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg24721873	chr10:135334122	NA	0.58	4.43	0.34	1.77e-5	Gout;
PAAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.72	7.0	0.49	7.6e-11	Recombination rate (males);
PAAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg07689907	chr11:61582574	FADS1	0.53	4.54	0.35	1.14e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg18281939	chr5:77783895	LHFPL2	-0.51	-5.77	-0.42	4.22e-8	Triglycerides;
PAAD	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.82	9.74	0.62	9.96e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.47	-0.34	1.55e-5	Breast cancer;
PAAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.59	6.94	0.49	1.08e-10	Immature fraction of reticulocytes;
PAAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26545872	chr15:48681184	NA	-0.63	-6.54	-0.47	9.01e-10	Obesity-related traits;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.64	4.43	0.34	1.8e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.59	4.79	0.36	3.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2290419	0.730	rs76291348	chr11:68944514	T/G	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.42	0.34	1.84e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.65	-5.89	-0.43	2.36e-8	White matter hyperintensity burden;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.75	5.61	0.41	9.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg26939375	chr7:64535504	NA	-0.54	-5.89	-0.43	2.34e-8	Aortic root size;
PAAD	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.76	-8.54	-0.57	1.28e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	1.13	16.05	0.79	1.59e-34	Systemic lupus erythematosus;
PAAD	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg00277334	chr10:82204260	NA	0.56	5.63	0.42	8.64e-8	Post bronchodilator FEV1;
PAAD	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Educational attainment;
PAAD	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	5.57	0.41	1.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg08917208	chr2:24149416	ATAD2B	0.5	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18174246	chr2:43454224	ZFP36L2;LOC100129726	0.7	7.25	0.51	1.96e-11	Obesity-related traits;
PAAD	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg26585981	chr11:48327164	OR4S1	-0.5	-4.44	-0.34	1.72e-5	Migraine - clinic-based;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.74	-8.48	-0.57	1.83e-14	Renal function-related traits (BUN);
PAAD	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg24845578	chr5:95170808	NA	-0.62	-6.54	-0.47	8.91e-10	Body mass index;
PAAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.8	6.1	0.44	8.24e-9	Gut microbiome composition (summer);
PAAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.64	0.35	7.48e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.75	-6.15	-0.45	6.47e-9	Schizophrenia;
PAAD	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	1.09	15.35	0.78	1.02e-32	Breast cancer;
PAAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.82	-0.54	8.12e-13	Body mass index;
PAAD	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.5	4.91	0.37	2.34e-6	Psoriasis;
PAAD	cis	rs1008126	0.642	rs2382689	chr7:103097457	G/A	cg04218035	chr7:103086829	SLC26A5	0.35	4.98	0.37	1.72e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.55e-21	Breast cancer;
PAAD	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.49	7.84	0.54	7.48e-13	Neuroticism;
PAAD	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.7	7.74	0.53	1.27e-12	Prostate cancer;
PAAD	cis	rs747650	0.532	rs3922684	chr11:47121176	T/C	cg19486271	chr11:47235900	DDB2	0.68	6.3	0.45	3.07e-9	Acne (severe);
PAAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.54	5.7	0.42	5.93e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.46	-4.97	-0.37	1.82e-6	Educational attainment;
PAAD	cis	rs1075265	0.554	rs10168293	chr2:54200930	G/A	cg04546899	chr2:54196757	PSME4	0.32	4.81	0.36	3.57e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg14926445	chr8:58193284	C8orf71	-0.73	-5.53	-0.41	1.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.58	-5.72	-0.42	5.44e-8	Motion sickness;
PAAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-4.85	-0.37	2.99e-6	Fibrinogen levels;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.67	10.51	0.65	9.34e-20	Schizophrenia;
PAAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.7	-6.9	-0.49	1.32e-10	Asthma;
PAAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-7.36	-0.51	1.08e-11	Initial pursuit acceleration;
PAAD	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.73	8.21	0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-5.7	-0.42	6.04e-8	Schizophrenia;
PAAD	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.83	-4.72	-0.36	5.37e-6	Lung cancer in ever smokers;
PAAD	cis	rs13102973	0.965	rs13129208	chr4:135858263	A/G	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.89	11.58	0.68	1.21e-22	Body mass index;
PAAD	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.65	-7.1	-0.5	4.38e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	1.11	15.82	0.79	6.29e-34	Systemic lupus erythematosus;
PAAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.51	5.22	0.39	5.73e-7	Menopause (age at onset);
PAAD	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-11.6	-0.69	1.09e-22	Chronic sinus infection;
PAAD	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.38	0.56	3.29e-14	Homoarginine levels;
PAAD	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.61	-6.76	-0.48	2.76e-10	Testicular germ cell tumor;
PAAD	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg05373962	chr22:49881684	NA	-0.48	-4.72	-0.36	5.34e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11892454	0.533	rs10469884	chr2:26101632	G/T	cg25181710	chr2:26045287	ASXL2	0.39	4.32	0.33	2.78e-5	Heschl's gyrus morphology;
PAAD	cis	rs61905145	1	rs61905145	chr11:116718415	G/A	cg04087571	chr11:116723030	SIK3	-0.45	-4.58	-0.35	9.66e-6	Subjective well-being;
PAAD	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.52	5.42	0.4	2.3e-7	Quantitative traits;
PAAD	cis	rs3136739	0.614	rs12543326	chr8:42003663	G/A	cg17828057	chr8:42037527	PLAT	0.62	4.27	0.33	3.41e-5	Plasma plasminogen activator levels;
PAAD	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.92	11.97	0.7	1.08e-23	Mean corpuscular volume;
PAAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.62	-5.72	-0.42	5.4e-8	Multiple myeloma;
PAAD	cis	rs669446	0.591	rs649504	chr1:44105948	T/C	cg12908607	chr1:44402522	ARTN	-0.41	-4.37	-0.33	2.26e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7301826	0.557	rs7953184	chr12:131284852	T/G	cg11011512	chr12:131303247	STX2	-0.51	-5.29	-0.39	4.22e-7	Plasma plasminogen activator levels;
PAAD	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-4.92	-0.37	2.21e-6	Urinary tract infection frequency;
PAAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg17372223	chr3:52568218	NT5DC2	0.47	4.54	0.35	1.16e-5	Bipolar disorder;
PAAD	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.43	4.3	0.33	2.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.22	5.04	0.38	1.31e-6	Urinary tract infection frequency;
PAAD	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs797680	0.856	rs637646	chr1:93716383	A/C	cg04535902	chr1:92947332	GFI1	-0.45	-4.32	-0.33	2.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg13447295	chr6:887704	NA	-0.54	-4.97	-0.37	1.81e-6	Aging;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg22705602	chr4:152727874	NA	0.47	5.03	0.38	1.39e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg05579598	chr16:88989069	CBFA2T3	0.67	10.17	0.64	7.37e-19	Social autistic-like traits;
PAAD	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-5.69	-0.42	6.41e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.76	9.11	0.59	4.4e-16	Neuroticism;
PAAD	cis	rs988913	1.000	rs1393772	chr6:54838388	C/T	cg03513858	chr6:54763001	FAM83B	-0.42	-4.62	-0.35	8.22e-6	Menarche (age at onset);
PAAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.26	4.52	0.34	1.23e-5	Asthma;
PAAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg22710661	chr11:17411071	KCNJ11	0.46	4.69	0.36	5.94e-6	Type 2 diabetes;
PAAD	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.6	-6.08	-0.44	9.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.25	-5.12	-0.38	9.25e-7	Urinary metabolites;
PAAD	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.59	-0.35	9.09e-6	Pulmonary function;
PAAD	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.91	-8.12	-0.55	1.49e-13	IgG glycosylation;
PAAD	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.83	-5.88	-0.43	2.45e-8	Coronary artery disease;
PAAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.44	5.66	0.42	7.21e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg15832292	chr6:96025679	MANEA	0.58	4.27	0.33	3.42e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.15	7.97	0.54	3.51e-13	Thyroid stimulating hormone;
PAAD	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.86	8.08	0.55	1.92e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.9	-0.37	2.46e-6	Bipolar disorder;
PAAD	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-4.9	-0.37	2.46e-6	Personality dimensions;
PAAD	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.0	-0.44	1.39e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17347941	chr15:79387269	NA	-0.38	-4.32	-0.33	2.75e-5	Refractive error;
PAAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg14343924	chr8:8086146	FLJ10661	0.45	4.43	0.34	1.77e-5	Joint mobility (Beighton score);
PAAD	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.55	-0.47	8.27e-10	HDL cholesterol;
PAAD	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg21300403	chr2:198650112	BOLL	0.48	4.28	0.33	3.35e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.63	-0.35	7.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.69	-8.02	-0.55	2.62e-13	Age at first birth;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08766915	chr7:35734704	HERPUD2	-0.55	-6.43	-0.46	1.59e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	0.98	7.13	0.5	3.71e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg14346243	chr4:90757452	SNCA	-0.53	-4.68	-0.35	6.33e-6	Neuroticism;
PAAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.53	-4.94	-0.37	2.03e-6	Neurofibrillary tangles;
PAAD	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg27326032	chr3:127006922	NA	-0.7	-6.58	-0.47	7.03e-10	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg23461800	chr14:103021989	NA	-0.68	-4.86	-0.37	2.9e-6	Platelet count;
PAAD	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.63	-6.13	-0.44	7.4e-9	Primary sclerosing cholangitis;
PAAD	cis	rs2274459	1.000	rs3793080	chr6:33767803	A/G	cg06253072	chr6:33679850	C6orf125	-0.65	-4.7	-0.36	5.85e-6	Obesity (extreme);
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs10810935	0.689	rs10963462	chr9:18130036	G/T	cg01356653	chr12:50135491	TMBIM6	-0.79	-6.42	-0.46	1.63e-9	Alcohol dependence (age at onset);
PAAD	cis	rs4743820	0.503	rs10820835	chr9:93921227	C/T	cg14446406	chr9:93919335	NA	0.37	5.1	0.38	9.79e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.9	0.69	1.7e-23	Corneal structure;
PAAD	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.72	-7.46	-0.52	6.14e-12	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Primary biliary cholangitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18765479	chr12:132426275	PUS1	0.61	7.06	0.5	5.65e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg09473613	chr1:24152604	HMGCL	0.53	5.6	0.41	9.95e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg02887458	chr19:19495540	GATAD2A	-0.57	-5.42	-0.4	2.29e-7	Bipolar disorder;
PAAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.31e-6	Diastolic blood pressure;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11071397	chr17:73401925	GRB2	0.67	6.94	0.49	1.05e-10	Primary biliary cholangitis;
PAAD	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg11232448	chr19:2858854	NA	-0.46	-4.44	-0.34	1.74e-5	Total cholesterol levels;
PAAD	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.93	6.46	0.46	1.31e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.84	7.39	0.51	9.35e-12	IgG glycosylation;
PAAD	cis	rs75920871	0.748	rs7946399	chr11:116962753	G/C	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12123211	chr11:47290893	MADD	0.55	6.56	0.47	8.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs12612619	0.579	rs13029206	chr2:27077610	G/A	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.38	-0.33	2.22e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	5.97	0.44	1.59e-8	Schizophrenia;
PAAD	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg11177333	chr3:195857752	NA	0.45	4.3	0.33	3.07e-5	Non-small cell lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25157839	chr3:43626312	ANO10	-0.66	-6.67	-0.48	4.45e-10	Obesity-related traits;
PAAD	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg25050447	chr17:78165522	CARD14	0.36	4.44	0.34	1.71e-5	Yeast infection;
PAAD	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg16419906	chr5:132167176	NA	-0.61	-4.9	-0.37	2.4e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.75	0.53	1.21e-12	Prudent dietary pattern;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04740258	chr3:138553760	NA	-0.67	-7.98	-0.54	3.23e-13	Body fat percentage;
PAAD	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.7	-7.87	-0.54	6.32e-13	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17310611	chr1:113615709	LRIG2	0.58	6.6	0.47	6.51e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	7.65	0.53	2.14e-12	Educational attainment;
PAAD	cis	rs12773846	0.568	rs34635407	chr10:126267537	G/T	cg04949429	chr10:126290192	LHPP	0.64	5.71	0.42	5.64e-8	Subcutaneous adipose tissue;
PAAD	cis	rs12620038	0.525	rs7598661	chr2:47468955	C/T	cg13204236	chr2:47476732	NA	0.34	4.8	0.36	3.7e-6	Survival in pancreatic cancer;
PAAD	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg18898632	chr2:242989856	NA	-0.66	-5.03	-0.38	1.36e-6	Obesity-related traits;
PAAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.6	7.11	0.5	4.26e-11	Age at first birth;
PAAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg03959625	chr15:84868606	LOC388152	0.43	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs2908197	1.000	rs2908197	chr7:75937049	C/T	cg24580635	chr7:76178542	LOC100133091	0.46	4.35	0.33	2.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.37	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.51	-4.8	-0.36	3.83e-6	Multiple sclerosis;
PAAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.28e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.49	6.15	0.45	6.39e-9	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg18279126	chr7:2041391	MAD1L1	0.6	5.77	0.42	4.4e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg06697600	chr4:7070879	GRPEL1	0.8	5.11	0.38	9.67e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.62	5.55	0.41	1.22e-7	Mean platelet volume;
PAAD	cis	rs4455778	0.538	rs6583513	chr7:49123526	G/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs4742903	0.870	rs10991171	chr9:106976150	G/T	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.09e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs939584	1.000	rs4854347	chr2:641159	A/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7243821	1.000	rs4277423	chr18:52644244	T/C	cg16669619	chr18:52630472	NA	-0.43	-4.31	-0.33	2.94e-5	Chin dimples;
PAAD	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-5.82	-0.43	3.43e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs755249	0.567	rs16825887	chr1:39643382	A/G	cg14018543	chr1:39659967	MACF1	0.57	4.73	0.36	5.09e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.28	-0.45	3.39e-9	Hip circumference;
PAAD	cis	rs7567389	0.534	rs2069904	chr2:128175779	G/A	cg09760422	chr2:128146352	NA	0.4	5.99	0.44	1.43e-8	Self-rated health;
PAAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.58	6.49	0.47	1.12e-9	Blood metabolite levels;
PAAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.69	-0.58	5.25e-15	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg18612461	chr15:75251733	NA	-0.56	-6.98	-0.49	8.36e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.53	5.28	0.39	4.35e-7	Migraine;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg26459473	chr2:236838291	AGAP1	0.63	6.71	0.48	3.55e-10	Educational attainment (years of education);
PAAD	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.28	-0.33	3.31e-5	Aortic root size;
PAAD	cis	rs302972	0.826	rs303005	chr6:25086644	G/A	cg09546929	chr6:25930894	SLC17A2	0.77	4.37	0.33	2.29e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs790110	1.000	rs812047	chr3:122382074	C/G	cg16054280	chr3:122517974	DIRC2	0.86	4.53	0.34	1.21e-5	Acoustic startle blink response;
PAAD	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg07384165	chr1:10488281	NA	0.49	4.81	0.36	3.6e-6	Prostate cancer;
PAAD	cis	rs5753037	0.702	rs140143	chr22:30173109	G/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.57	-0.35	1.01e-5	Type 1 diabetes;
PAAD	cis	rs501120	1.000	rs1746047	chr10:44774086	T/G	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.48	4.68	0.36	6.19e-6	Lung cancer;
PAAD	cis	rs9535307	0.719	rs1009333	chr13:50383341	T/C	cg04663916	chr13:50265991	EBPL	-0.57	-4.31	-0.33	2.94e-5	Obesity-related traits;
PAAD	cis	rs16958440	0.581	rs11082564	chr18:44659149	C/G	cg17192377	chr18:44677553	HDHD2	0.61	4.26	0.33	3.51e-5	Sitting height ratio;
PAAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.82	7.36	0.51	1.08e-11	Coronary artery disease;
PAAD	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.06	0.5	5.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.7	-7.19	-0.5	2.78e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-14.1	-0.75	2.14e-29	Primary sclerosing cholangitis;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12738264	chr7:148725795	PDIA4	0.58	6.3	0.46	3.04e-9	Response to antipsychotic treatment;
PAAD	cis	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg00614314	chr15:82944287	LOC80154	0.47	4.78	0.36	4.07e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-5.57	-0.41	1.14e-7	Vitiligo;
PAAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.77	-5.52	-0.41	1.46e-7	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg26818257	chr2:241905806	NA	-0.46	-4.86	-0.37	2.92e-6	Joint mobility (Beighton score);
PAAD	cis	rs360071	0.528	rs360093	chr1:226064745	G/T	cg25552768	chr1:226077287	LEFTY1	0.44	4.78	0.36	4.08e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg14686297	chr22:46650375	NA	-0.44	-4.41	-0.34	1.95e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15145965	chr22:50218605	BRD1	0.54	4.61	0.35	8.37e-6	Schizophrenia;
PAAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-7.72	-0.53	1.48e-12	Systemic lupus erythematosus;
PAAD	cis	rs6782025	1.000	rs6806191	chr3:121160878	C/T	cg16417163	chr3:121280760	NA	-0.48	-4.85	-0.37	3e-6	Aging (facial);
PAAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.0	11.08	0.67	2.7e-21	Homoarginine levels;
PAAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.72	8.33	0.56	4.29e-14	Emphysema distribution in smoking;
PAAD	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg03352657	chr17:26684557	POLDIP2;TMEM199	0.64	6.68	0.48	4.26e-10	Primary biliary cholangitis;
PAAD	cis	rs11807834	0.522	rs3811489	chr1:230239259	T/C	cg09847368	chr1:230250326	GALNT2	-0.67	-8.22	-0.55	8.12e-14	Schizophrenia;
PAAD	cis	rs13070279	0.582	rs34586454	chr3:71799897	C/G	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg05110241	chr16:68378359	PRMT7	0.85	5.24	0.39	5.26e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20231940	chr2:129075198	HS6ST1	0.66	6.41	0.46	1.76e-9	Obesity-related traits;
PAAD	cis	rs12210050	1.000	rs12210050	chr6:475489	C/T	cg26187313	chr6:475429	NA	-0.55	-4.87	-0.37	2.73e-6	Tanning;Basal cell carcinoma;Schizophrenia;
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.94	-13.55	-0.74	6.26e-28	Age at first birth;
PAAD	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.52	-6.12	-0.44	7.7e-9	Alcohol dependence;
PAAD	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.34	-4.6	-0.35	8.66e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-7.07	-0.5	5.17e-11	Eye color traits;
PAAD	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.3	7.97	0.54	3.46e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg16342193	chr10:102329863	NA	-0.77	-8.33	-0.56	4.39e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21573947	chr3:65619088	MAGI1	0.58	6.61	0.47	6.04e-10	Smoking initiation;
PAAD	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg00277334	chr10:82204260	NA	-0.56	-5.73	-0.42	5.35e-8	Post bronchodilator FEV1;
PAAD	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.68	4.98	0.37	1.67e-6	Vitiligo;
PAAD	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.59	5.45	0.4	1.95e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06214831	chr4:8154121	ABLIM2	0.64	6.33	0.46	2.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2455799	1.000	rs1348983	chr3:15900429	A/C	cg13420985	chr3:16524424	RFTN1	-0.46	-4.33	-0.33	2.65e-5	Mean platelet volume;
PAAD	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg15660573	chr17:549704	VPS53	-0.76	-7.67	-0.53	1.94e-12	Prostate cancer;
PAAD	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-6.82	-0.48	2.07e-10	Monocyte percentage of white cells;
PAAD	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.53	5.73	0.42	5.25e-8	Schizophrenia;
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	5.46	0.4	1.89e-7	Obesity-related traits;
PAAD	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.61	-5.76	-0.42	4.53e-8	Obesity-related traits;
PAAD	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.68	6.22	0.45	4.55e-9	Platelet count;
PAAD	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.42	-4.65	-0.35	7.06e-6	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10657547	chr5:150632246	GM2A	-0.7	-6.39	-0.46	1.9e-9	Neuroticism;
PAAD	cis	rs1134634	1.000	rs1134634	chr4:15603069	C/G	cg16509355	chr4:15471240	CC2D2A	0.36	4.39	0.34	2.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs317865	0.867	rs73234637	chr4:16178866	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.93	6.5	0.47	1.1e-9	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.84	-9.11	-0.59	4.39e-16	Mortality in heart failure;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.66	7.03	0.5	6.6e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.51	5.61	0.41	9.25e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	4.99	0.38	1.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35740288	0.822	rs17637142	chr15:86240503	T/C	cg07943548	chr15:86304357	KLHL25	-0.64	-5.45	-0.4	1.95e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.6	-5.2	-0.39	6.41e-7	Resistin levels;
PAAD	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg09075268	chr16:1270372	CACNA1H	0.48	4.61	0.35	8.56e-6	Blood protein levels;
PAAD	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	1.02	12.06	0.7	6.26e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs288342	0.797	rs288294	chr2:183630328	T/C	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.86	-0.54	6.37e-13	Hemoglobin concentration;
PAAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg14820908	chr5:178986412	RUFY1	-0.62	-6.49	-0.47	1.17e-9	Lung cancer;
PAAD	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.44	5.52	0.41	1.42e-7	Mean corpuscular volume;
PAAD	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.76	8.19	0.55	9.75e-14	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg08198773	chr8:1697536	NA	0.42	4.63	0.35	7.78e-6	Systolic blood pressure;
PAAD	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	7.26	0.51	1.91e-11	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7707921	1.000	rs891159	chr5:81491087	A/G	cg21483461	chr5:81570383	RPS23	-0.51	-4.32	-0.33	2.83e-5	Breast cancer;
PAAD	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg12633918	chr20:23549525	CST9L	-0.42	-4.59	-0.35	9.16e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.45	0.4	1.98e-7	Life satisfaction;
PAAD	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.53	6.22	0.45	4.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.86	-0.37	2.89e-6	Bone mineral density;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.55	5.54	0.41	1.29e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.68	6.78	0.48	2.56e-10	Alcohol dependence;
PAAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.63	-7.28	-0.51	1.65e-11	Huntington's disease progression;
PAAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.64	-7.22	-0.51	2.34e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.37	0.4	2.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.7	-0.36	5.82e-6	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09504196	chr7:148823235	ZNF425;ZNF398	0.62	7.14	0.5	3.57e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.64	-4.53	-0.35	1.18e-5	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
PAAD	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg05935833	chr10:81318306	SFTPA2	-0.66	-4.78	-0.36	4.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg27205649	chr11:78285834	NARS2	0.62	4.44	0.34	1.72e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg03605463	chr16:89740564	NA	-0.52	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.44	5.64	0.42	8.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg19026207	chr17:26645466	TMEM97	-0.4	-4.38	-0.33	2.19e-5	Osteoprotegerin levels;
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg13206674	chr6:150067644	NUP43	0.64	6.79	0.48	2.37e-10	Testicular germ cell tumor;
PAAD	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-5.25	-0.39	5.08e-7	Coronary artery disease;
PAAD	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.35	-12.67	-0.72	1.42e-25	Corneal structure;
PAAD	cis	rs11260013	0.839	rs12973278	chr19:7758158	G/C	cg04764898	chr19:7562249	C19orf45	0.41	4.33	0.33	2.7e-5	Blood protein levels;
PAAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg04160749	chr8:58172571	NA	0.67	4.8	0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10943724	0.704	rs4706851	chr6:81273266	C/T	cg19323245	chr6:80716898	TTK	-0.42	-4.49	-0.34	1.38e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg20295408	chr7:1910781	MAD1L1	0.54	5.25	0.39	4.99e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16262614	chr3:133464971	TF	0.5	5.43	0.4	2.22e-7	Iron status biomarkers;
PAAD	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs2247341	0.577	rs2236996	chr4:1703646	A/G	cg05874882	chr4:1763078	NA	-0.27	-4.64	-0.35	7.45e-6	Hip circumference adjusted for BMI;Height;
PAAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.13	-0.55	1.42e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.79	-7.85	-0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg03094675	chr11:5960213	NA	-0.46	-4.26	-0.33	3.57e-5	DNA methylation (variation);
PAAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.32	-0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.55	-5.89	-0.43	2.45e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg13271783	chr10:134563150	INPP5A	-0.61	-6.12	-0.44	7.73e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09695851	chr17:3907499	NA	-0.83	-9.04	-0.59	6.97e-16	Type 2 diabetes;
PAAD	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.71	-6.66	-0.48	4.75e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25833597	chr17:30823145	MYO1D	-0.52	-5.0	-0.38	1.55e-6	Schizophrenia;
PAAD	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.74e-8	Life satisfaction;
PAAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg12215294	chr3:40350768	EIF1B	-0.48	-4.53	-0.34	1.2e-5	Renal cell carcinoma;
PAAD	cis	rs863345	0.564	rs7540999	chr1:158504570	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06680921	chr19:41903350	BCKDHA;EXOSC5	0.59	6.58	0.47	7.26e-10	Monocyte percentage of white cells;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg16714605	chr19:10765132	ILF3;LOC147727	0.63	6.39	0.46	1.94e-9	Primary biliary cholangitis;
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg05457628	chr5:178986728	RUFY1	0.56	5.39	0.4	2.68e-7	Lung cancer;
PAAD	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg01338255	chr20:30176054	NA	0.46	4.3	0.33	3.09e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.52	4.87	0.37	2.76e-6	Monocyte count;
PAAD	cis	rs7711186	0.529	rs10035557	chr5:178026573	G/T	cg07427642	chr5:177944298	COL23A1	0.65	4.3	0.33	3.09e-5	Urate levels in obese individuals;
PAAD	cis	rs12612619	0.732	rs11126857	chr2:27297757	G/A	cg00617064	chr2:27272375	NA	0.54	5.81	0.43	3.62e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.67	-7.68	-0.53	1.84e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.5	4.83	0.37	3.24e-6	Endometrial cancer;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg11218175	chr11:495084	RNH1	0.76	4.35	0.33	2.45e-5	Body mass index;
PAAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.75	7.47	0.52	5.87e-12	Corneal astigmatism;
PAAD	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.6	5.45	0.4	1.99e-7	Retinal vascular caliber;
PAAD	cis	rs6066835	1.000	rs6095270	chr20:47356062	T/C	cg18078177	chr20:47281410	PREX1	0.98	4.49	0.34	1.39e-5	Multiple myeloma;
PAAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	8.77	0.58	3.46e-15	Colorectal cancer;
PAAD	cis	rs7188861	0.681	rs72773819	chr16:11406792	C/A	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24368962	chr11:111570978	SIK2	-0.69	-6.92	-0.49	1.16e-10	Obesity-related traits;
PAAD	cis	rs10851478	0.529	rs12901929	chr15:49675308	T/C	cg14549078	chr15:48752032	FBN1	0.34	4.48	0.34	1.46e-5	Oral cavity cancer;
PAAD	cis	rs1499972	0.529	rs2062509	chr3:117803039	T/G	cg07612923	chr3:117604196	NA	-0.74	-5.3	-0.39	4e-7	Schizophrenia;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.73	-0.48	3.17e-10	Bipolar disorder;
PAAD	cis	rs364477	0.762	rs9299103	chr9:1001231	G/T	cg13952963	chr9:998547	NA	-0.6	-4.49	-0.34	1.43e-5	Major depressive disorder;
PAAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs62264129	0.500	rs62278771	chr3:112030789	G/A	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.05	-0.38	1.25e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4899554	0.640	rs1569328	chr14:75741751	A/G	cg18117039	chr14:75741733	NA	-0.42	-4.88	-0.37	2.61e-6	Inflammatory bowel disease;
PAAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.57	-0.41	1.12e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.64	5.85	0.43	2.96e-8	Mean platelet volume;
PAAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg06740227	chr12:86229804	RASSF9	0.54	4.93	0.37	2.15e-6	Major depressive disorder;
PAAD	cis	rs1569175	1.000	rs281777	chr2:200839613	T/C	cg23649088	chr2:200775458	C2orf69	-0.89	-5.16	-0.39	7.71e-7	Response to treatment for acute lymphoblastic leukemia;
PAAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg22138327	chr13:27999177	GTF3A	0.77	6.45	0.46	1.4e-9	Weight;
PAAD	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	trans	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg01620082	chr3:125678407	NA	-1.46	-7.4	-0.51	8.48e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.63	6.55	0.47	8.43e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs7119038	0.865	rs4938573	chr11:118741842	C/T	cg04176122	chr11:118779835	BCL9L	-0.46	-4.59	-0.35	9.25e-6	Sjögren's syndrome;
PAAD	cis	rs7766436	0.614	rs2066335	chr6:22566590	C/T	cg13666174	chr6:22585274	NA	-0.5	-4.45	-0.34	1.64e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10338465	chr15:78424072	CIB2	0.57	6.47	0.46	1.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs375066	0.935	rs425217	chr19:44393975	C/T	cg11993925	chr19:44307056	LYPD5	0.55	6.95	0.49	9.87e-11	Breast cancer;
PAAD	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.78	8.98	0.59	9.75e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs73206853	0.534	rs73205062	chr12:110511136	G/C	cg12870014	chr12:110450643	ANKRD13A	0.84	5.03	0.38	1.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06322639	chr15:80883928	ARNT2	0.59	6.33	0.46	2.58e-9	Warfarin maintenance dose;
PAAD	cis	rs6494488	0.500	rs72744714	chr15:65016050	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg24747557	chr10:131355152	MGMT	-0.44	-4.76	-0.36	4.48e-6	Response to temozolomide;
PAAD	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.55	4.68	0.35	6.41e-6	Blood metabolite levels;
PAAD	cis	rs793571	0.822	rs17302038	chr15:59168802	G/A	cg05156742	chr15:59063176	FAM63B	0.59	4.71	0.36	5.44e-6	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.49	-0.34	1.38e-5	Breast cancer;
PAAD	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	6.28	0.45	3.41e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg16606324	chr3:10149918	C3orf24	0.68	4.8	0.36	3.82e-6	Alzheimer's disease;
PAAD	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.41	4.9	0.37	2.4e-6	Uric acid levels;
PAAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.88	0.37	2.62e-6	Myopia (pathological);
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20887711	chr4:1340912	KIAA1530	0.47	4.57	0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.58	5.64	0.42	8.16e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.11	0.38	9.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.72	8.77	0.58	3.33e-15	Motion sickness;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14215459	chr19:10764813	ILF3;LOC147727	0.58	6.53	0.47	9.13e-10	Pancreatic cancer;
PAAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg23947450	chr7:900037	UNC84A	-0.51	-4.25	-0.33	3.78e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.54	0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.57	-6.35	-0.46	2.38e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.82	9.78	0.62	7.88e-18	Monocyte percentage of white cells;
PAAD	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-6.07	-0.44	9.59e-9	Schizophrenia;
PAAD	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.49	-4.75	-0.36	4.74e-6	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03041730	chr4:903314	GAK	0.56	6.51	0.47	1.03e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.92	8.31	0.56	4.88e-14	Gut microbiome composition (summer);
PAAD	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg04450456	chr4:17643702	FAM184B	0.46	4.85	0.37	3.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg08390786	chr10:135334061	NA	0.49	4.71	0.36	5.57e-6	Obesity-related traits;
PAAD	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.36	-0.33	2.35e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg19337854	chr7:99768885	GPC2	0.51	5.31	0.4	3.84e-7	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg07362569	chr17:61921086	SMARCD2	0.42	4.78	0.36	4.04e-6	Height;
PAAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.35	-0.68	5.25e-22	Height;
PAAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08989932	chr10:65390526	NA	-0.77	-6.92	-0.49	1.18e-10	Neuroticism;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg10985347	chr2:127963512	CYP27C1	0.49	4.73	0.36	5.17e-6	Protein C levels;
PAAD	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.39	0.46	1.97e-9	Morning vs. evening chronotype;
PAAD	cis	rs10267417	0.603	rs10263119	chr7:19872844	C/G	cg05791153	chr7:19748676	TWISTNB	0.68	4.5	0.34	1.32e-5	Night sleep phenotypes;
PAAD	cis	rs11252926	0.529	rs10904398	chr10:562805	G/A	cg18196295	chr10:418757	DIP2C	0.42	4.47	0.34	1.54e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs1903068	0.785	rs12331538	chr4:55998086	A/C	cg20092376	chr4:56023423	NA	0.43	4.25	0.33	3.71e-5	Endometriosis;
PAAD	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.54	5.19	0.39	6.73e-7	Pancreatic cancer;
PAAD	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	4.72	0.36	5.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-5.49	-0.41	1.69e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.69	8.75	0.58	3.76e-15	Coronary artery disease;
PAAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.49	5.8	0.43	3.77e-8	Height;
PAAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.78	0.62	7.97e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg25722041	chr1:8623473	RERE	-0.54	-4.65	-0.35	7.11e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04745698	chr10:12084977	UPF2	0.6	6.65	0.47	5.02e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg14773178	chr5:1868261	NA	0.35	4.7	0.36	5.73e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7945718	0.621	rs6485989	chr11:12695171	C/T	cg25843174	chr11:12811716	TEAD1	0.32	4.65	0.35	7.03e-6	Educational attainment (years of education);
PAAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg18892244	chr7:807596	HEATR2	0.71	5.48	0.41	1.69e-7	Initial pursuit acceleration;
PAAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.62	6.69	0.48	4.09e-10	Lung cancer;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.45	-0.4	1.95e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	1.01	7.59	0.52	2.94e-12	Dental caries;
PAAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.75	8.64	0.57	7.03e-15	Methadone dose in opioid dependence;
PAAD	cis	rs10916814	0.610	rs1890005	chr1:20899016	T/C	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-4.6	-0.35	9.02e-6	Dupuytren's disease;
PAAD	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26926768	chr12:34528122	NA	0.37	4.64	0.35	7.48e-6	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.565	rs11117105	chr12:86319157	A/G	cg06740227	chr12:86229804	RASSF9	0.47	4.27	0.33	3.4e-5	Major depressive disorder;
PAAD	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.97	0.49	9.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.54	0.71	3.2e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8083432	0.733	rs112613248	chr18:22708494	C/T	cg13981356	chr18:22006370	IMPACT	0.66	4.73	0.36	5.17e-6	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg01631408	chr1:248437212	OR2T33	0.61	5.89	0.43	2.38e-8	Common traits (Other);
PAAD	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.65	6.89	0.49	1.41e-10	Testicular germ cell tumor;
PAAD	cis	rs655641	0.520	rs677909	chr11:85757589	C/T	cg07180834	chr11:85838833	NA	-0.44	-4.98	-0.37	1.74e-6	Platelet count;
PAAD	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg10167378	chr1:228756711	NA	0.43	4.25	0.33	3.65e-5	Diastolic blood pressure;
PAAD	cis	rs1519814	0.659	rs7829279	chr8:121023514	A/G	cg22335954	chr8:121166405	COL14A1	-0.64	-4.97	-0.37	1.82e-6	Breast cancer;
PAAD	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.02	11.36	0.68	4.9e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.68	-7.04	-0.5	6.05e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.49	5.24	0.39	5.35e-7	Menopause (age at onset);
PAAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.86	-9.28	-0.6	1.62e-16	Colorectal cancer;
PAAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3812762	0.871	rs3862352	chr11:8818020	C/T	cg11156914	chr11:8892616	ST5	0.51	4.46	0.34	1.59e-5	Hypospadias;
PAAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.33	0.4	3.49e-7	Systolic blood pressure;
PAAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.74	7.34	0.51	1.21e-11	Menarche (age at onset);
PAAD	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.66	6.22	0.45	4.6e-9	Platelet count;
PAAD	cis	rs2120243	0.592	rs1456110	chr3:157106072	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.55	0.35	1.09e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.88	9.43	0.61	6.45e-17	Cognitive function;
PAAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.61	6.41	0.46	1.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08677398	chr8:58056175	NA	0.71	4.93	0.37	2.14e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1572438	0.760	rs7740748	chr6:869509	T/C	cg21062780	chr6:887772	NA	-0.44	-4.48	-0.34	1.44e-5	Aging;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg17064520	chr10:98591758	LCOR	-0.71	-6.57	-0.47	7.73e-10	Blood protein levels;
PAAD	cis	rs921968	0.541	rs72965147	chr2:219341827	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.44	-0.34	1.69e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs76419734	0.558	rs11730082	chr4:106521866	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.43	0.34	1.8e-5	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26561187	chr22:28073992	NA	-0.61	-6.35	-0.46	2.35e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg14926445	chr8:58193284	C8orf71	-0.62	-4.8	-0.36	3.73e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	1.02	8.39	0.56	3.18e-14	IgG glycosylation;
PAAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg09597638	chr17:3907349	NA	0.85	8.91	0.59	1.5e-15	Type 2 diabetes;
PAAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-5.42	-0.4	2.25e-7	Mood instability;
PAAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.08	0.38	1.1e-6	Rheumatoid arthritis;
PAAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.89	-10.76	-0.66	1.96e-20	Menopause (age at onset);
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg24213567	chr19:53496664	ZNF702P	-0.49	-5.08	-0.38	1.08e-6	Psoriasis;
PAAD	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg21589280	chr1:85930151	DDAH1	0.58	4.49	0.34	1.38e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.46	-4.71	-0.36	5.64e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg13022888	chr14:82000246	SEL1L	-0.68	-6.73	-0.48	3.3e-10	Blood protein levels;
PAAD	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-4.34	-0.33	2.64e-5	Self-reported allergy;
PAAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	8.01	0.54	2.86e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.52	-4.97	-0.37	1.77e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg19673125	chr6:150240577	RAET1G	0.42	5.91	0.43	2.16e-8	Testicular germ cell tumor;
PAAD	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-8.04	-0.55	2.39e-13	Brugada syndrome;
PAAD	cis	rs4588572	0.561	rs10942858	chr5:77803267	A/C	cg11547950	chr5:77652471	NA	-0.77	-6.48	-0.47	1.21e-9	Triglycerides;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.56	4.28	0.33	3.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs13034020	0.522	rs12464096	chr2:61239332	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg14343924	chr8:8086146	FLJ10661	0.58	5.19	0.39	6.57e-7	Mood instability;
PAAD	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.85	10.0	0.63	2.05e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.45	-0.34	1.67e-5	Subjective well-being;
PAAD	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.57	-5.41	-0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.65	-0.35	7.11e-6	Total body bone mineral density;
PAAD	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg03538708	chr1:25844672	NA	-0.52	-5.41	-0.4	2.41e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.33	-0.33	2.71e-5	Tonsillectomy;
PAAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9398803	0.713	rs9401888	chr6:126877523	A/G	cg19875578	chr6:126661172	C6orf173	0.42	4.45	0.34	1.64e-5	Male-pattern baldness;
PAAD	cis	rs9942416	0.533	rs12109685	chr5:75024066	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.53	4.52	0.34	1.24e-5	Age-related disease endophenotypes;
PAAD	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Educational attainment;
PAAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.52	5.2	0.39	6.25e-7	Breast cancer;
PAAD	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.49	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.11	-0.5	4.35e-11	Life satisfaction;
PAAD	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-5.84	-0.43	3e-8	Morning vs. evening chronotype;
PAAD	cis	rs28493229	0.786	rs3815912	chr19:41190726	G/A	cg21869046	chr19:41225005	ITPKC	0.62	6.42	0.46	1.66e-9	Kawasaki disease;
PAAD	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg18338521	chr10:69995036	NA	-0.34	-4.43	-0.34	1.76e-5	Optic disc area;
PAAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg15847926	chr7:2749597	AMZ1	-0.37	-4.63	-0.35	7.7e-6	Height;
PAAD	cis	rs11671653	1.000	rs11669253	chr19:10836329	A/C	cg16667279	chr19:11591998	ELAVL3	-0.53	-4.27	-0.33	3.39e-5	LDL cholesterol;
PAAD	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg17971929	chr21:40555470	PSMG1	-0.49	-4.83	-0.36	3.29e-6	Menarche (age at onset);
PAAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02071572	chr4:1403502	NA	0.38	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg10778310	chr7:128509080	NA	0.46	5.18	0.39	6.98e-7	Calcium levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24740632	chr5:134486678	NA	0.62	6.76	0.48	2.81e-10	Myopia (pathological);
PAAD	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-11.13	-0.67	2.02e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9411298	0.550	rs4880192	chr9:139927062	A/G	cg14024893	chr9:139943146	ENTPD2	0.66	7.36	0.51	1.1e-11	Monocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13560548	chr3:10150139	C3orf24	0.57	5.23	0.39	5.45e-7	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg27478167	chr7:817139	HEATR2	-0.78	-5.9	-0.43	2.27e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15128208	chr22:42549153	NA	-0.46	-4.58	-0.35	9.67e-6	Cognitive function;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.82	5.95	0.43	1.74e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs427941	0.632	rs201502	chr7:101759561	C/T	cg06246474	chr7:101738831	CUX1	-0.43	-4.28	-0.33	3.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.88	9.58	0.61	2.66e-17	Cognitive function;
PAAD	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.77	0.36	4.34e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11252688	1.000	rs11252682	chr10:4769161	T/C	cg23898951	chr10:4511903	NA	0.77	4.58	0.35	9.54e-6	Major depressive disorder;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg03983715	chr16:68378420	PRMT7	-0.98	-6.98	-0.49	8.42e-11	Magnesium levels;
PAAD	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-4.49	-0.34	1.38e-5	Morning vs. evening chronotype;
PAAD	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg05791153	chr7:19748676	TWISTNB	0.59	5.04	0.38	1.33e-6	Thyroid stimulating hormone;
PAAD	cis	rs35955747	0.869	rs34873968	chr22:31581773	C/T	cg07969918	chr22:31682909	PIK3IP1	-0.33	-4.25	-0.33	3.65e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6065	0.529	rs1056626	chr17:4931553	G/T	cg02990439	chr17:4875527	CAMTA2	-0.77	-4.55	-0.35	1.09e-5	Platelet count;
PAAD	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.78	-5.67	-0.42	6.88e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4924935	0.683	rs34413375	chr17:18802028	C/A	cg26378065	chr17:18585709	ZNF286B	-0.67	-5.0	-0.38	1.56e-6	Pancreatic cancer;
PAAD	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.14e-10	Cutaneous nevi;
PAAD	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg10820045	chr2:198174542	NA	-0.48	-4.98	-0.37	1.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg07362569	chr17:61921086	SMARCD2	0.41	4.58	0.35	9.74e-6	Height;
PAAD	cis	rs2835872	0.733	rs1787400	chr21:39038217	G/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.27	0.45	3.65e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg24747557	chr10:131355152	MGMT	0.5	5.16	0.39	7.74e-7	Response to temozolomide;
PAAD	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	4.57	0.35	9.94e-6	Educational attainment;
PAAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.04	-0.5	6.09e-11	Schizophrenia;
PAAD	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs7711186	0.881	rs721143	chr5:178019031	T/G	cg07427642	chr5:177944298	COL23A1	0.68	4.41	0.34	1.93e-5	Urate levels in obese individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17781879	chr2:32234829	MEMO1	0.68	6.7	0.48	3.9e-10	Obesity-related traits;
PAAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26926768	chr12:34528122	NA	0.37	4.58	0.35	9.79e-6	Morning vs. evening chronotype;
PAAD	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.98	11.67	0.69	6.94e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1982963	0.627	rs3783632	chr14:52498111	C/A	cg20550154	chr14:52487779	NID2	0.59	4.81	0.36	3.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04919944	chr15:28520031	HERC2	-0.57	-6.52	-0.47	9.92e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-1.12	-12.21	-0.7	2.56e-24	Blood pressure (smoking interaction);
PAAD	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.41	-0.51	8.33e-12	Coronary artery disease;
PAAD	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.5	4.61	0.35	8.65e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs2131877	0.871	rs28569214	chr3:194871488	A/G	cg19760965	chr3:194868843	C3orf21	0.43	4.63	0.35	7.73e-6	Non-small cell lung cancer;
PAAD	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.83	10.12	0.63	1.02e-18	Monocyte percentage of white cells;
PAAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.66	-0.35	7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.601	rs59357103	chr3:49890967	G/A	cg03060546	chr3:49711283	APEH	-0.56	-4.43	-0.34	1.77e-5	Menarche (age at onset);
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.71	-6.92	-0.49	1.19e-10	Blood metabolite levels;
PAAD	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-8.87	-0.58	1.82e-15	Vitiligo;
PAAD	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg04824913	chr4:887549	GAK	0.61	4.82	0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg04106633	chr4:1044584	NA	0.64	5.4	0.4	2.52e-7	Recombination rate (females);
PAAD	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg13814708	chr10:81144099	ZCCHC24	-0.39	-4.31	-0.33	2.93e-5	Height;
PAAD	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.65	4.89	0.37	2.52e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.44	7.06	0.5	5.65e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12936587	0.692	rs12943416	chr17:17535535	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-4.53	-0.34	1.21e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.83	8.69	0.58	5.31e-15	Corneal astigmatism;
PAAD	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.76	8.42	0.56	2.68e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs4774830	1.000	rs11071227	chr15:56130286	A/T	cg24530489	chr15:56299380	NA	1.06	4.37	0.33	2.27e-5	Delta-5 desaturase activity;
PAAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.45	-0.34	1.68e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.65	7.19	0.5	2.72e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs2290402	0.536	rs4690339	chr4:854712	T/C	cg09237302	chr4:906077	GAK	-0.45	-4.73	-0.36	5e-6	Type 2 diabetes;
PAAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12935418	0.524	rs9933697	chr16:80973534	A/G	cg16651780	chr16:81037892	C16orf61	0.56	5.25	0.39	5.14e-7	Mean corpuscular volume;
PAAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	1.24	12.11	0.7	4.81e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg18031326	chr11:68079681	LRP5	0.34	4.28	0.33	3.32e-5	Mean corpuscular volume;
PAAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg03188948	chr7:1209495	NA	0.42	4.31	0.33	2.94e-5	Longevity;Endometriosis;
PAAD	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.47	-4.35	-0.33	2.47e-5	Uric acid levels;
PAAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.47	4.65	0.35	7.15e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.75	-7.69	-0.53	1.73e-12	DNA methylation (variation);
PAAD	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.64	0.35	7.51e-6	Hepatocellular carcinoma;
PAAD	cis	rs1419980	0.730	rs11054862	chr12:7769951	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.31	-0.33	2.95e-5	Lung cancer;
PAAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	trans	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.89	-0.49	1.39e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	6.1	0.44	8.39e-9	Obesity-related traits;
PAAD	cis	rs1008126	0.600	rs2528869	chr7:103134964	A/G	cg04218035	chr7:103086829	SLC26A5	0.33	4.63	0.35	7.91e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.46	6.63	0.47	5.41e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	6.08	0.44	9.38e-9	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27003776	chr7:2093976	MAD1L1	0.58	6.38	0.46	2.06e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg00806126	chr19:22604979	ZNF98	-0.39	-5.0	-0.38	1.59e-6	Pain;
PAAD	cis	rs2139634	0.965	rs11130094	chr3:46541503	A/G	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.33	-4.79	-0.36	3.99e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.36	0.33	2.43e-5	Retinal vascular caliber;
PAAD	cis	rs728616	0.510	rs34817075	chr10:81749740	A/G	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.81	-0.36	3.68e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15576692	chr20:18548019	LOC388789	0.56	6.32	0.46	2.82e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4713118	1.000	rs9468195	chr6:27676309	A/G	cg23281280	chr6:28129359	ZNF389	0.49	4.34	0.33	2.61e-5	Parkinson's disease;
PAAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg25753631	chr6:25732923	NA	-0.48	-5.49	-0.41	1.63e-7	Iron status biomarkers;
PAAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14159672	chr1:205819179	PM20D1	0.54	5.18	0.39	6.96e-7	Parkinson's disease;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg00262122	chr8:11665843	FDFT1	0.5	4.3	0.33	3.01e-5	Retinal vascular caliber;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg16520800	chr1:202936341	CYB5R1	-0.55	-6.31	-0.46	2.83e-9	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-7.87	-0.54	6.25e-13	Morning vs. evening chronotype;
PAAD	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	5.19	0.39	6.7e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-4.28	-0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.61	5.85	0.43	2.95e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.62	-6.07	-0.44	9.74e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.3	0.6	1.4e-16	Rheumatoid arthritis;
PAAD	cis	rs3781663	0.500	rs10160730	chr11:70021687	T/C	cg06393558	chr11:69982916	ANO1	-0.58	-6.02	-0.44	1.28e-8	Survival in rectal cancer;
PAAD	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.23	0.51	2.19e-11	Neuroticism;
PAAD	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.52	0.65	8.52e-20	Bladder cancer;
PAAD	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.37	5.26	0.39	4.78e-7	Educational attainment (years of education);
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.87	5.18	0.39	6.93e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg21479132	chr6:26055353	NA	0.97	5.83	0.43	3.16e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.53	4.25	0.33	3.66e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs9557754	0.705	rs3916917	chr13:102560610	T/C	cg17910274	chr13:102068234	NALCN	-0.36	-4.25	-0.33	3.65e-5	QT interval;
PAAD	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg25930673	chr12:123319894	HIP1R	1.23	6.4	0.46	1.87e-9	Adiponectin levels;
PAAD	cis	rs6685188	1.000	rs1172199	chr1:205658939	C/T	cg11965913	chr1:205819406	PM20D1	0.57	5.49	0.41	1.67e-7	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg14346243	chr4:90757452	SNCA	0.51	4.38	0.33	2.21e-5	Neuroticism;
PAAD	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs17155006	0.746	rs425623	chr7:107747465	C/T	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-4.72	-0.36	5.39e-6	Mean corpuscular volume;
PAAD	cis	rs258892	0.843	rs11950068	chr5:72032998	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.27	-0.39	4.55e-7	Prudent dietary pattern;
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-5.8	-0.43	3.77e-8	Prevalent atrial fibrillation;
PAAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg16362232	chr11:430036	ANO9	0.84	5.21	0.39	6.16e-7	Body mass index;
PAAD	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.7	-7.2	-0.5	2.54e-11	Alzheimer's disease (late onset);
PAAD	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg05554000	chr7:158905015	VIPR2	0.6	5.6	0.41	9.98e-8	Facial morphology (factor 20);
PAAD	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.52	0.65	8.66e-20	Total body bone mineral density;
PAAD	cis	rs12541635	1.000	rs1540420	chr8:107088426	C/T	cg10147462	chr8:107024639	NA	-0.44	-4.71	-0.36	5.54e-6	Age of smoking initiation;
PAAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-5.27	-0.39	4.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg21132104	chr15:45694354	SPATA5L1	0.56	5.3	0.4	3.92e-7	Glomerular filtration rate;
PAAD	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.49	5.59	0.41	1.01e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.69	8.17	0.55	1.09e-13	Type 2 diabetes;
PAAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.57	5.81	0.43	3.57e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	7.68	0.53	1.85e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.5	4.61	0.35	8.63e-6	Renal cell carcinoma;
PAAD	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-4.31	-0.33	2.95e-5	Fear of minor pain;
PAAD	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.4	-0.56	2.92e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4743820	0.651	rs4237213	chr9:93932708	A/T	cg14446406	chr9:93919335	NA	-0.5	-6.2	-0.45	5.07e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13560548	chr3:10150139	C3orf24	0.48	4.28	0.33	3.32e-5	Alzheimer's disease;
PAAD	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.8	7.15	0.5	3.34e-11	Blood protein levels;
PAAD	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.49e-5	Coronary artery disease;
PAAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg14196790	chr5:131705035	SLC22A5	0.5	5.44	0.4	2.09e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs16933812	0.510	rs10114416	chr9:36990635	T/C	cg13738729	chr9:36989127	PAX5	0.54	7.71	0.53	1.56e-12	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09963654	chr16:2806322	SRRM2	-0.65	-6.54	-0.47	8.97e-10	Obesity-related traits;
PAAD	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg10434728	chr15:90938212	IQGAP1	-0.49	-5.01	-0.38	1.48e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs12144049	0.705	rs7512558	chr1:152438596	G/A	cg25605289	chr1:151974222	NA	-0.33	-4.36	-0.33	2.43e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg07338119	chr7:157211683	NA	-0.46	-4.59	-0.35	9.04e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs76419734	0.614	rs72669979	chr4:106523289	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.45	0.34	1.62e-5	Post bronchodilator FEV1;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg10579128	chr15:59225866	SLTM	0.93	6.48	0.47	1.22e-9	Lung function (FEV1/FVC);
PAAD	cis	rs5009270	0.553	rs34571206	chr7:112225870	G/A	cg23628563	chr7:112262597	NA	0.64	5.61	0.41	9.32e-8	Osteoarthritis (hip);
PAAD	cis	rs9567406	1.000	rs2031995	chr13:44873359	C/T	cg08635097	chr13:44833857	NA	-0.64	-4.49	-0.34	1.41e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs66530629	0.917	rs66519614	chr1:25164778	G/T	cg01905478	chr1:25040257	NA	0.5	5.6	0.41	9.73e-8	Plateletcrit;
PAAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26556186	chr7:128431582	CCDC136	-0.75	-6.61	-0.47	6.13e-10	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.82	-8.67	-0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02071572	chr4:1403502	NA	0.39	4.8	0.36	3.81e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	6.5	0.47	1.06e-9	Mood instability;
PAAD	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.88	-7.03	-0.5	6.39e-11	Schizophrenia;
PAAD	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.75	4.75	0.36	4.69e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg02367709	chr17:66097352	LOC651250	0.43	4.43	0.34	1.82e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.93	0.43	1.92e-8	Coffee consumption (cups per day);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15107349	chr2:70121099	SNRNP27	0.55	6.63	0.47	5.66e-10	Monocyte percentage of white cells;
PAAD	cis	rs6681460	0.535	rs6588204	chr1:66991008	C/T	cg02459107	chr1:67143332	SGIP1	0.51	4.49	0.34	1.41e-5	Presence of antiphospholipid antibodies;
PAAD	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.18	0.45	5.69e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.66	-6.19	-0.45	5.36e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2051773	0.567	rs6486347	chr11:17050008	A/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9880211	0.800	rs35100027	chr3:136467561	T/A	cg17177318	chr3:135913615	MSL2	0.57	4.38	0.33	2.24e-5	Body mass index;Height;
PAAD	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13560548	chr3:10150139	C3orf24	0.63	5.51	0.41	1.53e-7	Alzheimer's disease;
PAAD	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg23461800	chr14:103021989	NA	0.72	4.62	0.35	8.02e-6	Platelet count;
PAAD	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.86	10.1	0.63	1.13e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.75	-6.48	-0.47	1.23e-9	Diastolic blood pressure;
PAAD	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg08501292	chr6:25962987	TRIM38	0.83	5.03	0.38	1.39e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2412488	1.000	rs2090117	chr4:54300591	G/T	cg19408398	chr4:54243328	FIP1L1	0.5	4.37	0.33	2.3e-5	DNA methylation (variation);
PAAD	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.47	-4.75	-0.36	4.63e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs76917914	0.820	rs3739670	chr9:100819192	C/T	cg21225548	chr9:100864335	TRIM14	-0.56	-5.95	-0.43	1.82e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2834288	0.500	rs4817602	chr21:35324657	C/A	cg22542663	chr21:34915757	GART;SON	0.44	4.36	0.33	2.4e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg08501292	chr6:25962987	TRIM38	0.81	4.28	0.33	3.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.24	0.64	4.73e-19	Bone mineral density;
PAAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.73	6.92	0.49	1.21e-10	Methadone dose in opioid dependence;
PAAD	cis	rs8032158	1.000	rs7162435	chr15:56121334	C/T	cg02198044	chr15:56286336	NEDD4	0.53	5.53	0.41	1.34e-7	Keloid;
PAAD	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-7.25	-0.51	1.92e-11	Mosquito bite size;
PAAD	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.5	-4.25	-0.33	3.78e-5	Lymphocyte counts;
PAAD	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg21775007	chr8:11205619	TDH	-0.55	-4.85	-0.37	3.06e-6	Neuroticism;
PAAD	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.13	-0.38	8.71e-7	Systolic blood pressure;
PAAD	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.63	6.62	0.47	5.8e-10	Testicular germ cell tumor;
PAAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.6	-5.52	-0.41	1.45e-7	Menarche (age at onset);
PAAD	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.37	-0.46	2.15e-9	Hip circumference;
PAAD	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg08027265	chr7:2291960	NA	-0.54	-5.42	-0.4	2.33e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs9434723	0.844	rs2239561	chr1:9304205	C/T	cg04199779	chr1:9294473	H6PD	-0.56	-4.86	-0.37	2.85e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14282407	chr17:7835499	TRAPPC1;CNTROB	0.67	7.02	0.49	6.88e-11	Obesity-related traits;
PAAD	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.37	-5.44	-0.4	2.07e-7	Neuroticism;
PAAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.34	-4.34	-0.33	2.63e-5	Mean platelet volume;
PAAD	cis	rs1642645	0.793	rs6695748	chr1:42481707	G/T	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.46	-0.41	1.86e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.57	5.26	0.39	4.8e-7	Malaria;
PAAD	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.53	-6.38	-0.46	2.04e-9	Lewy body disease;
PAAD	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.73	7.36	0.51	1.08e-11	Prostate cancer;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg07362569	chr17:61921086	SMARCD2	0.42	4.81	0.36	3.65e-6	Height;
PAAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-5.06	-0.38	1.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.77	9.55	0.61	3.17e-17	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg09980403	chr19:12975529	MAST1	0.29	4.77	0.36	4.36e-6	Mean corpuscular volume;
PAAD	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.24	0.45	4.17e-9	Ileal carcinoids;
PAAD	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.94	-0.49	1.09e-10	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05237820	chr20:39945987	NA	0.61	6.81	0.48	2.1e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.77	-6.76	-0.48	2.8e-10	Exhaled nitric oxide output;
PAAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.48	4.52	0.34	1.25e-5	RR interval (heart rate);
PAAD	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs6782228	0.585	rs6774515	chr3:128415878	C/T	cg16766828	chr3:128327626	NA	-0.46	-6.21	-0.45	4.77e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg20607287	chr7:12443886	VWDE	-0.77	-5.64	-0.42	8.26e-8	Coronary artery disease;
PAAD	cis	rs9346353	0.664	rs7749324	chr6:70483082	T/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.97e-5	Sleep duration;
PAAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.57	5.64	0.42	8.02e-8	Resistin levels;
PAAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg24101359	chr6:42928495	GNMT	-0.55	-4.49	-0.34	1.41e-5	Blood protein levels;
PAAD	cis	rs7503168	1.000	rs7503168	chr17:33885904	A/G	cg05299278	chr17:33885742	SLFN14	-0.5	-4.58	-0.35	9.56e-6	Plateletcrit;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.78	-8.95	-0.59	1.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg13565585	chr5:132299512	AFF4	0.62	4.3	0.33	3.07e-5	Breast cancer;
PAAD	cis	rs11696845	0.787	rs6031771	chr20:43363590	C/T	cg25301532	chr20:43378953	KCNK15	0.52	5.8	0.43	3.63e-8	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.73	8.24	0.56	7.3e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.6	-0.41	9.91e-8	Lung cancer;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.51	6.73	0.48	3.3e-10	Life satisfaction;
PAAD	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.58	6.68	0.48	4.3e-10	Major depressive disorder;
PAAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg19930314	chr7:98593876	TRRAP	-0.49	-4.71	-0.36	5.55e-6	Breast cancer;
PAAD	cis	rs62238980	1.000	rs117536534	chr22:32585631	T/C	cg02631450	chr22:32366979	NA	0.95	4.59	0.35	9.06e-6	Childhood ear infection;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg14820908	chr5:178986412	RUFY1	-0.54	-5.67	-0.42	6.9e-8	Lung cancer;
PAAD	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg07817648	chr10:79422355	NA	-0.6	-5.94	-0.43	1.88e-8	Mortality in heart failure;
PAAD	cis	rs2133450	0.526	rs13327304	chr3:7341120	C/G	cg19930620	chr3:7340148	GRM7	-0.51	-5.5	-0.41	1.55e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.53	-4.47	-0.34	1.51e-5	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.42	-0.34	1.85e-5	Dupuytren's disease;
PAAD	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	10.05	0.63	1.56e-18	Smoking behavior;
PAAD	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs2730260	0.537	rs73169239	chr7:158884305	C/A	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.51	4.96	0.37	1.86e-6	Morning vs. evening chronotype;
PAAD	cis	rs9361491	0.608	rs9448542	chr6:79444365	G/T	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.39e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.77	9.25	0.6	1.9e-16	Lung cancer;
PAAD	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.65	0.53	2.19e-12	Motion sickness;
PAAD	trans	rs4382726	0.585	rs1933601	chr1:209415940	C/T	cg14042241	chr19:1474872	C19orf25	0.53	6.36	0.46	2.22e-9	Response to amphetamines;
PAAD	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg12218747	chr21:37451666	NA	-0.47	-5.14	-0.38	8.5e-7	Mitral valve prolapse;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.63	7.05	0.5	5.79e-11	Vitiligo;
PAAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.66	0.72	1.5e-25	Bone mineral density;
PAAD	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg03340356	chr1:67600835	NA	-0.45	-5.25	-0.39	4.94e-7	Psoriasis;
PAAD	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.43	-4.44	-0.34	1.73e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs3738772	0.633	rs919958	chr1:110053148	C/G	cg08704217	chr1:110036942	CYB561D1	0.46	4.55	0.35	1.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02071572	chr4:1403502	NA	0.38	4.71	0.36	5.43e-6	Obesity-related traits;
PAAD	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.54	5.05	0.38	1.25e-6	Resting heart rate;
PAAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.56	-5.66	-0.42	7.3900000000000007e-08	Childhood ear infection;
PAAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg20673091	chr1:2541236	MMEL1	0.74	7.83	0.54	7.64e-13	Ulcerative colitis;
PAAD	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.41	4.92	0.37	2.27e-6	Uric acid levels;
PAAD	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.48	-5.97	-0.44	1.64e-8	Crohn's disease;
PAAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.75	8.9	0.59	1.56e-15	Colorectal cancer;
PAAD	cis	rs62400317	0.821	rs72857080	chr6:45198373	G/A	cg18551225	chr6:44695536	NA	-0.68	-6.68	-0.48	4.27e-10	Total body bone mineral density;
PAAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg07648498	chr16:89883185	FANCA	0.46	4.44	0.34	1.72e-5	Vitiligo;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg03909863	chr11:638404	DRD4	-0.6	-5.45	-0.4	1.94e-7	Systemic lupus erythematosus;
PAAD	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg05418105	chr22:50981406	NA	0.5	4.7	0.36	5.89e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg03289416	chr15:75166202	SCAMP2	0.54	5.91	0.43	2.14e-8	Breast cancer;
PAAD	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.62	-5.92	-0.43	2.02e-8	Tourette syndrome;
PAAD	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg09659197	chr4:152720779	NA	-0.37	-5.16	-0.39	7.61e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs834811	1.000	rs834811	chr7:135884571	A/G	cg01726295	chr7:135938950	NA	0.43	4.66	0.35	6.83e-6	Post-traumatic stress disorder;
PAAD	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-4.99	-0.37	1.66e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1975974	1.000	rs7210944	chr17:21727476	C/T	cg18423549	chr17:21743878	NA	-0.51	-4.93	-0.37	2.13e-6	Psoriasis;
PAAD	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	9.7	0.62	1.27e-17	Response to antipsychotic treatment;
PAAD	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.69	7.5	0.52	4.98e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg18850127	chr7:39170497	POU6F2	0.43	5.98	0.44	1.54e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.77	8.42	0.56	2.61e-14	Lung cancer;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.02	-0.44	1.27e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg02917321	chr22:38215204	NA	-0.4	-4.26	-0.33	3.62e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.6	4.85	0.37	2.99e-6	Behavioural disinhibition (generation interaction);
PAAD	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.63	4.58	0.35	9.43e-6	Blood protein levels;
PAAD	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.24	-0.51	2.04e-11	Retinal vascular caliber;
PAAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.39	-5.34	-0.4	3.34e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg09168692	chr1:7887560	PER3	0.49	4.63	0.35	7.72e-6	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.79	8.25	0.56	7.17e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1015291	0.708	rs1492126	chr12:20007501	C/A	cg25401612	chr12:20009446	NA	-0.55	-5.46	-0.4	1.93e-7	Diastolic blood pressure;
PAAD	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.75	-6.65	-0.47	4.95e-10	Diabetic retinopathy;
PAAD	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.87	-6.73	-0.48	3.24e-10	D-dimer levels;
PAAD	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg15557168	chr22:42548783	NA	-0.43	-4.41	-0.34	1.97e-5	Cognitive function;
PAAD	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.35	-6.57	-0.47	7.36e-10	Type 2 diabetes;
PAAD	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg06606381	chr12:133084897	FBRSL1	-0.9	-6.5	-0.47	1.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs9657904	0.805	rs971110	chr3:105547464	T/C	cg16975614	chr3:105601834	NA	-0.47	-4.61	-0.35	8.48e-6	Multiple sclerosis;
PAAD	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg05895507	chr15:77155635	SCAPER	-0.39	-4.31	-0.33	2.96e-5	Blood metabolite levels;
PAAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg05110241	chr16:68378359	PRMT7	-0.82	-5.27	-0.39	4.56e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg09835421	chr16:68378352	PRMT7	-0.92	-7.24	-0.51	2.14e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17209837	1.000	rs17209662	chr7:87121968	G/A	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.74	8.18	0.55	1.06e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.2	9.61	0.61	2.18e-17	Alzheimer's disease (late onset);
PAAD	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg01620082	chr3:125678407	NA	-1.43	-8.54	-0.57	1.33e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.82	6.03	0.44	1.19e-8	Vitiligo;
PAAD	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.5	5.39	0.4	2.67e-7	Bladder cancer;
PAAD	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.15	-0.45	6.46e-9	Schizophrenia;
PAAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg24253500	chr15:84953950	NA	0.44	4.64	0.35	7.37e-6	Schizophrenia;
PAAD	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.59	0.57	9.48e-15	Lung cancer;
PAAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg19254793	chr6:44695348	NA	-0.49	-4.71	-0.36	5.62e-6	Total body bone mineral density;
PAAD	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-6.8	-0.48	2.28e-10	Menarche (age at onset);
PAAD	cis	rs7071247	1.000	rs7071247	chr10:105257786	G/T	cg20028483	chr10:104949090	NT5C2	0.68	4.84	0.37	3.14e-6	Platelet aggregation;
PAAD	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg03732007	chr1:2071316	PRKCZ	-0.46	-4.45	-0.34	1.65e-5	Height;
PAAD	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.79	7.87	0.54	6.16e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.85	8.84	0.58	2.18e-15	Corneal astigmatism;
PAAD	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg10985347	chr2:127963512	CYP27C1	0.49	4.39	0.34	2.12e-5	Protein C levels;
PAAD	cis	rs2446066	0.872	rs10876449	chr12:53779775	T/C	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.7	7.73	0.53	1.4e-12	Prostate cancer;
PAAD	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg08992911	chr2:238395768	MLPH	-0.73	-6.59	-0.47	6.87e-10	Prostate cancer;
PAAD	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.47	-0.34	1.49e-5	Joint mobility (Beighton score);
PAAD	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.48	5.19	0.39	6.6e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.33e-9	Blood metabolite levels;
PAAD	cis	rs10901513	0.826	rs56040808	chr10:127668048	A/C	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.25	-0.33	3.69e-5	Ileal carcinoids;
PAAD	cis	rs8105895	1.000	rs62112907	chr19:22209569	A/G	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs939584	1.000	rs11127487	chr2:639900	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg00147160	chr1:26503991	CNKSR1	0.41	4.43	0.34	1.76e-5	Height;
PAAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7640424	0.649	rs62262371	chr3:107896108	C/T	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	6.57	0.47	7.64e-10	Schizophrenia;
PAAD	cis	rs7639513	0.545	rs12714874	chr3:12719928	C/T	cg23032965	chr3:12705835	RAF1	0.89	7.81	0.54	8.77e-13	Itch intensity from mosquito bite;
PAAD	cis	rs564309	0.681	rs1188483	chr1:228618088	A/C	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg13207630	chr7:32358064	NA	0.88	4.69	0.36	6.03e-6	Body mass index;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg03289416	chr15:75166202	SCAMP2	0.52	5.32	0.4	3.57e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs10512697	0.536	rs62336073	chr5:3505717	T/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05527272	chr21:45079307	HSF2BP;RRP1B	0.59	6.32	0.46	2.77e-9	Myopia (pathological);
PAAD	cis	rs1032355	0.558	rs114505328	chr4:100513694	T/A	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg11619707	chr19:22235551	ZNF257	-0.57	-5.62	-0.41	9.02e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.49	-4.38	-0.34	2.16e-5	Menarche (age at onset);
PAAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.62	6.87	0.49	1.53e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.9	-7.11	-0.5	4.34e-11	Total cholesterol levels;
PAAD	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.58	-5.18	-0.39	6.98e-7	Sudden cardiac arrest;
PAAD	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.66	-6.13	-0.45	7.25e-9	Platelet count;
PAAD	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs4281086	0.897	rs28485845	chr8:10346269	A/T	cg01072821	chr8:10382165	T-SP1	-0.47	-4.62	-0.35	8.3e-6	Obesity-related traits;
PAAD	trans	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg15838301	chr4:7719899	SORCS2	0.62	6.46	0.46	1.32e-9	Schizophrenia;
PAAD	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg14019146	chr3:50243930	SLC38A3	0.48	4.94	0.37	2.05e-6	Body mass index;
PAAD	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg22532475	chr10:104410764	TRIM8	0.4	4.56	0.35	1.03e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.83	4.81	0.36	3.6e-6	Body mass index;
PAAD	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg05313129	chr8:58192883	C8orf71	-0.76	-6.62	-0.47	5.72e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg15383120	chr6:291909	DUSP22	-0.65	-7.05	-0.5	5.76e-11	Menopause (age at onset);
PAAD	cis	rs16854884	0.770	rs6782024	chr3:143816936	G/C	cg06585982	chr3:143692056	C3orf58	0.5	4.92	0.37	2.18e-6	Economic and political preferences (feminism/equality);
PAAD	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03375212	chr4:39368138	RFC1	0.7	7.08	0.5	4.86e-11	Obesity-related traits;
PAAD	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.64	-7.49	-0.52	5.16e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg01028140	chr2:1542097	TPO	-1.04	-9.36	-0.6	9.9900000000000006e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26296408	chr8:9414115	TNKS	0.56	6.48	0.47	1.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12230513	0.732	rs7294659	chr12:55866519	T/C	cg06899799	chr12:56650233	ANKRD52	0.35	4.26	0.33	3.56e-5	Contrast sensitivity;
PAAD	cis	rs2046867	0.661	rs6790583	chr3:72901701	G/T	cg25664220	chr3:72788482	NA	-0.56	-5.56	-0.41	1.17e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.39	-0.4	2.65e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs483180	0.512	rs866321	chr1:120224469	T/C	cg19096424	chr1:120255104	PHGDH	0.53	4.67	0.35	6.48e-6	Macular telangiectasia type 2;
PAAD	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg18551225	chr6:44695536	NA	-0.72	-7.32	-0.51	1.37e-11	Total body bone mineral density;
PAAD	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg22467129	chr15:76604101	ETFA	0.51	4.74	0.36	4.9100000000000004e-06	Blood metabolite levels;
PAAD	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg17366294	chr4:99064904	C4orf37	-0.46	-5.15	-0.39	7.79e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg25233709	chr10:116636983	FAM160B1	0.42	5.33	0.4	3.43e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.62	6.38	0.46	1.98e-9	Testicular germ cell tumor;
PAAD	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-4.7	-0.36	5.7e-6	Biliary atresia;
PAAD	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	1.05	15.19	0.78	2.8e-32	Height;
PAAD	cis	rs10887741	0.646	rs1358864	chr10:89426630	A/C	cg13926569	chr10:89418898	PAPSS2	0.48	4.82	0.36	3.48e-6	Exercise (leisure time);
PAAD	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg03999872	chr20:62272968	STMN3	-0.61	-5.43	-0.4	2.18e-7	Atopic dermatitis;
PAAD	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg10483660	chr13:112241077	NA	0.53	4.91	0.37	2.34e-6	Menarche (age at onset);
PAAD	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-4.94	-0.37	2e-6	Schizophrenia;
PAAD	cis	rs8102137	1.000	rs62104473	chr19:30289779	C/T	cg27475126	chr19:30303651	CCNE1	-0.45	-5.01	-0.38	1.47e-6	Bladder cancer;
PAAD	cis	rs288342	0.797	rs288295	chr2:183628964	A/G	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.38	-0.51	9.79e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg09473613	chr1:24152604	HMGCL	0.46	4.72	0.36	5.2e-6	Immature fraction of reticulocytes;
PAAD	cis	rs727479	0.543	rs2414096	chr15:51529779	G/A	cg21478137	chr15:51532386	CYP19A1	0.53	5.25	0.39	5e-7	Estradiol levels;
PAAD	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	11.2	0.67	1.34e-21	Nonalcoholic fatty liver disease;
PAAD	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs496300	0.903	rs634978	chr21:44782732	A/C	cg18342814	chr21:45755740	C21orf2	-0.46	-4.28	-0.33	3.23e-5	Metabolic syndrome;
PAAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.93	-8.85	-0.58	2.05e-15	Asthma;
PAAD	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-4.29	-0.33	3.13e-5	Lung cancer;
PAAD	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.83	10.31	0.64	3.1400000000000002e-19	Bladder cancer;
PAAD	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg01942863	chr7:99769432	GPC2	0.47	4.34	0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs11105468	0.595	rs7961385	chr12:90538755	C/T	cg16962463	chr12:89968675	NA	0.41	4.84	0.37	3.23e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.95	-8.27	-0.56	6.19e-14	Vitiligo;
PAAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.56	-6.47	-0.46	1.3e-9	Aortic root size;
PAAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg10356904	chr22:49881777	NA	-0.52	-5.7	-0.42	6.07e-8	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.8	-5.06	-0.38	1.19e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	8.0	0.54	2.88e-13	Lymphocyte counts;
PAAD	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg22764639	chr12:106532701	NUAK1	0.42	4.3	0.33	2.99e-5	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.47	0.34	1.53e-5	Personality dimensions;
PAAD	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg10223061	chr2:219282414	VIL1	0.37	4.39	0.34	2.1e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs876084	0.505	rs10738134	chr8:121168145	T/C	cg06265175	chr8:121136014	COL14A1	0.46	4.48	0.34	1.45e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.65	8.2	0.55	9.24e-14	Inflammatory bowel disease;
PAAD	cis	rs4073221	0.654	rs13065016	chr3:18291793	A/G	cg07694806	chr3:18168406	NA	-0.66	-4.77	-0.36	4.3e-6	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.47e-7	Life satisfaction;
PAAD	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.63	7.06	0.5	5.55e-11	Menarche (age at onset);
PAAD	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg22467129	chr15:76604101	ETFA	0.52	4.88	0.37	2.69e-6	Blood metabolite levels;
PAAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.63	8.28	0.56	6.02e-14	Renal cell carcinoma;
PAAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.85e-6	Personality dimensions;
PAAD	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg13207630	chr7:32358064	NA	0.83	4.68	0.35	6.28e-6	Body mass index;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.74	0.42	5.05e-8	Prudent dietary pattern;
PAAD	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.68	7.16	0.5	3.14e-11	Height;
PAAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg25456477	chr12:86230367	RASSF9	0.5	4.53	0.34	1.2e-5	Major depressive disorder;
PAAD	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.45	0.65	1.32e-19	Cognitive test performance;
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.77	8.39	0.56	3.08e-14	Lung cancer;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg05133090	chr11:89463427	NA	0.55	6.35	0.46	2.31e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg21132104	chr15:45694354	SPATA5L1	0.89	8.44	0.57	2.27e-14	Homoarginine levels;
PAAD	cis	rs11252688	1.000	rs11252688	chr10:4774565	T/C	cg04204118	chr10:4194429	NA	0.81	4.29	0.33	3.17e-5	Major depressive disorder;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7771547	0.855	rs9368942	chr6:36566513	C/G	cg07856975	chr6:36356162	ETV7	0.46	5.17	0.39	7.11e-7	Platelet distribution width;
PAAD	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-1.11	-11.89	-0.69	1.81e-23	Longevity;
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg20406979	chr6:167373233	NA	-0.38	-5.14	-0.38	8.48e-7	Lung cancer;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg17667988	chr19:797342	PTBP1	0.68	6.31	0.46	2.95e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.14	-0.38	8.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.38	0.4	2.81e-7	Ileal carcinoids;
PAAD	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.75	-0.58	3.77e-15	Exhaled nitric oxide output;
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs13065560	0.534	rs4318494	chr3:38886804	A/G	cg01426195	chr3:39028469	NA	-0.47	-4.52	-0.34	1.22e-5	Interleukin-18 levels;
PAAD	cis	rs9815354	1.000	rs1717027	chr3:41987920	T/C	cg03022575	chr3:42003672	ULK4	-0.75	-5.4	-0.4	2.47e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg23254163	chr1:152506842	NA	-0.59	-6.98	-0.49	8.34e-11	Hair morphology;
PAAD	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.74	-0.36	4.82e-6	Mean platelet volume;
PAAD	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg24687543	chr11:63912206	MACROD1	0.58	5.45	0.4	2.02e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg13010199	chr12:38710504	ALG10B	-0.47	-4.4	-0.34	2.07e-5	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.29	-0.51	1.57e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs590121	0.876	rs585821	chr11:75282882	C/T	cg26104986	chr11:75275303	SERPINH1	-0.44	-4.31	-0.33	2.94e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17021463	0.676	rs12512832	chr4:95310216	G/T	cg11021082	chr4:95130006	SMARCAD1	0.54	5.39	0.4	2.69e-7	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg10556349	chr10:835070	NA	0.58	4.9	0.37	2.45e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07550016	chr4:1989575	WHSC2;MIR943	-0.61	-6.39	-0.46	1.92e-9	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Mean corpuscular volume;
PAAD	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	7.02	0.49	6.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs6594713	0.648	rs36023163	chr5:112891009	A/G	cg12552261	chr5:112820674	MCC	0.74	5.08	0.38	1.1e-6	Brain cytoarchitecture;
PAAD	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20487152	chr13:99095054	FARP1	-0.6	-5.24	-0.39	5.35e-7	Neuroticism;
PAAD	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.61	0.35	8.52e-6	Thyroid stimulating hormone;
PAAD	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.59	5.18	0.39	6.96e-7	Plateletcrit;
PAAD	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.06	-0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2790216	0.950	rs2440857	chr10:59965702	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.61	7.07	0.5	5.37e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26415393	chr7:155574244	NA	-0.59	-6.61	-0.47	6.03e-10	Monocyte percentage of white cells;
PAAD	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	17.63	0.82	1.42e-38	Height;
PAAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.6	-7.98	-0.54	3.3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.62	6.71	0.48	3.55e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg15181151	chr6:150070149	PCMT1	0.5	5.13	0.38	8.85e-7	Lung cancer;
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.76	0.36	4.43e-6	Asthma;
PAAD	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg22482690	chr17:47019901	SNF8	0.5	5.43	0.4	2.19e-7	Type 2 diabetes;
PAAD	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.7	7.13	0.5	3.73e-11	Body mass index;
PAAD	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg21253087	chr9:139290292	SNAPC4	0.49	4.48	0.34	1.46e-5	White blood cell count;
PAAD	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg04315214	chr1:2043799	PRKCZ	-0.37	-4.62	-0.35	8.15e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.32	8.14	0.55	1.33e-13	Prostate cancer;
PAAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.99	-0.38	1.61e-6	Initial pursuit acceleration;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15336196	chr18:42261241	SETBP1	-0.56	-6.36	-0.46	2.26e-9	Lung cancer in ever smokers;
PAAD	cis	rs4790333	0.537	rs898750	chr17:2255193	A/G	cg02569219	chr17:2266849	SGSM2	0.51	4.77	0.36	4.2e-6	Proinsulin levels;
PAAD	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.57	-6.68	-0.48	4.2e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.42	-5.19	-0.39	6.52e-7	Schizophrenia;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02424630	chr12:118810744	TAOK3	0.6	6.78	0.48	2.54e-10	Monocyte percentage of white cells;
PAAD	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	4.98	0.37	1.73e-6	Tonsillectomy;
PAAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.42	-5.87	-0.43	2.6e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg10729496	chr3:10149963	C3orf24	0.88	7.32	0.51	1.32e-11	Alzheimer's disease;
PAAD	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg02187348	chr16:89574699	SPG7	0.58	5.72	0.42	5.42e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.42	-0.52	7.9e-12	Coronary artery disease;
PAAD	cis	rs8025118	0.583	rs11856016	chr15:79545422	T/C	cg11862246	chr15:78730200	IREB2	-0.52	-4.35	-0.33	2.49e-5	Cognitive function;
PAAD	cis	rs75920871	0.623	rs7928320	chr11:116942753	C/T	cg04087571	chr11:116723030	SIK3	-0.42	-5.92	-0.43	2.08e-8	Subjective well-being;
PAAD	cis	rs9361491	0.508	rs9343786	chr6:79414728	A/C	cg05283184	chr6:79620031	NA	0.4	5.04	0.38	1.32e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-7.64	-0.53	2.21e-12	Body mass index;
PAAD	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.91	7.53	0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.83	10.72	0.66	2.62e-20	Height;
PAAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg11802864	chr11:65308245	LTBP3	0.45	4.57	0.35	1.01e-5	Bone mineral density;
PAAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	6.45	0.46	1.43e-9	Menarche (age at onset);
PAAD	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.88e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	cis	rs939584	1.000	rs7585056	chr2:631528	A/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs4834770	1.000	rs4834770	chr4:120241849	A/G	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg03188948	chr7:1209495	NA	1.04	5.49	0.41	1.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.41	4.89	0.37	2.59e-6	Tonsillectomy;
PAAD	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01114163	chr5:1856713	NA	-0.41	-4.34	-0.33	2.61e-5	Cardiovascular disease risk factors;
PAAD	cis	rs375066	0.935	rs367283	chr19:44406127	A/G	cg21496419	chr19:44306685	LYPD5	0.4	4.95	0.37	1.92e-6	Breast cancer;
PAAD	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	1.1	6.73	0.48	3.28e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.57	6.87	0.49	1.56e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2130392	0.702	rs34605630	chr4:185573937	A/G	cg21366198	chr4:185655624	MLF1IP	0.56	4.91	0.37	2.37e-6	Kawasaki disease;
PAAD	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.93	11.02	0.67	4.07e-21	White blood cell count;
PAAD	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	9.23	0.6	2.13e-16	Response to antipsychotic treatment;
PAAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg20542592	chr8:11973495	FAM66D	-0.47	-4.31	-0.33	2.88e-5	Retinal vascular caliber;
PAAD	cis	rs728616	0.867	rs17886286	chr10:81703852	C/G	cg19423196	chr10:82049429	MAT1A	0.64	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	4.67	0.35	6.59e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg05554000	chr7:158905015	VIPR2	0.57	5.07	0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.58	-0.47	7.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.54	-5.45	-0.4	1.96e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09360796	chr7:77682715	MAGI2	-0.53	-6.39	-0.46	1.97e-9	Monocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg23153227	chr6:27725408	NA	0.49	4.69	0.36	6.12e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.96	-10.78	-0.66	1.75e-20	Coronary artery disease;
PAAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9487051	0.597	rs12664455	chr6:109590739	C/T	cg21918786	chr6:109611834	NA	-0.47	-4.91	-0.37	2.31e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.68	-6.41	-0.46	1.75e-9	Corneal astigmatism;
PAAD	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg17974515	chr1:2252516	NA	0.58	6.16	0.45	6.34e-9	Coronary artery disease;
PAAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.65	-6.12	-0.44	7.75e-9	Blood metabolite levels;
PAAD	cis	rs62238980	1.000	rs62238980	chr22:32578912	C/T	cg02631450	chr22:32366979	NA	1.02	4.96	0.37	1.87e-6	Childhood ear infection;
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg26939375	chr7:64535504	NA	-0.76	-9.14	-0.6	3.8e-16	Calcium levels;
PAAD	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	12.54	0.71	3.28e-25	Colorectal cancer;
PAAD	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.54	-4.39	-0.34	2.08e-5	Metabolite levels;
PAAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	9.86	0.62	4.78e-18	Smoking behavior;
PAAD	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.88	-8.11	-0.55	1.59e-13	Exhaled nitric oxide output;
PAAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.33	0.33	2.71e-5	Renal cell carcinoma;
PAAD	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg12673499	chr10:104412063	TRIM8	-0.37	-4.33	-0.33	2.74e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15895391	chr5:14463177	TRIO	-0.63	-6.32	-0.46	2.73e-9	Obesity-related traits;
PAAD	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.33	-4.52	-0.34	1.25e-5	Oropharynx cancer;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.43	-0.34	1.81e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15113064	chr3:124774855	HEG1	0.65	6.72	0.48	3.35e-10	Myopia (pathological);
PAAD	cis	rs1983170	0.668	rs17131491	chr1:92017649	A/C	cg07011357	chr1:92949813	GFI1	-0.53	-4.32	-0.33	2.76e-5	Eosinophil percentage of white cells;
PAAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs10450586	0.932	rs10835155	chr11:27317812	C/T	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs17232800	0.866	rs689193	chr18:66313774	C/G	cg03686067	chr18:66504389	CCDC102B	-0.68	-4.4	-0.34	2.02e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.97	11.97	0.7	1.14e-23	Coronary artery disease;
PAAD	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.48	-4.94	-0.37	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg27411982	chr8:10470053	RP1L1	0.46	4.98	0.37	1.69e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg09659197	chr4:152720779	NA	0.39	5.69	0.42	6.24e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.51	-4.72	-0.36	5.41e-6	Response to temozolomide;
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg22189786	chr22:42395067	WBP2NL	0.45	4.98	0.37	1.74e-6	Cognitive function;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs2289328	0.882	rs16970633	chr15:40642877	G/T	cg13931752	chr15:40660718	DISP2	0.58	5.31	0.4	3.82e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg10556349	chr10:835070	NA	0.51	4.37	0.33	2.26e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg27411982	chr8:10470053	RP1L1	0.42	4.28	0.33	3.26e-5	Retinal vascular caliber;
PAAD	cis	rs59888335	0.858	rs2372666	chr3:81037101	T/C	cg21735741	chr3:80819488	NA	0.52	4.28	0.33	3.34e-5	Schizophrenia;
PAAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg11663144	chr21:46675770	NA	-0.44	-4.88	-0.37	2.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7072216	0.853	rs6584194	chr10:100160399	T/C	cg19567339	chr10:100142640	NA	0.45	4.85	0.37	3.01e-6	Metabolite levels;
PAAD	cis	rs3026101	0.671	rs56019636	chr17:5297551	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg05555928	chr11:63887634	MACROD1	-0.57	-5.52	-0.41	1.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.66	8.0	0.54	2.89e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs2882667	0.690	rs288009	chr5:138228662	G/A	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	Schizophrenia;
PAAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg12564285	chr5:131593104	PDLIM4	0.48	4.91	0.37	2.33e-6	Blood metabolite levels;
PAAD	cis	rs16852403	1.000	rs16852403	chr1:178039226	T/C	cg00404053	chr1:178313656	RASAL2	0.44	4.42	0.34	1.9e-5	Childhood ear infection;
PAAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	0.92	5.58	0.41	1.06e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.79	-9.76	-0.62	9.17e-18	Bipolar disorder and schizophrenia;
PAAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	8.6	0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.49	-5.36	-0.4	3.1e-7	Cognitive function;
PAAD	cis	rs3026101	0.671	rs58832024	chr17:5306536	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.46	-0.34	1.59e-5	Vitiligo;
PAAD	cis	rs17095355	0.710	rs2481106	chr10:111832438	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.86	-0.37	2.94e-6	Biliary atresia;
PAAD	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg25233709	chr10:116636983	FAM160B1	0.43	5.58	0.41	1.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg26031613	chr14:104095156	KLC1	0.48	4.48	0.34	1.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg12482260	chr6:97345915	NDUFAF4	0.48	4.68	0.36	6.19e-6	Body mass index;
PAAD	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-4.84	-0.37	3.21e-6	Height;
PAAD	cis	rs2764208	0.550	rs3736896	chr6:34735883	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-4.35	-0.33	2.49e-5	Systemic lupus erythematosus;
PAAD	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg24519413	chr1:26490540	NA	0.58	5.13	0.38	8.9e-7	QRS complex (12-leadsum);
PAAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg21496419	chr19:44306685	LYPD5	0.44	5.43	0.4	2.15e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.76	8.92	0.59	1.39e-15	Methadone dose in opioid dependence;
PAAD	cis	rs2658782	0.901	rs10466368	chr11:93229756	T/C	cg15737290	chr11:93063684	CCDC67	0.76	5.67	0.42	6.98e-8	Pulmonary function decline;
PAAD	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.39	4.71	0.36	5.5e-6	Menarche (age at onset);
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.19	-0.5	2.8e-11	Gut microbiome composition (summer);
PAAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.64	6.8	0.48	2.22e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7711186	0.881	rs721142	chr5:178019208	C/A	cg17371294	chr5:178012716	COL23A1	-0.83	-4.43	-0.34	1.78e-5	Urate levels in obese individuals;
PAAD	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.58	-5.68	-0.42	6.62e-8	Cancer;
PAAD	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg09127314	chr1:152161683	NA	-0.72	-5.14	-0.38	8.45e-7	Atopic dermatitis;
PAAD	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.65	-0.35	7.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg10705379	chr10:99080932	FRAT1	0.38	4.44	0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3018712	0.590	rs10791993	chr11:68493712	T/C	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.3	-0.33	3.04e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.71	7.29	0.51	1.55e-11	Schizophrenia;
PAAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.47	-0.34	1.54e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.74	0.36	4.97e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg12218747	chr21:37451666	NA	-0.47	-5.13	-0.38	8.6e-7	Mitral valve prolapse;
PAAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg11494091	chr17:61959527	GH2	0.52	4.31	0.33	2.93e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02573121	chr1:46806359	NSUN4	-0.8	-6.97	-0.49	8.93e-11	Neuroticism;
PAAD	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.98	13.95	0.75	5.27e-29	Heart rate;
PAAD	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.74	-8.16	-0.55	1.19e-13	Schizophrenia;
PAAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12667521	chr19:29218732	NA	0.75	6.95	0.49	9.94e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs11016883	1.000	rs4750764	chr10:131496457	A/G	cg14312783	chr10:131504572	MGMT	-0.49	-4.58	-0.35	9.68e-6	Waist-to-hip circumference ratio (ever vs never smoking interaction);
PAAD	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.76	0.42	4.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1499972	0.824	rs705219	chr3:117702270	T/A	cg07612923	chr3:117604196	NA	-0.99	-6.41	-0.46	1.76e-9	Schizophrenia;
PAAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg04520793	chr17:42248056	ASB16	0.42	5.09	0.38	1.03e-6	Total body bone mineral density;
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.9	-0.37	2.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg10556349	chr10:835070	NA	0.57	4.85	0.37	3.09e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.7	5.23	0.39	5.51e-7	Alzheimer's disease;
PAAD	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.53	-5.78	-0.42	4.09e-8	Metabolite levels;
PAAD	cis	rs804292	0.800	rs8191542	chr8:11629809	C/G	cg26752888	chr8:11627280	NEIL2	1.14	10.02	0.63	1.82e-18	Alcohol dependence;Nicotine use;
PAAD	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg07291445	chr7:39015928	NA	0.28	4.34	0.33	2.56e-5	IgG glycosylation;
PAAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.48	0.65	1.09e-19	Smoking behavior;
PAAD	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	4.55	0.35	1.09e-5	Axial length;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Lymphocyte counts;
PAAD	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg25197388	chr11:66278006	BBS1	-0.43	-4.3	-0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs2271400	0.541	rs7017876	chr8:56651634	A/G	cg08894788	chr8:56792171	LYN	-0.5	-4.68	-0.35	6.34e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.56	0.65	6.74e-20	Platelet count;
PAAD	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg11441379	chr12:63026424	NA	0.88	6.41	0.46	1.78e-9	IgG glycosylation;
PAAD	cis	rs375066	1.000	rs375066	chr19:44423570	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg13722127	chr7:150037890	RARRES2	0.55	5.4	0.4	2.52e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.87e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.62	-5.7	-0.42	6.12e-8	Neuroticism;
PAAD	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-4.81	-0.36	3.63e-6	Itch intensity from mosquito bite;
PAAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg19257562	chr1:2043853	PRKCZ	0.48	5.82	0.43	3.37e-8	Height;
PAAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.85	4.51	0.34	1.28e-5	Plasma clusterin levels;
PAAD	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	5.95	0.43	1.81e-8	Eye color traits;
PAAD	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.53	-0.34	1.21e-5	Educational attainment (years of education);
PAAD	cis	rs7582720	0.731	rs1971819	chr2:203705787	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.79	-5.86	-0.43	2.78e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.38	0.4	2.81e-7	Rheumatoid arthritis;
PAAD	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg08562672	chr19:21860753	NA	-0.46	-4.86	-0.37	2.9e-6	Pain;
PAAD	cis	rs2562456	0.834	rs2650848	chr19:21586637	C/T	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-5.62	-0.41	9e-8	Common traits (Other);
PAAD	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg00147160	chr1:26503991	CNKSR1	0.42	4.56	0.35	1.05e-5	Height;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27032056	chr7:155674731	NA	0.58	6.65	0.47	5.04e-10	Body fat percentage;
PAAD	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs2422052	0.792	rs4849637	chr2:118645575	A/G	cg22545206	chr2:118617499	NA	0.56	5.57	0.41	1.11e-7	Mosquito bite size;
PAAD	cis	rs11825064	0.666	rs73596941	chr11:134495285	A/G	cg06603561	chr11:134479413	NA	-0.94	-6.25	-0.45	4.02e-9	Seasonality;
PAAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.46	4.36	0.33	2.42e-5	Menopause (age at onset);
PAAD	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.69	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg20252443	chr19:13049313	CALR	0.62	6.61	0.47	6.23e-10	Iris heterochromicity;
PAAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.47	-4.75	-0.36	4.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6137287	0.924	rs2093070	chr20:21157510	G/T	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.7	-0.36	5.74e-6	Height;
PAAD	trans	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg05163071	chr3:108476540	RETNLB	0.96	6.83	0.48	1.88e-10	Dental caries;
PAAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.09	-0.44	8.66e-9	Schizophrenia;
PAAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg09873201	chr16:3507582	NAT15	0.56	5.07	0.38	1.17e-6	Tuberculosis;
PAAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg17077180	chr1:38461687	NA	0.6	6.77	0.48	2.68e-10	Coronary artery disease;
PAAD	cis	rs12304921	1.000	rs224454	chr12:51393116	C/T	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.42	-0.34	1.89e-5	Type 2 diabetes;
PAAD	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.43	0.34	1.77e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.96	-4.99	-0.38	1.65e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
PAAD	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.6	-5.49	-0.41	1.65e-7	Total body bone mineral density;
PAAD	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg18612461	chr15:75251733	NA	-0.43	-4.57	-0.35	9.86e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2033908	0.502	rs12361858	chr11:12857064	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-4.58	-0.35	9.53e-6	Sitting height ratio;
PAAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Body mass index;
PAAD	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-4.43	-0.34	1.79e-5	Tonsillectomy;
PAAD	cis	rs728616	0.867	rs41298231	chr10:81682461	C/T	cg19423196	chr10:82049429	MAT1A	0.62	4.53	0.35	1.17e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.52	-0.41	1.42e-7	Bipolar disorder;
PAAD	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg14146966	chr2:61757674	XPO1	-0.36	-4.65	-0.35	7.06e-6	Tuberculosis;
PAAD	cis	rs4729127	1.000	rs8180725	chr7:94010953	G/C	cg20814616	chr7:94014465	NA	-0.59	-4.27	-0.33	3.46e-5	Intelligence;
PAAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.57	-5.54	-0.41	1.29e-7	Obesity-related traits;
PAAD	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.59	0.57	9.63e-15	Vitiligo;
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	trans	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.33	-0.46	2.61e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10819733	chr22:24237672	NA	-0.6	-6.44	-0.46	1.45e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs60617249	0.579	rs10264737	chr7:50933370	A/G	cg15805451	chr7:51135775	COBL	0.38	4.29	0.33	3.15e-5	Major depression and alcohol dependence;
PAAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg10494973	chr17:80897199	TBCD	0.56	4.69	0.36	6.09e-6	Breast cancer;
PAAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.59	-5.63	-0.42	8.34e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4668356	1.000	rs16859177	chr2:172006576	C/T	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs4561483	0.843	rs35153773	chr16:11936317	C/T	cg08843971	chr16:11963173	GSPT1	0.48	4.99	0.38	1.61e-6	Testicular germ cell tumor;
PAAD	cis	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.74	-0.36	4.82e-6	Menarche (age at onset);
PAAD	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Cannabis dependence symptom count;
PAAD	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	5.82	0.43	3.38e-8	Schizophrenia;
PAAD	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.41	-0.4	2.41e-7	Mood instability;
PAAD	cis	rs1075265	0.868	rs4671872	chr2:54361172	T/C	cg04546899	chr2:54196757	PSME4	0.35	4.94	0.37	2.07e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17030841	chr2:240323363	HDAC4	0.62	6.35	0.46	2.39e-9	Obesity-related traits;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.45	4.91	0.37	2.34e-6	Life satisfaction;
PAAD	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs375066	0.868	rs453950	chr19:44403055	G/A	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.51e-7	Type 2 diabetes;
PAAD	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.97	11.94	0.7	1.35e-23	Bone mineral density;
PAAD	cis	rs6141769	0.542	rs7360824	chr20:31315158	A/G	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs17095355	0.818	rs12268910	chr10:111878510	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.66	-5.08	-0.38	1.09e-6	Biliary atresia;
PAAD	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg15676125	chr6:33679581	C6orf125	0.49	4.79	0.36	3.86e-6	Plateletcrit;
PAAD	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12963246	chr6:28129442	ZNF389	0.56	4.47	0.34	1.5e-5	Cardiac Troponin-T levels;
PAAD	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-14.75	-0.77	4.04e-31	Height;
PAAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-6.83	-0.48	1.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.33	0.6	1.19e-16	Prudent dietary pattern;
PAAD	cis	rs6684428	0.610	rs12120132	chr1:56322054	G/A	cg11651538	chr1:56320950	NA	-0.5	-4.35	-0.33	2.46e-5	Airflow obstruction;
PAAD	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.72e-6	Height;
PAAD	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-4.49	-0.34	1.39e-5	Educational attainment;
PAAD	cis	rs72827839	1.000	rs17696392	chr17:46427160	A/T	cg23391107	chr17:45924227	SP6	-0.6	-5.12	-0.38	8.93e-7	Ease of getting up in the morning;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06457625	chr4:153021157	NA	-0.67	-6.62	-0.47	5.75e-10	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15525562	chr14:50101964	C14orf104	-0.75	-6.34	-0.46	2.47e-9	Neuroticism;
PAAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.0	13.97	0.75	4.74e-29	Multiple system atrophy;
PAAD	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.92	-8.22	-0.55	8.51e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.93	0.7	1.4e-23	Smoking behavior;
PAAD	cis	rs955333	0.543	rs11155986	chr6:154933171	C/T	cg20019720	chr6:154832845	CNKSR3	0.32	4.32	0.33	2.83e-5	Diabetic kidney disease;
PAAD	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.61	6.71	0.48	3.54e-10	Coronary artery disease;
PAAD	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-6.7	-0.48	3.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs669446	0.529	rs6697354	chr1:44151015	T/G	cg12908607	chr1:44402522	ARTN	-0.42	-4.56	-0.35	1.06e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.84	-0.37	3.18e-6	Triglycerides;
PAAD	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.13e-5	Pain;
PAAD	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg00071950	chr4:10020882	SLC2A9	0.51	4.25	0.33	3.75e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6460942	0.908	rs6979124	chr7:12232551	G/T	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg12126869	chr10:346505	DIP2C	-0.79	-4.31	-0.33	2.89e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.95e-17	Rheumatoid arthritis;
PAAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.73	-8.62	-0.57	7.94e-15	Height;
PAAD	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.92	12.38	0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2286503	0.966	rs6949233	chr7:22858191	T/G	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.34e-5	Fibrinogen;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	6.14	0.45	6.77e-9	Prudent dietary pattern;
PAAD	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	4.3	0.33	2.99e-5	Height;
PAAD	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22509189	chr2:225307070	NA	-0.47	-4.71	-0.36	5.43e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.79	6.5	0.47	1.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs863345	0.967	rs10908681	chr1:158522712	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.67	5.57	0.41	1.12e-7	Obesity (extreme);
PAAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.43	5.59	0.41	1.03e-7	Childhood ear infection;
PAAD	trans	rs901683	1.000	rs12763285	chr10:46082869	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg15123519	chr2:136567270	LCT	0.38	4.58	0.35	9.63e-6	Mosquito bite size;
PAAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.22e-6	Menopause (age at onset);
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg07212818	chr11:638076	DRD4	-0.7	-7.03	-0.5	6.38e-11	Systemic lupus erythematosus;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg18279126	chr7:2041391	MAD1L1	0.58	5.88	0.43	2.53e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12432203	1.000	rs72622433	chr14:51733912	T/C	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs375066	0.935	rs430308	chr19:44400375	C/G	cg11993925	chr19:44307056	LYPD5	0.49	6.22	0.45	4.48e-9	Breast cancer;
PAAD	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.69	4.89	0.37	2.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-1.08	-4.89	-0.37	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg06042504	chr8:55087323	NA	-0.76	-8.41	-0.56	2.85e-14	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs11825064	0.673	rs79389752	chr11:134496974	A/T	cg02089395	chr11:134479357	NA	-0.93	-5.53	-0.41	1.34e-7	Seasonality;
PAAD	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.99	0.54	3.13e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.85	10.21	0.64	5.66e-19	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs10450586	0.932	rs7483162	chr11:27316394	A/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.69	-7.68	-0.53	1.78e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs80346118	0.673	rs6019433	chr20:47422568	G/A	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.59	-4.49	-0.34	1.38e-5	Diastolic blood pressure;
PAAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.66	6.86	0.49	1.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.26e-9	Personality dimensions;
PAAD	cis	rs2237349	0.609	rs7801187	chr7:28830977	T/C	cg04422003	chr7:28448295	CREB5	0.39	4.42	0.34	1.87e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg16358155	chr3:195490169	MUC4	0.58	4.51	0.34	1.31e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs9677476	0.587	rs62197354	chr2:232168727	T/C	cg07929768	chr2:232055508	NA	0.41	5.02	0.38	1.42e-6	Food antigen IgG levels;
PAAD	cis	rs7009110	0.677	rs11784307	chr8:81312277	C/T	cg21158561	chr8:81178149	NA	0.44	4.63	0.35	7.81e-6	Asthma and hay fever;
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1075265	0.633	rs10183655	chr2:54210781	C/T	cg04546899	chr2:54196757	PSME4	0.31	4.68	0.35	6.39e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.58	5.5	0.41	1.61e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6684428	0.706	rs11206677	chr1:56335237	C/A	cg11651538	chr1:56320950	NA	-0.51	-4.45	-0.34	1.62e-5	Airflow obstruction;
PAAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.62	-7.69	-0.53	1.72e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg27490568	chr2:178487706	NA	0.43	4.69	0.36	5.92e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg23982607	chr1:1823379	GNB1	-0.89	-10.73	-0.66	2.45e-20	Body mass index;
PAAD	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-5.35	-0.4	3.17e-7	Body mass index;
PAAD	cis	rs12042938	0.507	rs1655303	chr1:231731439	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-6.74	-0.48	3.12e-10	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.54	5.68	0.42	6.64e-8	Red blood cell count;
PAAD	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.78	7.7	0.53	1.59e-12	Breast cancer;
PAAD	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.74	7.18	0.5	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.62	4.81	0.36	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12304921	0.683	rs56335028	chr12:51441680	G/T	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-1.19	-11.48	-0.68	2.35e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.62	6.99	0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.82	5.41	0.4	2.38e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.95	-0.66	6.15e-21	Heart rate;
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg18084798	chr19:33555255	RHPN2	0.47	5.01	0.38	1.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs72627123	0.881	rs17094011	chr14:74392128	A/G	cg19860245	chr14:74300557	NA	-0.72	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs6496932	0.802	rs56306166	chr15:85870079	G/A	cg19183879	chr15:85880815	NA	0.52	4.76	0.36	4.56e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs11563648	0.553	rs9791822	chr7:127018589	C/T	cg21885361	chr7:127911034	NA	-0.4	-4.4	-0.34	2.04e-5	Resting heart rate;
PAAD	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.9	11.74	0.69	4.54e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg13385521	chr17:29058706	SUZ12P	-0.7	-4.82	-0.36	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.48	-4.44	-0.34	1.74e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12282928	1.000	rs10769343	chr11:48321098	G/A	cg04721828	chr11:48285200	OR4X1	0.48	6.09	0.44	8.91e-9	Migraine - clinic-based;
PAAD	cis	rs66530629	0.917	rs12027779	chr1:25148367	G/A	cg22509179	chr1:25234806	RUNX3	0.48	4.45	0.34	1.66e-5	Plateletcrit;
PAAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg08514558	chr10:81106712	PPIF	0.51	6.24	0.45	4.17e-9	Height;
PAAD	cis	rs3733418	0.799	rs13137799	chr4:165928937	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-4.95	-0.37	1.98e-6	Obesity-related traits;
PAAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs900145	0.906	rs4757139	chr11:13300456	C/T	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs951266	0.505	rs11639372	chr15:78966655	C/T	cg00540400	chr15:79124168	NA	-0.45	-5.12	-0.38	9.16e-7	Post bronchodilator FEV1/FVC ratio in COPD;Pre bronchodilator FEV1;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg09127314	chr1:152161683	NA	0.75	5.4	0.4	2.53e-7	Atopic dermatitis;
PAAD	cis	rs501120	0.925	rs1746052	chr10:44778546	G/T	cg09554077	chr10:44749378	NA	-0.45	-5.49	-0.41	1.64e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg08648136	chr8:956695	NA	0.47	5.08	0.38	1.12e-6	Schizophrenia;
PAAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg02869306	chr7:64672164	INTS4L1	0.4	4.65	0.35	7.17e-6	Aortic root size;
PAAD	cis	rs7567389	0.719	rs6738690	chr2:127992725	T/C	cg11380483	chr2:127933992	NA	-0.47	-4.68	-0.36	6.23e-6	Self-rated health;
PAAD	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-8.46	-0.57	2.03e-14	Morning vs. evening chronotype;
PAAD	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05212510	chr18:77623544	KCNG2	-0.45	-4.63	-0.35	7.93e-6	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.58	5.79	0.43	3.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg20744362	chr22:50050164	C22orf34	0.68	8.27	0.56	6.29e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2004318	0.850	rs113095728	chr19:55066223	T/C	cg03320607	chr19:54800032	LILRA3	-1.06	-5.77	-0.42	4.21e-8	Blood protein levels;
PAAD	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg00166722	chr3:10149974	C3orf24	0.72	6.44	0.46	1.48e-9	Alzheimer's disease;
PAAD	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-1.02	-13.29	-0.73	3.09e-27	Multiple myeloma;
PAAD	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg13160058	chr8:26243215	BNIP3L	-0.36	-4.48	-0.34	1.48e-5	Red cell distribution width;
PAAD	trans	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg20587970	chr11:113659929	NA	-1.09	-8.42	-0.56	2.54e-14	Hip circumference adjusted for BMI;
PAAD	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21659725	chr3:3221576	CRBN	-0.84	-9.97	-0.63	2.45e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.45	0.4	2.02e-7	Life satisfaction;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.44	4.55	0.35	1.11e-5	Tonsillectomy;
PAAD	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.1e-12	Colorectal cancer;
PAAD	cis	rs2997447	0.761	rs2802314	chr1:26431337	T/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.7e-6	QRS complex (12-leadsum);
PAAD	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	7.67	0.53	1.87e-12	Coronary artery disease;
PAAD	cis	rs427941	0.703	rs1637257	chr7:101740606	T/G	cg06246474	chr7:101738831	CUX1	0.45	4.66	0.35	6.96e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs8121916	0.865	rs6041320	chr20:12392473	G/A	cg16404259	chr20:12988931	SPTLC3	-0.45	-4.57	-0.35	1e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs76917914	0.589	rs55972150	chr9:100863941	G/T	cg21225548	chr9:100864335	TRIM14	-0.49	-5.53	-0.41	1.39e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2340727	0.668	rs12081397	chr1:161817371	A/G	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.64	-5.71	-0.42	5.63e-8	Coronary artery disease;
PAAD	cis	rs288342	0.731	rs288335	chr2:183620214	A/C	cg02625481	chr2:183667124	NA	-0.43	-4.25	-0.33	3.77e-5	Recurrent major depressive disorder;
PAAD	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.56	-5.62	-0.41	8.78e-8	Blood protein levels;
PAAD	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.38	4.43	0.34	1.81e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	9.42	0.61	6.94e-17	Response to antipsychotic treatment;
PAAD	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg01064725	chr1:204461714	NA	-0.51	-4.65	-0.35	7.21e-6	Schizophrenia;
PAAD	cis	rs6537837	0.762	rs6691984	chr1:110144024	G/T	cg05049280	chr1:110155535	GNAT2	0.53	5.12	0.38	8.95e-7	Major depressive disorder;
PAAD	cis	rs9810890	1.000	rs73196961	chr3:128436383	T/C	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.28	-0.45	3.3e-9	Cystic fibrosis severity;
PAAD	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs300774	0.925	rs300717	chr2:136638	G/A	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs2286379	0.596	rs7955261	chr12:1789371	C/T	cg05227549	chr12:1770782	NA	-0.44	-5.02	-0.38	1.45e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg13446199	chr8:143762866	PSCA	0.37	4.41	0.34	1.92e-5	Urinary tract infection frequency;
PAAD	trans	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg26939375	chr7:64535504	NA	-0.66	-7.39	-0.51	9.32e-12	Aortic root size;
PAAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg16205897	chr5:131564050	P4HA2	-0.48	-5.34	-0.4	3.38e-7	Blood metabolite levels;
PAAD	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.8	-0.43	3.63e-8	Life satisfaction;
PAAD	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.84	9.75	0.62	9.33e-18	Blood metabolite ratios;
PAAD	cis	rs8113142	0.614	rs1861173	chr19:29128097	C/A	cg04546413	chr19:29218101	NA	0.42	4.3	0.33	3.03e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs3779195	0.627	rs6950023	chr7:97915635	T/G	cg21770322	chr7:97807741	LMTK2	0.53	4.62	0.35	8.2e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.46	1.24e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.72	4.34	0.33	2.63e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg07671805	chr5:74907694	NA	-0.56	-4.34	-0.33	2.58e-5	Coronary artery disease;
PAAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.8	7.15	0.5	3.4e-11	Exhaled nitric oxide levels;
PAAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.14	-0.45	6.76e-9	Bone mineral density;
PAAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs797680	0.856	rs10874759	chr1:93630172	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.94	0.54	4.14e-13	Prudent dietary pattern;
PAAD	cis	rs1277203	0.559	rs6704266	chr1:109386174	A/G	cg08274380	chr1:109419600	GPSM2	0.53	4.27	0.33	3.39e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22947322	chr17:47091978	IGF2BP1	0.38	4.53	0.34	1.19e-5	Type 2 diabetes;
PAAD	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg03030879	chr14:75389066	RPS6KL1	0.41	4.28	0.33	3.24e-5	Height;
PAAD	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg05627522	chr15:75251581	NA	0.53	6.49	0.47	1.14e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.37	7.32	0.51	1.33e-11	Skin colour saturation;
PAAD	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.46	-0.4	1.89e-7	Fear of minor pain;
PAAD	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.42	-5.53	-0.41	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.8	5.89	0.43	2.45e-8	White matter hyperintensity burden;
PAAD	cis	rs12220238	0.915	rs10824148	chr10:76078014	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs4959799	1.000	rs7752394	chr6:3293649	T/C	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.77e-5	Survival in rectal cancer;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26392495	chr13:46536976	ZC3H13	-0.53	-6.39	-0.46	1.94e-9	Energy expenditure (24h);
PAAD	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	4.99	0.38	1.61e-6	Blood protein levels;
PAAD	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.92e-6	Oral cavity cancer;
PAAD	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.53	-4.99	-0.38	1.62e-6	Itch intensity from mosquito bite;
PAAD	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	4.67	0.35	6.48e-6	Breast cancer;
PAAD	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg21918786	chr6:109611834	NA	-0.43	-4.8	-0.36	3.82e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7580658	0.857	rs17015199	chr2:128094053	A/G	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg00933542	chr6:150070202	PCMT1	0.56	5.89	0.43	2.39e-8	Lung cancer;
PAAD	cis	rs863345	0.967	rs7517254	chr1:158469882	A/G	cg12129480	chr1:158549410	OR10X1	-0.46	-5.26	-0.39	4.91e-7	Pneumococcal bacteremia;
PAAD	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.6	5.71	0.42	5.7e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.61	-4.59	-0.35	9.17e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.61	-6.25	-0.45	3.97e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20003800	chr4:6718463	CNO	-0.73	-6.37	-0.46	2.12e-9	Neuroticism;
PAAD	cis	rs17162190	0.698	rs12093376	chr1:26849973	T/C	cg17456097	chr1:26900765	RPS6KA1	0.6	4.93	0.37	2.13e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-1.31	-12.7	-0.72	1.23e-25	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg20744362	chr22:50050164	C22orf34	0.63	7.58	0.52	3.18e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.58	-5.24	-0.39	5.27e-7	Post bronchodilator FEV1;
PAAD	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg18551225	chr6:44695536	NA	-0.71	-7.11	-0.5	4.29e-11	Total body bone mineral density;
PAAD	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.71	8.99	0.59	8.99e-16	Dupuytren's disease;
PAAD	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg13482628	chr17:19912719	NA	0.51	4.99	0.38	1.61e-6	Schizophrenia;
PAAD	trans	rs31251	0.835	rs2420148	chr5:130595408	C/A	cg18182399	chr2:220283175	DES	0.5	6.48	0.47	1.2e-9	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.6	-5.77	-0.42	4.25e-8	YKL-40 levels;
PAAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg24253500	chr15:84953950	NA	0.44	4.68	0.35	6.31e-6	Schizophrenia;
PAAD	cis	rs12935418	0.616	rs62054238	chr16:80999650	T/C	cg16651780	chr16:81037892	C16orf61	0.57	4.69	0.36	5.99e-6	Mean corpuscular volume;
PAAD	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.9	0.37	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	5.03e-7	Pulmonary function;
PAAD	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07031916	chr1:222886071	C1orf58;AIDA	-0.73	-6.77	-0.48	2.68e-10	Neuroticism;
PAAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	cis	rs4523957	0.583	rs2984939	chr17:2023965	T/C	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg16973527	chr15:70767570	NA	-0.4	-6.29	-0.45	3.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.75	-9.62	-0.62	2.12e-17	Educational attainment;
PAAD	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-7.39	-0.51	9.32e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4280164	0.943	rs2516564	chr14:24778643	C/T	cg07162820	chr14:24837146	NFATC4	0.38	4.41	0.34	1.92e-5	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.92	0.54	4.63e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg16083429	chr3:49237500	CCDC36	0.45	4.42	0.34	1.84e-5	Menarche (age at onset);
PAAD	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.89	10.94	0.66	6.37e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.63	8.8	0.58	2.77e-15	Airflow obstruction;
PAAD	trans	rs4915077	1.000	rs78288858	chr1:108362293	A/T	cg18565342	chr10:124714098	C10orf88	-1.19	-6.35	-0.46	2.34e-9	Hypothyroidism;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.97	6.14	0.45	6.71e-9	Body mass index;
PAAD	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.52	-5.13	-0.38	8.81e-7	Iron status biomarkers;
PAAD	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.68	8.51	0.57	1.54e-14	Dupuytren's disease;
PAAD	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.6	6.32	0.46	2.73e-9	Morning vs. evening chronotype;
PAAD	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.7	6.94	0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs2594989	0.895	rs2442789	chr3:11540188	C/T	cg01796438	chr3:11312864	ATG7	-0.58	-4.43	-0.34	1.8e-5	Circulating chemerin levels;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs904092	0.786	rs1497375	chr4:100161833	T/A	cg12011299	chr4:100065546	ADH4	0.6	5.53	0.41	1.35e-7	Alcohol dependence;
PAAD	cis	rs2882667	0.690	rs825672	chr5:138095643	A/G	cg09476006	chr5:138032270	NA	-0.43	-5.39	-0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-8.48	-0.57	1.89e-14	Vitiligo;
PAAD	cis	rs3764400	0.567	rs2109983	chr17:46207148	A/G	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg18833306	chr6:118973337	C6orf204	0.43	4.43	0.34	1.83e-5	Electrocardiographic conduction measures;
PAAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg03340356	chr1:67600835	NA	0.52	6.42	0.46	1.64e-9	Psoriasis;
PAAD	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-4.34	-0.33	2.57e-5	Coronary artery disease;
PAAD	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.84	7.06	0.5	5.52e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.73	-5.69	-0.42	6.32e-8	Resting heart rate;
PAAD	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-5.16	-0.39	7.46e-7	Total body bone mineral density;
PAAD	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	18.91	0.84	9.14e-42	Testicular germ cell tumor;
PAAD	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg17294928	chr15:75287854	SCAMP5	0.44	4.45	0.34	1.63e-5	Caffeine consumption;
PAAD	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg12568669	chr8:11666485	FDFT1	0.27	4.46	0.34	1.56e-5	Retinal vascular caliber;
PAAD	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.93	5.79	0.43	3.9e-8	Major depressive disorder;
PAAD	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-10.23	-0.64	5.01e-19	Blood trace element (Zn levels);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14039299	chr9:135251409	TTF1	-0.7	-7.34	-0.51	1.18e-11	Obesity-related traits;
PAAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.54e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg01852476	chr1:2232063	SKI	-0.27	-4.29	-0.33	3.12e-5	Ulcerative colitis;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg14926445	chr8:58193284	C8orf71	-0.69	-5.0	-0.38	1.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.39	0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg10395934	chr14:104002654	TRMT61A	0.53	5.06	0.38	1.18e-6	Body mass index;
PAAD	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.51	-4.68	-0.35	6.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6066835	0.572	rs56258328	chr20:47283781	C/G	cg18078177	chr20:47281410	PREX1	1.15	5.24	0.39	5.4e-7	Multiple myeloma;
PAAD	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.55	4.74	0.36	4.95e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs6710503	0.574	rs55649310	chr2:24833463	T/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.27	-0.33	3.41e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs4668356	0.881	rs73976125	chr2:172009420	T/A	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg09760422	chr2:128146352	NA	-0.41	-7.08	-0.5	5.09e-11	Protein C levels;
PAAD	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.57	-5.48	-0.41	1.77e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg26929925	chr5:138714136	SLC23A1	0.54	4.99	0.38	1.61e-6	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6691722	0.583	rs7535482	chr1:24695114	A/C	cg18323236	chr1:24743029	NIPAL3	0.42	4.45	0.34	1.65e-5	Response to interferon beta in multiple sclerosis;
PAAD	cis	rs1532557	1.000	rs12096245	chr1:224778770	T/C	cg09988837	chr1:224811939	CNIH3	0.67	5.0	0.38	1.54e-6	Cancer;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.34	-0.64	2.6e-19	Cognitive function;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs732765	0.734	rs17782707	chr14:75179102	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs9646944	0.501	rs34946515	chr2:103043320	C/T	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.41e-5	Blood protein levels;
PAAD	cis	rs904092	0.529	rs4699737	chr4:100163050	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-4.53	-0.34	1.21e-5	Alcohol dependence;
PAAD	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.81	9.2	0.6	2.69e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs4281086	0.544	rs6601476	chr8:10355179	C/G	cg01072821	chr8:10382165	T-SP1	-0.43	-4.59	-0.35	9.32e-6	Obesity-related traits;
PAAD	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.73e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12935418	0.672	rs7197370	chr16:81051125	A/G	cg16651780	chr16:81037892	C16orf61	0.69	6.25	0.45	3.88e-9	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.81	-0.36	3.65e-6	Lung cancer;
PAAD	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.48	4.64	0.35	7.5e-6	Hip circumference;
PAAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.71	6.18	0.45	5.62e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.57	7.19	0.5	2.71e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	9.3	0.6	1.42e-16	Nonalcoholic fatty liver disease;
PAAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg06766960	chr11:133703094	NA	-0.65	-6.66	-0.48	4.76e-10	Childhood ear infection;
PAAD	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.56	5.13	0.38	8.68e-7	Type 2 diabetes;
PAAD	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.51	5.33	0.4	3.42e-7	Male-pattern baldness;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05025164	chr4:1340916	KIAA1530	0.6	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.67	-6.38	-0.46	2.05e-9	Tourette syndrome;
PAAD	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg27449745	chr7:23145252	KLHL7	-0.54	-4.72	-0.36	5.41e-6	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25741567	chr21:35747810	FAM165B	-0.75	-8.57	-0.57	1.1e-14	Smoking initiation;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-5.64	-0.42	8.11e-8	Prudent dietary pattern;
PAAD	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.92	7.26	0.51	1.87e-11	Blood protein levels;
PAAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.68	-6.81	-0.48	2.11e-10	Blood metabolite levels;
PAAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24549020	chr5:56110836	MAP3K1	-0.7	-5.12	-0.38	9.16e-7	Initial pursuit acceleration;
PAAD	cis	rs4372836	0.541	rs6710080	chr2:28989975	A/G	cg09009506	chr2:28216851	BRE	0.41	4.37	0.33	2.28e-5	Body mass index;
PAAD	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.64	6.13	0.45	7.28e-9	Hip circumference;
PAAD	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.5	6.72	0.48	3.42e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.69	7.34	0.51	1.21e-11	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg19223190	chr17:80058835	NA	0.51	5.13	0.38	8.73e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.76	7.7	0.53	1.65e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14617014	chr1:87112050	CLCA3P	-0.66	-6.35	-0.46	2.31e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-5.79	-0.43	3.9e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12936587	0.595	rs9911672	chr17:17528670	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.47	4.88	0.37	2.62e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.6	4.67	0.35	6.62e-6	Alzheimer's disease;
PAAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-4.61	-0.35	8.57e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.72	-7.98	-0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs11264213	0.792	rs709309	chr1:36441148	G/T	cg27506609	chr1:36549197	TEKT2	0.79	5.41	0.4	2.45e-7	Schizophrenia;
PAAD	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.47	5.72	0.42	5.37e-8	Vitiligo;
PAAD	cis	rs9463078	0.585	rs1285019	chr6:45167672	C/T	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10239991	chr2:240046227	HDAC4	0.56	6.47	0.46	1.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17155006	0.530	rs408867	chr7:107743244	C/T	cg05962710	chr7:107745446	LAMB4	-0.54	-7.2	-0.5	2.52e-11	Pneumococcal bacteremia;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.5	0.68	1.99e-22	Platelet count;
PAAD	cis	rs2421770	0.532	rs2901605	chr11:35340431	A/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.22	-0.39	5.91e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.92	-0.49	1.19e-10	Neuroticism;
PAAD	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.86	0.37	2.94e-6	Alzheimer's disease;
PAAD	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.61	-6.23	-0.45	4.41e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.4	0.56	2.96e-14	Homoarginine levels;
PAAD	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.47	4.58	0.35	9.56e-6	Crohn's disease;
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.87	10.75	0.66	2.13e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.63	7.12	0.5	4.1e-11	Emphysema distribution in smoking;
PAAD	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.63	-6.37	-0.46	2.14e-9	Type 2 diabetes;
PAAD	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.57	4.9	0.37	2.39e-6	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22084302	chr13:20246166	MPHOSPH8	-0.64	-6.31	-0.46	2.96e-9	Obesity-related traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03122602	chr16:89799836	ZNF276	0.6	6.72	0.48	3.45e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6071524	0.818	rs4368395	chr20:37470453	G/A	cg09937324	chr20:37376998	ACTR5	-0.49	-4.28	-0.33	3.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg14349672	chr11:133703707	NA	-0.55	-6.39	-0.46	1.91e-9	Childhood ear infection;
PAAD	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs112392416	chr10:46070466	C/T	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg16257655	chr7:1659720	NA	0.43	4.44	0.34	1.74e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.86	-0.37	2.87e-6	Mood instability;
PAAD	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.17	0.6	3.17e-16	Asthma;
PAAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs6076065	0.723	rs6083110	chr20:23373674	C/T	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14509299	chr9:36489476	NA	-0.64	-6.3	-0.46	3.08e-9	Obesity-related traits;
PAAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg10935138	chr17:73851978	WBP2	0.82	4.81	0.36	3.59e-6	Psoriasis;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg19130645	chr7:65235666	NA	-0.43	-4.52	-0.34	1.24e-5	Calcium levels;
PAAD	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.95	12.16	0.7	3.37e-24	Heart rate;
PAAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.55	-0.35	1.07e-5	Mood instability;
PAAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.61	0.41	9.13e-8	Tonsillectomy;
PAAD	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg13263323	chr15:86062960	AKAP13	0.48	4.87	0.37	2.78e-6	Coronary artery disease;
PAAD	cis	rs863345	0.604	rs879637	chr1:158462697	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.92	-0.37	2.25e-6	Pneumococcal bacteremia;
PAAD	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.5	-6.21	-0.45	4.75e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.76	0.48	2.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.64	0.42	8.2e-8	Prudent dietary pattern;
PAAD	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.11	10.12	0.63	9.86e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs11051970	0.918	rs11051969	chr12:32537123	T/C	cg24626660	chr12:32551988	NA	0.43	4.79	0.36	3.93e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs12044355	0.929	rs6667123	chr1:231851991	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.06	0.38	1.22e-6	Alzheimer's disease;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg07362569	chr17:61921086	SMARCD2	0.42	4.96	0.37	1.86e-6	Height;
PAAD	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.81	0.54	8.53e-13	Eotaxin levels;
PAAD	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06850241	chr22:41845214	NA	0.55	5.04	0.38	1.33e-6	Vitiligo;
PAAD	cis	rs12612619	0.732	rs1465881	chr2:27237614	A/G	cg00617064	chr2:27272375	NA	-0.45	-4.73	-0.36	4.98e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.7	-7.16	-0.5	3.2e-11	Primary sclerosing cholangitis;
PAAD	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.76	-10.48	-0.65	1.13e-19	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20054983	chr11:124496361	TBRG1	-0.69	-6.77	-0.48	2.58e-10	Obesity-related traits;
PAAD	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg15145965	chr22:50218605	BRD1	0.6	5.21	0.39	5.92e-7	Schizophrenia;
PAAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.83	0.36	3.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-8.31	-0.56	4.98e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg04154034	chr17:28927549	LRRC37B2	0.68	4.33	0.33	2.68e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	6.01	0.44	1.31e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09828236	chr1:10502470	APITD1	-0.66	-6.66	-0.48	4.75e-10	Obesity-related traits;
PAAD	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg00129232	chr17:37814104	STARD3	-0.53	-4.72	-0.36	5.32e-6	Self-reported allergy;
PAAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs76419734	0.558	rs10032269	chr4:106525703	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.45	0.34	1.62e-5	Post bronchodilator FEV1;
PAAD	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.78	-6.81	-0.48	2.1e-10	Coronary artery disease;
PAAD	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-4.25	-0.33	3.65e-5	Height;
PAAD	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg24881330	chr22:46731750	TRMU	1.16	5.73	0.42	5.27e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.93	-10.23	-0.64	4.99e-19	Parkinson's disease;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.59	0.41	1e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1062753	0.700	rs58874647	chr22:42386269	C/T	cg22189786	chr22:42395067	WBP2NL	0.52	4.48	0.34	1.47e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs16958440	0.867	rs62095427	chr18:44594221	G/A	cg17192377	chr18:44677553	HDHD2	0.85	4.63	0.35	7.81e-6	Sitting height ratio;
PAAD	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	0.54	6.11	0.44	8.11e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.66	4.78	0.36	4.19e-6	Plateletcrit;
PAAD	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2882667	0.690	rs13177415	chr5:138249940	G/T	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.6	0.57	9.35e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	8.57	0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg20913747	chr6:44695427	NA	0.58	4.92	0.37	2.21e-6	Total body bone mineral density;
PAAD	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg23649088	chr2:200775458	C2orf69	0.65	5.53	0.41	1.36e-7	Schizophrenia;
PAAD	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.6	-5.48	-0.41	1.75e-7	Total body bone mineral density;
PAAD	cis	rs8077577	0.945	rs62073604	chr17:18065888	T/C	cg16794390	chr17:18148240	FLII	0.59	4.96	0.37	1.89e-6	Obesity-related traits;
PAAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.68	-5.0	-0.38	1.55e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.5	5.38	0.4	2.82e-7	Carotid intima media thickness;
PAAD	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	Cognitive function;
PAAD	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26926768	chr12:34528122	NA	0.37	4.58	0.35	9.65e-6	Morning vs. evening chronotype;
PAAD	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.49	-0.41	1.68e-7	Blood metabolite levels;
PAAD	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg20356878	chr3:121714668	ILDR1	0.53	5.05	0.38	1.25e-6	Cognitive performance;
PAAD	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg13263323	chr15:86062960	AKAP13	-0.61	-6.89	-0.49	1.4e-10	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	8.63	0.57	7.82e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.97	-11.04	-0.67	3.46e-21	Schizophrenia;
PAAD	cis	rs12826942	0.718	rs12827742	chr12:42542861	A/G	cg19980929	chr12:42632907	YAF2	0.5	4.44	0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.56	-5.45	-0.4	1.95e-7	Gut microbiome composition (summer);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06833647	chr7:100966076	RABL5	0.68	8.52	0.57	1.43e-14	Smoking initiation;
PAAD	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs10991814	1.000	rs76067199	chr9:93959395	C/T	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22846334	chr15:43941042	CATSPER2	0.61	7.18	0.5	2.82e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.55	-0.41	1.22e-7	Lung cancer;
PAAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14895029	chr7:2775587	GNA12	-0.47	-4.41	-0.34	1.95e-5	Height;
PAAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg05785598	chr3:49045655	WDR6	0.42	4.9	0.37	2.44e-6	Parkinson's disease;
PAAD	cis	rs9652601	0.919	rs12924729	chr16:11187783	C/T	cg04616529	chr16:11181986	CLEC16A	0.47	5.07	0.38	1.17e-6	Systemic lupus erythematosus;
PAAD	cis	rs2124910	0.935	rs10409713	chr19:52026801	G/T	cg12008991	chr19:52034861	SIGLEC6	0.35	4.58	0.35	9.47e-6	Blood protein levels;
PAAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.49	4.47	0.34	1.54e-5	Height;
PAAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg16205897	chr5:131564050	P4HA2	-0.54	-6.05	-0.44	1.09e-8	Blood metabolite levels;
PAAD	cis	rs9535307	0.719	rs1198315	chr13:50370168	C/T	cg04663916	chr13:50265991	EBPL	-0.57	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs3136739	0.614	rs77758638	chr8:42014917	C/T	cg12054981	chr8:42037387	PLAT	0.71	5.21	0.39	6.15e-7	Plasma plasminogen activator levels;
PAAD	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.81	10.62	0.65	4.73e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg02264943	chr11:130785842	SNX19	0.35	4.36	0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.47	-4.92	-0.37	2.25e-6	Eosinophil percentage of white cells;
PAAD	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.64	6.06	0.44	1.01e-8	Aortic root size;
PAAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg16176600	chr6:116381609	FRK	0.28	4.34	0.33	2.57e-5	Total cholesterol levels;
PAAD	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.88	-7.87	-0.54	6.09e-13	Blood protein levels;
PAAD	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg02254261	chr7:158964346	NA	-0.61	-4.72	-0.36	5.42e-6	Myopia (pathological);
PAAD	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.72	9.21	0.6	2.52e-16	Cancer;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13560548	chr3:10150139	C3orf24	0.62	5.47	0.41	1.78e-7	Alzheimer's disease;
PAAD	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg21194808	chr1:2205498	SKI	0.43	4.29	0.33	3.23e-5	Coronary artery disease;
PAAD	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg14146966	chr2:61757674	XPO1	0.4	4.83	0.36	3.31e-6	Tuberculosis;
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg17105886	chr17:28927953	LRRC37B2	0.62	4.3	0.33	3.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg00280220	chr17:61926910	NA	0.43	4.53	0.35	1.17e-5	Prudent dietary pattern;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.2e-18	Prudent dietary pattern;
PAAD	cis	rs17032980	0.956	rs3770659	chr2:67307294	T/C	cg06994420	chr2:66672553	MEIS1	-0.51	-4.49	-0.34	1.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg20356878	chr3:121714668	ILDR1	0.53	5.07	0.38	1.17e-6	Cognitive performance;
PAAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07167872	chr1:205819463	PM20D1	0.79	8.8	0.58	2.89e-15	Menarche (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26576196	chr1:214563988	PTPN14	-0.62	-6.42	-0.46	1.63e-9	Obesity-related traits;
PAAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-4.45	-0.34	1.62e-5	Platelet count;
PAAD	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg22601191	chr20:60968625	CABLES2	-0.56	-5.44	-0.4	2.06e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.45	5.31	0.4	3.85e-7	Intelligence;
PAAD	cis	rs943466	1.000	rs747692	chr6:33737436	C/T	cg04704449	chr6:33738291	NA	-0.47	-4.74	-0.36	4.83e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	trans	rs901683	1.000	rs9422654	chr10:46051401	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs595018	0.505	rs2074421	chr11:60610056	G/C	cg23904249	chr11:60608951	CCDC86	0.68	4.95	0.37	1.92e-6	Wegener's granulomatosis;
PAAD	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg07622451	chr1:3079886	PRDM16	0.38	4.5	0.34	1.36e-5	Migraine;
PAAD	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13870426	chr17:30244630	NA	-0.66	-6.38	-0.46	2.03e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.37	-0.33	2.29e-5	IgG glycosylation;
PAAD	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.65	-0.35	7.04e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1318772	1.000	rs11746828	chr5:112718008	C/A	cg12552261	chr5:112820674	MCC	0.59	4.31	0.33	2.9e-5	F-cell distribution;
PAAD	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-4.41	-0.34	1.91e-5	Skin colour saturation;
PAAD	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg26205652	chr12:48591994	NA	0.93	9.03	0.59	7.18e-16	Longevity (90 years and older);
PAAD	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg02459107	chr1:67143332	SGIP1	0.74	7.62	0.53	2.54e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs990171	1.000	rs2058660	chr2:103054449	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg20965017	chr5:231967	SDHA	0.6	4.4	0.34	2.02e-5	Breast cancer;
PAAD	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg24253500	chr15:84953950	NA	-0.47	-5.2	-0.39	6.45e-7	P wave terminal force;
PAAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.81	11.28	0.68	7.98e-22	Bone mineral density;
PAAD	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs939584	1.000	rs6719518	chr2:623935	A/G	cg03610516	chr2:642275	NA	-0.65	-5.73	-0.42	5.28e-8	Body mass index;
PAAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-4.64	-0.35	7.4e-6	Bone mineral density;
PAAD	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-1.01	-9.07	-0.59	5.57e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs11785693	0.602	rs73190403	chr8:4954798	T/C	cg26367366	chr8:4980734	NA	0.65	4.71	0.36	5.66e-6	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.69	-0.36	6.14e-6	Breast cancer;
PAAD	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg14583973	chr4:3374767	RGS12	0.39	5.93	0.43	1.94e-8	Serum sulfate level;
PAAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.62	6.57	0.47	7.46e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs62120679	0.552	rs4807227	chr19:2318180	C/T	cg12199618	chr19:2353492	SPPL2B	-0.51	-4.43	-0.34	1.77e-5	Parkinson's disease;
PAAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.64	0.35	7.35e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.92	-0.37	2.27e-6	QT interval;
PAAD	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.71	-6.55	-0.47	8.39e-10	Diabetic retinopathy;
PAAD	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.87	9.45	0.61	5.91e-17	Anterior chamber depth;
PAAD	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.55	-4.85	-0.37	2.97e-6	P wave terminal force;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.27	-0.33	3.39e-5	Cognitive function;
PAAD	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.72	8.15	0.55	1.22e-13	Colorectal cancer;
PAAD	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.12e-13	Prostate cancer;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.62	-6.61	-0.47	6e-10	Lymphocyte counts;
PAAD	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.26	-0.33	3.61e-5	Multiple sclerosis;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.57	-5.46	-0.41	1.87e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.6200000000000003e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs911555	0.926	rs2756121	chr14:103989581	T/A	cg12935359	chr14:103987150	CKB	0.77	8.86	0.58	1.97e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs4668356	0.892	rs2676139	chr2:171811546	T/A	cg13882835	chr2:172017928	TLK1	-0.87	-4.35	-0.33	2.53e-5	Cognitive performance;
PAAD	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1144713	0.531	rs2683491	chr12:32250865	A/T	cg01321189	chr12:32259338	BICD1	0.48	5.05	0.38	1.27e-6	Obesity-related traits;
PAAD	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06002616	chr8:101225028	SPAG1	0.46	5.46	0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg05338066	chr1:7812865	CAMTA1	0.52	4.41	0.34	1.93e-5	Inflammatory bowel disease;
PAAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.8	-0.48	2.26e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.41	-0.4	2.42e-7	Height;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg05313129	chr8:58192883	C8orf71	-0.66	-5.74	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4787491	0.729	rs12446378	chr16:30043110	T/G	cg06015834	chr16:30021696	DOC2A	-0.4	-4.29	-0.33	3.17e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-4.63	-0.35	7.93e-6	Lung cancer;
PAAD	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06679752	chr13:50367340	KPNA3	0.72	8.36	0.56	3.67e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3093024	0.904	rs3093017	chr6:167541258	C/G	cg07741184	chr6:167504864	NA	-0.51	-6.26	-0.45	3.78e-9	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg04287289	chr16:89883240	FANCA	-0.42	-4.25	-0.33	3.7e-5	Vitiligo;
PAAD	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.75	5.41	0.4	2.42e-7	Blood protein levels;
PAAD	cis	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.43	0.34	1.82e-5	Depression;
PAAD	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg09491104	chr22:46646882	C22orf40	-1.0	-5.82	-0.43	3.37e-8	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg16584676	chr17:46985605	UBE2Z	0.58	5.69	0.42	6.45e-8	Type 2 diabetes;
PAAD	cis	rs6466055	0.589	rs17708070	chr7:104959297	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs438034	0.775	rs34721280	chr1:214798580	C/T	cg16144317	chr1:214725524	PTPN14	0.4	4.3	0.33	3.03e-5	Response to antineoplastic agents;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01593751	chr17:52977904	TOM1L1	0.68	6.78	0.48	2.5e-10	Obesity-related traits;
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg07689907	chr11:61582574	FADS1	0.46	4.48	0.34	1.46e-5	Trans fatty acid levels;
PAAD	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.49	-5.26	-0.39	4.85e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg12193833	chr17:30244370	NA	-0.61	-4.84	-0.37	3.23e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2190422	0.677	rs2190419	chr7:103073087	C/G	cg04218035	chr7:103086829	SLC26A5	0.35	4.98	0.37	1.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.51	5.15	0.39	7.96e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6496667	0.642	rs60597654	chr15:91066771	C/G	cg22089800	chr15:90895588	ZNF774	0.61	4.76	0.36	4.4e-6	Rheumatoid arthritis;
PAAD	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg18825076	chr15:78729989	IREB2	-0.61	-5.97	-0.44	1.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg04153130	chr7:4456396	NA	-0.69	-5.28	-0.39	4.32e-7	Borderline personality disorder;
PAAD	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.51	-5.0	-0.38	1.59e-6	Multiple myeloma;
PAAD	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.72	-9.4	-0.61	7.67e-17	Survival in pancreatic cancer;
PAAD	cis	rs8060686	0.858	rs7206671	chr16:67807146	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.32	-0.4	3.63e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-4.96	-0.37	1.84e-6	Tonsillectomy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16813767	chr1:155224842	FAM189B	-0.73	-6.34	-0.46	2.43e-9	Neuroticism;
PAAD	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg23912435	chr1:150601613	ENSA	0.52	4.79	0.36	3.86e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10140922	0.713	rs1885151	chr14:35816139	G/A	cg07166546	chr14:35805898	NA	-0.29	-4.59	-0.35	9.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12304921	0.935	rs17125116	chr12:51343976	C/G	cg18059802	chr12:51347058	HIGD1C	-0.71	-5.57	-0.41	1.13e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11951952	chr5:175395053	THOC3	0.58	6.42	0.46	1.64e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.54	-6.13	-0.45	7.06e-9	Major depressive disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04616447	chr8:41348488	GOLGA7	0.58	6.49	0.47	1.14e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58521262	0.556	rs289351	chr19:23145338	A/G	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs10991814	1.000	rs17579908	chr9:93948636	G/C	cg14446406	chr9:93919335	NA	0.51	4.26	0.33	3.59e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg08738300	chr3:44038990	NA	0.66	6.24	0.45	4.12e-9	Coronary artery disease;
PAAD	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs3136739	0.614	rs113455175	chr8:42007622	C/T	cg17828057	chr8:42037527	PLAT	0.62	4.27	0.33	3.41e-5	Plasma plasminogen activator levels;
PAAD	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.46	0.65	1.26e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg03959625	chr15:84868606	LOC388152	-0.5	-5.62	-0.42	8.73e-8	Schizophrenia;
PAAD	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.77	-7.91	-0.54	4.9e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg15654264	chr1:150340011	RPRD2	-0.5	-4.87	-0.37	2.78e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.61	-5.4	-0.4	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.65	6.31	0.46	2.92e-9	Type 2 diabetes;
PAAD	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.71	10.22	0.64	5.47e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg17385448	chr1:15911702	AGMAT	0.35	4.36	0.33	2.41e-5	Systolic blood pressure;
PAAD	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs78707713	0.841	rs79069746	chr10:71205473	T/C	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.28	-0.39	4.47e-7	Venous thromboembolism;
PAAD	trans	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg00626422	chr7:22894849	SNORD93	-0.54	-6.38	-0.46	2.04e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.48	5.12	0.38	9.02e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.86	5.36	0.4	3.07e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.73	-5.87	-0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11073060	0.569	rs7161746	chr15:34987432	T/A	cg03492641	chr15:34807679	NA	0.45	4.34	0.33	2.57e-5	Hyperopia;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.67	-6.68	-0.48	4.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.85	9.54	0.61	3.5e-17	Pancreatic cancer;
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.75	-6.07	-0.44	9.95e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs735539	0.521	rs2818995	chr13:21420964	T/G	cg27234864	chr13:21295941	IL17D	0.6	4.86	0.37	2.91e-6	Dental caries;
PAAD	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.76	-0.48	2.75e-10	Neuroticism;
PAAD	cis	rs375246367	1	rs375246367	chr14:103841352	CTT/C	cg12935359	chr14:103987150	CKB	-0.6	-5.74	-0.42	4.96e-8	Monocyte percentage of white cells;
PAAD	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.86	-0.43	2.81e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs58521262	0.556	rs289297	chr19:23176140	T/C	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg07622451	chr1:3079886	PRDM16	0.39	4.69	0.36	6.14e-6	Migraine;
PAAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	7.02	0.49	6.82e-11	Alzheimer's disease;
PAAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg03714773	chr7:91764589	CYP51A1	0.32	4.31	0.33	2.95e-5	Breast cancer;
PAAD	cis	rs7772697	0.635	rs6570932	chr6:149411333	C/T	cg21368479	chr6:149415018	NA	0.45	4.81	0.36	3.59e-6	Diabetic retinopathy;
PAAD	cis	rs10901513	0.932	rs11244740	chr10:127662829	A/G	cg22975853	chr10:127789788	ADAM12	0.4	4.31	0.33	2.97e-5	Visceral fat;
PAAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs72634258	0.945	rs2641116	chr1:8029494	T/G	cg26816564	chr1:7831052	VAMP3	0.74	5.72	0.42	5.36e-8	Inflammatory bowel disease;
PAAD	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	5.28	0.39	4.3e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.85	0.58	2.1e-15	Motion sickness;
PAAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.81	0.36	3.65e-6	Cognitive ability;
PAAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg09796270	chr17:17721594	SREBF1	0.44	5.04	0.38	1.31e-6	Total body bone mineral density;
PAAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	6.02	0.44	1.25e-8	Platelet count;
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.37	0.46	2.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.56	-5.82	-0.43	3.36e-8	Lung cancer;
PAAD	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.74	-8.8	-0.58	2.8e-15	Body mass index;
PAAD	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.65	8.1	0.55	1.68e-13	Coronary artery disease;
PAAD	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg25811867	chr2:3488468	NA	0.47	4.36	0.33	2.4e-5	Neurofibrillary tangles;
PAAD	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg08886695	chr4:3369023	RGS12	0.53	5.26	0.39	4.77e-7	Mean platelet volume;
PAAD	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg05562828	chr17:3906858	NA	-0.55	-6.28	-0.45	3.4e-9	Type 2 diabetes;
PAAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-5.81	-0.43	3.54e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-5.14	-0.38	8.5e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-4.47	-0.34	1.52e-5	Body mass index;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg00738919	chr7:1100172	C7orf50	0.66	4.95	0.37	1.98e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21584983	chr19:11640070	ECSIT	0.62	6.84	0.49	1.86e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.96	12.69	0.72	1.28e-25	Menarche (age at onset);
PAAD	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.92	9.2	0.6	2.68e-16	Orofacial clefts;
PAAD	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.63	6.02	0.44	1.25e-8	Height;
PAAD	cis	rs11235843	0.565	rs1723840	chr11:73473885	T/A	cg18195628	chr11:73498948	MRPL48	0.69	5.09	0.38	1.03e-6	Hand grip strength;
PAAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.54	0.47	8.85e-10	Personality dimensions;
PAAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06217245	chr20:33103252	DYNLRB1	0.4	4.82	0.36	3.39e-6	Coronary artery disease;
PAAD	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-4.52	-0.34	1.21e-5	Height;
PAAD	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22153463	chr1:85462885	MCOLN2	0.65	5.1	0.38	9.91e-7	Serum sulfate level;
PAAD	cis	rs4737010	0.644	rs777870	chr8:41610234	G/A	cg17182837	chr8:41585554	ANK1	0.48	4.71	0.36	5.47e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.39	4.43	0.34	1.81e-5	Calcium levels;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.43	0.4	2.24e-7	Prudent dietary pattern;
PAAD	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg01426195	chr3:39028469	NA	0.62	5.85	0.43	2.85e-8	Handedness;
PAAD	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg25722041	chr1:8623473	RERE	0.51	4.4	0.34	2.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7188861	0.768	rs12922733	chr16:11380670	C/G	cg01510278	chr16:11456238	NA	0.43	4.3	0.33	3.08e-5	HDL cholesterol;
PAAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.85	0.58	2.13e-15	Lung cancer;
PAAD	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.82	-8.13	-0.55	1.39e-13	Response to antineoplastic agents;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05482956	chr11:16635016	NA	0.51	6.39	0.46	1.94e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.82	8.03	0.55	2.53e-13	Corneal astigmatism;
PAAD	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs10792830	0.707	rs613222	chr11:85769105	T/G	cg07180834	chr11:85838833	NA	-0.53	-6.21	-0.45	4.88e-9	Psychosis and Alzheimer's disease;
PAAD	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.29e-9	Breast cancer;
PAAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.8	-9.13	-0.6	3.87e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.82	-8.84	-0.58	2.2e-15	Morning vs. evening chronotype;
PAAD	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.22	0.6	2.31e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-8.92	-0.59	1.38e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs72827839	1.000	rs72827839	chr17:46420996	G/A	cg23391107	chr17:45924227	SP6	0.7	5.44	0.4	2.07e-7	Ease of getting up in the morning;
PAAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg09473613	chr1:24152604	HMGCL	0.42	4.29	0.33	3.21e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.8	8.98	0.59	9.54e-16	Lung cancer;
PAAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.92	11.2	0.67	1.29e-21	Blood protein levels;
PAAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg00474734	chr12:53645975	MFSD5	0.65	6.4	0.46	1.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.67	-7.01	-0.49	7.17e-11	DNA methylation (variation);
PAAD	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.65	-6.87	-0.49	1.58e-10	Multiple myeloma (IgH translocation);
PAAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.57	0.57	1.1e-14	Lung cancer;
PAAD	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	1.01	9.56	0.61	3.04e-17	Psoriasis;
PAAD	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10046574	0.634	rs10266715	chr7:135155366	C/T	cg27474649	chr7:135195673	CNOT4	-0.78	-4.38	-0.33	2.22e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04301682	chr4:76598670	G3BP2	0.64	6.4	0.46	1.85e-9	Obesity-related traits;
PAAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg09658497	chr7:2847517	GNA12	-0.42	-4.44	-0.34	1.72e-5	Height;
PAAD	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.71	4.99	0.38	1.65e-6	HDL cholesterol levels;
PAAD	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.69	5.1	0.38	9.91e-7	Exhaled nitric oxide output;
PAAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.81	-8.3	-0.56	5.13e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6563943	0.963	rs2067861	chr16:83632487	C/T	cg01935413	chr16:83636749	CDH13	0.53	5.01	0.38	1.52e-6	Height;
PAAD	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.75	8.32	0.56	4.56e-14	Alcohol dependence;
PAAD	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.08	0.44	9.17e-9	Height;
PAAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.75	6.91	0.49	1.27e-10	Obesity-related traits;
PAAD	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.38	-0.33	2.22e-5	Height;
PAAD	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-9.5	-0.61	4.39e-17	Body mass index;
PAAD	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.66	9.28	0.6	1.63e-16	Airflow obstruction;
PAAD	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg12046867	chr14:103022105	NA	-0.63	-4.89	-0.37	2.57e-6	Platelet count;
PAAD	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg23024343	chr7:107201750	COG5	0.59	4.82	0.36	3.52e-6	Coronary artery disease;
PAAD	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.58	5.51	0.41	1.5e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08677398	chr8:58056175	NA	0.68	4.76	0.36	4.45e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg06565975	chr8:143823917	SLURP1	-0.23	-4.79	-0.36	3.88e-6	Urinary tract infection frequency;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs6681460	0.584	rs7528182	chr1:67067369	C/T	cg02459107	chr1:67143332	SGIP1	0.55	5.15	0.39	7.96e-7	Presence of antiphospholipid antibodies;
PAAD	cis	rs4917300	0.626	rs13254582	chr8:143121547	T/G	cg26003909	chr8:143102224	NA	-0.33	-5.46	-0.4	1.94e-7	Amyotrophic lateral sclerosis;
PAAD	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.15	-13.74	-0.74	1.91e-28	Schizophrenia;
PAAD	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg02487422	chr3:49467188	NICN1	0.49	4.93	0.37	2.16e-6	Resting heart rate;
PAAD	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.49e-9	Atopic dermatitis;
PAAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21545522	chr1:205238299	TMCC2	0.47	4.34	0.33	2.56e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.91	8.09	0.55	1.72e-13	IgG glycosylation;
PAAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.53	4.58	0.35	9.8e-6	Menopause (age at onset);
PAAD	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.45	-4.54	-0.35	1.13e-5	Mean corpuscular volume;
PAAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.57	-7.8	-0.53	9.02e-13	Height;
PAAD	cis	rs10861342	1.000	rs10861353	chr12:105515290	T/C	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs54211	0.572	rs79290	chr22:39685832	G/A	cg24399712	chr22:39784796	NA	-0.62	-4.29	-0.33	3.21e-5	Sudden cardiac arrest;
PAAD	cis	rs111544199	1	rs111544199	chr19:50091221	GT/G	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.59	-5.04	-0.38	1.3e-6	Red blood cell count;
PAAD	cis	rs943466	0.911	rs72880511	chr6:33729820	G/A	cg04704449	chr6:33738291	NA	-0.51	-5.06	-0.38	1.2e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.59	6.09	0.44	8.85e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg14180030	chr9:123475675	MEGF9	-0.47	-5.15	-0.39	8.12e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs7224685	0.637	rs35618711	chr17:4229258	A/T	cg11204139	chr17:3907470	NA	0.66	5.34	0.4	3.28e-7	Type 2 diabetes;
PAAD	cis	rs10516089	0.504	rs10068044	chr5:171139868	G/A	cg21066063	chr5:171570130	STK10	0.35	4.4	0.34	2e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg14583973	chr4:3374767	RGS12	-0.35	-5.31	-0.4	3.84e-7	Parental longevity (mother's age at death);
PAAD	cis	rs4716602	0.898	rs4717047	chr7:156160671	T/C	cg04090468	chr7:156181990	NA	0.5	4.78	0.36	4.15e-6	Anti-saccade response;
PAAD	cis	rs12580194	0.593	rs11171430	chr12:55755254	A/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.34	0.33	2.56e-5	Cancer;
PAAD	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg00536532	chr6:33561449	C6orf227	0.41	4.26	0.33	3.58e-5	Plateletcrit;
PAAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.21e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg15117754	chr3:10150083	C3orf24	0.71	5.99	0.44	1.43e-8	Alzheimer's disease;
PAAD	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6589563	0.655	rs12221682	chr11:116578217	C/G	cg15806780	chr11:117515100	DSCAML1	-0.57	-4.55	-0.35	1.09e-5	Eosinophil counts;
PAAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg24253500	chr15:84953950	NA	0.42	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.61	6.41	0.46	1.73e-9	Testicular germ cell tumor;
PAAD	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.34	-0.33	2.61e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7251275	0.744	rs17655646	chr19:44134936	G/A	cg17121205	chr19:44009353	PHLDB3	0.37	4.42	0.34	1.86e-5	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.44	6.17	0.45	5.78e-9	Vitiligo;
PAAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.89	9.22	0.6	2.3e-16	Cognitive function;
PAAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg18209359	chr17:80159595	CCDC57	0.44	4.47	0.34	1.51e-5	Life satisfaction;
PAAD	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg23587288	chr2:27483067	SLC30A3	-0.72	-5.88	-0.43	2.5e-8	Blood metabolite levels;
PAAD	cis	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg16818395	chr3:128274084	NA	0.54	4.77	0.36	4.25e-6	Dental caries;
PAAD	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-4.77	-0.36	4.3e-6	Vitiligo;
PAAD	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.75	6.99	0.49	8.3e-11	Asthma;
PAAD	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.52	-0.34	1.23e-5	Atopic dermatitis;
PAAD	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg15956490	chr3:53032818	SFMBT1	-0.74	-4.3	-0.33	2.98e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.78	-9.98	-0.63	2.42e-18	Coronary artery disease;
PAAD	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.69	7.8	0.53	9.1e-13	Alcohol dependence;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.49	4.85	0.37	3.06e-6	Testicular germ cell tumor;
PAAD	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg14515779	chr1:101123966	NA	-0.41	-4.47	-0.34	1.5e-5	Monocyte count;
PAAD	cis	rs28489187	0.706	rs233119	chr1:85788052	T/C	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs354225	0.544	rs7599241	chr2:54801856	G/A	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.74	-6.81	-0.48	2.11e-10	Asthma;
PAAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.28	-0.33	3.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg00540400	chr15:79124168	NA	0.7	8.87	0.58	1.84e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.63	7.51	0.52	4.68e-12	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.51	-5.1	-0.38	1.02e-6	Menarche (age at onset);
PAAD	cis	rs4481887	0.751	rs10159227	chr1:248425898	G/C	cg00666640	chr1:248458726	OR2T12	0.57	4.68	0.36	6.25e-6	Common traits (Other);
PAAD	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.69	-7.5	-0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-1.03	-14.46	-0.76	2.35e-30	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg07395648	chr5:131743802	NA	0.56	5.15	0.39	7.97e-7	Breast cancer;
PAAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.73	0.53	1.33e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.89	7.62	0.53	2.56e-12	Triglycerides;
PAAD	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.02	0.38	1.4e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg19483011	chr3:158453295	NA	-0.63	-5.43	-0.4	2.22e-7	Tetralogy of Fallot;
PAAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.53	5.42	0.4	2.33e-7	Major depressive disorder;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg22482690	chr17:47019901	SNF8	0.47	5.06	0.38	1.19e-6	Type 2 diabetes;
PAAD	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg22482690	chr17:47019901	SNF8	0.5	5.43	0.4	2.19e-7	Type 2 diabetes;
PAAD	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.9	10.95	0.66	6.04e-21	Metabolic syndrome;
PAAD	cis	rs425535	0.702	rs168450	chr4:74793605	C/A	cg01447579	chr4:74847100	PF4	0.66	4.32	0.33	2.86e-5	Blood protein levels;
PAAD	cis	rs1227969	0.965	rs1052179	chr10:71267010	G/A	cg12610070	chr10:71211762	TSPAN15	-0.3	-4.29	-0.33	3.22e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg21565972	chr17:80109576	CCDC57	0.56	6.42	0.46	1.65e-9	Life satisfaction;
PAAD	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-7.11	-0.5	4.21e-11	Menarche (age at onset);
PAAD	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.97	13.7	0.74	2.43e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.65	-7.96	-0.54	3.66e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg07204747	chr5:141030761	FCHSD1	-0.49	-4.43	-0.34	1.77e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.66	6.62	0.47	5.83e-10	Coronary artery disease or large artery stroke;
PAAD	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs4538187	1.000	rs6546029	chr2:64069732	G/A	cg08613950	chr2:64719184	NA	-0.65	-4.3	-0.33	3.08e-5	Systolic blood pressure;
PAAD	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg05250797	chr16:70222502	NA	0.83	6.35	0.46	2.31e-9	IgE levels;
PAAD	cis	rs1823874	0.653	rs12902823	chr15:100352218	G/A	cg16400843	chr15:100339927	C15orf51	0.4	5.14	0.38	8.43e-7	IgG glycosylation;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05930133	chr2:66661280	MEIS1	-0.76	-6.38	-0.46	2.03e-9	Neuroticism;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20271681	chr21:44299600	WDR4	-0.69	-7.78	-0.53	1.05e-12	Smoking initiation;
PAAD	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.66	5.92	0.43	2.1e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1042026	0.771	rs2156733	chr4:100134089	T/C	cg09112717	chr4:100009950	ADH5	-0.53	-4.79	-0.36	3.93e-6	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg16205897	chr5:131564050	P4HA2	0.43	4.51	0.34	1.27e-5	Acylcarnitine levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07077900	chr3:53916135	ACTR8	-0.55	-6.4	-0.46	1.79e-9	Body fat percentage;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15261897	chr10:37969553	NA	-0.64	-6.51	-0.47	1.03e-9	Obesity-related traits;
PAAD	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.91	-8.88	-0.58	1.73e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg03959625	chr15:84868606	LOC388152	0.43	4.4	0.34	2.04e-5	Schizophrenia;
PAAD	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.63	0.82	1.36e-38	Height;
PAAD	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	7.4	0.51	8.48e-12	Fuchs's corneal dystrophy;
PAAD	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.7	7.05	0.5	5.89e-11	Schizophrenia;
PAAD	cis	rs9810890	1.000	rs73198895	chr3:128565161	A/G	cg19129842	chr3:128565090	NA	-0.86	-4.92	-0.37	2.2e-6	Dental caries;
PAAD	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.49	-0.57	1.77e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg03037974	chr15:76606532	NA	0.51	5.7	0.42	5.9e-8	Blood metabolite levels;
PAAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.8	-0.43	3.81e-8	Lung cancer;
PAAD	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.28	0.39	4.29e-7	Free thyroxine concentration;
PAAD	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.64	6.82	0.48	2.03e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.61	5.51	0.41	1.49e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9646944	0.501	rs11687768	chr2:103025738	A/G	cg03938978	chr2:103052716	IL18RAP	0.5	4.25	0.33	3.67e-5	Blood protein levels;
PAAD	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6585424	1.000	rs61860035	chr10:81932453	C/G	cg19423196	chr10:82049429	MAT1A	0.46	4.79	0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.35	4.76	0.36	4.45e-6	Asthma;
PAAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg03959625	chr15:84868606	LOC388152	0.49	5.51	0.41	1.5e-7	Schizophrenia;
PAAD	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-6.33	-0.46	2.66e-9	Depression;
PAAD	cis	rs1668873	0.562	rs10157145	chr1:205261963	T/C	cg21545522	chr1:205238299	TMCC2	-0.45	-4.42	-0.34	1.87e-5	Mean platelet volume;
PAAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg10547527	chr2:198650123	BOLL	-0.73	-4.97	-0.37	1.8e-6	Ulcerative colitis;
PAAD	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs6604026	0.656	rs12065253	chr1:93392309	G/A	cg13858687	chr1:93297071	RPL5	0.5	4.56	0.35	1.06e-5	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23602684	chr14:24584099	DCAF11	0.64	7.0	0.49	7.53e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs76917914	0.780	rs2417727	chr9:100846475	T/C	cg21225548	chr9:100864335	TRIM14	-0.51	-5.3	-0.39	4.05e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg04510874	chr15:91427884	FES	-0.38	-4.52	-0.34	1.24e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-6.59	-0.47	6.76e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg01631408	chr1:248437212	OR2T33	-0.61	-5.62	-0.41	9e-8	Common traits (Other);
PAAD	cis	rs818427	0.964	rs351767	chr5:112200098	A/G	cg06941702	chr5:112196734	SRP19	-0.47	-4.48	-0.34	1.43e-5	Total body bone mineral density;
PAAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg14500267	chr11:67383377	NA	0.45	4.5	0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg15654264	chr1:150340011	RPRD2	-0.49	-4.71	-0.36	5.53e-6	Migraine;
PAAD	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.61	5.27	0.39	4.7e-7	Type 2 diabetes;
PAAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg23281280	chr6:28129359	ZNF389	0.52	4.36	0.33	2.36e-5	Parkinson's disease;
PAAD	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.58	6.85	0.49	1.73e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	4.87	0.37	2.75e-6	Iron status biomarkers;
PAAD	cis	rs9990220	0.586	rs9755930	chr3:112022870	A/G	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.73	-0.36	5.18e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.82	-9.69	-0.62	1.38e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg07537917	chr2:241836409	C2orf54	-0.27	-4.92	-0.37	2.23e-6	Urinary metabolites;
PAAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.5	-4.28	-0.33	3.31e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg12661370	chr5:149340060	SLC26A2	0.66	5.6	0.41	9.92e-8	HIV-1 control;
PAAD	cis	rs17095355	0.605	rs2274978	chr10:111631665	C/G	cg00817464	chr10:111662876	XPNPEP1	0.63	4.48	0.34	1.47e-5	Biliary atresia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24464101	chr4:38690487	KLF3	0.56	6.36	0.46	2.21e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	7.37	0.51	1e-11	Eotaxin levels;
PAAD	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.59	-5.72	-0.42	5.36e-8	Crohn's disease;
PAAD	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg26248373	chr2:1572462	NA	-1.03	-7.95	-0.54	4.02e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg00717180	chr2:96193071	NA	-0.62	-7.51	-0.52	4.7e-12	HDL cholesterol;
PAAD	cis	rs11209002	1.000	rs11209002	chr1:67590461	C/T	cg02640540	chr1:67518911	SLC35D1	-0.6	-4.44	-0.34	1.72e-5	Crohn's disease;
PAAD	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.68	0.53	1.81e-12	Prudent dietary pattern;
PAAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs4740619	0.901	rs10810431	chr9:15706641	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.37	-0.33	2.25e-5	Body mass index;
PAAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.55	5.04	0.38	1.32e-6	Multiple sclerosis;
PAAD	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.34	-0.33	2.61e-5	Joint mobility (Beighton score);
PAAD	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg04330084	chr7:123175371	IQUB	0.5	4.34	0.33	2.57e-5	Plateletcrit;Platelet count;
PAAD	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Breast cancer;
PAAD	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.13e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.38	-4.29	-0.33	3.11e-5	Type 2 diabetes;
PAAD	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.08	16.45	0.8	1.46e-35	Body mass index (adult);
PAAD	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22482690	chr17:47019901	SNF8	-0.43	-4.51	-0.34	1.27e-5	Type 2 diabetes;
PAAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-4.57	-0.35	9.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.65	-7.1	-0.5	4.55e-11	Menarche (age at onset);
PAAD	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.78	5.94	0.43	1.86e-8	Mean platelet volume;
PAAD	cis	rs13011075	0.535	rs6747545	chr2:68633069	T/A	cg06275642	chr2:68546038	CNRIP1	0.34	4.5	0.34	1.35e-5	Mean corpuscular volume;
PAAD	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg20628663	chr10:43360327	NA	0.76	4.73	0.36	5.06e-6	Pediatric bone mineral content (radius);
PAAD	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	High light scatter reticulocyte count;
PAAD	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.26	-0.33	3.5e-5	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg20406979	chr6:167373233	NA	0.32	4.42	0.34	1.88e-5	Crohn's disease;
PAAD	cis	rs9364554	0.718	rs2292334	chr6:160858188	C/T	cg25313204	chr6:160768801	SLC22A3	0.52	4.83	0.37	3.25e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.75	6.68	0.48	4.22e-10	Asthma;
PAAD	cis	rs300774	0.925	rs300727	chr2:132469	C/A	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	6.38	0.46	2.07e-9	Attention deficit hyperactivity disorder;
PAAD	cis	rs4074493	1.000	rs4074493	chr1:231172281	C/T	cg22172038	chr1:231176991	FAM89A	0.52	4.89	0.37	2.57e-6	Carotid plaque burden (smoking interaction);
PAAD	cis	rs4900538	0.827	rs3742444	chr14:102971050	T/G	cg18135206	chr14:102964638	TECPR2	0.92	11.46	0.68	2.64e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26913058	chr16:419975	MRPL28	-0.47	-4.55	-0.35	1.09e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs926392	0.965	rs714108	chr20:37687838	G/A	cg16355469	chr20:37678765	NA	0.46	4.36	0.33	2.39e-5	Dialysis-related mortality;
PAAD	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.26	-0.39	4.76e-7	Vitamin D levels;
PAAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.8	-0.36	3.69e-6	Lung cancer;
PAAD	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg18939081	chr1:31884902	SERINC2	-0.5	-5.85	-0.43	2.88e-8	Alcohol dependence;
PAAD	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	5.77	0.42	4.27e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.49e-5	Life satisfaction;
PAAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	trans	rs75583333	0.502	rs6896192	chr5:159626821	C/T	cg14222307	chr15:61097246	RORA	-0.82	-6.33	-0.46	2.6e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.79	0.48	2.36e-10	IgG glycosylation;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.95	11.15	0.67	1.74e-21	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg27394845	chr17:28928406	LRRC37B2	0.64	4.36	0.33	2.35e-5	Body mass index;
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg07559730	chr19:53497048	ZNF702P	-0.52	-5.59	-0.41	1.05e-7	Psoriasis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04802407	chr22:21356391	THAP7;FLJ39582	0.59	6.41	0.46	1.7e-9	Myopia (pathological);
PAAD	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.6	-5.67	-0.42	6.85e-8	Itch intensity from mosquito bite;
PAAD	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.92	-0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9409082	0.677	rs9299121	chr9:108912412	T/A	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2567992	1.000	rs11065495	chr12:121661688	C/T	cg26872792	chr12:120763815	PLA2G1B	-0.72	-4.42	-0.34	1.86e-5	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.64	-0.35	7.42e-6	Lung cancer in ever smokers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14861047	chr3:48657326	NA	-0.58	-6.51	-0.47	1.04e-9	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09450037	chr19:663107	RNF126	0.58	6.44	0.46	1.46e-9	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.15	0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs89107	0.675	rs283080	chr6:118606000	C/A	cg18833306	chr6:118973337	C6orf204	0.5	5.84	0.43	3.01e-8	Cardiac structure and function;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11132698	chr1:895988	KLHL17;NOC2L	0.74	8.09	0.55	1.75e-13	Myopia (pathological);
PAAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.52	-5.9	-0.43	2.3e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs1035491	0.715	rs10063301	chr5:63925947	A/T	cg01791865	chr5:63954708	NA	0.52	5.54	0.41	1.28e-7	Body mass index;
PAAD	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg17178900	chr1:205818956	PM20D1	0.57	5.43	0.4	2.16e-7	White blood cell types;
PAAD	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.82	-0.36	3.52e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.72	8.94	0.59	1.22e-15	Dupuytren's disease;
PAAD	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.87	-10.22	-0.64	5.58e-19	Sudden cardiac arrest;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23441090	chr1:2126425	C1orf86;LOC100128003	-0.76	-8.81	-0.58	2.66e-15	Smoking initiation;
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.59	6.02	0.44	1.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg15017067	chr4:17643749	FAM184B	0.49	5.88	0.43	2.57e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg20790798	chr5:1857306	NA	-0.41	-4.38	-0.33	2.2e-5	Cardiovascular disease risk factors;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg17105886	chr17:28927953	LRRC37B2	0.66	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-5.7	-0.42	6.01e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg20893579	chr22:38215064	NA	0.48	4.72	0.36	5.33e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	1.29	9.2	0.6	2.66e-16	Prostate cancer;
PAAD	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg10556349	chr10:835070	NA	0.6	4.99	0.38	1.61e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.3	0.33	3.04e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.43	-4.48	-0.34	1.44e-5	Ulcerative colitis;
PAAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.88	8.41	0.56	2.78e-14	Eosinophil percentage of granulocytes;
PAAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.75	10.13	0.63	9.61e-19	Iron status biomarkers;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24847757	chr3:32909493	TRIM71	0.71	7.34	0.51	1.23e-11	Lung cancer in ever smokers;
PAAD	cis	rs58521262	0.519	rs12610143	chr19:22994991	G/A	cg07749055	chr19:23076870	NA	-0.61	-4.58	-0.35	9.64e-6	Testicular germ cell tumor;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg02841227	chr6:26021843	HIST1H4A	0.49	4.56	0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2061333	0.500	rs10408901	chr19:44634552	T/A	cg20607764	chr19:44506953	ZNF230	-0.71	-5.06	-0.38	1.19e-6	Alzheimer's disease;
PAAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-4.85	-0.37	2.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-14.92	-0.77	1.44e-31	Ulcerative colitis;
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.75	-7.04	-0.5	6.08e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3106136	0.586	rs12498518	chr4:95070236	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-4.86	-0.37	2.84e-6	Capecitabine sensitivity;
PAAD	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg21770322	chr7:97807741	LMTK2	-0.71	-10.1	-0.63	1.16e-18	Breast cancer;
PAAD	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22159341	chr2:152893963	CACNB4	0.64	7.25	0.51	1.94e-11	Smoking initiation;
PAAD	trans	rs61931739	0.649	rs861526	chr12:33726434	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.6	6.61	0.47	6.07e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs9942416	0.503	rs253393	chr5:74929647	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.48	-4.6	-0.35	8.72e-6	Age-related disease endophenotypes;
PAAD	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.76e-10	Plateletcrit;Platelet count;
PAAD	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.6e-14	Colorectal cancer;
PAAD	cis	rs66530629	0.917	rs11249177	chr1:25171088	A/G	cg01905478	chr1:25040257	NA	0.47	5.23	0.39	5.49e-7	Plateletcrit;
PAAD	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-7.97	-0.54	3.42e-13	Brugada syndrome;
PAAD	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2834288	0.500	rs7280837	chr21:35323836	A/C	cg22542663	chr21:34915757	GART;SON	0.44	4.36	0.33	2.4e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg09619624	chr22:18985632	NA	0.39	4.69	0.36	6.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	-0.95	-5.07	-0.38	1.13e-6	Childhood ear infection;
PAAD	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg01620082	chr3:125678407	NA	-1.48	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg19337854	chr7:99768885	GPC2	-0.48	-4.92	-0.37	2.19e-6	Coronary artery disease;
PAAD	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.4	0.61	7.84e-17	Response to antipsychotic treatment;
PAAD	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.85	-11.26	-0.67	8.95e-22	Height;
PAAD	cis	rs992157	0.764	rs3731861	chr2:219191256	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.76	-7.65	-0.53	2.16e-12	Colorectal cancer;
PAAD	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12292205	chr6:26970375	C6orf41	-0.51	-4.73	-0.36	5.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg05874882	chr4:1763078	NA	0.36	4.49	0.34	1.41e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs288326	0.561	rs74953433	chr2:183872665	T/C	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.52	5.61	0.41	9.31e-8	Menopause (age at onset);
PAAD	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.18	-0.39	6.88e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	9.58	0.61	2.68e-17	Lymphocyte counts;
PAAD	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.9	0.49	1.3100000000000001e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03338584	chr11:507455	RNH1	0.62	4.33	0.33	2.74e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-0.93	-8.88	-0.58	1.77e-15	Exhaled nitric oxide output;
PAAD	cis	rs17095355	0.818	rs10509907	chr10:111781715	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.47	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs111342015	0.803	rs112422722	chr6:43190230	G/A	cg17076780	chr6:43251928	TTBK1	0.61	4.36	0.33	2.42e-5	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg27581211	chr16:11219954	CLEC16A	0.63	7.43	0.52	7.27e-12	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02509370	chr12:49932779	KCNH3	0.61	6.76	0.48	2.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg14393609	chr7:65229607	NA	0.47	4.49	0.34	1.37e-5	Aortic root size;
PAAD	cis	rs2964802	0.505	rs6865234	chr5:10829742	C/A	cg14521931	chr5:10832172	NA	-0.47	-4.91	-0.37	2.31e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg07969918	chr22:31682909	PIK3IP1	-0.33	-4.3	-0.33	3.07e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.47	5.98	0.44	1.5e-8	Menopause (age at onset);
PAAD	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg06606381	chr12:133084897	FBRSL1	-0.88	-6.37	-0.46	2.18e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.28	-0.51	1.68e-11	Colorectal cancer;
PAAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.73	-5.98	-0.44	1.53e-8	Neuroticism;
PAAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.74	7.55	0.52	3.76e-12	Prostate cancer;
PAAD	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.85	6.75	0.48	2.96e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.78	8.67	0.58	5.94e-15	Lung cancer;
PAAD	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	1.02	12.41	0.71	7.08e-25	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Breast cancer;
PAAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.29	-0.33	3.15e-5	Skin colour saturation;
PAAD	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.57	-4.94	-0.37	2.08e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	1.08	17.87	0.82	3.57e-39	Colorectal adenoma (advanced);
PAAD	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26926768	chr12:34528122	NA	0.4	4.92	0.37	2.27e-6	Morning vs. evening chronotype;
PAAD	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.74	7.08	0.5	4.97e-11	Obesity-related traits;
PAAD	cis	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-4.89	-0.37	2.54e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.59	4.94	0.37	2e-6	Atopic dermatitis;
PAAD	cis	rs3753841	0.798	rs1451043	chr1:103278901	A/T	cg24495344	chr1:103574097	COL11A1	0.39	4.53	0.35	1.17e-5	Glaucoma (primary angle closure);
PAAD	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg08926642	chr1:7887455	PER3	0.53	4.32	0.33	2.83e-5	Inflammatory bowel disease;
PAAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs6782025	0.837	rs1523509	chr3:120719563	G/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.64	-6.17	-0.45	5.86e-9	Schizophrenia;
PAAD	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-5.1	-0.38	9.9e-7	Initial pursuit acceleration;
PAAD	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.75	7.36	0.51	1.09e-11	Cognitive function;
PAAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg24737193	chr18:12778029	NA	0.63	5.42	0.4	2.31e-7	Inflammatory skin disease;
PAAD	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.45	-0.46	1.43e-9	Monocyte count;
PAAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.87	-10.14	-0.64	8.88e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.84	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs1979541	0.688	rs10452575	chr6:159104769	A/G	cg24836281	chr19:41100790	LTBP4	0.47	6.32	0.46	2.79e-9	Lipoprotein (a) levels;
PAAD	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.46	-4.88	-0.37	2.65e-6	Birth weight;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.89	12.79	0.72	7.05e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg09017928	chr7:158110068	PTPRN2	0.59	5.35	0.4	3.25e-7	Response to amphetamines;
PAAD	cis	rs7766436	0.621	rs6903615	chr6:22602569	T/C	cg13666174	chr6:22585274	NA	-0.5	-6.17	-0.45	5.81e-9	Coronary artery disease;
PAAD	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.76	0.42	4.49e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.21	-0.55	8.74e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.45	0.71	5.5e-25	Cognitive ability;
PAAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.61	6.14	0.45	6.94e-9	Blood metabolite levels;
PAAD	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6834538	0.965	rs2101391	chr4:113531599	A/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	4.58	0.35	9.62e-6	Free thyroxine concentration;
PAAD	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg08758996	chr17:66097529	LOC651250	0.55	4.48	0.34	1.48e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-4.29	-0.33	3.12e-5	Breast cancer;
PAAD	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2976388	0.566	rs4736301	chr8:143829499	T/G	cg02415014	chr8:143852576	LYNX1	0.37	4.49	0.34	1.42e-5	Urinary tract infection frequency;
PAAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-1.12	-13.84	-0.75	1.02e-28	Height;
PAAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg17986701	chr20:44574422	PCIF1	0.58	6.01	0.44	1.33e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.92	5.96	0.44	1.68e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs73019876	0.934	rs431346	chr19:22228215	T/C	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg11196182	chr7:1989412	MAD1L1	0.4	4.25	0.33	3.69e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg21605333	chr4:119757512	SEC24D	1.85	10.45	0.65	1.33e-19	Cannabis dependence symptom count;
PAAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.71	-8.27	-0.56	6.35e-14	Huntington's disease progression;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18297960	chr7:1142765	C7orf50	-0.56	-4.42	-0.34	1.89e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9810890	1.000	rs116835720	chr3:128547280	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.19	-0.39	6.77e-7	Life satisfaction;
PAAD	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	10.05	0.63	1.55e-18	Smoking behavior;
PAAD	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg15192750	chr16:69999425	NA	0.68	5.14	0.39	8.17e-7	IgE levels;
PAAD	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.49	5.77	0.42	4.41e-8	Urinary metabolites (H-NMR features);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13066546	chr21:46046042	C21orf29;KRTAP10-9	-0.63	-6.49	-0.47	1.15e-9	Obesity-related traits;
PAAD	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.94	7.72	0.53	1.42e-12	Vitiligo;
PAAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.65	7.33	0.51	1.25e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	12.07	0.7	6.08e-24	Chronic sinus infection;
PAAD	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg13357408	chr7:157437802	PTPRN2	1.14	10.36	0.64	2.3e-19	Colorectal cancer;
PAAD	cis	rs6596100	0.538	rs66481372	chr5:132179592	T/A	cg16419906	chr5:132167176	NA	-0.58	-4.41	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg03289416	chr15:75166202	SCAMP2	0.62	6.34	0.46	2.43e-9	Breast cancer;
PAAD	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.61	-5.94	-0.43	1.9e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.98	10.3	0.64	3.42e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.91	-7.47	-0.52	5.91e-12	Orofacial clefts;
PAAD	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg05585544	chr11:47624801	NA	-0.48	-5.37	-0.4	2.94e-7	Subjective well-being;
PAAD	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.79	0.48	2.37e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	5.94	0.43	1.84e-8	Mean platelet volume;
PAAD	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg14631576	chr9:95140430	CENPP	-0.56	-5.45	-0.4	1.98e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9463078	0.585	rs4352679	chr6:45239658	G/A	cg18551225	chr6:44695536	NA	-0.41	-4.29	-0.33	3.11e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-5.42	-0.4	2.28e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-4.83	-0.36	3.37e-6	Cognitive function;
PAAD	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg08992911	chr2:238395768	MLPH	0.51	5.21	0.39	6.08e-7	Prostate cancer;
PAAD	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg25801113	chr15:45476975	SHF	0.42	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.13	0.38	8.59e-7	Personality dimensions;
PAAD	cis	rs9715521	0.803	rs28676590	chr4:59808524	T/C	cg11281224	chr4:60001000	NA	-0.54	-5.23	-0.39	5.64e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg08198773	chr8:1697536	NA	0.42	4.63	0.35	7.78e-6	Systolic blood pressure;
PAAD	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05372578	chr7:8301660	ICA1	0.65	7.08	0.5	4.92e-11	Myopia (pathological);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg27606288	chr2:96783070	ADRA2B	-0.6	-6.75	-0.48	2.9e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg15181151	chr6:150070149	PCMT1	0.56	6.11	0.44	7.86e-9	Lung cancer;
PAAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.54	5.7	0.42	5.96e-8	Menopause (age at onset);
PAAD	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg15660573	chr17:549704	VPS53	0.62	5.75	0.42	4.68e-8	Prostate cancer;
PAAD	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.51	5.36	0.4	2.99e-7	Male-pattern baldness;
PAAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.51	5.26	0.39	4.91e-7	Testicular germ cell tumor;
PAAD	cis	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.98e-8	Lymphocyte counts;
PAAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg21698718	chr17:80085957	CCDC57	0.4	4.27	0.33	3.47e-5	Life satisfaction;
PAAD	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13051058	chr15:34629706	SLC12A6	0.63	6.76	0.48	2.79e-10	Monocyte percentage of white cells;
PAAD	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.52	4.89	0.37	2.55e-6	Vitiligo;
PAAD	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg12757816	chr2:10669957	NA	-0.53	-5.67	-0.42	7.01e-8	Prostate cancer;
PAAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.59	0.41	1e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.72	-7.48	-0.52	5.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00627621	chr8:126442449	TRIB1	-0.67	-7.02	-0.49	6.89e-11	Smoking initiation;
PAAD	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.9	8.72	0.58	4.46e-15	Corneal astigmatism;
PAAD	trans	rs7915414	0.951	rs1998591	chr10:96407978	G/A	cg00735080	chr21:47285121	PCBP3	0.51	6.4	0.46	1.84e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs12999616	0.602	rs905484	chr2:98590083	T/A	cg26665480	chr2:98280029	ACTR1B	0.6	5.71	0.42	5.89e-8	Colorectal cancer;
PAAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.72	6.67	0.48	4.5e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.54	5.52	0.41	1.41e-7	Longevity;Endometriosis;
PAAD	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg22437258	chr11:111473054	SIK2	-0.5	-4.92	-0.37	2.19e-6	Primary sclerosing cholangitis;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.52	5.57	0.41	1.11e-7	Obesity-related traits;
PAAD	cis	rs728616	0.571	rs113030473	chr10:81649031	G/T	cg19423196	chr10:82049429	MAT1A	0.57	4.29	0.33	3.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg20007245	chr22:24372913	LOC391322	-0.68	-7.17	-0.5	3e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15510118	chr2:174774395	SP3	-0.6	-6.95	-0.49	9.88e-11	Energy expenditure (24h);
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg12143784	chr7:64541923	NA	-0.33	-4.26	-0.33	3.55e-5	Aortic root size;
PAAD	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg08648136	chr8:956695	NA	0.42	4.46	0.34	1.59e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.69	7.31	0.51	1.38e-11	Obesity-related traits;
PAAD	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.47	4.52	0.34	1.22e-5	Hepatocellular carcinoma;
PAAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-4.56	-0.35	1.07e-5	Fat distribution (HIV);
PAAD	cis	rs7624766	0.743	rs6781371	chr3:160523671	G/A	cg22637730	chr3:160473554	PPM1L	0.52	4.7	0.36	5.73e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15557168	chr22:42548783	NA	0.56	6.35	0.46	2.33e-9	Cognitive function;
PAAD	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg09066997	chr16:75300724	BCAR1	0.58	4.33	0.33	2.72e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg19592336	chr6:28129416	ZNF389	-0.62	-4.4	-0.34	2.05e-5	Parkinson's disease;
PAAD	cis	rs9395066	0.545	rs3799977	chr6:44837356	G/T	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Height;
PAAD	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg00035074	chr7:2701567	TTYH3	0.66	4.54	0.35	1.12e-5	Bipolar disorder;
PAAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	4.47	0.34	1.54e-5	Rheumatoid arthritis;
PAAD	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.51	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.35	-0.51	1.13e-11	Total body bone mineral density;
PAAD	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.71	-7.62	-0.53	2.52e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg21546286	chr11:48923668	NA	-0.59	-6.22	-0.45	4.61e-9	HDL cholesterol;
PAAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.46	0.34	1.55e-5	Personality dimensions;
PAAD	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.5	-5.3	-0.4	3.98e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs6604026	0.656	rs4351651	chr1:93414508	A/C	cg17283838	chr1:93427260	FAM69A	0.6	5.64	0.42	8.22e-8	Multiple sclerosis;
PAAD	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-8.87	-0.58	1.89e-15	Body mass index;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg19630374	chr17:18023558	MYO15A	-0.43	-4.48	-0.34	1.48e-5	Total body bone mineral density;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg05527609	chr1:210001259	C1orf107	0.56	5.49	0.41	1.67e-7	Orofacial clefts;
PAAD	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.53	5.01	0.38	1.52e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.69	-7.47	-0.52	5.99e-12	Schizophrenia;
PAAD	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.34	-0.33	2.54e-5	QT interval;
PAAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg15017067	chr4:17643749	FAM184B	0.45	5.38	0.4	2.8e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10044254	0.813	rs12519807	chr5:15714022	C/T	cg07238450	chr5:15720153	FBXL7	0.55	4.63	0.35	7.68e-6	Asthma (corticosteroid response);
PAAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.57	-7.04	-0.5	6.3e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg26668713	chr11:65405903	SIPA1	0.6	5.47	0.41	1.81e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs9810890	1.000	rs9840633	chr3:128568202	C/A	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs939584	0.935	rs6725549	chr2:630323	C/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.39	0.56	3.08e-14	Lung cancer;
PAAD	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-1.01	-6.97	-0.49	8.83e-11	Coronary artery disease;
PAAD	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.53	7.28	0.51	1.7e-11	Crohn's disease;
PAAD	cis	rs883565	0.740	rs6599003	chr3:39093326	A/G	cg01426195	chr3:39028469	NA	0.68	7.23	0.51	2.18e-11	Handedness;
PAAD	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg16342193	chr10:102329863	NA	-0.83	-8.56	-0.57	1.15e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.7	7.19	0.5	2.8e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22442454	chr1:209979470	IRF6	0.54	4.44	0.34	1.72e-5	Cleft lip with or without cleft palate;
PAAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg10547527	chr2:198650123	BOLL	-0.68	-4.49	-0.34	1.41e-5	Ulcerative colitis;
PAAD	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.13	-0.38	8.79e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.64	4.71	0.36	5.61e-6	Biliary atresia;
PAAD	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	3.04e-18	Response to antipsychotic treatment;
PAAD	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.99	10.42	0.65	1.61e-19	Pulmonary function decline;
PAAD	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.5	4.9	0.37	2.38e-6	Longevity;Endometriosis;
PAAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24729792	chr2:113192114	RGPD8;RGPD5	0.61	4.77	0.36	4.3e-6	Yeast infection;
PAAD	cis	rs1043763	0.826	rs28707600	chr12:122604658	A/G	cg26218692	chr12:122497826	BCL7A	-0.59	-5.66	-0.42	7.37e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
PAAD	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg14686297	chr22:46650375	NA	0.46	4.72	0.36	5.3e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg04154034	chr17:28927549	LRRC37B2	0.79	4.61	0.35	8.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg03289416	chr15:75166202	SCAMP2	0.57	6.03	0.44	1.18e-8	Breast cancer;
PAAD	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg08121117	chr13:112575735	NA	-0.41	-5.06	-0.38	1.19e-6	Axial length;
PAAD	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06850241	chr22:41845214	NA	-0.5	-4.87	-0.37	2.78e-6	Vitiligo;
PAAD	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg23950597	chr19:37808831	NA	-0.73	-4.84	-0.37	3.18e-6	Coronary artery calcification;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.55	5.79	0.43	3.82e-8	Renal function-related traits (BUN);
PAAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs501120	1.000	rs504799	chr10:44753456	C/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg19582115	chr14:103436037	CDC42BPB	-0.47	-4.6	-0.35	8.99e-6	Blood metabolite levels;
PAAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg09471204	chr22:42347991	LOC339674	0.34	4.46	0.34	1.59e-5	Cognitive function;
PAAD	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.65	-0.35	7.27e-6	Chronic sinus infection;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg10864074	chr7:100318194	EPO	-0.48	-4.83	-0.36	3.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.91	4.73	0.36	5.1e-6	Plasma clusterin levels;
PAAD	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.27	-0.39	4.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.73	-8.56	-0.57	1.18e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.85	-0.37	3.04e-6	Schizophrenia;
PAAD	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs75920871	0.589	rs67201490	chr11:117083004	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-5.08	-0.38	1.08e-6	Subjective well-being;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05025164	chr4:1340916	KIAA1530	0.57	5.33	0.4	3.56e-7	Obesity-related traits;
PAAD	cis	rs8112211	0.911	rs8106895	chr19:38848861	C/G	cg01275006	chr19:38876250	GGN	-0.64	-4.76	-0.36	4.55e-6	Blood protein levels;
PAAD	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.44	-4.43	-0.34	1.83e-5	Schizophrenia;
PAAD	trans	rs9409082	0.666	rs13299139	chr9:108989445	G/A	cg07010948	chr13:79181613	NA	-0.35	-6.46	-0.46	1.31e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs883565	0.740	rs6796837	chr3:39076188	C/T	cg01426195	chr3:39028469	NA	-0.7	-7.43	-0.52	7.5e-12	Handedness;
PAAD	cis	rs67981189	0.519	rs2526853	chr14:71415952	G/A	cg15910301	chr14:71632612	NA	-0.38	-4.25	-0.33	3.73e-5	Schizophrenia;
PAAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.84	7.52	0.52	4.37e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-4.45	-0.34	1.68e-5	Obesity (extreme);
PAAD	cis	rs2327429	0.858	rs10457618	chr6:134188626	C/T	cg06296503	chr6:134217401	NA	0.48	4.95	0.37	1.96e-6	Coronary artery disease;
PAAD	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	6.19	0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.44	-5.61	-0.41	9.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg25319279	chr11:5960081	NA	-0.61	-5.77	-0.42	4.4e-8	DNA methylation (variation);
PAAD	cis	rs7765175	0.598	rs9387128	chr6:113620948	G/T	cg19037598	chr6:113666021	NA	-0.4	-4.35	-0.33	2.46e-5	Coronary artery calcification;
PAAD	cis	rs174601	0.684	rs174528	chr11:61543499	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.44	4.43	0.34	1.77e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs375066	0.935	rs384329	chr19:44423981	A/G	cg08633290	chr19:44405433	NA	-0.52	-5.15	-0.39	7.92e-7	Breast cancer;
PAAD	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	1.0	6.37	0.46	2.18e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.77	-0.42	4.36e-8	Testicular germ cell tumor;
PAAD	cis	rs1499972	0.941	rs62263115	chr3:117622116	G/A	cg07612923	chr3:117604196	NA	1.06	7.25	0.51	1.99e-11	Schizophrenia;
PAAD	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg27490568	chr2:178487706	NA	0.43	4.8	0.36	3.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs11811982	0.793	rs79246828	chr1:227508935	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.38	-0.4	2.74e-7	Daytime sleep phenotypes;
PAAD	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg04165759	chr1:150448943	RPRD2	-0.51	-5.36	-0.4	2.97e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.81	5.34	0.4	3.36e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.84	-5.15	-0.39	7.94e-7	Cholesterol, total;
PAAD	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg03959625	chr15:84868606	LOC388152	0.43	4.47	0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	1.01	11.73	0.69	4.83e-23	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-14.46	-0.76	2.31e-30	Headache;
PAAD	cis	rs11807834	0.522	rs12564901	chr1:230244337	G/C	cg00566187	chr1:230250356	GALNT2	-0.65	-6.88	-0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.46	-4.84	-0.37	3.2e-6	Eosinophil percentage of white cells;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13560548	chr3:10150139	C3orf24	0.52	4.47	0.34	1.49e-5	Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14976342	chr1:15255231	KIAA1026	0.67	6.95	0.49	1.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02071572	chr4:1403502	NA	-0.41	-5.42	-0.4	2.24e-7	Obesity-related traits;
PAAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.58	-0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.62	-6.62	-0.47	5.76e-10	Neuroticism;
PAAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.56	6.05	0.44	1.06e-8	Major depressive disorder;
PAAD	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.54	-4.63	-0.35	7.89e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	trans	rs553086	0.878	rs11228857	chr11:56722160	C/A	cg26329020	chr12:32909488	YARS2	0.65	6.31	0.46	2.86e-9	Fear of severe pain;
PAAD	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg19044706	chr2:241829685	C2orf54	0.52	5.01	0.38	1.52e-6	Urinary metabolites;
PAAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00982548	chr2:198649783	BOLL	-0.81	-5.68	-0.42	6.74e-8	Ulcerative colitis;
PAAD	cis	rs2072735	0.915	rs2072734	chr1:9356065	A/G	cg25755851	chr1:9335794	NA	0.35	4.25	0.33	3.71e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.7	4.44	0.34	1.75e-5	Recalcitrant atopic dermatitis;
PAAD	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.43	0.4	2.17e-7	Menarche (age at onset);
PAAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.82	-9.36	-0.6	9.79e-17	Lung cancer;
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.25	0.33	3.75e-5	Platelet count;
PAAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg20673091	chr1:2541236	MMEL1	0.84	10.01	0.63	1.92e-18	Ulcerative colitis;
PAAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.73	8.54	0.57	1.3e-14	Lung cancer;
PAAD	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg04018474	chr16:31008003	STX1B	-0.28	-4.36	-0.33	2.4e-5	Dementia with Lewy bodies;
PAAD	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg00280220	chr17:61926910	NA	0.44	4.65	0.35	7.23e-6	Prudent dietary pattern;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.49	4.5	0.34	1.33e-5	Lung cancer;
PAAD	cis	rs11615916	0.790	rs73137525	chr12:62724404	T/C	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-10.9	-0.66	8.44e-21	Heart rate;
PAAD	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.56	5.12	0.38	9e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.8	8.99	0.59	9.27e-16	Lung cancer;
PAAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16262614	chr3:133464971	TF	0.41	4.36	0.33	2.41e-5	Iron status biomarkers;
PAAD	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.55	4.99	0.38	1.61e-6	Type 2 diabetes;
PAAD	trans	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg14171944	chr9:126323477	DENND1A	0.54	6.49	0.47	1.13e-9	Intelligence;Intelligence (multi-trait analysis);
PAAD	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg15211996	chr1:2936768	ACTRT2	-0.49	-4.82	-0.36	3.42e-6	Plateletcrit;
PAAD	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.97	9.95	0.63	2.88e-18	Orofacial clefts;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.64	0.62	1.91e-17	Lymphocyte counts;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14762234	chr7:44788270	ZMIZ2	0.7	7.68	0.53	1.78e-12	Myopia (pathological);
PAAD	trans	rs2982694	0.681	rs1884050	chr6:152287395	C/G	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg21951975	chr1:209979733	IRF6	0.52	4.82	0.36	3.51e-6	Coronary artery disease;
PAAD	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.89	6.86	0.49	1.59e-10	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08579753	chr1:39174525	NA	-0.64	-6.48	-0.47	1.21e-9	Smoking initiation;
PAAD	cis	rs4743820	0.651	rs16907199	chr9:93923617	A/G	cg14446406	chr9:93919335	NA	0.45	5.47	0.41	1.79e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	4.56	0.35	1.06e-5	Iron status biomarkers;
PAAD	trans	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	trans	rs1015213	0.609	rs78373786	chr8:52868159	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs2019216	0.500	rs11651446	chr17:21967129	C/T	cg22648282	chr17:21454238	C17orf51	-0.54	-4.96	-0.37	1.85e-6	Pelvic organ prolapse;
PAAD	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17347941	chr15:79387269	NA	0.38	4.33	0.33	2.73e-5	Refractive error;
PAAD	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg14019146	chr3:50243930	SLC38A3	-0.48	-5.01	-0.38	1.49e-6	Body mass index;
PAAD	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg25568297	chr16:30077541	ALDOA	-0.58	-6.49	-0.47	1.13e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	1.18	13.56	0.74	5.96e-28	Eosinophil percentage of granulocytes;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg15772133	chr2:33585815	LTBP1	0.54	6.42	0.46	1.62e-9	Educational attainment (years of education);
PAAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.57	-0.35	1e-5	Skin colour saturation;
PAAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.47	-4.4	-0.34	2.05e-5	Renal cell carcinoma;
PAAD	cis	rs6499755	0.768	rs31086	chr16:55362542	C/G	cg02859129	chr16:55357253	IRX6	0.37	5.16	0.39	7.47e-7	Hypospadias;
PAAD	cis	rs66530629	0.917	rs58521331	chr1:25163173	A/T	cg22509179	chr1:25234806	RUNX3	0.49	4.58	0.35	9.43e-6	Plateletcrit;
PAAD	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg13530377	chr2:235902088	SH3BP4	-0.42	-4.51	-0.34	1.28e-5	Dialysis-related mortality;
PAAD	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg18833306	chr6:118973337	C6orf204	0.44	4.68	0.36	6.23e-6	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2446066	0.872	rs10876455	chr12:53825325	A/G	cg19225099	chr12:53243489	KRT78	-0.63	-4.87	-0.37	2.75e-6	Red blood cell count;
PAAD	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg01796438	chr3:11312864	ATG7	-0.55	-4.29	-0.33	3.18e-5	Circulating chemerin levels;
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg13269407	chr22:46450107	C22orf26;LOC150381	0.52	4.67	0.35	6.58e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.7	-4.83	-0.36	3.34e-6	Platelet distribution width;
PAAD	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg21479132	chr6:26055353	NA	1.0	6.44	0.46	1.5e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg10820045	chr2:198174542	NA	0.46	4.55	0.35	1.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs78707713	0.841	rs28463525	chr10:71215578	A/T	cg12610070	chr10:71211762	TSPAN15	-0.56	-5.29	-0.39	4.18e-7	Venous thromboembolism;
PAAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.26	-0.39	4.74e-7	Monocyte count;
PAAD	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.91e-10	Bladder cancer;
PAAD	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.61	6.43	0.46	1.53e-9	Tonsillectomy;
PAAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.77	-11.07	-0.67	3.01e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg22482690	chr17:47019901	SNF8	0.51	5.54	0.41	1.29e-7	Type 2 diabetes;
PAAD	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.58	0.68	1.24e-22	Total body bone mineral density;
PAAD	cis	rs516243	0.584	rs7523471	chr1:10740335	C/G	cg02903756	chr1:10750680	CASZ1	-0.43	-4.61	-0.35	8.32e-6	Migraine - clinic-based;
PAAD	cis	rs1144333	0.655	rs114383686	chr1:76325327	C/T	cg22875332	chr1:76189707	ACADM	0.6	4.31	0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.55	-5.84	-0.43	2.99e-8	Cortisol levels (saliva);
PAAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg25204440	chr1:209979598	IRF6	0.6	5.21	0.39	6.05e-7	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg21479132	chr6:26055353	NA	0.79	4.33	0.33	2.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.88	9.45	0.61	5.87e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	trans	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg05086975	chr17:48945232	NA	0.59	6.36	0.46	2.22e-9	Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.28	0.45	3.35e-9	Lung cancer;
PAAD	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.49	4.52	0.34	1.22e-5	Self-reported allergy;
PAAD	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.57	-6.17	-0.45	5.83e-9	Pelvic organ prolapse;
PAAD	cis	rs731174	0.797	rs686083	chr1:38149193	C/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.79	5.74	0.42	5.05e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg12310025	chr6:25882481	NA	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs900145	0.612	rs11605776	chr11:13318524	C/A	cg15603424	chr11:13300592	ARNTL	0.49	4.34	0.33	2.61e-5	Menarche (age at onset);
PAAD	cis	rs3106136	0.586	rs56161035	chr4:95059232	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-4.77	-0.36	4.35e-6	Capecitabine sensitivity;
PAAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.64	5.89	0.43	2.43e-8	IgG glycosylation;
PAAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs732765	0.734	rs12323528	chr14:75152068	G/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.51	0.34	1.27e-5	Non-small cell lung cancer;
PAAD	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg08198773	chr8:1697536	NA	-0.47	-5.06	-0.38	1.22e-6	Systolic blood pressure;
PAAD	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.73	-8.39	-0.56	3.15e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs34658409	1	rs34658409	chr8:42433985	TC/T	cg09913449	chr8:42400586	C8orf40	0.55	6.18	0.45	5.71e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg26174226	chr8:58114915	NA	-0.61	-4.32	-0.33	2.8e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg11335335	chr11:637885	DRD4	-0.38	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05059613	chr2:224821947	MRPL44	-0.76	-7.0	-0.49	7.87e-11	Neuroticism;
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg07501729	chr16:846077	CHTF18	0.65	5.97	0.44	1.59e-8	Mean corpuscular volume;
PAAD	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-1.11	-11.88	-0.69	1.91e-23	Longevity;
PAAD	cis	rs528301	0.868	rs570305	chr2:45142726	C/G	cg15393275	chr2:45165193	NA	-0.51	-5.65	-0.42	7.85e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.51e-6	Lung cancer;
PAAD	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg04117972	chr1:227635322	NA	0.61	4.26	0.33	3.61e-5	Major depressive disorder;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.26e-8	Life satisfaction;
PAAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-5.51	-0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs9992101	0.547	rs10029777	chr4:77411030	C/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.55	4.99	0.38	1.63e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.37	0.46	2.15e-9	Platelet count;
PAAD	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	1.19	13.24	0.73	4.34e-27	Eosinophil percentage of granulocytes;
PAAD	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg06606381	chr12:133084897	FBRSL1	-1.31	-7.94	-0.54	4.14e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.45	5.29	0.39	4.26e-7	Coronary artery disease;
PAAD	cis	rs6494488	0.500	rs67533952	chr15:65024574	G/C	cg16425858	chr15:64791681	ZNF609	0.88	4.59	0.35	9.04e-6	Coronary artery disease;
PAAD	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.46	4.7	0.36	5.73e-6	Type 2 diabetes;
PAAD	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.01	-0.55	2.72e-13	Homoarginine levels;
PAAD	cis	rs863345	0.604	rs7512592	chr1:158489945	G/A	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs2562456	0.839	rs2562411	chr19:21601983	T/G	cg08562672	chr19:21860753	NA	-0.44	-4.47	-0.34	1.5e-5	Pain;
PAAD	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.5	5.21	0.39	6.03e-7	Morning vs. evening chronotype;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	7.04	0.5	6.1e-11	Renal function-related traits (BUN);
PAAD	cis	rs3112530	1.000	rs170029	chr5:152719589	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg15598662	chr11:61582890	MIR1908;FADS1	0.53	4.74	0.36	4.8e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16268778	chr17:37824529	PNMT	-0.6	-7.51	-0.52	4.69e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg06191203	chr2:152266755	RIF1	0.57	5.26	0.39	4.77e-7	Lung cancer;
PAAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg01851573	chr8:8652454	MFHAS1	0.49	4.26	0.33	3.62e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.52	0.41	1.41e-7	Educational attainment (years of education);
PAAD	cis	rs2579500	0.807	rs10177168	chr2:97280240	A/G	cg09304357	chr2:97220596	NA	-0.48	-5.11	-0.38	9.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24123712	chr3:49967161	MON1A	-0.66	-6.9	-0.49	1.28e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.58	6.33	0.46	2.59e-9	Mean corpuscular volume;
PAAD	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.64	5.91	0.43	2.19e-8	Mosquito bite size;
PAAD	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.53	-5.71	-0.42	5.67e-8	Testicular germ cell tumor;
PAAD	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.1	-0.38	1.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg15309053	chr8:964076	NA	0.39	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg19774624	chr17:42201019	HDAC5	0.62	4.38	0.33	2.18e-5	Bone mineral density (hip);Bone mineral density (spine);
PAAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.55	4.61	0.35	8.54e-6	Height;Educational attainment;Head circumference (infant);
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg09509183	chr1:209979624	IRF6	0.55	5.34	0.4	3.34e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07648498	chr16:89883185	FANCA	0.68	7.17	0.5	3.1e-11	Vitiligo;
PAAD	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.64	6.14	0.45	6.75e-9	Lymphocyte counts;
PAAD	cis	rs9581857	0.585	rs9581875	chr13:28099678	A/G	cg22138327	chr13:27999177	GTF3A	0.85	5.44	0.4	2.05e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs9287719	0.614	rs12329184	chr2:10722764	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-5.79	-0.42	3.95e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-5.96	-0.44	1.7e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.57	6.45	0.46	1.38e-9	Blood metabolite levels;
PAAD	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.96	-0.44	1.7e-8	Alcohol dependence;
PAAD	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg18551225	chr6:44695536	NA	-0.75	-7.58	-0.52	3.1e-12	Total body bone mineral density;
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-5.49	-0.41	1.68e-7	Mean corpuscular volume;
PAAD	cis	rs78132593	0.723	rs115291189	chr1:150675007	C/A	cg13175981	chr1:150552382	MCL1	0.5	4.34	0.33	2.59e-5	High light scatter reticulocyte count;
PAAD	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	5.06	0.38	1.18e-6	Height;
PAAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg09835421	chr16:68378352	PRMT7	-1.07	-7.74	-0.53	1.3e-12	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23097143	chr19:51339488	NA	0.62	6.57	0.47	7.72e-10	Myopia (pathological);
PAAD	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.86	-0.37	2.84e-6	Renal cell carcinoma;
PAAD	cis	rs939584	0.935	rs7569102	chr2:631335	G/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs2117029	0.554	rs7954530	chr12:49573525	A/G	cg05368762	chr12:50135785	TMBIM6	0.47	4.65	0.35	7.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.44	4.4	0.34	2.07e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.6	5.54	0.41	1.33e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.09	-14.88	-0.77	1.79e-31	Testicular germ cell tumor;
PAAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg22601191	chr20:60968625	CABLES2	0.45	4.26	0.33	3.59e-5	Pelvic organ prolapse;
PAAD	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.52	4.37	0.33	2.31e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15330255	chr10:103454985	FBXW4	-0.61	-6.31	-0.46	2.9e-9	Smoking initiation;
PAAD	cis	rs17095355	0.818	rs56367935	chr10:111783266	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.47	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-7.39	-0.51	9.27e-12	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11820497	chr19:10654946	ATG4D	0.66	7.54	0.52	4.07e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg05554000	chr7:158905015	VIPR2	-0.58	-4.54	-0.35	1.15e-5	Facial morphology (factor 20);
PAAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-5.64	-0.42	8e-8	Glomerular filtration rate;
PAAD	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg24565620	chr2:194026	NA	0.65	5.12	0.38	8.99e-7	Blood protein levels;
PAAD	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg01426195	chr3:39028469	NA	0.65	6.5	0.47	1.1e-9	Handedness;
PAAD	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.74	8.33	0.56	4.35e-14	Prostate cancer;
PAAD	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.91	-12.35	-0.71	1.04e-24	Ulcerative colitis;
PAAD	cis	rs2124910	0.933	rs2305772	chr19:52033742	G/A	cg12008991	chr19:52034861	SIGLEC6	0.39	5.11	0.38	9.57e-7	Blood protein levels;
PAAD	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg14686297	chr22:46650375	NA	-0.46	-4.57	-0.35	1.01e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.95e-17	Rheumatoid arthritis;
PAAD	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg14146966	chr2:61757674	XPO1	0.39	4.82	0.36	3.49e-6	Tuberculosis;
PAAD	cis	rs11009175	0.615	rs6481817	chr10:33299247	C/T	cg00146027	chr10:33299147	NA	-0.4	-4.87	-0.37	2.81e-6	Depression (quantitative trait);
PAAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg11764359	chr7:65958608	NA	-0.75	-4.96	-0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg24565620	chr2:194026	NA	-0.63	-4.59	-0.35	9.15e-6	Blood protein levels;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.97	-6.78	-0.48	2.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.43	-5.45	-0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.96	0.63	2.65e-18	Cognitive function;
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02071572	chr4:1403502	NA	0.5	6.46	0.46	1.31e-9	Longevity;
PAAD	cis	rs5756391	0.523	rs2049908	chr22:37311089	A/G	cg16356956	chr22:37317934	CSF2RB	0.37	4.52	0.34	1.25e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg26031613	chr14:104095156	KLC1	0.5	5.53	0.41	1.37e-7	Schizophrenia;
PAAD	cis	rs6445967	1.000	rs13059916	chr3:58316364	A/G	cg23715586	chr3:58305044	RPP14	0.48	4.28	0.33	3.24e-5	Platelet count;
PAAD	cis	rs12780845	1.000	rs34500464	chr10:17191996	T/C	cg00857480	chr10:17188594	TRDMT1	0.38	4.94	0.37	2.07e-6	Homocysteine levels;
PAAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.68	0.62	1.48e-17	Rheumatoid arthritis;
PAAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	10.2	0.64	6.1e-19	Response to antipsychotic treatment;
PAAD	cis	rs7831492	0.564	rs60792897	chr8:41609623	C/T	cg17182837	chr8:41585554	ANK1	-0.59	-6.69	-0.48	4.11e-10	Colorectal cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05325934	chr7:28220606	JAZF1	-0.65	-6.43	-0.46	1.55e-9	Lung cancer in ever smokers;
PAAD	cis	rs2073499	0.872	rs77097132	chr3:50301050	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	6.0	0.44	1.39e-8	Schizophrenia;
PAAD	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	1.25	6.02	0.44	1.26e-8	Skin colour saturation;
PAAD	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg07469887	chr10:131262384	NA	-0.38	-4.27	-0.33	3.46e-5	Response to temozolomide;
PAAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs501120	0.584	rs7097076	chr10:44701352	C/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.28	0.33	3.23e-5	Lymphocyte counts;
PAAD	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.9	-10.08	-0.63	1.31e-18	Obesity-related traits;
PAAD	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.46	-4.28	-0.33	3.25e-5	Endometrial cancer;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.22e-11	Life satisfaction;
PAAD	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.6	-5.4	-0.4	2.57e-7	Total body bone mineral density;
PAAD	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.57	7.3	0.51	1.48e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.4	0.46	1.82e-9	Personality dimensions;
PAAD	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.36	0.4	3.09e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.54	0.35	1.13e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg09796270	chr17:17721594	SREBF1	-0.41	-4.5	-0.34	1.33e-5	Total body bone mineral density;
PAAD	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-5.7	-0.42	6.17e-8	Colorectal cancer;
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-6.27	-0.45	3.55e-9	Bipolar disorder;
PAAD	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.99	-10.14	-0.64	8.94e-19	Prostate cancer;
PAAD	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.65	5.44	0.4	2.1e-7	Common traits (Other);
PAAD	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	4.32	0.33	2.85e-5	Uric acid levels;
PAAD	cis	rs7792596	0.539	rs13221576	chr7:94006994	C/T	cg20814616	chr7:94014465	NA	-0.57	-4.28	-0.33	3.25e-5	Intelligence;
PAAD	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg20503657	chr10:835505	NA	0.83	5.99	0.44	1.44e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.45	4.26	0.33	3.56e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.02e-9	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.55	6.88	0.49	1.49e-10	Crohn's disease;
PAAD	cis	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.61	-0.41	9.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs73416724	1.000	rs74766084	chr6:43287804	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.82	-0.54	8.1e-13	Colorectal cancer;
PAAD	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	0.5	4.5	0.34	1.37e-5	Testicular germ cell tumor;
PAAD	cis	rs901683	0.850	rs77364880	chr10:45996100	G/A	cg16908948	chr10:45500256	ZNF22	0.82	4.35	0.33	2.46e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.64	0.35	7.43e-6	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	4.31	0.33	2.91e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Myopia (pathological);
PAAD	cis	rs7279771	0.561	rs11701906	chr21:35841562	G/A	cg16756527	chr21:35891075	RCAN1	0.41	4.26	0.33	3.6e-5	Cancer;
PAAD	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.75	9.33	0.6	1.22e-16	Body mass index;
PAAD	cis	rs9567406	1.000	rs9562547	chr13:44874267	C/T	cg08635097	chr13:44833857	NA	-0.64	-4.47	-0.34	1.52e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9472414	0.547	rs6458432	chr6:45205017	T/C	cg11115867	chr6:45345767	RUNX2;SUPT3H	-0.6	-4.25	-0.33	3.69e-5	Height;
PAAD	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.49	4.64	0.35	7.4e-6	RR interval (heart rate);
PAAD	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.23	0.39	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2882667	0.690	rs6860780	chr5:138160056	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg14515779	chr1:101123966	NA	-0.42	-4.64	-0.35	7.56e-6	Monocyte count;
PAAD	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg23093090	chr10:104574429	C10orf26	-0.4	-4.26	-0.33	3.53e-5	Arsenic metabolism;
PAAD	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.69	-0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg21698718	chr17:80085957	CCDC57	0.45	5.1	0.38	9.8e-7	Life satisfaction;
PAAD	cis	rs507080	0.697	rs656287	chr11:118571790	A/G	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.84	8.37	0.56	3.51e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.44	5.28	0.39	4.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3206736	0.548	rs329242	chr7:35059667	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.6	-0.35	8.84e-6	Diastolic blood pressure;
PAAD	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	4.61	0.35	8.42e-6	Educational attainment;
PAAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg06375148	chr1:209958343	C1orf74	-0.42	-4.32	-0.33	2.81e-5	Monobrow;
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.44	-4.28	-0.33	3.27e-5	Trans fatty acid levels;
PAAD	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.11	8.4	0.56	2.92e-14	Alzheimer's disease;
PAAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.5	-6.54	-0.47	8.62e-10	Height;
PAAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.51	6.56	0.47	8.1e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg22705602	chr4:152727874	NA	-0.48	-5.18	-0.39	7.01e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs360071	0.528	rs360098	chr1:226066690	C/G	cg25552768	chr1:226077287	LEFTY1	0.46	4.63	0.35	7.92e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg23024343	chr7:107201750	COG5	0.5	4.38	0.33	2.18e-5	Coronary artery disease;
PAAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	4.79	0.36	3.91e-6	Bipolar disorder;
PAAD	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.13	-0.38	8.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs3734905	0.614	rs73239077	chr6:170010821	A/G	cg11181693	chr6:169825345	NA	-0.83	-5.2	-0.39	6.28e-7	HIV-1 control;
PAAD	cis	rs6689305	0.674	rs10875252	chr1:100214998	T/C	cg22872634	chr1:100462710	SLC35A3	-0.49	-4.33	-0.33	2.74e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-7.81	-0.54	8.68e-13	Longevity;Endometriosis;
PAAD	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.52	5.12	0.38	9.06e-7	Cognitive function;
PAAD	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs4268898	0.582	rs1559472	chr2:24455830	A/G	cg02683114	chr2:24398427	C2orf84	0.5	5.18	0.39	6.84e-7	Asthma;
PAAD	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg20607287	chr7:12443886	VWDE	-0.62	-4.93	-0.37	2.14e-6	Coronary artery disease;
PAAD	cis	rs6718203	1.000	rs71541918	chr2:60665053	A/G	cg10480506	chr2:60280451	NA	0.77	4.65	0.35	7.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.45	4.63	0.35	7.84e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs735539	0.521	rs2585897	chr13:21398979	A/G	cg27234864	chr13:21295941	IL17D	-0.6	-4.86	-0.37	2.91e-6	Dental caries;
PAAD	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	4.9	0.37	2.39e-6	Iron status biomarkers;
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg07648498	chr16:89883185	FANCA	-0.45	-4.46	-0.34	1.61e-5	Vitiligo;
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.64	-6.32	-0.46	2.7e-9	Blood metabolite levels;
PAAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg02012338	chr4:187126139	CYP4V2	0.63	4.37	0.33	2.29e-5	Blood protein levels;
PAAD	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03829176	chr3:81810355	GBE1	0.66	6.43	0.46	1.55e-9	Obesity-related traits;
PAAD	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.67	-0.35	6.57e-6	Endometrial cancer;
PAAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.55	5.21	0.39	6.11e-7	Obesity-related traits;
PAAD	cis	rs9372498	0.536	rs9489428	chr6:118852935	T/C	cg07617317	chr6:118971624	C6orf204	0.55	4.59	0.35	9.14e-6	Diastolic blood pressure;
PAAD	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs1198430	0.673	rs7511979	chr1:23747425	G/T	cg19827787	chr1:23763612	ASAP3	0.53	4.49	0.34	1.37e-5	Total cholesterol levels;
PAAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18621852	chr3:10150065	C3orf24	0.66	5.82	0.43	3.32e-8	Alzheimer's disease;
PAAD	cis	rs10450586	0.897	rs6484288	chr11:27317367	T/C	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.4	4.38	0.33	2.17e-5	Retinal vascular caliber;
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg03676636	chr4:99064102	C4orf37	0.33	5.79	0.43	3.89e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.71	8.25	0.56	7.21e-14	Colorectal cancer;
PAAD	cis	rs6693295	0.729	rs6680996	chr1:246214432	C/T	cg26013412	chr1:247094486	AHCTF1	-0.6	-4.42	-0.34	1.87e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.78	-7.24	-0.51	2.11e-11	Platelet distribution width;
PAAD	cis	rs7714584	1.000	rs6874560	chr5:150182713	A/C	cg22134413	chr5:150180641	NA	0.95	6.41	0.46	1.71e-9	Crohn's disease;
PAAD	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg09659197	chr4:152720779	NA	0.33	4.83	0.36	3.33e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs3818638	0.520	rs11795026	chr9:124916693	T/C	cg14107457	chr9:124889836	NA	-0.45	-4.41	-0.34	1.98e-5	Obesity-related traits;
PAAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.87	0.49	1.5e-10	Systemic lupus erythematosus;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18370318	chr1:16258580	SPEN	-0.6	-6.87	-0.49	1.58e-10	Monocyte percentage of white cells;
PAAD	cis	rs2410601	0.520	rs1426916	chr8:18882501	C/G	cg19414122	chr8:18896631	NA	0.46	5.62	0.41	8.84e-8	Urinary albumin excretion rate in type 1 diabetes;
PAAD	cis	rs2562456	0.833	rs62109223	chr19:21532393	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg26751094	chr13:95954534	ABCC4	-0.45	-4.73	-0.36	4.99e-6	Blood metabolite levels;
PAAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs72634501	0.517	rs7522362	chr1:39605091	G/A	cg11070191	chr1:39582205	MACF1	0.49	4.47	0.34	1.54e-5	HDL cholesterol;
PAAD	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.69	0.58	5.35e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-6.86	-0.49	1.62e-10	Prudent dietary pattern;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg13385521	chr17:29058706	SUZ12P	-0.72	-4.65	-0.35	7.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.48	0.41	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.81	-9.22	-0.6	2.35e-16	Type 2 diabetes;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.63	-6.16	-0.45	6.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07648498	chr16:89883185	FANCA	0.7	7.41	0.52	8.11e-12	Vitiligo;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18621852	chr3:10150065	C3orf24	0.68	5.91	0.43	2.14e-8	Alzheimer's disease;
PAAD	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.81	8.93	0.59	1.32e-15	Body mass index;
PAAD	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg10556349	chr10:835070	NA	0.62	4.4	0.34	2.07e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs9910055	0.550	rs850856	chr17:42157739	C/T	cg19774624	chr17:42201019	HDAC5	0.7	5.6	0.41	9.7e-8	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs35955747	0.869	rs8141987	chr22:31587155	C/G	cg07969918	chr22:31682909	PIK3IP1	-0.34	-4.43	-0.34	1.76e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6715793	0.740	rs17640469	chr2:33392365	A/G	cg26672287	chr2:33391915	LTBP1	-0.4	-4.7	-0.36	5.88e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.68	9.15	0.6	3.52e-16	Systolic blood pressure;
PAAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.29	0.56	5.61e-14	Menopause (age at onset);
PAAD	cis	rs72960926	0.744	rs115559526	chr6:75027796	T/G	cg03266952	chr6:74778945	NA	-1.13	-6.02	-0.44	1.24e-8	Metabolite levels (MHPG);
PAAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg16306870	chr3:194868790	C3orf21	0.42	4.34	0.33	2.56e-5	Non-small cell lung cancer;
PAAD	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.79	-0.53	9.56e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg13798912	chr7:905769	UNC84A	0.58	4.42	0.34	1.9e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.95	12.44	0.71	6.02e-25	Menarche (age at onset);
PAAD	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg13207630	chr7:32358064	NA	0.91	4.48	0.34	1.43e-5	Body mass index;
PAAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-4.37	-0.33	2.25e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg25070565	chr17:20044324	CYTSB	-0.47	-5.03	-0.38	1.34e-6	Obesity-related traits;
PAAD	cis	rs7188861	0.723	rs12599908	chr16:11395915	G/A	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.75	5.68	0.42	6.68e-8	Coronary artery calcification;
PAAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.35	0.33	2.49e-5	Obesity-related traits;
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21016266	chr12:122356598	WDR66	0.65	6.81	0.48	2.1e-10	Mean corpuscular volume;
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg16316162	chr8:144660157	NAPRT1	0.85	4.47	0.34	1.51e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.9	-10.52	-0.65	8.75e-20	Iron status biomarkers;
PAAD	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs3026101	0.671	rs748486	chr17:5290824	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.75	0.42	4.68e-8	Body mass index;
PAAD	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.61	-4.69	-0.36	6.1e-6	Breast cancer;
PAAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	7.55	0.52	3.78e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs72681920	0.881	rs72679827	chr4:100076962	T/C	cg12011299	chr4:100065546	ADH4	-0.8	-4.58	-0.35	9.67e-6	Alcohol dependence;
PAAD	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.78	-5.83	-0.43	3.19e-8	Coronary artery calcification;
PAAD	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg23254163	chr1:152506842	NA	0.6	7.11	0.5	4.21e-11	Hair morphology;
PAAD	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.73	-8.45	-0.57	2.2e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13210728	chr8:104427320	SLC25A32;DCAF13	0.75	7.02	0.49	6.91e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg20761395	chr17:511517	VPS53	0.7	7.84	0.54	7.39e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.83	-9.24	-0.6	2e-16	Aortic root size;
PAAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.8	-0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9463078	0.605	rs927658	chr6:45168053	T/C	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.51	-5.85	-0.43	2.94e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.73	-6.21	-0.45	4.9e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.97	7.42	0.52	7.72e-12	Eosinophilic esophagitis;
PAAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg15847926	chr7:2749597	AMZ1	-0.43	-5.04	-0.38	1.33e-6	Height;
PAAD	cis	rs7766436	0.767	rs6456497	chr6:22603559	G/A	cg13666174	chr6:22585274	NA	-0.52	-5.75	-0.42	4.65e-8	Coronary artery disease;
PAAD	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg25649188	chr17:73499917	CASKIN2	0.64	5.75	0.42	4.69e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg14393609	chr7:65229607	NA	-0.64	-6.57	-0.47	7.47e-10	Aortic root size;
PAAD	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.28	0.45	3.4e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.51	-4.67	-0.35	6.66e-6	Hypospadias;
PAAD	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.93	9.15	0.6	3.44e-16	Corneal astigmatism;
PAAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.79	-0.36	3.95e-6	Monocyte percentage of white cells;
PAAD	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.67	-7.04	-0.5	6.27e-11	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg02631450	chr22:32366979	NA	1.03	5.61	0.41	9.21e-8	Childhood ear infection;
PAAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.59	5.16	0.39	7.51e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6460942	0.908	rs6978857	chr7:12232665	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg14440974	chr22:39074834	NA	0.55	6.23	0.45	4.34e-9	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20113888	chr7:100732273	TRIM56	0.56	6.63	0.47	5.63e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.95	-8.2	-0.55	9.48e-14	Body mass index;
PAAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.53	4.65	0.35	7.11e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7923609	0.818	rs10761716	chr10:64882300	C/G	cg01631684	chr10:65280961	REEP3	-0.46	-4.8	-0.36	3.81e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.89	5.8	0.43	3.66e-8	Blood protein levels;
PAAD	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.23	-0.39	5.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg04450456	chr4:17643702	FAM184B	-0.44	-4.5	-0.34	1.36e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.76	0.53	1.17e-12	Schizophrenia;
PAAD	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg19337854	chr7:99768885	GPC2	0.42	4.42	0.34	1.83e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18621852	chr3:10150065	C3orf24	0.66	5.57	0.41	1.11e-7	Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.08	-0.59	5.3e-16	Prostate cancer;
PAAD	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg10395934	chr14:104002654	TRMT61A	0.55	5.65	0.42	7.56e-8	Body mass index;
PAAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.33	0.4	3.52e-7	Bipolar disorder;
PAAD	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-4.37	-0.33	2.26e-5	Bone mineral density (hip);Bone mineral density (spine);
PAAD	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg17796960	chr10:135278976	LOC619207	-0.39	-4.35	-0.33	2.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg23033748	chr14:75592666	NEK9	0.4	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg19223190	chr17:80058835	NA	0.57	5.79	0.42	3.99e-8	Life satisfaction;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03904534	chr16:78466521	WWOX	-0.56	-6.83	-0.48	1.87e-10	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg02725872	chr8:58115012	NA	-0.61	-4.91	-0.37	2.32e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.5	4.64	0.35	7.52e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1625975	1.000	rs1625975	chr10:73422284	C/T	cg26005973	chr10:72643678	PCBD1	-0.72	-4.82	-0.36	3.42e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg21890820	chr11:65308645	LTBP3	-0.71	-8.84	-0.58	2.2e-15	Bone mineral density;
PAAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.5	4.96	0.37	1.91e-6	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.06	0.38	1.21e-6	Breast cancer;
PAAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24549020	chr5:56110836	MAP3K1	0.73	5.15	0.39	7.92e-7	Initial pursuit acceleration;
PAAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg14092988	chr3:52407081	DNAH1	0.39	4.63	0.35	7.89e-6	Bipolar disorder;
PAAD	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.69	-0.36	6.03e-6	Height;
PAAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10556349	chr10:835070	NA	-0.73	-5.95	-0.43	1.75e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs10214930	0.697	rs1030003	chr7:27639859	A/C	cg22168087	chr7:27702803	HIBADH	0.47	4.41	0.34	1.91e-5	Hypospadias;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02072376	chr1:153606637	C1orf77;S100A13	0.54	6.35	0.46	2.39e-9	Immature fraction of reticulocytes;
PAAD	cis	rs12325245	0.536	rs34161389	chr16:58622604	G/A	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.94	0.37	2e-6	High light scatter reticulocyte count;
PAAD	cis	rs10821973	0.527	rs2393867	chr10:64021749	T/A	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16207974	chr18:12431241	SLMO1	0.57	6.54	0.47	8.9e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs9463078	0.546	rs4714836	chr6:45019777	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.34	-0.4	3.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg19131313	chr8:1704013	NA	-0.43	-4.67	-0.35	6.61e-6	Systolic blood pressure;
PAAD	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg06599209	chr2:1746509	PXDN	0.25	4.25	0.33	3.75e-5	Response to antipsychotic treatment;
PAAD	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg24747557	chr10:131355152	MGMT	-0.46	-4.71	-0.36	5.49e-6	Response to temozolomide;
PAAD	cis	rs6594713	0.837	rs7714221	chr5:112751378	A/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs72960926	1.000	rs72958987	chr6:75129721	T/G	cg03266952	chr6:74778945	NA	-1.27	-6.69	-0.48	3.94e-10	Metabolite levels (MHPG);
PAAD	cis	rs11615916	0.790	rs7970042	chr12:62774159	A/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg25452165	chr22:42524984	CYP2D6	0.54	4.99	0.37	1.67e-6	Schizophrenia;
PAAD	cis	rs1190596	0.732	rs7156564	chr14:102558588	A/G	cg23289024	chr14:102554846	HSP90AA1	-0.45	-4.87	-0.37	2.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14180030	chr9:123475675	MEGF9	-0.45	-4.97	-0.37	1.77e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.74	7.26	0.51	1.91e-11	Mood instability;
PAAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.2	-0.39	6.47e-7	Mean platelet volume;
PAAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.98	12.7	0.72	1.22e-25	Systemic lupus erythematosus;
PAAD	cis	rs10929159	0.964	rs3754659	chr2:236950634	C/T	cg14226755	chr2:236923322	AGAP1	-0.27	-4.27	-0.33	3.46e-5	Parkinson's disease;
PAAD	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.65	5.14	0.38	8.26e-7	Serum sulfate level;
PAAD	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg20913747	chr6:44695427	NA	-0.53	-4.72	-0.36	5.3e-6	Total body bone mineral density;
PAAD	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.55	5.01	0.38	1.46e-6	Macular telangiectasia type 2;
PAAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.17	-0.55	1.09e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg07212818	chr11:638076	DRD4	-0.77	-7.02	-0.5	6.76e-11	Systemic lupus erythematosus;
PAAD	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg13918804	chr1:2043761	PRKCZ	0.39	4.98	0.37	1.7e-6	Height;
PAAD	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg01028140	chr2:1542097	TPO	-0.91	-6.94	-0.49	1.04e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg05562828	chr17:3906858	NA	0.53	5.76	0.42	4.47e-8	Type 2 diabetes;
PAAD	trans	rs7172971	0.688	rs77356331	chr15:42387272	C/T	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.88	0.43	2.55e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.61	-6.38	-0.46	1.99e-9	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.46	-4.49	-0.34	1.4e-5	Breast cancer;
PAAD	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg25753631	chr6:25732923	NA	0.37	4.25	0.33	3.74e-5	Iron status biomarkers;
PAAD	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs3736485	0.903	rs4545756	chr15:51877790	A/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17601876	0.545	rs10851498	chr15:51537012	T/C	cg21478137	chr15:51532386	CYP19A1	0.48	4.81	0.36	3.61e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.62	5.47	0.41	1.8e-7	Initial pursuit acceleration;
PAAD	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10850408	0.922	rs7970471	chr12:115365549	T/A	cg05726002	chr12:115341178	NA	-0.41	-4.83	-0.36	3.36e-6	Alzheimer's disease;
PAAD	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.0	0.38	1.57e-6	Neutrophil percentage of white cells;
PAAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.75	8.65	0.57	6.91e-15	IgG glycosylation;
PAAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.94	-0.37	2.05e-6	Resting heart rate;
PAAD	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-4.49	-0.34	1.42e-5	Daytime sleep phenotypes;
PAAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.66	-0.53	2e-12	Height;
PAAD	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-7.4	-0.51	8.58e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.69	-7.03	-0.5	6.5e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs9398803	0.588	rs970403	chr6:126645966	G/A	cg19875578	chr6:126661172	C6orf173	0.53	5.09	0.38	1.06e-6	Male-pattern baldness;
PAAD	cis	rs34311866	0.701	rs6599391	chr4:979179	T/G	cg07828340	chr4:882639	GAK	0.72	5.28	0.39	4.33e-7	Parkinson's disease;
PAAD	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.42	-4.71	-0.36	5.65e-6	Refractive error;
PAAD	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg09796270	chr17:17721594	SREBF1	-0.44	-4.98	-0.37	1.71e-6	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17400609	chr11:68154098	LRP5	0.55	6.35	0.46	2.34e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1413885	0.516	rs10789183	chr1:65856779	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.76	0.36	4.43e-6	Anticoagulant levels;
PAAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.68	-7.31	-0.51	1.45e-11	Blood protein levels;
PAAD	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg10305780	chr14:103851757	MARK3	-0.79	-6.84	-0.49	1.84e-10	Neuroticism;
PAAD	cis	rs10886094	1.000	rs10886089	chr10:119270675	T/C	cg09660043	chr10:118395444	PNLIPRP2	-0.42	-4.26	-0.33	3.61e-5	Photic sneeze reflex;
PAAD	cis	rs7627468	1.000	rs6776376	chr3:121932197	G/C	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.5	-5.59	-0.41	1.02e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs1413885	1.000	rs6588134	chr1:65816050	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	4.96	0.37	1.9e-6	Anticoagulant levels;
PAAD	cis	rs1113500	0.548	rs3853495	chr1:108643245	A/C	cg06207961	chr1:108661230	NA	0.44	4.35	0.33	2.47e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.98e-8	Bipolar disorder;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.59	-6.51	-0.47	1.04e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.79	0.36	4.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12935418	0.672	rs9925780	chr16:81045176	C/T	cg16651780	chr16:81037892	C16orf61	0.63	5.92	0.43	2.11e-8	Mean corpuscular volume;
PAAD	cis	rs8064454	1.000	rs11651755	chr17:36099840	A/G	cg04198914	chr17:36106025	HNF1B	0.33	4.32	0.33	2.83e-5	Prostate cancer;
PAAD	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.91	5.91	0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-4.31	-0.33	2.86e-5	Myopia (pathological);
PAAD	cis	rs16854884	0.770	rs4450810	chr3:143809091	C/A	cg06585982	chr3:143692056	C3orf58	0.56	5.43	0.4	2.19e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg11993925	chr19:44307056	LYPD5	0.51	6.9	0.49	1.32e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.35	-0.51	1.16e-11	Monocyte count;
PAAD	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.32	0.33	2.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.53	-5.82	-0.43	3.32e-8	Total body bone mineral density;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg20821713	chr7:1055600	C7orf50	0.42	4.62	0.35	8.11e-6	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs185694	1.000	rs1099860	chr13:30883168	C/T	cg07600127	chr13:30881527	KATNAL1	-0.68	-4.43	-0.34	1.79e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.62	5.95	0.43	1.81e-8	Height;
PAAD	cis	rs10512697	0.655	rs34299253	chr5:3510569	T/C	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6864727	1.000	rs217267	chr5:137421274	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.04	0.38	1.31e-6	Atrial fibrillation;
PAAD	cis	rs2221894	0.922	rs11136056	chr8:28864075	C/T	cg20212339	chr8:28908912	HMBOX1	0.5	5.22	0.39	5.71e-7	Obesity-related traits;
PAAD	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.26	0.6	1.87e-16	Morning vs. evening chronotype;
PAAD	cis	rs2859741	0.608	rs534853	chr1:37474726	T/C	cg09363841	chr1:37513479	NA	-0.57	-6.85	-0.49	1.7e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-4.88	-0.37	2.63e-6	Multiple sclerosis;
PAAD	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.67	7.8	0.53	9.13e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg17385448	chr1:15911702	AGMAT	0.35	4.3	0.33	3.09e-5	Systolic blood pressure;
PAAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.33	-0.33	2.75e-5	Skin colour saturation;
PAAD	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-1.09	-13.38	-0.74	1.74e-27	Headache;
PAAD	cis	rs8077577	0.895	rs11871491	chr17:18105656	T/C	cg16794390	chr17:18148240	FLII	0.59	4.82	0.36	3.44e-6	Obesity-related traits;
PAAD	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.7	7.69	0.53	1.71e-12	Inflammatory bowel disease;
PAAD	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35740288	0.685	rs12899481	chr15:86308970	C/T	cg07943548	chr15:86304357	KLHL25	-0.57	-4.9	-0.37	2.44e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6137287	0.889	rs1884763	chr20:21128127	A/G	cg04219410	chr20:21106687	PLK1S1	0.38	4.46	0.34	1.56e-5	Height;
PAAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.6	-5.82	-0.43	3.31e-8	Coronary artery disease;
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg20295408	chr7:1910781	MAD1L1	-0.48	-4.47	-0.34	1.54e-5	Schizophrenia;
PAAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.7	5.87	0.43	2.65e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs2361763	0.511	rs34256051	chr16:85999305	T/C	cg20368988	chr16:86542943	FOXF1	-0.47	-4.4	-0.34	1.99e-5	Classic bladder exstrophy;Monocyte percentage of white cells;
PAAD	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg18939081	chr1:31884902	SERINC2	0.48	5.41	0.4	2.42e-7	Alcohol dependence;
PAAD	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg08648136	chr8:956695	NA	0.51	5.45	0.4	2.02e-7	Schizophrenia;
PAAD	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.66	6.36	0.46	2.28e-9	Heart rate;
PAAD	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg09709951	chr12:54017699	ATF7	0.54	4.78	0.36	4.18e-6	Height;
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.89	5.85	0.43	2.95e-8	Body mass index;
PAAD	cis	rs11247915	0.622	rs36024412	chr1:26670444	G/T	cg15628303	chr1:26608928	UBXN11	0.66	6.57	0.47	7.47e-10	Obesity-related traits;
PAAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.77	-7.87	-0.54	6.26e-13	Body mass index;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.74	-10.11	-0.63	1.06e-18	Iron status biomarkers;
PAAD	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.65	4.9	0.37	2.39e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg21253087	chr9:139290292	SNAPC4	0.45	4.64	0.35	7.61e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.19	0.39	6.68e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.55	5.26	0.39	4.85e-7	Height;
PAAD	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-5.55	-0.41	1.24e-7	Schizophrenia;
PAAD	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.98	-9.85	-0.62	5.17e-18	Metabolite levels (HVA/5-HIAA ratio);
PAAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.78	0.36	4.1e-6	Bone mineral density;
PAAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.86	9.7	0.62	1.31e-17	Multiple system atrophy;
PAAD	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.26	0.33	3.54e-5	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00767846	chr2:170655407	SSB	-0.76	-7.01	-0.49	7.16e-11	Neuroticism;
PAAD	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.34	4.49	0.34	1.37e-5	Atrial fibrillation;
PAAD	cis	rs2548003	0.518	rs1157974	chr5:28765229	C/T	cg22863700	chr5:28928346	NA	-0.56	-5.45	-0.4	1.99e-7	Hip geometry;
PAAD	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	10.51	0.65	9.34e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4664308	0.618	rs55668231	chr2:160882066	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.8	-0.43	3.76e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	5.66	0.42	7.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg13770153	chr20:60521292	NA	-0.48	-4.7	-0.36	5.75e-6	Body mass index;
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19483330	chr2:153191749	FMNL2	-0.64	-6.38	-0.46	1.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.78	7.39	0.51	9.23e-12	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-1.1	-11.66	-0.69	7.53e-23	Longevity;
PAAD	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg05342945	chr12:48394962	COL2A1	-0.67	-4.45	-0.34	1.62e-5	Prostate cancer;
PAAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-1.0	-10.73	-0.66	2.32e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.87	-9.39	-0.61	8.5e-17	Calcium levels;
PAAD	cis	rs2882667	0.690	rs274117	chr5:138065048	A/G	cg09476006	chr5:138032270	NA	0.49	6.4	0.46	1.86e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.89	11.52	0.68	1.81e-22	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.54	-6.83	-0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg11766577	chr21:47581405	C21orf56	0.43	4.95	0.37	1.91e-6	Testicular germ cell tumor;
PAAD	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg23461800	chr14:103021989	NA	-0.58	-4.38	-0.33	2.23e-5	Platelet count;
PAAD	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.66	7.08	0.5	5.1e-11	Crohn's disease;
PAAD	trans	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg16973527	chr15:70767570	NA	0.4	6.36	0.46	2.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.97	11.33	0.68	5.74e-22	Gestational age at birth (maternal effect);
PAAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg21859623	chr20:33103246	DYNLRB1	-0.47	-4.71	-0.36	5.61e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1144333	0.655	rs4949619	chr1:76463974	C/G	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.88	-6.91	-0.49	1.24e-10	Psoriasis;
PAAD	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.74	-7.69	-0.53	1.75e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.65	-6.31	-0.46	2.85e-9	Morning vs. evening chronotype;
PAAD	cis	rs1678618	0.585	rs1245521	chr10:73785726	C/T	cg20897136	chr10:74034667	DDIT4	0.38	4.52	0.34	1.24e-5	Smoking behavior;
PAAD	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	7.23	0.51	2.15e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.62	-5.95	-0.43	1.82e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.71	0.48	3.63e-10	Morning vs. evening chronotype;
PAAD	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.66	-6.93	-0.49	1.11e-10	Lymphocyte counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00143700	chr13:49107116	RCBTB2	0.59	6.66	0.48	4.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.47	-0.41	1.79e-7	Reticulocyte count;
PAAD	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-1.28	-11.31	-0.68	6.75e-22	Obesity-related traits;
PAAD	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.78e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.64	-7.67	-0.53	1.97e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.11	14.63	0.76	8.45e-31	Primary sclerosing cholangitis;
PAAD	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.15	-0.39	7.81e-7	High light scatter reticulocyte count;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-7.67	-0.53	1.87e-12	Longevity;Endometriosis;
PAAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg03983715	chr16:68378420	PRMT7	-0.89	-6.32	-0.46	2.76e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs25422	0.938	rs62424176	chr6:118798602	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.08	-0.38	1.1e-6	Renal cell carcinoma;
PAAD	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-4.93	-0.37	2.17e-6	Platelet count;Platelet distribution width;Mean platelet volume;
PAAD	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.68	-6.89	-0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs735539	0.645	rs9552250	chr13:21175217	C/G	cg27499820	chr13:21296301	IL17D	0.52	4.97	0.37	1.81e-6	Dental caries;
PAAD	cis	rs10029851	0.704	rs1436506	chr4:109630951	C/T	cg16525761	chr4:109541525	LOC285456;RPL34	-0.47	-4.39	-0.34	2.07e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs8018808	0.875	rs7250	chr14:77935520	G/A	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg16584676	chr17:46985605	UBE2Z	0.57	5.72	0.42	5.44e-8	Type 2 diabetes;
PAAD	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.68	6.68	0.48	4.23e-10	Anterior chamber depth;
PAAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.53e-10	Bipolar disorder;
PAAD	cis	rs17824933	0.731	rs2074224	chr11:60774656	A/G	cg16817237	chr11:60793675	NA	0.52	6.76	0.48	2.71e-10	Multiple sclerosis;
PAAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.67	5.54	0.41	1.28e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04020590	chr13:113978800	GRTP1	0.61	7.34	0.51	1.23e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.77	7.8	0.53	9.01e-13	Coronary artery disease;
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.96	-12.78	-0.72	7.37e-26	Menarche (age at onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg06619466	chr10:112772261	SHOC2	-0.55	-6.46	-0.46	1.34e-9	Energy expenditure (24h);
PAAD	cis	rs2662368	0.542	rs13170734	chr5:77117673	G/A	cg02570643	chr5:77531473	AP3B1	-0.43	-4.58	-0.35	9.65e-6	Platelet distribution width;
PAAD	cis	rs3857067	0.550	rs12502728	chr4:94999892	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.23	-0.39	5.56e-7	QT interval;
PAAD	cis	rs501916	0.634	rs61333299	chr15:48066806	G/A	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs137887	0.845	rs4838877	chr22:50464740	G/C	cg23116504	chr22:50470537	TTLL8	-0.49	-5.0	-0.38	1.56e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.38	0.34	2.17e-5	Eosinophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2131877	0.871	rs62290352	chr3:194864191	G/A	cg11177333	chr3:195857752	NA	0.52	4.28	0.33	3.3e-5	Non-small cell lung cancer;
PAAD	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09065629	chr16:1709722	CRAMP1L	0.47	4.97	0.37	1.79e-6	Coronary artery disease;
PAAD	trans	rs3758141	0.790	rs13263453	chr8:18729496	G/A	cg02479022	chr8:22250005	SLC39A14	-1.04	-6.47	-0.46	1.3e-9	Body mass index (change over time) in gastrointestinal cancer;
PAAD	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.83	-9.57	-0.61	2.78e-17	Superior crus of antihelix expression;
PAAD	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg12568669	chr8:11666485	FDFT1	-0.3	-4.9	-0.37	2.46e-6	Monocyte count;
PAAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04362095	chr11:63592001	C11orf84	-0.51	-5.05	-0.38	1.25e-6	Pulse pressure;
PAAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.95	-10.86	-0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.48	-4.61	-0.35	8.32e-6	Height;
PAAD	cis	rs7922314	0.571	rs61865688	chr10:64727120	A/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg06375148	chr1:209958343	C1orf74	0.67	4.97	0.37	1.78e-6	Coronary artery disease;
PAAD	cis	rs863345	0.604	rs949398	chr1:158461983	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.57	-5.43	-0.4	2.22e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg14393609	chr7:65229607	NA	-0.64	-7.0	-0.49	7.83e-11	Aortic root size;
PAAD	cis	rs28489187	0.577	rs6697083	chr1:85887775	A/T	cg16011679	chr1:85725395	C1orf52	-0.45	-4.49	-0.34	1.38e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.9	-11.4	-0.68	3.88e-22	Prudent dietary pattern;
PAAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg04154034	chr17:28927549	LRRC37B2	0.69	4.83	0.36	3.37e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.5	-0.71	4.1e-25	Ulcerative colitis;
PAAD	cis	rs1997066	0.831	rs80134684	chr10:106828456	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.69	6.78	0.48	2.46e-10	Blood protein levels;
PAAD	cis	rs797680	0.658	rs11164904	chr1:93780742	G/A	cg04535902	chr1:92947332	GFI1	0.43	4.26	0.33	3.5e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg02725872	chr8:58115012	NA	-0.64	-5.45	-0.4	1.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.51	0.57	1.55e-14	Schizophrenia;
PAAD	cis	rs10821973	0.527	rs7096738	chr10:63980874	A/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-4.94	-0.37	2.04e-6	Testicular germ cell tumor;
PAAD	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.53	5.11	0.38	9.7e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg09659197	chr4:152720779	NA	0.44	5.25	0.39	5.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.5	-4.99	-0.38	1.64e-6	Fibrinogen levels;
PAAD	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.53	0.41	1.35e-7	Ileal carcinoids;
PAAD	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg03934865	chr2:198174659	NA	-0.47	-4.75	-0.36	4.69e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs901683	1.000	rs35464392	chr10:45972880	C/G	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.96	-12.73	-0.72	1.03e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg03934865	chr2:198174659	NA	-0.46	-4.59	-0.35	9.07e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-5.92	-0.43	2.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg02475695	chr16:616220	NHLRC4	0.48	5.59	0.41	1.01e-7	Height;
PAAD	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.61	-0.41	9.38e-8	HDL cholesterol;
PAAD	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-6.51	-0.47	1.01e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2908197	0.653	rs2961034	chr7:75961550	T/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.51	-4.36	-0.33	2.43e-5	Cocaine dependence;
PAAD	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg16928487	chr17:17741425	SREBF1	0.36	4.89	0.37	2.52e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-6.58	-0.47	7.2e-10	Prudent dietary pattern;
PAAD	cis	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg21775007	chr8:11205619	TDH	0.79	7.91	0.54	5.05e-13	Retinal vascular caliber;
PAAD	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.71	7.95	0.54	3.82e-13	Prostate cancer;
PAAD	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.59	5.55	0.41	1.21e-7	Gut microbiome composition (summer);
PAAD	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg25401027	chr5:176370377	UIMC1	0.53	5.22	0.39	5.89e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg00579200	chr11:133705235	NA	-0.4	-4.42	-0.34	1.9e-5	Childhood ear infection;
PAAD	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4478858	0.746	rs60073066	chr1:31689589	G/A	cg00250761	chr1:31883323	NA	0.4	4.45	0.34	1.68e-5	Alcohol dependence;
PAAD	cis	rs3126085	0.515	rs10788838	chr1:152363201	A/C	cg26876637	chr1:152193138	HRNR	-0.6	-4.45	-0.34	1.66e-5	Atopic dermatitis;
PAAD	cis	rs1264202	0.844	rs686356	chr8:102248843	A/G	cg13211302	chr8:102236731	NA	-0.34	-4.47	-0.34	1.52e-5	Response to antipsychotic treatment in schizophrenia (reasoning);
PAAD	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.38	0.33	2.21e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17554472	chr22:41940697	POLR3H	0.6	4.26	0.33	3.55e-5	Vitiligo;
PAAD	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.69	-8.43	-0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg11601000	chr22:42348013	LOC339674	0.43	4.81	0.36	3.62e-6	Cognitive function;
PAAD	cis	rs17162190	0.698	rs2290588	chr1:26797508	C/T	cg17456097	chr1:26900765	RPS6KA1	0.59	4.7	0.36	5.71e-6	Mean corpuscular volume;
PAAD	cis	rs1863918	0.533	rs2278222	chr5:178581797	C/T	cg05656566	chr5:178593924	ADAMTS2	-0.45	-4.69	-0.36	6.11e-6	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg24733560	chr20:60626293	TAF4	0.53	6.62	0.47	5.87e-10	Body mass index;
PAAD	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg04896959	chr15:78267971	NA	-0.49	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs7915414	0.951	rs1326837	chr10:96386206	C/T	cg00735080	chr21:47285121	PCBP3	-0.51	-6.44	-0.46	1.48e-9	Clopidogrel active metabolite levels;
PAAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs61861422	0.516	rs12767762	chr10:134443032	A/G	cg20090690	chr10:134436459	INPP5A	0.6	5.18	0.39	6.88e-7	Primary sclerosing cholangitis;
PAAD	cis	rs2221894	0.922	rs1858462	chr8:28760737	C/T	cg20212339	chr8:28908912	HMBOX1	0.5	5.26	0.39	4.74e-7	Obesity-related traits;
PAAD	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg16447950	chr5:562315	NA	-0.48	-4.55	-0.35	1.09e-5	Ulcerative colitis;
PAAD	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-0.93	-6.19	-0.45	5.38e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.7	-6.61	-0.47	6.22e-10	Urate levels in lean individuals;
PAAD	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg15478930	chr2:27652102	NRBP1	0.52	4.27	0.33	3.38e-5	Blood metabolite levels;
PAAD	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.88	10.8	0.66	1.56e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	7.28	0.51	1.71e-11	Monocyte count;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.82e-5	Life satisfaction;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg27478167	chr7:817139	HEATR2	-0.61	-4.83	-0.36	3.32e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.47	-4.51	-0.34	1.27e-5	Urinary tract infection frequency;
PAAD	cis	rs6688613	1.000	rs6656999	chr1:166956807	C/G	cg07049167	chr1:166818506	POGK	0.46	4.52	0.34	1.21e-5	Refractive astigmatism;
PAAD	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg11266682	chr4:10021025	SLC2A9	0.61	4.92	0.37	2.21e-6	Blood metabolite levels;
PAAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.75	9.55	0.61	3.24e-17	Bone mineral density;
PAAD	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18364779	chr6:26104403	HIST1H4C	0.46	4.52	0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.62	0.47	5.84e-10	Tonsillectomy;
PAAD	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.3	0.4	3.93e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg07943548	chr15:86304357	KLHL25	-0.65	-5.74	-0.42	4.93e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.78	8.91	0.59	1.48e-15	Heart rate;
PAAD	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.21	0.45	4.75e-9	Lung cancer in ever smokers;
PAAD	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.13	0.5	3.71e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.47	4.42	0.34	1.84e-5	Optic cup area;
PAAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg19257562	chr1:2043853	PRKCZ	-0.42	-5.06	-0.38	1.19e-6	Height;
PAAD	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg00181669	chr3:44000978	NA	-0.44	-4.38	-0.33	2.24e-5	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	trans	rs2790216	0.951	rs1698383	chr10:59928596	A/T	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.43	-5.23	-0.39	5.47e-7	Lewy body disease;
PAAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg04165759	chr1:150448943	RPRD2	0.51	5.31	0.4	3.8e-7	Migraine;
PAAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.59	6.32	0.46	2.78e-9	Tonsillectomy;
PAAD	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-0.96	-6.28	-0.45	3.37e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg14784868	chr12:69753453	YEATS4	0.52	4.35	0.33	2.45e-5	Response to diuretic therapy;
PAAD	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg07838603	chr6:28411030	ZSCAN23	0.35	4.34	0.33	2.55e-5	Pubertal anthropometrics;
PAAD	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg26205652	chr12:48591994	NA	0.77	6.97	0.49	9.25e-11	Longevity (90 years and older);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05650458	chr1:228270764	ARF1	0.66	6.48	0.47	1.23e-9	Obesity-related traits;
PAAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg16584676	chr17:46985605	UBE2Z	0.55	5.58	0.41	1.09e-7	Type 2 diabetes;
PAAD	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg10871876	chr19:53194124	ZNF83	0.46	4.35	0.33	2.53e-5	Response to paliperidone in schizophrenia (PANSS score);
PAAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12963246	chr6:28129442	ZNF389	0.59	4.25	0.33	3.65e-5	Parkinson's disease;
PAAD	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg08641963	chr20:44451973	TNNC2	0.3	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.87	6.98	0.49	8.42e-11	Axial length;
PAAD	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	1.05	7.31	0.51	1.43e-11	Major depressive disorder;
PAAD	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.51	6.05	0.44	1.07e-8	Alcohol dependence;
PAAD	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg22508957	chr16:3507546	NAT15	0.81	5.92	0.43	2.1e-8	Tuberculosis;
PAAD	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.51	-4.33	-0.33	2.67e-5	IgG glycosylation;
PAAD	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg20312557	chr2:97357134	FER1L5	-0.83	-4.33	-0.33	2.74e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg16898833	chr6:26189333	HIST1H4D	0.63	4.75	0.36	4.62e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg04165759	chr1:150448943	RPRD2	-0.48	-4.81	-0.36	3.65e-6	Migraine;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.05	0.38	1.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.1	-0.55	1.7e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-6.09	-0.44	8.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-5.33	-0.4	3.47e-7	Sitting height ratio;
PAAD	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.96	-13.68	-0.74	2.8e-28	Heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08414068	chr5:31857916	PDZD2	-0.69	-7.0	-0.49	7.51e-11	Obesity-related traits;
PAAD	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.53	5.0	0.38	1.53e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05491587	chr18:77659695	KCNG2	0.47	4.29	0.33	3.18e-5	Schizophrenia;
PAAD	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	10.4	0.64	1.86e-19	Cognitive test performance;
PAAD	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.57	5.27	0.39	4.67e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg03268063	chr7:1337281	NA	-0.52	-4.5	-0.34	1.33e-5	Neuroticism;
PAAD	cis	rs6834538	0.964	rs12644868	chr4:113579162	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	4.46	0.34	1.58e-5	Free thyroxine concentration;
PAAD	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	4.92	0.37	2.26e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs73195822	0.527	rs55728229	chr12:111169374	T/A	cg12870014	chr12:110450643	ANKRD13A	0.64	4.48	0.34	1.47e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg12447832	chr2:3383257	TTC15	-0.35	-4.33	-0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg16342193	chr10:102329863	NA	-0.8	-8.9	-0.59	1.58e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs74181299	0.684	rs12713532	chr2:65356552	G/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.31	-0.33	2.86e-5	Pulse pressure;
PAAD	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs3112530	1.000	rs172570	chr5:152718836	C/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs12325245	0.536	rs8058781	chr16:58653838	G/A	cg00758881	chr16:58534681	NDRG4	-0.96	-5.0	-0.38	1.58e-6	Schizophrenia;
PAAD	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-4.37	-0.33	2.33e-5	Personality dimensions;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08037937	chr2:46769513	RHOQ	-0.74	-6.82	-0.48	1.97e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-0.57	-7.56	-0.52	3.47e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09695851	chr17:3907499	NA	-0.68	-6.91	-0.49	1.22e-10	Type 2 diabetes;
PAAD	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg02640540	chr1:67518911	SLC35D1	-0.53	-4.63	-0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.24	-0.39	5.4e-7	Schizophrenia;
PAAD	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg03264133	chr6:25882463	NA	0.43	4.25	0.33	3.76e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3736485	0.899	rs7183479	chr15:51942207	C/G	cg19558802	chr15:51695713	GLDN	-0.44	-4.37	-0.33	2.3e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.63	5.85	0.43	2.98e-8	Monocyte count;
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg08676812	chr11:65308423	LTBP3	1.55	8.01	0.54	2.85e-13	Height;
PAAD	cis	rs6681460	0.576	rs7355221	chr1:66986301	G/C	cg02459107	chr1:67143332	SGIP1	0.51	4.49	0.34	1.38e-5	Presence of antiphospholipid antibodies;
PAAD	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.42	4.37	0.33	2.33e-5	Response to antidepressants in depression;
PAAD	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18429646	chr18:21594021	TTC39C	0.66	6.82	0.48	2.01e-10	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02152992	chr13:48877591	RB1	0.65	7.28	0.51	1.67e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.69	-8.65	-0.57	7.02e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.48	-4.78	-0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	1.25	12.98	0.73	2.11e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs12799264	1.000	rs12787443	chr11:19973306	C/G	cg17303119	chr11:19974895	NAV2	-0.71	-4.28	-0.33	3.32e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.72	8.87	0.58	1.86e-15	Obesity (extreme);
PAAD	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-7.15	-0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-5.34	-0.4	3.35e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg13722127	chr7:150037890	RARRES2	0.67	6.6	0.47	6.48e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.58	-0.52	3.25e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.66	6.97	0.49	8.99e-11	Cognitive function;
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.7	7.67	0.53	1.9e-12	Longevity;
PAAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.36	0.33	2.36e-5	Eosinophil percentage of white cells;
PAAD	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-4.55	-0.35	1.07e-5	Personality dimensions;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.85	10.4	0.64	1.83e-19	Menopause (age at onset);
PAAD	cis	rs7818688	0.697	rs3802191	chr8:95987584	C/T	cg16049864	chr8:95962084	TP53INP1	-0.56	-4.49	-0.34	1.39e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg26879891	chr1:152191343	HRNR	0.54	4.72	0.36	5.34e-6	Inflammatory skin disease;
PAAD	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg13821571	chr21:34406537	NA	-0.45	-4.33	-0.33	2.65e-5	Gastritis;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs16958440	0.708	rs62096462	chr18:44625179	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-5.33	-0.4	3.47e-7	Sitting height ratio;
PAAD	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-4.34	-0.33	2.56e-5	Educational attainment;
PAAD	cis	rs6701037	0.522	rs7521981	chr1:175091151	C/T	cg14847009	chr1:175162515	KIAA0040	-0.29	-4.58	-0.35	9.51e-6	Alcohol dependence;
PAAD	cis	rs55692468	0.583	rs7425826	chr2:153338538	A/G	cg22159341	chr2:152893963	CACNB4	0.44	4.27	0.33	3.48e-5	Intraocular pressure;
PAAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.21	0.45	4.88e-9	Lung cancer;
PAAD	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-4.51	-0.34	1.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00982548	chr2:198649783	BOLL	-0.82	-5.91	-0.43	2.16e-8	Ulcerative colitis;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg21698718	chr17:80085957	CCDC57	0.45	5.11	0.38	9.61e-7	Life satisfaction;
PAAD	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05665937	chr4:1216051	CTBP1	0.48	4.95	0.37	1.94e-6	Obesity-related traits;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13939156	chr17:80058883	NA	0.44	4.9	0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg09659197	chr4:152720779	NA	0.35	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs601339	0.838	rs2454702	chr12:123209159	C/T	cg18578876	chr12:123200353	GPR109B	0.54	4.39	0.34	2.08e-5	Adiponectin levels;
PAAD	cis	rs569214	0.620	rs577731	chr8:27513653	A/T	cg04264299	chr8:27491209	SCARA3	0.52	4.74	0.36	4.89e-6	Alzheimer's disease;
PAAD	cis	rs1062746	0.545	rs3815947	chr16:87359648	C/T	cg02258303	chr16:87377426	FBXO31	-0.58	-5.5	-0.41	1.57e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs3087591	0.683	rs2854303	chr17:29716342	C/G	cg24425628	chr17:29625626	OMG;NF1	0.45	4.27	0.33	3.42e-5	Hip circumference;
PAAD	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13664964	chr2:43454185	ZFP36L2;LOC100129726	0.58	6.53	0.47	9.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs2725236	0.520	rs13107640	chr4:88910425	A/G	cg23656380	chr20:60877581	ADRM1	-0.61	-6.3	-0.46	2.98e-9	Caffeine consumption;
PAAD	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg10864074	chr7:100318194	EPO	0.43	4.98	0.37	1.74e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.75e-5	Calcium levels;
PAAD	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg14393609	chr7:65229607	NA	0.5	4.33	0.33	2.7e-5	Aortic root size;
PAAD	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg15117754	chr3:10150083	C3orf24	0.65	5.75	0.42	4.79e-8	Alzheimer's disease;
PAAD	cis	rs12144049	0.696	rs10888487	chr1:152388633	G/A	cg25605289	chr1:151974222	NA	-0.35	-4.45	-0.34	1.65e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.71	7.06	0.5	5.61e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.52	5.31	0.4	3.79e-7	Schizophrenia;
PAAD	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg22452520	chr1:24121378	LYPLA2	-0.6	-4.58	-0.35	9.8e-6	Psoriasis vulgaris;
PAAD	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs7627468	0.874	rs6783368	chr3:121934177	A/G	cg17240004	chr3:121949083	CASR	-0.46	-4.29	-0.33	3.17e-5	Kidney stones;
PAAD	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg09491104	chr22:46646882	C22orf40	0.71	4.98	0.37	1.74e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.43	4.51	0.34	1.27e-5	Menopause (age at onset);
PAAD	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs1499972	0.941	rs55979908	chr3:117598306	A/C	cg07612923	chr3:117604196	NA	1.04	7.02	0.5	6.75e-11	Schizophrenia;
PAAD	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.56	0.35	1.03e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg02012338	chr4:187126139	CYP4V2	0.65	4.45	0.34	1.66e-5	Blood protein levels;
PAAD	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-4.99	-0.38	1.64e-6	Bipolar disorder;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg03236992	chr16:78133292	WWOX	-0.61	-6.59	-0.47	6.93e-10	Immature fraction of reticulocytes;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.39	-0.68	3.96e-22	Total body bone mineral density;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.54	-4.63	-0.35	7.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg06713675	chr4:122721982	EXOSC9	0.47	4.56	0.35	1.04e-5	Type 2 diabetes;
PAAD	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.88	-10.18	-0.64	6.86e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.51	6.7	0.48	3.75e-10	Height;
PAAD	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.39	0.51	8.96e-12	Multiple sclerosis;
PAAD	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.34	-0.46	2.51e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	5.61	0.41	9.27e-8	Lung cancer in ever smokers;
PAAD	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-5.55	-0.41	1.22e-7	Adiposity;
PAAD	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.94	-10.1	-0.63	1.16e-18	Parkinson's disease;
PAAD	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.63	5.89	0.43	2.42e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.4	-5.11	-0.38	9.66e-7	Electrocardiographic conduction measures;
PAAD	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg27490568	chr2:178487706	NA	0.39	4.41	0.34	1.93e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg18850127	chr7:39170497	POU6F2	0.54	7.16	0.5	3.31e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs899997	1.000	rs2219939	chr15:79029723	G/A	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.89e-8	Ileal carcinoids;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.65	7.46	0.52	6.29e-12	Longevity;Endometriosis;
PAAD	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg26876637	chr1:152193138	HRNR	-0.81	-5.64	-0.42	8.03e-8	Atopic dermatitis;
PAAD	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22509189	chr2:225307070	NA	-0.51	-4.84	-0.37	3.22e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6032067	0.640	rs13043809	chr20:43753220	A/G	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.71	8.32	0.56	4.66e-14	Morning vs. evening chronotype;
PAAD	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.68	-0.36	6.25e-6	Bipolar disorder;
PAAD	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg13468214	chr4:1046988	NA	-0.5	-5.38	-0.4	2.82e-7	Recombination rate (males);
PAAD	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg14346243	chr4:90757452	SNCA	-0.49	-4.28	-0.33	3.24e-5	Neuroticism;
PAAD	cis	rs2908197	0.806	rs12534035	chr7:75980946	G/C	cg22830091	chr7:75961684	YWHAG	-0.62	-7.2	-0.5	2.64e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg21279865	chr17:18430908	FAM106A	0.44	4.58	0.35	9.55e-6	Multiple sclerosis;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.54	5.23	0.39	5.58e-7	Prudent dietary pattern;
PAAD	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg21605333	chr4:119757512	SEC24D	1.82	9.18	0.6	2.91e-16	Cannabis dependence symptom count;
PAAD	trans	rs11794666	0.929	rs17182339	chr9:31742399	T/C	cg05628366	chr6:35744188	C6orf126	0.94	6.46	0.46	1.31e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	0.95	6.67	0.48	4.4e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.51	-4.54	-0.35	1.15e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg12072164	chr19:44306565	LYPD5	-0.42	-4.63	-0.35	7.82e-6	Breast cancer;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.69	6.83	0.48	1.95e-10	Menarche (age at onset);
PAAD	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg27449745	chr7:23145252	KLHL7	0.58	5.53	0.41	1.35e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs73206853	0.841	rs73206847	chr12:110672353	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.36	0.33	2.35e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.61	5.28	0.39	4.46e-7	Neutrophil percentage of white cells;
PAAD	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.35	-0.33	2.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7168592	1.000	rs6598435	chr15:101742947	A/G	cg24254196	chr15:101719523	CHSY1	-0.68	-4.83	-0.37	3.24e-6	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs12523822	0.957	rs9479915	chr6:154960735	T/G	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2030114	0.904	rs11859019	chr16:51613694	G/A	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.53	-5.39	-0.4	2.61e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.55	5.4	0.4	2.53e-7	Morning vs. evening chronotype;
PAAD	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.44	4.54	0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.93	0.43	1.98e-8	Blood metabolite levels;
PAAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.85	-10.39	-0.64	1.89e-19	Aortic root size;
PAAD	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg11335335	chr11:637885	DRD4	-0.38	-5.26	-0.39	4.9e-7	Systemic lupus erythematosus;
PAAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg20761395	chr17:511517	VPS53	0.64	7.03	0.5	6.41e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.87	10.69	0.66	2.98e-20	Height;
PAAD	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.68	5.24	0.39	5.38e-7	Body mass index;
PAAD	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.33	-0.4	3.43e-7	Pulmonary function;
PAAD	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.39	-0.34	2.1e-5	Height;
PAAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	0.78	7.06	0.5	5.5e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.78	-7.76	-0.53	1.18e-12	Primary sclerosing cholangitis;
PAAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.56	7.36	0.51	1.1e-11	Renal cell carcinoma;
PAAD	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg18551225	chr6:44695536	NA	0.78	7.74	0.53	1.33e-12	Total body bone mineral density;
PAAD	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.86	5.42	0.4	2.31e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.01	-0.44	1.35e-8	Coffee consumption (cups per day);
PAAD	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.73	-0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2033711	0.936	rs882609	chr19:58991479	G/A	cg13877915	chr19:58951672	ZNF132	0.47	4.35	0.33	2.51e-5	Uric acid clearance;
PAAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg09179987	chr1:167433047	CD247	0.41	5.05	0.38	1.23e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg10820045	chr2:198174542	NA	0.45	4.57	0.35	9.96e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg23250157	chr14:64679961	SYNE2	0.53	5.36	0.4	3.09e-7	Atrial fibrillation;
PAAD	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.38	0.33	2.24e-5	Height;
PAAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs258892	0.895	rs34658	chr5:72148496	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13071672	chr1:206807879	DYRK3	-0.69	-6.36	-0.46	2.25e-9	Lung cancer in ever smokers;
PAAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.31e-26	Breast cancer;
PAAD	cis	rs7727544	0.558	rs7733502	chr5:131556203	A/C	cg14196790	chr5:131705035	SLC22A5	0.48	4.92	0.37	2.18e-6	Blood metabolite levels;
PAAD	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg01605746	chr5:669925	TPPP	0.39	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.59	5.66	0.42	7.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.62	5.58	0.41	1.08e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.62	5.96	0.44	1.69e-8	Primary sclerosing cholangitis;
PAAD	cis	rs802075	0.967	rs187233	chr6:49659703	C/T	cg20364632	chr6:49636226	NA	-0.52	-5.85	-0.43	2.87e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	1.05	9.41	0.61	7.31e-17	Neutrophil percentage of white cells;
PAAD	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.13	14.99	0.77	9.16e-32	Testicular germ cell tumor;
PAAD	cis	rs2721173	0.619	rs997258	chr8:145903077	C/A	cg11211951	chr8:145729740	GPT	-0.43	-4.73	-0.36	5.1e-6	Educational attainment;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
PAAD	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.48	5.66	0.42	7.31e-8	Height;
PAAD	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.55	5.37	0.4	2.84e-7	Itch intensity from mosquito bite;
PAAD	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg10705379	chr10:99080932	FRAT1	-0.45	-5.28	-0.39	4.34e-7	Monocyte count;
PAAD	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs4834770	1.000	rs2282688	chr4:120243722	T/C	cg09307838	chr4:120376055	NA	0.56	5.47	0.41	1.83e-7	Blood protein levels;
PAAD	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.82	-7.95	-0.54	3.89e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13560548	chr3:10150139	C3orf24	0.54	4.94	0.37	2.01e-6	Alzheimer's disease;
PAAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg26022315	chr17:47021804	SNF8	0.47	4.94	0.37	2.02e-6	Type 2 diabetes;
PAAD	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.3	-0.4	3.96e-7	Mean platelet volume;
PAAD	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg07159951	chr1:45983175	PRDX1	0.41	4.54	0.35	1.15e-5	High light scatter reticulocyte count;
PAAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.5	-7.43	-0.52	7.18e-12	Diastolic blood pressure;
PAAD	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg18867708	chr6:26865862	GUSBL1	-0.45	-4.66	-0.35	6.92e-6	Schizophrenia;
PAAD	cis	rs7713065	0.840	rs10039559	chr5:131804507	T/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.17	-0.39	7.19e-7	Lung function (FEV1/FVC);
PAAD	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg09168692	chr1:7887560	PER3	-0.43	-4.4	-0.34	2.04e-5	Inflammatory bowel disease;
PAAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-1.07	-15.51	-0.78	3.95e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1455213	0.562	rs28567921	chr4:15170365	G/A	cg12377275	chr4:15005593	CPEB2	0.49	4.68	0.35	6.35e-6	Parental longevity (mother's age at death);
PAAD	cis	rs10916814	1.000	rs4654863	chr1:20902244	G/A	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12799264	1.000	rs2585775	chr11:19974151	T/C	cg17303119	chr11:19974895	NAV2	0.71	4.76	0.36	4.51e-6	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.87	-8.73	-0.58	4.37e-15	Obesity-related traits;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.73	-8.17	-0.55	1.11e-13	Prostate cancer;
PAAD	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg15956490	chr3:53032818	SFMBT1	0.79	4.54	0.35	1.12e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.65	7.83	0.54	7.7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg00540400	chr15:79124168	NA	-0.55	-6.59	-0.47	6.65e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg01884057	chr2:25150051	NA	-0.37	-4.48	-0.34	1.43e-5	Body mass index in non-asthmatics;
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11245990	chr11:68621969	NA	0.39	5.19	0.39	6.52e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14065008	chr6:128374435	PTPRK	-0.6	-6.54	-0.47	8.72e-10	Obesity-related traits;
PAAD	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.57	-5.39	-0.4	2.65e-7	Daytime sleep phenotypes;
PAAD	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.69	5.09	0.38	1.06e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.44	-0.34	1.73e-5	Diastolic blood pressure;
PAAD	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg12310025	chr6:25882481	NA	0.52	5.01	0.38	1.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs59191668	0.903	rs4774437	chr15:62834113	A/G	cg12918536	chr15:62891943	NA	0.35	4.78	0.36	4.08e-6	Immature fraction of reticulocytes;
PAAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.48	-6.06	-0.44	1.01e-8	Iron status biomarkers;
PAAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.49	5.8	0.43	3.77e-8	Height;
PAAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg00576331	chr11:65640516	EFEMP2	0.48	4.36	0.33	2.35e-5	Eosinophil percentage of white cells;
PAAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.62	-0.35	8.14e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03745244	chr1:16399725	FAM131C	-0.8	-6.85	-0.49	1.72e-10	Neuroticism;
PAAD	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-5.31	-0.4	3.81e-7	Psoriasis;
PAAD	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.74	6.86	0.49	1.63e-10	Neuroticism;
PAAD	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg21300403	chr2:198650112	BOLL	0.48	4.26	0.33	3.6e-5	Dermatomyositis;
PAAD	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	4.58	0.35	9.64e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.41	5.44	0.4	2.08e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	11.16	0.67	1.73e-21	Menopause (age at onset);
PAAD	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs7833787	0.827	rs1022758	chr8:18678705	T/G	cg17701159	chr8:18705777	PSD3	-0.46	-5.17	-0.39	7.35e-7	Obesity-related traits;
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.63	-6.64	-0.47	5.13e-10	Prostate cancer;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg00450029	chr8:599525	NA	0.79	4.94	0.37	2e-6	IgG glycosylation;
PAAD	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	5.97e-20	Electrocardiographic conduction measures;
PAAD	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	8.9	0.59	1.52e-15	Monocyte percentage of white cells;
PAAD	cis	rs4450131	0.898	rs3824804	chr10:126326606	C/T	cg20435097	chr10:126320824	FAM53B	0.46	5.15	0.39	7.94e-7	White blood cell count (basophil);
PAAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg05042697	chr2:10830656	NOL10	-0.48	-4.76	-0.36	4.44e-6	Prostate cancer;
PAAD	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg13535736	chr9:111863775	C9orf5	-0.37	-4.58	-0.35	9.8e-6	Menarche (age at onset);
PAAD	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.33	6.07	0.44	9.9e-9	Skin colour saturation;
PAAD	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg00383909	chr3:49044727	WDR6	0.82	5.4	0.4	2.53e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-1.12	-6.74	-0.48	3.08e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9815354	1.000	rs2371627	chr3:41839219	A/G	cg03022575	chr3:42003672	ULK4	0.75	5.54	0.41	1.31e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.64	6.34	0.46	2.49e-9	Corneal astigmatism;
PAAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.29	-0.39	4.12e-7	Height;
PAAD	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg03808351	chr9:123631620	PHF19	0.41	4.31	0.33	2.97e-5	Rheumatoid arthritis;
PAAD	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.71	9.52	0.61	3.81e-17	Eosinophil percentage of white cells;
PAAD	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg07777115	chr5:623756	CEP72	-0.69	-4.42	-0.34	1.86e-5	Lung disease severity in cystic fibrosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21271961	chr1:95285780	SLC44A3	0.69	8.53	0.57	1.38e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.38e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.07	0.55	1.99e-13	Prudent dietary pattern;
PAAD	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg05627522	chr15:75251581	NA	-0.46	-5.41	-0.4	2.37e-7	Breast cancer;
PAAD	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.41	4.5	0.34	1.37e-5	Aortic root size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13797775	chr9:108320518	FKTN	-0.73	-6.63	-0.47	5.57e-10	Neuroticism;
PAAD	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.58	7.31	0.51	1.41e-11	Schizophrenia;
PAAD	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.7	9.06	0.59	6.1e-16	Asthma;
PAAD	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg04497992	chr16:616212	NHLRC4	0.37	4.25	0.33	3.71e-5	Height;
PAAD	cis	rs7017697	0.507	rs3816246	chr8:19682545	A/G	cg03894339	chr8:19674705	INTS10	-0.58	-4.42	-0.34	1.85e-5	Breast cancer;
PAAD	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg09754948	chr16:28834200	ATXN2L	0.5	4.67	0.35	6.65e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg04330084	chr7:123175371	IQUB	-0.5	-4.65	-0.35	7.14e-6	Migraine;
PAAD	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.64	6.53	0.47	9.31e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25256661	chr17:7137939	DVL2	-0.83	-8.43	-0.56	2.4e-14	Diastolic blood pressure;
PAAD	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.62	6.0	0.44	1.35e-8	Vitamin D levels;
PAAD	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.98	11.59	0.68	1.17e-22	Bone mineral density;
PAAD	cis	rs10788264	0.504	rs10749452	chr10:124028141	A/G	cg09507567	chr10:124027408	NA	0.41	4.87	0.37	2.76e-6	Total body bone mineral density;
PAAD	cis	rs2599510	0.783	rs2568464	chr2:32848658	C/T	cg02381751	chr2:32503542	YIPF4	-0.55	-5.7	-0.42	6.07e-8	Interleukin-18 levels;
PAAD	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.5	-4.68	-0.35	6.33e-6	Multiple sclerosis;
PAAD	cis	rs507080	0.845	rs667982	chr11:118562767	T/C	cg08498647	chr11:118550644	TREH	-0.38	-4.46	-0.34	1.61e-5	Serum metabolite levels;
PAAD	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg21855830	chr2:127963489	CYP27C1	0.44	4.28	0.33	3.28e-5	Protein C levels;
PAAD	cis	rs9768139	0.512	rs1121014	chr7:158081769	T/C	cg25566285	chr7:158114605	PTPRN2	-0.51	-4.62	-0.35	8.14e-6	Calcium levels;
PAAD	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-9.36	-0.6	1.01e-16	Brugada syndrome;
PAAD	cis	rs7752195	0.555	rs76671369	chr6:25191039	G/C	cg26336265	chr6:25042955	NA	0.71	4.81	0.36	3.61e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14749448	chr11:65325872	LTBP3	0.5	6.41	0.46	1.75e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.0	-0.44	1.41e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.54e-6	Bipolar disorder;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.58	6.77	0.48	2.7e-10	Calcium levels;
PAAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.9	6.52	0.47	9.93e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.72	0.42	5.46e-8	Tonsillectomy;
PAAD	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg08134877	chr2:44394819	PPM1B	0.45	4.44	0.34	1.73e-5	Height;
PAAD	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs1018697	1.000	rs7092346	chr10:104559764	A/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.7	8.07	0.55	1.97e-13	Emphysema distribution in smoking;
PAAD	cis	rs730532	0.556	rs1497086	chr14:52517190	C/G	cg16066272	chr14:52535949	NID2	-0.57	-4.3	-0.33	3.01e-5	Pulmonary function;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg05585630	chr7:157510462	PTPRN2	-0.77	-8.8	-0.58	2.81e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs4455778	0.580	rs3924858	chr7:49121340	G/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.28	0.33	3.27e-5	Total body bone mineral density;
PAAD	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-6.31	-0.46	2.91e-9	Hypospadias;
PAAD	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.44	-4.88	-0.37	2.66e-6	Pneumonia;
PAAD	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-5.7	-0.42	6.07e-8	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19486585	chr2:109151054	NA	0.62	7.11	0.5	4.21e-11	Monocyte percentage of white cells;
PAAD	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg04165759	chr1:150448943	RPRD2	0.52	5.38	0.4	2.82e-7	Migraine;
PAAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg25251562	chr2:3704773	ALLC	-0.56	-5.99	-0.44	1.46e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1539053	0.966	rs12755476	chr1:58098949	C/T	cg20292791	chr1:58089357	DAB1	-0.53	-5.16	-0.39	7.56e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-5.27	-0.39	4.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.74	-0.42	5.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.35	-0.33	2.46e-5	Resting heart rate;
PAAD	cis	rs8077577	0.836	rs11652964	chr17:18040404	C/T	cg16794390	chr17:18148240	FLII	0.66	5.35	0.4	3.12e-7	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.55	-0.47	8.34e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.17	-10.51	-0.65	9.01e-20	Vitiligo;
PAAD	cis	rs9467160	0.871	rs7762593	chr6:24449417	G/A	cg16211469	chr6:24423932	MRS2	0.54	5.39	0.4	2.63e-7	Liver enzyme levels;
PAAD	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.44	-4.66	-0.35	6.74e-6	Platelet count;
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg10072921	chr12:121022843	NA	0.42	5.02	0.38	1.41e-6	Type 1 diabetes nephropathy;
PAAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.26	0.33	3.55e-5	Iron status biomarkers;
PAAD	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg26898376	chr11:64110657	CCDC88B	0.54	4.52	0.34	1.24e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4774830	0.590	rs79693462	chr15:56202398	C/T	cg24530489	chr15:56299380	NA	-1.09	-4.84	-0.37	3.18e-6	Delta-5 desaturase activity;
PAAD	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs1413885	0.549	rs1334879	chr1:65846051	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	4.71	0.36	5.56e-6	Anticoagulant levels;
PAAD	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.44	7.06	0.5	5.62e-11	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs61931739	0.592	rs61927752	chr12:33697205	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-7.48	-0.52	5.62e-12	Morning vs. evening chronotype;
PAAD	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.75	6.1	0.44	8.21e-9	Obesity-related traits;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19459542	chr2:21265912	APOB	-0.66	-6.38	-0.46	2.02e-9	Lung cancer in ever smokers;
PAAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg15117754	chr3:10150083	C3orf24	0.65	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg13535736	chr9:111863775	C9orf5	-0.35	-4.47	-0.34	1.53e-5	Menarche (age at onset);
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg16926213	chr1:1841314	NA	0.37	4.47	0.34	1.5e-5	Body mass index;
PAAD	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-6.95	-0.49	1e-10	Total cholesterol levels;
PAAD	cis	rs79149102	0.579	rs67538199	chr15:75361650	T/C	cg17294928	chr15:75287854	SCAMP5	-1.0	-7.59	-0.52	3.03e-12	Lung cancer;
PAAD	cis	rs11811982	0.793	rs77291093	chr1:227498752	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg17346650	chr17:80929145	B3GNTL1	0.41	4.86	0.37	2.93e-6	Glycated hemoglobin levels;
PAAD	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.89	9.76	0.62	8.75e-18	Height;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08219700	chr8:58056026	NA	0.71	5.26	0.39	4.78e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.08	15.42	0.78	6.78e-33	Multiple system atrophy;
PAAD	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.4	-4.56	-0.35	1.05e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.49	-4.51	-0.34	1.29e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.51	-4.89	-0.37	2.57e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg04287289	chr16:89883240	FANCA	-0.71	-4.88	-0.37	2.64e-6	Caffeine consumption;
PAAD	cis	rs73072330	1.000	rs73072330	chr3:48165089	G/A	cg04507495	chr3:47563649	NA	1.03	4.86	0.37	2.92e-6	Stem cell growth factor beta levels;
PAAD	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.57	5.68	0.42	6.69e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Birth weight;
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10512697	0.655	rs13157404	chr5:3473854	C/T	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27370759	chr17:26902152	ALDOC	-0.7	-6.99	-0.49	8.11e-11	Obesity-related traits;
PAAD	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg27234864	chr13:21295941	IL17D	-0.66	-5.88	-0.43	2.54e-8	Dental caries;
PAAD	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.56	-7.4	-0.51	8.64e-12	Urate levels in overweight individuals;
PAAD	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.47	4.29	0.33	3.13e-5	Tuberculosis;
PAAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18364779	chr6:26104403	HIST1H4C	0.45	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4948102	0.642	rs4948104	chr7:56142519	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.39	5.35	0.4	3.2e-7	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.35	-0.4	3.17e-7	Total body bone mineral density;
PAAD	cis	rs9361491	0.608	rs4141594	chr6:79461195	A/C	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.62	-7.49	-0.52	5.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-4.63	-0.35	7.88e-6	Fat distribution (HIV);
PAAD	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg20243544	chr17:37824526	PNMT	0.51	4.54	0.35	1.13e-5	Self-reported allergy;
PAAD	cis	rs2013441	0.579	rs34370440	chr17:20003430	A/G	cg13482628	chr17:19912719	NA	0.49	4.73	0.36	5.06e-6	Obesity-related traits;
PAAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs2562456	0.520	rs660063	chr19:21453905	T/G	cg08562672	chr19:21860753	NA	0.46	4.5	0.34	1.37e-5	Pain;
PAAD	cis	rs78761021	0.617	rs7207058	chr17:9767243	T/C	cg26853458	chr17:9805074	RCVRN	0.45	5.29	0.39	4.25e-7	Type 2 diabetes;
PAAD	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.63	0.65	4.29e-20	Electrocardiographic conduction measures;
PAAD	cis	rs3106136	0.814	rs6532482	chr4:95277414	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.03	-0.44	1.17e-8	Capecitabine sensitivity;
PAAD	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs4750440	0.585	rs7072791	chr10:14028195	A/C	cg27542038	chr10:14027202	FRMD4A	-0.45	-4.44	-0.34	1.71e-5	Adiponectin levels;
PAAD	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.52	-4.88	-0.37	2.68e-6	Daytime sleep phenotypes;
PAAD	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.54	4.66	0.35	6.89e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg23188684	chr11:67383651	NA	0.48	5.0	0.38	1.57e-6	Mean corpuscular volume;
PAAD	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg09839279	chr12:125627357	AACS	-0.55	-5.56	-0.41	1.2e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.32	0.46	2.75e-9	Calcium levels;
PAAD	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg18898632	chr2:242989856	NA	-0.73	-5.71	-0.42	5.65e-8	Obesity-related traits;
PAAD	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.75	-8.09	-0.55	1.8e-13	Migraine;Coronary artery disease;
PAAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-4.73	-0.36	5.19e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.53	4.88	0.37	2.67e-6	Dialysis-related mortality;
PAAD	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.64	4.37	0.33	2.27e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.71	6.37	0.46	2.09e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.43	-5.06	-0.38	1.19e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.93	10.73	0.66	2.44e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg10434728	chr15:90938212	IQGAP1	-0.45	-4.47	-0.34	1.53e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.77	-5.83	-0.43	3.16e-8	Mean platelet volume;
PAAD	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg04374321	chr14:90722782	PSMC1	0.51	4.27	0.33	3.43e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-11.46	-0.68	2.55e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg18084798	chr19:33555255	RHPN2	-0.39	-4.25	-0.33	3.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.64	6.57	0.47	7.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6431644	0.588	rs4663979	chr2:234803432	C/A	cg08343899	chr2:234847554	TRPM8	0.49	4.78	0.36	4.14e-6	Left atrial antero-posterior diameter;
PAAD	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.74	-0.42	5.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6880778	0.505	rs13186168	chr5:40376047	T/A	cg05240017	chr5:40756081	TTC33	0.54	4.64	0.35	7.38e-6	Inflammatory bowel disease;
PAAD	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.89	13.03	0.73	1.6e-26	Dental caries;
PAAD	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg17595323	chr11:93583763	C11orf90	-0.36	-4.48	-0.34	1.43e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.59	4.64	0.35	7.59e-6	Bipolar disorder;
PAAD	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	4.71	0.36	5.59e-6	Mood instability;
PAAD	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.36	5.96e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.72	5.13	0.38	8.85e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-5.85	-0.43	2.94e-8	Prostate cancer;
PAAD	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg16506815	chr2:162101123	NA	0.64	7.04	0.5	6.14e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs3104707	1.000	rs3104707	chr16:10071158	A/G	cg06299307	chr16:10133466	GRIN2A	-0.74	-4.59	-0.35	9.24e-6	Subjective well-being;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg07362569	chr17:61921086	SMARCD2	0.4	4.57	0.35	1.01e-5	Height;
PAAD	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.18	0.6	2.92e-16	Bipolar disorder;
PAAD	cis	rs2834288	0.500	rs2834304	chr21:35321853	T/C	cg22542663	chr21:34915757	GART;SON	0.42	4.26	0.33	3.6e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.62	5.64	0.42	8.09e-8	Type 1 diabetes nephropathy;
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg17514665	chr17:1657533	SERPINF2	0.65	6.01	0.44	1.32e-8	Serum albumin level;
PAAD	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.2	-0.6	2.64e-16	Response to antipsychotic treatment;
PAAD	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg13918804	chr1:2043761	PRKCZ	0.36	4.8	0.36	3.73e-6	Height;
PAAD	cis	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg20159608	chr7:32802032	NA	0.59	6.11	0.44	8.17e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs300774	0.925	rs300723	chr2:134131	C/T	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.97	-0.37	1.79e-6	Body mass index;
PAAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Depression;
PAAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23161317	chr6:28129485	ZNF389	0.54	4.27	0.33	3.36e-5	Depression;
PAAD	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg25482853	chr8:67687455	SGK3	0.87	6.85	0.49	1.72e-10	Obesity-related traits;
PAAD	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.13	0.38	8.91e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg27205649	chr11:78285834	NARS2	-0.6	-4.43	-0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs4538187	0.865	rs35474183	chr2:63982523	C/T	cg08613950	chr2:64719184	NA	0.65	4.33	0.33	2.74e-5	Systolic blood pressure;
PAAD	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.65	-4.75	-0.36	4.75e-6	Blood protein levels;
PAAD	cis	rs929596	0.603	rs2602363	chr2:234520525	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg15478930	chr2:27652102	NRBP1	-0.55	-4.58	-0.35	9.43e-6	Blood metabolite levels;
PAAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.38	0.34	2.17e-5	Asthma;
PAAD	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg15047889	chr8:124780837	FAM91A1	-0.7	-5.5	-0.41	1.55e-7	Pancreatic cancer;
PAAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.34	-0.33	2.55e-5	Menarche (age at onset);
PAAD	cis	rs2718812	0.935	rs1867502	chr3:133410625	C/A	cg08048268	chr3:133502702	NA	0.42	5.23	0.39	5.51e-7	Iron status biomarkers;
PAAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg04257695	chr17:30186438	C17orf79	-0.57	-4.3	-0.33	3.09e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-4.84	-0.37	3.1e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Vitiligo;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24314279	chr1:23695347	C1orf213;ZNF436	0.56	6.3	0.46	3.06e-9	Monocyte percentage of white cells;
PAAD	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.5	4.55	0.35	1.1e-5	Platelet count;
PAAD	cis	rs6681460	0.800	rs481681	chr1:67194378	G/A	cg02459107	chr1:67143332	SGIP1	-0.7	-6.65	-0.47	5.06e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.53	8.0	0.54	3.01e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg22764044	chr5:178986830	RUFY1	-0.48	-5.06	-0.38	1.17e-6	Lung cancer;
PAAD	cis	rs656900	0.740	rs1675181	chr15:80111638	C/T	cg02196730	chr15:80188777	MTHFS	-0.43	-4.57	-0.35	1.02e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7627468	1.000	rs9875636	chr3:121947301	G/A	cg17240004	chr3:121949083	CASR	0.52	4.62	0.35	8.11e-6	Kidney stones;
PAAD	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.63	-6.32	-0.46	2.78e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23708337	chr7:1209742	NA	0.63	4.51	0.34	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg22029157	chr1:209979665	IRF6	0.71	6.49	0.47	1.15e-9	Coronary artery disease;
PAAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs227833	1.000	rs227833	chr6:44681840	G/C	cg18551225	chr6:44695536	NA	0.49	4.94	0.37	2.01e-6	Monobrow;
PAAD	cis	rs3733418	1.000	rs3733418	chr4:165878335	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.67	-0.42	6.89e-8	Obesity-related traits;
PAAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg08155347	chr16:88704957	IL17C	0.46	4.28	0.33	3.26e-5	Menopause (age at onset);
PAAD	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg23995914	chr4:10459228	ZNF518B	-0.37	-4.25	-0.33	3.65e-5	Schizophrenia (age at onset);
PAAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg06632027	chr4:90757378	SNCA	-0.55	-4.85	-0.37	2.99e-6	Neuroticism;
PAAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.32	-5.72	-0.42	5.59e-8	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg23465465	chr6:26364728	BTN3A2	0.83	5.14	0.39	8.2e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.55	-8.23	-0.56	7.92e-14	Diastolic blood pressure;
PAAD	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg09127314	chr1:152161683	NA	0.74	5.45	0.4	1.95e-7	Atopic dermatitis;
PAAD	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.64	-4.7	-0.36	5.79e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.94	10.73	0.66	2.32e-20	Longevity;
PAAD	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.67	7.15	0.5	3.44e-11	Morning vs. evening chronotype;
PAAD	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	0.6	5.27	0.39	4.58e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7551345	1.000	rs16834280	chr1:31717050	C/G	cg17086398	chr1:31896392	SERINC2	-0.48	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07362569	chr17:61921086	SMARCD2	0.59	6.91	0.49	1.27e-10	Prudent dietary pattern;
PAAD	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.77	-8.06	-0.55	2.06e-13	Gut microbiome composition (winter);
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	14.4	0.76	3.36e-30	Height;
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18621852	chr3:10150065	C3orf24	0.71	6.06	0.44	1.01e-8	Alzheimer's disease;
PAAD	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg19567339	chr10:100142640	NA	0.41	4.27	0.33	3.39e-5	Metabolite levels;
PAAD	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.65	-5.46	-0.41	1.87e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21654379	chr3:32864307	TRIM71	-0.56	-6.54	-0.47	8.9e-10	Monocyte percentage of white cells;
PAAD	cis	rs2030114	0.555	rs34065507	chr16:51595451	G/A	cg03758633	chr16:51611768	NA	0.51	4.98	0.37	1.69e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs731174	0.592	rs6699887	chr1:38192604	G/A	cg06917450	chr1:38156652	C1orf109	-0.58	-4.96	-0.37	1.85e-6	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs901683	1.000	rs12774690	chr10:45989745	G/T	cg11747279	chr17:21096632	NA	0.81	6.41	0.46	1.69e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.88	-10.64	-0.65	4.24e-20	Resting heart rate;
PAAD	cis	rs9810890	1.000	rs73198849	chr3:128507879	G/C	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg03289416	chr15:75166202	SCAMP2	0.53	5.6	0.41	9.77e-8	Breast cancer;
PAAD	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.44	-5.05	-0.38	1.28e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-4.58	-0.35	9.67e-6	Type 2 diabetes;
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.52	-5.17	-0.39	7.31e-7	Testicular germ cell tumor;
PAAD	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg27494647	chr7:150038898	RARRES2	0.41	4.47	0.34	1.51e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs258892	0.947	rs258895	chr5:72331687	T/C	cg21869765	chr5:72125136	TNPO1	-0.64	-4.77	-0.36	4.26e-6	Small cell lung carcinoma;
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-4.4	-0.34	2.03e-5	Vitiligo;
PAAD	cis	rs11112613	0.609	rs4388999	chr12:106047758	G/T	cg03607813	chr12:105948248	NA	0.79	5.79	0.43	3.89e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg14847009	chr1:175162515	KIAA0040	0.3	4.59	0.35	9.1e-6	Alcohol dependence;
PAAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg22189786	chr22:42395067	WBP2NL	-0.42	-4.42	-0.34	1.91e-5	Cognitive function;
PAAD	cis	rs12136530	0.593	rs4911988	chr1:19724480	C/T	cg03321592	chr1:19991676	HTR6	0.5	4.44	0.34	1.71e-5	Lead levels in blood;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08190410	chr16:67217759	KIAA0895L	0.63	7.38	0.51	9.46e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05733554	chr14:58618292	C14orf37	0.59	7.39	0.51	9.08e-12	Metabolite levels  (X-11787);
PAAD	cis	rs12922040	0.701	rs12149912	chr16:15868655	G/A	cg01223135	chr16:15826468	MYH11	-0.42	-4.45	-0.34	1.62e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	12.1	0.7	5.03e-24	Smoking behavior;
PAAD	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.4	-4.34	-0.33	2.57e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.95	9.5	0.61	4.22e-17	Resting heart rate;
PAAD	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12667521	chr19:29218732	NA	0.61	5.39	0.4	2.61e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.8	0.72	6.54e-26	Chronic sinus infection;
PAAD	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.6	6.37	0.46	2.16e-9	Body mass index;
PAAD	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-10.45	-0.65	1.32e-19	Electrocardiographic conduction measures;
PAAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs11723261	0.564	rs60994255	chr4:77446	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.67	5.44	0.4	2.06e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg10515125	chr16:89437361	ANKRD11	0.47	4.39	0.34	2.14e-5	Squamous cell carcinoma;
PAAD	cis	rs113779084	0.728	rs12530827	chr7:11965059	A/G	cg15090509	chr7:11872073	THSD7A	-0.39	-4.93	-0.37	2.16e-6	Educational attainment (years of education);
PAAD	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg27236539	chr20:62289627	RTEL1	0.58	4.69	0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs1912528	0.778	rs769657	chr4:140877659	A/G	cg11128457	chr4:140864437	MAML3	-0.33	-4.48	-0.34	1.49e-5	Educational attainment (years of education);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14368592	chr20:61981657	CHRNA4	0.6	7.53	0.52	4.25e-12	Body fat percentage;
PAAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg05110241	chr16:68378359	PRMT7	-1.05	-7.11	-0.5	4.27e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg03007772	chr4:3409324	RGS12	-0.59	-4.29	-0.33	3.1e-5	Blood protein levels;
PAAD	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	8.72	0.58	4.44e-15	Exhaled nitric oxide output;
PAAD	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	trans	rs3131337	1	rs3131337	chr6:28796071	G/C	cg06606381	chr12:133084897	FBRSL1	-1.4	-9.31	-0.6	1.35e-16	Cold sores;
PAAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.45	-6.21	-0.45	4.93e-9	Height;
PAAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.82	11.11	0.67	2.31e-21	Emphysema distribution in smoking;
PAAD	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg23112188	chr14:24563095	PCK2	0.49	5.31	0.4	3.8e-7	IgG glycosylation;
PAAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg21448613	chr3:49828315	CDH29	0.44	4.29	0.33	3.16e-5	Menarche (age at onset);
PAAD	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.1	9.81	0.62	6.5e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg07212818	chr11:638076	DRD4	-0.69	-6.8	-0.48	2.3e-10	Systemic lupus erythematosus;
PAAD	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.77	-8.55	-0.57	1.21e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9341808	0.714	rs4256394	chr6:80882142	C/T	cg08355045	chr6:80787529	NA	0.4	4.85	0.37	2.97e-6	Sitting height ratio;
PAAD	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.69	6.02	0.44	1.23e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Depression;
PAAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs1891275	0.551	rs7087959	chr10:93415917	T/C	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10851478	0.558	rs4389093	chr15:49743069	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.55	5.12	0.38	9.24e-7	Oral cavity cancer;
PAAD	cis	rs3736485	0.966	rs10851500	chr15:51783820	T/C	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.52	-5.09	-0.38	1.02e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.53	-5.1	-0.38	1.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.35	0.33	2.5e-5	Renal cell carcinoma;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.26e-8	Life satisfaction;
PAAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.88	10.66	0.65	3.58e-20	Aortic root size;
PAAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.9	-0.54	5.09e-13	Blood metabolite levels;
PAAD	trans	rs2250644	0.510	rs2071509	chr10:90988250	C/G	cg13099106	chr12:120525172	CCDC64	-0.63	-6.35	-0.46	2.31e-9	Fibrinogen levels;
PAAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs17641971	0.708	rs974781	chr8:49931055	T/A	cg00325661	chr8:49890786	NA	0.48	4.71	0.36	5.58e-6	Blood metabolite levels;
PAAD	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.49	5.79	0.43	3.92e-8	Sitting height ratio;
PAAD	cis	rs282587	0.542	rs282563	chr13:113374551	C/T	cg02820901	chr13:113351484	ATP11A	0.65	4.73	0.36	5.11e-6	Glycated hemoglobin levels;
PAAD	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.76	9.51	0.61	3.99e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg18367735	chr17:79674897	NA	0.9	7.26	0.51	1.85e-11	Dental caries;
PAAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06028605	chr16:24865363	SLC5A11	0.47	5.69	0.42	6.49e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.61	-0.47	6.01e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7101446	0.545	rs6591805	chr11:63217249	G/T	cg10713715	chr11:63533656	C11orf95	0.36	4.28	0.33	3.33e-5	Economic and political preferences;
PAAD	cis	rs7101446	0.545	rs510713	chr11:63215072	A/C	cg10713715	chr11:63533656	C11orf95	0.36	4.31	0.33	2.93e-5	Economic and political preferences;
PAAD	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.69	-7.48	-0.52	5.64e-12	Morning vs. evening chronotype;
PAAD	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg18279126	chr7:2041391	MAD1L1	-0.63	-6.23	-0.45	4.4e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg22875332	chr1:76189707	ACADM	-0.49	-4.89	-0.37	2.58e-6	Daytime sleep phenotypes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14063817	chr6:537496	EXOC2	0.68	7.05	0.5	5.79e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8179	0.645	rs11764331	chr7:92282624	C/T	cg03496780	chr7:92466842	CDK6	0.5	4.65	0.35	7.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	8.04e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg23250157	chr14:64679961	SYNE2	0.54	5.54	0.41	1.28e-7	Atrial fibrillation;
PAAD	cis	rs17023223	0.537	rs10923741	chr1:119604473	A/T	cg17326555	chr1:119535693	NA	-0.43	-5.28	-0.39	4.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05564831	chr3:52568323	NT5DC2	0.48	4.93	0.37	2.11e-6	Bipolar disorder;
PAAD	cis	rs9463078	0.546	rs2186062	chr6:45023732	T/C	cg18551225	chr6:44695536	NA	-0.42	-4.4	-0.34	2.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg23912435	chr1:150601613	ENSA	-0.49	-4.44	-0.34	1.73e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00166722	chr3:10149974	C3orf24	0.91	6.96	0.49	9.64e-11	Alzheimer's disease;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg07202610	chr7:1142643	C7orf50	-0.66	-5.44	-0.4	2.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg07617317	chr6:118971624	C6orf204	0.56	4.68	0.35	6.32e-6	Diastolic blood pressure;
PAAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.5	0.34	1.35e-5	Chronic sinus infection;
PAAD	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs863345	0.604	rs7533071	chr1:158504479	T/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs9652601	0.748	rs9927527	chr16:11212681	A/G	cg04616529	chr16:11181986	CLEC16A	0.42	4.62	0.35	8.29e-6	Systemic lupus erythematosus;
PAAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg07154921	chr7:157260426	NA	0.45	4.37	0.33	2.31e-5	Body mass index;
PAAD	cis	rs743757	0.818	rs2236961	chr3:50446524	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.7	4.74	0.36	4.92e-6	Diastolic blood pressure;
PAAD	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26871386	chr18:77514064	CTDP1	-0.7	-6.67	-0.48	4.48e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg04450456	chr4:17643702	FAM184B	0.53	5.74	0.42	5.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.56	-6.81	-0.48	2.15e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg04165759	chr1:150448943	RPRD2	0.51	5.23	0.39	5.44e-7	Migraine;
PAAD	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.61	7.38	0.51	9.72e-12	Birth weight;
PAAD	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg00614314	chr15:82944287	LOC80154	0.49	4.82	0.36	3.47e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12923728	chr3:195709715	SDHAP1	-0.87	-8.36	-0.56	3.65e-14	Pancreatic cancer;
PAAD	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg22875332	chr1:76189707	ACADM	-0.5	-4.96	-0.37	1.84e-6	Daytime sleep phenotypes;
PAAD	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.44	-5.31	-0.4	3.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs4740619	0.619	rs10738425	chr9:16041576	T/C	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	8.0	0.54	2.91e-13	Multiple sclerosis;
PAAD	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.74	-0.53	1.31e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg21433313	chr16:3507492	NAT15	0.91	7.74	0.53	1.28e-12	Tuberculosis;
PAAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs11638815	0.626	rs11635624	chr15:83315731	A/C	cg00614314	chr15:82944287	LOC80154	0.49	4.67	0.35	6.56e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs740474	0.707	rs251019	chr5:140899784	G/C	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.41	4.61	0.35	8.43e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs6137287	0.668	rs6082331	chr20:21108350	A/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.74	0.36	4.79e-6	Height;
PAAD	cis	rs10821973	0.533	rs10740062	chr10:63975842	T/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-4.95	-0.37	1.95e-6	Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.89	0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17331151	0.505	rs13066389	chr3:52565317	C/T	cg27565382	chr3:53032988	SFMBT1	0.91	4.5	0.34	1.34e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14180030	chr9:123475675	MEGF9	-0.46	-5.1	-0.38	9.88e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.66	6.58	0.47	7.3e-10	Coronary artery disease;
PAAD	cis	rs346785	0.666	rs379503	chr17:74308358	A/C	cg09812376	chr17:74270190	QRICH2	-0.44	-5.77	-0.42	4.36e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs478665	0.661	rs495588	chr1:65523020	C/T	cg24306340	chr1:64937451	CACHD1	-1.02	-4.97	-0.37	1.8e-6	Estradiol plasma levels (breast cancer);
PAAD	cis	rs7742824	1.000	rs73429729	chr6:44086727	C/A	cg21657043	chr6:44035552	NA	0.51	5.2	0.39	6.27e-7	Major depressive disorder;
PAAD	cis	rs6723162	0.773	rs2900674	chr2:71109060	G/T	cg14911521	chr2:71113568	NA	-0.4	-4.32	-0.33	2.77e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.71	8.09	0.55	1.77e-13	Height;
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.32	-0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10768122	0.642	rs10836376	chr11:35366551	A/C	cg13971030	chr11:35366721	SLC1A2	0.42	4.98	0.37	1.74e-6	Vitiligo;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-8.38	-0.56	3.23e-14	Alzheimer's disease;
PAAD	cis	rs6466055	0.661	rs55949446	chr7:104911827	C/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.67	5.71	0.42	5.71e-8	Gut microbiome composition (summer);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26770281	chr19:56109975	FIZ1	0.61	6.43	0.46	1.6e-9	Obesity-related traits;
PAAD	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg10547527	chr2:198650123	BOLL	-0.61	-4.38	-0.33	2.21e-5	Ulcerative colitis;
PAAD	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.46	5.05	0.38	1.24e-6	Carotid intima media thickness;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.57	6.24	0.45	4.18e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	4.67	0.35	6.53e-6	Height;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.62	-5.82	-0.43	3.45e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg12184421	chr1:167409136	CD247	0.37	4.29	0.33	3.21e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs2882667	0.690	rs160400	chr5:138063019	A/G	cg09476006	chr5:138032270	NA	-0.5	-6.5	-0.47	1.09e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg02230254	chr11:65586170	NA	-0.36	-5.4	-0.4	2.46e-7	Eosinophil percentage of white cells;
PAAD	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg16576597	chr16:28551801	NUPR1	-0.66	-6.72	-0.48	3.46e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.82	-8.71	-0.58	4.69e-15	Multiple sclerosis;
PAAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	trans	rs901683	1.000	rs35131026	chr10:46014759	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	4.47	0.34	1.55e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg14631576	chr9:95140430	CENPP	-0.54	-5.3	-0.39	4.02e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.55	5.37	0.4	2.84e-7	Itch intensity from mosquito bite;
PAAD	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.82	-9.25	-0.6	2e-16	Total body bone mineral density;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg21138405	chr5:131827807	IRF1	0.36	4.67	0.35	6.54e-6	Asthma;
PAAD	cis	rs6800768	0.633	rs59715267	chr3:24100414	C/A	cg10674438	chr3:24145617	LOC152024	-0.47	-4.34	-0.33	2.54e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.84	5.63	0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg02463844	chr16:88152170	NA	0.31	5.16	0.39	7.65e-7	Menopause (age at onset);
PAAD	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs56011263	0.532	rs55990625	chr4:736485	C/T	cg17689763	chr4:710664	PCGF3	-0.59	-5.79	-0.43	3.92e-8	White blood cell count;
PAAD	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg02135003	chr7:105160482	PUS7	-0.86	-6.24	-0.45	4.25e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	6.37	0.46	2.1e-9	Body mass index;
PAAD	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.67	7.45	0.52	6.47e-12	Coronary artery disease;
PAAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.65	7.37	0.51	1.01e-11	Height;
PAAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg10534938	chr5:1868639	NA	0.47	6.08	0.44	9.32e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.45	-6.28	-0.45	3.43e-9	Vitiligo;
PAAD	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01412419	chr16:87856264	NA	0.69	6.35	0.46	2.37e-9	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	7.14	0.5	3.58e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-11.2	-0.67	1.33e-21	Electrocardiographic conduction measures;
PAAD	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13870426	chr17:30244630	NA	0.7	6.9	0.49	1.34e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs2271001	0.955	rs10741761	chr11:19146531	A/G	cg00161556	chr11:19138045	ZDHHC13	0.48	5.06	0.38	1.18e-6	Gut microbiome composition (winter);
PAAD	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.92	4.92	0.37	2.26e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11811982	0.793	rs11806633	chr1:227308416	C/T	cg24860534	chr1:227506868	CDC42BPA	-0.5	-4.83	-0.36	3.29e-6	Optic disc area;
PAAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg23093090	chr10:104574429	C10orf26	-0.41	-4.52	-0.34	1.22e-5	Arsenic metabolism;
PAAD	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.66	6.31	0.46	2.95e-9	Asthma;
PAAD	cis	rs4752700	0.840	rs760337	chr10:124238949	G/A	cg20417071	chr10:124901456	NA	0.3	4.29	0.33	3.12e-5	Coronary artery disease;
PAAD	cis	rs35123781	0.580	rs431184	chr5:138962408	G/A	cg11459648	chr5:138714337	SLC23A1	-0.63	-5.84	-0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.79	-7.81	-0.54	8.79e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg14343924	chr8:8086146	FLJ10661	-0.58	-4.9	-0.37	2.38e-6	Mood instability;
PAAD	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg13002189	chr3:66846049	NA	0.53	5.16	0.39	7.69e-7	Type 2 diabetes;
PAAD	cis	rs8105895	0.935	rs10406485	chr19:22245002	G/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.87	8.83	0.58	2.35e-15	Response to antineoplastic agents;
PAAD	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.6	0.35	8.8e-6	Coronary artery disease;
PAAD	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.52	-0.34	1.24e-5	Educational attainment (years of education);
PAAD	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	4.51	0.34	1.27e-5	Schizophrenia;
PAAD	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.64	-0.8	4.76e-36	Height;
PAAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-1.06	-15.11	-0.77	4.46e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.16	0.39	7.74e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6496932	1.000	rs12917518	chr15:85827249	C/T	cg19183879	chr15:85880815	NA	0.52	4.47	0.34	1.53e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.49	5.43	0.4	2.18e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg20913747	chr6:44695427	NA	-0.7	-6.91	-0.49	1.26e-10	Total body bone mineral density;
PAAD	cis	rs112427907	1	rs112427907	chr3:47995270	G/A	cg09665691	chr3:47563885	NA	1.15	5.36	0.4	2.99e-7	Stem cell growth factor beta levels;
PAAD	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.79	4.52	0.34	1.22e-5	Childhood ear infection;
PAAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.97	-0.54	3.41e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10277546	chr21:34960952	DONSON	0.6	6.85	0.49	1.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.56	4.46	0.34	1.56e-5	Behavioural disinhibition (generation interaction);
PAAD	trans	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg24289452	chr6:170231220	NA	-1.05	-4.42	-0.34	1.9e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11245990	chr11:68621969	NA	0.38	4.79	0.36	3.88e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg02841227	chr6:26021843	HIST1H4A	0.58	4.67	0.35	6.58e-6	Gout;Renal underexcretion gout;
PAAD	cis	rs6466055	0.720	rs7800928	chr7:105007470	T/C	cg04380332	chr7:105027541	SRPK2	-0.65	-7.44	-0.52	7.07e-12	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.3	-0.39	4.05e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.48	4.78	0.36	4.07e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.87	7.36	0.51	1.06e-11	Coronary artery disease;
PAAD	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg27411982	chr8:10470053	RP1L1	0.47	4.98	0.37	1.7e-6	Retinal vascular caliber;
PAAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.88	7.53	0.52	4.26e-12	Alzheimer's disease;
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22601191	chr20:60968625	CABLES2	0.52	4.59	0.35	9.24e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9972944	0.651	rs12601958	chr17:63820304	A/G	cg07283582	chr17:63770753	CCDC46	-0.58	-6.87	-0.49	1.54e-10	Total body bone mineral density;
PAAD	cis	rs732765	0.657	rs8016513	chr14:75238261	C/T	cg15943584	chr14:75472643	EIF2B2	-0.47	-4.35	-0.33	2.44e-5	Non-small cell lung cancer;
PAAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.22	0.39	5.86e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.62	-6.99	-0.49	8.31e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg15816464	chr17:2026533	SMG6	0.52	5.73	0.42	5.14e-8	Total body bone mineral density;
PAAD	cis	rs8077577	0.747	rs8081155	chr17:18191948	C/G	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs1395	0.778	rs1439768	chr2:27389660	C/A	cg23587288	chr2:27483067	SLC30A3	-0.86	-7.35	-0.51	1.11e-11	Blood metabolite levels;
PAAD	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.93	0.37	2.11e-6	Ovarian reserve;
PAAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.12	-0.44	7.54e-9	Type 2 diabetes;
PAAD	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.3	0.33	3.06e-5	Educational attainment;
PAAD	cis	rs662064	0.748	rs2026792	chr1:10594790	A/G	cg17425144	chr1:10567563	PEX14	-0.38	-4.26	-0.33	3.51e-5	Asthma;
PAAD	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.6	-5.49	-0.41	1.62e-7	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg19761014	chr17:28927070	LRRC37B2	0.95	6.45	0.46	1.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg03999872	chr20:62272968	STMN3	-0.81	-7.48	-0.52	5.47e-12	Atopic dermatitis;
PAAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg04106633	chr4:1044584	NA	0.64	5.34	0.4	3.36e-7	Recombination rate (females);
PAAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.49	4.38	0.33	2.23e-5	Mean corpuscular volume;
PAAD	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.15e-8	Vitiligo;
PAAD	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-4.26	-0.33	3.58e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs11614333	0.959	rs12426616	chr12:14994659	C/T	cg00431549	chr12:15039025	MGP	-0.36	-4.33	-0.33	2.75e-5	Hand grip strength;
PAAD	cis	rs11992162	0.636	rs113416335	chr8:11809421	C/T	cg12568669	chr8:11666485	FDFT1	0.31	5.15	0.39	8.09e-7	Monocyte count;
PAAD	cis	rs62264129	0.500	rs62278770	chr3:112029121	T/C	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.94	-0.37	2.08e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs10865541	1.000	rs11692425	chr2:3395383	A/G	cg21040360	chr2:3383326	TTC15	-0.42	-4.49	-0.34	1.4e-5	Obesity-related traits;
PAAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.89	9.59	0.61	2.56e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09296044	chr15:43477606	CCNDBP1	0.63	6.87	0.49	1.57e-10	Myopia (pathological);
PAAD	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-4.63	-0.35	7.76e-6	Mosquito bite size;
PAAD	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg05805236	chr11:65401703	PCNXL3	-0.45	-5.18	-0.39	7.07e-7	Systemic lupus erythematosus;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.65	-7.32	-0.51	1.38e-11	Iron status biomarkers;
PAAD	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg10356904	chr22:49881777	NA	-0.47	-5.16	-0.39	7.69e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23827867	chr20:306044	SOX12	0.6	6.61	0.47	6.03e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.61	-4.58	-0.35	9.81e-6	Resting heart rate;
PAAD	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.28	0.45	3.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.6	0.57	8.97e-15	Homoarginine levels;
PAAD	cis	rs6942407	0.592	rs886787	chr7:86850210	C/T	cg02420886	chr7:86849541	C7orf23	0.69	5.33	0.4	3.47e-7	Food allergy;
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.83	-10.38	-0.64	2.04e-19	Menopause (age at onset);
PAAD	cis	rs8049634	0.732	rs2875860	chr16:84231580	G/A	cg26466773	chr16:84211947	TAF1C	0.57	5.18	0.39	6.94e-7	Small cell lung carcinoma;
PAAD	cis	rs13242816	1.000	rs66985071	chr7:116130433	C/T	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs8112211	0.816	rs80248244	chr19:38841714	A/C	cg14299480	chr19:38876666	GGN	-0.51	-5.45	-0.4	1.97e-7	Blood protein levels;
PAAD	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.7	6.1	0.44	8.32e-9	Radiation response;
PAAD	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.49	-4.34	-0.33	2.54e-5	Triglycerides;
PAAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.82	-0.36	3.38e-6	Aortic root size;
PAAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg21565972	chr17:80109576	CCDC57	-0.61	-7.1	-0.5	4.43e-11	Life satisfaction;
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.86	10.54	0.65	7.49e-20	Menopause (age at onset);
PAAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg03983476	chr2:10830698	NOL10	0.44	4.35	0.33	2.5e-5	Prostate cancer;
PAAD	cis	rs3112530	1.000	rs2615172	chr5:152715563	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg09127314	chr1:152161683	NA	-0.72	-4.99	-0.38	1.6e-6	Atopic dermatitis;
PAAD	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg16576597	chr16:28551801	NUPR1	0.62	6.87	0.49	1.53e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg03303774	chr4:1407052	NA	0.48	6.09	0.44	8.79e-9	Obesity-related traits;
PAAD	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.02	-0.44	1.28e-8	Menopause (age at onset);
PAAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs10078545	0.649	rs4703920	chr5:82128879	C/A	cg26647646	chr5:82516009	XRCC4	0.49	4.34	0.33	2.59e-5	Chin dimples;
PAAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg25456477	chr12:86230367	RASSF9	0.48	4.32	0.33	2.82e-5	Major depressive disorder;
PAAD	trans	rs9408817	1	rs9408817	chr9:108911979	G/A	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Age at voice drop;
PAAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg11601000	chr22:42348013	LOC339674	0.42	4.76	0.36	4.56e-6	Cognitive function;
PAAD	cis	rs2858942	0.780	rs2858014	chr16:248357	T/C	cg16367168	chr16:231905	NA	-0.32	-4.51	-0.34	1.31e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-0.75	-5.98	-0.44	1.56e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.71	6.87	0.49	1.58e-10	Renal function-related traits (BUN);
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs863345	0.604	rs1873510	chr1:158461418	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.65e-6	Alzheimer's disease;
PAAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs9463078	0.727	rs9463054	chr6:44917197	T/C	cg25276700	chr6:44698697	NA	-0.47	-5.37	-0.4	2.91e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg02734326	chr4:10020555	SLC2A9	0.48	4.91	0.37	2.3e-6	Bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27319730	chr6:36237037	PNPLA1	0.6	6.35	0.46	2.31e-9	Myopia (pathological);
PAAD	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.76	-4.91	-0.37	2.29e-6	Platelet distribution width;
PAAD	cis	rs2131877	0.830	rs62290329	chr3:194843634	G/A	cg24618514	chr3:194868507	C3orf21	0.48	4.48	0.34	1.44e-5	Non-small cell lung cancer;
PAAD	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26876637	chr1:152193138	HRNR	0.89	6.91	0.49	1.26e-10	Atopic dermatitis;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18337363	chr3:52569053	NT5DC2	-0.42	-4.5	-0.34	1.36e-5	Bipolar disorder;
PAAD	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.35	4.28	0.33	3.25e-5	Electrocardiographic conduction measures;
PAAD	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.32	9.06	0.59	6.18e-16	Diabetic retinopathy;
PAAD	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	6.91	0.49	1.25e-10	Colorectal cancer;
PAAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.69	7.16	0.5	3.22e-11	Permanent tooth development;
PAAD	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg19442545	chr10:75533431	FUT11	-0.55	-5.76	-0.42	4.58e-8	Inflammatory bowel disease;
PAAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	5.1	0.38	9.87e-7	Neuroticism;
PAAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.06	0.55	2.05e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.54	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.72	10.21	0.64	5.86e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.6	6.82	0.48	2.04e-10	Menarche (age at onset);
PAAD	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.47	4.7	0.36	5.78e-6	Schizophrenia;
PAAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.05	0.38	1.27e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09861318	chr3:149530987	RNF13	0.72	7.33	0.51	1.28e-11	Obesity-related traits;
PAAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.84	11.61	0.69	1.03e-22	Emphysema distribution in smoking;
PAAD	cis	rs12612619	0.732	rs6547401	chr2:27284845	A/G	cg00617064	chr2:27272375	NA	-0.55	-5.93	-0.43	1.97e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.43	4.39	0.34	2.11e-5	Sarcoidosis;
PAAD	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.38	-0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7771547	0.574	rs9366907	chr6:36549554	G/C	cg07856975	chr6:36356162	ETV7	0.44	4.6	0.35	8.76e-6	Platelet distribution width;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.74	-8.52	-0.57	1.49e-14	Height;
PAAD	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.96	9.31	0.6	1.38e-16	Psoriasis;
PAAD	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg22256960	chr15:77711686	NA	0.53	4.33	0.33	2.65e-5	Type 2 diabetes;
PAAD	cis	rs1570884	0.539	rs7983291	chr13:50111931	G/C	cg08779649	chr13:50194554	NA	0.34	4.25	0.33	3.65e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg05791153	chr7:19748676	TWISTNB	0.67	5.23	0.39	5.41e-7	Thyroid stimulating hormone;
PAAD	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.59	-0.41	1.05e-7	Neuroticism;
PAAD	trans	rs901683	1.000	rs12762495	chr10:46013615	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.83	0.48	1.95e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.73	-0.36	5.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.55	6.06	0.44	1.01e-8	Height;
PAAD	cis	rs988913	0.957	rs960835	chr6:54823422	A/G	cg03513858	chr6:54763001	FAM83B	-0.45	-4.91	-0.37	2.37e-6	Menarche (age at onset);
PAAD	cis	rs13242816	1.000	rs36011826	chr7:116118336	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg26939375	chr7:64535504	NA	0.76	9.16	0.6	3.26e-16	Aortic root size;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.63e-5	Life satisfaction;
PAAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.81e-7	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg14458575	chr2:238380390	NA	0.54	4.68	0.35	6.31e-6	Prostate cancer;
PAAD	trans	rs901683	1.000	rs79490183	chr10:46080241	C/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.47	-4.44	-0.34	1.73e-5	Breast cancer;
PAAD	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg14119001	chr9:139324193	INPP5E	-0.51	-4.87	-0.37	2.73e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs564309	0.681	rs4581279	chr1:228622347	A/G	cg00655913	chr1:228633920	NA	0.56	4.42	0.34	1.84e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg23649088	chr2:200775458	C2orf69	-0.71	-5.84	-0.43	3.04e-8	Schizophrenia;
PAAD	cis	rs12410462	0.591	rs2132366	chr1:227787102	C/T	cg23173402	chr1:227635558	NA	0.55	4.34	0.33	2.62e-5	Major depressive disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15074876	chr1:110950234	HBXIP	0.68	7.06	0.5	5.7e-11	Myopia (pathological);
PAAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	4.63	0.35	7.72e-6	Platelet count;
PAAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg21130718	chr4:1044621	NA	0.5	4.81	0.36	3.58e-6	Recombination rate (males);
PAAD	cis	rs7084783	0.519	rs2281584	chr10:105358980	A/G	cg09754828	chr10:105363329	SH3PXD2A	0.47	4.69	0.36	5.96e-6	Fear of pain;
PAAD	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs1620921	0.505	rs13203571	chr6:161208765	A/G	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs901683	1.000	rs12775527	chr10:46024990	G/A	cg11747279	chr17:21096632	NA	0.78	6.35	0.46	2.41e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	6.46	0.46	1.33e-9	Myopia (pathological);
PAAD	cis	rs2133450	0.508	rs17047073	chr3:7349612	A/G	cg19930620	chr3:7340148	GRM7	-0.46	-4.98	-0.37	1.73e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6604026	0.630	rs12081675	chr1:93461495	C/G	cg13858687	chr1:93297071	RPL5	0.48	4.28	0.33	3.31e-5	Multiple sclerosis;
PAAD	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.72	-6.01	-0.44	1.29e-8	Breast cancer;
PAAD	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs1723838	0.826	rs1792197	chr11:73585860	G/A	cg26954736	chr11:73693896	UCP2	1.04	4.61	0.35	8.51e-6	Obesity-related traits;
PAAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25809561	chr17:30822961	MYO1D	0.74	8.34	0.56	4.05e-14	Schizophrenia;
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14274895	chr9:98638211	C9orf130;C9orf102	-0.76	-6.83	-0.48	1.92e-10	Neuroticism;
PAAD	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg02250501	chr15:90694978	NA	-0.46	-4.32	-0.33	2.76e-5	Rheumatoid arthritis;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg00738919	chr7:1100172	C7orf50	0.62	5.11	0.38	9.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs732765	0.657	rs67898541	chr14:75236420	C/T	cg17347104	chr14:75034677	LTBP2	0.55	4.27	0.33	3.38e-5	Non-small cell lung cancer;
PAAD	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.54	-5.12	-0.38	8.94e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.27	0.67	8.75e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	1.08	9.81	0.62	6.83e-18	Corneal structure;
PAAD	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg00186954	chr11:8933980	ST5;C11orf17	0.45	4.64	0.35	7.37e-6	Hemoglobin concentration;
PAAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg05785598	chr3:49045655	WDR6	0.44	5.11	0.38	9.55e-7	Parkinson's disease;
PAAD	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.95	-10.21	-0.64	5.73e-19	Parkinson's disease;
PAAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.47	4.97	0.37	1.75e-6	Longevity;Endometriosis;
PAAD	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg00982548	chr2:198649783	BOLL	-0.75	-5.25	-0.39	5.02e-7	Ulcerative colitis;
PAAD	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26501599	chr3:127310131	TPRA1	-0.54	-6.46	-0.46	1.33e-9	Body fat percentage;
PAAD	cis	rs28489187	0.683	rs67611930	chr1:85846592	A/G	cg16011679	chr1:85725395	C1orf52	0.55	5.29	0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6867032	0.527	rs4975792	chr5:2010496	T/G	cg26168224	chr5:2018326	NA	0.81	9.71	0.62	1.25e-17	Gut microbiome composition (winter);
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.92	12.18	0.7	2.97e-24	Prudent dietary pattern;
PAAD	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.29	0.33	3.16e-5	Lymphocyte counts;
PAAD	cis	rs7627468	0.770	rs1463891	chr3:121970131	A/G	cg03198317	chr3:121949109	CASR	0.48	4.43	0.34	1.8e-5	Kidney stones;
PAAD	trans	rs1853207	0.708	rs1072753	chr10:96678687	G/A	cg15015722	chr7:6204774	CYTH3	0.87	6.42	0.46	1.63e-9	Blood metabolite levels;
PAAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg05342682	chr7:94953680	PON1	-0.53	-4.65	-0.35	7.3e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg00717180	chr2:96193071	NA	-0.58	-6.55	-0.47	8.18e-10	HDL cholesterol;
PAAD	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg03289416	chr15:75166202	SCAMP2	0.5	4.87	0.37	2.83e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.78	-8.82	-0.58	2.48e-15	Longevity;
PAAD	cis	rs7631605	0.935	rs7639375	chr3:37107022	C/A	cg17445812	chr3:36986805	TRANK1	0.32	4.26	0.33	3.61e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.63	7.94	0.54	4.17e-13	Hypertriglyceridemia;
PAAD	cis	rs4919087	0.561	rs34288920	chr10:99083483	C/T	cg25902810	chr10:99078978	FRAT1	-0.57	-5.18	-0.39	6.98e-7	Monocyte count;
PAAD	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg23004174	chr6:74404879	CD109	0.5	5.17	0.39	7.2e-7	Blood protein levels;Calcium levels;
PAAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg02725872	chr8:58115012	NA	-0.54	-4.33	-0.33	2.64e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg08975724	chr8:8085496	FLJ10661	-0.7	-7.15	-0.5	3.33e-11	Triglycerides;
PAAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.55	5.52	0.41	1.45e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.64	-5.23	-0.39	5.57e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-1.14	-12.71	-0.72	1.14e-25	Gut microbiota (bacterial taxa);
PAAD	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.73	-7.91	-0.54	4.96e-13	Menarche (age at onset);
PAAD	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.52	-5.99	-0.44	1.47e-8	Migraine;
PAAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg01620082	chr3:125678407	NA	-0.93	-6.96	-0.49	9.41e-11	Depression;
PAAD	cis	rs3736485	0.966	rs9920124	chr15:51908942	T/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg20406979	chr6:167373233	NA	-0.37	-5.11	-0.38	9.56e-7	Crohn's disease;
PAAD	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg07148914	chr20:33460835	GGT7	-0.48	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.52	0.34	1.24e-5	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00295835	chr11:113644563	ZW10	0.63	7.18	0.5	2.89e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.33	-0.4	3.55e-7	Corneal astigmatism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06937024	chr6:35695489	FKBP5;LOC285847	-0.72	-6.35	-0.46	2.34e-9	Neuroticism;
PAAD	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	5.54	0.41	1.28e-7	Body mass index;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07677032	chr17:61819896	STRADA	0.52	4.96	0.37	1.83e-6	Prudent dietary pattern;
PAAD	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg05925327	chr15:68127851	NA	-0.58	-5.33	-0.4	3.5e-7	Restless legs syndrome;
PAAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.72	-8.04	-0.55	2.32e-13	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	7.79	0.53	1e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2274459	0.915	rs77577915	chr6:33732804	G/A	cg06253072	chr6:33679850	C6orf125	0.68	4.79	0.36	3.93e-6	Obesity (extreme);
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.95	7.36	0.51	1.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	1.05	12.98	0.73	2.15e-26	Breast cancer;
PAAD	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg03576123	chr11:487126	PTDSS2	-1.07	-5.59	-0.41	1.03e-7	Body mass index;
PAAD	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Colorectal cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13285934	chr22:31503646	SELM	-0.54	-6.31	-0.46	2.87e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13939156	chr17:80058883	NA	-0.41	-4.45	-0.34	1.64e-5	Life satisfaction;
PAAD	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.9	11.17	0.67	1.62e-21	Dental caries;
PAAD	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg20913747	chr6:44695427	NA	-0.7	-6.98	-0.49	8.49e-11	Total body bone mineral density;
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs9397240	0.789	rs10499303	chr6:155615239	G/A	cg07943832	chr6:155568918	TIAM2	-0.35	-4.26	-0.33	3.61e-5	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12296079	chr11:61849674	NA	0.68	7.89	0.54	5.49e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9463078	0.605	rs2396504	chr6:45316202	C/G	cg18551225	chr6:44695536	NA	-0.41	-4.31	-0.33	2.98e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg03367679	chr17:38183553	MED24;SNORD124	-0.38	-4.96	-0.37	1.88e-6	Myeloid white cell count;
PAAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.62	7.88	0.54	5.69e-13	Hypertriglyceridemia;
PAAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.3	0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs12826942	0.876	rs17548889	chr12:42722219	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.66	4.99	0.38	1.65e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.58	5.84	0.43	3.12e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-4.57	-0.35	9.93e-6	Daytime sleep phenotypes;
PAAD	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.85	-9.39	-0.61	8.53e-17	Mortality in heart failure;
PAAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.64	5.63	0.42	8.59e-8	Mood instability;
PAAD	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.72	7.58	0.52	3.1e-12	Schizophrenia;
PAAD	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.72	-0.53	1.46e-12	Brugada syndrome;
PAAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.27	-0.33	3.46e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs134594	0.807	rs134622	chr22:29479090	T/G	cg01361351	chr22:29467363	NA	-0.4	-4.47	-0.34	1.53e-5	Birth weight;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.5	-5.86	-0.43	2.72e-8	Testicular germ cell tumor;
PAAD	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs57786342	0.569	rs8019383	chr14:69277341	A/G	cg03189333	chr14:69283534	NA	-0.53	-4.38	-0.33	2.22e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs35000415	0.873	rs12539741	chr7:128596805	C/T	cg19972273	chr7:128594194	NA	0.97	5.64	0.42	7.88e-8	Systemic lupus erythematosus;
PAAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.76	-8.82	-0.58	2.51e-15	Eye color traits;
PAAD	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.48	0.34	1.44e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg01181863	chr3:195395398	SDHAP2	-0.8	-7.63	-0.53	2.45e-12	Pancreatic cancer;
PAAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.75	9.0	0.59	8.8e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.75	6.36	0.46	2.21e-9	Pediatric autoimmune diseases;
PAAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.56	-5.31	-0.4	3.89e-7	Breast size;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.63	5.02	0.38	1.42e-6	Obesity (extreme);
PAAD	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.64	-5.73	-0.42	5.2100000000000003e-08	Personality dimensions;
PAAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs11615916	0.790	rs7316131	chr12:62669425	G/A	cg11441379	chr12:63026424	NA	0.69	4.57	0.35	1.02e-5	Pulmonary function decline;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.49	0.41	1.67e-7	Platelet count;
PAAD	cis	rs367943	0.608	rs6594744	chr5:112990207	T/C	cg12552261	chr5:112820674	MCC	0.56	6.02	0.44	1.23e-8	Type 2 diabetes;
PAAD	cis	rs354225	0.544	rs7340302	chr2:54803671	A/C	cg01766943	chr2:54829624	SPTBN1	0.51	4.6	0.35	8.96e-6	Schizophrenia;
PAAD	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.47	-4.26	-0.33	3.64e-5	Response to temozolomide;
PAAD	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg06530960	chr19:49140787	SEC1;DBP	0.62	5.17	0.39	7.14e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
PAAD	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.39	-4.6	-0.35	8.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.73	-7.93	-0.54	4.48e-13	Colorectal cancer;
PAAD	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.84	-0.37	3.15e-6	Blood pressure;
PAAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg15193198	chr20:60906057	LAMA5	-0.52	-5.59	-0.41	1.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs662064	0.926	rs589400	chr1:10561282	A/G	cg07384165	chr1:10488281	NA	0.45	4.25	0.33	3.76e-5	Asthma;
PAAD	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.54	4.94	0.37	2.05e-6	Blood metabolite levels;
PAAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.5	4.72	0.36	5.24e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg18551225	chr6:44695536	NA	-0.68	-6.77	-0.48	2.59e-10	Total body bone mineral density;
PAAD	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg00230899	chr16:89766723	SPATA2L	0.82	4.25	0.33	3.69e-5	Red blood cell count;
PAAD	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.63	0.35	7.86e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.85	-9.87	-0.62	4.66e-18	Coronary artery disease;
PAAD	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.23e-6	Type 2 diabetes;
PAAD	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.75	6.74	0.48	3.12e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.6	5.82	0.43	3.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg12395012	chr8:11607386	GATA4	0.43	4.46	0.34	1.59e-5	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg06740227	chr12:86229804	RASSF9	0.59	5.2	0.39	6.35e-7	Major depressive disorder;
PAAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg19442545	chr10:75533431	FUT11	-0.51	-5.34	-0.4	3.35e-7	Inflammatory bowel disease;
PAAD	cis	rs7678296	1.000	rs73142714	chr4:37179884	G/A	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	6.71	0.48	3.64e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs74181299	0.712	rs2241160	chr2:65291546	A/G	cg20592124	chr2:65290738	CEP68	0.58	5.75	0.42	4.85e-8	Pulse pressure;
PAAD	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg02820901	chr13:113351484	ATP11A	0.72	4.77	0.36	4.36e-6	Glycated hemoglobin levels;
PAAD	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	1.13	8.99	0.59	9.14e-16	Left atrial antero-posterior diameter;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21801223	chr12:98648287	NA	-0.52	-6.43	-0.46	1.55e-9	Monocyte percentage of white cells;
PAAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.71	7.14	0.5	3.55e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.54	-5.25	-0.39	5.07e-7	Menarche (age at onset);
PAAD	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg11380483	chr2:127933992	NA	0.75	5.6	0.41	9.68e-8	Protein C levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04232466	chr8:21988724	HR	0.6	6.65	0.47	5.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg10356904	chr22:49881777	NA	-0.47	-4.76	-0.36	4.48e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs9372498	1.000	rs62421486	chr6:118576652	C/T	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07332563	chr6:291687	DUSP22	-0.76	-8.04	-0.55	2.32e-13	Menopause (age at onset);
PAAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.11	-0.38	9.53e-7	Platelet count;
PAAD	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.88	9.48	0.61	4.77e-17	Corneal astigmatism;
PAAD	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.55	4.63	0.35	7.78e-6	Red blood cell count;
PAAD	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13151498	chr3:185541792	IGF2BP2	-0.43	-4.55	-0.35	1.11e-5	Myopia (pathological);
PAAD	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.56	4.46	0.34	1.56e-5	Bone mineral density (spine);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11543196	chr17:36958457	CCDC49	-0.56	-6.8	-0.48	2.27e-10	Monocyte percentage of white cells;
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18357526	chr6:26021779	HIST1H4A	0.68	6.93	0.49	1.09e-10	Blood metabolite levels;
PAAD	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg13858687	chr1:93297071	RPL5	0.46	4.34	0.33	2.55e-5	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07607066	chr22:47457123	TBC1D22A	0.57	6.5	0.47	1.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.27	-0.33	3.38e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.91	-10.7	-0.66	2.8e-20	Total body bone mineral density;
PAAD	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.6	-4.68	-0.36	6.17e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	1.07	14.99	0.77	8.97e-32	Systemic lupus erythematosus;
PAAD	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.62	5.7	0.42	5.95e-8	Platelet count;
PAAD	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.7	6.1	0.44	8.32e-9	Radiation response;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09678228	chr12:44230058	TMEM117	0.63	6.68	0.48	4.16e-10	Myopia (pathological);
PAAD	cis	rs12200560	0.562	rs986103	chr6:97075319	A/C	cg06623918	chr6:96969491	KIAA0776	0.51	4.38	0.33	2.18e-5	Coronary heart disease;
PAAD	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-4.28	-0.33	3.31e-5	Dupuytren's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18527119	chr7:66119851	NA	-0.76	-8.15	-0.55	1.25e-13	Smoking initiation;
PAAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	10.49	0.65	1.05e-19	Cognitive test performance;
PAAD	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg10920065	chr6:169824652	NA	-0.48	-4.7	-0.36	5.77e-6	Obesity-related traits;
PAAD	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.76	7.41	0.52	8.23e-12	Retinal vascular caliber;
PAAD	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.85e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg11897209	chr6:86302888	SNX14	-0.45	-4.26	-0.33	3.62e-5	Response to antipsychotic treatment;
PAAD	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.47	-0.34	1.55e-5	Recombination measurement;
PAAD	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg15181151	chr6:150070149	PCMT1	0.56	5.9	0.43	2.31e-8	Lung cancer;
PAAD	cis	rs11671653	1.000	rs8105939	chr19:10831801	G/A	cg18582342	chr19:11591989	ELAVL3	-0.55	-4.56	-0.35	1.07e-5	LDL cholesterol;
PAAD	cis	rs75920871	0.925	rs4936362	chr11:116952200	C/T	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg21153622	chr11:89784906	NA	-0.56	-6.41	-0.46	1.76e-9	HDL cholesterol;
PAAD	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.58	-5.8	-0.43	3.79e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.82	8.08	0.55	1.89e-13	Vitamin D levels;
PAAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.53	-0.41	1.36e-7	Monocyte count;
PAAD	trans	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.49	5.38	0.4	2.78e-7	Schizophrenia;
PAAD	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg09659197	chr4:152720779	NA	-0.37	-5.21	-0.39	6.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.49	-4.97	-0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	trans	rs61677309	1.000	rs56318049	chr11:118166608	T/C	cg15548380	chr1:19984784	NBL1	-0.64	-6.6	-0.47	6.4e-10	Lung cancer in ever smokers;
PAAD	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.13e-5	Pain;
PAAD	cis	rs793571	0.774	rs4775096	chr15:59140329	A/G	cg05156742	chr15:59063176	FAM63B	0.66	5.88	0.43	2.52e-8	Schizophrenia;
PAAD	cis	rs375066	0.935	rs426534	chr19:44412583	T/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg01851573	chr8:8652454	MFHAS1	-0.5	-4.49	-0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg18898632	chr2:242989856	NA	-0.81	-5.84	-0.43	3.11e-8	Obesity-related traits;
PAAD	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.51	-6.34	-0.46	2.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16700650	chr16:69344975	VPS4A	0.67	7.94	0.54	4.18e-13	Myopia (pathological);
PAAD	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.71	-8.81	-0.58	2.59e-15	Educational attainment;
PAAD	cis	rs10186876	0.561	rs13009669	chr2:44195809	A/C	cg09541576	chr2:44873248	C2orf34	0.44	4.39	0.34	2.07e-5	Hand grip strength;
PAAD	cis	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.66	0.48	4.78e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9361491	0.587	rs9352694	chr6:79800818	A/G	cg05283184	chr6:79620031	NA	-0.45	-5.29	-0.39	4.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.46	4.87	0.37	2.73e-6	QRS complex (12-leadsum);
PAAD	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs1364705	1.000	rs13281087	chr8:120224470	T/C	cg09273054	chr8:120220131	MAL2	0.44	5.01	0.38	1.52e-6	Hippocampal atrophy;
PAAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.44e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-4.59	-0.35	9.1e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg22143856	chr6:28129313	ZNF389	0.55	4.31	0.33	2.86e-5	Parkinson's disease;
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-0.87	-7.67	-0.53	1.91e-12	Attention deficit hyperactivity disorder;
PAAD	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	1.27	13.09	0.73	1.04e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.81	8.46	0.57	2.12e-14	Cognitive function;
PAAD	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.52	5.99	0.44	1.45e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.55	-5.25	-0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg01980928	chr19:1952821	C19orf34;CSNK1G2	-0.47	-4.55	-0.35	1.1e-5	Coronary artery disease;
PAAD	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	8.01	0.54	2.77e-13	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20096409	chr22:19009485	DGCR10	-0.54	-6.6	-0.47	6.48e-10	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.37	0.46	2.12e-9	Lung cancer;
PAAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.05	-0.38	1.26e-6	Longevity;
PAAD	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05049329	chr1:226924846	ITPKB	0.54	7.34	0.51	1.19e-11	Parkinson's disease;
PAAD	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	4.65	0.35	7.14e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12900929	chr12:108154862	PRDM4	0.5	6.37	0.46	2.1e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18621852	chr3:10150065	C3orf24	0.64	5.52	0.41	1.45e-7	Alzheimer's disease;
PAAD	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg18569988	chr3:195679450	NA	0.42	4.26	0.33	3.57e-5	Pancreatic cancer;
PAAD	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.5	5.09	0.38	1.04e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-4.32	-0.33	2.82e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	7.58	0.52	3.14e-12	Longevity;
PAAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg13722127	chr7:150037890	RARRES2	0.62	6.59	0.47	6.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.9	0.37	2.48e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.08	-0.5	4.87e-11	Neuroticism;
PAAD	cis	rs1334894	1.000	rs72913423	chr6:35575707	A/G	cg07213720	chr6:35227408	ZNF76	-0.89	-4.88	-0.37	2.65e-6	Coronary artery disease;
PAAD	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.51	-0.34	1.31e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73086581	0.947	rs73084523	chr20:3875626	T/C	cg02187196	chr20:3869020	PANK2	0.6	4.94	0.37	2.02e-6	Response to antidepressants in depression;
PAAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.7	7.58	0.52	3.14e-12	Longevity;
PAAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.08	-0.38	1.11e-6	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg21433313	chr16:3507492	NAT15	0.92	7.32	0.51	1.31e-11	Tuberculosis;
PAAD	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs9287719	0.649	rs12473957	chr2:10717714	C/G	cg00105475	chr2:10696890	NA	-0.62	-6.55	-0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7816613	0.920	rs1080598	chr8:102744049	T/A	cg20585841	chr8:102729926	NCALD	-0.58	-5.16	-0.39	7.74e-7	Age-related hearing impairment;
PAAD	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg05625103	chr10:2543513	NA	0.61	6.59	0.47	6.8e-10	Age-related hearing impairment;
PAAD	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.63	4.58	0.35	9.43e-6	Alzheimer's disease (survival time);
PAAD	cis	rs757081	0.648	rs214102	chr11:17288298	G/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.46	-0.41	1.86e-7	Systolic blood pressure;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.7	7.37	0.51	1e-11	Vitiligo;
PAAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg21724239	chr8:58056113	NA	0.67	5.33	0.4	3.5e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.35	0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.46e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.71	-8.55	-0.57	1.22e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.68	-7.59	-0.52	3.02e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs1468333	0.724	rs7726580	chr5:137608666	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.53	-5.55	-0.41	1.22e-7	Resting heart rate;
PAAD	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg25902810	chr10:99078978	FRAT1	-0.6	-5.44	-0.4	2.08e-7	Monocyte count;
PAAD	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.59	-5.36	-0.4	2.99e-7	Total body bone mineral density;
PAAD	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.81	8.85	0.58	2.05e-15	Mortality in heart failure;
PAAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg10729496	chr3:10149963	C3orf24	0.86	7.36	0.51	1.06e-11	Alzheimer's disease;
PAAD	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg14583973	chr4:3374767	RGS12	0.33	4.71	0.36	5.58e-6	Mean platelet volume;
PAAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg21929781	chr1:2537748	MMEL1	0.5	5.31	0.4	3.86e-7	Ulcerative colitis;
PAAD	cis	rs6430538	0.646	rs6734820	chr2:135536808	A/G	cg16200531	chr2:135532566	NA	0.36	4.54	0.35	1.12e-5	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.73	-8.34	-0.56	4.22e-14	White blood cell count (basophil);
PAAD	cis	rs78761021	0.860	rs62066047	chr17:9772011	T/A	cg26853458	chr17:9805074	RCVRN	0.71	8.33	0.56	4.52e-14	Type 2 diabetes;
PAAD	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.46	4.75	0.36	4.57e-6	Breast cancer;
PAAD	cis	rs11264799	0.608	rs7520133	chr1:157701831	C/T	cg18268488	chr1:157545234	FCRL4	0.66	5.3	0.4	3.98e-7	IgA nephropathy;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03779258	chr22:34316655	LARGE	0.58	6.74	0.48	3.07e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17155006	0.746	rs985152	chr7:107750357	G/A	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.81	8.32	0.56	4.68e-14	Alzheimer's disease (late onset);
PAAD	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.84	-8.05	-0.55	2.23e-13	Colorectal adenoma (advanced);
PAAD	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.89	6.9	0.49	1.34e-10	Prostate cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25806492	chr1:24970113	SRRM1	0.61	6.7	0.48	3.87e-10	Myopia (pathological);
PAAD	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.61	5.38	0.4	2.73e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.61	5.9	0.43	2.3e-8	Schizophrenia;
PAAD	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg14631576	chr9:95140430	CENPP	0.53	5.32	0.4	3.66e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.74	5.12	0.38	9.23e-7	Vitiligo;
PAAD	cis	rs78579285	0.583	rs1061238	chr16:88781850	A/G	cg03615921	chr16:89375284	ANKRD11	0.67	4.35	0.33	2.52e-5	Joint mobility (Beighton score);
PAAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.62	5.75	0.42	4.78e-8	Coronary artery disease;
PAAD	cis	rs6804624	0.621	rs2880364	chr3:99156869	G/A	cg02646433	chr3:99218170	NA	0.41	4.29	0.33	3.15e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs11159840	0.588	rs10782474	chr14:88597021	C/T	cg18078958	chr14:88630771	NA	-0.42	-5.21	-0.39	5.98e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23708337	chr7:1209742	NA	0.46	4.87	0.37	2.82e-6	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg23920097	chr1:209922102	NA	-0.49	-4.53	-0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.61	-5.98	-0.44	1.54e-8	Calcium levels;
PAAD	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-4.91	-0.37	2.3e-6	Diabetic retinopathy;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.65	-6.24	-0.45	4.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.78	8.01	0.54	2.73e-13	Schizophrenia;
PAAD	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.64	7.34	0.51	1.19e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.29	-0.39	4.15e-7	Subjective well-being;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10944144	chr5:64777807	ADAMTS6	-0.53	-6.35	-0.46	2.33e-9	Body fat percentage;
PAAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.52	-5.3	-0.39	4.09e-7	Testicular germ cell tumor;
PAAD	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs6810498	0.800	rs2007354	chr4:26052969	C/T	cg02513547	chr4:26029960	NA	-0.48	-4.39	-0.34	2.08e-5	Alcohol dependence;
PAAD	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg05083358	chr7:2394359	EIF3B	-0.75	-5.38	-0.4	2.72e-7	Multiple sclerosis;
PAAD	cis	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg21546286	chr11:48923668	NA	-0.54	-5.54	-0.41	1.29e-7	HDL cholesterol;
PAAD	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.79	9.13	0.6	3.94e-16	Hemoglobin concentration;
PAAD	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg15047889	chr8:124780837	FAM91A1	-0.69	-5.46	-0.41	1.87e-7	Pancreatic cancer;
PAAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.53	-0.41	1.38e-7	Monocyte count;
PAAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.96	8.52	0.57	1.48e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.5	4.52	0.34	1.22e-5	Neuroticism;
PAAD	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	5.13	0.38	8.82e-7	Lung cancer;Intelligence (multi-trait analysis);
PAAD	cis	rs2790216	1.000	rs1856564	chr10:60017452	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.13e-13	Dupuytren's disease;
PAAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06544989	chr22:39130855	UNC84B	0.45	4.39	0.34	2.09e-5	Menopause (age at onset);
PAAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.35	-0.33	2.44e-5	Bone mineral density;
PAAD	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.69	7.72	0.53	1.45e-12	QT interval;
PAAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg22101045	chr11:47927509	NA	0.57	4.38	0.33	2.21e-5	Intraocular pressure;
PAAD	cis	rs3784262	0.565	rs4646606	chr15:58287526	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	4.48	0.34	1.49e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.47	-5.35	-0.4	3.22e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25076767	chr14:24836148	NFATC4	0.69	6.83	0.48	1.9e-10	Obesity-related traits;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg16300553	chr8:8131077	NA	-0.36	-4.32	-0.33	2.81e-5	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg15181151	chr6:150070149	PCMT1	0.59	6.15	0.45	6.44e-9	Lung cancer;
PAAD	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg14003231	chr6:33640908	ITPR3	0.35	4.66	0.35	6.99e-6	Plateletcrit;
PAAD	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg22134325	chr11:66188745	NPAS4	0.32	4.71	0.36	5.52e-6	Airway imaging phenotypes;
PAAD	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.6	-5.61	-0.41	9.22e-8	Lymphocyte counts;
PAAD	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.99	10.33	0.64	2.71e-19	Pulmonary function decline;
PAAD	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-5.66	-0.42	7.45e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.69	-0.36	6.14e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	16.39	0.8	2.03e-35	Prudent dietary pattern;
PAAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20979732	chr11:64546243	SF1	-0.61	-6.53	-0.47	9.1e-10	Smoking initiation;
PAAD	trans	rs2817937	1.000	rs2817937	chr6:121098457	C/T	cg22125214	chr7:135612081	LUZP6;MTPN	-1.11	-6.54	-0.47	9.01e-10	Primary tooth development (number of teeth);
PAAD	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg01420254	chr6:26195488	NA	0.89	4.91	0.37	2.34e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-5.91	-0.43	2.17e-8	Longevity;
PAAD	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-4.39	-0.34	2.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.45	0.34	1.67e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18936471	chr4:99186446	RAP1GDS1	-0.55	-6.49	-0.47	1.14e-9	Energy expenditure (24h);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25066490	chr10:105253950	NEURL	0.64	6.82	0.48	2.07e-10	Monocyte percentage of white cells;
PAAD	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.66	-0.65	3.61e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.59	-0.35	9.05e-6	Vitiligo;
PAAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg21890820	chr11:65308645	LTBP3	0.66	7.91	0.54	4.86e-13	Bone mineral density;
PAAD	cis	rs17776563	0.959	rs1348003	chr15:89113441	G/C	cg27664085	chr15:89157815	NA	0.32	4.28	0.33	3.25e-5	Thyroid hormone levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg18779695	chr6:36164024	BRPF3	0.57	6.57	0.47	7.41e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.4	5.0	0.38	1.58e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg05861140	chr6:150128134	PCMT1	-0.55	-6.24	-0.45	4.08e-9	Lung cancer;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg00576331	chr11:65640516	EFEMP2	0.48	4.57	0.35	1.01e-5	Eosinophil percentage of white cells;
PAAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	11.26	0.67	8.8e-22	Smoking behavior;
PAAD	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.72e-5	Systolic blood pressure;
PAAD	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.55	5.47	0.41	1.77e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.47	4.67	0.35	6.7e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.48	0.68	2.31e-22	Smoking behavior;
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg22633769	chr20:60982531	CABLES2	-0.44	-4.36	-0.33	2.34e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.67	6.78	0.48	2.51e-10	Schizophrenia;
PAAD	cis	rs5757949	0.529	rs1022533	chr22:40972547	C/T	cg14701072	chr22:41075428	MCHR1	-0.45	-4.36	-0.33	2.4e-5	Height;
PAAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.27	0.33	3.4e-5	Aortic root size;
PAAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.39	-4.52	-0.34	1.23e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-4.99	-0.38	1.63e-6	Mood instability;
PAAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg02297831	chr4:17616191	MED28	0.58	5.54	0.41	1.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg01800442	chr17:74086473	EXOC7	0.53	4.26	0.33	3.55e-5	Psoriasis;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg24879335	chr3:133465180	TF	0.55	5.91	0.43	2.15e-8	Iron status biomarkers;
PAAD	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.6	-6.08	-0.44	9.14e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.51	5.27	0.39	4.59e-7	Schizophrenia;
PAAD	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg09695851	chr17:3907499	NA	0.67	6.71	0.48	3.63e-10	Type 2 diabetes;
PAAD	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg12215294	chr3:40350768	EIF1B	0.48	5.01	0.38	1.49e-6	Renal cell carcinoma;
PAAD	cis	rs1035491	0.690	rs6876731	chr5:63930252	A/G	cg01791865	chr5:63954708	NA	0.44	4.58	0.35	9.66e-6	Body mass index;
PAAD	cis	rs28647808	1.000	rs2285484	chr9:136271841	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	1.14	18.47	0.83	1.12e-40	Menarche (age at onset);
PAAD	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.49	-0.34	1.38e-5	Glomerular filtration rate;
PAAD	cis	rs2004318	1.000	rs56320534	chr19:55122395	C/T	cg03320607	chr19:54800032	LILRA3	-0.94	-5.68	-0.42	6.77e-8	Blood protein levels;
PAAD	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.43	4.91	0.37	2.38e-6	Refractive error;
PAAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg20481416	chr6:167803413	NA	0.45	4.68	0.36	6.22e-6	Gut microbiome composition (summer and winter);
PAAD	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19904058	chr10:135279010	LOC619207	-0.63	-7.61	-0.53	2.62e-12	Systemic lupus erythematosus;
PAAD	cis	rs12760731	0.565	rs7536856	chr1:178057927	A/G	cg00404053	chr1:178313656	RASAL2	0.65	4.85	0.37	3.04e-6	Obesity-related traits;
PAAD	cis	rs1879734	0.773	rs4927025	chr1:54131753	C/T	cg14659662	chr1:54151053	GLIS1	-0.4	-5.48	-0.41	1.72e-7	Mitral valve prolapse;
PAAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg23346134	chr3:49453900	TCTA	-0.47	-5.01	-0.38	1.46e-6	Menarche (age at onset);
PAAD	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.39	4.52	0.34	1.25e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg12310025	chr6:25882481	NA	0.48	4.7	0.36	5.82e-6	Blood metabolite levels;
PAAD	cis	rs1529711	0.500	rs11666111	chr19:10900633	C/T	cg16667279	chr19:11591998	ELAVL3	-0.63	-4.69	-0.36	6.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg11494091	chr17:61959527	GH2	-0.51	-4.3	-0.33	3.01e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-8.71	-0.58	4.81e-15	Blood trace element (Zn levels);
PAAD	cis	rs722864	0.744	rs1809139	chr2:173982876	C/T	cg02106116	chr2:174074460	ZAK	-0.45	-4.31	-0.33	2.93e-5	Lung cancer;
PAAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg14393609	chr7:65229607	NA	-0.59	-6.22	-0.45	4.6e-9	Aortic root size;
PAAD	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11411865	chr7:2701802	TTYH3	-0.65	-4.65	-0.35	7.24e-6	Bipolar disorder;
PAAD	trans	rs901683	0.850	rs36109121	chr10:46039511	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg14343924	chr8:8086146	FLJ10661	0.56	4.85	0.37	3.08e-6	Schizophrenia;
PAAD	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	2.98e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs8063160	0.740	rs71396950	chr16:89726550	G/A	cg07984980	chr16:89898383	SPIRE2	0.89	5.01	0.38	1.49e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-5.02	-0.38	1.43e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs9810890	1.000	rs73196979	chr3:128450276	T/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.66	4.78	0.36	4.14e-6	Diisocyanate-induced asthma;
PAAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.43	0.34	1.76e-5	Blood metabolite levels;
PAAD	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg03700679	chr2:178418002	TTC30B	-0.53	-4.47	-0.34	1.52e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.39	-0.46	1.97e-9	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00780250	chr4:39979372	PDS5A	0.64	6.36	0.46	2.25e-9	Obesity-related traits;
PAAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	6.01	0.44	1.3e-8	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06697439	chr19:59031463	ZBTB45	-0.62	-6.29	-0.45	3.18e-9	Smoking initiation;
PAAD	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg16558253	chr16:72132732	DHX38	-0.56	-5.12	-0.38	9.26e-7	Coronary artery disease;
PAAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.91	5.83	0.43	3.27e-8	Prostate cancer;
PAAD	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg02049472	chr2:177466316	MIR1246	-0.43	-4.34	-0.33	2.59e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.64e-5	Bipolar disorder;
PAAD	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg26897989	chr16:1907736	C16orf73	-0.46	-4.79	-0.36	3.92e-6	Insulin-like growth factors;
PAAD	cis	rs1996152	0.543	rs9906415	chr17:72389282	A/G	cg23221732	chr17:72383708	NA	0.54	5.23	0.39	5.42e-7	Interleukin-12p70 levels;
PAAD	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.28	0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg08898775	chr15:59042684	ADAM10	0.37	4.85	0.37	2.96e-6	Schizophrenia;
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.5	9.64	0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.13	14.65	0.77	7.27e-31	Subjective well-being;
PAAD	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-4.64	-0.35	7.58e-6	Breast cancer;
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18337363	chr3:52569053	NT5DC2	0.44	4.96	0.37	1.9e-6	Electroencephalogram traits;
PAAD	cis	rs28493229	0.737	rs2288450	chr19:41209177	C/T	cg21869046	chr19:41225005	ITPKC	0.63	6.33	0.46	2.68e-9	Kawasaki disease;
PAAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs7561273	0.545	rs13035774	chr2:24358652	C/T	cg04809136	chr2:24300158	SF3B14	0.46	5.22	0.39	5.88e-7	Quantitative traits;
PAAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	5.7	0.42	5.93e-8	Schizophrenia;
PAAD	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg17372223	chr3:52568218	NT5DC2	-0.5	-4.91	-0.37	2.33e-6	Bipolar disorder;
PAAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.57	-6.87	-0.49	1.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.67	-7.93	-0.54	4.37e-13	Recombination rate (males);
PAAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg02297831	chr4:17616191	MED28	0.62	6.26	0.45	3.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg09222892	chr1:25734099	RHCE	0.48	4.78	0.36	4.12e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.4e-12	Recombination rate (females);
PAAD	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs11166927	0.703	rs2126127	chr8:140788362	G/A	cg16909799	chr8:140841666	TRAPPC9	0.49	5.36	0.4	3.01e-7	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg24330906	chr2:85765176	MAT2A	0.58	5.6	0.41	9.75e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	4.64	0.35	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.91	-6.33	-0.46	2.61e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.7e-5	Pulmonary function;
PAAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.33	0.33	2.67e-5	IgG glycosylation;
PAAD	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.69	-8.02	-0.55	2.57e-13	Testicular germ cell tumor;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22162314	chr17:61951766	CSH2	-0.53	-5.32	-0.4	3.58e-7	Height;
PAAD	trans	rs34112283	0.592	rs3795872	chr2:144245287	G/A	cg10530280	chr1:167759869	MPZL1	-0.68	-6.56	-0.47	8.14e-10	Neuroticism;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.44e-7	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.34	0.56	4.09e-14	Lung cancer;
PAAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.61	6.59	0.47	6.98e-10	Lung cancer;
PAAD	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg03885332	chr11:832357	CD151	-0.45	-5.26	-0.39	4.91e-7	Mean platelet volume;
PAAD	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06984945	chr6:26660160	ZNF322A	0.64	7.45	0.52	6.69e-12	Metabolite levels  (X-11787);
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg00291981	chr3:49591748	BSN	0.61	4.67	0.35	6.69e-6	Schizophrenia;
PAAD	trans	rs901683	1.000	rs71494789	chr10:45972481	C/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.74	-8.03	-0.55	2.46e-13	Uric acid levels;
PAAD	cis	rs66530629	1.000	rs16829945	chr1:25040315	C/T	cg22509179	chr1:25234806	RUNX3	0.5	4.42	0.34	1.84e-5	Plateletcrit;
PAAD	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-1.06	-8.26	-0.56	6.67e-14	Menopause (age at onset);
PAAD	cis	rs9657904	0.738	rs13060223	chr3:105495841	A/C	cg16975614	chr3:105601834	NA	-0.47	-4.63	-0.35	7.78e-6	Multiple sclerosis;
PAAD	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.56	5.66	0.42	7.21e-8	Psychosis in Alzheimer's disease;
PAAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg20517616	chr2:26468218	HADHA;HADHB	-0.59	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs7719624	0.840	rs916951	chr5:135384443	A/G	cg16684184	chr5:135415129	NA	-0.35	-4.37	-0.33	2.28e-5	Response to cytidine analogues (gemcitabine);
PAAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.94	10.73	0.66	2.32e-20	Longevity;
PAAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-8.84	-0.58	2.17e-15	Glomerular filtration rate (creatinine);
PAAD	trans	rs1850744	0.702	rs1961552	chr4:9608306	A/C	cg08077071	chr2:157176106	NA	0.92	6.33	0.46	2.65e-9	Economic and political preferences;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg10544611	chr16:67998164	SLC12A4	-0.59	-4.25	-0.33	3.72e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.39	0.34	2.08e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.62	5.86	0.43	2.74e-8	Androgen levels;
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg15226275	chr6:116381976	FRK	-0.41	-7.67	-0.53	1.88e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs35160687	0.712	rs1863057	chr2:86502101	C/T	cg10973622	chr2:86423274	IMMT	-0.45	-4.98	-0.37	1.7e-6	Night sleep phenotypes;
PAAD	cis	rs8133932	0.701	rs2839021	chr21:47280016	C/T	cg13695288	chr21:47294981	PCBP3	0.44	4.44	0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.62	-4.84	-0.37	3.22e-6	Sjögren's syndrome;
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.66	-7.35	-0.51	1.13e-11	Total body bone mineral density;
PAAD	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg17385448	chr1:15911702	AGMAT	0.37	4.4	0.34	2.03e-5	Systolic blood pressure;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19580847	chr19:41857554	TGFB1	-0.53	-6.34	-0.46	2.45e-9	Body fat percentage;
PAAD	cis	rs3736485	0.934	rs2899475	chr15:51883051	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.45	-6.14	-0.45	7e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg17724175	chr1:150552817	MCL1	-0.47	-5.28	-0.39	4.36e-7	Tonsillectomy;
PAAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14008862	chr17:28927542	LRRC37B2	0.77	5.75	0.42	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.45	7.14	0.5	3.57e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.73	6.53	0.47	9.26e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs10850408	0.922	rs12318789	chr12:115376084	G/A	cg05726002	chr12:115341178	NA	-0.41	-4.82	-0.36	3.4e-6	Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs35049879	chr10:46081744	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.28e-10	HDL cholesterol;
PAAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.36	-0.33	2.34e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.18e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9815354	0.767	rs115702638	chr3:42058594	C/T	cg03022575	chr3:42003672	ULK4	0.79	5.65	0.42	7.78e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg06636001	chr8:8085503	FLJ10661	0.78	8.48	0.57	1.85e-14	Neuroticism;
PAAD	cis	rs728616	0.681	rs55855057	chr10:82034729	G/A	cg05935833	chr10:81318306	SFTPA2	-0.51	-4.47	-0.34	1.54e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg21605333	chr4:119757512	SEC24D	1.24	7.71	0.53	1.56e-12	Cannabis dependence symptom count;
PAAD	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.45	4.61	0.35	8.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.67	-7.62	-0.53	2.55e-12	Huntington's disease progression;
PAAD	cis	rs5753037	0.838	rs140149	chr22:30185613	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.62	-0.35	8.22e-6	Type 1 diabetes;
PAAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.45	4.79	0.36	3.98e-6	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7692976	0.578	rs2298978	chr4:110837667	G/A	cg06981781	chr4:110842888	EGF	-0.36	-4.31	-0.33	2.88e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs643506	0.874	rs609007	chr11:111719593	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.53	-4.52	-0.34	1.26e-5	Breast cancer;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7896471	0.655	rs112855585	chr10:101787581	T/C	cg09956859	chr10:101293089	NKX2-3	-0.8	-4.51	-0.34	1.29e-5	Blood protein levels;
PAAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	13.14	0.73	7.7e-27	Platelet count;
PAAD	cis	rs10426930	0.690	rs710956	chr19:5054510	T/C	cg25246084	chr19:4971487	KDM4B	0.37	4.92	0.37	2.18e-6	Monocyte percentage of white cells;
PAAD	cis	rs10929159	0.928	rs4442947	chr2:236931642	G/C	cg14226755	chr2:236923322	AGAP1	0.3	4.75	0.36	4.68e-6	Parkinson's disease;
PAAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg05342682	chr7:94953680	PON1	-0.55	-4.7	-0.36	5.69e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2286379	0.595	rs10773988	chr12:1856181	A/G	cg05227549	chr12:1770782	NA	-0.46	-5.34	-0.4	3.39e-7	Blood pressure (smoking interaction);
PAAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	7.91	0.54	4.93e-13	Homoarginine levels;
PAAD	cis	rs2810114	0.804	rs36567	chr14:71350617	C/G	cg15910301	chr14:71632612	NA	-0.39	-4.43	-0.34	1.77e-5	Alcohol dependence;
PAAD	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.47	0.46	1.27e-9	Testicular germ cell tumor;
PAAD	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.92	8.25	0.56	6.82e-14	Obesity-related traits;
PAAD	cis	rs787274	0.867	rs2798316	chr9:115462552	T/C	cg13803584	chr9:115635662	SNX30	0.91	6.12	0.44	7.78e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs16958440	0.867	rs74845165	chr18:44690852	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.03	-0.38	1.38e-6	Bone mineral density;
PAAD	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Blood protein levels;
PAAD	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.74	-7.44	-0.52	6.99e-12	QT interval;
PAAD	cis	rs12936587	0.633	rs12951181	chr17:17502453	T/C	cg03427841	chr17:16610318	CCDC144A	-0.43	-4.36	-0.33	2.4e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	trans	rs3105169	0.660	rs10955206	chr8:100202482	C/G	cg13150344	chr11:67889062	CHKA	0.61	6.36	0.46	2.25e-9	Smoking initiation;
PAAD	cis	rs9810890	1.000	rs73196967	chr3:128437236	C/T	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.66	-0.42	7.27e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.74	7.44	0.52	7e-12	Obesity-related traits;
PAAD	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-4.49	-0.34	1.4e-5	Blood protein levels;
PAAD	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-6.62	-0.47	5.95e-10	Morning vs. evening chronotype;
PAAD	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg16898833	chr6:26189333	HIST1H4D	0.48	4.4	0.34	2.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg02640540	chr1:67518911	SLC35D1	0.53	4.63	0.35	7.89e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	1.27	12.48	0.71	4.69e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22509189	chr2:225307070	NA	-0.49	-4.81	-0.36	3.66e-6	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg14443077	chr11:68606701	CPT1A	0.58	6.3	0.46	3.06e-9	Iris heterochromicity;
PAAD	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.62	-5.07	-0.38	1.15e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.36	15.59	0.78	2.44e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs3996993	0.702	rs9395821	chr6:52654220	C/A	cg20803780	chr6:52668592	GSTA1	-0.34	-4.26	-0.33	3.55e-5	Hemoglobin concentration;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	8.11	0.55	1.59e-13	Height;
PAAD	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs939584	0.932	rs2867111	chr2:651286	A/C	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg20243544	chr17:37824526	PNMT	-0.57	-4.68	-0.35	6.34e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.8	8.6	0.57	9.22e-15	Blood metabolite levels;
PAAD	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.54	-0.35	1.13e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.2	-0.39	6.3e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.05e-7	Life satisfaction;
PAAD	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.87	8.03	0.55	2.43e-13	Response to diuretic therapy;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-1.12	-13.96	-0.75	4.97e-29	Height;
PAAD	cis	rs10037758	0.618	rs11241981	chr5:128287181	A/G	cg25555059	chr5:128301488	SLC27A6	0.28	5.02	0.38	1.43e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17209837	1.000	rs58083477	chr7:87117706	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-4.87	-0.37	2.74e-6	Mean platelet volume;
PAAD	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.46	4.38	0.33	2.2e-5	Mean platelet volume;
PAAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.77	0.42	4.25e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg01851573	chr8:8652454	MFHAS1	0.57	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.61	0.41	9.37e-8	Prudent dietary pattern;
PAAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg02297831	chr4:17616191	MED28	0.62	6.26	0.45	3.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg06917634	chr15:78832804	PSMA4	-0.44	-4.34	-0.33	2.54e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs8032158	0.702	rs2288345	chr15:56122461	T/C	cg02198044	chr15:56286336	NEDD4	-0.42	-4.38	-0.33	2.21e-5	Keloid;
PAAD	cis	rs7127900	0.821	rs10743180	chr11:2229573	G/T	cg25635251	chr11:2234043	NA	0.84	7.45	0.52	6.39e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12450239	0.666	rs12452636	chr17:77435185	C/T	cg07832143	chr17:77435199	HRNBP3	0.5	4.44	0.34	1.71e-5	Body mass index;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.68	0.48	4.29e-10	Height;
PAAD	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.89	-5.71	-0.42	5.82e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.3	0.46	3.04e-9	Alzheimer's disease (late onset);
PAAD	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg24503407	chr1:205819492	PM20D1	0.62	4.95	0.37	1.98e-6	Basophil percentage of granulocytes;
PAAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-5.64	-0.42	8.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg11508406	chr4:1595515	NA	0.42	4.39	0.34	2.07e-5	Obesity-related traits;
PAAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.47	-4.26	-0.33	3.56e-5	IgG glycosylation;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg20731562	chr3:109128745	FLJ25363	0.67	6.63	0.47	5.63e-10	Body mass index;
PAAD	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	4.8	0.36	3.72e-6	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.08	0.5	4.96e-11	Rheumatoid arthritis;
PAAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg14440974	chr22:39074834	NA	-0.59	-6.99	-0.49	7.95e-11	Menopause (age at onset);
PAAD	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-5.62	-0.42	8.69e-8	Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs1463132	0.636	rs17682922	chr16:10120473	A/T	cg17485021	chr4:13530094	NA	0.56	6.29	0.45	3.15e-9	HIV-1 control;
PAAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg23442198	chr4:187126114	CYP4V2	0.64	4.55	0.35	1.1e-5	Blood protein levels;
PAAD	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.49	6.39	0.46	1.93e-9	Electrocardiographic conduction measures;
PAAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg02966332	chr20:62369605	LIME1	-0.48	-4.52	-0.34	1.24e-5	Prostate cancer;
PAAD	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.62	0.62	2.05e-17	Electrocardiographic conduction measures;
PAAD	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.62	6.87	0.49	1.53e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.38	-5.57	-0.41	1.12e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07230380	chr10:102106358	SCD	-0.73	-6.35	-0.46	2.34e-9	Neuroticism;
PAAD	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	1.09	6.52	0.47	9.75e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4668356	0.773	rs73017290	chr2:172049216	G/C	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg26174226	chr8:58114915	NA	-0.66	-5.93	-0.43	1.94e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg04117972	chr1:227635322	NA	0.7	4.62	0.35	8.06e-6	Major depressive disorder;
PAAD	cis	rs894157	0.563	rs72752568	chr15:90253828	C/T	cg20467658	chr15:89933347	LOC254559	0.79	4.42	0.34	1.9e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.63	-0.35	7.84e-6	Iron status biomarkers;
PAAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.83	10.27	0.64	3.95e-19	Menopause (age at onset);
PAAD	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.55	-4.87	-0.37	2.78e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.53	-5.28	-0.39	4.36e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs134594	0.885	rs134592	chr22:29467221	A/G	cg01361351	chr22:29467363	NA	0.41	4.41	0.34	1.92e-5	Birth weight;
PAAD	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.75	5.31	0.4	3.85e-7	Carotid intima media thickness;
PAAD	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg05627522	chr15:75251581	NA	-0.4	-4.69	-0.36	5.98e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6074578	0.535	rs1858592	chr20:138606	A/G	cg16931068	chr20:139680	DEFB127	0.39	5.26	0.39	4.85e-7	Hirschsprung disease;
PAAD	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.14	0.39	8.16e-7	Motion sickness;
PAAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.89	0.37	2.57e-6	Longevity;
PAAD	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.5e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03041046	chr12:53473136	SPRYD3	0.66	6.43	0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.41	4.96	0.37	1.83e-6	Uric acid levels;
PAAD	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.65	-6.17	-0.45	5.81e-9	Asthma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26771998	chr10:75490334	BMS1P4	0.61	6.52	0.47	9.87e-10	Smoking initiation;
PAAD	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.54	-4.91	-0.37	2.35e-6	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs17032980	0.910	rs6750984	chr2:67326312	G/A	cg06994420	chr2:66672553	MEIS1	-0.5	-4.43	-0.34	1.79e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	7.82	0.54	8.26e-13	LDL cholesterol;
PAAD	cis	rs9395066	0.527	rs1590864	chr6:44906151	C/A	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.62	5.37	0.4	2.85e-7	Height;
PAAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg01503450	chr10:980765	NA	-0.53	-4.79	-0.36	4e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	5.75	0.42	4.83e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.55	0.35	1.08e-5	Asthma;
PAAD	cis	rs12403795	1.000	rs12403795	chr1:150278389	A/G	cg17724175	chr1:150552817	MCL1	-0.61	-5.36	-0.4	2.97e-7	Illicit drug use;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg00280220	chr17:61926910	NA	0.43	4.6	0.35	8.84e-6	Prudent dietary pattern;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.48	-4.7	-0.36	5.84e-6	Lymphocyte counts;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.01	0.54	2.84e-13	Menarche (age at onset);
PAAD	cis	rs7896729	0.882	rs11253084	chr10:5345656	G/C	cg07902545	chr10:6194255	PFKFB3	-0.43	-4.48	-0.34	1.47e-5	Intelligence;
PAAD	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.81	-8.93	-0.59	1.29e-15	Menopause (age at onset);
PAAD	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.9e-7	Resting heart rate;
PAAD	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg25122841	chr14:24911839	SDR39U1	0.5	4.25	0.33	3.73e-5	IgG glycosylation;
PAAD	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.84	6.12	0.44	7.7e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs11264799	0.669	rs12082378	chr1:157634567	C/A	cg18268488	chr1:157545234	FCRL4	0.41	4.66	0.35	6.74e-6	IgA nephropathy;
PAAD	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.49	5.05	0.38	1.24e-6	Schizophrenia;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg05110241	chr16:68378359	PRMT7	-1.05	-7.11	-0.5	4.27e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	4.7	0.36	5.68e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs17123764	0.605	rs73305085	chr12:50056233	G/A	cg14846292	chr12:49726500	C1QL4	-0.74	-4.33	-0.33	2.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg04510874	chr15:91427884	FES	-0.38	-4.49	-0.34	1.42e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.57	5.48	0.41	1.7e-7	Red cell distribution width;
PAAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg23033748	chr14:75592666	NEK9	-0.43	-5.21	-0.39	6.01e-7	Height;
PAAD	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg02476566	chr12:106696527	TCP11L2	0.53	4.96	0.37	1.87e-6	Tourette syndrome;
PAAD	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg21145140	chr5:110409467	TSLP	0.46	4.49	0.34	1.4e-5	Eosinophilic esophagitis;
PAAD	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg09491104	chr22:46646882	C22orf40	-1.0	-5.82	-0.43	3.37e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg10820045	chr2:198174542	NA	0.45	4.49	0.34	1.38e-5	Dermatomyositis;
PAAD	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg12661370	chr5:149340060	SLC26A2	0.81	6.54	0.47	8.69e-10	HIV-1 control;
PAAD	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg23254163	chr1:152506842	NA	0.59	6.84	0.49	1.78e-10	Hair morphology;
PAAD	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg23465465	chr6:26364728	BTN3A2	0.61	4.87	0.37	2.79e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-7.43	-0.52	7.31e-12	Gut microbiome composition (summer);
PAAD	cis	rs35883536	1.000	rs1855798	chr1:101114191	T/C	cg14515779	chr1:101123966	NA	-0.54	-6.83	-0.48	1.9e-10	Monocyte count;
PAAD	trans	rs34112283	0.592	rs13024145	chr2:144251789	T/A	cg10530280	chr1:167759869	MPZL1	-0.65	-6.41	-0.46	1.7e-9	Neuroticism;
PAAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs7580717	1.000	rs7580717	chr2:232176541	A/G	cg07929768	chr2:232055508	NA	-0.45	-5.76	-0.42	4.59e-8	Multiple myeloma;
PAAD	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg20673841	chr7:107026890	COG5	0.51	4.3	0.33	3e-5	Coronary artery disease;
PAAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg07648498	chr16:89883185	FANCA	-0.47	-4.58	-0.35	9.78e-6	Vitiligo;
PAAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg21546286	chr11:48923668	NA	-0.44	-4.69	-0.36	5.93e-6	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00765254	chr10:103815936	C10orf76	0.66	7.19	0.5	2.78e-11	Myopia (pathological);
PAAD	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-5.81	-0.43	3.58e-8	Yeast infection;
PAAD	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.42	0.34	1.89e-5	Tonsillectomy;
PAAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.72	7.08	0.5	5.12e-11	Blood metabolite levels;
PAAD	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.6	4.85	0.37	3.06e-6	Birth weight;
PAAD	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg14583973	chr4:3374767	RGS12	-0.36	-5.49	-0.41	1.64e-7	Mean platelet volume;
PAAD	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.73	7.58	0.52	3.22e-12	Schizophrenia;
PAAD	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.43	0.34	1.81e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.67	-10.7	-0.66	2.85e-20	Diastolic blood pressure;
PAAD	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg13722127	chr7:150037890	RARRES2	0.66	6.37	0.46	2.11e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs939584	1.000	rs7606023	chr2:638566	C/G	cg14515364	chr2:636606	NA	0.47	4.27	0.33	3.46e-5	Body mass index;
PAAD	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.98	8.24	0.56	7.62e-14	Dupuytren's disease;
PAAD	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.45	-4.67	-0.35	6.56e-6	Arsenic metabolism;
PAAD	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-1.06	-18.77	-0.84	2.02e-41	Urate levels in lean individuals;
PAAD	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg03188948	chr7:1209495	NA	1.0	8.02	0.55	2.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.15	0.39	7.94e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs11723261	0.582	rs11248006	chr4:166703	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.54	4.45	0.34	1.64e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	-0.61	-4.72	-0.36	5.22e-6	Breast cancer;
PAAD	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.14	-14.33	-0.76	5.25e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-1.03	-6.99	-0.49	8.14e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg11464842	chr2:97427975	CNNM4	0.69	4.67	0.35	6.5e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.87	8.11	0.55	1.56e-13	Gestational age at birth (maternal effect);
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.98	6.7	0.48	3.76e-10	IgG glycosylation;
PAAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs4787951	0.560	rs2382720	chr16:27350012	C/T	cg08008352	chr16:27322356	NA	0.44	4.33	0.33	2.71e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10090774	0.965	rs13253978	chr8:141981754	T/C	cg02508881	chr8:142216119	NA	-0.41	-4.38	-0.33	2.21e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7816613	0.833	rs16868197	chr8:102682851	T/G	cg20585841	chr8:102729926	NCALD	-0.57	-4.73	-0.36	4.99e-6	Age-related hearing impairment;
PAAD	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-4.81	-0.36	3.67e-6	Mood instability;
PAAD	cis	rs6066835	0.867	rs11698214	chr20:47359603	G/A	cg18078177	chr20:47281410	PREX1	0.89	4.56	0.35	1.06e-5	Multiple myeloma;
PAAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12165864	chr7:66369176	NA	0.83	5.43	0.4	2.21e-7	Diabetic kidney disease;
PAAD	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg27449745	chr7:23145252	KLHL7	-0.58	-5.22	-0.39	5.75e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg23254163	chr1:152506842	NA	0.6	6.86	0.49	1.62e-10	Hair morphology;
PAAD	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7989332	0.925	rs7324189	chr13:21050176	C/T	cg06710890	chr13:21477865	XPO4	0.43	4.35	0.33	2.52e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg05785598	chr3:49045655	WDR6	0.43	5.15	0.39	7.98e-7	Parkinson's disease;
PAAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Tonsillectomy;
PAAD	cis	rs6466055	0.661	rs6979284	chr7:104935730	A/T	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.42	0.46	1.67e-9	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14306683	chr22:43300632	PACSIN2	-0.67	-6.67	-0.48	4.5e-10	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01998682	chr6:151712546	ZBTB2	0.59	6.37	0.46	2.16e-9	Myopia (pathological);
PAAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg11764359	chr7:65958608	NA	-0.75	-4.96	-0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2790216	1.000	rs2590317	chr10:59987658	T/C	cg20442379	chr10:60024634	IPMK	-0.59	-4.46	-0.34	1.58e-5	Inflammatory bowel disease;
PAAD	cis	rs16867321	0.950	rs2887180	chr2:181449305	C/A	cg23363182	chr2:181467187	NA	-0.57	-5.13	-0.38	8.87e-7	Obesity;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg20936604	chr3:58311152	NA	-0.78	-4.25	-0.33	3.7e-5	Cholesterol, total;
PAAD	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.98	-5.2	-0.39	6.24e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3784262	0.740	rs2044071	chr15:58270804	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.52	-5.95	-0.43	1.75e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.78	7.71	0.53	1.56e-12	Corneal astigmatism;
PAAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-1.12	-9.16	-0.6	3.36e-16	Developmental language disorder (linguistic errors);
PAAD	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	8.12	0.55	1.51e-13	Eotaxin levels;
PAAD	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg20636351	chr8:55087400	NA	-0.83	-8.92	-0.59	1.37e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs17407555	0.738	rs73212898	chr4:10121994	C/T	cg00071950	chr4:10020882	SLC2A9	-0.67	-5.69	-0.42	6.2e-8	Schizophrenia (age at onset);
PAAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Calcium levels;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	6.01	0.44	1.31e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg08807892	chr2:162101083	NA	-0.53	-4.75	-0.36	4.65e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18621852	chr3:10150065	C3orf24	0.57	5.28	0.39	4.3e-7	Alzheimer's disease;
PAAD	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg25204440	chr1:209979598	IRF6	0.61	5.28	0.39	4.47e-7	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.5	4.58	0.35	9.46e-6	Homoarginine levels;
PAAD	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg24296786	chr1:45957014	TESK2	0.49	4.55	0.35	1.1e-5	Homocysteine levels;
PAAD	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.48	-4.44	-0.34	1.72e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11794666	0.929	rs1596769	chr9:31758478	G/A	cg05628366	chr6:35744188	C6orf126	1.11	7.4	0.51	8.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.7	8.12	0.55	1.51e-13	Age-related hearing impairment;
PAAD	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg22325292	chr17:80708367	FN3K	0.6	4.25	0.33	3.64e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-8.3	-0.56	5.4e-14	Body mass index;
PAAD	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.05	0.63	1.57e-18	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16303074	chr11:77524766	RSF1	0.57	6.76	0.48	2.84e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.77	8.72	0.58	4.58e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg21905437	chr5:178450457	ZNF879	0.64	5.36	0.4	3.08e-7	Pubertal anthropometrics;
PAAD	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg17986701	chr20:44574422	PCIF1	-0.47	-4.36	-0.33	2.38e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.55	-4.83	-0.37	3.25e-6	Lymphocyte counts;
PAAD	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg11802864	chr11:65308245	LTBP3	0.46	4.75	0.36	4.76e-6	Bone mineral density;
PAAD	cis	rs1539053	0.899	rs7548624	chr1:58106887	A/G	cg00026909	chr1:58089001	DAB1	-0.65	-7.49	-0.52	5.11e-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.78	-6.73	-0.48	3.23e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg13332499	chr17:408570	NA	0.49	5.22	0.39	5.87e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.4	4.62	0.35	8.21e-6	Longevity;
PAAD	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.65	5.82	0.43	3.45e-8	Platelet count;
PAAD	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg26816564	chr1:7831052	VAMP3	-0.64	-5.43	-0.4	2.21e-7	Inflammatory bowel disease;
PAAD	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.62	-4.76	-0.36	4.4e-6	Post bronchodilator FEV1;
PAAD	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.75	-8.5	-0.57	1.63e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.507	rs1023089	chr6:45012346	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.5	-0.34	1.33e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.98	8.04	0.55	2.41e-13	Vitiligo;
PAAD	cis	rs35955747	0.934	rs926928	chr22:31821719	G/A	cg07969918	chr22:31682909	PIK3IP1	-0.37	-4.62	-0.35	8.08e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs375066	0.736	rs62114649	chr19:44416567	T/C	cg21496419	chr19:44306685	LYPD5	-0.42	-4.93	-0.37	2.17e-6	Breast cancer;
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg20849893	chr7:64541193	NA	-0.53	-5.14	-0.38	8.45e-7	Calcium levels;
PAAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg11657440	chr19:46296263	DMWD	0.64	4.79	0.36	3.93e-6	Eosinophil counts;
PAAD	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg02527881	chr3:46936655	PTH1R	0.38	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.67	6.68	0.48	4.35e-10	Multiple sclerosis;
PAAD	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.55	6.02	0.44	1.27e-8	Major depressive disorder;
PAAD	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-5.69	-0.42	6.41e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg09222892	chr1:25734099	RHCE	0.48	4.78	0.36	4.12e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.24e-6	Mortality in heart failure;
PAAD	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.86	0.37	2.91e-6	Ovarian reserve;
PAAD	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.95	-6.1	-0.44	8.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9356171	0.572	rs2322175	chr6:164328086	G/C	cg25752492	chr6:164341247	NA	-0.48	-5.22	-0.39	5.67e-7	Diisocyanate-induced asthma;
PAAD	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs12681288	0.963	rs35220148	chr8:1027602	G/A	cg04851639	chr8:1020857	NA	-0.64	-7.95	-0.54	3.97e-13	Schizophrenia;
PAAD	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.39	-4.69	-0.36	6.01e-6	Intelligence;
PAAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg19413350	chr8:57351067	NA	-0.48	-4.64	-0.35	7.59e-6	Obesity-related traits;
PAAD	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg02389323	chr16:88786976	FAM38A	0.93	5.02	0.38	1.44e-6	Hair color;
PAAD	cis	rs4908768	0.501	rs12061328	chr1:8531963	C/T	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg12568669	chr8:11666485	FDFT1	0.3	4.65	0.35	7.29e-6	Rheumatoid arthritis;
PAAD	cis	rs6689305	0.545	rs12038936	chr1:100240050	A/G	cg22872634	chr1:100462710	SLC35A3	-0.45	-4.3	-0.33	3.09e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs7771547	0.788	rs10214849	chr6:36601445	A/G	cg07856975	chr6:36356162	ETV7	0.45	4.99	0.38	1.62e-6	Platelet distribution width;
PAAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.59	-6.88	-0.49	1.45e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11235843	0.929	rs12366033	chr11:73378974	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-4.48	-0.34	1.45e-5	Total body bone mineral density;
PAAD	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-4.57	-0.35	1.02e-5	Diabetic retinopathy;
PAAD	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-4.78	-0.36	4.05e-6	Blood metabolite levels;
PAAD	cis	rs682748	0.810	rs6888760	chr5:17112174	C/T	cg23987134	chr5:17158319	LOC285696	-0.37	-4.68	-0.35	6.37e-6	Hippocampal atrophy;
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	1.18	13.56	0.74	5.96e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs4474465	0.915	rs12277503	chr11:78140373	A/C	cg12700464	chr11:78128424	GAB2	-0.62	-4.62	-0.35	8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs9333029	0.524	rs2269232	chr1:47401466	T/C	cg08644498	chr1:46502608	NA	-0.47	-4.35	-0.33	2.49e-5	Blood metabolite levels;
PAAD	cis	rs17381960	0.655	rs61960456	chr13:50529888	G/A	cg25486979	chr13:50510739	C13orf1	-1.12	-4.73	-0.36	5.04e-6	Breastfeeding duration;Mumps;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-4.75	-0.36	4.73e-6	Obesity-related traits;
PAAD	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.89	0.54	5.51e-13	Monocyte percentage of white cells;
PAAD	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg00601450	chr5:74908170	NA	0.48	4.44	0.34	1.7e-5	Coronary artery disease;
PAAD	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	5.95	0.43	1.76e-8	Body mass index;
PAAD	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.58	-5.98	-0.44	1.51e-8	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.19	-10.11	-0.63	1.04e-18	Vitiligo;
PAAD	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.46	-4.79	-0.36	3.99e-6	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs11671653	1.000	rs8112837	chr19:10837030	C/T	cg18582342	chr19:11591989	ELAVL3	-0.52	-4.47	-0.34	1.51e-5	LDL cholesterol;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs2051773	0.567	rs7924495	chr11:17038728	G/T	cg15432903	chr11:17409602	KCNJ11	0.49	4.43	0.34	1.8e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.55	-0.57	1.26e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4742903	0.967	rs10991120	chr9:106909051	C/T	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg26597838	chr10:835615	NA	0.88	6.69	0.48	4e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.76	0.48	2.73e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.07	-0.59	5.73e-16	Mean platelet volume;
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs4523957	0.647	rs12950603	chr17:2194937	T/A	cg16513277	chr17:2031491	SMG6	0.52	5.2	0.39	6.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.65	-0.35	7.06e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.76	7.91	0.54	4.83e-13	Retinal vascular caliber;
PAAD	cis	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.56	4.46	0.34	1.57e-5	Depression;
PAAD	cis	rs2290416	0.892	rs2278898	chr8:144691512	G/C	cg17524265	chr8:144659883	NAPRT1	0.84	4.33	0.33	2.68e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs3925075	0.553	rs3087796	chr16:31343653	A/G	cg02846316	chr16:31340340	ITGAM	0.47	5.47	0.41	1.77e-7	IgA nephropathy;
PAAD	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.6	-6.59	-0.47	6.86e-10	Testicular germ cell tumor;
PAAD	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.62	5.38	0.4	2.82e-7	Lymphocyte counts;
PAAD	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.64	5.23	0.39	5.63e-7	Morning vs. evening chronotype;
PAAD	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-4.4	-0.34	1.99e-5	Height;
PAAD	cis	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg04733911	chr16:78082701	NA	-0.53	-5.52	-0.41	1.41e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.71	7.67	0.53	1.91e-12	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.6	7.08	0.5	4.93e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.45	-4.78	-0.36	4.18e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs755249	0.567	rs4660543	chr1:39678990	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.62	-0.35	8.15e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs4740619	0.689	rs10756725	chr9:15952222	G/A	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg04482110	chr17:41364121	TMEM106A	0.39	4.39	0.34	2.09e-5	Menopause (age at onset);
PAAD	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg15841412	chr13:111365552	ING1	0.52	4.32	0.33	2.83e-5	Coronary artery disease;
PAAD	cis	rs5756391	0.546	rs9607398	chr22:37316041	C/T	cg16356956	chr22:37317934	CSF2RB	0.39	4.67	0.35	6.49e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2252790	1.000	rs957529	chr6:116604549	C/T	cg26893134	chr6:116381904	FRK	-0.27	-4.28	-0.33	3.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs893363	1.000	rs893363	chr3:53847062	G/A	cg27292417	chr3:53850724	CHDH	0.41	4.36	0.33	2.41e-5	Axial length;
PAAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.49	-5.14	-0.38	8.3e-7	Platelet distribution width;
PAAD	cis	rs639012	0.859	rs683912	chr11:85794760	C/T	cg07180834	chr11:85838833	NA	-0.42	-4.37	-0.33	2.28e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12395259	chr2:63271927	LOC100132215;EHBP1	-0.57	-6.44	-0.46	1.47e-9	Energy expenditure (24h);
PAAD	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	5.33	0.4	3.47e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg08513622	chr7:1889785	MAD1L1	-0.47	-4.31	-0.33	2.96e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6445967	0.932	rs13093235	chr3:58296706	A/T	cg23715586	chr3:58305044	RPP14	0.51	4.37	0.33	2.3e-5	Platelet count;
PAAD	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	9.73	0.62	1.06e-17	Electrocardiographic conduction measures;
PAAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg26557270	chr6:116382179	FRK	-0.29	-5.21	-0.39	6.09e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1419980	0.556	rs11054516	chr12:7724875	C/T	cg25828445	chr12:7781288	NA	-0.81	-5.63	-0.42	8.6e-8	HDL cholesterol levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16935789	chr8:144450687	C8orf51;RHPN1	0.66	7.16	0.5	3.17e-11	Myopia (pathological);
PAAD	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg06057569	chr22:50219754	BRD1	0.67	4.9	0.37	2.41e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.87	11.0	0.67	4.45e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-4.66	-0.35	6.95e-6	Major depressive disorder;
PAAD	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.4	-4.5	-0.34	1.34e-5	Cognitive function;
PAAD	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.82	-8.46	-0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.97	13.29	0.73	3.05e-27	Heart rate;
PAAD	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg19052272	chr2:3704530	ALLC	-0.7	-6.85	-0.49	1.75e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.84	-10.14	-0.64	9.15e-19	Brugada syndrome;
PAAD	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.55	6.1	0.44	8.59e-9	Heart rate;
PAAD	cis	rs4843747	0.762	rs4843294	chr16:88035356	G/T	cg17633681	chr16:88106987	BANP	0.46	5.47	0.41	1.83e-7	Menopause (age at onset);
PAAD	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.75	0.58	3.69e-15	Menopause (age at onset);
PAAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-4.81	-0.36	3.63e-6	Major depressive disorder;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.46	0.57	2.09e-14	Alzheimer's disease;
PAAD	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.52	6.92	0.49	1.17e-10	Primary biliary cholangitis;
PAAD	cis	rs4740619	0.905	rs10756697	chr9:15728517	A/G	cg14451791	chr9:16040625	NA	-0.4	-4.66	-0.35	6.94e-6	Body mass index;
PAAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.46	-5.24	-0.39	5.38e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2880058	0.958	rs10753744	chr1:162030284	T/C	cg23260004	chr1:161736072	ATF6	-0.5	-4.49	-0.34	1.4e-5	QT interval;
PAAD	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.64	6.24	0.45	4.17e-9	Coronary artery disease;
PAAD	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.4	-0.4	2.55e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.67	0.58	6.03e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.52	-0.34	1.21e-5	Bipolar disorder;
PAAD	cis	rs28408315	0.914	rs34577742	chr15:79215568	C/T	cg00540400	chr15:79124168	NA	0.46	4.28	0.33	3.26e-5	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25303396	chr1:59282018	NA	-0.74	-6.91	-0.49	1.26e-10	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06635552	chr4:104119320	CENPE	-0.75	-6.53	-0.47	9.12e-10	Neuroticism;
PAAD	cis	rs7172971	0.542	rs11630163	chr15:42391261	T/C	cg07013680	chr15:42186124	SPTBN5	0.47	4.74	0.36	4.96e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs72781680	0.566	rs72794293	chr2:23898149	A/G	cg08917208	chr2:24149416	ATAD2B	0.74	5.76	0.42	4.41e-8	Lymphocyte counts;
PAAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	6.29	0.45	3.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg06656553	chr16:89960601	TCF25	-0.81	-4.47	-0.34	1.51e-5	Skin colour saturation;
PAAD	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-8.22	-0.55	8.29e-14	Hemoglobin concentration;
PAAD	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.35	11.59	0.69	1.14e-22	Corneal structure;
PAAD	cis	rs2992756	0.663	rs3007734	chr1:18803022	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.35	-0.46	2.32e-9	Breast cancer;
PAAD	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-1.05	-18.91	-0.84	8.91e-42	Urate levels in lean individuals;
PAAD	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg23465465	chr6:26364728	BTN3A2	-0.83	-4.83	-0.36	3.31e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.72	0.62	1.15e-17	Chronic sinus infection;
PAAD	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg24375607	chr4:120327624	NA	-0.55	-5.03	-0.38	1.34e-6	Corneal astigmatism;
PAAD	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs732505	0.717	rs7260385	chr19:5598357	C/T	cg26242866	chr19:5711310	LONP1	-0.98	-5.47	-0.41	1.79e-7	vWF and FVIII levels;
PAAD	cis	rs2085601	0.542	rs1708678	chr4:89976467	A/G	cg17769793	chr4:89976368	FAM13A	-0.43	-5.23	-0.39	5.44e-7	Hair greying;
PAAD	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.65	-7.08	-0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs804280	0.593	rs2645396	chr8:11608126	C/A	cg12568669	chr8:11666485	FDFT1	-0.35	-4.61	-0.35	8.5e-6	Myopia (pathological);
PAAD	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.62	6.24	0.45	4.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.65	-7.21	-0.5	2.43e-11	Age at first birth;
PAAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.87	0.43	2.6e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.69	-6.69	-0.48	4.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.62	5.22e-18	Cognitive function;
PAAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.63	7.55	0.52	3.84e-12	Longevity;Endometriosis;
PAAD	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.5	5.13	0.38	8.84e-7	Plasma plasminogen activator levels;
PAAD	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.77	5.43	0.4	2.18e-7	Vitiligo;
PAAD	cis	rs2457480	0.571	rs61857479	chr10:44705516	A/G	cg09554077	chr10:44749378	NA	0.33	4.6	0.35	8.99e-6	Coronary artery disease;
PAAD	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg01601518	chr4:2404284	ZFYVE28	-0.45	-4.68	-0.35	6.27e-6	Cognitive function;
PAAD	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.77	8.87	0.58	1.83e-15	Blood metabolite ratios;
PAAD	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.55	-4.67	-0.35	6.48e-6	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15941665	chr18:77464622	CTDP1	-0.72	-8.59	-0.57	9.8e-15	Obesity-related traits;
PAAD	cis	rs4739066	0.579	rs77106515	chr8:63860297	A/G	cg12194929	chr8:63776755	NKAIN3	0.72	4.51	0.34	1.28e-5	Myocardial infarction;
PAAD	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg16589663	chr20:23618590	CST3	0.79	6.89	0.49	1.38e-10	Chronic kidney disease;
PAAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg05484376	chr2:27715224	FNDC4	0.48	4.85	0.37	3.03e-6	Total body bone mineral density;
PAAD	cis	rs7973719	0.868	rs2053887	chr12:7346530	G/A	cg08099141	chr12:7053170	C12orf57	0.43	4.37	0.33	2.33e-5	IgG glycosylation;
PAAD	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-8.53	-0.57	1.39e-14	Exhaled nitric oxide output;
PAAD	cis	rs7737355	1.000	rs27873	chr5:130731151	T/C	cg06307176	chr5:131281290	NA	-0.52	-4.65	-0.35	7.31e-6	Life satisfaction;
PAAD	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg12549451	chr6:135224345	NA	0.42	4.57	0.35	1e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.69	4.75	0.36	4.73e-6	Vitiligo;
PAAD	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	4.86	0.37	2.93e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	4.7	0.36	5.79e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-1.07	-12.59	-0.71	2.4e-25	Breast cancer;
PAAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-6.67	-0.48	4.46e-10	Neuroticism;
PAAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00152838	chr16:24741724	TNRC6A	-0.53	-4.41	-0.34	1.99e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2835872	0.584	rs1709816	chr21:39077259	A/C	cg06728970	chr21:39037746	KCNJ6	0.52	6.07	0.44	9.56e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs1519814	0.736	rs7822384	chr8:121071789	A/G	cg22335954	chr8:121166405	COL14A1	-0.64	-5.31	-0.4	3.91e-7	Breast cancer;
PAAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.53e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24270191	chr3:33840469	PDCD6IP	-0.66	-6.63	-0.47	5.53e-10	Smoking initiation;
PAAD	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg06217245	chr20:33103252	DYNLRB1	0.42	4.29	0.33	3.18e-5	Skin pigmentation;
PAAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.52	4.97	0.37	1.77e-6	Mortality in heart failure;
PAAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.6	-6.44	-0.46	1.47e-9	Lymphocyte counts;
PAAD	cis	rs59104589	0.617	rs59487360	chr2:242270433	A/G	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg17252645	chr8:143867129	LY6D	0.51	4.86	0.37	2.84e-6	Urinary tract infection frequency;
PAAD	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.6	5.26	0.39	4.72e-7	Retinal vascular caliber;
PAAD	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.5	-4.66	-0.35	6.95e-6	Breast cancer;
PAAD	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.91	5.42	0.4	2.28e-7	Alzheimer's disease (late onset);
PAAD	cis	rs13423976	0.600	rs35776111	chr2:38742229	C/T	cg12043428	chr2:38892958	GALM	0.49	4.25	0.33	3.71e-5	Gut microbiome composition (summer);
PAAD	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg01329690	chr21:38580129	DSCR9	-0.33	-4.46	-0.34	1.55e-5	Eye color traits;
PAAD	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.56	5.03	0.38	1.36e-6	Neutrophil percentage of white cells;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.59	6.45	0.46	1.39e-9	Cardiovascular disease risk factors;
PAAD	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	6.41	0.46	1.7e-9	Alzheimer's disease (late onset);
PAAD	cis	rs28829049	0.861	rs10492996	chr1:19365552	C/T	cg17445618	chr1:19577962	KIAA0090;MRTO4	-0.48	-4.4	-0.34	2.03e-5	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.83	-9.35	-0.6	1.1e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.68	-7.77	-0.53	1.1e-12	Iron status biomarkers;
PAAD	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.65	-6.72	-0.48	3.52e-10	Testicular germ cell tumor;
PAAD	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg07548982	chr5:13769939	DNAH5	-0.61	-5.81	-0.43	3.46e-8	Subclinical atherosclerosis traits (other);
PAAD	cis	rs11825685	0.887	rs4359223	chr11:134563721	T/G	cg06603561	chr11:134479413	NA	-0.88	-5.51	-0.41	1.47e-7	IgG glycosylation;
PAAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg08029281	chr1:67600428	NA	0.48	5.51	0.41	1.47e-7	Psoriasis;
PAAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg11062466	chr8:58055876	NA	0.69	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.61	6.06	0.44	1.02e-8	Depressive symptoms;
PAAD	cis	rs4731207	0.596	rs6971179	chr7:124592351	G/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.53	-0.34	1.2e-5	Cutaneous malignant melanoma;
PAAD	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.56	5.71	0.42	5.8e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-4.86	-0.37	2.91e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-0.57	-7.5	-0.52	5.03e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.5	5.14	0.38	8.5e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.68	-0.58	5.66e-15	Total body bone mineral density;
PAAD	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.77	4.51	0.34	1.31e-5	Response to cognitive-behavioural therapy in anxiety disorder;
PAAD	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.5	4.58	0.35	9.72e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.61	4.68	0.35	6.41e-6	Cholesterol, total;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.46	5.68	0.42	6.6e-8	Iron status biomarkers;
PAAD	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.31	-0.56	4.88e-14	Morning vs. evening chronotype;
PAAD	trans	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg00717180	chr2:96193071	NA	-0.64	-6.78	-0.48	2.5e-10	Migraine - clinic-based;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.51	5.09	0.38	1.03e-6	Longevity;Endometriosis;
PAAD	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.6	7.05	0.5	5.78e-11	Aortic root size;
PAAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.79	-7.14	-0.5	3.65e-11	Systemic lupus erythematosus;
PAAD	cis	rs10861342	1.000	rs10778370	chr12:105603139	T/C	cg23923672	chr12:105501055	KIAA1033	0.75	4.52	0.34	1.26e-5	IgG glycosylation;
PAAD	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.32	-0.56	4.61e-14	Mean corpuscular volume;
PAAD	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg14682080	chr5:6737778	POLS	0.38	4.34	0.33	2.61e-5	Menopause (age at onset);
PAAD	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16386425	chr10:429943	DIP2C	0.52	5.57	0.41	1.14e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg10729496	chr3:10149963	C3orf24	0.88	7.58	0.52	3.18e-12	Alzheimer's disease;
PAAD	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg27499820	chr13:21296301	IL17D	0.59	5.76	0.42	4.46e-8	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg07291445	chr7:39015928	NA	0.29	4.28	0.33	3.3e-5	IgG glycosylation;
PAAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.45	0.52	6.5e-12	IgG glycosylation;
PAAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.87	7.64	0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs12753569	0.934	rs6593523	chr1:76486908	C/T	cg00791851	chr1:76518896	NA	-0.44	-4.74	-0.36	4.97e-6	Personality dimensions;
PAAD	cis	rs7180079	1.000	rs12101870	chr15:64526817	A/G	cg18210365	chr15:65066710	RBPMS2	-0.66	-4.75	-0.36	4.6e-6	Monocyte count;
PAAD	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.69	6.65	0.47	4.91e-10	Schizophrenia;
PAAD	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg12560992	chr17:57184187	TRIM37	0.65	4.76	0.36	4.44e-6	Vitamin D levels;
PAAD	cis	rs2061333	1.000	rs2061332	chr19:44613661	G/T	cg18700516	chr19:44507157	ZNF230	0.64	5.0	0.38	1.56e-6	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-5.23	-0.39	5.55e-7	Cervical cancer;
PAAD	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.76	9.21	0.6	2.47e-16	Alcohol dependence;
PAAD	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs2562456	0.520	rs25760	chr19:21394177	A/C	cg25650185	chr19:21324782	ZNF431	-0.51	-4.25	-0.33	3.66e-5	Pain;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22077997	chr3:127399377	ABTB1	-0.68	-6.77	-0.48	2.59e-10	Obesity-related traits;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.32	-0.33	2.77e-5	Mood instability;
PAAD	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg04865290	chr3:52927548	TMEM110	0.68	4.5	0.34	1.35e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.18	0.6	2.91e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.97	0.44	1.59e-8	Coffee consumption (cups per day);
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.66	0.48	4.69e-10	Height;
PAAD	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-5.16	-0.39	7.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14169450	chr9:139327907	INPP5E	0.54	5.28	0.39	4.41e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1879734	0.731	rs72660653	chr1:54157283	G/C	cg14659662	chr1:54151053	GLIS1	-0.42	-5.61	-0.41	9.3e-8	Mitral valve prolapse;
PAAD	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.73	-5.49	-0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg02297831	chr4:17616191	MED28	0.58	5.81	0.43	3.61e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.31	5.96	0.44	1.66e-8	Skin colour saturation;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-9.95	-0.63	2.76e-18	Electrocardiographic conduction measures;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.57	-4.95	-0.37	1.98e-6	Large artery stroke;
PAAD	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.2	0.39	6.32e-7	Electrocardiographic conduction measures;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.52	5.42	0.4	2.31e-7	Longevity;Endometriosis;
PAAD	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.92e-12	Height;
PAAD	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Birth weight;
PAAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03676636	chr4:99064102	C4orf37	0.31	5.63	0.42	8.4e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.13e-5	Parkinson's disease;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.74	-8.81	-0.58	2.6e-15	Body mass index;
PAAD	cis	rs58521262	0.556	rs289351	chr19:23145338	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2073499	0.872	rs77097132	chr3:50301050	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.79	5.69	0.42	6.22e-8	Schizophrenia;
PAAD	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg04877966	chr15:75135169	ULK3	0.54	4.54	0.35	1.12e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg06873352	chr17:61820015	STRADA	0.87	10.79	0.66	1.65e-20	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03437924	chr16:25123326	LCMT1	0.57	6.76	0.48	2.82e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24610274	chr1:155107802	RAG1AP1	-0.67	-6.52	-0.47	9.87e-10	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22099404	chr17:4458623	MYBBP1A	0.63	6.73	0.48	3.18e-10	Obesity-related traits;
PAAD	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg11995313	chr8:8860691	ERI1	0.48	4.67	0.35	6.58e-6	Joint mobility (Beighton score);
PAAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.74	-8.57	-0.57	1.07e-14	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.46	4.54	0.35	1.15e-5	Lung cancer;
PAAD	cis	rs12136530	0.593	rs12121242	chr1:19740609	G/C	cg03321592	chr1:19991676	HTR6	0.55	4.98	0.37	1.72e-6	Lead levels in blood;
PAAD	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.83e-5	Blood protein levels;
PAAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.45	-4.67	-0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg10621924	chr7:39171070	POU6F2	0.37	5.7	0.42	6.11e-8	IgG glycosylation;
PAAD	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.49	-4.48	-0.34	1.45e-5	Diastolic blood pressure;
PAAD	cis	rs1891275	0.551	rs2421621	chr10:93400101	T/C	cg07889827	chr10:93443413	NA	-0.4	-4.29	-0.33	3.17e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.45	4.71	0.36	5.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.06e-7	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-5.72	-0.42	5.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.77	-8.6	-0.57	8.93e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs714031	0.934	rs2235341	chr22:40068679	T/G	cg21377881	chr22:40064566	CACNA1I	-0.46	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.26	0.71	1.83e-24	Chronic sinus infection;
PAAD	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.51	4.85	0.37	3.07e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.6	5.85	0.43	2.92e-8	Schizophrenia;
PAAD	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.5	4.83	0.37	3.24e-6	Endometrial cancer;
PAAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.95	8.72	0.58	4.4e-15	Gut microbiome composition (summer);
PAAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg06521852	chr22:38141419	TRIOBP	0.42	4.26	0.33	3.61e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-1.12	-8.97	-0.59	1e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8025118	0.583	rs1434467	chr15:79543970	C/T	cg11862246	chr15:78730200	IREB2	-0.52	-4.28	-0.33	3.24e-5	Cognitive function;
PAAD	cis	rs9394152	0.817	rs4428487	chr6:33468394	G/A	cg13560919	chr6:33536144	NA	0.53	5.08	0.38	1.1e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg23665729	chr3:49977591	RBM6	0.61	4.46	0.34	1.59e-5	Schizophrenia;
PAAD	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.68	5.46	0.41	1.87e-7	Prostate cancer;
PAAD	cis	rs7101446	0.738	rs4454724	chr11:63216978	T/C	cg26116525	chr11:62371596	EML3	0.43	4.25	0.33	3.69e-5	Economic and political preferences;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg08888203	chr3:10149979	C3orf24	0.68	6.15	0.45	6.55e-9	Alzheimer's disease;
PAAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.65	7.33	0.51	1.29e-11	Dupuytren's disease;
PAAD	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.52	-5.55	-0.41	1.22e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13198984	chr17:80129470	CCDC57	0.45	5.64	0.42	8.26e-8	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05647208	chr19:18527971	NA	0.69	6.77	0.48	2.66e-10	Obesity-related traits;
PAAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.96	10.07	0.63	1.35e-18	Diastolic blood pressure;
PAAD	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.63	7.2	0.5	2.57e-11	Coronary artery disease;
PAAD	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.62	-6.61	-0.47	6.06e-10	IgG glycosylation;
PAAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.66	6.54	0.47	9e-10	Blood metabolite levels;
PAAD	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	5.07	0.38	1.17e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	4.42	0.34	1.86e-5	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg08345082	chr10:99160200	RRP12	-0.31	-4.51	-0.34	1.27e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3106136	0.619	rs4699846	chr4:95341606	T/C	cg11021082	chr4:95130006	SMARCAD1	0.45	4.29	0.33	3.19e-5	Capecitabine sensitivity;
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.43	4.28	0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.81	8.2	0.55	9.25e-14	Schizophrenia;
PAAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.47	6.2	0.45	5.15e-9	Ulcerative colitis;
PAAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.99	-0.37	1.66e-6	Schizophrenia;
PAAD	trans	rs6694672	0.571	rs4915338	chr1:197093832	T/C	cg26994526	chr18:47719735	MYO5B	-0.79	-6.45	-0.46	1.44e-9	Asthma;
PAAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.54	-5.71	-0.42	5.79e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.28	0.45	3.3e-9	Body mass index;
PAAD	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-4.65	-0.35	7.1e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.84e-19	Coronary artery disease;
PAAD	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.83	10.02	0.63	1.81e-18	Monocyte percentage of white cells;
PAAD	cis	rs6735179	0.565	rs73182754	chr2:1747733	A/C	cg08534653	chr2:1747700	PXDN	0.24	4.3	0.33	3.09e-5	Response to antipsychotic treatment;
PAAD	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.7	-6.09	-0.44	8.8e-9	Lymphocyte percentage of white cells;
PAAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs6466055	0.661	rs6954692	chr7:104926021	C/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.44	-4.52	-0.34	1.25e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg27394845	chr17:28928406	LRRC37B2	0.65	4.68	0.36	6.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg04330084	chr7:123175371	IQUB	-0.5	-4.66	-0.35	6.92e-6	Migraine;
PAAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg00976097	chr5:421733	AHRR	-0.44	-4.39	-0.34	2.09e-5	Cystic fibrosis severity;
PAAD	trans	rs11794666	1.000	rs11794666	chr9:31665125	C/A	cg05628366	chr6:35744188	C6orf126	1.0	6.41	0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg26513180	chr16:89883248	FANCA	-0.45	-4.73	-0.36	5e-6	Vitiligo;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25568297	chr16:30077541	ALDOA	0.58	6.33	0.46	2.67e-9	Monocyte percentage of white cells;
PAAD	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg14631576	chr9:95140430	CENPP	-0.53	-5.25	-0.39	5.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg12935359	chr14:103987150	CKB	-0.59	-6.14	-0.45	6.97e-9	Body mass index;
PAAD	cis	rs6076065	0.676	rs6083084	chr20:23335582	A/G	cg11657817	chr20:23433608	CST11	-0.5	-5.05	-0.38	1.26e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.23	0.39	5.51e-7	Bipolar disorder;
PAAD	cis	rs8081395	0.836	rs1295926	chr17:57909373	A/G	cg02344993	chr17:57696989	CLTC	-0.45	-4.48	-0.34	1.45e-5	White blood cell count;
PAAD	cis	rs12752838	0.777	rs11121246	chr1:8917102	T/G	cg24027679	chr1:9086621	SLC2A7	0.38	4.61	0.35	8.38e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12431939	1.000	rs66680859	chr14:51656399	A/G	cg23942311	chr14:51606299	NA	-0.62	-5.13	-0.38	8.55e-7	Cancer;
PAAD	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.66	-6.9	-0.49	1.33e-10	Corneal astigmatism;
PAAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.84	-8.86	-0.58	1.98e-15	Prostate cancer;
PAAD	cis	rs287982	0.611	rs115657324	chr2:9983856	A/G	cg10881225	chr2:9984929	TAF1B	0.7	4.57	0.35	1.02e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg16417436	chr16:28758564	NA	0.45	4.41	0.34	1.94e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.94	-10.94	-0.66	6.75e-21	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19383577	chr16:57279285	ARL2BP	0.6	6.56	0.47	7.9e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg02100629	chr10:71892760	AIFM2	-0.37	-4.26	-0.33	3.5e-5	Blood protein levels;
PAAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.38	0.34	2.16e-5	Tonsillectomy;
PAAD	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg11657817	chr20:23433608	CST11	-0.49	-5.03	-0.38	1.38e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.5	-4.86	-0.37	2.87e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.76	-8.47	-0.57	1.94e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg00806126	chr19:22604979	ZNF98	0.41	5.18	0.39	7.1e-7	Pain;
PAAD	cis	rs6142102	0.602	rs4911145	chr20:32615223	C/T	cg06115741	chr20:33292138	TP53INP2	-0.57	-5.15	-0.39	7.96e-7	Skin pigmentation;
PAAD	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.64	-6.41	-0.46	1.7e-9	Coronary artery disease;
PAAD	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04262392	chr16:2136746	TSC2	0.57	6.87	0.49	1.51e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1190596	0.830	rs3736807	chr14:102552775	T/G	cg23289024	chr14:102554846	HSP90AA1	-0.45	-5.02	-0.38	1.43e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.56	-5.13	-0.38	8.88e-7	Blood metabolite levels;
PAAD	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.61	-4.66	-0.35	6.77e-6	Rheumatoid arthritis;
PAAD	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg02951883	chr7:2050386	MAD1L1	0.59	5.28	0.39	4.33e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-8.17	-0.55	1.09e-13	Depression;
PAAD	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.18	0.39	6.91e-7	Common traits (Other);
PAAD	cis	rs597480	0.652	rs10898415	chr11:85521232	C/A	cg11817631	chr11:85522609	SYTL2	0.52	5.13	0.38	8.79e-7	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-6.75	-0.48	2.93e-10	Colorectal cancer;
PAAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13012494	chr21:47604986	C21orf56	0.47	4.97	0.37	1.76e-6	Testicular germ cell tumor;
PAAD	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-4.81	-0.36	3.61e-6	Diabetic retinopathy;
PAAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.52	-0.34	1.23e-5	Total body bone mineral density;
PAAD	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	trans	rs3905000	0.667	rs62568183	chr9:107650345	T/G	cg25813864	chr17:38334176	RAPGEFL1	0.94	6.79	0.48	2.39e-10	Peripheral arterial disease (traffic-related air pollution interaction);HDL cholesterol;Whole-brain volume (Alzheimer's disease interaction);
PAAD	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-4.81	-0.36	3.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.67	7.68	0.53	1.77e-12	High light scatter reticulocyte count;
PAAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	4.3	0.33	3.03e-5	Self-reported allergy;
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	5.38	0.4	2.73e-7	Menarche (age at onset);
PAAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.06	7.66	0.53	2.05e-12	Diabetic kidney disease;
PAAD	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.48	-4.6	-0.35	8.72e-6	Mean platelet volume;
PAAD	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.77	-5.61	-0.41	9.52e-8	Vitiligo;
PAAD	cis	rs955333	0.685	rs884924	chr6:154894207	A/G	cg20019720	chr6:154832845	CNKSR3	0.36	4.71	0.36	5.52e-6	Diabetic kidney disease;
PAAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg20243544	chr17:37824526	PNMT	0.5	4.34	0.33	2.63e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg22027985	chr11:4115532	RRM1	0.49	4.4	0.34	2.02e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.57	6.31	0.46	2.92e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg06883089	chr1:45254480	BEST4	0.36	4.62	0.35	8.12e-6	High light scatter reticulocyte count;
PAAD	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-4.59	-0.35	9.06e-6	Body mass index;
PAAD	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg06207120	chr15:45996521	NA	-0.3	-4.44	-0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.7	8.11	0.55	1.61e-13	Colorectal cancer;
PAAD	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.72	7.24	0.51	2.08e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12760731	0.720	rs12047646	chr1:178274083	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.11	0.38	9.47e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17757117	chr3:129158717	IFT122;MBD4	0.68	7.1	0.5	4.59e-11	Obesity-related traits;
PAAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7741085	0.560	rs1021129	chr6:44627544	A/G	cg18551225	chr6:44695536	NA	0.45	4.3	0.33	3.06e-5	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg10523679	chr1:76189770	ACADM	-0.55	-5.25	-0.39	5.02e-7	Daytime sleep phenotypes;
PAAD	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg20503657	chr10:835505	NA	0.58	4.64	0.35	7.53e-6	Eosinophil percentage of granulocytes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12897782	chr12:118573888	PEBP1	-0.73	-6.64	-0.47	5.13e-10	Neuroticism;
PAAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg27394845	chr17:28928406	LRRC37B2	-0.65	-4.49	-0.34	1.42e-5	Body mass index;
PAAD	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg26685658	chr5:74633012	HMGCR	-0.52	-4.38	-0.33	2.18e-5	Age-related disease endophenotypes;
PAAD	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.06	-0.5	5.43e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg21479132	chr6:26055353	NA	0.97	5.83	0.43	3.16e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.73	-8.11	-0.55	1.5700000000000001e-13	Schizophrenia;
PAAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.93	8.98	0.59	9.97e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	1.09	6.02	0.44	1.24e-8	Body mass index;
PAAD	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs3764563	0.935	rs622886	chr19:15698696	C/T	cg20725493	chr19:15740067	CYP4F8	0.96	5.3	0.4	3.97e-7	Inflammatory biomarkers;
PAAD	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	8.74	0.58	4.1e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2882667	0.690	rs6421921	chr5:138167270	T/G	cg09476006	chr5:138032270	NA	-0.41	-4.93	-0.37	2.1e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg26149184	chr10:133730230	NA	0.8	6.91	0.49	1.26e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.49	4.58	0.35	9.55e-6	Height;
PAAD	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.95e-6	Renal cell carcinoma;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	8.75	0.58	3.82e-15	Alzheimer's disease;
PAAD	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg26935685	chr1:15502881	TMEM51	-0.53	-4.3	-0.33	3e-5	Systolic blood pressure;
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-7.65	-0.53	2.16e-12	Body mass index;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg15181151	chr6:150070149	PCMT1	0.51	5.2	0.39	6.22e-7	Lung cancer;
PAAD	cis	rs8070740	0.559	rs1000940	chr17:5283252	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	4.49	0.34	1.39e-5	Menopause (age at onset);
PAAD	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20167471	chr1:16528984	ARHGEF19	0.49	4.87	0.37	2.82e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	4.89e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.79	7.53	0.52	4.23e-12	Mean platelet volume;
PAAD	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.38	0.4	2.74e-7	Lung cancer;
PAAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	6.4	0.46	1.84e-9	Initial pursuit acceleration;
PAAD	cis	rs494459	0.838	rs488219	chr11:118620697	T/C	cg08498647	chr11:118550644	TREH	-0.34	-4.25	-0.33	3.69e-5	Height;
PAAD	cis	rs6499755	0.768	rs31103	chr16:55373850	C/T	cg02859129	chr16:55357253	IRX6	0.37	5.19	0.39	6.78e-7	Hypospadias;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21518248	chr2:162101506	NA	0.68	7.61	0.53	2.72e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs73198847	chr3:128507476	C/G	cg19129842	chr3:128565090	NA	-0.87	-5.55	-0.41	1.24e-7	Dental caries;
PAAD	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.79	-9.51	-0.61	4.19e-17	White blood cell count (basophil);
PAAD	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.63	-7.1	-0.5	4.39e-11	Vitiligo;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.5	5.07	0.38	1.12e-6	Glycated hemoglobin levels;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg00599163	chr2:162100495	NA	0.52	7.38	0.51	9.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13773689	chr17:5372292	DHX33	0.67	6.81	0.48	2.14e-10	Obesity-related traits;
PAAD	cis	rs4655537	0.568	rs4655783	chr1:66143044	T/C	cg04111102	chr1:66153794	NA	0.44	4.58	0.35	9.53e-6	Blood protein levels;
PAAD	cis	rs7873102	0.654	rs3802414	chr9:37974481	G/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-5.35	-0.4	3.25e-7	Renal function-related traits (BUN);
PAAD	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.78	-7.74	-0.53	1.28e-12	Paraoxonase activity;
PAAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg15017067	chr4:17643749	FAM184B	0.45	5.3	0.4	3.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.49	-4.93	-0.37	2.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7567389	0.677	rs4662720	chr2:128076607	T/C	cg09760422	chr2:128146352	NA	-0.39	-5.93	-0.43	1.95e-8	Self-rated health;
PAAD	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.71	9.53	0.61	3.62e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs2997447	0.761	rs56078964	chr1:26442600	C/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-5.17	-0.39	7.23e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs332507	0.711	rs3772793	chr3:124405723	A/G	cg05980111	chr3:124395277	KALRN	0.45	4.51	0.34	1.29e-5	Plateletcrit;
PAAD	cis	rs11807834	0.522	rs2057234	chr1:230233014	A/T	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.5e-13	Schizophrenia;
PAAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg02710119	chr21:45078694	RRP1B;HSF2BP	0.48	4.37	0.33	2.33e-5	Mean corpuscular volume;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.54	5.87	0.43	2.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.75	0.69	4.36e-23	Lymphocyte percentage of white cells;
PAAD	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg03517284	chr6:25882590	NA	0.44	4.31	0.33	2.93e-5	Blood metabolite levels;
PAAD	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.71	7.09	0.5	4.64e-11	Systolic blood pressure;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.66	-0.42	7.22e-8	Life satisfaction;
PAAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.89	0.37	2.59e-6	Breast cancer;
PAAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.6	6.24	0.45	4.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9815354	1.000	rs9842261	chr3:41822708	A/G	cg03022575	chr3:42003672	ULK4	-0.81	-6.2	-0.45	5.15e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12304921	1.000	rs67654320	chr12:51356459	A/G	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	trans	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.25e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.92	9.9	0.63	3.79e-18	Cognitive function;
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.56	-5.17	-0.39	7.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg10556349	chr10:835070	NA	0.57	4.94	0.37	2.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.43	0.34	1.8e-5	Plateletcrit;Platelet count;
PAAD	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.94	8.19	0.55	9.82e-14	IgG glycosylation;
PAAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.89e-11	Personality dimensions;
PAAD	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg26528668	chr16:1614120	IFT140	0.56	5.21	0.39	5.97e-7	Coronary artery disease;
PAAD	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg08017634	chr8:144659831	NAPRT1	0.89	4.69	0.36	5.95e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.61	6.34	0.46	2.47e-9	Testicular germ cell tumor;
PAAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg08885800	chr1:201084119	NA	0.75	8.42	0.56	2.6e-14	Permanent tooth development;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.81	8.32	0.56	4.68e-14	Alzheimer's disease (late onset);
PAAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg16576597	chr16:28551801	NUPR1	0.63	6.86	0.49	1.59e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35160687	0.712	rs4832270	chr2:86490188	A/G	cg10973622	chr2:86423274	IMMT	-0.43	-4.65	-0.35	7.2e-6	Night sleep phenotypes;
PAAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.67	-6.87	-0.49	1.57e-10	Height;
PAAD	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	1.09	7.0	0.49	7.71e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg18551225	chr6:44695536	NA	-0.69	-6.91	-0.49	1.25e-10	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.72	-9.04	-0.59	6.65e-16	Educational attainment;
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18099408	chr3:52552593	STAB1	-0.56	-6.14	-0.45	6.94e-9	Electroencephalogram traits;
PAAD	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs4908760	0.827	rs6692693	chr1:8707116	T/G	cg20416874	chr1:8611966	RERE	-0.46	-4.39	-0.34	2.11e-5	Vitiligo;
PAAD	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.8	-8.37	-0.56	3.45e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs73019876	0.901	rs424465	chr19:22233678	C/T	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	1.99e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12187049	chr5:70882888	MCCC2	0.57	6.46	0.46	1.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg14092988	chr3:52407081	DNAH1	0.44	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.62	5.37	0.4	2.87e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.61	6.61	0.47	6.28e-10	Lung cancer;
PAAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg26958924	chr4:6296934	WFS1	0.46	4.29	0.33	3.2e-5	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg03605463	chr16:89740564	NA	-0.52	-4.79	-0.36	3.96e-6	Vitiligo;
PAAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.66	-7.58	-0.52	3.24e-12	Renal function-related traits (BUN);
PAAD	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	trans	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg01620082	chr3:125678407	NA	-1.13	-6.52	-0.47	9.89e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs2479106	0.926	rs7868740	chr9:126502000	A/G	cg16191174	chr9:126692580	DENND1A	0.49	4.45	0.34	1.68e-5	Polycystic ovary syndrome;
PAAD	cis	rs308971	0.563	rs454615	chr3:12077010	A/G	cg02700894	chr3:12045449	SYN2	0.63	4.6	0.35	8.71e-6	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7638995	0.878	rs7620430	chr3:69169602	G/A	cg26574240	chr3:69171822	LMOD3	-0.74	-5.69	-0.42	6.48e-8	Alzheimer's disease (late onset);
PAAD	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.84	-9.98	-0.63	2.33e-18	Eosinophil percentage of white cells;
PAAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg17366294	chr4:99064904	C4orf37	0.46	5.06	0.38	1.19e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs790123	0.579	rs9881748	chr3:122391934	A/T	cg15604389	chr3:122379662	NA	0.51	4.75	0.36	4.7e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.6	5.47	0.41	1.83e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.38	-0.33	2.17e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17554472	chr22:41940697	POLR3H	0.59	4.27	0.33	3.48e-5	Vitiligo;
PAAD	cis	rs2241685	0.850	rs7565890	chr2:1942959	G/A	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.38	-0.33	2.24e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	8.23	0.56	7.67e-14	Longevity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20206224	chr6:43543771	POLH;XPO5	0.6	6.54	0.47	8.88e-10	Myopia (pathological);
PAAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Electroencephalogram traits;
PAAD	cis	rs2072732	0.716	rs72856433	chr1:2954061	G/A	cg15211996	chr1:2936768	ACTRT2	0.47	4.67	0.35	6.69e-6	Plateletcrit;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg03396347	chr1:1875803	NA	0.52	6.24	0.45	4.08e-9	Body mass index;
PAAD	cis	rs8102137	1.000	rs62104478	chr19:30295306	G/A	cg27475126	chr19:30303651	CCNE1	-0.46	-5.13	-0.38	8.6e-7	Bladder cancer;
PAAD	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.69	6.57	0.47	7.71e-10	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.81e-15	Lung cancer;
PAAD	cis	rs7608623	0.840	rs1533440	chr2:24194314	C/T	cg08917208	chr2:24149416	ATAD2B	-0.46	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs787274	1.000	rs787275	chr9:115550523	C/G	cg13803584	chr9:115635662	SNX30	-0.99	-6.54	-0.47	8.98e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg18357526	chr6:26021779	HIST1H4A	0.55	4.86	0.37	2.84e-6	Height;
PAAD	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg00700412	chr12:58011837	NA	0.4	4.32	0.33	2.79e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs783147	1.000	rs783147	chr6:161137990	C/T	cg01280913	chr6:161186852	NA	0.46	4.82	0.36	3.4e-6	Lp (a) levels;
PAAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.64	-0.35	7.56e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-4.26	-0.33	3.64e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.09	14.88	0.77	1.79e-31	Testicular germ cell tumor;
PAAD	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	1.08	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.62	-4.69	-0.36	5.93e-6	Breast cancer;
PAAD	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.65	4.69	0.36	6.09e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.58	-5.1	-0.38	9.82e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.59	5.19	0.39	6.75e-7	Obesity-related traits;
PAAD	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.89	-0.37	2.56e-6	Monocyte percentage of white cells;
PAAD	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.64	6.37	0.46	2.16e-9	Multiple myeloma (IgH translocation);
PAAD	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.81	8.03	0.55	2.53e-13	Corneal astigmatism;
PAAD	trans	rs61931739	0.649	rs708139	chr12:33733265	C/A	cg26384229	chr12:38710491	ALG10B	0.69	7.15	0.5	3.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.46	-0.34	1.57e-5	Obesity-related traits;
PAAD	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.55	-4.8	-0.36	3.8e-6	Itch intensity from mosquito bite;
PAAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.78	-9.65	-0.62	1.75e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.5	0.34	1.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg10589385	chr1:150898437	SETDB1	0.37	4.61	0.35	8.47e-6	Urate levels;
PAAD	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.36	-0.4	3.04e-7	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs28647808	1.000	rs4962140	chr9:136272507	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.63	-5.89	-0.43	2.4e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.51	-0.34	1.28e-5	Coronary artery disease;
PAAD	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.86	-5.12	-0.38	9.07e-7	Cholesterol, total;
PAAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.55	7.42	0.52	7.58e-12	Renal cell carcinoma;
PAAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.5	-5.29	-0.39	4.12e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg11508406	chr4:1595515	NA	0.42	4.35	0.33	2.53e-5	Obesity-related traits;
PAAD	cis	rs66573146	0.808	rs60048916	chr4:6983276	C/A	cg00086871	chr4:6988644	TBC1D14	1.11	4.92	0.37	2.24e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4690686	0.500	rs17062804	chr4:177262892	A/G	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.96	8.4	0.56	2.99e-14	Alzheimer's disease;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-5.84	-0.43	3.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	1.08	8.26	0.56	6.78e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1957429	0.708	rs73279839	chr14:65353834	T/C	cg23373153	chr14:65346875	NA	-1.13	-5.78	-0.42	4.07e-8	Pediatric areal bone mineral density (radius);
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg04520793	chr17:42248056	ASB16	0.48	6.49	0.47	1.14e-9	Total body bone mineral density;
PAAD	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.84	6.71	0.48	3.58e-10	Mean platelet volume;
PAAD	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.95	0.37	1.94e-6	Common traits (Other);
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg19761014	chr17:28927070	LRRC37B2	0.78	5.77	0.42	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.53	-4.51	-0.34	1.28e-5	Dementia with Lewy bodies;
PAAD	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.64	6.37	0.46	2.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs992157	0.932	rs10194082	chr2:219188577	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.7	7.29	0.51	1.58e-11	Colorectal cancer;
PAAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.55	-7.23	-0.51	2.17e-11	Height;
PAAD	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs375066	0.935	rs423320	chr19:44422982	G/A	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs1529711	0.500	rs11672096	chr19:10899112	C/G	cg16667279	chr19:11591998	ELAVL3	-0.63	-4.69	-0.36	6.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg10932868	chr11:921992	NA	0.47	5.06	0.38	1.2e-6	Alzheimer's disease (late onset);
PAAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg22903657	chr4:1355424	KIAA1530	0.44	4.75	0.36	4.59e-6	Obesity-related traits;
PAAD	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg13319975	chr6:146136371	FBXO30	0.52	4.48	0.34	1.46e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.31	-0.33	2.87e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9367125	0.816	rs9367126	chr6:41997698	T/C	cg12151296	chr6:42013349	CCND3	-0.65	-4.69	-0.36	6.03e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2668423	0.960	rs2668427	chr19:1372132	C/T	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.74	-0.48	3.16e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg19176072	chr10:135083742	ADAM8	0.87	4.37	0.33	2.32e-5	Lifespan;
PAAD	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.76	-5.85	-0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.47	5.94	0.43	1.89e-8	Childhood ear infection;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.83	0.43	3.28e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.95	9.89	0.63	3.97e-18	Corneal astigmatism;
PAAD	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg19192590	chr2:178524533	PDE11A	0.43	5.14	0.38	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.48	-4.37	-0.33	2.32e-5	Red blood cell count;
PAAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.2	13.77	0.75	1.57e-28	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-4.29	-0.33	3.17e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.23	0.39	5.53e-7	Lung cancer;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72772090	0.710	rs17478897	chr5:96062617	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-5.84	-0.43	3.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1642645	1.000	rs1642645	chr1:42502281	A/C	cg01990334	chr1:42801334	FOXJ3	-0.68	-6.0	-0.44	1.4e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.4	-0.34	2.06e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.65	0.35	7.25e-6	Bipolar disorder;
PAAD	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.03	-13.14	-0.73	8.06e-27	Cognitive ability;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg12035532	chr1:1886765	KIAA1751	0.4	4.35	0.33	2.52e-5	Body mass index;
PAAD	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg00717180	chr2:96193071	NA	-0.6	-6.59	-0.47	6.88e-10	HDL cholesterol;
PAAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.96	11.84	0.69	2.42e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.66	6.43	0.46	1.55e-9	Corneal astigmatism;
PAAD	cis	rs755249	0.567	rs17264671	chr1:39818052	A/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.66	-0.35	6.94e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg01796438	chr3:11312864	ATG7	-0.64	-4.95	-0.37	1.96e-6	Circulating chemerin levels;
PAAD	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.51	4.99	0.38	1.63e-6	Pancreatic cancer;
PAAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.57	-6.36	-0.46	2.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.57	-6.0	-0.44	1.41e-8	Response to antidepressants and depression;
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.54	5.94	0.43	1.9e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.35	0.33	2.47e-5	IgG glycosylation;
PAAD	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.52	-5.53	-0.41	1.36e-7	Mitral valve prolapse;
PAAD	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4823006	0.846	rs3178915	chr22:29453027	A/G	cg23896685	chr22:29451551	ZNRF3	0.45	4.67	0.35	6.57e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.46	-0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg07154921	chr7:157260426	NA	0.44	4.25	0.33	3.71e-5	Body mass index;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	1.12	16.66	0.8	4.06e-36	Menarche (age at onset);
PAAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg00982548	chr2:198649783	BOLL	-0.9	-6.38	-0.46	2.04e-9	Ulcerative colitis;
PAAD	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.45	-5.16	-0.39	7.5e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.6	8.26	0.56	6.57e-14	Eye color traits;
PAAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.83	9.95	0.63	2.89e-18	Colorectal cancer;
PAAD	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-6.38	-0.46	2.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg07636037	chr3:49044803	WDR6	-0.55	-4.35	-0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.48	4.59	0.35	9.35e-6	Lung cancer;
PAAD	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.21	0.5	2.44e-11	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg14709524	chr16:89940631	TCF25	0.98	4.55	0.35	1.09e-5	Skin colour saturation;
PAAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.7	0.48	3.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.69	0.48	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg23033748	chr14:75592666	NEK9	0.42	5.04	0.38	1.32e-6	Height;
PAAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.98	11.24	0.67	1e-21	Parkinson's disease;
PAAD	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	6.56	0.47	7.87e-10	Breast cancer;
PAAD	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg00369613	chr2:3483100	TTC15	0.55	4.25	0.33	3.74e-5	Type 2 diabetes;
PAAD	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg05309399	chr4:106552544	FLJ20184	-0.53	-4.25	-0.33	3.7e-5	Post bronchodilator FEV1;
PAAD	cis	rs10411262	0.935	rs314666	chr19:47176825	T/C	cg13467550	chr19:47212573	PRKD2	0.48	4.94	0.37	2.06e-6	Tonsillectomy;
PAAD	cis	rs804280	0.525	rs17153755	chr8:11611500	C/G	cg12395012	chr8:11607386	GATA4	-0.58	-7.11	-0.5	4.22e-11	Myopia (pathological);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08448040	chr3:13521693	HDAC11	0.57	6.29	0.45	3.16e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12304921	1.000	rs12305170	chr12:51345265	T/C	cg18059802	chr12:51347058	HIGD1C	-0.72	-5.94	-0.43	1.88e-8	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.83	6.98	0.49	8.68e-11	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.9e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03676636	chr4:99064102	C4orf37	0.33	6.07	0.44	9.97e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg27411982	chr8:10470053	RP1L1	0.47	5.13	0.38	8.52e-7	Neuroticism;
PAAD	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.48	-0.41	1.75e-7	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.5	-5.0	-0.38	1.6e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.97	-0.37	1.78e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.76	5.42	0.4	2.31e-7	Phospholipid levels (plasma);
PAAD	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.0	9.56	0.61	3e-17	Monocyte percentage of white cells;
PAAD	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg15956490	chr3:53032818	SFMBT1	0.74	4.27	0.33	3.38e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	6.63	0.47	5.47e-10	IgG glycosylation;
PAAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.46	-0.46	1.35e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06753367	chr22:24256600	NA	-0.42	-4.39	-0.34	2.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-7.33	-0.51	1.27e-11	Body mass index;
PAAD	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.57	-7.38	-0.51	9.67e-12	Lewy body disease;
PAAD	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18621852	chr3:10150065	C3orf24	-0.64	-5.52	-0.41	1.45e-7	Alzheimer's disease;
PAAD	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.34	14.78	0.77	3.39e-31	Hip circumference adjusted for BMI;
PAAD	cis	rs1997066	0.831	rs73342207	chr10:106816860	C/G	cg17321814	chr10:106440892	SORCS3	0.64	4.27	0.33	3.42e-5	Diabetic kidney disease;
PAAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg24375607	chr4:120327624	NA	0.45	4.68	0.36	6.25e-6	Diastolic blood pressure;
PAAD	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.56	-5.83	-0.43	3.26e-8	Testicular germ cell tumor;
PAAD	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs12311304	1.000	rs16910711	chr12:15395799	C/T	cg08258403	chr12:15378311	NA	0.35	4.52	0.34	1.26e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13515842	chr9:127215440	GPR144	0.42	4.61	0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg03605463	chr16:89740564	NA	-0.62	-5.78	-0.42	4.14e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs10493340	1.000	rs67243639	chr1:63596864	T/G	cg08634298	chr1:64337861	ROR1	-0.45	-4.31	-0.33	2.98e-5	Blood pressure;
PAAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26246411	chr19:1753483	ONECUT3	-0.56	-6.46	-0.46	1.33e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.19	-20.22	-0.85	6.08e-45	Myeloid white cell count;
PAAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.27	-7.13	-0.5	3.86e-11	Body mass index;
PAAD	cis	rs35160687	0.862	rs12476706	chr2:86528370	C/T	cg10973622	chr2:86423274	IMMT	0.45	4.92	0.37	2.23e-6	Night sleep phenotypes;
PAAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs939584	0.935	rs7604752	chr2:643428	C/A	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs375066	0.935	rs403137	chr19:44427626	A/G	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs990171	0.520	rs10195948	chr2:103125736	T/C	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.74	8.37	0.56	3.4e-14	Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg25620797	chr2:55921863	PNPT1	-0.53	-5.16	-0.39	7.63e-7	Metabolic syndrome;
PAAD	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7792596	0.539	rs17252513	chr7:94010623	C/T	cg20814616	chr7:94014465	NA	-0.57	-4.28	-0.33	3.25e-5	Intelligence;
PAAD	cis	rs13278732	0.500	rs3088121	chr8:99048049	A/G	cg27313044	chr8:99903985	NA	0.49	4.36	0.33	2.4e-5	Eosinophilic esophagitis (pediatric);
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05665937	chr4:1216051	CTBP1	-0.42	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg13212159	chr17:38075554	GSDMB	-0.56	-6.37	-0.46	2.1e-9	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23697861	chr7:6616078	ZDHHC4	0.57	6.49	0.47	1.13e-9	Myopia (pathological);
PAAD	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.44	-4.48	-0.34	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14401372	chr7:2272828	MAD1L1	-0.68	-6.66	-0.48	4.64e-10	Lung cancer in ever smokers;
PAAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12165864	chr7:66369176	NA	0.83	5.49	0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg06714761	chr1:201096289	NA	0.38	5.22	0.39	5.81e-7	Permanent tooth development;
PAAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22947322	chr17:47091978	IGF2BP1	0.38	4.44	0.34	1.75e-5	Type 2 diabetes;
PAAD	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg04165759	chr1:150448943	RPRD2	-0.49	-4.98	-0.37	1.71e-6	Migraine;
PAAD	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs17683430	0.558	rs4488763	chr22:32380164	C/G	cg00543991	chr22:32367038	NA	0.78	5.42	0.4	2.26e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs2421770	0.532	rs7945449	chr11:35369110	C/T	cg13971030	chr11:35366721	SLC1A2	-0.56	-5.37	-0.4	2.83e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4478147	0.506	rs56255533	chr4:87284233	G/T	cg10685359	chr4:87814065	C4orf36	-0.52	-5.36	-0.4	2.98e-7	Migraine - clinic-based;
PAAD	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	13.51	0.74	7.8e-28	Intracerebral hemorrhage;White matter hyperintensity burden;
PAAD	cis	rs7766436	0.648	rs6908475	chr6:22572798	A/G	cg13666174	chr6:22585274	NA	-0.47	-4.89	-0.37	2.53e-6	Coronary artery disease;
PAAD	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.85	9.47	0.61	5.19e-17	Multiple sclerosis;
PAAD	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.81	5.6	0.41	9.55e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	4.45	0.34	1.62e-5	Hip circumference;
PAAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.7	8.08	0.55	1.81e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs490234	0.966	rs569408	chr9:128304824	G/A	cg14078157	chr9:128172775	NA	0.39	4.25	0.33	3.65e-5	Mean arterial pressure;
PAAD	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs4903604	0.581	rs11159278	chr14:78034001	C/G	cg18872420	chr14:78023429	SPTLC2	0.45	4.75	0.36	4.61e-6	Gut microbiome composition (winter);
PAAD	cis	rs10186876	0.665	rs35813524	chr2:44133774	C/G	cg26828767	chr2:44457733	PPM1B	-0.48	-4.43	-0.34	1.82e-5	Hand grip strength;
PAAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg02917321	chr22:38215204	NA	0.44	4.28	0.33	3.35e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4454254	0.736	rs13268179	chr8:141070606	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.32	-4.42	-0.34	1.85e-5	Pulse pressure;
PAAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg11062466	chr8:58055876	NA	0.65	4.67	0.35	6.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg13057898	chr1:3703894	LRRC47	0.44	4.74	0.36	4.94e-6	Red cell distribution width;
PAAD	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg24623649	chr8:11872141	NA	-0.47	-4.58	-0.35	9.72e-6	Monocyte count;
PAAD	cis	rs1190596	0.558	rs3087686	chr14:102695563	A/G	cg23289024	chr14:102554846	HSP90AA1	0.4	4.6	0.35	8.87e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.66	7.82	0.54	8.17e-13	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg03340356	chr1:67600835	NA	0.54	6.16	0.45	6.37e-9	Psoriasis;
PAAD	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	6.86	0.49	1.6e-10	Blood protein levels;
PAAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-10.0	-0.63	2.12e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg23093090	chr10:104574429	C10orf26	-0.45	-4.89	-0.37	2.52e-6	Arsenic metabolism;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.6	-5.78	-0.42	4.16e-8	Adiposity;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.41	0.82	5.02e-38	Prudent dietary pattern;
PAAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg14820908	chr5:178986412	RUFY1	0.58	6.06	0.44	1.04e-8	Lung cancer;
PAAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.47	5.65	0.42	7.72e-8	Vitiligo;
PAAD	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	0.92	10.79	0.66	1.69e-20	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	7.96	0.54	3.68e-13	Prudent dietary pattern;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.72	0.58	4.47e-15	Lung cancer;
PAAD	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg09127314	chr1:152161683	NA	0.6	4.41	0.34	1.91e-5	Atopic dermatitis;
PAAD	trans	rs717267	0.548	rs9298763	chr9:16420174	T/C	cg12478165	chr22:39785435	NA	-0.57	-6.34	-0.46	2.52e-9	Gestational age at birth (maternal effect);
PAAD	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg19000871	chr14:103996768	TRMT61A	-0.47	-4.96	-0.37	1.85e-6	Reticulocyte count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04546292	chr12:12764792	CREBL2	0.63	6.57	0.47	7.41e-10	Myopia (pathological);
PAAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07701084	chr6:150067640	NUP43	0.6	6.03	0.44	1.21e-8	Lung cancer;
PAAD	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg18898632	chr2:242989856	NA	0.79	6.18	0.45	5.72e-9	Obesity-related traits;
PAAD	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg18357526	chr6:26021779	HIST1H4A	0.54	4.94	0.37	2.04e-6	Height;
PAAD	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg00383909	chr3:49044727	WDR6	0.44	4.53	0.34	1.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4908768	0.501	rs1024197	chr1:8537058	C/G	cg20416874	chr1:8611966	RERE	-0.48	-4.64	-0.35	7.53e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.97	-9.65	-0.62	1.71e-17	Blood protein levels;
PAAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.83	-10.45	-0.65	1.37e-19	Height;
PAAD	cis	rs28489187	0.638	rs233055	chr1:85798486	A/C	cg16011679	chr1:85725395	C1orf52	0.51	4.76	0.36	4.53e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.82	-8.86	-0.58	1.96e-15	Obesity-related traits;
PAAD	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg27205649	chr11:78285834	NARS2	-0.59	-4.36	-0.33	2.34e-5	Alzheimer's disease (survival time);
PAAD	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2249694	0.878	rs2480256	chr10:135352514	A/G	cg16964102	chr10:135390573	NA	-0.43	-4.48	-0.34	1.49e-5	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.9	-6.23	-0.45	4.26e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.97	-0.54	3.57e-13	Neuroticism;
PAAD	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12778183	chr17:56769387	TEX14;RAD51C	-0.52	-4.58	-0.35	9.76e-6	Testicular germ cell tumor;
PAAD	cis	rs2275731	1.000	rs2275731	chr10:16526840	G/A	cg04254609	chr10:16479192	PTER	-0.49	-4.88	-0.37	2.69e-6	Bone fracture in osteoporosis;
PAAD	cis	rs761746	0.577	rs5998136	chr22:32224673	C/T	cg01338084	chr22:32026380	PISD	0.55	4.84	0.37	3.13e-6	Intelligence;
PAAD	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg19264203	chr11:92714893	MTNR1B	0.4	4.56	0.35	1.03e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg06307176	chr5:131281290	NA	-0.49	-4.34	-0.33	2.58e-5	Life satisfaction;
PAAD	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.04	8.32	0.56	4.69e-14	Corneal structure;
PAAD	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-4.59	-0.35	9.38e-6	Menarche (age at onset);
PAAD	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.36	-0.4	2.97e-7	Bladder cancer;
PAAD	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg02404636	chr22:31891804	SFI1	0.6	5.43	0.4	2.15e-7	Colorectal cancer;
PAAD	cis	rs7795096	0.776	rs62480474	chr7:151542840	C/G	cg17008978	chr7:151542804	PRKAG2	0.41	4.69	0.36	6.12e-6	Bipolar disorder (age of onset and psychotic symptoms);
PAAD	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-6.35	-0.46	2.35e-9	Psoriasis;
PAAD	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg07475973	chr22:42306951	NA	0.46	4.25	0.33	3.68e-5	Neuroticism;
PAAD	cis	rs7224685	0.689	rs4508454	chr17:4198650	C/T	cg05562828	chr17:3906858	NA	-0.5	-4.7	-0.36	5.81e-6	Type 2 diabetes;
PAAD	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.79	9.25	0.6	1.93e-16	Colorectal cancer;
PAAD	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg10818794	chr15:86012489	AKAP13	-0.46	-4.96	-0.37	1.88e-6	Interstitial lung disease;
PAAD	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg14008862	chr17:28927542	LRRC37B2	0.73	5.34	0.4	3.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg06671706	chr8:8559999	CLDN23	0.63	6.62	0.47	5.83e-10	Obesity-related traits;
PAAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.6	6.23	0.45	4.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg08717414	chr16:71523259	ZNF19	-0.91	-5.55	-0.41	1.26e-7	Post bronchodilator FEV1;
PAAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.48	-4.65	-0.35	7.12e-6	Pulse pressure;
PAAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.15	-0.45	6.65e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs354033	1.000	rs354045	chr7:149300608	G/T	cg06920324	chr7:149264011	ZNF767	0.66	5.51	0.41	1.51e-7	Multiple sclerosis;
PAAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.855	rs9897160	chr17:2121566	A/G	cg16513277	chr17:2031491	SMG6	-0.49	-4.96	-0.37	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6024905	0.551	rs2425364	chr20:36969340	G/T	cg07053727	chr20:36965646	BPI	0.55	6.35	0.46	2.41e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-5.97	-0.44	1.6e-8	Lung cancer;
PAAD	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg10818794	chr15:86012489	AKAP13	-0.46	-5.05	-0.38	1.23e-6	Interstitial lung disease;
PAAD	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.48	-0.41	1.69e-7	Triglycerides;
PAAD	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg01620082	chr3:125678407	NA	-1.14	-6.56	-0.47	8.13e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.57	5.53	0.41	1.36e-7	Corneal astigmatism;
PAAD	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.27	-0.51	1.79e-11	Alcohol dependence;
PAAD	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05139081	chr12:113706669	TPCN1	0.58	6.59	0.47	6.89e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.5	-7.01	-0.49	7.23e-11	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.67	-0.35	6.63e-6	Subjective well-being;
PAAD	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.48	4.85	0.37	2.97e-6	Immature fraction of reticulocytes;
PAAD	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.25e-11	Childhood ear infection;
PAAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg27335999	chr10:556044	DIP2C	0.33	4.39	0.34	2.13e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg16898833	chr6:26189333	HIST1H4D	0.68	5.16	0.39	7.74e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg08717414	chr16:71523259	ZNF19	-0.85	-4.85	-0.37	3e-6	Post bronchodilator FEV1;
PAAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg20913747	chr6:44695427	NA	-0.54	-4.77	-0.36	4.2e-6	Total body bone mineral density;
PAAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg07362569	chr17:61921086	SMARCD2	0.43	4.79	0.36	3.98e-6	Height;
PAAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.77	6.24	0.45	4.14e-9	Gut microbiome composition (summer);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20584198	chr12:57637690	STAC3	0.6	7.43	0.52	7.29e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.47	5.12	0.38	9.27e-7	Motion sickness;
PAAD	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.66	-7.37	-0.51	1.02e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.38	-0.56	3.32e-14	Prostate cancer;
PAAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.68	6.41	0.46	1.72e-9	Platelet count;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.52	6.67	0.48	4.36e-10	Childhood ear infection;
PAAD	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.82	8.21	0.55	8.86e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.57	6.49	0.47	1.17e-9	Major depressive disorder;
PAAD	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.71	-0.48	3.62e-10	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg20406979	chr6:167373233	NA	0.37	4.75	0.36	4.72e-6	Crohn's disease;
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.46	-4.63	-0.35	7.73e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.94	-9.73	-0.62	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5751901	0.614	rs874852	chr22:24987964	G/A	cg08808123	chr22:24999002	GGT1	-0.45	-4.68	-0.35	6.3e-6	Protein quantitative trait loci;
PAAD	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.03	0.38	1.35e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-1.07	-11.35	-0.68	5.34e-22	Longevity;
PAAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.7	-0.36	5.7e-6	Diastolic blood pressure;
PAAD	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.54	5.43	0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs256277	0.657	rs173898	chr5:111369570	T/C	cg17919331	chr5:112312406	DCP2	0.51	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg02264943	chr11:130785842	SNX19	0.37	4.76	0.36	4.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs16975963	0.843	rs241954	chr19:38277530	C/T	cg25793785	chr19:38281423	NA	0.57	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs57244997	0.582	rs73030429	chr6:162438902	A/G	cg17173639	chr6:162384350	PARK2	-0.61	-4.63	-0.35	7.9e-6	Mosquito bite size;
PAAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.45	-4.41	-0.34	1.94e-5	Height;
PAAD	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-4.34	-0.33	2.55e-5	Body mass index;
PAAD	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.78	-6.76	-0.48	2.75e-10	Exhaled nitric oxide output;
PAAD	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.57	-0.47	7.54e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3772130	0.926	rs66653099	chr3:121393089	T/G	cg20356878	chr3:121714668	ILDR1	0.54	5.2	0.39	6.34e-7	Cognitive performance;
PAAD	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg18084798	chr19:33555255	RHPN2	0.45	4.66	0.35	6.97e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-7.95	-0.54	3.95e-13	Total body bone mineral density;
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.68	-6.63	-0.47	5.43e-10	Blood metabolite levels;
PAAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.35	0.4	3.23e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg14092988	chr3:52407081	DNAH1	0.44	5.55	0.41	1.25e-7	Bipolar disorder;
PAAD	cis	rs72681920	0.881	rs2226896	chr4:100067337	A/G	cg12011299	chr4:100065546	ADH4	-0.83	-4.88	-0.37	2.71e-6	Alcohol dependence;
PAAD	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg06156847	chr2:113672199	IL1F7	-0.53	-5.54	-0.41	1.33e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.66	7.17	0.5	2.99e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.67	-6.96	-0.49	9.3e-11	Type 2 diabetes;
PAAD	cis	rs1730008	0.533	rs10936143	chr3:158179972	T/C	cg16708174	chr3:158430962	RARRES1	0.55	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22120094	chr8:123794578	ZHX2	0.61	6.64	0.47	5.25e-10	Monocyte percentage of white cells;
PAAD	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg11874272	chr3:121773564	CD86	-0.41	-4.29	-0.33	3.13e-5	Multiple sclerosis;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg13264159	chr8:625131	ERICH1	-0.76	-5.2	-0.39	6.21e-7	IgG glycosylation;
PAAD	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg14196790	chr5:131705035	SLC22A5	0.43	4.7	0.36	5.77e-6	Breast cancer;
PAAD	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.28	0.39	4.4e-7	Morning vs. evening chronotype;
PAAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg12310025	chr6:25882481	NA	0.46	4.56	0.35	1.06e-5	Schizophrenia;
PAAD	cis	rs8060686	0.920	rs4474673	chr16:67758778	C/T	cg27539214	chr16:67997921	SLC12A4	-0.67	-4.5	-0.34	1.34e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs8112211	0.954	rs7252835	chr19:38832946	G/A	cg14299480	chr19:38876666	GGN	-0.58	-7.26	-0.51	1.85e-11	Blood protein levels;
PAAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.66	6.44	0.46	1.51e-9	Tuberculosis;
PAAD	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg20988073	chr3:125900093	ALDH1L1	0.51	5.59	0.41	1e-7	Metabolite levels;
PAAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15874048	chr14:45369753	C14orf28	-0.69	-6.6	-0.47	6.37e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.4	-0.34	2.06e-5	Joint mobility (Beighton score);
PAAD	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs900145	0.953	rs4146386	chr11:13291979	A/G	cg15603424	chr11:13300592	ARNTL	0.54	4.85	0.37	3.02e-6	Menarche (age at onset);
PAAD	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.63	5.64	0.42	7.88e-8	Crohn's disease;
PAAD	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.84	-5.9	-0.43	2.23e-8	Coronary artery disease;
PAAD	cis	rs9283706	0.608	rs1428407	chr5:66330416	C/T	cg11590213	chr5:66331682	MAST4	0.56	4.49	0.34	1.42e-5	Coronary artery disease;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.01	-16.97	-0.81	6.6e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	5.99	0.44	1.45e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	1.06	8.27	0.56	6.09e-14	Menopause (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg08802604	chr6:167039963	RPS6KA2	0.59	6.9	0.49	1.35e-10	Metabolite levels  (X-11787);
PAAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg02353165	chr6:42928485	GNMT	0.93	12.66	0.72	1.57e-25	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg24253500	chr15:84953950	NA	0.55	6.5	0.47	1.06e-9	Schizophrenia;
PAAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.24	-0.45	4.21e-9	Lung cancer;
PAAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs458685	0.636	rs391037	chr21:31189738	T/G	cg24620508	chr21:31310605	GRIK1	-0.49	-4.52	-0.34	1.23e-5	Breast cancer;
PAAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.87	7.02	0.5	6.75e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	4.44	0.34	1.73e-5	Total cholesterol levels;
PAAD	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg25722041	chr1:8623473	RERE	0.5	4.29	0.33	3.21e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg18939081	chr1:31884902	SERINC2	0.48	5.58	0.41	1.09e-7	Alcohol dependence;
PAAD	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg14019695	chr9:139328340	INPP5E	0.5	4.59	0.35	9.25e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs755249	0.567	rs16826009	chr1:39716902	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.79	-0.36	4e-6	Alcohol dependence;
PAAD	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg11547950	chr5:77652471	NA	-0.68	-6.03	-0.44	1.18e-8	Triglycerides;
PAAD	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg09699651	chr6:150184138	LRP11	0.49	5.07	0.38	1.13e-6	Lung cancer;
PAAD	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg14631576	chr9:95140430	CENPP	-0.54	-5.3	-0.39	4.02e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs10186876	0.728	rs6759659	chr2:44143756	A/G	cg09541576	chr2:44873248	C2orf34	-0.46	-4.77	-0.36	4.29e-6	Hand grip strength;
PAAD	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg08779649	chr13:50194554	NA	0.45	6.1	0.44	8.39e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-5.55	-0.41	1.24e-7	Bladder cancer;
PAAD	cis	rs3771514	0.543	rs1880039	chr2:70687052	C/T	cg18150120	chr2:71134936	VAX2	0.39	4.69	0.36	6.01e-6	Obesity-related traits;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.88	10.83	0.66	1.33e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg10483660	chr13:112241077	NA	0.55	5.03	0.38	1.34e-6	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11590700	chr3:169381241	MECOM	0.54	6.81	0.48	2.14e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg15192750	chr16:69999425	NA	0.77	6.06	0.44	1.03e-8	IgE levels;
PAAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.9	-7.71	-0.53	1.5e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.48	7.61	0.53	2.68e-12	IgG glycosylation;
PAAD	cis	rs7567389	0.719	rs4150499	chr2:128028792	T/C	cg11380483	chr2:127933992	NA	-0.44	-4.39	-0.34	2.15e-5	Self-rated health;
PAAD	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12760731	0.720	rs10913553	chr1:178423062	G/C	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.45	4.64	0.35	7.52e-6	Corneal astigmatism;
PAAD	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg00383909	chr3:49044727	WDR6	-0.67	-4.41	-0.34	1.95e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.55	4.89	0.37	2.54e-6	Personality dimensions;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	0.69	4.69	0.36	6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06239143	chr8:67588502	C8orf44	0.61	6.35	0.46	2.35e-9	Smoking initiation;
PAAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.46	-0.46	1.33e-9	Total body bone mineral density;
PAAD	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.68	7.02	0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.74	-8.36	-0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.72	7.36	0.51	1.06e-11	Corneal astigmatism;
PAAD	cis	rs740474	0.569	rs4912761	chr5:140881474	G/T	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.31	4.66	0.35	6.97e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.69	0.58	5.44e-15	Lung cancer;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.08e-11	Life satisfaction;
PAAD	cis	rs3736485	0.789	rs12913493	chr15:51735296	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.25	-0.33	3.74e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.75	4.79	0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.96	8.02	0.55	2.71e-13	Alzheimer's disease;
PAAD	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	4.4	0.34	2.03e-5	Breast cancer;
PAAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.45	-0.46	1.43e-9	Prudent dietary pattern;
PAAD	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg14458575	chr2:238380390	NA	0.5	4.44	0.34	1.72e-5	Prostate cancer;
PAAD	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.74e-8	Colorectal cancer;
PAAD	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.38	-0.4	2.79e-7	Metabolite levels;
PAAD	cis	rs1198430	0.714	rs946265	chr1:23775296	T/G	cg27447006	chr1:23763279	ASAP3	0.65	5.02	0.38	1.4e-6	Total cholesterol levels;
PAAD	trans	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg15770106	chr1:208133116	NA	-0.68	-6.63	-0.47	5.45e-10	Corneal structure;
PAAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.9	5.89	0.43	2.45e-8	Diabetic kidney disease;
PAAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18302933	chr2:88491318	NA	-0.45	-5.28	-0.39	4.41e-7	Response to metformin (IC50);
PAAD	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg22875332	chr1:76189707	ACADM	-0.48	-4.75	-0.36	4.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.11	-0.38	9.44e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg05484376	chr2:27715224	FNDC4	0.45	4.55	0.35	1.08e-5	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15209934	chr19:52800385	ZNF480	-0.58	-6.58	-0.47	7.2e-10	Body fat percentage;
PAAD	cis	rs7210086	0.808	rs8073267	chr17:70639514	G/C	cg04206342	chr17:70636940	NA	-0.5	-6.47	-0.46	1.3e-9	Ulcerative colitis;
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg26385993	chr17:80788710	TBCD;ZNF750	-0.41	-4.29	-0.33	3.21e-5	Glycated hemoglobin levels;
PAAD	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs3112530	1.000	rs3101131	chr5:152625452	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	-0.86	-4.57	-0.35	1.02e-5	Aging (time to event);
PAAD	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg11900509	chr10:81946545	ANXA11	-0.75	-4.25	-0.33	3.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs75920871	1.000	rs75858236	chr11:116872263	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.79	-5.94	-0.43	1.9e-8	Initial pursuit acceleration;
PAAD	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.46	-0.34	1.6e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.74	5.97	0.44	1.59e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg27499820	chr13:21296301	IL17D	-0.52	-5.17	-0.39	7.35e-7	Dental caries;
PAAD	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.86	7.88	0.54	5.86e-13	Dilated cardiomyopathy;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.61	-7.12	-0.5	3.99e-11	Urate levels;
PAAD	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg14582100	chr15:45693742	SPATA5L1	0.43	6.53	0.47	9.44e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.48	0.57	1.86e-14	Coffee consumption (cups per day);
PAAD	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg01329690	chr21:38580129	DSCR9	0.32	4.26	0.33	3.55e-5	Eye color traits;
PAAD	cis	rs8077059	1.000	rs8075326	chr17:55813869	G/T	cg12582317	chr17:55822272	NA	0.53	4.97	0.37	1.75e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs6688613	0.840	rs10918607	chr1:166957803	T/C	cg07049167	chr1:166818506	POGK	0.62	6.09	0.44	8.77e-9	Refractive astigmatism;
PAAD	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	4.53	0.34	1.19e-5	Height;
PAAD	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.5	-5.51	-0.41	1.48e-7	Monocyte count;
PAAD	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.48	-4.38	-0.33	2.19e-5	Rheumatoid arthritis;
PAAD	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg27565382	chr3:53032988	SFMBT1	0.74	4.46	0.34	1.62e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.61	-6.54	-0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs11159086	0.793	rs10150696	chr14:74943426	C/A	cg10195687	chr14:74926396	NA	-0.48	-5.36	-0.4	3.02e-7	Advanced glycation end-product levels;
PAAD	cis	rs72960926	0.590	rs72959619	chr6:74995975	A/G	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.72e-10	Metabolite levels (MHPG);
PAAD	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.76	7.92	0.54	4.77e-13	Blood protein levels;
PAAD	cis	rs1419980	0.730	rs11054572	chr12:7729868	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.72	8.27	0.56	6.18e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.68	-8.98	-0.59	9.48e-16	Hemoglobin concentration;
PAAD	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg19090574	chr1:205240910	TMCC2	0.41	4.39	0.34	2.08e-5	Red blood cell count;
PAAD	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.98	-12.17	-0.7	3.13e-24	Refractive error;
PAAD	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01154392	chr12:48167362	SLC48A1	0.66	6.83	0.48	1.88e-10	Pancreatic cancer;
PAAD	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg14703610	chr5:56206110	C5orf35	0.61	5.54	0.41	1.3e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg05627522	chr15:75251581	NA	-0.52	-6.31	-0.46	2.95e-9	Caffeine consumption;
PAAD	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	5.97	0.44	1.58e-8	HIV-1 control;
PAAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	1.03	13.52	0.74	7.62e-28	Gestational age at birth (maternal effect);
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13939156	chr17:80058883	NA	-0.4	-4.26	-0.33	3.51e-5	Life satisfaction;
PAAD	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.48	-0.52	5.61e-12	Colorectal cancer;
PAAD	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.66	6.05	0.44	1.08e-8	Platelet count;
PAAD	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.66	6.67	0.48	4.54e-10	Depressive symptoms;
PAAD	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-4.64	-0.35	7.52e-6	Joint mobility (Beighton score);
PAAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.48	5.23	0.39	5.45e-7	Breast cancer;Mosquito bite size;
PAAD	cis	rs62408225	0.962	rs1604830	chr6:90969221	T/C	cg03795776	chr6:90687632	BACH2	0.43	4.3	0.33	3.09e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.7	-6.97	-0.49	9.18e-11	Morning vs. evening chronotype;
PAAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs881827	0.962	rs2839329	chr21:47984563	A/G	cg12016809	chr21:47604291	C21orf56	-0.47	-4.47	-0.34	1.5e-5	Lymphocyte counts;
PAAD	cis	rs66530629	0.874	rs9332415	chr1:25098245	T/C	cg22509179	chr1:25234806	RUNX3	-0.49	-4.54	-0.35	1.16e-5	Plateletcrit;
PAAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.92	7.51	0.52	4.62e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.58	-5.23	-0.39	5.64e-7	White blood cell count;
PAAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.57	4.27	0.33	3.42e-5	Fat distribution (HIV);
PAAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.67	-4.8	-0.36	3.73e-6	Depression;
PAAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.56	-6.78	-0.48	2.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13848568	chr1:45965625	CCDC163P;MMACHC	0.6	6.65	0.47	5.01e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.86	-9.68	-0.62	1.47e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.99	12.46	0.71	5.37e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.61	7.32	0.51	1.36e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9287719	0.674	rs12620209	chr2:10720441	T/C	cg00105475	chr2:10696890	NA	0.62	6.52	0.47	9.64e-10	Prostate cancer;
PAAD	cis	rs11031096	0.933	rs12292367	chr11:4131724	A/G	cg18678763	chr11:4115507	RRM1	0.42	4.35	0.33	2.44e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg05585544	chr11:47624801	NA	0.48	5.23	0.39	5.54e-7	Subjective well-being;
PAAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.82	-8.94	-0.59	1.24e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2286503	0.650	rs1990279	chr7:22890742	A/G	cg04907244	chr7:22894795	SNORD93	-0.42	-4.57	-0.35	1.02e-5	Fibrinogen;
PAAD	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.58	4.77	0.36	4.37e-6	Alzheimer's disease (cognitive decline);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02999463	chr8:37707322	BRF2	-0.79	-6.62	-0.47	5.77e-10	Neuroticism;
PAAD	cis	rs1499972	0.680	rs62264772	chr3:117647281	G/A	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-4.98	-0.37	1.72e-6	Diastolic blood pressure;
PAAD	cis	rs80282103	0.618	rs76068439	chr10:1121018	T/A	cg05228244	chr10:1102351	WDR37	1.03	4.53	0.34	1.21e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg00255919	chr5:131827918	IRF1	-0.6	-8.29	-0.56	5.65e-14	Asthma (sex interaction);
PAAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.83	-5.21	-0.39	5.96e-7	Tuberculosis;
PAAD	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg04450456	chr4:17643702	FAM184B	0.44	4.47	0.34	1.5e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3136739	0.681	rs7014440	chr8:41993474	C/T	cg12054981	chr8:42037387	PLAT	0.64	4.75	0.36	4.68e-6	Plasma plasminogen activator levels;
PAAD	cis	rs6834538	0.931	rs6854311	chr4:113545454	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.53	0.35	1.17e-5	Free thyroxine concentration;
PAAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg17775713	chr3:133465469	TF	0.5	5.71	0.42	5.86e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.62	8.12	0.55	1.48e-13	Renal cell carcinoma;
PAAD	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg02476566	chr12:106696527	TCP11L2	0.71	6.75	0.48	2.9e-10	Tourette syndrome;
PAAD	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg19640517	chr22:41707109	ZC3H7B	-0.48	-4.41	-0.34	1.98e-5	Vitiligo;
PAAD	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg08992911	chr2:238395768	MLPH	0.67	6.58	0.47	7.11e-10	Prostate cancer;
PAAD	cis	rs7264396	0.887	rs8116304	chr20:34054409	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.74	0.58	3.99e-15	Lung cancer;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.64	-0.42	7.97e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg13263323	chr15:86062960	AKAP13	-0.48	-4.89	-0.37	2.51e-6	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.56	5.52	0.41	1.42e-7	Osteoporosis;
PAAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg09796270	chr17:17721594	SREBF1	0.47	4.98	0.37	1.71e-6	Total body bone mineral density;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.9	12.77	0.72	7.97e-26	Vitiligo;
PAAD	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.65	-0.35	7.31e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.76	7.61	0.53	2.62e-12	Retinal vascular caliber;
PAAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs357618	1.000	rs165351	chr5:150854881	C/T	cg03212797	chr5:150827313	SLC36A1	-0.54	-4.92	-0.37	2.18e-6	Basophil percentage of white cells;
PAAD	cis	rs28830936	0.932	rs1105881	chr15:42072530	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-7.1	-0.5	4.38e-11	Diastolic blood pressure;
PAAD	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.75	8.52	0.57	1.44e-14	Airflow obstruction;
PAAD	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.99	-12.76	-0.72	8.17e-26	Systemic lupus erythematosus;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.72	9.66	0.62	1.65e-17	Iron status biomarkers;
PAAD	cis	rs11615916	0.722	rs17716977	chr12:62744750	A/G	cg11441379	chr12:63026424	NA	0.63	4.25	0.33	3.7e-5	Pulmonary function decline;
PAAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.49	-5.24	-0.39	5.3e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-5.04	-0.38	1.32e-6	Blood metabolite levels;
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.53	-6.98	-0.49	8.73e-11	Hypertriglyceridemia;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.16	-0.39	7.61e-7	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.03	0.38	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18308527	chr3:33481283	UBP1	-0.67	-6.67	-0.48	4.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.18e-12	Height;
PAAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-4.98	-0.37	1.74e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7591163	1.000	rs2135481	chr2:228706657	A/G	cg22994281	chr2:228029448	COL4A3;COL4A4	0.43	4.34	0.33	2.6e-5	Blood pressure;
PAAD	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	12.18	0.7	2.96e-24	Chronic sinus infection;
PAAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.42	5.33	0.4	3.47e-7	Ulcerative colitis;
PAAD	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.73	7.87	0.54	6.23e-13	Type 2 diabetes;
PAAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg21496419	chr19:44306685	LYPD5	0.37	4.66	0.35	6.96e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.79	5.08	0.38	1.11e-6	Systolic blood pressure;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72960926	1.000	rs56047394	chr6:75172828	T/C	cg03266952	chr6:74778945	NA	-1.28	-6.61	-0.47	6.06e-10	Metabolite levels (MHPG);
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.49	5.32	0.4	3.64e-7	Educational attainment;
PAAD	cis	rs1497828	0.956	rs2818976	chr1:217548956	A/C	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.22	0.67	1.19e-21	Menopause (age at onset);
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.2	-0.39	6.47e-7	Mean platelet volume;
PAAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg21698718	chr17:80085957	CCDC57	0.41	4.43	0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs12935418	0.616	rs9937731	chr16:81012303	C/A	cg16651780	chr16:81037892	C16orf61	0.65	5.97	0.44	1.6e-8	Mean corpuscular volume;
PAAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg09835421	chr16:68378352	PRMT7	-0.95	-7.34	-0.51	1.17e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.25	-0.56	6.88e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.82	-0.62	6.08e-18	Lung cancer;
PAAD	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg03030879	chr14:75389066	RPS6KL1	0.42	4.34	0.33	2.58e-5	Height;
PAAD	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.52	6.4	0.46	1.86e-9	Sitting height ratio;
PAAD	cis	rs1801239	0.867	rs74440730	chr10:16920892	A/C	cg00939682	chr10:16933505	CUBN	0.67	5.02	0.38	1.4e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.14	0.45	6.99e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.48	7.0	0.49	7.66e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.79	-9.15	-0.6	3.57e-16	Heart rate;
PAAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.88	10.84	0.66	1.2e-20	Methadone dose in opioid dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00552226	chr2:70475288	TIA1	0.68	7.71	0.53	1.5e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg22437258	chr11:111473054	SIK2	-0.59	-5.82	-0.43	3.41e-8	Primary sclerosing cholangitis;
PAAD	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.53	5.28	0.39	4.41e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.47	-0.41	1.85e-7	Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08754095	chr5:69783979	NA	0.54	6.51	0.47	1.01e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg04450456	chr4:17643702	FAM184B	0.48	5.06	0.38	1.22e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7765175	0.598	rs6929486	chr6:113656016	T/C	cg19037598	chr6:113666021	NA	-0.4	-4.37	-0.33	2.3e-5	Coronary artery calcification;
PAAD	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	6.3	0.46	3.04e-9	Schizophrenia;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg01815783	chr4:1047043	NA	-0.48	-4.55	-0.35	1.07e-5	Recombination rate (females);
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg17178900	chr1:205818956	PM20D1	0.46	4.53	0.35	1.16e-5	Parkinson's disease;
PAAD	cis	rs863345	0.604	rs11264991	chr1:158472861	T/G	cg12129480	chr1:158549410	OR10X1	-0.43	-5.04	-0.38	1.32e-6	Pneumococcal bacteremia;
PAAD	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.56	5.62	0.41	8.94e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.71	-5.12	-0.38	8.92e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-6.76	-0.48	2.81e-10	Breast cancer;
PAAD	cis	rs9287719	0.601	rs13427815	chr2:10707985	C/T	cg12757816	chr2:10669957	NA	-0.43	-4.42	-0.34	1.87e-5	Prostate cancer;
PAAD	trans	rs795484	0.856	rs1151900	chr12:118686282	A/G	cg06703803	chr12:110811045	ANAPC7	-0.59	-6.58	-0.47	7.23e-10	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00791764	chr4:53727839	RASL11B	0.63	4.57	0.35	1.01e-5	Optic nerve measurement (cup area);
PAAD	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.67	5.96	0.44	1.66e-8	Intelligence;Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05454323	chr22:42978119	RRP7B	0.59	6.33	0.46	2.59e-9	Obesity-related traits;
PAAD	trans	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg25214090	chr10:38739885	LOC399744	0.62	6.72	0.48	3.4e-10	Diastolic blood pressure;
PAAD	cis	rs2555155	0.837	rs2723631	chr11:6537730	A/G	cg10208301	chr11:6592745	DNHD1	0.42	4.27	0.33	3.41e-5	DNA methylation (variation);
PAAD	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.6	5.56	0.41	1.19e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg17986701	chr20:44574422	PCIF1	0.58	6.05	0.44	1.07e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.92	-10.48	-0.65	1.13e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.81	-8.88	-0.58	1.72e-15	Menopause (age at onset);
PAAD	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.69	-6.85	-0.49	1.7e-10	Triglycerides;
PAAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs61863408	0.925	rs12767127	chr10:127848780	C/T	cg03862225	chr10:126850454	CTBP2	0.64	4.8	0.36	3.8e-6	Itch intensity from mosquito bite;
PAAD	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg18171855	chr10:2543474	NA	0.42	4.28	0.33	3.31e-5	Age-related hearing impairment;
PAAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg14092988	chr3:52407081	DNAH1	0.45	5.44	0.4	2.12e-7	Bipolar disorder;
PAAD	cis	rs42648	0.564	rs39267	chr7:89771509	A/G	cg27367526	chr7:89841692	STEAP2	-0.31	-4.34	-0.33	2.61e-5	Homocysteine levels;
PAAD	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.76	8.64	0.57	7.11e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14180030	chr9:123475675	MEGF9	-0.44	-4.94	-0.37	2e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.77	-0.53	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.76	-8.7	-0.58	5.15e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg01631408	chr1:248437212	OR2T33	-0.62	-5.27	-0.39	4.63e-7	Common traits (Other);
PAAD	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.62	7.12	0.5	3.93e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg08835956	chr7:39171034	POU6F2	0.32	5.58	0.41	1.07e-7	IgG glycosylation;
PAAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21862992	chr11:68658383	NA	0.47	5.2	0.39	6.47e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7081476	0.737	rs7900533	chr10:27512553	C/T	cg20349793	chr10:26911186	NA	0.79	4.37	0.33	2.3e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.96	0.44	1.66e-8	Prudent dietary pattern;
PAAD	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	11.19	0.67	1.37e-21	Ulcerative colitis;
PAAD	cis	rs10276303	0.551	rs2614951	chr7:3581125	T/G	cg24872851	chr7:4265468	SDK1	0.43	4.47	0.34	1.55e-5	Dupuytren's disease;
PAAD	cis	rs727479	0.543	rs12900487	chr15:51523159	T/C	cg21478137	chr15:51532386	CYP19A1	0.54	5.25	0.39	4.96e-7	Estradiol levels;
PAAD	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg01329690	chr21:38580129	DSCR9	0.32	4.28	0.33	3.35e-5	Eye color traits;
PAAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.6	-6.01	-0.44	1.33e-8	Longevity;Endometriosis;
PAAD	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg02986791	chr19:1062178	ABCA7	-0.49	-4.3	-0.33	3.04e-5	Alzheimer's disease (late onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18993778	chr7:139313985	HIPK2	-0.66	-6.59	-0.47	6.98e-10	Obesity-related traits;
PAAD	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg20406979	chr6:167373233	NA	0.35	5.04	0.38	1.32e-6	Crohn's disease;
PAAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg21300403	chr2:198650112	BOLL	-0.64	-4.43	-0.34	1.79e-5	Ulcerative colitis;
PAAD	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.61	-6.78	-0.48	2.45e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.81	-8.92	-0.59	1.42e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.46	-4.69	-0.36	6.08e-6	Menarche (age at onset);
PAAD	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg05554000	chr7:158905015	VIPR2	-0.71	-5.07	-0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs12544026	0.609	rs16868698	chr8:102920513	A/G	cg13954531	chr8:103613429	NA	0.59	4.4	0.34	2.07e-5	Major depression and alcohol dependence;
PAAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg19192590	chr2:178524533	PDE11A	0.38	4.41	0.34	1.91e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15870184	chr7:99517151	TRIM4	-0.56	-6.4	-0.46	1.8e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg01426195	chr3:39028469	NA	0.63	6.31	0.46	2.92e-9	Handedness;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07833955	chr17:60349109	TBC1D3P2	-0.49	-6.42	-0.46	1.64e-9	Myopia (pathological);
PAAD	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12935418	0.616	rs9936366	chr16:81045262	A/G	cg16651780	chr16:81037892	C16orf61	0.65	6.13	0.45	7.13e-9	Mean corpuscular volume;
PAAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.47	-6.36	-0.46	2.26e-9	Childhood ear infection;
PAAD	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.63	6.1	0.44	8.43e-9	Coronary artery disease;
PAAD	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.83	5.36	0.4	2.97e-7	Systolic blood pressure;
PAAD	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg07541023	chr7:19748670	TWISTNB	0.61	4.26	0.33	3.54e-5	Thyroid stimulating hormone;
PAAD	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg19418318	chr19:17219073	MYO9B	0.41	5.36	0.4	3.06e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.72	10.14	0.64	8.95e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs11700980	0.551	rs2251445	chr21:30109148	G/A	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.87e-7	Bladder cancer;
PAAD	cis	rs10998941	0.591	rs2812541	chr10:71466637	A/C	cg26770870	chr10:71561502	COL13A1	0.47	4.3	0.33	3.02e-5	CSF tryptophan concentration in tuberculous meningitis;
PAAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.89	11.82	0.69	2.79e-23	Methadone dose in opioid dependence;
PAAD	cis	rs11581903	0.929	rs6679249	chr1:53050461	A/G	cg18087326	chr1:53067637	GPX7	0.56	5.23	0.39	5.48e-7	Joint mobility (Beighton score);
PAAD	cis	rs76917914	0.780	rs1059273	chr9:100849500	G/T	cg21225548	chr9:100864335	TRIM14	-0.54	-5.28	-0.39	4.42e-7	Immature fraction of reticulocytes;
PAAD	cis	rs13242816	1.000	rs34234085	chr7:116114066	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg08898775	chr15:59042684	ADAM10	-0.41	-5.36	-0.4	3.07e-7	Asperger disorder;
PAAD	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.26	0.33	3.51e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.74	8.36	0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.23e-26	Breast cancer;
PAAD	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.07	6.37	0.46	2.19e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
PAAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg15571903	chr15:79123663	NA	0.48	6.3	0.45	3.09e-9	Coronary artery disease;
PAAD	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg13698168	chr13:111522651	C13orf29	-0.52	-4.74	-0.36	4.96e-6	Sitting height ratio;
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.72	7.71	0.53	1.5e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.6	7.49	0.52	5.38e-12	Multiple system atrophy;
PAAD	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg15956490	chr3:53032818	SFMBT1	0.77	4.67	0.35	6.5e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg14393609	chr7:65229607	NA	-0.5	-4.35	-0.33	2.49e-5	Aortic root size;
PAAD	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg04450456	chr4:17643702	FAM184B	0.51	5.53	0.41	1.38e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg27395922	chr11:50257633	LOC441601	-0.41	-4.75	-0.36	4.74e-6	Height;
PAAD	cis	rs7624766	0.743	rs2886909	chr3:160542117	G/A	cg22637730	chr3:160473554	PPM1L	0.51	4.59	0.35	9.16e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-4.49	-0.34	1.39e-5	Bipolar disorder;
PAAD	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-6.89	-0.49	1.37e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2274459	1.000	rs12211554	chr6:33725788	C/A	cg06253072	chr6:33679850	C6orf125	0.67	4.78	0.36	4.17e-6	Obesity (extreme);
PAAD	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.51	-6.26	-0.45	3.78e-9	Rheumatoid arthritis;
PAAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg05484376	chr2:27715224	FNDC4	0.5	4.91	0.37	2.38e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg25037394	chr1:24152592	HMGCL	0.42	4.59	0.35	9.25e-6	Immature fraction of reticulocytes;
PAAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg18370025	chr7:2749541	AMZ1	-0.38	-4.52	-0.34	1.22e-5	Height;
PAAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg14926445	chr8:58193284	C8orf71	-0.65	-4.79	-0.36	3.87e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg04896959	chr15:78267971	NA	0.56	5.1	0.38	1.02e-6	Coronary artery disease or large artery stroke;
PAAD	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.07	8.64	0.57	7.05e-15	Corneal structure;
PAAD	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg00024416	chr22:24240387	NA	-0.55	-5.74	-0.42	5.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.51	6.53	0.47	9.19e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs77880822	0.562	rs79435587	chr20:1241915	T/C	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	6.79	0.48	2.32e-10	Mean platelet volume;
PAAD	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.53	5.02	0.38	1.45e-6	Red blood cell count;
PAAD	cis	rs71520386	0.632	rs9654968	chr7:22876316	C/T	cg04907244	chr7:22894795	SNORD93	0.5	5.34	0.4	3.39e-7	Fibrinogen levels;
PAAD	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg23254163	chr1:152506842	NA	0.54	6.29	0.45	3.27e-9	Hair morphology;
PAAD	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	1.01	10.54	0.65	7.62e-20	Blood trace element (Zn levels);
PAAD	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg04257695	chr17:30186438	C17orf79	-0.57	-4.31	-0.33	2.98e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.76	-6.42	-0.46	1.62e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg00988841	chr10:134556463	INPP5A	0.47	4.43	0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.44	-5.02	-0.38	1.43e-6	Blood pressure (smoking interaction);
PAAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg14024328	chr4:719362	PCGF3	-0.57	-5.83	-0.43	3.25e-8	White blood cell count;
PAAD	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.56	5.4	0.4	2.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.54	5.17	0.39	7.24e-7	Mortality in heart failure;
PAAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.85	5.45	0.4	2.02e-7	Body mass index;
PAAD	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-5.6	-0.41	9.79e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.67	7.3	0.51	1.51e-11	Melanoma;
PAAD	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.02	0.38	1.44e-6	Parkinson's disease;
PAAD	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.64	0.42	8.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	0.64	4.55	0.35	1.1e-5	Blood protein levels;
PAAD	cis	rs6679454	1.000	rs12141442	chr1:58361293	G/A	cg17491850	chr1:57888480	DAB1	-0.41	-4.7	-0.36	5.83e-6	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg21483461	chr5:81570383	RPS23	0.53	4.91	0.37	2.32e-6	Breast cancer;
PAAD	cis	rs1419980	0.730	rs11054608	chr12:7733687	G/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.86	9.35	0.6	1.08e-16	Coronary artery disease;
PAAD	cis	rs72960926	1.000	rs55813969	chr6:75099746	C/T	cg13997649	chr6:74171430	MTO1	0.78	4.4	0.34	2e-5	Metabolite levels (MHPG);
PAAD	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	9.06	0.59	6.14e-16	Colorectal cancer;
PAAD	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.74	-7.77	-0.53	1.1e-12	Cognitive function;
PAAD	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.6	5.26	0.39	4.72e-7	Retinal vascular caliber;
PAAD	cis	rs9463078	0.715	rs9296455	chr6:45236781	G/A	cg25276700	chr6:44698697	NA	-0.5	-5.58	-0.41	1.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	7.93	0.54	4.39e-13	Eotaxin levels;
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.48	-0.34	1.44e-5	Longevity;Endometriosis;
PAAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.09	0.5	4.64e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg00490450	chr3:139108681	COPB2	-0.66	-5.89	-0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.79	6.55	0.47	8.31e-10	Neutrophil percentage of white cells;
PAAD	cis	rs1075265	0.811	rs805322	chr2:54139895	C/T	cg04546899	chr2:54196757	PSME4	-0.32	-4.77	-0.36	4.2e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg02569219	chr17:2266849	SGSM2	-0.52	-4.4	-0.34	2.05e-5	Total body bone mineral density;
PAAD	cis	rs7301826	0.627	rs4334059	chr12:131314214	T/C	cg11011512	chr12:131303247	STX2	0.44	4.6	0.35	8.98e-6	Plasma plasminogen activator levels;
PAAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg14343924	chr8:8086146	FLJ10661	0.55	4.97	0.37	1.76e-6	Mood instability;
PAAD	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26306683	chr17:18585705	ZNF286B	0.51	4.89	0.37	2.54e-6	Educational attainment (years of education);
PAAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg23506979	chr15:79090958	ADAMTS7	0.25	4.3	0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.55	7.17	0.5	3.11e-11	Hypertriglyceridemia;
PAAD	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.8	7.35	0.51	1.12e-11	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23537865	chr3:159706591	IL12A	0.59	6.38	0.46	2e-9	Monocyte percentage of white cells;
PAAD	cis	rs13410504	0.730	rs13428512	chr2:134852419	T/G	cg00897703	chr2:135434956	TMEM163	-0.59	-4.28	-0.33	3.31e-5	Gestational age at birth in labor-initiated deliveries (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21075678	chr7:137557164	NA	-0.67	-6.66	-0.48	4.64e-10	Obesity-related traits;
PAAD	cis	rs300774	1.000	rs300778	chr2:111964	C/A	cg21211680	chr2:198530	NA	-0.58	-5.39	-0.4	2.61e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs3745621	0.963	rs8107443	chr19:47707427	T/G	cg24326880	chr19:47634349	SAE1	-0.54	-4.38	-0.33	2.21e-5	Lymphocyte counts;
PAAD	cis	rs4792901	0.802	rs79934399	chr17:41571961	C/T	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.95e-5	Dupuytren's disease;
PAAD	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg19217778	chr13:113420270	ATP11A	0.63	4.37	0.33	2.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.85	8.18	0.55	1.05e-13	Cognitive function;
PAAD	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.51	5.43	0.4	2.21e-7	Menopause (age at onset);
PAAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg25952890	chr19:58913133	NA	0.67	5.67	0.42	6.85e-8	Mean platelet volume;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.63	-0.57	7.66e-15	Body mass index;
PAAD	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.57	-6.51	-0.47	1.03e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs6494488	0.500	rs72742923	chr15:64855696	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.12	-0.38	9.25e-7	Pulmonary function;
PAAD	cis	rs1535500	0.967	rs10947804	chr6:39282036	T/C	cg03252829	chr6:39282164	KCNK17	-0.54	-5.52	-0.41	1.45e-7	Type 2 diabetes;
PAAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.33	-0.33	2.7e-5	Aortic root size;
PAAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.51e-9	Bipolar disorder;
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10274279	0.660	rs9638055	chr7:157379914	A/G	cg26886268	chr7:157387156	PTPRN2	-0.51	-4.61	-0.35	8.6e-6	Myopia (pathological);
PAAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.1	-0.7	5.01e-24	Obesity-related traits;
PAAD	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16262614	chr3:133464971	TF	0.48	5.48	0.41	1.71e-7	Iron status biomarkers;
PAAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.61	0.41	9.36e-8	Schizophrenia;
PAAD	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.5	4.39	0.34	2.12e-5	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg01503450	chr10:980765	NA	-0.52	-4.35	-0.33	2.44e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs2236267	0.661	rs2245688	chr14:88595873	G/A	cg18078958	chr14:88630771	NA	-0.52	-6.59	-0.47	6.7e-10	Food antigen IgG levels;
PAAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25833597	chr17:30823145	MYO1D	0.49	4.77	0.36	4.33e-6	Schizophrenia;
PAAD	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg00522288	chr12:125625016	AACS	-0.56	-5.79	-0.43	3.86e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	4.66	0.35	6.98e-6	Resting heart rate;
PAAD	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-5.77	-0.42	4.37e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg00431813	chr7:1051703	C7orf50	0.76	4.58	0.35	9.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg24699146	chr1:24152579	HMGCL	0.43	4.31	0.33	2.97e-5	Immature fraction of reticulocytes;
PAAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-1.05	-11.69	-0.69	6.48e-23	Cancer (pleiotropy);
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.5	5.14	0.38	8.27e-7	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02858214	chr3:182400605	NA	-0.79	-6.78	-0.48	2.46e-10	Neuroticism;
PAAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3784262	0.740	rs4646596	chr15:58300895	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-5.78	-0.42	4.05e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs59191668	0.502	rs2437128	chr15:62792131	G/A	cg12918536	chr15:62891943	NA	0.35	4.67	0.35	6.44e-6	Immature fraction of reticulocytes;
PAAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.58	-7.78	-0.53	1.03e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-4.79	-0.36	4e-6	Mean platelet volume;
PAAD	cis	rs58521262	0.556	rs289303	chr19:23169015	A/G	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-12.55	-0.71	3.03e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.55	-6.87	-0.49	1.52e-10	Atrioventricular conduction;
PAAD	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-1.07	-15.53	-0.78	3.58e-33	Height;
PAAD	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.14	0.6	3.74e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg05579037	chr7:27184853	NA	0.45	4.25	0.33	3.65e-5	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21178979	chr7:1889533	MAD1L1	0.4	4.42	0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.68	0.62	1.48e-17	Rheumatoid arthritis;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg09417038	chr21:47716443	C21orf57	0.59	6.41	0.46	1.76e-9	Testicular germ cell tumor;
PAAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.4	4.85	0.37	3.06e-6	Schizophrenia;
PAAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	8.48	0.57	1.79e-14	Menarche (age at onset);
PAAD	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2030114	1.000	rs2030114	chr16:51609947	A/G	cg03758633	chr16:51611768	NA	-0.56	-4.77	-0.36	4.21e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.62	-7.42	-0.52	7.66e-12	Non-substance related behavioral disinhibition;
PAAD	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-4.96	-0.37	1.9e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg18209359	chr17:80159595	CCDC57	0.47	4.73	0.36	5.09e-6	Life satisfaction;
PAAD	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.46	-0.57	2.04e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	6.01	0.44	1.32e-8	Lung cancer in ever smokers;
PAAD	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24655899	chr17:79519568	C17orf70	0.56	6.34	0.46	2.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg18612461	chr15:75251733	NA	-0.54	-5.1	-0.38	9.85e-7	Blood trace element (Zn levels);
PAAD	cis	rs6499755	0.768	rs31083	chr16:55362131	C/T	cg02859129	chr16:55357253	IRX6	0.37	5.16	0.39	7.47e-7	Hypospadias;
PAAD	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27099511	chr16:88729703	MGC23284;MVD	-0.9	-4.65	-0.35	7.03e-6	Hair color;
PAAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg14393609	chr7:65229607	NA	0.49	4.94	0.37	2.05e-6	Aortic root size;
PAAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs2834188	0.924	rs2834177	chr21:34676806	T/C	cg04842828	chr21:34696676	IFNAR1	0.48	4.68	0.35	6.36e-6	Narcolepsy;
PAAD	cis	rs4356203	0.905	rs17472886	chr11:17086167	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.88e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	cis	rs10426930	0.621	rs6510833	chr19:5008399	G/A	cg25246084	chr19:4971487	KDM4B	-0.46	-4.5	-0.34	1.34e-5	Monocyte percentage of white cells;
PAAD	cis	rs9810890	1.000	rs73198899	chr3:128566430	A/G	cg15676455	chr3:128564943	NA	-0.87	-4.88	-0.37	2.68e-6	Dental caries;
PAAD	cis	rs2013441	0.613	rs7215803	chr17:19998377	C/T	cg25070565	chr17:20044324	CYTSB	-0.45	-4.73	-0.36	5.07e-6	Obesity-related traits;
PAAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.6	-5.65	-0.42	7.7e-8	Blood metabolite levels;
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10819733	chr22:24237672	NA	0.52	5.33	0.4	3.41e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	7.19	0.5	2.78e-11	Colorectal cancer;
PAAD	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.47	4.7	0.36	5.86e-6	Schizophrenia;
PAAD	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11245990	chr11:68621969	NA	0.39	5.17	0.39	7.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.94	0.49	1.07e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg00459043	chr17:30771460	PSMD11	-0.53	-4.39	-0.34	2.12e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg13699009	chr12:122356056	WDR66	-0.46	-6.61	-0.47	6.08e-10	Mean corpuscular volume;
PAAD	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	cis	rs1015291	1.000	rs1358292	chr12:19991869	G/A	cg25401612	chr12:20009446	NA	-0.49	-4.69	-0.36	5.98e-6	Diastolic blood pressure;
PAAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.92	-6.8	-0.48	2.23e-10	Psoriasis vulgaris;
PAAD	cis	rs2092319	0.649	rs2744770	chr1:26059650	C/T	cg02327719	chr1:26185386	C1orf135	-0.9	-5.25	-0.39	4.97e-7	Nose morphology;
PAAD	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.5	-4.76	-0.36	4.54e-6	Crohn's disease;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26844909	chr10:21788134	NA	-0.35	-4.25	-0.33	3.66e-5	Monocyte percentage of white cells;
PAAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.73	8.86	0.58	2.01e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg14008862	chr17:28927542	LRRC37B2	0.8	6.0	0.44	1.38e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg11235426	chr6:292522	DUSP22	-0.75	-7.84	-0.54	7.37e-13	Menopause (age at onset);
PAAD	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.45	-4.99	-0.38	1.62e-6	Pneumonia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08216368	chr11:237063	SIRT3;PSMD13	0.6	6.84	0.49	1.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.63	5.67	0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg16447950	chr5:562315	NA	-0.47	-4.85	-0.37	3.06e-6	Obesity-related traits;
PAAD	cis	rs6679454	1.000	rs6670853	chr1:58352715	C/T	cg17491850	chr1:57888480	DAB1	-0.39	-4.32	-0.33	2.82e-5	Immune reponse to smallpox (secreted IL-10);
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	4.8	0.36	3.81e-6	Bipolar disorder;
PAAD	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg10761708	chr20:43804764	PI3	0.56	4.46	0.34	1.6e-5	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14008862	chr17:28927542	LRRC37B2	0.84	5.79	0.43	3.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	6.0	0.44	1.36e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.41	4.56	0.35	1.07e-5	Thyroid hormone levels;
PAAD	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.56	-5.23	-0.39	5.65e-7	Blood metabolite levels;
PAAD	cis	rs6494488	0.500	rs55960029	chr15:65047080	G/A	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.61	-5.84	-0.43	3.02e-8	Lymphocyte percentage of white cells;
PAAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18099408	chr3:52552593	STAB1	-0.51	-5.79	-0.43	3.91e-8	Hemoglobin concentration;
PAAD	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg17283838	chr1:93427260	FAM69A	-0.63	-5.85	-0.43	2.98e-8	Multiple sclerosis;
PAAD	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg17306686	chr7:157230923	NA	0.34	4.34	0.33	2.62e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.82	9.16	0.6	3.37e-16	Colorectal cancer;
PAAD	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.95	-0.49	9.9e-11	Systolic blood pressure;
PAAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.74	-7.52	-0.52	4.35e-12	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7873102	0.608	rs56100777	chr9:38008846	G/A	cg03528946	chr9:38069800	SHB	-0.5	-4.97	-0.37	1.77e-6	Brain structure;
PAAD	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	8.85	0.58	2.13e-15	Monocyte percentage of white cells;
PAAD	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-6.59	-0.47	6.63e-10	Body mass index;
PAAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.75	-6.37	-0.46	2.18e-9	Blood protein levels;
PAAD	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.47	-4.37	-0.33	2.26e-5	Neutrophil percentage of white cells;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.78	8.11	0.55	1.55e-13	Prostate cancer;
PAAD	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg12486944	chr17:80159399	CCDC57	0.53	4.68	0.36	6.17e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.92	11.07	0.67	2.92e-21	White blood cell count;
PAAD	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-11.53	-0.68	1.71e-22	Schizophrenia;
PAAD	cis	rs1274963	0.601	rs784503	chr3:39197731	A/G	cg02254461	chr3:39195904	CSRNP1	-0.58	-5.01	-0.38	1.46e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg07168214	chr17:7380112	ZBTB4	-0.62	-5.79	-0.42	3.96e-8	Androgen levels;
PAAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.83	0.58	2.32e-15	Lung cancer;
PAAD	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-6.07	-0.44	1e-8	Dental caries;
PAAD	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg08308459	chr2:38893161	GALM	-0.65	-4.34	-0.33	2.59e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg18612461	chr15:75251733	NA	-0.39	-4.26	-0.33	3.51e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00540400	chr15:79124168	NA	0.6	6.85	0.49	1.69e-10	Coronary artery disease;
PAAD	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs965469	0.857	rs6037523	chr20:3249463	A/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.71	6.49	0.47	1.12e-9	Coronary artery disease;
PAAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg26174226	chr8:58114915	NA	-0.65	-5.83	-0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.99	13.12	0.73	8.67e-27	Menopause (age at onset);
PAAD	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.18	-0.39	6.89e-7	High light scatter reticulocyte count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00552387	chr12:51477546	CSRNP2	0.54	6.53	0.47	9.12e-10	Monocyte percentage of white cells;
PAAD	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.8	9.66	0.62	1.65e-17	Height;
PAAD	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg14515779	chr1:101123966	NA	-0.54	-6.36	-0.46	2.29e-9	Monocyte count;
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg15181151	chr6:150070149	PCMT1	0.55	5.93	0.43	1.97e-8	Lung cancer;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.68	-7.83	-0.54	7.77e-13	Prudent dietary pattern;
PAAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg26727032	chr16:67993705	SLC12A4	-0.73	-6.19	-0.45	5.32e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs732765	0.734	rs12891243	chr14:75208656	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.54	-0.35	1.16e-5	Non-small cell lung cancer;
PAAD	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg10072921	chr12:121022843	NA	0.39	4.56	0.35	1.03e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.51	4.88	0.37	2.67e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.61	0.35	8.48e-6	Homocysteine levels;
PAAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.53	0.41	1.34e-7	Platelet count;
PAAD	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Osteoarthritis;
PAAD	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.76	5.85	0.43	2.88e-8	HDL cholesterol;
PAAD	cis	rs1667255	0.830	rs17660933	chr18:29155702	C/G	cg18808318	chr18:29669225	NA	0.52	5.01	0.38	1.53e-6	Retinol levels;
PAAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.6	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs7814319	0.833	rs13249716	chr8:97228412	G/T	cg20787634	chr8:97240163	UQCRB	-0.66	-6.93	-0.49	1.11e-10	Lung function (FVC);
PAAD	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.48	4.46	0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.92	-0.37	2.21e-6	Bipolar disorder;
PAAD	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.5	4.65	0.35	7.24e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.61	-6.11	-0.44	8.18e-9	Pancreatic cancer;
PAAD	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg25114630	chr15:101792522	CHSY1	-0.55	-4.93	-0.37	2.1e-6	Corneal structure;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.53	-0.41	1.36e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg08601574	chr20:25228251	PYGB	-0.52	-5.35	-0.4	3.22e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.48	-4.9	-0.37	2.48e-6	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.75	5.68	0.42	6.63e-8	Initial pursuit acceleration;
PAAD	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg26205652	chr12:48591994	NA	0.77	6.97	0.49	9.25e-11	Longevity (90 years and older);
PAAD	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg20243544	chr17:37824526	PNMT	0.51	4.44	0.34	1.72e-5	Self-reported allergy;
PAAD	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.74	0.48	3.1e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs17331151	0.505	rs7614424	chr3:52566354	C/T	cg27565382	chr3:53032988	SFMBT1	0.91	4.5	0.34	1.34e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.5e-5	Total body bone mineral density;
PAAD	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg15309053	chr8:964076	NA	0.46	5.14	0.39	8.16e-7	Schizophrenia;
PAAD	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	5.52	0.41	1.43e-7	Mean platelet volume;
PAAD	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.97	11.83	0.69	2.68e-23	Bone mineral density;
PAAD	cis	rs76793172	1.000	rs77461667	chr19:46341177	G/A	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.29e-8	Menopause (age at onset);
PAAD	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg20913747	chr6:44695427	NA	-0.71	-7.12	-0.5	4.05e-11	Total body bone mineral density;
PAAD	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg00579200	chr11:133705235	NA	-0.47	-5.24	-0.39	5.28e-7	Childhood ear infection;
PAAD	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-13.33	-0.73	2.38e-27	Coronary artery disease;
PAAD	cis	rs72901758	0.810	rs61740716	chr17:76244648	G/A	cg26068271	chr17:76253126	NA	0.56	5.45	0.4	2.01e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.62	6.18	0.45	5.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11161846	chr1:160990452	F11R	-0.61	-6.26	-0.45	3.8e-9	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.52	4.94	0.37	2e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.64	-5.75	-0.42	4.73e-8	Primary sclerosing cholangitis;
PAAD	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.53	5.01	0.38	1.48e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs559555	0.612	rs564310	chr2:31892342	C/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.25	-0.33	3.77e-5	Blood metabolite ratios;Blood metabolite levels;
PAAD	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.85	-6.98	-0.49	8.62e-11	Body mass index;
PAAD	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg20913747	chr6:44695427	NA	-0.69	-6.79	-0.48	2.41e-10	Total body bone mineral density;
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.68	0.58	5.55e-15	Exhaled nitric oxide output;
PAAD	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.83	8.06	0.55	2.09e-13	Vitamin D levels;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07234876	chr8:600039	NA	1.03	7.65	0.53	2.17e-12	IgG glycosylation;
PAAD	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.7	0.62	1.27e-17	Diabetic retinopathy;
PAAD	cis	rs1975974	0.590	rs113830378	chr17:21744147	G/C	cg18423549	chr17:21743878	NA	-0.66	-6.02	-0.44	1.27e-8	Psoriasis;
PAAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg15847926	chr7:2749597	AMZ1	-0.39	-4.71	-0.36	5.53e-6	Height;
PAAD	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.79	6.38	0.46	2.06e-9	HDL cholesterol;
PAAD	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg19787841	chr12:53845606	PCBP2	0.44	4.38	0.33	2.22e-5	Height;
PAAD	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs793571	0.662	rs964285	chr15:59170964	A/G	cg05156742	chr15:59063176	FAM63B	-0.64	-5.97	-0.44	1.58e-8	Schizophrenia;
PAAD	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.8	9.07	0.59	5.75e-16	Caffeine consumption;
PAAD	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs3018712	0.526	rs6591351	chr11:68487508	T/A	cg23009355	chr11:68451396	GAL	-0.44	-4.25	-0.33	3.75e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22182451	chr15:72486158	GRAMD2	-0.64	-6.53	-0.47	9.26e-10	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.28	0.45	3.46e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg14393609	chr7:65229607	NA	0.64	6.87	0.49	1.57e-10	Calcium levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23231729	chr1:151882143	THEM4	-0.64	-6.29	-0.45	3.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.64	7.0	0.49	7.82e-11	Hemoglobin concentration;
PAAD	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg17105886	chr17:28927953	LRRC37B2	0.66	4.44	0.34	1.74e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1997066	0.831	rs73340290	chr10:106813383	T/A	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg19257562	chr1:2043853	PRKCZ	-0.42	-5.06	-0.38	1.19e-6	Height;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs2019216	0.500	rs1877497	chr17:21940171	C/T	cg22648282	chr17:21454238	C17orf51	-0.52	-4.85	-0.37	3e-6	Pelvic organ prolapse;
PAAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg27478167	chr7:817139	HEATR2	0.7	5.35	0.4	3.18e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2133450	0.712	rs9867566	chr3:7368673	C/T	cg19930620	chr3:7340148	GRM7	-0.47	-5.23	-0.39	5.54e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.32	-10.27	-0.64	4.15e-19	Breast cancer;
PAAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.52	-5.67	-0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.43e-7	Type 2 diabetes;
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	5.28	0.39	4.44e-7	Menarche (age at onset);
PAAD	cis	rs7577696	0.695	rs212713	chr2:32457537	C/T	cg02381751	chr2:32503542	YIPF4	0.4	4.27	0.33	3.47e-5	Inflammatory biomarkers;
PAAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-4.73	-0.36	5.09e-6	Personality dimensions;
PAAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.11	0.38	9.35e-7	Common traits (Other);
PAAD	cis	rs10490913	1.000	rs17097528	chr10:120144304	G/T	cg04126427	chr10:120840676	EIF3A	-0.46	-4.79	-0.36	3.89e-6	Cancer;
PAAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.48	4.99	0.38	1.6e-6	Type 2 diabetes;
PAAD	cis	rs7714584	1.000	rs59321715	chr5:150313480	C/A	cg22134413	chr5:150180641	NA	1.09	6.76	0.48	2.76e-10	Crohn's disease;
PAAD	cis	rs7264396	0.887	rs6120951	chr20:34045191	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.73	5.16	0.39	7.57e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.99	-9.36	-0.6	9.96e-17	Dilated cardiomyopathy;
PAAD	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	5.0	0.38	1.53e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-7.65	-0.53	2.16e-12	Body mass index;
PAAD	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.51	-5.52	-0.41	1.4e-7	Lung cancer;
PAAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg14830002	chr1:247616686	OR2B11	0.69	5.77	0.42	4.29e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs3136739	0.614	rs8178893	chr8:42033913	C/T	cg12054981	chr8:42037387	PLAT	-0.75	-5.5	-0.41	1.58e-7	Plasma plasminogen activator levels;
PAAD	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.86	-8.11	-0.55	1.61e-13	Colorectal adenoma (advanced);
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg07234876	chr8:600039	NA	-1.01	-7.27	-0.51	1.8e-11	IgG glycosylation;
PAAD	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.36	4.42	0.34	1.84e-5	Response to Dalcetrapib treatment in acute coronary syndrome;
PAAD	cis	rs2790216	1.000	rs1550773	chr10:60044441	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg04257695	chr17:30186438	C17orf79	-0.63	-5.03	-0.38	1.38e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg03989125	chr22:38214979	NA	-0.53	-4.99	-0.38	1.65e-6	Glioblastoma;Glioma;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg26174226	chr8:58114915	NA	-0.6	-4.29	-0.33	3.2e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10988449	0.657	rs12335819	chr9:132395316	A/G	cg18327994	chr9:132372705	NA	-0.59	-4.29	-0.33	3.2e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.55	-5.24	-0.39	5.23e-7	Neuroticism;
PAAD	cis	rs6604026	0.656	rs2811594	chr1:93343282	A/G	cg13858687	chr1:93297071	RPL5	-0.48	-4.34	-0.33	2.58e-5	Multiple sclerosis;
PAAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-5.29	-0.39	4.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8077577	0.895	rs11658477	chr17:18044893	G/A	cg16794390	chr17:18148240	FLII	0.66	5.48	0.41	1.77e-7	Obesity-related traits;
PAAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.62	-5.76	-0.42	4.46e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-7.07	-0.5	5.28e-11	Gut microbiome composition (summer);
PAAD	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg04106633	chr4:1044584	NA	0.52	4.91	0.37	2.36e-6	Recombination rate (males);
PAAD	cis	rs7873102	0.654	rs6476669	chr9:37976663	C/T	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs4356203	0.870	rs7925692	chr11:17271122	A/G	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.24e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.49	5.17	0.39	7.16e-7	Eye color traits;
PAAD	cis	rs58521262	0.556	rs289324	chr19:23156905	A/G	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	4.77	0.36	4.31e-6	Height;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg02754945	chr1:152161885	NA	0.46	4.74	0.36	4.78e-6	Inflammatory skin disease;
PAAD	cis	rs939584	0.935	rs13391851	chr2:642467	A/G	cg14515364	chr2:636606	NA	0.47	4.28	0.33	3.26e-5	Body mass index;
PAAD	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg14146966	chr2:61757674	XPO1	0.42	5.22	0.39	5.88e-7	Tuberculosis;
PAAD	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg20607287	chr7:12443886	VWDE	-0.68	-6.15	-0.45	6.62e-9	Coronary artery disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04100724	chr12:92539208	BTG1	0.64	7.15	0.5	3.49e-11	Metabolite levels  (X-11787);
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs507080	0.736	rs642224	chr11:118570919	G/A	cg08498647	chr11:118550644	TREH	-0.39	-4.5	-0.34	1.35e-5	Serum metabolite levels;
PAAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-7.04	-0.5	6.29e-11	Immature fraction of reticulocytes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12784625	chr2:46524557	EPAS1	0.67	6.55	0.47	8.25e-10	Obesity-related traits;
PAAD	cis	rs4141404	0.737	rs5998058	chr22:32006408	C/T	cg02404636	chr22:31891804	SFI1	0.6	5.8	0.43	3.72e-8	Paclitaxel-induced neuropathy;
PAAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2229238	0.780	rs61698846	chr1:154504854	C/T	cg21262032	chr1:154437693	IL6R	-0.45	-4.79	-0.36	3.92e-6	Coronary heart disease;
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg14725641	chr11:61582763	MIR1908;FADS1	0.52	4.62	0.35	7.99e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.94	0.37	2.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6867913	1.000	rs6867913	chr5:141445980	C/T	cg23435118	chr5:141488016	NDFIP1	0.48	4.5	0.34	1.34e-5	Asthma;
PAAD	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.88	-0.37	2.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg27304813	chr3:120068385	LRRC58	0.57	6.41	0.46	1.74e-9	Metabolite levels  (X-11787);
PAAD	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.69	-6.71	-0.48	3.68e-10	Post bronchodilator FEV1;
PAAD	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg02353165	chr6:42928485	GNMT	0.61	5.39	0.4	2.58e-7	Blood protein levels;
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-6.18	-0.45	5.68e-9	Prudent dietary pattern;
PAAD	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-4.98	-0.37	1.7e-6	Mean platelet volume;
PAAD	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.55	-5.14	-0.38	8.24e-7	Coronary artery disease or large artery stroke;
PAAD	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	5.6	0.41	9.85e-8	Neuroticism;
PAAD	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.58	5.35	0.4	3.25e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.39	0.68	4e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs3764400	0.567	rs208011	chr17:46258345	A/G	cg10706073	chr17:46328419	SKAP1	1.07	6.33	0.46	2.65e-9	Body mass index;
PAAD	cis	rs11971779	0.680	rs6947215	chr7:139026638	A/G	cg07862535	chr7:139043722	LUC7L2	0.58	4.4	0.34	2.03e-5	Diisocyanate-induced asthma;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22162314	chr17:61951766	CSH2	-0.61	-6.29	-0.45	3.15e-9	Height;
PAAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg07148914	chr20:33460835	GGT7	-0.49	-4.74	-0.36	4.89e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03676636	chr4:99064102	C4orf37	-0.34	-6.18	-0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7580658	0.926	rs79789049	chr2:128145472	G/A	cg09760422	chr2:128146352	NA	-0.44	-7.58	-0.52	3.13e-12	Protein C levels;
PAAD	cis	rs73416724	0.610	rs111981370	chr6:43255380	G/T	cg17076780	chr6:43251928	TTBK1	0.71	5.89	0.43	2.39e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg15501526	chr10:2543763	NA	0.9	12.6	0.71	2.22e-25	Age-related hearing impairment;
PAAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.49	-4.76	-0.36	4.39e-6	Pulse pressure;
PAAD	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg04106633	chr4:1044584	NA	0.53	4.89	0.37	2.5e-6	Recombination rate (males);
PAAD	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.93	-0.37	2.15e-6	Pulmonary function;
PAAD	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs9463078	0.585	rs1629542	chr6:45158485	A/G	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.58	5.83	0.43	3.2e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.9	0.43	2.26e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg14345882	chr6:26364793	BTN3A2	0.73	5.01	0.38	1.52e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10905065	0.965	rs2244755	chr10:5754611	G/A	cg11519256	chr10:5708881	ASB13	0.5	4.27	0.33	3.44e-5	Menopause (age at onset);
PAAD	cis	rs11641365	0.651	rs2879902	chr16:88778133	C/A	cg00751100	chr16:88787639	FAM38A	0.44	4.31	0.33	2.97e-5	Autism spectrum disorder-related traits;
PAAD	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.76	-8.29	-0.56	5.55e-14	Neuroticism;
PAAD	cis	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg25886479	chr11:50257625	LOC441601	-0.39	-4.3	-0.33	3.07e-5	Height;
PAAD	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.54	5.22	0.39	5.66e-7	Essential tremor;
PAAD	cis	rs76917914	0.780	rs2417727	chr9:100846475	T/C	cg03040243	chr9:100819229	NANS	0.55	4.42	0.34	1.84e-5	Immature fraction of reticulocytes;
PAAD	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg00277334	chr10:82204260	NA	-0.55	-5.66	-0.42	7.22e-8	Post bronchodilator FEV1;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17392909	chr10:135187035	ECHS1	-0.66	-7.76	-0.53	1.15e-12	Body fat percentage;
PAAD	cis	rs375066	0.577	rs7508701	chr19:44312862	T/G	cg11993925	chr19:44307056	LYPD5	-0.43	-4.64	-0.35	7.32e-6	Breast cancer;
PAAD	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.64	6.17	0.45	5.86e-9	Cognitive test performance;
PAAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg00310523	chr12:86230176	RASSF9	0.51	5.72	0.42	5.53e-8	Major depressive disorder;
PAAD	cis	rs642743	0.967	rs569967	chr10:105942337	G/C	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.7	0.36	5.82e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.78	8.17	0.55	1.14e-13	Prostate cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04985097	chr5:74807689	COL4A3BP;POLK	0.71	6.78	0.48	2.45e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg09579323	chr1:150459698	TARS2	-0.46	-4.3	-0.33	2.99e-5	Migraine;
PAAD	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.86	-9.26	-0.6	1.82e-16	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19538885	chr2:45878667	PRKCE	0.7	6.97	0.49	8.87e-11	Obesity-related traits;
PAAD	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.76	6.89	0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg07061783	chr6:25882402	NA	-0.55	-5.48	-0.41	1.77e-7	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg15061591	chr7:98625706	SMURF1	-0.46	-4.25	-0.33	3.78e-5	Breast cancer;
PAAD	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.93	8.3	0.56	5.35e-14	Obesity-related traits;
PAAD	cis	rs2735839	0.573	rs266878	chr19:51359114	C/G	cg03162314	chr19:51600935	CTU1	0.51	4.26	0.33	3.56e-5	Prostate-specific antigen levels;Prostate cancer (SNP x SNP interaction);Elevated serum prostate-specific antigen levels in healthy men;Prostate cancer;
PAAD	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg03999872	chr20:62272968	STMN3	-0.73	-6.71	-0.48	3.71e-10	Atopic dermatitis;
PAAD	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.74	-0.42	4.91e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg09659197	chr4:152720779	NA	0.45	5.32	0.4	3.59e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.27	6.92	0.49	1.19e-10	Severe influenza A (H1N1) infection;
PAAD	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06850241	chr22:41845214	NA	0.55	5.05	0.38	1.24e-6	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18911861	chr6:42858743	C6orf226	0.57	6.5	0.47	1.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7301826	0.651	rs10744485	chr12:131298550	A/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg17848003	chr1:3704513	LRRC47	0.39	4.35	0.33	2.47e-5	Red cell distribution width;
PAAD	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.63	7.5	0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11414415	chr11:57069640	TNKS1BP1	0.64	7.68	0.53	1.84e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg01765077	chr12:122356316	WDR66	0.58	6.06	0.44	1.05e-8	Mean corpuscular volume;
PAAD	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12625057	0.541	rs12624940	chr20:57777894	C/T	cg17286326	chr20:57796491	ZNF831	0.71	4.25	0.33	3.76e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.72	-7.62	-0.53	2.53e-12	Age at first birth;
PAAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.96	-8.75	-0.58	3.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg00531865	chr16:30841666	NA	-0.51	-4.98	-0.37	1.74e-6	Dementia with Lewy bodies;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16025584	chr9:139887217	C9orf142	0.69	7.92	0.54	4.53e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7715811	1.000	rs9688222	chr5:13760906	C/A	cg07548982	chr5:13769939	DNAH5	-0.65	-6.33	-0.46	2.62e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10849004	1.000	rs10849005	chr12:4295871	C/T	cg03803796	chr12:3575061	NA	0.54	4.48	0.34	1.48e-5	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.63	6.6	0.47	6.62e-10	Resting heart rate;
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.12	-0.38	9.07e-7	Total body bone mineral density;
PAAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02187348	chr16:89574699	SPG7	0.47	4.25	0.33	3.72e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs12754538	0.687	rs10864363	chr1:8767311	G/T	cg06159269	chr1:8767347	RERE	-0.37	-4.25	-0.33	3.74e-5	Subjective well-being;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21445541	chr1:167424621	CD247	-0.61	-6.29	-0.45	3.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.81	8.65	0.57	6.72e-15	Prostate cancer;
PAAD	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02543470	chr2:105862877	NA	-0.51	-4.92	-0.37	2.18e-6	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-5.68	-0.42	6.6e-8	Prostate cancer;
PAAD	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.61	5.75	0.42	4.84e-8	Height;
PAAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15145965	chr22:50218605	BRD1	0.6	5.1	0.38	9.86e-7	Schizophrenia;
PAAD	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	6.25	0.45	3.86e-9	LDL cholesterol;
PAAD	cis	rs9398803	0.687	rs4549631	chr6:126966308	A/G	cg19875578	chr6:126661172	C6orf173	0.42	4.3	0.33	3.03e-5	Male-pattern baldness;
PAAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg17328665	chr1:7887199	PER3	-0.5	-4.81	-0.36	3.66e-6	Crohn's disease;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.76	5.44	0.4	2.1e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg16591659	chr17:78472290	NA	-0.49	-4.68	-0.35	6.37e-6	Fractional excretion of uric acid;
PAAD	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.28	-9.48	-0.61	4.8e-17	Blood pressure (smoking interaction);
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg04844267	chr4:1394941	NA	0.42	4.82	0.36	3.51e-6	Obesity-related traits;
PAAD	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.36	4.3	0.33	3.06e-5	Pulmonary function;
PAAD	cis	rs4959799	1.000	rs56026460	chr6:3291264	C/T	cg05283252	chr6:3273439	SLC22A23	0.71	4.32	0.33	2.82e-5	Survival in rectal cancer;
PAAD	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg00228799	chr9:131580591	ENDOG	0.64	6.43	0.46	1.58e-9	Blood metabolite levels;
PAAD	cis	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg00262122	chr8:11665843	FDFT1	0.53	4.67	0.35	6.63e-6	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13674574	chr14:64971270	ZBTB25;ZBTB1	0.68	7.37	0.51	1.04e-11	Myopia (pathological);
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg07212818	chr11:638076	DRD4	-0.7	-6.93	-0.49	1.13e-10	Systemic lupus erythematosus;
PAAD	cis	rs11618113	0.634	rs56359935	chr13:111182139	A/G	cg11688093	chr13:111178359	RAB20	-0.73	-4.56	-0.35	1.03e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg14343924	chr8:8086146	FLJ10661	-0.67	-5.67	-0.42	7.13e-8	Mood instability;
PAAD	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg20761395	chr17:511517	VPS53	0.7	7.84	0.54	7.39e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg07784872	chr16:85687041	KIAA0182	0.56	4.74	0.36	4.77e-6	Platelet distribution width;
PAAD	cis	rs950881	0.867	rs10197862	chr2:102966549	A/G	cg20060108	chr2:102954350	IL1RL1	0.59	4.64	0.35	7.5e-6	Allergy;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg27094323	chr7:1216898	NA	-0.54	-6.16	-0.45	6.33e-9	Longevity;Endometriosis;
PAAD	cis	rs593531	0.513	rs479968	chr11:74038274	C/G	cg23327896	chr11:73669290	DNAJB13	0.34	4.64	0.35	7.44e-6	Neuroticism;
PAAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.99	0.38	1.62e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg16606324	chr3:10149918	C3orf24	0.79	6.28	0.45	3.4e-9	Alzheimer's disease;
PAAD	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	1.11	17.49	0.82	3.2e-38	Colorectal adenoma (advanced);
PAAD	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.74	-6.79	-0.48	2.39e-10	Total body bone mineral density;
PAAD	cis	rs2030114	1.000	rs11863831	chr16:51613425	A/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21747090	chr2:27597821	SNX17	-0.44	-4.29	-0.33	3.12e-5	Total body bone mineral density;
PAAD	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03750407	chr11:67159770	RAD9A	0.66	6.97	0.49	9.07e-11	Myopia (pathological);
PAAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.76	8.72	0.58	4.52e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.56	5.17	0.39	7.41e-7	Resting heart rate;
PAAD	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.58	6.3	0.46	3.01e-9	Psychosis in Alzheimer's disease;
PAAD	cis	rs9535307	0.745	rs2181185	chr13:50311925	C/T	cg03658251	chr13:50265850	EBPL	0.83	5.67	0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.48	7.67	0.53	1.87e-12	Neuroticism;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.11	0.55	1.56e-13	Prudent dietary pattern;
PAAD	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.8	9.76	0.62	9.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs2120991	0.818	rs7139337	chr12:54294595	G/A	cg23795217	chr12:54812000	ITGA5	0.35	4.71	0.36	5.59e-6	Biliary atresia;
PAAD	cis	rs5758511	0.573	rs2267438	chr22:42237565	C/T	cg03131358	chr22:42195972	CCDC134	-0.48	-4.99	-0.37	1.65e-6	Birth weight;
PAAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-1.19	-11.54	-0.68	1.63e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg20592124	chr2:65290738	CEP68	0.47	4.54	0.35	1.13e-5	Pulse pressure;
PAAD	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.52e-9	Obesity-related traits;
PAAD	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.16	8.34	0.56	4.27e-14	Lymphocyte counts;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.55	5.7	0.42	5.97e-8	Longevity;Endometriosis;
PAAD	cis	rs9815354	1.000	rs9838965	chr3:41927938	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.85	-6.12	-0.44	7.66e-9	Ulcerative colitis;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-1.27	-9.43	-0.61	6.78e-17	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19334895	chr19:18942619	UPF1	0.6	6.36	0.46	2.26e-9	Myopia (pathological);
PAAD	cis	rs748404	0.534	rs489509	chr15:43586907	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.99	0.44	1.46e-8	Lung cancer;
PAAD	cis	rs6466055	0.777	rs10953470	chr7:104871892	G/T	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-4.74	-0.36	4.82e-6	Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3809060	0.959	rs2301251	chr11:32457985	G/T	cg27259320	chr11:32460587	WIT1	0.36	4.63	0.35	7.65e-6	Inguinal hernia;
PAAD	cis	rs642743	0.967	rs556292	chr10:105961957	C/T	cg03775802	chr10:105978702	MIR609;C10orf79	0.32	4.42	0.34	1.85e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.43	4.86	0.37	2.84e-6	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12560527	chr6:28186878	LOC222699	-0.69	-6.75	-0.48	2.97e-10	Lung cancer in ever smokers;
PAAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.86	-9.27	-0.6	1.7e-16	Menopause (age at onset);
PAAD	cis	rs4908768	0.657	rs12144099	chr1:8816175	G/A	cg00590817	chr1:8272081	NA	-0.36	-4.37	-0.33	2.27e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.27e-7	Life satisfaction;
PAAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.59	-8.01	-0.54	2.84e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg18769074	chr3:133464867	TF	0.4	4.6	0.35	8.68e-6	Iron status biomarkers;
PAAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg05564831	chr3:52568323	NT5DC2	-0.43	-4.4	-0.34	2.05e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.86	0.37	2.87e-6	Breast cancer;
PAAD	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.88	0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs7660520	0.623	rs4455461	chr4:183744854	G/A	cg04181038	chr4:183730758	NA	0.6	4.57	0.35	1.02e-5	Pediatric autoimmune diseases;
PAAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.73	-8.33	-0.56	4.32e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	8.97	0.59	1.04e-15	Motion sickness;
PAAD	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.76	6.53	0.47	9.16e-10	Chronic kidney disease;
PAAD	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs11676676	1.000	rs11681754	chr2:109770720	G/A	cg23046629	chr2:109745841	LOC100287216;SH3RF3	0.54	4.46	0.34	1.59e-5	Pediatric bone mineral density (spine);
PAAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.63	-7.13	-0.5	3.79e-11	Huntington's disease progression;
PAAD	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg09491104	chr22:46646882	C22orf40	-1.03	-6.06	-0.44	1.05e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs35955747	0.714	rs4820048	chr22:31854370	A/G	cg02404636	chr22:31891804	SFI1	-0.5	-5.09	-0.38	1.05e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20251008	chr1:161136045	PPOX	-0.66	-6.46	-0.46	1.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8005172	0.778	rs12879345	chr14:88463019	T/A	cg18078958	chr14:88630771	NA	0.48	5.66	0.42	7.25e-8	Parkinson's disease;
PAAD	cis	rs892961	1.000	rs2898646	chr17:75399117	A/G	cg05865280	chr17:75406074	SEPT9	0.69	9.57	0.61	2.9e-17	Airflow obstruction;
PAAD	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.48	4.42	0.34	1.89e-5	Diastolic blood pressure;
PAAD	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.55	-6.83	-0.48	1.9e-10	Educational attainment;
PAAD	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg22189786	chr22:42395067	WBP2NL	0.68	4.87	0.37	2.71e-6	Birth weight;
PAAD	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.47	4.41	0.34	1.95e-5	High light scatter reticulocyte count;
PAAD	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.65	6.06	0.44	1.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.71	6.04	0.44	1.16e-8	Type 2 diabetes;
PAAD	cis	rs2092319	0.649	rs2744781	chr1:26023077	C/T	cg02327719	chr1:26185386	C1orf135	-0.87	-4.97	-0.37	1.81e-6	Nose morphology;
PAAD	cis	rs279612	0.620	rs279619	chr8:122785676	G/A	cg15153412	chr8:121823462	SNTB1	-0.6	-4.31	-0.33	2.94e-5	Metabolite levels (5-HIAA);
PAAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg27539214	chr16:67997921	SLC12A4	-0.64	-4.92	-0.37	2.19e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1697938	0.634	rs1450657	chr5:40949776	T/G	cg17351974	chr5:40835760	RPL37	0.41	4.26	0.33	3.52e-5	Multiple system atrophy;
PAAD	cis	rs9469890	0.604	rs7754038	chr6:34505194	T/G	cg17674042	chr6:34482479	PACSIN1	-1.0	-6.66	-0.48	4.59e-10	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs1884136	0.908	rs6134068	chr20:10863048	A/T	cg12909741	chr20:10199469	SNAP25	-0.71	-4.68	-0.36	6.23e-6	Information processing speed;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.45	5.43	0.4	2.15e-7	Iron status biomarkers;
PAAD	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6976053	0.868	rs10953305	chr7:100492568	G/A	cg22425096	chr7:100417404	EPHB4	0.5	4.33	0.33	2.73e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs6574988	0.514	rs11625907	chr14:88625605	T/C	cg18078958	chr14:88630771	NA	-0.49	-4.3	-0.33	3.02e-5	Bipolar disorder;
PAAD	cis	rs2034088	0.930	rs9907540	chr17:448042	A/G	cg13332499	chr17:408570	NA	0.67	7.21	0.5	2.47e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg17551891	chr7:1960795	MAD1L1	-0.54	-4.9	-0.37	2.45e-6	Bipolar disorder;
PAAD	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.58	0.35	9.56e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.35	-0.51	1.16e-11	Diastolic blood pressure;
PAAD	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.66	6.51	0.47	1.01e-9	Obesity-related traits;
PAAD	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.67	-6.4	-0.46	1.84e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg06042504	chr8:55087323	NA	-0.77	-8.67	-0.58	6.01e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg16342193	chr10:102329863	NA	0.75	8.25	0.56	6.82e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg27565382	chr3:53032988	SFMBT1	0.72	4.31	0.33	2.96e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg01270228	chr10:1369114	ADARB2	-0.49	-4.25	-0.33	3.65e-5	Radiation response;
PAAD	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs73195822	0.667	rs7967278	chr12:111239011	C/T	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.27	-0.33	3.4e-5	Itch intensity from mosquito bite;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg05062148	chr1:25757186	TMEM57	-0.65	-6.44	-0.46	1.47e-9	Dental caries;
PAAD	cis	rs8067545	0.640	rs10083840	chr17:19965972	A/G	cg13482628	chr17:19912719	NA	0.55	5.25	0.39	5.08e-7	Schizophrenia;
PAAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg00579200	chr11:133705235	NA	-0.46	-4.99	-0.38	1.64e-6	Childhood ear infection;
PAAD	cis	rs2412208	0.796	rs4500344	chr1:7090814	G/T	cg26570804	chr1:6352357	ACOT7	0.59	5.5	0.41	1.54e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-5.59	-0.41	1.03e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.62	9.4	0.61	7.8e-17	Asthma (sex interaction);
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs57244997	0.725	rs7746052	chr6:162436267	G/A	cg17173639	chr6:162384350	PARK2	-0.63	-4.75	-0.36	4.63e-6	Mosquito bite size;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.59	-5.5	-0.41	1.56e-7	Menarche (age at onset);
PAAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.58	0.61	2.62e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.59	6.58	0.47	7.04e-10	Iron status biomarkers;
PAAD	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	1.21	7.28	0.51	1.7e-11	Severe influenza A (H1N1) infection;
PAAD	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs10958605	0.702	rs1823964	chr8:40038193	A/G	cg14545590	chr8:40388592	ZMAT4	-0.4	-4.53	-0.35	1.16e-5	Parkinson's disease (motor and cognition);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26126750	chr3:195809198	TFRC	0.59	6.41	0.46	1.7e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.66	-6.41	-0.46	1.72e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg03676636	chr4:99064102	C4orf37	0.25	4.38	0.34	2.16e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.71	0.77	5.07e-31	Chronic sinus infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06158533	chr10:104221034	TMEM180	0.57	6.35	0.46	2.32e-9	Monocyte percentage of white cells;
PAAD	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg09796270	chr17:17721594	SREBF1	0.45	5.25	0.39	5.03e-7	Total body bone mineral density;
PAAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.26	-0.33	3.6e-5	Life satisfaction;
PAAD	cis	rs3779195	0.591	rs77968419	chr7:97866480	G/A	cg24562669	chr7:97807699	LMTK2	-0.55	-4.79	-0.36	3.91e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs9314614	0.789	rs4840640	chr8:6712688	A/G	cg27319216	chr8:6693540	XKR5	-0.4	-5.34	-0.4	3.26e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10912509	chr3:193789070	NA	0.56	6.3	0.46	3.08e-9	Monocyte percentage of white cells;
PAAD	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.4	-4.95	-0.37	1.99e-6	Corneal astigmatism;
PAAD	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg22153407	chr1:230290089	GALNT2	0.48	4.77	0.36	4.25e-6	Coronary artery disease;
PAAD	cis	rs501120	0.810	rs683297	chr10:44746140	A/G	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1358748	0.555	rs7528804	chr1:67593819	C/T	cg02640540	chr1:67518911	SLC35D1	0.68	4.51	0.34	1.28e-5	Tuberculosis;
PAAD	cis	rs375066	0.762	rs10424336	chr19:44392100	C/T	cg21496419	chr19:44306685	LYPD5	0.42	4.88	0.37	2.7e-6	Breast cancer;
PAAD	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg01851573	chr8:8652454	MFHAS1	-0.47	-4.8	-0.36	3.8e-6	Parkinson's disease;
PAAD	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	0.78	5.29	0.39	4.27e-7	Body mass index;
PAAD	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.71	7.68	0.53	1.79e-12	Platelet distribution width;
PAAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg17372223	chr3:52568218	NT5DC2	-0.54	-5.36	-0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg20243544	chr17:37824526	PNMT	-0.49	-4.25	-0.33	3.7e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg14092988	chr3:52407081	DNAH1	0.46	5.62	0.41	9.01e-8	Bipolar disorder;
PAAD	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs761746	0.960	rs7289075	chr22:32013745	T/C	cg01338084	chr22:32026380	PISD	0.5	4.48	0.34	1.46e-5	Intelligence;
PAAD	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg20917491	chr3:195578259	NA	0.56	6.11	0.44	7.82e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs9810890	1.000	rs116835720	chr3:128547280	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.63	0.42	8.58e-8	Major depressive disorder;
PAAD	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg14092988	chr3:52407081	DNAH1	0.39	4.81	0.36	3.53e-6	Electroencephalogram traits;
PAAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00152838	chr16:24741724	TNRC6A	-0.52	-4.38	-0.33	2.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.833	rs62109218	chr19:21528861	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg20891558	chr2:74357851	NA	0.95	9.78	0.62	8.14e-18	Gestational age at birth (maternal effect);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11793701	chr2:206547163	NRP2	0.64	7.45	0.52	6.65e-12	Monocyte percentage of white cells;
PAAD	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.41	0.4	2.4e-7	Lung cancer in ever smokers;
PAAD	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	4.61	0.35	8.31e-6	Thyroid stimulating hormone;
PAAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.4	-0.46	1.86e-9	Neuroticism;
PAAD	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.68	6.62	0.47	5.8e-10	Response to antidepressants and depression;
PAAD	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	1.05	6.62	0.47	5.75e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	0.8	5.2	0.39	6.39e-7	Body mass index;
PAAD	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.46e-7	Crohn's disease;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3784262	0.715	rs1994927	chr15:58347949	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-5.88	-0.43	2.49e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11853189	0.938	rs2090679	chr15:78596906	A/G	cg22935921	chr15:78556834	DNAJA4	0.76	5.13	0.38	8.54e-7	Red cell distribution width;
PAAD	cis	rs3736757	1.000	rs9425633	chr1:184657251	T/C	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs11020478	0.599	rs11020470	chr11:93394286	T/A	cg10523193	chr11:93463762	SNORA25	0.43	4.44	0.34	1.73e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.61	-5.85	-0.43	2.87e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.72	7.78	0.53	1.01e-12	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs501120	1.000	rs620828	chr10:44760958	A/G	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4417704	0.526	rs4130554	chr2:241881642	G/A	cg04034577	chr2:241836375	C2orf54	-0.33	-4.4	-0.34	2e-5	Joint mobility (Beighton score);
PAAD	cis	rs41271473	0.687	rs12078883	chr1:228875567	C/T	cg10167378	chr1:228756711	NA	0.53	4.58	0.35	9.72e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.27	-0.39	4.64e-7	Schizophrenia;
PAAD	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.73	0.36	5.16e-6	Serum sulfate level;
PAAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.53	-5.98	-0.44	1.54e-8	Lung cancer;
PAAD	cis	rs73019876	0.502	rs8107039	chr19:22238990	G/A	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-8.68	-0.58	5.66e-15	Total body bone mineral density;
PAAD	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.66	5.28	0.39	4.49e-7	Prostate cancer;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	7.73	0.53	1.34e-12	Height;
PAAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.84	-0.48	1.84e-10	Lymphocyte counts;
PAAD	cis	rs27434	0.583	rs151954	chr5:96157689	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	cis	rs3781663	1.000	rs10160639	chr11:69999122	A/C	cg06393558	chr11:69982916	ANO1	-0.42	-4.52	-0.34	1.23e-5	Survival in rectal cancer;
PAAD	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.55	-5.41	-0.4	2.43e-7	Educational attainment (years of education);
PAAD	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.04	-6.83	-0.48	1.93e-10	Body mass index;
PAAD	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.5	4.63	0.35	7.83e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.18	-0.5	2.83e-11	Personality dimensions;
PAAD	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.58	0.35	9.57e-6	Hepatocellular carcinoma;
PAAD	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg07741184	chr6:167504864	NA	0.37	4.48	0.34	1.48e-5	Crohn's disease;
PAAD	cis	rs2456568	0.695	rs55756119	chr11:93689909	A/G	cg19264203	chr11:92714893	MTNR1B	-0.43	-4.88	-0.37	2.63e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7688540	0.800	rs9328738	chr4:278196	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.46	-4.59	-0.35	9.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.48	-4.27	-0.33	3.46e-5	Obesity-related traits;
PAAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.14	-0.38	8.27e-7	Ulcerative colitis;
PAAD	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg02250501	chr15:90694978	NA	-0.47	-4.38	-0.33	2.24e-5	Rheumatoid arthritis;
PAAD	cis	rs6142102	0.961	rs4911407	chr20:32683565	C/A	cg06115741	chr20:33292138	TP53INP2	0.53	4.35	0.33	2.49e-5	Skin pigmentation;
PAAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.81	-0.48	2.16e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7923609	0.905	rs7088799	chr10:65016174	T/G	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.34	-0.33	2.58e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3018712	0.650	rs10791990	chr11:68445573	G/A	cg02340541	chr11:68451699	GAL	-0.61	-5.12	-0.38	8.94e-7	Total body bone mineral density;
PAAD	cis	rs6499755	0.768	rs31096	chr16:55367403	T/C	cg02859129	chr16:55357253	IRX6	0.37	5.16	0.39	7.5e-7	Hypospadias;
PAAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.82	-0.43	3.37e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05628107	chr10:89419384	PAPSS2	0.66	6.48	0.47	1.19e-9	Obesity-related traits;
PAAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg13866156	chr1:1669148	SLC35E2	-0.75	-8.52	-0.57	1.48e-14	Body mass index;
PAAD	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg25828445	chr12:7781288	NA	0.76	5.48	0.41	1.69e-7	HDL cholesterol levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11025519	chr12:124119657	GTF2H3;EIF2B1	0.68	7.4	0.51	8.41e-12	Smoking initiation;
PAAD	cis	rs1018697	1.000	rs11191397	chr10:104558274	C/A	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.33	-0.33	2.68e-5	Colorectal adenoma (advanced);
PAAD	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg15208524	chr1:10270712	KIF1B	0.48	4.3	0.33	2.99e-5	Hepatocellular carcinoma;
PAAD	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg20742385	chr13:113633654	MCF2L	-0.46	-4.66	-0.35	6.74e-6	Systolic blood pressure;
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.63	-6.58	-0.47	7.11e-10	Lymphocyte counts;
PAAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.53	5.36	0.4	3e-7	Parkinson's disease;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.47	-4.7	-0.36	5.84e-6	Inflammatory skin disease;
PAAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	5.97	0.44	1.58e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	5.64	0.42	7.97e-8	Alzheimer's disease;
PAAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.94	0.37	2.03e-6	Childhood ear infection;
PAAD	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg13565585	chr5:132299512	AFF4	0.51	4.98	0.37	1.71e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.59	-5.22	-0.39	5.92e-7	Systemic lupus erythematosus;
PAAD	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.67	5.99	0.44	1.48e-8	Vitamin D levels;
PAAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	4.82	0.36	3.51e-6	Blood protein levels;
PAAD	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.56	7.66	0.53	2.05e-12	IgA nephropathy;
PAAD	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	cis	rs6785206	0.554	rs12054283	chr3:128505829	A/G	cg19205850	chr3:128446370	RAB7A	0.67	5.15	0.39	7.95e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.41	4.62	0.35	7.96e-6	IgG glycosylation;
PAAD	cis	rs4356203	0.846	rs1685932	chr11:17223903	G/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.46	-0.34	1.57e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg01763666	chr17:80159506	CCDC57	-0.45	-4.58	-0.35	9.62e-6	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01839850	chr22:38240395	ANKRD54;MIR658	0.6	6.42	0.46	1.61e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg23920097	chr1:209922102	NA	0.51	4.92	0.37	2.25e-6	Red blood cell count;
PAAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.5	5.02	0.38	1.41e-6	Menopause (age at onset);
PAAD	cis	rs7188861	0.768	rs243315	chr16:11385011	C/T	cg01510278	chr16:11456238	NA	0.44	4.68	0.36	6.21e-6	HDL cholesterol;
PAAD	cis	rs12612619	0.732	rs7560595	chr2:27229372	C/G	cg00617064	chr2:27272375	NA	-0.48	-5.11	-0.38	9.44e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7688540	0.511	rs6841415	chr4:197383	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.59	4.91	0.37	2.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.61	6.1	0.44	8.31e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.71	-7.1	-0.5	4.5e-11	Total body bone mineral density;
PAAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.3	0.45	3.07e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.33	-4.42	-0.34	1.87e-5	Vitiligo;
PAAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	8.72	0.58	4.44e-15	Exhaled nitric oxide output;
PAAD	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-6.69	-0.48	4.08e-10	Colorectal cancer;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21788624	chr2:20251350	LAPTM4A	0.65	6.35	0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs73419609	1.000	rs11630671	chr15:54724142	C/A	cg11288833	chr15:55489084	RSL24D1	-0.98	-4.29	-0.33	3.22e-5	Post-traumatic stress disorder;
PAAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg12072164	chr19:44306565	LYPD5	0.48	5.01	0.38	1.52e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.77	9.12	0.59	4.16e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs10901513	0.932	rs3812683	chr10:127675607	A/C	cg22975853	chr10:127789788	ADAM12	0.43	4.62	0.35	8.21e-6	Visceral fat;
PAAD	cis	rs10916814	0.959	rs2101731	chr1:20901922	G/A	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.51	-5.91	-0.43	2.19e-8	Testicular germ cell tumor;
PAAD	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	5.36	0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs731174	0.802	rs609437	chr1:38184316	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.41	-4.98	-0.37	1.74e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.52	-5.55	-0.41	1.23e-7	Bladder cancer;
PAAD	cis	rs2387326	1.000	rs12252465	chr10:129932395	G/A	cg16087940	chr10:129947807	NA	-0.51	-4.34	-0.33	2.6e-5	Select biomarker traits;
PAAD	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.07	-0.55	2.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg16576597	chr16:28551801	NUPR1	-0.63	-7.01	-0.49	7.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.78	-0.48	2.44e-10	Life satisfaction;
PAAD	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.16e-8	Total body bone mineral density;
PAAD	cis	rs7684253	0.548	rs62308071	chr4:57716886	C/T	cg24291500	chr4:57773398	REST	-0.45	-4.74	-0.36	4.92e-6	Migraine;
PAAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.52	-5.92	-0.43	2.04e-8	Prostate cancer;
PAAD	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	trans	rs901683	0.702	rs77676696	chr10:45967258	A/G	cg13065504	chr15:42448234	PLA2G4F	0.82	6.41	0.46	1.72e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.65	0.42	7.53e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs8099014	1.000	rs7234602	chr18:56111593	G/T	cg12907477	chr18:56117327	MIR122	0.52	4.25	0.33	3.74e-5	Platelet count;
PAAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.84	5.41	0.4	2.36e-7	Diabetic kidney disease;
PAAD	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg16576597	chr16:28551801	NUPR1	0.77	8.04	0.55	2.4e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg00490450	chr3:139108681	COPB2	-0.66	-5.89	-0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs12476592	0.602	rs262482	chr2:63877042	C/T	cg10828910	chr2:63850056	LOC388955	0.52	4.58	0.35	9.5e-6	Childhood ear infection;
PAAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.59	-6.91	-0.49	1.26e-10	Immature fraction of reticulocytes;
PAAD	cis	rs10821973	0.527	rs10733770	chr10:63982386	C/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	trans	rs901683	1.000	rs12779976	chr10:46042932	C/T	cg23720331	chr10:123873670	TACC2	0.83	6.45	0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs899997	1.000	rs1904920	chr15:79029587	C/T	cg22753661	chr15:79092743	ADAMTS7	0.53	4.48	0.34	1.46e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs7508679	0.692	rs10413734	chr19:7227871	T/G	cg00428638	chr19:7224713	INSR	-0.51	-5.18	-0.39	6.9e-7	Hypothyroidism;
PAAD	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16083429	chr3:49237500	CCDC36	-0.46	-5.17	-0.39	7.26e-7	Menarche (age at onset);
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22162314	chr17:61951766	CSH2	-0.6	-6.2	-0.45	5.05e-9	Height;
PAAD	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.64	-0.35	7.47e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26330133	chr20:35089838	DLGAP4	-0.66	-8.06	-0.55	2.14e-13	Body fat percentage;
PAAD	cis	rs10450586	0.863	rs1478690	chr11:27295878	A/G	cg10370305	chr11:27303972	NA	-0.36	-4.33	-0.33	2.73e-5	Total body bone mineral density;
PAAD	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg15956490	chr3:53032818	SFMBT1	0.77	4.37	0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7714584	1.000	rs77698001	chr5:150250367	C/T	cg22134413	chr5:150180641	NA	0.78	5.48	0.41	1.7e-7	Crohn's disease;
PAAD	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg23153227	chr6:27725408	NA	0.43	4.29	0.33	3.21e-5	Depression;
PAAD	cis	rs10186876	0.665	rs35813524	chr2:44133774	C/G	cg09541576	chr2:44873248	C2orf34	-0.47	-4.72	-0.36	5.23e-6	Hand grip strength;
PAAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.48	4.6	0.35	8.73e-6	Body mass index;
PAAD	cis	rs797680	0.964	rs2296558	chr1:93736555	C/T	cg04535902	chr1:92947332	GFI1	-0.45	-4.39	-0.34	2.14e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg06606381	chr12:133084897	FBRSL1	-1.48	-9.34	-0.6	1.11e-16	Breast cancer;
PAAD	cis	rs4834770	1.000	rs878375	chr4:120237574	T/C	cg09307838	chr4:120376055	NA	0.55	5.26	0.39	4.85e-7	Blood protein levels;
PAAD	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.73	10.6	0.65	5.33e-20	Breast cancer;
PAAD	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.54	-4.36	-0.33	2.4e-5	Diastolic blood pressure;
PAAD	cis	rs12760731	0.720	rs16852801	chr1:178403134	A/T	cg00404053	chr1:178313656	RASAL2	-0.69	-5.04	-0.38	1.31e-6	Obesity-related traits;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg11764359	chr7:65958608	NA	0.77	5.18	0.39	6.91e-7	Diabetic kidney disease;
PAAD	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg21546286	chr11:48923668	NA	-0.45	-4.74	-0.36	4.86e-6	HDL cholesterol;
PAAD	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg10006428	chr1:248814059	OR2T27	0.42	4.9	0.37	2.43e-6	Common traits (Other);
PAAD	cis	rs10814247	1.000	rs10814247	chr9:35507290	C/T	cg18130437	chr9:35658183	CCDC107;RMRP	0.42	4.32	0.33	2.77e-5	Psoriasis;
PAAD	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.75	5.38	0.4	2.81e-7	Carotid intima media thickness;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16988970	chr17:42248062	ASB16	0.36	5.17	0.39	7.25e-7	Total body bone mineral density;
PAAD	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.46	-5.42	-0.4	2.32e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs7300001	0.667	rs7298716	chr12:110506181	A/T	cg12870014	chr12:110450643	ANKRD13A	0.95	5.84	0.43	3.04e-8	Headache;
PAAD	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.62	6.46	0.46	1.33e-9	Testicular germ cell tumor;
PAAD	cis	rs9287604	1.000	rs4663675	chr2:237785907	C/G	cg15065627	chr2:237796583	NA	-0.53	-4.33	-0.33	2.71e-5	White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.79	-9.93	-0.63	3.29e-18	Vitiligo;
PAAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.72	6.21	0.45	4.79e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.63e-11	Eye color traits;
PAAD	cis	rs57920188	0.585	rs12127463	chr1:4079127	C/T	cg20703997	chr1:4087676	NA	0.49	4.41	0.34	1.97e-5	Interleukin-17 levels;
PAAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg03605463	chr16:89740564	NA	-0.52	-4.79	-0.36	3.96e-6	Vitiligo;
PAAD	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.39	4.9	0.37	2.47e-6	Pulmonary function;
PAAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.16	0.45	6.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	7.65	0.53	2.12e-12	Mean platelet volume;
PAAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.61	-5.31	-0.4	3.76e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg20406979	chr6:167373233	NA	0.37	4.82	0.36	3.51e-6	Crohn's disease;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.28	0.81	1.06e-37	Height;
PAAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.68	6.54	0.47	8.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11650494	0.710	rs2233666	chr17:47484286	T/C	cg08112188	chr17:47440006	ZNF652	1.71	7.81	0.53	8.87e-13	Prostate cancer;
PAAD	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	6.4	0.46	1.83e-9	Adiposity;
PAAD	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26926768	chr12:34528122	NA	0.4	4.95	0.37	1.95e-6	Morning vs. evening chronotype;
PAAD	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.83	0.48	1.89e-10	IgG glycosylation;
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09826364	chr7:158789723	NA	-0.42	-5.44	-0.4	2.07e-7	Facial morphology (factor 20);
PAAD	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.53	-5.67	-0.42	6.95e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg18515171	chr17:58156344	HEATR6	-0.7	-7.26	-0.51	1.92e-11	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs3857067	1.000	rs7694820	chr4:95017026	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-5.42	-0.4	2.34e-7	QT interval;
PAAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg03060546	chr3:49711283	APEH	0.48	4.36	0.33	2.38e-5	Parkinson's disease;
PAAD	cis	rs943466	1.000	rs12524768	chr6:33760478	G/A	cg04704449	chr6:33738291	NA	-0.46	-4.86	-0.37	2.96e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg21351543	chr2:191399470	TMEM194B	-0.7	-5.29	-0.39	4.1e-7	Diastolic blood pressure;
PAAD	cis	rs1018697	0.966	rs11191396	chr10:104552865	A/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.29	-0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.9	10.95	0.66	6.04e-21	Metabolic syndrome;
PAAD	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.62	6.12	0.44	7.62e-9	Pancreatic cancer;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg15117754	chr3:10150083	C3orf24	0.67	5.59	0.41	1e-7	Alzheimer's disease;
PAAD	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-4.89	-0.37	2.49e-6	Body mass index;
PAAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.69	0.42	6.32e-8	Alzheimer's disease;
PAAD	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg00944433	chr1:107599041	PRMT6	-0.44	-5.08	-0.38	1.1e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-1.21	-9.9	-0.63	3.79e-18	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08324950	chr19:1315962	NA	0.59	6.49	0.47	1.12e-9	Myopia (pathological);
PAAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.57	7.21	0.51	2.4e-11	Schizophrenia;
PAAD	cis	rs17155006	0.718	rs370533	chr7:107746215	G/C	cg05962710	chr7:107745446	LAMB4	-0.55	-7.22	-0.51	2.35e-11	Pneumococcal bacteremia;
PAAD	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg14851346	chr12:38532713	NA	-0.48	-4.63	-0.35	7.95e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg17372223	chr3:52568218	NT5DC2	0.55	5.51	0.41	1.52e-7	Bipolar disorder;
PAAD	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg10985347	chr2:127963512	CYP27C1	-0.49	-4.73	-0.36	5.02e-6	Protein C levels;
PAAD	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-8.66	-0.57	6.46e-15	Corneal structure;
PAAD	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.82	-6.11	-0.44	7.94e-9	Coronary artery calcification;
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.47	5.22	0.39	5.8e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs288342	0.797	rs288332	chr2:183625350	C/T	cg02625481	chr2:183667124	NA	-0.45	-4.55	-0.35	1.1e-5	Recurrent major depressive disorder;
PAAD	cis	rs9463078	0.585	rs10807319	chr6:45229123	C/G	cg25276700	chr6:44698697	NA	0.45	5.1	0.38	1.01e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11491056	chr17:39845092	EIF1	-0.74	-6.54	-0.47	8.72e-10	Neuroticism;
PAAD	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg01489256	chr8:11204017	TDH	0.47	4.96	0.37	1.87e-6	Neuroticism;
PAAD	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs78661209	chr10:46074939	G/A	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.59	5.55	0.41	1.25e-7	Mood instability;
PAAD	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.69	-0.36	5.92e-6	Atopic dermatitis;
PAAD	cis	rs950881	0.601	rs11465705	chr2:103058810	T/G	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Allergy;
PAAD	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.48	-5.28	-0.39	4.42e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.53	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs60154123	0.730	rs58366398	chr1:210471924	G/A	cg25204440	chr1:209979598	IRF6	0.62	5.13	0.38	8.55e-7	Coronary artery disease;
PAAD	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.97	8.31	0.56	5.04e-14	Alzheimer's disease;
PAAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.59	-5.75	-0.42	4.64e-8	Corneal astigmatism;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg10011062	chr15:43941034	CATSPER2	-0.81	-4.92	-0.37	2.26e-6	Lung cancer in ever smokers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14759740	chr20:60962311	RPS21	0.65	7.18	0.5	2.95e-11	Monocyte percentage of white cells;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.41	-6.27	-0.45	3.64e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.36	-0.33	2.39e-5	Fear of minor pain;
PAAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg09796270	chr17:17721594	SREBF1	0.44	5.09	0.38	1.03e-6	Total body bone mineral density;
PAAD	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13736514	chr6:26305472	NA	0.44	4.74	0.36	4.87e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-5.39	-0.4	2.61e-7	Tonsillectomy;
PAAD	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.63	-8.1	-0.55	1.67e-13	Multiple sclerosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08379496	chr3:50336790	HYAL3;NAT6	0.63	6.46	0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs2944755	0.723	rs13250299	chr8:141589584	A/G	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.55	-0.35	1.07e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.49	-0.34	1.43e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4141404	0.512	rs2070274	chr22:31999223	G/A	cg02404636	chr22:31891804	SFI1	-0.53	-5.01	-0.38	1.5e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.58	-6.86	-0.49	1.67e-10	Menopause (age at onset);
PAAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg02250501	chr15:90694978	NA	-0.47	-4.44	-0.34	1.71e-5	Rheumatoid arthritis;
PAAD	trans	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg02569823	chr6:5851330	NA	0.61	6.67	0.48	4.4e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.48e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.85	10.08	0.63	1.29e-18	Tuberculosis;
PAAD	cis	rs7084783	0.519	rs10883885	chr10:105333852	T/C	cg09754828	chr10:105363329	SH3PXD2A	0.45	4.32	0.33	2.82e-5	Fear of pain;
PAAD	cis	rs6908034	0.607	rs77753186	chr6:19812980	G/C	cg02682789	chr6:19804855	NA	0.82	4.78	0.36	4.17e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.57	5.42	0.4	2.34e-7	Mood instability;
PAAD	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	7.6	0.52	2.87e-12	Menopause (age at onset);
PAAD	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg00717180	chr2:96193071	NA	-0.58	-6.5	-0.47	1.11e-9	HDL cholesterol;
PAAD	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.52	-4.74	-0.36	4.96e-6	Life satisfaction;
PAAD	cis	rs12410462	0.551	rs67216605	chr1:227901637	A/G	cg23173402	chr1:227635558	NA	0.55	4.27	0.33	3.48e-5	Major depressive disorder;
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg08835956	chr7:39171034	POU6F2	0.37	5.94	0.43	1.89e-8	IgG glycosylation;
PAAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg00786201	chr11:61583134	MIR1908;FADS1	-0.46	-4.37	-0.33	2.26e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg01851573	chr8:8652454	MFHAS1	0.91	7.0	0.49	7.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.68	0.35	6.33e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09827037	chr3:5028674	NA	0.63	6.35	0.46	2.37e-9	Obesity-related traits;
PAAD	cis	rs7772172	0.502	rs2237166	chr6:16647158	C/T	cg26843612	chr6:16636157	ATXN1	0.41	4.51	0.34	1.3e-5	Educational attainment (years of education);
PAAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22442454	chr1:209979470	IRF6	0.39	4.32	0.33	2.78e-5	Monobrow;
PAAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.51	-5.69	-0.42	6.41e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2790216	1.000	rs2590299	chr10:59969000	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg24553058	chr2:113831203	IL1F10	0.46	5.17	0.39	7.36e-7	Protein quantitative trait loci;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.56	5.85	0.43	2.9e-8	Immature fraction of reticulocytes;
PAAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg18721089	chr20:30220636	NA	-0.6	-4.55	-0.35	1.11e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.6	-6.58	-0.47	6.98e-10	Testicular germ cell tumor;
PAAD	cis	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-6.29	-0.45	3.25e-9	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.57	-5.44	-0.4	2.05e-7	Blood metabolite levels;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg17650747	chr5:1873721	NA	0.46	4.73	0.36	5.19e-6	Cardiovascular disease risk factors;
PAAD	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9217	1.000	rs9217	chr17:7363088	T/C	cg15792487	chr17:7348316	CHRNB1	-0.47	-5.17	-0.39	7.33e-7	Height;
PAAD	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-5.68	-0.42	6.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.64	5.47	0.41	1.83e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.65	7.69	0.53	1.75e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.09	0.63	1.2e-18	Platelet count;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.65e-8	Life satisfaction;
PAAD	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs73206853	0.534	rs13313211	chr12:110509616	A/T	cg12870014	chr12:110450643	ANKRD13A	0.85	5.06	0.38	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9467603	0.800	rs4236040	chr6:25761209	T/C	cg23465465	chr6:26364728	BTN3A2	-0.78	-4.64	-0.35	7.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7853377	0.723	rs4147132	chr9:86559213	T/C	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs780096	0.967	rs1260334	chr2:27748597	C/A	cg22903471	chr2:27725779	GCKR	-0.39	-4.28	-0.33	3.33e-5	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01557844	chr1:151432001	POGZ	-0.73	-6.45	-0.46	1.41e-9	Neuroticism;
PAAD	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg10935138	chr17:73851978	WBP2	0.49	4.4	0.34	2.01e-5	White matter hyperintensity burden;
PAAD	cis	rs73416724	1.000	rs113163694	chr6:43283410	C/T	cg26312998	chr6:43337775	ZNF318	0.68	5.43	0.4	2.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9677476	0.863	rs58383275	chr2:232063946	T/C	cg07929768	chr2:232055508	NA	0.39	4.34	0.33	2.54e-5	Food antigen IgG levels;
PAAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22162314	chr17:61951766	CSH2	-0.61	-6.25	-0.45	4.03e-9	Height;
PAAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.47	-0.52	5.77e-12	Height;
PAAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg14440974	chr22:39074834	NA	-0.53	-6.29	-0.45	3.21e-9	Menopause (age at onset);
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.61	-5.67	-0.42	6.86e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6076065	0.723	rs2236022	chr20:23373534	G/A	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.97e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.57	-5.9	-0.43	2.3e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11700980	0.551	rs2832022	chr21:30112718	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.13	-0.44	7.39e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.47e-11	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.56	5.46	0.41	1.88e-7	Platelet count;
PAAD	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-5.7	-0.42	6.01e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.83	-5.62	-0.41	8.83e-8	Systolic blood pressure;
PAAD	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.59	-6.09	-0.44	8.86e-9	Hypospadias;
PAAD	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.68	6.39	0.46	1.95e-9	Uric acid levels;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.94	6.1	0.44	8.5e-9	Body mass index;
PAAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.88	10.62	0.65	4.8e-20	Aortic root size;
PAAD	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg01489256	chr8:11204017	TDH	0.44	4.68	0.35	6.3e-6	Neuroticism;
PAAD	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.36	4.88	0.37	2.69e-6	Obesity-related traits;
PAAD	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-6.38	-0.46	2.07e-9	Eye color traits;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07402062	chr16:89894098	SPIRE2	0.38	4.77	0.36	4.3e-6	Vitiligo;
PAAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs12541635	0.677	rs13439705	chr8:106967268	T/C	cg10147462	chr8:107024639	NA	0.46	4.95	0.37	1.97e-6	Age of smoking initiation;
PAAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs621942	0.718	rs590055	chr11:85767985	A/C	cg07180834	chr11:85838833	NA	-0.51	-5.07	-0.38	1.12e-6	Tourette syndrome;
PAAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06850241	chr22:41845214	NA	-0.58	-4.96	-0.37	1.88e-6	Vitiligo;
PAAD	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.36	0.46	2.25e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.56	0.61	2.96e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg03162506	chr22:38580953	NA	0.4	4.3	0.33	3.09e-5	Breast cancer;
PAAD	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.68	-6.76	-0.48	2.72e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.86	9.98	0.63	2.29e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.98	-10.8	-0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.84	-0.37	3.2e-6	Educational attainment;
PAAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg04154034	chr17:28927549	LRRC37B2	0.64	4.27	0.33	3.45e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg21479132	chr6:26055353	NA	0.93	5.23	0.39	5.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.74	7.55	0.52	3.65e-12	Corneal astigmatism;
PAAD	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg01620082	chr3:125678407	NA	-1.51	-9.57	-0.61	2.88e-17	Depression;
PAAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.3	-0.33	3.02e-5	Life satisfaction;
PAAD	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.29	-4.27	-0.33	3.39e-5	Psoriasis;
PAAD	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	7.92	0.54	4.73e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.9	0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.6	-0.35	8.97e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.84	-0.49	1.77e-10	Coffee consumption (cups per day);
PAAD	cis	rs7155603	1.000	rs4903324	chr14:75961511	C/T	cg01624173	chr14:75981868	NA	-0.75	-6.4	-0.46	1.82e-9	Rheumatoid arthritis;
PAAD	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	8.12	0.55	1.51e-13	Lung cancer in ever smokers;
PAAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg18944383	chr4:111397179	ENPEP	0.65	7.19	0.5	2.75e-11	Coronary artery disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11235871	chr3:49142143	QARS	0.62	6.8	0.48	2.28e-10	Metabolite levels  (X-11787);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04440597	chr8:28573618	EXTL3	0.59	6.94	0.49	1.04e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.76	-8.04	-0.55	2.3e-13	Blood metabolite levels;
PAAD	cis	rs858239	0.899	rs28458177	chr7:23294872	G/A	cg27449745	chr7:23145252	KLHL7	-0.52	-4.6	-0.35	8.74e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-6.44	-0.46	1.49e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4460629	0.742	rs7368345	chr1:155080090	C/T	cg14171486	chr1:155139557	NA	0.34	4.68	0.35	6.39e-6	Serum magnesium levels;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg14789911	chr21:47582049	C21orf56	-0.47	-4.79	-0.36	3.99e-6	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg11766577	chr21:47581405	C21orf56	-0.43	-4.82	-0.36	3.4e-6	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.46	-0.61	5.46e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.54	0.41	1.29e-7	Carotid intima media thickness;
PAAD	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.91	-9.33	-0.6	1.21e-16	Asthma;
PAAD	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.39	-0.34	2.12e-5	Post bronchodilator FEV1;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21230774	chr5:73980437	HEXB	0.54	6.31	0.46	2.89e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg10729496	chr3:10149963	C3orf24	0.85	7.22	0.51	2.3e-11	Alzheimer's disease;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	1.08	8.82	0.58	2.46e-15	Initial pursuit acceleration;
PAAD	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Colorectal cancer;
PAAD	cis	rs7752195	0.643	rs78252389	chr6:25257530	C/T	cg26336265	chr6:25042955	NA	0.87	4.84	0.37	3.15e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs939584	0.932	rs13013021	chr2:632723	C/T	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs2033732	0.955	rs2033731	chr8:85079720	T/G	cg05716166	chr8:85095498	RALYL	0.48	4.26	0.33	3.59e-5	Body mass index;
PAAD	cis	rs11825685	0.887	rs76149265	chr11:134571697	T/C	cg02089395	chr11:134479357	NA	-0.64	-4.46	-0.34	1.6e-5	IgG glycosylation;
PAAD	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg00179576	chr16:74483694	GLG1	-0.39	-4.38	-0.33	2.23e-5	Testicular germ cell tumor;
PAAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.57	5.82	0.43	3.38e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg10591111	chr5:226296	SDHA	-0.63	-4.39	-0.34	2.11e-5	Breast cancer;
PAAD	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15757022	chr11:71163853	NADSYN1	0.63	6.91	0.49	1.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg24920358	chr1:40204285	PPIE	0.62	6.32	0.46	2.73e-9	Blood protein levels;
PAAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Gout;
PAAD	cis	rs8025118	0.583	rs7177417	chr15:79547515	A/C	cg24739098	chr15:79297159	RASGRF1	0.38	4.37	0.33	2.25e-5	Cognitive function;
PAAD	cis	rs62264129	0.500	rs13316383	chr3:112039067	C/G	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.25	-0.33	3.72e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs12449964	0.524	rs897457	chr17:17572987	A/T	cg04398451	chr17:18023971	MYO15A	0.49	4.83	0.36	3.36e-6	Coronary artery disease or ischemic stroke;
PAAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg04154034	chr17:28927549	LRRC37B2	0.71	4.84	0.37	3.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.82	10.18	0.64	6.95e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00933542	chr6:150070202	PCMT1	0.57	6.11	0.44	8.16e-9	Lung cancer;
PAAD	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.26	-0.39	4.72e-7	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2051773	0.510	rs11024129	chr11:17056417	C/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24549020	chr5:56110836	MAP3K1	-0.69	-5.05	-0.38	1.22e-6	Initial pursuit acceleration;
PAAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.73	-8.57	-0.57	1.06e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg13859433	chr6:33739653	LEMD2	-0.64	-4.98	-0.37	1.67e-6	Schizophrenia;
PAAD	cis	rs959260	1.000	rs9900002	chr17:73382018	T/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18364779	chr6:26104403	HIST1H4C	0.44	4.43	0.34	1.83e-5	Schizophrenia;
PAAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg06618935	chr21:46677482	NA	-0.58	-6.96	-0.49	9.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.74	-7.96	-0.54	3.68e-13	Blood metabolite levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20144521	chr1:2237543	SKI	0.57	6.58	0.47	7.34e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-9.52	-0.61	3.9e-17	Personality dimensions;
PAAD	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.69	-8.07	-0.55	1.97e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.84	10.67	0.65	3.54e-20	Height;
PAAD	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.45	-4.42	-0.34	1.83e-5	Dupuytren's disease;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	10.05	0.63	1.54e-18	Platelet count;
PAAD	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg05791153	chr7:19748676	TWISTNB	-0.75	-5.72	-0.42	5.56e-8	Thyroid stimulating hormone;
PAAD	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.47	-4.97	-0.37	1.76e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	6.39	0.46	1.92e-9	Neuroticism;
PAAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.4	4.68	0.36	6.18e-6	Tonsillectomy;
PAAD	cis	rs9888739	0.800	rs7193268	chr16:31340997	A/G	cg15817542	chr16:31343056	ITGAM	0.41	4.37	0.33	2.27e-5	Systemic lupus erythematosus;
PAAD	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg19000871	chr14:103996768	TRMT61A	-0.56	-6.07	-0.44	9.67e-9	Coronary artery disease;
PAAD	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.38e-17	Metabolic syndrome;
PAAD	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.72	-7.72	-0.53	1.47e-12	Triglyceride levels;
PAAD	cis	rs73195822	0.667	rs117806977	chr12:111235324	C/T	cg09298818	chr12:111181546	PPP1CC	-0.58	-4.27	-0.33	3.4e-5	Itch intensity from mosquito bite;
PAAD	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg26248373	chr2:1572462	NA	-1.01	-9.17	-0.6	3.21e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.79	12.41	0.71	7.26e-25	Schizophrenia;
PAAD	cis	rs17032980	0.956	rs10200196	chr2:67308410	T/C	cg02551743	chr2:66673428	MEIS1	-0.5	-4.46	-0.34	1.6e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs6710503	0.574	rs62142286	chr2:24793703	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.3	-0.33	3.07e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.48	4.76	0.36	4.53e-6	Common traits (Other);
PAAD	cis	rs8010715	0.816	rs1134340	chr14:24594213	C/T	cg23112188	chr14:24563095	PCK2	-0.47	-5.14	-0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.52	-0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs7792596	0.565	rs58784836	chr7:93985600	G/C	cg20814616	chr7:94014465	NA	-0.62	-5.94	-0.43	1.85e-8	Intelligence;
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	5.36	0.4	3.1e-7	Parkinson's disease;
PAAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.16	-0.39	7.65e-7	Mean corpuscular volume;
PAAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg04450456	chr4:17643702	FAM184B	0.5	5.41	0.4	2.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.97	-11.83	-0.69	2.58e-23	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg11783602	chr8:55087084	NA	-0.64	-7.73	-0.53	1.35e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.85	-9.72	-0.62	1.12e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.4	9.95	0.63	2.76e-18	Diabetic retinopathy;
PAAD	cis	rs35110281	0.601	rs7278282	chr21:44981958	T/G	cg21573476	chr21:45109991	RRP1B	-0.5	-4.61	-0.35	8.36e-6	Mean corpuscular volume;
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.91	-0.37	2.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.96	-9.57	-0.61	2.75e-17	Bronchopulmonary dysplasia;
PAAD	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg22827986	chr11:48284249	OR4X1	-0.37	-4.78	-0.36	4.09e-6	Migraine - clinic-based;
PAAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.54	-5.2	-0.39	6.26e-7	P wave terminal force;
PAAD	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	11.91	0.69	1.66e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.5	5.26	0.39	4.75e-7	Obesity-related traits;
PAAD	cis	rs10899021	0.920	rs61901540	chr11:74314865	A/G	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.52	4.76	0.36	4.49e-6	Corneal astigmatism;
PAAD	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.48	5.62	0.41	8.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10267417	0.535	rs4275125	chr7:19911004	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.7	-0.42	5.99e-8	Tonsillectomy;
PAAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.4	0.68	3.72e-22	Platelet count;
PAAD	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-4.93	-0.37	2.14e-6	Fear of minor pain;
PAAD	cis	rs10488172	0.857	rs17167076	chr7:133116871	A/G	cg10665199	chr7:133106180	EXOC4	0.54	4.36	0.33	2.4e-5	Tonometry;
PAAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.62	5.14	0.38	8.27e-7	Gut microbiome composition (summer);
PAAD	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.68	6.41	0.46	1.72e-9	Platelet count;
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg05697835	chr1:2722811	NA	-0.42	-4.73	-0.36	5.16e-6	Multiple sclerosis;
PAAD	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.39	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01765077	chr12:122356316	WDR66	0.61	6.22	0.45	4.51e-9	Mean corpuscular volume;
PAAD	cis	rs6496044	0.507	rs1471455	chr15:86154727	T/A	cg10818794	chr15:86012489	AKAP13	0.44	4.61	0.35	8.33e-6	Interstitial lung disease;
PAAD	cis	rs58521262	0.556	rs2548890	chr19:23195872	C/T	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.62	0.47	5.94e-10	Educational attainment;
PAAD	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg00631329	chr6:26305371	NA	-0.48	-4.84	-0.37	3.15e-6	Educational attainment;
PAAD	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg10985347	chr2:127963512	CYP27C1	0.46	4.28	0.33	3.26e-5	Protein C levels;
PAAD	cis	rs734999	0.967	rs10910089	chr1:2498618	G/T	cg18854424	chr1:2615690	NA	0.44	5.75	0.42	4.82e-8	Ulcerative colitis;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.83	-0.48	1.93e-10	Lymphocyte counts;
PAAD	cis	rs7567389	0.504	rs41280570	chr2:128176230	C/T	cg11380483	chr2:127933992	NA	0.51	4.91	0.37	2.31e-6	Self-rated health;
PAAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.47	-4.96	-0.37	1.86e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg02459107	chr1:67143332	SGIP1	0.77	7.5	0.52	4.88e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs743757	0.557	rs2236950	chr3:50420554	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	4.52	0.34	1.26e-5	Diastolic blood pressure;
PAAD	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.69	7.09	0.5	4.64e-11	Schizophrenia;
PAAD	cis	rs802075	1.000	rs360559	chr6:49659871	A/C	cg20364632	chr6:49636226	NA	-0.52	-6.03	-0.44	1.21e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg05717871	chr11:638507	DRD4	-0.68	-5.76	-0.42	4.6e-8	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Total body bone mineral density;
PAAD	cis	rs11020478	0.681	rs11020479	chr11:93409562	A/G	cg10523193	chr11:93463762	SNORA25	0.43	4.51	0.34	1.27e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10791323	0.604	rs7928888	chr11:133703696	A/C	cg15485101	chr11:133734466	NA	0.44	5.63	0.42	8.4e-8	Childhood ear infection;
PAAD	cis	rs78761021	0.898	rs79871388	chr17:9776839	C/T	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.53	-6.33	-0.46	2.68e-9	Mean corpuscular volume;
PAAD	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.26	0.45	3.8e-9	Schizophrenia;
PAAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.67	-7.28	-0.51	1.63e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.78	7.87	0.54	6.17e-13	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.8	-0.58	2.77e-15	Gut microbiome composition (summer);
PAAD	cis	rs57244997	0.725	rs11964513	chr6:162414779	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-4.43	-0.34	1.78e-5	Mosquito bite size;
PAAD	cis	rs58521262	0.519	rs35294157	chr19:22999407	C/A	cg07749055	chr19:23076870	NA	-0.6	-4.58	-0.35	9.65e-6	Testicular germ cell tumor;
PAAD	cis	rs12940923	0.507	rs10853005	chr17:56371149	C/T	cg14843216	chr17:56064736	VEZF1	-0.51	-4.3	-0.33	3.09e-5	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.52	0.65	8.81e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.51	5.33	0.4	3.44e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.63	9.21	0.6	2.48e-16	Cannabis dependence symptom count;
PAAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg14393609	chr7:65229607	NA	0.47	4.92	0.37	2.26e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7300001	0.667	rs7302198	chr12:110506280	T/C	cg12870014	chr12:110450643	ANKRD13A	0.95	5.84	0.43	3.04e-8	Headache;
PAAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.49	-5.23	-0.39	5.6e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27143824	chr4:184580738	C4orf41;RWDD4A	-0.75	-6.68	-0.48	4.24e-10	Neuroticism;
PAAD	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg21775007	chr8:11205619	TDH	0.52	4.84	0.37	3.2e-6	Systolic blood pressure;
PAAD	cis	rs3857067	0.571	rs6836113	chr4:95033949	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.26	-0.39	4.9e-7	QT interval;
PAAD	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.89	7.41	0.52	7.96e-12	Obesity-related traits;
PAAD	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg18964960	chr10:1102726	WDR37	-0.87	-4.27	-0.33	3.49e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.49	6.1	0.44	8.3e-9	Crohn's disease;
PAAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg22875332	chr1:76189707	ACADM	-0.47	-4.69	-0.36	5.99e-6	Daytime sleep phenotypes;
PAAD	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.69	-8.54	-0.57	1.26e-14	Educational attainment;
PAAD	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg22878388	chr2:105853796	NA	-0.45	-4.98	-0.37	1.72e-6	Type 2 diabetes;
PAAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg09796270	chr17:17721594	SREBF1	0.44	4.67	0.35	6.7e-6	Total body bone mineral density;
PAAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg02696790	chr15:75250997	RPP25	-0.37	-4.45	-0.34	1.66e-5	Breast cancer;
PAAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.6	6.85	0.49	1.73e-10	Age at first birth;
PAAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.46	5.83	0.43	3.14e-8	Ulcerative colitis;
PAAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.68	0.35	6.34e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.56	-7.23	-0.51	2.22e-11	Schizophrenia;
PAAD	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.85	-6.38	-0.46	2.07e-9	Atopic dermatitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23064797	chr3:46875872	PRSS42	-0.68	-7.11	-0.5	4.2e-11	Obesity-related traits;
PAAD	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs11871801	0.560	rs8068844	chr17:40571284	T/C	cg21692620	chr17:40835849	CNTNAP1	-0.55	-5.65	-0.42	7.73e-8	Crohn's disease;
PAAD	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg17372223	chr3:52568218	NT5DC2	0.55	5.49	0.41	1.64e-7	Bipolar disorder;
PAAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg21448613	chr3:49828315	CDH29	0.47	4.4	0.34	2.03e-5	Menarche (age at onset);
PAAD	cis	rs904092	0.671	rs4355398	chr4:100158325	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-4.53	-0.34	1.21e-5	Alcohol dependence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06158944	chr4:99182422	RAP1GDS1	0.55	6.34	0.46	2.48e-9	Monocyte percentage of white cells;
PAAD	cis	rs35740288	0.787	rs727379	chr15:86229890	A/G	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11650494	0.634	rs8072520	chr17:47466640	T/G	cg08112188	chr17:47440006	ZNF652	1.3	6.56	0.47	8.09e-10	Prostate cancer;
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.82	9.41	0.61	7.23e-17	Methadone dose in opioid dependence;
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06915872	chr16:87998081	BANP	0.57	5.25	0.39	5.14e-7	Menopause (age at onset);
PAAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.26	0.33	3.59e-5	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20822109	chr3:183146412	MCF2L2	0.66	6.88	0.49	1.48e-10	Myopia (pathological);
PAAD	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.47	5.1	0.38	1.01e-6	Age of smoking initiation;
PAAD	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-4.78	-0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg06809295	chr11:2722625	KCNQ1OT1;KCNQ1	0.39	4.43	0.34	1.81e-5	Calcium levels;
PAAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg14349672	chr11:133703707	NA	0.52	5.83	0.43	3.24e-8	Childhood ear infection;
PAAD	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg05717871	chr11:638507	DRD4	-0.59	-5.19	-0.39	6.69e-7	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.61	5.08	0.38	1.1e-6	Red blood cell count;
PAAD	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.55	5.38	0.4	2.78e-7	Alcohol dependence;
PAAD	cis	rs2051773	0.567	rs7130826	chr11:17037793	T/G	cg15084286	chr11:17036142	PLEKHA7	0.57	5.17	0.39	7.42e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.87	-7.18	-0.5	2.88e-11	Triglycerides;
PAAD	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.56	-5.26	-0.39	4.71e-7	Schizophrenia;
PAAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	10.81	0.66	1.46e-20	Total body bone mineral density;
PAAD	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs2221894	0.881	rs2693	chr8:28924858	C/T	cg20212339	chr8:28908912	HMBOX1	-0.49	-5.21	-0.39	5.94e-7	Obesity-related traits;
PAAD	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	0.97	9.08	0.59	5.48e-16	Monocyte percentage of white cells;
PAAD	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.69	0.36	6.14e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.22	-17.4	-0.82	5.3e-38	IgG glycosylation;
PAAD	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.76	7.88	0.54	5.94e-13	Corneal astigmatism;
PAAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg25251562	chr2:3704773	ALLC	-0.48	-5.42	-0.4	2.27e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05564831	chr3:52568323	NT5DC2	0.41	4.26	0.33	3.6e-5	Electroencephalogram traits;
PAAD	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg21724239	chr8:58056113	NA	0.72	5.39	0.4	2.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg04717802	chr22:42394638	WBP2NL	0.48	4.67	0.35	6.55e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	1.0	9.53	0.61	3.65e-17	Psoriasis;
PAAD	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.55	-7.08	-0.5	5.12e-11	Longevity;
PAAD	cis	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg00614314	chr15:82944287	LOC80154	0.43	4.35	0.33	2.47e-5	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.74e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.61	-8.6	-0.57	9.37e-15	Huntington's disease progression;
PAAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.36	4.33	0.33	2.7e-5	Pulmonary function;
PAAD	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-5.45	-0.4	1.98e-7	Adiposity;
PAAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-10.34	-0.64	2.6e-19	Cognitive function;
PAAD	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.29	7.42	0.52	7.89e-12	Type 2 diabetes nephropathy;
PAAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.68	8.11	0.55	1.5700000000000001e-13	Multiple sclerosis;
PAAD	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.79	0.66	1.61e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg06636001	chr8:8085503	FLJ10661	0.74	7.33	0.51	1.3e-11	Retinal vascular caliber;
PAAD	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.89	-5.93	-0.43	1.95e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg08885800	chr1:201084119	NA	0.51	4.58	0.35	9.77e-6	Permanent tooth development;
PAAD	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07297397	chr7:23510112	IGF2BP3	-0.65	-6.62	-0.47	5.8e-10	Smoking initiation;
PAAD	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.51	-5.91	-0.43	2.2e-8	Coronary artery disease;
PAAD	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-10.84	-0.66	1.2e-20	Platelet distribution width;
PAAD	cis	rs9463078	0.605	rs7763421	chr6:44877313	A/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05598845	chr1:145477534	LIX1L	0.66	6.74	0.48	3.02e-10	Obesity-related traits;
PAAD	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.34	0.6	1.11e-16	Bipolar disorder;
PAAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.54	4.9	0.37	2.43e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-1.03	-8.28	-0.56	5.91e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg00334542	chr7:100209784	MOSPD3	-0.69	-5.25	-0.39	5.1e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.62	6.04	0.44	1.16e-8	Breast cancer;
PAAD	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.64	7.4	0.51	8.7e-12	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17070338	chr13:111268441	CARKD	0.56	6.32	0.46	2.83e-9	Monocyte percentage of white cells;
PAAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs9302065	0.636	rs2389235	chr13:95955623	G/T	cg24476569	chr13:95954382	ABCC4	-0.43	-4.73	-0.36	5.06e-6	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.55	4.87	0.37	2.79e-6	White matter hyperintensity burden;
PAAD	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg03098721	chr1:84464084	TTLL7	0.46	4.33	0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs4792901	0.802	rs9907507	chr17:41587045	T/G	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	1.18	18.4	0.83	1.61e-40	Gut microbiome composition (winter);
PAAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg02743256	chr7:2109353	MAD1L1	-0.59	-5.29	-0.39	4.25e-7	Neuroticism;
PAAD	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.63	5.41	0.4	2.42e-7	Red blood cell count;
PAAD	trans	rs1282545	0.560	rs3914624	chr3:107181434	G/A	cg22635088	chr5:2096922	NA	-0.41	-6.46	-0.46	1.35e-9	Neuroticism;
PAAD	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.71	5.64	0.42	8.18e-8	Height;
PAAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.45	4.48	0.34	1.48e-5	Aortic root size;
PAAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg20933634	chr6:27740509	NA	0.66	6.21	0.45	4.93e-9	Parkinson's disease;
PAAD	cis	rs6782025	0.837	rs12487633	chr3:120835613	C/T	cg16417163	chr3:121280760	NA	0.45	4.68	0.35	6.3e-6	Aging (facial);
PAAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.84	10.49	0.65	1.06e-19	Menopause (age at onset);
PAAD	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.12	-0.55	1.45e-13	Coffee consumption (cups per day);
PAAD	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.59	-5.35	-0.4	3.12e-7	Height;
PAAD	cis	rs17002988	0.568	rs9307352	chr4:79081466	C/T	cg07442568	chr4:78980533	FRAS1	-0.56	-4.73	-0.36	5.09e-6	Uric acid levels;
PAAD	cis	rs8170	0.554	rs60397819	chr19:17451369	G/T	cg01047959	chr19:17666446	GLT25D1	0.47	4.26	0.33	3.53e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.78	7.77	0.53	1.08e-12	Corneal astigmatism;
PAAD	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.9	0.37	2.39e-6	Birth weight;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03508928	chr3:47324552	KIF9;KLHL18	0.58	6.39	0.46	1.9e-9	Monocyte percentage of white cells;
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg07841815	chr7:100318223	EPO	-0.48	-4.54	-0.35	1.15e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.73	7.43	0.52	7.15e-12	Schizophrenia;
PAAD	cis	rs1075265	0.749	rs2357693	chr2:53962836	A/C	cg04546899	chr2:54196757	PSME4	0.3	4.54	0.35	1.12e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	1.3	10.96	0.66	5.86e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg11062466	chr8:58055876	NA	0.71	5.13	0.38	8.86e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.93	-11.27	-0.67	8.4e-22	Refractive error;
PAAD	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg01851573	chr8:8652454	MFHAS1	0.56	4.94	0.37	2.04e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17504096	chr1:205649242	SLC45A3	0.62	6.37	0.46	2.11e-9	Myopia (pathological);
PAAD	cis	rs4073221	0.615	rs13068577	chr3:18230439	T/C	cg07694806	chr3:18168406	NA	-0.61	-4.29	-0.33	3.16e-5	Parkinson's disease;
PAAD	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.55	-0.47	8.38e-10	Hip circumference;
PAAD	cis	rs4969178	0.569	rs938348	chr17:76381021	C/T	cg05887092	chr17:76393375	PGS1	0.55	6.17	0.45	5.9e-9	HDL cholesterol levels;
PAAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.56	5.89	0.43	2.34e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg03938978	chr2:103052716	IL18RAP	0.66	8.43	0.56	2.52e-14	Asthma;
PAAD	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.82	8.85	0.58	2.16e-15	Colorectal cancer;
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg00431813	chr7:1051703	C7orf50	0.75	4.77	0.36	4.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg08079166	chr15:68083412	MAP2K5	0.6	5.7	0.42	5.96e-8	Restless legs syndrome;
PAAD	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.81	5.91	0.43	2.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9346649	0.777	rs9346522	chr6:168490164	T/A	cg02770688	chr6:168491649	NA	-0.41	-4.34	-0.33	2.6e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.62	6.14	0.45	6.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.73	6.29	0.45	3.2e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.56	-0.41	1.17e-7	Prostate cancer;
PAAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.93	-11.38	-0.68	4.38e-22	Rheumatoid arthritis;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.04	0.38	1.3e-6	Childhood ear infection;
PAAD	cis	rs375066	0.935	rs367283	chr19:44406127	A/G	cg11993925	chr19:44307056	LYPD5	0.49	6.46	0.46	1.31e-9	Breast cancer;
PAAD	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	0.99	12.89	0.72	3.7e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg00543991	chr22:32367038	NA	1.13	6.91	0.49	1.23e-10	Childhood ear infection;
PAAD	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.47	0.34	1.5e-5	Plateletcrit;
PAAD	cis	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.85	10.18	0.64	7.12e-19	Methadone dose in opioid dependence;
PAAD	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.78	-7.62	-0.53	2.49e-12	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.74	0.66	2.21e-20	Homoarginine levels;
PAAD	cis	rs1015291	0.836	rs1815192	chr12:19990265	G/A	cg25401612	chr12:20009446	NA	-0.5	-4.94	-0.37	2.06e-6	Diastolic blood pressure;
PAAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg05341575	chr12:125625032	AACS	-0.53	-4.89	-0.37	2.57e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg20893579	chr22:38215064	NA	-0.44	-4.68	-0.35	6.42e-6	Glioblastoma;Glioma;
PAAD	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.74	7.9	0.54	5.13e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg11779900	chr17:80519722	FOXK2	-0.49	-5.02	-0.38	1.41e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.73	6.08	0.44	9.37e-9	Exhaled nitric oxide output;
PAAD	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-7.17	-0.5	3.06e-11	Colorectal cancer;
PAAD	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg14146966	chr2:61757674	XPO1	0.43	5.36	0.4	2.97e-7	Tuberculosis;
PAAD	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.5	4.64	0.35	7.55e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.77	-8.12	-0.55	1.52e-13	Prostate cancer;
PAAD	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.77	7.56	0.52	3.6e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg18944383	chr4:111397179	ENPEP	-0.63	-7.38	-0.51	9.81e-12	Coronary artery disease;
PAAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.57	0.47	7.65e-10	Platelet count;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.52	4.98	0.37	1.69e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg07636037	chr3:49044803	WDR6	0.56	4.39	0.34	2.1e-5	Menarche (age at onset);
PAAD	cis	rs10044254	0.763	rs10520821	chr5:15706220	C/G	cg07238450	chr5:15720153	FBXL7	-0.54	-4.56	-0.35	1.05e-5	Asthma (corticosteroid response);
PAAD	cis	rs72960926	1.000	rs72969218	chr6:75042124	T/G	cg03266952	chr6:74778945	NA	-1.04	-5.73	-0.42	5.19e-8	Metabolite levels (MHPG);
PAAD	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.47	-4.44	-0.34	1.74e-5	Uric acid levels;
PAAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.78	6.9	0.49	1.3100000000000001e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs55728055	1.000	rs8142355	chr22:32081681	C/T	cg01338084	chr22:32026380	PISD	1.58	8.57	0.57	1.07e-14	Age-related hearing impairment;
PAAD	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.74	-5.01	-0.38	1.52e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7301826	0.610	rs4759789	chr12:131296380	A/C	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg20406979	chr6:167373233	NA	0.38	5.26	0.39	4.85e-7	Crohn's disease;
PAAD	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.52	-4.34	-0.33	2.62e-5	IFN-related cytopenia;
PAAD	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.86e-6	Monocyte percentage of white cells;
PAAD	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.64	5.31	0.4	3.86e-7	LDL cholesterol to HDL cholesterol ratio;
PAAD	cis	rs10207060	0.500	rs6731870	chr2:240708096	C/A	cg07506560	chr2:240697449	NA	0.55	5.76	0.42	4.62e-8	Obesity-related traits;
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.83	6.74	0.48	3.02e-10	Lung function (FEV1/FVC);
PAAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs2835872	0.758	rs1709835	chr21:39037636	A/G	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg04520793	chr17:42248056	ASB16	-0.46	-6.16	-0.45	6.31e-9	Total body bone mineral density;
PAAD	cis	rs7945718	0.621	rs4514397	chr11:12689768	G/T	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg23346134	chr3:49453900	TCTA	0.44	4.83	0.36	3.29e-6	Menarche (age at onset);
PAAD	cis	rs793571	0.518	rs12912327	chr15:58986134	C/T	cg05156742	chr15:59063176	FAM63B	0.62	4.29	0.33	3.18e-5	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg09796270	chr17:17721594	SREBF1	0.39	4.3	0.33	3.04e-5	Total body bone mineral density;
PAAD	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.52	-0.52	4.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg08999081	chr20:33150536	PIGU	0.52	5.6	0.41	9.89e-8	Height;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs863345	0.604	rs10797022	chr1:158494193	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg07325041	chr3:17783979	TBC1D5	0.79	4.9	0.37	2.39e-6	Myocardial infarction;
PAAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg18551225	chr6:44695536	NA	0.71	7.52	0.52	4.37e-12	Total body bone mineral density;
PAAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg15571903	chr15:79123663	NA	-0.49	-6.28	-0.45	3.38e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6694270	1.000	rs12139558	chr1:19121246	G/A	cg13786083	chr1:19110734	NA	-0.59	-5.09	-0.38	1.04e-6	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02244288	chr16:89573955	SPG7	-0.33	-4.29	-0.33	3.19e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.81	7.73	0.53	1.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs1697139	0.710	rs6888412	chr5:66526800	G/C	cg16691251	chr5:66510806	NA	0.67	6.76	0.48	2.79e-10	Breast cancer;
PAAD	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-7.02	-0.49	6.79e-11	Blood pressure (smoking interaction);
PAAD	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg25547332	chr5:131281432	NA	-0.56	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg13320842	chr19:46175254	GIPR	0.55	5.02	0.38	1.41e-6	Eosinophil counts;
PAAD	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.39	4.37	0.33	2.29e-5	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.36	0.33	2.43e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.47	4.29	0.33	3.16e-5	White matter hyperintensity burden;
PAAD	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.52	0.61	3.87e-17	Mortality in heart failure;
PAAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.77	8.13	0.55	1.41e-13	Height;
PAAD	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.65	0.35	7.06e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.16	17.57	0.82	1.94e-38	Cognitive function;
PAAD	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.63	-4.58	-0.35	9.43e-6	Blood protein levels;
PAAD	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.57	-0.35	1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.78	7.78	0.53	1.04e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg15590007	chr10:45870220	ALOX5	0.51	5.38	0.4	2.74e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-5.36	-0.4	3.02e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg20169779	chr10:135381914	SYCE1	-0.46	-4.77	-0.36	4.24e-6	Obesity-related traits;
PAAD	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg19847866	chr10:1019161	NA	-0.6	-4.64	-0.35	7.32e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.29	0.39	4.18e-7	Colorectal cancer;
PAAD	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg01422370	chr2:73384389	NA	0.39	5.13	0.38	8.8e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6466055	0.666	rs12671047	chr7:104999535	C/A	cg04380332	chr7:105027541	SRPK2	-0.67	-7.51	-0.52	4.77e-12	Schizophrenia;
PAAD	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.52	5.41	0.4	2.45e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.78e-7	Body mass index;
PAAD	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.26e-6	Neuroticism;
PAAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-9.01	-0.59	8.03e-16	Height;
PAAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07701084	chr6:150067640	NUP43	0.61	6.14	0.45	7.03e-9	Testicular germ cell tumor;
PAAD	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg02367144	chr2:237146137	ASB18	0.42	5.42	0.4	2.24e-7	Educational attainment;
PAAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-5.91	-0.43	2.13e-8	Response to antipsychotic treatment;
PAAD	cis	rs1400816	0.850	rs1982288	chr2:172821739	G/T	cg23624723	chr2:173292262	ITGA6	-0.76	-4.41	-0.34	1.97e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.47	4.78	0.36	4.17e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.83	0.36	3.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.66	-6.08	-0.44	9.11e-9	Platelet count;
PAAD	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.53	5.1	0.38	1.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs501120	0.810	rs684196	chr10:44745950	A/T	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg07741184	chr6:167504864	NA	-0.4	-4.84	-0.37	3.16e-6	Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24666355	chr1:222923875	FAM177B	-0.5	-6.36	-0.46	2.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.78	9.24	0.6	2.06e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	6.31	0.46	2.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg15181151	chr6:150070149	PCMT1	0.55	5.68	0.42	6.5e-8	Lung cancer;
PAAD	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-6.29	-0.45	3.28e-9	Morning vs. evening chronotype;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg26554054	chr8:600488	NA	-1.0	-6.22	-0.45	4.58e-9	IgG glycosylation;
PAAD	cis	rs12999616	0.857	rs34459720	chr2:98325447	T/C	cg26665480	chr2:98280029	ACTR1B	0.65	6.5	0.47	1.09e-9	Colorectal cancer;
PAAD	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.96	-9.43	-0.61	6.58e-17	Blood protein levels;
PAAD	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg02555727	chr12:129281546	SLC15A4	0.44	4.65	0.35	7.27e-6	Systemic lupus erythematosus;
PAAD	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg01851573	chr8:8652454	MFHAS1	0.62	5.03	0.38	1.38e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg19744528	chr7:157553346	PTPRN2	0.4	4.31	0.33	2.97e-5	Body mass index;
PAAD	cis	rs8070740	0.592	rs2189338	chr17:5326341	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	5.97	0.44	1.64e-8	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3736485	0.966	rs2124878	chr15:51906337	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.85	-9.86	-0.62	4.98e-18	Iron status biomarkers;
PAAD	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.55e-9	Hepatitis;
PAAD	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg26950739	chr16:89183275	ACSF3	0.76	5.35	0.4	3.17e-7	Red blood cell count;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.57	0.47	7.51e-10	Lung cancer;
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-4.98	-0.37	1.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg21994822	chr11:66741747	C11orf86	0.39	4.33	0.33	2.72e-5	HIV-1 susceptibility;
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg21479132	chr6:26055353	NA	0.79	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.57	5.27	0.39	4.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-1.06	-7.14	-0.5	3.6e-11	Post bronchodilator FEV1;
PAAD	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg14171486	chr1:155139557	NA	-0.34	-4.66	-0.35	6.98e-6	Serum magnesium levels;
PAAD	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg12633918	chr20:23549525	CST9L	-0.42	-4.61	-0.35	8.35e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27335386	chr3:195808921	TFRC	0.65	6.35	0.46	2.36e-9	Obesity-related traits;
PAAD	cis	rs795943	0.527	rs7300526	chr12:78652449	T/C	cg00023351	chr12:79187938	NA	0.66	4.62	0.35	8.12e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.85	-9.91	-0.63	3.68e-18	Ulcerative colitis;
PAAD	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.68	4.89	0.37	2.55e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7246760	1.000	rs112124298	chr19:9923154	T/C	cg16876255	chr19:9731953	ZNF561	0.95	4.56	0.35	1.06e-5	Pursuit maintenance gain;
PAAD	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg14789911	chr21:47582049	C21orf56	0.53	5.67	0.42	6.92e-8	Testicular germ cell tumor;
PAAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	7.95	0.54	4.02e-13	Prudent dietary pattern;
PAAD	cis	rs2882667	0.690	rs1651358	chr5:138081007	A/G	cg09476006	chr5:138032270	NA	-0.43	-5.27	-0.39	4.56e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.89	7.38	0.51	9.69e-12	Gastritis;
PAAD	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.42	-0.4	2.32e-7	Mean corpuscular volume;
PAAD	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg19636519	chr7:99541626	NA	-0.42	-4.66	-0.35	6.81e-6	Coronary artery disease;
PAAD	cis	rs7742824	1.000	rs7742824	chr6:44065311	G/A	cg21657043	chr6:44035552	NA	0.53	5.42	0.4	2.32e-7	Major depressive disorder;
PAAD	cis	rs11264213	0.901	rs644095	chr1:36363172	C/T	cg27506609	chr1:36549197	TEKT2	0.76	5.18	0.39	7e-7	Schizophrenia;
PAAD	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.04e-5	Eye color traits;
PAAD	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.5	5.99	0.44	1.48e-8	Height;
PAAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg08807892	chr2:162101083	NA	0.73	8.27	0.56	6.2e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.51	0.57	1.57e-14	Platelet count;
PAAD	cis	rs10982213	1.000	rs4979375	chr9:117156596	T/C	cg00078025	chr9:117159975	NA	0.59	4.31	0.33	2.94e-5	Interleukin-6 levels;
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.77	9.25	0.6	1.9e-16	Lung cancer;
PAAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.2	-0.5	2.55e-11	Cognitive function;
PAAD	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	1.04	6.94	0.49	1.08e-10	Thyroid stimulating hormone;
PAAD	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg10820045	chr2:198174542	NA	0.51	5.2	0.39	6.29e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.25e-8	Prostate cancer;
PAAD	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg09140281	chr5:131563492	P4HA2	-0.54	-4.58	-0.35	9.48e-6	Breast cancer;
PAAD	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.5	5.13	0.38	8.8e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg03959625	chr15:84868606	LOC388152	0.5	5.46	0.4	1.91e-7	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg21546286	chr11:48923668	NA	0.55	5.72	0.42	5.41e-8	HDL cholesterol;
PAAD	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.28	-0.45	3.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.49	-4.72	-0.36	5.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.7	9.37	0.61	9.35e-17	Hemoglobin concentration;
PAAD	cis	rs8112211	1.000	rs12609247	chr19:38821697	C/T	cg14299480	chr19:38876666	GGN	-0.54	-6.91	-0.49	1.26e-10	Blood protein levels;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14166846	chr1:220268091	IARS2	0.58	6.56	0.47	7.96e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	7.43	0.52	7.25e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs10029851	0.560	rs3910459	chr4:109612288	C/G	cg16525761	chr4:109541525	LOC285456;RPL34	-0.51	-4.76	-0.36	4.48e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27012203	chr1:11865920	CLCN6;MTHFR	0.62	6.91	0.49	1.24e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg15691649	chr6:25882328	NA	0.54	5.03	0.38	1.35e-6	Blood metabolite levels;
PAAD	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.7	7.03	0.5	6.38e-11	Callous-unemotional behaviour;
PAAD	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	5.79	0.42	3.96e-8	Blood protein levels;
PAAD	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	4.31	0.33	2.88e-5	Tonsillectomy;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.9	7.85	0.54	6.93e-13	Alzheimer's disease;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-6.12	-0.44	7.68e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs757081	0.578	rs7109536	chr11:17255512	G/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.62	-0.41	9e-8	Systolic blood pressure;
PAAD	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.85	8.27	0.56	6.23e-14	Response to hepatitis C treatment;
PAAD	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.26	0.33	3.6e-5	Cancer;
PAAD	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg04990556	chr1:26633338	UBXN11	0.6	4.25	0.33	3.68e-5	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18621852	chr3:10150065	C3orf24	0.64	5.51	0.41	1.5e-7	Alzheimer's disease;
PAAD	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg17385448	chr1:15911702	AGMAT	0.38	4.67	0.35	6.59e-6	Systolic blood pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11704751	chr12:63329118	PPM1H	-0.65	-6.83	-0.48	1.92e-10	Smoking initiation;
PAAD	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg00522288	chr12:125625016	AACS	0.43	4.53	0.34	1.21e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8037137	0.749	rs12594925	chr15:91520287	G/A	cg23684204	chr15:91497937	RCCD1	0.75	4.62	0.35	8e-6	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs7009516	0.716	rs371439	chr8:24225477	T/A	cg01759110	chr8:24241694	ADAMDEC1	0.41	4.9	0.37	2.46e-6	Hair greying;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.57	-5.36	-0.4	3.04e-7	Longevity;Endometriosis;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg16606324	chr3:10149918	C3orf24	0.81	6.31	0.46	2.95e-9	Alzheimer's disease;
PAAD	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg04330084	chr7:123175371	IQUB	-0.53	-5.01	-0.38	1.48e-6	Migraine;
PAAD	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.12	-0.38	9.01e-7	Common traits (Other);
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.97e-8	Lymphocyte counts;
PAAD	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg10167378	chr1:228756711	NA	-0.62	-4.44	-0.34	1.71e-5	Chronic lymphocytic leukemia;
PAAD	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg23244877	chr17:73518230	TSEN54	-0.5	-4.31	-0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27665769	chr4:2757761	TNIP2	0.55	6.43	0.46	1.55e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.54	-5.14	-0.38	8.52e-7	Mortality in heart failure;
PAAD	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.68	6.59	0.47	6.97e-10	Coronary artery disease;
PAAD	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.57	4.99	0.38	1.63e-6	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.93	-9.74	-0.62	1.04e-17	Cancer (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg09559324	chr16:31475905	ARMC5	0.55	6.48	0.47	1.22e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-7.82	-0.54	8.2e-13	Response to antipsychotic treatment;
PAAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs35916836	chr10:46082516	C/T	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg27124370	chr19:33622961	WDR88	0.61	5.88	0.43	2.54e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.9	7.67	0.53	1.93e-12	Alzheimer's disease;
PAAD	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.56	-0.41	1.19e-7	Mean platelet volume;
PAAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.76	-8.86	-0.58	2.03e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.98	-8.49	-0.57	1.69e-14	Alopecia areata;
PAAD	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.6	5.99	0.44	1.45e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.49	-4.66	-0.35	6.8e-6	Blood metabolite levels;
PAAD	cis	rs12044355	0.827	rs1977797	chr1:231825074	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.87	0.43	2.59e-8	Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.35	-0.46	2.4e-9	Lung cancer;
PAAD	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.12	0.5	4.09e-11	Lung cancer in ever smokers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06090383	chr4:174292579	SAP30	0.59	6.36	0.46	2.21e-9	Myopia (pathological);
PAAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg09626299	chr10:82213104	TSPAN14	-0.39	-4.33	-0.33	2.71e-5	Post bronchodilator FEV1;
PAAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.18	11.74	0.69	4.59e-23	Corneal structure;
PAAD	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg10434728	chr15:90938212	IQGAP1	-0.44	-4.45	-0.34	1.65e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs246395	0.803	rs7736526	chr5:149489242	C/T	cg26247309	chr5:149501835	PDGFRB	0.36	4.28	0.33	3.25e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg14343924	chr8:8086146	FLJ10661	0.49	4.69	0.36	6.1e-6	Joint mobility (Beighton score);
PAAD	cis	rs864745	0.600	rs849327	chr7:28232457	A/G	cg01883759	chr7:28220576	JAZF1	-0.51	-5.36	-0.4	2.97e-7	Crohn's disease;Type 2 diabetes;
PAAD	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.43	5.45	0.4	2.01e-7	Ulcerative colitis;
PAAD	cis	rs2908197	0.737	rs6978009	chr7:75992234	A/C	cg22830091	chr7:75961684	YWHAG	0.62	7.27	0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg24739098	chr15:79297159	RASGRF1	0.34	4.35	0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs11700980	0.551	rs62222158	chr21:30110372	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.67	6.54	0.47	8.66e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.95	8.38	0.56	3.3e-14	Gut microbiome composition (summer);
PAAD	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.57	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg12568669	chr8:11666485	FDFT1	-0.3	-5.16	-0.39	7.58e-7	Neuroticism;
PAAD	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.58	-5.61	-0.41	9.51e-8	Cancer;
PAAD	cis	rs9810890	0.850	rs62265295	chr3:128654636	C/T	cg16818395	chr3:128274084	NA	0.51	4.82	0.36	3.48e-6	Dental caries;
PAAD	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.54	4.37	0.33	2.33e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg08648136	chr8:956695	NA	0.51	5.34	0.4	3.27e-7	Schizophrenia;
PAAD	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.58	-0.61	2.68e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.93	-0.43	2.01e-8	Menarche (age at onset);
PAAD	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.82	8.78	0.58	3.18e-15	Height;
PAAD	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs75920871	0.843	rs17120111	chr11:116744018	C/T	cg04087571	chr11:116723030	SIK3	-0.46	-4.58	-0.35	9.63e-6	Subjective well-being;
PAAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-7.59	-0.52	3.04e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg09355652	chr11:64668475	ATG2A	0.48	4.46	0.34	1.58e-5	Breast cancer;
PAAD	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26605046	chr4:2439731	NA	-0.44	-4.62	-0.35	8.26e-6	Cognitive function;
PAAD	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.5	4.46	0.34	1.59e-5	Morning vs. evening chronotype;
PAAD	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.8	9.42	0.61	7.14e-17	Sudden cardiac arrest;
PAAD	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.84	9.01	0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs8099014	1.000	rs7241204	chr18:56130246	G/A	cg12907477	chr18:56117327	MIR122	0.53	4.29	0.33	3.19e-5	Platelet count;
PAAD	cis	rs1879734	0.953	rs2948042	chr1:54152703	G/A	cg14659662	chr1:54151053	GLIS1	0.4	6.29	0.45	3.21e-9	Mitral valve prolapse;
PAAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.62	-5.81	-0.43	3.55e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.67	-6.93	-0.49	1.09e-10	Schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg04374231	chr1:121261146	LOC647121	0.56	6.34	0.46	2.44e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg10253484	chr15:75165896	SCAMP2	0.5	4.8	0.36	3.84e-6	Systemic lupus erythematosus;
PAAD	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.45	-4.6	-0.35	8.9e-6	IgG glycosylation;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.8	8.85	0.58	2.1e-15	Cleft lip with or without cleft palate;
PAAD	cis	rs6604026	0.656	rs10874751	chr1:93384540	T/A	cg17283838	chr1:93427260	FAM69A	0.63	5.81	0.43	3.59e-8	Multiple sclerosis;
PAAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17213078	0.505	rs6735859	chr2:106744603	T/C	cg15412446	chr2:106886593	NA	0.57	5.66	0.42	7.4e-8	Facial morphology (factor 23);
PAAD	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-4.71	-0.36	5.47e-6	Recombination measurement;
PAAD	cis	rs6942407	0.649	rs6952384	chr7:86859551	T/C	cg02420886	chr7:86849541	C7orf23	0.59	4.6	0.35	8.86e-6	Food allergy;
PAAD	cis	rs528301	0.868	rs542883	chr2:45143382	C/G	cg15393275	chr2:45165193	NA	-0.52	-5.71	-0.42	5.63e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.56	-5.04	-0.38	1.31e-6	Macular telangiectasia type 2;
PAAD	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.67	6.11	0.44	7.87e-9	Platelet count;
PAAD	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.94	-10.17	-0.64	7.32e-19	Morning vs. evening chronotype;
PAAD	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs116248771	0.739	rs114379619	chr3:158338781	C/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03140557	chr16:595690	SOLH	0.52	4.47	0.34	1.49e-5	Mean corpuscular volume;
PAAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.55	7.3	0.51	1.51e-11	Hypertriglyceridemia;
PAAD	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.5	-5.34	-0.4	3.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg14349672	chr11:133703707	NA	-0.55	-6.54	-0.47	8.73e-10	Childhood ear infection;
PAAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.49	0.47	1.16e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	5.16	0.39	7.53e-7	Tonsillectomy;
PAAD	cis	rs1879734	0.648	rs7554633	chr1:54163128	A/G	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg14515779	chr1:101123966	NA	-0.5	-6.35	-0.46	2.31e-9	Monocyte count;
PAAD	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.65	5.14	0.39	8.17e-7	Breast cancer;
PAAD	cis	rs1656368	0.726	rs55765541	chr3:158213547	G/A	cg16708174	chr3:158430962	RARRES1	0.59	5.34	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg09659197	chr4:152720779	NA	0.35	5.13	0.38	8.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6782025	0.837	rs2331709	chr3:121041799	C/T	cg16417163	chr3:121280760	NA	-0.44	-4.59	-0.35	9.41e-6	Aging (facial);
PAAD	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs600550	0.519	rs7931525	chr11:60103826	G/A	cg05040360	chr11:60102449	MS4A6E	0.41	4.67	0.35	6.69e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.73	7.75	0.53	1.25e-12	Mood instability;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	5.76	0.42	4.51e-8	Breast cancer;
PAAD	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg24687543	chr11:63912206	MACROD1	0.62	5.47	0.41	1.84e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-8.73	-0.58	4.2e-15	Coronary artery disease;
PAAD	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	5.11	0.38	9.5e-7	Neuroticism;
PAAD	cis	rs2531992	0.686	rs12922685	chr16:4028621	G/C	cg05927578	chr16:4029543	ADCY9	-0.77	-6.3	-0.45	3.12e-9	Waist circumference;
PAAD	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg06271696	chr7:157225062	NA	-0.72	-8.43	-0.56	2.41e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23558158	chr2:220094171	ANKZF1;ATG9A	0.58	6.44	0.46	1.5e-9	Monocyte percentage of white cells;
PAAD	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.53e-9	Obesity-related traits;
PAAD	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.1	8.86	0.58	1.98e-15	Vitiligo;
PAAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.75	5.39	0.4	2.67e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22162314	chr17:61951766	CSH2	-0.56	-5.75	-0.42	4.72e-8	Height;
PAAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg13722127	chr7:150037890	RARRES2	0.62	6.12	0.44	7.74e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Calcium levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16020436	chr1:203763483	ZC3H11A	-0.6	-6.38	-0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs13006833	0.668	rs291462	chr2:191181678	T/C	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	6.15	0.45	6.61e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg02462569	chr6:150064036	NUP43	-0.47	-5.23	-0.39	5.51e-7	Lung cancer;
PAAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.75	-0.42	4.67e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.96	12.47	0.71	5.01e-25	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-6.11	-0.44	8e-9	Personality dimensions;
PAAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27567548	chr12:76496388	NA	-0.64	-6.86	-0.49	1.66e-10	Obesity-related traits;
PAAD	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.29e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs2286379	0.745	rs9300298	chr12:1866204	A/T	cg05227549	chr12:1770782	NA	-0.41	-4.82	-0.36	3.45e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg03983715	chr16:68378420	PRMT7	-0.99	-6.87	-0.49	1.54e-10	Magnesium levels;
PAAD	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs863345	0.604	rs12041348	chr1:158482042	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-5.0	-0.38	1.59e-6	Pneumococcal bacteremia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09732190	chr7:150754731	CDK5	-0.69	-7.03	-0.5	6.52e-11	Lung cancer in ever smokers;
PAAD	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg21823605	chr1:152486609	CRCT1	0.49	6.18	0.45	5.54e-9	Hair morphology;
PAAD	cis	rs10426930	0.621	rs10409229	chr19:5009545	C/T	cg25246084	chr19:4971487	KDM4B	-0.47	-4.78	-0.36	4.08e-6	Monocyte percentage of white cells;
PAAD	cis	rs11235843	0.853	rs12365044	chr11:73452511	C/A	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	trans	rs12127679	0.614	rs12062173	chr1:244171508	C/T	cg03519879	chr14:74227499	C14orf43	-0.86	-6.46	-0.46	1.32e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs73019876	0.901	rs390852	chr19:22232576	T/C	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg14703610	chr5:56206110	C5orf35	0.54	5.06	0.38	1.2e-6	Coronary artery disease;
PAAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.57	-6.15	-0.45	6.45e-9	Schizophrenia;
PAAD	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg16964102	chr10:135390573	NA	0.44	4.99	0.38	1.62e-6	Obesity-related traits;
PAAD	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.33	-0.33	2.69e-5	Lung cancer in ever smokers;
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14069279	chr9:98113462	NA	-0.66	-6.77	-0.48	2.7e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	8.31	0.56	4.94e-14	Lymphocyte counts;
PAAD	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg04374321	chr14:90722782	PSMC1	0.53	4.61	0.35	8.51e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.98	10.42	0.65	1.63e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.4	4.85	0.37	3.06e-6	Schizophrenia;
PAAD	cis	rs6088813	1.000	rs6142373	chr20:33983314	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg10495392	chr1:46806563	NSUN4	0.6	5.87	0.43	2.66e-8	Menopause (age at onset);
PAAD	cis	rs821931	1.000	rs821945	chr10:108477352	A/G	cg16415058	chr10:108923781	SORCS1	0.37	4.35	0.33	2.52e-5	Asparaginase hypersensitivity in acute lymphoblastic leukemia;
PAAD	cis	rs10916814	1.000	rs10916814	chr1:20892931	A/G	cg04087271	chr1:20915334	CDA	-0.4	-4.79	-0.36	3.92e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-1.07	-14.97	-0.77	1.05e-31	Breast cancer;
PAAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.82	0.43	3.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	11.78	0.69	3.67e-23	Smoking behavior;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.31	-0.56	4.84e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg26528668	chr16:1614120	IFT140	-0.56	-5.27	-0.39	4.65e-7	Coronary artery disease;
PAAD	cis	rs1144	0.537	rs2470943	chr7:104583843	C/T	cg04380332	chr7:105027541	SRPK2	-0.62	-6.46	-0.46	1.31e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
PAAD	cis	rs4586057	1.000	rs74529341	chr10:92646725	G/T	cg05934333	chr10:93372513	LOC100188947	0.5	4.26	0.33	3.63e-5	Economic and political preferences (time);
PAAD	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg02770688	chr6:168491649	NA	0.48	4.98	0.37	1.73e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.76	-0.36	4.47e-6	Fibrinogen levels;
PAAD	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.62	5.38	0.4	2.76e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs4478037	1.000	rs9841225	chr3:33156335	A/G	cg19404215	chr3:33155277	CRTAP	0.81	4.42	0.34	1.91e-5	Major depressive disorder;
PAAD	cis	rs11834862	0.770	rs10444603	chr12:132694910	C/G	cg14525755	chr12:132671672	NA	-0.5	-4.27	-0.33	3.44e-5	Anti-saccade response;
PAAD	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.65	7.12	0.5	4.02e-11	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.25	0.6	1.96e-16	Response to antipsychotic treatment;
PAAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg03808351	chr9:123631620	PHF19	0.45	4.89	0.37	2.51e-6	Rheumatoid arthritis;
PAAD	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-4.56	-0.35	1.07e-5	Bipolar disorder;
PAAD	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg25722041	chr1:8623473	RERE	-0.5	-4.28	-0.33	3.35e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22307297	chr20:60903441	LAMA5	-0.43	-4.62	-0.35	7.96e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.45	0.4	1.99e-7	Height;
PAAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg09835421	chr16:68378352	PRMT7	-0.87	-6.98	-0.49	8.58e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg12143784	chr7:64541923	NA	0.33	4.25	0.33	3.75e-5	Calcium levels;
PAAD	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg14003231	chr6:33640908	ITPR3	0.48	5.65	0.42	7.52e-8	Platelet count;
PAAD	cis	rs75757892	0.542	rs9505154	chr6:7324974	G/A	cg02954307	chr6:7269328	NA	0.5	4.27	0.33	3.44e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.52	5.11	0.38	9.65e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2721811	0.745	rs2529042	chr7:24607175	A/G	cg17569154	chr7:24781545	DFNA5	-0.41	-4.33	-0.33	2.74e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.49	-0.47	1.13e-9	Chronic sinus infection;
PAAD	trans	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.95	-0.49	9.94e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg01494348	chr8:144660395	NAPRT1	0.92	4.26	0.33	3.57e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.61	5.13	0.38	8.7e-7	Mood instability;
PAAD	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	4.44	0.34	1.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg27447006	chr1:23763279	ASAP3	0.6	4.29	0.33	3.12e-5	Total cholesterol levels;
PAAD	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.59	4.53	0.34	1.18e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	4.9	0.37	2.46e-6	Renal function-related traits (BUN);
PAAD	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	1.2	13.25	0.73	4.05e-27	Eosinophil percentage of granulocytes;
PAAD	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.47	4.35	0.33	2.52e-5	Tuberculosis;
PAAD	cis	rs1891275	0.551	rs4933213	chr10:93417704	C/T	cg07889827	chr10:93443413	NA	-0.4	-4.27	-0.33	3.46e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg21605333	chr4:119757512	SEC24D	1.89	10.46	0.65	1.25e-19	Cannabis dependence symptom count;
PAAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.73	7.68	0.53	1.84e-12	Height;
PAAD	cis	rs375066	0.762	rs17713001	chr19:44421225	C/T	cg08633290	chr19:44405433	NA	0.51	4.82	0.36	3.41e-6	Breast cancer;
PAAD	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.72	-7.11	-0.5	4.22e-11	Morning vs. evening chronotype;
PAAD	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg01777861	chr4:56023843	NA	0.36	4.56	0.35	1.06e-5	Endometriosis;
PAAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Body mass index;
PAAD	cis	rs2017305	0.749	rs12249735	chr10:70791235	A/G	cg25290552	chr10:70751067	KIAA1279	-0.87	-5.4	-0.4	2.54e-7	Depression (quantitative trait);
PAAD	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.31	-0.4	3.83e-7	Breast cancer;
PAAD	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.89e-8	Ileal carcinoids;
PAAD	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg27411982	chr8:10470053	RP1L1	-0.46	-5.22	-0.39	5.92e-7	Systolic blood pressure;
PAAD	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-1.14	-8.68	-0.58	5.66e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.73	-8.47	-0.57	1.9e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.58	-5.13	-0.38	8.55e-7	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.62	-5.52	-0.41	1.44e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg13266496	chr6:110720918	DDO	-0.43	-4.58	-0.35	9.49e-6	Platelet distribution width;
PAAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6494488	0.500	rs113494617	chr15:64836505	C/T	cg16425858	chr15:64791681	ZNF609	0.99	4.66	0.35	6.83e-6	Coronary artery disease;
PAAD	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.52	5.93	0.43	1.93e-8	Alcohol dependence;
PAAD	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.52	-5.94	-0.43	1.82e-8	Alcohol dependence;
PAAD	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.83	0.43	3.17e-8	Lung cancer;
PAAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.48	5.74	0.42	4.92e-8	Coronary artery disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01154392	chr12:48167362	SLC48A1	-0.69	-6.85	-0.49	1.71e-10	Smoking initiation;
PAAD	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	1.18	18.12	0.83	8.29e-40	Gut microbiome composition (winter);
PAAD	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg27211696	chr2:191398769	TMEM194B	0.45	4.49	0.34	1.41e-5	Urinary metabolites;
PAAD	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.73	-5.94	-0.43	1.83e-8	Gallbladder cancer;
PAAD	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg06805348	chr4:37245195	KIAA1239	-0.68	-4.8	-0.36	3.77e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6580110	0.793	rs10039709	chr5:154090511	G/A	cg17263206	chr5:154071247	NA	0.49	5.1	0.38	9.83e-7	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.64	6.31	0.46	2.95e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.67	-4.87	-0.37	2.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg08992911	chr2:238395768	MLPH	0.53	5.4	0.4	2.54e-7	Prostate cancer;
PAAD	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.68	0.42	6.75e-8	Height;
PAAD	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg03934865	chr2:198174659	NA	-0.44	-4.52	-0.34	1.25e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.28	-0.45	3.47e-9	Menarche (age at onset);
PAAD	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg24330906	chr2:85765176	MAT2A	0.55	5.32	0.4	3.69e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	6.73	0.48	3.22e-10	Response to antipsychotic treatment;
PAAD	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg04389838	chr3:44770851	ZNF501	-0.51	-4.34	-0.33	2.6e-5	Depressive symptoms;
PAAD	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg00147160	chr1:26503991	CNKSR1	0.47	5.24	0.39	5.29e-7	Height;
PAAD	cis	rs728616	0.681	rs12413174	chr10:82062404	G/A	cg19423196	chr10:82049429	MAT1A	0.5	4.87	0.37	2.78e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.59	-0.52	3.07e-12	Coronary artery disease;
PAAD	cis	rs9616064	0.670	rs9616045	chr22:46949292	C/T	cg03318428	chr22:46971703	NA	0.41	4.97	0.37	1.81e-6	Urate levels in obese individuals;
PAAD	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg01851573	chr8:8652454	MFHAS1	0.67	5.71	0.42	5.89e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg07689907	chr11:61582574	FADS1	0.48	4.66	0.35	6.91e-6	Trans fatty acid levels;
PAAD	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.37	-0.4	2.86e-7	Reticulocyte count;
PAAD	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3755397	1	rs3755397	chr2:242294913	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.82	-4.89	-0.37	2.5e-6	Chronic lymphocytic leukemia;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.76	-5.72	-0.42	5.49e-8	Mean platelet volume;
PAAD	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.59	5.42	0.4	2.26e-7	Breast cancer;
PAAD	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg06484146	chr7:12443880	VWDE	-0.63	-4.73	-0.36	5.11e-6	Coronary artery disease;
PAAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.45	4.86	0.37	2.89e-6	Cystic fibrosis severity;
PAAD	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.56	4.87	0.37	2.76e-6	Life satisfaction;
PAAD	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg15942720	chr14:51706980	TMX1	0.51	4.46	0.34	1.56e-5	Cancer;
PAAD	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.52	-5.22	-0.39	5.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.59	-6.76	-0.48	2.78e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg21300403	chr2:198650112	BOLL	-0.63	-4.25	-0.33	3.73e-5	Ulcerative colitis;
PAAD	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg19026207	chr17:26645466	TMEM97	-0.41	-4.38	-0.33	2.21e-5	Osteoprotegerin levels;
PAAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg24699146	chr1:24152579	HMGCL	0.48	5.15	0.39	7.88e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.35	4.82	0.36	3.44e-6	Lymphocyte counts;
PAAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.56	-5.27	-0.39	4.52e-7	Neurofibrillary tangles;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.49	7.3	0.51	1.49e-11	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.67	-5.37	-0.4	2.85e-7	Obesity (extreme);
PAAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.06e-8	Blood metabolite levels;
PAAD	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.4	0.46	1.82e-9	Coffee consumption (cups per day);
PAAD	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.48	-0.34	1.48e-5	Dementia with Lewy bodies;
PAAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs7627468	0.955	rs6438712	chr3:121933505	A/G	cg17240004	chr3:121949083	CASR	0.52	4.52	0.34	1.22e-5	Kidney stones;
PAAD	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.06	14.05	0.75	2.8e-29	Body mass index;
PAAD	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.66	-7.19	-0.5	2.67e-11	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25130672	chr12:104850576	CHST11	0.64	7.05	0.5	5.98e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg03517284	chr6:25882590	NA	-0.54	-4.47	-0.34	1.5e-5	Iron status biomarkers;
PAAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-1.06	-15.18	-0.78	2.96e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.91	-0.37	2.36e-6	Neuroticism;
PAAD	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.4	0.34	1.99e-5	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24365846	chr2:55844806	SMEK2	0.65	6.65	0.47	4.87e-10	Obesity-related traits;
PAAD	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg13332499	chr17:408570	NA	0.74	9.1	0.59	4.72e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs62025270	0.547	rs338520	chr15:86214798	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-4.62	-0.35	8.24e-6	Idiopathic pulmonary fibrosis;
PAAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.86	14.58	0.76	1.15e-30	Schizophrenia;
PAAD	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.7	-6.94	-0.49	1.04e-10	Retinal vascular caliber;
PAAD	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.5	-5.11	-0.38	9.56e-7	Breast cancer;
PAAD	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.66	7.19	0.5	2.81e-11	Corneal astigmatism;
PAAD	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.68	7.74	0.53	1.27e-12	Age at first birth;
PAAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg10518543	chr12:38710700	ALG10B	0.51	4.96	0.37	1.86e-6	Morning vs. evening chronotype;
PAAD	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.51	-4.9	-0.37	2.48e-6	Mortality in heart failure;
PAAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.58	-6.6	-0.47	6.31e-10	Prostate cancer;
PAAD	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg18939081	chr1:31884902	SERINC2	0.49	5.61	0.41	9.22e-8	Alcohol dependence;
PAAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-4.52	-0.34	1.22e-5	Breast cancer;
PAAD	cis	rs9649465	0.967	rs12706546	chr7:123353414	G/A	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.85	9.98	0.63	2.43e-18	Blood metabolite ratios;
PAAD	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.72	7.33	0.51	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-4.41	-0.34	1.93e-5	Putamen volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14259179	chr1:92545768	BTBD8	0.57	6.47	0.46	1.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg27411982	chr8:10470053	RP1L1	0.4	4.34	0.33	2.59e-5	Neuroticism;
PAAD	cis	rs11718455	0.585	rs11710794	chr3:43930119	T/G	cg00181669	chr3:44000978	NA	-0.55	-5.85	-0.43	2.9e-8	Coronary artery disease;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.59	-5.68	-0.42	6.77e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	trans	rs3935740	0.649	rs7167946	chr15:81628546	C/T	cg27605748	chr5:42951711	NA	-0.9	-6.57	-0.47	7.44e-10	Parkinson's disease;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg00945038	chr17:61921165	SMARCD2	0.45	5.34	0.4	3.36e-7	Prudent dietary pattern;
PAAD	cis	rs4073221	0.929	rs7371812	chr3:18281071	C/T	cg07694806	chr3:18168406	NA	0.73	4.78	0.36	4.06e-6	Parkinson's disease;
PAAD	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.79	0.42	3.99e-8	Ileal carcinoids;
PAAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.87	10.09	0.63	1.24e-18	Ulcerative colitis;
PAAD	cis	rs7246865	0.510	rs2305752	chr19:17186127	A/C	cg19418318	chr19:17219073	MYO9B	0.32	4.62	0.35	8.06e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16625916	chr2:80085213	CTNNA2	0.61	6.82	0.48	2.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.2	-0.5	2.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg10411590	chr13:21900810	NA	0.63	7.16	0.5	3.2e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.54	-0.35	1.14e-5	Systemic lupus erythematosus;
PAAD	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.61	-4.46	-0.34	1.59e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1570884	0.503	rs7982555	chr13:50111510	G/A	cg03651054	chr13:50194643	NA	0.34	4.34	0.33	2.58e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.82	-0.54	8.43e-13	Parkinson's disease;
PAAD	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg10820045	chr2:198174542	NA	0.45	4.38	0.34	2.16e-5	Dermatomyositis;
PAAD	cis	rs3026101	0.671	rs3026136	chr17:5310308	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg12454169	chr2:30669597	LCLAT1	0.81	7.04	0.5	6.27e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.49	-4.85	-0.37	3.03e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.48	0.34	1.47e-5	Educational attainment;
PAAD	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg02016764	chr4:38805732	TLR1	-0.54	-4.26	-0.33	3.64e-5	Breast cancer;
PAAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.49	5.02	0.38	1.42e-6	Corneal astigmatism;
PAAD	cis	rs6141769	0.542	rs6058819	chr20:31303942	T/C	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg20240860	chr11:44087423	ACCS	-0.78	-4.86	-0.37	2.94e-6	IgA nephropathy;
PAAD	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.17	19.44	0.84	4.72e-43	Multiple myeloma;
PAAD	cis	rs17227506	0.730	rs35380952	chr8:13457292	G/A	cg02718516	chr8:13424094	C8orf48	-0.32	-4.26	-0.33	3.59e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.08	15.6	0.78	2.26e-33	Multiple system atrophy;
PAAD	cis	rs7640424	0.502	rs326359	chr3:107820619	G/A	cg09227934	chr3:107805635	CD47	0.69	11.08	0.67	2.84e-21	Body mass index;
PAAD	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs2342371	0.756	rs4916492	chr3:196106306	G/A	cg09821211	chr3:195954098	OSTalpha	0.64	6.01	0.44	1.34e-8	Fat distribution (HIV);
PAAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.65	-7.8	-0.53	9.37e-13	Longevity;Endometriosis;
PAAD	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.47	5.13	0.38	8.77e-7	Heart rate;
PAAD	cis	rs4666360	1.000	rs6725416	chr2:20336773	C/T	cg23291376	chr2:20336282	NA	-0.41	-4.61	-0.35	8.58e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg05895507	chr15:77155635	SCAPER	0.36	4.41	0.34	1.97e-5	Blood metabolite levels;
PAAD	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.71	7.04	0.5	6.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.56	5.79	0.42	4e-8	Testicular germ cell tumor;
PAAD	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg25753631	chr6:25732923	NA	0.39	4.99	0.38	1.63e-6	Blood metabolite levels;
PAAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-7.43	-0.52	7.32e-12	Colorectal cancer;
PAAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg03983715	chr16:68378420	PRMT7	-0.8	-5.74	-0.42	4.87e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-1.12	-8.97	-0.59	1e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs364477	0.818	rs438293	chr9:979610	A/T	cg13952963	chr9:998547	NA	0.58	4.69	0.36	5.97e-6	Major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19381814	chr7:50800426	GRB10	-0.59	-6.77	-0.48	2.65e-10	Obesity-related traits;
PAAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg14440974	chr22:39074834	NA	-0.6	-7.33	-0.51	1.27e-11	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10951786	chr1:104068603	RNPC3	0.62	6.59	0.47	6.7e-10	Obesity-related traits;
PAAD	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26926768	chr12:34528122	NA	0.4	4.73	0.36	5.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	1.12	8.42	0.56	2.68e-14	Inflammatory bowel disease;
PAAD	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg22875332	chr1:76189707	ACADM	-0.49	-4.86	-0.37	2.86e-6	Daytime sleep phenotypes;
PAAD	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-8.77	-0.58	3.28e-15	Depression;
PAAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12963246	chr6:28129442	ZNF389	0.57	4.54	0.35	1.14e-5	Cardiac Troponin-T levels;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-6.69	-0.48	3.95e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.21	-0.39	5.99e-7	Systemic lupus erythematosus;
PAAD	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.74	-5.27	-0.39	4.55e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.49	4.7	0.36	5.79e-6	Resistin levels;
PAAD	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.94	12.31	0.71	1.34e-24	Mean corpuscular volume;
PAAD	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1.01e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.71	8.34	0.56	4.23e-14	Extrinsic epigenetic age acceleration;
PAAD	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.21	6.46	0.46	1.37e-9	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs901683	1.000	rs71496621	chr10:46076348	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.98	7.89	0.54	5.47e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	4.59	0.35	9.12e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg20578329	chr17:80767326	TBCD	-0.8	-5.41	-0.4	2.42e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.44	4.32	0.33	2.79e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg17099306	chr13:50123645	RCBTB1	-0.42	-4.28	-0.33	3.26e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs61542988	0.532	rs10240168	chr7:22819334	C/G	cg11367502	chr7:22862612	TOMM7	0.62	5.96	0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.42	5.18	0.39	6.87e-7	Thyroid stimulating hormone;
PAAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.96	-9.77	-0.62	8.63e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.6	7.25	0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg06463185	chr17:3833770	ATP2A3	-0.88	-7.51	-0.52	4.65e-12	Glucose homeostasis traits;
PAAD	cis	rs4356203	0.870	rs214901	chr11:17227728	A/G	cg15432903	chr11:17409602	KCNJ11	0.43	4.54	0.35	1.11e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg18764771	chr6:116381957	FRK	0.41	7.01	0.49	7.28e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg25753631	chr6:25732923	NA	-0.47	-5.38	-0.4	2.8e-7	Iron status biomarkers;
PAAD	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.61	-5.9	-0.43	2.28e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.44	-4.51	-0.34	1.31e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-6.62	-0.47	5.85e-10	Glomerular filtration rate;
PAAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg26174226	chr8:58114915	NA	-0.66	-4.93	-0.37	2.11e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.63	5.89	0.43	2.37e-8	Height;
PAAD	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.73	7.79	0.53	9.97e-13	Type 2 diabetes;
PAAD	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.45	5.86	0.43	2.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.6	6.98	0.49	8.52e-11	HDL cholesterol levels;
PAAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.89	12.56	0.71	2.95e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.6	6.04	0.44	1.12e-8	Essential tremor;
PAAD	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.94	-0.37	2.07e-6	Pulmonary function;
PAAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09191750	chr10:124222331	HTRA1	-0.72	-6.64	-0.47	5.14e-10	Neuroticism;
PAAD	cis	rs12760731	0.641	rs10798605	chr1:178294872	G/A	cg00404053	chr1:178313656	RASAL2	0.72	5.42	0.4	2.29e-7	Obesity-related traits;
PAAD	cis	rs6545883	0.602	rs11125871	chr2:61470126	C/T	cg14146966	chr2:61757674	XPO1	-0.37	-4.55	-0.35	1.09e-5	Tuberculosis;
PAAD	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	1.15	17.78	0.82	5.69e-39	Multiple myeloma;
PAAD	cis	rs621942	1.000	rs621942	chr11:85783738	A/C	cg07180834	chr11:85838833	NA	0.46	4.48	0.34	1.44e-5	Tourette syndrome;
PAAD	cis	rs89107	0.688	rs283081	chr6:118605821	G/A	cg21191810	chr6:118973309	C6orf204	0.46	6.34	0.46	2.52e-9	Cardiac structure and function;
PAAD	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	4.27	0.33	3.46e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-4.68	-0.35	6.4e-6	Joint mobility (Beighton score);
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-7.43	-0.52	7.41e-12	Longevity;Endometriosis;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13732083	chr21:47605072	C21orf56	0.44	4.32	0.33	2.84e-5	Testicular germ cell tumor;
PAAD	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-4.44	-0.34	1.75e-5	Red blood cell count;
PAAD	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg02631450	chr22:32366979	NA	1.08	5.76	0.42	4.44e-8	Childhood ear infection;
PAAD	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg13897122	chr2:103039542	IL18RAP	0.35	4.38	0.33	2.22e-5	Asthma;
PAAD	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.62	-5.34	-0.4	3.33e-7	Resistin levels;
PAAD	cis	rs71520386	0.898	rs12536091	chr7:22828200	C/G	cg04907244	chr7:22894795	SNORD93	0.49	4.37	0.33	2.28e-5	Fibrinogen levels;
PAAD	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-5.24	-0.39	5.37e-7	Response to antipsychotic treatment;
PAAD	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.49	-4.68	-0.35	6.36e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.8	0.43	3.66e-8	Blood protein levels;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.7	-7.62	-0.53	2.46e-12	Lung cancer;
PAAD	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.45	5.42	0.4	2.29e-7	Systemic lupus erythematosus;
PAAD	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg20283391	chr11:68216788	NA	-0.53	-5.21	-0.39	6.12e-7	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00988491	chr5:17275894	BASP1	-0.64	-6.51	-0.47	1.02e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-4.53	-0.34	1.2e-5	Lung cancer;
PAAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.77	9.23	0.6	2.2e-16	Emphysema distribution in smoking;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.65	6.46	0.46	1.36e-9	Triglycerides;
PAAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.81	8.76	0.58	3.59e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg05082376	chr22:42548792	NA	-0.52	-5.38	-0.4	2.81e-7	Cognitive function;
PAAD	cis	rs34156428	0.657	rs10734249	chr11:16775254	A/G	cg15111638	chr11:16631993	NA	0.43	4.37	0.33	2.29e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11665867	0.616	rs2604909	chr19:41297615	C/T	cg08367223	chr19:41255304	C19orf54;SNRPA	0.48	4.43	0.34	1.77e-5	Hematocrit;
PAAD	cis	rs73198271	0.628	rs56188408	chr8:8592158	G/C	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18621852	chr3:10150065	C3orf24	0.72	6.03	0.44	1.22e-8	Alzheimer's disease;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.95	-0.43	1.74e-8	Fear of minor pain;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.61	6.07	0.44	9.58e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg24966363	chr8:8932588	NA	-0.36	-4.43	-0.34	1.78e-5	Cervical cancer;
PAAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg25883020	chr8:41504993	NKX6-3	0.36	4.31	0.33	2.94e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg27478167	chr7:817139	HEATR2	-0.6	-4.72	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.74	7.96	0.54	3.77e-13	Lung cancer;
PAAD	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.67	5.19	0.39	6.53e-7	Alzheimer's disease (survival time);
PAAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.89	7.15	0.5	3.35e-11	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg15017067	chr4:17643749	FAM184B	0.39	4.46	0.34	1.61e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	4.67	0.35	6.71e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	7.26	0.51	1.92e-11	Lymphocyte counts;
PAAD	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg19442545	chr10:75533431	FUT11	0.45	4.62	0.35	8.24e-6	Inflammatory bowel disease;
PAAD	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.23	-0.45	4.39e-9	Chronic sinus infection;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.82	0.54	8.19e-13	Prudent dietary pattern;
PAAD	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.53	-4.67	-0.35	6.67e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.78e-7	White blood cell count;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.63	5.63	0.42	8.58e-8	Lung cancer;
PAAD	cis	rs735539	0.521	rs9552289	chr13:21427839	C/T	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.69	-6.52	-0.47	9.67e-10	Obesity-related traits;
PAAD	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg02297831	chr4:17616191	MED28	0.56	5.14	0.38	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.6	-5.47	-0.41	1.84e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.2	0.55	9.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.6	6.24	0.45	4.05e-9	Testicular germ cell tumor;
PAAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg10589385	chr1:150898437	SETDB1	-0.35	-4.3	-0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.51	5.17	0.39	7.15e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.63	-6.33	-0.46	2.67e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg27490568	chr2:178487706	NA	0.43	4.61	0.35	8.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.71	-7.1	-0.5	4.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.59e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.92	-0.37	2.2e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-1.01	-4.96	-0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.65	-6.02	-0.44	1.29e-8	White matter hyperintensity burden;
PAAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg00579200	chr11:133705235	NA	-0.51	-5.79	-0.43	3.81e-8	Childhood ear infection;
PAAD	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.9	-7.65	-0.53	2.13e-12	Obesity-related traits;
PAAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.92	8.25	0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs3026101	0.671	rs2107151	chr17:5297338	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg11416102	chr8:651193	ERICH1	0.91	5.69	0.42	6.24e-8	IgG glycosylation;
PAAD	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg02683114	chr2:24398427	C2orf84	-0.51	-4.88	-0.37	2.61e-6	Asthma;
PAAD	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.8	0.36	3.74e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-7.02	-0.49	7.08e-11	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.44	-0.68	2.92e-22	Chronic sinus infection;
PAAD	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.71	7.04	0.5	6.36e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.62	4.94	0.37	2e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14119001	chr9:139324193	INPP5E	-0.53	-5.06	-0.38	1.18e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.52	6.78	0.48	2.52e-10	Schizophrenia;
PAAD	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.44	7.1	0.5	4.56e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs61759167	0.863	rs1393064	chr1:3099138	G/C	cg22396632	chr1:3079212	PRDM16	-0.56	-5.16	-0.39	7.53e-7	Motion sickness;
PAAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.73	7.38	0.51	9.51e-12	Height;
PAAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.9	10.11	0.63	1.07e-18	Total cholesterol levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18921030	chr2:207678451	NA	-0.6	-6.5	-0.47	1.1e-9	Obesity-related traits;
PAAD	cis	rs308971	0.656	rs2648347	chr3:12057200	T/G	cg02700894	chr3:12045449	SYN2	0.6	5.11	0.38	9.4e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-7.85	-0.54	6.91e-13	Systemic lupus erythematosus;
PAAD	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24110177	chr3:50126178	RBM5	-0.6	-6.66	-0.48	4.6e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg01766943	chr2:54829624	SPTBN1	0.54	4.98	0.37	1.68e-6	Schizophrenia;
PAAD	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg26205652	chr12:48591994	NA	0.7	4.83	0.36	3.34e-6	Prostate cancer;
PAAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.38	-4.84	-0.37	3.22e-6	Prostate cancer;
PAAD	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.62	6.79	0.48	2.35e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.79	9.93	0.63	3.19e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	6.4	0.46	1.82e-9	IgG glycosylation;
PAAD	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg10932868	chr11:921992	NA	0.44	4.67	0.35	6.7e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.68	-0.48	4.27e-10	Mood instability;
PAAD	cis	rs883565	0.740	rs2037655	chr3:39072754	T/C	cg01426195	chr3:39028469	NA	-0.7	-7.43	-0.52	7.5e-12	Handedness;
PAAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg18764771	chr6:116381957	FRK	0.45	7.87	0.54	6.14e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1329189	1.000	rs7088525	chr10:130004489	C/T	cg17972361	chr10:130010134	NA	-0.47	-4.74	-0.36	4.86e-6	Orofacial clefts;
PAAD	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.72	9.52	0.61	3.91e-17	Educational attainment;
PAAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22307297	chr20:60903441	LAMA5	-0.41	-4.25	-0.33	3.7e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg14784868	chr12:69753453	YEATS4	-0.52	-4.49	-0.34	1.43e-5	Response to diuretic therapy;
PAAD	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.56	-5.12	-0.38	8.95e-7	Menopause (age at onset);
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.81	-10.58	-0.65	5.83e-20	Vitiligo;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.49	-6.09	-0.44	8.81e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.9	7.19	0.5	2.75e-11	Chronic kidney disease;
PAAD	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg24687543	chr11:63912206	MACROD1	0.53	4.68	0.36	6.24e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.61	-5.45	-0.4	2.03e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.77	8.26	0.56	6.56e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.83	-9.15	-0.6	3.55e-16	Prudent dietary pattern;
PAAD	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg03315344	chr16:75512273	CHST6	0.64	7.37	0.51	1.04e-11	Dupuytren's disease;
PAAD	cis	rs9549328	0.837	rs9549330	chr13:113648404	G/T	cg08614441	chr13:113633676	MCF2L	-0.43	-4.29	-0.33	3.13e-5	Systolic blood pressure;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg17541715	chr7:1216824	NA	-0.5	-5.71	-0.42	5.72e-8	Longevity;Endometriosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23257840	chr19:57703144	ZNF264	0.63	6.59	0.47	6.66e-10	Myopia (pathological);
PAAD	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs1499972	0.938	rs817500	chr3:117713444	G/T	cg07612923	chr3:117604196	NA	0.93	6.36	0.46	2.3e-9	Schizophrenia;
PAAD	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg14458575	chr2:238380390	NA	0.5	4.39	0.34	2.12e-5	Prostate cancer;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg09835421	chr16:68378352	PRMT7	-1.03	-7.02	-0.49	7.06e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	7.65	0.53	2.17e-12	Platelet count;
PAAD	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.63	-5.39	-0.4	2.66e-7	Corneal structure;
PAAD	cis	rs3736485	1.000	rs11631408	chr15:51746236	A/G	cg19558802	chr15:51695713	GLDN	-0.44	-4.4	-0.34	2e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.7	-6.39	-0.46	1.88e-9	Type 2 diabetes;
PAAD	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.94	0.66	6.43e-21	Chronic sinus infection;
PAAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg02640540	chr1:67518911	SLC35D1	0.55	4.74	0.36	4.96e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs7631605	0.518	rs2276808	chr3:36986992	C/T	cg10333520	chr3:36987040	TRANK1	0.41	5.66	0.42	7.16e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-1.14	-10.89	-0.66	8.98e-21	Corneal structure;
PAAD	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg08155312	chr18:77659949	NA	-0.44	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-4.76	-0.36	4.38e-6	Asthma and hay fever;
PAAD	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.62	6.36	0.46	2.25e-9	Resting heart rate;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg11416102	chr8:651193	ERICH1	-0.87	-5.06	-0.38	1.21e-6	IgG glycosylation;
PAAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg18765565	chr5:669397	TPPP	0.43	4.64	0.35	7.55e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	5.64	0.42	8.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.72	7.45	0.52	6.61e-12	Type 2 diabetes;
PAAD	cis	rs4273100	0.790	rs2048230	chr17:19276199	G/A	cg18093559	chr17:18951025	GRAP	-0.52	-4.38	-0.33	2.17e-5	Schizophrenia;
PAAD	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.75	8.53	0.57	1.37e-14	Systemic lupus erythematosus;
PAAD	cis	rs2031532	0.589	rs4941643	chr13:50068387	C/T	cg03651054	chr13:50194643	NA	0.33	4.39	0.34	2.1e-5	Cardiac hypertrophy;
PAAD	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.84	-0.43	3.12e-8	Mood instability;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.79	7.67	0.53	1.95e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12913538	0.862	rs7162434	chr15:62888070	A/G	cg09983546	chr15:62884068	NA	0.63	7.2	0.5	2.6e-11	Sleep depth;
PAAD	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.62	6.21	0.45	4.86e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.65	7.15	0.5	3.42e-11	Menopause (age at onset);
PAAD	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.54	-5.4	-0.4	2.47e-7	Migraine;
PAAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.54	-7.34	-0.51	1.17e-11	Renal cell carcinoma;
PAAD	cis	rs2415984	0.579	rs8010773	chr14:46956863	T/C	cg14871534	chr14:47121158	RPL10L	-0.49	-5.08	-0.38	1.11e-6	Number of children ever born;
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg15181151	chr6:150070149	PCMT1	0.53	5.64	0.42	7.95e-8	Lung cancer;
PAAD	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs12989701	0.877	rs36085158	chr2:127869982	C/T	cg00091827	chr2:127863656	BIN1	0.6	4.54	0.35	1.14e-5	Alzheimer's disease (late onset);
PAAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.68	6.13	0.45	7.26e-9	Breast cancer;
PAAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.55	7.42	0.52	7.58e-12	Renal cell carcinoma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01861603	chr16:4732973	MGRN1	0.62	6.94	0.49	1.06e-10	Smoking initiation;
PAAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	5.99	0.44	1.47e-8	Joint mobility (Beighton score);
PAAD	cis	rs10207060	0.522	rs62183177	chr2:240712665	A/G	cg07506560	chr2:240697449	NA	0.47	4.83	0.36	3.32e-6	Obesity-related traits;
PAAD	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.35	-0.33	2.44e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.74	-8.5	-0.57	1.68e-14	Childhood ear infection;
PAAD	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.6	6.69	0.48	4.04e-10	Resting heart rate;
PAAD	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.4	-4.69	-0.36	6.08e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.91	-9.2	-0.6	2.57e-16	Response to antineoplastic agents;
PAAD	cis	rs818427	0.508	rs2909787	chr5:112168130	G/C	cg06941702	chr5:112196734	SRP19	-0.52	-4.89	-0.37	2.52e-6	Total body bone mineral density;
PAAD	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.65	-6.81	-0.48	2.12e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25910443	chr9:97488953	C9orf3	-0.65	-5.54	-0.41	1.31e-7	Neuroticism;
PAAD	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	7.28	0.51	1.7e-11	Leprosy;
PAAD	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.72	-0.36	5.32e-6	Type 2 diabetes;
PAAD	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.71	-8.22	-0.55	8.56e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs694739	0.861	rs479552	chr11:64110683	G/C	cg22916017	chr11:64110731	CCDC88B	0.4	4.64	0.35	7.45e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg11062466	chr8:58055876	NA	0.69	4.79	0.36	3.92e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs73787773	0.866	rs60370278	chr5:111484212	T/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.72	-4.28	-0.33	3.29e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs7591163	0.883	rs11891398	chr2:228723357	C/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.48	4.8	0.36	3.72e-6	Blood pressure;
PAAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.93	-16.19	-0.8	6.66e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.56	-0.35	1.04e-5	Mean corpuscular volume;
PAAD	cis	rs950880	0.710	rs2160202	chr2:102986154	G/A	cg23450938	chr2:102972792	NA	0.45	4.59	0.35	9.03e-6	Serum protein levels (sST2);
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs7255045	0.788	rs2290689	chr19:12958360	T/C	cg14181355	chr19:12984996	MAST1	-0.46	-4.57	-0.35	1.02e-5	Mean corpuscular volume;
PAAD	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-5.13	-0.38	8.54e-7	Menarche (age at onset);
PAAD	cis	rs1519814	1.000	rs4271006	chr8:121146640	T/G	cg22335954	chr8:121166405	COL14A1	-0.63	-5.5	-0.41	1.58e-7	Breast cancer;
PAAD	cis	rs6142102	0.602	rs4911395	chr20:32579901	T/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.93	0.37	2.18e-6	Skin pigmentation;
PAAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.92	-0.37	2.18e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.71	-7.35	-0.51	1.11e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.78	-0.62	7.99e-18	Alzheimer's disease (late onset);
PAAD	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14179383	chr20:33133265	MAP1LC3A	-0.66	-6.35	-0.46	2.36e-9	Obesity-related traits;
PAAD	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.67	-6.34	-0.46	2.49e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.61	6.91	0.49	1.22e-10	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-5.3	-0.4	3.93e-7	Testicular germ cell tumor;
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.4	-0.34	2e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.45	0.57	2.21e-14	Bipolar disorder;
PAAD	cis	rs13315871	0.929	rs35007301	chr3:58230352	G/A	cg20936604	chr3:58311152	NA	-0.78	-4.25	-0.33	3.7e-5	Cholesterol, total;
PAAD	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12431939	0.626	rs7160810	chr14:51716467	G/A	cg23942311	chr14:51606299	NA	0.53	4.71	0.36	5.44e-6	Cancer;
PAAD	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.72	8.07	0.55	2.01e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.95	-7.87	-0.54	6.18e-13	Initial pursuit acceleration;
PAAD	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	trans	rs901683	1.000	rs9422657	chr10:46053061	G/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg06285486	chr11:65729635	SART1	0.42	4.25	0.33	3.72e-5	Eosinophil percentage of white cells;
PAAD	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.73	6.64	0.47	5.11e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg17845761	chr1:175162550	KIAA0040	-0.3	-4.56	-0.35	1.06e-5	Alcohol dependence;
PAAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg25837213	chr17:80849375	TBCD	-0.56	-4.65	-0.35	7.18e-6	Breast cancer;
PAAD	cis	rs7577696	0.785	rs7592239	chr2:32370258	C/A	cg02381751	chr2:32503542	YIPF4	-0.48	-4.64	-0.35	7.61e-6	Inflammatory biomarkers;
PAAD	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.44	4.32	0.33	2.8e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.34e-5	Longevity (90 years and older);
PAAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.39	-0.51	9.03e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.96	-11.64	-0.69	8.85e-23	Cognitive function;
PAAD	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg24553058	chr2:113831203	IL1F10	0.39	4.39	0.34	2.15e-5	Inflammatory biomarkers;
PAAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.61	-6.19	-0.45	5.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.24	0.56	7.54e-14	Hypertriglyceridemia;
PAAD	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg00181669	chr3:44000978	NA	-0.44	-4.38	-0.33	2.24e-5	Coronary artery disease;
PAAD	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg23024343	chr7:107201750	COG5	0.56	4.6	0.35	8.96e-6	Coronary artery disease;
PAAD	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.63	-5.18	-0.39	6.96e-7	Fibrinogen levels;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.8	0.66	1.52e-20	Platelet count;
PAAD	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.97	7.53	0.52	4.18e-12	Lymphocyte counts;
PAAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	8.02	0.55	2.69e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.5e-9	Hepatitis;
PAAD	cis	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs7189233	1.000	rs62048543	chr16:53534624	T/C	cg00221382	chr16:54322308	NA	-0.28	-4.29	-0.33	3.11e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.73	8.57	0.57	1.12e-14	Type 2 diabetes;
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.49	4.29	0.33	3.13e-5	Platelet count;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.7	6.93	0.49	1.15e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs1334894	0.892	rs11545925	chr6:35542526	T/A	cg07213720	chr6:35227408	ZNF76	-0.82	-4.47	-0.34	1.55e-5	Coronary artery disease;
PAAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg07061783	chr6:25882402	NA	0.45	4.35	0.33	2.52e-5	Blood metabolite levels;
PAAD	cis	rs988913	1.000	rs9370343	chr6:54820676	G/A	cg03513858	chr6:54763001	FAM83B	-0.42	-4.59	-0.35	9.39e-6	Menarche (age at onset);
PAAD	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg04721828	chr11:48285200	OR4X1	-0.4	-5.13	-0.38	8.91e-7	Migraine - clinic-based;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.57	0.52	3.34e-12	Alzheimer's disease;
PAAD	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.02	0.55	2.7e-13	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.75	8.41	0.56	2.74e-14	Lung cancer;
PAAD	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.66	6.25	0.45	3.88e-9	Refractive astigmatism;
PAAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg23920097	chr1:209922102	NA	-0.48	-4.78	-0.36	4.03e-6	Red blood cell count;
PAAD	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg14703610	chr5:56206110	C5orf35	0.61	5.5	0.41	1.59e-7	Coronary artery disease;
PAAD	cis	rs1499972	0.648	rs57945129	chr3:117641724	C/T	cg07612923	chr3:117604196	NA	0.72	5.31	0.4	3.76e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.58	6.0	0.44	1.36e-8	Personality dimensions;
PAAD	cis	rs12900413	0.687	rs12908489	chr15:90304269	A/G	cg24249390	chr15:90295951	MESP1	-0.5	-5.28	-0.39	4.37e-7	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.5	-0.41	1.58e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	0.95	11.04	0.67	3.53e-21	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.96	0.54	3.62e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-5.96	-0.43	1.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.63	-5.77	-0.42	4.23e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.02	-0.63	1.9e-18	Response to antipsychotic treatment;
PAAD	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.64e-9	Educational attainment;
PAAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.5	6.07	0.44	9.98e-9	Monobrow;
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.74	8.28	0.56	5.98e-14	Prostate cancer;
PAAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.74	-9.58	-0.61	2.75e-17	Breast cancer;
PAAD	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	6.18	0.45	5.76e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-4.86	-0.37	2.96e-6	Retinal vascular caliber;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.42	-0.46	1.61e-9	Body mass index;
PAAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs710216	0.619	rs11210771	chr1:43444560	T/C	cg07803811	chr1:43423981	SLC2A1	-0.46	-4.42	-0.34	1.83e-5	Red cell distribution width;
PAAD	cis	rs1891275	0.515	rs2421694	chr10:93516104	A/G	cg07889827	chr10:93443413	NA	-0.45	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01764079	chr8:144718741	ZNF623	0.63	6.61	0.47	6.18e-10	Pancreatic cancer;
PAAD	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.33	-0.51	1.29e-11	Neuroticism;
PAAD	cis	rs3126085	0.515	rs7534742	chr1:152362727	C/T	cg26876637	chr1:152193138	HRNR	-0.6	-4.45	-0.34	1.66e-5	Atopic dermatitis;
PAAD	cis	rs11037575	0.739	rs10838154	chr11:43725619	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2e-5	Neuroblastoma;
PAAD	cis	rs7301016	1.000	rs11613132	chr12:62856444	A/C	cg11441379	chr12:63026424	NA	0.85	6.18	0.45	5.51e-9	IgG glycosylation;
PAAD	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.04	14.87	0.77	1.92e-31	Body mass index (adult);
PAAD	cis	rs709400	0.598	rs11627529	chr14:104004557	C/T	cg26031613	chr14:104095156	KLC1	0.81	8.3	0.56	5.18e-14	Body mass index;
PAAD	cis	rs76878669	0.917	rs10219183	chr11:66090032	A/C	cg10685839	chr11:66611485	RCE1	-0.48	-4.71	-0.36	5.55e-6	Educational attainment (years of education);
PAAD	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.56	6.07	0.44	9.66e-9	Bladder cancer;
PAAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00292662	chr22:38071168	LGALS1	-0.64	-6.7	-0.48	3.91e-10	Fat distribution (HIV);
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg05554000	chr7:158905015	VIPR2	0.57	4.99	0.38	1.64e-6	Facial morphology (factor 20);
PAAD	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.73	5.62	0.41	9.01e-8	Crohn's disease;
PAAD	cis	rs2885056	0.891	rs12460574	chr19:10689955	G/A	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.63	6.81	0.48	2.12e-10	Bladder cancer;
PAAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.49	4.65	0.35	7.05e-6	Monocyte count;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg21724239	chr8:58056113	NA	0.7	5.5	0.41	1.55e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs797680	0.856	rs602204	chr1:93727579	A/G	cg04535902	chr1:92947332	GFI1	-0.45	-4.3	-0.33	3.1e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.57	-7.29	-0.51	1.56e-11	Lewy body disease;
PAAD	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs6987853	0.933	rs2356610	chr8:42446238	T/G	cg09913449	chr8:42400586	C8orf40	0.48	5.12	0.38	9.02e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2134046	0.587	rs11854289	chr15:82558802	C/T	cg00614314	chr15:82944287	LOC80154	-0.54	-5.19	-0.39	6.74e-7	Cognitive ability;
PAAD	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg16576597	chr16:28551801	NUPR1	0.63	6.79	0.48	2.37e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	8.13	0.55	1.37e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	1.25	7.74	0.53	1.32e-12	Skin colour saturation;
PAAD	cis	rs11892454	0.544	rs6739177	chr2:25952796	T/C	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.05e-6	Heschl's gyrus morphology;
PAAD	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.96	12.16	0.7	3.35e-24	Menopause (age at onset);
PAAD	cis	rs12776158	0.901	rs12414706	chr10:71214729	G/A	cg12610070	chr10:71211762	TSPAN15	-0.5	-4.98	-0.37	1.67e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg00990874	chr7:1149470	C7orf50	-0.89	-8.84	-0.58	2.2e-15	Bronchopulmonary dysplasia;
PAAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.71	-8.3	-0.56	5.34e-14	Bone mineral density;
PAAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07677032	chr17:61819896	STRADA	-0.53	-5.39	-0.4	2.63e-7	Prudent dietary pattern;
PAAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.69	-5.68	-0.42	6.57e-8	Neuroticism;
PAAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.76	9.47	0.61	5.07e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4443100	0.874	rs6003483	chr22:23379625	T/C	cg14186256	chr22:23484241	RTDR1	0.52	4.59	0.35	9.31e-6	Serum parathyroid hormone levels;
PAAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.78	8.25	0.56	7.18e-14	Tonsillectomy;
PAAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg15847926	chr7:2749597	AMZ1	-0.38	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg20933634	chr6:27740509	NA	0.74	4.72	0.36	5.37e-6	Breast cancer;
PAAD	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg09941381	chr10:64027924	RTKN2	0.37	4.35	0.33	2.49e-5	Rheumatoid arthritis;
PAAD	cis	rs4417704	0.551	rs6437221	chr2:241896418	C/T	cg26818257	chr2:241905806	NA	-0.51	-5.5	-0.41	1.56e-7	Joint mobility (Beighton score);
PAAD	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.72	5.92	0.43	2.09e-8	Common traits (Other);
PAAD	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22601191	chr20:60968625	CABLES2	0.62	6.28	0.45	3.43e-9	Colorectal cancer;
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.03	0.44	1.2e-8	Platelet count;
PAAD	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg17325771	chr7:75508891	RHBDD2	0.35	4.89	0.37	2.52e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	4.55	0.35	1.1e-5	Iron status biomarkers;
PAAD	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.96	-13.33	-0.73	2.47e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg00179576	chr16:74483694	GLG1	-0.4	-4.36	-0.33	2.43e-5	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27306034	chr1:155224863	FAM189B	0.68	7.23	0.51	2.2e-11	Myopia (pathological);
PAAD	trans	rs901683	1.000	rs12779204	chr10:46064255	A/G	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.18e-5	Life satisfaction;
PAAD	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.71	7.87	0.54	6.14e-13	Hemoglobin concentration;
PAAD	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	10.75	0.66	2.06e-20	Cognitive test performance;
PAAD	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg05625103	chr10:2543513	NA	0.59	6.15	0.45	6.52e-9	Age-related hearing impairment;
PAAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.85	10.53	0.65	8.41e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10267836	0.777	rs6948130	chr7:30787806	T/A	cg17421561	chr7:31726639	C7orf16	-0.67	-4.86	-0.37	2.91e-6	Glucose homeostasis traits;
PAAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg14926445	chr8:58193284	C8orf71	-0.69	-5.0	-0.38	1.6e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.68	-7.84	-0.54	7.4e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg11802864	chr11:65308245	LTBP3	1.17	6.23	0.45	4.46e-9	Height;
PAAD	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.43	5.99	0.44	1.48e-8	Vitiligo;
PAAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg00206168	chr11:65308501	LTBP3	0.85	5.91	0.43	2.22e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs6547631	0.622	rs10206121	chr2:85930169	T/A	cg24620635	chr2:85921963	GNLY	0.42	5.56	0.41	1.18e-7	Blood protein levels;
PAAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.36	-4.54	-0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs7713065	0.802	rs10036896	chr5:131785178	C/T	cg14196790	chr5:131705035	SLC22A5	-0.47	-4.37	-0.33	2.33e-5	Lung function (FEV1/FVC);
PAAD	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-5.24	-0.39	5.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg25952890	chr19:58913133	NA	-0.66	-5.61	-0.41	9.52e-8	Mean platelet volume;
PAAD	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg01966878	chr4:90757139	SNCA	-0.62	-4.8	-0.36	3.73e-6	Neuroticism;
PAAD	cis	rs11671005	0.572	rs11669127	chr19:59003830	A/G	cg25952890	chr19:58913133	NA	-0.69	-5.51	-0.41	1.51e-7	Mean platelet volume;
PAAD	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg19729930	chr2:74357872	NA	1.03	13.07	0.73	1.18e-26	Gestational age at birth (maternal effect);
PAAD	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg24733560	chr20:60626293	TAF4	0.45	5.67	0.42	7.14e-8	Body mass index;
PAAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs688181	0.523	rs643293	chr6:158114386	G/A	cg10378795	chr6:158080676	ZDHHC14	0.45	4.37	0.33	2.25e-5	Platelet distribution width;
PAAD	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg05425664	chr17:57184151	TRIM37	0.51	4.79	0.36	3.93e-6	Testicular germ cell tumor;
PAAD	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.8	5.94	0.43	1.85e-8	Height;
PAAD	cis	rs17162190	0.698	rs12045800	chr1:26845366	A/G	cg17456097	chr1:26900765	RPS6KA1	0.58	4.7	0.36	5.71e-6	Mean corpuscular volume;
PAAD	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	8.44	0.56	2.38e-14	Body mass index (adult);
PAAD	cis	rs375066	0.935	rs403137	chr19:44427626	A/G	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.65	8.53	0.57	1.38e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.91	-9.85	-0.62	5.3e-18	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9506514	0.722	rs10400670	chr13:21253489	G/A	cg27234864	chr13:21295941	IL17D	0.45	4.46	0.34	1.61e-5	Coronary artery calcification;
PAAD	trans	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg26939375	chr7:64535504	NA	-0.76	-9.02	-0.59	7.55e-16	Aortic root size;
PAAD	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.45	4.64	0.35	7.52e-6	Corneal astigmatism;
PAAD	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.72	6.59	0.47	6.69e-10	Mean platelet volume;
PAAD	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.11	-0.44	8.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs6840360	0.642	rs2724574	chr4:152381800	A/T	cg22705602	chr4:152727874	NA	0.45	4.3	0.33	3.09e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8025118	0.583	rs16970772	chr15:79546155	C/T	cg11862246	chr15:78730200	IREB2	-0.52	-4.34	-0.33	2.58e-5	Cognitive function;
PAAD	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs10065203	0.527	rs173948	chr5:14347771	A/G	cg26595256	chr5:14380529	TRIO	-0.54	-5.87	-0.43	2.65e-8	Paclitaxel-induced neuropathy;
PAAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15728439	chr2:208793660	PLEKHM3	-0.67	-7.01	-0.49	7.11e-11	Obesity-related traits;
PAAD	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.7	6.84	0.49	1.82e-10	Schizophrenia;
PAAD	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg24747557	chr10:131355152	MGMT	0.47	4.61	0.35	8.61e-6	Response to temozolomide;
PAAD	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs55728055	0.661	rs55997441	chr22:31627989	A/G	cg01338084	chr22:32026380	PISD	1.47	7.17	0.5	3.06e-11	Age-related hearing impairment;
PAAD	cis	rs9463078	0.528	rs12196818	chr6:44911414	G/A	cg18551225	chr6:44695536	NA	-0.41	-4.32	-0.33	2.83e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.62	-0.35	8.23e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.45	4.8	0.36	3.73e-6	Age of smoking initiation;
PAAD	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22509189	chr2:225307070	NA	-0.53	-5.18	-0.39	6.96e-7	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7945718	0.810	rs10831910	chr11:12830974	A/G	cg25843174	chr11:12811716	TEAD1	-0.37	-5.13	-0.38	8.6e-7	Educational attainment (years of education);
PAAD	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg12193833	chr17:30244370	NA	-0.62	-4.92	-0.37	2.24e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10957242	chr4:184826299	STOX2	-0.62	-6.54	-0.47	8.87e-10	Smoking initiation;
PAAD	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.87	-0.49	1.51e-10	Triglycerides;
PAAD	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg19630374	chr17:18023558	MYO15A	0.58	6.2	0.45	5.02e-9	Total body bone mineral density;
PAAD	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24133241	chr19:11771597	NA	-0.59	-6.36	-0.46	2.28e-9	Obesity-related traits;
PAAD	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs12422267	0.590	rs12425240	chr12:132418421	G/A	cg23149010	chr12:133378385	GOLGA3	1.0	4.25	0.33	3.69e-5	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-4.79	-0.36	3.93e-6	Educational attainment;
PAAD	cis	rs10490913	1.000	rs1473141	chr10:120143158	A/G	cg04126427	chr10:120840676	EIF3A	0.47	4.98	0.37	1.68e-6	Cancer;
PAAD	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.88	-0.49	1.47e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	6.28	0.45	3.44e-9	Mood instability;
PAAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg14789911	chr21:47582049	C21orf56	-0.51	-5.07	-0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg17541715	chr7:1216824	NA	-0.51	-5.66	-0.42	7.45e-8	Longevity;Endometriosis;
PAAD	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.65	7.37	0.51	1.02e-11	High light scatter reticulocyte count;
PAAD	cis	rs8060686	0.844	rs73597581	chr16:67682234	G/A	cg27539214	chr16:67997921	SLC12A4	-0.74	-4.53	-0.34	1.19e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.54	5.22	0.39	5.72e-7	Height;
PAAD	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg18323236	chr1:24743029	NIPAL3	0.43	4.6	0.35	8.92e-6	Response to interferon beta in multiple sclerosis;
PAAD	trans	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg17745251	chr10:21806139	C10orf140	0.63	6.59	0.47	6.78e-10	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
PAAD	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.88	10.01	0.63	1.95e-18	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04738447	chr16:708575	WDR90	0.55	6.72	0.48	3.49e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg04034577	chr2:241836375	C2orf54	0.33	5.0	0.38	1.53e-6	Urinary metabolites;
PAAD	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	4.56	0.35	1.06e-5	Blood protein levels;
PAAD	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg13207630	chr7:32358064	NA	0.82	4.44	0.34	1.7e-5	Body mass index;
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg00262122	chr8:11665843	FDFT1	0.5	4.76	0.36	4.51e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg06287003	chr12:125626642	AACS	-0.46	-4.54	-0.35	1.14e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs116175783	0.557	rs16845757	chr2:162156260	C/T	cg08807892	chr2:162101083	NA	-0.68	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.52	5.05	0.38	1.23e-6	Hip circumference;
PAAD	cis	rs10950821	0.770	rs2285556	chr7:20692016	A/C	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg20003494	chr4:90757398	SNCA	-0.74	-7.13	-0.5	3.82e-11	Neuroticism;
PAAD	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg08501292	chr6:25962987	TRIM38	0.82	4.35	0.33	2.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.53	5.44	0.4	2.09e-7	Personality dimensions;
PAAD	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.64	4.86	0.37	2.86e-6	Osteoarthritis;
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg00024416	chr22:24240387	NA	-0.61	-4.94	-0.37	2.02e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg08992911	chr2:238395768	MLPH	0.42	4.32	0.33	2.81e-5	Prostate cancer;
PAAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.72	7.95	0.54	3.99e-13	Mood instability;
PAAD	cis	rs3736485	0.934	rs8036609	chr15:51861426	C/G	cg08986416	chr15:51914746	DMXL2	-0.45	-4.29	-0.33	3.22e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-11.96	-0.7	1.21e-23	Chronic sinus infection;
PAAD	cis	rs863345	0.901	rs1117126	chr1:158509383	A/G	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	1.02e-6	Pneumococcal bacteremia;
PAAD	cis	rs10899021	0.790	rs11236180	chr11:74342928	A/G	cg25880958	chr11:74394337	NA	-0.76	-4.79	-0.36	3.9e-6	Response to metformin (IC50);
PAAD	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg21130718	chr4:1044621	NA	-0.51	-4.87	-0.37	2.75e-6	Recombination rate (males);
PAAD	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.52	5.68	0.42	6.71e-8	Carotid intima media thickness;
PAAD	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-6.11	-0.44	8.01e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7619427	0.544	rs9809968	chr3:44042297	A/T	cg12796028	chr3:44040206	NA	-0.56	-4.77	-0.36	4.22e-6	Schizophrenia;
PAAD	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.37	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.68	7.1	0.5	4.4e-11	Pulse pressure;
PAAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.43	-4.81	-0.36	3.63e-6	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06115741	chr20:33292138	TP53INP2	-0.6	-6.14	-0.45	6.76e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.72	8.39	0.56	3.08e-14	Height;
PAAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg24253500	chr15:84953950	NA	0.42	4.41	0.34	1.92e-5	Schizophrenia;
PAAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	12.29	0.71	1.55e-24	Menopause (age at onset);
PAAD	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.72	-7.49	-0.52	5.27e-12	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg04089426	chr11:65307791	LTBP3	1.1	5.14	0.38	8.49e-7	Height;
PAAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.91	0.37	2.3e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg22875332	chr1:76189707	ACADM	-0.5	-5.06	-0.38	1.21e-6	Daytime sleep phenotypes;
PAAD	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.53	5.19	0.39	6.53e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.74	-0.48	3.02e-10	Triglycerides;
PAAD	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-4.47	-0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs72960926	0.590	rs72955123	chr6:74760355	C/T	cg03266952	chr6:74778945	NA	-1.23	-7.33	-0.51	1.3e-11	Metabolite levels (MHPG);
PAAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-6.12	-0.44	7.74e-9	Total body bone mineral density;
PAAD	trans	rs12406019	0.548	rs11579434	chr1:78610022	T/C	cg20826526	chr3:156266748	SSR3	-0.65	-6.48	-0.47	1.22e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6545883	0.894	rs2167566	chr2:61519408	G/T	cg14146966	chr2:61757674	XPO1	0.36	4.53	0.34	1.2e-5	Tuberculosis;
PAAD	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg19423196	chr10:82049429	MAT1A	0.59	4.36	0.33	2.41e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7127900	1.000	rs7481129	chr11:2230460	A/C	cg25635251	chr11:2234043	NA	0.84	7.53	0.52	4.15e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg01267373	chr18:77410094	NA	0.4	4.38	0.33	2.2e-5	Monocyte count;
PAAD	cis	rs9463078	0.809	rs9357469	chr6:45049811	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.51	-0.41	1.48e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg00626422	chr7:22894849	SNORD93	0.55	6.29	0.45	3.2e-9	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.15	0.45	6.6e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg23465465	chr6:26364728	BTN3A2	0.56	4.41	0.34	1.98e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs6066835	0.572	rs6066804	chr20:47262322	G/A	cg18078177	chr20:47281410	PREX1	1.11	5.12	0.38	9.22e-7	Multiple myeloma;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.61	-6.51	-0.47	1.05e-9	Lung cancer;
PAAD	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	6.08	0.44	9.21e-9	Cognitive test performance;
PAAD	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg13263323	chr15:86062960	AKAP13	-0.62	-6.97	-0.49	8.82e-11	Interstitial lung disease;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg07153921	chr17:41440717	NA	-0.41	-4.28	-0.33	3.27e-5	Menopause (age at onset);
PAAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19346786	chr7:2764209	NA	-0.35	-4.7	-0.36	5.85e-6	Height;
PAAD	cis	rs6137287	0.847	rs4815021	chr20:21120543	A/G	cg04219410	chr20:21106687	PLK1S1	-0.38	-4.5	-0.34	1.37e-5	Height;
PAAD	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.51	-0.41	1.52e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	1.13	13.26	0.73	3.68e-27	Cognitive function;
PAAD	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.92	-0.37	2.21e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs4792901	0.765	rs9892162	chr17:41600800	T/C	cg05614735	chr17:40936078	WNK4	-0.36	-4.28	-0.33	3.28e-5	Dupuytren's disease;
PAAD	cis	rs427941	0.595	rs201477	chr7:101746915	G/A	cg06246474	chr7:101738831	CUX1	0.43	4.25	0.33	3.67e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7853377	0.660	rs963459	chr9:86507442	G/C	cg03531853	chr9:86535572	KIF27	0.41	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06508976	chr9:131940586	IER5L	0.61	6.75	0.48	2.93e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg03909863	chr11:638404	DRD4	-0.6	-5.44	-0.4	2.05e-7	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.858	rs56071820	chr16:67712018	A/G	cg09835421	chr16:68378352	PRMT7	-0.66	-4.55	-0.35	1.11e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.71	-7.09	-0.5	4.62e-11	Retinal vascular caliber;
PAAD	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.68	-5.94	-0.43	1.89e-8	Blood trace element (Zn levels);
PAAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.13	14.99	0.77	9.16e-32	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg27490568	chr2:178487706	NA	0.41	4.4	0.34	2.03e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg17105886	chr17:28927953	LRRC37B2	0.76	4.86	0.37	2.95e-6	Body mass index;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	5.29	0.39	4.29e-7	Mood instability;
PAAD	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.97	10.77	0.66	1.8899999999999998e-20	Primary sclerosing cholangitis;
PAAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.65	6.59	0.47	6.83e-10	DNA methylation (variation);
PAAD	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg09579323	chr1:150459698	TARS2	-0.45	-4.25	-0.33	3.67e-5	Migraine;
PAAD	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.66	7.28	0.51	1.63e-11	Hemoglobin concentration;
PAAD	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20307385	chr11:47447363	PSMC3	0.54	4.72	0.36	5.21e-6	Subjective well-being;
PAAD	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg19875578	chr6:126661172	C6orf173	0.47	4.82	0.36	3.39e-6	Male-pattern baldness;
PAAD	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.55	-6.65	-0.47	5.05e-10	Total body bone mineral density;
PAAD	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg08992911	chr2:238395768	MLPH	0.57	4.9	0.37	2.45e-6	Prostate cancer;
PAAD	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09597638	chr17:3907349	NA	-0.72	-7.72	-0.53	1.46e-12	Type 2 diabetes;
PAAD	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24837026	chr3:155607265	GMPS	0.52	6.3	0.46	3.08e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.89	10.43	0.65	1.51e-19	Resting heart rate;
PAAD	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-1.06	-7.5	-0.52	4.86e-12	Alzheimer's disease or small vessel stroke;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs7071247	0.915	rs3014183	chr10:105274270	C/T	cg14553436	chr10:104822996	CNNM2	-0.66	-4.92	-0.37	2.22e-6	Platelet aggregation;
PAAD	cis	rs12815613	0.754	rs3751151	chr12:121442199	A/T	cg02419362	chr12:121203948	SPPL3	-0.49	-4.82	-0.36	3.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.98	0.59	9.75e-16	Lung cancer;
PAAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.41	-0.34	1.98e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.51	5.26	0.39	4.74e-7	Schizophrenia;
PAAD	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs11997175	0.631	rs7826866	chr8:33665090	A/T	ch.8.33884649F	chr8:33765107	NA	0.49	5.16	0.39	7.51e-7	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14257449	chr1:185285846	IVNS1ABP	0.61	6.79	0.48	2.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6076065	0.723	rs6083087	chr20:23341529	C/T	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.75	-7.89	-0.54	5.41e-13	Type 2 diabetes;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.53	5.98	0.44	1.57e-8	Testicular germ cell tumor;
PAAD	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.79	5.59	0.41	1e-7	Carotid intima media thickness;
PAAD	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-4.96	-0.37	1.87e-6	Common traits (Other);
PAAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg22143856	chr6:28129313	ZNF389	0.63	4.7	0.36	5.67e-6	Depression;
PAAD	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13893634	chr17:48229117	PPP1R9B	-0.54	-5.51	-0.41	1.51e-7	Temporomandibular joint disorder;
PAAD	cis	rs12935418	0.672	rs12448656	chr16:81042481	G/T	cg16651780	chr16:81037892	C16orf61	0.65	6.08	0.44	9.11e-9	Mean corpuscular volume;
PAAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg09491104	chr22:46646882	C22orf40	-0.96	-5.41	-0.4	2.35e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.56	-4.33	-0.33	2.67e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.66	-0.48	4.61e-10	Exhaled nitric oxide output;
PAAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.75	-5.88	-0.43	2.56e-8	Coronary artery disease;
PAAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg11494091	chr17:61959527	GH2	0.53	4.4	0.34	2.06e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg08222618	chr4:941054	TMEM175	-0.45	-5.1	-0.38	9.91e-7	Parkinson's disease;
PAAD	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.65	6.93	0.49	1.1e-10	Body mass index;
PAAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.75	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs7627468	0.837	rs6764544	chr3:121948114	G/A	cg17240004	chr3:121949083	CASR	0.52	4.83	0.36	3.33e-6	Kidney stones;
PAAD	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.62	7.07	0.5	5.39e-11	Hemoglobin concentration;
PAAD	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.64	-6.84	-0.48	1.86e-10	Mosquito bite size;
PAAD	cis	rs2562456	0.833	rs4644962	chr19:21520927	C/T	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.43e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12019520	chr4:8012176	ABLIM2	0.47	6.46	0.46	1.37e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg26031613	chr14:104095156	KLC1	-0.5	-5.56	-0.41	1.18e-7	Schizophrenia;
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.68	-0.53	1.85e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg15117754	chr3:10150083	C3orf24	0.58	4.3	0.33	3.06e-5	Alzheimer's disease;
PAAD	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg11993925	chr19:44307056	LYPD5	0.5	6.66	0.48	4.66e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.36	4.64e-6	Common traits (Other);
PAAD	cis	rs4588572	0.686	rs4470742	chr5:77657957	T/G	cg11547950	chr5:77652471	NA	0.92	7.72	0.53	1.42e-12	Triglycerides;
PAAD	cis	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg22863700	chr5:28928346	NA	-0.58	-5.47	-0.41	1.8e-7	Hip geometry;
PAAD	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg07148914	chr20:33460835	GGT7	0.48	4.75	0.36	4.75e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs329648	1.000	rs329648	chr11:133765367	A/G	cg03392386	chr11:133800800	IGSF9B	0.46	4.85	0.37	2.96e-6	Parkinson's disease;
PAAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.78	-9.09	-0.59	5.06e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.6	-5.79	-0.43	3.93e-8	Diastolic blood pressure;
PAAD	cis	rs73019876	0.869	rs8103214	chr19:22158992	C/T	cg11619707	chr19:22235551	ZNF257	-0.4	-4.3	-0.33	3.07e-5	Testicular germ cell tumor;
PAAD	cis	rs55871839	0.547	rs3780001	chr8:59872615	G/T	cg07426533	chr8:59803705	TOX	-0.43	-4.32	-0.33	2.78e-5	Pneumonia;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.21e-7	Life satisfaction;
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.29e-8	Electroencephalogram traits;
PAAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24549020	chr5:56110836	MAP3K1	-0.69	-5.0	-0.38	1.55e-6	Initial pursuit acceleration;
PAAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.75	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-4.35	-0.33	2.46e-5	Vitiligo;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.68	-0.35	6.28e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.967	rs441344	chr19:44404682	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs860295	0.580	rs6672284	chr1:155277963	C/T	cg02153340	chr1:155202674	NA	-0.53	-4.91	-0.37	2.28e-6	Body mass index;
PAAD	cis	rs877529	0.605	rs139412	chr22:39553003	A/G	cg18708252	chr22:39545030	CBX7	0.68	7.09	0.5	4.64e-11	Multiple myeloma;
PAAD	cis	rs4905558	0.606	rs736929	chr14:97343323	T/C	cg04184208	chr14:96505874	C14orf132	-0.44	-4.25	-0.33	3.7e-5	Neutrophil count;
PAAD	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg23306229	chr2:178417860	TTC30B	-0.61	-4.38	-0.33	2.17e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.7	-5.91	-0.43	2.16e-8	Fibrinogen levels;
PAAD	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-4.45	-0.34	1.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.68	-0.35	6.28e-6	Breast cancer;
PAAD	cis	rs11252688	1.000	rs11252682	chr10:4769161	T/C	cg26552733	chr10:5542941	CALML5	0.84	5.09	0.38	1.05e-6	Major depressive disorder;
PAAD	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04045327	chr4:905805	GAK	-0.37	-4.6	-0.35	8.9e-6	Systemic sclerosis;
PAAD	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-18.17	-0.83	6.2e-40	Exhaled nitric oxide output;
PAAD	cis	rs4908768	0.555	rs55939938	chr1:8863664	A/T	cg25722041	chr1:8623473	RERE	0.52	4.5	0.34	1.35e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.75	-8.77	-0.58	3.34e-15	Lung function (FVC);
PAAD	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.61	6.45	0.46	1.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.8	-7.67	-0.53	1.88e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs73416724	0.920	rs76088627	chr6:43311851	G/A	cg17076780	chr6:43251928	TTBK1	0.56	4.36	0.33	2.4e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg11247378	chr22:39784982	NA	0.57	6.17	0.45	5.93e-9	IgG glycosylation;
PAAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.86	7.4	0.51	8.59e-12	Recombination rate (females);
PAAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs137887	1.000	rs137886	chr22:50464397	A/G	cg23116504	chr22:50470537	TTLL8	-0.49	-5.0	-0.38	1.56e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg23283495	chr1:209979779	IRF6	0.64	6.3	0.46	2.99e-9	Coronary artery disease;
PAAD	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg02230254	chr11:65586170	NA	-0.34	-4.75	-0.36	4.66e-6	Eosinophil percentage of white cells;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20389472	chr2:171568526	NA	-0.73	-7.26	-0.51	1.89e-11	Lung cancer in ever smokers;
PAAD	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-8.47	-0.57	1.93e-14	Total body bone mineral density;
PAAD	cis	rs727479	0.502	rs2304463	chr15:51508120	A/C	cg21478137	chr15:51532386	CYP19A1	0.44	4.39	0.34	2.14e-5	Estradiol levels;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg26338869	chr17:61819248	STRADA	0.5	4.78	0.36	4.14e-6	Height;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg02117656	chr17:79614917	TSPAN10	0.58	6.32	0.46	2.72e-9	Eye color traits;
PAAD	cis	rs1113500	0.524	rs12145813	chr1:108569904	C/T	cg06207961	chr1:108661230	NA	0.49	5.16	0.39	7.69e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.79	9.77	0.62	8.47e-18	Bladder cancer;
PAAD	cis	rs2718812	0.792	rs1867504	chr3:133410661	C/T	cg08439880	chr3:133502540	NA	-0.42	-4.64	-0.35	7.47e-6	Iron status biomarkers;
PAAD	cis	rs758324	0.738	rs399714	chr5:131318788	C/T	cg06307176	chr5:131281290	NA	-0.54	-4.56	-0.35	1.07e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.5	-4.85	-0.37	3.06e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.76	5.53	0.41	1.39e-7	White matter hyperintensity burden;
PAAD	cis	rs962856	0.822	rs6546307	chr2:67644053	C/T	cg09028215	chr2:67624308	ETAA1	-0.47	-4.34	-0.33	2.63e-5	Pancreatic cancer;
PAAD	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg07389463	chr12:132296394	NA	-0.59	-7.61	-0.53	2.7e-12	Migraine;
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13115616	chr1:17338059	ATP13A2	-0.58	-6.32	-0.46	2.81e-9	Myopia (pathological);
PAAD	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg03367679	chr17:38183553	MED24;SNORD124	-0.34	-4.39	-0.34	2.07e-5	White blood cell count;
PAAD	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.73	-4.79	-0.36	3.85e-6	Lung cancer;
PAAD	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9361491	0.657	rs4706730	chr6:79467903	C/T	cg05283184	chr6:79620031	NA	-0.38	-4.52	-0.34	1.25e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7631605	0.905	rs7620643	chr3:37152131	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.6	-0.35	8.8e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-1.08	-11.46	-0.68	2.6e-22	Platelet distribution width;
PAAD	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.26	0.33	3.62e-5	Lung cancer;
PAAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.49	-4.75	-0.36	4.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.6	6.11	0.44	8.02e-9	Menopause (age at onset);
PAAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.87	10.14	0.64	8.89e-19	Blood protein levels;
PAAD	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.67	5.42	0.4	2.29e-7	Height;
PAAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01765077	chr12:122356316	WDR66	0.65	6.67	0.48	4.55e-10	Mean corpuscular volume;
PAAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg00206168	chr11:65308501	LTBP3	-0.51	-5.36	-0.4	3.06e-7	Bone mineral density;
PAAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.53	5.44	0.4	2.06e-7	Major depressive disorder;
PAAD	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05048372	chr18:60382543	PHLPP1	-0.63	-6.48	-0.47	1.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.88	6.88	0.49	1.44e-10	Alzheimer's disease;
PAAD	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.64	-6.16	-0.45	6.33e-9	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.71	-0.48	3.6e-10	Uric acid levels;
PAAD	trans	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg01620082	chr3:125678407	NA	-1.16	-6.66	-0.48	4.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg06899799	chr12:56650233	ANKRD52	0.35	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs56046484	0.871	rs71397837	chr15:85563561	G/A	cg08123816	chr15:85640762	PDE8A	-0.43	-4.34	-0.33	2.6e-5	Testicular germ cell tumor;
PAAD	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.62	-7.9	-0.54	5.26e-13	Systolic blood pressure;
PAAD	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-7.62	-0.53	2.51e-12	Lung cancer;
PAAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-1.06	-15.11	-0.77	4.46e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.77	-7.87	-0.54	6.26e-13	Body mass index;
PAAD	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.62	6.7	0.48	3.83e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.8	-7.74	-0.53	1.26e-12	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg11833968	chr6:79620685	NA	-0.42	-4.33	-0.33	2.68e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.42	-0.52	7.62e-12	Hemoglobin concentration;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01823079	chr12:131273348	NA	0.61	7.4	0.51	8.63e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg00631329	chr6:26305371	NA	-0.42	-4.33	-0.33	2.74e-5	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg23024343	chr7:107201750	COG5	0.58	4.72	0.36	5.36e-6	Coronary artery disease;
PAAD	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	4.3	0.33	3.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs62264129	0.500	rs56294743	chr3:112028863	G/A	cg15541583	chr3:112013063	SLC9A10	-0.31	-5.03	-0.38	1.36e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs7833787	1.000	rs17468166	chr8:18705047	C/T	cg17701159	chr8:18705777	PSD3	-0.45	-5.35	-0.4	3.15e-7	Obesity-related traits;
PAAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.78	-7.72	-0.53	1.42e-12	Tuberculosis;
PAAD	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.73	-6.44	-0.46	1.5e-9	Breast cancer;
PAAD	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg23752985	chr2:85803571	VAMP8	0.59	6.31	0.46	2.94e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.61	6.67	0.48	4.57e-10	Lung cancer;
PAAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.54	6.0	0.44	1.4e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2299587	0.527	rs7843715	chr8:17733526	C/A	cg08627089	chr8:17753878	FGL1	-0.48	-4.6	-0.35	8.87e-6	Economic and political preferences;
PAAD	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg10495392	chr1:46806563	NSUN4	0.58	5.66	0.42	7.35e-8	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08238444	chr1:39952373	MACF1	-0.52	-6.29	-0.45	3.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg12639453	chr1:2035780	PRKCZ	0.53	5.69	0.42	6.38e-8	Height;
PAAD	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.43e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6734238	0.739	rs7575402	chr2:113844110	A/G	cg06156847	chr2:113672199	IL1F7	-0.43	-4.47	-0.34	1.53e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	1.07	13.84	0.75	1.07e-28	Breast cancer;
PAAD	cis	rs2147959	0.739	rs11587839	chr1:228630979	C/T	cg02753203	chr1:228287806	NA	-0.6	-4.84	-0.37	3.16e-6	Adult asthma;
PAAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg16083429	chr3:49237500	CCDC36	-0.43	-4.51	-0.34	1.26e-5	Parkinson's disease;
PAAD	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg01426195	chr3:39028469	NA	-0.64	-6.45	-0.46	1.4e-9	Handedness;
PAAD	cis	rs12931792	0.782	rs6565176	chr16:30174926	T/C	cg17640201	chr16:30407289	ZNF48	0.6	6.36	0.46	2.21e-9	Tonsillectomy;
PAAD	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg15736062	chr7:158136485	PTPRN2	-0.5	-4.45	-0.34	1.64e-5	Response to amphetamines;
PAAD	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	1.03	8.02	0.55	2.63e-13	IgG glycosylation;
PAAD	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-1.25	-8.84	-0.58	2.17e-15	Plateletcrit;
PAAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.58	-5.1	-0.38	9.82e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.06	0.59	5.93e-16	Menopause (age at onset);
PAAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19784903	chr17:45786737	TBKBP1	-0.52	-5.51	-0.41	1.53e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9992101	0.547	rs2137153	chr4:77411660	G/A	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs6750047	0.771	rs2855658	chr2:38296890	T/C	cg19753864	chr2:38320028	NA	0.41	4.5	0.34	1.35e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	1.18	8.82	0.58	2.51e-15	Lymphocyte counts;
PAAD	cis	rs9815354	1.000	rs9311288	chr3:41804581	C/G	cg03022575	chr3:42003672	ULK4	0.72	5.29	0.39	4.18e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg18833306	chr6:118973337	C6orf204	0.51	5.64	0.42	8.19e-8	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17856907	chr10:91353162	MIR107;PANK1	-0.67	-6.67	-0.48	4.56e-10	Obesity-related traits;
PAAD	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.76	-8.75	-0.58	3.8e-15	Handedness;
PAAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.56	6.17	0.45	5.86e-9	Testicular germ cell tumor;
PAAD	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.59	6.21	0.45	4.71e-9	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2061333	0.557	rs2168778	chr19:44631219	T/C	cg20607764	chr19:44506953	ZNF230	-0.77	-5.38	-0.4	2.78e-7	Alzheimer's disease;
PAAD	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.89	6.64	0.47	5.35e-10	Pulse pressure;
PAAD	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.41	4.88	0.37	2.64e-6	Intraocular pressure;
PAAD	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.96	-8.01	-0.54	2.76e-13	Bronchopulmonary dysplasia;
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-6.27	-0.45	3.59e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	1.06	6.63	0.47	5.59e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs863345	0.967	rs17630699	chr1:158463086	C/T	cg12129480	chr1:158549410	OR10X1	0.41	4.63	0.35	7.91e-6	Pneumococcal bacteremia;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.49	5.12	0.38	9.19e-7	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06782748	chr10:35416372	CREM	0.68	7.45	0.52	6.38e-12	Myopia (pathological);
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg07202610	chr7:1142643	C7orf50	-0.67	-5.56	-0.41	1.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	5.96	0.44	1.72e-8	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15210127	chr18:56148617	ALPK2	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.88	-8.18	-0.55	1.06e-13	Exhaled nitric oxide output;
PAAD	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.44	5.47	0.41	1.81e-7	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg13660082	chr14:53194042	PSMC6	-0.68	-4.34	-0.33	2.63e-5	Alzheimer's disease (late onset);
PAAD	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.73	8.09	0.55	1.73e-13	Response to antipsychotic treatment;
PAAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.52	4.59	0.35	9.13e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.66	-5.85	-0.43	2.88e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg03538708	chr1:25844672	NA	0.53	5.46	0.41	1.86e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.82	0.48	2.04e-10	Alzheimer's disease;
PAAD	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.63	7.03	0.5	6.53e-11	Coronary artery disease;
PAAD	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.31	0.33	2.87e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13273891	0.915	rs10093645	chr8:58978805	T/C	cg05901852	chr8:59757290	TOX	-0.46	-4.36	-0.33	2.4e-5	Pit-and-Fissure caries;
PAAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.51	-5.33	-0.4	3.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.67	-6.47	-0.46	1.24e-9	Blood metabolite levels;
PAAD	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg15764593	chr10:829463	NA	-0.82	-4.54	-0.35	1.13e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2579500	0.702	rs6576974	chr2:97244385	A/G	cg09304357	chr2:97220596	NA	-0.47	-5.05	-0.38	1.25e-6	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs10865541	0.571	rs4854186	chr2:3383957	C/T	cg21040360	chr2:3383326	TTC15	0.43	4.75	0.36	4.67e-6	Obesity-related traits;
PAAD	cis	rs73206853	0.686	rs7974047	chr12:111119631	C/T	cg12870014	chr12:110450643	ANKRD13A	0.72	4.86	0.37	2.9e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.38	-0.56	3.29e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg14433983	chr11:636460	DRD4	-0.47	-4.95	-0.37	1.91e-6	Systemic lupus erythematosus;
PAAD	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.51	-5.16	-0.39	7.52e-7	Schizophrenia;
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.87	-9.85	-0.62	5.29e-18	Tonsillectomy;
PAAD	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.89	-11.87	-0.69	2.12e-23	Body mass index;
PAAD	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.85	-6.13	-0.45	7.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-4.86	-0.37	2.94e-6	Testicular germ cell tumor;
PAAD	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.65	-6.93	-0.49	1.11e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.52	-4.76	-0.36	4.5e-6	Height;
PAAD	cis	rs12432203	1.000	rs4635253	chr14:51741830	A/G	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-11.74	-0.69	4.76e-23	Prudent dietary pattern;
PAAD	cis	rs1639906	0.729	rs17186614	chr7:2231002	G/A	cg02951883	chr7:2050386	MAD1L1	0.55	4.74	0.36	4.9e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.48	-5.02	-0.38	1.41e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10342447	chr17:26645325	TMEM97	-0.46	-6.03	-0.44	1.17e-8	Osteoprotegerin levels;
PAAD	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg05250797	chr16:70222502	NA	0.83	6.18	0.45	5.52e-9	IgE levels;
PAAD	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.43e-7	Type 2 diabetes;
PAAD	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg19486271	chr11:47235900	DDB2	0.53	5.51	0.41	1.46e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs1476670	0.710	rs2477616	chr1:44504809	G/A	cg09470012	chr1:44509516	NA	0.49	4.88	0.37	2.7e-6	Eotaxin levels;
PAAD	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.24	10.68	0.65	3.29e-20	Uric acid levels;
PAAD	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	1.1	7.48	0.52	5.63e-12	IgG glycosylation;
PAAD	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg20130138	chr11:64956067	CAPN1	0.6	4.27	0.33	3.43e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	1.13	17.86	0.82	3.65e-39	Menarche (age at onset);
PAAD	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-4.91	-0.37	2.33e-6	Type 1 diabetes;
PAAD	trans	rs72960926	1.000	rs11751066	chr6:75177049	G/A	cg01373369	chr2:27600323	ZNF513	-1.13	-6.42	-0.46	1.65e-9	Metabolite levels (MHPG);
PAAD	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.7	9.06	0.59	6.1e-16	Asthma (childhood onset);
PAAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg05132306	chr1:1846340	CALML6	-0.44	-5.17	-0.39	7.43e-7	Body mass index;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg04160749	chr8:58172571	NA	-0.78	-7.78	-0.53	1.03e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs227833	0.826	rs227854	chr6:44701035	C/T	cg18551225	chr6:44695536	NA	-0.46	-4.83	-0.36	3.3e-6	Monobrow;
PAAD	cis	rs7182948	0.914	rs28766285	chr15:49992095	G/A	cg23441248	chr15:50140549	NA	0.38	4.32	0.33	2.86e-5	Lung adenocarcinoma;
PAAD	cis	rs17641971	0.672	rs74220310	chr8:50049429	G/A	cg00325661	chr8:49890786	NA	-0.47	-4.36	-0.33	2.39e-5	Blood metabolite levels;
PAAD	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg09873201	chr16:3507582	NAT15	0.52	4.81	0.36	3.65e-6	Tuberculosis;
PAAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.68	-6.63	-0.47	5.43e-10	Blood metabolite levels;
PAAD	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	6.28	0.45	3.34e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.58	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-4.49	-0.34	1.42e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.97	-7.55	-0.52	3.7e-12	Initial pursuit acceleration;
PAAD	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg02683114	chr2:24398427	C2orf84	-0.46	-4.81	-0.36	3.67e-6	Sjögren's syndrome;
PAAD	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg00472393	chr6:97730957	C6orf167;MIR548H3	-0.5	-4.8	-0.36	3.69e-6	Body mass index;
PAAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.57	-6.24	-0.45	4.14e-9	Electroencephalogram traits;
PAAD	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.39	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-5.5	-0.41	1.6e-7	Reticulocyte count;
PAAD	cis	rs2017305	0.834	rs12252761	chr10:70780296	C/T	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.54	-0.41	1.31e-7	Depression (quantitative trait);
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.4	-5.46	-0.4	1.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg25246084	chr19:4971487	KDM4B	-0.46	-5.71	-0.42	5.65e-8	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg00280220	chr17:61926910	NA	0.46	4.76	0.36	4.47e-6	Prudent dietary pattern;
PAAD	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.82	-8.97	-0.59	1.03e-15	Body mass index;
PAAD	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg15556689	chr8:8085844	FLJ10661	0.73	7.32	0.51	1.37e-11	Neuroticism;
PAAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.96	-11.66	-0.69	7.76e-23	Height;
PAAD	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	1.27	10.66	0.65	3.7799999999999997e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.4	0.34	2.03e-5	Aortic root size;
PAAD	cis	rs3026101	0.671	rs1544399	chr17:5305887	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs7583236	0.500	rs7565597	chr2:70336070	T/G	cg00752969	chr2:70311984	NA	0.57	4.33	0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.63	-7.27	-0.51	1.75e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.99	-0.38	1.61e-6	Initial pursuit acceleration;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg19630374	chr17:18023558	MYO15A	-0.4	-4.3	-0.33	3.07e-5	Total body bone mineral density;
PAAD	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7127900	0.898	rs11043135	chr11:2232696	A/C	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg14024328	chr4:719362	PCGF3	-0.57	-5.83	-0.43	3.25e-8	White blood cell count;
PAAD	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.69	-5.34	-0.4	3.39e-7	Bipolar disorder;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07677032	chr17:61819896	STRADA	-0.52	-5.23	-0.39	5.59e-7	Prudent dietary pattern;
PAAD	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.77	8.23	0.56	8.04e-14	Body mass index;
PAAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg05627522	chr15:75251581	NA	0.5	5.98	0.44	1.57e-8	Caffeine consumption;
PAAD	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs9810890	0.850	rs72977135	chr3:128661260	G/T	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.73	7.98	0.54	3.3e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs3018712	0.590	rs7110468	chr11:68484014	G/A	cg23009355	chr11:68451396	GAL	-0.44	-4.27	-0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg09835421	chr16:68378352	PRMT7	-0.67	-5.22	-0.39	5.76e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.58e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs2422052	0.614	rs13033724	chr2:118644670	C/T	cg22545206	chr2:118617499	NA	0.45	4.37	0.33	2.25e-5	Mosquito bite size;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg10729496	chr3:10149963	C3orf24	0.67	5.99	0.44	1.49e-8	Alzheimer's disease;
PAAD	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.65	0.42	7.66e-8	Mood instability;
PAAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg13777783	chr17:79615861	NA	-0.41	-4.3	-0.33	3.04e-5	Eye color traits;
PAAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2976388	0.566	rs4736301	chr8:143829499	T/G	cg06565975	chr8:143823917	SLURP1	-0.2	-4.44	-0.34	1.69e-5	Urinary tract infection frequency;
PAAD	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.79	0.53	9.59e-13	Eotaxin levels;
PAAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.03	-0.55	2.53e-13	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19844325	chr19:18314808	RAB3A	0.61	6.99	0.49	8.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg20435097	chr10:126320824	FAM53B	-0.48	-4.69	-0.36	6.13e-6	Cocaine dependence;
PAAD	cis	rs300774	0.925	rs300706	chr2:141540	A/C	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-5.81	-0.43	3.55e-8	Inflammatory bowel disease;
PAAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.64	5.71	0.42	5.84e-8	Menarche (age at onset);
PAAD	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25650185	chr19:21324782	ZNF431	-0.48	-4.34	-0.33	2.58e-5	Pain;
PAAD	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg09551160	chr10:80828924	ZMIZ1	-0.78	-6.69	-0.48	4.01e-10	Parkinson's disease;
PAAD	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs537626	0.725	rs72927565	chr11:69289737	C/T	cg08353955	chr11:69289746	NA	-1.28	-7.68	-0.53	1.76e-12	Breast cancer (early onset);
PAAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-4.75	-0.36	4.71e-6	Total body bone mineral density;
PAAD	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg01420254	chr6:26195488	NA	0.92	4.95	0.37	1.93e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.39	-0.4	2.6e-7	Height;
PAAD	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	1.07	10.95	0.66	6.03e-21	Platelet distribution width;
PAAD	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.61	-0.35	8.37e-6	Blood protein levels;
PAAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.51	5.26	0.39	4.84e-7	Testicular germ cell tumor;
PAAD	cis	rs11615916	0.790	rs17716446	chr12:62708958	G/A	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.71	10.96	0.66	5.71e-21	Breast cancer;
PAAD	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.81	8.5	0.57	1.66e-14	Selective IgA deficiency;
PAAD	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	8.18	0.55	1.08e-13	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.54	0.57	1.33e-14	Bipolar disorder;
PAAD	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-1.03	-13.62	-0.74	4.14e-28	Refractive error;
PAAD	cis	rs6460942	0.597	rs13232817	chr7:12551909	C/A	cg20607287	chr7:12443886	VWDE	-0.71	-4.74	-0.36	4.87e-6	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	5.12	0.38	8.98e-7	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.88	11.2	0.67	1.31e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73206853	0.841	rs73191808	chr12:110904685	T/C	cg12870014	chr12:110450643	ANKRD13A	0.73	4.65	0.35	7.14e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.78	-8.63	-0.57	7.87e-15	Height;
PAAD	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.4	-4.43	-0.34	1.79e-5	Prostate cancer;
PAAD	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg07486100	chr7:132562508	CHCHD3	-0.39	-4.3	-0.33	3.06e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.75	7.5	0.52	4.9e-12	Tonsillectomy;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25107608	chr1:154155675	TPM3	-0.62	-6.41	-0.46	1.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg00531865	chr16:30841666	NA	0.52	5.0	0.38	1.55e-6	Dementia with Lewy bodies;
PAAD	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.3	0.56	5.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs4678145	0.901	rs17843797	chr3:124453022	T/G	cg07063911	chr3:125197837	SNX4	0.7	4.26	0.33	3.52e-5	Coronary artery disease;
PAAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.88	0.37	2.64e-6	Coronary artery disease;
PAAD	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg13010199	chr12:38710504	ALG10B	0.48	4.53	0.34	1.19e-5	Morning vs. evening chronotype;
PAAD	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Bladder cancer;
PAAD	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.42	-0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg24881330	chr22:46731750	TRMU	1.22	5.78	0.42	4.05e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.78	-0.36	4.04e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg14458575	chr2:238380390	NA	0.54	4.68	0.35	6.31e-6	Prostate cancer;
PAAD	cis	rs12989701	0.877	rs35860453	chr2:127866047	C/T	cg08168897	chr2:127865431	BIN1	0.69	5.9	0.43	2.23e-8	Alzheimer's disease (late onset);
PAAD	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg20933634	chr6:27740509	NA	0.44	4.25	0.33	3.76e-5	Hepatitis A;
PAAD	cis	rs9913156	0.708	rs9915105	chr17:4568742	G/C	cg00122941	chr17:4613640	ARRB2	-0.84	-8.65	-0.57	6.63e-15	Lymphocyte counts;
PAAD	cis	rs7326068	0.595	rs2785741	chr13:21421240	C/T	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg08992911	chr2:238395768	MLPH	0.67	6.41	0.46	1.7e-9	Prostate cancer;
PAAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg14789911	chr21:47582049	C21orf56	-0.47	-4.71	-0.36	5.48e-6	Testicular germ cell tumor;
PAAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.6	-6.61	-0.47	6.08e-10	Monocyte count;
PAAD	cis	rs2944755	0.723	rs9694342	chr8:141587404	C/T	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.61	-0.35	8.34e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.58	-7.15	-0.5	3.42e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.29	0.33	3.16e-5	Lung cancer;
PAAD	cis	rs7766436	0.621	rs9460765	chr6:22601221	G/A	cg13666174	chr6:22585274	NA	-0.5	-6.19	-0.45	5.37e-9	Coronary artery disease;
PAAD	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg19337854	chr7:99768885	GPC2	0.44	4.59	0.35	9.38e-6	Coronary artery disease;
PAAD	cis	rs2898681	0.874	rs4864691	chr4:53755972	C/T	cg00791764	chr4:53727839	RASL11B	0.52	4.35	0.33	2.45e-5	Optic nerve measurement (cup area);
PAAD	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.89	0.63	3.97e-18	Platelet count;
PAAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23281280	chr6:28129359	ZNF389	0.7	5.42	0.4	2.31e-7	Parkinson's disease;
PAAD	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.36	-0.46	2.28e-9	Hip circumference;
PAAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg16205897	chr5:131564050	P4HA2	-0.47	-4.93	-0.37	2.12e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg04721828	chr11:48285200	OR4X1	0.41	5.41	0.4	2.4e-7	Migraine - clinic-based;
PAAD	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.98	-8.53	-0.57	1.41e-14	Dilated cardiomyopathy;
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.42	-0.52	7.54e-12	Total body bone mineral density;
PAAD	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.65	0.35	7.22e-6	Red cell distribution width;
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg04257695	chr17:30186438	C17orf79	-0.63	-4.99	-0.38	1.62e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-5.14	-0.39	8.18e-7	Total body bone mineral density;
PAAD	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg15478930	chr2:27652102	NRBP1	-0.52	-4.27	-0.33	3.38e-5	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07210466	chr3:33444388	UBP1	0.55	6.49	0.47	1.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-5.63	-0.42	8.31e-8	Menarche (age at onset);
PAAD	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg18252515	chr7:66147081	NA	-0.4	-4.27	-0.33	3.39e-5	Aortic root size;
PAAD	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg04717802	chr22:42394638	WBP2NL	0.47	4.48	0.34	1.47e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.61	6.34	0.46	2.55e-9	Pancreatic cancer;
PAAD	cis	rs12304921	1.000	rs12306808	chr12:51354803	C/T	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15128208	chr22:42549153	NA	-0.43	-4.41	-0.34	1.94e-5	Cognitive function;
PAAD	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.9	0.49	1.32e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.15	-0.45	6.48e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs3125734	0.710	rs10821967	chr10:63941939	A/G	cg19640130	chr10:64028056	RTKN2	-0.36	-4.39	-0.34	2.12e-5	Rheumatoid arthritis;
PAAD	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg23465465	chr6:26364728	BTN3A2	0.79	4.4	0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7259965	0.582	rs3895941	chr19:41531212	T/C	cg27089200	chr19:41531976	NA	0.43	4.91	0.37	2.34e-6	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg02067580	chr1:153606662	C1orf77;S100A13	0.59	6.97	0.49	8.94e-11	Immature fraction of reticulocytes;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.84	0.58	2.17e-15	Schizophrenia;
PAAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg00786952	chr1:21763130	NA	0.48	4.83	0.36	3.35e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.89	8.91	0.59	1.51e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg00280220	chr17:61926910	NA	0.46	4.77	0.36	4.24e-6	Prudent dietary pattern;
PAAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg17372223	chr3:52568218	NT5DC2	0.55	5.48	0.41	1.76e-7	Bipolar disorder;
PAAD	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.48	-4.44	-0.34	1.75e-5	Vitiligo;
PAAD	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg18281939	chr5:77783895	LHFPL2	0.49	5.6	0.41	9.92e-8	Triglycerides;
PAAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.96	12.28	0.71	1.61e-24	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.81	6.84	0.49	1.78e-10	Alzheimer's disease;
PAAD	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg01953289	chr20:60874239	NA	0.72	5.49	0.41	1.65e-7	Obesity-related traits;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14347670	chr6:41908995	CCND3	0.58	6.42	0.46	1.69e-9	Response to antipsychotic treatment;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7567389	0.719	rs4150471	chr2:128034539	A/G	cg11380483	chr2:127933992	NA	-0.47	-4.67	-0.35	6.58e-6	Self-rated health;
PAAD	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg01631408	chr1:248437212	OR2T33	-0.6	-5.8	-0.43	3.69e-8	Common traits (Other);
PAAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg02462569	chr6:150064036	NUP43	-0.42	-4.46	-0.34	1.57e-5	Lung cancer;
PAAD	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg23093090	chr10:104574429	C10orf26	-0.44	-5.18	-0.39	6.85e-7	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00864171	chr11:67383662	NA	0.58	6.07	0.44	9.61e-9	Mean corpuscular volume;
PAAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.52	5.47	0.41	1.83e-7	Blood metabolite levels;
PAAD	cis	rs6782228	0.606	rs7613073	chr3:128388503	T/G	cg16766828	chr3:128327626	NA	-0.46	-6.14	-0.45	7e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-6.48	-0.47	1.2e-9	Colorectal cancer;
PAAD	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg14019146	chr3:50243930	SLC38A3	0.49	5.16	0.39	7.56e-7	Body mass index;
PAAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg07883600	chr3:53528162	CACNA1D	-0.43	-4.48	-0.34	1.49e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg14440974	chr22:39074834	NA	-0.56	-6.5	-0.47	1.08e-9	Menopause (age at onset);
PAAD	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.5	5.32	0.4	3.68e-7	Red blood cell count;
PAAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	1.1	5.88	0.43	2.47e-8	Plasma clusterin levels;
PAAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.46	5.83	0.43	3.25e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg11416102	chr8:651193	ERICH1	0.91	5.69	0.42	6.24e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23281280	chr6:28129359	ZNF389	0.66	5.22	0.39	5.75e-7	Depression;
PAAD	cis	rs9395066	0.545	rs66604011	chr6:45053059	G/T	cg25276700	chr6:44698697	NA	0.45	5.18	0.39	6.98e-7	Height;
PAAD	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.55	4.52	0.34	1.21e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08893839	chr5:154027129	NA	0.79	6.05	0.44	1.08e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	trans	rs6030712	0.948	rs1744765	chr20:35722830	A/G	cg12612947	chr3:25706262	TOP2B	-0.82	-6.75	-0.48	2.95e-10	Height;
PAAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.66	-7.45	-0.52	6.47e-12	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.98	-0.59	9.92e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.58	-7.01	-0.49	7.28e-11	Breast cancer;
PAAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.6	7.15	0.5	3.41e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	5.22	0.39	5.91e-7	Schizophrenia;
PAAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12165864	chr7:66369176	NA	-0.74	-4.76	-0.36	4.43e-6	Diabetic kidney disease;
PAAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	9.31	0.6	1.33e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.88	11.71	0.69	5.7e-23	Vitiligo;
PAAD	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg10820045	chr2:198174542	NA	-0.45	-4.53	-0.34	1.21e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.57	5.99	0.44	1.49e-8	Pancreatic cancer;
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg15997130	chr1:24165203	NA	0.59	6.21	0.45	4.78e-9	Immature fraction of reticulocytes;
PAAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-4.58	-0.35	9.57e-6	Obesity-related traits;
PAAD	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.93	-9.2	-0.6	2.58e-16	Lung disease severity in cystic fibrosis;
PAAD	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	5.93	0.43	2.01e-8	Eosinophil percentage of white cells;
PAAD	cis	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.7	6.7	0.48	3.83e-10	Platelet distribution width;
PAAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-5.08	-0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg27449745	chr7:23145252	KLHL7	-0.53	-4.66	-0.35	6.79e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-4.71	-0.36	5.62e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-4.4	-0.34	1.99e-5	Prevalent atrial fibrillation;
PAAD	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.54	4.34	0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg00982548	chr2:198649783	BOLL	-0.77	-5.53	-0.41	1.37e-7	Ulcerative colitis;
PAAD	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg21479132	chr6:26055353	NA	0.8	4.42	0.34	1.84e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.46	0.65	1.26e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.41	4.38	0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-5.49	-0.41	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	8.94e-7	Motion sickness;
PAAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.54	5.2	0.39	6.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15616946	chr18:11689206	GNAL	0.67	6.86	0.49	1.64e-10	Obesity-related traits;
PAAD	cis	rs76917914	0.780	rs16912622	chr9:100843660	A/C	cg21225548	chr9:100864335	TRIM14	0.52	5.38	0.4	2.79e-7	Immature fraction of reticulocytes;
PAAD	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.96	11.67	0.69	7.23e-23	Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26325430	chr13:33639059	KL	-0.64	-6.59	-0.47	6.74e-10	Obesity-related traits;
PAAD	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg04398451	chr17:18023971	MYO15A	0.52	4.83	0.36	3.36e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.43	4.51	0.34	1.28e-5	Menopause (age at onset);
PAAD	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg03910582	chr17:19030146	GRAPL	0.46	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-0.98	-6.49	-0.47	1.13e-9	Post bronchodilator FEV1;
PAAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02421172	chr7:1938701	MAD1L1	0.62	4.51	0.34	1.3e-5	Bipolar disorder;
PAAD	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg07159951	chr1:45983175	PRDX1	0.4	4.44	0.34	1.7e-5	High light scatter reticulocyte count;
PAAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	7.32	0.51	1.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs1497828	0.956	rs2646819	chr1:217525691	T/G	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.53	4.77	0.36	4.19e-6	Testicular germ cell tumor;
PAAD	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.74	8.83	0.58	2.4e-15	Morning vs. evening chronotype;
PAAD	cis	rs300774	0.925	rs300710	chr2:139574	C/T	cg23649280	chr2:140451	NA	0.46	4.28	0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.07	0.59	5.76e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.73	-7.76	-0.53	1.17e-12	Aortic root size;
PAAD	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.95	13.09	0.73	1.09e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-6.47	-0.46	1.3e-9	Lymphocyte counts;
PAAD	cis	rs17032980	0.866	rs10181214	chr2:67306395	G/A	cg02551743	chr2:66673428	MEIS1	-0.49	-4.38	-0.33	2.17e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	7.66	0.53	2.06e-12	Hemoglobin concentration;
PAAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-17.81	-0.82	4.98e-39	Height;
PAAD	cis	rs2481665	0.765	rs2481679	chr1:62634303	T/A	cg18591186	chr1:62594603	INADL	-0.61	-5.26	-0.39	4.71e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.45	-0.34	1.68e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.7	-5.09	-0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.72	-6.35	-0.46	2.4e-9	Breast cancer;
PAAD	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.09	-9.2	-0.6	2.65e-16	Alzheimer's disease (late onset);
PAAD	cis	rs35160687	0.644	rs4832265	chr2:86488265	A/G	cg10973622	chr2:86423274	IMMT	-0.48	-5.35	-0.4	3.19e-7	Night sleep phenotypes;
PAAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.94	-9.89	-0.63	4.18e-18	Cognitive function;
PAAD	cis	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.38	0.34	2.16e-5	Depression;
PAAD	cis	rs2786865	0.708	rs2982292	chr1:26040139	A/G	cg12074707	chr1:27019787	NA	-0.66	-4.43	-0.34	1.8e-5	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs12714314	0.756	rs1469647	chr2:1950243	C/T	cg22350835	chr2:1868857	MYT1L	0.48	4.64	0.35	7.51e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.92	-0.37	2.26e-6	Life satisfaction;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg23119463	chr10:134592391	INPP5A	-0.5	-4.7	-0.36	5.82e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg08853572	chr16:1843915	IGFALS	-0.26	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.54	8.35	0.56	3.82e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg03060546	chr3:49711283	APEH	0.54	4.6	0.35	8.9e-6	Menarche (age at onset);
PAAD	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.71	-7.66	-0.53	2.08e-12	Neuroticism;
PAAD	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.91	-10.74	-0.66	2.18e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.7	9.57	0.61	2.77e-17	Crohn's disease;
PAAD	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.42	5.13	0.38	8.78e-7	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.36	-0.4	3.03e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.68	-7.26	-0.51	1.92e-11	Post bronchodilator FEV1;
PAAD	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg23346134	chr3:49453900	TCTA	0.43	4.5	0.34	1.34e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg09654669	chr8:57350985	NA	-0.5	-4.25	-0.33	3.67e-5	Obesity-related traits;
PAAD	cis	rs11051970	0.611	rs56146365	chr12:32529634	A/G	cg02745156	chr12:32552066	NA	0.4	4.48	0.34	1.44e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-8.22	-0.55	8.29e-14	Hemoglobin concentration;
PAAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg08355456	chr11:67383691	NA	0.47	4.71	0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs8095374	0.869	rs9955853	chr18:43829655	C/T	cg20581250	chr18:44676959	HDHD2	0.49	4.6	0.35	8.94e-6	Clinical laboratory measurements;
PAAD	cis	rs3809060	0.762	rs5030176	chr11:32448895	C/G	cg27259320	chr11:32460587	WIT1	0.34	4.39	0.34	2.15e-5	Inguinal hernia;
PAAD	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.53	-0.41	1.39e-7	Rheumatoid arthritis;
PAAD	cis	rs7577696	0.597	rs212689	chr2:32437338	G/A	cg02381751	chr2:32503542	YIPF4	0.51	4.91	0.37	2.37e-6	Inflammatory biomarkers;
PAAD	cis	rs17125944	0.686	rs7145242	chr14:53349842	G/A	cg00686598	chr14:53173677	PSMC6	-0.83	-5.01	-0.38	1.49e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01765077	chr12:122356316	WDR66	0.59	6.76	0.48	2.71e-10	Mean corpuscular volume;
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	11.09	0.67	2.59e-21	Platelet count;
PAAD	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.42	-0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22509189	chr2:225307070	NA	0.43	4.32	0.33	2.79e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1468333	1.000	rs4552585	chr5:137533159	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.95e-9	Resting heart rate;
PAAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.5	5.75	0.42	4.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.48	6.75	0.48	2.87e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.63	5.23	0.39	5.5e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	4.63	0.35	7.91e-6	Obesity-related traits;
PAAD	cis	rs2997447	0.739	rs72884784	chr1:26432246	G/A	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.58	6.1	0.44	8.58e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg20850873	chr3:10149803	C3orf24	0.54	4.31	0.33	2.93e-5	Alzheimer's disease;
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21678189	chr6:10838625	NA	0.57	6.34	0.46	2.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.7	8.24	0.56	7.35e-14	Bone mineral density;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg14926445	chr8:58193284	C8orf71	-0.66	-5.48	-0.41	1.72e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.45	-5.64	-0.42	8.08e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs77880822	0.562	rs76129906	chr20:1242215	A/G	cg23117778	chr20:1206693	RAD21L1	0.92	5.06	0.38	1.21e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.43	4.25	0.33	3.64e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg20893579	chr22:38215064	NA	0.48	4.72	0.36	5.33e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.59	0.35	9.11e-6	Schizophrenia;
PAAD	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-6.37	-0.46	2.18e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27215578	chr6:26569043	NA	-0.77	-7.09	-0.5	4.81e-11	Neuroticism;
PAAD	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg23912435	chr1:150601613	ENSA	0.51	4.74	0.36	4.87e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10078	0.559	rs6893791	chr5:430413	T/C	cg07599136	chr5:415885	AHRR	0.66	5.01	0.38	1.48e-6	Fat distribution (HIV);
PAAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.95	-0.37	1.93e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg26935685	chr1:15502881	TMEM51	-0.53	-4.45	-0.34	1.64e-5	Systolic blood pressure;
PAAD	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs6127978	0.818	rs6127988	chr20:55834342	C/T	cg07908223	chr20:56225978	PMEPA1	0.54	4.55	0.35	1.09e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.5	5.05	0.38	1.27e-6	Monocyte count;
PAAD	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-6.66	-0.48	4.66e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.43	-4.85	-0.37	2.99e-6	Lung cancer;
PAAD	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg01305830	chr4:1604576	NA	-0.47	-4.43	-0.34	1.79e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.78	-5.81	-0.43	3.52e-8	Coronary artery calcification;
PAAD	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg15956490	chr3:53032818	SFMBT1	0.82	4.81	0.36	3.58e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.86	-0.54	6.72e-13	Hemoglobin concentration;
PAAD	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.77	6.11	0.44	7.91e-9	Diisocyanate-induced asthma;
PAAD	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg15117754	chr3:10150083	C3orf24	0.74	6.45	0.46	1.42e-9	Alzheimer's disease;
PAAD	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg00540400	chr15:79124168	NA	0.62	7.25	0.51	1.97e-11	Coronary artery disease;
PAAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-4.39	-0.34	2.08e-5	Blood metabolite levels;
PAAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg03037974	chr15:76606532	NA	0.54	6.4	0.46	1.85e-9	Blood metabolite levels;
PAAD	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg24296786	chr1:45957014	TESK2	0.66	7.35	0.51	1.16e-11	High light scatter reticulocyte count;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg00291981	chr3:49591748	BSN	-0.58	-4.37	-0.33	2.3e-5	Schizophrenia;
PAAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.59	-5.94	-0.43	1.9e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs62408225	0.962	rs2325292	chr6:90986749	T/C	cg03795776	chr6:90687632	BACH2	0.43	4.27	0.33	3.5e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg04607699	chr11:48328132	OR4S1	-0.52	-5.0	-0.38	1.54e-6	Migraine - clinic-based;
PAAD	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.63	6.81	0.48	2.16e-10	Mean corpuscular volume;
PAAD	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.83	-7.64	-0.53	2.3e-12	Neurofibrillary tangles;
PAAD	cis	rs6508941	0.513	rs814538	chr19:41025243	G/A	cg26971411	chr19:41016501	SPTBN4	-0.45	-4.53	-0.34	1.19e-5	Antibody level in response to infection;
PAAD	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg05044414	chr3:183734942	ABCC5	0.53	4.75	0.36	4.62e-6	Anterior chamber depth;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg10047026	chr17:4613992	ARRB2	0.59	6.29	0.45	3.18e-9	Primary biliary cholangitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27434584	chr18:19114052	ESCO1	-0.61	-7.34	-0.51	1.21e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-8.45	-0.57	2.18e-14	Total body bone mineral density;
PAAD	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs1879734	0.648	rs11206193	chr1:54158762	C/G	cg14659662	chr1:54151053	GLIS1	-0.44	-6.14	-0.45	6.72e-9	Mitral valve prolapse;
PAAD	cis	rs5756391	0.568	rs11705504	chr22:37317493	G/A	cg16356956	chr22:37317934	CSF2RB	0.4	4.79	0.36	3.86e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.53	6.01	0.44	1.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.65	4.73	0.36	5.14e-6	Blood protein levels;
PAAD	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.33	0.6	1.17e-16	Cognitive test performance;
PAAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg12963866	chr19:57752005	ZNF805	0.49	4.75	0.36	4.68e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs59888335	0.964	rs11715319	chr3:80682087	T/C	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.77	7.65	0.53	2.1e-12	Coronary artery disease;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.53	-5.43	-0.4	2.14e-7	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-4.99	-0.38	1.64e-6	Bipolar disorder;
PAAD	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.84	9.24	0.6	2.04e-16	Mortality in heart failure;
PAAD	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg04450456	chr4:17643702	FAM184B	-0.49	-4.82	-0.36	3.49e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20067338	chr8:128692091	NA	-0.57	-6.3	-0.46	3.11e-9	Obesity-related traits;
PAAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.8	-8.26	-0.56	6.61e-14	Facial morphology (factor 23);
PAAD	cis	rs13102973	0.720	rs67429820	chr4:135888003	G/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs427941	0.655	rs2529095	chr7:101749663	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.28	-0.33	3.34e-5	Longevity;Endometriosis;
PAAD	cis	rs61861422	0.516	rs12416102	chr10:134456648	G/T	cg24416232	chr10:134405482	INPP5A	-0.46	-4.81	-0.36	3.62e-6	Primary sclerosing cholangitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02988267	chr1:78149396	ZZZ3	-0.73	-6.71	-0.48	3.71e-10	Neuroticism;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg03259038	chr19:41630690	CYP2F1	0.63	6.7	0.48	3.85e-10	Educational attainment (years of education);
PAAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.64	0.35	7.37e-6	Plateletcrit;
PAAD	cis	rs6942407	0.542	rs744136	chr7:86747081	T/C	cg14887563	chr7:86849180	C7orf23	0.49	4.27	0.33	3.45e-5	Food allergy;
PAAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg14433983	chr11:636460	DRD4	-0.46	-4.75	-0.36	4.64e-6	Systemic lupus erythematosus;
PAAD	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg00531865	chr16:30841666	NA	0.53	5.25	0.39	5.12e-7	Dementia with Lewy bodies;
PAAD	cis	rs151997	0.671	rs27845	chr5:50197420	A/C	cg06027927	chr5:50259733	NA	0.67	6.63	0.47	5.43e-10	Callous-unemotional behaviour;
PAAD	cis	rs8049603	0.697	rs5732	chr16:23197562	A/G	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg20673091	chr1:2541236	MMEL1	0.72	7.39	0.51	9.01e-12	Ulcerative colitis;
PAAD	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.46	-4.35	-0.33	2.47e-5	Red blood cell count;
PAAD	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.49	-4.92	-0.37	2.21e-6	Daytime sleep phenotypes;
PAAD	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg20569369	chr22:51173646	NA	-0.46	-4.66	-0.35	6.94e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg06917634	chr15:78832804	PSMA4	-0.45	-4.36	-0.33	2.36e-5	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs13333054	0.950	rs68143182	chr16:86005838	C/T	cg08215318	chr16:86016387	NA	0.5	4.89	0.37	2.57e-6	Multiple sclerosis;
PAAD	cis	rs4678145	1.000	rs17282064	chr3:124454449	C/T	cg07063911	chr3:125197837	SNX4	0.7	4.26	0.33	3.52e-5	Coronary artery disease;
PAAD	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.45	-5.29	-0.39	4.11e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg07784872	chr16:85687041	KIAA0182	0.61	5.31	0.4	3.76e-7	Platelet distribution width;
PAAD	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.16	-0.39	7.7e-7	Morning vs. evening chronotype;
PAAD	cis	rs16975963	0.644	rs73035164	chr19:38146720	G/C	cg25793785	chr19:38281423	NA	0.51	4.27	0.33	3.39e-5	Longevity;
PAAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.87	-9.1	-0.59	4.73e-16	Colorectal cancer;
PAAD	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioma;Non-glioblastoma glioma;Glioblastoma;
PAAD	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.16	-16.88	-0.81	1.13e-36	Exhaled nitric oxide output;
PAAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4740619	0.619	rs1328280	chr9:16030903	C/T	cg14451791	chr9:16040625	NA	0.47	5.71	0.42	5.76e-8	Body mass index;
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.51	5.35	0.4	3.19e-7	Obesity-related traits;
PAAD	cis	rs863345	0.526	rs2051666	chr1:158507160	T/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.25e-6	Pneumococcal bacteremia;
PAAD	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.72	-9.56	-0.61	3.08e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12580194	0.593	rs11171431	chr12:55757609	G/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.35	0.33	2.52e-5	Cancer;
PAAD	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.61	-5.33	-0.4	3.49e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg19875578	chr6:126661172	C6orf173	-0.57	-5.76	-0.42	4.41e-8	Male-pattern baldness;
PAAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.83	9.11	0.59	4.43e-16	Vitiligo;
PAAD	cis	rs76010824	0.892	rs74429267	chr3:67443246	C/CTT	cg05068866	chr3:66633374	NA	-0.66	-4.43	-0.34	1.78e-5	Prostate cancer (survival);
PAAD	cis	rs116175783	0.557	rs62188136	chr2:162255950	A/G	cg08807892	chr2:162101083	NA	-0.65	-4.77	-0.36	4.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs12906542	0.544	rs35472584	chr15:78266727	C/T	cg20329220	chr15:78286521	LOC91450	-0.39	-4.25	-0.33	3.67e-5	Breast cancer;
PAAD	cis	rs9616064	0.688	rs117095143	chr22:46973214	T/C	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.56	-0.35	1.05e-5	Urate levels in obese individuals;
PAAD	cis	rs9857275	0.527	rs11709875	chr3:141180511	A/G	cg25967872	chr3:141205623	RASA2	0.51	4.42	0.34	1.86e-5	Prion diseases;
PAAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg25204440	chr1:209979598	IRF6	0.67	5.73	0.42	5.33e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	8.34	0.56	4.15e-14	Cognitive test performance;
PAAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00142150	chr22:38071001	LGALS1	0.7	7.87	0.54	6.2800000000000005e-13	Fat distribution (HIV);
PAAD	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-4.83	-0.36	3.26e-6	Total body bone mineral density;
PAAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23281280	chr6:28129359	ZNF389	0.68	5.23	0.39	5.59e-7	Depression;
PAAD	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg13535736	chr9:111863775	C9orf5	-0.35	-4.34	-0.33	2.63e-5	Menarche (age at onset);
PAAD	cis	rs42648	0.596	rs194520	chr7:89854446	T/G	cg27367526	chr7:89841692	STEAP2	-0.31	-4.27	-0.33	3.37e-5	Homocysteine levels;
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-7.71	-0.53	1.5e-12	Prostate cancer;
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07167872	chr1:205819463	PM20D1	-0.51	-4.87	-0.37	2.72e-6	Parkinson's disease;
PAAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.59	-6.87	-0.49	1.51e-10	Lung cancer;
PAAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.51	6.66	0.48	4.69e-10	Renal cell carcinoma;
PAAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Coronary artery disease;
PAAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg13468214	chr4:1046988	NA	-0.55	-5.06	-0.38	1.19e-6	Recombination rate (females);
PAAD	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.58	5.1	0.38	1.01e-6	Interleukin-17 levels;
PAAD	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg27119904	chr13:114814333	RASA3	0.42	4.56	0.35	1.04e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg06395392	chr16:89406307	ANKRD11	-0.75	-4.38	-0.33	2.18e-5	Red blood cell count;
PAAD	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg17644776	chr2:200775616	C2orf69	-0.63	-5.06	-0.38	1.19e-6	Schizophrenia;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.83	6.18	0.45	5.63e-9	Tuberculosis;
PAAD	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.87	-9.75	-0.62	9.5e-18	Body mass index;
PAAD	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.61	6.42	0.46	1.64e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.92e-15	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.72	5.25	0.39	5.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg16342193	chr10:102329863	NA	0.75	8.19	0.55	9.67e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16794633	chr3:143690145	C3orf58	-0.57	-6.65	-0.47	4.98e-10	Body fat percentage;
PAAD	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.44	4.52	0.34	1.22e-5	Pulmonary function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23958457	chr10:16859509	RSU1	0.58	6.32	0.46	2.75e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	4.27	0.33	3.36e-5	Height;
PAAD	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs3018712	0.590	rs4433574	chr11:68499026	A/T	cg23009355	chr11:68451396	GAL	0.44	4.27	0.33	3.41e-5	Total body bone mineral density;
PAAD	cis	rs78707713	0.524	rs10823377	chr10:71213327	G/A	cg14388049	chr10:71211838	TSPAN15	-0.41	-4.62	-0.35	8.29e-6	Venous thromboembolism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02532971	chr7:2491292	NA	-0.77	-6.62	-0.47	5.92e-10	Neuroticism;
PAAD	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg26703956	chr19:39260304	NA	-0.42	-5.19	-0.39	6.61e-7	Heart rate;
PAAD	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.88	-0.43	2.56e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	4.35	0.33	2.47e-5	Multiple sclerosis;
PAAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.72	-6.63	-0.47	5.5e-10	Dilated cardiomyopathy;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg06815965	chr1:205818668	PM20D1	-0.49	-5.31	-0.4	3.77e-7	Monocyte percentage of white cells;
PAAD	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.05	13.13	0.73	8.43e-27	Testicular germ cell tumor;
PAAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.5	5.27	0.39	4.7e-7	Obesity-related traits;
PAAD	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.21	-18.92	-0.84	8.69e-42	Exhaled nitric oxide output;
PAAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg03959625	chr15:84868606	LOC388152	-0.42	-4.33	-0.33	2.7e-5	Schizophrenia;
PAAD	cis	rs7766436	0.767	rs7764914	chr6:22601548	T/G	cg13666174	chr6:22585274	NA	-0.52	-5.75	-0.42	4.65e-8	Coronary artery disease;
PAAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg00738919	chr7:1100172	C7orf50	0.67	5.4	0.4	2.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg24253500	chr15:84953950	NA	0.57	6.39	0.46	1.93e-9	Schizophrenia;
PAAD	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27099511	chr16:88729703	MGC23284;MVD	-0.89	-4.55	-0.35	1.1e-5	Plateletcrit;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.74	-7.11	-0.5	4.27e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9463078	0.546	rs1284983	chr6:45081916	A/G	cg18551225	chr6:44695536	NA	0.42	4.35	0.33	2.49e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.59	4.45	0.34	1.66e-5	Systolic blood pressure;
PAAD	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-1.15	-9.32	-0.6	1.31e-16	Obesity-related traits;
PAAD	cis	rs7567389	0.677	rs72845991	chr2:128107907	A/G	cg11380483	chr2:127933992	NA	0.45	4.52	0.34	1.24e-5	Self-rated health;
PAAD	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.78	-0.53	1.03e-12	Colorectal cancer;
PAAD	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.74	-7.56	-0.52	3.61e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.87	6.02	0.44	1.26e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg03983715	chr16:68378420	PRMT7	-0.72	-5.24	-0.39	5.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10823500	0.614	rs10999172	chr10:71942522	C/T	cg02100629	chr10:71892760	AIFM2	0.4	4.28	0.33	3.24e-5	Blood protein levels;
PAAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg03538708	chr1:25844672	NA	0.48	4.96	0.37	1.83e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.48	-4.68	-0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-0.88	-8.3	-0.56	5.12e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg03538708	chr1:25844672	NA	-0.49	-5.03	-0.38	1.39e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg01631408	chr1:248437212	OR2T33	-0.57	-5.06	-0.38	1.22e-6	Common traits (Other);
PAAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.68	-8.08	-0.55	1.83e-13	Eye color traits;
PAAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.06	0.38	1.18e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.48	4.85	0.37	3.03e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	4.82	0.36	3.4e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.59	-6.64	-0.47	5.35e-10	Colorectal or endometrial cancer;
PAAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.65	-7.32	-0.51	1.38e-11	Iron status biomarkers;
PAAD	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.13	0.45	7.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.8	8.93	0.59	1.28e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs42648	0.596	rs194513	chr7:89850170	G/T	cg27367526	chr7:89841692	STEAP2	-0.3	-4.25	-0.33	3.67e-5	Homocysteine levels;
PAAD	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.5	-5.62	-0.41	9.01e-8	Breast cancer;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.8	5.42	0.4	2.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg26554054	chr8:600488	NA	0.9	5.68	0.42	6.56e-8	IgG glycosylation;
PAAD	cis	rs863345	0.967	rs11265002	chr1:158489063	T/C	cg12129480	chr1:158549410	OR10X1	-0.45	-5.23	-0.39	5.48e-7	Pneumococcal bacteremia;
PAAD	cis	rs1434579	0.865	rs12980701	chr19:44948014	C/A	cg23218533	chr19:44645662	ZNF234	-0.52	-4.44	-0.34	1.72e-5	Tuberculosis;
PAAD	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.87	9.28	0.6	1.65e-16	Schizophrenia;
PAAD	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg20283391	chr11:68216788	NA	0.55	5.39	0.4	2.68e-7	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg15117754	chr3:10150083	C3orf24	0.68	5.68	0.42	6.58e-8	Alzheimer's disease;
PAAD	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg26247942	chr15:43984922	CKMT1A	-0.34	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg14393609	chr7:65229607	NA	-0.45	-4.68	-0.35	6.35e-6	Aortic root size;
PAAD	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg04545296	chr12:48745243	ZNF641	-0.35	-4.55	-0.35	1.1e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	5.49	0.41	1.61e-7	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7084921	0.552	rs1324693	chr10:101890617	A/G	cg04359915	chr10:101825029	CPN1	-0.29	-4.32	-0.33	2.81e-5	Bone mineral density;
PAAD	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.68	-6.74	-0.48	3.03e-10	Callous-unemotional behaviour;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23868141	chr19:3275646	BRUNOL5	-0.53	-6.33	-0.46	2.55e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.76	-9.09	-0.59	4.98e-16	Bipolar disorder and schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07501049	chr1:981392	AGRN	0.57	6.51	0.47	1.02e-9	Body fat percentage;
PAAD	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg03999872	chr20:62272968	STMN3	-0.6	-5.32	-0.4	3.65e-7	Atopic dermatitis;
PAAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg10589385	chr1:150898437	SETDB1	0.39	4.8	0.36	3.8e-6	Melanoma;
PAAD	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.22e-11	Eye color traits;
PAAD	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.74	8.21	0.55	8.82e-14	Morning vs. evening chronotype;
PAAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.82	9.49	0.61	4.53e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg06728252	chr6:26598149	ABT1	-0.39	-4.57	-0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg06437144	chr17:45973627	SP2	-0.57	-6.37	-0.46	2.11e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2421770	0.561	rs3899569	chr11:35358513	C/T	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.3	-0.4	3.92e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.87	11.7	0.69	6.12e-23	Height;
PAAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.33	11.41	0.68	3.48e-22	Uric acid levels;
PAAD	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.58	-8.16	-0.55	1.19e-13	Urate levels in overweight individuals;
PAAD	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.87	10.23	0.64	5.05e-19	Body mass index;
PAAD	cis	rs9815354	0.951	rs9868066	chr3:41794161	T/A	cg03022575	chr3:42003672	ULK4	0.64	4.5	0.34	1.37e-5	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.64	6.97	0.49	8.99e-11	IgG glycosylation;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.32	0.81	8.35e-38	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25806492	chr1:24970113	SRRM1	0.59	6.9	0.49	1.28e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.86	9.86	0.62	4.97e-18	Gout;
PAAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg02917321	chr22:38215204	NA	0.44	4.28	0.33	3.35e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.04	0.5	6.28e-11	Coffee consumption (cups per day);
PAAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.64	9.96	0.63	2.68e-18	Asthma (sex interaction);
PAAD	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	4.77	0.36	4.31e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.24	7.31	0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	cis	rs988913	0.581	rs1108887	chr6:54857207	C/T	cg03513858	chr6:54763001	FAM83B	0.42	4.72	0.36	5.28e-6	Menarche (age at onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15554682	chr11:67195844	RPS6KB2	-0.64	-6.58	-0.47	7.07e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.72	6.93	0.49	1.13e-10	Sum neutrophil eosinophil counts;
PAAD	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg22827986	chr11:48284249	OR4X1	0.43	5.27	0.39	4.56e-7	Migraine - clinic-based;
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg06115741	chr20:33292138	TP53INP2	-0.44	-4.26	-0.33	3.55e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10121009	0.565	rs4498642	chr9:35436662	C/G	cg11846315	chr9:35647073	NA	-0.48	-4.32	-0.33	2.81e-5	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15459742	chr9:111775564	CTNNAL1	0.59	6.62	0.47	5.91e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg00431813	chr7:1051703	C7orf50	-0.61	-6.31	-0.46	2.92e-9	Bronchopulmonary dysplasia;
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.63	-6.22	-0.45	4.48e-9	Blood metabolite levels;
PAAD	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.97	7.85	0.54	6.87e-13	Vitiligo;
PAAD	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg15117754	chr3:10150083	C3orf24	0.66	5.5	0.41	1.58e-7	Alzheimer's disease;
PAAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg04106633	chr4:1044584	NA	0.81	5.9	0.43	2.26e-8	Recombination rate (females);
PAAD	cis	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg11619707	chr19:22235551	ZNF257	-0.58	-5.67	-0.42	7.11e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8060686	0.858	rs8051587	chr16:67796315	A/C	cg09835421	chr16:68378352	PRMT7	-0.62	-4.63	-0.35	7.91e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.11e-5	Blood metabolite levels;
PAAD	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.56	5.11	0.38	9.71e-7	Testicular germ cell tumor;
PAAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg21951975	chr1:209979733	IRF6	0.59	5.39	0.4	2.67e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.92e-7	Ulcerative colitis;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.16	-0.45	6.32e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg05342682	chr7:94953680	PON1	-0.57	-4.83	-0.36	3.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs2252790	0.794	rs1204808	chr6:116550917	A/G	cg26893134	chr6:116381904	FRK	-0.28	-4.52	-0.34	1.23e-5	Fast beta electroencephalogram;
PAAD	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg00181669	chr3:44000978	NA	-0.45	-4.47	-0.34	1.53e-5	Coronary artery disease;
PAAD	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.56	-0.35	1.06e-5	Neuroticism;
PAAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.84	7.31	0.51	1.42e-11	Recombination rate (females);
PAAD	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg18551225	chr6:44695536	NA	-0.68	-6.76	-0.48	2.75e-10	Total body bone mineral density;
PAAD	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.1	0.38	1.01e-6	Breast cancer;
PAAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.05e-6	Coronary artery disease;
PAAD	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg08390786	chr10:135334061	NA	0.58	4.85	0.37	2.98e-6	Gout;
PAAD	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.85	0.49	1.67e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg07701084	chr6:150067640	NUP43	-0.53	-4.59	-0.35	9.36e-6	Lung cancer;
PAAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.64	-7.17	-0.5	3.08e-11	Menarche (age at onset);
PAAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.78	8.01	0.54	2.73e-13	Schizophrenia;
PAAD	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg03605463	chr16:89740564	NA	0.79	8.39	0.56	3.11e-14	Vitiligo;
PAAD	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-5.37	-0.4	2.84e-7	Personality dimensions;
PAAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-6.76	-0.48	2.82e-10	Breast cancer;
PAAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.88	8.04	0.55	2.31e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1011018	0.955	rs11770283	chr7:139436551	G/T	cg03224163	chr7:139420300	HIPK2	-0.6	-4.27	-0.33	3.47e-5	Systolic blood pressure;
PAAD	cis	rs7580658	0.554	rs2069915	chr2:128178378	G/A	cg10985347	chr2:127963512	CYP27C1	0.51	4.99	0.37	1.65e-6	Protein C levels;
PAAD	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.4	0.56	2.86e-14	Rheumatoid arthritis;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg26174226	chr8:58114915	NA	-0.63	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-5.53	-0.41	1.36e-7	Cognitive function;
PAAD	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.49	-4.8	-0.36	3.81e-6	Breast cancer;
PAAD	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.5	0.41	1.55e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg03684893	chr10:554711	DIP2C	-0.5	-4.74	-0.36	4.9e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	1.02	7.66	0.53	2.08e-12	Dental caries;
PAAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.88	6.26	0.45	3.66e-9	Alzheimer's disease;
PAAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs58521262	0.556	rs289331	chr19:23154436	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg06565975	chr8:143823917	SLURP1	0.23	5.47	0.41	1.82e-7	Urinary tract infection frequency;
PAAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.76	8.92	0.59	1.38e-15	Lung cancer;
PAAD	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.7	4.76	0.36	4.4e-6	Major depressive disorder;
PAAD	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-1.18	-7.26	-0.51	1.85e-11	Severe influenza A (H1N1) infection;
PAAD	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.42	5.31	0.4	3.82e-7	Colorectal cancer;
PAAD	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg08975724	chr8:8085496	FLJ10661	0.48	4.64	0.35	7.38e-6	Recombination measurement;
PAAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.56	0.35	1.04e-5	Breast cancer;
PAAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.63e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4742903	0.904	rs12380062	chr9:106941903	A/G	cg14250997	chr9:106856677	SMC2	0.44	4.66	0.35	6.98e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.55	-4.43	-0.34	1.82e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2790216	0.951	rs1769020	chr10:59929343	C/T	cg19897495	chr11:659770	DEAF1	0.84	6.39	0.46	1.92e-9	Inflammatory bowel disease;
PAAD	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.73	-0.42	5.35e-8	Total cholesterol levels;
PAAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10150615	chr22:24372951	LOC391322	0.49	4.35	0.33	2.49e-5	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4774830	0.744	rs62046394	chr15:56316356	C/A	cg24530489	chr15:56299380	NA	-0.94	-4.44	-0.34	1.69e-5	Delta-5 desaturase activity;
PAAD	cis	rs10121009	0.635	rs10114937	chr9:35271817	C/T	cg11846315	chr9:35647073	NA	0.49	4.64	0.35	7.52e-6	Parkinson's disease;
PAAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	4.97	0.37	1.78e-6	Total body bone mineral density;
PAAD	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.79	-0.43	3.91e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	2.85e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.75	9.35	0.6	1.08e-16	Bladder cancer;
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.53	5.18	0.39	6.82e-7	Parkinson's disease;
PAAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg16928487	chr17:17741425	SREBF1	-0.36	-4.88	-0.37	2.65e-6	Total body bone mineral density;
PAAD	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.79	5.82	0.43	3.41e-8	Vitiligo;
PAAD	cis	rs58521262	0.556	rs2645878	chr19:23210946	G/A	cg03433597	chr19:22806448	NA	0.24	4.26	0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.84	7.3	0.51	1.5e-11	Menarche (age at onset);
PAAD	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.17	-0.45	5.87e-9	Schizophrenia;
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg06629702	chr1:2706960	NA	-0.37	-4.33	-0.33	2.74e-5	Ulcerative colitis;
PAAD	cis	rs6460942	0.908	rs74801929	chr7:12232715	C/G	cg20607287	chr7:12443886	VWDE	-0.79	-5.54	-0.41	1.3e-7	Coronary artery disease;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg14660007	chr13:78271894	SLAIN1	-0.68	-6.39	-0.46	1.93e-9	Blood protein levels;
PAAD	cis	rs7945718	0.621	rs11022463	chr11:12685395	T/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.1e-5	Educational attainment (years of education);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15837119	chr8:28479995	NA	-0.85	-7.5	-0.52	4.9e-12	Neuroticism;
PAAD	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	1.07	8.48	0.57	1.87e-14	Inflammatory bowel disease;
PAAD	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg15193198	chr20:60906057	LAMA5	-0.4	-4.34	-0.33	2.55e-5	Pelvic organ prolapse;
PAAD	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.67	5.19	0.39	6.53e-7	Alzheimer's disease (survival time);
PAAD	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg06606381	chr12:133084897	FBRSL1	-1.36	-8.5	-0.57	1.64e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1656368	0.726	rs17628958	chr3:158256567	C/G	cg16708174	chr3:158430962	RARRES1	0.52	4.72	0.36	5.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg06899799	chr12:56650233	ANKRD52	0.35	4.54	0.35	1.12e-5	Cancer;
PAAD	cis	rs2518049	0.539	rs7086771	chr10:5151817	C/G	cg13585175	chr10:5228106	AKR1CL1	0.49	5.27	0.39	4.66e-7	Metabolic traits;
PAAD	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.48	-5.52	-0.41	1.44e-7	Height;
PAAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg19847866	chr10:1019161	NA	0.7	6.92	0.49	1.2e-10	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg03684893	chr10:554711	DIP2C	-0.44	-4.7	-0.36	5.8e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16091543	chr12:123718047	C12orf65	0.66	6.33	0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4780401	0.678	rs7193441	chr16:11764821	C/T	cg01061890	chr16:11836724	TXNDC11	-0.58	-5.63	-0.42	8.45e-8	Rheumatoid arthritis;
PAAD	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.71	8.4	0.56	3.02e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4757319	0.532	rs4756807	chr11:15430004	T/C	cg03245590	chr11:15329459	NA	0.38	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg23024343	chr7:107201750	COG5	0.54	4.5	0.34	1.32e-5	Coronary artery disease;
PAAD	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs375066	0.935	rs399098	chr19:44418824	C/T	cg21496419	chr19:44306685	LYPD5	0.41	4.95	0.37	1.97e-6	Breast cancer;
PAAD	cis	rs2882667	0.690	rs700623	chr5:138098682	A/G	cg09476006	chr5:138032270	NA	-0.49	-6.33	-0.46	2.66e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.7	-6.98	-0.49	8.51e-11	Uric acid levels;
PAAD	trans	rs2982694	0.681	rs2982699	chr6:152286130	A/G	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.63	8.89	0.58	1.63e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	4.38	0.33	2.21e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs16975963	0.744	rs11672724	chr19:38457488	C/T	cg08679971	chr19:38281047	NA	0.56	5.35	0.4	3.22e-7	Longevity;
PAAD	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.09e-5	Cancer;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg00579200	chr11:133705235	NA	-0.49	-5.53	-0.41	1.37e-7	Childhood ear infection;
PAAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	6.06	0.44	1.02e-8	Personality dimensions;
PAAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg22143856	chr6:28129313	ZNF389	0.48	4.46	0.34	1.61e-5	Parkinson's disease;
PAAD	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04398603	chr3:9439238	SETD5;LOC440944	0.64	6.33	0.46	2.61e-9	Obesity-related traits;
PAAD	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs2274459	0.500	rs34517899	chr6:33635309	C/G	cg06253072	chr6:33679850	C6orf125	0.68	4.88	0.37	2.66e-6	Obesity (extreme);
PAAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.35	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs6681460	0.576	rs7354983	chr1:66988149	T/C	cg02459107	chr1:67143332	SGIP1	0.52	4.62	0.35	8.26e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg10932868	chr11:921992	NA	0.45	4.78	0.36	4.07e-6	Alzheimer's disease (late onset);
PAAD	cis	rs3112530	0.818	rs167357	chr5:152717402	G/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg21419209	chr3:44054225	NA	-0.72	-7.34	-0.51	1.2e-11	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg05110241	chr16:68378359	PRMT7	-0.94	-7.41	-0.52	8.1e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02187348	chr16:89574699	SPG7	0.51	4.93	0.37	2.11e-6	Multiple myeloma (IgH translocation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19187486	chr15:74833838	ARID3B	0.57	6.67	0.48	4.39e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19744158	chr22:42196655	CCDC134	-0.73	-6.47	-0.46	1.28e-9	Neuroticism;
PAAD	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.42	6.21	0.45	4.82e-9	Subjective well-being;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	6.31	0.46	2.85e-9	Platelet count;
PAAD	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.55	-5.42	-0.4	2.3e-7	Fibrinogen levels;
PAAD	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg00531865	chr16:30841666	NA	0.52	4.94	0.37	2.02e-6	Dementia with Lewy bodies;
PAAD	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.85	-0.49	1.69e-10	Atrioventricular conduction;
PAAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg14631576	chr9:95140430	CENPP	-0.46	-4.48	-0.34	1.46e-5	Height;
PAAD	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.22	0.45	4.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-6.05	-0.44	1.09e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.58	5.13	0.38	8.61e-7	Life satisfaction;
PAAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-9.49	-0.61	4.57e-17	Tonsillectomy;
PAAD	cis	rs11264799	0.598	rs2275232	chr1:157718430	T/G	cg18268488	chr1:157545234	FCRL4	0.66	5.92	0.43	2.09e-8	IgA nephropathy;
PAAD	cis	rs11105468	0.695	rs7980592	chr12:90460256	G/A	cg16962463	chr12:89968675	NA	0.45	4.77	0.36	4.27e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.99	6.98	0.49	8.79e-11	Major depressive disorder;
PAAD	cis	rs686320	0.748	rs481335	chr11:65207469	T/C	cg21890820	chr11:65308645	LTBP3	0.78	5.32	0.4	3.71e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.57	4.81	0.36	3.64e-6	Alcohol dependence (age at onset);
PAAD	cis	rs4740619	0.933	rs4741534	chr9:15715215	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.39	-0.34	2.15e-5	Body mass index;
PAAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg07617317	chr6:118971624	C6orf204	0.53	4.49	0.34	1.43e-5	Renal cell carcinoma;
PAAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.84	11.44	0.68	3.06e-22	Emphysema distribution in smoking;
PAAD	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.58	6.79	0.48	2.36e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg21659725	chr3:3221576	CRBN	0.76	7.99	0.54	3.13e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.71	-7.96	-0.54	3.75e-13	Schizophrenia;
PAAD	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.68	5.47	0.41	1.78e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg07202610	chr7:1142643	C7orf50	-0.79	-5.51	-0.41	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.49	5.37	0.4	2.85e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg00495681	chr13:53174319	NA	0.48	4.66	0.35	6.83e-6	Lewy body disease;
PAAD	cis	rs3112530	1.000	rs2199123	chr5:152651765	A/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07050032	chr17:78009173	CCDC40;TBC1D16	-0.59	-7.16	-0.5	3.23e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg00206168	chr11:65308501	LTBP3	-0.51	-5.24	-0.39	5.36e-7	Bone mineral density;
PAAD	cis	rs6594713	0.921	rs10051115	chr5:112719597	T/C	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-4.57	-0.35	1.01e-5	Eosinophil percentage of white cells;
PAAD	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.01	14.04	0.75	2.99e-29	Heart rate;
PAAD	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.65	7.35	0.51	1.11e-11	Height;
PAAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.62	-6.86	-0.49	1.62e-10	Longevity;Endometriosis;
PAAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.32e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs12282928	0.837	rs10742851	chr11:48534771	A/G	cg22827986	chr11:48284249	OR4X1	-0.44	-5.63	-0.42	8.38e-8	Migraine - clinic-based;
PAAD	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.35	-0.33	2.46e-5	Asthma (childhood onset);
PAAD	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs2051773	0.567	rs4456241	chr11:17043041	G/A	cg15084286	chr11:17036142	PLEKHA7	0.56	5.01	0.38	1.48e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs114540395	0.858	rs79692612	chr10:103322878	G/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.27	-0.33	3.42e-5	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21564660	chr12:50236950	BCDIN3D	0.57	6.64	0.47	5.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6066835	1.000	rs6122720	chr20:47351095	G/A	cg18078177	chr20:47281410	PREX1	0.99	4.91	0.37	2.38e-6	Multiple myeloma;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.62	-6.98	-0.49	8.6e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg21546286	chr11:48923668	NA	-0.46	-4.68	-0.36	6.17e-6	Coronary artery disease;
PAAD	cis	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.67	-0.35	6.55e-6	Eotaxin levels;
PAAD	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.43	7.14	0.5	3.66e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.22	4.95	0.37	1.96e-6	Urinary tract infection frequency;
PAAD	cis	rs4867766	0.585	rs6556141	chr5:173952640	C/T	cg20434911	chr5:173954559	NA	-0.58	-5.16	-0.39	7.77e-7	Stroke;
PAAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.83	8.46	0.57	2.11e-14	Uric acid levels;
PAAD	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.28	-9.09	-0.59	5.14e-16	Plateletcrit;
PAAD	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.73	-7.87	-0.54	6.2800000000000005e-13	Type 2 diabetes;
PAAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg26138144	chr22:38071188	LGALS1	0.5	5.55	0.41	1.24e-7	Fat distribution (HIV);
PAAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.85	-9.86	-0.62	5.01e-18	Ulcerative colitis;
PAAD	cis	rs3753841	0.780	rs1015747	chr1:103374930	C/A	cg24495344	chr1:103574097	COL11A1	0.4	4.42	0.34	1.84e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26241174	chr14:65381212	CHURC1	0.65	6.32	0.46	2.69e-9	Obesity-related traits;
PAAD	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg09127314	chr1:152161683	NA	0.74	5.43	0.4	2.14e-7	Atopic dermatitis;
PAAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.5	-7.31	-0.51	1.43e-11	Diastolic blood pressure;
PAAD	cis	rs75920871	0.688	rs7109876	chr11:116848648	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.86	-4.52	-0.34	1.21e-5	Subjective well-being;
PAAD	cis	rs11811982	0.793	rs11804271	chr1:227563700	T/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.62	5.91	0.43	2.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg25883020	chr8:41504993	NKX6-3	0.36	4.31	0.33	2.92e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10556349	chr10:835070	NA	0.72	6.26	0.45	3.67e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg02404636	chr22:31891804	SFI1	-0.57	-5.19	-0.39	6.76e-7	Colorectal cancer;
PAAD	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg27417659	chr7:98567827	TRRAP	-0.47	-4.39	-0.34	2.15e-5	Breast cancer;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.86	6.35	0.46	2.32e-9	Intraocular pressure;
PAAD	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.88	-10.91	-0.66	7.68e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-7.04	-0.5	6.03e-11	Type 2 diabetes;
PAAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-1.1	-15.66	-0.79	1.65e-33	Total body bone mineral density;
PAAD	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	4.9	0.37	2.45e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.7	7.16	0.5	3.3e-11	Response to antidepressants and depression;
PAAD	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.65	-7.12	-0.5	4.01e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.54	4.67	0.35	6.57e-6	Red blood cell count;
PAAD	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg06484146	chr7:12443880	VWDE	-0.64	-4.51	-0.34	1.28e-5	Coronary artery disease;
PAAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02071572	chr4:1403502	NA	0.38	4.87	0.37	2.8e-6	Longevity;
PAAD	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.64	-5.4	-0.4	2.52e-7	Lymphocyte counts;
PAAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.45	0.61	5.79e-17	Parkinson's disease;
PAAD	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.52	4.5	0.34	1.34e-5	Lymphocyte counts;
PAAD	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.62	5.45	0.4	2.04e-7	Obesity-related traits;
PAAD	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.81	0.54	8.56e-13	Motion sickness;
PAAD	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.49	5.76	0.42	4.57e-8	QRS complex (12-leadsum);
PAAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-7.06	-0.5	5.65e-11	Gut microbiome composition (summer);
PAAD	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.9	0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.39	4.6	0.35	9.01e-6	Total body bone mineral density;
PAAD	cis	rs2013441	1.000	rs2386429	chr17:20210809	G/A	cg25070565	chr17:20044324	CYTSB	0.45	4.33	0.33	2.72e-5	Obesity-related traits;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.59	6.29	0.45	3.29e-9	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs795484	0.890	rs61945179	chr12:118652976	A/G	cg06703803	chr12:110811045	ANAPC7	-0.58	-6.48	-0.47	1.24e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs11892454	0.544	rs10490569	chr2:26001427	T/C	cg25181710	chr2:26045287	ASXL2	0.43	4.88	0.37	2.65e-6	Heschl's gyrus morphology;
PAAD	cis	rs732765	0.657	rs11844957	chr14:75224651	T/C	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.46	-0.41	1.88e-7	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg08999081	chr20:33150536	PIGU	0.58	6.53	0.47	9.09e-10	Height;
PAAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	1.06	14.49	0.76	1.96e-30	Menarche (age at onset);
PAAD	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg18595228	chr15:67193261	NA	-0.73	-5.47	-0.41	1.77e-7	Lung cancer (smoking interaction);
PAAD	cis	rs6710503	0.574	rs62142310	chr2:24862242	A/C	cg21151432	chr2:25142229	ADCY3	-0.36	-4.28	-0.33	3.28e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	cis	rs9469913	0.799	rs9469890	chr6:34763982	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03348474	chr12:54400021	NA	0.7	7.09	0.5	4.7e-11	Obesity-related traits;
PAAD	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg13263323	chr15:86062960	AKAP13	-0.62	-7.17	-0.5	3.02e-11	Interstitial lung disease;
PAAD	cis	rs1797885	0.714	rs299635	chr3:12535739	T/C	cg07775309	chr3:12595852	NA	0.4	4.42	0.34	1.89e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2422052	0.639	rs1433531	chr2:118646201	A/C	cg22545206	chr2:118617499	NA	0.45	4.41	0.34	1.94e-5	Mosquito bite size;
PAAD	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.79	-0.43	3.82e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg15764593	chr10:829463	NA	-0.88	-4.31	-0.33	2.94e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.58	-5.66	-0.42	7.46e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.15	7.9	0.54	5.11e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-8.74	-0.58	4.05e-15	Total body bone mineral density;
PAAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg21496419	chr19:44306685	LYPD5	0.43	5.38	0.4	2.71e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.31	0.4	3.89e-7	Lung cancer;
PAAD	cis	rs3916	0.688	rs9204	chr12:121177778	A/G	cg21892295	chr12:121157589	UNC119B	-0.43	-4.77	-0.36	4.26e-6	Urinary metabolites (H-NMR features);
PAAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	5.34	0.4	3.26e-7	Calcium levels;
PAAD	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	4.49	0.34	1.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.52	-5.69	-0.42	6.4e-8	Heart rate;
PAAD	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg04018474	chr16:31008003	STX1B	-0.27	-4.26	-0.33	3.51e-5	Dementia with Lewy bodies;
PAAD	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17376030	chr22:41985996	PMM1	-0.67	-4.55	-0.35	1.09e-5	Vitiligo;
PAAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.93	10.52	0.65	8.65e-20	Parkinson's disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23712314	chr7:4721836	FOXK1	0.66	6.85	0.49	1.72e-10	Myopia (pathological);
PAAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-0.88	-9.59	-0.61	2.52e-17	Body mass index;
PAAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12537386	chr22:42978064	RRP7B	0.61	6.45	0.46	1.39e-9	Myopia (pathological);
PAAD	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2017305	0.764	rs2805918	chr10:70782514	T/C	cg25290552	chr10:70751067	KIAA1279	-0.85	-5.47	-0.41	1.79e-7	Depression (quantitative trait);
PAAD	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.64	5.48	0.41	1.69e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg10845886	chr2:3471009	TTC15	-0.61	-5.93	-0.43	1.98e-8	Neurofibrillary tangles;
PAAD	cis	rs7714584	1.000	rs9324660	chr5:150257054	C/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.58	-0.35	9.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg11416102	chr8:651193	ERICH1	0.94	5.9	0.43	2.27e-8	IgG glycosylation;
PAAD	cis	rs476633	0.708	rs28770904	chr15:41438881	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.29	-0.56	5.65e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs795484	0.963	rs1277441	chr12:118605989	G/A	cg16572268	chr12:118583242	PEBP1	-0.45	-4.41	-0.34	1.97e-5	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19445205	chr2:242585285	ATG4B	0.51	6.69	0.48	3.95e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	5.81	0.43	3.52e-8	Schizophrenia;
PAAD	cis	rs8105895	0.800	rs62112872	chr19:22192425	T/C	cg20662725	chr19:22235022	ZNF257	-0.59	-4.6	-0.35	8.82e-6	Body mass index (change over time);
PAAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg14349672	chr11:133703707	NA	0.56	6.63	0.47	5.4e-10	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs59888335	0.895	rs68161603	chr3:80864848	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.15	0.39	8.02e-7	Educational attainment;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.45	4.58	0.35	9.5e-6	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg15117754	chr3:10150083	C3orf24	0.81	7.11	0.5	4.14e-11	Alzheimer's disease;
PAAD	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.61	-7.2	-0.5	2.55e-11	Aortic root size;
PAAD	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.67	-7.15	-0.5	3.42e-11	Obesity-related traits;
PAAD	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.72	8.21	0.55	8.84e-14	Prostate cancer;
PAAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-6.21	-0.45	4.84e-9	Total body bone mineral density;
PAAD	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.79	7.22	0.51	2.34e-11	Breast cancer;
PAAD	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.6	0.57	9.26e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.37	0.33	2.29e-5	Bipolar disorder;
PAAD	cis	rs10821973	0.527	rs4322347	chr10:64023097	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.41	-0.34	1.95e-5	Hypothyroidism;
PAAD	cis	rs728616	0.867	rs61859977	chr10:81883689	A/T	cg05935833	chr10:81318306	SFTPA2	-0.74	-5.05	-0.38	1.22e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.66	0.53	2.03e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.58	4.92	0.37	2.23e-6	Intraocular pressure;
PAAD	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16989378	chr2:230786828	FBXO36;TRIP12	0.68	7.33	0.51	1.27e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.52	-5.02	-0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg05554000	chr7:158905015	VIPR2	-0.71	-5.07	-0.38	1.15e-6	Facial morphology (factor 20);
PAAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.44	-0.34	1.72e-5	Mean corpuscular volume;
PAAD	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.89	-8.38	-0.56	3.4e-14	Bone mineral density;
PAAD	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg21419209	chr3:44054225	NA	-0.59	-5.85	-0.43	2.89e-8	Coronary artery disease;
PAAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.66	-5.29	-0.39	4.13e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.57	5.75	0.42	4.67e-8	Multiple sclerosis;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg09677638	chr11:61582810	MIR1908;FADS1	0.54	4.83	0.36	3.25e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10120112	chr2:85132396	TMSB10	0.63	6.38	0.46	2.04e-9	Myopia (pathological);
PAAD	cis	rs412050	0.501	rs78329092	chr22:22126203	C/T	cg17089214	chr22:22089827	YPEL1	0.67	4.54	0.35	1.12e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	4.89	0.37	2.54e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	0.94	9.73	0.62	1.05e-17	Exhaled nitric oxide output;
PAAD	cis	rs2274459	0.915	rs35797388	chr6:33731984	A/G	cg06253072	chr6:33679850	C6orf125	0.67	4.79	0.36	3.95e-6	Obesity (extreme);
PAAD	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs288342	0.763	rs190830	chr2:183627619	C/G	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg24250549	chr1:154909240	PMVK	0.77	7.85	0.54	6.9e-13	Prostate cancer;
PAAD	cis	rs4704187	0.687	rs9293650	chr5:74497084	C/T	cg03227963	chr5:74354835	NA	0.48	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs12044355	0.927	rs61835384	chr1:231833422	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	4.99	0.38	1.65e-6	Alzheimer's disease;
PAAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg13722127	chr7:150037890	RARRES2	0.55	5.56	0.41	1.17e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg24053715	chr22:38214548	NA	0.57	5.25	0.39	4.95e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.73	7.49	0.52	5.32e-12	Alcohol dependence;
PAAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24549020	chr5:56110836	MAP3K1	-0.49	-4.29	-0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs965469	1.000	rs6133036	chr20:3349682	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs516243	0.634	rs6540943	chr1:10738531	G/A	cg02903756	chr1:10750680	CASZ1	-0.41	-4.35	-0.33	2.5e-5	Migraine - clinic-based;
PAAD	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.53	6.3	0.46	3.04e-9	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.55	5.97	0.44	1.63e-8	Monocyte percentage of white cells;
PAAD	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.51	-4.71	-0.36	5.56e-6	IgG glycosylation;
PAAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg15448220	chr1:150897856	SETDB1	-0.56	-5.67	-0.42	6.83e-8	Tonsillectomy;
PAAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.8	9.11	0.59	4.58e-16	Lung cancer;
PAAD	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	12.72	0.72	1.06e-25	Body mass index (adult);
PAAD	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-5.65	-0.42	7.66e-8	Personality dimensions;
PAAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18621852	chr3:10150065	C3orf24	-0.66	-5.05	-0.38	1.25e-6	Alzheimer's disease;
PAAD	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.01	-0.38	1.49e-6	Mean corpuscular volume;
PAAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg02734326	chr4:10020555	SLC2A9	0.49	4.87	0.37	2.73e-6	Bone mineral density;
PAAD	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg00750074	chr16:89608354	SPG7	-0.57	-5.42	-0.4	2.34e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs2017305	0.834	rs79520726	chr10:70781956	T/C	cg25290552	chr10:70751067	KIAA1279	-0.86	-5.54	-0.41	1.31e-7	Depression (quantitative trait);
PAAD	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	4.8	0.36	3.75e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.53	-5.23	-0.39	5.63e-7	Colorectal cancer;
PAAD	cis	rs7771547	0.547	rs1076931	chr6:36562021	G/C	cg07856975	chr6:36356162	ETV7	0.55	5.83	0.43	3.14e-8	Platelet distribution width;
PAAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.5	0.34	1.33e-5	Tonsillectomy;
PAAD	cis	rs74544699	1.000	rs353029	chr4:74776804	C/T	cg02530824	chr4:74847766	PF4	1.18	4.39	0.34	2.11e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.33	-4.86	-0.37	2.9e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg14593290	chr7:50529359	DDC	-0.46	-4.42	-0.34	1.84e-5	Malaria;
PAAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg02683114	chr2:24398427	C2orf84	0.47	5.36	0.4	3.09e-7	Asthma;
PAAD	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-6.76	-0.48	2.74e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6466055	0.720	rs2040914	chr7:104972174	A/G	cg04380332	chr7:105027541	SRPK2	0.63	7.21	0.5	2.48e-11	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16779626	chr15:41709933	RTF1	0.61	6.54	0.47	8.72e-10	Myopia (pathological);
PAAD	cis	rs2415984	0.622	rs2415997	chr14:46930446	A/C	cg14871534	chr14:47121158	RPL10L	-0.52	-5.46	-0.4	1.89e-7	Number of children ever born;
PAAD	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-8.76	-0.58	3.47e-15	Exhaled nitric oxide output;
PAAD	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	7.31	0.51	1.43e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.69	8.09	0.55	1.76e-13	Bone mineral density;
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.94	6.79	0.48	2.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.74	-6.11	-0.44	8e-9	Neuroticism;
PAAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.56	5.43	0.4	2.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10915437	0.531	rs4131508	chr1:4194800	A/G	cg27165836	chr1:4193882	NA	0.52	5.36	0.4	3.01e-7	Migraine - clinic-based;
PAAD	cis	rs2242420	0.920	rs12090311	chr1:21960194	G/T	cg26362272	chr1:22108717	USP48	0.55	4.3	0.33	3.09e-5	Hematological and biochemical traits;
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg01765077	chr12:122356316	WDR66	0.68	6.99	0.49	7.9e-11	Mean corpuscular volume;
PAAD	cis	rs7187994	0.672	rs35307127	chr16:84798089	T/C	cg07647771	chr16:84786436	USP10	-0.35	-4.26	-0.33	3.62e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg08676812	chr11:65308423	LTBP3	0.45	4.53	0.34	1.19e-5	Bone mineral density;
PAAD	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs3736485	0.844	rs7174495	chr15:51895291	A/G	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.7e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.64	-7.65	-0.53	2.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg24737193	chr18:12778029	NA	-0.67	-5.6	-0.41	9.71e-8	Inflammatory skin disease;
PAAD	cis	rs12760731	0.641	rs12036834	chr1:178236583	G/A	cg00404053	chr1:178313656	RASAL2	0.67	5.22	0.39	5.81e-7	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.92	6.44	0.46	1.51e-9	Blood protein levels;
PAAD	cis	rs1011018	0.955	rs10952510	chr7:139431350	A/T	cg03224163	chr7:139420300	HIPK2	-0.61	-4.36	-0.33	2.41e-5	Systolic blood pressure;
PAAD	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg01868782	chr6:126071099	HEY2	0.45	5.31	0.4	3.86e-7	Brugada syndrome;
PAAD	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg13010199	chr12:38710504	ALG10B	0.41	4.33	0.33	2.73e-5	Morning vs. evening chronotype;
PAAD	cis	rs11811982	0.793	rs9660532	chr1:227515679	A/G	cg24860534	chr1:227506868	CDC42BPA	-0.52	-5.02	-0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-8.12	-0.55	1.46e-13	Inflammatory bowel disease;
PAAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.69	0.42	6.19e-8	Tonsillectomy;
PAAD	cis	rs11696501	0.688	rs6124726	chr20:44307866	T/A	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.98	-7.84	-0.54	7.26e-13	Blood protein levels;
PAAD	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg03871329	chr12:110338662	TCHP	-0.64	-4.85	-0.37	3.03e-6	Neuroticism;
PAAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs11105468	0.596	rs56019171	chr12:90481431	T/C	cg16962463	chr12:89968675	NA	0.41	4.72	0.36	5.27e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.74	-0.42	5.04e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.84	-10.14	-0.64	9.18e-19	Brugada syndrome;
PAAD	cis	rs3733418	0.929	rs2280325	chr4:165928254	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.67	-0.42	6.93e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.62	-6.2	-0.45	5.16e-9	Monocyte count;
PAAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.99	10.27	0.64	4.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.53	-5.53	-0.41	1.38e-7	Daytime sleep phenotypes;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg23958373	chr8:599963	NA	1.03	6.65	0.47	5e-10	IgG glycosylation;
PAAD	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg05712903	chr5:178977398	RUFY1	0.59	4.54	0.35	1.14e-5	Lung cancer;
PAAD	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	4.75	0.36	4.63e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.61	0.35	8.48e-6	HDL cholesterol;
PAAD	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	5.72	0.42	5.44e-8	Mood instability;
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs2457480	0.778	rs11238933	chr10:44714250	C/G	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;
PAAD	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-5.59	-0.41	1.01e-7	Reticulocyte count;
PAAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	6.37	0.46	2.13e-9	Rheumatoid arthritis;
PAAD	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg01267373	chr18:77410094	NA	0.4	4.5	0.34	1.34e-5	Monocyte count;
PAAD	cis	rs61884328	0.852	rs17790390	chr11:47151897	A/G	cg23433285	chr11:47201945	PACSIN3	-0.81	-4.62	-0.35	8.17e-6	Total body bone mineral density (age over 60);
PAAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.57	4.27	0.33	3.42e-5	Fat distribution (HIV);
PAAD	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg12757816	chr2:10669957	NA	0.44	4.46	0.34	1.61e-5	Prostate cancer;
PAAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-8.65	-0.57	6.99e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg01097406	chr16:89675127	NA	-0.37	-4.37	-0.33	2.29e-5	Vitiligo;
PAAD	cis	rs6466055	0.661	rs6954844	chr7:104926183	A/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.54	-7.23	-0.51	2.14e-11	Life satisfaction;
PAAD	cis	rs6782025	0.837	rs2203078	chr3:121053570	A/G	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.35	6.3e-6	Aging (facial);
PAAD	cis	rs11669133	1.000	rs117239870	chr19:11081601	A/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.55	0.35	1.08e-5	LDL cholesterol;
PAAD	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg11410649	chr1:24122853	GALE	-0.57	-4.25	-0.33	3.71e-5	Psoriasis vulgaris;
PAAD	cis	rs516243	0.688	rs284312	chr1:10737226	C/T	cg02903756	chr1:10750680	CASZ1	-0.43	-4.63	-0.35	7.71e-6	Migraine - clinic-based;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.28	-7.69	-0.53	1.7e-12	Body mass index;
PAAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg06799790	chr17:61951754	CSH2	0.44	4.52	0.34	1.23e-5	Height;
PAAD	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.75	8.37	0.56	3.6e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg12143784	chr7:64541923	NA	0.34	4.32	0.33	2.78e-5	Aortic root size;
PAAD	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.91	11.78	0.69	3.55e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.54	0.35	1.15e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.98	-12.01	-0.7	8.56e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	5.25	0.39	5.08e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.87	-0.43	2.64e-8	Mood instability;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25487370	chr4:160025088	NA	0.62	6.49	0.47	1.12e-9	Myopia (pathological);
PAAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg11764359	chr7:65958608	NA	0.76	5.07	0.38	1.12e-6	Gout;
PAAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg08562672	chr19:21860753	NA	-0.47	-4.93	-0.37	2.14e-6	Pain;
PAAD	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-4.94	-0.37	2.04e-6	Testicular germ cell tumor;
PAAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.53	0.41	1.35e-7	Bipolar disorder;
PAAD	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg25233709	chr10:116636983	FAM160B1	0.36	4.29	0.33	3.11e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.92	-8.56	-0.57	1.16e-14	Body mass index;
PAAD	cis	rs10878977	0.542	rs9645828	chr12:69814792	G/A	cg13322954	chr12:69198953	NA	0.68	4.32	0.33	2.79e-5	Colorectal cancer;
PAAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.74	-7.68	-0.53	1.86e-12	DNA methylation (variation);
PAAD	cis	rs4740619	0.811	rs954664	chr9:15695882	A/T	cg14451791	chr9:16040625	NA	0.4	4.37	0.33	2.33e-5	Body mass index;
PAAD	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg02264943	chr11:130785842	SNX19	0.38	4.63	0.35	7.7e-6	Schizophrenia;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01016459	chr16:53468960	RBL2	-0.57	-6.55	-0.47	8.33e-10	Body fat percentage;
PAAD	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	4.47	0.34	1.53e-5	IgG glycosylation;
PAAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.66	-0.35	6.73e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.61	-5.85	-0.43	2.91e-8	Schizophrenia;
PAAD	cis	rs2153535	0.518	rs6912560	chr6:8564111	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	4.27	0.33	3.42e-5	Motion sickness;
PAAD	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	4.27	0.33	3.48e-5	Menarche (age at onset);
PAAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.48	-4.29	-0.33	3.22e-5	Menarche (age at onset);
PAAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.7	-0.36	5.73e-6	Parkinson's disease;
PAAD	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg10820045	chr2:198174542	NA	0.52	5.32	0.4	3.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.56	-5.5	-0.41	1.57e-7	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.68	7.53	0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12913538	0.862	rs4774441	chr15:62887791	C/T	cg09983546	chr15:62884068	NA	0.65	7.42	0.52	7.91e-12	Sleep depth;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg24829409	chr8:58192753	C8orf71	-0.91	-8.1	-0.55	1.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs564309	0.764	rs541959	chr1:228552571	T/C	cg01328119	chr1:228783545	DUSP5P	0.65	4.29	0.33	3.12e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.76	-7.86	-0.54	6.7e-13	Mosquito bite size;
PAAD	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26538529	chr2:222437130	EPHA4	-0.55	-6.29	-0.45	3.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs877282	0.797	rs35927768	chr10:753095	T/C	cg17470449	chr10:769945	NA	0.66	6.1	0.44	8.35e-9	Uric acid levels;
PAAD	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg02404636	chr22:31891804	SFI1	0.64	6.09	0.44	8.94e-9	Colorectal cancer;
PAAD	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.97	6.74	0.48	3.08e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.82	0.36	3.45e-6	Schizophrenia;
PAAD	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.67	6.41	0.46	1.75e-9	Subjective well-being;
PAAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.33	6.0	0.44	1.37e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.45	-6.16	-0.45	6.13e-9	Height;
PAAD	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.58	5.72	0.42	5.6e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.49	-4.83	-0.36	3.32e-6	Longevity;
PAAD	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.57	-7.43	-0.52	7.43e-12	Longevity;
PAAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.48	0.34	1.45e-5	Breast cancer;
PAAD	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg13206674	chr6:150067644	NUP43	0.57	5.31	0.4	3.85e-7	Lung cancer;
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg17524265	chr8:144659883	NAPRT1	0.83	4.59	0.35	9.35e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg18551225	chr6:44695536	NA	-0.69	-7.08	-0.5	4.95e-11	Total body bone mineral density;
PAAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.55	-5.19	-0.39	6.72e-7	Breast size;
PAAD	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02985541	chr2:219472218	PLCD4	0.31	4.8	0.36	3.73e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.64	-7.16	-0.5	3.17e-11	Type 2 diabetes;
PAAD	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2985684	0.557	rs2985689	chr14:50098031	C/A	cg02151108	chr14:50098012	C14orf104	-0.72	-5.3	-0.4	3.95e-7	Carotid intima media thickness;
PAAD	trans	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.35	-0.46	2.33e-9	Mean corpuscular volume;
PAAD	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.14	0.64	8.85e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.47	4.57	0.35	9.96e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.59	6.17	0.45	6.04e-9	Pancreatic cancer;
PAAD	cis	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg07460842	chr6:66804631	NA	0.52	4.49	0.34	1.39e-5	Type 2 diabetes;
PAAD	cis	rs2274459	0.841	rs10947432	chr6:33676556	A/G	cg06253072	chr6:33679850	C6orf125	-0.64	-4.87	-0.37	2.82e-6	Obesity (extreme);
PAAD	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg04450456	chr4:17643702	FAM184B	-0.45	-4.7	-0.36	5.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.71	7.24	0.51	2.14e-11	Bipolar disorder;
PAAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.07	-18.7	-0.83	3.04e-41	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26378065	chr17:18585709	ZNF286B	0.55	5.41	0.4	2.36e-7	Educational attainment (years of education);
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13198984	chr17:80129470	CCDC57	0.42	5.2	0.39	6.23e-7	Life satisfaction;
PAAD	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg26939375	chr7:64535504	NA	0.52	5.73	0.42	5.2100000000000003e-08	Aortic root size;
PAAD	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.6	8.48	0.57	1.82e-14	Urate levels in overweight individuals;
PAAD	cis	rs1903068	0.853	rs10012701	chr4:56002776	A/G	cg09978860	chr4:56023921	NA	0.38	4.34	0.33	2.61e-5	Endometriosis;
PAAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-5.3	-0.4	3.96e-7	Monocyte count;
PAAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg20295408	chr7:1910781	MAD1L1	0.59	5.98	0.44	1.52e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.51	5.7	0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg08353955	chr11:69289746	NA	0.68	5.82	0.43	3.36e-8	Breast cancer (early onset);
PAAD	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg09179987	chr1:167433047	CD247	0.49	5.77	0.42	4.21e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs77880822	0.562	rs17779586	chr20:1230185	A/C	cg23117778	chr20:1206693	RAD21L1	-0.93	-5.15	-0.39	7.95e-7	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	5.64	0.42	8.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg21589280	chr1:85930151	DDAH1	-0.58	-4.39	-0.34	2.13e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.7	6.83	0.48	1.91e-10	Blood metabolite levels;
PAAD	trans	rs10861342	1.000	rs703683	chr12:105567135	T/C	cg11421182	chr20:36153479	BLCAP	-0.56	-6.72	-0.48	3.35e-10	IgG glycosylation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24273718	chr3:129158802	IFT122;MBD4	0.64	6.76	0.48	2.85e-10	Myopia (pathological);
PAAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16988970	chr17:42248062	ASB16	-0.36	-5.07	-0.38	1.14e-6	Total body bone mineral density;
PAAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	9.37	0.6	9.71e-17	Lymphocyte counts;
PAAD	trans	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg02404636	chr22:31891804	SFI1	0.64	5.93	0.43	1.99e-8	Colorectal cancer;
PAAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs1144333	1.000	rs1586936	chr1:76366877	T/C	cg22875332	chr1:76189707	ACADM	0.6	4.29	0.33	3.23e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18849300	chr3:48723061	NCKIPSD	0.68	7.43	0.52	7.38e-12	Myopia (pathological);
PAAD	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg10820045	chr2:198174542	NA	0.43	4.34	0.33	2.56e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.88	10.58	0.65	6.14e-20	Total body bone mineral density;
PAAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.48	-5.1	-0.38	1.02e-6	Bipolar disorder;
PAAD	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg05579598	chr16:88989069	CBFA2T3	0.55	8.03	0.55	2.44e-13	Social autistic-like traits;
PAAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.92	11.53	0.68	1.72e-22	Coronary artery disease;
PAAD	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.71	0.48	3.55e-10	Resting heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15584258	chr20:44718691	NCOA5	0.7	6.77	0.48	2.64e-10	Obesity-related traits;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.67	7.59	0.52	3.02e-12	Longevity;Endometriosis;
PAAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.51	4.85	0.37	3.03e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.75	7.54	0.52	3.87e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.81	8.69	0.58	5.29e-15	Multiple sclerosis;
PAAD	cis	rs4455778	0.580	rs7455537	chr7:49076576	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.71	6.85	0.49	1.68e-10	Obesity-related traits;
PAAD	cis	rs12767760	0.651	rs3814554	chr10:99331201	C/T	cg25247692	chr10:99313390	UBTD1	-0.49	-4.89	-0.37	2.59e-6	Obesity-related traits;
PAAD	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg25554036	chr4:6271136	WFS1	0.71	10.17	0.64	7.26e-19	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs727479	0.543	rs4324076	chr15:51510868	A/C	cg21478137	chr15:51532386	CYP19A1	0.44	4.45	0.34	1.65e-5	Estradiol levels;
PAAD	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.56	-6.77	-0.48	2.6200000000000003e-10	Total body bone mineral density;
PAAD	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.13	0.38	8.59e-7	Total body bone mineral density;
PAAD	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.79	7.43	0.52	7.46e-12	Obesity-related traits;
PAAD	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-6.74	-0.48	3.15e-10	High light scatter reticulocyte count;
PAAD	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.79	7.54	0.52	3.9e-12	Platelet distribution width;
PAAD	cis	rs8027181	0.583	rs730180	chr15:73007893	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.66	-5.68	-0.42	6.69e-8	Triglyceride levels;
PAAD	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.78	9.08	0.59	5.27e-16	Menopause (age at onset);
PAAD	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.59	6.89	0.49	1.39e-10	Menopause (age at onset);
PAAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.49	5.19	0.39	6.63e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.42	4.57	0.35	9.9e-6	HDL cholesterol levels;
PAAD	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.41	4.56	0.35	1.04e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.83	-9.64	-0.62	1.88e-17	Extrinsic epigenetic age acceleration;
PAAD	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35160687	0.623	rs718292	chr2:86473740	A/G	cg10973622	chr2:86423274	IMMT	0.49	5.58	0.41	1.1e-7	Night sleep phenotypes;
PAAD	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg17372223	chr3:52568218	NT5DC2	0.56	5.49	0.41	1.65e-7	Bipolar disorder;
PAAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4711350	0.723	rs6915136	chr6:33651322	A/G	cg13859433	chr6:33739653	LEMD2	0.76	5.3	0.39	4e-7	Schizophrenia;
PAAD	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.71	5.02	0.38	1.41e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00427847	chr20:46286754	SULF2	-0.56	-6.39	-0.46	1.9e-9	Monocyte percentage of white cells;
PAAD	cis	rs9810890	0.850	rs73196995	chr3:128458070	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg08648136	chr8:956695	NA	0.42	4.41	0.34	1.93e-5	Schizophrenia;
PAAD	cis	rs793571	0.822	rs28529423	chr15:59173382	G/A	cg05156742	chr15:59063176	FAM63B	0.59	4.71	0.36	5.44e-6	Schizophrenia;
PAAD	cis	rs16838233	1.000	rs12134081	chr1:29750827	A/C	cg12609322	chr1:29490924	SFRS4	0.53	4.3	0.33	3.09e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.21	0.67	1.21e-21	Total body bone mineral density;
PAAD	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg05134918	chr12:132603531	EP400NL	-0.65	-5.33	-0.4	3.51e-7	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs7766436	0.767	rs6909752	chr6:22612629	G/A	cg13666174	chr6:22585274	NA	-0.47	-4.87	-0.37	2.73e-6	Coronary artery disease;
PAAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.79	12.45	0.71	5.67e-25	Schizophrenia;
PAAD	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.86	-10.39	-0.64	1.97e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg10011062	chr15:43941034	CATSPER2	-0.76	-4.52	-0.34	1.24e-5	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs804280	0.564	rs804263	chr8:11630915	C/T	cg12395012	chr8:11607386	GATA4	-0.67	-8.41	-0.56	2.79e-14	Myopia (pathological);
PAAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg15478930	chr2:27652102	NRBP1	0.48	4.46	0.34	1.57e-5	Total body bone mineral density;
PAAD	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	4.51	0.34	1.3e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg08999081	chr20:33150536	PIGU	0.62	6.78	0.48	2.54e-10	Height;
PAAD	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.36	-0.4	2.97e-7	Mean corpuscular volume;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.82	-8.83	-0.58	2.3e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs11563648	0.573	rs2010417	chr7:126959186	A/G	cg21885361	chr7:127911034	NA	-0.4	-4.28	-0.33	3.3e-5	Resting heart rate;
PAAD	cis	rs8005172	0.684	rs12880714	chr14:88391116	A/G	cg18078958	chr14:88630771	NA	-0.47	-5.55	-0.41	1.21e-7	Parkinson's disease;
PAAD	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-5.98	-0.44	1.54e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.74	7.9	0.54	5.11e-13	Lung cancer;
PAAD	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.56	5.91	0.43	2.2e-8	Dupuytren's disease;
PAAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg15654264	chr1:150340011	RPRD2	-0.49	-4.59	-0.35	9.14e-6	Migraine;
PAAD	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg04415270	chr2:102091202	RFX8	0.59	7.61	0.53	2.65e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.75	-8.17	-0.55	1.09e-13	Schizophrenia;
PAAD	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-6.74	-0.48	3.07e-10	Morning vs. evening chronotype;
PAAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	6.75	0.48	2.87e-10	Total body bone mineral density;
PAAD	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.65	5.97	0.44	1.6e-8	Blood metabolite levels;
PAAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13198984	chr17:80129470	CCDC57	0.43	5.36	0.4	3.06e-7	Life satisfaction;
PAAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg17366294	chr4:99064904	C4orf37	0.61	6.51	0.47	1.03e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.37	0.61	9.5e-17	Total body bone mineral density;
PAAD	cis	rs1075265	0.568	rs959286	chr2:54306078	A/G	cg04546899	chr2:54196757	PSME4	0.32	4.69	0.36	6.09e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.49	-0.34	1.38e-5	Glomerular filtration rate;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9463078	0.804	rs9463081	chr6:45233108	G/A	cg25276700	chr6:44698697	NA	-0.48	-5.46	-0.41	1.89e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25190491	chr1:2518505	C1orf93	0.64	7.45	0.52	6.68e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.68	-8.62	-0.57	8.34e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.63	-0.35	7.69e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24549020	chr5:56110836	MAP3K1	-0.69	-5.0	-0.38	1.55e-6	Initial pursuit acceleration;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.68	7.23	0.51	2.16e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.55	-4.94	-0.37	2.04e-6	Monocyte count;
PAAD	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.45	4.59	0.35	9.22e-6	Pulmonary function;
PAAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-1.09	-15.31	-0.78	1.32e-32	Total body bone mineral density;
PAAD	cis	rs970548	0.643	rs7080474	chr10:45931899	C/T	cg15590007	chr10:45870220	ALOX5	0.44	4.75	0.36	4.73e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg11783602	chr8:55087084	NA	-0.52	-5.29	-0.39	4.26e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs11696501	0.688	rs6065861	chr20:44311056	A/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.45	-0.46	1.4e-9	Brain structure;
PAAD	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg22189786	chr22:42395067	WBP2NL	0.42	4.36	0.33	2.41e-5	Cognitive function;
PAAD	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.62	6.69	0.48	3.97e-10	High light scatter reticulocyte count;
PAAD	cis	rs55823223	0.680	rs3744020	chr17:73871773	G/A	cg14829360	chr17:73884958	NA	-0.67	-5.83	-0.43	3.18e-8	Psoriasis;
PAAD	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-6.93	-0.49	1.12e-10	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.09	0.38	1.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg18084798	chr19:33555255	RHPN2	0.46	4.73	0.36	5.14e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg00999904	chr2:3704751	ALLC	-0.81	-8.03	-0.55	2.51e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg09127314	chr1:152161683	NA	-0.7	-4.84	-0.37	3.09e-6	Atopic dermatitis;
PAAD	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.79	-9.14	-0.6	3.64e-16	Eosinophil percentage of white cells;
PAAD	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg16342193	chr10:102329863	NA	0.74	8.13	0.55	1.43e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg20159608	chr7:32802032	NA	-0.48	-5.04	-0.38	1.28e-6	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9900972	0.918	rs8065599	chr17:76877073	T/C	cg00961940	chr17:76876995	TIMP2	0.58	5.37	0.4	2.91e-7	Obesity-related traits;
PAAD	cis	rs10044254	0.641	rs2937074	chr5:15751645	G/A	cg07238450	chr5:15720153	FBXL7	-0.55	-5.09	-0.38	1.03e-6	Asthma (corticosteroid response);
PAAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg19847866	chr10:1019161	NA	-0.54	-4.34	-0.33	2.56e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg04522676	chr10:134968826	NA	0.47	4.43	0.34	1.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.72	-9.24	-0.6	2.08e-16	Educational attainment;
PAAD	cis	rs73568641	0.583	rs1892360	chr6:154111701	T/C	cg15658985	chr6:154448740	OPRM1	0.51	4.27	0.33	3.38e-5	Methadone dose in opioid dependence;
PAAD	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg12623918	chr2:306882	NA	0.59	4.36	0.33	2.41e-5	Blood protein levels;
PAAD	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-5.66	-0.42	7.33e-8	Intelligence;
PAAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23158103	chr7:148848205	ZNF398	-0.62	-5.98	-0.44	1.55e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.6	-6.47	-0.46	1.27e-9	Calcium levels;
PAAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs11209185	0.522	rs9436358	chr1:68452984	T/A	cg22082780	chr1:68452167	NA	0.43	4.57	0.35	9.98e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.09	0.55	1.76e-13	Lung cancer;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg13047869	chr3:10149882	C3orf24	0.56	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg26338869	chr17:61819248	STRADA	-0.62	-6.24	-0.45	4.06e-9	Prudent dietary pattern;
PAAD	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.05	-0.44	1.06e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14030997	chr9:108420639	NA	-0.66	-7.62	-0.53	2.49e-12	Obesity-related traits;
PAAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.53	-7.08	-0.5	5.09e-11	Life satisfaction;
PAAD	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.84	7.0	0.49	7.62e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6594713	0.603	rs58268366	chr5:112638398	T/C	cg12552261	chr5:112820674	MCC	0.66	4.44	0.34	1.72e-5	Brain cytoarchitecture;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07242783	chr1:28052377	FAM76A	-0.61	-7.37	-0.51	1.04e-11	Body fat percentage;
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.76	5.06	0.38	1.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-5.17	-0.39	7.18e-7	Body mass index;
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg04520793	chr17:42248056	ASB16	-0.44	-5.14	-0.38	8.3e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.64	-0.53	2.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.55	-5.23	-0.39	5.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7246865	0.510	rs1551551	chr19:17170541	G/T	cg19418318	chr19:17219073	MYO9B	0.35	5.01	0.38	1.5e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7896729	0.943	rs11253089	chr10:5346772	G/A	cg07902545	chr10:6194255	PFKFB3	-0.43	-4.48	-0.34	1.47e-5	Intelligence;
PAAD	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.64	-0.57	7.34e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.78	-6.7	-0.48	3.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10849004	1.000	rs10849004	chr12:4292862	A/G	cg03803796	chr12:3575061	NA	-0.62	-5.13	-0.38	8.52e-7	Glucocorticoid-induced osteonecrosis;
PAAD	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.61	-6.21	-0.45	4.76e-9	Glioblastoma;
PAAD	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1903068	0.719	rs73236106	chr4:55996712	C/T	cg20092376	chr4:56023423	NA	0.43	4.31	0.33	2.94e-5	Endometriosis;
PAAD	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.64	5.57	0.41	1.12e-7	Response to diuretic therapy;
PAAD	cis	rs9815354	1.000	rs9866092	chr3:41895967	A/C	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.55	-0.35	1.09e-5	Mean corpuscular volume;
PAAD	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.7	7.69	0.53	1.69e-12	Cognitive function;
PAAD	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg03517284	chr6:25882590	NA	-0.54	-4.45	-0.34	1.63e-5	Iron status biomarkers;
PAAD	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.68	6.17	0.45	5.89e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg12517394	chr11:61582795	MIR1908;FADS1	0.65	5.89	0.43	2.39e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.86e-6	Refractive error;
PAAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.57	7.48	0.52	5.39e-12	Hypertriglyceridemia;
PAAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	cis	rs7517847	0.629	rs7518660	chr1:67685443	G/A	cg22500004	chr1:68516272	DIRAS3	-0.48	-4.73	-0.36	5.01e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs516243	0.660	rs284310	chr1:10737562	C/T	cg02903756	chr1:10750680	CASZ1	-0.43	-4.63	-0.35	7.71e-6	Migraine - clinic-based;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.79	8.58	0.57	1.04e-14	Menarche (age at onset);
PAAD	cis	rs12986413	1.000	rs11882273	chr19:2173836	T/C	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.13e-6	Height;
PAAD	cis	rs6893300	0.826	rs7715356	chr5:179129492	A/G	cg14593053	chr5:179126677	CANX	-0.47	-4.5	-0.34	1.33e-5	Resting heart rate;
PAAD	cis	rs6494488	0.500	rs72741373	chr15:64800861	C/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg10761708	chr20:43804764	PI3	0.54	4.46	0.34	1.58e-5	Blood protein levels;
PAAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.83	7.42	0.52	7.6e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6142102	0.812	rs761238	chr20:32519988	A/C	cg08999081	chr20:33150536	PIGU	-0.46	-4.31	-0.33	2.9e-5	Skin pigmentation;
PAAD	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.95	-11.59	-0.69	1.14e-22	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.16	0.45	6.22e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.69	5.55	0.41	1.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16417436	chr16:28758564	NA	0.43	4.39	0.34	2.08e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg05342682	chr7:94953680	PON1	-0.54	-4.86	-0.37	2.88e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg07944420	chr16:89185293	ACSF3	0.48	4.32	0.33	2.82e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.01	0.38	1.51e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg14703610	chr5:56206110	C5orf35	-0.55	-5.04	-0.38	1.29e-6	Initial pursuit acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12963312	chr6:52441723	TRAM2	0.71	8.56	0.57	1.19e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1969821	1	rs1969821	chr10:89415148	G/A	cg13926569	chr10:89418898	PAPSS2	-0.51	-5.13	-0.38	8.66e-7	Magnesium levels;
PAAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.3	-0.33	3.1e-5	Skin colour saturation;
PAAD	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.94	7.72	0.53	1.42e-12	Vitiligo;
PAAD	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.5	4.64	0.35	7.56e-6	Neutrophil percentage of white cells;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg08699206	chr4:1595414	NA	0.46	4.58	0.35	9.64e-6	Obesity-related traits;
PAAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-4.92	-0.37	2.23e-6	Morning vs. evening chronotype;
PAAD	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg10434728	chr15:90938212	IQGAP1	0.48	4.83	0.36	3.32e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg07648498	chr16:89883185	FANCA	0.48	4.56	0.35	1.06e-5	Vitiligo;
PAAD	cis	rs10988802	0.866	rs7862296	chr9:98385584	G/A	cg16575184	chr9:99179480	ZNF367	-0.7	-4.5	-0.34	1.33e-5	Chemerin levels;
PAAD	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-4.96	-0.37	1.9e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs4427176	0.507	rs10464998	chr8:9584450	A/G	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-7.84	-0.54	7.13e-13	Hemoglobin concentration;
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg08641963	chr20:44451973	TNNC2	0.3	4.33	0.33	2.74e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.45	5.16	0.39	7.76e-7	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.61	5.05	0.38	1.27e-6	Prostate cancer;
PAAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg09509183	chr1:209979624	IRF6	0.54	5.04	0.38	1.29e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.69	6.71	0.48	3.67e-10	Cystic fibrosis severity;
PAAD	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg17514665	chr17:1657533	SERPINF2	0.65	6.03	0.44	1.18e-8	Serum albumin level;
PAAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.15	-0.39	8.1e-7	Lung cancer;
PAAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.5	-4.85	-0.37	2.97e-6	Crohn's disease;
PAAD	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs921916	1.000	rs921916	chr7:50228698	C/T	cg02697348	chr7:50199187	C7orf72	-0.62	-4.28	-0.33	3.34e-5	Systemic lupus erythematosus;
PAAD	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.04	-0.38	1.28e-6	Pulmonary function;
PAAD	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs858239	0.712	rs199650	chr7:23367189	C/T	cg23682824	chr7:23144976	KLHL7	-0.49	-4.52	-0.34	1.24e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9463078	0.546	rs1284975	chr6:45079345	T/A	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.85	6.79	0.48	2.4e-10	Prostate cancer;
PAAD	cis	rs62264129	0.500	rs56008438	chr3:112034103	A/G	cg03352173	chr3:112013130	SLC9A10	-0.26	-4.25	-0.33	3.72e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs7627468	0.955	rs9814686	chr3:121932624	A/G	cg17240004	chr3:121949083	CASR	0.53	4.47	0.34	1.51e-5	Kidney stones;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.78e-5	Bipolar disorder;
PAAD	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-5.82	-0.43	3.29e-8	Breast cancer;
PAAD	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg24112000	chr20:60950667	NA	-0.71	-9.47	-0.61	5.2e-17	Colorectal cancer;
PAAD	cis	rs4676482	0.577	rs72864176	chr3:39263419	G/A	cg02254461	chr3:39195904	CSRNP1	0.63	4.46	0.34	1.58e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2834902	0.605	rs35265519	chr21:36683674	T/C	cg04915566	chr21:36421472	RUNX1	-0.33	-4.49	-0.34	1.38e-5	Corneal curvature;
PAAD	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg15440763	chr7:158190612	PTPRN2	0.47	4.6	0.35	8.8e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12181217	chr19:34850565	NA	-0.7	-7.0	-0.49	7.86e-11	Lung cancer in ever smokers;
PAAD	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg08601574	chr20:25228251	PYGB	0.54	5.51	0.41	1.47e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3106136	0.681	rs28458965	chr4:95302476	A/G	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg18769074	chr3:133464867	TF	-0.42	-4.79	-0.36	3.86e-6	Iron status biomarkers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13785189	chr17:73150884	HN1	0.63	6.44	0.46	1.46e-9	Obesity-related traits;
PAAD	cis	rs11124272	0.857	rs12479192	chr2:31923042	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-4.71	-0.36	5.45e-6	Interleukin-18 levels;
PAAD	cis	rs4853525	0.559	rs34997637	chr2:191858830	C/T	cg21351543	chr2:191399470	TMEM194B	-0.62	-4.55	-0.35	1.09e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg16898833	chr6:26189333	HIST1H4D	1.05	5.36	0.4	3.06e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72960926	0.744	rs72957999	chr6:74973822	T/C	cg03266952	chr6:74778945	NA	-1.2	-6.6	-0.47	6.3e-10	Metabolite levels (MHPG);
PAAD	cis	rs7264396	0.887	rs2281849	chr20:34060286	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-5.05	-0.38	1.28e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.48	-4.99	-0.37	1.67e-6	Iron status biomarkers;
PAAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.36	-0.6	1.01e-16	Type 2 diabetes;
PAAD	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.49	0.57	1.73e-14	Vitiligo;
PAAD	cis	rs16857609	0.564	rs3732009	chr2:218291393	G/A	cg15335768	chr2:218268053	DIRC3	-0.49	-5.09	-0.38	1.05e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
PAAD	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg24739098	chr15:79297159	RASGRF1	0.34	4.41	0.34	1.97e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.68	-0.35	6.37e-6	Body mass index;
PAAD	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg13444538	chr7:158905317	VIPR2	-0.7	-5.29	-0.39	4.16e-7	Facial morphology (factor 20);
PAAD	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.61	6.54	0.47	8.89e-10	Menarche (age at onset);
PAAD	cis	rs35160687	0.736	rs6746198	chr2:86542113	A/G	cg10973622	chr2:86423274	IMMT	-0.4	-4.52	-0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.58	0.61	2.59e-17	Rheumatoid arthritis;
PAAD	cis	rs12304921	0.549	rs11169691	chr12:51454952	G/C	cg18059802	chr12:51347058	HIGD1C	-0.6	-4.79	-0.36	4e-6	Type 2 diabetes;
PAAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.83	-0.48	1.89e-10	Personality dimensions;
PAAD	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.71	8.89	0.59	1.63e-15	Dupuytren's disease;
PAAD	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.65	-0.47	4.91e-10	Neuroticism;
PAAD	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.22	-6.39	-0.46	1.95e-9	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
PAAD	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.13	-0.38	8.73e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg00750074	chr16:89608354	SPG7	-0.61	-5.84	-0.43	3.11e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-6.03	-0.44	1.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	5.33	0.4	3.47e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.93	-8.08	-0.55	1.85e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16083429	chr3:49237500	CCDC36	-0.47	-5.09	-0.38	1.03e-6	Menarche (age at onset);
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.68	-0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg11130432	chr3:121712080	ILDR1	0.52	4.63	0.35	7.73e-6	Multiple sclerosis;
PAAD	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.4	-7.48	-0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs4919087	0.590	rs7915926	chr10:99054052	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-4.85	-0.37	2.97e-6	Monocyte count;
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.74	-8.32	-0.56	4.59e-14	Prostate cancer;
PAAD	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg27149285	chr3:50375164	RASSF1	0.67	4.6	0.35	8.89e-6	Schizophrenia;
PAAD	cis	rs988913	0.706	rs7749072	chr6:54951918	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-4.25	-0.33	3.77e-5	Menarche (age at onset);
PAAD	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg19052272	chr2:3704530	ALLC	0.49	5.77	0.42	4.31e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.72	8.64	0.57	7.24e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.84	7.83	0.54	7.69e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.6	-6.74	-0.48	3.15e-10	Nonalcoholic fatty liver disease;
PAAD	cis	rs2885056	0.891	rs4804509	chr19:10681641	A/G	cg06392426	chr19:10676186	KRI1	0.58	5.78	0.42	4.1e-8	Red cell distribution width;
PAAD	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg21775007	chr8:11205619	TDH	0.78	7.86	0.54	6.6e-13	Retinal vascular caliber;
PAAD	cis	rs6460942	0.597	rs7798779	chr7:12543490	A/G	cg20607287	chr7:12443886	VWDE	-0.7	-4.83	-0.37	3.25e-6	Coronary artery disease;
PAAD	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.68	7.43	0.52	7.3e-12	Corneal astigmatism;
PAAD	cis	rs2139634	0.965	rs60986461	chr3:46548046	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.48	0.34	1.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg25902810	chr10:99078978	FRAT1	-0.61	-5.58	-0.41	1.08e-7	Monocyte count;
PAAD	cis	rs9913156	0.696	rs9905711	chr17:4558662	G/A	cg19197139	chr17:4613644	ARRB2	-0.83	-8.67	-0.58	6.06e-15	Lymphocyte counts;
PAAD	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.68	-0.48	4.23e-10	Total body bone mineral density;
PAAD	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.58	5.17	0.39	7.18e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.51	-4.88	-0.37	2.62e-6	Psoriasis;
PAAD	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.44	4.36	0.33	2.34e-5	Dupuytren's disease;
PAAD	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.75	6.52	0.47	9.88e-10	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs858239	0.899	rs10085838	chr7:23298415	C/A	cg27449745	chr7:23145252	KLHL7	-0.54	-4.68	-0.35	6.33e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs11966931	0.948	rs17528372	chr6:108093657	A/G	cg10566610	chr6:108093680	SCML4	0.48	4.5	0.34	1.33e-5	Neutrophil percentage of white cells;
PAAD	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg09659197	chr4:152720779	NA	0.35	5.11	0.38	9.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1642645	0.872	rs238675	chr1:42470274	C/T	cg01990334	chr1:42801334	FOXJ3	-0.65	-5.82	-0.43	3.29e-8	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12997166	chr7:6048663	PMS2;AIMP2	0.61	7.04	0.5	6.27e-11	Monocyte percentage of white cells;
PAAD	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.75	-8.91	-0.59	1.44e-15	Motion sickness;
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs900145	0.906	rs4757138	chr11:13297925	A/G	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.6	-5.88	-0.43	2.57e-8	Proinsulin levels;
PAAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.26	-0.33	3.53e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg16083429	chr3:49237500	CCDC36	-0.45	-4.79	-0.36	3.98e-6	Parkinson's disease;
PAAD	cis	rs2153535	0.518	rs6925765	chr6:8566704	C/A	cg07606381	chr6:8435919	SLC35B3	0.43	4.3	0.33	3.09e-5	Motion sickness;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06676603	chr18:74692265	MBP	-0.54	-6.33	-0.46	2.66e-9	Monocyte percentage of white cells;
PAAD	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg09659197	chr4:152720779	NA	0.34	4.95	0.37	1.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg07700843	chr1:2391317	NA	-0.66	-6.82	-0.48	2.03e-10	Non-obstructive azoospermia;
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-6.76	-0.48	2.85e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg13821571	chr21:34406537	NA	-0.48	-4.61	-0.35	8.52e-6	Gastritis;
PAAD	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.52	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16950088	chr4:899775	GAK	0.5	6.38	0.46	2.03e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-6.45	-0.46	1.41e-9	Neuroticism;
PAAD	cis	rs9926296	0.632	rs8048331	chr16:89793042	G/T	cg27121462	chr16:89883253	FANCA	-0.44	-4.5	-0.34	1.32e-5	Vitiligo;
PAAD	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg02631450	chr22:32366979	NA	0.99	5.43	0.4	2.14e-7	Childhood ear infection;
PAAD	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs582384	0.630	rs614281	chr2:45866456	C/T	cg13704086	chr2:45177125	NA	0.45	4.27	0.33	3.36e-5	Coronary artery disease;
PAAD	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.73	4.78	0.36	4.19e-6	Major depressive disorder;
PAAD	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.94	8.19	0.55	9.82e-14	IgG glycosylation;
PAAD	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.36	0.51	1.06e-11	Coffee consumption (cups per day);
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.63	6.05	0.44	1.1e-8	Corneal astigmatism;
PAAD	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07550278	chr10:95462365	C10orf4	-0.81	-7.54	-0.52	3.95e-12	Neuroticism;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20577728	chr15:23034331	NIPA2	-0.75	-6.32	-0.46	2.76e-9	Neuroticism;
PAAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.45	5.83	0.43	3.16e-8	Monobrow;
PAAD	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg10820045	chr2:198174542	NA	0.5	5.19	0.39	6.59e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg20761395	chr17:511517	VPS53	0.48	4.75	0.36	4.75e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.67	-8.73	-0.58	4.29e-15	Schizophrenia;
PAAD	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.49	-0.34	1.42e-5	Osteoarthritis;
PAAD	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.27	19.41	0.84	5.52e-43	IgG glycosylation;
PAAD	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg08992911	chr2:238395768	MLPH	0.6	5.03	0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-4.62	-0.35	8.25e-6	Subjective well-being;
PAAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-8.16	-0.55	1.21e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6594713	0.533	rs6872020	chr5:112960035	T/C	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg14132834	chr19:41945861	ATP5SL	-0.46	-4.34	-0.33	2.61e-5	Height;
PAAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg17105886	chr17:28927953	LRRC37B2	0.86	5.07	0.38	1.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	4.5	0.34	1.33e-5	Post bronchodilator FEV1;
PAAD	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg03060546	chr3:49711283	APEH	0.61	6.15	0.45	6.4e-9	Resting heart rate;
PAAD	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.62	-6.91	-0.49	1.23e-10	Monocyte count;
PAAD	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg22437258	chr11:111473054	SIK2	0.64	6.44	0.46	1.52e-9	Primary sclerosing cholangitis;
PAAD	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg18551225	chr6:44695536	NA	-0.68	-6.76	-0.48	2.75e-10	Total body bone mineral density;
PAAD	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg18551225	chr6:44695536	NA	-0.7	-6.97	-0.49	9.26e-11	Total body bone mineral density;
PAAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg04738700	chr2:239367308	NA	0.4	4.34	0.33	2.55e-5	Multiple system atrophy;
PAAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg07061783	chr6:25882402	NA	-0.45	-4.28	-0.33	3.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-8.42	-0.56	2.59e-14	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs61784830	0.710	rs61783196	chr1:46291790	C/T	cg22524514	chr11:65779676	CST6	1.0	6.49	0.47	1.12e-9	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.81	-7.78	-0.53	1.06e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg13729891	chr17:7108468	DLG4	0.47	4.38	0.33	2.23e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02725872	chr8:58115012	NA	-0.63	-4.61	-0.35	8.65e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	-0.48	-4.3	-0.33	2.98e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs1941184	0.526	rs1460601	chr18:29028877	T/G	cg03238162	chr18:29027701	DSG3	0.42	4.81	0.36	3.63e-6	Parkinson's disease (age of onset);
PAAD	cis	rs757978	0.810	rs2055569	chr2:242401439	C/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.75	-4.67	-0.35	6.71e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.77	-0.53	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11113894	0.792	rs34773576	chr12:108860979	C/T	cg06834313	chr12:108851556	NA	-0.75	-4.59	-0.35	9.14e-6	Obesity-related traits;
PAAD	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.51	-7.04	-0.5	6.24e-11	Frontotemporal dementia;
PAAD	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg27182935	chr16:89790473	ZNF276	-0.81	-4.44	-0.34	1.75e-5	Skin colour saturation;
PAAD	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.91	5.89	0.43	2.36e-8	Severe influenza A (H1N1) infection;
PAAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.24	-7.13	-0.5	3.73e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11578532	chr1:161008127	TSTD1	0.47	5.29	0.39	4.27e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.59	-6.24	-0.45	4.15e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2275731	0.723	rs10904757	chr10:16548382	A/G	cg04254609	chr10:16479192	PTER	-0.48	-4.92	-0.37	2.24e-6	Bone fracture in osteoporosis;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.57	-7.06	-0.5	5.69e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22293286	chr19:44429476	ZNF45	-0.68	-6.54	-0.47	8.62e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg07648498	chr16:89883185	FANCA	-0.56	-5.61	-0.41	9.2e-8	Vitiligo;
PAAD	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg00806126	chr19:22604979	ZNF98	0.42	5.22	0.39	5.85e-7	Pain;
PAAD	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	7.87	0.54	6.33e-13	Response to antipsychotic treatment;
PAAD	cis	rs72772090	0.539	rs72773991	chr5:96163775	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.45	-0.46	1.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs61776719	0.520	rs72661887	chr1:38416310	C/T	cg04673462	chr1:38461896	NA	0.42	5.7	0.42	6.04e-8	Coronary artery disease;
PAAD	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	10.26	0.64	4.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.81	0.43	3.62e-8	Personality dimensions;
PAAD	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg13897122	chr2:103039542	IL18RAP	0.37	4.56	0.35	1.07e-5	Asthma;
PAAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.83	0.48	1.89e-10	Yeast infection;
PAAD	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs7941600	0.708	rs12287120	chr11:9311760	C/T	cg19415743	chr11:9336845	TMEM41B	0.91	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg23298862	chr7:158159286	PTPRN2	0.57	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs9630089	0.513	rs12571098	chr10:99095208	A/G	cg25902810	chr10:99078978	FRAT1	0.56	5.45	0.4	1.99e-7	Neutrophil percentage of white cells;
PAAD	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg16342193	chr10:102329863	NA	-0.8	-8.74	-0.58	4.01e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.55	0.41	1.22e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.8	9.4	0.61	8.03e-17	Bladder cancer;
PAAD	cis	rs7577696	0.889	rs212727	chr2:32469728	C/T	cg02381751	chr2:32503542	YIPF4	0.43	4.76	0.36	4.53e-6	Inflammatory biomarkers;
PAAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg14829360	chr17:73884958	NA	-0.68	-6.15	-0.45	6.69e-9	Psoriasis;
PAAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.84	10.97	0.66	5.59e-21	Vitiligo;
PAAD	cis	rs4478147	0.510	rs1031739	chr4:87229677	G/A	cg10685359	chr4:87814065	C4orf36	-0.46	-4.52	-0.34	1.22e-5	Migraine - clinic-based;
PAAD	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg27099511	chr16:88729703	MGC23284;MVD	-0.89	-4.55	-0.35	1.07e-5	Plateletcrit;
PAAD	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg12395012	chr8:11607386	GATA4	-0.43	-4.74	-0.36	4.82e-6	Myopia (pathological);
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.58	-6.61	-0.47	6.16e-10	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs9810890	1.000	rs73196966	chr3:128436824	G/A	cg19129842	chr3:128565090	NA	-0.82	-4.96	-0.37	1.88e-6	Dental caries;
PAAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.8	-0.58	2.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.88	-0.37	2.64e-6	Menarche (age at onset);
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg00450029	chr8:599525	NA	0.85	6.06	0.44	1.02e-8	IgG glycosylation;
PAAD	cis	rs9815354	1.000	rs17064124	chr3:41890803	A/G	cg03022575	chr3:42003672	ULK4	0.84	6.12	0.44	7.66e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9815354	0.812	rs73075250	chr3:42063734	A/G	cg03022575	chr3:42003672	ULK4	0.78	5.48	0.41	1.74e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.48	-4.83	-0.36	3.28e-6	Immature fraction of reticulocytes;
PAAD	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg05309399	chr4:106552544	FLJ20184	-0.54	-4.28	-0.33	3.34e-5	Post bronchodilator FEV1;
PAAD	cis	rs10214930	0.697	rs12668430	chr7:27633518	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg25547332	chr5:131281432	NA	-0.56	-4.4	-0.34	2.02e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	1.08	15.1	0.77	4.79e-32	Menarche (age at onset);
PAAD	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg00181669	chr3:44000978	NA	-0.42	-4.25	-0.33	3.73e-5	Coronary artery disease;
PAAD	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.67	5.74	0.42	5.07e-8	Exhaled nitric oxide output;
PAAD	cis	rs11694441	0.618	rs12104811	chr2:119577598	A/T	cg14634534	chr2:119616825	NA	-0.41	-4.48	-0.34	1.46e-5	Monobrow;
PAAD	cis	rs75757892	0.544	rs112411878	chr6:7315550	C/A	cg02954307	chr6:7269328	NA	0.54	4.52	0.34	1.23e-5	Hematocrit;Red blood cell count;
PAAD	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	7.57	0.52	3.29e-12	Eotaxin levels;
PAAD	cis	rs4417704	0.525	rs12694990	chr2:241883621	C/G	cg26818257	chr2:241905806	NA	0.51	5.41	0.4	2.35e-7	Joint mobility (Beighton score);
PAAD	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19810433	chr1:120343387	REG4	0.42	4.26	0.33	3.62e-5	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08567916	chr12:53473383	SPRYD3	0.66	7.87	0.54	6.06e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.42	-4.98	-0.37	1.7e-6	Body mass index;
PAAD	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.22	0.39	5.7e-7	Educational attainment;
PAAD	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg25838818	chr2:108905173	SULT1C2	-0.5	-5.09	-0.38	1.02e-6	Blood pressure;
PAAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.07	0.44	9.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.71	-0.36	5.55e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.07	-0.38	1.16e-6	Body mass index;
PAAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg12645284	chr15:79092878	ADAMTS7	0.49	4.25	0.33	3.67e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.61	-0.47	6.14e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.67	-6.35	-0.46	2.38e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.26	-0.51	1.87e-11	Personality dimensions;
PAAD	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12611296	chr13:76056336	TBC1D4	0.7	7.05	0.5	5.8e-11	Obesity-related traits;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18621852	chr3:10150065	C3orf24	0.58	4.55	0.35	1.08e-5	Alzheimer's disease;
PAAD	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg14074305	chr2:106260513	NA	0.45	4.39	0.34	2.14e-5	AIDS;
PAAD	cis	rs11588062	0.660	rs12738055	chr1:46701222	T/A	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.61	5.71	0.42	5.8e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9815354	1.000	rs6599178	chr3:41842129	C/T	cg03022575	chr3:42003672	ULK4	0.75	5.54	0.41	1.31e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4750829	0.581	rs7917753	chr10:132468412	C/T	cg07517739	chr10:132364391	NA	-0.62	-4.39	-0.34	2.09e-5	Obesity-related traits;
PAAD	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.88	-12.37	-0.71	9.39e-25	Height;
PAAD	cis	rs7727544	0.508	rs11739935	chr5:131380658	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	4.28	0.33	3.36e-5	Blood metabolite levels;
PAAD	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.52	-5.3	-0.39	4e-7	IgG glycosylation;
PAAD	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-4.36	-0.33	2.43e-5	Subjective well-being;
PAAD	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.35	5.54	0.41	1.29e-7	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg22587600	chr2:46883368	NA	0.33	4.59	0.35	9.39e-6	Height;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg11995594	chr8:103613219	NA	0.57	6.71	0.48	3.59e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg04160749	chr8:58172571	NA	-0.71	-4.73	-0.36	5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.96	10.51	0.65	9.12e-20	Obesity;Body mass index;
PAAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.67	0.42	6.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg10434728	chr15:90938212	IQGAP1	0.44	4.71	0.36	5.56e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.9	-7.42	-0.52	7.74e-12	Blood trace element (Zn levels);
PAAD	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg24721873	chr10:135334122	NA	0.57	4.3	0.33	3.02e-5	Gout;
PAAD	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg09127314	chr1:152161683	NA	-0.71	-4.95	-0.37	1.94e-6	Atopic dermatitis;
PAAD	trans	rs901683	0.850	rs113722818	chr10:46093208	G/A	cg07567308	chr20:3149320	ProSAPiP1	0.74	6.5	0.47	1.09e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.65	0.57	6.67e-15	Corneal astigmatism;
PAAD	cis	rs6734238	0.739	rs4368340	chr2:113845080	A/T	cg06156847	chr2:113672199	IL1F7	-0.43	-4.31	-0.33	2.96e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.87	-11.11	-0.67	2.26e-21	Breast cancer;
PAAD	cis	rs2944591	0.505	rs747462	chr2:233790171	A/C	cg08000102	chr2:233561755	GIGYF2	-0.47	-4.63	-0.35	7.68e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.47	-4.86	-0.37	2.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.82	6.98	0.49	8.34e-11	Menarche (age at onset);
PAAD	cis	rs2275731	0.505	rs7910712	chr10:16479256	T/C	cg04254609	chr10:16479192	PTER	-0.55	-6.03	-0.44	1.22e-8	Bone fracture in osteoporosis;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.69	4.94	0.37	2.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7936247	0.961	rs10765573	chr11:92683332	T/A	cg26929280	chr11:92402250	FAT3	-0.42	-4.25	-0.33	3.78e-5	Glycemic traits (pregnancy);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27657525	chr19:30432971	C19orf2	0.6	7.41	0.52	8.39e-12	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2944755	0.580	rs13251004	chr8:141586126	G/A	cg18491938	chr8:141590271	EIF2C2	-0.53	-4.88	-0.37	2.7e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	1.0	6.0	0.44	1.38e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.54	-5.17	-0.39	7.31e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11971779	0.527	rs1076349	chr7:139126494	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.69	7.16	0.5	3.2e-11	Glycated hemoglobin levels;
PAAD	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.71	-0.36	5.56e-6	Dupuytren's disease;
PAAD	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.71	-4.41	-0.34	1.96e-5	Skin colour saturation;
PAAD	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-4.85	-0.37	3.08e-6	Pulmonary function;
PAAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.87	10.29	0.64	3.56e-19	Metabolic syndrome;
PAAD	cis	rs2790216	1.000	rs2790212	chr10:60013138	T/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06799790	chr17:61951754	CSH2	-0.47	-4.9	-0.37	2.41e-6	Height;
PAAD	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07702100	chr11:88178390	NA	0.54	6.63	0.47	5.41e-10	Smoking initiation;
PAAD	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15699874	chr11:126152981	TIRAP	-0.61	-7.25	-0.51	1.99e-11	Body fat percentage;
PAAD	cis	rs3736485	0.816	rs11070851	chr15:51763249	C/G	cg08986416	chr15:51914746	DMXL2	0.45	4.32	0.33	2.75e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.83	-10.65	-0.65	4.02e-20	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08304084	chr16:51171082	SALL1	0.58	6.77	0.48	2.6e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.46	4.99	0.38	1.62e-6	Fibrinogen levels;
PAAD	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-4.73	-0.36	5.16e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.47	5.82	0.43	3.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg12215294	chr3:40350768	EIF1B	-0.44	-4.36	-0.33	2.35e-5	Renal cell carcinoma;
PAAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.89	15.2	0.78	2.55e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg05555928	chr11:63887634	MACROD1	0.6	5.95	0.43	1.74e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7300001	0.510	rs73205069	chr12:110550885	G/T	cg12870014	chr12:110450643	ANKRD13A	0.98	5.26	0.39	4.75e-7	Headache;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg12807937	chr2:240965920	NDUFA10	-0.47	-4.74	-0.36	4.88e-6	Odorant perception (isobutyraldehyde);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01020399	chr1:249153122	ZNF692	0.65	6.91	0.49	1.22e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.62	7.5	0.52	4.95e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg13206674	chr6:150067644	NUP43	0.63	6.67	0.48	4.55e-10	Testicular germ cell tumor;
PAAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg15478930	chr2:27652102	NRBP1	0.47	4.39	0.34	2.13e-5	Total body bone mineral density;
PAAD	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	5.06	0.38	1.2e-6	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11077225	chr11:94300493	PIWIL4	0.57	6.79	0.48	2.43e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg22654517	chr2:96458247	NA	0.37	4.32	0.33	2.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.89	-9.87	-0.63	4.57e-18	Calcium levels;
PAAD	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-6.74	-0.48	3.12e-10	Neuroticism;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.44	-5.04	-0.38	1.31e-6	Height;
PAAD	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.21	-0.39	5.99e-7	Systemic lupus erythematosus;
PAAD	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg22143635	chr11:980567	AP2A2	0.53	5.59	0.41	1e-7	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs16867321	0.755	rs10201806	chr2:181318726	C/T	cg23363182	chr2:181467187	NA	-0.52	-4.4	-0.34	1.99e-5	Obesity;
PAAD	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.49	-5.24	-0.39	5.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg14851346	chr12:38532713	NA	0.49	4.6	0.35	8.99e-6	Morning vs. evening chronotype;
PAAD	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3749237	0.964	rs10049413	chr3:49892896	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	6.53	0.47	9.21e-10	Resting heart rate;
PAAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	0.87	6.39	0.46	1.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.56	5.03	0.38	1.36e-6	Neutrophil percentage of white cells;
PAAD	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.81	-8.99	-0.59	8.89e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg10820045	chr2:198174542	NA	0.55	5.71	0.42	5.64e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.49	-0.47	1.16e-9	HDL cholesterol;
PAAD	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	5.87	0.43	2.58e-8	Schizophrenia;
PAAD	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma;
PAAD	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.78	-6.66	-0.48	4.79e-10	Other erythrocyte phenotypes;
PAAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg02475695	chr16:616220	NHLRC4	0.47	5.42	0.4	2.27e-7	Height;
PAAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.84	-9.98	-0.63	2.42e-18	Body mass index;
PAAD	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg01657329	chr11:68192670	LRP5	-0.64	-4.69	-0.36	5.93e-6	Total body bone mineral density (age 45-60);
PAAD	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.61	-5.67	-0.42	6.82e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg00206168	chr11:65308501	LTBP3	0.52	5.42	0.4	2.28e-7	Bone mineral density;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.49	4.44	0.34	1.75e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	4.76	0.36	4.47e-6	Menarche (age at onset);
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.63	-5.66	-0.42	7.3e-8	Renal function-related traits (BUN);
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.47	5.29	0.39	4.17e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg05250797	chr16:70222502	NA	-0.68	-5.19	-0.39	6.76e-7	IgE levels;
PAAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13931999	chr9:35815441	HINT2	0.74	7.47	0.52	5.93e-12	Obesity-related traits;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.72	0.48	3.51e-10	Life satisfaction;
PAAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.77	8.14	0.55	1.34e-13	Calcium levels;
PAAD	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.36	4.64e-6	Common traits (Other);
PAAD	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.78	7.12	0.5	3.97e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23716696	chr17:34957853	MRM1	0.7	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.5	-0.41	1.54e-7	Bladder cancer;
PAAD	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.44	-0.34	1.71e-5	Coronary artery disease;
PAAD	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.67	5.34	0.4	3.38e-7	Obesity (extreme);
PAAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg06629702	chr1:2706960	NA	0.36	4.28	0.33	3.25e-5	Ulcerative colitis;
PAAD	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg05895507	chr15:77155635	SCAPER	0.4	4.4	0.34	2.03e-5	Blood metabolite levels;
PAAD	cis	rs10504229	0.861	rs60346509	chr8:58196050	G/T	cg08219700	chr8:58056026	NA	0.69	5.22	0.39	5.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9395066	0.545	rs66604011	chr6:45053059	G/T	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs11112613	0.609	rs2374534	chr12:106047897	A/T	cg03607813	chr12:105948248	NA	0.77	5.26	0.39	4.83e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13870426	chr17:30244630	NA	-0.78	-7.63	-0.53	2.46e-12	Hip circumference adjusted for BMI;
PAAD	cis	rs17152411	0.947	rs7079199	chr10:126590820	A/C	cg07906193	chr10:126599966	NA	0.77	6.06	0.44	1.04e-8	Height;
PAAD	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.47	7.48	0.52	5.68e-12	IgG glycosylation;
PAAD	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.86	10.12	0.63	9.96e-19	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.46	4.25	0.33	3.78e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs73206853	0.841	rs55634798	chr12:110833748	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.66	6.74	0.48	3.15e-10	Blood protein levels;
PAAD	cis	rs6686889	1	rs6686889	chr1:25030470	C/T	cg22509179	chr1:25234806	RUNX3	0.51	4.53	0.35	1.16e-5	Diastolic blood pressure;
PAAD	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.19	-0.6	2.71e-16	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg03983476	chr2:10830698	NOL10	0.54	5.59	0.41	1.01e-7	Prostate cancer;
PAAD	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.61	-6.28	-0.45	3.35e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs4594175	0.926	rs72688717	chr14:51614493	C/T	cg23942311	chr14:51606299	NA	0.69	6.59	0.47	6.84e-10	Cancer;
PAAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs6929812	0.676	rs760880	chr6:27408181	G/T	cg10279314	chr6:27185896	NA	-0.39	-4.45	-0.34	1.62e-5	Neuroticism (multi-trait analysis);
PAAD	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg20913747	chr6:44695427	NA	-0.7	-7.02	-0.49	7.04e-11	Total body bone mineral density;
PAAD	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	4.97	0.37	1.77e-6	HDL cholesterol;
PAAD	cis	rs2526932	0.625	rs2803958	chr14:73048944	A/G	cg13588403	chr14:73209128	DPF3	-0.4	-5.33	-0.4	3.41e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.55	-5.56	-0.41	1.21e-7	Iron status biomarkers;
PAAD	cis	rs2422052	0.766	rs1583330	chr2:118650028	T/C	cg22545206	chr2:118617499	NA	0.55	5.5	0.41	1.6e-7	Mosquito bite size;
PAAD	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg11657440	chr19:46296263	DMWD	-0.69	-6.0	-0.44	1.4e-8	Coronary artery disease;
PAAD	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.64	-7.2	-0.5	2.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	4.66	0.35	6.93e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.48	-4.65	-0.35	7.24e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	5.38	0.4	2.82e-7	Joint mobility (Beighton score);
PAAD	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg05250797	chr16:70222502	NA	0.83	6.35	0.46	2.31e-9	IgE levels;
PAAD	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs950880	0.710	rs56386507	chr2:102971165	C/T	cg23450938	chr2:102972792	NA	0.43	4.41	0.34	1.96e-5	Serum protein levels (sST2);
PAAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.67	7.33	0.51	1.25e-11	Lung cancer;
PAAD	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.57	6.44	0.46	1.49e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg20159608	chr7:32802032	NA	-0.59	-6.11	-0.44	8.17e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.74	4.98	0.37	1.68e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10768122	1.000	rs3794102	chr11:35294186	A/G	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.32	-0.33	2.76e-5	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23803172	chr1:763119	NCRNA00115;LOC643837	-0.6	-6.49	-0.47	1.12e-9	Smoking initiation;
PAAD	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	7.76	0.53	1.12e-12	Alzheimer's disease;
PAAD	cis	rs6688613	0.721	rs2312675	chr1:166922533	T/C	cg07049167	chr1:166818506	POGK	0.61	6.03	0.44	1.22e-8	Refractive astigmatism;
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg19223190	chr17:80058835	NA	0.51	5.27	0.39	4.51e-7	Life satisfaction;
PAAD	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.37	-0.4	2.87e-7	Pulmonary function;
PAAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg01320130	chr1:67600311	NA	0.54	6.06	0.44	1.03e-8	Psoriasis;
PAAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	8.36	0.56	3.68e-14	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg16876255	chr19:9731953	ZNF561	0.93	4.5	0.34	1.35e-5	Pursuit maintenance gain;
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.41	4.83	0.37	3.24e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-4.51	-0.34	1.31e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg06899799	chr12:56650233	ANKRD52	0.34	4.37	0.33	2.25e-5	Cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15911239	chr2:24299251	SF3B14	-0.67	-6.85	-0.49	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs7804356	0.651	rs3801857	chr7:26811484	C/T	cg03456212	chr7:26904342	SKAP2	-0.57	-4.86	-0.37	2.95e-6	Type 1 diabetes;
PAAD	cis	rs593531	0.571	rs7934621	chr11:74090928	A/C	cg15851278	chr11:73669449	DNAJB13	-0.38	-4.46	-0.34	1.58e-5	Neuroticism;
PAAD	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.53	4.52	0.34	1.22e-5	Diastolic blood pressure;
PAAD	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg23465465	chr6:26364728	BTN3A2	0.92	5.3	0.39	4.09e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg05110241	chr16:68378359	PRMT7	-0.94	-7.52	-0.52	4.33e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg26071806	chr7:100318239	EPO	-0.46	-4.54	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg03983715	chr16:68378420	PRMT7	-0.99	-6.87	-0.49	1.54e-10	Schizophrenia;
PAAD	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.57	0.35	1.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06915872	chr16:87998081	BANP	0.47	4.34	0.33	2.55e-5	Menopause (age at onset);
PAAD	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.55	-6.75	-0.48	2.87e-10	Atrioventricular conduction;
PAAD	cis	rs35000415	1.000	rs35000415	chr7:128585616	C/T	cg19972273	chr7:128594194	NA	0.99	5.73	0.42	5.35e-8	Systemic lupus erythematosus;
PAAD	cis	rs11048434	0.518	rs759469	chr12:9175704	A/G	cg04548204	chr12:9162872	KLRG1	-0.39	-4.32	-0.33	2.82e-5	Sjögren's syndrome;
PAAD	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.44	4.41	0.34	1.98e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.84	0.43	3.11e-8	Platelet count;
PAAD	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.76	7.4	0.51	8.7e-12	Retinal vascular caliber;
PAAD	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.32	-0.33	2.78e-5	Blood protein levels;
PAAD	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.84	0.37	3.21e-6	Axial length;
PAAD	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.4	-7.54	-0.52	4.01e-12	Psoriasis vulgaris;
PAAD	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.86	6.68	0.48	4.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg10518543	chr12:38710700	ALG10B	-0.5	-4.55	-0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg27499820	chr13:21296301	IL17D	-0.53	-5.3	-0.4	3.93e-7	Dental caries;
PAAD	trans	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05612758	chr12:131356676	RAN	0.62	6.7	0.48	3.81e-10	Myopia (pathological);
PAAD	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.68	-0.48	4.28e-10	Body mass index;
PAAD	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.67	5.25	0.39	5.07e-7	Alzheimer's disease (survival time);
PAAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.79	6.65	0.47	4.92e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg01763666	chr17:80159506	CCDC57	0.45	4.6	0.35	8.91e-6	Life satisfaction;
PAAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.77	-6.69	-0.48	3.99e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs116175783	0.557	rs62188123	chr2:162241846	T/C	cg08807892	chr2:162101083	NA	-0.65	-4.66	-0.35	6.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.5	4.68	0.35	6.35e-6	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.64	7.64	0.53	2.26e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg20243544	chr17:37824526	PNMT	0.51	4.53	0.35	1.17e-5	Lymphocyte counts;
PAAD	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg00864860	chr1:7907996	UTS2	-0.56	-5.01	-0.38	1.52e-6	Crohn's disease;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.59	6.58	0.47	7.22e-10	Cardiovascular disease risk factors;
PAAD	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.4	-4.68	-0.36	6.2e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3785309	0.519	rs72765807	chr16:279885	G/C	cg27201940	chr16:1219628	CACNA1H	0.82	4.52	0.34	1.26e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.64	0.35	7.48e-6	Bipolar disorder;
PAAD	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg08916839	chr5:415575	AHRR	0.5	4.35	0.33	2.48e-5	Fat distribution (HIV);
PAAD	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg22601191	chr20:60968625	CABLES2	-0.56	-5.44	-0.4	2.06e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.76	-0.36	4.51e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6142102	0.625	rs1883705	chr20:32552878	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.8	7.16	0.5	3.22e-11	Cognitive function;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg09509183	chr1:209979624	IRF6	0.51	4.74	0.36	4.81e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs7554547	0.967	rs4845888	chr1:11971003	C/G	cg07603449	chr1:11986842	KIAA2013	-0.28	-4.25	-0.33	3.72e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg15556689	chr8:8085844	FLJ10661	0.72	7.29	0.51	1.59e-11	Neuroticism;
PAAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg03289416	chr15:75166202	SCAMP2	0.52	5.32	0.4	3.57e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.77	7.09	0.5	4.82e-11	Obesity-related traits;
PAAD	cis	rs7180079	1.000	rs1033206	chr15:64656762	T/C	cg18210365	chr15:65066710	RBPMS2	0.64	4.9	0.37	2.47e-6	Monocyte count;
PAAD	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-4.55	-0.35	1.08e-5	Self-reported allergy;
PAAD	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.61	5.34	0.4	3.26e-7	Dialysis-related mortality;
PAAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg04522676	chr10:134968826	NA	0.47	4.46	0.34	1.56e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs11700980	0.551	rs2832036	chr21:30115170	T/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs288342	0.829	rs438248	chr2:183589360	G/T	cg02625481	chr2:183667124	NA	-0.45	-4.46	-0.34	1.56e-5	Recurrent major depressive disorder;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15332604	chr10:106051268	GSTO2	0.57	6.3	0.46	3.05e-9	Monocyte percentage of white cells;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs757081	0.658	rs214101	chr11:17289354	A/G	cg22710661	chr11:17411071	KCNJ11	-0.44	-4.51	-0.34	1.3e-5	Systolic blood pressure;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg02725872	chr8:58115012	NA	-0.6	-5.23	-0.39	5.64e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1190596	0.525	rs7153005	chr14:102698599	G/T	cg23904247	chr14:102554826	HSP90AA1	-0.39	-4.39	-0.34	2.09e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.07	0.44	9.85e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.21	-0.39	5.93e-7	Life satisfaction;
PAAD	cis	rs7539409	0.667	rs56210083	chr1:84181701	G/A	cg10977910	chr1:84465055	TTLL7	-0.88	-4.83	-0.36	3.28e-6	Alzheimer's disease;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.88	6.72	0.48	3.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.46	4.75	0.36	4.62e-6	Electroencephalogram traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10351617	chr21:47580738	NA	0.64	7.68	0.53	1.77e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2290405	0.591	rs7687129	chr4:939883	T/C	cg09237302	chr4:906077	GAK	-0.38	-4.79	-0.36	4e-6	Systemic sclerosis;
PAAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.61	6.71	0.48	3.67e-10	Vitiligo;
PAAD	cis	rs4481887	0.597	rs6587475	chr1:248578622	C/T	cg00666640	chr1:248458726	OR2T12	0.54	4.65	0.35	7.17e-6	Common traits (Other);
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs501120	0.564	rs11238904	chr10:44684707	C/T	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.42	5.14	0.38	8.42e-7	Corneal astigmatism;
PAAD	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-5.93	-0.43	2e-8	Homocysteine levels;
PAAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.67	8.68	0.58	5.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7766436	0.614	rs55663812	chr6:22562881	G/A	cg13666174	chr6:22585274	NA	-0.5	-4.42	-0.34	1.88e-5	Coronary artery disease;
PAAD	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-9.35	-0.6	1.08e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-4.93	-0.37	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg20607287	chr7:12443886	VWDE	-0.6	-4.87	-0.37	2.77e-6	Coronary artery disease;
PAAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.29	-4.27	-0.33	3.39e-5	Psoriasis;
PAAD	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.7	-7.32	-0.51	1.32e-11	Body mass index;
PAAD	cis	rs2013441	0.613	rs11204422	chr17:19996429	A/T	cg13482628	chr17:19912719	NA	-0.49	-4.94	-0.37	2.05e-6	Obesity-related traits;
PAAD	cis	rs2904967	0.562	rs239255	chr11:64987128	G/A	cg21890820	chr11:65308645	LTBP3	-0.54	-5.29	-0.39	4.24e-7	Mean corpuscular volume;
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.57	-6.73	-0.48	3.31e-10	Aortic root size;
PAAD	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg03959625	chr15:84868606	LOC388152	0.41	4.27	0.33	3.49e-5	Schizophrenia;
PAAD	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs9467160	1.000	rs6922313	chr6:24438719	C/T	cg16211469	chr6:24423932	MRS2	0.47	4.71	0.36	5.53e-6	Liver enzyme levels;
PAAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.74	-0.36	4.93e-6	Parkinson's disease;
PAAD	cis	rs11051970	0.918	rs11051969	chr12:32537123	T/C	cg02745156	chr12:32552066	NA	0.48	4.91	0.37	2.34e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg02734326	chr4:10020555	SLC2A9	-0.49	-4.9	-0.37	2.39e-6	Bone mineral density;
PAAD	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg20169779	chr10:135381914	SYCE1	-0.45	-4.66	-0.35	7e-6	Obesity-related traits;
PAAD	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.68	6.08	0.44	9.1e-9	Mean platelet volume;
PAAD	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.73	6.21	0.45	4.9e-9	Schizophrenia;
PAAD	cis	rs6987853	0.527	rs3935700	chr8:42364121	T/C	cg09913449	chr8:42400586	C8orf40	-0.52	-5.99	-0.44	1.46e-8	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.78	7.59	0.52	3.06e-12	Urate levels in lean individuals;
PAAD	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg18764771	chr6:116381957	FRK	0.45	7.83	0.54	7.81e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg00383909	chr3:49044727	WDR6	0.82	5.16	0.39	7.61e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02187348	chr16:89574699	SPG7	0.56	5.67	0.42	7.14e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs2479106	0.892	rs12347057	chr9:126694094	T/A	cg16191174	chr9:126692580	DENND1A	0.56	5.09	0.38	1.04e-6	Polycystic ovary syndrome;
PAAD	cis	rs2412488	1.000	rs6827269	chr4:54320617	C/T	cg19408398	chr4:54243328	FIP1L1	-0.5	-4.37	-0.33	2.3e-5	DNA methylation (variation);
PAAD	cis	rs35160687	0.862	rs13024964	chr2:86511868	G/A	cg10973622	chr2:86423274	IMMT	0.46	5.06	0.38	1.21e-6	Night sleep phenotypes;
PAAD	cis	rs9469913	0.799	rs6936177	chr6:34783717	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.49	-4.28	-0.33	3.26e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	10.1	0.63	1.16e-18	Platelet count;
PAAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.76	7.8	0.53	9.11e-13	Prostate cancer;
PAAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.56	7.36	0.51	1.1e-11	Renal cell carcinoma;
PAAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.47	4.26	0.33	3.59e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.69	7.76	0.53	1.17e-12	Melanoma;
PAAD	cis	rs16944613	0.510	rs8030781	chr15:91143072	T/C	cg15547629	chr15:90437138	AP3S2	-0.51	-4.42	-0.34	1.9e-5	Colorectal cancer;
PAAD	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.62	-0.47	5.72e-10	Hip circumference;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	5.22	0.39	5.71e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg26597838	chr10:835615	NA	0.51	5.48	0.41	1.71e-7	Survival in rectal cancer;
PAAD	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs3736757	1.000	rs2024767	chr1:184705437	C/T	cg05045817	chr1:184633523	NA	0.41	4.51	0.34	1.31e-5	Obesity-related traits;
PAAD	trans	rs9393777	0.920	rs34196306	chr6:27425644	G/C	cg01620082	chr3:125678407	NA	-1.54	-8.86	-0.58	2.01e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.32	-0.33	2.78e-5	Height;
PAAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.87	6.6	0.47	6.4e-10	Tuberculosis;
PAAD	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.78	-7.06	-0.5	5.7e-11	Vitamin D levels;
PAAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-4.76	-0.36	4.44e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.74	-7.06	-0.5	5.7e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg17105886	chr17:28927953	LRRC37B2	0.76	4.86	0.37	2.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.54	5.87	0.43	2.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg14181355	chr19:12984996	MAST1	-0.45	-4.45	-0.34	1.66e-5	Mean corpuscular volume;
PAAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.42	0.34	1.87e-5	Iron status biomarkers;
PAAD	cis	rs820218	0.787	rs1093995	chr17:73614914	T/C	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.32	-0.33	2.78e-5	Rotator cuff tears;
PAAD	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	8.36	0.56	3.77e-14	Bipolar disorder;
PAAD	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg20312557	chr2:97357134	FER1L5	-0.82	-4.37	-0.33	2.34e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.23	-0.39	5.56e-7	Life satisfaction;
PAAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.54	-0.52	3.86e-12	Height;
PAAD	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	4.32	0.33	2.79e-5	Thyroid stimulating hormone;
PAAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06544989	chr22:39130855	UNC84B	0.5	4.96	0.37	1.88e-6	Menopause (age at onset);
PAAD	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.74	8.11	0.55	1.55e-13	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.51	0.57	1.54e-14	Lung cancer;
PAAD	trans	rs11794666	0.799	rs72717584	chr9:31727639	T/G	cg05628366	chr6:35744188	C6orf126	0.95	6.65	0.47	4.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.72	7.32	0.51	1.33e-11	Neurofibrillary tangles;
PAAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.75	8.19	0.55	9.91e-14	Lung cancer;
PAAD	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-6.24	-0.45	4.08e-9	Lung cancer;
PAAD	cis	rs10888329	0.708	rs6587435	chr1:248355585	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Autism spectrum disorder;
PAAD	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.09	0.38	1.04e-6	Tonsillectomy;
PAAD	cis	rs806794	0.810	rs62396185	chr6:26180634	G/C	cg13736514	chr6:26305472	NA	-0.5	-5.18	-0.39	7.1e-7	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.62	-7.1	-0.5	4.52e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs9583531	0.760	rs9521916	chr13:111385509	A/G	cg24331049	chr13:111365604	ING1	-0.74	-5.21	-0.39	5.99e-7	Coronary artery disease;
PAAD	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	6.44	0.46	1.5e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.32e-12	Height;
PAAD	cis	rs116979167	0.507	rs12705314	chr7:105215905	G/A	cg02135003	chr7:105160482	PUS7	0.54	4.96	0.37	1.87e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.75	-7.11	-0.5	4.24e-11	Pancreatic cancer;
PAAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2278796	0.608	rs6700188	chr1:204969066	A/G	cg17947172	chr1:204966197	NFASC	0.43	4.68	0.35	6.44e-6	Mean platelet volume;
PAAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.83	-0.36	3.26e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg00717180	chr2:96193071	NA	-0.6	-6.77	-0.48	2.67e-10	HDL cholesterol;
PAAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.39	4.48	0.34	1.48e-5	Fat distribution (HIV);
PAAD	cis	rs6088813	0.883	rs2425061	chr20:33915571	A/G	cg14752227	chr20:34000481	UQCC	0.52	5.22	0.39	5.83e-7	Height;
PAAD	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg07541023	chr7:19748670	TWISTNB	-0.51	-4.35	-0.33	2.48e-5	Thyroid stimulating hormone;
PAAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13939156	chr17:80058883	NA	0.42	4.56	0.35	1.07e-5	Life satisfaction;
PAAD	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.61	5.37	0.4	2.88e-7	Morning vs. evening chronotype;
PAAD	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg18721089	chr20:30220636	NA	-0.6	-5.01	-0.38	1.48e-6	Mean corpuscular volume;
PAAD	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg04254540	chr16:71951199	KIAA0174	-0.44	-4.43	-0.34	1.83e-5	Fibrinogen levels;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.48	-0.47	1.21e-9	Bipolar disorder;
PAAD	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	7.95	0.54	3.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.77	7.92	0.54	4.75e-13	Corneal astigmatism;
PAAD	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.71	-6.8	-0.48	2.25e-10	Platelet distribution width;
PAAD	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.91	9.45	0.61	5.77e-17	Corneal astigmatism;
PAAD	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs8060686	0.844	rs73597581	chr16:67682234	G/A	cg09835421	chr16:68378352	PRMT7	-0.95	-4.88	-0.37	2.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.93	11.11	0.67	2.36e-21	Longevity;
PAAD	cis	rs2031532	0.544	rs35980977	chr13:50057936	A/G	cg03651054	chr13:50194643	NA	0.32	4.36	0.33	2.39e-5	Cardiac hypertrophy;
PAAD	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	ch.11.42038R	chr11:967971	AP2A2	0.65	6.28	0.45	3.34e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.14	16.54	0.8	8.23e-36	Cognitive function;
PAAD	trans	rs61931739	0.649	rs815043	chr12:33722599	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.55	0.41	1.24e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	0.95	12.14	0.7	3.99e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs9341808	0.530	rs3805877	chr6:81031529	T/A	cg08355045	chr6:80787529	NA	0.44	5.44	0.4	2.07e-7	Sitting height ratio;
PAAD	cis	rs6466055	0.661	rs17640644	chr7:104918169	A/G	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.5	-5.41	-0.4	2.4e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	trans	rs901683	1.000	rs35070150	chr10:46079833	A/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2446066	0.872	rs2683522	chr12:53783396	C/T	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.15e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs901683	1.000	rs34937315	chr10:45970717	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7631605	0.875	rs4678921	chr3:37022803	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs2072735	1.000	rs2072735	chr1:9355472	A/C	cg25755851	chr1:9335794	NA	-0.37	-4.42	-0.34	1.89e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg21775007	chr8:11205619	TDH	-0.46	-4.26	-0.33	3.57e-5	Neuroticism;
PAAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.6	4.83	0.36	3.36e-6	Type 2 diabetes;
PAAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg21448613	chr3:49828315	CDH29	0.46	4.48	0.34	1.47e-5	Menarche (age at onset);
PAAD	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.57	5.24	0.39	5.25e-7	Self-reported allergy;
PAAD	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-4.31	-0.33	2.87e-5	Vitiligo;
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg04520793	chr17:42248056	ASB16	-0.47	-6.34	-0.46	2.44e-9	Total body bone mineral density;
PAAD	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg08562672	chr19:21860753	NA	-0.45	-4.8	-0.36	3.68e-6	Pain;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg17541715	chr7:1216824	NA	-0.56	-6.7	-0.48	3.79e-10	Longevity;Endometriosis;
PAAD	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02985541	chr2:219472218	PLCD4	0.29	4.51	0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs3736485	0.934	rs17609812	chr15:51879260	G/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16851699	chr7:5938193	C7orf28A	-0.65	-6.74	-0.48	3.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.66e-7	Lung cancer;
PAAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs1075265	0.875	rs12616212	chr2:54266246	T/C	cg04546899	chr2:54196757	PSME4	0.35	5.12	0.38	8.95e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.71	5.04	0.38	1.29e-6	Iron status biomarkers;
PAAD	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg08992911	chr2:238395768	MLPH	0.74	5.68	0.42	6.62e-8	Prostate cancer;
PAAD	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.97	13.77	0.74	1.66e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.14	6.88	0.49	1.46e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13448378	chr8:103250761	RRM2B	0.61	6.84	0.49	1.8e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.56	-0.47	7.78e-10	Bipolar disorder;
PAAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.46	-0.46	1.31e-9	Prudent dietary pattern;
PAAD	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.67	0.58	6.08e-15	Fuchs's corneal dystrophy;
PAAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.68	0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg24253500	chr15:84953950	NA	0.44	4.67	0.35	6.68e-6	Schizophrenia;
PAAD	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.4	-4.56	-0.35	1.07e-5	IgG glycosylation;
PAAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.51	-0.34	1.29e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2133450	1.000	rs2133450	chr3:7336452	A/C	cg19930620	chr3:7340148	GRM7	-0.46	-4.83	-0.36	3.26e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs9659323	1.000	rs10923715	chr1:119535334	A/T	cg26570165	chr1:119541833	NA	0.48	5.09	0.38	1.02e-6	Body mass index;
PAAD	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19824661	chr19:36727978	ZNF146	0.62	6.55	0.47	8.25e-10	Smoking initiation;
PAAD	cis	rs2445762	0.518	rs6493496	chr15:51628119	A/T	cg20344442	chr15:51633704	GLDN	0.44	4.39	0.34	2.09e-5	Hormone measurements;
PAAD	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg04165759	chr1:150448943	RPRD2	-0.53	-5.6	-0.41	9.74e-8	Migraine;
PAAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg20933634	chr6:27740509	NA	0.67	6.31	0.46	2.92e-9	Parkinson's disease;
PAAD	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.94	-10.08	-0.63	1.31e-18	Homoarginine levels;
PAAD	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06850241	chr22:41845214	NA	-0.54	-5.25	-0.39	4.95e-7	Vitiligo;
PAAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg12215294	chr3:40350768	EIF1B	-0.45	-4.48	-0.34	1.44e-5	Renal cell carcinoma;
PAAD	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.67	8.85	0.58	2.14e-15	Hemoglobin concentration;
PAAD	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg23024343	chr7:107201750	COG5	0.51	4.29	0.33	3.15e-5	Coronary artery disease;
PAAD	cis	rs360071	0.528	rs360098	chr1:226066690	C/G	cg11967457	chr1:226128626	LEFTY2	0.56	5.24	0.39	5.25e-7	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
PAAD	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.49	7.86	0.54	6.41e-13	Neuroticism;
PAAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.56	4.96	0.37	1.84e-6	Testicular germ cell tumor;
PAAD	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	7.84	0.54	7.32e-13	Coronary artery disease;
PAAD	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.09e-6	Life satisfaction;
PAAD	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.25	0.33	3.73e-5	Lung cancer in ever smokers;
PAAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.64	-7.3	-0.51	1.52e-11	Coronary artery disease;
PAAD	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10203711	0.531	rs10181391	chr2:239565575	C/T	cg03761885	chr2:238707879	RBM44	0.44	4.42	0.34	1.88e-5	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-6.81	-0.48	2.1e-10	Neuroticism;
PAAD	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.61	6.42	0.46	1.63e-9	Body mass index;
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-5.4	-0.4	2.48e-7	Prudent dietary pattern;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.75	7.41	0.52	8.25e-12	Resting heart rate;
PAAD	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	5.61	0.41	9.48e-8	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.62	-0.35	8.12e-6	Renal cell carcinoma;
PAAD	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06850241	chr22:41845214	NA	-0.61	-5.37	-0.4	2.93e-7	Vitiligo;
PAAD	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.43	-6.38	-0.46	1.99e-9	Subjective well-being;
PAAD	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	5.04	0.38	1.29e-6	Colorectal cancer;
PAAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.55	5.98	0.44	1.55e-8	Facial morphology (factor 20);
PAAD	cis	rs11809230	0.541	rs11799793	chr1:70185045	A/C	cg01791338	chr1:70606906	NA	0.76	4.9	0.37	2.43e-6	Cannabis use (initiation);
PAAD	cis	rs55871839	0.536	rs10091451	chr8:59814953	A/T	cg07426533	chr8:59803705	TOX	-0.43	-4.57	-0.35	9.85e-6	Pneumonia;
PAAD	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.04	8.37	0.56	3.48e-14	Corneal structure;
PAAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.68	-7.66	-0.53	2.02e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.55	5.09	0.38	1.04e-6	Type 2 diabetes;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20481837	chr4:151501627	MAB21L2;LRBA	-0.68	-6.43	-0.46	1.53e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.75	-6.62	-0.47	5.74e-10	Blood pressure (smoking interaction);
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.62	6.21	0.45	4.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.55	5.92	0.43	2.06e-8	Longevity;Endometriosis;
PAAD	cis	rs877426	0.681	rs41291225	chr13:114839462	T/C	cg00571178	chr13:114841904	RASA3	-0.55	-4.62	-0.35	8.02e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.81	-9.08	-0.59	5.35e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1879734	0.648	rs7549345	chr1:54145288	T/C	cg14659662	chr1:54151053	GLIS1	-0.4	-5.51	-0.41	1.47e-7	Mitral valve prolapse;
PAAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.96	11.62	0.69	9.89e-23	Menarche (age at onset);
PAAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg21929781	chr1:2537748	MMEL1	0.45	4.8	0.36	3.82e-6	Ulcerative colitis;
PAAD	cis	rs3206736	0.521	rs329232	chr7:35054951	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs590121	0.876	rs650241	chr11:75277757	C/G	cg26104986	chr11:75275303	SERPINH1	-0.46	-4.57	-0.35	1.01e-5	Coronary artery disease;
PAAD	cis	rs8099014	0.906	rs4940695	chr18:56106483	T/G	cg12907477	chr18:56117327	MIR122	0.56	4.26	0.33	3.59e-5	Platelet count;
PAAD	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-4.43	-0.34	1.81e-5	Neuroticism;
PAAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	1.11	10.58	0.65	5.89e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs77633900	0.772	rs494268	chr15:76815713	T/C	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	0.98	9.44	0.61	6.3e-17	Monocyte percentage of white cells;
PAAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg09835421	chr16:68378352	PRMT7	-1.1	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.64	6.87	0.49	1.54e-10	Leprosy;
PAAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.8	-8.48	-0.57	1.83e-14	Menarche (age at onset);
PAAD	cis	rs243505	0.559	rs2072408	chr7:148508197	A/G	cg09806900	chr7:148480153	CUL1	0.56	5.02	0.38	1.43e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.66	5.36	0.4	3.1e-7	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.73	-0.42	5.12e-8	Life satisfaction;
PAAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.57	6.83	0.48	1.88e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1468333	1.000	rs1468333	chr5:137552970	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.61	6.57	0.47	7.46e-10	Resting heart rate;
PAAD	cis	rs2479106	0.791	rs12237685	chr9:126689557	T/C	cg16191174	chr9:126692580	DENND1A	0.62	5.59	0.41	1.03e-7	Polycystic ovary syndrome;
PAAD	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.61	-6.17	-0.45	5.97e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg22800045	chr5:56110881	MAP3K1	-0.55	-4.94	-0.37	2.08e-6	Initial pursuit acceleration;
PAAD	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs859767	0.741	rs10803548	chr2:135396738	C/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.42	-0.34	1.83e-5	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04710571	chr19:38853176	CATSPERG	0.58	6.62	0.47	5.85e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.75	8.11	0.55	1.59e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg04450456	chr4:17643702	FAM184B	0.49	5.29	0.39	4.22e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.54	5.04	0.38	1.34e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.94	-8.06	-0.55	2.12e-13	Dupuytren's disease;
PAAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05628381	chr19:982985	WDR18	0.63	7.52	0.52	4.4e-12	Monocyte percentage of white cells;
PAAD	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.83	6.81	0.48	2.08e-10	Brain cytoarchitecture;
PAAD	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.95	-0.37	1.93e-6	Bipolar disorder;
PAAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07739727	chr11:85339663	TMEM126B;DLG2	-0.58	-6.29	-0.45	3.15e-9	Smoking initiation;
PAAD	cis	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-5.9	-0.43	2.3e-8	Atopic dermatitis;
PAAD	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	6.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.48	-0.34	1.46e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7584330	0.554	rs74003110	chr2:238448188	C/T	cg08992911	chr2:238395768	MLPH	0.56	4.8	0.36	3.76e-6	Prostate cancer;
PAAD	cis	rs735539	0.521	rs2818998	chr13:21369911	T/C	cg27499820	chr13:21296301	IL17D	0.55	5.13	0.38	8.62e-7	Dental caries;
PAAD	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-11.55	-0.68	1.48e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9857275	0.788	rs13091182	chr3:141133960	G/A	cg00789793	chr3:141329863	RASA2	0.49	4.29	0.33	3.16e-5	Prion diseases;
PAAD	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg20742385	chr13:113633654	MCF2L	-0.46	-4.66	-0.35	6.74e-6	Systolic blood pressure;
PAAD	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.61	6.59	0.47	6.81e-10	Neuroticism;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1198430	0.562	rs7523811	chr1:23789567	C/T	cg19827787	chr1:23763612	ASAP3	-0.53	-4.87	-0.37	2.8e-6	Total cholesterol levels;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.7	7.58	0.52	3.16e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.61	5.05	0.38	1.27e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg03116837	chr8:216703	NA	0.56	5.07	0.38	1.13e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.8	7.11	0.5	4.23e-11	Obesity-related traits;
PAAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.55	5.1	0.38	1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16447950	chr5:562315	NA	0.67	5.96	0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg01620082	chr3:125678407	NA	-1.42	-8.18	-0.55	1.03e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.72	7.33	0.51	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg16147221	chr4:10020634	SLC2A9	0.46	4.25	0.33	3.66e-5	Bone mineral density;
PAAD	cis	rs4273100	0.834	rs59415593	chr17:19223224	T/G	cg19949948	chr17:19361230	NA	-0.53	-4.39	-0.34	2.11e-5	Schizophrenia;
PAAD	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.67	6.36	0.46	2.28e-9	Myopia (pathological);
PAAD	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg26818257	chr2:241905806	NA	0.43	4.33	0.33	2.69e-5	Urinary metabolites;
PAAD	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.03e-6	Colorectal cancer;
PAAD	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	0.6	5.27	0.39	4.58e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Menopause (age at onset);
PAAD	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.85	6.93	0.49	1.13e-10	Chronic kidney disease;
PAAD	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Vitiligo;
PAAD	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg21890820	chr11:65308645	LTBP3	-0.9	-7.26	-0.51	1.83e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.99	0.38	1.65e-6	Diastolic blood pressure;
PAAD	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.85	9.51	0.61	4.07e-17	Mortality in heart failure;
PAAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.58	-5.34	-0.4	3.4e-7	Coronary artery disease;
PAAD	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.46	5.76	0.42	4.43e-8	Crohn's disease;
PAAD	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.03	6.28	0.45	3.36e-9	Mitochondrial DNA levels;
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.72	8.37	0.56	3.56e-14	Height;
PAAD	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg13207630	chr7:32358064	NA	0.76	4.25	0.33	3.68e-5	Body mass index;
PAAD	cis	rs12304921	0.935	rs4768948	chr12:51365168	C/T	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.45	-0.4	1.95e-7	Type 2 diabetes;
PAAD	cis	rs2241685	0.704	rs6548052	chr2:1951082	C/T	cg22511877	chr2:1942942	MYT1L	-0.62	-4.49	-0.34	1.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1334894	0.901	rs72911380	chr6:35519483	G/A	cg07213720	chr6:35227408	ZNF76	-0.78	-4.25	-0.33	3.73e-5	Coronary artery disease;
PAAD	cis	rs17601876	0.520	rs28757201	chr15:51503897	G/A	cg06258672	chr15:51387677	TNFAIP8L3	0.44	4.3	0.33	2.99e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg06217245	chr20:33103252	DYNLRB1	0.41	4.56	0.35	1.04e-5	Height;
PAAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.6	-5.88	-0.43	2.48e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.95	10.29	0.64	3.65e-19	Corneal astigmatism;
PAAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26796135	chr15:45671001	LOC145663;GATM	0.54	4.99	0.37	1.66e-6	Homoarginine levels;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7932354	0.528	rs7937950	chr11:47098445	A/C	cg19486271	chr11:47235900	DDB2	-0.59	-5.96	-0.44	1.7e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg10072921	chr12:121022843	NA	-0.34	-4.45	-0.34	1.68e-5	High light scatter reticulocyte count;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg00280220	chr17:61926910	NA	0.44	4.63	0.35	7.7e-6	Prudent dietary pattern;
PAAD	cis	rs16838233	1.000	rs12408864	chr1:29759970	G/A	cg12609322	chr1:29490924	SFRS4	0.55	4.48	0.34	1.44e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.45	4.8	0.36	3.73e-6	Age of smoking initiation;
PAAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.76	-8.83	-0.58	2.38e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.7	-6.55	-0.47	8.47e-10	Monocyte count;
PAAD	cis	rs12138061	0.954	rs1474910	chr1:50192150	T/C	cg09846084	chr1:50888024	DMRTA2	-0.55	-4.65	-0.35	7.07e-6	Schizophrenia;
PAAD	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.42	4.58	0.35	9.79e-6	Pulse pressure;
PAAD	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.44	4.45	0.34	1.63e-5	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07666984	chr4:153858209	NA	0.64	6.3	0.46	3.01e-9	Obesity-related traits;
PAAD	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg01256987	chr12:42539512	GXYLT1	-0.39	-4.53	-0.34	1.21e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.52	-4.97	-0.37	1.78e-6	Daytime sleep phenotypes;
PAAD	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.7	7.39	0.51	8.96e-12	Multiple sclerosis;
PAAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-1.08	-12.5	-0.71	4.23e-25	Obesity-related traits;
PAAD	cis	rs9810890	1.000	rs73196996	chr3:128458416	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26926768	chr12:34528122	NA	0.36	4.26	0.33	3.51e-5	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs8060686	0.777	rs73597580	chr16:67679879	G/A	cg05110241	chr16:68378359	PRMT7	-0.98	-5.02	-0.38	1.46e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.76	-0.53	1.13e-12	Response to antipsychotic treatment;
PAAD	cis	rs6142102	0.625	rs4012234	chr20:32553047	T/G	cg06115741	chr20:33292138	TP53INP2	0.55	4.85	0.37	2.96e-6	Skin pigmentation;
PAAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.89e-9	Lung cancer;
PAAD	cis	rs9659323	0.730	rs7512189	chr1:119542532	A/T	cg26570165	chr1:119541833	NA	-0.55	-6.02	-0.44	1.27e-8	Body mass index;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.74	-7.46	-0.52	6.17e-12	Menopause (age at onset);
PAAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Parkinson's disease;
PAAD	cis	rs10214930	0.752	rs10951173	chr7:27662898	C/A	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg22482690	chr17:47019901	SNF8	-0.45	-4.82	-0.36	3.52e-6	Type 2 diabetes;
PAAD	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg15440763	chr7:158190612	PTPRN2	-0.49	-5.0	-0.38	1.53e-6	Obesity-related traits;
PAAD	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.86	-7.61	-0.53	2.72e-12	HIV-1 control;
PAAD	cis	rs12484776	0.786	rs17323591	chr22:40534211	T/A	cg07138101	chr22:40742427	ADSL	0.6	4.42	0.34	1.84e-5	Uterine fibroids;
PAAD	cis	rs10943724	0.679	rs2322842	chr6:81266744	A/G	cg19323245	chr6:80716898	TTK	-0.42	-4.45	-0.34	1.68e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6992820	0.528	rs7826134	chr8:56721615	G/A	cg08894788	chr8:56792171	LYN	-0.46	-4.26	-0.33	3.58e-5	Mean platelet volume;
PAAD	cis	rs4740619	0.630	rs2987033	chr9:15995638	C/G	cg14451791	chr9:16040625	NA	0.37	4.36	0.33	2.41e-5	Body mass index;
PAAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.66	-5.37	-0.4	2.94e-7	Obesity (extreme);
PAAD	cis	rs8102137	0.706	rs7250389	chr19:30325332	G/T	cg27475126	chr19:30303651	CCNE1	-0.49	-5.05	-0.38	1.24e-6	Bladder cancer;
PAAD	cis	rs113835537	0.808	rs10896128	chr11:66324529	G/A	cg22134325	chr11:66188745	NPAS4	0.4	4.73	0.36	5.14e-6	Airway imaging phenotypes;
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg19223190	chr17:80058835	NA	0.53	5.42	0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13870426	chr17:30244630	NA	-0.69	-6.34	-0.46	2.47e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg08992911	chr2:238395768	MLPH	0.74	5.66	0.42	7.38e-8	Prostate cancer;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg00262122	chr8:11665843	FDFT1	0.5	4.76	0.36	4.51e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20913372	chr9:140190455	NA	0.58	6.42	0.46	1.66e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg00106254	chr7:1943704	MAD1L1	-0.57	-5.13	-0.38	8.67e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg10705379	chr10:99080932	FRAT1	0.41	4.61	0.35	8.41e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	11.65	0.69	7.89e-23	Breast cancer;
PAAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.75	-7.59	-0.52	3.03e-12	Body mass index;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg26247942	chr15:43984922	CKMT1A	0.35	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs72772090	1.000	rs72772095	chr5:96053853	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.73	-5.82	-0.43	3.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6129846	1.000	rs4812516	chr20:40116467	C/T	cg23060191	chr20:39666765	PRO0628;TOP1	-0.78	-4.65	-0.35	7.16e-6	Verbal declarative memory;
PAAD	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg01851573	chr8:8652454	MFHAS1	0.57	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs853679	0.567	rs9969098	chr6:28398748	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.67	-0.35	6.51e-6	Depression;
PAAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.53	5.79	0.42	3.96e-8	Height;
PAAD	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg16606324	chr3:10149918	C3orf24	0.7	4.89	0.37	2.56e-6	Alzheimer's disease;
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.6	4.74	0.36	4.98e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg16606324	chr3:10149918	C3orf24	0.53	4.48	0.34	1.43e-5	Alzheimer's disease;
PAAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-5.62	-0.42	8.69e-8	Monocyte count;
PAAD	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg14132834	chr19:41945861	ATP5SL	-0.5	-4.85	-0.37	3.07e-6	Height;
PAAD	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.51	-0.47	1.04e-9	Crohn's disease;
PAAD	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-5.98	-0.44	1.5e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02450064	chr17:40260053	DHX58	-0.37	-4.3	-0.33	3.03e-5	Fibrinogen levels;
PAAD	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	5.84	0.43	2.99e-8	Body mass index;
PAAD	cis	rs7210086	0.821	rs3935123	chr17:70641183	C/T	cg04206342	chr17:70636940	NA	0.4	5.38	0.4	2.79e-7	Ulcerative colitis;
PAAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg03676636	chr4:99064102	C4orf37	0.33	5.75	0.42	4.72e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs863345	0.625	rs6427439	chr1:158460357	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.8	-0.36	3.73e-6	Pneumococcal bacteremia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25710630	chr15:40685225	C15orf23	-0.55	-6.7	-0.48	3.77e-10	Monocyte percentage of white cells;
PAAD	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.62	6.86	0.49	1.64e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.52	5.03	0.38	1.35e-6	Hip circumference;
PAAD	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.51	0.34	1.3e-5	IgG glycosylation;
PAAD	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.94	-0.43	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs73206853	0.614	rs116919748	chr12:110851422	C/T	cg12870014	chr12:110450643	ANKRD13A	1.04	5.48	0.41	1.76e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24729792	chr2:113192114	RGPD8;RGPD5	0.58	4.84	0.37	3.12e-6	Yeast infection;
PAAD	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg05294307	chr14:35346193	BAZ1A	-0.52	-4.94	-0.37	2.02e-6	Psoriasis;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg15193198	chr20:60906057	LAMA5	-0.41	-4.55	-0.35	1.11e-5	Pelvic organ prolapse;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg11965913	chr1:205819406	PM20D1	0.59	4.94	0.37	2.07e-6	Prostate-specific antigen levels;
PAAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg05042697	chr2:10830656	NOL10	0.44	4.38	0.33	2.2e-5	Prostate cancer;
PAAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.78	-7.82	-0.54	8.2e-13	Menopause (age at onset);
PAAD	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.5	-5.41	-0.4	2.37e-7	Mitral valve prolapse;
PAAD	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.54e-6	Electrocardiographic conduction measures;
PAAD	cis	rs508970	0.556	rs662151	chr11:60923692	C/T	cg24692310	chr11:60915630	VPS37C	0.34	4.7	0.36	5.9e-6	Rheumatoid arthritis;
PAAD	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg08992911	chr2:238395768	MLPH	0.64	6.14	0.45	7.04e-9	Prostate cancer;
PAAD	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.41	4.27	0.33	3.48e-5	Gut microbiome composition (winter);
PAAD	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1018697	1.000	rs10786710	chr10:104548739	C/T	cg04362960	chr10:104952993	NT5C2	0.6	6.11	0.44	8.03e-9	Colorectal adenoma (advanced);
PAAD	cis	rs1982963	0.502	rs2073620	chr14:52500328	T/C	cg20550154	chr14:52487779	NID2	0.57	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg19729930	chr2:74357872	NA	0.98	10.68	0.65	3.32e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19671926	chr4:122722719	EXOSC9	0.6	5.7	0.42	6.13e-8	Type 2 diabetes;
PAAD	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg04165759	chr1:150448943	RPRD2	0.48	4.94	0.37	2.04e-6	Migraine;
PAAD	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-1.01	-7.15	-0.5	3.39e-11	Post bronchodilator FEV1;
PAAD	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.75	9.42	0.61	7.11e-17	Alcohol dependence;
PAAD	trans	rs901683	1.000	rs12768131	chr10:45986448	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.84	0.49	1.81e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg04450456	chr4:17643702	FAM184B	0.48	4.96	0.37	1.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322817	0.691	rs6922441	chr6:105216405	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-5.51	-0.41	1.5e-7	Thyroid stimulating hormone;
PAAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.93	-0.43	1.98e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11754676	chr12:133706789	ZNF10	0.59	6.77	0.48	2.66e-10	Metabolite levels  (X-11787);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24798493	chr7:5463336	TNRC18	0.6	6.8	0.48	2.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.54	-0.35	1.14e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.74	8.31	0.56	4.96e-14	Coronary artery disease;
PAAD	cis	rs7264396	0.832	rs224349	chr20:34045392	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs2446066	0.872	rs114075368	chr12:53801744	T/G	cg14275095	chr12:52828633	KRT75	-0.57	-4.27	-0.33	3.41e-5	Red blood cell count;
PAAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.63	0.57	7.58e-15	Hip circumference adjusted for BMI;
PAAD	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.8	-6.98	-0.49	8.72e-11	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg00792783	chr2:198669748	PLCL1	-0.46	-4.26	-0.33	3.51e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	-0.45	-4.41	-0.34	1.94e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg01075559	chr1:2537774	MMEL1	-0.48	-5.08	-0.38	1.1e-6	Ulcerative colitis;
PAAD	cis	rs7896691	0.777	rs7907949	chr10:3148056	G/A	cg15228268	chr10:3146741	PFKP	0.88	4.6	0.35	8.66e-6	Disc degeneration (lumbar);
PAAD	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.57	4.98	0.37	1.74e-6	Common traits (Other);
PAAD	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs4965869	0.866	rs28521402	chr15:101976951	A/C	cg12371147	chr15:101978424	PCSK6	-0.51	-4.51	-0.34	1.31e-5	Platelet-derived growth factor BB levels;
PAAD	cis	rs757081	0.867	rs2521999	chr11:17333183	G/A	cg15432903	chr11:17409602	KCNJ11	-0.65	-6.26	-0.45	3.71e-9	Systolic blood pressure;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg05053108	chr12:120632772	GCN1L1	0.56	6.73	0.48	3.3e-10	Metabolite levels  (X-11787);
PAAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg05341575	chr12:125625032	AACS	-0.54	-5.1	-0.38	1.01e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg26513180	chr16:89883248	FANCA	0.73	8.8	0.58	2.84e-15	Vitiligo;
PAAD	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg08992911	chr2:238395768	MLPH	0.68	6.47	0.46	1.3e-9	Prostate cancer;
PAAD	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg05874882	chr4:1763078	NA	-0.36	-5.08	-0.38	1.07e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg21191810	chr6:118973309	C6orf204	-0.51	-4.9	-0.37	2.45e-6	Diastolic blood pressure;
PAAD	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg26394196	chr10:1453818	ADARB2	-0.56	-6.43	-0.46	1.58e-9	Radiation response;
PAAD	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06850241	chr22:41845214	NA	0.53	4.43	0.34	1.81e-5	Vitiligo;
PAAD	cis	rs8105895	1.000	rs8105895	chr19:22215457	C/T	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.28	0.33	3.31e-5	Bipolar disorder;
PAAD	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg12700319	chr1:8272199	NA	-0.39	-4.3	-0.33	3.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg05085585	chr16:30420623	ZNF771	0.44	4.34	0.33	2.64e-5	Tonsillectomy;
PAAD	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.81	6.33	0.46	2.58e-9	Weight;
PAAD	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	cis	rs6715793	0.901	rs62146678	chr2:33401764	C/T	cg26672287	chr2:33391915	LTBP1	-0.45	-5.26	-0.39	4.83e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7627468	0.657	rs937626	chr3:121971802	G/A	cg17240004	chr3:121949083	CASR	0.51	4.82	0.36	3.52e-6	Kidney stones;
PAAD	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.11	0.55	1.61e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.32	-0.33	2.8e-5	Life satisfaction;
PAAD	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.07	-0.55	2e-13	Chronic sinus infection;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20348895	chr7:76163353	NA	-0.53	-6.37	-0.46	2.18e-9	Monocyte percentage of white cells;
PAAD	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.49	5.21	0.39	5.92e-7	Fibrinogen levels;
PAAD	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-4.76	-0.36	4.56e-6	Blood metabolite levels;
PAAD	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.5	-5.28	-0.39	4.34e-7	Metabolite levels;
PAAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg19630374	chr17:18023558	MYO15A	-0.46	-4.78	-0.36	4.15e-6	Total body bone mineral density;
PAAD	cis	rs533581	0.789	rs1673931	chr16:88976477	T/C	cg16701003	chr16:89028210	CBFA2T3	0.55	5.47	0.41	1.81e-7	Social autistic-like traits;
PAAD	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.72	-6.65	-0.47	4.99e-10	Primary sclerosing cholangitis;
PAAD	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma;
PAAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.15	16.83	0.81	1.54e-36	Cognitive function;
PAAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg27326032	chr3:127006922	NA	-0.7	-6.58	-0.47	7.03e-10	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs6785206	0.614	rs59241698	chr3:128509248	G/T	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg23346134	chr3:49453900	TCTA	0.41	4.38	0.33	2.23e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg20406979	chr6:167373233	NA	0.35	4.87	0.37	2.73e-6	Crohn's disease;
PAAD	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg02683114	chr2:24398427	C2orf84	0.61	6.85	0.49	1.69e-10	Asthma;
PAAD	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.48	-4.34	-0.33	2.64e-5	Corneal astigmatism;
PAAD	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg20913747	chr6:44695427	NA	-0.65	-6.55	-0.47	8.55e-10	Total body bone mineral density;
PAAD	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.67	-5.24	-0.39	5.17e-7	Mean platelet volume;
PAAD	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.58	-6.87	-0.49	1.54e-10	Aortic root size;
PAAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.73	7.75	0.53	1.21e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.54	5.32	0.4	3.73e-7	Rheumatoid arthritis;
PAAD	cis	rs2798269	0.604	rs2488803	chr13:22159277	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.51	-4.72	-0.36	5.31e-6	PR segment;
PAAD	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.1	-0.44	8.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1032355	0.558	rs745074	chr4:100532802	T/A	cg10031042	chr4:101090547	NA	0.57	4.25	0.33	3.67e-5	Celiac disease;
PAAD	cis	rs12753920	0.775	rs17578686	chr1:92678105	G/A	cg00856177	chr1:93645673	TMED5;CCDC18	-0.47	-4.44	-0.34	1.75e-5	Systemic lupus erythematosus;
PAAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.72	-7.56	-0.52	3.46e-12	Age at first birth;
PAAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs3753841	0.832	rs11164600	chr1:103244342	T/C	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg13406893	chr12:131568647	GPR133	-0.44	-4.31	-0.33	2.87e-5	Longevity;
PAAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-5.65	-0.42	7.57e-8	Initial pursuit acceleration;
PAAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg10290764	chr8:4849399	CSMD1	0.41	6.9	0.49	1.3e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.4	9.81	0.62	6.72e-18	Diabetic retinopathy;
PAAD	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg14768367	chr16:72042858	DHODH	-0.64	-4.7	-0.36	5.78e-6	Blood protein levels;
PAAD	cis	rs9467711	0.520	rs13211947	chr6:25864818	C/T	cg21479132	chr6:26055353	NA	0.86	4.3	0.33	3.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-1.06	-10.13	-0.63	9.31e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04180125	chr19:3557666	C19orf28	0.69	8.11	0.55	1.55e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.46	4.83	0.36	3.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.73	8.69	0.58	5.25e-15	Hand grip strength;
PAAD	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.55	-5.69	-0.42	6.3e-8	Breast size;
PAAD	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg21483461	chr5:81570383	RPS23	-0.51	-4.78	-0.36	4.04e-6	Breast cancer;
PAAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.46	5.12	0.38	9.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10267417	0.603	rs13307910	chr7:19858392	C/T	cg05791153	chr7:19748676	TWISTNB	0.84	5.45	0.4	1.97e-7	Night sleep phenotypes;
PAAD	cis	rs6076065	0.723	rs1936013	chr20:23363989	A/G	cg11657817	chr20:23433608	CST11	0.52	5.04	0.38	1.32e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg17192681	chr2:10953115	PDIA6	0.59	6.34	0.46	2.51e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9304742	0.888	rs8111514	chr19:53457246	G/A	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.39	-0.4	2.7e-7	Psoriasis;
PAAD	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.65	-5.47	-0.41	1.82e-7	Menarche (age at onset);
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.6	5.04	0.38	1.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg13859433	chr6:33739653	LEMD2	-0.62	-4.45	-0.34	1.65e-5	Schizophrenia;
PAAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.46	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg08648136	chr8:956695	NA	0.43	4.53	0.35	1.17e-5	Schizophrenia;
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18301423	chr5:131593218	PDLIM4	0.47	4.26	0.33	3.56e-5	Acylcarnitine levels;
PAAD	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg12560992	chr17:57184187	TRIM37	0.67	5.06	0.38	1.21e-6	Vitamin D levels;
PAAD	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.56	-5.13	-0.38	8.68e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg14346243	chr4:90757452	SNCA	-0.5	-4.39	-0.34	2.14e-5	Neuroticism;
PAAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.6	-5.89	-0.43	2.36e-8	Menarche (age at onset);
PAAD	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.92	-8.86	-0.58	1.98e-15	Body mass index;
PAAD	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.69	0.48	3.97e-10	High light scatter reticulocyte count;
PAAD	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	1.04	13.27	0.73	3.46e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg09597638	chr17:3907349	NA	0.65	4.54	0.35	1.13e-5	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
PAAD	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11731892	chr2:98207378	ANKRD36B	0.7	8.04	0.55	2.35e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.55	-7.48	-0.52	5.45e-12	Height;
PAAD	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.99	8.76	0.58	3.6e-15	Bipolar disorder;
PAAD	cis	rs773506	0.655	rs10991796	chr9:93930243	G/T	cg14446406	chr9:93919335	NA	-0.43	-5.76	-0.42	4.62e-8	Type 2 diabetes nephropathy;
PAAD	cis	rs58521262	0.516	rs10408398	chr19:23095426	A/G	cg03433597	chr19:22806448	NA	-0.25	-4.39	-0.34	2.1e-5	Testicular germ cell tumor;
PAAD	cis	rs6594713	0.533	rs13170795	chr5:112974969	A/G	cg12552261	chr5:112820674	MCC	0.75	4.92	0.37	2.2e-6	Brain cytoarchitecture;
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg05084668	chr3:125655381	ALG1L	-0.38	-4.29	-0.33	3.11e-5	Blood pressure (smoking interaction);
PAAD	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-8.42	-0.56	2.6e-14	Colorectal cancer;
PAAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.49	4.56	0.35	1.04e-5	Renal cell carcinoma;
PAAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.11	0.44	8.08e-9	Myopia (pathological);
PAAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.77e-5	Life satisfaction;
PAAD	cis	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg21605333	chr4:119757512	SEC24D	0.8	5.98	0.44	1.5e-8	Cannabis dependence symptom count;
PAAD	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.76	4.88	0.37	2.7e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg02966332	chr20:62369605	LIME1	-0.48	-4.52	-0.34	1.24e-5	Prostate cancer;
PAAD	cis	rs7627468	0.770	rs2173961	chr3:121968847	G/T	cg17240004	chr3:121949083	CASR	-0.47	-4.52	-0.34	1.23e-5	Kidney stones;
PAAD	trans	rs6694672	0.764	rs877897	chr1:197103975	G/A	cg26994526	chr18:47719735	MYO5B	-0.82	-6.55	-0.47	8.25e-10	Asthma;
PAAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14168621	chr7:2028884	MAD1L1	0.56	6.65	0.47	5.08e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.47	-5.1	-0.38	9.86e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2882667	0.690	rs288036	chr5:138210895	C/A	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.83	-7.66	-0.53	2.02e-12	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09461185	chr1:186649631	PTGS2	-0.56	-6.39	-0.46	1.97e-9	Body fat percentage;
PAAD	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg18551225	chr6:44695536	NA	-0.73	-7.44	-0.52	7.09e-12	Total body bone mineral density;
PAAD	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg08817983	chr4:3391423	RGS12	0.39	4.36	0.33	2.41e-5	Mean platelet volume;
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg11196182	chr7:1989412	MAD1L1	0.4	4.31	0.33	2.88e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg20636351	chr8:55087400	NA	-0.77	-8.11	-0.55	1.61e-13	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs992157	0.644	rs6741757	chr2:219182748	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.73	7.36	0.51	1.1e-11	Colorectal cancer;
PAAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.78	-8.7	-0.58	5.17e-15	Height;
PAAD	cis	rs10988802	0.673	rs4743091	chr9:98377191	A/G	cg16575184	chr9:99179480	ZNF367	0.59	4.3	0.33	3.07e-5	Chemerin levels;
PAAD	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.76	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg03252829	chr6:39282164	KCNK17	-0.56	-5.89	-0.43	2.38e-8	Type 2 diabetes;
PAAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	2.04e-10	Menopause (age at onset);
PAAD	cis	rs1642645	0.831	rs7541929	chr1:42479393	G/A	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs10905065	0.759	rs1533215	chr10:5869767	T/C	cg11519256	chr10:5708881	ASB13	0.54	4.76	0.36	4.43e-6	Menopause (age at onset);
PAAD	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.97	11.58	0.68	1.27e-22	Breast cancer;
PAAD	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.91	-7.29	-0.51	1.54e-11	Psoriasis;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21625146	chr5:486483	SLC9A3	-0.39	-5.0	-0.38	1.57e-6	Cystic fibrosis severity;
PAAD	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.17	0.39	7.2e-7	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.51	-5.92	-0.43	2.08e-8	Longevity;Endometriosis;
PAAD	cis	rs501120	0.564	rs4948857	chr10:44683281	C/T	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg11783602	chr8:55087084	NA	-0.5	-5.31	-0.4	3.87e-7	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs989128	0.517	rs1809284	chr17:48632310	A/G	cg16068336	chr17:48637367	CACNA1G	-0.58	-5.29	-0.39	4.21e-7	Type 2 diabetes;
PAAD	cis	rs6496932	0.663	rs8040940	chr15:85905048	G/A	cg19183879	chr15:85880815	NA	-0.54	-5.1	-0.38	1.01e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs10887741	0.646	rs1358865	chr10:89432645	C/A	cg13926569	chr10:89418898	PAPSS2	0.48	4.8	0.36	3.74e-6	Exercise (leisure time);
PAAD	cis	rs12799172	0.529	rs2741845	chr11:6819568	A/C	cg04793268	chr11:7728370	OVCH2	-0.4	-4.32	-0.33	2.78e-5	Periodontal disease-related phenotypes;
PAAD	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.22e-8	Subjective well-being;
PAAD	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.91	5.5	0.41	1.57e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs7627468	1.000	rs7639847	chr3:121949970	A/G	cg17240004	chr3:121949083	CASR	0.53	4.63	0.35	7.72e-6	Kidney stones;
PAAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg09473613	chr1:24152604	HMGCL	-0.42	-4.26	-0.33	3.54e-5	Immature fraction of reticulocytes;
PAAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.63	-6.09	-0.44	8.7e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.64	-0.35	7.37e-6	Body mass index;
PAAD	cis	rs528301	0.833	rs472140	chr2:45139904	C/T	cg15393275	chr2:45165193	NA	-0.52	-5.65	-0.42	7.86e-8	Alcohol and nicotine co-dependence;
PAAD	cis	rs11871801	1.000	rs12951640	chr17:40594298	G/A	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.62	-0.35	8.12e-6	Crohn's disease;
PAAD	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.96	13.9	0.75	7.16e-29	Age at first birth;
PAAD	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.29	-5.67	-0.42	6.86e-8	Urinary metabolites;
PAAD	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.45	0.61	5.9e-17	Platelet count;
PAAD	cis	rs10886094	0.881	rs4642994	chr10:119264842	C/T	cg09660043	chr10:118395444	PNLIPRP2	-0.43	-4.27	-0.33	3.49e-5	Photic sneeze reflex;
PAAD	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.1	9.41	0.61	7.47e-17	Red blood cell traits;
PAAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15145965	chr22:50218605	BRD1	0.6	4.96	0.37	1.87e-6	Schizophrenia;
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	4.85	0.37	3.08e-6	Vitiligo;
PAAD	cis	rs10214930	0.697	rs2391443	chr7:27625929	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.36	0.33	2.35e-5	Hypospadias;
PAAD	cis	rs375066	0.935	rs396973	chr19:44399306	C/T	cg11993925	chr19:44307056	LYPD5	-0.5	-6.45	-0.46	1.41e-9	Breast cancer;
PAAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.86	-10.25	-0.64	4.46e-19	Body mass index;
PAAD	cis	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-6.64	-0.47	5.29e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs17155006	0.563	rs451416	chr7:107738531	A/G	cg05962710	chr7:107745446	LAMB4	-0.54	-6.94	-0.49	1.07e-10	Pneumococcal bacteremia;
PAAD	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.64	4.42	0.34	1.84e-5	LDL cholesterol levels;
PAAD	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg19438565	chr8:143695827	ARC	-0.57	-5.56	-0.41	1.18e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.35	0.46	2.41e-9	Height;
PAAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.6	-0.35	8.91e-6	Aortic root size;
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.47	5.52	0.41	1.45e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11825685	0.895	rs73045858	chr11:134573292	A/G	cg06603561	chr11:134479413	NA	-0.61	-4.26	-0.33	3.53e-5	IgG glycosylation;
PAAD	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.09e-5	Renal cell carcinoma;
PAAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.79	7.94	0.54	4.25e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg01262667	chr19:19385393	TM6SF2	0.46	5.19	0.39	6.62e-7	Tonsillectomy;
PAAD	cis	rs7113874	0.802	rs10769936	chr11:8654528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.31	-0.33	2.95e-5	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-5.35	-0.4	3.25e-7	Renal function-related traits (BUN);
PAAD	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.74	-7.72	-0.53	1.46e-12	Cognitive function;
PAAD	cis	rs66530629	0.874	rs7535819	chr1:25173037	C/T	cg22509179	chr1:25234806	RUNX3	0.48	4.5	0.34	1.33e-5	Plateletcrit;
PAAD	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.82	-8.99	-0.59	9.07e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.24	0.64	4.76e-19	Menopause (age at onset);
PAAD	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.0	-0.38	1.59e-6	Diastolic blood pressure;
PAAD	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.17	-0.5	3.02e-11	Response to antipsychotic treatment;
PAAD	cis	rs9646944	0.501	rs10169676	chr2:103074919	G/A	cg20060108	chr2:102954350	IL1RL1	0.55	4.49	0.34	1.39e-5	Blood protein levels;
PAAD	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.8	0.58	2.8e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.43	-0.4	2.16e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs74874679	chr10:46050733	A/C	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10901513	0.932	rs2277217	chr10:127677676	G/A	cg22975853	chr10:127789788	ADAM12	0.44	4.65	0.35	7.14e-6	Visceral fat;
PAAD	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg03233332	chr7:66118400	NA	0.41	4.52	0.34	1.22e-5	Aortic root size;
PAAD	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.59	5.31	0.4	3.88e-7	Blood pressure;
PAAD	cis	rs9659323	1.000	rs6700415	chr1:119516174	A/T	cg17326555	chr1:119535693	NA	-0.41	-5.36	-0.4	3.07e-7	Body mass index;
PAAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg00334542	chr7:100209784	MOSPD3	-0.74	-5.55	-0.41	1.22e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.35	-0.33	2.53e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.91	-6.77	-0.48	2.57e-10	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11696501	0.739	rs6017637	chr20:44264190	G/A	cg11783356	chr20:44313418	WFDC10B	-0.62	-5.37	-0.4	2.83e-7	Brain structure;
PAAD	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs4668356	1.000	rs73013453	chr2:171998984	C/A	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.99	7.16	0.5	3.15e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8014252	0.803	rs12587714	chr14:71004376	G/C	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs3736485	0.966	rs11634180	chr15:51895757	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.32	-0.33	2.86e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7572263	0.916	rs12995124	chr2:209057014	G/C	cg23998903	chr2:209048830	C2orf80	0.48	4.44	0.34	1.72e-5	Glioma;Non-glioblastoma glioma;
PAAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg11766577	chr21:47581405	C21orf56	-0.41	-4.66	-0.35	6.75e-6	Testicular germ cell tumor;
PAAD	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.46	4.7	0.36	5.73e-6	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19346786	chr7:2764209	NA	-0.32	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg24110177	chr3:50126178	RBM5	0.57	4.4	0.34	2.04e-5	Menarche (age at onset);
PAAD	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.35	4.57	0.35	1.01e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.41	5.05	0.38	1.28e-6	Iron status biomarkers;
PAAD	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.51	-4.44	-0.34	1.75e-5	Serum parathyroid hormone levels;
PAAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.46	4.97	0.37	1.76e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.67	-5.73	-0.42	5.31e-8	Systemic lupus erythematosus;
PAAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13012494	chr21:47604986	C21orf56	0.47	4.96	0.37	1.83e-6	Testicular germ cell tumor;
PAAD	cis	rs2242420	0.920	rs6679565	chr1:21962551	A/G	cg26362272	chr1:22108717	USP48	-0.56	-4.41	-0.34	1.91e-5	Hematological and biochemical traits;
PAAD	cis	rs59888335	0.862	rs1157326	chr3:80538408	C/T	cg21735741	chr3:80819488	NA	0.59	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05048922	chr8:6565434	AGPAT5	0.63	6.98	0.49	8.79e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21397480	chr6:15246396	JARID2	0.63	7.21	0.5	2.43e-11	Monocyte percentage of white cells;
PAAD	cis	rs2061333	0.557	rs2168778	chr19:44631219	T/C	cg18700516	chr19:44507157	ZNF230	-0.79	-5.56	-0.41	1.21e-7	Alzheimer's disease;
PAAD	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.6	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg02404636	chr22:31891804	SFI1	0.64	6.1	0.44	8.54e-9	Colorectal cancer;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.71	-0.36	5.43e-6	Lung cancer;
PAAD	cis	rs1045714	0.943	rs1045711	chr7:2653571	C/T	cg20813462	chr7:2646259	IQCE	0.62	4.25	0.33	3.71e-5	Urate levels in lean individuals;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26372423	chr22:20067491	DGCR8	0.64	6.75	0.48	2.97e-10	Myopia (pathological);
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg08132940	chr7:1081526	C7orf50	-0.56	-4.34	-0.33	2.6e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs6074578	0.582	rs1469781	chr20:170642	G/A	cg16931068	chr20:139680	DEFB127	-0.36	-4.98	-0.37	1.7e-6	Hirschsprung disease;
PAAD	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.24	0.39	5.33e-7	Rheumatoid arthritis;
PAAD	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6782025	0.837	rs1688679	chr3:120760495	T/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.75	8.68	0.58	5.7e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs2112743	0.704	rs12653730	chr5:144728805	C/G	cg16512364	chr13:50513235	NA	0.42	6.31	0.46	2.96e-9	Acoustic startle blink response;
PAAD	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.82	-9.67	-0.62	1.55e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg18612461	chr15:75251733	NA	-0.39	-4.58	-0.35	9.52e-6	Systemic lupus erythematosus;
PAAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.61	6.97	0.49	9e-11	Prostate cancer;
PAAD	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	6.1	0.44	8.51e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs216303	1.000	rs216298	chr12:6156477	C/T	cg12895370	chr12:6755816	ACRBP	-0.5	-4.41	-0.34	1.96e-5	Low vWF levels;
PAAD	cis	rs7188861	0.681	rs34294744	chr16:11407623	C/G	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs13065560	0.659	rs4234135	chr3:38882479	C/T	cg01426195	chr3:39028469	NA	-0.52	-5.39	-0.4	2.59e-7	Interleukin-18 levels;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.9	7.13	0.5	3.78e-11	Chronic kidney disease;
PAAD	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg04287289	chr16:89883240	FANCA	0.93	4.63	0.35	7.91e-6	Skin colour saturation;
PAAD	cis	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.78	-4.96	-0.37	1.86e-6	Mononucleosis;
PAAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs7577696	0.785	rs12611678	chr2:32347785	G/A	cg02381751	chr2:32503542	YIPF4	-0.49	-4.83	-0.36	3.28e-6	Inflammatory biomarkers;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25084332	chr12:62997409	MIRLET7I;C12orf61	0.69	7.81	0.54	8.75e-13	Myopia (pathological);
PAAD	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	6.61	0.47	6.2e-10	Gastritis;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg22868518	chr11:507468	RNH1	-0.91	-4.78	-0.36	4.17e-6	Body mass index;
PAAD	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.42	-4.33	-0.33	2.71e-5	Asthma;
PAAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1007738	0.542	rs2279438	chr11:47204175	A/T	cg19486271	chr11:47235900	DDB2	-0.62	-5.72	-0.42	5.52e-8	Bone mineral density (hip);
PAAD	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.8	7.14	0.5	3.57e-11	Recombination rate (females);
PAAD	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.43	-4.49	-0.34	1.39e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg19930314	chr7:98593876	TRRAP	-0.48	-4.61	-0.35	8.33e-6	Breast cancer;
PAAD	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.74	-5.4	-0.4	2.47e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.46	5.62	0.41	9.05e-8	Sitting height ratio;
PAAD	cis	rs1497828	0.912	rs2815231	chr1:217538165	T/G	cg04411442	chr1:217543379	NA	-0.48	-4.73	-0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs561655	0.525	rs10898438	chr11:85858253	G/A	cg07180834	chr11:85838833	NA	-0.43	-4.79	-0.36	3.87e-6	Alzheimer's disease (late onset);
PAAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.54	-0.35	1.12e-5	Obesity-related traits;
PAAD	cis	rs58521262	0.556	rs289345	chr19:23148881	G/A	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.85	0.37	3.01e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.69	7.63	0.53	2.34e-12	Schizophrenia;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg20988073	chr3:125900093	ALDH1L1	-0.52	-5.67	-0.42	6.94e-8	Metabolite levels;
PAAD	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs758324	0.812	rs3756287	chr5:131135478	A/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7714584	1.000	rs76548544	chr5:150223515	T/A	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	trans	rs901683	0.850	rs74500471	chr10:46031735	A/T	cg11747279	chr17:21096632	NA	0.88	6.67	0.48	4.45e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12701112	chr3:187458780	BCL6	0.49	4.97	0.37	1.82e-6	Myopia (pathological);
PAAD	cis	rs76866386	0.892	rs77725792	chr2:44058201	G/A	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.85	-5.04	-0.38	1.32e-6	Cholesterol, total;
PAAD	cis	rs9323205	1.000	rs56298119	chr14:51591932	T/G	cg23942311	chr14:51606299	NA	-0.54	-4.92	-0.37	2.25e-6	Cancer;
PAAD	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-6.69	-0.48	4.02e-10	Coffee consumption (cups per day);
PAAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.7	-7.41	-0.52	8.08e-12	Coronary artery disease;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg03289416	chr15:75166202	SCAMP2	0.52	5.32	0.4	3.57e-7	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06250734	chr16:46723432	ORC6L;VPS35	0.57	6.6	0.47	6.41e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	7.08e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.54	6.66	0.48	4.76e-10	Crohn's disease;
PAAD	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg02670123	chr2:173330395	ITGA6	0.23	4.43	0.34	1.8e-5	Myopia;
PAAD	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-5.81	-0.43	3.49e-8	Blood protein levels;
PAAD	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-4.44	-0.34	1.75e-5	Schizophrenia;
PAAD	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.63	-6.06	-0.44	1.04e-8	White matter hyperintensity burden;
PAAD	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-4.47	-0.34	1.49e-5	Mood instability;
PAAD	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	6.59	0.47	6.7e-10	Schizophrenia;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02725872	chr8:58115012	NA	0.74	5.71	0.42	5.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg00086871	chr4:6988644	TBC1D14	0.84	4.46	0.34	1.58e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.93	10.9	0.66	8.21e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg09659197	chr4:152720779	NA	-0.47	-6.49	-0.47	1.12e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg21823605	chr1:152486609	CRCT1	0.52	6.76	0.48	2.8e-10	Hair morphology;
PAAD	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.38	0.46	1.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg18769074	chr3:133464867	TF	0.42	4.87	0.37	2.78e-6	Iron status biomarkers;
PAAD	cis	rs7070678	0.638	rs61849289	chr10:29796378	T/C	cg24726783	chr10:29759454	SVIL	-0.48	-4.55	-0.35	1.09e-5	Platelet thrombus formation;
PAAD	cis	rs9677476	0.821	rs6731682	chr2:232106245	G/C	cg07929768	chr2:232055508	NA	0.38	4.29	0.33	3.13e-5	Food antigen IgG levels;
PAAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19346786	chr7:2764209	NA	-0.39	-5.12	-0.38	9.02e-7	Height;
PAAD	cis	rs12304921	0.872	rs4768869	chr12:51347029	G/A	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.19	-0.39	6.74e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20206224	chr6:43543771	POLH;XPO5	0.6	6.99	0.49	8.16e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21780326	chr11:100558100	FLJ32810	0.54	6.31	0.46	2.95e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2526932	0.625	rs4903032	chr14:73049639	A/G	cg13588403	chr14:73209128	DPF3	-0.41	-5.48	-0.41	1.72e-7	C-reactive protein and white blood cell count;
PAAD	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19671926	chr4:122722719	EXOSC9	-0.64	-6.18	-0.45	5.48e-9	Type 2 diabetes;
PAAD	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.48	-4.3	-0.33	3.02e-5	Hypospadias;
PAAD	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	4.78	0.36	4.04e-6	Mood instability;
PAAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.11e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.72	8.17	0.55	1.13e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.34	0.56	4.11e-14	Mean corpuscular volume;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.9	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg25635251	chr11:2234043	NA	-0.7	-5.78	-0.42	4.09e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg09998033	chr7:158218633	PTPRN2	0.68	7.41	0.52	8.15e-12	Obesity-related traits;
PAAD	cis	rs2077654	0.822	rs4148627	chr11:17436271	G/A	cg25308976	chr11:17434268	ABCC8	0.92	6.22	0.45	4.49e-9	Gout;
PAAD	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg09127314	chr1:152161683	NA	-0.67	-4.68	-0.35	6.29e-6	Atopic dermatitis;
PAAD	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg07469887	chr10:131262384	NA	-0.46	-5.72	-0.42	5.43e-8	Response to temozolomide;
PAAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.4	-5.21	-0.39	6.08e-7	Colorectal cancer;
PAAD	cis	rs8105895	0.935	rs62110981	chr19:22246013	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.25	-0.33	3.71e-5	Body mass index (change over time);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg14235350	chr6:157802496	ZDHHC14	-0.57	-6.38	-0.46	2.07e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.87	9.32	0.6	1.3e-16	Parkinson's disease;
PAAD	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg10495392	chr1:46806563	NSUN4	0.46	4.26	0.33	3.64e-5	Menopause (age at onset);
PAAD	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.59	6.37	0.46	2.12e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs13053817	0.898	rs16987627	chr22:29835060	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.17	-0.39	7.24e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.81	8.27	0.56	6.25e-14	Response to diuretic therapy;
PAAD	cis	rs11811982	0.793	rs116404973	chr1:227389640	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg06714761	chr1:201096289	NA	-0.3	-4.68	-0.35	6.43e-6	Permanent tooth development;
PAAD	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.69	4.81	0.36	3.58e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs4281086	0.729	rs7008169	chr8:10346177	C/T	cg01072821	chr8:10382165	T-SP1	0.46	4.49	0.34	1.38e-5	Obesity-related traits;
PAAD	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.55	-0.47	8.31e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.45	6.53	0.47	9.19e-10	Cutaneous nevi;
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.85	0.37	3.07e-6	Blood metabolite levels;
PAAD	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-4.35	-0.33	2.51e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06844452	chr4:3324881	RGS12	0.6	7.21	0.5	2.44e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14840081	chr7:152551660	ACTR3B	0.6	7.03	0.5	6.61e-11	Body fat percentage;
PAAD	cis	rs4739066	0.579	rs16929963	chr8:63876244	A/G	cg12194929	chr8:63776755	NKAIN3	0.73	4.54	0.35	1.13e-5	Myocardial infarction;
PAAD	cis	rs727479	0.523	rs700518	chr15:51529112	C/T	cg21478137	chr15:51532386	CYP19A1	-0.53	-5.25	-0.39	5e-7	Estradiol levels;
PAAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg07395648	chr5:131743802	NA	-0.58	-5.32	-0.4	3.62e-7	Blood metabolite levels;
PAAD	cis	rs11203032	0.831	rs2902445	chr10:90934154	A/G	cg16672925	chr10:90967113	CH25H	0.72	5.57	0.41	1.13e-7	Heart failure;
PAAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.76	8.5	0.57	1.67e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13311886	chr15:22979752	CYFIP1	0.54	6.74	0.48	3.09e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07685180	chr8:600429	NA	0.92	6.66	0.48	4.83e-10	IgG glycosylation;
PAAD	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-5.67	-0.42	6.92e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4747197	1.000	rs10466026	chr10:73550969	G/A	cg04506911	chr10:72937119	NA	0.41	4.5	0.34	1.34e-5	Progranulin levels;
PAAD	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.19	-0.39	6.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg22143635	chr11:980567	AP2A2	0.53	5.65	0.42	7.56e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.38	1.64e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2117029	0.586	rs6580701	chr12:49557265	C/G	cg05368762	chr12:50135785	TMBIM6	0.46	4.5	0.34	1.33e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06850241	chr22:41845214	NA	-0.58	-4.72	-0.36	5.32e-6	Vitiligo;
PAAD	cis	rs2424590	1.000	rs2424591	chr20:23637093	G/T	cg16589663	chr20:23618590	CST3	-0.77	-4.87	-0.37	2.78e-6	Blood protein levels;
PAAD	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.7	-6.98	-0.49	8.51e-11	Uric acid levels;
PAAD	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.83	9.44	0.61	6.15e-17	Metabolic syndrome;
PAAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.68	0.42	6.6e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	8.65	0.57	6.93e-15	Chronic sinus infection;
PAAD	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.59	-4.82	-0.36	3.42e-6	Diabetic retinopathy;
PAAD	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg14481604	chr15:25334117	SNORD116-22	0.45	4.35	0.33	2.52e-5	Blood osmolality (transformed sodium);
PAAD	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.66	6.55	0.47	8.27e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.82	6.46	0.46	1.32e-9	Brain cytoarchitecture;
PAAD	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.96	-8.69	-0.58	5.54e-15	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24824245	chr12:22198725	CMAS	-0.7	-7.48	-0.52	5.54e-12	Obesity-related traits;
PAAD	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg27170260	chr1:38156575	C1orf109	-0.45	-4.28	-0.33	3.25e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg18093559	chr17:18951025	GRAP	0.47	5.05	0.38	1.25e-6	Schizophrenia;
PAAD	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.69	6.77	0.48	2.69e-10	Schizophrenia;
PAAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg23119463	chr10:134592391	INPP5A	-0.49	-4.55	-0.35	1.08e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.26	-4.83	-0.36	3.29e-6	IgG glycosylation;
PAAD	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.92	10.88	0.66	9.32e-21	Sudden cardiac arrest;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20046875	chr15:72766637	ARIH1	0.66	7.0	0.49	7.72e-11	Myopia (pathological);
PAAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg06671706	chr8:8559999	CLDN23	0.75	7.36	0.51	1.11e-11	Obesity-related traits;
PAAD	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg11271282	chr2:238384023	NA	0.49	4.47	0.34	1.55e-5	Prostate cancer;
PAAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg01075559	chr1:2537774	MMEL1	-0.5	-5.21	-0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.85e-5	Skin colour saturation;
PAAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08219700	chr8:58056026	NA	0.67	5.38	0.4	2.71e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs76866386	1.000	rs76866386	chr2:44075483	T/C	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.95	-5.63	-0.42	8.49e-8	Cholesterol, total;
PAAD	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg15017067	chr4:17643749	FAM184B	0.48	5.24	0.39	5.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12760731	0.641	rs12691479	chr1:178328754	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs1419980	0.558	rs74057892	chr12:7768803	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.23	10.3	0.64	3.3e-19	Uric acid levels;
PAAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-7.16	-0.5	3.17e-11	Neuroticism;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.9	10.98	0.67	5.07e-21	Menarche (age at onset);
PAAD	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	12.92	0.72	3e-26	Platelet count;
PAAD	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.59	-7.27	-0.51	1.74e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.87	-7.64	-0.53	2.26e-12	Recombination rate (females);
PAAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.55	-5.53	-0.41	1.36e-7	Multiple myeloma (IgH translocation);
PAAD	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs5742933	1.000	rs5743061	chr2:190694266	A/C	cg04003228	chr2:190539410	ANKAR	-0.58	-4.4	-0.34	1.99e-5	Ferritin levels;
PAAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs548726	1.000	rs548726	chr1:5913621	C/T	cg07599881	chr1:5907508	NA	-0.43	-4.73	-0.36	5.16e-6	Response to taxane treatment (placlitaxel);
PAAD	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.26	-0.51	1.83e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs682748	0.791	rs1875538	chr5:17145198	C/A	cg23987134	chr5:17158319	LOC285696	-0.37	-4.67	-0.35	6.58e-6	Hippocampal atrophy;
PAAD	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.84	-10.14	-0.64	9.15e-19	Brugada syndrome;
PAAD	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg01064725	chr1:204461714	NA	-0.51	-4.66	-0.35	6.91e-6	Schizophrenia;
PAAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.59	-4.38	-0.33	2.24e-5	Initial pursuit acceleration;
PAAD	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg05791153	chr7:19748676	TWISTNB	0.64	4.91	0.37	2.34e-6	Thyroid stimulating hormone;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.81	-0.36	3.53e-6	Life satisfaction;
PAAD	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	9.62	0.62	2.14e-17	Smoking behavior;
PAAD	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6782228	0.675	rs56141228	chr3:128386042	C/T	cg16766828	chr3:128327626	NA	-0.46	-6.1	-0.44	8.4e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg17644776	chr2:200775616	C2orf69	-0.68	-5.88	-0.43	2.56e-8	Schizophrenia;
PAAD	cis	rs12681288	0.578	rs73176535	chr8:971916	C/T	cg15309053	chr8:964076	NA	0.6	6.75	0.48	2.93e-10	Schizophrenia;
PAAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg18551225	chr6:44695536	NA	-0.69	-6.94	-0.49	1.08e-10	Total body bone mineral density;
PAAD	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs9657904	0.826	rs4894957	chr3:105578155	T/C	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.82	-0.36	3.38e-6	Aortic root size;
PAAD	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg00207856	chr7:1054120	C7orf50	-0.48	-4.51	-0.34	1.3e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg26876637	chr1:152193138	HRNR	-0.81	-5.52	-0.41	1.45e-7	Atopic dermatitis;
PAAD	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.5	5.57	0.41	1.14e-7	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.81	9.53	0.61	3.58e-17	Coronary artery disease;
PAAD	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.47	-0.41	1.81e-7	Coronary artery disease;
PAAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.84	6.57	0.47	7.55e-10	Menarche (age at onset);
PAAD	cis	rs501120	0.640	rs10900001	chr10:44695585	C/G	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg22143856	chr6:28129313	ZNF389	-0.69	-5.53	-0.41	1.36e-7	Depression;
PAAD	cis	rs10512697	0.655	rs34428582	chr5:3503596	A/G	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.42	7.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14890726	chr3:113233993	CCDC52	0.58	6.29	0.45	3.19e-9	Monocyte percentage of white cells;
PAAD	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.72	-7.75	-0.53	1.21e-12	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	8.88	0.58	1.8e-15	Alzheimer's disease;
PAAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.94	12.49	0.71	4.31e-25	Menopause (age at onset);
PAAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.51	4.76	0.36	4.43e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-5.14	-0.38	8.24e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.84	0.62	5.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs62025270	0.632	rs62022918	chr15:86218284	C/G	cg13263323	chr15:86062960	AKAP13	0.5	4.46	0.34	1.6e-5	Idiopathic pulmonary fibrosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06916552	chr4:139936817	CCRN4L	-0.75	-6.3	-0.46	3.13e-9	Neuroticism;
PAAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg19761014	chr17:28927070	LRRC37B2	0.87	5.67	0.42	7.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.46	6.34	0.46	2.52e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.54	5.77	0.42	4.22e-8	Obesity-related traits;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	8.54	0.57	1.33e-14	Lymphocyte counts;
PAAD	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.32	0.33	2.85e-5	Educational attainment;
PAAD	cis	rs4727443	0.736	rs4727444	chr7:99614851	T/A	cg22004693	chr7:99632812	ZKSCAN1	0.45	4.37	0.33	2.25e-5	Interstitial lung disease;
PAAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.58	-4.88	-0.37	2.71e-6	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg26338869	chr17:61819248	STRADA	0.51	4.82	0.36	3.43e-6	Height;
PAAD	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.37	9.8	0.62	7.1e-18	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.62	7.01	0.49	7.43e-11	Emphysema distribution in smoking;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04358685	chr3:12598421	MKRN2	0.67	6.86	0.49	1.67e-10	Obesity-related traits;
PAAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs12304921	0.816	rs67478184	chr12:51508050	C/T	cg04427360	chr12:51347099	HIGD1C	-0.65	-4.84	-0.37	3.19e-6	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.2	0.39	6.36e-7	Life satisfaction;
PAAD	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07157834	chr1:205819609	PM20D1	0.65	6.84	0.49	1.84e-10	Prostate cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10947003	chr16:67218230	KIAA0895L	0.71	8.13	0.55	1.43e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.73	7.42	0.52	7.6e-12	Asperger disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24823485	chr3:42626083	NA	-0.67	-6.74	-0.48	3.08e-10	Obesity-related traits;
PAAD	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.48	-4.31	-0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4523957	0.553	rs2131703	chr17:2025360	G/T	cg16513277	chr17:2031491	SMG6	-0.67	-7.01	-0.49	7.19e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs75920871	0.920	rs4938336	chr11:116948442	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.25	-0.33	3.71e-5	Subjective well-being;
PAAD	cis	rs12304921	1.000	rs73295896	chr12:51351846	G/C	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.8	-9.18	-0.6	2.98e-16	Lung cancer;
PAAD	cis	rs7165102	1.000	rs11636148	chr15:65796880	C/T	cg22900193	chr15:65823441	PTPLAD1	-0.48	-4.52	-0.34	1.22e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg08898775	chr15:59042684	ADAM10	0.41	5.39	0.4	2.66e-7	Schizophrenia;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg18357526	chr6:26021779	HIST1H4A	0.67	6.46	0.46	1.33e-9	Blood metabolite levels;
PAAD	cis	rs189798	0.738	rs330911	chr8:8996273	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	5.13	0.38	8.55e-7	Myopia (pathological);
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.73	9.32	0.6	1.28e-16	Cardiovascular disease risk factors;
PAAD	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.69	7.03	0.5	6.42e-11	Body mass index;
PAAD	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.72	7.14	0.5	3.66e-11	Osteoporosis;
PAAD	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	1.0	14.06	0.75	2.69e-29	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.72	0.58	4.6e-15	Coffee consumption (cups per day);
PAAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.63e-11	Eye color traits;
PAAD	cis	rs2320952	0.817	rs8081158	chr17:10487876	G/A	cg19806995	chr17:9728972	GLP2R	0.4	4.53	0.35	1.17e-5	Gut microbiome composition (winter);
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.54	-4.98	-0.37	1.67e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.49	4.81	0.36	3.65e-6	Airway imaging phenotypes;
PAAD	cis	rs6700896	0.931	rs7546242	chr1:66093030	C/T	cg04111102	chr1:66153794	NA	0.48	5.36	0.4	3.08e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.88	-8.38	-0.56	3.29e-14	Homoarginine levels;
PAAD	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.46	7.05	0.5	5.91e-11	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.67	-5.36	-0.4	2.98e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180233	0.892	rs6670197	chr1:30662181	C/G	cg06703062	chr1:31191648	MATN1	-0.49	-4.32	-0.33	2.78e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.85	10.93	0.66	6.8e-21	Aortic root size;
PAAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg07153921	chr17:41440717	NA	-0.42	-4.39	-0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.75	8.16	0.55	1.21e-13	Migraine;Coronary artery disease;
PAAD	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs4787491	0.704	rs35605010	chr16:30033428	A/G	cg06015834	chr16:30021696	DOC2A	-0.41	-4.33	-0.33	2.64e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg25783544	chr11:47291846	MADD	0.55	4.49	0.34	1.42e-5	HDL cholesterol;
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22736956	chr11:64893575	MRPL49	-0.53	-6.5	-0.47	1.07e-9	Monocyte percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12559670	chr7:1610220	PSMG3;KIAA1908	-0.56	-6.36	-0.46	2.23e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg11262906	chr1:85462892	MCOLN2	0.63	4.79	0.36	3.86e-6	Serum sulfate level;
PAAD	cis	rs9479482	0.686	rs2184452	chr6:150384827	T/C	cg08316699	chr6:150357289	NA	0.39	4.58	0.35	9.79e-6	Alopecia areata;
PAAD	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-6.32	-0.46	2.77e-9	Monocyte count;
PAAD	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.35	0.4	3.15e-7	Monocyte percentage of white cells;
PAAD	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg19254793	chr6:44695348	NA	-0.45	-4.33	-0.33	2.64e-5	Total body bone mineral density;
PAAD	cis	rs1891275	0.551	rs4933690	chr10:93419567	G/A	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.88	11.21	0.67	1.22e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7122937	0.861	rs7948693	chr11:2480473	C/G	cg27115973	chr11:2481206	KCNQ1	0.54	4.28	0.33	3.35e-5	QT interval;
PAAD	cis	rs4690686	0.500	rs35703625	chr4:177263286	G/A	cg17059388	chr4:177262070	NA	0.61	6.11	0.44	7.87e-9	Essential tremor;
PAAD	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg24562669	chr7:97807699	LMTK2	0.48	7.03	0.5	6.61e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg06375148	chr1:209958343	C1orf74	0.66	4.88	0.37	2.65e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.59	6.89	0.49	1.39e-10	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg05555928	chr11:63887634	MACROD1	-0.72	-5.58	-0.41	1.1e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-5.94	-0.43	1.85e-8	Body mass index;
PAAD	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg23112188	chr14:24563095	PCK2	0.47	5.14	0.38	8.24e-7	IgG glycosylation;
PAAD	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg10295955	chr4:187884368	NA	-1.03	-16.59	-0.8	6.16e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs9628987	1.000	rs11584095	chr1:8387779	G/A	cg14413262	chr1:8384046	SLC45A1	-0.62	-4.53	-0.34	1.19e-5	Breast cancer;
PAAD	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.31	5.96	0.44	1.66e-8	Skin colour saturation;
PAAD	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.48	-0.34	1.47e-5	Dermatomyositis;
PAAD	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg14146966	chr2:61757674	XPO1	-0.39	-4.83	-0.36	3.26e-6	Tuberculosis;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26493532	chr18:55254078	FECH	0.74	6.76	0.48	2.82e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6800768	0.633	rs59461522	chr3:24100377	G/A	cg10674438	chr3:24145617	LOC152024	-0.47	-4.34	-0.33	2.54e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg05134918	chr12:132603531	EP400NL	0.61	4.87	0.37	2.78e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.57	5.22	0.39	5.86e-7	Serum sulfate level;
PAAD	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26926768	chr12:34528122	NA	0.4	4.88	0.37	2.71e-6	Morning vs. evening chronotype;
PAAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.78	7.97	0.54	3.55e-13	Uric acid levels;
PAAD	cis	rs2070677	0.935	rs3020502	chr10:135381623	T/C	cg20169779	chr10:135381914	SYCE1	0.75	7.43	0.52	7.32e-12	Gout;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08161947	chr12:19592900	AEBP2	-0.55	-6.39	-0.46	1.95e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10189774	chr4:17578691	LAP3	0.6	6.79	0.48	2.36e-10	Monocyte percentage of white cells;
PAAD	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg26338869	chr17:61819248	STRADA	0.76	7.99	0.54	3.11e-13	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15045943	chr5:171614719	STK10	0.67	7.62	0.53	2.59e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.64	-5.94	-0.43	1.9e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.44	4.81	0.36	3.53e-6	Menarche (age at onset);
PAAD	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg23860436	chr12:58378763	NA	0.51	4.68	0.35	6.33e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg21665744	chr7:39171113	POU6F2	0.34	5.61	0.41	9.27e-8	IgG glycosylation;
PAAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.45	-4.52	-0.34	1.26e-5	Body mass index;
PAAD	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs7558233	0.614	rs59454437	chr2:23682476	A/G	cg00747342	chr2:23700632	KLHL29	0.66	4.25	0.33	3.7e-5	Cannabis use (initiation);
PAAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg14092988	chr3:52407081	DNAH1	0.42	5.21	0.39	6.08e-7	Bipolar disorder;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg14631576	chr9:95140430	CENPP	0.44	4.29	0.33	3.19e-5	Height;
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	12.29	0.71	1.5e-24	Platelet count;
PAAD	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg26898376	chr11:64110657	CCDC88B	0.44	4.7	0.36	5.68e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg00071950	chr4:10020882	SLC2A9	0.56	4.61	0.35	8.43e-6	Blood metabolite levels;
PAAD	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10090774	0.930	rs11774305	chr8:141981197	T/G	cg02508881	chr8:142216119	NA	-0.41	-4.38	-0.33	2.21e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.65	-5.33	-0.4	3.45e-7	IgG glycosylation;
PAAD	trans	rs10951933	0.632	rs2167876	chr7:47911320	G/A	cg05433557	chr7:158325024	PTPRN2	-0.55	-6.29	-0.45	3.29e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	trans	rs2309322	0.622	rs2309319	chr4:181239313	C/T	cg16231500	chr8:63998736	TTPA	-0.8	-6.29	-0.45	3.28e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.07	0.38	1.15e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs61542988	0.570	rs62448267	chr7:22822501	T/C	cg11367502	chr7:22862612	TOMM7	0.64	5.92	0.43	2.06e-8	Fibrinogen levels;
PAAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.52	4.62	0.35	8.2e-6	RR interval (heart rate);
PAAD	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.76	-5.67	-0.42	7.1e-8	Coronary artery calcification;
PAAD	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg26695010	chr11:65641043	EFEMP2	0.54	5.25	0.39	4.93e-7	Eosinophil percentage of white cells;
PAAD	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.65	5.37	0.4	2.83e-7	LDL cholesterol to HDL cholesterol ratio;
PAAD	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg18357526	chr6:26021779	HIST1H4A	0.54	4.8	0.36	3.84e-6	Height;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18125090	chr11:128860556	RICS	-0.52	-6.33	-0.46	2.6e-9	Energy expenditure (24h);
PAAD	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg06042504	chr8:55087323	NA	-0.79	-8.57	-0.57	1.12e-14	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs71496608	chr10:46017132	G/A	cg14076390	chr17:34947837	DHRS11	0.88	6.66	0.48	4.72e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg18569988	chr3:195679450	NA	0.45	4.39	0.34	2.13e-5	Pancreatic cancer;
PAAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg00024416	chr22:24240387	NA	-0.56	-6.13	-0.45	7.25e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.68	6.73	0.48	3.3e-10	Smoking initiation;
PAAD	cis	rs2786865	0.708	rs2065970	chr1:26051523	C/T	cg12074707	chr1:27019787	NA	-0.66	-4.27	-0.33	3.37e-5	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg02016764	chr4:38805732	TLR1	-0.58	-4.4	-0.34	2.03e-5	Breast cancer;
PAAD	cis	rs10885582	0.553	rs11196775	chr10:116279023	A/C	cg17056676	chr10:116301354	ABLIM1	-0.36	-4.63	-0.35	7.74e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	1.0	12.69	0.72	1.28e-25	Gestational age at birth (maternal effect);
PAAD	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.68	5.77	0.42	4.29e-8	Menarche (age at onset);
PAAD	trans	rs9409082	0.677	rs1516882	chr9:108912911	A/G	cg07010948	chr13:79181613	NA	-0.34	-6.58	-0.47	7.18e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs73198271	0.515	rs113056462	chr8:8638568	T/C	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.84	-5.15	-0.39	7.94e-7	Cholesterol, total;
PAAD	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg08125733	chr17:73851984	WBP2	0.5	4.49	0.34	1.38e-5	White matter hyperintensity burden;
PAAD	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.79	6.88	0.49	1.48e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg23465465	chr6:26364728	BTN3A2	0.73	5.06	0.38	1.17e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.28	13.09	0.73	1.07e-26	Corneal structure;
PAAD	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.84	10.59	0.65	5.69e-20	Breast cancer;
PAAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.47	-5.12	-0.38	8.98e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg12940439	chr1:67600707	NA	0.35	4.25	0.33	3.77e-5	Psoriasis;
PAAD	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg01966878	chr4:90757139	SNCA	0.6	4.55	0.35	1.09e-5	Neuroticism;
PAAD	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg15691649	chr6:25882328	NA	-0.52	-4.81	-0.36	3.54e-6	Blood metabolite levels;
PAAD	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg01851573	chr8:8652454	MFHAS1	-0.45	-4.64	-0.35	7.32e-6	Neuroticism;
PAAD	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.91	0.49	1.24e-10	Cognitive ability;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.89	11.04	0.67	3.62e-21	Menarche (age at onset);
PAAD	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.42	-0.4	2.24e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6894268	0.762	rs6892309	chr5:179031198	T/A	cg26135573	chr5:179059668	NA	0.73	6.2	0.45	5.13e-9	Eating disorders;
PAAD	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	6.3	0.46	3.11e-9	Retinal vascular caliber;
PAAD	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.69	7.16	0.5	3.16e-11	Monocyte count;
PAAD	cis	rs11671005	0.693	rs11666928	chr19:58914231	A/G	cg25952890	chr19:58913133	NA	0.64	5.26	0.39	4.83e-7	Mean platelet volume;
PAAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-4.62	-0.35	8.11e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs74544699	1.000	rs529312	chr4:74767982	A/T	cg16072462	chr4:74847758	PF4	1.12	4.28	0.33	3.28e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.62	-5.48	-0.41	1.72e-7	Type 2 diabetes;
PAAD	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.74	-5.13	-0.38	8.54e-7	Carotid intima media thickness;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.54e-7	Breast cancer;
PAAD	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.7	4.63	0.35	7.73e-6	HDL cholesterol;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10116456	chr1:231838098	TSNAX-DISC1;DISC1	-0.62	-6.84	-0.49	1.79e-10	Obesity-related traits;
PAAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15128208	chr22:42549153	NA	-0.45	-4.64	-0.35	7.55e-6	Cognitive function;
PAAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.74	9.98	0.63	2.38e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.72	0.36	5.24e-6	Schizophrenia;
PAAD	cis	rs216303	1.000	rs216294	chr12:6153750	A/G	cg12895370	chr12:6755816	ACRBP	-0.51	-4.26	-0.33	3.58e-5	Low vWF levels;
PAAD	cis	rs1925576	0.838	rs12416402	chr10:68650777	C/T	cg04444303	chr10:69634106	NA	-0.46	-4.55	-0.35	1.1e-5	Educational attainment (years of education);
PAAD	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.92	10.68	0.65	3.3e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.43	-5.3	-0.39	4.08e-7	Lewy body disease;
PAAD	cis	rs7804356	0.651	rs727449	chr7:26787577	C/T	cg03456212	chr7:26904342	SKAP2	0.57	4.86	0.37	2.95e-6	Type 1 diabetes;
PAAD	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg14773178	chr5:1868261	NA	0.38	4.99	0.38	1.64e-6	Cardiovascular disease risk factors;
PAAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg12143784	chr7:64541923	NA	-0.33	-4.26	-0.33	3.55e-5	Aortic root size;
PAAD	cis	rs375066	0.762	rs171238	chr19:44379554	A/C	cg21496419	chr19:44306685	LYPD5	0.42	4.89	0.37	2.49e-6	Breast cancer;
PAAD	cis	rs262147	0.592	rs2527212	chr7:158747040	G/A	cg05144285	chr7:158935647	VIPR2	-0.46	-4.33	-0.33	2.73e-5	Hippocampal volume;
PAAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg25037394	chr1:24152592	HMGCL	0.42	4.59	0.35	9.25e-6	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08699341	chr13:114193224	TMCO3	0.59	6.89	0.49	1.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg14709524	chr16:89940631	TCF25	0.88	4.58	0.35	9.63e-6	Skin colour saturation;
PAAD	cis	rs564309	0.764	rs573128	chr1:228553675	C/T	cg01328119	chr1:228783545	DUSP5P	0.67	4.45	0.34	1.65e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg01047959	chr19:17666446	GLT25D1	0.5	4.58	0.35	9.52e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg03983715	chr16:68378420	PRMT7	-0.7	-5.15	-0.39	7.94e-7	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2553218	0.756	rs8042341	chr15:54866218	A/G	cg06121207	chr16:3494155	NAT15;ZNF597	-0.66	-6.51	-0.47	1.01e-9	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs797680	0.822	rs2297707	chr1:93646207	T/C	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.25	-0.51	1.93e-11	Diastolic blood pressure;
PAAD	cis	rs7945705	0.935	rs2251536	chr11:8853177	G/C	cg00186954	chr11:8933980	ST5;C11orf17	0.46	4.74	0.36	4.83e-6	Hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14201635	chr9:124030411	GSN	0.56	6.42	0.46	1.62e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.51	4.66	0.35	6.83e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.47	-0.34	1.5e-5	Obesity-related traits;
PAAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.59	6.58	0.47	7.17e-10	Blood metabolite levels;
PAAD	cis	rs501120	1.000	rs487465	chr10:44758197	A/C	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.86	5.84	0.43	3.11e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg05012661	chr4:6891264	NA	0.5	4.26	0.33	3.54e-5	Platelet count;
PAAD	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.78	-4.97	-0.37	1.82e-6	White matter integrity;
PAAD	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.05	0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.51	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg24879335	chr3:133465180	TF	0.56	5.97	0.44	1.6e-8	Iron status biomarkers;
PAAD	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1512829	1.000	rs1512829	chr11:9951257	C/T	cg06876053	chr11:9810051	SBF2	-0.33	-4.29	-0.33	3.19e-5	Lung adenocarcinoma;
PAAD	cis	rs1144333	1.000	rs60144605	chr1:76359699	A/C	cg22875332	chr1:76189707	ACADM	0.6	4.31	0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.73	-8.51	-0.57	1.59e-14	Bone mineral density;
PAAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.9	-6.23	-0.45	4.34e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.96	12.28	0.71	1.66e-24	Bone mineral density;
PAAD	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-5.37	-0.4	2.89e-7	Total body bone mineral density;
PAAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg27478167	chr7:817139	HEATR2	-0.59	-4.67	-0.35	6.62e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg02696790	chr15:75250997	RPP25	0.41	4.55	0.35	1.1e-5	Breast cancer;
PAAD	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.95	-14.31	-0.76	5.84e-30	Height;
PAAD	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg16447950	chr5:562315	NA	-0.49	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.51	-5.85	-0.43	2.9e-8	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14383062	chr17:80889203	TBCD	-0.59	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg18898632	chr2:242989856	NA	-0.81	-6.41	-0.46	1.77e-9	Obesity-related traits;
PAAD	cis	rs9467711	0.516	rs501220	chr6:25873025	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	4.84	0.37	3.12e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.76	-9.04	-0.59	6.77e-16	Colorectal cancer;
PAAD	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.78	-5.25	-0.39	5.03e-7	Coronary artery calcification;
PAAD	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.46	-4.58	-0.35	9.79e-6	Coronary artery disease;
PAAD	cis	rs17169635	0.819	rs3800713	chr7:134500601	T/C	cg02516134	chr7:134575187	CALD1	-0.42	-4.34	-0.33	2.59e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs2790216	1.000	rs2790173	chr10:60031575	A/G	cg20442379	chr10:60024634	IPMK	-0.55	-4.28	-0.33	3.32e-5	Inflammatory bowel disease;
PAAD	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg09127314	chr1:152161683	NA	-0.73	-4.84	-0.37	3.15e-6	Atopic dermatitis;
PAAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.67	0.35	6.71e-6	Breast cancer;
PAAD	cis	rs112990264	1.000	rs111325995	chr1:213019980	G/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.5	-5.0	-0.38	1.55e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg09998033	chr7:158218633	PTPRN2	-0.78	-8.18	-0.55	1.06e-13	Obesity-related traits;
PAAD	cis	rs8005172	0.778	rs930467	chr14:88464880	G/T	cg18078958	chr14:88630771	NA	0.48	5.66	0.42	7.25e-8	Parkinson's disease;
PAAD	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-6.74	-0.48	3.14e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg26174226	chr8:58114915	NA	-0.63	-4.37	-0.33	2.27e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	0.89	6.1	0.44	8.44e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg15017067	chr4:17643749	FAM184B	0.43	4.94	0.37	2.02e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.03	-0.38	1.39e-6	QT interval;
PAAD	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.71	7.19	0.5	2.81e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.26e-11	Corneal astigmatism;
PAAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg14830002	chr1:247616686	OR2B11	-0.66	-5.44	-0.4	2.11e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.54	0.41	1.3e-7	Depression;
PAAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.71e-15	Lung cancer;
PAAD	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.43	-5.67	-0.42	7.03e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1570884	0.539	rs7982445	chr13:50111622	C/T	cg03651054	chr13:50194643	NA	0.34	4.34	0.33	2.58e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg21191810	chr6:118973309	C6orf204	0.52	5.09	0.38	1.04e-6	Diastolic blood pressure;
PAAD	cis	rs6088813	1.000	rs6142359	chr20:33960450	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.24	-0.39	5.27e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg20487152	chr13:99095054	FARP1	-0.51	-4.92	-0.37	2.23e-6	Longevity;
PAAD	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.64	5.87	0.43	2.69e-8	Alcohol dependence;
PAAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.78	7.41	0.52	8.24e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.47	-5.02	-0.38	1.41e-6	Type 2 diabetes;
PAAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.77	7.14	0.5	3.66e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs3026101	0.599	rs1058381	chr17:5288018	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	5.67	0.42	7.11e-8	Body mass index;
PAAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.55	7.28	0.51	1.71e-11	Renal cell carcinoma;
PAAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.85	4.29	0.33	3.12e-5	Plasma clusterin levels;
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	1.01	10.72	0.66	2.54e-20	Platelet count;
PAAD	cis	rs2421770	0.532	rs3847615	chr11:35347929	A/C	cg13971030	chr11:35366721	SLC1A2	-0.55	-5.3	-0.39	4.08e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs6137287	0.813	rs2424353	chr20:21222045	G/A	cg04219410	chr20:21106687	PLK1S1	0.39	4.35	0.33	2.52e-5	Height;
PAAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.91	-10.65	-0.65	3.95e-20	Total body bone mineral density;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19705676	chr22:44351290	SAMM50	0.62	6.49	0.47	1.18e-9	Myopia (pathological);
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.59	-5.49	-0.41	1.69e-7	Menarche (age at onset);
PAAD	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-1.06	-18.94	-0.84	7.72e-42	Urate levels in lean individuals;
PAAD	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.52	4.8	0.36	3.74e-6	Systemic lupus erythematosus;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.56	-5.18	-0.39	6.81e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg04851639	chr8:1020857	NA	-0.67	-8.25	-0.56	7.05e-14	Schizophrenia;
PAAD	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.95	-8.56	-0.57	1.14e-14	Lymphocyte percentage of white cells;
PAAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.15e-6	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11305259	chr19:6199442	NA	-0.63	-7.12	-0.5	4.08e-11	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13293296	chr2:99216068	C2orf64	-0.61	-6.61	-0.47	6.15e-10	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4740619	0.836	rs1891212	chr9:15900771	G/T	cg14451791	chr9:16040625	NA	-0.4	-4.72	-0.36	5.34e-6	Body mass index;
PAAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg21395723	chr22:39101663	GTPBP1	0.45	4.53	0.34	1.19e-5	Menopause (age at onset);
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	0.98	6.46	0.46	1.31e-9	IgG glycosylation;
PAAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	7.05	0.5	5.86e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.85	7.62	0.53	2.57e-12	Schizophrenia;
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3905706	0.882	rs7068246	chr10:28464753	G/A	cg07483709	chr10:29439573	NA	-0.51	-4.27	-0.33	3.37e-5	Bone mineral density;Bone mineral density (paediatric, skull);
PAAD	cis	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.25	-0.33	3.69e-5	Multiple myeloma (hyperdiploidy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17093809	chr6:125474841	TPD52L1	0.57	6.4	0.46	1.83e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs34375054	0.672	rs2291247	chr12:125618953	C/G	cg09839279	chr12:125627357	AACS	-0.49	-5.0	-0.38	1.58e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.57	0.41	1.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg20243544	chr17:37824526	PNMT	0.67	5.99	0.44	1.46e-8	Asthma;
PAAD	cis	rs11677203	0.958	rs34252971	chr2:12559810	A/G	cg01444004	chr2:11726968	GREB1	0.45	4.31	0.33	2.88e-5	Electroencephalogram traits;
PAAD	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.39	-4.65	-0.35	7.02e-6	Lewy body disease;
PAAD	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.73	5.21	0.39	6.17e-7	Major depressive disorder;
PAAD	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-7.8	-0.53	9.12e-13	Brugada syndrome;
PAAD	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.74	-0.36	4.88e-6	Daytime sleep phenotypes;
PAAD	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.93	-7.46	-0.52	6.05e-12	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg01851573	chr8:8652454	MFHAS1	0.53	4.62	0.35	8.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.22	0.39	5.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.57	5.67	0.42	7.04e-8	Eye color traits;
PAAD	cis	rs7155603	1.000	rs2359796	chr14:75960675	T/G	cg01624173	chr14:75981868	NA	-0.75	-6.4	-0.46	1.82e-9	Rheumatoid arthritis;
PAAD	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg07154921	chr7:157260426	NA	0.44	4.26	0.33	3.6e-5	Body mass index;
PAAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3796727	0.739	rs3796726	chr4:8613152	G/A	cg05284713	chr4:8621361	CPZ	-0.41	-4.27	-0.33	3.47e-5	Sporadic neuroblastoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16895254	chr4:26322328	RBPJ	0.66	6.48	0.47	1.18e-9	Obesity-related traits;
PAAD	cis	rs9463078	0.585	rs4714848	chr6:45231135	A/G	cg18551225	chr6:44695536	NA	-0.41	-4.28	-0.33	3.25e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg19413350	chr8:57351067	NA	-0.47	-4.63	-0.35	7.67e-6	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.87	-8.05	-0.55	2.28e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00262122	chr8:11665843	FDFT1	0.58	5.19	0.39	6.54e-7	Morning vs. evening chronotype;
PAAD	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg26695010	chr11:65641043	EFEMP2	-0.46	-4.5	-0.34	1.34e-5	Eosinophil percentage of white cells;
PAAD	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.53	-6.09	-0.44	8.99e-9	Mean arterial pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18983979	chr14:91779766	CCDC88C	-0.64	-6.31	-0.46	2.96e-9	Obesity-related traits;
PAAD	cis	rs16958440	0.867	rs12386092	chr18:44672058	C/T	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.52	5.9	0.43	2.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg04287289	chr16:89883240	FANCA	0.92	4.6	0.35	8.72e-6	Skin colour saturation;
PAAD	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.47	-5.46	-0.41	1.86e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-5.1	-0.38	9.86e-7	Monocyte count;
PAAD	trans	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.93	-0.49	1.13e-10	Neuroticism;
PAAD	cis	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.14e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7588746	0.621	rs10497859	chr2:201144446	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.42	-0.4	2.32e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg17372223	chr3:52568218	NT5DC2	0.51	4.79	0.36	3.92e-6	Bipolar disorder;
PAAD	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg18833306	chr6:118973337	C6orf204	0.43	4.59	0.35	9.41e-6	Electrocardiographic conduction measures;
PAAD	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg04087571	chr11:116723030	SIK3	-0.37	-5.39	-0.4	2.66e-7	Subjective well-being;
PAAD	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg09835421	chr16:68378352	PRMT7	-0.67	-5.22	-0.39	5.76e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs507080	0.501	rs625735	chr11:118575419	C/T	cg08498647	chr11:118550644	TREH	-0.43	-5.31	-0.4	3.85e-7	Serum metabolite levels;
PAAD	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.65	-5.17	-0.39	7.31e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.22	-0.51	2.32e-11	Response to amphetamines;
PAAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg04362960	chr10:104952993	NT5C2	-0.5	-4.5	-0.34	1.32e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.76e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20932251	chr11:72852302	FCHSD2	-0.74	-6.58	-0.47	7.05e-10	Neuroticism;
PAAD	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg20607287	chr7:12443886	VWDE	-0.78	-6.05	-0.44	1.06e-8	Coronary artery disease;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg19853194	chr18:9913725	VAPA	0.58	6.43	0.46	1.54e-9	Response to antipsychotic treatment;
PAAD	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-7.01	-0.49	7.11e-11	Total cholesterol levels;
PAAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.65	-6.96	-0.49	9.59e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.88	7.01	0.49	7.44e-11	Prostate cancer;
PAAD	cis	rs9810888	0.866	rs1599230	chr3:53649486	C/T	cg21574565	chr3:53855125	CHDH	-0.34	-4.36	-0.33	2.42e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg02463844	chr16:88152170	NA	-0.27	-4.58	-0.35	9.67e-6	Menopause (age at onset);
PAAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg09796270	chr17:17721594	SREBF1	-0.49	-5.59	-0.41	1.04e-7	Total body bone mineral density;
PAAD	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.69	-6.64	-0.47	5.2400000000000005e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg20731937	chr12:48336164	NA	0.51	4.29	0.33	3.11e-5	Longevity (90 years and older);
PAAD	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.66	6.59	0.47	6.83e-10	Multiple sclerosis;
PAAD	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs501916	1.000	rs599111	chr15:48053334	G/T	cg16110827	chr15:48056943	SEMA6D	-0.41	-4.51	-0.34	1.3e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg22431228	chr1:16359049	CLCNKA	-0.43	-5.16	-0.39	7.62e-7	Systolic blood pressure;
PAAD	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.51	-0.61	4.19e-17	Response to antipsychotic treatment;
PAAD	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg15890332	chr12:107067104	RFX4	0.42	4.71	0.36	5.48e-6	Total body bone mineral density;
PAAD	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg15654264	chr1:150340011	RPRD2	0.52	5.07	0.38	1.14e-6	Migraine;
PAAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12379764	chr21:47803548	PCNT	0.48	4.63	0.35	7.64e-6	Testicular germ cell tumor;
PAAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.75	-7.66	-0.53	1.97e-12	Menarche (age at onset);
PAAD	trans	rs901683	1.000	rs12779204	chr10:46064255	A/G	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg17644776	chr2:200775616	C2orf69	0.66	5.18	0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.84	0.37	3.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.75	8.63	0.57	7.8e-15	Lung cancer;
PAAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg10589385	chr1:150898437	SETDB1	0.37	4.37	0.33	2.29e-5	Melanoma;
PAAD	cis	rs643506	0.874	rs625477	chr11:111661686	A/T	cg09085632	chr11:111637200	PPP2R1B	0.57	4.91	0.37	2.29e-6	Breast cancer;
PAAD	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg12395012	chr8:11607386	GATA4	-0.4	-4.49	-0.34	1.42e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.48	-7.76	-0.53	1.18e-12	Cutaneous nevi;
PAAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.97e-5	Bipolar disorder;
PAAD	cis	rs1198430	0.636	rs2156087	chr1:23743581	C/G	cg19827787	chr1:23763612	ASAP3	-0.57	-5.47	-0.41	1.85e-7	Total cholesterol levels;
PAAD	cis	rs6137287	0.855	rs2103975	chr20:21156931	G/C	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.82	-0.48	2.07e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7679	0.681	rs2868346	chr20:44547970	C/T	cg27529037	chr20:44575021	PCIF1	0.49	4.54	0.35	1.15e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
PAAD	cis	rs9398803	0.687	rs1269195	chr6:127031550	C/T	cg19875578	chr6:126661172	C6orf173	-0.44	-4.59	-0.35	9.14e-6	Male-pattern baldness;
PAAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Electroencephalogram traits;
PAAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg23205692	chr1:25664452	TMEM50A	0.51	5.0	0.38	1.55e-6	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-4.62	-0.35	8.05e-6	Total body bone mineral density;
PAAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-11.31	-0.68	6.5600000000000005e-22	Cognitive function;
PAAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-7.88	-0.54	5.9e-13	Total body bone mineral density;
PAAD	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18364779	chr6:26104403	HIST1H4C	0.45	4.44	0.34	1.7e-5	Schizophrenia;
PAAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.57	6.97	0.49	9.05e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg12184421	chr1:167409136	CD247	0.38	4.39	0.34	2.12e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.42	0.46	1.66e-9	Lung cancer in ever smokers;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16110940	chr22:21400158	LOC400891	-0.57	-6.7	-0.48	3.88e-10	Body fat percentage;
PAAD	cis	rs9398803	0.723	rs861237	chr6:127073798	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-4.35	-0.33	2.5e-5	Male-pattern baldness;
PAAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.88	-0.58	1.8e-15	Type 2 diabetes;
PAAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.71	10.05	0.63	1.58e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg18163227	chr17:74554350	SNORD1C	0.67	4.27	0.33	3.42e-5	Airflow obstruction;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.49	-7.97	-0.54	3.56e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg24721873	chr10:135334122	NA	0.57	4.3	0.33	3.02e-5	Gout;
PAAD	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg02887458	chr19:19495540	GATAD2A	-0.51	-4.58	-0.35	9.68e-6	Bipolar disorder;
PAAD	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.46	5.78	0.42	4.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.43	0.46	1.54e-9	Schizophrenia;
PAAD	cis	rs4523957	0.928	rs216206	chr17:2196088	C/T	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg13175981	chr1:150552382	MCL1	0.77	7.84	0.54	7.21e-13	Tonsillectomy;
PAAD	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.93	11.09	0.67	2.58e-21	White blood cell count;
PAAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg06618935	chr21:46677482	NA	-0.54	-6.57	-0.47	7.46e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.24	-0.56	7.46e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.64	5.31	0.4	3.77e-7	Prostate cancer;
PAAD	cis	rs9810890	1.000	rs78675391	chr3:128472470	C/G	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg04851639	chr8:1020857	NA	-0.65	-8.05	-0.55	2.26e-13	Schizophrenia;
PAAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.58	0.71	2.51e-25	Prudent dietary pattern;
PAAD	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg05805236	chr11:65401703	PCNXL3	0.59	6.68	0.48	4.24e-10	Systemic lupus erythematosus;
PAAD	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.39	4.8	0.36	3.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.71	-7.94	-0.54	4.16e-13	Magnesium levels;
PAAD	cis	rs151997	0.629	rs152808	chr5:50207382	G/C	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg14709524	chr16:89940631	TCF25	0.95	4.37	0.33	2.27e-5	Skin colour saturation;
PAAD	cis	rs7646881	0.812	rs61696028	chr3:158455703	A/C	cg19483011	chr3:158453295	NA	-0.72	-5.88	-0.43	2.52e-8	Tetralogy of Fallot;
PAAD	cis	rs3026101	0.671	rs2871210	chr17:5305027	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07106432	chr2:27593462	SNX17;EIF2B4	-0.65	-6.56	-0.47	7.87e-10	Smoking initiation;
PAAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg01200585	chr1:228362443	C1orf69	0.65	6.55	0.47	8.42e-10	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg18825076	chr15:78729989	IREB2	0.47	4.48	0.34	1.48e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.07e-8	Life satisfaction;
PAAD	cis	rs6735179	0.565	rs73182756	chr2:1747826	A/G	cg08534653	chr2:1747700	PXDN	0.24	4.3	0.33	3.09e-5	Response to antipsychotic treatment;
PAAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.33	6.04	0.44	1.16e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.72	-7.58	-0.52	3.13e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.38	0.4	2.77e-7	Red blood cell count;
PAAD	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.53	5.2	0.39	6.35e-7	Myeloid white cell count;
PAAD	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.55	5.43	0.4	2.19e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7301826	0.651	rs7299281	chr12:131303132	G/A	cg11011512	chr12:131303247	STX2	-0.41	-4.28	-0.33	3.33e-5	Plasma plasminogen activator levels;
PAAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg17724175	chr1:150552817	MCL1	0.39	4.56	0.35	1.06e-5	Tonsillectomy;
PAAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg10591111	chr5:226296	SDHA	-0.67	-5.05	-0.38	1.28e-6	Breast cancer;
PAAD	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs2133450	0.526	rs56174360	chr3:7349316	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.22e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.65	6.3	0.46	3.01e-9	Schizophrenia;
PAAD	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	9.98	0.63	2.41e-18	Cognitive test performance;
PAAD	cis	rs902774	1.000	rs73108447	chr12:53275614	G/A	cg00800353	chr12:53273449	NA	0.6	4.34	0.33	2.58e-5	Prostate cancer;
PAAD	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.58	5.42	0.4	2.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.94	10.44	0.65	1.46e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg05299278	chr17:33885742	SLFN14	-0.44	-5.28	-0.39	4.37e-7	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.73	-6.08	-0.44	9.23e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.33	4.92	0.37	2.25e-6	IgG glycosylation;
PAAD	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg03289416	chr15:75166202	SCAMP2	0.57	6.01	0.44	1.31e-8	Breast cancer;
PAAD	cis	rs11588062	0.745	rs5019033	chr1:46735072	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.56	5.22	0.39	5.78e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4795519	0.922	rs8070275	chr17:22142172	T/C	cg22648282	chr17:21454238	C17orf51	-0.54	-5.55	-0.41	1.26e-7	Chronic myeloid leukemia;
PAAD	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	4.48	0.34	1.44e-5	Personality dimensions;
PAAD	cis	rs4880487	0.888	rs67699390	chr10:1252427	G/A	cg03183215	chr10:1252341	ADARB2	-0.48	-4.75	-0.36	4.77e-6	Migraine;
PAAD	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.08	-11.29	-0.68	7.68e-22	Blood pressure (smoking interaction);
PAAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10991814	0.920	rs78181783	chr9:94032205	C/T	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs2051773	0.567	rs6486347	chr11:17050008	A/G	cg15084286	chr11:17036142	PLEKHA7	0.53	4.69	0.36	6.11e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg27411982	chr8:10470053	RP1L1	0.43	4.67	0.35	6.65e-6	Retinal vascular caliber;
PAAD	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.67	4.95	0.37	1.98e-6	Vitiligo;
PAAD	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.61	-0.41	9.17e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg19223190	chr17:80058835	NA	-0.52	-5.2	-0.39	6.28e-7	Life satisfaction;
PAAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg04106633	chr4:1044584	NA	0.7	5.94	0.43	1.88e-8	Recombination rate (females);
PAAD	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg00666640	chr1:248458726	OR2T12	0.64	5.5	0.41	1.56e-7	Common traits (Other);
PAAD	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.92	-13.69	-0.74	2.63e-28	Height;
PAAD	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.54	5.12	0.38	9.11e-7	Uric acid clearance;
PAAD	cis	rs212524	0.649	rs212539	chr1:21592392	C/T	cg23992472	chr1:21503364	EIF4G3	-0.43	-4.35	-0.33	2.48e-5	Height;
PAAD	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg15956490	chr3:53032818	SFMBT1	-0.7	-4.3	-0.33	3.01e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.78	0.36	4.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4795519	0.556	rs4889760	chr17:22231756	A/G	cg22648282	chr17:21454238	C17orf51	-0.5	-5.2	-0.39	6.26e-7	Chronic myeloid leukemia;
PAAD	cis	rs6594713	0.921	rs35886114	chr5:112724197	C/T	cg12552261	chr5:112820674	MCC	0.67	5.37	0.4	2.88e-7	Brain cytoarchitecture;
PAAD	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.35	-4.47	-0.34	1.55e-5	Colorectal cancer;
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg03983476	chr2:10830698	NOL10	-0.62	-6.21	-0.45	4.72e-9	Prostate cancer;
PAAD	cis	rs490234	0.691	rs1250505	chr9:128193456	G/T	cg14078157	chr9:128172775	NA	-0.52	-6.09	-0.44	8.66e-9	Mean arterial pressure;
PAAD	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg01851573	chr8:8652454	MFHAS1	-0.43	-4.32	-0.33	2.84e-5	Neuroticism;
PAAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg10356904	chr22:49881777	NA	-0.48	-4.79	-0.36	3.88e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg03264133	chr6:25882463	NA	-0.44	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-4.99	-0.38	1.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.76	-8.82	-0.58	2.44e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	0.5	4.45	0.34	1.66e-5	Bipolar disorder;
PAAD	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.56	-5.93	-0.43	1.94e-8	Neuroticism;
PAAD	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg03805757	chr16:71968109	PKD1L3	-0.5	-4.32	-0.33	2.82e-5	Blood protein levels;
PAAD	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg01334972	chr11:72463230	ARAP1	0.69	5.06	0.38	1.22e-6	Type 2 diabetes;
PAAD	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg03684893	chr10:554711	DIP2C	0.5	5.06	0.38	1.22e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.73	8.54	0.57	1.3e-14	Lung cancer;
PAAD	cis	rs28735056	0.509	rs4799094	chr18:77621727	T/C	cg17174613	chr18:77631625	KCNG2	0.41	4.86	0.37	2.88e-6	Schizophrenia;
PAAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.8	8.85	0.58	2.15e-15	Body mass index;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.81	6.24	0.45	4.06e-9	Alzheimer's disease;
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg02462569	chr6:150064036	NUP43	-0.46	-4.96	-0.37	1.86e-6	Testicular germ cell tumor;
PAAD	cis	rs12760731	0.565	rs11583144	chr1:178222070	C/G	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs10450586	0.829	rs7478918	chr11:27295428	G/A	cg10370305	chr11:27303972	NA	0.36	4.29	0.33	3.14e-5	Total body bone mineral density;
PAAD	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs73416724	0.688	rs79761807	chr6:43341088	C/A	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4455778	0.580	rs10229899	chr7:49110363	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.54	-5.34	-0.4	3.32e-7	Educational attainment (years of education);
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	5.02	0.38	1.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg14008862	chr17:28927542	LRRC37B2	0.84	6.02	0.44	1.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	1.16	8.8	0.58	2.75e-15	Mitochondrial DNA levels;
PAAD	cis	rs11203032	1.000	rs61853072	chr10:90961500	A/T	cg16672925	chr10:90967113	CH25H	0.78	5.94	0.43	1.84e-8	Heart failure;
PAAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg25833597	chr17:30823145	MYO1D	0.55	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.9	0.49	1.32e-10	Menarche (age at onset);
PAAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.4	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.66	-6.63	-0.47	5.47e-10	Uric acid levels;
PAAD	cis	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Breast cancer;
PAAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.32	0.33	2.83e-5	Menarche (age at onset);
PAAD	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.36	-5.1	-0.38	9.88e-7	QT interval;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.74	9.42	0.61	7.05e-17	Cardiovascular disease risk factors;
PAAD	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.58e-10	Hair morphology;
PAAD	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.51	5.09	0.38	1.06e-6	Temperament;
PAAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg11738485	chr19:12877000	HOOK2	0.51	4.57	0.35	1.01e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
PAAD	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg08886695	chr4:3369023	RGS12	-0.49	-4.65	-0.35	7.14e-6	Serum sulfate level;
PAAD	cis	rs9640161	0.750	rs55974958	chr7:150037927	C/T	cg27494647	chr7:150038898	RARRES2	0.53	5.38	0.4	2.77e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.77	9.92	0.63	3.47e-18	Alcohol dependence;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20156080	chr11:68703600	IGHMBP2	-0.61	-6.9	-0.49	1.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13198984	chr17:80129470	CCDC57	-0.46	-5.71	-0.42	5.69e-8	Life satisfaction;
PAAD	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.55	-4.9	-0.37	2.41e-6	Lung cancer;
PAAD	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	6.86	0.49	1.63e-10	Exhaled nitric oxide levels;
PAAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-8.72	-0.58	4.6e-15	Coronary artery disease;
PAAD	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs4938096	0.661	rs67561239	chr11:114222648	G/A	cg00557402	chr11:114466517	FAM55D	0.67	4.28	0.33	3.28e-5	Asthma;
PAAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.69	-0.58	5.3e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.56	7.51	0.52	4.72e-12	Renal cell carcinoma;
PAAD	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	5.96	0.44	1.67e-8	Body mass index;
PAAD	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.71	-8.36	-0.56	3.66e-14	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10646633	chr19:44598471	ZNF224	0.59	6.52	0.47	9.64e-10	Monocyte percentage of white cells;
PAAD	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.61	0.57	8.75e-15	Menopause (age at onset);
PAAD	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg25200586	chr1:148000763	NA	-0.61	-6.38	-0.46	2.06e-9	Hip geometry;
PAAD	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26102512	chr17:1619670	WDR81;C17orf91	-0.58	-6.75	-0.48	2.88e-10	Body fat percentage;
PAAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.03	-0.44	1.2e-8	Schizophrenia;
PAAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg17178900	chr1:205818956	PM20D1	-0.46	-4.45	-0.34	1.66e-5	Parkinson's disease;
PAAD	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg23346134	chr3:49453900	TCTA	0.43	4.5	0.34	1.32e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.92	-5.66	-0.42	7.36e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-6.85	-0.49	1.71e-10	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.5	4.79	0.36	3.86e-6	Endometrial cancer;
PAAD	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs2371030	0.900	rs2371031	chr2:211570074	A/C	cg18417063	chr2:211583084	NA	-0.43	-4.27	-0.33	3.38e-5	Non-small cell lung cancer;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg16085695	chr2:209120094	IDH1	-0.67	-6.33	-0.46	2.68e-9	Primary biliary cholangitis;
PAAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.12	-10.51	-0.65	9.09e-20	Platelet count;
PAAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg00321850	chr1:175162397	KIAA0040	-0.41	-5.31	-0.4	3.75e-7	Alcohol dependence;
PAAD	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg01305830	chr4:1604576	NA	-0.47	-4.59	-0.35	9.16e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg00792783	chr2:198669748	PLCL1	0.47	4.4	0.34	1.99e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs11718455	0.585	rs11710794	chr3:43930119	T/G	cg21419209	chr3:44054225	NA	-0.59	-5.85	-0.43	2.89e-8	Coronary artery disease;
PAAD	cis	rs863345	0.836	rs10908652	chr1:158453924	C/T	cg12129480	chr1:158549410	OR10X1	-0.41	-4.57	-0.35	9.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	9.95	0.63	2.77e-18	Platelet count;
PAAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-5.4	-0.4	2.51e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.64	6.21	0.45	4.72e-9	Breast cancer;
PAAD	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg11494091	chr17:61959527	GH2	0.52	4.4	0.34	1.99e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.37e-18	Prudent dietary pattern;
PAAD	cis	rs7766436	0.621	rs1548236	chr6:22613919	G/A	cg13666174	chr6:22585274	NA	-0.46	-5.43	-0.4	2.19e-7	Coronary artery disease;
PAAD	cis	rs4073221	0.654	rs34904734	chr3:18306892	G/A	cg07694806	chr3:18168406	NA	-0.62	-4.58	-0.35	9.43e-6	Parkinson's disease;
PAAD	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.52	5.75	0.42	4.84e-8	Heart rate;
PAAD	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.31	-0.33	2.97e-5	Ileal carcinoids;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11863268	chr2:86423944	IMMT	-0.63	-6.43	-0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs7631605	0.905	rs17204675	chr3:37135797	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8077577	0.945	rs62073611	chr17:18071961	C/G	cg16794390	chr17:18148240	FLII	0.55	4.59	0.35	9.31e-6	Obesity-related traits;
PAAD	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13870426	chr17:30244630	NA	-0.69	-6.34	-0.46	2.47e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs59888335	0.858	rs13071103	chr3:80919950	C/T	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg16584676	chr17:46985605	UBE2Z	0.57	5.72	0.42	5.44e-8	Type 2 diabetes;
PAAD	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg11779900	chr17:80519722	FOXK2	0.49	5.13	0.38	8.78e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs12449964	0.524	rs4925092	chr17:17568931	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.49	5.13	0.38	8.61e-7	Coronary artery disease or ischemic stroke;
PAAD	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg14851346	chr12:38532713	NA	0.43	4.29	0.33	3.18e-5	Bladder cancer;
PAAD	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg21951975	chr1:209979733	IRF6	0.53	4.94	0.37	2.05e-6	Coronary artery disease;
PAAD	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.15	-0.5	3.45e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs6494488	0.500	rs77463022	chr15:65064841	G/A	cg16425858	chr15:64791681	ZNF609	0.97	4.38	0.33	2.19e-5	Coronary artery disease;
PAAD	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.63	6.91	0.49	1.24e-10	N-glycan levels;
PAAD	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.29	-0.45	3.27e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-5.13	-0.38	8.74e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg24733560	chr20:60626293	TAF4	0.5	6.25	0.45	3.88e-9	Body mass index;
PAAD	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg01868782	chr6:126071099	HEY2	0.45	5.35	0.4	3.14e-7	Brugada syndrome;
PAAD	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.58	6.27	0.45	3.63e-9	Bladder cancer;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg10729496	chr3:10149963	C3orf24	-0.94	-8.05	-0.55	2.17e-13	Alzheimer's disease;
PAAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.91	4.73	0.36	5.1e-6	Plasma clusterin levels;
PAAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg19257562	chr1:2043853	PRKCZ	-0.38	-4.5	-0.34	1.35e-5	Height;
PAAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg24733560	chr20:60626293	TAF4	0.45	5.68	0.42	6.78e-8	Body mass index;
PAAD	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg16606324	chr3:10149918	C3orf24	0.81	6.31	0.46	2.95e-9	Alzheimer's disease;
PAAD	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.79	0.43	3.83e-8	Eosinophil percentage of white cells;
PAAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg13647721	chr17:30228624	UTP6	-0.68	-5.07	-0.38	1.17e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-4.65	-0.35	7.23e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.77	9.05	0.59	6.3e-16	Blood metabolite ratios;
PAAD	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.97	-0.37	1.81e-6	Mean corpuscular volume;
PAAD	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg16342193	chr10:102329863	NA	-0.75	-8.2	-0.55	9.61e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg15047889	chr8:124780837	FAM91A1	-0.69	-5.39	-0.4	2.63e-7	Pancreatic cancer;
PAAD	cis	rs12304921	0.683	rs73103154	chr12:51468512	G/A	cg18059802	chr12:51347058	HIGD1C	-0.67	-5.41	-0.4	2.35e-7	Type 2 diabetes;
PAAD	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.52	4.88	0.37	2.71e-6	Educational attainment;
PAAD	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.64	5.8	0.43	3.77e-8	Crohn's disease;
PAAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.49	5.26	0.39	4.92e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg20406979	chr6:167373233	NA	0.36	4.76	0.36	4.52e-6	Crohn's disease;
PAAD	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.78	-7.6	-0.52	2.84e-12	HIV-1 control;
PAAD	cis	rs569214	0.648	rs519238	chr8:27513271	A/G	cg04264299	chr8:27491209	SCARA3	-0.47	-4.27	-0.33	3.36e-5	Alzheimer's disease;
PAAD	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg23244877	chr17:73518230	TSEN54	0.49	4.31	0.33	2.94e-5	Systemic lupus erythematosus;
PAAD	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.53	5.75	0.42	4.82e-8	Rheumatoid arthritis;
PAAD	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	4.93	0.37	2.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg14343924	chr8:8086146	FLJ10661	-0.49	-4.5	-0.34	1.33e-5	Joint mobility (Beighton score);
PAAD	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.73	7.76	0.53	1.15e-12	Heart rate;
PAAD	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg00262263	chr6:170184901	NA	0.58	4.25	0.33	3.72e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg18621852	chr3:10150065	C3orf24	0.55	5.13	0.38	8.91e-7	Alzheimer's disease;
PAAD	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.74	7.13	0.5	3.9e-11	Breast cancer;
PAAD	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg12583659	chr3:159706577	IL12A	0.63	6.57	0.47	7.54e-10	Iris heterochromicity;
PAAD	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.44	-6.81	-0.48	2.14e-10	Cutaneous nevi;
PAAD	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19125323	chr17:74733470	MIR636;SFRS2;MFSD11	0.56	6.41	0.46	1.7e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs7940866	0.678	rs11222394	chr11:130794272	C/T	cg02264943	chr11:130785842	SNX19	0.36	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.5	-4.4	-0.34	1.99e-5	Myopia (pathological);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13158990	chr17:21101960	TMEM11	0.55	6.6	0.47	6.62e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6723108	0.603	rs56271357	chr2:135720715	C/T	cg26890182	chr2:135621176	ACMSD	0.32	4.51	0.34	1.29e-5	Type 2 diabetes;
PAAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg25452165	chr22:42524984	CYP2D6	0.6	5.85	0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	1.0	14.12	0.75	1.92e-29	Menarche (age at onset);
PAAD	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.5	-5.22	-0.39	5.87e-7	Type 2 diabetes;
PAAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg20933634	chr6:27740509	NA	0.63	5.96	0.44	1.72e-8	Parkinson's disease;
PAAD	cis	rs2952768	0.772	rs6748491	chr2:208490745	G/A	cg22329743	chr2:208688774	PLEKHM3	0.25	4.72	0.36	5.22e-6	Opioid sensitivity;
PAAD	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.6	-5.81	-0.43	3.54e-8	Schizophrenia;
PAAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg12963246	chr6:28129442	ZNF389	0.58	4.65	0.35	7.29e-6	Parkinson's disease;
PAAD	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg02696790	chr15:75250997	RPP25	-0.38	-4.67	-0.35	6.69e-6	Systemic lupus erythematosus;
PAAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg20893579	chr22:38215064	NA	-0.49	-4.82	-0.36	3.44e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.71	-5.12	-0.38	9.17e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17155006	0.664	rs387981	chr7:107741337	T/A	cg05962710	chr7:107745446	LAMB4	-0.54	-7.13	-0.5	3.73e-11	Pneumococcal bacteremia;
PAAD	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4737010	0.644	rs555466	chr8:41610346	G/A	cg17182837	chr8:41585554	ANK1	0.48	4.71	0.36	5.47e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg10208897	chr5:178548229	ADAMTS2	0.49	4.42	0.34	1.84e-5	Pubertal anthropometrics;
PAAD	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.74	-5.85	-0.43	2.97e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
PAAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg25456477	chr12:86230367	RASSF9	0.47	4.29	0.33	3.13e-5	Major depressive disorder;
PAAD	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.67	7.23	0.51	2.22e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg22532475	chr10:104410764	TRIM8	-0.45	-5.25	-0.39	5.09e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1999930	0.505	rs1416190	chr6:116240514	T/A	cg05304507	chr6:116381966	FRK	0.27	4.36	0.33	2.41e-5	Age-related macular degeneration;
PAAD	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg10183150	chr4:120222239	C4orf3	-0.37	-5.14	-0.38	8.25e-7	Corneal astigmatism;
PAAD	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg27478167	chr7:817139	HEATR2	0.64	5.01	0.38	1.48e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1499972	0.618	rs7649429	chr3:117640167	G/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.71	-0.36	5.53e-6	Breast cancer;
PAAD	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg03938978	chr2:103052716	IL18RAP	0.51	5.19	0.39	6.7e-7	Blood protein levels;
PAAD	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.55	-4.36	-0.33	2.34e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.37	-0.33	2.34e-5	Resting heart rate;
PAAD	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.7	6.13	0.45	7.19e-9	Type 2 diabetes;
PAAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.92	9.28	0.6	1.65e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.7	0.36	5.88e-6	Testicular germ cell tumor;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.9	10.83	0.66	1.3e-20	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg20933634	chr6:27740509	NA	0.69	6.75	0.48	2.98e-10	Parkinson's disease;
PAAD	cis	rs10516089	0.504	rs254874	chr5:171138689	T/C	cg21066063	chr5:171570130	STK10	-0.35	-4.36	-0.33	2.35e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg18489755	chr3:183533873	MAP6D1	0.34	4.26	0.33	3.54e-5	Anterior chamber depth;
PAAD	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs72772090	0.539	rs11748795	chr5:96168056	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.89	-6.53	-0.47	9.09e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6025261	0.761	rs6099359	chr20:55509896	G/T	cg04763273	chr20:55502381	NA	-0.47	-5.36	-0.4	3.02e-7	Verbal memory performance (delayed recall level);
PAAD	cis	rs2019216	0.571	rs8070278	chr17:21979003	C/G	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.8e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.09	-0.44	8.84e-9	Schizophrenia;
PAAD	cis	rs4605213	0.528	rs11653126	chr17:49334706	C/T	cg22932220	chr17:49244634	NME2;NME1-NME2	0.45	5.59	0.41	1.05e-7	Height;
PAAD	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.76	8.64	0.57	7.3e-15	Colorectal cancer;
PAAD	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.4	4.64	0.35	7.53e-6	Total body bone mineral density;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.49	4.43	0.34	1.8e-5	Blood metabolite levels;
PAAD	cis	rs3812111	0.525	rs6755	chr6:116571255	G/A	cg18764771	chr6:116381957	FRK	-0.27	-4.26	-0.33	3.62e-5	Age-related macular degeneration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07165616	chr12:498868	KDM5A;CCDC77	0.66	7.72	0.53	1.43e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.21	-0.39	6e-7	Blood metabolite levels;
PAAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	1.11	6.57	0.47	7.49e-10	Body mass index;
PAAD	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	6.21	0.45	4.84e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.81	9.43	0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	4.56	0.35	1.05e-5	Cognitive test performance;
PAAD	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.81	0.43	3.61e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07575867	chr3:58223146	ABHD6	0.67	6.7	0.48	3.86e-10	Obesity-related traits;
PAAD	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.89	-10.71	-0.66	2.64e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg16329650	chr2:213403929	ERBB4	0.55	4.95	0.37	1.99e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.35	-6.52	-0.47	1e-9	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27511599	chr7:32358540	NA	0.94	5.19	0.39	6.58e-7	Body mass index;
PAAD	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.84	9.94	0.63	3.06e-18	Coronary artery disease;
PAAD	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg03605463	chr16:89740564	NA	-0.62	-5.78	-0.42	4.14e-8	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01925094	chr20:36322369	CTNNBL1	0.66	7.63	0.53	2.44e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs914615	0.552	rs7556304	chr1:155139509	T/C	cg18645493	chr1:154167437	MIR190B	0.45	4.34	0.33	2.61e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-9.55	-0.61	3.18e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs12780845	1.000	rs34558323	chr10:17184228	C/T	cg00857480	chr10:17188594	TRDMT1	0.39	4.95	0.37	1.97e-6	Homocysteine levels;
PAAD	cis	rs6988985	0.678	rs28710914	chr8:144003290	A/G	cg10324643	chr8:143916377	GML	0.43	4.78	0.36	4.11e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-5.71	-0.42	5.74e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.53	-5.2	-0.39	6.37e-7	Multiple myeloma;
PAAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.87	7.77	0.53	1.09e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs288326	0.561	rs74869113	chr2:183858306	C/T	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.99	6.58	0.47	7.08e-10	Parkinson's disease;
PAAD	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg15193198	chr20:60906057	LAMA5	0.53	5.66	0.42	7.3900000000000007e-08	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07328115	chr20:25228580	PYGB	0.56	6.36	0.46	2.27e-9	Metabolite levels  (X-11787);
PAAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.68	-5.69	-0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.44	4.56	0.35	1.06e-5	Obesity-related traits;
PAAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg05484376	chr2:27715224	FNDC4	0.5	5.13	0.38	8.63e-7	Total body bone mineral density;
PAAD	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.34	-0.33	2.62e-5	Ovarian reserve;
PAAD	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	5.31	0.4	3.89e-7	Lung cancer;
PAAD	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.63	4.73	0.36	5.13e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg00277334	chr10:82204260	NA	-0.71	-7.45	-0.52	6.43e-12	Post bronchodilator FEV1;
PAAD	cis	rs10899021	0.920	rs11236172	chr11:74330888	G/A	cg25880958	chr11:74394337	NA	-0.81	-5.1	-0.38	9.86e-7	Response to metformin (IC50);
PAAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02470373	chr11:555312	C11orf35	0.59	6.46	0.46	1.36e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg18402987	chr7:1209562	NA	0.52	4.46	0.34	1.57e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11051970	0.592	rs7132235	chr12:32536303	T/A	cg24626660	chr12:32551988	NA	0.44	4.54	0.35	1.12e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.82	-9.14	-0.6	3.84e-16	Body mass index;
PAAD	cis	rs4356203	0.905	rs214939	chr11:17187539	A/G	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.85	10.42	0.65	1.63e-19	Menarche (age at onset);
PAAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	9.97	0.63	2.58e-18	Platelet count;
PAAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	4.96	0.37	1.88e-6	Schizophrenia;
PAAD	cis	rs11998649	0.640	rs7812430	chr8:22631349	A/G	cg02046552	chr8:21914287	EPB49	-0.41	-4.25	-0.33	3.74e-5	Visceral fat;
PAAD	cis	rs364477	0.721	rs279876	chr9:996439	G/T	cg13952963	chr9:998547	NA	-0.59	-4.45	-0.34	1.63e-5	Major depressive disorder;
PAAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg05110241	chr16:68378359	PRMT7	-1.08	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.61	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs35955747	0.902	rs5997919	chr22:31623442	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-4.8	-0.36	3.78e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.36	6.24	0.45	4.07e-9	Skin colour saturation;
PAAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg22162314	chr17:61951766	CSH2	0.58	4.99	0.38	1.61e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.24	-0.39	5.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg20673091	chr1:2541236	MMEL1	0.71	7.38	0.51	9.52e-12	Ulcerative colitis;
PAAD	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg26031613	chr14:104095156	KLC1	0.49	5.09	0.38	1.02e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.94	8.07	0.55	1.92e-13	Alzheimer's disease;
PAAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.5	4.84	0.37	3.21e-6	Dupuytren's disease;Subjective well-being;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21638063	chr5:107717975	FBXL17	0.65	7.33	0.51	1.3e-11	Myopia (pathological);
PAAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.05e-5	Platelet count;
PAAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg22508957	chr16:3507546	NAT15	0.83	6.18	0.45	5.63e-9	Tuberculosis;
PAAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg18302933	chr2:88491318	NA	-0.42	-4.98	-0.37	1.69e-6	Response to metformin (IC50);
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01942863	chr7:99769432	GPC2	0.52	4.27	0.33	3.41e-5	Platelet count;
PAAD	cis	rs8099014	0.861	rs17669	chr18:56118493	C/T	cg12907477	chr18:56117327	MIR122	0.59	4.65	0.35	7.27e-6	Platelet count;
PAAD	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.65	7.05	0.5	6.02e-11	Body mass index;
PAAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.61	5.55	0.41	1.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg09998033	chr7:158218633	PTPRN2	-0.74	-7.97	-0.54	3.53e-13	Obesity-related traits;
PAAD	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.64	7.19	0.5	2.74e-11	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg25487775	chr2:162093969	NA	0.49	4.85	0.37	3.07e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1497828	0.956	rs2815240	chr1:217549651	A/T	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg20913747	chr6:44695427	NA	-0.63	-7.19	-0.5	2.72e-11	Total body bone mineral density;
PAAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.56	7.31	0.51	1.44e-11	Renal cell carcinoma;
PAAD	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.63	5.73	0.42	5.33e-8	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9463078	0.683	rs227847	chr6:44695493	A/G	cg25276700	chr6:44698697	NA	0.52	5.95	0.43	1.76e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.6	-6.03	-0.44	1.2e-8	Coronary artery disease;
PAAD	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.58	-7.12	-0.5	3.93e-11	Schizophrenia;
PAAD	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.64	-6.15	-0.45	6.46e-9	Cognitive test performance;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14235793	chr6:138482703	KIAA1244	0.67	6.78	0.48	2.52e-10	Obesity-related traits;
PAAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.51	-0.47	1.06e-9	Glomerular filtration rate;
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.74	8.78	0.58	3.17e-15	Lung cancer;
PAAD	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg26875137	chr12:53738046	NA	0.42	4.58	0.35	9.6e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.21	0.45	4.82e-9	Vitiligo;
PAAD	cis	rs1413885	0.516	rs6659883	chr1:65838618	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.85	0.43	2.98e-8	Anticoagulant levels;
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs35740288	0.770	rs11635711	chr15:86126486	C/G	cg07943548	chr15:86304357	KLHL25	-0.69	-5.82	-0.43	3.36e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.63	6.1	0.44	8.44e-9	Mosquito bite size;
PAAD	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.41	-5.99	-0.44	1.49e-8	Subjective well-being;
PAAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.77	-0.48	2.63e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.7	-7.09	-0.5	4.82e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.62	4.38	0.33	2.2e-5	Depression;
PAAD	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	4.35	0.33	2.54e-5	Refractive astigmatism;
PAAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.4	-0.34	2.02e-5	Total body bone mineral density;
PAAD	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.57	-5.85	-0.43	2.96e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.54	5.59	0.41	1e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs721399	0.539	rs2410561	chr8:18266774	G/A	cg18736775	chr8:18248649	NAT2	-0.6	-4.54	-0.35	1.13e-5	Blood metabolite levels;
PAAD	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.54	-5.67	-0.42	6.91e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12935418	0.672	rs1453327	chr16:81048564	A/C	cg16651780	chr16:81037892	C16orf61	-0.69	-6.53	-0.47	9.48e-10	Mean corpuscular volume;
PAAD	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg10395934	chr14:104002654	TRMT61A	0.56	6.04	0.44	1.15e-8	Body mass index;
PAAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	1.23	11.56	0.68	1.42e-22	Eosinophil percentage of granulocytes;
PAAD	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg06787764	chr1:46668870	C1orf190;POMGNT1	0.58	5.47	0.41	1.79e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs288326	0.561	rs17265824	chr2:183711970	C/G	cg09997497	chr2:183902928	NCKAP1	0.85	4.8	0.36	3.73e-6	Blood protein levels;
PAAD	cis	rs10140922	1.000	rs4981288	chr14:35828438	G/A	cg03549618	chr14:35838977	NA	-0.41	-4.29	-0.33	3.21e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23158103	chr7:148848205	ZNF398	-0.6	-5.92	-0.43	2.06e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.85	8.05	0.55	2.16e-13	Cognitive function;
PAAD	cis	rs1015291	0.708	rs941232	chr12:19993733	G/C	cg25401612	chr12:20009446	NA	0.56	5.4	0.4	2.52e-7	Diastolic blood pressure;
PAAD	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg14515779	chr1:101123966	NA	0.42	4.86	0.37	2.95e-6	Monocyte count;
PAAD	cis	rs1692580	0.807	rs10910036	chr1:2183754	C/G	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.33e-5	Coronary artery disease;
PAAD	cis	rs3784262	0.565	rs4646607	chr15:58285388	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-4.66	-0.35	6.88e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg08390786	chr10:135334061	NA	0.61	5.38	0.4	2.72e-7	Gout;
PAAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2882667	0.658	rs172664	chr5:138056306	G/A	cg09476006	chr5:138032270	NA	0.51	6.58	0.47	7e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.77	-0.48	2.6200000000000003e-10	Testicular germ cell tumor;
PAAD	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg21589280	chr1:85930151	DDAH1	-0.59	-4.29	-0.33	3.23e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg05785598	chr3:49045655	WDR6	0.42	5.02	0.38	1.44e-6	Parkinson's disease;
PAAD	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14180030	chr9:123475675	MEGF9	-0.42	-4.65	-0.35	7.24e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.91	0.54	4.89e-13	Prudent dietary pattern;
PAAD	cis	rs375066	0.935	rs398193	chr19:44420420	T/C	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.19	-10.26	-0.64	4.38e-19	Vitiligo;
PAAD	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.51	5.27	0.39	4.52e-7	Schizophrenia;
PAAD	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.48	-4.35	-0.33	2.47e-5	Schizophrenia;
PAAD	cis	rs375066	0.935	rs367283	chr19:44406127	A/G	cg08633290	chr19:44405433	NA	-0.56	-5.69	-0.42	6.4e-8	Breast cancer;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	5.18	0.39	6.88e-7	Initial pursuit acceleration;
PAAD	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.68	-7.41	-0.52	8.02e-12	Aortic root size;
PAAD	cis	rs59888335	1.000	rs67725048	chr3:80747904	C/G	cg21735741	chr3:80819488	NA	0.55	4.82	0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.63	7.24	0.51	2.13e-11	Testicular germ cell tumor;
PAAD	cis	rs7923609	0.846	rs9787438	chr10:65038030	G/C	cg08743896	chr10:65200160	JMJD1C	-0.43	-4.32	-0.33	2.82e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1015291	0.635	rs2694979	chr12:20010276	A/G	cg25401612	chr12:20009446	NA	-0.51	-4.93	-0.37	2.13e-6	Diastolic blood pressure;
PAAD	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg21918786	chr6:109611834	NA	-0.55	-5.91	-0.43	2.12e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.66	7.0	0.49	7.72e-11	Blood protein levels;
PAAD	cis	rs1144333	0.655	rs3920847	chr1:76435939	C/T	cg22875332	chr1:76189707	ACADM	0.76	4.45	0.34	1.62e-5	Attention function in attention deficit hyperactive disorder;
PAAD	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-5.14	-0.38	8.31e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs11828289	0.660	rs76379912	chr11:23182498	A/G	cg20040320	chr11:23191996	NA	-0.8	-5.74	-0.42	4.97e-8	Cancer;
PAAD	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.7	0.36	5.74e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg03400443	chr2:74347616	NA	-0.52	-4.43	-0.34	1.78e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.85	0.49	1.68e-10	Obesity-related traits;
PAAD	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg25703541	chr22:24373054	LOC391322	-0.67	-5.18	-0.39	7.06e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.8	8.5	0.57	1.6e-14	Selective IgA deficiency;
PAAD	cis	rs34734847	0.933	rs7975067	chr12:121099454	G/A	cg21892295	chr12:121157589	UNC119B	-0.45	-5.5	-0.41	1.55e-7	Mean corpuscular volume;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg26174226	chr8:58114915	NA	-0.56	-4.28	-0.33	3.26e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01947036	chr16:2802311	SRRM2;LOC100128788	-0.68	-6.65	-0.47	4.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.43	4.39	0.34	2.12e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.7	7.39	0.51	9.16e-12	Colorectal cancer;
PAAD	cis	rs2117029	0.521	rs1056875	chr12:49580180	T/C	cg05368762	chr12:50135785	TMBIM6	0.47	4.68	0.35	6.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.74	-0.36	4.83e-6	Type 2 diabetes;
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08439880	chr3:133502540	NA	-0.61	-6.75	-0.48	2.87e-10	Iron status biomarkers;
PAAD	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.75	-10.51	-0.65	9.18e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg25214090	chr10:38739885	LOC399744	0.81	8.28	0.56	5.95e-14	Educational attainment;
PAAD	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs73019876	0.901	rs440102	chr19:22233768	A/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.4	-0.34	1.99e-5	Testicular germ cell tumor;
PAAD	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.74	0.48	3.1e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	8.38	0.56	3.34e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.8	8.56	0.57	1.17e-14	Selective IgA deficiency;
PAAD	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.15	16.73	0.8	2.77e-36	Cognitive function;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02721336	chr13:99853153	UBAC2	-0.72	-6.52	-0.47	9.56e-10	Neuroticism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06505999	chr17:8059744	NA	-0.62	-6.69	-0.48	4.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.74	8.47	0.57	2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12612619	0.732	rs11677841	chr2:27239949	G/T	cg00617064	chr2:27272375	NA	-0.48	-5.06	-0.38	1.2e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.55	4.77	0.36	4.35e-6	Life satisfaction;
PAAD	cis	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.93	-0.37	2.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs600550	0.719	rs10897020	chr11:60037567	A/G	cg05699373	chr11:60609308	CCDC86	0.44	4.25	0.33	3.71e-5	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.74	4.71	0.36	5.5e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.74	8.61	0.57	8.52e-15	Lung cancer;
PAAD	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.83	-0.87	1.02e-48	Myeloid white cell count;
PAAD	cis	rs6681460	0.834	rs544258	chr1:67219209	T/C	cg02459107	chr1:67143332	SGIP1	-0.71	-6.57	-0.47	7.54e-10	Presence of antiphospholipid antibodies;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15553385	chr2:109065907	GCC2	0.68	7.22	0.51	2.29e-11	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs5998272	chr22:32560045	A/C	cg02631450	chr22:32366979	NA	0.88	5.19	0.39	6.73e-7	Childhood ear infection;
PAAD	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg00122941	chr17:4613640	ARRB2	0.81	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs6066835	1.000	rs4455220	chr20:47335017	A/G	cg18078177	chr20:47281410	PREX1	0.97	4.69	0.36	6.14e-6	Multiple myeloma;
PAAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1620921	0.505	rs1965092	chr6:161204889	C/T	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7127900	1.000	rs7123312	chr11:2232359	A/G	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	trans	rs1483035	0.623	rs13152358	chr4:156465498	A/T	cg00585174	chr10:134499472	INPP5A	-0.49	-6.75	-0.48	2.92e-10	Influenza A (H1N1) severity;
PAAD	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	1.06	14.29	0.76	6.47e-30	Headache;
PAAD	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.95	9.21	0.6	2.48e-16	Psoriasis;
PAAD	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg17524180	chr13:113633600	MCF2L	-0.48	-5.18	-0.39	6.95e-7	Systolic blood pressure;
PAAD	cis	rs75920871	0.688	rs61905678	chr11:116834785	C/T	cg04087571	chr11:116723030	SIK3	-0.45	-4.7	-0.36	5.69e-6	Subjective well-being;
PAAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.5	5.62	0.41	9.05e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg15117754	chr3:10150083	C3orf24	0.74	6.58	0.47	7.24e-10	Alzheimer's disease;
PAAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.36e-5	Tonsillectomy;
PAAD	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg03684893	chr10:554711	DIP2C	-0.47	-4.92	-0.37	2.2e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.56	5.93	0.43	1.96e-8	Pancreatic cancer;
PAAD	cis	rs4823006	0.901	rs2294239	chr22:29449477	A/G	cg23896685	chr22:29451551	ZNRF3	0.56	5.58	0.41	1.09e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10769393	chr19:2819754	ZNF554	0.63	7.26	0.51	1.85e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.65	-0.42	7.7e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs863345	0.604	rs2157687	chr1:158493000	C/T	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg14458575	chr2:238380390	NA	0.47	4.32	0.33	2.8e-5	Prostate cancer;
PAAD	cis	rs1572072	0.545	rs9550983	chr13:24123397	A/G	cg20334079	chr13:24144544	TNFRSF19	-0.41	-4.25	-0.33	3.7e-5	Nasopharyngeal carcinoma;
PAAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.48	-4.62	-0.35	8.05e-6	Coronary artery disease;
PAAD	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.93	-0.37	2.14e-6	LDL cholesterol levels;
PAAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	10.42	0.65	1.62e-19	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.8	-6.04	-0.44	1.12e-8	Coronary artery disease;
PAAD	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.65e-10	Hair morphology;
PAAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	1.04	16.89	0.81	1.06e-36	Height;
PAAD	cis	rs7932354	0.536	rs1551744	chr11:46865000	G/A	cg19486271	chr11:47235900	DDB2	-0.57	-5.65	-0.42	7.55e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs11811982	0.793	rs78707784	chr1:227286400	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-6.24	-0.45	4.23e-9	Migraine;
PAAD	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg12091567	chr17:66097778	LOC651250	-0.67	-5.24	-0.39	5.3e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-1.03	-8.69	-0.58	5.31e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs25422	0.878	rs55894300	chr6:118982076	T/A	cg18833306	chr6:118973337	C6orf204	-0.55	-4.41	-0.34	1.94e-5	Renal cell carcinoma;
PAAD	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.75	0.53	1.24e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg22830091	chr7:75961684	YWHAG	-0.43	-4.43	-0.34	1.79e-5	Multiple sclerosis;
PAAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.94	0.7	1.34e-23	Platelet count;
PAAD	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.64	6.5	0.47	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg24553058	chr2:113831203	IL1F10	-0.49	-5.52	-0.41	1.4e-7	Protein quantitative trait loci;
PAAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg27565382	chr3:53032988	SFMBT1	0.78	4.54	0.35	1.14e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.56	-5.49	-0.41	1.66e-7	Blood metabolite levels;
PAAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.72	5.35	0.4	3.14e-7	Fat distribution (HIV);
PAAD	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.54	0.35	1.14e-5	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Coronary artery disease;
PAAD	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.95	-8.65	-0.57	6.85e-15	Body mass index;
PAAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs30380	0.632	rs30186	chr5:96124447	G/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.2	-0.39	6.25e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.37	-5.41	-0.4	2.41e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	5.66	0.42	7.42e-8	Mean corpuscular volume;
PAAD	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.62	5.64	0.42	7.96e-8	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs34081402	chr10:45994427	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27164771	chr11:19138675	ZDHHC13	0.67	7.31	0.51	1.4e-11	Myopia (pathological);
PAAD	cis	rs9616064	0.813	rs9627512	chr22:46977702	C/T	cg05621596	chr22:47072043	GRAMD4	-0.57	-4.45	-0.34	1.67e-5	Urate levels in obese individuals;
PAAD	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg18898632	chr2:242989856	NA	-0.83	-6.67	-0.48	4.51e-10	Obesity-related traits;
PAAD	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.18	-10.31	-0.64	3.08e-19	Vitiligo;
PAAD	cis	rs4937076	1.000	rs1065398	chr11:125828007	T/C	cg25857886	chr11:126098838	FAM118B	0.45	4.67	0.35	6.57e-6	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg21698718	chr17:80085957	CCDC57	-0.48	-5.4	-0.4	2.51e-7	Life satisfaction;
PAAD	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.63	6.52	0.47	9.75e-10	Testicular germ cell tumor;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg02373152	chr6:52227767	PAQR8	-0.64	-6.52	-0.47	9.67e-10	Dental caries;
PAAD	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg13357408	chr7:157437802	PTPRN2	1.14	10.36	0.64	2.3e-19	Colorectal cancer;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-6.85	-0.49	1.75e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.57	5.89	0.43	2.33e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.7	-0.36	5.81e-6	Body mass index;
PAAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.6	6.08	0.44	9.32e-9	Coronary artery disease;
PAAD	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-8.43	-0.56	2.45e-14	Vitiligo;
PAAD	cis	rs12148477	0.543	rs2470172	chr15:51670476	A/G	cg25905881	chr15:51634250	GLDN	0.43	4.57	0.35	9.89e-6	Follicule stimulating hormone;
PAAD	trans	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg18543610	chr13:100627929	NA	-0.63	-6.39	-0.46	1.94e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11598897	chr5:37209268	C5orf42	0.47	6.39	0.46	1.95e-9	Immature fraction of reticulocytes;
PAAD	cis	rs10768122	0.966	rs932633	chr11:35264090	A/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.26	-0.33	3.59e-5	Vitiligo;
PAAD	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.74	-5.02	-0.38	1.45e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.92	10.62	0.65	4.72e-20	Intelligence (multi-trait analysis);
PAAD	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.75	8.67	0.58	6.01e-15	Lewy body disease;
PAAD	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.66	6.31	0.46	2.84e-9	Pulse pressure;
PAAD	cis	rs2236267	0.726	rs2093317	chr14:88609578	T/C	cg18078958	chr14:88630771	NA	-0.45	-5.7	-0.42	6.13e-8	Food antigen IgG levels;
PAAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	1.03	12.86	0.72	4.35e-26	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14316246	chr9:99800310	CTSL2	-0.66	-6.89	-0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17441280	chr6:41888715	MED20;BYSL	-0.66	-6.92	-0.49	1.21e-10	Lung cancer in ever smokers;
PAAD	cis	rs9646944	0.501	rs3771161	chr2:103003961	C/A	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.4e-5	Blood protein levels;
PAAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.32	0.4	3.6e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs4908768	0.501	rs6577488	chr1:8534529	T/C	cg20416874	chr1:8611966	RERE	-0.46	-4.47	-0.34	1.5e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4073221	0.860	rs67054573	chr3:18209808	T/A	cg07694806	chr3:18168406	NA	-0.78	-4.97	-0.37	1.76e-6	Parkinson's disease;
PAAD	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg24568646	chr21:30446238	CCT8	-0.63	-6.3	-0.46	3.02e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	6.51	0.47	1.05e-9	Lung cancer in ever smokers;
PAAD	cis	rs9361491	0.608	rs9350772	chr6:79456569	C/A	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs17209837	0.607	rs7789645	chr7:87122603	G/C	cg00919237	chr7:87102261	ABCB4	-0.75	-6.16	-0.45	6.2e-9	Gallbladder cancer;
PAAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg21605333	chr4:119757512	SEC24D	1.99	11.89	0.69	1.82e-23	Cannabis dependence symptom count;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.74	-0.48	3.13e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs17076896	0.520	rs73155762	chr13:19727885	C/G	cg20227530	chr10:79085138	KCNMA1	0.82	6.42	0.46	1.62e-9	Coronary artery aneurysm in Kawasaki disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01921777	chr1:40839564	SMAP2	0.67	6.65	0.47	5.01e-10	Obesity-related traits;
PAAD	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.46	7.66	0.53	1.98e-12	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17187048	chr2:122407283	CLASP1	0.77	9.56	0.61	2.94e-17	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.76	-6.22	-0.45	4.61e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2976388	0.647	rs2572898	chr8:143782274	G/C	cg06565975	chr8:143823917	SLURP1	0.21	4.97	0.37	1.75e-6	Urinary tract infection frequency;
PAAD	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.53	-5.66	-0.42	7.21e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9535307	0.584	rs9596197	chr13:50406988	G/T	cg03658251	chr13:50265850	EBPL	0.84	5.47	0.41	1.82e-7	Obesity-related traits;
PAAD	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.28	0.45	3.46e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2835872	0.758	rs1787396	chr21:39036487	A/C	cg06728970	chr21:39037746	KCNJ6	0.53	6.14	0.45	6.99e-9	Electroencephalographic traits in alcoholism;
PAAD	cis	rs300774	0.925	rs7562639	chr2:117690	G/T	cg21211680	chr2:198530	NA	-0.57	-5.23	-0.39	5.46e-7	Suicide attempts in bipolar disorder;
PAAD	trans	rs7615952	0.611	rs78137633	chr3:125775061	C/T	cg07211511	chr3:129823064	LOC729375	-1.26	-7.38	-0.51	9.78e-12	Blood pressure (smoking interaction);
PAAD	trans	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.66	-7.26	-0.51	1.91e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-4.41	-0.34	1.98e-5	Schizophrenia;
PAAD	cis	rs1334894	1.000	rs755658	chr6:35549670	A/G	cg07213720	chr6:35227408	ZNF76	0.79	4.38	0.33	2.21e-5	Coronary artery disease;
PAAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.37	4.35	0.33	2.52e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg27234864	chr13:21295941	IL17D	0.65	5.47	0.41	1.78e-7	Dental caries;
PAAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.59	-8.44	-0.57	2.28e-14	Huntington's disease progression;
PAAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	1.11	10.58	0.65	5.89e-20	Eosinophil percentage of granulocytes;
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	-0.65	-5.89	-0.43	2.39e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.68	6.73	0.48	3.19e-10	Body mass index;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs2790216	1.000	rs2790172	chr10:60008464	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs9815354	0.680	rs73075219	chr3:42038429	A/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.42	5.09	0.38	1.06e-6	Colorectal cancer;
PAAD	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs4704187	0.601	rs77819698	chr5:74530658	G/T	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs2124910	0.967	rs10853837	chr19:52029018	G/A	cg12008991	chr19:52034861	SIGLEC6	0.38	4.98	0.37	1.74e-6	Blood protein levels;
PAAD	cis	rs9463078	0.809	rs10948195	chr6:44957965	T/C	cg25276700	chr6:44698697	NA	-0.5	-5.88	-0.43	2.51e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.6	5.97	0.44	1.63e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs4662750	0.743	rs1835431	chr2:128375943	A/G	cg09760422	chr2:128146352	NA	0.31	4.57	0.35	1.01e-5	Renal cell carcinoma;
PAAD	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	1.97e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.58	5.83	0.43	3.14e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.56	5.95	0.43	1.81e-8	Mean corpuscular volume;
PAAD	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.6	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	cis	rs1345301	1.000	rs11686567	chr2:102876609	A/G	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.34	-0.33	2.57e-5	Waist circumference;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg26554054	chr8:600488	NA	-1.0	-6.7	-0.48	3.84e-10	IgG glycosylation;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-9.77	-0.62	8.26e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg02404636	chr22:31891804	SFI1	0.64	6.18	0.45	5.53e-9	Colorectal cancer;
PAAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.71	-6.07	-0.44	9.59e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7180079	1.000	rs77627789	chr15:64444276	G/C	cg18210365	chr15:65066710	RBPMS2	-0.71	-4.53	-0.34	1.18e-5	Monocyte count;
PAAD	cis	rs6782025	0.794	rs2686651	chr3:120691253	A/T	cg16417163	chr3:121280760	NA	0.43	4.34	0.33	2.57e-5	Aging (facial);
PAAD	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.43e-5	Resting heart rate;
PAAD	cis	rs3206736	0.548	rs328942	chr7:35051815	G/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg12395012	chr8:11607386	GATA4	0.42	4.37	0.33	2.25e-5	Morning vs. evening chronotype;
PAAD	cis	rs56046484	1.000	rs12911330	chr15:85630334	T/G	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.77	-9.25	-0.6	1.95e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.25	0.39	5.01e-7	Renal function-related traits (BUN);
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.95	-8.52	-0.57	1.47e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.81	9.26	0.6	1.85e-16	Heart rate;
PAAD	cis	rs4455778	0.538	rs6958308	chr7:49123900	C/T	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-6.61	-0.47	6.16e-10	Myopia (pathological);
PAAD	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	4.57	0.35	1.02e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg02527881	chr3:46936655	PTH1R	-0.42	-4.72	-0.36	5.25e-6	Colorectal cancer;
PAAD	cis	rs75920871	0.841	rs61905709	chr11:116897834	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs1336149	0.529	rs6427339	chr1:156954267	A/G	cg14265075	chr1:157016521	ARHGEF11	-0.43	-4.32	-0.33	2.86e-5	Chin dimples;
PAAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.6	5.57	0.41	1.13e-7	Schizophrenia;
PAAD	cis	rs10792830	0.741	rs636772	chr11:85724572	G/A	cg07180834	chr11:85838833	NA	-0.51	-6.13	-0.45	7.21e-9	Psychosis and Alzheimer's disease;
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.59	0.47	6.82e-10	Systemic lupus erythematosus;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.58	-7.12	-0.5	4.08e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.95	-12.76	-0.72	8.04e-26	Menarche (age at onset);
PAAD	cis	rs11811982	0.793	rs114006056	chr1:227537248	C/G	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg05697835	chr1:2722811	NA	0.4	4.54	0.35	1.14e-5	Ulcerative colitis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27638597	chr20:32031303	SNTA1	0.59	6.55	0.47	8.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg01851573	chr8:8652454	MFHAS1	0.49	4.38	0.33	2.19e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.32	0.33	2.76e-5	Educational attainment;
PAAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg04450456	chr4:17643702	FAM184B	0.54	5.93	0.43	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-6.23	-0.45	4.32e-9	Diabetic retinopathy;
PAAD	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.69	-6.39	-0.46	1.96e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1142	0.504	rs2470945	chr7:104585760	C/A	cg04380332	chr7:105027541	SRPK2	-0.65	-6.89	-0.49	1.35e-10	Advanced age-related macular degeneration;
PAAD	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21643547	chr1:205240462	TMCC2	-0.43	-5.01	-0.38	1.5e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12148477	0.623	rs4775942	chr15:51663597	A/G	cg25905881	chr15:51634250	GLDN	-0.39	-4.3	-0.33	3.05e-5	Follicule stimulating hormone;
PAAD	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg02225085	chr5:87975992	LOC645323	-0.62	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.51	5.93	0.43	2.01e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6495367	0.898	rs1443657	chr15:79386946	C/A	cg17347941	chr15:79387269	NA	-0.4	-4.35	-0.33	2.46e-5	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs367943	0.637	rs10039956	chr5:113010928	G/A	cg12552261	chr5:112820674	MCC	0.6	6.01	0.44	1.33e-8	Type 2 diabetes;
PAAD	cis	rs9361491	0.519	rs7768079	chr6:79437381	T/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs62408225	1.000	rs17513531	chr6:90951239	C/T	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg14583973	chr4:3374767	RGS12	0.33	4.76	0.36	4.56e-6	Mean platelet volume;
PAAD	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-5.31	-0.4	3.89e-7	Mean corpuscular volume;
PAAD	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.67	5.14	0.38	8.5e-7	Bipolar disorder;
PAAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.48	-5.31	-0.4	3.85e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.41	5.21	0.39	6.14e-7	Pulmonary function;
PAAD	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg17328964	chr8:145687451	CYHR1	-0.44	-4.64	-0.35	7.62e-6	Age at first birth;
PAAD	cis	rs847851	0.630	rs9469905	chr6:34797747	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.27	-0.39	4.5e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17601876	0.623	rs1062033	chr15:51547938	C/G	cg21478137	chr15:51532386	CYP19A1	0.52	5.15	0.39	7.95e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.45	-4.39	-0.34	2.15e-5	Breast cancer;
PAAD	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg12568669	chr8:11666485	FDFT1	0.29	4.54	0.35	1.12e-5	Morning vs. evening chronotype;
PAAD	cis	rs7537660	0.562	rs4417105	chr1:248016487	G/T	cg08944170	chr1:248100614	OR2L13	-0.44	-4.7	-0.36	5.8e-6	Platelet distribution width;
PAAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.69	5.57	0.41	1.13e-7	Schizophrenia;
PAAD	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.58	-5.28	-0.39	4.39e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.74	8.05	0.55	2.22e-13	Obesity-related traits;
PAAD	cis	rs7551222	0.714	rs4951404	chr1:204541342	G/C	cg01064725	chr1:204461714	NA	-0.58	-5.03	-0.38	1.37e-6	Schizophrenia;
PAAD	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.63	6.69	0.48	3.97e-10	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.52	-5.76	-0.42	4.44e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35740288	0.770	rs11636185	chr15:86183118	A/G	cg07943548	chr15:86304357	KLHL25	-0.62	-5.4	-0.4	2.53e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-1.01	-9.16	-0.6	3.35e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.93	-0.43	1.93e-8	Schizophrenia;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg26557270	chr6:116382179	FRK	0.28	5.04	0.38	1.32e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.26e-8	Blood metabolite levels;
PAAD	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.81	9.64	0.62	1.82e-17	Bladder cancer;
PAAD	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.57	6.52	0.47	9.79e-10	Total body bone mineral density;
PAAD	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.38	4.91	0.37	2.3e-6	Calcium levels;
PAAD	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg24220031	chr2:73402428	NA	0.34	5.24	0.39	5.37e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg12927641	chr6:109611667	NA	-0.46	-4.74	-0.36	4.85e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.63	6.7	0.48	3.88e-10	Gait speed in old age;
PAAD	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.68	-9.44	-0.61	6.03e-17	Venous thromboembolism;
PAAD	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg01657329	chr11:68192670	LRP5	-0.6	-4.32	-0.33	2.81e-5	Total body bone mineral density (age 45-60);
PAAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27297192	chr10:134578999	INPP5A	0.61	5.42	0.4	2.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.51	-5.43	-0.4	2.16e-7	Motion sickness;
PAAD	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.49	4.75	0.36	4.57e-6	Mortality in heart failure;
PAAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.71	9.79	0.62	7.67e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-6.19	-0.45	5.38e-9	Electroencephalogram traits;
PAAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.53	5.47	0.41	1.85e-7	Personality dimensions;
PAAD	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.73	-7.43	-0.52	7.12e-12	Retinal vascular caliber;
PAAD	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.81	-0.79	6.49e-34	Schizophrenia;
PAAD	cis	rs7729447	0.776	rs1458053	chr5:32690413	G/A	cg16267343	chr5:32710456	NPR3	0.49	4.65	0.35	7.11e-6	Blood pressure;
PAAD	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg08048268	chr3:133502702	NA	0.51	6.29	0.45	3.29e-9	Iron status biomarkers;
PAAD	cis	rs1667255	0.830	rs11081702	chr18:29155949	G/C	cg18808318	chr18:29669225	NA	0.52	5.01	0.38	1.53e-6	Retinol levels;
PAAD	cis	rs3736485	0.868	rs4774597	chr15:51919656	T/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.46e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg10729496	chr3:10149963	C3orf24	0.66	5.75	0.42	4.82e-8	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02573089	chr17:57233042	PRR11;SKA2	0.59	6.93	0.49	1.12e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25883219	chr12:130925181	RIMBP2	-0.66	-6.53	-0.47	9.16e-10	Obesity-related traits;
PAAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.61	5.43	0.4	2.21e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.91	0.37	2.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.64	7.72	0.53	1.42e-12	Iron status biomarkers;
PAAD	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06850241	chr22:41845214	NA	0.51	4.92	0.37	2.23e-6	Vitiligo;
PAAD	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg04520793	chr17:42248056	ASB16	0.4	4.51	0.34	1.3e-5	Total body bone mineral density;
PAAD	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg09179987	chr1:167433047	CD247	0.42	5.19	0.39	6.65e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.66	0.65	3.67e-20	Menopause (age at onset);
PAAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14169450	chr9:139327907	INPP5E	0.52	4.59	0.35	9.29e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6782025	0.802	rs11713725	chr3:121058675	A/C	cg16417163	chr3:121280760	NA	-0.45	-4.7	-0.36	5.69e-6	Aging (facial);
PAAD	cis	rs11811982	0.793	rs114087988	chr1:227532395	T/C	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	10.35	0.64	2.52e-19	Prudent dietary pattern;
PAAD	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.99	12.3	0.71	1.39e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.48	5.12	0.38	9.19e-7	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.6	5.82	0.43	3.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg00982548	chr2:198649783	BOLL	-0.75	-5.27	-0.39	4.55e-7	Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs9472414	0.510	rs3997503	chr6:44708416	G/A	cg20913747	chr6:44695427	NA	0.54	5.65	0.42	7.67e-8	Height;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs12826942	0.605	rs17801478	chr12:42481545	A/G	cg19980929	chr12:42632907	YAF2	0.49	4.27	0.33	3.43e-5	Coronary artery disease;
PAAD	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.62	-7.09	-0.5	4.6e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg18279126	chr7:2041391	MAD1L1	0.61	6.13	0.45	7.16e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg23912435	chr1:150601613	ENSA	0.47	4.25	0.33	3.71e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.94	7.44	0.52	6.76e-12	Chronic kidney disease;
PAAD	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.62	-5.87	-0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.52e-6	Prudent dietary pattern;
PAAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.54	5.02	0.38	1.46e-6	Type 2 diabetes;
PAAD	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-4.55	-0.35	1.08e-5	Rheumatoid arthritis;
PAAD	cis	rs684232	0.800	rs2002015	chr17:534525	G/T	cg20761395	chr17:511517	VPS53	0.51	5.02	0.38	1.42e-6	Prostate cancer;
PAAD	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11002851	chr4:37455729	C4orf19	0.74	7.41	0.52	8.09e-12	Obesity-related traits;
PAAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.38	-0.4	2.73e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs60154123	0.881	rs116161686	chr1:210473622	G/A	cg23283495	chr1:209979779	IRF6	0.65	5.23	0.39	5.41e-7	Coronary artery disease;
PAAD	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.4	4.64	0.35	7.53e-6	Total body bone mineral density;
PAAD	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.85	10.79	0.66	1.65e-20	Subjective well-being (multi-trait analysis);
PAAD	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.62e-8	Obesity-related traits;
PAAD	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.51	5.31	0.4	3.83e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1836229	0.874	rs1434254	chr9:8826278	A/G	cg02239209	chr15:76352489	C15orf27	-0.64	-6.36	-0.46	2.21e-9	Restless legs syndrome;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.04	0.38	1.33e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.4	-5.15	-0.39	8.08e-7	Prostate cancer;
PAAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.64	-8.38	-0.56	3.32e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.52	5.41	0.4	2.41e-7	Menopause (age at onset);
PAAD	cis	rs4296977	0.935	rs6977386	chr7:76975938	G/A	cg19348272	chr7:77044158	PION	0.61	4.37	0.33	2.3e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21775007	chr8:11205619	TDH	-0.56	-4.96	-0.37	1.86e-6	Neuroticism;
PAAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	trans	rs6694672	0.867	rs2336595	chr1:197000476	T/C	cg26994526	chr18:47719735	MYO5B	-0.81	-6.47	-0.46	1.28e-9	Asthma;
PAAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg23912435	chr1:150601613	ENSA	0.54	5.15	0.39	8.03e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.61	-5.85	-0.43	2.93e-8	Prudent dietary pattern;
PAAD	cis	rs741677	0.963	rs9907102	chr17:464832	C/T	cg20761395	chr17:511517	VPS53	0.66	7.41	0.52	8e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-1.49	-9.02	-0.59	7.87e-16	Depression;
PAAD	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09695851	chr17:3907499	NA	0.62	6.23	0.45	4.33e-9	Type 2 diabetes;
PAAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-8.37	-0.56	3.51e-14	Colorectal cancer;
PAAD	cis	rs818427	0.927	rs153548	chr5:112237724	A/C	cg06941702	chr5:112196734	SRP19	0.56	5.05	0.38	1.23e-6	Total body bone mineral density;
PAAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg02792821	chr20:44451783	NA	0.33	4.31	0.33	2.97e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.61	5.35	0.4	3.12e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.2	-0.39	6.31e-7	Fear of minor pain;
PAAD	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg13852791	chr20:30311386	BCL2L1	0.72	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.88	-10.44	-0.65	1.43e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.86	-8.63	-0.57	7.76e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10411696	0.872	rs3752243	chr19:1054060	C/T	cg18950617	chr19:1066959	HMHA1	0.5	4.94	0.37	2.06e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg03188948	chr7:1209495	NA	1.04	5.49	0.41	1.67e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.44	-5.49	-0.41	1.65e-7	Height;
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.71	7.78	0.53	1.05e-12	Colorectal cancer;
PAAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-0.99	-5.46	-0.41	1.87e-7	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.54	5.15	0.39	8.05e-7	Neurofibrillary tangles;
PAAD	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.62	5.62	0.41	8.76e-8	Mean platelet volume;
PAAD	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg00750074	chr16:89608354	SPG7	-0.55	-5.13	-0.38	8.79e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-5.48	-0.41	1.74e-7	Coronary artery disease;
PAAD	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg07617317	chr6:118971624	C6orf204	0.51	4.36	0.33	2.37e-5	Diastolic blood pressure;
PAAD	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.57e-9	Alcohol dependence;
PAAD	cis	rs8070740	0.579	rs28429022	chr17:5354471	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	5.02	0.38	1.46e-6	Menopause (age at onset);
PAAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.68	7.4	0.51	8.49e-12	Menopause (age at onset);
PAAD	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg23649088	chr2:200775458	C2orf69	-0.65	-5.09	-0.38	1.07e-6	Schizophrenia;
PAAD	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg12458913	chr13:53173898	NA	0.43	4.47	0.34	1.53e-5	Lewy body disease;
PAAD	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg22325292	chr17:80708367	FN3K	0.63	4.26	0.33	3.59e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.82	8.58	0.57	1.04e-14	Calcium levels;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.56	-6.32	-0.46	2.72e-9	Longevity;Endometriosis;
PAAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-6.34	-0.46	2.45e-9	Longevity;
PAAD	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1519814	0.624	rs2176749	chr8:121032434	T/C	cg22335954	chr8:121166405	COL14A1	-0.63	-4.84	-0.37	3.17e-6	Breast cancer;
PAAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg27395922	chr11:50257633	LOC441601	0.41	4.47	0.34	1.54e-5	Coronary artery disease;
PAAD	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.57	-0.47	7.49e-10	Total body bone mineral density;
PAAD	cis	rs9815354	0.638	rs75687617	chr3:42044664	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg18093559	chr17:18951025	GRAP	-0.46	-4.76	-0.36	4.39e-6	Schizophrenia;
PAAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.56	0.41	1.17e-7	Schizophrenia;
PAAD	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.91	-7.36	-0.51	1.05e-11	Dupuytren's disease;
PAAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg14393609	chr7:65229607	NA	0.46	4.68	0.35	6.43e-6	Aortic root size;
PAAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.59	7.47	0.52	5.73e-12	Diastolic blood pressure;
PAAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Body mass index;
PAAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.41	5.05	0.38	1.27e-6	Sitting height ratio;
PAAD	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.6	4.46	0.34	1.56e-5	Alcoholic chronic pancreatitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10590657	chr3:192538384	C3orf59	0.6	6.69	0.48	4.05e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg12935359	chr14:103987150	CKB	-0.55	-5.78	-0.42	4.13e-8	Body mass index;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	6.09	0.44	8.67e-9	Renal function-related traits (BUN);
PAAD	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.46	4.25	0.33	3.72e-5	Platelet count;
PAAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg12639453	chr1:2035780	PRKCZ	-0.53	-5.69	-0.42	6.3e-8	Height;
PAAD	cis	rs72772787	1.000	rs59203167	chr1:248014245	A/G	cg20507276	chr1:248100600	OR2L13	0.52	4.62	0.35	8.29e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.57	-6.45	-0.46	1.43e-9	Breast cancer;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.94	-12.53	-0.71	3.41e-25	Prudent dietary pattern;
PAAD	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26306683	chr17:18585705	ZNF286B	0.57	5.58	0.41	1.09e-7	Educational attainment (years of education);
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.2	-12.25	-0.7	2.02e-24	Platelet count;
PAAD	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.6	0.41	9.69e-8	Colorectal cancer;
PAAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg02683114	chr2:24398427	C2orf84	-0.57	-5.5	-0.41	1.57e-7	Asthma;
PAAD	cis	rs245880	0.740	rs245887	chr7:29190408	G/A	cg17163760	chr7:29186267	CPVL	-0.49	-5.84	-0.43	3.07e-8	Warfarin maintenance dose;
PAAD	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.79	8.68	0.58	5.82e-15	Caffeine consumption;
PAAD	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.84	10.36	0.64	2.33e-19	Dental caries;
PAAD	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.96	7.85	0.54	6.95e-13	Iron status biomarkers;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.89	6.34	0.46	2.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.97	-0.37	1.81e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08320014	chr12:133707169	ZNF10	0.67	6.73	0.48	3.19e-10	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-5.4	-0.4	2.51e-7	Personality dimensions;
PAAD	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg19486271	chr11:47235900	DDB2	-0.58	-5.9	-0.43	2.24e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs9463078	0.565	rs1797161	chr6:45150221	T/A	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg27471124	chr11:109292789	C11orf87	0.25	5.05	0.38	1.23e-6	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs4740619	0.569	rs3008732	chr9:16001924	T/C	cg14451791	chr9:16040625	NA	0.38	4.63	0.35	7.72e-6	Body mass index;
PAAD	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.87	0.37	2.75e-6	Cognitive ability;
PAAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-14.6	-0.76	9.87e-31	Height;
PAAD	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs75920871	0.920	rs4316540	chr11:116819241	C/T	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7922314	0.571	rs61865685	chr10:64721455	A/G	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.49	4.79	0.36	3.99e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs901683	1.000	rs71496612	chr10:46032505	C/A	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.93	9.65	0.62	1.77e-17	Cognitive function;
PAAD	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	1.03	6.44	0.46	1.47e-9	Fat distribution (HIV);
PAAD	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg06915872	chr16:87998081	BANP	-0.57	-5.47	-0.41	1.8e-7	Menopause (age at onset);
PAAD	cis	rs2880058	0.958	rs7547308	chr1:162027992	C/G	cg00101227	chr1:161280266	MPZ	-0.42	-4.44	-0.34	1.72e-5	QT interval;
PAAD	cis	rs4455778	0.580	rs62454353	chr7:49087900	C/A	cg26309511	chr7:48887640	NA	0.37	4.49	0.34	1.38e-5	Lung cancer in never smokers;
PAAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.39	0.34	2.1e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg22134325	chr11:66188745	NPAS4	0.29	4.66	0.35	6.92e-6	Airway imaging phenotypes;
PAAD	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-4.97	-0.37	1.79e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs11997175	0.595	rs6468204	chr8:33774748	T/C	ch.8.33884649F	chr8:33765107	NA	0.59	6.17	0.45	5.8e-9	Body mass index;
PAAD	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.84	6.75	0.48	2.93e-10	Lung function (FEV1/FVC);
PAAD	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.68	6.44	0.46	1.51e-9	Uric acid levels;
PAAD	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-6.96	-0.49	9.5e-11	Colorectal cancer;
PAAD	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.46	-5.16	-0.39	7.54e-7	Blood pressure (smoking interaction);
PAAD	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.45	5.07	0.38	1.14e-6	Pneumonia;
PAAD	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.83	-9.53	-0.61	3.64e-17	Height;
PAAD	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs791590	0.941	rs4625363	chr10:6072504	A/G	cg11519256	chr10:5708881	ASB13	-0.56	-4.36	-0.33	2.35e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04111992	chr7:158790115	NA	-0.51	-4.97	-0.37	1.75e-6	Facial morphology (factor 20);
PAAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg09592244	chr17:37024020	NA	0.47	5.08	0.38	1.11e-6	Height;
PAAD	cis	rs28830936	0.535	rs28657602	chr15:41869162	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.43	-4.67	-0.35	6.57e-6	Diastolic blood pressure;
PAAD	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.77	0.42	4.41e-8	Menopause (age at onset);
PAAD	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.54	5.58	0.41	1.1e-7	Testicular germ cell tumor;
PAAD	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.69	7.72	0.53	1.43e-12	Motion sickness;
PAAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.73	0.42	5.33e-8	Prudent dietary pattern;
PAAD	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.89	-0.43	2.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.65	6.64	0.47	5.31e-10	Alcohol dependence;
PAAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.86	9.23	0.6	2.24e-16	Cognitive function;
PAAD	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.49	-5.57	-0.41	1.15e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6942227	1.000	rs6942227	chr6:25177508	A/G	cg26336265	chr6:25042955	NA	0.58	4.39	0.34	2.12e-5	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg05585544	chr11:47624801	NA	0.46	5.13	0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg06740227	chr12:86229804	RASSF9	0.52	4.61	0.35	8.57e-6	Major depressive disorder;
PAAD	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.66	-6.83	-0.48	1.95e-10	Capecitabine sensitivity;
PAAD	cis	rs6787391	0.563	rs2306881	chr3:4753712	A/G	cg11584376	chr3:4789075	ITPR1	-0.44	-4.85	-0.37	3.05e-6	Breast cancer;
PAAD	cis	rs73416724	0.544	rs732691	chr6:43240390	C/T	cg00507679	chr6:43251876	TTBK1	0.59	4.74	0.36	4.87e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.679	rs6991074	chr8:11136046	T/C	cg21775007	chr8:11205619	TDH	-0.6	-5.17	-0.39	7.29e-7	Retinal vascular caliber;
PAAD	cis	rs1144333	0.655	rs75578876	chr1:76395586	A/C	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg08856118	chr10:27389908	ANKRD26	0.4	4.3	0.33	3e-5	Breast cancer;
PAAD	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg22587600	chr2:46883368	NA	0.34	4.59	0.35	9.38e-6	Height;
PAAD	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.75	7.75	0.53	1.24e-12	Schizophrenia;
PAAD	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.41	-0.34	1.96e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.77	4.89	0.37	2.52e-6	Lung cancer in ever smokers;
PAAD	cis	rs9810890	1.000	rs116479497	chr3:128545382	G/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg21823605	chr1:152486609	CRCT1	-0.5	-6.07	-0.44	9.96e-9	Hair morphology;
PAAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.42	-4.31	-0.33	2.86e-5	Aortic root size;
PAAD	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg18612461	chr15:75251733	NA	0.47	5.1	0.38	9.92e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.57	-5.83	-0.43	3.23e-8	Lung cancer;
PAAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg09473613	chr1:24152604	HMGCL	-0.47	-4.77	-0.36	4.31e-6	Immature fraction of reticulocytes;
PAAD	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.1	14.95	0.77	1.17e-31	Cognitive function;
PAAD	cis	rs6460942	0.597	rs12699388	chr7:12536336	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.91	0.49	1.22e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25674826	chr21:35446543	MRPS6;SLC5A3	0.64	6.64	0.47	5.34e-10	Obesity-related traits;
PAAD	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg02580895	chr19:2754563	NA	-0.52	-4.35	-0.33	2.49e-5	Total cholesterol levels;
PAAD	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.34	-4.47	-0.34	1.52e-5	Dupuytren's disease;
PAAD	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg20607287	chr7:12443886	VWDE	-0.7	-5.52	-0.41	1.4e-7	Coronary artery disease;
PAAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.54	4.72	0.36	5.25e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13418717	0.793	rs4663053	chr2:127638990	A/G	cg16909742	chr2:127635678	NA	-0.87	-4.87	-0.37	2.83e-6	Heart failure;
PAAD	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs9900972	1.000	rs9900972	chr17:76868614	A/G	cg20937029	chr17:76870563	TIMP2	0.53	4.77	0.36	4.24e-6	Obesity-related traits;
PAAD	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.02	-0.49	6.85e-11	Monocyte count;
PAAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg15847926	chr7:2749597	AMZ1	-0.38	-4.71	-0.36	5.64e-6	Height;
PAAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.89e-5	Bipolar disorder;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13732083	chr21:47605072	C21orf56	0.45	4.45	0.34	1.64e-5	Testicular germ cell tumor;
PAAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.49	4.65	0.35	7.05e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2271001	0.955	rs11025037	chr11:19178764	C/T	cg00161556	chr11:19138045	ZDHHC13	0.51	5.44	0.4	2.13e-7	Gut microbiome composition (winter);
PAAD	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	1.0	9.53	0.61	3.68e-17	Corneal structure;
PAAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.75	-8.07	-0.55	1.93e-13	Aortic root size;
PAAD	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs9652601	0.959	rs12927355	chr16:11194771	C/T	cg04616529	chr16:11181986	CLEC16A	0.43	4.59	0.35	9.32e-6	Systemic lupus erythematosus;
PAAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.61	-5.12	-0.38	8.97e-7	Schizophrenia;
PAAD	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg10518543	chr12:38710700	ALG10B	0.51	4.82	0.36	3.42e-6	Heart rate;
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg07689907	chr11:61582574	FADS1	-0.56	-5.0	-0.38	1.59e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.69	6.57	0.47	7.71e-10	Coronary artery disease;
PAAD	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14017326	chr1:206635571	SRGAP2	0.61	6.31	0.46	2.95e-9	Smoking initiation;
PAAD	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg00383909	chr3:49044727	WDR6	0.53	4.43	0.34	1.76e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2120243	0.539	rs2085315	chr3:157112622	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.32	0.33	2.77e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4605213	0.528	rs11868594	chr17:49316992	T/G	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.69	-0.36	6.1e-6	Parkinson's disease;
PAAD	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-7.42	-0.52	7.93e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg25809561	chr17:30822961	MYO1D	0.68	7.49	0.52	5.22e-12	Schizophrenia;
PAAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.77	8.49	0.57	1.7e-14	Lung cancer;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.72	-0.42	5.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.85	-9.43	-0.61	6.43e-17	Mortality in heart failure;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03224175	chr20:3996790	RNF24	-0.55	-6.31	-0.46	2.87e-9	Monocyte percentage of white cells;
PAAD	trans	rs7172971	0.566	rs117999754	chr15:42384292	A/C	cg11405695	chr1:1384091	ATAD3C	0.79	6.31	0.46	2.84e-9	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2790216	0.901	rs1988577	chr10:60003150	T/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg18850127	chr7:39170497	POU6F2	0.54	7.8	0.53	9.31e-13	IgG glycosylation;
PAAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.94	9.84	0.62	5.56e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6723108	0.591	rs13399952	chr2:135394404	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.57	-0.35	9.92e-6	Type 2 diabetes;
PAAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.61	6.14	0.45	6.97e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.7	-6.68	-0.48	4.3e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs16975963	0.843	rs73041047	chr19:38299289	T/C	cg14218481	chr19:38281219	NA	0.47	4.78	0.36	4.1e-6	Longevity;
PAAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.47	-4.32	-0.33	2.81e-5	Tuberculosis;
PAAD	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.71	-5.9	-0.43	2.25e-8	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.9	9.88	0.63	4.32e-18	Blood metabolite levels;
PAAD	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.72	-7.02	-0.49	7.04e-11	Hip circumference;
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg14345882	chr6:26364793	BTN3A2	0.6	4.45	0.34	1.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.92	-7.5	-0.52	4.87e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.48	4.64	0.35	7.47e-6	HDL cholesterol;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	trans	rs901683	1.000	rs71496606	chr10:46010098	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.62	-0.47	5.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2712184	0.652	rs13000985	chr2:217644361	T/G	cg05032264	chr2:217675019	NA	0.56	6.28	0.45	3.42e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.75	5.7	0.42	5.97e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs11718455	0.563	rs6809096	chr3:43902494	G/C	cg21419209	chr3:44054225	NA	-0.6	-6.05	-0.44	1.1e-8	Coronary artery disease;
PAAD	cis	rs59104589	0.521	rs886809	chr2:242397460	A/G	cg04488487	chr2:242709673	NA	0.58	4.7	0.36	5.84e-6	Fibrinogen levels;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	5.43	0.4	2.23e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg00253185	chr1:247542119	NA	0.56	4.64	0.35	7.63e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9815354	1.000	rs1716696	chr3:41935811	C/T	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.28	0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.51	5.18	0.39	6.87e-7	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01200104	chr16:87219442	NA	0.62	6.76	0.48	2.78e-10	Smoking initiation;
PAAD	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.55	5.41	0.4	2.44e-7	Educational attainment (years of education);
PAAD	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.45	-4.4	-0.34	2.07e-5	Crohn's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13430225	chr1:53662423	CPT2	0.6	6.75	0.48	3e-10	Monocyte percentage of white cells;
PAAD	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	5.01	0.38	1.48e-6	Ovarian reserve;
PAAD	cis	rs4638749	1.000	rs4638749	chr2:108884042	G/A	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.72	-0.36	5.4e-6	Blood pressure;
PAAD	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg00784671	chr22:46762841	CELSR1	-0.76	-4.42	-0.34	1.88e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs58521262	0.607	rs62120774	chr19:23038360	A/G	cg07749055	chr19:23076870	NA	-0.66	-4.76	-0.36	4.53e-6	Testicular germ cell tumor;
PAAD	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg02264943	chr11:130785842	SNX19	0.39	4.81	0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs490234	0.841	rs10123054	chr9:128452054	C/T	cg14078157	chr9:128172775	NA	-0.47	-5.4	-0.4	2.52e-7	Mean arterial pressure;
PAAD	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.65	6.76	0.48	2.75e-10	Height;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.64	5.58	0.41	1.1e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-7.01	-0.49	7.45e-11	Morning vs. evening chronotype;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg01097406	chr16:89675127	NA	-0.36	-4.3	-0.33	2.99e-5	Vitiligo;
PAAD	cis	rs2734839	0.896	rs11608109	chr11:113303448	G/C	cg14159747	chr11:113255604	NA	0.45	6.75	0.48	2.85e-10	Information processing speed;
PAAD	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.42	6e-8	Schizophrenia;
PAAD	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg18850127	chr7:39170497	POU6F2	0.48	7.53	0.52	4.18e-12	IgG glycosylation;
PAAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.81	8.3	0.56	5.13e-14	Vitiligo;
PAAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg07414643	chr4:187882934	NA	0.37	4.41	0.34	1.95e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg12700319	chr1:8272199	NA	-0.39	-4.3	-0.33	3.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs3764618	1.000	rs3764619	chr19:49497277	G/A	cg12515942	chr19:49552529	CGB8	-0.72	-4.39	-0.34	2.07e-5	Follicule stimulating hormone;
PAAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.68	-6.78	-0.48	2.46e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05564831	chr3:52568323	NT5DC2	0.43	4.37	0.33	2.25e-5	Bipolar disorder;
PAAD	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02419362	chr12:121203948	SPPL3	0.53	5.79	0.43	3.84e-8	Systemic lupus erythematosus;
PAAD	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.42	4.85	0.37	3.02e-6	Mean arterial pressure;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg13939156	chr17:80058883	NA	0.49	5.37	0.4	2.84e-7	Life satisfaction;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg17650747	chr5:1873721	NA	0.44	4.48	0.34	1.45e-5	Cardiovascular disease risk factors;
PAAD	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.87	-9.43	-0.61	6.65e-17	Mortality in heart failure;
PAAD	cis	rs709400	0.633	rs10135868	chr14:104004147	T/C	cg10395934	chr14:104002654	TRMT61A	0.54	5.48	0.41	1.73e-7	Body mass index;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20486897	chr18:47087108	LIPG	0.54	6.5	0.47	1.11e-9	Monocyte percentage of white cells;
PAAD	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg10174797	chr19:8464628	RAB11B	0.59	5.48	0.41	1.73e-7	HDL cholesterol;
PAAD	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.67	6.5	0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg22143856	chr6:28129313	ZNF389	0.53	4.89	0.37	2.52e-6	Parkinson's disease;
PAAD	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.58	5.12	0.38	9.08e-7	Sudden cardiac arrest;
PAAD	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg19682013	chr15:45996608	NA	0.32	4.27	0.33	3.39e-5	Waist circumference;Weight;
PAAD	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.88	9.12	0.59	4.22e-16	Height;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07157571	chr16:85496172	NA	0.59	6.86	0.49	1.64e-10	Metabolite levels  (X-11787);
PAAD	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg21269045	chr12:125625041	AACS	-0.51	-5.01	-0.38	1.5e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs10073892	0.703	rs9327822	chr5:101638065	T/C	cg17280723	chr5:101634495	NA	0.41	4.41	0.34	1.98e-5	Cognitive decline (age-related);
PAAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.59	-4.79	-0.36	3.99e-6	Platelet count;
PAAD	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.57	-6.41	-0.46	1.7e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs2790216	1.000	rs2590356	chr10:60019047	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs970548	0.643	rs7068039	chr10:45932264	T/C	cg15590007	chr10:45870220	ALOX5	0.45	4.79	0.36	3.88e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg19949948	chr17:19361230	NA	0.46	4.58	0.35	9.48e-6	Schizophrenia;
PAAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.91	9.63	0.62	2.01e-17	Blood metabolite levels;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg18127619	chr14:39511766	SEC23A	-0.6	-6.35	-0.46	2.33e-9	Alcohol dependence;
PAAD	cis	rs863345	0.604	rs2051451	chr1:158464265	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.9	-0.37	2.39e-6	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26066560	chr7:2086333	MAD1L1	-0.65	-6.53	-0.47	9.11e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.24	-0.39	5.2e-7	Life satisfaction;
PAAD	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg01475377	chr6:109611718	NA	-0.43	-4.74	-0.36	4.93e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.86	5.87	0.43	2.61e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg05585544	chr11:47624801	NA	-0.45	-4.86	-0.37	2.94e-6	Subjective well-being;
PAAD	cis	rs12541635	0.653	rs7014265	chr8:107026412	G/A	cg10147462	chr8:107024639	NA	0.47	5.04	0.38	1.28e-6	Age of smoking initiation;
PAAD	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.89	9.66	0.62	1.62e-17	Monocyte count;
PAAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg14580859	chr9:123691850	NA	0.4	4.43	0.34	1.78e-5	Rheumatoid arthritis;
PAAD	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-5.25	-0.39	5.06e-7	Monocyte percentage of white cells;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.62	-6.49	-0.47	1.13e-9	Prostate cancer;
PAAD	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04530015	chr2:215796436	ABCA12	0.49	4.29	0.33	3.2e-5	Neuroblastoma;
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg15117754	chr3:10150083	C3orf24	0.63	5.5	0.41	1.6e-7	Alzheimer's disease;
PAAD	cis	rs8067287	0.634	rs11652811	chr17:16843171	A/G	cg26910001	chr17:16838321	NA	-0.52	-4.85	-0.37	3.09e-6	Diabetic kidney disease;
PAAD	cis	rs375066	0.901	rs376457	chr19:44412757	C/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	trans	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6864727	0.963	rs10479177	chr5:137388440	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	5.27	0.39	4.58e-7	Atrial fibrillation;
PAAD	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-5.0	-0.38	1.59e-6	Self-reported allergy;
PAAD	cis	rs2492906	0.515	rs2451915	chr10:27979032	C/T	cg25523538	chr10:28031957	MKX	0.51	4.35	0.33	2.45e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.39	4.99	0.38	1.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04312406	chr1:226497240	LIN9	0.69	6.83	0.48	1.92e-10	Obesity-related traits;
PAAD	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.53	5.37	0.4	2.93e-7	Anterior chamber depth;
PAAD	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.84	-7.9	-0.54	5.36e-13	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.64	-6.92	-0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg15181151	chr6:150070149	PCMT1	0.57	6.31	0.46	2.9e-9	Lung cancer;
PAAD	cis	rs7619427	0.544	rs9872047	chr3:43991630	C/T	cg16646616	chr3:44040527	NA	-0.56	-4.55	-0.35	1.11e-5	Schizophrenia;
PAAD	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg00387621	chr1:208086895	NA	0.74	4.53	0.35	1.17e-5	Facial morphology (factor 18);
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg08888203	chr3:10149979	C3orf24	0.69	6.27	0.45	3.58e-9	Alzheimer's disease;
PAAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.55	7.55	0.52	3.66e-12	Renal cell carcinoma;
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.98	-7.67	-0.53	1.88e-12	Initial pursuit acceleration;
PAAD	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.89	-10.04	-0.63	1.61e-18	Cognitive function;
PAAD	trans	rs11426768	1	rs11426768	chr16:68800641	C/CT	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	7.15	0.5	3.46e-11	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.67	7.03	0.5	6.58e-11	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.96	-13.34	-0.73	2.23e-27	Height;
PAAD	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg26876637	chr1:152193138	HRNR	-0.83	-6.1	-0.44	8.24e-9	Atopic dermatitis;
PAAD	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.18e-14	Colorectal cancer;
PAAD	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg01329690	chr21:38580129	DSCR9	0.33	4.42	0.34	1.89e-5	Eye color traits;
PAAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.75e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-4.9	-0.37	2.44e-6	Psoriasis;
PAAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.26	0.64	4.29e-19	Platelet count;
PAAD	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs757081	0.533	rs56030184	chr11:17067849	C/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-4.52	-0.34	1.23e-5	Systolic blood pressure;
PAAD	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg20503657	chr10:835505	NA	0.55	5.8	0.43	3.73e-8	Survival in rectal cancer;
PAAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.18e-7	Eye color traits;
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.55	-5.31	-0.4	3.88e-7	Tonsillectomy;
PAAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.78	-10.69	-0.66	3.01e-20	Iron status biomarkers;
PAAD	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.86	-8.95	-0.59	1.15e-15	Body mass index;
PAAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.22e-10	Blood protein levels;
PAAD	cis	rs72960926	0.744	rs72967299	chr6:75034041	C/T	cg03266952	chr6:74778945	NA	-1.2	-6.76	-0.48	2.73e-10	Metabolite levels (MHPG);
PAAD	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg22256960	chr15:77711686	NA	-0.53	-4.25	-0.33	3.77e-5	Type 2 diabetes;
PAAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs4938096	0.661	rs11214958	chr11:114212268	G/C	cg00557402	chr11:114466517	FAM55D	0.71	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.56	-0.41	1.15e-7	Mean platelet volume;
PAAD	cis	rs4740619	0.875	rs10810442	chr9:15759359	G/A	cg14451791	chr9:16040625	NA	-0.37	-4.31	-0.33	2.96e-5	Body mass index;
PAAD	cis	rs9810890	1.000	rs9862461	chr3:128572314	C/G	cg15676455	chr3:128564943	NA	-0.67	-4.36	-0.33	2.37e-5	Dental caries;
PAAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17155006	0.746	rs435744	chr7:107748549	A/G	cg05962710	chr7:107745446	LAMB4	-0.59	-7.89	-0.54	5.38e-13	Pneumococcal bacteremia;
PAAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.61	8.14	0.55	1.32e-13	Renal cell carcinoma;
PAAD	cis	rs6674970	0.777	rs11204782	chr1:151118035	C/G	cg11822372	chr1:151115635	SEMA6C	-0.88	-8.33	-0.56	4.45e-14	Childhood ear infection;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg03199926	chr20:60860733	OSBPL2	-0.37	-4.58	-0.35	9.67e-6	Pelvic organ prolapse;
PAAD	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	4.45	0.34	1.62e-5	Breast cancer;
PAAD	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg05283184	chr6:79620031	NA	-0.5	-6.1	-0.44	8.35e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg21385522	chr1:16154831	NA	0.53	4.5	0.34	1.34e-5	Systolic blood pressure;
PAAD	cis	rs7119038	0.865	rs4936443	chr11:118740864	C/T	cg19308663	chr11:118741387	NA	-0.65	-5.18	-0.39	6.94e-7	Sjögren's syndrome;
PAAD	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.54	5.32	0.4	3.67e-7	Systolic blood pressure;
PAAD	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.77	4.55	0.35	1.1e-5	Obesity-related traits;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07638871	chr5:56247860	MIER3	0.66	7.02	0.49	6.73e-11	Pancreatic cancer;
PAAD	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg02631450	chr22:32366979	NA	1.03	5.44	0.4	2.08e-7	Childhood ear infection;
PAAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.78e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.92	9.47	0.61	5.15e-17	Urate levels in obese individuals;
PAAD	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs7188861	0.681	rs12928822	chr16:11403893	C/T	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.68	-7.72	-0.53	1.44e-12	White blood cell count (basophil);
PAAD	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.98	-0.49	8.54e-11	Mood instability;
PAAD	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.7	6.62	0.47	5.75e-10	Plateletcrit;Platelet count;
PAAD	cis	rs10924309	0.640	rs6700599	chr1:245854047	G/T	cg00036263	chr1:245852353	KIF26B	-0.62	-6.01	-0.44	1.33e-8	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs71636778	0.631	rs71636787	chr1:27185115	T/A	cg12203394	chr1:27248618	NUDC	0.63	4.49	0.34	1.37e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.65	-0.53	2.08e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.54	5.39	0.4	2.65e-7	Menarche (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22944632	chr2:63277684	OTX1	0.58	6.32	0.46	2.71e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11995313	chr8:8860691	ERI1	0.5	5.14	0.38	8.34e-7	Joint mobility (Beighton score);
PAAD	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.45	4.71	0.36	5.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.7e-6	Neuroticism;
PAAD	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.77	0.36	4.33e-6	Height;
PAAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.71	7.53	0.52	4.3e-12	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg15676125	chr6:33679581	C6orf125	-0.47	-4.55	-0.35	1.08e-5	Plateletcrit;
PAAD	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.59	0.41	1.05e-7	Lung cancer in ever smokers;
PAAD	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg13446199	chr8:143762866	PSCA	0.38	4.45	0.34	1.63e-5	Urinary tract infection frequency;
PAAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.6	6.54	0.47	8.75e-10	Longevity;
PAAD	cis	rs1468333	0.567	rs10045383	chr5:137689212	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.08	0.38	1.1e-6	Resting heart rate;
PAAD	cis	rs1572591	0.512	rs4112527	chr13:102119656	A/G	cg03165014	chr13:102106348	ITGBL1	-0.42	-4.51	-0.34	1.3e-5	Psychosis (atypical);
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg11764359	chr7:65958608	NA	0.75	4.92	0.37	2.2e-6	Diabetic kidney disease;
PAAD	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.84e-15	Coffee consumption (cups per day);
PAAD	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.91	-0.37	2.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.69	7.12	0.5	3.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3136441	0.543	rs78744550	chr11:46949601	T/C	cg19486271	chr11:47235900	DDB2	0.57	4.39	0.34	2.09e-5	HDL cholesterol;
PAAD	cis	rs3169166	0.500	rs12901552	chr15:78562160	G/A	cg09214398	chr15:78556534	DNAJA4	-0.29	-4.8	-0.36	3.81e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.61	5.25	0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg06740227	chr12:86229804	RASSF9	0.5	4.64	0.35	7.44e-6	Major depressive disorder;
PAAD	cis	rs12760731	0.516	rs12403484	chr1:178129059	C/A	cg00404053	chr1:178313656	RASAL2	0.7	5.22	0.39	5.78e-7	Obesity-related traits;
PAAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.68	-7.79	-0.53	9.58e-13	Height;
PAAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-17.86	-0.82	3.73e-39	Height;
PAAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.56	-5.17	-0.39	7.16e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.57	-5.78	-0.42	4.17e-8	Facial morphology (factor 20);
PAAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.37	0.33	2.25e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.56	-4.82	-0.36	3.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	5.72	0.42	5.36e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg15145965	chr22:50218605	BRD1	0.62	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.96	-11.66	-0.69	7.76e-23	Height;
PAAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs9283706	0.689	rs6889240	chr5:66320940	A/G	cg11590213	chr5:66331682	MAST4	0.59	4.82	0.36	3.49e-6	Coronary artery disease;
PAAD	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11671653	1.000	rs8112837	chr19:10837030	C/T	cg16667279	chr19:11591998	ELAVL3	-0.52	-4.3	-0.33	3.01e-5	LDL cholesterol;
PAAD	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.76	11.66	0.69	7.71e-23	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg02696790	chr15:75250997	RPP25	-0.37	-4.43	-0.34	1.77e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs8005172	0.750	rs10137195	chr14:88444882	A/C	cg18078958	chr14:88630771	NA	0.44	5.21	0.39	6.02e-7	Parkinson's disease;
PAAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.64	7.67	0.53	1.88e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2996428	1.000	rs2996428	chr1:3697291	C/T	cg17848003	chr1:3704513	LRRC47	0.41	4.44	0.34	1.75e-5	Red cell distribution width;
PAAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03885332	chr11:832357	CD151	-0.46	-5.4	-0.4	2.57e-7	Mean platelet volume;
PAAD	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.95	-8.2	-0.55	9.48e-14	Body mass index;
PAAD	cis	rs7567389	0.505	rs1518760	chr2:128140500	T/G	cg09760422	chr2:128146352	NA	0.39	6.17	0.45	5.83e-9	Self-rated health;
PAAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-1.02	-13.99	-0.75	4.1e-29	Breast cancer;
PAAD	cis	rs10779751	0.655	rs1884429	chr1:11112836	T/C	cg08854313	chr1:11322531	MTOR	0.79	7.98	0.54	3.37e-13	Body mass index;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.73	8.7	0.58	5.22e-15	Lung cancer;
PAAD	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg16898833	chr6:26189333	HIST1H4D	1.05	5.36	0.4	3.06e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs78411303	0.584	rs7611002	chr3:122379295	A/C	cg17380795	chr3:122379686	NA	-0.74	-5.56	-0.41	1.2e-7	Periodontitis (CDC/AAP);
PAAD	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.66	5.83	0.43	3.15e-8	Response to diuretic therapy;
PAAD	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14298577	chr7:100272703	GNB2	0.6	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7714584	1.000	rs7724558	chr5:150328866	T/C	cg22134413	chr5:150180641	NA	0.84	5.43	0.4	2.23e-7	Crohn's disease;
PAAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	trans	rs10500871	1.000	rs4757043	chr11:20223947	T/A	cg02956962	chr6:161097311	NA	0.62	6.33	0.46	2.64e-9	Educational attainment;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22548015	chr20:30539544	PDRG1	0.61	6.78	0.48	2.49e-10	Myopia (pathological);
PAAD	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs7551345	0.671	rs12080531	chr1:31893370	G/A	cg17086398	chr1:31896392	SERINC2	-0.62	-4.46	-0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.31	0.4	3.89e-7	Colorectal cancer;
PAAD	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-1.09	-15.29	-0.78	1.48e-32	Breast cancer;
PAAD	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.57	5.78	0.42	4.09e-8	Coronary artery disease;
PAAD	cis	rs2139634	0.930	rs28413725	chr3:46530685	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	0.31	4.36	0.33	2.39e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15156469	chr2:234112955	INPP5D	0.64	6.36	0.46	2.21e-9	Smoking initiation;
PAAD	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg01472176	chr1:226074946	LEFTY1	-0.57	-5.88	-0.43	2.46e-8	Preschool internalizing problems;
PAAD	cis	rs17665889	0.737	rs1857188	chr6:51277755	A/G	cg09582880	chr6:52050133	IL17A	-0.63	-4.31	-0.33	2.93e-5	Cannabis dependence symptom count;
PAAD	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg22830091	chr7:75961684	YWHAG	-0.62	-7.27	-0.51	1.79e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.85	9.3	0.6	1.47e-16	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07697569	chr11:118966186	H2AFX	0.61	6.78	0.48	2.48e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg05110241	chr16:68378359	PRMT7	-1.11	-8.12	-0.55	1.47e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs35952432	1	rs35952432	chr6:28074901	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Lung cancer;
PAAD	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg12963866	chr19:57752005	ZNF805	-0.48	-4.71	-0.36	5.55e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg25150519	chr12:98850993	NA	0.54	5.48	0.41	1.75e-7	Colorectal adenoma (advanced);
PAAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.34	0.33	2.59e-5	Renal cell carcinoma;
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs2637266	0.543	rs1907327	chr10:78254112	A/G	cg18941641	chr10:78392320	NA	0.36	4.26	0.33	3.57e-5	Pulmonary function;
PAAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg07068956	chr7:100330872	ZAN	-0.67	-5.04	-0.38	1.29e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg00086871	chr4:6988644	TBC1D14	0.88	4.71	0.36	5.58e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1535500	0.756	rs3807042	chr6:39290834	G/T	cg08315770	chr6:39281885	KCNK17	0.55	5.57	0.41	1.15e-7	Type 2 diabetes;
PAAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg24733560	chr20:60626293	TAF4	0.51	6.53	0.47	9.09e-10	Body mass index;
PAAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.49	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg12092346	chr18:77659572	KCNG2	-0.59	-4.67	-0.35	6.68e-6	Opioid sensitivity;
PAAD	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg20673841	chr7:107026890	COG5	0.47	4.28	0.33	3.31e-5	Coronary artery disease;
PAAD	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.44	1.71e-8	Obesity-related traits;
PAAD	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.54	0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.79	7.78	0.53	1.05e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.55	4.46	0.34	1.6e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-4.26	-0.33	3.55e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.69	-7.19	-0.5	2.71e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs728616	0.558	rs35547640	chr10:82139150	C/T	cg19423196	chr10:82049429	MAT1A	0.49	4.69	0.36	5.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.46	4.87	0.37	2.82e-6	Age of smoking initiation;
PAAD	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg18850127	chr7:39170497	POU6F2	0.49	7.71	0.53	1.5e-12	IgG glycosylation;
PAAD	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.8	-8.89	-0.59	1.63e-15	Lung cancer;
PAAD	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg02071572	chr4:1403502	NA	0.35	4.6	0.35	8.9e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg15181151	chr6:150070149	PCMT1	0.56	5.61	0.41	9.23e-8	Lung cancer;
PAAD	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2882667	0.621	rs55901834	chr5:138179783	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.61	6.52	0.47	9.77e-10	Crohn's disease;
PAAD	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg04087571	chr11:116723030	SIK3	-0.37	-5.39	-0.4	2.66e-7	Subjective well-being;
PAAD	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg00629941	chr15:75287862	SCAMP5	0.6	4.63	0.35	7.79e-6	Blood trace element (Zn levels);
PAAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.36	-0.82	6.54e-38	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15135914	chr11:65430544	RELA	0.55	6.98	0.49	8.48e-11	Myopia (pathological);
PAAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	10.85	0.66	1.16e-20	Monocyte count;
PAAD	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg18551225	chr6:44695536	NA	-0.74	-7.42	-0.52	7.65e-12	Total body bone mineral density;
PAAD	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	4.54	0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01585852	chr22:24235823	MIF	-0.47	-5.07	-0.38	1.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.66	-7.04	-0.5	6.14e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	4.84	0.37	3.12e-6	Mood instability;
PAAD	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.79	8.2	0.55	9.57e-14	Schizophrenia;
PAAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.75	-8.15	-0.55	1.25e-13	Coronary artery disease;
PAAD	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.47	-0.34	1.5e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12714314	0.957	rs10190598	chr2:1955017	T/C	cg22350835	chr2:1868857	MYT1L	0.48	4.76	0.36	4.47e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	7.75e-7	Aortic root size;
PAAD	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02711726	chr17:80685570	FN3KRP	-0.45	-4.51	-0.34	1.28e-5	Glycated hemoglobin levels;
PAAD	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg10356904	chr22:49881777	NA	-0.53	-5.07	-0.38	1.16e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7554547	0.595	rs12092731	chr1:11968395	T/C	cg07603449	chr1:11986842	KIAA2013	-0.36	-6.01	-0.44	1.32e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg20169779	chr10:135381914	SYCE1	0.47	4.76	0.36	4.51e-6	Obesity-related traits;
PAAD	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.41	0.34	1.98e-5	Tonsillectomy;
PAAD	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg10495392	chr1:46806563	NSUN4	-0.57	-5.69	-0.42	6.24e-8	Menopause (age at onset);
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.48	5.03	0.38	1.38e-6	Testicular germ cell tumor;
PAAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.48	4.97	0.37	1.75e-6	Interstitial lung disease;
PAAD	cis	rs80130819	0.688	rs4760698	chr12:48592872	C/T	cg26205652	chr12:48591994	NA	0.68	4.65	0.35	7.23e-6	Prostate cancer;
PAAD	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.73	8.38	0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.71	-6.92	-0.49	1.19e-10	Blood metabolite levels;
PAAD	cis	rs1519814	0.876	rs10955954	chr8:121108052	A/G	cg22335954	chr8:121166405	COL14A1	-0.61	-5.29	-0.39	4.13e-7	Breast cancer;
PAAD	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg00277334	chr10:82204260	NA	-0.62	-6.11	-0.44	8.16e-9	Post bronchodilator FEV1;
PAAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.62	1.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg00155535	chr12:132671473	NA	0.61	6.01	0.44	1.32e-8	Anti-saccade response;
PAAD	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.46	5.41	0.4	2.46e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs868943	0.582	rs12203127	chr6:116468315	A/T	cg18764771	chr6:116381957	FRK	0.27	4.42	0.34	1.89e-5	Total cholesterol levels;
PAAD	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-4.69	-0.36	6.11e-6	Joint mobility (Beighton score);
PAAD	cis	rs7937682	0.593	rs1113851	chr11:111354161	G/A	cg09085632	chr11:111637200	PPP2R1B	0.5	4.25	0.33	3.64e-5	Primary sclerosing cholangitis;
PAAD	cis	rs4448343	0.963	rs10512248	chr9:98259703	A/C	cg13428213	chr9:98267529	PTCH1	0.45	4.25	0.33	3.69e-5	Height;
PAAD	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.42	-0.34	1.88e-5	Height;
PAAD	cis	rs3905706	0.825	rs35494924	chr10:28466881	T/C	cg07483709	chr10:29439573	NA	-0.51	-4.34	-0.33	2.63e-5	Bone mineral density;Bone mineral density (paediatric, skull);
PAAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg07952391	chr2:88470173	THNSL2	-0.51	-4.9	-0.37	2.44e-6	Response to metformin (IC50);
PAAD	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.46	5.72	0.42	5.51e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.75	7.95	0.54	3.95e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6496932	0.663	rs4842878	chr15:85904232	C/T	cg19183879	chr15:85880815	NA	-0.54	-5.1	-0.38	1.01e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.67	-5.75	-0.42	4.63e-8	Total ventricular volume;
PAAD	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.03	-5.79	-0.42	3.98e-8	Lung cancer in ever smokers;
PAAD	cis	rs2342371	0.720	rs61345811	chr3:196143030	C/T	cg09821211	chr3:195954098	OSTalpha	0.62	5.6	0.41	9.82e-8	Fat distribution (HIV);
PAAD	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-14.83	-0.77	2.5e-31	Height;
PAAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.46	0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14895029	chr7:2775587	GNA12	-0.46	-4.33	-0.33	2.75e-5	Height;
PAAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.75	0.36	4.75e-6	Schizophrenia;
PAAD	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	4.32	0.33	2.77e-5	Aortic root size;
PAAD	cis	rs6762	0.748	rs28636471	chr11:840639	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-5.3	-0.4	3.96e-7	Mean platelet volume;
PAAD	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.79	8.01	0.54	2.74e-13	Prostate-specific antigen levels;
PAAD	cis	rs7714584	1.000	rs6579804	chr5:150255931	T/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.45	-0.4	1.97e-7	Monocyte percentage of white cells;
PAAD	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.56	-5.26	-0.39	4.71e-7	Dental caries;
PAAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg05697835	chr1:2722811	NA	0.39	4.3	0.33	3.06e-5	Ulcerative colitis;
PAAD	cis	rs7243821	0.921	rs11660000	chr18:52638161	A/G	cg16669619	chr18:52630472	NA	-0.51	-5.2	-0.39	6.36e-7	Chin dimples;
PAAD	cis	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg26621607	chr12:133180238	NA	0.63	4.3	0.33	2.99e-5	Urate levels in overweight individuals;
PAAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.92	-12.58	-0.71	2.52e-25	Prudent dietary pattern;
PAAD	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg06713675	chr4:122721982	EXOSC9	0.46	4.49	0.34	1.38e-5	Type 2 diabetes;
PAAD	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg04454073	chr16:22207163	NA	0.49	4.91	0.37	2.3e-6	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06002616	chr8:101225028	SPAG1	-0.48	-5.7	-0.42	6.18e-8	Atrioventricular conduction;
PAAD	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-4.41	-0.34	1.92e-5	Type 2 diabetes;
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.5	5.02	0.38	1.45e-6	Vitiligo;
PAAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.61	6.55	0.47	8.34e-10	Longevity;
PAAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.94	12.58	0.71	2.46e-25	Menopause (age at onset);
PAAD	cis	rs185694	1.000	rs202101	chr13:30897337	A/G	cg07600127	chr13:30881527	KATNAL1	-0.64	-4.34	-0.33	2.58e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.73	-7.29	-0.51	1.6e-11	Itch intensity from mosquito bite;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.93	6.88	0.49	1.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.39	-5.0	-0.38	1.55e-6	Prostate cancer;
PAAD	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25833597	chr17:30823145	MYO1D	-0.51	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg01214346	chr17:406501	NA	-0.46	-4.61	-0.35	8.46e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg03453431	chr7:157225567	NA	-0.48	-4.97	-0.37	1.81e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6782025	0.914	rs488888	chr3:121234337	T/G	cg16417163	chr3:121280760	NA	-0.49	-4.87	-0.37	2.78e-6	Aging (facial);
PAAD	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.8	0.48	2.23e-10	Heart rate;
PAAD	cis	rs7264396	0.832	rs224371	chr20:34074831	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	4.26	0.33	3.56e-5	Total cholesterol levels;
PAAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.48	-4.39	-0.34	2.08e-5	IgG glycosylation;
PAAD	cis	rs9287719	0.649	rs2160258	chr2:10717221	T/A	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.83	9.48	0.61	4.76e-17	Metabolic syndrome;
PAAD	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-10.11	-0.63	1.06e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.48	-4.44	-0.34	1.74e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10519680	chr8:37707506	BRF2	0.67	7.56	0.52	3.47e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.32	0.71	1.25e-24	Menopause (age at onset);
PAAD	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg09980403	chr19:12975529	MAST1	0.31	4.71	0.36	5.63e-6	Mean corpuscular volume;
PAAD	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15644404	chr18:77186268	NFATC1	-0.93	-5.49	-0.41	1.62e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg03264133	chr6:25882463	NA	0.48	4.58	0.35	9.78e-6	Blood metabolite levels;
PAAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.74	6.47	0.46	1.27e-9	Inflammatory skin disease;
PAAD	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.51	5.06	0.38	1.22e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.54	4.66	0.35	6.89e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-8.15	-0.55	1.25e-13	Total body bone mineral density;
PAAD	cis	rs8025118	0.559	rs1865365	chr15:79553571	C/T	cg24739098	chr15:79297159	RASGRF1	-0.39	-4.48	-0.34	1.46e-5	Cognitive function;
PAAD	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg08523384	chr5:141488047	NDFIP1	-0.63	-5.74	-0.42	4.9e-8	Crohn's disease;
PAAD	cis	rs2251260	0.891	rs2246695	chr14:62008065	C/T	cg23386212	chr14:62041363	NA	0.54	4.32	0.33	2.77e-5	Yeast infection;
PAAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg07371521	chr5:154026371	NA	0.54	6.84	0.49	1.82e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg18941348	chr6:13814973	CCDC90A	-0.6	-6.96	-0.49	9.28e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2131877	1.000	rs2131877	chr3:194858374	C/T	cg16306870	chr3:194868790	C3orf21	0.41	4.28	0.33	3.24e-5	Non-small cell lung cancer;
PAAD	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.49	0.65	1.04e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4662750	0.580	rs4662745	chr2:128352863	T/G	cg09760422	chr2:128146352	NA	0.35	5.15	0.39	7.83e-7	Renal cell carcinoma;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg07202610	chr7:1142643	C7orf50	-0.68	-5.68	-0.42	6.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs901683	1.000	rs71494788	chr10:45972325	C/G	cg23720331	chr10:123873670	TACC2	-0.86	-6.47	-0.46	1.3e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2880058	0.746	rs12090585	chr1:162038776	G/A	cg22816059	chr5:422114	AHRR	-0.62	-6.54	-0.47	8.87e-10	QT interval;
PAAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg10589385	chr1:150898437	SETDB1	0.37	4.52	0.34	1.24e-5	Melanoma;
PAAD	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.68	0.42	6.53e-8	Ileal carcinoids;
PAAD	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg12935359	chr14:103987150	CKB	0.56	4.84	0.37	3.23e-6	Monocyte count;
PAAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.71	-7.17	-0.5	3.01e-11	DNA methylation (variation);
PAAD	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.6	5.68	0.42	6.71e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7301016	1.000	rs11174495	chr12:62864931	A/G	cg19781863	chr12:62918364	MON2	0.75	4.44	0.34	1.7e-5	IgG glycosylation;
PAAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22633769	chr20:60982531	CABLES2	-0.49	-4.61	-0.35	8.36e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs75920871	0.623	rs17120244	chr11:116919511	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.1	-0.38	9.97e-7	Subjective well-being;
PAAD	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg27455613	chr17:80820699	TBCD	-0.51	-5.18	-0.39	6.89e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.8	9.87	0.63	4.53e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.8	-9.13	-0.6	3.87e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg19630374	chr17:18023558	MYO15A	-0.46	-4.73	-0.36	5e-6	Total body bone mineral density;
PAAD	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.04	-0.38	1.28e-6	Schizophrenia;
PAAD	cis	rs6715793	0.836	rs6543698	chr2:33402971	C/T	cg26672287	chr2:33391915	LTBP1	-0.36	-4.3	-0.33	2.99e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg24110177	chr3:50126178	RBM5	0.47	4.77	0.36	4.27e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-1.0	-10.39	-0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs4455778	0.538	rs34820160	chr7:49115948	C/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.66	-8.46	-0.57	2.03e-14	Body mass index;
PAAD	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg06740227	chr12:86229804	RASSF9	0.47	4.47	0.34	1.49e-5	Major depressive disorder;
PAAD	cis	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg03676636	chr4:99064102	C4orf37	0.3	5.68	0.42	6.75e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8077577	0.708	rs9913139	chr17:18153815	T/C	cg16794390	chr17:18148240	FLII	0.51	4.5	0.34	1.37e-5	Obesity-related traits;
PAAD	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.43	-4.84	-0.37	3.2e-6	Blood pressure (smoking interaction);
PAAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.66	9.59	0.61	2.59e-17	Height;
PAAD	cis	rs1451882	0.719	rs12546726	chr8:1053209	G/C	cg07395941	chr8:1078200	NA	0.6	4.53	0.34	1.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg11802864	chr11:65308245	LTBP3	-0.47	-4.85	-0.37	3.03e-6	Bone mineral density;
PAAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.51	5.08	0.38	1.11e-6	Personality dimensions;
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21518248	chr2:162101506	NA	-0.6	-6.58	-0.47	7.35e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.49	-4.84	-0.37	3.18e-6	Breast size;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	7.02e-13	Prudent dietary pattern;
PAAD	trans	rs901683	1.000	rs71496619	chr10:46068095	T/C	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.9	-0.37	2.44e-6	Schizophrenia;
PAAD	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg14981132	chr12:54675468	HNRNPA1;HNRPA1L-2	0.44	4.36	0.33	2.37e-5	Height;
PAAD	cis	rs13053817	1.000	rs13057382	chr22:29850334	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.54	-4.71	-0.36	5.51e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg11262906	chr1:85462892	MCOLN2	0.71	5.65	0.42	7.7e-8	Serum sulfate level;
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg12143784	chr7:64541923	NA	0.34	4.37	0.33	2.25e-5	Aortic root size;
PAAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.71	7.11	0.5	4.31e-11	Platelet count;
PAAD	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg22532475	chr10:104410764	TRIM8	-0.38	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.62	5.54	0.41	1.28e-7	Red blood cell count;
PAAD	cis	rs2295359	0.697	rs11209017	chr1:67666235	A/T	cg12940439	chr1:67600707	NA	0.36	4.32	0.33	2.78e-5	Psoriasis;
PAAD	cis	rs9810890	1.000	rs73198843	chr3:128502514	G/A	cg18531004	chr3:128564980	NA	-0.8	-5.15	-0.39	7.98e-7	Dental caries;
PAAD	cis	rs12986413	1.000	rs12982593	chr19:2175891	C/A	cg09261902	chr19:2140048	AP3D1	0.49	4.84	0.37	3.13e-6	Height;
PAAD	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg08975724	chr8:8085496	FLJ10661	0.66	6.75	0.48	2.87e-10	Neuroticism;
PAAD	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-4.44	-0.34	1.75e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.94	-0.37	2e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	5.25	0.39	5.06e-7	Ovarian reserve;
PAAD	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg02580895	chr19:2754563	NA	-0.51	-4.44	-0.34	1.69e-5	Total cholesterol levels;
PAAD	cis	rs1419980	0.730	rs11054897	chr12:7774251	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.3	-0.33	3.03e-5	HDL cholesterol levels;
PAAD	cis	rs6089829	0.747	rs57767914	chr20:61659108	C/G	cg03213289	chr20:61660250	NA	-0.51	-7.01	-0.49	7.27e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.86	-9.33	-0.6	1.18e-16	Obesity-related traits;
PAAD	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.78	5.9	0.43	2.26e-8	Diisocyanate-induced asthma;
PAAD	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.62	9.39	0.61	8.19e-17	Asthma (sex interaction);
PAAD	cis	rs3996993	0.703	rs1072341	chr6:52648906	T/A	cg20803780	chr6:52668592	GSTA1	-0.34	-4.26	-0.33	3.55e-5	Hemoglobin concentration;
PAAD	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.53	5.29	0.39	4.27e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4455778	0.580	rs7783068	chr7:49120791	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.62	5.04	0.38	1.31e-6	Breast cancer;
PAAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.79	0.58	3.01e-15	Menopause (age at onset);
PAAD	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.49	-4.72	-0.36	5.3e-6	Mean platelet volume;
PAAD	trans	rs901683	1.000	rs71496610	chr10:46021646	C/G	cg23720331	chr10:123873670	TACC2	-0.81	-6.39	-0.46	1.94e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs58521262	0.685	rs2935443	chr19:23214649	G/C	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.66e-5	Testicular germ cell tumor;
PAAD	cis	rs3206736	0.548	rs328908	chr7:35026008	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs787274	1.000	rs2796027	chr9:115529404	A/T	cg13803584	chr9:115635662	SNX30	-0.81	-4.62	-0.35	8.18e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7011049	1.000	rs72643585	chr8:53847651	A/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	9.38	0.61	8.83e-17	Lymphocyte counts;
PAAD	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.57	6.52	0.47	1e-9	Platelet distribution width;
PAAD	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.71	-6.73	-0.48	3.22e-10	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	4.51	0.34	1.31e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg06569542	chr10:98946673	SLIT1	0.5	5.59	0.41	1.05e-7	Monocyte count;
PAAD	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg07828024	chr6:149772892	ZC3H12D	0.33	4.74	0.36	4.79e-6	Dupuytren's disease;
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.64	-6.81	-0.48	2.15e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs901683	0.850	rs77876088	chr10:46094121	T/C	cg12869334	chr8:37699360	GPR124	0.96	6.46	0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-6.08	-0.44	9.37e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.33	-0.4	3.42e-7	Initial pursuit acceleration;
PAAD	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.78	8.95	0.59	1.15e-15	Heart rate;
PAAD	cis	rs9880211	0.800	rs9845862	chr3:136472573	T/C	cg17177318	chr3:135913615	MSL2	0.57	4.31	0.33	2.95e-5	Body mass index;Height;
PAAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.47	4.27	0.33	3.4e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02359409	chr6:42947317	PEX6	-0.47	-4.65	-0.35	7.07e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.28e-6	Height;
PAAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	4.73	0.36	5.12e-6	Bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17387746	chr19:2950636	NA	0.64	6.75	0.48	2.93e-10	Myopia (pathological);
PAAD	cis	rs501120	0.584	rs11511598	chr10:44716036	C/T	cg09554077	chr10:44749378	NA	0.44	5.25	0.39	5.13e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.19	0.39	6.6e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1620921	0.505	rs4709467	chr6:161203079	G/A	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs4727443	0.736	rs17295356	chr7:99569394	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.48	4.89	0.37	2.59e-6	Interstitial lung disease;
PAAD	cis	rs582384	0.630	rs600040	chr2:45867332	T/G	cg13704086	chr2:45177125	NA	-0.46	-4.36	-0.33	2.39e-5	Coronary artery disease;
PAAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-1.04	-17.48	-0.82	3.42e-38	Height;
PAAD	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg05564831	chr3:52568323	NT5DC2	0.45	4.68	0.35	6.26e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.26	-0.45	3.82e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.57	-6.22	-0.45	4.56e-9	Lung cancer;
PAAD	cis	rs6850606	0.537	rs10517057	chr4:42900562	A/C	cg24533989	chr4:42659536	ATP8A1	0.5	4.36	0.33	2.34e-5	Interferon alpha levels in systemic lupus erythematosus;
PAAD	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg16576597	chr16:28551801	NUPR1	0.66	7.06	0.5	5.42e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg04330084	chr7:123175371	IQUB	-0.52	-4.62	-0.35	8.24e-6	Plateletcrit;Platelet count;
PAAD	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg21698718	chr17:80085957	CCDC57	0.45	5.11	0.38	9.46e-7	Life satisfaction;
PAAD	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg15507776	chr3:136538369	TMEM22	0.47	4.64	0.35	7.45e-6	Neuroticism;
PAAD	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.4	-5.41	-0.4	2.42e-7	Myeloid white cell count;
PAAD	cis	rs2412208	0.683	rs12091438	chr1:7069503	G/A	cg26570804	chr1:6352357	ACOT7	0.51	4.78	0.36	4.06e-6	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.65	-6.54	-0.47	8.64e-10	Body mass index;
PAAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg19000871	chr14:103996768	TRMT61A	-0.51	-5.74	-0.42	5.1e-8	Coronary artery disease;
PAAD	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.45	-0.34	1.68e-5	Height;
PAAD	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.52	5.32	0.4	3.59e-7	Colorectal cancer;
PAAD	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.54	5.26	0.39	4.8e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2908197	0.765	rs2098205	chr7:75938888	A/G	cg15798862	chr7:76129360	DTX2	-0.34	-4.26	-0.33	3.64e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12773846	0.537	rs35103967	chr10:126272746	C/T	cg04949429	chr10:126290192	LHPP	0.66	5.74	0.42	4.95e-8	Subcutaneous adipose tissue;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11544257	chr2:102673734	NA	-0.56	-6.69	-0.48	3.98e-10	Immature fraction of reticulocytes;
PAAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.32	-0.33	2.84e-5	Obesity-related traits;
PAAD	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs13034020	0.522	rs62150978	chr2:61256222	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.47	0.34	1.52e-5	Hodgkin's lymphoma;
PAAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.52	7.9	0.54	5.32e-13	Rheumatoid arthritis;
PAAD	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16386425	chr10:429943	DIP2C	-0.49	-5.27	-0.39	4.63e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06850241	chr22:41845214	NA	-0.53	-4.68	-0.35	6.3e-6	Vitiligo;
PAAD	cis	rs2730260	0.800	rs73169216	chr7:158834662	G/A	cg13444538	chr7:158905317	VIPR2	-0.62	-4.47	-0.34	1.55e-5	Myopia (pathological);
PAAD	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	7.97	0.54	3.49e-13	Response to antipsychotic treatment;
PAAD	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.49	-4.67	-0.35	6.61e-6	Blood trace element (Cu levels);
PAAD	cis	rs7101378	0.577	rs2175173	chr11:108896600	G/C	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	IgG glycosylation;
PAAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg01426195	chr3:39028469	NA	0.69	7.17	0.5	3.06e-11	Handedness;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02503646	chr3:52444059	PHF7;BAP1	-0.58	-6.73	-0.48	3.19e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg05895507	chr15:77155635	SCAPER	0.37	4.4	0.34	2.05e-5	Blood metabolite levels;
PAAD	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.76	-6.85	-0.49	1.7e-10	Inhibitory control;
PAAD	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg25730555	chr22:47059586	GRAMD4	0.48	4.7	0.36	5.83e-6	Urate levels in obese individuals;
PAAD	cis	rs2885056	0.830	rs2360748	chr19:10693624	T/C	cg06392426	chr19:10676186	KRI1	0.53	5.16	0.39	7.49e-7	Red cell distribution width;
PAAD	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.75	-8.24	-0.56	7.42e-14	Sudden cardiac arrest;
PAAD	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.43	4.27	0.33	3.43e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg19429281	chr19:53496738	ZNF702P	-0.6	-6.26	-0.45	3.76e-9	Psoriasis;
PAAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04287289	chr16:89883240	FANCA	0.73	4.25	0.33	3.7e-5	Skin colour saturation;
PAAD	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.03e-6	Monocyte percentage of white cells;
PAAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg26939375	chr7:64535504	NA	0.75	8.94	0.59	1.24e-15	Calcium levels;
PAAD	cis	rs900145	0.953	rs10832011	chr11:13287938	G/A	cg15603424	chr11:13300592	ARNTL	0.49	4.31	0.33	2.97e-5	Menarche (age at onset);
PAAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.53	4.65	0.35	7.15e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg15117754	chr3:10150083	C3orf24	0.59	5.55	0.41	1.22e-7	Alzheimer's disease;
PAAD	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.81	-9.43	-0.61	6.7e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.92	-7.85	-0.54	6.97e-13	Gut microbiome composition (summer);
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.88	-12.78	-0.72	7.31e-26	Cystic fibrosis severity;
PAAD	cis	rs741013	1.000	rs73128700	chr3:64293762	G/A	cg20180538	chr3:64559102	ADAMTS9	-0.9	-4.34	-0.33	2.64e-5	Coronary artery calcification;
PAAD	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.47	-4.49	-0.34	1.41e-5	Type 2 diabetes;
PAAD	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.06	-6.91	-0.49	1.26e-10	Mitochondrial DNA levels;
PAAD	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.6	6.02	0.44	1.25e-8	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg04257695	chr17:30186438	C17orf79	0.62	5.09	0.38	1.05e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.66	-6.62	-0.47	5.89e-10	Uric acid levels;
PAAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg23298862	chr7:158159286	PTPRN2	-0.46	-4.26	-0.33	3.56e-5	Calcium levels;
PAAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg01685242	chr11:65405760	SIPA1	0.56	4.51	0.34	1.28e-5	Blood pressure (age interaction);
PAAD	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.44	6.23	0.45	4.33e-9	Oropharynx cancer;
PAAD	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg12935359	chr14:103987150	CKB	-0.62	-6.68	-0.48	4.26e-10	Body mass index;
PAAD	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.71	-7.53	-0.52	4.24e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.64	7.62	0.53	2.49e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6782228	0.509	rs6780447	chr3:128413808	T/C	cg16766828	chr3:128327626	NA	-0.46	-6.13	-0.45	7.17e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	5.88	0.43	2.57e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.98	8.28	0.56	5.73e-14	Triglycerides;
PAAD	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.46	5.97	0.44	1.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8040855	0.627	rs4980356	chr15:85608132	G/A	cg08123816	chr15:85640762	PDE8A	-0.44	-5.29	-0.39	4.23e-7	Bulimia nervosa;
PAAD	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.16	9.96	0.63	2.73e-18	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	5.94e-20	Electrocardiographic conduction measures;
PAAD	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg00666640	chr1:248458726	OR2T12	0.48	4.93	0.37	2.17e-6	Common traits (Other);
PAAD	cis	rs5753037	0.653	rs105311	chr22:30137262	G/A	cg01021169	chr22:30184971	ASCC2	-0.46	-4.79	-0.36	3.84e-6	Type 1 diabetes;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs6076065	0.723	rs6083095	chr20:23354090	C/T	cg11657817	chr20:23433608	CST11	0.5	5.27	0.39	4.56e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.18	0.5	2.92e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.43	-5.03	-0.38	1.4e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.74	7.72	0.53	1.43e-12	Body mass index;
PAAD	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.53	-0.41	1.36e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.58	5.56	0.41	1.18e-7	Graves' disease;
PAAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg27494647	chr7:150038898	RARRES2	0.41	4.42	0.34	1.86e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-7.44	-0.52	6.86e-12	Leprosy;
PAAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg12215294	chr3:40350768	EIF1B	-0.47	-4.38	-0.33	2.24e-5	Renal cell carcinoma;
PAAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11758127	chr1:2002884	PRKCZ	0.59	6.41	0.46	1.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.64e-8	Tonsillectomy;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.37	-4.26	-0.33	3.64e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs4795519	0.784	rs4889750	chr17:22185655	C/T	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.93	11.59	0.68	1.18e-22	Pulse pressure;
PAAD	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13798912	chr7:905769	UNC84A	0.61	4.58	0.35	9.81e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs863345	0.565	rs10908671	chr1:158502160	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	trans	rs62179067	0.708	rs62176027	chr2:179919552	G/A	cg13380624	chr19:7735426	NA	-0.73	-6.69	-0.48	4.05e-10	Late-onset Alzheimer's disease;
PAAD	cis	rs1497828	0.956	rs2815222	chr1:217522229	T/A	cg04411442	chr1:217543379	NA	-0.48	-4.76	-0.36	4.46e-6	Dialysis-related mortality;
PAAD	cis	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg21546286	chr11:48923668	NA	0.52	5.4	0.4	2.57e-7	HDL cholesterol;
PAAD	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg11779900	chr17:80519722	FOXK2	-0.47	-4.62	-0.35	8.16e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	6.66	0.48	4.62e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	8.44	0.56	2.38e-14	Mean corpuscular hemoglobin;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07575867	chr3:58223146	ABHD6	-0.64	-6.36	-0.46	2.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-10.21	-0.64	5.91e-19	Headache;
PAAD	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.41	-0.56	2.79e-14	Urate levels in overweight individuals;
PAAD	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.69	-0.36	5.97e-6	Breast cancer;
PAAD	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.75	5.35	0.4	3.23e-7	Schizophrenia;
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg23018236	chr17:30244563	NA	-0.63	-5.44	-0.4	2.13e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.77	-8.07	-0.55	1.95e-13	Neurofibrillary tangles;
PAAD	cis	rs6142102	0.961	rs2235596	chr20:32684309	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.32	-0.33	2.81e-5	Skin pigmentation;
PAAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg05861140	chr6:150128134	PCMT1	-0.57	-6.49	-0.47	1.12e-9	Lung cancer;
PAAD	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21646471	chr2:242523971	THAP4	0.65	5.05	0.38	1.24e-6	Prostate cancer;
PAAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg11335335	chr11:637885	DRD4	-0.38	-4.92	-0.37	2.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.62	-0.35	8.27e-6	Platelet count;
PAAD	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg07703079	chr11:430292	ANO9	0.95	5.92	0.43	2.05e-8	Body mass index;
PAAD	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg03453431	chr7:157225567	NA	-0.49	-5.22	-0.39	5.76e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.57	7.59	0.52	2.96e-12	Renal cell carcinoma;
PAAD	cis	rs2882667	0.690	rs10155636	chr5:138261990	A/G	cg09476006	chr5:138032270	NA	0.43	5.3	0.39	3.99e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg09127314	chr1:152161683	NA	-0.68	-5.11	-0.38	9.5e-7	Atopic dermatitis;
PAAD	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.63	6.7	0.48	3.85e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14163802	chr2:206547479	NRP2	0.56	6.47	0.46	1.29e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.92	-8.3	-0.56	5.22e-14	Diastolic blood pressure;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg05881682	chr3:95402607	NA	-0.5	-6.56	-0.47	8.04e-10	Energy expenditure (24h);
PAAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.5	-4.46	-0.34	1.6e-5	P wave terminal force;
PAAD	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg01620082	chr3:125678407	NA	-0.92	-6.64	-0.47	5.21e-10	Depression;
PAAD	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.57	-4.69	-0.36	5.93e-6	Vitiligo;
PAAD	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg08648136	chr8:956695	NA	0.43	4.46	0.34	1.61e-5	Schizophrenia;
PAAD	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-6.55	-0.47	8.28e-10	Multiple sclerosis;
PAAD	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg07841815	chr7:100318223	EPO	-0.51	-4.86	-0.37	2.93e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.39	-5.0	-0.38	1.56e-6	Thyroid stimulating hormone;
PAAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg13918804	chr1:2043761	PRKCZ	-0.34	-4.65	-0.35	7.25e-6	Height;
PAAD	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.49	5.43	0.4	2.21e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09559352	chr16:15978691	C16orf63	-0.61	-6.46	-0.46	1.36e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg03047570	chr10:32398778	NA	-0.66	-4.51	-0.34	1.31e-5	Anti-saccade response;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg22907277	chr7:1156413	C7orf50	0.87	4.49	0.34	1.4e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg17633681	chr16:88106987	BANP	0.52	5.87	0.43	2.64e-8	Menopause (age at onset);
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg16606324	chr3:10149918	C3orf24	0.62	4.4	0.34	2.03e-5	Alzheimer's disease;
PAAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg14851346	chr12:38532713	NA	-0.46	-4.25	-0.33	3.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs308971	0.656	rs307558	chr3:12095130	G/A	cg15873301	chr3:12045459	SYN2	0.64	5.34	0.4	3.3e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs12431939	1.000	rs58225416	chr14:51662196	C/T	cg23942311	chr14:51606299	NA	-0.72	-5.79	-0.42	3.94e-8	Cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18261461	chr6:138725231	HEBP2	-0.73	-6.46	-0.46	1.34e-9	Neuroticism;
PAAD	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.98	9.44	0.61	6.3e-17	Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.65	-5.59	-0.41	1.05e-7	Menarche (age at onset);
PAAD	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.97	-0.49	9.19e-11	Eye color traits;
PAAD	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.38	4.65	0.35	7.21e-6	Corneal astigmatism;
PAAD	cis	rs62238980	0.831	rs62239006	chr22:32593663	C/T	cg00543991	chr22:32367038	NA	1.1	5.84	0.43	3.1e-8	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12975709	chr7:47317262	TNS3	-0.59	-6.36	-0.46	2.2e-9	Immature fraction of reticulocytes;
PAAD	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.58	-6.33	-0.46	2.65e-9	Sense of smell;
PAAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	8.88	0.58	1.71e-15	Bone mineral density;
PAAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg26939375	chr7:64535504	NA	0.79	9.37	0.61	9.2e-17	Calcium levels;
PAAD	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg02875869	chr16:89901417	SPIRE2	-0.53	-5.13	-0.38	8.91e-7	Skin aging (microtopography measurement);
PAAD	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg21191810	chr6:118973309	C6orf204	0.48	6.11	0.44	8.03e-9	Electrocardiographic conduction measures;
PAAD	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.66	6.38	0.46	2.05e-9	Lymphocyte counts;
PAAD	cis	rs243505	0.762	rs3779036	chr7:148488507	C/T	cg09806900	chr7:148480153	CUL1	0.53	4.94	0.37	2.01e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-1.12	-8.8	-0.58	2.83e-15	Post bronchodilator FEV1;
PAAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg10935138	chr17:73851978	WBP2	0.88	7.28	0.51	1.67e-11	Psoriasis;
PAAD	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.6	5.12	0.38	9.06e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07476643	chr10:102729063	NA	0.6	6.48	0.47	1.21e-9	Myopia (pathological);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25846302	chr15:102501640	WASH3P	-0.68	-7.44	-0.52	6.95e-12	Smoking initiation;
PAAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.49	-4.39	-0.34	2.08e-5	P wave terminal force;
PAAD	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.93	7.11	0.5	4.2e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1468333	0.929	rs2107682	chr5:137543135	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	trans	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg22670128	chr1:1210100	UBE2J2	-0.58	-6.33	-0.46	2.63e-9	Menopause (age at onset);
PAAD	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21646471	chr2:242523971	THAP4	0.68	5.33	0.4	3.41e-7	Prostate cancer;
PAAD	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.06e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.96	-8.58	-0.57	1e-14	Bipolar disorder;
PAAD	cis	rs9657904	0.813	rs28533328	chr3:105559353	T/C	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	4.27	0.33	3.4e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.77	7.03	0.5	6.41e-11	Obesity-related traits;
PAAD	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.59	5.64	0.42	8.05e-8	Schizophrenia;
PAAD	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg18612461	chr15:75251733	NA	0.69	8.95	0.59	1.16e-15	Breast cancer;
PAAD	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg12721952	chr1:2337711	PEX10	0.48	4.57	0.35	1.02e-5	Plateletcrit;
PAAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.73	9.37	0.6	9.64e-17	Cancer;
PAAD	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg25401027	chr5:176370377	UIMC1	0.56	5.61	0.41	9.51e-8	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs4523957	0.548	rs7225623	chr17:2089548	T/C	cg16513277	chr17:2031491	SMG6	-0.64	-6.75	-0.48	2.86e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6681460	0.625	rs12127199	chr1:67103742	T/C	cg02459107	chr1:67143332	SGIP1	0.54	5.06	0.38	1.22e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg23127183	chr11:57508653	C11orf31	-0.51	-4.36	-0.33	2.34e-5	Schizophrenia;
PAAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg22189786	chr22:42395067	WBP2NL	-0.42	-4.42	-0.34	1.91e-5	Cognitive function;
PAAD	cis	rs10186876	0.541	rs12712902	chr2:44189487	G/A	cg09541576	chr2:44873248	C2orf34	0.44	4.46	0.34	1.56e-5	Hand grip strength;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04127825	chr1:167503222	NA	0.66	7.5	0.52	4.85e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg27490568	chr2:178487706	NA	0.45	4.97	0.37	1.76e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.8	7.43	0.52	7.33e-12	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.25e-10	Uric acid levels;
PAAD	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.68	6.76	0.48	2.78e-10	Callous-unemotional behaviour;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	16.15	0.79	8.6e-35	Height;
PAAD	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.17	0.39	7.34e-7	Tonsillectomy;
PAAD	cis	rs3106136	0.843	rs17021507	chr4:95274671	G/A	cg11021082	chr4:95130006	SMARCAD1	0.59	5.59	0.41	1.03e-7	Capecitabine sensitivity;
PAAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.36	-0.33	2.37e-5	Schizophrenia;
PAAD	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg00253185	chr1:247542119	NA	0.55	4.57	0.35	1e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg05694089	chr1:16159484	NA	-0.32	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.67	5.67	0.42	6.88e-8	Schizophrenia;
PAAD	cis	rs7615952	0.551	rs58274173	chr3:125800700	G/A	cg05084668	chr3:125655381	ALG1L	-0.92	-7.5	-0.52	4.86e-12	Blood pressure (smoking interaction);
PAAD	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs8081395	0.801	rs12938273	chr17:57901652	G/A	cg02344993	chr17:57696989	CLTC	-0.44	-4.32	-0.33	2.76e-5	White blood cell count;
PAAD	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg02286717	chr10:75415704	SYNPO2L	-0.44	-4.26	-0.33	3.54e-5	Incident atrial fibrillation;
PAAD	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg08079166	chr15:68083412	MAP2K5	0.63	4.86	0.37	2.93e-6	Restless legs syndrome;
PAAD	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg16434002	chr17:42200994	HDAC5	0.68	7.56	0.52	3.49e-12	Total body bone mineral density;
PAAD	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.18	-0.5	2.9e-11	Response to antipsychotic treatment;
PAAD	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.87	-0.37	2.71e-6	Height;
PAAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.73	0.36	5.08e-6	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg13047869	chr3:10149882	C3orf24	0.58	5.16	0.39	7.61e-7	Alzheimer's disease;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg06565975	chr8:143823917	SLURP1	-0.23	-4.79	-0.36	3.88e-6	Urinary tract infection frequency;
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg15181151	chr6:150070149	PCMT1	0.55	5.93	0.43	1.97e-8	Lung cancer;
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.5	4.91	0.37	2.34e-6	Prostate cancer;
PAAD	cis	rs73206853	0.620	rs73194027	chr12:111144317	C/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.45	0.34	1.66e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg04160749	chr8:58172571	NA	-0.71	-4.75	-0.36	4.71e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg20913747	chr6:44695427	NA	-0.66	-6.56	-0.47	7.84e-10	Total body bone mineral density;
PAAD	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	IgM levels;
PAAD	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	1.84	10.22	0.64	5.31e-19	Cannabis dependence symptom count;
PAAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.8	-6.12	-0.44	7.72e-9	Yeast infection;
PAAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.59	-0.35	9.09e-6	Breast cancer;
PAAD	cis	rs939584	0.778	rs6548239	chr2:635154	G/A	cg14515364	chr2:636606	NA	0.51	4.72	0.36	5.37e-6	Body mass index;
PAAD	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs863345	0.604	rs10908656	chr1:158461016	A/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.81	-0.36	3.68e-6	Pneumococcal bacteremia;
PAAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.47	4.87	0.37	2.81e-6	Major depressive disorder;
PAAD	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg01176363	chr20:62369445	LIME1	-0.52	-5.19	-0.39	6.57e-7	Prostate cancer;
PAAD	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16447950	chr5:562315	NA	-0.66	-5.86	-0.43	2.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg14393609	chr7:65229607	NA	0.46	4.5	0.34	1.34e-5	Aortic root size;
PAAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.84	7.5	0.52	5.07e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs13382275	1.000	rs13382275	chr2:965579	A/G	cg02924234	chr2:420061	NA	0.57	4.71	0.36	5.6e-6	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg09835421	chr16:68378352	PRMT7	-1.09	-8.09	-0.55	1.81e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.58	5.33	0.4	3.41e-7	Self-reported allergy;
PAAD	cis	rs901683	0.572	rs17157859	chr10:45989409	T/C	cg16908948	chr10:45500256	ZNF22	0.82	4.35	0.33	2.46e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.67	7.9	0.54	5.36e-13	Parkinson's disease;
PAAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.64	7.36	0.51	1.1e-11	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg06637938	chr14:75390232	RPS6KL1	0.48	4.74	0.36	4.78e-6	Height;
PAAD	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.12	-7.95	-0.54	4.01e-13	Mitochondrial DNA levels;
PAAD	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.42	-4.3	-0.33	3.02e-5	Corneal structure;
PAAD	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.4	-5.88	-0.43	2.53e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-4.79	-0.36	3.86e-6	Height;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.16	0.55	1.18e-13	Height;
PAAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.11	-0.5	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2421770	0.532	rs4459280	chr11:35343355	C/T	cg13971030	chr11:35366721	SLC1A2	-0.51	-4.97	-0.37	1.76e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg06131755	chr6:160182447	ACAT2	0.53	4.66	0.35	6.95e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11892454	0.544	rs35404220	chr2:26004120	T/C	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10359030	chr19:17326115	USE1	0.61	6.67	0.48	4.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.36e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg26695010	chr11:65641043	EFEMP2	-0.45	-4.31	-0.33	2.9e-5	Eosinophil percentage of white cells;
PAAD	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg19486271	chr11:47235900	DDB2	0.55	5.57	0.41	1.14e-7	Acne (severe);
PAAD	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.47	-5.22	-0.39	5.86e-7	Age at first birth;
PAAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.99	-0.49	8.15e-11	Life satisfaction;
PAAD	cis	rs500492	0.508	rs2744147	chr16:1073146	C/G	cg10293297	chr16:304604	ITFG3	0.6	4.46	0.34	1.6e-5	Polycystic ovary syndrome;
PAAD	cis	rs7577696	0.924	rs212760	chr2:32429222	A/G	cg02381751	chr2:32503542	YIPF4	0.43	4.54	0.35	1.14e-5	Inflammatory biomarkers;
PAAD	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.74	0.62	1.04e-17	Electrocardiographic conduction measures;
PAAD	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.66	9.42	0.61	7.11e-17	Breast cancer;
PAAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.8	10.11	0.63	1.09e-18	Vitiligo;
PAAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.57	-6.51	-0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs7498403	0.509	rs78867442	chr16:79610267	A/G	cg08091526	chr16:79156020	WWOX	0.94	4.4	0.34	2.06e-5	Height;
PAAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.9	7.78	0.53	1.01e-12	Alzheimer's disease;
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg26060667	chr1:247681242	NA	-0.46	-5.43	-0.4	2.23e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.26e-8	Prostate cancer;
PAAD	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.19	-0.39	6.53e-7	Height;
PAAD	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg15211996	chr1:2936768	ACTRT2	0.46	4.54	0.35	1.15e-5	Plateletcrit;
PAAD	cis	rs17127529	0.570	rs1325609	chr1:65805962	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	4.59	0.35	9.3e-6	Idiopathic osteonecrosis of the femoral head;
PAAD	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg22467129	chr15:76604101	ETFA	0.5	4.74	0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.77	7.13	0.5	3.88e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10490913	1.000	rs11198382	chr10:120149774	A/C	cg04126427	chr10:120840676	EIF3A	-0.47	-4.85	-0.37	2.97e-6	Cancer;
PAAD	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.85	7.1	0.5	4.39e-11	Pulmonary function decline;
PAAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.58	-0.35	9.48e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	1.05	6.47	0.46	1.29e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs8027181	0.740	rs8038247	chr15:73096573	A/G	cg25632853	chr15:73088954	NA	0.39	4.28	0.33	3.26e-5	Triglyceride levels;
PAAD	cis	rs1370916	0.583	rs12702315	chr7:47240517	T/C	cg17445213	chr7:47408746	TNS3	0.39	4.29	0.33	3.15e-5	Colorectal cancer (diet interaction);
PAAD	cis	rs1345301	1.000	rs13431601	chr2:102873713	G/A	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.33	-0.33	2.72e-5	Waist circumference;
PAAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.71	-0.36	5.43e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.87	0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs4795519	0.625	rs12325748	chr17:22213908	C/T	cg22648282	chr17:21454238	C17orf51	-0.5	-5.06	-0.38	1.19e-6	Chronic myeloid leukemia;
PAAD	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.45	5.31	0.4	3.75e-7	QRS complex (12-leadsum);
PAAD	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.77	-7.1	-0.5	4.46e-11	DNA methylation (variation);
PAAD	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04850017	chr11:63683019	RCOR2	0.39	4.44	0.34	1.72e-5	Pulse pressure;
PAAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00863271	chr17:76798776	USP36	0.55	6.67	0.48	4.35e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.53	-6.69	-0.48	3.99e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.98	-13.62	-0.74	4.12e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11105468	0.701	rs7963304	chr12:90436571	T/C	cg16962463	chr12:89968675	NA	0.45	4.36	0.33	2.4e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.72	7.91	0.54	4.99e-13	Morning vs. evening chronotype;
PAAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.51	-4.79	-0.36	3.98e-6	Hirschsprung disease;
PAAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg15017067	chr4:17643749	FAM184B	0.46	5.36	0.4	3.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg10818794	chr15:86012489	AKAP13	0.48	5.23	0.39	5.61e-7	Interstitial lung disease;
PAAD	cis	rs62045849	0.557	rs6500532	chr16:89174133	A/C	cg03605463	chr16:89740564	NA	-0.93	-4.56	-0.35	1.07e-5	Red blood cell count;
PAAD	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.57	4.61	0.35	8.34e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01585723	chr16:33734837	NA	0.42	4.34	0.33	2.62e-5	Menopause (age at onset);
PAAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg16898833	chr6:26189333	HIST1H4D	0.68	5.29	0.39	4.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg09659197	chr4:152720779	NA	0.35	5.25	0.39	4.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-0.64	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs7662987	1.000	rs28730595	chr4:100003333	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-4.25	-0.33	3.73e-5	Smoking initiation;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg10396713	chr8:602097	NA	-0.66	-4.45	-0.34	1.64e-5	IgG glycosylation;
PAAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg10556349	chr10:835070	NA	0.56	4.65	0.35	7.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.91	-0.37	2.33e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04306229	chr2:120771150	EPB41L5	0.61	7.56	0.52	3.49e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg12486944	chr17:80159399	CCDC57	-0.51	-4.53	-0.35	1.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-19.33	-0.84	8.45e-43	Myeloid white cell count;
PAAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.64	-6.84	-0.49	1.77e-10	Schizophrenia;
PAAD	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.89	-8.36	-0.56	3.75e-14	Colorectal adenoma (advanced);
PAAD	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg14146966	chr2:61757674	XPO1	0.42	5.22	0.39	5.88e-7	Tuberculosis;
PAAD	cis	rs939584	0.935	rs7604752	chr2:643428	C/A	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs9992101	0.547	rs10029860	chr4:77411101	C/A	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg19423196	chr10:82049429	MAT1A	0.59	4.41	0.34	1.93e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.35	0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.72	8.23	0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.8	-4.82	-0.36	3.45e-6	Obesity-related traits;
PAAD	trans	rs901683	0.850	rs76879426	chr10:46044857	G/A	cg13065504	chr15:42448234	PLA2G4F	0.81	6.49	0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.55	5.38	0.4	2.77e-7	Breast cancer;
PAAD	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	1.1	8.07	0.55	1.96e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg10934807	chr2:113191815	RGPD8;RGPD5	-0.9	-6.44	-0.46	1.5e-9	Yeast infection;
PAAD	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg08888203	chr3:10149979	C3orf24	0.75	6.58	0.47	7.06e-10	Alzheimer's disease;
PAAD	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg24585817	chr7:64895279	NA	0.45	4.45	0.34	1.66e-5	Aortic root size;
PAAD	cis	rs72960926	0.744	rs72950568	chr6:74913119	G/A	cg03266952	chr6:74778945	NA	-1.11	-6.04	-0.44	1.11e-8	Metabolite levels (MHPG);
PAAD	cis	rs1878047	0.665	rs8111753	chr19:51776137	T/G	cg14884932	chr19:51774451	NA	-0.4	-4.29	-0.33	3.17e-5	Body mass index;
PAAD	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs728616	0.867	rs55690691	chr10:81658942	G/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.8	-0.36	3.72e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs901683	1.000	rs75712637	chr10:45988192	T/C	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs682748	0.810	rs1482345	chr5:17114704	G/A	cg23987134	chr5:17158319	LOC285696	-0.37	-4.63	-0.35	7.9e-6	Hippocampal atrophy;
PAAD	cis	rs6831352	0.569	rs4148883	chr4:100066332	T/C	cg13256891	chr4:100009986	ADH5	0.43	4.38	0.33	2.2e-5	Alcohol dependence;
PAAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.72	0.42	5.61e-8	Tonsillectomy;
PAAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.5	5.73	0.42	5.14e-8	Major depressive disorder;
PAAD	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs116248771	0.739	rs4334688	chr3:158358666	C/G	cg16708174	chr3:158430962	RARRES1	0.71	5.35	0.4	3.16e-7	diarrhoeal disease at age 2;
PAAD	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.79	-7.02	-0.49	7.03e-11	Blood protein levels;
PAAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.42	-6.38	-0.46	2.03e-9	Subjective well-being;
PAAD	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg23649088	chr2:200775458	C2orf69	0.62	4.76	0.36	4.42e-6	Schizophrenia;
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01616529	chr11:638424	DRD4	-0.6	-5.55	-0.41	1.24e-7	Systemic lupus erythematosus;
PAAD	cis	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.9	11.17	0.67	1.61e-21	Blood protein levels;
PAAD	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.61	5.88	0.43	2.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg20887711	chr4:1340912	KIAA1530	0.78	8.57	0.57	1.08e-14	Longevity;
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2919917	1.000	rs1466526	chr8:79555474	C/G	cg24119481	chr19:16683605	SLC35E1	0.61	6.66	0.48	4.63e-10	Lymphocyte counts;
PAAD	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	4.56	0.35	1.06e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs72928364	0.872	rs13064121	chr3:100710713	C/A	cg23634451	chr3:100713646	ABI3BP	-0.62	-4.44	-0.34	1.73e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg04920474	chr2:44395004	PPM1B	0.45	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.86	-10.68	-0.65	3.22e-20	Coronary artery disease;
PAAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs10504390	0.524	rs80229839	chr8:66673706	C/G	cg21696208	chr8:66556075	MTFR1	0.85	4.42	0.34	1.83e-5	IgG glycosylation;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26418147	chr1:205743515	RAB7L1	-0.51	-6.2	-0.45	5e-9	Menarche (age at onset);
PAAD	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.88e-6	Type 2 diabetes;
PAAD	cis	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg14749448	chr11:65325872	LTBP3	-0.44	-5.11	-0.38	9.34e-7	Eosinophil percentage of white cells;
PAAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.8	0.36	3.75e-6	Melanoma;
PAAD	cis	rs4455778	0.580	rs56068416	chr7:49083226	T/C	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg13444538	chr7:158905317	VIPR2	-0.69	-5.02	-0.38	1.4e-6	Myopia (pathological);
PAAD	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.02	12.34	0.71	1.11e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.7	-7.13	-0.5	3.8e-11	Height;
PAAD	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.49	5.67	0.42	6.96e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg10356904	chr22:49881777	NA	-0.54	-5.08	-0.38	1.09e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14219317	chr6:594452	EXOC2	-0.54	-6.89	-0.49	1.4e-10	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-4.99	-0.38	1.63e-6	Obesity-related traits;
PAAD	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.47	-0.34	1.5e-5	Body mass index;
PAAD	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.79	0.43	3.84e-8	Ileal carcinoids;
PAAD	cis	rs2421770	0.532	rs3103239	chr11:35352117	A/C	cg13971030	chr11:35366721	SLC1A2	-0.53	-5.09	-0.38	1.03e-6	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg08317243	chr16:87101592	NA	0.52	5.21	0.39	5.98e-7	Menopause (age at onset);
PAAD	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.7	0.58	4.98e-15	Lung cancer;
PAAD	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.4	-5.46	-0.4	1.91e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg01557791	chr16:72042693	DHODH	-0.64	-6.1	-0.44	8.43e-9	Fibrinogen levels;
PAAD	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg09597638	chr17:3907349	NA	0.9	10.12	0.63	1.01e-18	Type 2 diabetes;
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.94	12.58	0.71	2.46e-25	Menopause (age at onset);
PAAD	cis	rs12304921	0.639	rs2306732	chr12:51455739	G/T	cg18059802	chr12:51347058	HIGD1C	-0.62	-4.89	-0.37	2.6e-6	Type 2 diabetes;
PAAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.45	-6.27	-0.45	3.59e-9	Height;
PAAD	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.87	4.45	0.34	1.69e-5	Plasma clusterin levels;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01283332	chr5:1856932	NA	-0.45	-4.76	-0.36	4.38e-6	Cardiovascular disease risk factors;
PAAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.59	-4.83	-0.36	3.27e-6	Platelet count;
PAAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.11	-0.38	9.39e-7	Blood metabolite levels;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13796796	chr2:26987250	C2orf18	-0.74	-6.34	-0.46	2.5e-9	Neuroticism;
PAAD	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.99	6.99	0.49	7.92e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.0	-0.38	1.59e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-4.44	-0.34	1.72e-5	Height;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.71	5.02	0.38	1.41e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2754412	1	rs2754412	chr10:38627834	A/G	cg25427524	chr10:38739819	LOC399744	-0.85	-9.74	-0.62	9.88e-18	Breast cancer;
PAAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.69	7.44	0.52	6.92e-12	Multiple myeloma (IgH translocation);
PAAD	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.49	4.84	0.37	3.16e-6	Airway imaging phenotypes;
PAAD	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg01516881	chr6:292596	DUSP22	-0.71	-6.97	-0.49	8.95e-11	Menopause (age at onset);
PAAD	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg23942311	chr14:51606299	NA	-0.72	-5.14	-0.39	8.21e-7	Cancer;
PAAD	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.9	-11.89	-0.69	1.78e-23	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.43	-0.34	1.79e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs7251275	0.744	rs13343696	chr19:44116956	A/G	cg17121205	chr19:44009353	PHLDB3	0.4	4.88	0.37	2.63e-6	Macrophage inflammatory protein 1b levels;
PAAD	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	4.75	0.36	4.68e-6	Menopause (age at onset);
PAAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.02	-0.49	7e-11	Capecitabine sensitivity;
PAAD	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg02376097	chr19:46275166	DMPK	-0.59	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	4.32	0.33	2.84e-5	Height;
PAAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs11696501	0.688	rs4810465	chr20:44311354	A/G	cg11783356	chr20:44313418	WFDC10B	0.71	6.45	0.46	1.38e-9	Brain structure;
PAAD	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg18850127	chr7:39170497	POU6F2	0.5	7.48	0.52	5.59e-12	IgG glycosylation;
PAAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.83	6.23	0.45	4.4e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.38	4.93	0.37	2.16e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg03367679	chr17:38183553	MED24;SNORD124	-0.36	-4.68	-0.35	6.33e-6	Myeloid white cell count;
PAAD	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.59	5.4	0.4	2.49e-7	Obesity-related traits;
PAAD	trans	rs2880058	0.788	rs16827673	chr1:162036704	C/A	cg22816059	chr5:422114	AHRR	-0.63	-6.31	-0.46	2.94e-9	QT interval;
PAAD	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.73	7.23	0.51	2.25e-11	Corneal astigmatism;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg21724239	chr8:58056113	NA	0.65	5.0	0.38	1.57e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4356203	0.905	rs7927240	chr11:17078228	G/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.42	-0.34	1.9e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	trans	rs4986811	0.500	rs72905043	chr11:32464103	A/G	cg16078836	chr3:185081374	MAP3K13	-0.94	-6.48	-0.47	1.22e-9	Rubella-specific interleukin-6 secretion;
PAAD	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg01388757	chr2:102091195	RFX8	-0.55	-6.97	-0.49	9.23e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.45	-4.65	-0.35	7.25e-6	Vitiligo;
PAAD	cis	rs8037137	0.915	rs79253100	chr15:91551876	C/T	cg23684204	chr15:91497937	RCCD1	0.72	4.35	0.33	2.48e-5	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg06287003	chr12:125626642	AACS	-0.46	-4.48	-0.34	1.44e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg18769074	chr3:133464867	TF	0.45	5.52	0.41	1.44e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	6.48	0.47	1.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.63	7.24	0.51	2.1e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.64	5.51	0.41	1.52e-7	Gut microbiome composition (summer);
PAAD	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg00922110	chr4:57842668	C4orf14	0.43	4.38	0.34	2.17e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6669119	1.000	rs6669119	chr1:19108549	C/T	cg26220594	chr1:19110978	NA	0.7	4.46	0.34	1.58e-5	Percentage gas trapping;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.06e-8	Life satisfaction;
PAAD	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg09184832	chr6:79620586	NA	-0.42	-4.28	-0.33	3.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.3	0.33	3.03e-5	Bipolar disorder;
PAAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.5	6.47	0.46	1.27e-9	Prostate cancer;
PAAD	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	8.32	0.56	4.6e-14	Coronary artery disease;
PAAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.81	0.72	6.14e-26	Breast cancer;
PAAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14180030	chr9:123475675	MEGF9	-0.44	-4.98	-0.37	1.7e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	4.42	0.34	1.86e-5	Personality dimensions;
PAAD	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.66	8.28	0.56	5.94e-14	Lipoprotein (a) levels;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.53	-6.27	-0.45	3.63e-9	Iron status biomarkers;
PAAD	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.62	0.35	8.11e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.74	-5.32	-0.4	3.57e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	4.31	0.33	2.93e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.21	0.55	8.68e-14	Menopause (age at onset);
PAAD	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.95	5.85	0.43	2.85e-8	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15145965	chr22:50218605	BRD1	0.6	5.27	0.39	4.52e-7	Schizophrenia;
PAAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg04450456	chr4:17643702	FAM184B	0.48	5.22	0.39	5.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8033133	0.836	rs11634716	chr15:25306646	C/T	cg14481604	chr15:25334117	SNORD116-22	0.52	5.23	0.39	5.58e-7	Blood osmolality (transformed sodium);
PAAD	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg26031613	chr14:104095156	KLC1	0.46	5.16	0.39	7.6e-7	Schizophrenia;
PAAD	trans	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg25482853	chr8:67687455	SGK3	1.03	6.47	0.46	1.26e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06217245	chr20:33103252	DYNLRB1	0.42	5.09	0.38	1.02e-6	Coronary artery disease;
PAAD	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg01299579	chr2:10830716	NOL10	0.44	4.32	0.33	2.86e-5	Prostate cancer;
PAAD	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.52	6.33	0.46	2.57e-9	Sitting height ratio;
PAAD	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.27	-0.51	1.74e-11	Coronary artery disease;
PAAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg10818794	chr15:86012489	AKAP13	-0.6	-4.87	-0.37	2.72e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg20855001	chr13:114761326	RASA3	-0.58	-6.35	-0.46	2.36e-9	Primary biliary cholangitis;
PAAD	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9973361	0.592	rs3764998	chr2:166732527	G/T	cg15739581	chr2:166626783	GALNT3	-0.53	-4.33	-0.33	2.71e-5	Total body bone mineral density;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04597389	chr17:79935740	ASPSCR1	0.58	6.35	0.46	2.36e-9	Myopia (pathological);
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg21724239	chr8:58056113	NA	0.71	5.35	0.4	3.14e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-10.84	-0.66	1.2e-20	Systemic lupus erythematosus;
PAAD	cis	rs60154123	0.730	rs12074229	chr1:210474602	A/G	cg22029157	chr1:209979665	IRF6	0.66	5.86	0.43	2.83e-8	Coronary artery disease;
PAAD	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg19337854	chr7:99768885	GPC2	-0.43	-4.4	-0.34	2.03e-5	Coronary artery disease;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg22162314	chr17:61951766	CSH2	-0.55	-5.57	-0.41	1.12e-7	Height;
PAAD	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.46	4.51	0.34	1.3e-5	Sudden cardiac arrest;
PAAD	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.54	-4.67	-0.35	6.46e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.58	-5.71	-0.42	5.64e-8	Height;
PAAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	6.86	0.49	1.64e-10	Schizophrenia;
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.78	-7.97	-0.54	3.5e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17347941	chr15:79387269	NA	0.38	4.29	0.33	3.15e-5	Refractive error;
PAAD	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-5.83	-0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg22633769	chr20:60982531	CABLES2	-0.45	-4.48	-0.34	1.44e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00166722	chr3:10149974	C3orf24	0.97	7.98	0.54	3.38e-13	Alzheimer's disease;
PAAD	cis	rs682748	0.840	rs297177	chr5:17114476	C/T	cg23987134	chr5:17158319	LOC285696	-0.36	-4.45	-0.34	1.67e-5	Hippocampal atrophy;
PAAD	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.58	5.51	0.41	1.52e-7	Alcohol dependence;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6504950	0.695	rs9904377	chr17:52985982	C/T	cg18040354	chr17:53800484	TMEM100	0.48	4.5	0.34	1.35e-5	Breast cancer;
PAAD	cis	rs7631605	0.875	rs56304874	chr3:37245983	G/T	cg17445812	chr3:36986805	TRANK1	0.36	4.71	0.36	5.58e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	13.82	0.75	1.21e-28	Prudent dietary pattern;
PAAD	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.78	-0.42	4.19e-8	Colorectal cancer;
PAAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.8	-8.26	-0.56	6.67e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7084783	0.538	rs11191734	chr10:105338128	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.47	4.75	0.36	4.63e-6	Fear of pain;
PAAD	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg16434002	chr17:42200994	HDAC5	0.61	5.55	0.41	1.22e-7	Total body bone mineral density;
PAAD	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.9e-10	Bladder cancer;
PAAD	cis	rs1035491	0.715	rs10078390	chr5:63926120	G/A	cg01791865	chr5:63954708	NA	0.52	5.54	0.41	1.28e-7	Body mass index;
PAAD	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg02244288	chr16:89573955	SPG7	-0.35	-4.54	-0.35	1.12e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.63	6.47	0.46	1.27e-9	Bladder cancer;
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg10011062	chr15:43941034	CATSPER2	-0.77	-4.47	-0.34	1.53e-5	Lung cancer in ever smokers;
PAAD	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg14054013	chr3:49894103	TRAIP	-0.6	-4.53	-0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs76917914	0.561	rs2224773	chr9:100824223	C/A	cg21225548	chr9:100864335	TRIM14	-0.48	-5.32	-0.4	3.66e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2131877	0.956	rs6775431	chr3:194859194	G/T	cg21937377	chr3:194868750	C3orf21	0.43	4.69	0.36	6.13e-6	Non-small cell lung cancer;
PAAD	cis	rs2278796	0.639	rs12139426	chr1:204970708	A/G	cg04862289	chr1:204966208	NFASC	-0.5	-5.18	-0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.7	6.22	0.45	4.53e-9	Platelet count;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	8.29	0.56	5.72e-14	Alzheimer's disease;
PAAD	cis	rs2019872	0.543	rs216175	chr17:2167690	A/C	cg02569219	chr17:2266849	SGSM2	0.61	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	7.98	0.54	3.23e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	1.05	5.75	0.42	4.69e-8	Plasma clusterin levels;
PAAD	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-10.56	-0.65	6.86e-20	Response to antipsychotic treatment;
PAAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg26138144	chr22:38071188	LGALS1	-0.5	-5.55	-0.41	1.27e-7	Fat distribution (HIV);
PAAD	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.53	-5.5	-0.41	1.57e-7	Daytime sleep phenotypes;
PAAD	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.99	9.42	0.61	7.01e-17	Triglycerides;
PAAD	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.61e-7	Monocyte count;
PAAD	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.33	-0.46	2.59e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.34	-6.41	-0.46	1.77e-9	Type 2 diabetes;
PAAD	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.68	7.47	0.52	5.77e-12	Cognitive function;
PAAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg03732007	chr1:2071316	PRKCZ	-0.46	-4.91	-0.37	2.3e-6	Height;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.16	0.55	1.21e-13	Lung cancer;
PAAD	cis	rs11892454	0.544	rs7560314	chr2:26007959	G/T	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.8e-5	Heschl's gyrus morphology;
PAAD	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs939584	1.000	rs2867113	chr2:651365	C/T	cg03610516	chr2:642275	NA	-0.57	-5.2	-0.39	6.42e-7	Body mass index;
PAAD	cis	rs6089829	0.632	rs62197308	chr20:61660705	T/C	cg08045932	chr20:61659980	NA	-0.56	-6.07	-0.44	9.67e-9	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14119001	chr9:139324193	INPP5E	-0.6	-5.39	-0.4	2.68e-7	White blood cell count;
PAAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.85	5.43	0.4	2.18e-7	Diabetic kidney disease;
PAAD	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs12580194	0.593	rs61957943	chr12:55749330	A/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.36	0.33	2.39e-5	Cancer;
PAAD	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.58	5.87	0.43	2.7e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.71	4.97	0.37	1.76e-6	HDL cholesterol levels;
PAAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.7	6.74	0.48	3.01e-10	Parkinson's disease;
PAAD	cis	rs12704294	0.532	rs2237566	chr7:86456100	A/G	cg24310667	chr7:86634072	KIAA1324L	-0.52	-4.58	-0.35	9.48e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.67e-5	Life satisfaction;
PAAD	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.66	-7.14	-0.5	3.5e-11	Schizophrenia;
PAAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12667521	chr19:29218732	NA	0.61	5.36	0.4	3.06e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.83e-5	Blood protein levels;
PAAD	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.07	0.38	1.16e-6	Educational attainment;
PAAD	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16579770	chr16:72058938	DHODH	0.37	4.36	0.33	2.38e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg18964960	chr10:1102726	WDR37	0.8	4.29	0.33	3.13e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.84e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	1.21	15.66	0.79	1.57e-33	Longevity;
PAAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.64	-5.47	-0.41	1.82e-7	Menarche (age at onset);
PAAD	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg27565382	chr3:53032988	SFMBT1	0.96	4.72	0.36	5.25e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2492906	0.502	rs2451921	chr10:27990406	G/A	cg25523538	chr10:28031957	MKX	0.53	4.55	0.35	1.07e-5	Prostate-specific antigen levels (conditioned on lead SNPs);
PAAD	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg16447950	chr5:562315	NA	-0.52	-4.93	-0.37	2.11e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs17641971	0.684	rs7835336	chr8:49957895	A/G	cg00325661	chr8:49890786	NA	0.54	5.35	0.4	3.14e-7	Blood metabolite levels;
PAAD	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-4.64	-0.35	7.52e-6	Joint mobility (Beighton score);
PAAD	cis	rs11264799	0.603	rs12731814	chr1:157585917	G/A	cg18268488	chr1:157545234	FCRL4	0.47	5.47	0.41	1.85e-7	IgA nephropathy;
PAAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg21951975	chr1:209979733	IRF6	0.41	5.24	0.39	5.33e-7	Monobrow;
PAAD	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg24296786	chr1:45957014	TESK2	-0.41	-4.33	-0.33	2.65e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs2279817	0.731	rs78474704	chr1:18010154	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.76	-0.42	4.5e-8	Neuroticism;
PAAD	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs35523062	0.645	rs28857822	chr4:11944206	A/G	cg22264307	chr4:11400815	HS3ST1	-0.43	-4.27	-0.33	3.39e-5	Familial hepatitis B virus-related hepatocellular carcinoma;
PAAD	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	11.0	0.67	4.43e-21	Cognitive test performance;
PAAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.49	-4.92	-0.37	2.23e-6	Iron status biomarkers;
PAAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.84	-9.22	-0.6	2.28e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg20302533	chr7:39170763	POU6F2	0.43	5.82	0.43	3.32e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg12046867	chr14:103022105	NA	0.73	4.85	0.37	3.02e-6	Platelet count;
PAAD	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg08390786	chr10:135334061	NA	0.48	4.68	0.36	6.22e-6	Obesity-related traits;
PAAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.89	-8.74	-0.58	4.03e-15	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.71	-8.06	-0.55	2.12e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.82	-9.71	-0.62	1.18e-17	Brugada syndrome;
PAAD	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg14703610	chr5:56206110	C5orf35	0.6	5.6	0.41	9.83e-8	Coronary artery disease;
PAAD	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg07475973	chr22:42306951	NA	0.47	4.36	0.33	2.41e-5	Neuroticism;
PAAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10186876	0.728	rs10205130	chr2:44151572	G/C	cg09541576	chr2:44873248	C2orf34	-0.45	-4.66	-0.35	6.83e-6	Hand grip strength;
PAAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.64	-6.9	-0.49	1.28e-10	Schizophrenia;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.61	6.43	0.46	1.57e-9	Lung cancer;
PAAD	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg12633918	chr20:23549525	CST9L	-0.44	-4.88	-0.37	2.68e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs8077577	0.747	rs62072541	chr17:18226699	G/A	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs62264129	0.500	rs13316383	chr3:112039067	C/G	cg01411366	chr3:112012867	SLC9A10	-0.31	-4.92	-0.37	2.27e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	4.29	0.33	3.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs34779708	0.832	rs12764283	chr10:35530460	G/A	cg03585969	chr10:35415529	CREM	0.56	5.09	0.38	1.07e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg05935833	chr10:81318306	SFTPA2	-0.52	-4.27	-0.33	3.48e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.4	-4.28	-0.33	3.27e-5	Longevity;Endometriosis;
PAAD	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-4.28	-0.33	3.3e-5	Systolic blood pressure;
PAAD	cis	rs12949688	0.967	rs12949028	chr17:55825470	A/C	cg12582317	chr17:55822272	NA	0.68	8.33	0.56	4.31e-14	Schizophrenia;
PAAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg10072921	chr12:121022843	NA	-0.43	-5.24	-0.39	5.33e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7260538	0.808	rs707265	chr19:41524087	A/G	cg13322449	chr19:42300200	CEACAM3	0.38	4.4	0.34	2.02e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg13263323	chr15:86062960	AKAP13	-0.61	-6.89	-0.49	1.4e-10	Coronary artery disease;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg14433983	chr11:636460	DRD4	-0.46	-4.74	-0.36	4.81e-6	Systemic lupus erythematosus;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04387010	chr17:53038315	COX11;TOM1L1	-0.48	-6.37	-0.46	2.09e-9	Energy expenditure (24h);
PAAD	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.76	7.19	0.5	2.68e-11	Neuroticism;
PAAD	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg01206211	chr2:36825736	FEZ2	0.5	4.65	0.35	7.1e-6	Height;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.17e-10	Life satisfaction;
PAAD	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.84	-0.37	3.15e-6	Prevalent atrial fibrillation;
PAAD	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Bladder cancer;
PAAD	cis	rs630539	1.000	rs6503716	chr17:40796211	T/A	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.69	-6.19	-0.45	5.39e-9	Systemic lupus erythematosus;
PAAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.94	0.7	1.34e-23	Platelet count;
PAAD	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.6	5.85	0.43	2.85e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09597638	chr17:3907349	NA	-0.71	-7.64	-0.53	2.3e-12	Type 2 diabetes;
PAAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.69	0.58	5.26e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg13722127	chr7:150037890	RARRES2	0.65	6.37	0.46	2.1e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.88	-0.43	2.56e-8	Airway imaging phenotypes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17643109	chr11:118443023	ARCN1	0.58	6.96	0.49	9.46e-11	Monocyte percentage of white cells;
PAAD	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-4.51	-0.34	1.29e-5	Menopause (age at onset);
PAAD	cis	rs17209837	1.000	rs998671	chr7:87123275	C/T	cg00919237	chr7:87102261	ABCB4	-0.8	-5.25	-0.39	5.14e-7	Gallbladder cancer;
PAAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.53	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16956456	chr5:172483378	C5orf41	0.61	6.88	0.49	1.5e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02357389	chr12:82752162	CCDC59;C12orf26	0.69	6.92	0.49	1.16e-10	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.29e-7	Prostate cancer;
PAAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-5.47	-0.41	1.81e-7	Initial pursuit acceleration;
PAAD	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.78	8.34	0.56	4.11e-14	Mean corpuscular volume;
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Intracranial aneurysm;
PAAD	cis	rs9434723	0.765	rs2268171	chr1:9302315	C/T	cg04199779	chr1:9294473	H6PD	0.57	4.81	0.36	3.59e-6	Height;
PAAD	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg24562669	chr7:97807699	LMTK2	0.67	10.01	0.63	1.93e-18	Breast cancer;
PAAD	trans	rs314580	0.655	rs673890	chr13:89771271	G/T	cg27422345	chr7:1715242	NA	-1.03	-6.37	-0.46	2.18e-9	Bipolar disorder and eating disorder;
PAAD	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.67	-6.46	-0.46	1.32e-9	Blood metabolite levels;
PAAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.53	5.65	0.42	7.85e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.77	0.58	3.32e-15	Lung cancer;
PAAD	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.89	-8.09	-0.55	1.79e-13	IgG glycosylation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10009236	chr16:128016	MPG	0.69	7.31	0.51	1.45e-11	Myopia (pathological);
PAAD	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.26	-0.39	4.75e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.59	-6.58	-0.47	7.09e-10	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
PAAD	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.65	-5.98	-0.44	1.54e-8	Red blood cell count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18173830	chr6:4776623	CDYL	0.72	8.29	0.56	5.41e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11556929	chr2:240323605	HDAC4	0.72	7.94	0.54	4.11e-13	Myopia (pathological);
PAAD	cis	rs6496932	1.000	rs11638110	chr15:85822884	A/G	cg19183879	chr15:85880815	NA	0.55	4.45	0.34	1.64e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.84	0.58	2.17e-15	Lung cancer;
PAAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.66	-6.99	-0.49	8.32e-11	Permanent tooth development;
PAAD	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg02887458	chr19:19495540	GATAD2A	0.53	5.05	0.38	1.24e-6	Bipolar disorder;
PAAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.59	-5.97	-0.44	1.59e-8	QT interval;
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	1.04	7.89	0.54	5.51e-13	Alzheimer's disease;
PAAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.42	-4.25	-0.33	3.77e-5	Plateletcrit;
PAAD	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.78	-7.44	-0.52	7.01e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs863345	0.933	rs11265020	chr1:158511642	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-4.99	-0.38	1.61e-6	Pneumococcal bacteremia;
PAAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg05627522	chr15:75251581	NA	0.47	5.84	0.43	3.11e-8	Breast cancer;
PAAD	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg23033748	chr14:75592666	NEK9	-0.45	-5.54	-0.41	1.29e-7	Height;
PAAD	cis	rs897984	0.920	rs12926295	chr16:30890538	C/T	cg02466173	chr16:30829666	NA	0.59	6.56	0.47	8.05e-10	Dementia with Lewy bodies;
PAAD	trans	rs790110	1.000	rs790130	chr3:122384661	C/G	cg15869492	chr17:36907295	NA	-1.05	-6.52	-0.47	9.94e-10	Acoustic startle blink response;
PAAD	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.86	-9.61	-0.61	2.29e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg05785598	chr3:49045655	WDR6	0.42	4.97	0.37	1.76e-6	Parkinson's disease;
PAAD	cis	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg14329783	chr7:75779857	NA	0.79	4.72	0.36	5.2e-6	Mononucleosis;
PAAD	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg13002189	chr3:66846049	NA	0.57	5.59	0.41	1.04e-7	Type 2 diabetes;
PAAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.7	7.63	0.53	2.34e-12	Tonsillectomy;
PAAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	5.93e-6	Obesity-related traits;
PAAD	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg19090574	chr1:205240910	TMCC2	-0.41	-4.61	-0.35	8.47e-6	Red blood cell count;
PAAD	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	4.38	0.33	2.19e-5	Uric acid levels;
PAAD	cis	rs8025118	0.583	rs4779040	chr15:79548374	T/G	cg24739098	chr15:79297159	RASGRF1	-0.4	-4.39	-0.34	2.09e-5	Cognitive function;
PAAD	cis	rs12304921	0.748	rs56847302	chr12:51506876	G/A	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.6	-0.35	8.99e-6	Type 2 diabetes;
PAAD	cis	rs892877	0.518	rs1550089	chr2:137877823	G/A	cg07757007	chr2:138734074	HNMT	-0.3	-4.44	-0.34	1.7e-5	Liver enzyme levels (aspartate transaminase);
PAAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.76	9.33	0.6	1.23e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01806965	chr8:144378397	ZNF696	0.61	6.29	0.45	3.14e-9	Warfarin maintenance dose;
PAAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg19847866	chr10:1019161	NA	-0.53	-4.25	-0.33	3.7e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs10044254	0.537	rs11133821	chr5:15693064	C/T	cg07238450	chr5:15720153	FBXL7	-0.53	-5.02	-0.38	1.45e-6	Asthma (corticosteroid response);
PAAD	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19346786	chr7:2764209	NA	-0.39	-5.35	-0.4	3.25e-7	Height;
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.73	-7.33	-0.51	1.29e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs59888335	0.861	rs7610673	chr3:81011573	A/G	cg21735741	chr3:80819488	NA	-0.52	-4.5	-0.34	1.32e-5	Schizophrenia;
PAAD	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.52	4.96	0.37	1.87e-6	Pulse pressure;
PAAD	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.71	-7.1	-0.5	4.36e-11	Retinal vascular caliber;
PAAD	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg26338869	chr17:61819248	STRADA	0.49	4.7	0.36	5.68e-6	Height;
PAAD	cis	rs3852764	0.588	rs2340753	chr16:5005945	A/C	cg06510647	chr16:5006106	NA	0.56	5.84	0.43	3e-8	Cancer;
PAAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.61	-6.15	-0.45	6.65e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg06606381	chr12:133084897	FBRSL1	0.88	6.29	0.45	3.14e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg24842760	chr6:133561719	EYA4	-0.9	-6.82	-0.48	1.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.24	0.51	2.07e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.6	5.83	0.43	3.28e-8	Blood metabolite levels;
PAAD	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	4.8	0.36	3.71e-6	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.5	6.67e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.9	11.6	0.69	1.11e-22	Body mass index;
PAAD	cis	rs11023332	0.706	rs11023379	chr11:14929960	C/T	cg16394018	chr11:14927549	NA	0.42	4.8	0.36	3.83e-6	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	5.16	0.39	7.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.52	5.19	0.39	6.71e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.58	0.52	3.21e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7633787	0.592	rs711721	chr3:23023079	C/T	cg00327796	chr3:23032191	NA	-0.46	-4.66	-0.35	6.91e-6	Facial morphology (factor 7, width of cartilaginous portion of nose);
PAAD	trans	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg25214090	chr10:38739885	LOC399744	0.66	7.19	0.5	2.75e-11	Corneal astigmatism;
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.7	-5.35	-0.4	3.17e-7	Initial pursuit acceleration;
PAAD	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg15193198	chr20:60906057	LAMA5	-0.48	-5.38	-0.4	2.73e-7	Colorectal cancer;
PAAD	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.84	-0.43	3.01e-8	Pulmonary function;
PAAD	cis	rs735539	0.521	rs509099	chr13:21453738	G/A	cg27499820	chr13:21296301	IL17D	0.51	4.51	0.34	1.27e-5	Dental caries;
PAAD	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26577658	chr16:84423876	ATP2C2	-0.66	-7.15	-0.5	3.46e-11	Myopia (pathological);
PAAD	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09695851	chr17:3907499	NA	-0.67	-6.9	-0.49	1.32e-10	Type 2 diabetes;
PAAD	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.89	7.22	0.51	2.31e-11	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.84	6.49	0.47	1.12e-9	Alzheimer's disease;
PAAD	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.62	6.01	0.44	1.33e-8	Lymphocyte counts;
PAAD	cis	rs8026198	0.778	rs4924660	chr15:42603708	A/G	cg22035320	chr15:42170125	SPTBN5	0.53	4.37	0.33	2.3e-5	Fibrinogen levels;
PAAD	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.8	9.32	0.6	1.27e-16	Eosinophil percentage of white cells;
PAAD	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg27326032	chr3:127006922	NA	-0.7	-6.58	-0.47	7.03e-10	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.53	5.0	0.38	1.54e-6	Red blood cell count;
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	6.17	0.45	5.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-5.56	-0.41	1.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-6.4	-0.46	1.84e-9	Bipolar disorder;
PAAD	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.76	9.19	0.6	2.84e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4823006	0.776	rs3208800	chr22:29451793	G/T	cg23896685	chr22:29451551	ZNRF3	0.47	4.91	0.37	2.31e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs7792596	0.861	rs6970279	chr7:94014889	A/C	cg20814616	chr7:94014465	NA	0.63	5.64	0.42	8.04e-8	Intelligence;
PAAD	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.1e-5	Subjective well-being;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17739026	chr1:27114420	PIGV	0.65	7.26	0.51	1.82e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9463078	0.526	rs1159131	chr6:44972209	T/C	cg25276700	chr6:44698697	NA	0.4	4.82	0.36	3.47e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2389339	0.773	rs10516632	chr4:117830724	G/T	cg21399832	chr4:117847410	NA	0.31	4.39	0.34	2.14e-5	IgG glycosylation;
PAAD	cis	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg08992911	chr2:238395768	MLPH	0.45	4.62	0.35	8.21e-6	Prostate cancer;
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.66	-6.82	-0.48	2.02e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-1.35	-12.6	-0.71	2.22e-25	Obesity-related traits;
PAAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.61	4.89	0.37	2.6e-6	Information processing speed;
PAAD	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.42	-6.24	-0.45	4.23e-9	Subjective well-being;
PAAD	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.49	-5.24	-0.39	5.25e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.31	0.81	9.13e-38	Prudent dietary pattern;
PAAD	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.36	-5.21	-0.39	6.03e-7	Educational attainment (years of education);
PAAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg11833968	chr6:79620685	NA	0.42	4.47	0.34	1.51e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.65	-6.72	-0.48	3.35e-10	Body mass index;
PAAD	cis	rs12989701	0.825	rs873270	chr2:127859418	T/C	cg08168897	chr2:127865431	BIN1	0.69	5.95	0.43	1.75e-8	Alzheimer's disease (late onset);
PAAD	cis	rs16958440	0.581	rs56395942	chr18:44672299	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.85	-5.33	-0.4	3.55e-7	Sitting height ratio;
PAAD	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.72	-5.93	-0.43	1.99e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6594713	0.605	rs72792189	chr5:112814965	A/G	cg12552261	chr5:112820674	MCC	0.74	5.34	0.4	3.32e-7	Brain cytoarchitecture;
PAAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.51	-5.52	-0.41	1.44e-7	IgG glycosylation;
PAAD	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.72	-9.11	-0.59	4.6e-16	Educational attainment;
PAAD	trans	rs62179067	0.867	rs62177280	chr2:180015750	A/G	cg23458843	chr12:58136445	AGAP2	0.96	6.39	0.46	1.94e-9	Late-onset Alzheimer's disease;
PAAD	trans	rs148696809	1	rs148696809	chr6:28934352	T/C	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Lung cancer;Squamous cell lung carcinoma;
PAAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.87	-11.94	-0.7	1.34e-23	Dental caries;
PAAD	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg00522288	chr12:125625016	AACS	0.4	4.27	0.33	3.37e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.67	0.35	6.47e-6	Homoarginine levels;
PAAD	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.74	-0.42	5.09e-8	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12342027	chr7:44835729	PPIA	-0.68	-6.62	-0.47	5.97e-10	Neuroticism;
PAAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg14709524	chr16:89940631	TCF25	0.87	4.6	0.35	8.74e-6	Skin colour saturation;
PAAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.59	-6.55	-0.47	8.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12963246	chr6:28129442	ZNF389	0.73	5.25	0.39	5.04e-7	Parkinson's disease;
PAAD	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.97e-5	Age-related disease endophenotypes;
PAAD	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg14709524	chr16:89940631	TCF25	0.88	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs12432203	1.000	rs61193236	chr14:51731752	C/G	cg23942311	chr14:51606299	NA	-0.69	-4.65	-0.35	7.08e-6	Cancer;
PAAD	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.05	14.17	0.75	1.38e-29	Body mass index (adult);
PAAD	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs72960926	1.000	rs16879383	chr6:75097185	A/G	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs12760731	0.565	rs35038893	chr1:178168417	C/T	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg16898833	chr6:26189333	HIST1H4D	1.0	5.59	0.41	1.01e-7	Lung cancer in ever smokers;
PAAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg12126869	chr10:346505	DIP2C	-0.81	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-5.31	-0.4	3.74e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.75	-7.63	-0.53	2.41e-12	Blood metabolite levels;
PAAD	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.77	-7.68	-0.53	1.81e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.26	-0.64	4.17e-19	Response to antipsychotic treatment;
PAAD	cis	rs2249296	0.504	rs7527390	chr1:86796171	C/A	cg17424433	chr1:86913263	CLCA2	0.45	4.4	0.34	2.03e-5	Crohn's disease-related phenotypes;
PAAD	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg04990556	chr1:26633338	UBXN11	0.64	4.69	0.36	5.95e-6	Obesity-related traits;
PAAD	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.83	-5.98	-0.44	1.55e-8	Coronary artery calcification;
PAAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.65	7.42	0.52	7.83e-12	Longevity;Endometriosis;
PAAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.43	-4.77	-0.36	4.29e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg23254163	chr1:152506842	NA	0.6	7.05	0.5	5.94e-11	Hair morphology;
PAAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg22162314	chr17:61951766	CSH2	-0.55	-5.58	-0.41	1.09e-7	Height;
PAAD	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.36	-0.56	3.75e-14	Mean corpuscular volume;
PAAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.9	0.66	8.1899999999999992e-21	Tonsillectomy;
PAAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.86	0.37	2.87e-6	Breast cancer;
PAAD	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.72	5.21	0.39	5.92e-7	Plateletcrit;
PAAD	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-6.36	-0.46	2.28e-9	Menarche (age at onset);
PAAD	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.67	6.53	0.47	9.31e-10	Hip circumference;
PAAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.74	7.75	0.53	1.21e-12	Total body bone mineral density;
PAAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.55	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg09659197	chr4:152720779	NA	0.37	5.26	0.39	4.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.33	8.31	0.56	4.93e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs2820914	0.668	rs10976083	chr9:7166791	G/T	cg13985597	chr9:6704574	NA	0.61	4.25	0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg07153921	chr17:41440717	NA	-0.41	-4.34	-0.33	2.63e-5	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg14343924	chr8:8086146	FLJ10661	0.49	4.56	0.35	1.03e-5	Mood instability;
PAAD	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg01304814	chr3:48885189	PRKAR2A	1.05	5.44	0.4	2.11e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.67	5.54	0.41	1.3e-7	Hip circumference adjusted for BMI;
PAAD	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.55	-0.47	8.18e-10	Triglycerides;
PAAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg03983715	chr16:68378420	PRMT7	-0.79	-5.53	-0.41	1.34e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.67	-5.32	-0.4	3.61e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg12451869	chr2:102867685	NA	-0.72	-4.27	-0.33	3.49e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg15604389	chr3:122379662	NA	0.57	6.26	0.45	3.76e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg09491104	chr22:46646882	C22orf40	-1.0	-6.31	-0.46	2.89e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13560548	chr3:10150139	C3orf24	0.56	5.04	0.38	1.32e-6	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20305142	chr7:86849011	C7orf23	-0.77	-6.33	-0.46	2.57e-9	Neuroticism;
PAAD	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.79	9.36	0.6	1.01e-16	Lewy body disease;
PAAD	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg13722127	chr7:150037890	RARRES2	0.54	5.5	0.41	1.58e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.72	-8.22	-0.55	8.33e-14	Colorectal cancer;
PAAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.17	17.66	0.82	1.14e-38	Cognitive function;
PAAD	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08392591	chr16:89556376	ANKRD11	0.46	4.58	0.35	9.72e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg12072164	chr19:44306565	LYPD5	0.4	4.34	0.33	2.57e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.59	6.04	0.44	1.16e-8	Coronary artery disease;
PAAD	cis	rs6681460	0.625	rs6679568	chr1:67074177	C/T	cg02459107	chr1:67143332	SGIP1	0.52	4.78	0.36	4.03e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs3733631	1.000	rs1905172	chr4:104636034	C/T	cg21490444	chr5:171095097	NA	0.79	6.66	0.48	4.82e-10	Menarche (age at onset);
PAAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.72	6.75	0.48	2.97e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.6	6.46	0.46	1.34e-9	High light scatter reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14186824	chr11:56259268	OR8U8;OR5M8	-0.68	-6.91	-0.49	1.23e-10	Obesity-related traits;
PAAD	cis	rs1468333	0.964	rs2350306	chr5:137512178	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.59	-6.29	-0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.19	0.45	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.13	0.7	4.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg00181669	chr3:44000978	NA	-0.47	-4.58	-0.35	9.72e-6	Coronary artery disease;
PAAD	cis	rs2637266	0.597	rs846615	chr10:78548489	A/G	cg18941641	chr10:78392320	NA	-0.35	-4.27	-0.33	3.42e-5	Pulmonary function;
PAAD	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.21	-0.45	4.83e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg21496419	chr19:44306685	LYPD5	0.44	5.45	0.4	2.01e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-4.82	-0.36	3.47e-6	Coronary artery disease;
PAAD	cis	rs786425	0.711	rs1060637	chr12:124110122	A/T	cg01240444	chr12:124247047	DNAH10	0.45	4.31	0.33	2.93e-5	Pubertal anthropometrics;
PAAD	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.82	9.49	0.61	4.64e-17	Lung cancer in ever smokers;
PAAD	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg24220031	chr2:73402428	NA	-0.44	-6.78	-0.48	2.56e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6494488	0.500	rs7172505	chr15:64816917	G/T	cg16425858	chr15:64791681	ZNF609	0.9	4.38	0.33	2.22e-5	Coronary artery disease;
PAAD	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7534824	0.625	rs12568338	chr1:101500622	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	4.71	0.36	5.52e-6	Refractive astigmatism;
PAAD	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.35	4.6	0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.36	-0.33	2.41e-5	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9616064	0.812	rs9284525	chr22:46974717	G/C	cg05621596	chr22:47072043	GRAMD4	-0.55	-4.46	-0.34	1.61e-5	Urate levels in obese individuals;
PAAD	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	trans	rs6732189	0.559	rs270932	chr2:161597537	C/T	cg02628561	chr17:18061605	MYO15A	0.62	6.87	0.49	1.56e-10	Educational attainment;
PAAD	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.09	0.38	1.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.79	-10.2	-0.64	6.07e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6142102	0.625	rs4243974	chr20:32547868	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	4.8	0.36	3.73e-6	Skin pigmentation;
PAAD	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.78	9.5	0.61	4.33e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.66	8.72	0.58	4.65e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.43	4.35	0.33	2.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg05042697	chr2:10830656	NOL10	-0.46	-4.52	-0.34	1.23e-5	Prostate cancer;
PAAD	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.48	-6.84	-0.49	1.78e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg21890820	chr11:65308645	LTBP3	0.64	7.73	0.53	1.4e-12	Bone mineral density;
PAAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs674424	1.000	rs674424	chr11:119030752	C/T	cg02076939	chr11:118042561	SCN2B	-0.51	-4.85	-0.37	3e-6	Neutrophil percentage of white cells;
PAAD	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg18200150	chr17:30822561	MYO1D	0.55	6.76	0.48	2.81e-10	Schizophrenia;
PAAD	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.97	8.89	0.59	1.61e-15	Tonometry;
PAAD	cis	rs868943	0.582	rs12203393	chr6:116461404	C/A	cg18764771	chr6:116381957	FRK	0.27	4.37	0.33	2.31e-5	Total cholesterol levels;
PAAD	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.68	-5.98	-0.44	1.56e-8	Body mass index;
PAAD	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg08562672	chr19:21860753	NA	0.41	4.26	0.33	3.61e-5	Pain;
PAAD	trans	rs7615952	0.611	rs114419739	chr3:125722490	C/T	cg07211511	chr3:129823064	LOC729375	-1.27	-7.48	-0.52	5.4e-12	Blood pressure (smoking interaction);
PAAD	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg04398893	chr6:170340417	NA	0.83	4.3	0.33	3.1e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.13	0.5	3.85e-11	Renal function-related traits (BUN);
PAAD	cis	rs10463316	0.817	rs10052992	chr5:150788602	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.86	-0.43	2.72e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11615916	0.790	rs73137521	chr12:62720287	T/C	cg11441379	chr12:63026424	NA	0.64	4.3	0.33	3.01e-5	Pulmonary function decline;
PAAD	cis	rs7765175	0.598	rs7742701	chr6:113660772	C/T	cg19037598	chr6:113666021	NA	0.4	4.35	0.33	2.46e-5	Coronary artery calcification;
PAAD	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg14768367	chr16:72042858	DHODH	-0.75	-5.69	-0.42	6.36e-8	Blood protein levels;
PAAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.28	-0.39	4.32e-7	Systemic lupus erythematosus;
PAAD	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.6	-5.81	-0.43	3.51e-8	Coronary artery disease;
PAAD	cis	rs9926296	0.632	rs4785590	chr16:89790167	G/C	cg04287289	chr16:89883240	FANCA	-0.61	-6.51	-0.47	1.03e-9	Vitiligo;
PAAD	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.45	-4.94	-0.37	2.02e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.63	7.61	0.53	2.71e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24708178	chr5:95019536	SPATA9	-0.63	-6.46	-0.46	1.35e-9	Obesity-related traits;
PAAD	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg00864171	chr11:67383662	NA	-0.49	-5.12	-0.38	9.15e-7	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4750440	0.671	rs1809305	chr10:14026780	G/A	cg27542038	chr10:14027202	FRMD4A	-0.44	-4.51	-0.34	1.31e-5	Adiponectin levels;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13852730	chr15:62745028	NA	-0.41	-4.53	-0.35	1.17e-5	Immature fraction of reticulocytes;
PAAD	cis	rs11264799	0.731	rs7522309	chr1:157685506	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.63	0.42	8.38e-8	IgA nephropathy;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26877631	chr10:21823297	MLLT10	0.7	6.41	0.46	1.76e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg08898775	chr15:59042684	ADAM10	0.39	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	4.4	0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.68	-7.03	-0.5	6.65e-11	Platelet distribution width;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-6.65	-0.47	4.85e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs35083325	1.000	rs35083325	chr2:153256712	C/T	cg00059089	chr2:153263288	FMNL2	0.68	5.7	0.42	5.96e-8	Asthma (childhood onset);
PAAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.71	-7.24	-0.51	2.05e-11	Neurofibrillary tangles;
PAAD	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4883201	0.536	rs7132930	chr12:9137288	C/T	cg15384867	chr12:8995808	A2ML1	-0.55	-4.5	-0.34	1.32e-5	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg08079166	chr15:68083412	MAP2K5	0.65	5.14	0.39	8.16e-7	Restless legs syndrome;
PAAD	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.05	-6.77	-0.48	2.59e-10	Mitochondrial DNA levels;
PAAD	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.89	-7.75	-0.53	1.22e-12	Obesity-related traits;
PAAD	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg10518543	chr12:38710700	ALG10B	-0.5	-4.55	-0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg01631408	chr1:248437212	OR2T33	-0.58	-5.15	-0.39	8.01e-7	Common traits (Other);
PAAD	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.62	-6.93	-0.49	1.11e-10	Menopause (age at onset);
PAAD	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg03386751	chr17:37843793	ERBB2;PGAP3	0.31	4.35	0.33	2.46e-5	Asthma;
PAAD	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg10761708	chr20:43804764	PI3	0.5	4.32	0.33	2.85e-5	Blood protein levels;
PAAD	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17376030	chr22:41985996	PMM1	0.69	4.67	0.35	6.69e-6	Vitiligo;
PAAD	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg18436246	chr17:1640651	WDR81	0.86	8.03	0.55	2.45e-13	Serum albumin level;
PAAD	cis	rs9810890	0.850	rs115721474	chr3:128430370	G/A	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.13	15.48	0.78	4.8e-33	Cognitive function;
PAAD	cis	rs7631605	0.623	rs2276807	chr3:36987083	A/C	cg10333520	chr3:36987040	TRANK1	0.34	4.41	0.34	1.94e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.48	4.88	0.37	2.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.45	4.49	0.34	1.4e-5	Coronary artery disease;
PAAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg06492744	chr11:65406254	SIPA1	0.46	5.41	0.4	2.41e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs508970	0.578	rs2186409	chr11:60894492	G/T	cg24692310	chr11:60915630	VPS37C	0.32	4.38	0.33	2.2e-5	Rheumatoid arthritis;
PAAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.83	9.12	0.59	4.31e-16	Prostate cancer;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg10556349	chr10:835070	NA	0.7	5.49	0.41	1.61e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg21300403	chr2:198650112	BOLL	0.47	4.26	0.33	3.58e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg24112000	chr20:60950667	NA	0.78	10.22	0.64	5.35e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs1062746	0.786	rs11649550	chr16:87366770	G/A	cg02258303	chr16:87377426	FBXO31	-0.57	-5.22	-0.39	5.67e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs2992756	0.663	rs2992764	chr1:18804144	A/G	cg24076588	chr1:18808559	KLHDC7A	0.39	4.62	0.35	8.25e-6	Breast cancer;
PAAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg01299579	chr2:10830716	NOL10	-0.61	-6.18	-0.45	5.6e-9	Prostate cancer;
PAAD	cis	rs78472555	0.633	rs325397	chr15:100226495	T/C	cg18869061	chr15:100272053	LYSMD4	-0.51	-4.38	-0.33	2.19e-5	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs11563648	0.553	rs11563470	chr7:126964180	C/T	cg21885361	chr7:127911034	NA	0.39	4.25	0.33	3.66e-5	Resting heart rate;
PAAD	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.8	8.72	0.58	4.4e-15	Gestational age at birth (maternal effect);
PAAD	cis	rs73198271	0.632	rs57281209	chr8:8602795	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	4.58	0.35	9.67e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg00536532	chr6:33561449	C6orf227	-0.41	-4.43	-0.34	1.77e-5	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16674323	chr3:42846108	HIGD1A	0.57	6.42	0.46	1.69e-9	Monocyte percentage of white cells;
PAAD	cis	rs11209002	1.000	rs10749771	chr1:67573730	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.34	1.32e-5	Crohn's disease;
PAAD	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.56	13.47	0.74	1.03e-27	Atopic dermatitis;
PAAD	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg22143635	chr11:980567	AP2A2	0.51	5.3	0.4	3.95e-7	Alzheimer's disease (late onset);
PAAD	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg05754148	chr16:3507555	NAT15	0.7	4.91	0.37	2.29e-6	Tuberculosis;
PAAD	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.6	6.29	0.45	3.14e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.75	8.61	0.57	8.38e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.51	-6.61	-0.47	6.04e-10	Perceived unattractiveness to mosquitoes;
PAAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg18944383	chr4:111397179	ENPEP	0.75	8.59	0.57	9.88e-15	Height;
PAAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg07952391	chr2:88470173	THNSL2	-0.48	-4.64	-0.35	7.6e-6	Response to metformin (IC50);
PAAD	cis	rs114540395	0.858	rs78446856	chr10:103119815	T/A	cg24760467	chr10:102760784	LZTS2	-0.71	-4.45	-0.34	1.62e-5	Schizophrenia;
PAAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.2	0.55	9.34e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20476171	chr8:143419223	TSNARE1	0.65	6.47	0.46	1.3e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg00717180	chr2:96193071	NA	-0.61	-7.18	-0.5	2.82e-11	Height;
PAAD	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg02440177	chr19:53496695	ZNF702P	0.63	6.6	0.47	6.32e-10	Psoriasis;
PAAD	cis	rs797680	0.856	rs1335679	chr1:93645182	C/T	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7249921	0.833	rs6510469	chr19:35672008	G/T	cg11856182	chr19:35264148	ZNF599	-0.53	-4.57	-0.35	1.01e-5	Platelet count;
PAAD	cis	rs7660520	0.623	rs4455461	chr4:183744854	G/A	cg25287198	chr4:183728479	NA	0.68	4.86	0.37	2.91e-6	Pediatric autoimmune diseases;
PAAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.59	6.27	0.45	3.53e-9	Longevity;
PAAD	cis	rs2694917	0.631	rs2657879	chr12:56865338	C/T	cg00694851	chr12:56985200	RBMS2	-0.58	-4.26	-0.33	3.59e-5	Blood metabolite ratios;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg21565972	chr17:80109576	CCDC57	0.58	6.78	0.48	2.49e-10	Life satisfaction;
PAAD	cis	rs6466055	0.661	rs6954830	chr7:104915462	A/G	cg04380332	chr7:105027541	SRPK2	0.51	4.98	0.37	1.75e-6	Schizophrenia;
PAAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.69	-7.61	-0.53	2.65e-12	Lung cancer;
PAAD	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg26585981	chr11:48327164	OR4S1	0.48	4.35	0.33	2.46e-5	Migraine - clinic-based;
PAAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg01262667	chr19:19385393	TM6SF2	0.45	4.93	0.37	2.1e-6	Tonsillectomy;
PAAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.53	0.52	4.26e-12	Melanoma;
PAAD	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.48	4.62	0.35	8.13e-6	Mean corpuscular volume;
PAAD	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.59	6.7	0.48	3.85e-10	Cognitive performance;
PAAD	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg21918786	chr6:109611834	NA	-0.46	-4.95	-0.37	1.92e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs9361491	0.508	rs9359338	chr6:79396751	T/C	cg05283184	chr6:79620031	NA	-0.39	-4.89	-0.37	2.49e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs597480	0.713	rs1445497	chr11:85518585	G/T	cg11817631	chr11:85522609	SYTL2	-0.48	-4.55	-0.35	1.09e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.41	-0.4	2.45e-7	Initial pursuit acceleration;
PAAD	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg19980771	chr6:110798022	SLC22A16	0.33	4.29	0.33	3.14e-5	Blood metabolite levels;
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg16535667	chr11:65410126	SIPA1	-0.53	-4.98	-0.37	1.69e-6	Blood pressure (age interaction);
PAAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.92	-11.55	-0.68	1.46e-22	Prudent dietary pattern;
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.61	-6.15	-0.45	6.65e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.61	7.68	0.53	1.85e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-6.05	-0.44	1.06e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11997175	0.603	rs7008747	chr8:33834886	G/A	ch.8.33884649F	chr8:33765107	NA	0.62	6.32	0.46	2.82e-9	Body mass index;
PAAD	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg12623918	chr2:306882	NA	0.48	5.06	0.38	1.19e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.48	-4.31	-0.33	2.93e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg06375148	chr1:209958343	C1orf74	0.67	5.25	0.39	5.14e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs4073221	0.789	rs35228011	chr3:18204652	G/A	cg07694806	chr3:18168406	NA	-0.85	-5.16	-0.39	7.47e-7	Parkinson's disease;
PAAD	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.61	-5.05	-0.38	1.22e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.49	-5.85	-0.43	2.88e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.75	-7.2	-0.5	2.66e-11	Height;
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.56	5.92	0.43	2.05e-8	Obesity-related traits;
PAAD	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg14583973	chr4:3374767	RGS12	0.42	6.19	0.45	5.36e-9	Serum sulfate level;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.74	-7.75	-0.53	1.22e-12	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.77	-7.99	-0.54	3.08e-13	Blood metabolite levels;
PAAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg03233332	chr7:66118400	NA	0.42	4.45	0.34	1.65e-5	Aortic root size;
PAAD	cis	rs9283706	0.623	rs1567316	chr5:66312103	T/G	cg11590213	chr5:66331682	MAST4	0.51	4.29	0.33	3.18e-5	Coronary artery disease;
PAAD	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg25364880	chr3:44379878	C3orf23	0.63	5.91	0.43	2.16e-8	Depressive symptoms;
PAAD	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg15478930	chr2:27652102	NRBP1	-0.54	-4.44	-0.34	1.7e-5	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.43	-0.34	1.77e-5	Testicular germ cell tumor;
PAAD	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.02	0.38	1.44e-6	Breast cancer;
PAAD	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.47	-4.4	-0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.66	-6.92	-0.49	1.2e-10	Menopause (age at onset);
PAAD	cis	rs950169	0.649	rs12901010	chr15:84699034	G/A	cg24253500	chr15:84953950	NA	0.58	6.31	0.46	2.84e-9	Schizophrenia;
PAAD	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.26	10.56	0.65	6.81e-20	Corneal structure;
PAAD	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-5.31	-0.4	3.74e-7	Myeloid white cell count;
PAAD	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-1.01	-10.25	-0.64	4.63e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.49	5.36	0.4	3.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.37	12.7	0.72	1.18e-25	Corneal structure;
PAAD	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.63	-6.09	-0.44	9e-9	Height;
PAAD	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.97	-8.5	-0.57	1.66e-14	Vitiligo;
PAAD	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10013645	chr10:35501529	CREM	-0.67	-6.97	-0.49	9.01e-11	Obesity-related traits;
PAAD	cis	rs6066835	1.000	rs6066837	chr20:47357337	A/C	cg18078177	chr20:47281410	PREX1	0.95	4.44	0.34	1.69e-5	Multiple myeloma;
PAAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Body mass index;
PAAD	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.84	-10.03	-0.63	1.78e-18	Coronary artery disease;
PAAD	cis	rs859767	0.704	rs9287437	chr2:135357502	C/T	cg12500956	chr2:135428796	TMEM163	-0.31	-4.51	-0.34	1.3e-5	Neuroticism;
PAAD	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg12395012	chr8:11607386	GATA4	0.45	4.3	0.33	3.04e-5	Neuroticism;
PAAD	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.45	4.41	0.34	1.95e-5	Chronic sinus infection;
PAAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.89	11.03	0.67	3.83e-21	Prudent dietary pattern;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16118367	chr8:27276153	PTK2B	-0.6	-6.3	-0.46	2.98e-9	Obesity-related traits;
PAAD	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.33	-0.33	2.67e-5	Mean corpuscular volume;
PAAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04362095	chr11:63592001	C11orf84	0.5	4.51	0.34	1.26e-5	Platelet count;
PAAD	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.73	6.29	0.45	3.2e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23371570	chr6:26457984	BTN2A1	0.6	6.31	0.46	2.94e-9	Obesity-related traits;
PAAD	cis	rs6804624	0.676	rs2670331	chr3:99160633	G/T	cg02646433	chr3:99218170	NA	0.42	4.35	0.33	2.5e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg22815214	chr1:201083145	CACNA1S	-0.65	-6.73	-0.48	3.21e-10	Permanent tooth development;
PAAD	cis	rs7640424	0.649	rs62262420	chr3:107909940	C/T	cg09227934	chr3:107805635	CD47	-0.41	-4.79	-0.36	3.97e-6	Body mass index;
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.64	-7.02	-0.49	6.93e-11	Colorectal cancer;
PAAD	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg05484376	chr2:27715224	FNDC4	-0.43	-4.4	-0.34	2.01e-5	Oral cavity cancer;
PAAD	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg18721089	chr20:30220636	NA	-0.63	-5.08	-0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21825840	chr11:66025173	KLC2	0.66	7.47	0.52	5.91e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg15770106	chr1:208133116	NA	-0.65	-6.52	-0.47	9.79e-10	Corneal structure;
PAAD	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.98	0.66	5.2e-21	Chronic sinus infection;
PAAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00292662	chr22:38071168	LGALS1	0.66	7.05	0.5	5.93e-11	Fat distribution (HIV);
PAAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg04673462	chr1:38461896	NA	-0.47	-6.4	-0.46	1.83e-9	Coronary artery disease;
PAAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19793034	chr4:1284190	MAEA	0.61	6.74	0.48	3.12e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.91	-11.61	-0.69	1.05e-22	Body mass index;
PAAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-4.67	-0.35	6.55e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.6	-6.7	-0.48	3.76e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11061033	chr14:23375497	RBM23	0.55	6.57	0.47	7.49e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	cis	rs11955175	1.000	rs11956743	chr5:40677593	G/A	cg17351974	chr5:40835760	RPL37	0.77	4.52	0.34	1.23e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.9	-11.8	-0.69	3.27e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.74	-9.74	-0.62	1.04e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg23719950	chr11:63933701	MACROD1	-0.54	-4.75	-0.36	4.72e-6	Platelet count;
PAAD	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg14515779	chr1:101123966	NA	-0.55	-6.44	-0.46	1.49e-9	Monocyte count;
PAAD	cis	rs11037575	0.715	rs7118766	chr11:43722213	A/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.85	4.37	0.33	2.31e-5	Plasma clusterin levels;
PAAD	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.56	-4.97	-0.37	1.8e-6	Alzheimer's disease (age of onset);
PAAD	cis	rs2120243	0.539	rs2168431	chr3:157120029	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-5.3	-0.39	4.07e-7	Electrocardiographic conduction measures;
PAAD	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.14	-7.32	-0.51	1.35e-11	Plateletcrit;
PAAD	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.48	4.42	0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.15	0.45	6.43e-9	Rheumatoid arthritis;
PAAD	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	12.07	0.7	6.13e-24	Platelet count;
PAAD	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.02	0.38	1.45e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.78	-7.04	-0.5	6.31e-11	Schizophrenia;
PAAD	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.96	-0.49	9.75e-11	Morning vs. evening chronotype;
PAAD	cis	rs564309	0.764	rs12065660	chr1:228534067	C/G	cg01328119	chr1:228783545	DUSP5P	0.71	4.41	0.34	1.98e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.57	-4.94	-0.37	2e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7940866	0.678	rs11222395	chr11:130794355	A/C	cg02264943	chr11:130785842	SNX19	0.36	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg06636001	chr8:8085503	FLJ10661	-0.8	-8.42	-0.56	2.6e-14	Neuroticism;
PAAD	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg15654264	chr1:150340011	RPRD2	0.52	5.02	0.38	1.45e-6	Migraine;
PAAD	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg23004174	chr6:74404879	CD109	0.51	5.28	0.39	4.29e-7	Blood protein levels;Calcium levels;
PAAD	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.59	6.11	0.44	7.83e-9	Testicular germ cell tumor;
PAAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg14024328	chr4:719362	PCGF3	-0.57	-5.86	-0.43	2.78e-8	White blood cell count;
PAAD	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg04450456	chr4:17643702	FAM184B	0.51	5.48	0.41	1.71e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg14092988	chr3:52407081	DNAH1	0.42	5.15	0.39	7.8e-7	Bipolar disorder;
PAAD	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-5.01	-0.38	1.5e-6	Common traits (Other);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10924691	chr14:21439548	NA	0.6	6.56	0.47	8.09e-10	Pancreatic cancer;
PAAD	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06671706	chr8:8559999	CLDN23	0.51	4.88	0.37	2.68e-6	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24823485	chr3:42626083	NA	0.64	6.51	0.47	1.06e-9	Smoking initiation;
PAAD	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.41	-4.6	-0.35	8.68e-6	Refractive error;
PAAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.4	-0.4	2.47e-7	Schizophrenia;
PAAD	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.09	0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11745092	chr7:42951893	C7orf25	0.64	7.08	0.5	4.96e-11	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.52	4.53	0.34	1.21e-5	Mean platelet volume;
PAAD	cis	rs1443512	0.588	rs10747688	chr12:54346495	C/G	cg25382128	chr12:54346509	NA	-0.66	-5.7	-0.42	6.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-7.69	-0.53	1.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6466055	0.589	rs6976394	chr7:104632980	A/G	cg04380332	chr7:105027541	SRPK2	-0.48	-4.56	-0.35	1.07e-5	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00330936	chr16:10837683	NUBP1	-0.68	-7.23	-0.51	2.15e-11	Lung cancer in ever smokers;
PAAD	cis	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.18	-0.39	6.92e-7	High light scatter reticulocyte count;
PAAD	cis	rs9535307	0.929	rs9535340	chr13:50357873	A/C	cg03658251	chr13:50265850	EBPL	0.83	5.68	0.42	6.7e-8	Obesity-related traits;
PAAD	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg05110241	chr16:68378359	PRMT7	-0.91	-7.29	-0.51	1.59e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs992157	0.764	rs2891076	chr2:219184398	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.09	0.5	4.83e-11	Colorectal cancer;
PAAD	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg08975724	chr8:8085496	FLJ10661	0.68	6.77	0.48	2.69e-10	Neuroticism;
PAAD	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.79	-7.3	-0.51	1.54e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9467711	0.516	rs555460	chr6:25870655	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.66	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs56309584	0.883	rs9896745	chr17:8142129	G/A	cg25053252	chr17:7589358	TP53;WRAP53	-0.48	-4.86	-0.37	2.9e-6	Initial pursuit acceleration;
PAAD	cis	rs1075265	0.840	rs2884254	chr2:54206463	C/A	cg04546899	chr2:54196757	PSME4	0.35	5.29	0.39	4.24e-7	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.75	8.03	0.55	2.45e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg13722127	chr7:150037890	RARRES2	0.58	5.96	0.44	1.72e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.26	-0.33	3.58e-5	Type 2 diabetes;
PAAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg08160980	chr1:46668840	C1orf190;POMGNT1	0.5	4.51	0.34	1.28e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-4.4	-0.34	2.05e-5	Menarche (age at onset);
PAAD	cis	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.72	-0.48	3.51e-10	Brain structure;
PAAD	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.29	-0.45	3.3e-9	Exhaled nitric oxide output;
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg25837213	chr17:80849375	TBCD	-0.48	-4.3	-0.33	3.07e-5	Breast cancer;
PAAD	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-1.11	-9.22	-0.6	2.35e-16	Post bronchodilator FEV1;
PAAD	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.65	-6.51	-0.47	1.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.4	5.01	0.38	1.5e-6	Pulmonary function;
PAAD	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.79	4.87	0.37	2.77e-6	Alzheimer's disease (late onset);
PAAD	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.53	-4.41	-0.34	1.95e-5	Heschl's gyrus morphology;
PAAD	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.72	7.02	0.5	6.73e-11	Schizophrenia;
PAAD	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.72	-8.23	-0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs12545912	0.909	rs7461376	chr8:9593469	G/A	cg01912921	chr6:1611712	FOXC1	0.8	6.41	0.46	1.7e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22633769	chr20:60982531	CABLES2	0.49	4.59	0.35	9.03e-6	Colorectal cancer;
PAAD	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.53	-5.44	-0.4	2.07e-7	Body mass index;
PAAD	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	9.88	0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs13144136	0.664	rs17267821	chr4:10653402	A/G	cg10242279	chr4:10666415	CLNK	-0.49	-6.44	-0.46	1.52e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.02	0.75	3.37e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13647721	chr17:30228624	UTP6	0.66	4.85	0.37	3.05e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs346785	0.640	rs11077809	chr17:74284854	A/C	cg09812376	chr17:74270190	QRICH2	-0.49	-6.2	-0.45	5e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg14847009	chr1:175162515	KIAA0040	0.33	5.26	0.39	4.72e-7	Alcohol dependence;
PAAD	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg07099767	chr17:78039528	CCDC40	-0.6	-5.22	-0.39	5.84e-7	Yeast infection;
PAAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg25319279	chr11:5960081	NA	-0.61	-5.95	-0.43	1.82e-8	DNA methylation (variation);
PAAD	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg14343924	chr8:8086146	FLJ10661	0.49	4.34	0.33	2.62e-5	Mood instability;
PAAD	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	4.95	0.37	1.97e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg15145965	chr22:50218605	BRD1	-0.61	-5.3	-0.4	3.98e-7	Schizophrenia;
PAAD	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg00383909	chr3:49044727	WDR6	0.53	4.43	0.34	1.77e-5	Educational attainment;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05197560	chr16:29937465	KCTD13	-0.68	-6.94	-0.49	1.07e-10	Smoking initiation;
PAAD	cis	rs329674	0.516	rs1682861	chr11:133759812	C/A	cg06766960	chr11:133703094	NA	-0.71	-4.5	-0.34	1.34e-5	Bipolar disorder;
PAAD	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-7.83	-0.54	7.85e-13	Morning vs. evening chronotype;
PAAD	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.55	6.56	0.47	7.98e-10	Schizophrenia;
PAAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.18	17.92	0.82	2.58e-39	Cognitive function;
PAAD	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.54	4.57	0.35	9.92e-6	Menopause (age at onset);
PAAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21862992	chr11:68658383	NA	0.44	4.72	0.36	5.36e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg12062639	chr20:23401060	NAPB	0.95	4.7	0.36	5.72e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-5.98	-0.44	1.56e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.49	0.34	1.41e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs73206853	0.764	rs55859138	chr12:110775610	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	4.31	0.33	2.91e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13870426	chr17:30244630	NA	0.57	5.01	0.38	1.52e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg16342193	chr10:102329863	NA	-0.78	-8.53	-0.57	1.41e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4474465	0.915	rs12277503	chr11:78140373	A/C	cg27205649	chr11:78285834	NARS2	-0.58	-4.36	-0.33	2.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg05895507	chr15:77155635	SCAPER	0.36	4.32	0.33	2.77e-5	Blood metabolite levels;
PAAD	cis	rs12612619	0.677	rs2053386	chr2:27244712	C/T	cg00617064	chr2:27272375	NA	-0.52	-5.46	-0.41	1.87e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs3857067	0.967	rs964843	chr4:95032367	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-4.34	-0.33	2.58e-5	QT interval;
PAAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.93	-7.22	-0.51	2.38e-11	Initial pursuit acceleration;
PAAD	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg00590817	chr1:8272081	NA	-0.39	-4.82	-0.36	3.38e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg09835421	chr16:68378352	PRMT7	-1.15	-8.66	-0.57	6.37e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6785206	0.554	rs13075151	chr3:128485750	T/C	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg08999081	chr20:33150536	PIGU	-0.48	-5.13	-0.38	8.78e-7	Height;
PAAD	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg15764593	chr10:829463	NA	-0.8	-4.33	-0.33	2.68e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.58	-0.35	9.53e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.47	-5.52	-0.41	1.42e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg08048268	chr3:133502702	NA	-0.49	-5.95	-0.43	1.82e-8	Iron status biomarkers;
PAAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.15	0.45	6.51e-9	Mean platelet volume;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03923535	chr7:1197113	ZFAND2A	0.43	4.32	0.33	2.8e-5	Longevity;Endometriosis;
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19346786	chr7:2764209	NA	-0.37	-5.13	-0.38	8.6e-7	Height;
PAAD	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.65	-6.81	-0.48	2.12e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27599033	chr16:2802711	SRRM2;LOC100128788	-0.63	-6.52	-0.47	9.91e-10	Smoking initiation;
PAAD	trans	rs1483035	0.596	rs36013585	chr4:156461601	G/T	cg00585174	chr10:134499472	INPP5A	0.5	6.64	0.47	5.1e-10	Influenza A (H1N1) severity;
PAAD	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg10756475	chr4:1757242	NA	0.48	4.54	0.35	1.15e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.35	-0.4	3.11e-7	Bipolar disorder;
PAAD	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.78	9.54	0.61	3.42e-17	Bladder cancer;
PAAD	cis	rs11051970	0.918	rs7309706	chr12:32538208	A/T	cg02745156	chr12:32552066	NA	0.47	4.77	0.36	4.24e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg27565382	chr3:53032988	SFMBT1	0.79	4.65	0.35	7.24e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs370915	0.578	rs1367932	chr4:187776654	A/G	cg12892747	chr4:187813459	NA	-0.47	-4.85	-0.37	2.97e-6	Gout;
PAAD	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7577696	0.752	rs212714	chr2:32460348	A/G	cg02381751	chr2:32503542	YIPF4	0.42	4.57	0.35	9.86e-6	Inflammatory biomarkers;
PAAD	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.73	5.38	0.4	2.81e-7	Initial pursuit acceleration;
PAAD	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg12568669	chr8:11666485	FDFT1	-0.3	-5.15	-0.39	7.88e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg02631450	chr22:32366979	NA	0.85	5.01	0.38	1.48e-6	Childhood ear infection;
PAAD	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.01	-0.38	1.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg27182935	chr16:89790473	ZNF276	-0.69	-4.37	-0.33	2.28e-5	Skin colour saturation;
PAAD	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-8.21	-0.55	8.69e-14	Alcohol dependence;
PAAD	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.4	-0.34	2.01e-5	Breast cancer;
PAAD	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.55	5.19	0.39	6.69e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10929159	0.928	rs1349732	chr2:236923716	G/A	cg14226755	chr2:236923322	AGAP1	0.29	4.55	0.35	1.08e-5	Parkinson's disease;
PAAD	cis	rs287982	0.935	rs1119632	chr2:9967664	C/A	cg01119585	chr2:10571959	NA	0.38	4.25	0.33	3.65e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs9715521	0.900	rs7696259	chr4:59810032	T/A	cg11281224	chr4:60001000	NA	-0.53	-5.26	-0.39	4.85e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg21178979	chr7:1889533	MAD1L1	-0.41	-4.43	-0.34	1.78e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.88	9.56	0.61	3.05e-17	Prudent dietary pattern;
PAAD	cis	rs7639513	0.520	rs4684111	chr3:12729485	T/G	cg23032965	chr3:12705835	RAF1	0.9	7.88	0.54	5.78e-13	Itch intensity from mosquito bite;
PAAD	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg02404636	chr22:31891804	SFI1	-0.58	-5.22	-0.39	5.85e-7	Colorectal cancer;
PAAD	cis	rs4478858	0.735	rs12129941	chr1:31871958	C/G	cg00250761	chr1:31883323	NA	-0.52	-5.89	-0.43	2.39e-8	Alcohol dependence;
PAAD	cis	rs10500715	0.715	rs10840331	chr11:9972479	T/C	cg06875754	chr11:10328428	ADM	-0.36	-4.96	-0.37	1.84e-6	Pancreatic cancer;
PAAD	cis	rs7624766	0.555	rs1829716	chr3:160477861	T/C	cg22637730	chr3:160473554	PPM1L	0.55	4.68	0.35	6.29e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs354033	0.959	rs4727087	chr7:149263687	T/C	cg06920324	chr7:149264011	ZNF767	-0.66	-5.15	-0.39	7.88e-7	Multiple sclerosis;
PAAD	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg02683114	chr2:24398427	C2orf84	-0.44	-5.13	-0.38	8.88e-7	Asthma;
PAAD	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.48	-5.51	-0.41	1.5e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.52	-0.41	1.46e-7	Obesity-related traits;
PAAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.04	0.44	1.13e-8	Colorectal cancer;
PAAD	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.71	-7.69	-0.53	1.67e-12	Alcohol dependence;
PAAD	cis	rs8067287	0.635	rs7225890	chr17:16840586	G/C	cg26910001	chr17:16838321	NA	-0.52	-4.84	-0.37	3.21e-6	Diabetic kidney disease;
PAAD	cis	rs3136441	1.000	rs75186174	chr11:46909498	C/T	cg19486271	chr11:47235900	DDB2	0.63	4.89	0.37	2.59e-6	HDL cholesterol;
PAAD	cis	rs3106136	0.609	rs28696050	chr4:95136630	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.68	-6.21	-0.45	4.9e-9	Capecitabine sensitivity;
PAAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg08132940	chr7:1081526	C7orf50	0.59	4.65	0.35	7.29e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.64	-7.59	-0.52	2.99e-12	Renal function-related traits (BUN);
PAAD	cis	rs375066	0.935	rs4803662	chr19:44359564	C/G	cg08633290	chr19:44405433	NA	-0.57	-5.75	-0.42	4.82e-8	Breast cancer;
PAAD	cis	rs9287719	0.593	rs13009015	chr2:10763118	T/A	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg07701084	chr6:150067640	NUP43	-0.53	-4.59	-0.35	9.36e-6	Lung cancer;
PAAD	cis	rs11696501	0.793	rs4812909	chr20:44167244	G/A	cg11783356	chr20:44313418	WFDC10B	-0.75	-6.38	-0.46	2.03e-9	Brain structure;
PAAD	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.46	5.83	0.43	3.25e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg03188948	chr7:1209495	NA	0.59	5.97	0.44	1.63e-8	Longevity;Endometriosis;
PAAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.78	-10.16	-0.64	7.7e-19	Breast cancer;
PAAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09065629	chr16:1709722	CRAMP1L	0.45	4.75	0.36	4.59e-6	Coronary artery disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01956865	chr17:79989929	RAC3	-0.63	-7.1	-0.5	4.49e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg08088566	chr11:430123	ANO9	0.87	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24549020	chr5:56110836	MAP3K1	-0.68	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.52	0.57	1.47e-14	Colorectal cancer;
PAAD	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.77	8.73	0.58	4.15e-15	Eosinophil percentage of white cells;
PAAD	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg05250797	chr16:70222502	NA	0.83	6.36	0.46	2.29e-9	IgE levels;
PAAD	cis	rs490234	0.702	rs13285587	chr9:128233058	G/T	cg14078157	chr9:128172775	NA	-0.44	-4.91	-0.37	2.29e-6	Mean arterial pressure;
PAAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg08856118	chr10:27389908	ANKRD26	-0.4	-4.3	-0.33	3e-5	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25303336	chr6:33756862	LEMD2	0.68	8.89	0.58	1.7e-15	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16135995	chr7:73668739	RFC2	-0.81	-7.08	-0.5	4.87e-11	Neuroticism;
PAAD	cis	rs13242816	1.000	rs62471202	chr7:116112562	G/A	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.5	-4.41	-0.34	1.94e-5	Blood metabolite levels;
PAAD	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.44	-4.69	-0.36	6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg22903657	chr4:1355424	KIAA1530	-0.48	-4.87	-0.37	2.75e-6	Obesity-related traits;
PAAD	cis	rs1497828	0.956	rs1497836	chr1:217562407	T/C	cg04411442	chr1:217543379	NA	0.49	4.82	0.36	3.5e-6	Dialysis-related mortality;
PAAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg09526685	chr4:187126073	CYP4V2	0.79	6.24	0.45	4.19e-9	Blood protein levels;
PAAD	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.71	0.53	1.55e-12	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02984159	chr7:1199847	ZFAND2A	0.62	7.05	0.5	5.9e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.63	0.35	7.73e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.48	-7.67	-0.53	1.95e-12	Cutaneous nevi;
PAAD	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-4.92	-0.37	2.27e-6	Vitiligo;
PAAD	trans	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg26939375	chr7:64535504	NA	0.75	9.02	0.59	7.72e-16	Aortic root size;
PAAD	cis	rs3764400	0.506	rs72827851	chr17:46452495	C/A	cg24322968	chr17:46507895	SKAP1	0.78	4.68	0.35	6.27e-6	Body mass index;
PAAD	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	4.92	0.37	2.19e-6	Ovarian reserve;
PAAD	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.55	4.91	0.37	2.34e-6	Type 2 diabetes;
PAAD	trans	rs4427176	0.507	rs7015963	chr8:9580854	G/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Mosquito bite size;
PAAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.68	-0.42	6.61e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg18281939	chr5:77783895	LHFPL2	0.51	6.46	0.46	1.37e-9	Triglycerides;
PAAD	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.63	-6.03	-0.44	1.22e-8	Mean corpuscular volume;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg02463844	chr16:88152170	NA	0.29	4.88	0.37	2.71e-6	Menopause (age at onset);
PAAD	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg20169779	chr10:135381914	SYCE1	-0.45	-4.63	-0.35	7.68e-6	Obesity-related traits;
PAAD	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.62	5.87	0.43	2.68e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs28595532	0.668	rs72670237	chr4:119320937	T/C	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.2	-0.39	6.37e-7	Multiple sclerosis;
PAAD	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.58e-11	Aortic root size;
PAAD	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg22875332	chr1:76189707	ACADM	-0.52	-5.13	-0.38	8.58e-7	Daytime sleep phenotypes;
PAAD	cis	rs2744375	0.600	rs2078438	chr6:7553229	G/A	cg27023638	chr6:7288726	SSR1	-0.41	-4.28	-0.33	3.34e-5	Resting heart rate;
PAAD	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.29	0.45	3.21e-9	Bladder cancer;
PAAD	cis	rs4965006	0.749	rs6598176	chr12:132425448	A/G	cg00588090	chr12:132412438	PUS1	-0.69	-7.37	-0.51	1.01e-11	Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg24250549	chr1:154909240	PMVK	0.74	7.67	0.53	1.86e-12	Prostate cancer;
PAAD	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.46	0.34	1.59e-5	Lung cancer;
PAAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.55	5.93	0.43	1.92e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg27499820	chr13:21296301	IL17D	0.49	4.81	0.36	3.67e-6	Dental caries;
PAAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.49	6.17	0.45	5.82e-9	Childhood ear infection;
PAAD	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00300879	chr1:26503847	CNKSR1	0.3	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.7	7.08	0.5	4.98e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.36	-0.33	2.41e-5	Life satisfaction;
PAAD	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.59	-5.42	-0.4	2.33e-7	Retinal vascular caliber;
PAAD	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.11	0.5	4.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.82	-6.09	-0.44	8.9e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.94	10.99	0.67	4.83e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9532580	0.614	rs17446614	chr13:41139877	A/G	cg21288729	chr13:41239152	FOXO1	-0.61	-5.11	-0.38	9.4e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.43	-0.4	2.24e-7	Response to temozolomide;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26294691	chr2:132435951	NA	-0.55	-7.18	-0.5	2.87e-11	Myopia (pathological);
PAAD	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.74	-7.26	-0.51	1.86e-11	Dilated cardiomyopathy;
PAAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.26	-0.39	4.72e-7	Personality dimensions;
PAAD	cis	rs8102137	1.000	rs56400371	chr19:30299634	A/C	cg27475126	chr19:30303651	CCNE1	-0.46	-5.13	-0.38	8.6e-7	Bladder cancer;
PAAD	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.7	-5.21	-0.39	5.93e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.35	0.4	3.19e-7	Personality dimensions;
PAAD	cis	rs7301826	0.967	rs4759790	chr12:131296390	T/G	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg21300403	chr2:198650112	BOLL	-0.65	-4.33	-0.33	2.72e-5	Ulcerative colitis;
PAAD	cis	rs13070279	0.655	rs11718929	chr3:71792688	G/A	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.92	-6.52	-0.47	9.64e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2408955	0.515	rs10875742	chr12:48493374	G/A	cg26205652	chr12:48591994	NA	0.64	6.22	0.45	4.62e-9	Glycated hemoglobin levels;
PAAD	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.45	-0.4	2.02e-7	Vitamin D levels;
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg05564831	chr3:52568323	NT5DC2	0.47	4.92	0.37	2.25e-6	Bipolar disorder;
PAAD	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg23024343	chr7:107201750	COG5	0.53	4.57	0.35	9.98e-6	Coronary artery disease;
PAAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14159672	chr1:205819179	PM20D1	0.52	5.03	0.38	1.37e-6	Parkinson's disease;
PAAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.8	10.09	0.63	1.22e-18	Bone mineral density;
PAAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg12963246	chr6:28129442	ZNF389	0.57	4.56	0.35	1.06e-5	Parkinson's disease;
PAAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17554472	chr22:41940697	POLR3H	0.61	4.42	0.34	1.87e-5	Vitiligo;
PAAD	cis	rs6708331	0.517	rs7579922	chr2:70361913	A/G	cg01613454	chr2:70366299	NA	0.43	4.65	0.35	7.12e-6	Obesity-related traits;
PAAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg00717180	chr2:96193071	NA	0.57	6.36	0.46	2.27e-9	HDL cholesterol;
PAAD	cis	rs2718812	0.904	rs2718809	chr3:133409418	A/G	cg12372414	chr3:134319805	KY	-0.41	-4.52	-0.34	1.22e-5	Iron status biomarkers;
PAAD	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-6.09	-0.44	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.61	-5.72	-0.42	5.58e-8	Mean corpuscular volume;
PAAD	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg14851346	chr12:38532713	NA	0.45	4.67	0.35	6.57e-6	Bladder cancer;
PAAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	7.63	0.53	2.39e-12	Menarche (age at onset);
PAAD	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg14146966	chr2:61757674	XPO1	-0.37	-4.55	-0.35	1.07e-5	Tuberculosis;
PAAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg13468214	chr4:1046988	NA	-0.56	-5.19	-0.39	6.66e-7	Recombination rate (females);
PAAD	cis	rs1007738	0.525	rs7130006	chr11:47217883	A/C	cg19486271	chr11:47235900	DDB2	0.51	4.75	0.36	4.62e-6	Bone mineral density (hip);
PAAD	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.8	7.95	0.54	4.01e-13	Retinal vascular caliber;
PAAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.68	-6.99	-0.49	7.92e-11	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19732566	chr8:145911660	NA	0.44	6.78	0.48	2.44e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.59	-5.55	-0.41	1.24e-7	Primary sclerosing cholangitis;
PAAD	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg21300403	chr2:198650112	BOLL	0.5	4.39	0.34	2.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.56	5.52	0.41	1.42e-7	Osteoporosis;
PAAD	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	1.19	8.77	0.58	3.46e-15	Lymphocyte counts;
PAAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg16147221	chr4:10020634	SLC2A9	0.48	4.37	0.33	2.33e-5	Bone mineral density;
PAAD	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg03101763	chr11:65319844	LTBP3	-0.8	-4.37	-0.33	2.28e-5	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15979172	chr19:15490570	AKAP8	0.59	6.56	0.47	7.8e-10	Monocyte percentage of white cells;
PAAD	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg08079166	chr15:68083412	MAP2K5	0.6	5.69	0.42	6.43e-8	Restless legs syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17593584	chr2:220025719	NHEJ1	0.67	7.07	0.5	5.39e-11	Obesity-related traits;
PAAD	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.5	-5.19	-0.39	6.61e-7	Motion sickness;
PAAD	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg13482628	chr17:19912719	NA	0.66	6.72	0.48	3.38e-10	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18519450	chr2:121746027	GLI2	-0.74	-6.95	-0.49	9.83e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1879734	0.636	rs1526911	chr1:54181942	C/G	cg14659662	chr1:54151053	GLIS1	-0.39	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02725872	chr8:58115012	NA	-0.62	-4.99	-0.38	1.63e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.66	7.06	0.5	5.6e-11	Blood protein levels;
PAAD	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg05585544	chr11:47624801	NA	-0.49	-5.43	-0.4	2.15e-7	Subjective well-being;
PAAD	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.7	7.0	0.49	7.88e-11	HIV-1 control;
PAAD	cis	rs761746	0.739	rs131233	chr22:32117100	C/A	cg01338084	chr22:32026380	PISD	0.65	5.45	0.4	2.01e-7	Intelligence;
PAAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.74	8.76	0.58	3.58e-15	Type 2 diabetes;
PAAD	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.56	5.16	0.39	7.52e-7	White matter hyperintensity burden;
PAAD	cis	rs17095355	1.000	rs7921609	chr10:111691599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.48	-0.34	1.47e-5	Biliary atresia;
PAAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-1.26	-7.72	-0.53	1.47e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs377457	0.821	rs755464	chr16:85738795	T/A	cg07784872	chr16:85687041	KIAA0182	-0.78	-8.47	-0.57	1.99e-14	Type 2 diabetes;
PAAD	cis	rs10915437	0.605	rs4131506	chr1:4194597	A/C	cg27165836	chr1:4193882	NA	0.53	5.55	0.41	1.25e-7	Migraine - clinic-based;
PAAD	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.97	8.7	0.58	4.93e-15	Pediatric autoimmune diseases;
PAAD	cis	rs877529	0.934	rs139419	chr22:39557340	T/G	cg18708252	chr22:39545030	CBX7	-0.48	-4.59	-0.35	9.28e-6	Multiple myeloma;
PAAD	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-1.01	-11.11	-0.67	2.28e-21	Cancer (pleiotropy);
PAAD	cis	rs72627123	1.000	rs72627127	chr14:74370098	G/A	cg19860245	chr14:74300557	NA	-0.75	-5.23	-0.39	5.49e-7	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.03	0.38	1.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs829661	0.948	rs829655	chr2:30729654	G/C	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2834256	0.961	rs2251854	chr21:35056247	A/G	cg14850771	chr21:34775459	IFNGR2	0.46	4.33	0.33	2.66e-5	Red cell distribution width;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10481617	chr6:12789309	PHACTR1	0.58	6.45	0.46	1.44e-9	Smoking initiation;
PAAD	cis	rs12153243	0.675	rs17401501	chr5:142894711	G/A	cg13907255	chr5:142895549	NA	-0.49	-4.48	-0.34	1.44e-5	Migraine;
PAAD	cis	rs10090774	0.965	rs62521937	chr8:141973524	T/C	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2790216	1.000	rs2440846	chr10:59974293	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02106180	chr16:845767	CHTF18	0.44	5.14	0.38	8.31e-7	Mean corpuscular volume;
PAAD	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg15212455	chr7:39170539	POU6F2	0.35	5.11	0.38	9.58e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3747547	0.710	rs11789061	chr9:37950230	A/G	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.83	-6.05	-0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg11266682	chr4:10021025	SLC2A9	-0.59	-5.28	-0.39	4.36e-7	Schizophrenia (age at onset);
PAAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg06740227	chr12:86229804	RASSF9	0.59	5.21	0.39	6.05e-7	Major depressive disorder;
PAAD	cis	rs2117029	0.523	rs12227296	chr12:49530495	T/A	cg05368762	chr12:50135785	TMBIM6	0.46	4.63	0.35	7.94e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg21665744	chr7:39171113	POU6F2	0.34	5.74	0.42	4.98e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg04160749	chr8:58172571	NA	0.67	4.5	0.34	1.37e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg07291445	chr7:39015928	NA	0.28	4.34	0.33	2.56e-5	IgG glycosylation;
PAAD	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.8	-9.04	-0.59	6.63e-16	IgG glycosylation;
PAAD	cis	rs5758511	0.573	rs1569451	chr22:42232291	C/T	cg03131358	chr22:42195972	CCDC134	-0.42	-4.37	-0.33	2.29e-5	Birth weight;
PAAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6074578	0.679	rs6086226	chr20:137310	C/A	cg16931068	chr20:139680	DEFB127	0.38	4.99	0.38	1.62e-6	Hirschsprung disease;
PAAD	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	1.1	8.61	0.57	8.58e-15	Iron status biomarkers;
PAAD	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg21191810	chr6:118973309	C6orf204	0.46	5.79	0.43	3.81e-8	Electrocardiographic conduction measures;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.85	-10.6	-0.65	5.38e-20	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg15181151	chr6:150070149	PCMT1	0.55	5.63	0.42	8.38e-8	Lung cancer;
PAAD	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg24879335	chr3:133465180	TF	0.64	7.01	0.49	7.29e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.48	7.13	0.5	3.73e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.62	-4.86	-0.37	2.89e-6	Vitiligo;
PAAD	cis	rs621942	0.950	rs547807	chr11:85709666	C/T	cg07180834	chr11:85838833	NA	-0.47	-4.37	-0.33	2.26e-5	Tourette syndrome;
PAAD	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.8	-6.98	-0.49	8.72e-11	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1345301	1.000	rs12470560	chr2:102868840	T/C	cg03938978	chr2:103052716	IL18RAP	-0.38	-4.33	-0.33	2.72e-5	Waist circumference;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23550947	chr3:108836912	MORC1	0.66	6.56	0.47	8.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg23018236	chr17:30244563	NA	-0.63	-5.43	-0.4	2.2e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.89	-8.94	-0.59	1.27e-15	Asthma;
PAAD	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.47	-4.9	-0.37	2.43e-6	Motion sickness;
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg21625146	chr5:486483	SLC9A3	-0.43	-5.26	-0.39	4.89e-7	Cystic fibrosis severity;
PAAD	cis	rs9944275	0.860	rs75336007	chr15:97214679	G/A	cg23969200	chr15:97326567	SPATA8	0.68	4.4	0.34	2.05e-5	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
PAAD	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.38	0.4	2.72e-7	Ileal carcinoids;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.64	6.66	0.48	4.74e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-4.92	-0.37	2.23e-6	Height;
PAAD	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	1.06	17.62	0.82	1.49e-38	Colorectal adenoma (advanced);
PAAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.49e-8	Lung cancer;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.43	-0.34	1.77e-5	Testicular germ cell tumor;
PAAD	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.64	0.62	1.9e-17	Bladder cancer;
PAAD	cis	rs11159086	0.793	rs11845370	chr14:74948290	T/A	cg10195687	chr14:74926396	NA	-0.47	-5.23	-0.39	5.55e-7	Advanced glycation end-product levels;
PAAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	6.28	0.45	3.38e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.8	-8.41	-0.56	2.8e-14	Prostate cancer;
PAAD	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.72	7.43	0.52	7.48e-12	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25101869	chr11:36531122	TRAF6	0.64	6.32	0.46	2.7e-9	Obesity-related traits;
PAAD	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.4	4.9	0.37	2.41e-6	Pulmonary function;
PAAD	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	5.85	0.43	2.9e-8	Fuchs's corneal dystrophy;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.25	-0.51	1.93e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg06899799	chr12:56650233	ANKRD52	0.34	4.26	0.33	3.6e-5	Cancer;
PAAD	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg20243544	chr17:37824526	PNMT	0.52	4.68	0.35	6.37e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.88	9.78	0.62	8.16e-18	Cognitive function;
PAAD	cis	rs4356203	0.519	rs214084	chr11:17298814	A/G	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.5	-0.34	1.32e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs11970254	0.560	rs12523921	chr6:67664612	C/T	cg18762500	chr6:67658480	NA	0.49	4.73	0.36	5.07e-6	Brain structure;
PAAD	cis	rs7631605	0.905	rs4647269	chr3:37057591	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.64	0.35	7.4e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9900972	0.918	rs8082515	chr17:76876769	C/A	cg20937029	chr17:76870563	TIMP2	0.58	5.08	0.38	1.08e-6	Obesity-related traits;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.81	0.36	3.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4795519	0.634	rs1850006	chr17:22183644	G/A	cg22648282	chr17:21454238	C17orf51	-0.51	-4.47	-0.34	1.54e-5	Chronic myeloid leukemia;
PAAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.73	-0.48	3.23e-10	Coronary artery disease;
PAAD	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.05	0.5	6e-11	Coffee consumption (cups per day);
PAAD	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-6.52	-0.47	1.01e-9	Eye color traits;
PAAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.54	0.35	1.12e-5	Tonsillectomy;
PAAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg18944383	chr4:111397179	ENPEP	0.73	8.09	0.55	1.78e-13	Coronary artery disease;
PAAD	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.13	-0.45	7.08e-9	Fibrinogen levels;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg26554054	chr8:600488	NA	-0.99	-6.24	-0.45	4.09e-9	IgG glycosylation;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.12	-0.5	4.08e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg26939375	chr7:64535504	NA	0.74	8.68	0.58	5.86e-15	Aortic root size;
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg04257695	chr17:30186438	C17orf79	-0.57	-4.58	-0.35	9.6e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.57	5.4	0.4	2.54e-7	Schizophrenia;
PAAD	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	4.54	0.35	1.12e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg23018236	chr17:30244563	NA	-0.6	-4.78	-0.36	4.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20893717	chr7:100318190	EPO	0.43	4.73	0.36	4.99e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg03909863	chr11:638404	DRD4	-0.68	-5.69	-0.42	6.22e-8	Systemic lupus erythematosus;
PAAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.35	4.79	0.36	3.9e-6	Height;
PAAD	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.47	4.38	0.33	2.19e-5	Neutrophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00275962	chr6:43484808	POLR1C;YIPF3	0.56	6.43	0.46	1.56e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.95	-0.37	1.91e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.7	7.43	0.52	7.15e-12	Aortic root size;
PAAD	cis	rs6921919	0.789	rs11970439	chr6:28303464	C/G	cg23153227	chr6:27725408	NA	0.55	4.71	0.36	5.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.64	-0.35	7.46e-6	Retinal vascular caliber;
PAAD	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs498136	1.000	rs12421629	chr11:69376121	T/C	cg24388239	chr11:68438018	NA	-0.42	-4.45	-0.34	1.64e-5	Cutaneous malignant melanoma;Melanoma;
PAAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.38	-0.4	2.75e-7	Breast cancer;
PAAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg03340356	chr1:67600835	NA	0.52	5.94	0.43	1.84e-8	Psoriasis;
PAAD	cis	rs2080501	0.571	rs1861657	chr16:49675807	G/T	cg27618369	chr16:49636483	ZNF423	0.45	4.66	0.35	6.73e-6	IgG glycosylation;
PAAD	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.83	-5.35	-0.4	3.13e-7	Lung cancer in ever smokers;
PAAD	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18138172	chr1:31191959	MATN1	0.69	7.03	0.5	6.52e-11	Obesity-related traits;
PAAD	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	0.93	10.14	0.64	8.65e-19	Testicular germ cell tumor;
PAAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg05132306	chr1:1846340	CALML6	-0.43	-5.1	-0.38	9.97e-7	Body mass index;
PAAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.48	-6.03	-0.44	1.18e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.65	0.42	7.82e-8	Red blood cell count;
PAAD	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.65	9.19	0.6	2.74e-16	Airflow obstruction;
PAAD	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.52	-0.41	1.46e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.55	7.26	0.51	1.87e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs3996993	0.737	rs4715318	chr6:52635331	T/C	cg20803780	chr6:52668592	GSTA1	-0.36	-4.37	-0.33	2.3e-5	Hemoglobin concentration;
PAAD	cis	rs10186876	0.522	rs7565148	chr2:44188396	T/G	cg14673618	chr2:45170322	SIX3	0.29	4.57	0.35	1.02e-5	Hand grip strength;
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.48	-0.34	1.47e-5	Testicular germ cell tumor;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.95	12.53	0.71	3.5e-25	Menarche (age at onset);
PAAD	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Total body bone mineral density;
PAAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs4343996	0.967	rs10276933	chr7:3349262	C/A	cg21248987	chr7:3385318	SDK1	0.47	5.21	0.39	6.18e-7	Motion sickness;
PAAD	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs11807834	0.522	rs754265	chr1:230249435	A/G	cg00566187	chr1:230250356	GALNT2	-0.68	-7.33	-0.51	1.27e-11	Schizophrenia;
PAAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.5	-4.95	-0.37	1.93e-6	Testicular germ cell tumor;
PAAD	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg24112000	chr20:60950667	NA	-0.71	-7.98	-0.54	3.29e-13	Colorectal cancer;
PAAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12165864	chr7:66369176	NA	0.83	5.53	0.41	1.4e-7	Diabetic kidney disease;
PAAD	cis	rs7866181	0.507	rs10982614	chr9:117981057	C/T	cg13910071	chr9:117023199	COL27A1	-0.54	-4.88	-0.37	2.66e-6	Dupuytren's disease;
PAAD	cis	rs288342	0.829	rs288243	chr2:183661310	C/G	cg02625481	chr2:183667124	NA	-0.45	-4.36	-0.33	2.39e-5	Recurrent major depressive disorder;
PAAD	cis	rs7213347	0.678	rs11658797	chr17:2088969	T/G	cg15816464	chr17:2026533	SMG6	0.47	5.1	0.38	1e-6	Total body bone mineral density;
PAAD	cis	rs1519814	1.000	rs4871045	chr8:121167814	T/C	cg22335954	chr8:121166405	COL14A1	-0.61	-5.28	-0.39	4.32e-7	Breast cancer;
PAAD	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg08508325	chr11:3079039	CARS	0.36	4.45	0.34	1.65e-5	Calcium levels;
PAAD	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.67	-6.94	-0.49	1.04e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg06569542	chr10:98946673	SLIT1	-0.53	-5.88	-0.43	2.47e-8	Monocyte count;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01373262	chr20:44034880	DBNDD2;SYS1-DBNDD2	0.6	6.45	0.46	1.38e-9	Pancreatic cancer;
PAAD	cis	rs10905065	0.804	rs2175630	chr10:5834736	A/C	cg11519256	chr10:5708881	ASB13	-0.52	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs11651753	0.561	rs11654010	chr17:45960865	C/T	cg24458315	chr17:46148407	CBX1	-0.41	-4.56	-0.35	1.04e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg18721089	chr20:30220636	NA	0.63	5.08	0.38	1.1e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-5.33	-0.4	3.55e-7	Mood instability;
PAAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	4.06e-10	Total body bone mineral density;
PAAD	cis	rs6942407	0.592	rs17766011	chr7:86749169	C/A	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg00531865	chr16:30841666	NA	-0.51	-4.8	-0.36	3.79e-6	Dementia with Lewy bodies;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.77	9.22	0.6	2.31e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.68	0.58	5.57e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.46	-4.74	-0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	7.98	0.54	3.35e-13	Parkinson's disease;
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg21548813	chr6:291882	DUSP22	-0.76	-8.29	-0.56	5.59e-14	Menopause (age at onset);
PAAD	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.46	0.34	1.59e-5	Self-reported allergy;
PAAD	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs2236267	0.726	rs6574991	chr14:88603502	T/C	cg18078958	chr14:88630771	NA	-0.53	-6.79	-0.48	2.4e-10	Food antigen IgG levels;
PAAD	cis	rs72960926	1.000	rs72958991	chr6:75130440	T/C	cg13997649	chr6:74171430	MTO1	0.88	4.63	0.35	7.91e-6	Metabolite levels (MHPG);
PAAD	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg22916017	chr11:64110731	CCDC88B	0.39	4.59	0.35	9.09e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.4	-0.46	1.85e-9	Lymphocyte counts;
PAAD	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-0.95	-10.91	-0.66	7.99e-21	Gut microbiome composition (winter);
PAAD	cis	rs6734238	0.739	rs6728590	chr2:113844600	A/G	cg06156847	chr2:113672199	IL1F7	-0.43	-4.31	-0.33	2.96e-5	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
PAAD	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26926768	chr12:34528122	NA	0.37	4.39	0.34	2.13e-5	Morning vs. evening chronotype;
PAAD	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.79	5.18	0.39	7.02e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.72	7.66	0.53	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-4.82	-0.36	3.42e-6	Ulcerative colitis;
PAAD	cis	rs16975963	0.594	rs73039018	chr19:38217894	C/A	cg08679971	chr19:38281047	NA	0.48	4.67	0.35	6.45e-6	Longevity;
PAAD	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	5.03	0.38	1.36e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.52	0.47	9.91e-10	Lung cancer;
PAAD	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg02421172	chr7:1938701	MAD1L1	0.62	4.35	0.33	2.49e-5	Bipolar disorder;
PAAD	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.45	5.76	0.42	4.55e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09994773	chr1:9212514	MIR34A	0.62	6.33	0.46	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08439880	chr3:133502540	NA	-0.51	-5.64	-0.42	7.9e-8	Iron status biomarkers;
PAAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.84	6.43	0.46	1.59e-9	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs59918340	0.738	rs3739241	chr8:142221361	C/G	cg16341495	chr8:142228727	SLC45A4	-0.59	-5.86	-0.43	2.76e-8	Immature fraction of reticulocytes;
PAAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	0.88	5.89	0.43	2.36e-8	IgG glycosylation;
PAAD	cis	rs17655565	0.537	rs12427183	chr12:52805775	C/T	cg22980804	chr12:52818037	KRT75	-0.55	-4.94	-0.37	2.05e-6	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs6596100	0.538	rs34592321	chr5:132181675	G/C	cg16419906	chr5:132167176	NA	-0.58	-4.41	-0.34	1.99e-5	Breast cancer;
PAAD	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg14196790	chr5:131705035	SLC22A5	0.43	4.53	0.34	1.21e-5	Blood metabolite levels;
PAAD	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg11868041	chr20:55503363	NA	0.41	4.48	0.34	1.43e-5	Verbal memory performance (delayed recall level);
PAAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.58	6.51	0.47	1.02e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.7	8.11	0.55	1.61e-13	Colorectal cancer;
PAAD	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.92	9.84	0.62	5.42e-18	Corneal astigmatism;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs932316	0.545	rs72838858	chr6:25659305	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.56	-4.25	-0.33	3.76e-5	Iron status biomarkers;
PAAD	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs903263	0.520	rs12756327	chr1:84664640	T/G	cg04407776	chr1:84465009	TTLL7	-0.56	-4.33	-0.33	2.73e-5	Breast cancer (male);
PAAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg14393609	chr7:65229607	NA	-0.61	-6.32	-0.46	2.76e-9	Calcium levels;
PAAD	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg04087571	chr11:116723030	SIK3	-0.37	-5.39	-0.4	2.66e-7	Blood protein levels;
PAAD	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.47	-4.37	-0.33	2.28e-5	Obesity-related traits;
PAAD	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-5.75	-0.42	4.66e-8	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02077085	chr14:64931880	AKAP5	0.65	6.33	0.46	2.68e-9	Obesity-related traits;
PAAD	cis	rs11887277	0.708	rs12474330	chr2:27063260	G/A	cg12368169	chr2:27073192	DPYSL5	-0.44	-4.79	-0.36	4e-6	Obesity-related traits;
PAAD	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg10512202	chr3:45649293	LIMD1	-0.48	-4.6	-0.35	8.85e-6	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg05457628	chr5:178986728	RUFY1	-0.67	-7.06	-0.5	5.68e-11	Lung cancer;
PAAD	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.57	4.36	0.33	2.38e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.6	6.4	0.46	1.85e-9	Mean corpuscular volume;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.59	-7.89	-0.54	5.63e-13	Schizophrenia;
PAAD	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.8	5.65	0.42	7.54e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg21546286	chr11:48923668	NA	0.58	5.98	0.44	1.5e-8	HDL cholesterol;
PAAD	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.72	-5.13	-0.38	8.61e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9976767	0.932	rs9784206	chr21:43823380	T/G	cg23042151	chr21:43824109	UBASH3A	-0.36	-4.25	-0.33	3.74e-5	Type 1 diabetes;
PAAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Gout;
PAAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	1.07	9.42	0.61	6.97e-17	Eosinophil percentage of granulocytes;
PAAD	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg00806126	chr19:22604979	ZNF98	0.42	5.4	0.4	2.52e-7	Pain;
PAAD	cis	rs4356203	0.870	rs10832748	chr11:17251731	A/C	cg15432903	chr11:17409602	KCNJ11	-0.43	-4.53	-0.34	1.18e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs73252553	0.548	rs4697564	chr4:25313136	C/T	cg04009456	chr4:25379436	ANAPC4	-0.4	-4.49	-0.34	1.39e-5	Cannabis dependence symptom count;
PAAD	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.54	-8.48	-0.57	1.83e-14	Urinary metabolites;
PAAD	cis	rs10929159	0.928	rs10929157	chr2:236920156	C/G	cg14226755	chr2:236923322	AGAP1	0.29	4.56	0.35	1.05e-5	Parkinson's disease;
PAAD	cis	rs9535307	0.719	rs9562927	chr13:50363677	A/G	cg04663916	chr13:50265991	EBPL	0.6	4.46	0.34	1.61e-5	Obesity-related traits;
PAAD	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg10705379	chr10:99080932	FRAT1	0.39	4.58	0.35	9.56e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs669446	0.561	rs517849	chr1:44081873	A/C	cg12908607	chr1:44402522	ARTN	-0.42	-4.46	-0.34	1.56e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.77	7.62	0.53	2.49e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12893428	chr3:195717962	SDHAP1	0.46	4.94	0.37	2.04e-6	Pancreatic cancer;
PAAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg23281280	chr6:28129359	ZNF389	0.54	4.86	0.37	2.88e-6	Parkinson's disease;
PAAD	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.7	-5.29	-0.39	4.24e-7	Diisocyanate-induced asthma;
PAAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.47	5.38	0.4	2.77e-7	Testicular germ cell tumor;
PAAD	cis	rs16975963	0.644	rs1478462	chr19:38147025	A/G	cg14218481	chr19:38281219	NA	0.43	4.58	0.35	9.45e-6	Longevity;
PAAD	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00791764	chr4:53727839	RASL11B	0.51	4.52	0.34	1.21e-5	Optic nerve measurement (cup area);
PAAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs7246760	0.867	rs2336090	chr19:9879584	A/G	cg16876255	chr19:9731953	ZNF561	0.93	4.59	0.35	9.12e-6	Pursuit maintenance gain;
PAAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg16928487	chr17:17741425	SREBF1	0.39	5.1	0.38	1.01e-6	Total body bone mineral density;
PAAD	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.3	0.46	2.98e-9	Lung cancer;
PAAD	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21643547	chr1:205240462	TMCC2	-0.38	-4.28	-0.33	3.31e-5	Red blood cell count;
PAAD	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.98	11.64	0.69	8.64e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg01059385	chr22:42394853	WBP2NL	0.53	4.36	0.33	2.34e-5	Birth weight;
PAAD	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.95	12.83	0.72	5.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.59	-6.05	-0.44	1.06e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.52	5.56	0.41	1.21e-7	Lung cancer;
PAAD	cis	rs11997175	0.600	rs6468188	chr8:33639478	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	6.35	0.46	2.37e-9	Body mass index;
PAAD	cis	rs1903068	0.853	rs9312655	chr4:56002665	T/C	cg20092376	chr4:56023423	NA	0.41	4.27	0.33	3.48e-5	Endometriosis;
PAAD	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.6	-6.42	-0.46	1.65e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.14	0.38	8.46e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg26818257	chr2:241905806	NA	0.45	4.62	0.35	8.05e-6	Joint mobility (Beighton score);
PAAD	cis	rs728616	0.681	rs36023925	chr10:81906846	T/C	cg19423196	chr10:82049429	MAT1A	0.46	4.32	0.33	2.79e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7301016	1.000	rs73141014	chr12:62891412	T/G	cg19781863	chr12:62918364	MON2	0.74	4.35	0.33	2.53e-5	IgG glycosylation;
PAAD	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.06	-0.38	1.22e-6	Mean corpuscular volume;
PAAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg05564831	chr3:52568323	NT5DC2	-0.44	-4.68	-0.36	6.18e-6	Bipolar disorder;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.48	5.25	0.39	5.05e-7	Longevity;Endometriosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10644772	chr12:123237461	DENR	0.66	6.39	0.46	1.88e-9	Obesity-related traits;
PAAD	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.09e-6	Asthma (childhood onset);
PAAD	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs8016982	0.589	rs12586249	chr14:81701004	T/C	cg01989461	chr14:81687754	GTF2A1	-0.57	-4.43	-0.34	1.78e-5	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs11808674	chr1:227516077	G/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.74	7.95	0.54	3.89e-13	Heart rate;
PAAD	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	8.15	0.55	1.27e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.78	8.2	0.55	9.09e-14	Sudden cardiac arrest;
PAAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg05313129	chr8:58192883	C8orf71	-0.44	-4.25	-0.33	3.65e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.56	-5.62	-0.41	9.08e-8	Prudent dietary pattern;
PAAD	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.74	-0.42	5.03e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg23346134	chr3:49453900	TCTA	-0.45	-4.84	-0.37	3.13e-6	Menarche (age at onset);
PAAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs2278796	0.639	rs12145998	chr1:204969419	C/T	cg04862289	chr1:204966208	NFASC	0.5	5.18	0.39	6.99e-7	Mean platelet volume;
PAAD	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg00490450	chr3:139108681	COPB2	-0.63	-5.54	-0.41	1.32e-7	Obesity-related traits;
PAAD	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.0	0.38	1.56e-6	Colorectal cancer;
PAAD	cis	rs16867335	0.652	rs1528439	chr2:181462035	C/T	cg23363182	chr2:181467187	NA	-0.46	-4.45	-0.34	1.64e-5	Survival in rectal cancer;
PAAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg04738700	chr2:239367308	NA	0.4	4.32	0.33	2.79e-5	Multiple system atrophy;
PAAD	cis	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.63	-5.36	-0.4	3.1e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.19	9.63	0.62	1.98e-17	Alzheimer's disease (late onset);
PAAD	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	1.06	8.32	0.56	4.78e-14	Menopause (age at onset);
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	1.08	15.0	0.77	8.63e-32	Breast cancer;
PAAD	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.73	5.71	0.42	5.71e-8	Post bronchodilator FEV1;
PAAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg07648498	chr16:89883185	FANCA	0.48	4.51	0.34	1.28e-5	Vitiligo;
PAAD	cis	rs564309	0.681	rs1188473	chr1:228612444	A/G	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg03983715	chr16:68378420	PRMT7	-0.82	-5.76	-0.42	4.52e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.48	-4.62	-0.35	8.19e-6	Uric acid levels;
PAAD	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.63	-6.73	-0.48	3.22e-10	Neuroticism;
PAAD	cis	rs797680	0.789	rs531514	chr1:93700212	C/T	cg04535902	chr1:92947332	GFI1	-0.46	-4.43	-0.34	1.78e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs13006833	0.668	rs291445	chr2:191176479	G/A	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.97	-7.55	-0.52	3.68e-12	Initial pursuit acceleration;
PAAD	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.39	4.47	0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg20673841	chr7:107026890	COG5	0.51	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg17366294	chr4:99064904	C4orf37	0.46	5.05	0.38	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.6	6.99	0.49	8.31e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	8.13	0.55	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.54	4.8	0.36	3.73e-6	Platelet count;
PAAD	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.68	-7.49	-0.52	5.18e-12	Alcohol dependence;
PAAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.41e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9659323	0.670	rs10157346	chr1:119633547	T/C	cg26570165	chr1:119541833	NA	-0.47	-5.05	-0.38	1.24e-6	Body mass index;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.61	0.41	9.37e-8	Prudent dietary pattern;
PAAD	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg26003909	chr8:143102224	NA	-0.35	-5.88	-0.43	2.46e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.74	-8.74	-0.58	3.95e-15	Morning vs. evening chronotype;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.55	-0.41	1.26e-7	Prostate cancer;
PAAD	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.91	12.02	0.7	8.36e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs2342371	0.848	rs7433483	chr3:196217038	C/T	cg05659262	chr3:195539315	MUC4	-0.49	-4.31	-0.33	2.93e-5	Fat distribution (HIV);
PAAD	cis	rs6563943	0.857	rs8053046	chr16:83636775	C/G	cg01935413	chr16:83636749	CDH13	0.55	5.18	0.39	6.85e-7	Height;
PAAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.51	-6.7	-0.48	3.88e-10	Life satisfaction;
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	cis	rs6782228	0.606	rs4634140	chr3:128424456	C/T	cg16766828	chr3:128327626	NA	0.42	5.59	0.41	1.01e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs72634258	0.945	rs2641116	chr1:8029494	T/G	cg08926642	chr1:7887455	PER3	0.54	4.66	0.35	6.97e-6	Inflammatory bowel disease;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26703520	chr6:34728146	SNRPC	-0.5	-6.32	-0.46	2.81e-9	Monocyte percentage of white cells;
PAAD	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.64	-7.15	-0.5	3.32e-11	Corneal astigmatism;
PAAD	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.25	-4.29	-0.33	3.15e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs17152411	0.600	rs4962711	chr10:126644482	T/C	cg07081759	chr10:126330905	FAM53B	-0.4	-4.42	-0.34	1.83e-5	Height;
PAAD	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.46	-4.45	-0.34	1.67e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.39	0.46	1.93e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.98	0.44	1.56e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs793571	0.876	rs4774315	chr15:59202598	G/T	cg05156742	chr15:59063176	FAM63B	-0.6	-5.13	-0.38	8.76e-7	Schizophrenia;
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.59	-4.76	-0.36	4.55e-6	Platelet count;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg00280220	chr17:61926910	NA	0.43	4.5	0.34	1.35e-5	Prudent dietary pattern;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13671590	chr9:125056607	MRRF	0.65	6.52	0.47	9.66e-10	Lung cancer in ever smokers;
PAAD	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Breast cancer;
PAAD	cis	rs10046574	0.831	rs10261625	chr7:135173544	C/T	cg27474649	chr7:135195673	CNOT4	0.8	4.3	0.33	3e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs6141769	0.542	rs28730896	chr20:31295844	A/G	cg13636640	chr20:31349939	DNMT3B	-0.51	-4.74	-0.36	4.88e-6	Subjective well-being;
PAAD	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.58	-5.46	-0.4	1.89e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs12311304	1.000	rs56269213	chr12:15383650	A/C	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09668216	chr3:30647919	TGFBR2	0.69	7.04	0.5	6.15e-11	Obesity-related traits;
PAAD	cis	rs16852403	0.583	rs4440820	chr1:178088698	T/C	cg00404053	chr1:178313656	RASAL2	0.44	4.28	0.33	3.27e-5	Childhood ear infection;
PAAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg00988841	chr10:134556463	INPP5A	0.49	4.55	0.35	1.07e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.48	4.51	0.34	1.29e-5	Neutrophil percentage of white cells;
PAAD	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.92	11.37	0.68	4.5e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.79	9.19	0.6	2.86e-16	Eosinophil percentage of white cells;
PAAD	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.0	-12.66	-0.72	1.56e-25	Dilated cardiomyopathy;
PAAD	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.61	-4.62	-0.35	8.05e-6	Breast cancer;
PAAD	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.73	6.39	0.46	1.91e-9	Obesity-related traits;
PAAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg15847926	chr7:2749597	AMZ1	-0.39	-4.68	-0.36	6.21e-6	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20869501	chr1:216774677	ESRRG	0.54	6.72	0.48	3.36e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08199273	chr10:131934535	GLRX3	0.64	7.39	0.51	8.99e-12	Monocyte percentage of white cells;
PAAD	cis	rs883565	0.740	rs6599006	chr3:39114276	T/G	cg01426195	chr3:39028469	NA	-0.67	-7.13	-0.5	3.75e-11	Handedness;
PAAD	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.35	11.33	0.68	6.03e-22	Uric acid levels;
PAAD	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg23306229	chr2:178417860	TTC30B	0.76	5.24	0.39	5.39e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-6.87	-0.49	1.57e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00026457	chr1:200116736	NR5A2	0.69	7.4	0.51	8.64e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2637030	0.515	rs381374	chr5:52927813	A/G	cg17674090	chr5:52083609	ITGA1;PELO	0.57	4.33	0.33	2.67e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg19223190	chr17:80058835	NA	0.56	5.76	0.42	4.62e-8	Life satisfaction;
PAAD	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg25008857	chr14:105974488	NA	0.39	4.28	0.33	3.23e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-5.81	-0.43	3.58e-8	Total cholesterol levels;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg15571903	chr15:79123663	NA	-0.48	-6.27	-0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.6	6.01	0.44	1.3e-8	Monocyte count;
PAAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.72	8.35	0.56	3.95e-14	Multiple sclerosis;
PAAD	cis	rs9463078	0.691	rs3920903	chr6:45040928	T/A	cg25276700	chr6:44698697	NA	-0.53	-5.91	-0.43	2.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19535980	chr5:159519152	PWWP2A	-0.73	-6.75	-0.48	3e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12304921	0.748	rs56353532	chr12:51364732	G/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.19	-0.39	6.74e-7	Type 2 diabetes;
PAAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg00579200	chr11:133705235	NA	-0.48	-5.33	-0.4	3.5e-7	Childhood ear infection;
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs1042026	0.813	rs12648974	chr4:100083128	G/C	cg09112717	chr4:100009950	ADH5	-0.5	-4.41	-0.34	1.91e-5	Esophageal cancer  (alcohol interaction);
PAAD	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg17552801	chr10:99332121	ANKRD2	-0.45	-4.65	-0.35	7.25e-6	Metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23354735	chr17:37077918	LASP1	0.61	6.71	0.48	3.63e-10	Smoking initiation;
PAAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-4.44	-0.34	1.75e-5	Prostate cancer;
PAAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7236492	0.748	rs113864961	chr18:77214594	G/A	cg15644404	chr18:77186268	NFATC1	-0.77	-4.87	-0.37	2.83e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.47	-5.13	-0.38	8.88e-7	Male-pattern baldness;
PAAD	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.27	0.39	4.51e-7	Ovarian reserve;
PAAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.51	4.47	0.34	1.51e-5	Coronary artery disease;
PAAD	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.47	4.93	0.37	2.17e-6	Breast cancer;Platelet count;
PAAD	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.45	0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg02569219	chr17:2266849	SGSM2	-0.49	-4.29	-0.33	3.19e-5	Total body bone mineral density;
PAAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg03676636	chr4:99064102	C4orf37	0.35	5.71	0.42	5.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9826463	0.702	rs28365824	chr3:142315114	C/A	cg20824294	chr3:142316082	PLS1	0.43	4.82	0.36	3.41e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs35740288	0.822	rs1961601	chr15:86229606	T/C	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.23	0.51	2.14e-11	Lung cancer in ever smokers;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13382275	0.915	rs28393260	chr2:972978	A/G	cg02924234	chr2:420061	NA	0.57	4.71	0.36	5.6e-6	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.89	11.3	0.68	7.2e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs357618	1.000	rs357623	chr5:150848500	G/A	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.67	6.46	0.46	1.35e-9	Morning vs. evening chronotype;
PAAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.46	-4.99	-0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.64	-0.53	2.23e-12	Morning vs. evening chronotype;
PAAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg08029281	chr1:67600428	NA	0.43	5.19	0.39	6.74e-7	Psoriasis;
PAAD	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg14440974	chr22:39074834	NA	0.59	7.29	0.51	1.61e-11	Menopause (age at onset);
PAAD	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.25	-8.63	-0.57	7.48e-15	Diabetic retinopathy;
PAAD	trans	rs901683	0.850	rs76395348	chr10:46082064	T/C	cg13065504	chr15:42448234	PLA2G4F	0.87	6.78	0.48	2.46e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg25204440	chr1:209979598	IRF6	0.59	5.08	0.38	1.11e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9649465	0.967	rs598115	chr7:123402603	C/G	cg04330084	chr7:123175371	IQUB	0.5	4.76	0.36	4.51e-6	Migraine;
PAAD	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg23688817	chr7:87105293	ABCB4	0.52	4.39	0.34	2.12e-5	Gallbladder cancer;
PAAD	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.48	-4.51	-0.34	1.3e-5	Mean platelet volume;
PAAD	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.22	0.39	5.77e-7	Mean platelet volume;
PAAD	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg20814179	chr4:940893	TMEM175	0.75	9.12	0.59	4.22e-16	Sjögren's syndrome;
PAAD	cis	rs7765004	1.000	rs9400667	chr6:114075819	A/C	cg13100190	chr6:114053961	NA	0.36	4.49	0.34	1.4e-5	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy;
PAAD	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.71	0.58	4.7e-15	Exhaled nitric oxide output;
PAAD	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg06060754	chr5:176797920	RGS14	0.66	6.74	0.48	3.13e-10	Urate levels in lean individuals;
PAAD	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg19413350	chr8:57351067	NA	-0.55	-5.55	-0.41	1.26e-7	Obesity-related traits;
PAAD	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.59	-8.35	-0.56	3.98e-14	Asthma (sex interaction);
PAAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Body mass index;
PAAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg04450456	chr4:17643702	FAM184B	0.47	5.01	0.38	1.48e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2997447	0.761	rs61776586	chr1:26438933	T/C	cg24519413	chr1:26490540	NA	0.52	4.69	0.36	6.08e-6	QRS complex (12-leadsum);
PAAD	cis	rs9715521	0.868	rs6848053	chr4:59839309	T/C	cg11281224	chr4:60001000	NA	-0.62	-5.94	-0.43	1.85e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg02404636	chr22:31891804	SFI1	0.59	5.36	0.4	2.97e-7	Colorectal cancer;
PAAD	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg18595228	chr15:67193261	NA	0.72	4.7	0.36	5.82e-6	Lung cancer (smoking interaction);
PAAD	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.88	0.37	2.67e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.66	4.88	0.37	2.69e-6	Exhaled nitric oxide output;
PAAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg21951975	chr1:209979733	IRF6	-0.57	-5.56	-0.41	1.21e-7	Coronary artery disease;
PAAD	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23203755	chr3:149182974	NA	-0.65	-6.67	-0.48	4.36e-10	Smoking initiation;
PAAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.95	-0.37	1.96e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.53	13.24	0.73	4.14e-27	Atopic dermatitis;
PAAD	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.23	5.51	0.41	1.49e-7	Urinary tract infection frequency;
PAAD	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.5	6.16	0.45	6.37e-9	Sitting height ratio;
PAAD	cis	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.63	-0.35	7.79e-6	Eotaxin levels;
PAAD	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.56	5.04	0.38	1.31e-6	Blood metabolite levels;
PAAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.55	-5.89	-0.43	2.39e-8	Birth weight;
PAAD	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.5	4.34	0.33	2.59e-5	Extraversion;
PAAD	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.58	-5.84	-0.43	3.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs13102973	0.965	rs7693757	chr4:135856609	C/T	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.76	-7.75	-0.53	1.23e-12	Cognitive function;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.72	5.1	0.38	9.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.78	-6.76	-0.48	2.83e-10	Blood pressure (smoking interaction);
PAAD	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg12870014	chr12:110450643	ANKRD13A	0.7	4.67	0.35	6.68e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.49	5.1	0.38	1e-6	Bladder cancer;
PAAD	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.54	-4.59	-0.35	9.16e-6	Total body bone mineral density;
PAAD	cis	rs2271001	0.955	rs11607797	chr11:19178169	A/T	cg00161556	chr11:19138045	ZDHHC13	0.51	5.44	0.4	2.13e-7	Gut microbiome composition (winter);
PAAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg23018236	chr17:30244563	NA	-0.63	-5.39	-0.4	2.65e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.64	5.88	0.43	2.57e-8	Tuberculosis;
PAAD	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.61	5.59	0.41	1.01e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	0.88	5.85	0.43	2.97e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs8099014	0.911	rs8098308	chr18:56130661	A/G	cg12907477	chr18:56117327	MIR122	0.53	4.29	0.33	3.19e-5	Platelet count;
PAAD	cis	rs8111071	1.000	rs8111071	chr19:46307406	C/T	cg14192299	chr19:46417639	NANOS2	-0.99	-5.01	-0.38	1.51e-6	Sudden cardiac arrest;
PAAD	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.6	-5.23	-0.39	5.61e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs62247992	0.698	rs11707627	chr3:43123223	C/T	cg12239580	chr3:43073058	FAM198A	0.49	4.72	0.36	5.36e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-4.4	-0.34	2.04e-5	Vitiligo;
PAAD	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.71	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12432203	0.736	rs4144433	chr14:51750412	C/A	cg23942311	chr14:51606299	NA	0.67	4.77	0.36	4.34e-6	Cancer;
PAAD	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.85	-10.3	-0.64	3.31e-19	Monocyte percentage of white cells;
PAAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg13072238	chr3:49761600	GMPPB	0.43	4.52	0.34	1.22e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01125608	chr5:646071	CEP72	0.63	7.42	0.52	7.75e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg05338066	chr1:7812865	CAMTA1	0.53	4.46	0.34	1.57e-5	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs17152411	1.000	rs17152433	chr10:126670356	G/A	cg07906193	chr10:126599966	NA	0.7	5.89	0.43	2.4e-8	Height;
PAAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.55	6.01	0.44	1.3e-8	Menopause (age at onset);
PAAD	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg05555928	chr11:63887634	MACROD1	-0.64	-4.85	-0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg12661370	chr5:149340060	SLC26A2	0.65	5.48	0.41	1.75e-7	HIV-1 control;
PAAD	cis	rs375066	0.935	rs10421518	chr19:44381286	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.33e-7	Breast cancer;
PAAD	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.0	0.49	7.86e-11	Lung cancer in ever smokers;
PAAD	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.44	5.14	0.38	8.3e-7	Coronary artery disease;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.42	5.85	0.43	2.97e-8	Vitiligo;
PAAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs4454254	0.589	rs883612	chr8:141076133	C/G	cg06693505	chr8:141057453	TRAPPC9	-0.35	-4.77	-0.36	4.36e-6	Pulse pressure;
PAAD	cis	rs72960926	0.590	rs114287599	chr6:74748504	C/T	cg03266952	chr6:74778945	NA	-1.23	-7.36	-0.51	1.05e-11	Metabolite levels (MHPG);
PAAD	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs4711336	0.712	rs942641	chr6:33687007	G/A	cg14003231	chr6:33640908	ITPR3	0.33	4.43	0.34	1.79e-5	Height;
PAAD	cis	rs5750250	1.000	rs5750250	chr22:36708483	A/G	cg07991675	chr22:36697055	MYH9	0.9	4.92	0.37	2.22e-6	Diabetic kidney disease;
PAAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-4.67	-0.35	6.68e-6	Blood metabolite levels;
PAAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.37	0.33	2.26e-5	Iron status biomarkers;
PAAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.39e-5	Bipolar disorder;
PAAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs35883536	0.967	rs4908091	chr1:101138171	G/A	cg14515779	chr1:101123966	NA	-0.54	-6.83	-0.48	1.94e-10	Monocyte count;
PAAD	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg02297831	chr4:17616191	MED28	-0.62	-5.71	-0.42	5.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4692589	0.581	rs6821641	chr4:170960193	C/T	cg19918862	chr4:170955249	NA	0.49	4.35	0.33	2.52e-5	Anxiety disorder;
PAAD	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.45	-5.49	-0.41	1.66e-7	Colorectal cancer;
PAAD	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.48	4.39	0.34	2.14e-5	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9810890	1.000	rs73198827	chr3:128489521	G/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.27	-0.67	8.44e-22	Total body bone mineral density;
PAAD	cis	rs72827839	0.846	rs72823530	chr17:46109371	G/A	cg23391107	chr17:45924227	SP6	0.62	5.38	0.4	2.77e-7	Ease of getting up in the morning;
PAAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg05373962	chr22:49881684	NA	-0.5	-4.89	-0.37	2.56e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11105468	1.000	rs10858937	chr12:90274437	G/A	cg16962463	chr12:89968675	NA	0.44	4.31	0.33	2.94e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.66	-6.49	-0.47	1.14e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.08e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35785195	0.593	rs35304519	chr12:114236677	C/T	cg23469448	chr12:114232746	NA	0.56	4.34	0.33	2.64e-5	Daytime sleep phenotypes;
PAAD	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs59888335	0.964	rs17455474	chr3:80691110	A/T	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs6445967	0.695	rs2292675	chr3:58235727	T/C	cg23715586	chr3:58305044	RPP14	0.51	4.32	0.33	2.77e-5	Platelet count;
PAAD	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.82	-9.27	-0.6	1.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs10090774	0.901	rs11166995	chr8:141719251	C/T	cg02508881	chr8:142216119	NA	0.38	4.32	0.33	2.77e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.47	4.55	0.35	1.08e-5	Lung cancer;
PAAD	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.68	-6.03	-0.44	1.18e-8	Mean corpuscular volume;
PAAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg16584676	chr17:46985605	UBE2Z	-0.54	-5.35	-0.4	3.15e-7	Type 2 diabetes;
PAAD	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.51	-0.41	1.51e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg09163369	chr1:210001066	C1orf107	0.71	6.73	0.48	3.19e-10	Orofacial clefts;
PAAD	cis	rs655641	0.520	rs631639	chr11:85798020	T/G	cg07180834	chr11:85838833	NA	-0.5	-5.41	-0.4	2.36e-7	Platelet count;
PAAD	cis	rs990171	0.506	rs4141632	chr2:102757139	A/G	cg22835712	chr2:102737379	NA	0.53	5.43	0.4	2.22e-7	Lymphocyte counts;
PAAD	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg08835956	chr7:39171034	POU6F2	-0.32	-5.74	-0.42	5.02e-8	IgG glycosylation;
PAAD	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg21775007	chr8:11205619	TDH	-0.5	-4.35	-0.33	2.51e-5	Triglycerides;
PAAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg03605463	chr16:89740564	NA	0.52	4.96	0.37	1.83e-6	Vitiligo;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg14926445	chr8:58193284	C8orf71	-0.69	-5.0	-0.38	1.6e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.75	7.62	0.53	2.58e-12	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08883955	chr16:11945066	RSL1D1	0.59	6.38	0.46	1.98e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.33	0.46	2.63e-9	IgG glycosylation;
PAAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.92	12.12	0.7	4.29e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.6	4.31	0.33	2.93e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg13397359	chr6:42928475	GNMT	0.73	7.91	0.54	5.03e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	1.04	6.66	0.48	4.8e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg07741184	chr6:167504864	NA	-0.4	-4.84	-0.37	3.16e-6	Graves' disease;
PAAD	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15506890	chr2:3487001	NA	-0.77	-7.78	-0.53	1.01e-12	Neurofibrillary tangles;
PAAD	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.58	-6.75	-0.48	2.99e-10	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-4.27	-0.33	3.47e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-1.07	-14.87	-0.77	1.86e-31	Breast cancer;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg15117754	chr3:10150083	C3orf24	0.75	6.77	0.48	2.69e-10	Alzheimer's disease;
PAAD	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.58	-4.87	-0.37	2.72e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18393722	chr15:85113863	UBE2QP1	0.63	6.29	0.45	3.16e-9	Smoking initiation;
PAAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.87	-0.37	2.83e-6	Recombination rate (females);
PAAD	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg26571870	chr16:85723150	GINS2	-0.49	-5.55	-0.41	1.27e-7	Platelet distribution width;
PAAD	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.96	5.17	0.39	7.17e-7	Childhood ear infection;
PAAD	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg08371190	chr1:87598514	LOC339524	0.3	4.28	0.33	3.26e-5	Smoking behavior;
PAAD	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.01	12.36	0.71	1e-24	Schizophrenia;
PAAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.77	7.23	0.51	2.14e-11	DNA methylation (variation);
PAAD	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.72	-7.38	-0.51	9.48e-12	Cognitive function;
PAAD	cis	rs114540395	0.858	rs3730467	chr10:103342783	G/T	cg21381511	chr10:104264849	SUFU	-0.87	-4.41	-0.34	1.93e-5	Schizophrenia;
PAAD	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16175294	chr11:35243965	CD44	-0.55	-6.36	-0.46	2.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.49	-6.23	-0.45	4.33e-9	Height;
PAAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg02421172	chr7:1938701	MAD1L1	0.55	4.54	0.35	1.14e-5	Bipolar disorder;
PAAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.51	-4.76	-0.36	4.53e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs8005172	0.648	rs3910683	chr14:88412509	T/C	cg18078958	chr14:88630771	NA	0.46	5.58	0.41	1.06e-7	Parkinson's disease;
PAAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.62	-6.42	-0.46	1.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11958404	0.615	rs7717235	chr5:157447772	C/G	cg05962755	chr5:157440814	NA	0.57	5.49	0.41	1.63e-7	IgG glycosylation;
PAAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.49	-0.34	1.4e-5	Mean platelet volume;
PAAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-4.61	-0.35	8.53e-6	Blood protein levels;
PAAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.66	-6.3	-0.45	3.06e-9	Tuberculosis;
PAAD	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.61	6.19	0.45	5.3e-9	Motion sickness;
PAAD	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg23024343	chr7:107201750	COG5	0.56	4.64	0.35	7.38e-6	Coronary artery disease;
PAAD	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.79	-7.36	-0.51	1.07e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs3736485	0.868	rs9744054	chr15:51933163	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.25	-0.33	3.74e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg22827986	chr11:48284249	OR4X1	0.36	4.75	0.36	4.59e-6	Migraine - clinic-based;
PAAD	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.45	-4.54	-0.35	1.16e-5	Response to statin therapy;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16654732	chr5:170846517	FGF18	-0.78	-6.7	-0.48	3.82e-10	Neuroticism;
PAAD	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg19254793	chr6:44695348	NA	-0.44	-4.34	-0.33	2.57e-5	Total body bone mineral density;
PAAD	cis	rs7945718	0.621	rs7943920	chr11:12695614	A/G	cg25843174	chr11:12811716	TEAD1	0.32	4.65	0.35	7.03e-6	Educational attainment (years of education);
PAAD	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.58	5.92	0.43	2.01e-8	Asthma (bronchodilator response);
PAAD	cis	rs755249	0.567	rs72661965	chr1:39846590	A/C	cg14018543	chr1:39659967	MACF1	-0.56	-4.66	-0.35	6.99e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg14847009	chr1:175162515	KIAA0040	0.31	4.88	0.37	2.68e-6	Alcohol dependence;
PAAD	cis	rs4704187	0.687	rs1592948	chr5:74504152	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs9463078	0.546	rs1324532	chr6:45075795	T/C	cg18551225	chr6:44695536	NA	0.42	4.4	0.34	2.05e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.69	-5.82	-0.43	3.44e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.37	4.44	0.34	1.69e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.9	5.63	0.42	8.51e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26796135	chr15:45671001	LOC145663;GATM	-0.51	-4.68	-0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.43	-0.4	2.14e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs16958440	0.867	rs80064497	chr18:44669653	A/G	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-4.48	-0.34	1.48e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.49e-5	Skin colour saturation;
PAAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.58	-0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg13468214	chr4:1046988	NA	-0.5	-4.77	-0.36	4.2e-6	Recombination rate (females);
PAAD	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.64	0.42	8.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs990171	1.000	rs4851575	chr2:103025203	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	4.51	0.34	1.31e-5	Lymphocyte counts;
PAAD	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg25070565	chr17:20044324	CYTSB	-0.43	-4.32	-0.33	2.8e-5	Schizophrenia;
PAAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12963246	chr6:28129442	ZNF389	0.56	4.46	0.34	1.62e-5	Parkinson's disease;
PAAD	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg05585544	chr11:47624801	NA	-0.52	-5.93	-0.43	1.94e-8	Subjective well-being;
PAAD	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.68	8.42	0.56	2.6e-14	Dupuytren's disease;
PAAD	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.76	-8.86	-0.58	1.92e-15	White blood cell count (basophil);
PAAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.83	6.96	0.49	9.58e-11	Alzheimer's disease;
PAAD	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.87	8.13	0.55	1.41e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs58521262	0.556	rs289300	chr19:23175330	T/C	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg25551287	chr1:205649424	SLC45A3	-0.49	-4.26	-0.33	3.61e-5	Mean platelet volume;
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.47	-4.66	-0.35	6.8e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6580110	0.793	rs6868098	chr5:154080958	G/A	cg17263206	chr5:154071247	NA	0.54	5.82	0.43	3.32e-8	Facial morphology (factor 9, facial height related to vertical position of nasion);
PAAD	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg18833306	chr6:118973337	C6orf204	0.49	5.71	0.42	5.89e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.67	7.75	0.53	1.19e-12	Metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00296938	chr3:49044463	P4HTM;WDR6	-0.77	-8.32	-0.56	4.56e-14	Smoking initiation;
PAAD	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg25753631	chr6:25732923	NA	-0.4	-4.48	-0.34	1.43e-5	Iron status biomarkers;
PAAD	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.84	-9.01	-0.59	8.36e-16	Corneal astigmatism;
PAAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.16	0.7	3.43e-24	Smoking behavior;
PAAD	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg27511599	chr7:32358540	NA	0.76	4.41	0.34	1.92e-5	Body mass index;
PAAD	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg02696790	chr15:75250997	RPP25	-0.43	-5.24	-0.39	5.39e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs73206853	0.688	rs57530940	chr12:110597842	C/T	cg12870014	chr12:110450643	ANKRD13A	0.71	4.47	0.34	1.55e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00469508	chr10:112327249	SMC3	0.64	6.99	0.49	8.16e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6062788	0.840	rs6090220	chr20:61702847	T/G	cg04970637	chr20:61718950	NA	0.4	4.66	0.35	6.76e-6	Body mass index;
PAAD	cis	rs375066	0.901	rs1978723	chr19:44383800	C/T	cg21496419	chr19:44306685	LYPD5	-0.42	-5.21	-0.39	6.15e-7	Breast cancer;
PAAD	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-1.06	-18.94	-0.84	7.72e-42	Urate levels in lean individuals;
PAAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.06	-0.44	1.03e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.65	-6.93	-0.49	1.11e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01765077	chr12:122356316	WDR66	-0.64	-6.8	-0.48	2.3e-10	Mean corpuscular volume;
PAAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.73	8.41	0.56	2.8e-14	Bone mineral density;
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.71	7.69	0.53	1.73e-12	Lung cancer;
PAAD	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs9810890	1.000	rs73196980	chr3:128451396	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.79	7.49	0.52	5.35e-12	Asthma;
PAAD	cis	rs6700896	0.522	rs12030543	chr1:66155027	C/T	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.54	5.69	0.42	6.5e-8	Eye color traits;
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg10207240	chr12:122356781	WDR66	0.54	5.6	0.41	9.57e-8	Mean corpuscular volume;
PAAD	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.53	4.61	0.35	8.34e-6	Lymphocyte counts;
PAAD	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.64	6.83	0.48	1.92e-10	QT interval;
PAAD	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.79	0.43	3.84e-8	Menopause (age at onset);
PAAD	cis	rs6466055	0.720	rs7357199	chr7:105019355	G/C	cg04380332	chr7:105027541	SRPK2	-0.66	-7.43	-0.52	7.13e-12	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs8005172	0.750	rs2119701	chr14:88429033	C/T	cg18078958	chr14:88630771	NA	-0.47	-5.4	-0.4	2.5e-7	Parkinson's disease;
PAAD	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-7.34	-0.51	1.17e-11	Cognitive function;
PAAD	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-6.93	-0.49	1.11e-10	Hip circumference;
PAAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24549020	chr5:56110836	MAP3K1	0.75	5.38	0.4	2.74e-7	Type 2 diabetes;
PAAD	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg03161606	chr19:29218774	NA	0.69	5.07	0.38	1.16e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02725872	chr8:58115012	NA	-0.66	-5.61	-0.41	9.26e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7631605	0.905	rs3821824	chr3:37130942	G/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	7.86	0.54	6.42e-13	Height;
PAAD	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg15478930	chr2:27652102	NRBP1	-0.55	-4.58	-0.35	9.43e-6	Blood metabolite levels;
PAAD	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.44	6.93	0.49	1.1e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg17346650	chr17:80929145	B3GNTL1	0.45	5.43	0.4	2.14e-7	Glycated hemoglobin levels;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06799790	chr17:61951754	CSH2	0.41	4.32	0.33	2.83e-5	Height;
PAAD	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.44	-4.45	-0.34	1.68e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg21238619	chr17:78079768	GAA	-0.35	-4.25	-0.33	3.65e-5	Yeast infection;
PAAD	cis	rs34375054	0.573	rs35698828	chr12:125658603	C/T	cg09839279	chr12:125627357	AACS	-0.49	-4.41	-0.34	1.94e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg21605333	chr4:119757512	SEC24D	1.24	7.69	0.53	1.74e-12	Cannabis dependence symptom count;
PAAD	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg24253500	chr15:84953950	NA	0.44	4.31	0.33	2.97e-5	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.65	4.82	0.36	3.5e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg02696790	chr15:75250997	RPP25	-0.4	-4.69	-0.36	6.01e-6	Caffeine consumption;
PAAD	cis	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg18582342	chr19:11591989	ELAVL3	-0.67	-5.55	-0.41	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19037388	chr19:19774945	ATP13A1	0.64	6.64	0.47	5.28e-10	Pancreatic cancer;
PAAD	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.98	0.54	3.24e-13	Schizophrenia;
PAAD	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05347473	chr6:146136440	FBXO30	0.48	4.52	0.34	1.22e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.72	-7.75	-0.53	1.21e-12	Menarche (age at onset);
PAAD	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.61	-0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.65	7.5	0.52	4.9e-12	Weight;
PAAD	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.55	4.69	0.36	5.97e-6	Lymphocyte counts;
PAAD	cis	rs1519814	0.696	rs2326430	chr8:121036898	G/A	cg22335954	chr8:121166405	COL14A1	-0.67	-5.12	-0.38	9.04e-7	Breast cancer;
PAAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01200585	chr1:228362443	C1orf69	-0.49	-5.47	-0.41	1.84e-7	Diastolic blood pressure;
PAAD	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.57	-5.47	-0.41	1.81e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg15145965	chr22:50218605	BRD1	-0.61	-5.3	-0.4	3.98e-7	Schizophrenia;
PAAD	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.89	9.63	0.62	1.99e-17	Anterior chamber depth;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.67	-7.01	-0.49	7.1e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg00277334	chr10:82204260	NA	-0.6	-5.49	-0.41	1.64e-7	Post bronchodilator FEV1;
PAAD	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.56	-4.6	-0.35	8.67e-6	Coronary artery disease;
PAAD	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.51	-6.05	-0.44	1.1e-8	Blood pressure (smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07121640	chr3:185303828	SENP2	0.67	6.84	0.49	1.85e-10	Obesity-related traits;
PAAD	cis	rs3126085	0.515	rs1923506	chr1:152359700	A/T	cg26876637	chr1:152193138	HRNR	-0.64	-4.71	-0.36	5.52e-6	Atopic dermatitis;
PAAD	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg22189786	chr22:42395067	WBP2NL	0.49	4.26	0.33	3.55e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-9.74	-0.62	1.04e-17	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18075627	chr12:120150487	CIT	-0.66	-6.38	-0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.61	7.12	0.5	4e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1062753	0.527	rs6002560	chr22:42356886	C/T	cg22189786	chr22:42395067	WBP2NL	-0.58	-5.62	-0.41	9.08e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg06697600	chr4:7070879	GRPEL1	0.8	5.23	0.39	5.64e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.91	-6.12	-0.44	7.73e-9	Systolic blood pressure;
PAAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.77	8.35	0.56	3.85e-14	Lung cancer;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg16316162	chr8:144660157	NAPRT1	-0.87	-6.86	-0.49	1.66e-10	Attention deficit hyperactivity disorder;
PAAD	cis	rs757081	0.507	rs10832727	chr11:17065289	A/G	cg15378786	chr11:17036137	PLEKHA7	0.49	4.3	0.33	3.04e-5	Systolic blood pressure;
PAAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.76	7.8	0.53	9.42e-13	Retinal vascular caliber;
PAAD	trans	rs901683	1.000	rs12763285	chr10:46082869	A/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	5.03	0.38	1.36e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg10729496	chr3:10149963	C3orf24	0.83	6.76	0.48	2.84e-10	Alzheimer's disease;
PAAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.6	6.78	0.48	2.45e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.73	-0.42	5.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.85	5.53	0.41	1.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs13433680	chr3:10136390	T/A	cg16606324	chr3:10149918	C3orf24	0.69	5.45	0.4	2.03e-7	Alzheimer's disease;
PAAD	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg03115019	chr17:80708279	FN3K	0.51	4.53	0.34	1.2e-5	Glycated hemoglobin levels;
PAAD	cis	rs561655	0.651	rs10898440	chr11:85859916	C/T	cg07180834	chr11:85838833	NA	-0.38	-4.35	-0.33	2.45e-5	Alzheimer's disease (late onset);
PAAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.86	-9.37	-0.6	9.59e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg25037394	chr1:24152592	HMGCL	0.41	4.43	0.34	1.77e-5	Immature fraction of reticulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23625084	chr7:139690881	TBXAS1	0.58	6.72	0.48	3.48e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg05555928	chr11:63887634	MACROD1	0.59	4.62	0.35	8.14e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg24565620	chr2:194026	NA	-0.68	-5.04	-0.38	1.32e-6	Blood protein levels;
PAAD	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.67	8.27	0.56	6.32e-14	Dupuytren's disease;
PAAD	cis	rs291096	0.661	rs1518108	chr1:207043174	C/T	cg16417028	chr1:207070825	IL24	-0.39	-4.27	-0.33	3.47e-5	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
PAAD	cis	rs7071247	0.915	rs3014204	chr10:105260229	G/T	cg18199807	chr10:106074281	ITPRIP	0.66	4.47	0.34	1.53e-5	Platelet aggregation;
PAAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.63	7.06	0.5	5.58e-11	Birth weight;
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.34	-0.4	3.37e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.63	6.85	0.49	1.75e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02398342	chr17:80708632	TBCD;FN3K	-0.52	-5.26	-0.39	4.79e-7	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg24829409	chr8:58192753	C8orf71	-0.83	-7.69	-0.53	1.74e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs900145	0.954	rs900147	chr11:13293840	G/A	cg15603424	chr11:13300592	ARNTL	0.52	4.7	0.36	5.84e-6	Menarche (age at onset);
PAAD	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.52	4.48	0.34	1.45e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10885582	0.904	rs11196796	chr10:116352988	C/T	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.03	-0.38	1.39e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01765077	chr12:122356316	WDR66	0.69	7.27	0.51	1.76e-11	Mean corpuscular volume;
PAAD	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.2	-0.39	6.35e-7	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.94	6.18	0.45	5.62e-9	Plateletcrit;
PAAD	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6687430	0.532	rs67488812	chr1:10614804	A/G	cg17425144	chr1:10567563	PEX14	-0.42	-4.62	-0.35	8.2e-6	Hand grip strength;
PAAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4743820	0.651	rs73494914	chr9:93923108	G/A	cg14446406	chr9:93919335	NA	0.45	5.44	0.4	2.1e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg08747591	chr11:789928	CEND1	0.58	5.78	0.42	4.03e-8	Breast cancer;
PAAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg14440974	chr22:39074834	NA	-0.59	-6.96	-0.49	9.33e-11	Menopause (age at onset);
PAAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-1.03	-18.92	-0.84	8.65e-42	Birth weight;
PAAD	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg25336900	chr3:50202831	SEMA3F	-0.71	-4.25	-0.33	3.75e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs10890920	0.587	rs10890931	chr11:108894917	C/A	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	QT interval (drug interaction);
PAAD	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg22903657	chr4:1355424	KIAA1530	-0.48	-4.69	-0.36	6e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17292583	chr3:184287196	EPHB3	0.57	6.8	0.48	2.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg26205652	chr12:48591994	NA	-0.87	-8.4	-0.56	2.98e-14	Longevity (90 years and older);
PAAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.46	4.68	0.35	6.29e-6	Menopause (age at onset);
PAAD	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.61	-5.68	-0.42	6.64e-8	Blood protein levels;
PAAD	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.94	12.95	0.72	2.58e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg08390786	chr10:135334061	NA	-0.5	-4.56	-0.35	1.06e-5	Obesity-related traits;
PAAD	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.25	-0.51	1.98e-11	Colorectal cancer;
PAAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.56	4.4	0.34	2.04e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-4.58	-0.35	9.77e-6	Testicular germ cell tumor;
PAAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.51	-5.46	-0.41	1.88e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-4.7	-0.36	5.75e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg11441379	chr12:63026424	NA	0.82	6.35	0.46	2.31e-9	IgG glycosylation;
PAAD	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg21994712	chr19:21861136	NA	0.45	4.31	0.33	2.93e-5	Pain;
PAAD	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.87	5.86	0.43	2.79e-8	Thyroid stimulating hormone;
PAAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg16031515	chr1:205743344	RAB7L1	-0.44	-5.2	-0.39	6.24e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13522118	chr2:121050252	RALB	-0.52	-6.85	-0.49	1.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs11885103	0.568	rs2724850	chr2:529833	G/A	cg25542745	chr2:497296	NA	-0.35	-4.31	-0.33	2.97e-5	Heschl's gyrus morphology;
PAAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg14343924	chr8:8086146	FLJ10661	0.49	4.39	0.34	2.09e-5	Mood instability;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11031096	0.746	rs7949663	chr11:4170123	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-4.34	-0.33	2.57e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg20406979	chr6:167373233	NA	0.34	4.56	0.35	1.06e-5	Crohn's disease;
PAAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.5	-0.34	1.36e-5	Mood instability;
PAAD	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.72	-7.22	-0.51	2.27e-11	Retinal vascular caliber;
PAAD	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs876537	1.000	rs876537	chr1:159674933	C/T	cg06974143	chr1:159907515	IGSF9	-0.44	-4.34	-0.33	2.63e-5	C-reactive protein;
PAAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg18402987	chr7:1209562	NA	0.96	5.32	0.4	3.68e-7	Longevity;Endometriosis;
PAAD	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.26e-6	Neuroticism;
PAAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.56	-7.58	-0.52	3.2e-12	Renal cell carcinoma;
PAAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.87	5.89	0.43	2.39e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg00981651	chr20:44574847	PCIF1	0.43	4.68	0.35	6.32e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg18045461	chr22:29601862	EMID1	0.62	6.36	0.46	2.28e-9	Primary biliary cholangitis;
PAAD	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.0	4.53	0.35	1.17e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.48	-4.52	-0.34	1.25e-5	Type 2 diabetes;
PAAD	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg25197388	chr11:66278006	BBS1	-0.43	-4.3	-0.33	3e-5	Mean corpuscular volume;
PAAD	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.48	4.25	0.33	3.65e-5	Anterior chamber depth;
PAAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.58	-0.47	7.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg17347104	chr14:75034677	LTBP2	0.56	4.64	0.35	7.33e-6	Non-small cell lung cancer;
PAAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg14345882	chr6:26364793	BTN3A2	0.83	5.97	0.44	1.62e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09695851	chr17:3907499	NA	0.7	7.08	0.5	4.93e-11	Type 2 diabetes;
PAAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg25809561	chr17:30822961	MYO1D	0.59	6.15	0.45	6.4e-9	Schizophrenia;
PAAD	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.45	-4.48	-0.34	1.46e-5	Immature fraction of reticulocytes;
PAAD	cis	rs58749629	0.506	rs3843763	chr20:44548193	C/T	cg13694471	chr20:43595031	STK4	0.53	4.28	0.33	3.33e-5	Abdominal aortic aneurysm;
PAAD	cis	rs4660214	0.568	rs967530	chr1:39596137	T/A	cg11070191	chr1:39582205	MACF1	0.52	4.7	0.36	5.69e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.22e-11	Blood metabolite levels;
PAAD	cis	rs4796354	0.604	rs7212842	chr17:6702837	A/G	cg12642237	chr17:6703447	TEKT1	-0.38	-4.51	-0.34	1.27e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.42	-4.59	-0.35	9.14e-6	Platelet count;
PAAD	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.44	-4.7	-0.36	5.69e-6	Psychosis in Alzheimer's disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02247898	chr14:55033728	SAMD4A	0.71	6.49	0.47	1.16e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.83	-8.99	-0.59	9.3e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-7.01	-0.49	7.2e-11	Neuroticism;
PAAD	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg23298862	chr7:158159286	PTPRN2	-0.63	-5.63	-0.42	8.27e-8	Calcium levels;
PAAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	5.82	0.43	3.4e-8	Personality dimensions;
PAAD	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.63	6.41	0.46	1.72e-9	Asthma (bronchodilator response);
PAAD	cis	rs7011192	0.793	rs7013904	chr8:10523848	G/C	cg04501334	chr8:10513686	RP1L1	-0.8	-5.51	-0.41	1.52e-7	Suicide;
PAAD	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.37	-0.33	2.32e-5	Ovarian reserve;
PAAD	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg19423196	chr10:82049429	MAT1A	0.58	4.37	0.33	2.3e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-4.4	-0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.8	7.14	0.5	3.59e-11	Exhaled nitric oxide levels;
PAAD	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg10820045	chr2:198174542	NA	0.51	5.26	0.39	4.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs73195822	0.614	rs1123852	chr12:111221408	C/G	cg09298818	chr12:111181546	PPP1CC	-0.53	-4.42	-0.34	1.89e-5	Itch intensity from mosquito bite;
PAAD	cis	rs7084921	0.521	rs12772820	chr10:101873824	A/G	cg04359915	chr10:101825029	CPN1	-0.28	-4.37	-0.33	2.3e-5	Bone mineral density;
PAAD	cis	rs4704187	0.687	rs6453123	chr5:74519049	G/A	cg03227963	chr5:74354835	NA	0.51	4.94	0.37	2.01e-6	Response to amphetamines;
PAAD	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.68	7.26	0.51	1.86e-11	Body mass index;
PAAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.67	5.79	0.42	3.98e-8	Breast cancer;
PAAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	8.71	0.58	4.68e-15	Platelet count;
PAAD	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.42	4.51	0.34	1.27e-5	Aortic root size;
PAAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg00206168	chr11:65308501	LTBP3	0.5	5.27	0.39	4.53e-7	Bone mineral density;
PAAD	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.73	9.37	0.6	9.59e-17	Cancer;
PAAD	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg19423196	chr10:82049429	MAT1A	0.61	4.72	0.36	5.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-6.66	-0.48	4.63e-10	Pancreatic cancer;
PAAD	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs3779195	0.524	rs80195155	chr7:97878153	G/A	cg21770322	chr7:97807741	LMTK2	-0.53	-4.45	-0.34	1.65e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.49	-4.33	-0.33	2.66e-5	Cerebrospinal fluid AB1-42 levels;
PAAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.79	0.42	3.98e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg09835421	chr16:68378352	PRMT7	-0.89	-7.13	-0.5	3.85e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg23205692	chr1:25664452	TMEM50A	-0.53	-5.1	-0.38	1.01e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.81	5.92	0.43	2.07e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17407555	0.632	rs12510726	chr4:10271067	T/A	cg00071950	chr4:10020882	SLC2A9	0.48	5.21	0.39	6.17e-7	Schizophrenia (age at onset);
PAAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.42	-0.61	7.1e-17	Alzheimer's disease (late onset);
PAAD	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg18551225	chr6:44695536	NA	-0.75	-7.59	-0.52	3.04e-12	Total body bone mineral density;
PAAD	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg06217245	chr20:33103252	DYNLRB1	0.41	4.62	0.35	8.27e-6	Height;
PAAD	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg26205652	chr12:48591994	NA	0.76	6.92	0.49	1.19e-10	Longevity (90 years and older);
PAAD	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	5.08	0.38	1.11e-6	Mood instability;
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.19	0.45	5.28e-9	Alzheimer's disease;
PAAD	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg20169779	chr10:135381914	SYCE1	0.44	4.31	0.33	2.92e-5	Obesity-related traits;
PAAD	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.69	7.28	0.51	1.64e-11	Economic and political preferences (feminism/equality);
PAAD	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.4	0.34	2.03e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg07810366	chr2:100720526	AFF3	0.38	4.9	0.37	2.47e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.82	-9.22	-0.6	2.32e-16	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-7.46	-0.52	6.36e-12	Exhaled nitric oxide output;
PAAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.99	13.62	0.74	4.17e-28	Menarche (age at onset);
PAAD	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs7714584	1.000	rs931058	chr5:150333698	A/T	cg22134413	chr5:150180641	NA	1.04	6.37	0.46	2.11e-9	Crohn's disease;
PAAD	cis	rs58521262	0.556	rs291769	chr19:23183941	T/C	cg02350677	chr19:23254381	NA	0.26	4.52	0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs4356203	0.905	rs7396382	chr11:17151472	G/C	cg15432903	chr11:17409602	KCNJ11	0.42	4.38	0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.57	4.69	0.36	6.05e-6	Lymphocyte counts;
PAAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg11859384	chr17:80120422	CCDC57	0.48	4.91	0.37	2.32e-6	Life satisfaction;
PAAD	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.85	-8.44	-0.56	2.35e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg14191688	chr11:70257035	CTTN	0.54	4.6	0.35	8.87e-6	Coronary artery disease;
PAAD	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.49	5.85	0.43	2.91e-8	Sitting height ratio;
PAAD	cis	rs30380	0.734	rs30376	chr5:96120259	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.54	5.38	0.4	2.77e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.54	4.7	0.36	5.79e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.17	-0.39	7.31e-7	Mortality in heart failure;
PAAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg04160749	chr8:58172571	NA	-0.71	-4.89	-0.37	2.51e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg10587741	chr22:38071170	LGALS1	0.46	5.09	0.38	1.02e-6	Fat distribution (HIV);
PAAD	cis	rs2744375	0.600	rs2744368	chr6:7553390	G/T	cg27023638	chr6:7288726	SSR1	-0.41	-4.28	-0.33	3.34e-5	Resting heart rate;
PAAD	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.77	-0.36	4.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.6	5.2	0.39	6.45e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.85	0.43	2.84e-8	Platelet count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10359929	chr2:227663721	IRS1	0.59	6.47	0.46	1.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09826364	chr7:158789723	NA	-0.39	-5.1	-0.38	9.78e-7	Facial morphology (factor 20);
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg09165964	chr15:75287851	SCAMP5	0.43	4.42	0.34	1.83e-5	Caffeine consumption;
PAAD	cis	rs10957961	0.586	rs12545300	chr8:81067598	G/A	cg10609868	chr8:81963379	PAG1	-0.37	-4.49	-0.34	1.42e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07701084	chr6:150067640	NUP43	0.62	6.17	0.45	5.91e-9	Testicular germ cell tumor;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-5.09	-0.38	1.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.63e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg05585544	chr11:47624801	NA	-0.51	-5.8	-0.43	3.69e-8	Subjective well-being;
PAAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs6782025	0.837	rs6784156	chr3:121038805	C/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg19254793	chr6:44695348	NA	-0.45	-4.37	-0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg20003494	chr4:90757398	SNCA	0.43	4.64	0.35	7.31e-6	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.57	6.52	0.47	9.79e-10	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.79	7.8	0.53	9.32e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.63	6.43	0.46	1.6e-9	Birth weight;
PAAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-9.78	-0.62	7.76e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs757110	0.524	rs214067	chr11:17305831	A/C	cg15432903	chr11:17409602	KCNJ11	-0.56	-5.88	-0.43	2.55e-8	Type 2 diabetes;
PAAD	cis	rs454510	0.726	rs838989	chr1:120182906	G/A	cg11530693	chr1:120165357	ZNF697	0.59	5.31	0.4	3.83e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.41e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.75	-10.0	-0.63	2.11e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09880681	chr16:30538664	ZNF768	0.6	7.27	0.51	1.74e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.03	0.38	1.36e-6	Mean platelet volume;
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg04810063	chr16:88703634	IL17C	0.51	4.76	0.36	4.4e-6	Menopause (age at onset);
PAAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg10556349	chr10:835070	NA	0.67	5.16	0.39	7.55e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg22338127	chr1:209979572	IRF6	0.53	4.3	0.33	3.01e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg11949866	chr1:10754891	CASZ1	0.51	4.42	0.34	1.89e-5	Ewing sarcoma;
PAAD	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.89	10.61	0.65	4.9e-20	Longevity;
PAAD	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.94	7.12	0.5	4.1e-11	Dental caries;
PAAD	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.78e-6	Type 2 diabetes;
PAAD	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-1.02	-10.64	-0.65	4.17e-20	Platelet distribution width;
PAAD	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg00262122	chr8:11665843	FDFT1	0.5	4.36	0.33	2.38e-5	Retinal vascular caliber;
PAAD	cis	rs9646944	0.501	rs11687768	chr2:103025738	A/G	cg20060108	chr2:102954350	IL1RL1	0.53	4.36	0.33	2.35e-5	Blood protein levels;
PAAD	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.94	8.2	0.55	9.46e-14	Bipolar disorder;
PAAD	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg23711669	chr6:146136114	FBXO30	0.92	9.76	0.62	9.02e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.09	0.38	1.02e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.88	10.72	0.66	2.59e-20	Prudent dietary pattern;
PAAD	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg07541023	chr7:19748670	TWISTNB	-0.65	-4.79	-0.36	3.94e-6	Thyroid stimulating hormone;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs990171	1.000	rs2041756	chr2:103049910	C/T	cg03938978	chr2:103052716	IL18RAP	-0.45	-4.43	-0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg05373962	chr22:49881684	NA	-0.45	-4.69	-0.36	6.04e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.43	-6.16	-0.45	6.36e-9	Information processing speed;
PAAD	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg12870014	chr12:110450643	ANKRD13A	0.7	4.97	0.37	1.81e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2242116	0.632	rs10049237	chr3:46941626	T/C	cg02527881	chr3:46936655	PTH1R	-0.6	-6.36	-0.46	2.2e-9	Birth weight;
PAAD	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.68	0.36	6.21e-6	Plateletcrit;
PAAD	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg10761708	chr20:43804764	PI3	0.55	4.42	0.34	1.87e-5	Blood protein levels;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg00738919	chr7:1100172	C7orf50	0.59	4.67	0.35	6.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.45	-4.59	-0.35	9.1e-6	Menopause (age at onset);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20149956	chr1:249132233	ZNF672	0.58	6.97	0.49	8.85e-11	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg10437265	chr15:77819839	NA	0.41	4.61	0.35	8.65e-6	Type 2 diabetes;
PAAD	cis	rs597583	0.715	rs11216436	chr11:117391374	G/A	cg27161313	chr11:117392002	DSCAML1	-0.76	-5.95	-0.43	1.76e-8	Putamen volume;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg12193833	chr17:30244370	NA	0.67	4.92	0.37	2.26e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2309322	0.702	rs9991876	chr4:181238144	T/C	cg24124977	chr17:78010277	CCDC40;TBC1D16	0.79	6.41	0.46	1.76e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.68	0.77	6.04e-31	Chronic sinus infection;
PAAD	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg00631329	chr6:26305371	NA	-0.45	-4.55	-0.35	1.11e-5	Educational attainment;
PAAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.58	-6.77	-0.48	2.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg14055004	chr2:241860995	NA	0.28	4.27	0.33	3.45e-5	Urinary metabolites;
PAAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.57e-8	Tonsillectomy;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-6.16	-0.45	6.3e-9	Prudent dietary pattern;
PAAD	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.64	6.61	0.47	6.12e-10	Testicular germ cell tumor;
PAAD	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4450131	0.618	rs3781458	chr10:126343931	C/T	cg20435097	chr10:126320824	FAM53B	-0.54	-5.77	-0.42	4.37e-8	White blood cell count (basophil);
PAAD	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs847577	0.550	rs6465654	chr7:97786282	G/A	cg15061591	chr7:98625706	SMURF1	-0.47	-4.51	-0.34	1.3e-5	Breast cancer;
PAAD	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs709400	0.633	rs8019578	chr14:103977724	A/G	cg26031613	chr14:104095156	KLC1	0.78	8.07	0.55	2.02e-13	Body mass index;
PAAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.58	-6.09	-0.44	8.77e-9	Blood metabolite levels;
PAAD	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg01620082	chr3:125678407	NA	-1.49	-9.02	-0.59	7.8e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs801193	0.773	rs801207	chr7:66020590	T/C	cg26939375	chr7:64535504	NA	-0.66	-7.31	-0.51	1.44e-11	Aortic root size;
PAAD	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.47	4.63	0.35	7.78e-6	Coronary artery disease;
PAAD	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg12092346	chr18:77659572	KCNG2	-0.64	-4.52	-0.34	1.24e-5	Opioid sensitivity;
PAAD	cis	rs2279463	0.666	rs10945656	chr6:160635886	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.32	0.33	2.84e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26856965	chr10:102802736	NA	-0.64	-6.37	-0.46	2.14e-9	Lung cancer in ever smokers;
PAAD	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.09	0.38	1.05e-6	Colorectal cancer;
PAAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg24519413	chr1:26490540	NA	0.46	5.95	0.43	1.8e-8	Height;
PAAD	cis	rs741013	1.000	rs741013	chr3:64292637	A/T	cg20180538	chr3:64559102	ADAMTS9	-0.88	-4.3	-0.33	3e-5	Coronary artery calcification;
PAAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.59	5.35	0.4	3.25e-7	Monocyte count;
PAAD	cis	rs2637266	0.626	rs1660914	chr10:78525319	T/A	cg18941641	chr10:78392320	NA	0.37	4.38	0.33	2.18e-5	Pulmonary function;
PAAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.38	4.57	0.35	9.94e-6	Tonsillectomy;
PAAD	cis	rs1270639	0.673	rs1263566	chr7:157455933	T/C	cg14404164	chr7:157455790	PTPRN2	-0.68	-5.4	-0.4	2.53e-7	Colorectal cancer;
PAAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.57	5.45	0.4	2e-7	Platelet count;
PAAD	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg04810063	chr16:88703634	IL17C	-0.57	-5.19	-0.39	6.5e-7	Menopause (age at onset);
PAAD	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.66	-0.48	4.74e-10	Total body bone mineral density;
PAAD	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.56	4.42	0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73198838	chr3:128498292	G/A	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.83	-0.36	3.28e-6	Lung cancer;
PAAD	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.0	0.49	7.65e-11	Coronary artery disease;
PAAD	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.47	-4.85	-0.37	3.04e-6	Breast cancer;
PAAD	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.7	0.53	1.62e-12	Melanoma;
PAAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.52	5.22	0.39	5.67e-7	Mean corpuscular volume;
PAAD	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg19978312	chr5:179634688	RASGEF1C	0.43	4.32	0.33	2.81e-5	LDL cholesterol;
PAAD	cis	rs682748	0.846	rs6859179	chr5:17141484	C/G	cg23987134	chr5:17158319	LOC285696	-0.35	-4.33	-0.33	2.7e-5	Hippocampal atrophy;
PAAD	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.56	6.91	0.49	1.26e-10	Crohn's disease;
PAAD	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.61	-5.66	-0.42	7.29e-8	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10165071	chr2:217557160	IGFBP5	-0.61	-6.5	-0.47	1.07e-9	Smoking initiation;
PAAD	cis	rs2073499	0.935	rs2624840	chr3:50199015	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.65	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs12136530	0.562	rs12125959	chr1:19735262	A/G	cg01468656	chr1:19991678	HTR6	0.48	4.34	0.33	2.56e-5	Lead levels in blood;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg19633808	chr20:35233942	C20orf24	-0.61	-6.89	-0.49	1.35e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.96	-9.66	-0.62	1.69e-17	Bronchopulmonary dysplasia;
PAAD	cis	rs6466055	0.777	rs2237613	chr7:104845253	G/C	cg04380332	chr7:105027541	SRPK2	-0.65	-7.33	-0.51	1.26e-11	Schizophrenia;
PAAD	cis	rs7765175	0.598	rs2637526	chr6:113657311	T/G	cg19037598	chr6:113666021	NA	-0.41	-4.4	-0.34	2.05e-5	Coronary artery calcification;
PAAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.81	8.69	0.58	5.31e-15	Cognitive function;
PAAD	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg03989125	chr22:38214979	NA	-0.53	-5.37	-0.4	2.83e-7	Glioblastoma;Glioma;
PAAD	cis	rs9486594	0.627	rs2500576	chr6:107651425	G/A	cg23052020	chr6:106960170	AIM1	0.63	4.46	0.34	1.6e-5	Airway responsiveness in chronic obstructive pulmonary disease;
PAAD	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Paclitaxel-induced neuropathy;
PAAD	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.42	-4.35	-0.33	2.47e-5	Plateletcrit;
PAAD	cis	rs6942407	0.546	rs10257953	chr7:86799726	C/T	cg02420886	chr7:86849541	C7orf23	0.64	4.88	0.37	2.6e-6	Food allergy;
PAAD	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-4.62	-0.35	8.16e-6	Testicular germ cell tumor;
PAAD	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg00490450	chr3:139108681	COPB2	0.66	6.0	0.44	1.37e-8	Obesity-related traits;
PAAD	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg04520793	chr17:42248056	ASB16	0.41	4.71	0.36	5.61e-6	Total body bone mineral density;
PAAD	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.81	8.8	0.58	2.74e-15	Colorectal cancer;
PAAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	6.52	0.47	9.77e-10	Initial pursuit acceleration;
PAAD	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.73	6.5	0.47	1.09e-9	Neuroticism;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg07068956	chr7:100330872	ZAN	-0.65	-5.12	-0.38	8.94e-7	Other erythrocyte phenotypes;
PAAD	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg00181669	chr3:44000978	NA	-0.44	-4.49	-0.34	1.4e-5	Coronary artery disease;
PAAD	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.78e-16	Asthma;
PAAD	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg12486944	chr17:80159399	CCDC57	-0.5	-4.38	-0.33	2.21e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg17120908	chr11:65337727	SSSCA1	-1.0	-4.67	-0.35	6.61e-6	Height;
PAAD	cis	rs6009527	1.000	rs6009188	chr22:49572751	G/A	cg12986453	chr22:49137906	FAM19A5	0.44	4.27	0.33	3.37e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.59	6.34	0.46	2.46e-9	Obesity-related traits;
PAAD	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg09579323	chr1:150459698	TARS2	-0.46	-4.39	-0.34	2.12e-5	Migraine;
PAAD	cis	rs7432375	0.641	rs1971397	chr3:136527300	C/G	cg15507776	chr3:136538369	TMEM22	0.47	4.31	0.33	2.95e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-5.45	-0.4	1.98e-7	Adiposity;
PAAD	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17467752	chr17:38218738	THRA	-0.53	-4.93	-0.37	2.09e-6	Asthma and hay fever;
PAAD	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.63	4.49	0.34	1.41e-5	Vitiligo;
PAAD	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.46	4.59	0.35	9.24e-6	Schizophrenia;
PAAD	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg22153463	chr1:85462885	MCOLN2	0.72	5.39	0.4	2.63e-7	Serum sulfate level;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.64	0.8	4.72e-36	Prudent dietary pattern;
PAAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	1.01	14.6	0.76	1.01e-30	Rheumatoid arthritis;
PAAD	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.48	-6.11	-0.44	7.94e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.49	-4.84	-0.37	3.18e-6	Lewy body disease;
PAAD	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs332507	0.789	rs10755078	chr3:124378412	A/G	cg05980111	chr3:124395277	KALRN	0.45	4.35	0.33	2.45e-5	Plateletcrit;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.69	-6.69	-0.48	4.06e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg15117754	chr3:10150083	C3orf24	0.69	5.96	0.44	1.66e-8	Alzheimer's disease;
PAAD	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.4	-4.63	-0.35	7.63e-6	Intelligence;
PAAD	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.53	-5.29	-0.39	4.27e-7	P wave terminal force;
PAAD	cis	rs4908768	0.579	rs11121237	chr1:8876392	A/G	cg00590817	chr1:8272081	NA	-0.39	-4.87	-0.37	2.73e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.25	0.45	3.9e-9	Educational attainment;
PAAD	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.69	6.83	0.48	1.91e-10	Mood instability;
PAAD	cis	rs10821973	0.527	rs7092005	chr10:63979909	A/G	cg19640130	chr10:64028056	RTKN2	-0.41	-4.39	-0.34	2.13e-5	Hypothyroidism;
PAAD	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.52	-5.5	-0.41	1.61e-7	Longevity;
PAAD	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg05925327	chr15:68127851	NA	-0.56	-5.11	-0.38	9.7e-7	Restless legs syndrome;
PAAD	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.79	9.11	0.59	4.43e-16	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg00280220	chr17:61926910	NA	0.46	4.76	0.36	4.47e-6	Prudent dietary pattern;
PAAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg12373951	chr3:133503437	NA	-0.45	-5.64	-0.42	8.16e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.8	-0.87	1.2e-48	Myeloid white cell count;
PAAD	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg03277515	chr1:153321198	PGLYRP4	0.41	4.87	0.37	2.83e-6	Psoriasis;
PAAD	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.86	8.67	0.58	5.95e-15	Response to antineoplastic agents;
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.49	-5.46	-0.4	1.92e-7	Calcium levels;
PAAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.47	-4.56	-0.35	1.06e-5	Vitiligo;
PAAD	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.75	7.25	0.51	1.92e-11	Neuroticism;
PAAD	cis	rs501916	0.634	rs1561480	chr15:48070050	C/G	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.37	-0.4	2.92e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg14725641	chr11:61582763	MIR1908;FADS1	0.44	4.33	0.33	2.69e-5	Trans fatty acid levels;
PAAD	cis	rs1572438	0.760	rs7766714	chr6:869519	C/T	cg21062780	chr6:887772	NA	-0.44	-4.48	-0.34	1.44e-5	Aging;
PAAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.58	-0.47	7.09e-10	Aortic root size;
PAAD	cis	rs1371614	0.545	rs4665930	chr2:27173520	C/T	cg07507200	chr2:27712693	IFT172	0.48	4.34	0.33	2.55e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.54	6.11	0.44	8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs322458	0.550	rs682394	chr3:120629446	A/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.59	0.35	9.27e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs10943724	0.704	rs9443799	chr6:81269597	G/A	cg19323245	chr6:80716898	TTK	-0.42	-4.45	-0.34	1.68e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg27398640	chr15:77910606	LINGO1	0.5	4.99	0.37	1.66e-6	Type 2 diabetes;
PAAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23281280	chr6:28129359	ZNF389	0.7	5.37	0.4	2.94e-7	Parkinson's disease;
PAAD	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg19254793	chr6:44695348	NA	-0.44	-4.26	-0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs2235573	0.685	rs4384887	chr22:38447365	T/C	cg20893579	chr22:38215064	NA	-0.46	-4.9	-0.37	2.4e-6	Glioblastoma;Glioma;
PAAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	1.01	9.12	0.59	4.28e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs375066	0.935	rs430308	chr19:44400375	C/G	cg21496419	chr19:44306685	LYPD5	0.38	4.58	0.35	9.53e-6	Breast cancer;
PAAD	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.0	8.35	0.56	3.9e-14	Dupuytren's disease;
PAAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.45	-5.68	-0.42	6.57e-8	Childhood ear infection;
PAAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.91e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	1.01	14.11	0.75	2e-29	Menarche (age at onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04875987	chr17:79981264	STRA13;LRRC45	0.62	6.57	0.47	7.47e-10	Myopia (pathological);
PAAD	cis	rs3736485	0.738	rs930920	chr15:51749726	A/C	cg08986416	chr15:51914746	DMXL2	-0.47	-4.44	-0.34	1.75e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-9.15	-0.6	3.44e-16	Birth weight;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg09699651	chr6:150184138	LRP11	0.53	5.53	0.41	1.34e-7	Lung cancer;
PAAD	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.65	-5.85	-0.43	2.95e-8	Psoriasis;
PAAD	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.44	-5.17	-0.39	7.29e-7	Mean arterial pressure;
PAAD	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-10.6	-0.65	5.4e-20	Electrocardiographic conduction measures;
PAAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.56	0.57	1.14e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.94	12.55	0.71	3.03e-25	Menopause (age at onset);
PAAD	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.46	4.33	0.33	2.74e-5	Hip circumference;
PAAD	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.69	4.9	0.37	2.44e-6	Inflammatory bowel disease;
PAAD	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg14631576	chr9:95140430	CENPP	-0.53	-5.29	-0.39	4.19e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs12325245	0.536	rs12925676	chr16:58625326	C/T	cg05725404	chr16:58534157	NDRG4	-0.82	-4.95	-0.37	1.99e-6	Schizophrenia;
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.59	-5.67	-0.42	6.88e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.26	-0.39	4.83e-7	Height;
PAAD	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.44	-6.79	-0.48	2.41e-10	Subjective well-being;
PAAD	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.66	-0.48	4.73e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.6	5.09	0.38	1.03e-6	Neutrophil percentage of white cells;
PAAD	cis	rs9324022	0.722	rs72698709	chr14:101165747	C/T	cg18089426	chr14:101175970	NA	0.72	5.18	0.39	6.96e-7	Plateletcrit;
PAAD	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11995313	chr8:8860691	ERI1	0.5	5.14	0.38	8.34e-7	Joint mobility (Beighton score);
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.81	-0.36	3.65e-6	Lung cancer;
PAAD	cis	rs7149242	0.771	rs8012970	chr14:101168491	T/C	cg08175591	chr14:101176152	NA	0.39	5.07	0.38	1.13e-6	Platelet count;
PAAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg19623624	chr10:135278901	LOC619207	-0.42	-4.41	-0.34	1.98e-5	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs58521262	0.530	rs289320	chr19:23157799	A/T	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.66	-7.96	-0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-5.69	-0.42	6.35e-8	Fear of minor pain;
PAAD	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	8.19	0.55	1.01e-13	Platelet count;
PAAD	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.66	-7.85	-0.54	6.87e-13	HDL cholesterol;
PAAD	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.23	19.05	0.84	4.09e-42	IgG glycosylation;
PAAD	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-4.74	-0.36	4.86e-6	Testicular germ cell tumor;
PAAD	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.16	-0.5	3.16e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg04850286	chr10:81895943	PLAC9	0.39	4.39	0.34	2.13e-5	Sarcoidosis;
PAAD	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.98	-7.82	-0.54	8.38e-13	Blood protein levels;
PAAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs73198878	chr3:128542084	G/A	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg06883089	chr1:45254480	BEST4	0.33	4.26	0.33	3.51e-5	High light scatter reticulocyte count;
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg14583973	chr4:3374767	RGS12	0.37	5.65	0.42	7.73e-8	Serum sulfate level;
PAAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg06632027	chr4:90757378	SNCA	-0.53	-4.68	-0.35	6.33e-6	Neuroticism;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.41	5.24	0.39	5.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9304742	0.888	rs8112137	chr19:53457255	T/C	cg16040993	chr19:53496440	ZNF702P	-0.47	-4.66	-0.35	6.78e-6	Psoriasis;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03338584	chr11:507455	RNH1	0.59	4.59	0.35	9.41e-6	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs28595532	0.858	rs58613168	chr4:119487013	T/G	cg21605333	chr4:119757512	SEC24D	1.64	8.16	0.55	1.18e-13	Cannabis dependence symptom count;
PAAD	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-5.17	-0.39	7.26e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.64	6.98	0.49	8.51e-11	Longevity;
PAAD	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.28	-0.39	4.38e-7	Height;
PAAD	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.47	-4.83	-0.36	3.28e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.9	9.53	0.61	3.72e-17	Testicular germ cell tumor;
PAAD	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg22029157	chr1:209979665	IRF6	-0.67	-6.32	-0.46	2.8e-9	Coronary artery disease;
PAAD	cis	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg21546286	chr11:48923668	NA	-0.46	-4.82	-0.36	3.42e-6	HDL cholesterol;
PAAD	cis	rs134594	0.885	rs134592	chr22:29467221	A/G	cg25916307	chr22:29467684	KREMEN1	0.46	4.35	0.33	2.47e-5	Birth weight;
PAAD	cis	rs3787159	0.573	rs561354	chr20:56880429	T/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs13359291	0.658	rs10077410	chr5:122450771	G/A	cg16368670	chr5:122501738	PRDM6	-0.56	-4.3	-0.33	3.09e-5	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg02631450	chr22:32366979	NA	-1.01	-5.35	-0.4	3.25e-7	Childhood ear infection;
PAAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.91	0.69	1.61e-23	Menopause (age at onset);
PAAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg07617317	chr6:118971624	C6orf204	0.53	4.49	0.34	1.43e-5	Diastolic blood pressure;
PAAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.76	-9.25	-0.6	1.99e-16	Intelligence (multi-trait analysis);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26240433	chr14:94547826	DDX24;IFI27L1	0.69	6.64	0.47	5.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.74	6.96	0.49	9.31e-11	Dilated cardiomyopathy;
PAAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.13	-0.45	7.3e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg12458913	chr13:53173898	NA	0.62	6.15	0.45	6.53e-9	Lewy body disease;
PAAD	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.6	-7.57	-0.52	3.28e-12	Diastolic blood pressure;
PAAD	cis	rs6782025	0.768	rs2331713	chr3:121064870	G/A	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.35	6.3e-6	Aging (facial);
PAAD	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.46	5.81	0.43	3.48e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13225881	chr11:108777990	DDX10	0.62	6.34	0.46	2.51e-9	Smoking initiation;
PAAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.74	8.74	0.58	3.97e-15	Parkinson's disease;
PAAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg26022315	chr17:47021804	SNF8	0.45	4.6	0.35	8.92e-6	Type 2 diabetes;
PAAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.76	8.48	0.57	1.83e-14	Longevity;
PAAD	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-5.35	-0.4	3.15e-7	Cognitive test performance;
PAAD	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.47	-4.47	-0.34	1.55e-5	Mean corpuscular volume;
PAAD	trans	rs875971	0.638	rs801216	chr7:66011667	T/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.73	5.71	0.42	5.76e-8	Diisocyanate-induced asthma;
PAAD	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg11802864	chr11:65308245	LTBP3	0.82	5.66	0.42	7.28e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg23708337	chr7:1209742	NA	0.39	4.29	0.33	3.17e-5	Longevity;Endometriosis;
PAAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.01	8.56	0.57	1.14e-14	Gut microbiome composition (summer);
PAAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.53	-4.34	-0.33	2.55e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs12780845	1.000	rs2181043	chr10:17217803	A/G	cg00857480	chr10:17188594	TRDMT1	0.33	4.41	0.34	1.97e-5	Homocysteine levels;
PAAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.54	5.29	0.39	4.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.64	-7.31	-0.51	1.43e-11	Iron status biomarkers;
PAAD	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	0.51	4.84	0.37	3.22e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07236798	chr8:131455818	NA	0.59	6.82	0.48	2.03e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.99	-9.53	-0.61	3.61e-17	Dilated cardiomyopathy;
PAAD	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7873102	0.630	rs2183130	chr9:38015327	C/G	cg03528946	chr9:38069800	SHB	-0.5	-4.98	-0.37	1.69e-6	Brain structure;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.52	-4.63	-0.35	7.77e-6	Smoking behavior;
PAAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg03188948	chr7:1209495	NA	0.72	5.83	0.43	3.15e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.22e-7	Alzheimer's disease (late onset);
PAAD	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg01980928	chr19:1952821	C19orf34;CSNK1G2	0.47	4.85	0.37	2.97e-6	Coronary artery disease;
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.74	7.56	0.52	3.48e-12	Prostate cancer;
PAAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.56	6.44	0.46	1.5e-9	Aortic root size;
PAAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg18944383	chr4:111397179	ENPEP	0.72	7.93	0.54	4.34e-13	Coronary artery disease;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.9	10.71	0.66	2.65e-20	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2070677	0.808	rs3020500	chr10:135381276	T/C	cg18984983	chr10:135342936	CYP2E1	-0.49	-4.52	-0.34	1.25e-5	Gout;
PAAD	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg16898833	chr6:26189333	HIST1H4D	1.0	5.21	0.39	5.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.6	-0.41	9.91e-8	Lung cancer;
PAAD	cis	rs2882667	0.690	rs9327827	chr5:138182328	A/G	cg09476006	chr5:138032270	NA	0.47	6.0	0.44	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.71	6.53	0.47	9.1e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg19784903	chr17:45786737	TBKBP1	-0.44	-4.32	-0.33	2.8e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-4.78	-0.36	4.04e-6	Metabolite levels (Pyroglutamine);
PAAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-1.07	-8.2	-0.55	9.18e-14	Post bronchodilator FEV1;
PAAD	cis	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg21605333	chr4:119757512	SEC24D	1.12	6.99	0.49	8.3e-11	Cannabis dependence symptom count;
PAAD	cis	rs6499755	0.739	rs31094	chr16:55366819	C/A	cg02859129	chr16:55357253	IRX6	0.35	4.89	0.37	2.55e-6	Hypospadias;
PAAD	cis	rs2415984	0.783	rs61993306	chr14:46951186	G/A	cg14871534	chr14:47121158	RPL10L	-0.45	-4.6	-0.35	8.72e-6	Number of children ever born;
PAAD	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.97	-0.49	8.88e-11	Type 2 diabetes;
PAAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19800591	chr15:44581430	CASC4	-0.47	-4.45	-0.34	1.63e-5	Lung cancer in ever smokers;
PAAD	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	0.41	4.76	0.36	4.56e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	0.69	4.71	0.36	5.47e-6	Body mass index;
PAAD	cis	rs73416724	0.544	rs45564136	chr6:43251880	C/G	cg17502394	chr6:43251710	TTBK1	0.65	4.54	0.35	1.12e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg15117754	chr3:10150083	C3orf24	0.66	6.23	0.45	4.42e-9	Alzheimer's disease;
PAAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-7.84	-0.54	7.24e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-4.74	-0.36	4.9100000000000004e-06	Daytime sleep phenotypes;
PAAD	cis	rs1015291	0.708	rs2638435	chr12:19999520	C/T	cg25401612	chr12:20009446	NA	-0.56	-5.57	-0.41	1.14e-7	Diastolic blood pressure;
PAAD	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.48	4.34	0.33	2.54e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9467160	0.644	rs3846833	chr6:24462367	C/T	cg16211469	chr6:24423932	MRS2	0.49	4.57	0.35	9.88e-6	Liver enzyme levels;
PAAD	cis	rs6466055	0.624	rs67162771	chr7:104951038	C/T	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs1376303	0.778	rs4723220	chr7:32954032	A/G	cg00566949	chr7:32927892	KBTBD2	-0.52	-4.28	-0.33	3.36e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.84	8.18	0.55	1.04e-13	Corneal astigmatism;
PAAD	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg14631576	chr9:95140430	CENPP	-0.44	-4.33	-0.33	2.74e-5	Height;
PAAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.64	6.8	0.48	2.22e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.76	10.24	0.64	4.78e-19	Bone mineral density;
PAAD	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg10395934	chr14:104002654	TRMT61A	-0.54	-5.75	-0.42	4.75e-8	Body mass index;
PAAD	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-4.77	-0.36	4.3e-6	Testicular germ cell tumor;
PAAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	6.1	0.44	8.47e-9	Mood instability;
PAAD	cis	rs4740619	0.590	rs1359955	chr9:16040879	C/T	cg14451791	chr9:16040625	NA	-0.45	-5.13	-0.38	8.58e-7	Body mass index;
PAAD	cis	rs13266463	0.858	rs13255588	chr8:143384727	C/G	cg16886403	chr8:143471632	TSNARE1	0.62	5.95	0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg08917208	chr2:24149416	ATAD2B	0.51	4.56	0.35	1.04e-5	Asthma;
PAAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg00253185	chr1:247542119	NA	0.54	4.57	0.35	1.02e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs2249625	0.739	rs2496543	chr6:72805811	C/T	cg04413069	chr12:9800446	LOC374443	0.59	6.53	0.47	9.35e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.68	8.89	0.59	1.62e-15	Hemoglobin concentration;
PAAD	cis	rs3169166	0.500	rs3743084	chr15:78562693	A/G	cg09214398	chr15:78556534	DNAJA4	-0.28	-4.68	-0.35	6.37e-6	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg02135003	chr7:105160482	PUS7	-0.7	-6.15	-0.45	6.59e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs955333	0.565	rs67309443	chr6:154906587	C/T	cg20019720	chr6:154832845	CNKSR3	0.38	5.17	0.39	7.21e-7	Diabetic kidney disease;
PAAD	cis	rs7945718	0.591	rs7926971	chr11:12698040	A/G	cg25843174	chr11:12811716	TEAD1	0.31	4.57	0.35	9.96e-6	Educational attainment (years of education);
PAAD	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.69	-7.28	-0.51	1.66e-11	Longevity;
PAAD	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs11825064	0.562	rs77914414	chr11:134513571	G/A	cg06603561	chr11:134479413	NA	-0.93	-5.82	-0.43	3.4e-8	Seasonality;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-6.83	-0.48	1.93e-10	Lymphocyte counts;
PAAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg03808351	chr9:123631620	PHF19	0.47	5.09	0.38	1.05e-6	Rheumatoid arthritis;
PAAD	cis	rs1891275	0.601	rs1970506	chr10:93428286	C/T	cg07889827	chr10:93443413	NA	-0.41	-4.48	-0.34	1.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-1.03	-8.9	-0.59	1.52e-15	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg00945038	chr17:61921165	SMARCD2	-0.37	-4.47	-0.34	1.49e-5	Prudent dietary pattern;
PAAD	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.52	6.96	0.49	9.36e-11	Life satisfaction;
PAAD	cis	rs282587	0.502	rs375741	chr13:113397794	G/C	cg02820901	chr13:113351484	ATP11A	-0.65	-4.96	-0.37	1.89e-6	Glycated hemoglobin levels;
PAAD	cis	rs7651511	1.000	rs11711318	chr3:141264369	C/T	cg25967872	chr3:141205623	RASA2	0.47	4.29	0.33	3.2e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.73	5.98	0.44	1.52e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.7	7.34	0.51	1.2e-11	Schizophrenia;
PAAD	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg14055004	chr2:241860995	NA	0.29	4.58	0.35	9.45e-6	Joint mobility (Beighton score);
PAAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg05484376	chr2:27715224	FNDC4	0.53	5.14	0.38	8.34e-7	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg17552801	chr10:99332121	ANKRD2	-0.45	-4.45	-0.34	1.66e-5	Metabolite levels;
PAAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.36	0.33	2.38e-5	Bipolar disorder;
PAAD	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-4.57	-0.35	1.02e-5	Parkinson's disease;
PAAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-6.17	-0.45	5.87e-9	Personality dimensions;
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg00738919	chr7:1100172	C7orf50	0.52	4.29	0.33	3.15e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg01503450	chr10:980765	NA	-0.53	-4.33	-0.33	2.68e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg26924012	chr15:45694286	SPATA5L1	0.47	4.44	0.34	1.69e-5	Uric acid levels;
PAAD	cis	rs2004318	1.000	rs2004318	chr19:55138232	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15465092	chr8:128747754	MYC	-0.71	-7.74	-0.53	1.29e-12	Smoking initiation;
PAAD	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.64	-0.35	7.44e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2030114	0.948	rs58518683	chr16:51607062	G/A	cg03758633	chr16:51611768	NA	0.61	4.93	0.37	2.16e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg27246729	chr12:121163418	ACADS	0.4	4.36	0.33	2.42e-5	Mean corpuscular volume;
PAAD	cis	rs8024058	0.843	rs11858257	chr15:89164874	C/T	cg00367546	chr15:89165046	AEN	0.69	5.86	0.43	2.73e-8	Night sleep phenotypes;
PAAD	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-4.94	-0.37	2.02e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.79	9.27	0.6	1.75e-16	Heart rate;
PAAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.48	-5.59	-0.41	1.04e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg17644776	chr2:200775616	C2orf69	-0.45	-4.37	-0.33	2.27e-5	Asthma (bronchodilator response);
PAAD	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.94	-8.91	-0.59	1.51e-15	Orofacial clefts;
PAAD	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg20129853	chr10:51489980	NA	-0.44	-4.49	-0.34	1.38e-5	Prostate-specific antigen levels;
PAAD	cis	rs2421770	0.651	rs3903687	chr11:35331642	G/A	cg13971030	chr11:35366721	SLC1A2	-0.51	-5.6	-0.41	9.93e-8	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs8014252	0.803	rs45523543	chr14:71051088	A/G	cg11204974	chr14:71022665	NA	-0.78	-5.01	-0.38	1.48e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.89	7.0	0.49	7.64e-11	Gut microbiome composition (summer);
PAAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg11204139	chr17:3907470	NA	-0.67	-6.82	-0.48	2.01e-10	Type 2 diabetes;
PAAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg05935833	chr10:81318306	SFTPA2	-0.65	-4.51	-0.34	1.29e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg09659197	chr4:152720779	NA	0.34	4.95	0.37	1.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-6.13	-0.45	7.07e-9	Caffeine consumption;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.32	-0.51	1.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1620921	0.505	rs4708888	chr6:161206490	A/C	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg09839279	chr12:125627357	AACS	-0.47	-4.54	-0.35	1.12e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.36	0.4	3.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg19784903	chr17:45786737	TBKBP1	0.58	6.44	0.46	1.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06799790	chr17:61951754	CSH2	-0.46	-4.89	-0.37	2.56e-6	Height;
PAAD	cis	rs11702148	0.552	rs9977929	chr21:34873716	C/G	cg14850771	chr21:34775459	IFNGR2	0.43	4.67	0.35	6.7e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.41	4.42	0.34	1.89e-5	Mean arterial pressure;
PAAD	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.64	6.97	0.49	9.27e-11	Corneal astigmatism;
PAAD	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	8.29	0.56	5.61e-14	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs3857067	0.550	rs10007153	chr4:95000871	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.77	6.16	0.45	6.24e-9	Height;
PAAD	trans	rs901683	0.850	rs74500471	chr10:46031735	A/T	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-1.03	-17.2	-0.81	1.68e-37	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.63	-6.01	-0.44	1.34e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.78	8.44	0.56	2.34e-14	Handedness;
PAAD	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.71	-6.1	-0.44	8.62e-9	IgG glycosylation;
PAAD	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-8.34	-0.56	4.21e-14	Mean corpuscular volume;
PAAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.62	5.27	0.39	4.61e-7	Initial pursuit acceleration;
PAAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.53	4.85	0.37	3.02e-6	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15436505	chr13:111927956	ARHGEF7	-0.69	-6.99	-0.49	7.95e-11	Obesity-related traits;
PAAD	cis	rs959260	1.000	rs4789188	chr17:73397871	A/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.38	-0.33	2.24e-5	Systemic lupus erythematosus;
PAAD	cis	rs4253772	0.530	rs2007791	chr22:46803469	C/A	cg24881330	chr22:46731750	TRMU	1.18	5.57	0.41	1.13e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.87	-8.28	-0.56	5.75e-14	Neurofibrillary tangles;
PAAD	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg05914723	chr15:78953907	NA	0.55	4.32	0.33	2.86e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg19761014	chr17:28927070	LRRC37B2	0.91	5.63	0.42	8.59e-8	Body mass index;
PAAD	cis	rs12580194	0.593	rs7960719	chr12:55722035	G/A	cg06899799	chr12:56650233	ANKRD52	0.34	4.39	0.34	2.08e-5	Cancer;
PAAD	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg21178979	chr7:1889533	MAD1L1	-0.41	-4.43	-0.34	1.78e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg05785598	chr3:49045655	WDR6	0.41	4.83	0.36	3.28e-6	Parkinson's disease;
PAAD	cis	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg22875332	chr1:76189707	ACADM	0.77	4.56	0.35	1.03e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs1419980	0.730	rs7976359	chr12:7738500	A/T	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.82	-0.54	8.05e-13	Total cholesterol levels;
PAAD	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg09065629	chr16:1709722	CRAMP1L	0.43	4.53	0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.69	6.82	0.48	2.03e-10	Lymphocyte counts;
PAAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.51	5.13	0.38	8.73e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg07202610	chr7:1142643	C7orf50	-0.71	-5.21	-0.39	5.96e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.76	-5.73	-0.42	5.13e-8	Mean platelet volume;
PAAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs2412208	0.753	rs11120817	chr1:7081233	A/T	cg26570804	chr1:6352357	ACOT7	0.57	5.4	0.4	2.47e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg23912435	chr1:150601613	ENSA	0.49	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.57	-0.52	3.31e-12	Height;
PAAD	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.1	-0.38	9.79e-7	Fear of minor pain;
PAAD	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.58	5.77	0.42	4.31e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.05	-0.44	1.11e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-5.96	-0.44	1.71e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg11657817	chr20:23433608	CST11	0.41	4.42	0.34	1.89e-5	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16789934	chr11:43380526	TTC17	-0.72	-6.39	-0.46	1.89e-9	Neuroticism;
PAAD	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg19978312	chr5:179634688	RASGEF1C	0.43	4.32	0.33	2.81e-5	LDL cholesterol;
PAAD	cis	rs2278796	0.639	rs6661266	chr1:204971452	C/T	cg04862289	chr1:204966208	NFASC	-0.51	-5.23	-0.39	5.54e-7	Mean platelet volume;
PAAD	cis	rs757081	0.648	rs7940253	chr11:17280596	G/A	cg04705435	chr11:17411270	KCNJ11	-0.51	-5.1	-0.38	9.91e-7	Systolic blood pressure;
PAAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.99	11.45	0.68	2.8e-22	Menarche (age at onset);
PAAD	cis	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg20893579	chr22:38215064	NA	-0.47	-4.7	-0.36	5.86e-6	Glioblastoma;Glioma;
PAAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21625146	chr5:486483	SLC9A3	-0.39	-5.01	-0.38	1.48e-6	Cystic fibrosis severity;
PAAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.61	-5.62	-0.41	9.03e-8	Menarche (age at onset);
PAAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19671926	chr4:122722719	EXOSC9	-0.66	-5.96	-0.44	1.7e-8	Type 2 diabetes;
PAAD	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06634786	chr22:41940651	POLR3H	0.62	5.03	0.38	1.4e-6	Vitiligo;
PAAD	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	1.0	7.17	0.5	2.99e-11	Alzheimer's disease;
PAAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-1.02	-5.38	-0.4	2.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg00490450	chr3:139108681	COPB2	-0.63	-5.55	-0.41	1.21e-7	Obesity-related traits;
PAAD	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs757978	1.000	rs2074771	chr2:242350944	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-4.95	-0.37	1.98e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.6	6.6	0.47	6.54e-10	Lung cancer;
PAAD	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.5	5.39	0.4	2.67e-7	Schizophrenia;
PAAD	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	1.13	9.52	0.61	3.8e-17	Height;
PAAD	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.55	5.59	0.41	1.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9918079	0.542	rs6414765	chr4:15626493	G/A	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg04851639	chr8:1020857	NA	-0.57	-6.48	-0.47	1.21e-9	Schizophrenia;
PAAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.15	-11.72	-0.69	5.2e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.25	0.33	3.71e-5	Rheumatoid arthritis;
PAAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.75	6.68	0.48	4.22e-10	Asthma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03031933	chr8:145598519	ADCK5	0.62	7.17	0.5	3.05e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.97	-12.13	-0.7	4.2e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-5.0	-0.38	1.59e-6	Fibrinogen levels;
PAAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04362095	chr11:63592001	C11orf84	-0.5	-4.46	-0.34	1.6e-5	Platelet count;
PAAD	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg04607699	chr11:48328132	OR4S1	-0.52	-5.0	-0.38	1.54e-6	Migraine - clinic-based;
PAAD	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg17514665	chr17:1657533	SERPINF2	0.65	6.03	0.44	1.18e-8	Serum albumin level;
PAAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.32	6.03	0.44	1.17e-8	Skin colour saturation;
PAAD	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.69	-5.04	-0.38	1.28e-6	Major depressive disorder;
PAAD	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.48	-4.31	-0.33	2.93e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.6	-0.35	8.97e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg09835421	chr16:68378352	PRMT7	-1.08	-7.78	-0.53	1.04e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-4.37	-0.33	2.3e-5	Ovarian reserve;
PAAD	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg20003494	chr4:90757398	SNCA	0.65	5.87	0.43	2.62e-8	Neuroticism;
PAAD	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.62	4.54	0.35	1.12e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg19536664	chr17:6899085	ALOX12	-0.56	-6.16	-0.45	6.12e-9	Tonsillectomy;
PAAD	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.46	4.74	0.36	4.88e-6	Type 2 diabetes;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10819733	chr22:24237672	NA	-0.63	-6.76	-0.48	2.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9715521	0.775	rs62301191	chr4:59842587	T/G	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.32	-0.33	2.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5.07e-7	Life satisfaction;
PAAD	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.61	0.35	8.64e-6	Hepatocellular carcinoma;
PAAD	cis	rs10861342	1.000	rs11112371	chr12:105499021	T/C	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.75	-9.24	-0.6	2.05e-16	Motion sickness;
PAAD	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg14003231	chr6:33640908	ITPR3	-0.37	-4.75	-0.36	4.74e-6	Plateletcrit;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	6.5	0.47	1.1e-9	Renal function-related traits (BUN);
PAAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.76	-8.08	-0.55	1.86e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-5.65	-0.42	7.58e-8	Menarche (age at onset);
PAAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-4.77	-0.36	4.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.6	-5.59	-0.41	1.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg17372657	chr7:1216933	NA	-0.35	-4.54	-0.35	1.15e-5	Longevity;Endometriosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03695708	chr19:14831237	ZNF333	-0.58	-6.76	-0.48	2.72e-10	Monocyte percentage of white cells;
PAAD	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.75	4.69	0.36	6.1e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08244522	chr20:23030533	THBD	0.57	6.77	0.48	2.68e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-11.9	-0.69	1.77e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg05212510	chr18:77623544	KCNG2	-0.44	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-6.87	-0.49	1.51e-10	Body mass index;
PAAD	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14169450	chr9:139327907	INPP5E	0.71	8.48	0.57	1.89e-14	Monocyte percentage of white cells;
PAAD	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.54	-5.14	-0.38	8.52e-7	Mortality in heart failure;
PAAD	cis	rs2786865	0.609	rs2744779	chr1:26014410	C/T	cg02327719	chr1:26185386	C1orf135	-0.73	-4.53	-0.34	1.19e-5	Facial morphology (factor 11, projection of the nose);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21647473	chr3:136581035	NCK1	0.55	6.36	0.46	2.22e-9	Monocyte percentage of white cells;
PAAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00300879	chr1:26503847	CNKSR1	0.28	4.39	0.34	2.09e-5	Height;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18621852	chr3:10150065	C3orf24	0.68	6.16	0.45	6.15e-9	Alzheimer's disease;
PAAD	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13265574	chr10:93804976	NA	0.67	6.39	0.46	1.9e-9	Neuroticism;
PAAD	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	7.91	0.54	5.01e-13	Post bronchodilator FEV1;
PAAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.62	-6.81	-0.48	2.18e-10	Longevity;Endometriosis;
PAAD	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.4	-5.85	-0.43	2.96e-8	Subjective well-being;
PAAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.36	4.25	0.33	3.75e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.67	6.66	0.48	4.64e-10	Coronary artery disease or large artery stroke;
PAAD	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.97	-11.22	-0.67	1.13e-21	Refractive error;
PAAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg06463185	chr17:3833770	ATP2A3	0.92	7.64	0.53	2.24e-12	Glucose homeostasis traits;
PAAD	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.9	10.08	0.63	1.28e-18	Total cholesterol levels;
PAAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.44	-0.4	2.07e-7	Personality dimensions;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07841312	chr22:20748432	ZNF74	0.63	6.72	0.48	3.39e-10	Myopia (pathological);
PAAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.13	-0.38	8.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg02297831	chr4:17616191	MED28	0.54	5.29	0.39	4.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.46	-5.61	-0.41	9.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4737010	0.644	rs518718	chr8:41611375	T/C	cg17182837	chr8:41585554	ANK1	0.49	4.8	0.36	3.72e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.61	5.5	0.41	1.57e-7	Malaria;
PAAD	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg21064579	chr19:49206444	FUT2	0.4	4.43	0.34	1.83e-5	Dietary macronutrient intake;
PAAD	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg07741184	chr6:167504864	NA	0.41	5.26	0.39	4.81e-7	Crohn's disease;
PAAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.54	4.56	0.35	1.04e-5	Type 2 diabetes;
PAAD	cis	rs9283706	0.594	rs7734953	chr5:66349943	G/T	cg11590213	chr5:66331682	MAST4	0.6	4.78	0.36	4.14e-6	Coronary artery disease;
PAAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.76	8.74	0.58	3.94e-15	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs287982	0.800	rs13429581	chr2:9963443	T/C	cg01119585	chr2:10571959	NA	0.41	4.52	0.34	1.22e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-7.38	-0.51	9.72e-12	Developmental language disorder (linguistic errors);
PAAD	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.73	-6.45	-0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg03700679	chr2:178418002	TTC30B	0.58	4.59	0.35	9.18e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-4.61	-0.35	8.61e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs6066835	0.867	rs6095283	chr20:47374382	G/A	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg02549819	chr16:58548995	SETD6	0.92	4.64	0.35	7.63e-6	Schizophrenia;
PAAD	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.89	-7.4	-0.51	8.43e-12	Triglycerides;
PAAD	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg22764044	chr5:178986830	RUFY1	0.52	5.22	0.39	5.89e-7	Lung cancer;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.45	5.3	0.4	3.93e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg00809820	chr17:80708513	TBCD;FN3K	0.48	4.8	0.36	3.77e-6	Glycated hemoglobin levels;
PAAD	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.33	0.33	2.68e-5	Rheumatoid arthritis;
PAAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.74	8.54	0.57	1.28e-14	Methadone dose in opioid dependence;
PAAD	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.36	5.45e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03605463	chr16:89740564	NA	-0.61	-5.7	-0.42	6.07e-8	Vitiligo;
PAAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg10589385	chr1:150898437	SETDB1	-0.4	-4.85	-0.37	3.02e-6	Melanoma;
PAAD	cis	rs2882667	0.690	rs288014	chr5:138195793	A/G	cg09476006	chr5:138032270	NA	-0.47	-5.98	-0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.8	8.96	0.59	1.07e-15	Birth weight;
PAAD	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg26149184	chr10:133730230	NA	0.78	6.79	0.48	2.4e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.45	0.34	1.66e-5	Body mass index;
PAAD	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.74	-0.36	4.92e-6	Biliary atresia;
PAAD	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg16964102	chr10:135390573	NA	0.42	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs6708331	0.517	rs12992553	chr2:70360262	A/G	cg01613454	chr2:70366299	NA	0.44	4.63	0.35	7.78e-6	Obesity-related traits;
PAAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.87	-0.43	2.68e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13147522	chr11:68228078	SAPS3	-0.71	-6.89	-0.49	1.41e-10	Lung cancer in ever smokers;
PAAD	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.69	-0.36	6.16e-6	Glomerular filtration rate;
PAAD	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-8.9	-0.59	1.52e-15	Exhaled nitric oxide output;
PAAD	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.62	-5.35	-0.4	3.22e-7	Corneal structure;
PAAD	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.57	7.73	0.53	1.36e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.44	4.86	0.37	2.89e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2120243	0.641	rs7639254	chr3:157141041	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.25	0.33	3.65e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg07153921	chr17:41440717	NA	-0.4	-4.33	-0.33	2.69e-5	Menopause (age at onset);
PAAD	cis	rs1539053	0.966	rs11207077	chr1:58097154	T/C	cg00026909	chr1:58089001	DAB1	-0.69	-8.01	-0.54	2.75e-13	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg14191688	chr11:70257035	CTTN	0.56	4.34	0.33	2.63e-5	Coronary artery disease;
PAAD	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-1.07	-7.64	-0.53	2.25e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.91	9.96	0.63	2.61e-18	Testicular germ cell tumor;
PAAD	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg03948781	chr1:205179583	DSTYK	0.48	4.48	0.34	1.46e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg00800038	chr16:89945340	TCF25	-0.84	-4.32	-0.33	2.83e-5	Skin colour saturation;
PAAD	cis	rs7715811	0.913	rs73749952	chr5:13762518	T/C	cg07548982	chr5:13769939	DNAH5	-0.66	-6.24	-0.45	4.1e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.58	-5.58	-0.41	1.07e-7	Red cell distribution width;
PAAD	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.44	-4.49	-0.34	1.39e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2070433	0.904	rs8130209	chr21:47925984	T/C	cg12379764	chr21:47803548	PCNT	0.54	4.77	0.36	4.37e-6	Lymphocyte counts;
PAAD	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-1.0	-6.88	-0.49	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.95e-17	IgG glycosylation;
PAAD	cis	rs4704187	0.687	rs6889429	chr5:74482183	C/T	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.05	-9.04	-0.59	6.88e-16	Alzheimer's disease;
PAAD	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.78	-0.36	4.18e-6	Height;
PAAD	cis	rs6537837	1.000	rs3525	chr1:110136846	T/A	cg05049280	chr1:110155535	GNAT2	0.46	4.6	0.35	8.69e-6	Major depressive disorder;
PAAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg21929781	chr1:2537748	MMEL1	0.5	5.33	0.4	3.45e-7	Multiple sclerosis;
PAAD	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.42	0.34	1.88e-5	Neuroticism;
PAAD	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg02531859	chr7:37888154	TXNDC3	-0.56	-4.51	-0.34	1.29e-5	Alzheimer's disease (late onset);
PAAD	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg13606994	chr1:44402422	ARTN	-0.43	-4.42	-0.34	1.86e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.74	-0.42	4.92e-8	Neuroticism;
PAAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10274279	0.660	rs2021743	chr7:157381899	T/C	cg09270525	chr7:157391030	PTPRN2	0.61	5.69	0.42	6.22e-8	Myopia (pathological);
PAAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.77	6.79	0.48	2.34e-10	Type 2 diabetes;
PAAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.81	8.71	0.58	4.91e-15	Schizophrenia;
PAAD	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg04330084	chr7:123175371	IQUB	-0.54	-4.75	-0.36	4.65e-6	Plateletcrit;Platelet count;
PAAD	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.4	4.81	0.36	3.65e-6	Intraocular pressure;
PAAD	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-8.51	-0.57	1.55e-14	Vitiligo;
PAAD	cis	rs6782025	0.837	rs9853078	chr3:120816605	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.68	6.22	0.45	4.55e-9	Platelet count;
PAAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg06297367	chr7:4456341	NA	-0.62	-4.98	-0.37	1.73e-6	Borderline personality disorder;
PAAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg14092988	chr3:52407081	DNAH1	0.44	5.42	0.4	2.32e-7	Bipolar disorder;
PAAD	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg17771515	chr6:154831774	CNKSR3	0.59	4.26	0.33	3.55e-5	Lipoprotein (a) levels;
PAAD	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg22143635	chr11:980567	AP2A2	-0.54	-5.78	-0.42	4.04e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.91	-11.42	-0.68	3.47e-22	Bipolar disorder;
PAAD	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs7660520	0.623	rs4455461	chr4:183744854	G/A	cg03209412	chr4:183728196	NA	0.75	5.48	0.41	1.73e-7	Pediatric autoimmune diseases;
PAAD	trans	rs901683	1.000	rs12779281	chr10:45977447	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6976053	0.846	rs4729616	chr7:100462565	G/T	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg02631450	chr22:32366979	NA	1.04	5.62	0.41	9.07e-8	Childhood ear infection;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.31e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.25	0.33	3.75e-5	Menopause (age at onset);
PAAD	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04852413	chr12:2986358	FOXM1;C12orf32	0.64	6.35	0.46	2.4e-9	Obesity-related traits;
PAAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11245990	chr11:68621969	NA	0.38	4.8	0.36	3.74e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.37	-0.33	2.26e-5	Height;
PAAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg05110241	chr16:68378359	PRMT7	1.06	7.87	0.54	6.04e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12431939	0.857	rs2999383	chr14:51648755	C/T	cg23942311	chr14:51606299	NA	-0.6	-5.28	-0.39	4.48e-7	Cancer;
PAAD	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.52	-4.74	-0.36	4.92e-6	Smoking behavior;
PAAD	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg15507776	chr3:136538369	TMEM22	0.47	4.57	0.35	1.01e-5	Neuroticism;
PAAD	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.49	-0.34	1.42e-5	Red blood cell count;
PAAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg07648498	chr16:89883185	FANCA	0.58	5.34	0.4	3.4e-7	Vitiligo;
PAAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg15604389	chr3:122379662	NA	0.58	6.26	0.45	3.83e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.42	0.52	7.55e-12	Monocyte percentage of white cells;
PAAD	cis	rs11892454	0.565	rs6748220	chr2:26101403	A/C	cg03373490	chr2:26702396	OTOF	0.51	4.31	0.33	2.95e-5	Heschl's gyrus morphology;
PAAD	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.52	-4.25	-0.33	3.73e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg27411982	chr8:10470053	RP1L1	-0.48	-5.27	-0.39	4.63e-7	Systolic blood pressure;
PAAD	cis	rs59888335	0.830	rs67307837	chr3:80514833	T/C	cg21735741	chr3:80819488	NA	0.59	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg03037974	chr15:76606532	NA	0.49	5.57	0.41	1.11e-7	Blood metabolite levels;
PAAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.92	0.43	2.06e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.57	0.35	9.86e-6	Skin colour saturation;
PAAD	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.1	0.38	1e-6	Lung cancer;
PAAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-4.35	-0.33	2.46e-5	Systemic lupus erythematosus;
PAAD	cis	rs6546886	0.750	rs71406850	chr2:74243258	G/A	cg20260610	chr2:74347274	NA	0.51	4.33	0.33	2.73e-5	Dialysis-related mortality;
PAAD	cis	rs4073221	0.654	rs34741569	chr3:18284731	T/C	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	cis	rs6473252	0.584	rs11777950	chr8:81801539	A/G	cg08595989	chr8:81827712	NA	-0.32	-4.44	-0.34	1.74e-5	Breast cancer;
PAAD	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-7.5	-0.52	4.95e-12	Hemoglobin concentration;
PAAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08640252	chr16:1820949	NME3	-0.45	-4.55	-0.35	1.11e-5	Insulin-like growth factors;
PAAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg19413350	chr8:57351067	NA	-0.54	-5.41	-0.4	2.46e-7	Obesity-related traits;
PAAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	5.51	0.41	1.49e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.96	-6.39	-0.46	1.92e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg00071950	chr4:10020882	SLC2A9	0.53	4.39	0.34	2.12e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.37	-0.4	2.84e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.38	-0.51	9.79e-12	Barrett's esophagus;
PAAD	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.6	6.53	0.47	9.1e-10	Colorectal cancer;
PAAD	cis	rs1879734	0.731	rs56368850	chr1:54159441	C/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.89	-0.43	2.43e-8	Mitral valve prolapse;
PAAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.76	-8.97	-0.59	1.02e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.62	-6.52	-0.47	9.97e-10	Capecitabine sensitivity;
PAAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Parkinson's disease;
PAAD	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg23957660	chr17:17878224	LRRC48	0.38	4.36	0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg03030879	chr14:75389066	RPS6KL1	0.41	4.28	0.33	3.24e-5	Height;
PAAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg08088566	chr11:430123	ANO9	0.71	4.36	0.33	2.42e-5	Body mass index;
PAAD	cis	rs3747547	0.818	rs3827519	chr9:37948724	T/C	cg13774184	chr9:37916125	SHB	-0.59	-4.34	-0.33	2.56e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg19337854	chr7:99768885	GPC2	0.49	4.53	0.34	1.2e-5	Platelet count;
PAAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.55	-6.28	-0.45	3.36e-9	Lung cancer;
PAAD	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.44	-5.56	-0.41	1.16e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-7.68	-0.53	1.77e-12	Hemoglobin concentration;
PAAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg21523564	chr15:75251491	NA	0.47	4.93	0.37	2.11e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg18850127	chr7:39170497	POU6F2	0.64	9.14	0.6	3.65e-16	IgG glycosylation;
PAAD	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg06307176	chr5:131281290	NA	-0.59	-5.33	-0.4	3.56e-7	Life satisfaction;
PAAD	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.61	6.39	0.46	1.91e-9	Blood protein levels;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg12044295	chr8:56686133	TMEM68;TGS1	0.88	6.3	0.46	3.13e-9	Lung function (FEV1/FVC);
PAAD	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs11690462	0.534	rs13432533	chr2:26571411	G/A	cg13255216	chr2:26625047	C2orf39	-0.44	-4.4	-0.34	2.02e-5	Coronary artery disease;
PAAD	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26190225	chr4:71570509	RUFY3	-0.54	-6.31	-0.46	2.96e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	6.21	0.45	4.91e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24110177	chr3:50126178	RBM5	0.61	6.86	0.49	1.64e-10	Blood protein levels;
PAAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg04370829	chr17:406249	NA	-0.44	-4.4	-0.34	2e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.6	8.51	0.57	1.53e-14	Asthma (sex interaction);
PAAD	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-8.04	-0.55	2.4e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg10395934	chr14:104002654	TRMT61A	0.53	5.06	0.38	1.18e-6	Body mass index;
PAAD	cis	rs10490913	1.000	rs10128523	chr10:120157792	C/T	cg04126427	chr10:120840676	EIF3A	-0.44	-4.44	-0.34	1.73e-5	Cancer;
PAAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg03289416	chr15:75166202	SCAMP2	0.59	6.09	0.44	8.64e-9	Breast cancer;
PAAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.48	4.29	0.33	3.18e-5	Blood metabolite levels;
PAAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	8.95	0.59	1.15e-15	Platelet count;
PAAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.5	-5.54	-0.41	1.29e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.56	-6.53	-0.47	9.1e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.59	6.34	0.46	2.46e-9	Obesity-related traits;
PAAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22658129	chr5:49962507	PARP8	0.59	6.52	0.47	9.74e-10	Pancreatic cancer;
PAAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06217245	chr20:33103252	DYNLRB1	0.41	4.91	0.37	2.32e-6	Coronary artery disease;
PAAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-1.08	-13.48	-0.74	9.9e-28	Breast cancer;
PAAD	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.39	5.21e-7	Chronic sinus infection;
PAAD	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.72	5.84	0.43	3.04e-8	Common traits (Other);
PAAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg06632027	chr4:90757378	SNCA	-0.5	-4.31	-0.33	2.89e-5	Neuroticism;
PAAD	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.29e-16	Asthma (childhood onset);
PAAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	4.66	0.35	6.98e-6	Height;
PAAD	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg05555928	chr11:63887634	MACROD1	-0.62	-4.54	-0.35	1.12e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2092319	0.536	rs2742942	chr1:26067461	G/A	cg12446045	chr1:25857419	NA	-0.47	-4.35	-0.33	2.5e-5	Nose morphology;
PAAD	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg05973401	chr12:123451056	ABCB9	0.5	4.5	0.34	1.35e-5	Platelet count;
PAAD	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	6.25	0.45	3.99e-9	Lung cancer in ever smokers;
PAAD	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.34	-0.4	3.32e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.78	8.73	0.58	4.34e-15	Obesity-related traits;
PAAD	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg05805236	chr11:65401703	PCNXL3	-0.43	-4.41	-0.34	1.93e-5	Eosinophil percentage of white cells;
PAAD	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.67	6.39	0.46	1.88e-9	Post bronchodilator FEV1;
PAAD	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg02743256	chr7:2109353	MAD1L1	-0.64	-4.67	-0.35	6.55e-6	Bipolar disorder;
PAAD	cis	rs11811982	1.000	rs115414844	chr1:227509265	C/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.47	-4.53	-0.34	1.2e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.71	-7.11	-0.5	4.33e-11	Retinal vascular caliber;
PAAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.91	8.21	0.55	8.89e-14	Diastolic blood pressure;
PAAD	cis	rs2904967	0.636	rs239256	chr11:64987391	C/T	cg11802864	chr11:65308245	LTBP3	-0.5	-4.5	-0.34	1.36e-5	Mean corpuscular volume;
PAAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs12148477	0.623	rs12595284	chr15:51655762	C/G	cg25905881	chr15:51634250	GLDN	0.41	4.38	0.33	2.17e-5	Follicule stimulating hormone;
PAAD	cis	rs2730260	0.537	rs73169248	chr7:158891742	T/G	cg02254261	chr7:158964346	NA	-0.59	-4.6	-0.35	8.71e-6	Myopia (pathological);
PAAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg09835421	chr16:68378352	PRMT7	-1.12	-8.51	-0.57	1.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg07061783	chr6:25882402	NA	-0.48	-4.35	-0.33	2.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs58521262	0.520	rs7253127	chr19:23032370	T/A	cg07749055	chr19:23076870	NA	-0.66	-4.76	-0.36	4.53e-6	Testicular germ cell tumor;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg07291445	chr7:39015928	NA	0.29	4.28	0.33	3.3e-5	IgG glycosylation;
PAAD	cis	rs9653442	0.500	rs72819191	chr2:100826572	A/G	cg07810366	chr2:100720526	AFF3	0.4	4.48	0.34	1.47e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.9	12.15	0.7	3.75e-24	Prudent dietary pattern;
PAAD	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.59	0.47	6.74e-10	IgG glycosylation;
PAAD	cis	rs2084881	0.521	rs9894188	chr17:46044031	C/T	cg10055580	chr17:46707781	NA	-0.37	-4.25	-0.33	3.77e-5	Ovarian cancer;
PAAD	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.55	5.17	0.39	7.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.7	4.79	0.36	3.85e-6	Major depressive disorder;
PAAD	cis	rs2882667	0.690	rs160402	chr5:138059288	G/T	cg09476006	chr5:138032270	NA	0.46	6.03	0.44	1.2e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6604026	0.656	rs2774953	chr1:93355254	G/A	cg17283838	chr1:93427260	FAM69A	-0.63	-5.82	-0.43	3.37e-8	Multiple sclerosis;
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23708337	chr7:1209742	NA	0.45	4.67	0.35	6.48e-6	Longevity;Endometriosis;
PAAD	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-4.41	-0.34	1.93e-5	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	0.78	7.07	0.5	5.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05462328	chr2:172963910	NA	0.58	6.5	0.47	1.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.62	0.35	8.18e-6	Breast cancer;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.91	-10.78	-0.66	1.79e-20	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg14055004	chr2:241860995	NA	0.28	4.46	0.34	1.62e-5	Joint mobility (Beighton score);
PAAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.78	-0.42	4.02e-8	Eye color traits;
PAAD	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg23033748	chr14:75592666	NEK9	-0.4	-4.95	-0.37	1.95e-6	Height;
PAAD	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	4.92	0.37	2.2e-6	Birth weight;
PAAD	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.44	-4.95	-0.37	1.98e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg24733560	chr20:60626293	TAF4	0.6	7.97	0.54	3.48e-13	Body mass index;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg24879335	chr3:133465180	TF	0.55	5.91	0.43	2.15e-8	Iron status biomarkers;
PAAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	1.17	6.97	0.49	9.16e-11	Skin colour saturation;
PAAD	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg23153227	chr6:27725408	NA	0.47	4.49	0.34	1.41e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.56	-5.75	-0.42	4.65e-8	Crohn's disease;
PAAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.88	6.25	0.45	3.96e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs10905065	0.965	rs12571639	chr10:5748052	G/A	cg11519256	chr10:5708881	ASB13	0.5	4.27	0.33	3.43e-5	Menopause (age at onset);
PAAD	cis	rs258892	0.842	rs10060065	chr5:72065830	T/C	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg19337854	chr7:99768885	GPC2	0.47	4.35	0.33	2.46e-5	Platelet count;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19426362	chr7:128379330	CALU	-0.77	-6.89	-0.49	1.37e-10	Neuroticism;
PAAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.51	5.36	0.4	3.05e-7	Obesity-related traits;
PAAD	cis	rs6137287	0.813	rs6035817	chr20:21221304	A/G	cg04219410	chr20:21106687	PLK1S1	0.39	4.39	0.34	2.1e-5	Height;
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10929159	0.928	rs3738993	chr2:236918671	C/T	cg14226755	chr2:236923322	AGAP1	0.29	4.61	0.35	8.39e-6	Parkinson's disease;
PAAD	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.76	8.65	0.57	6.7e-15	Eosinophil percentage of white cells;
PAAD	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.63	7.16	0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg09060608	chr5:178986726	RUFY1	-0.55	-5.7	-0.42	5.9e-8	Lung cancer;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.9	11.16	0.67	1.7e-21	Prudent dietary pattern;
PAAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg21237687	chr17:6899380	ALOX12	0.59	5.97	0.44	1.62e-8	Tonsillectomy;
PAAD	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg05110241	chr16:68378359	PRMT7	-0.96	-5.3	-0.39	4.04e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.67	5.99	0.44	1.46e-8	Breast cancer;
PAAD	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.86	7.14	0.5	3.7e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.8	8.33	0.56	4.54e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.5	-5.05	-0.38	1.26e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs62025270	0.547	rs1026722	chr15:86119399	C/T	cg13263323	chr15:86062960	AKAP13	-0.46	-4.4	-0.34	2.05e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg12568669	chr8:11666485	FDFT1	-0.28	-4.33	-0.33	2.71e-5	Monocyte count;
PAAD	trans	rs55692468	0.570	rs10193625	chr2:153314204	C/T	cg16346555	chr2:69374392	ANTXR1	-0.56	-6.32	-0.46	2.76e-9	Intraocular pressure;
PAAD	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.78	5.58	0.41	1.06e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.14e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.8	-10.13	-0.63	9.32e-19	Menopause (age at onset);
PAAD	cis	rs9810890	1.000	rs73198826	chr3:128487388	T/C	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg17644776	chr2:200775616	C2orf69	0.48	4.58	0.35	9.67e-6	Asthma (bronchodilator response);
PAAD	cis	rs9581857	0.512	rs9507886	chr13:27957286	G/A	cg22138327	chr13:27999177	GTF3A	0.76	5.29	0.39	4.21e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9283706	0.562	rs10471697	chr5:66328555	A/T	cg11590213	chr5:66331682	MAST4	0.57	4.67	0.35	6.64e-6	Coronary artery disease;
PAAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg24253500	chr15:84953950	NA	-0.56	-6.53	-0.47	9.33e-10	Schizophrenia;
PAAD	cis	rs8105895	0.935	rs10412953	chr19:22238482	C/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.75	-7.63	-0.53	2.4e-12	Itch intensity from mosquito bite;
PAAD	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-6.24	-0.45	4.08e-9	Subjective well-being;
PAAD	cis	rs600550	0.517	rs11525457	chr11:60089299	G/T	cg05040360	chr11:60102449	MS4A6E	-0.42	-4.85	-0.37	2.98e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.66	7.15	0.5	3.37e-11	Leprosy;
PAAD	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.64	6.38	0.46	2.03e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg20406979	chr6:167373233	NA	0.33	4.39	0.34	2.07e-5	Crohn's disease;
PAAD	cis	rs1865721	0.761	rs7242709	chr18:73222819	T/C	cg26385618	chr18:73139727	C18orf62	-0.45	-5.22	-0.39	5.86e-7	Intelligence;
PAAD	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.9	7.13	0.5	3.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg01866162	chr16:67596514	CTCF	0.57	4.28	0.33	3.26e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.55	-6.01	-0.44	1.33e-8	Hepatitis;
PAAD	cis	rs3747547	0.710	rs7864677	chr9:37949969	C/T	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-8.9	-0.59	1.52e-15	Type 2 diabetes;
PAAD	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6669119	1.000	rs6669119	chr1:19108549	C/T	cg19637330	chr1:19110922	NA	0.81	5.32	0.4	3.61e-7	Percentage gas trapping;
PAAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2342371	0.848	rs12632592	chr3:196219365	G/A	cg05659262	chr3:195539315	MUC4	0.49	4.31	0.33	2.93e-5	Fat distribution (HIV);
PAAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.96	-0.63	2.73e-18	Total body bone mineral density;
PAAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-5.29	-0.39	4.12e-7	Total body bone mineral density;
PAAD	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg12633918	chr20:23549525	CST9L	-0.43	-4.72	-0.36	5.38e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg08099141	chr12:7053170	C12orf57	0.43	4.44	0.34	1.72e-5	IgG glycosylation;
PAAD	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.67	7.86	0.54	6.51e-13	Schizophrenia;
PAAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.64	-6.73	-0.48	3.26e-10	Blood protein levels;
PAAD	cis	rs58521262	0.585	rs466772	chr19:23130984	G/C	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.29	0.81	9.98e-38	Prudent dietary pattern;
PAAD	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg22705602	chr4:152727874	NA	-0.5	-5.33	-0.4	3.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.55	-4.64	-0.35	7.31e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.72	6.59	0.47	6.76e-10	Morning vs. evening chronotype;
PAAD	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg00540400	chr15:79124168	NA	0.68	8.51	0.57	1.58e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.47	4.81	0.36	3.56e-6	Red cell distribution width;
PAAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14019695	chr9:139328340	INPP5E	0.58	5.04	0.38	1.32e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg02640540	chr1:67518911	SLC35D1	-0.52	-4.61	-0.35	8.34e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.48	-5.3	-0.4	3.95e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	0.72	6.56	0.47	8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg25025879	chr12:53359317	NA	-0.82	-9.82	-0.62	6.39e-18	Prostate cancer;
PAAD	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.48	-4.52	-0.34	1.22e-5	Mean platelet volume;
PAAD	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg18867708	chr6:26865862	GUSBL1	0.44	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26864130	chr11:119187858	MCAM	0.54	6.48	0.47	1.22e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.58	-5.41	-0.4	2.41e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg20169779	chr10:135381914	SYCE1	-0.67	-6.15	-0.45	6.59e-9	Gout;
PAAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-1.13	-11.7	-0.69	5.81e-23	Platelet distribution width;
PAAD	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg19254793	chr6:44695348	NA	0.48	4.65	0.35	7.26e-6	Total body bone mineral density;
PAAD	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg09597638	chr17:3907349	NA	0.72	7.51	0.52	4.56e-12	Type 2 diabetes;
PAAD	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	6.16	0.45	6.36e-9	Lymphocyte counts;Fibrinogen;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00172270	chr12:50101356	FMNL3	0.55	6.29	0.45	3.29e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg09491104	chr22:46646882	C22orf40	-1.03	-6.04	-0.44	1.16e-8	LDL cholesterol;Cholesterol, total;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18069705	chr4:128754061	HSPA4L	0.59	6.77	0.48	2.6e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.62	8.28	0.56	5.73e-14	Crohn's disease;
PAAD	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.7	-7.21	-0.5	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01864807	chr11:118442966	ARCN1	-0.68	-7.29	-0.51	1.58e-11	Smoking initiation;
PAAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-7.64	-0.53	2.21e-12	Menarche (age at onset);
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.45	5.01	0.38	1.49e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs91	0.575	rs6971081	chr7:24426983	G/A	cg13313214	chr7:23749942	STK31	-0.45	-4.64	-0.35	7.37e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg01489032	chr8:143877656	NA	-0.48	-5.18	-0.39	6.99e-7	Urinary tract infection frequency;
PAAD	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.51	-0.34	1.26e-5	Joint mobility (Beighton score);
PAAD	cis	rs75757892	0.544	rs9328412	chr6:7317569	C/T	cg02954307	chr6:7269328	NA	0.52	4.45	0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs10885582	0.809	rs11196786	chr10:116313397	C/T	cg17056676	chr10:116301354	ABLIM1	-0.38	-5.17	-0.39	7.34e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg21775007	chr8:11205619	TDH	0.51	4.66	0.35	6.72e-6	Morning vs. evening chronotype;
PAAD	cis	rs2075671	0.818	rs10953302	chr7:100365567	C/T	cg15510373	chr7:100224934	TFR2	-0.59	-4.82	-0.36	3.5e-6	Other erythrocyte phenotypes;
PAAD	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg18057887	chr11:133800913	IGSF9B	0.7	6.89	0.49	1.35e-10	Parkinson's disease;
PAAD	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.77	8.58	0.57	1.03e-14	Heart rate;
PAAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.02	-0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.16	16.6	0.8	5.87e-36	Cognitive function;
PAAD	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.6	-5.53	-0.41	1.36e-7	Mean corpuscular volume;
PAAD	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.56	-5.11	-0.38	9.49e-7	White matter hyperintensity burden;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02467054	chr16:4664854	FAM100A	-0.61	-6.44	-0.46	1.51e-9	Smoking initiation;
PAAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9815354	0.638	rs60525434	chr3:42044286	T/G	cg03022575	chr3:42003672	ULK4	0.8	5.56	0.41	1.17e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs939584	1.000	rs7570232	chr2:621185	T/C	cg14515364	chr2:636606	NA	0.48	4.25	0.33	3.72e-5	Body mass index;
PAAD	cis	rs1682825	0.615	rs5026889	chr3:10777448	C/G	cg25949513	chr3:9811735	CAMK1	-0.52	-4.32	-0.33	2.81e-5	Economic and political preferences (feminism/equality);
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.95	6.65	0.47	4.97e-10	Body mass index;
PAAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg14393609	chr7:65229607	NA	-0.67	-7.44	-0.52	6.95e-12	Calcium levels;
PAAD	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg16591659	chr17:78472290	NA	-0.52	-5.1	-0.38	9.98e-7	Fractional excretion of uric acid;
PAAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.21	-0.7	2.55e-24	Obesity-related traits;
PAAD	cis	rs12136530	0.593	rs12403041	chr1:19730927	A/G	cg03321592	chr1:19991676	HTR6	0.5	4.32	0.33	2.84e-5	Lead levels in blood;
PAAD	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.54	5.43	0.4	2.18e-7	Caffeine consumption;
PAAD	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.95	11.75	0.69	4.45e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14480723	chr9:99417103	C9orf21	-0.69	-6.38	-0.46	2e-9	Neuroticism;
PAAD	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.56	5.99	0.44	1.49e-8	Menopause (age at onset);
PAAD	cis	rs2124910	0.967	rs4802801	chr19:52021250	G/C	cg12008991	chr19:52034861	SIGLEC6	0.34	4.47	0.34	1.5e-5	Blood protein levels;
PAAD	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.46	5.87	0.43	2.63e-8	Cystic fibrosis severity;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27297192	chr10:134578999	INPP5A	0.57	5.11	0.38	9.49e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.55	5.07	0.38	1.13e-6	Blood metabolite levels;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.88	-12.26	-0.71	1.88e-24	Vitiligo;
PAAD	cis	rs62408225	1.000	rs17513415	chr6:90947867	C/T	cg03795776	chr6:90687632	BACH2	0.45	4.48	0.34	1.47e-5	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg24733560	chr20:60626293	TAF4	0.44	5.34	0.4	3.37e-7	Body mass index;
PAAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.94	10.65	0.65	3.92e-20	Gestational age at birth (maternal effect);
PAAD	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.62	-0.35	8.18e-6	Resting heart rate;
PAAD	cis	rs7678296	1.000	rs16993292	chr4:37172194	A/T	cg06805348	chr4:37245195	KIAA1239	0.61	4.48	0.34	1.45e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.66	6.59	0.47	6.94e-10	Birth weight;
PAAD	cis	rs6445525	1.000	rs4416407	chr3:65995747	T/C	cg06109867	chr3:66002991	MAGI1	-0.47	-4.68	-0.35	6.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg24846343	chr22:24311635	DDTL	0.7	5.59	0.41	1.04e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg12756303	chr2:74692479	MOGS	-0.48	-4.33	-0.33	2.73e-5	Metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25367318	chr6:138725211	HEBP2	0.67	7.69	0.53	1.68e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.7	-0.42	6.15e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-7.37	-0.51	1.03e-11	Monocyte percentage of white cells;
PAAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	1.0	13.77	0.75	1.56e-28	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.6	5.53	0.41	1.39e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg01616529	chr11:638424	DRD4	-0.6	-5.1	-0.38	9.91e-7	Systemic lupus erythematosus;
PAAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.81	-7.99	-0.54	3.03e-13	Schizophrenia;
PAAD	cis	rs3106136	0.710	rs6825431	chr4:95312121	T/A	cg11021082	chr4:95130006	SMARCAD1	0.54	5.01	0.38	1.53e-6	Capecitabine sensitivity;
PAAD	cis	rs4740619	0.935	rs10756696	chr9:15725282	A/G	cg14451791	chr9:16040625	NA	-0.39	-4.47	-0.34	1.52e-5	Body mass index;
PAAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-9.02	-0.59	7.67e-16	Type 2 diabetes;
PAAD	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.56	5.21	0.39	5.93e-7	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.18e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.94	0.49	1.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-5.43	-0.4	2.22e-7	Pulmonary function;
PAAD	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg14092571	chr14:90743983	NA	-0.57	-5.55	-0.41	1.23e-7	Mortality in heart failure;
PAAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg16653408	chr22:42313569	NA	-0.4	-4.25	-0.33	3.76e-5	Cognitive function;
PAAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg27532560	chr4:187881888	NA	-0.55	-6.72	-0.48	3.39e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.59	6.96	0.49	9.46e-11	Aortic root size;
PAAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.85e-6	Type 2 diabetes;
PAAD	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.57	5.87	0.43	2.66e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.66	5.18	0.39	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05863116	chr5:133562407	PPP2CA	0.66	8.15	0.55	1.28e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.64	7.36	0.51	1.09e-11	Carotid intima media thickness;
PAAD	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.62	-6.02	-0.44	1.25e-8	Lymphocyte counts;
PAAD	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.45	4.36	0.33	2.36e-5	Lung cancer;
PAAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg03959625	chr15:84868606	LOC388152	-0.45	-4.75	-0.36	4.67e-6	P wave terminal force;
PAAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.52	5.13	0.38	8.84e-7	Platelet count;
PAAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00049323	chr5:472564	LOC25845	0.42	4.93	0.37	2.14e-6	Cystic fibrosis severity;
PAAD	cis	rs1697938	0.590	rs6895963	chr5:40938445	C/T	cg22359217	chr5:41925772	FBXO4	-0.46	-4.58	-0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg00666640	chr1:248458726	OR2T12	0.53	5.29	0.39	4.27e-7	Common traits (Other);
PAAD	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.64	-6.1	-0.44	8.24e-9	Asthma;
PAAD	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg21253087	chr9:139290292	SNAPC4	0.42	4.35	0.33	2.47e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.61	-5.93	-0.43	1.95e-8	Ear protrusion;
PAAD	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg08048268	chr3:133502702	NA	-0.49	-5.95	-0.43	1.82e-8	Iron status biomarkers;
PAAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.46	5.94	0.43	1.88e-8	Psoriasis;
PAAD	cis	rs4740619	0.504	rs2987041	chr9:16002540	C/T	cg14451791	chr9:16040625	NA	0.38	4.63	0.35	7.72e-6	Body mass index;
PAAD	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg09667013	chr22:42394590	WBP2NL	0.53	5.19	0.39	6.71e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs8018808	0.935	rs11627385	chr14:77936343	T/C	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.52	4.94	0.37	2e-6	Endometrial cancer;
PAAD	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.52	-5.5	-0.41	1.54e-7	Motion sickness;
PAAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.61	5.34	0.4	3.29e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.55	-4.66	-0.35	6.86e-6	Atopic dermatitis;
PAAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.52	5.52	0.41	1.46e-7	Lung cancer;
PAAD	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg15733309	chr7:157513707	PTPRN2	0.63	7.74	0.53	1.29e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.36	-0.46	2.22e-9	Bipolar disorder;
PAAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	4.28	0.33	3.31e-5	Personality dimensions;
PAAD	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.86	-11.17	-0.67	1.56e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg04398451	chr17:18023971	MYO15A	0.74	7.81	0.54	8.74e-13	Total body bone mineral density;
PAAD	cis	rs10804591	0.524	rs2811462	chr3:129303436	T/G	cg18548199	chr3:129281892	PLXND1	-0.66	-5.6	-0.41	9.96e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg11062466	chr8:58055876	NA	0.68	4.99	0.38	1.62e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21815550	chr5:107009036	NA	0.65	6.55	0.47	8.6e-10	Obesity-related traits;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.61	6.96	0.49	9.28e-11	Iron status biomarkers;
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.52	5.55	0.41	1.25e-7	Menarche (age at onset);
PAAD	trans	rs61931739	0.583	rs1873011	chr12:33752808	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.52	0.52	4.53e-12	Morning vs. evening chronotype;
PAAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	7.27	0.51	1.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.66	-7.07	-0.5	5.22e-11	Iron status biomarkers;
PAAD	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg15017067	chr4:17643749	FAM184B	0.41	4.91	0.37	2.29e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.92	8.11	0.55	1.58e-13	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23270550	chr11:134026861	NCAPD3	-0.66	-6.58	-0.47	7.24e-10	Obesity-related traits;
PAAD	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.62	5.98	0.44	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.51	-4.81	-0.36	3.54e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.66	5.67	0.42	6.94e-8	Menarche (age at onset);
PAAD	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.77	7.75	0.53	1.2e-12	Retinal vascular caliber;
PAAD	cis	rs3812111	0.545	rs1931895	chr6:116572971	C/G	cg05304507	chr6:116381966	FRK	-0.27	-4.56	-0.35	1.03e-5	Age-related macular degeneration;
PAAD	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.82	8.5	0.57	1.63e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.48	6.34	0.46	2.51e-9	Childhood ear infection;
PAAD	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg21951975	chr1:209979733	IRF6	-0.49	-4.84	-0.37	3.19e-6	Coronary artery disease;
PAAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.84	-9.08	-0.59	5.25e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	1.09	11.66	0.69	7.79e-23	Longevity;
PAAD	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.61	6.06	0.44	1e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-4.54	-0.35	1.14e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg06221963	chr1:154839813	KCNN3	-0.75	-7.75	-0.53	1.19e-12	Prostate cancer;
PAAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg16584676	chr17:46985605	UBE2Z	0.58	5.72	0.42	5.62e-8	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs7567389	0.534	rs2069904	chr2:128175779	G/A	cg11380483	chr2:127933992	NA	0.51	4.91	0.37	2.31e-6	Self-rated health;
PAAD	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.82	-0.62	6.17e-18	Response to antipsychotic treatment;
PAAD	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.61e-8	Migraine;
PAAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.75	-6.93	-0.49	1.11e-10	Coronary artery disease;
PAAD	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg00409905	chr10:38381863	ZNF37A	0.56	5.08	0.38	1.08e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4727443	0.866	rs12531809	chr7:99620473	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.61	0.35	8.59e-6	Interstitial lung disease;
PAAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15145965	chr22:50218605	BRD1	-0.55	-4.63	-0.35	7.73e-6	Schizophrenia;
PAAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	4.69	0.36	6.09e-6	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-9.09	-0.59	5.1e-16	Vitiligo;
PAAD	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.46	4.27	0.33	3.39e-5	HDL cholesterol;
PAAD	cis	rs877529	0.966	rs5995688	chr22:39548027	A/G	cg18708252	chr22:39545030	CBX7	-0.44	-4.25	-0.33	3.73e-5	Multiple myeloma;
PAAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg20356878	chr3:121714668	ILDR1	0.48	4.53	0.34	1.2e-5	Cognitive performance;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.85e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg21175976	chr8:11421337	BLK	-0.39	-4.28	-0.33	3.33e-5	Retinal vascular caliber;
PAAD	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.38	9.43	0.61	6.68e-17	Prostate cancer;
PAAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.55	5.37	0.4	2.86e-7	Tonsillectomy;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.6	-5.86	-0.43	2.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg10183150	chr4:120222239	C4orf3	-0.4	-5.58	-0.41	1.07e-7	Corneal astigmatism;
PAAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.46	-0.52	6.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-6.01	-0.44	1.32e-8	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6494488	0.500	rs72742950	chr15:64896397	T/C	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	1.0	8.72	0.58	4.49e-15	Alzheimer's disease;
PAAD	cis	rs73019876	0.502	rs28881618	chr19:22254692	G/A	cg08394602	chr19:22123885	NA	-0.46	-4.8	-0.36	3.74e-6	Testicular germ cell tumor;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16211334	chr6:10695274	C6orf52;PAK1IP1	0.54	6.42	0.46	1.67e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg22587600	chr2:46883368	NA	0.31	4.27	0.33	3.38e-5	Height;
PAAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg17541715	chr7:1216824	NA	-0.46	-5.22	-0.39	5.78e-7	Longevity;Endometriosis;
PAAD	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.06	-0.55	2.05e-13	Coffee consumption (cups per day);
PAAD	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.85	-5.39	-0.4	2.66e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs5750830	0.594	rs6001566	chr22:39774448	A/G	cg24399712	chr22:39784796	NA	-0.77	-8.67	-0.58	5.94e-15	Intelligence (multi-trait analysis);
PAAD	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.63	7.13	0.5	3.81e-11	Diastolic blood pressure;
PAAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.94	-0.37	2e-6	Bipolar disorder;
PAAD	cis	rs2997447	0.723	rs56241003	chr1:26435919	C/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs617219	0.737	rs12518949	chr5:78436755	C/G	cg24856658	chr5:78533917	JMY	-0.41	-4.51	-0.34	1.28e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs3779195	0.585	rs7777991	chr7:97865757	A/G	cg21770322	chr7:97807741	LMTK2	-0.54	-4.45	-0.34	1.68e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.04	11.67	0.69	7.35e-23	Breast cancer;
PAAD	cis	rs13102973	0.640	rs6829739	chr4:135835789	G/A	cg14419869	chr4:135874104	NA	0.45	4.64	0.35	7.4e-6	Subjective well-being;
PAAD	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.2e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.59	-6.07	-0.44	9.97e-9	Aortic root size;
PAAD	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.66	0.53	2.02e-12	Body mass index;
PAAD	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.67	8.46	0.57	2.05e-14	Prostate cancer;
PAAD	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.68	7.48	0.52	5.48e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg07212818	chr11:638076	DRD4	-0.76	-7.27	-0.51	1.73e-11	Systemic lupus erythematosus;
PAAD	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19882132	chr14:106167949	NA	-0.56	-4.98	-0.37	1.71e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11411865	chr7:2701802	TTYH3	0.59	4.32	0.33	2.77e-5	Bipolar disorder;
PAAD	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg15956490	chr3:53032818	SFMBT1	-0.77	-4.37	-0.33	2.31e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.81	8.5	0.57	1.66e-14	Selective IgA deficiency;
PAAD	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.52	5.19	0.39	6.59e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.26	0.39	4.79e-7	Myopia (pathological);
PAAD	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg05250797	chr16:70222502	NA	0.88	6.8	0.48	2.19e-10	IgE levels;
PAAD	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.92	-9.9	-0.63	3.85e-18	Parkinson's disease;
PAAD	cis	rs8016982	0.520	rs7160599	chr14:81713739	C/T	cg01989461	chr14:81687754	GTF2A1	0.57	4.25	0.33	3.64e-5	Schizophrenia;
PAAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.39	-4.34	-0.33	2.56e-5	Parkinson's disease;
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27436995	chr16:743998	FBXL16	-0.38	-4.59	-0.35	9.28e-6	Height;
PAAD	cis	rs6604026	0.656	rs9439948	chr1:93370800	A/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.57	-4.83	-0.36	3.29e-6	Total body bone mineral density;
PAAD	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg03989125	chr22:38214979	NA	0.53	4.64	0.35	7.42e-6	Fat distribution (HIV);
PAAD	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg05895507	chr15:77155635	SCAPER	-0.38	-4.7	-0.36	5.68e-6	Blood metabolite levels;
PAAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.81	10.04	0.63	1.64e-18	Height;
PAAD	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.61	0.41	9.42e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.45	0.4	1.99e-7	Lung cancer;
PAAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.69	7.7	0.53	1.61e-12	Height;
PAAD	trans	rs901683	0.850	rs80021398	chr10:46039383	A/G	cg12869334	chr8:37699360	GPR124	0.98	6.78	0.48	2.44e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg20607287	chr7:12443886	VWDE	-0.71	-5.53	-0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs950881	0.932	rs10173081	chr2:102957348	C/T	cg03938978	chr2:103052716	IL18RAP	0.53	4.37	0.33	2.27e-5	Allergy;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01307693	chr12:56615766	RNF41	0.59	6.7	0.48	3.73e-10	Monocyte percentage of white cells;
PAAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.83	-9.07	-0.59	5.65e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs4702	0.611	rs7177338	chr15:91428636	G/A	cg00630237	chr15:91433507	FES	0.5	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-5.35	-0.4	3.13e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg03115019	chr17:80708279	FN3K	0.5	4.49	0.34	1.41e-5	Glycated hemoglobin levels;
PAAD	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs457162	0.643	rs166881	chr6:118618981	T/C	cg21191810	chr6:118973309	C6orf204	0.71	4.61	0.35	8.45e-6	QT interval;
PAAD	cis	rs58521262	0.729	rs7256784	chr19:23063726	A/C	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg14515779	chr1:101123966	NA	0.52	5.83	0.43	3.19e-8	Breast cancer;
PAAD	trans	rs6694672	0.867	rs1764800	chr1:197250615	G/A	cg26994526	chr18:47719735	MYO5B	-0.84	-6.49	-0.47	1.17e-9	Asthma;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg04844267	chr4:1394941	NA	0.44	4.98	0.37	1.7e-6	Obesity-related traits;
PAAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13798912	chr7:905769	UNC84A	0.59	4.39	0.34	2.14e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.86	9.24	0.6	2.01e-16	Corneal astigmatism;
PAAD	cis	rs78761021	0.867	rs7223866	chr17:9785346	C/G	cg26853458	chr17:9805074	RCVRN	0.66	7.59	0.52	2.92e-12	Type 2 diabetes;
PAAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg27478167	chr7:817139	HEATR2	-0.64	-5.0	-0.38	1.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.66	5.93	0.43	1.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-4.36	-0.33	2.4e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.88	-0.49	1.43e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs42235	0.683	rs60814640	chr7:92286918	A/G	cg03496780	chr7:92466842	CDK6	0.47	4.6	0.35	8.7e-6	Hip circumference adjusted for BMI;Height;
PAAD	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg27565382	chr3:53032988	SFMBT1	0.78	4.41	0.34	1.93e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.08	15.64	0.79	1.85e-33	Multiple system atrophy;
PAAD	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg10932868	chr11:921992	NA	0.5	5.91	0.43	2.21e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2307111	0.501	rs253415	chr5:74957121	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.47	-4.39	-0.34	2.14e-5	Obesity;
PAAD	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.4	-4.44	-0.34	1.7e-5	Pubertal anthropometrics;
PAAD	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.52e-5	Electrocardiographic conduction measures;
PAAD	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.88	-11.1	-0.67	2.5e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7873102	0.568	rs4262388	chr9:38081261	T/C	cg03528946	chr9:38069800	SHB	-0.45	-4.31	-0.33	2.94e-5	Brain structure;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.37e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.57	5.38	0.4	2.78e-7	Blood metabolite levels;
PAAD	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg10820045	chr2:198174542	NA	0.44	4.42	0.34	1.87e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.7	6.93	0.49	1.14e-10	Coronary artery disease;
PAAD	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs939584	0.627	rs13028310	chr2:632591	T/C	cg14515364	chr2:636606	NA	0.53	4.82	0.36	3.46e-6	Body mass index;
PAAD	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.49	4.83	0.36	3.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.48	5.66	0.42	7.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.55	-5.15	-0.39	7.95e-7	Brugada syndrome;
PAAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.2	0.5	2.66e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg21823605	chr1:152486609	CRCT1	0.53	6.06	0.44	1.01e-8	Hair morphology;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15305352	chr6:41375881	NA	-0.67	-7.17	-0.5	3.09e-11	Obesity-related traits;
PAAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg20003494	chr4:90757398	SNCA	-0.68	-6.72	-0.48	3.5e-10	Neuroticism;
PAAD	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.46e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg00647820	chr17:40259828	DHX58	-0.41	-4.87	-0.37	2.81e-6	Fibrinogen levels;
PAAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.47	6.06	0.44	1.05e-8	Childhood ear infection;
PAAD	cis	rs1198430	0.562	rs10917384	chr1:23798312	C/A	cg19827787	chr1:23763612	ASAP3	0.49	4.53	0.35	1.16e-5	Total cholesterol levels;
PAAD	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg09324608	chr17:30823087	MYO1D	0.56	5.85	0.43	2.87e-8	Schizophrenia;
PAAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs6700896	0.966	rs3790439	chr1:66085574	T/A	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.58e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.85	0.37	2.97e-6	Bipolar disorder;
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00166722	chr3:10149974	C3orf24	0.78	7.09	0.5	4.75e-11	Alzheimer's disease;
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg01444501	chr16:343706	AXIN1	0.54	4.51	0.34	1.3e-5	Mean corpuscular volume;
PAAD	cis	rs16975963	0.644	rs73033129	chr19:38080535	G/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg10396713	chr8:602097	NA	-0.69	-4.88	-0.37	2.65e-6	IgG glycosylation;
PAAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2526932	0.625	rs2526896	chr14:73055107	C/T	cg13588403	chr14:73209128	DPF3	0.41	5.65	0.42	7.85e-8	C-reactive protein and white blood cell count;
PAAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.86	-0.49	1.64e-10	Monocyte count;
PAAD	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg06392426	chr19:10676186	KRI1	0.68	6.53	0.47	9.27e-10	Red cell distribution width;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.85	0.54	6.78e-13	Prudent dietary pattern;
PAAD	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.72	7.18	0.5	2.86e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg14926445	chr8:58193284	C8orf71	-0.55	-4.41	-0.34	1.94e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.76	-0.36	4.46e-6	Educational attainment (years of education);
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.66	4.46	0.34	1.62e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00941241	chr1:9885960	CLSTN1	0.47	6.51	0.47	1.04e-9	Metabolite levels  (X-11787);
PAAD	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.92	12.94	0.72	2.67e-26	Height;
PAAD	cis	rs6496667	0.600	rs3902286	chr15:91075375	A/G	cg22089800	chr15:90895588	ZNF774	-0.6	-4.77	-0.36	4.25e-6	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.81	10.35	0.64	2.48e-19	Vitiligo;
PAAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.85e-10	Neurofibrillary tangles;
PAAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg01851573	chr8:8652454	MFHAS1	0.45	4.33	0.33	2.7e-5	Schizophrenia;
PAAD	cis	rs11735070	0.595	rs10009433	chr4:100725626	A/G	cg10031042	chr4:101090547	NA	0.4	4.55	0.35	1.09e-5	Response to antipsychotic treatment;
PAAD	cis	rs4343996	0.807	rs6964838	chr7:3509969	A/G	cg21248987	chr7:3385318	SDK1	-0.5	-5.55	-0.41	1.21e-7	Motion sickness;
PAAD	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg03934865	chr2:198174659	NA	-0.46	-4.56	-0.35	1.05e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13198984	chr17:80129470	CCDC57	0.45	5.7	0.42	5.98e-8	Life satisfaction;
PAAD	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.42e-11	Total body bone mineral density;
PAAD	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.54	-4.68	-0.35	6.34e-6	Total body bone mineral density;
PAAD	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.54	5.86	0.43	2.76e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs41311933	0.901	rs41260544	chr9:123744252	A/G	cg13567360	chr9:123745713	C5	-0.71	-4.42	-0.34	1.87e-5	Coronary artery disease;
PAAD	cis	rs643506	0.874	rs673679	chr11:111686800	C/T	cg09085632	chr11:111637200	PPP2R1B	0.58	5.01	0.38	1.51e-6	Breast cancer;
PAAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg07617317	chr6:118971624	C6orf204	0.53	4.39	0.34	2.09e-5	Diastolic blood pressure;
PAAD	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-12.61	-0.71	2.12e-25	Primary sclerosing cholangitis;
PAAD	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.34	-0.46	2.54e-9	Alcohol dependence;
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	cis	rs8027181	0.583	rs2012253	chr15:73008123	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.66	5.57	0.41	1.14e-7	Triglyceride levels;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.43	-6.11	-0.44	8.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.13	-0.44	7.4e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.31	-0.4	3.85e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.84	5.89	0.43	2.36e-8	Height;
PAAD	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.48	-4.76	-0.36	4.4e-6	Pulmonary function;
PAAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	8.72	0.58	4.57e-15	Personality dimensions;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.49e-7	Life satisfaction;
PAAD	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg14829360	chr17:73884958	NA	-0.54	-5.74	-0.42	4.87e-8	White matter hyperintensity burden;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09653879	chr12:54673490	HNRNPA1;HNRPA1L-2;CBX5	-0.66	-6.3	-0.46	3.01e-9	Lung cancer in ever smokers;
PAAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.07	15.18	0.78	2.84e-32	Multiple system atrophy;
PAAD	cis	rs35160687	0.644	rs28488524	chr2:86511144	G/A	cg10973622	chr2:86423274	IMMT	-0.46	-5.11	-0.38	9.37e-7	Night sleep phenotypes;
PAAD	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg14851346	chr12:38532713	NA	-0.45	-4.27	-0.33	3.43e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2677744	0.597	rs16945091	chr15:91499081	A/T	cg23684204	chr15:91497937	RCCD1	0.67	5.32	0.4	3.58e-7	Attention deficit hyperactivity disorder;
PAAD	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.41	-0.46	1.71e-9	Morning vs. evening chronotype;
PAAD	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-1.0	-14.96	-0.77	1.13e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg08888203	chr3:10149979	C3orf24	0.68	6.21	0.45	4.87e-9	Alzheimer's disease;
PAAD	cis	rs7246760	1.000	rs7250487	chr19:9886358	T/C	cg16876255	chr19:9731953	ZNF561	0.93	4.59	0.35	9.12e-6	Pursuit maintenance gain;
PAAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.2	0.6	2.63e-16	Gut microbiome composition (summer);
PAAD	cis	rs17123764	0.710	rs7962645	chr12:50150939	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	4.36	0.33	2.41e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg23029597	chr12:123009494	RSRC2	-0.84	-7.73	-0.53	1.4e-12	Body mass index;
PAAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg21969647	chr13:114767023	RASA3	-0.56	-4.35	-0.33	2.52e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg13397359	chr6:42928475	GNMT	0.9	11.0	0.67	4.4e-21	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.2	0.6	2.7e-16	Bipolar disorder;
PAAD	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg03684893	chr10:554711	DIP2C	0.43	4.35	0.33	2.44e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.87	-0.62	4.49e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.43	-4.39	-0.34	2.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.79	-6.28	-0.45	3.34e-9	Initial pursuit acceleration;
PAAD	cis	rs9810890	1.000	rs73198875	chr3:128540286	C/T	cg15676455	chr3:128564943	NA	-0.88	-5.49	-0.41	1.68e-7	Dental caries;
PAAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.97	11.56	0.68	1.44e-22	Cognitive function;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.29	-0.45	3.23e-9	Bone mineral density;
PAAD	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.56	-5.98	-0.44	1.55e-8	Body mass index;
PAAD	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg22532475	chr10:104410764	TRIM8	-0.41	-4.73	-0.36	5.11e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg09376583	chr16:88111425	NA	-0.49	-4.36	-0.33	2.34e-5	Menopause (age at onset);
PAAD	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	8.45	0.57	2.24e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg11417675	chr11:73694801	UCP2	0.96	4.27	0.33	3.47e-5	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.66	-0.53	2e-12	Height;
PAAD	cis	rs375066	0.935	rs384522	chr19:44405044	A/T	cg21496419	chr19:44306685	LYPD5	0.41	4.9	0.37	2.47e-6	Breast cancer;
PAAD	cis	rs34526934	0.619	rs17336374	chr2:177068638	T/G	cg17278528	chr2:177005719	NA	-0.5	-4.48	-0.34	1.44e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.68	-5.22	-0.39	5.71e-7	Vitiligo;
PAAD	cis	rs400736	0.801	rs226474	chr1:8009763	A/G	cg25007680	chr1:8021821	PARK7	0.58	6.18	0.45	5.71e-9	Response to antidepressants and depression;
PAAD	cis	rs1371614	0.679	rs4441421	chr2:27142091	G/A	cg00617064	chr2:27272375	NA	-0.43	-4.45	-0.34	1.63e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.48	4.99	0.38	1.6e-6	Type 2 diabetes;
PAAD	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg22691776	chr3:15032403	NR2C2	0.3	4.33	0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	7.67	0.53	1.87e-12	Coronary artery disease;
PAAD	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.49	5.33	0.4	3.52e-7	Fibrinogen levels;
PAAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg17724175	chr1:150552817	MCL1	-0.54	-6.29	-0.45	3.14e-9	Tonsillectomy;
PAAD	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg26205652	chr12:48591994	NA	0.98	9.89	0.63	4.05e-18	Longevity (90 years and older);
PAAD	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.52	-5.13	-0.38	8.68e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg21918786	chr6:109611834	NA	-0.51	-5.41	-0.4	2.37e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.75	9.92	0.63	3.32e-18	Bone mineral density;
PAAD	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.73	-0.36	5.15e-6	Neuroticism;
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg12757816	chr2:10669957	NA	-0.53	-5.63	-0.42	8.62e-8	Prostate cancer;
PAAD	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.53	-4.65	-0.35	7.25e-6	Testicular germ cell tumor;
PAAD	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs7998202	0.614	rs668967	chr13:113369948	G/A	cg02820901	chr13:113351484	ATP11A	0.7	4.69	0.36	5.95e-6	Glycated hemoglobin levels;
PAAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.91	-0.37	2.36e-6	Recombination rate (females);
PAAD	cis	rs3947	0.544	rs8191604	chr8:11636884	T/G	cg00262122	chr8:11665843	FDFT1	-0.57	-4.56	-0.35	1.03e-5	Blood protein levels;
PAAD	trans	rs11794666	0.799	rs72717590	chr9:31737651	A/G	cg05628366	chr6:35744188	C6orf126	0.95	6.68	0.48	4.29e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-6.85	-0.49	1.74e-10	Migraine;Coronary artery disease;
PAAD	cis	rs28489187	0.683	rs2177461	chr1:85861976	C/G	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg21466736	chr12:48725269	NA	0.43	4.47	0.34	1.54e-5	Plateletcrit;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15450278	chr22:41322449	XPNPEP3	-0.61	-6.34	-0.46	2.5e-9	Obesity-related traits;
PAAD	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs11168618	0.904	rs11495273	chr12:48929190	A/T	cg01881778	chr12:48919444	OR8S1	-0.49	-4.93	-0.37	2.09e-6	Adiponectin levels;
PAAD	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.35	-5.14	-0.38	8.31e-7	DNA methylation (variation);
PAAD	cis	rs4919087	0.532	rs56189004	chr10:99086632	A/G	cg06569542	chr10:98946673	SLIT1	0.42	4.32	0.33	2.83e-5	Monocyte count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10659575	chr11:102188233	BIRC3	0.6	6.67	0.48	4.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg13560548	chr3:10150139	C3orf24	0.75	5.76	0.42	4.52e-8	Alzheimer's disease;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg00976097	chr5:421733	AHRR	-0.44	-4.39	-0.34	2.09e-5	Cystic fibrosis severity;
PAAD	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.05	11.42	0.68	3.44e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.6	4.89	0.37	2.54e-6	Iron status biomarkers;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg13903179	chr13:21900392	NA	0.63	7.11	0.5	4.2e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.56	-0.41	1.18e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs911119	0.955	rs8115423	chr20:23605253	T/C	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg03989125	chr22:38214979	NA	0.56	5.48	0.41	1.74e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs501120	1.000	rs694425	chr10:44761804	C/G	cg09554077	chr10:44749378	NA	0.42	5.46	0.41	1.88e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	9.35	0.6	1.05e-16	Platelet count;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2.03e-5	Life satisfaction;
PAAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.74	0.36	4.98e-6	Menopause (age at onset);
PAAD	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg00262122	chr8:11665843	FDFT1	0.47	4.39	0.34	2.1e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9463078	0.774	rs9357484	chr6:45265882	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.33	-0.4	3.48e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.03	6.77	0.48	2.6200000000000003e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-5.96	-0.44	1.72e-8	Body mass index;
PAAD	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.75	8.19	0.55	9.68e-14	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs4343996	0.967	rs7811244	chr7:3342276	G/A	cg21248987	chr7:3385318	SDK1	0.48	5.32	0.4	3.63e-7	Motion sickness;
PAAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg19163074	chr7:65112434	INTS4L2	0.44	4.36	0.33	2.36e-5	Aortic root size;
PAAD	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.86	-8.11	-0.55	1.61e-13	Colorectal adenoma (advanced);
PAAD	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.9	7.72	0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg21823605	chr1:152486609	CRCT1	0.51	5.67	0.42	6.82e-8	Hair morphology;
PAAD	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	1.1	12.76	0.72	8.24e-26	Blood trace element (Zn levels);
PAAD	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.77	7.6	0.52	2.81e-12	Birth weight;
PAAD	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-1.33	-10.66	-0.65	3.72e-20	Magnesium levels;
PAAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.38	0.4	2.7e-7	Bipolar disorder;
PAAD	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.22	-8.81	-0.58	2.69e-15	Lung cancer in ever smokers;
PAAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.69	-6.98	-0.49	8.79e-11	Mosquito bite size;
PAAD	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg14311320	chr7:124405732	GPR37	0.43	4.3	0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg21479132	chr6:26055353	NA	0.89	4.71	0.36	5.51e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.46	-0.57	2.12e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.82	7.96	0.54	3.75e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6066835	1.000	rs73136396	chr20:47337174	T/A	cg18078177	chr20:47281410	PREX1	0.97	4.69	0.36	6.14e-6	Multiple myeloma;
PAAD	cis	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg26695010	chr11:65641043	EFEMP2	-0.64	-5.64	-0.42	7.97e-8	Breast cancer;
PAAD	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.89	-8.47	-0.57	1.95e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7737355	0.812	rs2108870	chr5:131088486	C/T	cg06307176	chr5:131281290	NA	0.5	4.36	0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-5.84	-0.43	3.06e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs1879734	0.773	rs7518284	chr1:54150890	A/T	cg14659662	chr1:54151053	GLIS1	-0.4	-5.51	-0.41	1.47e-7	Mitral valve prolapse;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.55	-0.47	8.34e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.646	rs11153165	chr6:109622159	G/A	cg01475377	chr6:109611718	NA	-0.4	-4.3	-0.33	2.98e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.4	-4.84	-0.37	3.2e-6	Schizophrenia;
PAAD	cis	rs9888739	1.000	rs9938063	chr16:31302938	C/T	cg02256631	chr16:31342952	ITGAM	0.53	4.25	0.33	3.66e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg11062466	chr8:58055876	NA	0.72	5.3	0.39	4.05e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs61677309	1.000	rs56357739	chr11:118158507	A/G	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.39	4.48	0.34	1.44e-5	IgG glycosylation;
PAAD	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg10820045	chr2:198174542	NA	0.53	5.18	0.39	7.09e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg20848291	chr7:100343083	ZAN	-0.79	-6.63	-0.47	5.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.63	-7.14	-0.5	3.57e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.69	6.53	0.47	9.22e-10	Obesity-related traits;
PAAD	cis	rs939584	1.000	rs7567570	chr2:615140	T/C	cg03610516	chr2:642275	NA	0.64	5.65	0.42	7.56e-8	Body mass index;
PAAD	trans	rs1075265	0.563	rs2692537	chr2:54015977	C/T	cg16115072	chr17:25938812	KSR1	0.6	6.35	0.46	2.32e-9	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16851699	chr7:5938193	C7orf28A	0.64	6.55	0.47	8.23e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14846380	chr12:125333322	SCARB1	-0.64	-6.5	-0.47	1.11e-9	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg17325771	chr7:75508891	RHBDD2	0.3	4.27	0.33	3.38e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.77	0.36	4.27e-6	Corneal astigmatism;
PAAD	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.58	5.69	0.42	6.31e-8	Asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18001844	chr8:119220574	SAMD12	-0.54	-6.3	-0.46	3.07e-9	Monocyte percentage of white cells;
PAAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg05304507	chr6:116381966	FRK	0.39	7.3	0.51	1.49e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.48	5.28	0.39	4.47e-7	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.49	-4.43	-0.34	1.76e-5	Selective IgA deficiency;
PAAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.51	-6.5	-0.47	1.09e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6907629	0.965	rs723558	chr6:167578405	A/G	cg21144340	chr6:167633022	NA	-0.44	-4.3	-0.33	2.99e-5	Asthma (childhood onset);
PAAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.68	6.21	0.45	4.84e-9	Monocyte count;
PAAD	cis	rs10901513	0.860	rs10794048	chr10:127671152	A/G	cg22975853	chr10:127789788	ADAM12	0.42	4.5	0.34	1.32e-5	Visceral fat;
PAAD	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg01620082	chr3:125678407	NA	0.92	6.48	0.47	1.2e-9	Depression;
PAAD	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg14515779	chr1:101123966	NA	-0.55	-6.49	-0.47	1.14e-9	Monocyte count;
PAAD	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg13736514	chr6:26305472	NA	-0.56	-5.9	-0.43	2.26e-8	Educational attainment;
PAAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.74	-7.61	-0.53	2.67e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9463078	0.691	rs12209727	chr6:45353100	C/T	cg25276700	chr6:44698697	NA	0.53	6.05	0.44	1.1e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg12395012	chr8:11607386	GATA4	0.41	4.36	0.33	2.38e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19882132	chr14:106167949	NA	-0.54	-4.77	-0.36	4.35e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	4.49	0.34	1.39e-5	Total body bone mineral density;
PAAD	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.19	0.5	2.69e-11	Lung cancer in ever smokers;
PAAD	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.74	8.57	0.57	1.09e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.61	-5.51	-0.41	1.49e-7	Total body bone mineral density;
PAAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.16	0.39	7.51e-7	Electroencephalogram traits;
PAAD	cis	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.67	-4.29	-0.33	3.21e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-4.61	-0.35	8.37e-6	Sudden cardiac arrest;
PAAD	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg18964960	chr10:1102726	WDR37	0.88	4.49	0.34	1.38e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.53	5.4	0.4	2.51e-7	Resting heart rate;
PAAD	cis	rs7577696	0.962	rs7581340	chr2:32337391	C/T	cg02381751	chr2:32503542	YIPF4	-0.44	-4.73	-0.36	5.15e-6	Inflammatory biomarkers;
PAAD	cis	rs9880211	0.752	rs13062352	chr3:136464762	G/A	cg17177318	chr3:135913615	MSL2	0.57	4.31	0.33	2.95e-5	Body mass index;Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14847628	chr20:56935421	RAB22A	-0.64	-6.46	-0.46	1.37e-9	Obesity-related traits;
PAAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.95	7.58	0.52	3.09e-12	Type 2 diabetes;
PAAD	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.73	7.18	0.5	2.94e-11	Schizophrenia;
PAAD	cis	rs939584	0.935	rs6735049	chr2:630569	T/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-1.19	-10.35	-0.64	2.48e-19	Height;
PAAD	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg17514665	chr17:1657533	SERPINF2	0.66	6.06	0.44	1.02e-8	Serum albumin level;
PAAD	cis	rs7873102	0.654	rs10814641	chr9:38014695	G/A	cg03528946	chr9:38069800	SHB	-0.5	-4.98	-0.37	1.69e-6	Brain structure;
PAAD	cis	rs258892	0.739	rs11952024	chr5:72020195	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs7932354	0.617	rs2306035	chr11:46911457	T/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.9	-0.43	2.31e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.79	9.72	0.62	1.15e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08068101	chr14:35099282	SNX6	0.6	6.91	0.49	1.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9283706	0.623	rs3857275	chr5:66315536	T/C	cg11590213	chr5:66331682	MAST4	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.79	-6.1	-0.44	8.28e-9	Coronary artery disease;
PAAD	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.48	-7.74	-0.53	1.28e-12	Cutaneous nevi;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.65	-6.43	-0.46	1.54e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9467160	0.834	rs10946701	chr6:24453878	T/A	cg16211469	chr6:24423932	MRS2	0.48	4.44	0.34	1.71e-5	Liver enzyme levels;
PAAD	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.63	6.74	0.48	3.03e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.15e-12	Calcium levels;
PAAD	cis	rs9936833	1.000	rs9936833	chr16:86403118	C/T	cg03554962	chr16:86404423	NA	0.38	4.38	0.33	2.22e-5	Barrett's esophagus;
PAAD	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.66	-7.2	-0.5	2.53e-11	Schizophrenia;
PAAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22442454	chr1:209979470	IRF6	0.39	4.37	0.33	2.31e-5	Monobrow;
PAAD	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg04907244	chr7:22894795	SNORD93	-0.38	-4.37	-0.33	2.31e-5	Fibrinogen;
PAAD	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.74	-8.5	-0.57	1.64e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs10949834	1.000	rs34346732	chr7:73485813	G/A	cg07137043	chr7:73588983	EIF4H	-0.58	-4.27	-0.33	3.49e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg22868518	chr11:507468	RNH1	-0.85	-4.52	-0.34	1.23e-5	Body mass index;
PAAD	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg10395934	chr14:104002654	TRMT61A	-0.54	-5.75	-0.42	4.75e-8	Body mass index;
PAAD	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.55	5.24	0.39	5.36e-7	Type 2 diabetes;
PAAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	10.66	0.65	3.72e-20	Smoking behavior;
PAAD	cis	rs1497828	0.912	rs2810764	chr1:217573645	T/C	cg04411442	chr1:217543379	NA	0.5	4.92	0.37	2.23e-6	Dialysis-related mortality;
PAAD	cis	rs3112530	0.901	rs304861	chr5:152719262	T/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.95	-0.43	1.78e-8	Mood instability;
PAAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.5	5.03	0.38	1.36e-6	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14867121	chr4:146297077	NA	-0.47	-6.37	-0.46	2.11e-9	Monocyte percentage of white cells;
PAAD	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg15145965	chr22:50218605	BRD1	0.61	5.24	0.39	5.26e-7	Schizophrenia;
PAAD	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.98	-10.46	-0.65	1.23e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2834288	0.500	rs7277248	chr21:35330251	T/C	cg22542663	chr21:34915757	GART;SON	0.43	4.35	0.33	2.51e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	1.15	7.79	0.53	9.97e-13	Pediatric areal bone mineral density (radius);
PAAD	cis	rs258892	0.793	rs34657	chr5:72148196	G/A	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.95	10.02	0.63	1.83e-18	Multiple sclerosis;
PAAD	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.67	5.51	0.41	1.47e-7	Prostate cancer;
PAAD	cis	rs11264799	0.639	rs6677622	chr1:157751356	C/T	cg18268488	chr1:157545234	FCRL4	0.54	4.75	0.36	4.62e-6	IgA nephropathy;
PAAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	1.08	7.41	0.51	8.32e-12	IgG glycosylation;
PAAD	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13047869	chr3:10149882	C3orf24	0.82	6.77	0.48	2.67e-10	Alzheimer's disease;
PAAD	cis	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg20159608	chr7:32802032	NA	-0.6	-6.19	-0.45	5.36e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.73	5.63	0.42	8.32e-8	Morning vs. evening chronotype;
PAAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.69	7.11	0.5	4.28e-11	Type 2 diabetes;
PAAD	cis	rs12476592	0.602	rs262503	chr2:63860437	G/A	cg10828910	chr2:63850056	LOC388955	0.5	4.26	0.33	3.6e-5	Childhood ear infection;
PAAD	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.91	9.11	0.59	4.4e-16	Corneal astigmatism;
PAAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.58	7.18	0.5	2.92e-11	Blood pressure (smoking interaction);
PAAD	cis	rs7552167	0.636	rs4090311	chr1:24513768	G/A	cg01960748	chr1:24522592	NA	-0.64	-4.48	-0.34	1.49e-5	Psoriasis vulgaris;
PAAD	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg27490568	chr2:178487706	NA	0.43	4.76	0.36	4.52e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.49	-4.5	-0.34	1.35e-5	Neutrophil percentage of white cells;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07790342	chr6:166919277	RPS6KA2	0.66	7.96	0.54	3.76e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs17407555	0.789	rs12648610	chr4:10114812	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.04	-0.38	1.29e-6	Schizophrenia (age at onset);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19306036	chr2:11758995	GREB1	0.65	6.53	0.47	9.5e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.94	-0.37	2.03e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10991814	0.920	rs16907323	chr9:94025459	A/G	cg14446406	chr9:93919335	NA	0.54	4.54	0.35	1.15e-5	Neutrophil percentage of granulocytes;
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.43	4.91	0.37	2.3e-6	Cystic fibrosis severity;
PAAD	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.62	6.35	0.46	2.37e-9	Birth weight;
PAAD	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs508970	0.556	rs530087	chr11:60914535	G/A	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg11003645	chr6:143382007	AIG1	-0.6	-6.5	-0.47	1.11e-9	Educational attainment (years of education);
PAAD	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16417436	chr16:28758564	NA	0.47	4.4	0.34	2.06e-5	Body mass index;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.91	8.7	0.58	4.95e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-9.41	-0.61	7.55e-17	Alzheimer's disease (late onset);
PAAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs1577917	0.559	rs2223788	chr6:86811920	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-7.07	-0.5	5.13e-11	Response to antipsychotic treatment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24640577	chr1:246939216	NA	0.64	7.46	0.52	6.21e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.65	7.72	0.53	1.45e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.83	6.98	0.49	8.54e-11	Pulmonary function decline;
PAAD	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs11811982	0.793	rs116045808	chr1:227420480	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.67	-0.62	1.57e-17	Blood trace element (Zn levels);
PAAD	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg10290764	chr8:4849399	CSMD1	-0.39	-6.56	-0.47	7.79e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.46	4.87	0.37	2.78e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.84	7.72	0.53	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.7	-8.03	-0.55	2.43e-13	Morning vs. evening chronotype;
PAAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg11271282	chr2:238384023	NA	0.7	4.33	0.33	2.66e-5	Prostate cancer;
PAAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.72	7.02	0.5	6.76e-11	Mood instability;
PAAD	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.63	0.42	8.49e-8	Ileal carcinoids;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.73	7.73	0.53	1.38e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.75	-7.86	-0.54	6.73e-13	Type 2 diabetes;
PAAD	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.85	7.16	0.5	3.22e-11	Initial pursuit acceleration;
PAAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs89107	0.688	rs422833	chr6:118608971	T/C	cg21191810	chr6:118973309	C6orf204	0.46	6.3	0.46	3.04e-9	Cardiac structure and function;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg06815965	chr1:205818668	PM20D1	0.65	7.37	0.51	9.92e-12	Menarche (age at onset);
PAAD	cis	rs1419980	0.730	rs11054820	chr12:7766021	G/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	6.86	0.49	1.6e-10	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs1018697	1.000	rs6584525	chr10:104551981	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.51	-5.21	-0.39	6e-7	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg14019146	chr3:50243930	SLC38A3	-0.57	-5.91	-0.43	2.15e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs922692	1.000	rs12901913	chr15:78981348	C/T	cg00540400	chr15:79124168	NA	-0.43	-4.8	-0.36	3.68e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg00280220	chr17:61926910	NA	0.44	4.67	0.35	6.69e-6	Prudent dietary pattern;
PAAD	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.86	10.64	0.65	4.03e-20	Coronary artery disease;
PAAD	cis	rs7180079	1.000	rs2062249	chr15:64672159	C/A	cg18210365	chr15:65066710	RBPMS2	0.68	4.93	0.37	2.12e-6	Monocyte count;
PAAD	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs1012068	0.662	rs11703779	chr22:32322384	T/C	cg01338084	chr22:32026380	PISD	0.57	5.12	0.38	9.07e-7	Chronic hepatitis C infection;
PAAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.36e-8	Prudent dietary pattern;
PAAD	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	5.26	0.39	4.87e-7	Total body bone mineral density;
PAAD	cis	rs1359582	0.757	rs1555842	chr10:90403071	G/A	cg15661332	chr10:90342814	RNLS	0.56	4.86	0.37	2.86e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg19223190	chr17:80058835	NA	-0.55	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.69	-6.47	-0.46	1.3e-9	Fractional excretion of uric acid;
PAAD	cis	rs4908768	0.520	rs7520025	chr1:8698277	C/T	cg20416874	chr1:8611966	RERE	-0.44	-4.26	-0.33	3.55e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4591517	1.000	rs11713229	chr3:23141765	A/G	cg00327796	chr3:23032191	NA	0.48	4.74	0.36	4.9e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16345521	chr12:107486801	CRY1	-0.69	-6.86	-0.49	1.63e-10	Smoking initiation;
PAAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-6.61	-0.47	6.18e-10	Bipolar disorder;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg15117754	chr3:10150083	C3orf24	0.55	5.15	0.39	7.9e-7	Alzheimer's disease;
PAAD	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg02297831	chr4:17616191	MED28	0.6	5.74	0.42	5.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1545257	0.505	rs11125570	chr2:24629577	G/A	cg02683114	chr2:24398427	C2orf84	-0.46	-4.85	-0.37	3.07e-6	Sjögren's syndrome;
PAAD	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9463078	0.565	rs10948183	chr6:44880881	T/C	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg14196790	chr5:131705035	SLC22A5	0.44	4.7	0.36	5.71e-6	Breast cancer;
PAAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs4668356	1.000	rs60730419	chr2:172025173	T/C	cg13882835	chr2:172017928	TLK1	0.92	4.51	0.34	1.27e-5	Cognitive performance;
PAAD	cis	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg22863700	chr5:28928346	NA	0.53	4.99	0.38	1.65e-6	Hip geometry;
PAAD	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.52	4.41	0.34	1.96e-5	Diastolic blood pressure;
PAAD	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-5.28	-0.39	4.35e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.02	-0.38	1.44e-6	Mood instability;
PAAD	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.65	6.53	0.47	9.45e-10	Primary sclerosing cholangitis;
PAAD	cis	rs735539	0.521	rs693814	chr13:21422910	A/T	cg27234864	chr13:21295941	IL17D	0.59	4.79	0.36	3.95e-6	Dental caries;
PAAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.82	9.41	0.61	7.23e-17	Methadone dose in opioid dependence;
PAAD	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.99	10.14	0.64	9.01e-19	Post bronchodilator FEV1;
PAAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg00431813	chr7:1051703	C7orf50	0.79	5.02	0.38	1.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.6	-5.46	-0.4	1.94e-7	Mean corpuscular volume;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00088026	chr12:117628347	FBXO21	-0.56	-6.4	-0.46	1.8e-9	Body fat percentage;
PAAD	cis	rs12799264	1.000	rs2625310	chr11:19974600	C/G	cg17303119	chr11:19974895	NAV2	-0.66	-4.4	-0.34	2e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.54	4.36	0.33	2.38e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4336470	0.547	rs9499924	chr6:105142638	C/G	cg02098413	chr6:105308735	HACE1	-0.41	-5.05	-0.38	1.24e-6	Neuroblastoma;
PAAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.68	0.53	1.81e-12	Prudent dietary pattern;
PAAD	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.64	4.47	0.34	1.53e-5	Cognitive test performance;
PAAD	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg05211768	chr15:91427848	FES	0.38	4.27	0.33	3.42e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.71	-6.75	-0.48	3e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.76	7.95	0.54	3.99e-13	Gout;
PAAD	cis	rs1867485	0.612	rs300029	chr16:86678875	A/G	cg04242078	chr16:86527164	NA	0.46	4.86	0.37	2.9e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.91	10.72	0.66	2.54e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs2882667	0.690	rs825769	chr5:138115355	G/A	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg02734326	chr4:10020555	SLC2A9	0.5	5.03	0.38	1.36e-6	Bone mineral density;
PAAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-0.53	-5.48	-0.41	1.73e-7	White blood cell count;
PAAD	cis	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg01631684	chr10:65280961	REEP3	-0.45	-4.58	-0.35	9.74e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2124910	0.717	rs7255948	chr19:52006563	T/C	cg14953197	chr19:52005651	SIGLEC12	0.49	5.24	0.39	5.2e-7	Blood protein levels;
PAAD	cis	rs2455601	0.744	rs2568085	chr11:8975748	G/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.49	-4.4	-0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.71	0.42	5.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6715793	0.869	rs4671010	chr2:33432858	A/C	cg26672287	chr2:33391915	LTBP1	-0.4	-4.62	-0.35	8.18e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg20487152	chr13:99095054	FARP1	0.6	5.26	0.39	4.78e-7	Neuroticism;
PAAD	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.83	-5.97	-0.44	1.65e-8	Facial morphology (factor 23);
PAAD	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.52	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg06307176	chr5:131281290	NA	0.55	4.88	0.37	2.67e-6	Life satisfaction;
PAAD	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.61	0.53	2.69e-12	Mean platelet volume;
PAAD	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.59e-5	Skin colour saturation;
PAAD	cis	rs12432203	1.000	rs58700439	chr14:51740421	T/G	cg23942311	chr14:51606299	NA	-0.79	-5.2	-0.39	6.38e-7	Cancer;
PAAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg09835421	chr16:68378352	PRMT7	-0.86	-6.89	-0.49	1.41e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg06375148	chr1:209958343	C1orf74	0.63	5.47	0.41	1.84e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24729792	chr2:113192114	RGPD8;RGPD5	0.57	4.68	0.36	6.18e-6	Yeast infection;
PAAD	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.21	0.6	2.46e-16	Cognitive test performance;
PAAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01616529	chr11:638424	DRD4	-0.58	-5.74	-0.42	4.89e-8	Systemic lupus erythematosus;
PAAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.77	-8.94	-0.59	1.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.87	-7.39	-0.51	9.32e-12	Vitiligo;
PAAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-6.52	-0.47	9.73e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23957911	chr4:2758084	TNIP2	-0.55	-6.54	-0.47	8.71e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	1.1	7.77	0.53	1.07e-12	Mitochondrial DNA levels;
PAAD	cis	rs74161807	0.610	rs2420314	chr10:118398658	C/T	cg10511988	chr10:118891706	VAX1	0.38	4.45	0.34	1.67e-5	Loneliness (multivariate analysis);Loneliness;
PAAD	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg10011062	chr15:43941034	CATSPER2	-0.82	-4.81	-0.36	3.66e-6	Lung cancer in ever smokers;
PAAD	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.9	11.32	0.68	6.12e-22	Metabolic syndrome;
PAAD	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg21823605	chr1:152486609	CRCT1	0.53	6.0	0.44	1.4e-8	Hair morphology;
PAAD	cis	rs2275565	0.872	rs3768153	chr1:237053645	C/T	cg17297354	chr1:237056641	MTR	-0.51	-4.51	-0.34	1.28e-5	Homocysteine levels;
PAAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.47	-5.12	-0.38	8.98e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-6.37	-0.46	2.12e-9	Height;
PAAD	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.84	4.81	0.36	3.66e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg06632027	chr4:90757378	SNCA	-0.58	-5.21	-0.39	6e-7	Neuroticism;
PAAD	cis	rs8121916	1.000	rs6033409	chr20:12410127	T/C	cg16404259	chr20:12988931	SPTLC3	-0.42	-4.28	-0.33	3.31e-5	Tumor necrosis factor alpha levels;
PAAD	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	4.53	0.34	1.2e-5	Iron status biomarkers;
PAAD	cis	rs7577696	0.925	rs212716	chr2:32460934	A/G	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.78e-6	Inflammatory biomarkers;
PAAD	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg05791153	chr7:19748676	TWISTNB	0.66	4.72	0.36	5.21e-6	Thyroid stimulating hormone;
PAAD	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg23461800	chr14:103021989	NA	-0.56	-4.29	-0.33	3.12e-5	Platelet count;
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03812309	chr1:46938281	NA	0.31	4.25	0.33	3.69e-5	High light scatter reticulocyte count;
PAAD	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.83	7.6	0.52	2.77e-12	Colorectal adenoma (advanced);
PAAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.7	7.83	0.54	7.69e-13	Melanoma;
PAAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.61	4.75	0.36	4.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs655641	0.539	rs636355	chr11:85724661	T/C	cg07180834	chr11:85838833	NA	-0.47	-5.16	-0.39	7.47e-7	Platelet count;
PAAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.69	7.32	0.51	1.31e-11	Obesity-related traits;
PAAD	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.66	-5.92	-0.43	2.07e-8	Mortality in heart failure;
PAAD	cis	rs114540395	0.858	rs116357148	chr10:103352082	T/A	cg21381511	chr10:104264849	SUFU	-0.86	-4.49	-0.34	1.42e-5	Schizophrenia;
PAAD	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.85	9.1	0.59	4.79e-16	Body mass index;
PAAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.57	-0.41	1.11e-7	Personality dimensions;
PAAD	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-4.95	-0.37	1.92e-6	Coronary artery disease;
PAAD	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-6.71	-0.48	3.7e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.49	-5.61	-0.41	9.37e-8	Coronary artery disease;
PAAD	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg12615879	chr12:58013172	SLC26A10	0.45	4.82	0.36	3.52e-6	Multiple sclerosis;
PAAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.68	-5.33	-0.4	3.55e-7	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.07	0.55	1.95e-13	Height;
PAAD	cis	rs12773846	0.522	rs7099522	chr10:126251518	A/G	cg04949429	chr10:126290192	LHPP	0.52	4.46	0.34	1.56e-5	Subcutaneous adipose tissue;
PAAD	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg09184832	chr6:79620586	NA	0.49	5.1	0.38	9.99e-7	Left atrial antero-posterior diameter;
PAAD	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.45	-5.54	-0.41	1.28e-7	Lewy body disease;
PAAD	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.58	5.51	0.41	1.51e-7	HDL cholesterol;
PAAD	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.68e-7	Type 2 diabetes;
PAAD	cis	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-1.04	-11.41	-0.68	3.63e-22	Lymphocyte counts;
PAAD	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.57	-8.02	-0.55	2.58e-13	Rheumatoid arthritis;
PAAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg06221963	chr1:154839813	KCNN3	0.49	4.3	0.33	3.04e-5	Atrial fibrillation;
PAAD	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.54	-5.33	-0.4	3.54e-7	Ulcerative colitis;
PAAD	cis	rs7542091	0.518	rs6675416	chr1:210061006	A/G	cg21951975	chr1:209979733	IRF6	-0.43	-5.4	-0.4	2.48e-7	Monobrow;
PAAD	cis	rs8099014	0.861	rs4245270	chr18:56112854	A/G	cg12907477	chr18:56117327	MIR122	0.65	5.02	0.38	1.45e-6	Platelet count;
PAAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-5.1	-0.38	1.02e-6	Lung cancer;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.84	9.88	0.63	4.3e-18	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	5.35	0.4	3.12e-7	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20574550	chr3:125876169	ALDH1L1	0.59	7.2	0.5	2.59e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs16858868	0.519	rs4682066	chr3:111680304	A/G	cg27125107	chr3:112117797	NA	0.39	4.32	0.33	2.86e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg18370025	chr7:2749541	AMZ1	-0.39	-4.67	-0.35	6.68e-6	Height;
PAAD	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-13.33	-0.73	2.43e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg26248373	chr2:1572462	NA	-1.04	-9.45	-0.61	5.93e-17	IgG glycosylation;
PAAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.63	-6.2	-0.45	5.06e-9	Blood metabolite levels;
PAAD	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.78	-9.25	-0.6	1.98e-16	Personality dimensions;
PAAD	cis	rs9377188	0.593	rs6935330	chr6:149401560	G/T	cg21368479	chr6:149415018	NA	0.4	4.35	0.33	2.44e-5	Cancer;
PAAD	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.5	6.67e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.48	0.47	1.21e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.53	-6.01	-0.44	1.33e-8	Stearic acid (18:0) levels;
PAAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.58	5.13	0.38	8.88e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg13446199	chr8:143762866	PSCA	0.37	4.36	0.33	2.34e-5	Urinary tract infection frequency;
PAAD	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.61	6.5	0.47	1.07e-9	Morning vs. evening chronotype;
PAAD	cis	rs4281086	0.582	rs4543507	chr8:10354324	T/C	cg01072821	chr8:10382165	T-SP1	-0.42	-4.54	-0.35	1.15e-5	Obesity-related traits;
PAAD	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.61	4.98	0.37	1.73e-6	Alzheimer's disease (late onset);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg02756231	chr15:31122726	NA	0.56	6.54	0.47	8.78e-10	Energy expenditure (24h);
PAAD	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19596204	chr19:18548583	ISYNA1	0.65	7.69	0.53	1.71e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg14393609	chr7:65229607	NA	-0.44	-4.38	-0.33	2.23e-5	Aortic root size;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11073926	chr1:43855438	MED8;C1orf84	0.68	6.58	0.47	7.17e-10	Primary biliary cholangitis;
PAAD	cis	rs6604026	0.922	rs11164825	chr1:93311707	C/T	cg17283838	chr1:93427260	FAM69A	0.52	4.35	0.33	2.45e-5	Multiple sclerosis;
PAAD	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.69	7.61	0.53	2.68e-12	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.13	-0.55	1.42e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	5.47	0.41	1.82e-7	Mean platelet volume;
PAAD	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.58	-4.98	-0.37	1.73e-6	Fibrinogen levels;
PAAD	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.05	0.55	2.23e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg13010199	chr12:38710504	ALG10B	0.61	5.2	0.39	6.43e-7	Morning vs. evening chronotype;
PAAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg19630374	chr17:18023558	MYO15A	-0.46	-4.79	-0.36	3.89e-6	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-6.08	-0.44	9.24e-9	Breast cancer;
PAAD	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg27211696	chr2:191398769	TMEM194B	0.45	4.54	0.35	1.12e-5	Urinary metabolites;
PAAD	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2271001	0.910	rs3802798	chr11:19182348	A/G	cg00161556	chr11:19138045	ZDHHC13	-0.53	-5.6	-0.41	9.67e-8	Gut microbiome composition (winter);
PAAD	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.99	-0.37	1.65e-6	Type 2 diabetes;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.18	-0.5	2.93e-11	Longevity;
PAAD	cis	rs564309	0.764	rs12096217	chr1:228534452	C/T	cg01328119	chr1:228783545	DUSP5P	0.73	4.28	0.33	3.29e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-5.94	-0.43	1.87e-8	Obesity (extreme);
PAAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg07153921	chr17:41440717	NA	-0.42	-4.46	-0.34	1.57e-5	Menopause (age at onset);
PAAD	cis	rs10490913	0.583	rs853927	chr10:120155750	A/T	cg04126427	chr10:120840676	EIF3A	0.43	4.26	0.33	3.52e-5	Cancer;
PAAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.67	-0.72	1.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-4.69	-0.36	6.1e-6	Obesity-related traits;
PAAD	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-1.04	-9.95	-0.63	2.8e-18	Prostate cancer;
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.6	-5.74	-0.42	4.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.16	0.39	7.51e-7	Electroencephalogram traits;
PAAD	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.64	9.17	0.6	3.09e-16	IgG glycosylation;
PAAD	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.54	-6.15	-0.45	6.51e-9	Lung cancer;
PAAD	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg23950597	chr19:37808831	NA	-0.73	-4.84	-0.37	3.18e-6	Coronary artery calcification;
PAAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg14092988	chr3:52407081	DNAH1	0.46	5.74	0.42	4.99e-8	Bipolar disorder;
PAAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.71	-0.42	5.83e-8	Schizophrenia;
PAAD	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg25952890	chr19:58913133	NA	0.7	5.36	0.4	2.99e-7	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26224574	chr8:74319976	NA	-0.61	-6.33	-0.46	2.62e-9	Obesity-related traits;
PAAD	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-1.21	-11.97	-0.7	1.11e-23	Platelet count;
PAAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-5.98	-0.44	1.5e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg00179576	chr16:74483694	GLG1	-0.39	-4.36	-0.33	2.36e-5	Testicular germ cell tumor;
PAAD	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-5.1	-0.38	1e-6	Common traits (Other);
PAAD	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg23649088	chr2:200775458	C2orf69	-0.69	-5.56	-0.41	1.16e-7	Schizophrenia;
PAAD	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.57	4.91	0.37	2.38e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs2147959	0.941	rs1886774	chr1:228633718	C/T	cg00655913	chr1:228633920	NA	0.47	4.35	0.33	2.49e-5	Adult asthma;
PAAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.62	6.95	0.49	1e-10	Multiple sclerosis;
PAAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11401866	chr7:75932851	HSPB1	-0.73	-6.42	-0.46	1.66e-9	Neuroticism;
PAAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.67	-5.55	-0.41	1.24e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.94	-11.02	-0.67	4.11e-21	Coronary artery disease;
PAAD	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.04	-0.38	1.32e-6	Fear of minor pain;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15900387	chr1:150738905	CTSS	-0.62	-6.55	-0.47	8.6e-10	Obesity-related traits;
PAAD	cis	rs2730260	0.611	rs73169221	chr7:158846316	T/A	cg02254261	chr7:158964346	NA	-0.6	-4.63	-0.35	7.7e-6	Myopia (pathological);
PAAD	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.64	-0.35	7.57e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.65	-5.55	-0.41	1.23e-7	Menarche (age at onset);
PAAD	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	1.07	14.99	0.77	9.43e-32	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20679309	chr2:238969453	SCLY	0.58	6.5	0.47	1.09e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.54	-6.26	-0.45	3.75e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg24375607	chr4:120327624	NA	0.53	5.05	0.38	1.23e-6	Corneal astigmatism;
PAAD	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	7.16	0.5	3.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.58	5.29	0.39	4.15e-7	Breast cancer;
PAAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg22815214	chr1:201083145	CACNA1S	0.65	6.57	0.47	7.65e-10	Permanent tooth development;
PAAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg01475735	chr3:40494733	NA	0.47	4.52	0.34	1.23e-5	Renal cell carcinoma;
PAAD	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg17551891	chr7:1960795	MAD1L1	-0.51	-4.68	-0.35	6.41e-6	Neuroticism;
PAAD	cis	rs9815354	0.716	rs73828280	chr3:41833907	A/T	cg03022575	chr3:42003672	ULK4	0.92	6.52	0.47	9.98e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg21929781	chr1:2537748	MMEL1	0.53	5.7	0.42	6.03e-8	Ulcerative colitis;
PAAD	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.85	-0.37	3.08e-6	Height;
PAAD	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg10483660	chr13:112241077	NA	0.54	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg12092346	chr18:77659572	KCNG2	-0.6	-4.39	-0.34	2.07e-5	Opioid sensitivity;
PAAD	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg15798862	chr7:76129360	DTX2	-0.52	-6.97	-0.49	9.06e-11	Multiple sclerosis;
PAAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.8	0.81	1.82e-36	Schizophrenia;
PAAD	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.24	-0.51	2.06e-11	Aortic root size;
PAAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.09	0.38	1.02e-6	Aortic root size;
PAAD	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.53	-5.2	-0.39	6.37e-7	Multiple myeloma;
PAAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.51	5.39	0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	4.72	0.36	5.4e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg24642439	chr20:33292090	TP53INP2	0.73	4.29	0.33	3.15e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.7	7.2	0.5	2.58e-11	Asperger disorder;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.8	0.62	6.9e-18	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09192760	chr19:54606228	NDUFA3	-0.64	-6.74	-0.48	3.02e-10	Smoking initiation;
PAAD	cis	rs9581857	0.547	rs9581871	chr13:28085767	G/A	cg22138327	chr13:27999177	GTF3A	0.83	5.45	0.4	2.01e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.08	0.38	1.11e-6	Multiple sclerosis or amyotrophic lateral sclerosis;
PAAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.59	6.19	0.45	5.28e-9	Obesity-related traits;
PAAD	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg02415014	chr8:143852576	LYNX1	0.39	4.55	0.35	1.07e-5	Urinary tract infection frequency;
PAAD	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg08704217	chr1:110036942	CYB561D1	0.49	4.43	0.34	1.82e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	6.5	0.47	1.11e-9	Hip circumference;
PAAD	cis	rs10958369	0.934	rs11779758	chr8:54414731	C/T	cg12485204	chr8:54507357	NA	0.44	4.35	0.33	2.52e-5	Response to antineoplastic agents;
PAAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg20517616	chr2:26468218	HADHA;HADHB	-0.59	-4.3	-0.33	3.1e-5	Gut microbiome composition (summer);
PAAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg13814708	chr10:81144099	ZCCHC24	-0.39	-4.29	-0.33	3.19e-5	Height;
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12923728	chr3:195709715	SDHAP1	-0.87	-9.15	-0.6	3.59e-16	Pancreatic cancer;
PAAD	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-4.95	-0.37	1.91e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12136530	0.651	rs12141760	chr1:19717901	C/T	cg25104613	chr1:20649108	VWA5B1	-0.37	-4.28	-0.33	3.33e-5	Lead levels in blood;
PAAD	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg02404636	chr22:31891804	SFI1	-0.58	-5.22	-0.39	5.85e-7	Colorectal cancer;
PAAD	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.64	6.92	0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg05717871	chr11:638507	DRD4	-0.58	-4.98	-0.37	1.67e-6	Systemic lupus erythematosus;
PAAD	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.9	8.91	0.59	1.49e-15	Pulmonary function decline;
PAAD	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs4704187	0.640	rs4704183	chr5:74471048	C/G	cg03227963	chr5:74354835	NA	0.49	4.71	0.36	5.55e-6	Response to amphetamines;
PAAD	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.61	-7.67	-0.53	1.92e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg04257695	chr17:30186438	C17orf79	-0.63	-5.03	-0.38	1.38e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg05187833	chr6:17706939	NUP153	0.66	6.41	0.46	1.77e-9	Primary biliary cholangitis;
PAAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-4.59	-0.35	9.24e-6	Inflammatory bowel disease;
PAAD	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg17366294	chr4:99064904	C4orf37	0.45	5.01	0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg07701084	chr6:150067640	NUP43	-0.55	-4.83	-0.36	3.31e-6	Lung cancer;
PAAD	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.31e-7	Migraine;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.15	-0.39	8.07e-7	Neuroticism;
PAAD	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg00945038	chr17:61921165	SMARCD2	0.51	6.35	0.46	2.35e-9	Prudent dietary pattern;
PAAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.41	0.34	1.91e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg19980929	chr12:42632907	YAF2	0.52	5.98	0.44	1.52e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs16944613	0.510	rs4476150	chr15:91147214	G/A	cg15547629	chr15:90437138	AP3S2	-0.5	-4.31	-0.33	2.94e-5	Colorectal cancer;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg04160749	chr8:58172571	NA	-0.61	-4.42	-0.34	1.85e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13072611	chr3:133524485	SRPRB	0.63	6.48	0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2637266	0.783	rs7900420	chr10:78476543	T/C	cg18941641	chr10:78392320	NA	0.36	4.38	0.33	2.2e-5	Pulmonary function;
PAAD	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs1982963	0.627	rs2073626	chr14:52488385	A/G	cg20550154	chr14:52487779	NID2	0.6	5.02	0.38	1.46e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.75	-6.22	-0.45	4.68e-9	Neuroticism;
PAAD	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.4	0.4	2.49e-7	Heart rate;
PAAD	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17376030	chr22:41985996	PMM1	-0.63	-4.35	-0.33	2.46e-5	Vitiligo;
PAAD	cis	rs2717559	0.568	rs35093407	chr8:143885501	G/A	cg02415014	chr8:143852576	LYNX1	0.42	5.61	0.41	9.48e-8	Urinary tract infection frequency;
PAAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.81	-8.41	-0.56	2.7e-14	DNA methylation (variation);
PAAD	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.51	4.78	0.36	4.03e-6	Malaria;
PAAD	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg26031613	chr14:104095156	KLC1	0.51	5.58	0.41	1.07e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.73	4.4	0.34	2.06e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01944302	chr16:894789	NA	0.6	6.63	0.47	5.51e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.48	7.09	0.5	4.81e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.79	-8.62	-0.57	8.33e-15	Menopause (age at onset);
PAAD	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg03938978	chr2:103052716	IL18RAP	0.67	8.43	0.56	2.49e-14	Asthma;
PAAD	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.43	-0.4	2.16e-7	Pulmonary function;
PAAD	cis	rs1870805	0.580	rs4736126	chr8:140991284	C/T	cg15997020	chr8:140990656	TRAPPC9	-0.66	-6.51	-0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.63e-5	Alzheimer's disease (survival time);
PAAD	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10547527	chr2:198650123	BOLL	0.49	4.4	0.34	2.03e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.14	-0.5	3.58e-11	Life satisfaction;
PAAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg05082376	chr22:42548792	NA	0.51	5.61	0.41	9.47e-8	Cognitive function;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg19536664	chr17:6899085	ALOX12	0.56	6.17	0.45	5.99e-9	Tonsillectomy;
PAAD	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.04	-13.44	-0.74	1.2100000000000001e-27	Schizophrenia;
PAAD	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg05484376	chr2:27715224	FNDC4	0.45	4.41	0.34	1.97e-5	Oral cavity cancer;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.93	8.14	0.55	1.35e-13	Alzheimer's disease;
PAAD	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06307176	chr5:131281290	NA	-0.52	-4.69	-0.36	6.1e-6	Life satisfaction;
PAAD	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.18	0.39	6.92e-7	Motion sickness;
PAAD	cis	rs2017305	0.749	rs7476854	chr10:70788552	A/G	cg25290552	chr10:70751067	KIAA1279	-0.84	-5.28	-0.39	4.36e-7	Depression (quantitative trait);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09433780	chr3:57262354	APPL1	0.67	7.45	0.52	6.37e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg15181151	chr6:150070149	PCMT1	0.56	5.61	0.41	9.23e-8	Lung cancer;
PAAD	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.49	6.96	0.49	9.72e-11	Homoarginine levels;
PAAD	cis	rs508970	0.556	rs7925800	chr11:60890869	A/G	cg24692310	chr11:60915630	VPS37C	0.31	4.31	0.33	2.89e-5	Rheumatoid arthritis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19019804	chr17:72919384	OTOP2;USH1G	-0.54	-6.39	-0.46	1.96e-9	Body fat percentage;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.85	7.08	0.5	4.99e-11	Alzheimer's disease;
PAAD	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.55	6.23	0.45	4.35e-9	Tumor biomarkers;
PAAD	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.66	-5.22	-0.39	5.73e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	5.11	0.38	9.74e-7	Colorectal cancer;
PAAD	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs9657904	0.813	rs4243427	chr3:105559821	T/C	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.59	0.41	1.04e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	1.37	8.11	0.55	1.58e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.51	4.74	0.36	4.77e-6	Sudden cardiac arrest;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.89	-10.33	-0.64	2.87e-19	Iron status biomarkers;
PAAD	cis	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg00400743	chr4:148603008	PRMT10	-0.71	-4.48	-0.34	1.48e-5	Pulse pressure;
PAAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg10544611	chr16:67998164	SLC12A4	-0.61	-4.31	-0.33	2.96e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.67	-4.8	-0.36	3.8e-6	LDL cholesterol levels;
PAAD	cis	rs9372149	0.532	rs9486549	chr6:107497837	C/T	cg26808436	chr6:108492696	NR2E1	0.32	4.67	0.35	6.45e-6	Childhood and early adolescence aggressive behavior;
PAAD	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-4.28	-0.33	3.24e-5	Height;
PAAD	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg18551225	chr6:44695536	NA	0.62	5.75	0.42	4.64e-8	Total body bone mineral density;
PAAD	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-4.41	-0.34	1.97e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-4.59	-0.35	9.08e-6	Homocysteine levels;
PAAD	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.47	4.75	0.36	4.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.83	-9.64	-0.62	1.88e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg13918804	chr1:2043761	PRKCZ	0.43	5.7	0.42	5.97e-8	Height;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.76	-7.57	-0.52	3.33e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs2019216	0.500	rs4325621	chr17:21926257	T/G	cg22648282	chr17:21454238	C17orf51	-0.59	-6.04	-0.44	1.15e-8	Pelvic organ prolapse;
PAAD	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg15226275	chr6:116381976	FRK	0.4	7.46	0.52	6.15e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs1419980	0.730	rs7959013	chr12:7741453	G/A	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs10746514	0.768	rs11122427	chr1:232261085	C/T	cg09506761	chr1:232265262	NA	-0.44	-4.51	-0.34	1.28e-5	Response to statin therapy;
PAAD	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg17347104	chr14:75034677	LTBP2	-0.49	-4.86	-0.37	2.85e-6	Caffeine consumption;
PAAD	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg21191810	chr6:118973309	C6orf204	-0.52	-7.3	-0.51	1.53e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.68	-0.36	6.24e-6	Breast cancer;
PAAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.71	9.53	0.61	3.62e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.61	6.26	0.45	3.65e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg27494647	chr7:150038898	RARRES2	-0.43	-4.52	-0.34	1.24e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.52	0.52	4.54e-12	Breast cancer;
PAAD	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.7	5.04	0.38	1.29e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15258722	chr13:110802573	COL4A1	-0.63	-6.41	-0.46	1.74e-9	Obesity-related traits;
PAAD	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.65	5.5	0.41	1.57e-7	Lymphocyte counts;
PAAD	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13870426	chr17:30244630	NA	0.66	6.31	0.46	2.88e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1371614	0.592	rs12613534	chr2:27138594	C/A	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9398803	0.723	rs1101556	chr6:127067803	T/G	cg19875578	chr6:126661172	C6orf173	-0.43	-4.46	-0.34	1.57e-5	Male-pattern baldness;
PAAD	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg02135003	chr7:105160482	PUS7	-0.68	-5.65	-0.42	7.51e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg24633833	chr3:10029261	TMEM111	-0.58	-4.29	-0.33	3.14e-5	Alzheimer's disease;
PAAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.54	5.02	0.38	1.46e-6	Type 2 diabetes;
PAAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg18769074	chr3:133464867	TF	0.43	4.93	0.37	2.14e-6	Iron status biomarkers;
PAAD	cis	rs5756391	0.546	rs1807546	chr22:37311425	A/C	cg21209356	chr22:37319042	CSF2RB	0.37	4.56	0.35	1.05e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4481887	0.508	rs6666148	chr1:248402758	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-4.82	-0.36	3.4e-6	Common traits (Other);
PAAD	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.55	-5.57	-0.41	1.13e-7	Testicular germ cell tumor;
PAAD	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	1.07	14.3	0.76	6.1e-30	Testicular germ cell tumor;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg23130651	chr10:22604242	COMMD3	-0.52	-6.31	-0.46	2.91e-9	Energy expenditure (24h);
PAAD	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg26816564	chr1:7831052	VAMP3	0.63	5.16	0.39	7.48e-7	Inflammatory bowel disease;
PAAD	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.76	-9.32	-0.6	1.26e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.19	-0.39	6.52e-7	Mosquito bite size;
PAAD	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.53	5.67	0.42	6.96e-8	Tonsillectomy;
PAAD	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.39	4.62	0.35	8e-6	Uric acid levels;
PAAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.04	0.5	6.08e-11	Rheumatoid arthritis;
PAAD	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.84	-0.43	3.06e-8	Height;
PAAD	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.79	9.21	0.6	2.4e-16	Morning vs. evening chronotype;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg19223106	chr19:58898630	RPS5	0.6	6.77	0.48	2.63e-10	Immature fraction of reticulocytes;
PAAD	cis	rs7220401	0.515	rs8080772	chr17:28413129	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.5	-4.47	-0.34	1.51e-5	Coronary artery disease;
PAAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs1925576	0.871	rs7902684	chr10:68670217	T/A	cg04444303	chr10:69634106	NA	-0.44	-4.38	-0.33	2.17e-5	Educational attainment (years of education);
PAAD	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg17372223	chr3:52568218	NT5DC2	-0.47	-4.46	-0.34	1.61e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3106136	0.678	rs11944941	chr4:95298169	C/T	cg11021082	chr4:95130006	SMARCAD1	0.54	5.04	0.38	1.31e-6	Capecitabine sensitivity;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25838125	chr15:52263597	LEO1	0.58	6.67	0.48	4.48e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg21269045	chr12:125625041	AACS	-0.47	-4.6	-0.35	8.85e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.49	4.84	0.37	3.21e-6	Testicular germ cell tumor;
PAAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg14703610	chr5:56206110	C5orf35	0.61	5.64	0.42	8.12e-8	Coronary artery disease;
PAAD	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.69	6.51	0.47	1.01e-9	Cleft lip with or without cleft palate;
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.72e-5	Prostate cancer;
PAAD	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg00666640	chr1:248458726	OR2T12	0.64	5.39	0.4	2.7e-7	Common traits (Other);
PAAD	cis	rs11816922	0.655	rs17401052	chr10:6909353	C/T	cg02181080	chr10:7564424	NA	0.81	4.56	0.35	1.04e-5	Migraine;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	1.11	16.91	0.81	9.4e-37	Menarche (age at onset);
PAAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.45	6.2	0.45	5.02e-9	Vitiligo;
PAAD	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg21419209	chr3:44054225	NA	-0.73	-7.29	-0.51	1.6e-11	Coronary artery disease;
PAAD	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.63	7.06	0.5	5.59e-11	Resting heart rate;
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg11335335	chr11:637885	DRD4	-0.37	-4.82	-0.36	3.44e-6	Systemic lupus erythematosus;
PAAD	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.49	5.44	0.4	2.08e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs72772090	0.539	rs72773986	chr5:96159717	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.85	-6.24	-0.45	4.08e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.46	4.63	0.35	7.7e-6	Obesity-related traits;
PAAD	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg08036796	chr19:5034282	KDM4B	0.46	4.44	0.34	1.7e-5	Monocyte percentage of white cells;
PAAD	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg13512537	chr8:22265999	SLC39A14	-0.42	-4.33	-0.33	2.69e-5	Verbal declarative memory;
PAAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg14349672	chr11:133703707	NA	-0.55	-5.97	-0.44	1.63e-8	Childhood ear infection;
PAAD	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.95	0.49	1.01e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.51	4.95	0.37	1.95e-6	Hirschsprung disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20250874	chr13:47127354	LRCH1	0.63	7.13	0.5	3.82e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg20673091	chr1:2541236	MMEL1	0.74	7.83	0.54	7.66e-13	Ulcerative colitis;
PAAD	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg10290764	chr8:4849399	CSMD1	-0.41	-6.81	-0.48	2.14e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg22907277	chr7:1156413	C7orf50	0.92	4.88	0.37	2.67e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg03948781	chr1:205179583	DSTYK	0.46	4.27	0.33	3.44e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs17407555	0.657	rs10013452	chr4:10276990	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	4.96	0.37	1.86e-6	Schizophrenia (age at onset);
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.97	0.54	3.44e-13	Eotaxin levels;
PAAD	cis	rs12257961	0.675	rs1914548	chr10:15345755	G/A	cg10616319	chr10:15468812	NA	-0.44	-4.25	-0.33	3.74e-5	Selective IgA deficiency;
PAAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.66	4.41	0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs9810890	1.000	rs73198826	chr3:128487388	T/C	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2637266	0.846	rs752006	chr10:78393136	G/T	cg18941641	chr10:78392320	NA	0.37	4.39	0.34	2.11e-5	Pulmonary function;
PAAD	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.58	-0.61	2.7e-17	Monocyte percentage of white cells;
PAAD	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg27119904	chr13:114814333	RASA3	0.41	4.51	0.34	1.27e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg12440380	chr16:67515168	ATP6V0D1	0.74	4.32	0.33	2.84e-5	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20661083	chr17:75211786	SEC14L1	-0.65	-6.77	-0.48	2.67e-10	Obesity-related traits;
PAAD	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg01620082	chr3:125678407	NA	-1.6	-9.93	-0.63	3.11e-18	Depression;
PAAD	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.49	-5.26	-0.39	4.79e-7	Vitamin D levels;
PAAD	cis	rs3737883	1.000	rs2275354	chr1:203036757	T/C	cg03900565	chr1:203031815	PPFIA4	0.35	5.93	0.43	1.96e-8	Early onset atrial fibrillation;
PAAD	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.5	-5.41	-0.4	2.36e-7	Coronary artery disease;
PAAD	cis	rs6043979	0.543	rs11087166	chr20:16406601	G/A	cg11932837	chr20:16553912	KIF16B	-0.63	-4.25	-0.33	3.71e-5	Intelligence;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19272144	chr3:64404616	NA	-0.64	-6.54	-0.47	8.78e-10	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg19682013	chr15:45996608	NA	0.32	4.27	0.33	3.39e-5	Waist circumference;Weight;
PAAD	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg23860436	chr12:58378763	NA	0.46	4.26	0.33	3.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-4.29	-0.33	3.18e-5	Circulating chemerin levels;
PAAD	cis	rs11159086	1.000	rs58384818	chr14:74953748	G/A	cg10195687	chr14:74926396	NA	-0.46	-4.88	-0.37	2.66e-6	Advanced glycation end-product levels;
PAAD	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg00250761	chr1:31883323	NA	-0.54	-6.24	-0.45	4.14e-9	Alcohol dependence;
PAAD	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg01028140	chr2:1542097	TPO	-0.9	-8.23	-0.56	7.86e-14	IgG glycosylation;
PAAD	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13515842	chr9:127215440	GPR144	-0.44	-4.76	-0.36	4.42e-6	Menarche (age at onset);
PAAD	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-1.27	-10.06	-0.63	1.46e-18	Obesity-related traits;
PAAD	cis	rs7945718	0.621	rs10831888	chr11:12665604	T/C	cg25843174	chr11:12811716	TEAD1	0.3	4.35	0.33	2.52e-5	Educational attainment (years of education);
PAAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg07959070	chr22:50026188	C22orf34	-0.36	-4.36	-0.33	2.36e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	4.98	0.37	1.69e-6	Educational attainment;
PAAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.2	-0.39	6.35e-7	Obesity-related traits;
PAAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	trans	rs901683	1.000	rs12779637	chr10:46081096	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02071572	chr4:1403502	NA	-0.48	-6.1	-0.44	8.51e-9	Obesity-related traits;
PAAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg02917321	chr22:38215204	NA	0.48	4.81	0.36	3.65e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs943466	1.000	rs751096	chr6:33742838	C/T	cg04704449	chr6:33738291	NA	0.47	4.56	0.35	1.03e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.61	6.38	0.46	1.99e-9	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.14	0.55	1.34e-13	Menopause (age at onset);
PAAD	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.51	5.0	0.38	1.56e-6	Mean corpuscular volume;
PAAD	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7923837	0.687	rs10882101	chr10:94462427	T/C	cg25093409	chr10:94429542	NA	0.4	4.38	0.33	2.21e-5	Body mass index;Multiple sclerosis;
PAAD	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg04398451	chr17:18023971	MYO15A	-0.78	-9.02	-0.59	7.44e-16	Total body bone mineral density;
PAAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg10587741	chr22:38071170	LGALS1	0.61	6.83	0.48	1.92e-10	Fat distribution (HIV);
PAAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.84	-6.48	-0.47	1.21e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	5.28	0.39	4.44e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.55	-0.35	1.09e-5	Mean corpuscular volume;
PAAD	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg03999872	chr20:62272968	STMN3	0.65	5.97	0.44	1.58e-8	Atopic dermatitis;
PAAD	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.54	-0.35	1.15e-5	Fear of minor pain;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11896211	chr11:820192	PNPLA2	0.57	6.56	0.47	7.8e-10	Metabolite levels  (X-11787);
PAAD	cis	rs308971	0.572	rs307559	chr3:12094965	G/T	cg02700894	chr3:12045449	SYN2	0.62	5.27	0.39	4.49e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.72	-0.36	5.2e-6	Breast cancer;
PAAD	trans	rs901683	1.000	rs901684	chr10:45966628	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.71e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.9	-7.42	-0.52	7.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.69	7.7	0.53	1.62e-12	Melanoma;
PAAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg19761014	chr17:28927070	LRRC37B2	0.92	6.27	0.45	3.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.5	4.86	0.37	2.93e-6	Common traits (Other);
PAAD	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg02404636	chr22:31891804	SFI1	-0.61	-5.53	-0.41	1.33e-7	Colorectal cancer;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.5	-0.41	1.57e-7	Bladder cancer;
PAAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.84	7.73	0.53	1.39e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs9907295	0.551	rs28595279	chr17:34153420	G/T	cg19411729	chr17:34207663	CCL5	-0.53	-4.74	-0.36	4.92e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05041596	chr11:89867385	NAALAD2	0.71	5.84	0.43	3.07e-8	White blood cell types;
PAAD	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-1.07	-7.48	-0.52	5.52e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.77	9.01	0.59	7.93e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.83	8.67	0.58	6.04e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19859290	chr11:20618399	NA	0.32	4.54	0.35	1.12e-5	Pursuit maintenance gain;
PAAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.09	8.67	0.58	5.89e-15	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.54	-5.13	-0.38	8.86e-7	Schizophrenia;
PAAD	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.23	17.24	0.81	1.36e-37	Schizophrenia;
PAAD	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg19875578	chr6:126661172	C6orf173	-0.47	-5.08	-0.38	1.1e-6	Male-pattern baldness;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5009270	0.512	rs62474618	chr7:112159829	G/A	cg23628563	chr7:112262597	NA	0.56	4.7	0.36	5.9e-6	Osteoarthritis (hip);
PAAD	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg08898775	chr15:59042684	ADAM10	0.4	4.96	0.37	1.89e-6	Asperger disorder;
PAAD	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg01028140	chr2:1542097	TPO	-1.08	-7.58	-0.52	3.08e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7755729	0.967	rs6917532	chr6:129788658	G/A	cg14315006	chr6:129823454	LAMA2	-0.42	-4.25	-0.33	3.76e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg14146966	chr2:61757674	XPO1	0.41	5.04	0.38	1.32e-6	Tuberculosis;
PAAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.51	4.83	0.36	3.26e-6	Blood metabolite levels;
PAAD	cis	rs11105468	0.695	rs61926989	chr12:90443360	G/A	cg16962463	chr12:89968675	NA	0.45	4.74	0.36	4.89e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs12780845	1.000	rs56394211	chr10:17186447	C/T	cg00857480	chr10:17188594	TRDMT1	0.38	4.88	0.37	2.65e-6	Homocysteine levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04969067	chr8:143858791	LYNX1	0.58	6.39	0.46	1.97e-9	Monocyte percentage of white cells;
PAAD	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg06217071	chr17:408420	NA	-0.58	-5.5	-0.41	1.55e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.55	5.29	0.39	4.2e-7	Testicular germ cell tumor;
PAAD	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg05805236	chr11:65401703	PCNXL3	-0.45	-5.08	-0.38	1.1e-6	Systemic lupus erythematosus;
PAAD	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs881827	0.851	rs55863940	chr21:48011048	A/T	cg14789911	chr21:47582049	C21orf56	-0.45	-4.33	-0.33	2.71e-5	Lymphocyte counts;
PAAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.66	-9.9	-0.63	3.82e-18	Longevity;Endometriosis;
PAAD	cis	rs3206736	0.548	rs59505449	chr7:35065852	T/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.54	-0.35	1.12e-5	Diastolic blood pressure;
PAAD	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.89	10.42	0.65	1.58e-19	Resting heart rate;
PAAD	cis	rs300774	0.858	rs300736	chr2:168466	C/G	cg23649280	chr2:140451	NA	-0.5	-4.5	-0.34	1.36e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.76	-7.27	-0.51	1.77e-11	Asthma;
PAAD	cis	rs7580658	0.963	rs62160261	chr2:128152661	G/T	cg09760422	chr2:128146352	NA	-0.44	-7.29	-0.51	1.57e-11	Protein C levels;
PAAD	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-6.96	-0.49	9.29e-11	Body mass index (adult);
PAAD	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.6	-5.79	-0.43	3.92e-8	Mean corpuscular volume;
PAAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.51	-0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg00490450	chr3:139108681	COPB2	0.66	5.89	0.43	2.41e-8	Obesity-related traits;
PAAD	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.03	-10.86	-0.66	1.06e-20	Ulcerative colitis;
PAAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1190596	0.525	rs28565231	chr14:102663248	C/T	cg23289024	chr14:102554846	HSP90AA1	0.36	4.35	0.33	2.44e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.75	-7.01	-0.49	7.14e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03909097	chr20:30555528	XKR7	0.67	6.49	0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs12767760	0.669	rs10748699	chr10:99306501	A/G	cg25247692	chr10:99313390	UBTD1	-0.59	-5.71	-0.42	5.67e-8	Obesity-related traits;
PAAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.05	0.38	1.27e-6	Rheumatoid arthritis;
PAAD	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.49	-4.61	-0.35	8.63e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.16	17.6	0.82	1.68e-38	Prudent dietary pattern;
PAAD	cis	rs7714584	1.000	rs11950957	chr5:150253914	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	6.4	0.46	1.79e-9	Body mass index;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.03e-8	Lung cancer;
PAAD	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.73	8.33	0.56	4.44e-14	Alcohol dependence;
PAAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.75	8.17	0.55	1.11e-13	Colorectal cancer;
PAAD	cis	rs1879734	0.953	rs3013768	chr1:54156434	G/A	cg14659662	chr1:54151053	GLIS1	0.42	6.76	0.48	2.72e-10	Mitral valve prolapse;
PAAD	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.61	-6.99	-0.49	8.26e-11	Schizophrenia;
PAAD	cis	rs1882538	0.504	rs6951416	chr7:133092278	A/G	cg10665199	chr7:133106180	EXOC4	0.67	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00292662	chr22:38071168	LGALS1	0.5	4.45	0.34	1.66e-5	Fat distribution (HIV);
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.83	0.43	3.25e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.54	7.12	0.5	3.91e-11	Primary biliary cholangitis;
PAAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg27121462	chr16:89883253	FANCA	0.8	4.67	0.35	6.54e-6	Skin colour saturation;
PAAD	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.76	-9.49	-0.61	4.49e-17	Motion sickness;
PAAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.66	-5.29	-0.39	4.13e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs2999052	1.000	rs9873786	chr3:127942379	C/T	cg18206867	chr2:62422351	B3GNT2	0.46	6.47	0.46	1.26e-9	Hypospadias;
PAAD	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.91	0.37	2.3e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7534824	0.625	rs12561853	chr1:101457863	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.66	-4.7	-0.36	5.77e-6	Refractive astigmatism;
PAAD	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.62	-5.56	-0.41	1.16e-7	Tonsillectomy;
PAAD	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.95	-10.4	-0.64	1.84e-19	Parkinson's disease;
PAAD	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	1.03	7.03	0.5	6.5500000000000006e-11	Alzheimer's disease (late onset);
PAAD	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	5.78	0.42	4.09e-8	Response to antipsychotic treatment;
PAAD	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg18196295	chr10:418757	DIP2C	0.44	4.69	0.36	6.02e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.9	-6.02	-0.44	1.24e-8	Systolic blood pressure;
PAAD	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.55e-15	Chronic sinus infection;
PAAD	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg07952391	chr2:88470173	THNSL2	-0.48	-4.75	-0.36	4.73e-6	Response to metformin (IC50);
PAAD	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg14196790	chr5:131705035	SLC22A5	0.46	4.94	0.37	2.06e-6	Blood metabolite levels;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00166722	chr3:10149974	C3orf24	0.72	6.52	0.47	9.74e-10	Alzheimer's disease;
PAAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.19	-0.45	5.42e-9	Hypospadias;
PAAD	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.53	5.58	0.41	1.08e-7	Selective IgA deficiency;
PAAD	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.74	-7.42	-0.52	7.68e-12	Uric acid levels;
PAAD	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.95	12.5	0.71	4.11e-25	Menopause (age at onset);
PAAD	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg17351974	chr5:40835760	RPL37	0.78	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.49	-0.61	4.7e-17	Alzheimer's disease (late onset);
PAAD	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg02683114	chr2:24398427	C2orf84	-0.55	-5.65	-0.42	7.52e-8	Asthma;
PAAD	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-1.14	-4.85	-0.37	3.04e-6	Blood metabolite levels;
PAAD	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.54	4.82	0.36	3.39e-6	Testicular germ cell tumor;
PAAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.77	-8.89	-0.58	1.63e-15	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.87	7.88	0.54	5.86e-13	Coronary artery disease;
PAAD	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg02887458	chr19:19495540	GATAD2A	0.53	5.05	0.38	1.24e-6	Bipolar disorder;
PAAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg21625146	chr5:486483	SLC9A3	0.37	5.43	0.4	2.19e-7	Cystic fibrosis severity;
PAAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.6	7.47	0.52	5.98e-12	Multiple system atrophy;
PAAD	cis	rs1879734	0.815	rs1780392	chr1:54175302	C/T	cg14659662	chr1:54151053	GLIS1	0.39	6.25	0.45	3.85e-9	Mitral valve prolapse;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15538428	chr4:733510	PCGF3	-0.62	-6.33	-0.46	2.6e-9	Obesity-related traits;
PAAD	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg19025524	chr12:109796872	NA	-0.53	-4.87	-0.37	2.76e-6	Neuroticism;
PAAD	cis	rs10875746	0.729	rs11168357	chr12:48412138	G/A	cg26205652	chr12:48591994	NA	0.88	8.41	0.56	2.72e-14	Longevity (90 years and older);
PAAD	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs75920871	0.841	rs7112967	chr11:116831912	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-4.38	-0.34	2.16e-5	Subjective well-being;
PAAD	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg23506979	chr15:79090958	ADAMTS7	-0.25	-4.29	-0.33	3.2e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	5.14	0.38	8.27e-7	Menarche (age at onset);
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg16083429	chr3:49237500	CCDC36	0.45	4.35	0.33	2.49e-5	Menarche (age at onset);
PAAD	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg02887458	chr19:19495540	GATAD2A	-0.6	-5.52	-0.41	1.41e-7	Bipolar disorder;
PAAD	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg10395934	chr14:104002654	TRMT61A	0.51	4.97	0.37	1.75e-6	Body mass index;
PAAD	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.46	-4.41	-0.34	1.98e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs17032980	0.866	rs10181214	chr2:67306395	G/A	cg06994420	chr2:66672553	MEIS1	-0.5	-4.45	-0.34	1.66e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg00531865	chr16:30841666	NA	-0.5	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg19264203	chr11:92714893	MTNR1B	0.4	4.56	0.35	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.51	5.03	0.38	1.38e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs308971	0.656	rs307563	chr3:12055011	G/T	cg02700894	chr3:12045449	SYN2	0.6	5.11	0.38	9.4e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.65	5.98	0.44	1.5e-8	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.98	0.44	1.56e-8	Prudent dietary pattern;
PAAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-5.18	-0.39	6.83e-7	Tonsillectomy;
PAAD	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg19980929	chr12:42632907	YAF2	0.57	6.58	0.47	7.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.52	-4.86	-0.37	2.93e-6	Inflammatory biomarkers;
PAAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs11811982	0.793	rs77116170	chr1:227577717	C/A	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg15145965	chr22:50218605	BRD1	0.59	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.97	-6.0	-0.44	1.4e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	5.77	0.42	4.27e-8	Eosinophil percentage of white cells;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs904092	0.671	rs6532811	chr4:100156892	A/C	cg12011299	chr4:100065546	ADH4	-0.47	-4.31	-0.33	2.87e-5	Alcohol dependence;
PAAD	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg18944383	chr4:111397179	ENPEP	-0.78	-7.92	-0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs4388249	0.687	rs2416218	chr5:109072212	G/C	cg17395555	chr5:108820864	NA	0.31	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg03264133	chr6:25882463	NA	0.43	4.25	0.33	3.76e-5	Schizophrenia;
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg03209412	chr4:183728196	NA	0.93	7.77	0.53	1.07e-12	Pediatric autoimmune diseases;
PAAD	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02556042	chr12:117471086	NA	0.49	5.04	0.38	1.3e-6	Subcortical brain region volumes;Hippocampal volume;
PAAD	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.71	8.42	0.56	2.56e-14	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9346353	0.663	rs1902650	chr6:70433527	T/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.41	-0.34	1.95e-5	Sleep duration;
PAAD	cis	rs528301	0.555	rs7584428	chr2:45128493	A/G	cg15393275	chr2:45165193	NA	-0.46	-4.76	-0.36	4.45e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.36	0.33	2.36e-5	Height;
PAAD	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.34	-0.33	2.6e-5	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.47	5.54	0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs3857067	0.530	rs72663756	chr4:95003498	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.55	-4.83	-0.37	3.24e-6	QT interval;
PAAD	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Height;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.49	4.93	0.37	2.09e-6	Height;
PAAD	cis	rs8040855	0.690	rs8041189	chr15:85686327	A/G	cg08123816	chr15:85640762	PDE8A	0.46	5.43	0.4	2.16e-7	Bulimia nervosa;
PAAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.81	7.13	0.5	3.84e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-5.07	-0.38	1.16e-6	Oropharynx cancer;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg09760422	chr2:128146352	NA	-0.34	-6.13	-0.45	7.23e-9	Protein C levels;
PAAD	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.23	-0.45	4.39e-9	Chronic sinus infection;
PAAD	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg17105886	chr17:28927953	LRRC37B2	0.67	4.47	0.34	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg18721089	chr20:30220636	NA	-0.58	-5.18	-0.39	6.85e-7	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg26031613	chr14:104095156	KLC1	0.52	4.72	0.36	5.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.78	-9.45	-0.61	5.83e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.9	-7.29	-0.51	1.63e-11	Orofacial clefts;
PAAD	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-5.67	-0.42	7.1e-8	Schizophrenia;
PAAD	cis	rs992157	0.730	rs2891078	chr2:219184432	C/T	cg00012203	chr2:219082015	ARPC2	0.59	5.63	0.42	8.67e-8	Colorectal cancer;
PAAD	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09695851	chr17:3907499	NA	-0.7	-7.12	-0.5	3.98e-11	Type 2 diabetes;
PAAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-4.89	-0.37	2.52e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.89	12.5	0.71	4.07e-25	Vitiligo;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08345372	chr16:21289812	CRYM	0.57	6.35	0.46	2.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs797680	0.856	rs2031225	chr1:93786714	A/G	cg04535902	chr1:92947332	GFI1	-0.46	-4.45	-0.34	1.62e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.48	-4.51	-0.34	1.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.9e-7	Ulcerative colitis;
PAAD	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg09222892	chr1:25734099	RHCE	-0.44	-4.34	-0.33	2.62e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs8032158	0.702	rs35040841	chr15:56124149	A/G	cg02198044	chr15:56286336	NEDD4	-0.42	-4.4	-0.34	2e-5	Keloid;
PAAD	cis	rs950037	0.710	rs9427965	chr1:89260091	C/T	cg13109106	chr1:89333529	GTF2B	-0.47	-4.55	-0.35	1.08e-5	Coronary artery disease;
PAAD	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg06015834	chr16:30021696	DOC2A	-0.44	-4.63	-0.35	7.9e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.55	4.85	0.37	3.09e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.6e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	7.91	0.54	5.01e-13	Post bronchodilator FEV1;
PAAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg06740227	chr12:86229804	RASSF9	0.59	5.19	0.39	6.62e-7	Major depressive disorder;
PAAD	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-4.64	-0.35	7.33e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.6	5.6	0.41	9.56e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9506514	0.712	rs11838795	chr13:21258328	T/C	cg27234864	chr13:21295941	IL17D	0.46	4.5	0.34	1.32e-5	Coronary artery calcification;
PAAD	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.49	4.72	0.36	5.29e-6	Airway imaging phenotypes;
PAAD	cis	rs2286492	0.881	rs78433057	chr7:22930238	A/G	cg04907244	chr7:22894795	SNORD93	0.61	4.42	0.34	1.85e-5	Bipolar disorder;
PAAD	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg00666640	chr1:248458726	OR2T12	0.74	5.61	0.41	9.1e-8	Common traits (Other);
PAAD	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.58	-5.65	-0.42	7.86e-8	Systolic blood pressure;
PAAD	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.47	4.32	0.33	2.78e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6782025	0.707	rs3845856	chr3:121075632	A/T	cg16417163	chr3:121280760	NA	-0.45	-4.66	-0.35	6.82e-6	Aging (facial);
PAAD	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg25558440	chr8:11882962	NA	-0.46	-4.35	-0.33	2.5e-5	Triglycerides;
PAAD	cis	rs2249694	1.000	rs2249695	chr10:135352168	T/C	cg08390786	chr10:135334061	NA	-0.48	-4.28	-0.33	3.31e-5	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs11807834	0.522	rs10746509	chr1:230237282	C/T	cg00566187	chr1:230250356	GALNT2	-0.63	-6.63	-0.47	5.4e-10	Schizophrenia;
PAAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.57	0.47	7.42e-10	Body mass index;
PAAD	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg08501292	chr6:25962987	TRIM38	0.9	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg20893579	chr22:38215064	NA	-0.56	-6.01	-0.44	1.33e-8	Glioblastoma;Glioma;
PAAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	5.36	0.4	3.09e-7	Total body bone mineral density;
PAAD	cis	rs630539	0.793	rs4793245	chr17:40730853	G/A	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs6137287	0.924	rs765585	chr20:21171172	C/T	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.66	-0.35	6.92e-6	Height;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02071572	chr4:1403502	NA	-0.44	-5.92	-0.43	2.11e-8	Obesity-related traits;
PAAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.83	-9.56	-0.61	3.05e-17	Ulcerative colitis;
PAAD	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg09941381	chr10:64027924	RTKN2	-0.38	-4.57	-0.35	1.01e-5	Rheumatoid arthritis;
PAAD	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20219876	chr18:12377275	AFG3L2	-0.55	-6.83	-0.48	1.96e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17655565	0.581	rs73093302	chr12:52763203	A/G	cg22980804	chr12:52818037	KRT75	-0.49	-4.35	-0.33	2.48e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.69	0.36	6.15e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.83	-10.2	-0.64	6.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.68	-7.72	-0.53	1.44e-12	White blood cell count (basophil);
PAAD	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.41	4.93	0.37	2.17e-6	Uric acid levels;
PAAD	cis	rs11250714	0.845	rs4880894	chr10:1682887	G/T	cg10435618	chr10:838112	NA	-0.5	-4.39	-0.34	2.15e-5	Gut microbiome composition (summer);
PAAD	cis	rs1347297	0.526	rs10201175	chr2:179265348	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.48	-4.33	-0.33	2.72e-5	Alzheimer disease and age of onset;
PAAD	cis	rs2786865	0.881	rs1543338	chr1:26031193	A/C	cg12074707	chr1:27019787	NA	0.67	4.48	0.34	1.43e-5	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs1372356	0.780	rs7156276	chr14:88550163	A/G	cg18078958	chr14:88630771	NA	0.49	6.22	0.45	4.58e-9	Food antigen IgG levels;
PAAD	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg03098721	chr1:84464084	TTLL7	0.5	4.77	0.36	4.26e-6	Obesity-related traits;
PAAD	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.45	4.68	0.35	6.32e-6	Corneal astigmatism;
PAAD	cis	rs7517847	0.567	rs7523955	chr1:67692132	G/C	cg22500004	chr1:68516272	DIRAS3	-0.47	-4.65	-0.35	7.02e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg03538708	chr1:25844672	NA	-0.53	-5.4	-0.4	2.52e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.4	-4.64	-0.35	7.53e-6	Inflammatory bowel disease;
PAAD	cis	rs742132	0.520	rs4140641	chr6:25635400	C/T	cg03517284	chr6:25882590	NA	0.66	4.34	0.33	2.59e-5	Uric acid levels;
PAAD	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.64	-5.89	-0.43	2.36e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-1.05	-8.52	-0.57	1.42e-14	Blood protein levels;
PAAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg02683114	chr2:24398427	C2orf84	-0.62	-6.91	-0.49	1.24e-10	Asthma;
PAAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.31	0.46	2.88e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg01143145	chr6:33547969	BAK1	-0.58	-6.36	-0.46	2.19e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-4.25	-0.33	3.76e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.41	10.83	0.66	1.33e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg24253500	chr15:84953950	NA	-0.56	-6.53	-0.47	9.33e-10	Schizophrenia;
PAAD	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg20487152	chr13:99095054	FARP1	-0.49	-4.73	-0.36	5.17e-6	Longevity;
PAAD	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.43	-0.4	2.24e-7	Response to temozolomide;
PAAD	trans	rs901683	1.000	rs36053776	chr10:46088145	C/A	cg06308084	chr22:50493570	TTLL8	0.85	6.33	0.46	2.62e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.02	-0.86	7.86e-47	Myeloid white cell count;
PAAD	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	9.96	0.63	2.69e-18	Colorectal cancer;
PAAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg03989125	chr22:38214979	NA	0.61	5.86	0.43	2.81e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg22143856	chr6:28129313	ZNF389	0.49	4.54	0.35	1.14e-5	Parkinson's disease;
PAAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg00786952	chr1:21763130	NA	0.52	5.17	0.39	7.38e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg16590910	chr6:42928470	GNMT	0.59	6.02	0.44	1.28e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.81	-0.54	8.77e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg00049323	chr5:472564	LOC25845	-0.49	-4.36	-0.33	2.35e-5	Cystic fibrosis severity;
PAAD	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.6	5.13	0.38	8.79e-7	QRS duration;
PAAD	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.7	-7.05	-0.5	5.76e-11	Schizophrenia;
PAAD	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg25686905	chr3:183603175	PARL	-0.33	-4.38	-0.33	2.22e-5	Menopause (age at onset);
PAAD	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg16558253	chr16:72132732	DHX38	-0.45	-4.73	-0.36	4.99e-6	Prostate cancer;
PAAD	cis	rs7922314	0.571	rs61865719	chr10:64741119	C/T	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.81	8.18	0.55	1.03e-13	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs5756391	0.546	rs9607398	chr22:37316041	C/T	cg21209356	chr22:37319042	CSF2RB	0.39	4.78	0.36	4.03e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4704187	0.687	rs1422696	chr5:74464415	T/C	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.61	-0.47	6.15e-10	Mood instability;
PAAD	cis	rs9463078	0.774	rs12199720	chr6:45307443	C/T	cg25276700	chr6:44698697	NA	0.45	5.2	0.39	6.37e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.51	-5.46	-0.4	1.91e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.2	0.5	2.6e-11	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.27	-0.33	3.4e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-4.86	-0.37	2.96e-6	Subjective well-being;
PAAD	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.99	11.66	0.69	7.52e-23	Breast cancer;
PAAD	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.61	-5.76	-0.42	4.56e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs818427	0.635	rs1966476	chr5:112172930	T/C	cg07820702	chr5:112228657	REEP5	0.54	4.96	0.37	1.87e-6	Total body bone mineral density;
PAAD	cis	rs859767	0.741	rs13432068	chr2:135382914	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.38	-0.33	2.18e-5	Neuroticism;
PAAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.36	-0.51	1.08e-11	Morning vs. evening chronotype;
PAAD	cis	rs12438356	0.881	rs75391032	chr15:69576265	G/A	cg02375503	chr15:69591110	PAQR5	-0.67	-4.57	-0.35	1.02e-5	CTACK levels;
PAAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg21132104	chr15:45694354	SPATA5L1	0.53	5.05	0.38	1.27e-6	Response to fenofibrate (adiponectin levels);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23939932	chr2:242664240	ING5	0.59	6.84	0.49	1.81e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.1	-0.38	9.81e-7	Monocyte percentage of white cells;
PAAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg03538708	chr1:25844672	NA	-0.51	-5.37	-0.4	2.94e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.87	10.21	0.64	5.68e-19	Migraine;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27505472	chr2:121036705	RALB	-0.64	-6.63	-0.47	5.39e-10	Obesity-related traits;
PAAD	cis	rs7190551	0.951	rs1622768	chr16:9030196	G/C	cg03441945	chr16:8862653	ABAT	-0.53	-4.25	-0.33	3.78e-5	Platelet distribution width;
PAAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.05	0.59	6.5e-16	Rheumatoid arthritis;
PAAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.52	4.94	0.37	2.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09839136	chr7:766187	HEATR2;PRKAR1B	-0.75	-6.76	-0.48	2.76e-10	Neuroticism;
PAAD	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg11214348	chr21:47283868	PCBP3	-0.49	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg05110241	chr16:68378359	PRMT7	-0.82	-5.27	-0.39	4.56e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23625931	chr3:49977418	RBM6	0.66	6.61	0.47	6.18e-10	Obesity-related traits;
PAAD	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg10729496	chr3:10149963	C3orf24	0.95	8.04	0.55	2.28e-13	Alzheimer's disease;
PAAD	cis	rs539096	0.715	rs6665014	chr1:44226004	G/T	cg12908607	chr1:44402522	ARTN	0.48	4.78	0.36	4.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.64	4.85	0.37	3.01e-6	Cholesterol, total;
PAAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg09526685	chr4:187126073	CYP4V2	0.74	5.6	0.41	9.87e-8	Blood protein levels;
PAAD	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg18171855	chr10:2543474	NA	0.56	6.29	0.45	3.15e-9	Age-related hearing impairment;
PAAD	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.44	-0.52	6.92e-12	Neuroticism;
PAAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg27094323	chr7:1216898	NA	-0.47	-5.11	-0.38	9.34e-7	Longevity;Endometriosis;
PAAD	cis	rs593531	0.513	rs7120394	chr11:74034473	G/T	cg15851278	chr11:73669449	DNAJB13	0.4	5.01	0.38	1.48e-6	Neuroticism;
PAAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg24687543	chr11:63912206	MACROD1	-0.5	-4.46	-0.34	1.6e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg19847866	chr10:1019161	NA	0.73	7.35	0.51	1.14e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.46	-0.34	1.57e-5	Obesity-related traits;
PAAD	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2133450	0.967	rs949731	chr3:7352379	G/A	cg19930620	chr3:7340148	GRM7	-0.45	-4.62	-0.35	8.19e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.42	-0.34	1.87e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
PAAD	cis	rs6066835	0.558	rs2104135	chr20:47397757	C/T	cg18078177	chr20:47281410	PREX1	-0.84	-4.36	-0.33	2.39e-5	Multiple myeloma;
PAAD	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs432925	0.600	rs379056	chr16:339291	G/C	cg08823186	chr16:347294	AXIN1	0.48	4.5	0.34	1.36e-5	Morning vs. evening chronotype;
PAAD	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.61	-4.38	-0.33	2.22e-5	Height;
PAAD	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.7	6.81	0.48	2.08e-10	Anterior chamber depth;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9810890	0.867	rs68127468	chr3:128583514	G/T	cg18531004	chr3:128564980	NA	-0.79	-5.01	-0.38	1.47e-6	Dental caries;
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg27490568	chr2:178487706	NA	0.42	4.44	0.34	1.7e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs8060686	0.858	rs56071820	chr16:67712018	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.99	-0.38	1.63e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.57	-5.3	-0.4	3.97e-7	Obesity-related traits;
PAAD	cis	rs11051970	0.879	rs2088806	chr12:32592125	C/T	cg24626660	chr12:32551988	NA	0.38	4.27	0.33	3.45e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.51	0.41	1.48e-7	Bipolar disorder;
PAAD	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.85	8.85	0.58	2.05e-15	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg05304507	chr6:116381966	FRK	0.44	8.39	0.56	3.18e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg27449745	chr7:23145252	KLHL7	-0.51	-4.42	-0.34	1.85e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg12184421	chr1:167409136	CD247	0.36	4.38	0.33	2.21e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg08773314	chr2:239334832	ASB1	0.38	6.19	0.45	5.27e-9	Multiple system atrophy;
PAAD	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-9.99	-0.63	2.25e-18	Chronic sinus infection;
PAAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg24690094	chr11:67383802	NA	-0.49	-4.5	-0.34	1.32e-5	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-4.76	-0.36	4.56e-6	Lung cancer;
PAAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg03161606	chr19:29218774	NA	0.59	4.73	0.36	5.07e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs9902453	0.817	rs8080078	chr17:28195773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.46	0.57	2.12e-14	Coffee consumption (cups per day);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00498591	chr3:9904557	NA	0.65	6.97	0.49	9.06e-11	Monocyte percentage of white cells;
PAAD	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.78e-7	White blood cell count;
PAAD	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.43	-4.58	-0.35	9.81e-6	Depression;
PAAD	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.69	-7.34	-0.51	1.21e-11	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.77	-0.53	1.1e-12	Bladder cancer;
PAAD	cis	rs4740619	0.630	rs2382544	chr9:15988500	A/G	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.17e-5	Body mass index;
PAAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg05484376	chr2:27715224	FNDC4	0.44	4.49	0.34	1.4e-5	Total body bone mineral density;
PAAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.72	5.7	0.42	5.96e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.14	-0.67	1.86e-21	Ulcerative colitis;
PAAD	cis	rs3771570	0.642	rs56241013	chr2:242185311	T/C	cg21646471	chr2:242523971	THAP4	0.71	5.29	0.39	4.29e-7	Prostate cancer;
PAAD	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.45	4.29	0.33	3.21e-5	Red blood cell count;
PAAD	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.52	5.42	0.4	2.25e-7	Monocyte percentage of white cells;
PAAD	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.46	4.91	0.37	2.37e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9487051	0.621	rs377436	chr6:109527104	A/G	cg21918786	chr6:109611834	NA	0.44	4.57	0.35	1.02e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.43	-5.2	-0.39	6.28e-7	Coronary artery disease;
PAAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg09835421	chr16:68378352	PRMT7	0.81	5.03	0.38	1.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.59	6.23	0.45	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-8.02	-0.55	2.6e-13	Colorectal cancer;
PAAD	cis	rs9810089	0.967	rs10935177	chr3:135851077	G/T	cg21827317	chr3:136751795	NA	-0.43	-4.29	-0.33	3.21e-5	Gestational age at birth (child effect);
PAAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.67	-0.35	6.49e-6	Breast cancer;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.88	-0.37	2.71e-6	Menarche (age at onset);
PAAD	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.59	5.54	0.41	1.29e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02725872	chr8:58115012	NA	-0.64	-5.49	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.8	6.08	0.44	9.45e-9	Alzheimer's disease;
PAAD	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.7	-8.71	-0.58	4.89e-15	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg01868782	chr6:126071099	HEY2	0.45	5.31	0.4	3.87e-7	Brugada syndrome;
PAAD	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.9	11.44	0.68	2.94e-22	Menarche (age at onset);
PAAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg17845761	chr1:175162550	KIAA0040	-0.28	-4.28	-0.33	3.35e-5	Alcohol dependence;
PAAD	trans	rs16977195	0.826	rs73451552	chr15:86831034	C/T	cg15572745	chr14:78870232	NRXN3	-1.18	-6.38	-0.46	2e-9	Schizophrenia;
PAAD	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.95	0.43	1.75e-8	Coffee consumption (cups per day);
PAAD	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.79	8.91	0.59	1.5e-15	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	cis	rs2173063	0.730	rs16947100	chr15:93143347	G/A	cg05917748	chr15:93139515	NA	0.78	4.73	0.36	5.14e-6	Subcutaneous adipose tissue;
PAAD	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg16419906	chr5:132167176	NA	-0.58	-4.71	-0.36	5.52e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-4.81	-0.36	3.53e-6	Coronary artery disease;
PAAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg22189786	chr22:42395067	WBP2NL	0.5	5.58	0.41	1.06e-7	Intelligence;
PAAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.67	7.35	0.51	1.11e-11	Melanoma;
PAAD	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.75	-5.12	-0.38	9.27e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.81	8.86	0.58	2.02e-15	Corneal astigmatism;
PAAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06850241	chr22:41845214	NA	-0.55	-5.13	-0.38	8.53e-7	Vitiligo;
PAAD	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg25902810	chr10:99078978	FRAT1	-0.64	-5.96	-0.44	1.68e-8	Monocyte count;
PAAD	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	10.59	0.65	5.59e-20	Smoking behavior;
PAAD	cis	rs9287719	0.649	rs6714787	chr2:10729032	C/T	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.6	6.81	0.48	2.08e-10	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.75	8.38	0.56	3.29e-14	Prostate cancer;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	trans	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg01957732	chr6:133561716	EYA4	-0.98	-7.15	-0.5	3.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.28	0.45	3.35e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg24154853	chr7:158122151	PTPRN2	-0.75	-6.96	-0.49	9.63e-11	Response to amphetamines;
PAAD	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.91	-0.49	1.24e-10	Systemic lupus erythematosus;
PAAD	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs4343996	0.837	rs10215256	chr7:3484884	T/C	cg21248987	chr7:3385318	SDK1	0.47	5.18	0.39	7.05e-7	Motion sickness;
PAAD	trans	rs2230624	1.000	rs76823085	chr1:11883548	A/T	cg09422450	chr16:79623618	NA	0.75	6.42	0.46	1.65e-9	Mosquito bite size;
PAAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.52	-6.96	-0.49	9.29e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg14343924	chr8:8086146	FLJ10661	0.59	5.23	0.39	5.58e-7	Mood instability;
PAAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.42	0.56	2.63e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02419362	chr12:121203948	SPPL3	0.53	6.05	0.44	1.09e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.86	10.22	0.64	5.58e-19	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg10729496	chr3:10149963	C3orf24	0.85	7.22	0.51	2.3e-11	Alzheimer's disease;
PAAD	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg00383909	chr3:49044727	WDR6	0.82	5.19	0.39	6.58e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg22467129	chr15:76604101	ETFA	0.53	4.96	0.37	1.86e-6	Blood metabolite levels;
PAAD	cis	rs7487075	0.619	rs10880969	chr12:46827023	T/C	cg14671384	chr12:47219920	SLC38A4	0.46	4.53	0.34	1.2e-5	Itch intensity from mosquito bite;
PAAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.36	7.19	0.5	2.68e-11	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.47	5.79	0.43	3.86e-8	Crohn's disease;
PAAD	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.68	-0.36	6.23e-6	Neuroticism;
PAAD	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.59	5.15	0.39	7.97e-7	Red blood cell count;
PAAD	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-4.27	-0.33	3.48e-5	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.9	-12.02	-0.7	8.21e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.67	-8.21	-0.55	8.63e-14	Bone mineral density;
PAAD	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09065629	chr16:1709722	CRAMP1L	0.44	4.63	0.35	7.9e-6	Coronary artery disease;
PAAD	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.43	-4.42	-0.34	1.87e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.83	8.52	0.57	1.48e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11245990	chr11:68621969	NA	0.37	4.87	0.37	2.75e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg11965913	chr1:205819406	PM20D1	0.66	5.4	0.4	2.57e-7	Parkinson's disease;
PAAD	cis	rs11892454	0.515	rs2176181	chr2:26030339	A/G	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg25566285	chr7:158114605	PTPRN2	0.85	8.84	0.58	2.2e-15	Calcium levels;
PAAD	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.61	6.6	0.47	6.59e-10	Bladder cancer;
PAAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.87	10.73	0.66	2.44e-20	Menopause (age at onset);
PAAD	cis	rs2153535	0.518	rs9393051	chr6:8638959	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	4.28	0.33	3.25e-5	Motion sickness;
PAAD	cis	rs4771122	0.728	rs7992289	chr13:28036430	G/A	cg22138327	chr13:27999177	GTF3A	-0.8	-6.51	-0.47	1.01e-9	Body mass index;
PAAD	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.78	8.95	0.59	1.14e-15	Eosinophil percentage of white cells;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg04844267	chr4:1394941	NA	0.43	4.72	0.36	5.26e-6	Obesity-related traits;
PAAD	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg12568669	chr8:11666485	FDFT1	0.29	4.34	0.33	2.55e-5	Retinal vascular caliber;
PAAD	cis	rs1879734	0.731	rs12026298	chr1:54126754	T/A	cg14659662	chr1:54151053	GLIS1	-0.38	-5.15	-0.39	7.91e-7	Mitral valve prolapse;
PAAD	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.71	7.41	0.52	8.19e-12	Body mass index;
PAAD	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.39	4.59	0.35	9.35e-6	Intraocular pressure;
PAAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.79	8.94	0.59	1.22e-15	Lung cancer;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21374208	chr10:22292859	DNAJC1	0.42	4.38	0.33	2.24e-5	Monocyte percentage of white cells;
PAAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg10864074	chr7:100318194	EPO	-0.46	-4.44	-0.34	1.75e-5	Other erythrocyte phenotypes;
PAAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg10729496	chr3:10149963	C3orf24	0.78	6.13	0.44	7.4e-9	Alzheimer's disease;
PAAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg07061783	chr6:25882402	NA	-0.53	-5.02	-0.38	1.45e-6	Blood metabolite levels;
PAAD	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Androgen levels;
PAAD	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.7	7.16	0.5	3.3e-11	Response to antidepressants and depression;
PAAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-4.41	-0.34	1.97e-5	Fat distribution (HIV);
PAAD	cis	rs364477	0.811	rs279882	chr9:984779	G/T	cg13952963	chr9:998547	NA	0.56	4.64	0.35	7.56e-6	Major depressive disorder;
PAAD	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.63	5.58	0.41	1.07e-7	Bipolar disorder;
PAAD	trans	rs901683	1.000	rs78363416	chr10:46046134	T/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9467160	1.000	rs7762901	chr6:24449639	G/A	cg16211469	chr6:24423932	MRS2	0.54	5.07	0.38	1.17e-6	Liver enzyme levels;
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.7	6.76	0.48	2.82e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs1730008	0.753	rs827120	chr3:158039605	G/A	cg01557547	chr3:157823089	SHOX2	0.41	4.28	0.33	3.31e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg25558440	chr8:11882962	NA	-0.45	-4.35	-0.33	2.5e-5	Retinal vascular caliber;
PAAD	cis	rs757110	1.000	rs757110	chr11:17418477	C/A	cg22710661	chr11:17411071	KCNJ11	0.45	4.39	0.34	2.15e-5	Type 2 diabetes;
PAAD	trans	rs1903068	0.853	rs12498317	chr4:56007093	G/A	cg05132782	chr7:150126392	NA	0.44	6.29	0.45	3.17e-9	Endometriosis;
PAAD	cis	rs258892	0.793	rs3846639	chr5:72019847	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg12215294	chr3:40350768	EIF1B	0.48	5.01	0.38	1.49e-6	Renal cell carcinoma;
PAAD	cis	rs1006703	0.544	rs35586043	chr17:3832981	A/G	cg06463185	chr17:3833770	ATP2A3	-0.88	-7.2	-0.5	2.62e-11	Glucose homeostasis traits;
PAAD	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg17644776	chr2:200775616	C2orf69	-0.62	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg04450456	chr4:17643702	FAM184B	0.44	4.47	0.34	1.5e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs55728055	0.661	rs16989620	chr22:31839244	G/A	cg01338084	chr22:32026380	PISD	1.57	7.81	0.54	8.82e-13	Age-related hearing impairment;
PAAD	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.7	6.76	0.48	2.71e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg07202610	chr7:1142643	C7orf50	-0.54	-4.37	-0.33	2.25e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg02631450	chr22:32366979	NA	1.03	5.4	0.4	2.54e-7	Childhood ear infection;
PAAD	cis	rs9810890	0.850	rs79042456	chr3:128517917	G/A	cg15676455	chr3:128564943	NA	-0.85	-5.17	-0.39	7.32e-7	Dental caries;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.2	0.39	6.36e-7	Life satisfaction;
PAAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.08	0.38	1.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs12136530	0.625	rs4911992	chr1:19750486	T/A	cg25104613	chr1:20649108	VWA5B1	-0.4	-4.49	-0.34	1.42e-5	Lead levels in blood;
PAAD	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.31	-0.33	2.86e-5	Pulmonary function;
PAAD	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg11897209	chr6:86302888	SNX14	0.44	4.28	0.33	3.27e-5	Response to antipsychotic treatment;
PAAD	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1519814	0.696	rs2139439	chr8:121037091	A/G	cg22335954	chr8:121166405	COL14A1	-0.66	-5.09	-0.38	1.03e-6	Breast cancer;
PAAD	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-6.16	-0.45	6.2e-9	Longevity;
PAAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg21906605	chr1:21766650	NBPF3	0.47	4.72	0.36	5.3e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg09796270	chr17:17721594	SREBF1	0.43	4.74	0.36	4.89e-6	Total body bone mineral density;
PAAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg03037974	chr15:76606532	NA	-0.52	-6.16	-0.45	6.19e-9	Blood metabolite levels;
PAAD	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.75	0.66	2.14e-20	Electrocardiographic conduction measures;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg23179321	chr10:15138793	C10orf111;RPP38	-0.68	-7.04	-0.5	6.33e-11	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	7.1	0.5	4.53e-11	Type 2 diabetes;
PAAD	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.12	-7.34	-0.51	1.18e-11	Plateletcrit;
PAAD	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.15	-9.43	-0.61	6.68e-17	Post bronchodilator FEV1;
PAAD	cis	rs9333029	0.524	rs9429106	chr1:47335986	A/C	cg08644498	chr1:46502608	NA	0.49	4.51	0.34	1.3e-5	Blood metabolite levels;
PAAD	cis	rs501120	0.584	rs1704218	chr10:44729599	C/T	cg09554077	chr10:44749378	NA	0.45	5.22	0.39	5.78e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs7319311	0.565	rs9588148	chr13:111021081	G/T	cg05272587	chr13:111038400	COL4A2	0.6	5.43	0.4	2.19e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs884843	0.839	rs868005	chr7:73445114	T/C	cg23513211	chr7:72726717	TRIM50	-0.36	-4.47	-0.34	1.51e-5	Pulse pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17457440	chr11:64086001	PRDX5;TRMT112	-0.79	-7.05	-0.5	5.89e-11	Neuroticism;
PAAD	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.58	-5.27	-0.39	4.62e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg10705379	chr10:99080932	FRAT1	0.37	4.25	0.33	3.71e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2268667	0.597	rs1403954	chr1:85940157	C/T	cg16011679	chr1:85725395	C1orf52	0.51	4.94	0.37	2.01e-6	Asymmetrical dimethylarginine levels;
PAAD	cis	rs9595066	0.627	rs4942287	chr13:44734696	C/T	cg04068111	chr13:44716778	NA	0.52	5.86	0.43	2.79e-8	Schizophrenia;
PAAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.43	6.61	0.47	6e-10	Height;
PAAD	cis	rs141342723	1	rs141342723	chr6:27622084	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg00864860	chr1:7907996	UTS2	-0.56	-5.15	-0.39	7.97e-7	Crohn's disease;
PAAD	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs747650	0.504	rs6485726	chr11:47082122	C/A	cg19486271	chr11:47235900	DDB2	-0.68	-6.29	-0.45	3.26e-9	Acne (severe);
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.64	-5.96	-0.44	1.69e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11112613	0.775	rs10861462	chr12:106019898	C/T	cg03607813	chr12:105948248	NA	-0.65	-5.48	-0.41	1.7e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.6	-6.59	-0.47	6.71e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.83	9.68	0.62	1.42e-17	Morning vs. evening chronotype;
PAAD	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.93e-5	Primary biliary cholangitis;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg16586182	chr3:47516702	SCAP	-0.68	-7.62	-0.53	2.53e-12	Colorectal cancer;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg07725925	chr16:89976287	TCF25	-0.68	-4.46	-0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg24562669	chr7:97807699	LMTK2	0.67	10.01	0.63	1.93e-18	Breast cancer;
PAAD	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.92	-0.37	2.18e-6	Schizophrenia;
PAAD	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.41	5.07	0.38	1.15e-6	Menopause (age at onset);
PAAD	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg20744362	chr22:50050164	C22orf34	0.63	7.25	0.51	2.02e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	4.44	0.34	1.73e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.96e-6	Vitiligo;
PAAD	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.37	-0.33	2.3e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.78	8.86	0.58	1.96e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	5.88	0.43	2.55e-8	Body mass index;
PAAD	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-5.58	-0.41	1.07e-7	Testicular germ cell tumor;
PAAD	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	5.53	0.41	1.34e-7	Joint mobility (Beighton score);
PAAD	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.11	0.44	8.01e-9	IgG glycosylation;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.86e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.39	4.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.63	4.99	0.38	1.63e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs427941	0.632	rs201522	chr7:101771546	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.38	0.33	2.18e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.63	3.93e-18	Vitiligo;
PAAD	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	5.27	0.39	4.55e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	8.6	0.57	9.22e-15	Cognitive test performance;
PAAD	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12984174	0.877	rs408484	chr19:18139771	C/T	cg21649277	chr19:18117794	ARRDC2	0.93	6.91	0.49	1.26e-10	Pulmonary function in asthmatics;
PAAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg18769074	chr3:133464867	TF	-0.38	-4.36	-0.33	2.35e-5	Iron status biomarkers;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21862992	chr11:68658383	NA	0.41	4.5	0.34	1.32e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.6	-4.83	-0.36	3.29e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs58521262	0.585	rs289368	chr19:23114428	C/A	cg03433597	chr19:22806448	NA	-0.24	-4.32	-0.33	2.84e-5	Testicular germ cell tumor;
PAAD	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.85	9.91	0.63	3.63e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1678618	0.615	rs4148947	chr10:73770117	T/C	cg20897136	chr10:74034667	DDIT4	0.36	4.34	0.33	2.58e-5	Smoking behavior;
PAAD	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg20302533	chr7:39170763	POU6F2	0.35	5.03	0.38	1.38e-6	IgG glycosylation;
PAAD	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-7.83	-0.54	7.85e-13	Colorectal cancer;
PAAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs56133113	0.710	rs77154202	chr11:72814580	T/G	cg25124030	chr11:73498278	MRPL48	0.49	4.46	0.34	1.57e-5	Mean platelet volume;
PAAD	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.64	-5.99	-0.44	1.43e-8	Hip circumference;
PAAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.76	7.14	0.5	3.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.03	-0.38	1.35e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg21665744	chr7:39171113	POU6F2	0.28	4.81	0.36	3.63e-6	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24545687	chr12:132537711	EP400	-0.66	-6.65	-0.47	4.84e-10	Obesity-related traits;
PAAD	cis	rs6496932	0.635	rs11074191	chr15:85932025	G/A	cg19183879	chr15:85880815	NA	-0.59	-5.46	-0.41	1.86e-7	Central corneal thickness;Corneal structure;
PAAD	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg14393609	chr7:65229607	NA	-0.46	-4.56	-0.35	1.03e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg07648498	chr16:89883185	FANCA	0.48	4.56	0.35	1.06e-5	Vitiligo;
PAAD	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.48	5.04	0.38	1.3e-6	Social autistic-like traits;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg08088566	chr11:430123	ANO9	0.91	5.69	0.42	6.32e-8	Body mass index;
PAAD	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.53	-5.24	-0.39	5.23e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.49	-4.72	-0.36	5.37e-6	Multiple sclerosis;
PAAD	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.76	-8.29	-0.56	5.55e-14	Neuroticism;
PAAD	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-5.91	-0.43	2.13e-8	Blood protein levels;
PAAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7190551	0.756	rs166231	chr16:9033590	T/C	cg03441945	chr16:8862653	ABAT	-0.5	-4.47	-0.34	1.49e-5	Platelet distribution width;
PAAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.24	-0.39	5.28e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7577599	0.589	rs7589394	chr2:25661744	C/G	cg23192403	chr2:25781496	DTNB	-0.27	-4.45	-0.34	1.64e-5	Multiple myeloma (IgH translocation);Multiple myeloma;
PAAD	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg20913747	chr6:44695427	NA	0.66	6.79	0.48	2.33e-10	Total body bone mineral density;
PAAD	cis	rs682748	0.810	rs6892968	chr5:17112350	A/T	cg23987134	chr5:17158319	LOC285696	-0.37	-4.63	-0.35	7.9e-6	Hippocampal atrophy;
PAAD	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs375066	0.935	rs10406290	chr19:44378877	G/T	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.49e-6	Breast cancer;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	4.25	0.33	3.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg12082025	chr19:1064218	ABCA7	-0.75	-7.25	-0.51	2.01e-11	Alzheimer's disease (late onset);
PAAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09826364	chr7:158789723	NA	-0.47	-6.27	-0.45	3.59e-9	Facial morphology (factor 20);
PAAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg12573674	chr2:1569213	NA	-0.69	-5.26	-0.39	4.71e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04362095	chr11:63592001	C11orf84	-0.53	-4.95	-0.37	1.97e-6	Schizophrenia;
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.6	-4.92	-0.37	2.19e-6	Platelet count;
PAAD	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.52	5.95	0.43	1.74e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.29	0.56	5.51e-14	Alzheimer's disease;
PAAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.94	-8.27	-0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.69	-0.62	1.4e-17	Response to antipsychotic treatment;
PAAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.22	-10.0	-0.63	2.09e-18	Breast cancer;
PAAD	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.63	6.02	0.44	1.25e-8	Height;
PAAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.68	6.05	0.44	1.08e-8	Menarche (age at onset);
PAAD	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg08898775	chr15:59042684	ADAM10	0.45	6.0	0.44	1.38e-8	Asperger disorder;
PAAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.74	-8.16	-0.55	1.19e-13	Schizophrenia;
PAAD	cis	rs9472414	0.510	rs227839	chr6:44685610	A/G	cg20913747	chr6:44695427	NA	0.59	6.02	0.44	1.28e-8	Height;
PAAD	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.57	6.44	0.46	1.49e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.35	-0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Electroencephalogram traits;
PAAD	cis	rs12936587	0.633	rs12937108	chr17:17499544	A/G	cg03427841	chr17:16610318	CCDC144A	0.41	4.26	0.33	3.5e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-4.46	-0.34	1.57e-5	Morning vs. evening chronotype;
PAAD	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.35	-0.33	2.44e-5	Coronary artery disease;
PAAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.4	0.34	2e-5	Tonsillectomy;
PAAD	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.02	-6.38	-0.46	1.99e-9	Lung cancer in ever smokers;
PAAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-7.97	-0.54	3.6e-13	Response to antipsychotic treatment;
PAAD	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.56	5.19	0.39	6.65e-7	Mood instability;
PAAD	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg26205652	chr12:48591994	NA	0.86	7.78	0.53	1.04e-12	Longevity (90 years and older);
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.98	12.67	0.72	1.46e-25	Menarche (age at onset);
PAAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg20933634	chr6:27740509	NA	0.67	6.25	0.45	3.93e-9	Parkinson's disease;
PAAD	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.79	-6.9	-0.49	1.28e-10	Diastolic blood pressure;
PAAD	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	1.03	12.97	0.72	2.31e-26	Breast cancer;
PAAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.71	6.91	0.49	1.22e-10	Alcohol dependence;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.92	12.1	0.7	4.84e-24	Menarche (age at onset);
PAAD	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg13264159	chr8:625131	ERICH1	-0.68	-4.64	-0.35	7.42e-6	IgG glycosylation;
PAAD	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.68	5.85	0.43	2.92e-8	Educational attainment;
PAAD	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg09471204	chr22:42347991	LOC339674	0.32	4.27	0.33	3.48e-5	Cognitive function;
PAAD	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.54	5.23	0.39	5.65e-7	Colorectal cancer;
PAAD	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg02117656	chr17:79614917	TSPAN10	0.5	4.98	0.37	1.68e-6	Eye color traits;
PAAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-8.39	-0.56	3.07e-14	Gut microbiome composition (summer);
PAAD	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg19217778	chr13:113420270	ATP11A	-0.63	-4.35	-0.33	2.51e-5	Glycated hemoglobin levels;
PAAD	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	0.95	6.86	0.49	1.6e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.76	-6.34	-0.46	2.47e-9	Initial pursuit acceleration;
PAAD	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-4.58	-0.35	9.76e-6	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20285609	chr1:41622030	SCMH1	-0.68	-7.08	-0.5	4.87e-11	Obesity-related traits;
PAAD	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.91	-0.37	2.29e-6	Pulmonary function;
PAAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.45	-0.57	2.23e-14	Longevity;Endometriosis;
PAAD	cis	rs2992756	0.663	rs2992732	chr1:18802825	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.97	0.59	1.04e-15	Motion sickness;
PAAD	cis	rs8112211	0.599	rs2887262	chr19:38831311	A/G	cg01275006	chr19:38876250	GGN	-0.87	-5.64	-0.42	8.23e-8	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05744073	chr17:1953268	MIR132	0.69	7.89	0.54	5.46e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg27094323	chr7:1216898	NA	-0.51	-6.18	-0.45	5.65e-9	Longevity;Endometriosis;
PAAD	cis	rs9810890	1.000	rs115221473	chr3:128547136	T/G	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14169450	chr9:139327907	INPP5E	0.56	5.61	0.41	9.41e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg01798341	chr17:80842262	TBCD	-0.4	-4.37	-0.33	2.29e-5	Breast cancer;
PAAD	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg19760965	chr3:194868843	C3orf21	0.45	4.74	0.36	4.96e-6	Non-small cell lung cancer;
PAAD	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.25	-0.39	4.98e-7	Pulmonary function;
PAAD	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg21479132	chr6:26055353	NA	0.8	4.38	0.33	2.22e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.22	-0.51	2.32e-11	Response to amphetamines;
PAAD	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-4.34	-0.33	2.64e-5	Self-reported allergy;
PAAD	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.74	8.07	0.55	1.99e-13	Heart rate;
PAAD	cis	rs6708331	0.540	rs28623550	chr2:70366392	T/C	cg01613454	chr2:70366299	NA	0.44	4.64	0.35	7.51e-6	Obesity-related traits;
PAAD	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	11.35	0.68	5.09e-22	Primary sclerosing cholangitis;
PAAD	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs561655	0.525	rs10898439	chr11:85859483	C/G	cg07180834	chr11:85838833	NA	0.41	4.61	0.35	8.61e-6	Alzheimer's disease (late onset);
PAAD	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-5.51	-0.41	1.49e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs6142102	0.602	rs2268086	chr20:32648738	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-5.05	-0.38	1.26e-6	Skin pigmentation;
PAAD	trans	rs901683	1.000	rs9422653	chr10:46048918	A/G	cg14076390	chr17:34947837	DHRS11	-0.87	-6.65	-0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg24253500	chr15:84953950	NA	0.58	6.82	0.48	1.98e-10	Schizophrenia;
PAAD	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-6.76	-0.48	2.76e-10	Migraine;Coronary artery disease;
PAAD	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.7	0.42	6.1e-8	Lung cancer;
PAAD	cis	rs12760731	0.641	rs10494513	chr1:178252377	C/G	cg00404053	chr1:178313656	RASAL2	0.59	4.64	0.35	7.5e-6	Obesity-related traits;
PAAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.5	4.68	0.35	6.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.54	-6.35	-0.46	2.41e-9	Total body bone mineral density;
PAAD	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-4.61	-0.35	8.44e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	9.75	0.62	9.83e-18	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13939156	chr17:80058883	NA	-0.42	-4.52	-0.34	1.23e-5	Life satisfaction;
PAAD	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.66	6.46	0.46	1.32e-9	Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7092929	0.941	rs661019	chr10:3586581	C/T	cg14308648	chr10:3568949	NA	0.63	4.55	0.35	1.09e-5	Coronary artery calcification;
PAAD	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.34	-0.33	2.56e-5	Metabolite levels;
PAAD	cis	rs9815354	1.000	rs9869207	chr3:41878661	C/G	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg08219700	chr8:58056026	NA	0.73	5.81	0.43	3.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.51	-4.75	-0.36	4.59e-6	Neuroticism;
PAAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13198984	chr17:80129470	CCDC57	0.42	5.21	0.39	5.99e-7	Life satisfaction;
PAAD	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg09760422	chr2:128146352	NA	-0.34	-5.99	-0.44	1.47e-8	Protein C levels;
PAAD	cis	rs11168618	0.846	rs11168580	chr12:48850424	G/T	cg01881778	chr12:48919444	OR8S1	-0.5	-4.99	-0.37	1.67e-6	Adiponectin levels;
PAAD	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.36	5.04	0.38	1.33e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9463078	0.528	rs12524323	chr6:45303853	C/A	cg25276700	chr6:44698697	NA	0.47	5.38	0.4	2.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	7.86	0.54	6.39e-13	Coronary artery disease;
PAAD	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs743757	1.000	rs762895	chr3:50429282	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	4.57	0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.6	-0.47	6.59e-10	Lung cancer;
PAAD	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2342371	0.599	rs7618690	chr3:196146039	T/C	cg09821211	chr3:195954098	OSTalpha	0.64	5.96	0.44	1.71e-8	Fat distribution (HIV);
PAAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.39	4.75	0.36	4.66e-6	Rheumatoid arthritis;
PAAD	cis	rs1190596	0.525	rs7152627	chr14:102698399	C/T	cg23904247	chr14:102554826	HSP90AA1	-0.46	-5.3	-0.39	4e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6547631	0.502	rs77067405	chr2:85927739	G/T	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.78e-7	Blood protein levels;
PAAD	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg21823605	chr1:152486609	CRCT1	0.52	6.77	0.48	2.65e-10	Hair morphology;
PAAD	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.91	-11.55	-0.68	1.51e-22	Coronary artery disease;
PAAD	cis	rs9394152	0.845	rs7743060	chr6:33470519	C/T	cg13560919	chr6:33536144	NA	0.53	5.02	0.38	1.45e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs735539	0.517	rs3809357	chr13:21140781	T/A	cg27499820	chr13:21296301	IL17D	0.47	4.35	0.33	2.49e-5	Dental caries;
PAAD	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.57	6.37	0.46	2.08e-9	High light scatter reticulocyte count;
PAAD	cis	rs17428704	0.522	rs12332644	chr5:14418569	G/C	cg12964346	chr5:14507533	TRIO	-0.86	-4.26	-0.33	3.54e-5	Electroencephalogram traits;
PAAD	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg22800045	chr5:56110881	MAP3K1	-0.95	-7.65	-0.53	2.09e-12	Initial pursuit acceleration;
PAAD	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.94	-0.37	2.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg22903657	chr4:1355424	KIAA1530	-0.46	-4.99	-0.38	1.64e-6	Obesity-related traits;
PAAD	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.79	-0.53	9.56e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.62	-5.92	-0.43	2.1e-8	Subjective well-being;
PAAD	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg04267008	chr7:1944627	MAD1L1	0.51	4.64	0.35	7.53e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-4.41	-0.34	1.97e-5	Paclitaxel-induced neuropathy;
PAAD	cis	rs4356203	0.840	rs214911	chr11:17242238	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	6.62	0.47	5.71e-10	Renal function-related traits (BUN);
PAAD	cis	rs7742824	0.917	rs4334980	chr6:44070931	C/T	cg21657043	chr6:44035552	NA	0.43	4.66	0.35	6.91e-6	Major depressive disorder;
PAAD	trans	rs901683	1.000	rs3764990	chr10:45956828	G/A	cg11747279	chr17:21096632	NA	0.81	6.4	0.46	1.81e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-1.1	-7.77	-0.53	1.1e-12	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.03	0.38	1.34e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.5	-6.64	-0.47	5.34e-10	Height;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.48	-5.64	-0.42	8.19e-8	Coronary artery disease;
PAAD	trans	rs901683	1.000	rs36070535	chr10:46022238	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6988985	0.678	rs7831617	chr8:144002283	G/T	cg10324643	chr8:143916377	GML	0.41	4.58	0.35	9.57e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.06	-0.38	1.18e-6	Reticulocyte count;
PAAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.6	7.4	0.51	8.81e-12	Multiple system atrophy;
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg14008862	chr17:28927542	LRRC37B2	0.78	4.73	0.36	5.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-6.25	-0.45	3.91e-9	Schizophrenia;
PAAD	cis	rs1934953	0.503	rs2253635	chr10:96700537	C/T	cg09036531	chr10:96991505	NA	-0.54	-5.12	-0.38	9.28e-7	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs6921919	1.000	rs6922111	chr6:28325308	C/T	cg23153227	chr6:27725408	NA	0.56	4.58	0.35	9.56e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg01320130	chr1:67600311	NA	0.57	5.84	0.43	3.1e-8	Psoriasis;
PAAD	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-6.7	-0.48	3.76e-10	Colorectal cancer;
PAAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs559928	0.524	rs4963222	chr11:64184735	T/C	cg05555928	chr11:63887634	MACROD1	-0.55	-5.28	-0.39	4.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-5.83	-0.43	3.21e-8	Cervical cancer;
PAAD	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	1.02	7.92	0.54	4.72e-13	IgG glycosylation;
PAAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.6	6.11	0.44	7.97e-9	Coronary artery disease;
PAAD	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg19483011	chr3:158453295	NA	-0.65	-5.58	-0.41	1.05e-7	Tetralogy of Fallot;
PAAD	cis	rs13102973	0.899	rs4541577	chr4:135901087	G/T	cg14419869	chr4:135874104	NA	0.48	4.85	0.37	3.02e-6	Subjective well-being;
PAAD	cis	rs1883415	0.534	rs2760149	chr6:24477848	C/T	cg20631270	chr6:24437470	GPLD1	0.45	4.39	0.34	2.09e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9810890	1.000	rs73198816	chr3:128474440	C/T	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg02462569	chr6:150064036	NUP43	-0.48	-5.43	-0.4	2.14e-7	Lung cancer;
PAAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg06618935	chr21:46677482	NA	-0.56	-7.22	-0.51	2.34e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09835421	chr16:68378352	PRMT7	-1.2	-8.47	-0.57	1.91e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12582317	chr17:55822272	NA	0.71	8.68	0.58	5.55e-15	Schizophrenia;
PAAD	cis	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-6.38	-0.46	2.01e-9	Brain structure;
PAAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.55	5.58	0.41	1.1e-7	Parkinson's disease;
PAAD	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.88	-0.49	1.43e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.77	-0.36	4.27e-6	Personality dimensions;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26026558	chr17:16934655	NA	0.61	6.59	0.47	6.98e-10	Smoking initiation;
PAAD	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.62	6.7	0.48	3.86e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg08562672	chr19:21860753	NA	-0.46	-4.93	-0.37	2.12e-6	Pain;
PAAD	cis	rs4743820	0.503	rs4604577	chr9:93904257	G/A	cg14446406	chr9:93919335	NA	-0.37	-5.03	-0.38	1.39e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-1.04	-10.94	-0.66	6.69e-21	Platelet distribution width;
PAAD	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.96	-0.37	1.88e-6	Recombination measurement;
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.73	8.67	0.58	6.01e-15	Height;
PAAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.62	5.67	0.42	7.08e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.72	6.06	0.44	1.05e-8	Schizophrenia;
PAAD	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.4	5.9	0.43	2.25e-8	Educational attainment (years of education);
PAAD	cis	rs4605213	0.686	rs9896627	chr17:49328705	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.56	-4.95	-0.37	1.99e-6	Height;
PAAD	cis	rs12997796	0.503	rs3020726	chr2:87016506	A/G	cg25203885	chr2:87302643	LOC285074	-0.85	-5.66	-0.42	7.3e-8	Schizophrenia;
PAAD	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg01631408	chr1:248437212	OR2T33	-0.58	-5.25	-0.39	5.15e-7	Common traits (Other);
PAAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.4	-0.46	1.85e-9	Aortic root size;
PAAD	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	6.25	0.45	3.96e-9	Body mass index;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.01	-16.37	-0.8	2.32e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.31	0.33	2.96e-5	Major depressive disorder;
PAAD	cis	rs1413885	0.516	rs4329545	chr1:65861060	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.82	0.36	3.46e-6	Anticoagulant levels;
PAAD	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg21589280	chr1:85930151	DDAH1	-0.57	-4.3	-0.33	2.98e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg13736514	chr6:26305472	NA	-0.59	-6.19	-0.45	5.26e-9	Educational attainment;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg08299880	chr5:26673548	NA	-0.58	-6.9	-0.49	1.29e-10	Energy expenditure (24h);
PAAD	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-7.0	-0.49	7.73e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg15654264	chr1:150340011	RPRD2	0.51	4.84	0.37	3.18e-6	Migraine;
PAAD	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg20731937	chr12:48336164	NA	0.52	4.36	0.33	2.34e-5	Longevity (90 years and older);
PAAD	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.99	-0.38	1.61e-6	Pulmonary function;
PAAD	cis	rs6066835	0.572	rs4616535	chr20:47248808	C/T	cg18078177	chr20:47281410	PREX1	0.86	4.51	0.34	1.3e-5	Multiple myeloma;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg21918786	chr6:109611834	NA	-0.4	-4.34	-0.33	2.59e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6782025	0.958	rs4676719	chr3:121111826	T/C	cg16417163	chr3:121280760	NA	-0.49	-4.96	-0.37	1.89e-6	Aging (facial);
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.51	4.95	0.37	1.94e-6	Resistin levels;
PAAD	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.72	9.12	0.59	4.31e-16	Asthma;
PAAD	cis	rs2659703	0.749	rs12488335	chr3:128176760	G/A	cg24680163	chr3:127842675	RUVBL1	0.51	4.35	0.33	2.49e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs7615952	0.611	rs78137633	chr3:125775061	C/T	cg05084668	chr3:125655381	ALG1L	-0.97	-7.94	-0.54	4.21e-13	Blood pressure (smoking interaction);
PAAD	cis	rs728616	0.867	rs12414877	chr10:81780708	A/G	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.84	-0.37	3.17e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg18867708	chr6:26865862	GUSBL1	0.46	4.67	0.35	6.62e-6	Schizophrenia;
PAAD	cis	rs6700896	0.931	rs11809906	chr1:66115064	C/T	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15557168	chr22:42548783	NA	-0.54	-6.01	-0.44	1.31e-8	Cognitive function;
PAAD	cis	rs9810890	1.000	rs73198823	chr3:128484405	G/T	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.48	-4.76	-0.36	4.4e-6	Pulmonary function;
PAAD	cis	rs3106136	0.678	rs6532484	chr4:95297118	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	4.9	0.37	2.42e-6	Capecitabine sensitivity;
PAAD	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.8	0.62	6.88e-18	Response to antipsychotic treatment;
PAAD	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg24154853	chr7:158122151	PTPRN2	0.79	6.92	0.49	1.16e-10	Response to amphetamines;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.66	7.53	0.52	4.25e-12	Mean corpuscular volume;
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg06026331	chr20:60912101	LAMA5	0.5	4.65	0.35	7.05e-6	Colorectal cancer;
PAAD	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.61	-5.42	-0.4	2.33e-7	Type 2 diabetes;
PAAD	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg00490450	chr3:139108681	COPB2	-0.66	-5.9	-0.43	2.23e-8	Obesity-related traits;
PAAD	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg06740227	chr12:86229804	RASSF9	-0.49	-4.9	-0.37	2.48e-6	Major depressive disorder;
PAAD	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg06569542	chr10:98946673	SLIT1	0.44	4.5	0.34	1.34e-5	Monocyte count;
PAAD	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.91	0.37	2.3e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg19025524	chr12:109796872	NA	-0.47	-4.41	-0.34	1.91e-5	Neuroticism;
PAAD	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.37	-5.29	-0.39	4.12e-7	Cutaneous nevi;
PAAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.77	-9.06	-0.59	6.15e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2004318	1.000	rs75741150	chr19:55129288	G/A	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs669446	0.622	rs623965	chr1:44111187	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-4.38	-0.33	2.22e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs643506	0.874	rs618031	chr11:111648863	A/C	cg09085632	chr11:111637200	PPP2R1B	0.56	4.95	0.37	1.91e-6	Breast cancer;
PAAD	cis	rs4907240	0.925	rs11164109	chr2:97300833	T/A	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.58	-0.35	9.59e-6	Event-related brain oscillations;
PAAD	cis	rs2070433	0.851	rs10854484	chr21:47926702	T/C	cg12379764	chr21:47803548	PCNT	0.53	4.66	0.35	6.72e-6	Lymphocyte counts;
PAAD	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg16928487	chr17:17741425	SREBF1	0.38	5.04	0.38	1.32e-6	Total body bone mineral density;
PAAD	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg02527881	chr3:46936655	PTH1R	0.38	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg22431228	chr1:16359049	CLCNKA	0.41	5.07	0.38	1.14e-6	Systolic blood pressure;
PAAD	cis	rs2281636	1.000	rs2804417	chr10:101516215	G/A	cg05149213	chr10:101381631	SLC25A28	-0.49	-4.74	-0.36	4.85e-6	Obesity-related traits;
PAAD	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	Cognitive function;
PAAD	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.82	-7.8	-0.53	9.43e-13	Body mass index;
PAAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.56	-0.35	1.07e-5	Bipolar disorder;
PAAD	trans	rs901683	0.702	rs77676696	chr10:45967258	A/G	cg12869334	chr8:37699360	GPR124	0.97	6.48	0.47	1.23e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.68e-10	Coronary artery disease;
PAAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.98	-11.3	-0.68	6.94e-22	Tonsillectomy;
PAAD	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs2882667	0.537	rs11743534	chr5:138409007	G/T	cg22797968	chr5:138629998	MATR3	0.46	4.57	0.35	9.88e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg22134325	chr11:66188745	NPAS4	-0.31	-4.6	-0.35	9.01e-6	Airway imaging phenotypes;
PAAD	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-4.86	-0.37	2.84e-6	Height;
PAAD	cis	rs2594989	1.000	rs2594986	chr3:11330964	G/A	cg01796438	chr3:11312864	ATG7	-0.65	-4.98	-0.37	1.72e-6	Circulating chemerin levels;
PAAD	cis	rs6445967	1.000	rs6786088	chr3:58315075	T/C	cg23715586	chr3:58305044	RPP14	0.5	4.36	0.33	2.34e-5	Platelet count;
PAAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg11833968	chr6:79620685	NA	-0.43	-4.48	-0.34	1.43e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.62	6.42	0.46	1.67e-9	Systemic lupus erythematosus;
PAAD	cis	rs2518049	0.539	rs1937913	chr10:5170495	A/G	cg13585175	chr10:5228106	AKR1CL1	-0.46	-4.83	-0.37	3.25e-6	Metabolic traits;
PAAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12165864	chr7:66369176	NA	-0.7	-4.45	-0.34	1.64e-5	Diabetic kidney disease;
PAAD	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-10.44	-0.65	1.4e-19	Platelet distribution width;
PAAD	cis	rs507080	0.733	rs517445	chr11:118573535	A/G	cg08498647	chr11:118550644	TREH	-0.39	-4.42	-0.34	1.83e-5	Serum metabolite levels;
PAAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.99	6.58	0.47	7.08e-10	Parkinson's disease;
PAAD	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.19	-8.5	-0.57	1.63e-14	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg23683012	chr15:78369302	TBC1D2B	0.72	6.52	0.47	9.65e-10	Breast cancer;
PAAD	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.1	-0.38	1.01e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12913538	0.926	rs12438162	chr15:62884463	A/G	cg09983546	chr15:62884068	NA	0.67	7.54	0.52	3.95e-12	Sleep depth;
PAAD	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-6.93	-0.49	1.15e-10	Total cholesterol levels;
PAAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.86	-10.23	-0.64	5.17e-19	Body mass index;
PAAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.63	-5.94	-0.43	1.91e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs6011002	1.000	rs56010802	chr20:62304114	G/C	cg01176363	chr20:62369445	LIME1	0.91	4.38	0.34	2.16e-5	Dental caries;
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg17120908	chr11:65337727	SSSCA1	-0.96	-4.5	-0.34	1.34e-5	Height;
PAAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg15181151	chr6:150070149	PCMT1	0.56	6.09	0.44	8.89e-9	Lung cancer;
PAAD	cis	rs7960581	0.673	rs17227697	chr12:99205826	T/C	cg17109042	chr12:99139387	ANKS1B	-0.71	-4.62	-0.35	8.28e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg16447950	chr5:562315	NA	-0.69	-6.08	-0.44	9.18e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg10434728	chr15:90938212	IQGAP1	0.45	4.71	0.36	5.48e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg19536664	chr17:6899085	ALOX12	0.55	6.21	0.45	4.85e-9	Tonsillectomy;
PAAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.85	-9.62	-0.62	2.06e-17	Iron status biomarkers;
PAAD	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.39	4.87	0.37	2.83e-6	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11142522	chr1:32673467	IQCC;DCDC2B	-0.69	-7.28	-0.51	1.67e-11	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	5.25	0.39	5e-7	Schizophrenia;
PAAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.51	-0.47	1.05e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.52e-5	Coronary artery disease;
PAAD	cis	rs6700896	0.966	rs4655729	chr1:66082471	A/G	cg04111102	chr1:66153794	NA	0.44	4.81	0.36	3.64e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-4.72	-0.36	5.33e-6	Neuroticism;
PAAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	0.89	8.84	0.58	2.28e-15	Exhaled nitric oxide output;
PAAD	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.42	0.65	1.6e-19	Bladder cancer;
PAAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg21995147	chr19:1064017	ABCA7	-0.61	-5.53	-0.41	1.37e-7	Alzheimer's disease (late onset);
PAAD	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.83e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg02811702	chr13:24901961	NA	0.52	5.56	0.41	1.2e-7	Obesity-related traits;
PAAD	cis	rs2790216	1.000	rs1199101	chr10:59947901	C/T	cg20442379	chr10:60024634	IPMK	-0.59	-4.48	-0.34	1.47e-5	Inflammatory bowel disease;
PAAD	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg06565975	chr8:143823917	SLURP1	0.21	4.93	0.37	2.15e-6	Urinary tract infection frequency;
PAAD	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.48	-4.97	-0.37	1.75e-6	Monocyte count;
PAAD	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.02	0.44	1.26e-8	Bladder cancer;
PAAD	cis	rs16858210	0.647	rs35369718	chr3:183621868	A/G	cg03417191	chr3:183542750	MAP6D1	-0.59	-4.29	-0.33	3.18e-5	Menopause (age at onset);
PAAD	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.34	0.33	2.57e-5	Height;
PAAD	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.58	6.3	0.46	3.04e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.87	-8.24	-0.56	7.59e-14	DNA methylation (variation);
PAAD	cis	rs6466055	0.669	rs10953468	chr7:104741842	A/T	cg04380332	chr7:105027541	SRPK2	-0.65	-7.12	-0.5	3.96e-11	Schizophrenia;
PAAD	cis	rs16975963	0.644	rs75499934	chr19:38113043	C/A	cg14218481	chr19:38281219	NA	0.41	4.4	0.34	2.03e-5	Longevity;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15412291	chr17:66244249	AMZ2	0.55	6.3	0.46	3.05e-9	Monocyte percentage of white cells;
PAAD	cis	rs992157	0.764	rs1870123	chr2:219187698	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.76	7.67	0.53	1.87e-12	Colorectal cancer;
PAAD	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg25204440	chr1:209979598	IRF6	0.62	5.43	0.4	2.16e-7	Coronary artery disease;
PAAD	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.69	5.66	0.42	7.45e-8	Menarche (age at onset);
PAAD	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg02683114	chr2:24398427	C2orf84	0.6	6.81	0.48	2.16e-10	Asthma;
PAAD	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg14593290	chr7:50529359	DDC	-0.51	-5.02	-0.38	1.43e-6	Malaria;
PAAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14180030	chr9:123475675	MEGF9	-0.48	-5.2	-0.39	6.26e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg12215294	chr3:40350768	EIF1B	0.48	4.84	0.37	3.1e-6	Renal cell carcinoma;
PAAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg18209359	chr17:80159595	CCDC57	0.48	4.97	0.37	1.81e-6	Life satisfaction;
PAAD	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.97	0.54	3.57e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg08758996	chr17:66097529	LOC651250	0.54	4.39	0.34	2.12e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19277926	chr18:74175020	ZNF516	-0.44	-4.77	-0.36	4.29e-6	Obesity-related traits;
PAAD	cis	rs7301016	0.947	rs10877862	chr12:62888647	T/C	cg11441379	chr12:63026424	NA	0.84	6.06	0.44	1.04e-8	IgG glycosylation;
PAAD	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg03938978	chr2:103052716	IL18RAP	0.57	6.39	0.46	1.9e-9	Asthma;
PAAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.81	-9.05	-0.59	6.48e-16	Aortic root size;
PAAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg10018233	chr7:150070692	REPIN1	0.58	6.2	0.45	5e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.02	-0.49	6.99e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62209	0.530	rs7093099	chr10:10990942	C/T	cg26901096	chr10:10994189	LOC254312	0.64	4.73	0.36	5.12e-6	Alzheimer's disease (late onset);
PAAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.86	10.14	0.64	8.92e-19	Ulcerative colitis;
PAAD	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.66	6.08	0.44	9.4e-9	Platelet count;
PAAD	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.61	-6.07	-0.44	9.99e-9	Systolic blood pressure;
PAAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg08807892	chr2:162101083	NA	0.6	6.45	0.46	1.42e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.5	4.91	0.37	2.37e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.5	-5.7	-0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.96e-18	Response to antipsychotic treatment;
PAAD	cis	rs3018712	0.564	rs7942697	chr11:68495462	T/G	cg23009355	chr11:68451396	GAL	-0.44	-4.25	-0.33	3.75e-5	Total body bone mineral density;
PAAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg23346134	chr3:49453900	TCTA	0.4	4.3	0.33	3.09e-5	Menarche (age at onset);
PAAD	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	4.52	0.34	1.23e-5	Multiple sclerosis;
PAAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.61	6.73	0.48	3.22e-10	Obesity-related traits;
PAAD	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.62	6.19	0.45	5.25e-9	Depressive symptoms;
PAAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.53	-4.38	-0.33	2.17e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1018697	0.897	rs2150929	chr10:104550937	T/A	cg04362960	chr10:104952993	NT5C2	0.6	6.12	0.44	7.72e-9	Colorectal adenoma (advanced);
PAAD	cis	rs1539053	0.899	rs7548624	chr1:58106887	A/G	cg20292791	chr1:58089357	DAB1	-0.53	-5.26	-0.39	4.92e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg05272587	chr13:111038400	COL4A2	0.5	4.86	0.37	2.89e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4668356	1.000	rs55995602	chr2:171967107	T/G	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg06236206	chr7:66120395	NA	0.54	4.48	0.34	1.43e-5	Diabetic kidney disease;
PAAD	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04714088	chr16:81478359	CMIP	0.58	6.55	0.47	8.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg03650551	chr16:1797383	MAPK8IP3	-0.82	-4.42	-0.34	1.86e-5	Snoring;
PAAD	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.79	8.93	0.59	1.28e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs758324	0.681	rs25879	chr5:131407044	A/G	cg06307176	chr5:131281290	NA	-0.52	-4.7	-0.36	5.78e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-4.86	-0.37	2.88e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.830	rs2501367	chr1:24205274	C/A	cg15997130	chr1:24165203	NA	0.59	6.2	0.45	5.14e-9	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.27	-0.33	3.37e-5	Aortic root size;
PAAD	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.57	5.36	0.4	3.07e-7	Corneal astigmatism;
PAAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	cis	rs10450586	0.863	rs7120368	chr11:27292742	C/T	cg10370305	chr11:27303972	NA	0.36	4.28	0.33	3.31e-5	Total body bone mineral density;
PAAD	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.5	5.11	0.38	9.6e-7	Colorectal cancer;
PAAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.82	9.52	0.61	3.92e-17	Gestational age at birth (maternal effect);
PAAD	cis	rs4742903	0.935	rs6479228	chr9:106980912	G/A	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg21191810	chr6:118973309	C6orf204	0.49	6.19	0.45	5.3300000000000004e-09	Electrocardiographic conduction measures;
PAAD	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg14181355	chr19:12984996	MAST1	-0.47	-4.34	-0.33	2.62e-5	Mean corpuscular volume;
PAAD	cis	rs2072732	0.861	rs10909867	chr1:2961402	G/T	cg22517653	chr1:2918612	NA	-0.62	-4.94	-0.37	2e-6	Plateletcrit;
PAAD	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-11.07	-0.67	3.02e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.61	6.5	0.47	1.11e-9	Caffeine consumption;
PAAD	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.61	-6.13	-0.45	7.07e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-7.55	-0.52	3.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.48	-4.52	-0.34	1.25e-5	Endometrial cancer;
PAAD	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.0	-0.38	1.55e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.48	-4.26	-0.33	3.64e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg17633681	chr16:88106987	BANP	0.6	7.28	0.51	1.67e-11	Menopause (age at onset);
PAAD	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.31	0.4	3.89e-7	Colorectal cancer;
PAAD	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.67	0.35	6.51e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.64	0.57	7.4e-15	Lung cancer;
PAAD	cis	rs9283706	0.623	rs10055631	chr5:66305438	A/C	cg11590213	chr5:66331682	MAST4	0.5	4.3	0.33	3.07e-5	Coronary artery disease;
PAAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.39	13.4	0.74	1.56e-27	Corneal structure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17739026	chr1:27114420	PIGV	0.78	8.71	0.58	4.9e-15	Myopia (pathological);
PAAD	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.44	-4.25	-0.33	3.67e-5	Height;
PAAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15884411	chr2:96932403	CIAO1;TMEM127	-0.59	-6.38	-0.46	2.08e-9	Height;
PAAD	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	7.93	0.54	4.36e-13	Lymphocyte counts;
PAAD	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-9.89	-0.63	4e-18	Height;
PAAD	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.71	-7.27	-0.51	1.8e-11	Retinal vascular caliber;
PAAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.88	-9.4	-0.61	8.04e-17	DNA methylation (variation);
PAAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.59	6.51	0.47	1.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3206736	0.556	rs328924	chr7:35035704	T/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg26816564	chr1:7831052	VAMP3	0.63	5.16	0.39	7.48e-7	Inflammatory bowel disease;
PAAD	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg01426195	chr3:39028469	NA	-0.72	-8.23	-0.56	7.71e-14	Handedness;
PAAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	1.03	16.86	0.81	1.26e-36	Height;
PAAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg16434002	chr17:42200994	HDAC5	-0.64	-5.94	-0.43	1.86e-8	Total body bone mineral density;
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03605463	chr16:89740564	NA	0.53	5.17	0.39	7.41e-7	Vitiligo;
PAAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.58	6.82	0.48	2.04e-10	Aortic root size;
PAAD	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.7	-7.16	-0.5	3.2e-11	Primary sclerosing cholangitis;
PAAD	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.51	4.66	0.35	6.72e-6	Triglycerides;
PAAD	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.88	6.24	0.45	4.06e-9	Height;
PAAD	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg09760422	chr2:128146352	NA	-0.35	-6.25	-0.45	3.95e-9	Protein C levels;
PAAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.76	0.42	4.61e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg05754148	chr16:3507555	NAT15	0.66	4.89	0.37	2.55e-6	Tuberculosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17928671	chr6:3459516	NA	-0.58	-6.8	-0.48	2.27e-10	Monocyte percentage of white cells;
PAAD	cis	rs786425	0.899	rs1515814	chr12:124108699	G/A	cg01240444	chr12:124247047	DNAH10	0.41	4.25	0.33	3.75e-5	Pubertal anthropometrics;
PAAD	cis	rs2286503	0.646	rs17147344	chr7:22880856	C/A	cg04907244	chr7:22894795	SNORD93	-0.45	-4.86	-0.37	2.91e-6	Fibrinogen;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06864275	chr19:1174154	SBNO2	0.62	7.34	0.51	1.19e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg02421172	chr7:1938701	MAD1L1	-0.61	-4.3	-0.33	2.99e-5	Bipolar disorder;
PAAD	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.87	10.46	0.65	1.29e-19	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg09854653	chr6:163834903	QKI	-0.69	-4.31	-0.33	2.87e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.67e-5	Breast cancer;
PAAD	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.93	-0.37	2.15e-6	Tuberculosis;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg14420613	chr2:204082562	NBEAL1	-0.61	-6.98	-0.49	8.52e-11	Energy expenditure (24h);
PAAD	cis	rs11264213	0.901	rs688833	chr1:36455600	C/T	cg27506609	chr1:36549197	TEKT2	0.73	5.2	0.39	6.3e-7	Schizophrenia;
PAAD	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.79	8.52	0.57	1.48e-14	Mean corpuscular volume;
PAAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.63	6.18	0.45	5.72e-9	Lung cancer;
PAAD	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.29	0.51	1.56e-11	Neuroticism;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	17.14	0.81	2.5e-37	Height;
PAAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14169450	chr9:139327907	INPP5E	0.53	4.68	0.35	6.42e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.58	6.57	0.47	7.71e-10	Cardiovascular disease risk factors;
PAAD	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg00536532	chr6:33561449	C6orf227	-0.42	-4.37	-0.33	2.26e-5	Plateletcrit;
PAAD	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg08501292	chr6:25962987	TRIM38	-0.83	-4.33	-0.33	2.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.59	-7.7	-0.53	1.6e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10611863	chr8:22722817	PEBP4	0.59	6.34	0.46	2.52e-9	Myopia (pathological);
PAAD	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs10887741	0.624	rs9633742	chr10:89432286	A/G	cg13926569	chr10:89418898	PAPSS2	0.48	4.95	0.37	1.95e-6	Exercise (leisure time);
PAAD	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg10847032	chr5:142784522	NR3C1	-0.63	-7.36	-0.51	1.07e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.78	0.62	7.97e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs5015933	0.815	rs13297440	chr9:128087200	C/G	cg14078157	chr9:128172775	NA	-0.37	-4.3	-0.33	3.04e-5	Body mass index;
PAAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-7.62	-0.53	2.48e-12	Bone mineral density;
PAAD	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.71	4.87	0.37	2.82e-6	Vitiligo;
PAAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg22764044	chr5:178986830	RUFY1	0.54	5.42	0.4	2.33e-7	Lung cancer;
PAAD	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg18190219	chr22:46762943	CELSR1	-0.72	-4.27	-0.33	3.48e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	5.7	0.42	5.92e-8	Height;
PAAD	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg17470449	chr10:769945	NA	0.52	5.16	0.39	7.72e-7	Uric acid levels;
PAAD	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	5.02	0.38	1.44e-6	Ovarian reserve;
PAAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs79839061	1.000	rs79839061	chr4:705884	G/A	cg07828340	chr4:882639	GAK	0.98	5.67	0.42	7.02e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg23465465	chr6:26364728	BTN3A2	0.8	4.69	0.36	6.06e-6	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.65	7.02	0.49	7.02e-11	Morning vs. evening chronotype;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26418147	chr1:205743515	RAB7L1	-0.43	-5.06	-0.38	1.21e-6	Monocyte percentage of white cells;
PAAD	cis	rs59104589	0.617	rs59934670	chr2:242207285	G/C	cg04488487	chr2:242709673	NA	0.57	4.39	0.34	2.15e-5	Fibrinogen levels;
PAAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.35	15.11	0.77	4.39e-32	Eosinophil percentage of granulocytes;
PAAD	cis	rs12136530	0.562	rs12125959	chr1:19735262	A/G	cg03321592	chr1:19991676	HTR6	0.54	4.86	0.37	2.84e-6	Lead levels in blood;
PAAD	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs11892454	0.515	rs13405775	chr2:26026986	C/T	cg25181710	chr2:26045287	ASXL2	0.43	5.0	0.38	1.53e-6	Heschl's gyrus morphology;
PAAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.89	11.82	0.69	2.79e-23	Methadone dose in opioid dependence;
PAAD	cis	rs7998202	0.667	rs410948	chr13:113370140	C/T	cg02820901	chr13:113351484	ATP11A	0.7	4.64	0.35	7.33e-6	Glycated hemoglobin levels;
PAAD	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.87	-11.09	-0.67	2.6e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.23	11.14	0.67	1.88e-21	Uric acid levels;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.59	4.76	0.36	4.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.83	5.36	0.4	2.97e-7	Systolic blood pressure;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.69	-5.82	-0.43	3.43e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.26	0.33	3.51e-5	Breast cancer;
PAAD	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs2734839	0.964	rs7122246	chr11:113304457	G/A	cg14159747	chr11:113255604	NA	0.45	6.75	0.48	2.94e-10	Information processing speed;
PAAD	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg05585630	chr7:157510462	PTPRN2	-0.77	-8.8	-0.58	2.81e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg06521852	chr22:38141419	TRIOBP	0.45	4.56	0.35	1.04e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02176678	chr2:219576539	TTLL4	0.46	7.27	0.51	1.75e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs73198271	0.595	rs56152067	chr8:8592992	G/A	cg01851573	chr8:8652454	MFHAS1	0.63	4.7	0.36	5.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.49e-9	Height;
PAAD	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg09184832	chr6:79620586	NA	-0.44	-4.36	-0.33	2.38e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg00758881	chr16:58534681	NDRG4	-0.91	-4.9	-0.37	2.47e-6	Schizophrenia;
PAAD	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg11518657	chr1:67396239	MIER1	0.7	5.15	0.39	8.01e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.38	5.55	0.41	1.23e-7	Educational attainment (years of education);
PAAD	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	1.2	13.91	0.75	6.79e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg10431340	chr1:161279108	MPZ	-0.62	-5.64	-0.42	7.99e-8	Rheumatoid arthritis;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.88	11.06	0.67	3.14e-21	Prudent dietary pattern;
PAAD	cis	rs2992756	0.663	rs1316327	chr1:18802387	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.29	7.48	0.52	5.43e-12	Psoriasis vulgaris;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25190491	chr1:2518505	C1orf93	0.63	6.86	0.49	1.65e-10	Myopia (pathological);
PAAD	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg02230254	chr11:65586170	NA	-0.34	-4.96	-0.37	1.83e-6	Eosinophil percentage of white cells;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.43	-0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.5	-6.23	-0.45	4.46e-9	Lewy body disease;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.11	-0.59	4.51e-16	Blood trace element (Zn levels);
PAAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg03948781	chr1:205179583	DSTYK	0.44	4.38	0.34	2.16e-5	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
PAAD	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.69	-0.36	6.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.21e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg01444801	chr10:135216882	MTG1	-0.67	-5.73	-0.42	5.31e-8	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg06217245	chr20:33103252	DYNLRB1	0.44	5.11	0.38	9.72e-7	Height;
PAAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg14926445	chr8:58193284	C8orf71	-0.66	-5.44	-0.4	2.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.82	7.75	0.53	1.21e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.66	5.79	0.42	3.94e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.51	-4.49	-0.34	1.41e-5	Dental caries;
PAAD	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-4.51	-0.34	1.28e-5	Mood instability;
PAAD	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.58	4.51	0.34	1.31e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.51	5.79	0.43	3.92e-8	Neuroticism;
PAAD	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg00262122	chr8:11665843	FDFT1	-0.46	-4.25	-0.33	3.7e-5	Monocyte count;
PAAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.93	9.81	0.62	6.55e-18	Cognitive function;
PAAD	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-5.48	-0.41	1.71e-7	Ankylosing spondylitis;
PAAD	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs6076065	0.723	rs2424552	chr20:23402833	G/A	cg11657817	chr20:23433608	CST11	0.5	4.99	0.38	1.65e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg10556349	chr10:835070	NA	0.55	4.96	0.37	1.86e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2131877	0.830	rs60922537	chr3:194842785	C/G	cg19760965	chr3:194868843	C3orf21	0.49	4.8	0.36	3.75e-6	Non-small cell lung cancer;
PAAD	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg23465465	chr6:26364728	BTN3A2	-0.74	-4.4	-0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.5	5.04	0.38	1.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.63	6.07	0.44	1e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs12760731	0.517	rs11587387	chr1:178229950	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.86	-7.06	-0.5	5.62e-11	Triglycerides;
PAAD	cis	rs8049603	0.812	rs4073931	chr16:23195717	C/T	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.81	-9.49	-0.61	4.67e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg02683114	chr2:24398427	C2orf84	0.45	5.22	0.39	5.69e-7	Asthma;
PAAD	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.76	7.52	0.52	4.45e-12	Callous-unemotional behaviour;
PAAD	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.0	-0.67	4.65e-21	Coronary artery disease;
PAAD	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.98	-0.49	8.48e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.77	-0.36	4.27e-6	Lung cancer;
PAAD	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg27246729	chr12:121163418	ACADS	0.43	4.38	0.33	2.18e-5	Mean corpuscular volume;
PAAD	cis	rs4889855	0.530	rs8080678	chr17:78544003	G/T	cg16591659	chr17:78472290	NA	0.51	4.93	0.37	2.17e-6	Fractional excretion of uric acid;
PAAD	cis	rs35160687	0.901	rs12714179	chr2:86514958	T/C	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs501120	0.925	rs1657345	chr10:44779078	A/G	cg09554077	chr10:44749378	NA	0.39	4.31	0.33	2.97e-5	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.05	-0.38	1.27e-6	Bipolar disorder;
PAAD	cis	rs3112530	0.901	rs308267	chr5:152685455	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.57	-4.83	-0.36	3.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.43	-4.87	-0.37	2.75e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg20917491	chr3:195578259	NA	0.45	4.44	0.34	1.73e-5	Pancreatic cancer;
PAAD	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs8016982	0.548	rs7149294	chr14:81711565	T/C	cg01989461	chr14:81687754	GTF2A1	0.59	4.48	0.34	1.44e-5	Schizophrenia;
PAAD	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.66	-5.95	-0.43	1.82e-8	Diabetic retinopathy;
PAAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10470200	chr5:106715906	EFNA5	-0.56	-6.39	-0.46	1.95e-9	Monocyte percentage of white cells;
PAAD	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.69	7.06	0.5	5.61e-11	Mosquito bite size;
PAAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs6032067	0.683	rs6032029	chr20:43786064	A/G	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.19	9.4	0.61	7.84e-17	Mitochondrial DNA levels;
PAAD	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.6	0.47	6.59e-10	Bladder cancer;
PAAD	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07677032	chr17:61819896	STRADA	-0.54	-5.48	-0.41	1.71e-7	Prudent dietary pattern;
PAAD	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg22467129	chr15:76604101	ETFA	0.53	4.91	0.37	2.3e-6	Blood metabolite levels;
PAAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg01866162	chr16:67596514	CTCF	0.58	4.45	0.34	1.65e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11679753	0.788	rs4672505	chr2:62560332	C/T	cg03282107	chr2:62521430	NA	0.37	4.25	0.33	3.77e-5	Crohn's disease;
PAAD	cis	rs11696501	0.688	rs6073842	chr20:44293841	G/C	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4513299	0.540	rs13000279	chr2:115018653	G/A	cg08267300	chr2:114334065	FAM138B	-0.32	-4.33	-0.33	2.68e-5	Inflammatory biomarkers;
PAAD	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22496380	chr5:211416	CCDC127	-0.97	-6.64	-0.47	5.18e-10	Breast cancer;
PAAD	cis	rs7894051	1.000	rs7907603	chr10:135195977	G/A	cg19176072	chr10:135083742	ADAM8	-0.97	-4.66	-0.35	6.81e-6	Lifespan;
PAAD	cis	rs2070677	0.932	rs3020499	chr10:135381215	A/G	cg20169779	chr10:135381914	SYCE1	0.75	7.36	0.51	1.07e-11	Gout;
PAAD	cis	rs7567389	0.677	rs72848604	chr2:128120118	G/C	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs12612619	0.732	rs11680096	chr2:27273571	T/C	cg00617064	chr2:27272375	NA	-0.54	-5.71	-0.42	5.7e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-4.71	-0.36	5.52e-6	Height;
PAAD	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg14311320	chr7:124405732	GPR37	-0.43	-4.35	-0.33	2.46e-5	Lewy body disease;
PAAD	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg17646820	chr3:66848679	NA	-0.39	-4.34	-0.33	2.61e-5	Type 2 diabetes;
PAAD	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17374651	chr3:195857635	NA	-0.68	-6.89	-0.49	1.4e-10	Obesity-related traits;
PAAD	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.24	-0.39	5.17e-7	Systolic blood pressure;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg11062466	chr8:58055876	NA	0.69	4.75	0.36	4.75e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.69	4.9	0.37	2.44e-6	Inflammatory bowel disease;
PAAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs282587	0.569	rs7987086	chr13:113409889	G/A	cg19217778	chr13:113420270	ATP11A	-0.54	-4.31	-0.33	2.88e-5	Glycated hemoglobin levels;
PAAD	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-5.03	-0.38	1.38e-6	Mean platelet volume;
PAAD	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.14e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	4.39	0.34	2.09e-5	Breast cancer;
PAAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg08999081	chr20:33150536	PIGU	0.5	4.38	0.34	2.16e-5	Protein C levels;
PAAD	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg09980403	chr19:12975529	MAST1	0.3	4.52	0.34	1.25e-5	Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg15181151	chr6:150070149	PCMT1	0.59	6.44	0.46	1.49e-9	Lung cancer;
PAAD	cis	rs7173419	0.607	rs11631735	chr15:28222780	G/A	cg20906524	chr15:28200668	OCA2	-0.46	-5.29	-0.39	4.1e-7	Eye color;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14227687	chr7:100303735	POP7	0.62	6.56	0.47	7.91e-10	Myopia (pathological);
PAAD	cis	rs331079	0.579	rs10036909	chr5:127861692	T/C	cg05209584	chr5:127873283	FBN2	-0.5	-4.36	-0.33	2.37e-5	Heschl's gyrus morphology;
PAAD	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg24553058	chr2:113831203	IL1F10	0.39	4.4	0.34	1.99e-5	Inflammatory biomarkers;
PAAD	cis	rs4662592	0.590	rs11892307	chr2:128863512	T/C	cg03222009	chr2:129077232	HS6ST1	-0.5	-4.68	-0.35	6.39e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg01852476	chr1:2232063	SKI	-0.27	-4.41	-0.34	1.93e-5	Ulcerative colitis;
PAAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg02917321	chr22:38215204	NA	0.47	4.81	0.36	3.55e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.8	-6.96	-0.49	9.7e-11	Blood metabolite levels;
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg19337854	chr7:99768885	GPC2	0.49	4.45	0.34	1.64e-5	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07422560	chr12:82752315	C12orf26;CCDC59	0.63	6.54	0.47	8.92e-10	Myopia (pathological);
PAAD	cis	rs75757892	0.544	rs79008177	chr6:7316276	A/G	cg02954307	chr6:7269328	NA	0.53	4.56	0.35	1.05e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.86	-10.75	-0.66	2.13e-20	Dental caries;
PAAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg25287198	chr4:183728479	NA	0.85	6.98	0.49	8.75e-11	Pediatric autoimmune diseases;
PAAD	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg21698718	chr17:80085957	CCDC57	-0.47	-5.3	-0.4	3.92e-7	Life satisfaction;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs4388249	0.687	rs2269204	chr5:109099103	G/T	cg17395555	chr5:108820864	NA	0.31	4.28	0.33	3.29e-5	Schizophrenia;
PAAD	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.53	-4.99	-0.38	1.62e-6	P wave terminal force;
PAAD	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg01868782	chr6:126071099	HEY2	0.37	4.3	0.33	3.02e-5	Brugada syndrome;
PAAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.57	6.21	0.45	4.73e-9	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.85	9.16	0.6	3.35e-16	Tuberculosis;
PAAD	cis	rs28830936	0.934	rs28401754	chr15:42116903	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.59	-7.31	-0.51	1.45e-11	Diastolic blood pressure;
PAAD	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.4	-5.76	-0.42	4.44e-8	Subjective well-being;
PAAD	cis	rs354225	0.544	rs12713264	chr2:54805218	A/C	cg01766943	chr2:54829624	SPTBN1	-0.5	-4.46	-0.34	1.56e-5	Schizophrenia;
PAAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg01299579	chr2:10830716	NOL10	-0.56	-5.91	-0.43	2.18e-8	Prostate cancer;
PAAD	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.71	-7.76	-0.53	1.16e-12	Eosinophil percentage of white cells;
PAAD	cis	rs8060686	0.858	rs12449157	chr16:67708897	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.99	-0.38	1.63e-6	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.8	-9.28	-0.6	1.58e-16	Height;
PAAD	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg27565382	chr3:53032988	SFMBT1	-0.72	-4.47	-0.34	1.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg11766577	chr21:47581405	C21orf56	0.41	4.63	0.35	7.9e-6	Testicular germ cell tumor;
PAAD	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-4.44	-0.34	1.75e-5	Testicular germ cell tumor;
PAAD	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.61e-6	Life satisfaction;
PAAD	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.0	-11.68	-0.69	6.69e-23	Primary sclerosing cholangitis;
PAAD	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg24747557	chr10:131355152	MGMT	-0.52	-5.43	-0.4	2.24e-7	Response to temozolomide;
PAAD	cis	rs2637030	0.559	rs2636991	chr5:52943067	T/G	cg17674090	chr5:52083609	ITGA1;PELO	0.56	4.27	0.33	3.47e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.51	5.51	0.41	1.53e-7	Height;
PAAD	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg16590910	chr6:42928470	GNMT	0.55	5.55	0.41	1.26e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg06042504	chr8:55087323	NA	-0.77	-8.67	-0.58	6.01e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.5	-4.95	-0.37	1.91e-6	Multiple myeloma;
PAAD	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.46	0.34	1.6e-5	Myopia (pathological);
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg01097406	chr16:89675127	NA	0.37	4.51	0.34	1.31e-5	Vitiligo;
PAAD	cis	rs12475964	0.574	rs12994644	chr2:37381658	G/T	cg22370082	chr2:37384244	EIF2AK2	0.46	4.51	0.34	1.3e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg20673841	chr7:107026890	COG5	0.5	4.29	0.33	3.21e-5	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.67	-0.35	6.71e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg02462569	chr6:150064036	NUP43	0.45	5.07	0.38	1.16e-6	Lung cancer;
PAAD	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg17333051	chr19:2783644	SGTA	0.46	5.1	0.38	1e-6	Total cholesterol levels;
PAAD	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.76	8.64	0.57	7.11e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg09471204	chr22:42347991	LOC339674	-0.39	-5.27	-0.39	4.54e-7	Intelligence;
PAAD	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg08999081	chr20:33150536	PIGU	0.53	5.88	0.43	2.51e-8	Height;
PAAD	cis	rs10121009	0.635	rs642223	chr9:35301959	A/G	cg11846315	chr9:35647073	NA	-0.47	-4.31	-0.33	2.92e-5	Parkinson's disease;
PAAD	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-11.49	-0.68	2.18e-22	Body mass index;
PAAD	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.11	0.55	1.56e-13	Asthma;
PAAD	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.72	5.36	0.4	3.02e-7	White matter hyperintensity burden;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg08699206	chr4:1595414	NA	0.45	4.42	0.34	1.86e-5	Obesity-related traits;
PAAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.88	-9.61	-0.61	2.29e-17	Colorectal cancer;
PAAD	cis	rs2882667	0.690	rs274118	chr5:138064887	A/G	cg09476006	chr5:138032270	NA	0.49	6.4	0.46	1.86e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.48	5.9	0.43	2.29e-8	Sitting height ratio;
PAAD	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.69	-0.48	4e-10	Psoriasis;
PAAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.75	-8.25	-0.56	6.98e-14	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4740619	0.935	rs10481557	chr9:15604746	G/T	cg14451791	chr9:16040625	NA	0.36	4.28	0.33	3.27e-5	Body mass index;
PAAD	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1819043	1.000	rs705747	chr1:202505283	C/T	cg01036148	chr1:201951866	RNPEP	-0.45	-4.31	-0.33	2.95e-5	Sex ratio;
PAAD	cis	rs2124910	0.717	rs1551556	chr19:52005669	G/A	cg14953197	chr19:52005651	SIGLEC12	0.49	5.24	0.39	5.2e-7	Blood protein levels;
PAAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.34	-0.33	2.64e-5	Aortic root size;
PAAD	cis	rs17534004	1.000	rs17599764	chr13:31469580	G/A	cg00570269	chr13:31480942	C13orf33	0.59	4.43	0.34	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11037575	0.654	rs7129029	chr11:43742477	A/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.38	-0.33	2.18e-5	Neuroblastoma;
PAAD	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.43	-4.27	-0.33	3.49e-5	Daytime sleep phenotypes;
PAAD	cis	rs6604026	0.630	rs11583491	chr1:93463949	C/T	cg17283838	chr1:93427260	FAM69A	0.64	5.82	0.43	3.42e-8	Multiple sclerosis;
PAAD	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	1.03	8.81	0.58	2.68e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.76	-7.2	-0.5	2.61e-11	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.66	-6.38	-0.46	2.03e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs7619427	1.000	rs6804901	chr3:44066663	G/A	cg12796028	chr3:44040206	NA	-0.53	-4.33	-0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.82	-0.62	6.35e-18	Alzheimer's disease (late onset);
PAAD	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.76	5.8	0.43	3.75e-8	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-4.48	-0.34	1.47e-5	Neuroticism;
PAAD	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg10434728	chr15:90938212	IQGAP1	-0.49	-5.01	-0.38	1.48e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs593531	0.513	rs7120394	chr11:74034473	G/T	cg23327896	chr11:73669290	DNAJB13	0.33	4.44	0.34	1.71e-5	Neuroticism;
PAAD	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg15685922	chr1:156045208	MEX3A	-0.67	-7.58	-0.52	3.18e-12	Ischemic stroke;
PAAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.84	-7.9	-0.54	5.31e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.46	5.74	0.42	5.05e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.23	0.6	2.21e-16	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06671706	chr8:8559999	CLDN23	0.68	6.11	0.44	7.83e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.54	5.35	0.4	3.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-5.52	-0.41	1.42e-7	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.1	-0.44	8.6e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg23752985	chr2:85803571	VAMP8	0.55	6.19	0.45	5.45e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.32	-0.46	2.74e-9	Retinal vascular caliber;
PAAD	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg11802864	chr11:65308245	LTBP3	0.81	5.65	0.42	7.64e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.55	5.09	0.38	1.03e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.39	-5.16	-0.39	7.44e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00259584	chr2:106986308	NA	0.59	6.52	0.47	9.89e-10	Smoking initiation;
PAAD	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.51	5.14	0.38	8.27e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg14388049	chr10:71211838	TSPAN15	-0.49	-5.22	-0.39	5.78e-7	Thrombosis;
PAAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.64	0.53	2.32e-12	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.82	-8.19	-0.55	1.02e-13	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg00579200	chr11:133705235	NA	-0.48	-5.54	-0.41	1.27e-7	Childhood ear infection;
PAAD	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.96	-13.58	-0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23549367	chr3:189720477	LEPREL1	-0.7	-7.05	-0.5	5.74e-11	Obesity-related traits;
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00166722	chr3:10149974	C3orf24	0.68	6.12	0.44	7.8e-9	Alzheimer's disease;
PAAD	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.49	4.76	0.36	4.49e-6	HDL cholesterol;
PAAD	cis	rs9815354	1.000	rs9826058	chr3:41762062	A/G	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	7.9e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg05865280	chr17:75406074	SEPT9	0.65	9.46	0.61	5.46e-17	Airflow obstruction;
PAAD	cis	rs8005172	0.712	rs12881373	chr14:88391333	A/G	cg18078958	chr14:88630771	NA	-0.47	-5.55	-0.41	1.21e-7	Parkinson's disease;
PAAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27323088	chr5:89770393	MBLAC2;POLR3G	-0.76	-6.59	-0.47	6.73e-10	Neuroticism;
PAAD	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.39	-4.89	-0.37	2.59e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-5.25	-0.39	5.15e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.95	-0.43	1.82e-8	QT interval;
PAAD	cis	rs7727544	0.647	rs7721882	chr5:131418948	A/G	cg14196790	chr5:131705035	SLC22A5	0.48	5.1	0.38	9.9e-7	Blood metabolite levels;
PAAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.61	-4.85	-0.37	2.96e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8177179	0.503	rs9985395	chr3:133413119	A/G	cg24879335	chr3:133465180	TF	-0.45	-5.06	-0.38	1.21e-6	Iron status biomarkers (transferrin levels);
PAAD	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg12560992	chr17:57184187	TRIM37	0.67	4.92	0.37	2.21e-6	Vitamin D levels;
PAAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.84	-9.57	-0.61	2.8e-17	Ulcerative colitis;
PAAD	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.9	0.37	2.4e-6	Interstitial lung disease;
PAAD	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.95	4.92	0.37	2.25e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg13722127	chr7:150037890	RARRES2	0.59	5.67	0.42	7.09e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	0.56	6.15	0.45	6.58e-9	Hypothyroidism;
PAAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.97	-9.94	-0.63	3.07e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs704	0.563	rs2239910	chr17:26723666	A/C	cg10342447	chr17:26645325	TMEM97	-0.4	-5.21	-0.39	6.13e-7	Osteoprotegerin levels;
PAAD	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg16898833	chr6:26189333	HIST1H4D	0.92	5.04	0.38	1.3e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.38	-4.7	-0.36	5.81e-6	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg00717180	chr2:96193071	NA	0.57	6.41	0.46	1.75e-9	HDL cholesterol;
PAAD	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs17286411	0.750	rs4788579	chr16:71951845	A/C	cg16558253	chr16:72132732	DHX38	-0.4	-4.49	-0.34	1.43e-5	Blood protein levels;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.62	6.74	0.48	3.04e-10	Mean corpuscular volume;
PAAD	cis	rs2030114	1.000	rs17340242	chr16:51612225	A/G	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.94	0.37	2.02e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6887276	0.504	rs28540272	chr5:127348899	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.47	-4.8	-0.36	3.81e-6	Height;
PAAD	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.15	0.6	3.5e-16	Asthma;
PAAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00292662	chr22:38071168	LGALS1	0.65	6.81	0.48	2.14e-10	Fat distribution (HIV);
PAAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.51	5.88	0.43	2.5e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.61	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12612619	0.704	rs2119026	chr2:27310393	A/G	cg07507200	chr2:27712693	IFT172	0.48	4.26	0.33	3.59e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.9	12.23	0.7	2.19e-24	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13734953	chr10:13708059	FRMD4A	0.55	6.82	0.48	1.97e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg07747251	chr5:1868357	NA	0.56	6.4	0.46	1.86e-9	Cardiovascular disease risk factors;
PAAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.54	-5.15	-0.39	7.9e-7	Aortic root size;
PAAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.59	6.9	0.49	1.35e-10	Bipolar disorder;
PAAD	cis	rs1355223	0.902	rs11607035	chr11:34718911	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-4.28	-0.33	3.24e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2031532	0.565	rs11619265	chr13:50057633	A/G	cg03651054	chr13:50194643	NA	0.32	4.36	0.33	2.39e-5	Cardiac hypertrophy;
PAAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.51	-0.34	1.27e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.4	-4.69	-0.36	6e-6	Pubertal anthropometrics;
PAAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.57	4.99	0.38	1.62e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00945038	chr17:61921165	SMARCD2	-0.45	-5.33	-0.4	3.48e-7	Prudent dietary pattern;
PAAD	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.63	4.7	0.36	5.78e-6	Thyroid stimulating hormone;
PAAD	cis	rs9649465	0.967	rs6944031	chr7:123299304	T/C	cg04330084	chr7:123175371	IQUB	-0.54	-5.18	-0.39	7.09e-7	Migraine;
PAAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.92	-10.53	-0.65	8.4e-20	Cancer (pleiotropy);
PAAD	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.47	-0.34	1.5e-5	Reticulocyte count;
PAAD	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs2790216	1.000	rs2790238	chr10:59983573	G/A	cg20442379	chr10:60024634	IPMK	-0.56	-4.25	-0.33	3.75e-5	Inflammatory bowel disease;
PAAD	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.44	4.54	0.35	1.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-4.45	-0.34	1.64e-5	Major depressive disorder;
PAAD	cis	rs8012	0.517	rs17706531	chr19:13015530	A/G	cg15585409	chr19:12750806	NA	0.47	4.32	0.33	2.75e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
PAAD	cis	rs988913	0.601	rs3125261	chr6:54846081	C/A	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs9888739	1.000	rs12928810	chr16:31311715	G/A	cg02256631	chr16:31342952	ITGAM	-0.53	-4.29	-0.33	3.11e-5	Systemic lupus erythematosus;
PAAD	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.07	0.59	5.6e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.41	0.34	1.94e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.64	-0.42	8.15e-8	Lung cancer;
PAAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg21351543	chr2:191399470	TMEM194B	-0.6	-4.62	-0.35	7.99e-6	Diastolic blood pressure;
PAAD	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.43	0.34	1.76e-5	Tonsillectomy;
PAAD	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.66	6.66	0.48	4.76e-10	Uric acid levels;
PAAD	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs11651753	0.636	rs4794332	chr17:46040567	C/G	cg24458315	chr17:46148407	CBX1	0.42	4.46	0.34	1.6e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-4.83	-0.36	3.32e-6	Longevity;
PAAD	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.23	-9.9	-0.63	3.81e-18	Corneal structure;
PAAD	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.91	11.1	0.67	2.5e-21	Schizophrenia;
PAAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg01966878	chr4:90757139	SNCA	-0.46	-4.35	-0.33	2.46e-5	Dementia with Lewy bodies;
PAAD	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg26751094	chr13:95954534	ABCC4	-0.46	-4.99	-0.38	1.63e-6	Blood metabolite levels;
PAAD	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg12290671	chr7:99195819	NA	-0.87	-4.78	-0.36	4.11e-6	Blood metabolite ratios;
PAAD	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.54	0.41	1.32e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25225968	chr3:8543159	LMCD1	0.6	6.72	0.48	3.42e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.57	-6.32	-0.46	2.8e-9	Sense of smell;
PAAD	cis	rs12936587	0.601	rs8068296	chr17:17554563	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-5.2	-0.39	6.42e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg27121462	chr16:89883253	FANCA	0.49	5.16	0.39	7.51e-7	Vitiligo;
PAAD	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.33	-6.17	-0.45	6e-9	Type 2 diabetes;
PAAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg10556349	chr10:835070	NA	0.58	4.64	0.35	7.35e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2506028	0.930	rs2506029	chr10:43445426	A/T	cg20628663	chr10:43360327	NA	-0.36	-4.29	-0.33	3.14e-5	Blood protein levels;
PAAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	9.88e-6	Melanoma;
PAAD	cis	rs2073499	0.935	rs2624840	chr3:50199015	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.67	-4.96	-0.37	1.84e-6	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg25401027	chr5:176370377	UIMC1	0.45	4.56	0.35	1.07e-5	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.54	5.39	0.4	2.66e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-1.03	-9.44	-0.61	6.06e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs16958440	0.867	rs58061761	chr18:44686165	T/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.65	-5.73	-0.42	5.32e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6976053	0.868	rs12705094	chr7:100477829	G/A	cg22425096	chr7:100417404	EPHB4	0.5	4.31	0.33	2.91e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	7.12	0.5	3.95e-11	Type 2 diabetes;
PAAD	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.86	-0.37	2.95e-6	Hirschsprung disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01937399	chr7:5233952	WIPI2	-0.61	-7.21	-0.5	2.45e-11	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22496380	chr5:211416	CCDC127	-0.9	-6.49	-0.47	1.14e-9	Breast cancer;
PAAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.528	rs12196818	chr6:44911414	G/A	cg25276700	chr6:44698697	NA	0.47	5.53	0.41	1.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09592456	chr22:19780308	GNB1L	-0.62	-6.69	-0.48	3.98e-10	Smoking initiation;
PAAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg07689907	chr11:61582574	FADS1	-0.49	-4.86	-0.37	2.91e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.55	-4.36	-0.33	2.37e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.21	11.68	0.69	6.63e-23	Platelet count;
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.44	-0.34	1.69e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.32	-0.4	3.6e-7	Reticulocyte count;
PAAD	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-8.93	-0.59	1.33e-15	Vitiligo;
PAAD	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.48	-4.5	-0.34	1.34e-5	Triglycerides;
PAAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.89	9.74	0.62	1.04e-17	Anterior chamber depth;
PAAD	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.64	-6.21	-0.45	4.92e-9	Breast size;
PAAD	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.48	5.49	0.41	1.65e-7	Coronary artery disease;
PAAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.99	13.53	0.74	7.28e-28	Menarche (age at onset);
PAAD	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.54	0.35	1.12e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10044254	0.563	rs12152734	chr5:15694406	A/G	cg07238450	chr5:15720153	FBXL7	-0.52	-4.79	-0.36	3.9e-6	Asthma (corticosteroid response);
PAAD	cis	rs9815354	0.723	rs61182696	chr3:42032511	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.27	10.47	0.65	1.15e-19	Uric acid levels;
PAAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.63	-0.35	7.63e-6	Personality dimensions;
PAAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg05785598	chr3:49045655	WDR6	0.42	5.15	0.39	7.88e-7	Parkinson's disease;
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg04520793	chr17:42248056	ASB16	-0.45	-4.93	-0.37	2.1e-6	Total body bone mineral density;
PAAD	cis	rs7631605	0.905	rs9832423	chr3:37176116	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20890180	chr2:106560771	NA	-0.61	-6.31	-0.46	2.83e-9	Obesity-related traits;
PAAD	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.58	-5.5	-0.41	1.54e-7	Menarche (age at onset);
PAAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.39	0.4	2.6e-7	Bipolar disorder;
PAAD	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.09	0.38	1.06e-6	Menarche (age at onset);
PAAD	cis	rs2004318	1.000	rs79359901	chr19:55078603	T/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20307385	chr11:47447363	PSMC3	-0.53	-5.15	-0.39	7.94e-7	Subjective well-being;
PAAD	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	ch.8.33884649F	chr8:33765107	NA	0.61	6.43	0.46	1.53e-9	Body mass index;
PAAD	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.76	9.71	0.62	1.24e-17	Height;
PAAD	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-0.8	-4.89	-0.37	2.54e-6	Lung cancer;
PAAD	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.88	-0.43	2.57e-8	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg02199589	chr7:77428242	PHTF2;TMEM60	0.67	7.43	0.52	7.51e-12	Myopia (pathological);
PAAD	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg16810054	chr20:33298113	TP53INP2	-0.6	-4.82	-0.36	3.41e-6	Neuroticism;
PAAD	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.54	7.49	0.52	5.38e-12	IgA nephropathy;
PAAD	cis	rs10850408	0.922	rs2195097	chr12:115373781	A/G	cg05726002	chr12:115341178	NA	0.4	4.73	0.36	5.03e-6	Alzheimer's disease;
PAAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.96	-7.92	-0.54	4.63e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs73719811	1.000	rs10488048	chr7:121220682	A/G	cg22032706	chr7:120498729	TSPAN12	0.67	4.41	0.34	1.98e-5	Total body bone mineral density;
PAAD	cis	rs75920871	0.588	rs6589580	chr11:116819873	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-4.42	-0.34	1.88e-5	Subjective well-being;
PAAD	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.65	0.57	6.65e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg25155006	chr6:37138205	PIM1	-0.55	-4.43	-0.34	1.76e-5	QRS duration;
PAAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg07148914	chr20:33460835	GGT7	0.5	4.87	0.37	2.76e-6	Coronary artery disease;
PAAD	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg23033748	chr14:75592666	NEK9	-0.43	-5.45	-0.4	1.99e-7	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04498032	chr1:155242826	CLK2	0.6	6.63	0.47	5.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg25902810	chr10:99078978	FRAT1	0.53	5.27	0.39	4.53e-7	Monocyte count;
PAAD	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg21427119	chr20:30132790	HM13	-0.51	-4.66	-0.35	6.78e-6	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.33	-0.46	2.67e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12286929	0.515	rs6589486	chr11:115084297	T/C	cg04055981	chr11:115044050	NA	0.49	4.92	0.37	2.19e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.51	4.99	0.37	1.66e-6	Parkinson's disease;
PAAD	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	0.42	4.74	0.36	4.8e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9581857	0.547	rs9581869	chr13:28082498	G/A	cg22138327	chr13:27999177	GTF3A	0.83	5.34	0.4	3.29e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01756814	chr4:111119868	ELOVL6	0.61	7.15	0.5	3.4e-11	Monocyte percentage of white cells;
PAAD	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.91	-0.37	2.36e-6	Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.73	8.35	0.56	4e-14	Lung cancer;
PAAD	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg16586182	chr3:47516702	SCAP	0.65	7.12	0.5	4.1e-11	Colorectal cancer;
PAAD	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.45	4.46	0.34	1.59e-5	Adiposity;
PAAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.87	8.68	0.58	5.62e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2790216	0.950	rs2440858	chr10:59965710	G/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.73	7.99	0.54	3.16e-13	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.46	-5.34	-0.4	3.25e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs30380	0.690	rs2216752	chr5:96185467	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.5	-5.05	-0.38	1.22e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6909229	0.613	rs650035	chr6:158622810	C/T	cg02332782	chr6:157801523	ZDHHC14	0.53	4.26	0.33	3.56e-5	Lipoprotein (a) levels;
PAAD	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.49	4.41	0.34	1.98e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg02733842	chr7:1102375	C7orf50	-0.53	-4.28	-0.33	3.31e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-1.13	-12.41	-0.71	7.16e-25	Hair shape;
PAAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.71	-7.78	-0.53	1.02e-12	Melanoma;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	10.43	0.65	1.47e-19	Platelet count;
PAAD	cis	rs116095464	1.000	rs116095464	chr5:345109	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg05110241	chr16:68378359	PRMT7	-0.88	-7.16	-0.5	3.24e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.49	-0.34	1.37e-5	Life satisfaction;
PAAD	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.76	-8.13	-0.55	1.39e-13	Prostate cancer;
PAAD	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg07313626	chr1:247681931	NA	0.49	5.13	0.38	8.56e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg03808351	chr9:123631620	PHF19	0.42	4.4	0.34	2.07e-5	Rheumatoid arthritis;
PAAD	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.42	0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12509435	chr12:94853886	CCDC41;LOC144486	-0.63	-7.22	-0.51	2.33e-11	Body fat percentage;
PAAD	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00142150	chr22:38071001	LGALS1	0.69	7.73	0.53	1.39e-12	Fat distribution (HIV);
PAAD	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg02421172	chr7:1938701	MAD1L1	0.6	4.82	0.36	3.44e-6	Bipolar disorder;
PAAD	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.5	5.71	0.42	5.69e-8	Coronary artery disease;
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.38	0.4	2.81e-7	Rheumatoid arthritis;
PAAD	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg13444538	chr7:158905317	VIPR2	-0.72	-5.59	-0.41	1.02e-7	Facial morphology (factor 20);
PAAD	cis	rs9467603	0.858	rs4712972	chr6:25772047	A/G	cg21479132	chr6:26055353	NA	-0.74	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg05528293	chr18:74961138	GALR1	-0.5	-4.69	-0.36	6.12e-6	Obesity-related traits;
PAAD	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.31	-0.33	2.97e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg13332499	chr17:408570	NA	0.57	6.2	0.45	5.01e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg09222892	chr1:25734099	RHCE	-0.45	-4.4	-0.34	2.04e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.57	7.11	0.5	4.26e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.83	9.03	0.59	7.05e-16	Mortality in heart failure;
PAAD	cis	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs1532557	1.000	rs73115953	chr1:224768958	G/T	cg09988837	chr1:224811939	CNIH3	0.62	4.54	0.35	1.15e-5	Cancer;
PAAD	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.57	0.35	9.93e-6	Alzheimer's disease (survival time);
PAAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.65	-0.57	6.99e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	1.23	15.54	0.78	3.4e-33	Ewing sarcoma;
PAAD	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg02725872	chr8:58115012	NA	-0.6	-4.93	-0.37	2.09e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.66	6.85	0.49	1.7e-10	Depressive symptoms;
PAAD	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	5.85	0.43	2.96e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.65	6.99	0.49	8.17e-11	Resting heart rate;
PAAD	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg13010199	chr12:38710504	ALG10B	0.59	5.15	0.39	7.9e-7	Morning vs. evening chronotype;
PAAD	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs7246760	1.000	rs10425775	chr19:9912917	G/A	cg16876255	chr19:9731953	ZNF561	0.94	4.49	0.34	1.42e-5	Pursuit maintenance gain;
PAAD	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.13e-5	Noise-induced hearing loss;
PAAD	cis	rs9366664	0.900	rs4713019	chr6:10898765	G/A	cg13620881	chr6:10888129	SYCP2L	-0.41	-4.26	-0.33	3.61e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs9810890	1.000	rs6768014	chr3:128592457	A/G	cg16818395	chr3:128274084	NA	0.45	4.44	0.34	1.74e-5	Dental caries;
PAAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg23281280	chr6:28129359	ZNF389	0.49	4.35	0.33	2.47e-5	Parkinson's disease;
PAAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg11764359	chr7:65958608	NA	0.75	4.95	0.37	1.91e-6	Diabetic kidney disease;
PAAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.86	-7.82	-0.54	8.17e-13	Obesity;Body mass index;
PAAD	cis	rs959260	1.000	rs2033609	chr17:73367021	C/T	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.36	-0.33	2.42e-5	Systemic lupus erythematosus;
PAAD	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs13144136	0.687	rs11737643	chr4:10658199	T/A	cg10242279	chr4:10666415	CLNK	-0.48	-6.09	-0.44	8.78e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg20636351	chr8:55087400	NA	-0.79	-8.68	-0.58	5.7e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2627282	0.577	rs921781	chr8:2772311	A/G	cg21769514	chr8:2743697	NA	-0.42	-4.34	-0.33	2.56e-5	Blood pressure measurement (high sodium intervention);
PAAD	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg21665744	chr7:39171113	POU6F2	0.29	4.92	0.37	2.19e-6	IgG glycosylation;
PAAD	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.98	7.98	0.54	3.34e-13	Bipolar disorder;
PAAD	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.41	-0.34	1.96e-5	Reticulocyte count;
PAAD	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	6.39	0.46	1.93e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg04315214	chr1:2043799	PRKCZ	0.68	9.84	0.62	5.63e-18	Height;
PAAD	cis	rs1605857	0.593	rs7585029	chr2:102176977	A/G	cg13504055	chr2:102234418	NA	-0.47	-4.35	-0.33	2.49e-5	Facial morphology (factor 17, height of vermillion upper lip);
PAAD	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg23127183	chr11:57508653	C11orf31	-0.52	-4.42	-0.34	1.88e-5	Schizophrenia;
PAAD	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.49	0.34	1.38e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg05425664	chr17:57184151	TRIM37	-0.51	-4.98	-0.37	1.72e-6	Testicular germ cell tumor;
PAAD	cis	rs7932354	0.798	rs2282686	chr11:46750638	T/C	cg19486271	chr11:47235900	DDB2	0.56	5.81	0.43	3.48e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg01444801	chr10:135216882	MTG1	0.59	5.38	0.4	2.82e-7	Systemic lupus erythematosus;
PAAD	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg12311346	chr5:56204834	C5orf35	-0.61	-5.04	-0.38	1.33e-6	Coronary artery disease;
PAAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.51	0.47	1.03e-9	Body mass index;
PAAD	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-4.71	-0.36	5.45e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg23465465	chr6:26364728	BTN3A2	0.78	4.51	0.34	1.29e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.4	-4.95	-0.37	1.97e-6	Iron status biomarkers;
PAAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg01494348	chr8:144660395	NAPRT1	0.94	4.88	0.37	2.68e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.72	-9.32	-0.6	1.3e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	trans	rs61931739	0.500	rs7134491	chr12:34443072	C/T	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.78e-13	Morning vs. evening chronotype;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05061393	chr2:220043337	FAM134A	-0.56	-6.47	-0.46	1.3e-9	Body fat percentage;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.71	7.65	0.53	2.15e-12	Uric acid levels;
PAAD	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.33	-0.46	2.66e-9	Exhaled nitric oxide output;
PAAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg15193198	chr20:60906057	LAMA5	-0.53	-5.22	-0.39	5.66e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.33	-0.64	2.79e-19	Response to antipsychotic treatment;
PAAD	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-4.29	-0.33	3.18e-5	Morning vs. evening chronotype;
PAAD	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.85	-8.78	-0.58	3.24e-15	Body mass index;
PAAD	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg10985347	chr2:127963512	CYP27C1	0.48	4.69	0.36	5.96e-6	Protein C levels;
PAAD	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg07164556	chr1:145727247	PDZK1	-0.69	-4.63	-0.35	7.7e-6	Mitochondrial DNA levels;
PAAD	cis	rs10207060	0.500	rs7600350	chr2:240716225	T/C	cg07506560	chr2:240697449	NA	0.56	5.81	0.43	3.58e-8	Obesity-related traits;
PAAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg09873201	chr16:3507582	NAT15	0.56	5.34	0.4	3.35e-7	Tuberculosis;
PAAD	cis	rs9810890	1.000	rs73198861	chr3:128516182	A/G	cg18531004	chr3:128564980	NA	-0.86	-4.96	-0.37	1.9e-6	Dental caries;
PAAD	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.33	-0.51	1.25e-11	Total cholesterol levels;
PAAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.96	8.29	0.56	5.53e-14	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg00280220	chr17:61926910	NA	0.42	4.3	0.33	3.01e-5	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22455660	chr9:128509791	PBX3	0.59	6.41	0.46	1.78e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.48	-6.13	-0.45	7.3e-9	Crohn's disease;
PAAD	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.59	-4.31	-0.33	2.97e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1499972	0.504	rs1353910	chr3:117778176	C/T	cg07612923	chr3:117604196	NA	-0.71	-5.05	-0.38	1.26e-6	Schizophrenia;
PAAD	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.75	6.09	0.44	8.83e-9	Blood protein levels;
PAAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.83	10.03	0.63	1.7e-18	Menopause (age at onset);
PAAD	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.39	-4.46	-0.34	1.6e-5	Pubertal anthropometrics;
PAAD	cis	rs4908768	0.657	rs6693466	chr1:8817938	C/T	cg13225830	chr1:9527173	NA	0.37	4.34	0.33	2.56e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11432751	chr19:40854313	C19orf47;PLD3	0.56	6.46	0.46	1.34e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14431619	chr19:11266544	SPC24	0.62	6.76	0.48	2.81e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	1.02	8.15	0.55	1.25e-13	Initial pursuit acceleration;
PAAD	cis	rs9659323	0.622	rs6689568	chr1:119502961	A/G	cg17326555	chr1:119535693	NA	-0.37	-4.59	-0.35	9.24e-6	Body mass index;
PAAD	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.72	7.32	0.51	1.36e-11	Uric acid levels;
PAAD	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.95	0.37	1.91e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg09491104	chr22:46646882	C22orf40	-1.02	-6.15	-0.45	6.46e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.37	0.33	2.29e-5	Menopause (age at onset);
PAAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	4.84	0.37	3.11e-6	Free thyroxine concentration;
PAAD	cis	rs5009270	0.512	rs75795332	chr7:112241690	G/A	cg25550468	chr7:112262557	NA	0.47	4.4	0.34	2e-5	Osteoarthritis (hip);
PAAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.71	7.95	0.54	3.94e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs4481887	0.751	rs10159227	chr1:248425898	G/C	cg01631408	chr1:248437212	OR2T33	-0.62	-5.63	-0.42	8.39e-8	Common traits (Other);
PAAD	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.72	5.6	0.41	9.86e-8	Schizophrenia;
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.54	-0.35	1.14e-5	Life satisfaction;
PAAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs7808424	0.651	rs17132543	chr7:116932534	A/G	cg00307073	chr7:116502428	CAPZA2	0.68	4.27	0.33	3.36e-5	Coronary heart disease;
PAAD	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.83	-9.58	-0.61	2.6e-17	Bipolar disorder;
PAAD	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.58	5.5	0.41	1.56e-7	HDL cholesterol;
PAAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg19223190	chr17:80058835	NA	0.52	5.35	0.4	3.21e-7	Life satisfaction;
PAAD	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11168618	0.870	rs7302209	chr12:48895384	T/C	cg01881778	chr12:48919444	OR8S1	-0.46	-4.63	-0.35	7.67e-6	Adiponectin levels;
PAAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.76	0.36	4.46e-6	Menopause (age at onset);
PAAD	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.51	6.23	0.45	4.3e-9	Sitting height ratio;
PAAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg04990556	chr1:26633338	UBXN11	-0.51	-4.29	-0.33	3.17e-5	Obesity-related traits;
PAAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs8040855	0.965	rs4843027	chr15:85715123	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.43	4.35	0.33	2.48e-5	Bulimia nervosa;
PAAD	trans	rs901683	0.850	rs76294334	chr10:45964279	T/C	cg13065504	chr15:42448234	PLA2G4F	0.82	6.42	0.46	1.67e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs80346118	0.673	rs2869676	chr20:47424026	C/T	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	-0.63	-4.58	-0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.32	-0.56	4.79e-14	Vitiligo;
PAAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg26695010	chr11:65641043	EFEMP2	0.46	4.46	0.34	1.62e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg23033748	chr14:75592666	NEK9	-0.4	-4.78	-0.36	4.08e-6	Height;
PAAD	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg24130564	chr14:104152367	KLC1	-0.47	-4.58	-0.35	9.81e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg08558340	chr7:100472263	SRRT	0.52	4.6	0.35	8.71e-6	Resting heart rate;
PAAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg10645314	chr2:3704589	ALLC	-0.5	-5.37	-0.4	2.95e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09247346	chr2:219081710	ARPC2	0.57	6.45	0.46	1.42e-9	Monocyte percentage of white cells;
PAAD	cis	rs3112530	1.000	rs300332	chr5:152723341	T/G	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-4.6	-0.35	8.78e-6	Ulcerative colitis;
PAAD	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg19254793	chr6:44695348	NA	-0.4	-4.36	-0.33	2.39e-5	Total body bone mineral density;
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg19445457	chr11:5799446	OR52N5	-0.51	-4.53	-0.35	1.17e-5	DNA methylation (variation);
PAAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-8.77	-0.58	3.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.71	-7.23	-0.51	2.19e-11	Type 2 diabetes;
PAAD	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg05895507	chr15:77155635	SCAPER	0.39	4.29	0.33	3.11e-5	Blood metabolite levels;
PAAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	5.07	0.38	1.15e-6	Schizophrenia;
PAAD	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg05585544	chr11:47624801	NA	0.47	5.16	0.39	7.46e-7	Subjective well-being;
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.86	-10.74	-0.66	2.27e-20	Body mass index;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-0.73	-5.29	-0.39	4.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6929137	0.632	rs66688403	chr6:151958153	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.55	-4.64	-0.35	7.5e-6	Bone mineral density (spine);
PAAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg18279126	chr7:2041391	MAD1L1	0.61	6.07	0.44	9.91e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg13870426	chr17:30244630	NA	-0.7	-6.61	-0.47	6.24e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs367943	0.666	rs6594703	chr5:112691999	A/G	cg12552261	chr5:112820674	MCC	0.64	6.31	0.46	2.89e-9	Type 2 diabetes;
PAAD	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-5.51	-0.41	1.5e-7	Pulmonary function;
PAAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg04520793	chr17:42248056	ASB16	-0.43	-5.11	-0.38	9.55e-7	Total body bone mineral density;
PAAD	cis	rs10450586	0.863	rs7484147	chr11:27298126	T/C	cg10370305	chr11:27303972	NA	0.36	4.32	0.33	2.84e-5	Total body bone mineral density;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg05552183	chr6:42928497	GNMT	0.87	10.84	0.66	1.18e-20	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.67	-5.36	-0.4	3.06e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2790216	1.000	rs1769045	chr10:59960522	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.43	4.4	0.34	2.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	5.83	0.43	3.18e-8	Obesity-related traits;
PAAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.3e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.35	-0.33	2.49e-5	Total body bone mineral density;
PAAD	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.78	6.19	0.45	5.22e-9	Schizophrenia;
PAAD	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg23920097	chr1:209922102	NA	-0.5	-4.47	-0.34	1.53e-5	Red blood cell count;
PAAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.81	0.62	6.47e-18	Cognitive function;
PAAD	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg26816564	chr1:7831052	VAMP3	0.75	5.77	0.42	4.21e-8	Inflammatory bowel disease;
PAAD	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg12568669	chr8:11666485	FDFT1	-0.3	-5.18	-0.39	7.04e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-7.75	-0.53	1.21e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24547863	chr10:134161674	LRRC27	-0.65	-6.55	-0.47	8.22e-10	Obesity-related traits;
PAAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-6.83	-0.48	1.88e-10	Lymphocyte counts;
PAAD	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.71	-0.42	5.68e-8	Bladder cancer;
PAAD	cis	rs1930961	1.000	rs6004671	chr22:25879474	T/G	cg07493324	chr22:26857165	HPS4	0.7	4.28	0.33	3.36e-5	Bipolar disorder with mood-incongruent psychosis;
PAAD	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.38	0.61	8.74e-17	Hemoglobin concentration;
PAAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.49	4.69	0.36	6.03e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7524258	0.900	rs4908611	chr1:7313861	G/A	cg07173049	chr1:7289937	CAMTA1	0.7	10.24	0.64	4.89e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg04663916	chr13:50265991	EBPL	0.66	5.46	0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06544989	chr22:39130855	UNC84B	0.5	4.95	0.37	1.93e-6	Menopause (age at onset);
PAAD	cis	rs1891275	0.551	rs7908547	chr10:93418987	A/T	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg18451016	chr1:38461880	NA	-0.63	-7.68	-0.53	1.83e-12	Coronary artery disease;
PAAD	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.75	-8.62	-0.57	7.96e-15	Eosinophil percentage of white cells;
PAAD	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	6.56	0.47	7.83e-10	Neuroticism;
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.47	0.57	1.98e-14	Bipolar disorder;
PAAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg11833968	chr6:79620685	NA	-0.43	-4.41	-0.34	1.94e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs55692468	0.540	rs4664586	chr2:153324071	C/T	cg04681845	chr2:153283485	FMNL2	-0.47	-5.85	-0.43	2.97e-8	Intraocular pressure;
PAAD	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg07777115	chr5:623756	CEP72	-0.67	-4.28	-0.33	3.27e-5	Obesity-related traits;
PAAD	cis	rs9322817	0.653	rs9399896	chr6:105216969	A/G	cg02098413	chr6:105308735	HACE1	-0.44	-5.51	-0.41	1.5e-7	Thyroid stimulating hormone;
PAAD	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.28	0.33	3.32e-5	Age-related disease endophenotypes;
PAAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.51	4.95	0.37	1.93e-6	Morning vs. evening chronotype;
PAAD	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg18196295	chr10:418757	DIP2C	0.47	5.11	0.38	9.37e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs73058052	0.597	rs2890072	chr19:50087876	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.52	-4.44	-0.34	1.69e-5	Fibrinogen levels;
PAAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	4.65	0.35	7.27e-6	Obesity-related traits;
PAAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg16926213	chr1:1841314	NA	0.37	4.33	0.33	2.65e-5	Body mass index;
PAAD	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.78	6.7	0.48	3.72e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs802075	0.905	rs6917380	chr6:49645611	T/C	cg20364632	chr6:49636226	NA	-0.51	-5.98	-0.44	1.5e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg26554054	chr8:600488	NA	0.98	7.34	0.51	1.18e-11	IgG glycosylation;
PAAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg08125733	chr17:73851984	WBP2	0.92	8.01	0.54	2.75e-13	Psoriasis;
PAAD	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg17347104	chr14:75034677	LTBP2	-0.49	-4.83	-0.36	3.28e-6	Caffeine consumption;
PAAD	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg18217622	chr6:170732253	NA	0.8	6.03	0.44	1.2e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs893363	0.559	rs877484	chr3:53846924	C/T	cg27292417	chr3:53850724	CHDH	-0.38	-4.37	-0.33	2.31e-5	Axial length;
PAAD	cis	rs2120243	0.539	rs1545596	chr3:157118526	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.33	0.33	2.74e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4880487	0.888	rs72760998	chr10:1251203	T/C	cg24515131	chr10:1263207	ADARB2	0.55	4.28	0.33	3.33e-5	Migraine;
PAAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.32	0.68	6.24e-22	Parkinson's disease;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg14725641	chr11:61582763	MIR1908;FADS1	0.5	4.46	0.34	1.6e-5	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs7823896	0.722	rs16879319	chr8:110338637	G/C	cg02458499	chr8:110280928	NUDCD1	0.76	4.72	0.36	5.32e-6	Myopia (pathological);
PAAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.84	10.37	0.64	2.14e-19	Menopause (age at onset);
PAAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.04	0.38	1.32e-6	Breast cancer;
PAAD	cis	rs412050	0.547	rs78907487	chr22:22151939	A/C	cg17089214	chr22:22089827	YPEL1	0.67	4.53	0.35	1.17e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.82	-10.34	-0.64	2.65e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Parkinson's disease;
PAAD	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	10.22	0.64	5.5e-19	Tonsillectomy;
PAAD	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg26816564	chr1:7831052	VAMP3	0.62	5.33	0.4	3.52e-7	Inflammatory bowel disease;
PAAD	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.74e-13	Monocyte percentage of white cells;
PAAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.85	7.1	0.5	4.38e-11	Pulmonary function decline;
PAAD	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.58	0.47	7.27e-10	Schizophrenia;
PAAD	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.58	-5.37	-0.4	2.85e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.51	-0.41	1.51e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg13206674	chr6:150067644	NUP43	-0.65	-6.08	-0.44	9.13e-9	Lung cancer;
PAAD	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.38	4.81	0.36	3.62e-6	Sitting height ratio;
PAAD	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.54	0.61	3.39e-17	Electrocardiographic conduction measures;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09948419	chr7:45019965	MYO1G	0.54	6.79	0.48	2.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.49	5.16	0.39	7.71e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs528301	0.642	rs895632	chr2:45165045	A/C	cg15393275	chr2:45165193	NA	-0.48	-5.15	-0.39	8.05e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.53	5.59	0.41	1.03e-7	Red blood cell count;
PAAD	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.66	6.01	0.44	1.3e-8	HIV-1 control;
PAAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.51	5.13	0.38	8.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4757319	0.515	rs4312044	chr11:15341931	G/A	cg03245590	chr11:15329459	NA	0.44	5.11	0.38	9.4e-7	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10310846	chr10:28821381	WAC	0.65	6.71	0.48	3.62e-10	Myopia (pathological);
PAAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.62	5.96	0.44	1.67e-8	Obesity-related traits;
PAAD	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.74	5.79	0.43	3.87e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs72827839	0.846	rs56407566	chr17:46148155	C/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.76	-7.62	-0.53	2.53e-12	Alcohol dependence;
PAAD	cis	rs3736485	0.966	rs1031664	chr15:51754897	C/A	cg19558802	chr15:51695713	GLDN	-0.45	-4.49	-0.34	1.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs375066	0.935	rs367741	chr19:44429180	T/C	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg00383909	chr3:49044727	WDR6	0.43	4.42	0.34	1.88e-5	Blood protein levels;
PAAD	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.9	-11.3	-0.68	6.95e-22	Refractive error;
PAAD	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg00806126	chr19:22604979	ZNF98	-0.39	-4.97	-0.37	1.8e-6	Pain;
PAAD	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	7.32	0.51	1.35e-11	Prudent dietary pattern;
PAAD	cis	rs10504390	0.656	rs17395190	chr8:66581058	A/T	cg21696208	chr8:66556075	MTFR1	0.98	4.78	0.36	4.15e-6	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs1499972	0.618	rs6795060	chr3:117642675	C/A	cg07612923	chr3:117604196	NA	0.73	5.45	0.4	2.02e-7	Schizophrenia;
PAAD	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg15621731	chr19:5074616	KDM4B	0.32	4.39	0.34	2.14e-5	Monocyte percentage of white cells;
PAAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.96	0.7	1.2e-23	Menopause (age at onset);
PAAD	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.69	4.92	0.37	2.19e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14242091	chr22:22337171	TOP3B	0.62	6.78	0.48	2.47e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg14580859	chr9:123691850	NA	0.39	4.41	0.34	1.92e-5	Rheumatoid arthritis;
PAAD	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg27449745	chr7:23145252	KLHL7	-0.61	-5.64	-0.42	8.12e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.28	-0.71	1.62e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg02023728	chr11:77925099	USP35	0.44	4.63	0.35	7.73e-6	Alzheimer's disease (survival time);
PAAD	cis	rs11651753	0.613	rs4793732	chr17:46033854	C/A	cg24458315	chr17:46148407	CBX1	0.45	4.64	0.35	7.32e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.77	8.58	0.57	1.02e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg27455613	chr17:80820699	TBCD	0.46	4.59	0.35	9.29e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg23463467	chr20:60627584	TAF4	0.46	5.02	0.38	1.43e-6	Body mass index;
PAAD	cis	rs2252790	0.640	rs10484838	chr6:116597724	C/G	cg26893134	chr6:116381904	FRK	-0.29	-4.38	-0.33	2.18e-5	Fast beta electroencephalogram;
PAAD	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.71	-0.48	3.55e-10	Retinal vascular caliber;
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.41	4.71	0.36	5.65e-6	Prostate cancer;
PAAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.58	-6.87	-0.49	1.51e-10	Menopause (age at onset);
PAAD	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	6.0	0.44	1.36e-8	IgG glycosylation;
PAAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg17366294	chr4:99064904	C4orf37	0.54	5.76	0.42	4.57e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17848003	chr1:3704513	LRRC47	0.4	4.35	0.33	2.53e-5	Red cell distribution width;
PAAD	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg06241208	chr11:30344200	C11orf46	0.51	4.59	0.35	9.16e-6	Morning vs. evening chronotype;
PAAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg04106633	chr4:1044584	NA	0.6	5.1	0.38	9.86e-7	Recombination rate (females);
PAAD	cis	rs6537837	0.642	rs6658641	chr1:110153198	G/A	cg05049280	chr1:110155535	GNAT2	0.76	7.11	0.5	4.22e-11	Major depressive disorder;
PAAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg27417659	chr7:98567827	TRRAP	-0.46	-4.44	-0.34	1.72e-5	Breast cancer;
PAAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs7737355	0.812	rs244738	chr5:130851170	A/G	cg06307176	chr5:131281290	NA	0.49	4.28	0.33	3.28e-5	Life satisfaction;
PAAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.51	4.98	0.37	1.68e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg23587288	chr2:27483067	SLC30A3	-0.76	-6.26	-0.45	3.68e-9	Blood metabolite levels;
PAAD	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.79	9.48	0.61	4.75e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg22710661	chr11:17411071	KCNJ11	0.46	4.57	0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg20913747	chr6:44695427	NA	-0.63	-7.18	-0.5	2.92e-11	Total body bone mineral density;
PAAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs9659323	0.700	rs2885226	chr1:119624163	A/G	cg17326555	chr1:119535693	NA	-0.38	-5.19	-0.39	6.64e-7	Body mass index;
PAAD	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs8016982	0.632	rs8010219	chr14:81696982	A/G	cg01989461	chr14:81687754	GTF2A1	0.57	4.54	0.35	1.14e-5	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.07	0.38	1.12e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10821973	0.527	rs7895575	chr10:63977537	G/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.47	-0.34	1.52e-5	Hypothyroidism;
PAAD	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg16691251	chr5:66510806	NA	0.73	7.79	0.53	9.84e-13	Breast cancer;
PAAD	cis	rs9522267	0.643	rs9522280	chr13:112221334	G/C	cg10483660	chr13:112241077	NA	-0.5	-5.26	-0.39	4.74e-7	Hepatitis;
PAAD	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.81	-8.0	-0.54	2.89e-13	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg02404636	chr22:31891804	SFI1	0.55	5.56	0.41	1.19e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg10729496	chr3:10149963	C3orf24	0.62	5.4	0.4	2.57e-7	Alzheimer's disease;
PAAD	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg23387401	chr17:4582204	PELP1	0.5	4.93	0.37	2.15e-6	Lymphocyte counts;
PAAD	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.29	0.45	3.14e-9	Personality dimensions;
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.48	6.4	0.46	1.78e-9	Ulcerative colitis;
PAAD	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-6.92	-0.49	1.2e-10	Total cholesterol levels;
PAAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14895029	chr7:2775587	GNA12	-0.48	-4.77	-0.36	4.27e-6	Height;
PAAD	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-5.49	-0.41	1.64e-7	Mean corpuscular volume;
PAAD	cis	rs10426930	0.700	rs10407399	chr19:5009466	A/C	cg25246084	chr19:4971487	KDM4B	0.46	5.72	0.42	5.4e-8	Monocyte percentage of white cells;
PAAD	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-7.66	-0.53	2.03e-12	Body mass index;
PAAD	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg09667013	chr22:42394590	WBP2NL	0.53	5.18	0.39	6.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-6.21	-0.45	4.86e-9	Lung cancer;
PAAD	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.49	-6.06	-0.44	1.05e-8	Crohn's disease;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg20295408	chr7:1910781	MAD1L1	-0.57	-5.47	-0.41	1.77e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg04705435	chr11:17411270	KCNJ11	0.49	4.58	0.35	9.74e-6	Body mass index;Social communication problems;
PAAD	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg23024343	chr7:107201750	COG5	0.62	4.63	0.35	7.69e-6	Coronary artery disease;
PAAD	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.67	-5.78	-0.42	4.01e-8	Serum sulfate level;
PAAD	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.18	-0.39	6.8e-7	Personality dimensions;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20248403	chr10:45690404	NA	0.63	7.46	0.52	6.31e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg08601574	chr20:25228251	PYGB	0.49	5.0	0.38	1.59e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.57	5.29	0.39	4.28e-7	Malaria;
PAAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.35	0.33	2.47e-5	IgG glycosylation;
PAAD	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg12395012	chr8:11607386	GATA4	-0.46	-5.2	-0.39	6.44e-7	Neuroticism;
PAAD	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.31	-0.4	3.9e-7	Pulmonary function;
PAAD	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.94	-0.63	2.99e-18	Response to antipsychotic treatment;
PAAD	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg16898833	chr6:26189333	HIST1H4D	1.0	5.2	0.39	6.25e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs35160687	0.901	rs34069316	chr2:86529792	T/C	cg10973622	chr2:86423274	IMMT	0.42	4.83	0.36	3.27e-6	Night sleep phenotypes;
PAAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21155852	chr7:2048760	MAD1L1	0.44	4.28	0.33	3.29e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.62	-0.41	9.08e-8	HDL cholesterol;
PAAD	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.55	5.84	0.43	3.03e-8	Subjective well-being;
PAAD	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.52	10.84	0.66	1.18e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11817910	chr12:31944836	H3F3C	-0.63	-6.45	-0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg04415270	chr2:102091202	RFX8	-0.52	-6.55	-0.47	8.3e-10	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg20019720	chr6:154832845	CNKSR3	0.76	10.53	0.65	8.08e-20	Lipoprotein (a) levels;
PAAD	cis	rs73019876	0.901	rs2214296	chr19:22133780	G/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.75	-8.27	-0.56	6.26e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	1.07	16.07	0.79	1.42e-34	Menarche (age at onset);
PAAD	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.46	4.36	0.33	2.38e-5	Inflammatory skin disease;
PAAD	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs12311304	1.000	rs17347323	chr12:15383037	C/T	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs72960926	0.744	rs11754468	chr6:74932522	C/T	cg03266952	chr6:74778945	NA	-1.1	-6.4	-0.46	1.79e-9	Metabolite levels (MHPG);
PAAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.94	0.37	2.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15231809	chr18:14747082	ANKRD30B	0.6	6.76	0.48	2.84e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11360819	chr6:15663360	DTNBP1	0.59	6.41	0.46	1.7e-9	Monocyte percentage of white cells;
PAAD	cis	rs198426	0.506	rs11230767	chr11:61426932	G/A	cg23038520	chr11:61406508	RPLP0P2	0.49	5.63	0.42	8.38e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
PAAD	cis	rs6908034	0.607	rs113592672	chr6:19806063	G/C	cg02682789	chr6:19804855	NA	0.8	4.4	0.34	1.99e-5	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
PAAD	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg10431340	chr1:161279108	MPZ	-0.62	-5.67	-0.42	7e-8	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00166722	chr3:10149974	C3orf24	0.74	5.59	0.41	1.01e-7	Alzheimer's disease;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.03e-7	Life satisfaction;
PAAD	trans	rs6712232	0.551	rs7600734	chr2:72156426	A/G	cg25123566	chr12:47610734	FAM113B;LOC100233209	-0.6	-6.36	-0.46	2.26e-9	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks);
PAAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.67	0.62	1.58e-17	Platelet count;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.65	8.31	0.56	5.06e-14	Prudent dietary pattern;
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	16.0	0.79	2.09e-34	Prudent dietary pattern;
PAAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.73	-7.75	-0.53	1.24e-12	Blood metabolite levels;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.49	0.57	1.77e-14	Coffee consumption (cups per day);
PAAD	cis	rs1075265	0.870	rs17268179	chr2:54264013	T/A	cg04546899	chr2:54196757	PSME4	0.38	5.74	0.42	4.91e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-1.0	-10.38	-0.64	2.07e-19	Mean platelet volume;
PAAD	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg06970076	chr16:1560791	IFT140	0.53	4.71	0.36	5.51e-6	Coronary artery disease;
PAAD	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.7	-7.0	-0.49	7.86e-11	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.51	-5.83	-0.43	3.23e-8	Obesity-related traits;
PAAD	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg00086871	chr4:6988644	TBC1D14	0.9	4.69	0.36	5.95e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9341808	0.529	rs2322765	chr6:81064596	A/G	cg08355045	chr6:80787529	NA	0.38	4.74	0.36	4.9100000000000004e-06	Sitting height ratio;
PAAD	cis	rs2133450	0.526	rs12489441	chr3:7346788	C/G	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg14349672	chr11:133703707	NA	-0.6	-6.9	-0.49	1.32e-10	Childhood ear infection;
PAAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23158103	chr7:148848205	ZNF398	-0.61	-5.96	-0.44	1.66e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	cis	rs9815354	0.627	rs80120812	chr3:42021760	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.35	-0.4	3.16e-7	Subjective well-being;
PAAD	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg10072921	chr12:121022843	NA	-0.43	-5.32	-0.4	3.6e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.28	-0.33	3.33e-5	Lung cancer in ever smokers;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg23648919	chr2:156787418	NA	-0.55	-6.62	-0.47	5.7e-10	Energy expenditure (24h);
PAAD	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg06265175	chr8:121136014	COL14A1	0.5	4.87	0.37	2.79e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.52	-5.37	-0.4	2.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-6.28	-0.45	3.37e-9	Bone mineral density;
PAAD	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg02297831	chr4:17616191	MED28	0.6	5.76	0.42	4.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-4.57	-0.35	1.02e-5	Type 2 diabetes;
PAAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg15017067	chr4:17643749	FAM184B	-0.4	-4.31	-0.33	2.89e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.73	-8.88	-0.58	1.75e-15	Body mass index;
PAAD	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.77	8.69	0.58	5.3e-15	Total body bone mineral density;
PAAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg25809561	chr17:30822961	MYO1D	0.59	6.11	0.44	8.01e-9	Schizophrenia;
PAAD	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg18721089	chr20:30220636	NA	-0.82	-6.23	-0.45	4.33e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg10290764	chr8:4849399	CSMD1	-0.39	-6.47	-0.46	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23281280	chr6:28129359	ZNF389	0.67	5.22	0.39	5.91e-7	Depression;
PAAD	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.97	-14.45	-0.76	2.45e-30	Dental caries;
PAAD	cis	rs6539288	0.674	rs989560	chr12:107285751	T/C	cg15890332	chr12:107067104	RFX4	0.39	4.27	0.33	3.38e-5	Total body bone mineral density;
PAAD	cis	rs2070997	0.607	rs2987902	chr9:133710246	A/T	cg11464064	chr9:133710261	ABL1	0.65	4.5	0.34	1.35e-5	Response to amphetamines;
PAAD	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg26904215	chr21:47823096	PCNT	-0.92	-4.74	-0.36	4.96e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.5	-5.05	-0.38	1.24e-6	High light scatter reticulocyte count;
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.44	-0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.66	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs10916814	0.632	rs6701759	chr1:20898400	G/T	cg04087271	chr1:20915334	CDA	0.37	4.61	0.35	8.62e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.54	-5.36	-0.4	2.97e-7	Mean platelet volume;
PAAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.41	-0.61	7.55e-17	Schizophrenia;
PAAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg13374026	chr7:158955107	NA	0.47	4.37	0.33	2.31e-5	Facial morphology (factor 20);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06351970	chr6:111280209	GTF3C6	0.55	6.47	0.46	1.26e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.53	-5.48	-0.41	1.76e-7	Prostate cancer;
PAAD	cis	rs4462272	0.605	rs7922807	chr10:102023006	C/T	cg02250046	chr10:101825185	CPN1	-0.4	-4.45	-0.34	1.66e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.44	-4.91	-0.37	2.29e-6	Mean arterial pressure;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.86	11.08	0.67	2.71e-21	Vitiligo;
PAAD	cis	rs569214	0.515	rs2640732	chr8:27517821	T/G	cg04264299	chr8:27491209	SCARA3	0.57	5.33	0.4	3.51e-7	Alzheimer's disease;
PAAD	cis	rs3787159	0.573	rs489355	chr20:56902567	T/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.39	-0.34	2.1e-5	Systolic blood pressure;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.01	-0.38	1.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.45	6.18	0.45	5.65e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.45	0.4	1.96e-7	Prudent dietary pattern;
PAAD	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.63	6.25	0.45	3.89e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-8.15	-0.55	1.25e-13	Total body bone mineral density;
PAAD	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg09376583	chr16:88111425	NA	-0.48	-4.3	-0.33	3.02e-5	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	8.31	0.56	5.09e-14	Homoarginine levels;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.88	9.67	0.62	1.52e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs17095355	0.818	rs12571549	chr10:111770013	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.66	-4.47	-0.34	1.49e-5	Biliary atresia;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.93e-10	Aortic root size;
PAAD	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7070678	0.662	rs12775779	chr10:29801848	A/G	cg05086789	chr10:29701805	LOC387647	0.47	4.41	0.34	1.97e-5	Platelet thrombus formation;
PAAD	cis	rs9810890	1.000	rs73198891	chr3:128553841	T/G	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.51	-0.47	1.06e-9	Glomerular filtration rate;
PAAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg05697835	chr1:2722811	NA	0.42	4.75	0.36	4.62e-6	Ulcerative colitis;
PAAD	cis	rs6494488	0.500	rs72742928	chr15:64868480	T/A	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.51	-5.81	-0.43	3.54e-8	Cardiovascular disease risk factors;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2131877	0.913	rs9825498	chr3:194848021	G/C	cg16306870	chr3:194868790	C3orf21	0.42	4.35	0.33	2.46e-5	Non-small cell lung cancer;
PAAD	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.35	0.33	2.5e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6893807	0.667	rs2304607	chr5:87988733	A/G	cg02225085	chr5:87975992	LOC645323	-0.66	-4.96	-0.37	1.84e-6	Body mass index;
PAAD	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.5	-4.83	-0.36	3.36e-6	Menarche (age at onset);
PAAD	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg23682824	chr7:23144976	KLHL7	0.48	4.49	0.34	1.38e-5	Cerebrospinal fluid biomarker levels;
PAAD	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg18944383	chr4:111397179	ENPEP	-0.77	-8.72	-0.58	4.45e-15	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg06392426	chr19:10676186	KRI1	0.59	5.83	0.43	3.14e-8	Red cell distribution width;
PAAD	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.61	-5.3	-0.4	3.94e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.48	5.16	0.39	7.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.44	-6.88	-0.49	1.47e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.77e-7	Migraine;
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg16342193	chr10:102329863	NA	-0.78	-8.59	-0.57	9.51e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.42	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.48	5.61	0.41	9.49e-8	QRS complex (12-leadsum);
PAAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.54	-5.45	-0.4	1.99e-7	Iron status biomarkers;
PAAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.22	0.45	4.63e-9	Coffee consumption (cups per day);
PAAD	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg17333051	chr19:2783644	SGTA	0.45	4.93	0.37	2.15e-6	Total cholesterol levels;
PAAD	cis	rs12780845	0.931	rs17466418	chr10:17244307	G/T	cg00857480	chr10:17188594	TRDMT1	0.34	4.3	0.33	3.05e-5	Homocysteine levels;
PAAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg12705353	chr12:122356852	WDR66	0.44	4.45	0.34	1.63e-5	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14234805	chr20:37101345	RALGAPB	0.58	6.48	0.47	1.21e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27297192	chr10:134578999	INPP5A	0.62	5.51	0.41	1.52e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg05342682	chr7:94953680	PON1	-0.55	-4.77	-0.36	4.36e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22804786	chr6:36842801	PPIL1	0.57	6.78	0.48	2.5e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.81	8.41	0.56	2.73e-14	Corneal astigmatism;
PAAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg03959625	chr15:84868606	LOC388152	0.48	4.95	0.37	1.92e-6	Schizophrenia;
PAAD	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.57	5.39	0.4	2.62e-7	Height;
PAAD	cis	rs8067354	0.574	rs2531899	chr17:58007193	A/G	cg02344993	chr17:57696989	CLTC	-0.53	-4.38	-0.33	2.19e-5	Hemoglobin concentration;
PAAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg14343924	chr8:8086146	FLJ10661	0.53	4.51	0.34	1.29e-5	Neuroticism;
PAAD	cis	rs75920871	0.925	rs17120237	chr11:116891046	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-4.29	-0.33	3.13e-5	Subjective well-being;
PAAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-4.64	-0.35	7.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.04	-0.38	1.29e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.67	-0.42	7.06e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-6.15	-0.45	6.52e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.7	0.48	3.88e-10	IgG glycosylation;
PAAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00934092	chr6:3119265	BPHL	-0.71	-6.36	-0.46	2.22e-9	Neuroticism;
PAAD	cis	rs7904985	0.751	rs11201994	chr10:88119927	A/T	cg07322936	chr10:88137208	NA	-0.54	-4.88	-0.37	2.71e-6	Barrett's esophagus;
PAAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg04450456	chr4:17643702	FAM184B	0.48	5.27	0.39	4.58e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs16975963	0.793	rs11666497	chr19:38464262	C/T	cg25793785	chr19:38281423	NA	0.57	4.67	0.35	6.72e-6	Longevity;
PAAD	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-6.19	-0.45	5.37e-9	Lymphocyte percentage of white cells;
PAAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg10589385	chr1:150898437	SETDB1	0.38	4.79	0.36	3.89e-6	Melanoma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24779751	chr19:36545850	WDR62;THAP8	0.6	6.93	0.49	1.14e-10	Monocyte percentage of white cells;
PAAD	cis	rs288342	0.797	rs288293	chr2:183631520	G/A	cg02625481	chr2:183667124	NA	-0.45	-4.47	-0.34	1.52e-5	Recurrent major depressive disorder;
PAAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.96	6.96	0.49	9.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.24	-10.34	-0.64	2.56e-19	Breast cancer;
PAAD	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.33	-0.33	2.69e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.29	-0.33	3.12e-5	Mood instability;
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg10621924	chr7:39171070	POU6F2	0.28	4.73	0.36	5.16e-6	IgG glycosylation;
PAAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs4713118	1.000	rs13215072	chr6:27677728	A/G	cg22143856	chr6:28129313	ZNF389	0.48	4.36	0.33	2.38e-5	Parkinson's disease;
PAAD	cis	rs34375054	0.573	rs34579346	chr12:125658174	T/C	cg25124228	chr12:125621409	AACS	-0.65	-5.9	-0.43	2.24e-8	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00047050	chr11:107879431	CUL5	-0.58	-6.73	-0.48	3.28e-10	Body fat percentage;
PAAD	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg16691251	chr5:66510806	NA	0.73	7.82	0.54	7.99e-13	Breast cancer;
PAAD	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.5	5.35	0.4	3.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1499972	0.590	rs62264780	chr3:117654869	T/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs75085172	chr1:227513630	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.56e-6	Breast cancer;
PAAD	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	4.75	0.36	4.59e-6	Homocysteine levels;
PAAD	cis	rs9346353	0.737	rs6935994	chr6:70502641	G/A	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.06e-6	Lung cancer;
PAAD	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.69	6.65	0.47	5.05e-10	Lymphocyte counts;
PAAD	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.47	-0.52	5.9e-12	Response to antipsychotic treatment;
PAAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.75	6.82	0.48	1.99e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.54	-7.0	-0.49	7.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.76	5.42	0.4	2.31e-7	Phospholipid levels (plasma);
PAAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg25319279	chr11:5960081	NA	-0.66	-6.26	-0.45	3.72e-9	DNA methylation (variation);
PAAD	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg20933634	chr6:27740509	NA	0.74	4.63	0.35	7.95e-6	Depression;
PAAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.68	-0.58	5.83e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.59	5.58	0.41	1.07e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09841758	chr17:72869237	FDXR	0.66	6.53	0.47	9.2e-10	Obesity-related traits;
PAAD	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.62	6.18	0.45	5.57e-9	Pancreatic cancer;
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg20302533	chr7:39170763	POU6F2	0.43	5.8	0.43	3.75e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.54	8.33	0.56	4.49e-14	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs13144136	0.687	rs11725559	chr4:10654270	A/G	cg10242279	chr4:10666415	CLNK	0.49	6.44	0.46	1.52e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg27499820	chr13:21296301	IL17D	0.53	5.19	0.39	6.64e-7	Dental caries;
PAAD	cis	rs1497828	0.956	rs2815250	chr1:217573979	C/T	cg04411442	chr1:217543379	NA	-0.47	-4.6	-0.35	8.72e-6	Dialysis-related mortality;
PAAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg03989125	chr22:38214979	NA	0.61	5.64	0.42	8.26e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg25456477	chr12:86230367	RASSF9	-0.48	-4.35	-0.33	2.46e-5	Major depressive disorder;
PAAD	cis	rs73416724	0.535	rs61729324	chr6:43258994	G/A	cg26312998	chr6:43337775	ZNF318	0.72	4.33	0.33	2.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.67	-7.57	-0.52	3.38e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	9.9e-6	Renal cell carcinoma;
PAAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg15847926	chr7:2749597	AMZ1	-0.38	-4.69	-0.36	6.14e-6	Height;
PAAD	cis	rs4144743	0.528	rs11868894	chr17:45353189	T/C	cg18085866	chr17:45331354	ITGB3	-0.59	-4.82	-0.36	3.48e-6	Body mass index;
PAAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.45	-4.42	-0.34	1.84e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.57	-0.41	1.14e-7	Mean platelet volume;
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-0.87	-13.86	-0.75	9.46e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.97	12.68	0.72	1.34e-25	Menopause (age at onset);
PAAD	cis	rs6102074	0.935	rs11698548	chr20:39271006	A/G	cg22477343	chr20:39312069	NA	0.3	4.26	0.33	3.62e-5	White blood cell count;
PAAD	cis	rs35164067	1.000	rs73923215	chr19:10514842	A/C	cg07306197	chr19:9546377	ZNF266	0.58	4.42	0.34	1.88e-5	Inflammatory bowel disease;
PAAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.42	0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.74	7.17	0.5	3e-11	Cognitive function;
PAAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-6.79	-0.48	2.31e-10	Life satisfaction;
PAAD	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg01489256	chr8:11204017	TDH	-0.45	-4.39	-0.34	2.12e-5	Retinal vascular caliber;
PAAD	cis	rs2292864	0.764	rs36046953	chr17:45381791	A/G	cg18085866	chr17:45331354	ITGB3	-0.96	-5.33	-0.4	3.46e-7	Left atrial antero-posterior diameter;
PAAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg24879335	chr3:133465180	TF	0.65	7.14	0.5	3.62e-11	Iron status biomarkers;
PAAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.92	10.89	0.66	8.93e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg07828024	chr6:149772892	ZC3H12D	0.32	4.26	0.33	3.51e-5	Dupuytren's disease;
PAAD	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.88	-0.49	1.43e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.78	-5.67	-0.42	7.13e-8	Vitiligo;
PAAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg11204139	chr17:3907470	NA	-0.66	-6.78	-0.48	2.49e-10	Type 2 diabetes;
PAAD	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	5.04	0.38	1.32e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.34	0.56	4.16e-14	Dupuytren's disease;
PAAD	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.34	-0.33	2.6e-5	Coronary artery disease;
PAAD	cis	rs1561288	0.681	rs13404336	chr2:25384961	T/C	cg02492873	chr2:25193821	DNAJC27	0.48	4.36	0.33	2.36e-5	Body mass index;
PAAD	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-15.52	-0.78	3.82e-33	Schizophrenia;
PAAD	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.47	4.28	0.33	3.24e-5	Mean platelet volume;
PAAD	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.54	-5.57	-0.41	1.13e-7	White matter hyperintensity burden;
PAAD	cis	rs10750165	0.716	rs7936400	chr11:119655589	A/G	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.49e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg10705379	chr10:99080932	FRAT1	0.37	4.29	0.33	3.18e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.52	4.51	0.34	1.31e-5	Menopause (age at onset);
PAAD	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.21	0.7	2.54e-24	Lung cancer in ever smokers;
PAAD	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.6	0.61	2.31e-17	Mortality in heart failure;
PAAD	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.56	4.82	0.36	3.48e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-6.15	-0.45	6.64e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg10645314	chr2:3704589	ALLC	-0.42	-4.5	-0.34	1.35e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.85	8.41	0.56	2.71e-14	Response to antineoplastic agents;
PAAD	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14169450	chr9:139327907	INPP5E	0.76	9.23	0.6	2.24e-16	Monocyte percentage of white cells;
PAAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg09796270	chr17:17721594	SREBF1	0.45	5.25	0.39	5.03e-7	Total body bone mineral density;
PAAD	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg04450456	chr4:17643702	FAM184B	0.47	4.74	0.36	4.84e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.93	-9.41	-0.61	7.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.79	-9.43	-0.61	6.75e-17	Cystic fibrosis severity;
PAAD	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	5.06	0.38	1.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs721399	0.719	rs12674710	chr8:18263663	A/C	cg18736775	chr8:18248649	NAT2	-0.72	-6.3	-0.46	3.06e-9	Blood metabolite levels;
PAAD	cis	rs2239785	0.727	rs136156	chr22:36656442	C/A	cg15716373	chr22:36655542	APOL1	-0.43	-4.27	-0.33	3.43e-5	Glomerulosclerosis;
PAAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.17	-0.5	3.02e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.62	-7.08	-0.5	4.89e-11	Eye color traits;
PAAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26850624	chr5:429559	AHRR	0.44	5.56	0.41	1.17e-7	Cystic fibrosis severity;
PAAD	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg24238205	chr11:58912174	FAM111A	-0.5	-4.28	-0.33	3.32e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	4.74	0.36	4.78e-6	Bone mineral density;
PAAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.81	-0.36	3.65e-6	Lung cancer;
PAAD	cis	rs7714584	1.000	rs6579803	chr5:150255559	C/T	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.83	-10.59	-0.65	5.55e-20	Breast cancer;
PAAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.52	-6.34	-0.46	2.46e-9	Psoriasis;
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	1.01	15.33	0.78	1.15e-32	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12760731	0.565	rs10913520	chr1:178200760	A/T	cg00404053	chr1:178313656	RASAL2	0.7	5.24	0.39	5.22e-7	Obesity-related traits;
PAAD	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.98	-12.42	-0.71	6.78e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.55	6.41	0.46	1.76e-9	Total body bone mineral density;
PAAD	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.7	8.08	0.55	1.82e-13	Colorectal cancer;
PAAD	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg01426195	chr3:39028469	NA	-0.62	-6.12	-0.44	7.69e-9	Handedness;
PAAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-1.19	-9.7	-0.62	1.26e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.66	6.64	0.47	5.16e-10	Coronary artery disease;
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg10621924	chr7:39171070	POU6F2	0.27	4.55	0.35	1.08e-5	IgG glycosylation;
PAAD	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.63	-4.35	-0.33	2.5e-5	Schizophrenia;
PAAD	cis	rs7631605	0.905	rs67233917	chr3:37157635	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg16928487	chr17:17741425	SREBF1	-0.36	-4.88	-0.37	2.6e-6	Total body bone mineral density;
PAAD	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg10437265	chr15:77819839	NA	0.41	4.66	0.35	6.75e-6	Type 2 diabetes;
PAAD	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.81	9.88	0.63	4.42e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17976731	chr17:46139285	NA	-0.69	-7.34	-0.51	1.17e-11	Obesity-related traits;
PAAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.53	-5.47	-0.41	1.82e-7	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4450131	0.522	rs34336231	chr10:126355662	C/T	cg20435097	chr10:126320824	FAM53B	0.49	5.01	0.38	1.52e-6	White blood cell count (basophil);
PAAD	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05564831	chr3:52568323	NT5DC2	0.46	4.92	0.37	2.25e-6	Bipolar disorder;
PAAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14180030	chr9:123475675	MEGF9	-0.41	-4.64	-0.35	7.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.76	-7.15	-0.5	3.38e-11	Asthma;
PAAD	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg20503657	chr10:835505	NA	0.55	5.77	0.42	4.32e-8	Survival in rectal cancer;
PAAD	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.53	-5.17	-0.39	7.22e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.49	6.3	0.46	3.02e-9	Vitiligo;
PAAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg05785598	chr3:49045655	WDR6	0.43	5.08	0.38	1.07e-6	Parkinson's disease;
PAAD	cis	rs2004318	0.850	rs112111168	chr19:55129529	C/T	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs17123764	1.000	rs11833411	chr12:50000387	T/C	cg14846292	chr12:49726500	C1QL4	-0.67	-4.29	-0.33	3.16e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.52	0.57	1.47e-14	Colorectal cancer;
PAAD	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	1.0	6.31	0.46	2.88e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg16262614	chr3:133464971	TF	-0.51	-5.93	-0.43	1.99e-8	Iron status biomarkers (transferrin levels);
PAAD	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg20159608	chr7:32802032	NA	-0.59	-6.05	-0.44	1.1e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00575088	chr19:17971045	RPL18AP3;RPL18A	0.59	6.82	0.48	2.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.97	-0.37	1.78e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04950839	chr2:172778879	HAT1	0.67	7.4	0.51	8.71e-12	Pancreatic cancer;
PAAD	trans	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	7.31	0.51	1.42e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-8.06	-0.55	2.04e-13	Morning vs. evening chronotype;
PAAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.81	-8.41	-0.56	2.81e-14	Glaucoma (primary open-angle);
PAAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.67	0.48	4.57e-10	Lung cancer;
PAAD	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg10495392	chr1:46806563	NSUN4	0.6	5.98	0.44	1.53e-8	Menopause (age at onset);
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.87	9.83	0.62	5.85e-18	Prudent dietary pattern;
PAAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.61	5.55	0.41	1.25e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs800160	0.777	rs2521288	chr11:2342763	T/G	cg09785033	chr11:2336066	TSPAN32	-0.54	-4.55	-0.35	1.09e-5	Bacteremia;
PAAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg04257695	chr17:30186438	C17orf79	0.61	4.86	0.37	2.86e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-4.88	-0.37	2.63e-6	Personality dimensions;
PAAD	trans	rs889956	0.626	rs1366798	chr2:57218797	G/T	cg20058506	chr2:72013035	NA	-0.54	-7.02	-0.49	7.06e-11	Educational attainment;
PAAD	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg11949866	chr1:10754891	CASZ1	0.51	4.42	0.34	1.89e-5	Ewing sarcoma;
PAAD	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.38	-0.33	2.21e-5	Cognitive function;
PAAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.49	4.46	0.34	1.56e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	4.71	0.36	5.46e-6	Axial length;
PAAD	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06850241	chr22:41845214	NA	0.58	5.05	0.38	1.24e-6	Vitiligo;
PAAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.27	0.33	3.46e-5	Total body bone mineral density;
PAAD	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	1.03	8.0	0.54	2.99e-13	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-6.56	-0.47	8.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	6.79	0.48	2.43e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs838147	0.844	rs8111208	chr19:49248022	A/C	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.67	-7.15	-0.5	3.49e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg00666640	chr1:248458726	OR2T12	0.52	5.07	0.38	1.15e-6	Common traits (Other);
PAAD	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.48	-0.52	5.62e-12	Hemoglobin concentration;
PAAD	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.49	4.67	0.35	6.71e-6	Airway imaging phenotypes;
PAAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg27539214	chr16:67997921	SLC12A4	-0.61	-4.9	-0.37	2.4e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17423423	chr7:33149143	RP9	0.59	6.52	0.47	9.71e-10	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.87	11.03	0.67	3.67e-21	Prudent dietary pattern;
PAAD	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.7	6.96	0.49	9.63e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11892454	0.544	rs10178552	chr2:25973309	C/T	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.05e-6	Heschl's gyrus morphology;
PAAD	cis	rs6028335	0.610	rs67743908	chr20:37572643	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.89	-0.37	2.59e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-6.96	-0.49	9.58e-11	Body mass index (adult);
PAAD	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-15.12	-0.78	4.12e-32	Ulcerative colitis;
PAAD	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-5.55	-0.41	1.25e-7	Reticulocyte count;
PAAD	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg04906043	chr13:21280425	IL17D	0.47	4.29	0.33	3.23e-5	Dental caries;
PAAD	cis	rs4517514	0.509	rs10830434	chr11:89912652	T/C	cg05041596	chr11:89867385	NAALAD2	0.66	4.83	0.36	3.31e-6	Trans fatty acid levels;
PAAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.57	-6.87	-0.49	1.58e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7180079	1.000	rs1033205	chr15:64656764	G/C	cg18210365	chr15:65066710	RBPMS2	0.64	4.9	0.37	2.47e-6	Monocyte count;
PAAD	cis	rs59918340	0.738	rs3739238	chr8:142222445	T/C	cg23750338	chr8:142222470	SLC45A4	0.58	6.7	0.48	3.83e-10	Immature fraction of reticulocytes;
PAAD	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg01422370	chr2:73384389	NA	0.37	4.95	0.37	1.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs4676482	0.529	rs17038577	chr3:39262791	G/C	cg02254461	chr3:39195904	CSRNP1	0.63	4.46	0.34	1.58e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.59	4.79	0.36	3.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg09941381	chr10:64027924	RTKN2	-0.37	-4.47	-0.34	1.55e-5	Rheumatoid arthritis;
PAAD	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg16579770	chr16:72058938	DHODH	0.39	4.64	0.35	7.58e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09946346	chr11:65244890	NA	0.64	6.63	0.47	5.41e-10	Myopia (pathological);
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.66	6.98	0.49	8.36e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg17644776	chr2:200775616	C2orf69	0.53	4.29	0.33	3.12e-5	Schizophrenia;
PAAD	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	4.95	0.37	1.95e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.6	-7.9	-0.54	5.26e-13	Longevity;
PAAD	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.55	-0.35	1.09e-5	Subjective well-being;
PAAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	8.3	0.56	5.2e-14	Bone mineral density;
PAAD	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg00405596	chr8:11794950	NA	-0.43	-4.4	-0.34	2.02e-5	Monocyte count;
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-7.23	-0.51	2.19e-11	Initial pursuit acceleration;
PAAD	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.45	-5.39	-0.4	2.68e-7	Colorectal cancer;
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-7.43	-0.52	7.21e-12	Body mass index;
PAAD	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.69	10.6	0.65	5.29e-20	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg25833597	chr17:30823145	MYO1D	0.55	5.38	0.4	2.75e-7	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15781397	chr7:23695266	NA	0.65	7.83	0.54	7.82e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9372498	0.536	rs17080292	chr6:118850266	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.67	-0.35	6.54e-6	Diastolic blood pressure;
PAAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg01097406	chr16:89675127	NA	-0.37	-4.43	-0.34	1.83e-5	Vitiligo;
PAAD	cis	rs375066	0.935	rs398099	chr19:44405281	G/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs17221829	0.931	rs10160803	chr11:89461859	C/T	cg02982614	chr11:89391479	FOLH1B	-0.43	-4.39	-0.34	2.12e-5	Anxiety in major depressive disorder;
PAAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg23205692	chr1:25664452	TMEM50A	0.51	4.99	0.38	1.63e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs11615916	0.720	rs1074958	chr12:62664272	C/T	cg11441379	chr12:63026424	NA	0.72	4.67	0.35	6.6e-6	Pulmonary function decline;
PAAD	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.83	10.39	0.64	1.91e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.41	-6.18	-0.45	5.52e-9	Subjective well-being;
PAAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg05697835	chr1:2722811	NA	0.43	4.92	0.37	2.22e-6	Ulcerative colitis;
PAAD	cis	rs8105895	0.935	rs4510150	chr19:22239669	A/G	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg02023728	chr11:77925099	USP35	0.42	4.28	0.33	3.35e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg07701084	chr6:150067640	NUP43	0.72	7.36	0.51	1.1e-11	Lung cancer;
PAAD	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.53	-4.9	-0.37	2.42e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.57	6.97	0.49	9.22e-11	Multiple system atrophy;
PAAD	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg10223061	chr2:219282414	VIL1	0.36	4.36	0.33	2.43e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg20406979	chr6:167373233	NA	0.33	4.44	0.34	1.75e-5	Crohn's disease;
PAAD	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.44	4.37	0.33	2.32e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg11416102	chr8:651193	ERICH1	0.89	5.7	0.42	6.07e-8	IgG glycosylation;
PAAD	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.92	9.27	0.6	1.71e-16	Post bronchodilator FEV1;
PAAD	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.59	-6.57	-0.47	7.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.76	0.62	8.8e-18	Prudent dietary pattern;
PAAD	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.51	-4.73	-0.36	5e-6	Hypospadias;
PAAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05025164	chr4:1340916	KIAA1530	0.56	5.45	0.4	2e-7	Obesity-related traits;
PAAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.8	-7.74	-0.53	1.28e-12	DNA methylation (variation);
PAAD	trans	rs901683	1.000	rs9422654	chr10:46051401	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.45	-0.46	1.4e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.39e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16971641	chr21:45979620	KRTAP10-3;C21orf29	-0.65	-6.64	-0.47	5.33e-10	Obesity-related traits;
PAAD	cis	rs2229238	0.911	rs10047079	chr1:154468135	T/C	cg21262032	chr1:154437693	IL6R	-0.48	-5.0	-0.38	1.56e-6	Coronary heart disease;
PAAD	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg14393609	chr7:65229607	NA	0.67	7.43	0.52	7.15e-12	Calcium levels;
PAAD	cis	rs595018	0.505	rs72916908	chr11:60601423	C/T	cg07588442	chr11:60673866	PRPF19	0.68	4.57	0.35	9.84e-6	Wegener's granulomatosis;
PAAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.54	4.72	0.36	5.33e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7264396	0.832	rs224416	chr20:34138406	G/A	cg17201900	chr20:34330562	RBM39	0.61	4.26	0.33	3.6e-5	Total cholesterol levels;
PAAD	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.72	-7.98	-0.54	3.23e-13	Airway imaging phenotypes;
PAAD	cis	rs35300120	0.757	rs12097489	chr1:233653532	T/A	cg23054119	chr1:233659267	NA	-0.58	-5.39	-0.4	2.61e-7	Cognitive function;
PAAD	cis	rs3127553	0.526	rs946106	chr1:49928489	C/T	cg09846084	chr1:50888024	DMRTA2	0.54	4.63	0.35	7.93e-6	Waist circumference;
PAAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg01605746	chr5:669925	TPPP	-0.41	-4.42	-0.34	1.89e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.8	-0.36	3.8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.64	6.03	0.44	1.2e-8	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06398481	chr20:35492283	C20orf117	0.7	7.09	0.5	4.79e-11	Obesity-related traits;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg23397278	chr11:64051699	GPR137;BAD	0.59	6.96	0.49	9.41e-11	Metabolite levels  (X-11787);
PAAD	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg15956490	chr3:53032818	SFMBT1	0.72	4.27	0.33	3.37e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg22532475	chr10:104410764	TRIM8	0.33	4.34	0.33	2.6e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-4.78	-0.36	4.09e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs3136441	0.892	rs4752936	chr11:46821078	A/C	cg19486271	chr11:47235900	DDB2	0.69	5.54	0.41	1.29e-7	HDL cholesterol;
PAAD	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg01620082	chr3:125678407	NA	0.92	6.48	0.47	1.2e-9	Depression;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs12431939	0.657	rs28852081	chr14:51699935	G/A	cg23942311	chr14:51606299	NA	0.53	4.78	0.36	4.11e-6	Cancer;
PAAD	cis	rs2070997	0.756	rs2987903	chr9:133711263	G/A	cg11464064	chr9:133710261	ABL1	0.68	4.31	0.33	2.95e-5	Response to amphetamines;
PAAD	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg06026331	chr20:60912101	LAMA5	0.54	4.55	0.35	1.11e-5	Colorectal cancer;
PAAD	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg05973401	chr12:123451056	ABCB9	0.5	4.56	0.35	1.05e-5	Platelet count;
PAAD	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.58	-5.91	-0.43	2.15e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.4	0.46	1.84e-9	Morning vs. evening chronotype;
PAAD	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.53	-0.41	1.38e-7	Sjögren's syndrome;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.99	5.72	0.42	5.46e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7940866	0.679	rs7944782	chr11:130795698	T/G	cg12179176	chr11:130786555	SNX19	0.79	8.88	0.58	1.71e-15	Schizophrenia;
PAAD	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	4.36	0.33	2.43e-5	Height;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.08	0.38	1.1e-6	Rheumatoid arthritis;
PAAD	cis	rs59888335	0.862	rs17391287	chr3:80792633	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.62	0.41	9.04e-8	Lung cancer;
PAAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg18964960	chr10:1102726	WDR37	0.61	4.25	0.33	3.67e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg16876255	chr19:9731953	ZNF561	0.94	4.42	0.34	1.85e-5	Pursuit maintenance gain;
PAAD	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.75	-6.9	-0.49	1.34e-10	Motion sickness;
PAAD	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg01657329	chr11:68192670	LRP5	-0.63	-4.55	-0.35	1.11e-5	Total body bone mineral density (age 45-60);
PAAD	cis	rs939584	1.000	rs1320332	chr2:621954	T/C	cg03610516	chr2:642275	NA	0.64	5.72	0.42	5.53e-8	Body mass index;
PAAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22633769	chr20:60982531	CABLES2	0.49	4.76	0.36	4.47e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16262614	chr3:133464971	TF	0.49	5.55	0.41	1.24e-7	Iron status biomarkers;
PAAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg08888203	chr3:10149979	C3orf24	0.66	5.95	0.43	1.8e-8	Alzheimer's disease;
PAAD	cis	rs3106136	0.586	rs72663782	chr4:95061207	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.86	-0.37	2.86e-6	Capecitabine sensitivity;
PAAD	cis	rs62045844	0.536	rs9940965	chr16:89180664	C/G	cg06636372	chr16:89349979	ANKRD11	-0.72	-4.3	-0.33	3.08e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.66	-6.11	-0.44	8.05e-9	Vitamin D levels;
PAAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg14440974	chr22:39074834	NA	-0.62	-7.57	-0.52	3.26e-12	Menopause (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22651508	chr13:98828958	FARP1;RNF113B	0.54	6.31	0.46	2.96e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg01620082	chr3:125678407	NA	-1.14	-7.45	-0.52	6.42e-12	Depression;
PAAD	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg24692254	chr21:30365293	RNF160	0.59	5.16	0.39	7.45e-7	Cognitive test performance;
PAAD	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.06	-0.44	1.01e-8	Heart rate;
PAAD	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	1.01	14.36	0.76	4.29e-30	Heart rate;
PAAD	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.99	8.79	0.58	2.93e-15	Bipolar disorder;
PAAD	cis	rs7809615	0.748	rs12533251	chr7:99115677	G/A	cg12290671	chr7:99195819	NA	-0.89	-5.1	-0.38	1.01e-6	Blood metabolite ratios;
PAAD	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.53	-5.0	-0.38	1.54e-6	Daytime sleep phenotypes;
PAAD	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg11657817	chr20:23433608	CST11	-0.51	-5.24	-0.39	5.2e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg00024416	chr22:24240387	NA	-0.57	-6.0	-0.44	1.42e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.65	-6.06	-0.44	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg22382021	chr8:145755756	MGC70857;KIAA1688	-0.41	-5.97	-0.44	1.64e-8	Age at first birth;
PAAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.9	12.83	0.72	5.49e-26	Bone mineral density;
PAAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12963246	chr6:28129442	ZNF389	0.56	4.46	0.34	1.62e-5	Parkinson's disease;
PAAD	cis	rs2133450	0.689	rs9829495	chr3:7268094	A/C	cg19930620	chr3:7340148	GRM7	0.42	4.45	0.34	1.68e-5	Early response to risperidone in schizophrenia;
PAAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.39	4.84	0.37	3.19e-6	Menarche (age at onset);
PAAD	cis	rs7829975	0.539	rs35571782	chr8:8141823	A/C	cg15556689	chr8:8085844	FLJ10661	0.7	6.43	0.46	1.57e-9	Mood instability;
PAAD	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.37	4.47	0.34	1.51e-5	Pulmonary function;
PAAD	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.6	-5.76	-0.42	4.52e-8	Subjective well-being;
PAAD	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.9e-7	Resting heart rate;
PAAD	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26804944	chr12:56660921	COQ10A	0.9	4.51	0.34	1.31e-5	Psoriasis vulgaris;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11224362	chr1:40041493	PABPC4	-0.8	-7.26	-0.51	1.9e-11	Neuroticism;
PAAD	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg03482866	chr13:111040579	COL4A2	0.52	4.87	0.37	2.74e-6	White matter hyperintensity burden;
PAAD	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.73	-7.41	-0.51	8.32e-12	Uric acid clearance;
PAAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg04844267	chr4:1394941	NA	-0.4	-4.56	-0.35	1.03e-5	Obesity-related traits;
PAAD	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg03255953	chr3:127056837	NA	-0.4	-4.5	-0.34	1.35e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-5.25	-0.39	4.99e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9463078	0.528	rs12214778	chr6:44924412	A/G	cg25276700	chr6:44698697	NA	0.47	5.53	0.41	1.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg06375148	chr1:209958343	C1orf74	0.64	4.7	0.36	5.78e-6	Coronary artery disease;
PAAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-7.6	-0.52	2.79e-12	Body mass index;
PAAD	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.51	4.95	0.37	1.96e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3774830	0.649	rs41268643	chr4:5469916	G/A	cg26943120	chr4:5472116	STK32B	0.4	5.18	0.39	6.8e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.89	11.1	0.67	2.49e-21	Sudden cardiac arrest;
PAAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg09796270	chr17:17721594	SREBF1	0.45	5.28	0.39	4.4e-7	Total body bone mineral density;
PAAD	cis	rs728616	0.867	rs1983775	chr10:81663575	G/A	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.8	-0.36	3.72e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.42	-0.34	1.83e-5	Biliary atresia;
PAAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.35	6.39	0.46	1.93e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.36	-0.46	2.26e-9	Fibrinogen levels;
PAAD	cis	rs4740619	0.741	rs10756728	chr9:15973288	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.46	-0.34	1.58e-5	Body mass index;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05918376	chr6:168898226	SMOC2	-0.62	-7.06	-0.5	5.56e-11	Obesity-related traits;
PAAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-4.87	-0.37	2.83e-6	Triglycerides;
PAAD	cis	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg20159608	chr7:32802032	NA	-0.59	-5.99	-0.44	1.45e-8	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs3106136	0.678	rs7658830	chr4:95295134	A/G	cg11021082	chr4:95130006	SMARCAD1	0.5	4.75	0.36	4.6e-6	Capecitabine sensitivity;
PAAD	cis	rs3106136	0.609	rs4693000	chr4:95107657	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.69	-6.16	-0.45	6.23e-9	Capecitabine sensitivity;
PAAD	cis	rs3925075	0.500	rs8057320	chr16:31269551	C/T	cg02846316	chr16:31340340	ITGAM	0.44	5.19	0.39	6.79e-7	IgA nephropathy;
PAAD	cis	rs12550646	0.652	rs13438989	chr8:41685845	T/G	cg19997384	chr8:41685595	ANK1	-0.32	-4.45	-0.34	1.65e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.51	-4.98	-0.37	1.68e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4740619	0.933	rs11789563	chr9:15699817	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.43	-0.34	1.76e-5	Body mass index;
PAAD	cis	rs282587	0.569	rs7982564	chr13:113398930	G/A	cg02820901	chr13:113351484	ATP11A	-0.65	-4.94	-0.37	2.07e-6	Glycated hemoglobin levels;
PAAD	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg20243544	chr17:37824526	PNMT	0.52	4.51	0.34	1.29e-5	Self-reported allergy;
PAAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg01796438	chr3:11312864	ATG7	-0.55	-4.29	-0.33	3.18e-5	Circulating chemerin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23667555	chr12:25403962	KRAS	0.67	6.4	0.46	1.87e-9	Obesity-related traits;
PAAD	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.78e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs28489187	0.577	rs3920521	chr1:85848866	A/C	cg16011679	chr1:85725395	C1orf52	0.45	4.46	0.34	1.57e-5	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6929137	0.632	rs12197785	chr6:151960605	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.49	-0.34	1.39e-5	Bone mineral density (spine);
PAAD	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.68	6.85	0.49	1.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2625529	0.526	rs16956623	chr15:72536695	T/C	cg16672083	chr15:72433130	SENP8	0.45	4.38	0.33	2.18e-5	Red blood cell count;
PAAD	cis	rs721399	0.553	rs13262341	chr8:18243097	A/G	cg18736775	chr8:18248649	NAT2	-0.81	-6.68	-0.48	4.33e-10	Blood metabolite levels;
PAAD	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg20913747	chr6:44695427	NA	-0.66	-6.54	-0.47	8.62e-10	Total body bone mineral density;
PAAD	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.47	4.55	0.35	1.09e-5	Red blood cell count;
PAAD	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg09127314	chr1:152161683	NA	0.69	5.04	0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs375066	0.762	rs171238	chr19:44379554	A/C	cg08633290	chr19:44405433	NA	-0.54	-5.12	-0.38	9.12e-7	Breast cancer;
PAAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.0	0.59	8.54e-16	Motion sickness;
PAAD	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6782228	0.606	rs1697	chr3:128356852	C/T	cg16766828	chr3:128327626	NA	-0.49	-6.63	-0.47	5.37e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs7631605	0.905	rs6809297	chr3:37181591	G/A	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	4.38	0.34	2.17e-5	Multiple sclerosis;
PAAD	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg14664628	chr15:75095509	CSK	-0.5	-4.81	-0.36	3.59e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.77	5.75	0.42	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.53	-0.47	9.4e-10	Aortic root size;
PAAD	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	1.09	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.57	4.84	0.37	3.11e-6	Response to diuretic therapy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22209616	chr15:68569728	FEM1B	0.56	6.3	0.46	3.01e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg07159951	chr1:45983175	PRDX1	0.43	4.72	0.36	5.33e-6	High light scatter reticulocyte count;
PAAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.62	-0.47	5.69e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.95	-7.99	-0.54	3.1400000000000003e-13	Schizophrenia;
PAAD	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.32	4.5	0.34	1.34e-5	Migraine;
PAAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.41	0.46	1.7e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.51	5.45	0.4	2.01e-7	Obesity-related traits;
PAAD	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.67	6.66	0.48	4.83e-10	Schizophrenia;
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.26	0.56	6.51e-14	Prudent dietary pattern;
PAAD	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18252515	chr7:66147081	NA	-0.47	-4.4	-0.34	2.05e-5	Corneal structure;
PAAD	cis	rs11066679	0.716	rs7967203	chr12:114120591	A/G	cg18842598	chr12:114273539	RBM19	0.53	4.61	0.35	8.31e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs75920871	0.764	rs61903394	chr11:116931898	G/A	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.56	-7.33	-0.51	1.27e-11	Longevity;
PAAD	cis	rs494459	0.838	rs1784543	chr11:118631653	A/T	cg08498647	chr11:118550644	TREH	-0.35	-4.28	-0.33	3.34e-5	Height;
PAAD	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-4.48	-0.34	1.47e-5	Morning vs. evening chronotype;
PAAD	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.15e-8	Colorectal cancer;
PAAD	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.52e-8	Coronary artery disease;
PAAD	cis	rs4704187	0.663	rs1477935	chr5:74448494	C/T	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg25809561	chr17:30822961	MYO1D	0.67	7.41	0.51	8.31e-12	Schizophrenia;
PAAD	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.79	4.83	0.36	3.27e-6	Obesity-related traits;
PAAD	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg00717180	chr2:96193071	NA	-0.61	-7.18	-0.5	2.82e-11	Height;
PAAD	cis	rs11264799	0.598	rs3818814	chr1:157718780	A/G	cg18268488	chr1:157545234	FCRL4	0.65	5.81	0.43	3.58e-8	IgA nephropathy;
PAAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg10934807	chr2:113191815	RGPD8;RGPD5	0.96	6.87	0.49	1.58e-10	Yeast infection;
PAAD	cis	rs346785	0.692	rs3803737	chr17:74289500	G/A	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.1	0.63	1.15e-18	Prudent dietary pattern;
PAAD	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg26338869	chr17:61819248	STRADA	-0.57	-4.48	-0.34	1.44e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2271001	0.955	rs11025025	chr11:19140352	C/A	cg00161556	chr11:19138045	ZDHHC13	0.5	5.3	0.4	3.96e-7	Gut microbiome composition (winter);
PAAD	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg23254163	chr1:152506842	NA	0.52	5.54	0.41	1.27e-7	Hair morphology;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26549601	chr10:134560360	INPP5A	-0.48	-4.6	-0.35	8.79e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs875971	0.660	rs801193	chr7:66030612	A/C	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.62	7.14	0.5	3.63e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.82	6.98	0.49	8.67e-11	Crohn's disease;
PAAD	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.91	10.3	0.64	3.3e-19	Breast cancer;
PAAD	cis	rs735539	0.521	rs2762998	chr13:21375752	A/G	cg27499820	chr13:21296301	IL17D	0.51	4.69	0.36	6.04e-6	Dental caries;
PAAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg10556349	chr10:835070	NA	0.71	5.53	0.41	1.39e-7	Response to angiotensin II receptor blocker therapy;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg15023313	chr10:37414759	ANKRD30A	-0.59	-6.68	-0.48	4.33e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.55	5.4	0.4	2.57e-7	Menopause (age at onset);
PAAD	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.68	7.02	0.5	6.76e-11	Uric acid levels;
PAAD	cis	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.33	-0.33	2.72e-5	Eotaxin levels;
PAAD	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.02	9.18	0.6	2.9e-16	Gut microbiome composition (summer);
PAAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.42	5.43	0.4	2.18e-7	Thyroid stimulating hormone;
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg24879335	chr3:133465180	TF	0.55	5.74	0.42	4.97e-8	Iron status biomarkers;
PAAD	cis	rs528301	0.833	rs340497	chr2:45134900	G/C	cg15393275	chr2:45165193	NA	-0.48	-5.25	-0.39	5.01e-7	Alcohol and nicotine co-dependence;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08789134	chr4:6579201	MAN2B2	0.71	8.56	0.57	1.14e-14	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-4.26	-0.33	3.62e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.73	8.15	0.55	1.22e-13	Lung cancer;
PAAD	cis	rs965469	0.779	rs8117749	chr20:3386692	A/C	cg25506879	chr20:3388711	C20orf194	-0.53	-4.55	-0.35	1.09e-5	IFN-related cytopenia;
PAAD	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.8	-5.81	-0.43	3.57e-8	Vitiligo;
PAAD	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.69	6.56	0.47	7.76e-10	Plateletcrit;Platelet count;
PAAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-4.59	-0.35	9.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg03030879	chr14:75389066	RPS6KL1	-0.44	-4.78	-0.36	4.07e-6	Height;
PAAD	cis	rs2997447	0.761	rs868174	chr1:26473224	G/C	cg24519413	chr1:26490540	NA	0.57	5.16	0.39	7.48e-7	QRS complex (12-leadsum);
PAAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg21890820	chr11:65308645	LTBP3	-0.71	-8.72	-0.58	4.58e-15	Bone mineral density;
PAAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	6.17	0.45	6e-9	Initial pursuit acceleration;
PAAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg19847866	chr10:1019161	NA	-0.54	-4.36	-0.33	2.38e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg05182265	chr7:156933206	UBE3C	0.69	5.51	0.41	1.51e-7	Type 2 diabetes;
PAAD	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06850241	chr22:41845214	NA	-0.45	-4.31	-0.33	2.88e-5	Vitiligo;
PAAD	cis	rs4085154	1.000	rs4846649	chr1:216860548	G/T	cg20869501	chr1:216774677	ESRRG	-0.42	-4.26	-0.33	3.62e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.51	4.73	0.36	5e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.48	-4.83	-0.36	3.35e-6	Tonsillectomy;
PAAD	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg10377582	chr12:51612794	POU6F1	-0.38	-4.44	-0.34	1.74e-5	Cisplatin-induced ototoxicity;
PAAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.8	10.11	0.63	1.09e-18	Vitiligo;
PAAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.65	4.37	0.33	2.25e-5	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.35	0.56	3.88e-14	Dupuytren's disease;
PAAD	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg18357526	chr6:26021779	HIST1H4A	0.5	4.52	0.34	1.22e-5	Height;
PAAD	cis	rs758324	0.504	rs55764014	chr5:131170905	G/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs802075	0.967	rs802068	chr6:49657330	C/T	cg20364632	chr6:49636226	NA	-0.51	-5.88	-0.43	2.54e-8	Bone mineral density (hip) and age at menarche;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08325383	chr11:65190187	NEAT1	0.57	6.55	0.47	8.23e-10	Monocyte percentage of white cells;
PAAD	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.52	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.5	6.04	0.44	1.16e-8	Vitiligo;
PAAD	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.59	-4.9	-0.37	2.48e-6	Atopic dermatitis;
PAAD	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	4.5	0.34	1.33e-5	HDL cholesterol;
PAAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.31	0.4	3.82e-7	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9398803	0.723	rs1262546	chr6:127075491	T/C	cg19875578	chr6:126661172	C6orf173	-0.45	-4.76	-0.36	4.52e-6	Male-pattern baldness;
PAAD	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.59	8.17	0.55	1.09e-13	Asthma (sex interaction);
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.5	-5.68	-0.42	6.75e-8	Cardiovascular disease risk factors;
PAAD	cis	rs17331151	0.505	rs35325270	chr3:52556369	C/T	cg27565382	chr3:53032988	SFMBT1	0.86	4.51	0.34	1.29e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg00334542	chr7:100209784	MOSPD3	-0.73	-5.18	-0.39	6.91e-7	Other erythrocyte phenotypes;
PAAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg09211372	chr6:168490623	NA	-0.44	-4.69	-0.36	6.14e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.35	6.34e-6	Vitiligo;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg04970839	chr7:1942763	MAD1L1	-0.71	-7.36	-0.51	1.1e-11	Primary biliary cholangitis;
PAAD	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.51	5.41	0.4	2.43e-7	Red blood cell count;
PAAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg15331088	chr8:600555	NA	0.71	4.59	0.35	9.18e-6	IgG glycosylation;
PAAD	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.81	-0.48	2.16e-10	Eye color traits;
PAAD	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg22467129	chr15:76604101	ETFA	0.55	5.12	0.38	8.99e-7	Blood metabolite levels;
PAAD	cis	rs4455778	0.580	rs6951015	chr7:49115139	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg10208897	chr5:178548229	ADAMTS2	0.52	4.57	0.35	1.02e-5	Pubertal anthropometrics;
PAAD	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.52	5.68	0.42	6.68e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10214930	0.752	rs7782422	chr7:27663503	A/G	cg22168087	chr7:27702803	HIBADH	0.49	4.42	0.34	1.85e-5	Hypospadias;
PAAD	cis	rs17761864	0.664	rs12449873	chr17:2058289	G/C	cg16513277	chr17:2031491	SMG6	0.47	4.69	0.36	6.07e-6	Esophageal cancer (squamous cell);
PAAD	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg00543991	chr22:32367038	NA	1.18	7.23	0.51	2.23e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg19257562	chr1:2043853	PRKCZ	0.47	5.81	0.43	3.57e-8	Height;
PAAD	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.39	13.52	0.74	7.43e-28	Corneal structure;
PAAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.48	-7.16	-0.5	3.29e-11	Mean corpuscular volume;
PAAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08677398	chr8:58056175	NA	0.6	4.38	0.33	2.19e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7246865	0.510	rs3816550	chr19:17173487	A/G	cg19418318	chr19:17219073	MYO9B	0.35	5.03	0.38	1.35e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs1472147	1.000	rs13225751	chr7:128504529	A/G	cg10778310	chr7:128509080	NA	-0.41	-4.76	-0.36	4.46e-6	Calcium levels;
PAAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg13057898	chr1:3703894	LRRC47	0.4	4.25	0.33	3.69e-5	Red cell distribution width;
PAAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg14393609	chr7:65229607	NA	0.71	7.73	0.53	1.33e-12	Aortic root size;
PAAD	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.51	-5.44	-0.4	2.08e-7	Mitral valve prolapse;
PAAD	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18364779	chr6:26104403	HIST1H4C	0.46	4.62	0.35	8.15e-6	Schizophrenia;
PAAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.56	-0.41	1.17e-7	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9659323	0.670	rs17023223	chr1:119631174	T/C	cg17326555	chr1:119535693	NA	-0.38	-5.24	-0.39	5.31e-7	Body mass index;
PAAD	cis	rs4790333	0.967	rs745400	chr17:2266799	G/A	cg02569219	chr17:2266849	SGSM2	0.65	6.27	0.45	3.6e-9	Proinsulin levels;
PAAD	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-7.24	-0.51	2.06e-11	Morning vs. evening chronotype;
PAAD	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg13002189	chr3:66846049	NA	0.57	5.53	0.41	1.35e-7	Type 2 diabetes;
PAAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg01097406	chr16:89675127	NA	0.35	4.3	0.33	3.1e-5	Vitiligo;
PAAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg16586182	chr3:47516702	SCAP	-0.45	-4.59	-0.35	9.03e-6	Birth weight;
PAAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.71	6.67	0.48	4.58e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs3764400	0.567	rs741058	chr17:46205353	T/C	cg24322968	chr17:46507895	SKAP1	-0.86	-5.26	-0.39	4.76e-7	Body mass index;
PAAD	cis	rs3136739	0.614	rs3827659	chr8:42025838	T/C	cg17828057	chr8:42037527	PLAT	0.7	4.84	0.37	3.19e-6	Plasma plasminogen activator levels;
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg15117754	chr3:10150083	C3orf24	0.6	5.77	0.42	4.39e-8	Alzheimer's disease;
PAAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg06740227	chr12:86229804	RASSF9	-0.56	-4.98	-0.37	1.73e-6	Major depressive disorder;
PAAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.78	-6.12	-0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.04	-0.38	1.32e-6	Mood instability;
PAAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg17724175	chr1:150552817	MCL1	-0.41	-4.75	-0.36	4.65e-6	Tonsillectomy;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.29	0.33	3.14e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.86	10.98	0.67	5e-21	Height;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26549601	chr10:134560360	INPP5A	-0.5	-4.82	-0.36	3.49e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.71	0.48	3.55e-10	Height;
PAAD	cis	rs11700980	0.591	rs2832046	chr21:30116806	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg19438565	chr8:143695827	ARC	-0.56	-5.41	-0.4	2.45e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.41	-4.89	-0.37	2.56e-6	Tonsillectomy;
PAAD	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg05272587	chr13:111038400	COL4A2	-0.51	-4.57	-0.35	1e-5	White matter hyperintensity burden;
PAAD	cis	rs2252790	0.965	rs2501048	chr6:116663479	C/G	cg18764771	chr6:116381957	FRK	-0.26	-4.36	-0.33	2.37e-5	Fast beta electroencephalogram;
PAAD	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.42	-6.33	-0.46	2.66e-9	Subjective well-being;
PAAD	cis	rs9341808	0.667	rs10943698	chr6:80934301	C/T	cg08355045	chr6:80787529	NA	0.38	4.69	0.36	6.09e-6	Sitting height ratio;
PAAD	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg01990225	chr2:97406019	LMAN2L	-0.9	-4.72	-0.36	5.24e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.36	-0.33	2.35e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.43	-6.38	-0.46	2.03e-9	Subjective well-being;
PAAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-4.81	-0.36	3.54e-6	Diabetic retinopathy;
PAAD	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg09579323	chr1:150459698	TARS2	0.45	4.26	0.33	3.51e-5	Migraine;
PAAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.19e-6	Life satisfaction;
PAAD	cis	rs600626	0.786	rs600518	chr11:75455373	A/T	cg24262691	chr11:75473276	NA	0.51	4.78	0.36	4.08e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06753367	chr22:24256600	NA	-0.45	-4.89	-0.37	2.58e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10982213	1.000	rs2274162	chr9:117187569	G/T	cg00078025	chr9:117159975	NA	0.63	4.7	0.36	5.71e-6	Interleukin-6 levels;
PAAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.59	5.68	0.42	6.64e-8	Graves' disease;
PAAD	cis	rs11992162	0.636	rs35995176	chr8:11809647	G/C	cg12568669	chr8:11666485	FDFT1	0.31	5.13	0.38	8.6e-7	Monocyte count;
PAAD	cis	rs4234798	1.000	rs4689088	chr4:7222253	G/A	cg18431297	chr4:7219810	SORCS2	0.39	4.6	0.35	8.85e-6	Insulin-like growth factors;
PAAD	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-5.46	-0.41	1.89e-7	Atrioventricular conduction;
PAAD	cis	rs256277	0.544	rs34942	chr5:111334801	G/A	cg17919331	chr5:112312406	DCP2	0.53	4.3	0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg01090926	chr14:75137805	KIAA0317	-0.54	-4.84	-0.37	3.17e-6	Non-small cell lung cancer;
PAAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.62	6.31	0.46	2.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.51	-6.32	-0.46	2.71e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1.01e-21	Prudent dietary pattern;
PAAD	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg03233332	chr7:66118400	NA	-0.4	-4.34	-0.33	2.6e-5	Aortic root size;
PAAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	1.09	15.32	0.78	1.28e-32	Breast cancer;
PAAD	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg01631408	chr1:248437212	OR2T33	-0.61	-5.74	-0.42	4.86e-8	Common traits (Other);
PAAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	0.52	4.46	0.34	1.56e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10768122	0.966	rs3794101	chr11:35295073	G/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.29	-0.33	3.18e-5	Vitiligo;
PAAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg27411982	chr8:10470053	RP1L1	-0.47	-5.26	-0.39	4.72e-7	Systolic blood pressure;
PAAD	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.89	-12.94	-0.72	2.72e-26	Dental caries;
PAAD	cis	rs7588746	0.621	rs10497859	chr2:201144446	G/A	cg23649088	chr2:200775458	C2orf69	-0.52	-4.88	-0.37	2.68e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs11235843	0.706	rs10898949	chr11:73581672	C/T	cg15851278	chr11:73669449	DNAJB13	-0.63	-4.5	-0.34	1.34e-5	Hand grip strength;
PAAD	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg02743256	chr7:2109353	MAD1L1	-0.6	-4.33	-0.33	2.7e-5	Bipolar disorder;
PAAD	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.56	-6.16	-0.45	6.28e-9	Post bronchodilator FEV1;
PAAD	cis	rs10982256	0.789	rs2296262	chr9:117265406	C/T	cg12877860	chr9:117266580	DFNB31	0.43	4.34	0.33	2.6e-5	Bipolar disorder;
PAAD	cis	rs1075265	0.818	rs12713253	chr2:54264460	T/C	cg04546899	chr2:54196757	PSME4	0.38	5.74	0.42	4.91e-8	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.43	-5.49	-0.41	1.69e-7	Lewy body disease;
PAAD	cis	rs501120	1.000	rs479596	chr10:44760473	C/T	cg09554077	chr10:44749378	NA	0.46	5.65	0.42	7.81e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.76	-0.36	4.55e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs863345	0.625	rs7534112	chr1:158532065	G/A	cg12129480	chr1:158549410	OR10X1	-0.42	-4.74	-0.36	4.78e-6	Pneumococcal bacteremia;
PAAD	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.82	-9.67	-0.62	1.55e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs2249694	0.572	rs9418984	chr10:135322356	C/G	cg20169779	chr10:135381914	SYCE1	-0.5	-4.57	-0.35	9.87e-6	Obesity-related traits;
PAAD	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg08501292	chr6:25962987	TRIM38	0.97	5.29	0.39	4.28e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07798295	chr16:89715839	CHMP1A	0.57	6.6	0.47	6.31e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg19337854	chr7:99768885	GPC2	0.47	4.33	0.33	2.73e-5	Platelet count;
PAAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.55	4.26	0.33	3.58e-5	Gut microbiome composition (summer);
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg21479132	chr6:26055353	NA	0.83	4.61	0.35	8.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00292662	chr22:38071168	LGALS1	0.52	5.49	0.41	1.68e-7	Fat distribution (HIV);
PAAD	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg15208524	chr1:10270712	KIF1B	0.51	4.75	0.36	4.66e-6	Hepatocellular carcinoma;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.72	8.24	0.56	7.33e-14	Lung cancer;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg07068956	chr7:100330872	ZAN	-0.69	-5.39	-0.4	2.66e-7	Other erythrocyte phenotypes;
PAAD	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.68	6.43	0.46	1.52e-9	Breast cancer;
PAAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	8.62	0.57	8.31e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs802075	0.765	rs2145331	chr6:49598877	G/C	cg20364632	chr6:49636226	NA	-0.52	-6.04	-0.44	1.12e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.89e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.53e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.08e-6	Pulmonary function;
PAAD	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.58e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.5	5.37	0.4	2.93e-7	Mean corpuscular volume;
PAAD	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.59	-5.43	-0.4	2.14e-7	Total body bone mineral density;
PAAD	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	4.25	0.33	3.77e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.5	-5.37	-0.4	2.87e-7	Calcium levels;
PAAD	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-7.62	-0.53	2.48e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs72827839	0.779	rs16954581	chr17:46359502	C/T	cg23391107	chr17:45924227	SP6	-0.55	-5.25	-0.39	4.93e-7	Ease of getting up in the morning;
PAAD	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg05342945	chr12:48394962	COL2A1	-0.66	-4.26	-0.33	3.59e-5	Lung cancer;
PAAD	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg02027945	chr11:20618230	NA	0.33	4.62	0.35	8.01e-6	Pursuit maintenance gain;
PAAD	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg22437258	chr11:111473054	SIK2	0.64	6.28	0.45	3.3e-9	Primary sclerosing cholangitis;
PAAD	cis	rs6782025	1.000	rs2127024	chr3:121128097	T/G	cg16417163	chr3:121280760	NA	-0.46	-4.78	-0.36	4.12e-6	Aging (facial);
PAAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.96e-5	Iron status biomarkers;
PAAD	cis	rs8005172	0.676	rs2301119	chr14:88401904	C/A	cg18078958	chr14:88630771	NA	0.46	5.58	0.41	1.06e-7	Parkinson's disease;
PAAD	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27511599	chr7:32358540	NA	0.75	4.43	0.34	1.83e-5	Body mass index;
PAAD	cis	rs72960926	0.744	rs2351778	chr6:74866814	T/G	cg03266952	chr6:74778945	NA	-1.12	-7.18	-0.5	2.85e-11	Metabolite levels (MHPG);
PAAD	cis	rs300774	1.000	rs300793	chr2:108411	A/T	cg23649280	chr2:140451	NA	-0.51	-4.74	-0.36	4.83e-6	Suicide attempts in bipolar disorder;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04190784	chr20:47894496	C20orf199;SNORD12C;ZNFX1	-0.57	-6.57	-0.47	7.45e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs12760731	0.720	rs12060844	chr1:178280816	T/C	cg00404053	chr1:178313656	RASAL2	0.7	5.46	0.4	1.92e-7	Obesity-related traits;
PAAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-5.99	-0.44	1.44e-8	Electroencephalogram traits;
PAAD	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.51	5.27	0.39	4.68e-7	Red blood cell count;
PAAD	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg01759136	chr6:27242945	NA	0.4	4.45	0.34	1.66e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.58	-7.43	-0.52	7.22e-12	Lewy body disease;
PAAD	cis	rs564309	0.681	rs6426501	chr1:228623243	C/G	cg13099616	chr1:227751251	ZNF678	0.72	4.45	0.34	1.63e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	8.28	0.56	5.99e-14	Schizophrenia;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.58	6.07	0.44	9.72e-9	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.98e-19	Response to antipsychotic treatment;
PAAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.63	8.28	0.56	6e-14	Renal cell carcinoma;
PAAD	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.72	6.25	0.45	3.97e-9	Diabetic retinopathy;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-5.19	-0.39	6.68e-7	Neuroticism;
PAAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg04673462	chr1:38461896	NA	0.41	5.58	0.41	1.06e-7	Coronary artery disease;
PAAD	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-4.94	-0.37	2.07e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs758324	0.812	rs10042334	chr5:131114979	A/T	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7092929	0.941	rs835325	chr10:3571175	A/G	cg14308648	chr10:3568949	NA	0.69	5.04	0.38	1.32e-6	Coronary artery calcification;
PAAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.85	-9.21	-0.6	2.47e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg09359103	chr1:154839909	KCNN3	-0.82	-8.93	-0.59	1.28e-15	Prostate cancer;
PAAD	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.79	6.06	0.44	1.04e-8	HIV-1 control;
PAAD	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.92	0.37	2.24e-6	Testicular germ cell tumor;
PAAD	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.89	-10.75	-0.66	2.15e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg19507638	chr5:93509721	C5orf36	-0.65	-4.31	-0.33	2.91e-5	Diabetic retinopathy;
PAAD	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	13.91	0.75	6.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7922314	0.571	rs61865723	chr10:64757951	T/A	cg08989932	chr10:65390526	NA	-0.94	-4.55	-0.35	1.09e-5	Cutaneous psoriasis;
PAAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-8.67	-0.58	6.08e-15	Coronary artery disease;
PAAD	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg05110241	chr16:68378359	PRMT7	-0.74	-5.73	-0.42	5.28e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.54	5.29	0.39	4.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7727544	0.558	rs7733502	chr5:131556203	A/C	cg16205897	chr5:131564050	P4HA2	-0.42	-4.28	-0.33	3.23e-5	Blood metabolite levels;
PAAD	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.96	9.76	0.62	8.76e-18	Corneal astigmatism;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.61	-6.88	-0.49	1.5e-10	Height;
PAAD	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-7.48	-0.52	5.62e-12	Hemoglobin concentration;
PAAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.04e-5	Total body bone mineral density;
PAAD	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg14169450	chr9:139327907	INPP5E	0.52	4.43	0.34	1.78e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs990171	0.913	rs4851009	chr2:103055644	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.76e-5	Lymphocyte counts;
PAAD	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg21823605	chr1:152486609	CRCT1	0.5	6.53	0.47	9.33e-10	Hair morphology;
PAAD	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.4	-4.44	-0.34	1.7e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.36	0.33	2.39e-5	Platelet count;
PAAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.8	7.06	0.5	5.7e-11	Psoriasis;
PAAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.92	-8.25	-0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.74	-7.28	-0.51	1.7e-11	White matter hyperintensity burden;
PAAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg23281280	chr6:28129359	ZNF389	0.51	4.33	0.33	2.75e-5	Parkinson's disease;
PAAD	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.68	-6.98	-0.49	8.6e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09597638	chr17:3907349	NA	-0.71	-7.55	-0.52	3.8e-12	Type 2 diabetes;
PAAD	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg23649088	chr2:200775458	C2orf69	-0.73	-5.08	-0.38	1.09e-6	Schizophrenia;
PAAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01200585	chr1:228362443	C1orf69	-0.53	-5.96	-0.44	1.7e-8	Diastolic blood pressure;
PAAD	trans	rs2982694	0.764	rs985694	chr6:152286625	T/C	cg08544209	chr10:10837368	SFTA1P	-0.7	-6.34	-0.46	2.47e-9	Sudden cardiac arrest;
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.82	-0.36	3.48e-6	Lung cancer;
PAAD	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02610550	chr13:74708579	KLF12	0.62	6.5	0.47	1.1e-9	Pancreatic cancer;
PAAD	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.42	4.39	0.34	2.1e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg24130564	chr14:104152367	KLC1	-0.47	-4.58	-0.35	9.81e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.45	-4.93	-0.37	2.12e-6	Fibrinogen levels;
PAAD	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.66	9.16	0.6	3.28e-16	Airflow obstruction;
PAAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.49	5.47	0.41	1.8e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.86	-4.78	-0.36	4.18e-6	Skin colour saturation;
PAAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg07148914	chr20:33460835	GGT7	0.47	4.63	0.35	7.95e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.46	5.83	0.43	3.22e-8	Cystic fibrosis severity;
PAAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.7	7.0	0.49	7.8e-11	Systolic blood pressure;
PAAD	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	5.44	0.4	2.11e-7	Colorectal cancer;
PAAD	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg09357268	chr20:43379437	KCNK15	0.44	4.63	0.35	7.66e-6	Obesity-related traits;
PAAD	cis	rs7551345	1.000	rs35033009	chr1:31857236	G/A	cg17086398	chr1:31896392	SERINC2	-0.46	-4.25	-0.33	3.65e-5	Schizophrenia;
PAAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.77	8.45	0.57	2.16e-14	Morning vs. evening chronotype;
PAAD	cis	rs988913	0.723	rs4490666	chr6:55000651	C/T	cg03513858	chr6:54763001	FAM83B	0.4	4.35	0.33	2.48e-5	Menarche (age at onset);
PAAD	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-1.12	-7.81	-0.53	8.88e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.29	-0.45	3.26e-9	Myopia (pathological);
PAAD	cis	rs4455778	0.580	rs10259971	chr7:49085752	A/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs7922314	0.571	rs16917950	chr10:64719616	T/A	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.53	4.81	0.36	3.54e-6	Airway imaging phenotypes;
PAAD	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg22356347	chr1:167427500	CD247	-0.45	-5.19	-0.39	6.68e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.32	0.4	3.64e-7	Heart rate;
PAAD	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg21130718	chr4:1044621	NA	0.54	4.48	0.34	1.44e-5	Recombination rate (females);
PAAD	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.75	-6.3	-0.46	3.06e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg26149184	chr10:133730230	NA	0.77	6.74	0.48	3.04e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.63	-5.67	-0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.06e-10	Testicular germ cell tumor;
PAAD	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.97	8.78	0.58	3.25e-15	Vitiligo;
PAAD	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.76	5.37	0.4	2.92e-7	Plateletcrit;
PAAD	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.87	-10.46	-0.65	1.27e-19	Menopause (age at onset);
PAAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.95	12.6	0.71	2.23e-25	Menopause (age at onset);
PAAD	cis	rs2790216	1.000	rs1867573	chr10:60042972	C/T	cg20442379	chr10:60024634	IPMK	0.57	4.33	0.33	2.71e-5	Inflammatory bowel disease;
PAAD	cis	rs597480	0.719	rs7103790	chr11:85523688	C/T	cg11817631	chr11:85522609	SYTL2	0.48	4.44	0.34	1.75e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.64	5.38	0.4	2.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.75	8.63	0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.79	-9.64	-0.62	1.84e-17	Height;
PAAD	cis	rs1863918	0.807	rs4701049	chr5:178545214	G/T	cg10208897	chr5:178548229	ADAMTS2	0.5	5.08	0.38	1.08e-6	Depression in response to interferon-based therapy in chronic hepatitis C;
PAAD	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.98	0.67	5.04e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg13175981	chr1:150552382	MCL1	0.61	5.53	0.41	1.37e-7	Urate levels;
PAAD	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.87	0.37	2.8e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.66	5.13	0.38	8.59e-7	Alzheimer's disease (survival time);
PAAD	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.62	5.29	0.39	4.12e-7	Height;
PAAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-6.33	-0.46	2.68e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.49	5.14	0.38	8.47e-7	Body mass index;
PAAD	cis	rs3917254	0.543	rs6543106	chr2:102746449	A/G	cg22835712	chr2:102737379	NA	-0.68	-5.01	-0.38	1.49e-6	Blood protein levels;
PAAD	cis	rs2694528	0.764	rs76486536	chr5:60355586	A/G	cg11474532	chr5:59995715	DEPDC1B	1.03	4.77	0.36	4.34e-6	Parkinson's disease;
PAAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.57	7.59	0.52	2.96e-12	Renal cell carcinoma;
PAAD	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg10645314	chr2:3704589	ALLC	-0.67	-6.19	-0.45	5.36e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.67	-6.88	-0.49	1.5e-10	Type 2 diabetes;
PAAD	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06028605	chr16:24865363	SLC5A11	0.47	5.69	0.42	6.49e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs34195613	chr10:46030374	G/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs955333	0.543	rs9478561	chr6:154933597	T/C	cg20019720	chr6:154832845	CNKSR3	0.32	4.32	0.33	2.83e-5	Diabetic kidney disease;
PAAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg16386425	chr10:429943	DIP2C	-0.43	-4.53	-0.34	1.21e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs10888329	0.707	rs6587437	chr1:248355867	T/G	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Autism spectrum disorder;
PAAD	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.54	5.18	0.39	6.93e-7	Multiple myeloma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08626888	chr12:121341326	SPPL3	0.57	6.65	0.47	4.85e-10	Monocyte percentage of white cells;
PAAD	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.67	-0.35	6.5e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.44	0.61	6.21e-17	Parkinson's disease;
PAAD	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg02696790	chr15:75250997	RPP25	-0.38	-4.64	-0.35	7.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.54	5.08	0.38	1.09e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.17	-17.84	-0.82	4.18e-39	Height;
PAAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-9.85	-0.62	5.09e-18	Total body bone mineral density;
PAAD	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.84	8.55	0.57	1.2e-14	Height;
PAAD	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg16579770	chr16:72058938	DHODH	0.38	4.41	0.34	1.94e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.7	8.24	0.56	7.57e-14	Type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	0.909	rs1716975	chr3:41960006	T/C	cg03022575	chr3:42003672	ULK4	-0.82	-5.91	-0.43	2.21e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg15890332	chr12:107067104	RFX4	0.47	5.1	0.38	1.02e-6	Total body bone mineral density;
PAAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.88	-10.07	-0.63	1.4e-18	Ulcerative colitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15925179	chr3:196159742	UBXN7	-0.67	-6.44	-0.46	1.5e-9	Lung cancer in ever smokers;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.51	5.7	0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg26174226	chr8:58114915	NA	-0.62	-5.14	-0.38	8.31e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg13482628	chr17:19912719	NA	0.46	4.46	0.34	1.59e-5	Obesity-related traits;
PAAD	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.06	7.5	0.52	4.92e-12	Lymphocyte counts;
PAAD	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.72	8.91	0.59	1.48e-15	Dupuytren's disease;
PAAD	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg07159951	chr1:45983175	PRDX1	0.4	4.42	0.34	1.89e-5	High light scatter reticulocyte count;
PAAD	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg11900509	chr10:81946545	ANXA11	-0.76	-4.25	-0.33	3.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	4.53	0.35	1.17e-5	Mood instability;
PAAD	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs7937127	0.600	rs3781803	chr11:43439363	C/T	cg16963683	chr11:44087684	ACCS	0.54	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg19445457	chr11:5799446	OR52N5	0.52	4.65	0.35	7.09e-6	DNA methylation (variation);
PAAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs10950821	0.734	rs11772926	chr7:20685900	T/C	cg21202529	chr7:20656503	ABCB5	-0.52	-5.03	-0.38	1.35e-6	Response to statin therapy;
PAAD	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg10208897	chr5:178548229	ADAMTS2	0.51	4.5	0.34	1.35e-5	Pubertal anthropometrics;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg19538917	chr5:177436178	FAM153C	-0.5	-6.4	-0.46	1.87e-9	Energy expenditure (24h);
PAAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.67	6.73	0.48	3.31e-10	Blood metabolite levels;
PAAD	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.15	-8.31	-0.56	5e-14	Height;
PAAD	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg02887458	chr19:19495540	GATAD2A	0.54	5.11	0.38	9.67e-7	Bipolar disorder;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.16	6.23	0.45	4.44e-9	Cognitive function;
PAAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.73	-7.37	-0.51	1.04e-11	Neurofibrillary tangles;
PAAD	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-4.38	-0.33	2.23e-5	Coronary artery disease;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg18850127	chr7:39170497	POU6F2	0.54	7.79	0.53	9.59e-13	IgG glycosylation;
PAAD	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.62	6.67	0.48	4.53e-10	Bladder cancer;
PAAD	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.79	8.48	0.57	1.88e-14	Corneal astigmatism;
PAAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.53	5.47	0.41	1.78e-7	Lung cancer;
PAAD	trans	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.35	-0.46	2.34e-9	Mean corpuscular volume;
PAAD	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg06970076	chr16:1560791	IFT140	0.53	4.66	0.35	6.98e-6	Coronary artery disease;
PAAD	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10556349	chr10:835070	NA	0.71	5.69	0.42	6.47e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg03417191	chr3:183542750	MAP6D1	-0.88	-7.03	-0.5	6.69e-11	Menopause (age at onset);
PAAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27297192	chr10:134578999	INPP5A	0.63	6.12	0.44	7.59e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.52	-4.31	-0.33	2.86e-5	Gut microbiome composition (summer);
PAAD	cis	rs4965006	0.915	rs4965004	chr12:132424700	A/G	cg00588090	chr12:132412438	PUS1	0.77	8.15	0.55	1.26e-13	Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.59	-0.41	1.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs131777	0.508	rs140518	chr22:50999182	C/T	cg25309564	chr22:51001381	C22orf41	0.93	9.05	0.59	6.34e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	5.38	0.4	2.78e-7	Lung cancer in ever smokers;
PAAD	cis	rs89107	0.576	rs6906287	chr6:118962740	T/C	cg21191810	chr6:118973309	C6orf204	0.38	4.47	0.34	1.5e-5	Cardiac structure and function;
PAAD	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.55	-4.55	-0.35	1.1e-5	Facial morphology (factor 19);
PAAD	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.25	-0.45	3.87e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.56	5.29	0.39	4.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.64	8.51	0.57	1.53e-14	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	6.65	0.47	4.92e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.63	6.53	0.47	9.21e-10	Crohn's disease;
PAAD	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.85	-7.95	-0.54	4.03e-13	Exhaled nitric oxide output;
PAAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg15691649	chr6:25882328	NA	0.53	4.74	0.36	4.92e-6	Blood metabolite levels;
PAAD	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.4	5.0	0.38	1.57e-6	Blood protein levels;
PAAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.68	-7.12	-0.5	4.01e-11	Schizophrenia;
PAAD	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg24687543	chr11:63912206	MACROD1	-0.51	-4.57	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs3026101	0.723	rs1806248	chr17:5310411	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg20621447	chr17:74928711	MGAT5B	0.59	4.39	0.34	2.08e-5	Airflow obstruction;
PAAD	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.41	-0.34	1.93e-5	Osteoarthritis;
PAAD	cis	rs3136441	1.000	rs3136449	chr11:46744470	G/A	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.08	-0.44	9.33e-9	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01366407	chr1:154955991	FLAD1	0.67	7.67	0.53	1.9e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg22601191	chr20:60968625	CABLES2	-0.57	-5.49	-0.41	1.63e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20391793	chr2:106135414	NA	0.53	6.29	0.45	3.29e-9	Smoking initiation;
PAAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg05110241	chr16:68378359	PRMT7	-0.82	-6.81	-0.48	2.14e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.37	4.87	0.37	2.72e-6	Calcium levels;
PAAD	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-5.6	-0.41	9.81e-8	Alcohol dependence;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.31	-4.56	-0.35	1.03e-5	Longevity;Endometriosis;
PAAD	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26926768	chr12:34528122	NA	0.4	4.86	0.37	2.87e-6	Morning vs. evening chronotype;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	5.92	0.43	2.06e-8	Systolic blood pressure;
PAAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs2278796	0.724	rs2794860	chr1:204968392	A/G	cg17947172	chr1:204966197	NFASC	0.39	4.27	0.33	3.44e-5	Mean platelet volume;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs3020418	0.893	rs2860321	chr6:152356619	C/T	cg09520904	chr11:69462943	CCND1	-0.54	-6.62	-0.47	5.7e-10	Height;
PAAD	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.93	0.54	4.33e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg05082376	chr22:42548792	NA	-0.5	-5.41	-0.4	2.41e-7	Cognitive function;
PAAD	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg27411982	chr8:10470053	RP1L1	0.46	4.92	0.37	2.19e-6	Triglycerides;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.66	-8.02	-0.55	2.67e-13	Menopause (age at onset);
PAAD	trans	rs1842896	0.534	rs6821533	chr4:156467316	G/C	cg00585174	chr10:134499472	INPP5A	0.49	6.43	0.46	1.59e-9	Coronary heart disease;
PAAD	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg19761014	chr17:28927070	LRRC37B2	0.94	6.21	0.45	4.73e-9	Body mass index;
PAAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.71	8.2	0.55	9.58e-14	Multiple sclerosis;
PAAD	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.99	8.54	0.57	1.31e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.84	5.31	0.4	3.87e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-9.73	-0.62	1.08e-17	Idiopathic membranous nephropathy;
PAAD	cis	rs9372498	0.536	rs62424199	chr6:118827252	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.03	-0.38	1.37e-6	Diastolic blood pressure;
PAAD	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.53	5.04	0.38	1.3e-6	Malaria;
PAAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg10616300	chr11:66138557	SLC29A2	0.35	4.74	0.36	4.81e-6	Educational attainment (years of education);
PAAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg03959625	chr15:84868606	LOC388152	-0.44	-4.69	-0.36	6.15e-6	P wave terminal force;
PAAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.52	-5.14	-0.38	8.43e-7	Breast cancer;
PAAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23158103	chr7:148848205	ZNF398	0.61	5.97	0.44	1.6e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.45	-0.46	1.44e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2051773	0.567	rs6486346	chr11:17049890	A/G	cg15378786	chr11:17036137	PLEKHA7	0.5	4.25	0.33	3.68e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs4356203	0.870	rs10741724	chr11:17253151	C/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.68	0.36	6.23e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs225245	0.755	rs226432	chr17:34043825	G/A	cg19694781	chr19:47549865	TMEM160	0.59	6.68	0.48	4.27e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.62	-4.29	-0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-5.63	-0.42	8.5e-8	Schizophrenia;
PAAD	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.14	0.6	3.84e-16	Colorectal cancer;
PAAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05564831	chr3:52568323	NT5DC2	0.46	4.94	0.37	2.07e-6	Bipolar disorder;
PAAD	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.61	-7.81	-0.54	8.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs12928939	0.768	rs71386932	chr16:71816191	G/A	cg03805757	chr16:71968109	PKD1L3	-0.56	-4.95	-0.37	1.91e-6	Post bronchodilator FEV1;
PAAD	cis	rs6142102	0.961	rs8123521	chr20:32668885	A/C	cg06115741	chr20:33292138	TP53INP2	0.53	4.37	0.33	2.3e-5	Skin pigmentation;
PAAD	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7737355	0.812	rs11746227	chr5:130961236	C/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg03538708	chr1:25844672	NA	0.48	4.94	0.37	2e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6840360	0.593	rs4696103	chr4:152564611	A/G	cg09659197	chr4:152720779	NA	0.41	5.27	0.39	4.7e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12136530	0.577	rs4912002	chr1:19793402	G/T	cg20786524	chr1:18954525	NA	-0.36	-4.4	-0.34	1.99e-5	Lead levels in blood;
PAAD	cis	rs17776563	1.000	rs11638818	chr15:89119711	C/T	cg27664085	chr15:89157815	NA	0.31	4.25	0.33	3.65e-5	Thyroid hormone levels;
PAAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.68	-7.58	-0.52	3.11e-12	Facial morphology (factor 20);
PAAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg09667013	chr22:42394590	WBP2NL	-0.51	-5.11	-0.38	9.74e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6748734	0.581	rs10207380	chr2:241860911	A/G	cg26818257	chr2:241905806	NA	0.46	4.5	0.34	1.35e-5	Urinary metabolites;
PAAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.76	10.21	0.64	5.84e-19	Coronary artery disease;
PAAD	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.82	0.48	2.02e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg06569542	chr10:98946673	SLIT1	-0.51	-5.7	-0.42	6.05e-8	Monocyte count;
PAAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.31	0.64	3.2e-19	Total body bone mineral density;
PAAD	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.93	5.25	0.39	5e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs11203032	0.901	rs4074851	chr10:90958618	A/G	cg16672925	chr10:90967113	CH25H	-0.78	-5.94	-0.43	1.84e-8	Heart failure;
PAAD	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.64	6.99	0.49	8.01e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg16342193	chr10:102329863	NA	-0.77	-8.51	-0.57	1.56e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.46	4.35	0.33	2.49e-5	HDL cholesterol;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10372372	chr17:40729705	PSMC3IP	0.59	6.44	0.46	1.47e-9	Monocyte percentage of white cells;
PAAD	cis	rs7715806	0.517	rs253392	chr5:74928883	G/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.49	-4.58	-0.35	9.7e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg08917208	chr2:24149416	ATAD2B	1.06	6.99	0.49	8.09e-11	Lymphocyte counts;
PAAD	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg27205649	chr11:78285834	NARS2	-0.61	-4.63	-0.35	7.88e-6	Alzheimer's disease (survival time);
PAAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg19680485	chr15:31195859	MTMR15	-0.44	-4.27	-0.33	3.49e-5	Huntington's disease progression;
PAAD	cis	rs3747547	0.818	rs72724194	chr9:37945506	A/G	cg13774184	chr9:37916125	SHB	-0.58	-4.27	-0.33	3.43e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg00250761	chr1:31883323	NA	-0.54	-6.25	-0.45	3.84e-9	Alcohol dependence;
PAAD	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg00922110	chr4:57842668	C4orf14	-0.43	-4.32	-0.33	2.75e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.78	6.66	0.48	4.74e-10	Bronchopulmonary dysplasia;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	8.53	0.57	1.35e-14	Alzheimer's disease;
PAAD	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.43	14.35	0.76	4.5e-30	Corneal structure;
PAAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.8e-13	Height;
PAAD	cis	rs732765	0.734	rs12893245	chr14:75168936	G/A	cg17347104	chr14:75034677	LTBP2	0.61	5.25	0.39	4.94e-7	Non-small cell lung cancer;
PAAD	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.08	0.38	1.09e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.63	-7.21	-0.5	2.47e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.42	6.33	0.46	2.68e-9	Subjective well-being;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24108215	chr1:39174820	NA	-0.63	-6.4	-0.46	1.83e-9	Smoking initiation;
PAAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg03115019	chr17:80708279	FN3K	0.51	4.64	0.35	7.51e-6	Glycated hemoglobin levels;
PAAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg06375148	chr1:209958343	C1orf74	0.45	4.57	0.35	1.01e-5	Monobrow;
PAAD	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.93	-11.28	-0.68	7.98e-22	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg01059385	chr22:42394853	WBP2NL	-0.42	-4.45	-0.34	1.66e-5	Cognitive function;
PAAD	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	7.0	0.49	7.86e-11	Lung cancer in ever smokers;
PAAD	cis	rs412050	0.547	rs79111189	chr22:22164597	T/G	cg17089214	chr22:22089827	YPEL1	0.67	4.48	0.34	1.44e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.63	7.11	0.5	4.24e-11	Testicular germ cell tumor;
PAAD	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06636551	chr8:101224915	SPAG1	0.59	7.51	0.52	4.81e-12	Atrioventricular conduction;
PAAD	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.5	-0.34	1.35e-5	Electroencephalogram traits;
PAAD	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.68	6.9	0.49	1.34e-10	Morning vs. evening chronotype;
PAAD	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.54	-5.25	-0.39	5.15e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg21130718	chr4:1044621	NA	0.56	4.79	0.36	4.01e-6	Recombination rate (females);
PAAD	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.67	7.36	0.51	1.08e-11	Longevity;
PAAD	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.83	-5.88	-0.43	2.45e-8	Coronary artery disease;
PAAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.23	-0.45	4.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg07595035	chr13:111291582	CARKD	0.8	4.98	0.37	1.71e-6	Coronary artery disease;
PAAD	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.46	4.59	0.35	9.23e-6	Aortic root size;
PAAD	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.5	-5.02	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12541635	0.934	rs7008840	chr8:107016404	T/C	cg10147462	chr8:107024639	NA	0.47	4.82	0.36	3.38e-6	Age of smoking initiation;
PAAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	1.1	15.29	0.78	1.48e-32	Breast cancer;
PAAD	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.82	-0.48	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg19418318	chr19:17219073	MYO9B	0.41	5.01	0.38	1.47e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.59	-6.81	-0.48	2.13e-10	Prostate cancer;
PAAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	1.04	16.73	0.81	2.7e-36	Height;
PAAD	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12893428	chr3:195717962	SDHAP1	0.46	4.85	0.37	3.04e-6	Pancreatic cancer;
PAAD	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg27539214	chr16:67997921	SLC12A4	-0.65	-4.96	-0.37	1.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg18643199	chr10:82363313	SH2D4B	-0.63	-4.94	-0.37	2.06e-6	Post bronchodilator FEV1;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg04160749	chr8:58172571	NA	-0.66	-4.69	-0.36	5.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.56	-5.85	-0.43	2.91e-8	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.76	8.53	0.57	1.38e-14	Lung cancer;
PAAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.57	6.62	0.47	5.7e-10	Lung cancer;
PAAD	cis	rs17032980	0.910	rs1921278	chr2:67329806	A/T	cg06994420	chr2:66672553	MEIS1	-0.5	-4.43	-0.34	1.79e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg00945038	chr17:61921165	SMARCD2	0.46	5.51	0.41	1.5e-7	Prudent dietary pattern;
PAAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg19257562	chr1:2043853	PRKCZ	0.47	5.8	0.43	3.66e-8	Height;
PAAD	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.5	4.5	0.34	1.35e-5	Lung cancer;
PAAD	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	1.05	15.14	0.78	3.63e-32	Height;
PAAD	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.76	0.42	4.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.74	4.9	0.37	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.82	7.95	0.54	3.89e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7737355	0.673	rs26006	chr5:130982768	A/G	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Life satisfaction;
PAAD	cis	rs1497828	0.912	rs2646827	chr1:217540571	G/A	cg04411442	chr1:217543379	NA	-0.48	-4.73	-0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs17095355	0.688	rs1349348	chr10:111794554	T/C	cg00817464	chr10:111662876	XPNPEP1	0.67	4.95	0.37	1.96e-6	Biliary atresia;
PAAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg00601450	chr5:74908170	NA	0.51	5.1	0.38	9.95e-7	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs1144333	0.655	rs17097864	chr1:76469596	C/T	cg22875332	chr1:76189707	ACADM	0.75	4.45	0.34	1.64e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17655565	0.581	rs949384	chr12:52767548	T/C	cg22980804	chr12:52818037	KRT75	-0.48	-4.32	-0.33	2.81e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg24733560	chr20:60626293	TAF4	-0.39	-4.38	-0.33	2.2e-5	Body mass index;
PAAD	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.78e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.53	4.97	0.37	1.77e-6	Menopause (age at onset);
PAAD	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.45	5.72	0.42	5.45e-8	Panic disorder;
PAAD	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs990171	0.538	rs11690932	chr2:103119029	G/A	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.58	-0.47	7.3e-10	Retinal vascular caliber;
PAAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.96	12.76	0.72	8.12e-26	Menarche (age at onset);
PAAD	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.6	-0.35	8.98e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg09344028	chr17:70110421	NA	0.54	6.87	0.49	1.52e-10	Thyroid hormone levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08692828	chr7:99055790	ATP5J2	-0.65	-7.34	-0.51	1.18e-11	Obesity-related traits;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-7.16	-0.5	3.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg13175173	chr14:55914753	NA	-0.33	-4.41	-0.34	1.98e-5	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs1529711	0.500	rs11673241	chr19:10894981	G/A	cg16667279	chr19:11591998	ELAVL3	-0.64	-4.7	-0.36	5.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs834811	0.583	rs10954517	chr7:135871947	T/C	cg01726295	chr7:135938950	NA	0.4	4.26	0.33	3.62e-5	Post-traumatic stress disorder;
PAAD	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg10437265	chr15:77819839	NA	0.43	4.77	0.36	4.37e-6	Type 2 diabetes;
PAAD	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-6.31	-0.46	2.91e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.87	-0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs818427	0.964	rs459102	chr5:112228765	C/A	cg07820702	chr5:112228657	REEP5	-0.56	-5.05	-0.38	1.24e-6	Total body bone mineral density;
PAAD	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.17	-9.98	-0.63	2.32e-18	Vitiligo;
PAAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg26497354	chr6:109612229	NA	-0.43	-4.56	-0.35	1.02e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs3736485	0.966	rs11070860	chr15:51892654	G/A	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.43	-0.34	1.8e-5	Joint mobility (Beighton score);
PAAD	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.69	-6.76	-0.48	2.72e-10	Retinal vascular caliber;
PAAD	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.28e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg03233332	chr7:66118400	NA	-0.4	-4.39	-0.34	2.13e-5	Aortic root size;
PAAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.79	7.77	0.53	1.08e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9469913	0.733	rs11756392	chr6:34807894	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.49	-4.32	-0.33	2.77e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg05861140	chr6:150128134	PCMT1	-0.6	-6.88	-0.49	1.46e-10	Lung cancer;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg02297831	chr4:17616191	MED28	0.62	5.9	0.43	2.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg26174226	chr8:58114915	NA	-0.59	-4.83	-0.36	3.26e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2562456	0.793	rs7259396	chr19:21523463	G/A	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg05110241	chr16:68378359	PRMT7	-1.11	-7.76	-0.53	1.15e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.76	-0.42	4.56e-8	Life satisfaction;
PAAD	cis	rs258892	0.895	rs6871969	chr5:72085036	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	1.02	12.17	0.7	3.31e-24	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.28	-0.33	3.36e-5	Aortic root size;
PAAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	0.81	7.29	0.51	1.58e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg17252645	chr8:143867129	LY6D	0.51	4.84	0.37	3.1e-6	Urinary tract infection frequency;
PAAD	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.52	-4.69	-0.36	6.04e-6	Height;
PAAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.84	8.85	0.58	2.09e-15	Tuberculosis;
PAAD	cis	rs10992471	0.580	rs7852698	chr9:95396409	C/T	cg14631576	chr9:95140430	CENPP	-0.52	-5.02	-0.38	1.43e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.58	5.05	0.38	1.24e-6	Life satisfaction;
PAAD	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.66	6.93	0.49	1.09e-10	Testicular germ cell tumor;
PAAD	cis	rs883565	0.740	rs9311203	chr3:39072079	T/C	cg01426195	chr3:39028469	NA	-0.7	-7.43	-0.52	7.5e-12	Handedness;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.76	-7.67	-0.53	1.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.21e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg25730555	chr22:47059586	GRAMD4	0.49	5.12	0.38	8.95e-7	Urate levels in obese individuals;
PAAD	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.64	6.18	0.45	5.69e-9	Breast cancer;
PAAD	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.82	-0.36	3.49e-6	Height;
PAAD	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-4.61	-0.35	8.64e-6	Dementia with Lewy bodies;
PAAD	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg00071950	chr4:10020882	SLC2A9	0.48	4.42	0.34	1.88e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg13206674	chr6:150067644	NUP43	0.6	6.38	0.46	2.07e-9	Testicular germ cell tumor;
PAAD	cis	rs72960926	0.744	rs67280742	chr6:75004753	T/C	cg03266952	chr6:74778945	NA	-1.11	-6.39	-0.46	1.96e-9	Metabolite levels (MHPG);
PAAD	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.54	8.31	0.56	4.97e-14	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg17830980	chr10:43048298	ZNF37B	0.68	7.89	0.54	5.43e-13	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.61	5.46	0.41	1.88e-7	Mean platelet volume;
PAAD	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.64	6.55	0.47	8.25e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.48	-5.28	-0.39	4.4e-7	Pneumonia;
PAAD	cis	rs3745672	1.000	rs1091350	chr19:12141527	A/G	cg26580856	chr19:11308243	KANK2	-1.05	-4.6	-0.35	9.02e-6	Multiple sclerosis;
PAAD	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.55	4.95	0.37	1.93e-6	Blood metabolite levels;
PAAD	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.52	5.27	0.39	4.51e-7	Ovarian reserve;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15229027	chr14:64805542	ESR2	0.58	6.53	0.47	9.16e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.84	-6.4	-0.46	1.84e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg05585544	chr11:47624801	NA	-0.49	-5.48	-0.41	1.69e-7	Subjective well-being;
PAAD	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06287003	chr12:125626642	AACS	0.49	4.78	0.36	4.07e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2446066	0.872	rs2683522	chr12:53783396	C/T	cg20591337	chr12:53693442	C12orf10	-0.63	-4.4	-0.34	2.05e-5	Red blood cell count;
PAAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg16342193	chr10:102329863	NA	-0.81	-8.71	-0.58	4.68e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg07362569	chr17:61921086	SMARCD2	0.42	4.69	0.36	6.04e-6	Height;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.72	-0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg08523384	chr5:141488047	NDFIP1	-0.63	-5.81	-0.43	3.49e-8	Crohn's disease;
PAAD	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-4.92	-0.37	2.25e-6	Cognitive test performance;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	0.65	7.42	0.52	7.58e-12	Monocyte percentage of white cells;
PAAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg21890820	chr11:65308645	LTBP3	0.67	8.02	0.55	2.69e-13	Bone mineral density;
PAAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg22143856	chr6:28129313	ZNF389	-0.6	-4.66	-0.35	6.96e-6	Parkinson's disease;
PAAD	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg14146966	chr2:61757674	XPO1	0.42	5.21	0.39	6.16e-7	Tuberculosis;
PAAD	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.59	6.49	0.47	1.12e-9	Mean corpuscular volume;
PAAD	cis	rs302972	0.826	rs416030	chr6:25071081	C/T	cg19882886	chr6:25043046	NA	0.87	4.62	0.35	8.13e-6	Creatinine levels in ischemic stroke;
PAAD	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg13263323	chr15:86062960	AKAP13	-0.64	-7.27	-0.51	1.74e-11	Coronary artery disease;
PAAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg05697835	chr1:2722811	NA	-0.45	-5.15	-0.39	8.07e-7	Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.66	-7.17	-0.5	3.09e-11	Iron status biomarkers;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.55	5.4	0.4	2.47e-7	Prudent dietary pattern;
PAAD	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.72	9.99	0.63	2.19e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.52	4.68	0.35	6.31e-6	Breast cancer;Mosquito bite size;
PAAD	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg15654264	chr1:150340011	RPRD2	0.49	4.77	0.36	4.31e-6	Migraine;
PAAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.96	8.04	0.55	2.31e-13	Alzheimer's disease;
PAAD	cis	rs17169634	0.557	rs17169628	chr7:34080552	A/G	cg24927974	chr7:35078269	DPY19L1	0.59	4.8	0.36	3.69e-6	Alzheimer's disease;
PAAD	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.62	-4.8	-0.36	3.73e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg26354017	chr1:205819088	PM20D1	0.54	4.28	0.33	3.33e-5	Prostate-specific antigen levels;
PAAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21545522	chr1:205238299	TMCC2	0.46	4.29	0.33	3.18e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.49	-0.34	1.39e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.72	-0.36	5.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	7.52	0.52	4.33e-12	Renal function-related traits (BUN);
PAAD	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs2286503	1.000	rs2286501	chr7:22856785	G/C	cg11367502	chr7:22862612	TOMM7	0.43	4.28	0.33	3.25e-5	Fibrinogen;
PAAD	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.83	0.43	3.26e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.52	4.9	0.37	2.44e-6	Childhood ear infection;
PAAD	cis	rs4605213	0.528	rs1860574	chr17:49299294	T/C	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.62	-0.35	8.04e-6	Height;
PAAD	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27394962	chr3:88107507	CGGBP1	0.58	6.51	0.47	1.05e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg07548257	chr22:31686466	PIK3IP1	0.35	4.29	0.33	3.18e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs595018	0.505	rs582246	chr11:60603647	C/T	cg23904249	chr11:60608951	CCDC86	-0.7	-5.18	-0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs5758659	0.810	rs5758623	chr22:42566314	G/C	cg15557168	chr22:42548783	NA	-0.61	-6.45	-0.46	1.38e-9	Cognitive function;
PAAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg09021430	chr5:549028	NA	-0.42	-4.36	-0.33	2.37e-5	Cystic fibrosis severity;
PAAD	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.83	9.51	0.61	4.05e-17	Lewy body disease;
PAAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07648498	chr16:89883185	FANCA	-0.68	-7.2	-0.5	2.58e-11	Vitiligo;
PAAD	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg10820045	chr2:198174542	NA	0.45	4.51	0.34	1.3e-5	Intracranial aneurysm;
PAAD	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-5.46	-0.4	1.93e-7	Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg23346134	chr3:49453900	TCTA	-0.46	-4.81	-0.36	3.56e-6	Menarche (age at onset);
PAAD	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	7.18	0.5	2.85e-11	Lymphocyte counts;
PAAD	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg06375148	chr1:209958343	C1orf74	0.5	5.37	0.4	2.92e-7	Monobrow;
PAAD	cis	rs73206853	0.841	rs57299791	chr12:110954021	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	4.44	0.34	1.73e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	7.85	0.54	7e-13	Schizophrenia;
PAAD	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-4.63	-0.35	7.84e-6	Joint mobility (Beighton score);
PAAD	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.75	-6.17	-0.45	5.96e-9	Coronary artery disease;
PAAD	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.69	6.66	0.48	4.74e-10	Subjective well-being;
PAAD	cis	rs8133932	0.701	rs2183599	chr21:47288873	C/G	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg00450029	chr8:599525	NA	0.84	6.15	0.45	6.41e-9	IgG glycosylation;
PAAD	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.61	6.33	0.46	2.56e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs7843479	0.898	rs13282562	chr8:21869727	G/A	cg17168535	chr8:21777572	XPO7	0.7	6.94	0.49	1.07e-10	Mean corpuscular volume;
PAAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.42	0.52	7.94e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs35955747	0.633	rs2006771	chr22:31998612	G/A	cg02404636	chr22:31891804	SFI1	-0.52	-5.15	-0.39	7.91e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.57	6.2	0.45	5.04e-9	Blood metabolite levels;
PAAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg26876637	chr1:152193138	HRNR	-0.79	-5.38	-0.4	2.78e-7	Atopic dermatitis;
PAAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg01631408	chr1:248437212	OR2T33	0.58	5.35	0.4	3.11e-7	Common traits (Other);
PAAD	cis	rs4343996	0.837	rs4722853	chr7:3517354	C/G	cg21248987	chr7:3385318	SDK1	0.52	5.68	0.42	6.56e-8	Motion sickness;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.5	-4.95	-0.37	1.98e-6	Lung cancer;
PAAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs9815354	0.680	rs73073280	chr3:42025772	T/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.72	7.25	0.51	1.94e-11	Mosquito bite size;
PAAD	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.82	10.17	0.64	7.53e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.89	-0.37	2.54e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.78	-8.3	-0.56	5.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg18919072	chr12:133130341	FBRSL1	0.62	7.35	0.51	1.17e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.46	0.61	5.55e-17	Rheumatoid arthritis;
PAAD	cis	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.83	-5.97	-0.44	1.65e-8	Facial morphology (factor 23);
PAAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.75	8.46	0.57	2.08e-14	Parkinson's disease;
PAAD	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg18595228	chr15:67193261	NA	0.72	4.7	0.36	5.82e-6	Lung cancer (smoking interaction);
PAAD	cis	rs3857067	0.550	rs58952293	chr4:95000962	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.24	-0.39	5.39e-7	QT interval;
PAAD	cis	rs9832727	0.526	rs9848779	chr3:142652069	C/G	cg03245962	chr3:142167057	XRN1	-0.47	-4.31	-0.33	2.87e-5	Phospholipid levels (plasma);
PAAD	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06307176	chr5:131281290	NA	0.53	4.86	0.37	2.84e-6	Life satisfaction;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg20007245	chr22:24372913	LOC391322	-0.83	-8.67	-0.58	6.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg24053715	chr22:38214548	NA	0.59	5.76	0.42	4.43e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6137287	0.924	rs6047296	chr20:21158239	C/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-6.07	-0.44	9.81e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.68	0.58	5.76e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.82	0.54	8.19e-13	Prudent dietary pattern;
PAAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.47	6.02	0.44	1.22e-8	Ulcerative colitis;
PAAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.52	4.93	0.37	2.1e-6	Acylcarnitine levels;
PAAD	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.75	-5.45	-0.4	2.03e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.85	10.95	0.66	6.05e-21	Methadone dose in opioid dependence;
PAAD	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-6.42	-0.46	1.63e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg21918786	chr6:109611834	NA	-0.39	-4.26	-0.33	3.57e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg14146966	chr2:61757674	XPO1	0.39	4.8	0.36	3.75e-6	Tuberculosis;
PAAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01765077	chr12:122356316	WDR66	0.62	6.54	0.47	8.81e-10	Mean corpuscular volume;
PAAD	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.58	5.19	0.39	6.7e-7	Platelet count;
PAAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.59	5.54	0.41	1.29e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2790216	1.000	rs2486483	chr10:60003000	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.72	7.64	0.53	2.24e-12	Schizophrenia;
PAAD	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.64	-6.4	-0.46	1.78e-9	Pubertal anthropometrics;
PAAD	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.58	6.14	0.45	6.86e-9	Bladder cancer;
PAAD	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg20503657	chr10:835505	NA	0.58	4.64	0.35	7.53e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs300774	0.925	rs384286	chr2:128345	C/T	cg21211680	chr2:198530	NA	-0.57	-5.44	-0.4	2.13e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-6.52	-0.47	9.82e-10	Gut microbiome composition (summer);
PAAD	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg18105134	chr13:113819100	PROZ	-0.97	-7.66	-0.53	2.01e-12	Platelet distribution width;
PAAD	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.72	7.17	0.5	3.02e-11	Prostate cancer;
PAAD	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.65	6.7	0.48	3.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg03605463	chr16:89740564	NA	-0.52	-4.88	-0.37	2.71e-6	Vitiligo;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21663181	chr18:5889750	NA	-0.62	-6.8	-0.48	2.3e-10	Obesity-related traits;
PAAD	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.51	4.96	0.37	1.84e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.46	0.71	5.4e-25	Chronic sinus infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16221875	chr6:21588597	NA	0.63	7.3	0.51	1.53e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.44	-4.52	-0.34	1.23e-5	Sense of smell;
PAAD	cis	rs58653258	0.614	rs2488212	chr1:234974278	T/G	cg03518729	chr1:235147744	NA	0.46	4.36	0.33	2.37e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs863345	0.564	rs10908667	chr1:158500121	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg02574844	chr11:5959923	NA	-0.64	-5.99	-0.44	1.45e-8	DNA methylation (variation);
PAAD	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg13010199	chr12:38710504	ALG10B	0.58	5.13	0.38	8.82e-7	Morning vs. evening chronotype;
PAAD	cis	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg11619707	chr19:22235551	ZNF257	-0.58	-5.58	-0.41	1.07e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.9	6.19	0.45	5.22e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.75	8.1	0.55	1.64e-13	Eye color traits;
PAAD	cis	rs4343996	0.967	rs34735349	chr7:3344115	C/G	cg21248987	chr7:3385318	SDK1	0.48	5.31	0.4	3.8e-7	Motion sickness;
PAAD	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.64	6.92	0.49	1.18e-10	Colorectal cancer;
PAAD	cis	rs73019876	0.901	rs2666449	chr19:22131924	T/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.37	-0.33	2.31e-5	Testicular germ cell tumor;
PAAD	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg10395934	chr14:104002654	TRMT61A	0.52	5.08	0.38	1.09e-6	Body mass index;
PAAD	cis	rs17655565	0.904	rs3809172	chr12:52695198	G/C	cg02645295	chr12:52705424	NA	-0.49	-4.53	-0.34	1.19e-5	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.43	5.41	0.4	2.36e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs12136530	0.593	rs12403329	chr1:19735793	G/C	cg25104613	chr1:20649108	VWA5B1	-0.43	-4.75	-0.36	4.68e-6	Lead levels in blood;
PAAD	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.73	8.85	0.58	2.05e-15	Obesity (extreme);
PAAD	cis	rs933688	0.652	rs4916856	chr5:90596403	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.75	-6.09	-0.44	9e-9	Smoking behavior;
PAAD	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.4	-0.34	2.02e-5	Metabolite levels;
PAAD	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	1.04	12.41	0.71	7.41e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	4.72	0.36	5.24e-6	Height;
PAAD	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg01075559	chr1:2537774	MMEL1	0.5	5.22	0.39	5.78e-7	Ulcerative colitis;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg04522676	chr10:134968826	NA	0.47	4.46	0.34	1.56e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.83	-10.36	-0.64	2.26e-19	Height;
PAAD	cis	rs66530629	0.917	rs4351587	chr1:25155188	G/C	cg01905478	chr1:25040257	NA	0.5	5.44	0.4	2.04e-7	Plateletcrit;
PAAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.47	4.43	0.34	1.76e-5	Morning vs. evening chronotype;
PAAD	cis	rs11105468	0.595	rs1438987	chr12:90535412	A/G	cg19406706	chr12:90907421	NA	-0.48	-4.34	-0.33	2.62e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs8077577	0.689	rs62072515	chr17:18213435	T/G	cg16794390	chr17:18148240	FLII	0.51	4.45	0.34	1.62e-5	Obesity-related traits;
PAAD	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26876637	chr1:152193138	HRNR	0.88	6.87	0.49	1.57e-10	Atopic dermatitis;
PAAD	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.69	-8.64	-0.57	7.3e-15	Educational attainment;
PAAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.37	4.52	0.34	1.22e-5	Mean corpuscular volume;
PAAD	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.58	5.65	0.42	7.86e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.14	-0.38	8.37e-7	Life satisfaction;
PAAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.3	14.49	0.76	1.99e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7714584	1.000	rs11951694	chr5:150254338	G/A	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs757978	0.733	rs41342147	chr2:242407588	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.75	-4.67	-0.35	6.71e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg21130718	chr4:1044621	NA	-0.56	-4.82	-0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg05895507	chr15:77155635	SCAPER	0.37	4.57	0.35	1.01e-5	Blood metabolite levels;
PAAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.75	8.69	0.58	5.33e-15	Colorectal cancer;
PAAD	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.32	-0.33	2.83e-5	Educational attainment;
PAAD	cis	rs2115386	1.000	rs2115386	chr19:7196565	C/T	cg09779027	chr19:7224513	INSR	0.44	4.41	0.34	1.95e-5	Diabetic retinopathy;
PAAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.8	9.36	0.6	1.01e-16	Schizophrenia;
PAAD	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.74e-7	Body mass index;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17678453	chr17:4607225	PELP1	-0.77	-6.56	-0.47	8.06e-10	Neuroticism;
PAAD	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.83	8.87	0.58	1.84e-15	Corneal astigmatism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15556748	chr1:154946326	SHC1;CKS1B	-0.67	-6.42	-0.46	1.67e-9	Lung cancer in ever smokers;
PAAD	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.86	-6.71	-0.48	3.62e-10	Total cholesterol levels;
PAAD	cis	rs2286379	0.682	rs12316367	chr12:1850146	G/A	cg11558135	chr12:861715	WNK1	-0.46	-4.52	-0.34	1.23e-5	Blood pressure (smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19402405	chr10:64576514	EGR2	0.72	8.01	0.54	2.86e-13	Myopia (pathological);
PAAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.59	-0.35	9.25e-6	Platelet count;
PAAD	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.23	-0.51	2.23e-11	Heart rate;
PAAD	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11219022	chr2:166810277	TTC21B	-0.57	-6.77	-0.48	2.68e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.48	-0.34	1.46e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs8014252	0.803	rs12586299	chr14:71085215	C/T	cg11204974	chr14:71022665	NA	-0.81	-4.94	-0.37	2.03e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	cis	rs7894051	1.000	rs7907603	chr10:135195977	G/A	cg24905316	chr10:135186343	ECHS1	-0.73	-4.49	-0.34	1.39e-5	Lifespan;
PAAD	cis	rs4073221	0.520	rs2002965	chr3:18201026	A/G	cg07694806	chr3:18168406	NA	-0.93	-5.69	-0.42	6.28e-8	Parkinson's disease;
PAAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.86	6.61	0.47	6.05e-10	Alzheimer's disease;
PAAD	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-8.01	-0.54	2.76e-13	Brugada syndrome;
PAAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.61	0.35	8.63e-6	Electroencephalogram traits;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg00945038	chr17:61921165	SMARCD2	0.46	5.44	0.4	2.07e-7	Prudent dietary pattern;
PAAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.36	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12681963	0.614	rs2958740	chr8:30092734	G/A	cg23406830	chr8:30012838	DCTN6	0.72	4.47	0.34	1.49e-5	Migraine;
PAAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg25797454	chr6:150327115	RAET1K	0.31	4.49	0.34	1.38e-5	Alopecia areata;
PAAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.25	-0.39	5.16e-7	Bone mineral density;
PAAD	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg03098721	chr1:84464084	TTLL7	0.49	4.6	0.35	8.69e-6	Obesity-related traits;
PAAD	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	6.85	0.49	1.69e-10	Schizophrenia;
PAAD	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.81	0.58	2.72e-15	Bladder cancer;
PAAD	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs8127571	0.593	rs11911413	chr21:47088698	A/G	cg11214348	chr21:47283868	PCBP3	-0.7	-5.16	-0.39	7.7300000000000005e-07	Immune reponse to smallpox (secreted IFN-alpha);
PAAD	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg06386533	chr2:46925753	SOCS5	0.54	4.56	0.35	1.05e-5	Height;
PAAD	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	1.02	7.92	0.54	4.72e-13	IgG glycosylation;
PAAD	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.53	0.41	1.36e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg21951975	chr1:209979733	IRF6	0.62	5.5	0.41	1.54e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg09324608	chr17:30823087	MYO1D	0.43	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.43	5.58	0.41	1.07e-7	Ulcerative colitis;
PAAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.34	4.63	0.35	7.84e-6	Height;
PAAD	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.58	6.25	0.45	3.95e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.37	-0.4	2.86e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6494488	0.500	rs72742927	chr15:64866305	G/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg16602846	chr15:78114278	NA	0.4	4.37	0.33	2.27e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	12.41	0.71	7.14e-25	Cognitive ability;
PAAD	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.72e-7	Body mass index;
PAAD	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-4.62	-0.35	7.98e-6	Dilated cardiomyopathy;
PAAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.3	-0.33	3.02e-5	Resting heart rate;
PAAD	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06307176	chr5:131281290	NA	-0.52	-4.73	-0.36	5.01e-6	Life satisfaction;
PAAD	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.41	9.51	0.61	4.1e-17	Atopic dermatitis;
PAAD	cis	rs6700896	0.864	rs11208691	chr1:66092570	A/G	cg04111102	chr1:66153794	NA	0.48	5.3	0.39	4.07e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg07841815	chr7:100318223	EPO	0.46	5.19	0.39	6.76e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	4.32	0.33	2.79e-5	Tonsillectomy;
PAAD	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs9652601	0.779	rs7203793	chr16:11182134	C/G	cg04616529	chr16:11181986	CLEC16A	0.46	5.27	0.39	4.6e-7	Systemic lupus erythematosus;
PAAD	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg21145140	chr5:110409467	TSLP	0.44	4.26	0.33	3.54e-5	Eosinophilic esophagitis;
PAAD	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.42	-4.41	-0.34	1.94e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs3736485	0.903	rs4545756	chr15:51877790	A/G	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg10208897	chr5:178548229	ADAMTS2	0.52	4.69	0.36	5.95e-6	Pubertal anthropometrics;
PAAD	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.73	6.45	0.46	1.39e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.49	-4.54	-0.35	1.12e-5	Tonsillectomy;
PAAD	cis	rs75920871	0.660	rs4938330	chr11:116928514	C/G	cg04087571	chr11:116723030	SIK3	-0.35	-4.88	-0.37	2.71e-6	Subjective well-being;
PAAD	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg01305547	chr4:1893307	WHSC1	0.69	4.29	0.33	3.15e-5	Systolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg24024426	chr20:4982196	SLC23A2	0.68	7.3	0.51	1.53e-11	Myopia (pathological);
PAAD	cis	rs17023223	0.553	rs55696509	chr1:119686656	A/G	cg17326555	chr1:119535693	NA	-0.42	-4.59	-0.35	9.17e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.68	10.67	0.65	3.47e-20	Airflow obstruction;
PAAD	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg14952266	chr13:112191215	NA	0.43	4.88	0.37	2.63e-6	Hepatitis;
PAAD	cis	rs2051773	0.567	rs7935677	chr11:17039832	A/G	cg15432903	chr11:17409602	KCNJ11	-0.51	-4.6	-0.35	8.89e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg16342193	chr10:102329863	NA	-0.75	-8.14	-0.55	1.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg09659197	chr4:152720779	NA	-0.41	-5.84	-0.43	3.11e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-5.55	-0.41	1.26e-7	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg07603449	chr1:11986842	KIAA2013	-0.36	-5.68	-0.42	6.67e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg25037394	chr1:24152592	HMGCL	0.41	4.48	0.34	1.49e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg23555395	chr2:238036564	NA	-0.49	-5.69	-0.42	6.32e-8	Systemic lupus erythematosus;
PAAD	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg14458575	chr2:238380390	NA	0.6	5.07	0.38	1.13e-6	Prostate cancer;
PAAD	cis	rs16889362	1.000	rs77757126	chr6:36956903	G/A	cg18891604	chr6:36319055	NA	0.48	4.99	0.37	1.67e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-6.7	-0.48	3.88e-10	Life satisfaction;
PAAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg14345882	chr6:26364793	BTN3A2	0.67	4.43	0.34	1.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.82	-8.88	-0.58	1.79e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs6009527	1.000	rs2318941	chr22:49573400	G/A	cg12746016	chr22:49560550	NA	0.47	4.75	0.36	4.73e-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
PAAD	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.69	5.11	0.38	9.64e-7	Vitiligo;
PAAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	4.67	0.35	6.51e-6	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.84	-7.49	-0.52	5.1e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7260329	0.670	rs4803413	chr19:41485977	G/A	cg23925301	chr19:41220945	ADCK4	-0.57	-4.88	-0.37	2.66e-6	Smoking behavior;
PAAD	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-17.57	-0.82	2.01e-38	Height;
PAAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.32e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg05250797	chr16:70222502	NA	-0.88	-6.75	-0.48	2.89e-10	IgE levels;
PAAD	cis	rs4295623	0.556	rs10903343	chr8:11695872	T/C	cg00262122	chr8:11665843	FDFT1	0.56	5.03	0.38	1.35e-6	Morning vs. evening chronotype;
PAAD	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg01851573	chr8:8652454	MFHAS1	-0.46	-4.43	-0.34	1.77e-5	Systolic blood pressure;
PAAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.8	-8.48	-0.57	1.89e-14	Coronary artery disease;
PAAD	cis	rs13053817	1.000	rs71324766	chr22:29839659	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.55	-4.96	-0.37	1.85e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs6782228	0.565	rs2811496	chr3:128359958	A/T	cg16766828	chr3:128327626	NA	-0.49	-6.62	-0.47	5.81e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs950169	0.649	rs12901010	chr15:84699034	G/A	cg03959625	chr15:84868606	LOC388152	0.47	4.75	0.36	4.65e-6	Schizophrenia;
PAAD	cis	rs12327666	0.522	rs7252770	chr19:14129161	C/T	cg09538921	chr19:14142201	IL27RA	-0.68	-4.69	-0.36	6.01e-6	Obesity-related traits;
PAAD	cis	rs6466055	0.777	rs3801285	chr7:104837801	C/A	cg04380332	chr7:105027541	SRPK2	-0.64	-7.31	-0.51	1.45e-11	Schizophrenia;
PAAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg14983838	chr19:29218262	NA	0.72	6.22	0.45	4.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg23283495	chr1:209979779	IRF6	0.61	5.7	0.42	6.01e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.89	5.85	0.43	2.85e-8	Major depressive disorder;
PAAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.93	0.59	1.34e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.66e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.44	4.6	0.35	8.76e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10450586	0.863	rs7125719	chr11:27288359	G/C	cg10370305	chr11:27303972	NA	0.36	4.26	0.33	3.62e-5	Total body bone mineral density;
PAAD	cis	rs1891275	0.551	rs4933692	chr10:93424633	A/G	cg07889827	chr10:93443413	NA	-0.41	-4.41	-0.34	1.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6987853	0.830	rs12542076	chr8:42360593	C/G	cg09913449	chr8:42400586	C8orf40	-0.44	-4.72	-0.36	5.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.32	6.06	0.44	1.01e-8	Skin colour saturation;
PAAD	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.5	5.08	0.38	1.09e-6	Coronary heart disease;
PAAD	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg14146966	chr2:61757674	XPO1	0.41	5.07	0.38	1.14e-6	Tuberculosis;
PAAD	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg19980929	chr12:42632907	YAF2	0.57	6.64	0.47	5.19e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg18165381	chr3:44552316	NA	-0.47	-4.3	-0.33	3.06e-5	Depressive symptoms;
PAAD	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg22189786	chr22:42395067	WBP2NL	-0.52	-4.41	-0.34	1.96e-5	Birth weight;
PAAD	cis	rs1912528	0.814	rs769673	chr4:140882750	G/A	cg11128457	chr4:140864437	MAML3	-0.33	-4.45	-0.34	1.67e-5	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15939899	chr15:90198503	KIF7	0.64	7.18	0.5	2.83e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs60617249	0.519	rs2107695	chr7:50950337	G/A	cg23002316	chr7:51698597	NA	-0.47	-4.49	-0.34	1.4e-5	Major depression and alcohol dependence;
PAAD	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg27234864	chr13:21295941	IL17D	0.58	5.02	0.38	1.46e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	4.86	0.37	2.9e-6	Neuroticism;
PAAD	cis	rs735539	0.555	rs2762990	chr13:21371427	T/C	cg27234864	chr13:21295941	IL17D	0.61	5.31	0.4	3.88e-7	Dental caries;
PAAD	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg08027265	chr7:2291960	NA	-0.52	-5.36	-0.4	2.97e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.39	0.34	2.13e-5	Bipolar disorder;
PAAD	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.84	6.52	0.47	1e-9	Alzheimer's disease;
PAAD	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-16.35	-0.8	2.55e-35	Height;
PAAD	cis	rs3736485	0.934	rs17609791	chr15:51874824	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.27	-0.33	3.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7217780	0.569	rs78025447	chr17:15233395	G/A	cg20358362	chr17:14248304	HS3ST3B1	-0.57	-4.75	-0.36	4.73e-6	Preterm birth (maternal effect);
PAAD	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.74	-5.13	-0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg09659197	chr4:152720779	NA	0.43	5.64	0.42	8.13e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9659323	0.706	rs1409160	chr1:119583854	C/A	cg17326555	chr1:119535693	NA	-0.41	-5.75	-0.42	4.73e-8	Body mass index;
PAAD	cis	rs58521262	0.556	rs289347	chr19:23147938	A/T	cg03433597	chr19:22806448	NA	-0.24	-4.35	-0.33	2.49e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs6922632	0.867	rs1343625	chr6:24112737	C/G	cg26194775	chr6:24126114	NRSN1	-0.71	-5.51	-0.41	1.47e-7	Information processing speed;
PAAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg03983476	chr2:10830698	NOL10	-0.54	-5.44	-0.4	2.08e-7	Prostate cancer;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg00450029	chr8:599525	NA	0.85	6.06	0.44	1.02e-8	IgG glycosylation;
PAAD	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.52	-5.53	-0.41	1.36e-7	Mitral valve prolapse;
PAAD	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.43	-4.26	-0.33	3.61e-5	Red blood cell count;
PAAD	cis	rs6256	1.000	rs11600801	chr11:13526239	A/G	cg11976911	chr11:13509032	NA	-0.66	-5.2	-0.39	6.22e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-5.11	-0.38	9.49e-7	Longevity;Endometriosis;
PAAD	trans	rs901683	1.000	rs4442500	chr10:46082498	C/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.85e-5	Height;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.77	-7.89	-0.54	5.57e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg21191810	chr6:118973309	C6orf204	0.47	6.06	0.44	1.01e-8	Electrocardiographic conduction measures;
PAAD	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.44	4.54	0.35	1.14e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.66	0.48	4.81e-10	IgG glycosylation;
PAAD	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.44	0.34	1.71e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg15017067	chr4:17643749	FAM184B	0.47	5.48	0.41	1.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.46	-4.68	-0.36	6.22e-6	IgG glycosylation;
PAAD	cis	rs3779195	0.585	rs58699591	chr7:97876704	C/T	cg24562669	chr7:97807699	LMTK2	-0.53	-4.54	-0.35	1.15e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.92	11.97	0.7	1.08e-23	Mean corpuscular volume;
PAAD	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg18833306	chr6:118973337	C6orf204	0.51	5.91	0.43	2.13e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg21665744	chr7:39171113	POU6F2	0.35	5.98	0.44	1.57e-8	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06850241	chr22:41845214	NA	-0.53	-5.18	-0.39	6.86e-7	Vitiligo;
PAAD	cis	rs1468333	1.000	rs2967784	chr5:137539239	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.25	0.45	3.84e-9	Resting heart rate;
PAAD	cis	rs2982694	0.764	rs2144024	chr6:152293574	G/A	cg26219152	chr6:152443475	SYNE1	-0.65	-4.34	-0.33	2.6e-5	Sudden cardiac arrest;
PAAD	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.51	-5.43	-0.4	2.2e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.63	6.8	0.48	2.23e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg21130718	chr4:1044621	NA	0.5	4.89	0.37	2.56e-6	Recombination rate (males);
PAAD	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg10006428	chr1:248814059	OR2T27	0.38	4.47	0.34	1.51e-5	Common traits (Other);
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.45	-4.57	-0.35	1.01e-5	Longevity;Endometriosis;
PAAD	cis	rs7136716	0.920	rs6488450	chr12:7708544	G/A	cg25757697	chr12:8220002	C3AR1	0.59	4.75	0.36	4.74e-6	Hematological and biochemical traits;
PAAD	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.72	5.19	0.39	6.6e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	trans	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg26939375	chr7:64535504	NA	-0.75	-8.88	-0.58	1.74e-15	Aortic root size;
PAAD	cis	rs11811982	0.793	rs74475302	chr1:227319072	A/G	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2274459	0.841	rs2281919	chr6:33663171	A/C	cg06253072	chr6:33679850	C6orf125	0.6	4.78	0.36	4.08e-6	Obesity (extreme);
PAAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.15	-0.81	2.36e-37	Height;
PAAD	cis	rs12425451	0.544	rs1990330	chr12:3147462	A/C	cg05389053	chr12:3131226	TEAD4	0.7	6.45	0.46	1.4e-9	Narcolepsy with cataplexy;
PAAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg20893579	chr22:38215064	NA	0.53	4.91	0.37	2.34e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.74	7.59	0.52	3.05e-12	Lung cancer;
PAAD	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg21601837	chr3:125900065	ALDH1L1	-0.51	-5.39	-0.4	2.63e-7	Metabolite levels;
PAAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.41	4.46	0.34	1.58e-5	Aortic root size;
PAAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02187348	chr16:89574699	SPG7	0.48	4.26	0.33	3.59e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.91	-6.84	-0.49	1.82e-10	IgE levels;
PAAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.92	6.07	0.44	9.76e-9	Diabetic kidney disease;
PAAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg09796270	chr17:17721594	SREBF1	-0.48	-5.33	-0.4	3.51e-7	Total body bone mineral density;
PAAD	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.74	8.67	0.58	5.89e-15	Height;
PAAD	cis	rs9659323	0.650	rs10923705	chr1:119498404	C/T	cg17326555	chr1:119535693	NA	-0.37	-4.59	-0.35	9.24e-6	Body mass index;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg13783244	chr4:140005441	ELF2	0.58	6.48	0.47	1.21e-9	Immature fraction of reticulocytes;
PAAD	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.74	-8.42	-0.56	2.69e-14	Coronary artery disease;
PAAD	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg12215294	chr3:40350768	EIF1B	-0.47	-4.68	-0.36	6.24e-6	Renal cell carcinoma;
PAAD	cis	rs492146	0.935	rs492825	chr6:52845393	C/T	cg24393602	chr6:52860404	GSTA4	-0.44	-4.29	-0.33	3.18e-5	Epilepsy (remission after treatment);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20316542	chr20:62693429	TCEA2	0.72	7.53	0.52	4.3e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25632853	chr15:73088954	NA	0.4	4.55	0.35	1.08e-5	Triglyceride levels;
PAAD	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-1.13	-8.66	-0.57	6.34e-15	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.69	7.69	0.53	1.66e-12	Motion sickness;
PAAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.62	0.35	8.04e-6	Personality dimensions;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14554176	chr9:139360056	SEC16A	-0.71	-6.64	-0.47	5.36e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.66	7.06	0.5	5.64e-11	Sjögren's syndrome;
PAAD	cis	rs17155006	0.664	rs410866	chr7:107744543	C/T	cg05962710	chr7:107745446	LAMB4	0.53	6.67	0.48	4.4e-10	Pneumococcal bacteremia;
PAAD	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01132100	chr3:186501723	SNORD2;EIF4A2	0.6	6.48	0.47	1.19e-9	Myopia (pathological);
PAAD	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg25922125	chr7:127225783	GCC1	0.68	4.93	0.37	2.11e-6	Type 2 diabetes;
PAAD	trans	rs62179067	0.708	rs1473577	chr2:179872750	G/T	cg21380341	chr12:94543978	PLXNC1	-0.71	-6.47	-0.46	1.26e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg10932868	chr11:921992	NA	0.5	5.93	0.43	1.98e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg16147221	chr4:10020634	SLC2A9	0.46	4.26	0.33	3.62e-5	Bone mineral density;
PAAD	cis	rs3925075	0.531	rs56392848	chr16:31360892	A/G	cg02846316	chr16:31340340	ITGAM	0.47	5.4	0.4	2.54e-7	IgA nephropathy;
PAAD	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-0.63	-5.03	-0.38	1.35e-6	IgG glycosylation;
PAAD	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.8	-8.67	-0.58	6.24e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg16176600	chr6:116381609	FRK	0.33	4.79	0.36	3.86e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs73416724	0.925	rs112053368	chr6:43382960	C/A	cg26312998	chr6:43337775	ZNF318	0.69	5.76	0.42	4.59e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.77	-0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.59	0.47	6.84e-10	Educational attainment;
PAAD	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.77	-6.01	-0.44	1.32e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg27417659	chr7:98567827	TRRAP	-0.47	-4.41	-0.34	1.92e-5	Breast cancer;
PAAD	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg09796270	chr17:17721594	SREBF1	-0.49	-5.39	-0.4	2.66e-7	Total body bone mineral density;
PAAD	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg09579323	chr1:150459698	TARS2	0.45	4.3	0.33	3.08e-5	Migraine;
PAAD	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.46	4.25	0.33	3.78e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14852238	chr1:28562670	ATPIF1	0.59	6.36	0.46	2.3e-9	Myopia (pathological);
PAAD	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg09127314	chr1:152161683	NA	-0.63	-4.34	-0.33	2.56e-5	Atopic dermatitis;
PAAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg19636519	chr7:99541626	NA	0.38	4.28	0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.63	-5.87	-0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs787274	1.000	rs2185769	chr9:115462594	A/G	cg13803584	chr9:115635662	SNX30	0.8	4.85	0.37	3.02e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg02743256	chr7:2109353	MAD1L1	-0.7	-6.0	-0.44	1.37e-8	Neuroticism;
PAAD	cis	rs4253772	0.515	rs77823653	chr22:46762266	C/T	cg09491104	chr22:46646882	C22orf40	-0.93	-5.31	-0.4	3.84e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg04156016	chr5:1868137	NA	0.49	4.93	0.37	2.09e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7429990	0.932	rs936428	chr3:48167281	A/G	cg11946769	chr3:48343235	NME6	-0.54	-5.36	-0.4	3.03e-7	Educational attainment (years of education);
PAAD	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg06740227	chr12:86229804	RASSF9	0.48	4.65	0.35	7.16e-6	Major depressive disorder;
PAAD	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	9.08	0.59	5.23e-16	Bipolar disorder;
PAAD	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg06219351	chr7:158114137	PTPRN2	0.76	7.01	0.49	7.3e-11	Calcium levels;
PAAD	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.6	5.33	0.4	3.45e-7	Height;
PAAD	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	4.58	0.35	9.56e-6	Cardiovascular disease risk factors;
PAAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01690735	chr5:175843712	CLTB	0.67	7.0	0.49	7.58e-11	Myopia (pathological);
PAAD	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-6.78	-0.48	2.45e-10	Crohn's disease;
PAAD	cis	rs4937076	1.000	rs4430526	chr11:125836428	G/A	cg25857886	chr11:126098838	FAM118B	0.44	4.6	0.35	8.8e-6	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.52	0.41	1.4e-7	Height;
PAAD	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	trans	rs901683	0.850	rs75748332	chr10:46065143	A/C	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.83	-9.35	-0.6	1.06e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.58	-6.31	-0.46	2.89e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg06629702	chr1:2706960	NA	-0.36	-4.27	-0.33	3.49e-5	Multiple sclerosis;
PAAD	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.59	4.99	0.37	1.66e-6	Neutrophil percentage of white cells;
PAAD	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	4.69	0.36	5.93e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-10.91	-0.66	7.69e-21	Ulcerative colitis;
PAAD	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.43	-0.34	1.82e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.37	5.09	0.38	1.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.59	-5.88	-0.43	2.57e-8	Height;
PAAD	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.69	7.46	0.52	6.13e-12	Tuberculosis;
PAAD	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05223675	chr11:118888923	RPS25;TRAPPC4	-0.66	-6.44	-0.46	1.52e-9	Lung cancer in ever smokers;
PAAD	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.93	0.37	2.11e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg03037974	chr15:76606532	NA	0.46	5.07	0.38	1.15e-6	Blood metabolite levels;
PAAD	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-6.67	-0.48	4.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.86	0.37	2.96e-6	Common traits (Other);
PAAD	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18762288	chr17:75954699	NA	-0.73	-7.5	-0.52	4.92e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	1.1	6.78	0.48	2.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.58	4.96	0.37	1.86e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.48	6.6	0.47	6.6e-10	Schizophrenia;
PAAD	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg14583973	chr4:3374767	RGS12	0.41	6.14	0.45	6.76e-9	Serum sulfate level;
PAAD	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg23254163	chr1:152506842	NA	0.49	4.89	0.37	2.51e-6	Hair morphology;
PAAD	cis	rs72960926	1.000	rs11756290	chr6:75093529	A/G	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.57	5.37	0.4	2.93e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.57	6.68	0.48	4.19e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.93	9.08	0.59	5.48e-16	Orofacial clefts;
PAAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.45	7.14	0.5	3.55e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.86	7.9	0.54	5.22e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg00717180	chr2:96193071	NA	0.58	6.59	0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs4417704	0.551	rs10204458	chr2:241899236	C/G	cg26818257	chr2:241905806	NA	0.5	5.22	0.39	5.89e-7	Joint mobility (Beighton score);
PAAD	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.43	0.4	2.15e-7	Mean platelet volume;
PAAD	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg05925327	chr15:68127851	NA	-0.57	-5.24	-0.39	5.4e-7	Restless legs syndrome;
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.8	-8.81	-0.58	2.73e-15	Prostate cancer;
PAAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.87	-7.04	-0.5	6.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.4	5.07	0.38	1.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.35	-4.47	-0.34	1.5e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.69	-6.3	-0.45	3.1e-9	Vitamin D levels;
PAAD	cis	rs9810890	1.000	rs115284166	chr3:128492511	A/G	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs27434	0.821	rs28337	chr5:96125314	A/T	cg16492584	chr5:96139282	ERAP1	-0.56	-5.2	-0.39	6.25e-7	Ankylosing spondylitis;
PAAD	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.48	-4.71	-0.36	5.48e-6	Mean corpuscular volume;
PAAD	cis	rs8063160	0.756	rs35026726	chr16:89791279	C/T	cg07984980	chr16:89898383	SPIRE2	0.92	4.91	0.37	2.33e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
PAAD	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.6	5.56	0.41	1.19e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9900972	0.918	rs2277700	chr17:76866711	C/T	cg00961940	chr17:76876995	TIMP2	0.53	4.98	0.37	1.67e-6	Obesity-related traits;
PAAD	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg23029597	chr12:123009494	RSRC2	-0.72	-6.61	-0.47	6.17e-10	Body mass index;
PAAD	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-4.62	-0.35	8.16e-6	Testicular germ cell tumor;
PAAD	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg17326555	chr1:119535693	NA	-0.35	-4.26	-0.33	3.6e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs16975963	0.644	rs12162238	chr19:38082385	A/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs3857067	0.530	rs17021364	chr4:95047893	C/T	cg11021082	chr4:95130006	SMARCAD1	0.58	5.26	0.39	4.81e-7	QT interval;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21016266	chr12:122356598	WDR66	0.63	6.81	0.48	2.16e-10	Mean corpuscular volume;
PAAD	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	10.07	0.63	1.36e-18	Response to antipsychotic treatment;
PAAD	cis	rs2882667	0.690	rs4835706	chr5:138164726	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg19217778	chr13:113420270	ATP11A	0.6	4.28	0.33	3.32e-5	Glycated hemoglobin levels;
PAAD	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19813030	chr13:30996374	NA	0.65	6.71	0.48	3.64e-10	Obesity-related traits;
PAAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg00105475	chr2:10696890	NA	0.73	7.88	0.54	5.86e-13	Prostate cancer;
PAAD	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.51	-4.5	-0.34	1.33e-5	Lung cancer;
PAAD	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.53	-4.33	-0.33	2.66e-5	Mean platelet volume;
PAAD	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.6	5.56	0.41	1.19e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	6.06	0.44	1.01e-8	Body mass index;
PAAD	cis	rs3126085	0.560	rs12408401	chr1:152371801	G/T	cg26876637	chr1:152193138	HRNR	-0.63	-4.36	-0.33	2.43e-5	Atopic dermatitis;
PAAD	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.68	8.74	0.58	3.94e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg22833147	chr4:178230858	NEIL3	0.55	6.36	0.46	2.2e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg21191810	chr6:118973309	C6orf204	-0.52	-4.92	-0.37	2.23e-6	Diastolic blood pressure;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.78	-7.52	-0.52	4.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3007168	1.000	rs3007167	chr14:51613041	C/T	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.03	-8.45	-0.57	2.17e-14	Diabetic kidney disease;
PAAD	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.68	-0.42	6.77e-8	Crohn's disease;
PAAD	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.55	5.56	0.41	1.15e-7	Menopause (age at onset);
PAAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.71	-6.49	-0.47	1.15e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07212644	chr1:114301956	PHTF1	0.56	6.33	0.46	2.63e-9	Monocyte percentage of white cells;
PAAD	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.61	6.39	0.46	1.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.46	-0.34	1.55e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.63	-0.57	7.83e-15	Exhaled nitric oxide output;
PAAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-4.72	-0.36	5.4e-6	Schizophrenia;
PAAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.36	-4.44	-0.34	1.71e-5	Cognitive performance;
PAAD	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg10072921	chr12:121022843	NA	-0.42	-5.3	-0.4	3.97e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs501120	0.584	rs545025	chr10:44736544	C/T	cg09554077	chr10:44749378	NA	0.46	5.51	0.41	1.51e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg14440974	chr22:39074834	NA	0.51	5.78	0.42	4.16e-8	Menopause (age at onset);
PAAD	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	5.36	0.4	3.03e-7	Monocyte percentage of white cells;
PAAD	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg19254793	chr6:44695348	NA	-0.45	-4.37	-0.33	2.28e-5	Total body bone mineral density;
PAAD	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.62	-6.39	-0.46	1.89e-9	Ovarian reserve;
PAAD	cis	rs8044995	0.636	rs12596500	chr16:68299771	G/A	cg03983715	chr16:68378420	PRMT7	-1.0	-6.02	-0.44	1.23e-8	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg03983476	chr2:10830698	NOL10	0.58	5.82	0.43	3.3e-8	Prostate cancer;
PAAD	cis	rs73198271	0.515	rs76224322	chr8:8635841	C/G	cg01851573	chr8:8652454	MFHAS1	0.85	5.73	0.42	5.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-5.02	-0.38	1.43e-6	Reticulocyte count;
PAAD	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg14343924	chr8:8086146	FLJ10661	0.54	4.85	0.37	3e-6	Joint mobility (Beighton score);
PAAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13798912	chr7:905769	UNC84A	0.58	4.28	0.33	3.34e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-6.94	-0.49	1.04e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.54	-0.35	1.13e-5	Type 1 diabetes;
PAAD	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.66	-5.27	-0.39	4.64e-7	Obesity (extreme);
PAAD	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg05925327	chr15:68127851	NA	-0.58	-5.2	-0.39	6.23e-7	Obesity;
PAAD	cis	rs593982	0.764	rs55796623	chr11:65411714	G/A	cg08755490	chr11:65554678	OVOL1	-1.47	-8.2	-0.55	9.57e-14	Atopic dermatitis;
PAAD	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg13045555	chr8:105342365	NA	-0.26	-4.49	-0.34	1.38e-5	Paget's disease;
PAAD	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg23153227	chr6:27725408	NA	0.43	4.47	0.34	1.53e-5	Cardiac Troponin-T levels;
PAAD	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.67	-6.79	-0.48	2.36e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg02770688	chr6:168491649	NA	0.48	5.09	0.38	1.05e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg05805236	chr11:65401703	PCNXL3	-0.58	-6.03	-0.44	1.21e-8	Acne (severe);
PAAD	cis	rs454510	0.726	rs376910	chr1:120181277	A/C	cg11530693	chr1:120165357	ZNF697	-0.6	-5.4	-0.4	2.47e-7	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg15181151	chr6:150070149	PCMT1	0.54	5.43	0.4	2.17e-7	Lung cancer;
PAAD	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg09127314	chr1:152161683	NA	-0.68	-4.7	-0.36	5.84e-6	Atopic dermatitis;
PAAD	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.52	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.82	-8.93	-0.59	1.33e-15	Mortality in heart failure;
PAAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24549020	chr5:56110836	MAP3K1	-0.5	-4.36	-0.33	2.43e-5	Initial pursuit acceleration;
PAAD	cis	rs2120991	0.967	rs2222818	chr12:54288840	C/G	cg25640699	chr12:54070114	ATP5G2	-0.43	-4.52	-0.34	1.25e-5	Biliary atresia;
PAAD	cis	rs6540	1.000	rs568373	chr11:255014	A/G	cg20282913	chr11:252683	PSMD13	-1.01	-4.31	-0.33	2.87e-5	Endometriosis;
PAAD	cis	rs2004318	1.000	rs57086032	chr19:55122276	T/C	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.98	0.49	8.48e-11	Menarche (age at onset);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg04577441	chr4:100870687	LOC256880;H2AFZ	0.56	6.8	0.48	2.27e-10	Immature fraction of reticulocytes;
PAAD	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	7.95	0.54	3.88e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg20312557	chr2:97357134	FER1L5	-0.83	-4.43	-0.34	1.79e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg15908580	chr10:134496731	INPP5A	-0.47	-4.25	-0.33	3.77e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.61	-5.87	-0.43	2.7e-8	Psoriasis;
PAAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.07	-8.59	-0.57	9.76e-15	Diabetic kidney disease;
PAAD	cis	rs1018697	1.000	rs1018697	chr10:104549224	C/A	cg04362960	chr10:104952993	NT5C2	0.6	6.17	0.45	5.83e-9	Colorectal adenoma (advanced);
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.44	-5.09	-0.38	1.06e-6	Abdominal aortic aneurysm;
PAAD	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg12756303	chr2:74692479	MOGS	-0.5	-4.49	-0.34	1.39e-5	Metabolite levels;
PAAD	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-4.64	-0.35	7.52e-6	Coronary artery disease;
PAAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.61	7.13	0.5	3.82e-11	Iron status biomarkers (transferrin levels);
PAAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.59	-5.78	-0.42	4.02e-8	IgG glycosylation;
PAAD	cis	rs800160	0.777	rs11529118	chr11:2343866	C/T	cg09785033	chr11:2336066	TSPAN32	0.5	4.32	0.33	2.83e-5	Bacteremia;
PAAD	cis	rs492146	0.935	rs316135	chr6:52846777	C/T	cg24393602	chr6:52860404	GSTA4	-0.44	-4.29	-0.33	3.18e-5	Epilepsy (remission after treatment);
PAAD	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.5	5.35	0.4	3.22e-7	Carotid intima media thickness;
PAAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg00579200	chr11:133705235	NA	-0.47	-5.52	-0.41	1.46e-7	Childhood ear infection;
PAAD	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.64	7.18	0.5	2.9100000000000002e-11	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.56	-12.97	-0.72	2.23e-26	Atopic dermatitis;
PAAD	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.71	-6.92	-0.49	1.16e-10	White matter hyperintensity burden;
PAAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg14393609	chr7:65229607	NA	-0.63	-6.76	-0.48	2.74e-10	Calcium levels;
PAAD	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.59	6.19	0.45	5.34e-9	Blood protein levels;
PAAD	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	1.01	7.18	0.5	2.87e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-7.19	-0.5	2.74e-11	Depression;
PAAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg14926445	chr8:58193284	C8orf71	-0.63	-4.77	-0.36	4.22e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-1.13	-9.66	-0.62	1.62e-17	Blood trace element (Zn levels);
PAAD	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg20893579	chr22:38215064	NA	-0.57	-6.0	-0.44	1.4e-8	Glioblastoma;Glioma;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg12858701	chr10:114894792	TCF7L2	0.72	6.53	0.47	9.14e-10	Photic sneeze reflex;
PAAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.59	-6.13	-0.44	7.4e-9	Type 2 diabetes;
PAAD	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Depression;
PAAD	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.27	0.6	1.71e-16	Hemoglobin concentration;
PAAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg15847926	chr7:2749597	AMZ1	-0.4	-4.81	-0.36	3.61e-6	Height;
PAAD	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs4343996	0.692	rs55848061	chr7:3454639	T/A	cg21248987	chr7:3385318	SDK1	0.47	5.02	0.38	1.42e-6	Motion sickness;
PAAD	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.44	4.31	0.33	2.86e-5	Red blood cell count;
PAAD	cis	rs3812111	0.525	rs2232472	chr6:116574455	G/A	cg26893134	chr6:116381904	FRK	-0.29	-4.31	-0.33	2.89e-5	Age-related macular degeneration;
PAAD	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.42	4.87	0.37	2.72e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.19e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.69	-0.36	6.16e-6	Smoking behavior;
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg09237302	chr4:906077	GAK	-0.43	-4.58	-0.35	9.45e-6	Type 2 diabetes;
PAAD	cis	rs7291412	0.662	rs6520015	chr22:46463431	C/T	cg05468064	chr22:46423449	NA	-0.39	-4.55	-0.35	1.11e-5	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	5.43	0.4	2.19e-7	HIV-1 control;
PAAD	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.74	0.36	4.82e-6	Colorectal cancer;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15064873	chr2:99953016	EIF5B;TXNDC9	0.57	6.29	0.45	3.24e-9	Monocyte percentage of white cells;
PAAD	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg10934807	chr2:113191815	RGPD8;RGPD5	0.86	5.94	0.43	1.91e-8	Yeast infection;
PAAD	cis	rs2718812	1.000	rs7626210	chr3:133398099	G/A	cg12372414	chr3:134319805	KY	-0.41	-4.48	-0.34	1.44e-5	Iron status biomarkers;
PAAD	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.76	7.47	0.52	5.76e-12	Response to diuretic therapy;
PAAD	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.84	-10.09	-0.63	1.2e-18	Brugada syndrome;
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg01831904	chr17:28903510	LRRC37B2	0.89	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00933542	chr6:150070202	PCMT1	0.51	5.3	0.4	3.95e-7	Lung cancer;
PAAD	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg14703610	chr5:56206110	C5orf35	0.56	5.23	0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	4.78	0.36	4.04e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.72	-6.27	-0.45	3.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg25952890	chr19:58913133	NA	0.67	5.71	0.42	5.73e-8	Mean platelet volume;
PAAD	trans	rs9428104	0.920	rs60560809	chr1:118916702	A/G	cg18701660	chr19:34012935	PEPD	0.67	6.29	0.45	3.17e-9	Height;
PAAD	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.44	0.56	2.31e-14	Bipolar disorder;
PAAD	cis	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15287987	chr7:118004330	NA	-0.63	-5.95	-0.43	1.79e-8	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1035491	0.720	rs10491469	chr5:63959834	C/A	cg01791865	chr5:63954708	NA	0.5	5.37	0.4	2.87e-7	Body mass index;
PAAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.8	-7.6	-0.52	2.86e-12	DNA methylation (variation);
PAAD	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.59	5.15	0.39	7.87e-7	Common traits (Other);
PAAD	cis	rs35164067	0.662	rs11666164	chr19:10576270	C/T	cg24189696	chr19:10585866	NA	0.5	5.02	0.38	1.45e-6	Inflammatory bowel disease;
PAAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.81	-7.78	-0.53	1.06e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.84	-5.9	-0.43	2.23e-8	Coronary artery disease;
PAAD	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs78761021	0.597	rs2277690	chr17:9783855	A/G	cg26853458	chr17:9805074	RCVRN	0.41	4.76	0.36	4.51e-6	Type 2 diabetes;
PAAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.73	7.75	0.53	1.23e-12	Menarche (age at onset);
PAAD	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.89	7.6	0.52	2.89e-12	IgG glycosylation;
PAAD	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.48	4.67	0.35	6.64e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg20607287	chr7:12443886	VWDE	-0.92	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs4481887	0.830	rs4364913	chr1:248515635	C/A	cg00666640	chr1:248458726	OR2T12	0.52	5.03	0.38	1.4e-6	Common traits (Other);
PAAD	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.82	-6.09	-0.44	8.9e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg09491104	chr22:46646882	C22orf40	-0.62	-4.98	-0.37	1.71e-6	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs4739066	0.579	rs12547848	chr8:63879389	G/A	cg25248160	chr8:63776642	NKAIN3	0.75	4.8	0.36	3.8e-6	Myocardial infarction;
PAAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06217245	chr20:33103252	DYNLRB1	0.4	4.73	0.36	5.07e-6	Coronary artery disease;
PAAD	cis	rs4690686	0.509	rs13147303	chr4:177256126	G/A	cg17059388	chr4:177262070	NA	0.53	4.74	0.36	4.8e-6	Essential tremor;
PAAD	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg20003494	chr4:90757398	SNCA	-0.4	-4.46	-0.34	1.57e-5	Dementia with Lewy bodies;
PAAD	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.22	7.14	0.5	3.63e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-4.71	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.97	-15.2	-0.78	2.52e-32	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7246865	0.510	rs2305752	chr19:17186127	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.53	5.33	0.4	3.55e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.7	-7.11	-0.5	4.14e-11	Body mass index;
PAAD	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.4	-8.02	-0.55	2.6e-13	Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11245990	chr11:68621969	NA	-0.38	-4.96	-0.37	1.87e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.31	-0.33	2.92e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.75	-7.98	-0.54	3.22e-13	Aortic root size;
PAAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.47	-4.5	-0.34	1.34e-5	Menarche (age at onset);
PAAD	cis	rs939584	1.000	rs13386627	chr2:650560	G/C	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs9463078	0.804	rs9395086	chr6:45225331	T/A	cg25276700	chr6:44698697	NA	-0.49	-5.72	-0.42	5.54e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.51	0.34	1.28e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg05585544	chr11:47624801	NA	-0.47	-5.24	-0.39	5.3e-7	Subjective well-being;
PAAD	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.93	0.37	2.13e-6	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15765054	chr17:900260	TIMM22	0.68	7.21	0.5	2.44e-11	Myopia (pathological);
PAAD	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg08523384	chr5:141488047	NDFIP1	-0.51	-4.91	-0.37	2.3e-6	Asthma;
PAAD	cis	rs858239	0.676	rs3807459	chr7:23389751	T/C	cg27449745	chr7:23145252	KLHL7	-0.51	-4.47	-0.34	1.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs4936891	0.599	rs10893128	chr11:123890745	C/T	cg22125253	chr11:123886957	OR10G4	-0.45	-4.56	-0.35	1.04e-5	Male fertility;
PAAD	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07234876	chr8:600039	NA	-1.06	-6.79	-0.48	2.31e-10	IgG glycosylation;
PAAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.51	-5.33	-0.4	3.46e-7	Type 2 diabetes;
PAAD	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.67	9.01	0.59	8.36e-16	Lipoprotein (a) levels;
PAAD	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg05341575	chr12:125625032	AACS	-0.52	-4.73	-0.36	5.15e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg12658694	chr1:38397304	INPP5B	0.61	6.72	0.48	3.37e-10	Coronary artery disease;
PAAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.73	9.92	0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg19930314	chr7:98593876	TRRAP	-0.49	-4.71	-0.36	5.55e-6	Breast cancer;
PAAD	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Myopia (pathological);
PAAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12949688	0.967	rs12950062	chr17:55825534	G/A	cg12582317	chr17:55822272	NA	0.69	8.47	0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-5.89	-0.43	2.35e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg23688817	chr7:87105293	ABCB4	0.52	4.28	0.33	3.28e-5	Gallbladder cancer;
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg11694433	chr15:63796712	USP3	-0.45	-4.64	-0.35	7.5e-6	Immature fraction of reticulocytes;
PAAD	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.26	-0.33	3.57e-5	QT interval;
PAAD	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.86	9.9	0.63	3.89e-18	Body mass index;
PAAD	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg10223061	chr2:219282414	VIL1	0.37	4.42	0.34	1.89e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	5.95	0.43	1.76e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.77	0.53	1.07e-12	Motion sickness;
PAAD	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	trans	rs6722456	1.000	rs76152671	chr2:134569856	G/C	cg06476693	chr11:130283454	ADAMTS8	0.81	6.4	0.46	1.85e-9	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs5771040	0.560	rs4824152	chr22:50911876	A/G	cg03450049	chr22:50913555	SBF1	0.57	4.85	0.37	3.02e-6	IgG glycosylation;
PAAD	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.15	0.55	1.24e-13	Coffee consumption (cups per day);
PAAD	cis	rs8102137	1.000	rs57894940	chr19:30293462	G/A	cg27475126	chr19:30303651	CCNE1	-0.44	-4.88	-0.37	2.67e-6	Bladder cancer;
PAAD	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02543470	chr2:105862877	NA	-0.5	-4.82	-0.36	3.47e-6	AIDS;
PAAD	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07685180	chr8:600429	NA	0.87	5.97	0.44	1.6e-8	IgG glycosylation;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg24699146	chr1:24152579	HMGCL	0.53	5.63	0.42	8.46e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11671653	0.688	rs11669103	chr19:10848224	C/T	cg16667279	chr19:11591998	ELAVL3	-0.72	-4.64	-0.35	7.42e-6	LDL cholesterol;
PAAD	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-6.32	-0.46	2.72e-9	Gallbladder cancer;
PAAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.67	6.88	0.49	1.47e-10	Urate levels in lean individuals;
PAAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	6.29	0.45	3.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg04851639	chr8:1020857	NA	-0.63	-8.06	-0.55	2.15e-13	Schizophrenia;
PAAD	cis	rs668210	0.793	rs615646	chr11:65777544	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	4.35	0.33	2.53e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.55	5.18	0.39	7.01e-7	Type 2 diabetes;
PAAD	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.69	7.8	0.53	9.1e-13	Alcohol dependence;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.52	5.88	0.43	2.55e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6142102	0.625	rs9753690	chr20:32540801	C/G	cg06115741	chr20:33292138	TP53INP2	0.51	4.47	0.34	1.49e-5	Skin pigmentation;
PAAD	cis	rs282587	0.569	rs378432	chr13:113398048	A/C	cg02820901	chr13:113351484	ATP11A	-0.65	-4.96	-0.37	1.89e-6	Glycated hemoglobin levels;
PAAD	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.78	-9.22	-0.6	2.38e-16	White blood cell count (basophil);
PAAD	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.55	-6.28	-0.45	3.37e-9	Coronary artery disease;
PAAD	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg19254793	chr6:44695348	NA	-0.45	-4.34	-0.33	2.58e-5	Total body bone mineral density;
PAAD	cis	rs10186876	0.665	rs6756365	chr2:44135997	A/C	cg09541576	chr2:44873248	C2orf34	0.48	4.97	0.37	1.76e-6	Hand grip strength;
PAAD	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg06740227	chr12:86229804	RASSF9	-0.55	-5.27	-0.39	4.57e-7	Major depressive disorder;
PAAD	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-5.65	-0.42	7.74e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	7.27	0.51	1.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8064299	0.636	rs9915279	chr17:72772848	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.96	10.65	0.65	3.92e-20	Monocyte count;
PAAD	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg26876637	chr1:152193138	HRNR	-0.83	-6.0	-0.44	1.38e-8	Atopic dermatitis;
PAAD	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs35740288	0.689	rs11630688	chr15:86253279	C/T	cg07943548	chr15:86304357	KLHL25	-0.62	-5.26	-0.39	4.86e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg12218747	chr21:37451666	NA	-0.48	-5.1	-0.38	9.99e-7	Mitral valve prolapse;
PAAD	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg08027265	chr7:2291960	NA	-0.62	-6.1	-0.44	8.28e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.56	5.7	0.42	6.05e-8	Testicular germ cell tumor;
PAAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg07617317	chr6:118971624	C6orf204	0.54	4.48	0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg18279126	chr7:2041391	MAD1L1	0.55	5.16	0.39	7.75e-7	Schizophrenia;
PAAD	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-1.25	-7.65	-0.53	2.2e-12	Plateletcrit;
PAAD	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.7	0.42	6.14e-8	Ileal carcinoids;
PAAD	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.62	-0.78	2.05e-33	Schizophrenia;
PAAD	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	7.64	0.53	2.32e-12	HIV-1 control;
PAAD	cis	rs7771547	0.855	rs9366911	chr6:36589340	C/G	cg07856975	chr6:36356162	ETV7	-0.47	-5.36	-0.4	3.01e-7	Platelet distribution width;
PAAD	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg03098721	chr1:84464084	TTLL7	0.47	4.45	0.34	1.68e-5	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs4740619	0.619	rs10738423	chr9:16027329	A/G	cg14451791	chr9:16040625	NA	-0.45	-5.22	-0.39	5.81e-7	Body mass index;
PAAD	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-5.88	-0.43	2.56e-8	Total body bone mineral density;
PAAD	cis	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.18e-7	HDL cholesterol;
PAAD	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg25809561	chr17:30822961	MYO1D	0.53	5.34	0.4	3.36e-7	Schizophrenia;
PAAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg00334542	chr7:100209784	MOSPD3	-0.72	-5.37	-0.4	2.85e-7	Other erythrocyte phenotypes;
PAAD	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg17644776	chr2:200775616	C2orf69	-0.66	-5.55	-0.41	1.27e-7	Schizophrenia;
PAAD	cis	rs7116495	0.609	rs567851	chr11:71592419	G/C	cg10763288	chr11:71158925	DHCR7	0.56	4.44	0.34	1.75e-5	Severe influenza A (H1N1) infection;
PAAD	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg24585817	chr7:64895279	NA	0.43	4.32	0.33	2.84e-5	Aortic root size;
PAAD	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.56	4.6	0.35	8.81e-6	RR interval (heart rate);
PAAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg06492744	chr11:65406254	SIPA1	0.45	5.38	0.4	2.71e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg21130718	chr4:1044621	NA	0.56	4.82	0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-4.71	-0.36	5.45e-6	Subjective well-being;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09381038	chr13:52585597	ALG11;ATP7B	-0.63	-6.61	-0.47	6.17e-10	Warfarin maintenance dose;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04777644	chr16:28752301	NA	0.56	6.66	0.48	4.79e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.44	-4.84	-0.37	3.2e-6	Breast cancer;
PAAD	cis	rs7714584	1.000	rs12054923	chr5:150249059	A/G	cg22134413	chr5:150180641	NA	0.78	5.48	0.41	1.7e-7	Crohn's disease;
PAAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.86	-7.73	-0.53	1.33e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03684571	chr16:87468092	ZCCHC14	0.57	6.39	0.46	1.97e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-9.54	-0.61	3.36e-17	Total body bone mineral density;
PAAD	cis	rs7552393	0.636	rs1408476	chr1:84278976	C/T	cg10977910	chr1:84465055	TTLL7	0.59	5.61	0.41	9.41e-8	Select biomarker traits;
PAAD	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.9	7.66	0.53	2.01e-12	Triglycerides;
PAAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.82	-6.68	-0.48	4.17e-10	Platelet count;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27570636	chr1:214454189	SMYD2	0.6	6.88	0.49	1.45e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg09835421	chr16:68378352	PRMT7	-0.95	-7.55	-0.52	3.79e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	6.26	0.45	3.77e-9	Mean platelet volume;
PAAD	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	0.95	11.67	0.69	7.33e-23	Breast cancer;
PAAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.51	-0.47	1.02e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.77	8.08	0.55	1.9e-13	Response to diuretic therapy;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16504641	chr6:137143711	PEX7	0.55	6.31	0.46	2.94e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02743256	chr7:2109353	MAD1L1	-0.76	-6.11	-0.44	7.98e-9	Bipolar disorder;
PAAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg12517394	chr11:61582795	MIR1908;FADS1	0.52	5.09	0.38	1.06e-6	Trans fatty acid levels;
PAAD	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.76	-0.42	4.6e-8	QT interval;
PAAD	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	0.84	5.86	0.43	2.78e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.6	-5.76	-0.42	4.43e-8	Eye color traits;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.54	5.54	0.41	1.28e-7	Longevity;Endometriosis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12261052	chr3:64009148	PSMD6	-0.63	-6.43	-0.46	1.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8077577	1.000	rs62073605	chr17:18066791	C/T	cg16794390	chr17:18148240	FLII	0.56	4.66	0.35	6.8e-6	Obesity-related traits;
PAAD	cis	rs8032158	0.963	rs7182397	chr15:56181052	A/T	cg02198044	chr15:56286336	NEDD4	-0.5	-5.16	-0.39	7.6e-7	Keloid;
PAAD	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg02527881	chr3:46936655	PTH1R	0.38	4.45	0.34	1.68e-5	Colorectal cancer;
PAAD	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg07703079	chr11:430292	ANO9	0.78	4.47	0.34	1.52e-5	Body mass index;
PAAD	cis	rs4509693	0.882	rs7071427	chr10:102491832	T/C	cg24179445	chr10:102496915	NA	0.5	5.03	0.38	1.34e-6	Alzheimer's disease;
PAAD	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12292205	chr6:26970375	C6orf41	-0.46	-4.33	-0.33	2.66e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs12282928	1.000	rs2134554	chr11:48262351	C/T	cg22827986	chr11:48284249	OR4X1	-0.41	-5.22	-0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg23708337	chr7:1209742	NA	0.62	4.54	0.35	1.11e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.97	11.03	0.67	3.74e-21	Parkinson's disease;
PAAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.55	6.8	0.48	2.22e-10	Psoriasis;
PAAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.7	-7.48	-0.52	5.65e-12	Colorectal cancer;
PAAD	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26897989	chr16:1907736	C16orf73	-0.52	-4.69	-0.36	6.08e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.41	-0.34	1.97e-5	Life satisfaction;
PAAD	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.17	0.5	3e-11	Eye color traits;
PAAD	cis	rs4780401	0.655	rs17606098	chr16:11789190	C/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-5.09	-0.38	1.03e-6	Rheumatoid arthritis;
PAAD	cis	rs7165102	1.000	rs7496335	chr15:65758868	A/T	cg22900193	chr15:65823441	PTPLAD1	0.48	4.53	0.35	1.17e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.03	12.99	0.73	1.99e-26	Cognitive ability;
PAAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.4	-0.4	2.53e-7	Glomerular filtration rate;
PAAD	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.89	7.04	0.5	6.09e-11	Chronic kidney disease;
PAAD	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-6.31	-0.46	2.94e-9	Longevity;Endometriosis;
PAAD	cis	rs4478147	0.506	rs2869433	chr4:87279096	C/T	cg10685359	chr4:87814065	C4orf36	-0.52	-5.36	-0.4	2.98e-7	Migraine - clinic-based;
PAAD	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.83	10.48	0.65	1.08e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-1.1	-14.41	-0.76	3.15e-30	Height;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-4.91	-0.37	2.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-6.65	-0.47	5.04e-10	Morning vs. evening chronotype;
PAAD	cis	rs1864585	0.520	rs73208775	chr8:10668281	A/G	cg21775007	chr8:11205619	TDH	-0.56	-4.47	-0.34	1.53e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg05895507	chr15:77155635	SCAPER	0.4	4.87	0.37	2.79e-6	Blood metabolite levels;
PAAD	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.63	5.44	0.4	2.1e-7	Plateletcrit;
PAAD	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg24375607	chr4:120327624	NA	0.46	4.7	0.36	5.73e-6	Diastolic blood pressure;
PAAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.89	-0.43	2.34e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-12.16	-0.7	3.35e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3136441	1.000	rs4752931	chr11:46762516	C/T	cg19486271	chr11:47235900	DDB2	0.64	4.88	0.37	2.69e-6	HDL cholesterol;
PAAD	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	0.98	6.0	0.44	1.37e-8	Fat distribution (HIV);
PAAD	cis	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.96	5.74	0.42	5.09e-8	Blood protein levels;
PAAD	cis	rs1190596	0.525	rs6575897	chr14:102647125	G/A	cg23289024	chr14:102554846	HSP90AA1	0.36	4.32	0.33	2.85e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-5.13	-0.38	8.54e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10929159	0.928	rs7596780	chr2:236924303	C/T	cg14226755	chr2:236923322	AGAP1	0.28	4.41	0.34	1.98e-5	Parkinson's disease;
PAAD	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.59	5.2	0.39	6.27e-7	Menarche (age at onset);
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	4.31	0.33	2.89e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.9	11.1	0.67	2.44e-21	Blood protein levels;
PAAD	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg14146966	chr2:61757674	XPO1	0.37	4.47	0.34	1.49e-5	Tuberculosis;
PAAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.55	5.7	0.42	6.05e-8	Menopause (age at onset);
PAAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg18892244	chr7:807596	HEATR2	-0.72	-5.38	-0.4	2.74e-7	Initial pursuit acceleration;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg15117754	chr3:10150083	C3orf24	0.7	5.94	0.43	1.9e-8	Alzheimer's disease;
PAAD	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.22	-0.39	5.69e-7	Daytime sleep phenotypes;
PAAD	cis	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg05084668	chr3:125655381	ALG1L	-0.42	-4.69	-0.36	6.01e-6	Blood pressure (smoking interaction);
PAAD	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.85	6.69	0.48	3.98e-10	Lung function (FEV1/FVC);
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs6494488	0.500	rs7173216	chr15:65023156	C/T	cg16425858	chr15:64791681	ZNF609	0.94	5.05	0.38	1.28e-6	Coronary artery disease;
PAAD	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg06609049	chr19:2785107	THOP1	0.88	9.85	0.62	5.36e-18	Total cholesterol levels;
PAAD	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.58	5.64	0.42	8.06e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.45	-0.34	1.62e-5	Height;
PAAD	cis	rs9815354	0.680	rs73073294	chr3:42028053	A/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.64	6.29	0.45	3.19e-9	Blood protein levels;
PAAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.52	-4.95	-0.37	1.94e-6	Monocyte count;
PAAD	cis	rs300774	1.000	rs300777	chr2:112026	T/C	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg03938978	chr2:103052716	IL18RAP	0.66	8.24	0.56	7.33e-14	Asthma;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.51	-5.7	-0.42	6.17e-8	Testicular germ cell tumor;
PAAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-4.34	-0.33	2.54e-5	Schizophrenia;
PAAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg21130718	chr4:1044621	NA	0.55	4.82	0.36	3.39e-6	Recombination rate (females);
PAAD	cis	rs4740619	0.933	rs10756695	chr9:15712674	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.47	-0.34	1.55e-5	Body mass index;
PAAD	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	7.37	0.51	9.93e-12	Coffee consumption (cups per day);
PAAD	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12315302	chr6:26189340	HIST1H4D	0.54	4.27	0.33	3.5e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg12757816	chr2:10669957	NA	0.45	4.7	0.36	5.76e-6	Prostate cancer;
PAAD	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg15047889	chr8:124780837	FAM91A1	-0.66	-4.86	-0.37	2.91e-6	Pancreatic cancer;
PAAD	cis	rs11563648	0.553	rs1057454	chr7:127032599	A/C	cg21885361	chr7:127911034	NA	-0.42	-4.49	-0.34	1.41e-5	Resting heart rate;
PAAD	cis	rs9527	0.518	rs10883802	chr10:104680362	C/T	cg14737131	chr10:104680354	CNNM2	-0.68	-6.06	-0.44	1.01e-8	Arsenic metabolism;
PAAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.79	8.14	0.55	1.33e-13	Prostate cancer;
PAAD	cis	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.53	-0.47	9.19e-10	Brain structure;
PAAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg24739098	chr15:79297159	RASGRF1	0.34	4.35	0.33	2.49e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10768122	0.966	rs10836367	chr11:35314455	T/C	cg13971030	chr11:35366721	SLC1A2	-0.37	-4.42	-0.34	1.86e-5	Vitiligo;
PAAD	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.45	5.09	0.38	1.06e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.49	4.54	0.35	1.12e-5	Cisplatin-induced ototoxicity;
PAAD	cis	rs6537837	0.838	rs6663547	chr1:110114229	A/C	cg05049280	chr1:110155535	GNAT2	0.43	4.45	0.34	1.67e-5	Major depressive disorder;
PAAD	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.95e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.57	6.43	0.46	1.6e-9	Platelet distribution width;
PAAD	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.11	0.38	9.37e-7	Monocyte percentage of white cells;
PAAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-6.17	-0.45	5.96e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.84	9.7	0.62	1.31e-17	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22165626	chr5:112796302	MCC	-0.61	-6.44	-0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg09659197	chr4:152720779	NA	0.44	5.72	0.42	5.53e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7631605	0.905	rs6764444	chr3:37173715	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9918079	0.560	rs12651550	chr4:15641018	G/C	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	4.69	0.36	5.93e-6	Joint mobility (Beighton score);
PAAD	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg20435097	chr10:126320824	FAM53B	-0.48	-4.61	-0.35	8.41e-6	Cocaine dependence;
PAAD	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.51	-4.85	-0.37	2.97e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs78761021	0.867	rs62067562	chr17:9785946	T/A	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.12e-13	Type 2 diabetes;
PAAD	cis	rs10274279	1.000	rs73163815	chr7:157388047	A/G	cg26886268	chr7:157387156	PTPRN2	-0.73	-5.79	-0.43	3.87e-8	Myopia (pathological);
PAAD	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.47	5.13	0.38	8.63e-7	Total body bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17918090	chr1:17751920	RCC2	0.57	6.43	0.46	1.54e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.85	9.87	0.62	4.62e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.65	5.74	0.42	5.07e-8	Coronary artery disease;
PAAD	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.52	-5.97	-0.44	1.65e-8	Alcohol dependence;
PAAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.4	-4.55	-0.35	1.08e-5	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.63	8.28	0.56	5.88e-14	Renal cell carcinoma;
PAAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-6.13	-0.45	7.28e-9	Schizophrenia;
PAAD	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg22546130	chr22:19950026	COMT	-0.33	-5.16	-0.39	7.52e-7	Blood metabolite levels;
PAAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs438465	0.786	rs430206	chr6:169827066	A/G	cg11181693	chr6:169825345	NA	-0.58	-4.6	-0.35	8.83e-6	Corneal astigmatism;
PAAD	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg01420254	chr6:26195488	NA	0.94	7.38	0.51	9.73e-12	Gout;Renal underexcretion gout;
PAAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg01283332	chr5:1856932	NA	-0.47	-4.88	-0.37	2.7e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.53e-5	Dementia with Lewy bodies;
PAAD	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.54	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg26727032	chr16:67993705	SLC12A4	-0.61	-5.07	-0.38	1.17e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.53	0.47	9.4e-10	Coffee consumption (cups per day);
PAAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.28e-9	Cardiovascular disease risk factors;
PAAD	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2531992	0.686	rs2531989	chr16:4028145	G/A	cg05927578	chr16:4029543	ADCY9	0.72	6.16	0.45	6.26e-9	Waist circumference;
PAAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.54	-4.31	-0.33	2.97e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11010242	chr7:26240470	CBX3;HNRNPA2B1	0.62	6.7	0.48	3.84e-10	Myopia (pathological);
PAAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.96	8.63	0.57	7.65e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26926768	chr12:34528122	NA	0.38	4.73	0.36	5.12e-6	Morning vs. evening chronotype;
PAAD	cis	rs10421328	0.848	rs10415278	chr19:19769157	C/A	cg11584989	chr19:19387371	SF4	0.89	6.81	0.48	2.17e-10	Parental longevity (combined parental age at death);
PAAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13560548	chr3:10150139	C3orf24	0.53	4.81	0.36	3.64e-6	Alzheimer's disease;
PAAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.99	11.36	0.68	4.92e-22	Parkinson's disease;
PAAD	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.54	-4.87	-0.37	2.8e-6	Schizophrenia;
PAAD	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-1.28	-8.04	-0.55	2.39e-13	Plateletcrit;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg10795710	chr1:16693622	C1orf144	0.62	7.16	0.5	3.27e-11	Metabolite levels  (X-11787);
PAAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-8.39	-0.56	3.07e-14	Gut microbiome composition (summer);
PAAD	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	6.87	0.49	1.56e-10	Educational attainment;
PAAD	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.53	4.64	0.35	7.61e-6	Height;
PAAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.45	-4.76	-0.36	4.38e-6	Tonsillectomy;
PAAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg03199926	chr20:60860733	OSBPL2	0.37	4.36	0.33	2.38e-5	Colorectal cancer;
PAAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg04705435	chr11:17411270	KCNJ11	0.61	6.49	0.47	1.15e-9	Type 2 diabetes;
PAAD	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg26876637	chr1:152193138	HRNR	0.86	6.84	0.49	1.77e-10	Atopic dermatitis;
PAAD	cis	rs9815354	1.000	rs1615243	chr3:41965234	C/T	cg03022575	chr3:42003672	ULK4	-0.81	-5.75	-0.42	4.81e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.31	11.35	0.68	5.05e-22	Uric acid levels;
PAAD	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg16417436	chr16:28758564	NA	0.48	4.44	0.34	1.72e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs761746	0.614	rs131250	chr22:32129603	A/G	cg01338084	chr22:32026380	PISD	0.61	5.44	0.4	2.05e-7	Intelligence;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg00280220	chr17:61926910	NA	0.44	4.64	0.35	7.62e-6	Prudent dietary pattern;
PAAD	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.37	-5.82	-0.43	3.4e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.8	-0.43	3.81e-8	Lung cancer;
PAAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-5.02	-0.38	1.41e-6	Total body bone mineral density;
PAAD	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.81	5.97	0.44	1.6e-8	Vitiligo;
PAAD	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg24699146	chr1:24152579	HMGCL	0.47	5.28	0.39	4.42e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06850241	chr22:41845214	NA	-0.48	-4.84	-0.37	3.14e-6	Vitiligo;
PAAD	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg19223190	chr17:80058835	NA	-0.55	-5.7	-0.42	6.08e-8	Life satisfaction;
PAAD	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg01868782	chr6:126071099	HEY2	0.45	5.3	0.39	3.99e-7	Brugada syndrome;
PAAD	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg24520871	chr10:73074265	NA	0.6	6.87	0.49	1.58e-10	Metabolite levels  (X-11787);
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27094323	chr7:1216898	NA	-0.5	-5.87	-0.43	2.65e-8	Longevity;Endometriosis;
PAAD	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg16596103	chr2:233749413	NGEF	0.41	4.43	0.34	1.76e-5	Schizophrenia;
PAAD	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg03098721	chr1:84464084	TTLL7	0.47	4.4	0.34	1.99e-5	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22846109	chr17:27230122	DHRS13	0.7	7.09	0.5	4.77e-11	Obesity-related traits;
PAAD	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs2944755	0.723	rs11996672	chr8:141586999	C/T	cg08632810	chr8:141609470	EIF2C2	-0.36	-4.54	-0.35	1.16e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	4.5	0.34	1.35e-5	Iron status biomarkers;
PAAD	cis	rs11203032	0.831	rs10430718	chr10:90937951	A/T	cg16672925	chr10:90967113	CH25H	0.72	5.62	0.41	8.85e-8	Heart failure;
PAAD	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.68	7.07	0.5	5.28e-11	Calcium levels;
PAAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg05484376	chr2:27715224	FNDC4	0.52	5.16	0.39	7.52e-7	Menopause (age at onset);
PAAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg03367679	chr17:38183553	MED24;SNORD124	-0.34	-4.37	-0.33	2.33e-5	White blood cell count;
PAAD	cis	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.52	4.36	0.33	2.36e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.81	-9.0	-0.59	8.81e-16	Idiopathic membranous nephropathy;
PAAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.3	-4.39	-0.34	2.12e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.6	-6.23	-0.45	4.3e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg23250157	chr14:64679961	SYNE2	0.48	4.9	0.37	2.45e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.62	5.65	0.42	7.68e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.48	-5.09	-0.38	1.04e-6	Platelet distribution width;
PAAD	cis	rs7580717	0.785	rs3731781	chr2:232159243	A/G	cg07929768	chr2:232055508	NA	0.48	5.45	0.4	2.01e-7	Multiple myeloma;
PAAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.32	0.33	2.86e-5	IgG glycosylation;
PAAD	cis	rs4006360	0.531	rs7502102	chr17:39307041	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.43	-4.31	-0.33	2.94e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs13242816	1.000	rs73208106	chr7:116173263	G/A	cg16553024	chr7:116138462	CAV2	-0.61	-4.29	-0.33	3.18e-5	P wave duration;
PAAD	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-7.84	-0.54	7.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg21565972	chr17:80109576	CCDC57	-0.57	-6.5	-0.47	1.11e-9	Life satisfaction;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20049927	chr15:45777254	SLC30A4	-0.52	-6.71	-0.48	3.7e-10	Energy expenditure (24h);
PAAD	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.36	0.51	1.08e-11	Neuroticism;
PAAD	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	6.12	0.44	7.54e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06850241	chr22:41845214	NA	0.57	5.0	0.38	1.59e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7127900	1.000	rs7109474	chr11:2233219	G/A	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs7561149	1.000	rs12469367	chr2:179691670	T/C	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.49	4.72	0.36	5.32e-6	QT interval;
PAAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	1.12	16.6	0.8	5.81e-36	Breast cancer;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26549601	chr10:134560360	INPP5A	-0.51	-4.97	-0.37	1.78e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.82	-8.83	-0.58	2.31e-15	Type 2 diabetes;
PAAD	cis	rs7009110	0.668	rs13274067	chr8:81267236	G/A	cg21158561	chr8:81178149	NA	0.43	4.63	0.35	7.67e-6	Asthma and hay fever;
PAAD	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.72	7.33	0.51	1.27e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs111547017	1	rs111547017	chr6:43341689	A/G	cg26312998	chr6:43337775	ZNF318	0.7	5.71	0.42	5.75e-8	Schizophrenia;
PAAD	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.59	-6.4	-0.46	1.81e-9	Schizophrenia;
PAAD	cis	rs2320952	0.874	rs2063271	chr17:10489730	A/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.29e-5	Gut microbiome composition (winter);
PAAD	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg13660082	chr14:53194042	PSMC6	-0.67	-4.27	-0.33	3.48e-5	Alzheimer's disease (late onset);
PAAD	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.78	-6.5	-0.47	1.07e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.65	-6.49	-0.47	1.16e-9	Ear protrusion;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02828054	chr19:8478160	MARCH2	0.68	6.65	0.47	4.84e-10	Obesity-related traits;
PAAD	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.79	-0.36	3.95e-6	Educational attainment;
PAAD	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.72	-8.33	-0.56	4.31e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.54	0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-4.72	-0.36	5.25e-6	Height;
PAAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg21130718	chr4:1044621	NA	0.56	4.74	0.36	4.8e-6	Recombination rate (females);
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.51	4.94	0.37	2.05e-6	Prostate-specific antigen levels;
PAAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.85	0.43	2.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26544786	chr15:89164951	AEN	0.6	6.84	0.49	1.83e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs593531	0.571	rs10898983	chr11:74093992	C/T	cg15851278	chr11:73669449	DNAJB13	-0.37	-4.48	-0.34	1.46e-5	Neuroticism;
PAAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12667521	chr19:29218732	NA	0.74	7.17	0.5	3.06e-11	Methadone dose in opioid dependence;
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03909863	chr11:638404	DRD4	-0.61	-5.46	-0.4	1.91e-7	Systemic lupus erythematosus;
PAAD	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.83	-9.64	-0.62	1.88e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.74	5.13	0.38	8.65e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.65	7.05	0.5	6e-11	Menarche (age at onset);
PAAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05025164	chr4:1340916	KIAA1530	0.56	5.43	0.4	2.22e-7	Obesity-related traits;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-5.14	-0.38	8.34e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.47	4.83	0.36	3.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.46	-5.16	-0.39	7.59e-7	Reticulocyte fraction of red cells;
PAAD	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.56	-5.03	-0.38	1.34e-6	White blood cell count;
PAAD	cis	rs9463078	0.547	rs4714822	chr6:44742290	T/C	cg25276700	chr6:44698697	NA	0.46	5.43	0.4	2.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg27471124	chr11:109292789	C11orf87	0.24	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.53e-15	Chronic sinus infection;
PAAD	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg23950597	chr19:37808831	NA	-0.74	-5.01	-0.38	1.49e-6	Coronary artery calcification;
PAAD	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg05342682	chr7:94953680	PON1	-0.55	-4.75	-0.36	4.75e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.9	-10.85	-0.66	1.17e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.41	-0.34	1.98e-5	IgG glycosylation;
PAAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.42e-38	Height;
PAAD	cis	rs9659323	0.640	rs11800444	chr1:119639675	T/C	cg17326555	chr1:119535693	NA	-0.38	-5.24	-0.39	5.24e-7	Body mass index;
PAAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.49	5.27	0.39	4.6e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg21823605	chr1:152486609	CRCT1	0.49	6.29	0.45	3.14e-9	Hair morphology;
PAAD	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.63	-6.13	-0.45	7.17e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg23033748	chr14:75592666	NEK9	-0.43	-5.46	-0.4	1.92e-7	Height;
PAAD	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg23024343	chr7:107201750	COG5	0.57	4.82	0.36	3.45e-6	Coronary artery disease;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08589981	chr10:22977154	PIP4K2A	-0.44	-4.79	-0.36	3.94e-6	Monocyte percentage of white cells;
PAAD	cis	rs9287719	0.649	rs6720112	chr2:10725719	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	1.01	14.17	0.75	1.34e-29	Heart rate;
PAAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.51	5.4	0.4	2.47e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.68	-6.18	-0.45	5.74e-9	Mean corpuscular volume;
PAAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.69	-6.32	-0.46	2.73e-9	DNA methylation (variation);
PAAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg01059385	chr22:42394853	WBP2NL	0.47	4.35	0.33	2.45e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs9397240	0.789	rs9371368	chr6:155551539	A/G	cg26934881	chr6:155569291	TIAM2	-0.57	-4.5	-0.34	1.34e-5	Life satisfaction;
PAAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	5.6	0.41	9.64e-8	LDL cholesterol;
PAAD	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.46	4.89	0.37	2.52e-6	Age of smoking initiation;
PAAD	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	6.3	0.46	3.04e-9	Personality dimensions;
PAAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg18209359	chr17:80159595	CCDC57	-0.48	-4.9	-0.37	2.48e-6	Life satisfaction;
PAAD	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg25200586	chr1:148000763	NA	-0.61	-6.38	-0.46	2.06e-9	Hip geometry;
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.74	8.65	0.57	6.91e-15	Lung cancer;
PAAD	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.45	-0.4	1.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs16975963	0.790	rs11083434	chr19:38283953	A/G	cg14218481	chr19:38281219	NA	0.44	4.6	0.35	8.92e-6	Longevity;
PAAD	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg10018233	chr7:150070692	REPIN1	0.61	6.53	0.47	9.07e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg23093090	chr10:104574429	C10orf26	-0.41	-4.25	-0.33	3.74e-5	Arsenic metabolism;
PAAD	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.84	-10.23	-0.64	5.07e-19	Coronary artery disease;
PAAD	cis	rs8112211	0.554	rs2302183	chr19:38853297	G/A	cg01275006	chr19:38876250	GGN	-0.98	-6.02	-0.44	1.27e-8	Blood protein levels;
PAAD	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg05935833	chr10:81318306	SFTPA2	-0.5	-4.3	-0.33	3.09e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.03	0.44	1.19e-8	Platelet count;
PAAD	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.52	-0.34	1.21e-5	Height;
PAAD	cis	rs7168353	0.500	rs4778100	chr15:93639244	G/T	cg12595281	chr15:93633172	RGMA	-0.4	-5.3	-0.4	3.98e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.51	-4.46	-0.34	1.56e-5	Multiple sclerosis;
PAAD	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.87	8.68	0.58	5.57e-15	Corneal astigmatism;
PAAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg13271783	chr10:134563150	INPP5A	-0.58	-5.94	-0.43	1.89e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6496932	1.000	rs34434405	chr15:85824668	G/T	cg19183879	chr15:85880815	NA	0.54	4.62	0.35	8.07e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs9487051	0.552	rs59272337	chr6:109638895	C/T	cg21918786	chr6:109611834	NA	-0.48	-5.33	-0.4	3.53e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-4.32	-0.33	2.83e-5	Chronic sinus infection;
PAAD	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-4.95	-0.37	1.97e-6	Bipolar disorder;
PAAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg00945038	chr17:61921165	SMARCD2	0.51	6.02	0.44	1.26e-8	Prudent dietary pattern;
PAAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.33e-7	Ulcerative colitis;
PAAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.53	-6.76	-0.48	2.71e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.62	-7.6	-0.52	2.85e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.63	-8.1	-0.55	1.67e-13	Multiple sclerosis;
PAAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.79	8.37	0.56	3.41e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.9	11.32	0.68	6.12e-22	Metabolic syndrome;
PAAD	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.95	9.58	0.61	2.7e-17	Corneal astigmatism;
PAAD	cis	rs4742903	0.967	rs10820610	chr9:106907819	G/A	cg14250997	chr9:106856677	SMC2	0.53	5.68	0.42	6.6e-8	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.54	7.25	0.51	1.99e-11	Renal cell carcinoma;
PAAD	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg05895507	chr15:77155635	SCAPER	0.41	5.09	0.38	1.06e-6	Blood metabolite levels;
PAAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	8.53	0.57	1.38e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.2	-0.39	6.27e-7	Triglycerides;
PAAD	cis	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg21546286	chr11:48923668	NA	0.57	5.97	0.44	1.63e-8	HDL cholesterol;
PAAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.79	8.0	0.54	2.92e-13	Tuberculosis;
PAAD	cis	rs1018697	1.000	rs7909612	chr10:104561456	G/A	cg04362960	chr10:104952993	NT5C2	0.6	6.16	0.45	6.28e-9	Colorectal adenoma (advanced);
PAAD	trans	rs4915077	1.000	rs2125747	chr1:108380533	G/C	cg18565342	chr10:124714098	C10orf88	-1.2	-6.4	-0.46	1.79e-9	Hypothyroidism;
PAAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	1.13	11.82	0.69	2.78e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs732765	0.734	rs2270424	chr14:75159007	G/A	cg17347104	chr14:75034677	LTBP2	0.62	5.33	0.4	3.49e-7	Non-small cell lung cancer;
PAAD	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.54	0.47	8.72e-10	Morning vs. evening chronotype;
PAAD	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.44	0.4	2.07e-7	Menarche (age at onset);
PAAD	cis	rs6681460	0.565	rs2147776	chr1:67107403	T/C	cg02459107	chr1:67143332	SGIP1	0.51	4.98	0.37	1.72e-6	Presence of antiphospholipid antibodies;
PAAD	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.73	-7.0	-0.49	7.68e-11	QRS duration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09623085	chr6:170471364	NA	-0.64	-6.59	-0.47	6.71e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg26513180	chr16:89883248	FANCA	-0.64	-7.4	-0.51	8.56e-12	Vitiligo;
PAAD	trans	rs61677309	1.000	rs55789743	chr11:118171949	C/A	cg15548380	chr1:19984784	NBL1	-0.64	-6.53	-0.47	9.25e-10	Lung cancer in ever smokers;
PAAD	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-5.23	-0.39	5.6e-7	Bipolar disorder;
PAAD	cis	rs630539	0.793	rs7225374	chr17:40817990	G/A	cg20669292	chr17:40823420	PLEKHH3	-0.47	-4.29	-0.33	3.15e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg21419209	chr3:44054225	NA	-0.74	-7.56	-0.52	3.46e-12	Coronary artery disease;
PAAD	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg13332499	chr17:408570	NA	0.65	7.05	0.5	5.79e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.38	-7.55	-0.52	3.66e-12	Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg06060754	chr5:176797920	RGS14	0.67	6.8	0.48	2.29e-10	Urate levels in lean individuals;
PAAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.92	7.68	0.53	1.77e-12	Psoriasis;
PAAD	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.26	9.88	0.63	4.27e-18	Corneal structure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19720079	chr12:117290980	RNFT2	-0.62	-6.56	-0.47	7.96e-10	Obesity-related traits;
PAAD	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	5.14	0.39	8.19e-7	Height;
PAAD	cis	rs2124910	0.815	rs7253637	chr19:52018717	A/C	cg14953197	chr19:52005651	SIGLEC12	-0.42	-4.59	-0.35	9.38e-6	Blood protein levels;
PAAD	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg01388757	chr2:102091195	RFX8	0.62	8.1	0.55	1.68e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.48	-4.72	-0.36	5.28e-6	Body mass index;
PAAD	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg26138144	chr22:38071188	LGALS1	0.41	4.63	0.35	7.92e-6	Fat distribution (HIV);
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.83	-12.12	-0.7	4.47e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.35	-0.33	2.44e-5	Tuberculosis;
PAAD	cis	rs2882667	0.690	rs9327830	chr5:138272249	T/C	cg09476006	chr5:138032270	NA	0.46	5.82	0.43	3.33e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.61	6.71	0.48	3.67e-10	Coronary artery disease;
PAAD	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-4.67	-0.35	6.51e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg00409905	chr10:38381863	ZNF37A	-0.59	-4.37	-0.33	2.33e-5	Obesity (extreme);
PAAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.44	4.71	0.36	5.55e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs151997	0.671	rs27281	chr5:50200764	C/T	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs12476592	0.530	rs12476786	chr2:64151723	C/T	cg10828910	chr2:63850056	LOC388955	-0.57	-4.65	-0.35	7.11e-6	Childhood ear infection;
PAAD	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg10370574	chr19:1840461	REXO1	-0.5	-4.64	-0.35	7.32e-6	Bipolar disorder;
PAAD	cis	rs35079168	0.735	rs3118541	chr9:137307147	C/T	cg00753924	chr9:137298813	RXRA	-0.52	-5.75	-0.42	4.63e-8	Intelligence;
PAAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.62	6.89	0.49	1.36e-10	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.91	-12.22	-0.7	2.41e-24	Body mass index;
PAAD	cis	rs56309584	0.710	rs7211247	chr17:8144153	T/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.45	-4.51	-0.34	1.3e-5	Initial pursuit acceleration;
PAAD	cis	rs9810890	1.000	rs73198815	chr3:128473832	C/G	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs959260	1.000	rs930299	chr17:73404668	A/C	cg20590849	chr17:73267439	MIF4GD	-0.53	-4.27	-0.33	3.49e-5	Systemic lupus erythematosus;
PAAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.8	0.66	1.53e-20	Menopause (age at onset);
PAAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg07559730	chr19:53497048	ZNF702P	-0.55	-5.98	-0.44	1.52e-8	Psoriasis;
PAAD	cis	rs364477	0.818	rs279892	chr9:970201	G/C	cg13952963	chr9:998547	NA	0.59	4.59	0.35	9.16e-6	Major depressive disorder;
PAAD	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.34e-7	Bipolar disorder;
PAAD	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.66	-0.48	4.73e-10	Retinal vascular caliber;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01655607	chr16:23464520	COG7	-0.57	-6.29	-0.45	3.23e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	5.52	0.41	1.42e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	8.93	0.59	1.34e-15	Menopause (age at onset);
PAAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.85	-0.43	2.86e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg19723775	chr5:179050963	HNRNPH1	-0.48	-4.4	-0.34	2.01e-5	Lung cancer;
PAAD	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.58	-0.65	5.97e-20	Heart rate;
PAAD	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10982213	1.000	rs3748174	chr9:117180008	C/T	cg00078025	chr9:117159975	NA	0.61	4.62	0.35	8.22e-6	Interleukin-6 levels;
PAAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.58	5.09	0.38	1.04e-6	Life satisfaction;
PAAD	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.71	-7.6	-0.52	2.88e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg21523528	chr20:32077966	CBFA2T2	0.59	4.53	0.34	1.2e-5	Height;
PAAD	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.7	-7.23	-0.51	2.15e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg12935359	chr14:103987150	CKB	-0.52	-5.56	-0.41	1.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2030114	1.000	rs11860186	chr16:51614839	G/A	cg03758633	chr16:51611768	NA	0.55	4.74	0.36	4.93e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.45	5.16	0.39	7.62e-7	Height;
PAAD	cis	rs863345	0.564	rs1418844	chr1:158457569	A/T	cg12129480	chr1:158549410	OR10X1	-0.42	-4.76	-0.36	4.39e-6	Pneumococcal bacteremia;
PAAD	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.41	4.75	0.36	4.66e-6	Schizophrenia;
PAAD	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.42	-4.42	-0.34	1.84e-5	IgG glycosylation;
PAAD	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-11.86	-0.69	2.25e-23	Primary sclerosing cholangitis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03530740	chr19:1619278	TCF3	-0.63	-6.72	-0.48	3.45e-10	Myopia (pathological);
PAAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04732357	chr2:96658324	NA	0.58	6.7	0.48	3.83e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.95	-0.49	1.02e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg01815783	chr4:1047043	NA	-0.41	-4.45	-0.34	1.68e-5	Recombination rate (males);
PAAD	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg26585981	chr11:48327164	OR4S1	0.48	4.29	0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg16602846	chr15:78114278	NA	-0.4	-4.29	-0.33	3.18e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.84	0.43	3.01e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.5	4.8	0.36	3.8e-6	Airway imaging phenotypes;
PAAD	cis	rs73252553	0.548	rs4697566	chr4:25313554	C/T	cg04009456	chr4:25379436	ANAPC4	0.4	4.49	0.34	1.39e-5	Cannabis dependence symptom count;
PAAD	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25310602	chr1:70687301	SFRS11	0.69	6.35	0.46	2.38e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14622017	chr9:89508657	NA	-0.59	-6.7	-0.48	3.88e-10	Obesity-related traits;
PAAD	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.5	6.16	0.45	6.37e-9	Sitting height ratio;
PAAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg02734326	chr4:10020555	SLC2A9	-0.51	-4.95	-0.37	1.95e-6	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg05272587	chr13:111038400	COL4A2	0.6	5.94	0.43	1.9e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.62	5.98	0.44	1.53e-8	Blood metabolite levels;
PAAD	cis	rs12714314	0.718	rs10167552	chr2:1952795	G/A	cg22350835	chr2:1868857	MYT1L	0.51	4.91	0.37	2.37e-6	Type 2 diabetes (age of onset);
PAAD	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-1.02	-10.08	-0.63	1.25e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.83	-9.36	-0.6	1.02e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs933117	0.892	rs363541	chr21:31060116	T/C	cg16812893	chr21:31813075	KRTAP15-1	-0.78	-4.29	-0.33	3.18e-5	Body mass index;
PAAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.44	0.46	1.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.73	5.6	0.41	9.82e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.78	7.76	0.53	1.17e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.46	4.88	0.37	2.69e-6	Lung cancer;
PAAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg05896524	chr21:47604654	C21orf56	0.47	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.53	-4.62	-0.35	8.09e-6	Testicular germ cell tumor;
PAAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.37	-0.33	2.34e-5	Breast cancer;
PAAD	cis	rs4654748	0.741	rs1106357	chr1:21817085	C/T	cg17800788	chr1:21766015	NBPF3	0.49	5.27	0.39	4.54e-7	Folate pathway vitamin levels;
PAAD	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg20799917	chr2:38894198	GALM	-0.49	-4.31	-0.33	2.9e-5	5-HTT brain serotonin transporter levels;
PAAD	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Colorectal cancer;
PAAD	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.74	-8.46	-0.57	2.08e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-4.71	-0.36	5.63e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.45	0.46	1.43e-9	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.61	5.85	0.43	2.92e-8	Menopause (age at onset);
PAAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg03934865	chr2:198174659	NA	-0.47	-4.67	-0.35	6.5e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg10494973	chr17:80897199	TBCD	0.57	4.77	0.36	4.25e-6	Breast cancer;
PAAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.87	-8.42	-0.56	2.68e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.98	-12.71	-0.72	1.1e-25	Coronary artery disease;
PAAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Vitiligo;
PAAD	cis	rs2992756	0.663	rs3007733	chr1:18800911	C/T	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.84	-5.15	-0.39	8e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.54	-0.47	8.64e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg17143192	chr8:8559678	CLDN23	0.63	5.92	0.43	2.07e-8	Obesity-related traits;
PAAD	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg05895507	chr15:77155635	SCAPER	-0.38	-4.29	-0.33	3.2e-5	Blood metabolite levels;
PAAD	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-6.94	-0.49	1.08e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1468333	0.897	rs2269957	chr5:137501396	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.4	0.46	1.87e-9	Resting heart rate;
PAAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg00579200	chr11:133705235	NA	-0.5	-5.65	-0.42	7.81e-8	Childhood ear infection;
PAAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-7.34	-0.51	1.22e-11	Personality dimensions;
PAAD	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg13263323	chr15:86062960	AKAP13	-0.61	-6.89	-0.49	1.4e-10	Coronary artery disease;
PAAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg03808351	chr9:123631620	PHF19	0.45	4.74	0.36	4.83e-6	Rheumatoid arthritis;
PAAD	cis	rs375066	0.935	rs398388	chr19:44425682	C/T	cg08633290	chr19:44405433	NA	-0.54	-5.39	-0.4	2.59e-7	Breast cancer;
PAAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg24760719	chr16:1790700	MAPK8IP3	0.47	4.34	0.33	2.56e-5	Mean corpuscular volume;
PAAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg04181038	chr4:183730758	NA	0.76	6.43	0.46	1.54e-9	Pediatric autoimmune diseases;
PAAD	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7824557	0.679	rs13279067	chr8:11135828	A/G	cg21775007	chr8:11205619	TDH	-0.58	-5.13	-0.38	8.8e-7	Retinal vascular caliber;
PAAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.55	5.26	0.39	4.85e-7	Height;
PAAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23519803	chr6:108845846	NA	-0.52	-6.33	-0.46	2.6e-9	Monocyte percentage of white cells;
PAAD	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.52	-4.95	-0.37	1.92e-6	Facial morphology (factor 20);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16618282	chr3:47018402	CCDC12	0.67	7.87	0.54	6.14e-13	Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.66	-5.85	-0.43	2.95e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	6.53	0.47	9.26e-10	Systemic lupus erythematosus;
PAAD	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg22875332	chr1:76189707	ACADM	-0.48	-4.77	-0.36	4.22e-6	Daytime sleep phenotypes;
PAAD	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.63	-8.01	-0.54	2.82e-13	Monocyte percentage of white cells;
PAAD	cis	rs6074578	0.679	rs11087791	chr20:140506	A/G	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.71	-4.84	-0.37	3.17e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-7.17	-0.5	3.06e-11	Colorectal cancer;
PAAD	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.9	7.19	0.5	2.75e-11	Chronic kidney disease;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.5	-5.34	-0.4	3.27e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg04154034	chr17:28927549	LRRC37B2	0.62	4.35	0.33	2.48e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13006833	0.739	rs12693568	chr2:191202637	A/G	cg27211696	chr2:191398769	TMEM194B	0.46	4.54	0.35	1.16e-5	Urinary metabolites;
PAAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.86	-4.78	-0.36	4.18e-6	Skin colour saturation;
PAAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.95	12.28	0.71	1.65e-24	Menopause (age at onset);
PAAD	cis	rs787274	0.867	rs786969	chr9:115449556	C/G	cg13803584	chr9:115635662	SNX30	0.74	4.25	0.33	3.65e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.68	-0.36	6.18e-6	Eotaxin levels;
PAAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.15	-0.45	6.48e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02543470	chr2:105862877	NA	-0.51	-4.92	-0.37	2.18e-6	Obesity-related traits;
PAAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.63e-8	Prostate cancer;
PAAD	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.36	-0.33	2.39e-5	Asthma (childhood onset);
PAAD	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12476592	0.563	rs78030021	chr2:64201422	C/A	cg20249169	chr2:64881356	SERTAD2	-0.52	-4.34	-0.33	2.62e-5	Childhood ear infection;
PAAD	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg08886695	chr4:3369023	RGS12	0.51	5.09	0.38	1.03e-6	Mean platelet volume;
PAAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs593531	0.513	rs7930193	chr11:74031557	G/T	cg15670924	chr11:73669256	DNAJB13	0.47	5.18	0.39	6.8e-7	Neuroticism;
PAAD	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.78	-7.06	-0.5	5.46e-11	Body mass index (adult);
PAAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg11143131	chr5:131608246	PDLIM4	-0.48	-4.51	-0.34	1.27e-5	Breast cancer;
PAAD	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg27490568	chr2:178487706	NA	-0.45	-4.86	-0.37	2.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	10.92	0.66	7.55e-21	Prudent dietary pattern;
PAAD	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.62	-0.47	5.68e-10	Systolic blood pressure;
PAAD	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.74	8.39	0.56	3.2e-14	Corneal astigmatism;
PAAD	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg20487152	chr13:99095054	FARP1	0.62	5.41	0.4	2.43e-7	Neuroticism;
PAAD	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.81	8.62	0.57	7.99e-15	Prostate cancer;
PAAD	cis	rs35160687	0.644	rs1863056	chr2:86491245	C/T	cg10973622	chr2:86423274	IMMT	-0.48	-5.35	-0.4	3.19e-7	Night sleep phenotypes;
PAAD	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg17767596	chr6:27861570	HIST1H2AM;HIST1H2BO	0.48	4.34	0.33	2.57e-5	Depression;
PAAD	cis	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg15676455	chr3:128564943	NA	-0.8	-4.6	-0.35	8.88e-6	Dental caries;
PAAD	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-4.42	-0.34	1.89e-5	Morning vs. evening chronotype;
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs375066	0.935	rs387689	chr19:44420111	C/T	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.88	-7.53	-0.52	4.18e-12	Bronchopulmonary dysplasia;
PAAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg19413350	chr8:57351067	NA	0.49	4.95	0.37	1.99e-6	Obesity-related traits;
PAAD	trans	rs7569716	0.640	rs6749647	chr2:22618537	A/C	cg03186962	chr2:594612	NA	-0.72	-6.39	-0.46	1.95e-9	Chronic obstructive pulmonary disease (moderate to severe);
PAAD	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.24	0.6	2.01e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.55	5.46	0.4	1.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.01	-11.78	-0.69	3.62e-23	Cognitive ability;
PAAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg19192590	chr2:178524533	PDE11A	0.39	4.49	0.34	1.4e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg08992911	chr2:238395768	MLPH	0.68	5.67	0.42	7.09e-8	Prostate cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27308557	chr20:56284912	PMEPA1	-0.64	-6.33	-0.46	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg02910952	chr12:132569714	EP400NL	0.62	4.84	0.37	3.2e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06850241	chr22:41845214	NA	-0.61	-5.3	-0.39	4.03e-7	Vitiligo;
PAAD	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs914615	0.552	rs4971088	chr1:155142883	T/A	cg18645493	chr1:154167437	MIR190B	0.46	4.52	0.34	1.25e-5	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs367943	0.712	rs9326884	chr5:112697520	C/A	cg12552261	chr5:112820674	MCC	0.65	6.35	0.46	2.41e-9	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg15117754	chr3:10150083	C3orf24	0.73	6.33	0.46	2.63e-9	Alzheimer's disease;
PAAD	cis	rs7873102	0.654	rs10115992	chr9:37962583	C/A	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	8.05e-8	Brain structure;
PAAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.45	6.28	0.45	3.44e-9	Cardiovascular disease risk factors;
PAAD	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.43	-6.73	-0.48	3.19e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.76	9.91	0.63	3.71e-18	Cancer;
PAAD	cis	rs253959	0.883	rs7708765	chr5:115714698	T/C	cg05931423	chr5:115697214	NA	-0.45	-4.28	-0.33	3.36e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs6445967	0.966	rs9857570	chr3:58280690	A/G	cg23715586	chr3:58305044	RPP14	0.52	4.61	0.35	8.34e-6	Platelet count;
PAAD	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.79	8.16	0.55	1.18e-13	Corneal astigmatism;
PAAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16447950	chr5:562315	NA	-0.67	-5.96	-0.43	1.73e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.85	-9.86	-0.62	5.04e-18	Ulcerative colitis;
PAAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	6.3	0.46	3.03e-9	Initial pursuit acceleration;
PAAD	cis	rs1012068	0.961	rs5994441	chr22:32266546	A/T	cg01338084	chr22:32026380	PISD	0.56	4.99	0.38	1.63e-6	Chronic hepatitis C infection;
PAAD	cis	rs9488822	0.702	rs540981	chr6:116266592	A/G	cg18764771	chr6:116381957	FRK	-0.26	-4.25	-0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg08079166	chr15:68083412	MAP2K5	-0.54	-4.99	-0.38	1.64e-6	Restless legs syndrome;
PAAD	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.53	-5.15	-0.39	8.02e-7	Body mass index;
PAAD	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs1198430	0.683	rs1198440	chr1:23780861	C/A	cg27447006	chr1:23763279	ASAP3	0.65	5.02	0.38	1.4e-6	Total cholesterol levels;
PAAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.75	-7.22	-0.51	2.27e-11	Monocyte count;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01959412	chr4:4861398	MSX1	0.59	6.86	0.49	1.65e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.75	-8.77	-0.58	3.34e-15	Lung function (FVC);
PAAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg09796270	chr17:17721594	SREBF1	0.45	4.66	0.35	6.74e-6	Total body bone mineral density;
PAAD	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-8.18	-0.55	1.07e-13	Urinary metabolites;
PAAD	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg00262122	chr8:11665843	FDFT1	0.54	4.97	0.37	1.75e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.7	-9.79	-0.62	7.51e-18	Birth weight;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.02	0.55	2.57e-13	Prudent dietary pattern;
PAAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7765175	0.598	rs2842840	chr6:113630776	C/G	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg01765077	chr12:122356316	WDR66	0.6	6.23	0.45	4.29e-9	Mean corpuscular volume;
PAAD	cis	rs9361491	0.608	rs9352628	chr6:79457447	T/G	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg09491104	chr22:46646882	C22orf40	-0.71	-4.27	-0.33	3.47e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.37	-0.46	2.11e-9	Capecitabine sensitivity;
PAAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.98	12.48	0.71	4.79e-25	Age-related hearing impairment;
PAAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19346786	chr7:2764209	NA	-0.37	-5.09	-0.38	1.04e-6	Height;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.7	-0.42	5.97e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26334671	chr3:172037094	FNDC3B	-0.61	-6.45	-0.46	1.42e-9	Obesity-related traits;
PAAD	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-11.22	-0.67	1.13e-21	Height;
PAAD	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.33	-0.46	2.67e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs1146751	0.674	rs1248820	chr3:84931323	T/C	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg19257562	chr1:2043853	PRKCZ	0.47	5.78	0.42	4.16e-8	Height;
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.79	6.01	0.44	1.3e-8	Lung function (FEV1/FVC);
PAAD	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg18984983	chr10:135342936	CYP2E1	0.46	4.3	0.33	3.01e-5	Gout;
PAAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg05082376	chr22:42548792	NA	-0.54	-5.13	-0.38	8.86e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs1355223	0.867	rs7943755	chr11:34691451	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.46	-4.72	-0.36	5.33e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	4.36	0.33	2.41e-5	Hip circumference;
PAAD	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg22143635	chr11:980567	AP2A2	0.53	5.53	0.41	1.36e-7	Alzheimer's disease (late onset);
PAAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg03983715	chr16:68378420	PRMT7	-0.55	-4.26	-0.33	3.54e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg12126869	chr10:346505	DIP2C	-0.79	-4.33	-0.33	2.65e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.36	0.4	3.02e-7	Rheumatoid arthritis;
PAAD	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.47	5.29	0.39	4.19e-7	Electroencephalogram traits;
PAAD	cis	rs77216612	0.877	rs72656645	chr12:12881055	A/G	cg04607235	chr12:12878440	APOLD1	-1.04	-11.41	-0.68	3.63e-22	Lymphocyte counts;
PAAD	cis	rs6893807	0.778	rs7721099	chr5:87936379	A/G	cg02225085	chr5:87975992	LOC645323	-0.66	-4.76	-0.36	4.42e-6	Body mass index;
PAAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.88	9.63	0.62	2.03e-17	Cognitive function;
PAAD	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.83	7.85	0.54	6.94e-13	Corneal astigmatism;
PAAD	cis	rs1144333	0.655	rs3765682	chr1:76333172	T/C	cg22875332	chr1:76189707	ACADM	0.77	4.73	0.36	5.08e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg03700679	chr2:178418002	TTC30B	-0.5	-4.33	-0.33	2.74e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.6	-5.81	-0.43	3.62e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.72	-11.01	-0.67	4.31e-21	Longevity;Endometriosis;
PAAD	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg02580895	chr19:2754563	NA	-0.51	-4.42	-0.34	1.88e-5	Total cholesterol levels;
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.8	-0.43	3.64e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg26939375	chr7:64535504	NA	0.78	9.27	0.6	1.74e-16	Aortic root size;
PAAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	9.44	0.61	6.34e-17	Total body bone mineral density;
PAAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.98	13.14	0.73	7.86e-27	Menarche (age at onset);
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.84	10.29	0.64	3.64e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg10006428	chr1:248814059	OR2T27	0.36	4.38	0.34	2.16e-5	Common traits (Other);
PAAD	cis	rs868943	0.714	rs13216178	chr6:116392629	T/G	cg26893134	chr6:116381904	FRK	0.32	5.19	0.39	6.7e-7	Total cholesterol levels;
PAAD	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.96	8.44	0.56	2.32e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg01489032	chr8:143877656	NA	-0.39	-4.44	-0.34	1.7e-5	Urinary tract infection frequency;
PAAD	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.5	-4.31	-0.33	2.9e-5	Resting heart rate;
PAAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-7.83	-0.54	7.74e-13	Vitiligo;
PAAD	cis	rs58521262	0.585	rs440580	chr19:23121679	T/C	cg22640819	chr19:22990650	NA	-0.29	-4.35	-0.33	2.47e-5	Testicular germ cell tumor;
PAAD	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.75	8.45	0.57	2.21e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.37	-0.33	2.32e-5	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.76	7.21	0.5	2.52e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-9.23	-0.6	2.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs225245	0.694	rs321616	chr17:33882720	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.23	0.39	5.54e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	5.19	0.39	6.68e-7	Mood instability;
PAAD	cis	rs1879734	0.636	rs6658137	chr1:54188994	T/C	cg14659662	chr1:54151053	GLIS1	-0.32	-4.55	-0.35	1.08e-5	Mitral valve prolapse;
PAAD	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.18	0.6	2.9e-16	Bipolar disorder;
PAAD	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.64	5.71	0.42	5.84e-8	Menarche (age at onset);
PAAD	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.73	7.3	0.51	1.5e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.72	11.23	0.67	1.09e-21	Breast cancer;
PAAD	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-7.37	-0.51	1.02e-11	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg00531865	chr16:30841666	NA	-0.62	-5.32	-0.4	3.59e-7	Multiple myeloma;
PAAD	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22128300	chr6:26018559	HIST1H1A	-0.59	-6.37	-0.46	2.11e-9	Obesity-related traits;
PAAD	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.76	6.06	0.44	1.01e-8	Neutrophil percentage of white cells;
PAAD	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.8	9.3	0.6	1.48e-16	Metabolic syndrome;
PAAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	4.34	0.33	2.57e-5	Platelet count;
PAAD	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.51	4.38	0.33	2.18e-5	Depression;
PAAD	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-7.08	-0.5	4.9e-11	Colorectal cancer;
PAAD	cis	rs144250387	1	rs144250387	chr10:16966414	GA/G	cg00939682	chr10:16933505	CUBN	0.62	4.76	0.36	4.52e-6	Urinary albumin-to-creatinine ratio;
PAAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27094323	chr7:1216898	NA	-0.52	-6.26	-0.45	3.71e-9	Longevity;Endometriosis;
PAAD	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg00601450	chr5:74908170	NA	-0.47	-4.4	-0.34	1.99e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs876084	0.505	rs4336644	chr8:121136128	G/C	cg06265175	chr8:121136014	COL14A1	0.46	4.49	0.34	1.39e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg21395723	chr22:39101663	GTPBP1	0.42	4.44	0.34	1.71e-5	Menopause (age at onset);
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg07677032	chr17:61819896	STRADA	0.45	4.33	0.33	2.68e-5	Height;
PAAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.59	5.21	0.39	5.96e-7	Initial pursuit acceleration;
PAAD	cis	rs2659067	1.000	rs2659067	chr19:51485622	A/G	cg19471655	chr19:51487109	KLK7	-0.96	-5.57	-0.41	1.11e-7	Blood protein levels;
PAAD	trans	rs3733631	1.000	rs6533106	chr4:104596455	A/G	cg21490444	chr5:171095097	NA	0.77	6.29	0.45	3.16e-9	Menarche (age at onset);
PAAD	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.68	7.51	0.52	4.63e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.4	-5.02	-0.38	1.44e-6	Electrocardiographic conduction measures;
PAAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg16341495	chr8:142228727	SLC45A4	-0.57	-5.62	-0.41	9.06e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.63	-8.03	-0.55	2.51e-13	Body mass index;
PAAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg01075559	chr1:2537774	MMEL1	0.51	5.3	0.39	4.07e-7	Multiple sclerosis;
PAAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg02961798	chr16:67687392	RLTPR	-0.39	-4.36	-0.33	2.37e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg00280220	chr17:61926910	NA	0.45	4.69	0.36	6.17e-6	Prudent dietary pattern;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.86	-9.72	-0.62	1.17e-17	Migraine;
PAAD	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.99	-0.54	3.09e-13	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg11779900	chr17:80519722	FOXK2	0.45	4.67	0.35	6.51e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg24829409	chr8:58192753	C8orf71	0.61	5.84	0.43	2.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg04160749	chr8:58172571	NA	-0.63	-4.5	-0.34	1.35e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	6.6	0.47	6.49e-10	IgG glycosylation;
PAAD	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26876637	chr1:152193138	HRNR	-0.87	-6.96	-0.49	9.64e-11	Atopic dermatitis;
PAAD	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg22852734	chr6:133119734	C6orf192	0.99	4.41	0.34	1.96e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.43	4.69	0.36	6.05e-6	Post-traumatic stress disorder;
PAAD	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.72	-5.77	-0.42	4.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.57	-0.41	1.12e-7	Lung cancer;
PAAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1018697	1.000	rs7911528	chr10:104551567	A/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.81e-5	Colorectal adenoma (advanced);
PAAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg14343924	chr8:8086146	FLJ10661	0.54	4.88	0.37	2.69e-6	Mood instability;
PAAD	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	1.06	14.45	0.76	2.55e-30	Headache;
PAAD	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.8	7.13	0.5	3.75e-11	Exhaled nitric oxide levels;
PAAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13126279	chr21:47581558	C21orf56	-0.41	-4.57	-0.35	1.01e-5	Testicular germ cell tumor;
PAAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.65e-17	Lymphocyte counts;
PAAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.67	-0.35	6.51e-6	Lung cancer;
PAAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.53	-5.16	-0.39	7.54e-7	Acylcarnitine levels;
PAAD	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs4917300	0.647	rs13272465	chr8:143120934	C/T	cg26003909	chr8:143102224	NA	-0.33	-5.31	-0.4	3.84e-7	Amyotrophic lateral sclerosis;
PAAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg11508406	chr4:1595515	NA	0.42	4.39	0.34	2.07e-5	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-6.97	-0.49	8.89e-11	Gut microbiome composition (summer);
PAAD	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.66	-5.44	-0.4	2.1e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg09854653	chr6:163834903	QKI	-0.69	-4.31	-0.33	2.87e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg21496419	chr19:44306685	LYPD5	0.39	4.97	0.37	1.76e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg16898833	chr6:26189333	HIST1H4D	0.52	4.27	0.33	3.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg21401794	chr1:90099060	LRRC8C	0.6	5.72	0.42	5.54e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.83	6.75	0.48	2.89e-10	Vitiligo;
PAAD	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.73	-5.97	-0.44	1.58e-8	Schizophrenia;
PAAD	cis	rs13185784	1.000	rs13185784	chr5:179694068	G/A	cg23221052	chr5:179740743	GFPT2	0.52	4.38	0.33	2.24e-5	TRAIL levels;
PAAD	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-4.57	-0.35	9.91e-6	Vitiligo;
PAAD	cis	rs9942416	0.533	rs12109685	chr5:75024066	A/G	cg07025548	chr5:74632477	HMGCR	-0.57	-4.36	-0.33	2.36e-5	Age-related disease endophenotypes;
PAAD	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6693295	0.887	rs2787993	chr1:246231383	A/G	cg26013412	chr1:247094486	AHCTF1	-0.64	-4.56	-0.35	1.06e-5	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-8.05	-0.55	2.18e-13	Systemic lupus erythematosus;
PAAD	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.83	-0.43	3.16e-8	QT interval;
PAAD	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	5.85	0.43	2.88e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.56	-5.62	-0.41	9.06e-8	Height;
PAAD	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	1.0	6.77	0.48	2.58e-10	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg11619707	chr19:22235551	ZNF257	0.58	5.74	0.42	4.99e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.68	7.47	0.52	5.85e-12	Morning vs. evening chronotype;
PAAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.63	-6.35	-0.46	2.4e-9	Multiple sclerosis;
PAAD	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg02640540	chr1:67518911	SLC35D1	0.61	4.83	0.37	3.24e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.48	4.83	0.37	3.25e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08886695	chr4:3369023	RGS12	-0.48	-4.65	-0.35	7.01e-6	Serum sulfate level;
PAAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.77e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08886695	chr4:3369023	RGS12	-0.52	-5.06	-0.38	1.22e-6	Serum sulfate level;
PAAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.6e-9	Childhood ear infection;
PAAD	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.79	0.36	4e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.88	-7.16	-0.5	3.16e-11	Psoriasis;
PAAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg10494973	chr17:80897199	TBCD	-0.59	-4.93	-0.37	2.09e-6	Breast cancer;
PAAD	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.82	-8.37	-0.56	3.45e-14	Corneal astigmatism;
PAAD	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.57	5.47	0.41	1.77e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.63	5.98	0.44	1.54e-8	Systolic blood pressure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27178948	chr12:48515787	PFKM	-0.53	-6.33	-0.46	2.62e-9	Monocyte percentage of white cells;
PAAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.45	-6.27	-0.45	3.59e-9	Height;
PAAD	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-12.69	-0.72	1.3e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg20821713	chr7:1055600	C7orf50	-0.38	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.42	-4.25	-0.33	3.68e-5	Adiposity;
PAAD	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.08	16.0	0.79	2.04e-34	Chronic sinus infection;
PAAD	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.33	10.95	0.66	6.13e-21	Uric acid levels;
PAAD	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.71	7.14	0.5	3.69e-11	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg16898833	chr6:26189333	HIST1H4D	0.63	4.76	0.36	4.41e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg05110241	chr16:68378359	PRMT7	-0.82	-6.79	-0.48	2.35e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg13918804	chr1:2043761	PRKCZ	0.4	5.37	0.4	2.85e-7	Height;
PAAD	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	0.84	10.15	0.64	8.39e-19	Breast cancer;
PAAD	cis	rs427941	1.000	rs10270614	chr7:101837744	C/T	cg06721601	chr7:101762633	CUX1	0.43	4.55	0.35	1.07e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05375405	chr1:156711303	MRPL24	0.61	6.72	0.48	3.36e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22219255	chr6:106525493	NA	0.59	6.72	0.48	3.46e-10	Smoking initiation;
PAAD	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg08614441	chr13:113633676	MCF2L	-0.43	-4.32	-0.33	2.76e-5	Systolic blood pressure;
PAAD	cis	rs16975963	0.843	rs2382624	chr19:38419025	A/G	cg14218481	chr19:38281219	NA	0.48	5.01	0.38	1.49e-6	Longevity;
PAAD	trans	rs1483035	0.623	rs5028604	chr4:156463239	T/C	cg00585174	chr10:134499472	INPP5A	0.5	6.76	0.48	2.8e-10	Influenza A (H1N1) severity;
PAAD	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.45	0.34	1.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg02887458	chr19:19495540	GATAD2A	-0.52	-4.81	-0.36	3.63e-6	Bipolar disorder;
PAAD	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	7.29	0.51	1.59e-11	IgG glycosylation;
PAAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.52	0.47	9.56e-10	Coronary artery disease;
PAAD	cis	rs2070677	0.799	rs3020498	chr10:135379710	A/C	cg08390786	chr10:135334061	NA	-0.66	-5.53	-0.41	1.37e-7	Gout;
PAAD	cis	rs3136739	0.614	rs1136159	chr8:42036577	A/G	cg17828057	chr8:42037527	PLAT	0.7	4.84	0.37	3.19e-6	Plasma plasminogen activator levels;
PAAD	cis	rs1018697	0.897	rs2150929	chr10:104550937	T/A	cg14489801	chr10:103603810	KCNIP2	-0.3	-4.33	-0.33	2.64e-5	Colorectal adenoma (advanced);
PAAD	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg10932868	chr11:921992	NA	0.53	6.28	0.45	3.45e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg17031739	chr1:67600172	NA	0.42	4.29	0.33	3.16e-5	Psoriasis;
PAAD	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.63	7.03	0.5	6.49e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.85	6.94	0.49	1.04e-10	Pulmonary function decline;
PAAD	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.65	-6.15	-0.45	6.44e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6011674	0.808	rs56946612	chr20:61849265	T/G	cg12207022	chr20:61734930	HAR1A;HAR1B	0.67	4.29	0.33	3.19e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.75	8.04	0.55	2.4e-13	Blood protein levels;
PAAD	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.1e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.43	6.53	0.47	9.3e-10	Cutaneous nevi;
PAAD	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg12037450	chr1:85513124	MCOLN3	-0.48	-4.56	-0.35	1.05e-5	Serum sulfate level;
PAAD	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg10011062	chr15:43941034	CATSPER2	-0.87	-5.29	-0.39	4.16e-7	Lung cancer in ever smokers;
PAAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.92	-8.9	-0.59	1.58e-15	Asthma;
PAAD	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg07810366	chr2:100720526	AFF3	-0.38	-4.74	-0.36	4.78e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg08601574	chr20:25228251	PYGB	0.57	5.71	0.42	5.9e-8	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.41	5.17	0.39	7.32e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.55	-0.35	1.08e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	trans	rs11794666	0.929	rs7024213	chr9:31797878	T/A	cg05628366	chr6:35744188	C6orf126	1.12	7.41	0.52	8.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg14146966	chr2:61757674	XPO1	-0.37	-4.78	-0.36	4.18e-6	Tuberculosis;
PAAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.42	5.02	0.38	1.4e-6	Psoriasis;
PAAD	cis	rs2147959	0.831	rs7555386	chr1:228630589	C/G	cg00655913	chr1:228633920	NA	0.51	4.65	0.35	7.14e-6	Adult asthma;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg13264159	chr8:625131	ERICH1	-0.74	-4.82	-0.36	3.5e-6	IgG glycosylation;
PAAD	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg03910582	chr17:19030146	GRAPL	0.45	4.37	0.33	2.28e-5	Schizophrenia;
PAAD	cis	rs1499972	0.941	rs1456182	chr3:117659680	C/T	cg07612923	chr3:117604196	NA	1.09	6.96	0.49	9.61e-11	Schizophrenia;
PAAD	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs113835537	0.877	rs2275998	chr11:66326581	T/C	cg22134325	chr11:66188745	NPAS4	0.4	5.04	0.38	1.28e-6	Airway imaging phenotypes;
PAAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22442454	chr1:209979470	IRF6	0.59	5.52	0.41	1.41e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.53	-0.65	8.1e-20	Total body bone mineral density;
PAAD	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17718515	chr1:201798817	IPO9	0.6	7.04	0.5	6.3e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg23587288	chr2:27483067	SLC30A3	-0.85	-7.5	-0.52	4.83e-12	Blood metabolite levels;
PAAD	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.51	-5.4	-0.4	2.51e-7	Psychosis in Alzheimer's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11838688	chr11:133907229	LOC100128239	-0.69	-6.86	-0.49	1.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12580194	0.593	rs59466585	chr12:55722736	T/G	cg06899799	chr12:56650233	ANKRD52	0.33	4.29	0.33	3.12e-5	Cancer;
PAAD	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-5.0	-0.38	1.59e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs2274459	1.000	rs12199132	chr6:33708250	G/A	cg06253072	chr6:33679850	C6orf125	0.61	4.67	0.35	6.61e-6	Obesity (extreme);
PAAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.63	5.64	0.42	8.17e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg16606324	chr3:10149918	C3orf24	0.71	5.53	0.41	1.39e-7	Alzheimer's disease;
PAAD	cis	rs34311866	0.577	rs6829197	chr4:971021	G/C	cg07828340	chr4:882639	GAK	0.83	6.65	0.47	4.94e-10	Parkinson's disease;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.56	0.35	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg13741927	chr9:139327495	INPP5E	0.48	4.58	0.35	9.65e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.82	-9.57	-0.61	2.8e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.68	-7.84	-0.54	7.4e-13	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01765077	chr12:122356316	WDR66	0.68	7.02	0.49	6.97e-11	Mean corpuscular volume;
PAAD	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.81	9.61	0.61	2.19e-17	Morning vs. evening chronotype;
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.93	0.49	1.13e-10	Menarche (age at onset);
PAAD	cis	rs427941	0.585	rs201511	chr7:101767653	A/G	cg06246474	chr7:101738831	CUX1	0.43	4.26	0.33	3.52e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg05562828	chr17:3906858	NA	-0.61	-6.9	-0.49	1.3100000000000001e-10	Type 2 diabetes;
PAAD	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg15445000	chr17:37608096	MED1	-0.43	-4.62	-0.35	8.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9558996	0.857	rs9558994	chr13:107937131	G/A	cg09252360	chr13:107220595	ARGLU1	0.57	4.34	0.33	2.62e-5	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg09127314	chr1:152161683	NA	-0.69	-5.04	-0.38	1.31e-6	Atopic dermatitis;
PAAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.67	-6.1	-0.44	8.52e-9	IgG glycosylation;
PAAD	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg09127314	chr1:152161683	NA	-0.63	-4.36	-0.33	2.42e-5	Atopic dermatitis;
PAAD	cis	rs441460	0.508	rs3804102	chr6:25617445	A/G	cg22949743	chr6:24646473	KIAA0319	0.42	4.32	0.33	2.77e-5	Platelet count;
PAAD	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.4	-0.46	1.8e-9	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg14709524	chr16:89940631	TCF25	0.76	4.35	0.33	2.51e-5	Skin colour saturation;
PAAD	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.47	4.87	0.37	2.8e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.51	-4.85	-0.37	3.05e-6	Acylcarnitine levels;
PAAD	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg17201900	chr20:34330562	RBM39	0.62	4.25	0.33	3.74e-5	Total cholesterol levels;
PAAD	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs72960926	0.590	rs78950961	chr6:74745847	T/C	cg03266952	chr6:74778945	NA	-1.08	-7.07	-0.5	5.15e-11	Metabolite levels (MHPG);
PAAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.74	7.99	0.54	3.12e-13	Total body bone mineral density;
PAAD	cis	rs9463078	0.565	rs1797161	chr6:45150221	T/A	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.41	5.03	0.38	1.35e-6	Pulmonary function;
PAAD	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Neuroticism;
PAAD	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	5.06	0.38	1.2e-6	Mean platelet volume;
PAAD	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-1.04	-11.01	-0.67	4.19e-21	Platelet distribution width;
PAAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.5	4.41	0.34	1.97e-5	Height;
PAAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.91	11.46	0.68	2.57e-22	Methadone dose in opioid dependence;
PAAD	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.54	0.52	3.93e-12	Alzheimer's disease;
PAAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.92	-11.79	-0.69	3.32e-23	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01822785	chr5:55032703	DDX4	-0.66	-6.83	-0.48	1.93e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg07701084	chr6:150067640	NUP43	0.6	5.15	0.39	8.08e-7	Lung cancer;
PAAD	cis	rs12979813	1.000	rs10406522	chr19:11341635	T/C	cg08405405	chr19:11485325	C19orf39	-0.62	-4.49	-0.34	1.4e-5	HDL cholesterol;
PAAD	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.66	6.41	0.46	1.7e-9	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73198901	chr3:128566520	G/A	cg18531004	chr3:128564980	NA	-0.91	-4.89	-0.37	2.51e-6	Dental caries;
PAAD	cis	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.5	4.81	0.36	3.66e-6	Resistin levels;
PAAD	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg06197492	chr11:2016605	H19	0.51	5.88	0.43	2.46e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	5.5	0.41	1.56e-7	Iron status biomarkers;
PAAD	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg03386751	chr17:37843793	ERBB2;PGAP3	0.36	5.09	0.38	1.05e-6	Asthma;
PAAD	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.61	6.0	0.44	1.41e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10067182	chr2:239974554	HDAC4	0.61	6.97	0.49	9.06e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.62e-6	Iron status biomarkers;
PAAD	cis	rs2085601	0.542	rs2704601	chr4:89980580	C/A	cg17769793	chr4:89976368	FAM13A	0.44	5.5	0.41	1.6e-7	Hair greying;
PAAD	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.79	8.62	0.57	8.14e-15	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-4.83	-0.36	3.26e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg15676125	chr6:33679581	C6orf125	-0.49	-4.65	-0.35	7.23e-6	Plateletcrit;
PAAD	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs2019872	1.000	rs2019872	chr17:2010318	C/T	cg15816464	chr17:2026533	SMG6	0.55	4.75	0.36	4.65e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.89	11.24	0.67	1e-21	Prudent dietary pattern;
PAAD	cis	rs10490913	1.000	rs10490913	chr10:120154436	T/C	cg04126427	chr10:120840676	EIF3A	-0.47	-4.85	-0.37	3.07e-6	Cancer;
PAAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg15693483	chr7:1102177	C7orf50	0.45	5.05	0.38	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7631605	0.905	rs7634972	chr3:37205716	C/T	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.44	-5.17	-0.39	7.29e-7	Mean arterial pressure;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.88	5.78	0.42	4.05e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16414030	chr3:133502952	NA	0.41	4.29	0.33	3.2e-5	Iron status biomarkers;
PAAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-1.04	-17.03	-0.81	4.78e-37	Height;
PAAD	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.86	-9.55	-0.61	3.15e-17	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09561419	chr16:57055798	NLRC5	-0.62	-6.48	-0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg14458575	chr2:238380390	NA	0.57	4.85	0.37	3.03e-6	Prostate cancer;
PAAD	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.53	-5.13	-0.38	8.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	4.65	0.35	7.04e-6	Testicular germ cell tumor;
PAAD	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-10.2	-0.64	6.32e-19	Electrocardiographic conduction measures;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.27	0.39	4.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.45	-4.51	-0.34	1.31e-5	Crohn's disease;
PAAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.88	10.97	0.66	5.31e-21	Prudent dietary pattern;
PAAD	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.03	-10.86	-0.66	1.06e-20	Ulcerative colitis;
PAAD	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	4.28	0.33	3.34e-5	Vitiligo;
PAAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg15181151	chr6:150070149	PCMT1	0.59	6.36	0.46	2.21e-9	Lung cancer;
PAAD	cis	rs730566	0.619	rs3731529	chr3:48213498	A/T	cg21581415	chr3:47460784	SCAP	-0.55	-4.64	-0.35	7.34e-6	Prion diseases;
PAAD	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.74	-5.81	-0.43	3.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.51	-5.16	-0.39	7.68e-7	Number of children ever born;
PAAD	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.64	5.84	0.43	3.06e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.41	5.5	0.41	1.58e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg17470449	chr10:769945	NA	0.52	5.16	0.39	7.72e-7	Uric acid levels;
PAAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.76	7.82	0.54	8.11e-13	Menarche (age at onset);
PAAD	cis	rs35160687	0.644	rs1863058	chr2:86509267	G/A	cg10973622	chr2:86423274	IMMT	-0.45	-4.98	-0.37	1.7e-6	Night sleep phenotypes;
PAAD	cis	rs8077577	0.747	rs11869582	chr17:18136581	G/A	cg16794390	chr17:18148240	FLII	0.58	4.73	0.36	5.16e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08677398	chr8:58056175	NA	0.68	4.66	0.35	6.99e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg00700412	chr12:58011837	NA	0.41	4.41	0.34	1.92e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg19744528	chr7:157553346	PTPRN2	-0.4	-4.27	-0.33	3.44e-5	Body mass index;
PAAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26549601	chr10:134560360	INPP5A	-0.46	-4.76	-0.36	4.53e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg26618903	chr10:100175079	PYROXD2	0.38	4.4	0.34	2.02e-5	Metabolite levels;
PAAD	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs2124910	0.717	rs9304718	chr19:52011930	A/G	cg14953197	chr19:52005651	SIGLEC12	-0.45	-4.94	-0.37	2.06e-6	Blood protein levels;
PAAD	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg02367709	chr17:66097352	LOC651250	0.43	4.43	0.34	1.82e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.62	6.59	0.47	6.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.77	7.42	0.52	7.92e-12	Coronary artery disease;
PAAD	trans	rs901683	0.850	rs76491632	chr10:45966598	T/C	cg12869334	chr8:37699360	GPR124	0.97	6.48	0.47	1.23e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.19	0.39	6.66e-7	Birth weight;
PAAD	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.61	-6.15	-0.45	6.62e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.67	-7.79	-0.53	9.53e-13	Height;
PAAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg20243544	chr17:37824526	PNMT	0.51	4.42	0.34	1.83e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.91	9.55	0.61	3.21e-17	Testicular germ cell tumor;
PAAD	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg02896835	chr1:92012615	NA	-0.52	-6.05	-0.44	1.06e-8	Breast cancer;
PAAD	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.61	5.24	0.39	5.27e-7	Lymphocyte counts;
PAAD	cis	rs9815354	0.597	rs73073281	chr3:42026366	C/T	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.52	6.05	0.44	1.06e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03115019	chr17:80708279	FN3K	0.51	4.54	0.35	1.14e-5	Glycated hemoglobin levels;
PAAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.35	15.11	0.77	4.39e-32	Eosinophil percentage of granulocytes;
PAAD	trans	rs901683	1.000	rs12778980	chr10:45994211	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24570346	chr2:238503119	NA	0.61	7.07	0.5	5.28e-11	Smoking initiation;
PAAD	cis	rs5015933	0.801	rs7848571	chr9:128141206	A/T	cg14078157	chr9:128172775	NA	-0.38	-4.35	-0.33	2.53e-5	Body mass index;
PAAD	trans	rs3130834	1	rs3130834	chr6:29248149	T/C	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Breast cancer;
PAAD	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.7	6.95	0.49	1.02e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.23	0.56	7.9e-14	Prudent dietary pattern;
PAAD	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg10820045	chr2:198174542	NA	0.45	4.45	0.34	1.66e-5	Dermatomyositis;
PAAD	cis	rs8077577	0.747	rs12449313	chr17:18221010	A/G	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00540400	chr15:79124168	NA	0.58	6.72	0.48	3.43e-10	Coronary artery disease;
PAAD	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13560548	chr3:10150139	C3orf24	0.6	5.35	0.4	3.24e-7	Alzheimer's disease;
PAAD	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03517284	chr6:25882590	NA	0.47	4.25	0.33	3.73e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1075265	0.547	rs11125520	chr2:54303833	A/T	cg04546899	chr2:54196757	PSME4	0.34	4.99	0.38	1.64e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs1113500	0.565	rs1781071	chr1:108571034	C/G	cg06207961	chr1:108661230	NA	0.47	4.92	0.37	2.2e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs2882667	0.628	rs3749663	chr5:138271187	A/T	cg09476006	chr5:138032270	NA	0.44	5.33	0.4	3.41e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18154662	chr1:146743407	CHD1L	-0.63	-6.35	-0.46	2.32e-9	Obesity-related traits;
PAAD	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg02683114	chr2:24398427	C2orf84	0.57	5.84	0.43	3.02e-8	Asthma;
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.95	8.24	0.56	7.5e-14	Alzheimer's disease;
PAAD	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.56	-5.41	-0.4	2.45e-7	Neuroticism;
PAAD	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg02887458	chr19:19495540	GATAD2A	-0.6	-5.34	-0.4	3.28e-7	Bipolar disorder;
PAAD	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs9381107	0.505	rs13208500	chr6:9479707	T/C	cg14735645	chr6:9486422	NA	-0.59	-4.98	-0.37	1.72e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.61	-6.09	-0.44	8.7e-9	Height;
PAAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg01815783	chr4:1047043	NA	-0.44	-4.27	-0.33	3.4e-5	Recombination rate (females);
PAAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14895029	chr7:2775587	GNA12	-0.47	-4.65	-0.35	7.07e-6	Height;
PAAD	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.63	-6.14	-0.45	7.03e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg18721089	chr20:30220636	NA	-0.79	-6.02	-0.44	1.23e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.62	-8.96	-0.59	1.12e-15	Huntington's disease progression;
PAAD	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.67	8.01	0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	1.16	6.23	0.45	4.38e-9	Skin colour saturation;
PAAD	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.78	-8.44	-0.56	2.39e-14	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.25	0.6	1.96e-16	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19026125	chr10:461847	DIP2C	-0.64	-6.41	-0.46	1.75e-9	Obesity-related traits;
PAAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.78	0.53	1.03e-12	Personality dimensions;
PAAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.62	-6.32	-0.46	2.69e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg05110241	chr16:68378359	PRMT7	-1.11	-8.15	-0.55	1.21e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg20607287	chr7:12443886	VWDE	-0.8	-6.05	-0.44	1.09e-8	Coronary artery disease;
PAAD	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.28	-0.39	4.48e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9463078	0.764	rs3846896	chr6:44834094	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.26	-0.39	4.82e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.6	-5.15	-0.39	8.07e-7	Common traits (Other);
PAAD	cis	rs9715521	0.615	rs7694230	chr4:59845356	A/G	cg11281224	chr4:60001000	NA	-0.54	-5.24	-0.39	5.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg12568669	chr8:11666485	FDFT1	-0.3	-5.22	-0.39	5.88e-7	Monocyte count;
PAAD	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.89	9.41	0.61	7.39e-17	Prostate cancer;
PAAD	cis	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg09913449	chr8:42400586	C8orf40	-0.43	-4.63	-0.35	7.65e-6	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs929596	0.958	rs17862873	chr2:234646722	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-6.78	-0.48	2.51e-10	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg11833968	chr6:79620685	NA	-0.42	-4.41	-0.34	1.98e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg08619932	chr19:49200058	FUT2	0.61	6.73	0.48	3.26e-10	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs911119	0.955	rs2067488	chr20:23594331	T/G	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg05585544	chr11:47624801	NA	-0.52	-5.93	-0.43	1.94e-8	Subjective well-being;
PAAD	cis	rs12042938	0.622	rs58403453	chr1:231813438	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.59	0.35	9.19e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg14146966	chr2:61757674	XPO1	0.41	5.05	0.38	1.24e-6	Tuberculosis;
PAAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg05579598	chr16:88989069	CBFA2T3	0.54	7.95	0.54	3.91e-13	Social autistic-like traits;
PAAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.45	5.3	0.39	4.02e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-10.39	-0.64	1.88e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21545522	chr1:205238299	TMCC2	0.59	5.59	0.41	1.02e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07377586	chr3:122283313	PARP9;DTX3L	0.61	6.48	0.47	1.24e-9	Myopia (pathological);
PAAD	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg23957660	chr17:17878224	LRRC48	-0.38	-4.3	-0.33	3.08e-5	Total body bone mineral density;
PAAD	cis	rs3007168	0.951	rs3007074	chr14:51604731	T/A	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg00101154	chr16:420108	MRPL28	-0.51	-5.37	-0.4	2.94e-7	Bone mineral density (spine);Bone mineral density;
PAAD	trans	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.35	-5.14	-0.38	8.31e-7	DNA methylation (variation);
PAAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg21130718	chr4:1044621	NA	-0.72	-9.44	-0.61	6.12e-17	Recombination rate (males);
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.67	-6.59	-0.47	6.79e-10	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24345349	chr20:24944010	C20orf3	-0.67	-6.84	-0.49	1.84e-10	Obesity-related traits;
PAAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	1.09	15.86	0.79	4.76e-34	Menarche (age at onset);
PAAD	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg15654264	chr1:150340011	RPRD2	0.52	4.94	0.37	2e-6	Migraine;
PAAD	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-5.14	-0.38	8.31e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21211367	chr2:162094118	NA	0.5	4.89	0.37	2.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.58	5.97	0.44	1.64e-8	Testicular germ cell tumor;
PAAD	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg19192590	chr2:178524533	PDE11A	0.41	4.89	0.37	2.58e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs6785206	0.614	rs13095694	chr3:128480065	A/G	cg19205850	chr3:128446370	RAB7A	0.8	5.65	0.42	7.54e-8	Lymphocyte percentage of white cells;
PAAD	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.95	9.58	0.61	2.67e-17	Post bronchodilator FEV1;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-7.82	-0.54	8.39e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2133450	0.967	rs6766479	chr3:7324186	C/G	cg19930620	chr3:7340148	GRM7	-0.46	-4.96	-0.37	1.87e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.52	0.34	1.21e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.52	5.29	0.39	4.29e-7	Resting heart rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24375287	chr13:50366190	KPNA3	0.59	6.36	0.46	2.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs1730008	0.835	rs827091	chr3:157985706	A/G	cg01557547	chr3:157823089	SHOX2	0.41	4.34	0.33	2.55e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.2	11.42	0.68	3.4e-22	Platelet count;
PAAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg03909863	chr11:638404	DRD4	-0.57	-5.25	-0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13575058	chr2:198380465	MOBKL3	0.67	6.86	0.49	1.66e-10	Obesity-related traits;
PAAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg08885800	chr1:201084119	NA	0.73	8.29	0.56	5.65e-14	Permanent tooth development;
PAAD	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.7	6.58	0.47	7.21e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
PAAD	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.58	-5.79	-0.42	3.98e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.53	-5.03	-0.38	1.38e-6	Red blood cell count;
PAAD	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.08	0.44	9.51e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg22963979	chr7:1858916	MAD1L1	0.77	9.06	0.59	5.87e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-1.28	-6.14	-0.45	6.82e-9	Prostate cancer;
PAAD	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.71	9.36	0.6	1.02e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.41	-4.55	-0.35	1.1e-5	Aortic root size;
PAAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.48	-6.8	-0.48	2.26e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7849585	1.000	rs7864754	chr9:139126120	C/T	cg14147151	chr9:138948000	NACC2	0.39	4.3	0.33	3e-5	Height;
PAAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.8	7.69	0.53	1.75e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6604026	0.656	rs34084844	chr1:93387592	A/G	cg17283838	chr1:93427260	FAM69A	0.61	5.59	0.41	1.02e-7	Multiple sclerosis;
PAAD	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.83	-4.53	-0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg07061783	chr6:25882402	NA	0.53	5.04	0.38	1.28e-6	Blood metabolite levels;
PAAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-4.52	-0.34	1.24e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.28e-10	Glomerular filtration rate (creatinine);
PAAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.8	-7.89	-0.54	5.64e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg21546286	chr11:48923668	NA	0.52	5.34	0.4	3.3e-7	HDL cholesterol;
PAAD	cis	rs58521262	0.592	rs11671459	chr19:23023747	G/A	cg07749055	chr19:23076870	NA	-0.66	-4.76	-0.36	4.53e-6	Testicular germ cell tumor;
PAAD	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-7.85	-0.54	6.83e-13	Response to antipsychotic treatment;
PAAD	cis	rs7916697	0.842	rs4746749	chr10:70009389	C/T	cg18338521	chr10:69995036	NA	0.33	4.3	0.33	3.01e-5	Optic disc area;
PAAD	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19671926	chr4:122722719	EXOSC9	-0.64	-6.18	-0.45	5.48e-9	Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.54	5.61	0.41	9.46e-8	Lung cancer;
PAAD	cis	rs2790457	0.833	rs1265846	chr10:28929097	A/G	cg05705492	chr10:28955341	NA	-0.47	-4.74	-0.36	4.8e-6	Multiple myeloma;
PAAD	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.45	-4.69	-0.36	6.03e-6	Motion sickness;
PAAD	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-4.95	-0.37	1.92e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.99	6.58	0.47	7.08e-10	Parkinson's disease;
PAAD	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.19	0.39	6.52e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10044254	0.614	rs11750054	chr5:15733602	T/C	cg07238450	chr5:15720153	FBXL7	-0.54	-5.05	-0.38	1.26e-6	Asthma (corticosteroid response);
PAAD	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg22517653	chr1:2918612	NA	-0.62	-4.86	-0.37	2.85e-6	Plateletcrit;
PAAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.51	-5.87	-0.43	2.67e-8	Cardiovascular disease risk factors;
PAAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg19784903	chr17:45786737	TBKBP1	-0.49	-4.79	-0.36	3.87e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg23465465	chr6:26364728	BTN3A2	0.55	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg08999081	chr20:33150536	PIGU	0.53	5.97	0.44	1.61e-8	Height;
PAAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22029157	chr1:209979665	IRF6	0.73	6.61	0.47	6.08e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs367943	0.712	rs26959	chr5:112736615	A/G	cg12552261	chr5:112820674	MCC	0.64	6.37	0.46	2.13e-9	Type 2 diabetes;
PAAD	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.53	5.37	0.4	2.89e-7	Resting heart rate;
PAAD	cis	rs7582720	1.000	rs72932753	chr2:203670122	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4742903	0.967	rs10820600	chr9:106856692	T/C	cg14250997	chr9:106856677	SMC2	0.47	5.08	0.38	1.12e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg20761395	chr17:511517	VPS53	0.7	7.84	0.54	7.23e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs733175	0.830	rs6834555	chr4:10062326	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	4.31	0.33	2.97e-5	Psychosis and Alzheimer's disease;
PAAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.78	-7.93	-0.54	4.42e-13	Body mass index;
PAAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.44	-4.53	-0.34	1.19e-5	Body mass index;
PAAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.94	-15.76	-0.79	8.91e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9472414	0.680	rs4714812	chr6:44700714	G/A	cg20913747	chr6:44695427	NA	0.54	5.1	0.38	1.02e-6	Height;
PAAD	cis	rs4740619	0.901	rs10756692	chr9:15710207	T/C	cg14451791	chr9:16040625	NA	-0.4	-4.69	-0.36	6.1e-6	Body mass index;
PAAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9810890	1.000	rs73198872	chr3:128537683	G/A	cg18531004	chr3:128564980	NA	-0.87	-5.01	-0.38	1.5e-6	Dental caries;
PAAD	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.37	-0.4	2.95e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11696501	0.739	rs6032411	chr20:44286542	C/G	cg11783356	chr20:44313418	WFDC10B	-0.58	-5.1	-0.38	1.01e-6	Brain structure;
PAAD	cis	rs2274459	0.841	rs35698850	chr6:33700132	A/G	cg06253072	chr6:33679850	C6orf125	0.62	4.88	0.37	2.7e-6	Obesity (extreme);
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg23708337	chr7:1209742	NA	0.63	4.48	0.34	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.41	5.2	0.39	6.23e-7	Electrocardiographic conduction measures;
PAAD	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.39	0.61	8.52e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3015497	0.527	rs3015473	chr14:51154010	A/G	cg26011998	chr14:51135199	SAV1	-0.46	-4.32	-0.33	2.85e-5	Mean platelet volume;
PAAD	cis	rs608114	0.623	rs73555958	chr6:96328898	A/G	cg03043157	chr6:97010903	FHL5	-0.93	-4.88	-0.37	2.68e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg00703273	chr17:61700589	MAP3K3	0.6	6.56	0.47	7.89e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.73	-4.92	-0.37	2.18e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.07e-7	Bipolar disorder;
PAAD	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-4.53	-0.34	1.2e-5	Breast cancer;
PAAD	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.19	18.4	0.83	1.69e-40	Gut microbiome composition (winter);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17680823	chr2:240016541	HDAC4	0.56	6.42	0.46	1.66e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	6.4	0.46	1.81e-9	Caffeine consumption;
PAAD	cis	rs7551345	0.806	rs16834397	chr1:31830077	C/G	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.65	-7.86	-0.54	6.45e-13	Schizophrenia;
PAAD	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.89	8.38	0.56	3.38e-14	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.89	-11.11	-0.67	2.35e-21	Prudent dietary pattern;
PAAD	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs787274	1.000	rs2645991	chr9:115519035	T/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.51	-0.34	1.3e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs35740288	0.770	rs62022867	chr15:86173281	A/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.6	-0.41	9.9e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.61	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.75	0.58	3.78e-15	Lung cancer;
PAAD	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.7	-4.8	-0.36	3.82e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7101378	0.577	rs7930745	chr11:108896923	T/C	cg10976287	chr11:108093109	ATM;NPAT	-0.49	-5.01	-0.38	1.52e-6	IgG glycosylation;
PAAD	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.93	7.14	0.5	3.69e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.49	7.86	0.54	6.39e-13	Cutaneous nevi;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00296938	chr3:49044463	P4HTM;WDR6	0.59	6.53	0.47	9.43e-10	Monocyte percentage of white cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14886150	chr11:47291490	MADD	-0.61	-6.29	-0.45	3.16e-9	Smoking initiation;
PAAD	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg18551225	chr6:44695536	NA	-0.7	-8.21	-0.55	8.7e-14	Total body bone mineral density;
PAAD	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.87	9.01	0.59	8.14e-16	Schizophrenia;
PAAD	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg00546117	chr1:8445545	RERE	-0.5	-5.09	-0.38	1.04e-6	Crohn's disease;
PAAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.85	8.47	0.57	2.01e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.07e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.75	7.64	0.53	2.32e-12	Body mass index;
PAAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.11e-20	Menopause (age at onset);
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg04810063	chr16:88703634	IL17C	-0.57	-5.26	-0.39	4.86e-7	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-4.25	-0.33	3.78e-5	Alzheimer's disease;
PAAD	cis	rs55788414	0.932	rs55991107	chr16:81181066	G/A	cg06400318	chr16:81190750	PKD1L2	-1.08	-7.18	-0.5	2.9e-11	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.61	6.07	0.44	9.84e-9	Blood protein levels;
PAAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg06740227	chr12:86229804	RASSF9	0.55	5.51	0.41	1.49e-7	Major depressive disorder;
PAAD	cis	rs6032067	0.538	rs6017488	chr20:43731022	A/G	cg10761708	chr20:43804764	PI3	0.49	4.31	0.33	2.9e-5	Blood protein levels;
PAAD	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.55	-5.13	-0.38	8.7e-7	Primary biliary cholangitis;
PAAD	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.11	-0.38	9.46e-7	Mortality in heart failure;
PAAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg21130718	chr4:1044621	NA	0.54	4.6	0.35	8.76e-6	Recombination rate (females);
PAAD	cis	rs877529	0.967	rs139411	chr22:39552888	A/G	cg18708252	chr22:39545030	CBX7	-0.45	-4.37	-0.33	2.29e-5	Multiple myeloma;
PAAD	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg17366294	chr4:99064904	C4orf37	0.45	5.01	0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	6.53	0.47	9.11e-10	Lung cancer in ever smokers;
PAAD	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-10.11	-0.63	1.05e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.85	-0.37	2.97e-6	Blood pressure;
PAAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.54	-5.63	-0.42	8.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00946381	chr16:2205241	TRAF7;SNORD60	0.6	6.86	0.49	1.63e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.14	0.6	3.69e-16	Menopause (age at onset);
PAAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.35e-6	Menopause (age at onset);
PAAD	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-5.29	-0.39	4.14e-7	Joint mobility (Beighton score);
PAAD	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.88	-9.53	-0.61	3.58e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21840599	chr3:196467454	PAK2	0.54	6.45	0.46	1.42e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.82	-8.28	-0.56	6.03e-14	Pancreatic cancer;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg11062466	chr8:58055876	NA	0.67	5.06	0.38	1.18e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.720	rs35757884	chr7:105020534	G/T	cg04380332	chr7:105027541	SRPK2	-0.66	-7.43	-0.52	7.13e-12	Schizophrenia;
PAAD	cis	rs7957197	0.628	rs692902	chr12:121197124	A/G	cg15965241	chr12:121570571	P2RX7	-0.53	-4.25	-0.33	3.71e-5	Type 2 diabetes;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-4.9	-0.37	2.42e-6	Lung cancer;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg01097406	chr16:89675127	NA	-0.37	-4.45	-0.34	1.67e-5	Vitiligo;
PAAD	cis	rs6604026	0.656	rs7550347	chr1:93401157	G/C	cg17283838	chr1:93427260	FAM69A	0.61	5.71	0.42	5.64e-8	Multiple sclerosis;
PAAD	cis	rs62392365	0.536	rs77078042	chr6:25148056	C/T	cg26336265	chr6:25042955	NA	1.0	5.56	0.41	1.18e-7	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20284440	chr14:52118688	FRMD6	0.58	6.51	0.47	1.01e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.6	-5.72	-0.42	5.6e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.96	8.19	0.55	1.02e-13	IgG glycosylation;
PAAD	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg19767477	chr5:127420684	SLC12A2	-0.58	-4.52	-0.34	1.25e-5	Ileal carcinoids;
PAAD	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg11764359	chr7:65958608	NA	0.72	5.1	0.38	1e-6	Diabetic kidney disease;
PAAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.96	8.84	0.58	2.27e-15	Resting heart rate;
PAAD	cis	rs17396122	1.000	rs17396440	chr2:48270256	A/T	cg21405109	chr2:48010105	MSH6	-0.61	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg27449745	chr7:23145252	KLHL7	-0.52	-4.41	-0.34	1.97e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-5.57	-0.41	1.12e-7	Total body bone mineral density;
PAAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg13798912	chr7:905769	UNC84A	0.57	4.4	0.34	2.06e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10768122	0.809	rs736374	chr11:35266944	A/G	cg13971030	chr11:35366721	SLC1A2	0.38	4.4	0.34	2.06e-5	Vitiligo;
PAAD	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg17920646	chr8:216578	NA	0.5	4.37	0.33	2.29e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23568998	chr7:155173032	NA	0.61	6.87	0.49	1.59e-10	Myopia (pathological);
PAAD	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.61	7.59	0.52	3.06e-12	Birth weight;
PAAD	cis	rs7945705	0.936	rs978636	chr11:8836596	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.76	8.13	0.55	1.41e-13	Hemoglobin concentration;
PAAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg02459107	chr1:67143332	SGIP1	0.75	6.94	0.49	1.09e-10	Presence of antiphospholipid antibodies;
PAAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg01075559	chr1:2537774	MMEL1	-0.49	-5.29	-0.39	4.27e-7	Ulcerative colitis;
PAAD	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.69	4.93	0.37	2.13e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.4	4.25	0.33	3.74e-5	Bipolar disorder;
PAAD	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.58	-5.85	-0.43	2.88e-8	Coronary artery disease;
PAAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.82	0.36	3.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.57	-6.21	-0.45	4.78e-9	Post bronchodilator FEV1;
PAAD	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.39	4.25	0.33	3.73e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	5.04	0.38	1.31e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs73198271	0.515	rs78922347	chr8:8627916	G/C	cg01851573	chr8:8652454	MFHAS1	0.92	6.84	0.49	1.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	10.11	0.63	1.07e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.43	4.66	0.35	7.01e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg27205649	chr11:78285834	NARS2	0.62	4.44	0.34	1.72e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg12549451	chr6:135224345	NA	0.44	4.52	0.34	1.22e-5	Red blood cell count;
PAAD	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg12568669	chr8:11666485	FDFT1	-0.27	-4.3	-0.33	2.99e-5	Monocyte count;
PAAD	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg16589663	chr20:23618590	CST3	0.79	6.85	0.49	1.75e-10	Chronic kidney disease;
PAAD	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.48	-5.3	-0.39	4e-7	Migraine - clinic-based;
PAAD	cis	rs4668356	1.000	rs2676143	chr2:171805870	C/T	cg13882835	chr2:172017928	TLK1	-0.87	-4.35	-0.33	2.53e-5	Cognitive performance;
PAAD	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.66	6.66	0.48	4.63e-10	Schizophrenia;
PAAD	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.61	5.85	0.43	2.92e-8	Subjective well-being;
PAAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-8.37	-0.56	3.45e-14	Prostate cancer;
PAAD	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg09491104	chr22:46646882	C22orf40	-0.94	-6.05	-0.44	1.07e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.9	6.56	0.47	8.16e-10	Alzheimer's disease;
PAAD	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.49	-5.74	-0.42	4.94e-8	Mean arterial pressure;
PAAD	cis	rs6585424	1.000	rs12779955	chr10:81940864	C/T	cg19423196	chr10:82049429	MAT1A	-0.46	-4.79	-0.36	3.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.36	-0.33	2.34e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg20813462	chr7:2646259	IQCE	0.66	4.65	0.35	7.21e-6	Urate levels in lean individuals;
PAAD	trans	rs61677309	0.964	rs55815657	chr11:118155074	G/A	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs12989701	0.877	rs7557280	chr2:127873161	T/A	cg08168897	chr2:127865431	BIN1	0.69	5.9	0.43	2.23e-8	Alzheimer's disease (late onset);
PAAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.46	-0.4	1.92e-7	Glomerular filtration rate;
PAAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.68	-0.42	6.68e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.78	9.42	0.61	7.16e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg26850624	chr5:429559	AHRR	-0.83	-11.38	-0.68	4.22e-22	Cystic fibrosis severity;
PAAD	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg02344993	chr17:57696989	CLTC	-0.61	-5.0	-0.38	1.57e-6	Hemoglobin concentration;
PAAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg19847866	chr10:1019161	NA	-0.6	-4.71	-0.36	5.44e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.65	0.35	7.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs859767	0.741	rs4954159	chr2:135426782	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs4704187	0.687	rs10805893	chr5:74507390	C/A	cg03227963	chr5:74354835	NA	0.53	5.09	0.38	1.04e-6	Response to amphetamines;
PAAD	cis	rs874628	0.686	rs11666281	chr19:18234588	C/T	cg02814054	chr19:18234911	MAST3	0.43	4.25	0.33	3.65e-5	Multiple sclerosis;
PAAD	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27467552	chr22:50353597	PIM3	-0.55	-5.68	-0.42	6.54e-8	Ulcerative colitis;
PAAD	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs17641971	0.622	rs818561	chr8:50035042	C/A	cg00325661	chr8:49890786	NA	0.67	6.82	0.48	2.03e-10	Blood metabolite levels;
PAAD	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.54	-4.93	-0.37	2.12e-6	Asthma;
PAAD	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg23119463	chr10:134592391	INPP5A	-0.48	-4.48	-0.34	1.44e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg01763666	chr17:80159506	CCDC57	-0.45	-4.58	-0.35	9.62e-6	Life satisfaction;
PAAD	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg12661370	chr5:149340060	SLC26A2	0.57	4.8	0.36	3.78e-6	HIV-1 control;
PAAD	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.8	6.04	0.44	1.15e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-4.69	-0.36	6.03e-6	Height;
PAAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg04160749	chr8:58172571	NA	-0.65	-4.67	-0.35	6.55e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.77	8.52	0.57	1.45e-14	Lung cancer;
PAAD	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.68	-0.42	6.69e-8	Subjective well-being;
PAAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	5.81	0.43	3.47e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.59	0.57	9.61e-15	Corneal astigmatism;
PAAD	cis	rs603424	0.551	rs525190	chr10:102087038	C/T	cg10365880	chr10:102089681	PKD2L1	-0.72	-4.77	-0.36	4.3e-6	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs303386	0.651	rs303388	chr1:99589869	T/C	cg03593336	chr1:99471295	LPPR5	0.53	4.88	0.37	2.64e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
PAAD	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.89	-9.98	-0.63	2.31e-18	Cognitive function;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2244497	0.698	rs1806448	chr17:64526395	C/T	cg26726141	chr17:64612159	PRKCA	0.49	4.78	0.36	4.03e-6	Neuroticism;
PAAD	cis	rs13242816	1.000	rs35364754	chr7:116109716	T/G	cg16553024	chr7:116138462	CAV2	-0.71	-5.03	-0.38	1.37e-6	P wave duration;
PAAD	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.54	4.97	0.37	1.75e-6	Height;
PAAD	cis	rs3106136	0.586	rs1605923	chr4:95063631	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.86	-0.37	2.86e-6	Capecitabine sensitivity;
PAAD	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg22189786	chr22:42395067	WBP2NL	-0.49	-5.37	-0.4	2.83e-7	Cognitive function;
PAAD	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.96	6.22	0.45	4.7e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3784262	0.528	rs34556514	chr15:58333769	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-4.38	-0.33	2.18e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs6499755	0.932	rs12928690	chr16:55343565	C/T	cg02859129	chr16:55357253	IRX6	0.33	4.54	0.35	1.13e-5	Hypospadias;
PAAD	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.11	-0.38	9.44e-7	Body mass index;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22428125	chr1:233086479	C1orf57	0.7	6.37	0.46	2.13e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs61677309	1.000	rs58093803	chr11:118168156	T/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.45	-0.46	1.41e-9	Lung cancer in ever smokers;
PAAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg10011062	chr15:43941034	CATSPER2	-0.76	-4.34	-0.33	2.63e-5	Lung cancer in ever smokers;
PAAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	5.53	0.41	1.36e-7	Total body bone mineral density;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.76	8.47	0.57	1.96e-14	Lung cancer;
PAAD	cis	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-4.69	-0.36	5.95e-6	Neuroticism;
PAAD	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.64	-7.13	-0.5	3.74e-11	Schizophrenia;
PAAD	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg09242541	chr1:10490025	APITD1	0.39	4.31	0.33	2.89e-5	Hand grip strength;
PAAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.09	8.1	0.55	1.67e-13	Alzheimer's disease;
PAAD	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.55	5.65	0.42	7.53e-8	Red blood cell count;
PAAD	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.74	-8.15	-0.55	1.26e-13	Inflammatory bowel disease;
PAAD	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.64	4.94	0.37	2.03e-6	IgE levels;
PAAD	cis	rs6074578	0.679	rs12624951	chr20:139409	G/A	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.54	5.18	0.39	6.88e-7	Aortic root size;
PAAD	cis	rs35955747	0.871	rs2013254	chr22:31690803	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.9	0.37	2.48e-6	Parkinson's disease;
PAAD	cis	rs939584	1.000	rs2867110	chr2:651105	C/G	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs7705042	0.828	rs1835966	chr5:141501508	C/T	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg01658259	chr14:24837143	NFATC4	0.45	4.56	0.35	1.03e-5	Height;
PAAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6499129	0.558	rs60626639	chr16:67625797	A/G	cg05110241	chr16:68378359	PRMT7	-0.78	-5.28	-0.39	4.38e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs17266958	0.792	rs62572810	chr9:83188156	G/A	cg13911576	chr9:84174038	NA	0.84	4.33	0.33	2.67e-5	Preschool internalizing problems;
PAAD	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs4757319	0.515	rs7116542	chr11:15436304	A/G	cg03245590	chr11:15329459	NA	0.44	5.19	0.39	6.53e-7	Breast cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23346625	chr5:146619708	STK32A	0.59	6.34	0.46	2.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	5.07	0.38	1.12e-6	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.62e-7	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.75	0.42	4.85e-8	Life satisfaction;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26796513	chr19:48685976	NA	0.57	6.67	0.48	4.36e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.83	-7.97	-0.54	3.58e-13	Body mass index;
PAAD	cis	rs4343996	1.000	rs6980323	chr7:3356207	A/G	cg21248987	chr7:3385318	SDK1	-0.47	-5.17	-0.39	7.13e-7	Motion sickness;
PAAD	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg13786083	chr1:19110734	NA	-0.49	-4.91	-0.37	2.3e-6	Knee osteoarthritis;
PAAD	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.89	11.68	0.69	6.89e-23	Body mass index;
PAAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs742132	0.520	rs2294344	chr6:25652225	C/A	cg12310025	chr6:25882481	NA	0.65	4.35	0.33	2.47e-5	Uric acid levels;
PAAD	cis	rs13070279	0.655	rs13079978	chr3:71786919	A/C	cg03457142	chr3:71804859	EIF4E3	-0.58	-4.63	-0.35	7.78e-6	Monocyte count;
PAAD	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg27394845	chr17:28928406	LRRC37B2	0.68	4.43	0.34	1.79e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs16910800	0.731	rs7125729	chr11:23181637	A/G	cg20040320	chr11:23191996	NA	-0.83	-7.06	-0.5	5.44e-11	Cancer;
PAAD	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.69	0.66	3.05e-20	Total body bone mineral density;
PAAD	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg00383909	chr3:49044727	WDR6	0.44	4.54	0.35	1.12e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	6.23	0.45	4.33e-9	Monocyte count;
PAAD	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18805028	chr19:44099413	IRGQ;ZNF576	0.64	7.19	0.5	2.68e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg03959625	chr15:84868606	LOC388152	0.49	5.38	0.4	2.71e-7	Schizophrenia;
PAAD	cis	rs9880406	0.641	rs72493123	chr3:126035132	T/C	cg11830761	chr3:126007485	NA	-0.52	-4.92	-0.37	2.18e-6	Macular telangiectasia type 2;
PAAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02359409	chr6:42947317	PEX6	-0.46	-4.42	-0.34	1.9e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-4.35	-0.33	2.52e-5	Neuroticism;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.81	6.18	0.45	5.7e-9	Alzheimer's disease;
PAAD	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg02660097	chr11:68866761	NA	-0.46	-5.33	-0.4	3.47e-7	Blond vs. brown hair color;
PAAD	cis	rs134594	0.885	rs713861	chr22:29485794	A/G	cg01361351	chr22:29467363	NA	0.42	4.74	0.36	4.89e-6	Birth weight;
PAAD	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.46	4.52	0.34	1.25e-5	Breast cancer;
PAAD	cis	rs2131877	0.913	rs3897755	chr3:194847325	A/G	cg21937377	chr3:194868750	C3orf21	0.4	4.38	0.33	2.17e-5	Non-small cell lung cancer;
PAAD	cis	rs1883415	0.534	rs760905	chr6:24479782	T/C	cg20631270	chr6:24437470	GPLD1	0.43	4.26	0.33	3.64e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.57	-0.52	3.28e-12	Migraine;Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15605011	chr1:110162477	AMPD2	0.62	6.29	0.45	3.27e-9	Myopia (pathological);
PAAD	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	4.3	0.33	2.99e-5	Resting heart rate;
PAAD	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.6	5.37	0.4	2.96e-7	Cognitive ability;
PAAD	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.51	4.87	0.37	2.8e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.39	-0.4	2.6e-7	Height;
PAAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.26	0.39	4.84e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-4.83	-0.36	3.28e-6	Hirschsprung disease;
PAAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs6577655	0.547	rs7841171	chr8:135591699	G/A	cg17885191	chr8:135476712	NA	0.53	4.37	0.33	2.33e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg15436174	chr10:43711423	RASGEF1A	0.48	4.71	0.36	5.47e-6	Hirschsprung disease;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg00806126	chr19:22604979	ZNF98	0.41	5.34	0.4	3.4e-7	Pain;
PAAD	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.35	-0.33	2.46e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	6.89	0.49	1.38e-10	Renal function-related traits (BUN);
PAAD	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.57	6.19	0.45	5.44e-9	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.63	-5.18	-0.39	6.96e-7	Fibrinogen levels;
PAAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.39	4.7	0.36	5.85e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6604026	0.656	rs34389767	chr1:93373780	T/G	cg13858687	chr1:93297071	RPL5	0.47	4.35	0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.58	-5.27	-0.39	4.63e-7	Life satisfaction;
PAAD	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.56	-7.33	-0.51	1.27e-11	Longevity;
PAAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.47	-4.47	-0.34	1.51e-5	Facial morphology (factor 20);
PAAD	cis	rs10267417	0.603	rs12666448	chr7:19859119	G/A	cg05791153	chr7:19748676	TWISTNB	0.84	5.45	0.4	1.97e-7	Night sleep phenotypes;
PAAD	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.51	5.23	0.39	5.42e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg10011062	chr15:43941034	CATSPER2	-0.8	-4.59	-0.35	9.25e-6	Lung cancer in ever smokers;
PAAD	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.68	-6.71	-0.48	3.55e-10	Uric acid levels;
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.49	-4.46	-0.34	1.55e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.81	9.13	0.59	4.08e-16	Body mass index;
PAAD	cis	rs7714584	1.000	rs10058943	chr5:150226586	A/G	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.39	4.41	0.34	1.93e-5	High light scatter reticulocyte count;
PAAD	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg25547332	chr5:131281432	NA	-0.56	-4.42	-0.34	1.87e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs1879734	0.731	rs12405835	chr1:54129732	C/G	cg09991173	chr1:54194996	GLIS1	0.51	4.41	0.34	1.93e-5	Mitral valve prolapse;
PAAD	cis	rs501120	0.584	rs661697	chr10:44740698	G/T	cg09554077	chr10:44749378	NA	0.46	5.45	0.4	1.96e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg15595755	chr5:1867978	NA	0.43	4.48	0.34	1.45e-5	Cardiovascular disease risk factors;
PAAD	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23544223	chr18:12777786	NA	-0.73	-6.24	-0.45	4.22e-9	Inflammatory skin disease;
PAAD	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.77	8.44	0.56	2.34e-14	Prostate cancer;
PAAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.74	6.63	0.47	5.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.73	-0.36	5.13e-6	Height;
PAAD	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.73	6.95	0.49	9.97e-11	Sum neutrophil eosinophil counts;
PAAD	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9314614	0.789	rs2951859	chr8:6713153	C/T	cg27319216	chr8:6693540	XKR5	-0.4	-5.35	-0.4	3.16e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.86	6.38	0.46	2.06e-9	Iron status biomarkers;
PAAD	cis	rs9900972	0.959	rs4789941	chr17:76877500	G/C	cg00961940	chr17:76876995	TIMP2	0.57	5.31	0.4	3.84e-7	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg20933634	chr6:27740509	NA	0.72	4.4	0.34	2.05e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.79	5.83	0.43	3.16e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg27234864	chr13:21295941	IL17D	0.5	4.64	0.35	7.46e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs2072732	0.731	rs10909862	chr1:2936815	G/A	cg15211996	chr1:2936768	ACTRT2	-0.51	-5.0	-0.38	1.55e-6	Plateletcrit;
PAAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.66	-5.98	-0.44	1.56e-8	Glioblastoma;
PAAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.06e-6	Lung cancer;
PAAD	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.62	-5.83	-0.43	3.27e-8	Multiple myeloma;
PAAD	cis	rs57214277	0.508	rs6828688	chr4:185257359	G/C	cg12654155	chr4:185238627	NA	0.61	6.99	0.49	8.05e-11	Chronic lymphocytic leukemia;
PAAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.61	6.0	0.44	1.41e-8	Blood protein levels;
PAAD	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs3733418	0.929	rs13110309	chr4:165889672	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.71	-0.42	5.66e-8	Obesity-related traits;
PAAD	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg12633918	chr20:23549525	CST9L	-0.42	-4.63	-0.35	7.63e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.7	-8.07	-0.55	1.99e-13	Diastolic blood pressure;
PAAD	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg05084668	chr3:125655381	ALG1L	-0.46	-5.09	-0.38	1.07e-6	Blood pressure (smoking interaction);
PAAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.52	5.32	0.4	3.67e-7	Menopause (age at onset);
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg03199926	chr20:60860733	OSBPL2	-0.42	-4.53	-0.34	1.19e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.32	11.26	0.67	8.95e-22	Uric acid levels;
PAAD	cis	rs7705042	0.865	rs4912804	chr5:141493614	T/C	cg08523384	chr5:141488047	NDFIP1	-0.54	-5.16	-0.39	7.64e-7	Asthma;
PAAD	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.58	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	5.13	0.38	8.56e-7	Obesity-related traits;
PAAD	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg02743256	chr7:2109353	MAD1L1	-0.57	-4.67	-0.35	6.45e-6	Bipolar disorder;
PAAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg20913747	chr6:44695427	NA	0.73	7.16	0.5	3.2e-11	Total body bone mineral density;
PAAD	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	6.26	0.45	3.68e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-8.65	-0.57	6.94e-15	Coronary artery disease;
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	-0.6	-4.6	-0.35	8.97e-6	Breast cancer;
PAAD	cis	rs797680	0.964	rs624131	chr1:93683210	A/G	cg04535902	chr1:92947332	GFI1	-0.47	-4.46	-0.34	1.61e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.19	0.39	6.6e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs34043524	1.000	rs34043524	chr4:117990454	A/G	cg14562394	chr4:117851367	NA	0.82	4.35	0.33	2.48e-5	Lateral ventricle volume in trauma-exposed individuals;
PAAD	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.54	-5.25	-0.39	5.15e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9810890	1.000	rs114441742	chr3:128547271	C/T	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.52	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.31	-4.56	-0.35	1.04e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4478858	0.684	rs12725881	chr1:31736123	C/T	cg00250761	chr1:31883323	NA	0.52	6.08	0.44	9.33e-9	Alcohol dependence;
PAAD	cis	rs4972806	0.814	rs966801	chr2:177037827	G/A	cg14324370	chr2:177042789	NA	0.34	5.04	0.38	1.29e-6	IgG glycosylation;
PAAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	5.54	0.41	1.32e-7	Monocyte count;
PAAD	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg22601191	chr20:60968625	CABLES2	0.48	4.58	0.35	9.72e-6	Colorectal cancer;
PAAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg24069376	chr3:38537580	EXOG	0.4	4.82	0.36	3.49e-6	Electrocardiographic conduction measures;
PAAD	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg14119001	chr9:139324193	INPP5E	-0.53	-4.65	-0.35	7.21e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.63	5.24	0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.58	-7.49	-0.52	5.1e-12	Longevity;
PAAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.67	7.48	0.52	5.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02290575	chr7:100964799	RABL5	0.55	6.31	0.46	2.96e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.99	-0.38	1.61e-6	Initial pursuit acceleration;
PAAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg14440974	chr22:39074834	NA	-0.56	-6.95	-0.49	1.01e-10	Menopause (age at onset);
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16262614	chr3:133464971	TF	-0.43	-4.55	-0.35	1.08e-5	Iron status biomarkers;
PAAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.51	4.49	0.34	1.38e-5	Height;
PAAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	2.66e-18	Menopause (age at onset);
PAAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.76	0.62	9.06e-18	Rheumatoid arthritis;
PAAD	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.66	5.55	0.41	1.25e-7	Schizophrenia;
PAAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg08200582	chr11:442649	ANO9	0.57	4.77	0.36	4.22e-6	Systemic lupus erythematosus;
PAAD	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg06917634	chr15:78832804	PSMA4	-0.49	-4.81	-0.36	3.62e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg02421172	chr7:1938701	MAD1L1	0.58	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.88	10.73	0.66	2.45e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.65	4.25	0.33	3.65e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.37	4.47	0.34	1.51e-5	Pulmonary function;
PAAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.99	-14.76	-0.77	3.69e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs35740288	0.822	rs2306225	chr15:86227952	A/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.52	-0.41	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-6.01	-0.44	1.33e-8	Personality dimensions;
PAAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.87	9.88	0.63	4.26e-18	Prudent dietary pattern;
PAAD	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg01047959	chr19:17666446	GLT25D1	0.48	4.48	0.34	1.46e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	5.95	0.43	1.77e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg03700679	chr2:178418002	TTC30B	0.59	4.54	0.35	1.14e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.62	-6.09	-0.44	8.69e-9	Multiple sclerosis;
PAAD	cis	rs9535307	0.584	rs61961501	chr13:50392956	A/G	cg03658251	chr13:50265850	EBPL	-0.76	-4.65	-0.35	7.14e-6	Obesity-related traits;
PAAD	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.58	-7.0	-0.49	7.79e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.56	-5.28	-0.39	4.48e-7	Strep throat;
PAAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	5.31	0.4	3.79e-7	Mood instability;
PAAD	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs939584	1.000	rs10172769	chr2:646345	G/A	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.9	9.44	0.61	6.32e-17	Homoarginine levels;
PAAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.35	0.4	3.12e-7	Rheumatoid arthritis;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg18209359	chr17:80159595	CCDC57	0.47	4.73	0.36	5.09e-6	Life satisfaction;
PAAD	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.37	0.61	9.2e-17	Hemoglobin concentration;
PAAD	cis	rs7107174	0.748	rs2458640	chr11:78035856	A/C	cg02023728	chr11:77925099	USP35	0.39	4.33	0.33	2.73e-5	Testicular germ cell tumor;
PAAD	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	trans	rs61931739	0.817	rs7297799	chr12:34260142	T/C	cg26384229	chr12:38710491	ALG10B	0.7	7.18	0.5	2.93e-11	Morning vs. evening chronotype;
PAAD	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.53	-0.41	1.35e-7	Monocyte percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01260103	chr11:68609203	CPT1A	-0.76	-6.36	-0.46	2.27e-9	Neuroticism;
PAAD	cis	rs10046574	0.731	rs10458299	chr7:135052348	C/T	cg27474649	chr7:135195673	CNOT4	0.84	4.44	0.34	1.75e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.75	8.19	0.55	9.68e-14	Eosinophil percentage of white cells;
PAAD	cis	rs4427176	0.765	rs17150478	chr8:9641034	C/T	cg03024720	chr8:9765601	NA	0.47	4.6	0.35	8.78e-6	Mosquito bite size;
PAAD	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-4.45	-0.34	1.63e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.39	-4.58	-0.35	9.7e-6	Lewy body disease;
PAAD	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-0.74	-4.93	-0.37	2.16e-6	Schizophrenia;
PAAD	cis	rs6028335	0.610	rs12624839	chr20:37573816	G/A	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.89	-0.37	2.59e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.49	-4.89	-0.37	2.56e-6	Ovarian reserve;
PAAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg05110241	chr16:68378359	PRMT7	-1.09	-8.38	-0.56	3.24e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.85	-4.65	-0.35	7.26e-6	Toenail selenium levels;
PAAD	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg12757816	chr2:10669957	NA	-0.53	-5.62	-0.41	8.82e-8	Prostate cancer;
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg08835956	chr7:39171034	POU6F2	0.3	4.86	0.37	2.86e-6	IgG glycosylation;
PAAD	trans	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.9	-0.49	1.34e-10	Neuroticism;
PAAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg15017067	chr4:17643749	FAM184B	0.42	4.99	0.38	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.73	8.34	0.56	4.27e-14	Huntington's disease progression;
PAAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg01815783	chr4:1047043	NA	-0.47	-4.4	-0.34	1.99e-5	Recombination rate (females);
PAAD	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg18742855	chr2:26800399	C2orf70	-0.55	-6.37	-0.46	2.15e-9	Periodontal microbiota;
PAAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg06243866	chr13:111019493	COL4A2	-0.65	-6.25	-0.45	4.01e-9	White matter hyperintensity burden;
PAAD	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.95	0.54	3.9e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.7	8.24	0.56	7.61e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-4.9	-0.37	2.46e-6	Major depressive disorder;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.46	4.57	0.35	9.8200000000000008e-06	Cognitive function;
PAAD	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg16850897	chr7:100343110	ZAN	-0.77	-6.34	-0.46	2.52e-9	Other erythrocyte phenotypes;
PAAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.69	-6.69	-0.48	4.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg15128208	chr22:42549153	NA	0.53	4.54	0.35	1.15e-5	Birth weight;
PAAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.99	11.37	0.68	4.55e-22	Parkinson's disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12727654	chr2:47143106	MCFD2	-0.68	-6.95	-0.49	1.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.68e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.57	4.98	0.37	1.67e-6	Common traits (Other);
PAAD	cis	rs12286929	0.687	rs6589485	chr11:115083875	G/A	cg04055981	chr11:115044050	NA	-0.44	-4.35	-0.33	2.45e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.38	5.23	0.39	5.49e-7	QT interval;
PAAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.15	16.59	0.8	6.39e-36	Cognitive function;
PAAD	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.12e-9	Type 2 diabetes;
PAAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.77	7.64	0.53	2.27e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg07636037	chr3:49044803	WDR6	0.72	6.55	0.47	8.5e-10	Menarche (age at onset);
PAAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	1.03	14.09	0.75	2.24e-29	Breast cancer;
PAAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.36	-4.97	-0.37	1.82e-6	QT interval;
PAAD	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.84	9.31	0.6	1.35e-16	Mortality in heart failure;
PAAD	cis	rs7011192	0.793	rs76894685	chr8:10523832	G/A	cg04501334	chr8:10513686	RP1L1	-0.9	-5.7	-0.42	5.91e-8	Suicide;
PAAD	cis	rs9810890	1.000	rs73196978	chr3:128450228	C/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg17595323	chr11:93583763	C11orf90	0.35	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.47	5.39	0.4	2.63e-7	Mean arterial pressure;
PAAD	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.65	0.35	7.06e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.51	6.17	0.45	5.86e-9	Sitting height ratio;
PAAD	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	1.05	8.37	0.56	3.45e-14	IgG glycosylation;
PAAD	cis	rs4453791	0.652	rs55991947	chr3:39077763	G/A	cg02254461	chr3:39195904	CSRNP1	0.58	5.21	0.39	6.11e-7	Social communication problems;
PAAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.83	9.14	0.6	3.7e-16	Height;
PAAD	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg03098721	chr1:84464084	TTLL7	0.47	4.38	0.33	2.18e-5	Obesity-related traits;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.99	7.47	0.52	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6687430	0.532	rs9430149	chr1:10612820	G/C	cg17425144	chr1:10567563	PEX14	-0.42	-4.6	-0.35	8.84e-6	Hand grip strength;
PAAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg03808351	chr9:123631620	PHF19	0.45	4.99	0.37	1.66e-6	Rheumatoid arthritis;
PAAD	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg01620082	chr3:125678407	NA	-1.06	-7.14	-0.5	3.5e-11	Depression;
PAAD	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-5.96	-0.44	1.65e-8	Menopause (age at onset);
PAAD	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.54	4.62	0.35	7.96e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg27057461	chr7:158136379	PTPRN2	-0.48	-4.36	-0.33	2.35e-5	Response to amphetamines;
PAAD	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.65	5.94	0.43	1.84e-8	Obesity-related traits;
PAAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.53	0.61	3.7e-17	Rheumatoid arthritis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08878188	chr12:109826583	MYO1H	0.62	7.05	0.5	5.85e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7684253	0.526	rs34112167	chr4:57719549	G/A	cg24291500	chr4:57773398	REST	-0.48	-5.0	-0.38	1.54e-6	Migraine;
PAAD	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg24747557	chr10:131355152	MGMT	0.46	5.09	0.38	1.05e-6	Response to temozolomide;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14038425	chr1:154833722	KCNN3	-0.7	-7.33	-0.51	1.26e-11	Obesity-related traits;
PAAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg07061783	chr6:25882402	NA	0.49	5.11	0.38	9.45e-7	Blood metabolite levels;
PAAD	cis	rs11235843	0.866	rs11235888	chr11:73470557	A/G	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs9467711	0.651	rs55912630	chr6:25866935	T/C	cg16898833	chr6:26189333	HIST1H4D	0.96	4.81	0.36	3.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs10861342	1.000	rs10861350	chr12:105484913	G/A	cg23923672	chr12:105501055	KIAA1033	0.78	4.62	0.35	8.11e-6	IgG glycosylation;
PAAD	cis	rs12042938	0.505	rs4603118	chr1:231754600	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-4.57	-0.35	1.02e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.86	10.95	0.66	6.3e-21	Bipolar disorder;
PAAD	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.99	6.26	0.45	3.8e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.57	-5.59	-0.41	1.02e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs2092319	0.649	rs807268	chr1:26066491	C/T	cg02327719	chr1:26185386	C1orf135	-0.85	-4.9	-0.37	2.4e-6	Nose morphology;
PAAD	cis	rs4454254	0.636	rs6997720	chr8:141047828	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.33	-4.53	-0.34	1.21e-5	Pulse pressure;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.46e-7	Prudent dietary pattern;
PAAD	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg02297831	chr4:17616191	MED28	-0.56	-5.29	-0.39	4.12e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2421770	0.594	rs10836355	chr11:35265444	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-5.37	-0.4	2.84e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg00531865	chr16:30841666	NA	0.56	4.33	0.33	2.64e-5	Dementia with Lewy bodies;
PAAD	cis	rs4690686	0.836	rs10015351	chr4:177258952	A/G	cg17059388	chr4:177262070	NA	0.5	4.95	0.37	1.98e-6	Essential tremor;
PAAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.58	-0.41	1.07e-7	Monocyte count;
PAAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.78	7.19	0.5	2.79e-11	Breast cancer;
PAAD	cis	rs41311933	0.656	rs80195731	chr9:123827963	G/T	cg13567360	chr9:123745713	C5	-0.69	-4.26	-0.33	3.56e-5	Coronary artery disease;
PAAD	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg14388049	chr10:71211838	TSPAN15	-0.49	-5.13	-0.38	8.74e-7	Thrombosis;
PAAD	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.86	-9.75	-0.62	9.82e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.38	-4.61	-0.35	8.39e-6	Rheumatoid arthritis;
PAAD	cis	rs73416724	0.688	rs76514175	chr6:43347125	A/G	cg17502394	chr6:43251710	TTBK1	0.72	4.47	0.34	1.54e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg04160749	chr8:58172571	NA	-0.65	-4.48	-0.34	1.48e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs990171	0.538	rs2075187	chr2:103120311	A/G	cg13897122	chr2:103039542	IL18RAP	0.42	4.55	0.35	1.08e-5	Lymphocyte counts;
PAAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.79	-0.36	3.9e-6	Lung cancer;
PAAD	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.36	4.7	0.36	5.73e-6	Mean corpuscular volume;
PAAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg10645314	chr2:3704589	ALLC	-0.53	-5.61	-0.41	9.31e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-9.12	-0.59	4.24e-16	Total body bone mineral density;
PAAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg06740227	chr12:86229804	RASSF9	0.49	4.65	0.35	7.17e-6	Major depressive disorder;
PAAD	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.74	7.03	0.5	6.37e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7873102	0.630	rs12343426	chr9:38001622	G/A	cg03528946	chr9:38069800	SHB	-0.5	-5.04	-0.38	1.28e-6	Brain structure;
PAAD	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg01064725	chr1:204461714	NA	-0.47	-4.39	-0.34	2.13e-5	Schizophrenia;
PAAD	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.52	-4.94	-0.37	2.02e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.59	-0.35	9.14e-6	Height;
PAAD	cis	rs2242194	0.515	rs60674412	chr1:155000370	C/T	cg24250549	chr1:154909240	PMVK	0.5	4.93	0.37	2.14e-6	Schizophrenia;
PAAD	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-4.3	-0.33	3.08e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.84	6.83	0.48	1.93e-10	Platelet count;
PAAD	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.72	9.24	0.6	2.02e-16	Eye color traits;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	cis	rs59888335	0.895	rs67610769	chr3:80819170	T/C	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg10729496	chr3:10149963	C3orf24	0.63	5.41	0.4	2.35e-7	Alzheimer's disease;
PAAD	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs2820315	0.541	rs10753906	chr1:201887382	C/G	cg06775570	chr1:201857621	SHISA4	-0.42	-4.89	-0.37	2.49e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
PAAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.89e-6	Skin colour saturation;
PAAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg20893579	chr22:38215064	NA	0.52	5.18	0.39	6.88e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg13870426	chr17:30244630	NA	-0.72	-6.43	-0.46	1.57e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.53	-4.74	-0.36	4.96e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16576597	chr16:28551801	NUPR1	0.78	8.31	0.56	5e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02578557	chr2:198175821	NA	-0.7	-7.54	-0.52	3.95e-12	Smoking initiation;
PAAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.88	10.95	0.66	6.03e-21	Prudent dietary pattern;
PAAD	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg12290671	chr7:99195819	NA	-0.96	-5.29	-0.39	4.27e-7	Blood metabolite ratios;
PAAD	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.52	5.91	0.43	2.21e-8	Skin aging (microtopography measurement);
PAAD	trans	rs901683	1.000	rs36102549	chr10:46082043	T/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg21419209	chr3:44054225	NA	0.72	7.23	0.51	2.16e-11	Coronary artery disease;
PAAD	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8113142	0.614	rs55898444	chr19:29192780	T/C	cg04546413	chr19:29218101	NA	0.39	4.26	0.33	3.55e-5	Femoral neck bone geometry and menarche (age at onset);
PAAD	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-7.13	-0.5	3.75e-11	Squamous cell lung carcinoma;
PAAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.64	-7.05	-0.5	5.74e-11	Facial morphology (factor 20);
PAAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg01299579	chr2:10830716	NOL10	0.58	5.99	0.44	1.47e-8	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10828910	chr2:63850056	LOC388955	-0.62	-6.3	-0.46	3.05e-9	Smoking initiation;
PAAD	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-7.6	-0.52	2.77e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9283706	0.673	rs2006323	chr5:66305992	T/C	cg11590213	chr5:66331682	MAST4	0.53	4.43	0.34	1.78e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg21698718	chr17:80085957	CCDC57	-0.48	-5.42	-0.4	2.25e-7	Life satisfaction;
PAAD	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.49	-4.59	-0.35	9.07e-6	Sudden cardiac arrest;
PAAD	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.96	-0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs332507	0.830	rs2242425	chr3:124398644	A/G	cg05980111	chr3:124395277	KALRN	0.43	4.34	0.33	2.61e-5	Plateletcrit;
PAAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.8	-7.62	-0.53	2.59e-12	DNA methylation (variation);
PAAD	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.44	-6.78	-0.48	2.49e-10	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.74	-7.78	-0.53	1.02e-12	Blood metabolite levels;
PAAD	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.3	-0.33	3.01e-5	Lewy body disease;
PAAD	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.1	8.86	0.58	1.98e-15	Vitiligo;
PAAD	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.91	10.55	0.65	7.42e-20	Primary sclerosing cholangitis;
PAAD	cis	rs9283706	0.593	rs10077634	chr5:66303346	G/A	cg11590213	chr5:66331682	MAST4	0.53	4.32	0.33	2.82e-5	Coronary artery disease;
PAAD	cis	rs9372149	0.510	rs9386620	chr6:107501429	G/T	cg26808436	chr6:108492696	NR2E1	0.3	4.29	0.33	3.14e-5	Childhood and early adolescence aggressive behavior;
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.34	0.56	4.14e-14	Lung cancer;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15064681	chr1:116312839	CASQ2	0.62	6.71	0.48	3.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6142102	0.602	rs6142069	chr20:32560542	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	4.87	0.37	2.75e-6	Skin pigmentation;
PAAD	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg00181669	chr3:44000978	NA	-0.54	-5.74	-0.42	4.88e-8	Coronary artery disease;
PAAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.24	0.51	2.1e-11	Yeast infection;
PAAD	cis	rs748404	0.578	rs538238	chr15:43585520	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	5.69	0.42	6.48e-8	Lung cancer;
PAAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.71e-9	Cognitive function;
PAAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg27494647	chr7:150038898	RARRES2	0.41	4.29	0.33	3.19e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2241047	0.526	rs738035	chr22:17594886	T/C	cg24435209	chr22:17640972	CECR5;CECR4	0.31	4.68	0.35	6.27e-6	Blood protein levels;
PAAD	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg09709951	chr12:54017699	ATF7	0.54	4.77	0.36	4.37e-6	Height;
PAAD	cis	rs7715811	1.000	rs1502042	chr5:13758344	G/A	cg07548982	chr5:13769939	DNAH5	-0.64	-6.22	-0.45	4.51e-9	Subclinical atherosclerosis traits (other);
PAAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.18	-0.39	6.81e-7	Dental caries;
PAAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.87	4.6	0.35	8.97e-6	Childhood ear infection;
PAAD	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg18944383	chr4:111397179	ENPEP	0.7	6.31	0.46	2.91e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7301016	0.652	rs2270732	chr12:62965149	T/C	cg11441379	chr12:63026424	NA	0.54	4.51	0.34	1.27e-5	IgG glycosylation;
PAAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-6.01	-0.44	1.31e-8	Schizophrenia;
PAAD	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-7.03	-0.5	6.44e-11	Hip circumference;
PAAD	cis	rs1018836	0.628	rs6471085	chr8:91463783	G/A	cg16814680	chr8:91681699	NA	-0.91	-11.03	-0.67	3.69e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.15	8.16	0.55	1.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.6	-5.29	-0.39	4.23e-7	Type 2 diabetes;
PAAD	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.58	-5.23	-0.39	5.64e-7	White blood cell count;
PAAD	cis	rs332507	0.830	rs62265580	chr3:124359842	C/T	cg05980111	chr3:124395277	KALRN	0.48	4.59	0.35	9.1e-6	Plateletcrit;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05074645	chr13:101327922	TMTC4	-0.69	-6.3	-0.46	3.04e-9	Neuroticism;
PAAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.64	6.53	0.47	9.14e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.62	5.97	0.44	1.64e-8	Acylcarnitine levels;
PAAD	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	6.79	0.48	2.39e-10	Lymphocyte counts;
PAAD	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.89	0.37	2.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.75	-7.35	-0.51	1.12e-11	DNA methylation (variation);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14899563	chr17:80656473	RAB40B	0.58	6.57	0.47	7.67e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg18828861	chr6:116576566	TSPYL4	0.58	6.31	0.46	2.83e-9	Age-related macular degeneration;
PAAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg11062466	chr8:58055876	NA	0.65	4.72	0.36	5.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg18944383	chr4:111397179	ENPEP	-0.73	-8.06	-0.55	2.04e-13	Coronary artery disease;
PAAD	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg14171486	chr1:155139557	NA	-0.34	-4.64	-0.35	7.35e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg02753203	chr1:228287806	NA	0.6	4.9	0.37	2.44e-6	Coronary artery disease;
PAAD	cis	rs797680	0.856	rs1535701	chr1:93805201	T/G	cg04535902	chr1:92947332	GFI1	0.46	4.45	0.34	1.65e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.44	-5.95	-0.43	1.75e-8	Congenital heart disease (maternal effect);
PAAD	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg23465465	chr6:26364728	BTN3A2	0.74	4.4	0.34	2.02e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.84	-0.48	1.86e-10	Platelet distribution width;
PAAD	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.53	5.37	0.4	2.89e-7	Resting heart rate;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18621852	chr3:10150065	C3orf24	0.73	6.49	0.47	1.16e-9	Alzheimer's disease;
PAAD	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.93	-8.92	-0.59	1.36e-15	Post bronchodilator FEV1;
PAAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs9815354	1.000	rs9852303	chr3:41759525	C/T	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.47	-5.46	-0.41	1.87e-7	Mean corpuscular volume;
PAAD	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.53	4.67	0.35	6.46e-6	Plateletcrit;
PAAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.58	-4.72	-0.36	5.28e-6	Schizophrenia;
PAAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.6	-5.74	-0.42	4.95e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.46	4.46	0.34	1.59e-5	Lung cancer;
PAAD	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.81	-0.36	3.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.84	-13.04	-0.73	1.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs12545912	0.866	rs10903318	chr8:9585483	A/T	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs2180233	0.785	rs12124046	chr1:30672845	C/T	cg06703062	chr1:31191648	MATN1	0.48	4.3	0.33	3e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.88	9.31	0.6	1.36e-16	Prostate cancer;
PAAD	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.5	-5.23	-0.39	5.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg20850873	chr3:10149803	C3orf24	0.55	4.34	0.33	2.63e-5	Alzheimer's disease;
PAAD	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg14393609	chr7:65229607	NA	0.48	4.58	0.35	9.76e-6	Aortic root size;
PAAD	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10277546	chr21:34960952	DONSON	0.66	6.5	0.47	1.07e-9	Myopia (pathological);
PAAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg16306870	chr3:194868790	C3orf21	0.47	4.29	0.33	3.21e-5	Non-small cell lung cancer;
PAAD	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.65	-0.42	7.87e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1126510	0.565	rs75660000	chr19:47119227	T/C	cg11822964	chr19:47129337	PTGIR	0.44	4.37	0.33	2.27e-5	Ulcerative colitis;
PAAD	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.05	0.38	1.23e-6	Childhood ear infection;
PAAD	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.58	-4.88	-0.37	2.66e-6	Atopic dermatitis;
PAAD	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg01075559	chr1:2537774	MMEL1	-0.53	-5.59	-0.41	1.01e-7	Ulcerative colitis;
PAAD	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.83	-0.48	1.93e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.28	0.45	3.37e-9	Schizophrenia;
PAAD	cis	rs7560272	0.538	rs12233112	chr2:73931764	G/A	cg12756303	chr2:74692479	MOGS	-0.47	-4.34	-0.33	2.61e-5	Schizophrenia;
PAAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.62	5.9	0.43	2.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	4.34	0.33	2.6e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg04775059	chr7:64541387	NA	-0.56	-5.87	-0.43	2.67e-8	Calcium levels;
PAAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.52	-4.9	-0.37	2.48e-6	Monocyte count;
PAAD	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.49	5.65	0.42	7.7e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg21300403	chr2:198650112	BOLL	-0.51	-4.5	-0.34	1.34e-5	Dermatomyositis;
PAAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.08e-11	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26098624	chr6:41511564	NA	-0.71	-7.22	-0.51	2.38e-11	Obesity-related traits;
PAAD	cis	rs55986470	0.763	rs10188853	chr2:239430558	G/C	cg18131467	chr2:239335373	ASB1	-0.65	-4.62	-0.35	8e-6	Chronotype;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.79	-9.23	-0.6	2.14e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs17309827	0.965	rs13206690	chr6:3433340	T/G	cg00476032	chr6:3446245	SLC22A23	-0.41	-4.31	-0.33	2.94e-5	Crohn's disease;
PAAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.63	-0.35	7.92e-6	Lung cancer;
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg00450029	chr8:599525	NA	0.82	5.38	0.4	2.79e-7	IgG glycosylation;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg01289902	chr10:75174282	ANXA7	0.55	6.36	0.46	2.2e-9	Metabolite levels  (X-11787);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg22763753	chr12:27397052	STK38L	0.55	6.3	0.46	3.01e-9	Immature fraction of reticulocytes;
PAAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.87	9.57	0.61	2.84e-17	Cognitive function;
PAAD	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg16586182	chr3:47516702	SCAP	0.65	7.22	0.51	2.34e-11	Colorectal cancer;
PAAD	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg21951679	chr5:178977648	RUFY1	-0.93	-6.65	-0.47	4.89e-10	Airflow obstruction;
PAAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26320663	chr1:152161521	NA	0.48	4.74	0.36	4.97e-6	Inflammatory skin disease;
PAAD	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Body mass index;
PAAD	cis	rs6137287	0.924	rs6047293	chr20:21154487	G/A	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.61	-5.84	-0.43	3.08e-8	Aortic root size;
PAAD	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.84	-5.93	-0.43	2e-8	Gallbladder cancer;
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07685180	chr8:600429	NA	0.83	5.16	0.39	7.62e-7	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25239767	chr7:130791807	FLJ43663	0.61	6.49	0.47	1.15e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	1.0	8.68	0.58	5.65e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs78472555	0.633	rs8029296	chr15:100238019	C/T	cg18869061	chr15:100272053	LYSMD4	0.5	4.36	0.33	2.4e-5	Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg10934807	chr2:113191815	RGPD8;RGPD5	0.96	6.87	0.49	1.58e-10	Yeast infection;
PAAD	cis	rs17152411	1.000	rs12571196	chr10:126597749	A/C	cg07906193	chr10:126599966	NA	0.71	5.55	0.41	1.27e-7	Height;
PAAD	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg04575393	chr19:53496094	ZNF702P	-0.45	-4.97	-0.37	1.77e-6	Psoriasis;
PAAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.6	-0.41	9.72e-8	Personality dimensions;
PAAD	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg10596483	chr8:143751796	JRK	-0.48	-4.25	-0.33	3.76e-5	Urinary tract infection frequency;
PAAD	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.55	-5.63	-0.42	8.52e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.78	-5.67	-0.42	7.13e-8	Vitiligo;
PAAD	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.41	-13.22	-0.73	4.79e-27	Uric acid levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01137537	chr1:162039502	NOS1AP	0.56	6.48	0.47	1.18e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-4.28	-0.33	3.23e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg15193198	chr20:60906057	LAMA5	0.59	6.68	0.48	4.27e-10	Colorectal cancer;
PAAD	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg21775007	chr8:11205619	TDH	-0.48	-4.37	-0.33	2.26e-5	Neuroticism;
PAAD	cis	rs2544527	0.557	rs2112101	chr2:15902679	C/T	cg26669897	chr2:15909070	NA	-0.48	-4.76	-0.36	4.42e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.48	4.64	0.35	7.47e-6	HDL cholesterol;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg27023235	chr10:94429569	NA	0.67	6.38	0.46	2.02e-9	Body mass index;
PAAD	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.64	5.78	0.42	4.11e-8	Height;
PAAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.49e-7	Life satisfaction;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.59	-5.63	-0.42	8.46e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	5.33	0.4	3.52e-7	Monocyte percentage of white cells;
PAAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.81	-0.43	3.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg23643435	chr2:38893251	GALM	-0.63	-4.47	-0.34	1.52e-5	5-HTT brain serotonin transporter levels;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23924603	chr19:38826365	CATSPERG	0.55	6.65	0.47	4.87e-10	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09256131	chr14:99738493	BCL11B	0.65	6.63	0.47	5.51e-10	Obesity-related traits;
PAAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg21929781	chr1:2537748	MMEL1	0.54	5.69	0.42	6.39e-8	Ulcerative colitis;
PAAD	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg14196790	chr5:131705035	SLC22A5	0.45	4.79	0.36	3.95e-6	Breast cancer;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.69	6.83	0.48	1.95e-10	Menarche (age at onset);
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.5	-5.11	-0.38	9.57e-7	Breast cancer;
PAAD	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg20003494	chr4:90757398	SNCA	-0.42	-4.56	-0.35	1.05e-5	Dementia with Lewy bodies;
PAAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg02462569	chr6:150064036	NUP43	-0.49	-5.41	-0.4	2.45e-7	Lung cancer;
PAAD	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4253772	0.515	rs6008784	chr22:46774317	T/C	cg00784671	chr22:46762841	CELSR1	-0.79	-4.55	-0.35	1.07e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06002616	chr8:101225028	SPAG1	0.46	5.38	0.4	2.74e-7	Atrioventricular conduction;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg16926213	chr1:1841314	NA	-0.38	-4.63	-0.35	7.79e-6	Body mass index;
PAAD	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg14458575	chr2:238380390	NA	0.86	6.54	0.47	8.93e-10	Prostate cancer;
PAAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-6.3	-0.46	2.98e-9	Menopause (age at onset);
PAAD	cis	rs897984	0.881	rs12920259	chr16:30881299	G/A	cg00531865	chr16:30841666	NA	0.59	5.76	0.42	4.46e-8	Dementia with Lewy bodies;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18548208	chr14:89259557	EML5	0.67	6.59	0.47	6.75e-10	Obesity-related traits;
PAAD	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg09980403	chr19:12975529	MAST1	0.31	4.71	0.36	5.63e-6	Mean corpuscular volume;
PAAD	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.62	-0.35	8.24e-6	Rheumatoid arthritis;
PAAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.31	0.33	2.87e-5	Personality dimensions;
PAAD	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.46e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs5758659	0.789	rs2413684	chr22:42574830	C/T	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.31	-0.33	2.87e-5	Cognitive function;
PAAD	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.68	-0.35	6.35e-6	Glomerular filtration rate;
PAAD	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg10327424	chr1:202611933	SYT2	-0.46	-4.74	-0.36	4.94e-6	Mean platelet volume;
PAAD	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.91	-8.45	-0.57	2.17e-14	Body mass index;
PAAD	cis	rs1723838	0.702	rs1623476	chr11:73581224	C/T	cg26954736	chr11:73693896	UCP2	1.09	4.73	0.36	5.14e-6	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.67	7.04	0.5	6.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg19442545	chr10:75533431	FUT11	-0.55	-5.76	-0.42	4.58e-8	Inflammatory bowel disease;
PAAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.72	-8.44	-0.56	2.33e-14	Diastolic blood pressure;
PAAD	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.32	0.4	3.67e-7	Schizophrenia;
PAAD	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-10.27	-0.64	3.96e-19	Height;
PAAD	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg19767477	chr5:127420684	SLC12A2	-0.6	-4.95	-0.37	1.93e-6	Ileal carcinoids;
PAAD	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.49e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.42e-7	Electroencephalogram traits;
PAAD	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.43	-4.51	-0.34	1.31e-5	Response to antidepressants in depression;
PAAD	cis	rs9659323	0.730	rs10802070	chr1:119541486	C/T	cg17326555	chr1:119535693	NA	-0.42	-5.91	-0.43	2.12e-8	Body mass index;
PAAD	trans	rs340029	0.539	rs7169364	chr15:60867545	A/T	cg15508193	chr19:17966537	NA	-0.79	-6.38	-0.46	2.02e-9	C-reactive protein levels;
PAAD	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg13870426	chr17:30244630	NA	-0.73	-6.47	-0.46	1.27e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21834860	chr7:35734805	HERPUD2	0.58	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs939584	1.000	rs35142762	chr2:636790	T/C	cg14515364	chr2:636606	NA	-0.5	-4.67	-0.35	6.69e-6	Body mass index;
PAAD	cis	rs732765	0.734	rs12893245	chr14:75168936	G/A	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-4.99	-0.38	1.61e-6	Personality dimensions;
PAAD	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.61	5.94	0.43	1.82e-8	Uric acid levels;
PAAD	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-8.56	-0.57	1.17e-14	Chronic sinus infection;
PAAD	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	6.82	0.48	2.01e-10	Hip circumference;
PAAD	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.35	4.47	0.34	1.52e-5	Educational attainment (years of education);
PAAD	trans	rs62179067	1.000	rs62175449	chr2:179990211	A/G	cg23458843	chr12:58136445	AGAP2	0.96	6.36	0.46	2.21e-9	Late-onset Alzheimer's disease;
PAAD	cis	rs6066835	1.000	rs6095272	chr20:47357517	A/G	cg18078177	chr20:47281410	PREX1	0.95	4.44	0.34	1.69e-5	Multiple myeloma;
PAAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.74	-8.5	-0.57	1.68e-14	Childhood ear infection;
PAAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.87	9.26	0.6	1.81e-16	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16583279	chr13:25086642	PARP4	0.58	6.82	0.48	1.97e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12431939	1.000	rs12431939	chr14:51692699	A/G	cg23942311	chr14:51606299	NA	0.64	5.15	0.39	7.96e-7	Cancer;
PAAD	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg06026331	chr20:60912101	LAMA5	0.75	6.43	0.46	1.53e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg21890820	chr11:65308645	LTBP3	0.65	7.78	0.53	1.03e-12	Bone mineral density;
PAAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.28	-0.33	3.36e-5	Iron status biomarkers;
PAAD	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.73	-8.3	-0.56	5.12e-14	Airway imaging phenotypes;
PAAD	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.25	-0.39	5.03e-7	Height;
PAAD	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.85	-6.02	-0.44	1.27e-8	Gallbladder cancer;
PAAD	cis	rs9467603	0.858	rs972087	chr6:25872579	A/G	cg23465465	chr6:26364728	BTN3A2	0.77	4.84	0.37	3.2e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.51	0.57	1.51e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733418	0.929	rs1401401	chr4:165927956	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.74	-0.42	4.98e-8	Obesity-related traits;
PAAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	1.07	15.03	0.77	7.43e-32	Breast cancer;
PAAD	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.56	6.21	0.45	4.77e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.66	8.61	0.57	8.52e-15	Skin aging (microtopography measurement);
PAAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.54	-6.94	-0.49	1.06e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg02734326	chr4:10020555	SLC2A9	0.53	5.39	0.4	2.58e-7	Bone mineral density;
PAAD	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.98	11.64	0.69	8.74e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.62	7.0	0.49	7.53e-11	Vitiligo;
PAAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg16205897	chr5:131564050	P4HA2	-0.55	-6.06	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.42	4.44	0.34	1.7e-5	Obesity-related traits;
PAAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg24733560	chr20:60626293	TAF4	0.5	6.3	0.45	3.09e-9	Body mass index;
PAAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.46	8.26	0.56	6.48e-14	Multiple system atrophy;
PAAD	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-6.48	-0.47	1.21e-9	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7555006	0.621	rs11579642	chr1:51468552	A/G	cg06082920	chr1:51796003	TTC39A	0.47	4.63	0.35	7.7e-6	Headache;
PAAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11264799	0.731	rs2873406	chr1:157692450	C/T	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.55	-5.36	-0.4	2.98e-7	Motion sickness;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.16	-0.45	6.08e-9	Longevity;Endometriosis;
PAAD	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.9	-6.23	-0.45	4.26e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.66	4.5	0.34	1.37e-5	Inflammatory bowel disease;
PAAD	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.93	-9.67	-0.62	1.58e-17	Response to antineoplastic agents;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27511208	chr1:33336611	FNDC5	0.63	7.41	0.52	8.22e-12	Monocyte percentage of white cells;
PAAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.16e-32	Height;
PAAD	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg23024343	chr7:107201750	COG5	0.54	4.32	0.33	2.79e-5	Osteoarthritis;
PAAD	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.08	14.39	0.76	3.65e-30	Primary sclerosing cholangitis;
PAAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg05484376	chr2:27715224	FNDC4	0.51	5.1	0.38	1.01e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.34	5.0	0.38	1.56e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs4281086	1.000	rs4281086	chr8:10352308	G/T	cg01072821	chr8:10382165	T-SP1	-0.45	-4.68	-0.35	6.39e-6	Obesity-related traits;
PAAD	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg14825688	chr5:132208181	LEAP2	-0.62	-6.34	-0.46	2.45e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.6	-5.48	-0.41	1.75e-7	Total body bone mineral density;
PAAD	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg00262122	chr8:11665843	FDFT1	0.5	4.77	0.36	4.34e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.61	5.89	0.43	2.4e-8	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	9.17	0.6	3.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	NT-proBNP levels in acute coronary syndrome;
PAAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.87	9.45	0.61	5.97e-17	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.76	8.96	0.59	1.1e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs75757892	0.542	rs9505153	chr6:7324780	G/T	cg02954307	chr6:7269328	NA	0.5	4.27	0.33	3.44e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.44	0.46	1.49e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.08	9.64	0.62	1.91e-17	Red blood cell traits;
PAAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.14	0.5	3.54e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.73	7.06	0.5	5.55e-11	Schizophrenia;
PAAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00292662	chr22:38071168	LGALS1	0.65	6.81	0.48	2.14e-10	Fat distribution (HIV);
PAAD	cis	rs9463078	0.625	rs6926370	chr6:44947280	G/C	cg25276700	chr6:44698697	NA	-0.54	-6.11	-0.44	8.01e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11825064	0.562	rs77092254	chr11:134512159	G/C	cg06603561	chr11:134479413	NA	-0.94	-5.82	-0.43	3.39e-8	Seasonality;
PAAD	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.45	-0.34	1.67e-5	Coronary artery disease;
PAAD	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg06217071	chr17:408420	NA	0.78	8.9	0.59	1.54e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.78	-6.12	-0.44	7.79e-9	HDL cholesterol;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg15117754	chr3:10150083	C3orf24	0.66	5.46	0.41	1.87e-7	Alzheimer's disease;
PAAD	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.96	13.27	0.73	3.52e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.2	0.5	2.6e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg10729496	chr3:10149963	C3orf24	0.84	7.11	0.5	4.24e-11	Alzheimer's disease;
PAAD	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.52	5.0	0.38	1.55e-6	Itch intensity from mosquito bite;
PAAD	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.52	4.59	0.35	9.2e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	9.8	0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	1.02	8.17	0.55	1.13e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg13191508	chr8:144600686	ZC3H3	-0.78	-4.6	-0.35	9e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg02574844	chr11:5959923	NA	-0.63	-6.13	-0.45	7.31e-9	DNA methylation (variation);
PAAD	trans	rs901683	1.000	rs12774690	chr10:45989745	G/T	cg14076390	chr17:34947837	DHRS11	0.92	6.81	0.48	2.15e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg08079166	chr15:68083412	MAP2K5	0.62	4.91	0.37	2.31e-6	Restless legs syndrome;
PAAD	cis	rs17032980	0.910	rs6712923	chr2:67313799	A/T	cg06994420	chr2:66672553	MEIS1	-0.51	-4.5	-0.34	1.35e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.44	-4.27	-0.33	3.48e-5	Chronic sinus infection;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02967152	chr11:64014589	PPP1R14B	0.59	6.52	0.47	1e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.62	5.48	0.41	1.73e-7	Diastolic blood pressure;
PAAD	cis	rs300774	0.925	rs300739	chr2:161605	A/G	cg23649280	chr2:140451	NA	-0.46	-4.28	-0.33	3.3e-5	Suicide attempts in bipolar disorder;
PAAD	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg04545296	chr12:48745243	ZNF641	0.35	4.39	0.34	2.13e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg19423196	chr10:82049429	MAT1A	0.58	4.31	0.33	2.95e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
PAAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.88	10.1	0.63	1.13e-18	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19678270	chr3:180630780	FXR1	0.57	6.52	0.47	9.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.0	-0.59	8.55e-16	Aortic root size;
PAAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg11494091	chr17:61959527	GH2	0.52	4.43	0.34	1.8e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg21665744	chr7:39171113	POU6F2	0.35	5.86	0.43	2.76e-8	IgG glycosylation;
PAAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.5	6.2	0.45	5.11e-9	Monobrow;
PAAD	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.25	-0.33	3.67e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg02493740	chr2:85810744	VAMP5	0.45	5.07	0.38	1.14e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18621852	chr3:10150065	C3orf24	-0.62	-5.27	-0.39	4.61e-7	Alzheimer's disease;
PAAD	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg16576597	chr16:28551801	NUPR1	0.63	6.8	0.48	2.2e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.49	-5.86	-0.43	2.8e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.15	0.39	7.96e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17626178	chr2:205410273	PARD3B	0.71	6.89	0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-4.98	-0.37	1.71e-6	Interstitial lung disease;
PAAD	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.46	4.87	0.37	2.73e-6	QRS complex (12-leadsum);
PAAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg23119463	chr10:134592391	INPP5A	-0.47	-4.35	-0.33	2.53e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.49	7.07	0.5	5.4e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg14703610	chr5:56206110	C5orf35	0.63	5.78	0.42	4.12e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.4	5.04	0.38	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg14906510	chr12:7781169	NA	0.63	4.54	0.35	1.15e-5	HDL cholesterol levels;
PAAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	4.26	0.33	3.54e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-5.17	-0.39	7.14e-7	Bone mineral density;
PAAD	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-12.87	-0.72	4.28e-26	Primary sclerosing cholangitis;
PAAD	cis	rs12600053	0.554	rs4783077	chr16:84848221	A/G	cg09249803	chr16:84846936	NA	0.52	4.34	0.33	2.64e-5	Asthma (childhood onset);
PAAD	cis	rs3736485	0.844	rs12593979	chr15:51741579	A/G	cg08986416	chr15:51914746	DMXL2	0.45	4.31	0.33	2.98e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs877529	0.967	rs12158877	chr22:39549426	T/G	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg07636037	chr3:49044803	WDR6	0.6	5.43	0.4	2.23e-7	Resting heart rate;
PAAD	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3026101	0.671	rs2301738	chr17:5308279	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.96	0.44	1.71e-8	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19839035	chr2:20424326	SDC1	-0.66	-6.83	-0.48	1.95e-10	Smoking initiation;
PAAD	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg16576597	chr16:28551801	NUPR1	0.63	6.98	0.49	8.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg09659197	chr4:152720779	NA	0.46	6.09	0.44	9.07e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.77	7.31	0.51	1.42e-11	Birth weight;
PAAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg14703610	chr5:56206110	C5orf35	0.61	5.64	0.42	8.12e-8	Coronary artery disease;
PAAD	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.93	-0.43	2e-8	Cervical cancer;
PAAD	cis	rs141342723	1	rs141342723	chr6:27622084	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.58	-4.78	-0.36	4.11e-6	Facial morphology (factor 19);
PAAD	cis	rs9992101	0.547	rs7654978	chr4:77409945	G/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.7	7.0	0.49	7.73e-11	Mosquito bite size;
PAAD	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg20761395	chr17:511517	VPS53	0.47	5.11	0.38	9.53e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs12475964	0.698	rs13008681	chr2:37383625	G/T	cg22370082	chr2:37384244	EIF2AK2	0.44	4.34	0.33	2.54e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg15654264	chr1:150340011	RPRD2	0.49	4.78	0.36	4.05e-6	Migraine;
PAAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg12858261	chr2:113808755	IL1F8	0.45	4.47	0.34	1.54e-5	Inflammatory biomarkers;
PAAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.53e-9	Bladder cancer;
PAAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.74	8.58	0.57	1.01e-14	Bipolar disorder and schizophrenia;
PAAD	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.42	-0.4	2.25e-7	Lung cancer;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.72	0.53	1.42e-12	Prudent dietary pattern;
PAAD	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg13444538	chr7:158905317	VIPR2	-0.68	-5.03	-0.38	1.39e-6	Myopia (pathological);
PAAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg09796270	chr17:17721594	SREBF1	-0.45	-5.25	-0.39	5.13e-7	Total body bone mineral density;
PAAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.79	-7.13	-0.5	3.73e-11	Bronchopulmonary dysplasia;
PAAD	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.46	-5.51	-0.41	1.51e-7	Colorectal cancer;
PAAD	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg18825076	chr15:78729989	IREB2	-0.69	-7.18	-0.5	2.96e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg12373951	chr3:133503437	NA	-0.47	-5.87	-0.43	2.62e-8	Alcohol consumption (transferrin glycosylation);
PAAD	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.64	6.81	0.48	2.14e-10	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg24955406	chr1:100503596	HIAT1	-0.65	-4.38	-0.33	2.21e-5	Carotid intima media thickness;
PAAD	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	4.32	0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg06637938	chr14:75390232	RPS6KL1	0.47	4.66	0.35	6.8e-6	Height;
PAAD	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg27449745	chr7:23145252	KLHL7	-0.49	-4.3	-0.33	3.08e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-4.29	-0.33	3.2e-5	Ulcerative colitis;
PAAD	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.85	-9.82	-0.62	6.29e-18	Gout;
PAAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.46	4.51	0.34	1.26e-5	Mean corpuscular volume;
PAAD	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg12215294	chr3:40350768	EIF1B	0.48	4.91	0.37	2.37e-6	Renal cell carcinoma;
PAAD	cis	rs7873102	0.654	rs10732212	chr9:37957598	A/G	cg03528946	chr9:38069800	SHB	0.56	5.64	0.42	7.96e-8	Brain structure;
PAAD	cis	rs6547631	0.808	rs13011848	chr2:85907694	G/A	cg24620635	chr2:85921963	GNLY	0.34	4.26	0.33	3.61e-5	Blood protein levels;
PAAD	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.32	8.14	0.55	1.3e-13	Psoriasis vulgaris;
PAAD	cis	rs6782025	0.837	rs339006	chr3:120991999	G/T	cg16417163	chr3:121280760	NA	-0.45	-4.68	-0.36	6.25e-6	Aging (facial);
PAAD	cis	rs1419980	0.730	rs9634125	chr12:7734246	C/T	cg25828445	chr12:7781288	NA	0.83	4.29	0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.71	7.38	0.51	9.78e-12	DNA methylation (variation);
PAAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.71	9.59	0.61	2.46e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs10850408	0.848	rs7959016	chr12:115370347	A/G	cg05726002	chr12:115341178	NA	-0.41	-4.83	-0.36	3.36e-6	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04136290	chr17:80477136	FOXK2	0.57	6.47	0.46	1.25e-9	Monocyte percentage of white cells;
PAAD	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.16	0.39	7.67e-7	Tonsillectomy;
PAAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.28	-0.33	3.32e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg27121462	chr16:89883253	FANCA	0.84	4.25	0.33	3.76e-5	Skin colour saturation;
PAAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.52	7.01	0.49	7.36e-11	Life satisfaction;
PAAD	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg06550200	chr5:1325588	CLPTM1L	0.64	6.49	0.47	1.17e-9	Lung cancer;
PAAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg22143856	chr6:28129313	ZNF389	0.55	5.17	0.39	7.4e-7	Parkinson's disease;
PAAD	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.5	5.11	0.38	9.73e-7	Height;
PAAD	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22162314	chr17:61951766	CSH2	-0.61	-6.29	-0.45	3.15e-9	Height;
PAAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-4.36	-0.33	2.43e-5	Tonsillectomy;
PAAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg11619707	chr19:22235551	ZNF257	0.59	5.98	0.44	1.55e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23708337	chr7:1209742	NA	0.63	4.51	0.34	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.59	-4.64	-0.35	7.39e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.53	6.01	0.44	1.32e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1419980	0.730	rs74785649	chr12:7768845	C/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10421011	chr17:57290399	C17orf71	-0.62	-6.39	-0.46	1.94e-9	Obesity-related traits;
PAAD	cis	rs8040855	0.627	rs12909971	chr15:85588998	C/G	cg08123816	chr15:85640762	PDE8A	-0.43	-5.03	-0.38	1.37e-6	Bulimia nervosa;
PAAD	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.64	7.48	0.52	5.58e-12	Dupuytren's disease;
PAAD	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	11.01	0.67	4.14e-21	Electrocardiographic conduction measures;
PAAD	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	7.08	0.5	4.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg10705379	chr10:99080932	FRAT1	-0.38	-4.44	-0.34	1.69e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9315702	1.000	rs9315702	chr13:40118068	G/T	cg26881651	chr13:39327640	FREM2	-0.34	-4.27	-0.33	3.43e-5	Hippocampal atrophy;
PAAD	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	5.84	0.43	3.13e-8	Blood protein levels;
PAAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.37	-0.51	1.02e-11	Chronic sinus infection;
PAAD	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08919486	chr4:859471	GAK	-0.7	-6.33	-0.46	2.57e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.77	-6.81	-0.48	2.13e-10	Morning vs. evening chronotype;
PAAD	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs58521262	0.729	rs58977014	chr19:23062229	G/A	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.65	6.77	0.48	2.64e-10	Systemic lupus erythematosus;
PAAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14895029	chr7:2775587	GNA12	-0.44	-4.52	-0.34	1.25e-5	Height;
PAAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg10494973	chr17:80897199	TBCD	0.56	4.58	0.35	9.57e-6	Breast cancer;
PAAD	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg00035074	chr7:2701567	TTYH3	0.65	4.44	0.34	1.74e-5	Bipolar disorder;
PAAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg21724239	chr8:58056113	NA	0.67	5.33	0.4	3.5e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1797885	0.738	rs1695227	chr3:12558890	C/A	cg07775309	chr3:12595852	NA	0.4	4.4	0.34	2.05e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	12.67	0.72	1.45e-25	Platelet count;
PAAD	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg03188948	chr7:1209495	NA	0.73	5.71	0.42	5.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg18093693	chr15:72668265	HEXA;C15orf34	0.62	6.75	0.48	2.94e-10	Response to antipsychotic treatment;
PAAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.57	8.63	0.57	7.56e-15	Hypertriglyceridemia;
PAAD	cis	rs9467711	0.516	rs523383	chr6:25869848	A/G	cg08501292	chr6:25962987	TRIM38	0.68	4.42	0.34	1.85e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg05484376	chr2:27715224	FNDC4	-0.48	-4.73	-0.36	5.09e-6	Total body bone mineral density;
PAAD	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.76	4.5	0.34	1.33e-5	Coronary artery disease;
PAAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg09017928	chr7:158110068	PTPRN2	0.45	4.45	0.34	1.68e-5	Calcium levels;
PAAD	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-6.67	-0.48	4.53e-10	Monocyte percentage of white cells;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.29	10.32	0.64	2.96e-19	Uric acid levels;
PAAD	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.98	-13.15	-0.73	7.44e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg22815214	chr1:201083145	CACNA1S	0.68	6.78	0.48	2.55e-10	Permanent tooth development;
PAAD	cis	rs11677203	0.958	rs34252971	chr2:12559810	A/G	cg01085830	chr2:11774354	GREB1	0.48	4.74	0.36	4.81e-6	Electroencephalogram traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24193339	chr22:43583738	TTLL12	0.74	7.52	0.52	4.34e-12	Obesity-related traits;
PAAD	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.71	-7.19	-0.5	2.8e-11	Lymphocyte percentage of white cells;
PAAD	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg10437265	chr15:77819839	NA	0.41	4.32	0.33	2.76e-5	Type 2 diabetes;
PAAD	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.75	8.69	0.58	5.24e-15	Lewy body disease;
PAAD	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg26003909	chr8:143102224	NA	0.35	5.79	0.43	3.82e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.97	-15.15	-0.78	3.44e-32	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-4.76	-0.36	4.42e-6	Schizophrenia;
PAAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg17541715	chr7:1216824	NA	-0.56	-6.35	-0.46	2.33e-9	Longevity;Endometriosis;
PAAD	cis	rs923375	0.604	rs35156626	chr17:3357244	T/C	cg02458198	chr17:3375211	SPATA22	0.57	4.86	0.37	2.84e-6	Myopia (pathological);
PAAD	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	6.76	0.48	2.8e-10	Blood protein levels;
PAAD	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.81	8.88	0.58	1.72e-15	Corneal astigmatism;
PAAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21211367	chr2:162094118	NA	-0.48	-4.78	-0.36	4.17e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35000415	0.938	rs12531711	chr7:128617466	A/G	cg19972273	chr7:128594194	NA	0.97	5.66	0.42	7.45e-8	Systemic lupus erythematosus;
PAAD	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	1.04	10.48	0.65	1.09e-19	Platelet distribution width;
PAAD	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17347941	chr15:79387269	NA	-0.4	-4.26	-0.33	3.64e-5	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9810890	1.000	rs73196972	chr3:128443796	C/T	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.55	-5.97	-0.44	1.61e-8	Colorectal or endometrial cancer;
PAAD	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.73	0.42	5.33e-8	Prudent dietary pattern;
PAAD	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.47	0.41	1.8e-7	Ileal carcinoids;
PAAD	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.55	-5.4	-0.4	2.49e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg15942720	chr14:51706980	TMX1	0.5	4.39	0.34	2.1e-5	Cancer;
PAAD	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg03233332	chr7:66118400	NA	0.4	4.27	0.33	3.42e-5	Aortic root size;
PAAD	cis	rs2882667	0.690	rs825758	chr5:138126977	G/A	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.73	6.77	0.48	2.57e-10	Obesity-related traits;
PAAD	cis	rs847851	1.000	rs847846	chr6:34925371	G/T	cg13196216	chr6:34231128	NA	0.62	5.14	0.39	8.16e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	0.93	10.14	0.64	8.65e-19	Testicular germ cell tumor;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07392897	chr7:32996733	FKBP9	0.62	7.27	0.51	1.81e-11	Monocyte percentage of white cells;
PAAD	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.64	6.06	0.44	1.04e-8	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg06632027	chr4:90757378	SNCA	-0.59	-5.28	-0.39	4.35e-7	Neuroticism;
PAAD	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg27057461	chr7:158136379	PTPRN2	-0.48	-4.36	-0.33	2.35e-5	Response to amphetamines;
PAAD	cis	rs2461451	0.559	rs72838423	chr2:128665361	C/A	cg00597225	chr2:128649830	NA	-0.67	-4.64	-0.35	7.32e-6	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs1413885	1.000	rs10789181	chr1:65816567	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.08	0.38	1.09e-6	Anticoagulant levels;
PAAD	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg05791153	chr7:19748676	TWISTNB	0.69	4.59	0.35	9.29e-6	Thyroid stimulating hormone;
PAAD	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.8	7.64	0.53	2.25e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg10935138	chr17:73851978	WBP2	0.93	7.71	0.53	1.55e-12	Psoriasis;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.08	13.61	0.74	4.37e-28	Subjective well-being;
PAAD	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.42	5.13	0.38	8.85e-7	Colorectal cancer;
PAAD	cis	rs89107	0.688	rs283081	chr6:118605821	G/A	cg18833306	chr6:118973337	C6orf204	0.5	5.84	0.43	3.01e-8	Cardiac structure and function;
PAAD	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.26	0.56	6.58e-14	Prudent dietary pattern;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.35	4.51	0.34	1.29e-5	Renal function-related traits (BUN);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24520589	chr17:33415888	RFFL	0.57	6.37	0.46	2.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.56	-7.5	-0.52	5.07e-12	Renal cell carcinoma;
PAAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12165864	chr7:66369176	NA	-0.8	-4.96	-0.37	1.89e-6	Diabetic kidney disease;
PAAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.53	-4.29	-0.33	3.19e-5	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg23281280	chr6:28129359	ZNF389	0.51	4.36	0.33	2.34e-5	Parkinson's disease;
PAAD	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	1.02	6.73	0.48	3.28e-10	Mitochondrial DNA levels;
PAAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.94	13.21	0.73	5.04e-27	Bone mineral density;
PAAD	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.66	6.6	0.47	6.59e-10	Height;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	6.62	0.47	5.68e-10	Systemic lupus erythematosus;
PAAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.55	-6.11	-0.44	8.2e-9	Total body bone mineral density;
PAAD	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg21823605	chr1:152486609	CRCT1	0.52	6.74	0.48	3.04e-10	Hair morphology;
PAAD	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07076661	chr18:9136556	ANKRD12	0.64	6.39	0.46	1.97e-9	Obesity-related traits;
PAAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	4.34	0.33	2.6e-5	Mood instability;
PAAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.52	-4.89	-0.37	2.53e-6	Monocyte count;
PAAD	cis	rs7517847	0.567	rs11209025	chr1:67693022	A/G	cg22500004	chr1:68516272	DIRAS3	-0.47	-4.65	-0.35	7.02e-6	Crohn's disease;Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2229238	0.911	rs111600849	chr1:154487489	G/A	cg21262032	chr1:154437693	IL6R	-0.45	-4.77	-0.36	4.32e-6	Coronary heart disease;
PAAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.57	-6.44	-0.46	1.47e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2446066	0.872	rs36065378	chr12:53774779	A/G	cg20591337	chr12:53693442	C12orf10	-0.61	-4.29	-0.33	3.15e-5	Red blood cell count;
PAAD	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.13	0.6	3.93e-16	Hemoglobin concentration;
PAAD	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.68	-7.26	-0.51	1.91e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.6	-0.35	8.77e-6	Breast cancer;
PAAD	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.34e-7	Obesity-related traits;
PAAD	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.89	10.0	0.63	2.12e-18	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.55	-5.15	-0.39	7.94e-7	Coronary artery disease;
PAAD	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs9896052	0.535	rs35615150	chr17:73433560	G/A	cg25649188	chr17:73499917	CASKIN2	0.62	5.7	0.42	6.18e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg23024343	chr7:107201750	COG5	-0.55	-4.64	-0.35	7.5e-6	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11099041	chr3:119041385	CDGAP	-0.65	-6.61	-0.47	6.2e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9409082	0.798	rs34013949	chr9:108918368	G/T	cg07010948	chr13:79181613	NA	-0.34	-6.31	-0.46	2.86e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
PAAD	cis	rs6456156	0.904	rs2021033	chr6:167524239	C/T	cg07741184	chr6:167504864	NA	-0.42	-5.57	-0.41	1.12e-7	Primary biliary cholangitis;
PAAD	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.52	-5.25	-0.39	5.14e-7	Eosinophil percentage of white cells;
PAAD	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.82	0.58	2.49e-15	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg08219700	chr8:58056026	NA	0.72	5.63	0.42	8.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs988913	0.957	rs72645372	chr6:54788822	C/T	cg03513858	chr6:54763001	FAM83B	-0.45	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15557168	chr22:42548783	NA	-0.54	-6.0	-0.44	1.41e-8	Cognitive function;
PAAD	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg01884057	chr2:25150051	NA	-0.36	-4.43	-0.34	1.83e-5	Type 1 diabetes;
PAAD	cis	rs2814982	0.605	rs35429796	chr6:34474639	G/T	cg14254433	chr6:34482411	PACSIN1	-1.14	-6.41	-0.46	1.76e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	4.75	0.36	4.64e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs939584	1.000	rs13386517	chr2:650479	G/C	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs3112530	1.000	rs2260878	chr5:152712583	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.64	-0.35	7.49e-6	Post bronchodilator FEV1;
PAAD	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.61	4.34	0.33	2.57e-5	Refractive astigmatism;
PAAD	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.61	-6.18	-0.45	5.5e-9	Motion sickness;
PAAD	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg16447950	chr5:562315	NA	-0.72	-6.22	-0.45	4.64e-9	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg16606324	chr3:10149918	C3orf24	0.53	4.48	0.34	1.43e-5	Alzheimer's disease;
PAAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.63	-0.57	7.72e-15	Longevity;
PAAD	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg09835421	chr16:68378352	PRMT7	-0.67	-5.22	-0.39	5.76e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.62	5.6	0.41	9.56e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.6	6.43	0.46	1.58e-9	Menarche (age at onset);
PAAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13560548	chr3:10150139	C3orf24	0.58	5.19	0.39	6.72e-7	Alzheimer's disease;
PAAD	cis	rs2645694	1.000	rs2645694	chr4:77833947	C/T	cg10057126	chr4:77819792	ANKRD56	0.58	5.91	0.43	2.15e-8	Emphysema distribution in smoking;
PAAD	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg01320130	chr1:67600311	NA	0.53	5.86	0.43	2.76e-8	Psoriasis;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14258857	chr14:105612971	JAG2	0.64	6.84	0.49	1.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg24733560	chr20:60626293	TAF4	0.6	7.97	0.54	3.48e-13	Body mass index;
PAAD	cis	rs8112211	1.000	rs2304176	chr19:38794895	T/C	cg14299480	chr19:38876666	GGN	-0.55	-6.44	-0.46	1.5e-9	Blood protein levels;
PAAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg03037974	chr15:76606532	NA	0.52	6.02	0.44	1.28e-8	Blood metabolite levels;
PAAD	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.65	-7.36	-0.51	1.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.5	4.41	0.34	1.98e-5	Systolic blood pressure;
PAAD	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.84	-10.39	-0.64	1.95e-19	Brugada syndrome;
PAAD	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg15309053	chr8:964076	NA	0.4	4.28	0.33	3.26e-5	Schizophrenia;
PAAD	cis	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg21605333	chr4:119757512	SEC24D	0.88	6.53	0.47	9.24e-10	Cannabis dependence symptom count;
PAAD	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-5.16	-0.39	7.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.63	6.76	0.48	2.77e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6540	0.744	rs4758629	chr11:228514	C/A	cg23856257	chr11:719828	EPS8L2	-1.04	-4.73	-0.36	5.03e-6	Endometriosis;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10819733	chr22:24237672	NA	-0.61	-6.8	-0.48	2.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05076971	chr7:117824189	NAA38	0.69	7.49	0.52	5.33e-12	Myopia (pathological);
PAAD	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	6.37	0.46	2.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-4.55	-0.35	1.1e-5	Joint mobility (Beighton score);
PAAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg07701084	chr6:150067640	NUP43	0.73	7.52	0.52	4.38e-12	Lung cancer;
PAAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-5.98	-0.44	1.55e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12476592	0.530	rs6708611	chr2:64168232	C/T	cg10828910	chr2:63850056	LOC388955	-0.57	-4.65	-0.35	7.11e-6	Childhood ear infection;
PAAD	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-1.12	-7.28	-0.51	1.69e-11	Plateletcrit;
PAAD	cis	rs2290416	0.792	rs4874169	chr8:144689686	A/G	cg01494348	chr8:144660395	NAPRT1	-0.95	-4.62	-0.35	8.22e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.9	9.83	0.62	5.78e-18	Developmental language disorder (linguistic errors);
PAAD	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.55	-4.56	-0.35	1.03e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10898856	chr6:155154782	RBM16	-0.62	-7.28	-0.51	1.71e-11	Energy expenditure (24h);
PAAD	cis	rs2882667	0.690	rs851278	chr5:138103266	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs73394838	0.590	rs6006249	chr22:30180911	A/G	cg14926439	chr22:29999402	NF2	-0.88	-4.37	-0.33	2.25e-5	Telomere length;
PAAD	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.62	7.1	0.5	4.36e-11	Heart rate;
PAAD	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg05484376	chr2:27715224	FNDC4	0.46	4.76	0.36	4.55e-6	Total body bone mineral density;
PAAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.93	-11.85	-0.69	2.31e-23	Monocyte percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23636324	chr1:92351686	TGFBR3	-0.65	-6.75	-0.48	2.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.79	-7.84	-0.54	7.37e-13	Blood protein levels;
PAAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.77	6.72	0.48	3.4e-10	Cognitive function;
PAAD	cis	rs11825685	0.790	rs56657264	chr11:134543459	C/T	cg02089395	chr11:134479357	NA	-0.78	-5.46	-0.41	1.87e-7	IgG glycosylation;
PAAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg02696790	chr15:75250997	RPP25	0.45	5.13	0.38	8.56e-7	Breast cancer;
PAAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	5.46	0.41	1.88e-7	Personality dimensions;
PAAD	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	1.1	8.61	0.57	8.58e-15	Iron status biomarkers;
PAAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.65	5.8	0.43	3.77e-8	Pediatric autoimmune diseases;
PAAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.88	10.37	0.64	2.13e-19	Ulcerative colitis;
PAAD	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.63	-6.02	-0.44	1.23e-8	Cognitive test performance;
PAAD	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.62	5.36	0.4	3.07e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg11262906	chr1:85462892	MCOLN2	0.6	4.83	0.36	3.3e-6	Serum sulfate level;
PAAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.55	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs16838233	1.000	rs16838255	chr1:29761148	A/C	cg12609322	chr1:29490924	SFRS4	-0.55	-4.48	-0.34	1.44e-5	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-0.7	-4.48	-0.34	1.48e-5	IgG glycosylation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22792063	chr14:23067579	ABHD4	-0.64	-6.83	-0.48	1.91e-10	Smoking initiation;
PAAD	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	trans	rs12127679	0.614	rs12068130	chr1:244171715	G/A	cg03519879	chr14:74227499	C14orf43	0.87	6.78	0.48	2.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.46	4.72	0.36	5.26e-6	Corneal astigmatism;
PAAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08219700	chr8:58056026	NA	0.63	4.92	0.37	2.24e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.37	4.61	0.35	8.37e-6	Corneal astigmatism;
PAAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.37	4.35	0.33	2.52e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs863345	0.504	rs2022386	chr1:158563076	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.95	-0.37	1.94e-6	Pneumococcal bacteremia;
PAAD	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg24562669	chr7:97807699	LMTK2	0.49	6.98	0.49	8.69e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.39	-0.64	1.93e-19	Chronic sinus infection;
PAAD	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-4.91	-0.37	2.29e-6	Vitiligo;
PAAD	cis	rs7932354	0.537	rs2290884	chr11:46890388	C/G	cg19486271	chr11:47235900	DDB2	-0.6	-5.72	-0.42	5.53e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	4.84	0.37	3.13e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.57	6.29	0.45	3.28e-9	Blood metabolite levels;
PAAD	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg08897044	chr19:12950850	MAST1	-0.35	-4.53	-0.34	1.18e-5	Mean corpuscular volume;
PAAD	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg06899799	chr12:56650233	ANKRD52	0.33	4.27	0.33	3.46e-5	Cancer;
PAAD	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg04450456	chr4:17643702	FAM184B	-0.48	-4.97	-0.37	1.8e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	5.94	0.43	1.83e-8	Lung cancer in ever smokers;
PAAD	cis	rs3127553	0.550	rs1167264	chr1:49933045	C/T	cg09846084	chr1:50888024	DMRTA2	0.55	4.77	0.36	4.36e-6	Waist circumference;
PAAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs58521262	0.530	rs289315	chr19:23161973	C/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg06627628	chr2:24431161	ITSN2	-0.57	-5.51	-0.41	1.48e-7	Sjögren's syndrome;
PAAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.87	8.3	0.56	5.26e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg06917634	chr15:78832804	PSMA4	-0.46	-4.56	-0.35	1.02e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg14132834	chr19:41945861	ATP5SL	0.5	4.79	0.36	3.87e-6	Height;
PAAD	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg12193833	chr17:30244370	NA	-0.65	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3106136	0.609	rs1876917	chr4:95099737	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.68	-6.14	-0.45	6.81e-9	Capecitabine sensitivity;
PAAD	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	1.02	11.21	0.67	1.26e-21	Breast cancer;
PAAD	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.61	7.97	0.54	3.59e-13	Breast cancer;
PAAD	cis	rs2120991	0.967	rs10876510	chr12:54266738	C/T	cg25640699	chr12:54070114	ATP5G2	-0.42	-4.48	-0.34	1.44e-5	Biliary atresia;
PAAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs732765	0.734	rs10137800	chr14:75170286	C/T	cg01090926	chr14:75137805	KIAA0317	0.49	4.33	0.33	2.7e-5	Non-small cell lung cancer;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	4.51	0.34	1.29e-5	Skin pigmentation;
PAAD	cis	rs7264396	0.887	rs1570841	chr20:34048161	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.57	-0.41	1.13e-7	Total cholesterol levels;
PAAD	cis	rs4443100	0.917	rs725984	chr22:23387642	A/G	cg14186256	chr22:23484241	RTDR1	0.51	4.47	0.34	1.49e-5	Serum parathyroid hormone levels;
PAAD	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.46	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.55	5.52	0.41	1.4e-7	Coronary artery disease;
PAAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg18833306	chr6:118973337	C6orf204	-0.53	-4.35	-0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.49	0.34	1.38e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg16205897	chr5:131564050	P4HA2	-0.43	-4.72	-0.36	5.25e-6	Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.7	-9.0	-0.59	8.53e-16	Survival in pancreatic cancer;
PAAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.69	-6.4	-0.46	1.79e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg21419209	chr3:44054225	NA	-0.73	-7.71	-0.53	1.55e-12	Coronary artery disease;
PAAD	cis	rs4417704	0.551	rs4610050	chr2:241891914	A/G	cg26818257	chr2:241905806	NA	0.52	5.47	0.41	1.8e-7	Joint mobility (Beighton score);
PAAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs595018	0.505	rs55653938	chr11:60597831	G/A	cg23904249	chr11:60608951	CCDC86	0.72	5.39	0.4	2.69e-7	Wegener's granulomatosis;
PAAD	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-5.63	-0.42	8.59e-8	Schizophrenia;
PAAD	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-20.29	-0.85	4.2e-45	Myeloid white cell count;
PAAD	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	4.53	0.34	1.2e-5	Height;
PAAD	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs35955747	0.902	rs4820961	chr22:31679449	C/T	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.67	-6.55	-0.47	8.49e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-21.1	-0.86	5.03e-47	Myeloid white cell count;
PAAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.5e-7	Bone mineral density;
PAAD	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	6.63	0.47	5.47e-10	IgG glycosylation;
PAAD	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.81	-11.5	-0.68	2.03e-22	Colorectal cancer;
PAAD	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	1.02	8.65	0.57	6.67e-15	Triglycerides;
PAAD	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs9411298	0.657	rs4880189	chr9:139923265	A/G	cg13592750	chr9:140003531	MAN1B1	0.44	4.38	0.33	2.21e-5	Monocyte percentage of white cells;
PAAD	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.72	7.42	0.52	7.53e-12	Uric acid levels;
PAAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-5.81	-0.43	3.62e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05704093	chr2:145248570	ZEB2	0.58	6.79	0.48	2.32e-10	Smoking initiation;
PAAD	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg19192590	chr2:178524533	PDE11A	0.42	4.28	0.33	3.32e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs11615916	0.790	rs56049136	chr12:62666521	A/C	cg11441379	chr12:63026424	NA	0.69	4.56	0.35	1.06e-5	Pulmonary function decline;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg22535103	chr8:58192502	C8orf71	-1.27	-11.43	-0.68	3.16e-22	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.53	-0.34	1.19e-5	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09466067	chr16:2581732	CEMP1	-0.54	-6.38	-0.46	2.03e-9	Body fat percentage;
PAAD	cis	rs3736485	0.932	rs2278990	chr15:51914662	G/A	cg08986416	chr15:51914746	DMXL2	-0.46	-4.4	-0.34	2.01e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72634258	0.786	rs7539807	chr1:8183789	C/T	cg26816564	chr1:7831052	VAMP3	0.6	4.85	0.37	3.02e-6	Inflammatory bowel disease;
PAAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-5.87	-0.43	2.58e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg01815783	chr4:1047043	NA	-0.45	-4.25	-0.33	3.72e-5	Recombination rate (females);
PAAD	cis	rs1075232	1.000	rs72722847	chr15:31682346	C/T	cg15751117	chr15:30700112	NA	0.94	4.75	0.36	4.59e-6	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.05e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.21	-0.5	2.44e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg02917321	chr22:38215204	NA	0.47	4.81	0.36	3.55e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.55	0.35	1.09e-5	Educational attainment (years of education);
PAAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.48	5.95	0.43	1.8e-8	Iron status biomarkers;
PAAD	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg09659197	chr4:152720779	NA	0.34	4.95	0.37	1.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs8025118	0.583	rs7177159	chr15:79547558	C/G	cg24739098	chr15:79297159	RASGRF1	-0.4	-4.38	-0.33	2.24e-5	Cognitive function;
PAAD	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.62	8.72	0.58	4.42e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	trans	rs78642028	0.561	rs4960947	chr8:88914760	T/C	cg02556155	chr3:114052269	NA	-0.66	-6.37	-0.46	2.13e-9	Congenital heart disease (maternal effect);
PAAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-1.1	-10.56	-0.65	7e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs6987853	0.661	rs6988493	chr8:42351328	C/T	cg09913449	chr8:42400586	C8orf40	-0.46	-4.99	-0.38	1.63e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	1.57	8.95	0.59	1.18e-15	Cannabis dependence symptom count;
PAAD	cis	rs7113874	0.802	rs885114	chr11:8678756	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.64	-0.35	7.54e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs66530629	0.917	rs3890756	chr1:25140825	A/G	cg22509179	chr1:25234806	RUNX3	0.51	4.73	0.36	5.11e-6	Plateletcrit;
PAAD	cis	rs17407555	0.657	rs12508233	chr4:10271037	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.21	0.39	6.17e-7	Schizophrenia (age at onset);
PAAD	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs1007738	0.580	rs11039028	chr11:46944196	G/A	cg19486271	chr11:47235900	DDB2	0.63	5.96	0.44	1.7e-8	Bone mineral density (hip);
PAAD	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg06606381	chr12:133084897	FBRSL1	-1.17	-7.59	-0.52	2.94e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07648498	chr16:89883185	FANCA	0.7	7.3	0.51	1.47e-11	Vitiligo;
PAAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg03934865	chr2:198174659	NA	0.47	4.78	0.36	4.14e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-4.88	-0.37	2.69e-6	Menarche (age at onset);
PAAD	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.27	-0.51	1.8e-11	Chronic sinus infection;
PAAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg02696790	chr15:75250997	RPP25	0.37	4.43	0.34	1.79e-5	Breast cancer;
PAAD	cis	rs6604026	0.656	rs4561051	chr1:93391346	A/C	cg13858687	chr1:93297071	RPL5	0.48	4.42	0.34	1.88e-5	Multiple sclerosis;
PAAD	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg13515842	chr9:127215440	GPR144	-0.44	-4.76	-0.36	4.42e-6	Menarche (age at onset);
PAAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.8	7.46	0.52	6.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.59	7.42	0.52	7.54e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-14.24	-0.76	8.94e-30	Height;
PAAD	cis	rs2153535	0.518	rs1328859	chr6:8562815	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	4.27	0.33	3.42e-5	Motion sickness;
PAAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.28	0.39	4.33e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8077577	0.708	rs4925151	chr17:18130132	G/C	cg16794390	chr17:18148240	FLII	-0.54	-4.6	-0.35	8.94e-6	Obesity-related traits;
PAAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	0.96	9.02	0.59	7.87e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.94	10.98	0.67	5.06e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9876781	1.000	rs10470686	chr3:48449956	C/T	cg24898236	chr3:49228699	LOC646498	0.39	4.31	0.33	2.9e-5	Longevity;
PAAD	cis	rs3753841	0.767	rs10430072	chr1:103320747	G/C	cg24495344	chr1:103574097	COL11A1	0.39	4.49	0.34	1.39e-5	Glaucoma (primary angle closure);
PAAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.61	4.51	0.34	1.29e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.66	-5.59	-0.41	1.01e-7	Menarche (age at onset);
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.84	-9.45	-0.61	5.88e-17	Prostate cancer;
PAAD	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16417436	chr16:28758564	NA	0.43	4.41	0.34	1.92e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs6466055	0.564	rs7809464	chr7:105035389	G/A	cg04380332	chr7:105027541	SRPK2	0.47	4.6	0.35	8.67e-6	Schizophrenia;
PAAD	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg24238205	chr11:58912174	FAM111A	-0.5	-4.25	-0.33	3.72e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.59e-7	Lung cancer;
PAAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	6.49	0.47	1.14e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-4.71	-0.36	5.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.46	-4.46	-0.34	1.6e-5	QT interval;
PAAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.4	-0.34	2e-5	Platelet count;
PAAD	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg19630374	chr17:18023558	MYO15A	-0.54	-5.97	-0.44	1.64e-8	Total body bone mineral density;
PAAD	trans	rs877282	0.731	rs67369760	chr10:791583	C/T	cg22713356	chr15:30763199	NA	1.28	11.23	0.67	1.1e-21	Uric acid levels;
PAAD	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs16958440	0.737	rs12327081	chr18:44744422	G/A	cg17192377	chr18:44677553	HDHD2	1.01	5.41	0.4	2.39e-7	Sitting height ratio;
PAAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.62	8.43	0.56	2.43e-14	Renal cell carcinoma;
PAAD	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	1.07	12.76	0.72	8.14e-26	Breast cancer;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.2	11.48	0.68	2.28e-22	Platelet count;
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.47	-4.25	-0.33	3.75e-5	Menarche (age at onset);
PAAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg11266682	chr4:10021025	SLC2A9	-0.66	-5.89	-0.43	2.44e-8	Schizophrenia (age at onset);
PAAD	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.56	4.65	0.35	7.01e-6	Red blood cell count;
PAAD	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg13263323	chr15:86062960	AKAP13	-0.63	-7.3	-0.51	1.54e-11	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.14	0.39	8.18e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs877529	1.000	rs713909	chr22:39532420	G/C	cg18708252	chr22:39545030	CBX7	-0.44	-4.25	-0.33	3.73e-5	Multiple myeloma;
PAAD	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg00540400	chr15:79124168	NA	0.68	8.73	0.58	4.2e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.41	4.46	0.34	1.55e-5	Life satisfaction;
PAAD	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs867529	0.620	rs335121	chr2:89084327	G/C	cg26627705	chr2:89060884	NA	0.45	4.35	0.33	2.51e-5	Height;
PAAD	cis	rs12760731	0.720	rs7524556	chr1:178446659	C/T	cg00404053	chr1:178313656	RASAL2	0.7	5.45	0.4	1.96e-7	Obesity-related traits;
PAAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-4.85	-0.37	2.99e-6	Bipolar disorder;
PAAD	cis	rs4751006	0.543	rs9794336	chr10:128777873	C/T	cg05702161	chr10:128779687	DOCK1	1.15	6.71	0.48	3.54e-10	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg07192240	chr11:3829780	PGAP2	0.64	6.7	0.48	3.81e-10	Primary biliary cholangitis;
PAAD	cis	rs9815354	1.000	rs6797165	chr3:41887777	A/G	cg03022575	chr3:42003672	ULK4	0.83	6.04	0.44	1.16e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	7.38	0.51	9.65e-12	Alzheimer's disease;
PAAD	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg07703079	chr11:430292	ANO9	0.9	5.74	0.42	5.06e-8	Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19910610	chr14:104389386	C14orf2	-0.69	-7.08	-0.5	4.88e-11	Obesity-related traits;
PAAD	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.78	9.64	0.62	1.9e-17	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg07362569	chr17:61921086	SMARCD2	0.44	4.86	0.37	2.89e-6	Height;
PAAD	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.49	-0.34	1.39e-5	Height;
PAAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	1.19	6.05	0.44	1.07e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.6	5.62	0.41	8.77e-8	IgG glycosylation;
PAAD	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11669133	1.000	rs11670256	chr19:11092387	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.54	0.35	1.12e-5	LDL cholesterol;
PAAD	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg08619932	chr19:49200058	FUT2	0.56	6.12	0.44	7.71e-9	Dietary macronutrient intake;
PAAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.76e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg04398451	chr17:18023971	MYO15A	-1.09	-14.74	-0.77	4.25e-31	Total body bone mineral density;
PAAD	cis	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.55	4.32	0.33	2.76e-5	Depression;
PAAD	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.07	9.37	0.61	9.33e-17	Vitiligo;
PAAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.22e-6	Menopause (age at onset);
PAAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg01489032	chr8:143877656	NA	0.44	4.66	0.35	6.99e-6	Urinary tract infection frequency;
PAAD	cis	rs75757892	0.544	rs9328415	chr6:7317694	A/G	cg02954307	chr6:7269328	NA	0.51	4.32	0.33	2.82e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs9649465	1.000	rs3779260	chr7:123348315	A/G	cg04330084	chr7:123175371	IQUB	0.5	4.66	0.35	6.92e-6	Migraine;
PAAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.61	5.65	0.42	7.82e-8	Prostate cancer;
PAAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.6	-6.02	-0.44	1.24e-8	Coronary artery disease;
PAAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg25833597	chr17:30823145	MYO1D	0.5	4.77	0.36	4.23e-6	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs7737355	0.773	rs3776006	chr5:130875538	C/T	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.76	7.53	0.52	4.12e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11645898	0.513	rs55741258	chr16:72112480	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-6.48	-0.47	1.21e-9	Blood protein levels;
PAAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.65	-0.42	7.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26850624	chr5:429559	AHRR	-0.86	-10.99	-0.67	4.68e-21	Cystic fibrosis severity;
PAAD	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.47	4.83	0.36	3.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg03340356	chr1:67600835	NA	0.52	6.0	0.44	1.38e-8	Psoriasis;
PAAD	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.83	6.0	0.44	1.41e-8	Height;
PAAD	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.39	-0.34	2.14e-5	Lung cancer in ever smokers;
PAAD	cis	rs2031532	0.544	rs7997737	chr13:50033188	G/A	cg08779649	chr13:50194554	NA	0.33	4.35	0.33	2.52e-5	Cardiac hypertrophy;
PAAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg23281280	chr6:28129359	ZNF389	-0.47	-4.27	-0.33	3.4e-5	Parkinson's disease;
PAAD	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg08888203	chr3:10149979	C3orf24	0.68	6.25	0.45	4e-9	Alzheimer's disease;
PAAD	cis	rs11166927	0.716	rs4736094	chr8:140802186	G/A	cg16909799	chr8:140841666	TRAPPC9	0.54	6.05	0.44	1.11e-8	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02393114	chr19:1241627	ATP5D	-0.74	-6.34	-0.46	2.54e-9	Neuroticism;
PAAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.3	-0.51	1.49e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.47	4.54	0.35	1.16e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00920043	chr1:11333412	UBIAD1	0.68	7.62	0.53	2.54e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.53	5.47	0.41	1.81e-7	Motion sickness;
PAAD	cis	rs73206853	0.563	rs7968913	chr12:111138558	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	4.4	0.34	1.99e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	5.34	0.4	3.27e-7	Lung cancer in ever smokers;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.84	-0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.56e-7	Type 2 diabetes;
PAAD	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg14311320	chr7:124405732	GPR37	-0.43	-4.25	-0.33	3.66e-5	Lewy body disease;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08677398	chr8:58056175	NA	0.67	4.63	0.35	7.95e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11081723	chr20:3869585	PANK2	0.6	6.43	0.46	1.53e-9	Monocyte percentage of white cells;
PAAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.33	-0.33	2.71e-5	Mood instability;
PAAD	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.72	7.45	0.52	6.51e-12	Body mass index;
PAAD	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg10820045	chr2:198174542	NA	0.48	4.88	0.37	2.66e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15972949	chr7:44240380	YKT6	0.62	7.11	0.5	4.18e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-4.46	-0.34	1.56e-5	Vitiligo;
PAAD	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.7	6.5	0.47	1.08e-9	Primary sclerosing cholangitis;
PAAD	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.49	4.34	0.33	2.59e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.6	-7.96	-0.54	3.74e-13	Height;
PAAD	cis	rs11159086	0.793	rs11621693	chr14:74939334	G/A	cg10195687	chr14:74926396	NA	-0.47	-5.31	-0.4	3.89e-7	Advanced glycation end-product levels;
PAAD	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	4.35	0.33	2.49e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18357526	chr6:26021779	HIST1H4A	0.67	6.72	0.48	3.47e-10	Height;
PAAD	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-13.67	-0.74	2.97e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs939584	1.000	rs2903492	chr2:624678	C/T	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg23346134	chr3:49453900	TCTA	0.43	4.77	0.36	4.23e-6	Menarche (age at onset);
PAAD	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg11779900	chr17:80519722	FOXK2	-0.5	-5.12	-0.38	9.25e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.8	-8.57	-0.57	1.06e-14	DNA methylation (variation);
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.59	4.62	0.35	8.11e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.52	5.11	0.38	9.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg20130138	chr11:64956067	CAPN1	0.48	4.27	0.33	3.41e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg27499820	chr13:21296301	IL17D	-0.48	-4.74	-0.36	4.9e-6	Dental caries;
PAAD	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11943008	chr12:117425016	FBXW8	-0.56	-6.69	-0.48	4e-10	Monocyte percentage of white cells;
PAAD	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.74	-0.36	4.79e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.57	-5.36	-0.4	3e-7	Serum thyroid-stimulating hormone levels;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27042667	chr1:163295979	NUF2	-0.54	-6.6	-0.47	6.43e-10	Energy expenditure (24h);
PAAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg13468214	chr4:1046988	NA	-0.53	-4.94	-0.37	2e-6	Recombination rate (females);
PAAD	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.63e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.35	-0.33	2.47e-5	Daytime sleep phenotypes;
PAAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.84e-8	Life satisfaction;
PAAD	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg23024343	chr7:107201750	COG5	0.57	4.67	0.35	6.67e-6	Coronary artery disease;
PAAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg26513180	chr16:89883248	FANCA	0.72	8.15	0.55	1.21e-13	Vitiligo;
PAAD	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg00543991	chr22:32367038	NA	1.17	7.35	0.51	1.12e-11	Childhood ear infection;
PAAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.77	-9.26	-0.6	1.79e-16	Height;
PAAD	cis	rs6690583	0.513	rs7545050	chr1:85552175	A/C	cg12037450	chr1:85513124	MCOLN3	-0.5	-4.49	-0.34	1.42e-5	Serum sulfate level;
PAAD	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg11619707	chr19:22235551	ZNF257	0.59	5.89	0.43	2.34e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.55	-5.21	-0.39	6.1e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.7	6.98	0.49	8.66e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.65	-5.18	-0.39	7e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.34	-0.33	2.61e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	9.8	0.62	6.88e-18	Response to antipsychotic treatment;
PAAD	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg12310025	chr6:25882481	NA	0.44	4.38	0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-6.28	-0.45	3.39e-9	Morning vs. evening chronotype;
PAAD	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.86	9.3	0.6	1.41e-16	Corneal astigmatism;
PAAD	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg01191920	chr7:158217561	PTPRN2	-0.76	-7.57	-0.52	3.44e-12	Obesity-related traits;
PAAD	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1472147	0.784	rs28584751	chr7:128504285	G/C	cg00734629	chr7:128471146	FLNC	0.44	4.86	0.37	2.96e-6	Calcium levels;
PAAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06544989	chr22:39130855	UNC84B	0.49	4.79	0.36	3.86e-6	Menopause (age at onset);
PAAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.67	0.35	6.48e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg27234864	chr13:21295941	IL17D	-0.52	-4.62	-0.35	8.29e-6	Dental caries;
PAAD	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg10183150	chr4:120222239	C4orf3	-0.39	-5.49	-0.41	1.63e-7	Corneal astigmatism;
PAAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	trans	rs901683	1.000	rs17157919	chr10:46044092	A/C	cg14076390	chr17:34947837	DHRS11	-0.87	-6.65	-0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.57	-4.86	-0.37	2.84e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs742132	0.520	rs113164182	chr6:25633829	A/C	cg03517284	chr6:25882590	NA	0.66	4.34	0.33	2.59e-5	Uric acid levels;
PAAD	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs9900972	0.918	rs8065599	chr17:76877073	T/C	cg20937029	chr17:76870563	TIMP2	0.59	5.24	0.39	5.32e-7	Obesity-related traits;
PAAD	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	7.28	0.51	1.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg20503657	chr10:835505	NA	-0.42	-4.44	-0.34	1.7e-5	Survival in rectal cancer;
PAAD	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.22	0.45	4.51e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg20045696	chr14:77926864	AHSA1	0.53	5.31	0.4	3.74e-7	Myeloid white cell count;
PAAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg15017067	chr4:17643749	FAM184B	0.44	5.16	0.39	7.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.58	-5.42	-0.4	2.33e-7	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs35079168	0.735	rs3118540	chr9:137307106	C/T	cg00753924	chr9:137298813	RXRA	-0.48	-5.25	-0.39	4.95e-7	Intelligence;
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.78	0.58	3.11e-15	Lung cancer;
PAAD	cis	rs12826942	0.571	rs17224156	chr12:42446725	C/T	cg19980929	chr12:42632907	YAF2	0.48	4.25	0.33	3.68e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.05e-7	Life satisfaction;
PAAD	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.14e-5	Noise-induced hearing loss;
PAAD	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.66	4.75	0.36	4.65e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.77	7.54	0.52	4e-12	Cognitive test performance;
PAAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.56	-6.8	-0.48	2.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg06569542	chr10:98946673	SLIT1	0.44	4.5	0.34	1.34e-5	Monocyte count;
PAAD	cis	rs71403859	0.730	rs71386933	chr16:71821800	A/T	cg08717414	chr16:71523259	ZNF19	-1.03	-6.92	-0.49	1.18e-10	Post bronchodilator FEV1;
PAAD	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.49	-5.8	-0.43	3.64e-8	Blood pressure (smoking interaction);
PAAD	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.57	-5.48	-0.41	1.77e-7	Multiple sclerosis;
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.77	0.58	3.32e-15	Lung cancer;
PAAD	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.95	7.79	0.53	9.59e-13	Eotaxin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15947721	chr8:42978149	SGK196	-0.67	-6.4	-0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg12963866	chr19:57752005	ZNF805	-0.46	-4.41	-0.34	1.91e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg04106633	chr4:1044584	NA	0.62	5.23	0.39	5.65e-7	Recombination rate (females);
PAAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg17633681	chr16:88106987	BANP	-0.54	-6.6	-0.47	6.44e-10	Menopause (age at onset);
PAAD	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.55	4.96	0.37	1.89e-6	Blood metabolite levels;
PAAD	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.92	-0.43	2.06e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15099273	chr21:35014195	ITSN1;CRYZL1	0.65	7.99	0.54	3.13e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26897989	chr16:1907736	C16orf73	-0.57	-4.97	-0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg02841227	chr6:26021843	HIST1H4A	0.51	4.94	0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.49	5.55	0.41	1.24e-7	Coronary artery disease;
PAAD	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	4.48	0.34	1.47e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.56	-6.95	-0.49	9.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs630539	0.655	rs607795	chr17:40699332	T/C	cg11807584	chr17:41132474	AARSD1;RUNDC1	-0.97	-4.28	-0.33	3.31e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.46	4.74	0.36	4.9100000000000004e-06	Corneal astigmatism;
PAAD	cis	rs2908197	0.843	rs2908193	chr7:75945945	A/G	cg22830091	chr7:75961684	YWHAG	-0.59	-6.69	-0.48	3.95e-10	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7646881	0.812	rs74618709	chr3:158455281	G/C	cg19483011	chr3:158453295	NA	-0.69	-5.69	-0.42	6.44e-8	Tetralogy of Fallot;
PAAD	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.5	5.17	0.39	7.16e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.44	-4.93	-0.37	2.11e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg01181863	chr3:195395398	SDHAP2	-0.67	-4.58	-0.35	9.72e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs595018	0.505	rs72916916	chr11:60604224	C/T	cg23904249	chr11:60608951	CCDC86	0.7	5.18	0.39	6.98e-7	Wegener's granulomatosis;
PAAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11245990	chr11:68621969	NA	0.39	5.06	0.38	1.18e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6494488	0.500	rs72744734	chr15:65042312	C/A	cg16425858	chr15:64791681	ZNF609	1.0	4.57	0.35	1.02e-5	Coronary artery disease;
PAAD	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.85	-9.6	-0.61	2.34e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.75	6.52	0.47	9.93e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.35	0.73	2.11e-27	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07040405	chr2:174828875	SP3	0.65	6.6	0.47	6.6e-10	Obesity-related traits;
PAAD	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.71	6.65	0.47	4.91e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs533581	0.789	rs1673931	chr16:88976477	T/C	cg05579598	chr16:88989069	CBFA2T3	0.64	9.63	0.62	1.95e-17	Social autistic-like traits;
PAAD	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.44	6.87	0.49	1.51e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.28	12.46	0.71	5.46e-25	Corneal structure;
PAAD	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.96	-13.19	-0.73	5.97e-27	Height;
PAAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-5.67	-0.42	6.94e-8	Schizophrenia;
PAAD	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.54	5.1	0.38	9.77e-7	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.8	9.0	0.59	8.85e-16	Lung cancer;
PAAD	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18621852	chr3:10150065	C3orf24	0.7	6.29	0.45	3.23e-9	Alzheimer's disease;
PAAD	cis	rs78761021	0.860	rs9674995	chr17:9773043	C/A	cg26853458	chr17:9805074	RCVRN	0.7	8.28	0.56	6.06e-14	Type 2 diabetes;
PAAD	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.63	5.72	0.42	5.48e-8	HIV-1 control;
PAAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg16205897	chr5:131564050	P4HA2	0.41	4.38	0.33	2.21e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs4704187	0.687	rs6891023	chr5:74500755	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03676636	chr4:99064102	C4orf37	0.31	5.76	0.42	4.53e-8	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09606015	chr3:182511586	ATP11B	-0.63	-6.72	-0.48	3.38e-10	Myopia (pathological);
PAAD	cis	rs2286503	1.000	rs1029740	chr7:22873586	C/A	cg11367502	chr7:22862612	TOMM7	0.44	4.44	0.34	1.7e-5	Fibrinogen;
PAAD	cis	rs7188861	0.681	rs2216763	chr16:11404428	G/A	cg16532467	chr16:11454386	NA	-0.56	-4.31	-0.33	2.96e-5	HDL cholesterol;
PAAD	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg16898833	chr6:26189333	HIST1H4D	0.86	4.74	0.36	4.9e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.85	4.29	0.33	3.12e-5	Plasma clusterin levels;
PAAD	cis	rs4704187	0.687	rs10051422	chr5:74502573	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.64	7.35	0.51	1.15e-11	Schizophrenia;
PAAD	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.43	-0.34	1.83e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg12140854	chr5:148520817	ABLIM3	-0.46	-4.55	-0.35	1.07e-5	Breast cancer;
PAAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-5.32	-0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs597480	0.864	rs2374683	chr11:85512157	C/T	cg11817631	chr11:85522609	SYTL2	-0.44	-4.34	-0.33	2.54e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.73	-7.8	-0.53	9.19e-13	Body mass index;
PAAD	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.37	4.77	0.36	4.28e-6	Schizophrenia;
PAAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.87	-8.05	-0.55	2.21e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-4.53	-0.34	1.2e-5	Bipolar disorder;
PAAD	cis	rs2594989	0.943	rs346073	chr3:11298181	G/A	cg01796438	chr3:11312864	ATG7	-0.63	-4.83	-0.36	3.3e-6	Circulating chemerin levels;
PAAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.87	5.77	0.42	4.29e-8	Diabetic kidney disease;
PAAD	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	7.13	0.5	3.83e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.54	5.94	0.43	1.87e-8	Major depressive disorder;
PAAD	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.75	6.81	0.48	2.11e-10	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19671926	chr4:122722719	EXOSC9	-0.58	-5.23	-0.39	5.6e-7	Type 2 diabetes;
PAAD	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg04143805	chr16:89395205	ANKRD11	-0.38	-4.53	-0.34	1.2e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg01763666	chr17:80159506	CCDC57	-0.44	-4.51	-0.34	1.29e-5	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg15181151	chr6:150070149	PCMT1	0.58	6.37	0.46	2.12e-9	Lung cancer;
PAAD	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.46	-4.64	-0.35	7.36e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg09835421	chr16:68378352	PRMT7	-0.95	-7.52	-0.52	4.4e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg21253087	chr9:139290292	SNAPC4	0.46	4.44	0.34	1.69e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.45	4.65	0.35	7.26e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.28	-0.39	4.49e-7	Daytime sleep phenotypes;
PAAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg02071572	chr4:1403502	NA	0.43	5.47	0.41	1.78e-7	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2415984	0.622	rs8022305	chr14:46946545	C/T	cg14871534	chr14:47121158	RPL10L	-0.52	-5.41	-0.4	2.37e-7	Number of children ever born;
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg26174226	chr8:58114915	NA	-0.63	-4.55	-0.35	1.1e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.91	4.97	0.37	1.77e-6	Plasma clusterin levels;
PAAD	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.71	9.19	0.6	2.86e-16	Asthma (childhood onset);
PAAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01023714	chr4:10084725	WDR1	-0.63	-6.26	-0.45	3.79e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg02287630	chr1:101361426	SLC30A7;EXTL2	-0.5	-4.26	-0.33	3.59e-5	Breast cancer;
PAAD	cis	rs2555155	1.000	rs2555154	chr11:6524556	C/T	cg24637308	chr11:6592297	DNHD1	0.48	4.97	0.37	1.75e-6	DNA methylation (variation);
PAAD	cis	rs1562242	0.505	rs245481	chr5:57623118	T/G	cg25655489	chr5:57484208	NA	0.34	4.74	0.36	4.83e-6	Educational attainment (years of education);
PAAD	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02985541	chr2:219472218	PLCD4	0.3	4.58	0.35	9.6e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4455778	0.580	rs9942682	chr7:49077999	G/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	4.39	0.34	2.15e-5	Total body bone mineral density;
PAAD	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18621852	chr3:10150065	C3orf24	0.69	6.22	0.45	4.57e-9	Alzheimer's disease;
PAAD	cis	rs8105895	0.935	rs9653157	chr19:22249490	T/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs7011049	1.000	rs72643600	chr8:53854530	T/G	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs59191668	0.804	rs12904839	chr15:62824684	T/C	cg12918536	chr15:62891943	NA	0.35	4.64	0.35	7.34e-6	Immature fraction of reticulocytes;
PAAD	cis	rs4455778	0.580	rs6944916	chr7:49113732	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.75	-7.76	-0.53	1.17e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.53	5.0	0.38	1.57e-6	Neurofibrillary tangles;
PAAD	cis	rs7523050	0.908	rs67425757	chr1:109398656	T/G	cg08274380	chr1:109419600	GPSM2	0.76	5.38	0.4	2.72e-7	Fat distribution (HIV);
PAAD	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.66	-8.44	-0.56	2.3e-14	Schizophrenia;
PAAD	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.87	9.34	0.6	1.16e-16	Schizophrenia;
PAAD	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.79	6.51	0.47	1.05e-9	Monocyte percentage of white cells;
PAAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.52	4.56	0.35	1.04e-5	Tonsillectomy;
PAAD	cis	rs1198430	0.636	rs2811963	chr1:23824242	A/C	cg27447006	chr1:23763279	ASAP3	0.63	4.75	0.36	4.59e-6	Total cholesterol levels;
PAAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23833352	chr13:77553666	NA	-0.56	-6.53	-0.47	9.35e-10	Monocyte percentage of white cells;
PAAD	cis	rs7577696	0.925	rs12617290	chr2:32341408	A/G	cg02381751	chr2:32503542	YIPF4	-0.44	-4.72	-0.36	5.2e-6	Inflammatory biomarkers;
PAAD	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.66	6.05	0.44	1.1e-8	Androgen levels;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.49	5.25	0.39	5.06e-7	Electroencephalogram traits;
PAAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg19673125	chr6:150240577	RAET1G	0.45	6.23	0.45	4.43e-9	Testicular germ cell tumor;
PAAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-5.24	-0.39	5.31e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	0.85	7.21	0.5	2.46e-11	Gestational age at birth (maternal effect);
PAAD	cis	rs4073221	0.654	rs13066958	chr3:18307712	T/A	cg07694806	chr3:18168406	NA	-0.63	-4.49	-0.34	1.43e-5	Parkinson's disease;
PAAD	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.6	-5.82	-0.43	3.31e-8	Coronary artery disease;
PAAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.92	7.85	0.54	6.79e-13	Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	8.75	0.58	3.89e-15	Alzheimer's disease;
PAAD	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg24851651	chr11:66362959	CCS	0.45	5.21	0.39	5.95e-7	HIV-1 susceptibility;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg16606324	chr3:10149918	C3orf24	0.61	4.68	0.35	6.29e-6	Alzheimer's disease;
PAAD	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.48	-4.35	-0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg23465465	chr6:26364728	BTN3A2	0.74	4.48	0.34	1.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.52	5.86	0.43	2.76e-8	Heart rate;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.89	10.9	0.66	8.15e-21	Prudent dietary pattern;
PAAD	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg21951975	chr1:209979733	IRF6	0.51	4.73	0.36	5.02e-6	Coronary artery disease;
PAAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.61	-0.53	2.62e-12	Height;
PAAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11168618	0.626	rs2731095	chr12:48881808	G/C	cg05152354	chr12:48152931	RAPGEF3	0.49	4.32	0.33	2.76e-5	Adiponectin levels;
PAAD	cis	rs10901513	0.932	rs9633754	chr10:127674353	G/T	cg22975853	chr10:127789788	ADAM12	0.43	4.65	0.35	7.3e-6	Visceral fat;
PAAD	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	19.75	0.85	8.4e-44	IgG glycosylation;
PAAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.83	0.36	3.3e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.68	6.43	0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg10395934	chr14:104002654	TRMT61A	0.56	5.72	0.42	5.49e-8	Body mass index;
PAAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg22143856	chr6:28129313	ZNF389	0.51	4.75	0.36	4.74e-6	Parkinson's disease;
PAAD	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	1.17	8.33	0.56	4.46e-14	Blood pressure (smoking interaction);
PAAD	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.35	11.33	0.68	6.03e-22	Uric acid levels;
PAAD	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg09659197	chr4:152720779	NA	0.34	4.93	0.37	2.17e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.59	-0.52	2.95e-12	Height;
PAAD	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21775007	chr8:11205619	TDH	0.48	4.34	0.33	2.6e-5	Neuroticism;
PAAD	cis	rs7577696	0.886	rs443609	chr2:32483593	C/T	cg02381751	chr2:32503542	YIPF4	0.43	4.63	0.35	7.78e-6	Inflammatory biomarkers;
PAAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg02869306	chr7:64672164	INTS4L1	-0.4	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.87	9.42	0.61	6.89e-17	Colorectal cancer;
PAAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.06	0.38	1.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00166722	chr3:10149974	C3orf24	0.84	7.22	0.51	2.35e-11	Alzheimer's disease;
PAAD	cis	rs11867934	0.531	rs3803761	chr17:17116412	A/G	cg05552144	chr17:17942551	ATPAF2;C17orf39	-0.5	-4.39	-0.34	2.09e-5	Diabetic retinopathy;
PAAD	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.78	6.08	0.44	9.3e-9	Crohn's disease;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs1903068	0.853	rs9312656	chr4:56002972	C/G	cg09978860	chr4:56023921	NA	0.38	4.34	0.33	2.61e-5	Endometriosis;
PAAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg15478930	chr2:27652102	NRBP1	0.47	4.29	0.33	3.16e-5	Total body bone mineral density;
PAAD	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	5.4	0.4	2.47e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.56	-7.1	-0.5	4.44e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg13206674	chr6:150067644	NUP43	0.61	6.41	0.46	1.71e-9	Testicular germ cell tumor;
PAAD	cis	rs2594989	0.943	rs2606733	chr3:11412319	C/T	cg01796438	chr3:11312864	ATG7	-0.64	-4.98	-0.37	1.69e-6	Circulating chemerin levels;
PAAD	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	2.98e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg14784868	chr12:69753453	YEATS4	0.72	7.41	0.52	8e-12	Blood protein levels;
PAAD	cis	rs1497828	0.956	rs2646799	chr1:217522196	T/C	cg04411442	chr1:217543379	NA	-0.5	-5.0	-0.38	1.56e-6	Dialysis-related mortality;
PAAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-8.68	-0.58	5.66e-15	Total body bone mineral density;
PAAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.5	4.56	0.35	1.04e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9810890	1.000	rs73198883	chr3:128543187	C/T	cg18531004	chr3:128564980	NA	-0.88	-4.56	-0.35	1.03e-5	Dental caries;
PAAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.51	5.1	0.38	9.81e-7	Height;
PAAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.49	4.29	0.33	3.19e-5	Height;
PAAD	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.83	-9.29	-0.6	1.5e-16	Schizophrenia;
PAAD	cis	rs6594713	0.796	rs4438866	chr5:112690644	G/A	cg12552261	chr5:112820674	MCC	0.63	4.25	0.33	3.69e-5	Brain cytoarchitecture;
PAAD	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.92	11.89	0.69	1.83e-23	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05596267	chr15:34331198	CHRM5;AVEN	0.56	6.64	0.47	5.32e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg19980929	chr12:42632907	YAF2	0.64	7.56	0.52	3.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs8016982	0.662	rs1951616	chr14:81671752	T/C	cg01989461	chr14:81687754	GTF2A1	0.58	4.65	0.35	7.14e-6	Schizophrenia;
PAAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg03983476	chr2:10830698	NOL10	0.61	6.21	0.45	4.72e-9	Prostate cancer;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	10.05	0.63	1.52e-18	Platelet count;
PAAD	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04824913	chr4:887549	GAK	-0.49	-4.67	-0.35	6.71e-6	Systemic sclerosis;
PAAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01616529	chr11:638424	DRD4	-0.58	-5.74	-0.42	4.89e-8	Systemic lupus erythematosus;
PAAD	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.77	-7.42	-0.52	7.55e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.65	-6.23	-0.45	4.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2278796	1.000	rs58066240	chr1:204953727	C/T	cg04862289	chr1:204966208	NFASC	0.46	4.82	0.36	3.47e-6	Mean platelet volume;
PAAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.52	-0.47	9.71e-10	Longevity;
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27297192	chr10:134578999	INPP5A	0.63	6.12	0.44	7.59e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs5753037	0.653	rs131265	chr22:30145591	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.79	-0.36	3.84e-6	Type 1 diabetes;
PAAD	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg08501292	chr6:25962987	TRIM38	0.74	4.46	0.34	1.57e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2061333	0.557	rs10406335	chr19:44633953	G/A	cg20607764	chr19:44506953	ZNF230	-0.78	-5.37	-0.4	2.83e-7	Alzheimer's disease;
PAAD	cis	rs56011263	0.532	rs55990625	chr4:736485	C/T	cg05835009	chr4:710272	PCGF3	0.61	5.0	0.38	1.57e-6	White blood cell count;
PAAD	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.65	-4.88	-0.37	2.69e-6	Post bronchodilator FEV1;
PAAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.55	5.23	0.39	5.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg12647257	chr2:47043387	NA	0.43	4.26	0.33	3.5e-5	Height;
PAAD	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.82	9.55	0.61	3.11e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7580717	0.785	rs62197352	chr2:232165233	C/G	cg07929768	chr2:232055508	NA	0.52	5.83	0.43	3.26e-8	Multiple myeloma;
PAAD	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg11783602	chr8:55087084	NA	-0.63	-7.43	-0.52	7.34e-12	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg03732007	chr1:2071316	PRKCZ	0.44	4.3	0.33	3.02e-5	Height;
PAAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07701084	chr6:150067640	NUP43	0.54	5.4	0.4	2.51e-7	Testicular germ cell tumor;
PAAD	cis	rs6952808	0.964	rs11761670	chr7:1904709	C/T	cg18279126	chr7:2041391	MAD1L1	0.64	6.37	0.46	2.19e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-1.03	-9.23	-0.6	2.16e-16	Monocyte percentage of white cells;
PAAD	cis	rs300774	0.858	rs1829220	chr2:118383	A/C	cg23649280	chr2:140451	NA	-0.52	-4.86	-0.37	2.85e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs3206736	0.548	rs329236	chr7:35056266	C/A	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	0.79	7.2	0.5	2.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.6	-4.3	-0.33	3.07e-5	Vitiligo;
PAAD	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.47	-0.34	1.5e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs597583	0.806	rs10892135	chr11:117392826	G/A	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.23	-0.45	4.34e-9	Putamen volume;
PAAD	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.64	7.05	0.5	6.01e-11	Smoking initiation;
PAAD	cis	rs3736485	0.966	rs4774595	chr15:51893161	C/T	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.49e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.48	-5.93	-0.43	1.98e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02591199	chr4:113066609	C4orf32	0.64	6.32	0.46	2.7e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.23	-0.7	2.21e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-4.42	-0.34	1.89e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16447950	chr5:562315	NA	-0.61	-5.42	-0.4	2.24e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.64	5.07	0.38	1.16e-6	Osteoarthritis;
PAAD	cis	rs12541635	1.000	rs12541635	chr8:107090000	C/T	cg10147462	chr8:107024639	NA	-0.44	-4.71	-0.36	5.54e-6	Age of smoking initiation;
PAAD	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	1.000	rs73196989	chr3:128454638	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg24179445	chr10:102496915	NA	0.57	6.13	0.45	7.21e-9	Alzheimer's disease;
PAAD	cis	rs7255436	0.965	rs2042900	chr19:8439702	T/C	cg10174797	chr19:8464628	RAB11B	0.55	5.22	0.39	5.73e-7	HDL cholesterol;
PAAD	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	10.55	0.65	7.04e-20	Total body bone mineral density;
PAAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.9	-9.81	-0.62	6.67e-18	Bronchopulmonary dysplasia;
PAAD	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-4.33	-0.33	2.74e-5	Colorectal cancer;
PAAD	cis	rs4948102	0.655	rs4947533	chr7:56071282	T/C	cg17804177	chr7:56019372	MRPS17	0.55	4.25	0.33	3.71e-5	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-5.61	-0.41	9.11e-8	Coronary artery disease;
PAAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.69	7.42	0.52	7.7e-12	Multiple sclerosis;
PAAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.85	11.78	0.69	3.7e-23	Emphysema distribution in smoking;
PAAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg12215294	chr3:40350768	EIF1B	-0.44	-4.25	-0.33	3.77e-5	Renal cell carcinoma;
PAAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.82	10.42	0.65	1.61e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.98	6.41	0.46	1.7e-9	Major depressive disorder;
PAAD	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.08	7.94	0.54	4.09e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg24699146	chr1:24152579	HMGCL	0.48	5.15	0.39	7.88e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.31	0.71	1.34e-24	Bone mineral density;
PAAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg02196655	chr2:10830764	NOL10	-0.52	-5.41	-0.4	2.43e-7	Prostate cancer;
PAAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03605463	chr16:89740564	NA	-0.47	-4.31	-0.33	2.93e-5	Vitiligo;
PAAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg20744362	chr22:50050164	C22orf34	0.7	7.99	0.54	3.04e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.96	-0.37	1.9e-6	Recombination rate (females);
PAAD	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs2235573	0.657	rs760973	chr22:38447266	C/A	cg03989125	chr22:38214979	NA	-0.55	-5.63	-0.42	8.63e-8	Glioblastoma;Glioma;
PAAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg25809561	chr17:30822961	MYO1D	0.62	6.81	0.48	2.1e-10	Schizophrenia;
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg09826364	chr7:158789723	NA	-0.36	-4.54	-0.35	1.13e-5	Facial morphology (factor 20);
PAAD	cis	rs2031532	0.544	rs3764089	chr13:50063238	C/T	cg03651054	chr13:50194643	NA	0.32	4.36	0.33	2.36e-5	Cardiac hypertrophy;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg17644776	chr2:200775616	C2orf69	-0.65	-5.04	-0.38	1.33e-6	Schizophrenia;
PAAD	cis	rs6782025	0.781	rs12495471	chr3:121119945	G/C	cg16417163	chr3:121280760	NA	-0.48	-4.87	-0.37	2.75e-6	Aging (facial);
PAAD	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.66	9.99	0.63	2.29e-18	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.58	5.47	0.41	1.8e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.64	-6.66	-0.48	4.61e-10	Body mass index;
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg15117754	chr3:10150083	C3orf24	0.65	5.62	0.41	9.02e-8	Alzheimer's disease;
PAAD	cis	rs7301826	1.000	rs4759793	chr12:131297238	A/G	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.67	5.22	0.39	5.77e-7	Alzheimer's disease (survival time);
PAAD	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.73	8.98	0.59	9.44e-16	Body mass index;
PAAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.37	-0.33	2.29e-5	Lung cancer;
PAAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.2	0.5	2.55e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.78	5.77	0.42	4.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg12549451	chr6:135224345	NA	-0.45	-4.82	-0.36	3.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7264396	0.887	rs224351	chr20:34052273	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.68	-0.42	6.78e-8	Total cholesterol levels;
PAAD	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.54	-5.67	-0.42	7.05e-8	Mean corpuscular volume;
PAAD	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.5	4.84	0.37	3.18e-6	High light scatter reticulocyte count;
PAAD	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.56	5.24	0.39	5.38e-7	Height;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14551503	chr6:168772834	NA	-0.62	-6.4	-0.46	1.81e-9	Obesity-related traits;
PAAD	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.78	-4.66	-0.35	6.74e-6	Cholesterol, total;
PAAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg24004478	chr7:855632	UNC84A	0.45	4.57	0.35	1.02e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs802075	1.000	rs802075	chr6:49654166	A/G	cg20364632	chr6:49636226	NA	-0.52	-6.0	-0.44	1.38e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.39	0.46	1.92e-9	Alzheimer's disease;
PAAD	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-1.05	-11.09	-0.67	2.58e-21	Platelet distribution width;
PAAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg06740227	chr12:86229804	RASSF9	0.57	5.68	0.42	6.73e-8	Major depressive disorder;
PAAD	cis	rs375066	0.935	rs428505	chr19:44428911	G/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-4.85	-0.37	3.01e-6	Eotaxin levels;
PAAD	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.94	-0.49	1.04e-10	Myopia (pathological);
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg15595755	chr5:1867978	NA	0.46	4.79	0.36	3.99e-6	Cardiovascular disease risk factors;
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.89	0.37	2.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06915872	chr16:87998081	BANP	0.47	4.36	0.33	2.38e-5	Menopause (age at onset);
PAAD	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg05338066	chr1:7812865	CAMTA1	0.56	4.59	0.35	9.36e-6	Inflammatory bowel disease;
PAAD	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg14181355	chr19:12984996	MAST1	-0.5	-4.59	-0.35	9.35e-6	Mean corpuscular volume;
PAAD	cis	rs2131877	0.830	rs1874104	chr3:194845226	A/C	cg24618514	chr3:194868507	C3orf21	-0.5	-4.77	-0.36	4.29e-6	Non-small cell lung cancer;
PAAD	cis	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.51	-0.41	1.47e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05942152	chr11:64902077	SYVN1	0.62	6.36	0.46	2.27e-9	Myopia (pathological);
PAAD	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.13	-0.38	8.73e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg08125733	chr17:73851984	WBP2	0.96	8.27	0.56	6.35e-14	Psoriasis;
PAAD	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	4.87	0.37	2.74e-6	Height;
PAAD	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.63	6.71	0.48	3.54e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs877529	0.605	rs139384	chr22:39527935	C/T	cg18708252	chr22:39545030	CBX7	-0.66	-6.87	-0.49	1.51e-10	Multiple myeloma;
PAAD	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.51	5.05	0.38	1.24e-6	Inflammatory bowel disease;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-7.19	-0.5	2.81e-11	Life satisfaction;
PAAD	cis	rs7534824	0.625	rs6676834	chr1:101463788	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.9	10.94	0.66	6.55e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01999229	chr19:49588434	SNRNP70	0.59	6.31	0.46	2.88e-9	Monocyte percentage of white cells;
PAAD	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg00404053	chr1:178313656	RASAL2	-0.7	-4.6	-0.35	8.71e-6	Obesity-related traits;
PAAD	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.43	4.61	0.35	8.37e-6	Post-traumatic stress disorder;
PAAD	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg18085866	chr17:45331354	ITGB3	-1.03	-5.69	-0.42	6.39e-8	Left atrial antero-posterior diameter;
PAAD	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02765225	chr15:44083979	SERF2	-0.53	-4.81	-0.36	3.55e-6	Lung cancer in ever smokers;
PAAD	cis	rs1975974	1.000	rs72842072	chr17:21730703	G/A	cg18423549	chr17:21743878	NA	-0.51	-4.93	-0.37	2.13e-6	Psoriasis;
PAAD	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.59	5.88	0.43	2.57e-8	Joint mobility (Beighton score);
PAAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg01299579	chr2:10830716	NOL10	0.53	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.55	7.2	0.5	2.64e-11	Ewing sarcoma;
PAAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.61	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.07	0.5	5.27e-11	Diastolic blood pressure;
PAAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg04194840	chr16:58545502	NDRG4	0.74	4.46	0.34	1.6e-5	Schizophrenia;
PAAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.88	8.3	0.56	5.29e-14	Gestational age at birth (maternal effect);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26778584	chr3:149691960	NA	-0.5	-6.29	-0.45	3.17e-9	Energy expenditure (24h);
PAAD	cis	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.54	-5.57	-0.41	1.13e-7	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9810890	1.000	rs73198894	chr3:128562396	T/C	cg15676455	chr3:128564943	NA	-0.86	-4.8	-0.36	3.78e-6	Dental caries;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17121955	chr11:6411382	SMPD1	0.56	6.43	0.46	1.58e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.57	-7.35	-0.51	1.15e-11	Menopause (age at onset);
PAAD	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.62	6.67	0.48	4.37e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.61	-5.58	-0.41	1.06e-7	Menarche (age at onset);
PAAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	8.58	0.57	1.01e-14	Homoarginine levels;
PAAD	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	6.24	0.45	4.07e-9	Body mass index;
PAAD	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	8.68	0.58	5.55e-15	Exhaled nitric oxide output;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16237715	chr15:85197625	WDR73	-0.75	-6.31	-0.46	2.93e-9	Neuroticism;
PAAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14895029	chr7:2775587	GNA12	-0.47	-4.84	-0.37	3.13e-6	Height;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg17810781	chr1:201082982	CACNA1S	0.43	5.0	0.38	1.53e-6	Permanent tooth development;
PAAD	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.68e-8	Schizophrenia;
PAAD	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg08523384	chr5:141488047	NDFIP1	-0.5	-4.84	-0.37	3.18e-6	Asthma;
PAAD	cis	rs35740288	0.822	rs2016517	chr15:86229618	C/T	cg07943548	chr15:86304357	KLHL25	-0.65	-5.55	-0.41	1.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg21546286	chr11:48923668	NA	-0.43	-4.63	-0.35	7.64e-6	HDL cholesterol;
PAAD	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg03303774	chr4:1407052	NA	0.48	6.01	0.44	1.34e-8	Obesity-related traits;
PAAD	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs16975963	0.545	rs12461753	chr19:38202515	G/A	cg08679971	chr19:38281047	NA	0.47	4.5	0.34	1.33e-5	Longevity;
PAAD	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.89	8.84	0.58	2.28e-15	Exhaled nitric oxide output;
PAAD	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.7	7.49	0.52	5.12e-12	Type 2 diabetes;
PAAD	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05347473	chr6:146136440	FBXO30	0.47	4.52	0.34	1.23e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg14345882	chr6:26364793	BTN3A2	0.67	4.43	0.34	1.78e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.48	4.42	0.34	1.84e-5	Mood instability;
PAAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.73	-4.8	-0.36	3.72e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs7873102	0.654	rs7033327	chr9:37962801	T/C	cg03528946	chr9:38069800	SHB	0.55	5.48	0.41	1.7e-7	Brain structure;
PAAD	cis	rs7771547	0.821	rs7755461	chr6:36574832	A/T	cg07856975	chr6:36356162	ETV7	0.43	4.7	0.36	5.67e-6	Platelet distribution width;
PAAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.84	0.54	7.51e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.5	-4.62	-0.35	8.25e-6	Mood instability;
PAAD	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.85	-6.14	-0.45	6.86e-9	Coronary artery disease;
PAAD	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.76	7.24	0.51	2.11e-11	Primary sclerosing cholangitis;
PAAD	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.5	4.44	0.34	1.74e-5	Corneal astigmatism;
PAAD	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	4.8	0.36	3.79e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg14132834	chr19:41945861	ATP5SL	-0.47	-4.52	-0.34	1.26e-5	Height;
PAAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg16205897	chr5:131564050	P4HA2	-0.55	-6.06	-0.44	1.03e-8	Blood metabolite levels;
PAAD	cis	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg14329783	chr7:75779857	NA	0.79	4.75	0.36	4.64e-6	Mononucleosis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22323120	chr2:231859348	SPATA3	-0.52	-6.31	-0.46	2.83e-9	Monocyte percentage of white cells;
PAAD	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.63	0.42	8.67e-8	HDL cholesterol;
PAAD	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg11897209	chr6:86302888	SNX14	0.47	4.57	0.35	1.02e-5	Response to antipsychotic treatment;
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg21959181	chr7:150755243	CDK5;SLC4A2	0.69	6.7	0.48	3.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs375066	0.868	rs453950	chr19:44403055	G/A	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg14926445	chr8:58193284	C8orf71	-0.71	-5.57	-0.41	1.11e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.62	6.73	0.48	3.22e-10	Leprosy;
PAAD	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.91	-9.15	-0.6	3.56e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.49e-7	Fibrinogen levels;
PAAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg08994789	chr17:28903642	LRRC37B2	0.63	4.71	0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.82	9.15	0.6	3.49e-16	Ulcerative colitis;
PAAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.46	4.88	0.37	2.6e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.86	0.37	2.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.91	7.01	0.49	7.15e-11	Inflammatory bowel disease;
PAAD	cis	rs11892454	0.544	rs6753192	chr2:25986729	C/A	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.83e-5	Heschl's gyrus morphology;
PAAD	cis	rs72627123	0.867	rs17094076	chr14:74400492	A/G	cg19860245	chr14:74300557	NA	-0.72	-5.01	-0.38	1.49e-6	Morning vs. evening chronotype;
PAAD	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg27499820	chr13:21296301	IL17D	-0.52	-4.97	-0.37	1.8e-6	Dental caries;
PAAD	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg15733309	chr7:157513707	PTPRN2	0.63	7.83	0.54	7.79e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.53	4.34	0.33	2.57e-5	Mean platelet volume;
PAAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg03477792	chr4:77819574	ANKRD56	0.83	11.09	0.67	2.52e-21	Emphysema distribution in smoking;
PAAD	cis	rs793571	0.666	rs544282	chr15:59022102	G/A	cg05156742	chr15:59063176	FAM63B	0.65	4.96	0.37	1.83e-6	Schizophrenia;
PAAD	cis	rs7771547	0.723	rs1812018	chr6:36557976	C/T	cg07856975	chr6:36356162	ETV7	0.44	4.45	0.34	1.65e-5	Platelet distribution width;
PAAD	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.3	-0.46	3.02e-9	Neuroticism;
PAAD	cis	rs986417	0.786	rs7156379	chr14:61110634	G/C	cg27398547	chr14:60952738	C14orf39	1.08	6.44	0.46	1.46e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.7	7.4	0.51	8.53e-12	Colorectal cancer;
PAAD	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.64	0.35	7.61e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.85	-7.91	-0.54	5.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.61	5.92	0.43	2.07e-8	Blood pressure;
PAAD	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg22437258	chr11:111473054	SIK2	-0.59	-5.58	-0.41	1.05e-7	Primary sclerosing cholangitis;
PAAD	cis	rs432925	0.600	rs379056	chr16:339291	G/C	cg06233593	chr16:337645	AXIN1	0.48	5.47	0.41	1.79e-7	Morning vs. evening chronotype;
PAAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg07527105	chr16:88053339	BANP	-0.47	-4.7	-0.36	5.74e-6	Menopause (age at onset);
PAAD	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	5.72	0.42	5.55e-8	Ileal carcinoids;
PAAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06217245	chr20:33103252	DYNLRB1	0.37	4.45	0.34	1.66e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg19636519	chr7:99541626	NA	0.38	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.51	4.44	0.34	1.74e-5	Height;
PAAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.53	-4.52	-0.34	1.25e-5	IgG glycosylation;
PAAD	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.88	-0.54	5.83e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg17541715	chr7:1216824	NA	-0.39	-4.3	-0.33	3.06e-5	Longevity;Endometriosis;
PAAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.68	7.77	0.53	1.12e-12	Height;
PAAD	cis	rs11807834	0.522	rs10489614	chr1:230247369	G/A	cg09847368	chr1:230250326	GALNT2	-0.69	-8.47	-0.57	1.99e-14	Schizophrenia;
PAAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	7.35	0.51	1.13e-11	Eosinophil percentage of white cells;
PAAD	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.64	6.12	0.44	7.71e-9	Blood protein levels;
PAAD	cis	rs881827	0.851	rs55863940	chr21:48011048	A/T	cg11766577	chr21:47581405	C21orf56	-0.41	-4.36	-0.33	2.36e-5	Lymphocyte counts;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16605523	chr12:124069475	TMED2	-0.75	-6.38	-0.46	2.03e-9	Neuroticism;
PAAD	cis	rs9287719	0.649	rs12621977	chr2:10721931	T/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg02683114	chr2:24398427	C2orf84	-0.52	-5.09	-0.38	1.07e-6	Asthma;
PAAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	1.03	13.44	0.74	1.22e-27	Gestational age at birth (maternal effect);
PAAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs59888335	0.964	rs13072956	chr3:80688041	T/C	cg21735741	chr3:80819488	NA	0.57	5.1	0.38	9.87e-7	Schizophrenia;
PAAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg02487422	chr3:49467188	NICN1	0.55	5.56	0.41	1.2e-7	Resting heart rate;
PAAD	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.49	4.52	0.34	1.22e-5	Self-reported allergy;
PAAD	cis	rs3106136	0.814	rs6839224	chr4:95279214	A/C	cg11021082	chr4:95130006	SMARCAD1	0.65	6.14	0.45	6.93e-9	Capecitabine sensitivity;
PAAD	cis	rs78761021	0.898	rs12150046	chr17:9766753	A/G	cg26853458	chr17:9805074	RCVRN	0.7	8.08	0.55	1.89e-13	Type 2 diabetes;
PAAD	cis	rs818427	0.858	rs461866	chr5:112231450	G/A	cg06941702	chr5:112196734	SRP19	0.52	4.76	0.36	4.51e-6	Total body bone mineral density;
PAAD	cis	rs17123764	0.892	rs11169097	chr12:50052596	A/C	cg14846292	chr12:49726500	C1QL4	-0.68	-4.45	-0.34	1.65e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg08601574	chr20:25228251	PYGB	0.53	5.45	0.4	2.01e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.45	-5.23	-0.39	5.64e-7	Intelligence;
PAAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-4.61	-0.35	8.35e-6	Height;
PAAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.96	0.54	3.63e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.48	5.75	0.42	4.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	6.39	0.46	1.93e-9	Cognitive ability;
PAAD	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.4	-0.4	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-6.96	-0.49	9.37e-11	Gut microbiome composition (summer);
PAAD	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs11811982	0.793	rs77973381	chr1:227432753	C/T	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.67	-8.35	-0.56	3.85e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.6	6.48	0.47	1.2e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.47	-0.41	1.77e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.61	-6.11	-0.44	7.98e-9	Post bronchodilator FEV1;
PAAD	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg14388049	chr10:71211838	TSPAN15	-0.46	-4.91	-0.37	2.3e-6	Thrombosis;
PAAD	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-1.06	-7.49	-0.52	5.14e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.71	6.86	0.49	1.67e-10	Platelet count;
PAAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.92	11.88	0.69	1.89e-23	Menarche (age at onset);
PAAD	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.59	6.34	0.46	2.46e-9	Obesity-related traits;
PAAD	cis	rs75920871	0.589	rs56061158	chr11:117087118	G/C	cg20748955	chr11:118016902	SCN4B	0.72	4.51	0.34	1.28e-5	Subjective well-being;
PAAD	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg09760422	chr2:128146352	NA	-0.41	-6.3	-0.45	3.06e-9	Self-rated health;
PAAD	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg20406979	chr6:167373233	NA	0.38	5.24	0.39	5.2e-7	Crohn's disease;
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.56	-4.99	-0.37	1.66e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg05484376	chr2:27715224	FNDC4	-0.44	-4.46	-0.34	1.61e-5	Oral cavity cancer;
PAAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg18854424	chr1:2615690	NA	0.45	5.8	0.43	3.77e-8	Ulcerative colitis;
PAAD	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg20913747	chr6:44695427	NA	-0.66	-6.62	-0.47	5.8e-10	Total body bone mineral density;
PAAD	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.79	8.48	0.57	1.84e-14	Mean corpuscular volume;
PAAD	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.57	5.83	0.43	3.18e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg03340356	chr1:67600835	NA	0.44	5.06	0.38	1.2e-6	Psoriasis;
PAAD	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.63	6.37	0.46	2.12e-9	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.53	-5.43	-0.4	2.14e-7	Testicular germ cell tumor;
PAAD	cis	rs877529	0.605	rs79504	chr22:39551555	T/C	cg18708252	chr22:39545030	CBX7	-0.66	-6.83	-0.48	1.93e-10	Multiple myeloma;
PAAD	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.9	10.81	0.66	1.49e-20	Monocyte count;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg21452766	chr1:70877088	CTH	-0.63	-6.63	-0.47	5.61e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs4073221	0.585	rs13093954	chr3:18326007	C/T	cg07694806	chr3:18168406	NA	-0.62	-4.56	-0.35	1.04e-5	Parkinson's disease;
PAAD	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.8	-9.01	-0.59	8.11e-16	Colorectal cancer;
PAAD	cis	rs929596	0.564	rs2741027	chr2:234518011	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-4.53	-0.34	1.2e-5	Total bilirubin levels in HIV-1 infection;
PAAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.88	9.7	0.62	1.28e-17	Cognitive function;
PAAD	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.81	9.11	0.59	4.53e-16	Colorectal cancer;
PAAD	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.59	-4.94	-0.37	2.07e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs733175	0.951	rs7669090	chr4:10028131	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	5.48	0.41	1.69e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.76	0.42	4.5e-8	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.66	6.04	0.44	1.16e-8	Red blood cell count;
PAAD	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.56	5.68	0.42	6.62e-8	Testicular germ cell tumor;
PAAD	cis	rs1329189	1.000	rs6482665	chr10:129994579	C/T	cg17972361	chr10:130010134	NA	0.48	4.93	0.37	2.15e-6	Orofacial clefts;
PAAD	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg19196401	chr6:110721138	DDO	-0.49	-5.41	-0.4	2.36e-7	Platelet distribution width;
PAAD	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16579770	chr16:72058938	DHODH	-0.4	-4.72	-0.36	5.24e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs884843	0.839	rs55855101	chr7:73443015	G/A	cg23513211	chr7:72726717	TRIM50	-0.36	-4.47	-0.34	1.51e-5	Pulse pressure;
PAAD	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.76	-6.98	-0.49	8.41e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.47	4.53	0.35	1.17e-5	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.65	-0.47	4.87e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-5.66	-0.42	7.28e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs7904985	0.961	rs34282419	chr10:88125834	C/A	cg07322936	chr10:88137208	NA	-0.49	-4.42	-0.34	1.9e-5	Barrett's esophagus;
PAAD	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.41	4.5	0.34	1.32e-5	HDL cholesterol levels;
PAAD	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.52	5.43	0.4	2.22e-7	Type 2 diabetes;
PAAD	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg16558253	chr16:72132732	DHX38	-0.51	-5.37	-0.4	2.95e-7	Fibrinogen levels;
PAAD	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg00614314	chr15:82944287	LOC80154	0.53	5.26	0.39	4.71e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.91	9.4	0.61	7.83e-17	Blood protein levels;
PAAD	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.53	-0.41	1.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg26248373	chr2:1572462	NA	-1.05	-7.26	-0.51	1.87e-11	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg27417294	chr10:81904244	PLAC9	0.56	4.28	0.33	3.31e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.92	11.39	0.68	4.01e-22	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.81	8.63	0.57	7.8e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.56	-5.33	-0.4	3.47e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg20406979	chr6:167373233	NA	-0.37	-5.07	-0.38	1.14e-6	Crohn's disease;
PAAD	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.65	0.53	2.19e-12	Motion sickness;
PAAD	cis	rs17824933	0.848	rs11230560	chr11:60771077	G/A	cg16817237	chr11:60793675	NA	0.52	6.11	0.44	8.07e-9	Multiple sclerosis;
PAAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	8.02	0.55	2.57e-13	Mood instability;
PAAD	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg18084798	chr19:33555255	RHPN2	0.46	4.77	0.36	4.23e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg10934807	chr2:113191815	RGPD8;RGPD5	0.98	7.75	0.53	1.23e-12	Yeast infection;
PAAD	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.52	4.95	0.37	1.98e-6	Hip circumference;
PAAD	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.83	-0.36	3.32e-6	Height;
PAAD	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.86	0.58	1.93e-15	Fuchs's corneal dystrophy;
PAAD	trans	rs901683	1.000	rs35713143	chr10:46088159	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.62	7.53	0.52	4.29e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.33	0.4	3.46e-7	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00612595	chr21:47717864	NA	-0.4	-4.25	-0.33	3.66e-5	Testicular germ cell tumor;
PAAD	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22674798	chr1:3096360	PRDM16	0.61	9.35	0.6	1.06e-16	Migraine;
PAAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.41	4.34	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg19680485	chr15:31195859	MTMR15	-0.45	-4.34	-0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.81	5.6	0.41	9.57e-8	Major depression and alcohol dependence;
PAAD	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.69	7.37	0.51	1.03e-11	Type 2 diabetes;
PAAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.81	8.93	0.59	1.29e-15	Menopause (age at onset);
PAAD	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg03004497	chr11:58874207	FAM111B	-0.52	-4.36	-0.33	2.4e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00149659	chr3:10157352	C3orf10	0.56	4.46	0.34	1.61e-5	Alzheimer's disease;
PAAD	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.41	-4.89	-0.37	2.54e-6	Lewy body disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24569251	chr6:36628087	NA	0.61	6.3	0.46	3.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.0	6.66	0.48	4.75e-10	Sexual dysfunction (female);
PAAD	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.22	21.24	0.86	2.36e-47	Testicular germ cell tumor;
PAAD	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.77	5.78	0.42	4.03e-8	Height;
PAAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs1903068	0.853	rs73236111	chr4:56019068	A/C	cg01777861	chr4:56023843	NA	0.36	4.67	0.35	6.64e-6	Endometriosis;
PAAD	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs988913	0.915	rs9475107	chr6:54853342	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-4.8	-0.36	3.81e-6	Menarche (age at onset);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06890779	chr16:10449523	NA	0.57	7.08	0.5	4.98e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.67	7.73	0.53	1.36e-12	Body mass index;
PAAD	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.41	4.27	0.33	3.37e-5	Schizophrenia;
PAAD	cis	rs7945705	0.935	rs2243566	chr11:8852239	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.64	6.75	0.48	2.94e-10	Hemoglobin concentration;
PAAD	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg22040403	chr1:23858016	E2F2	0.67	4.29	0.33	3.16e-5	Total cholesterol levels;
PAAD	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg16589663	chr20:23618590	CST3	0.8	6.9	0.49	1.32e-10	Chronic kidney disease;
PAAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg18351406	chr4:77819688	ANKRD56	0.76	8.88	0.58	1.8e-15	Emphysema distribution in smoking;
PAAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.74	-7.02	-0.49	6.94e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg16818395	chr3:128274084	NA	0.54	4.77	0.36	4.25e-6	Dental caries;
PAAD	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14008862	chr17:28927542	LRRC37B2	0.77	5.75	0.42	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.44	5.55	0.41	1.26e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.52	4.85	0.37	3e-6	Schizophrenia;
PAAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.73	0.53	1.36e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8074751	0.846	rs1859454	chr17:63633491	A/T	cg04573935	chr17:63133668	RGS9	-0.27	-4.25	-0.33	3.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg02917321	chr22:38215204	NA	-0.43	-4.75	-0.36	4.71e-6	Glioblastoma;Glioma;
PAAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.89	13.09	0.73	1.04e-26	Bone mineral density;
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22162314	chr17:61951766	CSH2	-0.56	-5.71	-0.42	5.68e-8	Height;
PAAD	cis	rs1419980	0.730	rs11054607	chr12:7733632	G/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.16	17.2	0.81	1.67e-37	Cognitive function;
PAAD	cis	rs66530629	0.917	rs9259	chr1:25168124	C/G	cg01905478	chr1:25040257	NA	-0.45	-4.9	-0.37	2.46e-6	Plateletcrit;
PAAD	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg23241863	chr10:102295624	HIF1AN	0.5	4.38	0.33	2.24e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg24253500	chr15:84953950	NA	0.43	4.5	0.34	1.35e-5	Schizophrenia;
PAAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg20933634	chr6:27740509	NA	0.66	6.29	0.45	3.26e-9	Parkinson's disease;
PAAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	10.32	0.64	2.95e-19	Smoking behavior;
PAAD	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.82	8.88	0.58	1.72e-15	Schizophrenia;
PAAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.77	-8.94	-0.59	1.24e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.71	-8.8	-0.58	2.89e-15	Breast cancer;
PAAD	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg21523528	chr20:32077966	CBFA2T2	0.53	4.37	0.33	2.32e-5	Height;
PAAD	cis	rs7127900	1.000	rs11043143	chr11:2234093	T/C	cg25635251	chr11:2234043	NA	0.83	7.49	0.52	5.27e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.01	11.71	0.69	5.51e-23	Breast cancer;
PAAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg00999904	chr2:3704751	ALLC	-0.5	-5.66	-0.42	7.44e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg09473613	chr1:24152604	HMGCL	-0.54	-5.7	-0.42	6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.99	0.67	4.82e-21	Smoking behavior;
PAAD	cis	rs818427	0.964	rs495794	chr5:112201094	A/G	cg07820702	chr5:112228657	REEP5	0.53	4.88	0.37	2.7e-6	Total body bone mineral density;
PAAD	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-5.15	-0.39	7.97e-7	Daytime sleep phenotypes;
PAAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	9.64	0.62	1.88e-17	Platelet count;
PAAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg11204139	chr17:3907470	NA	-0.66	-6.78	-0.48	2.49e-10	Type 2 diabetes;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08677398	chr8:58056175	NA	-0.66	-4.37	-0.33	2.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.58	5.06	0.38	1.2e-6	Lymphocyte counts;
PAAD	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg16701003	chr16:89028210	CBFA2T3	0.61	5.99	0.44	1.46e-8	Social autistic-like traits;
PAAD	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.65	6.88	0.49	1.43e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg08994789	chr17:28903642	LRRC37B2	0.64	5.07	0.38	1.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.62	8.51	0.57	1.59e-14	Renal cell carcinoma;
PAAD	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.64	8.8	0.58	2.76e-15	Airflow obstruction;
PAAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.78	0.36	4.07e-6	Lung cancer in ever smokers;
PAAD	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.48	7.01	0.49	7.28e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-4.68	-0.36	6.21e-6	Blood metabolite levels;
PAAD	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.71	-6.91	-0.49	1.23e-10	Hip circumference;
PAAD	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-5.37	-0.4	2.93e-7	Total body bone mineral density;
PAAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.55	6.85	0.49	1.74e-10	Psoriasis;
PAAD	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.4	-5.96	-0.44	1.71e-8	Cutaneous nevi;
PAAD	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.15	-0.39	8.11e-7	Retinal vascular caliber;
PAAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg01763666	chr17:80159506	CCDC57	-0.45	-4.58	-0.35	9.62e-6	Life satisfaction;
PAAD	cis	rs9810890	0.850	rs1466572	chr3:128543415	T/A	cg18531004	chr3:128564980	NA	-0.9	-4.82	-0.36	3.39e-6	Dental caries;
PAAD	trans	rs901683	0.850	rs35150810	chr10:46071142	T/G	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01434783	chr4:124319883	SPRY1	-0.56	-6.54	-0.47	8.63e-10	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-4.64	-0.35	7.35e-6	Alzheimer's disease;
PAAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg09222892	chr1:25734099	RHCE	-0.44	-4.27	-0.33	3.45e-5	Erythrocyte sedimentation rate;
PAAD	cis	rs7301826	0.560	rs12829294	chr12:131309972	A/G	cg11011512	chr12:131303247	STX2	-0.42	-4.3	-0.33	3.06e-5	Plasma plasminogen activator levels;
PAAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.63	-6.38	-0.46	2.03e-9	Monocyte count;
PAAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg11218175	chr11:495084	RNH1	0.85	4.87	0.37	2.82e-6	Body mass index;
PAAD	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.9	10.29	0.64	3.57e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	4.27	0.33	3.43e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs629922	0.855	rs542273	chr11:114050631	A/T	cg25009965	chr11:114031120	ZBTB16	0.43	4.35	0.33	2.49e-5	Paneth cell defects in Crohn's disease;
PAAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.4	0.34	1.99e-5	Breast cancer;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13939156	chr17:80058883	NA	-0.41	-4.4	-0.34	1.99e-5	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg24699146	chr1:24152579	HMGCL	0.44	4.5	0.34	1.34e-5	Immature fraction of reticulocytes;
PAAD	cis	rs8102137	0.851	rs62104477	chr19:30294991	G/T	cg27475126	chr19:30303651	CCNE1	-0.44	-4.89	-0.37	2.58e-6	Bladder cancer;
PAAD	cis	rs12752838	1.000	rs12752838	chr1:8913656	A/G	cg24027679	chr1:9086621	SLC2A7	0.38	4.45	0.34	1.68e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs3857067	0.550	rs1841926	chr4:95002846	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.48	4.9	0.37	2.38e-6	Major depressive disorder;
PAAD	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg20302533	chr7:39170763	POU6F2	0.45	6.92	0.49	1.17e-10	IgG glycosylation;
PAAD	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs4662750	0.798	rs777435	chr2:128369896	A/G	cg09760422	chr2:128146352	NA	0.31	4.57	0.35	1.01e-5	Renal cell carcinoma;
PAAD	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.81	-9.08	-0.59	5.35e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.56	6.48	0.47	1.23e-9	Lung cancer;
PAAD	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	8.6	0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-6.5	-0.47	1.11e-9	Neuroticism;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg27094323	chr7:1216898	NA	-0.43	-4.93	-0.37	2.17e-6	Longevity;Endometriosis;
PAAD	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.75e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21016266	chr12:122356598	WDR66	0.63	6.83	0.48	1.95e-10	Mean corpuscular volume;
PAAD	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg27490568	chr2:178487706	NA	-0.4	-4.34	-0.33	2.61e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.19	8.26	0.56	6.73e-14	Lung cancer in ever smokers;
PAAD	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.28	-0.33	3.26e-5	Fibrinogen levels;
PAAD	cis	rs10267417	0.603	rs4275127	chr7:19911062	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	4.88	0.37	2.61e-6	Night sleep phenotypes;
PAAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14180030	chr9:123475675	MEGF9	-0.46	-5.07	-0.38	1.15e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.66	6.45	0.46	1.4e-9	Smoking initiation;
PAAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.58	6.65	0.47	5.07e-10	Mean corpuscular volume;
PAAD	cis	rs2327429	0.858	rs7769954	chr6:134196381	A/G	cg06643013	chr6:134217242	NA	0.41	4.51	0.34	1.3e-5	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03757871	chr2:131555470	NA	0.58	6.47	0.46	1.28e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.59	-0.35	9.11e-6	Asthma;
PAAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.4e-8	Bipolar disorder;
PAAD	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.25	-4.62	-0.35	7.97e-6	Schizophrenia;
PAAD	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg26876637	chr1:152193138	HRNR	0.87	6.5	0.47	1.06e-9	Atopic dermatitis;
PAAD	cis	rs2120243	0.592	rs4640513	chr3:157115950	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.63	0.35	7.94e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg24846680	chr1:228362309	C1orf69	0.45	4.35	0.33	2.45e-5	Diastolic blood pressure;
PAAD	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	ch.11.42038R	chr11:967971	AP2A2	0.6	6.13	0.45	7.15e-9	Alzheimer's disease (late onset);
PAAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg11764359	chr7:65958608	NA	0.8	5.1	0.38	1.01e-6	Diabetic kidney disease;
PAAD	cis	rs2120243	0.592	rs1869857	chr3:157123357	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.44	-4.81	-0.36	3.63e-6	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.6	5.49	0.41	1.62e-7	HDL cholesterol;
PAAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.45	6.05	0.44	1.1e-8	Ulcerative colitis;
PAAD	cis	rs4740619	0.933	rs1396708	chr9:15705479	C/A	cg14451791	chr9:16040625	NA	-0.4	-4.69	-0.36	6.1e-6	Body mass index;
PAAD	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-5.64	-0.42	8.16e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.72	5.25	0.39	5.07e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-7.33	-0.51	1.27e-11	Morning vs. evening chronotype;
PAAD	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.55	-5.86	-0.43	2.83e-8	Height;
PAAD	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs62238980	0.614	rs5998272	chr22:32560045	A/C	cg00543991	chr22:32367038	NA	1.02	6.81	0.48	2.16e-10	Childhood ear infection;
PAAD	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.54	5.52	0.41	1.43e-7	Initial pursuit acceleration in psychotic disorders;
PAAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18892537	chr1:151966104	S100A10	0.68	6.44	0.46	1.49e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg00280220	chr17:61926910	NA	0.44	4.61	0.35	8.32e-6	Prudent dietary pattern;
PAAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03994053	chr1:10057168	RBP7	0.62	6.94	0.49	1.06e-10	Monocyte percentage of white cells;
PAAD	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.85	-9.35	-0.6	1.08e-16	Calcium levels;
PAAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs58521262	0.585	rs2548888	chr19:23211028	C/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg10705379	chr10:99080932	FRAT1	-0.4	-4.57	-0.35	1.02e-5	Monocyte count;
PAAD	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg09760422	chr2:128146352	NA	-0.43	-6.94	-0.49	1.06e-10	Protein C levels;
PAAD	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.45	4.47	0.34	1.54e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.53	5.85	0.43	2.98e-8	Major depressive disorder;
PAAD	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-1.0	-9.22	-0.6	2.31e-16	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.73	9.9	0.63	3.92e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg12623918	chr2:306882	NA	0.55	4.56	0.35	1.05e-5	Blood protein levels;
PAAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	1.06	9.09	0.59	5.13e-16	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.17e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7816613	0.833	rs7821322	chr8:102702187	C/T	cg20585841	chr8:102729926	NCALD	-0.6	-5.94	-0.43	1.87e-8	Age-related hearing impairment;
PAAD	cis	rs713477	0.505	rs8019209	chr14:55891329	C/T	cg13175173	chr14:55914753	NA	-0.35	-4.67	-0.35	6.61e-6	Pediatric bone mineral content (femoral neck);
PAAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.77	4.55	0.35	1.1e-5	Body mass index;
PAAD	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.35	0.4	3.11e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.85	9.4	0.61	7.81e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.84	9.43	0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.97	13.46	0.74	1.11e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.45	0.34	1.63e-5	Breast cancer;
PAAD	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.84	-8.37	-0.56	3.44e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	4.63	0.35	7.87e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs4867766	0.871	rs113284505	chr5:173954800	A/G	cg20434911	chr5:173954559	NA	-0.66	-6.66	-0.48	4.66e-10	Stroke;
PAAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg13870426	chr17:30244630	NA	-0.75	-6.61	-0.47	6.07e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg27511599	chr7:32358540	NA	0.76	4.52	0.34	1.22e-5	Body mass index;
PAAD	cis	rs3867498	0.941	rs11855991	chr15:25075105	G/A	cg08194505	chr15:25684383	UBE3A	-0.67	-4.62	-0.35	8.3e-6	Pulmonary function;
PAAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09529023	chr16:2097506	TSC2;NTHL1	-0.49	-4.39	-0.34	2.11e-5	Insulin-like growth factors;
PAAD	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-8.32	-0.56	4.7e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
PAAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg11764359	chr7:65958608	NA	0.8	5.22	0.39	5.73e-7	Diabetic kidney disease;
PAAD	cis	rs288326	0.561	rs17265894	chr2:183858168	A/G	cg09997497	chr2:183902928	NCKAP1	0.97	5.8	0.43	3.81e-8	Blood protein levels;
PAAD	cis	rs302972	0.826	rs79229624	chr6:25074656	A/C	cg09546929	chr6:25930894	SLC17A2	0.78	4.36	0.33	2.39e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.41	-4.34	-0.33	2.59e-5	QRS complex (12-leadsum);
PAAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg22800045	chr5:56110881	MAP3K1	-0.58	-5.15	-0.39	7.9e-7	Initial pursuit acceleration;
PAAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg14393609	chr7:65229607	NA	0.66	7.32	0.51	1.35e-11	Aortic root size;
PAAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.78	7.41	0.52	8.24e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.6	-5.59	-0.41	1.04e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs644799	0.562	rs1616015	chr11:95491685	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	-0.76	-8.16	-0.55	1.17e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14442939	chr10:27389572	ANKRD26	0.59	5.39	0.4	2.61e-7	Breast cancer;
PAAD	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg05625103	chr10:2543513	NA	-0.55	-5.41	-0.4	2.39e-7	Age-related hearing impairment;
PAAD	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg09659197	chr4:152720779	NA	0.46	5.98	0.44	1.54e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12476592	0.571	rs7606045	chr2:63826528	T/G	cg10828910	chr2:63850056	LOC388955	0.48	4.4	0.34	2.01e-5	Childhood ear infection;
PAAD	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.28	0.39	4.34e-7	Mean platelet volume;
PAAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.18e-6	Body mass index;
PAAD	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg22875332	chr1:76189707	ACADM	-0.5	-4.99	-0.37	1.67e-6	Daytime sleep phenotypes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20483215	chr17:72919318	OTOP2;USH1G	0.63	6.36	0.46	2.26e-9	Obesity-related traits;
PAAD	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs7714584	1.000	rs1428551	chr5:150259832	G/A	cg22134413	chr5:150180641	NA	0.73	5.21	0.39	5.93e-7	Crohn's disease;
PAAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.31	0.33	2.96e-5	Major depressive disorder;
PAAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs300774	0.925	rs300801	chr2:105259	C/T	cg21211680	chr2:198530	NA	-0.62	-5.66	-0.42	7.2e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.71	6.22	0.45	4.64e-9	Mean platelet volume;
PAAD	cis	rs3026101	0.671	rs12602061	chr17:5302645	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.41	-4.51	-0.34	1.29e-5	Refractive error;
PAAD	cis	rs12568771	1.000	rs12568771	chr1:17613809	A/G	cg08277548	chr1:17600880	PADI3	0.42	4.76	0.36	4.55e-6	IgA nephropathy;
PAAD	cis	rs288342	0.832	rs825668	chr2:183589615	G/T	cg02625481	chr2:183667124	NA	-0.44	-4.44	-0.34	1.7e-5	Recurrent major depressive disorder;
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-11.48	-0.68	2.26e-22	Longevity;Endometriosis;
PAAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg23281280	chr6:28129359	ZNF389	0.52	4.36	0.33	2.36e-5	Parkinson's disease;
PAAD	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.39	9.52	0.61	3.92e-17	Diabetic retinopathy;
PAAD	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.07	0.38	1.14e-6	Total body bone mineral density;
PAAD	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg14583973	chr4:3374767	RGS12	-0.35	-5.16	-0.39	7.76e-7	Mean platelet volume;
PAAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	10.68	0.65	3.31e-20	Total body bone mineral density;
PAAD	cis	rs3774830	0.534	rs7687596	chr4:5472092	C/T	cg26943120	chr4:5472116	STK32B	-0.41	-5.19	-0.39	6.73e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.62	-6.47	-0.46	1.27e-9	Motion sickness;
PAAD	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.95	10.12	0.63	1.01e-18	Alcohol dependence;
PAAD	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg15192750	chr16:69999425	NA	0.77	5.95	0.43	1.76e-8	IgE levels;
PAAD	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg20913747	chr6:44695427	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs4455778	0.559	rs6583511	chr7:49122876	G/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.75	8.77	0.58	3.32e-15	Methadone dose in opioid dependence;
PAAD	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13870426	chr17:30244630	NA	-0.7	-7.07	-0.5	5.38e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg27121462	chr16:89883253	FANCA	0.85	4.25	0.33	3.75e-5	Skin colour saturation;
PAAD	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg10253484	chr15:75165896	SCAMP2	0.59	5.09	0.38	1.05e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg10556349	chr10:835070	NA	0.59	4.95	0.37	1.96e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	9.56	0.61	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	9.37	0.61	9.55e-17	Schizophrenia;
PAAD	cis	rs2718812	1.000	rs2953740	chr3:133406351	T/C	cg12372414	chr3:134319805	KY	-0.41	-4.48	-0.34	1.46e-5	Iron status biomarkers;
PAAD	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg01214346	chr17:406501	NA	-0.42	-4.31	-0.33	2.88e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9657904	0.865	rs1470283	chr3:105557701	C/G	cg16975614	chr3:105601834	NA	-0.46	-4.46	-0.34	1.6e-5	Multiple sclerosis;
PAAD	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg00012203	chr2:219082015	ARPC2	0.62	6.09	0.44	8.93e-9	Colorectal cancer;
PAAD	cis	rs3136739	0.614	rs35076851	chr8:42017991	C/T	cg17828057	chr8:42037527	PLAT	0.68	4.63	0.35	7.76e-6	Plasma plasminogen activator levels;
PAAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26549601	chr10:134560360	INPP5A	-0.44	-4.43	-0.34	1.82e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.1	-14.38	-0.76	3.92e-30	Primary sclerosing cholangitis;
PAAD	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.94	-0.43	1.84e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg21211680	chr2:198530	NA	0.72	5.64	0.42	8.03e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.85	6.99	0.49	8.17e-11	Alzheimer's disease;
PAAD	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg01489256	chr8:11204017	TDH	-0.46	-4.98	-0.37	1.68e-6	Neuroticism;
PAAD	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.53	-4.3	-0.33	3.07e-5	Type 2 diabetes;
PAAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	5.6	0.41	9.93e-8	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.99	-10.13	-0.63	9.5e-19	Systemic lupus erythematosus;
PAAD	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.44	-4.71	-0.36	5.63e-6	Motion sickness;
PAAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.67	6.72	0.48	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg03732007	chr1:2071316	PRKCZ	-0.43	-4.53	-0.34	1.2e-5	Height;
PAAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.1e-6	Type 2 diabetes;
PAAD	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg00179576	chr16:74483694	GLG1	-0.39	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs761746	0.739	rs5998072	chr22:32048374	G/T	cg01338084	chr22:32026380	PISD	0.64	5.36	0.4	3.01e-7	Intelligence;
PAAD	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.92	-0.49	1.2e-10	Eye color traits;
PAAD	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.61	-5.59	-0.41	1.04e-7	Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22044901	chr15:68126292	NA	0.61	6.91	0.49	1.22e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg05342682	chr7:94953680	PON1	-0.53	-4.6	-0.35	8.89e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs151997	0.569	rs10035173	chr5:50276059	C/G	cg06027927	chr5:50259733	NA	0.62	5.57	0.41	1.15e-7	Callous-unemotional behaviour;
PAAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.88	7.27	0.51	1.74e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-7.03	-0.5	6.48e-11	Hemoglobin concentration;
PAAD	cis	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.69	6.98	0.49	8.48e-11	Retinal vascular caliber;
PAAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg05564831	chr3:52568323	NT5DC2	0.45	4.79	0.36	3.91e-6	Bipolar disorder;
PAAD	cis	rs11250714	1.000	rs11250714	chr10:1702581	A/G	cg10435618	chr10:838112	NA	0.49	4.57	0.35	9.92e-6	Gut microbiome composition (summer);
PAAD	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-15.51	-0.78	4.05e-33	Schizophrenia;
PAAD	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg17644776	chr2:200775616	C2orf69	-0.66	-5.18	-0.39	6.94e-7	Schizophrenia;
PAAD	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.82	0.43	3.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg05562828	chr17:3906858	NA	-0.55	-6.24	-0.45	4.2e-9	Type 2 diabetes;
PAAD	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg19303763	chr1:157108706	ETV3	0.46	4.46	0.34	1.56e-5	Tonsillectomy;
PAAD	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-4.37	-0.33	2.29e-5	Blood pressure;
PAAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.44	4.37	0.33	2.32e-5	Eosinophil percentage of white cells;
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.68	-0.42	6.59e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.64	6.62	0.47	5.77e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.94	-7.73	-0.53	1.4e-12	Alopecia areata;
PAAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.15	16.61	0.8	5.66e-36	Cognitive function;
PAAD	cis	rs8014252	0.708	rs8010473	chr14:70988993	G/C	cg11204974	chr14:71022665	NA	-0.68	-4.57	-0.35	1.01e-5	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
PAAD	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg00717180	chr2:96193071	NA	-0.61	-6.83	-0.48	1.96e-10	HDL cholesterol;
PAAD	cis	rs6496932	0.755	rs114623143	chr15:85890461	G/A	cg19183879	chr15:85880815	NA	-0.54	-4.82	-0.36	3.42e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg07703079	chr11:430292	ANO9	-0.91	-5.55	-0.41	1.22e-7	Body mass index;
PAAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.43	5.59	0.41	1.03e-7	Childhood ear infection;
PAAD	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.81	-10.16	-0.64	7.7e-19	Height;
PAAD	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg21064579	chr19:49206444	FUT2	0.4	4.28	0.33	3.32e-5	Dietary macronutrient intake;
PAAD	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-1.07	-15.19	-0.78	2.77e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg16928487	chr17:17741425	SREBF1	-0.36	-4.99	-0.37	1.67e-6	Total body bone mineral density;
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg07061783	chr6:25882402	NA	-0.54	-5.52	-0.41	1.44e-7	Blood metabolite levels;
PAAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.54e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg26031613	chr14:104095156	KLC1	-0.57	-5.84	-0.43	3.13e-8	Reticulocyte count;
PAAD	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg25547332	chr5:131281432	NA	0.54	4.3	0.33	3.05e-5	Life satisfaction;
PAAD	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.47	-4.87	-0.37	2.81e-6	Motion sickness;
PAAD	cis	rs116248771	0.793	rs12494750	chr3:158298411	T/G	cg16708174	chr3:158430962	RARRES1	0.66	5.04	0.38	1.28e-6	diarrhoeal disease at age 2;
PAAD	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.71	-6.5	-0.47	1.08e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.77	-7.94	-0.54	4.13e-13	Monocyte count;
PAAD	cis	rs6999452	0.967	rs1552108	chr8:106377021	C/T	cg12032713	chr8:106369363	ZFPM2	-0.39	-4.5	-0.34	1.36e-5	Gut microbiome composition (summer);
PAAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.65e-7	Bipolar disorder;
PAAD	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.63	5.89	0.43	2.42e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg04369109	chr6:150039330	LATS1	-0.47	-4.6	-0.35	8.8e-6	Lung cancer;
PAAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.69	9.97	0.63	2.54e-18	Huntington's disease progression;
PAAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.8	6.0	0.44	1.35e-8	Vitiligo;
PAAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.14	13.06	0.73	1.3e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs1572438	1.000	rs9379167	chr6:866372	C/T	cg13447295	chr6:887704	NA	-0.57	-5.29	-0.39	4.14e-7	Aging;
PAAD	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	cis	rs6942407	0.546	rs3789251	chr7:86793303	A/G	cg02420886	chr7:86849541	C7orf23	0.63	4.79	0.36	3.85e-6	Food allergy;
PAAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg01075559	chr1:2537774	MMEL1	0.46	4.86	0.37	2.85e-6	Ulcerative colitis;
PAAD	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg01256987	chr12:42539512	GXYLT1	0.38	4.34	0.33	2.54e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-11.01	-0.67	4.2e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.63	-7.02	-0.49	7.07e-11	Smoking initiation;
PAAD	cis	rs17209837	1.000	rs60541816	chr7:87127861	G/A	cg00919237	chr7:87102261	ABCB4	-0.76	-5.01	-0.38	1.47e-6	Gallbladder cancer;
PAAD	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.66	-7.88	-0.54	5.8e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.93	8.82	0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg27449745	chr7:23145252	KLHL7	-0.5	-4.35	-0.33	2.51e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6942407	0.542	rs744136	chr7:86747081	T/C	cg02420886	chr7:86849541	C7orf23	0.51	4.3	0.33	3.1e-5	Food allergy;
PAAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg23346134	chr3:49453900	TCTA	0.46	4.92	0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	6.06	0.44	1.01e-8	Neutrophil percentage of white cells;
PAAD	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.72	-9.17	-0.6	3.13e-16	Educational attainment;
PAAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs11807834	0.522	rs910498	chr1:230243837	G/C	cg09847368	chr1:230250326	GALNT2	-0.69	-8.44	-0.56	2.38e-14	Schizophrenia;
PAAD	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.93	7.88	0.54	5.98e-13	Alzheimer's disease;
PAAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	6.23	0.45	4.26e-9	Menopause (age at onset);
PAAD	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.6e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg15598662	chr11:61582890	MIR1908;FADS1	-0.44	-4.39	-0.34	2.14e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg24179445	chr10:102496915	NA	0.56	6.04	0.44	1.12e-8	Alzheimer's disease;
PAAD	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.55	5.84	0.43	3.12e-8	Tonsillectomy;
PAAD	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.04	0.38	1.33e-6	Educational attainment;
PAAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.47	4.3	0.33	3.07e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.59	-5.3	-0.4	3.95e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs454510	1.000	rs422647	chr1:120195840	T/C	cg11530693	chr1:120165357	ZNF697	0.56	4.77	0.36	4.29e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.91	-10.05	-0.63	1.57e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18337363	chr3:52569053	NT5DC2	0.45	4.93	0.37	2.15e-6	Electroencephalogram traits;
PAAD	cis	rs6960043	0.738	rs4721398	chr7:15045904	C/T	cg19272540	chr7:15055459	NA	0.33	5.78	0.42	4.2e-8	Type 2 diabetes;
PAAD	cis	rs12519773	0.526	rs4869191	chr5:92525434	A/T	cg18783429	chr5:92414398	NA	-0.32	-4.46	-0.34	1.6e-5	Migraine;
PAAD	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-5.48	-0.41	1.74e-7	Mean corpuscular volume;
PAAD	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.66	-7.31	-0.51	1.43e-11	Heart rate;
PAAD	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-15.37	-0.78	9.44e-33	Height;
PAAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.12	14.45	0.76	2.41e-30	Cognitive function;
PAAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.52	7.27	0.51	1.75e-11	Diastolic blood pressure;
PAAD	cis	rs7255	0.538	rs10193919	chr2:20880833	C/T	cg07755735	chr2:20870362	GDF7	-0.5	-5.57	-0.41	1.12e-7	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.37	4.32	0.33	2.79e-5	Schizophrenia;
PAAD	cis	rs7731390	0.614	rs34741321	chr5:131717423	G/A	cg07395648	chr5:131743802	NA	-0.7	-4.44	-0.34	1.73e-5	IgG glycosylation;
PAAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.51	4.45	0.34	1.62e-5	Tonsillectomy;
PAAD	cis	rs2415984	0.579	rs2123129	chr14:46960920	G/T	cg14871534	chr14:47121158	RPL10L	-0.5	-5.09	-0.38	1.04e-6	Number of children ever born;
PAAD	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.59	4.73	0.36	5.17e-6	Iron status biomarkers;
PAAD	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg08198773	chr8:1697536	NA	0.42	4.63	0.35	7.78e-6	Systolic blood pressure;
PAAD	cis	rs6137287	0.924	rs6035802	chr20:21153693	C/T	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	trans	rs901683	1.000	rs9422652	chr10:46047934	G/A	cg14076390	chr17:34947837	DHRS11	0.87	6.65	0.47	4.95e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00753739	chr10:11653489	USP6NL	0.63	7.19	0.5	2.73e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg10818794	chr15:86012489	AKAP13	-0.58	-4.9	-0.37	2.42e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.75	6.38	0.46	2.07e-9	Pulmonary function decline;
PAAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20887711	chr4:1340912	KIAA1530	-0.48	-4.8	-0.36	3.69e-6	Obesity-related traits;
PAAD	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08392591	chr16:89556376	ANKRD11	0.53	5.3	0.39	4.07e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg06917634	chr15:78832804	PSMA4	-0.45	-4.43	-0.34	1.82e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.55	-0.41	1.25e-7	Schizophrenia (age at onset);
PAAD	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-4.73	-0.36	5.06e-6	Height;
PAAD	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg06521331	chr12:34319734	NA	-0.44	-4.58	-0.35	9.52e-6	Resting heart rate;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17153363	chr7:100921869	NA	0.53	6.32	0.46	2.73e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.44	-7.03	-0.5	6.43e-11	Mean corpuscular volume;
PAAD	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.89	11.26	0.67	9.14e-22	Mean corpuscular volume;
PAAD	cis	rs6460942	0.597	rs62449509	chr7:12515013	C/T	cg20607287	chr7:12443886	VWDE	-0.78	-5.1	-0.38	1.01e-6	Coronary artery disease;
PAAD	cis	rs494459	0.657	rs614554	chr11:118635151	T/C	cg08498647	chr11:118550644	TREH	-0.34	-4.27	-0.33	3.43e-5	Height;
PAAD	trans	rs1075265	0.540	rs2542587	chr2:54015976	A/C	cg16115072	chr17:25938812	KSR1	0.6	6.35	0.46	2.32e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg14668889	chr17:73230827	NUP85	0.52	4.65	0.35	7.13e-6	Systemic lupus erythematosus;
PAAD	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg10705379	chr10:99080932	FRAT1	0.45	5.3	0.4	3.92e-7	Monocyte count;
PAAD	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	7.02e-7	Alzheimer's disease;
PAAD	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.57	5.48	0.41	1.76e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.88	-10.48	-0.65	1.08e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.48	-4.99	-0.37	1.66e-6	Renal function-related traits (BUN);
PAAD	cis	rs3126085	0.560	rs11204985	chr1:152333597	A/G	cg26876637	chr1:152193138	HRNR	0.68	5.15	0.39	8.05e-7	Atopic dermatitis;
PAAD	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.9	11.79	0.69	3.4e-23	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.12	0.5	4.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9535307	0.929	rs4942863	chr13:50314408	T/C	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.61	-7.11	-0.5	4.26e-11	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.84	-0.37	3.19e-6	Menarche (age at onset);
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.62	-6.11	-0.44	7.81e-9	Longevity;Endometriosis;
PAAD	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.62	4.81	0.36	3.66e-6	Osteoarthritis;
PAAD	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg19787841	chr12:53845606	PCBP2	0.43	4.27	0.33	3.39e-5	Height;
PAAD	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg10072921	chr12:121022843	NA	-0.37	-4.89	-0.37	2.54e-6	High light scatter reticulocyte count;
PAAD	cis	rs7925523	0.786	rs115702847	chr11:61447356	T/A	cg12472022	chr11:61462803	DAGLA	0.68	5.6	0.41	9.78e-8	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg05110241	chr16:68378359	PRMT7	-0.95	-7.52	-0.52	4.45e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg06740227	chr12:86229804	RASSF9	0.52	5.21	0.39	5.95e-7	Major depressive disorder;
PAAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs375066	0.935	rs432454	chr19:44398831	C/G	cg21496419	chr19:44306685	LYPD5	0.44	5.26	0.39	4.79e-7	Breast cancer;
PAAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg14092988	chr3:52407081	DNAH1	0.36	4.56	0.35	1.04e-5	Electroencephalogram traits;
PAAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.62	6.29	0.45	3.21e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.74	-0.36	4.88e-6	Type 2 diabetes;
PAAD	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.55	-5.78	-0.42	4.02e-8	Metabolic syndrome;
PAAD	cis	rs4073221	0.615	rs35098540	chr3:18207406	A/G	cg07694806	chr3:18168406	NA	-0.6	-4.32	-0.33	2.85e-5	Parkinson's disease;
PAAD	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.56	-6.23	-0.45	4.43e-9	Sense of smell;
PAAD	cis	rs16975963	0.843	rs241954	chr19:38277530	C/T	cg08679971	chr19:38281047	NA	0.47	4.6	0.35	8.74e-6	Longevity;
PAAD	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.47	4.68	0.35	6.28e-6	Schizophrenia;
PAAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.78	-6.25	-0.45	3.96e-9	Coronary artery disease;
PAAD	cis	rs9659323	0.730	rs10923720	chr1:119541879	T/C	cg26570165	chr1:119541833	NA	-0.54	-5.66	-0.42	7.3900000000000007e-08	Body mass index;
PAAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	4.76	0.36	4.52e-6	Vitiligo;
PAAD	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg02683114	chr2:24398427	C2orf84	-0.57	-5.5	-0.41	1.57e-7	Asthma;
PAAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.87	9.6	0.61	2.35e-17	Menopause (age at onset);
PAAD	cis	rs300774	1.000	rs436446	chr2:106409	T/C	cg21211680	chr2:198530	NA	-0.61	-5.33	-0.4	3.51e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02244288	chr16:89573955	SPG7	-0.33	-4.29	-0.33	3.19e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs6991838	0.778	rs7843697	chr8:66462768	G/A	cg15971335	chr8:66515592	ARMC1	0.45	4.6	0.35	8.85e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Tonsillectomy;
PAAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg26727032	chr16:67993705	SLC12A4	-0.7	-4.52	-0.34	1.25e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11700980	0.551	rs2832040	chr21:30115840	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs9659323	1.000	rs9659323	chr1:119504361	A/G	cg26570165	chr1:119541833	NA	-0.46	-4.63	-0.35	7.9e-6	Body mass index;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19404896	chr1:109969078	PSMA5	0.66	7.59	0.52	3.07e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7873102	0.654	rs4878730	chr9:37998754	A/G	cg03528946	chr9:38069800	SHB	-0.51	-5.14	-0.38	8.36e-7	Brain structure;
PAAD	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.89	7.78	0.53	1.04e-12	Resting heart rate;
PAAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-5.31	-0.4	3.79e-7	Monocyte count;
PAAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	7.11	0.5	4.14e-11	Menarche (age at onset);
PAAD	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.66	-7.05	-0.5	5.83e-11	Aortic root size;
PAAD	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-5.18	-0.39	6.91e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2790216	1.000	rs2790193	chr10:60046226	A/G	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-4.87	-0.37	2.75e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.86	-9.59	-0.61	2.53e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.52	-5.19	-0.39	6.58e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs10500871	1.000	rs4757904	chr11:20225937	T/G	cg02956962	chr6:161097311	NA	0.62	6.31	0.46	2.93e-9	Educational attainment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15816271	chr5:41968459	NA	0.56	6.65	0.47	4.97e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.68	-0.35	6.37e-6	Neuroticism;
PAAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg26939375	chr7:64535504	NA	0.53	5.89	0.43	2.44e-8	Aortic root size;
PAAD	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg21479132	chr6:26055353	NA	0.92	5.2	0.39	6.38e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	6.87	0.49	1.55e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.83	6.63	0.47	5.41e-10	Platelet count;
PAAD	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.47	6.06	0.44	1.01e-8	Breast cancer;Mosquito bite size;
PAAD	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.45	-4.38	-0.34	2.17e-5	Total body bone mineral density;
PAAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs818427	0.927	rs7213	chr5:112203564	T/A	cg07820702	chr5:112228657	REEP5	0.51	4.66	0.35	6.89e-6	Total body bone mineral density;
PAAD	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.84	9.9	0.63	3.91e-18	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	7.03	0.5	6.46e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.63	6.7	0.48	3.8e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs36715	0.904	rs36712	chr5:127561133	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.85	0.43	2.93e-8	Breast cancer;
PAAD	cis	rs1535500	0.967	rs10947804	chr6:39282036	T/C	cg08315770	chr6:39281885	KCNK17	-0.6	-6.2	-0.45	5.11e-9	Type 2 diabetes;
PAAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.76	7.53	0.52	4.12e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.89e-5	Total body bone mineral density;
PAAD	cis	rs4731207	0.967	rs2267708	chr7:124392512	C/T	cg14311320	chr7:124405732	GPR37	0.43	4.71	0.36	5.52e-6	Cutaneous malignant melanoma;
PAAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.85	-9.34	-0.6	1.12e-16	Prostate cancer;
PAAD	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.66	5.91	0.43	2.14e-8	Blood trace element (Zn levels);
PAAD	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.62	-4.29	-0.33	3.2e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg05425664	chr17:57184151	TRIM37	-0.52	-4.54	-0.35	1.12e-5	Testicular germ cell tumor;
PAAD	cis	rs58521262	0.585	rs2645877	chr19:23210811	G/A	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.18e-5	Testicular germ cell tumor;
PAAD	cis	rs11563648	0.553	rs4731356	chr7:127022714	C/A	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.54	-5.91	-0.43	2.19e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26634121	chr16:88897219	GALNS	0.56	6.32	0.46	2.74e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg21698718	chr17:80085957	CCDC57	-0.44	-5.02	-0.38	1.42e-6	Life satisfaction;
PAAD	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.12	0.55	1.52e-13	Morning vs. evening chronotype;
PAAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.8	7.88	0.54	5.88e-13	Blood protein levels;
PAAD	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.56	-5.86	-0.43	2.77e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	4.46	0.34	1.59e-5	Colorectal cancer;
PAAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.48	4.91	0.37	2.33e-6	Major depressive disorder;
PAAD	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.44	5.92	0.43	2.02e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg23250157	chr14:64679961	SYNE2	0.56	5.66	0.42	7.3900000000000007e-08	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg05250797	chr16:70222502	NA	-0.6	-4.85	-0.37	2.96e-6	Sjögren's syndrome;
PAAD	cis	rs4919087	0.887	rs1890966	chr10:99094436	G/A	cg25902810	chr10:99078978	FRAT1	-0.64	-6.26	-0.45	3.8e-9	Monocyte count;
PAAD	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	5.95	0.43	1.8e-8	Cognitive test performance;
PAAD	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.73	8.05	0.55	2.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs4523957	0.928	rs12949991	chr17:2197185	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.17	0.39	7.2e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18621852	chr3:10150065	C3orf24	0.64	5.49	0.41	1.68e-7	Alzheimer's disease;
PAAD	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	0.91	8.99	0.59	9.15e-16	Pulmonary function decline;
PAAD	cis	rs3812762	0.826	rs2292045	chr11:8806709	G/T	cg11156914	chr11:8892616	ST5	0.51	4.43	0.34	1.77e-5	Hypospadias;
PAAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.79	-7.49	-0.52	5.11e-12	DNA methylation (variation);
PAAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	6.77	0.48	2.67e-10	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18902035	chr2:134949357	NA	0.63	6.51	0.47	1.04e-9	Smoking initiation;
PAAD	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.78	8.5	0.57	1.61e-14	Morning vs. evening chronotype;
PAAD	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg00152799	chr18:54306261	TXNL1	-0.42	-4.71	-0.36	5.65e-6	Depression and alcohol dependence;
PAAD	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.96	-9.94	-0.63	2.99e-18	Monocyte percentage of white cells;
PAAD	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.66	5.52	0.41	1.45e-7	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.57	6.4	0.46	1.86e-9	Blood metabolite levels;
PAAD	cis	rs1797885	0.714	rs796173	chr3:12564302	A/G	cg07775309	chr3:12595852	NA	0.39	4.28	0.33	3.3e-5	Immature fraction of reticulocytes;
PAAD	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.6	6.78	0.48	2.45e-10	High light scatter reticulocyte count;
PAAD	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg21366198	chr4:185655624	MLF1IP	0.52	4.74	0.36	4.96e-6	Kawasaki disease;
PAAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09401463	chr16:12070306	RUNDC2A	-0.73	-6.38	-0.46	1.99e-9	Neuroticism;
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg25833597	chr17:30823145	MYO1D	0.55	5.34	0.4	3.32e-7	Schizophrenia;
PAAD	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21385522	chr1:16154831	NA	0.52	4.45	0.34	1.65e-5	Systolic blood pressure;
PAAD	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00540400	chr15:79124168	NA	0.59	6.83	0.48	1.91e-10	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22084302	chr13:20246166	MPHOSPH8	0.63	6.32	0.46	2.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.39	-0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs16966918	0.579	rs1253841	chr13:106269751	T/C	cg14363981	chr13:107186561	EFNB2	-0.79	-4.34	-0.33	2.58e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.47	4.68	0.35	6.43e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	trans	rs111756027	0.522	rs72800052	chr16:77277339	A/G	cg17418387	chr1:17761802	RCC2	-0.79	-6.42	-0.46	1.66e-9	Bone mineral density (Ward's triangle area);
PAAD	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg19510604	chr15:74901076	CLK3	0.53	4.31	0.33	2.93e-5	Blood trace element (Zn levels);
PAAD	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg15117754	chr3:10150083	C3orf24	0.75	6.21	0.45	4.89e-9	Alzheimer's disease;
PAAD	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg17325771	chr7:75508891	RHBDD2	-0.31	-4.39	-0.34	2.08e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg27565382	chr3:53032988	SFMBT1	0.78	4.52	0.34	1.24e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs58521262	0.530	rs289344	chr19:23149670	G/A	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.94	8.27	0.56	6.39e-14	Gut microbiome composition (summer);
PAAD	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	8.65	0.57	6.9e-15	Homoarginine levels;
PAAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	1.24	12.22	0.7	2.32e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.61	-5.7	-0.42	6.17e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3747547	0.892	rs11789473	chr9:37954424	T/G	cg13774184	chr9:37916125	SHB	-0.6	-4.25	-0.33	3.71e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg00571178	chr13:114841904	RASA3	-0.56	-4.79	-0.36	3.85e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	5.23	0.39	5.42e-7	Body mass index;
PAAD	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.49	-4.66	-0.35	6.96e-6	Glomerular filtration rate;
PAAD	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.63	6.38	0.46	2.03e-9	Testicular germ cell tumor;
PAAD	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.48	-4.79	-0.36	4.01e-6	Longevity;
PAAD	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg09491104	chr22:46646882	C22orf40	-0.94	-6.01	-0.44	1.35e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-6.16	-0.45	6.2e-9	Longevity;
PAAD	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.49	4.87	0.37	2.71e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73206853	0.688	rs56691704	chr12:110568623	A/G	cg12870014	chr12:110450643	ANKRD13A	0.72	4.73	0.36	5.09e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7593730	0.636	rs10170600	chr2:161118687	T/C	cg22609984	chr2:161126801	NA	0.51	4.4	0.34	2.02e-5	Type 2 diabetes;
PAAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.6	8.07	0.55	1.95e-13	Bipolar disorder;
PAAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.6	0.35	8.88e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9487051	0.621	rs351719	chr6:109552434	C/T	cg21918786	chr6:109611834	NA	0.43	4.42	0.34	1.87e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-4.51	-0.34	1.3e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2010672	0.500	rs7171218	chr15:91152085	T/G	cg15547629	chr15:90437138	AP3S2	-0.52	-4.42	-0.34	1.87e-5	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg04160749	chr8:58172571	NA	-0.7	-4.96	-0.37	1.9e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.580	rs419322	chr21:46551702	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	5.49	0.41	1.62e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.85	7.81	0.54	8.76e-13	Homoarginine levels;
PAAD	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	1.18	13.56	0.74	5.96e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.68	7.62	0.53	2.57e-12	Melanoma;
PAAD	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	5.69	0.42	6.23e-8	Height;
PAAD	cis	rs12949688	0.601	rs10083839	chr17:55835623	C/T	cg12582317	chr17:55822272	NA	0.43	4.99	0.37	1.66e-6	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-8.57	-0.57	1.07e-14	Homoarginine levels;
PAAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.68	-7.13	-0.5	3.71e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg08875078	chr22:50639485	SELO	0.48	4.41	0.34	1.91e-5	Late-onset Alzheimer's disease;
PAAD	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.77	-5.84	-0.43	3.13e-8	Coronary artery calcification;
PAAD	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	5.89	0.43	2.36e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg16341495	chr8:142228727	SLC45A4	-0.48	-4.47	-0.34	1.51e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg14146966	chr2:61757674	XPO1	0.38	4.63	0.35	7.72e-6	Tuberculosis;
PAAD	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.77	-6.84	-0.49	1.78e-10	Exhaled nitric oxide output;
PAAD	cis	rs2275565	0.872	rs10158822	chr1:237050176	G/T	cg17297354	chr1:237056641	MTR	0.51	4.45	0.34	1.62e-5	Homocysteine levels;
PAAD	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg27499820	chr13:21296301	IL17D	-0.53	-5.0	-0.38	1.54e-6	Dental caries;
PAAD	cis	rs6782228	0.606	rs10048945	chr3:128409680	C/T	cg16766828	chr3:128327626	NA	-0.45	-6.07	-0.44	9.68e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6594713	0.642	rs6890874	chr5:112787813	C/A	cg12552261	chr5:112820674	MCC	0.74	5.3	0.4	3.95e-7	Brain cytoarchitecture;
PAAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.48	4.68	0.36	6.18e-6	Testicular germ cell tumor;
PAAD	cis	rs10450586	0.932	rs7119931	chr11:27327385	A/G	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-1.49	-9.07	-0.59	5.68e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1625975	0.681	rs10740386	chr10:73394412	T/C	cg26005973	chr10:72643678	PCBD1	0.73	5.05	0.38	1.23e-6	Bipolar disorder (body mass index interaction);
PAAD	cis	rs597583	0.715	rs7936795	chr11:117391736	A/G	cg27161313	chr11:117392002	DSCAML1	-0.76	-5.95	-0.43	1.76e-8	Putamen volume;
PAAD	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg17640201	chr16:30407289	ZNF48	0.93	11.02	0.67	3.96e-21	Tonsillectomy;
PAAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg09699651	chr6:150184138	LRP11	0.47	4.9	0.37	2.39e-6	Lung cancer;
PAAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.52	-4.53	-0.34	1.2e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.76	-8.92	-0.59	1.42e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01942863	chr7:99769432	GPC2	0.52	4.3	0.33	3.02e-5	Platelet count;
PAAD	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg24466277	chr1:23519622	HTR1D	-0.56	-5.24	-0.39	5.24e-7	Height;
PAAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.69	7.51	0.52	4.7e-12	Bone mineral density;
PAAD	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs501120	0.584	rs1704226	chr10:44678387	C/A	cg09554077	chr10:44749378	NA	0.43	4.94	0.37	2.04e-6	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs11168854	0.719	rs11168890	chr12:49543913	A/G	cg05368762	chr12:50135785	TMBIM6	0.45	4.47	0.34	1.5e-5	Body mass index;
PAAD	cis	rs2555155	0.775	rs10769696	chr11:6547114	T/A	cg24637308	chr11:6592297	DNHD1	-0.47	-4.89	-0.37	2.51e-6	DNA methylation (variation);
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg02462569	chr6:150064036	NUP43	0.43	4.73	0.36	5.19e-6	Lung cancer;
PAAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.67	-8.8	-0.58	2.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	4.29	0.33	3.1e-5	Tonsillectomy;
PAAD	cis	rs6466055	0.720	rs1121194	chr7:104981133	T/C	cg04380332	chr7:105027541	SRPK2	0.65	7.28	0.51	1.71e-11	Schizophrenia;
PAAD	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.93	-9.46	-0.61	5.43e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg04554929	chr8:105342491	NA	-0.38	-6.16	-0.45	6.26e-9	Paget's disease;
PAAD	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg15017067	chr4:17643749	FAM184B	0.47	5.08	0.38	1.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.7	5.29	0.39	4.21e-7	Diastolic blood pressure;
PAAD	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10887741	0.532	rs2755430	chr10:89415605	C/T	cg13926569	chr10:89418898	PAPSS2	-0.5	-5.0	-0.38	1.54e-6	Exercise (leisure time);
PAAD	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.56	6.38	0.46	2.03e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg05299278	chr17:33885742	SLFN14	-0.42	-5.02	-0.38	1.45e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.68	9.86	0.62	4.86e-18	Huntington's disease progression;
PAAD	cis	rs904092	0.720	rs1230027	chr4:100183423	T/C	cg12011299	chr4:100065546	ADH4	0.58	5.43	0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.73	7.47	0.52	5.95e-12	Cognitive function;
PAAD	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.6	-5.92	-0.43	2.07e-8	Systolic blood pressure;
PAAD	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.69	-6.88	-0.49	1.5e-10	Morning vs. evening chronotype;
PAAD	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.59	5.65	0.42	7.73e-8	Graves' disease;
PAAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02598441	chr17:62777298	LOC146880	-0.54	-4.39	-0.34	2.14e-5	QT interval;
PAAD	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.53	5.62	0.41	8.75e-8	Longevity;Endometriosis;
PAAD	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02743256	chr7:2109353	MAD1L1	-0.61	-5.77	-0.42	4.36e-8	Neuroticism;
PAAD	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg13722127	chr7:150037890	RARRES2	0.59	5.87	0.43	2.62e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2798269	0.604	rs6490662	chr13:22153280	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.48	-4.32	-0.33	2.81e-5	PR segment;
PAAD	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.62	-6.34	-0.46	2.45e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs4747197	0.581	rs4747188	chr10:73538456	T/C	cg04506911	chr10:72937119	NA	0.36	4.25	0.33	3.72e-5	Progranulin levels;
PAAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03676636	chr4:99064102	C4orf37	-0.33	-6.06	-0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03106313	chr1:152009084	S100A11	-0.74	-6.54	-0.47	8.91e-10	Neuroticism;
PAAD	cis	rs16975963	0.793	rs12460735	chr19:38313550	C/T	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.89e-6	Longevity;
PAAD	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.58	-5.3	-0.4	3.94e-7	Breast cancer;
PAAD	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.71	5.8	0.43	3.68e-8	Chronic lymphocytic leukemia;
PAAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	1.0	11.78	0.69	3.72e-23	Cognitive function;
PAAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg26060667	chr1:247681242	NA	0.45	5.68	0.42	6.6e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7554547	0.756	rs6684539	chr1:11968273	A/G	cg07603449	chr1:11986842	KIAA2013	-0.37	-5.83	-0.43	3.26e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09102817	chr8:97273816	MTERFD1;PTDSS1	-0.78	-6.51	-0.47	1.06e-9	Neuroticism;
PAAD	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.77	-8.04	-0.55	2.31e-13	Cognitive test performance;
PAAD	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.81	9.29	0.6	1.56e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.49	5.8	0.43	3.77e-8	Height;
PAAD	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg01620082	chr3:125678407	NA	-0.98	-7.13	-0.5	3.8e-11	Depression;
PAAD	cis	rs904092	0.678	rs1230026	chr4:100185619	T/G	cg12011299	chr4:100065546	ADH4	0.58	5.43	0.4	2.2e-7	Alcohol dependence;
PAAD	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00166722	chr3:10149974	C3orf24	0.97	8.28	0.56	5.81e-14	Alzheimer's disease;
PAAD	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.64	5.98	0.44	1.5e-8	Platelet count;
PAAD	cis	rs939584	0.696	rs62105306	chr2:633660	C/T	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.5	5.04	0.38	1.28e-6	Height;
PAAD	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg23188684	chr11:67383651	NA	-0.43	-4.38	-0.33	2.24e-5	Mean corpuscular volume;
PAAD	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.79	6.87	0.49	1.59e-10	Morning vs. evening chronotype;
PAAD	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg09796270	chr17:17721594	SREBF1	-0.46	-4.96	-0.37	1.87e-6	Total body bone mineral density;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg21665744	chr7:39171113	POU6F2	0.36	6.12	0.44	7.54e-9	IgG glycosylation;
PAAD	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-10.22	-0.64	5.62e-19	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09622557	chr8:67417790	C8orf46	-0.71	-7.29	-0.51	1.54e-11	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.58	6.08	0.44	9.45e-9	Lung cancer;
PAAD	cis	rs6700896	0.931	rs12044840	chr1:66115213	C/G	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs939584	1.000	rs6717005	chr2:621910	A/C	cg03610516	chr2:642275	NA	0.64	5.74	0.42	4.91e-8	Body mass index;
PAAD	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg04990556	chr1:26633338	UBXN11	-0.5	-4.29	-0.33	3.11e-5	Obesity-related traits;
PAAD	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg24296786	chr1:45957014	TESK2	0.48	4.39	0.34	2.11e-5	Homocysteine levels;
PAAD	cis	rs35955747	0.669	rs878718	chr22:31552702	C/T	cg02404636	chr22:31891804	SFI1	0.48	4.83	0.36	3.35e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10819733	chr22:24237672	NA	-0.6	-6.53	-0.47	9.41e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.82	5.91	0.43	2.18e-8	Height;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11478273	chr8:128806682	PVT1	0.65	6.41	0.46	1.78e-9	Primary biliary cholangitis;
PAAD	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.21	-0.39	6.18e-7	Personality dimensions;
PAAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg09796270	chr17:17721594	SREBF1	-0.42	-4.61	-0.35	8.63e-6	Total body bone mineral density;
PAAD	cis	rs10512697	0.655	rs35099902	chr5:3473373	T/C	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04146151	chr16:2155961	PKD1	-0.71	-7.13	-0.5	3.89e-11	Metabolite levels (lipid measures);
PAAD	cis	rs62247992	0.698	rs615538	chr3:43105079	G/T	cg12239580	chr3:43073058	FAM198A	-0.45	-4.4	-0.34	2.01e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg25452165	chr22:42524984	CYP2D6	0.58	5.16	0.39	7.61e-7	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22385297	chr1:32224784	BAI2	0.61	6.58	0.47	7.29e-10	Smoking initiation;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.91	-10.28	-0.64	3.8e-19	Height;
PAAD	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.73	7.47	0.52	5.7e-12	Height;
PAAD	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg23254163	chr1:152506842	NA	0.6	6.92	0.49	1.19e-10	Hair morphology;
PAAD	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	4.43	0.34	1.8e-5	Axial length;
PAAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg19630374	chr17:18023558	MYO15A	0.46	4.89	0.37	2.55e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.16	10.02	0.63	1.87e-18	Vitiligo;
PAAD	cis	rs1468333	1.000	rs217263	chr5:137480666	G/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.6	6.3	0.45	3.13e-9	Resting heart rate;
PAAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs9535307	0.719	rs1211304	chr13:50381016	G/A	cg04663916	chr13:50265991	EBPL	-0.57	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.5	-5.54	-0.41	1.27e-7	Prostate cancer;
PAAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.59	-6.86	-0.49	1.63e-10	Glomerular filtration rate (creatinine);
PAAD	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.71	-5.04	-0.38	1.31e-6	Coronary artery calcification;
PAAD	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg20761395	chr17:511517	VPS53	0.47	4.92	0.37	2.27e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.85	10.35	0.64	2.54e-19	Morning vs. evening chronotype;
PAAD	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.6	6.43	0.46	1.55e-9	Bladder cancer;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg09044154	chr16:88155775	NA	-0.52	-4.26	-0.33	3.6e-5	Menopause (age at onset);
PAAD	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.34	-0.33	2.54e-5	Retinal vascular caliber;
PAAD	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg00086871	chr4:6988644	TBC1D14	1.11	5.09	0.38	1.03e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7771547	0.642	rs1003250	chr6:36437412	A/G	cg04289385	chr6:36355825	ETV7	-0.48	-5.03	-0.38	1.38e-6	Platelet distribution width;
PAAD	cis	rs1497828	0.913	rs2810778	chr1:217542793	G/A	cg04411442	chr1:217543379	NA	0.48	4.73	0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.76	-6.5	-0.47	1.09e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13198984	chr17:80129470	CCDC57	0.42	5.22	0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs488248	0.574	rs17448322	chr13:106590769	A/G	cg03898952	chr13:107069935	NA	0.7	4.48	0.34	1.48e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
PAAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg24147428	chr11:65409760	SIPA1	-0.44	-4.74	-0.36	4.86e-6	Blood pressure (age interaction);
PAAD	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg23587288	chr2:27483067	SLC30A3	-0.77	-6.48	-0.47	1.22e-9	Blood metabolite levels;
PAAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.7	-8.23	-0.55	8.08e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.32	0.33	2.78e-5	Iron status biomarkers;
PAAD	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.96	11.8	0.69	3.28e-23	Bone mineral density;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11229230	chr2:112944829	FBLN7	0.58	6.94	0.49	1.08e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6076065	0.683	rs2424528	chr20:23361613	C/T	cg11657817	chr20:23433608	CST11	0.5	5.24	0.39	5.32e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-5.76	-0.42	4.6e-8	QT interval;
PAAD	cis	rs727479	1.000	rs727479	chr15:51534547	C/A	cg21478137	chr15:51532386	CYP19A1	0.62	6.88	0.49	1.43e-10	Estradiol levels;
PAAD	cis	rs11024102	0.962	rs34927905	chr11:17001427	C/T	cg15378786	chr11:17036137	PLEKHA7	0.49	4.42	0.34	1.87e-5	Glaucoma (primary angle closure);
PAAD	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.74	6.95	0.49	1.03e-10	Obesity-related traits;
PAAD	cis	rs12780845	1.000	rs12782687	chr10:17223368	T/G	cg00857480	chr10:17188594	TRDMT1	0.34	4.46	0.34	1.58e-5	Homocysteine levels;
PAAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.8	-8.19	-0.55	9.9e-14	Calcium levels;
PAAD	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.38	-4.81	-0.36	3.66e-6	Educational attainment (years of education);
PAAD	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg11262906	chr1:85462892	MCOLN2	0.61	4.85	0.37	2.98e-6	Serum sulfate level;
PAAD	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.56	4.8	0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs6460942	0.597	rs6961238	chr7:12535428	C/T	cg20607287	chr7:12443886	VWDE	-0.7	-4.81	-0.36	3.57e-6	Coronary artery disease;
PAAD	cis	rs11159086	0.793	rs10136668	chr14:74958886	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.25	-0.39	5.15e-7	Advanced glycation end-product levels;
PAAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	4.82	0.36	3.43e-6	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	5.03	0.38	1.38e-6	Motion sickness;
PAAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg21130718	chr4:1044621	NA	0.56	4.79	0.36	4.01e-6	Recombination rate (females);
PAAD	cis	rs900145	0.773	rs7934154	chr11:13314148	G/T	cg15603424	chr11:13300592	ARNTL	-0.52	-4.47	-0.34	1.52e-5	Menarche (age at onset);
PAAD	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.78	8.94	0.59	1.24e-15	Morning vs. evening chronotype;
PAAD	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.55	4.52	0.34	1.22e-5	Dementia with Lewy bodies;
PAAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg05313129	chr8:58192883	C8orf71	-0.67	-6.27	-0.45	3.57e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.93	-8.28	-0.56	5.9e-14	Diastolic blood pressure;
PAAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.52	5.63	0.42	8.66e-8	Menopause (age at onset);
PAAD	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.52	5.27	0.39	4.6e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.6	5.95	0.43	1.79e-8	Longevity;
PAAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	trans	rs6532374	0.872	rs78592900	chr4:93468277	G/T	cg01163837	chr2:31457287	EHD3	-0.72	-6.31	-0.46	2.86e-9	Interleukin-12p70 levels;
PAAD	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg00147160	chr1:26503991	CNKSR1	0.41	4.43	0.34	1.76e-5	Height;
PAAD	cis	rs12523822	0.957	rs6927403	chr6:154959987	T/C	cg20019720	chr6:154832845	CNKSR3	0.29	4.26	0.33	3.52e-5	Diabetic kidney disease;
PAAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.84	-10.9	-0.66	8.55e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2242420	0.920	rs6658321	chr1:21968660	C/T	cg04297819	chr1:22260125	HSPG2	0.5	4.33	0.33	2.68e-5	Hematological and biochemical traits;
PAAD	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.02	8.1	0.55	1.64e-13	Vitiligo;
PAAD	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.44	4.52	0.34	1.25e-5	Plateletcrit;
PAAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00982548	chr2:198649783	BOLL	-0.77	-5.44	-0.4	2.08e-7	Ulcerative colitis;
PAAD	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.51	5.12	0.38	8.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.78	-9.22	-0.6	2.35e-16	Eye color traits;
PAAD	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.64	6.06	0.44	1.03e-8	Aortic root size;
PAAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg26174226	chr8:58114915	NA	-0.59	-4.45	-0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11892454	0.515	rs10173557	chr2:26077722	C/A	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.87	9.11	0.59	4.6e-16	Cleft lip with or without cleft palate;
PAAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.77	8.42	0.56	2.68e-14	Lung cancer;
PAAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-1.01	-8.26	-0.56	6.69e-14	Initial pursuit acceleration;
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg20917491	chr3:195578259	NA	-0.54	-5.89	-0.43	2.33e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs12773846	0.506	rs76395811	chr10:126272914	C/T	cg04949429	chr10:126290192	LHPP	0.66	5.74	0.42	4.95e-8	Subcutaneous adipose tissue;
PAAD	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	8.0	0.54	3.01e-13	Schizophrenia;
PAAD	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.69	7.65	0.53	2.18e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.47	4.66	0.35	6.88e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.85	0.43	2.95e-8	HIV-1 control;
PAAD	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-9.0	-0.59	8.84e-16	Dental caries;
PAAD	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.73	5.75	0.42	4.71e-8	Cognitive function;
PAAD	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.77	-8.0	-0.54	2.89e-13	Blood metabolite levels;
PAAD	trans	rs8177376	0.681	rs240548	chr11:126204967	C/T	cg02219016	chr2:44222742	LRPPRC	0.7	6.31	0.46	2.95e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg02176678	chr2:219576539	TTLL4	-0.48	-6.56	-0.47	8.12e-10	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1539053	0.932	rs11207086	chr1:58117341	A/C	cg00026909	chr1:58089001	DAB1	-0.63	-6.98	-0.49	8.69e-11	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.91	-10.81	-0.66	1.48e-20	Ulcerative colitis;
PAAD	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19623624	chr10:135278901	LOC619207	-0.54	-5.48	-0.41	1.69e-7	Systemic lupus erythematosus;
PAAD	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11700980	0.551	rs2832018	chr21:30111639	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs7816613	0.850	rs16868139	chr8:102666387	C/T	cg20585841	chr8:102729926	NCALD	0.63	5.39	0.4	2.58e-7	Age-related hearing impairment;
PAAD	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-6.33	-0.46	2.66e-9	Exhaled nitric oxide output;
PAAD	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg16417436	chr16:28758564	NA	0.42	4.26	0.33	3.64e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg05627522	chr15:75251581	NA	-0.44	-5.26	-0.39	4.73e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.86	9.61	0.61	2.29e-17	Prudent dietary pattern;
PAAD	cis	rs757978	1.000	rs73116396	chr2:242368693	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-4.93	-0.37	2.11e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.58	4.92	0.37	2.26e-6	Neutrophil percentage of white cells;
PAAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.6	-0.52	2.86e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg22143856	chr6:28129313	ZNF389	0.49	4.49	0.34	1.4e-5	Parkinson's disease;
PAAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.89	-10.39	-0.64	1.9e-19	Iron status biomarkers;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-4.61	-0.35	8.59e-6	Obesity-related traits;
PAAD	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.93	7.53	0.52	4.22e-12	Iron status biomarkers;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17924650	chr5:54523011	NA	-0.61	-6.69	-0.48	3.93e-10	Smoking initiation;
PAAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg25204440	chr1:209979598	IRF6	0.58	4.58	0.35	9.76e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg02462569	chr6:150064036	NUP43	-0.5	-5.65	-0.42	7.62e-8	Lung cancer;
PAAD	cis	rs3796727	0.690	rs6447885	chr4:8620023	G/A	cg05284713	chr4:8621361	CPZ	-0.43	-4.32	-0.33	2.81e-5	Sporadic neuroblastoma;
PAAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.74	0.53	1.26e-12	Prudent dietary pattern;
PAAD	cis	rs2555155	0.806	rs4758426	chr11:6544649	G/A	cg11185456	chr11:6592066	DNHD1	0.43	4.56	0.35	1.06e-5	DNA methylation (variation);
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg11707556	chr5:10655725	ANKRD33B	0.61	6.58	0.47	7.04e-10	Coronary artery disease;
PAAD	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.49	-5.27	-0.39	4.67e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.71	-7.2	-0.5	2.65e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.63	-6.73	-0.48	3.27e-10	IgG glycosylation;
PAAD	cis	rs9517320	0.633	rs35368417	chr13:99121347	T/C	cg07423050	chr13:99094983	FARP1	0.42	4.63	0.35	7.63e-6	Longevity;
PAAD	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.51	-4.92	-0.37	2.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.52	-6.82	-0.48	1.97e-10	Longevity;
PAAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.52	6.88	0.49	1.5e-10	Renal cell carcinoma;
PAAD	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.5	-6.15	-0.45	6.59e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.51	-6.32	-0.46	2.69e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg04240471	chr7:2420162	EIF3B	-0.95	-6.75	-0.48	2.92e-10	Lung function (FEV1/FVC);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10767703	chr3:186524559	RFC4	-0.67	-6.86	-0.49	1.64e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.47	4.42	0.34	1.83e-5	Morning vs. evening chronotype;
PAAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg01223673	chr11:15133828	INSC	0.35	4.5	0.34	1.35e-5	Mitochondrial DNA levels;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-7.01	-0.49	7.44e-11	Prudent dietary pattern;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.61	6.8	0.48	2.24e-10	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.06e-7	Life satisfaction;
PAAD	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.98e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg05484376	chr2:27715224	FNDC4	-0.46	-4.64	-0.35	7.46e-6	Oral cavity cancer;
PAAD	cis	rs1198430	0.639	rs16860685	chr1:23766644	A/G	cg19827787	chr1:23763612	ASAP3	0.59	4.93	0.37	2.16e-6	Total cholesterol levels;
PAAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.87	-8.06	-0.55	2.04e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg11062466	chr8:58055876	NA	0.69	4.79	0.36	3.92e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06544989	chr22:39130855	UNC84B	0.48	4.69	0.36	6.14e-6	Menopause (age at onset);
PAAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.89	-11.1	-0.67	2.38e-21	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.4	-4.36	-0.33	2.42e-5	Calcium levels;
PAAD	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.84	0.37	3.18e-6	Lung cancer;
PAAD	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg16898833	chr6:26189333	HIST1H4D	0.83	4.53	0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	10.83	0.66	1.26e-20	Homoarginine levels;
PAAD	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.36	0.33	2.35e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11814667	chr10:105156270	PDCD11;USMG5	-0.77	-6.66	-0.48	4.6e-10	Neuroticism;
PAAD	cis	rs117623576	0.680	rs16932874	chr10:32358438	T/C	cg03047570	chr10:32398778	NA	-0.68	-4.54	-0.35	1.12e-5	Anti-saccade response;
PAAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.81	-8.94	-0.59	1.24e-15	Iron status biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15034779	chr3:49027243	P4HTM	0.56	6.36	0.46	2.29e-9	Monocyte percentage of white cells;
PAAD	cis	rs4455778	0.501	rs10227306	chr7:49048026	A/G	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.32	-0.33	2.83e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg03233332	chr7:66118400	NA	0.4	4.34	0.33	2.6e-5	Aortic root size;
PAAD	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	0.91	4.33	0.33	2.67e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.86	6.92	0.49	1.19e-10	Left atrial antero-posterior diameter;
PAAD	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.74	7.58	0.52	3.22e-12	Uric acid levels;
PAAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.56	5.26	0.39	4.71e-7	Corneal astigmatism;
PAAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg13468214	chr4:1046988	NA	-0.53	-5.76	-0.42	4.58e-8	Recombination rate (males);
PAAD	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.96	8.41	0.56	2.82e-14	Bipolar disorder;
PAAD	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg22517653	chr1:2918612	NA	-0.65	-5.22	-0.39	5.88e-7	Plateletcrit;
PAAD	cis	rs294958	0.806	rs59349033	chr5:151529629	T/C	cg04453665	chr5:151504455	NA	0.44	4.94	0.37	2.08e-6	Periodontitis (PAL4Q3);
PAAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.54	-6.51	-0.47	1.03e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.06	-8.23	-0.56	7.83e-14	Diabetic kidney disease;
PAAD	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg25070565	chr17:20044324	CYTSB	0.44	4.25	0.33	3.78e-5	Obesity-related traits;
PAAD	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.54	4.52	0.34	1.21e-5	Dementia with Lewy bodies;
PAAD	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg09760422	chr2:128146352	NA	-0.44	-7.61	-0.53	2.73e-12	Protein C levels;
PAAD	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.44	-0.34	1.73e-5	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.48	5.43	0.4	2.14e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs6028335	0.610	rs1130247	chr20:37581437	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.65	-4.84	-0.37	3.17e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.83	-9.6	-0.61	2.38e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs7580658	0.929	rs13029237	chr2:128147854	C/T	cg09760422	chr2:128146352	NA	-0.45	-7.58	-0.52	3.11e-12	Protein C levels;
PAAD	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.53	-5.45	-0.4	1.98e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.35	4.67	0.35	6.45e-6	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.36	-0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.68	-6.69	-0.48	4.11e-10	Morning vs. evening chronotype;
PAAD	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.39	4.4	0.34	2.01e-5	Aortic root size;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05892156	chr18:8658686	NA	-0.59	-6.86	-0.49	1.59e-10	Monocyte percentage of white cells;
PAAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg22903657	chr4:1355424	KIAA1530	0.47	5.16	0.39	7.48e-7	Obesity-related traits;
PAAD	cis	rs13424612	1.000	rs4854058	chr2:240923677	C/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.86	-0.37	2.9e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-5.51	-0.41	1.52e-7	Crohn's disease;
PAAD	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.14	-14.09	-0.75	2.29e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.52	-4.4	-0.34	2.04e-5	Aortic root size;
PAAD	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg13263323	chr15:86062960	AKAP13	-0.59	-6.66	-0.48	4.75e-10	Interstitial lung disease;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg00024416	chr22:24240387	NA	-0.58	-5.88	-0.43	2.52e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs10214930	0.767	rs1980330	chr7:27630323	G/T	cg22168087	chr7:27702803	HIBADH	0.49	4.32	0.33	2.76e-5	Hypospadias;
PAAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.55	-4.7	-0.36	5.75e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.54	4.31	0.33	2.93e-5	Iron status biomarkers;
PAAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.88	8.84	0.58	2.24e-15	Orofacial clefts;
PAAD	cis	rs11264213	0.901	rs6665591	chr1:36411737	A/G	cg27506609	chr1:36549197	TEKT2	0.73	5.1	0.38	9.9e-7	Schizophrenia;
PAAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.68	0.69	6.61e-23	Menopause (age at onset);
PAAD	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg05082376	chr22:42548792	NA	0.51	5.6	0.41	9.98e-8	Cognitive function;
PAAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.25	19.25	0.84	1.34e-42	IgG glycosylation;
PAAD	cis	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg27411982	chr8:10470053	RP1L1	0.39	4.32	0.33	2.84e-5	Sjögren's syndrome;Systemic lupus erythematosus;
PAAD	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg19008133	chr3:123124015	ADCY5	0.61	4.28	0.33	3.3e-5	LDL cholesterol levels;
PAAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg00999904	chr2:3704751	ALLC	-0.81	-8.08	-0.55	1.91e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg10483660	chr13:112241077	NA	0.52	4.81	0.36	3.54e-6	Menarche (age at onset);
PAAD	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg13047869	chr3:10149882	C3orf24	0.58	5.04	0.38	1.28e-6	Alzheimer's disease;
PAAD	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg25204440	chr1:209979598	IRF6	0.59	4.9	0.37	2.47e-6	Coronary artery disease;
PAAD	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg27182935	chr16:89790473	ZNF276	-0.81	-4.44	-0.34	1.75e-5	Skin colour saturation;
PAAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.95	10.08	0.63	1.26e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs28647808	1.000	rs7857017	chr9:136271101	A/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.33e-7	Noise-induced hearing loss;
PAAD	cis	rs13160548	0.931	rs34836414	chr5:38789263	A/G	cg13976988	chr5:38607402	NA	0.43	4.47	0.34	1.52e-5	Microalbuminuria;
PAAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-4.35	-0.33	2.51e-5	Bipolar disorder;
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.68	7.81	0.54	8.76e-13	Vitiligo;
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07648498	chr16:89883185	FANCA	0.7	7.34	0.51	1.23e-11	Vitiligo;
PAAD	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	1.13	8.97	0.59	1.06e-15	Height;
PAAD	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg09455208	chr3:40491958	NA	0.45	5.8	0.43	3.7e-8	Renal cell carcinoma;
PAAD	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg24585035	chr5:32522852	NA	0.63	6.29	0.45	3.2e-9	Body mass index;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg01159004	chr20:48330681	B4GALT5	-0.65	-7.43	-0.52	7.2e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-6.71	-0.48	3.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5756391	0.782	rs5756384	chr22:37282093	C/T	cg16356956	chr22:37317934	CSF2RB	-0.36	-4.47	-0.34	1.54e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.74	0.66	2.24e-20	Electrocardiographic conduction measures;
PAAD	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg24881330	chr22:46731750	TRMU	1.17	6.35	0.46	2.42e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	6.79	0.48	2.32e-10	Mean platelet volume;
PAAD	cis	rs7873102	0.678	rs7025801	chr9:38017681	A/G	cg03528946	chr9:38069800	SHB	-0.53	-5.37	-0.4	2.92e-7	Brain structure;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23655934	chr3:32823185	NA	0.59	6.75	0.48	2.96e-10	Monocyte percentage of white cells;
PAAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg17366294	chr4:99064904	C4orf37	0.45	5.01	0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg13312174	chr5:178288687	ZNF354B	-0.6	-6.0	-0.44	1.36e-8	Sleep duration;
PAAD	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.56	0.41	1.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.67	6.76	0.48	2.72e-10	Schizophrenia;
PAAD	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.77	5.4	0.4	2.49e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.62	-5.92	-0.43	2.09e-8	Systolic blood pressure;
PAAD	cis	rs863345	0.967	rs863362	chr1:158549492	C/T	cg12129480	chr1:158549410	OR10X1	-0.43	-4.83	-0.36	3.37e-6	Pneumococcal bacteremia;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11141652	chr22:24348549	GSTTP1	0.49	4.34	0.33	2.6e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26926768	chr12:34528122	NA	0.36	4.26	0.33	3.51e-5	Morning vs. evening chronotype;
PAAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg10645314	chr2:3704589	ALLC	0.73	7.39	0.51	9.22e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs282587	0.569	rs9604422	chr13:113410586	C/T	cg02820901	chr13:113351484	ATP11A	-0.64	-4.82	-0.36	3.44e-6	Glycated hemoglobin levels;
PAAD	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs3106136	0.678	rs13144129	chr4:95284545	T/C	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.72	8.7	0.58	5.13e-15	Dental caries;
PAAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.69	7.05	0.5	5.9e-11	Menarche (age at onset);
PAAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-4.87	-0.37	2.82e-6	Bone mineral density;
PAAD	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg27471124	chr11:109292789	C11orf87	0.22	4.27	0.33	3.44e-5	Schizophrenia;
PAAD	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.46	4.39	0.34	2.14e-5	Mean platelet volume;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg23119463	chr10:134592391	INPP5A	-0.46	-4.27	-0.33	3.37e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg04087571	chr11:116723030	SIK3	-0.35	-4.65	-0.35	7.22e-6	Subjective well-being;
PAAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.11	0.44	7.91e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs8016947	0.583	rs12891895	chr14:35827557	A/C	cg03549618	chr14:35838977	NA	0.46	4.85	0.37	3.05e-6	Psoriasis;
PAAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg15478930	chr2:27652102	NRBP1	0.48	4.44	0.34	1.75e-5	Total body bone mineral density;
PAAD	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg21937377	chr3:194868750	C3orf21	0.47	4.99	0.38	1.6e-6	Non-small cell lung cancer;
PAAD	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-4.74	-0.36	4.94e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg15128208	chr22:42549153	NA	0.52	4.52	0.34	1.23e-5	Birth weight;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.88	10.9	0.66	8.34e-21	Prudent dietary pattern;
PAAD	cis	rs8049634	0.732	rs13332770	chr16:84232749	C/T	cg26466773	chr16:84211947	TAF1C	0.62	5.83	0.43	3.28e-8	Small cell lung carcinoma;
PAAD	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg04165759	chr1:150448943	RPRD2	0.48	4.89	0.37	2.56e-6	Migraine;
PAAD	cis	rs12476592	0.602	rs6732791	chr2:63788901	C/A	cg10828910	chr2:63850056	LOC388955	0.51	4.38	0.33	2.21e-5	Childhood ear infection;
PAAD	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.04e-6	Itch intensity from mosquito bite;
PAAD	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-4.6	-0.35	8.81e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35740288	0.752	rs11635956	chr15:86279928	G/A	cg07943548	chr15:86304357	KLHL25	-0.57	-4.82	-0.36	3.51e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.87	10.64	0.65	4.11e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.83	9.03	0.59	7.05e-16	Mortality in heart failure;
PAAD	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.4	-0.4	2.51e-7	Heart rate;
PAAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs728616	0.867	rs12781912	chr10:81918128	G/T	cg27417294	chr10:81904244	PLAC9	0.56	4.29	0.33	3.22e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg25037394	chr1:24152592	HMGCL	0.44	4.77	0.36	4.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg13515842	chr9:127215440	GPR144	-0.44	-4.76	-0.36	4.42e-6	Menarche (age at onset);
PAAD	cis	rs17539620	0.565	rs9918393	chr6:154843268	G/A	cg20019720	chr6:154832845	CNKSR3	0.64	7.33	0.51	1.26e-11	Lipoprotein (a) levels;
PAAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	1.03	14.07	0.75	2.54e-29	Breast cancer;
PAAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.52	-5.19	-0.39	6.76e-7	Menarche (age at onset);
PAAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg08029281	chr1:67600428	NA	0.49	6.08	0.44	9.18e-9	Psoriasis;
PAAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.73	8.09	0.55	1.8e-13	Emphysema distribution in smoking;
PAAD	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg23254163	chr1:152506842	NA	0.61	7.07	0.5	5.25e-11	Hair morphology;
PAAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg21395723	chr22:39101663	GTPBP1	-0.43	-4.58	-0.35	9.56e-6	Menopause (age at onset);
PAAD	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.94	-7.9	-0.54	5.32e-13	Dupuytren's disease;
PAAD	cis	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg00277334	chr10:82204260	NA	-0.58	-5.67	-0.42	6.92e-8	Post bronchodilator FEV1;
PAAD	cis	rs73198271	1.000	rs73198271	chr8:8606807	A/T	cg01851573	chr8:8652454	MFHAS1	0.59	4.8	0.36	3.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.52	-4.99	-0.37	1.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.647	rs1007013	chr1:31710270	C/T	cg00250761	chr1:31883323	NA	-0.52	-5.82	-0.43	3.3e-8	Alcohol dependence;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	5.63	0.42	8.59e-8	Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.78	8.43	0.56	2.44e-14	Prostate cancer;
PAAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.98	-13.44	-0.74	1.25e-27	Height;
PAAD	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.43	-4.53	-0.34	1.2e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.42e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg04826882	chr13:114838756	RASA3	-0.71	-5.84	-0.43	3.02e-8	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs773506	0.655	rs4744037	chr9:93932488	C/G	cg14446406	chr9:93919335	NA	-0.4	-5.48	-0.41	1.7e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.65	-4.86	-0.37	2.84e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs59888335	0.858	rs13070759	chr3:80919770	C/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg00383909	chr3:49044727	WDR6	0.53	4.42	0.34	1.9e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg18279126	chr7:2041391	MAD1L1	0.56	5.49	0.41	1.63e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.83	0.36	3.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.14	0.5	3.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs2999052	1.000	rs9830294	chr3:127946788	A/G	cg18206867	chr2:62422351	B3GNT2	0.46	6.41	0.46	1.74e-9	Hypospadias;
PAAD	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.65	-5.7	-0.42	5.99e-8	Type 2 diabetes;
PAAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg08885800	chr1:201084119	NA	-0.62	-6.75	-0.48	3.01e-10	Permanent tooth development;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00166722	chr3:10149974	C3orf24	0.94	7.87	0.54	6.27e-13	Alzheimer's disease;
PAAD	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg16558253	chr16:72132732	DHX38	-0.55	-5.62	-0.41	9.09e-8	Fibrinogen levels;
PAAD	cis	rs112990264	1.000	rs41307644	chr1:213025733	G/T	cg01785514	chr1:212988523	TATDN3	1.13	7.28	0.51	1.71e-11	Itch intensity from mosquito bite;
PAAD	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.33	-0.46	2.65e-9	Triglycerides;
PAAD	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.7	5.78	0.42	4.13e-8	Exhaled nitric oxide output;
PAAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-4.71	-0.36	5.61e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.83e-7	Motion sickness;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16856342	chr1:67895909	SERBP1	0.58	6.49	0.47	1.17e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg08316699	chr6:150357289	NA	0.39	4.52	0.34	1.25e-5	Alopecia areata;
PAAD	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.83	-5.84	-0.43	3.04e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.72	7.34	0.51	1.17e-11	Colorectal cancer;
PAAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.6	5.17	0.39	7.31e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg25809561	chr17:30822961	MYO1D	0.59	6.12	0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg25886479	chr11:50257625	LOC441601	-0.42	-4.58	-0.35	9.54e-6	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17416009	chr2:27805824	ZNF512	0.63	6.52	0.47	9.68e-10	Myopia (pathological);
PAAD	cis	rs4662750	0.580	rs6715608	chr2:128353705	A/T	cg09760422	chr2:128146352	NA	-0.33	-4.72	-0.36	5.21e-6	Renal cell carcinoma;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg20243544	chr17:37824526	PNMT	0.52	4.62	0.35	8.02e-6	Self-reported allergy;
PAAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.68	-0.35	6.4e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg27411982	chr8:10470053	RP1L1	-0.45	-4.84	-0.37	3.13e-6	Neuroticism;
PAAD	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg14343924	chr8:8086146	FLJ10661	-0.65	-5.55	-0.41	1.24e-7	Neuroticism;
PAAD	cis	rs4795519	0.704	rs1960379	chr17:22174216	A/G	cg22648282	chr17:21454238	C17orf51	-0.51	-5.19	-0.39	6.67e-7	Chronic myeloid leukemia;
PAAD	cis	rs7487075	0.619	rs10785627	chr12:46824229	G/A	cg14671384	chr12:47219920	SLC38A4	0.43	4.34	0.33	2.64e-5	Itch intensity from mosquito bite;
PAAD	cis	rs4356203	0.905	rs214940	chr11:17186855	A/G	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.39	-0.34	2.13e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs2587695	0.934	rs2587684	chr2:120290945	A/G	cg05839767	chr2:119914248	C1QL2	-0.41	-4.25	-0.33	3.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	5.08	0.38	1.1e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25770397	chr18:61034583	KDSR	0.66	6.81	0.48	2.13e-10	Obesity-related traits;
PAAD	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	5.3	0.39	4.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.82	8.61	0.57	8.87e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.43	5.3	0.39	4.06e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg07817883	chr1:32538562	TMEM39B	1.73	8.0	0.54	2.9e-13	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.93	-0.37	2.11e-6	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.8	-8.17	-0.55	1.14e-13	Corneal astigmatism;
PAAD	cis	rs35123781	0.554	rs356428	chr5:138992703	A/G	cg11459648	chr5:138714337	SLC23A1	-0.58	-5.1	-0.38	9.85e-7	Schizophrenia;
PAAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.85	-6.6	-0.47	6.57e-10	Psoriasis;
PAAD	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.5	-0.41	1.54e-7	Crohn's disease;
PAAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.4	-4.31	-0.33	2.91e-5	Cystic fibrosis severity;
PAAD	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg09127314	chr1:152161683	NA	-0.73	-4.84	-0.37	3.15e-6	Atopic dermatitis;
PAAD	cis	rs10501293	1.000	rs2114087	chr11:43133002	G/C	cg03447554	chr11:43094025	NA	-0.49	-4.87	-0.37	2.8e-6	Cognitive performance;
PAAD	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-5.1	-0.38	9.93e-7	Schizophrenia;
PAAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.08	15.45	0.78	5.84e-33	Multiple system atrophy;
PAAD	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg10920065	chr6:169824652	NA	-0.48	-4.7	-0.36	5.77e-6	Obesity-related traits;
PAAD	cis	rs2191566	0.887	rs55703004	chr19:44504781	T/G	cg18700516	chr19:44507157	ZNF230	-0.47	-4.34	-0.33	2.58e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.78	9.09	0.59	4.97e-16	Crohn's disease;
PAAD	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg20673841	chr7:107026890	COG5	0.51	4.33	0.33	2.74e-5	Coronary artery disease;
PAAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.84	11.8	0.69	3.18e-23	Bone mineral density;
PAAD	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18898632	chr2:242989856	NA	-0.74	-5.77	-0.42	4.31e-8	Obesity-related traits;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg27121462	chr16:89883253	FANCA	-0.45	-4.61	-0.35	8.55e-6	Vitiligo;
PAAD	cis	rs112990264	1.000	rs113605633	chr1:212939102	G/A	cg01785514	chr1:212988523	TATDN3	1.35	8.53	0.57	1.4e-14	Itch intensity from mosquito bite;
PAAD	cis	rs9857275	0.788	rs9821337	chr3:141096185	C/G	cg00789793	chr3:141329863	RASA2	0.49	4.32	0.33	2.78e-5	Prion diseases;
PAAD	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.57	4.85	0.37	2.99e-6	Menopause (age at onset);
PAAD	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg14583973	chr4:3374767	RGS12	0.33	4.76	0.36	4.56e-6	Mean platelet volume;
PAAD	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.78	5.58	0.41	1.08e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.57	6.7	0.48	3.91e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.53	5.95	0.43	1.76e-8	Schizophrenia;
PAAD	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg25279553	chr19:10444815	RAVER1;ICAM3	0.45	4.4	0.34	2.06e-5	Red cell distribution width;
PAAD	cis	rs114540395	0.858	rs116952915	chr10:103265796	C/T	cg21381511	chr10:104264849	SUFU	-0.85	-4.26	-0.33	3.5e-5	Schizophrenia;
PAAD	cis	rs9398803	0.687	rs4243491	chr6:126938536	T/C	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09826364	chr7:158789723	NA	0.43	5.48	0.41	1.74e-7	Facial morphology (factor 20);
PAAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg03885332	chr11:832357	CD151	-0.44	-5.12	-0.38	9.1e-7	Mean platelet volume;
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.45	-5.05	-0.38	1.26e-6	Testicular germ cell tumor;
PAAD	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3857067	1.000	rs1588385	chr4:95017161	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg03188948	chr7:1209495	NA	1.1	5.53	0.41	1.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.69	5.44	0.4	2.12e-7	Gut microbiome composition (summer);
PAAD	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg09659197	chr4:152720779	NA	0.42	5.51	0.41	1.52e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.54	4.94	0.37	2.08e-6	Testicular germ cell tumor;
PAAD	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.64	5.7	0.42	6.03e-8	Red blood cell count;
PAAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.65	6.21	0.45	4.77e-9	Height;
PAAD	cis	rs1443512	1.000	rs1443512	chr12:54342684	A/C	cg17410650	chr12:54324560	NA	-0.4	-5.91	-0.43	2.19e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.2	0.39	6.34e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.74	0.58	3.92e-15	Colorectal cancer;
PAAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.89	8.64	0.57	7.26e-15	Homoarginine levels;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg13699009	chr12:122356056	WDR66	0.49	6.98	0.49	8.35e-11	Mean corpuscular volume;
PAAD	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.53	-0.34	1.2e-5	Longevity;Endometriosis;
PAAD	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg22143635	chr11:980567	AP2A2	0.52	5.55	0.41	1.21e-7	Alzheimer's disease (late onset);
PAAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-4.32	-0.33	2.86e-5	Total body bone mineral density;
PAAD	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.84	5.73	0.42	5.35e-8	Gut microbiota (bacterial taxa);
PAAD	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg20607287	chr7:12443886	VWDE	-0.92	-6.87	-0.49	1.54e-10	Coronary artery disease;
PAAD	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.03	0.75	3.3e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.74	-7.97	-0.54	3.59e-13	Blood metabolite levels;
PAAD	cis	rs12780845	1.000	rs12772275	chr10:17204542	C/T	cg00857480	chr10:17188594	TRDMT1	0.37	4.72	0.36	5.32e-6	Homocysteine levels;
PAAD	cis	rs654384	1.000	rs654384	chr7:4166659	C/T	cg27574739	chr7:4176374	SDK1	-0.5	-4.97	-0.37	1.79e-6	Positive affect;
PAAD	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.66	-7.18	-0.5	2.84e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs797680	0.891	rs4847399	chr1:93584606	G/A	cg04535902	chr1:92947332	GFI1	0.45	4.35	0.33	2.48e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg06606381	chr12:133084897	FBRSL1	-0.98	-6.74	-0.48	3.06e-10	Breast cancer;
PAAD	cis	rs375066	0.935	rs108775	chr19:44405922	G/C	cg08633290	chr19:44405433	NA	-0.58	-5.87	-0.43	2.7e-8	Breast cancer;
PAAD	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.99	-6.42	-0.46	1.62e-9	Prostate cancer;
PAAD	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.68	-7.53	-0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.52	-4.28	-0.33	3.32e-5	Menarche (age at onset);
PAAD	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	9.41	0.61	7.24e-17	Schizophrenia;
PAAD	cis	rs9467603	0.925	rs1892253	chr6:25782314	G/T	cg23465465	chr6:26364728	BTN3A2	0.74	4.78	0.36	4.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02743256	chr7:2109353	MAD1L1	-0.72	-6.52	-0.47	9.66e-10	Neuroticism;
PAAD	cis	rs13053817	1.000	rs2106107	chr22:29835987	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.57	4.61	0.35	8.49e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg23506979	chr15:79090958	ADAMTS7	-0.25	-4.3	-0.33	3.06e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.78	8.93	0.59	1.34e-15	Colorectal cancer;
PAAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.56	-6.08	-0.44	9.4e-9	Menopause (age at onset);
PAAD	cis	rs1075265	0.610	rs6746965	chr2:54223525	G/C	cg04546899	chr2:54196757	PSME4	0.31	4.69	0.36	6.13e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	4.38	0.33	2.2e-5	Menarche (age at onset);
PAAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg03983715	chr16:68378420	PRMT7	-0.83	-6.0	-0.44	1.42e-8	HDL cholesterol;
PAAD	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg23465465	chr6:26364728	BTN3A2	0.79	4.41	0.34	1.99e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9463078	0.605	rs13215618	chr6:44936568	A/G	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4740619	0.967	rs9886779	chr9:15637447	T/A	cg14451791	chr9:16040625	NA	-0.43	-5.0	-0.38	1.54e-6	Body mass index;
PAAD	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.33	6.11	0.44	8.19e-9	Type 2 diabetes;
PAAD	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.75	8.73	0.58	4.31e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.87	-7.63	-0.53	2.4e-12	Lymphocyte percentage of white cells;
PAAD	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg03037974	chr15:76606532	NA	0.53	6.23	0.45	4.29e-9	Blood metabolite levels;
PAAD	trans	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-6.79	-0.48	2.38e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.89	9.54	0.61	3.34e-17	Parkinson's disease;
PAAD	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.3	-0.33	3.06e-5	Blood protein levels;
PAAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-5.7	-0.42	5.92e-8	Prostate cancer;
PAAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.51	-5.98	-0.44	1.53e-8	Height;
PAAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.47	-0.41	1.77e-7	Prevalent atrial fibrillation;
PAAD	cis	rs12714314	0.957	rs11678039	chr2:1951389	G/A	cg22350835	chr2:1868857	MYT1L	0.48	4.86	0.37	2.96e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs7612445	0.509	rs17358468	chr3:179027192	C/T	cg08825200	chr3:178984841	KCNMB3	0.43	4.66	0.35	6.85e-6	Resting heart rate;Heart rate;
PAAD	cis	rs12711490	0.559	rs4843866	chr16:85970650	C/T	cg05709598	chr16:85699621	KIAA0182	0.42	4.44	0.34	1.76e-5	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;
PAAD	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-5.02	-0.38	1.44e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg16898833	chr6:26189333	HIST1H4D	1.0	5.59	0.41	1.01e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23238603	chr1:31867686	NA	0.65	6.84	0.49	1.81e-10	Myopia (pathological);
PAAD	cis	rs2271001	0.955	rs7950788	chr11:19147479	G/A	cg00161556	chr11:19138045	ZDHHC13	0.5	5.48	0.41	1.76e-7	Gut microbiome composition (winter);
PAAD	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg05484376	chr2:27715224	FNDC4	-0.45	-4.63	-0.35	7.68e-6	Oral cavity cancer;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	4.48	0.34	1.45e-5	Breast cancer;
PAAD	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.57	5.56	0.41	1.17e-7	Lung cancer;
PAAD	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.46	-4.69	-0.36	6.1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg05304507	chr6:116381966	FRK	0.26	4.38	0.33	2.17e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16447950	chr5:562315	NA	-0.67	-5.73	-0.42	5.11e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs75920871	0.920	rs4938336	chr11:116948442	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.29	-0.33	3.19e-5	Subjective well-being;
PAAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg02734326	chr4:10020555	SLC2A9	-0.54	-5.34	-0.4	3.31e-7	Bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06710522	chr17:45908972	MRPL10;LRRC46	0.57	6.64	0.47	5.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.45	-0.34	1.62e-5	Blood metabolite levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03859186	chr16:30596757	ZNF785	0.58	6.49	0.47	1.12e-9	Monocyte percentage of white cells;
PAAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-4.68	-0.35	6.35e-6	Prostate cancer;
PAAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg11764359	chr7:65958608	NA	0.76	5.07	0.38	1.12e-6	Diabetic kidney disease;
PAAD	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06850241	chr22:41845214	NA	-0.48	-4.84	-0.37	3.14e-6	Vitiligo;
PAAD	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.47	5.93	0.43	1.93e-8	Renal cell carcinoma;
PAAD	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.5	5.69	0.42	6.36e-8	Coronary artery disease;
PAAD	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.51	-4.7	-0.36	5.89e-6	Response to temozolomide;
PAAD	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.47	4.53	0.34	1.19e-5	High light scatter reticulocyte count;
PAAD	cis	rs10821973	0.550	rs1432416	chr10:63975309	A/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs11811982	0.793	rs74782247	chr1:227275946	T/C	cg24860534	chr1:227506868	CDC42BPA	0.5	4.83	0.36	3.29e-6	Optic disc area;
PAAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.07	8.33	0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	6.11	0.44	7.92e-9	Response to bleomycin (chromatid breaks);
PAAD	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-5.42	-0.4	2.32e-7	Mean corpuscular volume;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.83	-7.02	-0.49	6.96e-11	Alzheimer's disease;
PAAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.61	-5.78	-0.42	4.03e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.92	-8.0	-0.54	2.87e-13	Gut microbiome composition (summer);
PAAD	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	5.39	0.4	2.62e-7	Response to bleomycin (chromatid breaks);
PAAD	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.71	-6.93	-0.49	1.11e-10	Obesity-related traits;
PAAD	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.45	-6.8	-0.48	2.27e-10	Breast cancer;
PAAD	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg14311320	chr7:124405732	GPR37	-0.43	-4.35	-0.33	2.46e-5	Lewy body disease;
PAAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.72	-0.48	3.35e-10	Lung cancer;
PAAD	cis	rs662064	0.963	rs1188529	chr1:10525914	A/T	cg09242541	chr1:10490025	APITD1	0.37	4.3	0.33	3.08e-5	Asthma;
PAAD	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13424612	0.860	rs34277046	chr2:240897331	G/A	cg12807937	chr2:240965920	NDUFA10	-0.49	-4.94	-0.37	2.08e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.67	6.57	0.47	7.52e-10	Obesity-related traits;
PAAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22442454	chr1:209979470	IRF6	0.63	5.53	0.41	1.36e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.74	-7.84	-0.54	7.33e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26717786	chr17:79139685	AATK;LOC388428	0.55	6.5	0.47	1.11e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg14008862	chr17:28927542	LRRC37B2	0.73	5.13	0.38	8.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12152867	chr6:56708725	DST	0.56	6.33	0.46	2.67e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg01304814	chr3:48885189	PRKAR2A	0.92	5.31	0.4	3.78e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg19337854	chr7:99768885	GPC2	0.47	4.3	0.33	2.98e-5	Platelet count;
PAAD	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-4.78	-0.36	4.13e-6	Coronary artery disease;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.07	0.55	1.95e-13	Height;
PAAD	cis	rs35740288	0.770	rs67253156	chr15:86105045	A/G	cg07943548	chr15:86304357	KLHL25	-0.64	-5.67	-0.42	6.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs682748	0.810	rs34630503	chr5:17139285	A/T	cg23987134	chr5:17158319	LOC285696	-0.35	-4.33	-0.33	2.7e-5	Hippocampal atrophy;
PAAD	cis	rs17641971	0.899	rs341828	chr8:50001946	A/G	cg00325661	chr8:49890786	NA	-0.51	-4.78	-0.36	4.16e-6	Blood metabolite levels;
PAAD	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.35	0.4	3.22e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22897701	chr14:103432870	CDC42BPB	0.6	6.32	0.46	2.77e-9	Smoking initiation;
PAAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg26497354	chr6:109612229	NA	-0.46	-4.58	-0.35	9.62e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.3	0.56	5.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs8099014	1.000	rs4940710	chr18:56135390	C/G	cg12907477	chr18:56117327	MIR122	0.55	4.68	0.36	6.25e-6	Platelet count;
PAAD	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg21823605	chr1:152486609	CRCT1	-0.49	-6.29	-0.45	3.14e-9	Hair morphology;
PAAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.59	0.61	2.44e-17	Rheumatoid arthritis;
PAAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg16083429	chr3:49237500	CCDC36	-0.46	-4.54	-0.35	1.12e-5	Menarche (age at onset);
PAAD	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26876637	chr1:152193138	HRNR	-0.86	-6.66	-0.48	4.8e-10	Atopic dermatitis;
PAAD	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg00717180	chr2:96193071	NA	0.59	6.66	0.48	4.64e-10	HDL cholesterol;
PAAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.94	-0.49	1.04e-10	Hip circumference;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg07689907	chr11:61582574	FADS1	0.56	4.99	0.38	1.63e-6	Trans fatty acid levels;
PAAD	cis	rs1198430	1.000	rs1198431	chr1:23755716	C/T	cg22040403	chr1:23858016	E2F2	-0.64	-4.33	-0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg04374321	chr14:90722782	PSMC1	0.51	4.3	0.33	3.02e-5	Longevity;
PAAD	cis	rs10413329	0.782	rs10408457	chr19:13101196	T/G	cg13338734	chr19:13113668	NFIX	0.37	4.83	0.36	3.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.77	-0.48	2.7e-10	Glomerular filtration rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21564803	chr22:43485544	TTLL1	0.56	6.34	0.46	2.47e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9815354	0.953	rs7631914	chr3:41813557	T/C	cg03022575	chr3:42003672	ULK4	0.79	5.93	0.43	1.92e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.9	8.43	0.56	2.41e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	trans	rs901683	1.000	rs17157852	chr10:45967801	C/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.46	-0.46	1.34e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9341808	0.556	rs10455370	chr6:81040867	A/G	cg08355045	chr6:80787529	NA	-0.39	-4.76	-0.36	4.56e-6	Sitting height ratio;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg02475695	chr16:616220	NHLRC4	0.45	5.22	0.39	5.85e-7	Height;
PAAD	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg05562828	chr17:3906858	NA	0.48	5.25	0.39	5e-7	Type 2 diabetes;
PAAD	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.58	5.97	0.44	1.64e-8	Testicular germ cell tumor;
PAAD	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.59	4.32	0.33	2.79e-5	Bipolar disorder (body mass index interaction);
PAAD	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.24e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9815354	1.000	rs1716999	chr3:41930041	C/G	cg03022575	chr3:42003672	ULK4	-0.83	-5.98	-0.44	1.52e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg17775713	chr3:133465469	TF	0.43	4.54	0.35	1.15e-5	Iron status biomarkers (transferrin levels);
PAAD	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21545522	chr1:205238299	TMCC2	0.48	4.35	0.33	2.48e-5	Red blood cell count;
PAAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg06375148	chr1:209958343	C1orf74	0.67	5.25	0.39	5.14e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.39	4.43	0.34	1.81e-5	Aortic root size;
PAAD	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.26	-0.39	4.87e-7	Menopause (age at onset);
PAAD	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.63	6.34	0.46	2.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.31e-7	Noise-induced hearing loss;
PAAD	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.78	-9.36	-0.6	9.88e-17	Height;
PAAD	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.83	-10.51	-0.65	9e-20	Height;
PAAD	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg03098721	chr1:84464084	TTLL7	0.46	4.42	0.34	1.84e-5	Obesity-related traits;
PAAD	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg06771106	chr2:113671356	IL1F7	-0.57	-5.99	-0.44	1.44e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-7.65	-0.53	2.12e-12	Migraine;Coronary artery disease;
PAAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg23281280	chr6:28129359	ZNF389	0.52	4.4	0.34	2.05e-5	Breast cancer;
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg19223190	chr17:80058835	NA	-0.52	-5.32	-0.4	3.66e-7	Life satisfaction;
PAAD	cis	rs7011192	0.793	rs10086770	chr8:10510511	A/G	cg04501334	chr8:10513686	RP1L1	0.68	4.46	0.34	1.59e-5	Suicide;
PAAD	cis	rs6594713	0.533	rs2162845	chr5:112988870	C/T	cg12552261	chr5:112820674	MCC	0.71	4.54	0.35	1.13e-5	Brain cytoarchitecture;
PAAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg09339527	chr5:178322752	ZFP2	-0.44	-4.47	-0.34	1.54e-5	Sleep duration;
PAAD	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.42	0.34	1.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg05627522	chr15:75251581	NA	-0.53	-6.61	-0.47	5.99e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg10395934	chr14:104002654	TRMT61A	0.52	5.38	0.4	2.78e-7	Body mass index;
PAAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg13722127	chr7:150037890	RARRES2	0.62	6.62	0.47	5.77e-10	Blood protein levels;Circulating chemerin levels;
PAAD	trans	rs901683	1.000	rs71494793	chr10:45985092	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08652369	chr3:66429805	LRIG1	-0.65	-6.85	-0.49	1.73e-10	Obesity-related traits;
PAAD	cis	rs354225	0.584	rs17046097	chr2:54888075	A/G	cg01766943	chr2:54829624	SPTBN1	-0.54	-4.82	-0.36	3.4e-6	Schizophrenia;
PAAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.75	7.67	0.53	1.87e-12	Coronary artery disease;
PAAD	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg16419906	chr5:132167176	NA	-0.43	-4.42	-0.34	1.9e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg20913747	chr6:44695427	NA	0.63	6.99	0.49	8.13e-11	Total body bone mineral density;
PAAD	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg06241208	chr11:30344200	C11orf46	-0.5	-4.56	-0.35	1.04e-5	Morning vs. evening chronotype;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg01059385	chr22:42394853	WBP2NL	0.41	4.38	0.33	2.17e-5	Cognitive function;
PAAD	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18621852	chr3:10150065	C3orf24	0.52	4.94	0.37	2.03e-6	Alzheimer's disease;
PAAD	cis	rs6988985	0.678	rs1799998	chr8:143999600	A/G	cg10324643	chr8:143916377	GML	0.4	4.48	0.34	1.43e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg00277334	chr10:82204260	NA	-0.58	-5.86	-0.43	2.76e-8	Post bronchodilator FEV1;
PAAD	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg00383909	chr3:49044727	WDR6	0.54	4.48	0.34	1.46e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.48	5.04	0.38	1.31e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg24879335	chr3:133465180	TF	0.59	6.46	0.46	1.35e-9	Iron status biomarkers;
PAAD	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg23587288	chr2:27483067	SLC30A3	-0.82	-7.13	-0.5	3.84e-11	Blood metabolite levels;
PAAD	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.69	7.1	0.5	4.51e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10078	0.660	rs11746538	chr5:427466	A/C	cg07599136	chr5:415885	AHRR	0.7	5.28	0.39	4.49e-7	Fat distribution (HIV);
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.25e-9	Lymphocyte counts;
PAAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.71	-5.96	-0.44	1.66e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.58	-5.05	-0.38	1.24e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	4.52	0.34	1.22e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3784262	0.740	rs12910267	chr15:58374603	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.63	-7.73	-0.53	1.33e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.85	8.57	0.57	1.1e-14	Corneal astigmatism;
PAAD	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg18281939	chr5:77783895	LHFPL2	0.52	6.7	0.48	3.9e-10	Triglycerides;
PAAD	cis	rs35740288	0.895	rs3743332	chr15:86303751	T/C	cg07943548	chr15:86304357	KLHL25	-0.58	-4.96	-0.37	1.89e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg15478930	chr2:27652102	NRBP1	0.5	4.47	0.34	1.54e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg16342193	chr10:102329863	NA	-0.81	-8.67	-0.58	5.9e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.72	-0.48	3.4e-10	Response to antipsychotic treatment;
PAAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.84	11.8	0.69	3.18e-23	Bone mineral density;
PAAD	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-0.94	-8.05	-0.55	2.16e-13	Blood protein levels;
PAAD	cis	rs354225	0.608	rs168505	chr2:54920968	C/T	cg26097391	chr2:54893211	SPTBN1	0.5	5.14	0.39	8.2e-7	Schizophrenia;
PAAD	cis	rs7714584	1.000	rs7732945	chr5:150261601	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.35	0.33	2.47e-5	IgG glycosylation;
PAAD	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg06632027	chr4:90757378	SNCA	-0.48	-4.44	-0.34	1.73e-5	Neuroticism;
PAAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	4.95	0.37	1.96e-6	Yeast infection;
PAAD	cis	rs2461751	0.929	rs1879951	chr2:176317599	A/G	cg25586410	chr2:175350621	GPR155	-0.5	-4.46	-0.34	1.58e-5	Electrocardiographic conduction measures;
PAAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.67	6.33	0.46	2.68e-9	Corneal astigmatism;
PAAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg21859623	chr20:33103246	DYNLRB1	-0.48	-4.88	-0.37	2.64e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.57	-0.41	1.15e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.74	6.02	0.44	1.29e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs17407555	0.821	rs73222526	chr4:10203917	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-4.51	-0.34	1.27e-5	Schizophrenia (age at onset);
PAAD	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.58	-4.45	-0.34	1.68e-5	Body mass index;
PAAD	cis	rs17169635	0.819	rs10954471	chr7:134496975	A/T	cg02516134	chr7:134575187	CALD1	-0.44	-4.49	-0.34	1.43e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs16910800	0.731	rs1065631	chr11:23186810	T/C	cg20040320	chr11:23191996	NA	-0.82	-6.89	-0.49	1.4e-10	Cancer;
PAAD	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	4.35	0.33	2.48e-5	Total body bone mineral density;
PAAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	11.78	0.69	3.68e-23	Platelet count;
PAAD	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg19254793	chr6:44695348	NA	-0.46	-4.39	-0.34	2.14e-5	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs453193	0.800	rs186975	chr2:8442736	C/G	cg12167548	chr2:8464763	NA	-0.43	-4.39	-0.34	2.11e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	10.01	0.63	2.01e-18	Platelet count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23026419	chr10:106098478	NA	-0.51	-6.29	-0.45	3.18e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14190943	chr14:105957502	C14orf80	0.65	6.35	0.46	2.39e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.41	-4.68	-0.35	6.44e-6	Blood pressure (smoking interaction);
PAAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6494488	0.500	rs67927052	chr15:64957323	G/T	cg16425858	chr15:64791681	ZNF609	0.93	5.05	0.38	1.27e-6	Coronary artery disease;
PAAD	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg00806126	chr19:22604979	ZNF98	0.41	5.16	0.39	7.5e-7	Pain;
PAAD	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.44	0.4	2.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg25193494	chr16:90016004	DEF8	0.44	4.37	0.33	2.27e-5	Squamous cell carcinoma;
PAAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg08698997	chr16:88989212	CBFA2T3	-0.54	-6.39	-0.46	1.95e-9	Social autistic-like traits;
PAAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs11105468	0.659	rs10777230	chr12:90543507	G/A	cg16962463	chr12:89968675	NA	0.47	4.9	0.37	2.43e-6	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.84	10.23	0.64	5.09e-19	Bladder cancer;
PAAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	4.4	0.34	2.01e-5	Platelet count;
PAAD	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-10.2	-0.64	6.14e-19	Obesity-related traits;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg00945038	chr17:61921165	SMARCD2	0.36	4.35	0.33	2.47e-5	Prudent dietary pattern;
PAAD	cis	rs988913	1.000	rs9382407	chr6:54836638	T/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.45e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20588892	chr5:87565114	TMEM161B	0.57	6.32	0.46	2.71e-9	Metabolite levels  (X-11787);
PAAD	cis	rs2229238	0.774	rs4240872	chr1:154436195	A/G	cg21262032	chr1:154437693	IL6R	-0.39	-4.29	-0.33	3.19e-5	Coronary heart disease;
PAAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.28	0.6	1.62e-16	Colorectal cancer;
PAAD	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg20742385	chr13:113633654	MCF2L	-0.46	-4.66	-0.35	6.74e-6	Systolic blood pressure;
PAAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg27532560	chr4:187881888	NA	0.52	5.67	0.42	6.82e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.75	8.02	0.55	2.69e-13	Total body bone mineral density;
PAAD	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg09436375	chr6:42928200	GNMT	-0.43	-5.85	-0.43	2.96e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13198984	chr17:80129470	CCDC57	-0.44	-5.49	-0.41	1.63e-7	Life satisfaction;
PAAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06544989	chr22:39130855	UNC84B	-0.48	-4.74	-0.36	4.93e-6	Menopause (age at onset);
PAAD	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.66	-5.46	-0.4	1.92e-7	Type 2 diabetes;
PAAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg12215294	chr3:40350768	EIF1B	0.44	4.38	0.33	2.17e-5	Renal cell carcinoma;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.71	7.31	0.51	1.43e-11	Resistin levels;
PAAD	cis	rs60154123	0.504	rs4844997	chr1:210486895	A/G	cg25204440	chr1:209979598	IRF6	0.61	5.0	0.38	1.54e-6	Coronary artery disease;
PAAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.44	5.56	0.41	1.19e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.37	-5.04	-0.38	1.29e-6	Blood protein levels;
PAAD	cis	rs863345	0.625	rs12063360	chr1:158499494	A/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.53	-4.88	-0.37	2.67e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.37	-4.97	-0.37	1.78e-6	Schizophrenia;
PAAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg05484376	chr2:27715224	FNDC4	0.46	4.67	0.35	6.5e-6	Total body bone mineral density;
PAAD	cis	rs911555	0.557	rs8022179	chr14:103847287	T/A	cg12935359	chr14:103987150	CKB	-0.62	-5.81	-0.43	3.52e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs59888335	0.858	rs35492571	chr3:80911413	A/G	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.5	-4.26	-0.33	3.51e-5	Neuroticism;
PAAD	cis	rs7894051	1.000	rs2185746	chr10:135195332	A/G	cg19176072	chr10:135083742	ADAM8	-0.96	-4.65	-0.35	7.09e-6	Lifespan;
PAAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.6	-5.58	-0.41	1.07e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs74161807	0.610	rs56012523	chr10:118401565	C/T	cg10511988	chr10:118891706	VAX1	0.36	4.25	0.33	3.65e-5	Loneliness (multivariate analysis);Loneliness;
PAAD	cis	rs9463078	0.546	rs10948191	chr6:44947281	G/T	cg25276700	chr6:44698697	NA	0.47	5.54	0.41	1.33e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.63	8.42	0.56	2.68e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg09163369	chr1:210001066	C1orf107	0.51	5.34	0.4	3.33e-7	Orofacial clefts;
PAAD	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg23024343	chr7:107201750	COG5	0.56	4.61	0.35	8.62e-6	Coronary artery disease;
PAAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.41	5.0	0.38	1.57e-6	Blood protein levels;
PAAD	cis	rs6604026	0.656	rs11164845	chr1:93416685	A/G	cg13858687	chr1:93297071	RPL5	0.47	4.35	0.33	2.52e-5	Multiple sclerosis;
PAAD	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg20019720	chr6:154832845	CNKSR3	0.66	7.86	0.54	6.7e-13	Lipoprotein (a) levels;
PAAD	cis	rs16975963	0.843	rs113690074	chr19:38375393	G/A	cg25793785	chr19:38281423	NA	0.6	4.86	0.37	2.92e-6	Longevity;
PAAD	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06850241	chr22:41845214	NA	-0.5	-4.51	-0.34	1.29e-5	Vitiligo;
PAAD	cis	rs988913	1.000	rs9382403	chr6:54825687	A/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13560548	chr3:10150139	C3orf24	-0.48	-4.25	-0.33	3.67e-5	Alzheimer's disease;
PAAD	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-4.32	-0.33	2.8e-5	Red blood cell traits;
PAAD	cis	rs55788414	0.725	rs55819896	chr16:81188466	G/A	cg06400318	chr16:81190750	PKD1L2	-1.16	-8.54	-0.57	1.3e-14	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg23024343	chr7:107201750	COG5	0.57	4.8	0.36	3.72e-6	Coronary artery disease;
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.89	-9.7	-0.62	1.28e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs12145833	1.000	rs12145833	chr1:243483754	G/T	cg02356786	chr1:243265016	LOC731275	-0.62	-4.36	-0.33	2.38e-5	Obesity (early onset extreme);
PAAD	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.02	0.38	1.46e-6	Educational attainment;
PAAD	cis	rs787274	1.000	rs7041965	chr9:115598341	T/G	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg05484376	chr2:27715224	FNDC4	-0.45	-4.7	-0.36	5.81e-6	Oral cavity cancer;
PAAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.58	5.91	0.43	2.22e-8	Personality dimensions;
PAAD	cis	rs6782228	0.675	rs9841987	chr3:128385142	G/T	cg16766828	chr3:128327626	NA	-0.45	-6.01	-0.44	1.31e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.23	-0.86	2.6e-47	Myeloid white cell count;
PAAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.6	5.47	0.41	1.78e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg26597838	chr10:835615	NA	0.52	5.69	0.42	6.28e-8	Survival in rectal cancer;
PAAD	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg07549590	chr16:15018862	NA	-0.46	-4.85	-0.37	2.99e-6	Triglycerides;
PAAD	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.76	-8.75	-0.58	3.8e-15	Handedness;
PAAD	cis	rs735539	0.521	rs9550675	chr13:21466641	C/A	cg27499820	chr13:21296301	IL17D	0.55	4.81	0.36	3.59e-6	Dental caries;
PAAD	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.77	6.66	0.48	4.63e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs6723226	0.766	rs455737	chr2:32528234	A/G	cg02381751	chr2:32503542	YIPF4	0.88	10.11	0.63	1.08e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.73	5.49	0.41	1.67e-7	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg08992911	chr2:238395768	MLPH	0.61	5.02	0.38	1.41e-6	Prostate cancer;
PAAD	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.92	-6.75	-0.48	2.87e-10	Opioid sensitivity;
PAAD	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.67	6.55	0.47	8.57e-10	Colorectal cancer;
PAAD	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.0	-0.49	7.84e-11	Triglycerides;
PAAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.06	-8.07	-0.55	1.95e-13	Diabetic kidney disease;
PAAD	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.47	4.55	0.35	1.09e-5	HDL cholesterol;
PAAD	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.63	-5.74	-0.42	4.88e-8	Restless legs syndrome;
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13732083	chr21:47605072	C21orf56	0.46	4.52	0.34	1.24e-5	Testicular germ cell tumor;
PAAD	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.62	6.87	0.49	1.58e-10	Colorectal cancer;
PAAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.62	-5.37	-0.4	2.94e-7	Mean corpuscular volume;
PAAD	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.47	4.51	0.34	1.31e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs11700980	0.748	rs17734876	chr21:30260144	C/T	cg24692254	chr21:30365293	RNF160	-0.72	-4.38	-0.33	2.24e-5	QRS complex (12-leadsum);
PAAD	cis	rs116248771	0.739	rs73156451	chr3:158365449	T/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22162314	chr17:61951766	CSH2	-0.59	-5.97	-0.44	1.61e-8	Height;
PAAD	cis	rs12044355	0.858	rs3738401	chr1:231830295	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.7	0.42	6.04e-8	Alzheimer's disease;
PAAD	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.4	-0.4	2.55e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.01	0.49	7.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6066825	0.555	rs4810849	chr20:47289944	C/T	cg18078177	chr20:47281410	PREX1	0.48	4.64	0.35	7.33e-6	Colorectal cancer;
PAAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg14349672	chr11:133703707	NA	-0.59	-6.88	-0.49	1.43e-10	Childhood ear infection;
PAAD	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.72	8.05	0.55	2.25e-13	Colorectal cancer;
PAAD	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.97	12.04	0.7	7.08e-24	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs9816226	0.591	rs74607912	chr3:185818559	G/A	cg00760338	chr3:185826511	ETV5	-0.72	-5.39	-0.4	2.61e-7	Obesity;Body mass index;
PAAD	cis	rs4148087	1.000	rs4148091	chr21:43635126	C/T	cg08841829	chr21:43638893	ABCG1	-0.74	-4.83	-0.36	3.35e-6	Eating disorder in bipolar disorder;
PAAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-4.65	-0.35	7.04e-6	Type 2 diabetes;
PAAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	12.16	0.7	3.53e-24	Platelet count;
PAAD	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg20503657	chr10:835505	NA	0.49	5.06	0.38	1.18e-6	Survival in rectal cancer;
PAAD	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs2839627	0.513	rs67571721	chr21:44306446	A/T	cg03543861	chr21:44258195	NA	0.65	4.75	0.36	4.7e-6	Information processing speed;
PAAD	cis	rs9535307	0.799	rs2146143	chr13:50245620	A/C	cg03658251	chr13:50265850	EBPL	0.78	5.51	0.41	1.51e-7	Obesity-related traits;
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12016809	chr21:47604291	C21orf56	0.42	4.25	0.33	3.71e-5	Testicular germ cell tumor;
PAAD	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg14346243	chr4:90757452	SNCA	-0.5	-4.33	-0.33	2.68e-5	Neuroticism;
PAAD	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg24375607	chr4:120327624	NA	0.47	4.25	0.33	3.69e-5	Corneal astigmatism;
PAAD	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-6.81	-0.48	2.11e-10	Asthma;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16490390	chr19:54694229	MBOAT7;TSEN34	0.6	6.35	0.46	2.33e-9	Monocyte percentage of white cells;
PAAD	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.52	-0.41	1.43e-7	White blood cell count;
PAAD	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.84	-9.99	-0.63	2.18e-18	Brugada syndrome;
PAAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.48	4.75	0.36	4.77e-6	Menopause (age at onset);
PAAD	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.12	0.55	1.51e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg11764359	chr7:65958608	NA	0.78	5.14	0.38	8.4e-7	Diabetic kidney disease;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg08219700	chr8:58056026	NA	0.67	5.23	0.39	5.56e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg10223061	chr2:219282414	VIL1	0.38	4.59	0.35	9.04e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs818427	0.783	rs57721139	chr5:112223870	G/A	cg06941702	chr5:112196734	SRP19	0.51	4.75	0.36	4.67e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.86	9.87	0.62	4.75e-18	Prudent dietary pattern;
PAAD	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	1.01	5.65	0.42	7.67e-8	Parkinson's disease;
PAAD	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	0.91	5.57	0.41	1.12e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.5	6.55	0.47	8.44e-10	Thyroid hormone levels;
PAAD	cis	rs773506	1.000	rs773509	chr9:93958422	C/T	cg14446406	chr9:93919335	NA	-0.31	-4.39	-0.34	2.15e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg11262906	chr1:85462892	MCOLN2	0.61	4.91	0.37	2.28e-6	Serum sulfate level;
PAAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.48	-0.47	1.18e-9	Eye color traits;
PAAD	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.69	6.86	0.49	1.63e-10	Cancer;
PAAD	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	1.17	6.71	0.48	3.58e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.65	-6.99	-0.49	8.12e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg00522288	chr12:125625016	AACS	-0.45	-4.56	-0.35	1.04e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.72	-0.58	4.61e-15	Eye color traits;
PAAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.79	-8.08	-0.55	1.92e-13	Neurofibrillary tangles;
PAAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.77	4.43	0.34	1.77e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg08134877	chr2:44394819	PPM1B	0.45	4.42	0.34	1.84e-5	Height;
PAAD	cis	rs603424	0.509	rs6584362	chr10:102087113	G/T	cg04387475	chr10:102747104	MRPL43;C10orf2	-0.63	-4.33	-0.33	2.74e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.58	5.94	0.43	1.82e-8	Lung cancer;
PAAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.69	9.82	0.62	6.27e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	8.44	0.56	2.29e-14	Neuroticism;
PAAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.75	7.16	0.5	3.15e-11	Total body bone mineral density;
PAAD	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.56	4.92	0.37	2.22e-6	Life satisfaction;
PAAD	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg27499820	chr13:21296301	IL17D	-0.53	-5.24	-0.39	5.37e-7	Dental caries;
PAAD	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg09366796	chr5:75012313	C5orf37	0.52	4.76	0.36	4.53e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7078160	0.766	rs61872990	chr10:118649443	T/C	cg17349199	chr10:118429452	C10orf82	-0.51	-4.67	-0.35	6.5e-6	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;
PAAD	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.67	7.4	0.51	8.68e-12	Schizophrenia;
PAAD	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.3	4.34	0.33	2.62e-5	Asthma;
PAAD	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	1.02	7.37	0.51	1.02e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg24830062	chr5:140700576	TAF7	-0.52	-4.29	-0.33	3.14e-5	Pulmonary function decline;
PAAD	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg15798862	chr7:76129360	DTX2	-0.42	-5.4	-0.4	2.56e-7	Multiple sclerosis;
PAAD	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg17595323	chr11:93583763	C11orf90	-0.36	-4.51	-0.34	1.27e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.94	12.47	0.71	5.12e-25	Menopause (age at onset);
PAAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.59	-5.56	-0.41	1.17e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-8.38	-0.56	3.34e-14	Height;
PAAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.57	-0.35	1e-5	Renal cell carcinoma;
PAAD	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-4.96	-0.37	1.87e-6	Resting heart rate;
PAAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	4.42	0.34	1.9e-5	Menarche (age at onset);
PAAD	cis	rs60154123	0.730	rs590380	chr1:210463071	C/T	cg23283495	chr1:209979779	IRF6	0.62	5.88	0.43	2.56e-8	Coronary artery disease;
PAAD	cis	rs13053817	0.948	rs7287166	chr22:29843932	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.56	-5.05	-0.38	1.24e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01722343	chr4:25235437	PI4K2B	0.68	6.94	0.49	1.08e-10	Obesity-related traits;
PAAD	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg12568669	chr8:11666485	FDFT1	0.27	4.37	0.33	2.25e-5	Neuroticism;
PAAD	cis	rs8067354	0.540	rs7221472	chr17:58036737	C/T	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.72	7.34	0.51	1.19e-11	Prostate cancer;
PAAD	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-5.44	-0.4	2.08e-7	Airway imaging phenotypes;
PAAD	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.48	4.76	0.36	4.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.67	6.34	0.46	2.5e-9	Tuberculosis;
PAAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg19630374	chr17:18023558	MYO15A	0.46	4.75	0.36	4.74e-6	Total body bone mineral density;
PAAD	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.6	5.31	0.4	3.8e-7	Height;
PAAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg23018236	chr17:30244563	NA	-0.58	-4.9	-0.37	2.39e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.46	5.01	0.38	1.51e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.93	-6.55	-0.47	8.2e-10	Body mass index;
PAAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs965469	1.000	rs6051808	chr20:3350697	A/T	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.85	-9.62	-0.62	2.06e-17	Iron status biomarkers;
PAAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.84	9.99	0.63	2.19e-18	Ulcerative colitis;
PAAD	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-4.74	-0.36	4.83e-6	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.79	0.62	7.38e-18	Prudent dietary pattern;
PAAD	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.8e-8	Alzheimer's disease (late onset);
PAAD	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.82	0.58	2.56e-15	Motion sickness;
PAAD	cis	rs5753037	0.809	rs17711377	chr22:30212986	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-4.51	-0.34	1.32e-5	Type 1 diabetes;
PAAD	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg11630242	chr17:19881632	AKAP10	-0.49	-4.71	-0.36	5.61e-6	Schizophrenia;
PAAD	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.6	4.32	0.33	2.82e-5	Systolic blood pressure;
PAAD	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.63	5.68	0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	5.08	0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg12193833	chr17:30244370	NA	-0.58	-4.31	-0.33	2.94e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg15798862	chr7:76129360	DTX2	-0.52	-6.87	-0.49	1.57e-10	Multiple sclerosis;
PAAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.84	7.3	0.51	1.5e-11	Menarche (age at onset);
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-7.4	-0.51	8.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs12476592	0.571	rs196125	chr2:63859268	C/T	cg10828910	chr2:63850056	LOC388955	0.5	4.26	0.33	3.6e-5	Childhood ear infection;
PAAD	cis	rs4711350	0.678	rs658087	chr6:33665020	A/T	cg13859433	chr6:33739653	LEMD2	0.85	5.36	0.4	2.99e-7	Schizophrenia;
PAAD	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.47	4.33	0.33	2.74e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg18904891	chr8:8559673	CLDN23	0.65	5.86	0.43	2.75e-8	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.52	0.57	1.44e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg27499820	chr13:21296301	IL17D	0.56	5.26	0.39	4.79e-7	Dental caries;
PAAD	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg27565382	chr3:53032988	SFMBT1	0.79	4.65	0.35	7.24e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg02841227	chr6:26021843	HIST1H4A	0.48	4.7	0.36	5.79e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg18129178	chr5:148520854	ABLIM3	-0.54	-5.24	-0.39	5.23e-7	Breast cancer;
PAAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.88	10.95	0.66	6.34e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01616529	chr11:638424	DRD4	-0.58	-5.74	-0.42	4.89e-8	Systemic lupus erythematosus;
PAAD	cis	rs6466055	0.661	rs6972563	chr7:104842960	T/C	cg04380332	chr7:105027541	SRPK2	0.51	4.99	0.38	1.6e-6	Schizophrenia;
PAAD	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-5.06	-0.38	1.18e-6	Menarche (age at onset);
PAAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg22800045	chr5:56110881	MAP3K1	-0.58	-4.65	-0.35	7.15e-6	Coronary artery disease;
PAAD	cis	rs737387	0.506	rs17105561	chr14:68877250	G/A	cg08106190	chr14:67937737	TMEM229B	0.37	4.33	0.33	2.73e-5	Breast cancer;
PAAD	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg12046867	chr14:103022105	NA	-0.61	-5.14	-0.38	8.28e-7	Platelet count;
PAAD	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg04772947	chr11:57363540	SERPING1	0.41	4.29	0.33	3.2e-5	Schizophrenia;
PAAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12311346	chr5:56204834	C5orf35	-0.55	-4.52	-0.34	1.25e-5	Coronary artery disease;
PAAD	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg10818794	chr15:86012489	AKAP13	-0.57	-4.61	-0.35	8.31e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs11051970	0.918	rs73084101	chr12:32544339	A/C	cg02745156	chr12:32552066	NA	0.49	4.95	0.37	1.95e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg02071572	chr4:1403502	NA	0.39	4.83	0.36	3.29e-6	Obesity-related traits;
PAAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.84	0.58	2.2e-15	Homoarginine levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15109730	chr1:156698192	C1orf66;ISG20L2	0.7	6.44	0.46	1.51e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-4.66	-0.35	6.97e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05457923	chr6:154831692	CNKSR3	0.66	7.35	0.51	1.11e-11	Myopia (pathological);
PAAD	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.51	4.66	0.35	6.83e-6	Hepatocellular carcinoma;
PAAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg26071806	chr7:100318239	EPO	-0.49	-4.9	-0.37	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.91	-11.29	-0.68	7.4e-22	Pulse pressure;
PAAD	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.99	11.97	0.7	1.13e-23	Breast cancer;
PAAD	cis	rs375066	0.868	rs378109	chr19:44421937	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs7260598	0.539	rs114482892	chr19:24063749	C/G	cg09235885	chr19:23456588	NA	-0.63	-4.35	-0.33	2.45e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg24220031	chr2:73402428	NA	-0.43	-6.7	-0.48	3.81e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2280630	0.529	rs784505	chr3:39168757	G/A	cg01426195	chr3:39028469	NA	0.67	7.2	0.5	2.53e-11	Verbal declarative memory;
PAAD	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	1.03	12.06	0.7	6.41e-24	Multiple myeloma;
PAAD	cis	rs10838532	0.633	rs72902484	chr11:45934889	G/A	cg24204282	chr11:45944920	GYLTL1B	0.48	4.44	0.34	1.7e-5	Axial length;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12823012	chr10:70480922	CCAR1	-0.71	-6.51	-0.47	1.03e-9	Neuroticism;
PAAD	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg00105475	chr2:10696890	NA	0.65	6.86	0.49	1.67e-10	Prostate cancer;
PAAD	cis	rs564309	0.681	rs6426501	chr1:228623243	C/G	cg00655913	chr1:228633920	NA	0.64	4.74	0.36	4.88e-6	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.68	-0.42	6.64e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	ch.11.42038R	chr11:967971	AP2A2	0.59	6.2	0.45	5.02e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.96	-0.37	1.86e-6	Height;
PAAD	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.57	-6.17	-0.45	5.83e-9	Pelvic organ prolapse;
PAAD	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.74	8.12	0.55	1.45e-13	Alcohol dependence;
PAAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.45	4.55	0.35	1.08e-5	Menarche (age at onset);
PAAD	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.59	4.34	0.33	2.59e-5	Alzheimer's disease (survival time);
PAAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg02071572	chr4:1403502	NA	0.38	4.49	0.34	1.42e-5	Obesity-related traits;
PAAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.7	7.84	0.54	7.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9397240	0.689	rs1048587	chr6:155578684	G/A	cg06694381	chr6:155569200	TIAM2	-0.47	-4.32	-0.33	2.75e-5	Life satisfaction;
PAAD	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg02683114	chr2:24398427	C2orf84	0.62	6.82	0.48	1.97e-10	Asthma;
PAAD	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.79	-0.53	9.56e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs11811982	0.793	rs78816618	chr1:227512424	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs642743	0.967	rs789970	chr10:105977721	A/G	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.31	0.33	2.87e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.02	-0.44	1.23e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22933807	chr19:47925425	NA	0.64	6.43	0.46	1.54e-9	Obesity-related traits;
PAAD	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.71	7.39	0.51	8.97e-12	Body mass index;
PAAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.65	-6.48	-0.47	1.2e-9	Urate levels in lean individuals;
PAAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	trans	rs3733631	1.000	rs10007754	chr4:104627442	T/G	cg11176159	chr1:28213800	NA	-0.48	-6.4	-0.46	1.87e-9	Menarche (age at onset);
PAAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.58	5.93	0.43	1.96e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg14349672	chr11:133703707	NA	-0.56	-6.45	-0.46	1.38e-9	Childhood ear infection;
PAAD	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	6.39	0.46	1.9e-9	Multiple sclerosis;
PAAD	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06569419	chr2:182827064	NA	-0.61	-6.55	-0.47	8.28e-10	Smoking initiation;
PAAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs1359582	0.793	rs7900987	chr10:90399072	G/C	cg15661332	chr10:90342814	RNLS	0.57	5.03	0.38	1.38e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6496044	0.507	rs2467096	chr15:86210678	G/A	cg13263323	chr15:86062960	AKAP13	0.5	5.35	0.4	3.21e-7	Interstitial lung disease;
PAAD	cis	rs1507153	0.775	rs7763429	chr6:79350769	G/A	cg05283184	chr6:79620031	NA	-0.38	-4.55	-0.35	1.09e-5	Sjögren's syndrome;
PAAD	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs682748	0.846	rs12657676	chr5:17144514	C/T	cg23987134	chr5:17158319	LOC285696	-0.36	-4.46	-0.34	1.6e-5	Hippocampal atrophy;
PAAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg16578609	chr1:2399051	NA	-0.44	-4.47	-0.34	1.53e-5	Non-obstructive azoospermia;
PAAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.42	-5.96	-0.43	1.73e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.56	-5.78	-0.42	4.02e-8	Hyperactive-impulsive symptoms;
PAAD	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-5.61	-0.41	9.23e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.51	6.19	0.45	5.43e-9	Vitiligo;
PAAD	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-4.65	-0.35	7.18e-6	Breast cancer;
PAAD	cis	rs6141769	0.542	rs6058846	chr20:31324035	A/C	cg13636640	chr20:31349939	DNMT3B	-0.5	-4.66	-0.35	6.99e-6	Subjective well-being;
PAAD	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.61	-0.35	8.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.02	0.38	1.46e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-6.01	-0.44	1.31e-8	Schizophrenia;
PAAD	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.28	0.39	4.44e-7	Educational attainment;
PAAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.68	7.84	0.54	7.37e-13	Body mass index;
PAAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.15	9.93	0.63	3.13e-18	Vitiligo;
PAAD	cis	rs7142002	0.881	rs78827849	chr14:102357959	G/A	cg16201061	chr14:102358090	PPP2R5C	0.97	4.99	0.38	1.6e-6	Autism;
PAAD	cis	rs245880	0.740	rs245897	chr7:29193940	C/T	cg17163760	chr7:29186267	CPVL	0.52	6.18	0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.9	-0.49	1.3100000000000001e-10	Type 2 diabetes;
PAAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-4.9	-0.37	2.45e-6	Schizophrenia;
PAAD	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.52	-4.55	-0.35	1.09e-5	Total body bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15679144	chr11:66725941	PC	-0.77	-7.2	-0.5	2.62e-11	Neuroticism;
PAAD	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-7.11	-0.5	4.19e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-6.0	-0.44	1.39e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-5.84	-0.43	3.07e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.6	-6.54	-0.47	8.74e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	16.64	0.8	4.72e-36	Prudent dietary pattern;
PAAD	cis	rs367943	0.698	rs7718310	chr5:112970628	A/G	cg12552261	chr5:112820674	MCC	0.52	5.52	0.41	1.46e-7	Type 2 diabetes;
PAAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.48	-4.84	-0.37	3.11e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg09324608	chr17:30823087	MYO1D	0.48	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24742294	chr1:247109025	NA	-0.75	-6.96	-0.49	9.43e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs34746873	0.588	rs7000539	chr8:63039751	A/G	cg03779660	chr8:62745097	NA	-0.47	-4.31	-0.33	2.96e-5	Neurofibrillary tangles;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23523434	chr12:124344211	DNAH10	-0.66	-6.48	-0.47	1.2e-9	Obesity-related traits;
PAAD	cis	rs4389656	0.857	rs274679	chr5:6751426	A/C	cg10857441	chr5:6722123	POLS	-0.39	-4.3	-0.33	2.99e-5	Coronary artery disease;
PAAD	cis	rs4750440	0.702	rs7911259	chr10:14031051	T/C	cg27542038	chr10:14027202	FRMD4A	-0.41	-4.27	-0.33	3.45e-5	Adiponectin levels;
PAAD	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	8.38	0.56	3.36e-14	Bipolar disorder;
PAAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg21929781	chr1:2537748	MMEL1	-0.49	-5.12	-0.38	8.92e-7	Ulcerative colitis;
PAAD	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.37	-0.33	2.26e-5	Cognitive function;
PAAD	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.72	-4.75	-0.36	4.73e-6	Body mass index;
PAAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.57	6.05	0.44	1.06e-8	Obesity-related traits;
PAAD	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.5	4.65	0.35	7.25e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg14926445	chr8:58193284	C8orf71	-0.55	-4.41	-0.34	1.94e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg01499736	chr6:36164655	BRPF3	0.63	6.39	0.46	1.91e-9	Primary biliary cholangitis;
PAAD	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.95	-0.37	1.92e-6	Retinal vascular caliber;
PAAD	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg21775007	chr8:11205619	TDH	-0.5	-4.69	-0.36	6e-6	Neuroticism;
PAAD	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.32	-0.33	2.84e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.53	5.62	0.41	8.87e-8	Mean platelet volume;
PAAD	cis	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg21546286	chr11:48923668	NA	0.54	5.68	0.42	6.6e-8	HDL cholesterol;
PAAD	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg14773178	chr5:1868261	NA	0.37	4.78	0.36	4.11e-6	Cardiovascular disease risk factors;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26906418	chr1:204379804	PPP1R15B	0.61	6.95	0.49	1.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg12193833	chr17:30244370	NA	-0.65	-4.93	-0.37	2.17e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.38	-5.53	-0.41	1.36e-7	Glomerular filtration rate;
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.55	-5.1	-0.38	9.88e-7	Total body bone mineral density;
PAAD	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.49	5.99	0.44	1.45e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.59	-0.35	9.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.9	10.02	0.63	1.85e-18	Total cholesterol levels;
PAAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	0.82	6.37	0.46	2.09e-9	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs58521262	0.530	rs289320	chr19:23157799	A/T	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg10483660	chr13:112241077	NA	0.52	4.84	0.37	3.1e-6	Menarche (age at onset);
PAAD	cis	rs4908768	0.657	rs6693466	chr1:8817938	C/T	cg00590817	chr1:8272081	NA	-0.37	-4.45	-0.34	1.64e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs4740619	1.000	rs2175082	chr9:15641279	A/G	cg14451791	chr9:16040625	NA	0.42	4.88	0.37	2.69e-6	Body mass index;
PAAD	cis	rs2651899	0.966	rs2742663	chr1:3084905	T/C	cg07622451	chr1:3079886	PRDM16	0.39	4.54	0.35	1.15e-5	Migraine;
PAAD	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.22	0.64	5.53e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.8	-8.47	-0.57	1.94e-14	Tuberculosis;
PAAD	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg18898632	chr2:242989856	NA	-0.81	-6.41	-0.46	1.77e-9	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-7.09	-0.5	4.66e-11	Gut microbiome composition (summer);
PAAD	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	0.98	11.27	0.67	8.26e-22	Testicular germ cell tumor;
PAAD	cis	rs11825685	0.708	rs73044092	chr11:134546621	G/A	cg02089395	chr11:134479357	NA	-0.68	-5.16	-0.39	7.62e-7	IgG glycosylation;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.46	-0.34	1.57e-5	Life satisfaction;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg07775675	chr17:74379922	SPHK1	0.65	8.0	0.54	3.02e-13	Metabolite levels  (X-11787);
PAAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	5.37	0.4	2.9e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.6	0.47	6.35e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.68	-5.9	-0.43	2.31e-8	Coronary artery disease;
PAAD	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.57	4.72	0.36	5.36e-6	Alzheimer's disease (cognitive decline);
PAAD	cis	rs17155006	0.628	rs397941	chr7:107727709	C/T	cg05962710	chr7:107745446	LAMB4	-0.45	-5.54	-0.41	1.29e-7	Pneumococcal bacteremia;
PAAD	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.5	5.69	0.42	6.36e-8	Coronary artery disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04439376	chr2:112812130	TMEM87B	-0.7	-6.85	-0.49	1.76e-10	Lung cancer in ever smokers;
PAAD	cis	rs2030114	0.768	rs34022899	chr16:51600060	C/T	cg03758633	chr16:51611768	NA	0.51	4.56	0.35	1.05e-5	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg01631408	chr1:248437212	OR2T33	-0.57	-5.27	-0.39	4.68e-7	Common traits (Other);
PAAD	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.73	-7.37	-0.51	1.04e-11	Itch intensity from mosquito bite;
PAAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg05784532	chr1:230284198	GALNT2	0.67	5.62	0.41	8.93e-8	Coronary artery disease;
PAAD	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.44e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.3e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.5	-4.92	-0.37	2.26e-6	Obesity-related traits;
PAAD	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	5.68	0.42	6.68e-8	Blood protein levels;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg05627522	chr15:75251581	NA	0.53	6.23	0.45	4.38e-9	Breast cancer;
PAAD	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	8.6	0.57	9.26e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6496932	0.676	rs7183651	chr15:85895721	A/G	cg19183879	chr15:85880815	NA	-0.49	-4.43	-0.34	1.82e-5	Central corneal thickness;Corneal structure;
PAAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.79	0.36	3.93e-6	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg00431813	chr7:1051703	C7orf50	0.54	4.68	0.35	6.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.7	4.33	0.33	2.72e-5	Lung cancer in ever smokers;
PAAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14192396	chr10:97416393	ALDH18A1	0.61	6.9	0.49	1.29e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg21479132	chr6:26055353	NA	0.98	5.87	0.43	2.61e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.64	-4.48	-0.34	1.49e-5	LDL cholesterol levels;
PAAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg19163074	chr7:65112434	INTS4L2	0.46	4.41	0.34	1.94e-5	Aortic root size;
PAAD	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg14343924	chr8:8086146	FLJ10661	0.49	4.41	0.34	1.98e-5	Neuroticism;
PAAD	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	7.46	0.52	6.34e-12	Multiple sclerosis;
PAAD	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Myopia (pathological);
PAAD	cis	rs4666360	1.000	rs4666361	chr2:20336215	G/C	cg23291376	chr2:20336282	NA	-0.4	-4.49	-0.34	1.39e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
PAAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.66	-7.35	-0.51	1.13e-11	Total body bone mineral density;
PAAD	cis	rs8060686	0.623	rs255049	chr16:68013471	T/C	cg01866162	chr16:67596514	CTCF	0.55	4.39	0.34	2.09e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3126085	0.560	rs3120666	chr1:152316981	G/C	cg26876637	chr1:152193138	HRNR	-0.68	-5.16	-0.39	7.62e-7	Atopic dermatitis;
PAAD	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.46	-0.4	1.94e-7	Waist circumference;Hip circumference;
PAAD	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19671926	chr4:122722719	EXOSC9	0.51	5.09	0.38	1.05e-6	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg20243544	chr17:37824526	PNMT	-0.49	-4.28	-0.33	3.36e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12460928	chr6:108584974	NA	0.57	6.4	0.46	1.81e-9	Smoking initiation;
PAAD	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.87	9.93	0.63	3.25e-18	Coronary artery disease;
PAAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg05697835	chr1:2722811	NA	0.42	4.81	0.36	3.63e-6	Ulcerative colitis;
PAAD	cis	rs10267417	0.657	rs7800274	chr7:19871184	G/T	cg05791153	chr7:19748676	TWISTNB	0.68	4.5	0.34	1.32e-5	Night sleep phenotypes;
PAAD	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg11288833	chr15:55489084	RSL24D1	0.57	4.53	0.34	1.21e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg21361702	chr7:150065534	REPIN1	0.57	4.89	0.37	2.57e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.45	4.26	0.33	3.54e-5	Depression;
PAAD	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.36	-5.6	-0.41	9.6e-8	Alzheimer's disease (late onset);
PAAD	cis	rs116248771	0.739	rs12630515	chr3:158346615	A/G	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.86	-0.62	4.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.8	6.46	0.46	1.36e-9	Lung function (FEV1/FVC);
PAAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.57	-5.73	-0.42	5.13e-8	Coronary artery disease;
PAAD	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.68	7.55	0.52	3.69e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs10943724	0.704	rs6933382	chr6:81263250	A/G	cg19323245	chr6:80716898	TTK	-0.46	-4.86	-0.37	2.9e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.72	7.33	0.51	1.29e-11	Response to diuretic therapy;
PAAD	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.79	7.77	0.53	1.12e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.6	6.2	0.45	5.04e-9	Bladder cancer;
PAAD	cis	rs35740288	0.770	rs11631660	chr15:86215412	G/T	cg07943548	chr15:86304357	KLHL25	0.62	5.47	0.41	1.84e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9916302	0.560	rs3764352	chr17:37790939	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-5.4	-0.4	2.49e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs17655565	0.537	rs67353063	chr12:52802345	C/T	cg22980804	chr12:52818037	KRT75	-0.54	-5.0	-0.38	1.59e-6	Plasma amyloid beta peptide concentrations (ABx-42);
PAAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-5.62	-0.41	8.9e-8	Bipolar disorder;
PAAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11141652	chr22:24348549	GSTTP1	0.5	4.79	0.36	3.88e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-4.58	-0.35	9.46e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-7.11	-0.5	4.35e-11	Educational attainment;
PAAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.58	0.41	1.06e-7	Tonsillectomy;
PAAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.42e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7187994	0.848	rs16974515	chr16:84782510	T/G	cg07647771	chr16:84786436	USP10	-0.35	-4.41	-0.34	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg07617317	chr6:118971624	C6orf204	0.53	4.49	0.34	1.43e-5	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08878188	chr12:109826583	MYO1H	-0.6	-6.71	-0.48	3.6e-10	Obesity-related traits;
PAAD	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06002616	chr8:101225028	SPAG1	-0.47	-5.58	-0.41	1.07e-7	Atrioventricular conduction;
PAAD	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.67	9.04	0.59	6.86e-16	Hemoglobin concentration;
PAAD	cis	rs7594192	0.744	rs11898801	chr2:199361421	T/C	cg01558212	chr2:200327336	NA	-0.34	-4.44	-0.34	1.7e-5	Educational attainment;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.88	-10.0	-0.63	2.11e-18	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs6828577	0.732	rs2200517	chr4:119462685	T/C	cg26518628	chr1:97050305	NA	-0.72	-6.32	-0.46	2.72e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.76	0.48	2.83e-10	Coffee consumption (cups per day);
PAAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg06737004	chr16:31226760	TRIM72	0.61	6.29	0.45	3.29e-9	Iris heterochromicity;
PAAD	cis	rs6782228	0.675	rs4443194	chr3:128383446	T/A	cg16766828	chr3:128327626	NA	-0.45	-5.98	-0.44	1.57e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.11	-0.59	4.43e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.46	4.34	0.33	2.64e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.59	5.92	0.43	2.02e-8	Systolic blood pressure;
PAAD	cis	rs4819143	0.517	rs454268	chr21:47373114	G/A	cg13695288	chr21:47294981	PCBP3	0.58	5.1	0.38	1e-6	Insulin resistance/response;
PAAD	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Bladder cancer;
PAAD	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs9810890	1.000	rs115201118	chr3:128552140	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg07234876	chr8:600039	NA	-1.07	-6.98	-0.49	8.57e-11	IgG glycosylation;
PAAD	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg25811867	chr2:3488468	NA	0.43	4.52	0.34	1.22e-5	Neurofibrillary tangles;
PAAD	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.77	-8.91	-0.59	1.51e-15	Total body bone mineral density;
PAAD	cis	rs950881	0.799	rs72823669	chr2:102982033	G/T	cg03938978	chr2:103052716	IL18RAP	0.54	4.45	0.34	1.67e-5	Allergy;
PAAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg24879335	chr3:133465180	TF	-0.53	-5.68	-0.42	6.75e-8	Iron status biomarkers;
PAAD	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg05110241	chr16:68378359	PRMT7	-0.95	-7.52	-0.52	4.45e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.63	-5.31	-0.4	3.84e-7	Cognitive test performance;
PAAD	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.48	-0.71	4.65e-25	Ulcerative colitis;
PAAD	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.66	6.93	0.49	1.1e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17534004	1.000	rs34538248	chr13:31468796	A/C	cg00570269	chr13:31480942	C13orf33	0.59	4.45	0.34	1.65e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.56	-4.32	-0.33	2.76e-5	Resting heart rate;
PAAD	cis	rs4722585	0.640	rs12700708	chr7:26186015	T/C	cg07876897	chr7:26191696	NFE2L3	0.53	4.83	0.36	3.26e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.52	-6.47	-0.46	1.26e-9	Lewy body disease;
PAAD	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.82	5.34	0.4	3.38e-7	Systolic blood pressure;
PAAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-7.22	-0.51	2.3e-11	Asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26421181	chr17:73937284	FBF1	-0.84	-7.54	-0.52	3.97e-12	Neuroticism;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.67	0.35	6.68e-6	Obesity-related traits;
PAAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.72	8.34	0.56	4.26e-14	Lung cancer;
PAAD	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.59	0.35	9.07e-6	Colorectal cancer;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.48	5.19	0.39	6.61e-7	Longevity;Endometriosis;
PAAD	cis	rs2120019	0.786	rs12911421	chr15:75287822	C/A	cg17294928	chr15:75287854	SCAMP5	1.08	10.89	0.66	8.93e-21	Blood trace element (Zn levels);
PAAD	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.12	10.25	0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs258892	0.895	rs6882092	chr5:72086928	G/A	cg21869765	chr5:72125136	TNPO1	-0.82	-5.55	-0.41	1.25e-7	Small cell lung carcinoma;
PAAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.65	5.3	0.4	3.95e-7	Gut microbiome composition (summer);
PAAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08377569	chr16:30538014	ZNF768	-0.64	-6.83	-0.48	1.88e-10	Warfarin maintenance dose;
PAAD	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg01612440	chr4:3296283	NA	0.46	4.54	0.35	1.12e-5	Serum sulfate level;
PAAD	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.5	0.61	4.33e-17	Diabetic retinopathy;
PAAD	cis	rs9434723	0.841	rs6685399	chr1:9299294	C/T	cg04199779	chr1:9294473	H6PD	0.58	4.97	0.37	1.75e-6	Height;
PAAD	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.49	-5.29	-0.39	4.26e-7	Longevity;
PAAD	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.4	4.74	0.36	4.78e-6	Blood protein levels;
PAAD	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg25922239	chr6:33757077	LEMD2	0.49	4.67	0.35	6.66e-6	Crohn's disease;
PAAD	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg06671706	chr8:8559999	CLDN23	0.6	5.54	0.41	1.31e-7	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs758324	0.812	rs4705839	chr5:131175258	G/A	cg06307176	chr5:131281290	NA	0.52	4.54	0.35	1.13e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.85	-8.79	-0.58	3.06e-15	Body mass index;
PAAD	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg04717802	chr22:42394638	WBP2NL	0.42	4.64	0.35	7.37e-6	Intelligence;
PAAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg05861140	chr6:150128134	PCMT1	0.52	5.78	0.42	4.14e-8	Lung cancer;
PAAD	cis	rs3106136	0.586	rs72663802	chr4:95086438	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-4.98	-0.37	1.69e-6	Capecitabine sensitivity;
PAAD	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg16589663	chr20:23618590	CST3	0.79	6.85	0.49	1.75e-10	Chronic kidney disease;
PAAD	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.43	-4.27	-0.33	3.37e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg08175591	chr14:101176152	NA	0.41	4.99	0.38	1.6e-6	Platelet count;
PAAD	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.62	-6.13	-0.45	7.25e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11563648	0.553	rs10249166	chr7:127016155	G/C	cg21885361	chr7:127911034	NA	-0.39	-4.27	-0.33	3.43e-5	Resting heart rate;
PAAD	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.41	4.42	0.34	1.85e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.8	5.76	0.42	4.43e-8	Alzheimer's disease;
PAAD	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs6460942	0.597	rs17448913	chr7:12533984	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.62	-5.48	-0.41	1.72e-7	Type 2 diabetes;
PAAD	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg21937377	chr3:194868750	C3orf21	0.52	4.92	0.37	2.22e-6	Non-small cell lung cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17575811	chr11:2466409	KCNQ1	0.6	6.32	0.46	2.8e-9	Myopia (pathological);
PAAD	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-9.72	-0.62	1.17e-17	Total body bone mineral density;
PAAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02071572	chr4:1403502	NA	-0.48	-6.1	-0.44	8.51e-9	Obesity-related traits;
PAAD	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg16898833	chr6:26189333	HIST1H4D	0.99	4.92	0.37	2.26e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.97	-0.44	1.57e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg07913137	chr13:60587694	DIAPH3	-0.56	-6.47	-0.46	1.24e-9	Energy expenditure (24h);
PAAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg07336987	chr11:625147	MUPCDH	-0.38	-4.72	-0.36	5.23e-6	Systemic lupus erythematosus;
PAAD	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg00571178	chr13:114841904	RASA3	-0.55	-4.77	-0.36	4.27e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.57	7.67	0.53	1.96e-12	Renal cell carcinoma;
PAAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.66	-0.48	4.61e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg25753631	chr6:25732923	NA	-0.49	-5.55	-0.41	1.26e-7	Iron status biomarkers;
PAAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg09877947	chr5:131593287	PDLIM4	0.58	5.29	0.39	4.24e-7	Acylcarnitine levels;
PAAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00166722	chr3:10149974	C3orf24	0.79	5.85	0.43	2.92e-8	Alzheimer's disease;
PAAD	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.56	5.51	0.41	1.51e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.59	6.71	0.48	3.6e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.42	9.7	0.62	1.27e-17	Prostate cancer;
PAAD	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.66	-7.64	-0.53	2.26e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg23759393	chr7:158110405	PTPRN2	0.37	4.48	0.34	1.48e-5	Response to amphetamines;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs787274	0.867	rs787269	chr9:115548676	T/C	cg13803584	chr9:115635662	SNX30	-0.99	-6.54	-0.47	8.98e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	4.97	0.37	1.78e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg09659197	chr4:152720779	NA	-0.36	-5.28	-0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12773846	0.537	rs35174510	chr10:126278913	C/T	cg04949429	chr10:126290192	LHPP	0.64	5.16	0.39	7.48e-7	Subcutaneous adipose tissue;
PAAD	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs6594713	0.842	rs1602862	chr5:112686942	T/C	cg12552261	chr5:112820674	MCC	0.66	5.06	0.38	1.19e-6	Brain cytoarchitecture;
PAAD	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs7711186	0.786	rs7715291	chr5:178025152	C/T	cg07427642	chr5:177944298	COL23A1	0.65	4.3	0.33	3.09e-5	Urate levels in obese individuals;
PAAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24326267	chr20:61435985	OGFR	0.71	7.05	0.5	5.96e-11	Obesity-related traits;
PAAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.59	-5.19	-0.39	6.75e-7	Obesity-related traits;
PAAD	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg07384165	chr1:10488281	NA	-0.52	-5.11	-0.38	9.47e-7	Prostate cancer;
PAAD	cis	rs656900	0.647	rs898436	chr15:80117132	C/T	cg02196730	chr15:80188777	MTHFS	-0.42	-4.52	-0.34	1.25e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg09796270	chr17:17721594	SREBF1	0.43	4.63	0.35	7.89e-6	Total body bone mineral density;
PAAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.09	-0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg24519413	chr1:26490540	NA	0.46	5.73	0.42	5.14e-8	Height;
PAAD	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.72	7.7	0.53	1.65e-12	Cognitive test performance;
PAAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.46	5.91	0.43	2.21e-8	Ulcerative colitis;
PAAD	cis	rs593531	0.614	rs655719	chr11:74042241	A/G	cg15670924	chr11:73669256	DNAJB13	-0.45	-4.57	-0.35	1.01e-5	Neuroticism;
PAAD	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg18833306	chr6:118973337	C6orf204	0.43	4.46	0.34	1.6e-5	Electrocardiographic conduction measures;
PAAD	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs11807834	0.522	rs1998068	chr1:230238063	C/G	cg00566187	chr1:230250356	GALNT2	-0.63	-6.59	-0.47	6.94e-10	Schizophrenia;
PAAD	cis	rs8083432	0.866	rs4315417	chr18:22706783	A/G	cg13981356	chr18:22006370	IMPACT	0.58	4.33	0.33	2.66e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14282207	chr12:97313586	NEDD1	0.52	6.39	0.46	1.94e-9	Smoking initiation;
PAAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg14580859	chr9:123691850	NA	0.39	4.55	0.35	1.1e-5	Rheumatoid arthritis;
PAAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.88	6.99	0.49	8.17e-11	Alzheimer's disease;
PAAD	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-7.43	-0.52	7.22e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.05	-0.44	1.09e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.47	-4.27	-0.33	3.43e-5	Schizophrenia;
PAAD	cis	rs427941	0.610	rs201489	chr7:101749901	C/T	cg06246474	chr7:101738831	CUX1	0.44	4.44	0.34	1.7e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.54	0.47	8.99e-10	Bladder cancer;
PAAD	cis	rs10875746	0.680	rs4760610	chr12:48418225	C/T	cg26205652	chr12:48591994	NA	0.86	8.28	0.56	5.92e-14	Longevity (90 years and older);
PAAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-6.71	-0.48	3.59e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs11235843	0.706	rs10898949	chr11:73581672	C/T	cg18195628	chr11:73498948	MRPL48	-0.82	-4.85	-0.37	3.09e-6	Hand grip strength;
PAAD	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs7172677	1.000	rs1806794	chr15:75422940	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.52	-0.34	1.22e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	5.44	0.4	2.04e-7	Lung cancer in ever smokers;
PAAD	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.51	-4.59	-0.35	9.3e-6	Neuroticism;
PAAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.63	7.16	0.5	3.18e-11	Emphysema distribution in smoking;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg00933542	chr6:150070202	PCMT1	0.54	5.4	0.4	2.54e-7	Lung cancer;
PAAD	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg22143635	chr11:980567	AP2A2	0.52	5.43	0.4	2.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.58	6.35	0.46	2.32e-9	Mean corpuscular volume;
PAAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.29	0.33	3.22e-5	Menarche (age at onset);
PAAD	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.93e-7	Motion sickness;
PAAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg06131755	chr6:160182447	ACAT2	0.57	5.06	0.38	1.18e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs797680	0.964	rs4000699	chr1:93779805	C/T	cg04535902	chr1:92947332	GFI1	0.46	4.46	0.34	1.58e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs10982213	1.000	rs10759698	chr9:117174781	G/A	cg00078025	chr9:117159975	NA	0.58	4.29	0.33	3.2e-5	Interleukin-6 levels;
PAAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.55	-7.2	-0.5	2.53e-11	Height;
PAAD	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg23939001	chr4:940644	TMEM175	0.83	10.23	0.64	5.19e-19	Sjögren's syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12433217	chr1:25758112	TMEM57	0.61	6.31	0.46	2.85e-9	Myopia (pathological);
PAAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg03983715	chr16:68378420	PRMT7	-0.71	-5.03	-0.38	1.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.86	-8.11	-0.55	1.61e-13	Colorectal adenoma (advanced);
PAAD	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg17201900	chr20:34330562	RBM39	0.62	4.28	0.33	3.27e-5	Total cholesterol levels;
PAAD	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.76	6.06	0.44	1.01e-8	Neutrophil percentage of white cells;
PAAD	cis	rs527409	1.000	rs78732889	chr1:58721806	C/T	cg26513689	chr1:58717632	DAB1	0.71	4.28	0.33	3.23e-5	Kawasaki disease;
PAAD	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05208423	chr11:13689596	FAR1	0.62	6.97	0.49	8.88e-11	Monocyte percentage of white cells;
PAAD	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.55	5.89	0.43	2.35e-8	Pancreatic cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg00776119	chr14:31494616	AP4S1;STRN3	-0.74	-7.1	-0.5	4.56e-11	Neuroticism;
PAAD	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg07648498	chr16:89883185	FANCA	0.46	4.34	0.33	2.56e-5	Vitiligo;
PAAD	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.41	5.16	0.39	7.52e-7	Corneal astigmatism;
PAAD	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg12757816	chr2:10669957	NA	-0.44	-4.53	-0.34	1.19e-5	Prostate cancer;
PAAD	cis	rs12044355	0.865	rs1340982	chr1:231862032	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	4.64	0.35	7.47e-6	Alzheimer's disease;
PAAD	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg08501292	chr6:25962987	TRIM38	0.55	4.3	0.33	3.01e-5	Homocysteine levels;
PAAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11467738	chr7:98972733	ARPC1B	0.63	7.13	0.5	3.8e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.3e-6	Neuroticism;
PAAD	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.01	0.38	1.48e-6	Axial length;
PAAD	cis	rs3136739	0.614	rs3827659	chr8:42025838	T/C	cg12054981	chr8:42037387	PLAT	0.75	5.5	0.41	1.58e-7	Plasma plasminogen activator levels;
PAAD	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.62	-5.89	-0.43	2.44e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs757081	0.547	rs11024220	chr11:17274534	G/A	cg04705435	chr11:17411270	KCNJ11	-0.55	-5.49	-0.41	1.63e-7	Systolic blood pressure;
PAAD	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg11262906	chr1:85462892	MCOLN2	0.62	4.96	0.37	1.84e-6	Serum sulfate level;
PAAD	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg26876637	chr1:152193138	HRNR	-0.79	-5.29	-0.39	4.21e-7	Atopic dermatitis;
PAAD	cis	rs58521262	0.585	rs289287	chr19:23181247	C/T	cg02350677	chr19:23254381	NA	0.26	4.47	0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.25e-6	Age of smoking initiation;
PAAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.89	9.72	0.62	1.16e-17	Cognitive function;
PAAD	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.94	-9.87	-0.63	4.55e-18	Response to antineoplastic agents;
PAAD	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.49	-4.96	-0.37	1.88e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7552393	0.622	rs12134669	chr1:84310193	A/C	cg10977910	chr1:84465055	TTLL7	-0.53	-4.74	-0.36	4.92e-6	Select biomarker traits;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg02493798	chr17:6899577	ALOX12	0.43	4.38	0.34	2.16e-5	Tonsillectomy;
PAAD	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg02367144	chr2:237146137	ASB18	0.42	5.42	0.4	2.24e-7	Educational attainment;
PAAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.75	7.5	0.52	5e-12	Tonsillectomy;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01744160	chr15:83680526	C15orf40	0.7	6.31	0.46	2.97e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg14583973	chr4:3374767	RGS12	0.33	4.71	0.36	5.58e-6	Mean platelet volume;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.73	7.34	0.51	1.2e-11	Lung cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04987827	chr17:66508605	PRKAR1A	-0.71	-6.31	-0.46	2.88e-9	Neuroticism;
PAAD	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg23018236	chr17:30244563	NA	-0.6	-4.52	-0.34	1.26e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs901683	1.000	rs35968565	chr10:46076196	G/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.67	4.91	0.37	2.36e-6	Vitiligo;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.45	5.55	0.41	1.25e-7	Iron status biomarkers;
PAAD	cis	rs758324	0.812	rs9327621	chr5:131118943	T/C	cg06307176	chr5:131281290	NA	0.49	4.32	0.33	2.79e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.9	-0.43	2.29e-8	Morning vs. evening chronotype;
PAAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.94	16.6	0.8	5.75e-36	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-5.95	-0.43	1.78e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg23033748	chr14:75592666	NEK9	-0.39	-4.8	-0.36	3.8e-6	Height;
PAAD	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg23815491	chr16:72088622	HP	0.4	4.43	0.34	1.82e-5	Fibrinogen levels;
PAAD	cis	rs3996993	0.737	rs2397105	chr6:52653324	G/A	cg20803780	chr6:52668592	GSTA1	-0.36	-4.45	-0.34	1.62e-5	Hemoglobin concentration;
PAAD	cis	rs11585357	0.501	rs4262593	chr1:17594263	T/C	cg08277548	chr1:17600880	PADI3	-0.91	-6.73	-0.48	3.24e-10	Hair shape;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.59	6.2	0.45	5.17e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1830074	1	rs1830074	chr7:6718674	T/C	cg09382002	chr7:6590564	GRID2IP	0.45	4.67	0.35	6.6e-6	Body mass index;
PAAD	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg21589280	chr1:85930151	DDAH1	0.56	4.28	0.33	3.32e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	4.81	0.36	3.55e-6	Multiple sclerosis;
PAAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg04520793	chr17:42248056	ASB16	-0.44	-5.88	-0.43	2.54e-8	Total body bone mineral density;
PAAD	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg06740227	chr12:86229804	RASSF9	-0.55	-5.27	-0.39	4.57e-7	Major depressive disorder;
PAAD	cis	rs7301016	0.817	rs7302456	chr12:62997643	G/T	cg19781863	chr12:62918364	MON2	0.75	4.32	0.33	2.77e-5	IgG glycosylation;
PAAD	cis	rs3812111	0.545	rs1931895	chr6:116572971	C/G	cg18764771	chr6:116381957	FRK	-0.27	-4.29	-0.33	3.22e-5	Age-related macular degeneration;
PAAD	cis	rs11076805	0.510	rs407642	chr16:4152318	C/G	cg01959050	chr16:4170088	NA	-0.53	-5.19	-0.39	6.69e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	4.82	0.36	3.45e-6	Mood instability;
PAAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.52	4.98	0.37	1.71e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg13206674	chr6:150067644	NUP43	0.61	5.5	0.41	1.56e-7	Lung cancer;
PAAD	trans	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg18543610	chr13:100627929	NA	-0.61	-6.5	-0.47	1.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.6	-6.4	-0.46	1.86e-9	Lewy body disease;
PAAD	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.29	-0.33	3.11e-5	Menarche (age at onset);
PAAD	cis	rs10768122	1.000	rs3794099	chr11:35295360	C/T	cg13971030	chr11:35366721	SLC1A2	0.37	4.51	0.34	1.28e-5	Vitiligo;
PAAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg22143856	chr6:28129313	ZNF389	0.74	5.87	0.43	2.61e-8	Parkinson's disease;
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.06	0.38	1.21e-6	Life satisfaction;
PAAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.71	5.56	0.41	1.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23544223	chr18:12777786	NA	0.65	5.7	0.42	6.05e-8	Inflammatory skin disease;
PAAD	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.92	9.66	0.62	1.65e-17	Nonalcoholic fatty liver disease;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01587190	chr19:45874071	ERCC2	-0.7	-6.79	-0.48	2.41e-10	Lung cancer in ever smokers;
PAAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.63	-8.04	-0.55	2.31e-13	Body mass index;
PAAD	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg12193833	chr17:30244370	NA	-0.63	-5.11	-0.38	9.57e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.43	-4.35	-0.33	2.47e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1497828	0.956	rs2810780	chr1:217543521	T/C	cg04411442	chr1:217543379	NA	0.48	4.73	0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.39	0.46	1.93e-9	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.97	0.54	3.5e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.78	-0.36	4.17e-6	Lung cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg25998860	chr5:126853954	PRRC1	0.64	7.48	0.52	5.66e-12	Metabolite levels  (X-11787);
PAAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.5	-4.96	-0.37	1.9e-6	Multiple sclerosis;
PAAD	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06850241	chr22:41845214	NA	-0.52	-4.9	-0.37	2.4e-6	Vitiligo;
PAAD	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.66	-7.3	-0.51	1.49e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg06606381	chr12:133084897	FBRSL1	-1.15	-6.38	-0.46	2.01e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-6.61	-0.47	6.29e-10	Homocysteine levels;
PAAD	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17347941	chr15:79387269	NA	-0.39	-4.33	-0.33	2.66e-5	Refractive error;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23069444	chr2:85839322	C2orf68	0.67	6.8	0.48	2.24e-10	Obesity-related traits;
PAAD	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg08501292	chr6:25962987	TRIM38	0.77	4.36	0.33	2.34e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19882132	chr14:106167949	NA	-0.53	-4.47	-0.34	1.51e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.74	7.72	0.53	1.44e-12	Mortality in heart failure;
PAAD	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg10483660	chr13:112241077	NA	0.53	4.84	0.37	3.22e-6	Menarche (age at onset);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.7	0.62	1.25e-17	Prudent dietary pattern;
PAAD	cis	rs10982213	1.000	rs3748175	chr9:117180005	C/T	cg00078025	chr9:117159975	NA	0.61	4.62	0.35	8.22e-6	Interleukin-6 levels;
PAAD	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.76	9.23	0.6	2.18e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg16584676	chr17:46985605	UBE2Z	0.56	5.55	0.41	1.22e-7	Coronary heart disease;
PAAD	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	4.45	0.34	1.68e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17972094	chr2:88355304	KRCC1	-0.65	-6.38	-0.46	2.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.44	-0.34	1.73e-5	Iron status biomarkers;
PAAD	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.95	10.51	0.65	9e-20	Obesity;Body mass index;
PAAD	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-4.97	-0.37	1.81e-6	Parkinson's disease;
PAAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.55	-0.41	1.24e-7	Lung cancer;
PAAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	5.92	0.43	2.04e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.93	10.02	0.63	1.82e-18	Testicular germ cell tumor;
PAAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.97	11.12	0.67	2.2e-21	Parkinson's disease;
PAAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-1.04	-14.62	-0.76	8.81e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.49	5.05	0.38	1.28e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06287708	chr2:179345168	MIR548N;PLEKHA3	-0.67	-7.15	-0.5	3.49e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.61	6.06	0.44	1.04e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.63	-0.35	7.64e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10861342	0.892	rs77479670	chr12:105516631	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	4.35	0.33	2.5e-5	IgG glycosylation;
PAAD	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.64	-5.54	-0.41	1.3e-7	Lung cancer;
PAAD	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg20169779	chr10:135381914	SYCE1	-0.46	-4.77	-0.36	4.24e-6	Obesity-related traits;
PAAD	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.6	6.05	0.44	1.07e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.68	7.16	0.5	3.26e-11	IgG glycosylation;
PAAD	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg03098721	chr1:84464084	TTLL7	0.46	4.27	0.33	3.47e-5	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21083161	chr7:6388591	C7orf70	0.61	6.66	0.48	4.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs72848980	0.706	rs12261058	chr10:105323948	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.57	4.83	0.36	3.27e-6	White matter hyperintensity burden;
PAAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.42	-5.15	-0.39	7.8e-7	Iron status biomarkers;
PAAD	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	4.31	0.33	2.98e-5	Breast cancer;
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs16958440	0.867	rs12326412	chr18:44683594	A/C	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20770540	chr3:123304003	PTPLB	-0.56	-6.67	-0.48	4.41e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.31e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.81	4.91	0.37	2.28e-6	Obesity-related traits;
PAAD	cis	rs7264396	0.887	rs6060431	chr20:34059337	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg09659197	chr4:152720779	NA	0.46	6.14	0.45	6.92e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.7	4.95	0.37	1.91e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg03277515	chr1:153321198	PGLYRP4	0.42	5.01	0.38	1.52e-6	Psoriasis;
PAAD	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	1.02	12.83	0.72	5.47e-26	Breast cancer;
PAAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg07362569	chr17:61921086	SMARCD2	0.43	4.86	0.37	2.88e-6	Height;
PAAD	cis	rs1572438	0.760	rs7740748	chr6:869509	T/C	cg13447295	chr6:887704	NA	-0.54	-5.3	-0.39	4e-7	Aging;
PAAD	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg17644776	chr2:200775616	C2orf69	-0.65	-5.16	-0.39	7.61e-7	Schizophrenia;
PAAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg21130718	chr4:1044621	NA	-0.56	-4.82	-0.36	3.52e-6	Recombination rate (females);
PAAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg02117656	chr17:79614917	TSPAN10	0.58	6.21	0.45	4.72e-9	Eye color traits;
PAAD	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.54	-5.47	-0.41	1.82e-7	Mortality in heart failure;
PAAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg01942863	chr7:99769432	GPC2	0.49	4.51	0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg04398451	chr17:18023971	MYO15A	-0.7	-7.5	-0.52	4.89e-12	Total body bone mineral density;
PAAD	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg23250157	chr14:64679961	SYNE2	0.56	5.66	0.42	7.3900000000000007e-08	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs12431939	0.857	rs6572737	chr14:51697392	C/A	cg23942311	chr14:51606299	NA	-0.66	-5.21	-0.39	6.13e-7	Cancer;
PAAD	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.78	-0.42	4.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.62	6.08	0.44	9.22e-9	Tonsillectomy;
PAAD	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg01059385	chr22:42394853	WBP2NL	0.47	5.15	0.39	8.06e-7	Intelligence;
PAAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.76	-6.69	-0.48	4.02e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9372253	0.509	rs2057149	chr6:110717493	C/T	cg01119278	chr6:110721349	DDO	-0.55	-5.13	-0.38	8.76e-7	Platelet distribution width;
PAAD	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg24747557	chr10:131355152	MGMT	-0.48	-5.01	-0.38	1.48e-6	Response to temozolomide;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08805662	chr2:70369329	NA	0.57	6.52	0.47	9.94e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.99	0.49	8.02e-11	Rheumatoid arthritis;
PAAD	cis	rs617219	0.698	rs72764983	chr5:78513806	T/C	cg24856658	chr5:78533917	JMY	-0.38	-4.34	-0.33	2.57e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	5.85	0.43	2.92e-8	Monocyte count;
PAAD	cis	rs9815354	0.951	rs1717028	chr3:41902964	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.96	0.44	1.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.5	5.1	0.38	1e-6	Height;
PAAD	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.9	5.02	0.38	1.42e-6	Type 2 diabetes nephropathy;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-4.71	-0.36	5.54e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.88	-10.06	-0.63	1.44e-18	Morning vs. evening chronotype;
PAAD	cis	rs10768122	1.000	rs10836360	chr11:35289240	C/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.27	-0.33	3.48e-5	Vitiligo;
PAAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg07148914	chr20:33460835	GGT7	0.47	4.63	0.35	7.95e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs4253772	0.626	rs9627428	chr22:46765823	G/C	cg09491104	chr22:46646882	C22orf40	-1.12	-6.9	-0.49	1.29e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-1.03	-10.88	-0.66	9.73e-21	Platelet distribution width;
PAAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.57	0.47	7.39e-10	Tonsillectomy;
PAAD	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.71	6.1	0.44	8.27e-9	Exhaled nitric oxide levels;
PAAD	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.48	5.13	0.38	8.61e-7	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg03885332	chr11:832357	CD151	-0.45	-5.28	-0.39	4.31e-7	Mean platelet volume;
PAAD	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.42	-0.34	1.86e-5	Tuberculosis;
PAAD	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.79	5.61	0.41	9.33e-8	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs901683	1.000	rs71496606	chr10:46010098	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.78	0.48	2.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.54	-5.94	-0.43	1.83e-8	Body mass index;
PAAD	cis	rs2964802	0.505	rs4314375	chr5:10803435	C/T	cg14521931	chr5:10832172	NA	0.47	4.76	0.36	4.43e-6	Major depressive disorder;Recurrent major depressive disorder;
PAAD	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg27335600	chr3:53528857	CACNA1D	-0.4	-4.35	-0.33	2.52e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.9	-7.39	-0.51	8.88e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.52	4.48	0.34	1.43e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.73	6.98	0.49	8.38e-11	Coronary artery disease;
PAAD	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.7	-7.69	-0.53	1.73e-12	Alcohol dependence;
PAAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.88	-10.46	-0.65	1.26e-19	Menarche (age at onset);
PAAD	cis	rs4708832	0.529	rs240862	chr6:159916242	T/C	cg04088182	chr6:159188303	EZR	-0.61	-4.4	-0.34	1.99e-5	QRS duration;
PAAD	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.51	-5.02	-0.38	1.43e-6	Malaria;
PAAD	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg15123519	chr2:136567270	LCT	-0.39	-4.66	-0.35	6.86e-6	Mosquito bite size;
PAAD	cis	rs2030114	0.948	rs10521235	chr16:51607000	C/T	cg03758633	chr16:51611768	NA	0.6	4.95	0.37	1.99e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.65	-10.0	-0.63	2.07e-18	Asthma (sex interaction);
PAAD	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	1.26	13.06	0.73	1.29e-26	Post bronchodilator FEV1;
PAAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.56	-8.33	-0.56	4.44e-14	Hypertriglyceridemia;
PAAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.66	-5.46	-0.41	1.87e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.44	4.51	0.34	1.29e-5	Longevity;Endometriosis;
PAAD	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.39	-5.03	-0.38	1.36e-6	Prostate cancer;
PAAD	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.45	4.49	0.34	1.41e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	6.85	0.49	1.7e-10	Total body bone mineral density;
PAAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24537038	chr9:99213506	HABP4	0.59	6.43	0.46	1.58e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.34	4.89	0.37	2.57e-6	Migraine;
PAAD	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.6e-7	Type 2 diabetes;
PAAD	cis	rs2736340	0.539	rs11250138	chr8:11323312	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.26	-0.33	3.55e-5	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
PAAD	cis	rs8181588	1.000	rs2074197	chr11:2825279	C/T	cg10890346	chr11:2207660	NA	0.72	4.81	0.36	3.6e-6	Type 2 diabetes;
PAAD	cis	rs1468333	0.582	rs13154749	chr5:137573519	C/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.58	4.91	0.37	2.33e-6	Resting heart rate;
PAAD	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-11.05	-0.67	3.36e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.48	5.04	0.38	1.33e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.55	-4.55	-0.35	1.1e-5	Facial morphology (factor 19);
PAAD	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.77	8.84	0.58	2.25e-15	Blood metabolite ratios;
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg00280220	chr17:61926910	NA	0.44	4.62	0.35	8.01e-6	Prudent dietary pattern;
PAAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.58	-5.5	-0.41	1.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.75	0.36	4.75e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16586970	chr2:3391459	TTC15	-0.65	-6.37	-0.46	2.1e-9	Obesity-related traits;
PAAD	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.84	9.42	0.61	7.08e-17	Schizophrenia;
PAAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg00105475	chr2:10696890	NA	-0.73	-8.48	-0.57	1.87e-14	Prostate cancer;
PAAD	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	7.07	0.5	5.36e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.68	8.95	0.59	1.19e-15	Hemoglobin concentration;
PAAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.92	7.76	0.53	1.15e-12	Alzheimer's disease;
PAAD	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.58	4.83	0.36	3.35e-6	Morning vs. evening chronotype;
PAAD	cis	rs10774547	0.965	rs7970534	chr12:120862195	G/C	cg10072921	chr12:121022843	NA	-0.35	-4.3	-0.33	3.03e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
PAAD	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg04454285	chr16:86016317	NA	0.58	5.02	0.38	1.44e-6	Multiple sclerosis;
PAAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg20406979	chr6:167373233	NA	-0.37	-5.09	-0.38	1.05e-6	Crohn's disease;
PAAD	cis	rs2227631	1.000	rs2227631	chr7:100769538	A/G	cg08053846	chr7:100769605	SERPINE1	-0.49	-5.93	-0.43	1.94e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs1519814	1.000	rs10104973	chr8:121104385	C/T	cg22335954	chr8:121166405	COL14A1	-0.63	-5.42	-0.4	2.32e-7	Breast cancer;
PAAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.51	4.83	0.36	3.31e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.36	4.42	0.34	1.85e-5	Menarche (age at onset);
PAAD	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6137287	0.924	rs6047277	chr20:21137558	A/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.58	0.35	9.67e-6	Height;
PAAD	cis	rs12311304	0.965	rs58368403	chr12:15359047	C/A	cg08258403	chr12:15378311	NA	0.34	4.41	0.34	1.96e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	11.21	0.67	1.21e-21	Total body bone mineral density;
PAAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.48	-0.41	1.69e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.98	12.15	0.7	3.73e-24	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.92	12.73	0.72	9.99e-26	Height;
PAAD	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg10290764	chr8:4849399	CSMD1	-0.38	-6.32	-0.46	2.78e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.09e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg24331049	chr13:111365604	ING1	-0.82	-4.41	-0.34	1.93e-5	Coronary artery disease;
PAAD	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.54	-4.91	-0.37	2.37e-6	Testicular germ cell tumor;
PAAD	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.55	-0.35	1.08e-5	Rheumatoid arthritis;
PAAD	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg07362569	chr17:61921086	SMARCD2	-0.46	-5.2	-0.39	6.29e-7	Prudent dietary pattern;
PAAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.72	6.23	0.45	4.42e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.75	8.72	0.58	4.47e-15	Lung cancer;
PAAD	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg21191810	chr6:118973309	C6orf204	0.48	6.18	0.45	5.71e-9	Electrocardiographic conduction measures;
PAAD	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.25	-0.33	3.68e-5	Mean corpuscular volume;
PAAD	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg09654669	chr8:57350985	NA	-0.52	-4.38	-0.33	2.21e-5	Obesity-related traits;
PAAD	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.13e-9	Educational attainment;
PAAD	cis	rs8077577	0.747	rs11868708	chr17:18244613	T/C	cg16794390	chr17:18148240	FLII	0.5	4.3	0.33	3.04e-5	Obesity-related traits;
PAAD	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg09915299	chr4:38666663	FLJ13197;KLF3	0.4	4.26	0.33	3.64e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.68	6.92	0.49	1.2e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg18884388	chr7:190334	NA	0.52	4.28	0.33	3.35e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs16975963	0.644	rs11083427	chr19:38074152	G/T	cg14218481	chr19:38281219	NA	0.42	4.52	0.34	1.25e-5	Longevity;
PAAD	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg22990158	chr14:24802150	ADCY4	-0.48	-5.17	-0.39	7.21e-7	Height;
PAAD	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.62	-0.35	7.98e-6	Height;
PAAD	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.45	5.83	0.43	3.26e-8	Renal cell carcinoma;
PAAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg02734326	chr4:10020555	SLC2A9	0.45	4.57	0.35	9.87e-6	Bone mineral density;
PAAD	cis	rs7182948	0.874	rs17404262	chr15:49967619	A/G	cg23441248	chr15:50140549	NA	0.39	4.37	0.33	2.3e-5	Lung adenocarcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15137643	chr11:78612545	ODZ4	-0.65	-6.5	-0.47	1.11e-9	Obesity-related traits;
PAAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg00484396	chr16:3507460	NAT15	-0.83	-5.29	-0.39	4.18e-7	Tuberculosis;
PAAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-5.97	-0.44	1.65e-8	Total body bone mineral density;
PAAD	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg05025164	chr4:1340916	KIAA1530	0.59	6.21	0.45	4.9e-9	Obesity-related traits;
PAAD	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.59	4.9	0.37	2.43e-6	Response to diuretic therapy;
PAAD	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.43	-4.51	-0.34	1.27e-5	Sense of smell;
PAAD	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg06917634	chr15:78832804	PSMA4	0.46	4.48	0.34	1.45e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.27	-0.39	4.5e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.34	12.41	0.71	7.05e-25	Corneal structure;
PAAD	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs1198872	0.812	rs1198867	chr2:10902407	A/G	cg07921008	chr2:10924176	ATP6V1C2;PDIA6	0.44	4.27	0.33	3.49e-5	Cardiac Troponin-T levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04919944	chr15:28520031	HERC2	-0.6	-6.45	-0.46	1.41e-9	Myopia (pathological);
PAAD	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-5.28	-0.39	4.32e-7	Systemic lupus erythematosus;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16779626	chr15:41709933	RTF1	0.65	7.69	0.53	1.68e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.59	5.09	0.38	1.02e-6	Type 2 diabetes;
PAAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg09376583	chr16:88111425	NA	-0.48	-4.3	-0.33	3.02e-5	Menopause (age at onset);
PAAD	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.9	0.37	2.44e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	5.47	0.41	1.85e-7	Lung cancer in ever smokers;
PAAD	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.63	-4.77	-0.36	4.24e-6	Coronary artery disease;
PAAD	cis	rs2275731	0.723	rs10508513	chr10:16548314	C/G	cg04254609	chr10:16479192	PTER	-0.41	-4.28	-0.33	3.26e-5	Bone fracture in osteoporosis;
PAAD	cis	rs617219	0.710	rs10474578	chr5:78542290	T/C	cg24856658	chr5:78533917	JMY	-0.4	-4.38	-0.33	2.17e-5	Betaine levels in individuals undergoing cardiac evaluation;
PAAD	cis	rs8099014	0.861	rs4940709	chr18:56134792	G/A	cg12907477	chr18:56117327	MIR122	0.62	4.77	0.36	4.34e-6	Platelet count;
PAAD	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.52	0.65	8.72e-20	Smoking behavior;
PAAD	cis	rs1943345	0.536	rs12269817	chr11:82858667	T/C	cg07047830	chr11:82868014	PCF11	0.75	8.51	0.57	1.57e-14	Obesity-related traits;
PAAD	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg24747557	chr10:131355152	MGMT	-0.42	-4.31	-0.33	2.93e-5	Response to temozolomide;
PAAD	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.63	6.21	0.45	4.93e-9	Bone properties (heel);
PAAD	cis	rs2415984	0.579	rs10151988	chr14:46955203	C/T	cg14871534	chr14:47121158	RPL10L	-0.48	-4.94	-0.37	2.03e-6	Number of children ever born;
PAAD	cis	rs17154702	0.506	rs2427	chr8:8641125	A/G	cg01851573	chr8:8652454	MFHAS1	-0.9	-6.23	-0.45	4.28e-9	Neurocognitive impairment in HIV-1 infection (continuous);
PAAD	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg18833306	chr6:118973337	C6orf204	0.42	4.28	0.33	3.32e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg23912435	chr1:150601613	ENSA	-0.51	-4.74	-0.36	4.79e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1448094	0.617	rs1354258	chr12:86485647	C/T	cg06740227	chr12:86229804	RASSF9	-0.53	-4.79	-0.36	3.91e-6	Major depressive disorder;
PAAD	cis	rs501120	0.564	rs2624681	chr10:44677301	G/C	cg09554077	chr10:44749378	NA	0.46	5.78	0.42	4.1e-8	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg26022315	chr17:47021804	SNF8	0.44	4.59	0.35	9.31e-6	Type 2 diabetes;
PAAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.74	-8.88	-0.58	1.74e-15	Childhood ear infection;
PAAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-7.68	-0.53	1.82e-12	Bipolar disorder and schizophrenia;
PAAD	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02071572	chr4:1403502	NA	0.38	4.87	0.37	2.8e-6	Longevity;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.69	7.6	0.52	2.79e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg22467129	chr15:76604101	ETFA	-0.52	-4.94	-0.37	2.08e-6	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg00945038	chr17:61921165	SMARCD2	0.47	5.61	0.41	9.34e-8	Prudent dietary pattern;
PAAD	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg10072921	chr12:121022843	NA	-0.37	-4.99	-0.38	1.65e-6	High light scatter reticulocyte count;
PAAD	cis	rs12935418	0.616	rs2549828	chr16:81018983	T/C	cg16651780	chr16:81037892	C16orf61	-0.64	-6.01	-0.44	1.33e-8	Mean corpuscular volume;
PAAD	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.53	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.58	6.01	0.44	1.31e-8	Testicular germ cell tumor;
PAAD	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.85	7.72	0.53	1.46e-12	Eosinophil percentage of granulocytes;
PAAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.49	-4.65	-0.35	7.02e-6	Menarche (age at onset);
PAAD	cis	rs7960581	0.585	rs79232389	chr12:99171092	A/T	cg17109042	chr12:99139387	ANKS1B	-0.67	-4.49	-0.34	1.42e-5	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg11062466	chr8:58055876	NA	0.69	5.14	0.38	8.22e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg00579200	chr11:133705235	NA	-0.46	-5.05	-0.38	1.25e-6	Childhood ear infection;
PAAD	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.51	-5.92	-0.43	2.05e-8	Coronary artery disease;
PAAD	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg25364880	chr3:44379878	C3orf23	0.55	5.46	0.4	1.93e-7	Depressive symptoms;
PAAD	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.54	-8.51	-0.57	1.56e-14	Urinary metabolites;
PAAD	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.93	14.21	0.76	1.1e-29	Alcohol dependence;
PAAD	cis	rs6137287	0.807	rs2328607	chr20:21121208	A/T	cg04219410	chr20:21106687	PLK1S1	0.38	4.38	0.33	2.19e-5	Height;
PAAD	cis	rs8112211	0.599	rs11669131	chr19:38830966	T/C	cg01275006	chr19:38876250	GGN	-0.97	-6.05	-0.44	1.06e-8	Blood protein levels;
PAAD	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.85	-7.43	-0.52	7.36e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	12.41	0.71	7.13e-25	Cognitive ability;
PAAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.42	0.4	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs501120	0.733	rs587375	chr10:44745808	T/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg24220031	chr2:73402428	NA	-0.35	-5.39	-0.4	2.62e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg25401027	chr5:176370377	UIMC1	0.55	5.41	0.4	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.37	4.42	0.34	1.86e-5	Schizophrenia;
PAAD	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg00717180	chr2:96193071	NA	0.57	6.37	0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs72843506	0.656	rs78325601	chr17:19921799	G/A	cg05625806	chr17:19284432	MAPK7	0.67	4.35	0.33	2.47e-5	Schizophrenia;
PAAD	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.7	-4.41	-0.34	1.94e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	1.11	9.4	0.61	7.77e-17	Vitiligo;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg00049323	chr5:472564	LOC25845	-0.42	-4.31	-0.33	2.95e-5	Cystic fibrosis severity;
PAAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.77	9.49	0.61	4.52e-17	Height;
PAAD	cis	rs13053817	1.000	rs13053817	chr22:29847722	A/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.55	4.82	0.36	3.49e-6	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg09796270	chr17:17721594	SREBF1	0.44	4.7	0.36	5.75e-6	Total body bone mineral density;
PAAD	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.31	0.33	2.92e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.68	7.26	0.51	1.91e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.63	-4.89	-0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.86	10.3	0.64	3.31e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15541040	chr2:3486749	NA	-0.74	-7.87	-0.54	6.33e-13	Neurofibrillary tangles;
PAAD	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24569637	chr2:201450560	AOX1	-0.58	-6.7	-0.48	3.81e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.39	-0.4	2.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.41	-0.34	1.99e-5	Menarche (age at onset);
PAAD	cis	rs1879734	0.689	rs11206201	chr1:54170963	C/A	cg14659662	chr1:54151053	GLIS1	-0.44	-5.93	-0.43	1.96e-8	Mitral valve prolapse;
PAAD	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.8	-0.43	3.7e-8	Eye color traits;
PAAD	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.66	-4.59	-0.35	9.06e-6	LDL cholesterol levels;
PAAD	cis	rs9815354	0.951	rs55835726	chr3:41763049	C/T	cg03022575	chr3:42003672	ULK4	0.83	5.81	0.43	3.55e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2271400	0.556	rs7835311	chr8:56648487	T/C	cg08894788	chr8:56792171	LYN	-0.49	-4.54	-0.35	1.14e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
PAAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.46	6.32	0.46	2.69e-9	Cardiovascular disease risk factors;
PAAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg16928487	chr17:17741425	SREBF1	-0.34	-4.66	-0.35	6.86e-6	Total body bone mineral density;
PAAD	cis	rs17169635	0.836	rs3800735	chr7:134536969	A/G	cg02516134	chr7:134575187	CALD1	-0.49	-4.75	-0.36	4.69e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs13102973	0.640	rs13113331	chr4:135838729	C/T	cg14419869	chr4:135874104	NA	0.44	4.51	0.34	1.28e-5	Subjective well-being;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.62	4.81	0.36	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.36	15.59	0.78	2.44e-33	Eosinophil percentage of granulocytes;
PAAD	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.33	10.95	0.66	6.13e-21	Uric acid levels;
PAAD	cis	rs2992756	0.663	rs1360916	chr1:18801697	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.4	-4.8	-0.36	3.78e-6	Breast cancer;
PAAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14119001	chr9:139324193	INPP5E	-0.61	-5.49	-0.41	1.68e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs258892	0.843	rs155431	chr5:72120916	A/T	cg21869765	chr5:72125136	TNPO1	-0.76	-4.75	-0.36	4.76e-6	Small cell lung carcinoma;
PAAD	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.9	-10.49	-0.65	1.06e-19	Refractive error;
PAAD	cis	rs1371614	0.523	rs893789	chr2:27183970	C/T	cg00617064	chr2:27272375	NA	-0.48	-5.02	-0.38	1.43e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.54	-0.47	8.84e-10	Morning vs. evening chronotype;
PAAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15433604	chr19:18942513	UPF1	0.63	6.3	0.46	3.06e-9	Obesity-related traits;
PAAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg27113419	chr16:58533979	NDRG4	-0.74	-4.6	-0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.51	-5.08	-0.38	1.07e-6	Ovarian reserve;
PAAD	cis	rs4950928	0.700	rs946263	chr1:203165381	A/G	cg17014757	chr1:203156097	CHI3L1	0.57	5.15	0.39	7.92e-7	YKL-40 levels;
PAAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.56	5.37	0.4	2.94e-7	Resistin levels;
PAAD	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.58	-5.75	-0.42	4.75e-8	Inflammatory bowel disease;
PAAD	cis	rs2637266	0.775	rs2579744	chr10:78311824	A/G	cg18941641	chr10:78392320	NA	0.36	4.29	0.33	3.15e-5	Pulmonary function;
PAAD	cis	rs10823500	0.523	rs12774848	chr10:71932436	T/C	cg02100629	chr10:71892760	AIFM2	-0.45	-5.37	-0.4	2.83e-7	Blood protein levels;
PAAD	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg15696662	chr1:46669221	C1orf190;POMGNT1	0.46	5.6	0.41	9.64e-8	Red blood cell count;Reticulocyte count;
PAAD	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.56	-4.87	-0.37	2.76e-6	Breast cancer;
PAAD	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.8	9.56	0.61	3.01e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg27490568	chr2:178487706	NA	0.9	8.55	0.57	1.23e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12936587	0.576	rs8073975	chr17:17555631	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-5.33	-0.4	3.46e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.68	6.06	0.44	1.04e-8	Obesity-related traits;
PAAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.74	-8.35	-0.56	3.99e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.44	-0.46	1.52e-9	Coffee consumption (cups per day);
PAAD	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg08135965	chr6:41755394	TOMM6	0.49	5.06	0.38	1.22e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.63	5.54	0.41	1.3e-7	Corneal astigmatism;
PAAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.77	-6.71	-0.48	3.62e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-6.64	-0.47	5.16e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7631605	0.905	rs4678940	chr3:37187513	G/A	cg17445812	chr3:36986805	TRANK1	0.33	4.43	0.34	1.8e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	7.19	0.5	2.69e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.63	5.87	0.43	2.67e-8	Red blood cell count;
PAAD	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg10729496	chr3:10149963	C3orf24	0.91	7.49	0.52	5.2e-12	Alzheimer's disease;
PAAD	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	cis	rs6074578	0.648	rs12624954	chr20:139456	G/A	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.0	-0.44	1.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11245990	chr11:68621969	NA	0.4	5.23	0.39	5.49e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.88	11.9	0.69	1.75e-23	Body mass index;
PAAD	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.35	-4.43	-0.34	1.78e-5	Colorectal cancer;
PAAD	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg04896959	chr15:78267971	NA	-0.49	-4.44	-0.34	1.72e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.58	6.23	0.45	4.36e-9	Menopause (age at onset);
PAAD	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.88	-10.78	-0.66	1.78e-20	Bipolar disorder;
PAAD	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg08422745	chr4:174089978	GALNT7	-0.58	-5.5	-0.41	1.6e-7	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg14582100	chr15:45693742	SPATA5L1	0.34	4.97	0.37	1.78e-6	Glomerular filtration rate;
PAAD	cis	rs73019876	0.901	rs2666448	chr19:22132508	G/A	cg11619707	chr19:22235551	ZNF257	-0.4	-4.38	-0.33	2.21e-5	Testicular germ cell tumor;
PAAD	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.82	-6.28	-0.45	3.39e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.88	0.49	1.44e-10	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg16584290	chr5:462447	EXOC3	-0.41	-4.43	-0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.76	5.09	0.38	1.03e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.71	-6.8	-0.48	2.25e-10	Schizophrenia;
PAAD	trans	rs1075265	0.597	rs10490471	chr2:53996583	G/C	cg16115072	chr17:25938812	KSR1	0.59	6.31	0.46	2.93e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs6594713	0.837	rs34682492	chr5:112752087	C/G	cg12552261	chr5:112820674	MCC	0.6	4.35	0.33	2.52e-5	Brain cytoarchitecture;
PAAD	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg03060546	chr3:49711283	APEH	-0.58	-4.25	-0.33	3.72e-5	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
PAAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.34	-0.4	3.31e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-9.33	-0.6	1.21e-16	Gut microbiome composition (summer);
PAAD	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg15733309	chr7:157513707	PTPRN2	0.64	7.95	0.54	3.82e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6810498	0.735	rs871384	chr4:26052506	A/T	cg02513547	chr4:26029960	NA	-0.49	-4.45	-0.34	1.63e-5	Alcohol dependence;
PAAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13560548	chr3:10150139	C3orf24	0.61	5.6	0.41	9.87e-8	Alzheimer's disease;
PAAD	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.6	6.83	0.48	1.93e-10	Height;
PAAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	7.19	0.5	2.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	5.7	0.42	5.92e-8	Body mass index;
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.6	-5.62	-0.42	8.7e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-5.82	-0.43	3.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.4	-4.4	-0.34	2.05e-5	Mean arterial pressure;
PAAD	trans	rs1442089	1.000	rs8098707	chr18:51132044	T/G	cg24118715	chr10:70232072	DNA2	0.74	6.39	0.46	1.89e-9	Survival in colorectal cancer (distant metastatic);
PAAD	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.63	-5.92	-0.43	2.07e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12760731	0.623	rs10913551	chr1:178410131	T/G	cg00404053	chr1:178313656	RASAL2	0.65	5.43	0.4	2.17e-7	Obesity-related traits;
PAAD	cis	rs6137287	0.924	rs2145100	chr20:21163799	A/G	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	cis	rs59888335	0.858	rs4856306	chr3:80957733	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg11062466	chr8:58055876	NA	0.65	4.72	0.36	5.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg26174226	chr8:58114915	NA	-0.44	-4.36	-0.33	2.42e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.92	-0.43	2.07e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.85	7.46	0.52	6.29e-12	Phospholipid levels (plasma);
PAAD	cis	rs7520050	0.581	rs6671303	chr1:46629653	A/C	cg01431908	chr1:46668882	C1orf190;POMGNT1	-0.45	-4.91	-0.37	2.29e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.49	5.32	0.4	3.66e-7	Metabolite levels;
PAAD	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.59	-5.91	-0.43	2.21e-8	Temperament;
PAAD	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.93	-8.6	-0.57	9.38e-15	Asthma;
PAAD	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg25070565	chr17:20044324	CYTSB	0.44	4.27	0.33	3.43e-5	Obesity-related traits;
PAAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Schizophrenia;
PAAD	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs9815354	1.000	rs9865127	chr3:41807448	C/T	cg03022575	chr3:42003672	ULK4	0.73	5.33	0.4	3.56e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg26939375	chr7:64535504	NA	0.76	9.07	0.59	5.75e-16	Aortic root size;
PAAD	cis	rs66530629	0.958	rs4543739	chr1:25049680	A/C	cg01905478	chr1:25040257	NA	0.56	6.1	0.44	8.6e-9	Plateletcrit;
PAAD	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg09945482	chr18:12777974	NA	0.67	5.85	0.43	2.94e-8	Inflammatory skin disease;
PAAD	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.91	-8.59	-0.57	9.69e-15	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	5.84	0.43	3.11e-8	Platelet count;
PAAD	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg06307176	chr5:131281290	NA	-0.49	-4.41	-0.34	1.95e-5	Life satisfaction;
PAAD	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-5.97	-0.44	1.64e-8	Blood trace element (Zn levels);
PAAD	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.85	9.04	0.59	6.62e-16	Anterior chamber depth;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00884529	chr7:16685823	BZW2;ANKMY2	0.57	6.52	0.47	9.92e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	1.1	9.32	0.6	1.3e-16	Vitiligo;
PAAD	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.48	5.66	0.42	7.31e-8	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14764050	chr21:46221651	UBE2G2	0.61	6.3	0.46	3.08e-9	Myopia (pathological);
PAAD	cis	rs375066	0.935	rs11673020	chr19:44374631	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.33e-7	Breast cancer;
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	0.98	6.48	0.47	1.22e-9	IgG glycosylation;
PAAD	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.83	9.79	0.62	7.6e-18	Breast cancer;
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.57	-7.06	-0.5	5.65e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.22	-0.39	5.67e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.4	-0.34	2.05e-5	Lung cancer in ever smokers;
PAAD	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-5.34	-0.4	3.27e-7	Schizophrenia;
PAAD	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg26898376	chr11:64110657	CCDC88B	0.44	4.71	0.36	5.46e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg08501292	chr6:25962987	TRIM38	0.91	4.45	0.34	1.63e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.85	7.2	0.5	2.55e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.53	5.8	0.43	3.79e-8	Obesity-related traits;
PAAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.35	0.56	3.85e-14	Lung cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07540917	chr16:87742602	KLHDC4	0.63	7.58	0.52	3.19e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.48	4.46	0.34	1.56e-5	Diastolic blood pressure;
PAAD	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg24881330	chr22:46731750	TRMU	1.08	5.71	0.42	5.9e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-5.16	-0.39	7.61e-7	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05766539	chr3:55572619	ERC2	-0.64	-6.8	-0.48	2.23e-10	Obesity-related traits;
PAAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.96	0.37	1.83e-6	Schizophrenia;
PAAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.56	-5.63	-0.42	8.28e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950027	0.967	rs2486280	chr15:45751889	T/C	cg26924012	chr15:45694286	SPATA5L1	0.61	5.7	0.42	6e-8	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg07617317	chr6:118971624	C6orf204	0.56	4.63	0.35	7.79e-6	Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.84	4.5	0.34	1.34e-5	Childhood ear infection;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg07202610	chr7:1142643	C7orf50	-0.71	-4.82	-0.36	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.81	8.07	0.55	1.94e-13	Response to diuretic therapy;
PAAD	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.59	5.26	0.39	4.88e-7	Corneal astigmatism;
PAAD	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg23436918	chr7:16685595	BZW2;ANKMY2	0.62	6.74	0.48	3.13e-10	Thyroid cancer;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.95	12.21	0.7	2.44e-24	Menarche (age at onset);
PAAD	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.98	5.71	0.42	5.84e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06435260	chr16:30886591	NA	-0.77	-6.81	-0.48	2.09e-10	Neuroticism;
PAAD	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	1.0	9.45	0.61	5.95e-17	Corneal structure;
PAAD	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.99	-0.38	1.65e-6	Pulmonary function;
PAAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg05255149	chr17:80675120	FN3KRP	-0.48	-4.34	-0.33	2.62e-5	Glycated hemoglobin levels;
PAAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.94	-0.49	1.08e-10	Coronary artery disease;
PAAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-4.68	-0.36	6.22e-6	Breast cancer;
PAAD	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.74	-6.23	-0.45	4.41e-9	Exhaled nitric oxide output;
PAAD	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg13722127	chr7:150037890	RARRES2	0.51	5.22	0.39	5.82e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg12143784	chr7:64541923	NA	0.35	4.54	0.35	1.15e-5	Aortic root size;
PAAD	cis	rs11892454	0.544	rs11894959	chr2:25997821	C/T	cg03373490	chr2:26702396	OTOF	0.51	4.32	0.33	2.81e-5	Heschl's gyrus morphology;
PAAD	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs4889911	0.571	rs9907480	chr17:77852292	C/T	cg26037614	chr17:77751273	CBX2	0.68	4.47	0.34	1.55e-5	Electroencephalogram traits;
PAAD	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs58521262	0.560	rs4933040	chr19:22980037	G/A	cg07749055	chr19:23076870	NA	-0.59	-4.39	-0.34	2.11e-5	Testicular germ cell tumor;
PAAD	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg21665744	chr7:39171113	POU6F2	0.3	4.69	0.36	6.07e-6	IgG glycosylation;
PAAD	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.5	4.68	0.36	6.21e-6	Schizophrenia;
PAAD	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.66	0.57	6.4e-15	Corneal astigmatism;
PAAD	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.68	9.02	0.59	7.61e-16	Hemoglobin concentration;
PAAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-6.46	-0.46	1.37e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23076591	chr22:28197571	MN1	-0.58	-6.89	-0.49	1.36e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.46e-14	Dupuytren's disease;
PAAD	cis	rs282587	0.530	rs428853	chr13:113387222	T/C	cg02820901	chr13:113351484	ATP11A	-0.66	-4.93	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.49	4.85	0.37	3.06e-6	Acylcarnitine levels;
PAAD	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.73	-5.52	-0.41	1.46e-7	Coronary artery calcification;
PAAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-5.6	-0.41	9.79e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.56e-11	Triglycerides;
PAAD	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg10932868	chr11:921992	NA	0.45	4.75	0.36	4.63e-6	Alzheimer's disease (late onset);
PAAD	cis	rs939584	0.935	rs6732341	chr2:629817	G/C	cg03610516	chr2:642275	NA	0.64	5.66	0.42	7.36e-8	Body mass index;
PAAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.42	7.67	0.53	1.93e-12	Multiple system atrophy;
PAAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.55	-5.28	-0.39	4.45e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19734201	chr4:39699603	UBE2K	0.65	7.45	0.52	6.47e-12	Myopia (pathological);
PAAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.97	10.85	0.66	1.12e-20	Menarche (age at onset);
PAAD	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.79	-7.03	-0.5	6.47e-11	Body mass index;
PAAD	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg05805236	chr11:65401703	PCNXL3	-0.61	-6.48	-0.47	1.21e-9	Acne (severe);
PAAD	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	4.73	0.36	5.11e-6	Thyroid stimulating hormone;
PAAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.73	-7.66	-0.53	2.08e-12	Neurofibrillary tangles;
PAAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.33	4.57	0.35	1.02e-5	Height;
PAAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8.13e-6	Life satisfaction;
PAAD	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.94	0.54	4.08e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.36	4.26	0.33	3.62e-5	Schizophrenia;
PAAD	cis	rs1879734	0.731	rs11206192	chr1:54158690	A/G	cg14659662	chr1:54151053	GLIS1	0.45	6.03	0.44	1.2e-8	Mitral valve prolapse;
PAAD	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.78	8.35	0.56	3.87e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.6	5.6	0.41	9.91e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.49	-5.04	-0.38	1.29e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7552393	0.636	rs11163849	chr1:84281197	A/G	cg10977910	chr1:84465055	TTLL7	0.57	5.26	0.39	4.78e-7	Select biomarker traits;
PAAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg07153921	chr17:41440717	NA	-0.41	-4.46	-0.34	1.61e-5	Menopause (age at onset);
PAAD	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.67	-7.02	-0.5	6.74e-11	Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg17366294	chr4:99064904	C4orf37	0.46	5.09	0.38	1.06e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.57	4.61	0.35	8.41e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-5.77	-0.42	4.22e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.14e-8	Menopause (age at onset);
PAAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.4	-8.33	-0.56	4.35e-14	Mean corpuscular volume;
PAAD	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.07	0.5	5.35e-11	Eye color traits;
PAAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.45	-4.93	-0.37	2.17e-6	Type 2 diabetes;
PAAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16262614	chr3:133464971	TF	-0.41	-4.28	-0.33	3.32e-5	Iron status biomarkers;
PAAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	6.43	0.46	1.53e-9	Initial pursuit acceleration;
PAAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg03538708	chr1:25844672	NA	-0.53	-5.4	-0.4	2.51e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.51	-6.52	-0.47	9.68e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12476592	0.602	rs262479	chr2:63872479	C/T	cg10828910	chr2:63850056	LOC388955	0.53	4.69	0.36	6.04e-6	Childhood ear infection;
PAAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.8	8.99	0.59	9.01e-16	Lung cancer;
PAAD	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-4.44	-0.34	1.7e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.72	-6.94	-0.49	1.04e-10	Hip circumference;
PAAD	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs1455213	0.643	rs2604554	chr4:15168679	G/A	cg12377275	chr4:15005593	CPEB2	0.52	4.96	0.37	1.83e-6	Parental longevity (mother's age at death);
PAAD	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs2286885	0.710	rs4836547	chr9:129254661	G/C	cg15282417	chr9:129245246	FAM125B	0.43	5.0	0.38	1.57e-6	Intraocular pressure;
PAAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1642645	0.831	rs768613	chr1:42485263	T/C	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs12935418	0.616	rs56299740	chr16:80964169	A/T	cg16651780	chr16:81037892	C16orf61	0.55	4.48	0.34	1.44e-5	Mean corpuscular volume;
PAAD	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.31	0.64	3.18e-19	White blood cell count (neutrophil);
PAAD	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-5.07	-0.38	1.16e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.56	6.17	0.45	6.02e-9	Menopause (age at onset);
PAAD	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-7.94	-0.54	4.09e-13	Lymphocyte counts;Red cell distribution width;
PAAD	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.43	-0.4	2.21e-7	Reticulocyte count;
PAAD	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.83e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.6	-6.0	-0.44	1.38e-8	Primary sclerosing cholangitis;
PAAD	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg10985347	chr2:127963512	CYP27C1	-0.48	-4.43	-0.34	1.8e-5	Self-rated health;
PAAD	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-1.18	-13.28	-0.73	3.29e-27	Hair shape;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg12705353	chr12:122356852	WDR66	0.45	4.89	0.37	2.56e-6	Mean corpuscular volume;
PAAD	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-4.48	-0.34	1.47e-5	Coronary artery disease;
PAAD	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg14851346	chr12:38532713	NA	-0.44	-4.25	-0.33	3.73e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6558530	0.666	rs4242538	chr8:1694010	G/C	cg19131313	chr8:1704013	NA	-0.41	-4.44	-0.34	1.7e-5	Systolic blood pressure;
PAAD	cis	rs28493229	0.521	rs2604878	chr19:41191971	G/C	cg21869046	chr19:41225005	ITPKC	0.51	5.6	0.41	1e-7	Kawasaki disease;
PAAD	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.7	6.81	0.48	2.12e-10	Schizophrenia;
PAAD	cis	rs6445967	1.000	rs12688	chr3:58305079	T/C	cg23715586	chr3:58305044	RPP14	0.48	4.27	0.33	3.48e-5	Platelet count;
PAAD	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.64	7.71	0.53	1.52e-12	Alcohol dependence;
PAAD	cis	rs10101158	0.558	rs1992805	chr8:142950775	C/T	cg07295586	chr8:142984467	NA	-0.42	-4.72	-0.36	5.36e-6	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
PAAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-6.45	-0.46	1.39e-9	Longevity;Endometriosis;
PAAD	cis	rs4668356	1.000	rs13389859	chr2:171948875	A/G	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg01059385	chr22:42394853	WBP2NL	-0.43	-4.62	-0.35	8.28e-6	Cognitive function;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg14926445	chr8:58193284	C8orf71	-0.76	-6.04	-0.44	1.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2929278	0.638	rs2016840	chr15:44211868	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-4.25	-0.33	3.73e-5	Schizophrenia;
PAAD	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg10006428	chr1:248814059	OR2T27	0.38	4.52	0.34	1.22e-5	Common traits (Other);
PAAD	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.45	5.05	0.38	1.23e-6	Dilated cardiomyopathy;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.87	-7.96	-0.54	3.8e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs78707713	0.891	rs17490626	chr10:71218646	G/C	cg12610070	chr10:71211762	TSPAN15	-0.58	-5.42	-0.4	2.25e-7	Venous thromboembolism;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11968436	chr19:51308133	C19orf48	-0.62	-7.13	-0.5	3.86e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg20731937	chr12:48336164	NA	0.51	4.31	0.33	2.89e-5	Longevity (90 years and older);
PAAD	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17467752	chr17:38218738	THRA	0.49	4.44	0.34	1.74e-5	Myeloid white cell count;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07362569	chr17:61921086	SMARCD2	0.61	7.3	0.51	1.46e-11	Prudent dietary pattern;
PAAD	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.55	-4.42	-0.34	1.9e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg14631576	chr9:95140430	CENPP	-0.61	-5.97	-0.44	1.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-1.05	-5.29	-0.39	4.27e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg11764359	chr7:65958608	NA	0.76	5.83	0.43	3.28e-8	Diabetic kidney disease;
PAAD	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.67	7.41	0.52	8.05e-12	Systemic lupus erythematosus;
PAAD	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg27121462	chr16:89883253	FANCA	0.79	4.59	0.35	9.14e-6	Skin colour saturation;
PAAD	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.82	8.99	0.59	9.36e-16	Prostate cancer;
PAAD	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg04520793	chr17:42248056	ASB16	0.41	4.72	0.36	5.41e-6	Total body bone mineral density;
PAAD	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.7	-8.68	-0.58	5.62e-15	Breast cancer;
PAAD	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg11530693	chr1:120165357	ZNF697	0.65	6.03	0.44	1.18e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.33	-0.46	2.56e-9	Longevity;Endometriosis;
PAAD	cis	rs12042107	0.570	rs4146669	chr1:91200191	C/T	cg13456504	chr1:91191583	NA	0.38	4.37	0.33	2.27e-5	Educational attainment;
PAAD	cis	rs7121446	0.555	rs6589903	chr11:121863966	C/T	cg13820391	chr11:121835505	NA	0.46	4.29	0.33	3.2e-5	Cardiovascular risk factors (age interaction);
PAAD	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg11367502	chr7:22862612	TOMM7	0.52	5.07	0.38	1.14e-6	Fibrinogen;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.48	5.99	0.44	1.48e-8	Iron status biomarkers;
PAAD	cis	rs987237	0.901	rs3798519	chr6:50788778	A/C	cg24161652	chr6:50813859	TFAP2B	0.35	4.29	0.33	3.14e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Childhood body mass index;Adiposity;Body mass index in physically active individuals;
PAAD	cis	rs16975963	0.644	rs7248397	chr19:38133211	A/G	cg08679971	chr19:38281047	NA	0.46	4.5	0.34	1.36e-5	Longevity;
PAAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.18	-0.81	1.9e-37	Height;
PAAD	cis	rs802075	0.783	rs2518103	chr6:49616512	G/A	cg20364632	chr6:49636226	NA	-0.53	-6.2	-0.45	5.17e-9	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.01	-0.44	1.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg15128208	chr22:42549153	NA	0.52	4.46	0.34	1.61e-5	Birth weight;
PAAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6024905	0.587	rs2154374	chr20:36963225	A/G	cg07053727	chr20:36965646	BPI	0.58	6.89	0.49	1.4e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg06131755	chr6:160182447	ACAT2	0.53	4.65	0.35	7.12e-6	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg13264159	chr8:625131	ERICH1	0.72	4.82	0.36	3.47e-6	IgG glycosylation;
PAAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.65	6.64	0.47	5.22e-10	Blood protein levels;
PAAD	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg02887458	chr19:19495540	GATAD2A	-0.49	-4.55	-0.35	1.1e-5	Bipolar disorder;
PAAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.71	6.18	0.45	5.62e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15198739	chr22:26908541	TFIP11	0.65	6.41	0.46	1.72e-9	Obesity-related traits;
PAAD	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg26816564	chr1:7831052	VAMP3	0.75	5.64	0.42	8.16e-8	Inflammatory bowel disease;
PAAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.63	-5.91	-0.43	2.19e-8	Coronary artery disease;
PAAD	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg12560992	chr17:57184187	TRIM37	0.66	5.02	0.38	1.43e-6	Vitamin D levels;
PAAD	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg22437258	chr11:111473054	SIK2	-0.64	-5.78	-0.42	4.08e-8	Primary sclerosing cholangitis;
PAAD	cis	rs11811982	0.793	rs115755032	chr1:227436402	A/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.34	4.55	0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-4.8	-0.36	3.77e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.56	-5.14	-0.38	8.4e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.65	8.2	0.55	9.24e-14	Inflammatory bowel disease;
PAAD	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs372883	0.967	rs2832292	chr21:30738760	C/A	cg24692254	chr21:30365293	RNF160	0.43	4.43	0.34	1.81e-5	Pancreatic cancer;
PAAD	cis	rs10274279	1.000	rs10274279	chr7:157387441	C/T	cg09270525	chr7:157391030	PTPRN2	-0.71	-5.54	-0.41	1.32e-7	Myopia (pathological);
PAAD	trans	rs6694672	0.681	rs865071	chr1:197017976	G/A	cg26994526	chr18:47719735	MYO5B	-0.8	-6.43	-0.46	1.55e-9	Asthma;
PAAD	cis	rs1529711	0.500	rs80091992	chr19:10904902	A/G	cg16667279	chr19:11591998	ELAVL3	-0.59	-4.53	-0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14409850	chr12:27091377	C12orf11;FGFR1OP2	0.76	7.94	0.54	4.04e-13	Obesity-related traits;
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg11335335	chr11:637885	DRD4	-0.31	-4.43	-0.34	1.76e-5	Systemic lupus erythematosus;
PAAD	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg09127314	chr1:152161683	NA	0.74	5.43	0.4	2.14e-7	Atopic dermatitis;
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg11766577	chr21:47581405	C21orf56	-0.45	-5.07	-0.38	1.15e-6	Testicular germ cell tumor;
PAAD	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.69	0.36	6.15e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	7.65	0.53	2.16e-12	Hip circumference adjusted for BMI;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25633955	chr8:1616622	DLGAP2	-0.6	-6.34	-0.46	2.49e-9	Obesity-related traits;
PAAD	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.91	10.2	0.64	6.2e-19	Colorectal adenoma (advanced);
PAAD	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	6.63	0.47	5.44e-10	Breast cancer;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg18279126	chr7:2041391	MAD1L1	-0.59	-6.03	-0.44	1.18e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg14349672	chr11:133703707	NA	-0.56	-6.26	-0.45	3.83e-9	Childhood ear infection;
PAAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.52	-0.34	1.23e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.58	0.35	9.51e-6	Skin colour saturation;
PAAD	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-4.74	-0.36	4.96e-6	Electrocardiographic conduction measures;
PAAD	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00992913	chr1:156698515	C1orf66;ISG20L2	0.63	7.03	0.5	6.46e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	9.84	0.62	5.66e-18	Platelet count;
PAAD	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.56	-7.3	-0.51	1.5e-11	Longevity;
PAAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	1.09	15.11	0.77	4.47e-32	Breast cancer;
PAAD	cis	rs12325245	0.536	rs12931051	chr16:58626534	C/T	cg27113419	chr16:58533979	NDRG4	-0.78	-4.65	-0.35	7.03e-6	Schizophrenia;
PAAD	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg06071746	chr17:57297518	GDPD1	0.3	4.55	0.35	1.1e-5	Cognitive test performance;
PAAD	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.6	-0.57	8.97e-15	Electrocardiographic conduction measures;
PAAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.96	-11.68	-0.69	6.7e-23	Height;
PAAD	cis	rs55728055	0.661	rs16989379	chr22:32058269	G/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00489988	chr12:133245207	POLE	-0.57	-6.32	-0.46	2.73e-9	Myopia (pathological);
PAAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.51	-0.47	1.02e-9	Life satisfaction;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24313640	chr11:57425161	CLP1	0.7	7.03	0.5	6.47e-11	Obesity-related traits;
PAAD	cis	rs2200578	0.836	rs72957179	chr2:99693578	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	4.26	0.33	3.54e-5	IgG glycosylation;
PAAD	cis	rs2242420	0.920	rs16825734	chr1:21956199	C/A	cg04297819	chr1:22260125	HSPG2	0.49	4.35	0.33	2.53e-5	Hematological and biochemical traits;
PAAD	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-4.84	-0.37	3.23e-6	Mean corpuscular volume;
PAAD	cis	rs4594175	0.926	rs72688713	chr14:51598375	C/T	cg23942311	chr14:51606299	NA	0.7	6.86	0.49	1.64e-10	Cancer;
PAAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.77	9.19	0.6	2.73e-16	Eye color traits;
PAAD	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.5	-0.47	1.09e-9	Monocyte count;
PAAD	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg01620082	chr3:125678407	NA	-0.9	-6.5	-0.47	1.11e-9	Depression;
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.74	6.63	0.47	5.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs375066	0.710	rs11881193	chr19:44421516	G/T	cg08633290	chr19:44405433	NA	0.51	4.8	0.36	3.83e-6	Breast cancer;
PAAD	cis	rs4756864	0.504	rs11024041	chr11:16817072	C/T	cg19428160	chr11:17761718	KCNC1	-0.49	-4.52	-0.34	1.23e-5	Systolic blood pressure change trajectories;
PAAD	cis	rs501916	0.605	rs8031169	chr15:48080330	G/C	cg16110827	chr15:48056943	SEMA6D	-0.49	-5.27	-0.39	4.65e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg19254793	chr6:44695348	NA	-0.45	-4.31	-0.33	2.93e-5	Total body bone mineral density;
PAAD	cis	rs4281086	0.862	rs13255425	chr8:10368593	G/A	cg01072821	chr8:10382165	T-SP1	0.45	4.27	0.33	3.37e-5	Obesity-related traits;
PAAD	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg22532475	chr10:104410764	TRIM8	0.33	4.34	0.33	2.6e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	4.71	0.36	5.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.75	5.69	0.42	6.37e-8	Diisocyanate-induced asthma;
PAAD	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.74	8.06	0.55	2.09e-13	Menopause (age at onset);
PAAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.61	6.14	0.45	6.86e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg19000871	chr14:103996768	TRMT61A	-0.45	-4.75	-0.36	4.64e-6	Reticulocyte count;
PAAD	cis	rs4742903	0.935	rs975253	chr9:106928260	G/C	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.95e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.91	-9.54	-0.61	3.43e-17	Homoarginine levels;
PAAD	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-4.81	-0.36	3.62e-6	Daytime sleep phenotypes;
PAAD	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg14345882	chr6:26364793	BTN3A2	0.64	4.33	0.33	2.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.75	0.48	2.97e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12993927	chr12:12878755	APOLD1	0.67	6.47	0.46	1.29e-9	Obesity-related traits;
PAAD	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.48	-4.56	-0.35	1.05e-5	Fractional excretion of uric acid;
PAAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Depression;
PAAD	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg21918786	chr6:109611834	NA	-0.43	-4.9	-0.37	2.45e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg21890820	chr11:65308645	LTBP3	0.63	7.56	0.52	3.48e-12	Bone mineral density;
PAAD	cis	rs11871801	1.000	rs71367913	chr17:40589869	G/A	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg08992911	chr2:238395768	MLPH	0.7	5.71	0.42	5.65e-8	Prostate cancer;
PAAD	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.38	-0.4	2.78e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.92	-9.59	-0.61	2.46e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	11.33	0.68	5.94e-22	Menopause (age at onset);
PAAD	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	12.02	0.7	8.21e-24	Testicular germ cell tumor;
PAAD	cis	rs9905704	0.633	rs2526369	chr17:56469113	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.73	8.05	0.55	2.24e-13	Morning vs. evening chronotype;
PAAD	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-5.0	-0.38	1.53e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg04482110	chr17:41364121	TMEM106A	-0.38	-4.31	-0.33	2.87e-5	Menopause (age at onset);
PAAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg14393609	chr7:65229607	NA	0.67	7.35	0.51	1.11e-11	Aortic root size;
PAAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg13870426	chr17:30244630	NA	0.74	6.6	0.47	6.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.76	0.48	2.71e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.38	9.7	0.62	1.28e-17	Atopic dermatitis;
PAAD	cis	rs1075232	1.000	rs72722861	chr15:31704288	G/A	cg01030201	chr15:31746330	NA	-1.09	-4.47	-0.34	1.54e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs28719689	0.730	rs62483952	chr8:1259343	G/A	cg22761795	chr8:1265118	NA	0.91	5.84	0.43	3.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.61	0.47	6.13e-10	Aortic root size;
PAAD	cis	rs11113894	0.901	rs17040591	chr12:108860695	A/T	cg25832824	chr12:108733253	CMKLR1	-0.63	-4.36	-0.33	2.38e-5	Obesity-related traits;
PAAD	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.48	4.45	0.34	1.65e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08439880	chr3:133502540	NA	0.54	5.83	0.43	3.25e-8	Iron status biomarkers;
PAAD	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.39	-4.86	-0.37	2.89e-6	Blood metabolite levels;
PAAD	cis	rs2031532	0.819	rs3794378	chr13:50103217	G/A	cg08779649	chr13:50194554	NA	0.38	4.71	0.36	5.65e-6	Cardiac hypertrophy;
PAAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg04369109	chr6:150039330	LATS1	-0.45	-4.41	-0.34	1.94e-5	Lung cancer;
PAAD	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg13535736	chr9:111863775	C9orf5	0.35	4.39	0.34	2.08e-5	Menarche (age at onset);
PAAD	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.64	6.34	0.46	2.51e-9	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.58	-0.41	1.07e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg23461800	chr14:103021989	NA	-0.58	-4.33	-0.33	2.66e-5	Platelet count;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.68	-7.09	-0.5	4.6e-11	Menopause (age at onset);
PAAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.73	0.48	3.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18337363	chr3:52569053	NT5DC2	0.4	4.26	0.33	3.64e-5	Bipolar disorder;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.45	0.8	1.46e-35	Prudent dietary pattern;
PAAD	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26926768	chr12:34528122	NA	0.4	4.84	0.37	3.19e-6	Morning vs. evening chronotype;
PAAD	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.57	4.25	0.33	3.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg06212747	chr3:49208901	KLHDC8B	0.6	4.73	0.36	5.14e-6	Menarche (age at onset);
PAAD	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-7.67	-0.53	1.86e-12	Exhaled nitric oxide output;
PAAD	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-1.19	-13.46	-0.74	1.09e-27	Hair shape;
PAAD	cis	rs11077998	0.723	rs3829566	chr17:80528996	C/T	cg11779900	chr17:80519722	FOXK2	-0.65	-5.94	-0.43	1.88e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.62	6.47	0.46	1.29e-9	Blood protein levels;
PAAD	cis	rs4908768	0.657	rs11121229	chr1:8831283	C/T	cg00590817	chr1:8272081	NA	0.41	4.81	0.36	3.6e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs73388146	1.000	rs73388146	chr6:25170668	G/A	cg26336265	chr6:25042955	NA	1.09	6.24	0.45	4.13e-9	Schizophrenia;
PAAD	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg19401529	chr3:49056140	DALRD3	0.52	4.37	0.33	2.34e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg02404636	chr22:31891804	SFI1	-0.62	-5.56	-0.41	1.18e-7	Colorectal cancer;
PAAD	cis	rs3787159	0.655	rs502138	chr20:56918507	G/A	cg15032960	chr20:56888536	RAB22A	-0.4	-4.25	-0.33	3.73e-5	Systolic blood pressure;
PAAD	cis	rs9567406	1.000	rs912592	chr13:44871187	T/C	cg08635097	chr13:44833857	NA	-0.64	-4.49	-0.34	1.41e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg13264159	chr8:625131	ERICH1	-0.66	-4.25	-0.33	3.66e-5	IgG glycosylation;
PAAD	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.46	4.8	0.36	3.69e-6	Age of smoking initiation;
PAAD	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.33	0.4	3.54e-7	Life satisfaction;
PAAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.09	-0.5	4.61e-11	Cognitive function;
PAAD	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg14393609	chr7:65229607	NA	-0.65	-6.98	-0.49	8.52e-11	Aortic root size;
PAAD	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.18	-0.64	7.17e-19	Chronic sinus infection;
PAAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	9.41	0.61	7.24e-17	Lymphocyte counts;
PAAD	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg13002189	chr3:66846049	NA	0.47	4.53	0.34	1.18e-5	Type 2 diabetes;
PAAD	cis	rs3743832	0.931	rs12443681	chr16:9181690	T/C	cg08831531	chr16:9218945	NA	-0.44	-4.55	-0.35	1.08e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
PAAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.65	-6.15	-0.45	6.62e-9	DNA methylation (variation);
PAAD	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg16898833	chr6:26189333	HIST1H4D	1.04	5.69	0.42	6.38e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.88	8.12	0.55	1.45e-13	Response to diuretic therapy;
PAAD	cis	rs859767	0.704	rs6750788	chr2:135362981	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-4.56	-0.35	1.03e-5	Neuroticism;
PAAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg13770153	chr20:60521292	NA	-0.46	-4.37	-0.33	2.33e-5	Body mass index;
PAAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg06815965	chr1:205818668	PM20D1	0.63	7.08	0.5	4.95e-11	Menarche (age at onset);
PAAD	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg10356904	chr22:49881777	NA	-0.47	-4.73	-0.36	5.15e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg27644672	chr7:1858694	MAD1L1	-0.4	-4.31	-0.33	2.98e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7216064	1.000	rs62084208	chr17:65827443	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-5.66	-0.42	7.48e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00166722	chr3:10149974	C3orf24	0.91	7.9	0.54	5.14e-13	Alzheimer's disease;
PAAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs4474465	1.000	rs7933612	chr11:78209366	G/T	cg27205649	chr11:78285834	NARS2	0.57	4.27	0.33	3.37e-5	Alzheimer's disease (survival time);
PAAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07685180	chr8:600429	NA	0.83	5.32	0.4	3.71e-7	IgG glycosylation;
PAAD	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.63	6.62	0.47	5.8e-10	Testicular germ cell tumor;
PAAD	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06850241	chr22:41845214	NA	0.51	4.26	0.33	3.55e-5	Cannabis dependence symptom count;
PAAD	cis	rs7818688	0.697	rs35032356	chr8:95977484	G/T	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs9810890	1.000	rs73210606	chr3:128617426	A/G	cg16818395	chr3:128274084	NA	0.5	4.38	0.33	2.19e-5	Dental caries;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21783428	chr6:3118692	BPHL	0.65	6.85	0.49	1.69e-10	Myopia (pathological);
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-4.37	-0.33	2.28e-5	Longevity;Endometriosis;
PAAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.52	-5.08	-0.38	1.08e-6	Glomerular filtration rate;
PAAD	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-4.61	-0.35	8.35e-6	Height;
PAAD	cis	rs722864	0.704	rs11687539	chr2:174023857	A/G	cg09210666	chr2:173941575	ZAK	0.47	4.42	0.34	1.86e-5	Lung cancer;
PAAD	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.63	6.17	0.45	5.79e-9	Ovarian reserve;
PAAD	cis	rs5757949	0.551	rs35486251	chr22:40970439	T/C	cg14701072	chr22:41075428	MCHR1	-0.44	-4.33	-0.33	2.7e-5	Height;
PAAD	cis	rs9488822	0.549	rs195527	chr6:116250858	T/C	cg18764771	chr6:116381957	FRK	0.26	4.25	0.33	3.7e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.58	4.44	0.34	1.72e-5	IgG glycosylation;
PAAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.81	-7.99	-0.54	3.03e-13	Schizophrenia;
PAAD	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.9	7.39	0.51	9.06e-12	Cerebrospinal P-tau181p levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02333588	chr1:3352830	PRDM16	0.56	6.52	0.47	9.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10795433	0.541	rs6602163	chr10:16966766	A/G	cg00939682	chr10:16933505	CUBN	0.6	5.73	0.42	5.25e-8	Urinary albumin-to-creatinine ratio;Microalbuminuria;
PAAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.5	5.08	0.38	1.1e-6	Colorectal cancer;
PAAD	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.56	5.53	0.41	1.38e-7	Educational attainment (years of education);
PAAD	trans	rs901683	0.867	rs34144887	chr10:46086393	G/A	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24597927	chr20:45317651	TP53RK	-0.79	-6.86	-0.49	1.61e-10	Neuroticism;
PAAD	cis	rs3106136	0.678	rs6857185	chr4:95296089	C/T	cg11021082	chr4:95130006	SMARCAD1	0.49	4.67	0.35	6.52e-6	Capecitabine sensitivity;
PAAD	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.71	5.64	0.42	8.19e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg05790982	chr4:4861404	MSX1	-0.74	-6.6	-0.47	6.57e-10	Blood protein levels;
PAAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg08648136	chr8:956695	NA	0.43	4.66	0.35	6.95e-6	Schizophrenia;
PAAD	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.39	4.25	0.33	3.73e-5	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
PAAD	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.93	-7.04	-0.5	6.32e-11	Monocyte percentage of white cells;
PAAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg07068956	chr7:100330872	ZAN	-0.64	-4.9	-0.37	2.44e-6	Other erythrocyte phenotypes;
PAAD	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg14223017	chr19:2151266	AP3D1	0.57	6.37	0.46	2.19e-9	Iris heterochromicity;
PAAD	cis	rs757081	0.648	rs10832750	chr11:17260918	A/T	cg15432903	chr11:17409602	KCNJ11	0.59	6.04	0.44	1.15e-8	Systolic blood pressure;
PAAD	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.24	12.59	0.71	2.37e-25	Post bronchodilator FEV1;
PAAD	cis	rs11734570	0.824	rs4833071	chr4:38582859	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.57	4.97	0.37	1.75e-6	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg00024416	chr22:24240387	NA	0.55	5.74	0.42	4.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.84	8.18	0.55	1.08e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg23860436	chr12:58378763	NA	0.47	4.31	0.33	2.93e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs9581857	0.685	rs60787915	chr13:28022298	C/T	cg22138327	chr13:27999177	GTF3A	0.67	4.57	0.35	9.99e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.83	9.92	0.63	3.38e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.57	5.5	0.41	1.56e-7	Systolic blood pressure;
PAAD	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27511599	chr7:32358540	NA	0.76	4.46	0.34	1.56e-5	Body mass index;
PAAD	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.83	-6.89	-0.49	1.38e-10	Diastolic blood pressure;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg17541715	chr7:1216824	NA	-0.41	-4.44	-0.34	1.69e-5	Longevity;Endometriosis;
PAAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg27182935	chr16:89790473	ZNF276	-0.72	-4.52	-0.34	1.21e-5	Skin colour saturation;
PAAD	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg10154010	chr16:2326080	ABCA3	0.53	4.42	0.34	1.86e-5	Coronary artery disease;
PAAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg03959625	chr15:84868606	LOC388152	0.47	5.2	0.39	6.29e-7	Schizophrenia;
PAAD	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-6.88	-0.49	1.5e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg15242771	chr6:114292051	HDAC2	-0.45	-5.32	-0.4	3.72e-7	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05332869	chr20:39658073	TOP1	0.57	6.43	0.46	1.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg13444538	chr7:158905317	VIPR2	-0.55	-4.51	-0.34	1.3e-5	Facial morphology (factor 20);
PAAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.55	-6.22	-0.45	4.67e-9	Total body bone mineral density;
PAAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19346786	chr7:2764209	NA	-0.41	-5.3	-0.39	4.01e-7	Height;
PAAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg03959625	chr15:84868606	LOC388152	-0.45	-4.75	-0.36	4.61e-6	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.25	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26687565	chr4:141072046	MAML3	0.67	6.81	0.48	2.18e-10	Obesity-related traits;
PAAD	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.73	6.93	0.49	1.14e-10	Methadone dose in opioid dependence;
PAAD	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.52	-6.05	-0.44	1.07e-8	Mean arterial pressure;
PAAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.67	7.02	0.49	6.83e-11	Type 2 diabetes;
PAAD	cis	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg22863700	chr5:28928346	NA	0.53	4.99	0.38	1.65e-6	Hip geometry;
PAAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.72	5.15	0.39	7.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.47	-5.55	-0.41	1.24e-7	Coronary artery disease;
PAAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	4.57	0.35	1e-5	Schizophrenia;
PAAD	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg17552801	chr10:99332121	ANKRD2	-0.41	-4.26	-0.33	3.57e-5	Metabolite levels;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.66	4.52	0.34	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.4	4.81	0.36	3.65e-6	Intraocular pressure;
PAAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.87	11.05	0.67	3.38e-21	Aortic root size;
PAAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.73	7.02	0.49	6.89e-11	Migraine;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg26690034	chr1:75198963	CRYZ;TYW3	0.53	4.89	0.37	2.57e-6	Resistin levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23106865	chr7:142374345	NA	-0.58	-6.54	-0.47	8.68e-10	Smoking initiation;
PAAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.98	6.84	0.49	1.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg15017067	chr4:17643749	FAM184B	0.38	4.32	0.33	2.85e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.49	4.4	0.34	2.05e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs797680	0.856	rs7553465	chr1:93644410	C/T	cg04535902	chr1:92947332	GFI1	0.46	4.39	0.34	2.12e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	7.05	0.5	5.97e-11	Total body bone mineral density;
PAAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.69	5.8	0.43	3.8e-8	Gut microbiome composition (summer);
PAAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg13468214	chr4:1046988	NA	-0.52	-4.9	-0.37	2.45e-6	Recombination rate (females);
PAAD	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg07220939	chr11:64358617	SLC22A12	-0.45	-4.73	-0.36	5.07e-6	Urate levels in obese individuals;
PAAD	cis	rs28386778	0.863	rs3817182	chr17:61783908	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	13.62	0.74	4e-28	Prudent dietary pattern;
PAAD	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.14	-0.45	6.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.72	-0.42	5.44e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs427941	0.632	rs201504	chr7:101759878	C/G	cg06246474	chr7:101738831	CUX1	0.43	4.28	0.33	3.24e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs9640161	0.789	rs68107602	chr7:150054146	C/T	cg13722127	chr7:150037890	RARRES2	0.55	5.42	0.4	2.29e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3764400	0.508	rs2240119	chr17:46111172	C/T	cg10706073	chr17:46328419	SKAP1	1.02	6.02	0.44	1.25e-8	Body mass index;
PAAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg09237302	chr4:906077	GAK	0.41	5.23	0.39	5.64e-7	Systemic sclerosis;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-5.95	-0.43	1.79e-8	Longevity;Endometriosis;
PAAD	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg24375607	chr4:120327624	NA	0.46	4.7	0.36	5.73e-6	Diastolic blood pressure;
PAAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.47	-4.49	-0.34	1.38e-5	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs6142102	0.625	rs6142051	chr20:32533018	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	4.55	0.35	1.1e-5	Skin pigmentation;
PAAD	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.36	4.96	0.37	1.84e-6	Oropharynx cancer;
PAAD	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.29	-0.6	1.53e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg08648136	chr8:956695	NA	0.41	4.32	0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.59	5.36	0.4	2.97e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1656368	0.726	rs73154307	chr3:158212541	G/A	cg16708174	chr3:158430962	RARRES1	0.6	5.44	0.4	2.07e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.9	-6.23	-0.45	4.34e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.3	-0.33	3.07e-5	Crohn's disease;
PAAD	cis	rs2262909	1.000	rs431328	chr19:22222236	A/G	cg11619707	chr19:22235551	ZNF257	-0.54	-5.43	-0.4	2.14e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20064047	chr1:155532716	ASH1L;LOC645676	0.65	7.59	0.52	2.99e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs425277	0.958	rs17372341	chr1:2042350	G/A	cg12639453	chr1:2035780	PRKCZ	0.48	4.25	0.33	3.77e-5	Height;
PAAD	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.7	9.36	0.6	9.8e-17	Hemoglobin concentration;
PAAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg27182935	chr16:89790473	ZNF276	-0.86	-4.25	-0.33	3.72e-5	Skin colour saturation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23551859	chr12:51632676	DAZAP2	0.65	6.35	0.46	2.4e-9	Obesity-related traits;
PAAD	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	7.09	0.5	4.61e-11	Lymphocyte counts;
PAAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.67	-7.11	-0.5	4.16e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9287719	0.649	rs2024433	chr2:10731504	G/C	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-8.8	-0.58	2.87e-15	Total body bone mineral density;
PAAD	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.6	5.36	0.4	2.98e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-4.82	-0.36	3.47e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.24	-0.56	7.33e-14	Hemoglobin concentration;
PAAD	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg15485101	chr11:133734466	NA	0.39	4.78	0.36	4.11e-6	Childhood ear infection;
PAAD	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.12	-0.7	4.33e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg26060667	chr1:247681242	NA	0.47	5.64	0.42	8.03e-8	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.59	-6.61	-0.47	6.16e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-5.52	-0.41	1.42e-7	Coronary artery disease;
PAAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.79	9.19	0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23161317	chr6:28129485	ZNF389	0.6	4.58	0.35	9.8e-6	Parkinson's disease;
PAAD	cis	rs8005172	0.712	rs10142867	chr14:88391765	A/G	cg18078958	chr14:88630771	NA	0.46	5.58	0.41	1.06e-7	Parkinson's disease;
PAAD	cis	rs2092319	0.649	rs2744770	chr1:26059650	C/T	cg12446045	chr1:25857419	NA	-0.47	-4.32	-0.33	2.77e-5	Nose morphology;
PAAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14119001	chr9:139324193	INPP5E	-0.63	-5.67	-0.42	6.88e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg21479132	chr6:26055353	NA	0.8	4.27	0.33	3.44e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs7301826	1.000	rs10773822	chr12:131289107	C/G	cg11011512	chr12:131303247	STX2	0.41	4.26	0.33	3.51e-5	Plasma plasminogen activator levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11865585	chr19:57752014	ZNF805	0.58	6.58	0.47	7.09e-10	Monocyte percentage of white cells;
PAAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.67	6.8	0.48	2.28e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg07733198	chr16:11096966	CLEC16A	-0.52	-5.07	-0.38	1.15e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.52	4.31	0.33	2.9e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01953317	chr2:55642894	CCDC88A	0.65	7.21	0.5	2.4e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	6.0	0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg03983476	chr2:10830698	NOL10	-0.59	-5.78	-0.42	4.18e-8	Prostate cancer;
PAAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.84	-0.37	3.22e-6	Breast cancer;
PAAD	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs28489187	0.667	rs233114	chr1:85786957	T/G	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.89	-9.8	-0.62	6.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg05709478	chr1:6581295	PLEKHG5	-0.73	-4.66	-0.35	6.79e-6	Body mass index;
PAAD	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.78	0.36	4.09e-6	Hirschsprung disease;
PAAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg01966878	chr4:90757139	SNCA	-0.64	-5.0	-0.38	1.58e-6	Neuroticism;
PAAD	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.58	6.14	0.45	6.81e-9	Testicular germ cell tumor;
PAAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.74	6.06	0.44	1.05e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
PAAD	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg08999081	chr20:33150536	PIGU	-0.5	-5.36	-0.4	2.97e-7	Height;
PAAD	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.46	-0.34	1.6e-5	Joint mobility (Beighton score);
PAAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.71	-6.56	-0.47	8.08e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.64	-5.96	-0.44	1.69e-8	Obesity-related traits;
PAAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.62	-6.34	-0.46	2.54e-9	Obesity-related traits;
PAAD	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-6.34	-0.46	2.54e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg00129232	chr17:37814104	STARD3	-0.55	-4.75	-0.36	4.58e-6	Self-reported allergy;
PAAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Body mass index;
PAAD	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.11e-20	Menopause (age at onset);
PAAD	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.83	-6.0	-0.44	1.35e-8	Coronary artery disease;
PAAD	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg14196790	chr5:131705035	SLC22A5	-0.46	-4.98	-0.37	1.68e-6	Blood metabolite levels;
PAAD	cis	rs8077577	0.945	rs11655731	chr17:18107525	G/T	cg16794390	chr17:18148240	FLII	0.6	4.83	0.36	3.26e-6	Obesity-related traits;
PAAD	cis	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg18809830	chr7:99032528	PTCD1	-0.97	-4.31	-0.33	2.89e-5	Blood metabolite levels;
PAAD	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.79	7.08	0.5	5.08e-11	Exhaled nitric oxide levels;
PAAD	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.15	-0.39	7.82e-7	Aortic root size;
PAAD	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg10208897	chr5:178548229	ADAMTS2	0.51	4.61	0.35	8.37e-6	Pubertal anthropometrics;
PAAD	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg10587741	chr22:38071170	LGALS1	0.43	4.76	0.36	4.5e-6	Fat distribution (HIV);
PAAD	cis	rs7713065	0.765	rs28655019	chr5:131770881	C/A	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.6	-0.35	8.93e-6	Lung function (FEV1/FVC);
PAAD	cis	rs2882667	0.598	rs288020	chr5:138224298	A/G	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs603424	0.554	rs10786586	chr10:102087962	A/G	cg10365880	chr10:102089681	PKD2L1	0.52	4.25	0.33	3.66e-5	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg14008862	chr17:28927542	LRRC37B2	0.76	4.73	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.74	8.5	0.57	1.61e-14	Height;
PAAD	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06850241	chr22:41845214	NA	-0.59	-5.08	-0.38	1.11e-6	Vitiligo;
PAAD	cis	rs2017305	0.915	rs116293147	chr10:70681113	A/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.72	7.34	0.51	1.2e-11	Uric acid levels;
PAAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg16205897	chr5:131564050	P4HA2	0.41	4.38	0.33	2.21e-5	Breast cancer;Mosquito bite size;
PAAD	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-5.21	-0.39	6.05e-7	QT interval;
PAAD	cis	rs4917300	0.647	rs2201176	chr8:143118987	A/G	cg26003909	chr8:143102224	NA	-0.33	-5.56	-0.41	1.2e-7	Amyotrophic lateral sclerosis;
PAAD	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16761752	chr17:38474378	RARA	-0.7	-6.52	-0.47	9.59e-10	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg16606324	chr3:10149918	C3orf24	0.67	5.4	0.4	2.51e-7	Alzheimer's disease;
PAAD	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.49	4.94	0.37	2.03e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6710503	0.574	rs56383418	chr2:24849053	A/G	cg21151432	chr2:25142229	ADCY3	-0.36	-4.25	-0.33	3.75e-5	Lung cancer in ever smokers;Breast cancer;
PAAD	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.77	7.38	0.51	9.52e-12	Corneal astigmatism;
PAAD	cis	rs4946717	0.740	rs6941301	chr6:106472457	T/C	cg02270332	chr6:106475062	NA	0.59	6.03	0.44	1.22e-8	Inflammatory bowel disease;
PAAD	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg07943548	chr15:86304357	KLHL25	-0.71	-5.93	-0.43	1.99e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1570884	0.503	rs7982555	chr13:50111510	G/A	cg08779649	chr13:50194554	NA	0.34	4.25	0.33	3.65e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg21977766	chr11:1107580	NA	0.43	4.37	0.33	2.33e-5	Alzheimer's disease (late onset);
PAAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg13444538	chr7:158905317	VIPR2	-0.51	-4.86	-0.37	2.84e-6	Facial morphology (factor 20);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16919615	chr2:55459782	RPS27A;C2orf63	0.71	7.24	0.51	2.12e-11	Obesity-related traits;
PAAD	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.46	-4.82	-0.36	3.52e-6	Red blood cell count;Reticulocyte count;
PAAD	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	5.54	0.41	1.33e-7	Monocyte percentage of white cells;
PAAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg02942461	chr3:52017566	ACY1	-0.6	-6.78	-0.48	2.5e-10	Body fat percentage;
PAAD	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg14146966	chr2:61757674	XPO1	0.39	4.71	0.36	5.46e-6	Tuberculosis;
PAAD	cis	rs4523957	0.928	rs216204	chr17:2196659	G/A	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	7.67	0.53	1.9e-12	Alzheimer's disease;
PAAD	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg06217245	chr20:33103252	DYNLRB1	0.39	4.38	0.34	2.17e-5	Height;
PAAD	cis	rs939584	1.000	rs6711039	chr2:624084	G/A	cg03610516	chr2:642275	NA	0.65	5.77	0.42	4.26e-8	Body mass index;
PAAD	cis	rs1419980	0.730	rs10505732	chr12:7726289	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg02743256	chr7:2109353	MAD1L1	-0.63	-4.58	-0.35	9.8e-6	Bipolar disorder;
PAAD	cis	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs12714314	0.756	rs10175420	chr2:1938138	C/T	cg22350835	chr2:1868857	MYT1L	0.53	5.08	0.38	1.07e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.55	-6.11	-0.44	8.16e-9	Body mass index;
PAAD	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.51	-0.34	1.31e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg02462569	chr6:150064036	NUP43	-0.51	-5.69	-0.42	6.49e-8	Lung cancer;
PAAD	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg03538708	chr1:25844672	NA	-0.52	-5.31	-0.4	3.86e-7	Plateletcrit;Mean corpuscular volume;
PAAD	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg13535736	chr9:111863775	C9orf5	-0.38	-4.32	-0.33	2.76e-5	Menarche (age at onset);
PAAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg05132306	chr1:1846340	CALML6	-0.42	-4.98	-0.37	1.73e-6	Body mass index;
PAAD	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.63	6.04	0.44	1.12e-8	Itch intensity from mosquito bite;
PAAD	cis	rs4835937	0.587	rs10213776	chr5:127314909	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	4.6	0.35	8.89e-6	Cancer;
PAAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.99	7.43	0.52	7.48e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17405427	chr6:135173473	NA	-0.61	-6.36	-0.46	2.19e-9	Obesity-related traits;
PAAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	6.52	0.47	9.77e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-1.16	-9.89	-0.63	4.04e-18	Height;
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.73	8.44	0.56	2.31e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs62264129	0.500	rs55947719	chr3:112033323	A/T	cg15541583	chr3:112013063	SLC9A10	-0.3	-4.82	-0.36	3.5e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg22442454	chr1:209979470	IRF6	0.53	4.59	0.35	9.05e-6	Coronary artery disease;
PAAD	cis	rs1801239	1.000	rs1801239	chr10:16919052	T/C	cg00939682	chr10:16933505	CUBN	0.67	5.02	0.38	1.4e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
PAAD	cis	rs1497406	0.898	rs36086195	chr1:16510894	C/T	cg20167471	chr1:16528984	ARHGEF19	0.45	4.42	0.34	1.87e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.64	-6.68	-0.48	4.25e-10	Iron status biomarkers;
PAAD	trans	rs1146751	0.674	rs1691483	chr3:84954203	A/C	cg21856205	chr7:94953877	PON1	0.68	6.55	0.47	8.54e-10	Photic sneeze reflex;
PAAD	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.72	8.39	0.56	3.08e-14	Height;
PAAD	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg00490450	chr3:139108681	COPB2	0.65	5.77	0.42	4.25e-8	Obesity-related traits;
PAAD	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	4.52	0.34	1.23e-5	Menarche (age at onset);
PAAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.11	-8.62	-0.57	8.04e-15	Diabetic kidney disease;
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.61	-0.35	8.49e-6	Prevalent atrial fibrillation;
PAAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg07703079	chr11:430292	ANO9	1.03	6.39	0.46	1.94e-9	Body mass index;
PAAD	cis	rs508970	0.556	rs639643	chr11:60920746	G/A	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.4	-4.27	-0.33	3.44e-5	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.53	0.57	1.41e-14	Lung cancer;
PAAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg26597838	chr10:835615	NA	0.51	5.55	0.41	1.25e-7	Survival in rectal cancer;
PAAD	cis	rs2115386	0.717	rs8108661	chr19:7204619	A/C	cg00428638	chr19:7224713	INSR	0.48	5.02	0.38	1.41e-6	Diabetic retinopathy;
PAAD	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.51	-8.24	-0.56	7.32e-14	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16263701	chr12:48213605	HDAC7	0.57	6.42	0.46	1.67e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07615351	chr16:75087014	ZNRF1	-0.66	-7.07	-0.5	5.26e-11	Obesity-related traits;
PAAD	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.87	-10.47	-0.65	1.16e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9557207	0.724	rs9557201	chr13:99989538	C/T	cg01259362	chr13:99101761	FARP1	0.45	4.63	0.35	7.9e-6	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
PAAD	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg11941060	chr3:133502564	NA	0.49	5.15	0.39	7.78e-7	Iron status biomarkers;
PAAD	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.64	6.41	0.46	1.77e-9	Blood protein levels;
PAAD	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.67	-6.23	-0.45	4.47e-9	Obesity-related traits;
PAAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg24737193	chr18:12778029	NA	0.63	5.58	0.41	1.09e-7	Inflammatory skin disease;
PAAD	cis	rs4742903	0.935	rs10991186	chr9:106996153	C/T	cg14250997	chr9:106856677	SMC2	-0.44	-4.78	-0.36	4.15e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg24130564	chr14:104152367	KLC1	-0.46	-4.53	-0.34	1.19e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.28	0.51	1.65e-11	Obesity-related traits;
PAAD	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.39	4.92	0.37	2.19e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg12963866	chr19:57752005	ZNF805	-0.47	-4.55	-0.35	1.09e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs9463078	0.801	rs9395079	chr6:45154433	C/T	cg25276700	chr6:44698697	NA	-0.48	-5.56	-0.41	1.2e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.87	9.18	0.6	3.02e-16	Diastolic blood pressure;
PAAD	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.73	5.86	0.43	2.74e-8	Schizophrenia;
PAAD	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.68	6.65	0.47	5.02e-10	Hip circumference;
PAAD	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs17155006	0.702	rs418255	chr7:107730034	A/G	cg05962710	chr7:107745446	LAMB4	-0.38	-4.53	-0.34	1.18e-5	Pneumococcal bacteremia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13707768	chr11:65081977	CDC42EP2	0.62	6.51	0.47	1.05e-9	Obesity-related traits;
PAAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.16	-11.91	-0.69	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg06042504	chr8:55087323	NA	0.62	6.06	0.44	1.05e-8	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1144333	0.655	rs1438175	chr1:76474728	T/C	cg22875332	chr1:76189707	ACADM	0.75	4.29	0.33	3.15e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg27449745	chr7:23145252	KLHL7	-0.51	-4.36	-0.33	2.43e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.88	0.37	2.61e-6	Personality dimensions;
PAAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.46	-6.19	-0.45	5.4e-9	Myeloid white cell count;
PAAD	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.69	10.28	0.64	3.86e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs11615916	0.790	rs73135231	chr12:62647835	T/G	cg11441379	chr12:63026424	NA	0.7	4.49	0.34	1.4e-5	Pulmonary function decline;
PAAD	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.68	0.42	6.59e-8	Schizophrenia;
PAAD	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg16506815	chr2:162101123	NA	-0.47	-4.74	-0.36	4.93e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.68	-7.58	-0.52	3.11e-12	Facial morphology (factor 20);
PAAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg05110241	chr16:68378359	PRMT7	-1.15	-8.45	-0.57	2.14e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg06714761	chr1:201096289	NA	0.33	4.87	0.37	2.83e-6	Permanent tooth development;
PAAD	cis	rs3136441	1.000	rs4752946	chr11:46896908	C/G	cg19486271	chr11:47235900	DDB2	0.53	4.3	0.33	3.04e-5	HDL cholesterol;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.44	0.46	1.51e-9	Alzheimer's disease;
PAAD	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.36	3.38e-6	Menarche (age at onset);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg20644453	chr21:33985338	C21orf59	0.62	7.02	0.49	7.06e-11	Metabolite levels  (X-11787);
PAAD	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.52	6.86	0.49	1.63e-10	Homoarginine levels;
PAAD	cis	rs4690686	0.836	rs10003662	chr4:177258951	C/G	cg17059388	chr4:177262070	NA	0.5	4.95	0.37	1.98e-6	Essential tremor;
PAAD	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-4.45	-0.34	1.67e-5	Lung cancer;
PAAD	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.99	0.54	3.12e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg00666640	chr1:248458726	OR2T12	0.49	5.03	0.38	1.37e-6	Common traits (Other);
PAAD	cis	rs7259965	0.654	rs71358950	chr19:41458434	G/A	cg20630647	chr19:41531805	NA	0.49	4.3	0.33	3.07e-5	Midgestational circulating levels of PBDEs;Midgestational circulating levels of organochlorine pesticides;
PAAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.57	5.97	0.44	1.65e-8	Menopause (age at onset);
PAAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.81	9.31	0.6	1.36e-16	Lung cancer;
PAAD	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg27490568	chr2:178487706	NA	0.79	6.66	0.48	4.67e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7225151	0.522	rs56229705	chr17:5014789	G/A	cg24768135	chr17:4805392	CHRNE;C17orf107	-0.69	-4.3	-0.33	3.09e-5	Alzheimer's disease (late onset);
PAAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs4455778	0.580	rs4437600	chr7:49090274	G/A	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg08699206	chr4:1595414	NA	0.48	4.57	0.35	1.01e-5	Obesity-related traits;
PAAD	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg01631408	chr1:248437212	OR2T33	-0.58	-5.31	-0.4	3.75e-7	Common traits (Other);
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg02725872	chr8:58115012	NA	-0.6	-4.91	-0.37	2.35e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1667255	0.830	rs4799579	chr18:29155172	T/C	cg18808318	chr18:29669225	NA	0.49	4.71	0.36	5.65e-6	Retinol levels;
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.87	11.33	0.68	6.02e-22	Vitiligo;
PAAD	cis	rs743757	0.878	rs12493985	chr3:50544715	T/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	4.94	0.37	2.07e-6	Diastolic blood pressure;
PAAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.46	6.32	0.46	2.69e-9	Cardiovascular disease risk factors;
PAAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs62408225	1.000	rs2021716	chr6:90941289	C/T	cg03795776	chr6:90687632	BACH2	0.47	4.73	0.36	5.17e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.27e-11	Vitamin D levels;
PAAD	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.81	-0.36	3.62e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg23119463	chr10:134592391	INPP5A	-0.44	-4.5	-0.34	1.33e-5	Migraine;
PAAD	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	4.33	0.33	2.73e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18357526	chr6:26021779	HIST1H4A	0.68	6.67	0.48	4.36e-10	Blood metabolite levels;
PAAD	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg10395934	chr14:104002654	TRMT61A	0.52	5.35	0.4	3.13e-7	Body mass index;
PAAD	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.48	4.83	0.36	3.3e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.14	17.58	0.82	1.82e-38	Cognitive function;
PAAD	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-1.0	-12.73	-0.72	1.01e-25	Refractive error;
PAAD	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-4.78	-0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs990171	1.000	rs6746271	chr2:103052995	G/C	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg04106633	chr4:1044584	NA	0.7	5.85	0.43	2.91e-8	Recombination rate (females);
PAAD	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.8	8.96	0.59	1.07e-15	Birth weight;
PAAD	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.89	-9.46	-0.61	5.54e-17	Corneal astigmatism;
PAAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.16	0.5	3.25e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg17372223	chr3:52568218	NT5DC2	0.45	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-4.93	-0.37	2.17e-6	QT interval;
PAAD	cis	rs3812111	0.545	rs2235980	chr6:116565504	G/A	cg18828861	chr6:116576566	TSPYL4	0.48	5.07	0.38	1.13e-6	Age-related macular degeneration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01889020	chr15:66545863	MEGF11	0.66	6.73	0.48	3.26e-10	Obesity-related traits;
PAAD	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.69	7.16	0.5	3.19e-11	Schizophrenia;
PAAD	trans	rs1440372	0.876	rs2119260	chr15:67011946	T/C	cg17375167	chr15:99192228	IGF1R	0.63	6.36	0.46	2.24e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.03	-0.44	1.21e-8	Prostate cancer;
PAAD	cis	rs16958440	0.867	rs114475395	chr18:44691010	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.46	4.34	0.33	2.61e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	7.52	0.52	4.33e-12	Renal function-related traits (BUN);
PAAD	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.45	4.63	0.35	7.75e-6	Longevity;Endometriosis;
PAAD	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg03433033	chr1:76189801	ACADM	0.5	5.21	0.39	5.93e-7	Daytime sleep phenotypes;
PAAD	cis	rs6076065	0.723	rs8183442	chr20:23415563	C/T	cg11657817	chr20:23433608	CST11	0.48	4.68	0.36	6.24e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9876781	1.000	rs9826195	chr3:48433635	A/C	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg02462569	chr6:150064036	NUP43	-0.47	-5.22	-0.39	5.78e-7	Lung cancer;
PAAD	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg08704217	chr1:110036942	CYB561D1	-0.5	-4.26	-0.33	3.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs72960926	1.000	rs72959000	chr6:75134312	A/T	cg13435101	chr6:74171350	MTO1	0.92	4.65	0.35	7.13e-6	Metabolite levels (MHPG);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20905746	chr15:79165638	MORF4L1	0.67	7.65	0.53	2.15e-12	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6694672	0.867	rs6679189	chr1:197100556	C/A	cg26994526	chr18:47719735	MYO5B	-0.8	-6.47	-0.46	1.24e-9	Asthma;
PAAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg12757816	chr2:10669957	NA	-0.46	-4.78	-0.36	4.14e-6	Prostate cancer;
PAAD	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.67	6.44	0.46	1.48e-9	Coronary artery disease;
PAAD	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg12633918	chr20:23549525	CST9L	-0.43	-4.76	-0.36	4.55e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.83	8.21	0.55	9.06e-14	Methadone dose in opioid dependence;
PAAD	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg26585981	chr11:48327164	OR4S1	-0.49	-4.36	-0.33	2.41e-5	Migraine - clinic-based;
PAAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg10556349	chr10:835070	NA	0.58	4.7	0.36	5.79e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.85	9.89	0.63	4e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.22	-0.55	8.24e-14	Hemoglobin concentration;
PAAD	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.71	7.91	0.54	5.06e-13	Schizophrenia;
PAAD	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg24881330	chr22:46731750	TRMU	1.08	5.55	0.41	1.27e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.88	-5.78	-0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-4.31	-0.33	2.96e-5	Height;
PAAD	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.76	7.71	0.53	1.55e-12	Retinal vascular caliber;
PAAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	5.12	0.38	9.13e-7	Rheumatoid arthritis;
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	6.8	0.48	2.25e-10	Lymphocyte counts;
PAAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.95	12.08	0.7	5.76e-24	Menopause (age at onset);
PAAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00125455	chr20:44574271	PCIF1	0.42	4.33	0.33	2.72e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.57	5.83	0.43	3.14e-8	Coronary artery disease;
PAAD	cis	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg15676455	chr3:128564943	NA	-0.8	-4.62	-0.35	8.2e-6	Dental caries;
PAAD	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.98	14.58	0.76	1.13e-30	Dental caries;
PAAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.62	6.17	0.45	5.98e-9	Multiple sclerosis;
PAAD	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	6.82	0.48	2.01e-10	Pulse pressure;
PAAD	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.47	5.42	0.4	2.24e-7	Platelet distribution width;
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.42	-6.2	-0.45	4.98e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.55	5.87	0.43	2.6e-8	Menopause (age at onset);
PAAD	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	12.0	0.7	9.02e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg05861140	chr6:150128134	PCMT1	-0.53	-6.06	-0.44	1.04e-8	Lung cancer;
PAAD	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.88	10.39	0.64	1.89e-19	Metabolic syndrome;
PAAD	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg18833306	chr6:118973337	C6orf204	-0.54	-4.39	-0.34	2.1e-5	Diastolic blood pressure;
PAAD	cis	rs4455778	0.501	rs35433930	chr7:49059052	T/C	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.36e-5	Lung cancer in never smokers;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.93	0.63	3.18e-18	Platelet count;
PAAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-5.54	-0.41	1.29e-7	Schizophrenia;
PAAD	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.74	6.18	0.45	5.52e-9	Schizophrenia;
PAAD	cis	rs7539409	0.667	rs4907039	chr1:84218227	A/G	cg10977910	chr1:84465055	TTLL7	0.89	5.02	0.38	1.44e-6	Alzheimer's disease;
PAAD	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg22143856	chr6:28129313	ZNF389	-0.52	-4.92	-0.37	2.26e-6	Parkinson's disease;
PAAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.8	8.29	0.56	5.67e-14	Schizophrenia;
PAAD	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg04829521	chr16:1839114	NUBP2	0.53	4.59	0.35	9.19e-6	Mean corpuscular volume;
PAAD	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.8	8.58	0.57	1.05e-14	Caffeine consumption;
PAAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.71	-6.58	-0.47	7.2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-6.53	-0.47	9.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.48	4.69	0.36	6.02e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6804624	0.636	rs2670330	chr3:99178087	A/T	cg02646433	chr3:99218170	NA	0.44	4.45	0.34	1.64e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	1.02	16.42	0.8	1.75e-35	Height;
PAAD	cis	rs61759167	1.000	rs2376495	chr1:3095126	C/G	cg22674798	chr1:3096360	PRDM16	-0.41	-4.73	-0.36	5.04e-6	Motion sickness;
PAAD	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.71	6.98	0.49	8.6e-11	Platelet distribution width;
PAAD	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg08835956	chr7:39171034	POU6F2	0.3	4.86	0.37	2.86e-6	IgG glycosylation;
PAAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg17105886	chr17:28927953	LRRC37B2	0.7	4.72	0.36	5.28e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg09980403	chr19:12975529	MAST1	0.29	4.77	0.36	4.36e-6	Mean corpuscular volume;
PAAD	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.57	6.42	0.46	1.64e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs75757892	0.505	rs113316204	chr6:7316956	T/C	cg02954307	chr6:7269328	NA	0.55	4.74	0.36	4.9e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	1.01	7.11	0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.78	8.47	0.57	1.96e-14	Obesity-related traits;
PAAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.08	0.55	1.91e-13	Prudent dietary pattern;
PAAD	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.39	-5.65	-0.42	7.55e-8	Breast cancer;
PAAD	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.65	6.48	0.47	1.19e-9	Coronary artery disease;
PAAD	cis	rs10915437	0.516	rs12409803	chr1:4193426	G/A	cg27165836	chr1:4193882	NA	0.58	5.95	0.43	1.8e-8	Migraine - clinic-based;
PAAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.58	0.61	2.62e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg27394845	chr17:28928406	LRRC37B2	0.7	4.42	0.34	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg02640540	chr1:67518911	SLC35D1	-0.52	-4.46	-0.34	1.58e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.54	-5.63	-0.42	8.48e-8	Homocysteine levels;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.53	5.77	0.42	4.36e-8	Life satisfaction;
PAAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00142150	chr22:38071001	LGALS1	0.8	9.02	0.59	7.44e-16	Fat distribution (HIV);
PAAD	cis	rs7897654	0.571	rs12765002	chr10:104635348	C/T	cg15744005	chr10:104629667	AS3MT	-0.5	-4.68	-0.36	6.24e-6	Schizophrenia;
PAAD	cis	rs7577696	0.924	rs6747488	chr2:32311284	C/T	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.67e-6	Inflammatory biomarkers;
PAAD	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg18551225	chr6:44695536	NA	-0.64	-7.31	-0.51	1.39e-11	Chin dimples;
PAAD	cis	rs6494488	0.500	rs72741344	chr15:64767531	C/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.77	-6.84	-0.49	1.78e-10	Exhaled nitric oxide output;
PAAD	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg21037935	chr19:58911965	NA	0.5	4.32	0.33	2.81e-5	Mean platelet volume;
PAAD	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-6.85	-0.49	1.76e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.63	6.0	0.44	1.35e-8	Hip circumference;
PAAD	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.52	-4.46	-0.34	1.62e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.51	4.59	0.35	9.3e-6	Height;
PAAD	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.48	5.08	0.38	1.07e-6	Morning vs. evening chronotype;
PAAD	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs12476592	0.602	rs4671509	chr2:63686004	C/T	cg10828910	chr2:63850056	LOC388955	0.52	4.49	0.34	1.42e-5	Childhood ear infection;
PAAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.57	4.79	0.36	3.96e-6	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg23283495	chr1:209979779	IRF6	0.63	5.95	0.43	1.74e-8	Coronary artery disease;
PAAD	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg16211469	chr6:24423932	MRS2	-0.57	-5.28	-0.39	4.37e-7	Liver enzyme levels;
PAAD	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26209169	chr5:1316264	NA	-0.37	-4.39	-0.34	2.13e-5	Lung cancer;
PAAD	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.53	-4.59	-0.35	9.32e-6	IgG glycosylation;
PAAD	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg03233332	chr7:66118400	NA	0.4	4.39	0.34	2.13e-5	Aortic root size;
PAAD	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.68	6.52	0.47	9.73e-10	Plateletcrit;Platelet count;
PAAD	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg01942863	chr7:99769432	GPC2	-0.49	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg02404636	chr22:31891804	SFI1	-0.49	-4.82	-0.36	3.42e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg23346134	chr3:49453900	TCTA	0.44	4.8	0.36	3.84e-6	Menarche (age at onset);
PAAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg07061783	chr6:25882402	NA	-0.48	-4.65	-0.35	7.28e-6	Blood metabolite levels;
PAAD	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-4.98	-0.37	1.7e-6	Inflammatory bowel disease;
PAAD	cis	rs2286503	0.839	rs2240726	chr7:22853135	C/T	cg11367502	chr7:22862612	TOMM7	0.52	5.28	0.39	4.4e-7	Fibrinogen;
PAAD	cis	rs9469913	0.542	rs114863007	chr6:34729158	G/A	cg14254433	chr6:34482411	PACSIN1	-0.82	-4.79	-0.36	3.99e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.55	5.64	0.42	8.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.19e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	1.05	13.07	0.73	1.23e-26	Breast cancer;
PAAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.86	9.91	0.63	3.71e-18	Gestational age at birth (maternal effect);
PAAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.72	-5.64	-0.42	7.91e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg16579770	chr16:72058938	DHODH	0.42	4.93	0.37	2.15e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.66	0.65	3.65e-20	Prudent dietary pattern;
PAAD	cis	rs7101378	0.577	rs7952458	chr11:108899235	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs6137287	0.889	rs4815022	chr20:21124872	T/C	cg04219410	chr20:21106687	PLK1S1	0.38	4.39	0.34	2.14e-5	Height;
PAAD	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.61	6.51	0.47	1.03e-9	Coronary artery disease;
PAAD	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.76	-5.96	-0.44	1.69e-8	Coronary artery disease;
PAAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.61	-8.14	-0.55	1.29e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs76866386	1.000	rs6756629	chr2:44065090	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.96	-5.58	-0.41	1.05e-7	Cholesterol, total;
PAAD	cis	rs8077577	0.895	rs11654741	chr17:18124470	C/A	cg16794390	chr17:18148240	FLII	0.6	4.89	0.37	2.53e-6	Obesity-related traits;
PAAD	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg09242541	chr1:10490025	APITD1	-0.41	-5.01	-0.38	1.52e-6	Prostate cancer;
PAAD	cis	rs790123	0.666	rs28666491	chr3:122389184	G/A	cg15604389	chr3:122379662	NA	0.53	4.85	0.37	3.01e-6	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.45	-6.96	-0.49	9.32e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9346353	0.699	rs9346355	chr6:70508966	A/G	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.36	-0.33	2.4e-5	Sleep duration;
PAAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.25	-0.33	3.7e-5	Life satisfaction;
PAAD	cis	rs10851478	0.500	rs10519225	chr15:49720778	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.58	5.5	0.41	1.55e-7	Oral cavity cancer;
PAAD	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-7.25	-0.51	2.01e-11	Colorectal cancer;
PAAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	4.33	0.33	2.7e-5	Tonsillectomy;
PAAD	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.62	6.67	0.48	4.39e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg14711859	chr11:8959438	ASCL3	0.37	4.41	0.34	1.94e-5	Immature fraction of reticulocytes;
PAAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg20090690	chr10:134436459	INPP5A	0.51	4.32	0.33	2.81e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg19980929	chr12:42632907	YAF2	0.59	6.93	0.49	1.1e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.92	-7.36	-0.51	1.09e-11	Blood protein levels;
PAAD	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.66	6.25	0.45	3.88e-9	Refractive astigmatism;
PAAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs7714584	1.000	rs10463240	chr5:150256853	A/C	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24475545	chr6:25153422	NA	-0.65	-6.57	-0.47	7.68e-10	Obesity-related traits;
PAAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg00666640	chr1:248458726	OR2T12	-0.51	-5.07	-0.38	1.13e-6	Common traits (Other);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13392534	chr20:3827558	MAVS	0.64	6.92	0.49	1.19e-10	Myopia (pathological);
PAAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.86	11.02	0.67	4.08e-21	Body mass index;
PAAD	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg14393609	chr7:65229607	NA	0.5	4.33	0.33	2.66e-5	Aortic root size;
PAAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	6.01	0.44	1.34e-8	Total body bone mineral density;
PAAD	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.55	5.38	0.4	2.81e-7	Morning vs. evening chronotype;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.53	0.47	9.1e-10	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.46	4.33	0.33	2.75e-5	Hip circumference;
PAAD	cis	rs8062405	0.728	rs8056890	chr16:28897452	G/A	cg09754948	chr16:28834200	ATXN2L	0.5	4.66	0.35	7e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.46	5.76	0.42	4.5e-8	Crohn's disease;
PAAD	cis	rs1144333	0.655	rs1144337	chr1:76278877	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-4.31	-0.33	2.92e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg00105475	chr2:10696890	NA	-0.67	-7.64	-0.53	2.32e-12	Prostate cancer;
PAAD	cis	rs1155998	1.000	rs1031868	chr8:98640062	A/G	cg18233405	chr8:98290148	TSPYL5	0.69	4.26	0.33	3.53e-5	Red cell distribution width;
PAAD	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.46	4.46	0.34	1.59e-5	High light scatter reticulocyte count;
PAAD	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.15	0.39	8.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.49	4.83	0.36	3.34e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs75920871	0.925	rs4936360	chr11:116893769	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.72	4.28	0.33	3.23e-5	Subjective well-being;
PAAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.49e-8	Obesity-related traits;
PAAD	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.5	-0.34	1.37e-5	Height;
PAAD	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.7	-0.48	3.84e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg01966878	chr4:90757139	SNCA	-0.46	-4.46	-0.34	1.59e-5	Dementia with Lewy bodies;
PAAD	cis	rs7255	0.545	rs9306895	chr2:20878153	T/C	cg07755735	chr2:20870362	GDF7	-0.44	-4.9	-0.37	2.48e-6	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23712970	chr14:23540735	ACIN1	0.69	8.04	0.55	2.32e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg20406979	chr6:167373233	NA	0.4	5.59	0.41	1.04e-7	Crohn's disease;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.74	5.6	0.41	9.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-8.81	-0.58	2.59e-15	Morning vs. evening chronotype;
PAAD	cis	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg11619707	chr19:22235551	ZNF257	0.58	5.77	0.42	4.26e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7715811	1.000	rs13436952	chr5:13773993	A/G	cg07548982	chr5:13769939	DNAH5	-0.57	-5.46	-0.4	1.9e-7	Subclinical atherosclerosis traits (other);
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9810890	1.000	rs73198894	chr3:128562396	T/C	cg19129842	chr3:128565090	NA	-0.87	-5.16	-0.39	7.67e-7	Dental caries;
PAAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.71	7.46	0.52	6.32e-12	Mean corpuscular volume;
PAAD	cis	rs11958404	0.615	rs10058832	chr5:157431866	T/A	cg05962755	chr5:157440814	NA	0.55	5.37	0.4	2.85e-7	IgG glycosylation;
PAAD	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-10.36	-0.64	2.37e-19	Morning vs. evening chronotype;
PAAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.76	5.68	0.42	6.69e-8	Initial pursuit acceleration;
PAAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg21951975	chr1:209979733	IRF6	0.57	5.74	0.42	4.93e-8	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24480577	chr20:62169334	PTK6	0.55	6.45	0.46	1.39e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.47	5.05	0.38	1.23e-6	Aortic root size;
PAAD	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-4.39	-0.34	2.13e-5	Magnesium levels;
PAAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.97	-0.37	1.76e-6	Personality dimensions;
PAAD	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.68	7.4	0.51	8.85e-12	Longevity;
PAAD	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.68	8.35	0.56	3.83e-14	Dupuytren's disease;
PAAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.77	5.96	0.44	1.71e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.5	5.09	0.38	1.04e-6	Red blood cell count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14538502	chr12:77269813	CSRP2	-0.53	-6.52	-0.47	9.62e-10	Monocyte percentage of white cells;
PAAD	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.66	7.05	0.5	5.97e-11	Platelet distribution width;
PAAD	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg09574807	chr5:156570058	MED7	-0.55	-6.55	-0.47	8.34e-10	Alzheimer's disease (survival time);
PAAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg26939375	chr7:64535504	NA	0.76	9.17	0.6	3.06e-16	Aortic root size;
PAAD	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg18612461	chr15:75251733	NA	-0.58	-7.2	-0.5	2.56e-11	Caffeine consumption;
PAAD	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg22827986	chr11:48284249	OR4X1	-0.37	-4.8	-0.36	3.74e-6	Migraine - clinic-based;
PAAD	trans	rs405795	1.000	rs2774180	chr13:89786288	C/T	cg27422345	chr7:1715242	NA	0.99	6.36	0.46	2.22e-9	Yeast infection;
PAAD	cis	rs7591163	1.000	rs940341	chr2:228724726	A/G	cg22994281	chr2:228029448	COL4A3;COL4A4	0.48	4.79	0.36	3.95e-6	Blood pressure;
PAAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13939156	chr17:80058883	NA	-0.42	-4.52	-0.34	1.23e-5	Life satisfaction;
PAAD	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.47	-5.07	-0.38	1.15e-6	Educational attainment;
PAAD	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-5.39	-0.4	2.65e-7	Daytime sleep phenotypes;
PAAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-4.58	-0.35	9.54e-6	Schizophrenia;
PAAD	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg18964960	chr10:1102726	WDR37	0.95	4.73	0.36	5.15e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs62229266	0.625	rs2051395	chr21:37431265	A/C	cg08632701	chr21:37451849	NA	0.61	6.77	0.48	2.59e-10	Mitral valve prolapse;
PAAD	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.6	-8.07	-0.55	1.98e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22162314	chr17:61951766	CSH2	-0.54	-5.52	-0.41	1.44e-7	Height;
PAAD	cis	rs735539	0.521	rs2763002	chr13:21369982	T/C	cg27499820	chr13:21296301	IL17D	0.51	4.65	0.35	7.22e-6	Dental caries;
PAAD	cis	rs4908768	0.629	rs12410886	chr1:8878809	A/C	cg25722041	chr1:8623473	RERE	0.5	4.27	0.33	3.45e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs72960926	0.744	rs1931273	chr6:74950660	A/T	cg03266952	chr6:74778945	NA	-1.17	-6.25	-0.45	3.94e-9	Metabolite levels (MHPG);
PAAD	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.31	-0.4	3.75e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11811982	0.793	rs115273856	chr1:227393091	G/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs10121009	0.587	rs750548	chr9:35385359	T/C	cg11846315	chr9:35647073	NA	-0.52	-4.68	-0.35	6.43e-6	Parkinson's disease;
PAAD	cis	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-5.04	-0.38	1.33e-6	Blood pressure (smoking interaction);
PAAD	cis	rs3136441	1.000	rs60258676	chr11:46897787	T/C	cg19486271	chr11:47235900	DDB2	0.53	4.36	0.33	2.42e-5	HDL cholesterol;
PAAD	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-4.34	-0.33	2.54e-5	Longevity;Endometriosis;
PAAD	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-1.34	-8.72	-0.58	4.53e-15	Depression;
PAAD	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	4.54	0.35	1.12e-5	Schizophrenia;
PAAD	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg08493051	chr2:3487164	NA	-0.76	-7.42	-0.52	7.83e-12	Neurofibrillary tangles;
PAAD	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.62	4.6	0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs901683	0.850	rs78999882	chr10:46076813	A/T	cg12869334	chr8:37699360	GPR124	1.07	7.25	0.51	1.94e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs1015213	0.609	rs117105522	chr8:52881328	G/T	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.78	6.18	0.45	5.55e-9	Neutrophil percentage of white cells;
PAAD	cis	rs57709857	0.957	rs55796824	chr8:38243128	A/G	cg16625770	chr8:38300134	FGFR1	-0.46	-4.29	-0.33	3.19e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1105228	0.679	rs4709933	chr6:165702705	C/T	cg20535254	chr6:165714960	C6orf118	0.42	4.34	0.33	2.54e-5	Number of pregnancies;Number of children;
PAAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg09324608	chr17:30823087	MYO1D	0.47	4.81	0.36	3.54e-6	Schizophrenia;
PAAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.14	-0.38	8.41e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg09473613	chr1:24152604	HMGCL	-0.47	-4.78	-0.36	4.07e-6	Immature fraction of reticulocytes;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg09165964	chr15:75287851	SCAMP5	0.43	4.42	0.34	1.83e-5	Caffeine consumption;
PAAD	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg01426195	chr3:39028469	NA	-0.64	-6.45	-0.46	1.4e-9	Handedness;
PAAD	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.64	6.5	0.47	1.1e-9	Height;
PAAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.76	8.06	0.55	2.14e-13	Menarche (age at onset);
PAAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	0.99	11.03	0.67	3.75e-21	Homoarginine levels;
PAAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.96	7.48	0.52	5.55e-12	Gut microbiome composition (summer);
PAAD	cis	rs10516089	0.504	rs10061285	chr5:171136523	C/T	cg21066063	chr5:171570130	STK10	0.34	4.25	0.33	3.74e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24921720	chr7:32909090	KBTBD2	-0.63	-6.34	-0.46	2.51e-9	Obesity-related traits;
PAAD	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.48	5.16	0.39	7.49e-7	Breast cancer;
PAAD	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.71	6.28	0.45	3.46e-9	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg01777861	chr4:56023843	NA	0.36	4.55	0.35	1.1e-5	Endometriosis;
PAAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.56	6.03	0.44	1.2e-8	Testicular germ cell tumor;
PAAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	9.49	0.61	4.67e-17	Gut microbiome composition (summer);
PAAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg23855989	chr12:50355821	AQP5	0.57	5.5	0.41	1.59e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.75	-8.11	-0.55	1.54e-13	Schizophrenia;
PAAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13012494	chr21:47604986	C21orf56	0.47	4.95	0.37	1.97e-6	Testicular germ cell tumor;
PAAD	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.69	-6.9	-0.49	1.33e-10	White matter hyperintensity burden;
PAAD	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.36	3.26e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26144002	chr17:74395472	UBE2O	-0.67	-6.74	-0.48	3.04e-10	Obesity-related traits;
PAAD	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.84	9.76	0.62	8.82e-18	Ulcerative colitis;
PAAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.62e-6	Breast cancer;
PAAD	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.72	5.49	0.41	1.66e-7	Mean corpuscular volume;
PAAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.38	4.25	0.33	3.71e-5	Melanoma;
PAAD	cis	rs9583531	0.891	rs3742182	chr13:111375132	C/T	cg24331049	chr13:111365604	ING1	0.77	5.29	0.39	4.1e-7	Coronary artery disease;
PAAD	cis	rs639012	0.599	rs472486	chr11:85831690	A/G	cg07180834	chr11:85838833	NA	-0.5	-5.77	-0.42	4.28e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.31	-0.33	2.91e-5	Coronary artery disease;
PAAD	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.68	5.65	0.42	7.63e-8	Alzheimer's disease;
PAAD	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.56	5.89	0.43	2.39e-8	Dupuytren's disease;
PAAD	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.76	8.05	0.55	2.17e-13	Hypertriglyceridemia;
PAAD	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg06713675	chr4:122721982	EXOSC9	0.47	4.58	0.35	9.53e-6	Type 2 diabetes;
PAAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg16342193	chr10:102329863	NA	-0.83	-8.94	-0.59	1.25e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg14181355	chr19:12984996	MAST1	-0.47	-4.34	-0.33	2.62e-5	Mean corpuscular volume;
PAAD	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.86	8.81	0.58	2.71e-15	Corneal astigmatism;
PAAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-4.72	-0.36	5.23e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg00450029	chr8:599525	NA	-0.8	-4.95	-0.37	1.94e-6	IgG glycosylation;
PAAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg04844267	chr4:1394941	NA	0.53	5.79	0.43	3.91e-8	Obesity-related traits;
PAAD	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.78	9.03	0.59	7.2e-16	Morning vs. evening chronotype;
PAAD	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.55	6.3	0.46	3.01e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06808430	chr7:102984880	DNAJC2	-0.71	-6.49	-0.47	1.17e-9	Neuroticism;
PAAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.45	6.14	0.45	6.99e-9	Cardiovascular disease risk factors;
PAAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.87	-9.68	-0.62	1.44e-17	Cognitive function;
PAAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.79	8.91	0.59	1.46e-15	Lung cancer;
PAAD	cis	rs11264799	0.648	rs6427395	chr1:157690469	T/G	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg24687543	chr11:63912206	MACROD1	0.62	5.39	0.4	2.67e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	10.21	0.64	5.68e-19	Platelet count;
PAAD	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg10534938	chr5:1868639	NA	0.47	6.23	0.45	4.38e-9	Cardiovascular disease risk factors;
PAAD	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.51	5.42	0.4	2.26e-7	Male-pattern baldness;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19410378	chr7:152551811	ACTR3B	0.56	6.54	0.47	8.77e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg21937377	chr3:194868750	C3orf21	0.48	4.31	0.33	2.94e-5	Non-small cell lung cancer;
PAAD	cis	rs6594713	0.533	rs35280754	chr5:112967800	G/C	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	1.15	8.42	0.56	2.65e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.42	4.39	0.34	2.08e-5	Height;
PAAD	trans	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.55	5.44	0.4	2.06e-7	Lung cancer;
PAAD	cis	rs4343996	0.811	rs6462030	chr7:3392526	G/A	cg21248987	chr7:3385318	SDK1	-0.48	-5.1	-0.38	1.01e-6	Motion sickness;
PAAD	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-4.42	-0.34	1.89e-5	Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.02	-0.49	6.86e-11	Life satisfaction;
PAAD	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg27539214	chr16:67997921	SLC12A4	-0.73	-4.84	-0.37	3.1e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.76	9.07	0.59	5.82e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs7713065	0.765	rs4235801	chr5:131782444	T/C	cg14196790	chr5:131705035	SLC22A5	0.44	4.36	0.33	2.36e-5	Lung function (FEV1/FVC);
PAAD	cis	rs75757892	0.544	rs75689467	chr6:7316253	T/C	cg02954307	chr6:7269328	NA	0.54	4.49	0.34	1.41e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.46	-0.34	1.57e-5	Renal cell carcinoma;
PAAD	cis	rs1075265	0.692	rs805318	chr2:54135052	C/T	cg04546899	chr2:54196757	PSME4	0.31	4.5	0.34	1.35e-5	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14282440	chr2:27593116	EIF2B4;SNX17	0.67	6.63	0.47	5.61e-10	Obesity-related traits;
PAAD	cis	rs2017305	1.000	rs78309176	chr10:70715307	G/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs1692580	0.807	rs12040414	chr1:2192948	T/C	cg21194808	chr1:2205498	SKI	0.44	4.37	0.33	2.33e-5	Coronary artery disease;
PAAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.6	-6.27	-0.45	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	5.67	0.42	7.05e-8	Lymphocyte counts;
PAAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg21395723	chr22:39101663	GTPBP1	0.45	4.44	0.34	1.7e-5	Menopause (age at onset);
PAAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.81	7.88	0.54	5.99e-13	Tuberculosis;
PAAD	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.7	-7.57	-0.52	3.39e-12	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg16898833	chr6:26189333	HIST1H4D	0.86	5.73	0.42	5.25e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.98	-0.49	8.77e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.35	-0.4	3.11e-7	Bipolar disorder;
PAAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg22601191	chr20:60968625	CABLES2	0.57	4.86	0.37	2.92e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg19254793	chr6:44695348	NA	0.45	4.31	0.33	2.94e-5	Total body bone mineral density;
PAAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-5.15	-0.39	8.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.65	6.79	0.48	2.34e-10	Coronary artery disease;
PAAD	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.58	4.86	0.37	2.84e-6	Response to antidepressants in depression;
PAAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.48	5.17	0.39	7.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7072216	0.687	rs10883086	chr10:100155743	A/G	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.93	12.12	0.7	4.26e-24	Mean corpuscular volume;
PAAD	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.61	-5.79	-0.43	3.87e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.28e-10	Eye color traits;
PAAD	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.86e-5	Height;
PAAD	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg27565382	chr3:53032988	SFMBT1	0.73	4.36	0.33	2.36e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs8040855	0.756	rs2342118	chr15:85693016	C/T	cg08123816	chr15:85640762	PDE8A	0.39	4.53	0.34	1.18e-5	Bulimia nervosa;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg01244601	chr4:120671846	NA	-0.5	-4.28	-0.33	3.23e-5	Corneal astigmatism;
PAAD	cis	rs11235843	0.636	rs2140892	chr11:73422879	A/G	cg18195628	chr11:73498948	MRPL48	-0.69	-5.09	-0.38	1.03e-6	Hand grip strength;
PAAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.7	-5.78	-0.42	4.19e-8	Neuroticism;
PAAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.34	0.33	2.59e-5	Personality dimensions;
PAAD	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.4	0.4	2.56e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7737355	0.812	rs13172003	chr5:131087656	T/C	cg06307176	chr5:131281290	NA	0.5	4.36	0.33	2.42e-5	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg06131755	chr6:160182447	ACAT2	-0.47	-4.27	-0.33	3.45e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.59	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.85	5.33	0.4	3.52e-7	Schizophrenia;
PAAD	cis	rs3762637	0.882	rs9856011	chr3:122093570	G/A	cg24169773	chr3:122142474	KPNA1	-0.65	-4.45	-0.34	1.69e-5	LDL cholesterol levels;
PAAD	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.66	6.3	0.46	2.98e-9	Corneal astigmatism;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26144002	chr17:74395472	UBE2O	0.63	6.3	0.46	3.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19784903	chr17:45786737	TBKBP1	-0.52	-5.51	-0.41	1.53e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.84	6.12	0.44	7.7e-9	Eosinophil percentage of granulocytes;
PAAD	cis	rs1499972	0.618	rs62264769	chr3:117643464	A/T	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.89	0.54	5.42e-13	Prudent dietary pattern;
PAAD	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg18551225	chr6:44695536	NA	-0.64	-7.29	-0.51	1.56e-11	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.58	6.11	0.44	7.92e-9	Schizophrenia;
PAAD	cis	rs1667255	0.830	rs1473342	chr18:29183812	T/C	cg18808318	chr18:29669225	NA	0.49	4.69	0.36	5.97e-6	Retinol levels;
PAAD	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg03517284	chr6:25882590	NA	-0.54	-4.45	-0.34	1.63e-5	Iron status biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20495540	chr11:30431965	MPPED2	-0.52	-6.42	-0.46	1.61e-9	Monocyte percentage of white cells;
PAAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.85	10.29	0.64	3.64e-19	Menopause (age at onset);
PAAD	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	1.0	12.85	0.72	4.62e-26	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg23019889	chr1:146544044	NA	0.37	4.38	0.33	2.2e-5	HIV-1 control;
PAAD	cis	rs9888739	0.764	rs8056276	chr16:31323916	A/T	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.42	0.56	2.68e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2555155	0.935	rs2555158	chr11:6520164	T/A	cg11185456	chr11:6592066	DNHD1	0.41	4.37	0.33	2.26e-5	DNA methylation (variation);
PAAD	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.62	5.85	0.43	2.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.9e-5	Life satisfaction;
PAAD	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.35	4.57	0.35	1.01e-5	Educational attainment (years of education);
PAAD	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg10208897	chr5:178548229	ADAMTS2	0.51	4.56	0.35	1.06e-5	Pubertal anthropometrics;
PAAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14180030	chr9:123475675	MEGF9	0.46	4.98	0.37	1.69e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.89	6.93	0.49	1.14e-10	Prostate cancer;
PAAD	cis	rs16975963	0.790	rs11083434	chr19:38283953	A/G	cg08679971	chr19:38281047	NA	0.51	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.51	-0.34	1.29e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11644478	chr21:40555479	PSMG1	0.87	8.33	0.56	4.37e-14	Cognitive function;
PAAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.5	4.78	0.36	4.08e-6	Mood instability;
PAAD	cis	rs58521262	0.585	rs11669602	chr19:22952249	C/T	cg07749055	chr19:23076870	NA	-0.57	-4.28	-0.33	3.29e-5	Testicular germ cell tumor;
PAAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.62	-5.08	-0.38	1.12e-6	Platelet count;
PAAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-8.01	-0.54	2.77e-13	Lymphocyte counts;
PAAD	cis	rs621942	0.950	rs637193	chr11:85724509	G/A	cg07180834	chr11:85838833	NA	-0.46	-4.28	-0.33	3.24e-5	Tourette syndrome;
PAAD	cis	rs3771514	0.543	rs12464815	chr2:70689913	A/G	cg18150120	chr2:71134936	VAX2	-0.38	-4.52	-0.34	1.22e-5	Obesity-related traits;
PAAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.74	8.73	0.58	4.27e-15	Emphysema distribution in smoking;
PAAD	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.65	4.36	0.33	2.41e-5	Skin colour saturation;
PAAD	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.58	-0.35	9.55e-6	Mood instability;
PAAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.75	-0.42	4.83e-8	Coronary artery disease;
PAAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06850241	chr22:41845214	NA	0.61	5.4	0.4	2.56e-7	Vitiligo;
PAAD	trans	rs901683	1.000	rs34654893	chr10:45979828	C/T	cg14076390	chr17:34947837	DHRS11	0.95	6.97	0.49	9.02e-11	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs61931739	0.649	rs815046	chr12:33720602	C/T	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg04254540	chr16:71951199	KIAA0174	-0.6	-5.17	-0.39	7.27e-7	Coronary artery disease;
PAAD	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.55	6.2	0.45	5.12e-9	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.56	5.44	0.4	2.05e-7	Endometrial cancer;
PAAD	cis	rs939584	1.000	rs4854344	chr2:638144	G/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg20893579	chr22:38215064	NA	0.52	4.91	0.37	2.29e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.98	10.7	0.66	2.79e-20	Corneal astigmatism;
PAAD	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.21	8.19	0.55	9.88e-14	Lung cancer in ever smokers;
PAAD	cis	rs308971	0.563	rs167408	chr3:12088448	A/G	cg02700894	chr3:12045449	SYN2	0.62	4.48	0.34	1.46e-5	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.13e-5	Noise-induced hearing loss;
PAAD	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-4.81	-0.36	3.67e-6	Coffee consumption (cups per day);
PAAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.61	4.34	0.33	2.59e-5	Pulse pressure;
PAAD	cis	rs12753569	0.967	rs6696116	chr1:76483732	C/T	cg00791851	chr1:76518896	NA	-0.41	-4.25	-0.33	3.7e-5	Personality dimensions;
PAAD	cis	rs4834770	0.685	rs4496567	chr4:120175625	A/T	cg09307838	chr4:120376055	NA	0.55	5.13	0.38	8.75e-7	Blood protein levels;
PAAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.56	-7.07	-0.5	5.4e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.31	0.46	2.94e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-1.0	-7.07	-0.5	5.28e-11	Dupuytren's disease;
PAAD	cis	rs2371030	0.965	rs2216403	chr2:211573391	G/T	cg18417063	chr2:211583084	NA	-0.43	-4.26	-0.33	3.61e-5	Non-small cell lung cancer;
PAAD	cis	rs9659323	1.000	rs11584380	chr1:119517420	C/T	cg26570165	chr1:119541833	NA	-0.45	-4.54	-0.35	1.12e-5	Body mass index;
PAAD	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.53	4.77	0.36	4.29e-6	Optic cup area;
PAAD	trans	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg02765225	chr15:44083979	SERF2	0.62	6.39	0.46	1.94e-9	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.53	-4.27	-0.33	3.47e-5	Coronary artery disease;
PAAD	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg25839482	chr15:75931953	IMP3	0.44	4.3	0.33	3.08e-5	Sudden cardiac arrest;
PAAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg19008133	chr3:123124015	ADCY5	0.63	4.47	0.34	1.53e-5	LDL cholesterol levels;
PAAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.1	0.55	1.67e-13	Height;
PAAD	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg11766577	chr21:47581405	C21orf56	0.4	4.5	0.34	1.34e-5	Testicular germ cell tumor;
PAAD	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg05895507	chr15:77155635	SCAPER	-0.41	-4.58	-0.35	9.56e-6	Blood metabolite levels;
PAAD	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.68	-7.68	-0.53	1.86e-12	Menopause (age at onset);
PAAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-5.13	-0.38	8.77e-7	Acylcarnitine levels;
PAAD	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.48	6.0	0.44	1.37e-8	Crohn's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20643362	chr19:30206369	C19orf12	-0.54	-6.79	-0.48	2.4e-10	Body fat percentage;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04571941	chr7:5463284	TNRC18	0.51	6.31	0.46	2.89e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.93	7.83	0.54	7.54e-13	Alzheimer's disease;
PAAD	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.7	6.72	0.48	3.47e-10	Obesity-related traits;
PAAD	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.68	-6.18	-0.45	5.74e-9	Mean corpuscular volume;
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg24879335	chr3:133465180	TF	0.56	5.99	0.44	1.45e-8	Iron status biomarkers;
PAAD	cis	rs7631605	0.935	rs3774341	chr3:37045233	A/C	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.26e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.92	12.63	0.72	1.85e-25	Prudent dietary pattern;
PAAD	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.99	8.74	0.58	4.02e-15	Bipolar disorder;
PAAD	cis	rs10540	0.915	rs35333170	chr11:526478	A/G	cg03576123	chr11:487126	PTDSS2	-1.2	-6.28	-0.45	3.45e-9	Body mass index;
PAAD	cis	rs30380	0.632	rs27640	chr5:96127905	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-5.24	-0.39	5.17e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-7.01	-0.49	7.33e-11	Type 2 diabetes;
PAAD	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.46	5.43	0.4	2.14e-7	Atrioventricular conduction;
PAAD	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg00262122	chr8:11665843	FDFT1	0.56	5.21	0.39	6.16e-7	Neuroticism;
PAAD	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.27	-0.56	6.4e-14	Eye color traits;
PAAD	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg25558440	chr8:11882962	NA	-0.45	-4.3	-0.33	3.04e-5	Neuroticism;
PAAD	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.09	0.38	1.03e-6	High light scatter reticulocyte count;
PAAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs28830936	0.966	rs28432037	chr15:42126779	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.99e-10	Diastolic blood pressure;
PAAD	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.88	11.23	0.67	1.1e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-4.44	-0.34	1.7e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs3733418	0.860	rs869867	chr4:165930747	C/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.57	-5.17	-0.39	7.38e-7	Obesity-related traits;
PAAD	cis	rs4239252	0.929	rs4251787	chr17:34172581	G/A	cg19411729	chr17:34207663	CCL5	-0.53	-4.69	-0.36	6.05e-6	Blood protein levels;
PAAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg23346134	chr3:49453900	TCTA	-0.46	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg00579200	chr11:133705235	NA	0.46	5.04	0.38	1.28e-6	Childhood ear infection;
PAAD	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg19423196	chr10:82049429	MAT1A	0.5	4.92	0.37	2.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9467160	0.834	rs9467172	chr6:24455175	A/G	cg16211469	chr6:24423932	MRS2	0.48	4.44	0.34	1.71e-5	Liver enzyme levels;
PAAD	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg16174234	chr19:33463305	C19orf40;CCDC123	-0.55	-4.78	-0.36	4.14e-6	Red blood cell traits;
PAAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.91	-6.93	-0.49	1.12e-10	Initial pursuit acceleration;
PAAD	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg07725925	chr16:89976287	TCF25	0.68	4.42	0.34	1.83e-5	Skin colour saturation;
PAAD	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2019216	0.521	rs10871487	chr17:21939193	G/A	cg22648282	chr17:21454238	C17orf51	-0.56	-5.51	-0.41	1.49e-7	Pelvic organ prolapse;
PAAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.63	5.4	0.4	2.5e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.45	-4.83	-0.36	3.35e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs67072384	1.000	rs7120700	chr11:72444676	A/G	cg04827223	chr11:72435913	ARAP1	-0.59	-4.46	-0.34	1.56e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
PAAD	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	9.93	0.63	3.14e-18	Cognitive test performance;
PAAD	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg00738919	chr7:1100172	C7orf50	0.76	5.33	0.4	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg02254261	chr7:158964346	NA	-0.61	-4.74	-0.36	4.79e-6	Myopia (pathological);
PAAD	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.68	6.82	0.48	1.99e-10	Orofacial clefts;
PAAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.76	7.25	0.51	1.97e-11	Pancreatic cancer;
PAAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-6.28	-0.45	3.44e-9	Menarche (age at onset);
PAAD	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.63	-6.24	-0.45	4.11e-9	Uric acid clearance;
PAAD	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg11601000	chr22:42348013	LOC339674	0.42	4.88	0.37	2.68e-6	Cognitive function;
PAAD	cis	rs12311304	0.965	rs56148413	chr12:15391157	G/A	cg08258403	chr12:15378311	NA	0.37	4.7	0.36	5.73e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg21226059	chr5:178986404	RUFY1	-0.6	-7.04	-0.5	6.11e-11	Lung cancer;
PAAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-4.78	-0.36	4.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.62	-7.15	-0.5	3.37e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg06606381	chr12:133084897	FBRSL1	-1.21	-7.57	-0.52	3.29e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.49	-4.58	-0.35	9.44e-6	Multiple sclerosis;
PAAD	cis	rs910187	0.678	rs6066231	chr20:45818895	C/T	cg27589058	chr20:45804311	EYA2	-0.48	-5.31	-0.4	3.88e-7	Migraine;
PAAD	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.46	5.83	0.43	3.28e-8	Sitting height ratio;
PAAD	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.69	9.0	0.59	8.53e-16	Hemoglobin concentration;
PAAD	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	8.3	0.56	5.25e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	5.95e-6	Lung cancer;
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.58e-5	Life satisfaction;
PAAD	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg18892244	chr7:807596	HEATR2	-0.61	-6.43	-0.46	1.6e-9	Subjective well-being;
PAAD	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.49	4.83	0.36	3.37e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4919087	0.590	rs1088187	chr10:99027581	T/C	cg25902810	chr10:99078978	FRAT1	-0.55	-4.9	-0.37	2.47e-6	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21909643	chr6:20534796	CDKAL1	0.61	6.37	0.46	2.13e-9	Obesity-related traits;
PAAD	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-6.07	-0.44	1e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.42	0.46	1.64e-9	Personality dimensions;
PAAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg14092988	chr3:52407081	DNAH1	-0.43	-5.35	-0.4	3.2e-7	Bipolar disorder;
PAAD	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg18612461	chr15:75251733	NA	-0.56	-6.98	-0.49	8.36e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg14008862	chr17:28927542	LRRC37B2	0.8	5.39	0.4	2.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs4919087	0.561	rs793522	chr10:99022614	T/G	cg25902810	chr10:99078978	FRAT1	-0.55	-4.9	-0.37	2.47e-6	Monocyte count;
PAAD	cis	rs4462272	0.584	rs7923726	chr10:101963299	G/T	cg02250046	chr10:101825185	CPN1	-0.39	-4.35	-0.33	2.54e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg04330084	chr7:123175371	IQUB	0.51	4.43	0.34	1.8e-5	Plateletcrit;Platelet count;
PAAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs4740619	0.716	rs10810505	chr9:15955155	C/T	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.53	-4.96	-0.37	1.9e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.72	0.53	1.46e-12	Metabolite levels;
PAAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.64	5.32	0.4	3.7e-7	Gut microbiome composition (summer);
PAAD	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.86	0.49	1.67e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	trans	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-5.46	-0.4	1.92e-7	Reticulocyte count;
PAAD	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.66	6.44	0.46	1.5e-9	Coronary artery disease;
PAAD	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs42648	0.564	rs259134	chr7:89795852	G/A	cg27367526	chr7:89841692	STEAP2	-0.32	-4.47	-0.34	1.51e-5	Homocysteine levels;
PAAD	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg09945482	chr18:12777974	NA	0.6	5.35	0.4	3.18e-7	Inflammatory skin disease;
PAAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.96	11.64	0.69	8.56e-23	Longevity;
PAAD	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	ch.11.42038R	chr11:967971	AP2A2	0.6	6.23	0.45	4.46e-9	Alzheimer's disease (late onset);
PAAD	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.74	-8.32	-0.56	4.76e-14	Colorectal cancer;
PAAD	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.23	-0.51	2.26e-11	Neuroticism;
PAAD	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.36	0.46	2.2e-9	Aortic root size;
PAAD	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg16386425	chr10:429943	DIP2C	0.5	5.49	0.41	1.61e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg27411982	chr8:10470053	RP1L1	0.47	4.83	0.36	3.26e-6	Retinal vascular caliber;
PAAD	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.44	0.34	1.75e-5	Educational attainment;
PAAD	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.83	-8.47	-0.57	1.93e-14	Educational attainment;
PAAD	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg03417191	chr3:183542750	MAP6D1	-0.59	-5.26	-0.39	4.77e-7	Menopause (age at onset);
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg02555727	chr12:129281546	SLC15A4	-0.45	-4.71	-0.36	5.62e-6	Systemic lupus erythematosus;
PAAD	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg17326555	chr1:119535693	NA	-0.43	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs939584	1.000	rs11127489	chr2:646081	C/T	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-4.58	-0.35	9.46e-6	Resting heart rate;
PAAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6466055	0.748	rs10281422	chr7:104844519	G/A	cg04380332	chr7:105027541	SRPK2	-0.66	-7.47	-0.52	5.85e-12	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.75	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg14146966	chr2:61757674	XPO1	0.38	4.83	0.36	3.37e-6	Tuberculosis;
PAAD	cis	rs59888335	1.000	rs11127706	chr3:80677767	T/A	cg21735741	chr3:80819488	NA	0.57	5.13	0.38	8.77e-7	Schizophrenia;
PAAD	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	9.25	0.6	1.96e-16	Response to antipsychotic treatment;
PAAD	cis	rs1420338	0.933	rs10253869	chr7:34149922	A/G	cg01275685	chr7:34179230	BMPER	-0.53	-5.02	-0.38	1.46e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-4.65	-0.35	7.23e-6	Mean corpuscular volume;
PAAD	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.77	8.37	0.56	3.52e-14	Aortic root size;
PAAD	cis	rs2834188	1.000	rs2834187	chr21:34687410	A/G	cg04842828	chr21:34696676	IFNAR1	0.46	4.44	0.34	1.69e-5	Narcolepsy;
PAAD	cis	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg21546286	chr11:48923668	NA	-0.54	-5.57	-0.41	1.14e-7	HDL cholesterol;
PAAD	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-12.99	-0.73	1.99e-26	Height;
PAAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08871383	chr2:46524363	EPAS1	0.61	6.76	0.48	2.82e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2133450	0.712	rs1499213	chr3:7370210	T/A	cg19930620	chr3:7340148	GRM7	-0.47	-5.31	-0.4	3.84e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs76917914	0.537	rs3780471	chr9:100847551	G/T	cg21225548	chr9:100864335	TRIM14	-0.47	-5.01	-0.38	1.49e-6	Immature fraction of reticulocytes;
PAAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.63	8.14	0.55	1.33e-13	Renal cell carcinoma;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24352075	chr11:125462730	STT3A	-0.58	-6.74	-0.48	3.12e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.61	3.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.66	-5.95	-0.43	1.82e-8	Coronary heart disease;
PAAD	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.41	4.27	0.33	3.39e-5	Breast cancer;
PAAD	cis	rs6142102	0.847	rs4911413	chr20:32721775	T/A	cg06115741	chr20:33292138	TP53INP2	0.51	4.36	0.33	2.37e-5	Skin pigmentation;
PAAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-4.59	-0.35	9.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4148087	1.000	rs9975154	chr21:43639741	C/G	cg08841829	chr21:43638893	ABCG1	-0.74	-4.93	-0.37	2.08e-6	Eating disorder in bipolar disorder;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16333971	chr13:30424821	UBL3	-0.81	-7.39	-0.51	8.97e-12	Neuroticism;
PAAD	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.66	5.94	0.43	1.87e-8	Mean platelet volume;
PAAD	cis	rs9372253	0.564	rs2057151	chr6:110716608	G/C	cg01119278	chr6:110721349	DDO	-0.48	-4.47	-0.34	1.51e-5	Platelet distribution width;
PAAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.43	4.67	0.35	6.53e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs590121	0.876	rs589203	chr11:75275808	C/T	cg26104986	chr11:75275303	SERPINH1	-0.46	-4.53	-0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.31	-0.33	2.98e-5	Biliary atresia;
PAAD	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.56	5.83	0.43	3.17e-8	Cognitive function;
PAAD	cis	rs6460942	0.818	rs73299043	chr7:12251595	C/G	cg06484146	chr7:12443880	VWDE	-0.67	-4.94	-0.37	2.02e-6	Coronary artery disease;
PAAD	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.52	5.24	0.39	5.28e-7	Dupuytren's disease;
PAAD	cis	rs17266958	1.000	rs79636454	chr9:83228420	C/A	cg13911576	chr9:84174038	NA	0.81	4.36	0.33	2.39e-5	Preschool internalizing problems;
PAAD	cis	rs9463078	0.605	rs17422760	chr6:44885288	C/T	cg25276700	chr6:44698697	NA	0.4	4.8	0.36	3.8e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9638182	0.848	rs34121855	chr7:73040814	T/G	cg07467649	chr7:72856462	BAZ1B	0.51	4.59	0.35	9.18e-6	Triglycerides;
PAAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs74161807	0.540	rs74161808	chr10:118389209	A/G	cg10511988	chr10:118891706	VAX1	0.37	4.4	0.34	2.01e-5	Loneliness (multivariate analysis);Loneliness;
PAAD	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-5.25	-0.39	5.07e-7	Morning vs. evening chronotype;
PAAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.74	-6.32	-0.46	2.7e-9	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-7.69	-0.53	1.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.5	-4.3	-0.33	3.03e-5	Neuroticism;
PAAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg14703610	chr5:56206110	C5orf35	0.56	5.23	0.39	5.44e-7	Initial pursuit acceleration;
PAAD	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04215944	chr14:24712033	TINF2	0.63	6.52	0.47	1.01e-9	Obesity-related traits;
PAAD	cis	rs2247341	0.577	rs2236995	chr4:1704542	T/G	cg05874882	chr4:1763078	NA	-0.27	-4.64	-0.35	7.45e-6	Hip circumference adjusted for BMI;Height;
PAAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.72	6.33	0.46	2.68e-9	Inflammatory skin disease;
PAAD	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.58	-5.69	-0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg04254540	chr16:71951199	KIAA0174	-0.58	-5.13	-0.38	8.68e-7	Coronary artery disease;
PAAD	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	5.31	0.4	3.89e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.71	7.56	0.52	3.56e-12	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-5.16	-0.39	7.44e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.58	-0.35	9.67e-6	Height;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03605463	chr16:89740564	NA	-0.49	-4.56	-0.35	1.03e-5	Vitiligo;
PAAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.85	7.72	0.53	1.47e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27511599	chr7:32358540	NA	0.94	5.17	0.39	7.33e-7	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09174502	chr11:130079372	ST14	0.64	6.48	0.47	1.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.2	12.3	0.71	1.4e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	4.8	0.36	3.83e-6	Hip circumference;
PAAD	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.55e-15	Chronic sinus infection;
PAAD	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.78	-6.52	-0.47	9.79e-10	Mean corpuscular hemoglobin;
PAAD	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-6.87	-0.49	1.55e-10	Morning vs. evening chronotype;
PAAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.72	-7.23	-0.51	2.16e-11	Urate levels in lean individuals;
PAAD	cis	rs7631605	0.905	rs1860968	chr3:37091325	G/A	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9961915	0.647	rs11661254	chr18:24678996	A/G	cg02576938	chr4:89442616	PIGY	-0.62	-6.53	-0.47	9.17e-10	Dental caries;
PAAD	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.74	6.19	0.45	5.32e-9	Exhaled nitric oxide output;
PAAD	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg00629941	chr15:75287862	SCAMP5	-0.56	-4.28	-0.33	3.3e-5	Blood trace element (Zn levels);
PAAD	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.83	-8.03	-0.55	2.49e-13	Body mass index;
PAAD	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-8.12	-0.55	1.48e-13	Alcohol dependence;
PAAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.55	-5.33	-0.4	3.48e-7	Blood metabolite levels;
PAAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg11783356	chr20:44313418	WFDC10B	-0.72	-6.39	-0.46	1.93e-9	Brain structure;
PAAD	cis	rs10991814	0.764	rs75828717	chr9:93964907	T/A	cg14446406	chr9:93919335	NA	0.57	4.73	0.36	5.1e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	5.77	0.42	4.23e-8	Adiposity;
PAAD	cis	rs2456568	0.722	rs883845	chr11:93686645	G/C	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.14	-0.38	8.49e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg08495239	chr10:135273341	LOC619207	-0.42	-4.36	-0.33	2.38e-5	Systemic lupus erythematosus;
PAAD	cis	rs6066835	1.000	rs6066838	chr20:47359951	C/T	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.53	-6.07	-0.44	9.83e-9	Prostate cancer;
PAAD	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.88	-12.54	-0.71	3.28e-25	Height;
PAAD	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs4144743	1.000	rs7208170	chr17:45330759	G/A	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	0.85	6.64	0.47	5.12e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-7.08	-0.5	4.97e-11	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg03037974	chr15:76606532	NA	0.52	6.32	0.46	2.71e-9	Blood metabolite levels;
PAAD	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	9.34	0.6	1.11e-16	Bipolar disorder;
PAAD	trans	rs901683	1.000	rs12781506	chr10:46038702	T/C	cg23720331	chr10:123873670	TACC2	-0.84	-6.5	-0.47	1.1e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.54	-0.47	8.95e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg00864171	chr11:67383662	NA	-0.49	-5.11	-0.38	9.56e-7	Mean corpuscular volume;
PAAD	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg25233709	chr10:116636983	FAM160B1	0.37	4.48	0.34	1.48e-5	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs4281086	0.932	rs7838337	chr8:10346781	C/T	cg01072821	chr8:10382165	T-SP1	-0.47	-4.62	-0.35	8.3e-6	Obesity-related traits;
PAAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.45	-4.78	-0.36	4.12e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs4455778	0.543	rs4132419	chr7:49066633	A/G	cg26309511	chr7:48887640	NA	0.37	4.5	0.34	1.34e-5	Lung cancer in never smokers;
PAAD	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.74	-5.99	-0.44	1.44e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-4.61	-0.35	8.48e-6	Daytime sleep phenotypes;
PAAD	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-6.05	-0.44	1.1e-8	Menopause (age at onset);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17274378	chr17:79168726	AZI1	-0.56	-6.74	-0.48	3.04e-10	Body fat percentage;
PAAD	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg05785598	chr3:49045655	WDR6	0.41	4.3	0.33	3e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16988970	chr17:42248062	ASB16	-0.36	-5.11	-0.38	9.47e-7	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03443205	chr2:43454133	LOC100129726;ZFP36L2	0.58	6.33	0.46	2.63e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2950393	0.509	rs10459247	chr12:57171516	T/C	cg02954252	chr12:57119365	NACA	-0.52	-4.27	-0.33	3.47e-5	Platelet distribution width;
PAAD	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.46	4.91	0.37	2.33e-6	Age of smoking initiation;
PAAD	cis	rs7707921	0.881	rs2407153	chr5:81555328	T/G	cg21483461	chr5:81570383	RPS23	0.54	4.55	0.35	1.11e-5	Breast cancer;
PAAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.71	6.98	0.49	8.6e-11	Renal function-related traits (BUN);
PAAD	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	10.47	0.65	1.2e-19	Platelet count;
PAAD	cis	rs2790216	1.000	rs2440855	chr10:59964744	T/A	cg20442379	chr10:60024634	IPMK	-0.57	-4.38	-0.34	2.16e-5	Inflammatory bowel disease;
PAAD	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.4	7.48	0.52	5.43e-12	Psoriasis vulgaris;
PAAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.25	0.64	4.48e-19	Platelet count;
PAAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	7.82	0.54	8.25e-13	Platelet count;
PAAD	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg02056144	chr12:54070517	ATP5G2	-0.47	-5.02	-0.38	1.44e-6	Height;
PAAD	cis	rs9972944	0.651	rs1819910	chr17:63814576	C/A	cg07283582	chr17:63770753	CCDC46	-0.58	-6.87	-0.49	1.54e-10	Total body bone mineral density;
PAAD	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.78	8.17	0.55	1.14e-13	Height;
PAAD	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4704187	0.687	rs10942732	chr5:74538259	A/G	cg03227963	chr5:74354835	NA	0.48	4.65	0.35	7.3e-6	Response to amphetamines;
PAAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.6	-7.15	-0.5	3.42e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg12927641	chr6:109611667	NA	-0.41	-4.39	-0.34	2.15e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.1	0.44	8.57e-9	Skin colour saturation;
PAAD	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.63	3.93e-18	Vitiligo;
PAAD	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	6.14	0.45	6.9e-9	Schizophrenia;
PAAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.92	-10.43	-0.65	1.52e-19	Tonsillectomy;
PAAD	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg02795151	chr17:7402630	POLR2A	0.65	5.57	0.41	1.12e-7	Androgen levels;
PAAD	cis	rs7082209	1.000	rs2146807	chr10:44813738	A/G	cg13191911	chr10:44806660	NA	-0.82	-4.83	-0.36	3.28e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.62	5.9	0.43	2.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg07362569	chr17:61921086	SMARCD2	0.4	4.48	0.34	1.48e-5	Height;
PAAD	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg10518543	chr12:38710700	ALG10B	0.46	4.66	0.35	6.88e-6	Morning vs. evening chronotype;
PAAD	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.07	0.38	1.14e-6	Motion sickness;
PAAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg25614726	chr1:10490058	APITD1	0.36	4.25	0.33	3.72e-5	Prostate cancer;
PAAD	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.59e-21	Breast cancer;
PAAD	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-9.25	-0.6	1.94e-16	Electrocardiographic conduction measures;
PAAD	cis	rs9346455	0.614	rs9360445	chr6:72000866	G/T	cg27238071	chr6:71998145	OGFRL1	0.76	4.54	0.35	1.13e-5	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
PAAD	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10547527	chr2:198650123	BOLL	0.49	4.27	0.33	3.42e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs116175783	0.557	rs1267058	chr2:162121445	A/G	cg08807892	chr2:162101083	NA	0.69	5.09	0.38	1.06e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.63	-0.35	7.79e-6	Breast cancer;
PAAD	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg12311346	chr5:56204834	C5orf35	0.54	4.37	0.33	2.3e-5	Coronary artery disease;
PAAD	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs8077059	1.000	rs8076475	chr17:55814749	C/T	cg12582317	chr17:55822272	NA	0.51	4.78	0.36	4.04e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.39	-4.77	-0.36	4.29e-6	Menarche (age at onset);
PAAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.53	0.34	1.19e-5	Trans fatty acid levels;
PAAD	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.71	-7.56	-0.52	3.61e-12	Response to antipsychotic treatment;
PAAD	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.36	-0.51	1.05e-11	Colorectal cancer;
PAAD	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13012494	chr21:47604986	C21orf56	0.47	4.98	0.37	1.74e-6	Testicular germ cell tumor;
PAAD	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.88	-10.28	-0.64	3.9e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.09e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.48	4.66	0.35	6.91e-6	HDL cholesterol;
PAAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.66	-0.42	7.45e-8	Coronary artery disease;
PAAD	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.43	4.89	0.37	2.56e-6	Refractive error;
PAAD	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.78	8.95	0.59	1.15e-15	Heart rate;
PAAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.09e-6	Life satisfaction;
PAAD	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10213488	chr14:93799600	KIAA1409;BTBD7	0.62	7.16	0.5	3.28e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.49	4.42	0.34	1.88e-5	White blood cell count;Multiple sclerosis;
PAAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-6.11	-0.44	8.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2252790	1.000	rs12212556	chr6:116613907	A/G	cg18764771	chr6:116381957	FRK	0.26	4.41	0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs6076065	0.723	rs4813493	chr20:23367373	G/C	cg11657817	chr20:23433608	CST11	0.5	5.05	0.38	1.23e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs9810890	1.000	rs73198892	chr3:128559117	G/A	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.79e-5	Bone mineral density;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6496667	0.609	rs7183707	chr15:90883733	G/T	cg26662049	chr15:89903672	NA	-0.32	-4.28	-0.33	3.31e-5	Rheumatoid arthritis;
PAAD	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.52	-4.7	-0.36	5.77e-6	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04957198	chr10:25241883	PRTFDC1	-0.6	-7.44	-0.52	7.02e-12	Body fat percentage;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.48	5.17	0.39	7.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg06606381	chr12:133084897	FBRSL1	-1.34	-8.59	-0.57	9.95e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs4704187	0.649	rs9942407	chr5:74540187	C/T	cg03227963	chr5:74354835	NA	0.48	4.66	0.35	6.9e-6	Response to amphetamines;
PAAD	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	1.85	10.44	0.65	1.42e-19	Cannabis dependence symptom count;
PAAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.14	0.55	1.34e-13	Menopause (age at onset);
PAAD	trans	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg23947450	chr7:900037	UNC84A	-0.56	-4.65	-0.35	7.24e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.45	6.2	0.45	4.97e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg11619707	chr19:22235551	ZNF257	-0.58	-5.82	-0.43	3.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01616529	chr11:638424	DRD4	-0.61	-5.95	-0.43	1.78e-8	Systemic lupus erythematosus;
PAAD	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg12639453	chr1:2035780	PRKCZ	-0.55	-5.61	-0.41	9.48e-8	Height;
PAAD	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.54	5.81	0.43	3.59e-8	Menopause (age at onset);
PAAD	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.6	6.13	0.45	7.21e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg12549451	chr6:135224345	NA	0.44	4.67	0.35	6.67e-6	Red blood cell count;
PAAD	cis	rs1190596	0.525	rs6575897	chr14:102647125	G/A	cg23904247	chr14:102554826	HSP90AA1	0.42	5.01	0.38	1.49e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs2422052	0.505	rs7569755	chr2:118648261	G/A	cg22545206	chr2:118617499	NA	-0.48	-4.3	-0.33	3.07e-5	Mosquito bite size;
PAAD	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.66	4.36	0.33	2.34e-5	Lung cancer in ever smokers;
PAAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.44	4.9	0.37	2.47e-6	Vitiligo;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.5	-8.15	-0.55	1.28e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.5	-5.94	-0.43	1.86e-8	Ankle injury;
PAAD	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.87	6.63	0.47	5.64e-10	Eosinophil percentage of granulocytes;
PAAD	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.76	8.36	0.56	3.81e-14	Colorectal cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11687746	chr2:88354768	KRCC1	0.61	7.0	0.49	7.62e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs939584	1.000	rs939581	chr2:623224	C/T	cg14515364	chr2:636606	NA	0.48	4.35	0.33	2.47e-5	Body mass index;
PAAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	8.21	0.55	8.82e-14	Schizophrenia;
PAAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	6.86	0.49	1.66e-10	Height;
PAAD	cis	rs6466055	0.777	rs66599006	chr7:104934271	A/G	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.9	0.54	5.16e-13	Prudent dietary pattern;
PAAD	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg03938978	chr2:103052716	IL18RAP	0.5	5.16	0.39	7.61e-7	Blood protein levels;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg13412003	chr19:35455007	ZNF792	-0.6	-6.46	-0.46	1.34e-9	Myopia (pathological);
PAAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg25930673	chr12:123319894	HIP1R	1.23	6.4	0.46	1.87e-9	Adiponectin levels;
PAAD	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.0	11.89	0.69	1.77e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg08873628	chr1:175162347	KIAA0040	-0.45	-4.33	-0.33	2.73e-5	Alcohol dependence;
PAAD	cis	rs12760731	0.720	rs34194793	chr1:178329065	G/T	cg00404053	chr1:178313656	RASAL2	0.71	5.27	0.39	4.54e-7	Obesity-related traits;
PAAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg11833968	chr6:79620685	NA	-0.41	-4.25	-0.33	3.7e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.58	-6.44	-0.46	1.46e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.86	5.54	0.41	1.3e-7	Diabetic kidney disease;
PAAD	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.45	4.54	0.35	1.12e-5	Trans fatty acid levels;
PAAD	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Depression;
PAAD	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg23912435	chr1:150601613	ENSA	-0.49	-4.51	-0.34	1.32e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.07	-8.33	-0.56	4.3e-14	Diabetic kidney disease;
PAAD	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg11494091	chr17:61959527	GH2	0.55	4.46	0.34	1.6e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7487075	0.619	rs10880971	chr12:46839498	G/A	cg14671384	chr12:47219920	SLC38A4	0.45	4.52	0.34	1.21e-5	Itch intensity from mosquito bite;
PAAD	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.72	-0.36	5.37e-6	Resting heart rate;
PAAD	cis	rs868943	0.714	rs66475830	chr6:116408802	T/C	cg18764771	chr6:116381957	FRK	0.34	5.93	0.43	1.92e-8	Total cholesterol levels;
PAAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.08	0.44	9.16e-9	Lung cancer;
PAAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.66	-0.35	6.93e-6	Personality dimensions;
PAAD	cis	rs13242816	1.000	rs13221364	chr7:116083544	C/T	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.96	-11.38	-0.68	4.28e-22	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg21937377	chr3:194868750	C3orf21	0.46	4.9	0.37	2.42e-6	Non-small cell lung cancer;
PAAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg21698718	chr17:80085957	CCDC57	-0.47	-5.29	-0.39	4.14e-7	Life satisfaction;
PAAD	cis	rs501120	0.564	rs11598314	chr10:44685795	A/G	cg09554077	chr10:44749378	NA	0.43	5.5	0.41	1.59e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg08824895	chr13:115047677	UPF3A	0.52	4.84	0.37	3.14e-6	Schizophrenia;
PAAD	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.71	7.18	0.5	2.89e-11	Anterior chamber depth;
PAAD	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.97	6.25	0.45	3.98e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg01612440	chr4:3296283	NA	0.44	4.4	0.34	2.01e-5	Serum sulfate level;
PAAD	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg05272587	chr13:111038400	COL4A2	-0.52	-4.61	-0.35	8.44e-6	White matter hyperintensity burden;
PAAD	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.6	5.88	0.43	2.49e-8	Testicular germ cell tumor;
PAAD	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.74	7.52	0.52	4.34e-12	Retinal vascular caliber;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16423265	chr20:60697137	LSM14B	0.71	7.95	0.54	3.99e-13	Myopia (pathological);
PAAD	cis	rs71520386	1.000	rs71520386	chr7:22853521	C/T	cg04907244	chr7:22894795	SNORD93	0.57	4.95	0.37	1.95e-6	Fibrinogen levels;
PAAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.54	5.13	0.38	8.76e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs9463078	0.774	rs4446571	chr6:45257662	T/C	cg25276700	chr6:44698697	NA	-0.47	-5.44	-0.4	2.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg03989125	chr22:38214979	NA	-0.63	-6.55	-0.47	8.47e-10	Glioblastoma;Glioma;
PAAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg05627522	chr15:75251581	NA	0.59	7.21	0.5	2.45e-11	Breast cancer;
PAAD	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg09839279	chr12:125627357	AACS	-0.48	-4.71	-0.36	5.63e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg14847009	chr1:175162515	KIAA0040	0.3	4.68	0.36	6.21e-6	Alcohol dependence;
PAAD	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-9.59	-0.61	2.48e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21206133	chr1:151511319	TUFT1	-0.55	-6.49	-0.47	1.13e-9	Monocyte percentage of white cells;
PAAD	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.58	5.56	0.41	1.2e-7	Alcohol dependence;
PAAD	cis	rs8044476	0.895	rs12598219	chr16:72777225	A/G	cg00207534	chr16:71929512	KIAA0174	0.69	4.66	0.35	6.99e-6	Blood protein levels;
PAAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.76	-7.52	-0.52	4.5e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.62	-6.76	-0.48	2.75e-10	Coronary artery disease;
PAAD	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg22532475	chr10:104410764	TRIM8	-0.36	-4.34	-0.33	2.62e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs965604	1.000	rs12904234	chr15:78779384	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-4.57	-0.35	1.02e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3026101	0.671	rs56113612	chr17:5297761	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.99	0.44	1.42e-8	Body mass index;
PAAD	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.91	-9.06	-0.59	5.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.93	7.92	0.54	4.67e-13	Alzheimer's disease;
PAAD	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.45	4.4	0.34	2.06e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs13034020	0.522	rs35976602	chr2:61241582	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	4.26	0.33	3.52e-5	Hodgkin's lymphoma;
PAAD	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.87	8.7	0.58	5.13e-15	Response to hepatitis C treatment;
PAAD	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg22517653	chr1:2918612	NA	-0.59	-4.65	-0.35	7.11e-6	Plateletcrit;
PAAD	cis	rs1555895	0.656	rs4881532	chr10:845449	A/G	cg26597838	chr10:835615	NA	0.47	5.05	0.38	1.27e-6	Survival in rectal cancer;
PAAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.63	6.94	0.49	1.05e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg19163074	chr7:65112434	INTS4L2	0.46	4.33	0.33	2.71e-5	Aortic root size;
PAAD	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg14709524	chr16:89940631	TCF25	0.92	4.84	0.37	3.13e-6	Skin colour saturation;
PAAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg27539214	chr16:67997921	SLC12A4	-0.64	-5.28	-0.39	4.38e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg02770688	chr6:168491649	NA	0.46	4.83	0.37	3.25e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg09399716	chr2:46890238	NA	-0.53	-4.65	-0.35	7.17e-6	Height;
PAAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg14019146	chr3:50243930	SLC38A3	0.44	4.44	0.34	1.75e-5	Body mass index;
PAAD	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs4919087	0.561	rs793522	chr10:99022614	T/G	cg10374248	chr10:99083645	NA	0.5	4.57	0.35	1e-5	Monocyte count;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.64	-7.92	-0.54	4.67e-13	Prudent dietary pattern;
PAAD	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-4.62	-0.35	8.22e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs11700980	0.551	rs73898412	chr21:30118790	T/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.69	7.2	0.5	2.57e-11	Osteoporosis;
PAAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.43	4.29	0.33	3.19e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.41	5.11	0.38	9.47e-7	Pulmonary function;
PAAD	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg10354474	chr3:50350760	HYAL1	-0.49	-4.28	-0.33	3.35e-5	Resting heart rate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07483245	chr15:23034598	NIPA2	0.65	7.49	0.52	5.22e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg19680485	chr15:31195859	MTMR15	-0.45	-4.34	-0.33	2.59e-5	Huntington's disease progression;
PAAD	cis	rs6460942	0.597	rs13221702	chr7:12519076	A/G	cg20607287	chr7:12443886	VWDE	0.73	4.95	0.37	1.95e-6	Coronary artery disease;
PAAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.69	-6.9	-0.49	1.32e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.56	-6.49	-0.47	1.14e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.64	-6.18	-0.45	5.62e-9	Itch intensity from mosquito bite;
PAAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg05082376	chr22:42548792	NA	0.52	5.6	0.41	9.67e-8	Cognitive function;
PAAD	cis	rs7651511	1.000	rs9868956	chr3:141233836	A/T	cg25967872	chr3:141205623	RASA2	0.51	4.53	0.35	1.16e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.88	0.54	5.76e-13	Prudent dietary pattern;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.66	-6.57	-0.47	7.69e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.4	5.41	0.4	2.38e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs12257961	0.675	rs4750619	chr10:15347175	T/A	cg10616319	chr10:15468812	NA	-0.44	-4.3	-0.33	3.05e-5	Selective IgA deficiency;
PAAD	cis	rs730532	0.597	rs57847444	chr14:52504950	T/C	cg00766845	chr14:52536022	NID2	-0.58	-4.33	-0.33	2.67e-5	Pulmonary function;
PAAD	cis	rs6977660	0.943	rs10227692	chr7:19850199	T/C	cg05791153	chr7:19748676	TWISTNB	0.55	4.67	0.35	6.55e-6	Thyroid stimulating hormone;
PAAD	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg08847533	chr14:75593920	NEK9	-0.46	-4.72	-0.36	5.31e-6	Caffeine consumption;
PAAD	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg18589874	chr11:47608310	FAM180B	-0.44	-4.39	-0.34	2.09e-5	Subjective well-being;
PAAD	cis	rs7707921	1.000	rs749401	chr5:81561369	T/C	cg21483461	chr5:81570383	RPS23	-0.54	-4.55	-0.35	1.11e-5	Breast cancer;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.47	-0.34	1.54e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs72681920	0.748	rs10026860	chr4:100058770	C/A	cg12011299	chr4:100065546	ADH4	-0.72	-4.44	-0.34	1.72e-5	Alcohol dependence;
PAAD	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.43	-5.06	-0.38	1.2e-6	Uric acid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24764834	chr4:119645048	SEC24D	-0.67	-7.17	-0.5	3.06e-11	Obesity-related traits;
PAAD	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.14	-0.64	9.12e-19	Response to antipsychotic treatment;
PAAD	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg14019146	chr3:50243930	SLC38A3	-0.51	-4.74	-0.36	4.82e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs900145	0.861	rs1481880	chr11:13269548	G/A	cg15603424	chr11:13300592	ARNTL	0.49	4.3	0.33	3.07e-5	Menarche (age at onset);
PAAD	cis	rs11078597	0.731	rs8065251	chr17:1637458	G/A	cg17514665	chr17:1657533	SERPINF2	0.66	5.98	0.44	1.51e-8	Serum albumin level;
PAAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.62	0.35	7.97e-6	Menopause (age at onset);
PAAD	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.76	5.78	0.42	4.02e-8	Triglycerides;
PAAD	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg05555928	chr11:63887634	MACROD1	0.57	4.48	0.34	1.47e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs926392	0.965	rs6028258	chr20:37692844	T/A	cg16355469	chr20:37678765	NA	0.45	4.3	0.33	3.06e-5	Dialysis-related mortality;
PAAD	cis	rs2790216	0.853	rs1698374	chr10:59955301	G/A	cg20442379	chr10:60024634	IPMK	-0.57	-4.38	-0.34	2.16e-5	Inflammatory bowel disease;
PAAD	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.99	14.11	0.75	1.94e-29	Heart rate;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12516959	chr21:47718080	NA	0.44	4.32	0.33	2.8e-5	Testicular germ cell tumor;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.58	6.94	0.49	1.06e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.59	6.23	0.45	4.43e-9	Immature fraction of reticulocytes;
PAAD	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-6.25	-0.45	3.98e-9	Blood protein levels;
PAAD	cis	rs3106136	0.609	rs28613890	chr4:95088558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-4.86	-0.37	2.87e-6	Capecitabine sensitivity;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg08132940	chr7:1081526	C7orf50	0.62	4.57	0.35	9.91e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.89	0.37	2.53e-6	Longevity;
PAAD	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg22705602	chr4:152727874	NA	-0.49	-5.4	-0.4	2.54e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs12304921	0.683	rs56060103	chr12:51452662	C/T	cg18059802	chr12:51347058	HIGD1C	-0.63	-5.03	-0.38	1.34e-6	Type 2 diabetes;
PAAD	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-7.93	-0.54	4.35e-13	Dental caries;
PAAD	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg06243866	chr13:111019493	COL4A2	-0.64	-5.98	-0.44	1.51e-8	White matter hyperintensity burden;
PAAD	cis	rs7009516	0.625	rs13262293	chr8:24263618	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.61	-0.41	9.48e-8	Hair greying;
PAAD	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26926768	chr12:34528122	NA	0.38	4.5	0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs10905065	0.804	rs2175630	chr10:5834736	A/C	cg18989491	chr10:6185502	PFKFB3	0.48	4.34	0.33	2.55e-5	Menopause (age at onset);
PAAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.61	0.35	8.62e-6	Personality dimensions;
PAAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg10544611	chr16:67998164	SLC12A4	-0.64	-4.35	-0.33	2.48e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg00450029	chr8:599525	NA	-0.76	-4.96	-0.37	1.89e-6	IgG glycosylation;
PAAD	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs863345	0.604	rs12133791	chr1:158506682	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.47	4.41	0.34	1.92e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg02696790	chr15:75250997	RPP25	0.4	4.68	0.35	6.33e-6	Breast cancer;
PAAD	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.58	-7.66	-0.53	1.98e-12	Longevity;
PAAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg04450456	chr4:17643702	FAM184B	0.53	5.99	0.44	1.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00912467	chr1:161369970	NA	0.66	6.92	0.49	1.16e-10	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.94e-7	Alzheimer's disease;
PAAD	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	1.01	12.61	0.72	2.11e-25	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14943877	chr10:112257612	DUSP5	0.58	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs4740619	0.836	rs4740628	chr9:15888333	A/G	cg14451791	chr9:16040625	NA	-0.4	-4.72	-0.36	5.41e-6	Body mass index;
PAAD	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg08390786	chr10:135334061	NA	0.61	5.32	0.4	3.66e-7	Gout;
PAAD	cis	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg09187486	chr12:32908527	YARS2	0.45	4.55	0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.66	-5.79	-0.43	3.87e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg26174226	chr8:58114915	NA	-0.58	-4.41	-0.34	1.94e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg17347104	chr14:75034677	LTBP2	0.56	4.64	0.35	7.33e-6	Non-small cell lung cancer;
PAAD	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.54	-4.8	-0.36	3.78e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
PAAD	cis	rs4668356	0.881	rs60396936	chr2:171993586	A/T	cg13882835	chr2:172017928	TLK1	0.89	4.8	0.36	3.78e-6	Cognitive performance;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11056045	chr7:44835684	PPIA	-0.73	-6.49	-0.47	1.17e-9	Neuroticism;
PAAD	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg19767477	chr5:127420684	SLC12A2	-0.56	-4.49	-0.34	1.39e-5	Ileal carcinoids;
PAAD	cis	rs134594	0.885	rs134669	chr22:29499810	G/A	cg01361351	chr22:29467363	NA	-0.38	-4.33	-0.33	2.65e-5	Birth weight;
PAAD	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.38	4.71	0.36	5.62e-6	Mean corpuscular volume;
PAAD	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg07648498	chr16:89883185	FANCA	0.51	4.81	0.36	3.62e-6	Vitiligo;
PAAD	cis	rs6466055	0.661	rs6466051	chr7:104897225	A/G	cg04380332	chr7:105027541	SRPK2	-0.48	-4.6	-0.35	8.75e-6	Schizophrenia;
PAAD	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02743256	chr7:2109353	MAD1L1	-0.74	-5.24	-0.39	5.32e-7	Neuroticism;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16505464	chr13:37393242	RFXAP	0.61	6.43	0.46	1.57e-9	Myopia (pathological);
PAAD	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg02917321	chr22:38215204	NA	0.5	4.75	0.36	4.58e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.45	-5.89	-0.43	2.37e-8	Primary biliary cholangitis;
PAAD	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.6	-4.46	-0.34	1.59e-5	Neuroblastoma;
PAAD	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg01426195	chr3:39028469	NA	-0.74	-8.5	-0.57	1.68e-14	Handedness;
PAAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg15017067	chr4:17643749	FAM184B	0.4	4.39	0.34	2.08e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.76	-6.04	-0.44	1.12e-8	Initial pursuit acceleration;
PAAD	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.93	-10.7	-0.66	2.94e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs7247513	0.859	rs35945052	chr19:12703230	G/A	cg01871581	chr19:12707946	ZNF490	-0.92	-11.48	-0.68	2.39e-22	Bipolar disorder;
PAAD	trans	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg10400843	chr16:29915329	ASPHD1	-0.47	-6.34	-0.46	2.45e-9	Mean corpuscular volume;
PAAD	cis	rs225245	0.610	rs321607	chr17:33880584	A/G	cg05299278	chr17:33885742	SLFN14	0.35	4.26	0.33	3.6e-5	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg24642844	chr7:1081250	C7orf50	0.57	4.5	0.34	1.33e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg15571903	chr15:79123663	NA	0.47	6.34	0.46	2.53e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg16680214	chr1:154839983	KCNN3	-0.5	-5.65	-0.42	7.63e-8	Prostate cancer;
PAAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.43	4.39	0.34	2.14e-5	Red cell distribution width;
PAAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.84	9.61	0.61	2.19e-17	Ulcerative colitis;
PAAD	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg05134918	chr12:132603531	EP400NL	-0.61	-4.87	-0.37	2.78e-6	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.35	-0.4	3.12e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs686320	0.748	rs550894	chr11:65211940	C/A	cg21890820	chr11:65308645	LTBP3	0.83	5.5	0.41	1.57e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.82	-6.01	-0.44	1.34e-8	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg01763666	chr17:80159506	CCDC57	-0.43	-4.38	-0.33	2.24e-5	Life satisfaction;
PAAD	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.82	-5.25	-0.39	4.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.52	6.87	0.49	1.54e-10	Abdominal aortic aneurysm;
PAAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.76	-9.66	-0.62	1.69e-17	Bone mineral density;
PAAD	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.58	5.26	0.39	4.84e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.44	-4.68	-0.35	6.4e-6	Electroencephalogram traits;
PAAD	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.46	-5.74	-0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.95	10.96	0.66	5.85e-21	Total cholesterol levels;
PAAD	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.75	-6.51	-0.47	1.06e-9	Motion sickness;
PAAD	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	6.44	0.46	1.48e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11853189	0.938	rs16969710	chr15:78606362	G/T	cg22935921	chr15:78556834	DNAJA4	-0.69	-4.68	-0.35	6.38e-6	Red cell distribution width;
PAAD	cis	rs732765	0.657	rs10135451	chr14:75229187	C/A	cg17347104	chr14:75034677	LTBP2	0.57	4.26	0.33	3.58e-5	Non-small cell lung cancer;
PAAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg13266496	chr6:110720918	DDO	-0.44	-4.61	-0.35	8.31e-6	Platelet distribution width;
PAAD	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.9	11.18	0.67	1.47e-21	Metabolic syndrome;
PAAD	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg20243544	chr17:37824526	PNMT	-0.53	-4.32	-0.33	2.83e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	1.09	11.15	0.67	1.77e-21	Platelet distribution width;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11913894	chr6:161412392	MAP3K4	-0.72	-7.06	-0.5	5.48e-11	Lung cancer in ever smokers;
PAAD	cis	rs2278796	0.697	rs2278795	chr1:204954993	A/G	cg17947172	chr1:204966197	NFASC	0.42	4.78	0.36	4.08e-6	Mean platelet volume;
PAAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	4.54	0.35	1.15e-5	Bipolar disorder and schizophrenia;
PAAD	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.75	6.59	0.47	6.95e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg00179576	chr16:74483694	GLG1	-0.4	-4.46	-0.34	1.56e-5	Testicular germ cell tumor;
PAAD	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.46	4.79	0.36	3.9e-6	Menopause (age at onset);
PAAD	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.22	-0.39	5.67e-7	Prevalent atrial fibrillation;
PAAD	cis	rs1113500	0.565	rs1777455	chr1:108590288	C/A	cg06207961	chr1:108661230	NA	-0.5	-5.32	-0.4	3.72e-7	Growth-regulated protein alpha levels;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg07202610	chr7:1142643	C7orf50	-0.76	-5.38	-0.4	2.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08206623	chr11:2907334	CDKN1C	-0.55	-6.44	-0.46	1.45e-9	Body fat percentage;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.76	-0.48	2.71e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10943724	0.679	rs6921723	chr6:81268558	G/C	cg19323245	chr6:80716898	TTK	-0.42	-4.45	-0.34	1.68e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs6445967	0.898	rs4336086	chr3:58297390	C/T	cg23715586	chr3:58305044	RPP14	0.49	4.33	0.33	2.71e-5	Platelet count;
PAAD	cis	rs12478296	0.605	rs35046041	chr2:242986505	A/G	cg06360820	chr2:242988706	NA	-0.71	-5.74	-0.42	5.02e-8	Obesity-related traits;
PAAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg26354017	chr1:205819088	PM20D1	-0.47	-4.33	-0.33	2.64e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs939584	1.000	rs4452188	chr2:648810	A/G	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.57	-7.3	-0.51	1.49e-11	Lewy body disease;
PAAD	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.37	-0.33	2.28e-5	Tuberculosis;
PAAD	cis	rs2073300	1.000	rs6036424	chr20:23459976	A/C	cg12062639	chr20:23401060	NAPB	-0.93	-5.08	-0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg00280220	chr17:61926910	NA	0.44	4.51	0.34	1.3e-5	Prudent dietary pattern;
PAAD	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg03700679	chr2:178418002	TTC30B	-0.54	-4.37	-0.33	2.25e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs73019876	0.869	rs10418985	chr19:22147952	T/C	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg24399712	chr22:39784796	NA	0.67	5.58	0.41	1.08e-7	IgG glycosylation;
PAAD	cis	rs6782025	0.837	rs7616466	chr3:120793617	C/T	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.29	0.64	3.56e-19	Platelet count;
PAAD	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	6.32	0.46	2.7e-9	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03944266	chr4:141445314	ELMOD2	0.66	6.83	0.48	1.9e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg23587288	chr2:27483067	SLC30A3	-0.7	-6.59	-0.47	6.67e-10	Blood metabolite levels;
PAAD	cis	rs11264799	0.648	rs2275233	chr1:157718645	T/C	cg18268488	chr1:157545234	FCRL4	0.65	5.81	0.43	3.58e-8	IgA nephropathy;
PAAD	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.41	-0.52	8.19e-12	Body mass index;
PAAD	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.68	-7.27	-0.51	1.78e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-0.75	-5.55	-0.41	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.62	-5.95	-0.43	1.82e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.72	7.51	0.52	4.56e-12	Mood instability;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg11866396	chr17:5322940	RPAIN;NUP88	-0.59	-6.57	-0.47	7.64e-10	Blood protein levels;
PAAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg11143131	chr5:131608246	PDLIM4	0.47	4.42	0.34	1.9e-5	Breast cancer;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-6.23	-0.45	4.27e-9	Lymphocyte counts;
PAAD	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.69	7.59	0.52	3.08e-12	Testicular germ cell tumor;
PAAD	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.41	13.32	0.73	2.59e-27	Uric acid levels;
PAAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	1.01	13.38	0.74	1.81e-27	Gestational age at birth (maternal effect);
PAAD	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.99	-10.79	-0.66	1.65e-20	Corneal astigmatism;
PAAD	cis	rs73198271	0.729	rs67653033	chr8:8605044	G/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.51	0.34	1.28e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg16606324	chr3:10149918	C3orf24	0.82	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.88	10.9	0.66	8.2e-21	Methadone dose in opioid dependence;
PAAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	6.25	0.45	4.02e-9	Renal function-related traits (BUN);
PAAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg16176600	chr6:116381609	FRK	-0.33	-4.93	-0.37	2.15e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09640425	chr7:158790006	NA	-0.54	-6.02	-0.44	1.23e-8	Facial morphology (factor 20);
PAAD	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg23708337	chr7:1209742	NA	0.61	4.47	0.34	1.49e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.62	6.65	0.47	5.09e-10	Testicular germ cell tumor;
PAAD	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg11441379	chr12:63026424	NA	0.85	6.63	0.47	5.44e-10	IgG glycosylation;
PAAD	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg20936604	chr3:58311152	NA	-0.77	-4.38	-0.34	2.17e-5	Cholesterol, total;
PAAD	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg03934865	chr2:198174659	NA	-0.47	-4.71	-0.36	5.56e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg15650694	chr5:65439990	SFRS12	0.67	7.01	0.49	7.21e-11	Myopia (pathological);
PAAD	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.77	9.94	0.63	3e-18	Height;
PAAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-17.51	-0.82	2.78e-38	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10604396	chr10:64577901	EGR2	0.64	6.37	0.46	2.16e-9	Myopia (pathological);
PAAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg09017928	chr7:158110068	PTPRN2	0.45	4.42	0.34	1.89e-5	Calcium levels;
PAAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	1.0	15.88	0.79	4.28e-34	Height;
PAAD	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	4.93	0.37	2.15e-6	Lung cancer in ever smokers;
PAAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.65	-0.42	7.53e-8	Iron status biomarkers;
PAAD	cis	rs11623869	0.695	rs3759579	chr14:103851272	A/G	cg12935359	chr14:103987150	CKB	0.59	7.15	0.5	3.38e-11	Bone mineral density;
PAAD	cis	rs6460942	0.597	rs6944517	chr7:12515283	C/T	cg20607287	chr7:12443886	VWDE	-0.76	-5.11	-0.38	9.64e-7	Coronary artery disease;
PAAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.06	0.55	2.05e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.11	0.81	2.9e-37	Prudent dietary pattern;
PAAD	cis	rs6142102	0.602	rs932388	chr20:32657378	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	5.08	0.38	1.09e-6	Skin pigmentation;
PAAD	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-7.57	-0.52	3.44e-12	Gout;
PAAD	cis	rs60154123	0.730	rs588197	chr1:210463515	A/T	cg21951975	chr1:209979733	IRF6	0.54	5.31	0.4	3.74e-7	Coronary artery disease;
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg10729496	chr3:10149963	C3orf24	0.83	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs7925523	0.891	rs4963308	chr11:61456426	G/A	cg12472022	chr11:61462803	DAGLA	0.61	5.02	0.38	1.43e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7707921	0.881	rs6875409	chr5:81297077	A/G	cg21483461	chr5:81570383	RPS23	-0.51	-4.27	-0.33	3.38e-5	Breast cancer;
PAAD	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.32	-4.51	-0.34	1.27e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg08501292	chr6:25962987	TRIM38	0.9	4.36	0.33	2.38e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.73	6.96	0.49	9.3e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.58	5.14	0.38	8.26e-7	Common traits (Other);
PAAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.65	0.42	7.85e-8	Major depressive disorder;
PAAD	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg05042697	chr2:10830656	NOL10	-0.44	-4.33	-0.33	2.72e-5	Prostate cancer;
PAAD	cis	rs10792830	0.771	rs629343	chr11:85811138	C/T	cg07180834	chr11:85838833	NA	0.53	6.1	0.44	8.5e-9	Psychosis and Alzheimer's disease;
PAAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.58	-6.58	-0.47	7.32e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.59	-5.61	-0.41	9.45e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06056004	chr5:44809616	MRPS30	0.58	6.38	0.46	2.07e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs8027181	0.682	rs4777546	chr15:73104435	C/T	cg25632853	chr15:73088954	NA	-0.42	-4.69	-0.36	5.97e-6	Triglyceride levels;
PAAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Vascular endothelial growth factor levels;
PAAD	cis	rs9397240	0.789	rs9397801	chr6:155614192	C/T	cg06694381	chr6:155569200	TIAM2	-0.48	-4.35	-0.33	2.51e-5	Life satisfaction;
PAAD	cis	rs4629180	1.000	rs59246268	chr2:102089021	G/A	cg04415270	chr2:102091202	RFX8	-0.64	-7.98	-0.54	3.28e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.54	5.22	0.39	5.68e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.7	7.59	0.52	2.93e-12	Type 2 diabetes;
PAAD	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.25	-0.39	5.06e-7	Systemic lupus erythematosus;
PAAD	cis	rs597480	0.963	rs290202	chr11:85423200	G/T	cg11817631	chr11:85522609	SYTL2	-0.46	-4.31	-0.33	2.89e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg05896524	chr21:47604654	C21orf56	0.42	4.29	0.33	3.2e-5	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23081397	chr3:9291180	SRGAP3	0.61	6.65	0.47	5.01e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7326068	0.543	rs2785740	chr13:21423525	C/G	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	trans	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-6.59	-0.47	6.76e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.94	-8.71	-0.58	4.77e-15	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.57	6.53	0.47	9.1e-10	Schizophrenia;
PAAD	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.03	-0.38	1.34e-6	Daytime sleep phenotypes;
PAAD	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.52	-4.69	-0.36	6.03e-6	Aortic root size;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.55	-0.41	1.25e-7	Longevity;Endometriosis;
PAAD	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.95	9.6	0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg14346243	chr4:90757452	SNCA	-0.5	-4.39	-0.34	2.14e-5	Neuroticism;
PAAD	cis	rs6785206	0.655	rs35627944	chr3:128534490	C/T	cg19205850	chr3:128446370	RAB7A	0.74	4.64	0.35	7.42e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.78	-0.53	1.02e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg22764044	chr5:178986830	RUFY1	0.48	4.86	0.37	2.86e-6	Lung cancer;
PAAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13798912	chr7:905769	UNC84A	0.61	4.58	0.35	9.8e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9395066	0.545	rs10948192	chr6:44947321	G/A	cg18551225	chr6:44695536	NA	-0.45	-4.66	-0.35	6.9e-6	Height;
PAAD	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.74	-10.26	-0.64	4.24e-19	Birth weight;
PAAD	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg19254793	chr6:44695348	NA	-0.47	-4.47	-0.34	1.5e-5	Total body bone mineral density;
PAAD	cis	rs10875746	0.669	rs11168516	chr12:48702065	C/T	cg26205652	chr12:48591994	NA	0.76	7.1	0.5	4.58e-11	Longevity (90 years and older);
PAAD	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg26850624	chr5:429559	AHRR	0.96	4.73	0.36	5.01e-6	Breast cancer;
PAAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg13057898	chr1:3703894	LRRC47	0.4	4.25	0.33	3.69e-5	Red cell distribution width;
PAAD	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.73	8.08	0.55	1.89e-13	Morning vs. evening chronotype;
PAAD	cis	rs6597981	0.543	rs3901233	chr11:749452	T/A	cg01741372	chr11:783889	NA	0.78	9.42	0.61	6.94e-17	Breast cancer;
PAAD	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.8	7.95	0.54	4.01e-13	Retinal vascular caliber;
PAAD	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg26954736	chr11:73693896	UCP2	1.24	5.25	0.39	5.03e-7	Obesity-related traits;
PAAD	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.79	10.42	0.65	1.59e-19	Height;
PAAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.91	9.63	0.62	2.01e-17	Blood metabolite levels;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg21607453	chr9:98783545	NCRNA00092	0.6	6.59	0.47	6.98e-10	Response to antipsychotic treatment;
PAAD	cis	rs75920871	0.623	rs59097294	chr11:116964437	T/C	cg04087571	chr11:116723030	SIK3	-0.43	-6.08	-0.44	9.42e-9	Subjective well-being;
PAAD	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg23417306	chr2:180868811	CWC22	-0.49	-4.53	-0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.31	-0.51	1.45e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.82	6.16	0.45	6.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg08886695	chr4:3369023	RGS12	0.5	4.93	0.37	2.13e-6	Parental longevity (mother's age at death);
PAAD	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.43	0.4	2.21e-7	Lung cancer;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.02	0.63	1.82e-18	Prudent dietary pattern;
PAAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.29	-4.3	-0.33	3.01e-5	Longevity;Endometriosis;
PAAD	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-5.57	-0.41	1.14e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.89	9.95	0.63	2.89e-18	Total cholesterol levels;
PAAD	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg04415270	chr2:102091202	RFX8	-0.56	-6.98	-0.49	8.36e-11	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.72	-9.02	-0.59	7.57e-16	Educational attainment;
PAAD	cis	rs17824933	0.943	rs2074230	chr11:60783804	C/T	cg16817237	chr11:60793675	NA	0.54	6.58	0.47	7.05e-10	Multiple sclerosis;
PAAD	cis	rs3733418	0.860	rs13142064	chr4:165943549	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.57	-5.16	-0.39	7.75e-7	Obesity-related traits;
PAAD	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.52	-6.09	-0.44	8.99e-9	Alcohol dependence;
PAAD	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg21419209	chr3:44054225	NA	-0.74	-7.56	-0.52	3.46e-12	Coronary artery disease;
PAAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg23346134	chr3:49453900	TCTA	-0.42	-4.43	-0.34	1.79e-5	Menarche (age at onset);
PAAD	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.5	-5.66	-0.42	7.28e-8	Obesity-related traits;
PAAD	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.58	-6.04	-0.44	1.16e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg19630374	chr17:18023558	MYO15A	-0.57	-6.03	-0.44	1.19e-8	Total body bone mineral density;
PAAD	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.93	-5.28	-0.39	4.44e-7	Type 2 diabetes nephropathy;
PAAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.44	4.46	0.34	1.56e-5	Obesity-related traits;
PAAD	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.63	-5.1	-0.38	9.9e-7	HIV-1 control;
PAAD	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.64	5.97	0.44	1.6e-8	Height;
PAAD	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg22705602	chr4:152727874	NA	-0.53	-5.71	-0.42	5.87e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg21698718	chr17:80085957	CCDC57	0.39	4.26	0.33	3.58e-5	Life satisfaction;
PAAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	4.42	0.34	1.84e-5	Platelet count;
PAAD	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg26850624	chr5:429559	AHRR	1.0	4.58	0.35	9.8200000000000008e-06	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg09864156	chr10:70939728	SUPV3L1	0.67	7.8	0.53	9.17e-13	Metabolite levels  (X-11787);
PAAD	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.52	5.43	0.4	2.21e-7	Mean corpuscular volume;
PAAD	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.46	4.74	0.36	4.88e-6	Type 2 diabetes;
PAAD	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs6499766	0.696	rs4402561	chr16:55564797	A/G	cg00427604	chr16:55542751	LPCAT2	-0.37	-4.33	-0.33	2.67e-5	Thyroid hormone levels;
PAAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg06046430	chr4:77819534	ANKRD56	0.78	9.22	0.6	2.29e-16	Emphysema distribution in smoking;
PAAD	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg21775007	chr8:11205619	TDH	-0.52	-4.52	-0.34	1.26e-5	Neuroticism;
PAAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.61	-6.78	-0.48	2.51e-10	DNA methylation (variation);
PAAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg12143784	chr7:64541923	NA	-0.42	-4.62	-0.35	8.08e-6	Aortic root size;
PAAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg12639453	chr1:2035780	PRKCZ	0.53	5.61	0.41	9.2e-8	Height;
PAAD	cis	rs3764400	0.567	rs3897789	chr17:46312777	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.31	-0.46	2.88e-9	Body mass index;
PAAD	cis	rs863345	0.604	rs1873509	chr1:158461563	A/G	cg12129480	chr1:158549410	OR10X1	0.42	4.8	0.36	3.82e-6	Pneumococcal bacteremia;
PAAD	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg18518183	chr2:172544446	DYNC1I2	0.48	4.28	0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs876084	0.505	rs4871044	chr8:121158773	C/T	cg06265175	chr8:121136014	COL14A1	0.46	4.49	0.34	1.39e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.95	11.5	0.68	2.05e-22	Breast cancer;
PAAD	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.81	6.17	0.45	5.88e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.08	0.44	9.34e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg14830002	chr1:247616686	OR2B11	-0.63	-5.23	-0.39	5.55e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02985541	chr2:219472218	PLCD4	0.29	4.55	0.35	1.11e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs746265	0.818	rs7172230	chr15:39584848	C/A	cg10099207	chr15:39544144	C15orf54	0.56	4.28	0.33	3.23e-5	PR interval;
PAAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg27490568	chr2:178487706	NA	0.43	4.8	0.36	3.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4234284	1.000	rs13075436	chr3:126961148	C/T	cg27326032	chr3:127006922	NA	-0.48	-4.95	-0.37	1.96e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg17178900	chr1:205818956	PM20D1	0.82	9.26	0.6	1.81e-16	Monocyte percentage of white cells;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02711726	chr17:80685570	FN3KRP	-0.46	-4.6	-0.35	8.74e-6	Glycated hemoglobin levels;
PAAD	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	-0.5	-4.32	-0.33	2.78e-5	Resistin levels;
PAAD	cis	rs12425791	0.500	rs34336285	chr12:721769	G/T	cg08089041	chr12:751692	NINJ2	0.64	4.39	0.34	2.13e-5	Stroke;Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.27	-0.33	3.38e-5	Blood metabolite levels;
PAAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg14349672	chr11:133703707	NA	-0.47	-5.07	-0.38	1.16e-6	Childhood ear infection;
PAAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18621852	chr3:10150065	C3orf24	0.66	5.8	0.43	3.65e-8	Alzheimer's disease;
PAAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.97	-0.77	1.03e-31	Height;
PAAD	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg19000871	chr14:103996768	TRMT61A	-0.47	-5.01	-0.38	1.51e-6	Reticulocyte count;
PAAD	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.22	-0.39	5.69e-7	Plateletcrit;
PAAD	cis	rs10411262	0.868	rs7250264	chr19:47187438	T/A	cg13467550	chr19:47212573	PRKD2	0.47	4.72	0.36	5.27e-6	Tonsillectomy;
PAAD	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	0.98	7.15	0.5	3.5e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.59	-0.41	1.02e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-6.55	-0.47	8.53e-10	Schizophrenia;
PAAD	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg23587288	chr2:27483067	SLC30A3	0.69	6.38	0.46	2.01e-9	Blood metabolite levels;
PAAD	cis	rs829880	0.558	rs249821	chr12:98897811	T/C	cg25150519	chr12:98850993	NA	0.71	6.71	0.48	3.69e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.72	6.44	0.46	1.51e-9	Menarche (age at onset);
PAAD	cis	rs10950821	0.770	rs2285557	chr7:20692413	T/G	cg21202529	chr7:20656503	ABCB5	-0.54	-4.86	-0.37	2.84e-6	Response to statin therapy;
PAAD	cis	rs9913156	0.748	rs56124631	chr17:4561378	A/G	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg27565382	chr3:53032988	SFMBT1	0.76	4.35	0.33	2.52e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.81	7.41	0.52	8.06e-12	Psoriasis;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.77	8.47	0.57	1.92e-14	Lung cancer;
PAAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg03983715	chr16:68378420	PRMT7	0.94	7.11	0.5	4.2e-11	Schizophrenia;
PAAD	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.71	7.39	0.51	8.97e-12	Body mass index;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21362455	chr6:24495072	ALDH5A1	0.64	6.59	0.47	6.92e-10	Myopia (pathological);
PAAD	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.55	5.83	0.43	3.23e-8	Dupuytren's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16978263	chr3:160118452	SMC4;IFT80	0.57	6.36	0.46	2.19e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.63	4.33	0.33	2.68e-5	Vitiligo;
PAAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg14393609	chr7:65229607	NA	0.46	4.49	0.34	1.39e-5	Aortic root size;
PAAD	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-4.65	-0.35	7.3e-6	Ulcerative colitis;
PAAD	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.49	-4.34	-0.33	2.63e-5	Testicular germ cell tumor;
PAAD	cis	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Lung cancer in ever smokers;
PAAD	cis	rs10901513	0.932	rs2280173	chr10:127677374	A/G	cg22975853	chr10:127789788	ADAM12	0.44	4.65	0.35	7.14e-6	Visceral fat;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04499797	chr7:7222060	C1GALT1	-0.63	-7.13	-0.5	3.73e-11	Body fat percentage;
PAAD	cis	rs6604026	0.656	rs2481713	chr1:93354889	G/T	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs9815354	1.000	rs76471037	chr3:41799414	T/C	cg03022575	chr3:42003672	ULK4	0.66	4.68	0.36	6.2e-6	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs28655083	0.529	rs4550465	chr16:77104785	A/G	cg06128999	chr16:77247126	NA	-0.37	-4.38	-0.33	2.18e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.52	-5.14	-0.38	8.31e-7	Myeloid white cell count;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25887294	chr6:90539239	CASP8AP2	0.54	5.79	0.43	3.82e-8	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7762544	0.690	rs605991	chr6:41362621	A/G	cg18315060	chr6:41374532	NA	0.48	4.39	0.34	2.13e-5	Periodontitis;
PAAD	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.68	6.46	0.46	1.34e-9	Recombination rate (males);
PAAD	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.6	-5.89	-0.43	2.43e-8	Post bronchodilator FEV1;
PAAD	cis	rs1419980	0.730	rs7959765	chr12:7738544	G/A	cg25828445	chr12:7781288	NA	-0.87	-4.48	-0.34	1.45e-5	HDL cholesterol levels;
PAAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.02e-6	Aortic root size;
PAAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-6.11	-0.44	8.05e-9	Schizophrenia;
PAAD	cis	rs1144333	0.655	rs79322031	chr1:76391978	C/T	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg12560992	chr17:57184187	TRIM37	-0.52	-4.63	-0.35	7.93e-6	Primary tooth development (time to first tooth eruption);
PAAD	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-6.15	-0.45	6.6e-9	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.49	4.64	0.35	7.43e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-8.01	-0.54	2.81e-13	Neuroticism;
PAAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs59888335	0.964	rs13098888	chr3:80707325	T/C	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs74161807	0.666	rs2420315	chr10:118398699	A/C	cg10511988	chr10:118891706	VAX1	0.38	4.45	0.34	1.67e-5	Loneliness (multivariate analysis);Loneliness;
PAAD	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.53	-5.25	-0.39	5.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg12568669	chr8:11666485	FDFT1	-0.29	-4.98	-0.37	1.69e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	7.3	0.51	1.53e-11	Renal function-related traits (BUN);
PAAD	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg15128208	chr22:42549153	NA	0.52	4.4	0.34	2.03e-5	Birth weight;
PAAD	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg26031613	chr14:104095156	KLC1	-0.45	-4.54	-0.35	1.12e-5	Coronary artery disease;
PAAD	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-1.1	-8.29	-0.56	5.71e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.73	7.32	0.51	1.34e-11	HIV-1 control;
PAAD	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs1371614	0.513	rs562311	chr2:27098086	G/A	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.3	-0.33	3.06e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs939584	0.935	rs6725686	chr2:630436	C/A	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg27121462	chr16:89883253	FANCA	0.85	4.26	0.33	3.58e-5	Skin colour saturation;
PAAD	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-5.39	-0.4	2.62e-7	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7081476	0.737	rs61149145	chr10:27533456	C/T	cg20349793	chr10:26911186	NA	0.87	4.56	0.35	1.04e-5	Age-related diseases and mortality;Age-related diseases, mortality and associated endophenotypes;
PAAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.96	11.12	0.67	2.11e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-7.03	-0.5	6.53e-11	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16469441	chr22:20850308	KLHL22	0.68	7.14	0.5	3.69e-11	Myopia (pathological);
PAAD	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.37	4.92	0.37	2.27e-6	Schizophrenia;
PAAD	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.87	-6.55	-0.47	8.23e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6466055	0.720	rs4730072	chr7:104832260	A/T	cg04380332	chr7:105027541	SRPK2	-0.64	-7.31	-0.51	1.45e-11	Schizophrenia;
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-4.87	-0.37	2.82e-6	Body mass index;
PAAD	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg15181151	chr6:150070149	PCMT1	0.58	6.36	0.46	2.22e-9	Lung cancer;
PAAD	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg07689907	chr11:61582574	FADS1	0.43	4.33	0.33	2.74e-5	Trans fatty acid levels;
PAAD	cis	rs76917914	0.735	rs4742716	chr9:100851420	C/T	cg21225548	chr9:100864335	TRIM14	-0.53	-5.19	-0.39	6.52e-7	Immature fraction of reticulocytes;
PAAD	cis	rs3026101	0.624	rs60691290	chr17:5318503	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.19	0.45	5.44e-9	Body mass index;
PAAD	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.63	6.25	0.45	3.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14019695	chr9:139328340	INPP5E	-0.47	-4.39	-0.34	2.12e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.62	-4.62	-0.35	8.07e-6	Resting heart rate;
PAAD	cis	rs10768122	0.642	rs7942586	chr11:35362979	G/A	cg13971030	chr11:35366721	SLC1A2	-0.46	-5.49	-0.41	1.68e-7	Vitiligo;
PAAD	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs5009270	0.553	rs6973084	chr7:112206747	T/C	cg23628563	chr7:112262597	NA	0.57	4.82	0.36	3.5e-6	Osteoarthritis (hip);
PAAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.32	0.33	2.86e-5	IgG glycosylation;
PAAD	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg09582351	chr12:29534625	ERGIC2	-0.36	-4.83	-0.36	3.26e-6	QT interval;
PAAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg10351095	chr21:47802916	PCNT	-0.48	-4.69	-0.36	5.92e-6	Testicular germ cell tumor;
PAAD	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg18551225	chr6:44695536	NA	-0.69	-6.99	-0.49	7.97e-11	Total body bone mineral density;
PAAD	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.85	5.33	0.4	3.52e-7	Schizophrenia;
PAAD	cis	rs75920871	0.562	rs68137714	chr11:117025357	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.82	-4.69	-0.36	6.05e-6	Subjective well-being;
PAAD	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	8.75	0.58	3.79e-15	Bipolar disorder;
PAAD	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.59	4.31	0.33	2.97e-5	Initial pursuit acceleration;
PAAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-4.57	-0.35	1e-5	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.78	8.71	0.58	4.71e-15	Lung cancer;
PAAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.55	5.51	0.41	1.53e-7	Mean corpuscular volume;
PAAD	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.89	12.67	0.72	1.41e-25	Bone mineral density;
PAAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-7.22	-0.51	2.29e-11	Neuroticism;
PAAD	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.5	4.32	0.33	2.85e-5	Atopic dermatitis;
PAAD	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg13332499	chr17:408570	NA	0.49	5.2	0.39	6.46e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg16898833	chr6:26189333	HIST1H4D	0.79	4.54	0.35	1.14e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.53	5.35	0.4	3.15e-7	Multiple sclerosis;
PAAD	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.74	-6.57	-0.47	7.73e-10	Inhibitory control;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.52	5.19	0.39	6.58e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg27490568	chr2:178487706	NA	0.45	5.02	0.38	1.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.7	4.31	0.33	2.87e-5	Skin colour saturation;
PAAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg17178900	chr1:205818956	PM20D1	0.48	4.73	0.36	5.14e-6	Parkinson's disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02876066	chr19:18632993	ELL	0.64	6.99	0.49	8.26e-11	Pancreatic cancer;
PAAD	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.57	-5.21	-0.39	6.16e-7	Response to antineoplastic agents;
PAAD	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.71	-0.36	5.65e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.8	-9.02	-0.59	7.57e-16	Height;
PAAD	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.53	4.93	0.37	2.12e-6	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04155756	chr4:6988785	TBC1D14	0.58	6.51	0.47	1.05e-9	Monocyte percentage of white cells;
PAAD	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.37	0.33	2.34e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.6	-5.94	-0.43	1.89e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	1.08	9.51	0.61	4.08e-17	Orofacial clefts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09448314	chr17:73496215	KIAA0195	-0.64	-6.46	-0.46	1.35e-9	Obesity-related traits;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg00431813	chr7:1051703	C7orf50	-0.36	-4.57	-0.35	9.87e-6	Longevity;Endometriosis;
PAAD	cis	rs74181299	0.648	rs1050676	chr2:65310831	A/T	cg20592124	chr2:65290738	CEP68	-0.46	-4.26	-0.33	3.64e-5	Pulse pressure;
PAAD	cis	rs7572733	0.765	rs2164068	chr2:198943852	T/A	cg10820045	chr2:198174542	NA	0.43	4.29	0.33	3.18e-5	Dermatomyositis;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg21869046	chr19:41225005	ITPKC	0.59	5.96	0.44	1.65e-8	Kawasaki disease;
PAAD	cis	rs655641	0.520	rs669813	chr11:85762244	C/T	cg07180834	chr11:85838833	NA	-0.44	-4.76	-0.36	4.47e-6	Platelet count;
PAAD	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	0.58	4.69	0.36	6.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg21775007	chr8:11205619	TDH	-0.54	-4.84	-0.37	3.17e-6	Morning vs. evening chronotype;
PAAD	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg16898833	chr6:26189333	HIST1H4D	0.76	4.28	0.33	3.27e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.42	-4.26	-0.33	3.64e-5	Ulcerative colitis;
PAAD	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.24	0.45	4.12e-9	Lung cancer in ever smokers;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg22907277	chr7:1156413	C7orf50	0.83	4.41	0.34	1.98e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg14146966	chr2:61757674	XPO1	-0.39	-4.82	-0.36	3.45e-6	Tuberculosis;
PAAD	cis	rs8051149	0.688	rs16943315	chr16:87869640	G/A	cg01412419	chr16:87856264	NA	0.69	6.3	0.46	3.04e-9	Blood metabolite levels;
PAAD	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.76	-10.95	-0.66	6.11e-21	Schizophrenia;
PAAD	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg13961179	chr15:64285879	DAPK2	-0.64	-6.63	-0.47	5.42e-10	Obesity-related traits;
PAAD	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg23281280	chr6:28129359	ZNF389	0.66	5.08	0.38	1.11e-6	Parkinson's disease;
PAAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg24253500	chr15:84953950	NA	-0.47	-5.22	-0.39	5.77e-7	P wave terminal force;
PAAD	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.58	-0.47	7.21e-10	Total body bone mineral density;
PAAD	cis	rs9567406	1.000	rs2093939	chr13:44876701	A/G	cg08635097	chr13:44833857	NA	-0.63	-4.34	-0.33	2.55e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.84	-8.77	-0.58	3.4e-15	Total body bone mineral density;
PAAD	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.54	5.54	0.41	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs939584	0.935	rs2867123	chr2:624524	C/G	cg14515364	chr2:636606	NA	0.5	4.58	0.35	9.76e-6	Body mass index;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19090068	chr1:9804532	CLSTN1	0.58	7.07	0.5	5.29e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.18	-0.39	7.05e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10916814	0.632	rs10916819	chr1:20901000	A/G	cg04087271	chr1:20915334	CDA	0.38	4.68	0.35	6.41e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs134594	0.885	rs5752864	chr22:29484348	G/A	cg01361351	chr22:29467363	NA	-0.4	-4.47	-0.34	1.53e-5	Birth weight;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg24154853	chr7:158122151	PTPRN2	0.79	7.37	0.51	1.03e-11	Response to amphetamines;
PAAD	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.68	6.66	0.48	4.6e-10	Coronary artery disease;
PAAD	cis	rs5758659	0.810	rs5758623	chr22:42566314	G/C	cg05082376	chr22:42548792	NA	-0.57	-5.93	-0.43	1.93e-8	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01805347	chr1:39457128	AKIRIN1	0.61	6.74	0.48	3.07e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs6748734	0.543	rs73012754	chr2:241754034	G/A	cg04034577	chr2:241836375	C2orf54	0.32	4.44	0.34	1.71e-5	Urinary metabolites;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07560035	chr8:127570383	FAM84B	0.6	6.45	0.46	1.44e-9	Myopia (pathological);
PAAD	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	7.6	0.52	2.87e-12	Menopause (age at onset);
PAAD	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.49	5.44	0.4	2.12e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.6	4.42	0.34	1.89e-5	Pulse pressure;
PAAD	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs78761021	0.720	rs55735457	chr17:9796710	C/T	cg26853458	chr17:9805074	RCVRN	0.74	8.59	0.57	9.42e-15	Type 2 diabetes;
PAAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.69	-7.85	-0.54	6.91e-13	Height;
PAAD	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.4	0.4	2.47e-7	Type 2 diabetes;
PAAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg07061783	chr6:25882402	NA	-0.53	-5.47	-0.41	1.83e-7	Blood metabolite levels;
PAAD	cis	rs7101378	0.557	rs7948895	chr11:108892607	C/T	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.16	-0.39	7.6e-7	IgG glycosylation;
PAAD	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg12395012	chr8:11607386	GATA4	0.4	4.25	0.33	3.73e-5	Triglycerides;
PAAD	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.87	0.69	2.09e-23	Cannabis dependence symptom count;
PAAD	cis	rs7119038	0.865	rs4938573	chr11:118741842	C/T	cg19308663	chr11:118741387	NA	-0.63	-4.85	-0.37	2.99e-6	Sjögren's syndrome;
PAAD	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.84	-0.49	1.81e-10	Response to antipsychotic treatment;
PAAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.7	5.61	0.41	9.54e-8	Schizophrenia;
PAAD	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.97	8.41	0.56	2.71e-14	Triglycerides;
PAAD	cis	rs75757892	0.542	rs9505151	chr6:7324109	G/A	cg02954307	chr6:7269328	NA	0.5	4.29	0.33	3.13e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs28830936	0.966	rs2241522	chr15:42127734	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-6.75	-0.48	2.99e-10	Diastolic blood pressure;
PAAD	cis	rs10186876	0.541	rs12712901	chr2:44189338	G/A	cg14673618	chr2:45170322	SIX3	0.3	4.74	0.36	4.78e-6	Hand grip strength;
PAAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg23708337	chr7:1209742	NA	0.63	4.47	0.34	1.52e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	12.29	0.71	1.55e-24	Menopause (age at onset);
PAAD	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.85	10.3	0.64	3.33e-19	Lung cancer;
PAAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.63	6.16	0.45	6.09e-9	Menopause (age at onset);
PAAD	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.59	-5.3	-0.4	3.94e-7	Total body bone mineral density;
PAAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.88	-0.49	1.5e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26897989	chr16:1907736	C16orf73	0.57	4.97	0.37	1.77e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-5.98	-0.44	1.54e-8	Cystic fibrosis severity;
PAAD	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg26685658	chr5:74633012	HMGCR	-0.52	-4.44	-0.34	1.74e-5	Age-related disease endophenotypes;
PAAD	cis	rs10958605	0.761	rs10090108	chr8:40041710	C/T	cg14545590	chr8:40388592	ZMAT4	-0.4	-4.5	-0.34	1.34e-5	Parkinson's disease (motor and cognition);
PAAD	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg03999872	chr20:62272968	STMN3	0.64	5.87	0.43	2.59e-8	Atopic dermatitis;
PAAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg24585817	chr7:64895279	NA	0.46	4.6	0.35	8.88e-6	Aortic root size;
PAAD	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.93	-0.43	1.99e-8	Idiopathic membranous nephropathy;
PAAD	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg01953289	chr20:60874239	NA	0.72	5.49	0.41	1.65e-7	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.83	-8.7	-0.58	5.15e-15	Itch intensity from mosquito bite;
PAAD	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02985541	chr2:219472218	PLCD4	0.3	4.51	0.34	1.28e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.72	8.06	0.55	2.08e-13	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs8024058	0.919	rs3826039	chr15:89173136	G/T	cg00367546	chr15:89165046	AEN	-0.68	-5.84	-0.43	3e-8	Night sleep phenotypes;
PAAD	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg00806126	chr19:22604979	ZNF98	0.42	5.57	0.41	1.13e-7	Pain;
PAAD	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg06636001	chr8:8085503	FLJ10661	0.74	7.57	0.52	3.31e-12	Triglycerides;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21178979	chr7:1889533	MAD1L1	0.39	4.26	0.33	3.62e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg11494091	chr17:61959527	GH2	0.51	4.3	0.33	3.09e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs7731390	0.614	rs3792881	chr5:131645105	C/T	cg07395648	chr5:131743802	NA	-0.7	-4.47	-0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg17401720	chr7:158221031	PTPRN2	-0.48	-5.09	-0.38	1.06e-6	Obesity-related traits;
PAAD	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-5.88	-0.43	2.56e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.83	-10.13	-0.63	9.63e-19	Coronary artery disease;
PAAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs9992101	0.547	rs7675258	chr4:77413179	A/G	cg20311846	chr4:77356250	SHROOM3	0.36	4.54	0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg20821713	chr7:1055600	C7orf50	-0.55	-4.83	-0.36	3.26e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.81	9.43	0.61	6.67e-17	Schizophrenia;
PAAD	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-7.27	-0.51	1.77e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.39	0.46	1.88e-9	Lung cancer;
PAAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08219700	chr8:58056026	NA	0.73	5.82	0.43	3.33e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.52	8.53	0.57	1.39e-14	IgG glycosylation;
PAAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg02869306	chr7:64672164	INTS4L1	-0.41	-4.77	-0.36	4.31e-6	Calcium levels;
PAAD	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.55	-6.7	-0.48	3.78e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.49	-4.75	-0.36	4.67e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg21546286	chr11:48923668	NA	-0.52	-5.4	-0.4	2.52e-7	HDL cholesterol;
PAAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.84	10.31	0.64	3.19e-19	Body mass index;
PAAD	cis	rs73206853	0.764	rs9737665	chr12:111031847	A/C	cg12870014	chr12:110450643	ANKRD13A	0.65	4.73	0.36	5.16e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.7	10.28	0.64	3.81e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10821973	0.527	rs1432414	chr10:63977069	A/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.64	7.59	0.52	3.08e-12	Schizophrenia;
PAAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08677398	chr8:58056175	NA	0.59	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.55	-5.72	-0.42	5.37e-8	Multiple sclerosis;
PAAD	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06850241	chr22:41845214	NA	0.52	4.54	0.35	1.16e-5	Vitiligo;
PAAD	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg20813462	chr7:2646259	IQCE	0.66	4.65	0.35	7.21e-6	Urate levels in lean individuals;
PAAD	cis	rs6700896	0.500	rs11208699	chr1:66131377	A/G	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.99	10.63	0.65	4.32e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.07	-19.6	-0.85	1.89e-43	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	-0.56	-4.82	-0.36	3.49e-6	Atopic dermatitis;
PAAD	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg02404636	chr22:31891804	SFI1	0.66	6.21	0.45	4.87e-9	Colorectal cancer;
PAAD	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.68	-7.03	-0.5	6.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg25753631	chr6:25732923	NA	-0.49	-5.57	-0.41	1.14e-7	Iron status biomarkers;
PAAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.54	-6.59	-0.47	6.65e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg25457927	chr22:38595422	NA	-0.38	-5.4	-0.4	2.5e-7	Triglycerides;
PAAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.58e-11	Alzheimer's disease;
PAAD	cis	rs7532866	1.000	rs7532866	chr1:26741544	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.51	-4.33	-0.33	2.69e-5	Height;
PAAD	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg02876276	chr17:77834299	NA	-0.62	-4.29	-0.33	3.16e-5	Electroencephalogram traits;
PAAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-5.49	-0.41	1.67e-7	Mood instability;
PAAD	cis	rs10055631	0.518	rs2662226	chr5:66313218	T/C	cg11590213	chr5:66331682	MAST4	0.45	4.5	0.34	1.37e-5	Coronary artery disease;
PAAD	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg06697600	chr4:7070879	GRPEL1	0.76	5.13	0.38	8.64e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg25547332	chr5:131281432	NA	-0.56	-4.4	-0.34	2.02e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	4.61	0.35	8.47e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg10434728	chr15:90938212	IQGAP1	0.44	4.61	0.35	8.42e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs13100165	1.000	rs13100165	chr3:73274289	C/A	cg07385778	chr3:72320634	NA	-0.29	-4.54	-0.35	1.12e-5	Serum uric acid levels in response to allopurinol in gout;
PAAD	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.52	-4.99	-0.38	1.62e-6	Hypospadias;
PAAD	cis	rs8051149	0.625	rs28483765	chr16:87882509	C/T	cg01412419	chr16:87856264	NA	0.56	5.03	0.38	1.39e-6	Blood metabolite levels;
PAAD	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg05925327	chr15:68127851	NA	-0.57	-5.11	-0.38	9.59e-7	Restless legs syndrome;
PAAD	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.24	-5.02	-0.38	1.45e-6	Urinary tract infection frequency;
PAAD	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.71	5.02	0.38	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.58	-5.67	-0.42	6.98e-8	Crohn's disease;
PAAD	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.46	7.56	0.52	3.48e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.58	-6.5	-0.47	1.07e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.83	6.66	0.48	4.83e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9913156	0.748	rs7215274	chr17:4561834	A/G	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	1.03	8.45	0.57	2.23e-14	Initial pursuit acceleration;
PAAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg20848291	chr7:100343083	ZAN	-0.79	-6.63	-0.47	5.54e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.67	-5.14	-0.38	8.5e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-5.94	-0.43	1.87e-8	Schizophrenia;
PAAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10982213	1.000	rs7038862	chr9:117163312	C/T	cg00078025	chr9:117159975	NA	0.59	4.33	0.33	2.68e-5	Interleukin-6 levels;
PAAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg02743256	chr7:2109353	MAD1L1	-0.6	-5.5	-0.41	1.59e-7	Neuroticism;
PAAD	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.68	-4.68	-0.35	6.35e-6	Coronary artery disease;
PAAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	0.39	4.47	0.34	1.54e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02760553	chr17:73975121	ACOX1;C17orf106	0.6	6.55	0.47	8.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	10.71	0.66	2.74e-20	Menopause (age at onset);
PAAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.67	-6.21	-0.45	4.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg23283495	chr1:209979779	IRF6	0.64	6.38	0.46	2.05e-9	Coronary artery disease;
PAAD	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.77	-0.36	4.36e-6	Body mass index;
PAAD	cis	rs783540	1.000	rs783531	chr15:83249119	C/T	cg00614314	chr15:82944287	LOC80154	0.44	4.52	0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs12313068	0.709	rs11829777	chr12:110503770	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.08	0.44	9.09e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.71	5.08	0.38	1.1e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.9	10.06	0.63	1.48e-18	Prudent dietary pattern;
PAAD	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg03098721	chr1:84464084	TTLL7	0.47	4.4	0.34	1.99e-5	Obesity-related traits;
PAAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.96	12.31	0.71	1.35e-24	Menopause (age at onset);
PAAD	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.85	-0.58	2.16e-15	Exhaled nitric oxide output;
PAAD	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.09	-0.38	1.04e-6	Systemic lupus erythematosus;
PAAD	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.46	-7.44	-0.52	7.01e-12	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg01620082	chr3:125678407	NA	-1.49	-8.75	-0.58	3.73e-15	Depression;
PAAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.61	-6.03	-0.44	1.2e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.48	-7.78	-0.53	1.01e-12	Cutaneous nevi;
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.8	0.43	3.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.32	-0.33	2.83e-5	Blood protein levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05539622	chr2:73298971	SFXN5	-0.69	-6.99	-0.49	7.99e-11	Smoking initiation;
PAAD	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-4.68	-0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-4.49	-0.34	1.39e-5	Mood instability;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.8	7.89	0.54	5.49e-13	Vitamin D levels;
PAAD	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.73	7.24	0.51	2.14e-11	Corneal astigmatism;
PAAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg02475695	chr16:616220	NHLRC4	0.47	5.4	0.4	2.54e-7	Height;
PAAD	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.49	5.53	0.41	1.35e-7	Coronary artery disease;
PAAD	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.64	5.56	0.41	1.18e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg22467129	chr15:76604101	ETFA	0.51	4.78	0.36	4.02e-6	Blood metabolite levels;
PAAD	cis	rs12911832	0.727	rs682619	chr15:59098773	T/C	cg05156742	chr15:59063176	FAM63B	0.78	8.22	0.55	8.15e-14	Schizophrenia;
PAAD	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	6.54	0.47	8.81e-10	Mood instability;
PAAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.16	0.45	6.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.88	10.51	0.65	8.99e-20	Metabolic syndrome;
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.86	-8.86	-0.58	1.97e-15	Pancreatic cancer;
PAAD	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-9.06	-0.59	5.88e-16	Exhaled nitric oxide output;
PAAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-8.24	-0.56	7.59e-14	Longevity;Endometriosis;
PAAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.59	-6.48	-0.46	1.24e-9	Coronary artery disease;
PAAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	7.03	0.5	6.49e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.86	10.46	0.65	1.23e-19	Menarche (age at onset);
PAAD	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg21483461	chr5:81570383	RPS23	-0.53	-4.98	-0.37	1.74e-6	Breast cancer;
PAAD	cis	rs16975963	0.644	rs12151280	chr19:38067890	A/C	cg14218481	chr19:38281219	NA	0.41	4.44	0.34	1.69e-5	Longevity;
PAAD	cis	rs4743820	0.620	rs7848226	chr9:93920117	C/G	cg14446406	chr9:93919335	NA	0.48	5.74	0.42	5.01e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.52	-0.57	1.45e-14	Vitiligo;
PAAD	cis	rs901683	0.702	rs77676696	chr10:45967258	A/G	cg16908948	chr10:45500256	ZNF22	0.82	4.34	0.33	2.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7132746	0.672	rs77697757	chr12:86182893	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-4.75	-0.36	4.64e-6	Lewy body disease;
PAAD	cis	rs75757892	0.544	rs10080677	chr6:7315275	G/A	cg02954307	chr6:7269328	NA	0.52	4.54	0.35	1.16e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.77e-7	Migraine;
PAAD	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.78	8.06	0.55	2.06e-13	Morning vs. evening chronotype;
PAAD	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-4.68	-0.35	6.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12304921	0.683	rs56060103	chr12:51452662	C/T	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.69	-0.36	6.09e-6	Type 2 diabetes;
PAAD	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.56	4.71	0.36	5.55e-6	Atopic dermatitis;
PAAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.75	7.93	0.54	4.39e-13	Height;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.51	5.36	0.4	2.99e-7	Male-pattern baldness;
PAAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg14349672	chr11:133703707	NA	-0.53	-6.01	-0.44	1.29e-8	Childhood ear infection;
PAAD	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.74	6.84	0.49	1.79e-10	Coronary artery disease;
PAAD	cis	rs2017305	0.915	rs114235605	chr10:70778487	C/T	cg25290552	chr10:70751067	KIAA1279	-0.89	-4.9	-0.37	2.47e-6	Depression (quantitative trait);
PAAD	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.8	-8.53	-0.57	1.37e-14	Multiple sclerosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01091156	chr16:87991122	BANP	0.57	6.79	0.48	2.43e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.75	-8.87	-0.58	1.88e-15	Body mass index;
PAAD	cis	rs4751006	0.543	rs61875503	chr10:128771532	G/A	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg16606324	chr3:10149918	C3orf24	0.67	5.22	0.39	5.68e-7	Alzheimer's disease;
PAAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg00944433	chr1:107599041	PRMT6	0.42	4.67	0.35	6.58e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg06606381	chr12:133084897	FBRSL1	-1.2	-6.83	-0.48	1.9e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.86	6.71	0.48	3.61e-10	Prostate cancer;
PAAD	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.51	5.54	0.41	1.29e-7	Metabolite levels;
PAAD	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg06606381	chr12:133084897	FBRSL1	-1.26	-8.03	-0.55	2.5e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.73	8.57	0.57	1.08e-14	Emphysema distribution in smoking;
PAAD	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.16	-0.55	1.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs7101378	0.599	rs1509709	chr11:108900874	G/A	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16781275	chr4:135248854	NA	-0.55	-6.46	-0.46	1.37e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.67	-4.27	-0.33	3.38e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
PAAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	5.06	0.38	1.19e-6	Childhood ear infection;
PAAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg19163074	chr7:65112434	INTS4L2	-0.45	-4.36	-0.33	2.38e-5	Aortic root size;
PAAD	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.55	4.86	0.37	2.9e-6	Type 2 diabetes;
PAAD	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.54	4.82	0.36	3.38e-6	Lymphocyte counts;
PAAD	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.65	-8.25	-0.56	6.98e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg14580859	chr9:123691850	NA	0.38	4.31	0.33	2.93e-5	Rheumatoid arthritis;
PAAD	cis	rs6547631	0.622	rs4240201	chr2:85925667	G/A	cg24620635	chr2:85921963	GNLY	0.42	5.57	0.41	1.11e-7	Blood protein levels;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.66	0.62	1.65e-17	Prudent dietary pattern;
PAAD	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-6.31	-0.46	2.85e-9	Schizophrenia;
PAAD	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20916646	chr4:852691	GAK	0.7	6.1	0.44	8.57e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
PAAD	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.49	7.79	0.53	9.5e-13	Neuroticism;
PAAD	cis	rs258892	0.895	rs155427	chr5:72115763	A/G	cg21869765	chr5:72125136	TNPO1	-0.8	-5.32	-0.4	3.63e-7	Small cell lung carcinoma;
PAAD	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.64	6.77	0.48	2.65e-10	Diastolic blood pressure;
PAAD	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.76	8.19	0.55	9.75e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.58	5.59	0.41	1.01e-7	Type 2 diabetes;
PAAD	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-1.0	-8.35	-0.56	3.9e-14	Blood trace element (Zn levels);
PAAD	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.72	-8.23	-0.56	7.73e-14	Diastolic blood pressure;
PAAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.76	-6.04	-0.44	1.12e-8	Initial pursuit acceleration;
PAAD	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.68	9.14	0.6	3.66e-16	Systolic blood pressure;
PAAD	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.58	5.69	0.42	6.43e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.22	-0.51	2.29e-11	Response to antipsychotic treatment;
PAAD	cis	rs35955747	0.902	rs7288643	chr22:31679669	C/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs258892	0.846	rs266441	chr5:72197677	A/G	cg21869765	chr5:72125136	TNPO1	0.76	5.26	0.39	4.87e-7	Small cell lung carcinoma;
PAAD	cis	rs12220238	0.822	rs10824160	chr10:76132267	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	4.35	0.33	2.44e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.72	-6.4	-0.46	1.8e-9	Menarche (age at onset);
PAAD	cis	rs8105895	0.935	rs10420042	chr19:22251926	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.7	6.46	0.46	1.34e-9	Obesity-related traits;
PAAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg26893134	chr6:116381904	FRK	0.46	7.36	0.51	1.09e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.52	4.99	0.38	1.64e-6	Resistin levels;
PAAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	4.61	0.35	8.52e-6	Iron status biomarkers;
PAAD	cis	rs10128251	0.962	rs10752281	chr10:5711220	C/T	cg24097872	chr10:5724021	NA	-0.55	-4.57	-0.35	1.01e-5	Childhood ear infection;
PAAD	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.8	-8.94	-0.59	1.26e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	8.95	0.59	1.15e-15	Platelet count;
PAAD	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.39	-4.89	-0.37	2.59e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21646471	chr2:242523971	THAP4	0.66	5.29	0.39	4.21e-7	Prostate cancer;
PAAD	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg03037974	chr15:76606532	NA	0.5	5.73	0.42	5.14e-8	Blood metabolite levels;
PAAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg23119463	chr10:134592391	INPP5A	-0.53	-5.16	-0.39	7.62e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg07164556	chr1:145727247	PDZK1	-0.79	-4.31	-0.33	2.87e-5	Mitochondrial DNA levels;
PAAD	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg08436684	chr16:88034427	BANP	-0.49	-4.37	-0.33	2.27e-5	Menopause (age at onset);
PAAD	cis	rs4740619	0.688	rs1927698	chr9:15934144	T/G	cg14451791	chr9:16040625	NA	-0.4	-4.54	-0.35	1.14e-5	Body mass index;
PAAD	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg23254163	chr1:152506842	NA	0.59	6.98	0.49	8.34e-11	Hair morphology;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16144447	chr1:36184773	C1orf216	0.69	7.54	0.52	3.86e-12	Myopia (pathological);
PAAD	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg05342945	chr12:48394962	COL2A1	0.74	5.05	0.38	1.24e-6	Lung cancer;
PAAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	7.74	0.53	1.33e-12	Schizophrenia;
PAAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg04315214	chr1:2043799	PRKCZ	0.65	9.24	0.6	2.09e-16	Height;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05134987	chr12:7948531	NANOG	0.6	6.58	0.47	7.35e-10	Smoking initiation;
PAAD	cis	rs62025270	0.688	rs79083718	chr15:86263529	T/A	cg13263323	chr15:86062960	AKAP13	0.5	4.46	0.34	1.6e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-5.55	-0.41	1.25e-7	Mean corpuscular volume;
PAAD	cis	rs941898	0.578	rs4905934	chr14:100608652	A/G	cg26002632	chr14:100625216	DEGS2	-0.33	-4.25	-0.33	3.78e-5	White matter hyperintensity burden;
PAAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-4.4	-0.34	2e-5	Obesity-related traits;
PAAD	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg24324837	chr19:49891574	CCDC155	0.62	4.62	0.35	8.06e-6	Multiple sclerosis;
PAAD	cis	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg23465465	chr6:26364728	BTN3A2	-0.83	-4.94	-0.37	1.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	7.8	0.53	8.96e-13	Schizophrenia;
PAAD	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.51	-4.96	-0.37	1.88e-6	Mean platelet volume;
PAAD	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.69	-6.19	-0.45	5.29e-9	Serum sulfate level;
PAAD	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.56	4.71	0.36	5.59e-6	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20795428	chr22:39715674	SNORD43;RPL3	0.62	6.34	0.46	2.51e-9	Myopia (pathological);
PAAD	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-4.99	-0.38	1.61e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20294457	chr1:146082674	NA	0.7	6.34	0.46	2.51e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07685180	chr8:600429	NA	-0.89	-5.73	-0.42	5.35e-8	IgG glycosylation;
PAAD	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg10434728	chr15:90938212	IQGAP1	-0.5	-5.01	-0.38	1.47e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.73	7.47	0.52	5.85e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.89	-8.7	-0.58	4.99e-15	Bone mineral density;
PAAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.75	5.81	0.43	3.61e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10792830	0.741	rs532470	chr11:85686096	G/T	cg07180834	chr11:85838833	NA	0.47	5.46	0.4	1.91e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg10437265	chr15:77819839	NA	0.42	4.73	0.36	5.03e-6	Type 2 diabetes;
PAAD	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg11779900	chr17:80519722	FOXK2	-0.49	-5.02	-0.38	1.41e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.65	8.11	0.55	1.5700000000000001e-13	Prudent dietary pattern;
PAAD	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.63	5.03	0.38	1.38e-6	Information processing speed;
PAAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26418147	chr1:205743515	RAB7L1	-0.49	-5.83	-0.43	3.21e-8	Menarche (age at onset);
PAAD	cis	rs6494488	0.500	rs79939025	chr15:64860985	G/T	cg16425858	chr15:64791681	ZNF609	0.93	5.05	0.38	1.22e-6	Coronary artery disease;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01208787	chr7:29526309	CHN2	0.66	6.77	0.48	2.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.38	9.61	0.61	2.2e-17	Diabetic retinopathy;
PAAD	cis	rs796364	0.570	rs35733345	chr2:200647533	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.29	-0.39	4.27e-7	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.93	9.75	0.62	9.69e-18	Cognitive function;
PAAD	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg07943548	chr15:86304357	KLHL25	-0.74	-6.09	-0.44	8.64e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.82	-7.04	-0.5	6.08e-11	Developmental language disorder (linguistic errors);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15991546	chr1:98386723	DPYD	-0.57	-6.9	-0.49	1.33e-10	Body fat percentage;
PAAD	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.58	6.87	0.49	1.54e-10	Aortic root size;
PAAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.43	4.37	0.33	2.31e-5	Bipolar disorder;
PAAD	cis	rs4073221	0.654	rs66790792	chr3:18284981	G/A	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.84	8.81	0.58	2.67e-15	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.51	5.1	0.38	9.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg26876637	chr1:152193138	HRNR	-0.8	-5.32	-0.4	3.6e-7	Atopic dermatitis;
PAAD	cis	rs1478898	0.526	rs1478897	chr8:11395232	A/T	cg08224773	chr8:11311868	FAM167A	0.39	4.89	0.37	2.55e-6	Morning vs. evening chronotype;
PAAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.18	17.8	0.82	5.17e-39	Cognitive function;
PAAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg03352409	chr22:21336370	LZTR1	0.6	6.65	0.47	5.1e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg26003909	chr8:143102224	NA	-0.35	-5.88	-0.43	2.46e-8	Amyotrophic lateral sclerosis;
PAAD	cis	rs1730008	0.731	rs73164066	chr3:157828781	T/C	cg16708174	chr3:158430962	RARRES1	0.55	5.03	0.38	1.36e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10982256	0.763	rs1535965	chr9:117273208	C/T	cg12877860	chr9:117266580	DFNB31	0.42	4.31	0.33	2.88e-5	Bipolar disorder;
PAAD	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.58	-5.71	-0.42	5.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg16419906	chr5:132167176	NA	-0.59	-4.47	-0.34	1.5e-5	Breast cancer;
PAAD	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.84	-9.34	-0.6	1.16e-16	Mortality in heart failure;
PAAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13560548	chr3:10150139	C3orf24	0.63	5.71	0.42	5.79e-8	Alzheimer's disease;
PAAD	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.56	5.11	0.38	9.71e-7	Testicular germ cell tumor;
PAAD	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.77	8.84	0.58	2.28e-15	Coronary artery disease;
PAAD	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.59	8.0	0.54	2.88e-13	Breast cancer;
PAAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg16083429	chr3:49237500	CCDC36	-0.45	-4.8	-0.36	3.69e-6	Parkinson's disease;
PAAD	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.43	-0.46	1.58e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.89	0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs4742903	0.870	rs10991172	chr9:106976151	C/T	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.09e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6977660	0.652	rs10275246	chr7:19851059	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	4.79	0.36	3.98e-6	Thyroid stimulating hormone;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.61	6.45	0.46	1.4e-9	Tonsillectomy;
PAAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs603424	0.551	rs610745	chr10:102089436	G/A	cg10365880	chr10:102089681	PKD2L1	0.83	5.29	0.39	4.17e-7	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs9810259	0.586	rs17817276	chr3:12397392	A/G	cg23514324	chr3:12329213	PPARG	-0.48	-4.28	-0.33	3.31e-5	Platelet count;
PAAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg00024416	chr22:24240387	NA	0.54	5.03	0.38	1.4e-6	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19327137	chr7:38886074	VPS41	0.43	4.38	0.33	2.19e-5	Subjective well-being (multi-trait analysis);
PAAD	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg05333889	chr7:157238977	NA	-0.44	-4.54	-0.35	1.16e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.52	-6.55	-0.47	8.34e-10	Schizophrenia;
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.0	-0.44	1.39e-8	Cystic fibrosis severity;
PAAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23632979	chr17:7531125	SHBG;SAT2	0.71	7.44	0.52	6.88e-12	Obesity-related traits;
PAAD	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg12437481	chr16:420112	MRPL28	-0.56	-5.01	-0.38	1.52e-6	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs8077577	0.747	rs7405677	chr17:18131236	C/T	cg16794390	chr17:18148240	FLII	-0.54	-4.6	-0.35	8.94e-6	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg15181151	chr6:150070149	PCMT1	0.55	5.58	0.41	1.08e-7	Lung cancer;
PAAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg02917321	chr22:38215204	NA	0.49	4.83	0.36	3.32e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg05791153	chr7:19748676	TWISTNB	0.63	4.52	0.34	1.24e-5	Thyroid stimulating hormone;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07568517	chr2:3381687	TSSC1	0.6	6.81	0.48	2.11e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Acylcarnitine levels;
PAAD	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg15676125	chr6:33679581	C6orf125	0.48	4.69	0.36	5.98e-6	Plateletcrit;
PAAD	cis	rs4857855	0.716	rs13060840	chr3:128238682	G/A	cg06796779	chr3:128204927	GATA2	-0.33	-4.25	-0.33	3.77e-5	Eosinophil counts;
PAAD	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg02135003	chr7:105160482	PUS7	-0.8	-6.12	-0.44	7.78e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg16584676	chr17:46985605	UBE2Z	-0.64	-6.54	-0.47	8.97e-10	Type 2 diabetes;
PAAD	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10829534	0.564	rs10764837	chr10:130768215	G/A	cg06937395	chr10:131718323	EBF3	0.47	5.07	0.38	1.13e-6	Cisplatin-induced ototoxicity;
PAAD	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.59	0.35	9.05e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg23465465	chr6:26364728	BTN3A2	0.79	4.4	0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg02640540	chr1:67518911	SLC35D1	0.55	4.74	0.36	4.96e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.9	10.73	0.66	2.34e-20	Heart rate;
PAAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg03714773	chr7:91764589	CYP51A1	0.33	4.56	0.35	1.03e-5	Breast cancer;
PAAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-4.89	-0.37	2.51e-6	Obesity-related traits;
PAAD	cis	rs4919087	0.590	rs1253396	chr10:99045230	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-4.82	-0.36	3.43e-6	Monocyte count;
PAAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.52	5.84	0.43	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.67	-7.47	-0.52	5.81e-12	Heart rate;
PAAD	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg02344993	chr17:57696989	CLTC	0.58	5.46	0.41	1.88e-7	Hemoglobin concentration;
PAAD	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.56	6.03	0.44	1.2e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg07099767	chr17:78039528	CCDC40	-0.55	-4.67	-0.35	6.62e-6	Yeast infection;
PAAD	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg07636037	chr3:49044803	WDR6	0.55	4.35	0.33	2.52e-5	Menarche (age at onset);
PAAD	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	4.79	0.36	3.93e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.62	-6.04	-0.44	1.12e-8	White matter hyperintensity burden;
PAAD	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg04289385	chr6:36355825	ETV7	-0.44	-4.65	-0.35	7.1e-6	Platelet distribution width;
PAAD	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs11807834	0.522	rs12086717	chr1:230255859	C/T	cg00566187	chr1:230250356	GALNT2	-0.68	-7.27	-0.51	1.73e-11	Schizophrenia;
PAAD	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.99	13.86	0.75	9.14e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-5.26	-0.39	4.92e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.01	-0.49	7.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.45	4.46	0.34	1.62e-5	Breast cancer;
PAAD	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.08	8.15	0.55	1.22e-13	Left atrial antero-posterior diameter;
PAAD	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	1.11	5.97	0.44	1.58e-8	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg22134325	chr11:66188745	NPAS4	0.32	4.71	0.36	5.52e-6	Airway imaging phenotypes;
PAAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg04810063	chr16:88703634	IL17C	-0.53	-4.7	-0.36	5.83e-6	Menopause (age at onset);
PAAD	cis	rs4704187	0.687	rs7711762	chr5:74461675	C/T	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.77	8.62	0.57	8.32e-15	Prudent dietary pattern;
PAAD	cis	rs941898	0.598	rs7157599	chr14:100625902	A/G	cg26002632	chr14:100625216	DEGS2	0.4	5.1	0.38	9.93e-7	White matter hyperintensity burden;
PAAD	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-4.66	-0.35	6.89e-6	Type 2 diabetes;
PAAD	cis	rs2814982	0.514	rs73405691	chr6:34468767	A/G	cg14254433	chr6:34482411	PACSIN1	-0.83	-6.03	-0.44	1.21e-8	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs8133932	0.701	rs2839021	chr21:47280016	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-4.26	-0.33	3.61e-5	Schizophrenia;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg21565972	chr17:80109576	CCDC57	-0.6	-6.9	-0.49	1.29e-10	Life satisfaction;
PAAD	cis	rs4668356	0.687	rs16859206	chr2:172043803	A/G	cg13882835	chr2:172017928	TLK1	0.72	4.26	0.33	3.61e-5	Cognitive performance;
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg15729578	chr3:195576390	NA	0.45	4.77	0.36	4.33e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.84	-8.51	-0.57	1.55e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg16205897	chr5:131564050	P4HA2	0.41	4.46	0.34	1.56e-5	Blood metabolite levels;
PAAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg01942863	chr7:99769432	GPC2	-0.45	-4.35	-0.33	2.53e-5	Coronary artery disease;
PAAD	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.82	9.49	0.61	4.52e-17	Brugada syndrome;
PAAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-5.35	-0.4	3.23e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.62	0.62	2.09e-17	Rheumatoid arthritis;
PAAD	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.54	0.65	7.64e-20	Cognitive test performance;
PAAD	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg10290764	chr8:4849399	CSMD1	-0.39	-6.47	-0.46	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.55	5.24	0.39	5.23e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.08	0.59	5.29e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs2839619	0.521	rs2839621	chr21:44440024	C/T	cg19312314	chr21:44473962	CBS	-0.41	-4.3	-0.33	3.04e-5	Biochemical measures;
PAAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.93	0.37	2.12e-6	Parkinson's disease;
PAAD	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-5.04	-0.38	1.28e-6	Testicular germ cell tumor;
PAAD	cis	rs12136530	0.593	rs881246	chr1:19733255	C/A	cg03321592	chr1:19991676	HTR6	0.5	4.32	0.33	2.84e-5	Lead levels in blood;
PAAD	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7092929	1.000	rs7092929	chr10:3538794	A/C	cg14308648	chr10:3568949	NA	0.61	4.72	0.36	5.25e-6	Coronary artery calcification;
PAAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-5.85	-0.43	2.86e-8	Joint mobility (Beighton score);
PAAD	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.96	-10.78	-0.66	1.75e-20	Coronary artery disease;
PAAD	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs12257961	0.675	rs4750619	chr10:15347175	T/A	cg02073427	chr10:15252052	NA	-0.48	-4.39	-0.34	2.1e-5	Selective IgA deficiency;
PAAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg11802864	chr11:65308245	LTBP3	0.44	4.47	0.34	1.52e-5	Bone mineral density;
PAAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-13.02	-0.73	1.65e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg00262122	chr8:11665843	FDFT1	0.49	4.62	0.35	8.26e-6	Neuroticism;
PAAD	cis	rs2051773	0.510	rs11024131	chr11:17056440	C/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs114540395	0.858	rs7073902	chr10:103291893	A/C	cg21381511	chr10:104264849	SUFU	-0.86	-4.32	-0.33	2.78e-5	Schizophrenia;
PAAD	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-5.62	-0.41	9.02e-8	Schizophrenia;
PAAD	cis	rs9826463	0.757	rs73240314	chr3:142255090	T/C	cg20824294	chr3:142316082	PLS1	0.44	5.03	0.38	1.37e-6	QRS duration in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13560548	chr3:10150139	C3orf24	0.55	5.01	0.38	1.49e-6	Alzheimer's disease;
PAAD	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.57	5.22	0.39	5.9e-7	Resting heart rate;
PAAD	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.48	9.19	0.6	2.86e-16	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg05861140	chr6:150128134	PCMT1	-0.56	-6.37	-0.46	2.09e-9	Lung cancer;
PAAD	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.61	-6.02	-0.44	1.27e-8	Mortality in heart failure;
PAAD	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg27471124	chr11:109292789	C11orf87	0.29	5.1	0.38	1.01e-6	Schizophrenia;
PAAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16434002	chr17:42200994	HDAC5	-0.67	-7.41	-0.52	8.04e-12	Total body bone mineral density;
PAAD	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.57	-4.31	-0.33	2.9e-5	Alzheimer's disease (survival time);
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg21280320	chr1:152162025	NA	0.59	6.04	0.44	1.11e-8	Inflammatory skin disease;
PAAD	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg27182935	chr16:89790473	ZNF276	-0.82	-4.49	-0.34	1.42e-5	Skin colour saturation;
PAAD	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-6.09	-0.44	8.98e-9	Gallbladder cancer;
PAAD	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-4.94	-0.37	2.03e-6	Glomerular filtration rate;
PAAD	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4073221	0.654	rs67148103	chr3:18279461	G/A	cg07694806	chr3:18168406	NA	-0.66	-4.88	-0.37	2.71e-6	Parkinson's disease;
PAAD	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.46	4.69	0.36	5.99e-6	Corneal astigmatism;
PAAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg10705379	chr10:99080932	FRAT1	-0.44	-5.15	-0.39	8e-7	Monocyte count;
PAAD	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.88	10.35	0.64	2.51e-19	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.63	6.77	0.48	2.63e-10	Crohn's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11359849	chr12:77718577	NA	-0.75	-6.36	-0.46	2.22e-9	Neuroticism;
PAAD	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.79	7.98	0.54	3.36e-13	Coronary artery disease;
PAAD	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg00806126	chr19:22604979	ZNF98	-0.37	-4.92	-0.37	2.2e-6	Pain;
PAAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg05562828	chr17:3906858	NA	0.55	6.43	0.46	1.55e-9	Type 2 diabetes;
PAAD	cis	rs1941184	0.759	rs7236769	chr18:29025257	A/T	cg03238162	chr18:29027701	DSG3	0.43	4.94	0.37	2.06e-6	Parkinson's disease (age of onset);
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.94	-0.43	1.85e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15320075	chr8:145703422	NA	0.55	5.78	0.42	4.19e-8	Age at first birth;
PAAD	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg14311320	chr7:124405732	GPR37	-0.44	-4.37	-0.33	2.27e-5	Lewy body disease;
PAAD	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.26	-0.39	4.82e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg17105886	chr17:28927953	LRRC37B2	0.72	4.66	0.35	6.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.62	-6.11	-0.44	8.1e-9	Bone properties (heel);
PAAD	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg18551225	chr6:44695536	NA	-0.68	-6.85	-0.49	1.75e-10	Total body bone mineral density;
PAAD	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	5.95	0.43	1.78e-8	Lung function (FEV1/FVC);
PAAD	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.56	7.08	0.5	4.94e-11	Atrioventricular conduction;
PAAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.75e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs17095355	0.818	rs7086057	chr10:111867076	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-5.34	-0.4	3.3e-7	Biliary atresia;
PAAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.87	-10.17	-0.64	7.63e-19	Iron status biomarkers;
PAAD	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.45	-4.57	-0.35	1e-5	Ovarian reserve;
PAAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg05132306	chr1:1846340	CALML6	-0.43	-5.04	-0.38	1.3e-6	Body mass index;
PAAD	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.02e-7	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21659725	chr3:3221576	CRBN	0.84	9.84	0.62	5.39e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg09835421	chr16:68378352	PRMT7	0.81	6.51	0.47	1.01e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.6	-6.12	-0.44	7.61e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg04165759	chr1:150448943	RPRD2	-0.51	-5.27	-0.39	4.7e-7	Migraine;
PAAD	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.16	-0.39	7.46e-7	Common traits (Other);
PAAD	cis	rs73206853	0.764	rs76044375	chr12:110901339	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.54	4.56	0.35	1.04e-5	Lymphocyte counts;
PAAD	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg04721828	chr11:48285200	OR4X1	0.4	5.22	0.39	5.71e-7	Migraine - clinic-based;
PAAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.59	7.14	0.5	3.54e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	5.14	0.39	8.19e-7	HIV-1 control;
PAAD	cis	rs2274459	1.000	rs729376	chr6:33704823	C/T	cg06253072	chr6:33679850	C6orf125	0.61	4.67	0.35	6.61e-6	Obesity (extreme);
PAAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.06e-8	Life satisfaction;
PAAD	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.5	-4.96	-0.37	1.84e-6	Coronary artery disease;
PAAD	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.97	-0.49	8.95e-11	Mood instability;
PAAD	trans	rs9942416	0.858	rs2307111	chr5:75003678	T/C	cg03931927	chr7:65215969	CCT6P1	-0.63	-6.39	-0.46	1.93e-9	Age-related disease endophenotypes;
PAAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg07685180	chr8:600429	NA	-0.9	-5.42	-0.4	2.28e-7	IgG glycosylation;
PAAD	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg00792783	chr2:198669748	PLCL1	-0.47	-4.29	-0.33	3.19e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs1539053	0.932	rs1404384	chr1:58109829	A/G	cg20292791	chr1:58089357	DAB1	0.52	4.98	0.37	1.71e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
PAAD	cis	rs10988449	0.891	rs62586368	chr9:132387882	C/T	cg18327994	chr9:132372705	NA	-0.59	-4.33	-0.33	2.65e-5	Response to anti-depressant treatment in major depressive disorder;
PAAD	cis	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	7.81	0.53	8.88e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	17.0	0.81	5.43e-37	Prudent dietary pattern;
PAAD	cis	rs11037575	0.739	rs7130849	chr11:43730455	G/A	cg24662154	chr11:44118094	EXT2	-0.43	-4.4	-0.34	2.06e-5	Neuroblastoma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03370490	chr11:1380305	NA	-0.57	-6.77	-0.48	2.57e-10	Myopia (pathological);
PAAD	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.4e-17	Longevity (90 years and older);
PAAD	cis	rs829661	0.947	rs829677	chr2:30709977	A/G	cg12454169	chr2:30669597	LCLAT1	0.64	5.02	0.38	1.43e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27207452	chr12:56551679	MYL6B;MYL6	0.65	6.53	0.47	9.16e-10	Obesity-related traits;
PAAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg22710661	chr11:17411071	KCNJ11	0.43	4.26	0.33	3.52e-5	Type 2 diabetes;
PAAD	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.72	7.34	0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.61	-5.93	-0.43	1.98e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs17534004	1.000	rs35646895	chr13:31469604	C/T	cg00570269	chr13:31480942	C13orf33	0.59	4.43	0.34	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.62	6.29	0.45	3.19e-9	Mood instability;
PAAD	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.99	11.62	0.69	9.53e-23	Breast cancer;
PAAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.88	-8.44	-0.56	2.31e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg10645314	chr2:3704589	ALLC	-0.83	-7.35	-0.51	1.11e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs11077998	0.967	rs901373	chr17:80506559	A/G	cg27455613	chr17:80820699	TBCD	-0.43	-4.25	-0.33	3.79e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7072216	0.650	rs10883089	chr10:100163120	A/C	cg26618903	chr10:100175079	PYROXD2	-0.53	-5.79	-0.43	3.85e-8	Metabolite levels;
PAAD	cis	rs6585424	1.000	rs2304410	chr10:81921810	T/C	cg19423196	chr10:82049429	MAT1A	0.44	4.56	0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.54	0.35	1.15e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06002616	chr8:101225028	SPAG1	0.47	5.61	0.41	9.54e-8	Atrioventricular conduction;
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.887	rs2236165	chr20:34096725	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.53	5.08	0.38	1.08e-6	Aortic root size;
PAAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.94	-9.01	-0.59	8.23e-16	Bronchopulmonary dysplasia;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg23000153	chr5:1212434	SLC6A19	0.81	6.5	0.47	1.08e-9	Photic sneeze reflex;
PAAD	cis	rs9395066	0.545	rs10948185	chr6:44901727	C/T	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	10.32	0.64	3e-19	Smoking behavior;
PAAD	cis	rs2992756	0.553	rs2992745	chr1:18809896	A/T	cg14356550	chr1:18808102	KLHDC7A	-0.52	-5.63	-0.42	8.48e-8	Breast cancer;
PAAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg21565972	chr17:80109576	CCDC57	-0.57	-6.42	-0.46	1.66e-9	Life satisfaction;
PAAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.28	0.45	3.32e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.61	-6.98	-0.49	8.38e-11	Huntington's disease progression;
PAAD	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.64	7.04	0.5	6.14e-11	Height;
PAAD	cis	rs4780401	0.933	rs1579258	chr16:11824903	C/G	cg01061890	chr16:11836724	TXNDC11	-0.53	-5.14	-0.38	8.28e-7	Rheumatoid arthritis;
PAAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.53	4.85	0.37	3.06e-6	Facial morphology (factor 20);
PAAD	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.73	-7.37	-0.51	9.96e-12	Morning vs. evening chronotype;
PAAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.6	-5.61	-0.41	9.4e-8	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg11619707	chr19:22235551	ZNF257	0.58	5.82	0.43	3.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	10.07	0.63	1.39e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.55	5.43	0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg04034577	chr2:241836375	C2orf54	-0.34	-5.15	-0.39	7.79e-7	Urinary metabolites;
PAAD	cis	rs9677476	0.774	rs1973016	chr2:232117513	C/G	cg07929768	chr2:232055508	NA	0.39	4.41	0.34	1.96e-5	Food antigen IgG levels;
PAAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs859767	0.501	rs10928507	chr2:135396631	C/T	cg12500956	chr2:135428796	TMEM163	0.31	4.43	0.34	1.82e-5	Neuroticism;
PAAD	cis	rs12431939	1.000	rs4567626	chr14:51647640	A/T	cg23942311	chr14:51606299	NA	0.77	6.2	0.45	5.02e-9	Cancer;
PAAD	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.69	-4.87	-0.37	2.81e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs72960926	0.744	rs3846756	chr6:75061918	A/T	cg03266952	chr6:74778945	NA	-1.06	-5.59	-0.41	1.01e-7	Metabolite levels (MHPG);
PAAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.68	7.43	0.52	7.4e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg03199926	chr20:60860733	OSBPL2	-0.35	-4.3	-0.33	3.01e-5	Colorectal cancer;
PAAD	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.84	10.33	0.64	2.87e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.51	4.88	0.37	2.71e-6	Pancreatic cancer;
PAAD	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.77	7.41	0.52	8.08e-12	Response to diuretic therapy;
PAAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-5.91	-0.43	2.14e-8	Fear of minor pain;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04013166	chr16:89971882	TCF25	0.65	4.39	0.34	2.11e-5	Skin colour saturation;
PAAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.84	10.42	0.65	1.62e-19	Menopause (age at onset);
PAAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.09e-10	Tonsillectomy;
PAAD	cis	rs7192380	0.651	rs920191	chr16:69689120	G/A	cg05250797	chr16:70222502	NA	0.65	5.74	0.42	5.03e-8	Sjögren's syndrome;
PAAD	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.63	7.04	0.5	6.26e-11	Lupus nephritis in systemic lupus erythematosus;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19000611	chr14:92198288	CATSPERB	0.61	6.41	0.46	1.78e-9	Smoking initiation;
PAAD	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.34	-0.33	2.55e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2191566	1.000	rs7253205	chr19:44503607	T/C	cg18700516	chr19:44507157	ZNF230	-0.47	-4.34	-0.33	2.58e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	trans	rs901683	1.000	rs35183751	chr10:46081358	T/C	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.15e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	5.33	0.4	3.46e-7	Height;
PAAD	cis	rs10159528	0.691	rs4418740	chr10:87481980	C/T	cg03356747	chr10:88126089	GRID1	0.38	4.34	0.33	2.64e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg16341495	chr8:142228727	SLC45A4	-0.59	-5.34	-0.4	3.32e-7	Immature fraction of reticulocytes;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.02	-8.76	-0.58	3.58e-15	Vitiligo;
PAAD	cis	rs582384	0.630	rs798830	chr2:45868240	T/C	cg13704086	chr2:45177125	NA	-0.46	-4.36	-0.33	2.35e-5	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01996304	chr16:31085596	ZNF668;ZNF646	-0.59	-6.45	-0.46	1.44e-9	Myopia (pathological);
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22395299	chr21:47706029	MCM3AP;C21orf57	0.56	6.49	0.47	1.16e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs13424612	0.930	rs4149545	chr2:240942818	G/T	cg01812947	chr2:240904978	NDUFA10	0.59	5.17	0.39	7.36e-7	Odorant perception (isobutyraldehyde);
PAAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg05082376	chr22:42548792	NA	-0.55	-5.67	-0.42	6.93e-8	Cognitive function;
PAAD	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg15309053	chr8:964076	NA	0.43	4.78	0.36	4.12e-6	Schizophrenia;
PAAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg15448220	chr1:150897856	SETDB1	0.6	6.09	0.44	8.82e-9	Tonsillectomy;
PAAD	cis	rs3736485	0.844	rs28680710	chr15:51788991	G/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.28	-0.33	3.32e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg25233709	chr10:116636983	FAM160B1	0.45	5.74	0.42	4.92e-8	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.49	-5.86	-0.43	2.8e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.34	-0.4	3.32e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.53	7.35	0.51	1.15e-11	Crohn's disease;
PAAD	cis	rs9463078	0.774	rs9381383	chr6:45271893	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.32	-0.4	3.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg14458575	chr2:238380390	NA	0.77	6.13	0.45	7.15e-9	Prostate cancer;
PAAD	trans	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg25214090	chr10:38739885	LOC399744	0.81	8.28	0.56	5.95e-14	Educational attainment;
PAAD	cis	rs73621547	0.558	rs28365646	chr9:132102188	G/A	cg18217252	chr9:133027791	NA	-0.8	-4.26	-0.33	3.53e-5	Caudate activity during reward;
PAAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.56	-5.59	-0.41	1.01e-7	Obesity-related traits;
PAAD	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.86	-5.97	-0.44	1.6e-8	Coronary artery disease;
PAAD	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg18357526	chr6:26021779	HIST1H4A	0.73	4.3	0.33	3.06e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.36	3.64e-6	Coronary artery disease;
PAAD	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.86	-7.07	-0.5	5.28e-11	Chronic kidney disease;
PAAD	cis	rs10450586	0.932	rs10450562	chr11:27310006	A/G	cg10370305	chr11:27303972	NA	0.37	4.54	0.35	1.14e-5	Total body bone mineral density;
PAAD	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-4.89	-0.37	2.6e-6	Vitiligo;
PAAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs1656368	0.770	rs12495085	chr3:158272632	G/A	cg16708174	chr3:158430962	RARRES1	0.55	5.01	0.38	1.47e-6	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.81	8.73	0.58	4.29e-15	IgG glycosylation;
PAAD	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	1.21	11.77	0.69	3.9699999999999997e-23	Corneal structure;
PAAD	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg10433327	chr15:56209506	NEDD4	-0.32	-4.45	-0.34	1.67e-5	Keloid;
PAAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.55	5.84	0.43	3.02e-8	Lung cancer;
PAAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg14092988	chr3:52407081	DNAH1	0.51	6.59	0.47	6.8e-10	Bipolar disorder;
PAAD	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg19682013	chr15:45996608	NA	0.32	4.35	0.33	2.47e-5	Waist circumference;Weight;
PAAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Parkinson's disease;
PAAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg20578329	chr17:80767326	TBCD	-0.87	-5.62	-0.41	9.09e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00166722	chr3:10149974	C3orf24	0.91	7.89	0.54	5.52e-13	Alzheimer's disease;
PAAD	cis	rs8179	0.700	rs42043	chr7:92247333	A/G	cg03496780	chr7:92466842	CDK6	0.46	4.28	0.33	3.25e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19082920	chr1:202830751	LOC148709	0.58	6.31	0.46	2.83e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02359409	chr6:42947317	PEX6	-0.5	-4.76	-0.36	4.39e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-6.24	-0.45	4.18e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg11900509	chr10:81946545	ANXA11	-0.76	-4.3	-0.33	3.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.2	13.77	0.75	1.57e-28	Post bronchodilator FEV1;
PAAD	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-4.3	-0.33	2.98e-5	Coronary artery disease;
PAAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg20607287	chr7:12443886	VWDE	-0.71	-5.49	-0.41	1.62e-7	Coronary artery disease;
PAAD	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.43	4.41	0.34	1.97e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg23387401	chr17:4582204	PELP1	0.51	5.02	0.38	1.41e-6	Lymphocyte counts;
PAAD	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg19223190	chr17:80058835	NA	0.51	5.28	0.39	4.44e-7	Life satisfaction;
PAAD	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-0.63	-5.03	-0.38	1.35e-6	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.88	-11.27	-0.67	8.44e-22	Total body bone mineral density;
PAAD	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.66	9.59	0.61	2.54e-17	Airflow obstruction;
PAAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg03808351	chr9:123631620	PHF19	0.57	6.25	0.45	3.98e-9	Birth weight;
PAAD	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.59	6.07	0.44	9.96e-9	Coronary artery disease;
PAAD	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg02613624	chr11:2154386	INS-IGF2;IGF2	0.38	4.33	0.33	2.72e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.95	-8.54	-0.57	1.3e-14	Bipolar disorder;
PAAD	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.7	-6.82	-0.48	2.06e-10	Post bronchodilator FEV1;
PAAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg21565972	chr17:80109576	CCDC57	0.58	6.71	0.48	3.54e-10	Life satisfaction;
PAAD	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.62	7.03	0.5	6.48e-11	Resting heart rate;
PAAD	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg15017067	chr4:17643749	FAM184B	0.41	4.39	0.34	2.14e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg04877966	chr15:75135169	ULK3	0.54	4.67	0.35	6.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2594989	0.895	rs2606739	chr3:11394611	C/A	cg01796438	chr3:11312864	ATG7	-0.63	-4.79	-0.36	3.87e-6	Circulating chemerin levels;
PAAD	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.85	-9.44	-0.61	6.38e-17	Coronary artery disease;
PAAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg09699651	chr6:150184138	LRP11	0.52	5.37	0.4	2.93e-7	Lung cancer;
PAAD	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-7.93	-0.54	4.28e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.57	6.7	0.48	3.91e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs329648	0.553	rs329653	chr11:133771179	G/A	cg18057887	chr11:133800913	IGSF9B	0.61	6.82	0.48	1.97e-10	Parkinson's disease;
PAAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.93	4.96	0.37	1.9e-6	Childhood ear infection;
PAAD	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.59	5.73	0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	6.1	0.44	8.36e-9	Mean platelet volume;
PAAD	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.69	7.62	0.53	2.55e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg19257562	chr1:2043853	PRKCZ	-0.39	-4.38	-0.33	2.18e-5	Coronary artery disease;
PAAD	cis	rs11686241	0.688	rs284538	chr2:217375647	G/A	cg15830940	chr2:217278069	SMARCAL1	-0.49	-4.39	-0.34	2.08e-5	Cancer;
PAAD	cis	rs1358748	0.555	rs2815388	chr1:67538853	C/T	cg02640540	chr1:67518911	SLC35D1	0.66	4.41	0.34	1.92e-5	Tuberculosis;
PAAD	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.62	-0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs6499755	0.768	rs31098	chr16:55369098	T/A	cg02859129	chr16:55357253	IRX6	0.37	5.16	0.39	7.5e-7	Hypospadias;
PAAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4729127	1.000	rs17166206	chr7:94004197	C/T	cg20814616	chr7:94014465	NA	-0.61	-4.53	-0.35	1.17e-5	Intelligence;
PAAD	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.68	8.43	0.56	2.51e-14	Coronary artery disease;
PAAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-5.97	-0.44	1.6e-8	Lung cancer;
PAAD	cis	rs2190422	0.677	rs2382693	chr7:103076969	A/G	cg04218035	chr7:103086829	SLC26A5	-0.35	-5.03	-0.38	1.37e-6	Morning vs. evening chronotype;
PAAD	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg22532475	chr10:104410764	TRIM8	-0.38	-4.59	-0.35	9.11e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs10404486	1.000	rs10404486	chr19:53284135	A/G	cg18671199	chr19:53289524	ZNF600	-0.62	-4.34	-0.33	2.64e-5	Phospholipid levels (plasma);
PAAD	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.46	4.47	0.34	1.53e-5	Cognitive ability (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17819702	chr2:180128907	SESTD1	0.62	7.04	0.5	6.24e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.68	10.39	0.64	1.91e-19	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	7.52	0.52	4.54e-12	Eosinophil percentage of white cells;
PAAD	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg15557168	chr22:42548783	NA	-0.55	-6.15	-0.45	6.61e-9	Cognitive function;
PAAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.6	0.35	8.7e-6	Personality dimensions;
PAAD	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.72	-6.99	-0.49	8.06e-11	QRS duration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07342512	chr1:65886002	LEPROT;LEPR	0.61	6.9	0.49	1.3e-10	Myopia (pathological);
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg15476425	chr17:78836403	RPTOR	-0.6	-6.91	-0.49	1.25e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.67	-5.84	-0.43	3.09e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9323205	0.765	rs12232228	chr14:51658072	A/G	cg23942311	chr14:51606299	NA	0.46	4.45	0.34	1.65e-5	Cancer;
PAAD	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.53	-5.25	-0.39	5.14e-7	Adiposity;
PAAD	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg23254163	chr1:152506842	NA	0.6	6.89	0.49	1.42e-10	Hair morphology;
PAAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg09835421	chr16:68378352	PRMT7	-1.16	-8.32	-0.56	4.58e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.4	-9.86	-0.62	4.79e-18	Diabetic retinopathy;
PAAD	cis	rs8060686	0.858	rs12449157	chr16:67708897	A/G	cg05110241	chr16:68378359	PRMT7	-0.73	-5.12	-0.38	9.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4455778	0.538	rs7795732	chr7:49127493	T/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg09659197	chr4:152720779	NA	0.36	5.21	0.39	6.1e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11825064	0.562	rs77092254	chr11:134512159	G/C	cg02089395	chr11:134479357	NA	-0.93	-5.96	-0.44	1.68e-8	Seasonality;
PAAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.78	6.05	0.44	1.06e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg12757816	chr2:10669957	NA	-0.55	-5.82	-0.43	3.43e-8	Prostate cancer;
PAAD	cis	rs11024102	1.000	rs11024101	chr11:17005544	T/C	cg15378786	chr11:17036137	PLEKHA7	0.5	4.45	0.34	1.65e-5	Glaucoma (primary angle closure);
PAAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	1.01	10.31	0.64	3.11e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg01320130	chr1:67600311	NA	0.56	6.25	0.45	3.91e-9	Psoriasis;
PAAD	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.57	-5.01	-0.38	1.51e-6	Schizophrenia;
PAAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	4.31	0.33	2.91e-5	Tonsillectomy;
PAAD	cis	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg00262122	chr8:11665843	FDFT1	-0.67	-5.79	-0.42	3.97e-8	Neuroticism;
PAAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg22800045	chr5:56110881	MAP3K1	-0.59	-5.3	-0.39	4.01e-7	Initial pursuit acceleration;
PAAD	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.59	-8.15	-0.55	1.25e-13	Asthma (sex interaction);
PAAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.88	0.63	4.36e-18	Platelet count;
PAAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg10547527	chr2:198650123	BOLL	-0.69	-4.74	-0.36	4.9100000000000004e-06	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.59	5.69	0.42	6.46e-8	Lymphocyte counts;
PAAD	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg24829409	chr8:58192753	C8orf71	-0.94	-8.14	-0.55	1.3e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs743757	1.000	rs2236956	chr3:50440390	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.66	4.58	0.35	9.75e-6	Diastolic blood pressure;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02774380	chr1:114447516	AP4B1;DCLRE1B	-0.65	-6.43	-0.46	1.56e-9	Lung cancer in ever smokers;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.66	-7.7	-0.53	1.6e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg16928487	chr17:17741425	SREBF1	0.38	5.06	0.38	1.22e-6	Total body bone mineral density;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg03864326	chr16:67927170	PSKH1	-0.65	-7.55	-0.52	3.66e-12	Body fat percentage;
PAAD	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.58	4.44	0.34	1.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.25	0.64	4.6e-19	Bladder cancer;
PAAD	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg07469887	chr10:131262384	NA	0.42	4.97	0.37	1.81e-6	Response to temozolomide;
PAAD	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.7	6.18	0.45	5.6e-9	Platelet count;
PAAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg26939375	chr7:64535504	NA	0.77	9.22	0.6	2.29e-16	Aortic root size;
PAAD	cis	rs2885056	0.891	rs12978787	chr19:10691557	G/A	cg06392426	chr19:10676186	KRI1	0.54	5.32	0.4	3.72e-7	Red cell distribution width;
PAAD	cis	rs6494488	0.500	rs72742931	chr15:64871996	C/T	cg16425858	chr15:64791681	ZNF609	0.96	4.59	0.35	9.36e-6	Coronary artery disease;
PAAD	cis	rs800160	0.844	rs2937373	chr11:2358621	C/G	cg09785033	chr11:2336066	TSPAN32	-0.53	-4.38	-0.34	2.16e-5	Bacteremia;
PAAD	cis	rs57024841	0.819	rs11145949	chr9:139857958	A/G	cg00693599	chr9:139836323	FBXW5	-0.48	-4.49	-0.34	1.38e-5	Beta-trace protein levels;
PAAD	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-6.75	-0.48	2.92e-10	Menopause (age at onset);
PAAD	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.27	0.33	3.37e-5	Educational attainment;
PAAD	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.97	-0.44	1.6e-8	Menarche (age at onset);
PAAD	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12893428	chr3:195717962	SDHAP1	0.47	4.91	0.37	2.36e-6	Pancreatic cancer;
PAAD	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg03233332	chr7:66118400	NA	0.41	4.52	0.34	1.22e-5	Aortic root size;
PAAD	cis	rs11696501	0.637	rs6130865	chr20:44211845	C/T	cg11783356	chr20:44313418	WFDC10B	-0.77	-6.47	-0.46	1.25e-9	Brain structure;
PAAD	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg10494973	chr17:80897199	TBCD	0.52	4.82	0.36	3.43e-6	Breast cancer;
PAAD	cis	rs1859596	0.646	rs10252126	chr7:79097483	G/A	cg06809544	chr7:79081666	MAGI2	-0.41	-4.26	-0.33	3.61e-5	Reading or mathematical ability;
PAAD	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg02135003	chr7:105160482	PUS7	-0.86	-6.24	-0.45	4.25e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7326068	0.504	rs7983020	chr13:21239941	C/T	cg27499820	chr13:21296301	IL17D	-0.49	-4.97	-0.37	1.8e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13560548	chr3:10150139	C3orf24	-0.64	-5.94	-0.43	1.9e-8	Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.78	-0.36	4.17e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg10616974	chr17:74511719	NA	0.41	6.3	0.46	3.01e-9	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.51	-0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs138087875	1	rs138087875	chr18:72260729	A/AC	cg13203249	chr18:72265586	LOC400657	-0.97	-4.67	-0.35	6.59e-6	Brain volume in infants (grey matter);
PAAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg06236206	chr7:66120395	NA	0.51	4.25	0.33	3.75e-5	Diabetic kidney disease;
PAAD	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg14146966	chr2:61757674	XPO1	-0.42	-5.24	-0.39	5.17e-7	Tuberculosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07360250	chr5:176830358	F12	-0.61	-6.91	-0.49	1.28e-10	Body fat percentage;
PAAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.74	-7.29	-0.51	1.56e-11	Cognitive function;
PAAD	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.44	-4.97	-0.37	1.79e-6	Blood pressure (smoking interaction);
PAAD	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.51	-4.92	-0.37	2.21e-6	Mean platelet volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09268313	chr19:3613573	C19orf29	-0.66	-6.44	-0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg18279126	chr7:2041391	MAD1L1	0.56	5.77	0.42	4.36e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.66	6.55	0.47	8.38e-10	Body mass index;
PAAD	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.91	-0.37	2.29e-6	LDL cholesterol levels;
PAAD	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.63	6.8	0.48	2.23e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.44	5.9	0.43	2.26e-8	Alcohol dependence;
PAAD	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-6.4	-0.46	1.83e-9	Body mass index;
PAAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9462846	1.000	rs2395939	chr6:42851396	G/A	cg02353165	chr6:42928485	GNMT	0.61	4.72	0.36	5.38e-6	Blood protein levels;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg25741794	chr1:15736999	EFHD2	-0.55	-6.43	-0.46	1.55e-9	Body fat percentage;
PAAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.85	9.17	0.6	3.12e-16	Osteoporosis;
PAAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg05084668	chr3:125655381	ALG1L	-0.46	-5.09	-0.38	1.07e-6	Blood pressure (smoking interaction);
PAAD	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.29e-5	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.64	-6.44	-0.46	1.46e-9	Vitiligo;
PAAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg02462569	chr6:150064036	NUP43	-0.53	-5.71	-0.42	5.77e-8	Lung cancer;
PAAD	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.3	0.33	3.06e-5	Educational attainment;
PAAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg17644776	chr2:200775616	C2orf69	-0.71	-5.84	-0.43	3.09e-8	Schizophrenia;
PAAD	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-8.54	-0.57	1.29e-14	Exhaled nitric oxide output;
PAAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.55	7.31	0.51	1.42e-11	Renal cell carcinoma;
PAAD	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.9	8.88	0.58	1.71e-15	Exhaled nitric oxide output;
PAAD	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg01320130	chr1:67600311	NA	0.54	5.96	0.44	1.66e-8	Psoriasis;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.37	-4.55	-0.35	1.09e-5	Rheumatoid arthritis;
PAAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg15510373	chr7:100224934	TFR2	-0.52	-4.27	-0.33	3.4e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.54	5.91	0.43	2.19e-8	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	6.66	0.48	4.78e-10	Lung function (FEV1/FVC);
PAAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.51	5.75	0.42	4.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.55	5.37	0.4	2.88e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.89	-0.43	2.44e-8	Retinal vascular caliber;
PAAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.67	-7.42	-0.52	7.56e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.5	5.11	0.38	9.74e-7	Height;
PAAD	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26926768	chr12:34528122	NA	0.39	4.66	0.35	6.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.54	4.64	0.35	7.36e-6	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg00383909	chr3:49044727	WDR6	-0.43	-4.42	-0.34	1.88e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg26536354	chr8:144654954	C8orf73	0.65	4.36	0.33	2.39e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.51	9.44	0.61	6.32e-17	Self-rated health;
PAAD	cis	rs1419980	0.643	rs59734904	chr12:7771437	G/A	cg25828445	chr12:7781288	NA	-0.83	-4.27	-0.33	3.38e-5	HDL cholesterol levels;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg11601000	chr22:42348013	LOC339674	0.43	4.91	0.37	2.35e-6	Cognitive function;
PAAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-5.61	-0.41	9.37e-8	Prudent dietary pattern;
PAAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg14346243	chr4:90757452	SNCA	-0.52	-4.49	-0.34	1.41e-5	Neuroticism;
PAAD	cis	rs1329189	1.000	rs10829354	chr10:129995746	G/A	cg17972361	chr10:130010134	NA	-0.46	-4.71	-0.36	5.64e-6	Orofacial clefts;
PAAD	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.3	-0.51	1.48e-11	Menarche (age at onset);
PAAD	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.47	-5.38	-0.4	2.72e-7	Mean arterial pressure;
PAAD	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.6	-5.63	-0.42	8.66e-8	Schizophrenia;
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.47	5.27	0.39	4.53e-7	Calcium levels;
PAAD	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.47	-4.89	-0.37	2.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-4.35	-0.33	2.5e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.68	7.45	0.52	6.55e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.62	-6.62	-0.47	5.69e-10	Dementia with Lewy bodies;
PAAD	cis	rs6132905	0.590	rs80219859	chr20:2606491	G/T	cg24848351	chr20:2622020	TMC2	-0.7	-4.98	-0.37	1.72e-6	Mumps;
PAAD	cis	rs10957961	0.586	rs12543484	chr8:81067378	A/T	cg10609868	chr8:81963379	PAG1	-0.37	-4.49	-0.34	1.42e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-4.59	-0.35	9.18e-6	Testicular germ cell tumor;
PAAD	cis	rs11892454	0.604	rs7574653	chr2:25943777	T/C	cg25181710	chr2:26045287	ASXL2	0.39	4.46	0.34	1.61e-5	Heschl's gyrus morphology;
PAAD	cis	rs6466055	0.589	rs6963395	chr7:104721374	T/C	cg04380332	chr7:105027541	SRPK2	-0.51	-4.98	-0.37	1.73e-6	Schizophrenia;
PAAD	trans	rs1015213	0.609	rs78232489	chr8:52877249	A/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg08392591	chr16:89556376	ANKRD11	0.51	5.09	0.38	1.06e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7688540	0.800	rs10003142	chr4:291759	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.66	0.35	6.98e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs732765	0.734	rs10142036	chr14:75126992	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.44	-0.34	1.69e-5	Non-small cell lung cancer;
PAAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.94	0.49	1.08e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg27539214	chr16:67997921	SLC12A4	-0.6	-4.82	-0.36	3.38e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6942227	0.947	rs1986731	chr6:25174070	C/T	cg12883629	chr6:25042497	NA	-0.4	-4.36	-0.33	2.43e-5	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs728616	0.867	rs17606361	chr10:81845411	G/C	cg05935833	chr10:81318306	SFTPA2	-0.63	-4.7	-0.36	5.78e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6596100	0.538	rs66481372	chr5:132179592	T/A	cg14825688	chr5:132208181	LEAP2	-0.68	-4.84	-0.37	3.15e-6	Breast cancer;
PAAD	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.55	4.88	0.37	2.67e-6	Type 2 diabetes;
PAAD	cis	rs2286379	0.837	rs9805049	chr12:1893650	C/A	cg05227549	chr12:1770782	NA	0.4	4.61	0.35	8.33e-6	Blood pressure (smoking interaction);
PAAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-13.32	-0.73	2.63e-27	Coronary artery disease;
PAAD	cis	rs11892454	0.573	rs7564262	chr2:25968196	G/C	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.05e-6	Heschl's gyrus morphology;
PAAD	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg21775007	chr8:11205619	TDH	-0.47	-4.41	-0.34	1.91e-5	Systolic blood pressure;
PAAD	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.35	6.34e-6	Vitiligo;
PAAD	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.82	8.39	0.56	3.05e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg10705379	chr10:99080932	FRAT1	-0.47	-5.5	-0.41	1.59e-7	Monocyte count;
PAAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.57	-5.65	-0.42	7.56e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00555438	chr3:195578280	NA	-0.53	-5.08	-0.38	1.11e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg23188684	chr11:67383651	NA	0.46	4.77	0.36	4.33e-6	Mean corpuscular volume;
PAAD	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.1	-10.19	-0.64	6.54e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs9469913	0.668	rs2764205	chr6:34712010	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.5	-4.36	-0.33	2.41e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
PAAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.23	-0.39	5.42e-7	Cervical cancer;
PAAD	cis	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.52	-0.41	1.42e-7	HDL cholesterol;
PAAD	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.85	-6.13	-0.45	7.2e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1263173	0.566	rs4225	chr11:116703671	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.5	4.32	0.33	2.78e-5	HDL cholesterol;
PAAD	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.8	0.48	2.24e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7765175	0.698	rs4945494	chr6:113672212	G/A	cg19037598	chr6:113666021	NA	-0.42	-4.59	-0.35	9.07e-6	Coronary artery calcification;
PAAD	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.9	-6.12	-0.44	7.54e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.64	-6.11	-0.44	8.05e-9	Body mass index;
PAAD	cis	rs9535307	0.860	rs1127021	chr13:50296115	C/T	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4280164	0.551	rs882726	chr14:24797997	C/A	cg07162820	chr14:24837146	NFATC4	0.38	4.75	0.36	4.58e-6	Parent of origin effect on language impairment (paternal);
PAAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12963246	chr6:28129442	ZNF389	0.57	4.55	0.35	1.11e-5	Cardiac Troponin-T levels;
PAAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg00475322	chr7:917719	C7orf20	0.49	5.37	0.4	2.84e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs59888335	0.895	rs10511111	chr3:80599757	A/G	cg21735741	chr3:80819488	NA	0.59	5.11	0.38	9.7e-7	Schizophrenia;
PAAD	cis	rs988913	0.624	rs1580892	chr6:54859213	C/G	cg03513858	chr6:54763001	FAM83B	-0.42	-4.68	-0.36	6.23e-6	Menarche (age at onset);
PAAD	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg16306870	chr3:194868790	C3orf21	0.43	4.52	0.34	1.26e-5	Non-small cell lung cancer;
PAAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.1	0.55	1.66e-13	Schizophrenia;
PAAD	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg06808227	chr14:105710500	BRF1	-0.52	-4.9	-0.37	2.45e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.49	5.68	0.42	6.56e-8	Coronary artery disease;
PAAD	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.79	5.83	0.43	3.15e-8	Vitiligo;
PAAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg24519413	chr1:26490540	NA	-0.51	-4.73	-0.36	5.16e-6	Height;
PAAD	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg03115019	chr17:80708279	FN3K	0.51	4.62	0.35	8.17e-6	Glycated hemoglobin levels;
PAAD	cis	rs2790216	0.901	rs2590329	chr10:60008214	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11647719	chr20:61542561	DIDO1	0.56	6.36	0.46	2.3e-9	Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00173787	chr1:156698861	C1orf66;ISG20L2	0.66	7.05	0.5	5.95e-11	Myopia (pathological);
PAAD	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	4.47	0.34	1.54e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	4.98	0.37	1.69e-6	Lymphocyte counts;Fibrinogen;
PAAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.61	0.35	8.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg08614441	chr13:113633676	MCF2L	-0.43	-4.32	-0.33	2.76e-5	Systolic blood pressure;
PAAD	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.51	0.34	1.29e-5	Self-reported allergy;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg06026331	chr20:60912101	LAMA5	0.59	5.62	0.41	8.85e-8	Pelvic organ prolapse;
PAAD	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg10820045	chr2:198174542	NA	0.46	4.63	0.35	7.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	0.84	5.47	0.41	1.82e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.79	-0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.7	5.11	0.38	9.64e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09526135	chr4:85603757	WDFY3	0.6	6.46	0.46	1.31e-9	Smoking initiation;
PAAD	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.74	-7.57	-0.52	3.34e-12	Neuroticism;
PAAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg21132104	chr15:45694354	SPATA5L1	0.54	5.01	0.38	1.5e-6	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg00864171	chr11:67383662	NA	-0.49	-5.11	-0.38	9.56e-7	Mean corpuscular volume;
PAAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07677032	chr17:61819896	STRADA	-0.52	-5.06	-0.38	1.19e-6	Prudent dietary pattern;
PAAD	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.52	5.0	0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg25753631	chr6:25732923	NA	-0.45	-4.94	-0.37	2.02e-6	Iron status biomarkers;
PAAD	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg00280220	chr17:61926910	NA	0.43	4.55	0.35	1.1e-5	Prudent dietary pattern;
PAAD	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.76	8.62	0.57	7.94e-15	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs1020064	0.583	rs2576775	chr2:105973212	T/C	cg02543470	chr2:105862877	NA	-0.46	-4.9	-0.37	2.43e-6	AIDS;
PAAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.98	0.37	1.72e-6	Longevity;
PAAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg04106633	chr4:1044584	NA	0.64	5.39	0.4	2.66e-7	Recombination rate (females);
PAAD	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.68	-0.35	6.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.47	-4.92	-0.37	2.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.62	-0.35	8.12e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.25	0.64	4.48e-19	Platelet count;
PAAD	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.5	4.71	0.36	5.46e-6	Eosinophilic esophagitis;
PAAD	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.68	-7.2	-0.5	2.6e-11	Platelet distribution width;
PAAD	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	4.95	0.37	1.95e-6	Schizophrenia;
PAAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09826364	chr7:158789723	NA	0.47	5.66	0.42	7.16e-8	Facial morphology (factor 20);
PAAD	cis	rs66530629	0.874	rs7548438	chr1:25098341	C/T	cg01905478	chr1:25040257	NA	-0.46	-5.03	-0.38	1.35e-6	Plateletcrit;
PAAD	cis	rs17761864	0.664	rs12449843	chr17:2058207	G/A	cg16513277	chr17:2031491	SMG6	0.47	4.69	0.36	6.07e-6	Esophageal cancer (squamous cell);
PAAD	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg01620082	chr3:125678407	NA	-1.44	-8.11	-0.55	1.61e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.91	12.09	0.7	5.41e-24	Superior crus of antihelix expression;
PAAD	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	5.45	0.4	1.95e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg08523384	chr5:141488047	NDFIP1	-0.53	-5.02	-0.38	1.45e-6	Asthma;
PAAD	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.5	-4.42	-0.34	1.85e-5	Testicular germ cell tumor;
PAAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	1.06	6.88	0.49	1.49e-10	IgG glycosylation;
PAAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg12373951	chr3:133503437	NA	-0.45	-5.64	-0.42	8.16e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs12304921	1.000	rs4768943	chr12:51355939	C/A	cg18059802	chr12:51347058	HIGD1C	-0.69	-5.71	-0.42	5.87e-8	Type 2 diabetes;
PAAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg09699651	chr6:150184138	LRP11	0.52	5.37	0.4	2.93e-7	Lung cancer;
PAAD	cis	rs9467160	1.000	rs9467157	chr6:24440644	C/T	cg16211469	chr6:24423932	MRS2	0.47	4.71	0.36	5.53e-6	Liver enzyme levels;
PAAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg18281939	chr5:77783895	LHFPL2	-0.48	-5.48	-0.41	1.69e-7	Triglycerides;
PAAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg00431813	chr7:1051703	C7orf50	0.74	4.53	0.34	1.18e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-1.01	-13.72	-0.74	2.2e-28	Breast cancer;
PAAD	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg14343924	chr8:8086146	FLJ10661	0.51	4.37	0.33	2.31e-5	Neuroticism;
PAAD	cis	rs245880	0.765	rs245893	chr7:29191507	G/C	cg17163760	chr7:29186267	CPVL	-0.52	-6.18	-0.45	5.68e-9	Warfarin maintenance dose;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.78	5.71	0.42	5.76e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20749916	chr13:111767003	ARHGEF7	0.6	6.54	0.47	8.86e-10	Monocyte percentage of white cells;
PAAD	cis	rs7172971	0.626	rs7176443	chr15:42381196	G/A	cg07013680	chr15:42186124	SPTBN5	0.55	4.32	0.33	2.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.83	0.36	3.3e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	5.04	0.38	1.32e-6	Axial length;
PAAD	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.46	-4.87	-0.37	2.8e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05564831	chr3:52568323	NT5DC2	0.44	4.72	0.36	5.37e-6	Bipolar disorder;
PAAD	cis	rs3736485	0.966	rs4775959	chr15:51891636	T/C	cg08986416	chr15:51914746	DMXL2	-0.45	-4.35	-0.33	2.47e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.5	6.72	0.48	3.46e-10	Life satisfaction;
PAAD	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19671926	chr4:122722719	EXOSC9	-0.62	-6.0	-0.44	1.41e-8	Type 2 diabetes;
PAAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg10591111	chr5:226296	SDHA	-0.69	-4.88	-0.37	2.7e-6	Breast cancer;
PAAD	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.52	-4.63	-0.35	7.71e-6	White blood cell count (basophil);White blood cell count;
PAAD	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.53	4.84	0.37	3.21e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.67	-5.5	-0.41	1.6e-7	Gut microbiome composition (summer);
PAAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg23939001	chr4:940644	TMEM175	-0.51	-5.54	-0.41	1.27e-7	Parkinson's disease;
PAAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.76	-8.18	-0.55	1.07e-13	Blood metabolite levels;
PAAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg14703610	chr5:56206110	C5orf35	0.61	5.56	0.41	1.21e-7	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.46	6.04	0.44	1.12e-8	Childhood ear infection;
PAAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg06115741	chr20:33292138	TP53INP2	-0.44	-4.26	-0.33	3.55e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg04520793	chr17:42248056	ASB16	-0.44	-5.14	-0.38	8.3e-7	Total body bone mineral density;
PAAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-1.1	-8.25	-0.56	6.92e-14	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.54	-0.41	1.3e-7	Prostate cancer;
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09256448	chr16:638327	NA	0.44	4.56	0.35	1.06e-5	Height;
PAAD	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	4.49	0.34	1.41e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg18279126	chr7:2041391	MAD1L1	0.61	5.96	0.44	1.72e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs6466055	0.661	rs6949073	chr7:104837009	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.51e-6	Schizophrenia;
PAAD	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	5.39	0.4	2.67e-7	Mood instability;
PAAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg16417436	chr16:28758564	NA	0.43	4.33	0.33	2.72e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-4.65	-0.35	7.09e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.58	-6.81	-0.48	2.12e-10	Menarche (age at onset);
PAAD	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-4.86	-0.37	2.94e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg12458913	chr13:53173898	NA	0.48	4.83	0.37	3.25e-6	Lewy body disease;
PAAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs7833787	0.965	rs6586777	chr8:18702471	A/C	cg17701159	chr8:18705777	PSD3	0.47	5.46	0.41	1.86e-7	Obesity-related traits;
PAAD	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5.07e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs863345	0.625	rs12119672	chr1:158500285	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.98	8.21	0.55	8.91e-14	Neutrophil percentage of white cells;
PAAD	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.48	-4.3	-0.33	3.08e-5	Triglycerides;
PAAD	cis	rs13102973	0.899	rs13122646	chr4:135906123	T/C	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs10274279	0.660	rs4716760	chr7:157376644	A/G	cg26886268	chr7:157387156	PTPRN2	0.49	4.27	0.33	3.46e-5	Myopia (pathological);
PAAD	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.49	4.93	0.37	2.12e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-4.27	-0.33	3.46e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	5.99e-7	Tonsillectomy;
PAAD	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.49	0.57	1.73e-14	Vitiligo;
PAAD	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.64	4.66	0.35	6.91e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26876637	chr1:152193138	HRNR	-0.82	-6.03	-0.44	1.18e-8	Atopic dermatitis;
PAAD	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	4.56	0.35	1.06e-5	Homocysteine levels;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg04025307	chr7:1156635	C7orf50	0.64	7.29	0.51	1.6e-11	Longevity;Endometriosis;
PAAD	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.65	-6.15	-0.45	6.62e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg19445457	chr11:5799446	OR52N5	-0.52	-4.65	-0.35	7.09e-6	DNA methylation (variation);
PAAD	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg23024343	chr7:107201750	COG5	0.53	4.55	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg01631684	chr10:65280961	REEP3	0.43	4.31	0.33	2.91e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24249390	chr15:90295951	MESP1	-0.54	-5.74	-0.42	5.02e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	1.06	12.62	0.72	2.03e-25	Headache;
PAAD	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg05250797	chr16:70222502	NA	0.89	6.74	0.48	3.03e-10	IgE levels;
PAAD	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg00277334	chr10:82204260	NA	-0.65	-6.77	-0.48	2.58e-10	Post bronchodilator FEV1;
PAAD	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.49	-4.5	-0.34	1.35e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.48	5.99	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg21859623	chr20:33103246	DYNLRB1	-0.46	-4.61	-0.35	8.53e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg04607699	chr11:48328132	OR4S1	-0.52	-4.91	-0.37	2.3e-6	Migraine - clinic-based;
PAAD	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.56	-4.94	-0.37	2.07e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg10621924	chr7:39171070	POU6F2	0.37	5.74	0.42	4.95e-8	IgG glycosylation;
PAAD	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.92	-0.37	2.22e-6	Educational attainment;
PAAD	cis	rs1443512	0.541	rs1443509	chr12:54340622	T/C	cg25382128	chr12:54346509	NA	-0.64	-5.45	-0.4	2.01e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.35	4.95	0.37	1.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11816922	0.655	rs17309788	chr10:6908358	T/C	cg02181080	chr10:7564424	NA	0.81	4.56	0.35	1.04e-5	Migraine;
PAAD	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.58	6.29	0.45	3.14e-9	Colorectal cancer;
PAAD	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg26031613	chr14:104095156	KLC1	1.16	16.35	0.8	2.52e-35	Body mass index;
PAAD	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.4	-4.8	-0.36	3.82e-6	Uric acid levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12779445	chr7:157367462	MIR153-2;PTPRN2	-0.69	-7.02	-0.49	6.86e-11	Obesity-related traits;
PAAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.67	6.67	0.48	4.58e-10	Body mass index;
PAAD	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg09491104	chr22:46646882	C22orf40	-1.02	-6.87	-0.49	1.59e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13198984	chr17:80129470	CCDC57	-0.43	-5.42	-0.4	2.27e-7	Life satisfaction;
PAAD	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.21	-0.39	6.16e-7	Monocyte percentage of white cells;
PAAD	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg21191810	chr6:118973309	C6orf204	0.48	6.15	0.45	6.65e-9	Electrocardiographic conduction measures;
PAAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg14346243	chr4:90757452	SNCA	-0.55	-4.86	-0.37	2.96e-6	Neuroticism;
PAAD	cis	rs10821973	0.527	rs10740069	chr10:63982984	A/G	cg09941381	chr10:64027924	RTKN2	-0.41	-4.33	-0.33	2.69e-5	Hypothyroidism;
PAAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.45	7.62	0.53	2.58e-12	Multiple system atrophy;
PAAD	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg21427119	chr20:30132790	HM13	-0.79	-6.16	-0.45	6.14e-9	Mean corpuscular hemoglobin;
PAAD	cis	rs2120991	0.967	rs7305034	chr12:54262854	T/A	cg21845580	chr12:53472882	SPRYD3	-0.45	-4.25	-0.33	3.76e-5	Biliary atresia;
PAAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.81	-4.96	-0.37	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.3	0.33	3.03e-5	Breast cancer;
PAAD	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg01631408	chr1:248437212	OR2T33	0.55	5.38	0.4	2.73e-7	Common traits (Other);
PAAD	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.56	5.41	0.4	2.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11811982	0.793	rs11801012	chr1:227350198	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs6976053	0.846	rs314378	chr7:100458795	T/C	cg22425096	chr7:100417404	EPHB4	0.48	4.34	0.33	2.64e-5	Plasminogen activator inhibitor type 1 levels (PAI-1);
PAAD	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.62	-6.33	-0.46	2.68e-9	Obesity;
PAAD	cis	rs6466055	0.589	rs17270450	chr7:105013788	G/A	cg04380332	chr7:105027541	SRPK2	0.5	4.88	0.37	2.66e-6	Schizophrenia;
PAAD	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.44	4.96	0.37	1.87e-6	Dietary macronutrient intake;
PAAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03188948	chr7:1209495	NA	0.44	4.4	0.34	2.05e-5	Longevity;Endometriosis;
PAAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-9.51	-0.61	3.99e-17	Total body bone mineral density;
PAAD	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg27490568	chr2:178487706	NA	0.39	4.34	0.33	2.64e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg01851573	chr8:8652454	MFHAS1	0.87	6.92	0.49	1.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg06492744	chr11:65406254	SIPA1	0.45	5.31	0.4	3.85e-7	Blood pressure (age interaction);
PAAD	cis	rs2213920	0.569	rs4979524	chr9:118177617	C/G	cg13918206	chr9:118159781	DEC1	0.73	5.16	0.39	7.67e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.63	-5.96	-0.44	1.7e-8	Total body bone mineral density;
PAAD	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	5.09	0.38	1.04e-6	Fear of minor pain;
PAAD	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.59	0.47	6.89e-10	Systolic blood pressure;
PAAD	cis	rs74544699	1.000	rs149611	chr4:74780396	C/A	cg06834998	chr4:74847824	PF4	1.09	4.35	0.33	2.44e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs12432203	1.000	rs72622430	chr14:51732708	T/C	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01555270	chr19:41945599	ATP5SL	-0.68	-6.47	-0.46	1.28e-9	Lung cancer in ever smokers;
PAAD	cis	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg18531004	chr3:128564980	NA	-0.89	-5.02	-0.38	1.43e-6	Dental caries;
PAAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg07153921	chr17:41440717	NA	-0.42	-4.48	-0.34	1.48e-5	Menopause (age at onset);
PAAD	cis	rs818427	0.896	rs712671	chr5:112211786	T/C	cg06941702	chr5:112196734	SRP19	-0.51	-4.76	-0.36	4.53e-6	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21575667	chr19:1621692	TCF3	-0.58	-6.34	-0.46	2.51e-9	Monocyte percentage of white cells;
PAAD	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.71	-6.39	-0.46	1.89e-9	Type 2 diabetes;
PAAD	cis	rs12098973	0.591	rs78944762	chr11:131806892	A/T	cg13055484	chr11:132662455	OPCML	0.52	4.38	0.34	2.16e-5	Cardiac Troponin-T levels;
PAAD	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.89	12.93	0.72	2.87e-26	Dental caries;
PAAD	cis	rs12760731	0.565	rs12028024	chr1:178087423	G/T	cg00404053	chr1:178313656	RASAL2	0.66	4.84	0.37	3.21e-6	Obesity-related traits;
PAAD	cis	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg21546286	chr11:48923668	NA	-0.46	-4.9	-0.37	2.46e-6	Height;
PAAD	cis	rs4324798	1	rs4324798	chr6:28776117	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.59	4.58	0.35	9.61e-6	Lung adenocarcinoma;
PAAD	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.64	5.29	0.39	4.14e-7	Morning vs. evening chronotype;
PAAD	cis	rs1109114	0.738	rs10073851	chr5:148623217	C/T	cg06539116	chr5:148597365	ABLIM3	-0.36	-4.53	-0.35	1.17e-5	Body mass index;
PAAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18621852	chr3:10150065	C3orf24	0.64	5.51	0.41	1.5e-7	Alzheimer's disease;
PAAD	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.73	7.85	0.54	6.91e-13	Body mass index;
PAAD	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.46	5.19	0.39	6.66e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.48	-0.41	1.7e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.58	0.47	7.27e-10	Schizophrenia;
PAAD	cis	rs654384	0.545	rs4723419	chr7:4174716	C/T	cg27574739	chr7:4176374	SDK1	-0.49	-4.61	-0.35	8.48e-6	Positive affect;
PAAD	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.78	0.36	4.05e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.63	7.87	0.54	6.33e-13	Prudent dietary pattern;
PAAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.53	-5.86	-0.43	2.72e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	10.0	0.63	2.05e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg21892295	chr12:121157589	UNC119B	-0.43	-4.31	-0.33	2.88e-5	Urinary metabolites (H-NMR features);
PAAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	6.55	0.47	8.4e-10	Height;
PAAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg05785598	chr3:49045655	WDR6	0.42	5.21	0.39	6.03e-7	Parkinson's disease;
PAAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg15478930	chr2:27652102	NRBP1	-0.47	-4.4	-0.34	2e-5	Total body bone mineral density;
PAAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs1678618	0.585	rs1245519	chr10:73784791	T/C	cg20897136	chr10:74034667	DDIT4	0.37	4.31	0.33	2.94e-5	Smoking behavior;
PAAD	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	5.04e-16	Motion sickness;
PAAD	cis	rs7714584	1.000	rs11957134	chr5:150230950	A/G	cg22134413	chr5:150180641	NA	-0.86	-6.01	-0.44	1.33e-8	Crohn's disease;
PAAD	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.58	-5.56	-0.41	1.19e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg22508957	chr16:3507546	NAT15	0.82	6.03	0.44	1.22e-8	Tuberculosis;
PAAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg05304507	chr6:116381966	FRK	0.39	7.27	0.51	1.74e-11	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs7172971	0.511	rs1008782	chr15:42396609	C/T	cg07013680	chr15:42186124	SPTBN5	0.45	4.62	0.35	8.16e-6	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.25	-10.3	-0.64	3.35e-19	Breast cancer;
PAAD	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.99	-0.38	1.61e-6	Pulmonary function;
PAAD	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg09399716	chr2:46890238	NA	-0.55	-4.45	-0.34	1.68e-5	Height;
PAAD	cis	rs847851	1.000	rs847846	chr6:34925371	G/T	cg05379947	chr6:35436047	RPL10A	-0.51	-4.29	-0.33	3.13e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.72	8.04	0.55	2.32e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.98	9.36	0.6	9.77e-17	Psoriasis;
PAAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	5.96	0.44	1.72e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.51	4.55	0.35	1.1e-5	Arsenic metabolism;
PAAD	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.79	-7.3	-0.51	1.54e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.64	7.19	0.5	2.7e-11	Smoking initiation;
PAAD	cis	rs116248771	0.690	rs73156492	chr3:158416799	G/C	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.58	7.31	0.51	1.41e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.78e-6	Recombination rate (females);
PAAD	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-4.8	-0.36	3.72e-6	Ulcerative colitis;
PAAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.69	7.59	0.52	2.93e-12	Aortic root size;
PAAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.43	4.29	0.33	3.22e-5	Aortic root size;
PAAD	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.46	6.58	0.47	7.27e-10	Schizophrenia;
PAAD	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.74	6.67	0.48	4.41e-10	Asthma;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.57	4.6	0.35	8.67e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.74	-0.42	5.08e-8	Blood metabolite levels;
PAAD	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg11995313	chr8:8860691	ERI1	-0.49	-4.71	-0.36	5.44e-6	Joint mobility (Beighton score);
PAAD	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.42	4.25	0.33	3.77e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.43	-0.34	1.77e-5	Coronary artery disease;
PAAD	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.58	5.07	0.38	1.12e-6	Life satisfaction;
PAAD	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.53	-5.27	-0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg07689907	chr11:61582574	FADS1	0.48	4.61	0.35	8.5e-6	Trans fatty acid levels;
PAAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.47	-4.59	-0.35	9.19e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg01426195	chr3:39028469	NA	0.68	6.51	0.47	1.04e-9	Handedness;
PAAD	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs622217	0.838	rs543159	chr6:160776017	C/A	cg25313204	chr6:160768801	SLC22A3	-0.43	-4.29	-0.33	3.2e-5	Type 2 diabetes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25270632	chr7:43751042	C7orf44	0.56	6.61	0.47	6.17e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.47	-4.88	-0.37	2.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.87	7.52	0.52	4.46e-12	Recombination rate (females);
PAAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg09658497	chr7:2847517	GNA12	0.39	4.37	0.33	2.27e-5	Plateletcrit;
PAAD	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07741184	chr6:167504864	NA	-0.44	-5.8	-0.43	3.65e-8	Primary biliary cholangitis;
PAAD	cis	rs4975616	0.686	rs40182	chr5:1350397	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.68	-6.84	-0.49	1.83e-10	Lung cancer;
PAAD	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	15.82	0.79	6.11e-34	Testicular germ cell tumor;
PAAD	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08733453	chr10:101380344	SLC25A28	-0.67	-6.63	-0.47	5.52e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9372498	0.505	rs9320655	chr6:118830981	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.0	-0.38	1.59e-6	Diastolic blood pressure;
PAAD	cis	rs1499972	0.941	rs6794831	chr3:117642484	C/A	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-5.28	-0.39	4.32e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg18827107	chr12:86230957	RASSF9	-0.44	-4.6	-0.35	8.75e-6	Major depressive disorder;
PAAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg26557270	chr6:116382179	FRK	0.31	5.47	0.41	1.83e-7	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg17346650	chr17:80929145	B3GNTL1	0.45	5.49	0.41	1.63e-7	Glycated hemoglobin levels;
PAAD	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.58	6.42	0.46	1.63e-9	Morning vs. evening chronotype;
PAAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-4.95	-0.37	1.94e-6	Height;
PAAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.89	7.6	0.52	2.87e-12	Alzheimer's disease;
PAAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg10589385	chr1:150898437	SETDB1	0.39	4.88	0.37	2.67e-6	Melanoma;
PAAD	cis	rs9346353	0.737	rs6920725	chr6:70502619	T/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.48e-5	Sleep duration;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22011436	chr11:45310837	NA	-0.63	-6.57	-0.47	7.49e-10	Obesity-related traits;
PAAD	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg11380483	chr2:127933992	NA	-0.47	-4.88	-0.37	2.64e-6	Self-rated health;
PAAD	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.14	-9.16	-0.6	3.27e-16	Vitiligo;
PAAD	cis	rs8105895	0.935	rs7247147	chr19:22249858	G/C	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.63	-0.42	8.67e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg01612440	chr4:3296283	NA	0.46	4.6	0.35	8.82e-6	Serum sulfate level;
PAAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.41	-0.46	1.74e-9	Fibrinogen levels;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.26	0.8	4.44e-35	Prudent dietary pattern;
PAAD	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-5.66	-0.42	7.22e-8	Crohn's disease;
PAAD	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg00405596	chr8:11794950	NA	0.42	4.3	0.33	3.06e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs558003	0.702	rs797486	chr13:51221618	G/T	cg24585282	chr13:51257555	NA	0.63	4.42	0.34	1.87e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs901683	1.000	rs12773263	chr10:45984346	A/G	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.54	-0.41	1.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19671926	chr4:122722719	EXOSC9	-0.54	-4.85	-0.37	3.03e-6	Type 2 diabetes;
PAAD	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-4.62	-0.35	8e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg08677398	chr8:58056175	NA	0.59	4.44	0.34	1.72e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	1.000	rs35632234	chr10:45983379	G/T	cg23720331	chr10:123873670	TACC2	-0.85	-6.49	-0.47	1.16e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg16584676	chr17:46985605	UBE2Z	-0.5	-4.95	-0.37	1.94e-6	Type 2 diabetes;
PAAD	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.52	4.95	0.37	1.94e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.78	-8.26	-0.56	6.46e-14	Menarche (age at onset);
PAAD	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	5.89	0.43	2.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg16205897	chr5:131564050	P4HA2	-0.49	-5.42	-0.4	2.28e-7	Blood metabolite levels;
PAAD	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-4.96	-0.37	1.86e-6	Mean corpuscular volume;
PAAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-4.69	-0.36	6.13e-6	Lung cancer;
PAAD	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg03894339	chr8:19674705	INTS10	0.45	4.34	0.33	2.62e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg13468214	chr4:1046988	NA	-0.55	-5.14	-0.38	8.5e-7	Recombination rate (females);
PAAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.65	-7.32	-0.51	1.38e-11	Iron status biomarkers;
PAAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.59	5.39	0.4	2.67e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.75	9.41	0.61	7.36e-17	Bone mineral density;
PAAD	cis	rs795484	0.926	rs353897	chr12:118639841	A/G	cg16572268	chr12:118583242	PEBP1	-0.52	-5.14	-0.38	8.45e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.67	5.83	0.43	3.17e-8	Hemoglobin concentration;
PAAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.35	-4.88	-0.37	2.6e-6	Breast cancer;
PAAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg23788917	chr6:8435910	SLC35B3	-0.59	-6.25	-0.45	3.87e-9	Motion sickness;
PAAD	cis	rs2016586	0.895	rs4821438	chr22:36114047	C/T	cg26342177	chr22:36113512	APOL5	-0.47	-4.69	-0.36	6.03e-6	Body mass index;
PAAD	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.51	4.77	0.36	4.27e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.59	4.41	0.34	1.97e-5	Plateletcrit;Platelet count;
PAAD	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg10705379	chr10:99080932	FRAT1	-0.39	-4.48	-0.34	1.47e-5	Monocyte count;
PAAD	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-5.33	-0.4	3.43e-7	Congenital heart disease (maternal effect);
PAAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg02696790	chr15:75250997	RPP25	0.44	5.23	0.39	5.43e-7	Caffeine consumption;
PAAD	cis	rs7127900	0.904	rs7123180	chr11:2232272	A/G	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03647317	chr4:187891568	NA	-0.54	-6.96	-0.49	9.62e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.65	4.58	0.35	9.74e-6	Mean platelet volume;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.52	-0.34	1.24e-5	Neuroticism;
PAAD	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.64	-5.45	-0.4	1.97e-7	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.71	8.02	0.55	2.67e-13	Melanoma;
PAAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-5.51	-0.41	1.53e-7	Major depressive disorder;
PAAD	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.06	-0.55	2.14e-13	Hemoglobin concentration;
PAAD	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.94	9.9	0.63	3.9e-18	Height;
PAAD	cis	rs7084921	0.578	rs12783521	chr10:101871748	C/A	cg04359915	chr10:101825029	CPN1	-0.34	-5.21	-0.39	6.18e-7	Bone mineral density;
PAAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.8	-5.05	-0.38	1.27e-6	Diabetic kidney disease;
PAAD	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg00383909	chr3:49044727	WDR6	0.53	4.4	0.34	2.01e-5	Educational attainment;
PAAD	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.55	0.35	1.09e-5	Oropharynx cancer;
PAAD	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.64	7.01	0.49	7.39e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg04002187	chr5:40835754	RPL37	0.78	4.25	0.33	3.75e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.51	6.43	0.46	1.56e-9	Childhood ear infection;
PAAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.54	5.64	0.42	7.93e-8	Obesity-related traits;
PAAD	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.08	0.38	1.08e-6	Motion sickness;
PAAD	cis	rs6585424	1.000	rs6585454	chr10:81940701	C/T	cg19423196	chr10:82049429	MAT1A	-0.44	-4.56	-0.35	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg02415014	chr8:143852576	LYNX1	0.5	6.07	0.44	9.94e-9	Urinary tract infection frequency;
PAAD	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.75	7.1	0.5	4.37e-11	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs17137412	0.920	rs11982195	chr7:7796886	A/G	cg06444755	chr7:8473990	NXPH1	0.45	4.36	0.33	2.37e-5	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
PAAD	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg23254163	chr1:152506842	NA	0.6	6.99	0.49	8.28e-11	Hair morphology;
PAAD	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg27471124	chr11:109292789	C11orf87	0.23	4.66	0.35	6.83e-6	Schizophrenia;
PAAD	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg21823605	chr1:152486609	CRCT1	0.5	6.4	0.46	1.86e-9	Hair morphology;
PAAD	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.56	6.33	0.46	2.6e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	5.47	0.41	1.8e-7	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.44	-0.34	1.72e-5	Aortic root size;
PAAD	cis	rs2820914	0.531	rs10976071	chr9:7153489	C/T	cg13985597	chr9:6704574	NA	0.63	4.68	0.35	6.42e-6	Obesity-related traits;
PAAD	cis	rs17407555	0.741	rs12509713	chr4:10107069	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-6.16	-0.45	6.29e-9	Schizophrenia (age at onset);
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg16898833	chr6:26189333	HIST1H4D	0.58	4.43	0.34	1.76e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.63	-7.16	-0.5	3.21e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.6	-6.43	-0.46	1.58e-9	Calcium levels;
PAAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg14507445	chr22:49886340	NA	-0.5	-4.53	-0.34	1.19e-5	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg06697600	chr4:7070879	GRPEL1	0.99	4.9	0.37	2.38e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	5.84	0.43	3.01e-8	LDL cholesterol;
PAAD	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.73	0.36	4.99e-6	Obesity-related traits;
PAAD	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg13859433	chr6:33739653	LEMD2	-0.64	-4.45	-0.34	1.63e-5	Schizophrenia;
PAAD	cis	rs1992660	0.523	rs10045016	chr5:40328325	T/A	cg05240017	chr5:40756081	TTC33	0.52	4.46	0.34	1.56e-5	Crohn's disease;
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg25753631	chr6:25732923	NA	0.46	5.32	0.4	3.65e-7	Iron status biomarkers;
PAAD	cis	rs1957429	0.614	rs62621845	chr14:65403525	T/A	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.41	-6.1	-0.44	8.6e-9	Subjective well-being;
PAAD	cis	rs11264799	0.598	rs10489681	chr1:157720009	A/G	cg18268488	chr1:157545234	FCRL4	-0.62	-5.53	-0.41	1.39e-7	IgA nephropathy;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.93	-10.92	-0.66	7.53e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	10.86	0.66	1.1e-20	Smoking behavior;
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg07841815	chr7:100318223	EPO	0.46	5.11	0.38	9.64e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg20169779	chr10:135381914	SYCE1	0.47	4.63	0.35	7.84e-6	Obesity-related traits;
PAAD	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.56	-5.92	-0.43	2.02e-8	Menarche (age at onset);
PAAD	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.56	5.86	0.43	2.73e-8	Dupuytren's disease;
PAAD	cis	rs66530629	0.837	rs12439	chr1:25169634	A/G	cg01905478	chr1:25040257	NA	0.47	5.23	0.39	5.49e-7	Plateletcrit;
PAAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03676636	chr4:99064102	C4orf37	0.33	6.06	0.44	1.05e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg21466736	chr12:48725269	NA	0.5	4.65	0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.74	8.47	0.57	1.92e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9535307	0.799	rs2146143	chr13:50245620	A/C	cg04663916	chr13:50265991	EBPL	0.6	4.66	0.35	6.89e-6	Obesity-related traits;
PAAD	cis	rs9463078	0.774	rs3923353	chr6:45256482	C/G	cg25276700	chr6:44698697	NA	-0.47	-5.44	-0.4	2.08e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	4.54	0.35	1.15e-5	Electroencephalogram traits;
PAAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg14343924	chr8:8086146	FLJ10661	0.51	4.79	0.36	3.89e-6	Mood instability;
PAAD	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-7.75	-0.53	1.2e-12	Colorectal cancer;
PAAD	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs282587	0.569	rs395246	chr13:113415392	C/A	cg04656015	chr13:113407548	ATP11A	0.56	4.48	0.34	1.44e-5	Glycated hemoglobin levels;
PAAD	cis	rs9918079	0.506	rs7696127	chr4:15642953	T/A	cg16509355	chr4:15471240	CC2D2A	-0.34	-4.33	-0.33	2.65e-5	Obesity-related traits;
PAAD	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg11608241	chr8:8085544	FLJ10661	-0.52	-4.35	-0.33	2.45e-5	Cervical cancer;
PAAD	cis	rs2790216	1.000	rs2590367	chr10:60041574	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23621652	chr2:207630148	FASTKD2;MDH1B	0.64	6.42	0.46	1.65e-9	Obesity-related traits;
PAAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.69	-8.74	-0.58	3.96e-15	Eye color traits;
PAAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.78	8.51	0.57	1.57e-14	Lewy body disease;
PAAD	cis	rs17407555	0.683	rs4697998	chr4:10274626	G/T	cg00071950	chr4:10020882	SLC2A9	0.48	5.13	0.38	8.89e-7	Schizophrenia (age at onset);
PAAD	cis	rs16958440	1.000	rs16958440	chr18:44632884	C/G	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-11.19	-0.67	1.36e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg14349672	chr11:133703707	NA	-0.56	-6.35	-0.46	2.42e-9	Childhood ear infection;
PAAD	cis	rs6466055	0.777	rs10238507	chr7:104807207	G/T	cg04380332	chr7:105027541	SRPK2	0.64	7.23	0.51	2.17e-11	Schizophrenia;
PAAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06873352	chr17:61820015	STRADA	-0.75	-9.3	-0.6	1.45e-16	Prudent dietary pattern;
PAAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.64	7.94	0.54	4.14e-13	Renal cell carcinoma;
PAAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg07153921	chr17:41440717	NA	-0.41	-4.39	-0.34	2.14e-5	Menopause (age at onset);
PAAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.95	-12.53	-0.71	3.46e-25	Height;
PAAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg15448220	chr1:150897856	SETDB1	-0.64	-6.63	-0.47	5.44e-10	Tonsillectomy;
PAAD	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	5.07	0.38	1.15e-6	Breast cancer;
PAAD	cis	rs9039	0.959	rs12148920	chr16:9183900	C/G	cg08831531	chr16:9218945	NA	0.64	6.69	0.48	3.93e-10	Menopause (age at onset);
PAAD	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.06	-0.63	1.45e-18	Response to antipsychotic treatment;
PAAD	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-6.91	-0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17032980	0.910	rs6748553	chr2:67320714	G/A	cg06994420	chr2:66672553	MEIS1	-0.5	-4.47	-0.34	1.53e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg14926445	chr8:58193284	C8orf71	-0.64	-4.82	-0.36	3.42e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.79	-7.8	-0.53	9.38e-13	Coronary artery disease;
PAAD	cis	rs2440129	0.611	rs1042357	chr17:6905061	T/G	cg02493798	chr17:6899577	ALOX12	0.44	4.41	0.34	1.97e-5	Tonsillectomy;
PAAD	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	9.12	0.59	4.19e-16	Cognitive test performance;
PAAD	cis	rs639012	0.594	rs586274	chr11:85814486	T/G	cg07180834	chr11:85838833	NA	-0.41	-4.37	-0.33	2.27e-5	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg10011062	chr15:43941034	CATSPER2	-0.9	-5.56	-0.41	1.17e-7	Lung cancer in ever smokers;
PAAD	cis	rs12927656	1	rs12927656	chr16:86455297	T/A	cg06405820	chr16:86951397	NA	-0.4	-4.51	-0.34	1.27e-5	Hepatitis B;
PAAD	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg15556689	chr8:8085844	FLJ10661	0.61	5.93	0.43	1.95e-8	Myopia (pathological);
PAAD	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.47	0.34	1.54e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg26338869	chr17:61819248	STRADA	0.49	4.66	0.35	6.79e-6	Height;
PAAD	cis	rs6700896	0.500	rs2186245	chr1:66118064	C/T	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.07e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg06217245	chr20:33103252	DYNLRB1	-0.43	-4.95	-0.37	1.97e-6	Height;
PAAD	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.8	-5.93	-0.43	1.97e-8	Coronary artery calcification;
PAAD	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg02353165	chr6:42928485	GNMT	0.63	5.17	0.39	7.33e-7	Blood protein levels;
PAAD	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26926768	chr12:34528122	NA	0.38	4.72	0.36	5.4e-6	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1075232	1.000	rs16956707	chr15:31641633	G/A	cg06530883	chr15:30699977	NA	0.96	4.46	0.34	1.56e-5	Survival in colorectal cancer (non-distant metastatic);
PAAD	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg02404636	chr22:31891804	SFI1	-0.59	-5.28	-0.39	4.36e-7	Colorectal cancer;
PAAD	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-5.84	-0.43	2.98e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Depression;
PAAD	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.64	6.15	0.45	6.61e-9	Subjective well-being;
PAAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.93	8.62	0.57	8.22e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04964966	chr14:99947093	SETD3;CCNK	-0.65	-6.49	-0.47	1.17e-9	Smoking initiation;
PAAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg10591111	chr5:226296	SDHA	-0.66	-4.66	-0.35	6.92e-6	Breast cancer;
PAAD	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	6.01	0.44	1.33e-8	Renal function-related traits (BUN);
PAAD	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.5	4.84	0.37	3.11e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-4.64	-0.35	7.47e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.72	-7.37	-0.51	1.01e-11	Morning vs. evening chronotype;
PAAD	cis	rs2885056	0.891	rs115850646	chr19:10689027	A/G	cg04833646	chr19:10679720	CDKN2D	1.0	10.01	0.63	1.95e-18	Red cell distribution width;
PAAD	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg18964960	chr10:1102726	WDR37	0.81	4.35	0.33	2.48e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg14709524	chr16:89940631	TCF25	0.91	4.67	0.35	6.7e-6	Skin colour saturation;
PAAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg18612461	chr15:75251733	NA	0.59	7.09	0.5	4.81e-11	Caffeine consumption;
PAAD	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.68	-6.27	-0.45	3.58e-9	DNA methylation (variation);
PAAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.7	8.11	0.55	1.54e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.5	6.07	0.44	9.98e-9	Monobrow;
PAAD	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	5.08	0.38	1.11e-6	Schizophrenia;
PAAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.45	-4.58	-0.35	9.55e-6	Multiple sclerosis;Ankylosing spondylitis;
PAAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.66	-7.2	-0.5	2.53e-11	Aortic root size;
PAAD	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.8	0.48	2.28e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.34	-6.28	-0.45	3.42e-9	Type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21054968	chr7:155089542	INSIG1	-0.65	-6.33	-0.46	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg13814708	chr10:81144099	ZCCHC24	-0.4	-4.46	-0.34	1.58e-5	Height;
PAAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg07527105	chr16:88053339	BANP	-0.43	-4.41	-0.34	1.95e-5	Menopause (age at onset);
PAAD	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg15145965	chr22:50218605	BRD1	0.59	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs41311933	1.000	rs2900181	chr9:123756881	T/A	cg13567360	chr9:123745713	C5	-0.72	-4.59	-0.35	9.12e-6	Coronary artery disease;
PAAD	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.69	6.9	0.49	1.3e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs911555	0.755	rs2403192	chr14:103974235	C/T	cg12935359	chr14:103987150	CKB	-0.61	-6.13	-0.45	7.14e-9	Intelligence (multi-trait analysis);
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg20386705	chr6:38607295	BTBD9	0.57	6.56	0.47	7.9e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.59	8.3	0.56	5.29e-14	Asthma (sex interaction);
PAAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	8.96	0.59	1.07e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg10932868	chr11:921992	NA	0.5	5.94	0.43	1.82e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.43	4.99	0.38	1.62e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12599982	chr1:44399894	ARTN	0.47	5.0	0.38	1.58e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.86	7.3	0.51	1.53e-11	Neutrophil percentage of white cells;
PAAD	cis	rs7264396	0.887	rs224343	chr20:34036699	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.35	0.33	2.48e-5	Total cholesterol levels;
PAAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.89	11.82	0.69	2.79e-23	Methadone dose in opioid dependence;
PAAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.59	-5.96	-0.44	1.68e-8	Calcium levels;
PAAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.73	6.98	0.49	8.69e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	5.39	0.4	2.61e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.8	6.51	0.47	1.04e-9	Gut microbiome composition (summer);
PAAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-5.81	-0.43	3.58e-8	Yeast infection;
PAAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg19630374	chr17:18023558	MYO15A	-0.45	-4.77	-0.36	4.34e-6	Total body bone mineral density;
PAAD	cis	rs9584850	0.834	rs9584855	chr13:99119000	G/T	cg20487152	chr13:99095054	FARP1	-0.61	-5.53	-0.41	1.34e-7	Neuroticism;
PAAD	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg15571903	chr15:79123663	NA	0.39	4.68	0.35	6.29e-6	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.56	6.09	0.44	8.64e-9	Menopause (age at onset);
PAAD	cis	rs9395066	0.545	rs4714830	chr6:44955528	C/T	cg25276700	chr6:44698697	NA	0.49	5.63	0.42	8.38e-8	Height;
PAAD	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.44	4.82	0.36	3.46e-6	Menarche (age at onset);
PAAD	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.54e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.6	5.96	0.44	1.69e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs5746492	0.642	rs7284335	chr22:18352968	G/A	cg06148736	chr22:18985691	NA	-0.4	-4.39	-0.34	2.09e-5	Eotaxin levels;
PAAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.98	9.57	0.61	2.84e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-4.27	-0.33	3.49e-5	Testicular germ cell tumor;
PAAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg25566285	chr7:158114605	PTPRN2	0.85	8.84	0.58	2.2e-15	Calcium levels;
PAAD	cis	rs1371614	0.501	rs6745807	chr2:27185317	A/C	cg00617064	chr2:27272375	NA	-0.47	-4.93	-0.37	2.17e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg17385448	chr1:15911702	AGMAT	0.36	4.42	0.34	1.86e-5	Systolic blood pressure;
PAAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg10587741	chr22:38071170	LGALS1	0.6	6.75	0.48	2.87e-10	Fat distribution (HIV);
PAAD	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.82	0.36	3.4e-6	Testicular germ cell tumor;
PAAD	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.73	-8.51	-0.57	1.56e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg13468214	chr4:1046988	NA	-0.65	-9.17	-0.6	3.16e-16	Recombination rate (males);
PAAD	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg09127314	chr1:152161683	NA	-0.71	-5.34	-0.4	3.32e-7	Atopic dermatitis;
PAAD	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg24375607	chr4:120327624	NA	0.46	4.7	0.36	5.73e-6	Diastolic blood pressure;
PAAD	cis	rs364477	0.818	rs279883	chr9:984459	A/T	cg13952963	chr9:998547	NA	0.58	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.54	5.25	0.39	5.05e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-4.56	-0.35	1.07e-5	Mean corpuscular volume;
PAAD	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.28	7.24	0.51	2.12e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs4774830	0.744	rs17819312	chr15:56297427	G/A	cg24530489	chr15:56299380	NA	-1.0	-4.64	-0.35	7.6e-6	Delta-5 desaturase activity;
PAAD	cis	rs332507	0.830	rs3772786	chr3:124395250	A/C	cg05980111	chr3:124395277	KALRN	0.43	4.25	0.33	3.76e-5	Plateletcrit;
PAAD	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	1.14	10.46	0.65	1.29e-19	Colorectal cancer;
PAAD	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-4.61	-0.35	8.39e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs6929137	0.632	rs73001924	chr6:151955995	A/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.49	-0.34	1.4e-5	Bone mineral density (spine);
PAAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg23281280	chr6:28129359	ZNF389	0.49	4.44	0.34	1.71e-5	Parkinson's disease;
PAAD	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.6	5.01	0.38	1.5e-6	Neutrophil percentage of white cells;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg15117754	chr3:10150083	C3orf24	0.65	5.48	0.41	1.73e-7	Alzheimer's disease;
PAAD	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.81	-7.12	-0.5	4e-11	Cognitive function;
PAAD	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.19	6.82	0.48	2e-10	Granulocyte percentage of myeloid white cells;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17152658	chr8:132916406	EFR3A	-0.65	-7.7	-0.53	1.62e-12	Body fat percentage;
PAAD	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg23973274	chr1:155060172	NA	-0.43	-4.36	-0.33	2.38e-5	Breast cancer;
PAAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.55	6.61	0.47	5.97e-10	Multiple system atrophy;
PAAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.49	-4.92	-0.37	2.18e-6	Blood metabolite levels;
PAAD	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg18084798	chr19:33555255	RHPN2	-0.47	-4.9	-0.37	2.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs5756391	0.568	rs2075941	chr22:37318515	T/C	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.91e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg19052272	chr2:3704530	ALLC	-0.62	-6.73	-0.48	3.21e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2241047	0.526	rs738035	chr22:17594886	T/C	cg06707910	chr22:17640812	CECR5;CECR4	0.27	4.55	0.35	1.08e-5	Blood protein levels;
PAAD	cis	rs8005677	0.649	rs11629120	chr14:23458457	T/C	cg02316283	chr14:23313866	MMP14	0.41	4.92	0.37	2.27e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs10821973	0.527	rs10740065	chr10:63976415	A/C	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25043643	chr14:102609274	WDR20	-0.64	-6.29	-0.45	3.24e-9	Obesity-related traits;
PAAD	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	5.92	0.43	2.11e-8	Personality dimensions;
PAAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.58	6.21	0.45	4.72e-9	Obesity-related traits;
PAAD	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg24881330	chr22:46731750	TRMU	0.6	4.45	0.34	1.65e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6689305	0.545	rs7541580	chr1:100235426	A/G	cg22872634	chr1:100462710	SLC35A3	-0.44	-4.25	-0.33	3.68e-5	White matter integrity (bipolar disorder risk interaction);
PAAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-5.56	-0.41	1.15e-7	Mean platelet volume;
PAAD	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg15798862	chr7:76129360	DTX2	-0.42	-5.37	-0.4	2.92e-7	Multiple sclerosis;
PAAD	cis	rs1514658	0.903	rs7661210	chr4:119280167	G/T	cg23709618	chr4:119273073	PRSS12	0.31	4.38	0.33	2.22e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs7224685	0.689	rs4508454	chr17:4198650	C/T	cg11204139	chr17:3907470	NA	-0.67	-5.6	-0.41	9.81e-8	Type 2 diabetes;
PAAD	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04733989	chr22:42467013	NAGA	0.62	6.33	0.46	2.56e-9	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg15117754	chr3:10150083	C3orf24	0.6	5.68	0.42	6.57e-8	Alzheimer's disease;
PAAD	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg13540341	chr19:49222985	MAMSTR	0.44	5.15	0.39	7.85e-7	Dietary macronutrient intake;
PAAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.5	4.57	0.35	1.01e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.46	5.94	0.43	1.88e-8	Psoriasis;
PAAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	1.1	15.13	0.78	4e-32	Breast cancer;
PAAD	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.55	5.12	0.38	9.11e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg05709478	chr1:6581295	PLEKHG5	0.72	4.81	0.36	3.59e-6	Body mass index;
PAAD	cis	rs13102973	0.829	rs55951114	chr4:135897925	T/C	cg14419869	chr4:135874104	NA	0.45	4.49	0.34	1.42e-5	Subjective well-being;
PAAD	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.51	-4.9	-0.37	2.39e-6	Inflammatory biomarkers;
PAAD	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	1.06	6.83	0.48	1.89e-10	Plateletcrit;
PAAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg13918804	chr1:2043761	PRKCZ	0.41	5.41	0.4	2.35e-7	Height;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18238374	chr14:89507124	NA	0.57	7.28	0.51	1.64e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.63	5.47	0.41	1.79e-7	Red blood cell count;
PAAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.95	-0.37	1.98e-6	Initial pursuit acceleration;
PAAD	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg17764715	chr19:33622953	WDR88	0.67	6.47	0.46	1.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg00053010	chr17:46089788	NA	0.64	7.45	0.52	6.58e-12	Monocyte percentage of white cells;
PAAD	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.36	-5.16	-0.39	7.62e-7	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.42	-4.91	-0.37	2.34e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.36	-0.33	2.38e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-8.64	-0.57	7.07e-15	Longevity;Endometriosis;
PAAD	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.76	7.96	0.54	3.73e-13	Blood protein levels;
PAAD	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.34	5.12	0.38	9.25e-7	Alopecia areata;
PAAD	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.91	0.37	2.34e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg27411982	chr8:10470053	RP1L1	0.48	4.99	0.38	1.64e-6	Retinal vascular caliber;
PAAD	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.48	0.47	1.2e-9	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.78	8.19	0.55	9.82e-14	Mean corpuscular volume;
PAAD	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	11.47	0.68	2.4e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-6.79	-0.48	2.35e-10	Coffee consumption (cups per day);
PAAD	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.44	-4.57	-0.35	1.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06850241	chr22:41845214	NA	-0.52	-4.9	-0.37	2.4e-6	Vitiligo;
PAAD	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.44	4.88	0.37	2.63e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs35084382	1.000	rs35084382	chr5:172197039	T/C	cg19801141	chr5:172198162	DUSP1	1.25	5.95	0.43	1.74e-8	Optic cup area;
PAAD	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.54	5.63	0.42	8.58e-8	Subjective well-being;
PAAD	cis	rs11811982	0.793	rs11803651	chr1:227471650	C/G	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.53	-5.02	-0.38	1.4e-6	Mortality in heart failure;
PAAD	cis	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.48	4.68	0.35	6.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	1.04	17.48	0.82	3.33e-38	Height;
PAAD	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg08392591	chr16:89556376	ANKRD11	0.47	4.57	0.35	1.01e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.47	-5.53	-0.41	1.34e-7	Intelligence;
PAAD	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg06042504	chr8:55087323	NA	-0.61	-6.08	-0.44	9.15e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.57	5.73	0.42	5.12e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.86	5.61	0.41	9.12e-8	Diabetic kidney disease;
PAAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.89	11.12	0.67	2.14e-21	Prudent dietary pattern;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg07233135	chr10:33623121	NRP1	-0.64	-6.57	-0.47	7.7e-10	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.59	0.41	1.04e-7	Lung cancer in ever smokers;
PAAD	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.44	4.94	0.37	2.05e-6	Neuroticism;
PAAD	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.57	4.95	0.37	1.94e-6	Common traits (Other);
PAAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg01262667	chr19:19385393	TM6SF2	-0.43	-4.66	-0.35	6.92e-6	Tonsillectomy;
PAAD	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg02487422	chr3:49467188	NICN1	0.57	5.6	0.41	9.83e-8	Resting heart rate;
PAAD	cis	rs728616	0.764	rs56196124	chr10:81902655	A/T	cg19423196	chr10:82049429	MAT1A	0.46	4.3	0.33	3.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.68	7.14	0.5	3.69e-11	Schizophrenia;
PAAD	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.56	5.52	0.41	1.4e-7	Alcohol dependence;
PAAD	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.49	-4.61	-0.35	8.44e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12193833	chr17:30244370	NA	0.57	4.72	0.36	5.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.55	5.5	0.41	1.57e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6496667	0.565	rs7162107	chr15:90889046	A/G	cg22089800	chr15:90895588	ZNF774	0.58	5.21	0.39	6.04e-7	Rheumatoid arthritis;
PAAD	cis	rs1499972	0.504	rs1159496	chr3:117796083	A/G	cg07612923	chr3:117604196	NA	-0.72	-5.16	-0.39	7.6e-7	Schizophrenia;
PAAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.82	-6.99	-0.49	8.06e-11	Gut microbiome composition (summer);
PAAD	cis	rs1642645	0.831	rs2886564	chr1:42496924	G/A	cg01990334	chr1:42801334	FOXJ3	-0.59	-5.48	-0.41	1.7e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.72	-8.21	-0.55	8.68e-14	Dental caries;
PAAD	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg13332499	chr17:408570	NA	0.65	7.05	0.5	5.79e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.95	9.83	0.62	5.95e-18	Cognitive function;
PAAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg17724175	chr1:150552817	MCL1	-0.41	-4.72	-0.36	5.32e-6	Tonsillectomy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg09378497	chr16:1525169	CLCN7	0.61	6.29	0.45	3.26e-9	Myopia (pathological);
PAAD	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02743256	chr7:2109353	MAD1L1	-0.76	-6.26	-0.45	3.81e-9	Bipolar disorder;
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.75	6.56	0.47	7.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.62	-7.5	-0.52	5e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.79	9.29	0.6	1.55e-16	Morning vs. evening chronotype;
PAAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-4.35	-0.33	2.52e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.79	10.16	0.64	8.02e-19	Vitiligo;
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg10864074	chr7:100318194	EPO	0.45	5.28	0.39	4.36e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	10.29	0.64	3.53e-19	Response to antipsychotic treatment;
PAAD	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.74	-0.48	3.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg08856118	chr10:27389908	ANKRD26	-0.39	-4.31	-0.33	2.97e-5	Breast cancer;
PAAD	cis	rs4841398	1.000	rs4841398	chr8:10462806	C/T	cg27411982	chr8:10470053	RP1L1	-0.51	-4.41	-0.34	1.98e-5	Obesity-related traits;
PAAD	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7614311	0.681	rs60505027	chr3:63844966	T/A	cg22134162	chr3:63841271	THOC7	-0.54	-4.3	-0.33	3.01e-5	Lung function (FVC);Lung function (FEV1);
PAAD	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.56	-0.35	1.03e-5	Biliary atresia;
PAAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg23346134	chr3:49453900	TCTA	-0.46	-4.88	-0.37	2.62e-6	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	4.93	0.37	2.17e-6	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs9434723	0.765	rs2268172	chr1:9300747	C/A	cg04199779	chr1:9294473	H6PD	0.57	4.82	0.36	3.38e-6	Height;
PAAD	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.45	-4.5	-0.34	1.37e-5	Dementia with Lewy bodies;
PAAD	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-5.68	-0.42	6.78e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.56	6.27	0.45	3.58e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.53	4.96	0.37	1.85e-6	Schizophrenia;
PAAD	cis	rs11686241	0.748	rs11892361	chr2:217288955	A/T	cg15830940	chr2:217278069	SMARCAL1	-0.54	-5.01	-0.38	1.51e-6	Cancer;
PAAD	cis	rs4750440	0.702	rs4750445	chr10:14030314	C/T	cg27542038	chr10:14027202	FRMD4A	-0.42	-4.26	-0.33	3.53e-5	Adiponectin levels;
PAAD	cis	rs7713065	1.000	rs3749833	chr5:131799626	T/C	cg14196790	chr5:131705035	SLC22A5	-0.54	-5.73	-0.42	5.28e-8	Lung function (FEV1/FVC);
PAAD	cis	rs6424115	0.830	rs6424119	chr1:24204143	A/G	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.56	5.87	0.43	2.66e-8	Immature fraction of reticulocytes;
PAAD	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.73	-8.22	-0.55	8.18e-14	Dental caries;
PAAD	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.79	-7.12	-0.5	4.1e-11	Inhibitory control;
PAAD	trans	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.98	9.97	0.63	2.54e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.48	-4.73	-0.36	5.06e-6	Type 2 diabetes;
PAAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.13	9.67	0.62	1.54e-17	Vitiligo;
PAAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg01223673	chr11:15133828	INSC	0.34	4.46	0.34	1.58e-5	Mitochondrial DNA levels;
PAAD	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.86	-7.12	-0.5	3.93e-11	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.88	5.78	0.42	4.05e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	5.13	0.38	8.91e-7	Lung function (FEV1/FVC);
PAAD	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg10932868	chr11:921992	NA	0.5	6.03	0.44	1.19e-8	Alzheimer's disease (late onset);
PAAD	cis	rs10821973	0.527	rs4979776	chr10:63981857	G/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	4.53	0.34	1.21e-5	Height;
PAAD	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg03264133	chr6:25882463	NA	0.52	4.79	0.36	3.89e-6	Iron status biomarkers;
PAAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.11	-0.55	1.6e-13	Height;
PAAD	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.57	-5.32	-0.4	3.67e-7	Malaria;
PAAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	9e-9	Prostate cancer;
PAAD	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10951983	0.861	rs79949326	chr7:6461310	C/T	cg13912435	chr7:6750462	NA	0.42	4.29	0.33	3.11e-5	Coronary artery disease;
PAAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.58	-0.41	1.09e-7	Prostate cancer;
PAAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.51	-6.28	-0.45	3.35e-9	Schizophrenia;
PAAD	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.66	-6.08	-0.44	9.36e-9	White matter hyperintensity burden;
PAAD	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-4.45	-0.34	1.66e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg16501237	chr10:99081016	FRAT1	0.35	4.29	0.33	3.21e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.42	5.23	0.39	5.47e-7	Pulmonary function;
PAAD	cis	rs2531992	0.764	rs66768878	chr16:4022638	T/C	cg05927578	chr16:4029543	ADCY9	-0.78	-6.07	-0.44	9.56e-9	Waist circumference;
PAAD	cis	rs6688613	0.685	rs11579987	chr1:166889364	C/G	cg07049167	chr1:166818506	POGK	-0.66	-6.26	-0.45	3.8e-9	Refractive astigmatism;
PAAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.28	0.68	7.8e-22	Menopause (age at onset);
PAAD	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.65	7.64	0.53	2.3e-12	Schizophrenia;
PAAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg16928487	chr17:17741425	SREBF1	0.34	4.49	0.34	1.37e-5	Total body bone mineral density;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg02301978	chr19:7069707	ZNF557	0.57	6.63	0.47	5.38e-10	Primary biliary cholangitis;
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00166722	chr3:10149974	C3orf24	-0.7	-6.35	-0.46	2.4e-9	Alzheimer's disease;
PAAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg07061783	chr6:25882402	NA	-0.55	-5.49	-0.41	1.65e-7	Blood metabolite levels;
PAAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg00800569	chr2:239229395	TRAF3IP1	-0.55	-4.88	-0.37	2.6e-6	Multiple system atrophy;
PAAD	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04717802	chr22:42394638	WBP2NL	-0.4	-4.35	-0.33	2.49e-5	Cognitive function;
PAAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg06970076	chr16:1560791	IFT140	0.57	4.95	0.37	1.97e-6	Coronary artery disease;
PAAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg06375148	chr1:209958343	C1orf74	-0.66	-4.93	-0.37	2.17e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg17178900	chr1:205818956	PM20D1	0.48	4.73	0.36	5.14e-6	Parkinson's disease;
PAAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg07148914	chr20:33460835	GGT7	-0.48	-4.77	-0.36	4.25e-6	Glomerular filtration rate (creatinine);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17829314	chr1:38274017	C1orf122;YRDC	-0.62	-7.32	-0.51	1.34e-11	Body fat percentage;
PAAD	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.42	5.14	0.38	8.49e-7	Pulmonary function;
PAAD	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.34	6.49	0.47	1.15e-9	Mean corpuscular volume;
PAAD	cis	rs2073300	1.000	rs6132631	chr20:23461848	T/C	cg12062639	chr20:23401060	NAPB	0.93	5.08	0.38	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.62	6.94	0.49	1.09e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.5	5.21	0.39	6.12e-7	Male-pattern baldness;
PAAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.52	5.08	0.38	1.1e-6	Prudent dietary pattern;
PAAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg26022315	chr17:47021804	SNF8	0.45	4.69	0.36	6.05e-6	Coronary heart disease;
PAAD	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg10729496	chr3:10149963	C3orf24	0.82	6.09	0.44	8.66e-9	Alzheimer's disease;
PAAD	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.82	8.05	0.55	2.18e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.51	5.27	0.39	4.67e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01331649	chr15:76196562	FBXO22	-0.78	-6.78	-0.48	2.44e-10	Neuroticism;
PAAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg21698718	chr17:80085957	CCDC57	0.4	4.27	0.33	3.48e-5	Life satisfaction;
PAAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.7	-7.77	-0.53	1.07e-12	Aortic root size;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg23827867	chr20:306044	SOX12	0.6	6.78	0.48	2.45e-10	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.29	-0.39	4.2e-7	Schizophrenia;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03642425	chr3:122746419	SEMA5B	0.59	6.36	0.46	2.26e-9	Monocyte percentage of white cells;
PAAD	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.8	-0.43	3.74e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.41	-0.34	1.92e-5	Educational attainment;
PAAD	cis	rs3126085	0.825	rs4298736	chr1:152240269	A/T	cg26876637	chr1:152193138	HRNR	0.88	6.55	0.47	8.4e-10	Atopic dermatitis;
PAAD	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.65	5.48	0.41	1.76e-7	Common traits (Other);
PAAD	cis	rs1385374	0.920	rs61946177	chr12:129273347	C/T	cg09035930	chr12:129282057	SLC15A4	-0.79	-4.57	-0.35	1.02e-5	Systemic lupus erythematosus;
PAAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16447950	chr5:562315	NA	-0.64	-5.65	-0.42	7.65e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1997066	0.831	rs60316882	chr10:106799002	A/C	cg17321814	chr10:106440892	SORCS3	0.64	4.29	0.33	3.16e-5	Diabetic kidney disease;
PAAD	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs8053891	0.507	rs66553600	chr16:72028198	G/C	cg16558253	chr16:72132732	DHX38	-0.46	-4.71	-0.36	5.53e-6	Coronary artery disease;
PAAD	cis	rs7594192	0.744	rs6434973	chr2:199369099	A/G	cg01558212	chr2:200327336	NA	0.34	4.57	0.35	9.88e-6	Educational attainment;
PAAD	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg08743896	chr10:65200160	JMJD1C	-0.42	-4.28	-0.33	3.24e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6076065	0.723	rs6083099	chr20:23358233	A/G	cg11657817	chr20:23433608	CST11	-0.49	-5.04	-0.38	1.31e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.78	-9.49	-0.61	4.68e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs9581857	0.547	rs1235848	chr13:28111559	G/T	cg25877436	chr13:27998191	GTF3A	-0.46	-4.35	-0.33	2.52e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs17681684	0.541	rs12150176	chr17:9764547	C/T	cg26853458	chr17:9805074	RCVRN	0.73	7.76	0.53	1.18e-12	GIP levels in response to oral glucose tolerance test (fasting);
PAAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg22868518	chr11:507468	RNH1	-0.92	-4.95	-0.37	1.93e-6	Body mass index;
PAAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.46	0.65	1.26e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2790216	0.950	rs1416765	chr10:60047077	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08219700	chr8:58056026	NA	0.67	5.47	0.41	1.84e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.23	-18.11	-0.83	8.67e-40	Triglycerides;
PAAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.47	4.48	0.34	1.45e-5	Resistin levels;
PAAD	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.66	-6.14	-0.45	6.97e-9	White matter hyperintensity burden;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26403284	chr3:122512611	DIRC2;HSPBAP1	0.56	6.35	0.46	2.36e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.41	-0.34	1.93e-5	Colorectal cancer;
PAAD	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-8.83	-0.58	2.43e-15	Colorectal cancer;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.66	7.01	0.49	7.38e-11	Childhood ear infection;
PAAD	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg11380483	chr2:127933992	NA	0.5	4.82	0.36	3.38e-6	Self-rated health;
PAAD	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.88	-9.29	-0.6	1.51e-16	Parkinson's disease;
PAAD	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg17595323	chr11:93583763	C11orf90	-0.34	-4.34	-0.33	2.58e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.92	11.1	0.67	2.38e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.65	5.07	0.38	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.88	7.75	0.53	1.25e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg10006428	chr1:248814059	OR2T27	-0.41	-4.8	-0.36	3.84e-6	Common traits (Other);
PAAD	cis	rs939584	1.000	rs7588007	chr2:631255	T/C	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.52	-4.58	-0.35	9.52e-6	Total body bone mineral density;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10722938	chr19:14317606	LPHN1	-0.66	-6.63	-0.47	5.54e-10	Smoking initiation;
PAAD	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.6	5.36	0.4	2.99e-7	Dialysis-related mortality;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.77	-5.6	-0.41	9.81e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	4.57	0.35	9.83e-6	Asthma and hay fever;
PAAD	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.47	6.72	0.48	3.35e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9463078	0.546	rs1285026	chr6:45120834	C/T	cg18551225	chr6:44695536	NA	0.42	4.37	0.33	2.28e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.2	0.45	4.97e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.67	-6.24	-0.45	4.2e-9	Height;
PAAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.78	-8.82	-0.58	2.48e-15	Longevity;
PAAD	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg10985347	chr2:127963512	CYP27C1	0.46	4.28	0.33	3.26e-5	Protein C levels;
PAAD	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.52	-4.42	-0.34	1.9e-5	IgG glycosylation;
PAAD	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.91	7.9	0.54	5.22e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg16414030	chr3:133502952	NA	-0.5	-5.1	-0.38	1e-6	Iron status biomarkers;
PAAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.47	-4.97	-0.37	1.79e-6	Vitiligo;
PAAD	cis	rs8083432	0.935	rs45473096	chr18:22711523	T/C	cg13981356	chr18:22006370	IMPACT	0.55	4.4	0.34	2.05e-5	Adverse response to lamotrigine and phenytoin;
PAAD	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.91	0.49	1.27e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7070678	0.625	rs2025855	chr10:29789738	G/A	cg05086789	chr10:29701805	LOC387647	-0.5	-4.68	-0.36	6.18e-6	Platelet thrombus formation;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.66	-6.63	-0.47	5.61e-10	Height;
PAAD	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	4.6	0.35	8.79e-6	Colorectal cancer;
PAAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.42	-0.34	1.85e-5	Hip circumference adjusted for BMI;
PAAD	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.09	-6.78	-0.48	2.45e-10	Mitochondrial DNA levels;
PAAD	cis	rs2019216	0.506	rs12150291	chr17:21974340	C/G	cg05591447	chr17:21909280	FLJ36000	-0.32	-4.26	-0.33	3.63e-5	Pelvic organ prolapse;
PAAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg03517284	chr6:25882590	NA	-0.53	-4.46	-0.34	1.58e-5	Iron status biomarkers;
PAAD	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg17372223	chr3:52568218	NT5DC2	0.53	5.23	0.39	5.51e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg18370025	chr7:2749541	AMZ1	-0.38	-4.61	-0.35	8.61e-6	Height;
PAAD	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-6.4	-0.46	1.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.7	6.82	0.48	2.06e-10	Coronary artery disease;
PAAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.92	-7.33	-0.51	1.25e-11	Initial pursuit acceleration;
PAAD	cis	rs1997066	0.831	rs73344310	chr10:106825217	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs6074578	0.679	rs4142303	chr20:139841	A/T	cg16931068	chr20:139680	DEFB127	-0.37	-4.96	-0.37	1.88e-6	Hirschsprung disease;
PAAD	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.98	-10.46	-0.65	1.23e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs12304921	0.683	rs60910794	chr12:51507634	T/G	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.71	-0.36	5.55e-6	Type 2 diabetes;
PAAD	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg00105475	chr2:10696890	NA	0.64	6.8	0.48	2.29e-10	Prostate cancer;
PAAD	cis	rs561655	0.544	rs9787874	chr11:85860305	G/A	cg07180834	chr11:85838833	NA	-0.39	-4.36	-0.33	2.41e-5	Alzheimer's disease (late onset);
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3026101	0.671	rs2285746	chr17:5311742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.57	0.47	7.66e-10	High light scatter reticulocyte count;
PAAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.12e-5	Breast cancer;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.49	4.92	0.37	2.25e-6	Mean corpuscular volume;
PAAD	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.57	6.75	0.48	2.93e-10	Total body bone mineral density;
PAAD	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg23127183	chr11:57508653	C11orf31	0.51	4.47	0.34	1.51e-5	Schizophrenia;
PAAD	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	5.32	0.4	3.63e-7	Blood metabolite levels;
PAAD	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	9.18	0.6	3e-16	Motion sickness;
PAAD	cis	rs12153243	0.686	rs7732768	chr5:142933619	C/T	cg13907255	chr5:142895549	NA	0.5	4.45	0.34	1.66e-5	Migraine;
PAAD	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.73	-11.24	-0.67	1.02e-21	Body mass index;
PAAD	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.76	7.65	0.53	2.18e-12	Resting heart rate;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.04	-0.44	1.12e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-5.71	-0.42	5.86e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05346688	chr15:92459525	SLCO3A1	0.59	6.83	0.48	1.9e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.19e-8	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.69	-6.55	-0.47	8.21e-10	Primary sclerosing cholangitis;
PAAD	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg01796438	chr3:11312864	ATG7	-0.7	-5.64	-0.42	7.89e-8	Circulating chemerin levels;
PAAD	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.59	5.15	0.39	7.84e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs16854884	0.632	rs60505453	chr3:143643864	C/G	cg06585982	chr3:143692056	C3orf58	0.71	7.73	0.53	1.37e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.64	-5.87	-0.43	2.64e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2790216	0.951	rs2790215	chr10:59998203	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg15847926	chr7:2749597	AMZ1	-0.38	-4.56	-0.35	1.05e-5	Height;
PAAD	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.5	5.7	0.42	5.94e-8	Coronary artery disease;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12016809	chr21:47604291	C21orf56	0.42	4.25	0.33	3.71e-5	Testicular germ cell tumor;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14560775	chr19:14952078	OR7A10	0.53	6.5	0.47	1.07e-9	Myopia (pathological);
PAAD	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.52	5.44	0.4	2.13e-7	Male-pattern baldness;
PAAD	cis	rs1595825	1.000	rs1440088	chr2:198871417	A/C	cg00982548	chr2:198649783	BOLL	-0.67	-4.83	-0.36	3.32e-6	Ulcerative colitis;
PAAD	cis	rs9467160	1.000	rs10946700	chr6:24442158	G/T	cg16211469	chr6:24423932	MRS2	0.47	4.71	0.36	5.53e-6	Liver enzyme levels;
PAAD	trans	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg05036337	chr6:5851912	NA	0.57	6.34	0.46	2.48e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg11630242	chr17:19881632	AKAP10	-0.47	-4.34	-0.33	2.59e-5	Schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00367532	chr15:74703141	SEMA7A	0.55	6.53	0.47	9.47e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3206736	0.548	rs10243141	chr7:35062566	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.6	-0.35	8.84e-6	Diastolic blood pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11874451	chr3:12949735	IQSEC1	-0.67	-6.62	-0.47	5.85e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.75	8.85	0.58	2.07e-15	Lung cancer;
PAAD	cis	rs35740288	0.651	rs34257708	chr15:86184267	G/A	cg07943548	chr15:86304357	KLHL25	-0.63	-4.86	-0.37	2.89e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.42	-4.69	-0.36	6.17e-6	Aortic root size;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg25405238	chr17:79254455	SLC38A10	0.61	7.4	0.51	8.81e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.78	-9.23	-0.6	2.15e-16	Height;
PAAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.91	12.47	0.71	5.07e-25	Prudent dietary pattern;
PAAD	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg01064725	chr1:204461714	NA	0.49	4.73	0.36	5.04e-6	Schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19077271	chr20:37063995	LOC388796;SNORA71D	0.66	7.09	0.5	4.77e-11	Myopia (pathological);
PAAD	cis	rs501120	1.000	rs607760	chr10:44756236	A/G	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg20587970	chr11:113659929	NA	-0.97	-9.81	-0.62	6.7e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.77	9.12	0.59	4.19e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.01	0.44	1.33e-8	Schizophrenia;
PAAD	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-6.76	-0.48	2.81e-10	Exhaled nitric oxide output;
PAAD	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs35160687	0.842	rs1863052	chr2:86559358	A/G	cg10973622	chr2:86423274	IMMT	0.4	4.52	0.34	1.26e-5	Night sleep phenotypes;
PAAD	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-4.45	-0.34	1.63e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.56	7.65	0.53	2.09e-12	IgA nephropathy;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs758324	0.773	rs608834	chr5:131271528	G/C	cg06307176	chr5:131281290	NA	-0.55	-4.7	-0.36	5.89e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.81	9.43	0.61	6.67e-17	Schizophrenia;
PAAD	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.97	8.02	0.55	2.64e-13	Blood trace element (Cu levels);
PAAD	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.5	4.7	0.36	5.78e-6	Eosinophilic esophagitis;
PAAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg21395723	chr22:39101663	GTPBP1	-0.46	-4.63	-0.35	7.77e-6	Menopause (age at onset);
PAAD	cis	rs1572438	0.929	rs9378520	chr6:861685	C/T	cg21062780	chr6:887772	NA	-0.46	-4.44	-0.34	1.71e-5	Aging;
PAAD	cis	rs7714584	1.000	rs11748158	chr5:150226345	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.81	6.11	0.44	7.82e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-6.6	-0.47	6.54e-10	Chronic sinus infection;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16716993	chr18:21977874	OSBPL1A	-0.74	-6.6	-0.47	6.6e-10	Neuroticism;
PAAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.5	-5.16	-0.39	7.77e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg01338084	chr22:32026380	PISD	0.49	4.42	0.34	1.85e-5	Intelligence;
PAAD	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.34	-0.33	2.59e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.64	6.17	0.45	6.01e-9	Subjective well-being;
PAAD	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg00717180	chr2:96193071	NA	-0.64	-7.95	-0.54	3.95e-13	Height;
PAAD	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.47	-4.43	-0.34	1.79e-5	Type 2 diabetes;
PAAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.71	7.61	0.53	2.66e-12	Colorectal cancer;
PAAD	cis	rs17092148	1.000	rs6088579	chr20:33284624	A/G	cg16810054	chr20:33298113	TP53INP2	-0.59	-4.57	-0.35	9.92e-6	Neuroticism;
PAAD	cis	rs11669133	1.000	rs78921492	chr19:11139657	T/G	cg25243385	chr19:11167475	SMARCA4	0.98	4.58	0.35	9.81e-6	LDL cholesterol;
PAAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-4.32	-0.33	2.8e-5	Obesity-related traits;
PAAD	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg07636037	chr3:49044803	WDR6	-0.8	-6.32	-0.46	2.82e-9	Menarche (age at onset);
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.75	6.63	0.47	5.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg10495392	chr1:46806563	NSUN4	0.59	5.78	0.42	4.11e-8	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.89	0.69	1.84e-23	Smoking behavior;
PAAD	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg24397884	chr7:158709396	WDR60	0.94	9.91	0.63	3.61e-18	Height;
PAAD	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.48	5.59	0.41	1.03e-7	Coronary artery disease;
PAAD	cis	rs116175783	0.557	rs62197075	chr2:162169124	C/A	cg08807892	chr2:162101083	NA	-0.69	-4.89	-0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17169635	0.731	rs974403	chr7:134509484	G/A	cg02516134	chr7:134575187	CALD1	-0.42	-4.33	-0.33	2.68e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg00166722	chr3:10149974	C3orf24	0.85	7.03	0.5	6.54e-11	Alzheimer's disease;
PAAD	cis	rs10512697	0.772	rs34012000	chr5:3536248	T/C	cg19473799	chr5:3511975	NA	-1.02	-4.55	-0.35	1.09e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs818427	0.929	rs431287	chr5:112197986	A/T	cg06941702	chr5:112196734	SRP19	-0.47	-4.47	-0.34	1.51e-5	Total body bone mineral density;
PAAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12165864	chr7:66369176	NA	-0.77	-4.96	-0.37	1.88e-6	Diabetic kidney disease;
PAAD	cis	rs9810890	1.000	rs73196988	chr3:128453467	G/A	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs10426930	0.844	rs58250802	chr19:5034575	C/T	cg08036796	chr19:5034282	KDM4B	0.49	4.88	0.37	2.71e-6	Monocyte percentage of white cells;
PAAD	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.71	-0.48	3.69e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-10.93	-0.66	6.83e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7627468	0.770	rs1965358	chr3:121970301	G/A	cg17240004	chr3:121949083	CASR	0.5	4.76	0.36	4.48e-6	Kidney stones;
PAAD	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.79	-5.3	-0.39	4.09e-7	Platelet distribution width;
PAAD	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-15.88	-0.79	4.35e-34	Ulcerative colitis;
PAAD	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16556892	chr16:89787480	ZNF276;C16orf7	-0.71	-7.25	-0.51	2.01e-11	Smoking initiation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26549185	chr6:136793098	MAP7	-0.59	-6.39	-0.46	1.88e-9	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.86	9.7	0.62	1.25e-17	Prudent dietary pattern;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09739896	chr9:116038089	PRPF4;CDC26	-0.57	-6.38	-0.46	2.05e-9	Body fat percentage;
PAAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	7.59	0.52	3.02e-12	Prudent dietary pattern;
PAAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.71	-8.27	-0.56	6.37e-14	Height;
PAAD	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.14	-0.64	8.97e-19	Response to antipsychotic treatment;
PAAD	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.68	-6.98	-0.49	8.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.92	7.49	0.52	5.25e-12	Tuberculosis;
PAAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.49	6.17	0.45	5.82e-9	Childhood ear infection;
PAAD	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.45	-4.32	-0.33	2.78e-5	Male sexual orientation;
PAAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.76	8.86	0.58	2e-15	Lung cancer;
PAAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg03037974	chr15:76606532	NA	0.52	6.11	0.44	7.81e-9	Blood metabolite levels;
PAAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.86	9.76	0.62	8.92e-18	Prudent dietary pattern;
PAAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	6.8	0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg03161606	chr19:29218774	NA	0.73	5.47	0.41	1.79e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs6066835	0.867	rs11086263	chr20:47365285	G/A	cg18078177	chr20:47281410	PREX1	0.89	4.35	0.33	2.5e-5	Multiple myeloma;
PAAD	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.47	0.46	1.27e-9	Morning vs. evening chronotype;
PAAD	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg00262122	chr8:11665843	FDFT1	-0.57	-5.21	-0.39	6.04e-7	Morning vs. evening chronotype;
PAAD	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.82	8.1	0.55	1.65e-13	Callous-unemotional behaviour;
PAAD	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.6	-6.03	-0.44	1.2e-8	Coronary artery disease;
PAAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.52	5.28	0.39	4.43e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg04257695	chr17:30186438	C17orf79	-0.65	-5.17	-0.39	7.12e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06998765	chr14:75389618	RPS6KL1	-0.27	-4.85	-0.37	3.02e-6	Caffeine consumption;
PAAD	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg20913747	chr6:44695427	NA	-0.71	-7.02	-0.49	7.01e-11	Total body bone mineral density;
PAAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.63	-6.38	-0.46	2.03e-9	Monocyte count;
PAAD	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-5.79	-0.43	3.88e-8	Body mass index;
PAAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.85	10.63	0.65	4.38e-20	Height;
PAAD	cis	rs4150161	0.656	rs4150162	chr16:84214214	A/T	cg10106505	chr16:84220380	TAF1C	-1.1	-6.09	-0.44	9.03e-9	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-1.35	-10.05	-0.63	1.55e-18	Schizophrenia;
PAAD	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg01426195	chr3:39028469	NA	0.46	4.5	0.34	1.35e-5	Interleukin-18 levels;
PAAD	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.89	-0.43	2.36e-8	Mood instability;
PAAD	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-7.86	-0.54	6.72e-13	Bladder cancer;
PAAD	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg10437265	chr15:77819839	NA	-0.37	-4.29	-0.33	3.1e-5	Type 2 diabetes;
PAAD	cis	rs4740619	0.619	rs4741557	chr9:16031080	C/T	cg14451791	chr9:16040625	NA	0.46	5.38	0.4	2.7e-7	Body mass index;
PAAD	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.14	-0.7	3.87e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.01	0.49	7.38e-11	Eye color traits;
PAAD	cis	rs761746	0.672	rs5753684	chr22:31939973	A/G	cg01338084	chr22:32026380	PISD	0.49	4.28	0.33	3.28e-5	Intelligence;
PAAD	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.96e-7	Electrocardiographic conduction measures;
PAAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.57	-0.41	1.12e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7580717	0.540	rs62197320	chr2:232060366	T/G	cg07929768	chr2:232055508	NA	0.45	5.27	0.39	4.6e-7	Multiple myeloma;
PAAD	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.35	-0.68	5.09e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.61	-8.78	-0.58	3.23e-15	Huntington's disease progression;
PAAD	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.42	-5.6	-0.41	9.77e-8	Longevity;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.85	6.43	0.46	1.54e-9	Alzheimer's disease;
PAAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.75	7.82	0.54	8.43e-13	Height;
PAAD	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg23860436	chr12:58378763	NA	-0.47	-4.58	-0.35	9.63e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg02297831	chr4:17616191	MED28	0.56	5.14	0.38	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.3e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs62238980	0.708	rs3986033	chr22:32589417	C/G	cg00543991	chr22:32367038	NA	1.14	6.29	0.45	3.21e-9	Childhood ear infection;
PAAD	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-1.0	-8.6	-0.57	9.18e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs5746492	0.539	rs4819639	chr22:18347127	C/T	cg06148736	chr22:18985691	NA	-0.37	-4.3	-0.33	3e-5	Eotaxin levels;
PAAD	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.61	7.47	0.52	5.8e-12	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg12610070	chr10:71211762	TSPAN15	-0.59	-7.9	-0.54	5.25e-13	Venous thromboembolism;
PAAD	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.95	13.12	0.73	9.1e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.98	-11.93	-0.7	1.45e-23	Coronary artery disease;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.52	5.26	0.39	4.75e-7	Lewy body disease;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.66	-6.5	-0.47	1.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg12092346	chr18:77659572	KCNG2	-0.56	-4.35	-0.33	2.47e-5	Opioid sensitivity;
PAAD	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg25309567	chr17:79516362	C17orf70	-0.48	-4.5	-0.34	1.34e-5	Myopia;
PAAD	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg25838818	chr2:108905173	SULT1C2	0.42	5.03	0.38	1.37e-6	Blood pressure;
PAAD	cis	rs4740619	0.933	rs1396707	chr9:15705395	G/T	cg14451791	chr9:16040625	NA	-0.39	-4.55	-0.35	1.11e-5	Body mass index;
PAAD	cis	rs13111989	0.947	rs11947473	chr4:177550252	C/A	cg11287292	chr4:178277261	NEIL3	-0.53	-4.27	-0.33	3.45e-5	HIV-1 viral setpoint;
PAAD	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg14343924	chr8:8086146	FLJ10661	-0.65	-5.62	-0.41	8.76e-8	Mood instability;
PAAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-7.1	-0.5	4.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs943072	0.915	rs72862287	chr6:43795301	G/A	cg06892548	chr6:43243945	TTBK1	0.62	4.57	0.35	9.98e-6	Ulcerative colitis;
PAAD	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-15.88	-0.79	4.2e-34	Ulcerative colitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04677061	chr11:32112634	RCN1	0.59	6.44	0.46	1.5e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.65	7.86	0.54	6.7e-13	Weight;
PAAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	4.88	0.37	2.71e-6	Joint mobility (Beighton score);
PAAD	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.86	8.65	0.57	6.95e-15	Uric acid levels;
PAAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg06740227	chr12:86229804	RASSF9	0.6	5.86	0.43	2.72e-8	Major depressive disorder;
PAAD	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.49	7.67	0.53	1.91e-12	Cutaneous nevi;
PAAD	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg19418318	chr19:17219073	MYO9B	-0.4	-4.79	-0.36	3.87e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg12661370	chr5:149340060	SLC26A2	0.68	6.06	0.44	1.02e-8	HIV-1 control;
PAAD	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.46	-5.25	-0.39	5.11e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17104099	chr18:72799745	NA	-0.48	-5.29	-0.39	4.17e-7	Obesity-related traits;
PAAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.73	0.36	5.18e-6	Schizophrenia;
PAAD	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-5.47	-0.41	1.79e-7	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.14	6.89	0.49	1.38e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg23018236	chr17:30244563	NA	-0.58	-4.42	-0.34	1.89e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	5.33	0.4	3.54e-7	Total body bone mineral density;
PAAD	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.92	12.45	0.71	5.67e-25	Body mass index;
PAAD	cis	rs16895831	0.531	rs12195803	chr6:42527571	G/A	cg10605015	chr6:42532144	UBR2	-0.72	-5.46	-0.41	1.88e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg24289452	chr6:170231220	NA	-1.07	-4.38	-0.34	2.16e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs731174	0.802	rs12123842	chr1:38187989	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.4	-4.73	-0.36	5.05e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1997066	0.831	rs73342213	chr10:106818682	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.78e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.63	0.47	5.66e-10	Educational attainment;
PAAD	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg14092988	chr3:52407081	DNAH1	-0.42	-5.17	-0.39	7.41e-7	Bipolar disorder;
PAAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg10523679	chr1:76189770	ACADM	0.5	4.77	0.36	4.23e-6	Daytime sleep phenotypes;
PAAD	cis	rs990171	0.571	rs3771202	chr2:102772669	C/G	cg22835712	chr2:102737379	NA	0.46	4.41	0.34	1.92e-5	Lymphocyte counts;
PAAD	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.79	-0.42	3.94e-8	Mood instability;
PAAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg07362569	chr17:61921086	SMARCD2	0.42	4.78	0.36	4.04e-6	Height;
PAAD	cis	rs4561483	0.667	rs3743590	chr16:11930337	A/C	cg08843971	chr16:11963173	GSPT1	-0.39	-4.39	-0.34	2.09e-5	Testicular germ cell tumor;
PAAD	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.79	0.53	9.72e-13	Motion sickness;
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.78	6.73	0.48	3.25e-10	Response to amphetamines;
PAAD	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg04398451	chr17:18023971	MYO15A	0.72	7.73	0.53	1.38e-12	Total body bone mineral density;
PAAD	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.74	6.98	0.49	8.65e-11	Obesity-related traits;
PAAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19671926	chr4:122722719	EXOSC9	-0.67	-6.15	-0.45	6.57e-9	Type 2 diabetes;
PAAD	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.85	-7.11	-0.5	4.19e-11	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-4.39	-0.34	2.11e-5	Mood instability;
PAAD	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.16	-0.45	6.16e-9	Crohn's disease;
PAAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg26174226	chr8:58114915	NA	-0.68	-6.12	-0.44	7.66e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.85	-9.2	-0.6	2.55e-16	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.62	7.87	0.54	6.15e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.34e-6	Hepatocellular carcinoma;
PAAD	cis	rs1941184	0.526	rs9964117	chr18:29029429	A/G	cg03238162	chr18:29027701	DSG3	0.42	4.81	0.36	3.65e-6	Parkinson's disease (age of onset);
PAAD	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-9.35	-0.6	1.04e-16	Electrocardiographic conduction measures;
PAAD	cis	rs990171	0.607	rs3917245	chr2:102775155	G/A	cg22835712	chr2:102737379	NA	0.45	4.26	0.33	3.51e-5	Lymphocyte counts;
PAAD	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.9	9.68	0.62	1.44e-17	Pulse pressure;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08537794	chr12:132237138	SFRS8	-0.63	-6.41	-0.46	1.69e-9	Obesity-related traits;
PAAD	cis	rs4704187	0.617	rs7356697	chr5:74354542	A/G	cg03227963	chr5:74354835	NA	0.47	4.57	0.35	1.01e-5	Response to amphetamines;
PAAD	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs75757892	0.543	rs17604371	chr6:7312423	G/A	cg02954307	chr6:7269328	NA	0.59	4.75	0.36	4.72e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.34	-0.33	2.54e-5	QT interval;
PAAD	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg02459107	chr1:67143332	SGIP1	0.76	7.54	0.52	3.95e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.52	-5.76	-0.42	4.48e-8	Migraine;
PAAD	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-5.62	-0.41	8.84e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.77	-8.85	-0.58	2.05e-15	Mean platelet volume;
PAAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.74	7.62	0.53	2.49e-12	Menarche (age at onset);
PAAD	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg12568669	chr8:11666485	FDFT1	0.27	4.31	0.33	2.91e-5	Retinal vascular caliber;
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.65	-6.32	-0.46	2.82e-9	Hip circumference;
PAAD	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg10158843	chr11:60776172	CD6	0.63	6.56	0.47	8.12e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.56	-5.54	-0.41	1.3e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.74	-0.53	1.27e-12	Height;
PAAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg00982548	chr2:198649783	BOLL	-0.77	-5.15	-0.39	7.96e-7	Ulcerative colitis;
PAAD	cis	rs2120243	0.539	rs12638732	chr3:157113871	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.32	0.33	2.77e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg04719120	chr6:96025338	MANEA	0.53	4.37	0.33	2.33e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg10168330	chr8:27262164	PTK2B	0.37	4.45	0.34	1.69e-5	Neuroticism;
PAAD	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-4.42	-0.34	1.85e-5	Dupuytren's disease;
PAAD	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg15798862	chr7:76129360	DTX2	-0.52	-6.96	-0.49	9.54e-11	Multiple sclerosis;
PAAD	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.01	-0.38	1.48e-6	Mean platelet volume;
PAAD	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.41	-4.68	-0.35	6.44e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-5.01	-0.38	1.51e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg08798685	chr6:27730294	NA	0.36	4.27	0.33	3.37e-5	Parkinson's disease;
PAAD	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.72	-5.19	-0.39	6.64e-7	Ulcerative colitis;
PAAD	cis	rs7011049	0.915	rs78887309	chr8:53860016	A/C	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg11916758	chr5:133512809	SKP1	-0.57	-6.51	-0.47	1.04e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.84	10.19	0.64	6.47e-19	Brugada syndrome;
PAAD	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg10616300	chr11:66138557	SLC29A2	0.34	4.65	0.35	7.02e-6	Educational attainment (years of education);
PAAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.46	5.27	0.39	4.62e-7	Electroencephalogram traits;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.4	-0.34	2.03e-5	Eosinophil percentage of white cells;
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg15181151	chr6:150070149	PCMT1	0.58	6.34	0.46	2.55e-9	Lung cancer;
PAAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg04106633	chr4:1044584	NA	0.64	5.4	0.4	2.52e-7	Recombination rate (females);
PAAD	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.51	4.64	0.35	7.5e-6	Life satisfaction;
PAAD	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.55	-6.35	-0.46	2.38e-9	Dilated cardiomyopathy;
PAAD	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	4.92	0.37	2.21e-6	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.84	-9.52	-0.61	3.75e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs820218	0.728	rs820148	chr17:73615887	A/G	cg06491139	chr17:74467828	RHBDF2	-0.39	-4.34	-0.33	2.59e-5	Rotator cuff tears;
PAAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.66	-0.35	6.8e-6	Height;
PAAD	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.95	0.59	1.15e-15	Motion sickness;
PAAD	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.76	7.69	0.53	1.74e-12	Coronary artery disease;
PAAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.03	-17.46	-0.82	3.85e-38	Height;
PAAD	cis	rs7301826	0.651	rs4759794	chr12:131297348	T/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	10.71	0.66	2.64e-20	Smoking behavior;
PAAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00103685	chr14:75536130	FAM164C	0.58	6.35	0.46	2.32e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12304921	0.935	rs224587	chr12:51397433	T/C	cg04427360	chr12:51347099	HIGD1C	-0.6	-4.39	-0.34	2.09e-5	Type 2 diabetes;
PAAD	cis	rs7551345	1.000	rs16834408	chr1:31837942	G/A	cg17086398	chr1:31896392	SERINC2	-0.5	-4.53	-0.35	1.18e-5	Schizophrenia;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08219700	chr8:58056026	NA	0.65	5.26	0.39	4.9e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.74	8.09	0.55	1.73e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6499129	1.000	rs55966046	chr16:67466726	C/A	cg10189135	chr16:67516162	ATP6V0D1	-0.59	-4.5	-0.34	1.32e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs761746	0.921	rs12171042	chr22:32011225	T/C	cg01338084	chr22:32026380	PISD	0.49	4.34	0.33	2.54e-5	Intelligence;
PAAD	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg05299278	chr17:33885742	SLFN14	0.42	5.04	0.38	1.32e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.23	-19.38	-0.84	6.47e-43	IgG glycosylation;
PAAD	cis	rs533581	0.873	rs529900	chr16:88976968	G/C	cg05579598	chr16:88989069	CBFA2T3	0.64	9.63	0.62	1.95e-17	Social autistic-like traits;
PAAD	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.74	-8.24	-0.56	7.63e-14	Prion diseases;
PAAD	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg00531865	chr16:30841666	NA	-0.61	-5.63	-0.42	8.6e-8	Multiple myeloma;
PAAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.49	4.43	0.34	1.8e-5	Sudden cardiac arrest;
PAAD	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.41	-0.34	1.98e-5	IgG glycosylation;
PAAD	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.68	-0.53	1.85e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18212924	chr14:105608474	JAG2	-0.63	-6.67	-0.48	4.58e-10	Obesity-related traits;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01878750	chr7:2776006	GNA12	-0.71	-7.2	-0.5	2.66e-11	Obesity-related traits;
PAAD	cis	rs7291412	0.601	rs7292407	chr22:46453712	A/C	cg09693106	chr22:46449821	C22orf26;LOC150381	-0.41	-4.36	-0.33	2.37e-5	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.75	8.36	0.56	3.75e-14	Dental caries;
PAAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-6.93	-0.49	1.13e-10	Colorectal cancer;
PAAD	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg02683114	chr2:24398427	C2orf84	-0.46	-4.99	-0.38	1.64e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.49	-5.35	-0.4	3.17e-7	Height;
PAAD	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg14092988	chr3:52407081	DNAH1	-0.42	-5.24	-0.39	5.33e-7	Bipolar disorder;
PAAD	cis	rs35955747	0.902	rs4820961	chr22:31679449	C/T	cg02404636	chr22:31891804	SFI1	-0.49	-4.88	-0.37	2.61e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.69	5.45	0.4	2.02e-7	Neuroticism;
PAAD	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs7932354	0.550	rs12807111	chr11:46924174	T/A	cg19486271	chr11:47235900	DDB2	-0.61	-6.02	-0.44	1.25e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.53	5.21	0.39	6.06e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg14847009	chr1:175162515	KIAA0040	-0.3	-4.65	-0.35	7.17e-6	Alcohol dependence;
PAAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.52	-5.4	-0.4	2.49e-7	Lung cancer;
PAAD	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.63	6.82	0.48	2.05e-10	Colorectal cancer;
PAAD	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	8.86	0.58	1.96e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.47	4.38	0.33	2.19e-5	Renal cell carcinoma;
PAAD	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00079375	chr15:79125835	NA	-0.42	-4.51	-0.34	1.27e-5	Coronary artery disease;
PAAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.5	-4.65	-0.35	7.15e-6	Monocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12268531	chr1:92102055	HSP90B3P	-0.55	-6.32	-0.46	2.75e-9	Obesity-related traits;
PAAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg19413350	chr8:57351067	NA	-0.48	-4.57	-0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg21775007	chr8:11205619	TDH	-0.52	-4.6	-0.35	9.01e-6	Neuroticism;
PAAD	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg10110957	chr16:89460751	ANKRD11	-0.47	-4.42	-0.34	1.87e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg24375607	chr4:120327624	NA	0.43	4.44	0.34	1.76e-5	Diastolic blood pressure;
PAAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg09324608	chr17:30823087	MYO1D	0.43	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg01448562	chr3:133502909	NA	0.51	4.89	0.37	2.51e-6	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs58521262	0.530	rs289367	chr19:23114530	A/T	cg03433597	chr19:22806448	NA	-0.24	-4.32	-0.33	2.84e-5	Testicular germ cell tumor;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06589161	chr5:180618230	NA	0.56	6.5	0.47	1.07e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.48	-4.89	-0.37	2.54e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.93	10.55	0.65	7.06e-20	Parkinson's disease;
PAAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.4	-0.4	2.48e-7	Personality dimensions;
PAAD	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.66	8.42	0.56	2.6e-14	Platelet count;
PAAD	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.69	8.99	0.59	9.04e-16	Hemoglobin concentration;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.76	7.97	0.54	3.5e-13	Hypertriglyceridemia;
PAAD	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.75	-8.17	-0.55	1.1e-13	Inflammatory bowel disease;
PAAD	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.63	-6.8	-0.48	2.22e-10	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg01620082	chr3:125678407	NA	-1.1	-6.38	-0.46	2.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg09941381	chr10:64027924	RTKN2	-0.37	-4.35	-0.33	2.49e-5	Rheumatoid arthritis;
PAAD	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.74	-9.29	-0.6	1.57e-16	Educational attainment;
PAAD	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08693792	chr2:120786380	EPB41L5	-0.66	-6.51	-0.47	1.04e-9	Obesity-related traits;
PAAD	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg23682824	chr7:23144976	KLHL7	0.5	4.42	0.34	1.88e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7107174	0.748	rs4415799	chr11:77976475	C/T	cg02023728	chr11:77925099	USP35	-0.43	-4.77	-0.36	4.37e-6	Testicular germ cell tumor;
PAAD	cis	rs12304921	0.683	rs17125286	chr12:51454210	T/C	cg04427360	chr12:51347099	HIGD1C	-0.62	-4.64	-0.35	7.56e-6	Type 2 diabetes;
PAAD	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg15145965	chr22:50218605	BRD1	0.61	5.24	0.39	5.26e-7	Schizophrenia;
PAAD	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.69	-7.8	-0.53	9.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.81	10.08	0.63	1.27e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14895029	chr7:2775587	GNA12	-0.48	-4.79	-0.36	3.96e-6	Height;
PAAD	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.27	0.64	3.96e-19	Post bronchodilator FEV1;
PAAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.7	7.94	0.54	4.27e-13	Multiple sclerosis;
PAAD	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg23250157	chr14:64679961	SYNE2	0.55	5.61	0.41	9.28e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg15942720	chr14:51706980	TMX1	0.51	4.45	0.34	1.67e-5	Cancer;
PAAD	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg04455712	chr21:45112962	RRP1B	0.43	4.31	0.33	2.93e-5	Mean corpuscular volume;
PAAD	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-4.8	-0.36	3.74e-6	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs595018	0.505	rs7117870	chr11:60597424	C/T	cg07588442	chr11:60673866	PRPF19	0.65	4.56	0.35	1.04e-5	Wegener's granulomatosis;
PAAD	cis	rs13144136	0.687	rs11726388	chr4:10660245	G/A	cg10242279	chr4:10666415	CLNK	-0.48	-6.1	-0.44	8.62e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.94	-11.36	-0.68	4.76e-22	Height;
PAAD	cis	rs7552393	0.622	rs2296257	chr1:84311412	A/G	cg10977910	chr1:84465055	TTLL7	0.52	4.64	0.35	7.34e-6	Select biomarker traits;
PAAD	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.62	-6.94	-0.49	1.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg15145965	chr22:50218605	BRD1	0.56	4.48	0.34	1.45e-5	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.59	-8.01	-0.54	2.84e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-6.34	-0.46	2.51e-9	Height;
PAAD	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.72	8.15	0.55	1.22e-13	Colorectal cancer;
PAAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	4.47	0.34	1.55e-5	Breast cancer;
PAAD	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02985541	chr2:219472218	PLCD4	0.29	4.57	0.35	9.86e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg25050447	chr17:78165522	CARD14	0.36	4.44	0.34	1.72e-5	Yeast infection;
PAAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.87	-0.49	1.57e-10	Total body bone mineral density;
PAAD	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.51	4.32	0.33	2.78e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.38	-0.4	2.78e-7	Personality dimensions;
PAAD	cis	rs6785206	0.554	rs9867598	chr3:128460628	C/T	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.66	-7.14	-0.5	3.63e-11	Aortic root size;
PAAD	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs62577244	0.645	rs111342974	chr9:138434448	G/A	cg14582108	chr9:138439003	OBP2A	0.53	4.79	0.36	3.95e-6	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
PAAD	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg09462578	chr12:12878428	APOLD1	-0.9	-9.1	-0.59	4.85e-16	Lymphocyte counts;
PAAD	cis	rs1113500	0.548	rs9970655	chr1:108643537	G/T	cg06207961	chr1:108661230	NA	0.44	4.35	0.33	2.47e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	6.62	0.47	5.94e-10	Educational attainment;
PAAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg15017067	chr4:17643749	FAM184B	0.43	5.14	0.38	8.36e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg19429281	chr19:53496738	ZNF702P	-0.61	-6.41	-0.46	1.73e-9	Psoriasis;
PAAD	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.91	7.25	0.51	1.93e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg07541023	chr7:19748670	TWISTNB	0.57	4.32	0.33	2.79e-5	Thyroid stimulating hormone;
PAAD	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-13.07	-0.73	1.22e-26	Primary sclerosing cholangitis;
PAAD	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.97	14.71	0.77	5.05e-31	Dental caries;
PAAD	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.6	-6.58	-0.47	7.21e-10	Red blood cell count;Reticulocyte count;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg19108055	chr3:160219522	KPNA4	-0.64	-6.76	-0.48	2.8e-10	Alcohol dependence;
PAAD	cis	rs10957961	0.586	rs2052712	chr8:81071367	A/G	cg10609868	chr8:81963379	PAG1	-0.38	-4.57	-0.35	1.01e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.41	0.34	1.98e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09758742	chr8:11059062	XKR6	0.57	6.62	0.47	5.95e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13006833	0.739	rs291468	chr2:191188119	A/G	cg27211696	chr2:191398769	TMEM194B	0.46	4.55	0.35	1.08e-5	Urinary metabolites;
PAAD	cis	rs2904967	0.636	rs514076	chr11:64990041	G/C	cg21890820	chr11:65308645	LTBP3	-0.55	-5.18	-0.39	7.06e-7	Mean corpuscular volume;
PAAD	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-4.73	-0.36	5.16e-6	Menarche (age at onset);
PAAD	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.52	5.26	0.39	4.82e-7	Social autistic-like traits;
PAAD	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	9.94	0.63	2.94e-18	Nonalcoholic fatty liver disease;
PAAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg12215294	chr3:40350768	EIF1B	-0.45	-4.26	-0.33	3.52e-5	Renal cell carcinoma;
PAAD	cis	rs6844506	1.000	rs4862357	chr4:185220362	C/T	cg12654155	chr4:185238627	NA	-0.53	-5.25	-0.39	5.12e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg01064725	chr1:204461714	NA	-0.5	-4.61	-0.35	8.33e-6	Schizophrenia;
PAAD	cis	rs10090774	0.965	rs6578147	chr8:141965868	C/G	cg02508881	chr8:142216119	NA	0.4	4.27	0.33	3.37e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.63	6.08	0.44	9.17e-9	White matter hyperintensity burden;
PAAD	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-6.59	-0.47	6.76e-10	Colorectal cancer;
PAAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg27411982	chr8:10470053	RP1L1	0.42	4.45	0.34	1.64e-5	Schizophrenia;
PAAD	cis	rs10849893	0.535	rs7965954	chr12:121918732	G/T	cg01154721	chr12:121881891	KDM2B	0.52	4.86	0.37	2.92e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.66	5.4	0.4	2.56e-7	Vitiligo;
PAAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg18944383	chr4:111397179	ENPEP	-0.73	-8.09	-0.55	1.78e-13	Coronary artery disease;
PAAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs7714584	1.000	rs57406211	chr5:150170966	C/T	cg22134413	chr5:150180641	NA	0.96	6.38	0.46	2.03e-9	Crohn's disease;
PAAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.82	10.76	0.66	1.99e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg19223190	chr17:80058835	NA	-0.53	-5.44	-0.4	2.13e-7	Life satisfaction;
PAAD	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg05082376	chr22:42548792	NA	-0.49	-5.33	-0.4	3.53e-7	Cognitive function;
PAAD	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.53	5.9	0.43	2.22e-8	Heart rate;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg05313129	chr8:58192883	C8orf71	-0.66	-5.71	-0.42	5.82e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg23024343	chr7:107201750	COG5	0.58	4.77	0.36	4.26e-6	Coronary artery disease;
PAAD	cis	rs1419980	0.730	rs11054880	chr12:7772069	A/G	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16579770	chr16:72058938	DHODH	0.39	4.51	0.34	1.29e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs300774	0.858	rs1829220	chr2:118383	A/C	cg21211680	chr2:198530	NA	-0.56	-4.99	-0.38	1.61e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs9549328	0.577	rs4907571	chr13:113618496	T/C	cg17524180	chr13:113633600	MCF2L	-0.42	-4.48	-0.34	1.49e-5	Systolic blood pressure;
PAAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-9.57	-0.61	2.82e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	6.86	0.49	1.59e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17601876	0.814	rs7181429	chr15:51559496	G/A	cg21478137	chr15:51532386	CYP19A1	0.42	4.32	0.33	2.75e-5	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-8.94	-0.59	1.23e-15	Total body bone mineral density;
PAAD	trans	rs4942242	1.000	rs9562501	chr13:44205683	C/T	cg19169023	chr15:41853346	TYRO3	-0.68	-7.06	-0.5	5.44e-11	Response to tocilizumab in rheumatoid arthritis;
PAAD	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.11	-11.92	-0.7	1.48e-23	Blood pressure (smoking interaction);
PAAD	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	8.79	0.58	2.93e-15	Lymphocyte counts;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg21698718	chr17:80085957	CCDC57	0.45	5.02	0.38	1.41e-6	Life satisfaction;
PAAD	cis	rs11051970	0.592	rs11051985	chr12:32555090	G/A	cg24626660	chr12:32551988	NA	0.43	4.56	0.35	1.03e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9463078	0.546	rs1284983	chr6:45081916	A/G	cg25276700	chr6:44698697	NA	-0.45	-5.06	-0.38	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.92	9.13	0.6	3.97e-16	Orofacial clefts;
PAAD	cis	rs1371614	0.501	rs4992933	chr2:27178972	C/A	cg00617064	chr2:27272375	NA	-0.46	-4.82	-0.36	3.44e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg26497354	chr6:109612229	NA	-0.43	-4.33	-0.33	2.72e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.63	-6.8	-0.48	2.21e-10	Schizophrenia;
PAAD	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.96	8.88	0.58	1.75e-15	Resting heart rate;
PAAD	cis	rs4513299	0.601	rs882575	chr2:115018255	T/C	cg12978357	chr2:114426529	NA	-0.45	-4.34	-0.33	2.64e-5	Inflammatory biomarkers;
PAAD	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.48	-4.85	-0.37	3.03e-6	Ovarian reserve;
PAAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-5.15	-0.39	7.98e-7	Mean corpuscular volume;
PAAD	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.52	0.41	1.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.94	12.57	0.71	2.69e-25	Menopause (age at onset);
PAAD	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-7.28	-0.51	1.68e-11	Heart rate;
PAAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18621852	chr3:10150065	C3orf24	0.66	5.64	0.42	8.03e-8	Alzheimer's disease;
PAAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	7.51	0.52	4.61e-12	Height;
PAAD	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	6.72	0.48	3.5e-10	Educational attainment;
PAAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13939156	chr17:80058883	NA	0.43	4.7	0.36	5.72e-6	Life satisfaction;
PAAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg15017067	chr4:17643749	FAM184B	0.4	4.46	0.34	1.61e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs12257961	0.609	rs10906892	chr10:15389924	T/A	cg10616319	chr10:15468812	NA	-0.47	-4.46	-0.34	1.56e-5	Selective IgA deficiency;
PAAD	cis	rs4455778	0.580	rs6970665	chr7:49124091	T/A	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.47	5.81	0.43	3.47e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg10985347	chr2:127963512	CYP27C1	0.46	4.28	0.33	3.26e-5	Protein C levels;
PAAD	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg27455613	chr17:80820699	TBCD	-0.45	-4.29	-0.33	3.17e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg25880537	chr1:2365337	NA	0.35	4.46	0.34	1.59e-5	Height;
PAAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg16898833	chr6:26189333	HIST1H4D	0.57	4.72	0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.55	-4.98	-0.37	1.7e-6	IgG glycosylation;
PAAD	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.62	-6.16	-0.45	6.32e-9	Ear protrusion;
PAAD	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.95	-9.41	-0.61	7.49e-17	Post bronchodilator FEV1;
PAAD	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.64	-6.05	-0.44	1.06e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-8.17	-0.55	1.14e-13	Coffee consumption (cups per day);
PAAD	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.72	7.75	0.53	1.19e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2221894	0.853	rs11781448	chr8:28793927	T/C	cg20212339	chr8:28908912	HMBOX1	0.48	5.0	0.38	1.53e-6	Obesity-related traits;
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.84	6.63	0.47	5.65e-10	Schizophrenia;
PAAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Gout;
PAAD	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.86	6.65	0.47	4.9e-10	Atopic dermatitis;
PAAD	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.58	4.67	0.35	6.68e-6	Common traits (Other);
PAAD	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.04	-0.5	6.15e-11	Response to antipsychotic treatment;
PAAD	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.54	4.89	0.37	2.57e-6	Body mass index;
PAAD	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.11	14.58	0.76	1.1e-30	Testicular germ cell tumor;
PAAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.51	-5.35	-0.4	3.13e-7	Obesity-related traits;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg24699146	chr1:24152579	HMGCL	0.55	5.91	0.43	2.12e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11997175	0.546	rs11778519	chr8:33615873	G/A	ch.8.33884649F	chr8:33765107	NA	0.62	6.65	0.47	4.89e-10	Body mass index;
PAAD	cis	rs4908768	0.501	rs1473420	chr1:8616838	T/G	cg20416874	chr1:8611966	RERE	-0.46	-4.35	-0.33	2.44e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs868943	0.582	rs34224224	chr6:116464219	A/T	cg18764771	chr6:116381957	FRK	0.27	4.37	0.33	2.31e-5	Total cholesterol levels;
PAAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.5	5.81	0.43	3.63e-8	Height;
PAAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	11.24	0.67	1.02e-21	Platelet count;
PAAD	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.67	5.23	0.39	5.58e-7	Blood protein levels;
PAAD	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.55	5.4	0.4	2.55e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.78	9.09	0.59	5.14e-16	Heart rate;
PAAD	cis	rs643506	0.845	rs7114594	chr11:111768113	A/G	cg09085632	chr11:111637200	PPP2R1B	0.55	4.59	0.35	9.04e-6	Breast cancer;
PAAD	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	7.8	0.53	9.43e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs12431939	0.948	rs12436364	chr14:51671320	T/C	cg23942311	chr14:51606299	NA	-0.62	-5.11	-0.38	9.45e-7	Cancer;
PAAD	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.97	6.89	0.49	1.42e-10	Dental caries;
PAAD	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg04265051	chr11:68079686	LRP5	-0.38	-4.64	-0.35	7.47e-6	Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.81	0.43	3.54e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.66	7.87	0.54	6.2800000000000005e-13	Colorectal cancer;
PAAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.83	-0.58	2.38e-15	Calcium levels;
PAAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.55	5.98	0.44	1.56e-8	Testicular germ cell tumor;
PAAD	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.8	5.75	0.42	4.71e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.6	5.74	0.42	4.86e-8	Lymphocyte counts;
PAAD	cis	rs802075	1.000	rs360564	chr6:49658090	T/C	cg20364632	chr6:49636226	NA	-0.51	-5.87	-0.43	2.6e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	1.26	6.07	0.44	9.9e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg24733560	chr20:60626293	TAF4	0.52	6.4	0.46	1.8e-9	Body mass index;
PAAD	cis	rs6076065	0.509	rs2000261	chr20:23311090	G/T	cg11657817	chr20:23433608	CST11	0.53	5.41	0.4	2.4e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg21724239	chr8:58056113	NA	0.72	5.71	0.42	5.8e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg02887458	chr19:19495540	GATAD2A	-0.55	-5.13	-0.38	8.54e-7	Bipolar disorder;
PAAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg14008862	chr17:28927542	LRRC37B2	0.73	4.66	0.35	6.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg23920097	chr1:209922102	NA	-0.5	-4.86	-0.37	2.86e-6	Red blood cell count;
PAAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.42	-4.33	-0.33	2.7e-5	Aortic root size;
PAAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.72	0.66	2.5e-20	Prudent dietary pattern;
PAAD	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	5.45	0.4	2.03e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-10.23	-0.64	5.03e-19	Response to antipsychotic treatment;
PAAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg06815965	chr1:205818668	PM20D1	0.46	4.96	0.37	1.87e-6	Prostate cancer;
PAAD	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.52	5.15	0.39	7.95e-7	Common traits (Other);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg01581637	chr12:49463804	RHEBL1	0.61	6.54	0.47	9.04e-10	Myopia (pathological);
PAAD	cis	rs501120	1.000	rs604674	chr10:44756894	G/T	cg09554077	chr10:44749378	NA	0.51	6.72	0.48	3.36e-10	Coronary artery disease;Coronary heart disease;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06488666	chr20:33104140	DYNLRB1	0.62	6.94	0.49	1.07e-10	Metabolite levels  (X-11787);
PAAD	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.73	-0.36	5.1e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	4.68	0.35	6.3e-6	Breast cancer;
PAAD	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.64	-6.9	-0.49	1.28e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.46	-4.7	-0.36	5.74e-6	Iron status biomarkers;
PAAD	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg05212510	chr18:77623544	KCNG2	-0.44	-4.44	-0.34	1.71e-5	Schizophrenia;
PAAD	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.7	-0.48	3.79e-10	Educational attainment;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-5.0	-0.38	1.55e-6	Lung cancer;
PAAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.56	6.38	0.46	2.07e-9	Tonsillectomy;
PAAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.66	-6.94	-0.49	1.05e-10	Systemic lupus erythematosus;
PAAD	trans	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg05144285	chr7:158935647	VIPR2	-0.52	-4.62	-0.35	8.13e-6	Height;
PAAD	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg20893579	chr22:38215064	NA	-0.47	-4.9	-0.37	2.41e-6	Glioblastoma;Glioma;
PAAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.81	8.55	0.57	1.25e-14	Cleft lip with or without cleft palate;
PAAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-6.35	-0.46	2.35e-9	Height;
PAAD	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.86e-10	Primary sclerosing cholangitis;
PAAD	cis	rs494459	0.691	rs607472	chr11:118680072	C/G	cg08498647	chr11:118550644	TREH	-0.37	-4.56	-0.35	1.03e-5	Height;
PAAD	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Breast cancer;
PAAD	cis	rs4073221	0.654	rs7373842	chr3:18294022	T/C	cg07694806	chr3:18168406	NA	-0.65	-4.76	-0.36	4.38e-6	Parkinson's disease;
PAAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18313221	chr7:116311878	MET	0.55	6.31	0.46	2.97e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.63	5.74	0.42	5.01e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.64	-5.75	-0.42	4.73e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs76917914	0.820	rs7020081	chr9:100823360	C/A	cg21225548	chr9:100864335	TRIM14	-0.55	-5.8	-0.43	3.72e-8	Immature fraction of reticulocytes;
PAAD	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg10616300	chr11:66138557	SLC29A2	0.33	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs3126085	0.515	rs4322234	chr1:152353768	A/G	cg26876637	chr1:152193138	HRNR	-0.69	-5.13	-0.38	8.86e-7	Atopic dermatitis;
PAAD	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg15211996	chr1:2936768	ACTRT2	0.46	4.54	0.35	1.14e-5	Plateletcrit;
PAAD	cis	rs2131877	0.956	rs955825	chr3:194870922	T/C	cg19760965	chr3:194868843	C3orf21	0.44	4.77	0.36	4.34e-6	Non-small cell lung cancer;
PAAD	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg05272587	chr13:111038400	COL4A2	-0.54	-4.77	-0.36	4.32e-6	White matter hyperintensity burden;
PAAD	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	6.13	0.45	7.19e-9	Schizophrenia;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.82	-10.15	-0.64	8.46e-19	Monocyte percentage of white cells;
PAAD	cis	rs7570971	0.517	rs10187402	chr2:135771974	C/G	cg07169764	chr2:136633963	MCM6	0.74	7.28	0.51	1.69e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
PAAD	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.84	-0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg00277334	chr10:82204260	NA	-0.6	-5.38	-0.4	2.73e-7	Post bronchodilator FEV1;
PAAD	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg03959625	chr15:84868606	LOC388152	0.5	5.51	0.41	1.49e-7	Schizophrenia;
PAAD	cis	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-4.62	-0.35	8.03e-6	Depression;
PAAD	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	8.98	0.59	9.85e-16	Motion sickness;
PAAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.81	-8.41	-0.56	2.81e-14	Glaucoma (primary open-angle);
PAAD	cis	rs17023223	0.537	rs2765533	chr1:119597395	T/C	cg17326555	chr1:119535693	NA	-0.43	-5.26	-0.39	4.84e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg05447483	chr17:74381280	SPHK1	0.69	6.8	0.48	2.27e-10	Obesity-related traits;
PAAD	cis	rs2952768	0.772	rs17520056	chr2:208478055	A/G	cg22329743	chr2:208688774	PLEKHM3	0.25	4.79	0.36	3.9e-6	Opioid sensitivity;
PAAD	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.83	-7.73	-0.53	1.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23281280	chr6:28129359	ZNF389	-0.71	-5.55	-0.41	1.24e-7	Depression;
PAAD	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.31	0.33	2.87e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg06484146	chr7:12443880	VWDE	-0.8	-5.38	-0.4	2.79e-7	Coronary artery disease;
PAAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.82	7.04	0.5	6.23e-11	Alzheimer's disease;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.67	7.69	0.53	1.75e-12	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg08132940	chr7:1081526	C7orf50	-0.65	-4.66	-0.35	6.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg11519256	chr10:5708881	ASB13	0.62	5.42	0.4	2.31e-7	Childhood ear infection;
PAAD	cis	rs2816062	0.813	rs2816057	chr1:18902257	G/C	cg18795169	chr1:18902165	NA	-1.07	-19.5	-0.85	3.3e-43	Urate levels in lean individuals;
PAAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg01800442	chr17:74086473	EXOC7	0.54	4.37	0.33	2.33e-5	Psoriasis;
PAAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.48	5.07	0.38	1.13e-6	IgG glycosylation;
PAAD	trans	rs9463078	0.774	rs6934594	chr6:45319876	A/G	cg00236302	chr12:69004867	RAP1B	-0.58	-6.7	-0.48	3.77e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.25	-0.39	4.97e-7	Reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14240072	chr19:2835667	ZNF554	-0.65	-6.67	-0.48	4.58e-10	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18273818	chr5:5422589	KIAA0947	0.58	6.33	0.46	2.68e-9	Monocyte percentage of white cells;
PAAD	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	1.08	12.49	0.71	4.56e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.67	4.62	0.35	7.99e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg02876276	chr17:77834299	NA	0.6	4.31	0.33	2.94e-5	Electroencephalogram traits;
PAAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.36	0.33	2.35e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.59	6.0	0.44	1.36e-8	Huntington's disease progression;
PAAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.98	-0.37	1.68e-6	Initial pursuit acceleration;
PAAD	cis	rs9815354	1.000	rs7624372	chr3:41881107	T/A	cg03022575	chr3:42003672	ULK4	0.76	5.53	0.41	1.34e-7	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-7.51	-0.52	4.61e-12	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg18944383	chr4:111397179	ENPEP	-0.77	-8.72	-0.58	4.45e-15	Coronary artery disease;
PAAD	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.61	6.58	0.47	7.04e-10	High light scatter reticulocyte count;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.58	2.38e-15	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.2	12.34	0.71	1.11e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.42	5.18	0.39	6.87e-7	Thyroid stimulating hormone;
PAAD	cis	rs731174	0.759	rs591567	chr1:38149847	A/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-11.76	-0.69	4.12e-23	Primary sclerosing cholangitis;
PAAD	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.6	-5.14	-0.38	8.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.54	5.19	0.39	6.68e-7	Longevity;
PAAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg02156692	chr7:2749751	AMZ1	-0.31	-4.32	-0.33	2.77e-5	Height;
PAAD	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-5.96	-0.44	1.66e-8	Fibrinogen levels;
PAAD	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.57	-5.2	-0.39	6.35e-7	Diastolic blood pressure;
PAAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.88	7.3	0.51	1.48e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.7	-0.42	6.05e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.64	5.15	0.39	7.82e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	1.57	8.94	0.59	1.22e-15	Cannabis dependence symptom count;
PAAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs992157	0.764	rs1870123	chr2:219187698	G/A	cg00012203	chr2:219082015	ARPC2	0.6	5.78	0.42	4.1e-8	Colorectal cancer;
PAAD	cis	rs17401966	0.898	rs1396	chr1:10247143	C/A	cg15208524	chr1:10270712	KIF1B	0.51	4.69	0.36	5.94e-6	Hepatocellular carcinoma;
PAAD	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg00179576	chr16:74483694	GLG1	-0.42	-4.59	-0.35	9.39e-6	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	4.92	0.37	2.2e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg02016764	chr4:38805732	TLR1	-0.67	-5.06	-0.38	1.18e-6	Breast cancer;
PAAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	1.08	5.98	0.44	1.5e-8	Body mass index;
PAAD	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg19197139	chr17:4613644	ARRB2	-0.83	-8.6	-0.57	9.18e-15	Lymphocyte counts;
PAAD	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs992157	0.764	rs2891077	chr2:219184430	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.71	7.13	0.5	3.84e-11	Colorectal cancer;
PAAD	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.61	-6.05	-0.44	1.08e-8	Hemoglobin concentration;
PAAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.61	6.14	0.45	6.93e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs35123781	0.518	rs13160670	chr5:138969179	G/A	cg11459648	chr5:138714337	SLC23A1	-0.6	-5.2	-0.39	6.27e-7	Schizophrenia;
PAAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.47	4.97	0.37	1.79e-6	Vitiligo;
PAAD	cis	rs4757319	0.532	rs10766251	chr11:15443681	A/G	cg03245590	chr11:15329459	NA	-0.39	-4.72	-0.36	5.41e-6	Breast cancer;
PAAD	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg01494348	chr8:144660395	NAPRT1	-0.9	-6.86	-0.49	1.67e-10	Attention deficit hyperactivity disorder;
PAAD	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg14019146	chr3:50243930	SLC38A3	-0.51	-5.41	-0.4	2.41e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.53	5.58	0.41	1.07e-7	Height;
PAAD	cis	rs2491441	1.000	rs3010053	chr1:183816266	C/T	cg08905629	chr1:183188297	LAMC2	0.47	4.37	0.33	2.33e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg07068956	chr7:100330872	ZAN	-0.71	-5.37	-0.4	2.95e-7	Other erythrocyte phenotypes;
PAAD	cis	rs790123	0.692	rs790126	chr3:122387655	G/A	cg15604389	chr3:122379662	NA	0.54	5.19	0.39	6.78e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.57	6.12	0.44	7.65e-9	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04301682	chr4:76598670	G3BP2	-0.65	-6.63	-0.47	5.42e-10	Smoking initiation;
PAAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-0.85	-5.62	-0.41	8.77e-8	IgG glycosylation;
PAAD	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.18	-0.39	6.92e-7	High light scatter reticulocyte count;
PAAD	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.62	-5.66	-0.42	7.38e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.46	-4.75	-0.36	4.65e-6	Breast cancer;
PAAD	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.85e-6	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23000811	chr4:2464397	NA	0.58	6.47	0.46	1.27e-9	Monocyte percentage of white cells;
PAAD	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg26031613	chr14:104095156	KLC1	0.5	5.56	0.41	1.18e-7	Schizophrenia;
PAAD	cis	rs7567389	0.677	rs11680877	chr2:128090450	A/G	cg09760422	chr2:128146352	NA	0.38	5.92	0.43	2.05e-8	Self-rated health;
PAAD	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg11494091	chr17:61959527	GH2	0.51	4.28	0.33	3.25e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg12552261	chr5:112820674	MCC	0.64	6.44	0.46	1.5e-9	Type 2 diabetes;
PAAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg07202610	chr7:1142643	C7orf50	-0.6	-4.55	-0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.66	-8.33	-0.56	4.37e-14	Myopia (pathological);
PAAD	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg07148914	chr20:33460835	GGT7	-0.58	-5.65	-0.42	7.71e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg05805236	chr11:65401703	PCNXL3	-0.57	-5.94	-0.43	1.86e-8	Acne (severe);
PAAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.68	-6.27	-0.45	3.58e-9	DNA methylation (variation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08638395	chr1:180601032	XPR1	0.62	7.05	0.5	5.76e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg26031613	chr14:104095156	KLC1	-0.53	-5.54	-0.41	1.28e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs12913538	0.547	rs4573888	chr15:62896704	A/G	cg09983546	chr15:62884068	NA	0.68	6.54	0.47	8.87e-10	Sleep depth;
PAAD	cis	rs4072705	0.585	rs10760365	chr9:127230891	G/A	cg13476313	chr9:127244764	NR5A1	0.31	4.68	0.36	6.19e-6	Menarche (age at onset);
PAAD	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg23912435	chr1:150601613	ENSA	0.5	4.74	0.36	4.88e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.59	6.56	0.47	8.04e-10	Cognitive function;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08804013	chr16:69600791	NFAT5;MIR1538	0.6	6.57	0.47	7.64e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.43	5.46	0.41	1.86e-7	Ulcerative colitis;
PAAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg03303774	chr4:1407052	NA	0.4	4.7	0.36	5.7e-6	Obesity-related traits;
PAAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.66	8.9	0.59	1.55e-15	Eye color traits;
PAAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22482690	chr17:47019901	SNF8	0.46	4.99	0.38	1.65e-6	Type 2 diabetes;
PAAD	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.53	5.22	0.39	5.81e-7	Rheumatoid arthritis;
PAAD	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg08992911	chr2:238395768	MLPH	0.69	5.47	0.41	1.81e-7	Prostate cancer;
PAAD	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.52	-4.8	-0.36	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs73019876	0.502	rs10403779	chr19:22258396	C/G	cg08394602	chr19:22123885	NA	-0.46	-4.81	-0.36	3.6e-6	Testicular germ cell tumor;
PAAD	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg08885076	chr2:99613938	TSGA10	-0.54	-5.33	-0.4	3.41e-7	Chronic sinus infection;
PAAD	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg00976097	chr5:421733	AHRR	-0.65	-5.82	-0.43	3.42e-8	Cystic fibrosis severity;
PAAD	cis	rs10992471	0.580	rs7020104	chr9:95416524	A/G	cg14631576	chr9:95140430	CENPP	-0.48	-4.61	-0.35	8.63e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07648498	chr16:89883185	FANCA	0.67	6.87	0.49	1.57e-10	Vitiligo;
PAAD	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg23912435	chr1:150601613	ENSA	0.49	4.51	0.34	1.27e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26552784	chr18:74203038	NA	0.51	4.91	0.37	2.31e-6	Obesity-related traits;
PAAD	cis	rs3996993	0.809	rs7747087	chr6:52713999	G/A	cg20803780	chr6:52668592	GSTA1	-0.36	-4.58	-0.35	9.65e-6	Hemoglobin concentration;
PAAD	cis	rs4965006	1.000	rs11246900	chr12:132506784	G/T	cg00588090	chr12:132412438	PUS1	0.78	8.15	0.55	1.23e-13	Posterior cortical atrophy and Alzheimer's disease;
PAAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14330853	chr17:33446982	RAD51L3	0.6	7.15	0.5	3.48e-11	Monocyte percentage of white cells;
PAAD	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.79	8.68	0.58	5.82e-15	Birth weight;
PAAD	cis	rs4740619	0.688	rs10962225	chr9:15936528	C/T	cg14451791	chr9:16040625	NA	-0.42	-4.77	-0.36	4.23e-6	Body mass index;
PAAD	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg03700679	chr2:178418002	TTC30B	0.55	4.63	0.35	7.74e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.21	0.45	4.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs227833	0.826	rs4714813	chr6:44709890	C/A	cg20913747	chr6:44695427	NA	0.5	5.28	0.39	4.4e-7	Monobrow;
PAAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg17385448	chr1:15911702	AGMAT	0.4	4.61	0.35	8.41e-6	Systolic blood pressure;
PAAD	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.91	0.37	2.33e-6	Self-reported allergy;
PAAD	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.79	8.04	0.55	2.4e-13	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.71e-10	Life satisfaction;
PAAD	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg19192590	chr2:178524533	PDE11A	0.4	4.55	0.35	1.08e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg20813462	chr7:2646259	IQCE	-0.66	-4.87	-0.37	2.77e-6	Urate levels in lean individuals;
PAAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.57	7.64	0.53	2.23e-12	Renal cell carcinoma;
PAAD	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs847851	1.000	rs57951780	chr6:34852891	C/T	cg05379947	chr6:35436047	RPL10A	0.54	4.55	0.35	1.1e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.48	4.65	0.35	7.15e-6	Hepatocellular carcinoma;
PAAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg23985595	chr17:80112537	CCDC57	0.45	5.67	0.42	6.89e-8	Life satisfaction;
PAAD	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.66	-6.45	-0.46	1.4e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs818427	0.656	rs818430	chr5:112219961	T/C	cg06941702	chr5:112196734	SRP19	0.53	5.05	0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.43	-4.39	-0.34	2.14e-5	Red cell distribution width;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13395698	chr11:74146974	NA	0.53	6.3	0.46	3.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.59	5.76	0.42	4.5e-8	Lung cancer;
PAAD	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	7.17	0.5	3e-11	Eye color traits;
PAAD	cis	rs10044254	0.563	rs4701641	chr5:15697062	C/T	cg07238450	chr5:15720153	FBXL7	-0.58	-5.44	-0.4	2.06e-7	Asthma (corticosteroid response);
PAAD	cis	rs73019876	0.869	rs4932723	chr19:22180721	C/G	cg11619707	chr19:22235551	ZNF257	-0.41	-4.41	-0.34	1.91e-5	Testicular germ cell tumor;
PAAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.1	-0.5	4.53e-11	Longevity;Endometriosis;
PAAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.84	-8.21	-0.55	9.03e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.68	-0.35	6.27e-6	Lung cancer;
PAAD	cis	rs7172971	0.592	rs78171718	chr15:42386342	C/T	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.58	-6.21	-0.45	4.76e-9	Pelvic organ prolapse;
PAAD	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.7	0.48	3.78e-10	Resting heart rate;
PAAD	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.66	-6.98	-0.49	8.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10991814	1.000	rs16907277	chr9:93972658	A/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.68	6.74	0.48	3.03e-10	Uric acid levels;
PAAD	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.98	9.98	0.63	2.4e-18	Post bronchodilator FEV1;
PAAD	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.74	7.53	0.52	4.3e-12	Obesity-related traits;
PAAD	cis	rs300774	0.925	rs300740	chr2:164169	G/A	cg23649280	chr2:140451	NA	-0.47	-4.37	-0.33	2.31e-5	Suicide attempts in bipolar disorder;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.63	7.19	0.5	2.71e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-4.42	-0.34	1.87e-5	Tonsillectomy;
PAAD	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg02917321	chr22:38215204	NA	0.49	4.72	0.36	5.24e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg00383909	chr3:49044727	WDR6	0.74	6.23	0.45	4.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg23855989	chr12:50355821	AQP5	0.53	5.54	0.41	1.33e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg20159608	chr7:32802032	NA	-0.51	-5.12	-0.38	8.94e-7	Metabolite levels (HVA/MHPG ratio);
PAAD	cis	rs9815354	0.812	rs794890	chr3:42062339	G/T	cg03022575	chr3:42003672	ULK4	-0.74	-5.33	-0.4	3.46e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg16898833	chr6:26189333	HIST1H4D	0.63	5.02	0.38	1.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.05e-13	Callous-unemotional behaviour;
PAAD	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma;
PAAD	cis	rs12447804	0.863	rs12929002	chr16:58085882	A/G	cg04270274	chr16:58662988	CNOT1	-0.55	-4.42	-0.34	1.87e-5	Pulmonary function;Pulmonary function (smoking interaction);
PAAD	cis	rs7250872	0.606	rs1078229	chr19:1826383	A/C	cg10370574	chr19:1840461	REXO1	-0.5	-4.64	-0.35	7.32e-6	Bipolar disorder;
PAAD	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg19442545	chr10:75533431	FUT11	-0.5	-5.28	-0.39	4.46e-7	Inflammatory bowel disease;
PAAD	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-1.27	-7.78	-0.53	1.03e-12	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs2587695	0.967	rs2579618	chr2:120288463	T/G	cg05839767	chr2:119914248	C1QL2	-0.41	-4.25	-0.33	3.71e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.77	8.11	0.55	1.54e-13	Coronary artery disease;
PAAD	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-4.66	-0.35	6.92e-6	Glomerular filtration rate;
PAAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26796135	chr15:45671001	LOC145663;GATM	0.49	4.39	0.34	2.12e-5	Homoarginine levels;
PAAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg03233332	chr7:66118400	NA	0.41	4.47	0.34	1.52e-5	Aortic root size;
PAAD	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.82	4.57	0.35	1.02e-5	Severe influenza A (H1N1) infection;
PAAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.52	6.86	0.49	1.65e-10	Hypertriglyceridemia;
PAAD	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.91	12.07	0.7	6.12e-24	Body mass index;
PAAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg07202610	chr7:1142643	C7orf50	-0.54	-4.64	-0.35	7.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	1.03	7.12	0.5	4.02e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs3867498	0.943	rs35816817	chr15:25071549	T/G	cg08194505	chr15:25684383	UBE3A	-0.63	-4.52	-0.34	1.22e-5	Pulmonary function;
PAAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg15571903	chr15:79123663	NA	-0.44	-5.74	-0.42	5.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.72	5.2	0.39	6.23e-7	Plateletcrit;
PAAD	cis	rs6686423	0.543	rs72704579	chr1:157392393	G/A	cg24251193	chr1:156676542	CRABP2	-0.44	-4.31	-0.33	2.91e-5	Renal sinus fat;
PAAD	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg01338084	chr22:32026380	PISD	1.62	8.6	0.57	8.93e-15	Age-related hearing impairment;
PAAD	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.5	5.93	0.43	2e-8	Rheumatoid arthritis;
PAAD	cis	rs2004318	1.000	rs2781771	chr19:55142300	A/G	cg03320607	chr19:54800032	LILRA3	-1.18	-6.67	-0.48	4.49e-10	Blood protein levels;
PAAD	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.67	7.46	0.52	6.19e-12	Prostate cancer;
PAAD	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.73	-8.12	-0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-4.81	-0.36	3.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.42	-5.68	-0.42	6.52e-8	Abdominal aortic aneurysm;
PAAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg05110241	chr16:68378359	PRMT7	-1.14	-8.31	-0.56	5e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs16975963	0.793	rs73027418	chr19:38361020	C/T	cg08679971	chr19:38281047	NA	0.55	5.18	0.39	6.92e-7	Longevity;
PAAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg02462569	chr6:150064036	NUP43	-0.51	-5.93	-0.43	1.96e-8	Lung cancer;
PAAD	cis	rs11700980	0.551	rs2832029	chr21:30114574	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.0	-0.38	1.58e-6	QRS complex (12-leadsum);
PAAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.47	4.81	0.36	3.56e-6	Red cell distribution width;
PAAD	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.93	-12.59	-0.71	2.42e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg27234864	chr13:21295941	IL17D	0.61	5.29	0.39	4.28e-7	Dental caries;
PAAD	cis	rs7577696	0.505	rs539213	chr2:31876492	G/A	cg02381751	chr2:32503542	YIPF4	0.45	4.26	0.33	3.51e-5	Inflammatory biomarkers;
PAAD	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.88	-10.8	-0.66	1.55e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg11601000	chr22:42348013	LOC339674	0.42	4.76	0.36	4.56e-6	Cognitive function;
PAAD	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg14393609	chr7:65229607	NA	0.45	4.48	0.34	1.47e-5	Aortic root size;
PAAD	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.85	9.66	0.62	1.68e-17	Lewy body disease;
PAAD	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg22467129	chr15:76604101	ETFA	0.51	4.76	0.36	4.42e-6	Blood metabolite levels;
PAAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12516959	chr21:47718080	NA	0.44	4.34	0.33	2.58e-5	Testicular germ cell tumor;
PAAD	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	7.75	0.53	1.25e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.95	-13.17	-0.73	6.71e-27	Height;
PAAD	cis	rs7568498	0.517	rs197261	chr2:161904823	A/G	cg16506815	chr2:162101123	NA	-0.53	-5.14	-0.38	8.44e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg09324608	chr17:30823087	MYO1D	-0.44	-4.41	-0.34	1.94e-5	Schizophrenia;
PAAD	cis	rs7116495	0.609	rs1791456	chr11:71594888	G/C	cg10381502	chr11:71823885	C11orf51	1.05	5.18	0.39	7.05e-7	Severe influenza A (H1N1) infection;
PAAD	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.74	7.93	0.54	4.49e-13	Blood protein levels;
PAAD	cis	rs2997447	0.706	rs12062488	chr1:26466253	G/A	cg24519413	chr1:26490540	NA	0.58	5.21	0.39	5.95e-7	QRS complex (12-leadsum);
PAAD	cis	rs375066	0.935	rs388685	chr19:44418680	C/G	cg08633290	chr19:44405433	NA	-0.55	-5.42	-0.4	2.31e-7	Breast cancer;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg06629702	chr1:2706960	NA	0.36	4.3	0.33	3.03e-5	Ulcerative colitis;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05040891	chr16:15744639	NDE1	-0.76	-7.47	-0.52	5.87e-12	Lung cancer in ever smokers;
PAAD	cis	rs2446066	0.872	rs7300593	chr12:53790450	T/C	cg20591337	chr12:53693442	C12orf10	-0.63	-4.47	-0.34	1.49e-5	Red blood cell count;
PAAD	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00982548	chr2:198649783	BOLL	-0.64	-4.34	-0.33	2.58e-5	Ulcerative colitis;
PAAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	8.42	0.56	2.56e-14	Hip circumference adjusted for BMI;
PAAD	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.51	-4.74	-0.36	4.82e-6	Menarche (age at onset);
PAAD	cis	rs7684253	0.548	rs922570	chr4:57717358	C/T	cg24291500	chr4:57773398	REST	-0.45	-4.74	-0.36	4.87e-6	Migraine;
PAAD	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg10864074	chr7:100318194	EPO	0.45	5.3	0.4	3.93e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.82	6.41	0.46	1.77e-9	Axial length;
PAAD	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	6.3	0.46	2.99e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.63	7.18	0.5	2.89e-11	Emphysema distribution in smoking;
PAAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-7.26	-0.51	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23949612	chr12:70636659	CNOT2	-0.69	-6.38	-0.46	1.99e-9	Neuroticism;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.49	5.4	0.4	2.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs56309584	0.755	rs12603646	chr17:8138643	A/C	cg25053252	chr17:7589358	TP53;WRAP53	-0.44	-4.43	-0.34	1.76e-5	Initial pursuit acceleration;
PAAD	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.42	-0.46	1.61e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22482690	chr17:47019901	SNF8	0.48	5.18	0.39	6.81e-7	Type 2 diabetes;
PAAD	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs11807834	0.522	rs12083455	chr1:230253034	C/T	cg09847368	chr1:230250326	GALNT2	-0.69	-8.5	-0.57	1.67e-14	Schizophrenia;
PAAD	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	cis	rs17152411	0.625	rs4962713	chr10:126654536	A/T	cg04726013	chr10:126223236	LHPP	-0.31	-4.52	-0.34	1.23e-5	Height;
PAAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.91	0.69	1.58e-23	Platelet count;
PAAD	cis	rs7873102	0.654	rs10814636	chr9:37991699	G/A	cg03528946	chr9:38069800	SHB	-0.5	-5.07	-0.38	1.12e-6	Brain structure;
PAAD	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg06599209	chr2:1746509	PXDN	0.25	4.27	0.33	3.47e-5	Response to antipsychotic treatment;
PAAD	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg04450456	chr4:17643702	FAM184B	0.47	5.05	0.38	1.25e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.52	-4.96	-0.37	1.86e-6	Multiple sclerosis;
PAAD	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg08648136	chr8:956695	NA	0.43	4.59	0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.77	8.56	0.57	1.16e-14	Schizophrenia;
PAAD	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg10932868	chr11:921992	NA	0.5	5.92	0.43	2.11e-8	Alzheimer's disease (late onset);
PAAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.94	12.25	0.7	1.93e-24	Menopause (age at onset);
PAAD	cis	rs988913	0.957	rs4712081	chr6:54756529	A/G	cg03513858	chr6:54763001	FAM83B	0.45	4.98	0.37	1.71e-6	Menarche (age at onset);
PAAD	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg12661370	chr5:149340060	SLC26A2	0.68	6.6	0.47	6.61e-10	HIV-1 control;
PAAD	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg06028605	chr16:24865363	SLC5A11	-0.38	-5.0	-0.38	1.53e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.82	10.32	0.64	2.95e-19	Bone mineral density;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg10534938	chr5:1868639	NA	0.47	6.03	0.44	1.2e-8	Cardiovascular disease risk factors;
PAAD	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-8.71	-0.58	4.8e-15	Lung function (FVC);
PAAD	cis	rs1903068	0.925	rs1551645	chr4:55994314	T/G	cg01777861	chr4:56023843	NA	0.36	4.3	0.33	3.06e-5	Endometriosis;
PAAD	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.45	5.83	0.43	3.27e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	5.68	0.42	6.54e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-11.07	-0.67	3.01e-21	Sudden cardiac arrest;
PAAD	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg01631408	chr1:248437212	OR2T33	0.61	5.43	0.4	2.21e-7	Common traits (Other);
PAAD	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.75	-8.63	-0.57	7.85e-15	White blood cell count (basophil);
PAAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg12623918	chr2:306882	NA	0.47	4.96	0.37	1.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.53	6.77	0.48	2.61e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg04545296	chr12:48745243	ZNF641	0.36	4.41	0.34	1.91e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs939584	1.000	rs13007080	chr2:630024	A/C	cg03610516	chr2:642275	NA	0.63	5.45	0.4	2.03e-7	Body mass index;
PAAD	cis	rs12760731	0.623	rs12038759	chr1:178262700	A/C	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.94	7.27	0.51	1.74e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-5.57	-0.41	1.13e-7	Bladder cancer;
PAAD	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs1879734	0.521	rs1879731	chr1:54175861	G/A	cg14659662	chr1:54151053	GLIS1	-0.39	-5.51	-0.41	1.53e-7	Mitral valve prolapse;
PAAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-6.06	-0.44	1.05e-8	Bipolar disorder and schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03016189	chr15:75744035	SIN3A	-0.75	-6.94	-0.49	1.09e-10	Neuroticism;
PAAD	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg07384165	chr1:10488281	NA	-0.51	-5.15	-0.39	7.87e-7	Prostate cancer;
PAAD	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.43	5.68	0.42	6.66e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.88	-10.09	-0.63	1.25e-18	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13146426	chr11:122932858	HSPA8	0.64	7.31	0.51	1.43e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs507080	0.922	rs546890	chr11:118557198	T/C	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.16e-8	Life satisfaction;
PAAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.71	6.37	0.46	2.16e-9	Obesity-related traits;
PAAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg25456477	chr12:86230367	RASSF9	0.48	4.25	0.33	3.76e-5	Major depressive disorder;
PAAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.87	10.64	0.65	4.19e-20	Prudent dietary pattern;
PAAD	cis	rs7180079	1.000	rs8031895	chr15:64487863	C/A	cg18210365	chr15:65066710	RBPMS2	-0.61	-4.44	-0.34	1.75e-5	Monocyte count;
PAAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.58	5.95	0.43	1.77e-8	Testicular germ cell tumor;
PAAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.76	8.82	0.58	2.45e-15	Height;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.48	4.49	0.34	1.41e-5	Educational attainment (years of education);
PAAD	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg15598662	chr11:61582890	MIR1908;FADS1	0.53	4.73	0.36	5.15e-6	Trans fatty acid levels;
PAAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.81	-0.43	3.51e-8	Lung cancer;
PAAD	cis	rs13006833	0.739	rs6434387	chr2:191205969	C/T	cg27211696	chr2:191398769	TMEM194B	0.46	4.53	0.34	1.2e-5	Urinary metabolites;
PAAD	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg11335335	chr11:637885	DRD4	-0.36	-4.46	-0.34	1.56e-5	Systemic lupus erythematosus;
PAAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.73	-7.38	-0.51	9.8e-12	Neurofibrillary tangles;
PAAD	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg21523528	chr20:32077966	CBFA2T2	0.52	4.35	0.33	2.5e-5	Height;
PAAD	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.12e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.63	-5.68	-0.42	6.54e-8	Corneal astigmatism;
PAAD	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg03871329	chr12:110338662	TCHP	-0.68	-5.05	-0.38	1.25e-6	Neuroticism;
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg00786201	chr11:61583134	MIR1908;FADS1	0.51	4.37	0.33	2.3e-5	Trans fatty acid levels;
PAAD	cis	rs2229238	0.911	rs4633282	chr1:154507899	T/C	cg21262032	chr1:154437693	IL6R	-0.46	-4.89	-0.37	2.53e-6	Coronary heart disease;
PAAD	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.83	10.0	0.63	2.07e-18	Blood metabolite ratios;
PAAD	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg22143635	chr11:980567	AP2A2	0.53	5.61	0.41	9.36e-8	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.79	-8.74	-0.58	4.07e-15	Aortic root size;
PAAD	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.56	-5.95	-0.43	1.78e-8	White matter hyperintensity burden;
PAAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.47	-5.1	-0.38	9.93e-7	Motion sickness;
PAAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.51	5.29	0.39	4.26e-7	Longevity;Endometriosis;
PAAD	cis	rs12044355	0.827	rs10429978	chr1:231823662	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	5.87	0.43	2.59e-8	Alzheimer's disease;
PAAD	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg02743256	chr7:2109353	MAD1L1	-0.62	-4.73	-0.36	5.01e-6	Bipolar disorder;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02954052	chr3:194324527	TMEM44	0.67	6.74	0.48	3.12e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.57	-0.41	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg17385448	chr1:15911702	AGMAT	0.36	4.45	0.34	1.65e-5	Systolic blood pressure;
PAAD	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.77	7.56	0.52	3.5e-12	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg17848003	chr1:3704513	LRRC47	0.41	4.41	0.34	1.96e-5	Red cell distribution width;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20803783	chr1:6673301	PHF13	-0.62	-6.31	-0.46	2.94e-9	Smoking initiation;
PAAD	cis	rs2133450	0.712	rs28368666	chr3:7367258	C/G	cg19930620	chr3:7340148	GRM7	-0.48	-5.25	-0.39	5.09e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3733346	0.510	rs6815138	chr4:941290	A/C	cg15105011	chr4:940614	TMEM175	0.66	7.85	0.54	6.83e-13	Sjögren's syndrome;
PAAD	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.69	6.89	0.49	1.41e-10	Morning vs. evening chronotype;
PAAD	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.64	-4.48	-0.34	1.49e-5	LDL cholesterol levels;
PAAD	cis	rs7429990	0.901	rs7374482	chr3:48168390	A/G	cg11946769	chr3:48343235	NME6	-0.54	-5.36	-0.4	3.03e-7	Educational attainment (years of education);
PAAD	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg09796270	chr17:17721594	SREBF1	-0.47	-5.0	-0.38	1.54e-6	Body mass index;
PAAD	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.62	5.65	0.42	7.68e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.49	-0.34	1.37e-5	Life satisfaction;
PAAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.76	-8.52	-0.57	1.43e-14	Childhood ear infection;
PAAD	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.81	8.99	0.59	9.23e-16	Bipolar disorder;
PAAD	cis	rs6137287	0.924	rs2328608	chr20:21153138	G/A	cg04219410	chr20:21106687	PLK1S1	0.41	4.66	0.35	6.92e-6	Height;
PAAD	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.76	8.88	0.58	1.79e-15	Morning vs. evening chronotype;
PAAD	cis	rs3857067	1.000	rs1509943	chr4:95013366	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-5.28	-0.39	4.33e-7	QT interval;
PAAD	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.71	7.51	0.52	4.76e-12	Mean corpuscular volume;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	Myopia (pathological);
PAAD	cis	rs7671266	0.532	rs28730480	chr4:10048867	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.54	0.35	1.14e-5	Cardiovascular disease risk factors;
PAAD	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.96	-11.36	-0.68	4.8e-22	Chronic sinus infection;
PAAD	cis	rs12304921	1.000	rs58999537	chr12:51357104	A/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg16342193	chr10:102329863	NA	-0.79	-8.6	-0.57	8.92e-15	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.8	-12.1	-0.7	5.01e-24	Endometriosis;
PAAD	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.67	7.18	0.5	2.97e-11	Testicular germ cell tumor;
PAAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.65	7.81	0.54	8.47e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.59	5.92	0.43	2.08e-8	Acylcarnitine levels;
PAAD	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg05791153	chr7:19748676	TWISTNB	0.73	5.29	0.39	4.28e-7	Thyroid stimulating hormone;
PAAD	cis	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg21775007	chr8:11205619	TDH	-0.48	-4.45	-0.34	1.66e-5	Neuroticism;
PAAD	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.75	-7.83	-0.54	7.97e-13	Obesity-related traits;
PAAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18621852	chr3:10150065	C3orf24	0.65	5.87	0.43	2.64e-8	Alzheimer's disease;
PAAD	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg15145965	chr22:50218605	BRD1	0.71	4.37	0.33	2.25e-5	Schizophrenia;
PAAD	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.38	4.62	0.35	7.97e-6	Tonsillectomy;
PAAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.87	-9.77	-0.62	8.32e-18	Cancer (pleiotropy);
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	5.57	0.41	1.12e-7	Renal function-related traits (BUN);
PAAD	cis	rs1012068	0.624	rs4820997	chr22:32324140	C/T	cg01338084	chr22:32026380	PISD	0.57	5.03	0.38	1.36e-6	Chronic hepatitis C infection;
PAAD	cis	rs11671653	0.688	rs79011483	chr19:10852708	T/A	cg16667279	chr19:11591998	ELAVL3	-0.71	-4.7	-0.36	5.9e-6	LDL cholesterol;
PAAD	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.39	-0.4	2.63e-7	Total cholesterol levels;
PAAD	cis	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg06057569	chr22:50219754	BRD1	0.61	4.48	0.34	1.47e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs4780401	0.755	rs8049633	chr16:11768810	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-5.92	-0.43	2.08e-8	Rheumatoid arthritis;
PAAD	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg18084798	chr19:33555255	RHPN2	0.47	4.92	0.37	2.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg13525197	chr6:28411240	ZSCAN23	0.38	4.43	0.34	1.82e-5	Pubertal anthropometrics;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13531509	chr10:79793353	RPS24	-0.66	-6.62	-0.47	5.81e-10	Lung cancer in ever smokers;
PAAD	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-4.27	-0.33	3.38e-5	Bipolar disorder;
PAAD	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.77	9.21	0.6	2.41e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.29	0.56	5.49e-14	Morning vs. evening chronotype;
PAAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.59	-4.83	-0.36	3.35e-6	Gut microbiome composition (summer);
PAAD	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	1.04	7.14	0.5	3.58e-11	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.61	6.2	0.45	5.01e-9	Blood metabolite levels;
PAAD	cis	rs9314614	0.872	rs2951864	chr8:6709922	G/C	cg27319216	chr8:6693540	XKR5	-0.35	-4.79	-0.36	3.88e-6	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs7192380	0.624	rs11075730	chr16:69650522	C/T	cg05250797	chr16:70222502	NA	0.65	5.72	0.42	5.43e-8	Sjögren's syndrome;
PAAD	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.55	-6.5	-0.47	1.08e-9	Urate levels in overweight individuals;
PAAD	cis	rs34845616	0.514	rs4937835	chr11:133691060	G/C	cg06067394	chr11:133789110	IGSF9B	0.41	4.28	0.33	3.33e-5	Hand grip strength;
PAAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.71	-8.23	-0.56	8.01e-14	Height;
PAAD	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.62	-5.94	-0.43	1.89e-8	Fractional excretion of uric acid;
PAAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.48	-0.52	5.47e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.72	-7.1	-0.5	4.5e-11	Retinal vascular caliber;
PAAD	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.93	6.15	0.45	6.51e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4740619	0.716	rs9969817	chr9:15954123	T/A	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	4.28	0.33	3.29e-5	Coronary artery disease;
PAAD	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.74	7.9	0.54	5.18e-13	Menopause (age at onset);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00713605	chr2:232063387	ARMC9	0.57	6.34	0.46	2.51e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.71	7.47	0.52	5.98e-12	Cognitive function;
PAAD	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.8	7.83	0.54	7.73e-13	Vitamin D levels;
PAAD	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.58	-5.77	-0.42	4.3e-8	Height;
PAAD	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.61	-6.71	-0.48	3.71e-10	Schizophrenia;
PAAD	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.4	-0.51	8.56e-12	Morning vs. evening chronotype;
PAAD	cis	rs11718455	0.767	rs13075535	chr3:43954612	G/A	cg21419209	chr3:44054225	NA	-0.69	-6.73	-0.48	3.24e-10	Coronary artery disease;
PAAD	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg07423050	chr13:99094983	FARP1	0.38	4.28	0.33	3.34e-5	Longevity;
PAAD	cis	rs8181166	0.637	rs790549	chr9:89097532	G/A	cg14198768	chr9:89109504	NA	-0.29	-4.52	-0.34	1.21e-5	Height;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.94	12.81	0.72	5.99e-26	Prudent dietary pattern;
PAAD	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs1529711	0.500	rs11672991	chr19:10907425	T/A	cg18543610	chr13:100627929	NA	-0.63	-6.34	-0.46	2.43e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
PAAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg21770322	chr7:97807741	LMTK2	0.74	11.62	0.69	9.52e-23	Breast cancer;
PAAD	cis	rs2882667	0.690	rs288013	chr5:138195817	A/G	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.56	5.5	0.41	1.56e-7	Free thyroxine concentration;
PAAD	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.5	-6.2	-0.45	5e-9	Menopause (age at onset);
PAAD	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.54	5.16	0.39	7.59e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.64e-8	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04444761	chr8:126442446	TRIB1	-0.72	-7.71	-0.53	1.57e-12	Smoking initiation;
PAAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg05110241	chr16:68378359	PRMT7	-1.15	-8.78	-0.58	3.23e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg15691649	chr6:25882328	NA	0.51	4.59	0.35	9.34e-6	Blood metabolite levels;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	4.78	0.36	4.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.46	4.68	0.35	6.28e-6	Type 2 diabetes;
PAAD	cis	rs990171	0.506	rs6543107	chr2:102750730	A/T	cg22835712	chr2:102737379	NA	0.53	5.4	0.4	2.46e-7	Lymphocyte counts;
PAAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.54	7.1	0.5	4.55e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg01320130	chr1:67600311	NA	0.56	6.35	0.46	2.42e-9	Psoriasis;
PAAD	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-1.23	-7.55	-0.52	3.77e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg14500798	chr7:98100126	NA	0.43	4.56	0.35	1.03e-5	Breast cancer;
PAAD	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg01304814	chr3:48885189	PRKAR2A	0.67	4.55	0.35	1.09e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.44	-0.46	1.49e-9	Bipolar disorder;
PAAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.59	6.34	0.46	2.52e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	1.08	7.09	0.5	4.71e-11	IgG glycosylation;
PAAD	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg03999872	chr20:62272968	STMN3	-0.76	-7.08	-0.5	4.94e-11	Atopic dermatitis;
PAAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.6	6.2	0.45	5.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.87	9.56	0.61	2.98e-17	Cognitive function;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.94	12.62	0.72	1.95e-25	Prudent dietary pattern;
PAAD	cis	rs73206853	0.563	rs1050587	chr12:111158161	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	4.94	0.37	2.04e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg01028140	chr2:1542097	TPO	-0.87	-6.49	-0.47	1.13e-9	Placebo response in major depressive disorder (% change in symptom score);
PAAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.64	-8.14	-0.55	1.29e-13	Coronary artery disease;
PAAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.17	-0.39	7.27e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-5.51	-0.41	1.51e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs17592366	0.517	rs7147621	chr14:35275704	G/A	cg09327582	chr14:35236912	BAZ1A	0.56	5.14	0.38	8.32e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
PAAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.74	10.03	0.63	1.75e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg05313129	chr8:58192883	C8orf71	-0.61	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.85	0.54	7.02e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.85	0.58	2.11e-15	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.68	8.41	0.56	2.71e-14	Dupuytren's disease;
PAAD	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-5.45	-0.4	1.96e-7	Schizophrenia;
PAAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06217245	chr20:33103252	DYNLRB1	0.37	4.47	0.34	1.54e-5	Glomerular filtration rate (creatinine);
PAAD	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	1.03	7.25	0.51	2e-11	Alzheimer's disease;
PAAD	cis	rs1198430	0.925	rs7534474	chr1:23773851	A/G	cg22040403	chr1:23858016	E2F2	0.74	4.71	0.36	5.51e-6	Total cholesterol levels;
PAAD	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.79	9.48	0.61	4.92e-17	Brugada syndrome;
PAAD	cis	rs7818688	0.697	rs78088250	chr8:95972718	G/A	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.85	11.97	0.7	1.1e-23	Vitiligo;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.77	8.54	0.57	1.27e-14	Lung cancer;
PAAD	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.42	-5.75	-0.42	4.83e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.62	-7.16	-0.5	3.18e-11	Huntington's disease progression;
PAAD	cis	rs3733418	0.860	rs11942750	chr4:165930299	G/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-4.8	-0.36	3.8e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.11	0.44	7.88e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2446066	0.872	rs10876452	chr12:53814258	T/A	cg20591337	chr12:53693442	C12orf10	-0.64	-4.4	-0.34	2.04e-5	Red blood cell count;
PAAD	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	-0.49	-4.26	-0.33	3.61e-5	Resistin levels;
PAAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg14343924	chr8:8086146	FLJ10661	-0.56	-5.16	-0.39	7.52e-7	Joint mobility (Beighton score);
PAAD	cis	rs2033908	0.620	rs1992334	chr11:12851645	C/T	cg25843174	chr11:12811716	TEAD1	-0.36	-4.87	-0.37	2.83e-6	Sitting height ratio;
PAAD	cis	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.67	-0.35	6.55e-6	Eotaxin levels;
PAAD	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg26935685	chr1:15502881	TMEM51	-0.53	-4.54	-0.35	1.14e-5	Systolic blood pressure;
PAAD	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.43	4.29	0.33	3.16e-5	Lung cancer;
PAAD	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-5.46	-0.4	1.9e-7	Ulcerative colitis;
PAAD	cis	rs76793172	1.000	rs61703905	chr19:46370301	C/T	cg13320842	chr19:46175254	GIPR	0.62	4.7	0.36	5.86e-6	Eosinophil counts;
PAAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.67	-4.55	-0.35	1.08e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.91	-0.49	1.27e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.5	4.68	0.35	6.36e-6	Dilated cardiomyopathy;
PAAD	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg26898376	chr11:64110657	CCDC88B	0.55	5.85	0.43	2.85e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs139515701	1	rs139515701	chr10:5219539	G/C	cg13585175	chr10:5228106	AKR1CL1	0.57	5.0	0.38	1.55e-6	Pursuit maintenance gain;
PAAD	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg12560992	chr17:57184187	TRIM37	0.66	5.26	0.39	4.81e-7	Vitamin D levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21858106	chr21:46974883	NA	0.63	6.46	0.46	1.35e-9	Obesity-related traits;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15898408	chr1:161720174	DUSP12	0.55	6.31	0.46	2.85e-9	Energy expenditure (24h);
PAAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.83	-9.04	-0.59	6.89e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-5.44	-0.4	2.13e-7	Aortic root size;
PAAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg25036284	chr2:26402008	FAM59B	0.57	4.45	0.34	1.68e-5	Gut microbiome composition (summer);
PAAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.98	0.54	3.36e-13	Prudent dietary pattern;
PAAD	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.15	0.39	8.12e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg18939081	chr1:31884902	SERINC2	-0.47	-5.49	-0.41	1.65e-7	Alcohol dependence;
PAAD	cis	rs858239	0.829	rs2268744	chr7:23332280	C/T	cg27449745	chr7:23145252	KLHL7	-0.52	-4.45	-0.34	1.63e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg07841815	chr7:100318223	EPO	-0.52	-4.95	-0.37	1.93e-6	Other erythrocyte phenotypes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26934072	chr16:2033910	GFER	-0.78	-6.74	-0.48	3.06e-10	Neuroticism;
PAAD	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.99	5.2	0.39	6.43e-7	Childhood ear infection;
PAAD	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07234876	chr8:600039	NA	-1.07	-6.52	-0.47	9.96e-10	IgG glycosylation;
PAAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg10072921	chr12:121022843	NA	-0.43	-5.24	-0.39	5.33e-7	Type 1 diabetes nephropathy;
PAAD	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg07099767	chr17:78039528	CCDC40	-0.55	-4.82	-0.36	3.41e-6	Yeast infection;
PAAD	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg05935833	chr10:81318306	SFTPA2	-0.7	-4.83	-0.36	3.36e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13418717	1.000	rs10496658	chr2:127663497	C/T	cg16909742	chr2:127635678	NA	0.86	4.29	0.33	3.15e-5	Heart failure;
PAAD	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.82	-7.67	-0.53	1.87e-12	Blood metabolite levels;
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg11766577	chr21:47581405	C21orf56	-0.38	-4.5	-0.34	1.35e-5	Testicular germ cell tumor;
PAAD	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg15212455	chr7:39170539	POU6F2	0.36	5.33	0.4	3.56e-7	IgG glycosylation;
PAAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg21929781	chr1:2537748	MMEL1	0.5	5.24	0.39	5.17e-7	Ulcerative colitis;
PAAD	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.8	0.66	1.51e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs2327429	0.827	rs1535616	chr6:134171132	C/T	cg06296503	chr6:134217401	NA	0.5	5.12	0.38	8.98e-7	Coronary artery disease;
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg27394845	chr17:28928406	LRRC37B2	0.73	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg00001793	chr12:11905390	ETV6	0.55	6.43	0.46	1.53e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6700896	0.864	rs12030956	chr1:66115298	G/T	cg04111102	chr1:66153794	NA	0.49	5.57	0.41	1.14e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-4.41	-0.34	1.98e-5	IgG glycosylation;
PAAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.62	6.09	0.44	8.66e-9	Blood protein levels;
PAAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12165864	chr7:66369176	NA	-0.77	-4.95	-0.37	1.94e-6	Diabetic kidney disease;
PAAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	5.1	0.38	9.81e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10792830	0.707	rs579406	chr11:85657759	A/C	cg07180834	chr11:85838833	NA	-0.45	-5.25	-0.39	4.97e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.86	9.7	0.62	1.31e-17	Multiple system atrophy;
PAAD	cis	rs1015291	0.708	rs10770561	chr12:19999041	C/T	cg25401612	chr12:20009446	NA	0.56	5.46	0.4	1.94e-7	Diastolic blood pressure;
PAAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.52	-5.19	-0.39	6.76e-7	IgG glycosylation;
PAAD	cis	rs3763048	0.963	rs6894522	chr5:169456788	G/A	cg01585372	chr5:169931363	KCNIP1	-0.43	-4.28	-0.33	3.27e-5	IgG glycosylation;
PAAD	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.62	-5.42	-0.4	2.32e-7	Coronary artery disease;
PAAD	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg13476313	chr9:127244764	NR5A1	-0.31	-4.81	-0.36	3.53e-6	Menarche (age at onset);
PAAD	trans	rs901683	0.850	rs75748332	chr10:46065143	A/C	cg11747279	chr17:21096632	NA	0.9	6.56	0.47	7.91e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg16606324	chr3:10149918	C3orf24	0.57	4.82	0.36	3.47e-6	Alzheimer's disease;
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg05082376	chr22:42548792	NA	-0.51	-5.48	-0.41	1.76e-7	Cognitive function;
PAAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.67	6.91	0.49	1.26e-10	Schizophrenia;
PAAD	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg12568669	chr8:11666485	FDFT1	0.31	5.41	0.4	2.37e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.52e-5	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01244034	chr16:25078253	NA	0.61	6.74	0.48	3.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.52	0.57	1.43e-14	Bipolar disorder;
PAAD	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg27478167	chr7:817139	HEATR2	-0.64	-4.97	-0.37	1.79e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.94	-6.17	-0.45	5.89e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg06346307	chr22:19949965	COMT	-0.31	-4.78	-0.36	4.09e-6	Blood metabolite levels;
PAAD	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.1	-8.57	-0.57	1.1e-14	Vitiligo;
PAAD	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	5.21	0.39	6.06e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs8102137	1.000	rs59592823	chr19:30297516	A/G	cg27475126	chr19:30303651	CCNE1	-0.46	-5.1	-0.38	1e-6	Bladder cancer;
PAAD	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg13482628	chr17:19912719	NA	0.52	5.0	0.38	1.59e-6	Schizophrenia;
PAAD	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg20302533	chr7:39170763	POU6F2	0.36	5.16	0.39	7.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	5.49	0.41	1.68e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs346785	0.692	rs2279057	chr17:74309425	A/G	cg09812376	chr17:74270190	QRICH2	-0.45	-5.84	-0.43	3.12e-8	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-4.93	-0.37	2.15e-6	Blood metabolite levels;
PAAD	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-6.29	-0.45	3.24e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg27129171	chr3:47204927	SETD2	0.8	8.33	0.56	4.33e-14	Birth weight;
PAAD	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.39	4.93	0.37	2.16e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9810890	1.000	rs16851607	chr3:128570263	G/C	cg15676455	chr3:128564943	NA	-0.69	-4.47	-0.34	1.49e-5	Dental caries;
PAAD	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg00631329	chr6:26305371	NA	-0.45	-4.69	-0.36	5.97e-6	Educational attainment;
PAAD	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg06096015	chr1:231504339	EGLN1	-0.7	-9.45	-0.61	5.83e-17	Hemoglobin concentration;
PAAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg00206168	chr11:65308501	LTBP3	1.54	8.86	0.58	1.93e-15	Height;
PAAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.66	6.76	0.48	2.83e-10	Menarche (age at onset);
PAAD	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.88	-11.07	-0.67	2.98e-21	Total body bone mineral density;
PAAD	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg13047869	chr3:10149882	C3orf24	0.66	5.19	0.39	6.66e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg13047869	chr3:10149882	C3orf24	0.96	7.29	0.51	1.61e-11	Alzheimer's disease;
PAAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg09835421	chr16:68378352	PRMT7	-0.99	-7.44	-0.52	6.78e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.58	6.51	0.47	1.02e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6466055	0.589	rs10953475	chr7:104961873	A/G	cg04380332	chr7:105027541	SRPK2	0.5	4.97	0.37	1.79e-6	Schizophrenia;
PAAD	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg14146966	chr2:61757674	XPO1	0.38	4.65	0.35	7.24e-6	Tuberculosis;
PAAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.54	-6.17	-0.45	5.89e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg19761014	chr17:28927070	LRRC37B2	0.69	4.9	0.37	2.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-1.09	-15.22	-0.78	2.25e-32	Total body bone mineral density;
PAAD	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.58	0.41	1.08e-7	HDL cholesterol;
PAAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs3106136	0.534	rs13109764	chr4:95304506	T/C	cg11021082	chr4:95130006	SMARCAD1	0.52	4.9	0.37	2.42e-6	Capecitabine sensitivity;
PAAD	cis	rs735539	0.521	rs2763001	chr13:21378018	A/C	cg27499820	chr13:21296301	IL17D	0.52	4.73	0.36	5.16e-6	Dental caries;
PAAD	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.61	-5.87	-0.43	2.67e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.75	7.98	0.54	3.34e-13	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.37	6.3	0.46	3.04e-9	Skin colour saturation;
PAAD	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg21479132	chr6:26055353	NA	0.94	5.68	0.42	6.65e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.63	-0.35	7.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.38e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs597480	1.000	rs641393	chr11:85436352	G/A	cg11817631	chr11:85522609	SYTL2	-0.44	-4.26	-0.33	3.63e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.66	-7.19	-0.5	2.7e-11	Mean corpuscular volume;
PAAD	cis	rs11887277	0.900	rs1434058	chr2:27073853	T/C	cg12368169	chr2:27073192	DPYSL5	-0.45	-4.59	-0.35	9.04e-6	Obesity-related traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg22151941	chr17:1957066	HIC1	0.67	7.85	0.54	6.89e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg20744362	chr22:50050164	C22orf34	0.65	7.45	0.52	6.37e-12	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.75	7.57	0.52	3.39e-12	Prudent dietary pattern;
PAAD	cis	rs4343996	0.869	rs6949513	chr7:3496731	C/T	cg21248987	chr7:3385318	SDK1	0.5	5.66	0.42	7.23e-8	Motion sickness;
PAAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.68	0.35	6.38e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg18589874	chr11:47608310	FAM180B	0.43	4.26	0.33	3.52e-5	Subjective well-being;
PAAD	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.72	7.09	0.5	4.66e-11	HIV-1 control;
PAAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg10729496	chr3:10149963	C3orf24	0.78	6.13	0.44	7.4e-9	Alzheimer's disease;
PAAD	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.83	9.69	0.62	1.4e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.52	-4.92	-0.37	2.22e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.7	8.88	0.58	1.78e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs877529	0.934	rs139419	chr22:39557340	T/G	cg13455509	chr22:39551605	NA	-0.5	-4.9	-0.37	2.41e-6	Multiple myeloma;
PAAD	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg27455613	chr17:80820699	TBCD	-0.44	-4.35	-0.33	2.5e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.85	10.06	0.63	1.45e-18	Blood protein levels;
PAAD	cis	rs375066	0.935	rs396874	chr19:44397225	G/C	cg21496419	chr19:44306685	LYPD5	0.42	5.17	0.39	7.11e-7	Breast cancer;
PAAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.52	-5.53	-0.41	1.36e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg07883600	chr3:53528162	CACNA1D	0.41	4.36	0.33	2.36e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17051395	chr17:78644292	RPTOR	0.63	7.75	0.53	1.22e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg14631576	chr9:95140430	CENPP	-0.54	-5.3	-0.39	4.02e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15854668	chr3:124449432	UMPS	0.72	8.46	0.57	2.01e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.53	4.47	0.34	1.51e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	14.38	0.76	3.75e-30	Headache;
PAAD	cis	rs1499972	0.938	rs866001	chr3:117724023	G/A	cg07612923	chr3:117604196	NA	-0.99	-6.67	-0.48	4.56e-10	Schizophrenia;
PAAD	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	6.53	0.47	9.38e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.91	-12.0	-0.7	9.39e-24	Prudent dietary pattern;
PAAD	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.55	7.33	0.51	1.27e-11	Primary biliary cholangitis;
PAAD	cis	rs2033732	0.954	rs10808859	chr8:85085400	A/T	cg05716166	chr8:85095498	RALYL	-0.52	-4.79	-0.36	3.93e-6	Body mass index;
PAAD	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.96	-12.14	-0.7	3.85e-24	Refractive error;
PAAD	cis	rs1957429	1.000	rs1998333	chr14:65353632	A/G	cg23373153	chr14:65346875	NA	1.01	7.09	0.5	4.83e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.85	0.43	2.84e-8	Prudent dietary pattern;
PAAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-6.08	-0.44	9.32e-9	Personality dimensions;
PAAD	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.8	4.3	0.33	3.06e-5	Coronary artery disease;
PAAD	cis	rs13065560	0.534	rs9857724	chr3:38897005	C/T	cg01426195	chr3:39028469	NA	-0.46	-4.38	-0.34	2.16e-5	Interleukin-18 levels;
PAAD	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	4.97	0.37	1.8e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg23708337	chr7:1209742	NA	0.63	4.49	0.34	1.38e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.48	4.95	0.37	1.92e-6	QRS complex (12-leadsum);
PAAD	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg07777115	chr5:623756	CEP72	-0.67	-4.28	-0.33	3.27e-5	Obesity-related traits;
PAAD	cis	rs2882667	0.690	rs10038162	chr5:138236755	A/G	cg09476006	chr5:138032270	NA	-0.45	-5.66	-0.42	7.41e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-4.84	-0.37	3.13e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.66	-8.62	-0.57	8.07e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs883565	0.740	rs11708354	chr3:39115626	A/T	cg01426195	chr3:39028469	NA	-0.67	-7.13	-0.5	3.75e-11	Handedness;
PAAD	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.49	4.83	0.36	3.34e-6	Motion sickness;
PAAD	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05585630	chr7:157510462	PTPRN2	-0.78	-9.04	-0.59	6.93e-16	Bipolar disorder and schizophrenia;
PAAD	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-8.57	-0.57	1.11e-14	Electrocardiographic conduction measures;
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg04575393	chr19:53496094	ZNF702P	-0.5	-5.49	-0.41	1.68e-7	Psoriasis;
PAAD	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.34	-4.55	-0.35	1.08e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg18367735	chr17:79674897	NA	0.88	6.31	0.46	2.88e-9	Dental caries;
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.44	4.53	0.35	1.18e-5	Bipolar disorder;
PAAD	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg13565585	chr5:132299512	AFF4	0.68	5.17	0.39	7.28e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.4	-4.26	-0.33	3.53e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg15654264	chr1:150340011	RPRD2	0.52	5.09	0.38	1.06e-6	Migraine;
PAAD	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-4.31	-0.33	2.9e-5	Tuberculosis;
PAAD	cis	rs16975963	0.793	rs73041034	chr19:38286272	G/A	cg08679971	chr19:38281047	NA	0.51	4.9	0.37	2.48e-6	Longevity;
PAAD	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.81	0.43	3.57e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9395066	0.545	rs1831310	chr6:44976725	G/A	cg18551225	chr6:44695536	NA	-0.42	-4.42	-0.34	1.85e-5	Height;
PAAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.44e-10	Lung cancer;
PAAD	cis	rs35160687	0.644	rs4832276	chr2:86545018	A/G	cg10973622	chr2:86423274	IMMT	0.47	5.21	0.39	6.07e-7	Night sleep phenotypes;
PAAD	cis	rs8037137	0.731	rs78029804	chr15:91538920	C/T	cg23684204	chr15:91497937	RCCD1	0.86	5.17	0.39	7.26e-7	Platelet count;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
PAAD	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg00262122	chr8:11665843	FDFT1	-0.57	-5.16	-0.39	7.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.54	5.2	0.39	6.32e-7	Multiple myeloma;
PAAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg27182935	chr16:89790473	ZNF276	-0.86	-4.27	-0.33	3.46e-5	Skin colour saturation;
PAAD	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.57	6.09	0.44	8.73e-9	Schizophrenia;
PAAD	cis	rs12599426	0.850	rs71378680	chr16:35001646	G/A	cg08331635	chr16:34430078	NA	-0.63	-4.62	-0.35	8.3e-6	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.68	6.95	0.49	1.02e-10	Mood instability;
PAAD	cis	rs6074578	0.649	rs1935387	chr20:137127	A/G	cg16931068	chr20:139680	DEFB127	-0.38	-5.06	-0.38	1.19e-6	Hirschsprung disease;
PAAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.44e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	7.01	0.49	7.45e-11	Response to antipsychotic treatment;
PAAD	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.52	6.01	0.44	1.34e-8	QRS complex (12-leadsum);
PAAD	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.31	0.6	1.35e-16	Cognitive test performance;
PAAD	trans	rs901683	1.000	rs35750365	chr10:46013143	A/G	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.41	4.42	0.34	1.83e-5	Prevalent atrial fibrillation;
PAAD	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.71	8.29	0.56	5.7e-14	Metabolite levels;
PAAD	cis	rs6800435	0.920	rs3900076	chr3:10801251	C/T	cg00691123	chr3:11632974	VGLL4	0.61	4.48	0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.67	-6.06	-0.44	1.05e-8	Mean corpuscular volume;
PAAD	cis	rs6494488	0.500	rs7161793	chr15:64908682	G/C	cg16425858	chr15:64791681	ZNF609	0.93	5.05	0.38	1.22e-6	Coronary artery disease;
PAAD	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.44	-0.34	1.74e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg15117754	chr3:10150083	C3orf24	-0.7	-6.07	-0.44	9.61e-9	Alzheimer's disease;
PAAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg12436631	chr1:155007014	DCST1;DCST2	-0.37	-4.86	-0.37	2.95e-6	Prostate cancer;
PAAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.73	-8.38	-0.56	3.3e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-5.62	-0.42	8.71e-8	Electroencephalogram traits;
PAAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27297192	chr10:134578999	INPP5A	-0.58	-5.27	-0.39	4.7e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.72	6.18	0.45	5.76e-9	LDL cholesterol to HDL cholesterol ratio;
PAAD	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs939584	1.000	rs7571970	chr2:646849	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.5	-4.95	-0.37	1.91e-6	Multiple myeloma;
PAAD	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.83	8.62	0.57	8.03e-15	Corneal astigmatism;
PAAD	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24305970	chr3:93692925	PROS1	0.57	6.82	0.48	2.06e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.27	-14.32	-0.76	5.38e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.5	4.9	0.37	2.38e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg05250797	chr16:70222502	NA	0.8	6.4	0.46	1.85e-9	IgE levels;
PAAD	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg23024343	chr7:107201750	COG5	0.58	4.75	0.36	4.61e-6	Coronary artery disease;
PAAD	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	cis	rs9657904	0.865	rs11711088	chr3:105588069	G/A	cg16975614	chr3:105601834	NA	-0.45	-4.35	-0.33	2.49e-5	Multiple sclerosis;
PAAD	cis	rs926392	1.000	rs2867898	chr20:37690952	G/A	cg16355469	chr20:37678765	NA	0.45	4.27	0.33	3.39e-5	Dialysis-related mortality;
PAAD	cis	rs9304742	0.924	rs8111196	chr19:53457223	A/G	cg07559730	chr19:53497048	ZNF702P	-0.57	-6.16	-0.45	6.32e-9	Psoriasis;
PAAD	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.61	6.32	0.46	2.8e-9	High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.42	-6.17	-0.45	5.77e-9	Migraine;
PAAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg21565972	chr17:80109576	CCDC57	-0.57	-6.59	-0.47	6.71e-10	Life satisfaction;
PAAD	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.56	7.65	0.53	2.09e-12	IgA nephropathy;
PAAD	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg02640540	chr1:67518911	SLC35D1	0.53	4.6	0.35	8.74e-6	Lymphocyte percentage of white cells;
PAAD	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.56	-0.52	3.6e-12	Colorectal cancer;
PAAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.88	10.61	0.65	5.11e-20	Total body bone mineral density;
PAAD	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg03528137	chr13:111589969	NA	0.66	6.52	0.47	9.89e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg00738919	chr7:1100172	C7orf50	0.71	5.27	0.39	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.43	0.52	7.21e-12	Body mass index;
PAAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.92	9.09	0.59	4.98e-16	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg21770322	chr7:97807741	LMTK2	-0.73	-10.31	-0.64	3.1e-19	Breast cancer;
PAAD	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.81	10.06	0.63	1.47e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6473252	0.584	rs4739766	chr8:81821656	C/T	cg08595989	chr8:81827712	NA	-0.34	-4.75	-0.36	4.73e-6	Breast cancer;
PAAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.23	16.6	0.8	5.83e-36	Schizophrenia;
PAAD	cis	rs9314614	0.865	rs2978898	chr8:6692378	T/C	cg27319216	chr8:6693540	XKR5	-0.33	-4.26	-0.33	3.54e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-4.25	-0.33	3.76e-5	Diabetic retinopathy;
PAAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7172677	0.538	rs1806795	chr15:75422744	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.52	-0.34	1.22e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs7627468	0.955	rs56242285	chr3:121946765	A/C	cg17240004	chr3:121949083	CASR	0.53	4.64	0.35	7.36e-6	Kidney stones;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12470011	chr1:205473662	CDK18	-0.77	-6.63	-0.47	5.63e-10	Neuroticism;
PAAD	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.44	-4.41	-0.34	1.96e-5	Primary biliary cholangitis;
PAAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.57	6.13	0.45	7.09e-9	Menopause (age at onset);
PAAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.89	-13.53	-0.74	7.09e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg15445000	chr17:37608096	MED1	-0.44	-4.92	-0.37	2.25e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.52	4.81	0.36	3.58e-6	Optic cup area;
PAAD	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.57	-5.17	-0.39	7.3e-7	Obesity-related traits;
PAAD	cis	rs10924309	0.765	rs1122735	chr1:245853299	G/A	cg00036263	chr1:245852353	KIF26B	-0.56	-5.36	-0.4	3.03e-7	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.61	6.67	0.48	4.57e-10	Lung cancer;
PAAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg01176363	chr20:62369445	LIME1	-0.61	-5.91	-0.43	2.12e-8	Prostate cancer;
PAAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-6.05	-0.44	1.05e-8	Blood metabolite levels;
PAAD	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.51	5.1	0.38	9.87e-7	Airway imaging phenotypes;
PAAD	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.59	4.89	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg06883089	chr1:45254480	BEST4	-0.34	-4.26	-0.33	3.61e-5	High light scatter reticulocyte count;
PAAD	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.53	0.57	1.42e-14	Caffeine consumption;
PAAD	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.24	-9.14	-0.6	3.67e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs2131877	0.956	rs6775431	chr3:194859194	G/T	cg16306870	chr3:194868790	C3orf21	0.4	4.28	0.33	3.35e-5	Non-small cell lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01657694	chr22:20849950	KLHL22	0.59	6.6	0.47	6.33e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-5.22	-0.39	5.76e-7	Morning vs. evening chronotype;
PAAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg14092988	chr3:52407081	DNAH1	0.45	5.61	0.41	9.3e-8	Bipolar disorder;
PAAD	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.77	-6.93	-0.49	1.09e-10	Blood protein levels;
PAAD	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg27411982	chr8:10470053	RP1L1	0.47	4.91	0.37	2.32e-6	Retinal vascular caliber;
PAAD	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.47	4.85	0.37	3.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.57	6.15	0.45	6.53e-9	Bladder cancer;
PAAD	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.64	-6.58	-0.47	7.25e-10	Height;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg02462569	chr6:150064036	NUP43	-0.44	-4.88	-0.37	2.66e-6	Lung cancer;
PAAD	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.81	8.86	0.58	1.92e-15	Mortality in heart failure;
PAAD	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg02696790	chr15:75250997	RPP25	-0.41	-4.97	-0.37	1.77e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.33	-0.51	1.3e-11	Morning vs. evening chronotype;
PAAD	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.71	4.27	0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg14329783	chr7:75779857	NA	0.78	4.6	0.35	8.75e-6	Mononucleosis;
PAAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.81	7.14	0.5	3.62e-11	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.58	-6.11	-0.44	7.84e-9	Blood metabolite levels;
PAAD	cis	rs288326	0.561	rs79775314	chr2:183752749	C/A	cg09997497	chr2:183902928	NCKAP1	0.88	4.9	0.37	2.41e-6	Blood protein levels;
PAAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg19847866	chr10:1019161	NA	0.73	7.31	0.51	1.38e-11	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11411904	chr1:153935719	SLC39A1	0.56	6.85	0.49	1.72e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2075671	0.818	rs6942733	chr7:100350763	T/G	cg20848291	chr7:100343083	ZAN	-0.86	-7.37	-0.51	1.01e-11	Other erythrocyte phenotypes;
PAAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg05658771	chr16:89884179	FANCA	-0.92	-4.27	-0.33	3.4e-5	Skin colour saturation;
PAAD	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.2	0.39	6.47e-7	Mean platelet volume;
PAAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg16898833	chr6:26189333	HIST1H4D	0.69	5.34	0.4	3.31e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.51	-4.83	-0.36	3.33e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg21724239	chr8:58056113	NA	0.67	5.16	0.39	7.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs868943	0.582	rs9488861	chr6:116502405	A/G	cg15226275	chr6:116381976	FRK	0.26	4.46	0.34	1.57e-5	Total cholesterol levels;
PAAD	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	4.36	0.33	2.35e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9398803	0.723	rs853973	chr6:127068347	A/G	cg19875578	chr6:126661172	C6orf173	-0.43	-4.46	-0.34	1.57e-5	Male-pattern baldness;
PAAD	cis	rs258892	0.895	rs11948547	chr5:72041022	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg10432947	chr4:2062441	NAT8L	0.52	4.5	0.34	1.33e-5	Systolic blood pressure;
PAAD	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.53	5.27	0.39	4.5e-7	Resting heart rate;
PAAD	cis	rs1143633	0.662	rs12990810	chr2:113642532	G/T	cg06156847	chr2:113672199	IL1F7	0.55	5.78	0.42	4.19e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.71	5.05	0.38	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	6.29	0.45	3.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg05895507	chr15:77155635	SCAPER	0.39	4.87	0.37	2.74e-6	Blood metabolite levels;
PAAD	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg12661370	chr5:149340060	SLC26A2	0.65	5.48	0.41	1.75e-7	HIV-1 control;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16028793	chr1:212004275	LPGAT1	0.65	6.62	0.47	5.69e-10	Obesity-related traits;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg21565972	chr17:80109576	CCDC57	0.58	6.76	0.48	2.75e-10	Life satisfaction;
PAAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.54	-0.35	1.12e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs77880822	0.562	rs79345139	chr20:1247829	C/T	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.4	9.71	0.62	1.19e-17	Diabetic retinopathy;
PAAD	cis	rs17407555	0.683	rs2192095	chr4:10274173	T/C	cg00071950	chr4:10020882	SLC2A9	0.46	4.98	0.37	1.74e-6	Schizophrenia (age at onset);
PAAD	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.74	7.23	0.51	2.19e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.7	8.02	0.55	2.67e-13	Colorectal cancer;
PAAD	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg13263323	chr15:86062960	AKAP13	0.61	7.1	0.5	4.53e-11	Interstitial lung disease;
PAAD	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.88	7.29	0.51	1.58e-11	Triglycerides;
PAAD	cis	rs73568641	0.583	rs73568694	chr6:154050883	A/C	cg15658985	chr6:154448740	OPRM1	0.57	4.67	0.35	6.46e-6	Methadone dose in opioid dependence;
PAAD	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	4.9	0.37	2.47e-6	Ovarian reserve;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00940140	chr20:57480494	GNAS	0.7	7.18	0.5	2.85e-11	Smoking initiation;
PAAD	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.32	-0.4	3.59e-7	Daytime sleep phenotypes;
PAAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.73	8.15	0.55	1.24e-13	Systemic lupus erythematosus;
PAAD	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.55	-5.41	-0.4	2.43e-7	Educational attainment (years of education);
PAAD	cis	rs7572733	0.522	rs7573001	chr2:198929896	G/C	cg10820045	chr2:198174542	NA	0.42	4.36	0.33	2.36e-5	Dermatomyositis;
PAAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.68	8.48	0.57	1.86e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22587327	chr2:71357290	MCEE;MPHOSPH10	-0.65	-6.4	-0.46	1.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.7	5.89	0.43	2.39e-8	Common traits (Other);
PAAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg14393609	chr7:65229607	NA	0.46	4.57	0.35	9.97e-6	Aortic root size;
PAAD	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.46	4.65	0.35	7.03e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.82	9.55	0.61	3.3e-17	Methadone dose in opioid dependence;
PAAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.73	6.64	0.47	5.11e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs3996993	0.724	rs2749014	chr6:52627322	G/A	cg00536792	chr6:53530503	KLHL31	0.45	4.55	0.35	1.07e-5	Hemoglobin concentration;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg16606324	chr3:10149918	C3orf24	0.65	4.72	0.36	5.38e-6	Alzheimer's disease;
PAAD	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	7.08	0.5	4.98e-11	Body mass index;
PAAD	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg13206674	chr6:150067644	NUP43	-0.55	-4.99	-0.37	1.67e-6	Lung cancer;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06819775	chr12:69004359	RAP1B	0.53	6.32	0.46	2.81e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	11.14	0.67	1.87e-21	Primary sclerosing cholangitis;
PAAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.64	7.32	0.51	1.32e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg16691251	chr5:66510806	NA	0.73	7.8	0.53	9.08e-13	Breast cancer;
PAAD	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.52	4.94	0.37	2e-6	Endometrial cancer;
PAAD	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.88	-7.28	-0.51	1.67e-11	Triglycerides;
PAAD	cis	rs9937943	0.667	rs9945	chr16:74490556	G/A	cg01733217	chr16:74700730	RFWD3	0.61	4.4	0.34	2.06e-5	Neutrophil percentage of white cells;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02071572	chr4:1403502	NA	0.45	5.67	0.42	7.09e-8	Obesity-related traits;
PAAD	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02743256	chr7:2109353	MAD1L1	-0.77	-6.19	-0.45	5.47e-9	Bipolar disorder;
PAAD	cis	rs787274	1.000	rs2645994	chr9:115483322	C/T	cg13803584	chr9:115635662	SNX30	0.78	4.33	0.33	2.71e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-5.4	-0.4	2.52e-7	Personality dimensions;
PAAD	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.68e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.58	-5.6	-0.41	9.87e-8	Endometrial cancer;
PAAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.59	5.42	0.4	2.29e-7	Obesity-related traits;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg17820247	chr12:6579852	VAMP1	0.48	6.33	0.46	2.59e-9	Primary biliary cholangitis;
PAAD	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.68	-6.01	-0.44	1.3e-8	Vitamin D levels;
PAAD	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.55	4.81	0.36	3.62e-6	Dilated cardiomyopathy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03823539	chr17:57785039	PTRH2;TMEM49	0.63	6.38	0.46	2.06e-9	Obesity-related traits;
PAAD	cis	rs7705042	0.865	rs2043280	chr5:141513691	C/G	cg08523384	chr5:141488047	NDFIP1	0.5	4.84	0.37	3.18e-6	Asthma;
PAAD	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg24110177	chr3:50126178	RBM5	-0.56	-4.33	-0.33	2.67e-5	Menarche (age at onset);
PAAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.7	0.48	3.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.75	-0.88	8.21e-51	Myeloid white cell count;
PAAD	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg25155006	chr6:37138205	PIM1	-0.52	-4.6	-0.35	8.88e-6	QRS duration;
PAAD	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg11783602	chr8:55087084	NA	-0.59	-6.57	-0.47	7.47e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs931127	0.658	rs4244812	chr11:65480768	A/G	cg05805236	chr11:65401703	PCNXL3	-0.48	-5.35	-0.4	3.21e-7	Systemic lupus erythematosus;
PAAD	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.8	-6.95	-0.49	1e-10	Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23276673	chr2:136577322	LCT	0.62	6.68	0.48	4.34e-10	Myopia (pathological);
PAAD	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg04165759	chr1:150448943	RPRD2	0.52	5.34	0.4	3.38e-7	Migraine;
PAAD	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg18964960	chr10:1102726	WDR37	0.85	4.62	0.35	8.05e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.95	9.42	0.61	6.92e-17	Post bronchodilator FEV1;
PAAD	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.63e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs3206736	0.548	rs10254796	chr7:35070935	A/C	cg20495677	chr7:34801759	AAA1;NPSR1	-0.49	-4.63	-0.35	7.71e-6	Diastolic blood pressure;
PAAD	cis	rs7577696	0.924	rs6749336	chr2:32271710	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-4.6	-0.35	8.75e-6	Inflammatory biomarkers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26011105	chr7:43590148	HECW1	-0.59	-6.97	-0.49	8.88e-11	Monocyte percentage of white cells;
PAAD	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.73	-0.42	5.3e-8	Coronary artery disease;
PAAD	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.58	-6.21	-0.45	4.76e-9	Pelvic organ prolapse;
PAAD	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.06	11.41	0.68	3.6e-22	Lymphocyte percentage of white cells;
PAAD	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.87	6.93	0.49	1.09e-10	Axial length;
PAAD	cis	rs7260329	0.670	rs892216	chr19:41489851	T/C	cg23925301	chr19:41220945	ADCK4	-0.48	-4.27	-0.33	3.37e-5	Smoking behavior;
PAAD	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.19	0.39	6.73e-7	Tonsillectomy;
PAAD	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg26876637	chr1:152193138	HRNR	-0.82	-5.82	-0.43	3.3e-8	Atopic dermatitis;
PAAD	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg20607287	chr7:12443886	VWDE	-0.59	-4.43	-0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.78	6.33	0.46	2.61e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs58521262	0.729	rs7246529	chr19:23065123	C/T	cg07749055	chr19:23076870	NA	-0.68	-4.85	-0.37	3.08e-6	Testicular germ cell tumor;
PAAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.75	8.71	0.58	4.79e-15	Lung cancer;
PAAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.59	7.47	0.52	5.73e-12	Diastolic blood pressure;
PAAD	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg01371477	chr1:150207822	ANP32E	0.48	4.39	0.34	2.15e-5	Migraine;
PAAD	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-8.6	-0.57	9.35e-15	Electrocardiographic conduction measures;
PAAD	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.1	9.13	0.6	3.96e-16	Left atrial antero-posterior diameter;
PAAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.78	7.25	0.51	1.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-7.2	-0.5	2.53e-11	Chronic sinus infection;
PAAD	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.62	-5.92	-0.43	2.1e-8	Subjective well-being;
PAAD	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg03367679	chr17:38183553	MED24;SNORD124	-0.33	-4.33	-0.33	2.69e-5	White blood cell count;
PAAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.63	5.7	0.42	5.95e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.94	10.2	0.64	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-5.66	-0.42	7.22e-8	Crohn's disease;
PAAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg01851573	chr8:8652454	MFHAS1	0.49	4.72	0.36	5.35e-6	Mood instability;
PAAD	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.57	-6.6	-0.47	6.31e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	4.61	0.35	8.5e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg06740227	chr12:86229804	RASSF9	0.6	5.37	0.4	2.94e-7	Major depressive disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14567414	chr17:41910795	MPP3	0.68	6.86	0.49	1.62e-10	Obesity-related traits;
PAAD	cis	rs17032980	0.910	rs13399908	chr2:67306158	G/A	cg02551743	chr2:66673428	MEIS1	-0.49	-4.38	-0.33	2.17e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1564892	0.615	rs11553764	chr12:104415244	C/T	cg08101375	chr12:104443925	GLT8D2	0.61	4.71	0.36	5.66e-6	Corneal structure;
PAAD	cis	rs8005172	0.689	rs4243680	chr14:88512371	C/G	cg18078958	chr14:88630771	NA	0.35	4.43	0.34	1.78e-5	Parkinson's disease;
PAAD	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.76	6.95	0.49	1.02e-10	Obesity-related traits;
PAAD	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg09085632	chr11:111637200	PPP2R1B	0.61	5.92	0.43	2.06e-8	Primary sclerosing cholangitis;
PAAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.47	4.44	0.34	1.7e-5	Renal cell carcinoma;
PAAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.88	0.54	5.76e-13	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2.02e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg20243544	chr17:37824526	PNMT	-0.52	-4.55	-0.35	1.1e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.7	6.64	0.47	5.2400000000000005e-10	Asthma;
PAAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.46	4.59	0.35	9.42e-6	Aortic root size;
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg16898833	chr6:26189333	HIST1H4D	1.08	5.85	0.43	2.92e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	5.14	0.38	8.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-6.46	-0.46	1.31e-9	Triglycerides;
PAAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg27539214	chr16:67997921	SLC12A4	-0.63	-4.41	-0.34	1.98e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7692976	0.545	rs6850557	chr4:110911015	G/A	cg06981781	chr4:110842888	EGF	-0.41	-4.64	-0.35	7.45e-6	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.55	-4.92	-0.37	2.18e-6	Glycated hemoglobin levels;
PAAD	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-6.36	-0.46	2.23e-9	Triglycerides;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19114999	chr3:181669865	NA	-0.65	-6.82	-0.48	2.07e-10	Obesity-related traits;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07742499	chr19:55851016	SUV420H2	0.61	6.93	0.49	1.12e-10	Monocyte percentage of white cells;
PAAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.84	10.01	0.63	1.91e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg19090574	chr1:205240910	TMCC2	-0.41	-4.47	-0.34	1.53e-5	Red blood cell count;
PAAD	cis	rs959260	0.925	rs7207506	chr17:73409410	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-4.42	-0.34	1.9e-5	Systemic lupus erythematosus;
PAAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.44	5.12	0.38	8.92e-7	Coronary artery disease;
PAAD	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg01448562	chr3:133502909	NA	0.44	4.34	0.33	2.64e-5	Iron status biomarkers;
PAAD	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.8	-9.29	-0.6	1.57e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7714584	0.793	rs7709721	chr5:150246858	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.56	5.89	0.43	2.43e-8	Pancreatic cancer;
PAAD	cis	rs932316	0.607	rs56246159	chr6:25668700	T/C	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.56	-4.25	-0.33	3.76e-5	Iron status biomarkers;
PAAD	cis	rs11037575	0.739	rs7932905	chr11:43727577	C/T	cg24662154	chr11:44118094	EXT2	-0.43	-4.29	-0.33	3.15e-5	Neuroblastoma;
PAAD	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg23860436	chr12:58378763	NA	0.48	4.53	0.34	1.18e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.44	-4.64	-0.35	7.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	4.79	0.36	3.87e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.44	-4.34	-0.33	2.56e-5	Blood osmolality (transformed sodium);
PAAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg05110241	chr16:68378359	PRMT7	-1.16	-8.18	-0.55	1.03e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs111342015	0.686	rs73736734	chr6:43186794	G/T	cg17076780	chr6:43251928	TTBK1	0.57	4.38	0.33	2.19e-5	Breast cancer;
PAAD	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	7.79	0.53	9.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs72960926	0.744	rs72959615	chr6:74991323	C/T	cg03266952	chr6:74778945	NA	-1.18	-6.62	-0.47	5.72e-10	Metabolite levels (MHPG);
PAAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg19636519	chr7:99541626	NA	0.41	4.53	0.35	1.17e-5	Coronary artery disease;
PAAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.67	7.14	0.5	3.59e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.68	-5.95	-0.43	1.77e-8	Triglycerides;
PAAD	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.87	4.5	0.34	1.36e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg00531865	chr16:30841666	NA	-0.53	-4.82	-0.36	3.52e-6	Dementia with Lewy bodies;
PAAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.57	-5.36	-0.4	3.02e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9346353	0.713	rs2502597	chr6:70412603	G/C	cg03001484	chr6:70507230	LMBRD1	-0.31	-4.35	-0.33	2.53e-5	Sleep duration;
PAAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg03676636	chr4:99064102	C4orf37	0.3	5.2	0.39	6.34e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1468734	1.000	rs11642379	chr16:5003326	C/T	cg23172606	chr16:4784147	ANKS3;C16orf71	-0.56	-4.55	-0.35	1.08e-5	Cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18683606	chr7:100471612	SRRT	0.62	6.9	0.49	1.34e-10	Smoking initiation;
PAAD	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-6.68	-0.48	4.31e-10	Uric acid levels;
PAAD	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg08886695	chr4:3369023	RGS12	0.54	5.33	0.4	3.56e-7	Mean platelet volume;
PAAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg04287289	chr16:89883240	FANCA	0.88	4.26	0.33	3.53e-5	Skin colour saturation;
PAAD	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg12395012	chr8:11607386	GATA4	-0.42	-4.67	-0.35	6.7e-6	Neuroticism;
PAAD	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg05110241	chr16:68378359	PRMT7	-0.74	-5.78	-0.42	4e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.55	-5.88	-0.43	2.51e-8	Subjective well-being;
PAAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.59	-6.92	-0.49	1.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-5.14	-0.39	8.18e-7	QT interval;
PAAD	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.7	6.56	0.47	7.93e-10	Uric acid levels;
PAAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.96	0.49	9.59e-11	Morning vs. evening chronotype;
PAAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.62	6.69	0.48	4.1e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	6.3	0.46	2.98e-9	Lung function (FEV1/FVC);
PAAD	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.11	-0.38	9.63e-7	Monocyte percentage of white cells;
PAAD	cis	rs7084921	0.547	rs12780035	chr10:101874844	C/T	cg04359915	chr10:101825029	CPN1	-0.34	-5.21	-0.39	6.18e-7	Bone mineral density;
PAAD	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.53	-5.3	-0.4	3.92e-7	Mortality in heart failure;
PAAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg24220031	chr2:73402428	NA	-0.34	-4.87	-0.37	2.78e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs77880822	0.562	rs117017570	chr20:1258151	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs375066	0.868	rs453950	chr19:44403055	G/A	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.48	4.45	0.34	1.63e-5	Obesity-related traits;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg08935663	chr5:140309344	PCDHAC1;PCDHA7;PCDHA12;PCDHA6;PCDHA10;PCDHA4;PCDHA11;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA13;PCDHA5;PCDHA3	-0.5	-6.32	-0.46	2.77e-9	Energy expenditure (24h);
PAAD	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.55	-6.08	-0.44	9.23e-9	Rheumatoid arthritis;
PAAD	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.58	5.38	0.4	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs10887741	0.532	rs791884	chr10:89410076	T/C	cg13926569	chr10:89418898	PAPSS2	-0.52	-5.21	-0.39	6.01e-7	Exercise (leisure time);
PAAD	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-7.82	-0.54	8.17e-13	Obesity;Body mass index;
PAAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg07747251	chr5:1868357	NA	0.58	6.47	0.46	1.27e-9	Cardiovascular disease risk factors;
PAAD	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.56	5.46	0.4	1.89e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg02555727	chr12:129281546	SLC15A4	0.45	4.83	0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-1.08	-15.07	-0.77	5.83e-32	Breast cancer;
PAAD	cis	rs3126085	0.515	rs10788835	chr1:152330945	T/C	cg26876637	chr1:152193138	HRNR	-0.72	-5.36	-0.4	3.06e-7	Atopic dermatitis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23656386	chr16:68003240	SLC12A4	0.56	6.92	0.49	1.16e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg00543991	chr22:32367038	NA	1.18	7.23	0.51	2.23e-11	Childhood ear infection;
PAAD	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg23912435	chr1:150601613	ENSA	0.51	4.77	0.36	4.35e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1620921	0.505	rs13216458	chr6:161204262	T/C	cg01280913	chr6:161186852	NA	-0.47	-5.12	-0.38	9.01e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.61	-5.87	-0.43	2.7e-8	Psoriasis;
PAAD	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.74e-7	Morning vs. evening chronotype;
PAAD	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg07154921	chr7:157260426	NA	0.46	4.42	0.34	1.88e-5	Body mass index;
PAAD	cis	rs3996993	0.724	rs2608629	chr6:52625794	G/A	cg00536792	chr6:53530503	KLHL31	0.47	4.95	0.37	1.94e-6	Hemoglobin concentration;
PAAD	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.93	12.48	0.71	4.61e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7084921	0.578	rs12765808	chr10:101872687	A/C	cg04359915	chr10:101825029	CPN1	-0.34	-5.21	-0.39	6.18e-7	Bone mineral density;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19980148	chr14:39639590	TRAPPC6B	-0.78	-6.93	-0.49	1.12e-10	Neuroticism;
PAAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs11690462	0.514	rs11126465	chr2:26627689	T/C	cg13255216	chr2:26625047	C2orf39	0.47	4.89	0.37	2.5e-6	Coronary artery disease;
PAAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg22143856	chr6:28129313	ZNF389	0.49	4.55	0.35	1.09e-5	Parkinson's disease;
PAAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4629180	0.917	rs7560926	chr2:102125098	C/A	cg01388757	chr2:102091195	RFX8	0.69	8.24	0.56	7.64e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01850785	chr2:69870150	AAK1	-0.74	-6.64	-0.47	5.31e-10	Neuroticism;
PAAD	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.78	-5.94	-0.43	1.87e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs797680	0.930	rs622608	chr1:93715219	G/A	cg04535902	chr1:92947332	GFI1	-0.45	-4.31	-0.33	2.97e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.31	-12.51	-0.71	3.83e-25	Corneal structure;
PAAD	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg11783602	chr8:55087084	NA	-0.49	-5.05	-0.38	1.24e-6	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs9535307	0.745	rs2181185	chr13:50311925	C/T	cg04663916	chr13:50265991	EBPL	0.6	4.53	0.35	1.16e-5	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs11615916	0.790	rs73135297	chr12:62698858	A/T	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.7	0.42	6.18e-8	Prudent dietary pattern;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.69	7.59	0.52	2.93e-12	Calcium levels;
PAAD	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg00166722	chr3:10149974	C3orf24	0.9	7.81	0.54	8.61e-13	Alzheimer's disease;
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg24250549	chr1:154909240	PMVK	0.76	7.93	0.54	4.51e-13	Prostate cancer;
PAAD	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.75	-8.63	-0.57	7.66e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg19223190	chr17:80058835	NA	0.53	5.44	0.4	2.07e-7	Life satisfaction;
PAAD	cis	rs6718203	1.000	rs918054	chr2:60629883	T/C	cg10480506	chr2:60280451	NA	0.8	4.49	0.34	1.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg13468214	chr4:1046988	NA	-0.52	-4.95	-0.37	1.98e-6	Recombination rate (females);
PAAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg00540400	chr15:79124168	NA	0.71	9.07	0.59	5.7e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9535307	0.719	rs1201716	chr13:50378425	T/G	cg04663916	chr13:50265991	EBPL	-0.57	-4.27	-0.33	3.41e-5	Obesity-related traits;
PAAD	cis	rs654384	0.898	rs11766511	chr7:4173613	A/G	cg27574739	chr7:4176374	SDK1	-0.5	-5.04	-0.38	1.31e-6	Positive affect;
PAAD	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.58	6.26	0.45	3.77e-9	Bladder cancer;
PAAD	cis	rs72772787	1.000	rs59203167	chr1:248014245	A/G	cg03748376	chr1:248100585	OR2L13	0.56	4.51	0.34	1.29e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg21361702	chr7:150065534	REPIN1	0.56	4.91	0.37	2.34e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.46	5.45	0.4	1.97e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2456568	0.695	rs2895491	chr11:93687780	C/A	cg19264203	chr11:92714893	MTNR1B	-0.46	-5.16	-0.39	7.52e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.96	12.24	0.7	2.13e-24	Coronary artery disease;
PAAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.57	-6.28	-0.45	3.46e-9	Mean corpuscular volume;
PAAD	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg19767477	chr5:127420684	SLC12A2	-0.53	-4.31	-0.33	2.97e-5	Ileal carcinoids;
PAAD	cis	rs35740288	0.770	rs10520592	chr15:86114142	G/C	cg07943548	chr15:86304357	KLHL25	-0.64	-5.66	-0.42	7.32e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.74	-6.55	-0.47	8.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg18367735	chr17:79674897	NA	1.0	7.3	0.51	1.46e-11	Dental caries;
PAAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	5.95	0.43	1.75e-8	Coffee consumption (cups per day);
PAAD	cis	rs112990264	1.000	rs79248963	chr1:213015033	G/A	cg01785514	chr1:212988523	TATDN3	1.43	9.9	0.63	3.88e-18	Itch intensity from mosquito bite;
PAAD	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.55	-5.55	-0.41	1.21e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	0.95	6.86	0.49	1.6e-10	Lung disease severity in cystic fibrosis;
PAAD	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.66	-6.7	-0.48	3.79e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs10768122	0.966	rs10742340	chr11:35317712	T/C	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.29	-0.33	3.17e-5	Vitiligo;
PAAD	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-1.14	-15.37	-0.78	8.96e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.51	-6.95	-0.49	1.01e-10	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	4.25	0.33	3.69e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10819733	chr22:24237672	NA	-0.61	-6.59	-0.47	6.8e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7264396	0.887	rs4281980	chr20:34096581	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.75	-0.42	4.73e-8	Total cholesterol levels;
PAAD	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.79	8.9	0.59	1.52e-15	Colorectal cancer;
PAAD	cis	rs11825685	0.790	rs80204957	chr11:134545553	A/T	cg06603561	chr11:134479413	NA	-0.9	-6.28	-0.45	3.45e-9	IgG glycosylation;
PAAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg20933634	chr6:27740509	NA	-0.67	-5.27	-0.39	4.52e-7	Parkinson's disease;
PAAD	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-7.34	-0.51	1.19e-11	Asthma;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05142592	chr10:135097800	TUBGCP2	0.58	7.07	0.5	5.38e-11	Smoking initiation;
PAAD	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.75	6.56	0.47	7.92e-10	Morning vs. evening chronotype;
PAAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs1879734	0.953	rs3006882	chr1:54152487	G/A	cg14659662	chr1:54151053	GLIS1	0.41	6.49	0.47	1.17e-9	Mitral valve prolapse;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09586322	chr1:32706085	MTMR9L	0.64	7.13	0.5	3.83e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg05082376	chr22:42548792	NA	0.53	5.81	0.43	3.5e-8	Cognitive function;
PAAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16083429	chr3:49237500	CCDC36	0.48	5.34	0.4	3.28e-7	Menarche (age at onset);
PAAD	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.43	6.24	0.45	4.12e-9	Information processing speed;
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.04	0.55	2.35e-13	Lung function (FEV1/FVC);
PAAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-8.17	-0.55	1.09e-13	Depression;
PAAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.48	5.68	0.42	6.57e-8	Psoriasis;
PAAD	cis	rs877529	0.934	rs79503	chr22:39528440	A/G	cg18708252	chr22:39545030	CBX7	-0.44	-4.31	-0.33	2.95e-5	Multiple myeloma;
PAAD	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.15	-0.39	7.81e-7	High light scatter reticulocyte count;
PAAD	cis	rs1656368	0.726	rs11708784	chr3:158255687	T/C	cg16708174	chr3:158430962	RARRES1	0.52	4.72	0.36	5.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.85	6.66	0.48	4.63e-10	Prostate cancer;
PAAD	cis	rs936229	0.769	rs1543927	chr15:75063573	T/C	cg14664628	chr15:75095509	CSK	-1.03	-11.08	-0.67	2.71e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs4704187	0.663	rs965735	chr5:74459220	A/G	cg03227963	chr5:74354835	NA	0.48	4.73	0.36	5.01e-6	Response to amphetamines;
PAAD	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg25837213	chr17:80849375	TBCD	-0.57	-4.58	-0.35	9.74e-6	Breast cancer;
PAAD	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg25905881	chr15:51634250	GLDN	0.52	4.76	0.36	4.53e-6	Hormone measurements;
PAAD	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.63	-5.61	-0.41	9.41e-8	Lung cancer;
PAAD	cis	rs797680	0.789	rs35940311	chr1:93663604	G/A	cg04535902	chr1:92947332	GFI1	0.46	4.47	0.34	1.55e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg17366294	chr4:99064904	C4orf37	-0.45	-4.99	-0.37	1.66e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg07148914	chr20:33460835	GGT7	0.48	4.75	0.36	4.59e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.61	-5.81	-0.43	3.61e-8	Total body bone mineral density;
PAAD	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg18944383	chr4:111397179	ENPEP	0.78	7.92	0.54	4.7e-13	Coronary artery disease;
PAAD	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.68	-7.44	-0.52	6.86e-12	Dilated cardiomyopathy;
PAAD	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.94	9.98	0.63	2.37e-18	Height;
PAAD	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.79	6.0	0.44	1.42e-8	Coronary artery calcification;
PAAD	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg20003494	chr4:90757398	SNCA	-0.57	-5.52	-0.41	1.44e-7	Neuroticism;
PAAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg11707556	chr5:10655725	ANKRD33B	0.62	6.72	0.48	3.45e-10	Coronary artery disease;
PAAD	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.67	4.87	0.37	2.76e-6	Neuroticism;
PAAD	cis	rs829661	0.947	rs2167969	chr2:30773746	A/T	cg12454169	chr2:30669597	LCLAT1	0.66	5.06	0.38	1.19e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.53	5.61	0.41	9.42e-8	Obesity-related traits;
PAAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.1	8.08	0.55	1.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.55	5.21	0.39	6.1e-7	Tonsillectomy;
PAAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.64	6.01	0.44	1.32e-8	Mean corpuscular volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14797887	chr15:56757312	MNS1	0.62	6.96	0.49	9.67e-11	Myopia (pathological);
PAAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg21361702	chr7:150065534	REPIN1	0.61	5.01	0.38	1.5e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	6.98	0.49	8.72e-11	Lung function (FEV1/FVC);
PAAD	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg07220939	chr11:64358617	SLC22A12	-0.43	-4.66	-0.35	6.92e-6	Urate levels in obese individuals;
PAAD	cis	rs2882667	0.690	rs288024	chr5:138223792	A/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-4.71	-0.36	5.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3800461	0.544	rs11754548	chr6:34504767	G/C	cg17674042	chr6:34482479	PACSIN1	-1.0	-6.81	-0.48	2.12e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-1.08	-7.68	-0.53	1.8e-12	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-7.32	-0.51	1.34e-11	Gut microbiome composition (summer);
PAAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-4.82	-0.36	3.43e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10726226	chr11:133907750	LOC100128239	0.58	6.55	0.47	8.3e-10	Monocyte percentage of white cells;
PAAD	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.75	-9.55	-0.61	3.17e-17	Coronary artery disease;
PAAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.87	7.02	0.5	6.75e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.13	7.2	0.5	2.54e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4731207	0.741	rs1557969	chr7:124405738	A/G	cg14311320	chr7:124405732	GPR37	0.42	4.61	0.35	8.39e-6	Cutaneous malignant melanoma;
PAAD	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.63	-5.69	-0.42	6.46e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20198948	chr17:42297002	UBTF	-0.55	-6.47	-0.46	1.24e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.11	-0.44	8.05e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	4.91	0.37	2.35e-6	Height;
PAAD	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.61	-0.35	8.45e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg27449745	chr7:23145252	KLHL7	-0.59	-5.37	-0.4	2.96e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.53	5.61	0.41	9.19e-8	Subjective well-being;
PAAD	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg16766828	chr3:128327626	NA	-0.46	-6.2	-0.45	5.2e-9	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg26939375	chr7:64535504	NA	-0.75	-9.02	-0.59	7.72e-16	Aortic root size;
PAAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.54	-5.65	-0.42	7.78e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-5.84	-0.43	3.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs282587	0.569	rs4907750	chr13:113391348	C/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs77741769	0.591	rs73413868	chr12:121301732	T/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.53e-8	Mean corpuscular volume;
PAAD	cis	rs1992660	0.523	rs6897022	chr5:40336546	A/G	cg05240017	chr5:40756081	TTC33	-0.5	-4.43	-0.34	1.76e-5	Crohn's disease;
PAAD	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.84	8.54	0.57	1.29e-14	Corneal astigmatism;
PAAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.26	0.33	3.6e-5	Personality dimensions;
PAAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.95	-8.4	-0.56	2.99e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs9488822	0.585	rs7768026	chr6:116274313	A/G	cg18764771	chr6:116381957	FRK	-0.27	-4.44	-0.34	1.75e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg02404636	chr22:31891804	SFI1	-0.54	-4.86	-0.37	2.94e-6	Paclitaxel-induced neuropathy;
PAAD	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg19025524	chr12:109796872	NA	-0.52	-4.75	-0.36	4.65e-6	Neuroticism;
PAAD	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg26031613	chr14:104095156	KLC1	0.55	5.7	0.42	6.05e-8	Schizophrenia;
PAAD	cis	rs4908768	0.501	rs1463051	chr1:8596893	A/T	cg20416874	chr1:8611966	RERE	0.47	4.63	0.35	7.75e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs11615916	0.722	rs73137504	chr12:62704551	G/A	cg11441379	chr12:63026424	NA	0.66	4.37	0.33	2.32e-5	Pulmonary function decline;
PAAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.72	-6.28	-0.45	3.43e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.61	6.19	0.45	5.24e-9	Dialysis-related mortality;
PAAD	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.64	7.09	0.5	4.76e-11	Smoking initiation;
PAAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg03808351	chr9:123631620	PHF19	0.41	4.37	0.33	2.29e-5	Rheumatoid arthritis;
PAAD	cis	rs7534824	0.625	rs7514731	chr1:101449675	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	4.68	0.35	6.34e-6	Refractive astigmatism;
PAAD	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg23024343	chr7:107201750	COG5	0.56	4.52	0.34	1.22e-5	Osteoarthritis;
PAAD	trans	rs225245	0.791	rs720774	chr17:34017453	T/G	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg01570182	chr17:44337453	NA	-0.84	-7.91	-0.54	4.98e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.14	14.24	0.76	8.74e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs2741200	0.845	rs2958687	chr8:134132261	G/T	cg07421261	chr8:134158758	NA	0.51	4.27	0.33	3.48e-5	Bone erosion in rheumatoid arthritis;Temperament;
PAAD	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-1.03	-9.4	-0.61	7.67e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs9926296	0.632	rs4785590	chr16:89790167	G/C	cg27121462	chr16:89883253	FANCA	-0.44	-4.49	-0.34	1.42e-5	Vitiligo;
PAAD	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-1.0	-6.86	-0.49	1.59e-10	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg19257562	chr1:2043853	PRKCZ	0.44	5.23	0.39	5.63e-7	Height;
PAAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.59	-5.68	-0.42	6.78e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs10861342	1.000	rs11112396	chr12:105568359	T/G	cg11421182	chr20:36153479	BLCAP	-0.55	-6.89	-0.49	1.4e-10	IgG glycosylation;
PAAD	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg11874272	chr3:121773564	CD86	-0.43	-4.53	-0.34	1.2e-5	Multiple sclerosis;
PAAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg01631408	chr1:248437212	OR2T33	-0.6	-5.64	-0.42	7.88e-8	Common traits (Other);
PAAD	cis	rs10267417	0.603	rs10279352	chr7:19903294	T/G	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.46	5.48	0.41	1.73e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.37	4.33	0.33	2.69e-5	Schizophrenia;
PAAD	cis	rs9534288	0.577	rs7999168	chr13:46680264	A/C	cg15192986	chr13:46630673	CPB2	-0.69	-5.9	-0.43	2.26e-8	Blood protein levels;
PAAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.54	-4.89	-0.37	2.56e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg01320130	chr1:67600311	NA	0.54	5.56	0.41	1.17e-7	Psoriasis;
PAAD	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg19488206	chr2:242435732	STK25	0.45	4.25	0.33	3.78e-5	Fibrinogen levels;
PAAD	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg10223061	chr2:219282414	VIL1	0.37	4.39	0.34	2.1e-5	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg03735013	chr11:61582769	MIR1908;FADS1	-0.46	-4.59	-0.35	9.05e-6	Trans fatty acid levels;
PAAD	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	7.69	0.53	1.69e-12	Cognitive test performance;
PAAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-1.06	-15.15	-0.78	3.55e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg21929781	chr1:2537748	MMEL1	0.48	5.12	0.38	9.15e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.83	5.67	0.42	7.1e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17014947	chr15:35529521	LOC723972	-0.59	-6.29	-0.45	3.18e-9	Myopia (pathological);
PAAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.55	7.18	0.5	2.9100000000000002e-11	Schizophrenia;
PAAD	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.51	6.14	0.45	7.02e-9	Coronary artery disease;
PAAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	1.24	12.33	0.71	1.2e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12963246	chr6:28129442	ZNF389	0.56	4.52	0.34	1.21e-5	Parkinson's disease;
PAAD	cis	rs367943	0.608	rs6898912	chr5:112989978	C/T	cg12552261	chr5:112820674	MCC	0.56	6.02	0.44	1.23e-8	Type 2 diabetes;
PAAD	cis	rs17253792	0.822	rs10483646	chr14:56103872	A/C	cg01858014	chr14:56050164	KTN1	-0.77	-4.27	-0.33	3.49e-5	Putamen volume;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.82	6.92	0.49	1.21e-10	Alzheimer's disease;
PAAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.86	0.62	5.02e-18	Total body bone mineral density;
PAAD	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.17	-0.45	5.92e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-7.28	-0.51	1.68e-11	Gut microbiome composition (summer);
PAAD	cis	rs80346118	0.673	rs6012536	chr20:47423563	C/T	cg14630947	chr20:47894888	C20orf199;ZNFX1;SNORD12C	0.63	4.58	0.35	9.75e-6	Diastolic blood pressure;
PAAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.49	5.2	0.39	6.4e-7	Obesity-related traits;
PAAD	trans	rs12545912	0.908	rs35159871	chr8:9580934	T/C	cg01912921	chr6:1611712	FOXC1	0.79	6.33	0.46	2.61e-9	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.89	10.22	0.64	5.35e-19	Breast cancer;
PAAD	cis	rs6743376	0.556	rs2515401	chr2:113820476	C/T	cg12858261	chr2:113808755	IL1F8	-0.43	-4.34	-0.33	2.61e-5	Inflammatory biomarkers;
PAAD	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg14393609	chr7:65229607	NA	0.48	4.56	0.35	1.03e-5	Aortic root size;
PAAD	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg16606324	chr3:10149918	C3orf24	0.66	5.13	0.38	8.62e-7	Alzheimer's disease;
PAAD	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg05562828	chr17:3906858	NA	-0.55	-6.24	-0.45	4.2e-9	Type 2 diabetes;
PAAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18301423	chr5:131593218	PDLIM4	0.47	4.26	0.33	3.56e-5	Acylcarnitine levels;
PAAD	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.61	6.47	0.46	1.27e-9	Crohn's disease;
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.5	4.84	0.37	3.22e-6	Longevity;
PAAD	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.74	-0.36	4.97e-6	Daytime sleep phenotypes;
PAAD	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg18964960	chr10:1102726	WDR37	0.92	4.46	0.34	1.57e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	6.64	0.47	5.26e-10	High light scatter reticulocyte count;
PAAD	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07685180	chr8:600429	NA	0.88	5.41	0.4	2.45e-7	IgG glycosylation;
PAAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg07068956	chr7:100330872	ZAN	0.53	4.75	0.36	4.62e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs804280	0.544	rs804261	chr8:11631562	A/G	cg12395012	chr8:11607386	GATA4	-0.67	-8.49	-0.57	1.69e-14	Myopia (pathological);
PAAD	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg10761708	chr20:43804764	PI3	0.51	4.39	0.34	2.11e-5	Blood protein levels;
PAAD	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.83	8.76	0.58	3.58e-15	Itch intensity from mosquito bite;
PAAD	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	0.92	6.22	0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.55	-5.12	-0.38	9.04e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14180030	chr9:123475675	MEGF9	-0.42	-4.67	-0.35	6.63e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	6.98	0.49	8.58e-11	Mood instability;
PAAD	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.62	-6.34	-0.46	2.49e-9	Monocyte count;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.61	-8.31	-0.56	5.07e-14	Longevity;Endometriosis;
PAAD	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.51	-5.12	-0.38	9.22e-7	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.66	-6.35	-0.46	2.38e-9	Hip circumference;
PAAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg04257695	chr17:30186438	C17orf79	-0.57	-4.3	-0.33	3.09e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.55	-0.52	3.83e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.42	6.24	0.45	4.15e-9	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs58521262	0.519	rs11673079	chr19:22999095	T/A	cg07749055	chr19:23076870	NA	-0.59	-4.64	-0.35	7.36e-6	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24082826	chr12:26985738	ITPR2	0.58	6.47	0.46	1.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	1.13	6.12	0.44	7.48e-9	Plasma clusterin levels;
PAAD	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-4.42	-0.34	1.88e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg15049549	chr3:48732213	IP6K2	0.5	4.25	0.33	3.66e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs28489187	0.706	rs233091	chr1:85823044	G/C	cg16011679	chr1:85725395	C1orf52	0.52	4.85	0.37	2.99e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.84	9.2	0.6	2.6e-16	Mortality in heart failure;
PAAD	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.14	15.84	0.79	5.6e-34	Schizophrenia;
PAAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-5.84	-0.43	3.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.89	12.93	0.72	2.87e-26	Dental caries;
PAAD	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.45	-4.67	-0.35	6.56e-6	Arsenic metabolism;
PAAD	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-22.31	-0.88	8.47e-50	Myeloid white cell count;
PAAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-1.05	-14.78	-0.77	3.4e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7165102	1.000	rs12906196	chr15:65884888	T/C	cg22900193	chr15:65823441	PTPLAD1	0.46	4.41	0.34	1.96e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.96	10.49	0.65	1.05e-19	Parkinson's disease;
PAAD	cis	rs62392365	0.686	rs79070667	chr6:25194649	T/C	cg26336265	chr6:25042955	NA	0.67	4.69	0.36	6.05e-6	Schizophrenia;Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.97	0.63	2.45e-18	Platelet count;
PAAD	cis	rs10821973	0.527	rs4979762	chr10:64008308	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-4.28	-0.33	3.29e-5	Hypothyroidism;
PAAD	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.79e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.88	6.0	0.44	1.35e-8	Triglycerides;
PAAD	cis	rs6988985	0.818	rs3802228	chr8:143992218	A/G	cg10324643	chr8:143916377	GML	0.42	4.34	0.33	2.62e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.54	-5.15	-0.39	8e-7	Red blood cell count;
PAAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg01262667	chr19:19385393	TM6SF2	-0.45	-5.16	-0.39	7.61e-7	Tonsillectomy;
PAAD	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.62	-0.41	9.06e-8	Coronary artery disease;
PAAD	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg08134877	chr2:44394819	PPM1B	0.44	4.3	0.33	3.04e-5	Height;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.59	-0.47	6.84e-10	Longevity;Endometriosis;
PAAD	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg18029778	chr7:104654746	MLL5;LOC100216545	0.64	6.82	0.48	2.06e-10	Iris heterochromicity;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg18209359	chr17:80159595	CCDC57	0.48	4.86	0.37	2.85e-6	Life satisfaction;
PAAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.19e-9	Life satisfaction;
PAAD	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-9.29	-0.6	1.54e-16	Caffeine consumption;
PAAD	cis	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg08198132	chr6:114292539	HDAC2	-0.53	-6.14	-0.45	6.86e-9	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00167539	chr7:150066156	REPIN1	-0.67	-6.63	-0.47	5.45e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.53	5.23	0.39	5.51e-7	Asthma;
PAAD	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.67	-6.68	-0.48	4.32e-10	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg27565382	chr3:53032988	SFMBT1	0.77	4.4	0.34	2.04e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.5	-0.47	1.07e-9	Glomerular filtration rate;
PAAD	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg23887609	chr12:130822674	PIWIL1	0.61	6.01	0.44	1.34e-8	Menopause (age at onset);
PAAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9361491	0.548	rs9350777	chr6:79464181	A/C	cg05283184	chr6:79620031	NA	-0.39	-4.72	-0.36	5.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg04330084	chr7:123175371	IQUB	-0.51	-4.76	-0.36	4.39e-6	Migraine;
PAAD	cis	rs8051149	0.625	rs876985	chr16:87882124	T/C	cg01412419	chr16:87856264	NA	0.56	5.02	0.38	1.44e-6	Blood metabolite levels;
PAAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg15117754	chr3:10150083	C3orf24	0.67	5.56	0.41	1.2e-7	Alzheimer's disease;
PAAD	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg23688817	chr7:87105293	ABCB4	-0.55	-4.53	-0.35	1.17e-5	Gallbladder cancer;
PAAD	cis	rs3784262	0.740	rs8032572	chr15:58311280	A/G	cg12031962	chr15:58353849	ALDH1A2	0.51	5.83	0.43	3.21e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-4.32	-0.33	2.76e-5	Metabolite levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06652112	chr3:193853919	HES1	0.65	6.54	0.47	8.84e-10	Obesity-related traits;
PAAD	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.47	-5.08	-0.38	1.09e-6	Educational attainment;
PAAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg05754148	chr16:3507555	NAT15	-0.7	-5.54	-0.41	1.3e-7	Tuberculosis;
PAAD	cis	rs30380	0.632	rs26498	chr5:96138812	C/T	cg16492584	chr5:96139282	ERAP1	0.56	5.21	0.39	6.19e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.59	-4.92	-0.37	2.21e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg22143856	chr6:28129313	ZNF389	0.54	4.92	0.37	2.23e-6	Parkinson's disease;
PAAD	cis	rs1561176	1.000	rs11768000	chr7:155009198	G/T	cg25063631	chr7:155025500	NA	-0.51	-4.29	-0.33	3.16e-5	Personality dimensions;
PAAD	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-4.27	-0.33	3.4e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg06219351	chr7:158114137	PTPRN2	-0.82	-8.6	-0.57	9.05e-15	Calcium levels;
PAAD	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg14146966	chr2:61757674	XPO1	0.37	4.71	0.36	5.43e-6	Tuberculosis;
PAAD	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-4.54	-0.35	1.15e-5	Red blood cell count;
PAAD	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg15693483	chr7:1102177	C7orf50	0.42	4.84	0.37	3.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.22	12.57	0.71	2.63e-25	Night sleep phenotypes;
PAAD	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.62	-6.01	-0.44	1.29e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
PAAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.83	-8.96	-0.59	1.11e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs12906542	0.516	rs12593545	chr15:78337939	A/G	cg23683012	chr15:78369302	TBC1D2B	0.69	5.15	0.39	8.04e-7	Breast cancer;
PAAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.57	7.75	0.53	1.23e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.69	-0.36	6.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9395066	0.560	rs9395065	chr6:45074392	A/G	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Height;
PAAD	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg11630242	chr17:19881632	AKAP10	-0.49	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs13319406	0.546	rs6788289	chr3:189832810	G/A	cg03343083	chr3:189718843	LEPREL1	-0.82	-5.59	-0.41	1.04e-7	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg25833597	chr17:30823145	MYO1D	0.52	4.85	0.37	2.97e-6	Schizophrenia;
PAAD	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Hypertriglyceridemia;
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg26935685	chr1:15502881	TMEM51	-0.52	-4.44	-0.34	1.69e-5	Systolic blood pressure;
PAAD	cis	rs1497828	0.956	rs2815233	chr1:217539236	T/C	cg04411442	chr1:217543379	NA	-0.5	-4.93	-0.37	2.14e-6	Dialysis-related mortality;
PAAD	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg00071950	chr4:10020882	SLC2A9	0.53	4.39	0.34	2.12e-5	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg22467129	chr15:76604101	ETFA	0.54	4.84	0.37	3.17e-6	Blood metabolite levels;
PAAD	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg03999872	chr20:62272968	STMN3	-0.7	-6.22	-0.45	4.63e-9	Atopic dermatitis;
PAAD	trans	rs1015213	0.609	rs80295940	chr8:52875564	T/G	cg21665747	chr11:70967143	NA	-1.01	-6.64	-0.47	5.3e-10	Glaucoma (primary angle closure);
PAAD	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.84	-9.86	-0.62	4.85e-18	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.47	-4.37	-0.33	2.26e-5	Uric acid levels;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg00262263	chr6:170184901	NA	0.49	4.96	0.37	1.89e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2131877	0.956	rs955825	chr3:194870922	T/C	cg21937377	chr3:194868750	C3orf21	0.46	5.05	0.38	1.23e-6	Non-small cell lung cancer;
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg02462569	chr6:150064036	NUP43	-0.5	-5.49	-0.41	1.69e-7	Lung cancer;
PAAD	cis	rs11892454	0.515	rs10173557	chr2:26077722	C/A	cg03373490	chr2:26702396	OTOF	0.5	4.32	0.33	2.82e-5	Heschl's gyrus morphology;
PAAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.19	-0.39	6.6e-7	Tonsillectomy;
PAAD	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.44	0.34	1.7e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg00750074	chr16:89608354	SPG7	-0.52	-4.85	-0.37	2.98e-6	Multiple myeloma (IgH translocation);
PAAD	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.73	7.63	0.53	2.4e-12	Schizophrenia;
PAAD	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.49	-0.47	1.13e-9	Plateletcrit;Platelet count;
PAAD	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg04717802	chr22:42394638	WBP2NL	0.48	4.6	0.35	8.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-5.16	-0.39	7.61e-7	Asthma;
PAAD	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg11143131	chr5:131608246	PDLIM4	0.5	5.02	0.38	1.4e-6	Blood metabolite levels;
PAAD	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.49	-0.47	1.12e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.73	9.11	0.59	4.5e-16	Bone mineral density;
PAAD	cis	rs904092	0.605	rs7669784	chr4:100177349	G/A	cg12011299	chr4:100065546	ADH4	-0.49	-4.44	-0.34	1.74e-5	Alcohol dependence;
PAAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-7.78	-0.53	1e-12	Colorectal cancer;
PAAD	cis	rs4453791	0.769	rs4676585	chr3:38951040	A/T	cg02254461	chr3:39195904	CSRNP1	0.58	5.09	0.38	1.03e-6	Social communication problems;
PAAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.71	-7.35	-0.51	1.15e-11	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04527260	chr10:5979201	FBXO18	-0.55	-6.64	-0.47	5.22e-10	Monocyte percentage of white cells;
PAAD	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00166722	chr3:10149974	C3orf24	0.97	7.98	0.54	3.38e-13	Alzheimer's disease;
PAAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg23611525	chr11:129765612	NFRKB	0.95	6.59	0.47	6.68e-10	Lung function (FEV1/FVC);
PAAD	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.49	-4.7	-0.36	5.86e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-6.84	-0.49	1.81e-10	Triglycerides;
PAAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg10862848	chr6:42927986	GNMT	-0.48	-7.55	-0.52	3.84e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.97	10.65	0.65	3.79e-20	Gut microbiome composition (winter);
PAAD	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg13565585	chr5:132299512	AFF4	0.6	4.3	0.33	3.04e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-6.45	-0.46	1.4e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-6.22	-0.45	4.61e-9	Diabetic retinopathy;
PAAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-8.73	-0.58	4.2e-15	Coronary artery disease;
PAAD	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.86	9.23	0.6	2.16e-16	Colorectal cancer;
PAAD	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.4	0.34	2.05e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11892454	0.543	rs9941574	chr2:26055668	C/T	cg25181710	chr2:26045287	ASXL2	0.44	5.05	0.38	1.24e-6	Heschl's gyrus morphology;
PAAD	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.92	-7.97	-0.54	3.47e-13	Obesity-related traits;
PAAD	cis	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg18464790	chr6:90539804	CASP8AP2	0.51	5.43	0.4	2.2e-7	Vitiligo;Type 1 diabetes;
PAAD	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14019695	chr9:139328340	INPP5E	0.57	4.87	0.37	2.76e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg11802864	chr11:65308245	LTBP3	-0.45	-4.46	-0.34	1.6e-5	Bone mineral density;
PAAD	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg25554036	chr4:6271136	WFS1	0.71	7.87	0.54	6.2800000000000005e-13	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg06042504	chr8:55087323	NA	-0.8	-8.66	-0.57	6.59e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg06740227	chr12:86229804	RASSF9	0.51	4.83	0.36	3.32e-6	Major depressive disorder;
PAAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.91	-8.79	-0.58	3.01e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21650422	chr2:149402622	EPC2	-0.61	-6.36	-0.46	2.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	6.42	0.46	1.61e-9	Renal function-related traits (BUN);
PAAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.53	-4.5	-0.34	1.35e-5	Cocaine dependence;
PAAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg27304813	chr3:120068385	LRRC58	0.6	6.72	0.48	3.42e-10	Response to antipsychotic treatment;
PAAD	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.61	5.04	0.38	1.33e-6	Common traits (Other);
PAAD	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-0.73	-4.51	-0.34	1.32e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10121009	0.635	rs7031549	chr9:35281626	G/A	cg11846315	chr9:35647073	NA	0.49	4.56	0.35	1.04e-5	Parkinson's disease;
PAAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.44	-4.89	-0.37	2.53e-6	Bipolar disorder;
PAAD	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.56	-4.81	-0.36	3.63e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs259282	0.646	rs34182086	chr19:33125823	A/C	cg02997394	chr19:33096574	ANKRD27	-0.4	-4.35	-0.33	2.53e-5	Schizophrenia;
PAAD	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.68	-6.17	-0.45	5.8e-9	Response to antineoplastic agents;
PAAD	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	4.64	0.35	7.31e-6	Depressive symptoms;
PAAD	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-5.05	-0.38	1.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	ch.11.42038R	chr11:967971	AP2A2	0.6	5.81	0.43	3.57e-8	Alzheimer's disease (late onset);
PAAD	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.88	-6.46	-0.46	1.37e-9	Psoriasis vulgaris;
PAAD	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	10.86	0.66	1.1e-20	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.73	-8.4	-0.56	2.98e-14	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg01270228	chr10:1369114	ADARB2	0.48	4.59	0.35	9.4e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	6.05	0.44	1.09e-8	Prudent dietary pattern;
PAAD	cis	rs12681288	0.723	rs11784252	chr8:1027964	T/C	cg15309053	chr8:964076	NA	0.41	4.36	0.33	2.38e-5	Schizophrenia;
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.61	5.54	0.41	1.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg24692254	chr21:30365293	RNF160	-0.66	-5.72	-0.42	5.45e-8	Cognitive test performance;
PAAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg19680485	chr15:31195859	MTMR15	-0.43	-4.38	-0.33	2.18e-5	Huntington's disease progression;
PAAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg09796270	chr17:17721594	SREBF1	0.45	4.85	0.37	3.06e-6	Total body bone mineral density;
PAAD	cis	rs6604026	0.656	rs35367625	chr1:93399705	G/A	cg17283838	chr1:93427260	FAM69A	0.62	5.71	0.42	5.65e-8	Multiple sclerosis;
PAAD	cis	rs2460882	1	rs2460882	chr12:53787953	T/C	cg23431730	chr12:53887070	MAP3K12	-0.61	-4.29	-0.33	3.11e-5	Percentage gas trapping;
PAAD	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.28	4.54	0.35	1.16e-5	Asthma;
PAAD	cis	rs7092929	0.941	rs615019	chr10:3563318	T/C	cg14308648	chr10:3568949	NA	0.69	5.06	0.38	1.18e-6	Coronary artery calcification;
PAAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg23018236	chr17:30244563	NA	-0.58	-4.46	-0.34	1.62e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.71	6.72	0.48	3.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2555155	0.935	rs2723655	chr11:6516755	C/A	cg11185456	chr11:6592066	DNHD1	0.41	4.32	0.33	2.82e-5	DNA methylation (variation);
PAAD	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg18551225	chr6:44695536	NA	-0.7	-7.18	-0.5	2.84e-11	Total body bone mineral density;
PAAD	cis	rs11249608	0.789	rs7733067	chr5:178425714	T/C	cg21905437	chr5:178450457	ZNF879	-0.6	-4.79	-0.36	3.99e-6	Pubertal anthropometrics;
PAAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg19413350	chr8:57351067	NA	-0.48	-4.57	-0.35	1.02e-5	Obesity-related traits;
PAAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-7.93	-0.54	4.32e-13	Longevity;Endometriosis;
PAAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00166722	chr3:10149974	C3orf24	0.84	6.42	0.46	1.65e-9	Alzheimer's disease;
PAAD	cis	rs2790216	1.000	rs2790161	chr10:59968090	A/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg02710119	chr21:45078694	RRP1B;HSF2BP	-0.47	-4.45	-0.34	1.67e-5	Mean corpuscular volume;
PAAD	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.74	7.49	0.52	5.23e-12	Uric acid levels;
PAAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg10207240	chr12:122356781	WDR66	-0.57	-6.11	-0.44	7.9e-9	Mean corpuscular volume;
PAAD	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.58	5.61	0.41	9.3e-8	Primary sclerosing cholangitis;
PAAD	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg17326555	chr1:119535693	NA	-0.35	-4.42	-0.34	1.84e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	5.94	0.43	1.86e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.43	-6.55	-0.47	8.18e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.28	-0.45	3.43e-9	Chronic sinus infection;
PAAD	cis	rs7714584	1.000	rs17800886	chr5:150309539	C/G	cg22134413	chr5:150180641	NA	0.93	6.49	0.47	1.14e-9	Crohn's disease;
PAAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs6466055	0.589	rs1029596	chr7:104698848	C/G	cg04380332	chr7:105027541	SRPK2	-0.51	-4.93	-0.37	2.1e-6	Schizophrenia;
PAAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg26513180	chr16:89883248	FANCA	-0.44	-4.42	-0.34	1.85e-5	Vitiligo;
PAAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-0.68	-4.75	-0.36	4.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17347941	chr15:79387269	NA	0.38	4.27	0.33	3.39e-5	Refractive error;
PAAD	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.48	4.4	0.34	2.06e-5	White matter hyperintensity burden;
PAAD	cis	rs4780401	0.933	rs4780395	chr16:11809940	A/G	cg01061890	chr16:11836724	TXNDC11	-0.51	-4.95	-0.37	1.91e-6	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23858591	chr12:132497671	EP400	-0.64	-6.4	-0.46	1.86e-9	Obesity-related traits;
PAAD	cis	rs7932354	0.583	rs2306027	chr11:46907827	C/T	cg19486271	chr11:47235900	DDB2	-0.61	-5.92	-0.43	2.11e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg02848875	chr15:64387786	SNX1	-0.4	-4.27	-0.33	3.45e-5	Monocyte count;
PAAD	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.13	0.38	8.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07963189	chr19:3761808	MRPL54;APBA3	-0.74	-6.63	-0.47	5.51e-10	Neuroticism;
PAAD	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.8	7.08	0.5	4.87e-11	Exhaled nitric oxide levels;
PAAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.82	9.46	0.61	5.49e-17	Menarche (age at onset);
PAAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.66	7.42	0.52	7.55e-12	Iron status biomarkers;
PAAD	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg22089800	chr15:90895588	ZNF774	-0.57	-5.28	-0.39	4.37e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-7.32	-0.51	1.35e-11	Diastolic blood pressure;
PAAD	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06002616	chr8:101225028	SPAG1	0.48	5.63	0.42	8.5e-8	Atrioventricular conduction;
PAAD	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	5.52	0.41	1.41e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.61	-6.66	-0.48	4.66e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.62	-5.61	-0.41	9.2e-8	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs1572438	1.000	rs873559	chr6:875336	G/A	cg21062780	chr6:887772	NA	0.44	4.32	0.33	2.83e-5	Aging;
PAAD	cis	rs8005172	0.705	rs12433598	chr14:88414875	C/T	cg18078958	chr14:88630771	NA	0.43	5.19	0.39	6.53e-7	Parkinson's disease;
PAAD	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.54	4.96	0.37	1.86e-6	Schizophrenia;
PAAD	cis	rs9472414	0.510	rs609699	chr6:44705266	G/A	cg20913747	chr6:44695427	NA	0.54	5.65	0.42	7.67e-8	Height;
PAAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-1.05	-15.13	-0.78	4.01e-32	Height;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.51	-5.3	-0.4	3.97e-7	Iron status biomarkers;
PAAD	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.4	4.46	0.34	1.59e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg20735989	chr4:730612	PCGF3	-0.54	-4.82	-0.36	3.43e-6	White blood cell count;
PAAD	cis	rs6142102	0.961	rs4911401	chr20:32654562	C/A	cg06115741	chr20:33292138	TP53INP2	0.52	4.26	0.33	3.52e-5	Skin pigmentation;
PAAD	cis	rs728616	0.510	rs12416084	chr10:81749215	A/G	cg05935833	chr10:81318306	SFTPA2	-0.59	-4.81	-0.36	3.68e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg15017067	chr4:17643749	FAM184B	0.43	4.83	0.36	3.31e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg18551225	chr6:44695536	NA	-0.7	-7.01	-0.49	7.24e-11	Total body bone mineral density;
PAAD	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg09597638	chr17:3907349	NA	0.89	10.12	0.63	9.95e-19	Type 2 diabetes;
PAAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg21399703	chr1:247681439	NA	0.65	6.26	0.45	3.72e-9	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.82	-7.8	-0.53	9.43e-13	Body mass index;
PAAD	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.4	-5.05	-0.38	1.27e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.45	5.32	0.4	3.64e-7	QRS complex (12-leadsum);
PAAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.78	-7.8	-0.53	9.19e-13	Coronary artery disease;
PAAD	cis	rs732765	0.734	rs6574189	chr14:75166493	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	4.55	0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.72	-7.14	-0.5	3.56e-11	Platelet distribution width;
PAAD	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg00750074	chr16:89608354	SPG7	-0.6	-5.67	-0.42	6.94e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs5417	0.636	rs2074218	chr17:7156186	A/G	cg25256661	chr17:7137939	DVL2	-0.92	-9.62	-0.62	2.1e-17	Diastolic blood pressure;
PAAD	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg10208897	chr5:178548229	ADAMTS2	0.49	4.4	0.34	2.02e-5	Pubertal anthropometrics;
PAAD	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.51	4.92	0.37	2.24e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.78	6.18	0.45	5.55e-9	Neutrophil percentage of white cells;
PAAD	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.56e-5	Height;
PAAD	cis	rs4443100	0.916	rs9612218	chr22:23381814	A/C	cg14186256	chr22:23484241	RTDR1	0.53	4.66	0.35	6.84e-6	Serum parathyroid hormone levels;
PAAD	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.44	5.21	0.39	6.08e-7	Systemic lupus erythematosus;
PAAD	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.64	-6.27	-0.45	3.62e-9	Body mass index;
PAAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.66	-6.77	-0.48	2.57e-10	Testicular germ cell tumor;
PAAD	cis	rs4740619	0.870	rs2382539	chr9:15793592	A/T	cg14451791	chr9:16040625	NA	-0.38	-4.36	-0.33	2.39e-5	Body mass index;
PAAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00300879	chr1:26503847	CNKSR1	0.3	4.71	0.36	5.54e-6	Height;
PAAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-5.06	-0.38	1.19e-6	Height;
PAAD	cis	rs2899832	0.866	rs10136978	chr14:35788948	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	4.41	0.34	1.91e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs228568	0.590	rs12405598	chr1:79613708	A/C	cg18592365	chr1:79472536	ELTD1	0.37	4.7	0.36	5.71e-6	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-4.31	-0.33	2.87e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.65	7.76	0.53	1.14e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg13160058	chr8:26243215	BNIP3L	-0.37	-4.68	-0.35	6.3e-6	Red cell distribution width;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01616529	chr11:638424	DRD4	-0.58	-5.74	-0.42	4.89e-8	Systemic lupus erythematosus;
PAAD	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	6.09	0.44	8.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg11783602	chr8:55087084	NA	-0.58	-6.3	-0.45	3.12e-9	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.8	9.5	0.61	4.35e-17	Colorectal cancer;
PAAD	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg23920097	chr1:209922102	NA	-0.49	-4.46	-0.34	1.6e-5	Red blood cell count;
PAAD	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg06740227	chr12:86229804	RASSF9	-0.55	-5.27	-0.39	4.57e-7	Major depressive disorder;
PAAD	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg21951975	chr1:209979733	IRF6	-0.53	-5.16	-0.39	7.45e-7	Coronary artery disease;
PAAD	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg24053715	chr22:38214548	NA	0.54	5.37	0.4	2.91e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg15181151	chr6:150070149	PCMT1	0.56	6.03	0.44	1.18e-8	Lung cancer;
PAAD	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.61	-5.88	-0.43	2.5e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.63	7.04	0.5	6.19e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg17333051	chr19:2783644	SGTA	0.49	5.32	0.4	3.61e-7	Total cholesterol levels;
PAAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.79	-0.36	3.87e-6	Life satisfaction;
PAAD	cis	rs2061333	0.557	rs9304638	chr19:44634086	C/T	cg18700516	chr19:44507157	ZNF230	-0.75	-5.15	-0.39	8.06e-7	Alzheimer's disease;
PAAD	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg07416916	chr2:36825888	FEZ2	0.46	4.36	0.33	2.34e-5	Height;
PAAD	cis	rs73416724	1.000	rs76658194	chr6:43357601	C/T	cg26312998	chr6:43337775	ZNF318	0.7	5.79	0.42	3.98e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.8	6.79	0.48	2.43e-10	Alzheimer's disease;
PAAD	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-4.78	-0.36	4.02e-6	Type 2 diabetes;
PAAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.44	-4.25	-0.33	3.68e-5	Daytime sleep phenotypes;
PAAD	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg01304814	chr3:48885189	PRKAR2A	0.92	5.36	0.4	2.98e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs12286929	0.644	rs12099024	chr11:115082142	A/G	cg04055981	chr11:115044050	NA	0.51	5.14	0.38	8.22e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.42	-6.59	-0.47	6.96e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs1014246	0.826	rs11197801	chr10:118471693	C/T	cg14471191	chr10:117818509	GFRA1	0.38	4.34	0.33	2.54e-5	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12778183	chr17:56769387	TEX14;RAD51C	-0.55	-4.84	-0.37	3.21e-6	Testicular germ cell tumor;
PAAD	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg16606324	chr3:10149918	C3orf24	0.77	6.33	0.46	2.67e-9	Alzheimer's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07661849	chr4:146686236	ZNF827	-0.68	-6.83	-0.48	1.95e-10	Smoking initiation;
PAAD	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg19486271	chr11:47235900	DDB2	0.6	6.26	0.45	3.77e-9	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.45	0.46	1.43e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.76	-6.25	-0.45	3.93e-9	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	6.16	0.45	6.12e-9	Personality dimensions;
PAAD	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	6.09	0.44	9.02e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.33	5.22	0.39	5.76e-7	Alcohol dependence;
PAAD	cis	rs6442522	0.678	rs12494919	chr3:15498272	G/A	cg16303742	chr3:15540471	COLQ	0.46	4.82	0.36	3.39e-6	Uric acid levels;
PAAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06850241	chr22:41845214	NA	-0.61	-5.23	-0.39	5.49e-7	Vitiligo;
PAAD	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.29	14.27	0.76	7.5e-30	Eosinophil percentage of granulocytes;
PAAD	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg21994712	chr19:21861136	NA	-0.47	-4.54	-0.35	1.15e-5	Pain;
PAAD	trans	rs61677309	1.000	rs2120269	chr11:118151135	T/C	cg15548380	chr1:19984784	NBL1	-0.63	-6.58	-0.47	7.01e-10	Lung cancer in ever smokers;
PAAD	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.51	-4.69	-0.36	6.15e-6	Asthma;
PAAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.79	-9.78	-0.62	7.74e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg15764593	chr10:829463	NA	-0.76	-6.02	-0.44	1.27e-8	Uric acid levels;
PAAD	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg08698997	chr16:88989212	CBFA2T3	0.4	5.05	0.38	1.27e-6	Social autistic-like traits;
PAAD	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.52	5.41	0.4	2.37e-7	Height;
PAAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.78	8.34	0.56	4.13e-14	Prostate cancer;
PAAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	6.58	0.47	7.13e-10	Coronary artery disease;
PAAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-0.71	-7.21	-0.5	2.41e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-1.15	-13.6	-0.74	4.5e-28	Longevity;
PAAD	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg17325771	chr7:75508891	RHBDD2	0.35	4.91	0.37	2.32e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-5.3	-0.39	4.08e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg21546286	chr11:48923668	NA	-0.43	-4.68	-0.35	6.36e-6	Coronary artery disease;
PAAD	cis	rs332507	0.830	rs12631364	chr3:124405042	A/T	cg05980111	chr3:124395277	KALRN	0.46	4.59	0.35	9.04e-6	Plateletcrit;
PAAD	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg01489032	chr8:143877656	NA	0.45	4.77	0.36	4.28e-6	Urinary tract infection frequency;
PAAD	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg20893579	chr22:38215064	NA	-0.48	-5.14	-0.38	8.38e-7	Glioblastoma;Glioma;
PAAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.57	-6.9	-0.49	1.28e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg05313129	chr8:58192883	C8orf71	-0.68	-6.21	-0.45	4.87e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg18764771	chr6:116381957	FRK	0.31	4.86	0.37	2.95e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg06606381	chr12:133084897	FBRSL1	-1.46	-9.51	-0.61	4.11e-17	Breast cancer;
PAAD	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg05791153	chr7:19748676	TWISTNB	0.54	4.46	0.34	1.62e-5	Thyroid stimulating hormone;
PAAD	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	8.3	0.56	5.2e-14	Hemoglobin concentration;
PAAD	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg23995914	chr4:10459228	ZNF518B	-0.36	-4.26	-0.33	3.6e-5	Schizophrenia (age at onset);
PAAD	cis	rs6693295	0.536	rs12118406	chr1:246230312	G/A	cg11798871	chr1:246315928	SMYD3	-0.77	-5.57	-0.41	1.11e-7	Migraine - clinic-based;Migraine with aura;
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21862992	chr11:68658383	NA	0.42	4.61	0.35	8.35e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-4.6	-0.35	9.02e-6	Non-small cell lung cancer;
PAAD	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.07	0.38	1.15e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.87	12.14	0.7	3.85e-24	Vitiligo;
PAAD	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg04287289	chr16:89883240	FANCA	0.92	4.61	0.35	8.61e-6	Skin colour saturation;
PAAD	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.26	-0.71	1.79e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7705042	0.833	rs12653848	chr5:141489853	A/G	cg08523384	chr5:141488047	NDFIP1	0.54	5.17	0.39	7.23e-7	Asthma;
PAAD	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg19760965	chr3:194868843	C3orf21	0.44	4.71	0.36	5.48e-6	Non-small cell lung cancer;
PAAD	cis	rs4239252	0.929	rs4251791	chr17:34172715	A/G	cg19411729	chr17:34207663	CCL5	-0.55	-4.97	-0.37	1.75e-6	Blood protein levels;
PAAD	cis	rs9815354	0.680	rs75308766	chr3:42031894	G/A	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg13918804	chr1:2043761	PRKCZ	0.42	5.68	0.42	6.61e-8	Height;
PAAD	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.45	-4.64	-0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-4.3	-0.33	3.02e-5	Testicular germ cell tumor;
PAAD	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.86	8.43	0.56	2.41e-14	Vitamin D levels;
PAAD	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.51	4.97	0.37	1.77e-6	High light scatter reticulocyte count;
PAAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.94	9.84	0.62	5.56e-18	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3733418	0.929	rs13134940	chr4:165889612	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.63	-5.71	-0.42	5.66e-8	Obesity-related traits;
PAAD	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg17105886	chr17:28927953	LRRC37B2	0.68	4.56	0.35	1.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2000999	0.524	rs36125653	chr16:72190805	G/A	cg16558253	chr16:72132732	DHX38	-0.71	-4.65	-0.35	7.3e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
PAAD	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.91	-0.63	3.55e-18	Response to antipsychotic treatment;
PAAD	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.99	6.23	0.45	4.46e-9	Major depressive disorder;
PAAD	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.52	4.29	0.33	3.11e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg05084668	chr3:125655381	ALG1L	-0.72	-8.31	-0.56	4.96e-14	Blood pressure (smoking interaction);
PAAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-5.15	-0.39	8.11e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.6	-5.7	-0.42	5.92e-8	Total body bone mineral density;
PAAD	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Breast cancer;
PAAD	cis	rs10512697	0.655	rs62338651	chr5:3472166	C/A	cg19473799	chr5:3511975	NA	-1.09	-4.77	-0.36	4.21e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg05044414	chr3:183734942	ABCC5	0.53	4.76	0.36	4.53e-6	Anterior chamber depth;
PAAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs4388249	0.687	rs3797689	chr5:109100515	T/C	cg17395555	chr5:108820864	NA	0.31	4.37	0.33	2.25e-5	Schizophrenia;
PAAD	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.56	4.87	0.37	2.81e-6	Common traits (Other);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08990198	chr1:202318195	PPP1R12B	0.6	6.71	0.48	3.61e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9395066	0.525	rs1971482	chr6:44991113	C/T	cg25276700	chr6:44698697	NA	0.49	5.55	0.41	1.25e-7	Height;
PAAD	cis	rs2286379	0.682	rs6489326	chr12:1842237	T/C	cg05227549	chr12:1770782	NA	-0.42	-4.69	-0.36	5.93e-6	Blood pressure (smoking interaction);
PAAD	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.64	-7.16	-0.5	3.25e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	4.49	0.34	1.39e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.45	-5.13	-0.38	8.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.49	-4.75	-0.36	4.73e-6	Mean platelet volume;
PAAD	cis	rs7577696	0.785	rs7572964	chr2:32372096	A/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.74	-0.36	4.9e-6	Inflammatory biomarkers;
PAAD	cis	rs8105895	0.935	rs10405613	chr19:22244772	C/T	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg13047869	chr3:10149882	C3orf24	1.02	7.39	0.51	9.08e-12	Alzheimer's disease;
PAAD	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs6604026	0.656	rs2811593	chr1:93343891	C/T	cg13858687	chr1:93297071	RPL5	0.48	4.44	0.34	1.72e-5	Multiple sclerosis;
PAAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs4629180	0.917	rs1110947	chr2:102118712	T/C	cg01388757	chr2:102091195	RFX8	-0.64	-7.89	-0.54	5.41e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg08135965	chr6:41755394	TOMM6	0.48	5.05	0.38	1.25e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg22710661	chr11:17411071	KCNJ11	0.47	4.7	0.36	5.69e-6	Type 2 diabetes;
PAAD	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.68	-5.24	-0.39	5.3e-7	Platelet count;
PAAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-5.38	-0.4	2.74e-7	Total body bone mineral density;
PAAD	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.54	5.5	0.41	1.58e-7	Multiple sclerosis;
PAAD	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg09237515	chr14:105715926	BTBD6;BRF1	-0.49	-4.34	-0.33	2.58e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	9.46	0.61	5.64e-17	Mean corpuscular hemoglobin;
PAAD	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.57	-5.55	-0.41	1.22e-7	Chronic sinus infection;
PAAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.88	5.78	0.42	4.03e-8	Diabetic kidney disease;
PAAD	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.4	-5.06	-0.38	1.22e-6	Prostate cancer;
PAAD	cis	rs73416724	0.841	rs75782786	chr6:43320055	C/A	cg26312998	chr6:43337775	ZNF318	0.64	4.43	0.34	1.77e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.54	5.13	0.38	8.59e-7	Mood instability;
PAAD	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.59	-5.35	-0.4	3.21e-7	Psoriasis;
PAAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4908768	0.579	rs56280806	chr1:8875542	G/A	cg25722041	chr1:8623473	RERE	0.52	4.56	0.35	1.06e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg23254163	chr1:152506842	NA	0.59	6.91	0.49	1.24e-10	Hair morphology;
PAAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	4.36	0.33	2.36e-5	Breast cancer;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg12143784	chr7:64541923	NA	0.37	4.67	0.35	6.44e-6	Calcium levels;
PAAD	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg12395012	chr8:11607386	GATA4	0.4	4.41	0.34	1.93e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.47	-4.37	-0.33	2.26e-5	White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs75920871	0.920	rs4316540	chr11:116819241	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.77	-4.34	-0.33	2.58e-5	Subjective well-being;
PAAD	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.51	5.3	0.4	3.92e-7	Male-pattern baldness;
PAAD	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg22753661	chr15:79092743	ADAMTS7	0.51	4.27	0.33	3.36e-5	Coronary artery disease or large artery stroke;
PAAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	1.13	16.98	0.81	6.35e-37	Breast cancer;
PAAD	cis	rs7247513	0.930	rs34321000	chr19:12713088	C/T	cg01871581	chr19:12707946	ZNF490	-0.92	-11.6	-0.69	1.09e-22	Bipolar disorder;
PAAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg19680485	chr15:31195859	MTMR15	-0.44	-4.27	-0.33	3.49e-5	Huntington's disease progression;
PAAD	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.8	9.32	0.6	1.25e-16	Hemoglobin concentration;
PAAD	cis	rs911119	0.955	rs61035931	chr20:23595714	A/G	cg16589663	chr20:23618590	CST3	0.78	6.83	0.48	1.89e-10	Chronic kidney disease;
PAAD	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg22467129	chr15:76604101	ETFA	0.53	4.88	0.37	2.67e-6	Blood metabolite levels;
PAAD	cis	rs9401295	0.546	rs4839713	chr6:98263613	G/A	cg00987395	chr6:98934664	NA	0.37	4.36	0.33	2.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg01214346	chr17:406501	NA	-0.45	-4.59	-0.35	9.04e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg05935833	chr10:81318306	SFTPA2	-0.71	-4.83	-0.36	3.37e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.79	7.16	0.5	3.17e-11	Response to amphetamines;
PAAD	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.2	-0.39	6.3e-7	Bipolar disorder;
PAAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.49	4.85	0.37	2.98e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-7.25	-0.51	2e-11	Extrinsic epigenetic age acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04314525	chr22:42196960	CCDC134	0.6	6.62	0.47	5.76e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs6892884	0.807	rs2879420	chr5:170998791	A/G	cg01069451	chr20:3210387	SLC4A11	0.61	6.41	0.46	1.72e-9	Height;
PAAD	cis	rs1218582	0.772	rs3738026	chr1:154919565	A/G	cg03351412	chr1:154909251	PMVK	0.72	7.34	0.51	1.19e-11	Prostate cancer;
PAAD	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25809561	chr17:30822961	MYO1D	0.46	4.65	0.35	7.26e-6	Schizophrenia;
PAAD	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.52	-5.31	-0.4	3.76e-7	Inflammatory bowel disease;
PAAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.74	-8.36	-0.56	3.79e-14	Huntington's disease progression;
PAAD	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.58	5.87	0.43	2.58e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs11615916	0.790	rs56117810	chr12:62656247	A/G	cg11441379	chr12:63026424	NA	0.62	4.46	0.34	1.58e-5	Pulmonary function decline;
PAAD	cis	rs9381107	0.505	rs1001384	chr6:9485556	G/A	cg14735645	chr6:9486422	NA	-0.59	-4.95	-0.37	1.95e-6	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.77	-0.42	4.26e-8	Bipolar disorder;
PAAD	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.78	-0.36	4.06e-6	Mean corpuscular volume;
PAAD	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.7	6.72	0.48	3.44e-10	Schizophrenia;
PAAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.85	-9.46	-0.61	5.46e-17	Iron status biomarkers;
PAAD	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.75	-0.88	8.21e-51	Myeloid white cell count;
PAAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg15847926	chr7:2749597	AMZ1	-0.39	-4.68	-0.36	6.21e-6	Height;
PAAD	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16417436	chr16:28758564	NA	0.45	4.3	0.33	3.06e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.5	5.36	0.4	3.02e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	5.57	0.41	1.11e-7	HIV-1 control;
PAAD	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	0.98	9.56	0.61	3.03e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.9	8.76	0.58	3.5e-15	Methadone dose in opioid dependence;
PAAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.51	-5.37	-0.4	2.96e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg18531004	chr3:128564980	NA	-0.94	-5.35	-0.4	3.14e-7	Dental caries;
PAAD	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.49	4.87	0.37	2.72e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.49	4.66	0.35	6.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg14345882	chr6:26364793	BTN3A2	0.71	5.18	0.39	6.94e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6782228	1.000	rs11718130	chr3:128330027	G/C	cg15607142	chr3:128420513	NA	-0.5	-5.15	-0.39	8.01e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg04415270	chr2:102091202	RFX8	-0.51	-6.39	-0.46	1.92e-9	Chronic rhinosinusitis with nasal polyps;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13662262	chr21:30364895	RNF160	0.6	6.57	0.47	7.42e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	0.85	6.64	0.47	5.12e-10	Gout;Urate levels;Serum uric acid levels;
PAAD	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.51	-4.27	-0.33	3.48e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	0.91	5.52	0.41	1.46e-7	Gut microbiota (bacterial taxa);
PAAD	cis	rs7922314	0.571	rs60400542	chr10:64731148	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs11023332	0.706	rs11023380	chr11:14930058	A/G	cg16394018	chr11:14927549	NA	0.42	4.71	0.36	5.53e-6	Adiponectin levels;Vitamin D levels;
PAAD	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.92	-8.33	-0.56	4.34e-14	Vitiligo;
PAAD	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.49	-4.72	-0.36	5.22e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg23947450	chr7:900037	UNC84A	-0.57	-4.69	-0.36	6.14e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg00934597	chr7:893267	UNC84A	-0.48	-4.4	-0.34	2e-5	Subjective well-being;
PAAD	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.64	-5.73	-0.42	5.32e-8	Type 2 diabetes;
PAAD	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Neuroticism;
PAAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-1.13	-10.38	-0.64	2.08e-19	Initial pursuit acceleration;
PAAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	1.0	14.38	0.76	3.9e-30	Menarche (age at onset);
PAAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.81	-8.88	-0.58	1.8e-15	Bipolar disorder and schizophrenia;
PAAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.7	8.3	0.56	5.28e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.86	-7.68	-0.53	1.84e-12	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg23708337	chr7:1209742	NA	0.67	5.11	0.38	9.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.6	5.35	0.4	3.17e-7	Menarche (age at onset);
PAAD	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.54	-5.76	-0.42	4.6e-8	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg10006428	chr1:248814059	OR2T27	0.42	4.93	0.37	2.15e-6	Common traits (Other);
PAAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.61	-5.72	-0.42	5.58e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs1499972	0.941	rs62264763	chr3:117637305	G/A	cg07612923	chr3:117604196	NA	1.08	7.1	0.5	4.55e-11	Schizophrenia;
PAAD	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.26	0.56	6.47e-14	Rheumatoid arthritis;
PAAD	cis	rs10916814	1.000	rs12145310	chr1:20901064	C/A	cg04087271	chr1:20915334	CDA	0.38	4.43	0.34	1.77e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.31	0.6	1.36e-16	Parkinson's disease;
PAAD	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs11159840	0.609	rs7141583	chr14:88621760	T/C	cg18078958	chr14:88630771	NA	-0.42	-5.37	-0.4	2.85e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.57	5.78	0.42	4.16e-8	Menopause (age at onset);
PAAD	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-9.88	-0.63	4.27e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg09876464	chr15:85330779	ZNF592	0.44	4.41	0.34	1.93e-5	P wave terminal force;
PAAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg04106633	chr4:1044584	NA	0.67	5.66	0.42	7.24e-8	Recombination rate (females);
PAAD	cis	rs9810890	1.000	rs56003071	chr3:128596048	T/C	cg16818395	chr3:128274084	NA	0.44	4.35	0.33	2.49e-5	Dental caries;
PAAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg11247378	chr22:39784982	NA	-0.69	-7.12	-0.5	3.98e-11	IgG glycosylation;
PAAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.89	10.66	0.65	3.65e-20	Ulcerative colitis;
PAAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.06	0.38	1.2e-6	Aortic root size;
PAAD	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.48	5.16	0.39	7.74e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs7551222	0.614	rs4951386	chr1:204454547	A/G	cg01064725	chr1:204461714	NA	-0.51	-4.61	-0.35	8.64e-6	Schizophrenia;
PAAD	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Blood protein levels;
PAAD	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg19438565	chr8:143695827	ARC	-0.43	-4.27	-0.33	3.36e-5	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.52	7.0	0.49	7.6e-11	Life satisfaction;
PAAD	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg01620082	chr3:125678407	NA	-1.06	-7.18	-0.5	2.9e-11	Depression;
PAAD	cis	rs2885056	0.713	rs58573889	chr19:10679733	A/G	cg04833646	chr19:10679720	CDKN2D	1.02	10.28	0.64	3.77e-19	Red cell distribution width;
PAAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	5.5	0.41	1.6e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-0.94	-9.21	-0.6	2.51e-16	Exhaled nitric oxide output;
PAAD	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.66	6.28	0.45	3.34e-9	IgG glycosylation;
PAAD	cis	rs282587	0.569	rs282601	chr13:113392619	A/G	cg02820901	chr13:113351484	ATP11A	-0.66	-4.99	-0.38	1.61e-6	Glycated hemoglobin levels;
PAAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg06453172	chr10:134556979	INPP5A	-0.5	-4.72	-0.36	5.31e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs62025270	0.632	rs111906684	chr15:86221936	A/G	cg13263323	chr15:86062960	AKAP13	0.5	4.46	0.34	1.6e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.95	8.08	0.55	1.91e-13	Bipolar disorder;
PAAD	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg03233332	chr7:66118400	NA	-0.4	-4.34	-0.33	2.6e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.37	-0.33	2.28e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs58521262	0.505	rs457599	chr19:23132717	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.61	-0.35	8.57e-6	Testicular germ cell tumor;
PAAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.81	7.9	0.54	5.11e-13	Body mass index;
PAAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg10935138	chr17:73851978	WBP2	0.81	7.13	0.5	3.8e-11	Psoriasis;
PAAD	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	0.87	8.5	0.57	1.6e-14	Blood protein levels;
PAAD	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg23024343	chr7:107201750	COG5	0.53	4.41	0.34	1.98e-5	Coronary artery disease;
PAAD	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-5.69	-0.42	6.3e-8	Response to antipsychotic treatment;
PAAD	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.46	5.58	0.41	1.06e-7	Coronary artery disease;
PAAD	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	6.86	0.49	1.6e-10	Blood protein levels;
PAAD	cis	rs1190596	0.525	rs34440178	chr14:102711201	G/C	cg23904247	chr14:102554826	HSP90AA1	0.44	5.1	0.38	9.98e-7	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9463078	0.585	rs1748231	chr6:45133354	T/G	cg25276700	chr6:44698697	NA	-0.46	-5.3	-0.4	3.94e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg25883020	chr8:41504993	NKX6-3	0.36	4.31	0.33	2.92e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs78460081	chr3:128446113	A/G	cg18531004	chr3:128564980	NA	-0.84	-4.75	-0.36	4.72e-6	Dental caries;
PAAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.62	-8.26	-0.56	6.75e-14	Renal cell carcinoma;
PAAD	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.44	4.98	0.37	1.7e-6	Blood protein levels;
PAAD	cis	rs955333	0.542	rs55887937	chr6:154909005	C/T	cg20019720	chr6:154832845	CNKSR3	0.38	5.21	0.39	6.19e-7	Diabetic kidney disease;
PAAD	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15920621	chr6:168396727	NA	0.61	6.45	0.46	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.23	-0.45	4.45e-9	Aortic root size;
PAAD	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.42	0.56	2.6e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12475964	0.637	rs13026696	chr2:37382197	T/C	cg22370082	chr2:37384244	EIF2AK2	0.44	4.37	0.33	2.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.53	5.75	0.42	4.85e-8	Bladder cancer;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.61	6.86	0.49	1.65e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	4.91	0.37	2.33e-6	Cognitive ability;
PAAD	cis	rs2457480	0.866	rs7079375	chr10:44730310	T/C	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;
PAAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06799790	chr17:61951754	CSH2	-0.46	-4.77	-0.36	4.29e-6	Height;
PAAD	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg13565585	chr5:132299512	AFF4	0.63	4.56	0.35	1.06e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.6	5.53	0.41	1.34e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg25547332	chr5:131281432	NA	-0.56	-4.33	-0.33	2.74e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.78	7.84	0.54	7.32e-13	Coronary artery disease;
PAAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11245990	chr11:68621969	NA	0.38	4.91	0.37	2.35e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.39	4.67	0.35	6.63e-6	Tonsillectomy;
PAAD	cis	rs7583236	1.000	rs7567025	chr2:70185108	C/G	cg19638749	chr2:70312615	NA	-0.7	-4.59	-0.35	9.4e-6	Obesity-related traits;
PAAD	cis	rs2421770	0.963	rs3847607	chr11:35321585	A/C	cg13971030	chr11:35366721	SLC1A2	-0.53	-6.41	-0.46	1.77e-9	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs797680	0.964	rs797668	chr1:93694789	C/G	cg04535902	chr1:92947332	GFI1	-0.47	-4.47	-0.34	1.53e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg20159608	chr7:32802032	NA	-0.6	-6.09	-0.44	8.94e-9	Metabolite levels (HVA/MHPG ratio);
PAAD	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg25270899	chr13:101315319	TMTC4	0.65	6.3	0.46	3.06e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg05697835	chr1:2722811	NA	0.43	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.63	6.52	0.47	9.7e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.44	-4.31	-0.33	2.88e-5	Body mass index;
PAAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg13498757	chr1:152161927	NA	0.58	5.69	0.42	6.31e-8	Inflammatory skin disease;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	9.35	0.6	1.04e-16	Alzheimer's disease;
PAAD	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg02951883	chr7:2050386	MAD1L1	0.54	5.04	0.38	1.33e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.33	-0.46	2.56e-9	Bipolar disorder (body mass index interaction);
PAAD	cis	rs977987	0.669	rs1001861	chr16:75306455	G/A	cg03315344	chr16:75512273	CHST6	0.6	6.84	0.48	1.86e-10	Dupuytren's disease;
PAAD	cis	rs797680	0.964	rs12139009	chr1:93573493	A/G	cg04535902	chr1:92947332	GFI1	0.45	4.35	0.33	2.48e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.47	4.86	0.37	2.95e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	1.15	7.79	0.53	9.97e-13	Pediatric areal bone mineral density (radius);
PAAD	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-4.29	-0.33	3.14e-5	Type 2 diabetes;
PAAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg23719950	chr11:63933701	MACROD1	-0.5	-4.36	-0.33	2.43e-5	Platelet count;
PAAD	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.68	0.58	5.83e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14396892	chr9:96623032	NA	-0.4	-4.4	-0.34	2.02e-5	DNA methylation (variation);
PAAD	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-4.35	-0.33	2.45e-5	Blood protein levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22268271	chr22:39548261	CBX7	0.7	7.96	0.54	3.8e-13	Myopia (pathological);
PAAD	cis	rs6066825	0.590	rs729663	chr20:47304306	C/T	cg18078177	chr20:47281410	PREX1	-0.45	-4.39	-0.34	2.08e-5	Colorectal cancer;
PAAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	6.65	0.47	5.07e-10	Menarche (age at onset);
PAAD	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16417436	chr16:28758564	NA	0.45	4.3	0.33	3.05e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg05163071	chr3:108476540	RETNLB	0.96	6.83	0.48	1.88e-10	Dental caries;
PAAD	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.6	5.44	0.4	2.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9652601	0.622	rs8056098	chr16:11138812	G/A	cg04616529	chr16:11181986	CLEC16A	0.39	4.58	0.35	9.65e-6	Systemic lupus erythematosus;
PAAD	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.54	-6.76	-0.48	2.76e-10	Atrioventricular conduction;
PAAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	1.1	12.1	0.7	4.92e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg08132940	chr7:1081526	C7orf50	0.62	4.78	0.36	4.07e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	4.97	0.37	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.79	8.6	0.57	9.16e-15	Prostate cancer;
PAAD	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.4	4.8	0.36	3.82e-6	Uric acid levels;
PAAD	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.57	4.82	0.36	3.43e-6	Menopause (age at onset);
PAAD	cis	rs2398893	0.960	rs11788176	chr9:96829243	C/T	cg14459158	chr9:96720562	NA	0.34	4.4	0.34	2.06e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg10556349	chr10:835070	NA	0.7	5.36	0.4	3.07e-7	Eosinophil percentage of granulocytes;
PAAD	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg04018474	chr16:31008003	STX1B	-0.28	-4.37	-0.33	2.32e-5	Dementia with Lewy bodies;
PAAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.72	6.73	0.48	3.27e-10	Total body bone mineral density;
PAAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg21625146	chr5:486483	SLC9A3	0.36	5.31	0.4	3.75e-7	Cystic fibrosis severity;
PAAD	cis	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg05084668	chr3:125655381	ALG1L	0.53	5.43	0.4	2.19e-7	Blood pressure (smoking interaction);
PAAD	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.82	9.27	0.6	1.72e-16	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-11.67	-0.69	6.96e-23	Cognitive function;
PAAD	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24000259	chr5:55488291	ANKRD55	0.56	6.65	0.47	4.84e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.58	-6.88	-0.49	1.43e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs955333	0.601	rs78453013	chr6:154902249	T/A	cg20019720	chr6:154832845	CNKSR3	0.35	4.83	0.36	3.35e-6	Diabetic kidney disease;
PAAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.6	5.81	0.43	3.46e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	4.38	0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg24747557	chr10:131355152	MGMT	-0.49	-5.57	-0.41	1.1e-7	Response to temozolomide;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12958836	chr12:8185024	FOXJ2	0.68	6.4	0.46	1.86e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg11498726	chr8:26250323	BNIP3L	0.51	4.76	0.36	4.51e-6	Height;
PAAD	cis	rs4150161	0.656	rs77958073	chr16:84223622	T/G	cg10106505	chr16:84220380	TAF1C	-1.26	-7.09	-0.5	4.68e-11	Systolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	5.65	0.42	7.83e-8	Prudent dietary pattern;
PAAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.56e-9	Bipolar disorder;
PAAD	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.41e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.59	7.14	0.5	3.54e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.77	-7.47	-0.52	5.75e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26378065	chr17:18585709	ZNF286B	0.56	5.55	0.41	1.24e-7	Educational attainment (years of education);
PAAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.72	7.79	0.53	9.72e-13	Morning vs. evening chronotype;
PAAD	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg23127183	chr11:57508653	C11orf31	-0.5	-4.39	-0.34	2.15e-5	Schizophrenia;
PAAD	cis	rs7631605	0.935	rs9854641	chr3:37218461	T/C	cg17445812	chr3:36986805	TRANK1	0.33	4.47	0.34	1.53e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.67	6.47	0.46	1.28e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs1499972	0.941	rs56204450	chr3:117604215	G/A	cg07612923	chr3:117604196	NA	1.05	7.06	0.5	5.61e-11	Schizophrenia;
PAAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.82	-8.91	-0.59	1.44e-15	Prostate cancer;
PAAD	trans	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.63	-0.47	5.61e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg12092346	chr18:77659572	KCNG2	-0.64	-4.51	-0.34	1.29e-5	Opioid sensitivity;
PAAD	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	10.96	0.66	5.62e-21	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg12508331	chr16:3208203	NA	0.5	4.59	0.35	9.13e-6	Body mass index (adult);
PAAD	cis	rs17092148	0.887	rs6058104	chr20:33271052	G/A	cg16810054	chr20:33298113	TP53INP2	-0.58	-4.33	-0.33	2.7e-5	Neuroticism;
PAAD	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.03	7.19	0.5	2.81e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.49	-4.61	-0.35	8.4e-6	Renal cell carcinoma;
PAAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg22143856	chr6:28129313	ZNF389	0.68	5.42	0.4	2.31e-7	Depression;
PAAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.66	4.45	0.34	1.64e-5	Blood protein levels;
PAAD	cis	rs4140564	0.730	rs1569485	chr1:186690435	C/T	cg16721191	chr1:185703526	HMCN1	-0.75	-4.37	-0.33	2.28e-5	Knee osteoarthritis;
PAAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.4	-0.83	1.66e-40	Ulcerative colitis;
PAAD	trans	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg19694781	chr19:47549865	TMEM160	-0.57	-6.61	-0.47	6.1e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.51	4.55	0.35	1.08e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.94	7.41	0.52	8.2e-12	Lymphocyte counts;
PAAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.51	6.2	0.45	5.07e-9	Monobrow;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg13560548	chr3:10150139	C3orf24	0.59	5.12	0.38	9.25e-7	Alzheimer's disease;
PAAD	cis	rs73388146	1.000	rs73388146	chr6:25170668	G/A	cg08126211	chr6:24357720	KAAG1;DCDC2	-0.91	-4.65	-0.35	7.18e-6	Schizophrenia;
PAAD	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	1.27	8.28	0.56	5.74e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.23	-10.06	-0.63	1.47e-18	Breast cancer;
PAAD	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg05585544	chr11:47624801	NA	0.46	5.13	0.38	8.87e-7	Subjective well-being;
PAAD	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg24053715	chr22:38214548	NA	0.58	5.74	0.42	5.07e-8	Glioblastoma;Glioma;
PAAD	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-0.92	-6.22	-0.45	4.61e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.73	8.24	0.56	7.56e-14	Birth weight;
PAAD	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.53	5.75	0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18364779	chr6:26104403	HIST1H4C	0.53	5.24	0.39	5.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.81	9.72	0.62	1.12e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1329189	1.000	rs10764765	chr10:130007730	C/T	cg17972361	chr10:130010134	NA	-0.46	-4.64	-0.35	7.52e-6	Orofacial clefts;
PAAD	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg27236539	chr20:62289627	RTEL1	0.57	4.62	0.35	8.24e-6	Atopic dermatitis;
PAAD	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs34311866	0.656	rs11731377	chr4:971266	T/G	cg07828340	chr4:882639	GAK	0.87	6.32	0.46	2.75e-9	Parkinson's disease;
PAAD	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg09127314	chr1:152161683	NA	0.71	5.34	0.4	3.32e-7	Atopic dermatitis;
PAAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.52	-5.28	-0.39	4.35e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg11822372	chr1:151115635	SEMA6C	0.59	5.32	0.4	3.62e-7	Childhood ear infection;
PAAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.57	6.06	0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs7631605	0.686	rs6550443	chr3:36999582	A/T	cg17445812	chr3:36986805	TRANK1	0.33	4.44	0.34	1.75e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.55	-0.35	1.1e-5	Blood metabolite levels;
PAAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.71	-8.4	-0.56	3e-14	Eye color traits;
PAAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg19673125	chr6:150240577	RAET1G	0.44	6.28	0.45	3.37e-9	Testicular germ cell tumor;
PAAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg21130718	chr4:1044621	NA	0.51	4.5	0.34	1.35e-5	Recombination rate (females);
PAAD	cis	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-5.07	-0.38	1.13e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.74	7.57	0.52	3.29e-12	Alcohol dependence;
PAAD	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-4.78	-0.36	4.03e-6	Menopause (age at onset);
PAAD	cis	rs8112211	0.689	rs4802327	chr19:38793319	G/A	cg14299480	chr19:38876666	GGN	-0.5	-4.27	-0.33	3.46e-5	Blood protein levels;
PAAD	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-5.5	-0.41	1.58e-7	Mean corpuscular volume;
PAAD	cis	rs7140150	0.734	rs1950909	chr14:52029007	C/T	cg05008843	chr14:52622696	NA	0.38	4.45	0.34	1.62e-5	Brain structure;
PAAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.94	9.32	0.6	1.3e-16	Corneal astigmatism;
PAAD	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.16	-0.45	6.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-6.01	-0.44	1.35e-8	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	9.07	0.59	5.84e-16	Motion sickness;
PAAD	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg22916017	chr11:64110731	CCDC88B	0.47	4.49	0.34	1.4e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.09	0.59	4.93e-16	Motion sickness;
PAAD	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.89	-7.54	-0.52	3.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs987237	0.901	rs2076308	chr6:50791640	G/C	cg24161652	chr6:50813859	TFAP2B	0.35	4.29	0.33	3.14e-5	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Childhood body mass index;Adiposity;Body mass index in physically active individuals;
PAAD	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.63	6.05	0.44	1.1e-8	Corneal astigmatism;
PAAD	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg16434002	chr17:42200994	HDAC5	0.46	4.55	0.35	1.1e-5	Red cell distribution width;Reticulocyte count;
PAAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-5.79	-0.43	3.85e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7662987	1.000	rs1803037	chr4:99993151	C/T	cg12011299	chr4:100065546	ADH4	-0.68	-4.48	-0.34	1.44e-5	Smoking initiation;
PAAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.51	5.36	0.4	3.05e-7	Obesity-related traits;
PAAD	cis	rs1420338	0.967	rs10224203	chr7:34149593	C/T	cg01275685	chr7:34179230	BMPER	-0.53	-5.03	-0.38	1.35e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-1.03	-8.05	-0.55	2.24e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.57	-5.49	-0.41	1.65e-7	Personality dimensions;
PAAD	cis	rs4708832	0.564	rs240855	chr6:159923390	G/A	cg04088182	chr6:159188303	EZR	-0.59	-4.25	-0.33	3.69e-5	QRS duration;
PAAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.47	4.71	0.36	5.63e-6	Schizophrenia;
PAAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.73	-7.3	-0.51	1.47e-11	Height;
PAAD	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg22138327	chr13:27999177	GTF3A	0.85	5.31	0.4	3.75e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg00080972	chr5:178986291	RUFY1	-0.52	-5.03	-0.38	1.37e-6	Lung cancer;
PAAD	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.78	8.12	0.55	1.44e-13	Corneal astigmatism;
PAAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.53	6.23	0.45	4.38e-9	Mean corpuscular volume;
PAAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.75	7.58	0.52	3.23e-12	Lung cancer;
PAAD	cis	rs13248545	0.600	rs7386669	chr8:17613795	A/T	cg13252206	chr8:16970768	EFHA2	0.53	4.27	0.33	3.49e-5	Yeast infection;
PAAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.67	-6.27	-0.45	3.57e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg14926445	chr8:58193284	C8orf71	-0.65	-5.11	-0.38	9.39e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.7	-6.79	-0.48	2.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	1.02	8.83	0.58	2.33e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg21605333	chr4:119757512	SEC24D	1.84	9.3	0.6	1.4e-16	Cannabis dependence symptom count;
PAAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg18769074	chr3:133464867	TF	0.42	4.85	0.37	3.02e-6	Iron status biomarkers;
PAAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.95	-12.96	-0.72	2.4e-26	Height;
PAAD	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.62	-6.63	-0.47	5.39e-10	IgG glycosylation;
PAAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-5.15	-0.39	7.88e-7	Gut microbiome composition (summer);
PAAD	cis	rs6681460	0.932	rs2483705	chr1:67191180	C/G	cg02459107	chr1:67143332	SGIP1	-0.7	-6.5	-0.47	1.11e-9	Presence of antiphospholipid antibodies;
PAAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.53	-6.1	-0.44	8.52e-9	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg01338084	chr22:32026380	PISD	1.57	9.72	0.62	1.15e-17	Age-related hearing impairment;
PAAD	cis	rs1008126	0.600	rs2528856	chr7:103142795	T/C	cg04218035	chr7:103086829	SLC26A5	0.37	5.17	0.39	7.42e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2555155	0.807	rs2253104	chr11:6500309	A/G	cg24637308	chr11:6592297	DNHD1	0.43	4.57	0.35	1e-5	DNA methylation (variation);
PAAD	cis	rs72960926	1.000	rs16884858	chr6:75107741	C/A	cg13997649	chr6:74171430	MTO1	0.81	4.5	0.34	1.37e-5	Metabolite levels (MHPG);
PAAD	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.65	5.5	0.41	1.56e-7	Morning vs. evening chronotype;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16997989	chr18:9136565	ANKRD12	-0.67	-7.16	-0.5	3.27e-11	Smoking initiation;
PAAD	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.59	-0.35	9.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.57	-5.55	-0.41	1.26e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	1.13	16.69	0.8	3.44e-36	Breast cancer;
PAAD	cis	rs863345	0.967	rs10399681	chr1:158525551	C/T	cg12129480	chr1:158549410	OR10X1	-0.45	-5.1	-0.38	9.88e-7	Pneumococcal bacteremia;
PAAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg10396713	chr8:602097	NA	0.73	5.44	0.4	2.05e-7	IgG glycosylation;
PAAD	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.89	13.38	0.74	1.8e-27	Gait variability;
PAAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.13	-10.3	-0.64	3.33e-19	Initial pursuit acceleration;
PAAD	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg12215294	chr3:40350768	EIF1B	-0.47	-4.85	-0.37	3.03e-6	Renal cell carcinoma;
PAAD	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.97	-10.24	-0.64	4.69e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.72	-0.48	3.39e-10	Response to antipsychotic treatment;
PAAD	cis	rs2080501	0.628	rs28542020	chr16:49660588	T/C	cg00535248	chr16:50588226	NKD1	-0.44	-4.51	-0.34	1.27e-5	IgG glycosylation;
PAAD	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg10547527	chr2:198650123	BOLL	-0.66	-4.49	-0.34	1.4e-5	Ulcerative colitis;
PAAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.93	6.86	0.49	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.75	-5.42	-0.4	2.32e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.52	5.46	0.4	1.94e-7	Red blood cell count;
PAAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.95	8.45	0.57	2.15e-14	Alzheimer's disease;
PAAD	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17347941	chr15:79387269	NA	0.39	4.44	0.34	1.7e-5	Refractive error;
PAAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.78	9.8	0.62	7.19e-18	Bone mineral density;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg11143131	chr5:131608246	PDLIM4	-0.52	-5.32	-0.4	3.67e-7	Blood metabolite levels;
PAAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg07148914	chr20:33460835	GGT7	-0.47	-4.65	-0.35	7.14e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs7188861	0.681	rs12922409	chr16:11415289	C/T	cg16532467	chr16:11454386	NA	-0.55	-4.31	-0.33	2.89e-5	HDL cholesterol;
PAAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.93	-10.12	-0.63	9.94e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs12780845	1.000	rs7096692	chr10:17180828	G/A	cg00857480	chr10:17188594	TRDMT1	0.39	4.96	0.37	1.83e-6	Homocysteine levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14353208	chr7:155573845	RBM33	-0.71	-6.46	-0.46	1.32e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.96	8.39	0.56	3.1e-14	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.66	-0.42	7.27e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg12315302	chr6:26189340	HIST1H4D	0.86	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	1.19	15.54	0.78	3.23e-33	Longevity;
PAAD	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	4.52	0.34	1.22e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.06e-10	Testicular germ cell tumor;
PAAD	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.47	-0.34	1.49e-5	Joint mobility (Beighton score);
PAAD	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.56	7.16	0.5	3.26e-11	Ewing sarcoma;
PAAD	cis	rs72843506	0.656	rs77090106	chr17:19948145	G/A	cg05625806	chr17:19284432	MAPK7	0.68	4.47	0.34	1.52e-5	Schizophrenia;
PAAD	cis	rs3935685	0.845	rs7175083	chr15:78006842	T/C	cg25212270	chr15:78015279	NA	0.41	4.39	0.34	2.15e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-5.54	-0.41	1.28e-7	Reticulocyte count;
PAAD	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.73	-8.36	-0.56	3.71e-14	Mononucleosis;
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05665937	chr4:1216051	CTBP1	-0.42	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06217245	chr20:33103252	DYNLRB1	-0.39	-4.78	-0.36	4.16e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs838147	0.844	rs11083948	chr19:49248120	A/G	cg13540341	chr19:49222985	MAMSTR	0.42	4.8	0.36	3.84e-6	Dietary macronutrient intake;
PAAD	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.39	-9.59	-0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg08731068	chr17:77960689	TBC1D16	-0.52	-6.36	-0.46	2.19e-9	Pulmonary function;
PAAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg02462569	chr6:150064036	NUP43	-0.49	-5.47	-0.41	1.85e-7	Lung cancer;
PAAD	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.57	6.7	0.48	3.91e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
PAAD	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	5.74	0.42	4.98e-8	Multiple sclerosis;
PAAD	cis	rs8032158	1.000	rs10851599	chr15:56154064	T/G	cg02198044	chr15:56286336	NEDD4	-0.49	-5.15	-0.39	7.81e-7	Keloid;
PAAD	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg02421172	chr7:1938701	MAD1L1	0.6	4.58	0.35	9.43e-6	Bipolar disorder;
PAAD	cis	rs4811196	0.518	rs1330020	chr20:36381365	A/T	cg04608177	chr20:37230389	C20orf95	-0.39	-4.43	-0.34	1.81e-5	Bone mineral density;
PAAD	cis	rs8105895	0.666	rs62110991	chr19:22260842	C/T	cg20662725	chr19:22235022	ZNF257	-0.53	-4.3	-0.33	3.04e-5	Body mass index (change over time);
PAAD	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg24747557	chr10:131355152	MGMT	0.54	5.56	0.41	1.2e-7	Response to temozolomide;
PAAD	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-4.69	-0.36	5.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.88	6.95	0.49	1e-10	Axial length;
PAAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.59	6.0	0.44	1.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.88	8.49	0.57	1.72e-14	Homoarginine levels;
PAAD	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	1.02	7.98	0.54	3.22e-13	Menopause (age at onset);
PAAD	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.7	7.62	0.53	2.49e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg18892244	chr7:807596	HEATR2	-0.69	-5.25	-0.39	4.95e-7	Initial pursuit acceleration;
PAAD	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.81	6.34	0.46	2.45e-9	Platelet count;
PAAD	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.67	4.56	0.35	1.03e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg08198773	chr8:1697536	NA	0.47	5.17	0.39	7.19e-7	Systolic blood pressure;
PAAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10214930	0.625	rs2391453	chr7:27690587	T/C	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23158103	chr7:148848205	ZNF398	-0.52	-4.71	-0.36	5.54e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg02997394	chr19:33096574	ANKRD27	-0.4	-4.32	-0.33	2.77e-5	Schizophrenia;
PAAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg10356904	chr22:49881777	NA	-0.5	-5.53	-0.41	1.39e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01771876	chr2:11886613	LPIN1	0.58	6.36	0.46	2.23e-9	Monocyte percentage of white cells;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21219666	chr17:40166108	DNAJC7	-0.59	-6.68	-0.48	4.32e-10	Monocyte percentage of white cells;
PAAD	cis	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	3.43e-18	Cognitive function;
PAAD	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg01631684	chr10:65280961	REEP3	-0.45	-4.55	-0.35	1.09e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.6	-6.42	-0.46	1.69e-9	Blood metabolite levels;
PAAD	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg19217778	chr13:113420270	ATP11A	0.63	4.37	0.33	2.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	4.25	0.33	3.67e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.54	5.77	0.42	4.27e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14019695	chr9:139328340	INPP5E	0.57	4.95	0.37	1.95e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg13225830	chr1:9527173	NA	0.37	4.3	0.33	3.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.97	8.43	0.56	2.49e-14	Alzheimer's disease;
PAAD	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.52	5.0	0.38	1.54e-6	Dialysis-related mortality;
PAAD	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.91	-7.22	-0.51	2.36e-11	Total cholesterol levels;
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	4.82	0.36	3.46e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06850241	chr22:41845214	NA	0.55	5.04	0.38	1.32e-6	Cannabis dependence symptom count;
PAAD	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.6	5.84	0.43	3.07e-8	Alcohol dependence;
PAAD	cis	rs11825685	0.887	rs78806216	chr11:134568320	C/T	cg06603561	chr11:134479413	NA	-0.79	-5.1	-0.38	1e-6	IgG glycosylation;
PAAD	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.25	-0.39	4.94e-7	Fear of minor pain;
PAAD	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg10434728	chr15:90938212	IQGAP1	-0.45	-4.54	-0.35	1.14e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.79	-9.21	-0.6	2.48e-16	Type 2 diabetes;
PAAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg15571903	chr15:79123663	NA	0.49	6.3	0.46	3.04e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg23346134	chr3:49453900	TCTA	0.43	4.72	0.36	5.23e-6	Menarche (age at onset);
PAAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	1.11	16.56	0.8	7.51e-36	Breast cancer;
PAAD	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg01631408	chr1:248437212	OR2T33	-0.58	-5.25	-0.39	5.15e-7	Common traits (Other);
PAAD	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg22089800	chr15:90895588	ZNF774	0.58	5.61	0.41	9.39e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs818427	0.593	rs456531	chr5:112216189	T/C	cg06941702	chr5:112196734	SRP19	0.53	5.05	0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.47	-5.54	-0.41	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.13	-0.5	3.82e-11	Migraine;Coronary artery disease;
PAAD	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg01631408	chr1:248437212	OR2T33	-0.56	-5.01	-0.38	1.48e-6	Common traits (Other);
PAAD	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	4.31	0.33	2.89e-5	Educational attainment;
PAAD	cis	rs639012	0.667	rs526904	chr11:85811364	T/C	cg07180834	chr11:85838833	NA	-0.5	-5.66	-0.42	7.46e-8	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.63	6.71	0.48	3.54e-10	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.74e-17	Type 2 diabetes;
PAAD	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs76866386	0.786	rs4507142	chr2:44086591	G/A	cg26706238	chr2:44066206	ABCG5;ABCG8	-0.91	-5.26	-0.39	4.72e-7	Cholesterol, total;
PAAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	0.9	5.98	0.44	1.51e-8	IgG glycosylation;
PAAD	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg18612461	chr15:75251733	NA	-0.4	-4.72	-0.36	5.31e-6	Systemic lupus erythematosus;
PAAD	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.76	-6.62	-0.47	5.85e-10	Body mass index;
PAAD	trans	rs901683	1.000	rs34268168	chr10:45988526	G/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.49	-0.47	1.13e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7617773	0.638	rs7644414	chr3:48299079	A/T	cg11946769	chr3:48343235	NME6	0.62	5.7	0.42	5.93e-8	Coronary artery disease;
PAAD	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg06740227	chr12:86229804	RASSF9	0.49	4.67	0.35	6.5e-6	Major depressive disorder;
PAAD	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg05309399	chr4:106552544	FLJ20184	-0.56	-4.5	-0.34	1.36e-5	Post bronchodilator FEV1;
PAAD	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.93	11.68	0.69	6.53e-23	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg03386751	chr17:37843793	ERBB2;PGAP3	0.34	4.66	0.35	6.82e-6	Asthma;
PAAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg21191810	chr6:118973309	C6orf204	0.52	4.94	0.37	2.03e-6	Diastolic blood pressure;
PAAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.83	6.03	0.44	1.18e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs2952768	1.000	rs2709409	chr2:208511233	C/A	cg22329743	chr2:208688774	PLEKHM3	0.22	4.38	0.34	2.16e-5	Opioid sensitivity;
PAAD	cis	rs9287719	0.649	rs6721857	chr2:10721210	C/T	cg00105475	chr2:10696890	NA	-0.61	-6.43	-0.46	1.59e-9	Prostate cancer;
PAAD	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.51	5.37	0.4	2.92e-7	Male-pattern baldness;
PAAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg14343924	chr8:8086146	FLJ10661	-0.67	-6.03	-0.44	1.22e-8	Mood instability;
PAAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg00504896	chr12:9437009	LOC642846	-0.46	-4.28	-0.33	3.28e-5	Breast size;
PAAD	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	1.24	15.69	0.79	1.33e-33	Ewing sarcoma;
PAAD	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg12858261	chr2:113808755	IL1F8	0.45	4.5	0.34	1.36e-5	Inflammatory biomarkers;
PAAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.42	-5.12	-0.38	9.01e-7	Body mass index in non-asthmatics;
PAAD	cis	rs28595532	0.720	rs72670224	chr4:119301885	G/T	cg21605333	chr4:119757512	SEC24D	1.43	7.59	0.52	3.02e-12	Cannabis dependence symptom count;
PAAD	cis	rs11264213	0.901	rs72661646	chr1:36454954	A/T	cg27506609	chr1:36549197	TEKT2	1.12	6.19	0.45	5.45e-9	Schizophrenia;
PAAD	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg02683114	chr2:24398427	C2orf84	-0.48	-5.15	-0.39	8.13e-7	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg09945482	chr18:12777974	NA	-0.64	-5.49	-0.41	1.63e-7	Inflammatory skin disease;
PAAD	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg04545296	chr12:48745243	ZNF641	0.35	4.42	0.34	1.84e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs7631605	0.518	rs6777217	chr3:36979042	A/G	cg17445812	chr3:36986805	TRANK1	0.36	5.08	0.38	1.11e-6	Cerebrospinal P-tau181p levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10702113	chr3:196664466	NCBP2	-0.61	-6.44	-0.46	1.46e-9	Myopia (pathological);
PAAD	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.55	-6.09	-0.44	8.65e-9	Metabolite levels;
PAAD	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg21823605	chr1:152486609	CRCT1	0.51	6.44	0.46	1.5e-9	Hair morphology;
PAAD	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg15192750	chr16:69999425	NA	0.76	5.87	0.43	2.69e-8	IgE levels;
PAAD	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.81	-5.38	-0.4	2.82e-7	Major depressive disorder;
PAAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg22868518	chr11:507468	RNH1	-0.9	-4.65	-0.35	7.04e-6	Body mass index;
PAAD	cis	rs714031	0.785	rs11704439	chr22:40069493	T/G	cg21377881	chr22:40064566	CACNA1I	-0.48	-4.53	-0.35	1.17e-5	Schizophrenia;
PAAD	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-6.01	-0.44	1.31e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs4523957	0.583	rs2984940	chr17:2023825	A/G	cg16513277	chr17:2031491	SMG6	-0.62	-6.47	-0.46	1.25e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.64	-5.94	-0.43	1.87e-8	Diisocyanate-induced asthma;
PAAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.95	11.53	0.68	1.7e-22	Longevity;
PAAD	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg21479132	chr6:26055353	NA	0.99	6.41	0.46	1.72e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.67	0.48	4.52e-10	Lung cancer;
PAAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.59	8.88	0.58	1.81e-15	Hypertriglyceridemia;
PAAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg09835421	chr16:68378352	PRMT7	-1.36	-10.23	-0.64	5.22e-19	Magnesium levels;
PAAD	cis	rs4356203	0.905	rs621246	chr11:17203765	G/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-4.38	-0.33	2.2e-5	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.43	-6.48	-0.47	1.22e-9	Breast cancer;
PAAD	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg16417436	chr16:28758564	NA	0.44	4.38	0.33	2.21e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.49	4.6	0.35	8.9e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.89	5.87	0.43	2.7e-8	Blood protein levels;
PAAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-17.37	-0.82	6.5e-38	Height;
PAAD	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.73	0.58	4.17e-15	Morning vs. evening chronotype;
PAAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.55	5.87	0.43	2.6e-8	Menopause (age at onset);
PAAD	cis	rs34845616	0.551	rs4936209	chr11:133686106	C/G	cg06766960	chr11:133703094	NA	0.55	4.56	0.35	1.05e-5	Hand grip strength;
PAAD	cis	rs2120243	0.504	rs114107407	chr3:157062635	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	4.3	0.33	3.04e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	6.64	0.47	5.18e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.72	7.37	0.51	1.02e-11	Colorectal cancer;
PAAD	cis	rs9810890	1.000	rs73196968	chr3:128438798	G/C	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.88	7.58	0.52	3.21e-12	Alzheimer's disease;
PAAD	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	10.53	0.65	8.04e-20	Menopause (age at onset);
PAAD	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg00522288	chr12:125625016	AACS	-0.48	-5.15	-0.39	7.88e-7	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.64	-5.56	-0.41	1.18e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.71	-6.04	-0.44	1.16e-8	Bone mineral density;
PAAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg10556349	chr10:835070	NA	0.58	4.97	0.37	1.8e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.86	7.52	0.52	4.38e-12	Alzheimer's disease;
PAAD	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg19626725	chr5:178986131	RUFY1	-0.51	-5.52	-0.41	1.4e-7	Lung cancer;
PAAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.86	11.01	0.67	4.34e-21	Height;
PAAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.51	4.96	0.37	1.86e-6	Morning vs. evening chronotype;
PAAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.49	4.53	0.34	1.19e-5	Height;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03604172	chr1:36349543	EIF2C1	-0.69	-6.73	-0.48	3.22e-10	Lung cancer in ever smokers;
PAAD	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.53	-5.75	-0.42	4.7e-8	Dementia with Lewy bodies;
PAAD	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg14019146	chr3:50243930	SLC38A3	-0.49	-5.08	-0.38	1.08e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7011049	1.000	rs72648409	chr8:53857307	T/C	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg16591659	chr17:78472290	NA	0.51	4.93	0.37	2.14e-6	Fractional excretion of uric acid;
PAAD	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-6.11	-0.44	7.94e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-0.77	-7.83	-0.54	7.89e-13	Prostate cancer;
PAAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.7	-8.29	-0.56	5.62e-14	Eye color traits;
PAAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.34e-7	Life satisfaction;
PAAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.77	-6.97	-0.49	9.23e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg01942863	chr7:99769432	GPC2	0.52	4.29	0.33	3.11e-5	Lung function (FEV1/FVC);
PAAD	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg13870426	chr17:30244630	NA	-0.79	-6.47	-0.46	1.3e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.95	-0.43	1.78e-8	Schizophrenia;
PAAD	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.53	5.31	0.4	3.77e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg08501292	chr6:25962987	TRIM38	0.99	5.83	0.43	3.14e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.28	4.43	0.34	1.82e-5	Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	4.51	0.34	1.27e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.45	4.6	0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg21546286	chr11:48923668	NA	0.58	6.09	0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs4729127	0.908	rs55746023	chr7:94006138	G/A	cg20814616	chr7:94014465	NA	-0.6	-4.41	-0.34	1.96e-5	Intelligence;
PAAD	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.62	-5.83	-0.43	3.16e-8	Malaria;
PAAD	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-4.67	-0.35	6.57e-6	Resting heart rate;
PAAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-7.67	-0.53	1.89e-12	Vitiligo;
PAAD	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.7	-8.2	-0.55	9.22e-14	Educational attainment;
PAAD	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.19	-0.39	6.57e-7	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg18827107	chr12:86230957	RASSF9	0.4	4.26	0.33	3.52e-5	Major depressive disorder;
PAAD	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg05250797	chr16:70222502	NA	0.84	6.39	0.46	1.89e-9	IgE levels;
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-4.63	-0.35	7.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06544989	chr22:39130855	UNC84B	0.5	4.93	0.37	2.08e-6	Menopause (age at onset);
PAAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg25753631	chr6:25732923	NA	-0.46	-5.29	-0.39	4.29e-7	Iron status biomarkers;
PAAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-5.97	-0.44	1.64e-8	Lymphocyte counts;
PAAD	cis	rs7168353	0.519	rs725458	chr15:93634933	A/G	cg12595281	chr15:93633172	RGMA	-0.37	-4.81	-0.36	3.52e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.59	-5.54	-0.41	1.28e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.54	-5.38	-0.4	2.7e-7	Prudent dietary pattern;
PAAD	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.12e-9	Type 2 diabetes;
PAAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.65	-7.41	-0.52	8.21e-12	Iron status biomarkers;
PAAD	cis	rs3018712	0.522	rs4930593	chr11:68434181	A/C	cg23009355	chr11:68451396	GAL	-0.45	-5.34	-0.4	3.28e-7	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4236601	0.586	rs6466581	chr7:116162985	T/A	cg12739419	chr7:116140593	CAV2	-0.31	-4.27	-0.33	3.41e-5	Intraocular pressure;Glaucoma (primary open-angle);
PAAD	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	6.77	0.48	2.57e-10	Systolic blood pressure;
PAAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg11764359	chr7:65958608	NA	0.77	5.07	0.38	1.14e-6	Diabetic kidney disease;
PAAD	cis	rs2131877	0.830	rs1874100	chr3:194849022	G/A	cg16306870	chr3:194868790	C3orf21	0.48	4.32	0.33	2.84e-5	Non-small cell lung cancer;
PAAD	cis	rs9815354	0.951	rs9837273	chr3:41813104	T/C	cg03022575	chr3:42003672	ULK4	0.8	5.99	0.44	1.46e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4629180	1.000	rs59246268	chr2:102089021	G/A	cg01388757	chr2:102091195	RFX8	-0.63	-7.75	-0.53	1.25e-12	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg17551891	chr7:1960795	MAD1L1	-0.5	-4.4	-0.34	1.99e-5	Neuroticism;
PAAD	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.63	6.78	0.48	2.52e-10	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.59	5.36	0.4	3e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs12523822	0.957	rs55737042	chr6:154955676	T/C	cg20019720	chr6:154832845	CNKSR3	0.3	4.45	0.34	1.68e-5	Diabetic kidney disease;
PAAD	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14119001	chr9:139324193	INPP5E	-0.67	-6.04	-0.44	1.12e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs300703	0.655	rs300798	chr2:105917	A/G	cg24565620	chr2:194026	NA	0.65	4.93	0.37	2.17e-6	Blood protein levels;
PAAD	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg04920474	chr2:44395004	PPM1B	0.44	4.25	0.33	3.76e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18621852	chr3:10150065	C3orf24	0.55	5.01	0.38	1.48e-6	Alzheimer's disease;
PAAD	cis	rs10214930	0.697	rs6963421	chr7:27692428	T/G	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs3106136	0.678	rs11932054	chr4:95289694	A/G	cg11021082	chr4:95130006	SMARCAD1	0.55	5.28	0.39	4.46e-7	Capecitabine sensitivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06482044	chr16:31191169	FUS	0.71	7.47	0.52	5.93e-12	Obesity-related traits;
PAAD	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.9	8.97	0.59	1.03e-15	Corneal astigmatism;
PAAD	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg01305830	chr4:1604576	NA	0.51	4.55	0.35	1.11e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-1.2	-11.64	-0.69	8.8e-23	Developmental language disorder (linguistic errors);
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.79	5.31	0.4	3.76e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.73	7.19	0.5	2.72e-11	Asperger disorder;
PAAD	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.5	-4.88	-0.37	2.64e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.56	6.29	0.45	3.22e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	6.15	0.45	6.48e-9	Schizophrenia;
PAAD	cis	rs12767760	0.625	rs10748700	chr10:99313438	G/C	cg25247692	chr10:99313390	UBTD1	0.56	5.47	0.41	1.84e-7	Obesity-related traits;
PAAD	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.67	5.24	0.39	5.22e-7	Alzheimer's disease (survival time);
PAAD	cis	rs1879734	0.731	rs12082358	chr1:54156624	A/C	cg14659662	chr1:54151053	GLIS1	-0.43	-6.01	-0.44	1.34e-8	Mitral valve prolapse;
PAAD	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg14581129	chr12:53358946	NA	-1.03	-11.71	-0.69	5.67e-23	Cancer (pleiotropy);
PAAD	trans	rs10767455	1.000	rs16914608	chr11:25794091	C/T	cg09986774	chr16:69166346	CHTF8;CIRH1A	0.57	6.38	0.46	1.98e-9	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.79	-9.19	-0.6	2.72e-16	Huntington's disease progression;
PAAD	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg09237302	chr4:906077	GAK	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs5020097	chr17:61814198	G/C	cg00280220	chr17:61926910	NA	0.46	4.76	0.36	4.5e-6	Prudent dietary pattern;
PAAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.97	12.44	0.71	6.03e-25	Menopause (age at onset);
PAAD	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	5.72	0.42	5.36e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.14	-0.5	3.59e-11	Personality dimensions;
PAAD	cis	rs877529	0.932	rs139398	chr22:39544970	C/G	cg18708252	chr22:39545030	CBX7	-0.45	-4.48	-0.34	1.47e-5	Multiple myeloma;
PAAD	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg25418670	chr11:30344373	C11orf46	-0.61	-5.87	-0.43	2.68e-8	Morning vs. evening chronotype;
PAAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.76	6.75	0.48	2.87e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.5e-5	Testicular germ cell tumor;
PAAD	cis	rs883565	0.543	rs784497	chr3:39179909	G/A	cg01426195	chr3:39028469	NA	0.58	5.63	0.42	8.51e-8	Handedness;
PAAD	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.2	0.84	1.81e-42	IgG glycosylation;
PAAD	cis	rs12936587	0.601	rs11655881	chr17:17553133	G/A	cg04398451	chr17:18023971	MYO15A	0.48	4.46	0.34	1.57e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.77	7.51	0.52	4.75e-12	Gestational age at birth (maternal effect);
PAAD	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.46	-4.48	-0.34	1.43e-5	Mean platelet volume;
PAAD	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg00531865	chr16:30841666	NA	-0.56	-4.33	-0.33	2.64e-5	Dementia with Lewy bodies;
PAAD	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.49	-4.7	-0.36	5.72e-6	Longevity;
PAAD	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.5	5.1	0.38	9.89e-7	Red blood cell count;
PAAD	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-4.59	-0.35	9.07e-6	Testicular germ cell tumor;
PAAD	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-7.12	-0.5	3.95e-11	Menarche (age at onset);
PAAD	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.42	-5.78	-0.42	4.01e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg12215294	chr3:40350768	EIF1B	-0.46	-4.63	-0.35	7.67e-6	Renal cell carcinoma;
PAAD	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.59	5.28	0.39	4.4e-7	Retinal vascular caliber;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg09226986	chr6:160852328	SLC22A3	-0.47	-4.41	-0.34	1.93e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.85	5.99	0.44	1.44e-8	Total cholesterol levels;
PAAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.59	0.41	1.01e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs12936587	0.633	rs12937108	chr17:17499544	A/G	cg03641529	chr17:17716218	SREBF1	0.41	4.53	0.35	1.18e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-10.81	-0.66	1.48e-20	Ulcerative colitis;
PAAD	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.98	-6.64	-0.47	5.13e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.19	-0.45	5.46e-9	Morning vs. evening chronotype;
PAAD	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.61	5.21	0.39	5.94e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.49	-5.22	-0.39	5.69e-7	Menarche (age at onset);
PAAD	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg18984983	chr10:135342936	CYP2E1	0.47	4.33	0.33	2.64e-5	Gout;
PAAD	cis	rs116175783	0.557	rs1146024	chr2:162139251	G/A	cg08807892	chr2:162101083	NA	-0.69	-4.89	-0.37	2.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.63	-6.59	-0.47	6.68e-10	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.81	-0.36	3.55e-6	Blood metabolite levels;
PAAD	cis	rs28489187	0.706	rs233066	chr1:85804930	T/C	cg16011679	chr1:85725395	C1orf52	0.54	5.17	0.39	7.31e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs7072216	0.687	rs10883085	chr10:100155613	A/T	cg19567339	chr10:100142640	NA	0.42	4.48	0.34	1.45e-5	Metabolite levels;
PAAD	cis	rs2286379	0.773	rs2068491	chr12:1847870	A/G	cg05227549	chr12:1770782	NA	-0.42	-4.69	-0.36	5.93e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-12.1	-0.7	5.12e-24	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1497406	0.802	rs28629977	chr1:16497272	G/C	cg20167471	chr1:16528984	ARHGEF19	0.46	4.53	0.34	1.2e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg06217245	chr20:33103252	DYNLRB1	0.41	4.71	0.36	5.55e-6	Height;
PAAD	cis	rs7624766	0.555	rs1455869	chr3:160475488	C/T	cg22637730	chr3:160473554	PPM1L	0.55	4.68	0.35	6.29e-6	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.88	-7.86	-0.54	6.58e-13	Diastolic blood pressure;
PAAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.58	5.44	0.4	2.12e-7	Schizophrenia;
PAAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg04289385	chr6:36355825	ETV7	0.44	4.65	0.35	7.1e-6	Platelet distribution width;
PAAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.54	5.79	0.43	3.93e-8	Obesity-related traits;
PAAD	cis	rs16854884	0.673	rs34379944	chr3:143785766	G/A	cg06585982	chr3:143692056	C3orf58	0.59	5.8	0.43	3.72e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02743256	chr7:2109353	MAD1L1	-0.77	-5.49	-0.41	1.62e-7	Neuroticism;
PAAD	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.53	5.88	0.43	2.53e-8	Mean corpuscular volume;
PAAD	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.61	5.94	0.43	1.86e-8	Height;
PAAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.69	7.61	0.53	2.73e-12	Melanoma;
PAAD	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg23024343	chr7:107201750	COG5	0.57	4.62	0.35	8e-6	Coronary artery disease;
PAAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.53	4.75	0.36	4.67e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.46	-5.39	-0.4	2.68e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	5.19	0.39	6.57e-7	Neuranatomic and neurocognitive phenotypes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03710140	chr20:5986599	CRLS1	-0.66	-6.44	-0.46	1.52e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg09035930	chr12:129282057	SLC15A4	-0.75	-4.42	-0.34	1.88e-5	Systemic lupus erythematosus;
PAAD	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.66	7.47	0.52	5.93e-12	Platelet count;Platelet distribution width;
PAAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	1.16	12.78	0.72	7.43e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.42	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.56	5.45	0.4	1.97e-7	Prudent dietary pattern;
PAAD	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.78	-4.83	-0.36	3.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.54	0.52	4.03e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs2070677	0.877	rs2987791	chr10:135370060	G/C	cg08390786	chr10:135334061	NA	-0.65	-5.48	-0.41	1.7e-7	Gout;
PAAD	cis	rs6782025	0.837	rs7645582	chr3:120808919	T/C	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.59	5.54	0.41	1.31e-7	Blood pressure;
PAAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.14	-0.45	6.77e-9	Reticulocyte fraction of red cells;
PAAD	trans	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg26875522	chr6:28219796	ZKSCAN4	0.65	6.9	0.49	1.29e-10	Hand grip strength;
PAAD	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03934478	chr11:495069	RNH1	1.15	5.3	0.4	3.93e-7	Body mass index;
PAAD	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.47	-4.44	-0.34	1.72e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.54	7.07	0.5	5.38e-11	Body mass index;
PAAD	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02985541	chr2:219472218	PLCD4	-0.31	-4.81	-0.36	3.62e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-1.02	-17.74	-0.82	7.36e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg00579200	chr11:133705235	NA	-0.46	-5.03	-0.38	1.35e-6	Childhood ear infection;
PAAD	cis	rs17407555	0.955	rs56099802	chr4:10179379	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-5.27	-0.39	4.66e-7	Schizophrenia (age at onset);
PAAD	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.71	7.04	0.5	6.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.52	5.06	0.38	1.22e-6	Menarche (age at onset);
PAAD	cis	rs7873102	0.702	rs943938	chr9:37983770	C/T	cg03528946	chr9:38069800	SHB	0.53	5.22	0.39	5.78e-7	Brain structure;
PAAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.01	0.44	1.33e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	1.08	7.45	0.52	6.7e-12	IgG glycosylation;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.69	0.36	5.99e-6	Electroencephalogram traits;
PAAD	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	5.01	0.38	1.5e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-4.9	-0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.84	-6.18	-0.45	5.68e-9	Height;
PAAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.49	5.31	0.4	3.74e-7	Longevity;Endometriosis;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18072871	chr22:50919961	ADM2	-0.67	-8.09	-0.55	1.74e-13	Body fat percentage;
PAAD	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg12568669	chr8:11666485	FDFT1	0.27	4.47	0.34	1.49e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.5	0.47	1.11e-9	Multiple sclerosis;
PAAD	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-4.77	-0.36	4.33e-6	Obesity-related traits;
PAAD	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.61	4.68	0.35	6.41e-6	Menarche (age at onset);
PAAD	cis	rs2117029	0.521	rs2114845	chr12:49558533	T/C	cg05368762	chr12:50135785	TMBIM6	0.46	4.66	0.35	6.89e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-4.49	-0.34	1.41e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.57	7.03	0.5	6.56e-11	Monobrow;
PAAD	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.6	-5.24	-0.39	5.27e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs4455778	0.538	rs13236051	chr7:49097829	T/C	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs79146658	0.688	rs12693171	chr2:179748447	A/G	cg17765952	chr2:179737173	CCDC141	-0.6	-4.5	-0.34	1.37e-5	Diastolic blood pressure;
PAAD	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-5.49	-0.41	1.67e-7	Total cholesterol levels;
PAAD	cis	rs9815354	1.000	rs1125203	chr3:41760895	T/C	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.32	-0.4	3.57e-7	Mononucleosis;
PAAD	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.82	9.43	0.61	6.75e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg16558253	chr16:72132732	DHX38	-0.55	-5.08	-0.38	1.1e-6	Coronary artery disease;
PAAD	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	6.73	0.48	3.26e-10	Breast cancer;
PAAD	cis	rs732765	0.734	rs12323361	chr14:75171706	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-4.55	-0.35	1.09e-5	Non-small cell lung cancer;
PAAD	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs16958440	0.581	rs11875768	chr18:44689360	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-4.61	-0.35	8.51e-6	Sitting height ratio;
PAAD	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.57	-5.91	-0.43	2.13e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-6.44	-0.46	1.49e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9913156	0.841	rs4522461	chr17:4621773	T/G	cg19197139	chr17:4613644	ARRB2	-0.84	-8.48	-0.57	1.84e-14	Lymphocyte counts;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11245990	chr11:68621969	NA	-0.39	-5.2	-0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.95	-7.82	-0.54	8.18e-13	Cerebrospinal P-tau181p levels;
PAAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.35	6.23	0.45	4.42e-9	Skin colour saturation;
PAAD	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.6	6.45	0.46	1.38e-9	Testicular germ cell tumor;
PAAD	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.53	-5.08	-0.38	1.1e-6	Mortality in heart failure;
PAAD	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.54	4.53	0.34	1.2e-5	Red blood cell count;
PAAD	cis	rs2072732	0.706	rs112690788	chr1:2954055	A/G	cg15211996	chr1:2936768	ACTRT2	0.45	4.4	0.34	2.01e-5	Plateletcrit;
PAAD	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.5	-4.95	-0.37	1.91e-6	Anterior chamber depth;
PAAD	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.94	11.29	0.68	7.63e-22	Menopause (age at onset);
PAAD	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.36	-0.33	2.43e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12986413	0.559	rs1859951	chr19:2142633	C/G	cg09261902	chr19:2140048	AP3D1	0.6	6.07	0.44	9.88e-9	Height;
PAAD	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg16211469	chr6:24423932	MRS2	0.57	5.22	0.39	5.75e-7	Liver enzyme levels;
PAAD	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.88	-7.29	-0.51	1.58e-11	Triglycerides;
PAAD	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.7	6.5	0.47	1.08e-9	Primary sclerosing cholangitis;
PAAD	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg26031613	chr14:104095156	KLC1	0.48	4.7	0.36	5.8e-6	Reticulocyte count;
PAAD	cis	rs4481887	0.752	rs12046632	chr1:248479995	A/G	cg00666640	chr1:248458726	OR2T12	0.71	5.19	0.39	6.65e-7	Common traits (Other);
PAAD	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.48	4.64	0.35	7.42e-6	Malaria;
PAAD	cis	rs12511469	0.505	rs11731813	chr4:155379883	A/G	cg22744079	chr4:155410860	DCHS2	0.46	4.68	0.35	6.42e-6	Fibrinogen;
PAAD	cis	rs2051773	0.539	rs34902253	chr11:17049380	T/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-4.87	-0.37	2.71e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.66	6.73	0.48	3.21e-10	Blood protein levels;
PAAD	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.37	-0.33	2.27e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.78	8.81	0.58	2.71e-15	Multiple sclerosis;
PAAD	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.71	0.42	5.67e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg27449745	chr7:23145252	KLHL7	-0.6	-5.4	-0.4	2.49e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs569214	0.648	rs473266	chr8:27514546	C/T	cg04264299	chr8:27491209	SCARA3	0.52	4.66	0.35	6.93e-6	Alzheimer's disease;
PAAD	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-15.53	-0.78	3.47e-33	Ulcerative colitis;
PAAD	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.91	11.67	0.69	7.36e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg26695010	chr11:65641043	EFEMP2	-0.62	-5.45	-0.4	2.01e-7	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.8	0.58	2.82e-15	Lung cancer;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Body mass index;
PAAD	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.75	6.44	0.46	1.5e-9	Pulmonary function decline;
PAAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.52	0.57	1.45e-14	Vitiligo;
PAAD	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.56	5.83	0.43	3.22e-8	Cognitive function;
PAAD	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.22	0.51	2.35e-11	IgG glycosylation;
PAAD	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.41	5.14	0.38	8.32e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.19	-0.39	6.54e-7	Breast cancer;
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg11766577	chr21:47581405	C21orf56	-0.47	-5.36	-0.4	3.04e-7	Testicular germ cell tumor;
PAAD	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.54	4.48	0.34	1.46e-5	Mean platelet volume;
PAAD	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg07469887	chr10:131262384	NA	-0.42	-4.88	-0.37	2.61e-6	Response to temozolomide;
PAAD	cis	rs4795519	0.736	rs3964488	chr17:22180324	A/G	cg22648282	chr17:21454238	C17orf51	-0.55	-5.24	-0.39	5.32e-7	Chronic myeloid leukemia;
PAAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg14092988	chr3:52407081	DNAH1	0.37	4.77	0.36	4.26e-6	Electroencephalogram traits;
PAAD	cis	rs6019826	0.524	rs6012664	chr20:48052612	A/G	cg20488617	chr20:48599436	SNAI1	-0.78	-4.5	-0.34	1.36e-5	Schizophrenia;
PAAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg18279126	chr7:2041391	MAD1L1	0.62	6.07	0.44	9.98e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.5	-4.67	-0.35	6.53e-6	Daytime sleep phenotypes;
PAAD	cis	rs9364554	0.676	rs1810126	chr6:160872151	C/T	cg25313204	chr6:160768801	SLC22A3	0.53	4.85	0.37	3.01e-6	Prostate cancer (SNP x SNP interaction);Prostate cancer;
PAAD	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.24	-0.39	5.26e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg12700464	chr11:78128424	GAB2	-0.59	-4.45	-0.34	1.66e-5	Alzheimer's disease (survival time);
PAAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.51	-5.75	-0.42	4.73e-8	Personality dimensions;
PAAD	cis	rs7534824	0.543	rs61780299	chr1:101403471	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	4.63	0.35	7.93e-6	Refractive astigmatism;
PAAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.61	3.95e-17	Rheumatoid arthritis;
PAAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	4.7	0.36	5.85e-6	Menarche (age at onset);
PAAD	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg14926445	chr8:58193284	C8orf71	-0.68	-4.94	-0.37	2.05e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg08345082	chr10:99160200	RRP12	-0.31	-4.32	-0.33	2.83e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.76	-8.23	-0.56	8.05e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.72	-7.35	-0.51	1.15e-11	DNA methylation (variation);
PAAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12931792	0.875	rs58175255	chr16:30155290	C/A	cg17640201	chr16:30407289	ZNF48	0.58	6.11	0.44	7.87e-9	Tonsillectomy;
PAAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.62	6.58	0.47	7.11e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.52	-0.34	1.22e-5	Total body bone mineral density;
PAAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg21546286	chr11:48923668	NA	0.53	5.6	0.41	9.72e-8	HDL cholesterol;
PAAD	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg19744528	chr7:157553346	PTPRN2	-0.39	-4.26	-0.33	3.63e-5	Body mass index;
PAAD	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.94	-11.0	-0.67	4.65e-21	Coronary artery disease;
PAAD	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13084569	chr6:19759319	NA	0.61	6.29	0.45	3.14e-9	Neuroticism;
PAAD	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.52	-0.34	1.25e-5	Inflammatory bowel disease;
PAAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg15145965	chr22:50218605	BRD1	0.59	5.09	0.38	1.03e-6	Schizophrenia;
PAAD	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.24	6.21	0.45	4.85e-9	Psoriasis vulgaris;
PAAD	cis	rs6909834	0.596	rs6917097	chr6:12851768	C/T	cg17869960	chr6:12718530	PHACTR1	-0.39	-4.4	-0.34	2e-5	Gait speed in old age;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07080756	chr10:104192239	CUEDC2	0.6	6.32	0.46	2.71e-9	Myopia (pathological);
PAAD	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.55	5.64	0.42	8.04e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg13207630	chr7:32358064	NA	0.79	4.37	0.33	2.29e-5	Body mass index;
PAAD	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.47	-0.46	1.25e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.54	6.13	0.45	7.06e-9	Major depressive disorder;
PAAD	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.15	9.44	0.61	6.1e-17	Sexual dysfunction (female);
PAAD	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.79	9.3	0.6	1.42e-16	Colorectal cancer;
PAAD	cis	rs10804591	1.000	rs2811434	chr3:129339615	G/T	cg18548199	chr3:129281892	PLXND1	0.52	4.39	0.34	2.08e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs2790457	0.760	rs1265834	chr10:28941861	A/G	cg05705492	chr10:28955341	NA	0.5	4.8	0.36	3.74e-6	Multiple myeloma;
PAAD	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.55	-5.34	-0.4	3.4e-7	Mortality in heart failure;
PAAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg26174226	chr8:58114915	NA	-0.68	-6.12	-0.44	7.66e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg20291162	chr17:40259547	DHX58	-0.61	-6.49	-0.47	1.16e-9	Fibrinogen levels;
PAAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.72	-7.68	-0.53	1.79e-12	Pulse pressure;
PAAD	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.4	-4.27	-0.33	3.48e-5	Lung cancer;
PAAD	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-4.51	-0.34	1.3e-5	Alzheimer's disease (survival time);
PAAD	cis	rs3931020	0.745	rs10874274	chr1:75252134	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.49	4.88	0.37	2.67e-6	Resistin levels;
PAAD	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg10932868	chr11:921992	NA	0.5	6.02	0.44	1.25e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6494488	0.500	rs56266896	chr15:64946127	G/T	cg16425858	chr15:64791681	ZNF609	0.93	5.05	0.38	1.27e-6	Coronary artery disease;
PAAD	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.66	-7.3	-0.51	1.49e-11	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.5	-0.47	1.1e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg12126869	chr10:346505	DIP2C	-0.81	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.99	12.39	0.71	8.05e-25	Coronary artery disease;
PAAD	cis	rs7976059	0.895	rs73109505	chr12:52244921	G/A	cg13698196	chr12:52257893	NA	0.56	6.62	0.47	5.73e-10	Urate levels;
PAAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg11601000	chr22:42348013	LOC339674	0.4	4.5	0.34	1.32e-5	Cognitive function;
PAAD	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.56	6.44	0.46	1.5e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11264799	0.731	rs7524764	chr1:157685739	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.63	0.42	8.38e-8	IgA nephropathy;
PAAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	5.99e-6	Life satisfaction;
PAAD	cis	rs76793172	1.000	rs56006974	chr19:46330636	C/A	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg04315214	chr1:2043799	PRKCZ	0.6	8.13	0.55	1.37e-13	Height;
PAAD	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	1.0	12.2	0.7	2.63e-24	Primary sclerosing cholangitis;
PAAD	cis	rs6782228	0.848	rs6439140	chr3:128418760	C/T	cg15607142	chr3:128420513	NA	-0.43	-4.73	-0.36	5.14e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	cis	rs13070279	0.655	rs4677042	chr3:71781701	C/G	cg03457142	chr3:71804859	EIF4E3	-0.55	-4.43	-0.34	1.77e-5	Monocyte count;
PAAD	cis	rs1419980	0.730	rs11054556	chr12:7727778	C/T	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.55	0.65	7.27e-20	Electrocardiographic conduction measures;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09217565	chr14:45605027	FKBP3;FANCM	0.68	6.47	0.46	1.26e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.8	6.35	0.46	2.31e-9	Gastritis;
PAAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.24e-10	Life satisfaction;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg06160221	chr16:89734445	C16orf55	-0.61	-6.75	-0.48	2.96e-10	Myopia (pathological);
PAAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.8	-0.43	3.81e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.96	12.15	0.7	3.57e-24	Menopause (age at onset);
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.87	0.69	2.12e-23	Platelet count;
PAAD	cis	rs561341	1.000	rs56362439	chr17:30253140	T/A	cg23018236	chr17:30244563	NA	-0.64	-5.41	-0.4	2.4e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg01631408	chr1:248437212	OR2T33	-0.56	-4.91	-0.37	2.32e-6	Common traits (Other);
PAAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg19163074	chr7:65112434	INTS4L2	-0.46	-4.33	-0.33	2.71e-5	Aortic root size;
PAAD	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	4.84	0.37	3.21e-6	Height;
PAAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.47	4.81	0.36	3.56e-6	Red cell distribution width;
PAAD	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg09659197	chr4:152720779	NA	0.41	5.2	0.39	6.39e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2421770	0.601	rs3843609	chr11:35331173	T/C	cg13971030	chr11:35366721	SLC1A2	-0.52	-5.37	-0.4	2.85e-7	Staphylococcus aureus nasal carriage (persistent);
PAAD	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02985541	chr2:219472218	PLCD4	0.3	4.61	0.35	8.38e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.57	-5.69	-0.42	6.27e-8	P wave terminal force;
PAAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.03e-5	Blood metabolite levels;
PAAD	cis	rs499368	0.519	rs216246	chr12:310466	C/G	cg02925805	chr12:298484	NA	0.48	4.81	0.36	3.61e-6	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-5.09	-0.38	1.05e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg21191810	chr6:118973309	C6orf204	0.4	4.86	0.37	2.91e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9488822	0.662	rs496311	chr6:116274730	A/G	cg18764771	chr6:116381957	FRK	0.26	4.3	0.33	3.09e-5	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	5.09	0.38	1.04e-6	Blood metabolite levels;
PAAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs28489187	0.706	rs233059	chr1:85798936	G/A	cg16011679	chr1:85725395	C1orf52	0.52	4.88	0.37	2.71e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9581857	0.547	rs9581868	chr13:28070682	C/T	cg22138327	chr13:27999177	GTF3A	0.85	5.33	0.4	3.51e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.7	9.26	0.6	1.88e-16	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.51	-5.06	-0.38	1.21e-6	Lung cancer;
PAAD	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg06565975	chr8:143823917	SLURP1	0.22	5.22	0.39	5.72e-7	Urinary tract infection frequency;
PAAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.67	-0.35	6.64e-6	Platelet count;
PAAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	4.78	0.36	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.78	-0.42	4.17e-8	Bipolar disorder;
PAAD	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.88	-6.4	-0.46	1.78e-9	Blood protein levels;
PAAD	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.65	6.09	0.44	9.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.73	-5.11	-0.38	9.66e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.48	4.29	0.33	3.15e-5	Corneal astigmatism;
PAAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.47	5.87	0.43	2.66e-8	Childhood ear infection;
PAAD	cis	rs66478310	0.793	rs67888384	chr12:108714212	C/G	cg04872675	chr12:108983234	NA	0.77	4.68	0.36	6.23e-6	Plasma clusterin levels;
PAAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg19673125	chr6:150240577	RAET1G	0.43	5.97	0.44	1.63e-8	Testicular germ cell tumor;
PAAD	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.83	9.87	0.62	4.62e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2562456	0.833	rs1626404	chr19:21483788	C/A	cg08562672	chr19:21860753	NA	-0.46	-4.8	-0.36	3.69e-6	Pain;
PAAD	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg05973401	chr12:123451056	ABCB9	0.5	4.5	0.34	1.35e-5	Platelet count;
PAAD	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	1.09	15.35	0.78	1.02e-32	Breast cancer;
PAAD	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg12395012	chr8:11607386	GATA4	-0.41	-4.61	-0.35	8.64e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.68	-8.85	-0.58	2.14e-15	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg04257695	chr17:30186438	C17orf79	-0.57	-4.31	-0.33	2.98e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg00334542	chr7:100209784	MOSPD3	-0.75	-5.5	-0.41	1.58e-7	Other erythrocyte phenotypes;
PAAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.53	0.34	1.18e-5	Personality dimensions;
PAAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg04106633	chr4:1044584	NA	0.51	4.73	0.36	5.02e-6	Recombination rate (males);
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg05347473	chr6:146136440	FBXO30	-0.71	-6.33	-0.46	2.65e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.61	-6.41	-0.46	1.78e-9	Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.74	-8.29	-0.56	5.64e-14	Menopause (age at onset);
PAAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.28	-0.33	3.32e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60154123	0.730	rs12030512	chr1:210466886	A/G	cg25204440	chr1:209979598	IRF6	0.63	5.2	0.39	6.33e-7	Coronary artery disease;
PAAD	cis	rs8062405	0.558	rs3743963	chr16:28604686	A/G	cg02850742	chr16:28853947	TUFM	-0.39	-4.25	-0.33	3.71e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08120951	chr16:88734359	MGC23284	-0.7	-7.13	-0.5	3.7e-11	Obesity-related traits;
PAAD	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.62	5.57	0.41	1.12e-7	Red blood cell count;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	4.79	0.36	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg21395723	chr22:39101663	GTPBP1	0.42	4.55	0.35	1.07e-5	Menopause (age at onset);
PAAD	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	cis	rs6011674	1.000	rs6011674	chr20:61854452	A/G	cg08263991	chr20:62715781	OPRL1;C20orf201	0.65	4.31	0.33	2.87e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.49	-5.05	-0.38	1.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.58	7.25	0.51	2e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.94	11.31	0.68	6.54e-22	Longevity;
PAAD	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	5.47	0.41	1.79e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-1.09	-7.72	-0.53	1.41e-12	Post bronchodilator FEV1;
PAAD	cis	rs6991838	0.806	rs4285523	chr8:66464330	A/C	cg15971335	chr8:66515592	ARMC1	0.44	4.37	0.33	2.28e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg27449745	chr7:23145252	KLHL7	-0.6	-5.63	-0.42	8.45e-8	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.33	-6.17	-0.45	6e-9	Type 2 diabetes;
PAAD	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.49	4.43	0.34	1.8e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg25037394	chr1:24152592	HMGCL	0.41	4.46	0.34	1.58e-5	Immature fraction of reticulocytes;
PAAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg09324608	chr17:30823087	MYO1D	0.54	5.68	0.42	6.6e-8	Schizophrenia;
PAAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.57	5.15	0.39	7.97e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg18357526	chr6:26021779	HIST1H4A	0.52	4.63	0.35	7.94e-6	Height;
PAAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.72	7.59	0.52	2.98e-12	Mood instability;
PAAD	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.37	5.4	0.4	2.48e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7792596	1.000	rs7792596	chr7:94009634	T/C	cg20814616	chr7:94014465	NA	-0.44	-4.48	-0.34	1.46e-5	Intelligence;
PAAD	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg13045555	chr8:105342365	NA	-0.25	-4.35	-0.33	2.49e-5	Paget's disease;
PAAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.52	-5.02	-0.38	1.43e-6	Testicular germ cell tumor;
PAAD	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.56	-5.13	-0.38	8.77e-7	Personality dimensions;
PAAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.59	-5.57	-0.41	1.12e-7	Malaria;
PAAD	cis	rs258892	0.947	rs266436	chr5:72174553	G/A	cg21869765	chr5:72125136	TNPO1	0.77	5.36	0.4	3e-7	Small cell lung carcinoma;
PAAD	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.57	5.23	0.39	5.45e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs35955747	0.738	rs2012451	chr22:31844373	A/C	cg02404636	chr22:31891804	SFI1	-0.51	-5.16	-0.39	7.77e-7	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.38	7.55	0.52	3.78e-12	Skin colour saturation;
PAAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg03037974	chr15:76606532	NA	0.4	4.42	0.34	1.88e-5	Blood metabolite levels;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05446464	chr6:86387543	SNORD50B;SNHG5;SNORD50A	-0.69	-6.81	-0.48	2.13e-10	Lung cancer in ever smokers;
PAAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.43	5.8	0.43	3.78e-8	Vitiligo;
PAAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.63	6.01	0.44	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7301016	0.802	rs73139054	chr12:62842227	T/C	cg19781863	chr12:62918364	MON2	0.78	4.39	0.34	2.13e-5	IgG glycosylation;
PAAD	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.54	4.55	0.35	1.08e-5	RR interval (heart rate);
PAAD	cis	rs8060686	0.858	rs1109166	chr16:67977382	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-6.29	-0.45	3.28e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.56	-6.16	-0.45	6.15e-9	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.41	13.54	0.74	6.71e-28	Corneal structure;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18621852	chr3:10150065	C3orf24	0.54	5.08	0.38	1.08e-6	Alzheimer's disease;
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg00280220	chr17:61926910	NA	0.42	4.3	0.33	3.01e-5	Prudent dietary pattern;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-6.65	-0.47	4.88e-10	Lymphocyte counts;
PAAD	cis	rs300774	1.000	rs167282	chr2:117174	A/G	cg21211680	chr2:198530	NA	-0.57	-5.31	-0.4	3.85e-7	Suicide attempts in bipolar disorder;
PAAD	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.52	-5.1	-0.38	1.01e-6	Knee osteoarthritis;
PAAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.64	7.49	0.52	5.11e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2131877	0.913	rs12634646	chr3:194842911	A/G	cg21937377	chr3:194868750	C3orf21	0.42	4.57	0.35	1.01e-5	Non-small cell lung cancer;
PAAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Body mass index;
PAAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg10729496	chr3:10149963	C3orf24	0.83	6.81	0.48	2.17e-10	Alzheimer's disease;
PAAD	cis	rs1350666	0.608	rs1017734	chr4:75253120	G/T	cg19308222	chr4:75230391	EREG	-0.47	-4.39	-0.34	2.08e-5	Attention deficit hyperactivity disorder;
PAAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.8	-7.89	-0.54	5.64e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg01851573	chr8:8652454	MFHAS1	0.48	4.63	0.35	7.84e-6	Mood instability;
PAAD	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.9	-7.72	-0.53	1.41e-12	Obesity-related traits;
PAAD	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg06606381	chr12:133084897	FBRSL1	-1.27	-7.89	-0.54	5.37e-13	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.91	0.43	2.21e-8	Prudent dietary pattern;
PAAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-5.5	-0.41	1.57e-7	Menarche (age at onset);
PAAD	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg04607699	chr11:48328132	OR4S1	-0.52	-4.89	-0.37	2.5e-6	Migraine - clinic-based;
PAAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg20850873	chr3:10149803	C3orf24	0.55	4.34	0.33	2.63e-5	Alzheimer's disease;
PAAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	9.85	0.62	5.28e-18	Total body bone mineral density;
PAAD	cis	rs4389656	0.743	rs34681760	chr5:6712834	T/C	cg10857441	chr5:6722123	POLS	-0.39	-4.27	-0.33	3.37e-5	Coronary artery disease;
PAAD	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg15733309	chr7:157513707	PTPRN2	0.72	8.42	0.56	2.59e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-5.33	-0.4	3.55e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg03877680	chr5:178157825	ZNF354A	0.83	6.66	0.48	4.73e-10	Neutrophil percentage of white cells;
PAAD	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	5.3	0.39	4.01e-7	Iron status biomarkers;
PAAD	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg00012203	chr2:219082015	ARPC2	0.6	5.79	0.43	3.82e-8	Colorectal cancer;
PAAD	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.74	8.21	0.55	8.82e-14	Morning vs. evening chronotype;
PAAD	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.83	-4.83	-0.36	3.33e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg14393609	chr7:65229607	NA	-0.52	-4.49	-0.34	1.41e-5	Aortic root size;
PAAD	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg03098721	chr1:84464084	TTLL7	0.5	4.77	0.36	4.26e-6	Obesity-related traits;
PAAD	cis	rs1997066	0.831	rs57854172	chr10:106823938	C/A	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.77	8.76	0.58	3.66e-15	Obesity-related traits;
PAAD	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.79	9.41	0.61	7.23e-17	Eosinophil percentage of white cells;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23459409	chr17:56296705	MKS1	-0.77	-6.87	-0.49	1.51e-10	Neuroticism;
PAAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.71	-0.36	5.43e-6	Lung cancer;
PAAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg19787841	chr12:53845606	PCBP2	0.42	4.25	0.33	3.78e-5	Height;
PAAD	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.94	0.49	1.05e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.79	-0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg16434002	chr17:42200994	HDAC5	-0.64	-6.29	-0.45	3.16e-9	Total body bone mineral density;
PAAD	cis	rs11264799	0.731	rs12561819	chr1:157687878	A/C	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.75	-9.76	-0.62	9.17e-18	Breast cancer;
PAAD	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.64	-0.65	4.11e-20	Ulcerative colitis;
PAAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg03264133	chr6:25882463	NA	-0.51	-4.37	-0.33	2.28e-5	Iron status biomarkers;
PAAD	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.55	5.48	0.41	1.75e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg07454742	chr17:42254645	ASB16;C17orf65	-0.4	-4.33	-0.33	2.68e-5	Total body bone mineral density;
PAAD	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.51	-4.69	-0.36	6.08e-6	Multiple sclerosis;
PAAD	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	cg07049167	chr1:166818506	POGK	0.62	5.76	0.42	4.53e-8	Refractive astigmatism;
PAAD	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.78	0.36	4.08e-6	Menopause (age at onset);
PAAD	cis	rs4780401	0.728	rs4781136	chr16:11767978	G/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-5.85	-0.43	2.9e-8	Rheumatoid arthritis;
PAAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.75	6.15	0.45	6.58e-9	Alzheimer's disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18866806	chr14:89259551	EML5	0.68	6.51	0.47	1.06e-9	Obesity-related traits;
PAAD	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.86	8.47	0.57	1.93e-14	Vitamin D levels;
PAAD	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26876637	chr1:152193138	HRNR	-0.86	-6.78	-0.48	2.53e-10	Atopic dermatitis;
PAAD	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg12395012	chr8:11607386	GATA4	-0.4	-4.36	-0.33	2.39e-5	Neuroticism;
PAAD	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.65	6.89	0.49	1.41e-10	Testicular germ cell tumor;
PAAD	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg02135003	chr7:105160482	PUS7	-0.81	-6.6	-0.47	6.6e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg01214346	chr17:406501	NA	-0.45	-4.62	-0.35	8e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.46	5.96	0.44	1.7e-8	Renal cell carcinoma;
PAAD	cis	rs12986413	0.846	rs2240127	chr19:2187271	A/G	cg09261902	chr19:2140048	AP3D1	0.45	4.3	0.33	3.04e-5	Height;
PAAD	cis	rs2997447	0.846	rs3008233	chr1:26403991	C/T	cg24519413	chr1:26490540	NA	0.49	4.33	0.33	2.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs3857067	0.550	rs1588383	chr4:95001442	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-5.52	-0.41	1.44e-7	QT interval;
PAAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.63	0.42	8.61e-8	Tonsillectomy;
PAAD	cis	rs6942407	0.592	rs1859125	chr7:86752074	C/T	cg02420886	chr7:86849541	C7orf23	0.51	4.31	0.33	2.88e-5	Food allergy;
PAAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.59	-6.15	-0.45	6.69e-9	Blood metabolite levels;
PAAD	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg00540400	chr15:79124168	NA	0.68	9.08	0.59	5.3e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2790216	1.000	rs2068737	chr10:59999575	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg03340356	chr1:67600835	NA	0.46	5.36	0.4	3.01e-7	Psoriasis;
PAAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg10356904	chr22:49881777	NA	-0.47	-4.68	-0.35	6.31e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.47	4.66	0.35	6.98e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7577696	0.962	rs4952250	chr2:32343699	T/G	cg02381751	chr2:32503542	YIPF4	-0.44	-4.72	-0.36	5.2e-6	Inflammatory biomarkers;
PAAD	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.75	-8.14	-0.55	1.3e-13	Mean platelet volume;
PAAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg06740227	chr12:86229804	RASSF9	0.6	5.94	0.43	1.89e-8	Major depressive disorder;
PAAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.69	-5.53	-0.41	1.37e-7	Neuroticism;
PAAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-4.92	-0.37	2.21e-6	Electroencephalogram traits;
PAAD	cis	rs7752195	0.643	rs77006546	chr6:25219582	T/C	cg26336265	chr6:25042955	NA	0.86	4.84	0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.56	-6.23	-0.45	4.41e-9	Type 2 diabetes;
PAAD	cis	rs2031532	0.731	rs9526569	chr13:50102219	C/T	cg08779649	chr13:50194554	NA	0.38	4.71	0.36	5.65e-6	Cardiac hypertrophy;
PAAD	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg02027945	chr11:20618230	NA	-0.32	-4.42	-0.34	1.89e-5	Pursuit maintenance gain;
PAAD	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.72	-7.71	-0.53	1.55e-12	Aortic root size;
PAAD	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.6	-6.32	-0.46	2.81e-9	Morning vs. evening chronotype;
PAAD	cis	rs4792901	0.765	rs9908030	chr17:41587891	A/G	cg05614735	chr17:40936078	WNK4	-0.36	-4.31	-0.33	2.97e-5	Dupuytren's disease;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.49	-4.84	-0.37	3.18e-6	Lewy body disease;
PAAD	cis	rs7818688	0.697	rs11782590	chr8:95970158	G/C	cg16049864	chr8:95962084	TP53INP1	0.52	4.27	0.33	3.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.47	-5.12	-0.38	8.94e-7	Motion sickness;
PAAD	trans	rs10861342	1.000	rs11112403	chr12:105586649	A/G	cg11421182	chr20:36153479	BLCAP	-0.56	-6.78	-0.48	2.46e-10	IgG glycosylation;
PAAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-6.67	-0.48	4.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.61	5.88	0.43	2.48e-8	Mosquito bite size;
PAAD	cis	rs17095355	1.000	rs55683820	chr10:111665376	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.37	-0.33	2.27e-5	Biliary atresia;
PAAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg17347104	chr14:75034677	LTBP2	-0.5	-4.98	-0.37	1.67e-6	Caffeine consumption;
PAAD	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	5.31	0.4	3.79e-7	Cognitive test performance;
PAAD	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg05341575	chr12:125625032	AACS	-0.48	-4.57	-0.35	9.93e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg09473613	chr1:24152604	HMGCL	0.54	5.6	0.41	9.78e-8	Immature fraction of reticulocytes;
PAAD	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg06148736	chr22:18985691	NA	0.37	4.73	0.36	5e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.28	-0.51	1.68e-11	Response to antipsychotic treatment;
PAAD	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg27335999	chr10:556044	DIP2C	0.34	4.39	0.34	2.12e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-5.42	-0.4	2.25e-7	Height;
PAAD	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg23024343	chr7:107201750	COG5	0.55	4.5	0.34	1.34e-5	Coronary artery disease;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg10534938	chr5:1868639	NA	0.47	6.27	0.45	3.5e-9	Cardiovascular disease risk factors;
PAAD	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg20813462	chr7:2646259	IQCE	0.66	4.75	0.36	4.69e-6	Urate levels in lean individuals;
PAAD	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg05338066	chr1:7812865	CAMTA1	0.59	4.8	0.36	3.81e-6	Inflammatory bowel disease;
PAAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg23995914	chr4:10459228	ZNF518B	-0.39	-4.81	-0.36	3.65e-6	Schizophrenia (age at onset);
PAAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15320075	chr8:145703422	NA	-0.65	-7.22	-0.51	2.33e-11	Age at first birth;
PAAD	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.6	-5.94	-0.43	1.84e-8	Post bronchodilator FEV1;
PAAD	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg10432947	chr4:2062441	NAT8L	-0.53	-4.53	-0.35	1.17e-5	Systolic blood pressure;
PAAD	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg19197139	chr17:4613644	ARRB2	0.86	8.94	0.59	1.2e-15	Lymphocyte counts;
PAAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.72	-5.89	-0.43	2.35e-8	Alzheimer's disease;
PAAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg13385521	chr17:29058706	SUZ12P	-0.63	-4.33	-0.33	2.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-5.0	-0.38	1.57e-6	Menarche (age at onset);
PAAD	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.91	10.07	0.63	1.35e-18	Testicular germ cell tumor;
PAAD	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.6	-5.79	-0.43	3.91e-8	Subjective well-being;
PAAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg23463467	chr20:60627584	TAF4	0.41	4.45	0.34	1.64e-5	Body mass index;
PAAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.63	-7.32	-0.51	1.34e-11	Bipolar disorder;
PAAD	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg17456097	chr1:26900765	RPS6KA1	-0.5	-4.26	-0.33	3.59e-5	Glucose homeostasis traits;
PAAD	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg00543991	chr22:32367038	NA	1.23	7.12	0.5	3.95e-11	Childhood ear infection;
PAAD	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.78	6.18	0.45	5.55e-9	Neutrophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14084312	chr14:88459488	GALC	0.6	6.48	0.47	1.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs302972	0.826	rs303010	chr6:25082105	C/T	cg01382804	chr6:25931017	SLC17A2	-0.76	-4.45	-0.34	1.66e-5	Creatinine levels in ischemic stroke;
PAAD	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg14631576	chr9:95140430	CENPP	0.53	4.99	0.38	1.64e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15767191	chr11:123900083	OR10G8	-0.48	-6.35	-0.46	2.34e-9	Energy expenditure (24h);
PAAD	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.63	6.46	0.46	1.31e-9	Blood protein levels;
PAAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg10547527	chr2:198650123	BOLL	-0.74	-5.2	-0.39	6.33e-7	Ulcerative colitis;
PAAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.14	-0.5	3.69e-11	Body mass index;
PAAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.58	7.92	0.54	4.72e-13	Renal cell carcinoma;
PAAD	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.87	10.63	0.65	4.31e-20	Mean corpuscular volume;
PAAD	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-4.97	-0.37	1.75e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.78	-9.31	-0.6	1.39e-16	Facial morphology (factor 20);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13730859	chr3:183887905	DVL3	-0.59	-6.58	-0.47	7.18e-10	Monocyte percentage of white cells;
PAAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.46	4.93	0.37	2.14e-6	Longevity;Endometriosis;
PAAD	cis	rs13034020	0.594	rs10496090	chr2:61254033	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.67	4.66	0.35	6.77e-6	Hodgkin's lymphoma;
PAAD	cis	rs1497828	0.956	rs1021620	chr1:217564392	A/C	cg04411442	chr1:217543379	NA	0.5	4.89	0.37	2.54e-6	Dialysis-related mortality;
PAAD	cis	rs858239	1.000	rs199357	chr7:23288309	A/G	cg27449745	chr7:23145252	KLHL7	0.56	5.16	0.39	7.67e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.51	5.86	0.43	2.8e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
PAAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.6	5.19	0.39	6.5e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs2011503	0.509	rs10403579	chr19:19770329	T/C	cg11584989	chr19:19387371	SF4	0.86	6.43	0.46	1.53e-9	Bipolar disorder;
PAAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg27406664	chr17:2294951	MNT	0.39	4.94	0.37	2e-6	Autism spectrum disorder;
PAAD	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.68	5.68	0.42	6.73e-8	Response to antidepressants in depression;
PAAD	cis	rs950027	0.967	rs2486280	chr15:45751889	T/C	cg14582100	chr15:45693742	SPATA5L1	0.33	4.34	0.33	2.59e-5	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.36	0.4	2.99e-7	Lung cancer;
PAAD	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs7552393	0.595	rs7551130	chr1:84268628	G/A	cg10977910	chr1:84465055	TTLL7	0.59	5.52	0.41	1.41e-7	Select biomarker traits;
PAAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg24733560	chr20:60626293	TAF4	0.43	5.13	0.38	8.78e-7	Body mass index;
PAAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.6	6.09	0.44	8.72e-9	Menopause (age at onset);
PAAD	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg00614314	chr15:82944287	LOC80154	-0.51	-5.28	-0.39	4.29e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg17480646	chr11:65405466	SIPA1	0.93	4.5	0.34	1.33e-5	Height;
PAAD	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg02367144	chr2:237146137	ASB18	0.42	5.42	0.4	2.24e-7	Educational attainment;
PAAD	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg02683114	chr2:24398427	C2orf84	-0.47	-4.92	-0.37	2.27e-6	Sjögren's syndrome;
PAAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.88	-0.37	2.64e-6	Menarche (age at onset);
PAAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.58e-7	Life satisfaction;
PAAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.63	-5.25	-0.39	5.14e-7	Platelet count;
PAAD	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-4.31	-0.33	2.92e-5	Metabolite levels;
PAAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-4.66	-0.35	6.8e-6	Height;
PAAD	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg14703610	chr5:56206110	C5orf35	0.61	5.62	0.41	8.97e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg18721089	chr20:30220636	NA	-0.79	-6.02	-0.44	1.23e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg03255953	chr3:127056837	NA	-0.4	-4.5	-0.34	1.35e-5	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.5	4.32	0.33	2.79e-5	Mean corpuscular volume;
PAAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.94	6.45	0.46	1.42e-9	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.75	-11.88	-0.69	1.98e-23	Body mass index;
PAAD	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg26752003	chr8:145688521	CYHR1	-0.59	-6.26	-0.45	3.74e-9	Age at first birth;
PAAD	cis	rs11113894	0.901	rs11113902	chr12:108858635	C/T	cg06834313	chr12:108851556	NA	-0.77	-4.68	-0.35	6.41e-6	Obesity-related traits;
PAAD	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	1.04	6.44	0.46	1.48e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs12134040	0.557	rs61835534	chr1:236521578	A/G	cg26797158	chr1:236511546	NA	-0.48	-4.47	-0.34	1.52e-5	Urate levels (BMI interaction);
PAAD	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.5	-5.16	-0.39	7.72e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13750326	chr7:64498824	NA	-0.57	-6.36	-0.46	2.29e-9	Body fat percentage;
PAAD	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.35	13.37	0.74	1.94e-27	Corneal structure;
PAAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg05342682	chr7:94953680	PON1	-0.53	-4.71	-0.36	5.46e-6	Yu-Zhi constitution type in type 2 diabetes;
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.89	-13.54	-0.74	6.75e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	4.99	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12599982	chr1:44399894	ARTN	0.43	4.61	0.35	8.61e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6804624	1.000	rs6804624	chr3:99159147	T/C	cg02646433	chr3:99218170	NA	0.41	4.3	0.33	3.03e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.51	5.15	0.39	7.99e-7	Colorectal adenoma (advanced);
PAAD	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg03233332	chr7:66118400	NA	-0.4	-4.34	-0.33	2.6e-5	Aortic root size;
PAAD	cis	rs2594989	0.836	rs1546231	chr3:11513678	T/G	cg01796438	chr3:11312864	ATG7	-0.57	-4.44	-0.34	1.69e-5	Circulating chemerin levels;
PAAD	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg05250797	chr16:70222502	NA	-0.96	-6.93	-0.49	1.1e-10	IgE levels;
PAAD	cis	rs6494488	0.500	rs72742999	chr15:65010510	G/A	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg14146966	chr2:61757674	XPO1	-0.38	-4.71	-0.36	5.44e-6	Tuberculosis;
PAAD	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg00717180	chr2:96193071	NA	-0.6	-6.61	-0.47	6.27e-10	HDL cholesterol;
PAAD	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.74	6.91	0.49	1.24e-10	Schizophrenia (inflammation and infection response interaction);
PAAD	cis	rs1997066	0.831	rs75954658	chr10:106828108	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.44	4.33	0.33	2.73e-5	Schizophrenia;
PAAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.81	8.91	0.59	1.44e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7582720	0.945	rs72932709	chr2:203639501	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	7.32	0.51	1.32e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs11172134	0.508	rs1800175	chr12:57561379	G/T	cg01515074	chr12:57585135	LRP1	0.51	4.77	0.36	4.2e-6	Urate levels in overweight individuals;
PAAD	cis	rs9314614	0.763	rs2977796	chr8:6709725	G/A	cg27319216	chr8:6693540	XKR5	-0.33	-4.47	-0.34	1.51e-5	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs7508	0.512	rs28562392	chr8:17890431	G/A	cg08627089	chr8:17753878	FGL1	-0.44	-4.34	-0.33	2.54e-5	Atrial fibrillation;
PAAD	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs859767	0.741	rs1467194	chr2:135430621	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-4.54	-0.35	1.15e-5	Neuroticism;
PAAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg21361702	chr7:150065534	REPIN1	0.61	5.26	0.39	4.79e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6762	0.748	rs28551040	chr11:840740	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.39	-4.34	-0.33	2.62e-5	Mean platelet volume;
PAAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg27182935	chr16:89790473	ZNF276	-0.73	-4.46	-0.34	1.56e-5	Skin colour saturation;
PAAD	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	4.25	0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.33	-0.4	3.41e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg15145965	chr22:50218605	BRD1	-0.64	-4.3	-0.33	3.09e-5	Schizophrenia;
PAAD	cis	rs12760731	0.623	rs10913556	chr1:178436678	C/T	cg00404053	chr1:178313656	RASAL2	0.51	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21279828	chr8:48343009	KIAA0146	0.54	6.43	0.46	1.56e-9	Body fat percentage;
PAAD	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.24	-8.67	-0.58	6.04e-15	Metabolite levels (HVA/5-HIAA ratio);
PAAD	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs7127900	0.583	rs67379609	chr11:2233630	C/T	cg25635251	chr11:2234043	NA	0.8	7.68	0.53	1.81e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg23214565	chr6:116600728	DSE;TSPYL1	0.47	4.25	0.33	3.67e-5	Age-related macular degeneration;
PAAD	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.6	5.5	0.41	1.56e-7	Height;
PAAD	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg12082025	chr19:1064218	ABCA7	-0.75	-7.29	-0.51	1.57e-11	Alzheimer's disease (late onset);
PAAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.51	4.81	0.36	3.66e-6	Menarche (age at onset);
PAAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg01631408	chr1:248437212	OR2T33	-0.54	-5.12	-0.38	9.01e-7	Common traits (Other);
PAAD	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg23461800	chr14:103021989	NA	0.59	4.33	0.33	2.7e-5	Platelet count;
PAAD	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg15448220	chr1:150897856	SETDB1	-0.65	-6.69	-0.48	4.1e-10	Tonsillectomy;
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13732083	chr21:47605072	C21orf56	0.46	4.47	0.34	1.54e-5	Testicular germ cell tumor;
PAAD	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.81	9.86	0.62	4.93e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg27494647	chr7:150038898	RARRES2	0.45	4.72	0.36	5.39e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg10705379	chr10:99080932	FRAT1	0.39	4.49	0.34	1.4e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.65	6.37	0.46	2.09e-9	Schizophrenia;
PAAD	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Educational attainment;
PAAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg24879335	chr3:133465180	TF	0.59	6.5	0.47	1.1e-9	Iron status biomarkers;
PAAD	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.79	9.59	0.61	2.48e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg23461800	chr14:103021989	NA	-0.66	-5.16	-0.39	7.61e-7	Platelet count;
PAAD	cis	rs11083475	0.573	rs73040743	chr19:39269893	T/G	cg26703956	chr19:39260304	NA	-0.44	-5.2	-0.39	6.22e-7	Heart rate;
PAAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.51	5.8	0.43	3.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.66	7.56	0.52	3.6e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.63	5.67	0.42	6.94e-8	Schizophrenia;
PAAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.31	0.56	4.98e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.12e-5	Breast cancer;
PAAD	cis	rs300774	0.925	rs405258	chr2:145646	T/A	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-1.04	-13.92	-0.75	6.41e-29	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9296095	0.607	rs9366824	chr6:33521577	C/T	cg14003231	chr6:33640908	ITPR3	0.44	5.67	0.42	6.94e-8	Platelet count;
PAAD	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.99	11.73	0.69	5.07e-23	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.41	-4.26	-0.33	3.58e-5	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3136441	1.000	rs2306033	chr11:46897446	G/A	cg19486271	chr11:47235900	DDB2	0.63	4.83	0.36	3.31e-6	HDL cholesterol;
PAAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg09699651	chr6:150184138	LRP11	0.49	5.22	0.39	5.73e-7	Lung cancer;
PAAD	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg25246084	chr19:4971487	KDM4B	-0.46	-5.64	-0.42	8.25e-8	Monocyte percentage of white cells;
PAAD	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.87	9.89	0.63	4.11e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg02631450	chr22:32366979	NA	1.06	5.75	0.42	4.69e-8	Childhood ear infection;
PAAD	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.61	5.88	0.43	2.48e-8	Mosquito bite size;
PAAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg05484376	chr2:27715224	FNDC4	0.46	4.7	0.36	5.88e-6	Total body bone mineral density;
PAAD	cis	rs60154123	0.730	rs583148	chr1:210463553	A/C	cg25204440	chr1:209979598	IRF6	0.61	5.39	0.4	2.61e-7	Coronary artery disease;
PAAD	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg11232448	chr19:2858854	NA	-0.49	-4.81	-0.36	3.58e-6	Total cholesterol levels;
PAAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.54	-0.35	1.14e-5	Major depressive disorder;
PAAD	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-4.46	-0.34	1.61e-5	Educational attainment;
PAAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg24879335	chr3:133465180	TF	0.55	5.93	0.43	1.97e-8	Iron status biomarkers;
PAAD	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg02524346	chr8:600233	NA	-1.06	-6.67	-0.48	4.57e-10	IgG glycosylation;
PAAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg24699146	chr1:24152579	HMGCL	-0.53	-5.55	-0.41	1.24e-7	Immature fraction of reticulocytes;
PAAD	cis	rs1198430	0.925	rs1767148	chr1:23765472	A/G	cg22040403	chr1:23858016	E2F2	0.71	4.55	0.35	1.09e-5	Total cholesterol levels;
PAAD	cis	rs7246760	1.000	rs7246760	chr19:9918229	G/A	cg16876255	chr19:9731953	ZNF561	0.95	4.56	0.35	1.06e-5	Pursuit maintenance gain;
PAAD	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.52	5.1	0.38	1.01e-6	Systemic lupus erythematosus;
PAAD	cis	rs3791556	0.501	rs3791533	chr2:240100616	G/A	cg03281426	chr2:240109471	HDAC4	0.57	4.57	0.35	1.01e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs787274	0.867	rs10739374	chr9:115602703	G/C	cg13803584	chr9:115635662	SNX30	-0.81	-4.44	-0.34	1.74e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg02023728	chr11:77925099	USP35	0.45	4.6	0.35	8.73e-6	Alzheimer's disease (survival time);
PAAD	cis	rs3017493	1.000	rs3017493	chr11:70665521	A/G	cg22964396	chr11:71524540	NA	0.78	4.66	0.35	6.82e-6	Renal transplant outcome;
PAAD	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg24053715	chr22:38214548	NA	-0.5	-5.09	-0.38	1.03e-6	Glioblastoma;Glioma;
PAAD	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17554472	chr22:41940697	POLR3H	0.57	4.31	0.33	2.98e-5	Vitiligo;
PAAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.54	6.72	0.48	3.5e-10	Psoriasis;
PAAD	cis	rs2555155	0.840	rs11040911	chr11:6551889	C/A	cg24637308	chr11:6592297	DNHD1	-0.5	-5.07	-0.38	1.15e-6	DNA methylation (variation);
PAAD	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.37	4.38	0.33	2.22e-5	Pulmonary function;
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.99	0.49	8.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.43	6.8	0.48	2.26e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-6.72	-0.48	3.38e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg22143856	chr6:28129313	ZNF389	0.53	4.91	0.37	2.32e-6	Parkinson's disease;
PAAD	cis	rs73019876	0.805	rs2522106	chr19:22140621	T/A	cg11619707	chr19:22235551	ZNF257	-0.41	-4.42	-0.34	1.83e-5	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg24330906	chr2:85765176	MAT2A	-0.43	-4.35	-0.33	2.51e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.99	11.7	0.69	5.89e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13453053	chr17:26662113	TNFAIP1;IFT20	0.59	7.32	0.51	1.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.18	7.44	0.52	6.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs11590090	1.000	rs11590090	chr1:113313563	C/A	cg25707805	chr1:113285387	NA	0.35	4.66	0.35	6.72e-6	Hyperactive-impulsive symptoms;
PAAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg25833597	chr17:30823145	MYO1D	0.53	5.04	0.38	1.29e-6	Schizophrenia;
PAAD	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-4.68	-0.36	6.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7539409	0.915	rs761404	chr1:84226766	G/T	cg10977910	chr1:84465055	TTLL7	-1.03	-6.14	-0.45	6.93e-9	Alzheimer's disease;
PAAD	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.65	7.55	0.52	3.85e-12	Coronary artery disease;
PAAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-1.1	-10.58	-0.65	5.96e-20	Developmental language disorder (linguistic errors);
PAAD	cis	rs73206853	0.686	rs11829358	chr12:111126636	A/G	cg12870014	chr12:110450643	ANKRD13A	0.74	4.62	0.35	8.23e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.68	5.55	0.41	1.23e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7224685	0.815	rs8070159	chr17:4073447	A/G	cg11204139	chr17:3907470	NA	0.55	5.07	0.38	1.14e-6	Type 2 diabetes;
PAAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-5.51	-0.41	1.48e-7	Total body bone mineral density;
PAAD	cis	rs8067354	0.574	rs2526353	chr17:57988607	G/T	cg02344993	chr17:57696989	CLTC	0.54	4.41	0.34	1.96e-5	Hemoglobin concentration;
PAAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.55	6.79	0.48	2.34e-10	Multiple system atrophy;
PAAD	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg02631450	chr22:32366979	NA	1.03	5.61	0.41	9.46e-8	Childhood ear infection;
PAAD	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.06	-0.5	5.51e-11	Heart rate;Heart rate variability traits (RMSSD);
PAAD	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg14092571	chr14:90743983	NA	0.46	4.61	0.35	8.51e-6	Mortality in heart failure;
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.58	6.27	0.45	3.56e-9	Lung cancer;
PAAD	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-5.59	-0.41	1.02e-7	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.73	5.87	0.43	2.69e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs10479542	0.671	rs4701192	chr5:178966274	C/T	cg05457628	chr5:178986728	RUFY1	0.48	4.65	0.35	7.14e-6	Lung cancer;
PAAD	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.5	0.34	1.37e-5	Height;
PAAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.91	7.88	0.54	5.86e-13	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs68114352	chr8:58196081	C/T	cg24829409	chr8:58192753	C8orf71	-0.91	-8.1	-0.55	1.67e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	1.07	8.9	0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7941600	1.000	rs7941600	chr11:9280284	G/A	cg19415743	chr11:9336845	TMEM41B	0.8	4.66	0.35	7e-6	Coronary artery disease;
PAAD	cis	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.62	-0.35	7.99e-6	Type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00331096	chr20:22564947	FOXA2	0.58	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.33e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	4.48	0.34	1.48e-5	Lymphocyte percentage of white cells;
PAAD	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13870426	chr17:30244630	NA	-0.6	-5.88	-0.43	2.47e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg14345882	chr6:26364793	BTN3A2	0.58	4.39	0.34	2.09e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.87	-9.17	-0.6	3.19e-16	Parkinson's disease;
PAAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg02781088	chr2:113192302	RGPD8;RGPD5	0.9	6.97	0.49	8.91e-11	Yeast infection;
PAAD	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg14825688	chr5:132208181	LEAP2	-0.65	-4.91	-0.37	2.33e-6	Apolipoprotein A-IV levels;
PAAD	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.76	4.88	0.37	2.7e-6	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.96	9.6	0.61	2.4e-17	Blood protein levels;
PAAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg01763666	chr17:80159506	CCDC57	-0.44	-4.43	-0.34	1.77e-5	Life satisfaction;
PAAD	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-5.87	-0.43	2.64e-8	Colorectal cancer;
PAAD	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-8.68	-0.58	5.63e-15	Colorectal cancer;
PAAD	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.77	6.2	0.45	5.12e-9	Schizophrenia;
PAAD	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.56	5.57	0.41	1.11e-7	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.58	5.57	0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7828089	0.935	rs1568569	chr8:22249943	T/G	cg12081754	chr8:22256438	SLC39A14	0.45	4.64	0.35	7.62e-6	Verbal declarative memory;
PAAD	cis	rs12760731	0.720	rs10913552	chr1:178411543	G/A	cg00404053	chr1:178313656	RASAL2	0.71	5.62	0.41	9.04e-8	Obesity-related traits;
PAAD	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg13897122	chr2:103039542	IL18RAP	0.37	4.59	0.35	9.09e-6	Asthma;
PAAD	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.54	-5.34	-0.4	3.32e-7	Educational attainment (years of education);
PAAD	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.5	4.86	0.37	2.94e-6	Mean corpuscular volume;
PAAD	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.46	-5.39	-0.4	2.6e-7	Height;
PAAD	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg20302533	chr7:39170763	POU6F2	0.36	5.05	0.38	1.23e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06771106	chr2:113671356	IL1F7	0.64	6.84	0.48	1.85e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs17054480	0.681	rs6841966	chr4:169618743	T/G	cg18174542	chr22:41956861	CSDC2	0.8	6.44	0.46	1.48e-9	Advanced glycation end-product levels;
PAAD	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.58	-5.13	-0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.73	-6.84	-0.49	1.83e-10	Systemic lupus erythematosus;
PAAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.87	9.89	0.63	4.11e-18	Prudent dietary pattern;
PAAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg10589385	chr1:150898437	SETDB1	-0.44	-5.38	-0.4	2.75e-7	Tonsillectomy;
PAAD	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.61	7.02	0.49	6.91e-11	Cognitive performance;
PAAD	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg00630237	chr15:91433507	FES	0.49	4.75	0.36	4.69e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.61	5.52	0.41	1.43e-7	Mean platelet volume;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03899609	chr16:29911630	SEZ6L2;ASPHD1	0.69	7.5	0.52	4.87e-12	Myopia (pathological);
PAAD	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.9	12.86	0.72	4.52e-26	Dental caries;
PAAD	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg10518543	chr12:38710700	ALG10B	0.45	4.6	0.35	8.72e-6	Morning vs. evening chronotype;
PAAD	cis	rs12286929	0.589	rs4938190	chr11:115087750	C/T	cg04055981	chr11:115044050	NA	0.49	4.76	0.36	4.55e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.49	4.58	0.35	9.57e-6	Hepatocellular carcinoma;
PAAD	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21646471	chr2:242523971	THAP4	0.59	4.67	0.35	6.44e-6	Prostate cancer;
PAAD	cis	rs1075265	0.547	rs41385746	chr2:54305030	C/T	cg04546899	chr2:54196757	PSME4	-0.32	-4.69	-0.36	6.09e-6	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg00546117	chr1:8445545	RERE	-0.48	-4.75	-0.36	4.72e-6	Crohn's disease;
PAAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.79	-0.43	3.9e-8	Ulcerative colitis;
PAAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.55	-5.31	-0.4	3.84e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4448343	0.963	rs28536201	chr9:98276753	C/T	cg13428213	chr9:98267529	PTCH1	0.46	4.29	0.33	3.14e-5	Height;
PAAD	cis	rs72627123	0.749	rs72627104	chr14:74305948	A/C	cg19860245	chr14:74300557	NA	-0.77	-5.5	-0.41	1.55e-7	Morning vs. evening chronotype;
PAAD	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg21775007	chr8:11205619	TDH	-0.59	-5.18	-0.39	6.93e-7	Retinal vascular caliber;
PAAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.57	6.86	0.49	1.66e-10	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg24626660	chr12:32551988	NA	0.44	5.0	0.38	1.56e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg14926445	chr8:58193284	C8orf71	-0.72	-5.54	-0.41	1.33e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17264618	chr3:40429014	ENTPD3	0.36	4.32	0.33	2.79e-5	Renal cell carcinoma;
PAAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg21130718	chr4:1044621	NA	0.56	4.83	0.36	3.34e-6	Recombination rate (females);
PAAD	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.62	5.91	0.43	2.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs12286929	0.617	rs11607928	chr11:115102224	A/G	cg04055981	chr11:115044050	NA	0.47	4.67	0.35	6.6e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00982548	chr2:198649783	BOLL	-0.79	-5.45	-0.4	1.95e-7	Ulcerative colitis;
PAAD	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.62	-6.59	-0.47	6.69e-10	Dementia with Lewy bodies;
PAAD	cis	rs4655582	0.510	rs11208700	chr1:66133443	A/T	cg04111102	chr1:66153794	NA	0.45	4.77	0.36	4.33e-6	Fibrinogen levels;
PAAD	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.44	4.28	0.33	3.27e-5	Red blood cell count;
PAAD	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.59	-6.55	-0.47	8.29e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg24747557	chr10:131355152	MGMT	-0.52	-5.42	-0.4	2.26e-7	Response to temozolomide;
PAAD	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.82	9.63	0.62	2.01e-17	Blood metabolite ratios;
PAAD	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.85	9.63	0.62	2e-17	Resting heart rate;
PAAD	cis	rs4800452	0.871	rs62093413	chr18:20740871	C/T	cg26136497	chr18:20735537	CABLES1	0.55	4.41	0.34	1.97e-5	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.65	5.99	0.44	1.45e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.37	0.33	2.28e-5	Educational attainment (years of education);
PAAD	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.81	-8.96	-0.59	1.08e-15	Mean platelet volume;
PAAD	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02985541	chr2:219472218	PLCD4	0.3	4.6	0.35	8.75e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg02683114	chr2:24398427	C2orf84	0.6	6.83	0.48	1.9e-10	Asthma;
PAAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.46	1.26e-9	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27367952	chr2:219221586	C2orf62	0.55	6.4	0.46	1.86e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg26942532	chr7:75678159	MDH2;STYXL1	-0.48	-4.29	-0.33	3.21e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs12899811	0.512	rs7164916	chr15:91561446	T/C	cg08919649	chr15:91565780	VPS33B	0.49	4.47	0.34	1.54e-5	Type 2 diabetes;
PAAD	cis	rs375066	0.967	rs436249	chr19:44399565	C/T	cg21496419	chr19:44306685	LYPD5	0.39	4.79	0.36	3.88e-6	Breast cancer;
PAAD	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.58	-5.31	-0.4	3.85e-7	Obesity-related traits;
PAAD	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.58	-6.11	-0.44	7.81e-9	Post bronchodilator FEV1;
PAAD	cis	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg06214716	chr4:10118677	WDR1	0.45	4.29	0.33	3.2e-5	Urate levels in overweight individuals;Urate levels in obese individuals;
PAAD	cis	rs7598759	0.712	rs7424111	chr2:232335966	T/G	cg19187155	chr2:232395269	NMUR1	0.52	5.38	0.4	2.79e-7	Noise-induced hearing loss;
PAAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.73	-6.09	-0.44	8.74e-9	Developmental language disorder (linguistic errors);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11636287	chr17:76836065	USP36	0.57	6.31	0.46	2.84e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.5	4.47	0.34	1.54e-5	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs258892	0.843	rs4288100	chr5:72031760	C/T	cg21869765	chr5:72125136	TNPO1	-0.81	-5.54	-0.41	1.33e-7	Small cell lung carcinoma;
PAAD	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg19254793	chr6:44695348	NA	-0.45	-4.35	-0.33	2.45e-5	Total body bone mineral density;
PAAD	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg27449745	chr7:23145252	KLHL7	-0.49	-4.33	-0.33	2.72e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.71	6.04	0.44	1.16e-8	Type 2 diabetes;
PAAD	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.24	0.39	5.37e-7	IgG glycosylation;
PAAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.56	6.45	0.46	1.38e-9	Mean corpuscular volume;
PAAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.89	0.49	1.4e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.72	8.06	0.55	2.08e-13	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.6	-6.32	-0.46	2.74e-9	Multiple myeloma (IgH translocation);
PAAD	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.49	-0.52	5.13e-12	Morning vs. evening chronotype;
PAAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.69	7.88	0.54	5.77e-13	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	4.25	0.33	3.67e-5	Personality dimensions;
PAAD	cis	rs11945232	0.624	rs13130945	chr4:88371491	G/A	cg23841344	chr4:88312519	HSD17B11	-0.56	-4.51	-0.34	1.3e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg19418458	chr7:158789849	NA	0.54	5.21	0.39	6.05e-7	Facial morphology (factor 20);
PAAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg17650747	chr5:1873721	NA	0.45	4.65	0.35	7.04e-6	Cardiovascular disease risk factors;
PAAD	cis	rs9616064	0.849	rs12168432	chr22:46972080	G/A	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.53	-0.34	1.19e-5	Urate levels in obese individuals;
PAAD	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-5.08	-0.38	1.11e-6	Common traits (Other);
PAAD	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.71	7.49	0.52	5.14e-12	Brugada syndrome;
PAAD	cis	rs704	0.790	rs13469	chr17:26676135	C/T	cg10342447	chr17:26645325	TMEM97	-0.36	-4.44	-0.34	1.72e-5	Osteoprotegerin levels;
PAAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02071572	chr4:1403502	NA	-0.44	-5.92	-0.43	2.11e-8	Obesity-related traits;
PAAD	trans	rs795484	0.890	rs811247	chr12:118622836	G/T	cg06703803	chr12:110811045	ANAPC7	-0.58	-6.44	-0.46	1.49e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg05338066	chr1:7812865	CAMTA1	0.58	4.61	0.35	8.4e-6	Inflammatory bowel disease;
PAAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7072216	0.687	rs11597428	chr10:100154247	G/C	cg19567339	chr10:100142640	NA	0.41	4.34	0.33	2.62e-5	Metabolite levels;
PAAD	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg15017067	chr4:17643749	FAM184B	0.42	4.63	0.35	7.66e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs16889362	1.000	rs16889362	chr6:36965705	A/G	cg18891604	chr6:36319055	NA	-0.48	-5.14	-0.38	8.47e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.54	-4.43	-0.34	1.76e-5	Cocaine dependence;
PAAD	cis	rs16854884	0.710	rs6782558	chr3:143817462	G/C	cg06585982	chr3:143692056	C3orf58	0.55	5.24	0.39	5.33e-7	Economic and political preferences (feminism/equality);
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.46e-5	Testicular germ cell tumor;
PAAD	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg10778310	chr7:128509080	NA	0.4	4.87	0.37	2.74e-6	Calcium levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12170917	chr14:24605255	PSME1	0.61	6.8	0.48	2.21e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4740619	0.682	rs1887664	chr9:16003597	A/G	cg14451791	chr9:16040625	NA	-0.4	-4.69	-0.36	6.14e-6	Body mass index;
PAAD	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.56	-5.27	-0.39	4.55e-7	Coronary artery disease;
PAAD	cis	rs2286379	0.597	rs9739162	chr12:1838008	G/T	cg05227549	chr12:1770782	NA	-0.44	-5.08	-0.38	1.11e-6	Blood pressure (smoking interaction);
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.98	14.57	0.76	1.16e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs13053817	1.000	rs13055556	chr22:29840367	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.57	-5.14	-0.38	8.27e-7	Carotid atherosclerosis in HIV infection;
PAAD	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.74	7.29	0.51	1.56e-11	Neuroticism;
PAAD	trans	rs61931739	0.592	rs815042	chr12:33724221	C/A	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.85	9.34	0.6	1.12e-16	Prostate cancer;
PAAD	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg04940515	chr1:76251865	SNORD45C;RABGGTB	-0.45	-4.35	-0.33	2.45e-5	Daytime sleep phenotypes;
PAAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.36	4.64	0.35	7.57e-6	Renal function-related traits (BUN);
PAAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-7.04	-0.5	6.22e-11	Life satisfaction;
PAAD	trans	rs62179067	0.708	rs1473577	chr2:179872750	G/T	cg13380624	chr19:7735426	NA	-0.81	-7.5	-0.52	5.08e-12	Late-onset Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg03037974	chr15:76606532	NA	0.52	6.03	0.44	1.2e-8	Blood metabolite levels;
PAAD	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-4.7	-0.36	5.84e-6	Axial length;
PAAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-5.11	-0.38	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.46	-0.46	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg06287003	chr12:125626642	AACS	-0.51	-4.91	-0.37	2.35e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg12260801	chr7:1045157	C7orf50	0.57	6.62	0.47	5.68e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1419980	0.730	rs7965446	chr12:7747134	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg08917208	chr2:24149416	ATAD2B	0.49	4.3	0.33	3.08e-5	Lymphocyte counts;
PAAD	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.49	4.9	0.37	2.43e-6	Height;
PAAD	cis	rs5753037	0.834	rs713656	chr22:30212194	C/G	cg01021169	chr22:30184971	ASCC2	-0.45	-4.51	-0.34	1.32e-5	Type 1 diabetes;
PAAD	cis	rs13326165	0.585	rs11717028	chr3:52354061	A/G	cg08438690	chr3:52279403	PPM1M	-0.44	-4.39	-0.34	2.12e-5	HDL cholesterol;HDL cholesterol levels;
PAAD	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-1.55	-9.13	-0.6	4e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg10932868	chr11:921992	NA	0.45	4.78	0.36	4.14e-6	Alzheimer's disease (late onset);
PAAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.44	4.63	0.35	7.77e-6	Type 2 diabetes;
PAAD	cis	rs10512697	0.655	rs13162816	chr5:3497691	C/T	cg19473799	chr5:3511975	NA	-1.12	-5.07	-0.38	1.16e-6	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.71	7.04	0.5	6.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.64	-6.09	-0.44	9.04e-9	DNA methylation (variation);
PAAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.35	-5.27	-0.39	4.62e-7	Glomerular filtration rate;
PAAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.69	7.91	0.54	4.95e-13	Parkinson's disease;
PAAD	cis	rs12612619	0.732	rs1866654	chr2:27263122	A/G	cg00617064	chr2:27272375	NA	-0.54	-5.73	-0.42	5.2e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.62	6.9	0.49	1.3100000000000001e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-8.14	-0.55	1.32e-13	Monocyte percentage of white cells;
PAAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Depression;
PAAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2275565	0.745	rs10925273	chr1:237087952	G/T	cg17297354	chr1:237056641	MTR	-0.53	-4.48	-0.34	1.45e-5	Homocysteine levels;
PAAD	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.49	4.49	0.34	1.39e-5	Platelet count;
PAAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg14393609	chr7:65229607	NA	-0.46	-4.5	-0.34	1.34e-5	Aortic root size;
PAAD	cis	rs329648	0.889	rs329647	chr11:133764666	G/C	cg15485101	chr11:133734466	NA	0.42	4.86	0.37	2.88e-6	Parkinson's disease;
PAAD	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg25401027	chr5:176370377	UIMC1	0.5	5.09	0.38	1.04e-6	Menarche and menopause (age at onset);Menopause (age at onset);
PAAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.67	-7.27	-0.51	1.75e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg27411982	chr8:10470053	RP1L1	-0.43	-4.69	-0.36	6.07e-6	Triglycerides;
PAAD	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.71	7.16	0.5	3.29e-11	Coronary artery disease;
PAAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.8e-9	Diastolic blood pressure;
PAAD	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg22875332	chr1:76189707	ACADM	-0.49	-4.86	-0.37	2.86e-6	Daytime sleep phenotypes;
PAAD	trans	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg15655154	chr3:113604241	GRAMD1C	-0.65	-6.64	-0.47	5.23e-10	Diastolic blood pressure;
PAAD	cis	rs4851870	0.581	rs3769495	chr2:106504176	C/G	cg21551182	chr2:106399873	NCK2	0.43	4.38	0.33	2.19e-5	Addiction;
PAAD	cis	rs6784615	0.744	rs34551211	chr3:52286825	C/T	cg27565382	chr3:53032988	SFMBT1	1.06	4.69	0.36	6.07e-6	Waist-hip ratio;
PAAD	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.47	4.91	0.37	2.34e-6	Eye color traits;
PAAD	cis	rs73416724	0.688	rs113247464	chr6:43261781	T/A	cg17502394	chr6:43251710	TTBK1	0.7	4.4	0.34	2.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg26205652	chr12:48591994	NA	0.96	9.69	0.62	1.42e-17	Longevity (90 years and older);
PAAD	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.47	-4.54	-0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs78761021	0.787	rs56346556	chr17:9777596	G/T	cg26853458	chr17:9805074	RCVRN	0.7	8.2	0.55	9.42e-14	Type 2 diabetes;
PAAD	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.65	6.03	0.44	1.19e-8	Red blood cell count;
PAAD	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-7.6	-0.52	2.77e-12	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.45	4.91	0.37	2.36e-6	Longevity;Endometriosis;
PAAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg15640734	chr5:494837	SLC9A3	-0.43	-4.34	-0.33	2.54e-5	Cystic fibrosis severity;
PAAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27297192	chr10:134578999	INPP5A	0.58	5.56	0.41	1.18e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.2	6.92	0.49	1.18e-10	Type 2 diabetes nephropathy;
PAAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.54	5.17	0.39	7.19e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.52	-4.96	-0.37	1.86e-6	Mortality in heart failure;
PAAD	cis	rs6942407	0.592	rs10085726	chr7:86851397	T/A	cg02420886	chr7:86849541	C7orf23	0.69	5.33	0.4	3.47e-7	Food allergy;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.85	9.89	0.63	4.09e-18	Prudent dietary pattern;
PAAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-4.85	-0.37	3.05e-6	Lung cancer;
PAAD	cis	rs9715521	0.775	rs62301195	chr4:59846934	G/T	cg11281224	chr4:60001000	NA	-0.6	-5.76	-0.42	4.58e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9616064	0.710	rs12053764	chr22:46999703	C/T	cg05621596	chr22:47072043	GRAMD4	-0.82	-7.64	-0.53	2.25e-12	Urate levels in obese individuals;
PAAD	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	4.91	0.37	2.37e-6	Monocyte percentage of white cells;
PAAD	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.52	-4.31	-0.33	2.98e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4757319	0.532	rs4456244	chr11:15439353	T/C	cg03245590	chr11:15329459	NA	0.38	4.56	0.35	1.07e-5	Breast cancer;
PAAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.28	-0.33	3.36e-5	Aortic root size;
PAAD	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg00717180	chr2:96193071	NA	-0.59	-6.51	-0.47	1.02e-9	HDL cholesterol;
PAAD	cis	rs7631605	0.905	rs11720073	chr3:37018991	C/T	cg17445812	chr3:36986805	TRANK1	0.35	4.64	0.35	7.6e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.61	4.99	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg07777115	chr5:623756	CEP72	-0.65	-4.28	-0.33	3.26e-5	Breast cancer;
PAAD	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.33	-0.33	2.66e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.35	4.35	0.33	2.5e-5	Body mass index in non-asthmatics;
PAAD	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	10.97	0.66	5.58e-21	Chronic sinus infection;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20801998	chr11:592585	PHRF1	0.57	6.76	0.48	2.78e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.48	-4.85	-0.37	3.01e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	4.72	0.36	5.3e-6	Mean corpuscular volume;
PAAD	cis	rs1879734	0.731	rs12086451	chr1:54157640	C/T	cg14659662	chr1:54151053	GLIS1	-0.44	-5.82	-0.43	3.37e-8	Mitral valve prolapse;
PAAD	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.94	0.37	2.08e-6	Motion sickness;
PAAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13198984	chr17:80129470	CCDC57	-0.42	-5.22	-0.39	5.9e-7	Life satisfaction;
PAAD	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.76	-6.69	-0.48	4.05e-10	Blood pressure (smoking interaction);
PAAD	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.71	-6.1	-0.44	8.51e-9	Alzheimer's disease;
PAAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.19	-0.45	5.31e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs346785	0.518	rs3803738	chr17:74303832	G/C	cg09812376	chr17:74270190	QRICH2	-0.48	-5.46	-0.4	1.93e-7	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.55	7.72	0.53	1.42e-12	Electrocardiographic conduction measures;
PAAD	cis	rs6893807	1.000	rs3814424	chr5:87968953	C/T	cg02225085	chr5:87975992	LOC645323	-0.63	-4.71	-0.36	5.66e-6	Body mass index;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18920858	chr17:64617748	PRKCA	0.6	6.36	0.46	2.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-4.92	-0.37	2.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4704187	0.687	rs9763362	chr5:74406316	T/C	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs4731207	0.623	rs34865746	chr7:124639919	T/A	cg14311320	chr7:124405732	GPR37	-0.43	-4.51	-0.34	1.27e-5	Cutaneous malignant melanoma;
PAAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-8.21	-0.55	8.88e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg04257695	chr17:30186438	C17orf79	-0.63	-4.62	-0.35	8.08e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg26570165	chr1:119541833	NA	0.47	4.35	0.33	2.51e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.98	10.76	0.66	1.93e-20	Coronary artery disease;
PAAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	4.66	0.35	7e-6	Lymphocyte counts;
PAAD	cis	rs375066	0.935	rs454559	chr19:44429120	C/T	cg21496419	chr19:44306685	LYPD5	0.41	4.95	0.37	1.97e-6	Breast cancer;
PAAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13939156	chr17:80058883	NA	-0.4	-4.31	-0.33	2.92e-5	Life satisfaction;
PAAD	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.63	6.57	0.47	7.72e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.72	-5.36	-0.4	3.08e-7	Psoriasis vulgaris;
PAAD	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.15	16.11	0.79	1.09e-34	Cognitive function;
PAAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg03101763	chr11:65319844	LTBP3	-0.87	-4.42	-0.34	1.86e-5	Height;
PAAD	trans	rs7594645	0.661	rs12463410	chr2:207715608	C/T	cg25244921	chr15:65342634	OSTBETA	-1.2	-6.36	-0.46	2.26e-9	Episodic memory;
PAAD	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.58	-6.59	-0.47	6.86e-10	Educational attainment;
PAAD	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.68	6.65	0.47	4.86e-10	Bone properties (heel);
PAAD	cis	rs17095355	0.901	rs10399964	chr10:111654109	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-4.43	-0.34	1.78e-5	Biliary atresia;
PAAD	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.68	-7.83	-0.54	7.78e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg18131467	chr2:239335373	ASB1	-0.73	-5.38	-0.4	2.72e-7	Lung function (FEV1/FVC);
PAAD	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11208039	chr11:19138753	ZDHHC13	0.56	6.37	0.46	2.17e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.79	7.85	0.54	7.09e-13	Callous-unemotional behaviour;
PAAD	cis	rs4450131	0.522	rs11245327	chr10:126358174	T/C	cg20435097	chr10:126320824	FAM53B	0.53	5.44	0.4	2.08e-7	White blood cell count (basophil);
PAAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg21130718	chr4:1044621	NA	0.57	4.8	0.36	3.84e-6	Recombination rate (females);
PAAD	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg16576597	chr16:28551801	NUPR1	-0.56	-5.31	-0.4	3.74e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs11105468	0.701	rs7975953	chr12:90436082	C/T	cg16962463	chr12:89968675	NA	0.45	4.36	0.33	2.4e-5	Febrile seizures;Febrile seizures (MMR vaccine-related);Febrile seizures (MMR vaccine-unrelated);
PAAD	cis	rs1419980	0.730	rs11561265	chr12:7744090	C/T	cg25828445	chr12:7781288	NA	-0.89	-4.59	-0.35	9.08e-6	HDL cholesterol levels;
PAAD	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg08501292	chr6:25962987	TRIM38	0.55	4.3	0.33	3.01e-5	Homocysteine levels;
PAAD	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.51	4.91	0.37	2.35e-6	High light scatter reticulocyte count;
PAAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg05434287	chr7:2030229	MAD1L1	0.44	4.79	0.36	3.86e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.5	-0.61	4.26e-17	Blood trace element (Zn levels);
PAAD	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	11.35	0.68	5.32e-22	Nonalcoholic fatty liver disease;
PAAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	1.01	8.31	0.56	4.84e-14	Initial pursuit acceleration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16144447	chr1:36184773	C1orf216	0.59	6.66	0.48	4.71e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg18984983	chr10:135342936	CYP2E1	0.47	4.32	0.33	2.81e-5	Gout;
PAAD	cis	rs2252790	1.000	rs1204853	chr6:116577113	A/G	cg18764771	chr6:116381957	FRK	0.26	4.41	0.34	1.93e-5	Fast beta electroencephalogram;
PAAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.02e-5	Blood protein levels;
PAAD	cis	rs6466055	0.777	rs3801282	chr7:104881530	A/G	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.98	0.44	1.5e-8	Lung cancer;
PAAD	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg23587288	chr2:27483067	SLC30A3	-0.71	-6.67	-0.48	4.42e-10	Blood metabolite levels;
PAAD	cis	rs2051773	0.567	rs4517490	chr11:17043054	G/T	cg15378786	chr11:17036137	PLEKHA7	0.53	4.56	0.35	1.06e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.47	-0.78	4.97e-33	Height;
PAAD	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg08632701	chr21:37451849	NA	-0.61	-6.42	-0.46	1.61e-9	Mitral valve prolapse;
PAAD	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg05895507	chr15:77155635	SCAPER	-0.41	-4.54	-0.35	1.15e-5	Blood metabolite levels;
PAAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg03948781	chr1:205179583	DSTYK	0.46	4.35	0.33	2.44e-5	Red blood cell count;
PAAD	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.97	5.71	0.42	5.89e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.46	4.72	0.36	5.35e-6	Response to antipsychotic treatment in schizophrenia (working memory);
PAAD	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.66	-5.59	-0.41	1.01e-7	Menarche (age at onset);
PAAD	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.15	0.55	1.24e-13	Coffee consumption (cups per day);
PAAD	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.64	5.14	0.38	8.31e-7	Schizophrenia;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	9.21	0.6	2.39e-16	Lymphocyte counts;
PAAD	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg21823605	chr1:152486609	CRCT1	0.5	6.15	0.45	6.6e-9	Hair morphology;
PAAD	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.54	4.36	0.33	2.38e-5	Mosquito bite size;
PAAD	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs6496044	0.507	rs1471455	chr15:86154727	T/A	cg13263323	chr15:86062960	AKAP13	0.53	5.58	0.41	1.09e-7	Interstitial lung disease;
PAAD	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.94	6.37	0.46	2.15e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.49	4.74	0.36	4.94e-6	Cystic fibrosis severity;
PAAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-5.49	-0.41	1.67e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg16322792	chr1:120165303	ZNF697	0.54	7.33	0.51	1.3e-11	Systemic lupus erythematosus;
PAAD	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg03004497	chr11:58874207	FAM111B	-0.52	-4.39	-0.34	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg26876637	chr1:152193138	HRNR	0.85	6.74	0.48	3.01e-10	Atopic dermatitis;
PAAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg13468214	chr4:1046988	NA	-0.53	-4.93	-0.37	2.09e-6	Recombination rate (females);
PAAD	cis	rs2730260	0.736	rs73169220	chr7:158846197	A/C	cg02254261	chr7:158964346	NA	-0.6	-4.63	-0.35	7.7e-6	Myopia (pathological);
PAAD	cis	rs1043515	0.935	rs2338115	chr17:36929578	C/T	cg20826740	chr17:37024042	NA	0.41	4.53	0.34	1.21e-5	Height;
PAAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg05484376	chr2:27715224	FNDC4	0.54	5.36	0.4	3.08e-7	Total body bone mineral density;
PAAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg12623918	chr2:306882	NA	0.47	4.97	0.37	1.82e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.93	9.83	0.62	6.03e-18	Cognitive function;
PAAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.7	7.34	0.51	1.18e-11	Calcium levels;
PAAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg09509183	chr1:209979624	IRF6	0.53	4.94	0.37	2.03e-6	Cleft lip with or without cleft palate;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs12967678	1	rs12967678	chr18:12805388	G/A	cg23544223	chr18:12777786	NA	-0.68	-4.31	-0.33	2.93e-5	Selective IgA deficiency;
PAAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18404041	chr3:52824283	ITIH1	0.43	4.6	0.35	8.83e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.6	6.45	0.46	1.42e-9	Lung cancer;
PAAD	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg18939081	chr1:31884902	SERINC2	0.48	5.31	0.4	3.78e-7	Alcohol dependence;
PAAD	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.63	0.35	7.95e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.64	6.72	0.48	3.48e-10	Obesity-related traits;
PAAD	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg13206674	chr6:150067644	NUP43	-0.56	-5.31	-0.4	3.88e-7	Lung cancer;
PAAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.7	5.09	0.38	1.06e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg18944383	chr4:111397179	ENPEP	0.74	8.14	0.55	1.31e-13	Height;
PAAD	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.83	9.43	0.61	6.45e-17	Metabolic syndrome;
PAAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.6	7.17	0.5	3.12e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs66887589	0.934	rs2715016	chr4:120452356	T/C	cg09307838	chr4:120376055	NA	-0.42	-4.29	-0.33	3.22e-5	Diastolic blood pressure;
PAAD	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-1.0	-5.1	-0.38	1.01e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.4	-4.77	-0.36	4.21e-6	Intraocular pressure;
PAAD	cis	rs9810890	1.000	rs9847759	chr3:128594373	C/T	cg18531004	chr3:128564980	NA	-0.76	-4.75	-0.36	4.7e-6	Dental caries;
PAAD	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg10072921	chr12:121022843	NA	-0.37	-4.96	-0.37	1.83e-6	High light scatter reticulocyte count;
PAAD	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.79	-8.49	-0.57	1.76e-14	Obesity-related traits;
PAAD	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.93	7.84	0.54	7.41e-13	Total cholesterol levels;
PAAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.58	-6.61	-0.47	6.16e-10	Prostate cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13783244	chr4:140005441	ELF2	-0.67	-6.76	-0.48	2.79e-10	Smoking initiation;
PAAD	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.71	7.54	0.52	4.04e-12	Colorectal cancer;
PAAD	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs282587	0.569	rs395246	chr13:113415392	C/A	cg02820901	chr13:113351484	ATP11A	-0.66	-4.97	-0.37	1.82e-6	Glycated hemoglobin levels;
PAAD	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg27449745	chr7:23145252	KLHL7	-0.5	-4.37	-0.33	2.27e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-4.97	-0.37	1.82e-6	Blood metabolite levels;
PAAD	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-1.02	-6.88	-0.49	1.48e-10	Post bronchodilator FEV1;
PAAD	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg06617341	chr2:177005611	NA	-0.48	-4.33	-0.33	2.69e-5	Obstructive sleep apnea trait (apnea hypopnea index);
PAAD	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-6.82	-0.48	1.98e-10	Platelet distribution width;
PAAD	cis	rs2637266	0.783	rs2588333	chr10:78538952	A/G	cg18941641	chr10:78392320	NA	0.38	4.64	0.35	7.32e-6	Pulmonary function;
PAAD	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg05393297	chr12:53359155	NA	-1.05	-6.28	-0.45	3.33e-9	Prostate cancer;
PAAD	cis	rs6084352	0.604	rs2208030	chr20:3355567	T/C	cg06251395	chr20:3663186	ADAM33	-0.38	-4.32	-0.33	2.76e-5	Asthma;
PAAD	cis	rs11077998	0.967	rs901373	chr17:80506559	A/G	cg10255544	chr17:80519551	FOXK2	0.58	5.95	0.43	1.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.99	-12.09	-0.7	5.18e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.76	6.54	0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	8.54	0.57	1.29e-14	Platelet count;
PAAD	cis	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg16685388	chr1:42384056	HIVEP3	0.38	4.25	0.33	3.69e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10100747	chr14:71787215	NA	0.7	6.95	0.49	1.01e-10	Obesity-related traits;
PAAD	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	1.08	7.06	0.5	5.45e-11	vWF and FVIII levels;
PAAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	7.83	0.54	7.67e-13	Eosinophilic esophagitis;
PAAD	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs7119038	0.607	rs12365699	chr11:118743286	C/T	cg19308663	chr11:118741387	NA	0.58	4.27	0.33	3.48e-5	Sjögren's syndrome;
PAAD	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	1.02	7.2	0.5	2.53e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.46	4.63	0.35	7.81e-6	Schizophrenia;
PAAD	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.55	4.93	0.37	2.13e-6	RR interval (heart rate);
PAAD	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.63	-0.62	2.03e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs874426	0.528	rs7943800	chr11:19573044	T/C	cg13922121	chr11:19575262	NAV2	0.39	4.37	0.33	2.32e-5	Attention deficit hyperactivity disorder (time to onset);
PAAD	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.77	4.71	0.36	5.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.35	4.81	0.36	3.67e-6	Sitting height ratio;
PAAD	cis	rs7729723	0.653	rs10055995	chr5:137698299	C/T	cg26069252	chr5:137800343	EGR1	-0.46	-4.28	-0.33	3.24e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
PAAD	cis	rs10214930	0.671	rs6945993	chr7:27681010	A/G	cg22168087	chr7:27702803	HIBADH	0.48	4.57	0.35	1.02e-5	Hypospadias;
PAAD	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.13	-0.45	7.19e-9	Mood instability;
PAAD	cis	rs12799264	0.915	rs6483623	chr11:19973240	C/G	cg17303119	chr11:19974895	NAV2	0.72	4.42	0.34	1.85e-5	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg03959625	chr15:84868606	LOC388152	0.51	5.65	0.42	7.87e-8	Schizophrenia;
PAAD	cis	rs7707921	0.958	rs6452447	chr5:81482522	A/G	cg21483461	chr5:81570383	RPS23	0.51	4.32	0.33	2.83e-5	Breast cancer;
PAAD	cis	rs13424612	0.764	rs2887406	chr2:240923147	C/T	cg01812947	chr2:240904978	NDUFA10	0.53	4.91	0.37	2.33e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.56	-0.47	8.12e-10	Eye color traits;
PAAD	cis	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg02982722	chr20:44486048	ZSWIM3;ACOT8	0.42	4.32	0.33	2.76e-5	Positive affect;
PAAD	cis	rs9938149	0.834	rs9922572	chr16:88334112	G/T	cg16723805	chr16:88516225	NA	0.47	4.37	0.33	2.34e-5	Corneal structure;Central corneal thickness;
PAAD	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16988970	chr17:42248062	ASB16	-0.38	-5.43	-0.4	2.23e-7	Total body bone mineral density;
PAAD	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg12193833	chr17:30244370	NA	-0.64	-5.41	-0.4	2.39e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.8	9.9	0.63	3.83e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8179	0.593	rs6948097	chr7:92281953	C/T	cg03496780	chr7:92466842	CDK6	0.5	4.68	0.36	6.2e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-1.05	-8.72	-0.58	4.4e-15	Vitiligo;
PAAD	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	4.64	0.35	7.6e-6	Homocysteine levels;
PAAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg23605961	chr7:751331	PRKAR1B	0.3	4.72	0.36	5.29e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.57	-5.37	-0.4	2.83e-7	Daytime sleep phenotypes;
PAAD	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg10392614	chr2:208977121	NA	0.5	5.12	0.38	9.22e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs9467603	0.800	rs1892252	chr6:25772639	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.73	-5.27	-0.39	4.58e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg13206674	chr6:150067644	NUP43	0.62	6.51	0.47	1.01e-9	Testicular germ cell tumor;
PAAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-11.03	-0.67	3.72e-21	Coronary artery disease;
PAAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.48	5.6	0.41	9.91e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.61	5.91	0.43	2.12e-8	Menopause (age at onset);
PAAD	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg06138931	chr13:21896616	NA	-0.65	-4.57	-0.35	9.97e-6	White matter hyperintensity burden;
PAAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg10547527	chr2:198650123	BOLL	-0.72	-4.83	-0.37	3.24e-6	Ulcerative colitis;
PAAD	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.88	9.45	0.61	5.77e-17	Anterior chamber depth;
PAAD	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg14851346	chr12:38532713	NA	-0.45	-4.29	-0.33	3.23e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06771106	chr2:113671356	IL1F7	-0.62	-6.74	-0.48	3.05e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-5.93	-0.43	1.99e-8	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg08029281	chr1:67600428	NA	0.54	6.16	0.45	6.13e-9	Psoriasis;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18902035	chr2:134949357	NA	-0.58	-6.63	-0.47	5.4e-10	Monocyte percentage of white cells;
PAAD	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-4.74	-0.36	4.84e-6	Vitiligo;
PAAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.56	-6.11	-0.44	8.15e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.79	10.04	0.63	1.68e-18	Height;
PAAD	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.5	-9.64	-0.62	1.81e-17	Alzheimer's disease (late onset);
PAAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg17541715	chr7:1216824	NA	-0.56	-6.7	-0.48	3.79e-10	Longevity;Endometriosis;
PAAD	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.53	0.35	1.17e-5	Educational attainment (years of education);
PAAD	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.25	19.24	0.84	1.41e-42	IgG glycosylation;
PAAD	cis	rs988913	1.000	rs6929930	chr6:54812710	G/A	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg19486271	chr11:47235900	DDB2	-0.54	-5.65	-0.42	7.83e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2299116	0.925	rs6980444	chr7:28801703	G/A	cg06647007	chr7:28747836	CREB5	-0.49	-4.69	-0.36	6.07e-6	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg19637330	chr1:19110922	NA	0.6	4.81	0.36	3.6e-6	Percentage gas trapping;
PAAD	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.24	-17.75	-0.82	7.15e-39	Triglycerides;
PAAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.71	-7.75	-0.53	1.23e-12	Renal function-related traits (BUN);
PAAD	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-7.85	-0.54	6.95e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.56	5.9	0.43	2.28e-8	Obesity-related traits;
PAAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.84	7.18	0.5	2.87e-11	Alzheimer's disease;
PAAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.73	-8.61	-0.57	8.87e-15	Childhood ear infection;
PAAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-9.08	-0.59	5.35e-16	Extrinsic epigenetic age acceleration;
PAAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-15.09	-0.77	5.12e-32	Height;
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-1.24	-12.31	-0.71	1.31e-24	Developmental language disorder (linguistic errors);
PAAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.94	-11.37	-0.68	4.46e-22	Height;
PAAD	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-4.83	-0.36	3.26e-6	Daytime sleep phenotypes;
PAAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-6.51	-0.47	1.03e-9	Bone mineral density;
PAAD	cis	rs6782025	0.837	rs173087	chr3:120937769	G/C	cg16417163	chr3:121280760	NA	-0.46	-4.73	-0.36	5.08e-6	Aging (facial);
PAAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.81	0.54	8.51e-13	Prudent dietary pattern;
PAAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.49	4.26	0.33	3.63e-5	Aortic root size;
PAAD	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs12431939	0.948	rs12433249	chr14:51669661	T/C	cg23942311	chr14:51606299	NA	-0.61	-5.03	-0.38	1.38e-6	Cancer;
PAAD	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.18	0.45	5.65e-9	Rheumatoid arthritis;
PAAD	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg26031613	chr14:104095156	KLC1	-0.56	-5.87	-0.43	2.7e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	4.43	0.34	1.76e-5	Iron status biomarkers;
PAAD	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg25155006	chr6:37138205	PIM1	-0.55	-4.43	-0.34	1.76e-5	QRS duration;
PAAD	cis	rs735539	0.555	rs2253017	chr13:21300909	C/T	cg27499820	chr13:21296301	IL17D	0.59	5.45	0.4	1.99e-7	Dental caries;
PAAD	trans	rs17054480	0.614	rs12639676	chr4:169622366	G/T	cg18174542	chr22:41956861	CSDC2	0.8	6.44	0.46	1.48e-9	Advanced glycation end-product levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07647798	chr19:16296063	FAM32A	0.56	6.82	0.48	1.99e-10	Monocyte percentage of white cells;
PAAD	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16576597	chr16:28551801	NUPR1	0.68	7.7	0.53	1.57e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg14393609	chr7:65229607	NA	0.49	4.32	0.33	2.83e-5	Aortic root size;
PAAD	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.53	-4.3	-0.33	3.07e-5	Type 2 diabetes;
PAAD	cis	rs9535307	0.719	rs1201716	chr13:50378425	T/G	cg03658251	chr13:50265850	EBPL	-0.82	-5.62	-0.42	8.68e-8	Obesity-related traits;
PAAD	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.27	-0.33	3.39e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs375066	0.935	rs413093	chr19:44426265	A/G	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14180030	chr9:123475675	MEGF9	-0.39	-4.4	-0.34	2.03e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.65	-7.46	-0.52	6.22e-12	Sense of smell;
PAAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg15691649	chr6:25882328	NA	-0.5	-4.52	-0.34	1.24e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.22	-0.45	4.53e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.62	-4.95	-0.37	1.98e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg20283391	chr11:68216788	NA	-0.5	-4.63	-0.35	7.75e-6	Total body bone mineral density;
PAAD	cis	rs1697139	0.698	rs1697138	chr5:66511787	C/G	cg16691251	chr5:66510806	NA	0.69	7.15	0.5	3.44e-11	Breast cancer;
PAAD	cis	rs375066	0.967	rs417400	chr19:44410846	A/G	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-8.06	-0.55	2.07e-13	Mean corpuscular volume;
PAAD	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.66	7.96	0.54	3.77e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs76793172	1.000	rs60283385	chr19:46329079	T/C	cg13320842	chr19:46175254	GIPR	0.63	4.77	0.36	4.26e-6	Eosinophil counts;
PAAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.43	-4.28	-0.33	3.32e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg17182837	chr8:41585554	ANK1	-0.44	-4.86	-0.37	2.94e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg23708337	chr7:1209742	NA	0.63	4.53	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.59	-0.47	6.88e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-9.45	-0.61	5.96e-17	Alzheimer's disease (late onset);
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg01763666	chr17:80159506	CCDC57	-0.44	-4.4	-0.34	2.06e-5	Life satisfaction;
PAAD	cis	rs1144333	0.655	rs76975224	chr1:76470793	T/C	cg22875332	chr1:76189707	ACADM	0.75	4.41	0.34	1.93e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.59	-6.81	-0.48	2.16e-10	Lung cancer;
PAAD	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.26	-0.45	3.7e-9	Mood instability;
PAAD	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.79	-6.95	-0.49	1.02e-10	Systemic lupus erythematosus;
PAAD	cis	rs3764628	0.714	rs11667450	chr19:18745522	C/G	cg14292368	chr19:18793705	CRTC1	0.55	5.1	0.38	1e-6	Orofacial clefts;
PAAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.71e-5	Life satisfaction;
PAAD	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.64	5.5	0.41	1.55e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg11601000	chr22:42348013	LOC339674	0.4	4.5	0.34	1.32e-5	Cognitive function;
PAAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.83	-9.08	-0.59	5.3e-16	Prostate cancer;
PAAD	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.6	-5.3	-0.39	4.01e-7	Type 2 diabetes;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.87	8.15	0.55	1.23e-13	Menarche (age at onset);
PAAD	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.49	5.56	0.41	1.16e-7	Coronary artery disease;
PAAD	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-5.55	-0.41	1.22e-7	Response to antineoplastic agents;
PAAD	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Lymphocyte counts;
PAAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg21951975	chr1:209979733	IRF6	0.41	5.21	0.39	6e-7	Monobrow;
PAAD	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7246865	0.510	rs8103578	chr19:17171227	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.56	5.6	0.41	9.66e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg01059385	chr22:42394853	WBP2NL	0.41	4.4	0.34	1.99e-5	Cognitive function;
PAAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg02733842	chr7:1102375	C7orf50	-0.65	-5.04	-0.38	1.32e-6	Bronchopulmonary dysplasia;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23410386	chr6:56637189	DST	0.61	6.34	0.46	2.47e-9	Smoking initiation;
PAAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.42	-0.34	1.86e-5	Coronary artery disease;
PAAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.05e-5	Skin colour saturation;
PAAD	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg10871876	chr19:53194124	ZNF83	-0.59	-5.3	-0.4	3.98e-7	Response to paliperidone in schizophrenia (PANSS score);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg26926632	chr1:150848739	ARNT	-0.56	-6.47	-0.46	1.29e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg15282417	chr9:129245246	FAM125B	0.42	5.04	0.38	1.33e-6	Intraocular pressure;
PAAD	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22903286	chr14:77564084	KIAA1737	-0.81	-7.16	-0.5	3.15e-11	Neuroticism;
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg08835956	chr7:39171034	POU6F2	0.33	5.75	0.42	4.75e-8	IgG glycosylation;
PAAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.53	-5.1	-0.38	9.8e-7	Multiple sclerosis;
PAAD	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg06484146	chr7:12443880	VWDE	-0.79	-5.37	-0.4	2.93e-7	Coronary artery disease;
PAAD	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.89	7.23	0.51	2.2e-11	Chronic kidney disease;
PAAD	cis	rs35740288	0.731	rs35085180	chr15:86102612	T/C	cg07943548	chr15:86304357	KLHL25	-0.64	-5.59	-0.41	1.02e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-5.43	-0.4	2.15e-7	Testicular germ cell tumor;
PAAD	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.97	10.39	0.64	1.9e-19	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.6	6.43	0.46	1.58e-9	Menarche (age at onset);
PAAD	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.71	5.12	0.38	9.09e-7	Type 2 diabetes;
PAAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.24	0.45	4.12e-9	Personality dimensions;
PAAD	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg23173402	chr1:227635558	NA	0.94	6.06	0.44	1.03e-8	Major depressive disorder;
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	6.53	0.47	9.38e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-4.74	-0.36	4.81e-6	Lung cancer;
PAAD	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-5.13	-0.38	8.56e-7	Pulmonary function;
PAAD	cis	rs2133450	0.935	rs7609608	chr3:7330179	G/A	cg19930620	chr3:7340148	GRM7	-0.5	-5.47	-0.41	1.77e-7	Early response to risperidone in schizophrenia;
PAAD	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg08926642	chr1:7887455	PER3	0.5	4.46	0.34	1.57e-5	Inflammatory bowel disease;
PAAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg13444538	chr7:158905317	VIPR2	-0.56	-4.6	-0.35	8.66e-6	Facial morphology (factor 20);
PAAD	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.89	-9.71	-0.62	1.2e-17	Bipolar disorder and schizophrenia;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg00692933	chr16:68877417	TMCO7	0.57	6.47	0.46	1.3e-9	Metabolite levels  (X-11787);
PAAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.99	10.13	0.63	9.64e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.91	8.21	0.55	8.89e-14	Diastolic blood pressure;
PAAD	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg06632027	chr4:90757378	SNCA	-0.61	-5.5	-0.41	1.59e-7	Neuroticism;
PAAD	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.55	4.8	0.36	3.73e-6	Corneal astigmatism;
PAAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.88	10.02	0.63	1.83e-18	Ulcerative colitis;
PAAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.81	6.09	0.44	8.68e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.77	-8.98	-0.59	9.73e-16	Total body bone mineral density;
PAAD	cis	rs7326068	0.524	rs2497488	chr13:21201476	A/T	cg27499820	chr13:21296301	IL17D	0.45	4.6	0.35	8.76e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	8.05	0.55	2.22e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.51	-5.4	-0.4	2.47e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg07202610	chr7:1142643	C7orf50	-0.71	-5.22	-0.39	5.74e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg08992911	chr2:238395768	MLPH	0.86	6.05	0.44	1.07e-8	Prostate cancer;
PAAD	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg23912435	chr1:150601613	ENSA	0.5	4.71	0.36	5.57e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg16898833	chr6:26189333	HIST1H4D	0.9	4.88	0.37	2.69e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17032980	0.956	rs10208188	chr2:67307672	A/C	cg06994420	chr2:66672553	MEIS1	-0.51	-4.49	-0.34	1.38e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg10761708	chr20:43804764	PI3	0.56	4.38	0.33	2.2e-5	Blood protein levels;
PAAD	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-6.78	-0.48	2.49e-10	Eye color traits;
PAAD	cis	rs113835537	0.597	rs3825065	chr11:66311011	A/G	cg24851651	chr11:66362959	CCS	0.49	4.67	0.35	6.71e-6	Airway imaging phenotypes;
PAAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.83	8.91	0.59	1.48e-15	Prostate cancer;
PAAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.58	0.74	5.31e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2327429	0.519	rs6906375	chr6:134152627	C/G	cg06296503	chr6:134217401	NA	0.43	4.5	0.34	1.37e-5	Coronary artery disease;
PAAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06217245	chr20:33103252	DYNLRB1	0.4	4.73	0.36	5.07e-6	Coronary artery disease;
PAAD	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg21518248	chr2:162101506	NA	-0.57	-5.28	-0.39	4.48e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.44	-5.69	-0.42	6.35e-8	Primary biliary cholangitis;
PAAD	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-4.27	-0.33	3.5e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs642743	0.967	rs569967	chr10:105942337	G/C	cg03775802	chr10:105978702	MIR609;C10orf79	0.31	4.31	0.33	2.9e-5	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.75	-8.73	-0.58	4.32e-15	Body mass index;
PAAD	cis	rs7714584	1.000	rs59980321	chr5:150241813	A/T	cg22134413	chr5:150180641	NA	0.79	5.61	0.41	9.49e-8	Crohn's disease;
PAAD	cis	rs1536827	0.748	rs9418986	chr10:135324276	T/C	cg16964102	chr10:135390573	NA	-0.56	-4.27	-0.33	3.42e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg04877966	chr15:75135169	ULK3	0.54	4.69	0.36	6.14e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs11702148	0.552	rs2300374	chr21:34885590	A/T	cg14850771	chr21:34775459	IFNGR2	0.43	4.67	0.35	6.7e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.85	-5.41	-0.4	2.39e-7	Mononucleosis;
PAAD	trans	rs901683	1.000	rs12776291	chr10:46038507	T/C	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.49	4.9	0.37	2.45e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.18	-0.39	6.95e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg11621586	chr10:70884670	VPS26A	0.99	7.37	0.51	1.01e-11	Left atrial antero-posterior diameter;
PAAD	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.55	8.65	0.57	6.95e-15	IgG glycosylation;
PAAD	cis	rs7714584	1.000	rs1428554	chr5:150257616	A/G	cg22134413	chr5:150180641	NA	0.71	5.03	0.38	1.39e-6	Crohn's disease;
PAAD	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.88	7.29	0.51	1.58e-11	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.55	-5.21	-0.39	5.97e-7	Total body bone mineral density;
PAAD	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.04	-13.07	-0.73	1.21e-26	Schizophrenia;
PAAD	cis	rs35063026	1.000	rs35063026	chr16:89736157	C/T	cg07984980	chr16:89898383	SPIRE2	0.88	4.91	0.37	2.28e-6	Facial pigmentation;Squamous cell carcinoma;
PAAD	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.88	-6.25	-0.45	3.91e-9	Hip circumference adjusted for BMI;
PAAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.82	-7.9	-0.54	5.33e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg02743256	chr7:2109353	MAD1L1	-0.62	-4.73	-0.36	5.01e-6	Bipolar disorder;
PAAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.59	-4.5	-0.34	1.37e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.72	-7.28	-0.51	1.72e-11	Mosquito bite size;
PAAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg15510373	chr7:100224934	TFR2	-0.52	-4.34	-0.33	2.54e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7816613	0.920	rs2275994	chr8:102700230	C/T	cg20585841	chr8:102729926	NCALD	-0.71	-5.63	-0.42	8.31e-8	Age-related hearing impairment;
PAAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01200585	chr1:228362443	C1orf69	-0.46	-5.2	-0.39	6.34e-7	Diastolic blood pressure;
PAAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.58	-7.88	-0.54	5.97e-13	Intelligence (multi-trait analysis);
PAAD	trans	rs6828577	0.560	rs2631147	chr4:119455854	C/T	cg26518628	chr1:97050305	NA	0.71	6.35	0.46	2.4e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6766510	1.000	rs17036821	chr3:12533148	A/C	cg07775309	chr3:12595852	NA	0.67	4.31	0.33	2.92e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg03615921	chr16:89375284	ANKRD11	-0.69	-4.44	-0.34	1.75e-5	Joint mobility (Beighton score);
PAAD	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06002616	chr8:101225028	SPAG1	-0.48	-5.65	-0.42	7.85e-8	Atrioventricular conduction;
PAAD	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg27411982	chr8:10470053	RP1L1	-0.53	-5.86	-0.43	2.78e-8	Retinal vascular caliber;
PAAD	cis	rs7627468	0.955	rs7638770	chr3:121928682	T/C	cg17240004	chr3:121949083	CASR	0.52	4.49	0.34	1.41e-5	Kidney stones;
PAAD	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.39	-4.4	-0.34	2.03e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13560548	chr3:10150139	C3orf24	0.56	5.04	0.38	1.28e-6	Alzheimer's disease;
PAAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-5.99	-0.44	1.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	4.68	0.35	6.42e-6	Obesity-related traits;
PAAD	cis	rs59104589	0.617	rs60614486	chr2:242274998	C/G	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg10820045	chr2:198174542	NA	0.46	4.61	0.35	8.31e-6	Dermatomyositis;
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.64	-0.35	7.54e-6	Lung cancer;
PAAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-5.75	-0.42	4.72e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg07703079	chr11:430292	ANO9	0.74	4.53	0.34	1.2e-5	Body mass index;
PAAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23281280	chr6:28129359	ZNF389	0.65	5.08	0.38	1.09e-6	Parkinson's disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06627077	chr19:47617100	ZC3H4	0.59	6.92	0.49	1.2e-10	Monocyte percentage of white cells;
PAAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg16205897	chr5:131564050	P4HA2	0.54	6.15	0.45	6.48e-9	Blood metabolite levels;
PAAD	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.52	-0.47	9.95e-10	Systolic blood pressure;
PAAD	cis	rs12042938	0.507	rs1655302	chr1:231731528	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.62	-0.47	5.83e-10	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg17366294	chr4:99064904	C4orf37	0.45	4.99	0.38	1.61e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg13206674	chr6:150067644	NUP43	0.63	6.45	0.46	1.39e-9	Testicular germ cell tumor;
PAAD	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.54	4.31	0.33	2.93e-5	Systolic blood pressure;
PAAD	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-6.33	-0.46	2.64e-9	Triglycerides;
PAAD	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.07	9.63	0.62	2.01e-17	Red blood cell traits;
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.91	-10.24	-0.64	4.82e-19	Bipolar disorder and schizophrenia;
PAAD	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.43	4.68	0.35	6.38e-6	HDL cholesterol levels;
PAAD	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg13870426	chr17:30244630	NA	-0.72	-6.48	-0.47	1.22e-9	Hip circumference adjusted for BMI;
PAAD	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-4.96	-0.37	1.9e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.74	-0.36	4.84e-6	Vitiligo;
PAAD	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.78	7.77	0.53	1.08e-12	Corneal astigmatism;
PAAD	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.82e-17	Platelet count;
PAAD	cis	rs6541297	0.757	rs2760537	chr1:230326412	C/T	cg05784532	chr1:230284198	GALNT2	-0.58	-4.38	-0.34	2.16e-5	Coronary artery disease;
PAAD	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.56	5.59	0.41	1.03e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs72827839	0.793	rs72823513	chr17:46048920	A/G	cg23391107	chr17:45924227	SP6	0.61	5.07	0.38	1.12e-6	Ease of getting up in the morning;
PAAD	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6782025	1.000	rs1987098	chr3:121124527	G/A	cg16417163	chr3:121280760	NA	-0.47	-4.85	-0.37	3.03e-6	Aging (facial);
PAAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs9535307	0.518	rs73194439	chr13:50403217	G/C	cg04663916	chr13:50265991	EBPL	-0.71	-5.31	-0.4	3.74e-7	Obesity-related traits;
PAAD	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.51	-0.34	1.31e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.59	5.45	0.4	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	1.77	9.96	0.63	2.72e-18	Cannabis dependence symptom count;
PAAD	cis	rs643506	0.817	rs1940392	chr11:111776846	G/A	cg09085632	chr11:111637200	PPP2R1B	0.58	4.87	0.37	2.8e-6	Breast cancer;
PAAD	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.73	-0.36	5.13e-6	Height;
PAAD	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg08648136	chr8:956695	NA	0.43	4.59	0.35	9.12e-6	Schizophrenia;
PAAD	cis	rs1799810	0.899	rs4662726	chr2:128170662	C/T	cg09760422	chr2:128146352	NA	-0.51	-9.15	-0.6	3.62e-16	Self-rated health;
PAAD	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.88	12.32	0.71	1.27e-24	Metabolite levels;
PAAD	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.5	-4.34	-0.33	2.58e-5	Triglyceride levels;
PAAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.84	7.36	0.51	1.1e-11	Schizophrenia;
PAAD	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.7	-11.07	-0.67	2.99e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg10356904	chr22:49881777	NA	-0.53	-5.09	-0.38	1.06e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg08992911	chr2:238395768	MLPH	0.69	6.84	0.49	1.78e-10	Prostate cancer;
PAAD	cis	rs9583531	0.714	rs79483970	chr13:111342298	G/A	cg07595035	chr13:111291582	CARKD	0.79	4.8	0.36	3.75e-6	Coronary artery disease;
PAAD	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.48	-5.52	-0.41	1.44e-7	Height;
PAAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg05564831	chr3:52568323	NT5DC2	0.45	4.75	0.36	4.63e-6	Bipolar disorder;
PAAD	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg04455712	chr21:45112962	RRP1B	0.58	6.13	0.45	7.23e-9	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10355708	chr8:145618298	ADCK5	-0.66	-6.3	-0.46	3.07e-9	Obesity-related traits;
PAAD	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.75	0.36	4.67e-6	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs1018697	1.000	rs7088711	chr10:104559266	A/G	cg14489801	chr10:103603810	KCNIP2	0.29	4.29	0.33	3.14e-5	Colorectal adenoma (advanced);
PAAD	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.53	4.48	0.34	1.46e-5	Personality dimensions;
PAAD	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg01191920	chr7:158217561	PTPRN2	-0.78	-7.75	-0.53	1.23e-12	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs71496621	chr10:46076348	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.56	0.52	3.5e-12	Lung function (FEV1/FVC);
PAAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26617929	chr16:1858877	NA	-0.54	-4.4	-0.34	2.04e-5	Ankle injury;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg07202610	chr7:1142643	C7orf50	-0.73	-5.22	-0.39	5.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2718812	1.000	rs2718815	chr3:133398786	A/G	cg11941060	chr3:133502564	NA	0.47	4.98	0.37	1.73e-6	Iron status biomarkers;
PAAD	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.53	5.03	0.38	1.39e-6	Endometrial cancer;
PAAD	cis	rs59888335	0.929	rs66517523	chr3:80842355	T/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02985541	chr2:219472218	PLCD4	-0.29	-4.38	-0.33	2.24e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.51	6.15	0.45	6.56e-9	Height;
PAAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.9	6.19	0.45	5.22e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
PAAD	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg02421172	chr7:1938701	MAD1L1	-0.65	-4.93	-0.37	2.15e-6	Bipolar disorder;
PAAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.56	5.12	0.38	9.06e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.68	-6.79	-0.48	2.36e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg18370025	chr7:2749541	AMZ1	-0.37	-4.49	-0.34	1.41e-5	Height;
PAAD	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.75	-12.73	-0.72	1.02e-25	Urate levels in overweight individuals;
PAAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.47	4.74	0.36	4.92e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.33	-6.16	-0.45	6.21e-9	Type 2 diabetes;
PAAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.94	-11.96	-0.7	1.16e-23	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.46	-5.24	-0.39	5.25e-7	Mean arterial pressure;
PAAD	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-1.27	-10.12	-0.63	1.02e-18	Obesity-related traits;
PAAD	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg11288833	chr15:55489084	RSL24D1	0.58	4.76	0.36	4.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg16342193	chr10:102329863	NA	-0.78	-8.57	-0.57	1.09e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg17154069	chr19:5690233	RPL36	0.59	6.37	0.46	2.12e-9	Myopia (pathological);
PAAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22442454	chr1:209979470	IRF6	0.43	4.85	0.37	3e-6	Monobrow;
PAAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-4.56	-0.35	1.06e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9463078	0.605	rs2396504	chr6:45316202	C/G	cg25276700	chr6:44698697	NA	0.44	5.09	0.38	1.03e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.6	5.91	0.43	2.15e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs533581	0.789	rs7404039	chr16:88975954	A/G	cg16701003	chr16:89028210	CBFA2T3	0.55	5.49	0.41	1.67e-7	Social autistic-like traits;
PAAD	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs2070433	0.749	rs718496	chr21:47904585	A/C	cg12379764	chr21:47803548	PCNT	0.54	4.79	0.36	4.01e-6	Lymphocyte counts;
PAAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg13722127	chr7:150037890	RARRES2	0.62	5.98	0.44	1.51e-8	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.92	11.07	0.67	2.86e-21	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01334232	chr3:178780279	ZMAT3	-0.71	-7.99	-0.54	3.07e-13	Obesity-related traits;
PAAD	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	5.36	0.4	3.04e-7	Personality dimensions;
PAAD	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.74e-5	Bone mineral density;
PAAD	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg18279126	chr7:2041391	MAD1L1	0.58	5.62	0.41	8.74e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.37	4.64	0.35	7.46e-6	Menarche (age at onset);
PAAD	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18364779	chr6:26104403	HIST1H4C	0.46	4.52	0.34	1.26e-5	Schizophrenia;
PAAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.74	-4.41	-0.34	1.91e-5	Tuberculosis;
PAAD	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.91	10.88	0.66	9.66e-21	Sudden cardiac arrest;
PAAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.55	5.02	0.38	1.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg23328922	chr3:111393453	PLCXD2	-0.56	-6.5	-0.47	1.09e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.59	-6.22	-0.45	4.53e-9	Body mass index;
PAAD	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.87	9.89	0.63	4.11e-18	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg14440974	chr22:39074834	NA	-0.61	-6.89	-0.49	1.41e-10	Menopause (age at onset);
PAAD	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.64	6.75	0.48	2.89e-10	Testicular germ cell tumor;
PAAD	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00166722	chr3:10149974	C3orf24	0.98	8.12	0.55	1.5e-13	Alzheimer's disease;
PAAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.42	-0.4	2.29e-7	Initial pursuit acceleration;
PAAD	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg23793686	chr15:68133972	NA	-0.54	-4.6	-0.35	8.99e-6	Obesity;
PAAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.69	0.58	5.35e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.57	6.49	0.47	1.17e-9	Major depressive disorder;
PAAD	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.84	6.99	0.49	8.2e-11	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.84	6.44	0.46	1.47e-9	Axial length;
PAAD	cis	rs2555155	0.904	rs720270	chr11:6529540	A/T	cg24637308	chr11:6592297	DNHD1	0.46	4.62	0.35	8.1e-6	DNA methylation (variation);
PAAD	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.53	5.43	0.4	2.21e-7	Diastolic blood pressure;
PAAD	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.49	6.94	0.49	1.05e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.6	4.47	0.34	1.5e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11079354	chr6:27740361	NA	0.56	6.39	0.46	1.94e-9	Metabolite levels  (X-11787);
PAAD	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg00717180	chr2:96193071	NA	-0.58	-6.45	-0.46	1.38e-9	HDL cholesterol;
PAAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.62	-7.37	-0.51	9.96e-12	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg04450456	chr4:17643702	FAM184B	0.5	5.7	0.42	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3106136	0.678	rs7680426	chr4:95294837	G/A	cg11021082	chr4:95130006	SMARCAD1	0.48	4.59	0.35	9.13e-6	Capecitabine sensitivity;
PAAD	cis	rs30380	0.632	rs27045	chr5:96138861	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-5.22	-0.39	5.87e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-6.04	-0.44	1.13e-8	Schizophrenia;
PAAD	cis	rs10267417	0.603	rs7791170	chr7:19905411	T/A	cg05791153	chr7:19748676	TWISTNB	0.68	4.82	0.36	3.4e-6	Night sleep phenotypes;
PAAD	cis	rs900145	0.731	rs10832006	chr11:13269792	C/T	cg15603424	chr11:13300592	ARNTL	0.52	4.51	0.34	1.26e-5	Menarche (age at onset);
PAAD	cis	rs4455778	0.580	rs7783777	chr7:49082560	G/A	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.81	9.05	0.59	6.48e-16	Aortic root size;
PAAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg02462569	chr6:150064036	NUP43	-0.52	-5.86	-0.43	2.76e-8	Lung cancer;
PAAD	cis	rs4819852	0.801	rs1990276	chr22:19996878	G/C	cg07821417	chr22:19972146	ARVCF	0.48	4.72	0.36	5.28e-6	Pulse pressure;
PAAD	cis	rs6493487	0.512	rs16953045	chr15:51251122	A/C	cg02888867	chr15:50978624	TRPM7	-0.64	-4.27	-0.33	3.48e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.54	-5.57	-0.41	1.11e-7	Testicular germ cell tumor;
PAAD	cis	rs11718455	0.538	rs1524887	chr3:44016371	C/T	cg21419209	chr3:44054225	NA	-0.53	-6.12	-0.44	7.78e-9	Coronary artery disease;
PAAD	cis	rs2882667	0.537	rs7701338	chr5:138405994	C/T	cg22797968	chr5:138629998	MATR3	0.47	4.61	0.35	8.57e-6	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25559849	chr10:134145543	LRRC27	-0.63	-6.43	-0.46	1.56e-9	Smoking initiation;
PAAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.76	-8.72	-0.58	4.44e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.77	-0.48	2.6200000000000003e-10	Life satisfaction;
PAAD	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.43	-4.28	-0.33	3.35e-5	Chronic sinus infection;
PAAD	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.48	-0.34	1.48e-5	Coronary artery disease;
PAAD	cis	rs9815354	1.000	rs28755797	chr3:41774446	C/T	cg03022575	chr3:42003672	ULK4	0.84	5.87	0.43	2.66e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4140564	0.730	rs10798055	chr1:186684442	T/C	cg16721191	chr1:185703526	HMCN1	-0.77	-4.45	-0.34	1.67e-5	Knee osteoarthritis;
PAAD	cis	rs7765175	0.698	rs9488157	chr6:113665595	T/A	cg19037598	chr6:113666021	NA	-0.44	-4.63	-0.35	7.87e-6	Coronary artery calcification;
PAAD	cis	rs28655083	0.509	rs285020	chr16:77099517	C/G	cg06128999	chr16:77247126	NA	-0.43	-5.2	-0.39	6.26e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.7	6.06	0.44	1.03e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	0.97	6.5	0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.56	4.82	0.36	3.47e-6	Atopic dermatitis;
PAAD	cis	rs732765	0.657	rs17782749	chr14:75298349	G/C	cg17347104	chr14:75034677	LTBP2	0.57	4.28	0.33	3.29e-5	Non-small cell lung cancer;
PAAD	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.41	-4.78	-0.36	4.05e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-4.85	-0.37	3.04e-6	Menopause (age at onset);
PAAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg15693483	chr7:1102177	C7orf50	0.44	4.95	0.37	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.09	-8.45	-0.57	2.25e-14	Diabetic kidney disease;
PAAD	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.59	6.0	0.44	1.39e-8	Ovarian reserve;
PAAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.05	0.38	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1667255	0.830	rs2420813	chr18:29161365	T/C	cg18808318	chr18:29669225	NA	0.52	4.96	0.37	1.9e-6	Retinol levels;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.54	5.27	0.39	4.68e-7	Prudent dietary pattern;
PAAD	cis	rs11696501	0.739	rs6104249	chr20:44250487	C/G	cg11783356	chr20:44313418	WFDC10B	0.71	6.31	0.46	2.84e-9	Brain structure;
PAAD	cis	rs4144743	1.000	rs11871447	chr17:45331618	C/G	cg18085866	chr17:45331354	ITGB3	-0.85	-6.91	-0.49	1.26e-10	Body mass index;
PAAD	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.78	0.36	4.07e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg09127314	chr1:152161683	NA	-0.64	-4.57	-0.35	9.97e-6	Atopic dermatitis;
PAAD	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.67	-8.01	-0.55	2.71e-13	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.46	-0.46	1.33e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs34599045	0.803	rs34198967	chr1:152869541	T/C	cg07796016	chr1:152779584	LCE1C	-0.96	-4.79	-0.36	3.87e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.95	0.54	4.03e-13	Prudent dietary pattern;
PAAD	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.51	-5.13	-0.38	8.76e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg05554000	chr7:158905015	VIPR2	0.56	4.85	0.37	3.05e-6	Facial morphology (factor 20);
PAAD	cis	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg07498013	chr19:22123504	NA	-0.41	-4.88	-0.37	2.63e-6	Telomere length;
PAAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	5.4	0.4	2.46e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.65	-5.32	-0.4	3.58e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg26939375	chr7:64535504	NA	0.72	8.16	0.55	1.21e-13	Calcium levels;
PAAD	cis	rs12304921	1.000	rs73090666	chr12:51356502	T/G	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg13647721	chr17:30228624	UTP6	-0.66	-4.85	-0.37	3.05e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-4.77	-0.36	4.34e-6	Lung disease severity in cystic fibrosis;
PAAD	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg22875332	chr1:76189707	ACADM	-0.49	-4.79	-0.36	3.87e-6	Daytime sleep phenotypes;
PAAD	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.8	9.92	0.63	3.36e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.68	-7.28	-0.51	1.66e-11	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17190864	chr8:22926862	TNFRSF10B	0.65	7.73	0.53	1.38e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.45	-0.46	1.38e-9	Crohn's disease;
PAAD	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	-1.08	-5.15	-0.39	8.03e-7	Breast cancer;
PAAD	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.4	4.94	0.37	2.03e-6	Corneal astigmatism;
PAAD	cis	rs9815354	1.000	rs3890604	chr3:41760625	C/T	cg03022575	chr3:42003672	ULK4	0.78	5.64	0.42	8e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.78	-0.42	4.12e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.92	-8.1	-0.55	1.63e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs16958440	0.521	rs16950323	chr18:44577327	G/A	cg17192377	chr18:44677553	HDHD2	0.8	5.27	0.39	4.67e-7	Sitting height ratio;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg06521088	chr21:39039848	KCNJ6	0.51	6.54	0.47	8.67e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs4742903	0.875	rs1605449	chr9:106976397	T/C	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.09e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg09659197	chr4:152720779	NA	0.4	5.23	0.39	5.56e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.99	6.46	0.46	1.33e-9	Myocardial infarction;
PAAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.71	-7.56	-0.52	3.63e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2274459	0.500	rs13220421	chr6:33622168	G/T	cg06253072	chr6:33679850	C6orf125	0.65	4.76	0.36	4.46e-6	Obesity (extreme);
PAAD	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.96	8.19	0.55	1.02e-13	IgG glycosylation;
PAAD	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg20406979	chr6:167373233	NA	0.38	5.23	0.39	5.42e-7	Crohn's disease;
PAAD	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg09339527	chr5:178322752	ZFP2	-0.43	-4.52	-0.34	1.24e-5	Sleep duration;
PAAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.73	7.46	0.52	6.13e-12	Height;
PAAD	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.53	-5.17	-0.39	7.29e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.83	-6.82	-0.48	1.99e-10	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.64	5.44	0.4	2.11e-7	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	10.39	0.64	1.9e-19	Post bronchodilator FEV1;
PAAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-5.02	-0.38	1.44e-6	Menopause (age at onset);
PAAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.92	-7.87	-0.54	6.26e-13	Gut microbiome composition (summer);
PAAD	cis	rs863345	0.967	rs4620544	chr1:158470747	C/T	cg12129480	chr1:158549410	OR10X1	-0.46	-5.2	-0.39	6.25e-7	Pneumococcal bacteremia;
PAAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg07703079	chr11:430292	ANO9	0.79	4.4	0.34	1.99e-5	Body mass index;
PAAD	trans	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg00717180	chr2:96193071	NA	-0.57	-6.3	-0.46	3.08e-9	HDL cholesterol;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16112844	chr11:2950638	PHLDA2	-0.64	-6.36	-0.46	2.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg25251562	chr2:3704773	ALLC	-0.57	-6.53	-0.47	9.2e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg14393609	chr7:65229607	NA	0.47	4.71	0.36	5.58e-6	Aortic root size;
PAAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07402062	chr16:89894098	SPIRE2	-0.36	-4.46	-0.34	1.57e-5	Vitiligo;
PAAD	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg21040360	chr2:3383326	TTC15	-0.45	-4.74	-0.36	4.81e-6	Obesity-related traits;
PAAD	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.71	8.22	0.55	8.18e-14	Colorectal cancer;
PAAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs2017305	0.680	rs116969388	chr10:70726489	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.07	-0.38	1.15e-6	Depression (quantitative trait);
PAAD	cis	rs733175	0.951	rs6846692	chr4:10031133	C/G	cg00071950	chr4:10020882	SLC2A9	0.6	5.38	0.4	2.82e-7	Psychosis and Alzheimer's disease;
PAAD	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.91	-6.26	-0.45	3.8e-9	Alzheimer's disease (late onset);
PAAD	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg27411982	chr8:10470053	RP1L1	-0.47	-5.01	-0.38	1.48e-6	Triglycerides;
PAAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.57	-6.64	-0.47	5.14e-10	Reticulocyte fraction of red cells;
PAAD	trans	rs61931739	0.620	rs7297316	chr12:33702261	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-7.24	-0.51	2.13e-11	Morning vs. evening chronotype;
PAAD	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg23587288	chr2:27483067	SLC30A3	-0.66	-5.73	-0.42	5.35e-8	Blood metabolite levels;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02902124	chr2:70121106	SNRNP27	0.56	7.0	0.49	7.81e-11	Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15159880	chr19:7459989	ARHGEF18	0.55	6.41	0.46	1.73e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.59	6.18	0.45	5.76e-9	Testicular germ cell tumor;
PAAD	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg24565620	chr2:194026	NA	0.68	5.21	0.39	6.17e-7	Blood protein levels;
PAAD	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.59	6.9	0.49	1.29e-10	Aortic root size;
PAAD	cis	rs721399	0.719	rs4646254	chr8:18262059	A/G	cg18736775	chr8:18248649	NAT2	-0.72	-6.43	-0.46	1.59e-9	Blood metabolite levels;
PAAD	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	8.64	0.57	7.43e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.38	-0.33	2.21e-5	Reticulocyte count;
PAAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	5.84	0.43	3.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15708219	chr10:22621481	NA	0.58	6.67	0.48	4.48e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.67	0.42	7e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-6.16	-0.45	6.12e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg20673841	chr7:107026890	COG5	0.48	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs7945718	0.621	rs12281511	chr11:12677295	A/C	cg25843174	chr11:12811716	TEAD1	0.31	4.55	0.35	1.08e-5	Educational attainment (years of education);
PAAD	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg21584241	chr15:63341463	TPM1	0.66	4.8	0.36	3.69e-6	Orofacial clefts;
PAAD	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.64	-5.56	-0.41	1.17e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-9.87	-0.62	4.6e-18	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06753367	chr22:24256600	NA	0.41	4.38	0.33	2.24e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.6	6.43	0.46	1.58e-9	Menarche (age at onset);
PAAD	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.38	4.72	0.36	5.3e-6	Intraocular pressure;
PAAD	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	14.47	0.76	2.2e-30	Testicular germ cell tumor;
PAAD	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg08885800	chr1:201084119	NA	0.51	4.34	0.33	2.63e-5	Permanent tooth development;
PAAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg01763666	chr17:80159506	CCDC57	-0.44	-4.45	-0.34	1.67e-5	Life satisfaction;
PAAD	cis	rs11741688	1.000	rs11741688	chr5:178395850	G/C	cg20935368	chr5:178288625	ZNF354B	-0.5	-5.03	-0.38	1.39e-6	Sleep duration;
PAAD	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.63	5.58	0.41	1.09e-7	Corneal astigmatism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14483856	chr9:133706938	ABL1	-0.61	-6.35	-0.46	2.38e-9	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4742903	0.935	rs17236663	chr9:106928402	G/A	cg14250997	chr9:106856677	SMC2	0.46	4.95	0.37	1.95e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.46	4.89	0.37	2.57e-6	QRS complex (12-leadsum);
PAAD	cis	rs6132905	0.548	rs4815444	chr20:2621036	A/G	cg24848351	chr20:2622020	TMC2	-0.75	-5.32	-0.4	3.63e-7	Mumps;
PAAD	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06307176	chr5:131281290	NA	0.49	4.49	0.34	1.41e-5	Life satisfaction;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg14799209	chr7:106809543	HBP1	0.51	6.49	0.47	1.17e-9	Primary biliary cholangitis;
PAAD	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.42	-0.34	1.9e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg10437265	chr15:77819839	NA	0.37	4.27	0.33	3.38e-5	Type 2 diabetes;
PAAD	cis	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg21546286	chr11:48923668	NA	-0.55	-5.65	-0.42	7.8e-8	HDL cholesterol;
PAAD	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	8.09	0.55	1.74e-13	Monocyte percentage of white cells;
PAAD	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-4.62	-0.35	8.16e-6	Testicular germ cell tumor;
PAAD	trans	rs61677309	0.964	rs56292628	chr11:118163872	G/A	cg15548380	chr1:19984784	NBL1	-0.64	-6.6	-0.47	6.4e-10	Lung cancer in ever smokers;
PAAD	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	6.99	0.49	8e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.91	6.84	0.48	1.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.7	-4.41	-0.34	1.94e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05025164	chr4:1340916	KIAA1530	0.5	4.85	0.37	3e-6	Obesity-related traits;
PAAD	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.47	4.35	0.33	2.52e-5	Tuberculosis;
PAAD	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.87	6.69	0.48	3.97e-10	Atopic dermatitis;
PAAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-4.82	-0.36	3.49e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg09796270	chr17:17721594	SREBF1	-0.43	-4.78	-0.36	4.08e-6	Total body bone mineral density;
PAAD	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg14581129	chr12:53358946	NA	-0.96	-10.45	-0.65	1.36e-19	Prostate cancer;
PAAD	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.63	-7.44	-0.52	6.74e-12	Reticulocyte fraction of red cells;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23873398	chr14:36278529	RALGAPA1	-0.67	-6.62	-0.47	5.92e-10	Smoking initiation;
PAAD	cis	rs6466055	0.739	rs7806591	chr7:104927776	C/T	cg04380332	chr7:105027541	SRPK2	0.66	7.45	0.52	6.63e-12	Schizophrenia;
PAAD	cis	rs7873102	0.536	rs776007	chr9:37921932	G/T	cg03528946	chr9:38069800	SHB	-0.49	-4.8	-0.36	3.83e-6	Brain structure;
PAAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-4.67	-0.35	6.58e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.83	-7.82	-0.54	8.18e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.45	0.46	1.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg09835421	chr16:68378352	PRMT7	-0.79	-6.53	-0.47	9.07e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.44	-0.46	1.46e-9	Mood instability;
PAAD	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	10.8	0.66	1.56e-20	Cognitive test performance;
PAAD	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.45	-5.1	-0.38	1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg26338869	chr17:61819248	STRADA	0.51	4.85	0.37	2.97e-6	Height;
PAAD	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-0.96	-4.3	-0.33	3.02e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3091242	0.806	rs35189848	chr1:25788422	A/G	cg27572855	chr1:25598939	RHD	-0.46	-4.61	-0.35	8.41e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.64	-5.68	-0.42	6.57e-8	Mean corpuscular volume;
PAAD	cis	rs12681963	0.688	rs4733444	chr8:30076255	T/C	cg23406830	chr8:30012838	DCTN6	-0.69	-4.41	-0.34	1.92e-5	Migraine;
PAAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg23033748	chr14:75592666	NEK9	-0.4	-4.92	-0.37	2.19e-6	Height;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.61	4.78	0.36	4.11e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	5.48	0.41	1.75e-7	Tonsillectomy;
PAAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.64	5.52	0.41	1.42e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg10090792	chr1:38198142	EPHA10	-0.4	-4.33	-0.33	2.74e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.66	7.09	0.5	4.79e-11	Longevity;
PAAD	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.55	-0.35	1.1e-5	Pulmonary function;
PAAD	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	10.81	0.66	1.48e-20	Homoarginine levels;
PAAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.66	-7.51	-0.52	4.81e-12	Bipolar disorder;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.51	-4.37	-0.33	2.29e-5	Depression;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09991975	chr22:39096760	JOSD1	0.7	8.26	0.56	6.57e-14	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg23461800	chr14:103021989	NA	0.59	4.48	0.34	1.43e-5	Platelet count;
PAAD	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.92	11.08	0.67	2.71e-21	White blood cell count;
PAAD	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.87	-9.46	-0.61	5.41e-17	Tonsillectomy;
PAAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.66	0.57	6.41e-15	Coronary artery disease;
PAAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-5.08	-0.38	1.1e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.48	-7.59	-0.52	3.04e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7809615	0.901	rs10261661	chr7:99189722	A/T	cg12290671	chr7:99195819	NA	-0.91	-5.3	-0.4	3.96e-7	Blood metabolite ratios;
PAAD	cis	rs1656368	0.726	rs28431969	chr3:158269154	A/C	cg16708174	chr3:158430962	RARRES1	0.55	5.01	0.38	1.47e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.97	12.41	0.71	7.1e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg23752985	chr2:85803571	VAMP8	0.6	6.4	0.46	1.82e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg22830091	chr7:75961684	YWHAG	-0.43	-4.47	-0.34	1.52e-5	Multiple sclerosis;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.87	-10.17	-0.64	7.63e-19	Iron status biomarkers;
PAAD	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg25922125	chr7:127225783	GCC1	0.68	4.93	0.37	2.11e-6	Type 2 diabetes;
PAAD	cis	rs12936587	0.569	rs8073683	chr17:17555596	C/T	cg04398451	chr17:18023971	MYO15A	0.46	4.29	0.33	3.13e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
PAAD	cis	rs3790645	0.958	rs1466286	chr1:26870730	C/G	cg23229016	chr1:26872525	RPS6KA1	0.27	4.25	0.33	3.73e-5	Glucose homeostasis traits;
PAAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg16590910	chr6:42928470	GNMT	0.5	4.99	0.37	1.66e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.62	5.95	0.43	1.8e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg26071806	chr7:100318239	EPO	-0.49	-4.8	-0.36	3.83e-6	Other erythrocyte phenotypes;
PAAD	cis	rs4538187	0.906	rs11695421	chr2:63954237	T/C	cg08613950	chr2:64719184	NA	0.66	4.41	0.34	1.92e-5	Systolic blood pressure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12471950	chr11:5706401	TRIM5	-0.65	-6.34	-0.46	2.5e-9	Neuroticism;
PAAD	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg07220939	chr11:64358617	SLC22A12	-0.45	-4.73	-0.36	5.07e-6	Urate levels in obese individuals;
PAAD	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.82	8.6	0.57	9.36e-15	Uric acid levels;
PAAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.53	5.47	0.41	1.84e-7	Major depressive disorder;
PAAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13198984	chr17:80129470	CCDC57	0.44	5.5	0.41	1.54e-7	Life satisfaction;
PAAD	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg26205652	chr12:48591994	NA	0.95	9.61	0.61	2.29e-17	Longevity (90 years and older);
PAAD	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.66	0.74	3.27e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11871801	1.000	rs11871801	chr17:40570772	A/C	cg21692620	chr17:40835849	CNTNAP1	-0.46	-4.57	-0.35	1.01e-5	Crohn's disease;
PAAD	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg18512352	chr11:47633146	NA	-0.38	-5.56	-0.41	1.21e-7	Neuroticism;
PAAD	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg07703079	chr11:430292	ANO9	0.8	4.44	0.34	1.74e-5	Body mass index;
PAAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	1.38	7.03	0.5	6.6e-11	Prostate cancer;
PAAD	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.35	-0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	1.07	14.33	0.76	5.31e-30	Headache;
PAAD	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	0.78	5.29	0.39	4.27e-7	Body mass index;
PAAD	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg23024343	chr7:107201750	COG5	0.5	4.3	0.33	3.05e-5	Coronary artery disease;
PAAD	trans	rs13418455	0.614	rs17179906	chr2:181003088	C/T	cg25152348	chr22:50946712	NCAPH2;LMF2	0.62	6.34	0.46	2.48e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs13253111	0.967	rs35737697	chr8:28059813	T/C	cg26534493	chr8:28060551	NA	0.39	4.27	0.33	3.47e-5	Childhood body mass index;
PAAD	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg02869306	chr7:64672164	INTS4L1	0.41	4.75	0.36	4.59e-6	Aortic root size;
PAAD	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	4.32	0.33	2.8e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg14092988	chr3:52407081	DNAH1	0.57	7.24	0.51	2.13e-11	Bipolar disorder;
PAAD	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-5.91	-0.43	2.18e-8	Menarche (age at onset);
PAAD	cis	rs7678555	0.502	rs4834827	chr4:120858180	C/T	cg09307838	chr4:120376055	NA	0.47	4.48	0.34	1.43e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-4.37	-0.33	2.25e-5	IgG glycosylation;
PAAD	cis	rs9816226	0.591	rs78785910	chr3:185812634	G/A	cg00760338	chr3:185826511	ETV5	-0.71	-5.59	-0.41	1.02e-7	Obesity;Body mass index;
PAAD	cis	rs9462027	0.628	rs9296129	chr6:34774414	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.44	5.2	0.39	6.37e-7	Systemic lupus erythematosus;
PAAD	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	1.09	6.82	0.48	1.97e-10	Skin colour saturation;
PAAD	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.72	8.12	0.55	1.5e-13	Corneal astigmatism;
PAAD	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg10828910	chr2:63850056	LOC388955	0.53	4.66	0.35	6.73e-6	Childhood ear infection;
PAAD	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg11601000	chr22:42348013	LOC339674	0.44	5.09	0.38	1.04e-6	Cognitive function;
PAAD	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg26071806	chr7:100318239	EPO	-0.51	-4.94	-0.37	1.99e-6	Other erythrocyte phenotypes;
PAAD	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg27481594	chr15:43623282	ADAL;LCMT2	0.44	4.39	0.34	2.11e-5	Lung cancer;
PAAD	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg24585817	chr7:64895279	NA	0.44	4.45	0.34	1.62e-5	Aortic root size;
PAAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg20850873	chr3:10149803	C3orf24	0.55	4.34	0.33	2.63e-5	Alzheimer's disease;
PAAD	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg00383909	chr3:49044727	WDR6	0.43	4.43	0.34	1.8e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.51	-5.02	-0.38	1.45e-6	Cognitive ability;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	6.22	0.45	4.53e-9	Renal function-related traits (BUN);
PAAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg11764359	chr7:65958608	NA	0.74	4.9	0.37	2.4e-6	Diabetic kidney disease;
PAAD	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg23688817	chr7:87105293	ABCB4	0.57	4.81	0.36	3.61e-6	Gallbladder cancer;
PAAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	6.57	0.47	7.6e-10	Mean platelet volume;
PAAD	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg15890332	chr12:107067104	RFX4	0.41	4.56	0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.37	-9.39	-0.61	8.17e-17	Diabetic retinopathy;
PAAD	cis	rs9463078	0.585	rs1748235	chr6:45141361	T/C	cg18551225	chr6:44695536	NA	0.4	4.27	0.33	3.45e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.67	-6.52	-0.47	1.01e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg10591111	chr5:226296	SDHA	-0.71	-4.95	-0.37	1.99e-6	Breast cancer;
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.92	6.64	0.47	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg14349672	chr11:133703707	NA	-0.59	-6.73	-0.48	3.27e-10	Childhood ear infection;
PAAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg06740227	chr12:86229804	RASSF9	0.58	5.18	0.39	7.01e-7	Major depressive disorder;
PAAD	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.92	11.04	0.67	3.47e-21	Ulcerative colitis;
PAAD	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.57	5.61	0.41	9.38e-8	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.34	0.33	2.59e-5	Height;
PAAD	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18217145	chr1:40254695	BMP8B	0.71	6.84	0.49	1.85e-10	Obesity-related traits;
PAAD	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.85	-0.54	7.08e-13	HDL cholesterol;
PAAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.51	5.4	0.4	2.47e-7	Menopause (age at onset);
PAAD	cis	rs2637266	0.686	rs1660915	chr10:78525318	T/A	cg18941641	chr10:78392320	NA	0.37	4.38	0.33	2.18e-5	Pulmonary function;
PAAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.59	7.17	0.5	3.1e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2718812	0.935	rs1867502	chr3:133410625	C/A	cg08439880	chr3:133502540	NA	0.42	4.81	0.36	3.66e-6	Iron status biomarkers;
PAAD	cis	rs9810890	1.000	rs73198826	chr3:128487388	T/C	cg18531004	chr3:128564980	NA	-0.84	-4.78	-0.36	4.08e-6	Dental caries;
PAAD	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.55	-6.01	-0.44	1.33e-8	Hepatitis;
PAAD	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.67	6.74	0.48	3.17e-10	Cancer;
PAAD	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.23	0.39	5.59e-7	Childhood ear infection;
PAAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.6	6.27	0.45	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg13535736	chr9:111863775	C9orf5	0.36	4.55	0.35	1.11e-5	Menarche (age at onset);
PAAD	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg23153227	chr6:27725408	NA	0.43	4.3	0.33	3.05e-5	Depression;
PAAD	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.73	-0.48	3.28e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.55	-4.96	-0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg00945038	chr17:61921165	SMARCD2	0.46	5.53	0.41	1.35e-7	Prudent dietary pattern;
PAAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	5.81	0.43	3.56e-8	Platelet count;
PAAD	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg03684893	chr10:554711	DIP2C	-0.44	-4.72	-0.36	5.33e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.79	9.09	0.59	5.07e-16	Diastolic blood pressure;
PAAD	cis	rs30380	1.000	rs151964	chr5:96123666	G/T	cg17330273	chr5:96107758	CAST;ERAP1	0.43	4.48	0.34	1.48e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.99	-8.07	-0.55	2.03e-13	Post bronchodilator FEV1;
PAAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg10729496	chr3:10149963	C3orf24	0.88	7.31	0.51	1.42e-11	Alzheimer's disease;
PAAD	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.47	-5.35	-0.4	3.13e-7	Age at first birth;
PAAD	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.63	-0.47	5.4e-10	Triglycerides;
PAAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg22143856	chr6:28129313	ZNF389	0.55	5.17	0.39	7.4e-7	Parkinson's disease;
PAAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg07212818	chr11:638076	DRD4	-0.69	-6.75	-0.48	2.91e-10	Systemic lupus erythematosus;
PAAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.97	11.14	0.67	1.9e-21	Parkinson's disease;
PAAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-5.62	-0.42	8.69e-8	Tonsillectomy;
PAAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.65	7.03	0.5	6.51e-11	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7925523	0.838	rs12274157	chr11:61477647	A/C	cg12472022	chr11:61462803	DAGLA	0.53	4.28	0.33	3.3e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.68e-8	Retinal vascular caliber;
PAAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.72	-7.75	-0.53	1.21e-12	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18328404	chr5:133706819	UBE2B	-0.65	-6.79	-0.48	2.32e-10	Smoking initiation;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-4.82	-0.36	3.48e-6	Testicular germ cell tumor;
PAAD	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.69	-7.4	-0.51	8.77e-12	Neuroticism;
PAAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.51	0.65	9.11e-20	Menopause (age at onset);
PAAD	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.54	-0.61	3.42e-17	Response to antipsychotic treatment;
PAAD	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	1.12	8.88	0.58	1.74e-15	Left atrial antero-posterior diameter;
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.64	-8.19	-0.55	9.72e-14	Body mass index;
PAAD	cis	rs12893597	0.715	rs4624098	chr14:76826256	G/A	cg20290672	chr14:76816747	NA	-0.59	-4.94	-0.37	2.01e-6	Maximal oxygen uptake response;
PAAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg00933542	chr6:150070202	PCMT1	0.52	5.25	0.39	5.09e-7	Lung cancer;
PAAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-9.76	-0.62	8.82e-18	Total body bone mineral density;
PAAD	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.47	-5.1	-0.38	1.02e-6	Educational attainment;
PAAD	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg09579323	chr1:150459698	TARS2	-0.46	-4.35	-0.33	2.52e-5	Migraine;
PAAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.88	-10.84	-0.66	1.22e-20	Body mass index;
PAAD	cis	rs282587	0.569	rs7986147	chr13:113398784	A/C	cg02820901	chr13:113351484	ATP11A	-0.65	-4.94	-0.37	2.07e-6	Glycated hemoglobin levels;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.82	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6864727	0.964	rs4574537	chr5:137419728	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.52	5.04	0.38	1.31e-6	Atrial fibrillation;
PAAD	cis	rs288342	0.797	rs288334	chr2:183622547	T/G	cg02625481	chr2:183667124	NA	-0.44	-4.53	-0.35	1.16e-5	Recurrent major depressive disorder;
PAAD	cis	rs988913	0.957	rs1503147	chr6:54759483	A/G	cg03513858	chr6:54763001	FAM83B	-0.47	-5.22	-0.39	5.83e-7	Menarche (age at onset);
PAAD	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.1	-0.38	9.84e-7	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg02524346	chr8:600233	NA	-1.06	-6.67	-0.48	4.57e-10	IgG glycosylation;
PAAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.88	-7.91	-0.54	4.93e-13	Diastolic blood pressure;
PAAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.78	-9.01	-0.59	8.31e-16	Body mass index;
PAAD	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg21918786	chr6:109611834	NA	-0.46	-4.94	-0.37	2e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs4621152	0.775	rs6716542	chr2:217890643	A/G	cg21875423	chr2:217559867	IGFBP5	-0.46	-4.5	-0.34	1.33e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.35	-0.4	3.14e-7	Blood metabolite levels;
PAAD	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00166722	chr3:10149974	C3orf24	0.87	7.59	0.52	2.97e-12	Alzheimer's disease;
PAAD	cis	rs10957961	0.586	rs1426148	chr8:81072332	A/G	cg10609868	chr8:81963379	PAG1	-0.36	-4.32	-0.33	2.83e-5	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2445762	0.659	rs12441170	chr15:51653898	G/A	cg25905881	chr15:51634250	GLDN	0.51	4.45	0.34	1.68e-5	Hormone measurements;
PAAD	cis	rs4740619	0.933	rs10810432	chr9:15707317	G/T	cg14451791	chr9:16040625	NA	-0.39	-4.4	-0.34	1.99e-5	Body mass index;
PAAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.73	7.34	0.51	1.17e-11	Methadone dose in opioid dependence;
PAAD	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-6.61	-0.47	6.19e-10	Eosinophil percentage of white cells;
PAAD	cis	rs2562456	0.833	rs4334427	chr19:21520892	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-7.14	-0.5	3.51e-11	Morning vs. evening chronotype;
PAAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.47	8.5	0.57	1.6e-14	Multiple system atrophy;
PAAD	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs9810890	1.000	rs73198839	chr3:128500442	C/T	cg15676455	chr3:128564943	NA	-0.82	-4.84	-0.37	3.22e-6	Dental caries;
PAAD	cis	rs12476592	0.602	rs6736029	chr2:63789170	G/A	cg10828910	chr2:63850056	LOC388955	0.51	4.39	0.34	2.14e-5	Childhood ear infection;
PAAD	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs7816613	0.850	rs6996060	chr8:102675564	G/A	cg20585841	chr8:102729926	NCALD	-0.7	-5.46	-0.41	1.88e-7	Age-related hearing impairment;
PAAD	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.77	6.73	0.48	3.19e-10	Morning vs. evening chronotype;
PAAD	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.26	-0.45	3.68e-9	Hip circumference;
PAAD	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg15654264	chr1:150340011	RPRD2	0.51	4.95	0.37	1.91e-6	Migraine;
PAAD	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.75	-7.59	-0.52	3.07e-12	Gout;
PAAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7932354	0.550	rs10769208	chr11:46822240	T/C	cg19486271	chr11:47235900	DDB2	-0.6	-5.96	-0.44	1.68e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13012494	chr21:47604986	C21orf56	0.48	5.08	0.38	1.07e-6	Testicular germ cell tumor;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg17767933	chr8:141541054	NA	0.65	7.61	0.53	2.66e-12	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06671706	chr8:8559999	CLDN23	0.7	6.85	0.49	1.68e-10	Obesity-related traits;
PAAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.72	8.56	0.57	1.14e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.62	-5.3	-0.39	4.1e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.57	5.44	0.4	2.09e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg24154853	chr7:158122151	PTPRN2	0.81	7.5	0.52	4.89e-12	Response to amphetamines;
PAAD	cis	rs10746514	0.804	rs11122429	chr1:232261532	G/A	cg09506761	chr1:232265262	NA	-0.43	-4.38	-0.33	2.2e-5	Response to statin therapy;
PAAD	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg00792783	chr2:198669748	PLCL1	-0.48	-4.28	-0.33	3.28e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg24699146	chr1:24152579	HMGCL	-0.53	-5.54	-0.41	1.32e-7	Immature fraction of reticulocytes;
PAAD	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	6.87	0.49	1.54e-10	Resting heart rate;
PAAD	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.99	6.46	0.46	1.35e-9	Major depressive disorder;
PAAD	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg16576597	chr16:28551801	NUPR1	0.66	7.11	0.5	4.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-4.44	-0.34	1.75e-5	Red blood cell count;
PAAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.46	-4.69	-0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.49	-5.1	-0.38	1.02e-6	Electroencephalogram traits;
PAAD	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg00976097	chr5:421733	AHRR	0.55	4.91	0.37	2.36e-6	Cystic fibrosis severity;
PAAD	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.67	6.49	0.47	1.15e-9	Schizophrenia;
PAAD	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg16606324	chr3:10149918	C3orf24	0.56	4.74	0.36	4.87e-6	Alzheimer's disease;
PAAD	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-14.15	-0.75	1.55e-29	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14910368	chr12:57610455	NXPH4	-0.62	-6.62	-0.47	5.84e-10	Smoking initiation;
PAAD	cis	rs13424612	1.000	rs4149556	chr2:240915307	C/T	cg12807937	chr2:240965920	NDUFA10	-0.48	-4.71	-0.36	5.57e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.47	5.47	0.41	1.77e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.75	0.74	1.85e-28	Platelet count;
PAAD	cis	rs4478858	0.775	rs59865338	chr1:31706643	A/G	cg18939081	chr1:31884902	SERINC2	0.46	5.15	0.39	8.13e-7	Alcohol dependence;
PAAD	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg23024343	chr7:107201750	COG5	0.51	4.39	0.34	2.09e-5	Coronary artery disease;
PAAD	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.56	-6.2	-0.45	5.07e-9	Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	5.46	0.41	1.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.26	0.56	6.7e-14	Schizophrenia;
PAAD	cis	rs35955747	0.902	rs11703927	chr22:31644964	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-4.9	-0.37	2.48e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.35	0.51	1.14e-11	IgG glycosylation;
PAAD	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.94	10.19	0.64	6.77e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.81	-8.51	-0.57	1.51e-14	DNA methylation (variation);
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13560548	chr3:10150139	C3orf24	0.54	4.97	0.37	1.78e-6	Alzheimer's disease;
PAAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-6.63	-0.47	5.5e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-1.12	-13.84	-0.75	1.02e-28	Height;
PAAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-5.09	-0.38	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.95	12.28	0.71	1.65e-24	Menopause (age at onset);
PAAD	cis	rs16975963	0.843	rs11672440	chr19:38250958	C/T	cg08679971	chr19:38281047	NA	0.51	4.77	0.36	4.23e-6	Longevity;
PAAD	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.72	0.53	1.48e-12	Motion sickness;
PAAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18099408	chr3:52552593	STAB1	-0.47	-5.47	-0.41	1.83e-7	Electroencephalogram traits;
PAAD	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.63	0.35	7.64e-6	Blood metabolite levels;
PAAD	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg16735072	chr8:11994639	FAM66D	0.43	4.4	0.34	2.04e-5	Triglycerides;
PAAD	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.74	7.04	0.5	6.29e-11	Obesity-related traits;
PAAD	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg26585981	chr11:48327164	OR4S1	-0.48	-4.29	-0.33	3.13e-5	Migraine - clinic-based;
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg18850127	chr7:39170497	POU6F2	0.54	7.2	0.5	2.64e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-1.05	-11.41	-0.68	3.52e-22	Hip circumference adjusted for BMI;
PAAD	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.78	7.99	0.54	3.16e-13	Uric acid levels;
PAAD	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg19217778	chr13:113420270	ATP11A	0.61	4.29	0.33	3.16e-5	Glycated hemoglobin levels;
PAAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.59	7.47	0.52	5.73e-12	Diastolic blood pressure;
PAAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	1.1	8.4	0.56	2.88e-14	Iron status biomarkers;
PAAD	cis	rs9326726	0.566	rs288147	chr5:107390303	C/A	cg19779370	chr5:108084990	FER	0.6	4.75	0.36	4.68e-6	Resting heart rate;
PAAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	5.26	0.39	4.9e-7	Obesity-related traits;
PAAD	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-8.86	-0.58	1.96e-15	Extrinsic epigenetic age acceleration;
PAAD	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04733989	chr22:42467013	NAGA	0.44	4.45	0.34	1.63e-5	Cognitive function;
PAAD	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.37	4.29	0.33	3.16e-5	Depression;
PAAD	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.52	4.85	0.37	3e-6	Night sleep phenotypes;
PAAD	cis	rs3925075	0.531	rs4261553	chr16:31349164	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.4	0.4	2.54e-7	IgA nephropathy;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg05983640	chr3:148847603	HPS3	0.6	6.63	0.47	5.59e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7247513	0.964	rs4371272	chr19:12711281	A/T	cg01871581	chr19:12707946	ZNF490	-0.87	-11.04	-0.67	3.49e-21	Bipolar disorder;
PAAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg21929781	chr1:2537748	MMEL1	-0.49	-5.21	-0.39	6.17e-7	Ulcerative colitis;
PAAD	cis	rs6787172	0.579	rs6799272	chr3:158188403	A/T	cg16708174	chr3:158430962	RARRES1	0.43	4.58	0.35	9.64e-6	Subjective well-being;
PAAD	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.88	6.72	0.48	3.51e-10	Bipolar disorder;
PAAD	cis	rs7651511	1.000	rs12695740	chr3:141284383	T/G	cg25967872	chr3:141205623	RASA2	0.47	4.27	0.33	3.38e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.92	-0.37	2.24e-6	Neuroticism;
PAAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg24879335	chr3:133465180	TF	0.64	7.09	0.5	4.78e-11	Iron status biomarkers;
PAAD	cis	rs3771514	0.543	rs35715946	chr2:70690337	G/C	cg18150120	chr2:71134936	VAX2	-0.38	-4.54	-0.35	1.13e-5	Obesity-related traits;
PAAD	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-11.21	-0.67	1.23e-21	Chronic sinus infection;
PAAD	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg04545296	chr12:48745243	ZNF641	0.36	4.41	0.34	1.91e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.63	5.21	0.39	6.17e-7	Gut microbiome composition (summer);
PAAD	cis	rs7631605	0.905	rs11707406	chr3:37160677	T/C	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg02459107	chr1:67143332	SGIP1	0.76	7.46	0.52	6.1e-12	Presence of antiphospholipid antibodies;
PAAD	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-5.91	-0.43	2.14e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.51	5.27	0.39	4.6e-7	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg00532901	chr16:30545962	ZNF747	0.58	6.32	0.46	2.76e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.14	0.38	8.28e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.66	-0.35	6.95e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg17385448	chr1:15911702	AGMAT	0.37	4.34	0.33	2.61e-5	Systolic blood pressure;
PAAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg20295408	chr7:1910781	MAD1L1	-0.57	-5.4	-0.4	2.55e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.48	4.65	0.35	7.1e-6	Mean platelet volume;
PAAD	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27099511	chr16:88729703	MGC23284;MVD	-0.9	-4.56	-0.35	1.03e-5	Plateletcrit;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04421424	chr19:57791681	ZNF460	0.66	7.36	0.51	1.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg25952890	chr19:58913133	NA	0.65	5.42	0.4	2.32e-7	Mean platelet volume;
PAAD	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.85	0.37	2.98e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.47	0.57	1.94e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.44	4.28	0.33	3.31e-5	Platelet count;
PAAD	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg18093559	chr17:18951025	GRAP	0.47	4.6	0.35	8.67e-6	Schizophrenia;
PAAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg15693483	chr7:1102177	C7orf50	0.38	4.37	0.33	2.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg14829360	chr17:73884958	NA	-0.59	-5.53	-0.41	1.39e-7	Psoriasis;
PAAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.75	5.61	0.41	9.15e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg16898833	chr6:26189333	HIST1H4D	0.81	4.35	0.33	2.48e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg10453019	chr3:16216215	GALNTL2	0.38	4.25	0.33	3.65e-5	Mean platelet volume;
PAAD	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.62	0.35	8e-6	Self-reported allergy;
PAAD	cis	rs3764400	0.567	rs12936369	chr17:46270696	C/T	cg10706073	chr17:46328419	SKAP1	-1.07	-6.33	-0.46	2.65e-9	Body mass index;
PAAD	cis	rs7176527	1.000	rs3762168	chr15:85142647	A/C	cg24253500	chr15:84953950	NA	-0.62	-5.06	-0.38	1.2e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
PAAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.09	-0.38	1.02e-6	Diastolic blood pressure;
PAAD	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.54	6.31	0.46	2.9e-9	Total body bone mineral density;
PAAD	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.62	0.47	5.7e-10	Morning vs. evening chronotype;
PAAD	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg11630242	chr17:19881632	AKAP10	0.47	4.39	0.34	2.09e-5	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	4.43	0.34	1.76e-5	Hip circumference;
PAAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.91	-11.35	-0.68	5.24e-22	Menopause (age at onset);
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg27411982	chr8:10470053	RP1L1	0.44	4.92	0.37	2.28e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7580658	0.857	rs2896980	chr2:128139959	T/C	cg09760422	chr2:128146352	NA	-0.41	-7.15	-0.5	3.42e-11	Protein C levels;
PAAD	cis	rs2898290	0.601	rs1478892	chr8:11448529	G/T	cg21775007	chr8:11205619	TDH	0.5	4.45	0.34	1.67e-5	Systolic blood pressure;
PAAD	cis	rs7188861	0.813	rs7189989	chr16:11442710	G/A	cg01510278	chr16:11456238	NA	-0.43	-4.27	-0.33	3.45e-5	HDL cholesterol;
PAAD	cis	rs4234284	1.000	rs959035	chr3:126956698	C/A	cg27326032	chr3:127006922	NA	-0.49	-4.98	-0.37	1.71e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
PAAD	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.57	-4.81	-0.36	3.64e-6	Alcohol dependence (age at onset);
PAAD	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.57	5.67	0.42	6.83e-8	Hemoglobin levels;
PAAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-6.51	-0.47	1.04e-9	Breast cancer;
PAAD	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.4	-4.56	-0.35	1.05e-5	Reticulocyte fraction of red cells;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg23719950	chr11:63933701	MACROD1	-0.54	-4.75	-0.36	4.72e-6	Platelet count;
PAAD	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.56	-5.63	-0.42	8.37e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	5.72	0.42	5.47e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.43	-0.46	1.56e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.58	-5.33	-0.4	3.43e-7	Corneal structure;
PAAD	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg24110177	chr3:50126178	RBM5	0.56	4.38	0.33	2.19e-5	Menarche (age at onset);
PAAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg20893579	chr22:38215064	NA	-0.44	-4.5	-0.34	1.33e-5	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg21565972	chr17:80109576	CCDC57	-0.57	-6.48	-0.47	1.22e-9	Life satisfaction;
PAAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.54	-5.74	-0.42	5.04e-8	Facial morphology (factor 20);
PAAD	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg14952266	chr13:112191215	NA	0.44	5.05	0.38	1.25e-6	Hepatitis;
PAAD	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	6.44	0.46	1.52e-9	Blood protein levels;
PAAD	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.49	4.82	0.36	3.45e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.31	0.33	2.87e-5	Personality dimensions;
PAAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16447950	chr5:562315	NA	-0.67	-5.91	-0.43	2.15e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.5	5.09	0.38	1.02e-6	Red blood cell count;
PAAD	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.75	6.42	0.46	1.68e-9	Glioblastoma;
PAAD	cis	rs1805008	0.568	rs17232826	chr16:89842784	C/T	cg02875869	chr16:89901417	SPIRE2	-0.78	-4.32	-0.33	2.85e-5	Skin colour saturation;
PAAD	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.57	-5.44	-0.4	2.13e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12304921	0.688	rs79111258	chr12:51361878	G/T	cg18059802	chr12:51347058	HIGD1C	-0.68	-5.19	-0.39	6.74e-7	Type 2 diabetes;
PAAD	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg11177333	chr3:195857752	NA	0.45	4.3	0.33	3.07e-5	Non-small cell lung cancer;
PAAD	cis	rs501120	0.810	rs622472	chr10:44749211	A/C	cg09554077	chr10:44749378	NA	0.49	6.65	0.47	5.09e-10	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09080909	chr16:1797204	MAPK8IP3	-0.9	-4.93	-0.37	2.15e-6	Snoring;
PAAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg27656614	chr16:81479309	CMIP	-0.74	-6.67	-0.48	4.58e-10	Blood protein levels;
PAAD	cis	rs11807834	0.522	rs10746509	chr1:230237282	C/T	cg09847368	chr1:230250326	GALNT2	-0.67	-8.24	-0.56	7.57e-14	Schizophrenia;
PAAD	cis	rs4294134	0.608	rs11767012	chr7:135246747	T/C	cg04619859	chr7:134855396	C7orf49	0.55	4.35	0.33	2.52e-5	Paget's disease;
PAAD	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.05	0.5	5.79e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs3206736	0.548	rs328900	chr7:35020280	C/T	cg20495677	chr7:34801759	AAA1;NPSR1	-0.5	-4.71	-0.36	5.56e-6	Diastolic blood pressure;
PAAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg21130718	chr4:1044621	NA	0.5	4.81	0.36	3.58e-6	Recombination rate (males);
PAAD	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.48	0.47	1.19e-9	Morning vs. evening chronotype;
PAAD	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.99	-12.78	-0.72	7.36e-26	Bone mineral density;
PAAD	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg03989125	chr22:38214979	NA	-0.65	-6.83	-0.48	1.89e-10	Glioblastoma;Glioma;
PAAD	cis	rs322458	0.550	rs590663	chr3:120632066	T/A	cg16417163	chr3:121280760	NA	0.45	4.63	0.35	7.76e-6	Aging (facial);
PAAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg00579200	chr11:133705235	NA	0.46	5.1	0.38	9.85e-7	Childhood ear infection;
PAAD	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.85	-8.75	-0.58	3.86e-15	Lymphocyte counts;
PAAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Coronary artery disease;
PAAD	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.5	-4.46	-0.34	1.61e-5	Vitiligo;
PAAD	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg14393609	chr7:65229607	NA	0.5	4.34	0.33	2.57e-5	Aortic root size;
PAAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg24253500	chr15:84953950	NA	-0.56	-6.53	-0.47	9.33e-10	Schizophrenia;
PAAD	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.05	-0.44	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.65	6.45	0.46	1.42e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.51	4.41	0.34	1.92e-5	Sudden cardiac arrest;
PAAD	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg21132104	chr15:45694354	SPATA5L1	0.54	5.13	0.38	8.72e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	5.41	0.4	2.36e-7	Mean platelet volume;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16229364	chr3:47866611	DHX30	0.56	6.43	0.46	1.54e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.9	6.0	0.44	1.39e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.73	-6.02	-0.44	1.28e-8	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs375066	0.935	rs398099	chr19:44405281	G/C	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg05562828	chr17:3906858	NA	0.53	5.83	0.43	3.2e-8	Type 2 diabetes;
PAAD	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.37	-0.46	2.09e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	1.36	6.28	0.45	3.3e-9	Skin colour saturation;
PAAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.65	-4.52	-0.34	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4971059	0.654	rs4971073	chr1:155113104	G/T	cg22049894	chr1:155113146	DPM3	0.47	4.44	0.34	1.72e-5	Breast cancer;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12814969	chr4:83934274	LIN54	0.61	6.38	0.46	1.98e-9	Myopia (pathological);
PAAD	cis	rs9815354	0.680	rs112310714	chr3:42024797	A/C	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg09659197	chr4:152720779	NA	0.44	5.77	0.42	4.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs501120	0.584	rs673778	chr10:44733739	G/T	cg09554077	chr10:44749378	NA	0.45	5.29	0.39	4.14e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18867708	chr6:26865862	GUSBL1	0.46	4.57	0.35	1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.69	-6.88	-0.49	1.44e-10	Retinal vascular caliber;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg15123519	chr2:136567270	LCT	0.37	4.48	0.34	1.45e-5	Mosquito bite size;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.69	-6.25	-0.45	4.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	4.28	0.33	3.29e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.81	6.77	0.48	2.61e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-4.4	-0.34	2.07e-5	Crohn's disease;
PAAD	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg15676125	chr6:33679581	C6orf125	0.5	4.88	0.37	2.64e-6	Plateletcrit;
PAAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.57	-7.02	-0.49	6.83e-11	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg07313626	chr1:247681931	NA	-0.47	-4.91	-0.37	2.34e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.12e-10	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg04809136	chr2:24300158	SF3B14	-0.41	-4.77	-0.36	4.22e-6	Quantitative traits;
PAAD	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg13206674	chr6:150067644	NUP43	-0.55	-5.18	-0.39	7.1e-7	Lung cancer;
PAAD	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-1.2	-9.88	-0.63	4.47e-18	Obesity-related traits;
PAAD	cis	rs757081	0.547	rs11024220	chr11:17274534	G/A	cg15432903	chr11:17409602	KCNJ11	-0.55	-5.5	-0.41	1.61e-7	Systolic blood pressure;
PAAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-4.46	-0.34	1.6e-5	Total body bone mineral density;
PAAD	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg25007680	chr1:8021821	PARK7	0.71	7.23	0.51	2.22e-11	Response to antidepressants and depression;
PAAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg05562828	chr17:3906858	NA	0.6	6.4	0.46	1.78e-9	Type 2 diabetes;
PAAD	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg00717180	chr2:96193071	NA	0.58	6.55	0.47	8.6e-10	HDL cholesterol;
PAAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.94e-7	Alzheimer's disease;
PAAD	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg19337854	chr7:99768885	GPC2	0.46	4.28	0.33	3.32e-5	Platelet count;
PAAD	cis	rs8077577	0.747	rs2290505	chr17:18137141	A/G	cg16794390	chr17:18148240	FLII	-0.53	-4.6	-0.35	8.75e-6	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.66	7.97	0.54	3.46e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg19792802	chr11:65647270	CTSW	0.61	7.27	0.51	1.73e-11	Crohn's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19705676	chr22:44351290	SAMM50	0.63	7.2	0.5	2.65e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.9	10.94	0.66	6.53e-21	Menarche (age at onset);
PAAD	cis	rs66530629	0.874	rs10903104	chr1:25136713	A/G	cg22509179	chr1:25234806	RUNX3	-0.5	-4.69	-0.36	6.16e-6	Plateletcrit;
PAAD	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-0.92	-9.14	-0.6	3.83e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-9.42	-0.61	6.83e-17	Vitiligo;
PAAD	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg12310025	chr6:25882481	NA	0.44	4.38	0.33	2.21e-5	Schizophrenia;
PAAD	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.5	-5.25	-0.39	5.01e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	4.7	0.36	5.76e-6	Schizophrenia;
PAAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.53	4.88	0.37	2.62e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-1.12	-10.25	-0.64	4.43e-19	Blood trace element (Zn levels);
PAAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.68	6.67	0.48	4.4e-10	Obesity-related traits;
PAAD	cis	rs16958440	0.867	rs78854354	chr18:44666924	C/G	cg17192377	chr18:44677553	HDHD2	0.96	5.85	0.43	2.85e-8	Sitting height ratio;
PAAD	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.63	-6.1	-0.44	8.41e-9	Itch intensity from mosquito bite;
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg05338745	chr12:82752188	CCDC59;C12orf26	0.64	7.37	0.51	1.03e-11	Immature fraction of reticulocytes;
PAAD	cis	rs939584	0.935	rs6732341	chr2:629817	G/C	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs6746082	0.550	rs682888	chr2:25757709	T/C	cg23192403	chr2:25781496	DTNB	-0.29	-4.38	-0.33	2.2e-5	Multiple myeloma;
PAAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.89	-0.43	2.34e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.41	-4.45	-0.34	1.63e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs58653258	0.730	rs2802975	chr1:234989370	A/T	cg03518729	chr1:235147744	NA	-0.48	-4.54	-0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg17105886	chr17:28927953	LRRC37B2	0.67	4.47	0.34	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg08807892	chr2:162101083	NA	0.73	8.27	0.56	6.2e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg22153463	chr1:85462885	MCOLN2	0.64	4.86	0.37	2.91e-6	Serum sulfate level;
PAAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg19630374	chr17:18023558	MYO15A	0.46	4.81	0.36	3.61e-6	Total body bone mineral density;
PAAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	5.94	0.43	1.9e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.49	4.62	0.35	8.24e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	trans	rs10951933	0.632	rs5018488	chr7:47911290	C/T	cg05433557	chr7:158325024	PTPRN2	-0.55	-6.29	-0.45	3.29e-9	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg26417346	chr17:41570143	DHX8	0.59	6.4	0.46	1.81e-9	Educational attainment (years of education);
PAAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22601191	chr20:60968625	CABLES2	0.52	5.1	0.38	1.01e-6	Colorectal cancer;
PAAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs35740288	0.770	rs11631018	chr15:86140534	G/A	cg07943548	chr15:86304357	KLHL25	-0.65	-5.79	-0.43	3.87e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg23912435	chr1:150601613	ENSA	0.49	4.55	0.35	1.09e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.71	-7.02	-0.49	6.9e-11	Neurofibrillary tangles;
PAAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	6.73	0.48	3.17e-10	Systemic lupus erythematosus;
PAAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05665937	chr4:1216051	CTBP1	-0.42	-4.25	-0.33	3.7e-5	Obesity-related traits;
PAAD	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	5.84	0.43	3.01e-8	Body mass index;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.27	-0.51	1.77e-11	Response to antipsychotic treatment;
PAAD	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg10820045	chr2:198174542	NA	0.48	4.91	0.37	2.32e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24118920	chr10:15001839	MEIG1	0.59	6.75	0.48	2.91e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12122100	0.774	rs12124149	chr1:146523897	G/T	cg19022274	chr1:146715514	CHD1L	-0.56	-4.47	-0.34	1.49e-5	HIV-1 control;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24763094	chr2:160569157	MARCH7	-0.6	-6.48	-0.47	1.21e-9	Smoking initiation;
PAAD	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.4	4.34	0.33	2.62e-5	Testicular germ cell tumor;
PAAD	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.34	4.45	0.34	1.65e-5	Educational attainment (years of education);
PAAD	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.59	-4.61	-0.35	8.33e-6	Schizophrenia;
PAAD	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg08917208	chr2:24149416	ATAD2B	0.47	4.25	0.33	3.77e-5	Asthma;
PAAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg03983715	chr16:68378420	PRMT7	-0.79	-5.93	-0.43	1.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg22482690	chr17:47019901	SNF8	-0.44	-4.63	-0.35	7.66e-6	Type 2 diabetes;
PAAD	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg20363699	chr7:23626180	CLK2P	0.36	4.37	0.33	2.33e-5	Schizophrenia;
PAAD	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.41	-4.66	-0.35	6.9e-6	Blood pressure (smoking interaction);
PAAD	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.25	17.24	0.81	1.38e-37	Schizophrenia;
PAAD	cis	rs6844506	0.898	rs11132238	chr4:185236382	G/C	cg12654155	chr4:185238627	NA	-0.5	-5.2	-0.39	6.23e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.6	-4.27	-0.33	3.43e-5	Vitiligo;
PAAD	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.65	6.57	0.47	7.41e-10	Primary sclerosing cholangitis;
PAAD	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.8	-5.09	-0.38	1.06e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg10437265	chr15:77819839	NA	0.41	4.64	0.35	7.42e-6	Type 2 diabetes;
PAAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.63	-5.62	-0.42	8.69e-8	Renal function-related traits (BUN);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.61	6.89	0.49	1.37e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11235843	0.929	rs3211165	chr11:73471778	A/G	cg18195628	chr11:73498948	MRPL48	0.78	4.33	0.33	2.73e-5	Hand grip strength;
PAAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	16.87	0.81	1.21e-36	Height;
PAAD	cis	rs12432203	1.000	rs72622435	chr14:51734596	A/G	cg23942311	chr14:51606299	NA	-0.69	-4.72	-0.36	5.22e-6	Cancer;
PAAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg09339527	chr5:178322752	ZFP2	-0.43	-4.52	-0.34	1.24e-5	Sleep duration;
PAAD	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.85	9.9	0.63	3.85e-18	Height;
PAAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg16584290	chr5:462447	EXOC3	-0.41	-4.41	-0.34	1.91e-5	Cystic fibrosis severity;
PAAD	cis	rs11807834	0.522	rs2057233	chr1:230232790	G/A	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.5e-13	Schizophrenia;
PAAD	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg10541313	chr22:46663664	TTC38	0.9	4.41	0.34	1.91e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	1.17	8.7	0.58	5.1e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	6.9	0.49	1.29e-10	Blood metabolite levels;
PAAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.57	-4.67	-0.35	6.64e-6	Platelet count;
PAAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.76	-0.48	2.82e-10	IgG glycosylation;
PAAD	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.51	-0.8	9.93e-36	Height;
PAAD	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.65	6.26	0.45	3.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg04271801	chr6:26272516	HIST1H3G;HIST1H2BI	-0.7	-4.46	-0.34	1.57e-5	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9463078	0.739	rs6941169	chr6:45173552	A/C	cg25276700	chr6:44698697	NA	-0.48	-5.57	-0.41	1.13e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.47	5.13	0.38	8.65e-7	Pelvic organ prolapse;
PAAD	cis	rs12780845	1.000	rs33993216	chr10:17204139	G/A	cg00857480	chr10:17188594	TRDMT1	0.37	4.67	0.35	6.45e-6	Homocysteine levels;
PAAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4740619	0.630	rs2987016	chr9:15983939	A/G	cg14451791	chr9:16040625	NA	0.37	4.37	0.33	2.33e-5	Body mass index;
PAAD	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.45	-0.4	1.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg06728252	chr6:26598149	ABT1	-0.39	-4.56	-0.35	1.03e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.97e-10	Resting heart rate;
PAAD	cis	rs755249	0.567	rs4660546	chr1:39679402	T/C	cg14018543	chr1:39659967	MACF1	-0.55	-4.6	-0.35	8.75e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg16205897	chr5:131564050	P4HA2	-0.41	-4.41	-0.34	1.95e-5	Blood metabolite levels;
PAAD	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.85	-4.37	-0.33	2.29e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-6.25	-0.45	4.04e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs11669133	1.000	rs74686233	chr19:11121869	G/A	cg25243385	chr19:11167475	SMARCA4	0.98	4.59	0.35	9.11e-6	LDL cholesterol;
PAAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg07148914	chr20:33460835	GGT7	0.47	4.65	0.35	7.22e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg21269045	chr12:125625041	AACS	-0.49	-4.67	-0.35	6.47e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23281280	chr6:28129359	ZNF389	0.72	5.61	0.41	9.51e-8	Depression;
PAAD	trans	rs4678145	1.000	rs17282064	chr3:124454449	C/T	cg03983498	chr1:55107291	C1orf175	1.06	6.63	0.47	5.58e-10	Coronary artery disease;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg25194201	chr17:27507560	MYO18A	0.73	8.15	0.55	1.23e-13	Myopia (pathological);
PAAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg05697835	chr1:2722811	NA	0.39	4.48	0.34	1.48e-5	Ulcerative colitis;
PAAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-8.48	-0.57	1.83e-14	Gut microbiome composition (summer);
PAAD	cis	rs72960926	0.744	rs72950579	chr6:74915560	G/A	cg03266952	chr6:74778945	NA	-1.11	-6.28	-0.45	3.34e-9	Metabolite levels (MHPG);
PAAD	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.82	9.59	0.61	2.48e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	17.38	0.82	5.92e-38	Prudent dietary pattern;
PAAD	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.84	10.49	0.65	1.04e-19	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4938933	0.506	rs61900467	chr11:60078475	C/T	cg18570331	chr11:60101691	MS4A6E	-0.48	-4.29	-0.33	3.21e-5	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.78	8.5	0.57	1.61e-14	Aortic root size;
PAAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.85	10.11	0.63	1.09e-18	Diastolic blood pressure;
PAAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.64	6.84	0.49	1.77e-10	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg02098413	chr6:105308735	HACE1	0.45	5.32	0.4	3.58e-7	Thyroid stimulating hormone;
PAAD	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.48	-7.99	-0.54	3.05e-13	Mean corpuscular volume;
PAAD	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg22139774	chr2:100720529	AFF3	-0.35	-4.28	-0.33	3.31e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg10556349	chr10:835070	NA	0.68	5.09	0.38	1.05e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg26924012	chr15:45694286	SPATA5L1	0.46	4.29	0.33	3.15e-5	Uric acid levels;
PAAD	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.73	-0.36	5.07e-6	Prevalent atrial fibrillation;
PAAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg21191810	chr6:118973309	C6orf204	-0.51	-4.9	-0.37	2.45e-6	Diastolic blood pressure;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg04098458	chr2:149402448	EPC2	-0.65	-8.15	-0.55	1.25e-13	Body fat percentage;
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg27644672	chr7:1858694	MAD1L1	-0.41	-4.41	-0.34	1.91e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.56	-0.35	1.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	5.41	0.4	2.45e-7	Type 2 diabetes;
PAAD	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.63	7.26	0.51	1.85e-11	Alcohol dependence;
PAAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.6	4.84	0.37	3.12e-6	Schizophrenia;
PAAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.08e-16	Diabetic kidney disease;
PAAD	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg21483461	chr5:81570383	RPS23	-0.51	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.58	-5.25	-0.39	4.97e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.46	5.78	0.42	4.02e-8	Crohn's disease;
PAAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.5	-4.58	-0.35	9.6e-6	IgG glycosylation;
PAAD	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.91	11.86	0.69	2.14e-23	Body mass index;
PAAD	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg18833306	chr6:118973337	C6orf204	0.43	4.47	0.34	1.52e-5	Electrocardiographic conduction measures;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg25314111	chr5:178204356	AACSL	-0.63	-6.29	-0.45	3.24e-9	Obesity-related traits;
PAAD	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.68	6.87	0.49	1.58e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.97	-0.49	9.06e-11	Depression;
PAAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.69	7.54	0.52	3.94e-12	Mean corpuscular volume;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14337129	chr9:131594230	NA	-0.7	-7.69	-0.53	1.69e-12	Obesity-related traits;
PAAD	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg11965913	chr1:205819406	PM20D1	0.66	5.4	0.4	2.53e-7	Parkinson's disease;
PAAD	cis	rs6499755	0.712	rs31093	chr16:55366176	C/G	cg02859129	chr16:55357253	IRX6	0.35	4.87	0.37	2.79e-6	Hypospadias;
PAAD	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg19767477	chr5:127420684	SLC12A2	-0.54	-4.38	-0.33	2.2e-5	Ileal carcinoids;
PAAD	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg03047570	chr10:32398778	NA	-0.66	-4.51	-0.34	1.31e-5	Anti-saccade response;
PAAD	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg27129171	chr3:47204927	SETD2	0.6	6.17	0.45	6e-9	Birth weight;
PAAD	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.77	-6.47	-0.46	1.28e-9	Inflammatory skin disease;
PAAD	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.65	6.99	0.49	8.04e-11	Body mass index;
PAAD	cis	rs138918	0.772	rs138932	chr22:43565443	C/T	cg00343092	chr22:43547974	TSPO	0.42	4.53	0.35	1.17e-5	Monocyte count;
PAAD	cis	rs3007168	1.000	rs3007076	chr14:51605352	G/T	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg10729496	chr3:10149963	C3orf24	0.89	7.22	0.51	2.27e-11	Alzheimer's disease;
PAAD	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.46	4.8	0.36	3.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs62264129	0.500	rs4682400	chr3:112045215	T/C	cg15541583	chr3:112013063	SLC9A10	-0.31	-4.96	-0.37	1.86e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg21466736	chr12:48725269	NA	0.51	4.79	0.36	3.86e-6	Glycated hemoglobin levels;
PAAD	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.91e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2017305	0.749	rs114004206	chr10:70790544	G/A	cg25290552	chr10:70751067	KIAA1279	-0.89	-5.46	-0.4	1.93e-7	Depression (quantitative trait);
PAAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.58	-7.18	-0.5	2.89e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12913538	0.890	rs4326998	chr15:62896609	A/G	cg09983546	chr15:62884068	NA	0.75	8.08	0.55	1.92e-13	Sleep depth;
PAAD	cis	rs990171	0.913	rs10190555	chr2:102994056	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	4.37	0.33	2.31e-5	Lymphocyte counts;
PAAD	cis	rs3736485	0.966	rs28376817	chr15:51889280	A/T	cg19558802	chr15:51695713	GLDN	-0.43	-4.42	-0.34	1.84e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.68	-6.72	-0.48	3.48e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs73058052	1.000	rs73058052	chr19:50099422	C/T	cg15607449	chr19:49990766	RPL13AP5;RPL13A	-0.74	-5.58	-0.41	1.05e-7	Fibrinogen levels;
PAAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.53	5.19	0.39	6.71e-7	Vitiligo;
PAAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg14709524	chr16:89940631	TCF25	0.98	4.59	0.35	9.29e-6	Skin colour saturation;
PAAD	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg00035074	chr7:2701567	TTYH3	0.63	4.31	0.33	2.94e-5	Bipolar disorder;
PAAD	cis	rs939584	0.877	rs13027828	chr2:632379	T/G	cg03610516	chr2:642275	NA	0.59	5.32	0.4	3.7e-7	Body mass index;
PAAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21862992	chr11:68658383	NA	0.38	4.28	0.33	3.36e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.93	10.92	0.66	7.64e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg17503389	chr5:90575422	NA	-0.63	-4.72	-0.36	5.39e-6	Smoking behavior;
PAAD	cis	rs6735179	0.565	rs736870	chr2:1748702	T/C	cg08534653	chr2:1747700	PXDN	0.24	4.28	0.33	3.29e-5	Response to antipsychotic treatment;
PAAD	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg25233709	chr10:116636983	FAM160B1	0.38	4.63	0.35	7.88e-6	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg22143635	chr11:980567	AP2A2	0.52	5.43	0.4	2.16e-7	Alzheimer's disease (late onset);
PAAD	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg23752985	chr2:85803571	VAMP8	0.53	5.96	0.44	1.71e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg23752985	chr2:85803571	VAMP8	0.59	6.33	0.46	2.68e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg13590414	chr9:128173245	NA	0.48	4.8	0.36	3.72e-6	Mean arterial pressure;
PAAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	7.64	0.53	2.32e-12	Bone mineral density;
PAAD	trans	rs2249625	0.739	rs580950	chr6:72766858	A/G	cg04413069	chr12:9800446	LOC374443	0.58	6.44	0.46	1.49e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-10.89	-0.66	8.88e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg21698718	chr17:80085957	CCDC57	-0.45	-5.09	-0.38	1.06e-6	Life satisfaction;
PAAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.74	-8.34	-0.56	4.1e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg08355456	chr11:67383691	NA	-0.46	-4.33	-0.33	2.64e-5	Mean corpuscular volume;
PAAD	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-7.96	-0.54	3.68e-13	Bladder cancer;
PAAD	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.74	8.46	0.57	2.05e-14	Age-related hearing impairment;
PAAD	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg04087571	chr11:116723030	SIK3	-0.38	-5.74	-0.42	5.04e-8	Blood protein levels;
PAAD	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-4.89	-0.37	2.57e-6	Body mass index;
PAAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.76	8.5	0.57	1.67e-14	Lung cancer;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.48	4.67	0.35	6.59e-6	Resistin levels;
PAAD	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg27539214	chr16:67997921	SLC12A4	-0.63	-5.01	-0.38	1.49e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11024102	0.925	rs7123383	chr11:17002985	G/A	cg15378786	chr11:17036137	PLEKHA7	0.5	4.45	0.34	1.65e-5	Glaucoma (primary angle closure);
PAAD	cis	rs9918079	0.560	rs4698409	chr4:15659766	G/A	cg16509355	chr4:15471240	CC2D2A	-0.35	-4.49	-0.34	1.41e-5	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23801475	chr11:64009419	FKBP2	-0.62	-6.49	-0.47	1.15e-9	Smoking initiation;
PAAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.25e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	1.71	9.48	0.61	4.78e-17	Height;
PAAD	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg19413350	chr8:57351067	NA	-0.55	-5.55	-0.41	1.26e-7	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.16	0.5	3.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58521262	0.556	rs465933	chr19:23128203	T/C	cg02350677	chr19:23254381	NA	-0.26	-4.52	-0.34	1.22e-5	Testicular germ cell tumor;
PAAD	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg23465465	chr6:26364728	BTN3A2	0.81	4.75	0.36	4.64e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-5.29	-0.39	4.11e-7	Mean platelet volume;
PAAD	cis	rs28489187	0.597	rs6576765	chr1:85871012	A/T	cg16011679	chr1:85725395	C1orf52	-0.52	-4.94	-0.37	2e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.72	-7.29	-0.51	1.6e-11	Lung cancer;
PAAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg05110241	chr16:68378359	PRMT7	-1.17	-8.25	-0.56	6.87e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-5.89	-0.43	2.35e-8	Obesity (extreme);
PAAD	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg14703610	chr5:56206110	C5orf35	0.61	5.62	0.41	8.97e-8	Breast cancer;Breast cancer (early onset);
PAAD	cis	rs9314998	1.000	rs7997640	chr13:30744080	G/T	cg12316290	chr13:30425969	UBL3	0.43	4.6	0.35	8.99e-6	Male-pattern baldness;
PAAD	cis	rs2120243	0.539	rs1456097	chr3:157098630	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	4.53	0.35	1.16e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg09376583	chr16:88111425	NA	-0.48	-4.32	-0.33	2.85e-5	Menopause (age at onset);
PAAD	cis	rs2296225	0.722	rs10916853	chr1:21053887	C/T	cg24673385	chr1:21051448	SH2D5	0.47	4.31	0.33	2.97e-5	Eosinophilic esophagitis;
PAAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.65	-6.74	-0.48	3.05e-10	Body mass index;
PAAD	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.43	4.47	0.34	1.54e-5	Plateletcrit;
PAAD	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.64	-6.37	-0.46	2.18e-9	Ear protrusion;
PAAD	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.96	-10.3	-0.64	3.45e-19	Multiple sclerosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17543973	chr11:2442163	TRPM5	0.59	6.65	0.47	4.89e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.06	0.55	2.11e-13	Alzheimer's disease;
PAAD	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg12437481	chr16:420112	MRPL28	-0.48	-4.33	-0.33	2.71e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg05315796	chr3:52349193	DNAH1	0.41	4.56	0.35	1.05e-5	Bipolar disorder;
PAAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg03676636	chr4:99064102	C4orf37	-0.31	-5.35	-0.4	3.23e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.12	-0.55	1.46e-13	Response to antipsychotic treatment;
PAAD	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	1.18	15.4	0.78	7.49e-33	Ewing sarcoma;
PAAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	8.74	0.58	4e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.82	8.53	0.57	1.4e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg00576331	chr11:65640516	EFEMP2	-0.5	-4.65	-0.35	7.13e-6	Eosinophil percentage of white cells;
PAAD	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.26	-14.16	-0.75	1.49e-29	Hip circumference adjusted for BMI;
PAAD	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.51	4.8	0.36	3.83e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6028335	0.610	rs16987687	chr20:37566737	T/C	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.63	-4.76	-0.36	4.45e-6	Alcohol and nicotine co-dependence;
PAAD	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.79	9.45	0.61	6e-17	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16892046	chr8:119124311	EXT1	0.56	6.47	0.46	1.27e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11828289	0.660	rs28825707	chr11:23224075	G/A	cg20040320	chr11:23191996	NA	-0.77	-5.48	-0.41	1.75e-7	Cancer;
PAAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.78	12.54	0.71	3.23e-25	Breast cancer;
PAAD	cis	rs58521262	0.530	rs289367	chr19:23114530	A/T	cg02350677	chr19:23254381	NA	-0.26	-4.62	-0.35	8.2e-6	Testicular germ cell tumor;
PAAD	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg27478167	chr7:817139	HEATR2	-0.78	-5.9	-0.43	2.27e-8	Cerebrospinal P-tau181p levels;
PAAD	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.36	0.33	2.41e-5	Total cholesterol levels;
PAAD	cis	rs11264799	0.520	rs849814	chr1:157542216	G/A	cg18268488	chr1:157545234	FCRL4	0.54	6.21	0.45	4.71e-9	IgA nephropathy;
PAAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-4.62	-0.35	8.16e-6	Menarche (age at onset);
PAAD	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg16342193	chr10:102329863	NA	0.73	7.69	0.53	1.73e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.57	-4.39	-0.34	2.11e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg04165759	chr1:150448943	RPRD2	0.51	5.4	0.4	2.55e-7	Migraine;
PAAD	cis	rs2548003	0.541	rs1895416	chr5:28754530	A/T	cg22863700	chr5:28928346	NA	0.56	5.45	0.4	1.99e-7	Hip geometry;
PAAD	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.49	4.93	0.37	2.11e-6	Schizophrenia;
PAAD	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg23682824	chr7:23144976	KLHL7	0.47	4.33	0.33	2.71e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs732505	1.000	rs8109716	chr19:5585245	G/A	cg26242866	chr19:5711310	LONP1	1.05	5.76	0.42	4.49e-8	vWF and FVIII levels;
PAAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-5.43	-0.4	2.18e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20222321	chr13:114290774	TFDP1	-0.7	-6.55	-0.47	8.6e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7922314	0.571	rs61865683	chr10:64720373	C/A	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	6.43	0.46	1.56e-9	Type 2 diabetes;
PAAD	cis	rs7731390	0.614	rs77318058	chr5:131696983	T/C	cg07395648	chr5:131743802	NA	-0.7	-4.47	-0.34	1.5e-5	IgG glycosylation;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg18764771	chr6:116381957	FRK	0.44	7.84	0.54	7.42e-13	Cholesterol, total;LDL cholesterol;
PAAD	trans	rs795484	0.926	rs1726390	chr12:118645384	A/G	cg06703803	chr12:110811045	ANAPC7	-0.58	-6.48	-0.47	1.24e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs6594713	0.533	rs35389274	chr5:112961118	C/T	cg12552261	chr5:112820674	MCC	0.76	5.05	0.38	1.26e-6	Brain cytoarchitecture;
PAAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.95	12.3	0.71	1.48e-24	Menopause (age at onset);
PAAD	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg01796438	chr3:11312864	ATG7	-0.65	-4.95	-0.37	1.99e-6	Circulating chemerin levels;
PAAD	cis	rs11681884	0.786	rs17042750	chr2:113823151	T/G	cg06156847	chr2:113672199	IL1F7	-0.74	-4.43	-0.34	1.76e-5	Stroke;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21183846	chr1:171283203	FMO4	0.57	6.61	0.47	6.15e-10	Monocyte percentage of white cells;
PAAD	cis	rs11811982	0.793	rs116657151	chr1:227530925	A/G	cg24860534	chr1:227506868	CDC42BPA	0.53	5.13	0.38	8.76e-7	Optic disc area;
PAAD	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg20406979	chr6:167373233	NA	0.38	5.13	0.38	8.71e-7	Crohn's disease;
PAAD	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.59	5.66	0.42	7.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06352072	chr18:59561651	RNF152	0.62	6.9	0.49	1.29e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-4.87	-0.37	2.81e-6	Lung cancer;
PAAD	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.83	0.43	3.15e-8	Colorectal cancer;
PAAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg22143856	chr6:28129313	ZNF389	0.69	5.53	0.41	1.36e-7	Parkinson's disease;
PAAD	cis	rs4740619	0.630	rs2987023	chr9:15986373	C/T	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.19e-5	Body mass index;
PAAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg11941060	chr3:133502564	NA	-0.5	-5.22	-0.39	5.86e-7	Iron status biomarkers;
PAAD	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg00792783	chr2:198669748	PLCL1	-0.46	-4.3	-0.33	3.04e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04141691	chr16:3285501	ZNF200	-0.64	-6.81	-0.48	2.15e-10	Smoking initiation;
PAAD	cis	rs2544527	0.586	rs2544534	chr2:15906466	T/C	cg26669897	chr2:15909070	NA	0.47	4.69	0.36	6.02e-6	Pulmonary function (smoking interaction);Pulmonary function;
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg14008862	chr17:28927542	LRRC37B2	0.82	5.45	0.4	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg19223190	chr17:80058835	NA	-0.53	-5.53	-0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-5.66	-0.42	7.2e-8	Mean corpuscular volume;
PAAD	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.65	6.99	0.49	7.98e-11	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22127314	chr5:54603891	DHX29;SKIV2L2	0.62	6.38	0.46	1.97e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.54	5.14	0.38	8.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg12740337	chr6:28058973	ZSCAN12L1	-0.48	-4.59	-0.35	9.34e-6	Depression;
PAAD	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.83	10.11	0.63	1.05e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.45	-4.65	-0.35	7.24e-6	Response to antidepressants in depression;
PAAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.68	5.69	0.42	6.39e-8	Gut microbiome composition (summer);
PAAD	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg26205652	chr12:48591994	NA	0.8	7.23	0.51	2.19e-11	Longevity (90 years and older);
PAAD	cis	rs62408225	1.000	rs11757155	chr6:90941240	C/T	cg03795776	chr6:90687632	BACH2	0.46	4.59	0.35	9.38e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.86	9.12	0.59	4.16e-16	Calcium levels;
PAAD	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.07	0.59	5.73e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs6494488	0.500	rs72742909	chr15:64841440	A/G	cg16425858	chr15:64791681	ZNF609	1.0	4.68	0.35	6.26e-6	Coronary artery disease;
PAAD	cis	rs2997447	0.802	rs72884792	chr1:26436688	G/C	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.84	-7.31	-0.51	1.41e-11	Coronary artery disease;
PAAD	cis	rs7627468	0.954	rs7614486	chr3:121924384	G/T	cg17240004	chr3:121949083	CASR	0.52	4.43	0.34	1.81e-5	Kidney stones;
PAAD	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg08079166	chr15:68083412	MAP2K5	0.62	4.91	0.37	2.31e-6	Restless legs syndrome;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg11494091	chr17:61959527	GH2	-0.94	-12.48	-0.71	4.75e-25	Prudent dietary pattern;
PAAD	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.71	8.87	0.58	1.9e-15	Cancer;
PAAD	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg15676125	chr6:33679581	C6orf125	0.5	5.01	0.38	1.51e-6	Plateletcrit;
PAAD	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg10518543	chr12:38710700	ALG10B	0.47	4.47	0.34	1.51e-5	Morning vs. evening chronotype;
PAAD	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	9.65	0.62	1.77e-17	Platelet count;
PAAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.43	4.92	0.37	2.18e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg08807101	chr21:30365312	RNF160	-0.61	-5.03	-0.38	1.34e-6	Cognitive test performance;
PAAD	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg14092571	chr14:90743983	NA	0.54	5.15	0.39	7.99e-7	Mortality in heart failure;
PAAD	trans	rs7071275	0.830	rs11200074	chr10:123439248	G/A	cg09994435	chr20:62404778	ZBTB46	0.81	6.6	0.47	6.62e-10	Dupuytren's disease;
PAAD	cis	rs2034650	0.563	rs12914710	chr15:40713849	C/T	cg05276125	chr15:40653601	DISP2	0.46	4.53	0.34	1.2e-5	Interstitial lung disease;
PAAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.48	-0.34	1.45e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.4	4.76	0.36	4.43e-6	HIV-1 susceptibility;
PAAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-4.32	-0.33	2.86e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs1143633	0.662	rs12990810	chr2:113642532	G/T	cg06771106	chr2:113671356	IL1F7	0.59	6.28	0.45	3.35e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-5.59	-0.41	1.01e-7	Menarche (age at onset);
PAAD	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-4.84	-0.37	3.17e-6	Monocyte percentage of white cells;
PAAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.48	-5.47	-0.41	1.85e-7	Cardiovascular disease risk factors;
PAAD	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.24	0.6	2.02e-16	Fuchs's corneal dystrophy;
PAAD	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.68	5.38	0.4	2.82e-7	Mammographic density (dense area);
PAAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00142150	chr22:38071001	LGALS1	0.79	8.87	0.58	1.85e-15	Fat distribution (HIV);
PAAD	cis	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg14924899	chr15:62937113	MGC15885	-0.46	-5.58	-0.41	1.05e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	7.84	0.54	7.36e-13	Coffee consumption (cups per day);
PAAD	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg03303774	chr4:1407052	NA	0.44	5.33	0.4	3.54e-7	Obesity-related traits;
PAAD	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-4.68	-0.36	6.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg17366294	chr4:99064904	C4orf37	-0.45	-5.01	-0.38	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-6.05	-0.44	1.07e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	0.8	5.55	0.41	1.26e-7	Body mass index;
PAAD	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.4	9.57	0.61	2.77e-17	Diabetic retinopathy;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.71	8.27	0.56	6.33e-14	Iron status biomarkers;
PAAD	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg24519413	chr1:26490540	NA	0.52	4.7	0.36	5.85e-6	QRS complex (12-leadsum);
PAAD	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg25753631	chr6:25732923	NA	-0.37	-4.31	-0.33	2.97e-5	Iron status biomarkers;
PAAD	cis	rs11124272	0.859	rs11678843	chr2:31961182	G/C	cg02381751	chr2:32503542	YIPF4	-0.48	-4.62	-0.35	8.11e-6	Interleukin-18 levels;
PAAD	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	cg25843174	chr11:12811716	TEAD1	0.38	5.57	0.41	1.15e-7	Educational attainment (years of education);
PAAD	cis	rs2718812	0.766	rs1822744	chr3:133366227	A/G	cg11941060	chr3:133502564	NA	-0.52	-5.51	-0.41	1.51e-7	Iron status biomarkers;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.73	5.29	0.39	4.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	1.0	5.32	0.4	3.65e-7	Childhood ear infection;
PAAD	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg12700464	chr11:78128424	GAB2	-0.57	-4.31	-0.33	2.87e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11051970	1.000	rs11051970	chr12:32537488	G/T	cg02745156	chr12:32552066	NA	0.48	5.14	0.38	8.44e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.34	-0.33	2.54e-5	QT interval;
PAAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10819733	chr22:24237672	NA	-0.6	-7.07	-0.5	5.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg22916017	chr11:64110731	CCDC88B	0.4	4.67	0.35	6.59e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	ch.3.2456622F	chr3:125269750	OSBPL11	-0.56	-6.79	-0.48	2.36e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg07153921	chr17:41440717	NA	-0.41	-4.42	-0.34	1.88e-5	Menopause (age at onset);
PAAD	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg01304814	chr3:48885189	PRKAR2A	0.86	5.14	0.39	8.16e-7	Cognitive function;
PAAD	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg27481594	chr15:43623282	ADAL;LCMT2	-0.46	-4.5	-0.34	1.32e-5	Lung cancer;
PAAD	cis	rs13102973	0.899	rs11735890	chr4:135902143	A/G	cg14419869	chr4:135874104	NA	0.46	4.71	0.36	5.47e-6	Subjective well-being;
PAAD	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.6	6.73	0.48	3.18e-10	Smoking initiation;
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.79	6.21	0.45	4.81e-9	Alzheimer's disease;
PAAD	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.66	4.93	0.37	2.17e-6	Obesity-related traits;
PAAD	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.59	-5.36	-0.4	3.02e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg11416102	chr8:651193	ERICH1	1.03	6.42	0.46	1.67e-9	IgG glycosylation;
PAAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	1.08	8.25	0.56	7.16e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.53	-4.98	-0.37	1.74e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-0.43	-4.26	-0.33	3.57e-5	Heart rate variability traits (SDNN);
PAAD	cis	rs28489187	0.617	rs233109	chr1:85783101	T/C	cg16011679	chr1:85725395	C1orf52	0.51	4.78	0.36	4.19e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg23708337	chr7:1209742	NA	0.62	4.29	0.33	3.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg21419209	chr3:44054225	NA	-0.63	-6.0	-0.44	1.4e-8	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.53	5.22	0.39	5.78e-7	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg10692932	chr12:49716863	TROAP	0.57	6.66	0.48	4.7e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-6.64	-0.47	5.28e-10	Homocysteine levels;
PAAD	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg05562828	chr17:3906858	NA	0.51	5.53	0.41	1.36e-7	Type 2 diabetes;
PAAD	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg16928487	chr17:17741425	SREBF1	-0.35	-4.79	-0.36	3.93e-6	Total body bone mineral density;
PAAD	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.78	-5.95	-0.43	1.8e-8	Coronary artery disease;
PAAD	trans	rs12786942	1.000	rs36111323	chr11:101359750	G/A	cg19874726	chr14:61114476	SIX1	-0.85	-6.34	-0.46	2.49e-9	Facial depth;
PAAD	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.55	-4.48	-0.34	1.47e-5	Diastolic blood pressure;
PAAD	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.36	0.46	2.24e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs76419734	0.558	rs17035939	chr4:106526544	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	4.56	0.35	1.05e-5	Post bronchodilator FEV1;
PAAD	cis	rs10450586	0.932	rs10734390	chr11:27332214	T/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.55	5.1	0.38	1.01e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-7.09	-0.5	4.66e-11	Gut microbiome composition (summer);
PAAD	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.7	7.79	0.53	9.62e-13	Longevity;
PAAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.58	-6.55	-0.47	8.56e-10	Vitiligo;
PAAD	cis	rs59901009	0.534	rs7935297	chr11:10024972	T/C	cg06876053	chr11:9810051	SBF2	-0.34	-4.45	-0.34	1.63e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.52	-5.18	-0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg02887458	chr19:19495540	GATAD2A	-0.54	-5.0	-0.38	1.55e-6	Bipolar disorder;
PAAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg13722127	chr7:150037890	RARRES2	0.65	6.41	0.46	1.72e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	1.02	9.18	0.6	2.94e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06850241	chr22:41845214	NA	-0.5	-4.76	-0.36	4.43e-6	Vitiligo;
PAAD	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.62	-6.53	-0.47	9.27e-10	Coronary artery disease;
PAAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.17	-0.5	3.07e-11	Personality dimensions;
PAAD	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.38	-4.43	-0.34	1.8e-5	Fat distribution (HIV);
PAAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.07	-18.36	-0.83	2.05e-40	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.83	0.36	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg04165759	chr1:150448943	RPRD2	-0.5	-5.19	-0.39	6.57e-7	Migraine;
PAAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02711726	chr17:80685570	FN3KRP	-0.5	-4.52	-0.34	1.23e-5	Glycated hemoglobin levels;
PAAD	cis	rs939584	1.000	rs4854346	chr2:638918	A/C	cg03610516	chr2:642275	NA	0.6	5.4	0.4	2.52e-7	Body mass index;
PAAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg03037974	chr15:76606532	NA	-0.52	-6.17	-0.45	6.05e-9	Blood metabolite levels;
PAAD	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.48	-5.11	-0.38	9.49e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs10905065	1.000	rs10795488	chr10:5755207	C/A	cg11519256	chr10:5708881	ASB13	0.5	4.27	0.33	3.44e-5	Menopause (age at onset);
PAAD	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.72	6.27	0.45	3.5e-9	Narcolepsy with cataplexy;
PAAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.77	-7.68	-0.53	1.82e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg24220031	chr2:73402428	NA	-0.3	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.5	5.13	0.38	8.57e-7	Obesity-related traits;
PAAD	cis	rs10227331	1.000	rs11979293	chr7:157293586	C/T	cg04156418	chr7:157293606	NA	0.48	5.49	0.41	1.63e-7	Inattentive symptoms;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg19715081	chr17:46048395	CDK5RAP3	-0.74	-6.55	-0.47	8.24e-10	Neuroticism;
PAAD	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.47	-4.72	-0.36	5.38e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.76	-5.67	-0.42	7.1e-8	Coronary artery calcification;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12529432	chr8:23538610	NKX3-1	-0.71	-7.03	-0.5	6.36e-11	Obesity-related traits;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12567615	chr8:11609706	GATA4	0.66	7.67	0.53	1.86e-12	Smoking initiation;
PAAD	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg24721873	chr10:135334122	NA	0.58	4.41	0.34	1.96e-5	Gout;
PAAD	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg17812751	chr4:3478348	DOK7	0.47	5.02	0.38	1.45e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.67	7.37	0.51	1e-11	Mean corpuscular volume;
PAAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg13385521	chr17:29058706	SUZ12P	-0.64	-4.44	-0.34	1.73e-5	Body mass index;
PAAD	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-4.52	-0.34	1.22e-5	Immature fraction of reticulocytes;Schizophrenia;
PAAD	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.64	5.79	0.43	3.86e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-5.0	-0.38	1.55e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.75	-9.28	-0.6	1.59e-16	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg15595755	chr5:1867978	NA	0.44	4.42	0.34	1.86e-5	Cardiovascular disease risk factors;
PAAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg09211372	chr6:168490623	NA	-0.41	-4.26	-0.33	3.58e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.43	5.21	0.39	5.94e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg02225085	chr5:87975992	LOC645323	-0.64	-4.65	-0.35	7.13e-6	Body mass index;
PAAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.25	0.45	3.93e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04810007	chr14:71788121	NA	-0.79	-7.22	-0.51	2.38e-11	Neuroticism;
PAAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08219700	chr8:58056026	NA	0.66	5.1	0.38	9.93e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12016809	chr21:47604291	C21orf56	0.42	4.27	0.33	3.42e-5	Testicular germ cell tumor;
PAAD	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.47	5.14	0.38	8.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs12438356	1.000	rs7166136	chr15:69588577	C/T	cg02375503	chr15:69591110	PAQR5	-0.62	-4.39	-0.34	2.13e-5	CTACK levels;
PAAD	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg06995285	chr7:2418615	EIF3B	0.58	4.32	0.33	2.8e-5	Multiple sclerosis;
PAAD	cis	rs7833787	0.965	rs7833694	chr8:18700346	T/C	cg17701159	chr8:18705777	PSD3	-0.45	-5.39	-0.4	2.59e-7	Obesity-related traits;
PAAD	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.8	6.15	0.45	6.5e-9	IgE levels;
PAAD	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg08732750	chr1:87598351	LOC339524	0.33	4.67	0.35	6.71e-6	Smoking behavior;
PAAD	cis	rs35740288	0.770	rs11630968	chr15:86118001	C/T	cg07943548	chr15:86304357	KLHL25	-0.64	-5.57	-0.41	1.12e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.35	-4.26	-0.33	3.52e-5	Menarche (age at onset);
PAAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.52	6.78	0.48	2.52e-10	Schizophrenia;
PAAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.64	5.71	0.42	5.84e-8	Menarche (age at onset);
PAAD	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.22	-0.39	5.8e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg13047869	chr3:10149882	C3orf24	0.57	5.08	0.38	1.1e-6	Alzheimer's disease;
PAAD	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.9	-7.74	-0.53	1.27e-12	Cognitive test performance;
PAAD	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.53	8.0	0.54	3.01e-13	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg13660082	chr14:53194042	PSMC6	0.72	4.44	0.34	1.7e-5	Alzheimer's disease (late onset);
PAAD	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.53	-0.35	1.16e-5	Joint mobility (Beighton score);
PAAD	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg10820045	chr2:198174542	NA	0.52	5.26	0.39	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.38	5.77	0.42	4.21e-8	Educational attainment (years of education);
PAAD	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.03	-0.5	6.41e-11	Response to antipsychotic treatment;
PAAD	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.69	6.28	0.45	3.38e-9	Obesity-related traits;
PAAD	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg19949948	chr17:19361230	NA	-0.43	-4.44	-0.34	1.74e-5	Schizophrenia;
PAAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	1.11	8.74	0.58	4.05e-15	Iron status biomarkers;
PAAD	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.66	5.89	0.43	2.4e-8	Response to diuretic therapy;
PAAD	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg14393609	chr7:65229607	NA	0.49	4.27	0.33	3.48e-5	Aortic root size;
PAAD	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.44	-4.51	-0.34	1.29e-5	Primary biliary cholangitis;
PAAD	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg24530489	chr15:56299380	NA	-0.92	-4.39	-0.34	2.07e-5	Delta-5 desaturase activity;
PAAD	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg01236616	chr12:121019343	POP5	0.45	4.25	0.33	3.78e-5	High light scatter reticulocyte count;
PAAD	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.67	0.62	1.59e-17	Electrocardiographic conduction measures;
PAAD	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.82	10.08	0.63	1.3e-18	Drug-induced liver injury (flucloxacillin);
PAAD	trans	rs795484	0.926	rs556081	chr12:118732675	C/T	cg06703803	chr12:110811045	ANAPC7	0.58	6.44	0.46	1.47e-9	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-7.86	-0.54	6.71e-13	Colorectal cancer;
PAAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.26	0.33	3.58e-5	Iron status biomarkers;
PAAD	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.46	-4.33	-0.33	2.66e-5	Prostate-specific antigen levels;
PAAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.64	5.61	0.41	9.51e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.48	4.77	0.36	4.22e-6	Menopause (age at onset);
PAAD	cis	rs911555	0.603	rs11621300	chr14:103844898	T/C	cg12935359	chr14:103987150	CKB	-0.61	-5.7	-0.42	6.02e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	4.69	0.36	5.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9535307	0.719	rs61961491	chr13:50384106	T/C	cg04663916	chr13:50265991	EBPL	-0.58	-4.34	-0.33	2.61e-5	Obesity-related traits;
PAAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.58	-6.71	-0.48	3.64e-10	Lung cancer;
PAAD	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.88	9.33	0.6	1.2e-16	Parkinson's disease;
PAAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg03289416	chr15:75166202	SCAMP2	0.58	5.95	0.43	1.75e-8	Breast cancer;
PAAD	cis	rs7975161	0.521	rs4630362	chr12:104727744	G/C	cg25273343	chr12:104657179	TXNRD1	-0.85	-4.28	-0.33	3.32e-5	Toenail selenium levels;
PAAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.94	-0.37	2.08e-6	Monocyte percentage of white cells;
PAAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg27539214	chr16:67997921	SLC12A4	-0.59	-4.65	-0.35	7.28e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	1.08	14.88	0.77	1.76e-31	Menarche (age at onset);
PAAD	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	1.12	8.43	0.56	2.53e-14	IgG glycosylation;
PAAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg01075559	chr1:2537774	MMEL1	-0.47	-4.99	-0.38	1.63e-6	Ulcerative colitis;
PAAD	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg02795151	chr17:7402630	POLR2A	0.62	5.76	0.42	4.58e-8	Androgen levels;
PAAD	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.51	4.7	0.36	5.81e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.7	6.53	0.47	9.43e-10	Primary sclerosing cholangitis;
PAAD	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-11.43	-0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs8060686	0.920	rs72556537	chr16:67691477	A/T	cg27539214	chr16:67997921	SLC12A4	-0.82	-4.86	-0.37	2.85e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg18551225	chr6:44695536	NA	-0.7	-8.25	-0.56	7.07e-14	Total body bone mineral density;
PAAD	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.65	-6.08	-0.44	9.5e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg21546286	chr11:48923668	NA	-0.58	-6.09	-0.44	9.05e-9	HDL cholesterol;
PAAD	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg20607287	chr7:12443886	VWDE	-0.75	-5.47	-0.41	1.85e-7	Coronary artery disease;
PAAD	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs72634501	0.574	rs111623477	chr1:39811205	C/T	cg14018543	chr1:39659967	MACF1	-0.56	-4.39	-0.34	2.14e-5	HDL cholesterol;
PAAD	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.14	0.38	8.39e-7	Childhood ear infection;
PAAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-4.97	-0.37	1.77e-6	Type 2 diabetes;
PAAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg01097406	chr16:89675127	NA	-0.36	-4.4	-0.34	1.99e-5	Vitiligo;
PAAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	6.11	0.44	8.08e-9	Obesity-related traits;
PAAD	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-4.85	-0.37	3.06e-6	Common traits (Other);
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.58	-6.75	-0.48	2.87e-10	Lung cancer;
PAAD	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.95	-0.43	1.74e-8	Joint mobility (Beighton score);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg11855759	chr17:9548802	USP43	0.63	6.38	0.46	2.04e-9	Primary biliary cholangitis;
PAAD	trans	rs200810	0.964	rs7760581	chr6:97840999	C/T	cg14454397	chr2:225450036	CUL3	-0.66	-6.51	-0.47	1.05e-9	Body mass index;
PAAD	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.5	-4.89	-0.37	2.56e-6	Longevity;
PAAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.43	0.56	2.41e-14	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg14008862	chr17:28927542	LRRC37B2	0.84	6.02	0.44	1.23e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg27490568	chr2:178487706	NA	0.39	4.34	0.33	2.64e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg05925327	chr15:68127851	NA	0.56	5.09	0.38	1.06e-6	Restless legs syndrome;
PAAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg18518183	chr2:172544446	DYNC1I2	0.48	4.3	0.33	3.05e-5	Schizophrenia;
PAAD	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.48	4.58	0.35	9.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.5	-5.6	-0.41	9.65e-8	Migraine;
PAAD	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	6.15	0.45	6.51e-9	Mean platelet volume;
PAAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26543989	chr17:42187485	HDAC5	-0.65	-6.32	-0.46	2.72e-9	Obesity-related traits;
PAAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-5.05	-0.38	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.77	5.35	0.4	3.14e-7	Inflammatory bowel disease;
PAAD	cis	rs9472414	0.510	rs7746032	chr6:44708613	A/T	cg20913747	chr6:44695427	NA	0.54	5.65	0.42	7.67e-8	Height;
PAAD	cis	rs2790216	1.000	rs2790216	chr10:59997926	G/A	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.77	9.3	0.6	1.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs12042938	0.505	rs10864689	chr1:231752067	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-4.7	-0.36	5.81e-6	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs7250872	0.568	rs12462721	chr19:1842884	G/A	cg10370574	chr19:1840461	REXO1	-0.49	-4.58	-0.35	9.6e-6	Bipolar disorder;
PAAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-4.35	-0.33	2.44e-5	Bone mineral density;
PAAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg14847009	chr1:175162515	KIAA0040	-0.4	-6.27	-0.45	3.49e-9	Alcohol dependence;
PAAD	cis	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg21605333	chr4:119757512	SEC24D	1.24	7.71	0.53	1.56e-12	Cannabis dependence symptom count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26351481	chr19:56458926	NLRP8	-0.57	-6.45	-0.46	1.41e-9	Obesity-related traits;
PAAD	cis	rs1884136	0.908	rs73604341	chr20:10860872	G/T	cg12909741	chr20:10199469	SNAP25	-0.66	-4.27	-0.33	3.4e-5	Information processing speed;
PAAD	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.96	10.37	0.64	2.12e-19	Multiple sclerosis;
PAAD	cis	rs682748	0.846	rs12655526	chr5:17128613	A/G	cg23987134	chr5:17158319	LOC285696	-0.36	-4.49	-0.34	1.39e-5	Hippocampal atrophy;
PAAD	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.46	-4.46	-0.34	1.55e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.55	-4.57	-0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg12639453	chr1:2035780	PRKCZ	-0.57	-6.13	-0.45	7.14e-9	Height;
PAAD	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.56	-5.44	-0.4	2.08e-7	Blood protein levels;
PAAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.44	4.84	0.37	3.18e-6	Bipolar disorder;
PAAD	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg23659134	chr10:106035168	GSTO2	-0.33	-4.73	-0.36	5e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.6	-6.99	-0.49	8.24e-11	Menopause (age at onset);
PAAD	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.44	-4.62	-0.35	8.17e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.67	4.62	0.35	7.99e-6	Mean platelet volume;
PAAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22601191	chr20:60968625	CABLES2	0.51	4.67	0.35	6.71e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.43	-4.65	-0.35	7.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg22517653	chr1:2918612	NA	-0.63	-5.01	-0.38	1.52e-6	Plateletcrit;
PAAD	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg08992911	chr2:238395768	MLPH	0.66	6.52	0.47	9.91e-10	Prostate cancer;
PAAD	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.52	-4.96	-0.37	1.86e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.98	10.76	0.66	2.03e-20	Multiple myeloma;
PAAD	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.59	-7.56	-0.52	3.6e-12	Lewy body disease;
PAAD	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.6	-7.05	-0.5	5.78e-11	Aortic root size;
PAAD	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg07159951	chr1:45983175	PRDX1	0.45	4.87	0.37	2.78e-6	High light scatter reticulocyte count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg14599284	chr5:167719687	WWC1	0.5	6.9	0.49	1.29e-10	Myopia (pathological);
PAAD	cis	rs3787159	0.573	rs556933	chr20:56890340	G/C	cg15032960	chr20:56888536	RAB22A	-0.41	-4.41	-0.34	1.96e-5	Systolic blood pressure;
PAAD	cis	rs988913	1.000	rs7744592	chr6:54826345	A/G	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.29	-12.33	-0.71	1.2e-24	Hip circumference adjusted for BMI;
PAAD	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.95	12.83	0.72	5.43e-26	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg23460851	chr4:1604456	NA	-0.41	-4.29	-0.33	3.18e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-5.8	-0.43	3.7e-8	Total body bone mineral density;
PAAD	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.26	-0.51	1.91e-11	Response to antipsychotic treatment;
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg20302533	chr7:39170763	POU6F2	0.45	6.92	0.49	1.17e-10	IgG glycosylation;
PAAD	cis	rs2882667	0.690	rs288032	chr5:138215328	G/A	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7551345	0.853	rs57186798	chr1:31794886	G/A	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg05895507	chr15:77155635	SCAPER	-0.42	-4.46	-0.34	1.57e-5	Blood metabolite levels;
PAAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.72	6.61	0.47	6.16e-10	Menarche (age at onset);
PAAD	cis	rs757081	0.648	rs10766382	chr11:17274441	A/T	cg04705435	chr11:17411270	KCNJ11	-0.54	-5.4	-0.4	2.5e-7	Systolic blood pressure;
PAAD	cis	rs2236267	0.700	rs11159841	chr14:88587120	T/C	cg18078958	chr14:88630771	NA	0.51	6.4	0.46	1.8e-9	Food antigen IgG levels;
PAAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.57	5.04	0.38	1.32e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg09127314	chr1:152161683	NA	0.62	4.61	0.35	8.61e-6	Atopic dermatitis;
PAAD	cis	rs12967884	1.000	rs12967884	chr18:76591635	A/G	cg16859165	chr18:76601647	NA	-0.54	-4.37	-0.33	2.26e-5	Subcutaneous adipose tissue;
PAAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.72	6.33	0.46	2.68e-9	Inflammatory skin disease;
PAAD	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.5	4.71	0.36	5.45e-6	Hepatocellular carcinoma;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg19493204	chr4:39184019	WDR19	0.58	6.31	0.46	2.96e-9	Myopia (pathological);
PAAD	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg22143856	chr6:28129313	ZNF389	0.52	4.79	0.36	3.98e-6	Parkinson's disease;
PAAD	cis	rs1012068	0.695	rs5998152	chr22:32263162	T/C	cg01338084	chr22:32026380	PISD	0.65	6.0	0.44	1.39e-8	Chronic hepatitis C infection;
PAAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.89	10.46	0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.86	11.26	0.67	9.12e-22	Vitiligo;
PAAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg15181151	chr6:150070149	PCMT1	0.51	5.29	0.39	4.1e-7	Lung cancer;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg25487775	chr2:162093969	NA	0.57	5.48	0.41	1.72e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-4.52	-0.34	1.25e-5	Personality dimensions;
PAAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg00579200	chr11:133705235	NA	-0.43	-4.74	-0.36	4.79e-6	Childhood ear infection;
PAAD	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg04717802	chr22:42394638	WBP2NL	0.5	4.29	0.33	3.23e-5	Birth weight;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.67	6.98	0.49	8.62e-11	Lung cancer;
PAAD	cis	rs6700896	0.500	rs12145237	chr1:66124882	C/T	cg04111102	chr1:66153794	NA	0.48	4.45	0.34	1.64e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg18850127	chr7:39170497	POU6F2	0.44	6.02	0.44	1.25e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01765077	chr12:122356316	WDR66	0.67	7.03	0.5	6.52e-11	Mean corpuscular volume;
PAAD	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.26	-0.39	4.89e-7	Neuroticism;
PAAD	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.47	-4.89	-0.37	2.56e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-6.85	-0.49	1.72e-10	Bipolar disorder and schizophrenia;
PAAD	trans	rs10438933	0.831	rs8093931	chr18:29256118	G/A	cg21088259	chr17:81039990	METRNL	-0.86	-6.3	-0.46	3.1e-9	Amyotrophic lateral sclerosis;
PAAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg20893579	chr22:38215064	NA	0.52	5.18	0.39	6.88e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.63	-7.89	-0.54	5.42e-13	Schizophrenia;
PAAD	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg08999081	chr20:33150536	PIGU	-0.54	-6.07	-0.44	9.68e-9	Height;
PAAD	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	6.6e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.56	-6.36	-0.46	2.23e-9	Post bronchodilator FEV1;
PAAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg02841227	chr6:26021843	HIST1H4A	0.46	4.56	0.35	1.04e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg26174226	chr8:58114915	NA	-0.65	-5.71	-0.42	5.85e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.33	6.11	0.44	8.05e-9	Type 2 diabetes;
PAAD	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.8	-0.62	6.88e-18	Response to antipsychotic treatment;
PAAD	cis	rs922692	1.000	rs4887077	chr15:78978364	A/G	cg00540400	chr15:79124168	NA	0.45	4.99	0.38	1.65e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs7172971	0.688	rs112154535	chr15:42381925	T/G	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.12	0.63	1.03e-18	Prudent dietary pattern;
PAAD	cis	rs8077577	0.689	rs16961133	chr17:18223548	C/T	cg16794390	chr17:18148240	FLII	0.5	4.33	0.33	2.71e-5	Obesity-related traits;
PAAD	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.51	-4.76	-0.36	4.43e-6	Dental caries;
PAAD	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.58	4.72	0.36	5.22e-6	Plateletcrit;
PAAD	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.74	-8.17	-0.55	1.12e-13	Bipolar disorder;
PAAD	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg00717180	chr2:96193071	NA	-0.61	-6.69	-0.48	3.96e-10	HDL cholesterol;
PAAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	Childhood ear infection;
PAAD	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.62	-5.63	-0.42	8.42e-8	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.55	-5.87	-0.43	2.69e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.87	9.79	0.62	7.42e-18	Prudent dietary pattern;
PAAD	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.93	-5.81	-0.43	3.55e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg26220594	chr1:19110978	NA	-0.65	-5.37	-0.4	2.9e-7	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg00576331	chr11:65640516	EFEMP2	0.64	5.73	0.42	5.12e-8	DNA methylation (variation);
PAAD	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.52	7.01	0.49	7.42e-11	Life satisfaction;
PAAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.75	7.33	0.51	1.3e-11	Obesity-related traits;
PAAD	trans	rs901683	1.000	rs71496610	chr10:46021646	C/G	cg11747279	chr17:21096632	NA	0.76	6.34	0.46	2.52e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg18769074	chr3:133464867	TF	0.42	4.9	0.37	2.4e-6	Iron status biomarkers;
PAAD	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.6	5.83	0.43	3.24e-8	Height;
PAAD	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.65	7.13	0.5	3.76e-11	Testicular germ cell tumor;
PAAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg24699146	chr1:24152579	HMGCL	-0.53	-5.51	-0.41	1.48e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.51	-4.28	-0.33	3.27e-5	Neuroticism;
PAAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.8	5.99	0.44	1.43e-8	Vitiligo;
PAAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-4.59	-0.35	9.24e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3996993	0.686	rs2608624	chr6:52622475	G/T	cg00536792	chr6:53530503	KLHL31	0.47	4.95	0.37	1.94e-6	Hemoglobin concentration;
PAAD	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg13263323	chr15:86062960	AKAP13	-0.63	-7.18	-0.5	2.84e-11	Interstitial lung disease;
PAAD	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.19	-0.5	2.67e-11	Response to antipsychotic treatment;
PAAD	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.57	5.5	0.41	1.56e-7	Neuroticism;
PAAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.4	2.08e-7	Testicular germ cell tumor;
PAAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.74	7.78	0.53	1e-12	Coronary artery disease;
PAAD	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.79	9.18	0.6	2.87e-16	Mean platelet volume;
PAAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg03676636	chr4:99064102	C4orf37	-0.25	-4.31	-0.33	2.94e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg05333889	chr7:157238977	NA	-0.46	-4.85	-0.37	3.07e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs9398803	0.624	rs9372837	chr6:126638124	G/A	cg19875578	chr6:126661172	C6orf173	0.49	4.62	0.35	8.18e-6	Male-pattern baldness;
PAAD	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg23601416	chr22:19950040	COMT	-0.3	-4.74	-0.36	4.92e-6	Blood metabolite levels;
PAAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.88	8.04	0.55	2.31e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg08732750	chr1:87598351	LOC339524	-0.34	-4.78	-0.36	4.07e-6	Smoking behavior;
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22601191	chr20:60968625	CABLES2	0.52	5.16	0.39	7.57e-7	Colorectal cancer;
PAAD	cis	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg19558802	chr15:51695713	GLDN	-0.42	-4.31	-0.33	2.9e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg21823605	chr1:152486609	CRCT1	-0.46	-5.82	-0.43	3.42e-8	Hair morphology;
PAAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7620363	0.859	rs6807929	chr3:34079439	C/T	cg02064073	chr3:33155252	CRTAP	-0.5	-4.31	-0.33	2.97e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg05697835	chr1:2722811	NA	0.38	4.35	0.33	2.53e-5	Ulcerative colitis;
PAAD	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.12	-0.38	9.31e-7	Mood instability;
PAAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.43	-4.35	-0.33	2.46e-5	Tonsillectomy;
PAAD	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.39	4.86	0.37	2.89e-6	Pulmonary function;
PAAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	4.83	0.36	3.26e-6	Menopause (age at onset);
PAAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06753367	chr22:24256600	NA	-0.42	-4.39	-0.34	2.16e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs939584	1.000	rs7591067	chr2:642846	G/A	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs829661	0.895	rs9309680	chr2:30785950	T/C	cg12454169	chr2:30669597	LCLAT1	0.63	4.97	0.37	1.78e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
PAAD	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg27478167	chr7:817139	HEATR2	0.7	5.35	0.4	3.18e-7	Cerebrospinal P-tau181p levels;
PAAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.13	-17.03	-0.81	4.59e-37	Prudent dietary pattern;
PAAD	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-1.07	-9.62	-0.62	2.05e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18621852	chr3:10150065	C3orf24	0.71	6.01	0.44	1.35e-8	Alzheimer's disease;
PAAD	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg16606324	chr3:10149918	C3orf24	0.57	4.81	0.36	3.53e-6	Alzheimer's disease;
PAAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21211367	chr2:162094118	NA	0.5	4.94	0.37	2.08e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs911555	0.713	rs11848796	chr14:103978686	T/C	cg12935359	chr14:103987150	CKB	-0.6	-5.97	-0.44	1.58e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.57	-6.89	-0.49	1.38e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-5.87	-0.43	2.66e-8	Schizophrenia;
PAAD	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-0.93	-9.23	-0.6	2.13e-16	Exhaled nitric oxide output;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.54	-0.41	1.27e-7	Mood instability;
PAAD	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.54	4.82	0.36	3.41e-6	Type 2 diabetes;
PAAD	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.84	10.72	0.66	2.6e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.67	5.71	0.42	5.71e-8	Gut microbiome composition (summer);
PAAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.92	-11.57	-0.68	1.35e-22	Coronary artery disease;
PAAD	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.93	5.76	0.42	4.56e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg16950941	chr11:66035639	RAB1B	0.59	4.67	0.35	6.56e-6	Electroencephalogram traits;
PAAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.42	4.29	0.33	3.14e-5	Tonsillectomy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26206990	chr15:63569719	APH1B	0.67	7.4	0.51	8.56e-12	Myopia (pathological);
PAAD	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg23587288	chr2:27483067	SLC30A3	-0.83	-7.27	-0.51	1.76e-11	Blood metabolite levels;
PAAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg21951975	chr1:209979733	IRF6	0.55	5.38	0.4	2.71e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg17633681	chr16:88106987	BANP	0.61	7.33	0.51	1.24e-11	Menopause (age at onset);
PAAD	cis	rs17125944	0.615	rs11629431	chr14:53320528	C/G	cg00686598	chr14:53173677	PSMC6	-0.96	-5.94	-0.43	1.88e-8	Alzheimer's disease (late onset);
PAAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.49	5.03	0.38	1.34e-6	Major depressive disorder;
PAAD	trans	rs3733631	1.000	rs28688000	chr4:104620713	A/G	cg21490444	chr5:171095097	NA	0.75	6.29	0.45	3.13e-9	Menarche (age at onset);
PAAD	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	1.79	10.27	0.64	4.02e-19	Cannabis dependence symptom count;
PAAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.57	-6.91	-0.49	1.22e-10	Blood pressure (smoking interaction);
PAAD	cis	rs2992756	0.663	rs2992735	chr1:18800387	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-6.44	-0.46	1.49e-9	Breast cancer;
PAAD	cis	rs58521262	0.556	rs289321	chr19:23157281	T/C	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg20913747	chr6:44695427	NA	-0.68	-6.72	-0.48	3.52e-10	Total body bone mineral density;
PAAD	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	trans	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.7	-5.3	-0.39	3.99e-7	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.57	4.99	0.38	1.65e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg04289385	chr6:36355825	ETV7	0.44	4.41	0.34	1.96e-5	Platelet distribution width;
PAAD	cis	rs12935418	0.672	rs2549879	chr16:81046101	A/G	cg16651780	chr16:81037892	C16orf61	-0.69	-6.53	-0.47	9.35e-10	Mean corpuscular volume;
PAAD	cis	rs11618113	0.634	rs28575062	chr13:111183199	C/T	cg11688093	chr13:111178359	RAB20	-0.72	-4.52	-0.34	1.26e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg24881330	chr22:46731750	TRMU	0.6	4.45	0.34	1.68e-5	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs7246865	0.531	rs8103913	chr19:17166229	G/C	cg19418318	chr19:17219073	MYO9B	0.36	5.23	0.39	5.59e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs4668356	1.000	rs55885449	chr2:171933839	G/C	cg13882835	chr2:172017928	TLK1	0.91	4.84	0.37	3.18e-6	Cognitive performance;
PAAD	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.94	-9.06	-0.59	6.07e-16	Exhaled nitric oxide output;
PAAD	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg12549451	chr6:135224345	NA	0.47	4.79	0.36	4.01e-6	Red blood cell count;
PAAD	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	1.03	8.3	0.56	5.29e-14	IgG glycosylation;
PAAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.64	6.84	0.49	1.77e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2904967	0.636	rs239253	chr11:64984743	C/T	cg11802864	chr11:65308245	LTBP3	-0.5	-4.45	-0.34	1.65e-5	Mean corpuscular volume;
PAAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg14393609	chr7:65229607	NA	0.46	4.72	0.36	5.32e-6	Aortic root size;
PAAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg03676636	chr4:99064102	C4orf37	0.24	4.33	0.33	2.69e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	4.52	0.34	1.25e-5	Tonsillectomy;
PAAD	cis	rs4740619	0.875	rs6474966	chr9:15757537	G/A	cg14451791	chr9:16040625	NA	-0.38	-4.45	-0.34	1.67e-5	Body mass index;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg09826364	chr7:158789723	NA	-0.4	-5.11	-0.38	9.39e-7	Facial morphology (factor 20);
PAAD	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.52	4.9	0.37	2.43e-6	Schizophrenia;
PAAD	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.4	4.97	0.37	1.79e-6	Pulmonary function;
PAAD	cis	rs258892	0.843	rs10053857	chr5:72042019	C/T	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.56	5.25	0.39	5e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.7	-5.86	-0.43	2.83e-8	Type 2 diabetes;Type 1 diabetes;
PAAD	cis	rs740474	0.831	rs2302103	chr5:140955777	C/T	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.29	4.28	0.33	3.31e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs501120	0.584	rs11591406	chr10:44690710	G/A	cg09554077	chr10:44749378	NA	0.45	5.3	0.4	3.94e-7	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs6558174	0.802	rs3758040	chr8:22487087	T/C	cg03733263	chr8:22462867	KIAA1967	0.47	4.34	0.33	2.58e-5	Breast cancer;
PAAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.94	10.49	0.65	1.03e-19	Tonsillectomy;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12593849	chr1:28150710	STX12	-0.6	-6.44	-0.46	1.47e-9	Obesity-related traits;
PAAD	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-1.01	-9.16	-0.6	3.35e-16	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03676636	chr4:99064102	C4orf37	0.29	5.44	0.4	2.06e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10949834	0.824	rs2285026	chr7:73530404	C/T	cg07137043	chr7:73588983	EIF4H	-0.6	-4.51	-0.34	1.29e-5	Verbal memory performance (residualized delayed recall change);
PAAD	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg26695010	chr11:65641043	EFEMP2	-0.64	-5.72	-0.42	5.62e-8	DNA methylation (variation);
PAAD	cis	rs2882667	0.654	rs2940595	chr5:138101037	A/G	cg09476006	chr5:138032270	NA	-0.46	-5.89	-0.43	2.38e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg07541023	chr7:19748670	TWISTNB	0.57	4.32	0.33	2.79e-5	Thyroid stimulating hormone;
PAAD	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	10.39	0.64	1.91e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg08200582	chr11:442649	ANO9	0.51	4.37	0.33	2.31e-5	Systemic lupus erythematosus;
PAAD	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg19217778	chr13:113420270	ATP11A	0.63	4.37	0.33	2.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.64	7.02	0.49	7.08e-11	Height;
PAAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.34	8.1	0.55	1.71e-13	Skin colour saturation;
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs12594515	0.694	rs2068295	chr15:45985546	T/C	cg06207120	chr15:45996521	NA	0.29	4.28	0.33	3.36e-5	Waist circumference;Weight;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07489553	chr2:9771190	YWHAQ	0.64	7.2	0.5	2.58e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg03433033	chr1:76189801	ACADM	-0.49	-5.09	-0.38	1.02e-6	Daytime sleep phenotypes;
PAAD	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26926768	chr12:34528122	NA	0.39	4.69	0.36	5.97e-6	Morning vs. evening chronotype;
PAAD	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg15605315	chr1:45957053	TESK2	0.4	4.44	0.34	1.7e-5	High light scatter reticulocyte count;
PAAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	4.36	0.33	2.36e-5	Aortic root size;
PAAD	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg00631329	chr6:26305371	NA	-0.61	-7.58	-0.52	3.1e-12	Educational attainment;
PAAD	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg23331303	chr5:5135948	NA	0.47	6.6	0.47	6.41e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.8	8.69	0.58	5.27e-15	Mortality in heart failure;
PAAD	cis	rs458685	0.636	rs459969	chr21:31189387	A/G	cg24620508	chr21:31310605	GRIK1	-0.49	-4.52	-0.34	1.23e-5	Breast cancer;
PAAD	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg20312557	chr2:97357134	FER1L5	-0.85	-4.39	-0.34	2.09e-5	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.45	4.81e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8133932	0.667	rs2839033	chr21:47296381	T/C	cg13695288	chr21:47294981	PCBP3	-0.48	-4.68	-0.35	6.27e-6	Schizophrenia;
PAAD	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg05585544	chr11:47624801	NA	-0.46	-5.09	-0.38	1.06e-6	Subjective well-being;
PAAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg18279126	chr7:2041391	MAD1L1	0.57	5.39	0.4	2.59e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17884169	chr20:31446444	EFCAB8	-0.74	-7.9	-0.54	5.09e-13	Obesity-related traits;
PAAD	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.68	8.84	0.58	2.23e-15	Hemoglobin concentration;
PAAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.61	4.96	0.37	1.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.76	8.34	0.56	4.15e-14	Body mass index;
PAAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg09677638	chr11:61582810	MIR1908;FADS1	-0.56	-4.94	-0.37	2.07e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
PAAD	cis	rs9900972	0.851	rs62077283	chr17:76868135	T/C	cg00961940	chr17:76876995	TIMP2	0.54	5.12	0.38	9.13e-7	Obesity-related traits;
PAAD	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg08601574	chr20:25228251	PYGB	-0.61	-6.84	-0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.74	8.33	0.56	4.35e-14	Prostate cancer;
PAAD	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.43	4.38	0.33	2.17e-5	Mean corpuscular volume;
PAAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.01	0.49	7.15e-11	Rheumatoid arthritis;
PAAD	cis	rs943466	1.000	rs6921487	chr6:33749293	G/A	cg04704449	chr6:33738291	NA	-0.46	-4.86	-0.37	2.96e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-7.77	-0.53	1.09e-12	Colorectal cancer;
PAAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-4.49	-0.34	1.39e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15432125	chr11:1593555	HCCA2;LOC338651;DUSP8	-0.68	-6.86	-0.49	1.59e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.46e-7	Migraine;
PAAD	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.7	7.88	0.54	6e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	6.69	0.48	3.97e-10	High light scatter reticulocyte count;
PAAD	cis	rs2899832	0.866	rs743226	chr14:35775561	A/G	cg09327582	chr14:35236912	BAZ1A	0.58	4.55	0.35	1.07e-5	Response to zileuton treatment in asthma (FEV1 change interaction);
PAAD	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg11380483	chr2:127933992	NA	-0.48	-4.71	-0.36	5.45e-6	Self-rated health;
PAAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.8	7.39	0.51	9.01e-12	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.36	4.64	0.35	7.62e-6	Prostate cancer;
PAAD	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.55	4.99	0.38	1.61e-6	Type 2 diabetes;
PAAD	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-5.99	-0.44	1.43e-8	Body mass index (adult);
PAAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg06074448	chr4:187884817	NA	-0.63	-8.08	-0.55	1.92e-13	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.12	-0.63	9.85e-19	Response to antipsychotic treatment;
PAAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	0.98	10.95	0.66	6.25e-21	Menopause (age at onset);
PAAD	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.91	11.81	0.69	2.99e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.61	6.51	0.47	1.02e-9	Crohn's disease;
PAAD	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg14458575	chr2:238380390	NA	0.93	4.73	0.36	5.08e-6	Prostate cancer;
PAAD	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.9	0.37	2.41e-6	Blood metabolite levels;
PAAD	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg13263323	chr15:86062960	AKAP13	-0.56	-6.11	-0.44	7.93e-9	Interstitial lung disease;
PAAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.44	-4.48	-0.34	1.46e-5	Iron status biomarkers;
PAAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	6.27	0.45	3.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg08132940	chr7:1081526	C7orf50	-0.65	-4.6	-0.35	8.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.3e-7	Monocyte percentage of white cells;
PAAD	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.91	12.07	0.7	6.12e-24	Body mass index;
PAAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	5.63	0.42	8.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.07	0.38	1.13e-6	Childhood ear infection;
PAAD	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.88	11.42	0.68	3.36e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.7	-7.55	-0.52	3.77e-12	Response to antipsychotic treatment;
PAAD	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg19197139	chr17:4613644	ARRB2	-0.82	-8.56	-0.57	1.15e-14	Lymphocyte counts;
PAAD	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	1.02	12.42	0.71	6.67e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg04482110	chr17:41364121	TMEM106A	0.39	4.33	0.33	2.64e-5	Menopause (age at onset);
PAAD	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.69	7.3	0.51	1.53e-11	Osteoporosis;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.47	0.46	1.26e-9	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19590674	chr17:25783100	NA	-0.57	-6.55	-0.47	8.42e-10	Body fat percentage;
PAAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-17.3	-0.81	9.35e-38	Height;
PAAD	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.82	9.65	0.62	1.74e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg23912435	chr1:150601613	ENSA	0.52	4.79	0.36	3.86e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.76	5.98	0.44	1.51e-8	Height;
PAAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.47	4.63	0.35	7.78e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.37	-0.33	2.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2320952	0.874	rs8072621	chr17:10485793	T/G	cg19806995	chr17:9728972	GLP2R	0.39	4.51	0.34	1.27e-5	Gut microbiome composition (winter);
PAAD	cis	rs79839061	0.732	rs11734742	chr4:821565	C/T	cg07828340	chr4:882639	GAK	1.22	6.41	0.46	1.74e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.55	-5.59	-0.41	1.03e-7	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.74	8.84	0.58	2.16e-15	Hand grip strength;
PAAD	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.68	-6.76	-0.48	2.81e-10	Subjective well-being;
PAAD	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.56	-7.05	-0.5	5.8e-11	Atrioventricular conduction;
PAAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-4.35	-0.33	2.53e-5	Height;
PAAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.07	0.44	9.69e-9	Schizophrenia;
PAAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.07	19.1	0.84	3.09e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1419980	0.730	rs11054878	chr12:7771564	C/G	cg25828445	chr12:7781288	NA	-0.9	-4.68	-0.35	6.37e-6	HDL cholesterol levels;
PAAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Body mass index;
PAAD	cis	rs6537837	1.000	rs6682956	chr1:110130264	G/A	cg05049280	chr1:110155535	GNAT2	0.46	4.61	0.35	8.43e-6	Major depressive disorder;
PAAD	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs2916733	0.607	rs2922821	chr8:6313859	G/A	cg02465761	chr8:6735510	DEFB1	0.47	4.53	0.35	1.18e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.83	-10.1	-0.63	1.14e-18	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg05552183	chr6:42928497	GNMT	0.7	5.85	0.43	2.96e-8	Blood protein levels;
PAAD	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	1.12	7.3	0.51	1.47e-11	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.75	-6.23	-0.45	4.32e-9	Neuroticism;
PAAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg03517284	chr6:25882590	NA	-0.57	-4.7	-0.36	5.73e-6	Iron status biomarkers;
PAAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.57	6.69	0.48	4.05e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.99	8.63	0.57	7.84e-15	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.56	5.53	0.41	1.39e-7	Menarche (age at onset);
PAAD	cis	rs6844506	1.000	rs4862356	chr4:185220262	A/G	cg12654155	chr4:185238627	NA	0.54	5.04	0.38	1.33e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
PAAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.75	10.64	0.65	4.15e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	6.92	0.49	1.17e-10	Renal function-related traits (BUN);
PAAD	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg04287289	chr16:89883240	FANCA	0.92	4.62	0.35	8.16e-6	Skin colour saturation;
PAAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg03517284	chr6:25882590	NA	-0.56	-4.63	-0.35	7.67e-6	Iron status biomarkers;
PAAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.79	5.47	0.41	1.84e-7	Gut microbiome composition (summer);
PAAD	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.67	6.98	0.49	8.37e-11	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs28795989	0.795	rs17833038	chr4:7918593	A/T	cg18538662	chr4:7941764	AFAP1	0.44	4.55	0.35	1.09e-5	Intraocular pressure;
PAAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg24846680	chr1:228362309	C1orf69	0.46	4.4	0.34	2.04e-5	Diastolic blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19189012	chr12:56401370	NA	0.65	7.63	0.53	2.34e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.88	5.87	0.43	2.58e-8	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs1371614	0.545	rs4665930	chr2:27173520	C/T	cg00617064	chr2:27272375	NA	0.45	4.6	0.35	8.67e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs818427	0.684	rs501250	chr5:112155793	C/G	cg06941702	chr5:112196734	SRP19	-0.49	-4.41	-0.34	1.98e-5	Total body bone mineral density;
PAAD	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.41	-4.97	-0.37	1.75e-6	Asthma;
PAAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.75	7.32	0.51	1.33e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	0.93	6.28	0.45	3.34e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	trans	rs10507419	1.000	rs3858856	chr13:35182959	A/G	cg07531020	chr16:48278143	LONP2	-0.77	-6.43	-0.46	1.58e-9	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
PAAD	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.03	0.5	6.42e-11	Eye color traits;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19280121	chr17:21117780	TMEM11	0.59	6.47	0.46	1.25e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.08	0.44	9.42e-9	Personality dimensions;
PAAD	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg03871329	chr12:110338662	TCHP	-0.68	-5.04	-0.38	1.33e-6	Neuroticism;
PAAD	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.62	-5.12	-0.38	9.01e-7	IgG glycosylation;
PAAD	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg10467557	chr13:21893662	NA	-0.45	-4.83	-0.36	3.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18032744	chr13:80914295	SPRY2	0.63	6.67	0.48	4.4e-10	Myopia (pathological);
PAAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.86	-10.81	-0.66	1.46e-20	Aortic root size;
PAAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2834256	0.527	rs9983901	chr21:34866853	C/T	cg14850771	chr21:34775459	IFNGR2	0.43	4.53	0.35	1.18e-5	Red cell distribution width;
PAAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.65	7.03	0.5	6.4e-11	Bipolar disorder and schizophrenia;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg25155009	chr1:206859067	MAPKAPK2	-0.58	-7.01	-0.49	7.19e-11	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg03517284	chr6:25882590	NA	-0.55	-4.59	-0.35	9.11e-6	Iron status biomarkers;
PAAD	cis	rs501120	1.000	rs527785	chr10:44762686	G/A	cg09554077	chr10:44749378	NA	0.48	6.2	0.45	5.14e-9	Coronary artery disease;Coronary heart disease;
PAAD	cis	rs7552393	0.568	rs2007415	chr1:84267113	A/C	cg10977910	chr1:84465055	TTLL7	0.56	5.28	0.39	4.39e-7	Select biomarker traits;
PAAD	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.62	-4.76	-0.36	4.38e-6	Breast cancer;
PAAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg05110241	chr16:68378359	PRMT7	-0.93	-7.29	-0.51	1.61e-11	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.54	-5.29	-0.39	4.26e-7	Tonsillectomy;
PAAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.24e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg20243544	chr17:37824526	PNMT	0.52	4.67	0.35	6.67e-6	Self-reported allergy;
PAAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12963246	chr6:28129442	ZNF389	0.67	4.8	0.36	3.73e-6	Depression;
PAAD	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.76	11.75	0.69	4.46e-23	Breast cancer;
PAAD	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.61	6.64	0.47	5.1e-10	Aortic root size;
PAAD	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg23649088	chr2:200775458	C2orf69	-0.65	-5.6	-0.41	9.71e-8	Schizophrenia;
PAAD	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg08601574	chr20:25228251	PYGB	0.66	7.33	0.51	1.29e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg18279126	chr7:2041391	MAD1L1	0.55	5.54	0.41	1.29e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.76	6.06	0.44	1.02e-8	HDL cholesterol;
PAAD	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	1.05	6.61	0.47	6.08e-10	Gut microbiota (bacterial taxa);
PAAD	cis	rs7009516	0.669	rs13270982	chr8:24248552	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.49	-5.78	-0.42	4.17e-8	Hair greying;
PAAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.06	0.38	1.21e-6	Breast cancer;
PAAD	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	1.17	10.97	0.66	5.35e-21	Colorectal cancer;
PAAD	cis	rs2279817	0.731	rs11203434	chr1:18010189	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-6.18	-0.45	5.69e-9	Neuroticism;
PAAD	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.62	5.53	0.41	1.39e-7	Diastolic blood pressure;
PAAD	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	1.07	8.42	0.56	2.65e-14	Inflammatory bowel disease;
PAAD	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.58	5.12	0.38	8.95e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13047869	chr3:10149882	C3orf24	0.79	6.59	0.47	6.78e-10	Alzheimer's disease;
PAAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg09471204	chr22:42347991	LOC339674	0.34	4.47	0.34	1.51e-5	Cognitive function;
PAAD	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.65	-5.54	-0.41	1.28e-7	Type 2 diabetes;
PAAD	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	1.01	4.96	0.37	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg09127314	chr1:152161683	NA	0.67	4.94	0.37	2.05e-6	Atopic dermatitis;
PAAD	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.49	-5.47	-0.41	1.85e-7	Migraine - clinic-based;
PAAD	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.89	-8.85	-0.58	2.12e-15	Ulcerative colitis;
PAAD	cis	rs990171	0.802	rs1558650	chr2:103060024	T/A	cg03938978	chr2:103052716	IL18RAP	0.45	4.43	0.34	1.77e-5	Lymphocyte counts;
PAAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.73	-6.0	-0.44	1.37e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.49	6.05	0.44	1.09e-8	Sitting height ratio;
PAAD	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.67	-6.36	-0.46	2.2e-9	Hip circumference;
PAAD	cis	rs868943	0.743	rs10457303	chr6:116413841	C/T	cg15226275	chr6:116381976	FRK	0.3	5.57	0.41	1.12e-7	Total cholesterol levels;
PAAD	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.67	-7.05	-0.5	5.78e-11	Systolic blood pressure;
PAAD	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.79	-8.11	-0.55	1.6e-13	Schizophrenia;
PAAD	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-4.91	-0.37	2.29e-6	Pulmonary function;
PAAD	cis	rs3018712	0.700	rs2510387	chr11:68445902	A/G	cg23009355	chr11:68451396	GAL	0.53	4.88	0.37	2.67e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.87	9.87	0.62	4.67e-18	Prudent dietary pattern;
PAAD	cis	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg21775007	chr8:11205619	TDH	-0.5	-4.78	-0.36	4.04e-6	Neuroticism;
PAAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg21890820	chr11:65308645	LTBP3	0.66	8.05	0.55	2.2e-13	Bone mineral density;
PAAD	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-4.36	-0.33	2.41e-5	White blood cell count;
PAAD	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg22143635	chr11:980567	AP2A2	0.53	5.6	0.41	9.69e-8	Alzheimer's disease (late onset);
PAAD	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.52	5.0	0.38	1.56e-6	Erythrocyte sedimentation rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17175136	chr7:98608857	TRRAP	-0.56	-6.29	-0.45	3.28e-9	Monocyte percentage of white cells;
PAAD	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.49	4.57	0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.54	-0.35	1.12e-5	Breast cancer;
PAAD	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.48	-7.9	-0.54	5.25e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs62025270	0.688	rs62022940	chr15:86252520	T/C	cg13263323	chr15:86062960	AKAP13	0.47	4.25	0.33	3.67e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.77	-8.99	-0.59	8.9e-16	Hemoglobin concentration;
PAAD	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.28	-0.39	4.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	4.41	0.34	1.95e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg18833306	chr6:118973337	C6orf204	-0.58	-4.63	-0.35	7.67e-6	Diastolic blood pressure;
PAAD	cis	rs11264799	0.716	rs1113662	chr1:157635825	T/C	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.88e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs600550	0.588	rs11230240	chr11:60072975	A/G	cg05040360	chr11:60102449	MS4A6E	0.42	4.88	0.37	2.61e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.63	-6.6	-0.47	6.59e-10	Body mass index;
PAAD	cis	rs8032158	1.000	rs11633263	chr15:56135559	A/C	cg02198044	chr15:56286336	NEDD4	-0.52	-5.51	-0.41	1.47e-7	Keloid;
PAAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg11764359	chr7:65958608	NA	0.75	4.96	0.37	1.86e-6	Diabetic kidney disease;
PAAD	cis	rs7127900	0.904	rs7123418	chr11:2232378	A/C	cg25635251	chr11:2234043	NA	0.84	7.4	0.51	8.47e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.52	4.67	0.35	6.65e-6	Lymphocyte counts;
PAAD	cis	rs793571	0.611	rs1446240	chr15:59296491	G/T	cg05156742	chr15:59063176	FAM63B	0.53	4.28	0.33	3.33e-5	Schizophrenia;
PAAD	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.78	9.92	0.63	3.34e-18	Bone mineral density;
PAAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	1.05	14.28	0.76	6.96e-30	Menarche (age at onset);
PAAD	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.34	8.06	0.55	2.06e-13	Skin colour saturation;
PAAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg14393609	chr7:65229607	NA	-0.46	-4.45	-0.34	1.64e-5	Aortic root size;
PAAD	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.53	-6.06	-0.44	1.04e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs6074578	0.709	rs1594917	chr20:143723	G/A	cg16931068	chr20:139680	DEFB127	0.38	5.19	0.39	6.71e-7	Hirschsprung disease;
PAAD	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.7	-5.78	-0.42	4.01e-8	Schizophrenia;
PAAD	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.61	-0.47	6.26e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.33	4.67	0.35	6.53e-6	Asthma;
PAAD	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.47	7.71	0.53	1.56e-12	Neuroticism;
PAAD	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs16975963	0.644	rs73037036	chr19:38161070	A/T	cg14218481	chr19:38281219	NA	0.43	4.58	0.35	9.45e-6	Longevity;
PAAD	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	cg13376598	chr11:24518225	LUZP2	-0.54	-4.5	-0.34	1.37e-5	Response to Homoharringtonine (cytotoxicity);
PAAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12751404	chr1:11866034	MTHFR;CLCN6	0.62	7.26	0.51	1.82e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.56	-0.35	1.03e-5	Menarche (age at onset);
PAAD	cis	rs2173063	0.730	rs16947100	chr15:93143347	G/A	cg05110962	chr15:93139494	NA	0.69	4.36	0.33	2.39e-5	Subcutaneous adipose tissue;
PAAD	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg05585544	chr11:47624801	NA	-0.51	-5.83	-0.43	3.17e-8	Subjective well-being;
PAAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg14926445	chr8:58193284	C8orf71	-0.69	-5.59	-0.41	1.02e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-10.03	-0.63	1.74e-18	Body mass index;
PAAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.69	8.16	0.55	1.15e-13	Schizophrenia;
PAAD	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg03989125	chr22:38214979	NA	0.6	5.48	0.41	1.76e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.93	-9.21	-0.6	2.52e-16	Asthma;
PAAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-5.18	-0.39	6.92e-7	Lymphocyte counts;
PAAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.62	6.25	0.45	3.97e-9	Menopause (age at onset);
PAAD	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg19423196	chr10:82049429	MAT1A	0.61	4.69	0.36	6.03e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.08	-0.5	4.96e-11	Colorectal cancer;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12772971	chr4:106630100	GSTCD;INTS12	-0.74	-6.6	-0.47	6.56e-10	Neuroticism;
PAAD	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.91	-8.28	-0.56	5.74e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.59	-0.35	9.2e-6	Biliary atresia;
PAAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	9.91	0.63	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs11853189	1.000	rs11853189	chr15:78565820	C/T	cg22935921	chr15:78556834	DNAJA4	0.77	5.28	0.39	4.31e-7	Red cell distribution width;
PAAD	cis	rs11615916	0.790	rs78983655	chr12:62658882	C/T	cg11441379	chr12:63026424	NA	0.64	4.41	0.34	1.98e-5	Pulmonary function decline;
PAAD	cis	rs10214930	0.647	rs7790498	chr7:27653207	A/G	cg22168087	chr7:27702803	HIBADH	0.48	4.5	0.34	1.37e-5	Hypospadias;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04976319	chr1:226070045	TMEM63A	0.71	6.33	0.46	2.59e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg05577437	chr8:1586825	DLGAP2	0.39	4.42	0.34	1.89e-5	Systolic blood pressure;
PAAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg15017067	chr4:17643749	FAM184B	0.39	4.36	0.33	2.34e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26523670	chr10:71078506	HK1	-0.77	-6.57	-0.47	7.4e-10	Neuroticism;
PAAD	cis	rs8070740	0.898	rs8078914	chr17:5323924	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.75	0.36	4.6e-6	Menopause (age at onset);
PAAD	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.62	-4.61	-0.35	8.35e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	1.54	9.51	0.61	4.03e-17	Age-related hearing impairment;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16583330	chr1:36916012	OSCP1	-0.59	-6.73	-0.48	3.33e-10	Body fat percentage;
PAAD	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.38	4.71	0.36	5.66e-6	Sitting height ratio;
PAAD	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17774058	chr20:6748719	BMP2	0.56	7.1	0.5	4.43e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg10167378	chr1:228756711	NA	0.43	4.27	0.33	3.43e-5	Diastolic blood pressure;
PAAD	cis	rs34421088	0.532	rs11782742	chr8:11165009	C/T	cg00622658	chr8:10469796	RP1L1	-0.43	-4.32	-0.33	2.86e-5	Neuroticism;
PAAD	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.83	9.51	0.61	4.12e-17	Metabolic syndrome;
PAAD	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-7.04	-0.5	6.09e-11	Parkinson's disease;
PAAD	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.63	6.23	0.45	4.4e-9	Monocyte count;
PAAD	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.09	-0.63	1.18e-18	Response to antipsychotic treatment;
PAAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg03983715	chr16:68378420	PRMT7	-0.54	-4.4	-0.34	2e-5	Schizophrenia;
PAAD	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.8	0.43	3.77e-8	Ileal carcinoids;
PAAD	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.42	0.4	2.3e-7	Heart rate;
PAAD	cis	rs4072705	0.904	rs721863	chr9:127536267	A/T	cg13476313	chr9:127244764	NR5A1	0.28	4.35	0.33	2.53e-5	Menarche (age at onset);
PAAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.76	0.36	4.47e-6	Bone mineral density;
PAAD	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.67	-0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2124910	0.779	rs7250820	chr19:52039859	T/A	cg12008991	chr19:52034861	SIGLEC6	0.33	4.33	0.33	2.71e-5	Blood protein levels;
PAAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.5	-4.54	-0.35	1.15e-5	Monocyte count;
PAAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.14	-0.5	3.63e-11	Aortic root size;
PAAD	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.62	5.43	0.4	2.22e-7	Response to diuretic therapy;
PAAD	cis	rs11264213	0.591	rs274732	chr1:36488199	T/G	cg27506609	chr1:36549197	TEKT2	-1.1	-6.59	-0.47	6.81e-10	Schizophrenia;
PAAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.95	12.44	0.71	5.9e-25	Menopause (age at onset);
PAAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg09324608	chr17:30823087	MYO1D	0.48	4.83	0.36	3.32e-6	Schizophrenia;
PAAD	cis	rs10121009	0.635	rs671875	chr9:35321865	G/A	cg11846315	chr9:35647073	NA	-0.47	-4.3	-0.33	3.07e-5	Parkinson's disease;
PAAD	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.55	-0.41	1.26e-7	Schizophrenia;
PAAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.39	-0.34	2.14e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	7.98	0.54	3.29e-13	Menopause (age at onset);
PAAD	cis	rs13273891	1.000	rs16922990	chr8:58983976	C/T	cg05901852	chr8:59757290	TOX	-0.48	-4.6	-0.35	8.95e-6	Pit-and-Fissure caries;
PAAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.71	0.36	5.44e-6	Tonsillectomy;
PAAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg21399703	chr1:247681439	NA	0.71	6.91	0.49	1.22e-10	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.78	-5.78	-0.42	4.19e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg16341495	chr8:142228727	SLC45A4	-0.58	-5.34	-0.4	3.4e-7	Immature fraction of reticulocytes;
PAAD	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg15571903	chr15:79123663	NA	0.48	6.17	0.45	5.97e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg15181151	chr6:150070149	PCMT1	0.57	6.19	0.45	5.4e-9	Lung cancer;
PAAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.9	-0.49	1.34e-10	Life satisfaction;
PAAD	cis	rs17155006	0.676	rs4730287	chr7:107770624	C/T	cg05962710	chr7:107745446	LAMB4	0.44	5.03	0.38	1.36e-6	Pneumococcal bacteremia;
PAAD	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg09127314	chr1:152161683	NA	-0.68	-4.84	-0.37	3.2e-6	Atopic dermatitis;
PAAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.4	0.56	2.99e-14	Prudent dietary pattern;
PAAD	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.46	-5.78	-0.42	4.13e-8	Crohn's disease;
PAAD	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.67	-6.03	-0.44	1.21e-8	Mortality in heart failure;
PAAD	cis	rs4668356	0.773	rs77144483	chr2:172049618	A/C	cg13882835	chr2:172017928	TLK1	0.93	4.51	0.34	1.29e-5	Cognitive performance;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26652302	chr19:1275448	C19orf24	0.61	6.49	0.47	1.16e-9	Myopia (pathological);
PAAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.83	-7.26	-0.51	1.87e-11	Tuberculosis;
PAAD	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	6.66	0.48	4.59e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.58	6.03	0.44	1.19e-8	Huntington's disease progression;
PAAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.51	-4.84	-0.37	3.22e-6	Neutrophil percentage of white cells;
PAAD	cis	rs4880487	0.888	rs7074199	chr10:1251022	C/T	cg03183215	chr10:1252341	ADARB2	-0.48	-4.75	-0.36	4.77e-6	Migraine;
PAAD	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-4.46	-0.34	1.57e-5	Circulating chemerin levels;
PAAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.84	-9.12	-0.59	4.29e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.53	-4.49	-0.34	1.39e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg20731937	chr12:48336164	NA	0.52	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	cis	rs4427176	0.654	rs12549064	chr8:9442027	A/C	cg03024720	chr8:9765601	NA	-0.44	-4.59	-0.35	9.19e-6	Mosquito bite size;
PAAD	cis	rs11159840	0.587	rs1940533	chr14:88612052	T/C	cg18078958	chr14:88630771	NA	-0.42	-5.37	-0.4	2.85e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.62	5.92	0.43	2.07e-8	Subjective well-being;
PAAD	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg26876637	chr1:152193138	HRNR	-0.84	-5.86	-0.43	2.76e-8	Atopic dermatitis;
PAAD	cis	rs1419980	0.643	rs11054601	chr12:7732636	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.48	4.76	0.36	4.48e-6	Lewy body disease;
PAAD	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.72	7.88	0.54	5.69e-13	Eosinophil percentage of white cells;
PAAD	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg23024343	chr7:107201750	COG5	0.55	4.62	0.35	8.21e-6	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.42	-4.56	-0.35	1.04e-5	Life satisfaction;
PAAD	cis	rs8095374	0.967	rs718515	chr18:43856297	G/A	cg20581250	chr18:44676959	HDHD2	0.49	4.64	0.35	7.31e-6	Clinical laboratory measurements;
PAAD	cis	rs6681460	0.549	rs4655620	chr1:67037194	G/A	cg02459107	chr1:67143332	SGIP1	0.66	7.11	0.5	4.24e-11	Presence of antiphospholipid antibodies;
PAAD	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.71e-5	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27270590	chr6:151685487	ZBTB2	-0.7	-7.69	-0.53	1.67e-12	Obesity-related traits;
PAAD	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.38	-5.99	-0.44	1.46e-8	Urate levels in overweight individuals;
PAAD	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-4.61	-0.35	8.48e-6	Total body bone mineral density;
PAAD	cis	rs3796352	0.667	rs17331178	chr3:52847544	C/A	cg07884673	chr3:53033167	SFMBT1	0.71	4.33	0.33	2.73e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg26338869	chr17:61819248	STRADA	-0.65	-6.54	-0.47	8.83e-10	Prudent dietary pattern;
PAAD	cis	rs13401104	0.587	rs6731967	chr2:237145606	G/C	cg02367144	chr2:237146137	ASB18	0.37	4.71	0.36	5.65e-6	Educational attainment;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	4.65	0.35	7.19e-6	Obesity-related traits;
PAAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg03094675	chr11:5960213	NA	-0.5	-4.27	-0.33	3.45e-5	DNA methylation (variation);
PAAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-4.75	-0.36	4.73e-6	Vitiligo;
PAAD	cis	rs75757892	0.544	rs111269201	chr6:7315543	G/C	cg02954307	chr6:7269328	NA	0.54	4.52	0.34	1.23e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06115741	chr20:33292138	TP53INP2	-0.57	-5.82	-0.43	3.39e-8	Glomerular filtration rate (creatinine);
PAAD	trans	rs10888690	0.582	rs12071347	chr1:50839158	A/C	cg18353550	chr5:52405491	MOCS2	-0.68	-6.38	-0.46	2.04e-9	Male-pattern baldness;
PAAD	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg17325771	chr7:75508891	RHBDD2	-0.3	-4.28	-0.33	3.28e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.74	9.99	0.63	2.19e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.49	4.45	0.34	1.62e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg06637938	chr14:75390232	RPS6KL1	0.46	4.49	0.34	1.4e-5	Height;
PAAD	cis	rs3026101	0.671	rs56190856	chr17:5297149	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.22	-15.43	-0.78	6.27e-33	Ulcerative colitis;
PAAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09835421	chr16:68378352	PRMT7	-1.18	-8.67	-0.58	6.19e-15	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.53	-0.47	9.14e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.72	6.67	0.48	4.5e-10	Obesity-related traits;
PAAD	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.07	11.57	0.68	1.32e-22	Lymphocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26402253	chr7:87849886	SRI	0.64	7.58	0.52	3.13e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg00401753	chr5:405986	AHRR;LOC100310782	0.71	5.06	0.38	1.22e-6	Breast cancer;
PAAD	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.5	-0.34	1.33e-5	IgG glycosylation;
PAAD	cis	rs258892	0.843	rs4560525	chr5:72031768	G/A	cg21869765	chr5:72125136	TNPO1	-0.81	-5.54	-0.41	1.33e-7	Small cell lung carcinoma;
PAAD	cis	rs4740619	0.607	rs2382543	chr9:15988490	C/T	cg14451791	chr9:16040625	NA	0.37	4.38	0.33	2.17e-5	Body mass index;
PAAD	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg08676812	chr11:65308423	LTBP3	1.4	7.5	0.52	4.95e-12	Height;
PAAD	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg17796960	chr10:135278976	LOC619207	0.39	4.42	0.34	1.87e-5	Systemic lupus erythematosus;
PAAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12989701	0.877	rs36085158	chr2:127869982	C/T	cg08168897	chr2:127865431	BIN1	0.68	5.9	0.43	2.26e-8	Alzheimer's disease (late onset);
PAAD	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg05768032	chr16:30646687	NA	0.54	4.88	0.37	2.6e-6	Multiple myeloma;
PAAD	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.73	7.76	0.53	1.17e-12	Aortic root size;
PAAD	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-7.43	-0.52	7.34e-12	Monocyte percentage of white cells;
PAAD	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg08601574	chr20:25228251	PYGB	-0.53	-5.34	-0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.65	7.23	0.51	2.2e-11	Corneal astigmatism;
PAAD	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.58	-5.03	-0.38	1.37e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg11062466	chr8:58055876	NA	0.66	4.76	0.36	4.47e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs11958404	0.932	rs11950881	chr5:157410550	C/T	cg05962755	chr5:157440814	NA	0.95	7.91	0.54	4.81e-13	IgG glycosylation;
PAAD	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.5	-5.47	-0.41	1.82e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.67	7.14	0.5	3.52e-11	Personality dimensions;
PAAD	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.25	-0.45	3.86e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.4e-5	Life satisfaction;
PAAD	cis	rs10895547	0.683	rs116372911	chr11:103782296	T/C	cg06560282	chr11:103830847	PDGFD	0.37	4.4	0.34	2.01e-5	LDL cholesterol;
PAAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.93	-8.8	-0.58	2.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13031595	chr20:47651108	ARFGEF2	0.62	6.57	0.47	7.52e-10	Smoking initiation;
PAAD	cis	rs9287719	0.649	rs12476554	chr2:10727747	A/G	cg00105475	chr2:10696890	NA	0.62	6.55	0.47	8.25e-10	Prostate cancer;
PAAD	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-5.21	-0.39	6.08e-7	Blood pressure (smoking interaction);
PAAD	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs75920871	0.614	rs10892045	chr11:116784824	C/A	cg01368799	chr11:117014884	PAFAH1B2	-0.83	-4.49	-0.34	1.4e-5	Subjective well-being;
PAAD	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.54	-5.05	-0.38	1.26e-6	Red blood cell count;
PAAD	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.52	-4.87	-0.37	2.8e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.56	5.92	0.43	2.07e-8	Lung cancer;
PAAD	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00540400	chr15:79124168	NA	0.6	6.95	0.49	1e-10	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-6.82	-0.48	2e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	1.1	17.43	0.82	4.37e-38	Menarche (age at onset);
PAAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg15017067	chr4:17643749	FAM184B	0.45	5.3	0.39	4.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.83	9.62	0.62	2.06e-17	Body mass index;
PAAD	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg05935833	chr10:81318306	SFTPA2	-0.69	-4.79	-0.36	3.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.85	-8.08	-0.55	1.86e-13	Pancreatic cancer;
PAAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-10.22	-0.64	5.34e-19	Longevity;Endometriosis;
PAAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-6.45	-0.46	1.43e-9	Gut microbiome composition (summer);
PAAD	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg16417436	chr16:28758564	NA	0.43	4.31	0.33	2.95e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.57	5.83	0.43	3.14e-8	Coronary artery disease;
PAAD	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg00277334	chr10:82204260	NA	0.54	6.19	0.45	5.45e-9	Sarcoidosis;
PAAD	cis	rs59104589	0.617	rs12233133	chr2:242256812	G/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs72827839	0.846	rs72825504	chr17:46139479	C/T	cg23391107	chr17:45924227	SP6	0.66	5.62	0.41	9.05e-8	Ease of getting up in the morning;
PAAD	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg07943548	chr15:86304357	KLHL25	-0.63	-5.57	-0.41	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
PAAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.7	9.08	0.59	5.24e-16	Menopause (age at onset);
PAAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg05484376	chr2:27715224	FNDC4	0.49	4.83	0.37	3.24e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
PAAD	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg23534315	chr17:78082725	GAA	0.46	4.76	0.36	4.52e-6	Yeast infection;
PAAD	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg08481491	chr3:125900108	ALDH1L1	-0.48	-5.35	-0.4	3.16e-7	Metabolite levels;
PAAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.14	0.55	1.31e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg13271783	chr10:134563150	INPP5A	-0.6	-6.04	-0.44	1.15e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03903647	chr4:40058344	N4BP2;LOC344967	0.61	6.37	0.46	2.14e-9	Myopia (pathological);
PAAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.73	7.37	0.51	1.02e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7631605	0.905	rs17811658	chr3:37214204	T/C	cg17445812	chr3:36986805	TRANK1	0.35	4.69	0.36	6.04e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs5756391	0.782	rs735561	chr22:37296999	G/A	cg16356956	chr22:37317934	CSF2RB	0.37	4.63	0.35	7.65e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.84	9.64	0.62	1.85e-17	Gout;
PAAD	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg23460851	chr4:1604456	NA	0.43	4.49	0.34	1.42e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	4.67	0.35	6.51e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-4.94	-0.37	2.06e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1667255	0.830	rs3764476	chr18:29176460	C/A	cg18808318	chr18:29669225	NA	0.47	4.33	0.33	2.66e-5	Retinol levels;
PAAD	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.81e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.29	0.33	3.12e-5	Type 2 diabetes;
PAAD	cis	rs6894268	0.722	rs6422331	chr5:179002951	G/T	cg26135573	chr5:179059668	NA	0.73	6.26	0.45	3.81e-9	Eating disorders;
PAAD	cis	rs10982256	0.817	rs2297814	chr9:117267172	G/A	cg12877860	chr9:117266580	DFNB31	0.43	4.34	0.33	2.6e-5	Bipolar disorder;
PAAD	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.8	8.07	0.55	2.01e-13	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg19761014	chr17:28927070	LRRC37B2	0.88	5.59	0.41	1.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.61	-6.0	-0.44	1.37e-8	Post bronchodilator FEV1;
PAAD	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.7	8.37	0.56	3.55e-14	Alcohol dependence;
PAAD	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.61	4.82	0.36	3.46e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.81	8.65	0.57	6.71e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.76	-7.35	-0.51	1.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04733989	chr22:42467013	NAGA	-0.46	-4.87	-0.37	2.76e-6	Cognitive function;
PAAD	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.7	8.94	0.59	1.22e-15	Prostate cancer (SNP x SNP interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03480535	chr4:87856849	AFF1	0.59	6.54	0.47	8.62e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18099408	chr3:52552593	STAB1	0.43	4.88	0.37	2.71e-6	Bipolar disorder;
PAAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.25e-6	Obesity-related traits;
PAAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.4	5.12	0.38	8.95e-7	Ulcerative colitis;
PAAD	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04717802	chr22:42394638	WBP2NL	0.41	4.45	0.34	1.63e-5	Cognitive function;
PAAD	cis	rs4974559	0.947	rs28649968	chr4:1362913	G/A	cg02980000	chr4:1222292	CTBP1	0.66	4.43	0.34	1.78e-5	Systolic blood pressure;
PAAD	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.61	-6.77	-0.48	2.68e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg27182935	chr16:89790473	ZNF276	-0.86	-4.29	-0.33	3.18e-5	Skin colour saturation;
PAAD	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg14393609	chr7:65229607	NA	-0.63	-6.83	-0.48	1.87e-10	Aortic root size;
PAAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.42	-4.35	-0.33	2.45e-5	Type 2 diabetes;
PAAD	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg20092376	chr4:56023423	NA	0.47	4.83	0.36	3.33e-6	Endometriosis;
PAAD	cis	rs61861422	0.516	rs12416102	chr10:134456648	G/T	cg15908580	chr10:134496731	INPP5A	-0.56	-4.82	-0.36	3.4e-6	Primary sclerosing cholangitis;
PAAD	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.06	-0.38	1.22e-6	Mean corpuscular volume;
PAAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.8	8.31	0.56	4.86e-14	Schizophrenia;
PAAD	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg09582351	chr12:29534625	ERGIC2	-0.31	-4.3	-0.33	3.03e-5	QT interval;
PAAD	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg25547332	chr5:131281432	NA	-0.56	-4.39	-0.34	2.08e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.73	6.75	0.48	2.92e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.8	-7.07	-0.5	5.13e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg06885757	chr1:42089581	HIVEP3	-0.53	-6.18	-0.45	5.75e-9	Airway imaging phenotypes;
PAAD	cis	rs7627468	1.000	rs7617898	chr3:121950068	C/G	cg17240004	chr3:121949083	CASR	0.53	4.63	0.35	7.72e-6	Kidney stones;
PAAD	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.85	9.48	0.61	4.77e-17	Mortality in heart failure;
PAAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.41	5.15	0.39	7.96e-7	Prostate cancer;
PAAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.54	5.77	0.42	4.21e-8	Life satisfaction;
PAAD	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg23920097	chr1:209922102	NA	-0.47	-4.3	-0.33	3.09e-5	Red blood cell count;
PAAD	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg00262122	chr8:11665843	FDFT1	0.48	4.58	0.35	9.47e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.81	-0.43	3.46e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs988913	0.647	rs3125263	chr6:54853970	G/A	cg03513858	chr6:54763001	FAM83B	-0.41	-4.57	-0.35	1.01e-5	Menarche (age at onset);
PAAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg05872129	chr22:39784769	NA	-0.64	-5.62	-0.41	8.95e-8	IgG glycosylation;
PAAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.86	-0.58	1.98e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.62	6.23	0.45	4.4e-9	Pancreatic cancer;
PAAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg13468214	chr4:1046988	NA	0.52	4.89	0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.29	-0.33	3.2e-5	Life satisfaction;
PAAD	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg25155006	chr6:37138205	PIM1	-0.49	-4.38	-0.34	2.17e-5	QRS duration;
PAAD	cis	rs3112530	1.000	rs2560231	chr5:152679176	C/T	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg10356904	chr22:49881777	NA	-0.51	-5.63	-0.42	8.53e-8	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs12760731	0.623	rs1342848	chr1:178296461	A/G	cg00404053	chr1:178313656	RASAL2	0.65	5.2	0.39	6.41e-7	Obesity-related traits;
PAAD	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-1.04	-12.34	-0.71	1.11e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg15733309	chr7:157513707	PTPRN2	-0.57	-6.72	-0.48	3.5e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.09	0.55	1.8e-13	Height;
PAAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.44	4.87	0.37	2.77e-6	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.52	6.54	0.47	8.94e-10	Crohn's disease;
PAAD	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.22	17.59	0.82	1.74e-38	Triglycerides;
PAAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.54	5.71	0.42	5.67e-8	Menopause (age at onset);
PAAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.43	4.61	0.35	8.39e-6	Aortic root size;
PAAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.46	-5.15	-0.39	7.78e-7	Breast size;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg27094323	chr7:1216898	NA	0.4	4.5	0.34	1.36e-5	Longevity;Endometriosis;
PAAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.54	-4.37	-0.33	2.25e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg03037974	chr15:76606532	NA	-0.53	-6.36	-0.46	2.26e-9	Blood metabolite levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21340129	chr7:72936681	BAZ1B	0.6	6.62	0.47	5.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.44	0.4	2.13e-7	Aortic root size;
PAAD	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg26205652	chr12:48591994	NA	0.95	9.53	0.61	3.69e-17	Longevity (90 years and older);
PAAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg05895507	chr15:77155635	SCAPER	0.39	4.83	0.36	3.31e-6	Blood metabolite levels;
PAAD	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.6	-5.56	-0.41	1.16e-7	Malaria;
PAAD	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg06883089	chr1:45254480	BEST4	0.34	4.39	0.34	2.1e-5	High light scatter reticulocyte count;
PAAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg25204440	chr1:209979598	IRF6	0.6	5.16	0.39	7.7300000000000005e-07	Coronary artery disease;
PAAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3764400	0.567	rs2240120	chr17:46142144	C/T	cg10706073	chr17:46328419	SKAP1	-1.08	-6.38	-0.46	2.02e-9	Body mass index;
PAAD	cis	rs12431939	0.948	rs12435444	chr14:51656071	C/T	cg23942311	chr14:51606299	NA	-0.75	-6.13	-0.44	7.41e-9	Cancer;
PAAD	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.3	0.56	5.23e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	7.06	0.5	5.55e-11	Leprosy;
PAAD	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.64	7.46	0.52	6.12e-12	Height;
PAAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg09835421	chr16:68378352	PRMT7	-0.91	-7.08	-0.5	4.91e-11	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10966500	chr12:110338339	TCHP	0.63	6.74	0.48	3.07e-10	Myopia (pathological);
PAAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.57	-6.27	-0.45	3.59e-9	Insulin-like growth factors;
PAAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg09796270	chr17:17721594	SREBF1	0.46	5.07	0.38	1.15e-6	Total body bone mineral density;
PAAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13198984	chr17:80129470	CCDC57	0.44	5.49	0.41	1.67e-7	Life satisfaction;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19800926	chr11:73087939	RELT	0.61	6.91	0.49	1.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.93	-11.56	-0.68	1.37e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-16.79	-0.81	1.9e-36	Height;
PAAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.36	-5.64	-0.42	8.05e-8	Urate levels in overweight individuals;
PAAD	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.63	8.9	0.59	1.53e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.66	-4.51	-0.34	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.62	5.64	0.42	7.93e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.6	6.72	0.48	3.5e-10	Emphysema distribution in smoking;
PAAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg04717802	chr22:42394638	WBP2NL	-0.6	-4.71	-0.36	5.61e-6	Birth weight;
PAAD	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.29	0.45	3.19e-9	Morning vs. evening chronotype;
PAAD	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg10253484	chr15:75165896	SCAMP2	-0.52	-4.86	-0.37	2.92e-6	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.74	-5.81	-0.43	3.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg23708337	chr7:1209742	NA	0.65	5.16	0.39	7.62e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.93	-11.07	-0.67	2.97e-21	Height;
PAAD	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.84	7.66	0.53	2.04e-12	Mosquito bite size;
PAAD	cis	rs16975963	0.644	rs73035164	chr19:38146720	G/C	cg14218481	chr19:38281219	NA	0.43	4.62	0.35	8.22e-6	Longevity;
PAAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg11764359	chr7:65958608	NA	0.78	5.2	0.39	6.44e-7	Diabetic kidney disease;
PAAD	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg02887458	chr19:19495540	GATAD2A	-0.57	-5.1	-0.38	1.02e-6	Bipolar disorder;
PAAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.56	-6.09	-0.44	8.76e-9	Educational attainment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24242981	chr11:73472417	RAB6A	0.61	6.96	0.49	9.33e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg18196295	chr10:418757	DIP2C	-0.49	-5.27	-0.39	4.51e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg18939081	chr1:31884902	SERINC2	-0.48	-5.32	-0.4	3.72e-7	Alcohol dependence;
PAAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg09835421	chr16:68378352	PRMT7	-0.83	-6.81	-0.48	2.09e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-6.54	-0.47	8.61e-10	Chronic sinus infection;
PAAD	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg02493740	chr2:85810744	VAMP5	-0.42	-4.73	-0.36	5.15e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.56	5.51	0.41	1.48e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.97	13.66	0.74	3.21e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg09184832	chr6:79620586	NA	-0.55	-5.9	-0.43	2.29e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg10556349	chr10:835070	NA	0.57	4.94	0.37	2.07e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.63	-0.35	7.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg05340240	chr16:88109993	BANP	0.6	7.03	0.5	6.49e-11	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17313118	chr5:127157258	NA	-0.66	-6.82	-0.48	1.99e-10	Obesity-related traits;
PAAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.85	9.33	0.6	1.23e-16	Prostate cancer;
PAAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.51	-7.03	-0.5	6.6e-11	Diastolic blood pressure;
PAAD	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.45	-4.37	-0.33	2.25e-5	Retinal vascular caliber;
PAAD	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.1	-10.17	-0.64	7.64e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.84	-9.75	-0.62	9.27e-18	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg27205649	chr11:78285834	NARS2	0.61	4.38	0.33	2.2e-5	Alzheimer's disease (survival time);
PAAD	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.72	-7.42	-0.52	7.88e-12	Colorectal cancer;
PAAD	cis	rs11264213	0.901	rs649152	chr1:36438649	T/G	cg27506609	chr1:36549197	TEKT2	0.74	5.19	0.39	6.77e-7	Schizophrenia;
PAAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.99	-0.49	7.92e-11	Gut microbiome composition (summer);
PAAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15145965	chr22:50218605	BRD1	0.62	5.1	0.38	9.78e-7	Schizophrenia;
PAAD	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.26	-14.24	-0.76	8.93e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs8032158	1.000	rs66462353	chr15:56186767	T/C	cg02198044	chr15:56286336	NEDD4	-0.51	-5.15	-0.39	7.83e-7	Keloid;
PAAD	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.7	7.93	0.54	4.48e-13	Economic and political preferences (feminism/equality);
PAAD	cis	rs3126085	0.560	rs4378206	chr1:152369913	A/G	cg26876637	chr1:152193138	HRNR	0.64	4.88	0.37	2.69e-6	Atopic dermatitis;
PAAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-5.73	-0.42	5.34e-8	Longevity;Endometriosis;
PAAD	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.77	5.63	0.42	8.61e-8	Small cell lung carcinoma;
PAAD	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.54	4.48	0.34	1.48e-5	HDL cholesterol;
PAAD	cis	rs12912251	0.947	rs36094159	chr15:38998395	G/A	cg10631289	chr15:39006617	NA	0.46	4.43	0.34	1.76e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
PAAD	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.54	-4.67	-0.35	6.46e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.58	-6.1	-0.44	8.59e-9	Hepatitis;
PAAD	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.91	-6.82	-0.48	2.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.32	0.33	2.82e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs10905065	0.898	rs2892078	chr10:5831138	A/G	cg11519256	chr10:5708881	ASB13	-0.53	-4.54	-0.35	1.13e-5	Menopause (age at onset);
PAAD	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.14	-0.5	3.62e-11	Chronic sinus infection;
PAAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.63	-6.28	-0.45	3.46e-9	Obesity-related traits;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-5.05	-0.38	1.26e-6	Migraine;
PAAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg04520793	chr17:42248056	ASB16	-0.47	-6.34	-0.46	2.44e-9	Total body bone mineral density;
PAAD	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.62	6.25	0.45	4.03e-9	Monocyte count;
PAAD	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg19760965	chr3:194868843	C3orf21	0.45	4.69	0.36	5.95e-6	Non-small cell lung cancer;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg12517394	chr11:61582795	MIR1908;FADS1	0.49	4.92	0.37	2.27e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.2	9.77	0.62	8.69e-18	Corneal structure;
PAAD	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg01305830	chr4:1604576	NA	-0.44	-4.31	-0.33	2.91e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs7246865	0.603	rs10423719	chr19:17211568	T/C	cg19418318	chr19:17219073	MYO9B	0.4	5.18	0.39	6.82e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.5	-5.85	-0.43	2.98e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs818427	0.896	rs818429	chr5:112220534	T/C	cg06941702	chr5:112196734	SRP19	0.51	4.77	0.36	4.33e-6	Total body bone mineral density;
PAAD	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.52	4.86	0.37	2.89e-6	Asthma;
PAAD	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg09127314	chr1:152161683	NA	0.69	5.02	0.38	1.42e-6	Atopic dermatitis;
PAAD	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg02574844	chr11:5959923	NA	0.68	6.61	0.47	6.25e-10	DNA methylation (variation);
PAAD	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.75	-6.67	-0.48	4.58e-10	Blood pressure (smoking interaction);
PAAD	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-5.05	-0.38	1.24e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22103764	chr4:120222006	C4orf3	-0.64	-6.94	-0.49	1.08e-10	Smoking initiation;
PAAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.96	10.78	0.66	1.81e-20	Parkinson's disease;
PAAD	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg03538708	chr1:25844672	NA	-0.53	-5.44	-0.4	2.12e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.5	-6.26	-0.45	3.67e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs7168592	1.000	rs3743193	chr15:101718927	C/T	cg24254196	chr15:101719523	CHSY1	-0.62	-4.37	-0.33	2.27e-5	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
PAAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg13175981	chr1:150552382	MCL1	0.53	4.85	0.37	2.98e-6	Monocyte chemoattractant protein-1 levels;
PAAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.34	-4.59	-0.35	9.13e-6	Height;
PAAD	cis	rs9472414	0.510	rs227844	chr6:44692212	A/C	cg18551225	chr6:44695536	NA	0.52	5.15	0.39	7.98e-7	Height;
PAAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg27205649	chr11:78285834	NARS2	-0.62	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs11992162	0.506	rs55948474	chr8:11809662	A/G	cg12395012	chr8:11607386	GATA4	0.41	4.34	0.33	2.56e-5	Monocyte count;
PAAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg25204440	chr1:209979598	IRF6	0.56	4.52	0.34	1.26e-5	Coronary artery disease;
PAAD	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	10.6	0.65	5.16e-20	Response to antipsychotic treatment;
PAAD	cis	rs12760731	0.623	rs10913541	chr1:178347714	G/A	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24549020	chr5:56110836	MAP3K1	0.49	4.29	0.33	3.2e-5	Initial pursuit acceleration;
PAAD	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.54	4.89	0.37	2.57e-6	Anterior chamber depth;
PAAD	cis	rs10861661	1.000	rs10861661	chr12:107174646	A/C	cg15890332	chr12:107067104	RFX4	0.5	4.97	0.37	1.78e-6	Triglyceride levels;
PAAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.78	-10.29	-0.64	3.64e-19	Iron status biomarkers (transferrin levels);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27089072	chr4:6988367	TBC1D14	0.65	7.24	0.51	2.04e-11	Monocyte percentage of white cells;
PAAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.83	8.76	0.58	3.6e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	1.08	15.2	0.78	2.63e-32	Breast cancer;
PAAD	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	6.64	0.47	5.29e-10	Lung cancer in ever smokers;
PAAD	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg26904215	chr21:47823096	PCNT	-0.81	-4.4	-0.34	2e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
PAAD	cis	rs4662592	0.554	rs17793615	chr2:128939695	A/G	cg03222009	chr2:129077232	HS6ST1	-0.45	-4.36	-0.33	2.42e-5	Antipsychotic drug-induced QTc interval change in schizophrenia;
PAAD	cis	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg23008825	chr10:20072678	NA	0.54	4.89	0.37	2.5e-6	Photic sneeze reflex;
PAAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.88	5.6	0.41	9.7e-8	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg15956490	chr3:53032818	SFMBT1	-0.75	-4.72	-0.36	5.42e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.9	11.79	0.69	3.44e-23	Intelligence (multi-trait analysis);
PAAD	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.7	-5.83	-0.43	3.15e-8	Common traits (Other);
PAAD	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg01612440	chr4:3296283	NA	-0.45	-4.43	-0.34	1.78e-5	Serum sulfate level;
PAAD	cis	rs1847202	0.826	rs7640629	chr3:72925997	C/T	cg25664220	chr3:72788482	NA	-0.48	-5.18	-0.39	6.8e-7	Motion sickness;
PAAD	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	6.34	0.46	2.52e-9	Cognitive test performance;
PAAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.83	-7.62	-0.53	2.54e-12	IgG glycosylation;
PAAD	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.33	-0.4	3.43e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.53	-4.98	-0.37	1.7e-6	Red blood cell count;
PAAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg09222892	chr1:25734099	RHCE	-0.47	-4.72	-0.36	5.42e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.44	-5.79	-0.42	3.98e-8	Primary biliary cholangitis;
PAAD	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg16898833	chr6:26189333	HIST1H4D	0.88	5.02	0.38	1.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1144333	0.655	rs946164	chr1:76383286	A/T	cg22875332	chr1:76189707	ACADM	0.77	4.74	0.36	4.89e-6	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.6	6.75	0.48	2.98e-10	Cardiovascular disease risk factors;
PAAD	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg10547527	chr2:198650123	BOLL	-0.66	-4.5	-0.34	1.36e-5	Ulcerative colitis;
PAAD	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	1.09	8.06	0.55	2.09e-13	Iron status biomarkers;
PAAD	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	1.02	6.71	0.48	3.63e-10	Lymphocyte counts;
PAAD	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg00717180	chr2:96193071	NA	-0.58	-6.59	-0.47	6.82e-10	HDL cholesterol;
PAAD	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.48	-4.39	-0.34	2.1e-5	Serum thyroid-stimulating hormone levels;
PAAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.7	0.36	5.83e-6	Breast cancer;
PAAD	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.46	-4.53	-0.34	1.18e-5	Schizophrenia;
PAAD	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.57	-5.79	-0.43	3.92e-8	Motion sickness;
PAAD	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.44	5.14	0.38	8.3e-7	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg01558307	chr20:3827325	MAVS	0.67	6.6	0.47	6.53e-10	Obesity-related traits;
PAAD	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg01329690	chr21:38580129	DSCR9	-0.32	-4.34	-0.33	2.55e-5	Eye color traits;
PAAD	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.67	6.65	0.47	5.08e-10	Smoking initiation;
PAAD	cis	rs11264799	0.731	rs2105108	chr1:157691177	G/A	cg18268488	chr1:157545234	FCRL4	0.64	5.62	0.41	8.88e-8	IgA nephropathy;
PAAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.94	10.16	0.64	7.67e-19	Blood metabolite levels;
PAAD	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	7.81	0.54	8.45e-13	Educational attainment;
PAAD	cis	rs2562456	0.833	rs11672583	chr19:21562165	A/G	cg08562672	chr19:21860753	NA	-0.43	-4.33	-0.33	2.73e-5	Pain;
PAAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.84	6.44	0.46	1.5e-9	Atopic dermatitis;
PAAD	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg14825688	chr5:132208181	LEAP2	-0.62	-6.34	-0.46	2.45e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs11700980	0.551	rs12481736	chr21:30113657	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg00786201	chr11:61583134	MIR1908;FADS1	0.46	4.34	0.33	2.6e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg04721828	chr11:48285200	OR4X1	0.49	6.13	0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg24623649	chr8:11872141	NA	-0.45	-4.36	-0.33	2.43e-5	Monocyte count;
PAAD	cis	rs12906542	0.516	rs4886992	chr15:78325229	T/C	cg23683012	chr15:78369302	TBC1D2B	0.67	4.95	0.37	1.99e-6	Breast cancer;
PAAD	cis	rs7619427	0.544	rs59081044	chr3:43967628	C/T	cg16646616	chr3:44040527	NA	-0.56	-4.57	-0.35	1.01e-5	Schizophrenia;
PAAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg15017067	chr4:17643749	FAM184B	0.44	5.19	0.39	6.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12049462	chr2:201983419	CFLAR	-0.59	-6.54	-0.47	8.9e-10	Smoking initiation;
PAAD	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.53	5.22	0.39	5.66e-7	Multiple myeloma;
PAAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.74	7.03	0.5	6.49e-11	Schizophrenia;
PAAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15145965	chr22:50218605	BRD1	0.62	5.29	0.39	4.25e-7	Schizophrenia;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17360299	chr2:16082032	MYCNOS;MYCN	-0.76	-7.97	-0.54	3.51e-13	Smoking initiation;
PAAD	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg20007245	chr22:24372913	LOC391322	0.69	5.84	0.43	3.11e-8	Urinary 1,3-butadiene metabolite levels in smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26534856	chr2:44223049	LRPPRC	0.65	6.69	0.48	4.09e-10	Obesity-related traits;
PAAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg07153921	chr17:41440717	NA	-0.42	-4.49	-0.34	1.42e-5	Menopause (age at onset);
PAAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08677398	chr8:58056175	NA	-0.68	-4.67	-0.35	6.7e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.49	-4.76	-0.36	4.47e-6	Pancreatic cancer;
PAAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.52	-6.78	-0.48	2.48e-10	Height;
PAAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg27113419	chr16:58533979	NDRG4	-0.74	-4.6	-0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs7619833	0.715	rs4973766	chr3:27413566	C/T	cg02860705	chr3:27208620	NA	0.42	4.26	0.33	3.55e-5	Breast cancer;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg13524873	chr10:104953185	NT5C2	-0.54	-6.34	-0.46	2.45e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg17366294	chr4:99064904	C4orf37	0.45	4.89	0.37	2.51e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21643547	chr1:205240462	TMCC2	-0.4	-4.67	-0.35	6.69e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.58	5.5	0.41	1.56e-7	HDL cholesterol;
PAAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.96	10.61	0.65	4.89e-20	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.45	6.17	0.45	5.77e-9	Cardiovascular disease risk factors;
PAAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg21130718	chr4:1044621	NA	0.73	9.67	0.62	1.55e-17	Recombination rate (males);
PAAD	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	4.36	0.33	2.35e-5	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.31	5.41	0.4	2.45e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg19337854	chr7:99768885	GPC2	0.44	4.54	0.35	1.15e-5	Coronary artery disease;
PAAD	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.55	5.49	0.41	1.62e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg13512537	chr8:22265999	SLC39A14	-0.42	-4.33	-0.33	2.69e-5	Verbal declarative memory;
PAAD	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.47	5.02	0.38	1.42e-6	Dementia with Lewy bodies;
PAAD	cis	rs2204008	0.720	rs10880697	chr12:38594529	G/C	cg26384229	chr12:38710491	ALG10B	0.88	9.96	0.63	2.6e-18	Bladder cancer;
PAAD	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.76	8.92	0.59	1.38e-15	Blood metabolite ratios;
PAAD	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg19254793	chr6:44695348	NA	-0.46	-4.38	-0.33	2.22e-5	Total body bone mineral density;
PAAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.78	6.16	0.45	6.21e-9	Alzheimer's disease;
PAAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	9.98	0.63	2.3e-18	Platelet count;
PAAD	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16447950	chr5:562315	NA	-0.75	-6.55	-0.47	8.56e-10	Lung disease severity in cystic fibrosis;
PAAD	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.61	6.42	0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.51	4.28	0.33	3.3e-5	Height;
PAAD	cis	rs12410462	0.591	rs11802190	chr1:227635162	A/C	cg23173402	chr1:227635558	NA	0.55	4.54	0.35	1.13e-5	Major depressive disorder;
PAAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.78	-8.37	-0.56	3.49e-14	Calcium levels;
PAAD	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-8.45	-0.57	2.18e-14	Total body bone mineral density;
PAAD	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.74	-5.48	-0.41	1.75e-7	Coronary artery calcification;
PAAD	cis	rs12935418	0.616	rs874054	chr16:81006142	T/C	cg16651780	chr16:81037892	C16orf61	0.66	6.1	0.44	8.57e-9	Mean corpuscular volume;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg14640481	chr7:97910728	BRI3	0.59	6.66	0.48	4.81e-10	Metabolite levels  (X-11787);
PAAD	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26897989	chr16:1907736	C16orf73	0.54	4.73	0.36	5.16e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg10729496	chr3:10149963	C3orf24	0.84	6.58	0.47	7.29e-10	Alzheimer's disease;
PAAD	cis	rs3736485	0.966	rs11633713	chr15:51908052	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.39	-0.34	2.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-4.47	-0.34	1.52e-5	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	4.54	0.35	1.14e-5	Height;
PAAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.61	6.09	0.44	8.65e-9	Longevity;
PAAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.7	-7.84	-0.54	7.16e-13	Height;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg08835956	chr7:39171034	POU6F2	0.32	5.68	0.42	6.7e-8	IgG glycosylation;
PAAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg16359550	chr11:109292809	C11orf87	0.22	4.29	0.33	3.13e-5	Schizophrenia;
PAAD	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	1.04	8.47	0.57	1.99e-14	IgG glycosylation;
PAAD	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.5	5.75	0.42	4.86e-8	Coronary artery disease;
PAAD	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.75	9.67	0.62	1.51e-17	Menopause (age at onset);
PAAD	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02743256	chr7:2109353	MAD1L1	-0.66	-4.98	-0.37	1.68e-6	Bipolar disorder;
PAAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	6.25	0.45	4.02e-9	Renal function-related traits (BUN);
PAAD	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.39	-4.73	-0.36	5.11e-6	Pubertal anthropometrics;
PAAD	cis	rs9361491	0.578	rs1180826	chr6:79434602	C/G	cg05283184	chr6:79620031	NA	-0.37	-4.46	-0.34	1.58e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03106307	chr4:25236057	PI4K2B	0.65	6.91	0.49	1.28e-10	Myopia (pathological);
PAAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.68	6.18	0.45	5.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.6	6.96	0.49	9.32e-11	Reticulocyte fraction of red cells;
PAAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-5.73	-0.42	5.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.56	-5.84	-0.43	3.06e-8	Tonsillectomy;
PAAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.55	-7.41	-0.52	8.13e-12	Renal cell carcinoma;
PAAD	cis	rs4908760	0.827	rs11121210	chr1:8708529	T/C	cg20416874	chr1:8611966	RERE	-0.46	-4.4	-0.34	2.07e-5	Vitiligo;
PAAD	cis	rs977987	0.864	rs40446	chr16:75496658	T/C	cg03315344	chr16:75512273	CHST6	-0.66	-8.12	-0.55	1.51e-13	Dupuytren's disease;
PAAD	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-4.5	-0.34	1.36e-5	Educational attainment (years of education);
PAAD	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.76	5.54	0.41	1.31e-7	Major depressive disorder;
PAAD	cis	rs1468333	1.000	rs3777113	chr5:137493897	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.59	6.29	0.45	3.14e-9	Resting heart rate;
PAAD	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.62	7.0	0.49	7.84e-11	Pediatric non-alcoholic fatty liver disease activity score;
PAAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg25204440	chr1:209979598	IRF6	-0.45	-4.81	-0.36	3.67e-6	Orofacial clefts;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.62	-5.97	-0.44	1.65e-8	Cystic fibrosis severity;
PAAD	cis	rs6715793	0.869	rs4670251	chr2:33406784	A/G	cg26672287	chr2:33391915	LTBP1	-0.43	-5.0	-0.38	1.54e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04733989	chr22:42467013	NAGA	0.48	4.9	0.37	2.43e-6	Cognitive function;
PAAD	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.7	6.88	0.49	1.5e-10	Lymphocyte counts;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16262614	chr3:133464971	TF	0.41	4.31	0.33	2.95e-5	Iron status biomarkers;
PAAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg19980929	chr12:42632907	YAF2	0.54	6.21	0.45	4.83e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg09796270	chr17:17721594	SREBF1	0.45	5.19	0.39	6.49e-7	Total body bone mineral density;
PAAD	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg16964102	chr10:135390573	NA	0.44	4.81	0.36	3.54e-6	Obesity-related traits;
PAAD	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-10.7	-0.66	2.81e-20	Late-onset Alzheimer's disease;
PAAD	cis	rs7260538	0.933	rs1987236	chr19:41509033	G/A	cg06653635	chr19:40910092	PRX	-0.43	-4.35	-0.33	2.51e-5	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.68	7.47	0.52	5.8e-12	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg04575393	chr19:53496094	ZNF702P	-0.47	-5.1	-0.38	1e-6	Psoriasis;
PAAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg15181151	chr6:150070149	PCMT1	0.56	6.15	0.45	6.39e-9	Lung cancer;
PAAD	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-5.6	-0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs7804356	0.651	rs1123156	chr7:26817044	C/T	cg03456212	chr7:26904342	SKAP2	-0.59	-5.0	-0.38	1.54e-6	Type 1 diabetes;
PAAD	cis	rs8067287	0.597	rs7223652	chr17:16864559	C/T	cg26910001	chr17:16838321	NA	0.44	4.37	0.33	2.25e-5	Diabetic kidney disease;
PAAD	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	4.66	0.35	6.83e-6	Resting heart rate;
PAAD	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	5.06	0.38	1.18e-6	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg02462569	chr6:150064036	NUP43	-0.45	-4.97	-0.37	1.79e-6	Lung cancer;
PAAD	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.48	-4.42	-0.34	1.86e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-4.95	-0.37	1.92e-6	Body mass index;
PAAD	cis	rs13144136	0.683	rs6828436	chr4:10675658	C/T	cg10242279	chr4:10666415	CLNK	-0.38	-4.72	-0.36	5.4e-6	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.5	4.82	0.36	3.42e-6	High light scatter reticulocyte count;
PAAD	cis	rs4919087	0.527	rs6584123	chr10:99132083	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-4.94	-0.37	2e-6	Monocyte count;
PAAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg12639453	chr1:2035780	PRKCZ	0.57	6.16	0.45	6.27e-9	Height;
PAAD	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg05754148	chr16:3507555	NAT15	0.69	4.82	0.36	3.46e-6	Tuberculosis;
PAAD	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.52	-5.71	-0.42	5.86e-8	Metabolite levels;
PAAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg05697835	chr1:2722811	NA	0.38	4.36	0.33	2.39e-5	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	8.84	0.58	2.23e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.5	-4.92	-0.37	2.24e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.77	8.69	0.58	5.28e-15	Age-related hearing impairment;
PAAD	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-4.61	-0.35	8.54e-6	Morning vs. evening chronotype;
PAAD	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg20742385	chr13:113633654	MCF2L	-0.44	-4.35	-0.33	2.46e-5	Systolic blood pressure;
PAAD	cis	rs116248771	0.739	rs4679833	chr3:158339835	G/A	cg16708174	chr3:158430962	RARRES1	0.73	5.41	0.4	2.42e-7	diarrhoeal disease at age 2;
PAAD	cis	rs2299587	0.580	rs2427739	chr8:17871829	A/T	cg08627089	chr8:17753878	FGL1	-0.48	-4.39	-0.34	2.15e-5	Economic and political preferences;
PAAD	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.95	-0.49	1.01e-10	Myopia (pathological);
PAAD	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg15212455	chr7:39170539	POU6F2	0.41	5.62	0.41	8.88e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs7594192	0.744	rs6434973	chr2:199369099	A/G	cg03163783	chr2:200326591	SATB2	0.31	4.3	0.33	3.05e-5	Educational attainment;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg16106770	chr11:120206550	ARHGEF12	0.62	6.97	0.49	9.21e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1997066	0.831	rs73342291	chr10:106823081	G/C	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs2241685	0.850	rs10865521	chr2:1943691	C/G	cg22511877	chr2:1942942	MYT1L	-0.71	-4.93	-0.37	2.12e-6	Attention deficit hyperactivity disorder;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03042113	chr11:65430511	RELA	0.61	6.48	0.47	1.22e-9	Myopia (pathological);
PAAD	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.13	0.38	8.78e-7	Height;
PAAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.46	5.82	0.43	3.45e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.91	9.84	0.62	5.68e-18	Prudent dietary pattern;
PAAD	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg10856724	chr12:34555212	NA	-0.41	-4.25	-0.33	3.75e-5	Morning vs. evening chronotype;
PAAD	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.92	13.7	0.74	2.55e-28	Height;
PAAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.84	0.43	3.09e-8	Schizophrenia;
PAAD	cis	rs2651899	0.934	rs3795268	chr1:3089976	G/A	cg22674798	chr1:3096360	PRDM16	-0.65	-9.69	-0.62	1.35e-17	Migraine;
PAAD	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	7.17	0.5	3.12e-11	Colorectal cancer;
PAAD	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg25649188	chr17:73499917	CASKIN2	0.76	5.05	0.38	1.24e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
PAAD	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.47	4.49	0.34	1.41e-5	Red blood cell count;
PAAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	4.4	0.34	2.05e-5	Obesity-related traits;
PAAD	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.95	-9.6	-0.61	2.31e-17	Corneal astigmatism;
PAAD	cis	rs818427	0.750	rs153562	chr5:112253119	G/A	cg06941702	chr5:112196734	SRP19	0.49	4.58	0.35	9.66e-6	Total body bone mineral density;
PAAD	cis	rs2281636	0.965	rs2006077	chr10:101492833	A/T	cg05149213	chr10:101381631	SLC25A28	-0.48	-4.58	-0.35	9.47e-6	Obesity-related traits;
PAAD	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg04342483	chr1:7259290	CAMTA1	-0.4	-4.26	-0.33	3.63e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg12215294	chr3:40350768	EIF1B	-0.48	-4.94	-0.37	2e-6	Renal cell carcinoma;
PAAD	cis	rs2244613	0.882	rs7205790	chr16:55795034	A/G	cg27396498	chr16:55794478	CES4	0.71	5.51	0.41	1.5e-7	Response to dabigatran etexilate treatment;
PAAD	cis	rs12989701	0.825	rs4663096	chr2:127861766	T/A	cg08168897	chr2:127865431	BIN1	0.59	5.68	0.42	6.6e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.81	8.51	0.57	1.53e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.71	-4.27	-0.33	3.42e-5	Intraocular pressure;Glaucoma (high intraocular pressure);
PAAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	3.61e-18	Menopause (age at onset);
PAAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg15117754	chr3:10150083	C3orf24	0.71	6.34	0.46	2.53e-9	Alzheimer's disease;
PAAD	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	5.29	0.39	4.1e-7	LDL cholesterol;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20716174	chr15:58766885	LIPC	0.68	7.18	0.5	2.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.47	5.56	0.41	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs11212737	0.765	rs2128243	chr11:108509754	A/G	cg13462821	chr8:86214814	NA	-0.57	-6.62	-0.47	5.78e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.63	-6.72	-0.48	3.4e-10	Iron status biomarkers;
PAAD	cis	rs59888335	1.000	rs12631290	chr3:80714876	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.62	6.72	0.48	3.5e-10	High light scatter reticulocyte count;
PAAD	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.86	-0.54	6.65e-13	Neuroticism;
PAAD	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.61	6.72	0.48	3.52e-10	Morning vs. evening chronotype;
PAAD	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.54	-4.75	-0.36	4.73e-6	Dental caries;
PAAD	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg27539214	chr16:67997921	SLC12A4	-0.74	-4.55	-0.35	1.09e-5	Hematocrit;Hemoglobin concentration;
PAAD	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.66	-10.46	-0.65	1.22e-19	Diastolic blood pressure;
PAAD	cis	rs11264799	0.520	rs849826	chr1:157546346	A/T	cg18268488	chr1:157545234	FCRL4	0.54	6.14	0.45	6.73e-9	IgA nephropathy;
PAAD	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg00277334	chr10:82204260	NA	-0.59	-5.33	-0.4	3.41e-7	Post bronchodilator FEV1;
PAAD	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	7.04	0.5	6.19e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg02016764	chr4:38805732	TLR1	-0.55	-4.31	-0.33	2.89e-5	Breast cancer;
PAAD	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg16989719	chr2:238392110	NA	-0.35	-4.36	-0.33	2.43e-5	Prostate cancer;
PAAD	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.74	7.81	0.54	8.63e-13	Brugada syndrome;
PAAD	cis	rs8170	0.603	rs4808622	chr19:17415457	C/G	cg04749549	chr19:17459798	NA	-0.45	-4.85	-0.37	3.02e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs7101378	0.577	rs10749932	chr11:108898886	C/T	cg02420102	chr11:108338162	C11orf65	-0.44	-4.3	-0.33	3.06e-5	IgG glycosylation;
PAAD	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14019695	chr9:139328340	INPP5E	0.57	6.0	0.44	1.38e-8	Monocyte percentage of white cells;
PAAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.56	5.78	0.42	4.13e-8	Tonsillectomy;
PAAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.77	-6.88	-0.49	1.49e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-6.5	-0.47	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs3136739	0.614	rs8178749	chr8:42044897	C/T	cg17828057	chr8:42037527	PLAT	0.7	4.76	0.36	4.49e-6	Plasma plasminogen activator levels;
PAAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	4.25	0.33	3.65e-5	Renal cell carcinoma;
PAAD	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.75	-0.36	4.65e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg23912435	chr1:150601613	ENSA	0.51	4.85	0.37	3.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.63	5.56	0.41	1.19e-7	Height;
PAAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg05785598	chr3:49045655	WDR6	0.43	5.15	0.39	8.08e-7	Parkinson's disease;
PAAD	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg16898833	chr6:26189333	HIST1H4D	0.98	4.84	0.37	3.21e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.05	-0.5	5.96e-11	Response to antipsychotic treatment;
PAAD	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg02745156	chr12:32552066	NA	0.43	4.77	0.36	4.26e-6	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs8112211	0.689	rs76682100	chr19:38794786	T/G	cg14299480	chr19:38876666	GGN	-0.52	-4.46	-0.34	1.57e-5	Blood protein levels;
PAAD	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.47	-0.41	1.8e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.53	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg08198773	chr8:1697536	NA	0.45	5.01	0.38	1.49e-6	Systolic blood pressure;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.83	5.98	0.44	1.5e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26963320	chr16:73489759	NA	-0.38	-4.83	-0.36	3.32e-6	Energy expenditure (24h);
PAAD	cis	rs761746	0.739	rs9621317	chr22:32094046	C/T	cg01338084	chr22:32026380	PISD	0.64	5.38	0.4	2.7e-7	Intelligence;
PAAD	cis	rs5417	0.636	rs2074218	chr17:7156186	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.72	7.75	0.53	1.25e-12	Diastolic blood pressure;
PAAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.49	-4.71	-0.36	5.56e-6	Coronary artery disease;
PAAD	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.41	5.07	0.38	1.16e-6	Pulmonary function;
PAAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.09	-0.5	4.73e-11	Menarche (age at onset);
PAAD	cis	rs7833090	0.603	rs4357254	chr8:128707295	C/G	cg21238284	chr8:127889295	NA	0.27	4.36	0.33	2.37e-5	Breast cancer;
PAAD	cis	rs11581903	0.568	rs7537727	chr1:53090345	A/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.83	4.52	0.34	1.24e-5	Joint mobility (Beighton score);
PAAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	ch.8.33884649F	chr8:33765107	NA	0.66	7.45	0.52	6.71e-12	Body mass index;
PAAD	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.5	5.32	0.4	3.6e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs73719811	0.850	rs6466798	chr7:121221761	A/G	cg22032706	chr7:120498729	TSPAN12	-0.64	-4.28	-0.33	3.28e-5	Total body bone mineral density;
PAAD	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	1.2	14.0	0.75	3.96e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs2980439	0.517	rs793753	chr8:8105359	T/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-5.3	-0.4	3.98e-7	Neuroticism;
PAAD	cis	rs10929159	0.665	rs7599602	chr2:236930373	C/T	cg14226755	chr2:236923322	AGAP1	0.29	4.66	0.35	6.77e-6	Parkinson's disease;
PAAD	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.72	7.88	0.54	5.79e-13	Schizophrenia;
PAAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg15693483	chr7:1102177	C7orf50	0.48	5.27	0.39	4.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7260329	0.670	rs7251950	chr19:41482742	A/G	cg07907917	chr19:40949191	SERTAD3	0.52	4.37	0.33	2.33e-5	Smoking behavior;
PAAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.36	-4.44	-0.34	1.72e-5	Schizophrenia;
PAAD	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg08758996	chr17:66097529	LOC651250	0.52	4.33	0.33	2.67e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs73568641	0.623	rs12664381	chr6:154054500	C/T	cg15658985	chr6:154448740	OPRM1	0.57	4.67	0.35	6.46e-6	Methadone dose in opioid dependence;
PAAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs686320	0.588	rs11602839	chr11:65177439	G/A	cg21890820	chr11:65308645	LTBP3	0.85	5.38	0.4	2.77e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs35785195	0.633	rs1035774	chr12:114230856	G/C	cg24771877	chr12:114234123	NA	0.67	5.31	0.4	3.8e-7	Daytime sleep phenotypes;
PAAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-6.98	-0.49	8.46e-11	Breast cancer;
PAAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	1.05	15.26	0.78	1.83e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg08601574	chr20:25228251	PYGB	0.53	5.34	0.4	3.33e-7	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg12517394	chr11:61582795	MIR1908;FADS1	0.48	4.72	0.36	5.21e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-4.86	-0.37	2.84e-6	Psoriasis;
PAAD	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg14146966	chr2:61757674	XPO1	-0.43	-5.36	-0.4	2.97e-7	Tuberculosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg21450730	chr1:53704239	MAGOH	0.58	6.53	0.47	9.35e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg19257562	chr1:2043853	PRKCZ	0.41	4.68	0.35	6.28e-6	Height;
PAAD	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.65	6.32	0.46	2.72e-9	Hip circumference;
PAAD	cis	rs4742903	0.904	rs1605448	chr9:106976405	T/G	cg14250997	chr9:106856677	SMC2	0.46	4.87	0.37	2.79e-6	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg16898833	chr6:26189333	HIST1H4D	0.83	4.53	0.34	1.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.87	7.36	0.51	1.1e-11	Lymphocyte counts;
PAAD	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-5.53	-0.41	1.34e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.74	7.92	0.54	4.7e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.79	-7.28	-0.51	1.64e-11	Breast cancer;
PAAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg03400443	chr2:74347616	NA	-0.5	-4.26	-0.33	3.56e-5	Gestational age at birth (maternal effect);
PAAD	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.85	9.96	0.63	2.74e-18	Metabolic syndrome;
PAAD	cis	rs3784262	0.565	rs12914603	chr15:58350896	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-5.51	-0.41	1.49e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.64	6.22	0.45	4.67e-9	Corneal astigmatism;
PAAD	cis	rs800160	0.777	rs2521294	chr11:2348778	C/T	cg09785033	chr11:2336066	TSPAN32	-0.55	-4.57	-0.35	1.01e-5	Bacteremia;
PAAD	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.69	6.1	0.44	8.47e-9	Height;
PAAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	5.12	0.38	9.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-4.61	-0.35	8.62e-6	Lung cancer;
PAAD	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg17401720	chr7:158221031	PTPRN2	-0.4	-4.64	-0.35	7.39e-6	Obesity-related traits;
PAAD	cis	rs9467603	0.925	rs4712969	chr6:25764192	A/G	cg23465465	chr6:26364728	BTN3A2	-0.78	-4.64	-0.35	7.6e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg19847866	chr10:1019161	NA	-0.53	-4.25	-0.33	3.7e-5	Eosinophil percentage of granulocytes;
PAAD	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg10820045	chr2:198174542	NA	0.46	4.64	0.35	7.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.47	4.27	0.33	3.47e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.44	-4.67	-0.35	6.45e-6	Type 2 diabetes;
PAAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.54	0.41	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg27411982	chr8:10470053	RP1L1	-0.49	-5.42	-0.4	2.25e-7	Neuroticism;
PAAD	cis	rs9463078	0.753	rs1329716	chr6:44953758	C/T	cg25276700	chr6:44698697	NA	-0.51	-5.97	-0.44	1.58e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg14773178	chr5:1868261	NA	0.38	4.85	0.37	3.05e-6	Cardiovascular disease risk factors;
PAAD	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg03909863	chr11:638404	DRD4	-0.59	-5.25	-0.39	5.02e-7	Systemic lupus erythematosus;
PAAD	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg21918786	chr6:109611834	NA	-0.45	-4.91	-0.37	2.31e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	8.59	0.57	9.41e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6594713	0.604	rs34324763	chr5:112937355	T/C	cg12552261	chr5:112820674	MCC	0.78	5.36	0.4	2.97e-7	Brain cytoarchitecture;
PAAD	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg06483076	chr3:194406458	FAM43A	0.53	5.03	0.38	1.36e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
PAAD	cis	rs9633835	0.519	rs61882381	chr11:13348243	G/T	cg15603424	chr11:13300592	ARNTL	-0.53	-4.31	-0.33	2.9e-5	Body mass index;
PAAD	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg08439880	chr3:133502540	NA	-0.44	-4.74	-0.36	4.9100000000000004e-06	Iron status biomarkers;
PAAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.94	12.72	0.72	1.04e-25	Prudent dietary pattern;
PAAD	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.59	4.98	0.37	1.69e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.35	4.6	0.35	8.74e-6	Schizophrenia;
PAAD	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.95	0.37	1.94e-6	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.71	8.18	0.55	1.08e-13	Parkinson's disease;
PAAD	trans	rs901683	1.000	rs35902429	chr10:46024335	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-8.8	-0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	5.95	0.43	1.79e-8	Lung function (FEV1/FVC);
PAAD	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg04374321	chr14:90722782	PSMC1	0.54	4.36	0.33	2.35e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs7219021	0.886	rs8068884	chr17:46869898	G/C	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.42	-0.34	1.85e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.52	-5.27	-0.39	4.56e-7	Iron status biomarkers;
PAAD	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.95	10.33	0.64	2.85e-19	Corneal astigmatism;
PAAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.62	-6.59	-0.47	6.89e-10	Iron status biomarkers;
PAAD	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.75	-7.02	-0.49	6.77e-11	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs72681920	0.881	rs12507078	chr4:100125868	G/A	cg12011299	chr4:100065546	ADH4	-0.8	-4.58	-0.35	9.67e-6	Alcohol dependence;
PAAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg10645314	chr2:3704589	ALLC	-0.42	-4.5	-0.34	1.35e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.76	7.63	0.53	2.36e-12	Cognitive function;
PAAD	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	9.34	0.6	1.16e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.56	5.85	0.43	2.96e-8	Dupuytren's disease;
PAAD	cis	rs13401620	0.655	rs2166436	chr2:120891111	A/G	cg06832677	chr2:119976764	NA	0.43	4.33	0.33	2.68e-5	Breast size;
PAAD	cis	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.3	0.33	3.02e-5	Depression;
PAAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-8.86	-0.58	1.97e-15	Prostate cancer;
PAAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.57	7.64	0.53	2.23e-12	Renal cell carcinoma;
PAAD	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg04359915	chr10:101825029	CPN1	-0.34	-5.18	-0.39	6.94e-7	Bone mineral density;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07362569	chr17:61921086	SMARCD2	0.58	6.76	0.48	2.84e-10	Prudent dietary pattern;
PAAD	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.47	-5.07	-0.38	1.15e-6	Educational attainment;
PAAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-9.09	-0.59	5e-16	Total body bone mineral density;
PAAD	cis	rs9810890	1.000	rs73198843	chr3:128502514	G/A	cg14212504	chr3:128564815	NA	-0.75	-4.37	-0.33	2.33e-5	Dental caries;
PAAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.26	0.56	6.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.64	8.42	0.56	2.6e-14	Skin aging (microtopography measurement);
PAAD	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	7.34	0.51	1.23e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.83	10.37	0.64	2.2e-19	Bladder cancer;
PAAD	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.68	6.75	0.48	2.98e-10	Schizophrenia;
PAAD	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg21300403	chr2:198650112	BOLL	-0.51	-4.52	-0.34	1.26e-5	Dermatomyositis;
PAAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg27113419	chr16:58533979	NDRG4	-0.73	-4.47	-0.34	1.5e-5	Schizophrenia;
PAAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg09835421	chr16:68378352	PRMT7	-1.3	-9.83	-0.62	6.03e-18	Magnesium levels;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg05313129	chr8:58192883	C8orf71	-0.65	-5.37	-0.4	2.91e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.14	0.45	6.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	4.98	0.37	1.74e-6	Thyroid stimulating hormone;
PAAD	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-7.05	-0.5	5.94e-11	Morning vs. evening chronotype;
PAAD	cis	rs7714584	1.000	rs75071288	chr5:150224379	C/T	cg22134413	chr5:150180641	NA	0.75	5.47	0.41	1.78e-7	Crohn's disease;
PAAD	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.86	8.22	0.55	8.29e-14	Homoarginine levels;
PAAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.52	-4.95	-0.37	1.98e-6	Aortic root size;
PAAD	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.79	8.68	0.58	5.82e-15	Caffeine consumption;
PAAD	cis	rs10982256	0.905	rs4979417	chr9:117263878	C/T	cg12877860	chr9:117266580	DFNB31	-0.39	-4.31	-0.33	2.97e-5	Bipolar disorder;
PAAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.33	-0.46	2.63e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg10011062	chr15:43941034	CATSPER2	-0.74	-4.46	-0.34	1.6e-5	Lung cancer in ever smokers;
PAAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07362569	chr17:61921086	SMARCD2	0.63	7.74	0.53	1.26e-12	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02569759	chr3:10052551	LOC401052	0.59	6.69	0.48	3.92e-10	Smoking initiation;
PAAD	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg04289385	chr6:36355825	ETV7	0.45	4.8	0.36	3.71e-6	Platelet distribution width;
PAAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.23	-0.39	5.41e-7	Pulmonary function;
PAAD	cis	rs12550646	0.585	rs74887565	chr8:41681935	T/C	cg19997384	chr8:41685595	ANK1	-0.31	-4.26	-0.33	3.62e-5	Reticulocyte fraction of red cells;Reticulocyte count;
PAAD	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.46	0.34	1.61e-5	Plateletcrit;Platelet count;
PAAD	cis	rs6424115	0.830	rs2502989	chr1:24205407	G/A	cg18888403	chr1:24152774	HMGCL	0.41	4.65	0.35	7.27e-6	Immature fraction of reticulocytes;
PAAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg05481257	chr2:20870211	GDF7	-0.43	-5.63	-0.42	8.44e-8	Abdominal aortic aneurysm;
PAAD	cis	rs2412208	0.585	rs11120824	chr1:7113591	G/A	cg20434152	chr1:7120926	CAMTA1	-0.5	-5.59	-0.41	1.03e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	trans	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg26939375	chr7:64535504	NA	-0.76	-9.0	-0.59	8.68e-16	Aortic root size;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07027912	chr3:197517962	LRCH3	-0.69	-6.61	-0.47	6.13e-10	Lung cancer in ever smokers;
PAAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.81e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg16386425	chr10:429943	DIP2C	0.5	4.51	0.34	1.31e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-6.91	-0.49	1.23e-10	Hemoglobin concentration;
PAAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg09914555	chr8:142094789	NA	-0.55	-4.9	-0.37	2.47e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.76	8.11	0.55	1.56e-13	Blood metabolite levels;
PAAD	cis	rs375066	0.935	rs430667	chr19:44413253	T/C	cg11993925	chr19:44307056	LYPD5	0.52	6.65	0.47	4.84e-10	Breast cancer;
PAAD	cis	rs287982	1.000	rs13404815	chr2:9967766	A/G	cg01119585	chr2:10571959	NA	0.39	4.43	0.34	1.78e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.99	8.71	0.58	4.67e-15	Vitiligo;
PAAD	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.78	-5.08	-0.38	1.07e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.53	-5.82	-0.43	3.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	1.27	12.66	0.72	1.52e-25	Eosinophil percentage of granulocytes;
PAAD	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg05784532	chr1:230284198	GALNT2	0.68	5.9	0.43	2.29e-8	Coronary artery disease;
PAAD	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-0.87	-7.59	-0.52	2.95e-12	Blood protein levels;
PAAD	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.43	-5.14	-0.38	8.35e-7	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-8.76	-0.58	3.48e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7567389	0.510	rs6755028	chr2:128195442	G/A	cg09760422	chr2:128146352	NA	-0.47	-7.72	-0.53	1.46e-12	Self-rated health;
PAAD	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.59	-5.21	-0.39	6.12e-7	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg19897017	chr7:2163380	MAD1L1	-0.52	-5.08	-0.38	1.12e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13198984	chr17:80129470	CCDC57	-0.43	-5.41	-0.4	2.42e-7	Life satisfaction;
PAAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg05373962	chr22:49881684	NA	-0.5	-4.88	-0.37	2.68e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.47	4.81	0.36	3.56e-6	Type 2 diabetes;
PAAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22633769	chr20:60982531	CABLES2	-0.47	-4.28	-0.33	3.3e-5	Colorectal cancer;
PAAD	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs3762637	0.941	rs28679619	chr3:122100349	C/A	cg24169773	chr3:122142474	KPNA1	-0.65	-4.45	-0.34	1.69e-5	LDL cholesterol levels;
PAAD	cis	rs4740619	0.967	rs6474945	chr9:15670492	G/T	cg14451791	chr9:16040625	NA	-0.38	-4.5	-0.34	1.37e-5	Body mass index;
PAAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg24053715	chr22:38214548	NA	0.57	5.54	0.41	1.33e-7	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.49	4.9	0.37	2.48e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg23024343	chr7:107201750	COG5	0.57	4.57	0.35	9.87e-6	Coronary artery disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11890603	chr11:207529	RIC8A;BET1L	0.57	6.6	0.47	6.6e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.66	-6.81	-0.48	2.12e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.76	7.89	0.54	5.41e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.34	4.73	0.36	5.07e-6	Oropharynx cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25683012	chr12:57030113	BAZ2A	0.57	6.45	0.46	1.4e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-5.75	-0.42	4.74e-8	Resting heart rate;
PAAD	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg10729496	chr3:10149963	C3orf24	0.65	5.72	0.42	5.51e-8	Alzheimer's disease;
PAAD	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg02869306	chr7:64672164	INTS4L1	0.42	4.89	0.37	2.52e-6	Aortic root size;
PAAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	4.39	0.34	2.08e-5	Breast cancer;
PAAD	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg06606381	chr12:133084897	FBRSL1	-1.38	-9.19	-0.6	2.83e-16	Depression;
PAAD	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.88	10.38	0.64	2.08e-19	Sudden cardiac arrest;
PAAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg21565972	chr17:80109576	CCDC57	-0.59	-6.78	-0.48	2.55e-10	Life satisfaction;
PAAD	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.89	7.98	0.54	3.24e-13	Body mass index;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.82	6.86	0.49	1.63e-10	Alzheimer's disease;
PAAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.58	-5.75	-0.42	4.74e-8	P wave terminal force;
PAAD	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.56	-7.31	-0.51	1.4e-11	Longevity;
PAAD	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.53	-4.94	-0.37	2.08e-6	Blood metabolite levels;
PAAD	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg02533289	chr5:1952807	NA	0.27	4.44	0.34	1.75e-5	Lung cancer;
PAAD	cis	rs2031532	0.731	rs7338494	chr13:50099188	C/A	cg08779649	chr13:50194554	NA	0.36	4.64	0.35	7.52e-6	Cardiac hypertrophy;
PAAD	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg15507776	chr3:136538369	TMEM22	0.47	4.61	0.35	8.63e-6	Neuroticism;
PAAD	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.68	7.52	0.52	4.53e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	6.08	0.44	9.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.74	-8.38	-0.56	3.29e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.64	7.69	0.53	1.74e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.6	6.08	0.44	9.33e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg21937377	chr3:194868750	C3orf21	0.48	4.31	0.33	2.94e-5	Non-small cell lung cancer;
PAAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.13	-9.01	-0.59	8.06e-16	Gout;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10769251	chr19:10679905	CDKN2D	0.58	6.46	0.46	1.35e-9	Monocyte percentage of white cells;
PAAD	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.58	5.13	0.38	8.73e-7	Common traits (Other);
PAAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19346786	chr7:2764209	NA	-0.41	-4.91	-0.37	2.29e-6	Height;
PAAD	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg25547332	chr5:131281432	NA	-0.57	-4.43	-0.34	1.82e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	8.09	0.55	1.78e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14275095	chr12:52828633	KRT75	-0.63	-6.33	-0.46	2.63e-9	Obesity-related traits;
PAAD	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg09184832	chr6:79620586	NA	-0.42	-4.3	-0.33	3.01e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg00738919	chr7:1100172	C7orf50	0.51	4.28	0.33	3.36e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg03948781	chr1:205179583	DSTYK	0.51	4.65	0.35	7.25e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-6.52	-0.47	9.79e-10	Morning vs. evening chronotype;
PAAD	cis	rs4605213	0.510	rs11651110	chr17:49299066	A/G	cg25022915	chr17:49243257	NME2;NME1-NME2	-0.36	-4.57	-0.35	1.02e-5	Height;
PAAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.47	0.46	1.25e-9	Height;
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg26174226	chr8:58114915	NA	-0.59	-4.33	-0.33	2.73e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21646471	chr2:242523971	THAP4	0.6	4.69	0.36	6.16e-6	Prostate cancer;
PAAD	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.63	-6.64	-0.47	5.22e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.76	8.94	0.59	1.22e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs2278796	0.697	rs4951150	chr1:204952849	C/A	cg09852221	chr1:205912646	SLC26A9	-0.37	-4.29	-0.33	3.11e-5	Mean platelet volume;
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg09473613	chr1:24152604	HMGCL	0.54	5.74	0.42	5.01e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.85	8.79	0.58	3e-15	Lymphocyte counts;
PAAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg19761014	chr17:28927070	LRRC37B2	0.94	6.32	0.46	2.78e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.83	-9.49	-0.61	4.69e-17	Height;
PAAD	cis	rs10426930	0.763	rs7257002	chr19:5043527	G/T	cg08036796	chr19:5034282	KDM4B	0.49	4.88	0.37	2.64e-6	Monocyte percentage of white cells;
PAAD	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg05338066	chr1:7812865	CAMTA1	0.64	4.88	0.37	2.62e-6	Inflammatory bowel disease;
PAAD	cis	rs507080	0.922	rs625513	chr11:118555719	A/C	cg08498647	chr11:118550644	TREH	-0.37	-4.28	-0.33	3.36e-5	Serum metabolite levels;
PAAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.1	0.59	4.73e-16	Parkinson's disease;
PAAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg14146966	chr2:61757674	XPO1	-0.39	-4.8	-0.36	3.74e-6	Tuberculosis;
PAAD	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-18.71	-0.84	2.79e-41	Exhaled nitric oxide output;
PAAD	cis	rs1443512	0.947	rs894739	chr12:54346869	T/C	cg25382128	chr12:54346509	NA	-0.62	-6.33	-0.46	2.64e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg03538708	chr1:25844672	NA	-0.49	-5.04	-0.38	1.29e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs6547631	0.622	rs10180547	chr2:85926305	G/A	cg24620635	chr2:85921963	GNLY	0.4	5.31	0.4	3.89e-7	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13784866	chr9:139269562	CARD9	0.58	6.67	0.48	4.57e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.76	8.42	0.56	2.61e-14	Menopause (age at onset);
PAAD	cis	rs3777722	0.584	rs3777723	chr6:167353701	C/T	cg01837879	chr6:166900442	RPS6KA2	-0.66	-4.78	-0.36	4.08e-6	Spontaneous preterm birth (preterm birth);
PAAD	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.64	-6.79	-0.48	2.43e-10	Post bronchodilator FEV1;
PAAD	cis	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg21546286	chr11:48923668	NA	0.55	5.73	0.42	5.18e-8	HDL cholesterol;
PAAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25833597	chr17:30823145	MYO1D	0.5	4.76	0.36	4.51e-6	Schizophrenia;
PAAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.52	5.23	0.39	5.52e-7	Bone mineral density;
PAAD	cis	rs6076065	0.723	rs6132604	chr20:23342226	G/A	cg11657817	chr20:23433608	CST11	0.51	5.15	0.39	7.79e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg16898833	chr6:26189333	HIST1H4D	0.48	4.33	0.33	2.75e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.91	-9.96	-0.63	2.73e-18	Headache;
PAAD	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg05250797	chr16:70222502	NA	0.87	6.74	0.48	3.04e-10	IgE levels;
PAAD	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.73	6.89	0.49	1.37e-10	Primary sclerosing cholangitis;
PAAD	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00540400	chr15:79124168	NA	0.57	6.41	0.46	1.77e-9	Coronary artery disease;
PAAD	cis	rs113123495	0.609	rs2436502	chr19:5645444	G/A	cg26242866	chr19:5711310	LONP1	1.07	5.27	0.39	4.7e-7	Obsessive-compulsive symptoms;
PAAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.73	6.24	0.45	4.19e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-4.6	-0.35	8.75e-6	Cystic fibrosis severity;
PAAD	cis	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.43	-0.4	2.15e-7	HDL cholesterol;
PAAD	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.7	7.03	0.5	6.69e-11	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs9982086	0.557	rs214480	chr21:27301934	C/T	cg04970570	chr5:87990145	NA	0.6	6.35	0.46	2.34e-9	Carboplatin disposition in epthelial ovarian cancer;
PAAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-6.43	-0.46	1.54e-9	Bipolar disorder;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08649707	chr8:11833191	DEFB136	-0.57	-6.49	-0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs9832625	0.748	rs6807880	chr3:29337198	T/G	cg06712285	chr3:29990487	RBMS3	-0.7	-4.31	-0.33	2.98e-5	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.88	8.6	0.57	9.34e-15	Homoarginine levels;
PAAD	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.8	-6.73	-0.48	3.3e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-4.8	-0.36	3.84e-6	Menopause (age at onset);
PAAD	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg24330906	chr2:85765176	MAT2A	0.57	5.61	0.41	9.15e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-7.11	-0.5	4.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2133450	0.526	rs12495356	chr3:7348994	T/C	cg19930620	chr3:7340148	GRM7	-0.47	-5.05	-0.38	1.24e-6	Early response to risperidone in schizophrenia;
PAAD	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg14146966	chr2:61757674	XPO1	-0.39	-4.96	-0.37	1.9e-6	Tuberculosis;
PAAD	cis	rs8102137	1.000	rs3218036	chr19:30305684	A/G	cg27475126	chr19:30303651	CCNE1	0.45	5.01	0.38	1.49e-6	Bladder cancer;
PAAD	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-6.47	-0.46	1.26e-9	Response to antipsychotic treatment;
PAAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.52	5.28	0.39	4.35e-7	Caffeine consumption;
PAAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-9.42	-0.61	7.18e-17	Gut microbiome composition (summer);
PAAD	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.61	0.47	6.09e-10	High light scatter reticulocyte count;
PAAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.85	-9.33	-0.6	1.23e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-7.53	-0.52	4.18e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.42	0.61	7.05e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs939584	0.935	rs13396119	chr2:637508	T/C	cg03610516	chr2:642275	NA	0.6	5.41	0.4	2.44e-7	Body mass index;
PAAD	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.69	6.44	0.46	1.51e-9	Obesity-related traits;
PAAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg09835421	chr16:68378352	PRMT7	-1.0	-6.52	-0.47	9.6e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.59	-5.16	-0.39	7.63e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.46	-5.49	-0.41	1.67e-7	Mean corpuscular volume;
PAAD	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.57	-5.23	-0.39	5.47e-7	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg08501292	chr6:25962987	TRIM38	0.91	4.41	0.34	1.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12667521	chr19:29218732	NA	0.75	7.2	0.5	2.64e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-7.25	-0.51	1.96e-11	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.02	17.88	0.82	3.3e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.52	-4.8	-0.36	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs1395	0.634	rs62130713	chr2:27525661	A/G	cg23587288	chr2:27483067	SLC30A3	-0.64	-4.89	-0.37	2.49e-6	Blood metabolite levels;
PAAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.5	-6.55	-0.47	8.19e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg24253500	chr15:84953950	NA	0.5	5.33	0.4	3.48e-7	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg09414773	chr4:41992992	SLC30A9	0.63	7.07	0.5	5.35e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg18508148	chr11:34937573	PDHX;APIP	0.53	5.13	0.38	8.57e-7	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg19423196	chr10:82049429	MAT1A	0.57	4.39	0.34	2.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.57	-4.33	-0.33	2.72e-5	Smoking behavior;
PAAD	cis	rs603424	0.509	rs598133	chr10:102082245	A/G	cg10365880	chr10:102089681	PKD2L1	0.77	5.17	0.39	7.34e-7	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
PAAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg00990874	chr7:1149470	C7orf50	-0.74	-5.82	-0.43	3.38e-8	Bronchopulmonary dysplasia;
PAAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg15061591	chr7:98625706	SMURF1	-0.47	-4.35	-0.33	2.49e-5	Breast cancer;
PAAD	cis	rs7765175	0.775	rs7766390	chr6:113682732	G/A	cg19037598	chr6:113666021	NA	-0.44	-4.82	-0.36	3.48e-6	Coronary artery calcification;
PAAD	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.64	0.57	7.12e-15	Corneal astigmatism;
PAAD	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.44	-0.34	1.69e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-4.28	-0.33	3.27e-5	Coronary artery disease;
PAAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.26	-10.07	-0.63	1.34e-18	Post bronchodilator FEV1;
PAAD	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg15049549	chr3:48732213	IP6K2	0.5	4.31	0.33	2.96e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg04257695	chr17:30186438	C17orf79	-0.54	-4.39	-0.34	2.11e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	6.19	0.45	5.37e-9	Prudent dietary pattern;
PAAD	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg01631408	chr1:248437212	OR2T33	-0.58	-5.16	-0.39	7.67e-7	Common traits (Other);
PAAD	cis	rs1519814	0.654	rs1543201	chr8:121018888	A/T	cg22335954	chr8:121166405	COL14A1	0.64	5.08	0.38	1.08e-6	Breast cancer;
PAAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.77	-7.87	-0.54	6.32e-13	Prudent dietary pattern;
PAAD	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg20406979	chr6:167373233	NA	-0.32	-4.34	-0.33	2.63e-5	Crohn's disease;
PAAD	cis	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.43	0.34	1.78e-5	Depression;
PAAD	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg14825688	chr5:132208181	LEAP2	-0.61	-4.39	-0.34	2.1e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg02532672	chr7:808649	HEATR2	-0.58	-6.18	-0.45	5.62e-9	Subjective well-being;
PAAD	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg03684893	chr10:554711	DIP2C	0.47	4.55	0.35	1.11e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1958023	0.624	rs912855	chr14:33658745	C/T	cg05836965	chr14:33403068	NA	-0.34	-4.39	-0.34	2.11e-5	Mitochondrial DNA levels;
PAAD	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg20356878	chr3:121714668	ILDR1	0.52	4.94	0.37	2.07e-6	Cognitive performance;
PAAD	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.61	-0.47	6.13e-10	Aortic root size;
PAAD	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg04106633	chr4:1044584	NA	0.63	5.23	0.39	5.63e-7	Recombination rate (females);
PAAD	cis	rs36096196	0.945	rs12080256	chr1:2251357	C/A	cg17974515	chr1:2252516	NA	0.62	6.32	0.46	2.76e-9	Coronary artery disease;
PAAD	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.51	4.98	0.37	1.73e-6	Motion sickness;
PAAD	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	10.46	0.65	1.25e-19	Post bronchodilator FEV1;
PAAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	7.75	0.53	1.22e-12	Personality dimensions;
PAAD	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg10174797	chr19:8464628	RAB11B	0.59	5.48	0.41	1.73e-7	HDL cholesterol;
PAAD	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.49	4.35	0.33	2.48e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.36	0.4	3.03e-7	Height;
PAAD	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.63	5.03	0.38	1.38e-6	Information processing speed;
PAAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.79	-9.81	-0.62	6.68e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg06740227	chr12:86229804	RASSF9	-0.56	-5.09	-0.38	1.06e-6	Major depressive disorder;
PAAD	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.69	8.75	0.58	3.76e-15	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.67	0.42	6.89e-8	Prudent dietary pattern;
PAAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg09835421	chr16:68378352	PRMT7	-1.07	-7.86	-0.54	6.6e-13	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg23283495	chr1:209979779	IRF6	0.63	5.9	0.43	2.3e-8	Coronary artery disease;
PAAD	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-13.25	-0.73	4.03e-27	Dental caries;
PAAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg02734326	chr4:10020555	SLC2A9	0.47	4.73	0.36	5.09e-6	Bone mineral density;
PAAD	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg14583973	chr4:3374767	RGS12	-0.36	-5.49	-0.41	1.64e-7	Mean platelet volume;
PAAD	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.7	4.88	0.37	2.64e-6	Vitiligo;
PAAD	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.66	6.32	0.46	2.77e-9	Corneal astigmatism;
PAAD	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg19254793	chr6:44695348	NA	-0.45	-4.42	-0.34	1.89e-5	Total body bone mineral density;
PAAD	cis	rs939584	1.000	rs7559018	chr2:645203	C/T	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs59888335	0.895	rs35806052	chr3:80865880	A/G	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12599982	chr1:44399894	ARTN	0.43	4.68	0.35	6.41e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.45	5.28	0.39	4.46e-7	Immature fraction of reticulocytes;
PAAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	6.79	0.48	2.38e-10	Height;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08996726	chr4:141067418	MAML3	-0.52	-6.31	-0.46	2.94e-9	Monocyte percentage of white cells;
PAAD	cis	rs6494488	0.500	rs59684202	chr15:65018501	A/C	cg16425858	chr15:64791681	ZNF609	0.88	4.71	0.36	5.43e-6	Coronary artery disease;
PAAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.72	7.06	0.5	5.52e-11	DNA methylation (variation);
PAAD	cis	rs7082209	0.540	rs800310	chr10:44815048	A/T	cg08683644	chr10:44853092	NA	0.5	4.31	0.33	2.97e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg09127314	chr1:152161683	NA	-0.66	-4.39	-0.34	2.09e-5	Atopic dermatitis;
PAAD	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-9.66	-0.62	1.67e-17	Alzheimer's disease (late onset);
PAAD	cis	rs904092	0.786	rs62305755	chr4:100150020	G/A	cg12011299	chr4:100065546	ADH4	0.6	5.53	0.41	1.35e-7	Alcohol dependence;
PAAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.59	7.04	0.5	6.3e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73206853	0.841	rs16940885	chr12:110971666	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.69	-4.88	-0.37	2.62e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.8	-5.97	-0.44	1.61e-8	Coronary artery calcification;
PAAD	cis	rs56011263	0.532	rs4234853	chr4:735150	G/A	cg05835009	chr4:710272	PCGF3	0.64	5.28	0.39	4.34e-7	White blood cell count;
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14008862	chr17:28927542	LRRC37B2	0.87	5.93	0.43	1.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs9467603	1.000	rs13201341	chr6:25822661	C/T	cg01620082	chr3:125678407	NA	-1.41	-7.82	-0.54	8.25e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-4.5	-0.34	1.37e-5	Morning vs. evening chronotype;
PAAD	cis	rs73416724	0.688	rs77241311	chr6:43364043	C/T	cg17076780	chr6:43251928	TTBK1	0.75	5.23	0.39	5.48e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.8	9.06	0.59	5.99e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.64	6.49	0.47	1.13e-9	Alcohol dependence;
PAAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.98	11.49	0.68	2.17e-22	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-15.71	-0.79	1.21e-33	Schizophrenia;
PAAD	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.35	4.6	0.35	8.74e-6	Schizophrenia;
PAAD	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg10483660	chr13:112241077	NA	-0.56	-5.14	-0.39	8.17e-7	Menarche (age at onset);
PAAD	cis	rs2241685	0.621	rs56919961	chr2:1902125	C/T	cg22511877	chr2:1942942	MYT1L	-0.74	-5.05	-0.38	1.28e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.49	4.51	0.34	1.31e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.51	5.54	0.41	1.33e-7	Noise-induced hearing loss;
PAAD	cis	rs8060686	0.841	rs73599506	chr16:67712366	T/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-4.99	-0.38	1.63e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg06057569	chr22:50219754	BRD1	0.68	5.05	0.38	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs939584	1.000	rs13386964	chr2:650828	A/G	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.43	-4.9	-0.37	2.47e-6	Testicular germ cell tumor;
PAAD	cis	rs58521262	0.516	rs1842018	chr19:23095233	A/G	cg22640819	chr19:22990650	NA	-0.29	-4.35	-0.33	2.47e-5	Testicular germ cell tumor;
PAAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg20243544	chr17:37824526	PNMT	0.52	4.53	0.34	1.19e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg14829360	chr17:73884958	NA	-0.69	-6.2	-0.45	4.98e-9	Psoriasis;
PAAD	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.49	-5.97	-0.44	1.64e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.96	6.77	0.48	2.63e-10	Pulse pressure;Diastolic blood pressure;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10219512	chr6:43337449	ZNF318	0.64	6.82	0.48	1.97e-10	Myopia (pathological);
PAAD	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.7	7.4	0.51	8.58e-12	IgG glycosylation;
PAAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg10556349	chr10:835070	NA	0.59	4.95	0.37	1.96e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg04705435	chr11:17411270	KCNJ11	0.59	6.14	0.45	7.03e-9	Type 2 diabetes;
PAAD	cis	rs8022179	0.566	rs62006258	chr14:103838909	A/C	cg12935359	chr14:103987150	CKB	0.54	4.65	0.35	7.15e-6	Monocyte count;
PAAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.54	5.74	0.42	4.98e-8	Menopause (age at onset);
PAAD	cis	rs6604026	0.656	rs12066638	chr1:93375391	C/G	cg13858687	chr1:93297071	RPL5	-0.47	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.62	5.69	0.42	6.23e-8	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.73	5.55	0.41	1.25e-7	Alzheimer's disease;
PAAD	cis	rs9361491	0.657	rs9343801	chr6:79462275	G/A	cg05283184	chr6:79620031	NA	-0.36	-4.43	-0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08246036	chr12:97301129	NEDD1	0.77	7.07	0.5	5.2e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs988913	0.706	rs6908568	chr6:54881564	C/G	cg03513858	chr6:54763001	FAM83B	-0.39	-4.25	-0.33	3.74e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg14440974	chr22:39074834	NA	0.57	6.52	0.47	9.95e-10	Menopause (age at onset);
PAAD	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.57	-5.71	-0.42	5.86e-8	Tonsillectomy;
PAAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.61	0.35	8.56e-6	Obesity-related traits;
PAAD	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-5.62	-0.41	9.01e-8	Alzheimer's disease (late onset);
PAAD	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg03264133	chr6:25882463	NA	-0.54	-4.93	-0.37	2.17e-6	Iron status biomarkers;
PAAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22442454	chr1:209979470	IRF6	0.59	5.52	0.41	1.41e-7	Cleft lip with or without cleft palate;
PAAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12165864	chr7:66369176	NA	-0.75	-4.79	-0.36	3.97e-6	Diabetic kidney disease;
PAAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.38	-4.6	-0.35	8.76e-6	Menarche (age at onset);
PAAD	cis	rs7187994	0.848	rs3751759	chr16:84778222	G/A	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg25452165	chr22:42524984	CYP2D6	-0.58	-4.33	-0.33	2.71e-5	Schizophrenia;
PAAD	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.61	-5.82	-0.43	3.37e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg16125397	chr14:35021983	NA	0.56	6.39	0.46	1.89e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.52	4.93	0.37	2.1e-6	Airway imaging phenotypes;
PAAD	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-4.93	-0.37	2.12e-6	Schizophrenia (age at onset);
PAAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.29	-0.51	1.61e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg23465465	chr6:26364728	BTN3A2	0.77	4.76	0.36	4.42e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.74	6.74	0.48	3.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.5	6.13	0.44	7.41e-9	Sitting height ratio;
PAAD	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.44	4.25	0.33	3.74e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs308971	0.656	rs307610	chr3:12064555	C/T	cg15873301	chr3:12045459	SYN2	0.64	5.3	0.4	3.95e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs7737355	0.853	rs10051003	chr5:131072410	C/T	cg06307176	chr5:131281290	NA	0.49	4.29	0.33	3.15e-5	Life satisfaction;
PAAD	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg09579323	chr1:150459698	TARS2	0.46	4.43	0.34	1.82e-5	Migraine;
PAAD	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.51	4.6	0.35	8.77e-6	Blood protein levels;
PAAD	cis	rs6578985	0.636	rs3213225	chr11:2156536	C/T	cg12383159	chr11:1262597	MUC5B	-0.39	-4.58	-0.35	9.49e-6	Femoral neck bone geometry and menarche (age at onset);
PAAD	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.52	-0.34	1.25e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	1.11	6.57	0.47	7.49e-10	Body mass index;
PAAD	cis	rs11671653	0.688	rs11669339	chr19:10836601	A/C	cg18582342	chr19:11591989	ELAVL3	-0.64	-4.28	-0.33	3.25e-5	LDL cholesterol;
PAAD	cis	rs10901513	0.932	rs56266020	chr10:127668033	G/A	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg10591111	chr5:226296	SDHA	-0.7	-5.44	-0.4	2.08e-7	Breast cancer;
PAAD	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.96	5.55	0.41	1.24e-7	Schizophrenia;
PAAD	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11644478	chr21:40555479	PSMG1	-0.47	-4.71	-0.36	5.62e-6	Menarche (age at onset);
PAAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg27511599	chr7:32358540	NA	0.72	4.38	0.33	2.23e-5	Body mass index;
PAAD	cis	rs66530629	0.874	rs1890449	chr1:25075801	G/T	cg01905478	chr1:25040257	NA	0.47	5.15	0.39	8.01e-7	Plateletcrit;
PAAD	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg19486271	chr11:47235900	DDB2	-0.59	-5.93	-0.43	1.99e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.91	-7.27	-0.51	1.79e-11	Triglycerides;
PAAD	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	5.73	0.42	5.34e-8	Lung cancer in ever smokers;
PAAD	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.89	-4.56	-0.35	1.03e-5	Toenail selenium levels;
PAAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.73	-8.1	-0.55	1.63e-13	Menopause (age at onset);
PAAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg13722127	chr7:150037890	RARRES2	0.54	5.45	0.4	1.95e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs4588572	0.644	rs9293751	chr5:77778296	A/G	cg11547950	chr5:77652471	NA	-0.69	-6.19	-0.45	5.35e-9	Triglycerides;
PAAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.51	-5.86	-0.43	2.76e-8	Cardiovascular disease risk factors;
PAAD	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.86	5.83	0.43	3.27e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
PAAD	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.77	5.88	0.43	2.46e-8	Schizophrenia;
PAAD	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg02917321	chr22:38215204	NA	0.49	4.72	0.36	5.24e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.98	13.95	0.75	5.27e-29	Heart rate;
PAAD	cis	rs1497828	0.956	rs2859771	chr1:217539502	G/C	cg04411442	chr1:217543379	NA	-0.48	-4.73	-0.36	5.1e-6	Dialysis-related mortality;
PAAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg10591111	chr5:226296	SDHA	-0.71	-5.52	-0.41	1.44e-7	Breast cancer;
PAAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.62	-8.28	-0.56	5.89e-14	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02569437	chr6:42947051	PEX6	0.61	6.95	0.49	1.02e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs58521262	0.585	rs11668997	chr19:22993762	A/G	cg07749055	chr19:23076870	NA	-0.59	-4.68	-0.35	6.41e-6	Testicular germ cell tumor;
PAAD	cis	rs1570989	0.543	rs6458035	chr6:12015296	A/G	cg17804551	chr6:12015979	HIVEP1	0.49	4.57	0.35	1.02e-5	Alcohol and nicotine co-dependence;
PAAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.76	9.85	0.62	5.29e-18	Iron status biomarkers (transferrin levels);
PAAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.53	0.47	9.28e-10	Coronary artery disease;
PAAD	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.65	-5.99	-0.44	1.42e-8	Multiple myeloma;
PAAD	cis	rs860295	0.557	rs7534795	chr1:155275553	C/T	cg02153340	chr1:155202674	NA	-0.48	-4.3	-0.33	3.04e-5	Body mass index;
PAAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg05484376	chr2:27715224	FNDC4	0.46	4.71	0.36	5.5e-6	Total body bone mineral density;
PAAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.31	0.33	2.97e-5	Bipolar disorder;
PAAD	cis	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg12740337	chr6:28058973	ZSCAN12L1	0.54	4.45	0.34	1.65e-5	Breast cancer;
PAAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.54	5.72	0.42	5.49e-8	Menopause (age at onset);
PAAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.55	-5.22	-0.39	5.85e-7	Blood metabolite levels;
PAAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-1.01	-6.71	-0.48	3.53e-10	IgG glycosylation;
PAAD	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.69	-6.26	-0.45	3.77e-9	Mean platelet volume;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg17372657	chr7:1216933	NA	-0.37	-4.4	-0.34	2e-5	Longevity;Endometriosis;
PAAD	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.45	4.42	0.34	1.88e-5	Schizophrenia;
PAAD	cis	rs11811982	0.793	rs79014060	chr1:227509081	T/C	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	trans	rs901683	1.000	rs35001302	chr10:46068936	G/A	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.27	0.33	3.37e-5	Aortic root size;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22466171	chr4:99850251	EIF4E	-0.69	-7.77	-0.53	1.1e-12	Smoking initiation;
PAAD	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg25547332	chr5:131281432	NA	0.58	4.55	0.35	1.09e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg10515125	chr16:89437361	ANKRD11	-0.48	-4.98	-0.37	1.68e-6	Melanoma;
PAAD	cis	rs11853189	0.938	rs1879152	chr15:78581840	T/C	cg22935921	chr15:78556834	DNAJA4	0.78	5.36	0.4	3.03e-7	Red cell distribution width;
PAAD	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.67	7.41	0.52	8.05e-12	Systemic lupus erythematosus;
PAAD	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-8.35	-0.56	3.9e-14	Total body bone mineral density;
PAAD	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.93	12.11	0.7	4.78e-24	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.59	-6.2	-0.45	4.97e-9	Eosinophil percentage of white cells;
PAAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg00431813	chr7:1051703	C7orf50	0.44	5.52	0.41	1.43e-7	Longevity;Endometriosis;
PAAD	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.97	7.53	0.52	4.18e-12	Lymphocyte counts;
PAAD	cis	rs75920871	1.000	rs17120233	chr11:116871223	A/G	cg04087571	chr11:116723030	SIK3	-0.41	-4.36	-0.33	2.4e-5	Subjective well-being;
PAAD	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.53	4.91	0.37	2.29e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.3	-0.39	4.08e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.63	6.24	0.45	4.22e-9	Lung cancer;
PAAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.17	0.55	1.13e-13	Schizophrenia;
PAAD	cis	rs4663866	0.522	rs111276182	chr2:239118832	G/A	cg03190769	chr2:238382720	NA	-0.79	-4.32	-0.33	2.81e-5	Irritable bowel syndrome;
PAAD	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg04330084	chr7:123175371	IQUB	0.5	4.32	0.33	2.84e-5	Plateletcrit;Platelet count;
PAAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.53	0.57	1.37e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.27	-0.33	3.38e-5	Eotaxin levels;
PAAD	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs75920871	0.920	rs61907594	chr11:116801811	C/T	cg04087571	chr11:116723030	SIK3	-0.47	-4.71	-0.36	5.46e-6	Subjective well-being;
PAAD	cis	rs7326068	0.610	rs3924006	chr13:21331779	T/A	cg27499820	chr13:21296301	IL17D	0.57	5.25	0.39	4.99e-7	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08677398	chr8:58056175	NA	0.68	4.76	0.36	4.45e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.87	-10.93	-0.66	6.91e-21	Aortic root size;
PAAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.5	4.36	0.33	2.39e-5	Tonsillectomy;
PAAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.55	0.65	7.17e-20	Menopause (age at onset);
PAAD	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.73	7.84	0.54	7.18e-13	Prostate cancer;
PAAD	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.45	-0.34	1.62e-5	Depression;
PAAD	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg13332499	chr17:408570	NA	0.67	7.11	0.5	4.29e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06850241	chr22:41845214	NA	-0.54	-4.69	-0.36	6.01e-6	Vitiligo;
PAAD	cis	rs3026101	0.671	rs3026145	chr17:5316742	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	6.02	0.44	1.28e-8	Body mass index;
PAAD	trans	rs12738007	0.933	rs6426352	chr1:29470843	G/C	cg05667379	chr2:115920764	DPP10	0.38	6.49	0.47	1.17e-9	Schizophrenia;
PAAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.77	5.71	0.42	5.71e-8	Initial pursuit acceleration;
PAAD	cis	rs11264799	0.765	rs66931510	chr1:157635085	C/T	cg18268488	chr1:157545234	FCRL4	0.42	4.55	0.35	1.07e-5	IgA nephropathy;
PAAD	cis	rs7984522	1.000	rs7984522	chr13:109347659	A/G	cg11693848	chr13:109793698	MYO16	0.42	4.36	0.33	2.38e-5	Blood pressure;
PAAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.35	-4.82	-0.36	3.44e-6	Lymphocyte counts;
PAAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.6	0.41	9.93e-8	Bipolar disorder;
PAAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-5.87	-0.43	2.61e-8	Total body bone mineral density;
PAAD	cis	rs7070678	0.638	rs61849287	chr10:29795756	C/T	cg05086789	chr10:29701805	LOC387647	-0.49	-4.58	-0.35	9.58e-6	Platelet thrombus formation;
PAAD	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.62	1.66e-17	Response to antipsychotic treatment;
PAAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-4.93	-0.37	2.11e-6	Neurofibrillary tangles;
PAAD	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg21466736	chr12:48725269	NA	-0.5	-4.65	-0.35	7.26e-6	Glycated hemoglobin levels;
PAAD	cis	rs58521262	0.505	rs289343	chr19:23150196	C/T	cg03433597	chr19:22806448	NA	-0.24	-4.33	-0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs7619427	0.544	rs9877020	chr3:43992455	A/G	cg12796028	chr3:44040206	NA	0.53	4.61	0.35	8.63e-6	Schizophrenia;
PAAD	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.61	5.52	0.41	1.4e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.47	4.46	0.34	1.61e-5	Crohn's disease;
PAAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.77	-8.31	-0.56	5.01e-14	Lung cancer;
PAAD	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.53	-5.56	-0.41	1.17e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	8.39	0.56	3.1e-14	Prudent dietary pattern;
PAAD	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.34	-0.33	2.6e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg12708802	chr3:50388878	TUSC4;CYB561D2	0.61	6.51	0.47	1.04e-9	Schizophrenia;
PAAD	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg00262122	chr8:11665843	FDFT1	0.62	6.0	0.44	1.36e-8	Myopia (pathological);
PAAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg18888403	chr1:24152774	HMGCL	0.41	4.68	0.36	6.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.48	4.31	0.33	2.95e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.67	6.14	0.45	6.77e-9	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	10.14	0.64	8.65e-19	Testicular germ cell tumor;
PAAD	cis	rs9815354	0.953	rs4615050	chr3:41942498	T/A	cg03022575	chr3:42003672	ULK4	-0.82	-5.79	-0.42	3.97e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.67	-7.47	-0.52	5.81e-12	Heart rate;
PAAD	cis	rs1697938	0.590	rs2455301	chr5:40938922	T/C	cg22359217	chr5:41925772	FBXO4	-0.46	-4.58	-0.35	9.71e-6	Multiple system atrophy;
PAAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.73	-8.62	-0.57	7.94e-15	Height;
PAAD	cis	rs59888335	0.929	rs2888347	chr3:80891157	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg21823605	chr1:152486609	CRCT1	-0.52	-6.77	-0.48	2.58e-10	Hair morphology;
PAAD	cis	rs7786877	0.587	rs56328569	chr7:100202219	C/G	cg00334542	chr7:100209784	MOSPD3	-0.68	-5.07	-0.38	1.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.44	4.71	0.36	5.53e-6	Age of smoking initiation;
PAAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg02917321	chr22:38215204	NA	0.47	4.78	0.36	4.12e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.58	-5.87	-0.43	2.67e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24862550	chr20:36661640	RPRD1B;KIAA0406	0.6	6.55	0.47	8.49e-10	Monocyte percentage of white cells;
PAAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.45	4.99	0.38	1.62e-6	Electroencephalogram traits;
PAAD	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg11993925	chr19:44307056	LYPD5	0.5	6.68	0.48	4.23e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.31	4.46	0.34	1.61e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs12311304	1.000	rs7358676	chr12:15382293	T/G	cg08258403	chr12:15378311	NA	0.35	4.42	0.34	1.88e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-5.97	-0.44	1.58e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg23465465	chr6:26364728	BTN3A2	-0.83	-4.94	-0.37	1.99e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg04160749	chr8:58172571	NA	-0.81	-8.05	-0.55	2.19e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.56	6.26	0.45	3.8e-9	Diastolic blood pressure;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04904530	chr17:18086472	ALKBH5	-0.7	-7.37	-0.51	1.03e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.5	4.72	0.36	5.3e-6	Lymphocyte percentage of white cells;
PAAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.61	-6.93	-0.49	1.11e-10	Longevity;Endometriosis;
PAAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg00262122	chr8:11665843	FDFT1	0.49	4.38	0.33	2.2e-5	Retinal vascular caliber;
PAAD	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs67478160	0.584	rs2295151	chr14:104193099	C/G	cg08213375	chr14:104286397	PPP1R13B	0.47	6.25	0.45	4.04e-9	Schizophrenia;
PAAD	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg21479132	chr6:26055353	NA	0.91	5.41	0.4	2.43e-7	Autism spectrum disorder or schizophrenia;
PAAD	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.33	-0.33	2.69e-5	Blood protein levels;
PAAD	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.42	6.41	0.46	1.7e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.8	-0.43	3.75e-8	Mood instability;
PAAD	trans	rs1146751	0.674	rs694795	chr3:84934038	T/A	cg21856205	chr7:94953877	PON1	0.7	6.57	0.47	7.71e-10	Photic sneeze reflex;
PAAD	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.82	9.22	0.6	2.3e-16	Ulcerative colitis;
PAAD	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg03233332	chr7:66118400	NA	-0.4	-4.41	-0.34	1.94e-5	Aortic root size;
PAAD	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-4.42	-0.34	1.9e-5	Coronary artery disease;
PAAD	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.59	-5.62	-0.41	8.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23799558	chr11:73745484	C2CD3	-0.66	-7.02	-0.49	6.83e-11	Obesity-related traits;
PAAD	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg00262122	chr8:11665843	FDFT1	0.49	4.63	0.35	7.77e-6	Neuroticism;
PAAD	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-5.63	-0.42	8.5e-8	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17554472	chr22:41940697	POLR3H	0.55	4.3	0.33	3.05e-5	Vitiligo;
PAAD	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg08758996	chr17:66097529	LOC651250	-0.52	-4.79	-0.36	3.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs9785234	0.793	rs714676	chr9:98940178	A/G	cg07115975	chr9:98273907	PTCH1	-0.51	-4.52	-0.34	1.26e-5	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.53	-5.03	-0.38	1.39e-6	Mortality in heart failure;
PAAD	cis	rs790110	1.000	rs812047	chr3:122382074	C/G	cg22468055	chr3:122334227	PARP15	0.84	4.67	0.35	6.47e-6	Acoustic startle blink response;
PAAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg25204440	chr1:209979598	IRF6	0.68	6.58	0.47	7.1e-10	Cleft lip with or without cleft palate;
PAAD	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-4.88	-0.37	2.66e-6	Blood pressure;
PAAD	cis	rs3206736	0.548	rs328929	chr7:35040038	A/G	cg20495677	chr7:34801759	AAA1;NPSR1	-0.48	-4.65	-0.35	7.01e-6	Diastolic blood pressure;
PAAD	cis	rs28386778	0.700	rs7209608	chr17:62003810	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.67	-6.53	-0.47	9.14e-10	Prudent dietary pattern;
PAAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-6.82	-0.48	2.05e-10	Gut microbiome composition (summer);
PAAD	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg09324608	chr17:30823087	MYO1D	0.54	5.25	0.39	5.05e-7	Schizophrenia;
PAAD	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	1.26	8.17	0.55	1.14e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs2051773	0.567	rs12293395	chr11:17047661	C/G	cg15378786	chr11:17036137	PLEKHA7	-0.5	-4.32	-0.33	2.76e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07685180	chr8:600429	NA	0.82	5.24	0.39	5.26e-7	IgG glycosylation;
PAAD	cis	rs8049603	0.812	rs12149882	chr16:23195924	T/G	cg16484020	chr16:23217411	SCNN1G	-0.49	-4.35	-0.33	2.51e-5	Multiple sclerosis;
PAAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.43	5.34	0.4	3.32e-7	Coronary artery disease;
PAAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-4.54	-0.35	1.14e-5	Blood metabolite levels;
PAAD	cis	rs2637266	0.655	rs846628	chr10:78538392	G/A	cg18941641	chr10:78392320	NA	0.38	4.59	0.35	9.2e-6	Pulmonary function;
PAAD	cis	rs2944755	0.723	rs13274041	chr8:141587915	T/C	cg18491938	chr8:141590271	EIF2C2	-0.52	-4.92	-0.37	2.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg14393609	chr7:65229607	NA	-0.64	-6.91	-0.49	1.23e-10	Aortic root size;
PAAD	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg06627628	chr2:24431161	ITSN2	0.56	5.52	0.41	1.4e-7	Sjögren's syndrome;
PAAD	cis	rs6723108	0.713	rs6728095	chr2:135376072	T/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.53	-0.35	1.17e-5	Type 2 diabetes;
PAAD	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg18302933	chr2:88491318	NA	-0.36	-4.28	-0.33	3.28e-5	Response to metformin (IC50);
PAAD	cis	rs728616	0.867	rs77376252	chr10:81809382	C/T	cg05935833	chr10:81318306	SFTPA2	-0.64	-4.92	-0.37	2.25e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	7.2	0.5	2.56e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.69	-5.04	-0.38	1.28e-6	Major depressive disorder;
PAAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.78	9.22	0.6	2.35e-16	Eye color traits;
PAAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.8	8.29	0.56	5.49e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6137287	0.924	rs4815030	chr20:21160783	G/A	cg04219410	chr20:21106687	PLK1S1	0.41	4.7	0.36	5.74e-6	Height;
PAAD	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg14343924	chr8:8086146	FLJ10661	-0.61	-5.34	-0.4	3.33e-7	Mood instability;
PAAD	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.74	8.46	0.57	2.12e-14	Age-related hearing impairment;
PAAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26418147	chr1:205743515	RAB7L1	-0.45	-5.12	-0.38	9.08e-7	Prostate-specific antigen levels;
PAAD	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-4.68	-0.36	6.24e-6	Vitiligo;
PAAD	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.8	7.29	0.51	1.6e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.77	8.28	0.56	5.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	5.09	0.38	1.05e-6	Schizophrenia;
PAAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-1.17	-11.21	-0.67	1.23e-21	Developmental language disorder (linguistic errors);
PAAD	cis	rs185694	0.947	rs202079	chr13:30879154	C/T	cg07600127	chr13:30881527	KATNAL1	-0.68	-4.38	-0.34	2.16e-5	Antineutrophil cytoplasmic antibody-associated vasculitis;
PAAD	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.69	9.08	0.59	5.41e-16	Hemoglobin concentration;
PAAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg16928487	chr17:17741425	SREBF1	-0.35	-4.84	-0.37	3.22e-6	Total body bone mineral density;
PAAD	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.74	-7.33	-0.51	1.28e-11	White matter hyperintensity burden;
PAAD	cis	rs11159086	0.793	rs8016972	chr14:74958536	T/C	cg10195687	chr14:74926396	NA	-0.46	-5.21	-0.39	5.99e-7	Advanced glycation end-product levels;
PAAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg21361702	chr7:150065534	REPIN1	0.58	4.78	0.36	4.16e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg21855830	chr2:127963489	CYP27C1	0.44	4.32	0.33	2.77e-5	Protein C levels;
PAAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-7.46	-0.52	6.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2411984	0.603	rs1317701	chr17:47444794	T/C	cg08112188	chr17:47440006	ZNF652	0.51	4.62	0.35	8.2e-6	Sex hormone-binding globulin levels;
PAAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg19636519	chr7:99541626	NA	0.48	5.28	0.39	4.32e-7	Coronary artery disease;
PAAD	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg23260525	chr10:116636907	FAM160B1	0.45	6.74	0.48	3.07e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg00383909	chr3:49044727	WDR6	0.53	4.47	0.34	1.55e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2440129	0.632	rs15966	chr17:6905643	T/C	cg05215272	chr17:6899095	ALOX12	0.39	4.38	0.33	2.2e-5	Tonsillectomy;
PAAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.79	-7.48	-0.52	5.48e-12	Pancreatic cancer;
PAAD	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.81	-0.43	3.56e-8	Adiposity;
PAAD	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg18551225	chr6:44695536	NA	-0.74	-7.53	-0.52	4.09e-12	Total body bone mineral density;
PAAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg16049864	chr8:95962084	TP53INP1	-0.75	-8.19	-0.55	9.9e-14	Type 2 diabetes;
PAAD	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg04990556	chr1:26633338	UBXN11	0.69	5.13	0.38	8.9e-7	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.42	4.58	0.35	9.47e-6	Type 2 diabetes;
PAAD	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.65	-5.94	-0.43	1.9e-8	Obesity-related traits;
PAAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.6	8.08	0.55	1.86e-13	Bipolar disorder;
PAAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg12389545	chr11:72353604	PDE2A	-0.51	-4.3	-0.33	3.09e-5	Blood protein levels;
PAAD	cis	rs9928842	0.823	rs11149811	chr16:75300708	C/G	cg09066997	chr16:75300724	BCAR1	0.63	4.66	0.35	6.8e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg13482628	chr17:19912719	NA	0.66	6.72	0.48	3.38e-10	Schizophrenia;
PAAD	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Vitiligo;
PAAD	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg16342193	chr10:102329863	NA	-0.77	-8.55	-0.57	1.26e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.57	5.59	0.41	1.02e-7	Prudent dietary pattern;
PAAD	cis	rs926392	0.932	rs6124105	chr20:37686081	G/A	cg16355469	chr20:37678765	NA	0.45	4.25	0.33	3.65e-5	Dialysis-related mortality;
PAAD	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg19483011	chr3:158453295	NA	-0.65	-5.6	-0.41	9.92e-8	Tetralogy of Fallot;
PAAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg02297831	chr4:17616191	MED28	0.61	6.21	0.45	4.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.85	-9.86	-0.62	5.01e-18	Ulcerative colitis;
PAAD	cis	rs16958440	1.000	rs75800624	chr18:44633605	G/C	cg17192377	chr18:44677553	HDHD2	0.93	5.89	0.43	2.42e-8	Sitting height ratio;
PAAD	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.45	4.84	0.37	3.18e-6	Age of smoking initiation;
PAAD	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.54	5.66	0.42	7.5e-8	Red blood cell count;
PAAD	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg07099767	chr17:78039528	CCDC40	-0.43	-4.26	-0.33	3.6e-5	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg10494973	chr17:80897199	TBCD	0.54	4.47	0.34	1.52e-5	Breast cancer;
PAAD	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.96	-9.88	-0.63	4.38e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.14	17.7	0.82	9.43e-39	Multiple myeloma;
PAAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.48	4.52	0.34	1.24e-5	Resistin levels;
PAAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.95	-16.05	-0.79	1.54e-34	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11700980	0.551	rs2409326	chr21:30109102	A/G	cg24692254	chr21:30365293	RNF160	-0.72	-5.2	-0.39	6.24e-7	QRS complex (12-leadsum);
PAAD	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02985541	chr2:219472218	PLCD4	-0.29	-4.5	-0.34	1.37e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg01287884	chr10:130110330	NA	-0.37	-4.3	-0.33	3.09e-5	Vitamin D levels;
PAAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg14709524	chr16:89940631	TCF25	0.74	4.37	0.33	2.33e-5	Skin colour saturation;
PAAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	1.09	16.1	0.79	1.17e-34	Menarche (age at onset);
PAAD	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg23331303	chr5:5135948	NA	0.45	6.53	0.47	9.4e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs11700980	0.551	rs2832035	chr21:30115032	C/T	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg07959490	chr17:80112427	CCDC57	-0.37	-4.43	-0.34	1.81e-5	Life satisfaction;
PAAD	cis	rs2278796	1.000	rs3892249	chr1:204947489	C/G	cg17947172	chr1:204966197	NFASC	0.42	4.56	0.35	1.05e-5	Mean platelet volume;
PAAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.72	8.47	0.57	1.96e-14	Lung cancer;
PAAD	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.64	-5.72	-0.42	5.45e-8	Coronary artery disease;
PAAD	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-5.83	-0.43	3.2e-8	Diastolic blood pressure;
PAAD	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg25200586	chr1:148000763	NA	-0.62	-6.48	-0.47	1.23e-9	Hip geometry;
PAAD	cis	rs8040855	0.627	rs72757059	chr15:85603149	C/T	cg08123816	chr15:85640762	PDE8A	-0.45	-5.33	-0.4	3.56e-7	Bulimia nervosa;
PAAD	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg14515779	chr1:101123966	NA	-0.54	-6.37	-0.46	2.1e-9	Monocyte count;
PAAD	cis	rs4987094	0.505	rs7928201	chr11:113213069	C/G	cg14632485	chr11:113216820	TTC12	0.55	4.74	0.36	4.95e-6	Schizophrenia;
PAAD	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.4	4.64	0.35	7.53e-6	Total body bone mineral density;
PAAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	17.32	0.81	8.37e-38	Prudent dietary pattern;
PAAD	cis	rs2733310	1.000	rs2733310	chr15:57498691	T/G	cg13626582	chr15:57592083	LOC283663	-0.36	-4.3	-0.33	3.08e-5	Mean platelet volume;
PAAD	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg11779900	chr17:80519722	FOXK2	-0.49	-5.13	-0.38	8.78e-7	Reticulocyte fraction of red cells;
PAAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.62	-6.56	-0.47	8.08e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.88	10.55	0.65	7.33e-20	White blood cell count;
PAAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.55	5.29	0.39	4.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	5.38	0.4	2.8e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.54	5.73	0.42	5.19e-8	Menopause (age at onset);
PAAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.43	0.34	1.8e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-4.56	-0.35	1.07e-5	Body mass index;
PAAD	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs17428704	0.522	rs10078445	chr5:14421080	C/T	cg12964346	chr5:14507533	TRIO	-0.86	-4.26	-0.33	3.53e-5	Electroencephalogram traits;
PAAD	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.36	0.73	2.07e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-8.33	-0.56	4.4e-14	Hemoglobin concentration;
PAAD	cis	rs9900062	0.560	rs11656678	chr17:62681505	G/A	cg02598441	chr17:62777298	LOC146880	-0.57	-4.69	-0.36	5.93e-6	QT interval;
PAAD	cis	rs7144011	0.628	rs8019980	chr14:79851148	A/G	cg18311665	chr14:79483171	NRXN3	0.33	4.32	0.33	2.82e-5	Waist circumference;Hip circumference;
PAAD	cis	rs965469	0.671	rs6139076	chr20:3305210	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.4	-0.34	2.04e-5	IFN-related cytopenia;
PAAD	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-4.88	-0.37	2.63e-6	Mean corpuscular volume;
PAAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg19630374	chr17:18023558	MYO15A	-0.55	-6.07	-0.44	9.96e-9	Total body bone mineral density;
PAAD	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	5.08	0.38	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.8	-9.93	-0.63	3.19e-18	Hemoglobin concentration;
PAAD	cis	rs6681460	0.576	rs2859914	chr1:66989840	A/G	cg02459107	chr1:67143332	SGIP1	0.51	4.49	0.34	1.41e-5	Presence of antiphospholipid antibodies;
PAAD	cis	rs6782228	0.585	rs2811492	chr3:128356279	A/G	cg16766828	chr3:128327626	NA	-0.49	-6.63	-0.47	5.37e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
PAAD	trans	rs2483519	0.501	rs12571587	chr10:116415598	A/G	cg26809043	chr11:34285529	ABTB2	0.51	6.45	0.46	1.45e-9	Paclitaxel disposition in epithelial ovarian cancer;
PAAD	trans	rs471756	0.594	rs4741691	chr9:255713	G/A	cg17093826	chr7:138458720	ATP6V0A4	0.51	6.4	0.46	1.82e-9	Mean platelet volume;
PAAD	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.75	-7.85	-0.54	7.09e-13	Breast cancer;
PAAD	cis	rs922692	1.000	rs11638372	chr15:78983559	A/G	cg00540400	chr15:79124168	NA	0.43	4.8	0.36	3.73e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3026101	0.697	rs1806267	chr17:5322106	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	5.88	0.43	2.53e-8	Body mass index;
PAAD	cis	rs34599045	1.000	rs34599045	chr1:152886874	G/C	cg07796016	chr1:152779584	LCE1C	-0.98	-5.06	-0.38	1.2e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg00498816	chr3:13665022	FBLN2	-0.37	-4.25	-0.33	3.66e-5	QRS complex (12-leadsum);
PAAD	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.52	-4.97	-0.37	1.81e-6	Mortality in heart failure;
PAAD	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.69	4.75	0.36	4.68e-6	IgG glycosylation;
PAAD	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.88	10.22	0.64	5.53e-19	Body mass index;
PAAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.61	6.95	0.49	9.94e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg00031303	chr3:195681400	NA	0.59	6.02	0.44	1.25e-8	Bronchopulmonary dysplasia;
PAAD	trans	rs901683	1.000	rs36074276	chr10:46055741	T/C	cg06308084	chr22:50493570	TTLL8	0.85	6.35	0.46	2.31e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg26935685	chr1:15502881	TMEM51	-0.54	-4.67	-0.35	6.67e-6	Systolic blood pressure;
PAAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-5.11	-0.38	9.64e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg05564831	chr3:52568323	NT5DC2	-0.42	-4.32	-0.33	2.77e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg08975724	chr8:8085496	FLJ10661	-0.71	-7.07	-0.5	5.35e-11	Neuroticism;
PAAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs2718812	0.792	rs1867503	chr3:133410648	G/A	cg08048268	chr3:133502702	NA	0.48	5.93	0.43	1.95e-8	Iron status biomarkers;
PAAD	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-1.05	-11.09	-0.67	2.58e-21	Platelet distribution width;
PAAD	cis	rs2944755	0.723	rs11996672	chr8:141586999	C/T	cg18491938	chr8:141590271	EIF2C2	-0.52	-4.82	-0.36	3.38e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg11961683	chr8:121824433	SNTB1	0.67	7.81	0.54	8.79e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-12.51	-0.71	3.93e-25	Longevity;Endometriosis;
PAAD	cis	rs1359582	0.793	rs861507	chr10:90410363	C/T	cg15661332	chr10:90342814	RNLS	0.55	4.84	0.37	3.16e-6	Depressive and manic episodes in bipolar disorder;
PAAD	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg00864171	chr11:67383662	NA	-0.49	-5.12	-0.38	9.15e-7	Mean corpuscular volume;
PAAD	cis	rs2882667	0.690	rs1976568	chr5:138180316	G/T	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.73	5.82	0.43	3.29e-8	Bipolar disorder (body mass index interaction);
PAAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.71	6.04	0.44	1.13e-8	Inflammatory skin disease;
PAAD	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15644404	chr18:77186268	NFATC1	-0.89	-6.23	-0.45	4.44e-9	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.49	0.41	1.65e-7	Body mass index;
PAAD	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.68	-8.75	-0.58	3.82e-15	Myopia (pathological);
PAAD	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-4.41	-0.34	1.96e-5	Coronary artery disease;
PAAD	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.56	4.65	0.35	7.01e-6	Prostate cancer;
PAAD	cis	rs10821973	0.527	rs6479793	chr10:63983295	C/A	cg09941381	chr10:64027924	RTKN2	-0.41	-4.33	-0.33	2.69e-5	Hypothyroidism;
PAAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg16584290	chr5:462447	EXOC3	-0.41	-4.43	-0.34	1.79e-5	Cystic fibrosis severity;
PAAD	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06016156	chr8:1399969	NA	-0.51	-4.36	-0.33	2.36e-5	Triglycerides;
PAAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.96	10.12	0.63	1e-18	Cognitive function;
PAAD	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.88	0.49	1.5e-10	Smoking initiation;
PAAD	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.95	0.49	9.99e-11	Coffee consumption (cups per day);
PAAD	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.58	-5.55	-0.41	1.23e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg06219351	chr7:158114137	PTPRN2	-0.82	-7.51	-0.52	4.66e-12	Response to amphetamines;
PAAD	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.29	0.33	3.21e-5	Educational attainment (years of education);
PAAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.08	-19.24	-0.84	1.44e-42	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.66	-7.15	-0.5	3.32e-11	Facial morphology (factor 20);
PAAD	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg06307176	chr5:131281290	NA	0.49	4.29	0.33	3.15e-5	Life satisfaction;
PAAD	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.82	-9.18	-0.6	2.98e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg25418670	chr11:30344373	C11orf46	-0.67	-6.5	-0.47	1.08e-9	Morning vs. evening chronotype;
PAAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.91	-7.45	-0.52	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs10958369	0.934	rs2068035	chr8:54414255	A/C	cg12485204	chr8:54507357	NA	0.55	5.58	0.41	1.07e-7	Response to antineoplastic agents;
PAAD	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.88	10.91	0.66	7.65e-21	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg09471204	chr22:42347991	LOC339674	0.33	4.38	0.33	2.19e-5	Cognitive function;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09818691	chr1:12226143	TNFRSF1B	-0.62	-6.49	-0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg15145965	chr22:50218605	BRD1	-0.61	-5.43	-0.4	2.19e-7	Schizophrenia;
PAAD	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.14	0.45	6.92e-9	Coffee consumption (cups per day);
PAAD	cis	rs1329189	1.000	rs4750942	chr10:129994167	A/G	cg17972361	chr10:130010134	NA	-0.45	-4.59	-0.35	9.16e-6	Orofacial clefts;
PAAD	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.91	-8.92	-0.59	1.36e-15	Exhaled nitric oxide output;
PAAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-4.28	-0.33	3.32e-5	Breast cancer;
PAAD	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.59	5.02	0.38	1.46e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2120991	0.967	rs10506325	chr12:54261760	A/G	cg23795217	chr12:54812000	ITGA5	0.31	4.56	0.35	1.06e-5	Biliary atresia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04575467	chr8:41997444	NA	0.6	6.55	0.47	8.53e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4938330	0.608	rs3830008	chr11:117093764	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.66	-4.81	-0.36	3.67e-6	Blood protein levels;
PAAD	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg27481594	chr15:43623282	ADAL;LCMT2	-0.44	-4.39	-0.34	2.11e-5	Lung cancer;
PAAD	cis	rs73206853	0.841	rs73191824	chr12:110936564	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	4.29	0.33	3.15e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.81	5.6	0.41	9.55e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.5	-4.81	-0.36	3.61e-6	Retinal vascular caliber;
PAAD	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg07154921	chr7:157260426	NA	0.45	4.32	0.33	2.76e-5	Body mass index;
PAAD	cis	rs1891275	0.551	rs4933681	chr10:93403122	G/A	cg07889827	chr10:93443413	NA	-0.4	-4.31	-0.33	2.89e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs499368	0.519	rs216246	chr12:310466	C/G	cg24087681	chr12:298268	NA	0.42	4.31	0.33	2.94e-5	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg03098721	chr1:84464084	TTLL7	0.48	4.6	0.35	8.72e-6	Obesity-related traits;
PAAD	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.41	5.08	0.38	1.1e-6	Pulmonary function;
PAAD	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg19682013	chr15:45996608	NA	0.32	4.25	0.33	3.75e-5	Waist circumference;Weight;
PAAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.54	5.25	0.39	4.98e-7	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11384718	chr3:121553940	IQCB1;EAF2	0.62	6.47	0.46	1.3e-9	Obesity-related traits;
PAAD	cis	rs2016266	0.929	rs7399003	chr12:53659536	C/T	cg26875137	chr12:53738046	NA	0.38	4.3	0.33	2.99e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-5.17	-0.39	7.3e-7	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg05627522	chr15:75251581	NA	0.53	6.21	0.45	4.8e-9	Caffeine consumption;
PAAD	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.63	7.0	0.49	7.69e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.82	8.67	0.58	5.94e-15	Schizophrenia;
PAAD	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.77	0.36	4.31e-6	Hepatocellular carcinoma;
PAAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg18827107	chr12:86230957	RASSF9	0.42	4.41	0.34	1.96e-5	Major depressive disorder;
PAAD	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.64	6.21	0.45	4.92e-9	White matter hyperintensity burden;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg07202610	chr7:1142643	C7orf50	-0.74	-5.02	-0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.6	7.06	0.5	5.41e-11	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs35160687	0.712	rs4832031	chr2:86478980	C/T	cg10973622	chr2:86423274	IMMT	0.44	4.9	0.37	2.41e-6	Night sleep phenotypes;
PAAD	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg16586182	chr3:47516702	SCAP	0.65	7.12	0.5	4.1e-11	Colorectal cancer;
PAAD	cis	rs151997	0.671	rs152099	chr5:50210091	A/G	cg06027927	chr5:50259733	NA	0.66	6.61	0.47	6.01e-10	Callous-unemotional behaviour;
PAAD	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.55	-6.59	-0.47	6.67e-10	Total body bone mineral density;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg01851573	chr8:8652454	MFHAS1	0.52	4.58	0.35	9.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.35	0.6	1.05e-16	Morning vs. evening chronotype;
PAAD	cis	rs4455778	0.538	rs67216951	chr7:49088028	C/T	cg26309511	chr7:48887640	NA	0.39	4.83	0.36	3.37e-6	Lung cancer in never smokers;
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23807559	chr17:71189217	COG1	0.56	5.41	0.4	2.36e-7	Smoking initiation;
PAAD	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-4.96	-0.37	1.84e-6	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.76	-0.48	2.79e-10	Life satisfaction;
PAAD	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg20243544	chr17:37824526	PNMT	-0.52	-4.83	-0.36	3.27e-6	Self-reported allergy;
PAAD	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg25902810	chr10:99078978	FRAT1	0.53	5.27	0.39	4.53e-7	Monocyte count;
PAAD	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-4.9	-0.37	2.45e-6	Self-reported allergy;
PAAD	cis	rs75757892	0.544	rs9328413	chr6:7317608	A/G	cg02954307	chr6:7269328	NA	-0.52	-4.45	-0.34	1.64e-5	Hematocrit;Red blood cell count;
PAAD	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-5.47	-0.41	1.84e-7	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13560548	chr3:10150139	C3orf24	0.63	5.65	0.42	7.64e-8	Alzheimer's disease;
PAAD	trans	rs225245	0.817	rs225284	chr17:33933006	A/C	cg19694781	chr19:47549865	TMEM160	-0.56	-6.32	-0.46	2.76e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.43	0.34	1.77e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.5	-5.05	-0.38	1.26e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.63	-7.81	-0.54	8.77e-13	Menarche (age at onset);
PAAD	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.67	-6.88	-0.49	1.44e-10	Pubertal anthropometrics;
PAAD	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-1.04	-10.69	-0.65	3.13e-20	Longevity;
PAAD	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.59	-6.07	-0.44	1e-8	Dental caries;
PAAD	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg03684893	chr10:554711	DIP2C	-0.44	-4.7	-0.36	5.72e-6	Psychosis in Alzheimer's disease;
PAAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg14709524	chr16:89940631	TCF25	0.98	4.58	0.35	9.75e-6	Skin colour saturation;
PAAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg14132834	chr19:41945861	ATP5SL	-0.49	-4.66	-0.35	6.98e-6	Height;
PAAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-6.73	-0.48	3.21e-10	Prudent dietary pattern;
PAAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-4.68	-0.35	6.28e-6	Height;
PAAD	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.61	-0.47	6.14e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs12410462	0.551	rs2814087	chr1:227632334	C/T	cg23173402	chr1:227635558	NA	-0.55	-4.55	-0.35	1.09e-5	Major depressive disorder;
PAAD	cis	rs7932354	0.583	rs3136447	chr11:46744368	T/C	cg19486271	chr11:47235900	DDB2	0.69	6.46	0.46	1.32e-9	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg17595323	chr11:93583763	C11orf90	-0.34	-4.33	-0.33	2.7e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.47	5.92	0.43	2.09e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.61	6.39	0.46	1.96e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg14926445	chr8:58193284	C8orf71	-0.58	-4.45	-0.34	1.63e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1975974	0.511	rs113941161	chr17:21741346	T/C	cg18423549	chr17:21743878	NA	-0.63	-5.64	-0.42	8.26e-8	Psoriasis;
PAAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg14440974	chr22:39074834	NA	-0.58	-7.09	-0.5	4.74e-11	Menopause (age at onset);
PAAD	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.69	5.87	0.43	2.59e-8	Pubertal anthropometrics;
PAAD	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg21994712	chr19:21861136	NA	0.46	4.48	0.34	1.46e-5	Pain;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03067192	chr7:72300134	SBDSP;TYW1B	0.58	6.75	0.48	3e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg10556349	chr10:835070	NA	0.56	4.66	0.35	6.83e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.51	5.22	0.39	5.91e-7	Lewy body disease;
PAAD	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg04160749	chr8:58172571	NA	-0.75	-4.87	-0.37	2.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.84	-0.37	3.22e-6	Breast cancer;
PAAD	cis	rs8067287	0.688	rs11654431	chr17:16844863	C/A	cg26910001	chr17:16838321	NA	-0.54	-5.13	-0.38	8.66e-7	Diabetic kidney disease;
PAAD	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg00543991	chr22:32367038	NA	1.18	7.18	0.5	2.86e-11	Childhood ear infection;
PAAD	cis	rs9535307	1.000	rs9535307	chr13:50291842	A/C	cg04663916	chr13:50265991	EBPL	0.61	4.69	0.36	6.07e-6	Obesity-related traits;
PAAD	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.88	-13.01	-0.73	1.73e-26	Dental caries;
PAAD	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg05562828	chr17:3906858	NA	0.54	5.97	0.44	1.61e-8	Type 2 diabetes;
PAAD	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.83	8.25	0.56	6.97e-14	Corneal astigmatism;
PAAD	cis	rs1419980	0.730	rs73258867	chr12:7768765	T/C	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.73	-6.01	-0.44	1.32e-8	Neuroticism;
PAAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.73	-7.97	-0.54	3.52e-13	Blood metabolite levels;
PAAD	trans	rs61931739	0.576	rs115230002	chr12:33648787	G/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.47	-0.46	1.3e-9	Morning vs. evening chronotype;
PAAD	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.39	-4.45	-0.34	1.67e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.75	9.35	0.6	1.08e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.31	0.64	3.2e-19	Total body bone mineral density;
PAAD	trans	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg16973527	chr15:70767570	NA	0.4	6.3	0.46	3.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2061333	0.557	rs9304638	chr19:44634086	C/T	cg20607764	chr19:44506953	ZNF230	-0.78	-5.37	-0.4	2.83e-7	Alzheimer's disease;
PAAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13939156	chr17:80058883	NA	-0.41	-4.41	-0.34	1.91e-5	Life satisfaction;
PAAD	cis	rs73384572	0.541	rs10829565	chr10:130859801	A/G	cg27413539	chr10:131576096	NA	-0.69	-4.64	-0.35	7.48e-6	Neuroticism;
PAAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.36	0.4	3.08e-7	Electroencephalogram traits;
PAAD	cis	rs12738007	0.933	rs6426352	chr1:29470843	G/C	cg03512248	chr1:28517610	PTAFR	0.43	4.36	0.33	2.36e-5	Schizophrenia;
PAAD	cis	rs11669133	1.000	rs115126258	chr19:11075749	C/T	cg25243385	chr19:11167475	SMARCA4	0.99	4.7	0.36	5.84e-6	LDL cholesterol;
PAAD	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.74	-5.48	-0.41	1.74e-7	Mean platelet volume;
PAAD	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.22	-18.56	-0.83	6.71e-41	Ulcerative colitis;
PAAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-7.38	-0.51	9.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.4	0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.64	5.72	0.42	5.53e-8	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04031504	chr1:32645060	TXLNA	0.59	6.8	0.48	2.25e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6494488	0.500	rs72742993	chr15:65006023	G/C	cg16425858	chr15:64791681	ZNF609	0.96	4.37	0.33	2.27e-5	Coronary artery disease;
PAAD	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.52	0.41	1.4e-7	Coronary heart disease;
PAAD	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02985541	chr2:219472218	PLCD4	0.3	4.53	0.34	1.18e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs6191	0.935	rs4634384	chr5:142780697	C/T	cg08845721	chr5:142780693	NR3C1	-0.4	-4.47	-0.34	1.55e-5	Night sleep phenotypes;
PAAD	cis	rs28489187	0.683	rs6704103	chr1:85868657	C/A	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg00490450	chr3:139108681	COPB2	-0.65	-5.69	-0.42	6.21e-8	Obesity-related traits;
PAAD	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-4.31	-0.33	2.97e-5	IFN-related cytopenia;
PAAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg18833306	chr6:118973337	C6orf204	-0.57	-4.6	-0.35	8.79e-6	Diastolic blood pressure;
PAAD	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.59	-7.28	-0.51	1.69e-11	Educational attainment;
PAAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11245990	chr11:68621969	NA	0.39	5.2	0.39	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.74	7.86	0.54	6.42e-13	Neurofibrillary tangles;
PAAD	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06850241	chr22:41845214	NA	-0.53	-4.47	-0.34	1.52e-5	Vitiligo;
PAAD	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.61	-6.62	-0.47	5.88e-10	Calcium levels;
PAAD	cis	rs7631605	0.875	rs726769	chr3:37117741	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg26385993	chr17:80788710	TBCD;ZNF750	-0.42	-4.42	-0.34	1.9e-5	Glycated hemoglobin levels;
PAAD	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.62	-0.41	8.96e-8	Bipolar disorder;
PAAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg18833306	chr6:118973337	C6orf204	-0.57	-4.7	-0.36	5.7e-6	Diastolic blood pressure;
PAAD	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg18357526	chr6:26021779	HIST1H4A	0.52	4.64	0.35	7.36e-6	Height;
PAAD	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-4.77	-0.36	4.26e-6	Blood metabolite levels;
PAAD	cis	rs7640424	0.649	rs35595234	chr3:107922116	C/T	cg09227934	chr3:107805635	CD47	-0.4	-4.68	-0.35	6.4e-6	Body mass index;
PAAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.57	-5.61	-0.41	9.54e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.11	0.5	4.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	4.97	0.37	1.75e-6	Menarche (age at onset);
PAAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg20381115	chr15:45671148	LOC145663;GATM	-0.41	-4.37	-0.33	2.25e-5	Glomerular filtration rate;
PAAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07362569	chr17:61921086	SMARCD2	0.64	8.06	0.55	2.04e-13	Prudent dietary pattern;
PAAD	cis	rs4938096	0.661	rs11214957	chr11:114212148	T/G	cg00557402	chr11:114466517	FAM55D	0.71	4.52	0.34	1.25e-5	Asthma;
PAAD	cis	rs8040855	0.894	rs4843023	chr15:85705872	A/C	cg08123816	chr15:85640762	PDE8A	0.39	4.73	0.36	5.03e-6	Bulimia nervosa;
PAAD	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.65	-4.82	-0.36	3.47e-6	Subjective well-being;
PAAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.27	4.41	0.34	1.92e-5	Asthma;
PAAD	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg09659197	chr4:152720779	NA	0.39	5.14	0.38	8.28e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8053891	0.664	rs34972708	chr16:72008225	A/G	cg16558253	chr16:72132732	DHX38	-0.53	-4.72	-0.36	5.25e-6	Coronary artery disease;
PAAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.92	7.66	0.53	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.82	-0.48	2.03e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg11204139	chr17:3907470	NA	-0.68	-6.97	-0.49	8.94e-11	Type 2 diabetes;
PAAD	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg23241863	chr10:102295624	HIF1AN	0.49	4.47	0.34	1.55e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.73	6.42	0.46	1.66e-9	Dilated cardiomyopathy;
PAAD	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.83	-7.97	-0.54	3.43e-13	Dilated cardiomyopathy;
PAAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg09915433	chr19:53449742	NA	-0.72	-9.37	-0.61	9.46e-17	Psoriasis;
PAAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.7	7.08	0.5	4.91e-11	Menarche (age at onset);
PAAD	cis	rs12760731	0.565	rs12036491	chr1:178163651	C/A	cg00404053	chr1:178313656	RASAL2	0.71	5.22	0.39	5.68e-7	Obesity-related traits;
PAAD	cis	rs11024102	1.000	rs11024101	chr11:17005544	T/C	cg15084286	chr11:17036142	PLEKHA7	0.51	4.69	0.36	6.01e-6	Glaucoma (primary angle closure);
PAAD	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.71	6.98	0.49	8.72e-11	Coronary artery disease;
PAAD	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.9	7.46	0.52	6.27e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.47	-4.56	-0.35	1.05e-5	Obesity-related traits;
PAAD	cis	rs2229238	0.911	rs73020246	chr1:154485640	A/G	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.91e-6	Coronary heart disease;
PAAD	cis	rs2249694	0.520	rs11815623	chr10:135329133	A/G	cg20169779	chr10:135381914	SYCE1	-0.54	-4.38	-0.33	2.2e-5	Obesity-related traits;
PAAD	cis	rs881375	0.501	rs10156413	chr9:123867782	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	7.41	0.52	8.16e-12	Rheumatoid arthritis;
PAAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.75	7.36	0.51	1.07e-11	Eosinophil percentage of granulocytes;
PAAD	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg14393609	chr7:65229607	NA	-0.61	-6.57	-0.47	7.57e-10	Aortic root size;
PAAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg25833597	chr17:30823145	MYO1D	0.48	4.67	0.35	6.63e-6	Schizophrenia;
PAAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15664640	chr17:80829946	TBCD	-0.68	-4.73	-0.36	5.11e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg17105886	chr17:28927953	LRRC37B2	0.76	4.82	0.36	3.4e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7210086	0.768	rs4395115	chr17:70640382	G/C	cg04206342	chr17:70636940	NA	-0.45	-5.39	-0.4	2.58e-7	Ulcerative colitis;
PAAD	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.29	-0.39	4.16e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1642645	0.872	rs639559	chr1:42425496	C/T	cg01990334	chr1:42801334	FOXJ3	-0.61	-5.44	-0.4	2.04e-7	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.88e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.51	-5.33	-0.4	3.41e-7	Red blood cell count;Hematocrit;Red blood cell traits;
PAAD	cis	rs3842397	1	rs3842397	chr18:43845880	CTT/C	cg20581250	chr18:44676959	HDHD2	0.47	4.56	0.35	1.03e-5	Red cell distribution width;Mean platelet volume;
PAAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.76	-8.17	-0.55	1.1e-13	Aortic root size;
PAAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.73	7.99	0.54	3.1400000000000003e-13	Prostate cancer;
PAAD	cis	rs950169	0.920	rs34672825	chr15:84703470	C/T	cg03959625	chr15:84868606	LOC388152	0.44	4.64	0.35	7.42e-6	Schizophrenia;
PAAD	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg00277334	chr10:82204260	NA	-0.57	-5.78	-0.42	4.17e-8	Post bronchodilator FEV1;
PAAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	6.85	0.49	1.73e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.7	7.0	0.49	7.66e-11	Prostate cancer;
PAAD	cis	rs4474633	1	rs4474633	chr15:49260601	A/G	cg21406786	chr15:48925049	FBN1	0.48	4.36	0.33	2.41e-5	Major depressive disorder;
PAAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.73	-7.72	-0.53	1.43e-12	Menarche (age at onset);
PAAD	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg22467129	chr15:76604101	ETFA	0.51	4.89	0.37	2.57e-6	Blood metabolite levels;
PAAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg09796270	chr17:17721594	SREBF1	0.45	4.76	0.36	4.48e-6	Total body bone mineral density;
PAAD	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg02421172	chr7:1938701	MAD1L1	-0.59	-4.63	-0.35	7.93e-6	Bipolar disorder;
PAAD	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.76	6.87	0.49	1.52e-10	Obesity-related traits;
PAAD	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.86	-10.31	-0.64	3.13e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg08917208	chr2:24149416	ATAD2B	0.5	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg24747557	chr10:131355152	MGMT	-0.5	-5.16	-0.39	7.62e-7	Response to temozolomide;
PAAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.82	8.67	0.58	6e-15	Calcium levels;
PAAD	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg22482690	chr17:47019901	SNF8	0.5	5.4	0.4	2.54e-7	Type 2 diabetes;
PAAD	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.4	0.64	1.85e-19	Morning vs. evening chronotype;
PAAD	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg14003231	chr6:33640908	ITPR3	0.36	4.7	0.36	5.72e-6	Plateletcrit;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22388850	chr4:48782544	FRYL	-0.78	-7.32	-0.51	1.32e-11	Neuroticism;
PAAD	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.86	9.73	0.62	1.11e-17	Intelligence (multi-trait analysis);
PAAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08893839	chr5:154027129	NA	0.79	6.1	0.44	8.53e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-5.68	-0.42	6.69e-8	Subjective well-being;
PAAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg20850873	chr3:10149803	C3orf24	0.55	4.29	0.33	3.2e-5	Alzheimer's disease;
PAAD	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.19	-20.12	-0.85	1.07e-44	Myeloid white cell count;
PAAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	17.27	0.81	1.13e-37	Prudent dietary pattern;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19760132	chr4:54930712	CHIC2	-0.65	-6.32	-0.46	2.72e-9	Smoking initiation;
PAAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.94	8.63	0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	4.36	0.33	2.42e-5	Height;
PAAD	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg07944420	chr16:89185293	ACSF3	0.48	4.43	0.34	1.76e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.65	-4.44	-0.34	1.69e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-1.23	-12.65	-0.72	1.64e-25	Hair shape;
PAAD	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.55	4.77	0.36	4.35e-6	White blood cell count;Multiple sclerosis;
PAAD	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-5.61	-0.41	9.45e-8	Prevalent atrial fibrillation;
PAAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.53	5.66	0.42	7.37e-8	Life satisfaction;
PAAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.61	6.87	0.49	1.59e-10	Testicular germ cell tumor;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24869834	chr4:139146513	SLC7A11	0.53	6.3	0.46	3.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.76	7.63	0.53	2.43e-12	Resting heart rate;
PAAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg26513180	chr16:89883248	FANCA	-0.45	-4.69	-0.36	5.96e-6	Vitiligo;
PAAD	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.92	-6.75	-0.48	2.87e-10	Opioid sensitivity;
PAAD	cis	rs13424612	1.000	rs4854058	chr2:240923677	C/A	cg01812947	chr2:240904978	NDUFA10	0.57	4.98	0.37	1.68e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.85	8.8	0.58	2.78e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.67	-6.7	-0.48	3.79e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg01097406	chr16:89675127	NA	0.35	4.26	0.33	3.55e-5	Hemoglobin concentration;
PAAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg06219351	chr7:158114137	PTPRN2	-0.78	-8.23	-0.56	7.91e-14	Calcium levels;
PAAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06799790	chr17:61951754	CSH2	0.44	4.57	0.35	9.88e-6	Height;
PAAD	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.16	19.73	0.85	8.96e-44	Multiple myeloma;
PAAD	cis	rs6604026	0.656	rs10874751	chr1:93384540	T/A	cg13858687	chr1:93297071	RPL5	0.48	4.36	0.33	2.34e-5	Multiple sclerosis;
PAAD	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.63	-5.24	-0.39	5.25e-7	Mean corpuscular hemoglobin;
PAAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.47	5.62	0.41	9.02e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.68	6.4	0.46	1.81e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs721399	0.553	rs59416053	chr8:18240800	G/C	cg18736775	chr8:18248649	NAT2	-0.82	-6.67	-0.48	4.45e-10	Blood metabolite levels;
PAAD	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	1.17	6.97	0.49	9.16e-11	Skin colour saturation;
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.62	6.8	0.48	2.22e-10	Menarche (age at onset);
PAAD	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.42	-4.43	-0.34	1.77e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.61	5.3	0.39	4.06e-7	Mean platelet volume;
PAAD	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.76	-9.06	-0.59	6.13e-16	Blood pressure (smoking interaction);
PAAD	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg05895507	chr15:77155635	SCAPER	-0.4	-4.26	-0.33	3.51e-5	Blood metabolite levels;
PAAD	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg15956490	chr3:53032818	SFMBT1	-0.71	-4.43	-0.34	1.76e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg08756266	chr6:88106569	C6orf164	-0.57	-6.32	-0.46	2.75e-9	Obesity-related traits;
PAAD	cis	rs755249	0.567	rs3768302	chr1:39880319	T/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.61	-0.35	8.34e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	trans	rs901683	1.000	rs34793991	chr10:46080590	A/C	cg06308084	chr22:50493570	TTLL8	0.88	6.47	0.46	1.28e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.92	10.93	0.66	6.94e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.73	7.75	0.53	1.22e-12	Morning vs. evening chronotype;
PAAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Melanoma;
PAAD	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.85	11.17	0.67	1.55e-21	Breast cancer;
PAAD	cis	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg27411982	chr8:10470053	RP1L1	0.43	4.77	0.36	4.26e-6	Schizophrenia;
PAAD	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg11995313	chr8:8860691	ERI1	0.46	4.31	0.33	2.92e-5	Joint mobility (Beighton score);
PAAD	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg22827986	chr11:48284249	OR4X1	0.42	5.22	0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs939584	1.000	rs35142762	chr2:636790	T/C	cg03610516	chr2:642275	NA	-0.6	-5.5	-0.41	1.57e-7	Body mass index;
PAAD	cis	rs988913	0.723	rs9464197	chr6:54998738	A/T	cg03513858	chr6:54763001	FAM83B	-0.41	-4.4	-0.34	2.03e-5	Menarche (age at onset);
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg00945038	chr17:61921165	SMARCD2	0.49	5.82	0.43	3.45e-8	Prudent dietary pattern;
PAAD	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.72	4.5	0.34	1.32e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.51	-0.34	1.31e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17473923	chr12:89745478	DUSP6	-0.86	-7.63	-0.53	2.39e-12	Neuroticism;
PAAD	cis	rs35260072	1	rs35260072	chr5:131630852	A/C	cg14196790	chr5:131705035	SLC22A5	0.51	5.3	0.39	3.99e-7	Itch intensity from mosquito bite;
PAAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.88	7.55	0.52	3.83e-12	Alzheimer's disease;
PAAD	cis	rs6076065	1.000	rs2424553	chr20:23403939	A/G	cg11657817	chr20:23433608	CST11	0.4	4.39	0.34	2.15e-5	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs4321325	0.733	rs4284778	chr2:127946326	A/G	cg11380483	chr2:127933992	NA	0.69	5.18	0.39	7.04e-7	Protein C levels;
PAAD	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.83	9.23	0.6	2.13e-16	Metabolic syndrome;
PAAD	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.36	4.47	0.34	1.53e-5	Systolic blood pressure;
PAAD	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg26585981	chr11:48327164	OR4S1	0.49	4.33	0.33	2.66e-5	Migraine - clinic-based;
PAAD	cis	rs1499972	0.590	rs62264775	chr3:117648002	A/C	cg07612923	chr3:117604196	NA	0.72	5.41	0.4	2.36e-7	Schizophrenia;
PAAD	trans	rs9863706	0.556	rs7628338	chr3:72432888	C/T	cg01534506	chr19:17326432	USE1	-0.7	-6.33	-0.46	2.66e-9	Height;
PAAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.85	8.5	0.57	1.62e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-7.46	-0.52	6.17e-12	Hemoglobin concentration;
PAAD	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.72	-7.28	-0.51	1.7e-11	Colorectal cancer;
PAAD	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg04362960	chr10:104952993	NT5C2	0.47	4.33	0.33	2.7e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.81	-10.17	-0.64	7.36e-19	Hemoglobin concentration;
PAAD	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg02683114	chr2:24398427	C2orf84	-0.44	-4.76	-0.36	4.46e-6	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg24642844	chr7:1081250	C7orf50	0.55	4.45	0.34	1.67e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg08501292	chr6:25962987	TRIM38	0.78	4.74	0.36	4.97e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg12046867	chr14:103022105	NA	0.64	4.87	0.37	2.81e-6	Platelet count;
PAAD	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg22134325	chr11:66188745	NPAS4	0.29	4.7	0.36	5.82e-6	Airway imaging phenotypes;
PAAD	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-5.47	-0.41	1.8e-7	Intelligence;
PAAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.62	6.68	0.48	4.17e-10	Lung cancer;
PAAD	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-4.81	-0.36	3.53e-6	Coronary artery disease;
PAAD	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs13315871	0.929	rs71311849	chr3:58230809	G/A	cg20936604	chr3:58311152	NA	-0.78	-4.25	-0.33	3.7e-5	Cholesterol, total;
PAAD	cis	rs2180233	0.892	rs976189	chr1:30662538	G/T	cg06703062	chr1:31191648	MATN1	-0.49	-4.32	-0.33	2.78e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs10821973	0.527	rs5006763	chr10:63977673	C/A	cg09941381	chr10:64027924	RTKN2	-0.42	-4.47	-0.34	1.52e-5	Hypothyroidism;
PAAD	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.44	4.72	0.36	5.33e-6	Platelet count;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07335806	chr15:99791569	LRRC28	0.66	7.01	0.49	7.41e-11	Myopia (pathological);
PAAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	4.67	0.35	6.49e-6	Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13576006	chr1:154193656	C1orf43;UBAP2L	0.59	6.57	0.47	7.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.69	-6.99	-0.49	8.06e-11	Bone properties (heel);
PAAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.64	-4.72	-0.36	5.31e-6	Depression;
PAAD	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg07930552	chr6:133119739	C6orf192	0.96	4.5	0.34	1.34e-5	Type 2 diabetes nephropathy;
PAAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.78	7.19	0.5	2.8e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs3112530	0.818	rs302738	chr5:152728482	C/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	1.98	11.82	0.69	2.9e-23	Cannabis dependence symptom count;
PAAD	cis	rs899997	1.000	rs2017091	chr15:79032744	G/A	cg04896959	chr15:78267971	NA	0.63	6.02	0.44	1.27e-8	Coronary artery disease or large artery stroke;
PAAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg11814155	chr7:99998594	ZCWPW1	0.53	4.33	0.33	2.68e-5	Platelet count;
PAAD	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.78	12.5	0.71	4.04e-25	Breast cancer;
PAAD	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.67	4.89	0.37	2.5e-6	Hip geometry;
PAAD	cis	rs818427	0.548	rs382427	chr5:112187436	A/G	cg06941702	chr5:112196734	SRP19	-0.52	-5.02	-0.38	1.43e-6	Total body bone mineral density;
PAAD	cis	rs2200578	0.786	rs62158261	chr2:99563210	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.64	4.52	0.34	1.26e-5	IgG glycosylation;
PAAD	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-4.49	-0.34	1.42e-5	Congenital heart disease (maternal effect);
PAAD	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.55	-0.47	8.31e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.18	0.55	1.05e-13	Menopause (age at onset);
PAAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	8.66	0.57	6.59e-15	Hip circumference adjusted for BMI;
PAAD	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06998765	chr14:75389618	RPS6KL1	0.28	4.95	0.37	1.91e-6	Caffeine consumption;
PAAD	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg16110827	chr15:48056943	SEMA6D	-0.5	-5.33	-0.4	3.5e-7	Inflammatory bowel disease;Ulcerative colitis;
PAAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg15123519	chr2:136567270	LCT	-0.39	-4.59	-0.35	9.35e-6	Mosquito bite size;
PAAD	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg20913747	chr6:44695427	NA	-0.7	-6.98	-0.49	8.49e-11	Total body bone mineral density;
PAAD	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg19176072	chr10:135083742	ADAM8	-0.94	-4.56	-0.35	1.04e-5	Lifespan;
PAAD	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.65	-5.17	-0.39	7.31e-7	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs375066	0.935	rs387689	chr19:44420111	C/T	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg01759136	chr6:27242945	NA	0.41	4.46	0.34	1.56e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg07384165	chr1:10488281	NA	-0.45	-4.25	-0.33	3.65e-5	Asthma;
PAAD	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.84	6.05	0.44	1.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.64	4.64	0.35	7.39e-6	Neuroticism;
PAAD	cis	rs9907295	0.591	rs4239252	chr17:34163565	A/G	cg19411729	chr17:34207663	CCL5	0.54	4.99	0.38	1.62e-6	Fibroblast growth factor basic levels;
PAAD	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-6.9	-0.49	1.3100000000000001e-10	Capecitabine sensitivity;
PAAD	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg27490568	chr2:178487706	NA	0.43	4.61	0.35	8.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.56	5.98	0.44	1.57e-8	Eosinophil percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg08158076	chr1:90287038	LRRC8D	0.66	7.75	0.53	1.2e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	4.89	0.37	2.58e-6	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs13102973	0.564	rs4418034	chr4:135886650	T/A	cg14419869	chr4:135874104	NA	0.44	4.34	0.33	2.55e-5	Subjective well-being;
PAAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.72	5.17	0.39	7.32e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs747650	0.504	rs10838640	chr11:46984629	C/T	cg19486271	chr11:47235900	DDB2	-0.6	-5.85	-0.43	2.86e-8	Acne (severe);
PAAD	cis	rs7192380	0.651	rs6499239	chr16:69686748	G/A	cg05250797	chr16:70222502	NA	0.65	5.74	0.42	5.03e-8	Sjögren's syndrome;
PAAD	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.47	-4.44	-0.34	1.73e-5	Breast cancer;
PAAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg03735013	chr11:61582769	MIR1908;FADS1	-0.44	-4.4	-0.34	2.02e-5	Trans fatty acid levels;
PAAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.69	6.73	0.48	3.24e-10	Initial pursuit acceleration;
PAAD	cis	rs2882667	0.690	rs9327828	chr5:138261548	T/G	cg09476006	chr5:138032270	NA	0.43	5.39	0.4	2.66e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg07164556	chr1:145727247	PDZK1	-0.68	-4.62	-0.35	8.15e-6	Mitochondrial DNA levels;
PAAD	cis	rs7243821	1.000	rs11152106	chr18:52646776	C/T	cg16669619	chr18:52630472	NA	-0.44	-4.35	-0.33	2.49e-5	Chin dimples;
PAAD	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.54	4.35	0.33	2.49e-5	Endometriosis;Drug-induced torsades de pointes;
PAAD	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.47	-5.2	-0.39	6.22e-7	Menarche (age at onset);
PAAD	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.87	11.26	0.67	9.04e-22	Subjective well-being (multi-trait analysis);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg13673779	chr18:48723081	MEX3C	-0.56	-6.79	-0.48	2.31e-10	Body fat percentage;
PAAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.61	-5.45	-0.4	2.01e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Lung disease severity in cystic fibrosis;
PAAD	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.38	-0.46	1.99e-9	HDL cholesterol;
PAAD	cis	rs901683	1.000	rs76422608	chr10:46041945	G/C	cg16908948	chr10:45500256	ZNF22	0.79	4.26	0.33	3.61e-5	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs12940923	0.507	rs12944679	chr17:56372280	C/T	cg26072851	chr17:56296444	MKS1	-0.58	-4.94	-0.37	2.02e-6	Circulating myeloperoxidase levels (plasma);
PAAD	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg24585817	chr7:64895279	NA	-0.49	-4.85	-0.37	3.03e-6	Aortic root size;
PAAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.57	5.96	0.44	1.65e-8	Immature fraction of reticulocytes;
PAAD	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.46	4.42	0.34	1.9e-5	Morning vs. evening chronotype;
PAAD	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.49	4.91	0.37	2.31e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg10820045	chr2:198174542	NA	0.5	5.14	0.39	8.19e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.84	-9.55	-0.61	3.17e-17	Height;
PAAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg08754654	chr5:154026448	NA	-0.39	-5.52	-0.41	1.41e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg16341495	chr8:142228727	SLC45A4	-0.46	-4.3	-0.33	3.04e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg03999872	chr20:62272968	STMN3	-0.74	-6.48	-0.47	1.18e-9	Atopic dermatitis;
PAAD	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg00031303	chr3:195681400	NA	-0.54	-4.28	-0.33	3.33e-5	Red cell distribution width;
PAAD	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.55	-6.5	-0.47	1.11e-9	Total body bone mineral density;
PAAD	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.43	-4.47	-0.34	1.54e-5	Plateletcrit;
PAAD	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg12395012	chr8:11607386	GATA4	-0.39	-4.29	-0.33	3.19e-5	Neuroticism;
PAAD	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	1.01	14.1	0.75	2.12e-29	Heart rate;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10090217	chr7:45151583	TBRG4	0.58	6.39	0.46	1.89e-9	Monocyte percentage of white cells;
PAAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg16586182	chr3:47516702	SCAP	0.59	6.36	0.46	2.24e-9	Colorectal cancer;
PAAD	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs901683	0.850	rs71496607	chr10:46010316	C/T	cg14076390	chr17:34947837	DHRS11	0.9	6.78	0.48	2.5e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.56	6.1	0.44	8.31e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg14345882	chr6:26364793	BTN3A2	0.8	5.88	0.43	2.49e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	4.56	0.35	1.05e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.03	0.44	1.22e-8	Schizophrenia;
PAAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	9.56	0.61	3.04e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.88	9.14	0.6	3.84e-16	Height;
PAAD	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.96	6.7	0.48	3.76e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg05658771	chr16:89884179	FANCA	-0.9	-4.27	-0.33	3.41e-5	Skin colour saturation;
PAAD	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.62	6.4	0.46	1.84e-9	Height;
PAAD	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.48	-4.27	-0.33	3.5e-5	Multiple sclerosis;
PAAD	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.53	-4.9	-0.37	2.4e-6	Blood protein levels;
PAAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.43	-6.59	-0.47	6.94e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.49	-5.89	-0.43	2.42e-8	Lewy body disease;
PAAD	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg22437258	chr11:111473054	SIK2	0.65	6.56	0.47	7.82e-10	Primary sclerosing cholangitis;
PAAD	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg12568669	chr8:11666485	FDFT1	0.31	5.39	0.4	2.64e-7	Monocyte count;
PAAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-7.07	-0.5	5.36e-11	Gut microbiome composition (summer);
PAAD	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Lymphocyte counts;
PAAD	cis	rs55665837	0.539	rs10766196	chr11:14913131	A/G	cg16394018	chr11:14927549	NA	0.45	4.97	0.37	1.79e-6	Vitamin D levels;
PAAD	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	5.65	0.42	7.66e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs11077998	0.967	rs901373	chr17:80506559	A/G	cg11779900	chr17:80519722	FOXK2	-0.47	-4.74	-0.36	4.86e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs375066	0.806	rs415168	chr19:44402574	C/G	cg11993925	chr19:44307056	LYPD5	0.53	6.65	0.47	5.09e-10	Breast cancer;
PAAD	cis	rs12474201	0.783	rs34606703	chr2:47014522	G/A	cg06386533	chr2:46925753	SOCS5	0.72	7.88	0.54	5.85e-13	Height;
PAAD	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs842828	1.000	rs842828	chr2:201247491	C/T	cg26842802	chr2:202125212	CASP8	-0.67	-4.81	-0.36	3.56e-6	Urate levels in lean individuals;
PAAD	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.62	-4.76	-0.36	4.53e-6	Rheumatoid arthritis;
PAAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07648498	chr16:89883185	FANCA	0.69	7.18	0.5	2.97e-11	Vitiligo;
PAAD	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.53	-5.92	-0.43	2.06e-8	Migraine;
PAAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg24519413	chr1:26490540	NA	0.44	5.63	0.42	8.6e-8	Height;
PAAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.96	-11.02	-0.67	4.11e-21	Height;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06449742	chr17:79633586	CCDC137;C17orf90	-0.69	-6.78	-0.48	2.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg01299579	chr2:10830716	NOL10	-0.61	-6.18	-0.45	5.64e-9	Prostate cancer;
PAAD	cis	rs7551345	0.853	rs7534378	chr1:31863558	C/T	cg17086398	chr1:31896392	SERINC2	-0.51	-4.53	-0.35	1.18e-5	Schizophrenia;
PAAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg13741927	chr9:139327495	INPP5E	-0.45	-4.45	-0.34	1.67e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs630539	1.000	rs675733	chr17:40703144	C/T	cg11807584	chr17:41132474	AARSD1;RUNDC1	-0.97	-4.28	-0.33	3.31e-5	Systolic blood pressure change trajectories;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25736830	chr11:66023582	KLC2	0.61	6.68	0.48	4.32e-10	Smoking initiation;
PAAD	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.7	5.51	0.41	1.51e-7	Height;
PAAD	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.54	-5.14	-0.38	8.52e-7	Mortality in heart failure;
PAAD	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg04165759	chr1:150448943	RPRD2	0.51	5.21	0.39	5.99e-7	Migraine;
PAAD	cis	rs939584	0.877	rs6731225	chr2:630224	A/T	cg14515364	chr2:636606	NA	0.52	4.65	0.35	7.19e-6	Body mass index;
PAAD	cis	rs11168618	0.703	rs11495272	chr12:48928826	G/A	cg01881778	chr12:48919444	OR8S1	-0.52	-5.62	-0.41	9.02e-8	Adiponectin levels;
PAAD	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.56	5.44	0.4	2.13e-7	Platelet count;
PAAD	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.6	-6.29	-0.45	3.13e-9	Monocyte count;
PAAD	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg02404636	chr22:31891804	SFI1	0.64	6.18	0.45	5.53e-9	Colorectal cancer;
PAAD	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	6.97	0.49	8.85e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	4.37	0.33	2.27e-5	Response to bleomycin (chromatid breaks);
PAAD	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg24253500	chr15:84953950	NA	0.54	6.03	0.44	1.18e-8	Schizophrenia;
PAAD	cis	rs7624766	0.555	rs972909	chr3:160509506	C/T	cg22637730	chr3:160473554	PPM1L	0.55	4.74	0.36	4.9100000000000004e-06	Response to methotrexate in rheumatoid arthritis;
PAAD	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.59	5.99	0.44	1.48e-8	Obesity;
PAAD	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.29	-14.39	-0.76	3.58e-30	Hip circumference adjusted for BMI;
PAAD	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.47	6.86	0.49	1.61e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	5.39	0.4	2.68e-7	Response to antipsychotic treatment;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg21852757	chr3:179424616	USP13	0.58	6.89	0.49	1.36e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg00717180	chr2:96193071	NA	0.62	6.61	0.47	6.2e-10	Migraine - clinic-based;
PAAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg00206168	chr11:65308501	LTBP3	-0.51	-5.25	-0.39	5.12e-7	Bone mineral density;
PAAD	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	6.24	0.45	4.15e-9	Lung cancer in ever smokers;
PAAD	cis	rs2415984	0.622	rs1761029	chr14:46934764	T/C	cg14871534	chr14:47121158	RPL10L	0.51	5.32	0.4	3.7e-7	Number of children ever born;
PAAD	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg15117754	chr3:10150083	C3orf24	0.65	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg06883089	chr1:45254480	BEST4	0.36	4.48	0.34	1.48e-5	High light scatter reticulocyte count;
PAAD	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	4.81	0.36	3.53e-6	Hip circumference;
PAAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg04482110	chr17:41364121	TMEM106A	0.38	4.39	0.34	2.13e-5	Menopause (age at onset);
PAAD	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.74	7.57	0.52	3.3e-12	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.08	0.55	1.83e-13	Lymphocyte counts;
PAAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.74	10.02	0.63	1.81e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg16362232	chr11:430036	ANO9	0.79	4.41	0.34	1.94e-5	Body mass index;
PAAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06915872	chr16:87998081	BANP	0.56	5.19	0.39	6.65e-7	Menopause (age at onset);
PAAD	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-9.09	-0.59	5.08e-16	Depression;
PAAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.5	5.0	0.38	1.56e-6	Airway imaging phenotypes;
PAAD	cis	rs1468333	0.824	rs28704868	chr5:137590786	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.57	5.93	0.43	2e-8	Resting heart rate;
PAAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.58	7.01	0.49	7.14e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.56	-6.73	-0.48	3.24e-10	Total body bone mineral density;
PAAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.89	-6.83	-0.48	1.87e-10	Initial pursuit acceleration;
PAAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.86	11.0	0.67	4.39e-21	Height;
PAAD	cis	rs3784262	0.740	rs4646582	chr15:58307381	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.51	-5.95	-0.43	1.76e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg21905437	chr5:178450457	ZNF879	0.69	6.01	0.44	1.33e-8	Pubertal anthropometrics;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04459481	chr16:74640951	GLG1	-0.64	-6.65	-0.47	5.07e-10	Smoking initiation;
PAAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg15017067	chr4:17643749	FAM184B	0.38	4.33	0.33	2.74e-5	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg19767477	chr5:127420684	SLC12A2	-0.52	-4.27	-0.33	3.44e-5	Ileal carcinoids;
PAAD	cis	rs4743820	0.651	rs10991797	chr9:93930671	A/G	cg14446406	chr9:93919335	NA	-0.56	-6.86	-0.49	1.59e-10	Ulcerative colitis;Inflammatory bowel disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25679870	chr19:7293776	INSR	0.6	6.55	0.47	8.41e-10	Monocyte percentage of white cells;
PAAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs2944755	0.723	rs34051681	chr8:141587701	G/A	cg08632810	chr8:141609470	EIF2C2	-0.38	-4.51	-0.34	1.3e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.83	-10.04	-0.63	1.68e-18	Brugada syndrome;
PAAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26549601	chr10:134560360	INPP5A	-0.43	-4.52	-0.34	1.23e-5	Migraine;
PAAD	cis	rs1003645	1.000	rs8075916	chr17:34343845	A/C	cg07880005	chr17:34842371	ZNHIT3	-0.57	-4.29	-0.33	3.12e-5	Blood protein levels;
PAAD	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg18518183	chr2:172544446	DYNC1I2	0.5	4.41	0.34	1.99e-5	Schizophrenia;
PAAD	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-1.0	-6.88	-0.49	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.56	5.93	0.43	1.98e-8	Subjective well-being;
PAAD	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-4.37	-0.33	2.33e-5	Aortic root size;
PAAD	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.71	8.28	0.56	6.05e-14	N-glycan levels;
PAAD	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.58	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22482690	chr17:47019901	SNF8	-0.43	-4.51	-0.34	1.27e-5	Type 2 diabetes;
PAAD	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	6.82	0.48	2.07e-10	Obesity-related traits;
PAAD	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg06569542	chr10:98946673	SLIT1	0.51	4.97	0.37	1.81e-6	Monocyte count;
PAAD	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.52	5.06	0.38	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7953249	0.722	rs2255531	chr12:121414915	G/A	cg02403541	chr12:121454288	C12orf43	0.64	6.82	0.48	1.99e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.48	-0.41	1.71e-7	Chronic sinus infection;
PAAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.68	7.31	0.51	1.42e-11	Longevity;Endometriosis;
PAAD	cis	rs5756391	0.546	rs9607397	chr22:37315988	C/T	cg16356956	chr22:37317934	CSF2RB	0.39	4.79	0.36	4e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.68	7.83	0.54	7.82e-13	Multiple sclerosis;
PAAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg05564831	chr3:52568323	NT5DC2	0.42	4.64	0.35	7.41e-6	Bipolar disorder;
PAAD	cis	rs10733682	0.659	rs3861879	chr9:129464856	A/G	cg00232160	chr9:129468157	NA	0.57	6.48	0.47	1.24e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg18357526	chr6:26021779	HIST1H4A	0.53	4.76	0.36	4.41e-6	Height;
PAAD	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg08562672	chr19:21860753	NA	0.43	4.61	0.35	8.47e-6	Pain;
PAAD	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.53	5.24	0.39	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg02811702	chr13:24901961	NA	0.52	5.57	0.41	1.14e-7	Obesity-related traits;
PAAD	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs12304921	1.000	rs12305170	chr12:51345265	T/C	cg04427360	chr12:51347099	HIGD1C	-0.68	-5.22	-0.39	5.78e-7	Type 2 diabetes;
PAAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.87	6.95	0.49	1.02e-10	Initial pursuit acceleration;
PAAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.81	9.51	0.61	4.12e-17	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-8.71	-0.58	4.74e-15	Longevity;Endometriosis;
PAAD	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.31	0.56	4.92e-14	Prudent dietary pattern;
PAAD	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.9	5.84	0.43	3.02e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs12931792	0.774	rs7204270	chr16:30156963	C/T	cg17640201	chr16:30407289	ZNF48	0.58	6.11	0.44	7.87e-9	Tonsillectomy;
PAAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.6	-0.47	6.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg18888403	chr1:24152774	HMGCL	0.38	4.32	0.33	2.76e-5	Immature fraction of reticulocytes;
PAAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg16898833	chr6:26189333	HIST1H4D	0.68	5.29	0.39	4.29e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg24879335	chr3:133465180	TF	-0.62	-7.36	-0.51	1.06e-11	Iron status biomarkers;
PAAD	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.54	5.22	0.39	5.66e-7	Essential tremor;
PAAD	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.97	6.18	0.45	5.49e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	4.95	0.37	1.99e-6	Mood instability;
PAAD	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.86	5.37	0.4	2.89e-7	Schizophrenia;
PAAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.87	10.0	0.63	2.15e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.72	0.42	5.39e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg08853572	chr16:1843915	IGFALS	-0.26	-4.42	-0.34	1.88e-5	Blood metabolite levels;
PAAD	cis	rs4561483	0.603	rs7202065	chr16:11951045	C/T	cg08843971	chr16:11963173	GSPT1	0.44	4.92	0.37	2.22e-6	Testicular germ cell tumor;
PAAD	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg10932868	chr11:921992	NA	0.45	4.84	0.37	3.21e-6	Alzheimer's disease (late onset);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01662117	chr14:38065435	FOXA1	-0.65	-6.85	-0.49	1.67e-10	Smoking initiation;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg19223190	chr17:80058835	NA	-0.54	-5.63	-0.42	8.57e-8	Life satisfaction;
PAAD	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.16e-8	Total body bone mineral density;
PAAD	cis	rs2741200	0.845	rs2979034	chr8:134123740	G/A	cg07421261	chr8:134158758	NA	0.5	4.26	0.33	3.52e-5	Bone erosion in rheumatoid arthritis;Temperament;
PAAD	cis	rs11871801	1.000	rs35272895	chr17:40580669	T/A	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.55	-0.35	1.08e-5	Crohn's disease;
PAAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs7646881	0.812	rs73015644	chr3:158447744	C/T	cg19483011	chr3:158453295	NA	-0.71	-5.83	-0.43	3.15e-8	Tetralogy of Fallot;
PAAD	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26306683	chr17:18585705	ZNF286B	0.56	5.54	0.41	1.32e-7	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg20822109	chr3:183146412	MCF2L2	0.62	6.87	0.49	1.59e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg24585817	chr7:64895279	NA	-0.44	-4.47	-0.34	1.49e-5	Aortic root size;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26978691	chr10:105128013	TAF5	0.6	6.66	0.48	4.65e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg19630374	chr17:18023558	MYO15A	-0.57	-6.2	-0.45	5.2e-9	Total body bone mineral density;
PAAD	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.88	-8.22	-0.55	8.37e-14	Breast cancer;
PAAD	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.51	4.83	0.36	3.33e-6	Hirschsprung disease;
PAAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg06799790	chr17:61951754	CSH2	0.44	4.57	0.35	9.95e-6	Height;
PAAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg14709524	chr16:89940631	TCF25	0.99	4.65	0.35	7.26e-6	Skin colour saturation;
PAAD	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg16417436	chr16:28758564	NA	0.44	4.38	0.33	2.22e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg07959490	chr17:80112427	CCDC57	-0.36	-4.27	-0.33	3.39e-5	Life satisfaction;
PAAD	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg16898833	chr6:26189333	HIST1H4D	0.91	5.13	0.38	8.61e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.58	6.02	0.44	1.27e-8	Coronary artery disease;
PAAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.73	-4.41	-0.34	1.97e-5	Tuberculosis;
PAAD	cis	rs7554547	0.739	rs7518827	chr1:11976745	A/G	cg07603449	chr1:11986842	KIAA2013	-0.37	-5.68	-0.42	6.71e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	0.52	4.46	0.34	1.6e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs11563648	0.535	rs6467122	chr7:127001087	A/C	cg13381984	chr7:127881344	LEP	-0.29	-4.32	-0.33	2.77e-5	Resting heart rate;
PAAD	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	9.02	0.59	7.8e-16	Motion sickness;
PAAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg12639453	chr1:2035780	PRKCZ	0.46	4.36	0.33	2.41e-5	Height;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.61	-6.33	-0.46	2.6e-9	Iron status biomarkers;
PAAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	5.73	0.42	5.15e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	4.62	0.35	8.23e-6	Breast cancer;
PAAD	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.31	0.4	3.75e-7	Morning vs. evening chronotype;
PAAD	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.68	6.38	0.46	1.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg00504896	chr12:9437009	LOC642846	-0.46	-4.28	-0.33	3.28e-5	Breast size;
PAAD	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-5.23	-0.39	5.42e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.52	-4.78	-0.36	4.16e-6	Dental caries;
PAAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.76	8.44	0.56	2.32e-14	Longevity;
PAAD	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg10754510	chr19:44488342	ZNF155	-0.49	-4.73	-0.36	5.15e-6	Tuberculosis;
PAAD	cis	rs4918918	0.868	rs4918916	chr10:97118537	C/T	cg14101359	chr10:97300930	SORBS1	-0.42	-4.29	-0.33	3.13e-5	Suicide risk;
PAAD	cis	rs7264396	0.887	rs6120951	chr20:34045191	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	4.33	0.33	2.68e-5	Total cholesterol levels;
PAAD	cis	rs357618	1.000	rs165353	chr5:150856757	C/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-4.53	-0.34	1.2e-5	Basophil percentage of white cells;
PAAD	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.5	-5.62	-0.41	8.97e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg14582100	chr15:45693742	SPATA5L1	0.43	6.59	0.47	6.84e-10	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	5.54	0.41	1.32e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs3818638	0.520	rs10985549	chr9:124911894	T/C	cg14107457	chr9:124889836	NA	-0.43	-4.38	-0.33	2.24e-5	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg10591111	chr5:226296	SDHA	-0.73	-5.63	-0.42	8.44e-8	Breast cancer;
PAAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg15181151	chr6:150070149	PCMT1	0.59	6.47	0.46	1.25e-9	Lung cancer;
PAAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18856214	chr7:4264980	SDK1	-0.62	-6.39	-0.46	1.93e-9	Obesity-related traits;
PAAD	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	1.17	15.15	0.78	3.48e-32	Ewing sarcoma;
PAAD	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.66	-6.18	-0.45	5.57e-9	Platelet distribution width;
PAAD	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.76	8.91	0.59	1.47e-15	Hemoglobin concentration;
PAAD	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	5.12	0.38	8.99e-7	Thyroid stimulating hormone;
PAAD	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.59	4.65	0.35	7.01e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg23346134	chr3:49453900	TCTA	-0.46	-4.92	-0.37	2.22e-6	Menarche (age at onset);
PAAD	cis	rs1371614	0.513	rs13010712	chr2:27087709	T/A	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.46	-0.34	1.59e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27309920	chr12:6798957	ZNF384	0.63	7.12	0.5	4.11e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg21929781	chr1:2537748	MMEL1	0.48	5.13	0.38	8.52e-7	Ulcerative colitis;
PAAD	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg10604476	chr19:10403908	ICAM5	0.33	4.27	0.33	3.37e-5	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
PAAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg26596419	chr16:1591503	IFT140;TMEM204	0.49	4.45	0.34	1.62e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.67e-8	Life satisfaction;
PAAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.51	4.83	0.36	3.37e-6	Bipolar disorder;
PAAD	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.38	0.4	2.74e-7	Diabetic retinopathy;
PAAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-7.06	-0.5	5.41e-11	Life satisfaction;
PAAD	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg10072921	chr12:121022843	NA	0.39	4.56	0.35	1.03e-5	Type 1 diabetes nephropathy;
PAAD	cis	rs7616330	0.887	rs1947150	chr3:71113096	A/G	cg01511742	chr3:71112437	FOXP1	-0.89	-6.42	-0.46	1.67e-9	QT interval;
PAAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.61	6.39	0.46	1.92e-9	Coronary artery disease;
PAAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-10.62	-0.65	4.65e-20	Total body bone mineral density;
PAAD	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.82	9.52	0.61	3.75e-17	Intelligence (multi-trait analysis);
PAAD	trans	rs3733631	1.000	rs7667662	chr4:104590704	A/G	cg21490444	chr5:171095097	NA	0.77	6.29	0.45	3.16e-9	Menarche (age at onset);
PAAD	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.54	5.32	0.4	3.67e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg23435118	chr5:141488016	NDFIP1	-0.54	-5.3	-0.4	3.94e-7	Crohn's disease;
PAAD	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.47	-4.55	-0.35	1.09e-5	Inflammatory bowel disease;
PAAD	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.08	0.38	1.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.77	-7.07	-0.5	5.17e-11	Vitamin D levels;
PAAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg16810054	chr20:33298113	TP53INP2	0.56	4.59	0.35	9.1e-6	Neuroticism;
PAAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs12612619	0.732	rs11126836	chr2:27273128	C/T	cg00617064	chr2:27272375	NA	-0.54	-5.75	-0.42	4.86e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.6	5.84	0.43	3.04e-8	Age-related hearing impairment;
PAAD	cis	rs6494488	0.500	rs112640485	chr15:64740810	G/A	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.63	-0.57	7.64e-15	Body mass index;
PAAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.61	0.61	2.25e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg23587288	chr2:27483067	SLC30A3	0.68	6.12	0.44	7.63e-9	Blood metabolite levels;
PAAD	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg26935685	chr1:15502881	TMEM51	-0.49	-4.25	-0.33	3.78e-5	Systolic blood pressure;
PAAD	cis	rs7009516	0.625	rs1907754	chr8:24259027	A/C	cg01759110	chr8:24241694	ADAMDEC1	-0.48	-5.57	-0.41	1.11e-7	Hair greying;
PAAD	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs1499972	0.527	rs66978872	chr3:117952174	C/T	cg07612923	chr3:117604196	NA	0.71	4.55	0.35	1.08e-5	Schizophrenia;
PAAD	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg01267373	chr18:77410094	NA	0.4	4.36	0.33	2.34e-5	Monocyte count;
PAAD	cis	rs73206853	0.841	rs73191834	chr12:110963841	T/G	cg12870014	chr12:110450643	ANKRD13A	0.77	4.88	0.37	2.66e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg09796270	chr17:17721594	SREBF1	0.44	5.14	0.38	8.36e-7	Total body bone mineral density;
PAAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs375066	0.967	rs376328	chr19:44407487	A/G	cg21496419	chr19:44306685	LYPD5	0.4	4.89	0.37	2.51e-6	Breast cancer;
PAAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.01	0.49	7.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23928525	chr17:19266198	B9D1	0.64	7.15	0.5	3.33e-11	Myopia (pathological);
PAAD	cis	rs8010715	0.596	rs12435995	chr14:24589464	A/C	cg23112188	chr14:24563095	PCK2	-0.53	-5.87	-0.43	2.6e-8	IgG glycosylation;
PAAD	cis	rs8105895	1.000	rs11882234	chr19:22145727	C/T	cg20662725	chr19:22235022	ZNF257	-0.57	-4.51	-0.34	1.31e-5	Body mass index (change over time);
PAAD	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg10818794	chr15:86012489	AKAP13	0.45	4.97	0.37	1.75e-6	Interstitial lung disease;
PAAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	5.1	0.38	9.82e-7	Mood instability;
PAAD	cis	rs1499972	0.941	rs55929115	chr3:117614158	T/A	cg07612923	chr3:117604196	NA	1.01	6.96	0.49	9.31e-11	Schizophrenia;
PAAD	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg04165759	chr1:150448943	RPRD2	-0.51	-5.18	-0.39	6.82e-7	Migraine;
PAAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.68	7.78	0.53	1e-12	Multiple sclerosis;
PAAD	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-8.06	-0.55	2.1e-13	Hemoglobin concentration;
PAAD	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.61	-5.21	-0.39	5.95e-7	Corneal structure;
PAAD	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21646471	chr2:242523971	THAP4	0.66	5.29	0.39	4.21e-7	Prostate cancer;
PAAD	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg23241863	chr10:102295624	HIF1AN	0.5	4.52	0.34	1.25e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg05585544	chr11:47624801	NA	0.48	5.3	0.39	4.09e-7	Subjective well-being;
PAAD	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg11416102	chr8:651193	ERICH1	-0.87	-5.06	-0.38	1.21e-6	IgG glycosylation;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg27023235	chr10:94429569	NA	-0.63	-6.43	-0.46	1.58e-9	Myopia (pathological);
PAAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.99	13.36	0.73	1.98e-27	Menopause (age at onset);
PAAD	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.55	7.26	0.51	1.82e-11	Primary biliary cholangitis;
PAAD	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg22827986	chr11:48284249	OR4X1	0.41	5.06	0.38	1.21e-6	Migraine - clinic-based;
PAAD	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.2	15.2	0.78	2.62e-32	IgG glycosylation;
PAAD	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg23254163	chr1:152506842	NA	0.59	6.83	0.48	1.95e-10	Hair morphology;
PAAD	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.84	-4.51	-0.34	1.29e-5	Schizophrenia;
PAAD	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg14851346	chr12:38532713	NA	-0.45	-4.42	-0.34	1.9e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.47	6.05	0.44	1.08e-8	Ulcerative colitis;
PAAD	cis	rs3106136	0.609	rs10433970	chr4:95134165	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.68	-6.21	-0.45	4.9e-9	Capecitabine sensitivity;
PAAD	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	IgG glycosylation;
PAAD	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	7.89	0.54	5.57e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg13918804	chr1:2043761	PRKCZ	0.4	5.4	0.4	2.57e-7	Height;
PAAD	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.97	-6.5	-0.47	1.1e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg19337854	chr7:99768885	GPC2	0.45	4.62	0.35	7.97e-6	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24094746	chr11:9287069	DENND5A	0.61	6.67	0.48	4.37e-10	Monocyte percentage of white cells;
PAAD	cis	rs9435341	0.762	rs3861909	chr1:107544176	A/G	cg09367891	chr1:107599246	PRMT6	-0.48	-4.95	-0.37	1.91e-6	Facial morphology (factor 21, depth of nasal alae);
PAAD	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg16586182	chr3:47516702	SCAP	0.65	7.12	0.5	4.1e-11	Colorectal cancer;
PAAD	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.48	4.4	0.34	2.03e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg04087571	chr11:116723030	SIK3	-0.34	-4.42	-0.34	1.86e-5	Subjective well-being;
PAAD	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.67	8.38	0.56	3.38e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg25790453	chr13:113633590	MCF2L	-0.4	-4.75	-0.36	4.66e-6	Systolic blood pressure;
PAAD	cis	rs12760731	0.720	rs10753178	chr1:178401000	A/T	cg00404053	chr1:178313656	RASAL2	0.72	5.65	0.42	7.71e-8	Obesity-related traits;
PAAD	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg15764593	chr10:829463	NA	-0.7	-5.5	-0.41	1.59e-7	Uric acid levels;
PAAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16576597	chr16:28551801	NUPR1	0.63	6.96	0.49	9.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg02841227	chr6:26021843	HIST1H4A	0.5	4.91	0.37	2.3e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg08562672	chr19:21860753	NA	0.43	4.44	0.34	1.73e-5	Pain;
PAAD	cis	rs58521262	0.530	rs289354	chr19:23144468	C/G	cg02350677	chr19:23254381	NA	-0.26	-4.47	-0.34	1.55e-5	Testicular germ cell tumor;
PAAD	cis	rs740474	0.831	rs2302103	chr5:140955777	C/T	cg08155325	chr5:140857813	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.43	5.23	0.39	5.62e-7	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.77	-10.87	-0.66	1.01e-20	Psoriasis;
PAAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg05697835	chr1:2722811	NA	-0.43	-4.82	-0.36	3.45e-6	Ulcerative colitis;
PAAD	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg23688817	chr7:87105293	ABCB4	0.55	4.53	0.35	1.17e-5	Gallbladder cancer;
PAAD	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.68	7.57	0.52	3.28e-12	Menopause (age at onset);
PAAD	cis	rs4918918	0.624	rs7084752	chr10:97070115	C/T	cg14101359	chr10:97300930	SORBS1	-0.43	-4.7	-0.36	5.86e-6	Suicide risk;
PAAD	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-7.1	-0.5	4.41e-11	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.53	-0.41	1.36e-7	Bipolar disorder;
PAAD	cis	rs73568641	0.546	rs12524666	chr6:154088541	A/T	cg15658985	chr6:154448740	OPRM1	0.56	4.62	0.35	8e-6	Methadone dose in opioid dependence;
PAAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.44	-0.34	1.69e-5	Breast cancer;
PAAD	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.24e-8	Childhood ear infection;
PAAD	cis	rs7580658	0.648	rs2069916	chr2:128178415	C/T	cg09760422	chr2:128146352	NA	-0.41	-6.42	-0.46	1.62e-9	Protein C levels;
PAAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.91	12.15	0.7	3.6e-24	Vitiligo;
PAAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg24733560	chr20:60626293	TAF4	0.46	5.49	0.41	1.66e-7	Body mass index;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs12453935	0.640	rs56294609	chr17:59933432	G/T	cg01765249	chr17:59476334	TBX2	-0.49	-4.45	-0.34	1.62e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.64	4.99	0.38	1.6e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-6.43	-0.46	1.6e-9	Morning vs. evening chronotype;
PAAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	5.78	0.42	4.04e-8	Body mass index;
PAAD	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.11	8.27	0.56	6.08e-14	Lymphocyte counts;
PAAD	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg18477163	chr1:228402036	OBSCN	0.49	5.21	0.39	6.04e-7	Coronary artery disease;
PAAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg01815783	chr4:1047043	NA	-0.45	-4.27	-0.33	3.4e-5	Recombination rate (females);
PAAD	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18283916	chr15:63797637	USP3	-0.58	-6.61	-0.47	6.25e-10	Body fat percentage;
PAAD	cis	rs9398803	0.687	rs7743860	chr6:126927717	T/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs9657904	0.826	rs9841500	chr3:105584066	C/T	cg16975614	chr3:105601834	NA	-0.45	-4.39	-0.34	2.12e-5	Multiple sclerosis;
PAAD	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-1.03	-8.6	-0.57	9.07e-15	Blood trace element (Zn levels);
PAAD	cis	rs6952808	0.931	rs7810038	chr7:1894116	T/C	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.71	-0.53	1.49e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg04738700	chr2:239367308	NA	0.41	4.43	0.34	1.76e-5	Multiple system atrophy;
PAAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.66	-5.41	-0.4	2.39e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.63	7.07	0.5	5.4e-11	Schizophrenia;
PAAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.75	8.15	0.55	1.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg23331303	chr5:5135948	NA	0.46	6.56	0.47	8.04e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.47	-4.77	-0.36	4.31e-6	Type 2 diabetes;
PAAD	cis	rs2301888	0.962	rs2240339	chr1:17674108	C/T	cg01790353	chr1:17674483	PADI4	0.47	5.57	0.41	1.15e-7	Rheumatoid arthritis;
PAAD	cis	rs72827839	0.649	rs80347400	chr17:46012502	A/G	cg23391107	chr17:45924227	SP6	0.84	6.32	0.46	2.79e-9	Ease of getting up in the morning;
PAAD	cis	rs3996993	0.724	rs2749029	chr6:52631188	A/G	cg00536792	chr6:53530503	KLHL31	0.45	4.55	0.35	1.07e-5	Hemoglobin concentration;
PAAD	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.59	6.17	0.45	6.01e-9	Multiple sclerosis;
PAAD	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.63	-6.4	-0.46	1.79e-9	Leprosy;
PAAD	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg10820045	chr2:198174542	NA	0.58	5.87	0.43	2.64e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg24044776	chr19:53454761	ZNF816A	-0.51	-5.55	-0.41	1.25e-7	Psoriasis;
PAAD	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg10239410	chr1:235292449	SNORA14B;TOMM20	0.42	4.44	0.34	1.75e-5	Adiposity;
PAAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.65	-6.51	-0.47	1.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-6.79	-0.48	2.42e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg19443311	chr22:18957678	DGCR5	-0.52	-4.52	-0.34	1.21e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	0.97	7.45	0.52	6.56e-12	Lymphocyte counts;
PAAD	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.63	-6.63	-0.47	5.45e-10	Capecitabine sensitivity;
PAAD	cis	rs7326068	0.610	rs2013546	chr13:21386229	G/A	cg27234864	chr13:21295941	IL17D	0.58	4.8	0.36	3.81e-6	Schizophrenia, bipolar disorder and depression (combined);
PAAD	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.47	5.27	0.39	4.53e-7	Body mass index;
PAAD	cis	rs4561483	0.583	rs1029285	chr16:11987118	G/A	cg08843971	chr16:11963173	GSPT1	0.44	4.83	0.36	3.29e-6	Testicular germ cell tumor;
PAAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.45	-4.91	-0.37	2.28e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs4751058	0.526	rs1377273	chr10:130860965	C/A	cg12123941	chr10:130493103	NA	-0.41	-4.31	-0.33	2.87e-5	Vitamin D levels;
PAAD	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg16586182	chr3:47516702	SCAP	-0.64	-7.27	-0.51	1.75e-11	Colorectal cancer;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14307304	chr9:97221786	HIATL1	0.61	6.29	0.45	3.24e-9	Smoking initiation;
PAAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.88	-6.82	-0.48	2.06e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-5.21	-0.39	6.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg20913747	chr6:44695427	NA	-0.65	-6.41	-0.46	1.75e-9	Total body bone mineral density;
PAAD	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg08134877	chr2:44394819	PPM1B	0.44	4.46	0.34	1.58e-5	Height;
PAAD	cis	rs528301	0.833	rs564207	chr2:45136742	T/C	cg15393275	chr2:45165193	NA	-0.5	-5.39	-0.4	2.59e-7	Alcohol and nicotine co-dependence;
PAAD	cis	rs9918079	0.580	rs13120905	chr4:15612288	A/T	cg16509355	chr4:15471240	CC2D2A	0.33	4.27	0.33	3.49e-5	Obesity-related traits;
PAAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-6.53	-0.47	9.44e-10	Bone mineral density;
PAAD	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.76	8.96	0.59	1.1e-15	Morning vs. evening chronotype;
PAAD	cis	rs3736485	0.932	rs4774592	chr15:51778879	C/T	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11771053	0.932	rs10807889	chr7:37447918	C/T	cg12515638	chr7:37956018	SFRP4	0.49	4.32	0.33	2.81e-5	Mean platelet volume;
PAAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.05	-8.06	-0.55	2.06e-13	Diabetic kidney disease;
PAAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.72	-8.09	-0.55	1.72e-13	Prostate cancer;
PAAD	cis	rs2117029	0.653	rs1476137	chr12:49523713	A/G	cg05368762	chr12:50135785	TMBIM6	0.43	4.26	0.33	3.57e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.84	10.2	0.64	6.19e-19	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg12633918	chr20:23549525	CST9L	-0.45	-4.92	-0.37	2.18e-6	Facial morphology (factor 15, philtrum width);
PAAD	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02621020	chr8:145159250	SHARPIN;MAF1	0.63	7.53	0.52	4.2e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs35955747	0.902	rs2413048	chr22:31686102	G/A	cg07548257	chr22:31686466	PIK3IP1	-0.36	-4.29	-0.33	3.11e-5	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.9	-7.68	-0.53	1.81e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.77e-5	Alzheimer's disease (survival time);
PAAD	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.0	14.32	0.76	5.6e-30	Heart rate;
PAAD	cis	rs55728055	0.661	rs16989519	chr22:31725416	C/T	cg01338084	chr22:32026380	PISD	1.47	7.18	0.5	2.82e-11	Age-related hearing impairment;
PAAD	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg08992911	chr2:238395768	MLPH	0.61	5.84	0.43	3.01e-8	Prostate cancer;
PAAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg19423196	chr10:82049429	MAT1A	0.57	4.38	0.33	2.2e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-7.3	-0.51	1.54e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs939584	1.000	rs13401686	chr2:650519	A/G	cg14515364	chr2:636606	NA	-0.46	-4.34	-0.33	2.57e-5	Body mass index;
PAAD	cis	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.73	-7.75	-0.53	1.2e-12	DNA methylation (variation);
PAAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13171016	chr1:40219054	PPIE	-0.62	-6.31	-0.46	2.95e-9	Smoking initiation;
PAAD	cis	rs11811982	0.793	rs80237401	chr1:227441012	G/A	cg24860534	chr1:227506868	CDC42BPA	0.52	5.02	0.38	1.4e-6	Optic disc area;
PAAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.51	-4.59	-0.35	9.23e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg21231944	chr12:82153410	PPFIA2	-0.51	-4.26	-0.33	3.63e-5	Resting heart rate;
PAAD	cis	rs9463078	0.587	rs1150806	chr6:44897787	C/T	cg25276700	chr6:44698697	NA	-0.54	-6.12	-0.44	7.68e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.79	9.18	0.6	3.03e-16	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26872149	chr2:157191396	NA	0.67	6.6	0.47	6.51e-10	Obesity-related traits;
PAAD	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-4.52	-0.34	1.24e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.7	7.69	0.53	1.76e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	8.08	0.55	1.84e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs6499129	0.558	rs9934328	chr16:67573367	G/C	cg09835421	chr16:68378352	PRMT7	-0.66	-4.36	-0.33	2.38e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.73	5.48	0.41	1.75e-7	Alzheimer's disease;
PAAD	cis	rs7577696	0.962	rs11691879	chr2:32274217	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.88e-6	Inflammatory biomarkers;
PAAD	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.47	-6.73	-0.48	3.27e-10	Schizophrenia;
PAAD	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.7	6.41	0.46	1.77e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.87	6.95	0.49	9.82e-11	Axial length;
PAAD	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg00459043	chr17:30771460	PSMD11	-0.56	-4.58	-0.35	9.43e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	7.29	0.51	1.58e-11	Response to hepatitis C treatment;
PAAD	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs367943	0.608	rs2972669	chr5:112983599	C/T	cg12552261	chr5:112820674	MCC	-0.58	-5.98	-0.44	1.53e-8	Type 2 diabetes;
PAAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-6.03	-0.44	1.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.4	0.34	2.03e-5	Plateletcrit;Platelet count;
PAAD	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-5.48	-0.41	1.72e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-6.96	-0.49	9.64e-11	Monocyte count;
PAAD	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg01657329	chr11:68192670	LRP5	-0.74	-6.82	-0.48	2.07e-10	Total body bone mineral density;
PAAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01765077	chr12:122356316	WDR66	0.62	6.54	0.47	8.81e-10	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.88	11.05	0.67	3.28e-21	Prudent dietary pattern;
PAAD	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.57	-0.35	1.02e-5	Depression;
PAAD	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	4.42	0.34	1.87e-5	Lipoprotein (a) levels;
PAAD	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.33	-0.51	1.24e-11	Response to antipsychotic treatment;
PAAD	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg00717180	chr2:96193071	NA	-0.59	-6.49	-0.47	1.12e-9	HDL cholesterol;
PAAD	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00149659	chr3:10157352	C3orf10	0.81	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-5.0	-0.38	1.56e-6	Vitiligo;
PAAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg19223190	chr17:80058835	NA	0.52	5.38	0.4	2.79e-7	Life satisfaction;
PAAD	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.38	0.4	2.74e-7	Mean platelet volume;
PAAD	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.49	5.6	0.41	9.68e-8	Coronary artery disease;
PAAD	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg00982548	chr2:198649783	BOLL	-0.74	-5.28	-0.39	4.42e-7	Ulcerative colitis;
PAAD	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.88	-6.94	-0.49	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.48	4.31	0.33	2.88e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14119001	chr9:139324193	INPP5E	-0.6	-5.37	-0.4	2.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.79	-0.36	4.01e-6	Educational attainment (years of education);
PAAD	cis	rs6977660	1.000	rs4719584	chr7:19823388	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	4.29	0.33	3.11e-5	Thyroid stimulating hormone;
PAAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.64	0.57	7.17e-15	Menopause (age at onset);
PAAD	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg19401529	chr3:49056140	DALRD3	0.52	4.35	0.33	2.52e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg04342483	chr1:7259290	CAMTA1	-0.4	-4.33	-0.33	2.67e-5	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs1497828	1.000	rs1032598	chr1:217548508	A/G	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg03732007	chr1:2071316	PRKCZ	-0.48	-5.44	-0.4	2.09e-7	Height;
PAAD	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.54	-4.36	-0.33	2.39e-5	Vitiligo;
PAAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.46	-4.93	-0.37	2.08e-6	Type 2 diabetes;
PAAD	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg19671926	chr4:122722719	EXOSC9	-0.61	-4.6	-0.35	8.98e-6	Type 2 diabetes;
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05564831	chr3:52568323	NT5DC2	0.42	4.39	0.34	2.15e-5	Electroencephalogram traits;
PAAD	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.67	-0.42	7e-8	Glomerular filtration rate (creatinine);
PAAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg12870014	chr12:110450643	ANKRD13A	0.65	4.67	0.35	6.51e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.58	-5.68	-0.42	6.54e-8	Motion sickness;
PAAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.49	5.81	0.43	3.6e-8	Immature fraction of reticulocytes;
PAAD	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.64	-4.64	-0.35	7.56e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
PAAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-1.16	-9.58	-0.61	2.65e-17	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.51	-4.76	-0.36	4.42e-6	Endometrial cancer;
PAAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13198984	chr17:80129470	CCDC57	-0.4	-4.95	-0.37	1.96e-6	Life satisfaction;
PAAD	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.61	6.47	0.46	1.26e-9	High light scatter reticulocyte count;
PAAD	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg22467129	chr15:76604101	ETFA	0.52	4.87	0.37	2.76e-6	Blood metabolite levels;
PAAD	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg06042504	chr8:55087323	NA	-0.7	-7.23	-0.51	2.15e-11	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.69	7.66	0.53	2.05e-12	Motion sickness;
PAAD	cis	rs12432203	1.000	rs72622442	chr14:51744868	A/G	cg23942311	chr14:51606299	NA	-0.79	-5.26	-0.39	4.86e-7	Cancer;
PAAD	cis	rs7904985	1.000	rs11201991	chr10:88117122	T/C	cg07322936	chr10:88137208	NA	-0.49	-4.44	-0.34	1.7e-5	Barrett's esophagus;
PAAD	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.81	7.95	0.54	3.9e-13	Corneal astigmatism;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24971957	chr17:67323276	ABCA5	0.54	6.31	0.46	2.94e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17376030	chr22:41985996	PMM1	-0.65	-4.62	-0.35	8.14e-6	Vitiligo;
PAAD	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.91	-8.04	-0.55	2.36e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs60154123	0.881	rs1774107	chr1:210453923	C/T	cg25204440	chr1:209979598	IRF6	0.58	5.02	0.38	1.41e-6	Coronary artery disease;
PAAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-1.01	-16.35	-0.8	2.64e-35	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg11214348	chr21:47283868	PCBP3	-0.48	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg26726589	chr20:306364	SOX12	0.64	6.85	0.49	1.74e-10	Primary biliary cholangitis;
PAAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.9	7.72	0.53	1.41e-12	Obesity-related traits;
PAAD	cis	rs3736485	0.844	rs7181470	chr15:51800882	T/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.3	-0.33	3.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-5.35	-0.4	3.14e-7	Height;
PAAD	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.82	6.49	0.47	1.18e-9	Pulmonary function decline;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02770252	chr6:14450312	NA	0.61	6.51	0.47	1.02e-9	Smoking initiation;
PAAD	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.59	-7.83	-0.54	7.75e-13	Menopause (age at onset);
PAAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-1.02	-8.75	-0.58	3.77e-15	Schizophrenia;
PAAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.84	9.17	0.6	3.22e-16	Total body bone mineral density;
PAAD	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.87	-6.58	-0.47	7.01e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26926768	chr12:34528122	NA	0.38	4.77	0.36	4.22e-6	Morning vs. evening chronotype;
PAAD	cis	rs3747547	0.710	rs7863948	chr9:37949409	A/C	cg13774184	chr9:37916125	SHB	-0.6	-4.45	-0.34	1.66e-5	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.02	0.44	1.26e-8	Rheumatoid arthritis;
PAAD	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-4.72	-0.36	5.25e-6	Height;
PAAD	cis	rs7301826	0.627	rs7978987	chr12:131281494	G/A	cg11011512	chr12:131303247	STX2	-0.45	-4.66	-0.35	6.87e-6	Plasma plasminogen activator levels;
PAAD	cis	rs12681288	0.782	rs12544713	chr8:1026697	C/T	cg08648136	chr8:956695	NA	0.41	4.34	0.33	2.63e-5	Schizophrenia;
PAAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.49	-4.86	-0.37	2.93e-6	Type 2 diabetes;
PAAD	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.62	-6.67	-0.48	4.43e-10	Capecitabine sensitivity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg04261066	chr19:3762669	MRPL54;APBA3	0.67	6.79	0.48	2.39e-10	Obesity-related traits;
PAAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	5.12	0.38	9.11e-7	Rheumatoid arthritis;
PAAD	cis	rs3784262	0.740	rs1441829	chr15:58289739	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-5.85	-0.43	2.97e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.72	6.94	0.49	1.07e-10	Schizophrenia;
PAAD	trans	rs901683	1.000	rs34011467	chr10:46059758	T/C	cg14076390	chr17:34947837	DHRS11	0.92	6.71	0.48	3.69e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.6	5.96	0.44	1.7e-8	Testicular germ cell tumor;
PAAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.85	-9.62	-0.62	2.09e-17	Prostate cancer;
PAAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	11.63	0.69	9.23e-23	Menopause (age at onset);
PAAD	cis	rs7765175	0.598	rs2637534	chr6:113654133	A/G	cg19037598	chr6:113666021	NA	0.42	4.62	0.35	7.96e-6	Coronary artery calcification;
PAAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.46	4.7	0.36	5.81e-6	Lymphocyte counts;
PAAD	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.7	8.23	0.56	7.95e-14	Dupuytren's disease;
PAAD	cis	rs17023223	0.537	rs2361269	chr1:119602215	A/G	cg17326555	chr1:119535693	NA	-0.43	-5.32	-0.4	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.53	-5.93	-0.43	1.97e-8	Migraine;
PAAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs282587	0.569	rs426765	chr13:113414798	A/T	cg04656015	chr13:113407548	ATP11A	0.56	4.48	0.34	1.44e-5	Glycated hemoglobin levels;
PAAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	1.07	14.97	0.77	1.05e-31	Breast cancer;
PAAD	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.76	-0.48	2.84e-10	Schizophrenia (age at onset);
PAAD	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg04165759	chr1:150448943	RPRD2	0.5	5.16	0.39	7.77e-7	Migraine;
PAAD	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.97	6.43	0.46	1.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs7172677	0.737	rs7169545	chr15:75436123	A/G	cg05627522	chr15:75251581	NA	0.37	4.29	0.33	3.14e-5	Systemic lupus erythematosus and Systemic sclerosis;
PAAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21028142	chr17:79581711	NPLOC4	0.43	5.02	0.38	1.42e-6	Eye color traits;
PAAD	cis	rs12144049	0.662	rs4845763	chr1:152388138	A/G	cg25605289	chr1:151974222	NA	0.34	4.39	0.34	2.14e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg08088566	chr11:430123	ANO9	-0.89	-5.52	-0.41	1.43e-7	Body mass index;
PAAD	cis	rs4938330	0.608	rs12418744	chr11:117084537	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-4.94	-0.37	2.03e-6	Blood protein levels;
PAAD	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-7.3	-0.51	1.47e-11	Chronic sinus infection;
PAAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06799790	chr17:61951754	CSH2	-0.47	-4.82	-0.36	3.4e-6	Height;
PAAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.77	-7.96	-0.54	3.6e-13	DNA methylation (variation);
PAAD	cis	rs990171	0.520	rs4851605	chr2:103120868	A/G	cg13897122	chr2:103039542	IL18RAP	-0.45	-5.0	-0.38	1.56e-6	Lymphocyte counts;
PAAD	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.72	0.58	4.6e-15	Chronic sinus infection;
PAAD	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.55	-5.37	-0.4	2.84e-7	Itch intensity from mosquito bite;
PAAD	cis	rs2786865	0.529	rs2744766	chr1:26052776	C/T	cg02327719	chr1:26185386	C1orf135	-0.79	-4.69	-0.36	6.11e-6	Facial morphology (factor 11, projection of the nose);
PAAD	cis	rs11871801	1.000	rs6503704	chr17:40592253	G/A	cg21692620	chr17:40835849	CNTNAP1	-0.47	-4.62	-0.35	8.12e-6	Crohn's disease;
PAAD	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.73	-7.5	-0.52	5.03e-12	Uric acid clearance;
PAAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.63	-7.5	-0.52	4.84e-12	Reticulocyte fraction of red cells;
PAAD	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg13870426	chr17:30244630	NA	-0.73	-7.39	-0.51	9.23e-12	Hip circumference adjusted for BMI;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02847575	chr16:30382517	TBC1D10B	0.61	6.72	0.48	3.46e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4668356	0.892	rs999837	chr2:171825673	T/C	cg13882835	chr2:172017928	TLK1	-0.89	-4.47	-0.34	1.52e-5	Cognitive performance;
PAAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg08888203	chr3:10149979	C3orf24	0.77	5.75	0.42	4.73e-8	Alzheimer's disease;
PAAD	cis	rs12681288	0.755	rs2123056	chr8:1033366	G/C	cg04851639	chr8:1020857	NA	-0.67	-8.26	-0.56	6.61e-14	Schizophrenia;
PAAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg00024989	chr19:17902242	NA	0.44	4.91	0.37	2.37e-6	Tumor biomarkers;
PAAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.39	0.4	2.69e-7	Electroencephalogram traits;
PAAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.27	-0.45	3.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg23283495	chr1:209979779	IRF6	0.81	7.45	0.52	6.38e-12	Cleft lip with or without cleft palate;
PAAD	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.9	-10.3	-0.64	3.38e-19	Refractive error;
PAAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.55	5.26	0.39	4.85e-7	Height;
PAAD	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.32	0.46	2.76e-9	Aortic root size;
PAAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.21	-0.39	6.03e-7	Pulmonary function;
PAAD	cis	rs6601530	0.504	rs11250075	chr8:10643759	A/G	cg21775007	chr8:11205619	TDH	-0.52	-4.29	-0.33	3.17e-5	Carotid intima media thickness;
PAAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg16176600	chr6:116381609	FRK	0.33	4.81	0.36	3.54e-6	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00300879	chr1:26503847	CNKSR1	0.28	4.31	0.33	2.98e-5	Height;
PAAD	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-8.37	-0.56	3.59e-14	Bladder cancer;
PAAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg08662619	chr6:150070041	PCMT1	0.43	4.25	0.33	3.73e-5	Lung cancer;
PAAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg05787120	chr3:50365854	TUSC2	-0.63	-6.36	-0.46	2.3e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg08501292	chr6:25962987	TRIM38	1.0	5.58	0.41	1.08e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.87	6.99	0.49	8.19e-11	Chronic kidney disease;
PAAD	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.5	6.21	0.45	4.81e-9	Sitting height ratio;
PAAD	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.7	-6.19	-0.45	5.35e-9	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.6	-5.15	-0.39	8.13e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.85	10.61	0.65	4.87e-20	Bladder cancer;
PAAD	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg25635251	chr11:2234043	NA	0.66	5.44	0.4	2.12e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.53	4.94	0.37	2.03e-6	Airway imaging phenotypes;
PAAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs4621152	0.775	rs10211546	chr2:217892397	G/A	cg21875423	chr2:217559867	IGFBP5	-0.45	-4.48	-0.34	1.44e-5	Gut microbiota (bacterial taxa);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06874334	chr12:108106067	PWP1	-0.61	-6.71	-0.48	3.64e-10	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.68	5.73	0.42	5.26e-8	Gut microbiome composition (summer);
PAAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg15181151	chr6:150070149	PCMT1	0.58	6.31	0.46	2.94e-9	Lung cancer;
PAAD	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13939156	chr17:80058883	NA	-0.4	-4.32	-0.33	2.76e-5	Life satisfaction;
PAAD	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.61	-0.35	8.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16434002	chr17:42200994	HDAC5	-0.67	-7.41	-0.52	8.04e-12	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04866628	chr4:187026225	NA	0.65	7.36	0.51	1.1e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11264799	0.581	rs2758680	chr1:157543746	C/T	cg18268488	chr1:157545234	FCRL4	0.48	5.36	0.4	3e-7	IgA nephropathy;
PAAD	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg10729496	chr3:10149963	C3orf24	0.61	5.3	0.4	3.96e-7	Alzheimer's disease;
PAAD	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg05935833	chr10:81318306	SFTPA2	-0.54	-4.47	-0.34	1.53e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02071572	chr4:1403502	NA	0.44	5.9	0.43	2.32e-8	Obesity-related traits;
PAAD	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.3	11.28	0.68	8.02e-22	Uric acid levels;
PAAD	cis	rs76917914	0.820	rs6478539	chr9:100818720	C/T	cg03040243	chr9:100819229	NANS	0.58	4.77	0.36	4.25e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.73	-7.49	-0.52	5.27e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	15.87	0.79	4.42e-34	Prudent dietary pattern;
PAAD	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.63	-6.93	-0.49	1.14e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.46	-0.61	5.37e-17	Alzheimer's disease (late onset);
PAAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.65	-6.07	-0.44	9.88e-9	Blood metabolite levels;
PAAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-4.96	-0.37	1.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.4	-4.77	-0.36	4.26e-6	HIV-1 susceptibility;
PAAD	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg17347104	chr14:75034677	LTBP2	0.52	4.5	0.34	1.36e-5	Non-small cell lung cancer;
PAAD	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-4.74	-0.36	4.84e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg09127314	chr1:152161683	NA	-0.68	-4.81	-0.36	3.67e-6	Atopic dermatitis;
PAAD	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg24053715	chr22:38214548	NA	-0.57	-5.89	-0.43	2.39e-8	Glioblastoma;Glioma;
PAAD	cis	rs7180079	1.000	rs8029682	chr15:64628534	C/T	cg18210365	chr15:65066710	RBPMS2	0.65	4.95	0.37	1.91e-6	Monocyte count;
PAAD	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.46	4.83	0.36	3.34e-6	QRS complex (12-leadsum);
PAAD	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.55	6.11	0.44	7.96e-9	Multiple sclerosis;
PAAD	cis	rs12476592	0.530	rs2080650	chr2:64227289	C/T	cg10828910	chr2:63850056	LOC388955	-0.52	-4.29	-0.33	3.18e-5	Childhood ear infection;
PAAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	9.93	0.63	3.18e-18	Platelet count;
PAAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg13859433	chr6:33739653	LEMD2	-0.64	-4.94	-0.37	2e-6	Schizophrenia;
PAAD	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg19337854	chr7:99768885	GPC2	0.52	4.43	0.34	1.81e-5	Lung function (FEV1/FVC);
PAAD	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06850241	chr22:41845214	NA	0.51	4.91	0.37	2.34e-6	Vitiligo;
PAAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg22549504	chr19:17448937	GTPBP3	0.54	4.29	0.33	3.21e-5	Systemic lupus erythematosus;
PAAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg21466736	chr12:48725269	NA	0.5	4.64	0.35	7.33e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.95	-7.57	-0.52	3.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7631605	0.905	rs9810355	chr3:37121074	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.58	0.35	9.53e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.47	-4.69	-0.36	5.92e-6	Type 2 diabetes;
PAAD	cis	rs2790216	1.000	rs2590340	chr10:60012271	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs755249	0.532	rs2296173	chr1:39913351	A/G	cg14018543	chr1:39659967	MACF1	-0.55	-4.68	-0.35	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.52	4.82	0.36	3.52e-6	Schizophrenia;
PAAD	cis	rs9876781	1.000	rs12487542	chr3:48426076	C/G	cg24898236	chr3:49228699	LOC646498	0.4	4.37	0.33	2.33e-5	Longevity;
PAAD	cis	rs62025270	0.649	rs12148610	chr15:86245928	A/G	cg13263323	chr15:86062960	AKAP13	0.49	4.4	0.34	2.02e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs1561176	1.000	rs1561176	chr7:155008713	T/G	cg08570118	chr7:155025533	NA	-0.53	-4.77	-0.36	4.32e-6	Personality dimensions;
PAAD	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.95	-7.78	-0.53	1.01e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs9652601	0.691	rs9933507	chr16:11201428	T/C	cg04616529	chr16:11181986	CLEC16A	0.39	4.66	0.35	6.9e-6	Systemic lupus erythematosus;
PAAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18621852	chr3:10150065	C3orf24	0.68	5.96	0.44	1.72e-8	Alzheimer's disease;
PAAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg26338869	chr17:61819248	STRADA	0.5	4.92	0.37	2.23e-6	Height;
PAAD	cis	rs494459	0.726	rs1784300	chr11:118679629	A/T	cg08498647	chr11:118550644	TREH	-0.35	-4.29	-0.33	3.18e-5	Height;
PAAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg14092988	chr3:52407081	DNAH1	0.46	5.77	0.42	4.31e-8	Electroencephalogram traits;
PAAD	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-4.74	-0.36	4.92e-6	Cognitive ability (multi-trait analysis);
PAAD	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg20636351	chr8:55087400	NA	-0.8	-9.08	-0.59	5.5e-16	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.61	5.92	0.43	2.05e-8	Schizophrenia;
PAAD	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.04	0.38	1.3e-6	Birth weight;
PAAD	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg01631408	chr1:248437212	OR2T33	-0.59	-5.36	-0.4	3.04e-7	Common traits (Other);
PAAD	cis	rs4417704	0.551	rs7594525	chr2:241893722	G/C	cg26818257	chr2:241905806	NA	0.51	5.25	0.39	4.97e-7	Joint mobility (Beighton score);
PAAD	cis	rs16854884	0.770	rs7621093	chr3:143814542	C/G	cg06585982	chr3:143692056	C3orf58	0.48	4.56	0.35	1.04e-5	Economic and political preferences (feminism/equality);
PAAD	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg15676125	chr6:33679581	C6orf125	0.45	4.28	0.33	3.24e-5	Plateletcrit;
PAAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.73	0.36	5.19e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.48	-4.31	-0.33	2.89e-5	Response to temozolomide;
PAAD	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	0.96	7.02	0.49	6.93e-11	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg08029281	chr1:67600428	NA	-0.57	-6.7	-0.48	3.83e-10	Psoriasis;
PAAD	cis	rs7216064	0.859	rs7502307	chr17:65989961	C/G	cg08758996	chr17:66097529	LOC651250	0.55	4.45	0.34	1.63e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.54	4.73	0.36	5.19e-6	Corneal astigmatism;
PAAD	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.79	6.72	0.48	3.51e-10	Chronic lymphocytic leukemia;
PAAD	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg22153407	chr1:230290089	GALNT2	0.49	5.01	0.38	1.51e-6	Coronary artery disease;
PAAD	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.44	-5.55	-0.41	1.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.89	10.21	0.64	5.84e-19	Tonsillectomy;
PAAD	cis	rs4790333	1.000	rs2429908	chr17:2268681	T/C	cg02569219	chr17:2266849	SGSM2	0.63	6.08	0.44	9.28e-9	Proinsulin levels;
PAAD	cis	rs16976116	0.901	rs3179664	chr15:55496853	G/A	cg11288833	chr15:55489084	RSL24D1	0.6	4.9	0.37	2.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.72	8.17	0.55	1.1e-13	Bladder cancer;
PAAD	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs804280	0.583	rs804262	chr8:11631504	C/T	cg00405596	chr8:11794950	NA	0.42	4.45	0.34	1.63e-5	Myopia (pathological);
PAAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.55	6.08	0.44	9.28e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.6	6.5	0.47	1.11e-9	Lung cancer;
PAAD	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	cis	rs8112211	0.648	rs77914289	chr19:38815372	G/A	cg14299480	chr19:38876666	GGN	-0.54	-4.66	-0.35	6.96e-6	Blood protein levels;
PAAD	cis	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg25886479	chr11:50257625	LOC441601	-0.42	-4.58	-0.35	9.52e-6	Coronary artery disease;
PAAD	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.96	8.45	0.57	2.24e-14	Vitiligo;
PAAD	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg20933634	chr6:27740509	NA	0.77	5.56	0.41	1.19e-7	Depression;
PAAD	cis	rs4073221	0.547	rs13076743	chr3:18235724	C/T	cg07694806	chr3:18168406	NA	-0.68	-4.73	-0.36	5.18e-6	Parkinson's disease;
PAAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09835421	chr16:68378352	PRMT7	-1.17	-8.34	-0.56	4.13e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.36	-0.4	3.09e-7	Longevity;Endometriosis;
PAAD	cis	rs12304921	1.000	rs2269684	chr12:51417758	A/T	cg18059802	chr12:51347058	HIGD1C	-0.71	-5.52	-0.41	1.45e-7	Type 2 diabetes;
PAAD	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.64	7.19	0.5	2.74e-11	Menopause (age at onset);
PAAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.56	-7.18	-0.5	2.9e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.29	-0.51	1.57e-11	Triglycerides;
PAAD	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg17325771	chr7:75508891	RHBDD2	0.3	4.26	0.33	3.61e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	7.05	0.5	5.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg15017067	chr4:17643749	FAM184B	0.46	5.3	0.39	4.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg27499820	chr13:21296301	IL17D	0.51	4.7	0.36	5.82e-6	Dental caries;
PAAD	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg04721828	chr11:48285200	OR4X1	-0.4	-5.13	-0.38	8.91e-7	Migraine - clinic-based;
PAAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.63	0.35	7.75e-6	Homoarginine levels;
PAAD	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.52	-4.53	-0.34	1.18e-5	P wave terminal force;
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg08677398	chr8:58056175	NA	0.62	4.32	0.33	2.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6594499	0.872	rs13161853	chr5:110446741	C/A	cg04022379	chr5:110408740	TSLP	0.45	4.26	0.33	3.52e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg06606381	chr12:133084897	FBRSL1	-1.31	-7.75	-0.53	1.22e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.78	9.84	0.62	5.58e-18	Height;
PAAD	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.35	-0.4	3.15e-7	P wave terminal force;
PAAD	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg08886695	chr4:3369023	RGS12	-0.5	-4.68	-0.35	6.29e-6	Serum sulfate level;
PAAD	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.45	-4.6	-0.35	8.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7082209	1.000	rs61856381	chr10:44811172	T/C	cg13191911	chr10:44806660	NA	-0.93	-5.39	-0.4	2.7e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
PAAD	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.71	11.08	0.67	2.78e-21	Tourette's syndrome or obsessive-compulsive disorder;
PAAD	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.51	4.77	0.36	4.23e-6	Endometrial cancer;
PAAD	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg06217071	chr17:408420	NA	0.6	6.39	0.46	1.9e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.89	4.69	0.36	6.12e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.42	-4.36	-0.33	2.42e-5	Height;
PAAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.68	8.27	0.56	6.29e-14	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.7	-8.16	-0.55	1.15e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg24179445	chr10:102496915	NA	0.53	5.58	0.41	1.09e-7	Alzheimer's disease;
PAAD	cis	rs62408225	1.000	rs72925996	chr6:90930513	T/C	cg03795776	chr6:90687632	BACH2	0.47	4.7	0.36	5.67e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.08	-0.44	9.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg11517269	chr6:28058789	ZSCAN12L1	0.58	4.39	0.34	2.08e-5	Depression;
PAAD	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg14631576	chr9:95140430	CENPP	-0.61	-5.87	-0.43	2.6e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
PAAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.98	-0.44	1.52e-8	Recombination rate (males);
PAAD	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.97	13.6	0.74	4.47e-28	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.53	4.54	0.35	1.16e-5	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-5.8	-0.43	3.65e-8	Acne (severe);
PAAD	cis	rs7631605	0.623	rs7619703	chr3:36981411	T/A	cg10333520	chr3:36987040	TRANK1	0.34	4.56	0.35	1.06e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.84	0.49	1.8e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.25	-0.33	3.71e-5	Blood protein levels;
PAAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12639453	chr1:2035780	PRKCZ	-0.62	-6.63	-0.47	5.5e-10	Height;
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg04160749	chr8:58172571	NA	0.72	4.77	0.36	4.28e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg05896524	chr21:47604654	C21orf56	0.46	4.8	0.36	3.77e-6	Testicular germ cell tumor;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.59	-5.88	-0.43	2.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg09996344	chr7:66093369	KCTD7	0.57	6.29	0.45	3.17e-9	Immature fraction of reticulocytes;
PAAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.52	4.87	0.37	2.76e-6	Monocyte count;
PAAD	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.58	6.97	0.49	9.05e-11	Acute lymphoblastic leukemia (childhood);
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06816077	chr16:88513379	NA	0.69	7.44	0.52	6.73e-12	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg00086871	chr4:6988644	TBC1D14	1.1	4.86	0.37	2.87e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	6.18	0.45	5.7e-9	Hip circumference;
PAAD	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.66	6.6	0.47	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
PAAD	cis	rs6971211	1.000	rs6971211	chr7:155664686	C/T	cg14601210	chr7:155671264	NA	-0.37	-4.31	-0.33	2.9e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.7	7.82	0.54	8.12e-13	Motion sickness;
PAAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.09	0.44	8.99e-9	Lung cancer;
PAAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg00786201	chr11:61583134	MIR1908;FADS1	0.49	4.8	0.36	3.84e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs8112211	0.648	rs4804016	chr19:38815665	C/A	cg01275006	chr19:38876250	GGN	-0.89	-5.72	-0.42	5.58e-8	Blood protein levels;
PAAD	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.31	-0.51	1.43e-11	Response to antipsychotic treatment;
PAAD	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.42	5.13	0.38	8.59e-7	Pulmonary function;
PAAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg24879335	chr3:133465180	TF	-0.57	-6.16	-0.45	6.16e-9	Iron status biomarkers;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22346355	chr17:29233327	C17orf42	-0.78	-6.99	-0.49	8.1e-11	Neuroticism;
PAAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg23887609	chr12:130822674	PIWIL1	0.58	5.79	0.42	4e-8	Menopause (age at onset);
PAAD	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13515842	chr9:127215440	GPR144	-0.42	-4.61	-0.35	8.46e-6	Menarche (age at onset);
PAAD	cis	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg22101045	chr11:47927509	NA	0.57	4.38	0.33	2.21e-5	Intraocular pressure;
PAAD	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	1.1	5.53	0.41	1.35e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg26220594	chr1:19110978	NA	0.59	4.65	0.35	7.28e-6	Percentage gas trapping;
PAAD	cis	rs11807834	0.522	rs910500	chr1:230244458	A/G	cg00566187	chr1:230250356	GALNT2	-0.65	-6.88	-0.49	1.5e-10	Schizophrenia;
PAAD	cis	rs9304742	0.540	rs10416138	chr19:53465152	C/T	cg09915433	chr19:53449742	NA	-0.7	-7.98	-0.54	3.35e-13	Psoriasis;
PAAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg18209359	chr17:80159595	CCDC57	0.44	4.46	0.34	1.57e-5	Life satisfaction;
PAAD	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg19217778	chr13:113420270	ATP11A	0.63	4.34	0.33	2.55e-5	Glycated hemoglobin levels;
PAAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.49	4.89	0.37	2.49e-6	Menarche (age at onset);
PAAD	cis	rs4917300	0.632	rs4917293	chr8:143116851	G/T	cg26003909	chr8:143102224	NA	-0.31	-4.37	-0.33	2.33e-5	Amyotrophic lateral sclerosis;
PAAD	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	5.28	0.39	4.32e-7	Lung cancer in ever smokers;
PAAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg01305625	chr5:131593812	PDLIM4	0.44	4.26	0.33	3.53e-5	Acylcarnitine levels;
PAAD	cis	rs6084352	0.506	rs1006681	chr20:3237547	A/G	cg06251395	chr20:3663186	ADAM33	0.38	4.3	0.33	3.09e-5	Asthma;
PAAD	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-15.05	-0.77	6.56e-32	Ulcerative colitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06858584	chr2:131904854	PLEKHB2	0.62	6.61	0.47	6.06e-10	Smoking initiation;
PAAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg10547527	chr2:198650123	BOLL	-0.71	-4.83	-0.36	3.29e-6	Ulcerative colitis;
PAAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg22143856	chr6:28129313	ZNF389	0.68	5.44	0.4	2.1e-7	Parkinson's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04496233	chr11:64863659	C11orf2	0.64	7.57	0.52	3.27e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.72	6.88	0.49	1.44e-10	Obesity-related traits;
PAAD	cis	rs2882667	0.659	rs12719515	chr5:138241318	A/G	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg09699651	chr6:150184138	LRP11	-0.47	-4.93	-0.37	2.09e-6	Lung cancer;
PAAD	cis	rs2790216	0.950	rs2790211	chr10:60003372	T/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.67	-5.54	-0.41	1.33e-7	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
PAAD	cis	rs2051773	0.538	rs4468326	chr11:17041034	A/G	cg15432903	chr11:17409602	KCNJ11	-0.53	-4.8	-0.36	3.76e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.86	0.66	1.07e-20	Tonsillectomy;
PAAD	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	5.49	0.41	1.67e-7	Coronary heart disease;
PAAD	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg08758996	chr17:66097529	LOC651250	0.58	4.99	0.38	1.61e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg15145965	chr22:50218605	BRD1	0.57	4.91	0.37	2.36e-6	Schizophrenia;
PAAD	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.49	-0.41	1.64e-7	Blood metabolite levels;
PAAD	cis	rs3771570	0.748	rs62186361	chr2:242168518	G/A	cg02700172	chr2:241377874	GPC1	-0.74	-4.98	-0.37	1.74e-6	Prostate cancer;
PAAD	cis	rs12714314	0.756	rs10439522	chr2:1945360	C/G	cg22350835	chr2:1868857	MYT1L	0.48	4.69	0.36	6.02e-6	Type 2 diabetes (age of onset);
PAAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg16147221	chr4:10020634	SLC2A9	0.49	4.43	0.34	1.82e-5	Bone mineral density;
PAAD	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.42	0.34	1.89e-5	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg14171486	chr1:155139557	NA	-0.33	-4.47	-0.34	1.52e-5	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.94	4.97	0.37	1.8e-6	Childhood ear infection;
PAAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.85	8.18	0.55	1.05e-13	Cognitive function;
PAAD	cis	rs6681460	0.576	rs7354930	chr1:66986377	T/C	cg02459107	chr1:67143332	SGIP1	0.52	4.62	0.35	8.26e-6	Presence of antiphospholipid antibodies;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13744822	chr11:64902092	SYVN1	-0.64	-6.65	-0.47	4.97e-10	Smoking initiation;
PAAD	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.6	5.73	0.42	5.27e-8	Schizophrenia;
PAAD	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.6	-4.96	-0.37	1.89e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.86	0.37	2.9e-6	Axial length;
PAAD	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.7	7.76	0.53	1.13e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.5	-0.41	1.55e-7	Monocyte percentage of white cells;
PAAD	cis	rs12282928	0.959	rs12790767	chr11:48332171	G/A	cg22827986	chr11:48284249	OR4X1	0.41	5.22	0.39	5.85e-7	Migraine - clinic-based;
PAAD	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	11.44	0.68	3.02e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.53	4.88	0.37	2.71e-6	Multiple sclerosis;
PAAD	trans	rs901683	0.850	rs76849715	chr10:46080433	G/A	cg13065504	chr15:42448234	PLA2G4F	0.87	6.78	0.48	2.46e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg12218747	chr21:37451666	NA	-0.45	-4.85	-0.37	3.01e-6	Mitral valve prolapse;
PAAD	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.66	8.06	0.55	2.13e-13	Dupuytren's disease;
PAAD	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.9	-8.88	-0.58	1.72e-15	Asthma;
PAAD	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg10547527	chr2:198650123	BOLL	-0.65	-4.44	-0.34	1.72e-5	Ulcerative colitis;
PAAD	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.7	-5.75	-0.42	4.72e-8	Non-small cell lung cancer;
PAAD	cis	rs755249	0.761	rs3768321	chr1:40035928	G/T	cg14018543	chr1:39659967	MACF1	-0.58	-4.45	-0.34	1.67e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg12193833	chr17:30244370	NA	-0.61	-5.32	-0.4	3.65e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg26097391	chr2:54893211	SPTBN1	0.44	4.29	0.33	3.22e-5	Schizophrenia;
PAAD	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.29	7.89	0.54	5.39e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	7.97	0.54	3.59e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	4.86	0.37	2.9e-6	Personality dimensions;
PAAD	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.89	5.8	0.43	3.66e-8	Blood protein levels;
PAAD	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg20487152	chr13:99095054	FARP1	0.47	4.99	0.38	1.65e-6	Longevity;
PAAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.32	0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg23912435	chr1:150601613	ENSA	-0.51	-4.71	-0.36	5.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.47	-5.22	-0.39	5.86e-7	Age at first birth;
PAAD	cis	rs17002988	0.568	rs7698326	chr4:79082750	T/A	cg07442568	chr4:78980533	FRAS1	0.66	5.48	0.41	1.74e-7	Uric acid levels;
PAAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-4.39	-0.34	2.14e-5	Gut microbiome composition (summer);
PAAD	cis	rs4332037	0.722	rs11973114	chr7:1913270	G/A	cg02421172	chr7:1938701	MAD1L1	0.6	4.33	0.33	2.64e-5	Bipolar disorder;
PAAD	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06002616	chr8:101225028	SPAG1	0.44	5.17	0.39	7.2e-7	Atrioventricular conduction;
PAAD	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26926768	chr12:34528122	NA	0.37	4.26	0.33	3.52e-5	Morning vs. evening chronotype;
PAAD	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg17182837	chr8:41585554	ANK1	-0.47	-4.93	-0.37	2.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
PAAD	cis	rs9810890	1.000	rs115639732	chr3:128555607	C/T	cg19129842	chr3:128565090	NA	-0.85	-4.89	-0.37	2.53e-6	Dental caries;
PAAD	cis	rs9660180	0.819	rs4648629	chr1:1695462	C/A	cg03396347	chr1:1875803	NA	0.58	7.2	0.5	2.59e-11	Body mass index;
PAAD	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	9.03	0.59	7.09e-16	Cognitive test performance;
PAAD	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg09796270	chr17:17721594	SREBF1	0.49	5.3	0.39	4.01e-7	Lymphocyte counts;
PAAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16447950	chr5:562315	NA	-0.64	-5.65	-0.42	7.65e-8	Lung disease severity in cystic fibrosis;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11940663	chr21:46962454	SLC19A1	0.68	7.08	0.5	4.88e-11	Myopia (pathological);
PAAD	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg26022315	chr17:47021804	SNF8	0.45	4.74	0.36	4.78e-6	Type 2 diabetes;
PAAD	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.76	7.61	0.53	2.65e-12	Response to diuretic therapy;
PAAD	cis	rs375066	0.935	rs408549	chr19:44425619	T/A	cg21496419	chr19:44306685	LYPD5	0.38	4.63	0.35	7.87e-6	Breast cancer;
PAAD	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.97	10.4	0.64	1.86e-19	Corneal astigmatism;
PAAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg13918804	chr1:2043761	PRKCZ	-0.38	-5.05	-0.38	1.24e-6	Height;
PAAD	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.54	-5.44	-0.4	2.1e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.49	5.46	0.4	1.94e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg13722127	chr7:150037890	RARRES2	0.55	5.4	0.4	2.52e-7	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.88	10.28	0.64	3.9e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.44	7.01	0.49	7.36e-11	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg26618903	chr10:100175079	PYROXD2	-0.43	-4.83	-0.37	3.25e-6	Metabolite levels;
PAAD	cis	rs12935418	0.583	rs12446698	chr16:80964421	G/A	cg16651780	chr16:81037892	C16orf61	0.57	4.73	0.36	5.15e-6	Mean corpuscular volume;
PAAD	cis	rs1135642	1.000	rs1135642	chr4:77953009	A/G	cg03477792	chr4:77819574	ANKRD56	-0.66	-4.33	-0.33	2.74e-5	Food addiction;
PAAD	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.69e-6	Height;
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.88	10.86	0.66	1.1e-20	Prudent dietary pattern;
PAAD	cis	rs1595825	1.000	rs1440091	chr2:198879457	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-4.57	-0.35	1.02e-5	Ulcerative colitis;
PAAD	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.56	-5.34	-0.4	3.26e-7	Subjective well-being;
PAAD	cis	rs6256	0.789	rs10832035	chr11:13459819	T/C	cg11976911	chr11:13509032	NA	-0.65	-4.72	-0.36	5.28e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
PAAD	cis	rs3026101	0.671	rs12602074	chr17:5302778	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	5.92	0.43	2.09e-8	Body mass index;
PAAD	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg02421172	chr7:1938701	MAD1L1	0.71	5.42	0.4	2.27e-7	Bipolar disorder;
PAAD	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.46	5.12	0.38	9.13e-7	Psychosis in Alzheimer's disease;
PAAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.69	7.57	0.52	3.36e-12	Aortic root size;
PAAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.39	4.76	0.36	4.52e-6	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.75	5.74	0.42	4.99e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.63	5.7	0.42	6.04e-8	Platelet count;
PAAD	cis	rs2834506	0.521	rs2300385	chr21:35900932	G/C	cg16756527	chr21:35891075	RCAN1	-0.33	-4.43	-0.34	1.77e-5	Cancer;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg22903657	chr4:1355424	KIAA1530	-0.48	-4.87	-0.37	2.72e-6	Obesity-related traits;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.83	5.67	0.42	7.1e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.26	-0.33	3.57e-5	Prostate cancer;
PAAD	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg27411982	chr8:10470053	RP1L1	-0.53	-5.87	-0.43	2.67e-8	Retinal vascular caliber;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-1.02	-8.38	-0.56	3.3e-14	Developmental language disorder (linguistic errors);
PAAD	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.95	-13.52	-0.74	7.53e-28	Post bronchodilator FEV1;
PAAD	cis	rs939584	1.000	rs7560246	chr2:643469	T/C	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg19000871	chr14:103996768	TRMT61A	-0.5	-5.71	-0.42	5.82e-8	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs6076065	0.723	rs2144381	chr20:23369940	C/T	cg11657817	chr20:23433608	CST11	0.5	5.14	0.38	8.39e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.5	-4.71	-0.36	5.63e-6	Putamen volume;
PAAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg07648498	chr16:89883185	FANCA	-0.46	-4.46	-0.34	1.6e-5	Vitiligo;
PAAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-5.32	-0.4	3.62e-7	Total body bone mineral density;
PAAD	cis	rs258892	0.895	rs7722344	chr5:72023608	A/G	cg21869765	chr5:72125136	TNPO1	-0.82	-5.56	-0.41	1.16e-7	Small cell lung carcinoma;
PAAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16417436	chr16:28758564	NA	0.47	4.4	0.34	2.06e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.84e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.66	6.98	0.49	8.45e-11	Mean corpuscular volume;
PAAD	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.48e-6	High light scatter reticulocyte count;
PAAD	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.6	6.61	0.47	6.13e-10	Testicular germ cell tumor;
PAAD	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg01796438	chr3:11312864	ATG7	-0.67	-5.13	-0.38	8.85e-7	Circulating chemerin levels;
PAAD	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg05585544	chr11:47624801	NA	-0.48	-5.4	-0.4	2.54e-7	Subjective well-being;
PAAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13560548	chr3:10150139	C3orf24	0.58	5.18	0.39	6.91e-7	Alzheimer's disease;
PAAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.55	6.65	0.47	4.86e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg10785373	chr7:4456119	NA	0.77	5.42	0.4	2.3e-7	Borderline personality disorder;
PAAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.9	-0.49	1.33e-10	Mood instability;
PAAD	cis	rs74181299	0.684	rs1420184	chr2:65315880	G/C	cg20592124	chr2:65290738	CEP68	-0.46	-4.26	-0.33	3.64e-5	Pulse pressure;
PAAD	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.7	8.44	0.57	2.29e-14	Dupuytren's disease;
PAAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.47	0.57	1.91e-14	Prudent dietary pattern;
PAAD	cis	rs11811982	0.793	rs11802399	chr1:227353753	C/T	cg24860534	chr1:227506868	CDC42BPA	-0.52	-4.96	-0.37	1.87e-6	Optic disc area;
PAAD	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.76e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.93	11.36	0.68	4.83e-22	Prudent dietary pattern;
PAAD	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.84	-5.63	-0.42	8.43e-8	Total cholesterol levels;
PAAD	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg20592124	chr2:65290738	CEP68	0.46	4.36	0.33	2.39e-5	Pulse pressure;
PAAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.67	-4.8	-0.36	3.73e-6	Depression;
PAAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.71	-0.36	5.61e-6	Bipolar disorder;
PAAD	cis	rs939584	0.877	rs7594220	chr2:643320	G/A	cg03610516	chr2:642275	NA	0.59	5.48	0.41	1.7e-7	Body mass index;
PAAD	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.14	0.38	8.45e-7	Menarche (age at onset);
PAAD	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.69	8.15	0.55	1.24e-13	Pursuit maintenance gain;
PAAD	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg10818794	chr15:86012489	AKAP13	-0.51	-5.6	-0.41	9.82e-8	Coronary artery disease;
PAAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16417436	chr16:28758564	NA	0.42	4.29	0.33	3.12e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.58	6.03	0.44	1.21e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	7.29	0.51	1.58e-11	Lung cancer in ever smokers;
PAAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	6.14	0.45	6.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.99	-10.5	-0.65	9.96e-20	Platelet distribution width;
PAAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.93	-7.71	-0.53	1.5e-12	Initial pursuit acceleration;
PAAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	5.92	0.43	2.04e-8	Height;
PAAD	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg01796438	chr3:11312864	ATG7	0.59	4.62	0.35	8.1e-6	Circulating chemerin levels;
PAAD	cis	rs758324	0.704	rs493829	chr5:131297043	T/C	cg06307176	chr5:131281290	NA	-0.53	-4.44	-0.34	1.7e-5	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg16898833	chr6:26189333	HIST1H4D	0.69	5.34	0.4	3.31e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.12	-10.25	-0.64	4.65e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
PAAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.67	8.43	0.56	2.5e-14	Coronary artery disease;
PAAD	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23281280	chr6:28129359	ZNF389	0.68	5.38	0.4	2.72e-7	Depression;
PAAD	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	1.18	13.56	0.74	5.96e-28	Eosinophil percentage of granulocytes;
PAAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.67	-8.69	-0.58	5.28e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg06207120	chr15:45996521	NA	0.3	4.44	0.34	1.75e-5	Waist circumference;Weight;
PAAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.34	-5.28	-0.39	4.46e-7	Alcohol dependence;
PAAD	cis	rs4731207	0.596	rs1026837	chr7:124673079	C/T	cg14311320	chr7:124405732	GPR37	-0.42	-4.34	-0.33	2.55e-5	Cutaneous malignant melanoma;
PAAD	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.55	-6.92	-0.49	1.16e-10	Lewy body disease;
PAAD	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg26939375	chr7:64535504	NA	0.76	9.15	0.6	3.49e-16	Calcium levels;
PAAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg04154034	chr17:28927549	LRRC37B2	0.72	4.88	0.37	2.6e-6	Body mass index;
PAAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.2	0.39	6.2e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg26935685	chr1:15502881	TMEM51	-0.5	-4.26	-0.33	3.59e-5	Systolic blood pressure;
PAAD	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.76	-8.05	-0.55	2.21e-13	Type 2 diabetes;
PAAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg01075559	chr1:2537774	MMEL1	-0.5	-5.18	-0.39	7.02e-7	Ulcerative colitis;
PAAD	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.46	-0.41	1.87e-7	Bladder cancer;
PAAD	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-6.81	-0.48	2.1e-10	Extrinsic epigenetic age acceleration;
PAAD	cis	rs2300603	0.881	rs4297627	chr14:76019696	A/G	cg01624173	chr14:75981868	NA	-0.54	-5.41	-0.4	2.42e-7	Multiple sclerosis;
PAAD	cis	rs116175783	0.557	rs2303318	chr2:162224495	A/C	cg08807892	chr2:162101083	NA	-0.65	-4.72	-0.36	5.36e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.67	-7.24	-0.51	2.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg18128536	chr17:47092178	IGF2BP1	-0.55	-6.71	-0.48	3.65e-10	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	trans	rs2249625	0.739	rs1528506	chr6:72787867	G/A	cg04413069	chr12:9800446	LOC374443	0.59	6.56	0.47	7.92e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
PAAD	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.45	5.41	0.4	2.37e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg17541715	chr7:1216824	NA	-0.55	-6.1	-0.44	8.43e-9	Longevity;Endometriosis;
PAAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg19673125	chr6:150240577	RAET1G	0.38	5.36	0.4	3.1e-7	Testicular germ cell tumor;
PAAD	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg14825688	chr5:132208181	LEAP2	-0.62	-6.34	-0.46	2.45e-9	Apolipoprotein A-IV levels;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.84	7.26	0.51	1.88e-11	Alzheimer's disease;
PAAD	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	9.96	0.63	2.69e-18	Colorectal cancer;
PAAD	cis	rs7189233	1.000	rs62048491	chr16:53456391	G/C	cg00221382	chr16:54322308	NA	-0.29	-4.5	-0.34	1.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2583612	0.643	rs57597755	chr4:120640021	A/C	cg05550861	chr4:120222222	C4orf3	-0.7	-4.53	-0.34	1.21e-5	Response to cytadine analogues (cytosine arabinoside);
PAAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg14703610	chr5:56206110	C5orf35	-0.57	-5.21	-0.39	6.07e-7	Coronary artery disease;
PAAD	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.15	0.45	6.65e-9	Alzheimer's disease (late onset);
PAAD	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.85	10.98	0.67	5.09e-21	Aortic root size;
PAAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg06740227	chr12:86229804	RASSF9	-0.61	-6.14	-0.45	6.88e-9	Major depressive disorder;
PAAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.84	8.4	0.56	2.93e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7577696	0.924	rs7566162	chr2:32324072	T/C	cg02381751	chr2:32503542	YIPF4	-0.43	-4.63	-0.35	7.69e-6	Inflammatory biomarkers;
PAAD	cis	rs300774	0.925	rs300714	chr2:138106	G/A	cg21211680	chr2:198530	NA	-0.6	-5.72	-0.42	5.44e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs16854884	1.000	rs1961542	chr3:143765503	G/A	cg06585982	chr3:143692056	C3orf58	0.61	5.89	0.43	2.42e-8	Economic and political preferences (feminism/equality);
PAAD	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg12092346	chr18:77659572	KCNG2	-0.64	-4.59	-0.35	9.28e-6	Opioid sensitivity;
PAAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.95	12.27	0.71	1.74e-24	Menopause (age at onset);
PAAD	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.93	-10.9	-0.66	8.24e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.39	0.4	2.62e-7	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg03983715	chr16:68378420	PRMT7	-0.83	-5.95	-0.43	1.75e-8	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg03517284	chr6:25882590	NA	-0.58	-4.83	-0.36	3.28e-6	Iron status biomarkers;
PAAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg05697835	chr1:2722811	NA	0.43	4.92	0.37	2.22e-6	Ulcerative colitis;
PAAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.33	-0.46	2.59e-9	Neuroticism;
PAAD	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.27	10.41	0.65	1.69e-19	Uric acid levels;
PAAD	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg04731861	chr2:219085781	ARPC2	-0.36	-4.52	-0.34	1.26e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-7.83	-0.54	7.87e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.24	-7.31	-0.51	1.41e-11	Mitochondrial DNA levels;
PAAD	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.93	-7.68	-0.53	1.77e-12	Total cholesterol levels;
PAAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.66	-0.69	7.46e-23	Cognitive function;
PAAD	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.45	-4.99	-0.37	1.67e-6	Mean arterial pressure;
PAAD	cis	rs7873102	0.593	rs2244203	chr9:37987144	C/A	cg03528946	chr9:38069800	SHB	0.5	5.07	0.38	1.12e-6	Brain structure;
PAAD	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg23024343	chr7:107201750	COG5	0.52	4.4	0.34	2.04e-5	Coronary artery disease;
PAAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.6	6.58	0.47	7.17e-10	Tonsillectomy;
PAAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.77	9.12	0.59	4.22e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-6.28	-0.45	3.33e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.69	-6.78	-0.48	2.53e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22482690	chr17:47019901	SNF8	0.47	5.11	0.38	9.5e-7	Type 2 diabetes;
PAAD	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg06917450	chr1:38156652	C1orf109	-0.49	-4.35	-0.33	2.44e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16417436	chr16:28758564	NA	0.45	4.64	0.35	7.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.81	8.57	0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4900538	0.827	rs3742444	chr14:102971050	T/G	cg05150608	chr14:102990211	NA	0.38	4.5	0.34	1.35e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg18450887	chr20:18548006	LOC388789	0.63	6.6	0.47	6.59e-10	Myopia (pathological);
PAAD	trans	rs1075265	0.621	rs2542593	chr2:54031436	C/T	cg16115072	chr17:25938812	KSR1	0.59	6.34	0.46	2.51e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.68	7.78	0.53	1e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs795484	0.963	rs795483	chr12:118590579	T/C	cg16572268	chr12:118583242	PEBP1	-0.47	-4.6	-0.35	8.81e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs818427	0.964	rs459102	chr5:112228765	C/A	cg06941702	chr5:112196734	SRP19	0.51	4.69	0.36	5.95e-6	Total body bone mineral density;
PAAD	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.42	-5.1	-0.38	1.01e-6	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg03585549	chr3:16926335	PLCL2	0.71	7.34	0.51	1.2e-11	Obesity-related traits;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.18	0.64	6.91e-19	Prudent dietary pattern;
PAAD	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.62	-5.6	-0.41	9.83e-8	Type 2 diabetes;
PAAD	trans	rs61931739	0.649	rs860088	chr12:33721807	T/C	cg26384229	chr12:38710491	ALG10B	0.71	7.52	0.52	4.42e-12	Morning vs. evening chronotype;
PAAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg13722127	chr7:150037890	RARRES2	0.62	6.59	0.47	6.84e-10	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg13482628	chr17:19912719	NA	0.51	4.99	0.38	1.61e-6	Schizophrenia;
PAAD	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.51	-5.19	-0.39	6.73e-7	Schizophrenia;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg04160749	chr8:58172571	NA	-0.72	-4.91	-0.37	2.38e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg22517653	chr1:2918612	NA	-0.66	-5.33	-0.4	3.46e-7	Plateletcrit;
PAAD	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-8.84	-0.58	2.19e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.6	6.16	0.45	6.36e-9	Type 2 diabetes;
PAAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.7	-6.56	-0.47	8.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.58	-6.2	-0.45	4.98e-9	Neuroticism;
PAAD	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg03948781	chr1:205179583	DSTYK	0.49	4.59	0.35	9.35e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg04450456	chr4:17643702	FAM184B	0.49	5.13	0.38	8.77e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7188861	0.813	rs12596260	chr16:11398265	T/G	cg16532467	chr16:11454386	NA	-0.54	-4.3	-0.33	3.09e-5	HDL cholesterol;
PAAD	cis	rs7873102	0.654	rs7037039	chr9:37972375	G/A	cg03528946	chr9:38069800	SHB	0.53	5.29	0.39	4.17e-7	Brain structure;
PAAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08219700	chr8:58056026	NA	0.67	5.21	0.39	6.13e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg05110241	chr16:68378359	PRMT7	-1.18	-8.45	-0.57	2.22e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg13010199	chr12:38710504	ALG10B	0.59	5.15	0.39	7.9e-7	Morning vs. evening chronotype;
PAAD	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg24253500	chr15:84953950	NA	0.42	4.33	0.33	2.7e-5	Schizophrenia;
PAAD	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg18939081	chr1:31884902	SERINC2	-0.46	-5.27	-0.39	4.51e-7	Alcohol dependence;
PAAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.94	7.12	0.5	3.97e-11	Alzheimer's disease;
PAAD	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.57	6.11	0.44	8.01e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs740474	0.831	rs1479585	chr5:140976528	G/C	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.29	4.28	0.33	3.31e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21028142	chr17:79581711	NPLOC4	0.5	5.8	0.43	3.76e-8	Eye color traits;
PAAD	cis	rs9535307	0.584	rs61961501	chr13:50392956	A/G	cg04663916	chr13:50265991	EBPL	-0.63	-4.38	-0.33	2.17e-5	Obesity-related traits;
PAAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg10207240	chr12:122356781	WDR66	0.55	5.79	0.42	3.95e-8	Mean corpuscular volume;
PAAD	cis	rs7922314	0.571	rs973577	chr10:64725175	C/T	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-8.67	-0.58	6.12e-15	Exhaled nitric oxide output;
PAAD	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.6	6.01	0.44	1.3e-8	Monocyte count;
PAAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.85e-8	Life satisfaction;
PAAD	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.41	9.51	0.61	4.1e-17	Atopic dermatitis;
PAAD	cis	rs7187994	0.848	rs7185949	chr16:84779248	T/G	cg07647771	chr16:84786436	USP10	-0.35	-4.34	-0.33	2.57e-5	Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25200453	chr10:21450066	NEBL	-0.38	-4.34	-0.33	2.62e-5	Monocyte percentage of white cells;
PAAD	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.55	4.85	0.37	3.05e-6	Type 2 diabetes;
PAAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.75	-8.64	-0.57	7.03e-15	Intelligence (multi-trait analysis);
PAAD	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.61	7.65	0.53	2.19e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.81	-6.87	-0.49	1.59e-10	Gut microbiome composition (summer);
PAAD	cis	rs7101378	0.577	rs7930665	chr11:108896862	T/G	cg10976287	chr11:108093109	ATM;NPAT	-0.5	-5.2	-0.39	6.25e-7	IgG glycosylation;
PAAD	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.91	6.74	0.48	3.03e-10	Axial length;
PAAD	cis	rs2252790	1.000	rs12203516	chr6:116638619	A/G	cg18764771	chr6:116381957	FRK	0.26	4.36	0.33	2.42e-5	Fast beta electroencephalogram;
PAAD	cis	rs728616	0.867	rs1537835	chr10:81830152	C/G	cg05935833	chr10:81318306	SFTPA2	-0.61	-4.85	-0.37	3.04e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs2384207	1.000	rs2384207	chr12:113607502	T/C	cg22376712	chr12:113623594	C12orf52;DDX54	0.6	5.17	0.39	7.14e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.55	6.39	0.46	1.94e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg16419906	chr5:132167176	NA	-0.42	-4.36	-0.33	2.39e-5	Apolipoprotein A-IV levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg12418357	chr1:31770205	ZCCHC17;SNRNP40	0.6	6.46	0.46	1.32e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg14139931	chr9:140268639	EXD3	-0.77	-6.34	-0.46	2.5e-9	Photic sneeze reflex;
PAAD	cis	rs10274279	0.614	rs12669550	chr7:157403743	G/A	cg26886268	chr7:157387156	PTPRN2	-0.64	-4.67	-0.35	6.65e-6	Myopia (pathological);
PAAD	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg13870426	chr17:30244630	NA	-0.74	-6.55	-0.47	8.33e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08822215	chr16:89438651	ANKRD11	-0.44	-4.26	-0.33	3.52e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg00579200	chr11:133705235	NA	-0.47	-5.42	-0.4	2.33e-7	Childhood ear infection;
PAAD	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs3736757	1.000	rs34618074	chr1:184701315	A/C	cg05045817	chr1:184633523	NA	0.41	4.47	0.34	1.55e-5	Obesity-related traits;
PAAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg16898833	chr6:26189333	HIST1H4D	0.53	4.48	0.34	1.45e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.07	13.97	0.75	4.7e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs6975373	0.643	rs12540089	chr7:4446121	C/A	cg27546065	chr7:4923383	RADIL	0.65	4.93	0.37	2.15e-6	Borderline personality disorder;
PAAD	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg04257695	chr17:30186438	C17orf79	-0.62	-4.8	-0.36	3.76e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.83	-8.81	-0.58	2.71e-15	DNA methylation (variation);
PAAD	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	0.41	4.57	0.35	9.93e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg01059385	chr22:42394853	WBP2NL	-0.45	-4.74	-0.36	4.81e-6	Cognitive function;
PAAD	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26549601	chr10:134560360	INPP5A	-0.41	-4.31	-0.33	2.91e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg09626299	chr10:82213104	TSPAN14	-0.42	-4.47	-0.34	1.54e-5	Post bronchodilator FEV1;
PAAD	cis	rs8112211	0.731	rs2368484	chr19:38825447	T/G	cg01275006	chr19:38876250	GGN	-0.95	-5.91	-0.43	2.18e-8	Blood protein levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08507806	chr6:36996068	FGD2	0.63	6.44	0.46	1.46e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg08436684	chr16:88034427	BANP	-0.49	-4.33	-0.33	2.67e-5	Menopause (age at onset);
PAAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16262614	chr3:133464971	TF	0.46	5.11	0.38	9.54e-7	Iron status biomarkers;
PAAD	cis	rs9815354	1.000	rs9882329	chr3:41767154	T/C	cg03022575	chr3:42003672	ULK4	0.8	5.7	0.42	5.99e-8	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg00543991	chr22:32367038	NA	1.22	7.63	0.53	2.39e-12	Childhood ear infection;
PAAD	cis	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg21546286	chr11:48923668	NA	-0.45	-4.83	-0.36	3.28e-6	Coronary artery disease;
PAAD	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.54	-5.89	-0.43	2.36e-8	Menopause (age at onset);
PAAD	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg26247942	chr15:43984922	CKMT1A	-0.35	-4.39	-0.34	2.08e-5	Schizophrenia;
PAAD	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg10518543	chr12:38710700	ALG10B	-0.5	-4.55	-0.35	1.08e-5	Morning vs. evening chronotype;
PAAD	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg05341575	chr12:125625032	AACS	-0.47	-4.49	-0.34	1.41e-5	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg05791153	chr7:19748676	TWISTNB	0.71	5.38	0.4	2.71e-7	Thyroid stimulating hormone;
PAAD	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg03568305	chr17:38183559	MED24;SNORD124	-0.41	-5.47	-0.41	1.78e-7	White blood cell count;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg14008862	chr17:28927542	LRRC37B2	0.78	4.79	0.36	3.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.81	-8.57	-0.57	1.08e-14	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	0.48	4.31	0.33	2.94e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.54	4.83	0.36	3.3e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs5009270	0.539	rs1319375	chr7:112161076	C/T	cg23628563	chr7:112262597	NA	0.59	4.76	0.36	4.38e-6	Osteoarthritis (hip);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg09929374	chr8:105479674	DPYS	-0.68	-7.45	-0.52	6.71e-12	Obesity-related traits;
PAAD	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	1.02	16.93	0.81	8.46e-37	Urate levels in lean individuals;
PAAD	cis	rs4841398	0.858	rs58309857	chr8:10464070	A/C	cg27411982	chr8:10470053	RP1L1	0.58	4.51	0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs2797160	0.904	rs1777197	chr6:126007401	G/A	cg05901451	chr6:126070800	HEY2	0.5	4.63	0.35	7.82e-6	Endometrial cancer;
PAAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.82	9.17	0.6	3.05e-16	Coronary artery disease;
PAAD	cis	rs10267836	0.844	rs6966354	chr7:30787798	G/T	cg17421561	chr7:31726639	C7orf16	-0.69	-4.51	-0.34	1.29e-5	Glucose homeostasis traits;
PAAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-7.5	-0.52	4.96e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	6.58	0.47	7.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-6.45	-0.46	1.44e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.51	-0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-7.3	-0.51	1.54e-11	Axial length;
PAAD	cis	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg27411982	chr8:10470053	RP1L1	0.41	4.46	0.34	1.61e-5	Neuroticism;
PAAD	cis	rs2278796	0.639	rs4951153	chr1:204970844	C/A	cg17947172	chr1:204966197	NFASC	0.43	4.7	0.36	5.86e-6	Mean platelet volume;
PAAD	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.96	6.42	0.46	1.65e-9	Prostate cancer;
PAAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-8.55	-0.57	1.26e-14	Homoarginine levels;
PAAD	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.73	7.3	0.51	1.5e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.35	-5.57	-0.41	1.11e-7	Urate levels in overweight individuals;
PAAD	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.59	5.01	0.38	1.48e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-12.86	-0.72	4.52e-26	Dental caries;
PAAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.6	-0.35	8.67e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg10356904	chr22:49881777	NA	-0.48	-5.48	-0.41	1.76e-7	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.63	-4.96	-0.37	1.86e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	4.25	0.33	3.75e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.97	9.89	0.63	4.16e-18	Corneal astigmatism;
PAAD	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg26248373	chr2:1572462	NA	-1.03	-7.95	-0.54	4.02e-13	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.65	7.42	0.52	7.89e-12	High light scatter reticulocyte count;
PAAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg19418458	chr7:158789849	NA	-0.6	-6.43	-0.46	1.54e-9	Facial morphology (factor 20);
PAAD	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.83	-0.48	1.89e-10	Systolic blood pressure;
PAAD	cis	rs2882667	0.690	rs7446631	chr5:138227065	A/G	cg09476006	chr5:138032270	NA	0.47	5.98	0.44	1.52e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.01	-0.38	1.52e-6	Cervical cancer;
PAAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24229701	chr12:130821962	PIWIL1	0.41	4.29	0.33	3.21e-5	Menopause (age at onset);
PAAD	cis	rs59888335	1.000	rs13094402	chr3:80710455	C/T	cg21735741	chr3:80819488	NA	-0.55	-4.82	-0.36	3.46e-6	Schizophrenia;
PAAD	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.61	8.69	0.58	5.54e-15	Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.06	-0.55	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg01420254	chr6:26195488	NA	0.79	4.62	0.35	8.19e-6	Iron status biomarkers (total iron binding capacity);
PAAD	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs4740619	0.836	rs1891211	chr9:15900709	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.43	-0.34	1.77e-5	Body mass index;
PAAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.76	-8.59	-0.57	9.92e-15	Body mass index;
PAAD	cis	rs6681460	0.604	rs11208920	chr1:67075312	C/A	cg02459107	chr1:67143332	SGIP1	0.55	5.12	0.38	9.3e-7	Presence of antiphospholipid antibodies;
PAAD	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.67	-7.94	-0.54	4.26e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.12	-0.38	9.05e-7	Cervical cancer;
PAAD	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.67	-6.45	-0.46	1.44e-9	Platelet distribution width;
PAAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.57	-5.58	-0.41	1.08e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.58	-6.84	-0.49	1.79e-10	Aortic root size;
PAAD	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg13877915	chr19:58951672	ZNF132	0.47	4.43	0.34	1.76e-5	Uric acid clearance;
PAAD	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.65	6.38	0.46	2.03e-9	Corneal astigmatism;
PAAD	cis	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs11825685	0.836	rs11822810	chr11:134581992	A/C	cg02089395	chr11:134479357	NA	-0.68	-4.85	-0.37	3.07e-6	IgG glycosylation;
PAAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.2	0.45	5.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg21452805	chr1:244014465	NA	0.47	4.4	0.34	2.06e-5	RR interval (heart rate);
PAAD	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.83	-10.14	-0.64	8.7e-19	Coronary artery disease;
PAAD	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-7.13	-0.5	3.84e-11	Neuroticism;
PAAD	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.78	9.31	0.6	1.37e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg08079166	chr15:68083412	MAP2K5	0.64	5.04	0.38	1.31e-6	Restless legs syndrome;
PAAD	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.71	7.29	0.51	1.55e-11	Schizophrenia;
PAAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.71	7.38	0.51	9.59e-12	Morning vs. evening chronotype;
PAAD	cis	rs1358748	0.522	rs6687611	chr1:67558169	T/C	cg02640540	chr1:67518911	SLC35D1	0.7	4.68	0.35	6.27e-6	Tuberculosis;
PAAD	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	6.76	0.48	2.81e-10	Mean platelet volume;
PAAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.95	10.48	0.65	1.12e-19	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7711186	0.786	rs4976798	chr5:178021280	A/G	cg07427642	chr5:177944298	COL23A1	0.68	4.41	0.34	1.93e-5	Urate levels in obese individuals;
PAAD	cis	rs11203032	0.901	rs7098394	chr10:90960906	T/A	cg16672925	chr10:90967113	CH25H	0.78	5.94	0.43	1.84e-8	Heart failure;
PAAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg23912435	chr1:150601613	ENSA	0.5	4.67	0.35	6.46e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6785206	0.554	rs7631994	chr3:128481450	T/G	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.74	-8.76	-0.58	3.55e-15	Blood pressure (smoking interaction);
PAAD	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.84	-8.26	-0.56	6.53e-14	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
PAAD	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg16745616	chr19:8428856	ANGPTL4	-0.54	-4.86	-0.37	2.94e-6	HDL cholesterol;
PAAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.66	-7.34	-0.51	1.22e-11	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.8	0.58	2.82e-15	Lung cancer;
PAAD	cis	rs9652601	0.748	rs8064154	chr16:11219419	A/G	cg04616529	chr16:11181986	CLEC16A	0.4	4.48	0.34	1.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	5.23	0.39	5.64e-7	Coffee consumption (cups per day);
PAAD	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.36	-4.37	-0.33	2.31e-5	Electrocardiographic conduction measures;
PAAD	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.69	-4.86	-0.37	2.84e-6	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.64	-6.7	-0.48	3.75e-10	Leprosy;
PAAD	cis	rs7172971	0.688	rs76779748	chr15:42386385	G/A	cg07013680	chr15:42186124	SPTBN5	0.56	4.26	0.33	3.62e-5	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-9.24	-0.6	2.02e-16	IgG glycosylation;
PAAD	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg08917208	chr2:24149416	ATAD2B	0.47	4.25	0.33	3.67e-5	Asthma;
PAAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg17105886	chr17:28927953	LRRC37B2	0.79	5.02	0.38	1.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs5756391	0.568	rs4821568	chr22:37316476	T/C	cg16356956	chr22:37317934	CSF2RB	0.39	4.77	0.36	4.28e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs863345	0.967	rs10908683	chr1:158522770	C/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.95	-0.37	1.99e-6	Pneumococcal bacteremia;
PAAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.61	-4.87	-0.37	2.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.46	4.92	0.37	2.23e-6	Age of smoking initiation;
PAAD	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.75	-5.98	-0.44	1.51e-8	Cancer;
PAAD	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12778183	chr17:56769387	TEX14;RAD51C	-0.51	-4.56	-0.35	1.06e-5	Testicular germ cell tumor;
PAAD	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-5.38	-0.4	2.73e-7	Height;
PAAD	cis	rs59888335	0.964	rs35766760	chr3:80799656	G/A	cg21735741	chr3:80819488	NA	0.56	4.87	0.37	2.81e-6	Schizophrenia;
PAAD	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.78	-7.59	-0.52	2.97e-12	Corneal astigmatism;
PAAD	cis	rs59104589	0.583	rs62186399	chr2:242225325	G/C	cg04488487	chr2:242709673	NA	0.57	4.31	0.33	2.9e-5	Fibrinogen levels;
PAAD	cis	rs686320	0.667	rs2904976	chr11:65185387	G/A	cg21890820	chr11:65308645	LTBP3	-0.78	-5.15	-0.39	8.07e-7	Hip circumference adjusted for BMI;
PAAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.83	-10.47	-0.65	1.17e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg24154853	chr7:158122151	PTPRN2	0.8	7.42	0.52	7.71e-12	Response to amphetamines;
PAAD	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg24687543	chr11:63912206	MACROD1	0.63	5.5	0.41	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg04359915	chr10:101825029	CPN1	-0.35	-5.27	-0.39	4.68e-7	Bone mineral density;
PAAD	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg11993925	chr19:44307056	LYPD5	0.51	7.02	0.49	7.04e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06047995	chr3:129035211	H1FX;C3orf47	0.59	6.49	0.47	1.13e-9	Vitiligo;Type 1 diabetes;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20299151	chr14:100758864	SLC25A29	-0.68	-6.49	-0.47	1.14e-9	Obesity-related traits;
PAAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg15017067	chr4:17643749	FAM184B	0.42	4.79	0.36	3.94e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.53	5.03	0.38	1.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs4604732	0.603	rs10925051	chr1:247641834	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.46	4.39	0.34	2.09e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	trans	rs11794666	0.872	rs56344871	chr9:31715492	C/T	cg05628366	chr6:35744188	C6orf126	1.18	7.5	0.52	4.84e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg14343924	chr8:8086146	FLJ10661	0.49	4.28	0.33	3.25e-5	Mood instability;
PAAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.47	-4.92	-0.37	2.25e-6	Eosinophil percentage of white cells;
PAAD	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.72	0.42	5.6e-8	Adiposity;
PAAD	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02985541	chr2:219472218	PLCD4	0.29	4.52	0.34	1.26e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2171564	0.727	rs6788567	chr3:112437047	A/C	cg06685282	chr3:112453648	NA	-0.41	-4.32	-0.33	2.77e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.36	4.89	0.37	2.52e-6	Migraine;
PAAD	cis	rs4742903	0.967	rs7023085	chr9:106904265	C/T	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.5	-4.41	-0.34	1.97e-5	Triglycerides;
PAAD	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	5.65	0.42	7.66e-8	Mood instability;
PAAD	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.67	7.99	0.54	3.04e-13	Metabolite levels;
PAAD	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.61	6.49	0.47	1.12e-9	Bladder cancer;
PAAD	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-5.69	-0.42	6.23e-8	Schizophrenia;
PAAD	cis	rs11825064	0.562	rs73596977	chr11:134512290	C/T	cg06603561	chr11:134479413	NA	-0.86	-5.36	-0.4	2.97e-7	Seasonality;
PAAD	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.82	4.45	0.34	1.65e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg02264943	chr11:130785842	SNX19	0.36	4.35	0.33	2.49e-5	Schizophrenia;
PAAD	cis	rs10464366	0.597	rs10951590	chr7:39091043	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.34	0.4	3.25e-7	IgG glycosylation;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15955341	chr1:110198890	GSTM4	0.66	7.42	0.52	7.6e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	9.31	0.6	1.37e-16	Parkinson's disease;
PAAD	cis	rs13177180	0.671	rs2052834	chr5:114952645	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-4.87	-0.37	2.8e-6	Conotruncal heart defects (inherited effects);
PAAD	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg12700464	chr11:78128424	GAB2	-0.61	-4.63	-0.35	7.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.68	7.27	0.51	1.72e-11	Mean platelet volume;
PAAD	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.97	12.63	0.72	1.88e-25	Bone mineral density;
PAAD	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.31	-0.33	2.91e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs12999616	0.571	rs35263587	chr2:98506906	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	5.71	0.42	5.63e-8	Colorectal cancer;
PAAD	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.51	-5.55	-0.41	1.22e-7	Vitamin D levels;
PAAD	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg10729496	chr3:10149963	C3orf24	0.85	6.69	0.48	3.92e-10	Alzheimer's disease;
PAAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg20406979	chr6:167373233	NA	-0.38	-5.2	-0.39	6.22e-7	Crohn's disease;
PAAD	cis	rs8049603	0.673	rs4073289	chr16:23196143	T/C	cg16484020	chr16:23217411	SCNN1G	-0.48	-4.26	-0.33	3.52e-5	Multiple sclerosis;
PAAD	cis	rs16882447	0.607	rs10052279	chr5:53491197	A/G	cg06461071	chr5:53490839	ARL15	0.45	4.78	0.36	4.14e-6	Systolic blood pressure (dietary potassium intake interaction);
PAAD	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.55	5.77	0.42	4.34e-8	Diastolic blood pressure;
PAAD	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg20525461	chr12:12867724	NA	-0.45	-4.38	-0.33	2.2e-5	Pulse pressure;
PAAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg02574844	chr11:5959923	NA	-0.69	-6.37	-0.46	2.14e-9	DNA methylation (variation);
PAAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-6.86	-0.49	1.63e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg05082376	chr22:42548792	NA	-0.49	-5.3	-0.39	4.02e-7	Cognitive function;
PAAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.57	-5.46	-0.4	1.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.75	-8.07	-0.55	1.93e-13	Aortic root size;
PAAD	cis	rs7577696	0.568	rs177082	chr2:32438350	A/T	cg02381751	chr2:32503542	YIPF4	0.51	4.91	0.37	2.37e-6	Inflammatory biomarkers;
PAAD	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg20636351	chr8:55087400	NA	-0.66	-6.58	-0.47	7.07e-10	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-6.9	-0.49	1.33e-10	Gut microbiome composition (summer);
PAAD	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg17077180	chr1:38461687	NA	0.57	6.97	0.49	8.97e-11	Coronary artery disease;
PAAD	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg04733989	chr22:42467013	NAGA	-0.68	-5.36	-0.4	3.07e-7	Schizophrenia;
PAAD	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.91	11.2	0.67	1.29e-21	Heart rate;
PAAD	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.23	20.64	0.86	6.17e-46	Testicular germ cell tumor;
PAAD	cis	rs2599510	0.783	rs2710626	chr2:32758754	G/C	cg02381751	chr2:32503542	YIPF4	0.51	5.24	0.39	5.37e-7	Interleukin-18 levels;
PAAD	cis	rs3809060	0.959	rs2234580	chr11:32457138	A/G	cg27259320	chr11:32460587	WIT1	0.35	4.5	0.34	1.33e-5	Inguinal hernia;
PAAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18867708	chr6:26865862	GUSBL1	0.44	4.4	0.34	2.06e-5	Schizophrenia;
PAAD	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-4.77	-0.36	4.25e-6	Longevity;
PAAD	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26926768	chr12:34528122	NA	0.38	4.55	0.35	1.11e-5	Morning vs. evening chronotype;
PAAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.48	4.99	0.37	1.66e-6	Major depressive disorder;
PAAD	cis	rs4332037	0.508	rs56758848	chr7:1868727	A/G	cg00035074	chr7:2701567	TTYH3	0.63	4.25	0.33	3.76e-5	Bipolar disorder;
PAAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg24585817	chr7:64895279	NA	0.46	4.62	0.35	7.99e-6	Aortic root size;
PAAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg17541715	chr7:1216824	NA	-0.52	-5.81	-0.43	3.56e-8	Longevity;Endometriosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27104869	chr10:75936335	ADK	0.57	6.51	0.47	1.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.62	5.22	0.39	5.66e-7	Gestational age at birth (maternal effect);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg22044401	chr12:113405926	OAS3	-0.68	-6.99	-0.49	8.08e-11	Obesity-related traits;
PAAD	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg01620082	chr3:125678407	NA	-1.06	-6.7	-0.48	3.81e-10	Breast cancer;
PAAD	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	1.01	8.32	0.56	4.8e-14	Vitiligo;
PAAD	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.76	8.21	0.55	8.61e-14	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-5.43	-0.4	2.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
PAAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.28	0.51	1.7e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.55	-5.17	-0.39	7.36e-7	Restless legs syndrome;
PAAD	cis	rs72960926	1.000	rs11751225	chr6:75138754	T/C	cg03266952	chr6:74778945	NA	-1.28	-6.75	-0.48	2.97e-10	Metabolite levels (MHPG);
PAAD	trans	rs901683	1.000	rs71494800	chr10:46002954	C/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.51	5.24	0.39	5.32e-7	Corneal astigmatism;
PAAD	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.45	6.34	0.46	2.49e-9	Schizophrenia;
PAAD	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.65	6.02	0.44	1.26e-8	Red blood cell count;
PAAD	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.83	-9.61	-0.61	2.26e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.4	-0.4	2.5e-7	HDL cholesterol;
PAAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.3	-0.33	3.09e-5	Aortic root size;
PAAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.53	-6.05	-0.44	1.06e-8	Cardiovascular disease risk factors;
PAAD	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-21.52	-0.87	5.29e-48	Myeloid white cell count;
PAAD	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-1.01	-6.97	-0.49	8.83e-11	Coronary artery disease;
PAAD	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.92	10.92	0.66	7.42e-21	Ulcerative colitis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg24868054	chr1:231557466	EGLN1	-0.75	-6.51	-0.47	1.02e-9	Neuroticism;
PAAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22947322	chr17:47091978	IGF2BP1	0.37	4.33	0.33	2.69e-5	Type 2 diabetes;
PAAD	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.51	4.77	0.36	4.23e-6	Endometrial cancer;
PAAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.62	8.51	0.57	1.59e-14	Renal cell carcinoma;
PAAD	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg27449745	chr7:23145252	KLHL7	-0.52	-4.61	-0.35	8.63e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg00738919	chr7:1100172	C7orf50	0.68	4.83	0.36	3.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg10591111	chr5:226296	SDHA	-0.94	-4.36	-0.33	2.4e-5	Breast cancer;
PAAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.8	-8.81	-0.58	2.73e-15	Prostate cancer;
PAAD	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg10616300	chr11:66138557	SLC29A2	0.34	4.66	0.35	6.92e-6	Educational attainment (years of education);
PAAD	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg01796438	chr3:11312864	ATG7	-0.63	-4.79	-0.36	3.87e-6	Circulating chemerin levels;
PAAD	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.81	-9.78	-0.62	8.08e-18	Height;
PAAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg17380795	chr3:122379686	NA	0.54	5.78	0.42	4.07e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.56	-0.41	1.18e-7	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.86	-8.55	-0.57	1.22e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg09659197	chr4:152720779	NA	0.32	4.61	0.35	8.47e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.51	5.51	0.41	1.51e-7	Bladder cancer;
PAAD	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	4.44	0.34	1.73e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10240725	chr12:97300803	NEDD1	0.65	7.29	0.51	1.57e-11	Monocyte percentage of white cells;
PAAD	cis	rs12760731	0.720	rs12072124	chr1:178366990	G/A	cg00404053	chr1:178313656	RASAL2	0.74	5.61	0.41	9.41e-8	Obesity-related traits;
PAAD	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.73	-5.71	-0.42	5.85e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg26897989	chr16:1907736	C16orf73	0.44	4.63	0.35	7.88e-6	Glomerular filtration rate in chronic kidney disease;
PAAD	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg14345882	chr6:26364793	BTN3A2	0.64	4.26	0.33	3.63e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.59	6.32	0.46	2.8e-9	Testicular germ cell tumor;
PAAD	cis	rs939584	1.000	rs10190052	chr2:646674	T/C	cg14515364	chr2:636606	NA	0.46	4.34	0.33	2.57e-5	Body mass index;
PAAD	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.9	11.19	0.67	1.41e-21	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg12198729	chr10:103113705	BTRC	0.56	6.36	0.46	2.26e-9	Monocyte percentage of white cells;
PAAD	cis	rs3996993	0.809	rs4144185	chr6:52702948	A/G	cg20803780	chr6:52668592	GSTA1	-0.36	-4.64	-0.35	7.41e-6	Hemoglobin concentration;
PAAD	cis	rs4343996	0.747	rs13237637	chr7:3503207	G/C	cg21248987	chr7:3385318	SDK1	0.49	5.29	0.39	4.11e-7	Motion sickness;
PAAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04156016	chr5:1868137	NA	0.46	4.69	0.36	6.16e-6	Cardiovascular disease risk factors;
PAAD	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.72	-8.23	-0.56	7.86e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.89	8.57	0.57	1.12e-14	Homoarginine levels;
PAAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg00450029	chr8:599525	NA	0.8	5.2	0.39	6.36e-7	IgG glycosylation;
PAAD	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-4.56	-0.35	1.05e-5	Systemic lupus erythematosus;
PAAD	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg21775007	chr8:11205619	TDH	-0.71	-7.03	-0.5	6.7e-11	Retinal vascular caliber;
PAAD	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.53	-6.34	-0.46	2.54e-9	Alcohol dependence;
PAAD	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.4	2.37e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.48	-5.04	-0.38	1.33e-6	Calcium levels;
PAAD	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg26695010	chr11:65641043	EFEMP2	0.55	5.16	0.39	7.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.54	0.47	9e-10	Multiple sclerosis;
PAAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	6.73	0.48	3.3e-10	Neuroticism;
PAAD	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg01267373	chr18:77410094	NA	0.42	4.59	0.35	9.13e-6	Monocyte count;
PAAD	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	1.0	13.85	0.75	9.72e-29	Rheumatoid arthritis;
PAAD	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.86	7.44	0.52	7e-12	Vitiligo;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03403113	chr17:7388450	ZBTB4;POLR2A	-0.79	-7.36	-0.51	1.1e-11	Neuroticism;
PAAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg26939375	chr7:64535504	NA	-0.71	-8.17	-0.55	1.08e-13	Calcium levels;
PAAD	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg16434002	chr17:42200994	HDAC5	0.6	5.74	0.42	4.93e-8	Total body bone mineral density;
PAAD	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg17105886	chr17:28927953	LRRC37B2	0.78	4.79	0.36	3.85e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg04450456	chr4:17643702	FAM184B	0.46	4.88	0.37	2.63e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.59	-5.92	-0.43	2.03e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg20917491	chr3:195578259	NA	0.52	5.56	0.41	1.18e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg14705208	chr19:41867418	B9D2	0.56	6.34	0.46	2.48e-9	Initial pursuit acceleration in psychotic disorders;
PAAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21028142	chr17:79581711	NPLOC4	-0.5	-5.8	-0.43	3.7e-8	Eye color traits;
PAAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.69	-0.42	6.28e-8	Personality dimensions;
PAAD	cis	rs10140922	1.000	rs4982267	chr14:35828489	T/C	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.46	-0.34	1.61e-5	Hip circumference adjusted for BMI;
PAAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg17372223	chr3:52568218	NT5DC2	0.54	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs4523957	0.855	rs143499	chr17:2132324	T/C	cg16513277	chr17:2031491	SMG6	0.49	4.93	0.37	2.09e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg10932868	chr11:921992	NA	-0.44	-4.63	-0.35	7.63e-6	Alzheimer's disease (late onset);
PAAD	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	1.16	7.25	0.51	1.99e-11	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.76	-0.36	4.51e-6	Eosinophil percentage of white cells;
PAAD	cis	rs35123781	0.502	rs355157	chr5:138993415	T/C	cg11459648	chr5:138714337	SLC23A1	-0.62	-5.81	-0.43	3.54e-8	Schizophrenia;
PAAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.9	11.6	0.69	1.1e-22	Menarche (age at onset);
PAAD	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.94	-8.14	-0.55	1.29e-13	Vitiligo;
PAAD	cis	rs300774	0.858	rs300712	chr2:138903	A/T	cg21211680	chr2:198530	NA	-0.65	-6.0	-0.44	1.41e-8	Suicide attempts in bipolar disorder;
PAAD	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.49	4.92	0.37	2.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	8.29	0.56	5.54e-14	Prudent dietary pattern;
PAAD	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.78	7.22	0.51	2.34e-11	Asthma;
PAAD	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.72	8.46	0.57	2.11e-14	Morning vs. evening chronotype;
PAAD	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg27511599	chr7:32358540	NA	0.75	4.39	0.34	2.12e-5	Body mass index;
PAAD	cis	rs12625057	0.618	rs1369236	chr20:57779762	A/G	cg17286326	chr20:57796491	ZNF831	0.72	4.43	0.34	1.81e-5	Response to antipsychotic therapy (extrapyramidal side effects);
PAAD	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.84	10.33	0.64	2.8e-19	Bladder cancer;
PAAD	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.59	-5.76	-0.42	4.53e-8	Red cell distribution width;
PAAD	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg17366294	chr4:99064904	C4orf37	0.45	4.96	0.37	1.88e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.47	7.01	0.49	7.33e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
PAAD	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.93	-10.13	-0.63	9.43e-19	Parkinson's disease;
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.9	6.17	0.45	5.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs559928	0.692	rs915987	chr11:64027888	G/A	cg22916017	chr11:64110731	CCDC88B	0.48	4.58	0.35	9.74e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	6.31	0.46	2.89e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs1997066	0.831	rs73342203	chr10:106816075	A/G	cg17321814	chr10:106440892	SORCS3	0.65	4.52	0.34	1.24e-5	Diabetic kidney disease;
PAAD	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg17633681	chr16:88106987	BANP	0.52	5.87	0.43	2.64e-8	Menopause (age at onset);
PAAD	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg20913747	chr6:44695427	NA	-0.67	-6.6	-0.47	6.5e-10	Total body bone mineral density;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg11646757	chr7:128095699	C7orf68	0.59	6.87	0.49	1.51e-10	Metabolite levels  (X-11787);
PAAD	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-5.58	-0.41	1.06e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.66	4.8	0.36	3.8e-6	Neuroticism;
PAAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.71	-7.39	-0.51	9.21e-12	DNA methylation (variation);
PAAD	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.55	5.84	0.43	3.08e-8	Response to anti-TNF therapy in rheumatoid arthritis;
PAAD	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.6	5.91	0.43	2.15e-8	Coronary artery disease;
PAAD	cis	rs3018712	0.553	rs948854	chr11:68450203	C/T	cg23009355	chr11:68451396	GAL	-0.52	-5.74	-0.42	5.07e-8	Total body bone mineral density;
PAAD	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.76	5.82	0.43	3.39e-8	Weight;
PAAD	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg08562672	chr19:21860753	NA	0.45	4.68	0.36	6.24e-6	Pain;
PAAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.88	-7.26	-0.51	1.9e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.27	-0.39	4.69e-7	Blood pressure;
PAAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.75	8.15	0.55	1.24e-13	Schizophrenia;
PAAD	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.61	6.73	0.48	3.27e-10	Tonsillectomy;
PAAD	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg00857998	chr1:205179979	DSTYK	0.47	4.25	0.33	3.68e-5	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.51	6.86	0.49	1.62e-10	Life satisfaction;
PAAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg12757816	chr2:10669957	NA	-0.55	-5.87	-0.43	2.68e-8	Prostate cancer;
PAAD	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	7.42	0.52	7.55e-12	Monocyte percentage of white cells;
PAAD	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.46	-6.57	-0.47	7.45e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.57	-5.64	-0.42	8.18e-8	Reticulocyte count;
PAAD	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.43	-4.89	-0.37	2.53e-6	Response to simvastatin treatment (PCSK9 protein level change);
PAAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.88	8.04	0.55	2.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.47	-5.32	-0.4	3.72e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18621852	chr3:10150065	C3orf24	0.59	5.25	0.39	5.02e-7	Alzheimer's disease;
PAAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg06740227	chr12:86229804	RASSF9	0.53	4.84	0.37	3.16e-6	Major depressive disorder;
PAAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.89	10.98	0.66	5.27e-21	Aortic root size;
PAAD	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.91	9.64	0.62	1.87e-17	Cognitive function;
PAAD	cis	rs1190596	0.525	rs7152627	chr14:102698399	C/T	cg23289024	chr14:102554846	HSP90AA1	-0.39	-4.42	-0.34	1.83e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.49	-0.61	4.62e-17	White blood cell count (basophil);
PAAD	cis	rs17169635	0.819	rs3800714	chr7:134500954	T/C	cg02516134	chr7:134575187	CALD1	-0.43	-4.47	-0.34	1.5e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.65	6.37	0.46	2.1e-9	Blood metabolite levels;
PAAD	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg01304814	chr3:48885189	PRKAR2A	0.89	4.8	0.36	3.8e-6	Cognitive function;
PAAD	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	1.06	10.75	0.66	2.14e-20	Post bronchodilator FEV1;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg03316107	chr7:5085477	RBAK	0.61	7.04	0.5	6.12e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.7	6.01	0.44	1.32e-8	Platelet count;
PAAD	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.74	-7.57	-0.52	3.32e-12	Dementia and core Alzheimer's disease neuropathologic changes;
PAAD	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg03959625	chr15:84868606	LOC388152	0.5	5.46	0.4	1.91e-7	Schizophrenia;
PAAD	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7487075	0.619	rs12298616	chr12:46842172	A/G	cg14671384	chr12:47219920	SLC38A4	0.44	4.41	0.34	1.92e-5	Itch intensity from mosquito bite;
PAAD	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.7	8.5	0.57	1.6e-14	Dupuytren's disease;
PAAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg03303774	chr4:1407052	NA	0.35	4.26	0.33	3.56e-5	Obesity-related traits;
PAAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg03517284	chr6:25882590	NA	-0.56	-4.67	-0.35	6.69e-6	Iron status biomarkers;
PAAD	cis	rs6494488	0.500	rs66586340	chr15:64983249	A/G	cg16425858	chr15:64791681	ZNF609	0.89	4.55	0.35	1.07e-5	Coronary artery disease;
PAAD	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.8	0.48	2.19e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.8	10.08	0.63	1.26e-18	Bone mineral density;
PAAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.77	9.68	0.62	1.48e-17	Bone mineral density;
PAAD	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.48	-4.78	-0.36	4.09e-6	Menarche (age at onset);
PAAD	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg14343924	chr8:8086146	FLJ10661	-0.51	-4.72	-0.36	5.32e-6	Myopia;Myopia (pathological);
PAAD	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.47	-0.41	1.84e-7	Blood metabolite levels;
PAAD	cis	rs73206853	0.620	rs28720928	chr12:111126609	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	4.79	0.36	3.97e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.54	5.03	0.38	1.35e-6	Airway imaging phenotypes;
PAAD	cis	rs3106136	0.807	rs7657805	chr4:95273659	C/T	cg11021082	chr4:95130006	SMARCAD1	0.59	5.59	0.41	1.03e-7	Capecitabine sensitivity;
PAAD	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg27449745	chr7:23145252	KLHL7	-0.49	-4.3	-0.33	3.01e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.86	6.59	0.47	6.98e-10	Alzheimer's disease;
PAAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.82	8.12	0.55	1.48e-13	Vitiligo;
PAAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.67	-6.46	-0.46	1.35e-9	Blood metabolite levels;
PAAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	9.17	0.6	3.15e-16	Bone mineral density;
PAAD	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.76	-7.63	-0.53	2.41e-12	Gout;
PAAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.25	-0.45	3.87e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.66	6.65	0.47	5.07e-10	Platelet count;
PAAD	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.45	4.85	0.37	3e-6	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs988913	1.000	rs7753255	chr6:54832973	C/T	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.51	0.65	9.45e-20	Total body bone mineral density;
PAAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.61	7.22	0.51	2.29e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg14709524	chr16:89940631	TCF25	0.87	4.54	0.35	1.14e-5	Skin colour saturation;
PAAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.7	-7.43	-0.52	7.32e-12	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs7591163	1.000	rs1721359	chr2:228751874	C/T	cg22994281	chr2:228029448	COL4A3;COL4A4	0.44	4.42	0.34	1.84e-5	Blood pressure;
PAAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.13	0.6	3.89e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.65	6.31	0.46	2.96e-9	IgG glycosylation;
PAAD	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs6700896	0.897	rs7518710	chr1:66168238	G/A	cg04111102	chr1:66153794	NA	-0.41	-4.67	-0.35	6.49e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg19418318	chr19:17219073	MYO9B	-0.37	-4.89	-0.37	2.49e-6	Reticulocyte fraction of red cells;
PAAD	trans	rs12738007	0.967	rs12032470	chr1:29464954	C/A	cg05667379	chr2:115920764	DPP10	0.38	6.34	0.46	2.52e-9	Schizophrenia;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.45	-0.34	1.65e-5	Longevity;Endometriosis;
PAAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.85	-8.08	-0.55	1.86e-13	Pancreatic cancer;
PAAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg13722127	chr7:150037890	RARRES2	0.63	6.51	0.47	1.02e-9	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs2124910	0.779	rs2168637	chr19:52037929	T/C	cg12008991	chr19:52034861	SIGLEC6	0.33	4.33	0.33	2.71e-5	Blood protein levels;
PAAD	cis	rs17155006	0.676	rs424866	chr7:107722869	T/C	cg05962710	chr7:107745446	LAMB4	-0.38	-4.54	-0.35	1.12e-5	Pneumococcal bacteremia;
PAAD	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.5	4.51	0.34	1.31e-5	Anterior chamber depth;
PAAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02228675	chr17:40259724	DHX58	-0.45	-5.4	-0.4	2.47e-7	Fibrinogen levels;
PAAD	cis	rs7156960	1.000	rs12590520	chr14:76715934	C/T	cg13981132	chr14:76734493	NA	0.48	4.77	0.36	4.21e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs12136530	0.593	rs12121189	chr1:19740421	G/A	cg03321592	chr1:19991676	HTR6	0.55	4.98	0.37	1.72e-6	Lead levels in blood;
PAAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg20295408	chr7:1910781	MAD1L1	-0.56	-5.23	-0.39	5.51e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg16590910	chr6:42928470	GNMT	0.5	5.09	0.38	1.06e-6	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.82	-9.94	-0.63	3.03e-18	Coronary artery disease;
PAAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs1997066	0.831	rs73340209	chr10:106801050	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.5	0.34	1.36e-5	Diabetic kidney disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13475271	chr9:6680923	NA	-0.65	-6.58	-0.47	7.25e-10	Smoking initiation;
PAAD	cis	rs28493229	0.582	rs78915350	chr19:41160609	A/G	cg21869046	chr19:41225005	ITPKC	0.51	5.17	0.39	7.26e-7	Kawasaki disease;
PAAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	1.25	12.98	0.73	2.11e-26	Eosinophil percentage of granulocytes;
PAAD	cis	rs11828289	0.660	rs79045664	chr11:23238737	G/A	cg20040320	chr11:23191996	NA	-0.72	-4.98	-0.37	1.73e-6	Cancer;
PAAD	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.82	8.7	0.58	5.16e-15	Corneal astigmatism;
PAAD	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.75	7.66	0.53	2e-12	Retinal vascular caliber;
PAAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.8	7.82	0.54	8.35e-13	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.58	-6.52	-0.47	9.87e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs2040771	0.745	rs361991	chr22:19263892	T/C	cg02655711	chr22:19163373	SLC25A1	0.58	6.67	0.48	4.35e-10	Metabolite levels (small molecules and protein measures);
PAAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26690034	chr1:75198963	CRYZ;TYW3	0.57	5.49	0.41	1.68e-7	Resistin levels;
PAAD	cis	rs427941	1.000	rs448665	chr7:101873515	G/A	cg06721601	chr7:101762633	CUX1	-0.44	-4.49	-0.34	1.38e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
PAAD	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-5.95	-0.43	1.79e-8	Schizophrenia;
PAAD	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.49	4.97	0.37	1.8e-6	Mean corpuscular hemoglobin;Red cell distribution width;
PAAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.8	6.2	0.45	5.18e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg04803944	chr8:27450844	NA	-0.41	-4.27	-0.33	3.41e-5	Bipolar disorder lithium response (categorical) or schizophrenia;
PAAD	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg23920097	chr1:209922102	NA	0.45	4.37	0.33	2.25e-5	Red blood cell count;
PAAD	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.99	-15.48	-0.78	4.61e-33	Height;
PAAD	cis	rs2916733	0.887	rs2440401	chr8:6321100	T/C	cg01691696	chr8:6734962	DEFB1	-0.54	-4.25	-0.33	3.65e-5	Epirubicin-induced leukopenia;
PAAD	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.98	8.22	0.55	8.53e-14	Neutrophil percentage of white cells;
PAAD	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg23024343	chr7:107201750	COG5	0.52	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	1.02	12.85	0.72	4.61e-26	Breast cancer;
PAAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.98	-14.07	-0.75	2.49e-29	Coronary artery disease;
PAAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	1.13	12.1	0.7	4.85e-24	Eosinophil percentage of granulocytes;
PAAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.69	8.77	0.58	3.4e-15	Menopause (age at onset);
PAAD	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.97	8.24	0.56	7.61e-14	Alzheimer's disease;
PAAD	cis	rs5756391	0.546	rs5756405	chr22:37310954	A/G	cg16356956	chr22:37317934	CSF2RB	0.37	4.52	0.34	1.25e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.7	7.58	0.52	3.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7567389	0.719	rs4150476	chr2:128032822	A/T	cg11380483	chr2:127933992	NA	-0.47	-4.67	-0.35	6.58e-6	Self-rated health;
PAAD	cis	rs3736485	0.966	rs10220909	chr15:51762412	C/A	cg08986416	chr15:51914746	DMXL2	-0.44	-4.25	-0.33	3.65e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11853189	1.000	rs78994386	chr15:78570725	G/A	cg22935921	chr15:78556834	DNAJA4	0.75	5.22	0.39	5.75e-7	Red cell distribution width;
PAAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	1.09	6.05	0.44	1.09e-8	Body mass index;
PAAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.27	-4.85	-0.37	2.98e-6	IgG glycosylation;
PAAD	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg00717180	chr2:96193071	NA	-0.57	-6.37	-0.46	2.15e-9	HDL cholesterol;
PAAD	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-4.55	-0.35	1.09e-5	Subjective well-being;
PAAD	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg03959625	chr15:84868606	LOC388152	0.49	5.3	0.4	3.92e-7	Schizophrenia;
PAAD	cis	rs12935418	0.552	rs2911148	chr16:81021894	A/G	cg16651780	chr16:81037892	C16orf61	-0.65	-6.01	-0.44	1.34e-8	Mean corpuscular volume;
PAAD	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.46	4.53	0.35	1.17e-5	Mean platelet volume;
PAAD	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.93	-12.69	-0.72	1.3e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg24253500	chr15:84953950	NA	0.53	6.15	0.45	6.53e-9	Schizophrenia;
PAAD	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27481594	chr15:43623282	ADAL;LCMT2	0.65	4.44	0.34	1.7e-5	Lung cancer in ever smokers;
PAAD	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.05	-0.38	1.23e-6	Reticulocyte count;High light scatter reticulocyte count;
PAAD	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.64	4.69	0.36	5.91e-6	Optic nerve measurement (cup area);
PAAD	cis	rs9549328	0.837	rs7988967	chr13:113651160	A/G	cg25790453	chr13:113633590	MCF2L	-0.39	-4.52	-0.34	1.26e-5	Systolic blood pressure;
PAAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.39	4.66	0.35	6.99e-6	Tonsillectomy;
PAAD	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.8	-5.25	-0.39	4.98e-7	Anti-saccade response;
PAAD	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs62264129	0.500	rs62278770	chr3:112029121	T/C	cg01411366	chr3:112012867	SLC9A10	-0.31	-5.0	-0.38	1.59e-6	Sum eosinophil basophil counts;Eosinophil counts;
PAAD	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.93	0.37	2.13e-6	IgG glycosylation;
PAAD	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.56	5.71	0.42	5.71e-8	Testicular germ cell tumor;
PAAD	cis	rs10875746	0.551	rs1471998	chr12:48712002	C/T	cg26205652	chr12:48591994	NA	0.76	7.03	0.5	6.6e-11	Longevity (90 years and older);
PAAD	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg06599209	chr2:1746509	PXDN	0.25	4.27	0.33	3.47e-5	Response to antipsychotic treatment;
PAAD	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.63	-5.68	-0.42	6.56e-8	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg17524180	chr13:113633600	MCF2L	-0.44	-4.78	-0.36	4.06e-6	Systolic blood pressure;
PAAD	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg11204139	chr17:3907470	NA	0.68	6.8	0.48	2.24e-10	Type 2 diabetes;
PAAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.95	-11.37	-0.68	4.69e-22	Height;
PAAD	cis	rs8105895	0.778	rs10401922	chr19:22253252	T/A	cg20662725	chr19:22235022	ZNF257	-0.54	-4.29	-0.33	3.19e-5	Body mass index (change over time);
PAAD	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs72960926	1.000	rs72956936	chr6:75092837	G/A	cg03266952	chr6:74778945	NA	-0.98	-5.32	-0.4	3.69e-7	Metabolite levels (MHPG);
PAAD	cis	rs12531458	0.967	rs11773650	chr7:39111866	G/A	cg02616653	chr7:39773034	LOC349114	-0.49	-4.3	-0.33	3.06e-5	Educational attainment (years of education);
PAAD	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24110177	chr3:50126178	RBM5	0.61	6.87	0.49	1.58e-10	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	1.000	rs35585999	chr10:46070159	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.75	0.48	2.99e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.23	0.39	5.45e-7	Colorectal cancer;
PAAD	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	5.28	0.39	4.44e-7	Response to fenofibrate (adiponectin levels);
PAAD	cis	rs17083533	1.000	rs80279563	chr6:121683818	G/A	cg13516479	chr6:122016629	NA	-0.82	-4.48	-0.34	1.44e-5	Heart rate;
PAAD	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg14393609	chr7:65229607	NA	0.5	4.35	0.33	2.49e-5	Aortic root size;
PAAD	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.55	5.86	0.43	2.78e-8	Height;
PAAD	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.88	5.83	0.43	3.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg15212455	chr7:39170539	POU6F2	0.33	4.55	0.35	1.07e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.93	8.43	0.56	2.49e-14	Cognitive function;
PAAD	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.68	-7.76	-0.53	1.12e-12	White blood cell count (basophil);
PAAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.68	-7.11	-0.5	4.35e-11	DNA methylation (variation);
PAAD	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	5.31	0.4	3.89e-7	Colorectal cancer;
PAAD	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.51	5.07	0.38	1.13e-6	Common traits (Other);
PAAD	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.47	6.88	0.49	1.48e-10	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg12935359	chr14:103987150	CKB	-0.52	-5.45	-0.4	1.99e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg04450456	chr4:17643702	FAM184B	0.48	4.92	0.37	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg04482110	chr17:41364121	TMEM106A	0.38	4.37	0.33	2.29e-5	Menopause (age at onset);
PAAD	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-4.33	-0.33	2.68e-5	Educational attainment;
PAAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.68	0.65	3.29e-20	Prudent dietary pattern;
PAAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg11764359	chr7:65958608	NA	0.78	5.23	0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs17158483	0.543	rs34511420	chr7:30010498	C/T	cg24448259	chr7:29186110	CPVL	0.86	4.26	0.33	3.53e-5	Obesity-related traits;
PAAD	cis	rs721399	0.539	rs10103029	chr8:18267338	A/G	cg18736775	chr8:18248649	NAT2	-0.6	-4.54	-0.35	1.13e-5	Blood metabolite levels;
PAAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.88	8.34	0.56	4.12e-14	Methadone dose in opioid dependence;
PAAD	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-1.07	-7.26	-0.51	1.9e-11	Post bronchodilator FEV1;
PAAD	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg00750074	chr16:89608354	SPG7	-0.55	-5.19	-0.39	6.78e-7	Multiple myeloma (IgH translocation);
PAAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.8	-8.9	-0.59	1.55e-15	Iron status biomarkers;
PAAD	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg06131755	chr6:160182447	ACAT2	0.51	4.48	0.34	1.48e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.84	-9.63	-0.62	2.03e-17	Extrinsic epigenetic age acceleration;
PAAD	cis	rs73416724	0.614	rs78882866	chr6:43263473	T/G	cg17502394	chr6:43251710	TTBK1	0.7	4.37	0.33	2.31e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Educational attainment;
PAAD	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.17	10.58	0.65	5.92e-20	Mitochondrial DNA levels;
PAAD	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.44	-4.63	-0.35	7.74e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg20965017	chr5:231967	SDHA	-0.63	-4.37	-0.33	2.3e-5	Breast cancer;
PAAD	cis	rs6076065	0.541	rs8118688	chr20:23320850	G/A	cg11657817	chr20:23433608	CST11	0.51	5.1	0.38	9.81e-7	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg15440763	chr7:158190612	PTPRN2	0.49	4.91	0.37	2.37e-6	Obesity-related traits;
PAAD	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-4.73	-0.36	5.1e-6	Reticulocyte count;
PAAD	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg27426351	chr10:43362370	NA	0.66	5.13	0.38	8.7e-7	Blood protein levels;
PAAD	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.78	7.27	0.51	1.76e-11	Corneal astigmatism;
PAAD	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.42	-4.25	-0.33	3.78e-5	Adiposity;
PAAD	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg26685658	chr5:74633012	HMGCR	-0.52	-4.31	-0.33	2.96e-5	Age-related disease endophenotypes;
PAAD	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-4.68	-0.35	6.29e-6	Mean corpuscular volume;
PAAD	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg25382128	chr12:54346509	NA	-0.45	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs375066	0.935	rs398099	chr19:44405281	G/C	cg08633290	chr19:44405433	NA	-0.57	-5.74	-0.42	4.86e-8	Breast cancer;
PAAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.0	-0.44	1.4e-8	Prostate cancer;
PAAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.96	11.72	0.69	5.3e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
PAAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-5.86	-0.43	2.75e-8	Prostate cancer;
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.8	-7.76	-0.53	1.14e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-1.02	-11.04	-0.67	3.5e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	4.49	0.34	1.41e-5	Breast cancer;
PAAD	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.65	-0.35	7.22e-6	Pulmonary function;
PAAD	cis	rs2300603	0.881	rs7359141	chr14:76017044	C/T	cg01624173	chr14:75981868	NA	0.53	5.41	0.4	2.41e-7	Multiple sclerosis;
PAAD	cis	rs7688540	0.511	rs10003260	chr4:184842	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.56	4.65	0.35	7.16e-6	Facial morphology (factor 6, height of vermillion lower lip);
PAAD	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg14500798	chr7:98100126	NA	0.42	4.34	0.33	2.55e-5	Breast cancer;
PAAD	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg07395648	chr5:131743802	NA	-0.78	-8.17	-0.55	1.1e-13	Blood metabolite levels;
PAAD	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.97	10.49	0.65	1.05e-19	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06873352	chr17:61820015	STRADA	-0.7	-7.93	-0.54	4.31e-13	Prudent dietary pattern;
PAAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg14500267	chr11:67383377	NA	0.47	4.69	0.36	5.98e-6	Mean corpuscular volume;
PAAD	cis	rs2950393	0.804	rs1466382	chr12:57116834	A/G	cg02954252	chr12:57119365	NACA	-0.49	-4.68	-0.35	6.31e-6	Platelet distribution width;
PAAD	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg20913747	chr6:44695427	NA	-0.66	-6.49	-0.47	1.12e-9	Total body bone mineral density;
PAAD	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.9	-0.54	5.28e-13	Alcohol dependence;
PAAD	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-10.32	-0.64	2.88e-19	Dental caries;
PAAD	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.54	4.93	0.37	2.11e-6	Testicular germ cell tumor;
PAAD	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.56	4.94	0.37	2.03e-6	Dilated cardiomyopathy;
PAAD	cis	rs3136739	0.614	rs34361836	chr8:42026968	A/T	cg12054981	chr8:42037387	PLAT	0.75	5.5	0.41	1.58e-7	Plasma plasminogen activator levels;
PAAD	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg06917634	chr15:78832804	PSMA4	-0.46	-4.54	-0.35	1.12e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg04287289	chr16:89883240	FANCA	-0.64	-7.12	-0.5	3.96e-11	Vitiligo;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09107180	chr10:92950766	NA	0.66	6.34	0.46	2.45e-9	Neuroticism;
PAAD	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.88	0.43	2.52e-8	Migraine;Coronary artery disease;
PAAD	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.43	-4.84	-0.37	3.2e-6	Blood pressure (smoking interaction);
PAAD	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg09659197	chr4:152720779	NA	0.46	6.11	0.44	8.11e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.35	0.33	2.52e-5	Language performance in older adults (adjusted for episodic memory);
PAAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.86	5.57	0.41	1.15e-7	Diabetic kidney disease;
PAAD	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.56	5.37	0.4	2.96e-7	Cancer;
PAAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00982548	chr2:198649783	BOLL	-0.8	-5.79	-0.43	3.82e-8	Ulcerative colitis;
PAAD	cis	rs11264799	0.520	rs1885561	chr1:157548669	T/A	cg18268488	chr1:157545234	FCRL4	0.57	6.46	0.46	1.32e-9	IgA nephropathy;
PAAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00049323	chr5:472564	LOC25845	0.42	4.97	0.37	1.76e-6	Cystic fibrosis severity;
PAAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27436995	chr16:743998	FBXL16	-0.37	-4.48	-0.34	1.45e-5	Height;
PAAD	cis	rs1997066	0.831	rs74401843	chr10:106820108	T/A	cg17321814	chr10:106440892	SORCS3	0.65	4.46	0.34	1.57e-5	Diabetic kidney disease;
PAAD	cis	rs11235843	0.929	rs4944033	chr11:73448646	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.48	5.04	0.38	1.33e-6	QRS complex (12-leadsum);
PAAD	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.57	5.99	0.44	1.48e-8	Testicular germ cell tumor;
PAAD	cis	rs593531	0.614	rs655719	chr11:74042241	A/G	cg15851278	chr11:73669449	DNAJB13	-0.42	-4.96	-0.37	1.87e-6	Neuroticism;
PAAD	cis	rs2030114	0.948	rs66794738	chr16:51604648	C/T	cg03758633	chr16:51611768	NA	0.6	4.94	0.37	2.07e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.26	11.84	0.69	2.48e-23	Corneal structure;
PAAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg19413350	chr8:57351067	NA	-0.56	-5.84	-0.43	3.1e-8	Obesity-related traits;
PAAD	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	4.54	0.35	1.15e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	0.98	6.48	0.47	1.22e-9	IgG glycosylation;
PAAD	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg10856724	chr12:34555212	NA	-0.42	-4.44	-0.34	1.69e-5	Morning vs. evening chronotype;
PAAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg14346243	chr4:90757452	SNCA	-0.51	-4.48	-0.34	1.49e-5	Neuroticism;
PAAD	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.35	0.4	3.22e-7	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs943466	1.000	rs11753083	chr6:33761111	C/G	cg04704449	chr6:33738291	NA	-0.47	-4.81	-0.36	3.58e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.6	0.41	9.93e-8	Tonsillectomy;
PAAD	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg12623918	chr2:306882	NA	0.47	4.94	0.37	2.04e-6	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-8.19	-0.55	9.66e-14	Morning vs. evening chronotype;
PAAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-4.79	-0.36	3.88e-6	Blood metabolite levels;
PAAD	cis	rs3112530	1.000	rs159973	chr5:152732841	A/C	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.83	4.37	0.33	2.26e-5	Aging (time to event);
PAAD	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.68	7.73	0.53	1.33e-12	Motion sickness;
PAAD	cis	rs58521262	0.556	rs158577	chr19:23201663	T/G	cg02350677	chr19:23254381	NA	0.25	4.38	0.33	2.2e-5	Testicular germ cell tumor;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14407177	chr2:38298023	CYP1B1	-0.63	-6.43	-0.46	1.6e-9	Obesity-related traits;
PAAD	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.79	8.59	0.57	9.96e-15	Colorectal cancer;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.91	11.98	0.7	1.04e-23	Prudent dietary pattern;
PAAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.54	6.74	0.48	3.03e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs282587	0.569	rs385656	chr13:113413234	C/T	cg02820901	chr13:113351484	ATP11A	-0.65	-5.15	-0.39	8.12e-7	Glycated hemoglobin levels;
PAAD	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-6.21	-0.45	4.89e-9	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.61	6.77	0.48	2.59e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	5.32	0.4	3.63e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg22532475	chr10:104410764	TRIM8	-0.39	-4.52	-0.34	1.23e-5	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs5746492	0.539	rs61377180	chr22:18357549	C/T	cg06148736	chr22:18985691	NA	-0.38	-4.41	-0.34	1.94e-5	Eotaxin levels;
PAAD	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg20582800	chr6:43612764	RSPH9	-0.51	-4.27	-0.33	3.44e-5	Blood protein levels;
PAAD	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.78	5.77	0.42	4.26e-8	Vitiligo;
PAAD	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.62	10.46	0.65	1.29e-19	IgG glycosylation;
PAAD	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg14393609	chr7:65229607	NA	0.63	6.83	0.48	1.93e-10	Aortic root size;
PAAD	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg09914555	chr8:142094789	NA	-0.53	-4.6	-0.35	8.8e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
PAAD	cis	rs9595066	0.627	rs4432167	chr13:44752361	C/G	cg04068111	chr13:44716778	NA	0.4	4.45	0.34	1.67e-5	Schizophrenia;
PAAD	cis	rs7631605	0.905	rs6550445	chr3:37066369	T/C	cg17445812	chr3:36986805	TRANK1	0.32	4.28	0.33	3.35e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Breast cancer;
PAAD	cis	rs60154123	0.881	rs116161686	chr1:210473622	G/A	cg22029157	chr1:209979665	IRF6	0.71	5.67	0.42	6.99e-8	Coronary artery disease;
PAAD	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-1.06	-9.51	-0.61	3.98e-17	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.65	0.57	6.71e-15	Menarche (age at onset);
PAAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.81	-0.48	2.12e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.47	-4.51	-0.34	1.31e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg14709524	chr16:89940631	TCF25	0.98	4.56	0.35	1.04e-5	Skin colour saturation;
PAAD	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg14458575	chr2:238380390	NA	0.66	5.28	0.39	4.49e-7	Prostate cancer;
PAAD	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.45	-4.3	-0.33	3.08e-5	Breast cancer;
PAAD	cis	rs1371614	0.655	rs4665927	chr2:27149366	A/T	cg00617064	chr2:27272375	NA	0.43	4.51	0.34	1.27e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg24253500	chr15:84953950	NA	0.56	6.3	0.46	3e-9	Schizophrenia;
PAAD	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.56	0.52	3.48e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7011192	0.793	rs76894685	chr8:10523832	G/A	cg25377605	chr8:10513717	RP1L1	-0.84	-5.27	-0.39	4.59e-7	Suicide;
PAAD	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.57	5.41	0.4	2.38e-7	Corneal astigmatism;
PAAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg10518543	chr12:38710700	ALG10B	0.52	4.95	0.37	1.94e-6	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.91	11.02	0.67	3.93e-21	Schizophrenia;
PAAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-4.27	-0.33	3.4e-5	Bipolar disorder;
PAAD	cis	rs4740619	0.967	rs6474942	chr9:15666712	A/G	cg14451791	chr9:16040625	NA	-0.38	-4.46	-0.34	1.58e-5	Body mass index;
PAAD	cis	rs7816613	0.850	rs3939935	chr8:102683331	A/G	cg20585841	chr8:102729926	NCALD	0.58	5.11	0.38	9.33e-7	Age-related hearing impairment;
PAAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.75	-10.13	-0.63	9.38e-19	Iron status biomarkers;
PAAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.67	5.48	0.41	1.76e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg21419209	chr3:44054225	NA	-0.72	-7.4	-0.51	8.85e-12	Coronary artery disease;
PAAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg03732007	chr1:2071316	PRKCZ	0.45	4.27	0.33	3.39e-5	Height;
PAAD	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	1.02	12.43	0.71	6.28e-25	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-4.33	-0.33	2.68e-5	Platelet count;
PAAD	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	4.62	0.35	8.11e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.94	-7.47	-0.52	5.76e-12	Initial pursuit acceleration;
PAAD	cis	rs2004318	1.000	rs10422997	chr19:55119730	G/A	cg03320607	chr19:54800032	LILRA3	-0.95	-5.73	-0.42	5.2e-8	Blood protein levels;
PAAD	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13870426	chr17:30244630	NA	-0.61	-5.88	-0.43	2.55e-8	Hip circumference adjusted for BMI;
PAAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08048268	chr3:133502702	NA	-0.49	-5.77	-0.42	4.28e-8	Iron status biomarkers;
PAAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg06026331	chr20:60912101	LAMA5	0.66	5.64	0.42	7.9e-8	Colorectal cancer;
PAAD	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-1.24	-12.74	-0.72	9.23e-26	Hair shape;
PAAD	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.89	11.03	0.67	3.85e-21	Dental caries;
PAAD	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.75	-4.79	-0.36	3.93e-6	Recalcitrant atopic dermatitis;
PAAD	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.05	0.5	6e-11	Coffee consumption (cups per day);
PAAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg03983715	chr16:68378420	PRMT7	-0.81	-5.67	-0.42	6.92e-8	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09852008	chr1:10092689	UBE4B	0.58	6.35	0.46	2.4e-9	Monocyte percentage of white cells;
PAAD	cis	rs17539620	0.702	rs57270563	chr6:154877150	A/T	cg20019720	chr6:154832845	CNKSR3	0.52	7.27	0.51	1.77e-11	Lipoprotein (a) levels;
PAAD	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-7.22	-0.51	2.37e-11	Eye color traits;
PAAD	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.28	7.35	0.51	1.15e-11	Type 2 diabetes nephropathy;
PAAD	cis	rs4462272	0.525	rs34955138	chr10:102039187	T/G	cg11888571	chr10:102027403	CWF19L1	-0.48	-4.34	-0.33	2.63e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.81	10.26	0.64	4.37e-19	Bone mineral density;
PAAD	cis	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg01338084	chr22:32026380	PISD	1.53	8.23	0.56	7.65e-14	Age-related hearing impairment;
PAAD	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg04920474	chr2:44395004	PPM1B	0.45	4.35	0.33	2.44e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
PAAD	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.63	6.76	0.48	2.81e-10	Longevity;
PAAD	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg00086871	chr4:6988644	TBC1D14	0.89	4.52	0.34	1.25e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs1075265	0.933	rs7560947	chr2:54314610	G/C	cg04546899	chr2:54196757	PSME4	0.31	4.37	0.33	2.25e-5	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	0.91	6.44	0.46	1.48e-9	Prostate cancer;
PAAD	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.8	9.64	0.62	1.89e-17	Bladder cancer;
PAAD	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-4.48	-0.34	1.45e-5	Lung cancer;
PAAD	cis	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-4.84	-0.37	3.23e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.45	4.64	0.35	7.61e-6	Type 2 diabetes;
PAAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg18833306	chr6:118973337	C6orf204	-0.56	-4.57	-0.35	1.01e-5	Diastolic blood pressure;
PAAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.85	5.89	0.43	2.43e-8	Initial pursuit acceleration;
PAAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.62	6.22	0.45	4.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.53	5.04	0.38	1.3e-6	Monocyte count;
PAAD	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02985541	chr2:219472218	PLCD4	-0.3	-4.7	-0.36	5.74e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.44	6.09	0.44	8.85e-9	Cardiovascular disease risk factors;
PAAD	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.6	-8.51	-0.57	1.53e-14	Asthma (sex interaction);
PAAD	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.84	6.21	0.45	4.92e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.68	-5.55	-0.41	1.27e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.69	5.2	0.39	6.42e-7	Vitiligo;
PAAD	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.63	5.92	0.43	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.12e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06850241	chr22:41845214	NA	0.57	5.05	0.38	1.23e-6	Vitiligo;
PAAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.62	5.97	0.44	1.64e-8	Monocyte count;
PAAD	cis	rs2440129	0.632	rs13396	chr17:6905624	T/C	cg03407747	chr17:6899364	ALOX12	0.51	5.37	0.4	2.83e-7	Tonsillectomy;
PAAD	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg17545662	chr6:170176663	C6orf70	0.63	4.26	0.33	3.56e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg20742385	chr13:113633654	MCF2L	-0.42	-4.36	-0.33	2.34e-5	Systolic blood pressure;
PAAD	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.31	-0.33	2.95e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg15145965	chr22:50218605	BRD1	0.61	5.24	0.39	5.26e-7	Schizophrenia;
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05025164	chr4:1340916	KIAA1530	0.54	5.14	0.38	8.22e-7	Obesity-related traits;
PAAD	cis	rs11811982	0.655	rs75813302	chr1:227572370	A/T	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg09163369	chr1:210001066	C1orf107	0.52	5.43	0.4	2.18e-7	Orofacial clefts;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg01314691	chr13:111367171	ING1	0.6	6.58	0.47	7.11e-10	Monocyte percentage of white cells;
PAAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.56	6.8	0.48	2.23e-10	Monobrow;
PAAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	5.15	0.39	8.01e-7	Schizophrenia;
PAAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg23283495	chr1:209979779	IRF6	0.77	7.05	0.5	5.97e-11	Cleft lip with or without cleft palate;
PAAD	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.48	7.87	0.54	6.16e-13	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg22163631	chr20:61643377	NA	0.89	6.32	0.46	2.75e-9	Childhood ear infection;
PAAD	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.3	0.64	3.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs7922314	0.571	rs4745960	chr10:64717040	G/A	cg08989932	chr10:65390526	NA	-0.9	-4.44	-0.34	1.72e-5	Cutaneous psoriasis;
PAAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.54	-4.88	-0.37	2.71e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg22827986	chr11:48284249	OR4X1	-0.37	-4.78	-0.36	4.09e-6	Migraine - clinic-based;
PAAD	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.75	8.04	0.55	2.33e-13	Magnesium levels;
PAAD	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.11	9.6	0.61	2.44e-17	Blood trace element (Zn levels);
PAAD	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.97	-7.34	-0.51	1.21e-11	Multiple sclerosis;
PAAD	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg03959625	chr15:84868606	LOC388152	0.43	4.49	0.34	1.4e-5	Schizophrenia;
PAAD	cis	rs9314614	0.789	rs4841776	chr8:6712219	T/G	cg27319216	chr8:6693540	XKR5	-0.4	-5.35	-0.4	3.2e-7	IgA nephropathy;White blood cell count (basophil);
PAAD	cis	rs655641	0.520	rs541458	chr11:85788351	C/T	cg07180834	chr11:85838833	NA	-0.49	-5.13	-0.38	8.54e-7	Platelet count;
PAAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.88	0.43	2.52e-8	Prudent dietary pattern;
PAAD	cis	rs7638995	0.701	rs34550101	chr3:69185670	C/T	cg26574240	chr3:69171822	LMOD3	-0.83	-5.17	-0.39	7.29e-7	Alzheimer's disease (late onset);
PAAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg09540629	chr10:134981759	KNDC1	0.56	6.87	0.49	1.54e-10	Educational attainment (years of education);
PAAD	cis	rs10905065	0.761	rs10905234	chr10:5860282	A/T	cg11519256	chr10:5708881	ASB13	0.53	4.66	0.35	6.9e-6	Menopause (age at onset);
PAAD	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg00922110	chr4:57842668	C4orf14	0.41	4.7	0.36	5.76e-6	Response to bleomycin (chromatid breaks);
PAAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.87	9.43	0.61	6.65e-17	Cleft lip with or without cleft palate;
PAAD	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.71	7.65	0.53	2.14e-12	Triglyceride levels;
PAAD	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-4.72	-0.36	5.27e-6	Cervical cancer;
PAAD	cis	rs11700980	0.551	rs2832024	chr21:30113692	C/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg09340386	chr2:1605954	NA	-0.64	-4.5	-0.34	1.33e-5	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg06632027	chr4:90757378	SNCA	-0.51	-4.51	-0.34	1.26e-5	Neuroticism;
PAAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.6	5.76	0.42	4.43e-8	Eye color traits;
PAAD	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.01	-0.38	1.46e-6	Systemic lupus erythematosus;
PAAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg14703610	chr5:56206110	C5orf35	0.62	5.74	0.42	5.02e-8	Coronary artery disease;
PAAD	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	6.06e-7	Bladder cancer;
PAAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg14393609	chr7:65229607	NA	-0.46	-4.49	-0.34	1.39e-5	Aortic root size;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg25886479	chr11:50257625	LOC441601	0.41	4.4	0.34	2.03e-5	Coronary artery disease;
PAAD	cis	rs300774	0.844	rs1810329	chr2:176395	A/T	cg21211680	chr2:198530	NA	0.57	4.83	0.36	3.28e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg07517944	chr15:51633816	GLDN	0.44	4.39	0.34	2.08e-5	Hormone measurements;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06798480	chr3:9439221	SETD5;LOC440944	0.74	7.34	0.51	1.19e-11	Obesity-related traits;
PAAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-4.98	-0.37	1.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg10756475	chr4:1757242	NA	0.47	4.61	0.35	8.35e-6	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.62	6.81	0.48	2.18e-10	Systemic lupus erythematosus;
PAAD	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.66	-7.82	-0.54	8.41e-13	Height;
PAAD	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg24812749	chr6:127587940	RNF146	0.74	8.95	0.59	1.14e-15	Breast cancer;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26952407	chr6:27219317	PRSS16	-0.65	-6.35	-0.46	2.34e-9	Lung cancer in ever smokers;
PAAD	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	5.7	0.42	6.15e-8	Coronary artery disease;
PAAD	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.56	5.54	0.41	1.28e-7	Breast cancer;
PAAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.81	-5.91	-0.43	2.17e-8	Yeast infection;
PAAD	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.61	7.02	0.49	6.91e-11	Cognitive performance;
PAAD	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.46	4.4	0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.77	9.24	0.6	2.04e-16	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9463078	0.845	rs9349315	chr6:45172289	A/G	cg25276700	chr6:44698697	NA	-0.48	-5.51	-0.41	1.5e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.47	-0.34	1.55e-5	Vitiligo;
PAAD	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	6.27	0.45	3.49e-9	Alzheimer's disease (late onset);
PAAD	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.53	-6.34	-0.46	2.54e-9	Alcohol dependence;
PAAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg05895507	chr15:77155635	SCAPER	0.38	4.82	0.36	3.49e-6	Blood metabolite levels;
PAAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12599982	chr1:44399894	ARTN	-0.44	-4.7	-0.36	5.85e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.81	-7.05	-0.5	5.87e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-6.78	-0.48	2.47e-10	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs116175783	0.557	rs6710414	chr2:162268515	T/G	cg08807892	chr2:162101083	NA	-0.65	-4.77	-0.36	4.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-4.46	-0.34	1.57e-5	Reticulocyte count;
PAAD	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg27121462	chr16:89883253	FANCA	0.48	4.99	0.38	1.63e-6	Vitiligo;
PAAD	cis	rs1879734	1.000	rs4927027	chr1:54141274	A/G	cg14659662	chr1:54151053	GLIS1	-0.39	-6.16	-0.45	6.24e-9	Mitral valve prolapse;
PAAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs11018874	0.709	rs11018854	chr11:89835191	A/G	cg05041596	chr11:89867385	NAALAD2	0.65	4.58	0.35	9.69e-6	White blood cell types;
PAAD	cis	rs11235843	0.929	rs72974866	chr11:73412291	C/T	cg18195628	chr11:73498948	MRPL48	0.78	4.29	0.33	3.17e-5	Hand grip strength;
PAAD	cis	rs2001970	1.000	rs8046568	chr16:55250343	A/G	cg06138439	chr16:54973128	NA	0.27	4.26	0.33	3.5e-5	Visceral fat;
PAAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.54	-6.57	-0.47	7.64e-10	Iron status biomarkers;
PAAD	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06850241	chr22:41845214	NA	0.55	5.06	0.38	1.2e-6	Vitiligo;
PAAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-5.78	-0.42	4.2e-8	Schizophrenia;
PAAD	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg05555928	chr11:63887634	MACROD1	-0.58	-5.61	-0.41	9.26e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.89	11.6	0.69	1.13e-22	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6828577	0.817	rs298996	chr4:119624745	C/T	cg02775129	chr4:119771670	NA	-0.52	-4.32	-0.33	2.77e-5	Perioperative myocardial infarction in coronary artery bypass surgery;
PAAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.63	6.73	0.48	3.19e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.47	-0.34	1.54e-5	Colorectal cancer;
PAAD	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.57	5.63	0.42	8.57e-8	Lung disease severity in cystic fibrosis;
PAAD	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.45	-4.55	-0.35	1.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-12.49	-0.71	4.45e-25	Ulcerative colitis;
PAAD	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.58	-5.39	-0.4	2.68e-7	Height;
PAAD	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	4.73	0.36	4.99e-6	Neuroticism;
PAAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg22373112	chr17:40307717	RAB5C	-0.47	-4.26	-0.33	3.53e-5	Fibrinogen levels;
PAAD	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.5	-0.52	4.84e-12	Neuroticism;
PAAD	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.75	-7.92	-0.54	4.53e-13	Blood metabolite levels;
PAAD	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.58	5.13	0.38	8.71e-7	QRS interval (sulfonylurea treatment interaction);
PAAD	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg03999872	chr20:62272968	STMN3	-0.75	-6.58	-0.47	6.99e-10	Atopic dermatitis;
PAAD	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg16596103	chr2:233749413	NGEF	-0.41	-4.36	-0.33	2.35e-5	Schizophrenia;
PAAD	cis	rs16975963	0.895	rs8103383	chr19:38327701	A/C	cg14218481	chr19:38281219	NA	0.43	4.44	0.34	1.72e-5	Longevity;
PAAD	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21646471	chr2:242523971	THAP4	0.65	5.03	0.38	1.39e-6	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.98	7.45	0.52	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg22875332	chr1:76189707	ACADM	-0.52	-5.14	-0.38	8.35e-7	Daytime sleep phenotypes;
PAAD	cis	rs863345	0.604	rs10908673	chr1:158503908	T/G	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg26816564	chr1:7831052	VAMP3	0.7	5.55	0.41	1.26e-7	Inflammatory bowel disease;
PAAD	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg00982548	chr2:198649783	BOLL	-0.77	-5.61	-0.41	9.41e-8	Ulcerative colitis;
PAAD	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.58	7.28	0.51	1.66e-11	Diastolic blood pressure;
PAAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.6	-7.2	-0.5	2.55e-11	Coronary artery disease;
PAAD	cis	rs8053891	0.756	rs35800852	chr16:72002105	G/T	cg16558253	chr16:72132732	DHX38	-0.54	-4.71	-0.36	5.47e-6	Coronary artery disease;
PAAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00982548	chr2:198649783	BOLL	-0.76	-5.41	-0.4	2.38e-7	Ulcerative colitis;
PAAD	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.9	-0.43	2.31e-8	Intelligence (multi-trait analysis);
PAAD	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.46e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg26174226	chr8:58114915	NA	-0.58	-4.43	-0.34	1.77e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs6960043	0.584	rs10244143	chr7:15042959	C/T	cg19272540	chr7:15055459	NA	0.32	5.65	0.42	7.77e-8	Type 2 diabetes;
PAAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg13611204	chr9:139324423	INPP5E	-0.55	-4.76	-0.36	4.38e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs13242816	1.000	rs2402079	chr7:116128670	T/A	cg16553024	chr7:116138462	CAV2	-0.68	-4.81	-0.36	3.59e-6	P wave duration;
PAAD	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.57	-5.59	-0.41	1.01e-7	Systolic blood pressure;
PAAD	cis	rs2882667	0.690	rs2351463	chr5:138258802	A/C	cg09476006	chr5:138032270	NA	0.45	5.56	0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.43	4.3	0.33	3e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg00280220	chr17:61926910	NA	0.44	4.68	0.35	6.34e-6	Prudent dietary pattern;
PAAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-10.28	-0.64	3.67e-19	Height;
PAAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg05110241	chr16:68378359	PRMT7	-1.08	-7.77	-0.53	1.11e-12	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg07166546	chr14:35805898	NA	-0.32	-4.83	-0.36	3.32e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-14.92	-0.77	1.44e-31	Height;
PAAD	cis	rs35000415	0.938	rs12531054	chr7:128644251	A/C	cg19972273	chr7:128594194	NA	-0.91	-5.55	-0.41	1.22e-7	Systemic lupus erythematosus;
PAAD	cis	rs16852403	0.904	rs6703721	chr1:178037791	C/T	cg00404053	chr1:178313656	RASAL2	0.49	4.82	0.36	3.4e-6	Childhood ear infection;
PAAD	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-6.08	-0.44	9.47e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06544989	chr22:39130855	UNC84B	0.53	5.26	0.39	4.75e-7	Menopause (age at onset);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07118866	chr11:36531924	TRAF6	0.58	6.3	0.46	3.03e-9	Monocyte percentage of white cells;
PAAD	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-1.39	-10.84	-0.66	1.19e-20	Obesity-related traits;
PAAD	cis	rs9905704	0.633	rs2680694	chr17:56469869	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.57	4.45	0.34	1.63e-5	Testicular germ cell tumor;
PAAD	cis	rs10501293	0.912	rs4755694	chr11:43088582	A/G	cg03447554	chr11:43094025	NA	-0.52	-5.16	-0.39	7.62e-7	Cognitive performance;
PAAD	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg06131755	chr6:160182447	ACAT2	0.48	4.25	0.33	3.75e-5	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.56	6.14	0.45	6.95e-9	Menopause (age at onset);
PAAD	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-4.44	-0.34	1.75e-5	Personality dimensions;
PAAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.59	5.44	0.4	2.05e-7	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.51	5.53	0.41	1.39e-7	Obesity-related traits;
PAAD	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.65	-6.95	-0.49	9.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs5167	0.506	rs11669173	chr19:45492559	G/A	cg20090143	chr19:45452003	APOC2	-0.44	-5.45	-0.4	1.98e-7	Blood protein levels;
PAAD	cis	rs7656342	0.622	rs10939558	chr4:9844162	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	4.28	0.33	3.35e-5	Gut microbiota (bacterial taxa);
PAAD	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.02	-0.49	6.85e-11	Monocyte count;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21999071	chr5:14313270	TRIO	-0.59	-6.5	-0.47	1.1e-9	Monocyte percentage of white cells;
PAAD	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg02493740	chr2:85810744	VAMP5	-0.46	-5.12	-0.38	9.2e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs10793968	0.688	rs7847796	chr9:133630768	C/T	cg01474677	chr9:133586259	NA	-0.6	-4.56	-0.35	1.05e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg24747557	chr10:131355152	MGMT	0.46	4.71	0.36	5.49e-6	Response to temozolomide;
PAAD	cis	rs6804624	0.613	rs2246151	chr3:99179308	C/A	cg02646433	chr3:99218170	NA	0.44	4.39	0.34	2.15e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg20406979	chr6:167373233	NA	-0.38	-5.17	-0.39	7.16e-7	Crohn's disease;
PAAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs12304921	0.748	rs73090619	chr12:51333033	C/A	cg04427360	chr12:51347099	HIGD1C	-0.61	-4.34	-0.33	2.54e-5	Type 2 diabetes;
PAAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.64	-8.23	-0.56	8.03e-14	Body mass index;
PAAD	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.96	-6.83	-0.48	1.94e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs75920871	0.858	rs11216168	chr11:116741553	G/A	cg04087571	chr11:116723030	SIK3	-0.48	-4.76	-0.36	4.49e-6	Subjective well-being;
PAAD	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.78	8.97	0.59	1.02e-15	Heart rate;
PAAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg16926213	chr1:1841314	NA	0.37	4.48	0.34	1.46e-5	Body mass index;
PAAD	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	5.77	0.42	4.32e-8	Mean platelet volume;
PAAD	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg06484146	chr7:12443880	VWDE	-0.76	-4.86	-0.37	2.94e-6	Coronary artery disease;
PAAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.53	5.66	0.42	7.5e-8	Menopause (age at onset);
PAAD	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg12486944	chr17:80159399	CCDC57	-0.49	-4.31	-0.33	2.98e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.55	5.17	0.39	7.32e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.89	-0.43	2.4e-8	Schizophrenia;
PAAD	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.06	0.55	2.08e-13	Lymphocyte counts;
PAAD	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.48	-0.41	1.74e-7	Schizophrenia;
PAAD	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.68	6.44	0.46	1.46e-9	Lymphocyte counts;
PAAD	cis	rs6448317	0.539	rs11931422	chr4:24936925	T/C	cg21108841	chr4:24914750	CCDC149	-0.58	-5.62	-0.41	8.98e-8	Heschl's gyrus morphology;
PAAD	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.54	-4.57	-0.35	9.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.82	8.46	0.57	2.04e-14	Corneal astigmatism;
PAAD	cis	rs8042680	0.688	rs4244883	chr15:91546497	T/G	cg08919649	chr15:91565780	VPS33B	0.46	4.29	0.33	3.2e-5	Type 2 diabetes;
PAAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg14983838	chr19:29218262	NA	0.69	5.92	0.43	2.02e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
PAAD	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.7	-7.68	-0.53	1.79e-12	Type 2 diabetes;
PAAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg14349672	chr11:133703707	NA	-0.59	-6.74	-0.48	3.12e-10	Childhood ear infection;
PAAD	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg04865290	chr3:52927548	TMEM110	-0.62	-4.37	-0.33	2.25e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.5	4.99	0.37	1.66e-6	Height;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg14559799	chr22:20760090	ZNF74	0.54	6.45	0.46	1.44e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-5.01	-0.38	1.47e-6	Mean corpuscular volume;
PAAD	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.76	-7.86	-0.54	6.7e-13	Mosquito bite size;
PAAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.7	7.65	0.53	2.18e-12	Longevity;Endometriosis;
PAAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.93	10.76	0.66	1.99e-20	Prudent dietary pattern;
PAAD	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.73	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.69	-7.34	-0.51	1.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs8018808	0.935	rs4903584	chr14:77934758	A/G	cg20045696	chr14:77926864	AHSA1	0.53	5.15	0.39	8.11e-7	Myeloid white cell count;
PAAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.78	9.28	0.6	1.58e-16	Emphysema distribution in smoking;
PAAD	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.56	-0.35	1.04e-5	Lung cancer in ever smokers;
PAAD	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.96	13.24	0.73	4.34e-27	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.81	-4.62	-0.35	7.99e-6	Skin colour saturation;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18621852	chr3:10150065	C3orf24	0.67	5.93	0.43	2.01e-8	Alzheimer's disease;
PAAD	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19945202	chr12:2788847	CACNA1C	-0.47	-5.2	-0.39	6.26e-7	Quantitative traits;
PAAD	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.5	6.22	0.45	4.54e-9	Crohn's disease;
PAAD	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.53	5.26	0.39	4.73e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.99	14.76	0.77	3.72e-31	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.54	-5.89	-0.43	2.39e-8	Total body bone mineral density;
PAAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07701084	chr6:150067640	NUP43	-0.6	-5.96	-0.44	1.66e-8	Testicular germ cell tumor;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16053281	chr3:196387058	LRRC33	0.63	6.5	0.47	1.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.85	-9.48	-0.61	4.77e-17	Mortality in heart failure;
PAAD	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-5.66	-0.42	7.5e-8	Homocysteine levels;
PAAD	cis	rs686320	0.748	rs673753	chr11:65206017	A/G	cg21890820	chr11:65308645	LTBP3	-0.73	-5.01	-0.38	1.51e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.61	6.4	0.46	1.79e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.72	7.05	0.5	5.81e-11	Schizophrenia;
PAAD	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.68	-7.53	-0.52	4.11e-12	Systemic lupus erythematosus;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24448849	chr1:113615747	LRIG2	0.73	7.79	0.53	9.75e-13	Obesity-related traits;
PAAD	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-1.26	-11.2	-0.67	1.31e-21	Obesity-related traits;
PAAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.38	-4.96	-0.37	1.83e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs2721195	0.614	rs12719778	chr8:145879883	T/C	cg15320075	chr8:145703422	NA	0.7	7.57	0.52	3.35e-12	Age at first birth;
PAAD	cis	rs4455778	0.579	rs6969891	chr7:49123598	T/G	cg26309511	chr7:48887640	NA	0.38	4.55	0.35	1.08e-5	Lung cancer in never smokers;
PAAD	cis	rs2615061	0.810	rs12046580	chr1:225941282	A/G	cg25287071	chr1:226878419	ITPKB	-0.52	-4.28	-0.33	3.34e-5	Monocyte count;
PAAD	trans	rs6547631	0.635	rs934773	chr2:85898094	A/G	cg14007156	chr9:138071294	NA	0.49	6.35	0.46	2.36e-9	Blood protein levels;
PAAD	cis	rs527409	1.000	rs556865	chr1:58726733	C/T	cg26345888	chr1:58716257	DAB1	0.64	4.29	0.33	3.17e-5	Kawasaki disease;
PAAD	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	12.0	0.7	9.14e-24	Body mass index (adult);
PAAD	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg04398451	chr17:18023971	MYO15A	0.8	8.81	0.58	2.64e-15	Total body bone mineral density;
PAAD	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	4.58	0.35	9.56e-6	Cardiovascular disease risk factors;
PAAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-5.29	-0.39	4.12e-7	Total body bone mineral density;
PAAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg25554036	chr4:6271136	WFS1	0.71	7.89	0.54	5.55e-13	Cisplatin-induced ototoxicity;
PAAD	cis	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25292698	chr18:3247809	MYL12A	0.41	4.41	0.34	1.91e-5	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.65	-0.35	7.13e-6	Lung cancer;
PAAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.95	12.38	0.71	8.49e-25	Menopause (age at onset);
PAAD	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.36	4.75	0.36	4.7e-6	Lung cancer;
PAAD	cis	rs8112211	0.561	rs117234139	chr19:38808504	A/G	cg14299480	chr19:38876666	GGN	-0.51	-6.49	-0.47	1.17e-9	Blood protein levels;
PAAD	cis	rs1933737	0.501	rs195502	chr6:116192026	A/G	cg18764771	chr6:116381957	FRK	0.26	4.33	0.33	2.72e-5	Urate levels;
PAAD	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-4.76	-0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.61	6.72	0.48	3.45e-10	Lung cancer;
PAAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-1.04	-14.64	-0.76	7.78e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.65	4.35	0.33	2.44e-5	Skin colour saturation;
PAAD	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg14851468	chr5:179071604	C5orf60	0.48	5.07	0.38	1.15e-6	Lung cancer;
PAAD	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.48	-4.6	-0.35	8.97e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11828289	0.599	rs75341566	chr11:23186941	C/A	cg20040320	chr11:23191996	NA	-0.78	-5.55	-0.41	1.27e-7	Cancer;
PAAD	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.99	7.97	0.54	3.59e-13	Eotaxin levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11200358	chr6:24719988	C6orf62	0.63	6.8	0.48	2.29e-10	Obesity-related traits;
PAAD	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.82	9.94	0.63	3.05e-18	Monocyte percentage of white cells;
PAAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg07148914	chr20:33460835	GGT7	0.51	4.85	0.37	3.01e-6	Coronary artery disease;
PAAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.5	4.9	0.37	2.42e-6	Morning vs. evening chronotype;
PAAD	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Educational attainment;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02711976	chr1:36023590	NCDN;KIAA0319L	-0.68	-7.42	-0.52	7.6e-12	Smoking initiation;
PAAD	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg16964102	chr10:135390573	NA	0.41	4.51	0.34	1.3e-5	Obesity-related traits;
PAAD	cis	rs2070677	0.736	rs12261564	chr10:135354594	C/T	cg08390786	chr10:135334061	NA	0.61	4.5	0.34	1.33e-5	Gout;
PAAD	cis	rs4588572	0.643	rs3885254	chr5:77686468	G/A	cg18281939	chr5:77783895	LHFPL2	-0.47	-5.24	-0.39	5.35e-7	Triglycerides;
PAAD	cis	rs6804624	0.597	rs2670343	chr3:99163341	A/C	cg02646433	chr3:99218170	NA	0.42	4.33	0.33	2.68e-5	Vertical cup-disc ratio;Optic cup area;
PAAD	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg15192750	chr16:69999425	NA	0.71	5.36	0.4	2.97e-7	IgE levels;
PAAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg04106633	chr4:1044584	NA	0.67	5.63	0.42	8.41e-8	Recombination rate (females);
PAAD	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.05	-0.63	1.58e-18	Response to antipsychotic treatment;
PAAD	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.69	6.57	0.47	7.71e-10	Coronary artery disease;
PAAD	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.03e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg25753631	chr6:25732923	NA	-0.5	-5.57	-0.41	1.12e-7	Iron status biomarkers;
PAAD	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.51	-0.52	4.64e-12	Neuroticism;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23283236	chr19:39616406	PAK4	0.68	6.87	0.49	1.53e-10	Obesity-related traits;
PAAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg03808351	chr9:123631620	PHF19	0.45	4.89	0.37	2.51e-6	Rheumatoid arthritis;
PAAD	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg21905437	chr5:178450457	ZNF879	-0.62	-5.14	-0.38	8.29e-7	Pubertal anthropometrics;
PAAD	cis	rs9687846	0.877	rs9687833	chr5:55861601	G/A	cg15001016	chr5:55860904	NA	-0.47	-4.53	-0.34	1.18e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.85	10.65	0.65	3.87e-20	Menopause (age at onset);
PAAD	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.55	-6.92	-0.49	1.21e-10	Atrioventricular conduction;
PAAD	cis	rs4795519	0.744	rs1913802	chr17:22173056	T/C	cg22648282	chr17:21454238	C17orf51	-0.51	-5.38	-0.4	2.72e-7	Chronic myeloid leukemia;
PAAD	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.79	4.47	0.34	1.5e-5	Coronary artery disease;
PAAD	trans	rs901683	0.850	rs35150810	chr10:46071142	T/G	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	5.91	0.43	2.21e-8	Obesity-related traits;
PAAD	cis	rs7301016	0.948	rs11614822	chr12:62931690	T/G	cg19781863	chr12:62918364	MON2	0.74	4.36	0.33	2.36e-5	IgG glycosylation;
PAAD	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg00383909	chr3:49044727	WDR6	0.52	4.44	0.34	1.72e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg03989125	chr22:38214979	NA	-0.63	-6.47	-0.46	1.29e-9	Glioblastoma;Glioma;
PAAD	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.54	-4.79	-0.36	3.96e-6	Total body bone mineral density;
PAAD	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.35	-0.6	1.05e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg08200582	chr11:442649	ANO9	0.51	4.46	0.34	1.59e-5	Systemic lupus erythematosus;
PAAD	cis	rs11969893	0.737	rs9386262	chr6:101427687	G/T	cg12253828	chr6:101329408	ASCC3	0.95	4.34	0.33	2.63e-5	Economic and political preferences (immigration/crime);
PAAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg16300553	chr8:8131077	NA	0.36	4.27	0.33	3.49e-5	Mood instability;
PAAD	cis	rs7084783	0.519	rs4918025	chr10:105342866	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.52	0.34	1.25e-5	Fear of pain;
PAAD	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25686074	chr17:70371847	NA	0.47	4.62	0.35	8.03e-6	Smoking initiation;
PAAD	cis	rs35955747	0.869	rs8141987	chr22:31587155	C/G	cg02404636	chr22:31891804	SFI1	-0.48	-4.87	-0.37	2.81e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.62	-5.9	-0.43	2.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.76	-6.99	-0.49	8.23e-11	Systemic lupus erythematosus;
PAAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.77	-7.13	-0.5	3.72e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.49	-4.72	-0.36	5.23e-6	Obesity-related traits;
PAAD	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	4.39	0.34	2.15e-5	Menarche (age at onset);
PAAD	cis	rs11252688	1.000	rs11252672	chr10:4752471	C/T	cg12359895	chr10:4697267	LOC100216001;LOC338588	0.78	4.66	0.35	6.75e-6	Major depressive disorder;
PAAD	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg18518183	chr2:172544446	DYNC1I2	-0.49	-4.32	-0.33	2.84e-5	Schizophrenia;
PAAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg24053715	chr22:38214548	NA	0.6	5.8	0.43	3.77e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.76	-6.54	-0.47	9e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-5.51	-0.41	1.53e-7	Schizophrenia;
PAAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-6.15	-0.45	6.64e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.62	-6.84	-0.48	1.85e-10	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg25037394	chr1:24152592	HMGCL	0.39	4.26	0.33	3.63e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.49	0.52	5.21e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.63	6.74	0.48	3.13e-10	Obesity-related traits;
PAAD	cis	rs2073300	1.000	rs6114137	chr20:23457264	G/A	cg12062639	chr20:23401060	NAPB	0.91	5.05	0.38	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.12	0.38	8.98e-7	Childhood ear infection;
PAAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.76	8.81	0.58	2.68e-15	Lung cancer;
PAAD	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.38	-4.7	-0.36	5.81e-6	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.62	7.71	0.53	1.54e-12	Coronary artery disease;
PAAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.56	4.51	0.34	1.3e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg25364880	chr3:44379878	C3orf23	0.57	5.09	0.38	1.04e-6	Depressive symptoms;
PAAD	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg27094323	chr7:1216898	NA	-0.48	-5.69	-0.42	6.4e-8	Longevity;Endometriosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07522644	chr6:43142093	SRF	-0.77	-6.47	-0.46	1.28e-9	Neuroticism;
PAAD	cis	rs10044254	0.813	rs7720498	chr5:15743911	T/C	cg07238450	chr5:15720153	FBXL7	-0.53	-4.46	-0.34	1.58e-5	Asthma (corticosteroid response);
PAAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.07	15.6	0.78	2.29e-33	Multiple system atrophy;
PAAD	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg10729496	chr3:10149963	C3orf24	0.76	6.23	0.45	4.33e-9	Alzheimer's disease;
PAAD	cis	rs7534824	0.625	rs61780284	chr1:101355166	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.58	0.35	9.48e-6	Refractive astigmatism;
PAAD	cis	rs2191566	1.000	rs7253205	chr19:44503607	T/C	cg20607764	chr19:44506953	ZNF230	-0.47	-4.36	-0.33	2.35e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	trans	rs6694672	0.867	rs2786114	chr1:197302717	T/C	cg26994526	chr18:47719735	MYO5B	-0.88	-6.78	-0.48	2.53e-10	Asthma;
PAAD	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	10.58	0.65	6.1e-20	Electrocardiographic conduction measures;
PAAD	cis	rs499368	0.519	rs216247	chr12:310571	C/T	cg24087681	chr12:298268	NA	-0.44	-4.72	-0.36	5.34e-6	Blood metabolite levels;Metabolite levels;
PAAD	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg07541023	chr7:19748670	TWISTNB	0.57	4.32	0.33	2.79e-5	Thyroid stimulating hormone;
PAAD	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs3736485	0.934	rs2899476	chr15:51903874	C/T	cg08986416	chr15:51914746	DMXL2	-0.46	-4.33	-0.33	2.71e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.62	-7.55	-0.52	3.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23387287	chr5:2568291	NA	0.59	6.41	0.46	1.71e-9	Smoking initiation;
PAAD	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.87	7.7	0.53	1.65e-12	Prostate-specific antigen levels;
PAAD	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23158103	chr7:148848205	ZNF398	-0.58	-5.2	-0.39	6.44e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs2858942	0.818	rs2685123	chr16:248418	T/C	cg08400316	chr16:204221	HBZ	0.51	5.6	0.41	9.71e-8	Mean corpuscular hemoglobin;
PAAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg09796270	chr17:17721594	SREBF1	0.44	5.04	0.38	1.3e-6	Total body bone mineral density;
PAAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.36	4.34	0.33	2.57e-5	Schizophrenia;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18029306	chr5:140998874	DIAPH1	-0.72	-7.05	-0.5	5.73e-11	Lung cancer in ever smokers;
PAAD	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg02404636	chr22:31891804	SFI1	0.5	4.98	0.37	1.72e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.34	-4.72	-0.36	5.37e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.84	10.4	0.64	1.8e-19	Bladder cancer;
PAAD	cis	rs16866061	0.816	rs115900205	chr2:225467840	G/C	cg12698349	chr2:225449008	CUL3	0.79	9.36	0.6	9.8e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.83	-0.48	1.95e-10	Coffee consumption;Coffee consumption (cups per day);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17605107	chr5:125936881	PHAX	0.59	6.49	0.47	1.15e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs12989701	0.877	rs12994718	chr2:127874226	T/A	cg00091827	chr2:127863656	BIN1	0.6	4.54	0.35	1.14e-5	Alzheimer's disease (late onset);
PAAD	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg10864074	chr7:100318194	EPO	-0.47	-4.49	-0.34	1.43e-5	Other erythrocyte phenotypes;
PAAD	cis	rs58521262	0.556	rs289338	chr19:23151425	C/T	cg03433597	chr19:22806448	NA	-0.24	-4.26	-0.33	3.55e-5	Testicular germ cell tumor;
PAAD	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	6.94	0.49	1.07e-10	IgG glycosylation;
PAAD	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg26942532	chr7:75678159	MDH2;STYXL1	0.52	4.45	0.34	1.67e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11245990	chr11:68621969	NA	0.37	4.84	0.37	3.17e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.77	9.07	0.59	5.74e-16	Crohn's disease;
PAAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02071572	chr4:1403502	NA	0.44	5.59	0.41	1.02e-7	Obesity-related traits;
PAAD	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg21605333	chr4:119757512	SEC24D	1.68	9.73	0.62	1.05e-17	Cannabis dependence symptom count;
PAAD	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.78	8.75	0.58	3.9e-15	Menarche (age at onset);
PAAD	cis	rs62025270	0.632	rs80036674	chr15:86114448	A/G	cg13263323	chr15:86062960	AKAP13	0.48	4.28	0.33	3.26e-5	Idiopathic pulmonary fibrosis;
PAAD	cis	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-4.35	-0.33	2.49e-5	Amyotrophic lateral sclerosis (sporadic);
PAAD	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.86	-10.21	-0.64	5.94e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-5.88	-0.43	2.53e-8	Testicular germ cell tumor;
PAAD	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.68	7.73	0.53	1.34e-12	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg27080348	chr5:140182129	PCDHA2;PCDHA1;PCDHA3	-0.42	-4.97	-0.37	1.75e-6	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.38	-4.39	-0.34	2.14e-5	Urate levels in lean individuals;
PAAD	trans	rs7071275	0.771	rs12356902	chr10:123432652	C/T	cg09994435	chr20:62404778	ZBTB46	0.78	6.64	0.47	5.26e-10	Dupuytren's disease;
PAAD	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg01953289	chr20:60874239	NA	0.63	4.6	0.35	8.74e-6	Obesity-related traits;
PAAD	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg20913747	chr6:44695427	NA	-0.66	-6.56	-0.47	8.09e-10	Total body bone mineral density;
PAAD	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	6.51	0.47	1.05e-9	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg03983715	chr16:68378420	PRMT7	-0.88	-6.16	-0.45	6.14e-9	HDL cholesterol;Metabolic syndrome;
PAAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-8.67	-0.58	6.08e-15	Coronary artery disease;
PAAD	cis	rs6499755	0.901	rs2042447	chr16:55352022	A/C	cg02859129	chr16:55357253	IRX6	-0.32	-4.28	-0.33	3.24e-5	Hypospadias;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18233595	chr5:126853378	PRRC1	-0.66	-6.6	-0.47	6.54e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00166722	chr3:10149974	C3orf24	0.7	6.25	0.45	3.98e-9	Alzheimer's disease;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13765785	chr11:123524938	SCN3B	0.52	6.55	0.47	8.56e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07362569	chr17:61921086	SMARCD2	0.63	7.67	0.53	1.88e-12	Prudent dietary pattern;
PAAD	cis	rs951366	0.677	rs1775140	chr1:205672107	C/CA	cg23034840	chr1:205782522	SLC41A1	-0.79	-5.96	-0.44	1.72e-8	Menarche (age at onset);
PAAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.86	0.54	6.39e-13	Prudent dietary pattern;
PAAD	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg10856724	chr12:34555212	NA	-0.41	-4.28	-0.33	3.34e-5	Morning vs. evening chronotype;
PAAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.97	12.36	0.71	9.68e-25	Breast cancer;
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg03983476	chr2:10830698	NOL10	-0.62	-6.22	-0.45	4.52e-9	Prostate cancer;
PAAD	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.52	-4.59	-0.35	9.04e-6	Mean corpuscular volume;
PAAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.2	0.39	6.46e-7	Coronary artery disease;
PAAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	8.09	0.55	1.75e-13	Prudent dietary pattern;
PAAD	trans	rs3749237	1.000	rs9819511	chr3:49884261	C/T	cg21659725	chr3:3221576	CRBN	0.71	6.56	0.47	7.78e-10	Resting heart rate;
PAAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.42	-5.59	-0.41	1.03e-7	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg04415270	chr2:102091202	RFX8	0.69	8.33	0.56	4.29e-14	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs2882667	0.893	rs10054796	chr5:138294344	G/A	cg09476006	chr5:138032270	NA	0.36	4.48	0.34	1.49e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs8179	0.645	rs7804293	chr7:92287849	T/G	cg03496780	chr7:92466842	CDK6	0.52	5.1	0.38	1.02e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
PAAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.76	8.4	0.56	2.88e-14	Menarche (age at onset);
PAAD	cis	rs7127900	1.000	rs6578999	chr11:2231774	G/T	cg25635251	chr11:2234043	NA	0.85	7.42	0.52	7.59e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
PAAD	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg13206674	chr6:150067644	NUP43	-0.54	-4.98	-0.37	1.7e-6	Lung cancer;
PAAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.66	-7.28	-0.51	1.69e-11	Childhood ear infection;
PAAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	0.6	4.86	0.37	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.71	-7.67	-0.53	1.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.75	-0.42	4.68e-8	Monocyte count;
PAAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg02776659	chr21:47717406	C21orf57	0.42	4.28	0.33	3.25e-5	Testicular germ cell tumor;
PAAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg03959625	chr15:84868606	LOC388152	0.47	4.85	0.37	3.05e-6	Schizophrenia;
PAAD	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.62	6.98	0.49	8.66e-11	Coronary artery disease;
PAAD	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-6.04	-0.44	1.16e-8	Total body bone mineral density;
PAAD	cis	rs6142102	0.961	rs6088355	chr20:32545887	A/G	cg08999081	chr20:33150536	PIGU	0.46	4.31	0.33	2.98e-5	Skin pigmentation;
PAAD	cis	rs6466055	0.661	rs17640599	chr7:104911576	T/C	cg04380332	chr7:105027541	SRPK2	0.51	5.07	0.38	1.16e-6	Schizophrenia;
PAAD	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.69	8.37	0.56	3.6e-14	Dupuytren's disease;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg23647530	chr1:155036154	EFNA4	-0.59	-7.55	-0.52	3.7e-12	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg07777115	chr5:623756	CEP72	-0.47	-4.34	-0.33	2.64e-5	Cystic fibrosis severity;
PAAD	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-7.31	-0.51	1.4e-11	Asthma;
PAAD	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	4.57	0.35	1.01e-5	Educational attainment;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14939370	chr17:67537942	MAP2K6	-0.65	-7.02	-0.49	6.92e-11	Obesity-related traits;
PAAD	cis	rs7631605	0.518	rs56231935	chr3:36979260	T/C	cg10333520	chr3:36987040	TRANK1	0.4	5.66	0.42	7.27e-8	Cerebrospinal P-tau181p levels;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24526587	chr1:164587676	PBX1	-0.57	-6.31	-0.46	2.83e-9	Obesity-related traits;
PAAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13560548	chr3:10150139	C3orf24	-0.64	-5.88	-0.43	2.49e-8	Alzheimer's disease;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09184467	chr10:14995699	DCLRE1C	-0.58	-6.76	-0.48	2.76e-10	Body fat percentage;
PAAD	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.42	-0.34	1.88e-5	Resting heart rate;
PAAD	trans	rs11687170	0.882	rs6757542	chr2:237053235	A/T	cg27438040	chr6:136611664	BCLAF1	-0.62	-6.37	-0.46	2.18e-9	Educational attainment;Educational attainment (years of education);
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg04154034	chr17:28927549	LRRC37B2	0.71	4.56	0.35	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg01851573	chr8:8652454	MFHAS1	0.57	4.95	0.37	1.96e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg22903657	chr4:1355424	KIAA1530	-0.45	-4.59	-0.35	9.16e-6	Obesity-related traits;
PAAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-4.33	-0.33	2.68e-5	Eosinophil percentage of white cells;
PAAD	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.54	-5.68	-0.42	6.68e-8	Height;
PAAD	cis	rs6594713	0.533	rs34471251	chr5:112970062	G/A	cg12552261	chr5:112820674	MCC	0.75	4.92	0.37	2.2e-6	Brain cytoarchitecture;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg02125191	chr6:41755473	TOMM6	0.62	6.8	0.48	2.24e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg14048834	chr19:49990801	RPL13AP5;RPL13A	-0.51	-4.41	-0.34	1.95e-5	Fibrinogen levels;
PAAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.94	11.11	0.67	2.33e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.62	7.0	0.49	7.62e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg05555928	chr11:63887634	MACROD1	-0.64	-4.86	-0.37	2.86e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.84	0.43	3.04e-8	Prudent dietary pattern;
PAAD	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.83	-10.6	-0.65	5.29e-20	Breast cancer;
PAAD	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.62	-6.06	-0.44	1.04e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.82	8.01	0.54	2.81e-13	Post bronchodilator FEV1;
PAAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.49	5.48	0.41	1.77e-7	Pulse pressure;
PAAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13198984	chr17:80129470	CCDC57	-0.43	-5.36	-0.4	3e-7	Life satisfaction;
PAAD	cis	rs9472414	0.510	rs227845	chr6:44695338	C/A	cg18551225	chr6:44695536	NA	0.53	5.33	0.4	3.55e-7	Height;
PAAD	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	6.07	0.44	9.64e-9	Blood protein levels;
PAAD	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.63	4.49	0.34	1.41e-5	Vitiligo;
PAAD	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.45	-5.78	-0.42	4.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.42	4.47	0.34	1.54e-5	Bipolar disorder;
PAAD	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg09640425	chr7:158790006	NA	-0.54	-6.11	-0.44	8.02e-9	Facial morphology (factor 20);
PAAD	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-6.05	-0.44	1.11e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-9.83	-0.62	5.81e-18	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.82	8.72	0.58	4.45e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg22482690	chr17:47019901	SNF8	0.5	5.39	0.4	2.62e-7	Type 2 diabetes;
PAAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.63	7.18	0.5	2.84e-11	High light scatter reticulocyte count;
PAAD	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg04721828	chr11:48285200	OR4X1	-0.49	-6.13	-0.45	7.12e-9	Migraine - clinic-based;
PAAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg01631684	chr10:65280961	REEP3	-0.44	-4.44	-0.34	1.75e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	5.72	0.42	5.36e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.4	-0.34	2.06e-5	Coronary artery disease;
PAAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04362095	chr11:63592001	C11orf84	-0.5	-4.47	-0.34	1.51e-5	Platelet count;
PAAD	cis	rs12773846	0.537	rs12775945	chr10:126269831	C/T	cg04949429	chr10:126290192	LHPP	0.65	5.74	0.42	4.94e-8	Subcutaneous adipose tissue;
PAAD	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	1.31	11.11	0.67	2.26e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
PAAD	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.57	-5.85	-0.43	2.96e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg04165759	chr1:150448943	RPRD2	0.51	5.18	0.39	6.82e-7	Migraine;
PAAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.64	-5.95	-0.43	1.75e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg00431813	chr7:1051703	C7orf50	0.76	4.55	0.35	1.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.73	-6.34	-0.46	2.43e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.57	-6.42	-0.46	1.67e-9	Educational attainment;
PAAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.91	11.32	0.68	6.18e-22	Methadone dose in opioid dependence;
PAAD	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.05	0.38	1.27e-6	Motion sickness;
PAAD	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg16937583	chr3:9997177	NA	-0.46	-4.38	-0.33	2.19e-5	Alzheimer's disease;
PAAD	cis	rs246395	0.966	rs17656204	chr5:149501803	C/T	cg26247309	chr5:149501835	PDGFRB	0.37	4.54	0.35	1.12e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
PAAD	cis	rs12612619	0.579	rs4552148	chr2:27080513	A/T	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.38	-0.33	2.22e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.41	0.34	1.97e-5	Hepatocellular carcinoma;
PAAD	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.52	5.28	0.39	4.45e-7	Bladder cancer;
PAAD	cis	rs6460942	0.659	rs17192500	chr7:12545379	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-4.85	-0.37	2.99e-6	Coronary artery disease;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.8	0.53	9.33e-13	Prudent dietary pattern;
PAAD	cis	rs12304921	0.745	rs7397054	chr12:51431740	G/C	cg04427360	chr12:51347099	HIGD1C	-0.63	-4.5	-0.34	1.33e-5	Type 2 diabetes;
PAAD	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg10495392	chr1:46806563	NSUN4	0.57	5.69	0.42	6.33e-8	Menopause (age at onset);
PAAD	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-7.44	-0.52	6.86e-12	Leprosy;
PAAD	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-4.88	-0.37	2.64e-6	Vitiligo;
PAAD	cis	rs9900972	0.918	rs8082041	chr17:76876542	A/G	cg00961940	chr17:76876995	TIMP2	0.58	5.37	0.4	2.91e-7	Obesity-related traits;
PAAD	cis	rs863345	0.933	rs863354	chr1:158542460	A/G	cg12129480	chr1:158549410	OR10X1	-0.44	-4.89	-0.37	2.57e-6	Pneumococcal bacteremia;
PAAD	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.54	-4.55	-0.35	1.09e-5	Obesity-related traits;
PAAD	cis	rs887829	0.694	rs7583278	chr2:234617407	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-5.23	-0.39	5.47e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
PAAD	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg12386194	chr3:101231763	SENP7	0.63	6.25	0.45	4.03e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	4.82	0.36	3.45e-6	Schizophrenia;
PAAD	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg23024343	chr7:107201750	COG5	0.57	4.65	0.35	7.09e-6	Coronary artery disease;
PAAD	cis	rs10479542	0.671	rs6601048	chr5:178971837	T/A	cg14820908	chr5:178986412	RUFY1	0.49	4.85	0.37	3.08e-6	Lung cancer;
PAAD	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-4.27	-0.33	3.39e-5	Schizophrenia;
PAAD	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.69	-7.12	-0.5	4.11e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-9.54	-0.61	3.47e-17	Height;
PAAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg01942863	chr7:99769432	GPC2	-0.49	-4.52	-0.34	1.21e-5	Coronary artery disease;
PAAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.03	-0.44	1.19e-8	Body mass index;
PAAD	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg13647721	chr17:30228624	UTP6	-0.66	-4.58	-0.35	9.46e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.37	-7.03	-0.5	6.44e-11	Psoriasis vulgaris;
PAAD	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg04018474	chr16:31008003	STX1B	-0.29	-4.48	-0.34	1.47e-5	Dementia with Lewy bodies;
PAAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.22	11.84	0.69	2.57e-23	Platelet count;
PAAD	cis	rs7301016	1.000	rs10877857	chr12:62872211	C/T	cg11441379	chr12:63026424	NA	0.84	6.09	0.44	8.76e-9	IgG glycosylation;
PAAD	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.5	-9.5	-0.61	4.39e-17	Alzheimer's disease (late onset);
PAAD	cis	rs35785195	0.593	rs12831240	chr12:114243590	A/G	cg11070030	chr12:114232702	NA	0.56	4.28	0.33	3.25e-5	Daytime sleep phenotypes;
PAAD	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.92	7.78	0.53	1.01e-12	Dupuytren's disease;
PAAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	5.02	0.38	1.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	9.67	0.62	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.87	9.75	0.62	9.66e-18	Myeloid white cell count;
PAAD	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.51	-5.58	-0.41	1.1e-7	Metabolite levels;
PAAD	cis	rs1823874	0.581	rs11855419	chr15:100327480	A/G	cg16400843	chr15:100339927	C15orf51	-0.52	-6.16	-0.45	6.13e-9	IgG glycosylation;
PAAD	cis	rs59888335	0.894	rs4342071	chr3:80997637	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25060020	chr19:40932140	SERTAD1	0.62	7.41	0.52	8.01e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg00431813	chr7:1051703	C7orf50	0.45	4.34	0.33	2.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg02555727	chr12:129281546	SLC15A4	-0.45	-4.83	-0.36	3.3e-6	Systemic lupus erythematosus;
PAAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.78	-0.36	4.09e-6	Life satisfaction;
PAAD	cis	rs17023223	0.537	rs2645302	chr1:119590398	A/C	cg17326555	chr1:119535693	NA	-0.41	-5.0	-0.38	1.54e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9463078	0.605	rs9472416	chr6:44950963	T/C	cg25276700	chr6:44698697	NA	0.4	4.79	0.36	3.87e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs4722404	0.592	rs13221367	chr7:3119823	C/T	cg19214707	chr7:3157722	NA	-0.5	-4.73	-0.36	5.1e-6	Atopic dermatitis;
PAAD	cis	rs7616330	0.790	rs73118209	chr3:71040857	A/C	cg01511742	chr3:71112437	FOXP1	-0.73	-5.21	-0.39	5.99e-7	QT interval;
PAAD	cis	rs258892	0.895	rs34670	chr5:72162863	T/C	cg21869765	chr5:72125136	TNPO1	0.76	5.18	0.39	7.06e-7	Small cell lung carcinoma;
PAAD	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	13.19	0.73	5.66e-27	Colorectal cancer;
PAAD	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-4.8	-0.36	3.72e-6	Mean platelet volume;
PAAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26711592	chr17:60501033	METTL2A	0.66	6.44	0.46	1.5e-9	Obesity-related traits;
PAAD	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.4	10.5	0.65	9.6e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg14092571	chr14:90743983	NA	0.5	4.87	0.37	2.72e-6	Mortality in heart failure;
PAAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	8.17	0.55	1.08e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.84	-0.43	3.13e-8	Schizophrenia;
PAAD	cis	rs6539288	0.691	rs10746071	chr12:107353595	C/T	cg15890332	chr12:107067104	RFX4	-0.41	-4.55	-0.35	1.07e-5	Total body bone mineral density;
PAAD	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.62	-0.41	8.96e-8	Metabolite levels (Pyroglutamine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21831898	chr1:150254439	C1orf51	0.66	6.84	0.49	1.84e-10	Obesity-related traits;
PAAD	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.71	4.49	0.34	1.42e-5	IgG glycosylation;
PAAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.9	-11.32	-0.68	6.33e-22	Menopause (age at onset);
PAAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.82	10.42	0.65	1.6e-19	Plasma homocysteine levels (post-methionine load test);
PAAD	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-4.99	-0.37	1.66e-6	Axial length;
PAAD	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.56	5.24	0.39	5.24e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.89	10.11	0.63	1.1e-18	Ulcerative colitis;
PAAD	cis	rs4979906	1.000	rs4979906	chr10:79444753	A/G	cg07817648	chr10:79422355	NA	-0.57	-5.07	-0.38	1.14e-6	Mortality in heart failure;
PAAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-1.14	-6.29	-0.45	3.26e-9	Inflammatory biomarkers;
PAAD	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg19442545	chr10:75533431	FUT11	-0.5	-5.23	-0.39	5.43e-7	Inflammatory bowel disease;
PAAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.26	4.65	0.35	7.22e-6	IgG glycosylation;
PAAD	cis	rs4742903	0.967	rs4743689	chr9:106909300	G/A	cg14250997	chr9:106856677	SMC2	0.5	5.47	0.41	1.84e-7	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.51	-0.34	1.31e-5	Height;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03067462	chr11:2422131	TSSC4	0.59	6.54	0.47	8.89e-10	Myopia (pathological);
PAAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.71	-8.35	-0.56	3.87e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	4.82	0.36	3.47e-6	Menarche (age at onset);
PAAD	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg16898833	chr6:26189333	HIST1H4D	0.8	4.71	0.36	5.55e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06799790	chr17:61951754	CSH2	-0.47	-4.9	-0.37	2.41e-6	Height;
PAAD	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14119001	chr9:139324193	INPP5E	-0.67	-6.04	-0.44	1.12e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs7260598	0.539	rs10425192	chr19:24090711	C/T	cg09235885	chr19:23456588	NA	-0.64	-4.47	-0.34	1.5e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs56346965	0.967	rs1978273	chr2:191532039	G/A	cg27211696	chr2:191398769	TMEM194B	-0.49	-4.3	-0.33	3.04e-5	Bone mineral density (Ward's triangle area);
PAAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.4	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs12541635	0.677	rs11781331	chr8:107066936	G/A	cg10147462	chr8:107024639	NA	-0.47	-4.91	-0.37	2.38e-6	Age of smoking initiation;
PAAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.95	-11.45	-0.68	2.77e-22	Height;
PAAD	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06771106	chr2:113671356	IL1F7	0.62	6.64	0.47	5.11e-10	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-6.61	-0.47	6.19e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.88	-11.03	-0.67	3.77e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg24879335	chr3:133465180	TF	0.55	5.92	0.43	2.08e-8	Iron status biomarkers;
PAAD	cis	rs10901513	0.932	rs35713731	chr10:127667412	A/G	cg22975853	chr10:127789788	ADAM12	0.43	4.61	0.35	8.64e-6	Visceral fat;
PAAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg25173405	chr17:45401733	C17orf57	-0.51	-4.6	-0.35	8.99e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4926611	0.736	rs2141079	chr1:54120873	A/G	cg15582833	chr1:54954348	NA	0.43	4.33	0.33	2.64e-5	Hand grip strength;
PAAD	cis	rs9788682	0.747	rs2869045	chr15:78718899	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-5.52	-0.41	1.44e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.73	-7.67	-0.53	1.86e-12	Sudden cardiac arrest;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27139841	chr20:44718745	NCOA5	0.61	7.06	0.5	5.63e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	12.77	0.72	7.93e-26	Platelet count;
PAAD	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg02344993	chr17:57696989	CLTC	0.57	5.29	0.39	4.28e-7	Hemoglobin concentration;
PAAD	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg27205649	chr11:78285834	NARS2	-0.61	-4.48	-0.34	1.44e-5	Alzheimer's disease (survival time);
PAAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-4.56	-0.35	1.04e-5	Platelet count;
PAAD	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27481594	chr15:43623282	ADAL;LCMT2	0.73	4.77	0.36	4.27e-6	Lung cancer in ever smokers;
PAAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.48	5.07	0.38	1.12e-6	Testicular germ cell tumor;
PAAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.67	-6.93	-0.49	1.09e-10	Schizophrenia;
PAAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-5.19	-0.39	6.59e-7	Personality dimensions;
PAAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	13.64	0.74	3.57e-28	Platelet count;
PAAD	cis	rs2229238	0.911	rs77184252	chr1:154492533	A/G	cg21262032	chr1:154437693	IL6R	-0.46	-4.86	-0.37	2.91e-6	Coronary heart disease;
PAAD	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg06740227	chr12:86229804	RASSF9	0.48	4.66	0.35	6.82e-6	Major depressive disorder;
PAAD	cis	rs56046484	0.956	rs12908535	chr15:85601525	C/G	cg08123816	chr15:85640762	PDE8A	-0.49	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.82	6.45	0.46	1.45e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg15181151	chr6:150070149	PCMT1	0.64	6.75	0.48	2.9e-10	Lung cancer;
PAAD	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26926768	chr12:34528122	NA	0.39	4.67	0.35	6.7e-6	Morning vs. evening chronotype;
PAAD	cis	rs2275565	0.872	rs10925250	chr1:237022130	A/G	cg17297354	chr1:237056641	MTR	-0.52	-4.57	-0.35	1.01e-5	Homocysteine levels;
PAAD	cis	rs17152411	0.744	rs10901835	chr10:126589712	G/T	cg07081759	chr10:126330905	FAM53B	-0.42	-4.45	-0.34	1.67e-5	Height;
PAAD	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg02811702	chr13:24901961	NA	-0.51	-5.45	-0.4	1.95e-7	Obesity-related traits;
PAAD	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.71	4.61	0.35	8.57e-6	Gut microbiota (bacterial taxa);
PAAD	cis	rs3736485	0.966	rs11634039	chr15:51895575	C/T	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2.03e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg08999081	chr20:33150536	PIGU	0.53	5.78	0.42	4.04e-8	Height;
PAAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg07061783	chr6:25882402	NA	0.53	5.03	0.38	1.38e-6	Blood metabolite levels;
PAAD	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.47	-4.51	-0.34	1.3e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	0.73	5.51	0.41	1.48e-7	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06217245	chr20:33103252	DYNLRB1	0.39	4.78	0.36	4.18e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg01059385	chr22:42394853	WBP2NL	-0.45	-4.74	-0.36	4.78e-6	Cognitive function;
PAAD	cis	rs1577917	0.687	rs34618171	chr6:86811165	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-8.68	-0.58	5.72e-15	Response to antipsychotic treatment;
PAAD	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.53e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg19558802	chr15:51695713	GLDN	-0.44	-4.61	-0.35	8.64e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7011049	1.000	rs77668788	chr8:53856407	C/T	cg26025543	chr8:53854495	NA	0.61	4.37	0.33	2.25e-5	Systolic blood pressure;
PAAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-15.09	-0.77	5.02e-32	Height;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11062635	chr2:65663833	NA	-0.75	-6.44	-0.46	1.46e-9	Neuroticism;
PAAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.55	5.29	0.39	4.22e-7	Prudent dietary pattern;
PAAD	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg08390786	chr10:135334061	NA	-0.51	-4.72	-0.36	5.26e-6	Obesity-related traits;
PAAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	6.24	0.45	4.23e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg10589385	chr1:150898437	SETDB1	0.36	4.4	0.34	1.99e-5	Melanoma;
PAAD	cis	rs7219021	0.886	rs9897440	chr17:46868142	C/G	cg12314713	chr17:47074576	IGF2BP1	-0.35	-4.42	-0.34	1.85e-5	Schizophrenia or bipolar disorder;
PAAD	cis	rs10751667	0.558	rs12276666	chr11:1022119	G/A	ch.11.42038R	chr11:967971	AP2A2	0.61	5.85	0.43	2.92e-8	Alzheimer's disease (late onset);
PAAD	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg10183150	chr4:120222239	C4orf3	-0.38	-5.3	-0.4	3.98e-7	Corneal astigmatism;
PAAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	4.56	0.35	1.06e-5	Eosinophil percentage of white cells;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	4.72	0.36	5.41e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg22338127	chr1:209979572	IRF6	0.54	4.54	0.35	1.13e-5	Coronary artery disease;
PAAD	cis	rs73568641	0.547	rs12663416	chr6:154057383	C/T	cg15658985	chr6:154448740	OPRM1	0.57	4.62	0.35	7.97e-6	Methadone dose in opioid dependence;
PAAD	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs11828289	0.607	rs79308902	chr11:23163835	G/A	cg20040320	chr11:23191996	NA	-0.81	-5.9	-0.43	2.29e-8	Cancer;
PAAD	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.95	8.07	0.55	1.93e-13	Bipolar disorder;
PAAD	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.5	4.9	0.37	2.41e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10479542	0.642	rs6601045	chr5:178969375	G/C	cg21226059	chr5:178986404	RUFY1	0.52	5.71	0.42	5.63e-8	Lung cancer;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04688917	chr3:179040469	ZNF639	0.65	7.26	0.51	1.89e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.46	4.52	0.34	1.23e-5	Schizophrenia;
PAAD	cis	rs28489187	0.660	rs6576767	chr1:85876316	G/A	cg16011679	chr1:85725395	C1orf52	-0.55	-5.29	-0.39	4.22e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
PAAD	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.57	-5.4	-0.4	2.52e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7627468	0.955	rs55708281	chr3:121946738	A/T	cg17240004	chr3:121949083	CASR	0.53	4.64	0.35	7.36e-6	Kidney stones;
PAAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg21698718	chr17:80085957	CCDC57	-0.47	-5.25	-0.39	5e-7	Life satisfaction;
PAAD	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg14393609	chr7:65229607	NA	0.61	6.57	0.47	7.57e-10	Aortic root size;
PAAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.46	-4.84	-0.37	3.2e-6	Eosinophil percentage of white cells;
PAAD	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.78	8.31	0.56	4.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
PAAD	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-1.0	-10.91	-0.66	8.04e-21	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.88	-7.59	-0.52	2.98e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs12760731	0.623	rs3791025	chr1:178357907	C/G	cg00404053	chr1:178313656	RASAL2	0.66	5.53	0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs55986470	0.670	rs6730810	chr2:239416329	C/T	cg18131467	chr2:239335373	ASB1	-0.62	-4.51	-0.34	1.27e-5	Chronotype;
PAAD	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg21253087	chr9:139290292	SNAPC4	0.51	4.52	0.34	1.22e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
PAAD	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.61	-4.66	-0.35	6.9e-6	Breast cancer;
PAAD	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.97	-8.07	-0.55	1.93e-13	Alopecia areata;
PAAD	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.88	7.07	0.5	5.2e-11	Axial length;
PAAD	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.81	5.21	0.39	5.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08219700	chr8:58056026	NA	0.67	5.11	0.38	9.69e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2069408	1.000	rs2069408	chr12:56364321	C/T	cg02629586	chr12:57345407	RDH16	-0.5	-5.04	-0.38	1.3e-6	Asthma;
PAAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.49	4.99	0.38	1.62e-6	Height;
PAAD	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg20406979	chr6:167373233	NA	0.32	4.42	0.34	1.88e-5	Crohn's disease;
PAAD	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.44	-5.01	-0.38	1.51e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.42	4.37	0.33	2.29e-5	Bulimia nervosa;
PAAD	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.69	7.8	0.53	9.1e-13	Alcohol dependence;
PAAD	cis	rs7631605	0.905	rs7639327	chr3:37099788	A/G	cg17445812	chr3:36986805	TRANK1	0.34	4.6	0.35	8.74e-6	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7534824	0.625	rs61780288	chr1:101389945	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	4.6	0.35	9e-6	Refractive astigmatism;
PAAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.65	6.22	0.45	4.57e-9	Corneal astigmatism;
PAAD	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.2	0.45	5.18e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9992101	0.547	rs7656186	chr4:77409818	C/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.65	-5.77	-0.42	4.27e-8	Obesity-related traits;
PAAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	6.58	0.47	7.01e-10	Height;
PAAD	cis	rs11051970	0.592	rs12227991	chr12:32540045	C/G	cg24626660	chr12:32551988	NA	0.43	4.43	0.34	1.76e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.47	-5.16	-0.39	7.66e-7	Body mass index;
PAAD	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	4.44	0.34	1.71e-5	Ulcerative colitis;Inflammatory bowel disease;
PAAD	cis	rs346785	0.692	rs8072944	chr17:74291733	T/G	cg09812376	chr17:74270190	QRICH2	-0.48	-6.07	-0.44	9.76e-9	White matter hyperintensities in ischemic stroke;
PAAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-6.47	-0.46	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.66	7.15	0.5	3.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs7620363	0.826	rs12485413	chr3:34088712	G/A	cg02064073	chr3:33155252	CRTAP	-0.51	-4.41	-0.34	1.95e-5	Non-substance related behavioral disinhibition;
PAAD	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.58	-6.92	-0.49	1.19e-10	Total body bone mineral density;
PAAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	6.41	0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.81	9.31	0.6	1.36e-16	Lung cancer;
PAAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.3	0.4	3.99e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg23250157	chr14:64679961	SYNE2	0.5	5.2	0.39	6.45e-7	Atrial fibrillation;
PAAD	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.8	0.58	2.87e-15	Coffee consumption (cups per day);
PAAD	cis	rs375066	0.935	rs367741	chr19:44429180	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.34	0.46	2.5e-9	Breast cancer;
PAAD	cis	rs7077446	0.733	rs4919606	chr10:103743852	C/G	cg11685391	chr10:103594334	KCNIP2	-0.36	-4.37	-0.33	2.26e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs75757892	0.500	rs2714315	chr6:7229346	T/C	cg15365232	chr6:7261319	NA	0.41	4.86	0.37	2.9e-6	Hematocrit;Red blood cell count;
PAAD	cis	rs10991814	1.000	rs79093642	chr9:93985704	A/G	cg14446406	chr9:93919335	NA	0.57	4.71	0.36	5.59e-6	Neutrophil percentage of granulocytes;
PAAD	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22509189	chr2:225307070	NA	-0.48	-4.41	-0.34	1.91e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg22764639	chr12:106532701	NUAK1	0.42	4.26	0.33	3.51e-5	Total body bone mineral density;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg27346851	chr15:85177284	SCAND2	0.64	6.87	0.49	1.52e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg05250797	chr16:70222502	NA	0.82	6.26	0.45	3.75e-9	IgE levels;
PAAD	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.53	5.27	0.39	4.58e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	7.66	0.53	2.02e-12	Body mass index;
PAAD	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.55	5.25	0.39	4.98e-7	Diastolic blood pressure;
PAAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg25809561	chr17:30822961	MYO1D	0.59	6.12	0.44	7.49e-9	Schizophrenia;
PAAD	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.44	-6.53	-0.47	9.45e-10	Breast cancer;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg06567423	chr11:125462867	STT3A	0.64	7.68	0.53	1.85e-12	Metabolite levels  (X-11787);
PAAD	cis	rs6066835	0.867	rs11696900	chr20:47336967	C/A	cg18078177	chr20:47281410	PREX1	0.97	4.69	0.36	6.06e-6	Multiple myeloma;
PAAD	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.78	9.37	0.61	9.57e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.68	-7.84	-0.54	7.22e-13	Educational attainment;
PAAD	cis	rs4739066	0.579	rs76538830	chr8:63862919	C/A	cg25248160	chr8:63776642	NKAIN3	0.74	4.77	0.36	4.27e-6	Myocardial infarction;
PAAD	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg27234864	chr13:21295941	IL17D	0.63	5.48	0.41	1.76e-7	Dental caries;
PAAD	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.87	0.54	6.14e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-6.61	-0.47	6.2e-10	Lymphocyte counts;
PAAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.77	4.59	0.35	9.14e-6	Body mass index;
PAAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg15226275	chr6:116381976	FRK	0.41	7.53	0.52	4.3e-12	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg11764359	chr7:65958608	NA	0.72	4.74	0.36	4.83e-6	Diabetic kidney disease;
PAAD	cis	rs78761021	0.838	rs79352577	chr17:9788198	G/A	cg26853458	chr17:9805074	RCVRN	0.68	7.75	0.53	1.24e-12	Type 2 diabetes;
PAAD	cis	rs308971	0.656	rs307610	chr3:12064555	C/T	cg02700894	chr3:12045449	SYN2	0.62	5.24	0.39	5.33e-7	Fasting blood insulin (BMI interaction);
PAAD	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09640425	chr7:158790006	NA	-0.56	-6.45	-0.46	1.41e-9	Facial morphology (factor 20);
PAAD	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.52	-5.1	-0.38	1.01e-6	Mean corpuscular volume;
PAAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg00988841	chr10:134556463	INPP5A	0.49	4.47	0.34	1.54e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.78	5.79	0.42	3.98e-8	Initial pursuit acceleration;
PAAD	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.67	-4.36	-0.33	2.35e-5	Obesity-related traits;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04535829	chr3:49694871	BSN	-0.58	-6.48	-0.47	1.22e-9	Myopia (pathological);
PAAD	cis	rs4925386	0.819	rs2890083	chr20:60911958	G/A	cg22633769	chr20:60982531	CABLES2	-0.49	-4.99	-0.38	1.6e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9395066	0.545	rs4711805	chr6:44870102	T/C	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.51e-5	Height;
PAAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg23506979	chr15:79090958	ADAMTS7	-0.26	-4.38	-0.33	2.22e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.74	6.7	0.48	3.74e-10	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.75	-6.29	-0.45	3.24e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs1730008	0.865	rs1724727	chr3:157899727	C/T	cg01557547	chr3:157823089	SHOX2	0.4	4.25	0.33	3.75e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg26338869	chr17:61819248	STRADA	0.51	4.88	0.37	2.65e-6	Height;
PAAD	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg05895507	chr15:77155635	SCAPER	-0.4	-4.5	-0.34	1.33e-5	Blood metabolite levels;
PAAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.52	6.96	0.49	9.36e-11	Life satisfaction;
PAAD	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.62	-5.69	-0.42	6.26e-8	Psoriasis;
PAAD	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.46	-5.71	-0.42	5.87e-8	Lewy body disease;
PAAD	cis	rs2236267	0.726	rs12431598	chr14:88630812	G/A	cg18078958	chr14:88630771	NA	0.46	5.69	0.42	6.41e-8	Food antigen IgG levels;
PAAD	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg20406979	chr6:167373233	NA	0.38	4.99	0.38	1.6e-6	Crohn's disease;
PAAD	cis	rs11651753	0.561	rs17616603	chr17:45959620	T/C	cg24458315	chr17:46148407	CBX1	0.41	4.52	0.34	1.25e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
PAAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07362569	chr17:61921086	SMARCD2	0.64	7.93	0.54	4.3e-13	Prudent dietary pattern;
PAAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.74	-0.62	1.04e-17	Bipolar disorder and schizophrenia;
PAAD	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.62	-7.16	-0.5	3.15e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
PAAD	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.77	9.38	0.61	8.77e-17	Metabolite levels;
PAAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.57	-6.66	-0.48	4.63e-10	Emphysema distribution in smoking;
PAAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	5.19	0.39	6.66e-7	Personality dimensions;
PAAD	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg14393609	chr7:65229607	NA	-0.52	-4.47	-0.34	1.52e-5	Aortic root size;
PAAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-4.39	-0.34	2.1e-5	Type 2 diabetes;
PAAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.87	6.13	0.45	7.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9341808	0.529	rs9352826	chr6:81059371	C/T	cg08355045	chr6:80787529	NA	0.4	4.9	0.37	2.42e-6	Sitting height ratio;
PAAD	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg01631408	chr1:248437212	OR2T33	-0.6	-5.51	-0.41	1.53e-7	Common traits (Other);
PAAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg21929781	chr1:2537748	MMEL1	-0.54	-5.73	-0.42	5.3e-8	Multiple sclerosis;
PAAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg03538708	chr1:25844672	NA	-0.52	-5.27	-0.39	4.56e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.65	4.76	0.36	4.49e-6	Biliary atresia;
PAAD	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg03938978	chr2:103052716	IL18RAP	0.66	8.21	0.55	8.74e-14	Asthma;
PAAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	1.33	14.21	0.76	1.07e-29	Eosinophil percentage of granulocytes;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg10729496	chr3:10149963	C3orf24	0.89	7.46	0.52	6.35e-12	Alzheimer's disease;
PAAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.67	6.67	0.48	4.58e-10	Body mass index;
PAAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg00738919	chr7:1100172	C7orf50	0.6	4.59	0.35	9.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg06697600	chr4:7070879	GRPEL1	0.87	4.59	0.35	9.26e-6	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-6.92	-0.49	1.2e-10	Life satisfaction;
PAAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg25037394	chr1:24152592	HMGCL	0.43	4.72	0.36	5.24e-6	Immature fraction of reticulocytes;
PAAD	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	9.21	0.6	2.47e-16	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs7260538	0.527	rs35131519	chr19:41526144	T/C	cg27089200	chr19:41531976	NA	0.42	4.72	0.36	5.38e-6	DDT metabolite (p,p'-DDE levels);
PAAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.51	5.24	0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs1371614	0.611	rs3910615	chr2:27131022	A/G	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.6	-6.03	-0.44	1.17e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12760731	0.623	rs10798604	chr1:178254568	A/G	cg00404053	chr1:178313656	RASAL2	-0.66	-5.53	-0.41	1.34e-7	Obesity-related traits;
PAAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg21496419	chr19:44306685	LYPD5	0.52	6.48	0.47	1.18e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.5	5.04	0.38	1.32e-6	Longevity;Endometriosis;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15236460	chr22:30163365	UCRC;ZMAT5	0.63	7.19	0.5	2.71e-11	Vitiligo;Type 1 diabetes;
PAAD	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.91	-5.61	-0.41	9.47e-8	Alzheimer's disease (late onset);
PAAD	cis	rs7551345	0.853	rs56105061	chr1:31795235	A/G	cg17086398	chr1:31896392	SERINC2	-0.51	-4.38	-0.34	2.16e-5	Schizophrenia;
PAAD	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg15208524	chr1:10270712	KIF1B	0.51	4.75	0.36	4.66e-6	Hepatocellular carcinoma;
PAAD	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.32	-0.33	2.81e-5	Resting heart rate;
PAAD	cis	rs72960926	0.744	rs118054597	chr6:74873831	A/T	cg03266952	chr6:74778945	NA	-1.14	-6.74	-0.48	3.06e-10	Metabolite levels (MHPG);
PAAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.6	7.29	0.51	1.54e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13673319	chr1:174968334	CACYBP	0.64	7.38	0.51	9.65e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6466055	0.661	rs6963624	chr7:104923811	T/C	cg04380332	chr7:105027541	SRPK2	0.5	4.89	0.37	2.59e-6	Schizophrenia;
PAAD	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg19723775	chr5:179050963	HNRNPH1	0.57	4.63	0.35	7.78e-6	Lung cancer;
PAAD	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.6	5.82	0.43	3.41e-8	Parkinson's disease;
PAAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.65	7.33	0.51	1.25e-11	Hemoglobin concentration;Hematocrit;
PAAD	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.62	6.25	0.45	3.92e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9463078	0.585	rs10807320	chr6:45238442	A/G	cg18551225	chr6:44695536	NA	-0.41	-4.29	-0.33	3.11e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.49	4.58	0.35	9.57e-6	Hepatocellular carcinoma;
PAAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg17524265	chr8:144659883	NAPRT1	0.84	4.68	0.36	6.18e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7873102	0.654	rs10758463	chr9:37952230	C/T	cg03528946	chr9:38069800	SHB	0.58	5.87	0.43	2.67e-8	Brain structure;
PAAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.41	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg03395511	chr6:291903	DUSP22	-0.8	-8.66	-0.57	6.34e-15	Menopause (age at onset);
PAAD	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	6.49	0.47	1.13e-9	Educational attainment;
PAAD	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg10290764	chr8:4849399	CSMD1	0.4	6.63	0.47	5.44e-10	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	1.05	14.29	0.76	6.43e-30	Headache;
PAAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg26727032	chr16:67993705	SLC12A4	-0.73	-5.58	-0.41	1.1e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
PAAD	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	1.01	7.11	0.5	4.3e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs10044254	0.774	rs6554900	chr5:15715322	A/C	cg07238450	chr5:15720153	FBXL7	-0.54	-4.56	-0.35	1.05e-5	Asthma (corticosteroid response);
PAAD	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.58	5.39	0.4	2.61e-7	Malaria;
PAAD	cis	rs13102973	0.720	rs4473702	chr4:135851159	C/G	cg14419869	chr4:135874104	NA	0.44	4.46	0.34	1.6e-5	Subjective well-being;
PAAD	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.64	-5.8	-0.43	3.65e-8	Response to antineoplastic agents;
PAAD	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.38	4.72	0.36	5.29e-6	Metabolite levels (MHPG);
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-6.04	-0.44	1.15e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.55	-5.14	-0.38	8.44e-7	Metabolite levels (Pyroglutamine);
PAAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg03909863	chr11:638404	DRD4	-0.57	-5.25	-0.39	5.13e-7	Systemic lupus erythematosus;
PAAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12599982	chr1:44399894	ARTN	0.4	4.34	0.33	2.57e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg14393609	chr7:65229607	NA	0.6	6.39	0.46	1.89e-9	Aortic root size;
PAAD	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg23752985	chr2:85803571	VAMP8	0.56	6.26	0.45	3.77e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.61	-4.32	-0.33	2.79e-5	Hypertriglyceridemia;
PAAD	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.65	-0.47	4.94e-10	Depression;
PAAD	cis	rs2030114	1.000	rs11645446	chr16:51612943	T/C	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg06728252	chr6:26598149	ABT1	-0.38	-4.39	-0.34	2.13e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08677398	chr8:58056175	NA	0.66	4.54	0.35	1.15e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	4.43	0.34	1.83e-5	Total body bone mineral density;
PAAD	cis	rs59104589	0.583	rs12624195	chr2:242254734	G/C	cg04488487	chr2:242709673	NA	0.57	4.36	0.33	2.4e-5	Fibrinogen levels;
PAAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.61	-8.28	-0.56	6.06e-14	Intelligence (multi-trait analysis);
PAAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.12	0.55	1.47e-13	Schizophrenia;
PAAD	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.12	0.38	9.21e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7577696	0.785	rs2886393	chr2:32371562	G/C	cg02381751	chr2:32503542	YIPF4	-0.48	-4.72	-0.36	5.21e-6	Inflammatory biomarkers;
PAAD	cis	rs71520386	0.861	rs35841035	chr7:22862606	G/A	cg04907244	chr7:22894795	SNORD93	0.57	5.04	0.38	1.28e-6	Fibrinogen levels;
PAAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	6.92	0.49	1.17e-10	Systemic lupus erythematosus;
PAAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	1.24	12.11	0.7	4.81e-24	Eosinophil percentage of granulocytes;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg07355262	chr7:5347698	TNRC18	0.52	6.52	0.47	9.86e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2030114	1.000	rs2030115	chr16:51609925	G/T	cg03758633	chr16:51611768	NA	0.58	4.89	0.37	2.52e-6	Blood pressure measurement (high sodium and potassium intervention);
PAAD	cis	rs1879734	0.906	rs2141081	chr1:54138552	C/T	cg14659662	chr1:54151053	GLIS1	-0.37	-5.51	-0.41	1.49e-7	Mitral valve prolapse;
PAAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg15736062	chr7:158136485	PTPRN2	0.49	4.35	0.33	2.48e-5	Response to amphetamines;
PAAD	cis	rs3136739	0.614	rs1136159	chr8:42036577	A/G	cg12054981	chr8:42037387	PLAT	0.75	5.5	0.41	1.58e-7	Plasma plasminogen activator levels;
PAAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.66	8.11	0.55	1.58e-13	Menopause (age at onset);
PAAD	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.53	4.56	0.35	1.04e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	11.31	0.68	6.7e-22	Primary sclerosing cholangitis;
PAAD	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg13897122	chr2:103039542	IL18RAP	-0.37	-4.53	-0.35	1.17e-5	Asthma;
PAAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	4.98	0.37	1.74e-6	Hip circumference adjusted for BMI;Body mass index;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg10335376	chr7:98565129	TRRAP	-0.74	-7.54	-0.52	3.95e-12	Obesity-related traits;
PAAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-5.92	-0.43	2.05e-8	Gut microbiome composition (summer);
PAAD	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.77	7.54	0.52	3.91e-12	Birth weight;
PAAD	cis	rs12068123	1	rs12068123	chr1:8894346	G/A	cg20416874	chr1:8611966	RERE	-0.43	-4.25	-0.33	3.66e-5	Tonsillectomy;
PAAD	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg13859433	chr6:33739653	LEMD2	0.64	5.0	0.38	1.57e-6	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.69	4.88	0.37	2.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.85	9.05	0.59	6.46e-16	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6496667	0.642	rs62019394	chr15:91060730	C/T	cg22089800	chr15:90895588	ZNF774	0.6	4.5	0.34	1.36e-5	Rheumatoid arthritis;
PAAD	cis	rs13242816	1.000	rs34295495	chr7:116068266	C/A	cg16553024	chr7:116138462	CAV2	-0.7	-4.82	-0.36	3.39e-6	P wave duration;
PAAD	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-11.95	-0.7	1.29e-23	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.5	-0.34	1.34e-5	Eotaxin levels;
PAAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	8.88	0.58	1.77e-15	Homoarginine levels;
PAAD	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.64	9.17	0.6	3.09e-16	IgG glycosylation;
PAAD	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.99	0.54	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	trans	rs11212737	0.765	rs2640767	chr11:108518303	A/C	cg13462821	chr8:86214814	NA	-0.57	-6.5	-0.47	1.07e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.54	6.74	0.48	3.05e-10	Crohn's disease;
PAAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.8	8.87	0.58	1.88e-15	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12802113	chr17:56741	NA	-0.65	-6.57	-0.47	7.51e-10	Obesity-related traits;
PAAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.52	-4.88	-0.37	2.62e-6	Vitiligo;
PAAD	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg14515779	chr1:101123966	NA	-0.53	-6.62	-0.47	5.73e-10	Monocyte count;
PAAD	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg12486944	chr17:80159399	CCDC57	-0.51	-4.53	-0.35	1.18e-5	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg22517653	chr1:2918612	NA	-0.64	-5.13	-0.38	8.59e-7	Plateletcrit;
PAAD	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	7.09	0.5	4.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs1371614	0.635	rs4316900	chr2:27140342	C/T	cg00617064	chr2:27272375	NA	0.45	4.77	0.36	4.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
PAAD	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.35	-4.3	-0.33	3.08e-5	Pulmonary function;
PAAD	cis	rs863345	1.000	rs863353	chr1:158541270	C/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.84	-0.37	3.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-6.4	-0.46	1.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.63	6.6	0.47	6.62e-10	Resting heart rate;
PAAD	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.53	-7.29	-0.51	1.58e-11	Crohn's disease;
PAAD	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg25566285	chr7:158114605	PTPRN2	0.75	6.42	0.46	1.63e-9	Response to amphetamines;
PAAD	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg18551225	chr6:44695536	NA	0.74	7.47	0.52	5.88e-12	Total body bone mineral density;
PAAD	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg18939081	chr1:31884902	SERINC2	0.47	5.39	0.4	2.67e-7	Alcohol dependence;
PAAD	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.86	-9.59	-0.61	2.58e-17	Coronary artery disease;
PAAD	cis	rs3996993	0.702	rs9370150	chr6:52654244	A/G	cg20803780	chr6:52668592	GSTA1	-0.34	-4.26	-0.33	3.55e-5	Hemoglobin concentration;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10924691	chr14:21439548	NA	-0.59	-6.5	-0.47	1.11e-9	Myopia (pathological);
PAAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg12215294	chr3:40350768	EIF1B	-0.47	-4.73	-0.36	4.98e-6	Renal cell carcinoma;
PAAD	cis	rs9858542	0.597	rs56116382	chr3:49606188	A/C	cg00383909	chr3:49044727	WDR6	0.79	5.82	0.43	3.38e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23109559	chr1:236902408	ACTN2	0.61	6.62	0.47	5.8e-10	Smoking initiation;
PAAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg05961700	chr2:169937750	DHRS9	-0.64	-6.42	-0.46	1.63e-9	Primary biliary cholangitis;
PAAD	cis	rs863345	0.604	rs2873594	chr1:158504790	T/C	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg14660024	chr17:7154518	C17orf81;DULLARD	0.67	7.08	0.5	5.11e-11	Diastolic blood pressure;
PAAD	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.96	-10.89	-0.66	8.73e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg14092988	chr3:52407081	DNAH1	0.44	5.46	0.4	1.92e-7	Bipolar disorder;
PAAD	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg08917208	chr2:24149416	ATAD2B	1.18	8.34	0.56	4.24e-14	Lymphocyte counts;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26715170	chr13:114163268	TMCO3	-0.66	-7.0	-0.49	7.77e-11	Obesity-related traits;
PAAD	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg17595323	chr11:93583763	C11orf90	-0.36	-4.67	-0.35	6.55e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	7.66	0.53	2.07e-12	Lymphocyte counts;
PAAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.85	6.91	0.49	1.22e-10	Alzheimer's disease;
PAAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23977767	chr7:28230554	NA	0.65	6.95	0.49	1.01e-10	Smoking initiation;
PAAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg09163369	chr1:210001066	C1orf107	0.38	4.59	0.35	9.32e-6	Monobrow;
PAAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.93	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.42e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg04809136	chr2:24300158	SF3B14	-0.42	-4.98	-0.37	1.74e-6	Quantitative traits;
PAAD	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg14825688	chr5:132208181	LEAP2	-0.6	-4.38	-0.33	2.21e-5	Apolipoprotein A-IV levels;
PAAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg12373951	chr3:133503437	NA	-0.45	-5.62	-0.41	8.97e-8	Alcohol consumption (transferrin glycosylation);
PAAD	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.99	-9.77	-0.62	8.43e-18	Body mass index;
PAAD	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg14583973	chr4:3374767	RGS12	0.42	6.26	0.45	3.72e-9	Serum sulfate level;
PAAD	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.12	0.44	7.58e-9	Rheumatoid arthritis;
PAAD	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg18357526	chr6:26021779	HIST1H4A	0.58	4.9	0.37	2.47e-6	Iron status biomarkers;
PAAD	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg04254540	chr16:71951199	KIAA0174	-0.45	-4.27	-0.33	3.41e-5	Fibrinogen levels;
PAAD	cis	rs7580717	0.785	rs13428268	chr2:232155641	T/G	cg07929768	chr2:232055508	NA	0.49	5.5	0.41	1.57e-7	Multiple myeloma;
PAAD	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg12218747	chr21:37451666	NA	-0.55	-6.21	-0.45	4.81e-9	Mitral valve prolapse;
PAAD	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg01953289	chr20:60874239	NA	0.69	5.13	0.38	8.68e-7	Obesity-related traits;
PAAD	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg18833306	chr6:118973337	C6orf204	0.44	4.61	0.35	8.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.84	8.91	0.59	1.51e-15	Osteoporosis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg20744546	chr11:62648932	SLC3A2	-0.61	-7.27	-0.51	1.74e-11	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg01953289	chr20:60874239	NA	0.68	5.14	0.38	8.25e-7	Obesity-related traits;
PAAD	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-4.95	-0.37	1.93e-6	Bipolar disorder;
PAAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-5.1	-0.38	1.02e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg12288994	chr5:1860383	NA	0.6	7.0	0.49	7.74e-11	Cardiovascular disease risk factors;
PAAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs9916302	0.560	rs907094	chr17:37790371	G/A	cg07936489	chr17:37558343	FBXL20	-0.63	-5.4	-0.4	2.49e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-4.47	-0.34	1.53e-5	Metabolite levels;
PAAD	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-5.06	-0.38	1.18e-6	Menarche (age at onset);
PAAD	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.51	9.26e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.61	-0.35	8.44e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.48	-5.11	-0.38	9.55e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.57	6.46	0.46	1.37e-9	Platelet distribution width;
PAAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.72	10.09	0.63	1.21e-18	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg01605746	chr5:669925	TPPP	0.41	4.4	0.34	2.07e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.16	-0.39	7.67e-7	High light scatter reticulocyte count;
PAAD	cis	rs4073221	0.654	rs7373213	chr3:18298889	C/T	cg07694806	chr3:18168406	NA	-0.64	-4.68	-0.35	6.33e-6	Parkinson's disease;
PAAD	cis	rs1879734	0.593	rs56087009	chr1:54182502	A/C	cg14659662	chr1:54151053	GLIS1	-0.39	-5.41	-0.4	2.41e-7	Mitral valve prolapse;
PAAD	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.98	-8.58	-0.57	1.03e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.62	6.55	0.47	8.49e-10	Bladder cancer;
PAAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	1.04	17.45	0.82	3.97e-38	Height;
PAAD	cis	rs1190596	0.689	rs2224460	chr14:102563797	A/T	cg23289024	chr14:102554846	HSP90AA1	-0.45	-5.04	-0.38	1.31e-6	Behavioural disinhibition (generation interaction);
PAAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-5.77	-0.42	4.21e-8	Colorectal cancer;
PAAD	cis	rs4455778	0.580	rs4268080	chr7:49117682	A/G	cg26309511	chr7:48887640	NA	0.37	4.48	0.34	1.45e-5	Lung cancer in never smokers;
PAAD	cis	rs6496932	0.635	rs67659163	chr15:85930904	G/A	cg19183879	chr15:85880815	NA	-0.61	-5.7	-0.42	6.17e-8	Central corneal thickness;Corneal structure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14274759	chr2:43999864	DYNC2LI1	0.57	6.62	0.47	5.89e-10	Smoking initiation;
PAAD	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.81	-6.26	-0.45	3.74e-9	Psoriasis;
PAAD	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg13263323	chr15:86062960	AKAP13	-0.64	-7.35	-0.51	1.12e-11	Coronary artery disease;
PAAD	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-11.86	-0.69	2.25e-23	Primary sclerosing cholangitis;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01523759	chr16:89202603	ACSF3	0.65	8.01	0.54	2.75e-13	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	11.11	0.67	2.26e-21	Platelet count;
PAAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-7.2	-0.5	2.53e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.89	-7.14	-0.5	3.54e-11	Total cholesterol levels;
PAAD	cis	rs9810890	0.850	rs73196995	chr3:128458070	G/A	cg19129842	chr3:128565090	NA	-0.86	-5.43	-0.4	2.17e-7	Dental caries;
PAAD	cis	rs2980439	0.517	rs17594065	chr8:8105405	T/C	cg08975724	chr8:8085496	FLJ10661	-0.56	-5.31	-0.4	3.77e-7	Neuroticism;
PAAD	trans	rs1155865	0.562	rs10031878	chr4:67814158	C/G	cg16734191	chr21:40194848	ETS2	-0.8	-6.48	-0.47	1.18e-9	Cognitive test performance;
PAAD	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	5.8	0.43	3.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg05313129	chr8:58192883	C8orf71	-0.44	-4.26	-0.33	3.54e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg00806126	chr19:22604979	ZNF98	-0.42	-5.33	-0.4	3.52e-7	Pain;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21242327	chr4:57829539	C4orf14	0.69	8.01	0.54	2.83e-13	Smoking initiation;
PAAD	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.47	4.73	0.36	5e-6	Coronary artery disease;
PAAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg04287289	chr16:89883240	FANCA	0.92	4.63	0.35	7.67e-6	Skin colour saturation;
PAAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-5.65	-0.42	7.82e-8	Schizophrenia;
PAAD	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-4.36	-0.33	2.38e-5	Resting heart rate;
PAAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg04160749	chr8:58172571	NA	-0.69	-4.69	-0.36	6.15e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.49	7.08	0.5	5.07e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-4.41	-0.34	1.98e-5	Alzheimer's disease;
PAAD	cis	rs8016982	0.611	rs11159493	chr14:81639159	A/T	cg01989461	chr14:81687754	GTF2A1	0.85	9.2	0.6	2.55e-16	Schizophrenia;
PAAD	cis	rs4443100	0.917	rs5996460	chr22:23393090	G/A	cg14186256	chr22:23484241	RTDR1	0.53	4.64	0.35	7.38e-6	Serum parathyroid hormone levels;
PAAD	cis	rs2070997	0.607	rs2314342	chr9:133707362	A/G	cg11464064	chr9:133710261	ABL1	0.61	4.26	0.33	3.57e-5	Response to amphetamines;
PAAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.37	4.42	0.34	1.86e-5	Schizophrenia;
PAAD	cis	rs9674544	0.556	rs9890278	chr17:47073949	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.55	-6.27	-0.45	3.57e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
PAAD	cis	rs6963495	0.818	rs1721500	chr7:105219233	T/G	cg02135003	chr7:105160482	PUS7	-0.83	-6.64	-0.47	5.21e-10	Bipolar disorder (body mass index interaction);
PAAD	cis	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg21546286	chr11:48923668	NA	-0.53	-5.44	-0.4	2.09e-7	HDL cholesterol;
PAAD	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.44	-5.0	-0.38	1.54e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.94	-0.37	2.06e-6	Triglycerides;
PAAD	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.84	-9.43	-0.61	6.43e-17	Type 2 diabetes;
PAAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-8.16	-0.55	1.16e-13	Longevity;Endometriosis;
PAAD	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg14343924	chr8:8086146	FLJ10661	0.49	4.54	0.35	1.13e-5	Mood instability;
PAAD	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.57	4.99	0.38	1.64e-6	Life satisfaction;
PAAD	cis	rs950880	0.710	rs3821204	chr2:102960281	C/G	cg23450938	chr2:102972792	NA	0.44	4.65	0.35	7.18e-6	Serum protein levels (sST2);
PAAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg19223190	chr17:80058835	NA	0.53	5.53	0.41	1.39e-7	Life satisfaction;
PAAD	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg02380750	chr20:61661411	NA	0.38	4.47	0.34	1.53e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.56	-4.65	-0.35	7.19e-6	Cocaine dependence;
PAAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.87	9.29	0.6	1.53e-16	Menopause (age at onset);
PAAD	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-5.38	-0.4	2.71e-7	Educational attainment;
PAAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22482690	chr17:47019901	SNF8	0.49	5.25	0.39	5.01e-7	Type 2 diabetes;
PAAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg03538708	chr1:25844672	NA	0.48	4.95	0.37	1.97e-6	Erythrocyte sedimentation rate;
PAAD	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg00536532	chr6:33561449	C6orf227	-0.4	-4.28	-0.33	3.27e-5	Plateletcrit;
PAAD	trans	rs901683	0.850	rs76849715	chr10:46080433	G/A	cg11747279	chr17:21096632	NA	0.9	6.5	0.47	1.08e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.66	6.87	0.49	1.52e-10	Schizophrenia;
PAAD	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.73	8.12	0.55	1.44e-13	Colorectal cancer;
PAAD	cis	rs7651511	1.000	rs9830055	chr3:141268822	G/A	cg25967872	chr3:141205623	RASA2	0.5	4.52	0.34	1.23e-5	Mean corpuscular hemoglobin;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg20112330	chr15:55700431	CCPG1	0.61	6.3	0.46	3.06e-9	Myopia (pathological);
PAAD	cis	rs1957429	0.614	rs79411360	chr14:65378856	T/C	cg23373153	chr14:65346875	NA	-1.45	-6.73	-0.48	3.24e-10	Pediatric areal bone mineral density (radius);
PAAD	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.8	-9.07	-0.59	5.75e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.3	4.47	0.34	1.52e-5	Alopecia areata;
PAAD	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.67	6.69	0.48	4.04e-10	Menopause (age at onset);
PAAD	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	7.48	0.52	5.54e-12	Nonalcoholic fatty liver disease;
PAAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg05025164	chr4:1340916	KIAA1530	0.51	4.95	0.37	1.93e-6	Obesity-related traits;
PAAD	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg14137381	chr5:502291	SLC9A3	0.43	4.3	0.33	3.04e-5	Lung disease severity in cystic fibrosis;
PAAD	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	5.26	0.39	4.77e-7	Menarche (age at onset);
PAAD	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	1.09	7.15	0.5	3.47e-11	Post bronchodilator FEV1;
PAAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.7	-7.94	-0.54	4.08e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg03983476	chr2:10830698	NOL10	0.53	5.36	0.4	2.99e-7	Prostate cancer;
PAAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.46	-5.91	-0.43	2.2e-8	Multiple sclerosis;
PAAD	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.82	5.25	0.39	4.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
PAAD	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.58	0.65	5.91e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3136441	1.000	rs1799867	chr11:46747979	T/C	cg19486271	chr11:47235900	DDB2	0.64	4.89	0.37	2.56e-6	HDL cholesterol;
PAAD	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.88	7.55	0.52	3.74e-12	Triglycerides;
PAAD	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.5	5.33	0.4	3.55e-7	Carotid intima media thickness;
PAAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.43	-0.4	2.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-1.23	-12.24	-0.7	2.14e-24	Developmental language disorder (linguistic errors);
PAAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.64	7.14	0.5	3.6e-11	Height;
PAAD	cis	rs287982	1.000	rs287979	chr2:9970967	T/C	cg01119585	chr2:10571959	NA	-0.38	-4.39	-0.34	2.08e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.49	4.55	0.35	1.09e-5	Renal cell carcinoma;
PAAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.99	7.69	0.53	1.67e-12	Initial pursuit acceleration;
PAAD	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg11905131	chr22:24372483	LOC391322	-0.63	-5.94	-0.43	1.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.73	-6.95	-0.49	9.86e-11	Corneal astigmatism;
PAAD	cis	rs58521262	0.556	rs1908942	chr19:23184109	A/G	cg03433597	chr19:22806448	NA	0.24	4.33	0.33	2.71e-5	Testicular germ cell tumor;
PAAD	cis	rs12893597	0.715	rs12896100	chr14:76825064	C/T	cg20290672	chr14:76816747	NA	-0.59	-4.94	-0.37	2.01e-6	Maximal oxygen uptake response;
PAAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.89	11.04	0.67	3.62e-21	Coronary artery disease;
PAAD	cis	rs621942	0.635	rs12786057	chr11:85858417	C/T	cg07180834	chr11:85838833	NA	-0.44	-4.71	-0.36	5.65e-6	Tourette syndrome;
PAAD	cis	rs7119038	0.509	rs11216961	chr11:118580338	C/G	cg08498647	chr11:118550644	TREH	0.4	4.43	0.34	1.81e-5	Sjögren's syndrome;
PAAD	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.86	8.93	0.59	1.32e-15	Lymphocyte counts;
PAAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.87	-0.43	2.64e-8	Mood instability;
PAAD	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.41	5.1	0.38	9.95e-7	Electrocardiographic conduction measures;
PAAD	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.96	11.61	0.69	1.01e-22	Breast cancer;
PAAD	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg10589385	chr1:150898437	SETDB1	-0.39	-4.27	-0.33	3.44e-5	Urate levels;
PAAD	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.62	-5.5	-0.41	1.61e-7	Type 2 diabetes;
PAAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.97	8.17	0.55	1.13e-13	Type 2 diabetes;
PAAD	cis	rs288342	0.832	rs825660	chr2:183597318	A/G	cg02625481	chr2:183667124	NA	-0.44	-4.42	-0.34	1.86e-5	Recurrent major depressive disorder;
PAAD	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.84	-8.39	-0.56	3.08e-14	Mean corpuscular hemoglobin;
PAAD	cis	rs9992101	0.547	rs4318673	chr4:77412338	A/T	cg20311846	chr4:77356250	SHROOM3	-0.36	-4.54	-0.35	1.13e-5	Creatinine levels;
PAAD	cis	rs11853189	0.882	rs78827644	chr15:78556250	G/A	cg22935921	chr15:78556834	DNAJA4	0.72	4.95	0.37	1.95e-6	Red cell distribution width;
PAAD	cis	rs950037	0.710	rs10801687	chr1:89307261	G/A	cg13109106	chr1:89333529	GTF2B	0.47	4.39	0.34	2.07e-5	Coronary artery disease;
PAAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg13870426	chr17:30244630	NA	-0.73	-6.57	-0.47	7.49e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg26031613	chr14:104095156	KLC1	-0.57	-5.78	-0.42	4.12e-8	Reticulocyte count;
PAAD	cis	rs2340727	0.668	rs114341500	chr1:161819499	A/G	cg25597117	chr1:161349116	NA	-0.6	-4.26	-0.33	3.59e-5	White blood cell count;Hematology traits;
PAAD	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.59	6.11	0.44	7.87e-9	Body mass index;
PAAD	cis	rs6547631	0.594	rs12620113	chr2:85936833	G/T	cg24620635	chr2:85921963	GNLY	0.41	5.25	0.39	5.08e-7	Blood protein levels;
PAAD	cis	rs16958440	0.867	rs16949157	chr18:44691324	A/G	cg17192377	chr18:44677553	HDHD2	1.01	5.4	0.4	2.5e-7	Sitting height ratio;
PAAD	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.57	-5.47	-0.41	1.84e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg13320842	chr19:46175254	GIPR	-0.55	-4.76	-0.36	4.4e-6	Eosinophil counts;
PAAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg19337854	chr7:99768885	GPC2	0.52	4.91	0.37	2.36e-6	Platelet count;
PAAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03909863	chr11:638404	DRD4	-0.66	-5.72	-0.42	5.53e-8	Systemic lupus erythematosus;
PAAD	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.66	5.26	0.39	4.74e-7	Breast cancer;
PAAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-7.63	-0.53	2.37e-12	Height;
PAAD	cis	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg05299278	chr17:33885742	SLFN14	0.43	5.08	0.38	1.08e-6	Response to radiotherapy in cancer (late toxicity);
PAAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.46	-7.5	-0.52	5.03e-12	Mean corpuscular volume;
PAAD	cis	rs111342015	0.667	rs76187039	chr6:43233990	G/T	cg17076780	chr6:43251928	TTBK1	0.59	4.89	0.37	2.49e-6	Breast cancer;
PAAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-7.45	-0.52	6.43e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.44	6.93	0.49	1.1e-10	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs2637266	0.655	rs10824436	chr10:78457848	T/C	cg18941641	chr10:78392320	NA	0.36	4.38	0.33	2.19e-5	Pulmonary function;
PAAD	cis	rs6987853	0.933	rs2923424	chr8:42382222	A/G	cg09913449	chr8:42400586	C8orf40	-0.48	-5.14	-0.38	8.27e-7	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs7932354	0.583	rs10769211	chr11:46872873	G/A	cg19486271	chr11:47235900	DDB2	-0.56	-5.5	-0.41	1.54e-7	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg01388757	chr2:102091195	RFX8	-0.62	-7.86	-0.54	6.53e-13	Chronic rhinosinusitis with nasal polyps;
PAAD	cis	rs11696501	0.637	rs3746596	chr20:44312028	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.58	-0.47	7.34e-10	Brain structure;
PAAD	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.25	18.2	0.83	5.1e-40	Schizophrenia;
PAAD	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg03260790	chr12:56211718	ORMDL2;SARNP	-0.66	-6.6	-0.47	6.33e-10	Primary biliary cholangitis;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06538660	chr2:202645935	ALS2	-0.63	-7.04	-0.5	6.17e-11	Smoking initiation;
PAAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.74	-9.19	-0.6	2.77e-16	Bone mineral density;
PAAD	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg08917208	chr2:24149416	ATAD2B	0.5	4.47	0.34	1.5e-5	Asthma;
PAAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg05564831	chr3:52568323	NT5DC2	0.46	4.92	0.37	2.25e-6	Bipolar disorder;
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg19761014	chr17:28927070	LRRC37B2	0.91	6.24	0.45	4.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.72	-5.45	-0.4	1.97e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.57	5.9	0.43	2.28e-8	Tonsillectomy;
PAAD	cis	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg21546286	chr11:48923668	NA	-0.56	-5.92	-0.43	2.11e-8	HDL cholesterol;
PAAD	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.95	-12.96	-0.72	2.43e-26	Height;
PAAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg04106633	chr4:1044584	NA	0.53	4.91	0.37	2.37e-6	Recombination rate (males);
PAAD	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.84	-7.9	-0.54	5.3e-13	Body mass index;
PAAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.87	-7.23	-0.51	2.23e-11	Initial pursuit acceleration;
PAAD	cis	rs1015291	0.708	rs1492115	chr12:19995164	T/C	cg25401612	chr12:20009446	NA	-0.55	-5.48	-0.41	1.76e-7	Diastolic blood pressure;
PAAD	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg16606324	chr3:10149918	C3orf24	0.57	4.81	0.36	3.53e-6	Alzheimer's disease;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12647142	chr7:26240901	CBX3;HNRNPA2B1	-0.8	-6.81	-0.48	2.12e-10	Neuroticism;
PAAD	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg19582115	chr14:103436037	CDC42BPB	-0.48	-4.54	-0.35	1.13e-5	Blood metabolite levels;
PAAD	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.02	12.5	0.71	4.16e-25	Cognitive ability;
PAAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-4.89	-0.37	2.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18404600	chr2:71295360	NAGK	-0.79	-6.91	-0.49	1.24e-10	Neuroticism;
PAAD	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg23024343	chr7:107201750	COG5	0.57	4.39	0.34	2.13e-5	Coronary artery disease;
PAAD	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.99	8.29	0.56	5.45e-14	Dupuytren's disease;
PAAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.81	-0.48	2.11e-10	Breast cancer;
PAAD	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.58	-5.58	-0.41	1.09e-7	Blood protein levels;
PAAD	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	13.02	0.73	1.65e-26	Platelet count;
PAAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.5	4.64	0.35	7.37e-6	Monocyte count;
PAAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-5.78	-0.42	4.19e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs2882667	0.690	rs891996	chr5:138267816	A/G	cg09476006	chr5:138032270	NA	0.44	5.44	0.4	2.09e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.59	5.79	0.43	3.88e-8	Acylcarnitine levels;
PAAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22601191	chr20:60968625	CABLES2	0.51	4.67	0.35	6.44e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Coronary artery disease;
PAAD	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.82	-8.93	-0.59	1.33e-15	Mortality in heart failure;
PAAD	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.7	6.94	0.49	1.06e-10	Total body bone mineral density;
PAAD	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.74	5.27	0.39	4.53e-7	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.64	-7.13	-0.5	3.85e-11	Diastolic blood pressure;
PAAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	5.6	0.41	9.61e-8	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg16606324	chr3:10149918	C3orf24	0.8	6.26	0.45	3.66e-9	Alzheimer's disease;
PAAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg27490568	chr2:178487706	NA	0.4	4.33	0.33	2.69e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	4.78	0.36	4.04e-6	Breast cancer;
PAAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-5.29	-0.39	4.13e-7	Testicular germ cell tumor;
PAAD	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg14458575	chr2:238380390	NA	0.47	4.27	0.33	3.44e-5	Prostate cancer;
PAAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg10578991	chr7:12443926	VWDE	-0.5	-4.38	-0.33	2.17e-5	Coronary artery disease;
PAAD	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg09659197	chr4:152720779	NA	0.41	5.22	0.39	5.81e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs847851	0.958	rs7753949	chr6:34882394	C/T	cg13196216	chr6:34231128	NA	-0.6	-4.9	-0.37	2.39e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs3112530	0.792	rs2926287	chr5:152647818	G/A	cg20435608	chr5:153418426	MFAP3;FAM114A2	0.94	5.25	0.39	5.1e-7	Aging (time to event);
PAAD	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.73	7.93	0.54	4.51e-13	Schizophrenia;
PAAD	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.62	6.72	0.48	3.46e-10	Height;
PAAD	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg02389323	chr16:88786976	FAM38A	0.89	4.73	0.36	5.14e-6	Plateletcrit;
PAAD	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg09744151	chr20:37058415	LOC388796;SNORA71C	-0.63	-4.71	-0.36	5.62e-6	Alcohol and nicotine co-dependence;
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg05784532	chr1:230284198	GALNT2	0.68	5.92	0.43	2.08e-8	Coronary artery disease;
PAAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg05082376	chr22:42548792	NA	-0.53	-5.75	-0.42	4.68e-8	Cognitive function;
PAAD	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.57	5.81	0.43	3.6e-8	Testicular germ cell tumor;
PAAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg14709524	chr16:89940631	TCF25	0.87	4.6	0.35	8.74e-6	Skin colour saturation;
PAAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13198984	chr17:80129470	CCDC57	-0.43	-5.36	-0.4	3e-7	Life satisfaction;
PAAD	cis	rs35160687	0.623	rs4832263	chr2:86485157	G/T	cg10973622	chr2:86423274	IMMT	-0.49	-5.68	-0.42	6.76e-8	Night sleep phenotypes;
PAAD	cis	rs9395066	0.545	rs10948193	chr6:44949176	G/A	cg18551225	chr6:44695536	NA	-0.43	-4.47	-0.34	1.53e-5	Height;
PAAD	cis	rs12541635	0.934	rs2029882	chr8:107022894	G/A	cg10147462	chr8:107024639	NA	0.47	4.83	0.36	3.35e-6	Age of smoking initiation;
PAAD	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.13	7.01	0.49	7.39e-11	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg14092988	chr3:52407081	DNAH1	0.43	5.36	0.4	3.03e-7	Bipolar disorder;
PAAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.63	-5.61	-0.41	9.12e-8	Response to metformin (IC50);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14544999	chr19:56740672	ZSCAN5A	-0.55	-6.45	-0.46	1.42e-9	Monocyte percentage of white cells;
PAAD	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.33	0.4	3.41e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg19129842	chr3:128565090	NA	-0.74	-4.5	-0.34	1.33e-5	Dental caries;
PAAD	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg19217778	chr13:113420270	ATP11A	0.63	4.37	0.33	2.33e-5	Glycated hemoglobin levels;
PAAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-7.62	-0.53	2.48e-12	Developmental language disorder (linguistic errors);
PAAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12165864	chr7:66369176	NA	-0.85	-5.62	-0.41	8.86e-8	Diabetic kidney disease;
PAAD	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.7	-7.22	-0.51	2.38e-11	Morning vs. evening chronotype;
PAAD	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	4.99	0.37	1.66e-6	Axial length;
PAAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.28	-0.33	3.3e-5	Life satisfaction;
PAAD	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.38	4.26	0.33	3.52e-5	IgG glycosylation;
PAAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.68	7.38	0.51	9.78e-12	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.66	-6.02	-0.44	1.23e-8	Lung cancer;
PAAD	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.87e-17	Chronic sinus infection;
PAAD	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	9.76	0.62	8.82e-18	Ulcerative colitis;
PAAD	cis	rs11807834	0.522	rs11122314	chr1:230236011	C/T	cg09847368	chr1:230250326	GALNT2	-0.66	-8.12	-0.55	1.49e-13	Schizophrenia;
PAAD	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.91	8.99	0.59	9e-16	Hip circumference adjusted for BMI;
PAAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.79	-8.22	-0.55	8.43e-14	Cleft lip with or without cleft palate;
PAAD	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.57	-4.66	-0.35	6.74e-6	Facial morphology (factor 19);
PAAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg21496419	chr19:44306685	LYPD5	0.48	6.05	0.44	1.09e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
PAAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-6.29	-0.45	3.21e-9	Bipolar disorder;
PAAD	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-5.59	-0.41	1.02e-7	QT interval;
PAAD	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg06241208	chr11:30344200	C11orf46	-0.49	-4.42	-0.34	1.87e-5	Morning vs. evening chronotype;
PAAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.78	-8.49	-0.57	1.7e-14	Bipolar disorder and schizophrenia;
PAAD	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	0.86	5.36	0.4	3.07e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs7714584	1.000	rs7709650	chr5:150246685	C/T	cg22134413	chr5:150180641	NA	0.78	5.48	0.41	1.7e-7	Crohn's disease;
PAAD	cis	rs1018697	1.000	rs1018696	chr10:104549066	A/G	cg14489801	chr10:103603810	KCNIP2	-0.29	-4.32	-0.33	2.81e-5	Colorectal adenoma (advanced);
PAAD	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg22256960	chr15:77711686	NA	-0.53	-4.25	-0.33	3.77e-5	Type 2 diabetes;
PAAD	cis	rs2579500	0.538	rs17634791	chr2:97328852	C/T	cg09304357	chr2:97220596	NA	-0.41	-4.5	-0.34	1.35e-5	Eosinophil counts;Eosinophil percentage of white cells;
PAAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg11143131	chr5:131608246	PDLIM4	0.46	4.27	0.33	3.37e-5	Breast cancer;
PAAD	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.56	-4.8	-0.36	3.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs78761021	0.867	rs74449008	chr17:9782376	C/T	cg26853458	chr17:9805074	RCVRN	0.69	7.94	0.54	4.12e-13	Type 2 diabetes;
PAAD	cis	rs735539	0.555	rs2922799	chr13:21302347	C/T	cg27234864	chr13:21295941	IL17D	0.59	4.89	0.37	2.59e-6	Dental caries;
PAAD	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg12595281	chr15:93633172	RGMA	0.41	5.1	0.38	9.88e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
PAAD	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.63	5.98	0.44	1.54e-8	Fractional excretion of uric acid;
PAAD	cis	rs77633900	0.772	rs506000	chr15:76817788	T/C	cg21673338	chr15:77095150	SCAPER	-0.83	-4.39	-0.34	2.08e-5	Non-glioblastoma glioma;Glioma;
PAAD	cis	rs920590	0.560	rs3758061	chr8:19674033	C/T	cg03894339	chr8:19674705	INTS10	-0.47	-4.49	-0.34	1.41e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.75	8.23	0.56	8.03e-14	Schizophrenia;
PAAD	cis	rs6539288	0.674	rs4964494	chr12:107284460	A/G	cg15890332	chr12:107067104	RFX4	0.39	4.36	0.33	2.34e-5	Total body bone mineral density;
PAAD	trans	rs901683	1.000	rs35294227	chr10:46006798	G/A	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	trans	rs656319	0.729	rs471480	chr8:9812462	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.94	-0.49	1.05e-10	Myopia (pathological);
PAAD	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.85	-5.63	-0.42	8.49e-8	Total cholesterol levels;
PAAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-6.16	-0.45	6.24e-9	Electroencephalogram traits;
PAAD	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-5.07	-0.38	1.16e-6	Osteoarthritis;
PAAD	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg12963866	chr19:57752005	ZNF805	-0.46	-4.47	-0.34	1.51e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg00031303	chr3:195681400	NA	0.55	5.57	0.41	1.12e-7	Bronchopulmonary dysplasia;
PAAD	trans	rs901683	0.850	rs12098366	chr10:46091616	G/A	cg13065504	chr15:42448234	PLA2G4F	0.81	6.5	0.47	1.07e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.46	-4.34	-0.33	2.58e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
PAAD	cis	rs4417704	0.551	rs4430951	chr2:241894333	G/A	cg26818257	chr2:241905806	NA	0.51	5.27	0.39	4.7e-7	Joint mobility (Beighton score);
PAAD	cis	rs2882667	0.659	rs311595	chr5:138071872	T/C	cg09476006	chr5:138032270	NA	0.5	6.51	0.47	1.05e-9	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg07395648	chr5:131743802	NA	0.51	4.4	0.34	2.06e-5	Asthma (sex interaction);
PAAD	cis	rs12612619	0.732	rs7585410	chr2:27202120	A/G	cg00617064	chr2:27272375	NA	-0.45	-4.8	-0.36	3.78e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg02877808	chr22:24236438	MIF	0.6	6.69	0.48	4.05e-10	Monocyte percentage of white cells;
PAAD	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.62	6.61	0.47	6.16e-10	Crohn's disease;
PAAD	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.82	7.97	0.54	3.53e-13	Corneal astigmatism;
PAAD	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg10208897	chr5:178548229	ADAMTS2	0.54	4.82	0.36	3.46e-6	Pubertal anthropometrics;
PAAD	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	5.13	0.38	8.59e-7	Mean platelet volume;
PAAD	cis	rs3747547	1.000	rs11790880	chr9:37918219	A/T	cg13774184	chr9:37916125	SHB	-0.66	-4.64	-0.35	7.58e-6	Metabolite levels (Dihydroxy docosatrienoic acid);
PAAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg05785598	chr3:49045655	WDR6	0.42	4.99	0.38	1.62e-6	Parkinson's disease;
PAAD	cis	rs564309	0.510	rs1188478	chr1:228614692	C/T	cg00655913	chr1:228633920	NA	0.57	4.54	0.35	1.16e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs72827839	0.846	rs72823591	chr17:46122628	C/T	cg23391107	chr17:45924227	SP6	0.6	5.24	0.39	5.33e-7	Ease of getting up in the morning;
PAAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.75	-7.83	-0.54	7.67e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
PAAD	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17467752	chr17:38218738	THRA	-0.53	-4.77	-0.36	4.36e-6	White blood cell count;
PAAD	cis	rs375066	0.935	rs448823	chr19:44406291	T/C	cg11993925	chr19:44307056	LYPD5	0.49	6.46	0.46	1.31e-9	Breast cancer;
PAAD	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.56	4.84	0.37	3.17e-6	Mean corpuscular hemoglobin;
PAAD	cis	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.55	-0.47	8.23e-10	Brain structure;
PAAD	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg08601574	chr20:25228251	PYGB	0.63	6.85	0.49	1.76e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.05	0.38	1.27e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7009516	0.819	rs13257101	chr8:24223583	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.47	-5.63	-0.42	8.56e-8	Hair greying;
PAAD	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-1.17	-8.15	-0.55	1.23e-13	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.49	-4.66	-0.35	6.76e-6	Breast cancer;
PAAD	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.25	-0.39	4.98e-7	Glomerular filtration rate;
PAAD	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.51	-4.68	-0.36	6.2e-6	Schizophrenia;
PAAD	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg26942532	chr7:75678159	MDH2;STYXL1	-0.52	-4.58	-0.35	9.58e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.76	-8.15	-0.55	1.25e-13	DNA methylation (variation);
PAAD	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.46	4.93	0.37	2.09e-6	Age of smoking initiation;
PAAD	cis	rs7487075	0.619	rs2131371	chr12:46796522	A/C	cg14671384	chr12:47219920	SLC38A4	0.44	4.31	0.33	2.88e-5	Itch intensity from mosquito bite;
PAAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.96	-0.44	1.7e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2652834	1.000	rs2729788	chr15:63400378	G/C	cg05507819	chr15:63340323	TPM1	0.72	4.76	0.36	4.4e-6	HDL cholesterol;
PAAD	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg23387401	chr17:4582204	PELP1	-0.49	-4.84	-0.37	3.18e-6	Lymphocyte counts;
PAAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.48	-0.34	1.45e-5	Iron status biomarkers;
PAAD	cis	rs8060686	0.858	rs56071820	chr16:67712018	A/G	cg05110241	chr16:68378359	PRMT7	-0.73	-5.12	-0.38	9.19e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.15	-0.6	3.45e-16	Response to antipsychotic treatment;
PAAD	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.23	21.97	0.87	5e-49	Testicular germ cell tumor;
PAAD	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.57	5.56	0.41	1.19e-7	Systemic lupus erythematosus;
PAAD	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.79	10.64	0.65	4.04e-20	Cancer;
PAAD	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-5.01	-0.38	1.47e-6	Coronary artery disease;
PAAD	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.61	5.85	0.43	2.91e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.9	9.57	0.61	2.85e-17	Systemic lupus erythematosus;
PAAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.47	4.98	0.37	1.72e-6	Breast cancer;Mosquito bite size;
PAAD	trans	rs12786942	1.000	rs12806241	chr11:101361028	G/C	cg19874726	chr14:61114476	SIX1	-0.84	-6.29	-0.45	3.22e-9	Facial depth;
PAAD	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.69	6.84	0.49	1.81e-10	Cancer;
PAAD	cis	rs10768122	0.966	rs3794091	chr11:35317353	A/G	cg13971030	chr11:35366721	SLC1A2	-0.37	-4.44	-0.34	1.75e-5	Vitiligo;
PAAD	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.61	-6.25	-0.45	3.97e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.41	4.56	0.35	1.05e-5	Schizophrenia;
PAAD	cis	rs2790216	0.950	rs2790177	chr10:60032735	G/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.68	0.42	6.78e-8	Tonsillectomy;
PAAD	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.64	6.56	0.47	7.91e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.95	9.78	0.62	8.12e-18	Corneal astigmatism;
PAAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.27	-0.45	3.49e-9	Mood instability;
PAAD	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-5.59	-0.41	1.02e-7	Intelligence;
PAAD	cis	rs17227506	0.679	rs67768235	chr8:13443286	T/C	cg02718516	chr8:13424094	C8orf48	-0.32	-4.33	-0.33	2.66e-5	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	5.33	0.4	3.54e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.47	4.61	0.35	8.59e-6	Interstitial lung disease;
PAAD	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-8.21	-0.55	8.64e-14	Cognitive function;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04400110	chr19:7198500	INSR	-0.8	-6.94	-0.49	1.06e-10	Neuroticism;
PAAD	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg08601574	chr20:25228251	PYGB	0.65	7.22	0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.07	0.38	1.17e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.45	0.61	5.92e-17	Rheumatoid arthritis;
PAAD	cis	rs6499244	0.530	rs11075738	chr16:69836125	T/C	cg00738113	chr16:70207722	CLEC18C	-0.4	-4.25	-0.33	3.74e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08219700	chr8:58056026	NA	0.71	5.66	0.42	7.49e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg03989125	chr22:38214979	NA	-0.51	-4.88	-0.37	2.67e-6	Glioblastoma;Glioma;
PAAD	cis	rs251130	0.915	rs251132	chr5:110859701	C/A	cg11925263	chr5:110849104	STARD4	0.37	4.52	0.34	1.25e-5	Menarche (age at onset);
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg14709524	chr16:89940631	TCF25	0.74	4.37	0.33	2.33e-5	Skin colour saturation;
PAAD	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	5.71	0.42	5.67e-8	Lung cancer in ever smokers;
PAAD	cis	rs3779195	0.524	rs76976120	chr7:97894172	C/G	cg21770322	chr7:97807741	LMTK2	-0.55	-4.52	-0.34	1.24e-5	Sex hormone-binding globulin levels;
PAAD	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	1.98	11.74	0.69	4.64e-23	Cannabis dependence symptom count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14385961	chr6:42952270	PPP2R5D	0.63	6.5	0.47	1.1e-9	Obesity-related traits;
PAAD	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	6.09	0.44	8.98e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs112990264	0.772	rs6540755	chr1:212878809	A/T	cg01785514	chr1:212988523	TATDN3	-1.14	-7.25	-0.51	2e-11	Itch intensity from mosquito bite;
PAAD	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.67	5.59	0.41	1.04e-7	Alzheimer's disease;
PAAD	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	4.53	0.35	1.16e-5	Schizophrenia;
PAAD	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	1.04	8.98	0.59	9.92e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs901683	1.000	rs74411575	chr10:46071967	A/T	cg23720331	chr10:123873670	TACC2	-0.86	-6.52	-0.47	9.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs9463078	0.546	rs1284988	chr6:45064772	G/A	cg25276700	chr6:44698697	NA	-0.46	-5.19	-0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-12.53	-0.71	3.47e-25	Primary sclerosing cholangitis;
PAAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.75	5.77	0.42	4.3e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs35160687	0.644	rs36079379	chr2:86545960	A/G	cg10973622	chr2:86423274	IMMT	-0.46	-5.09	-0.38	1.05e-6	Night sleep phenotypes;
PAAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.5	5.0	0.38	1.58e-6	Menopause (age at onset);
PAAD	cis	rs4704187	0.687	rs1422698	chr5:74443132	C/T	cg03227963	chr5:74354835	NA	0.5	4.91	0.37	2.33e-6	Response to amphetamines;
PAAD	cis	rs12304921	0.513	rs3751275	chr12:51518787	C/G	cg18059802	chr12:51347058	HIGD1C	0.57	4.37	0.33	2.26e-5	Type 2 diabetes;
PAAD	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.66	7.2	0.5	2.53e-11	Aortic root size;
PAAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.48e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.37	5.02	0.38	1.45e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23220623	chr17:79819037	P4HB	0.63	6.42	0.46	1.65e-9	Obesity-related traits;
PAAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.44	-4.35	-0.33	2.5e-5	Body mass index;
PAAD	cis	rs858239	0.614	rs10229956	chr7:23402936	C/G	cg27449745	chr7:23145252	KLHL7	0.51	4.62	0.35	7.96e-6	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10819733	chr22:24237672	NA	-0.5	-5.13	-0.38	8.88e-7	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg15693483	chr7:1102177	C7orf50	0.43	4.75	0.36	4.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg23281280	chr6:28129359	ZNF389	0.5	4.44	0.34	1.69e-5	Parkinson's disease;
PAAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.68	-5.35	-0.4	3.25e-7	Bronchopulmonary dysplasia;
PAAD	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg21171335	chr12:122356390	WDR66	-0.5	-4.96	-0.37	1.83e-6	Mean corpuscular volume;
PAAD	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.59	6.9	0.49	1.29e-10	Aortic root size;
PAAD	cis	rs1998418	0.866	rs7894089	chr10:126419153	T/C	cg04944537	chr10:125428817	GPR26	0.54	4.84	0.37	3.2e-6	Mean platelet volume;
PAAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg18209359	chr17:80159595	CCDC57	0.43	4.3	0.33	3.09e-5	Life satisfaction;
PAAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.32	5.83	0.43	3.19e-8	Skin colour saturation;
PAAD	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.72	6.98	0.49	8.73e-11	Coronary artery disease;
PAAD	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg20913747	chr6:44695427	NA	-0.71	-6.74	-0.48	3.09e-10	Total body bone mineral density;
PAAD	cis	rs9401295	0.641	rs7761172	chr6:98284050	T/G	cg00987395	chr6:98934664	NA	0.38	4.57	0.35	9.98e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.6	-6.41	-0.46	1.71e-9	Cognitive function;
PAAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	6.17	0.45	5.97e-9	Systolic blood pressure;
PAAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg19630374	chr17:18023558	MYO15A	-0.56	-6.04	-0.44	1.12e-8	Total body bone mineral density;
PAAD	cis	rs1419980	0.730	rs58468804	chr12:7767820	C/A	cg25828445	chr12:7781288	NA	-0.83	-4.29	-0.33	3.21e-5	HDL cholesterol levels;
PAAD	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.74	-5.06	-0.38	1.18e-6	HDL cholesterol levels;
PAAD	cis	rs3737883	1.000	rs11579558	chr1:203032038	G/T	cg03900565	chr1:203031815	PPFIA4	0.34	5.59	0.41	1.04e-7	Early onset atrial fibrillation;
PAAD	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.36	-0.46	2.19e-9	Triglycerides;
PAAD	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.69	4.89	0.37	2.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs300774	0.925	rs447775	chr2:106413	T/A	cg23649280	chr2:140451	NA	-0.54	-4.89	-0.37	2.5e-6	Suicide attempts in bipolar disorder;
PAAD	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg26205652	chr12:48591994	NA	0.45	4.33	0.33	2.7e-5	Plateletcrit;
PAAD	cis	rs9616064	0.678	rs6008916	chr22:46967630	A/G	cg03318428	chr22:46971703	NA	0.4	4.6	0.35	8.7e-6	Urate levels in obese individuals;
PAAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-4.52	-0.34	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs8044868	0.530	rs9924964	chr16:72085561	T/A	cg16579770	chr16:72058938	DHODH	0.4	4.58	0.35	9.44e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
PAAD	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.53	-4.7	-0.36	5.69e-6	Schizophrenia;
PAAD	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06850241	chr22:41845214	NA	-0.52	-4.32	-0.33	2.8e-5	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs8070740	0.740	rs980408	chr17:5338990	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	4.59	0.35	9.38e-6	Menopause (age at onset);
PAAD	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-5.54	-0.41	1.28e-7	Monocyte percentage of white cells;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19145272	chr2:180613571	ZNF385B	-0.57	-6.38	-0.46	2.05e-9	Obesity-related traits;
PAAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg02462569	chr6:150064036	NUP43	-0.5	-5.79	-0.42	3.99e-8	Lung cancer;
PAAD	cis	rs59698941	0.943	rs59634464	chr5:132178735	A/G	cg14825688	chr5:132208181	LEAP2	-0.68	-4.84	-0.37	3.15e-6	Apolipoprotein A-IV levels;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02222454	chr3:141762828	NA	0.54	6.43	0.46	1.56e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs6976664	1.000	rs62461377	chr7:45016935	G/A	cg13400493	chr7:44826786	NA	0.46	4.3	0.33	3.03e-5	Pursuit maintenance gain;
PAAD	cis	rs7619427	0.507	rs7616472	chr3:44016039	G/A	cg11632238	chr3:44040539	NA	-0.53	-4.28	-0.33	3.24e-5	Schizophrenia;
PAAD	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.63	0.53	2.35e-12	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-10.05	-0.63	1.5e-18	Intelligence (multi-trait analysis);
PAAD	trans	rs901683	0.850	rs78999882	chr10:46076813	A/T	cg05552035	chr8:37699239	GPR124	0.96	6.56	0.47	7.85e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	7.18	0.5	2.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg18551225	chr6:44695536	NA	-0.64	-7.31	-0.51	1.39e-11	Total body bone mineral density;
PAAD	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.76	0.62	8.88e-18	Chronic sinus infection;
PAAD	cis	rs990171	0.687	rs4851607	chr2:103125632	C/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.44	-0.34	1.73e-5	Lymphocyte counts;
PAAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	7.23	0.51	2.19e-11	Obesity-related traits;
PAAD	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.47	-7.0	-0.49	7.75e-11	Cutaneous nevi;
PAAD	cis	rs340029	0.828	rs103947	chr15:60911884	T/C	cg00200653	chr15:60883225	RORA	0.5	4.35	0.33	2.47e-5	C-reactive protein levels;
PAAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.9	11.09	0.67	2.64e-21	Methadone dose in opioid dependence;
PAAD	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.27	0.39	4.57e-7	Schizophrenia;
PAAD	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.7	-5.81	-0.43	3.47e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg04311227	chr1:32860059	BSDC1	0.61	6.98	0.49	8.65e-11	Vitiligo;Type 1 diabetes;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg12445378	chr8:48741753	PRKDC	-0.65	-7.26	-0.51	1.85e-11	Myopia (pathological);
PAAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.35	17.04	0.81	4.33e-37	Eosinophil percentage of granulocytes;
PAAD	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg16444942	chr12:129309117	SLC15A4	-0.7	-4.26	-0.33	3.57e-5	Systemic lupus erythematosus;
PAAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg27182935	chr16:89790473	ZNF276	-0.94	-4.6	-0.35	8.82e-6	Skin colour saturation;
PAAD	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-5.26	-0.39	4.86e-7	Glomerular filtration rate in chronic kidney disease;
PAAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg24415082	chr16:74700811	RFWD3	0.62	6.91	0.49	1.23e-10	Response to antipsychotic treatment;
PAAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.87	8.58	0.57	1.04e-14	Methadone dose in opioid dependence;
PAAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7210086	1.000	rs7210086	chr17:70641698	A/C	cg04206342	chr17:70636940	NA	-0.41	-4.74	-0.36	4.89e-6	Ulcerative colitis;
PAAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.89	10.08	0.63	1.3e-18	Prudent dietary pattern;
PAAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.73	7.05	0.5	6.02e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg23752985	chr2:85803571	VAMP8	0.62	6.69	0.48	4.08e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20893717	chr7:100318190	EPO	0.45	5.04	0.38	1.28e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
PAAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.64	8.26	0.56	6.67e-14	Hypertriglyceridemia;
PAAD	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.52	-5.93	-0.43	2e-8	Alcohol dependence;
PAAD	cis	rs1800795	0.553	rs1524099	chr7:22781657	G/A	cg05472934	chr7:22766657	IL6	0.67	7.22	0.51	2.34e-11	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
PAAD	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.39	4.82	0.36	3.39e-6	Pulmonary function;
PAAD	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	7.42	0.52	7.53e-12	Lymphocyte counts;
PAAD	cis	rs858239	0.512	rs55788996	chr7:23192849	G/A	cg27449745	chr7:23145252	KLHL7	-0.51	-4.29	-0.33	3.15e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs11971779	0.715	rs6467853	chr7:139127027	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	5.2	0.39	6.45e-7	Diisocyanate-induced asthma;
PAAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg18279126	chr7:2041391	MAD1L1	0.61	6.27	0.45	3.6e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.54	5.16	0.39	7.48e-7	Resting heart rate;
PAAD	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.2	-14.69	-0.77	5.8e-31	Type 1 diabetes nephropathy;
PAAD	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.43	0.61	6.74e-17	Morning vs. evening chronotype;
PAAD	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.87	-7.11	-0.5	4.18e-11	Triglycerides;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23055852	chr15:73909017	NPTN	-0.59	-6.8	-0.48	2.3e-10	Monocyte percentage of white cells;
PAAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.66	-5.75	-0.42	4.77e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg04824913	chr4:887549	GAK	0.73	5.38	0.4	2.75e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.64	-5.6	-0.41	9.91e-8	Coronary artery disease;
PAAD	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-10.53	-0.65	8.33e-20	Heart rate;
PAAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.99	11.38	0.68	4.28e-22	Parkinson's disease;
PAAD	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.57	6.48	0.47	1.21e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	12.04	0.7	6.99e-24	Bone mineral density;
PAAD	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.47	6.16	0.45	6.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02244288	chr16:89573955	SPG7	-0.33	-4.31	-0.33	2.93e-5	Multiple myeloma (IgH translocation);
PAAD	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.26	10.97	0.66	5.39e-21	Uric acid levels;
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg18209359	chr17:80159595	CCDC57	-0.46	-4.62	-0.35	8.13e-6	Life satisfaction;
PAAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.6	5.79	0.42	3.95e-8	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg07202610	chr7:1142643	C7orf50	-0.75	-5.3	-0.39	4.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg04165759	chr1:150448943	RPRD2	0.51	5.27	0.39	4.62e-7	Migraine;
PAAD	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg01059385	chr22:42394853	WBP2NL	-0.44	-4.66	-0.35	6.74e-6	Cognitive function;
PAAD	cis	rs6688613	0.840	rs6660048	chr1:166954186	C/T	cg07049167	chr1:166818506	POGK	-0.62	-6.09	-0.44	8.77e-9	Refractive astigmatism;
PAAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.05	14.92	0.77	1.43e-31	Prudent dietary pattern;
PAAD	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.69	8.43	0.56	2.5e-14	Dupuytren's disease;
PAAD	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.81	8.05	0.55	2.2e-13	Corneal astigmatism;
PAAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg18612461	chr15:75251733	NA	0.67	8.22	0.55	8.27e-14	Breast cancer;
PAAD	cis	rs12597422	0.522	rs55844219	chr16:53881219	C/T	cg16085531	chr16:54322938	NA	-0.33	-4.5	-0.34	1.34e-5	Eyebrow thickness;
PAAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18364779	chr6:26104403	HIST1H4C	0.52	5.25	0.39	4.94e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.65	6.36	0.46	2.28e-9	Type 2 diabetes;
PAAD	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	14.8	0.77	2.97e-31	Chronic sinus infection;
PAAD	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	12.73	0.72	1e-25	Chronic sinus infection;
PAAD	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	4.87	0.37	2.73e-6	Lung function (FEV1/FVC);
PAAD	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26926768	chr12:34528122	NA	0.39	4.64	0.35	7.35e-6	Morning vs. evening chronotype;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05193116	chr12:53845872	PCBP2	0.68	6.32	0.46	2.81e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	trans	rs901683	1.000	rs35131026	chr10:46014759	G/A	cg23720331	chr10:123873670	TACC2	-0.83	-6.5	-0.47	1.11e-9	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22509189	chr2:225307070	NA	-0.52	-5.07	-0.38	1.13e-6	IgE levels in asthmatics (D.p. specific);
PAAD	cis	rs6782025	0.837	rs9876935	chr3:120893389	A/G	cg16417163	chr3:121280760	NA	0.45	4.64	0.35	7.34e-6	Aging (facial);
PAAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06217245	chr20:33103252	DYNLRB1	-0.37	-4.47	-0.34	1.51e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.74	7.56	0.52	3.48e-12	Prostate cancer;
PAAD	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.47	4.52	0.34	1.24e-5	Morning vs. evening chronotype;
PAAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.54	5.36	0.4	3.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-4.5	-0.34	1.35e-5	Lung cancer;
PAAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.52	-4.78	-0.36	4.14e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.32	0.46	2.77e-9	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.36	-0.4	3.04e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.79	12.46	0.71	5.37e-25	Schizophrenia;
PAAD	cis	rs2031532	0.589	rs4941643	chr13:50068387	C/T	cg08779649	chr13:50194554	NA	0.35	4.69	0.36	6.01e-6	Cardiac hypertrophy;
PAAD	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-4.69	-0.36	5.93e-6	Vitiligo;
PAAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.22	0.45	4.51e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg26031613	chr14:104095156	KLC1	-0.55	-5.8	-0.43	3.7e-8	Schizophrenia;
PAAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.73	-7.73	-0.53	1.36e-12	Aortic root size;
PAAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.55	5.68	0.42	6.76e-8	Testicular germ cell tumor;
PAAD	cis	rs35785195	0.593	rs12821514	chr12:114233825	G/A	cg24771877	chr12:114234123	NA	0.68	5.33	0.4	3.45e-7	Daytime sleep phenotypes;
PAAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.63	0.53	2.39e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.68	-0.42	6.69e-8	Personality dimensions;
PAAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg23506979	chr15:79090958	ADAMTS7	0.26	4.38	0.33	2.18e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs3136739	0.614	rs11778382	chr8:42013295	A/G	cg12054981	chr8:42037387	PLAT	0.71	5.21	0.39	6.15e-7	Plasma plasminogen activator levels;
PAAD	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.89	7.52	0.52	4.46e-12	Alzheimer's disease;
PAAD	cis	rs642743	0.934	rs611372	chr10:105958464	G/A	cg23130731	chr10:105978651	MIR609;C10orf79	0.25	4.65	0.35	7.29e-6	Left ventricular obstructive tract defect (maternal effect);
PAAD	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.6	-4.86	-0.37	2.84e-6	Type 2 diabetes;
PAAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-4.6	-0.35	8.67e-6	Height;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24562465	chr2:105191709	NA	-0.63	-6.43	-0.46	1.58e-9	Obesity-related traits;
PAAD	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	10.29	0.64	3.56e-19	Platelet count;
PAAD	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	7.6	0.52	2.89e-12	Body mass index;
PAAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.28	-7.69	-0.53	1.7e-12	Body mass index;
PAAD	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.46	4.3	0.33	3.07e-5	HDL cholesterol;
PAAD	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg21905437	chr5:178450457	ZNF879	0.69	6.06	0.44	1.05e-8	Pubertal anthropometrics;
PAAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg11508406	chr4:1595515	NA	-0.42	-4.39	-0.34	2.07e-5	Obesity-related traits;
PAAD	cis	rs59888335	0.895	rs34340252	chr3:80818829	C/G	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.75e-11	Total body bone mineral density;
PAAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs939584	0.866	rs13405307	chr2:650973	T/C	cg03610516	chr2:642275	NA	-0.59	-5.48	-0.41	1.7e-7	Body mass index;
PAAD	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg20731937	chr12:48336164	NA	0.53	4.4	0.34	2e-5	Longevity (90 years and older);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22622667	chr10:134790769	NA	0.59	6.35	0.46	2.33e-9	Myopia (pathological);
PAAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg03030879	chr14:75389066	RPS6KL1	0.42	4.42	0.34	1.87e-5	Height;
PAAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg17366294	chr4:99064904	C4orf37	-0.54	-5.77	-0.42	4.21e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs12612619	0.732	rs1078809	chr2:27288915	C/T	cg00617064	chr2:27272375	NA	-0.56	-6.05	-0.44	1.1e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg24253500	chr15:84953950	NA	-0.57	-6.5	-0.47	1.12e-9	Schizophrenia;
PAAD	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg08888203	chr3:10149979	C3orf24	0.66	6.0	0.44	1.36e-8	Alzheimer's disease;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.42	4.28	0.33	3.26e-5	Bipolar disorder;
PAAD	cis	rs317865	0.867	rs56106162	chr4:16159062	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.86	5.91	0.43	2.12e-8	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.41	-5.05	-0.38	1.23e-6	Body mass index in non-asthmatics;
PAAD	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg22654517	chr2:96458247	NA	0.37	4.32	0.33	2.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
PAAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.8	-8.89	-0.58	1.66e-15	Iron status biomarkers;
PAAD	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg10621924	chr7:39171070	POU6F2	0.27	4.53	0.35	1.17e-5	IgG glycosylation;
PAAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.77	-7.33	-0.51	1.29e-11	Total bilirubin levels in HIV-1 infection;
PAAD	cis	rs12195424	0.558	rs77156915	chr6:56299661	T/C	cg10030658	chr6:56298004	NA	-0.73	-4.27	-0.33	3.43e-5	Cerebrospinal fluid clusterin levels;
PAAD	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.87	6.29	0.45	3.23e-9	Breast cancer;
PAAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg08029281	chr1:67600428	NA	0.47	5.29	0.39	4.24e-7	Psoriasis;
PAAD	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-5.98	-0.44	1.56e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg06885757	chr1:42089581	HIVEP3	-0.54	-6.15	-0.45	6.57e-9	Airway imaging phenotypes;
PAAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg21698718	chr17:80085957	CCDC57	-0.45	-5.02	-0.38	1.44e-6	Life satisfaction;
PAAD	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	1.17	5.82	0.43	3.34e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg09324608	chr17:30823087	MYO1D	0.53	5.59	0.41	1.04e-7	Schizophrenia;
PAAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg03983715	chr16:68378420	PRMT7	-0.97	-6.82	-0.48	2.02e-10	Schizophrenia;
PAAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23281280	chr6:28129359	ZNF389	0.71	5.55	0.41	1.24e-7	Depression;
PAAD	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg15193198	chr20:60906057	LAMA5	0.59	6.77	0.48	2.67e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs9913156	0.748	rs72835630	chr17:4562449	C/T	cg00122941	chr17:4613640	ARRB2	0.83	8.52	0.57	1.48e-14	Lymphocyte counts;
PAAD	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	5.17	0.39	7.37e-7	Coronary artery disease;
PAAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-4.37	-0.33	2.29e-5	Breast cancer;
PAAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.44	5.49	0.41	1.65e-7	Prostate cancer;
PAAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.44	-4.36	-0.33	2.37e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg18833306	chr6:118973337	C6orf204	0.44	4.58	0.35	9.51e-6	Electrocardiographic conduction measures;
PAAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg11802864	chr11:65308245	LTBP3	-0.45	-4.46	-0.34	1.6e-5	Bone mineral density;
PAAD	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.45	0.65	1.37e-19	Electrocardiographic conduction measures;
PAAD	cis	rs6563943	0.963	rs78221356	chr16:83631303	G/A	cg01935413	chr16:83636749	CDH13	0.53	5.01	0.38	1.52e-6	Height;
PAAD	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08109568	chr15:31115862	NA	-0.7	-7.94	-0.54	4.07e-13	Huntington's disease progression;
PAAD	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg08390786	chr10:135334061	NA	0.62	5.39	0.4	2.61e-7	Gout;
PAAD	cis	rs59104589	0.617	rs7568	chr2:242291743	A/G	cg04488487	chr2:242709673	NA	0.57	4.41	0.34	1.93e-5	Fibrinogen levels;
PAAD	cis	rs89107	0.688	rs283091	chr6:118588684	A/G	cg18833306	chr6:118973337	C6orf204	-0.49	-5.75	-0.42	4.7e-8	Cardiac structure and function;
PAAD	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.63	-7.22	-0.51	2.38e-11	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23991721	chr19:1237877	C19orf26	0.59	6.56	0.47	7.99e-10	Monocyte percentage of white cells;
PAAD	cis	rs4704187	0.687	rs10051572	chr5:74502797	G/A	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg14146966	chr2:61757674	XPO1	0.42	5.18	0.39	6.82e-7	Tuberculosis;
PAAD	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg16898833	chr6:26189333	HIST1H4D	0.56	4.63	0.35	7.78e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg23531748	chr20:60969906	CABLES2	0.43	4.3	0.33	3.04e-5	Colorectal cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23838308	chr17:57785056	PTRH2;TMEM49	0.68	6.57	0.47	7.4e-10	Obesity-related traits;
PAAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg18402987	chr7:1209562	NA	1.0	5.26	0.39	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-5.18	-0.39	7e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.51	-4.47	-0.34	1.55e-5	Obesity;
PAAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg21724239	chr8:58056113	NA	0.7	5.17	0.39	7.38e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	10.22	0.64	5.47e-19	Platelet count;
PAAD	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg00750074	chr16:89608354	SPG7	-0.48	-4.51	-0.34	1.27e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.79	-6.13	-0.45	7.36e-9	Schizophrenia;
PAAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg05861140	chr6:150128134	PCMT1	-0.52	-5.89	-0.43	2.42e-8	Lung cancer;
PAAD	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-4.92	-0.37	2.19e-6	Primary sclerosing cholangitis;
PAAD	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.49	5.49	0.41	1.62e-7	Total cholesterol levels;
PAAD	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14019695	chr9:139328340	INPP5E	0.54	5.71	0.42	5.88e-8	Monocyte percentage of white cells;
PAAD	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg14700524	chr10:3282231	NA	0.32	4.47	0.34	1.53e-5	Attention deficit hyperactivity disorder and conduct disorder;
PAAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.64	-5.96	-0.44	1.66e-8	Ankle injury;
PAAD	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.58	5.77	0.42	4.36e-8	Platelet count;
PAAD	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.37	0.4	2.91e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	6.06	0.44	1.01e-8	Lung cancer in ever smokers;
PAAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg19130645	chr7:65235666	NA	0.43	4.5	0.34	1.35e-5	Calcium levels;
PAAD	cis	rs58521262	0.585	rs2548888	chr19:23211028	C/A	cg03433597	chr19:22806448	NA	0.24	4.36	0.33	2.39e-5	Testicular germ cell tumor;
PAAD	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-6.14	-0.45	6.72e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11264799	0.539	rs11264775	chr1:157578884	A/G	cg18268488	chr1:157545234	FCRL4	0.49	5.78	0.42	4.05e-8	IgA nephropathy;
PAAD	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.64	5.76	0.42	4.62e-8	Blood metabolite levels;
PAAD	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	9.17	0.6	3.11e-16	Cognitive test performance;
PAAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.98	8.31	0.56	4.99e-14	Gut microbiome composition (summer);
PAAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg13897122	chr2:103039542	IL18RAP	-0.36	-4.35	-0.33	2.46e-5	Asthma;
PAAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg03338584	chr11:507455	RNH1	0.56	4.4	0.34	2.04e-5	Systemic lupus erythematosus;
PAAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	7.27	0.51	1.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1790761	0.505	rs34721562	chr11:67312708	T/C	cg00864171	chr11:67383662	NA	-0.46	-4.81	-0.36	3.55e-6	Mean corpuscular volume;
PAAD	cis	rs2412208	0.792	rs10864267	chr1:7094802	C/T	cg26570804	chr1:6352357	ACOT7	0.56	5.19	0.39	6.59e-7	Survival in sporadic amyotrophic lateral sclerosis;
PAAD	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.49	5.4	0.4	2.51e-7	Urate levels in lean individuals;
PAAD	cis	rs988913	1.000	rs9349740	chr6:54825708	A/C	cg03513858	chr6:54763001	FAM83B	-0.44	-4.82	-0.36	3.45e-6	Menarche (age at onset);
PAAD	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.6	-5.54	-0.41	1.31e-7	Malaria;
PAAD	cis	rs8112211	0.689	rs4802327	chr19:38793319	G/A	cg01275006	chr19:38876250	GGN	-0.81	-5.08	-0.38	1.07e-6	Blood protein levels;
PAAD	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg00981651	chr20:44574847	PCIF1	0.42	4.47	0.34	1.5e-5	Intelligence (multi-trait analysis);
PAAD	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.65	-6.31	-0.46	2.91e-9	Breast cancer;
PAAD	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg06138931	chr13:21896616	NA	-0.65	-4.43	-0.34	1.78e-5	White matter hyperintensity burden;
PAAD	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg00181669	chr3:44000978	NA	-0.43	-4.35	-0.33	2.52e-5	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg26447107	chr13:113465038	ATP11A	-0.55	-6.52	-0.47	9.84e-10	Monocyte percentage of white cells;
PAAD	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.43	5.3	0.39	4.02e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6700896	0.500	rs2186246	chr1:66118009	A/G	cg04111102	chr1:66153794	NA	0.47	4.39	0.34	2.07e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.68	7.14	0.5	3.52e-11	Height;
PAAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-8.45	-0.57	2.21e-14	Total body bone mineral density;
PAAD	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg10034588	chr2:232392055	NMUR1	-0.38	-4.54	-0.35	1.14e-5	Noise-induced hearing loss;
PAAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	9.64	0.62	1.86e-17	Platelet count;
PAAD	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.57	4.4	0.34	2e-5	IgG glycosylation;
PAAD	cis	rs564309	0.867	rs12691493	chr1:228580410	C/T	cg01328119	chr1:228783545	DUSP5P	0.69	4.31	0.33	2.89e-5	Hip circumference (psychosocial stress interaction);
PAAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-1.03	-9.22	-0.6	2.29e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs4668356	1.000	rs73976285	chr2:171983260	G/A	cg13882835	chr2:172017928	TLK1	0.84	4.59	0.35	9.34e-6	Cognitive performance;
PAAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.59	6.23	0.45	4.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg09184832	chr6:79620586	NA	-0.43	-4.27	-0.33	3.39e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs1015362	0.869	rs6088411	chr20:32739907	T/C	cg06217245	chr20:33103252	DYNLRB1	-0.46	-4.61	-0.35	8.34e-6	Skin sensitivity to sun;Red vs. non-red hair color;Burning and freckling;Freckles;
PAAD	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.84	6.44	0.46	1.47e-9	Axial length;
PAAD	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.89	0.37	2.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-4.53	-0.35	1.16e-5	Menopause (age at onset);
PAAD	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg23460851	chr4:1604456	NA	-0.4	-4.26	-0.33	3.59e-5	Bladder cancer;Urinary bladder cancer;
PAAD	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.63	6.04	0.44	1.12e-8	Itch intensity from mosquito bite;
PAAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.48	-5.57	-0.41	1.14e-7	Schizophrenia;
PAAD	cis	rs9659323	0.670	rs6701378	chr1:119638553	G/A	cg26570165	chr1:119541833	NA	-0.47	-5.19	-0.39	6.52e-7	Body mass index;
PAAD	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg12218747	chr21:37451666	NA	-0.48	-5.14	-0.38	8.32e-7	Mitral valve prolapse;
PAAD	cis	rs6466055	0.661	rs7802168	chr7:104925206	T/A	cg04380332	chr7:105027541	SRPK2	0.51	5.09	0.38	1.06e-6	Schizophrenia;
PAAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-6.02	-0.44	1.24e-8	Prostate cancer;
PAAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18357526	chr6:26021779	HIST1H4A	0.73	7.74	0.53	1.31e-12	Height;
PAAD	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.88	-10.93	-0.66	6.97e-21	Lobe attachment (rater-scored or self-reported);
PAAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.87	9.86	0.62	5.03e-18	Height;
PAAD	cis	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg11783356	chr20:44313418	WFDC10B	-0.73	-6.53	-0.47	9.14e-10	Brain structure;
PAAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-1.0	-7.93	-0.54	4.42e-13	Initial pursuit acceleration;
PAAD	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg02524346	chr8:600233	NA	-1.17	-7.69	-0.53	1.7e-12	IgG glycosylation;
PAAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg27411982	chr8:10470053	RP1L1	0.42	4.46	0.34	1.61e-5	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.79	-9.43	-0.61	6.41e-17	White blood cell count (basophil);
PAAD	cis	rs13223928	0.541	rs66883350	chr7:3136548	T/A	cg19214707	chr7:3157722	NA	-0.62	-5.76	-0.42	4.55e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.86	-0.49	1.64e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs2034650	0.544	rs661488	chr15:40721420	G/C	cg05276125	chr15:40653601	DISP2	0.51	4.82	0.36	3.43e-6	Interstitial lung disease;
PAAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.55	-0.41	1.25e-7	Longevity;Endometriosis;
PAAD	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg25233709	chr10:116636983	FAM160B1	0.42	5.19	0.39	6.78e-7	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg09659197	chr4:152720779	NA	0.36	5.22	0.39	5.66e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.37	5.4	0.4	2.54e-7	Educational attainment (years of education);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24485408	chr1:44679309	DMAP1	0.58	6.46	0.46	1.35e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.66	7.38	0.51	9.44e-12	Menarche (age at onset);
PAAD	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.55	8.65	0.57	6.95e-15	IgG glycosylation;
PAAD	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-6.02	-0.44	1.27e-8	Parkinson's disease;
PAAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.28	-7.24	-0.51	2.05e-11	Body mass index;
PAAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.73	7.58	0.52	3.08e-12	Morning vs. evening chronotype;
PAAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg01763666	chr17:80159506	CCDC57	-0.43	-4.31	-0.33	2.88e-5	Life satisfaction;
PAAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16988970	chr17:42248062	ASB16	0.36	5.1	0.38	9.81e-7	Total body bone mineral density;
PAAD	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.62	6.45	0.46	1.43e-9	Body mass index;
PAAD	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.54	-0.35	1.13e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs901683	1.000	rs12776291	chr10:46038507	T/C	cg14076390	chr17:34947837	DHRS11	0.87	6.66	0.48	4.67e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.94	-7.45	-0.52	6.45e-12	Initial pursuit acceleration;
PAAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg11802864	chr11:65308245	LTBP3	1.35	6.76	0.48	2.76e-10	Height;
PAAD	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg00982548	chr2:198649783	BOLL	-0.79	-5.64	-0.42	8.25e-8	Ulcerative colitis;
PAAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.62	4.63	0.35	7.83e-6	Fat distribution (HIV);
PAAD	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.8	9.24	0.6	2.02e-16	Breast cancer;
PAAD	cis	rs802075	1.000	rs12624	chr6:49660418	A/C	cg20364632	chr6:49636226	NA	-0.52	-6.04	-0.44	1.13e-8	Bone mineral density (hip) and age at menarche;
PAAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.77	9.22	0.6	2.29e-16	Parkinson's disease;
PAAD	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.68	-6.54	-0.47	8.79e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
PAAD	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.25	-5.13	-0.38	8.79e-7	Urinary metabolites;
PAAD	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	7.2	0.5	2.61e-11	Subcortical brain region volumes;Putamen volume;
PAAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.81	11.17	0.67	1.62e-21	Bone mineral density;
PAAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.78	5.62	0.41	8.76e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.57	0.41	1.12e-7	Bipolar disorder;
PAAD	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg09659197	chr4:152720779	NA	0.43	5.67	0.42	6.93e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19743433	chr2:240965015	NDUFA10	0.56	6.62	0.47	5.9e-10	Monocyte percentage of white cells;
PAAD	cis	rs2327429	0.541	rs11154750	chr6:134156979	A/T	cg06296503	chr6:134217401	NA	0.44	4.53	0.34	1.19e-5	Coronary artery disease;
PAAD	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.92	-8.6	-0.57	9.26e-15	Childhood ear infection;
PAAD	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.56	-5.05	-0.38	1.25e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.87	-8.72	-0.58	4.65e-15	Breast cancer;
PAAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg02462569	chr6:150064036	NUP43	-0.47	-5.19	-0.39	6.67e-7	Lung cancer;
PAAD	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg08439880	chr3:133502540	NA	0.44	4.83	0.36	3.37e-6	Iron status biomarkers;
PAAD	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	1.16	6.23	0.45	4.38e-9	Skin colour saturation;
PAAD	cis	rs17135859	1.000	rs13436223	chr5:112994345	T/C	cg12552261	chr5:112820674	MCC	0.69	4.44	0.34	1.73e-5	F-cell distribution;
PAAD	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.8	-0.48	2.26e-10	Eye color traits;
PAAD	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02598441	chr17:62777298	LOC146880	0.51	4.25	0.33	3.67e-5	QT interval;
PAAD	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.97	-8.91	-0.59	1.48e-15	Body mass index;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26116260	chr4:7069785	GRPEL1	-0.59	-6.62	-0.47	5.77e-10	Smoking initiation;
PAAD	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.75	8.23	0.56	7.81e-14	Menopause (age at onset);
PAAD	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.58	6.08	0.44	9.31e-9	Pancreatic cancer;
PAAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09835421	chr16:68378352	PRMT7	-1.17	-8.37	-0.56	3.6e-14	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11168618	0.740	rs10506281	chr12:48923774	A/G	cg01881778	chr12:48919444	OR8S1	0.5	5.44	0.4	2.1e-7	Adiponectin levels;
PAAD	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg01426195	chr3:39028469	NA	0.62	6.12	0.44	7.69e-9	Handedness;
PAAD	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg25200586	chr1:148000763	NA	-0.61	-6.4	-0.46	1.82e-9	Hip geometry;
PAAD	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.61	5.16	0.39	7.53e-7	White matter hyperintensity burden;
PAAD	cis	rs7264396	0.573	rs55969606	chr20:34075688	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.56	-0.41	1.16e-7	Total cholesterol levels;
PAAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.55	-5.5	-0.41	1.55e-7	Blood metabolite levels;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27530443	chr7:1977877	MAD1L1	0.63	6.71	0.48	3.56e-10	Smoking initiation;
PAAD	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.77	-0.48	2.63e-10	Eye color traits;
PAAD	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.71	7.78	0.53	1.01e-12	Corneal astigmatism;
PAAD	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.48	4.39	0.34	2.09e-5	Breast cancer;
PAAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-1.06	-17.41	-0.82	4.9e-38	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15160780	chr2:159825180	TANC1	0.64	6.49	0.47	1.16e-9	Obesity-related traits;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.76	-8.44	-0.56	2.3e-14	Monocyte percentage of white cells;
PAAD	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.5	-4.39	-0.34	2.15e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg14709524	chr16:89940631	TCF25	0.78	4.56	0.35	1.07e-5	Skin colour saturation;
PAAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.62	-6.28	-0.45	3.31e-9	IgG glycosylation;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg14037354	chr14:101505926	MIR654;MIR376B;MIR376A1;MIR376A2;MIR376C	-0.66	-6.54	-0.47	8.86e-10	Obesity-related traits;
PAAD	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-5.53	-0.41	1.38e-7	Personality dimensions;
PAAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.45	5.52	0.41	1.45e-7	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.83	-6.81	-0.48	2.12e-10	Developmental language disorder (linguistic errors);
PAAD	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.59	5.28	0.39	4.3e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.62	-6.56	-0.47	8.02e-10	Neuroticism;
PAAD	cis	rs7765175	0.598	rs12201269	chr6:113630195	G/C	cg19037598	chr6:113666021	NA	-0.39	-4.25	-0.33	3.68e-5	Coronary artery calcification;
PAAD	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg07541023	chr7:19748670	TWISTNB	0.56	4.56	0.35	1.03e-5	Thyroid stimulating hormone;
PAAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-1.07	-8.9	-0.59	1.55e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.81	0.36	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	trans	rs61931739	0.613	rs61927728	chr12:33667690	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-6.52	-0.47	9.96e-10	Morning vs. evening chronotype;
PAAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.05	-7.98	-0.54	3.33e-13	Diabetic kidney disease;
PAAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.83	-6.26	-0.45	3.83e-9	Initial pursuit acceleration;
PAAD	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.57	7.54	0.52	4.04e-12	Endometriosis;
PAAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.5	4.87	0.37	2.74e-6	Major depressive disorder;
PAAD	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg06565975	chr8:143823917	SLURP1	0.24	5.6	0.41	9.79e-8	Urinary tract infection frequency;
PAAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	4.33	0.33	2.68e-5	Schizophrenia;
PAAD	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg05895507	chr15:77155635	SCAPER	-0.39	-4.45	-0.34	1.66e-5	Blood metabolite levels;
PAAD	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.45	-5.03	-0.38	1.35e-6	Body mass index;
PAAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.78	-7.75	-0.53	1.22e-12	Menopause (age at onset);
PAAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.38	-0.33	2.19e-5	Life satisfaction;
PAAD	cis	rs60154123	0.504	rs4844997	chr1:210486895	A/G	cg23283495	chr1:209979779	IRF6	0.62	5.42	0.4	2.3e-7	Coronary artery disease;
PAAD	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.5	4.5	0.34	1.36e-5	Height;
PAAD	cis	rs4740619	0.689	rs10810502	chr9:15952197	C/T	cg14451791	chr9:16040625	NA	-0.45	-5.3	-0.39	4.07e-7	Body mass index;
PAAD	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	1.23	15.64	0.79	1.79e-33	Ewing sarcoma;
PAAD	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.93	7.53	0.52	4.22e-12	Iron status biomarkers;
PAAD	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg17385448	chr1:15911702	AGMAT	0.36	4.45	0.34	1.65e-5	Systolic blood pressure;
PAAD	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-6.29	-0.45	3.27e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
PAAD	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.88	-7.03	-0.5	6.39e-11	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.65	-7.37	-0.51	9.92e-12	Vitamin D levels;
PAAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.52	-5.58	-0.41	1.06e-7	Breast cancer;
PAAD	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.53	-5.45	-0.4	1.95e-7	Daytime sleep phenotypes;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03637781	chr3:37902564	CTDSPL	0.57	6.37	0.46	2.17e-9	Monocyte percentage of white cells;
PAAD	trans	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08418111	chr11:18433745	LDHC	0.6	6.33	0.46	2.63e-9	Calcium levels;
PAAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.56	-6.44	-0.46	1.45e-9	Mean corpuscular volume;
PAAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07362569	chr17:61921086	SMARCD2	0.64	7.96	0.54	3.68e-13	Prudent dietary pattern;
PAAD	cis	rs7714584	1.000	rs11748553	chr5:150184553	A/G	cg22134413	chr5:150180641	NA	0.95	6.41	0.46	1.71e-9	Crohn's disease;
PAAD	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.7	7.83	0.54	7.67e-13	Motion sickness;
PAAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg19413350	chr8:57351067	NA	-0.44	-4.39	-0.34	2.09e-5	Obesity-related traits;
PAAD	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	5.14	0.38	8.45e-7	Height;
PAAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.45	-4.37	-0.33	2.33e-5	Body mass index (alcohol intake interaction);
PAAD	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.46	4.38	0.33	2.22e-5	Hepatocellular carcinoma;
PAAD	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.68	-7.75	-0.53	1.23e-12	Alcohol dependence;
PAAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.8	7.16	0.5	3.22e-11	Cognitive function;
PAAD	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg00717180	chr2:96193071	NA	-0.59	-6.54	-0.47	8.78e-10	HDL cholesterol;
PAAD	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg22532475	chr10:104410764	TRIM8	-0.39	-4.58	-0.35	9.63e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-5.43	-0.4	2.16e-7	Obesity-related traits;
PAAD	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg23346134	chr3:49453900	TCTA	-0.46	-4.97	-0.37	1.8e-6	Menarche (age at onset);
PAAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	4.95	0.37	1.95e-6	Renal function-related traits (BUN);
PAAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.93	-15.0	-0.77	8.76e-32	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.82	9.94	0.63	3.05e-18	Monocyte percentage of white cells;
PAAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg05373962	chr22:49881684	NA	-0.55	-5.05	-0.38	1.22e-6	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.51	6.45	0.46	1.43e-9	Childhood ear infection;
PAAD	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-10.75	-0.66	2.07e-20	Ulcerative colitis;
PAAD	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.76	7.99	0.54	3.12e-13	Age at first birth;
PAAD	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.74	0.53	1.28e-12	Lung cancer in ever smokers;
PAAD	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg12568669	chr8:11666485	FDFT1	0.32	5.3	0.39	4.03e-7	Monocyte count;
PAAD	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	5.57	0.41	1.14e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg04257695	chr17:30186438	C17orf79	-0.63	-4.91	-0.37	2.37e-6	Hip circumference adjusted for BMI;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23460551	chr7:66325901	NA	0.55	6.59	0.47	6.84e-10	Smoking initiation;
PAAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg25452165	chr22:42524984	CYP2D6	-0.6	-5.77	-0.42	4.33e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg02734326	chr4:10020555	SLC2A9	0.51	5.09	0.38	1.04e-6	Bone mineral density;
PAAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.63	0.35	7.94e-6	Breast cancer;
PAAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.57	6.97	0.49	9.05e-11	Monocyte count;Monocyte percentage of white cells;
PAAD	cis	rs9532669	0.926	rs4254182	chr13:41453256	T/C	cg14924160	chr13:41496235	SUGT1L1	0.31	4.25	0.33	3.68e-5	Cervical cancer;
PAAD	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg05250797	chr16:70222502	NA	0.87	6.72	0.48	3.39e-10	IgE levels;
PAAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.8	9.16	0.6	3.23e-16	Lung cancer;
PAAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg22467129	chr15:76604101	ETFA	-0.54	-5.7	-0.42	6.15e-8	Blood metabolite levels;
PAAD	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.49	4.73	0.36	5.04e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4918918	0.624	rs10786200	chr10:97069542	C/A	cg14101359	chr10:97300930	SORBS1	0.41	4.43	0.34	1.83e-5	Suicide risk;
PAAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.89	-8.94	-0.59	1.27e-15	Asthma;
PAAD	cis	rs10766533	1.000	rs10766533	chr11:19224677	A/T	cg14704941	chr11:19224659	CSRP3	0.36	4.33	0.33	2.75e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
PAAD	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.84	6.32	0.46	2.78e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg12310025	chr6:25882481	NA	0.44	4.33	0.33	2.72e-5	Schizophrenia;
PAAD	cis	rs7804356	0.651	rs11980739	chr7:26818164	A/G	cg03456212	chr7:26904342	SKAP2	-0.6	-5.1	-0.38	1.02e-6	Type 1 diabetes;
PAAD	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.97	-9.94	-0.63	2.94e-18	Hip circumference adjusted for BMI;
PAAD	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05347473	chr6:146136440	FBXO30	0.48	4.52	0.34	1.26e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.65	-4.86	-0.37	2.87e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg00484396	chr16:3507460	NAT15	0.87	7.12	0.5	3.96e-11	Tuberculosis;
PAAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	9.14	0.6	3.85e-16	Alzheimer's disease;
PAAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.97	12.46	0.71	5.26e-25	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Body mass index;
PAAD	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg01667837	chr7:124405605	GPR37	-0.42	-4.28	-0.33	3.36e-5	Lewy body disease;
PAAD	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.69	7.06	0.5	5.61e-11	Mosquito bite size;
PAAD	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.95	-6.07	-0.44	9.58e-9	Alzheimer's disease (late onset);
PAAD	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg00543991	chr22:32367038	NA	1.19	7.23	0.51	2.2e-11	Childhood ear infection;
PAAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg15847926	chr7:2749597	AMZ1	0.36	4.52	0.34	1.23e-5	Plateletcrit;
PAAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs12760731	0.720	rs10913545	chr1:178360201	G/A	cg00404053	chr1:178313656	RASAL2	0.69	5.21	0.39	5.96e-7	Obesity-related traits;
PAAD	cis	rs9880211	0.706	rs9289513	chr3:136451746	G/T	cg17177318	chr3:135913615	MSL2	0.56	4.25	0.33	3.76e-5	Body mass index;Height;
PAAD	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	10.18	0.64	7.05e-19	Cognitive test performance;
PAAD	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06771106	chr2:113671356	IL1F7	0.6	6.27	0.45	3.6e-9	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.94	10.38	0.64	2.03e-19	Breast cancer;
PAAD	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	1.07	8.85	0.58	2.15e-15	Corneal structure;
PAAD	trans	rs2148307	0.607	rs10828120	chr10:21036186	C/T	cg11189177	chr17:1065204	ABR	0.73	6.3	0.46	3.05e-9	Photic sneeze reflex;
PAAD	cis	rs6782025	0.837	rs1688675	chr3:120755177	T/A	cg16417163	chr3:121280760	NA	0.44	4.59	0.35	9.41e-6	Aging (facial);
PAAD	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.22	-0.39	5.84e-7	Systemic lupus erythematosus;
PAAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg13444538	chr7:158905317	VIPR2	0.47	4.29	0.33	3.22e-5	Facial morphology (factor 20);
PAAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg22437258	chr11:111473054	SIK2	-0.53	-4.95	-0.37	1.98e-6	Primary sclerosing cholangitis;
PAAD	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg14092571	chr14:90743983	NA	-0.52	-4.99	-0.37	1.67e-6	Mortality in heart failure;
PAAD	cis	rs11168618	0.810	rs35338015	chr12:48839401	C/T	cg01881778	chr12:48919444	OR8S1	-0.5	-4.97	-0.37	1.8e-6	Adiponectin levels;
PAAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.4	-4.49	-0.34	1.43e-5	Mean platelet volume;
PAAD	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.78	-7.38	-0.51	9.82e-12	Asthma;
PAAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.48	-0.34	1.43e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg24053715	chr22:38214548	NA	0.63	6.03	0.44	1.21e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg08139522	chr20:34824291	C20orf4	0.62	6.89	0.49	1.42e-10	Myopia (pathological);
PAAD	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg14092988	chr3:52407081	DNAH1	0.47	5.73	0.42	5.28e-8	Bipolar disorder;
PAAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.56	8.17	0.55	1.1e-13	Diastolic blood pressure;
PAAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.83	6.05	0.44	1.11e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg17771515	chr6:154831774	CNKSR3	0.63	4.48	0.34	1.45e-5	Lipoprotein (a) levels;
PAAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.96	-13.23	-0.73	4.4e-27	Height;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-6.91	-0.49	1.27e-10	Life satisfaction;
PAAD	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg04087571	chr11:116723030	SIK3	-0.36	-5.44	-0.4	2.11e-7	Subjective well-being;
PAAD	cis	rs1126510	0.897	rs9304662	chr19:47121745	A/G	cg07844738	chr19:47129343	PTGIR	0.46	5.42	0.4	2.34e-7	Ulcerative colitis;
PAAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.69	-6.59	-0.47	6.85e-10	Neurofibrillary tangles;
PAAD	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-5.04	-0.38	1.32e-6	Chronic sinus infection;
PAAD	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.82	6.34	0.46	2.49e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-4.29	-0.33	3.13e-5	Schizophrenia (age at onset);
PAAD	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.98	-8.79	-0.58	2.95e-15	Dilated cardiomyopathy;
PAAD	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.04	-0.38	1.31e-6	Systemic lupus erythematosus;
PAAD	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.92	7.62	0.53	2.6e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.8	9.89	0.63	4.16e-18	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.49	-5.52	-0.41	1.4e-7	Dilated cardiomyopathy;
PAAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.52	-0.34	1.23e-5	Major depressive disorder;
PAAD	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg08501292	chr6:25962987	TRIM38	0.9	4.91	0.37	2.32e-6	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7180079	1.000	rs62021592	chr15:64522368	T/G	cg18210365	chr15:65066710	RBPMS2	-0.62	-4.34	-0.33	2.59e-5	Monocyte count;
PAAD	cis	rs1892094	0.507	rs754551	chr1:169087787	C/T	cg02837999	chr1:169338281	NME7;BLZF1	-0.6	-5.58	-0.41	1.09e-7	Coronary artery disease;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23349402	chr2:27603760	ZNF513	0.56	6.43	0.46	1.6e-9	Monocyte percentage of white cells;
PAAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg01262667	chr19:19385393	TM6SF2	0.42	4.28	0.33	3.31e-5	Nonalcoholic fatty liver disease;
PAAD	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg09066997	chr16:75300724	BCAR1	-0.59	-4.36	-0.33	2.39e-5	Alcoholic chronic pancreatitis;
PAAD	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.99	8.62	0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06636551	chr8:101224915	SPAG1	0.58	7.36	0.51	1.06e-11	Atrioventricular conduction;
PAAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13939156	chr17:80058883	NA	-0.4	-4.33	-0.33	2.67e-5	Life satisfaction;
PAAD	cis	rs73019876	0.901	rs423284	chr19:22232378	C/T	cg11619707	chr19:22235551	ZNF257	-0.42	-4.58	-0.35	9.6e-6	Testicular germ cell tumor;
PAAD	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.53	5.46	0.4	1.94e-7	Schizophrenia;
PAAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.55	-6.7	-0.48	3.9e-10	Reticulocyte fraction of red cells;
PAAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01200585	chr1:228362443	C1orf69	-0.52	-5.81	-0.43	3.5e-8	Diastolic blood pressure;
PAAD	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg06217245	chr20:33103252	DYNLRB1	-0.4	-4.59	-0.35	9.35e-6	Height;
PAAD	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.72	5.74	0.42	5.04e-8	Vitiligo;
PAAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg20757508	chr4:1318902	MAEA	-0.69	-6.5	-0.47	1.07e-9	Obesity-related traits;
PAAD	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg15192750	chr16:69999425	NA	-0.52	-4.35	-0.33	2.48e-5	Sjögren's syndrome;
PAAD	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.96	7.75	0.53	1.22e-12	Vitiligo;
PAAD	cis	rs34421088	0.532	rs1369368	chr8:11150213	C/A	cg00622658	chr8:10469796	RP1L1	-0.41	-4.29	-0.33	3.21e-5	Neuroticism;
PAAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg06629702	chr1:2706960	NA	-0.36	-4.34	-0.33	2.55e-5	Ulcerative colitis;
PAAD	cis	rs17095355	1.000	rs17126931	chr10:111754633	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-4.49	-0.34	1.42e-5	Biliary atresia;
PAAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.5	-5.58	-0.41	1.1e-7	Bipolar disorder;
PAAD	cis	rs17213078	0.505	rs737101	chr2:106732545	C/T	cg15412446	chr2:106886593	NA	0.59	5.85	0.43	2.95e-8	Facial morphology (factor 23);
PAAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00401753	chr5:405986	AHRR;LOC100310782	0.64	4.92	0.37	2.19e-6	Breast cancer;
PAAD	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.71e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg12395012	chr8:11607386	GATA4	-0.41	-4.62	-0.35	7.97e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
PAAD	cis	rs5756391	0.546	rs9607391	chr22:37314770	A/T	cg16356956	chr22:37317934	CSF2RB	-0.36	-4.4	-0.34	2.03e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-1.06	-14.77	-0.77	3.59e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.59	4.69	0.36	6.1e-6	Blood protein levels;
PAAD	cis	rs6445967	1.000	rs7622074	chr3:58312297	A/G	cg23715586	chr3:58305044	RPP14	0.48	4.25	0.33	3.66e-5	Platelet count;
PAAD	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg01320130	chr1:67600311	NA	0.58	5.58	0.41	1.06e-7	Psoriasis;
PAAD	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.74	-7.48	-0.52	5.51e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.43	-4.55	-0.35	1.09e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.47	-4.54	-0.35	1.14e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.43	-6.46	-0.46	1.36e-9	Red blood cell count;Amyotrophic lateral sclerosis;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	8.31	0.56	5.06e-14	Alzheimer's disease;
PAAD	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg12463550	chr7:65579703	CRCP	0.5	4.78	0.36	4.15e-6	Aortic root size;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07817686	chr4:16085401	PROM1	-0.66	-7.46	-0.52	6.21e-12	Body fat percentage;
PAAD	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.73	8.21	0.55	8.61e-14	Colorectal cancer;
PAAD	cis	rs12979813	0.901	rs10421382	chr19:11344973	G/C	cg08405405	chr19:11485325	C19orf39	-0.6	-4.39	-0.34	2.09e-5	HDL cholesterol;
PAAD	cis	rs58521262	0.615	rs289364	chr19:23117036	G/T	cg03433597	chr19:22806448	NA	-0.24	-4.28	-0.33	3.35e-5	Testicular germ cell tumor;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg03304078	chr16:67906908	EDC4	-0.6	-6.85	-0.49	1.7e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg12940439	chr1:67600707	NA	0.38	4.62	0.35	8.15e-6	Psoriasis;
PAAD	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.85	9.57	0.61	2.9e-17	Mortality in heart failure;
PAAD	cis	rs7943953	0.686	rs1453547	chr11:59189912	C/T	cg06466547	chr11:59191289	OR5A2	0.47	4.5	0.34	1.35e-5	Odorant perception (&beta-ionone);
PAAD	cis	rs61861422	0.543	rs34309159	chr10:134419166	C/T	cg27286337	chr10:134555280	INPP5A	0.65	5.46	0.4	1.9e-7	Primary sclerosing cholangitis;
PAAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-8.24	-0.56	7.47e-14	Height;
PAAD	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00086297	chr16:3662233	BTBD12	-0.72	-7.73	-0.53	1.39e-12	Lung cancer in ever smokers;
PAAD	cis	rs795484	0.926	rs353893	chr12:118631765	T/C	cg16572268	chr12:118583242	PEBP1	-0.49	-4.85	-0.37	2.97e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
PAAD	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.56	5.57	0.41	1.14e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs13144136	0.687	rs13119277	chr4:10658129	C/T	cg10242279	chr4:10666415	CLNK	-0.48	-6.09	-0.44	8.78e-9	Resistance to antihypertensive treatment in hypertension;
PAAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.39	-0.4	2.63e-7	Blood metabolite levels;
PAAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg21395723	chr22:39101663	GTPBP1	0.44	4.64	0.35	7.51e-6	Menopause (age at onset);
PAAD	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.75	8.0	0.54	2.87e-13	Lung cancer;
PAAD	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg24253500	chr15:84953950	NA	0.62	6.84	0.49	1.77e-10	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg10729496	chr3:10149963	C3orf24	0.93	7.96	0.54	3.74e-13	Alzheimer's disease;
PAAD	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.54	4.81	0.36	3.64e-6	RR interval (heart rate);
PAAD	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.59	5.99	0.44	1.48e-8	Obesity;
PAAD	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.62	-4.6	-0.35	8.8e-6	Alzheimer's disease (survival time);
PAAD	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06634786	chr22:41940651	POLR3H	0.65	4.92	0.37	2.26e-6	Vitiligo;
PAAD	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg07741184	chr6:167504864	NA	-0.39	-4.77	-0.36	4.25e-6	Crohn's disease;
PAAD	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg00571178	chr13:114841904	RASA3	-0.53	-4.66	-0.35	6.93e-6	Facial morphology (factor 14, intercanthal width);
PAAD	cis	rs8038465	0.638	rs56262972	chr15:73946745	G/A	cg15420318	chr15:73925796	NPTN	0.48	4.68	0.35	6.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.44	6.23	0.45	4.42e-9	Schizophrenia;
PAAD	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg10437265	chr15:77819839	NA	0.43	4.76	0.36	4.54e-6	Type 2 diabetes;
PAAD	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.79	8.22	0.55	8.34e-14	Body mass index;
PAAD	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.48	7.77	0.53	1.1e-12	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20630889	chr1:203764635	ZC3H11A	0.57	6.34	0.46	2.52e-9	Monocyte percentage of white cells;
PAAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.89	11.24	0.67	1.02e-21	Monocyte percentage of white cells;
PAAD	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-11.05	-0.67	3.41e-21	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.91	-0.37	2.36e-6	Bipolar disorder;
PAAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-5.69	-0.42	6.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg04907244	chr7:22894795	SNORD93	-0.38	-4.58	-0.35	9.8200000000000008e-06	Fibrinogen;
PAAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.6	9.09	0.59	5.19e-16	Homoarginine levels;
PAAD	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	1.99	11.84	0.69	2.55e-23	Cannabis dependence symptom count;
PAAD	cis	rs7763441	0.567	rs2281251	chr6:2434056	A/G	cg18740289	chr6:2437142	NA	-0.69	-6.77	-0.48	2.7e-10	Monobrow;
PAAD	cis	rs1499972	0.941	rs62263121	chr3:117630348	T/C	cg07612923	chr3:117604196	NA	1.09	7.25	0.51	1.98e-11	Schizophrenia;
PAAD	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.2	-0.45	5.14e-9	Morning vs. evening chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg24842889	chr12:105501362	KIAA1033	0.6	6.84	0.49	1.82e-10	Vitiligo;Type 1 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg19657201	chr12:69139816	SLC35E3	0.56	6.42	0.46	1.62e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg26174226	chr8:58114915	NA	-0.63	-4.5	-0.34	1.32e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs6132905	0.590	rs113594194	chr20:2626876	G/A	cg24848351	chr20:2622020	TMC2	-0.76	-5.54	-0.41	1.31e-7	Mumps;
PAAD	cis	rs73019876	0.720	rs1989118	chr19:22205679	A/G	cg11619707	chr19:22235551	ZNF257	-0.4	-4.28	-0.33	3.24e-5	Testicular germ cell tumor;
PAAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.49	5.47	0.41	1.78e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.55	5.26	0.39	4.72e-7	Prudent dietary pattern;
PAAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.57	-5.36	-0.4	2.98e-7	Obesity-related traits;
PAAD	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.78	8.1	0.55	1.66e-13	Alzheimer's disease (late onset);
PAAD	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg08079166	chr15:68083412	MAP2K5	0.64	5.07	0.38	1.16e-6	Restless legs syndrome;
PAAD	trans	rs225245	0.817	rs225269	chr17:33967931	G/T	cg19694781	chr19:47549865	TMEM160	-0.57	-6.46	-0.46	1.31e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
PAAD	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.32	0.46	2.79e-9	Morning vs. evening chronotype;
PAAD	cis	rs5498	0.809	rs2075742	chr19:10401607	G/C	cg10604476	chr19:10403908	ICAM5	0.33	4.27	0.33	3.48e-5	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
PAAD	cis	rs1358748	0.522	rs6588241	chr1:67586913	T/C	cg02640540	chr1:67518911	SLC35D1	0.65	4.47	0.34	1.54e-5	Tuberculosis;
PAAD	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	trans	rs9372498	1.000	rs6924560	chr6:118591401	C/T	cg15607664	chr12:57630422	NDUFA4L2	-0.85	-8.02	-0.55	2.62e-13	Diastolic blood pressure;
PAAD	cis	rs4343996	0.747	rs7791617	chr7:3504800	C/T	cg21248987	chr7:3385318	SDK1	-0.5	-5.26	-0.39	4.86e-7	Motion sickness;
PAAD	cis	rs12327666	0.522	rs7247679	chr19:14134172	T/C	cg19510472	chr19:14142205	IL27RA	-0.53	-4.34	-0.33	2.54e-5	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg01851573	chr8:8652454	MFHAS1	0.48	4.32	0.33	2.81e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg01605746	chr5:669925	TPPP	0.4	4.26	0.33	3.52e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-1.02	-7.99	-0.54	3.1e-13	Initial pursuit acceleration;
PAAD	cis	rs4787491	0.729	rs4788212	chr16:30034469	G/T	cg06015834	chr16:30021696	DOC2A	0.4	4.27	0.33	3.44e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.5	6.67e-11	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-4.7	-0.36	5.84e-6	Alcohol dependence;
PAAD	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg24112000	chr20:60950667	NA	-0.74	-9.41	-0.61	7.51e-17	Colorectal cancer;
PAAD	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg01966878	chr4:90757139	SNCA	-0.48	-4.47	-0.34	1.5e-5	Dementia with Lewy bodies;
PAAD	trans	rs901683	1.000	rs12779637	chr10:46081096	T/C	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.64	7.06	0.5	5.5e-11	Celiac disease or Rheumatoid arthritis;
PAAD	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg01620082	chr3:125678407	NA	-1.57	-9.64	-0.62	1.87e-17	Depression;
PAAD	cis	rs2274459	0.778	rs9296097	chr6:33660143	G/A	cg06253072	chr6:33679850	C6orf125	0.63	4.99	0.38	1.62e-6	Obesity (extreme);
PAAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg25456477	chr12:86230367	RASSF9	0.5	4.37	0.33	2.25e-5	Major depressive disorder;
PAAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg15181151	chr6:150070149	PCMT1	0.57	6.28	0.45	3.35e-9	Lung cancer;
PAAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.63	4.31	0.33	2.93e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.74	-7.01	-0.49	7.11e-11	Cognitive function;
PAAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg04844267	chr4:1394941	NA	0.41	4.5	0.34	1.33e-5	Obesity-related traits;
PAAD	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg00614314	chr15:82944287	LOC80154	0.5	5.04	0.38	1.34e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	4.73	0.36	5.03e-6	Breast cancer;
PAAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.59	-6.51	-0.47	1.02e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg21231944	chr12:82153410	PPFIA2	-0.52	-4.36	-0.33	2.42e-5	Resting heart rate;
PAAD	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg14458575	chr2:238380390	NA	0.54	6.2	0.45	5.16e-9	Prostate cancer;
PAAD	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-5.71	-0.42	5.87e-8	Mean corpuscular volume;
PAAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08677398	chr8:58056175	NA	0.66	4.66	0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	trans	rs901683	0.850	rs75748332	chr10:46065143	A/C	cg13065504	chr15:42448234	PLA2G4F	0.87	6.79	0.48	2.31e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7009516	0.625	rs3765124	chr8:24261526	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.48	-5.57	-0.41	1.12e-7	Hair greying;
PAAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.58	-7.23	-0.51	2.21e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs527409	0.850	rs649826	chr1:58748657	C/T	cg26345888	chr1:58716257	DAB1	-0.66	-4.45	-0.34	1.62e-5	Kawasaki disease;
PAAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.54	6.11	0.44	8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.43	-4.86	-0.37	2.96e-6	Testicular germ cell tumor;
PAAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.43	-6.74	-0.48	3.17e-10	Mean corpuscular hemoglobin concentration;
PAAD	trans	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17712092	chr4:129076599	LARP1B	-0.83	-9.7	-0.62	1.28e-17	Eosinophil percentage of white cells;
PAAD	cis	rs7582720	1.000	rs72932745	chr2:203662888	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	7.5	0.52	4.96e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg07959490	chr17:80112427	CCDC57	-0.36	-4.26	-0.33	3.64e-5	Life satisfaction;
PAAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg09835421	chr16:68378352	PRMT7	-0.85	-6.3	-0.46	3.02e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11645898	0.687	rs6499558	chr16:72102813	G/C	cg14768367	chr16:72042858	DHODH	-0.75	-6.46	-0.46	1.36e-9	Blood protein levels;
PAAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.42	-0.34	1.87e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11016883	1.000	rs11016883	chr10:131500940	C/G	cg14312783	chr10:131504572	MGMT	-0.46	-4.47	-0.34	1.55e-5	Waist-to-hip circumference ratio (ever vs never smoking interaction);
PAAD	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.77	8.22	0.55	8.14e-14	Hypertriglyceridemia;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.09e-7	Life satisfaction;
PAAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.86	8.7	0.58	5.19e-15	Coronary artery disease;
PAAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.58	-0.35	9.76e-6	Bipolar disorder;
PAAD	cis	rs1035491	0.753	rs6873572	chr5:63932398	C/T	cg01791865	chr5:63954708	NA	-0.46	-4.77	-0.36	4.27e-6	Body mass index;
PAAD	cis	rs74544699	1.000	rs353029	chr4:74776804	C/T	cg16072462	chr4:74847758	PF4	1.18	4.46	0.34	1.59e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg18357526	chr6:26021779	HIST1H4A	0.7	7.26	0.51	1.89e-11	Height;
PAAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10819733	chr22:24237672	NA	-0.61	-6.59	-0.47	6.8e-10	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9810890	1.000	rs73196970	chr3:128443193	A/G	cg15676455	chr3:128564943	NA	-0.79	-4.56	-0.35	1.06e-5	Dental caries;
PAAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.46	4.85	0.37	3.09e-6	Red cell distribution width;
PAAD	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg10820045	chr2:198174542	NA	0.46	4.57	0.35	9.94e-6	Dermatomyositis;
PAAD	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg16586182	chr3:47516702	SCAP	0.6	6.77	0.48	2.6200000000000003e-10	Colorectal cancer;
PAAD	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg05564831	chr3:52568323	NT5DC2	-0.41	-4.3	-0.33	3.1e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg23947450	chr7:900037	UNC84A	-0.5	-4.25	-0.33	3.73e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.4	4.3	0.33	3.1e-5	Obesity-related traits;
PAAD	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.35	0.4	3.15e-7	Multiple sclerosis;
PAAD	cis	rs6494488	0.500	rs116857608	chr15:64798168	C/T	cg16425858	chr15:64791681	ZNF609	1.02	4.6	0.35	8.88e-6	Coronary artery disease;
PAAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.49	-5.1	-0.38	9.87e-7	Bipolar disorder;
PAAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	16.35	0.8	2.65e-35	Prudent dietary pattern;
PAAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-1.07	-14.28	-0.76	7.02e-30	Total body bone mineral density;
PAAD	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg06899799	chr12:56650233	ANKRD52	0.33	4.31	0.33	2.94e-5	Cancer;
PAAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.81	-7.72	-0.53	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.86	9.73	0.62	1.08e-17	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs9463078	0.691	rs10948229	chr6:45306371	A/G	cg25276700	chr6:44698697	NA	0.51	5.68	0.42	6.63e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs9815354	1.000	rs61744388	chr3:41756965	C/T	cg03022575	chr3:42003672	ULK4	0.84	6.09	0.44	8.73e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.68	-7.1	-0.5	4.47e-11	Longevity;
PAAD	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.76	-8.28	-0.56	5.79e-14	Colorectal cancer;
PAAD	cis	rs790123	0.692	rs790129	chr3:122385170	C/T	cg15604389	chr3:122379662	NA	-0.56	-5.33	-0.4	3.57e-7	Response to angiotensin II receptor blocker therapy;
PAAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg10591111	chr5:226296	SDHA	-0.65	-4.58	-0.35	9.63e-6	Breast cancer;
PAAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg07701084	chr6:150067640	NUP43	0.76	8.19	0.55	9.77e-14	Lung cancer;
PAAD	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg08992911	chr2:238395768	MLPH	0.66	6.46	0.46	1.36e-9	Prostate cancer;
PAAD	cis	rs9876781	1.000	rs6442118	chr3:48440047	G/A	cg24898236	chr3:49228699	LOC646498	0.39	4.28	0.33	3.25e-5	Longevity;
PAAD	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.59	-6.14	-0.45	6.75e-9	Response to antidepressants and depression;
PAAD	cis	rs7539409	0.667	rs1160147	chr1:84216997	T/C	cg10977910	chr1:84465055	TTLL7	0.89	5.02	0.38	1.44e-6	Alzheimer's disease;
PAAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.92	-6.82	-0.48	2.05e-10	Breast cancer;
PAAD	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.94	8.48	0.57	1.85e-14	Vitiligo;
PAAD	cis	rs6834538	0.597	rs7676819	chr4:113552891	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	5.24	0.39	5.29e-7	Free thyroxine concentration;
PAAD	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-4.27	-0.33	3.37e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.74	8.76	0.58	3.53e-15	Monocyte percentage of white cells;
PAAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-5.95	-0.43	1.75e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.47	-0.52	5.8e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg14343924	chr8:8086146	FLJ10661	-0.47	-4.31	-0.33	2.87e-5	Joint mobility (Beighton score);
PAAD	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-5.21	-0.39	6.05e-7	QT interval;
PAAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-5.54	-0.41	1.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-4.9	-0.37	2.39e-6	Height;
PAAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.8	-8.87	-0.58	1.88e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs17123764	0.605	rs55812050	chr12:50088540	C/A	cg14846292	chr12:49726500	C1QL4	-0.67	-4.3	-0.33	3.1e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.76	-5.33	-0.4	3.56e-7	Monocyte percentage of white cells;
PAAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg11859384	chr17:80120422	CCDC57	-0.54	-5.75	-0.42	4.67e-8	Life satisfaction;
PAAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.85	10.95	0.66	6.05e-21	Methadone dose in opioid dependence;
PAAD	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	1.06	8.23	0.56	7.69e-14	Menopause (age at onset);
PAAD	cis	rs7627468	0.770	rs1463892	chr3:121970386	C/T	cg03198317	chr3:121949109	CASR	-0.48	-4.42	-0.34	1.86e-5	Kidney stones;
PAAD	cis	rs3996993	0.737	rs9474321	chr6:52648277	C/T	cg20803780	chr6:52668592	GSTA1	-0.36	-4.37	-0.33	2.3e-5	Hemoglobin concentration;
PAAD	cis	rs4789452	0.967	rs7217986	chr17:75369578	T/C	cg26747885	chr17:76355701	SOCS3	0.42	4.28	0.33	3.29e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
PAAD	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.66	7.06	0.5	5.6e-11	Blood protein levels;
PAAD	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.68	4.88	0.37	2.7e-6	Crohn's disease;Inflammatory bowel disease;
PAAD	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg26942532	chr7:75678159	MDH2;STYXL1	-0.5	-4.48	-0.34	1.43e-5	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-1.08	-11.39	-0.68	4.01e-22	Blood protein levels;
PAAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.76	5.76	0.42	4.52e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs60154123	0.730	rs12040684	chr1:210472053	C/T	cg22029157	chr1:209979665	IRF6	0.7	6.06	0.44	1.05e-8	Coronary artery disease;
PAAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg22903657	chr4:1355424	KIAA1530	-0.44	-4.51	-0.34	1.27e-5	Obesity-related traits;
PAAD	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.64	-6.9	-0.49	1.34e-10	Dilated cardiomyopathy;
PAAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.38e-14	Prostate cancer;
PAAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.51	5.03	0.38	1.34e-6	Mean corpuscular volume;
PAAD	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg22189786	chr22:42395067	WBP2NL	-0.48	-5.27	-0.39	4.56e-7	Cognitive function;
PAAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg18279126	chr7:2041391	MAD1L1	0.58	5.91	0.43	2.2e-8	Bipolar disorder and schizophrenia;
PAAD	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg17796960	chr10:135278976	LOC619207	-0.39	-4.35	-0.33	2.48e-5	Systemic lupus erythematosus;
PAAD	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg02887458	chr19:19495540	GATAD2A	0.49	4.68	0.35	6.3e-6	Bipolar disorder;
PAAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.8	-10.06	-0.63	1.48e-18	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	5.41	0.4	2.4e-7	Lymphocyte counts;
PAAD	cis	rs9487051	0.724	rs11751953	chr6:109635986	G/A	cg01475377	chr6:109611718	NA	-0.43	-4.75	-0.36	4.66e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-8.14	-0.55	1.32e-13	Monocyte percentage of white cells;
PAAD	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.69	6.3	0.46	3e-9	Menarche (age at onset);
PAAD	cis	rs6774280	0.656	rs60584817	chr3:6278219	A/G	cg18469270	chr3:5468035	NA	0.54	4.29	0.33	3.18e-5	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.0	11.23	0.67	1.1e-21	Homoarginine levels;
PAAD	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.34	4.87	0.37	2.78e-6	Alcoholic chronic pancreatitis;
PAAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.77	9.45	0.61	5.94e-17	Vitiligo;
PAAD	cis	rs7291412	0.662	rs7292297	chr22:46458123	T/G	cg05468064	chr22:46423449	NA	0.41	5.03	0.38	1.39e-6	Dupuytren's disease;Subjective well-being;
PAAD	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.43	0.68	3.22e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.44	4.32	0.33	2.81e-5	Renal cell carcinoma;
PAAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.39	-0.46	1.88e-9	Aortic root size;
PAAD	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	6.79	0.48	2.43e-10	Total body bone mineral density;
PAAD	cis	rs2016586	0.802	rs8142446	chr22:36115128	A/G	cg26342177	chr22:36113512	APOL5	-0.48	-4.79	-0.36	3.91e-6	Body mass index;
PAAD	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.12	15.4	0.78	7.84e-33	Schizophrenia;
PAAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-4.66	-0.35	6.76e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.77	5.37	0.4	2.94e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
PAAD	cis	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg16818395	chr3:128274084	NA	0.5	4.42	0.34	1.86e-5	Dental caries;
PAAD	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.62	-6.64	-0.47	5.25e-10	Calcium levels;
PAAD	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.96	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.49	-5.2	-0.39	6.21e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.84	0.54	7.34e-13	Alzheimer's disease;
PAAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.47	-0.34	1.54e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.61	-5.89	-0.43	2.34e-8	Blood metabolite levels;
PAAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.63	-8.29	-0.56	5.69e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	4.72	0.36	5.33e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.51	-5.0	-0.38	1.56e-6	Mean platelet volume;
PAAD	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg25952890	chr19:58913133	NA	0.66	5.6	0.41	9.64e-8	Mean platelet volume;
PAAD	cis	rs8105895	0.935	rs62112918	chr19:22227079	C/T	cg20662725	chr19:22235022	ZNF257	-0.55	-4.26	-0.33	3.55e-5	Body mass index (change over time);
PAAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.61	-8.34	-0.56	4.13e-14	Height;
PAAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg04106633	chr4:1044584	NA	0.64	5.42	0.4	2.31e-7	Recombination rate (females);
PAAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-5.42	-0.4	2.3e-7	Monocyte count;
PAAD	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg10168330	chr8:27262164	PTK2B	0.38	4.57	0.35	1.02e-5	Neuroticism;
PAAD	cis	rs1368882	0.758	rs1702019	chr1:55108159	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	0.55	6.12	0.44	7.47e-9	Non-substance related behavioral disinhibition;
PAAD	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg12908607	chr1:44402522	ARTN	-0.42	-4.62	-0.35	7.96e-6	Amyotrophic lateral sclerosis (age of onset);
PAAD	cis	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg00614314	chr15:82944287	LOC80154	0.52	5.15	0.39	7.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-0.98	-10.98	-0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs11892454	0.544	rs13004845	chr2:25959477	C/T	cg25181710	chr2:26045287	ASXL2	0.43	4.85	0.37	3.05e-6	Heschl's gyrus morphology;
PAAD	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.58	-5.38	-0.4	2.76e-7	Blood metabolite levels;
PAAD	cis	rs939584	0.935	rs5017302	chr2:631069	G/A	cg14515364	chr2:636606	NA	0.52	4.73	0.36	5.09e-6	Body mass index;
PAAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg01759136	chr6:27242945	NA	0.43	4.64	0.35	7.58e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg02951883	chr7:2050386	MAD1L1	0.59	5.2	0.39	6.46e-7	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05368115	chr19:901123	C19orf22	0.6	6.75	0.48	2.91e-10	Body fat percentage;
PAAD	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.57	-7.32	-0.51	1.34e-11	Longevity;
PAAD	cis	rs17331151	0.505	rs13066644	chr3:52565247	G/A	cg27565382	chr3:53032988	SFMBT1	0.95	4.65	0.35	7.14e-6	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg06917634	chr15:78832804	PSMA4	-0.43	-4.28	-0.33	3.32e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
PAAD	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg03871329	chr12:110338662	TCHP	-0.67	-4.99	-0.38	1.63e-6	Neuroticism;
PAAD	cis	rs16975963	0.793	rs11666497	chr19:38464262	C/T	cg14218481	chr19:38281219	NA	0.49	5.04	0.38	1.29e-6	Longevity;
PAAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg00543991	chr22:32367038	NA	1.2	7.42	0.52	7.69e-12	Childhood ear infection;
PAAD	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.88	-11.08	-0.67	2.77e-21	Heart rate;
PAAD	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	6.41	0.46	1.78e-9	Cognitive test performance;
PAAD	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-4.67	-0.35	6.67e-6	Retinal vascular caliber;
PAAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg13468214	chr4:1046988	NA	-0.52	-4.89	-0.37	2.58e-6	Recombination rate (females);
PAAD	cis	rs7771547	0.723	rs10807169	chr6:36556569	A/G	cg07856975	chr6:36356162	ETV7	0.44	4.56	0.35	1.05e-5	Platelet distribution width;
PAAD	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg01422370	chr2:73384389	NA	0.35	4.79	0.36	4.01e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs4838594	0.563	rs4838598	chr10:49679413	A/G	cg17291251	chr10:49678358	ARHGAP22	0.47	4.49	0.34	1.39e-5	Daytime sleep phenotypes;
PAAD	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.99	-0.38	1.61e-6	Height;
PAAD	cis	rs300703	0.719	rs378738	chr2:194039	A/G	cg24565620	chr2:194026	NA	-0.71	-5.74	-0.42	4.93e-8	Blood protein levels;
PAAD	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-4.72	-0.36	5.25e-6	Total body bone mineral density;
PAAD	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs75757892	0.626	rs9505167	chr6:7327634	T/C	cg02954307	chr6:7269328	NA	0.5	4.29	0.33	3.13e-5	Hematocrit;Red blood cell count;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg02631906	chr1:45987864	PRDX1	0.54	6.74	0.48	3.05e-10	Metabolite levels  (X-11787);
PAAD	cis	rs72627123	1.000	rs72627126	chr14:74370024	C/T	cg19860245	chr14:74300557	NA	-0.76	-5.3	-0.39	4.09e-7	Morning vs. evening chronotype;
PAAD	cis	rs9361491	0.608	rs9352632	chr6:79462226	G/C	cg05283184	chr6:79620031	NA	-0.39	-4.74	-0.36	4.97e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.64	-6.54	-0.47	8.86e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22633769	chr20:60982531	CABLES2	0.51	4.92	0.37	2.27e-6	Colorectal cancer;
PAAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.87	7.48	0.52	5.52e-12	Recombination rate (females);
PAAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg00738919	chr7:1100172	C7orf50	0.71	5.19	0.39	6.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.18	-0.39	7.03e-7	Life satisfaction;
PAAD	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.66	-8.06	-0.55	2.15e-13	Birth weight;
PAAD	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg10820045	chr2:198174542	NA	0.51	5.26	0.39	4.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs11686241	0.688	rs6739813	chr2:217370675	T/C	cg15830940	chr2:217278069	SMARCAL1	0.49	4.39	0.34	2.08e-5	Cancer;
PAAD	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.58	-6.21	-0.45	4.77e-9	HDL cholesterol;
PAAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.59	6.67	0.48	4.41e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9463078	0.677	rs1886345	chr6:45078266	A/G	cg25276700	chr6:44698697	NA	-0.52	-5.72	-0.42	5.39e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.02	7.5	0.52	4.96e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg02493798	chr17:6899577	ALOX12	-0.47	-4.7	-0.36	5.91e-6	Tonsillectomy;
PAAD	cis	rs11700980	0.551	rs2832019	chr21:30112207	A/G	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg04844267	chr4:1394941	NA	0.43	4.71	0.36	5.44e-6	Obesity-related traits;
PAAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.55	5.33	0.4	3.55e-7	Prudent dietary pattern;
PAAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg05313129	chr8:58192883	C8orf71	-0.64	-5.62	-0.41	8.81e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.84	-7.15	-0.5	3.48e-11	Triglycerides;
PAAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.82	0.36	3.4e-6	Breast cancer;
PAAD	cis	rs3867498	0.891	rs17772722	chr15:25068095	C/A	cg08194505	chr15:25684383	UBE3A	-0.66	-4.58	-0.35	9.81e-6	Pulmonary function;
PAAD	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.93	9.46	0.61	5.65e-17	Response to antineoplastic agents;
PAAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg17105886	chr17:28927953	LRRC37B2	0.73	4.71	0.36	5.52e-6	Body mass index;
PAAD	cis	rs11159086	0.793	rs10139029	chr14:74958987	A/G	cg10195687	chr14:74926396	NA	-0.47	-5.25	-0.39	5.15e-7	Advanced glycation end-product levels;
PAAD	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.84	6.57	0.47	7.66e-10	Diisocyanate-induced asthma;
PAAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.18	0.39	7e-7	Hip circumference adjusted for BMI;Body mass index;
PAAD	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	5.46	0.4	1.91e-7	Mean platelet volume;
PAAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00982548	chr2:198649783	BOLL	-0.81	-5.83	-0.43	3.28e-8	Ulcerative colitis;
PAAD	cis	rs73384572	0.541	rs11016651	chr10:130859932	G/C	cg27413539	chr10:131576096	NA	-0.69	-4.64	-0.35	7.48e-6	Neuroticism;
PAAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-4.87	-0.37	2.74e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	0.96	6.14	0.45	7.05e-9	Gut microbiota (bacterial taxa);
PAAD	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.5	5.64	0.42	8.23e-8	QRS complex (12-leadsum);
PAAD	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg00614314	chr15:82944287	LOC80154	0.53	5.39	0.4	2.65e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.13	8.24	0.56	7.26e-14	Alzheimer's disease;
PAAD	cis	rs2120991	1.000	rs10876513	chr12:54278222	C/T	cg25640699	chr12:54070114	ATP5G2	-0.42	-4.48	-0.34	1.44e-5	Biliary atresia;
PAAD	cis	rs4129585	0.928	rs13262595	chr8:143316970	A/G	cg16886403	chr8:143471632	TSNARE1	0.46	4.31	0.33	2.96e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.62	-7.38	-0.51	9.72e-12	Coronary artery disease;
PAAD	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.72	-5.55	-0.41	1.22e-7	Resting heart rate;
PAAD	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg21191810	chr6:118973309	C6orf204	0.47	6.07	0.44	9.89e-9	Electrocardiographic conduction measures;
PAAD	cis	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.59	0.35	9.41e-6	Depression;
PAAD	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg18084798	chr19:33555255	RHPN2	0.46	4.75	0.36	4.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
PAAD	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	7.61	0.53	2.64e-12	Lung cancer in ever smokers;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg16167639	chr10:103889899	NA	-0.54	-6.69	-0.48	3.97e-10	Monocyte percentage of white cells;
PAAD	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.39	9.59	0.61	2.52e-17	Diabetic retinopathy;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26058391	chr7:99717244	TAF6;CNPY4	0.71	8.01	0.54	2.86e-13	Myopia (pathological);
PAAD	cis	rs12042052	0.793	rs7534632	chr1:232910796	G/A	cg02903907	chr1:232941055	KIAA1383	0.85	4.56	0.35	1.07e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.52	-0.34	1.25e-5	Eotaxin levels;
PAAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.94	-8.63	-0.57	7.58e-15	Gut microbiome composition (summer);
PAAD	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.74	-0.42	5.06e-8	Adiposity;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.52	-6.22	-0.45	4.58e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.71	-0.36	5.46e-6	Breast cancer;
PAAD	cis	rs1113500	0.573	rs10748507	chr1:108631521	G/A	cg06207961	chr1:108661230	NA	0.44	4.36	0.33	2.42e-5	Growth-regulated protein alpha levels;
PAAD	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.5	4.51	0.34	1.29e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs4742903	0.935	rs1507509	chr9:106984902	A/T	cg14250997	chr9:106856677	SMC2	0.43	4.55	0.35	1.08e-5	High-grade serous ovarian cancer;Breast cancer;
PAAD	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg04877966	chr15:75135169	ULK3	0.54	4.69	0.36	6.14e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.54	-5.62	-0.41	8.96e-8	Schizophrenia;
PAAD	cis	rs12304921	1.000	rs4768943	chr12:51355939	C/A	cg04427360	chr12:51347099	HIGD1C	-0.64	-5.0	-0.38	1.56e-6	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.5	4.96	0.37	1.88e-6	Motion sickness;
PAAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg01299579	chr2:10830716	NOL10	-0.59	-6.09	-0.44	8.77e-9	Prostate cancer;
PAAD	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg08601574	chr20:25228251	PYGB	0.61	6.84	0.49	1.79e-10	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs9616064	1.000	rs9616064	chr22:46982293	T/C	cg25730555	chr22:47059586	GRAMD4	-0.43	-4.34	-0.33	2.64e-5	Urate levels in obese individuals;
PAAD	cis	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-4.82	-0.36	3.49e-6	Multiple myeloma (hyperdiploidy);
PAAD	cis	rs16975963	0.644	rs73033117	chr19:38073146	C/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	cis	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg27395922	chr11:50257633	LOC441601	-0.42	-4.55	-0.35	1.11e-5	Coronary artery disease;
PAAD	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.6	-7.38	-0.51	9.79e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
PAAD	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.64	9.05	0.59	6.27e-16	Airflow obstruction;
PAAD	cis	rs7818688	0.697	rs74861094	chr8:95981385	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	4.25	0.33	3.69e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.65	4.36	0.33	2.41e-5	Skin colour saturation;
PAAD	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.65	7.83	0.54	7.7e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg11764359	chr7:65958608	NA	-0.78	-5.23	-0.39	5.54e-7	Diabetic kidney disease;
PAAD	cis	rs7932354	0.583	rs4294527	chr11:46828799	A/T	cg19486271	chr11:47235900	DDB2	-0.6	-5.96	-0.44	1.68e-8	Bone mineral density (hip);Bone mineral density;
PAAD	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.46	-0.4	1.91e-7	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	6.95	0.49	9.85e-11	Blood protein levels;
PAAD	cis	rs6024905	1.000	rs6069760	chr20:36957751	C/T	cg07053727	chr20:36965646	BPI	0.46	4.87	0.37	2.77e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs740474	0.544	rs2299024	chr5:140880765	G/C	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.31	4.66	0.35	6.97e-6	Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-4.92	-0.37	2.2e-6	Menarche (age at onset);
PAAD	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.72	-0.53	1.47e-12	Parkinson's disease;
PAAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg17105886	chr17:28927953	LRRC37B2	0.87	5.3	0.4	3.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.96	-11.15	-0.67	1.8e-21	Blood metabolite levels;Acylcarnitine levels;
PAAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	8.03	0.55	2.45e-13	Prudent dietary pattern;
PAAD	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.56	-5.51	-0.41	1.48e-7	Immature fraction of reticulocytes;
PAAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.63	4.31	0.33	2.87e-5	Vitiligo;
PAAD	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.83	9.68	0.62	1.47e-17	Body mass index;
PAAD	cis	rs12431939	0.947	rs66478864	chr14:51597265	T/G	cg23942311	chr14:51606299	NA	-0.7	-5.57	-0.41	1.12e-7	Cancer;
PAAD	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.75	-7.0	-0.49	7.76e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.13	-0.38	8.56e-7	Daytime sleep phenotypes;
PAAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14895029	chr7:2775587	GNA12	-0.47	-4.69	-0.36	6.04e-6	Height;
PAAD	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.61	-5.66	-0.42	7.46e-8	Neuroticism;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg07161071	chr7:128578164	IRF5	0.53	6.33	0.46	2.57e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11615916	0.790	rs11612366	chr12:62657666	C/T	cg11441379	chr12:63026424	NA	0.63	4.37	0.33	2.3e-5	Pulmonary function decline;
PAAD	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-9.98	-0.63	2.4e-18	Height;
PAAD	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.92	-0.49	1.17e-10	Mood instability;
PAAD	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg19008133	chr3:123124015	ADCY5	0.61	4.39	0.34	2.15e-5	LDL cholesterol levels;
PAAD	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.25e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg05347473	chr6:146136440	FBXO30	0.51	4.9	0.37	2.42e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg26022315	chr17:47021804	SNF8	0.45	4.66	0.35	6.94e-6	Type 2 diabetes;
PAAD	cis	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	0.65	4.3	0.33	3.03e-5	Atrial fibrillation;
PAAD	cis	rs877529	0.967	rs139411	chr22:39552888	A/G	cg13455509	chr22:39551605	NA	-0.45	-4.46	-0.34	1.59e-5	Multiple myeloma;
PAAD	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.63	6.59	0.47	6.97e-10	Resting heart rate;
PAAD	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	11.53	0.68	1.68e-22	Lymphocyte percentage of white cells;
PAAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.82	10.14	0.64	8.97e-19	Menopause (age at onset);
PAAD	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.82	-7.96	-0.54	3.68e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg16339924	chr4:17578868	LAP3	0.71	7.12	0.5	3.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg20295408	chr7:1910781	MAD1L1	0.58	5.53	0.41	1.34e-7	Bipolar disorder and schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06610286	chr10:131731539	EBF3	-0.61	-6.43	-0.46	1.6e-9	Obesity-related traits;
PAAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg18005901	chr6:33739558	LEMD2	-0.57	-4.53	-0.34	1.18e-5	Schizophrenia;
PAAD	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.71	7.56	0.52	3.61e-12	Response to antipsychotic treatment;
PAAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	1.07	6.43	0.46	1.56e-9	Body mass index;
PAAD	trans	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg17217603	chr1:150552017	MCL1	-0.72	-6.3	-0.46	3.04e-9	Blood protein levels;
PAAD	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.59	-5.43	-0.4	2.14e-7	Total body bone mineral density;
PAAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.72	-8.02	-0.55	2.65e-13	Extrinsic epigenetic age acceleration;
PAAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.82	10.42	0.65	1.61e-19	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg02555727	chr12:129281546	SLC15A4	0.45	4.75	0.36	4.68e-6	Systemic lupus erythematosus;
PAAD	cis	rs1572438	1.000	rs9328455	chr6:864095	C/T	cg13447295	chr6:887704	NA	-0.57	-5.24	-0.39	5.32e-7	Aging;
PAAD	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.51	4.71	0.36	5.52e-6	Dialysis-related mortality;
PAAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.93	0.43	2e-8	Prudent dietary pattern;
PAAD	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.82	-7.87	-0.54	6.04e-13	Longevity;
PAAD	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.65	-4.93	-0.37	2.11e-6	Post bronchodilator FEV1;
PAAD	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-4.46	-0.34	1.6e-5	Resting heart rate;
PAAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.97	11.54	0.68	1.57e-22	Breast cancer;
PAAD	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg03522150	chr11:46969673	C11orf49	0.43	5.09	0.38	1.07e-6	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg12486944	chr17:80159399	CCDC57	0.52	4.64	0.35	7.45e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg18068537	chr15:74660088	CYP11A1	0.5	4.47	0.34	1.54e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
PAAD	cis	rs10121009	0.655	rs7032544	chr9:35290288	T/G	cg11846315	chr9:35647073	NA	0.5	4.59	0.35	9.28e-6	Parkinson's disease;
PAAD	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-6.47	-0.46	1.26e-9	Triglycerides;
PAAD	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	5.33	0.4	3.46e-7	Lung cancer in ever smokers;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27191131	chr3:134205014	CEP63;ANAPC13	0.65	6.53	0.47	9.19e-10	Obesity-related traits;
PAAD	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg10208897	chr5:178548229	ADAMTS2	0.5	4.43	0.34	1.81e-5	Pubertal anthropometrics;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18919915	chr5:66109872	MAST4	-0.65	-6.81	-0.48	2.11e-10	Obesity-related traits;
PAAD	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.69	7.16	0.5	3.16e-11	Monocyte count;
PAAD	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.68	6.43	0.46	1.59e-9	Post bronchodilator FEV1;
PAAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.54	5.83	0.43	3.17e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.64	-5.97	-0.44	1.6e-8	Red blood cell count;
PAAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg20933634	chr6:27740509	NA	0.73	4.51	0.34	1.31e-5	Depression;
PAAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg14393609	chr7:65229607	NA	0.48	4.8	0.36	3.73e-6	Aortic root size;
PAAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg03037974	chr15:76606532	NA	0.53	6.36	0.46	2.26e-9	Blood metabolite levels;
PAAD	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.14	0.38	8.39e-7	Diastolic blood pressure;
PAAD	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	4.91	0.37	2.31e-6	Height;
PAAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg03264133	chr6:25882463	NA	-0.53	-4.47	-0.34	1.54e-5	Iron status biomarkers;
PAAD	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	6.97	0.49	8.82e-11	Lung cancer in ever smokers;
PAAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15145965	chr22:50218605	BRD1	0.61	4.98	0.37	1.7e-6	Schizophrenia;
PAAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.61	-6.77	-0.48	2.6200000000000003e-10	Intelligence (multi-trait analysis);
PAAD	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg00749118	chr7:1938791	MAD1L1	0.66	4.92	0.37	2.26e-6	Bipolar disorder;
PAAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.75	7.87	0.54	6.19e-13	Blood metabolite levels;
PAAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-6.83	-0.48	1.93e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2051773	0.567	rs4517490	chr11:17043054	G/T	cg15084286	chr11:17036142	PLEKHA7	0.56	5.01	0.38	1.48e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.41	-0.34	1.97e-5	Height;
PAAD	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.71	8.39	0.56	3.08e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs1497828	1.000	rs2815241	chr1:217549909	G/A	cg04411442	chr1:217543379	NA	0.48	4.65	0.35	7.25e-6	Dialysis-related mortality;
PAAD	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.11	0.55	1.56e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.8	-9.36	-0.6	9.93e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-5.85	-0.43	2.98e-8	Mean corpuscular volume;
PAAD	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.72	-7.34	-0.51	1.19e-11	Alcohol dependence;
PAAD	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.27	0.39	4.67e-7	Heart rate;
PAAD	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.65	7.39	0.51	9.18e-12	Height;
PAAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg15571903	chr15:79123663	NA	0.48	6.27	0.45	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.58	5.3	0.39	4e-7	Mean platelet volume;
PAAD	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg10856724	chr12:34555212	NA	-0.41	-4.33	-0.33	2.66e-5	Morning vs. evening chronotype;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07880005	chr17:34842371	ZNHIT3	-0.73	-7.09	-0.5	4.67e-11	Neuroticism;
PAAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.55	-5.9	-0.43	2.26e-8	Depressive symptoms (multi-trait analysis);
PAAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.86	-7.73	-0.53	1.33e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.62e-11	Blood protein levels;
PAAD	cis	rs9398803	0.678	rs3861456	chr6:126898660	A/G	cg19875578	chr6:126661172	C6orf173	0.44	4.59	0.35	9.33e-6	Male-pattern baldness;
PAAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.51	-7.35	-0.51	1.16e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.99	-0.38	1.61e-6	Height;
PAAD	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.63	6.11	0.44	8.12e-9	Ovarian reserve;
PAAD	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.62	-6.74	-0.48	3.15e-10	High light scatter reticulocyte count;
PAAD	cis	rs597480	0.963	rs290195	chr11:85432420	A/G	cg11817631	chr11:85522609	SYTL2	-0.46	-4.33	-0.33	2.72e-5	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);
PAAD	cis	rs2659067	1.000	rs1654523	chr19:51485194	C/T	cg27497839	chr19:51487305	KLK7	-0.83	-4.74	-0.36	4.79e-6	Blood protein levels;
PAAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.46	-4.77	-0.36	4.37e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg03735013	chr11:61582769	MIR1908;FADS1	0.56	5.07	0.38	1.12e-6	Trans fatty acid levels;
PAAD	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg06307176	chr5:131281290	NA	-0.54	-4.7	-0.36	5.73e-6	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.16	16.62	0.8	5.11e-36	Cognitive function;
PAAD	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.62	6.9	0.49	1.3e-10	Menarche (age at onset);
PAAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg16362232	chr11:430036	ANO9	0.83	5.01	0.38	1.48e-6	Body mass index;
PAAD	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg05347473	chr6:146136440	FBXO30	0.46	4.38	0.33	2.24e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg03808351	chr9:123631620	PHF19	0.55	5.92	0.43	2.07e-8	Birth weight;
PAAD	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.54	-5.65	-0.42	7.57e-8	Coronary artery aneurysm in Kawasaki disease;
PAAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg22947322	chr17:47091978	IGF2BP1	0.37	4.32	0.33	2.81e-5	Coronary heart disease;
PAAD	cis	rs654384	0.898	rs13242365	chr7:4175025	G/T	cg27574739	chr7:4176374	SDK1	-0.48	-4.72	-0.36	5.22e-6	Positive affect;
PAAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.2	0.5	2.55e-11	Rheumatoid arthritis;
PAAD	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	5.85	0.43	2.93e-8	Lung cancer in ever smokers;
PAAD	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-4.62	-0.35	8.01e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs8170	0.603	rs4808622	chr19:17415457	C/G	cg10664184	chr19:17420304	DDA1	0.48	4.38	0.33	2.18e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
PAAD	cis	rs7922314	0.571	rs61865689	chr10:64727339	A/G	cg08989932	chr10:65390526	NA	-0.91	-4.52	-0.34	1.22e-5	Cutaneous psoriasis;
PAAD	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.76	8.16	0.55	1.19e-13	Blood metabolite levels;
PAAD	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-7.67	-0.53	1.95e-12	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.15	8.37	0.56	3.57e-14	Type 2 diabetes;
PAAD	cis	rs622217	0.541	rs10755578	chr6:160969738	C/G	cg25313204	chr6:160768801	SLC22A3	-0.44	-4.35	-0.33	2.51e-5	Type 2 diabetes;
PAAD	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.4	0.51	8.8e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg23912435	chr1:150601613	ENSA	0.5	4.61	0.35	8.37e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg15331088	chr8:600555	NA	-0.75	-4.63	-0.35	7.82e-6	IgG glycosylation;
PAAD	cis	rs11825685	0.836	rs56327979	chr11:134588757	A/T	cg06603561	chr11:134479413	NA	-0.73	-5.19	-0.39	6.69e-7	IgG glycosylation;
PAAD	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.57	-4.48	-0.34	1.46e-5	Schizophrenia;
PAAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	4.88	0.37	2.66e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.03	-0.44	1.17e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs9463078	0.656	rs227838	chr6:44684621	C/A	cg25276700	chr6:44698697	NA	0.52	5.79	0.43	3.82e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.79	9.16	0.6	3.42e-16	Intelligence (multi-trait analysis);
PAAD	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg08992911	chr2:238395768	MLPH	0.52	5.31	0.4	3.83e-7	Prostate cancer;
PAAD	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	6.5	0.47	1.1e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.48	-4.49	-0.34	1.42e-5	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs12541635	0.934	rs57715289	chr8:106967124	A/T	cg10147462	chr8:107024639	NA	0.45	4.61	0.35	8.53e-6	Age of smoking initiation;
PAAD	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.4	4.67	0.35	6.65e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.82	-8.55	-0.57	1.2e-14	Alzheimer's disease (late onset);
PAAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg14440974	chr22:39074834	NA	-0.58	-6.79	-0.48	2.42e-10	Menopause (age at onset);
PAAD	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.62	5.51	0.41	1.47e-7	Lung cancer;
PAAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg07204747	chr5:141030761	FCHSD1	0.47	4.27	0.33	3.44e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-10.91	-0.66	7.94e-21	Age at first birth;
PAAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-4.98	-0.37	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg06115741	chr20:33292138	TP53INP2	-0.46	-4.42	-0.34	1.87e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.5	5.18	0.39	7.04e-7	Plasma plasminogen activator levels;
PAAD	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg03538708	chr1:25844672	NA	-0.52	-5.39	-0.4	2.68e-7	Erythrocyte sedimentation rate;
PAAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.89	-6.72	-0.48	3.45e-10	Hip circumference adjusted for BMI;
PAAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.6	6.45	0.46	1.39e-9	Tonsillectomy;
PAAD	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	0.98	4.75	0.36	4.59e-6	Economic and political preferences (immigration/crime);
PAAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg14830002	chr1:247616686	OR2B11	0.58	4.72	0.36	5.33e-6	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg18357526	chr6:26021779	HIST1H4A	0.56	5.02	0.38	1.42e-6	Educational attainment;
PAAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg05895507	chr15:77155635	SCAPER	0.37	4.56	0.35	1.04e-5	Blood metabolite levels;
PAAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.75	-9.3	-0.6	1.48e-16	Prudent dietary pattern;
PAAD	cis	rs10207060	0.500	rs28540721	chr2:240714045	C/T	cg07506560	chr2:240697449	NA	0.56	5.81	0.43	3.58e-8	Obesity-related traits;
PAAD	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.57	4.64	0.35	7.57e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg19223190	chr17:80058835	NA	0.54	5.58	0.41	1.08e-7	Life satisfaction;
PAAD	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	9.06	0.59	5.92e-16	Motion sickness;
PAAD	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-6.2	-0.45	5.17e-9	Caffeine consumption;
PAAD	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.52	5.39	0.4	2.62e-7	Diastolic blood pressure;
PAAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	9.05	0.59	6.29e-16	Platelet count;
PAAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg08132940	chr7:1081526	C7orf50	0.6	4.42	0.34	1.89e-5	Bronchopulmonary dysplasia;
PAAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.67	-6.24	-0.45	4.1e-9	Coronary artery disease;
PAAD	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-4.97	-0.37	1.81e-6	Height;
PAAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.44	6.21	0.45	4.71e-9	Vitiligo;
PAAD	cis	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.53	4.35	0.33	2.49e-5	Depression;
PAAD	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg26497354	chr6:109612229	NA	-0.46	-4.74	-0.36	4.9100000000000004e-06	Reticulocyte fraction of red cells;
PAAD	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.72	-6.65	-0.47	4.94e-10	Primary sclerosing cholangitis;
PAAD	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg06606381	chr12:133084897	FBRSL1	-1.42	-8.79	-0.58	3e-15	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.8	9.45	0.61	6e-17	Fuchs's corneal dystrophy;
PAAD	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-8.45	-0.57	2.19e-14	Blood trace element (Zn levels);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg12992671	chr8:74373287	STAU2	-0.63	-6.84	-0.49	1.82e-10	Obesity-related traits;
PAAD	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.46	-4.4	-0.34	2e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01616529	chr11:638424	DRD4	-0.61	-5.7	-0.42	5.93e-8	Systemic lupus erythematosus;
PAAD	cis	rs2790216	1.000	rs1769046	chr10:59960630	C/T	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg04165759	chr1:150448943	RPRD2	0.5	5.18	0.39	6.93e-7	Migraine;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg01956158	chr8:132916947	EFR3A	0.65	7.43	0.52	7.28e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.65	5.16	0.39	7.52e-7	Alzheimer's disease;
PAAD	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg02230254	chr11:65586170	NA	-0.35	-5.28	-0.39	4.3e-7	Eosinophil percentage of white cells;
PAAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	4.68	0.35	6.27e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg18612461	chr15:75251733	NA	0.56	7.16	0.5	3.25e-11	Breast cancer;
PAAD	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.52	4.63	0.35	7.85e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.73	8.48	0.57	1.87e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
PAAD	cis	rs965604	1.000	rs1504549	chr15:78766629	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-4.4	-0.34	2.05e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.73	7.36	0.51	1.08e-11	Colorectal cancer;
PAAD	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-6.62	-0.47	5.91e-10	Neuranatomic and neurocognitive phenotypes;
PAAD	cis	rs6988985	0.560	rs4418320	chr8:143944138	G/A	cg10324643	chr8:143916377	GML	0.41	4.46	0.34	1.57e-5	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg23241863	chr10:102295624	HIF1AN	-0.46	-4.33	-0.33	2.69e-5	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-5.35	-0.4	3.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs1062746	0.527	rs35143469	chr16:87335483	T/C	cg02258303	chr16:87377426	FBXO31	-0.61	-6.08	-0.44	9.52e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
PAAD	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.15	0.55	1.23e-13	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs6594713	0.684	rs7708831	chr5:112933202	A/G	cg12552261	chr5:112820674	MCC	0.78	5.36	0.4	2.97e-7	Brain cytoarchitecture;
PAAD	cis	rs1126510	0.860	rs4803988	chr19:47131957	T/A	cg07844738	chr19:47129343	PTGIR	0.42	4.91	0.37	2.34e-6	Ulcerative colitis;
PAAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	4.28	0.33	3.32e-5	Breast cancer;
PAAD	cis	rs4795519	0.701	rs35275057	chr17:22173784	A/T	cg22648282	chr17:21454238	C17orf51	-0.51	-4.77	-0.36	4.3e-6	Chronic myeloid leukemia;
PAAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.45	4.56	0.35	1.03e-5	Immature fraction of reticulocytes;
PAAD	cis	rs10450586	0.932	rs10835157	chr11:27325462	G/A	cg10370305	chr11:27303972	NA	0.38	4.68	0.36	6.25e-6	Total body bone mineral density;
PAAD	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg04287289	chr16:89883240	FANCA	0.65	7.1	0.5	4.49e-11	Vitiligo;
PAAD	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg17812751	chr4:3478348	DOK7	0.45	5.03	0.38	1.39e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
PAAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-6.43	-0.46	1.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs1499972	0.536	rs6776498	chr3:117832569	G/C	cg07612923	chr3:117604196	NA	-0.83	-5.27	-0.39	4.5e-7	Schizophrenia;
PAAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.71	6.79	0.48	2.33e-10	Obesity-related traits;
PAAD	cis	rs1982963	0.627	rs61971554	chr14:52491583	A/G	cg20550154	chr14:52487779	NID2	0.6	5.02	0.38	1.46e-6	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs1997066	0.831	rs73344326	chr10:106828847	T/C	cg17321814	chr10:106440892	SORCS3	0.65	4.44	0.34	1.74e-5	Diabetic kidney disease;
PAAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg14926445	chr8:58193284	C8orf71	-0.6	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg26850624	chr5:429559	AHRR	1.02	4.76	0.36	4.4e-6	Breast cancer;
PAAD	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.62	5.88	0.43	2.5e-8	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg03386751	chr17:37843793	ERBB2;PGAP3	0.37	5.13	0.38	8.67e-7	Asthma;
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21054248	chr15:75664343	SIN3A	-0.57	-6.89	-0.49	1.38e-10	Energy expenditure (24h);
PAAD	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.72	5.1	0.38	9.77e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.52	5.67	0.42	7.1e-8	Major depressive disorder;
PAAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg10589385	chr1:150898437	SETDB1	0.38	4.57	0.35	1.01e-5	Melanoma;
PAAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	10.69	0.66	3.09e-20	Prudent dietary pattern;
PAAD	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg04450456	chr4:17643702	FAM184B	0.51	5.42	0.4	2.29e-7	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	1.02	8.7	0.58	5.02e-15	Triglycerides;
PAAD	cis	rs3736485	0.932	rs4774598	chr15:51919667	G/A	cg19558802	chr15:51695713	GLDN	-0.45	-4.56	-0.35	1.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.68	-6.14	-0.45	6.99e-9	Obesity-related traits;
PAAD	cis	rs13268772	0.523	rs270056	chr8:3253554	T/A	cg19923622	chr8:2793577	CSMD1	-0.43	-4.31	-0.33	2.92e-5	Schizophrenia;
PAAD	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.06	0.5	5.48e-11	Eye color traits;
PAAD	cis	rs59888335	0.858	rs6548729	chr3:80980062	T/C	cg21735741	chr3:80819488	NA	-0.52	-4.54	-0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg15676125	chr6:33679581	C6orf125	0.49	4.78	0.36	4.11e-6	Plateletcrit;
PAAD	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg25382128	chr12:54346509	NA	-0.45	-4.56	-0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
PAAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.76	8.38	0.56	3.34e-14	Total body bone mineral density;
PAAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.7	-5.86	-0.43	2.77e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.58	5.58	0.41	1.06e-7	Endometrial cancer;
PAAD	cis	rs863345	0.604	rs11265010	chr1:158498853	G/A	cg12129480	chr1:158549410	OR10X1	-0.43	-4.97	-0.37	1.81e-6	Pneumococcal bacteremia;
PAAD	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg10011062	chr15:43941034	CATSPER2	-0.83	-5.12	-0.38	9.06e-7	Lung cancer in ever smokers;
PAAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.61	-7.42	-0.52	7.65e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05025164	chr4:1340916	KIAA1530	0.92	10.74	0.66	2.25e-20	Longevity;
PAAD	cis	rs4759375	0.667	rs10773009	chr12:123818007	C/T	cg05908960	chr12:123472150	PITPNM2	0.63	4.5	0.34	1.32e-5	HDL cholesterol;
PAAD	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.45	4.65	0.35	7.11e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs6942407	0.546	rs3747807	chr7:86800351	A/G	cg02420886	chr7:86849541	C7orf23	0.65	5.02	0.38	1.45e-6	Food allergy;
PAAD	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.51	5.35	0.4	3.15e-7	Coronary heart disease;
PAAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg24253500	chr15:84953950	NA	0.56	6.57	0.47	7.64e-10	Schizophrenia;
PAAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.74	7.02	0.49	6.84e-11	Methadone dose in opioid dependence;
PAAD	cis	rs55692468	0.605	rs12617686	chr2:153351829	C/T	cg02024449	chr2:153032612	STAM2	0.46	4.29	0.33	3.19e-5	Intraocular pressure;
PAAD	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.03	0.38	1.36e-6	Mean platelet volume;
PAAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.55	4.26	0.33	3.51e-5	Depression;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17374034	chr15:39000613	NA	-0.68	-6.9	-0.49	1.34e-10	Obesity-related traits;
PAAD	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg01444801	chr10:135216882	MTG1	-0.59	-5.33	-0.4	3.42e-7	Systemic lupus erythematosus;
PAAD	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.79	0.48	2.36e-10	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.86	-6.7	-0.48	3.8e-10	Axial length;
PAAD	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	0.78	5.45	0.4	1.95e-7	Body mass index;
PAAD	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg12215294	chr3:40350768	EIF1B	-0.47	-4.84	-0.37	3.09e-6	Renal cell carcinoma;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg23368903	chr6:133559279	NA	-0.57	-6.4	-0.46	1.82e-9	Obesity-related traits;
PAAD	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-6.95	-0.49	1.03e-10	Colorectal cancer;
PAAD	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.58	5.61	0.41	9.13e-8	Systemic lupus erythematosus;
PAAD	cis	rs2814982	0.605	rs114672114	chr6:34480065	A/G	cg14254433	chr6:34482411	PACSIN1	-1.13	-6.4	-0.46	1.78e-9	Cholesterol, total;Total cholesterol levels;
PAAD	cis	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg14393609	chr7:65229607	NA	0.72	7.94	0.54	4.04e-13	Calcium levels;
PAAD	cis	rs1190596	0.581	rs1190571	chr14:102634901	C/A	cg23289024	chr14:102554846	HSP90AA1	-0.36	-4.36	-0.33	2.36e-5	Behavioural disinhibition (generation interaction);
PAAD	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.49	-5.6	-0.41	9.78e-8	Reticulocyte fraction of red cells;
PAAD	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.95	6.68	0.48	4.15e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.35	15.62	0.79	2e-33	Eosinophil percentage of granulocytes;
PAAD	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.71	7.75	0.53	1.24e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs67385638	0.962	rs10128556	chr11:5263683	C/T	cg12559170	chr11:5275217	HBG2	0.56	5.46	0.4	1.92e-7	Hemoglobin levels;
PAAD	cis	rs5753037	0.653	rs131266	chr22:30145717	G/T	cg01021169	chr22:30184971	ASCC2	-0.46	-4.79	-0.36	3.84e-6	Type 1 diabetes;
PAAD	cis	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.71	-4.59	-0.35	9.35e-6	Mononucleosis;
PAAD	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-9.05	-0.59	6.33e-16	Vitiligo;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19371681	chr19:50266990	TSKS	0.71	8.07	0.55	2e-13	Smoking initiation;
PAAD	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg03733263	chr8:22462867	KIAA1967	-0.77	-8.89	-0.58	1.64e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
PAAD	cis	rs728616	0.614	rs35193855	chr10:81788495	C/A	cg05935833	chr10:81318306	SFTPA2	-0.55	-4.33	-0.33	2.71e-5	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07080220	chr10:102295463	HIF1AN	-0.78	-7.79	-0.53	1e-12	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg17366294	chr4:99064904	C4orf37	0.53	5.65	0.42	7.67e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg12633918	chr20:23549525	CST9L	-0.44	-4.84	-0.37	3.18e-6	Facial morphology (factor 15, philtrum width);
PAAD	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.56	5.35	0.4	3.1e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.9	-11.14	-0.67	1.85e-21	Dental caries;
PAAD	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.64	-6.73	-0.48	3.27e-10	Colorectal cancer;
PAAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.71	-5.92	-0.43	2.09e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.86	-8.97	-0.59	1.03e-15	Homoarginine levels;
PAAD	cis	rs11563648	0.517	rs10263603	chr7:127035245	G/A	cg21885361	chr7:127911034	NA	-0.4	-4.38	-0.33	2.22e-5	Resting heart rate;
PAAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.78	7.65	0.53	2.09e-12	Schizophrenia;
PAAD	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.44	4.84	0.37	3.11e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
PAAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg15598662	chr11:61582890	MIR1908;FADS1	0.45	4.5	0.34	1.33e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg23464041	chr6:33663938	ITPR3	0.47	4.27	0.33	3.41e-5	Schizophrenia;
PAAD	cis	rs1075265	0.633	rs7591431	chr2:54222165	C/A	cg04546899	chr2:54196757	PSME4	0.32	4.67	0.35	6.6e-6	Morning vs. evening chronotype;Chronotype;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17675882	chr20:35374068	NDRG3	0.69	7.84	0.54	7.5e-13	Vitiligo;Type 1 diabetes;
PAAD	cis	rs943466	1.000	rs6930201	chr6:33738749	A/C	cg04704449	chr6:33738291	NA	-0.46	-4.86	-0.37	2.96e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.21	0.51	2.41e-11	Multiple sclerosis;
PAAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.89	-0.37	2.51e-6	Menarche (age at onset);
PAAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-6.7	-0.48	3.86e-10	Bipolar disorder and schizophrenia;
PAAD	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.62	6.92	0.49	1.2e-10	Smoking initiation;
PAAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	4.53	0.34	1.21e-5	Schizophrenia;
PAAD	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg12735025	chr18:44702766	IER3IP1	-0.76	-7.17	-0.5	3.11e-11	Neuroticism;
PAAD	cis	rs943466	1.000	rs12524835	chr6:33730843	G/C	cg04704449	chr6:33738291	NA	-0.48	-4.84	-0.37	3.11e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
PAAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.73	9.93	0.63	3.18e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg02631450	chr22:32366979	NA	1.07	5.77	0.42	4.38e-8	Childhood ear infection;
PAAD	cis	rs2241685	0.850	rs919718	chr2:1952576	A/G	cg22511877	chr2:1942942	MYT1L	0.75	5.16	0.39	7.5e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-6.07	-0.44	9.82e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.58	6.26	0.45	3.82e-9	Cardiovascular disease risk factors;
PAAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-6.57	-0.47	7.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.52	-0.34	1.23e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-4.38	-0.33	2.19e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg05347473	chr6:146136440	FBXO30	0.54	5.24	0.39	5.27e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.65	4.53	0.34	1.2e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg09701102	chr11:67373083	NDUFV1	0.41	4.29	0.33	3.15e-5	Mean corpuscular volume;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.69	-6.98	-0.49	8.61e-11	Smoking initiation;
PAAD	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.65	6.56	0.47	8.15e-10	Blood protein levels;
PAAD	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg03513858	chr6:54763001	FAM83B	-0.43	-4.63	-0.35	7.84e-6	Menarche (age at onset);
PAAD	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	4.31	0.33	2.9e-5	Multiple sclerosis;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17415989	chr19:17858330	FCHO1	-0.69	-6.3	-0.46	3.13e-9	Neuroticism;
PAAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.46	-5.04	-0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.5	4.85	0.37	2.96e-6	Height;
PAAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26796135	chr15:45671001	LOC145663;GATM	0.51	4.68	0.35	6.32e-6	Homoarginine levels;
PAAD	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	0.96	8.07	0.55	1.92e-13	Hip circumference adjusted for BMI;
PAAD	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.93	-11.27	-0.67	8.4e-22	Refractive error;
PAAD	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.77	-8.37	-0.56	3.52e-14	Aortic root size;
PAAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg03676636	chr4:99064102	C4orf37	0.33	5.79	0.43	3.89e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.7	7.9	0.54	5.09e-13	Cleft lip with or without cleft palate;
PAAD	cis	rs57786342	0.671	rs72731565	chr14:69281448	G/A	cg03189333	chr14:69283534	NA	-0.61	-4.4	-0.34	1.99e-5	Macrophage inflammatory protein 1a levels;
PAAD	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg16342193	chr10:102329863	NA	-0.74	-8.04	-0.55	2.29e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.57	5.08	0.38	1.09e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.51	-4.98	-0.37	1.73e-6	Motion sickness;
PAAD	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg10396713	chr8:602097	NA	-0.68	-4.43	-0.34	1.76e-5	IgG glycosylation;
PAAD	cis	rs6604026	0.656	rs6604029	chr1:93394125	C/G	cg17283838	chr1:93427260	FAM69A	0.6	5.57	0.41	1.15e-7	Multiple sclerosis;
PAAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07685180	chr8:600429	NA	0.81	5.19	0.39	6.67e-7	IgG glycosylation;
PAAD	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs4764124	0.556	rs3789999	chr12:14930055	G/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	5.48	0.41	1.73e-7	Pubertal anthropometrics;
PAAD	cis	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11411865	chr7:2701802	TTYH3	-0.63	-4.46	-0.34	1.59e-5	Bipolar disorder;
PAAD	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg13660082	chr14:53194042	PSMC6	0.74	4.5	0.34	1.32e-5	Alzheimer's disease (late onset);
PAAD	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.56	5.95	0.43	1.75e-8	Schizophrenia;
PAAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.62	6.5	0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg08758996	chr17:66097529	LOC651250	0.49	4.66	0.35	6.9e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs12760731	0.720	rs12691481	chr1:178392653	T/C	cg00404053	chr1:178313656	RASAL2	0.72	5.64	0.42	8.21e-8	Obesity-related traits;
PAAD	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg12315302	chr6:26189340	HIST1H4D	0.84	4.56	0.35	1.04e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.62	-7.66	-0.53	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-4.56	-0.35	1.03e-5	Total body bone mineral density;
PAAD	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.25	-5.35	-0.4	3.17e-7	Urinary tract infection frequency;
PAAD	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-6.43	-0.46	1.6e-9	Chronic sinus infection;
PAAD	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	8.74	0.58	4e-15	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.6	5.09	0.38	1.03e-6	Neutrophil percentage of white cells;
PAAD	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.74	6.91	0.49	1.27e-10	Asthma;
PAAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	10.98	0.66	5.22e-21	Smoking behavior;
PAAD	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg18721089	chr20:30220636	NA	-0.61	-5.08	-0.38	1.08e-6	Mean corpuscular hemoglobin;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15120237	chr17:7747620	KDM6B	0.61	6.56	0.47	7.76e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.48	5.64	0.42	7.88e-8	Height;
PAAD	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.47	4.47	0.34	1.54e-5	Sudden cardiac arrest;
PAAD	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21646471	chr2:242523971	THAP4	0.64	5.07	0.38	1.15e-6	Prostate cancer;
PAAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg15693483	chr7:1102177	C7orf50	0.45	5.02	0.38	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.83	10.48	0.65	1.08e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.55	5.76	0.42	4.62e-8	Menarche (age at onset);
PAAD	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg06307176	chr5:131281290	NA	-0.49	-4.41	-0.34	1.95e-5	Life satisfaction;
PAAD	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.57	-5.7	-0.42	6.01e-8	Metabolite levels (Pyroglutamine);
PAAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg21565972	chr17:80109576	CCDC57	-0.58	-6.74	-0.48	3.02e-10	Life satisfaction;
PAAD	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	12.34	0.71	1.1e-24	Chronic sinus infection;
PAAD	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg08601574	chr20:25228251	PYGB	-0.65	-7.22	-0.51	2.38e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.74	-10.02	-0.63	1.91e-18	Colorectal cancer;
PAAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg04160749	chr8:58172571	NA	-0.59	-4.36	-0.33	2.39e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	1.04	5.44	0.4	2.11e-7	Body mass index;
PAAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.63	6.53	0.47	9.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7264396	0.697	rs6142416	chr20:34174092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	5.21	0.39	6.18e-7	Total cholesterol levels;
PAAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-4.45	-0.34	1.68e-5	Longevity;Endometriosis;
PAAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg18370025	chr7:2749541	AMZ1	-0.4	-4.55	-0.35	1.08e-5	Height;
PAAD	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg10729496	chr3:10149963	C3orf24	0.77	6.33	0.46	2.57e-9	Alzheimer's disease;
PAAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.94	8.04	0.55	2.29e-13	Alzheimer's disease;
PAAD	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg06883089	chr1:45254480	BEST4	-0.35	-4.3	-0.33	3.02e-5	High light scatter reticulocyte count;
PAAD	cis	rs11867129	1.000	rs13332547	chr16:2367424	G/A	cg05196366	chr16:3239155	NA	-0.47	-4.46	-0.34	1.59e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
PAAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg13468214	chr4:1046988	NA	-0.55	-5.96	-0.44	1.68e-8	Recombination rate (males);
PAAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.81	6.18	0.45	5.62e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg17372223	chr3:52568218	NT5DC2	0.53	5.33	0.4	3.47e-7	Bipolar disorder;
PAAD	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.5	4.45	0.34	1.67e-5	Kawasaki disease;
PAAD	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.55	5.91	0.43	2.18e-8	Bladder cancer;
PAAD	trans	rs9345521	0.967	rs9360072	chr6:65489490	C/T	cg26414000	chr1:85721327	C1orf52	0.53	6.57	0.47	7.51e-10	Iris color (a* coordinate);
PAAD	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg00717180	chr2:96193071	NA	-0.6	-6.64	-0.47	5.28e-10	HDL cholesterol;
PAAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg19592336	chr6:28129416	ZNF389	0.6	4.31	0.33	2.96e-5	Depression;
PAAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10556349	chr10:835070	NA	0.7	5.65	0.42	7.63e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.49	-6.21	-0.45	4.74e-9	Height;
PAAD	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg22601191	chr20:60968625	CABLES2	-0.59	-5.65	-0.42	7.61e-8	Colorectal cancer;
PAAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg07489553	chr2:9771190	YWHAQ	0.66	6.99	0.49	8.12e-11	Myopia (pathological);
PAAD	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.6	6.19	0.45	5.32e-9	Reticulocyte fraction of red cells;
PAAD	cis	rs9888739	1.000	rs34767000	chr16:31330270	A/C	cg02256631	chr16:31342952	ITGAM	-0.56	-4.5	-0.34	1.37e-5	Systemic lupus erythematosus;
PAAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.74	9.26	0.6	1.83e-16	Bone mineral density;
PAAD	cis	rs10750165	0.716	rs10892460	chr11:119654058	T/C	cg24085502	chr11:119066850	CCDC153	-0.34	-4.27	-0.33	3.41e-5	Aggressiveness in attention deficit hyperactivity disorder;
PAAD	cis	rs3736485	0.932	rs4775966	chr15:51913788	A/G	cg19558802	chr15:51695713	GLDN	-0.44	-4.35	-0.33	2.53e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg14926445	chr8:58193284	C8orf71	0.72	5.12	0.38	9.27e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg16147221	chr4:10020634	SLC2A9	0.47	4.3	0.33	3.08e-5	Bone mineral density;
PAAD	cis	rs731174	0.759	rs12133523	chr1:38153110	T/A	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.36	-4.49	-0.34	1.4e-5	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-4.81	-0.36	3.54e-6	Large artery stroke;
PAAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.81	5.89	0.43	2.34e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs56046484	0.956	rs2174218	chr15:85624656	C/G	cg08123816	chr15:85640762	PDE8A	0.49	5.04	0.38	1.33e-6	Testicular germ cell tumor;
PAAD	cis	rs2290419	0.730	rs17400438	chr11:68941787	G/A	cg17042914	chr11:68898666	NA	-0.76	-4.46	-0.34	1.57e-5	Cutaneous malignant melanoma;
PAAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.93	5.02	0.38	1.43e-6	Childhood ear infection;
PAAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg03676636	chr4:99064102	C4orf37	-0.26	-4.45	-0.34	1.66e-5	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs9469890	0.604	rs77587944	chr6:34503644	T/G	cg14254433	chr6:34482411	PACSIN1	-0.85	-5.58	-0.41	1.08e-7	Pubertal anthropometrics;Coronary artery disease;
PAAD	cis	rs600626	0.529	rs11236527	chr11:75469310	A/G	cg24262691	chr11:75473276	NA	-0.67	-5.7	-0.42	6.12e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-5.18	-0.39	6.86e-7	Monocyte percentage of white cells;
PAAD	cis	rs4523957	0.553	rs2641440	chr17:2027182	G/C	cg16513277	chr17:2031491	SMG6	-0.68	-7.11	-0.5	4.25e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg04106633	chr4:1044584	NA	0.7	5.86	0.43	2.8e-8	Recombination rate (females);
PAAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.56	-6.49	-0.47	1.15e-9	Aortic root size;
PAAD	cis	rs8086028	1	rs8086028	chr18:10737779	A/G	cg22318872	chr18:11690145	GNAL	-0.45	-4.38	-0.33	2.21e-5	Venous thromboembolism (SNP x SNP interaction);
PAAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.45	5.36	0.4	2.97e-7	Tonsillectomy;
PAAD	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg26570165	chr1:119541833	NA	0.46	4.33	0.33	2.74e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.62	5.67	0.42	7.11e-8	Red blood cell count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27378486	chr7:4749573	FOXK1	-0.65	-6.32	-0.46	2.76e-9	Obesity-related traits;
PAAD	cis	rs10872587	0.500	rs362832	chr6:146660624	G/A	cg05347473	chr6:146136440	FBXO30	0.67	4.93	0.37	2.12e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.52	8.82	0.58	2.49e-15	IgG glycosylation;
PAAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02725872	chr8:58115012	NA	-0.63	-5.39	-0.4	2.68e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.89	-7.47	-0.52	5.92e-12	Lung disease severity in cystic fibrosis;
PAAD	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.74	-8.38	-0.56	3.24e-14	Morning vs. evening chronotype;
PAAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.66	6.19	0.45	5.27e-9	Prudent dietary pattern;
PAAD	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg10395934	chr14:104002654	TRMT61A	0.48	4.84	0.37	3.2e-6	Body mass index;
PAAD	cis	rs59888335	0.858	rs13077187	chr3:80920738	G/A	cg21735741	chr3:80819488	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
PAAD	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18621852	chr3:10150065	C3orf24	0.64	5.4	0.4	2.49e-7	Alzheimer's disease;
PAAD	cis	rs16975963	0.843	rs73041004	chr19:38263430	T/C	cg08679971	chr19:38281047	NA	0.5	4.88	0.37	2.68e-6	Longevity;
PAAD	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.64	6.29	0.45	3.19e-9	Coronary artery disease;
PAAD	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.94	-12.27	-0.71	1.73e-24	Intelligence (multi-trait analysis);
PAAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-7.66	-0.53	2.05e-12	Prudent dietary pattern;
PAAD	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.72	7.45	0.52	6.48e-12	Aortic root size;
PAAD	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg27394845	chr17:28928406	LRRC37B2	0.7	4.48	0.34	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.32	8.58	0.57	1.02e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg11143131	chr5:131608246	PDLIM4	-0.47	-4.39	-0.34	2.11e-5	Acylcarnitine levels;
PAAD	cis	rs6723108	0.651	rs35215000	chr2:135367656	C/A	cg12500956	chr2:135428796	TMEM163	-0.31	-4.53	-0.35	1.17e-5	Type 2 diabetes;
PAAD	cis	rs3753841	0.801	rs1451029	chr1:103255303	T/C	cg24495344	chr1:103574097	COL11A1	0.38	4.42	0.34	1.91e-5	Glaucoma (primary angle closure);
PAAD	cis	rs1797885	0.714	rs299637	chr3:12534923	A/G	cg07775309	chr3:12595852	NA	0.4	4.42	0.34	1.87e-5	Immature fraction of reticulocytes;
PAAD	cis	rs4343996	0.870	rs6974257	chr7:3392195	A/G	cg21248987	chr7:3385318	SDK1	-0.46	-5.01	-0.38	1.46e-6	Motion sickness;
PAAD	cis	rs7765175	0.698	rs7762238	chr6:113682472	G/T	cg19037598	chr6:113666021	NA	-0.44	-4.72	-0.36	5.42e-6	Coronary artery calcification;
PAAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.56	5.91	0.43	2.12e-8	Lung cancer;
PAAD	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-8.09	-0.55	1.75e-13	Alcohol dependence;
PAAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-0.99	-6.74	-0.48	3.08e-10	Breast cancer;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg18762288	chr17:75954699	NA	0.72	7.29	0.51	1.6e-11	Obesity-related traits;
PAAD	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.52	5.3	0.4	3.92e-7	Schizophrenia;
PAAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	1.1	8.36	0.56	3.62e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg13266496	chr6:110720918	DDO	-0.46	-4.94	-0.37	2.06e-6	Platelet distribution width;
PAAD	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.85	8.28	0.56	5.95e-14	Vitamin D levels;
PAAD	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-1.05	-9.52	-0.61	3.91e-17	Monocyte percentage of white cells;
PAAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	0.97	8.99	0.59	9.33e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg15181151	chr6:150070149	PCMT1	0.58	6.31	0.46	2.94e-9	Lung cancer;
PAAD	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.25	-0.33	3.78e-5	Vitiligo;
PAAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.61	5.85	0.43	2.95e-8	Cleft lip with or without cleft palate;
PAAD	cis	rs2908197	0.699	rs2908191	chr7:75962322	A/G	cg22830091	chr7:75961684	YWHAG	-0.6	-7.13	-0.5	3.85e-11	3-hydroxypropylmercapturic acid levels in smokers;
PAAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.65	-7.01	-0.49	7.15e-11	Iron status biomarkers;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg17609600	chr2:97535892	SEMA4C	0.67	7.74	0.53	1.26e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.92	12.36	0.71	9.6e-25	Prudent dietary pattern;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15188491	chr1:146644106	PRKAB2	0.61	6.78	0.48	2.47e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg10057126	chr4:77819792	ANKRD56	0.64	7.11	0.5	4.24e-11	Emphysema distribution in smoking;
PAAD	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg01777861	chr4:56023843	NA	0.39	4.95	0.37	1.95e-6	Endometriosis;
PAAD	cis	rs12949688	0.626	rs11869345	chr17:55839200	T/A	cg12582317	chr17:55822272	NA	0.41	4.77	0.36	4.27e-6	Schizophrenia;
PAAD	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg04330084	chr7:123175371	IQUB	0.51	4.43	0.34	1.8e-5	Plateletcrit;Platelet count;
PAAD	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg16342193	chr10:102329863	NA	-0.77	-8.43	-0.56	2.54e-14	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg15455643	chr13:111040242	COL4A2	0.5	5.54	0.41	1.28e-7	Coronary artery disease;
PAAD	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-10.15	-0.64	8.51e-19	Idiopathic membranous nephropathy;
PAAD	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.03	11.9	0.69	1.75e-23	Breast cancer;
PAAD	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.59	4.91	0.37	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg01763666	chr17:80159506	CCDC57	0.42	4.26	0.33	3.58e-5	Life satisfaction;
PAAD	cis	rs6952808	0.756	rs10263703	chr7:1895629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.7	-8.05	-0.55	2.25e-13	Bipolar disorder and schizophrenia;
PAAD	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	10.8	0.66	1.59e-20	Homoarginine levels;
PAAD	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	1.02	7.2	0.5	2.53e-11	Gout;Renal underexcretion gout;
PAAD	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg21518248	chr2:162101506	NA	-0.57	-5.28	-0.39	4.48e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
PAAD	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg10223061	chr2:219282414	VIL1	-0.36	-4.33	-0.33	2.73e-5	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.92	7.85	0.54	6.79e-13	Alzheimer's disease;
PAAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.49	6.28	0.45	3.33e-9	Schizophrenia;
PAAD	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.65	-4.38	-0.33	2.21e-5	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.65	-4.89	-0.37	2.56e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.69	7.57	0.52	3.26e-12	Lupus nephritis in systemic lupus erythematosus;
PAAD	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg21479132	chr6:26055353	NA	0.96	6.24	0.45	4.11e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.58	5.25	0.39	4.97e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg07883600	chr3:53528162	CACNA1D	-0.42	-4.52	-0.34	1.25e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg11593588	chr6:170863296	PSMB1;TBP	0.7	7.59	0.52	3.04e-12	Myopia (pathological);
PAAD	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.4	-0.46	1.86e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09695851	chr17:3907499	NA	-0.67	-6.92	-0.49	1.2e-10	Type 2 diabetes;
PAAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215272	chr17:6899095	ALOX12	-0.39	-4.33	-0.33	2.69e-5	Tonsillectomy;
PAAD	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.83	6.38	0.46	2.02e-9	Neuroticism (multi-trait analysis);Neuroticism;
PAAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg16898833	chr6:26189333	HIST1H4D	0.57	4.36	0.33	2.41e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-4.69	-0.36	6.06e-6	Colorectal cancer;
PAAD	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.68	8.19	0.55	1.02e-13	Dupuytren's disease;
PAAD	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg19217778	chr13:113420270	ATP11A	0.62	4.54	0.35	1.15e-5	Glycated hemoglobin levels;
PAAD	cis	rs2278796	0.697	rs2278798	chr1:204949767	A/G	cg04862289	chr1:204966208	NFASC	0.43	4.65	0.35	7.17e-6	Mean platelet volume;
PAAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg00049323	chr5:472564	LOC25845	-0.45	-4.58	-0.35	9.45e-6	Cystic fibrosis severity;
PAAD	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.9	11.02	0.67	4.02e-21	Ulcerative colitis;
PAAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-4.45	-0.34	1.62e-5	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.82	8.64	0.57	7.3e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs58521262	0.519	rs12459515	chr19:22997307	C/T	cg07749055	chr19:23076870	NA	-0.6	-4.68	-0.35	6.37e-6	Testicular germ cell tumor;
PAAD	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.49	4.76	0.36	4.55e-6	Breast cancer;
PAAD	cis	rs3748682	0.861	rs72661832	chr1:38260733	C/T	cg12658694	chr1:38397304	INPP5B	0.46	4.34	0.33	2.58e-5	Hypothyroidism;
PAAD	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg24664470	chr2:208976933	NA	0.56	5.24	0.39	5.35e-7	Attention deficit hyperactivity disorder;
PAAD	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-6.67	-0.48	4.38e-10	Uric acid levels;
PAAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-8.05	-0.55	2.24e-13	Glomerular filtration rate (creatinine);
PAAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.83	8.74	0.58	3.98e-15	Pancreatic cancer;
PAAD	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg22437258	chr11:111473054	SIK2	-0.51	-4.78	-0.36	4.05e-6	Primary sclerosing cholangitis;
PAAD	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg09169269	chr1:149859456	HIST2H2AB;HIST2H2BE	0.5	4.45	0.34	1.68e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
PAAD	cis	rs13102973	0.864	rs7697346	chr4:135899283	G/A	cg14419869	chr4:135874104	NA	0.45	4.47	0.34	1.55e-5	Subjective well-being;
PAAD	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.63	-7.08	-0.5	5.11e-11	Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg08501292	chr6:25962987	TRIM38	0.83	4.33	0.33	2.66e-5	Breast cancer;
PAAD	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.51	-5.48	-0.41	1.71e-7	Non-response to antidepressants and depression;
PAAD	cis	rs12760731	0.720	rs35905053	chr1:178441618	A/T	cg00404053	chr1:178313656	RASAL2	0.69	5.2	0.39	6.25e-7	Obesity-related traits;
PAAD	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg22467129	chr15:76604101	ETFA	0.51	4.72	0.36	5.37e-6	Blood metabolite levels;
PAAD	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.45	-4.56	-0.35	1.04e-5	Ovarian reserve;
PAAD	cis	rs2279817	0.863	rs13376033	chr1:18016590	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-5.78	-0.42	4.02e-8	Neuroticism;
PAAD	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.8	9.67	0.62	1.53e-17	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs72960926	0.744	rs6941436	chr6:74937191	C/T	cg03266952	chr6:74778945	NA	1.2	6.28	0.45	3.37e-9	Metabolite levels (MHPG);
PAAD	cis	rs1667255	0.830	rs3764479	chr18:29169825	C/T	cg18808318	chr18:29669225	NA	-0.49	-4.53	-0.34	1.18e-5	Retinol levels;
PAAD	cis	rs6496932	0.802	rs12442399	chr15:85854850	T/A	cg19183879	chr15:85880815	NA	0.52	4.78	0.36	4.07e-6	Central corneal thickness;Corneal structure;
PAAD	cis	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg11619707	chr19:22235551	ZNF257	-0.57	-5.45	-0.4	2.01e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg19640130	chr10:64028056	RTKN2	-0.37	-4.44	-0.34	1.74e-5	Rheumatoid arthritis;
PAAD	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg12700464	chr11:78128424	GAB2	-0.55	-4.31	-0.33	2.93e-5	Testicular germ cell tumor;
PAAD	cis	rs4233366	0.585	rs3924264	chr1:161178684	C/T	cg13853198	chr1:161185092	FCER1G	-0.3	-4.43	-0.34	1.82e-5	Asthma;
PAAD	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.34	9.21	0.6	2.54e-16	Diabetic retinopathy;
PAAD	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.8	0.43	3.64e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.74	5.77	0.42	4.28e-8	Developmental language disorder (linguistic errors);
PAAD	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg15117754	chr3:10150083	C3orf24	0.64	5.91	0.43	2.13e-8	Alzheimer's disease;
PAAD	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.53	-5.05	-0.38	1.22e-6	Mortality in heart failure;
PAAD	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.74e-7	Motion sickness;
PAAD	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.58	6.03	0.44	1.19e-8	Schizophrenia;
PAAD	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg04254540	chr16:71951199	KIAA0174	0.43	4.31	0.33	2.96e-5	Fibrinogen levels;
PAAD	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.69	6.41	0.46	1.76e-9	Primary sclerosing cholangitis;
PAAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg02196655	chr2:10830764	NOL10	-0.54	-5.57	-0.41	1.1e-7	Prostate cancer;
PAAD	cis	rs4740619	0.688	rs9969816	chr9:15954045	T/G	cg14451791	chr9:16040625	NA	-0.44	-5.01	-0.38	1.52e-6	Body mass index;
PAAD	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	4.46	0.34	1.59e-5	Self-reported allergy;
PAAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg23033748	chr14:75592666	NEK9	0.41	5.03	0.38	1.34e-6	Height;
PAAD	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.75	8.73	0.58	4.31e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
PAAD	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.49	-4.65	-0.35	7.18e-6	Pulmonary function;
PAAD	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	1.01	6.6	0.47	6.33e-10	Fat distribution (HIV);
PAAD	cis	rs6988985	0.647	rs28459852	chr8:143986436	T/A	cg10324643	chr8:143916377	GML	0.42	4.85	0.37	3.01e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
PAAD	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg21665744	chr7:39171113	POU6F2	0.3	4.58	0.35	9.42e-6	IgG glycosylation;
PAAD	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg05019905	chr6:29894831	HCG4P6	0.78	6.26	0.45	3.68e-9	Bipolar disorder and schizophrenia;
PAAD	cis	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.55	4.34	0.33	2.61e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.52	5.03	0.38	1.35e-6	Hip circumference;
PAAD	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.62	6.7	0.48	3.9e-10	Bladder cancer;
PAAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.97	5.1	0.38	1e-6	Childhood ear infection;
PAAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.52	0.41	1.42e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.98	-13.64	-0.74	3.49e-28	Height;
PAAD	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.55	5.15	0.39	7.89e-7	Inflammatory bowel disease;Crohn's disease;
PAAD	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.83	-8.54	-0.57	1.3e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
PAAD	cis	rs61863818	0.557	rs7895646	chr10:99167436	A/G	cg10705379	chr10:99080932	FRAT1	0.43	5.35	0.4	3.23e-7	Monocyte percentage of white cells;
PAAD	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00540400	chr15:79124168	NA	0.59	6.62	0.47	5.8e-10	Coronary artery disease;
PAAD	cis	rs6137287	0.642	rs2876594	chr20:21121472	A/T	cg04219410	chr20:21106687	PLK1S1	0.38	4.46	0.34	1.61e-5	Height;
PAAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.15	8.6	0.57	9.19e-15	Mean corpuscular hemoglobin;
PAAD	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-5.73	-0.42	5.22e-8	Blood protein levels;
PAAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.85	9.29	0.6	1.57e-16	Cognitive function;
PAAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg09835421	chr16:68378352	PRMT7	-0.93	-5.5	-0.41	1.54e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg16083429	chr3:49237500	CCDC36	-0.44	-4.68	-0.35	6.35e-6	Parkinson's disease;
PAAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.52	-5.81	-0.43	3.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg27449745	chr7:23145252	KLHL7	0.6	5.27	0.39	4.58e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.13	9.01	0.59	8.06e-16	Diabetic kidney disease;
PAAD	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg01620082	chr3:125678407	NA	-1.38	-8.29	-0.56	5.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	5.58	0.41	1.08e-7	Bipolar disorder;
PAAD	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	9.2	0.6	2.61e-16	Neutrophil percentage of white cells;
PAAD	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg10636054	chr15:40330586	SRP14	-1.1	-6.49	-0.47	1.13e-9	Corneal curvature;
PAAD	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg00543991	chr22:32367038	NA	1.22	7.43	0.52	7.36e-12	Childhood ear infection;
PAAD	cis	rs2051773	0.567	rs4255517	chr11:17043209	C/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-4.7	-0.36	5.75e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
PAAD	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.67	-7.13	-0.5	3.83e-11	Post bronchodilator FEV1;
PAAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.65	-7.01	-0.49	7.18e-11	Bipolar disorder and schizophrenia;
PAAD	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	4.42	0.34	1.84e-5	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	11.9	0.69	1.76e-23	Birth weight;
PAAD	cis	rs12282928	0.959	rs10769331	chr11:48249779	G/A	cg22827986	chr11:48284249	OR4X1	-0.43	-5.41	-0.4	2.38e-7	Migraine - clinic-based;
PAAD	cis	rs2229238	0.774	rs4341355	chr1:154436404	C/G	cg21262032	chr1:154437693	IL6R	0.39	4.29	0.33	3.19e-5	Coronary heart disease;
PAAD	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.9	7.46	0.52	6.27e-12	Cerebrospinal P-tau181p levels;
PAAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg26174226	chr8:58114915	NA	-0.58	-4.36	-0.33	2.41e-5	Developmental language disorder (linguistic errors);
PAAD	trans	rs17713676	0.510	rs889740	chr16:79074496	C/A	cg05696950	chr2:8715754	NA	-0.85	-6.57	-0.47	7.42e-10	Response to amphetamines;
PAAD	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg23254163	chr1:152506842	NA	-0.59	-6.98	-0.49	8.34e-11	Hair morphology;
PAAD	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.56	-7.06	-0.5	5.64e-11	Lewy body disease;
PAAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25833597	chr17:30823145	MYO1D	0.49	4.78	0.36	4.14e-6	Schizophrenia;
PAAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.6	6.67	0.48	4.51e-10	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	4.48	0.34	1.43e-5	Height;
PAAD	cis	rs4704187	0.687	rs6898116	chr5:74486778	T/G	cg03227963	chr5:74354835	NA	0.49	4.81	0.36	3.66e-6	Response to amphetamines;
PAAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.91	-7.53	-0.52	4.19e-12	Mean corpuscular hemoglobin;
PAAD	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg10495392	chr1:46806563	NSUN4	0.57	5.67	0.42	7.08e-8	Menopause (age at onset);
PAAD	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg19131313	chr8:1704013	NA	-0.38	-4.29	-0.33	3.21e-5	Systolic blood pressure;
PAAD	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.69	-6.47	-0.46	1.3e-9	Fractional excretion of uric acid;
PAAD	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.67	-6.7	-0.48	3.78e-10	Blood protein levels;
PAAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs73206853	0.688	rs73191809	chr12:110907639	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	4.26	0.33	3.59e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21331362	chr6:26221330	NA	-0.5	-6.39	-0.46	1.97e-9	Energy expenditure (24h);
PAAD	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg10818794	chr15:86012489	AKAP13	-0.47	-5.22	-0.39	5.8e-7	Interstitial lung disease;
PAAD	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11806084	chr6:43265339	SLC22A7	-0.56	-6.39	-0.46	1.88e-9	Pancreatic cancer;
PAAD	trans	rs10500871	1.000	rs11529168	chr11:20226442	C/T	cg02956962	chr6:161097311	NA	0.62	6.31	0.46	2.93e-9	Educational attainment;
PAAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.48	-4.99	-0.38	1.61e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg08923669	chr16:420230	MRPL28	-0.44	-4.34	-0.33	2.56e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg05791153	chr7:19748676	TWISTNB	0.63	4.85	0.37	2.98e-6	Thyroid stimulating hormone;
PAAD	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.67	4.62	0.35	7.99e-6	Mean platelet volume;
PAAD	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs10090774	0.862	rs62524109	chr8:141807467	A/G	cg02508881	chr8:142216119	NA	0.41	4.44	0.34	1.69e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.71	-7.28	-0.51	1.65e-11	Monocyte percentage of white cells;
PAAD	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.64	6.46	0.46	1.35e-9	Systemic lupus erythematosus;
PAAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.8	8.18	0.55	1.06e-13	Calcium levels;
PAAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.5	-7.26	-0.51	1.83e-11	Diastolic blood pressure;
PAAD	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg25197388	chr11:66278006	BBS1	-0.42	-4.27	-0.33	3.44e-5	Mean corpuscular volume;
PAAD	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19671926	chr4:122722719	EXOSC9	-0.63	-6.09	-0.44	8.66e-9	Type 2 diabetes;
PAAD	cis	rs72843506	0.656	rs79406817	chr17:19915127	C/T	cg05625806	chr17:19284432	MAPK7	0.69	4.53	0.34	1.2e-5	Schizophrenia;
PAAD	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.51	5.03	0.38	1.38e-6	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg12757816	chr2:10669957	NA	-0.56	-6.01	-0.44	1.35e-8	Prostate cancer;
PAAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.47	-4.5	-0.34	1.32e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs7180079	0.514	rs7403751	chr15:64979291	G/C	cg18210365	chr15:65066710	RBPMS2	0.49	4.37	0.33	2.29e-5	Monocyte count;
PAAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09597638	chr17:3907349	NA	0.88	9.44	0.61	6.19e-17	Type 2 diabetes;
PAAD	cis	rs2982694	0.867	rs2982738	chr6:152292345	C/T	cg26219152	chr6:152443475	SYNE1	-0.65	-4.34	-0.33	2.6e-5	Sudden cardiac arrest;
PAAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg09835421	chr16:68378352	PRMT7	-0.78	-6.48	-0.47	1.2e-9	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.68	6.92	0.49	1.15e-10	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg03983476	chr2:10830698	NOL10	0.58	5.96	0.44	1.66e-8	Prostate cancer;
PAAD	cis	rs375066	0.935	rs368089	chr19:44399084	A/G	cg21496419	chr19:44306685	LYPD5	0.42	5.13	0.38	8.7e-7	Breast cancer;
PAAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.45	4.41	0.34	1.96e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.38	-4.25	-0.33	3.71e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs72960926	0.744	rs11756265	chr6:74901250	T/C	cg03266952	chr6:74778945	NA	-1.18	-6.6	-0.47	6.43e-10	Metabolite levels (MHPG);
PAAD	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.42	-7.12	-0.5	4e-11	Psoriasis vulgaris;
PAAD	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-6.56	-0.47	7.93e-10	Chronic sinus infection;
PAAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.37	4.42	0.34	1.89e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.55	8.64	0.57	7.09e-15	IgG glycosylation;
PAAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	4.34	0.33	2.56e-5	Menopause (age at onset);
PAAD	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg23752985	chr2:85803571	VAMP8	0.63	6.72	0.48	3.47e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
PAAD	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.82	8.05	0.55	2.23e-13	Corneal astigmatism;
PAAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-8.12	-0.55	1.51e-13	Height;
PAAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.61	7.5	0.52	4.94e-12	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.66	-8.23	-0.56	7.65e-14	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14868726	chr18:2571660	METTL4;NDC80	0.68	7.65	0.53	2.15e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.46	-5.25	-0.39	5.01e-7	Testicular germ cell tumor;
PAAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-5.93	-0.43	1.98e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg03338584	chr11:507455	RNH1	0.57	4.5	0.34	1.35e-5	Systemic lupus erythematosus;
PAAD	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg21775007	chr8:11205619	TDH	-0.51	-4.59	-0.35	9.23e-6	Morning vs. evening chronotype;
PAAD	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg21483461	chr5:81570383	RPS23	0.59	5.26	0.39	4.91e-7	Breast cancer;
PAAD	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.96	14.23	0.76	9.84e-30	Intelligence (multi-trait analysis);
PAAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	4.59	0.35	9.28e-6	Obesity-related traits;
PAAD	cis	rs11997175	0.522	rs10954930	chr8:33588352	C/T	ch.8.33884649F	chr8:33765107	NA	0.59	6.24	0.45	4.08e-9	Body mass index;
PAAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg18209359	chr17:80159595	CCDC57	-0.47	-4.69	-0.36	6.06e-6	Life satisfaction;
PAAD	cis	rs597583	0.806	rs1940039	chr11:117393102	C/T	cg27161313	chr11:117392002	DSCAML1	-0.75	-6.23	-0.45	4.34e-9	Putamen volume;
PAAD	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.67	6.73	0.48	3.25e-10	Body mass index;
PAAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg06307176	chr5:131281290	NA	0.5	4.35	0.33	2.49e-5	Life satisfaction;
PAAD	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-0.99	-4.93	-0.37	2.11e-6	Erectile dysfunction and prostate cancer treatment;
PAAD	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.42	-4.33	-0.33	2.72e-5	Resting heart rate;
PAAD	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg10932868	chr11:921992	NA	0.45	4.75	0.36	4.63e-6	Alzheimer's disease (late onset);
PAAD	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-16.46	-0.8	1.35e-35	Height;
PAAD	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11700980	0.551	rs2832043	chr21:30116146	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-5.04	-0.38	1.29e-6	QRS complex (12-leadsum);
PAAD	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.8	7.88	0.54	5.75e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.91	-0.37	2.37e-6	Cervical cancer;
PAAD	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	4.47	0.34	1.49e-5	Height;
PAAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.61	-7.35	-0.51	1.16e-11	Inflammatory skin disease;
PAAD	cis	rs2274459	0.841	rs12661400	chr6:33696477	C/T	cg06253072	chr6:33679850	C6orf125	0.62	4.73	0.36	5.19e-6	Obesity (extreme);
PAAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg20243544	chr17:37824526	PNMT	0.52	4.53	0.34	1.19e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg25457927	chr22:38595422	NA	-0.31	-4.26	-0.33	3.63e-5	Melanoma;
PAAD	cis	rs16975963	0.644	rs73031326	chr19:38043022	G/T	cg08679971	chr19:38281047	NA	0.46	4.58	0.35	9.49e-6	Longevity;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg11451039	chr17:79131119	AATK	-0.63	-6.62	-0.47	5.72e-10	Obesity-related traits;
PAAD	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg15851278	chr11:73669449	DNAJB13	0.61	5.09	0.38	1.06e-6	Hand grip strength;
PAAD	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg01329690	chr21:38580129	DSCR9	0.33	4.56	0.35	1.03e-5	Eye color traits;
PAAD	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	1.91	11.33	0.68	5.9e-22	Cannabis dependence symptom count;
PAAD	cis	rs6137287	0.924	rs57940584	chr20:21169654	G/A	cg04219410	chr20:21106687	PLK1S1	-0.41	-4.74	-0.36	4.78e-6	Height;
PAAD	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.53	5.19	0.39	6.72e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg04160749	chr8:58172571	NA	-0.67	-4.8	-0.36	3.74e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.81	-7.59	-0.52	3.04e-12	Body mass index;
PAAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.54	0.35	1.15e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs17162190	0.698	rs12086684	chr1:26837067	C/A	cg17456097	chr1:26900765	RPS6KA1	0.59	4.79	0.36	3.88e-6	Mean corpuscular volume;
PAAD	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.7	9.58	0.61	2.6e-17	Hemoglobin concentration;
PAAD	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg00614314	chr15:82944287	LOC80154	0.49	4.82	0.36	3.47e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
PAAD	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-4.62	-0.35	7.96e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.27	-0.51	1.73e-11	Menarche (age at onset);
PAAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.55	-5.71	-0.42	5.78e-8	Daytime sleep phenotypes;
PAAD	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.47	5.02	0.38	1.41e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-4.56	-0.35	1.03e-5	Breast cancer;
PAAD	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.83	-9.96	-0.63	2.67e-18	Coronary artery disease;
PAAD	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg26939375	chr7:64535504	NA	0.72	8.56	0.57	1.17e-14	Aortic root size;
PAAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.87	5.14	0.38	8.48e-7	Tuberculosis;
PAAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-4.83	-0.36	3.32e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg16586182	chr3:47516702	SCAP	-0.71	-8.5	-0.57	1.63e-14	Colorectal cancer;
PAAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.63	7.64	0.53	2.29e-12	Bipolar disorder;
PAAD	cis	rs73206853	0.841	rs7959516	chr12:110622224	A/C	cg12870014	chr12:110450643	ANKRD13A	0.72	4.68	0.35	6.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs10821973	0.597	rs3864793	chr10:64002989	T/C	cg09941381	chr10:64027924	RTKN2	-0.4	-4.27	-0.33	3.42e-5	Hypothyroidism;
PAAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg00945038	chr17:61921165	SMARCD2	0.49	5.77	0.42	4.3e-8	Prudent dietary pattern;
PAAD	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg00531865	chr16:30841666	NA	0.6	4.5	0.34	1.36e-5	Dementia with Lewy bodies;
PAAD	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg27205649	chr11:78285834	NARS2	0.6	4.43	0.34	1.76e-5	Alzheimer's disease (survival time);
PAAD	cis	rs55637147	0.553	rs4570598	chr11:57123732	C/T	cg25492363	chr11:57319872	UBE2L6	-0.38	-4.33	-0.33	2.67e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.49	7.02	0.49	6.9e-11	Prostate cancer (SNP x SNP interaction);
PAAD	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg02023728	chr11:77925099	USP35	0.43	4.46	0.34	1.61e-5	Alzheimer's disease (survival time);
PAAD	cis	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg04733911	chr16:78082701	NA	-0.56	-5.93	-0.43	1.97e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.67	-4.28	-0.33	3.25e-5	Systemic lupus erythematosus;
PAAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs73416724	1.000	rs78014492	chr6:43289599	C/T	cg17076780	chr6:43251928	TTBK1	0.56	4.29	0.33	3.2e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15145965	chr22:50218605	BRD1	0.54	4.58	0.35	9.74e-6	Schizophrenia;
PAAD	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.47	4.6	0.35	8.76e-6	Airway imaging phenotypes;
PAAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.77	9.26	0.6	1.8e-16	Alzheimer's disease in APOE e4+ carriers;
PAAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg14440974	chr22:39074834	NA	-0.58	-6.82	-0.48	1.99e-10	Menopause (age at onset);
PAAD	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.64	6.42	0.46	1.63e-9	Coronary artery disease;
PAAD	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.67	-7.49	-0.52	5.35e-12	Colorectal cancer;
PAAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-4.57	-0.35	1.01e-5	Blood protein levels;
PAAD	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.47	4.35	0.33	2.52e-5	Tuberculosis;
PAAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.72	7.77	0.53	1.07e-12	Cystic fibrosis severity;
PAAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg00024416	chr22:24240387	NA	-0.59	-6.1	-0.44	8.58e-9	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg04520793	chr17:42248056	ASB16	0.47	6.47	0.46	1.29e-9	Total body bone mineral density;
PAAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	1.07	15.02	0.77	7.73e-32	Breast cancer;
PAAD	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-12.38	-0.71	8.74e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05041596	chr11:89867385	NAALAD2	0.63	4.74	0.36	4.95e-6	White blood cell types;
PAAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13198984	chr17:80129470	CCDC57	0.43	5.43	0.4	2.21e-7	Life satisfaction;
PAAD	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-4.71	-0.36	5.58e-6	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs7804356	0.871	rs4722630	chr7:26773364	G/T	cg03456212	chr7:26904342	SKAP2	0.53	4.37	0.33	2.25e-5	Type 1 diabetes;
PAAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.78	7.61	0.53	2.67e-12	DNA methylation (variation);
PAAD	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg04289385	chr6:36355825	ETV7	0.45	4.71	0.36	5.59e-6	Platelet distribution width;
PAAD	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.51	-4.95	-0.37	1.99e-6	Migraine;
PAAD	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg10556349	chr10:835070	NA	0.59	4.88	0.37	2.7e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2070632	0.630	rs1071592	chr3:186338425	A/C	cg25162301	chr3:186330055	AHSG	0.46	4.25	0.33	3.68e-5	Blood protein levels;
PAAD	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.47	-7.05	-0.5	5.9e-11	Cutaneous nevi;
PAAD	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.68	-5.42	-0.4	2.28e-7	Response to antidepressants in depression;
PAAD	cis	rs9472414	0.510	rs227857	chr6:44704392	A/T	cg20913747	chr6:44695427	NA	0.53	5.41	0.4	2.4e-7	Height;
PAAD	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.51	-4.98	-0.37	1.74e-6	Mean corpuscular volume;
PAAD	cis	rs728616	0.867	rs1983776	chr10:81663695	C/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.8	-0.36	3.72e-6	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13560548	chr3:10150139	C3orf24	0.62	5.49	0.41	1.64e-7	Alzheimer's disease;
PAAD	trans	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.81	-0.48	2.08e-10	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg12486944	chr17:80159399	CCDC57	0.55	4.92	0.37	2.23e-6	Peripheral arterial disease (traffic-related air pollution interaction);
PAAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.2	0.5	2.53e-11	Rheumatoid arthritis;
PAAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.59	4.8	0.36	3.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg20582800	chr6:43612764	RSPH9	-0.56	-4.44	-0.34	1.73e-5	Blood protein levels;
PAAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.58	-5.58	-0.41	1.05e-7	Blood protein levels;
PAAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	6.42	0.46	1.61e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg08085267	chr17:45401833	C17orf57	-0.75	-8.0	-0.54	2.91e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg12963866	chr19:57752005	ZNF805	-0.46	-4.47	-0.34	1.51e-5	Hyperactive-impulsive symptoms;
PAAD	cis	rs10943724	0.704	rs4547973	chr6:81270466	G/A	cg19323245	chr6:80716898	TTK	-0.42	-4.49	-0.34	1.38e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg16434372	chr6:166797387	BRP44L	0.65	6.89	0.49	1.39e-10	Obesity-related traits;
PAAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	5.28	0.39	4.44e-7	Menarche (age at onset);
PAAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-8.87	-0.58	1.88e-15	Developmental language disorder (linguistic errors);
PAAD	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.68	4.89	0.37	2.53e-6	Pancreatic cancer;
PAAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-8.21	-0.55	9.03e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-4.76	-0.36	4.55e-6	Electroencephalogram traits;
PAAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg01075559	chr1:2537774	MMEL1	0.5	5.32	0.4	3.6e-7	Ulcerative colitis;
PAAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.44	4.37	0.33	2.29e-5	Aortic root size;
PAAD	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-8.51	-0.57	1.57e-14	Vitiligo;
PAAD	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg16606324	chr3:10149918	C3orf24	0.75	5.84	0.43	3.13e-8	Alzheimer's disease;
PAAD	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-8.3	-0.56	5.15e-14	Hemoglobin concentration;
PAAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	4.44	0.34	1.7e-5	Longevity;
PAAD	cis	rs4372836	0.518	rs1128416	chr2:29001691	A/G	cg09009506	chr2:28216851	BRE	0.42	4.66	0.35	6.88e-6	Body mass index;
PAAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.54e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
PAAD	cis	rs17401966	0.965	rs61784566	chr1:10252185	C/T	cg15208524	chr1:10270712	KIF1B	0.48	4.29	0.33	3.22e-5	Hepatocellular carcinoma;
PAAD	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.47	4.45	0.34	1.65e-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
PAAD	cis	rs2250402	0.655	rs2307101	chr15:40322460	C/T	cg10636054	chr15:40330586	SRP14	-1.41	-7.09	-0.5	4.67e-11	Corneal curvature;
PAAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.52	4.82	0.36	3.39e-6	Schizophrenia;
PAAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.53	-5.0	-0.38	1.53e-6	Vitiligo;
PAAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.82	-0.43	3.37e-8	Schizophrenia;
PAAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg13191508	chr8:144600686	ZC3H3	-0.81	-4.68	-0.35	6.33e-6	Attention deficit hyperactivity disorder;
PAAD	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-7.31	-0.51	1.45e-11	Mosquito bite size;
PAAD	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	5.07	0.38	1.13e-6	Cognitive ability;
PAAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.51	-5.04	-0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg04359915	chr10:101825029	CPN1	-0.37	-5.67	-0.42	7.02e-8	Bone mineral density;
PAAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.53	-6.27	-0.45	3.55e-9	Alcohol dependence;
PAAD	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.55	4.63	0.35	7.88e-6	Tonsillectomy;
PAAD	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg06042504	chr8:55087323	NA	-0.75	-8.22	-0.55	8.35e-14	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.84	10.19	0.64	6.71e-19	Bladder cancer;
PAAD	cis	rs1879734	0.773	rs67319173	chr1:54133723	T/A	cg14659662	chr1:54151053	GLIS1	-0.4	-5.55	-0.41	1.26e-7	Mitral valve prolapse;
PAAD	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg19337854	chr7:99768885	GPC2	0.43	4.45	0.34	1.64e-5	Coronary artery disease;
PAAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg21698718	chr17:80085957	CCDC57	0.46	5.23	0.39	5.63e-7	Life satisfaction;
PAAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.78	-8.72	-0.58	4.43e-15	Height;
PAAD	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-4.39	-0.34	2.08e-5	Educational attainment;Liver enzyme levels (alkaline phosphatase);
PAAD	cis	rs1934953	0.545	rs7895223	chr10:96643213	A/C	cg09036531	chr10:96991505	NA	0.45	4.25	0.33	3.77e-5	Immune response to smallpox vaccine (IL-6);
PAAD	cis	rs4356203	0.870	rs10832747	chr11:17250019	G/T	cg15432903	chr11:17409602	KCNJ11	-0.44	-4.63	-0.35	7.64e-6	Schizophrenia;Schizophrenia or bipolar disorder;
PAAD	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	0.98	9.44	0.61	6.3e-17	Monocyte percentage of white cells;
PAAD	cis	rs2882667	0.690	rs10045605	chr5:138272147	T/C	cg09476006	chr5:138032270	NA	0.44	5.41	0.4	2.43e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg10547527	chr2:198650123	BOLL	-0.72	-4.78	-0.36	4.02e-6	Ulcerative colitis;
PAAD	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg05895507	chr15:77155635	SCAPER	-0.4	-4.49	-0.34	1.39e-5	Blood metabolite levels;
PAAD	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg22134325	chr11:66188745	NPAS4	0.29	4.62	0.35	8.21e-6	Airway imaging phenotypes;
PAAD	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.68	7.65	0.53	2.08e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs360798	0.744	rs35499742	chr2:62936454	G/A	cg27227250	chr2:62797865	NA	0.35	4.35	0.33	2.52e-5	Coronary artery disease;
PAAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.59	-7.11	-0.5	4.25e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg27565382	chr3:53032988	SFMBT1	-0.72	-4.46	-0.34	1.59e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-7.42	-0.52	7.66e-12	Hemoglobin concentration;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14272175	chr3:58318960	PXK	0.58	6.7	0.48	3.73e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6694270	0.529	rs12041777	chr1:19109193	T/C	cg13786083	chr1:19110734	NA	-0.71	-6.07	-0.44	9.74e-9	Drug-induced liver injury (nitrofurantoin);
PAAD	cis	rs2139634	0.757	rs17030627	chr3:46556948	G/T	cg21489266	chr3:46619131	LRRC2;TDGF1	0.37	4.44	0.34	1.76e-5	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg21589280	chr1:85930151	DDAH1	-0.64	-5.21	-0.39	6.18e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.68	-5.76	-0.42	4.57e-8	Plateletcrit;
PAAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.54	5.25	0.39	4.98e-7	Aortic root size;
PAAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg25456477	chr12:86230367	RASSF9	0.48	4.31	0.33	2.96e-5	Major depressive disorder;
PAAD	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.95	-0.49	1e-10	Response to antipsychotic treatment;
PAAD	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg20636351	chr8:55087400	NA	-0.79	-8.68	-0.58	5.7e-15	Pelvic organ prolapse (moderate/severe);
PAAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg15193198	chr20:60906057	LAMA5	-0.52	-5.45	-0.4	1.95e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
PAAD	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg08523384	chr5:141488047	NDFIP1	-0.52	-4.93	-0.37	2.09e-6	Asthma;
PAAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs8070740	0.503	rs1806246	chr17:5309711	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.45	4.62	0.35	8.21e-6	Menopause (age at onset);
PAAD	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17467752	chr17:38218738	THRA	0.53	4.94	0.37	2e-6	Asthma;
PAAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg19223190	chr17:80058835	NA	0.53	5.43	0.4	2.23e-7	Life satisfaction;
PAAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg08923669	chr16:420230	MRPL28	0.46	4.51	0.34	1.3e-5	Bone mineral density (spine);Bone mineral density;
PAAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12463550	chr7:65579703	CRCP	0.83	5.37	0.4	2.92e-7	Diabetic kidney disease;
PAAD	cis	rs2124969	0.527	rs56040145	chr2:160983850	A/G	cg03641300	chr2:160917029	PLA2R1	-0.64	-5.27	-0.39	4.55e-7	Waist circumference adjusted for body mass index;
PAAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg06815965	chr1:205818668	PM20D1	0.61	6.81	0.48	2.14e-10	Menarche (age at onset);
PAAD	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg01620082	chr3:125678407	NA	-1.48	-8.21	-0.55	8.7e-14	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.67	7.86	0.54	6.63e-13	Metabolite levels;
PAAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.74	8.24	0.56	7.49e-14	Prostate cancer;
PAAD	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.35	0.33	2.48e-5	Educational attainment (years of education);
PAAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	7.11	0.5	4.17e-11	Menarche (age at onset);
PAAD	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	0.72	4.35	0.33	2.5e-5	Immune reponse to smallpox (secreted IL-2);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02199239	chr17:39968091	FKBP10;SC65	-0.8	-7.04	-0.5	6.06e-11	Neuroticism;
PAAD	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.53	5.56	0.41	1.19e-7	Male-pattern baldness;
PAAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.66	8.65	0.57	6.94e-15	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg16920238	chr17:80076378	CCDC57	-0.45	-4.29	-0.33	3.15e-5	Life satisfaction;
PAAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg14440974	chr22:39074834	NA	-0.61	-6.91	-0.49	1.27e-10	Menopause (age at onset);
PAAD	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	7.03	0.5	6.69e-11	Blood protein levels;
PAAD	cis	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg25886479	chr11:50257625	LOC441601	-0.42	-4.53	-0.35	1.16e-5	Coronary artery disease;
PAAD	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-5.82	-0.43	3.37e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11168618	0.692	rs4760707	chr12:48848640	A/G	cg01881778	chr12:48919444	OR8S1	-0.53	-5.57	-0.41	1.13e-7	Adiponectin levels;
PAAD	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.52	5.19	0.39	6.51e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
PAAD	cis	rs155346	0.571	rs264339	chr5:139353502	A/G	cg27335544	chr5:139176304	PSD2	-0.4	-4.28	-0.33	3.31e-5	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
PAAD	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.7	5.68	0.42	6.69e-8	Plasma amyloid beta peptide concentrations (ABx-40);
PAAD	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.5	5.0	0.38	1.54e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
PAAD	cis	rs2882667	0.587	rs288015	chr5:138195217	T/C	cg09476006	chr5:138032270	NA	-0.45	-5.56	-0.41	1.2e-7	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs9377188	0.843	rs6930989	chr6:149354847	C/T	cg21368479	chr6:149415018	NA	0.4	4.53	0.34	1.19e-5	Cancer;
PAAD	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.39	4.75	0.36	4.74e-6	Uric acid levels;
PAAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.28	16.04	0.79	1.6e-34	Eosinophil percentage of granulocytes;
PAAD	trans	rs858239	0.601	rs6966776	chr7:23166008	C/T	cg11875500	chr19:36391588	NFKBID	-0.57	-6.31	-0.46	2.9e-9	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28647808	1.000	rs28489061	chr9:136270319	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.94	5.57	0.41	1.14e-7	Blood protein levels;
PAAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.87	9.74	0.62	1.04e-17	Prudent dietary pattern;
PAAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	7.64	0.53	2.22e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg06045225	chr5:65892993	MAST4	0.59	6.82	0.48	2.05e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg13207630	chr7:32358064	NA	0.97	4.96	0.37	1.91e-6	Body mass index;
PAAD	cis	rs1524927	0.566	rs12704876	chr7:96366342	C/T	cg26619624	chr7:96339434	SHFM1	-0.33	-4.38	-0.33	2.24e-5	Total body bone mineral density;
PAAD	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.72	7.5	0.52	4.85e-12	Intelligence (multi-trait analysis);
PAAD	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg01236616	chr12:121019343	POP5	0.45	4.26	0.33	3.52e-5	High light scatter reticulocyte count;
PAAD	cis	rs9535307	0.584	rs9596197	chr13:50406988	G/T	cg04663916	chr13:50265991	EBPL	0.68	4.89	0.37	2.51e-6	Obesity-related traits;
PAAD	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg23024343	chr7:107201750	COG5	0.59	4.91	0.37	2.34e-6	Coronary artery disease;
PAAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.92	8.33	0.56	4.51e-14	Gut microbiome composition (summer);
PAAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-1.03	-14.16	-0.75	1.43e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
PAAD	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.73	8.65	0.57	6.68e-15	Morning vs. evening chronotype;
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg22199361	chr20:5081567	C20orf30	0.57	6.33	0.46	2.6e-9	Myopia (pathological);
PAAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.6	6.44	0.46	1.52e-9	Tonsillectomy;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg03217964	chr16:75182191	ZFP1	0.6	6.81	0.48	2.09e-10	Metabolite levels  (X-11787);
PAAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	5.77	0.42	4.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg21483461	chr5:81570383	RPS23	-0.55	-4.57	-0.35	9.86e-6	Breast cancer;
PAAD	cis	rs12144049	0.662	rs1923492	chr1:152384833	T/C	cg25605289	chr1:151974222	NA	-0.33	-4.29	-0.33	3.12e-5	Inflammatory skin disease;Atopic dermatitis;
PAAD	cis	rs5417	0.751	rs1634381	chr17:7180007	C/T	cg25256661	chr17:7137939	DVL2	-0.76	-7.72	-0.53	1.43e-12	Diastolic blood pressure;
PAAD	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.85	-9.98	-0.63	2.42e-18	Sudden cardiac arrest;
PAAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.98	0.67	5.15e-21	Homoarginine levels;
PAAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.81	-5.18	-0.39	7e-7	Tuberculosis;
PAAD	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.12	9.52	0.61	3.94e-17	Red blood cell traits;
PAAD	cis	rs11638815	0.581	rs783535	chr15:83250425	T/A	cg00614314	chr15:82944287	LOC80154	0.5	5.01	0.38	1.52e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
PAAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.46	4.54	0.35	1.13e-5	Aortic root size;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg15783703	chr7:70209588	AUTS2	-0.79	-8.46	-0.57	2.02e-14	Obesity-related traits;
PAAD	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.31	0.46	2.94e-9	Bladder cancer;
PAAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg26174226	chr8:58114915	NA	-0.6	-4.48	-0.34	1.44e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg06740227	chr12:86229804	RASSF9	0.52	4.61	0.35	8.5e-6	Major depressive disorder;
PAAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg09796270	chr17:17721594	SREBF1	0.42	4.48	0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg18497280	chr19:42363952	RPS19	0.56	6.42	0.46	1.62e-9	Monocyte percentage of white cells;
PAAD	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg19640130	chr10:64028056	RTKN2	-0.38	-4.51	-0.34	1.27e-5	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg02567719	chr4:83350534	HNRPDL;ENOPH1	0.7	6.95	0.49	9.98e-11	Obesity-related traits;
PAAD	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.75	5.57	0.41	1.14e-7	Vitiligo;
PAAD	trans	rs3733631	1.000	rs28650409	chr4:104628577	C/T	cg11176159	chr1:28213800	NA	-0.48	-6.4	-0.46	1.87e-9	Menarche (age at onset);
PAAD	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.61	4.55	0.35	1.07e-5	Cholesterol, total;
PAAD	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.86	9.21	0.6	2.41e-16	Corneal astigmatism;
PAAD	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	1.91	11.38	0.68	4.42e-22	Cannabis dependence symptom count;
PAAD	cis	rs1485395	0.541	rs11170614	chr12:54017647	G/A	cg20730629	chr12:53886622	MAP3K12	-0.6	-4.25	-0.33	3.75e-5	Migraine without aura;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg00213967	chr3:12851900	CAND2	0.76	7.54	0.52	4.03e-12	Obesity-related traits;
PAAD	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	12.08	0.7	5.69e-24	Post bronchodilator FEV1;
PAAD	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.84	10.26	0.64	4.16e-19	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.95	-9.91	-0.63	3.68e-18	Monocyte percentage of white cells;
PAAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg18833306	chr6:118973337	C6orf204	-0.58	-4.71	-0.36	5.64e-6	Diastolic blood pressure;
PAAD	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.96	6.73	0.48	3.31e-10	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg20406979	chr6:167373233	NA	-0.37	-5.09	-0.38	1.05e-6	Crohn's disease;
PAAD	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg16419906	chr5:132167176	NA	-0.65	-5.24	-0.39	5.39e-7	Apolipoprotein A-IV levels;
PAAD	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.72	7.66	0.53	2.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
PAAD	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.91	8.85	0.58	2.06e-15	Exhaled nitric oxide output;
PAAD	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.55	5.51	0.41	1.47e-7	Eosinophil percentage of white cells;
PAAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg01815783	chr4:1047043	NA	-0.46	-4.33	-0.33	2.68e-5	Recombination rate (females);
PAAD	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg18518183	chr2:172544446	DYNC1I2	-0.48	-4.28	-0.33	3.25e-5	Schizophrenia;
PAAD	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.69	4.47	0.34	1.55e-5	Recalcitrant atopic dermatitis;
PAAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg17372223	chr3:52568218	NT5DC2	0.53	5.34	0.4	3.33e-7	Bipolar disorder;
PAAD	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.72	-7.98	-0.54	3.37e-13	Colorectal cancer;
PAAD	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06028605	chr16:24865363	SLC5A11	0.52	6.25	0.45	3.99e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.17	-0.39	7.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.78	6.77	0.48	2.68e-10	Morning vs. evening chronotype;
PAAD	cis	rs2211560	0.789	rs12726882	chr1:61281476	C/T	cg00575674	chr1:61314297	NA	-0.51	-4.66	-0.35	6.76e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
PAAD	cis	rs9913156	0.748	rs55986729	chr17:4560499	G/T	cg23387401	chr17:4582204	PELP1	0.49	4.88	0.37	2.64e-6	Lymphocyte counts;
PAAD	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.78	7.65	0.53	2.19e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.6	-5.52	-0.41	1.45e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
PAAD	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.59	-6.44	-0.46	1.49e-9	Fibrinogen levels;
PAAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.85	5.47	0.41	1.78e-7	Body mass index;
PAAD	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg08917208	chr2:24149416	ATAD2B	0.5	4.38	0.33	2.2e-5	Lymphocyte counts;
PAAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg08888203	chr3:10149979	C3orf24	0.82	6.24	0.45	4.16e-9	Alzheimer's disease;
PAAD	trans	rs72828912	0.516	rs9393515	chr6:24024396	G/A	cg10859177	chr4:189973211	NA	0.74	6.45	0.46	1.39e-9	Squamous cell lung carcinoma;
PAAD	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.71	-0.42	5.65e-8	Total cholesterol levels;
PAAD	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	1.0	11.27	0.67	8.62e-22	Diastolic blood pressure;Systolic blood pressure;
PAAD	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.78	6.69	0.48	4e-10	Schizophrenia;
PAAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.34	6.18	0.45	5.53e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg00738919	chr7:1100172	C7orf50	0.57	4.5	0.34	1.34e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.6	0.69	1.11e-22	Smoking behavior;
PAAD	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.61	-5.44	-0.4	2.12e-7	Schizophrenia;
PAAD	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.41	-6.82	-0.48	2.03e-10	Paget's disease;
PAAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.92	-8.25	-0.56	7.06e-14	Gut microbiome composition (summer);
PAAD	cis	rs12136530	0.625	rs12726614	chr1:19730957	G/C	cg25104613	chr1:20649108	VWA5B1	-0.42	-4.74	-0.36	4.88e-6	Lead levels in blood;
PAAD	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.99	-8.62	-0.57	8.07e-15	Glomerular filtration rate (creatinine);
PAAD	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg11177333	chr3:195857752	NA	0.45	4.3	0.33	3.07e-5	Non-small cell lung cancer;
PAAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.42	-5.42	-0.4	2.33e-7	Ulcerative colitis;
PAAD	cis	rs17095355	0.748	rs2076974	chr10:111820311	T/C	cg00817464	chr10:111662876	XPNPEP1	0.65	4.86	0.37	2.94e-6	Biliary atresia;
PAAD	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.77	8.57	0.57	1.08e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.77	9.23	0.6	2.21e-16	Lung cancer;
PAAD	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg14404164	chr7:157455790	PTPRN2	-0.61	-4.29	-0.33	3.17e-5	Colorectal cancer;
PAAD	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.42	-4.49	-0.34	1.38e-5	Longevity;
PAAD	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.53	4.76	0.36	4.44e-6	Height;
PAAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.93	8.82	0.58	2.56e-15	Gut microbiome composition (summer);
PAAD	cis	rs797680	0.786	rs555161	chr1:93676314	A/G	cg04535902	chr1:92947332	GFI1	0.46	4.42	0.34	1.88e-5	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
PAAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.47	5.28	0.39	4.42e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.45	-4.48	-0.34	1.47e-5	Total body bone mineral density;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg19027255	chr10:78943401	KCNMA1	-0.61	-6.29	-0.45	3.2e-9	Obesity-related traits;
PAAD	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.07	0.5	5.39e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.02	-17.98	-0.82	1.82e-39	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.1	9.06	0.59	6.04e-16	Vitiligo;
PAAD	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.63	6.32	0.46	2.72e-9	Schizophrenia;
PAAD	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.82	-6.35	-0.46	2.35e-9	Psoriasis;
PAAD	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.61	5.63	0.42	8.49e-8	Obesity-related traits;
PAAD	cis	rs1476670	0.565	rs2428965	chr1:44502909	A/G	cg09470012	chr1:44509516	NA	0.54	5.35	0.4	3.25e-7	Eotaxin levels;
PAAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg03983715	chr16:68378420	PRMT7	-0.74	-5.42	-0.4	2.3e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs9361491	0.608	rs1319575	chr6:79459051	T/C	cg05283184	chr6:79620031	NA	-0.37	-4.48	-0.34	1.47e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2004318	1.000	rs7257210	chr19:55080699	A/C	cg03320607	chr19:54800032	LILRA3	-1.11	-6.15	-0.45	6.62e-9	Blood protein levels;
PAAD	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.08	14.0	0.75	3.91e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.26	0.39	4.87e-7	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg26552233	chr6:72967959	RIMS1	0.57	6.5	0.47	1.08e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.52	5.24	0.39	5.37e-7	Rheumatoid arthritis;
PAAD	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs7254192	0.625	rs736625	chr19:41265201	C/T	cg10585486	chr19:41304133	EGLN2	-0.43	-4.45	-0.34	1.68e-5	Post bronchodilator FEV1;
PAAD	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.93	9.86	0.62	4.92e-18	Testicular germ cell tumor;
PAAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.61	-6.41	-0.46	1.74e-9	Glomerular filtration rate (creatinine);
PAAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.68	6.84	0.49	1.79e-10	Menarche (age at onset);
PAAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.89	-8.25	-0.56	7.01e-14	Developmental language disorder (linguistic errors);
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08045063	chr3:43147672	C3orf39	-0.67	-8.4	-0.56	2.88e-14	Body fat percentage;
PAAD	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.16	0.5	3.3e-11	IgG glycosylation;
PAAD	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg16512390	chr1:228756714	NA	0.71	4.61	0.35	8.41e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs7998202	0.667	rs282574	chr13:113361310	C/T	cg02820901	chr13:113351484	ATP11A	0.7	4.7	0.36	5.85e-6	Glycated hemoglobin levels;
PAAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg00253185	chr1:247542119	NA	0.54	4.42	0.34	1.88e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.74	-7.75	-0.53	1.22e-12	Obesity-related traits;
PAAD	cis	rs757978	0.777	rs11693232	chr2:242362240	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-4.93	-0.37	2.11e-6	Chronic lymphocytic leukemia;
PAAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.78	9.14	0.6	3.75e-16	Emphysema distribution in smoking;
PAAD	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.65	-6.94	-0.49	1.06e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
PAAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.79	-7.94	-0.54	4.16e-13	Colorectal cancer;
PAAD	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	4.33	0.33	2.69e-5	Blood metabolite levels;Amino acid levels;
PAAD	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.51	4.89	0.37	2.5e-6	High light scatter reticulocyte count;
PAAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg07841815	chr7:100318223	EPO	-0.48	-4.54	-0.35	1.15e-5	Other erythrocyte phenotypes;
PAAD	cis	rs7551345	1.000	rs3766287	chr1:31765685	T/C	cg17086398	chr1:31896392	SERINC2	-0.48	-4.55	-0.35	1.09e-5	Schizophrenia;
PAAD	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg17674042	chr6:34482479	PACSIN1	-1.06	-6.99	-0.49	8e-11	Chronic lymphocytic leukemia;
PAAD	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg00717180	chr2:96193071	NA	-0.64	-7.74	-0.53	1.29e-12	HDL cholesterol;
PAAD	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.84	9.25	0.6	1.99e-16	Mortality in heart failure;
PAAD	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.95	-6.0	-0.44	1.41e-8	Lung cancer in ever smokers;
PAAD	cis	rs13102973	0.863	rs13103492	chr4:135907685	A/C	cg14419869	chr4:135874104	NA	0.47	4.83	0.36	3.33e-6	Subjective well-being;
PAAD	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.62	4.71	0.36	5.53e-6	Menarche (age at onset);
PAAD	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.37	4.83	0.36	3.35e-6	Calcium levels;
PAAD	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.9	-6.56	-0.47	8.01e-10	Pulmonary function in asthmatics;
PAAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg21191810	chr6:118973309	C6orf204	-0.53	-5.06	-0.38	1.22e-6	Diastolic blood pressure;
PAAD	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.21	0.45	4.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs2790216	1.000	rs2095892	chr10:60023719	A/C	cg20442379	chr10:60024634	IPMK	-0.58	-4.38	-0.33	2.2e-5	Inflammatory bowel disease;
PAAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg21951975	chr1:209979733	IRF6	0.6	5.5	0.41	1.59e-7	Cleft lip with or without cleft palate;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14132460	chr6:79943592	HMGN3	0.6	6.73	0.48	3.23e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs10901513	0.869	rs2366343	chr10:127671666	C/T	cg22975853	chr10:127789788	ADAM12	0.42	4.47	0.34	1.52e-5	Visceral fat;
PAAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.61	-6.3	-0.45	3.09e-9	Iron status biomarkers;
PAAD	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-6.18	-0.45	5.73e-9	Hypospadias;
PAAD	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2120243	0.508	rs12492874	chr3:157113227	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.32	0.33	2.77e-5	Hepatocellular carcinoma in hepatitis B infection;
PAAD	cis	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.38	-0.33	2.23e-5	Eotaxin levels;
PAAD	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.92	6.19	0.45	5.46e-9	Pulse pressure;Diastolic blood pressure;
PAAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.72	8.0	0.54	3e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg26497354	chr6:109612229	NA	-0.44	-4.76	-0.36	4.44e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	4.39	0.34	2.1e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	9.3	0.6	1.45e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	1.04	13.5	0.74	8.76e-28	Platelet distribution width;
PAAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.33	0.33	2.64e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg12568669	chr8:11666485	FDFT1	0.29	4.74	0.36	4.88e-6	Monocyte count;
PAAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg05110241	chr16:68378359	PRMT7	0.85	6.86	0.49	1.67e-10	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.61	6.42	0.46	1.61e-9	Morning vs. evening chronotype;
PAAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg19847866	chr10:1019161	NA	-0.61	-4.92	-0.37	2.19e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg10011062	chr15:43941034	CATSPER2	-0.78	-4.69	-0.36	6.01e-6	Lung cancer in ever smokers;
PAAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.4	4.33	0.33	2.72e-5	Life satisfaction;
PAAD	cis	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg08394602	chr19:22123885	NA	-0.48	-4.98	-0.37	1.68e-6	Telomere length;
PAAD	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg21589280	chr1:85930151	DDAH1	-0.57	-4.36	-0.33	2.37e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg15181151	chr6:150070149	PCMT1	0.57	6.06	0.44	1.02e-8	Lung cancer;
PAAD	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg09237515	chr14:105715926	BTBD6;BRF1	-0.51	-4.39	-0.34	2.11e-5	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08219700	chr8:58056026	NA	0.67	5.22	0.39	5.82e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs6785206	0.502	rs7621587	chr3:128493760	A/T	cg19205850	chr3:128446370	RAB7A	0.74	5.59	0.41	1.04e-7	Lymphocyte percentage of white cells;
PAAD	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.63	-5.62	-0.41	8.85e-8	Type 2 diabetes;
PAAD	cis	rs10821973	0.527	rs7092005	chr10:63979909	A/G	cg09941381	chr10:64027924	RTKN2	-0.42	-4.45	-0.34	1.67e-5	Hypothyroidism;
PAAD	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg00750074	chr16:89608354	SPG7	-0.57	-5.7	-0.42	5.92e-8	Multiple myeloma (IgH translocation);
PAAD	cis	rs4481887	0.504	rs6587434	chr1:248355563	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-4.3	-0.33	3.02e-5	Common traits (Other);
PAAD	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.48	4.44	0.34	1.69e-5	Endometrial cancer;
PAAD	cis	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg11619707	chr19:22235551	ZNF257	0.58	5.82	0.43	3.37e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
PAAD	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.35	8.42e-6	Depression;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg04341544	chr16:87916394	NA	0.52	6.67	0.48	4.38e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.64	-6.54	-0.47	9.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
PAAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg14092988	chr3:52407081	DNAH1	0.43	5.31	0.4	3.79e-7	Bipolar disorder;
PAAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg14709524	chr16:89940631	TCF25	0.97	4.37	0.33	2.29e-5	Skin colour saturation;
PAAD	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg18281939	chr5:77783895	LHFPL2	0.52	6.71	0.48	3.63e-10	Triglycerides;
PAAD	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg15664640	chr17:80829946	TBCD	-0.68	-4.73	-0.36	5.11e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
PAAD	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.64	-6.69	-0.48	3.95e-10	Post bronchodilator FEV1;
PAAD	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	6.22	0.45	4.58e-9	Lung cancer in ever smokers;
PAAD	cis	rs60154123	1.000	rs12138216	chr1:210480361	G/A	cg25204440	chr1:209979598	IRF6	0.65	4.91	0.37	2.3e-6	Coronary artery disease;
PAAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.59	7.47	0.52	5.79e-12	Hypertriglyceridemia;
PAAD	cis	rs2882667	0.654	rs1972072	chr5:138185293	C/G	cg09476006	chr5:138032270	NA	-0.47	-5.99	-0.44	1.46e-8	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	6.62	0.47	5.81e-10	IgG glycosylation;
PAAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-1.01	-9.65	-0.62	1.76e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
PAAD	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg09760422	chr2:128146352	NA	-0.45	-7.66	-0.53	1.97e-12	Protein C levels;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21214715	chr1:184838445	FAM129A	-0.7	-6.97	-0.49	8.91e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg00262122	chr8:11665843	FDFT1	-0.5	-4.51	-0.34	1.28e-5	Neuroticism;
PAAD	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg06569542	chr10:98946673	SLIT1	-0.52	-5.84	-0.43	3.01e-8	Monocyte count;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg10706293	chr17:20920717	USP22	0.56	6.47	0.46	1.25e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17554472	chr22:41940697	POLR3H	0.59	4.25	0.33	3.65e-5	Vitiligo;
PAAD	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.45	-0.34	1.63e-5	IgG glycosylation;
PAAD	cis	rs12042052	1.000	rs12042052	chr1:232935719	C/T	cg02191044	chr1:232940990	KIAA1383	-0.9	-4.43	-0.34	1.78e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.74	8.33	0.56	4.34e-14	Corneal astigmatism;
PAAD	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-8.17	-0.55	1.09e-13	Morning vs. evening chronotype;
PAAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.72	-9.12	-0.59	4.25e-16	Glomerular filtration rate (creatinine);
PAAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg07148914	chr20:33460835	GGT7	0.49	4.74	0.36	4.93e-6	Coronary artery disease;
PAAD	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.73	7.33	0.51	1.3e-11	Mosquito bite size;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg06067032	chr13:26796571	RNF6	-0.8	-6.92	-0.49	1.19e-10	Neuroticism;
PAAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg27494647	chr7:150038898	RARRES2	0.46	4.8	0.36	3.82e-6	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg05585630	chr7:157510462	PTPRN2	-0.46	-4.49	-0.34	1.42e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.42	-4.78	-0.36	4.09e-6	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.49	5.14	0.38	8.36e-7	Red blood cell count;
PAAD	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.72	7.32	0.51	1.36e-11	Uric acid levels;
PAAD	cis	rs11614333	0.959	rs12305441	chr12:15043986	A/C	cg00431549	chr12:15039025	MGP	-0.35	-4.28	-0.33	3.36e-5	Hand grip strength;
PAAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg11204139	chr17:3907470	NA	0.82	8.32	0.56	4.73e-14	Type 2 diabetes;
PAAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-5.61	-0.41	9.14e-8	Electroencephalogram traits;
PAAD	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg00717180	chr2:96193071	NA	-0.6	-6.68	-0.48	4.18e-10	HDL cholesterol;
PAAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.46	4.55	0.35	1.08e-5	Blood protein levels;Circulating chemerin levels;
PAAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.82	6.63	0.47	5.48e-10	Platelet count;
PAAD	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.77	8.41	0.56	2.78e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg18279126	chr7:2041391	MAD1L1	0.57	5.4	0.4	2.48e-7	Bipolar disorder and schizophrenia;
PAAD	cis	rs4523957	0.928	rs216202	chr17:2197387	T/C	cg16513277	chr17:2031491	SMG6	0.52	5.18	0.39	6.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs7551345	0.671	rs67272103	chr1:31880285	C/T	cg17086398	chr1:31896392	SERINC2	-0.62	-4.26	-0.33	3.62e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg00738919	chr7:1100172	C7orf50	0.72	5.2	0.39	6.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg03938978	chr2:103052716	IL18RAP	0.65	8.16	0.55	1.17e-13	Asthma;
PAAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg18944383	chr4:111397179	ENPEP	0.55	6.29	0.45	3.15e-9	Height;
PAAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.47	4.95	0.37	1.94e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.61	4.47	0.34	1.49e-5	Exhaled nitric oxide output;
PAAD	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.46	-6.79	-0.48	2.32e-10	Cutaneous nevi;
PAAD	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg04731861	chr2:219085781	ARPC2	0.39	4.56	0.35	1.04e-5	Pyoderma gangrenosum in inflammatory bowel disease;
PAAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.65	8.18	0.55	1.05e-13	Prudent dietary pattern;
PAAD	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.93	-7.11	-0.5	4.2e-11	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	6.01	0.44	1.32e-8	Breast cancer;
PAAD	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg16606324	chr3:10149918	C3orf24	0.77	6.01	0.44	1.32e-8	Alzheimer's disease;
PAAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.48	6.41	0.46	1.7e-9	Ulcerative colitis;
PAAD	cis	rs713477	0.524	rs2341538	chr14:55895174	C/G	cg13175173	chr14:55914753	NA	0.33	4.26	0.33	3.62e-5	Pediatric bone mineral content (femoral neck);
PAAD	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.83	8.74	0.58	3.94e-15	Corneal astigmatism;
PAAD	cis	rs11615916	0.790	rs73135272	chr12:62681769	A/G	cg11441379	chr12:63026424	NA	0.65	4.41	0.34	1.93e-5	Pulmonary function decline;
PAAD	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg09796270	chr17:17721594	SREBF1	0.45	4.66	0.35	6.96e-6	Total body bone mineral density;
PAAD	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg02631450	chr22:32366979	NA	1.08	5.77	0.42	4.21e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
PAAD	cis	rs6460942	0.514	rs118124486	chr7:12470381	T/G	cg20607287	chr7:12443886	VWDE	-0.52	-5.95	-0.43	1.77e-8	Coronary artery disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg22633988	chr4:77610603	SHROOM3	-0.55	-6.5	-0.47	1.1e-9	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg12193833	chr17:30244370	NA	-0.62	-4.78	-0.36	4.03e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.46	7.13	0.5	3.87e-11	IgG glycosylation;
PAAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-1.0	-7.8	-0.53	9.1e-13	Initial pursuit acceleration;
PAAD	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	4.7	0.36	5.84e-6	Depressive symptoms;
PAAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.37	0.51	1.04e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg04370829	chr17:406249	NA	0.48	4.35	0.33	2.49e-5	Prostate cancer;
PAAD	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.63	-5.52	-0.41	1.42e-7	Obesity-related traits;
PAAD	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.72	-8.42	-0.56	2.67e-14	Extrinsic epigenetic age acceleration;
PAAD	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg14851346	chr12:38532713	NA	-0.45	-4.42	-0.34	1.9e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg06609049	chr19:2785107	THOP1	0.91	10.31	0.64	3.13e-19	Total cholesterol levels;
PAAD	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg06728252	chr6:26598149	ABT1	-0.37	-4.36	-0.33	2.36e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-4.29	-0.33	3.19e-5	Schizophrenia;
PAAD	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.74	-9.87	-0.63	4.58e-18	Body mass index;
PAAD	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.55	-6.12	-0.44	7.53e-9	Educational attainment;
PAAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12165864	chr7:66369176	NA	-0.83	-5.49	-0.41	1.66e-7	Diabetic kidney disease;
PAAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg17372223	chr3:52568218	NT5DC2	0.54	5.41	0.4	2.43e-7	Bipolar disorder;
PAAD	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg02404636	chr22:31891804	SFI1	0.49	4.99	0.37	1.66e-6	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg20003494	chr4:90757398	SNCA	-0.57	-5.52	-0.41	1.44e-7	Neuroticism;
PAAD	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-6.79	-0.48	2.35e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
PAAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	5.33	0.4	3.52e-7	Eosinophil percentage of white cells;
PAAD	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.49	5.6	0.41	9.7e-8	Educational attainment;
PAAD	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.38	9.5	0.61	4.32e-17	Diabetic retinopathy;
PAAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16262614	chr3:133464971	TF	0.46	5.09	0.38	1.05e-6	Iron status biomarkers;
PAAD	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.83	-6.31	-0.46	2.95e-9	Coronary artery calcification;
PAAD	cis	rs2120991	1.000	rs7133819	chr12:54262756	C/T	cg23795217	chr12:54812000	ITGA5	-0.34	-4.79	-0.36	3.99e-6	Biliary atresia;
PAAD	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.46	7.44	0.52	6.99e-12	Mean corpuscular hemoglobin concentration;
PAAD	cis	rs59888335	0.830	rs13090802	chr3:80521865	C/G	cg21735741	chr3:80819488	NA	0.59	5.13	0.38	8.8e-7	Schizophrenia;
PAAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg23018236	chr17:30244563	NA	0.58	4.86	0.37	2.89e-6	Hip circumference adjusted for BMI;
PAAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg22029157	chr1:209979665	IRF6	0.72	6.95	0.49	9.81e-11	Coronary artery disease;
PAAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	10.31	0.64	3.22e-19	Homoarginine levels;
PAAD	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.6	-6.15	-0.45	6.67e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
PAAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.7	7.46	0.52	6.1e-12	IgG glycosylation;
PAAD	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-5.64	-0.42	8.14e-8	Intelligence (multi-trait analysis);
PAAD	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04492929	chr16:2155436	PKD1	-0.69	-7.35	-0.51	1.16e-11	Triglycerides;
PAAD	cis	rs12612619	0.579	rs11887277	chr2:27083269	A/G	cg12368169	chr2:27073192	DPYSL5	-0.41	-4.26	-0.33	3.54e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs6499755	0.686	rs31102	chr16:55372522	C/T	cg02859129	chr16:55357253	IRX6	0.36	4.91	0.37	2.36e-6	Hypospadias;
PAAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.75	7.97	0.54	3.55e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.63	7.07	0.5	5.14e-11	Systemic lupus erythematosus;
PAAD	cis	rs12257961	0.579	rs2352776	chr10:15370036	C/T	cg10616319	chr10:15468812	NA	0.44	4.38	0.33	2.22e-5	Selective IgA deficiency;
PAAD	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg07747251	chr5:1868357	NA	0.59	6.42	0.46	1.61e-9	Cardiovascular disease risk factors;
PAAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg07689907	chr11:61582574	FADS1	0.49	4.72	0.36	5.26e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
PAAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.69	5.12	0.38	9.04e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs11828289	0.660	rs17306398	chr11:23192235	G/T	cg20040320	chr11:23191996	NA	0.75	5.32	0.4	3.72e-7	Cancer;
PAAD	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.43	4.5	0.34	1.32e-5	Psychosis in Alzheimer's disease;
PAAD	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.45	4.41	0.34	1.95e-5	Chronic sinus infection;
PAAD	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.76	5.41	0.4	2.36e-7	Vitiligo;
PAAD	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg02917321	chr22:38215204	NA	0.49	4.72	0.36	5.24e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg21827317	chr3:136751795	NA	0.5	5.32	0.4	3.69e-7	Gestational age at birth (child effect);
PAAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg06789500	chr7:2109450	MAD1L1	0.41	4.29	0.33	3.22e-5	Bipolar disorder and schizophrenia;
PAAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg01503450	chr10:980765	NA	-0.56	-4.92	-0.37	2.24e-6	Eosinophil percentage of granulocytes;
PAAD	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-6.56	-0.47	7.9e-10	Monocyte percentage of white cells;
PAAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg24540877	chr7:106661281	NA	-0.63	-6.52	-0.47	9.82e-10	Obesity-related traits;
PAAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	4.96	0.37	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	6.98	0.49	8.5e-11	Spherical equivalent (joint analysis main effects and education interaction);
PAAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.81	6.87	0.49	1.52e-10	Recombination rate (females);
PAAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg00431813	chr7:1051703	C7orf50	0.51	4.25	0.33	3.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.4	4.59	0.35	9.04e-6	Intelligence (multi-trait analysis);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg25978167	chr4:57301353	PAICS;PPAT	0.59	6.48	0.47	1.22e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs3007168	1.000	rs2999362	chr14:51605265	A/G	cg23942311	chr14:51606299	NA	0.55	4.28	0.33	3.32e-5	Cancer;
PAAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	8.17	0.55	1.09e-13	Cleft plate (environmental tobacco smoke interaction);
PAAD	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.5	-5.21	-0.39	5.98e-7	Morning vs. evening chronotype;
PAAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg17105886	chr17:28927953	LRRC37B2	0.84	5.0	0.38	1.57e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg10011062	chr15:43941034	CATSPER2	-0.83	-4.78	-0.36	4.18e-6	Lung cancer in ever smokers;
PAAD	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg08992911	chr2:238395768	MLPH	0.58	5.51	0.41	1.5e-7	Prostate cancer;
PAAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.96	-10.14	-0.64	8.96e-19	Intelligence (multi-trait analysis);
PAAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg00450029	chr8:599525	NA	0.72	4.57	0.35	9.94e-6	IgG glycosylation;
PAAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.72	-9.5	-0.61	4.37e-17	Glomerular filtration rate (creatinine);
PAAD	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg16691251	chr5:66510806	NA	-0.73	-7.83	-0.54	7.94e-13	Breast cancer;
PAAD	cis	rs7577696	0.513	rs212685	chr2:32434701	A/G	cg02381751	chr2:32503542	YIPF4	0.5	4.75	0.36	4.58e-6	Inflammatory biomarkers;
PAAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.78	8.89	0.58	1.64e-15	Lung cancer;
PAAD	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.44	-4.98	-0.37	1.68e-6	Coronary artery disease;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13972460	chr20:1165703	C20orf46	0.54	6.5	0.47	1.08e-9	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.37	5.1	0.38	9.99e-7	Permanent tooth development;
PAAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg01763666	chr17:80159506	CCDC57	0.44	4.52	0.34	1.25e-5	Life satisfaction;
PAAD	cis	rs7925523	0.891	rs2903825	chr11:61488968	C/T	cg12472022	chr11:61462803	DAGLA	0.59	4.36	0.33	2.43e-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
PAAD	cis	rs7180079	1.000	rs28550147	chr15:64517028	C/T	cg18210365	chr15:65066710	RBPMS2	-0.64	-4.6	-0.35	8.85e-6	Monocyte count;
PAAD	cis	rs6032067	0.537	rs6032033	chr20:43795081	G/C	cg10761708	chr20:43804764	PI3	0.47	4.25	0.33	3.73e-5	Blood protein levels;
PAAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.85	-10.69	-0.66	3.07e-20	Aortic root size;
PAAD	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg21040360	chr2:3383326	TTC15	-0.44	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs4751006	0.543	rs61875501	chr10:128769951	G/C	cg05702161	chr10:128779687	DOCK1	-1.24	-6.93	-0.49	1.15e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.95	-8.67	-0.58	6e-15	Body mass index;
PAAD	cis	rs7591163	1.000	rs4973380	chr2:228725402	T/A	cg22994281	chr2:228029448	COL4A3;COL4A4	0.48	4.79	0.36	3.95e-6	Blood pressure;
PAAD	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.45	4.73	0.36	5.05e-6	Age of smoking initiation;
PAAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.69	-8.16	-0.55	1.17e-13	Huntington's disease progression;
PAAD	cis	rs6866614	0.639	rs1858074	chr5:131371999	A/G	cg14196790	chr5:131705035	SLC22A5	0.42	4.28	0.33	3.36e-5	Perceived unattractiveness to mosquitoes;
PAAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg23298862	chr7:158159286	PTPRN2	0.57	4.84	0.37	3.17e-6	Response to amphetamines;
PAAD	cis	rs12432203	1.000	rs78769565	chr14:51726384	A/T	cg23942311	chr14:51606299	NA	-0.74	-4.79	-0.36	3.89e-6	Cancer;
PAAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg21698718	chr17:80085957	CCDC57	0.46	5.26	0.39	4.73e-7	Life satisfaction;
PAAD	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg18404041	chr3:52824283	ITIH1	0.4	4.27	0.33	3.42e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg12046867	chr14:103022105	NA	-0.64	-5.04	-0.38	1.29e-6	Platelet count;
PAAD	cis	rs7804356	0.798	rs727448	chr7:26787426	T/C	cg03456212	chr7:26904342	SKAP2	0.55	4.51	0.34	1.27e-5	Type 1 diabetes;
PAAD	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg01028140	chr2:1542097	TPO	-0.86	-6.75	-0.48	2.88e-10	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.72	6.54	0.47	8.78e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	4.9	0.37	2.44e-6	Depressive symptoms;
PAAD	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	5.62	0.41	8.75e-8	Schizophrenia;
PAAD	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.69	-6.62	-0.47	5.88e-10	Plateletcrit;Platelet count;
PAAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.95	10.38	0.64	1.99e-19	Diastolic blood pressure;
PAAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06753367	chr22:24256600	NA	-0.45	-4.86	-0.37	2.93e-6	Liver enzyme levels (gamma-glutamyl transferase);
PAAD	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.27	0.45	3.62e-9	Coffee consumption (cups per day);
PAAD	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-4.98	-0.37	1.69e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
PAAD	cis	rs12935418	0.583	rs2549856	chr16:81026927	C/T	cg16651780	chr16:81037892	C16orf61	-0.63	-5.88	-0.43	2.46e-8	Mean corpuscular volume;
PAAD	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.58	5.09	0.38	1.05e-6	Common traits (Other);
PAAD	cis	rs17032980	0.956	rs7569503	chr2:67325858	A/G	cg02551743	chr2:66673428	MEIS1	-0.49	-4.4	-0.34	2.03e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
PAAD	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	1.97	11.23	0.67	1.06e-21	Cannabis dependence symptom count;
PAAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.55	5.23	0.39	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg05562828	chr17:3906858	NA	0.53	5.83	0.43	3.2e-8	Type 2 diabetes;
PAAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.89	10.46	0.65	1.29e-19	Ulcerative colitis;
PAAD	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.66	6.63	0.47	5.57e-10	Coronary artery disease;
PAAD	cis	rs1113500	0.548	rs7541433	chr1:108645641	G/A	cg06207961	chr1:108661230	NA	0.45	4.68	0.35	6.26e-6	Growth-regulated protein alpha levels;
PAAD	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.64	6.15	0.45	6.48e-9	Intelligence (multi-trait analysis);
PAAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg15448220	chr1:150897856	SETDB1	0.61	6.48	0.47	1.23e-9	Tonsillectomy;
PAAD	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.64	6.83	0.48	1.94e-10	Crohn's disease;
PAAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg02117656	chr17:79614917	TSPAN10	0.55	5.56	0.41	1.2e-7	Eye color traits;
PAAD	cis	rs8040855	0.931	rs11855471	chr15:85719207	T/C	cg08123816	chr15:85640762	PDE8A	0.36	4.43	0.34	1.82e-5	Bulimia nervosa;
PAAD	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.56	5.4	0.4	2.51e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg24634471	chr8:143751801	JRK	-0.53	-5.07	-0.38	1.16e-6	Urinary tract infection frequency;
PAAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7587476	0.548	rs35982594	chr2:215706075	G/A	cg04004882	chr2:215674386	BARD1	0.65	4.53	0.34	1.2e-5	Neuroblastoma;
PAAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg00521551	chr11:64646313	EHD1	0.69	7.29	0.51	1.63e-11	Gut microbiota (bacterial taxa);
PAAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.46	5.04	0.38	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.68	-7.14	-0.5	3.62e-11	Coronary artery disease;
PAAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-7.0	-0.49	7.62e-11	Longevity;Endometriosis;
PAAD	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21646471	chr2:242523971	THAP4	0.63	4.93	0.37	2.15e-6	Prostate cancer;
PAAD	trans	rs901683	1.000	rs71496623	chr10:46085866	A/G	cg14076390	chr17:34947837	DHRS11	0.9	6.71	0.48	3.58e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg11941060	chr3:133502564	NA	-0.44	-4.37	-0.33	2.25e-5	Ankle injury;
PAAD	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	5.33	0.4	3.44e-7	Schizophrenia;
PAAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg00540400	chr15:79124168	NA	-0.69	-8.78	-0.58	3.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg02734326	chr4:10020555	SLC2A9	-0.49	-4.9	-0.37	2.39e-6	Bone mineral density;
PAAD	cis	rs16958440	0.581	rs56395942	chr18:44672299	G/T	cg17192377	chr18:44677553	HDHD2	0.65	4.38	0.33	2.21e-5	Sitting height ratio;
PAAD	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.53	5.74	0.42	4.99e-8	Schizophrenia;
PAAD	cis	rs12042052	1.000	rs72754230	chr1:232935071	A/G	cg02903907	chr1:232941055	KIAA1383	0.84	4.54	0.35	1.13e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6466055	0.777	rs10281886	chr7:104835888	T/C	cg04380332	chr7:105027541	SRPK2	-0.64	-7.31	-0.51	1.45e-11	Schizophrenia;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24344662	chr13:114018021	GRTP1	-0.64	-6.62	-0.47	5.9e-10	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs317865	1.000	rs1625980	chr4:16152859	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.65	4.65	0.35	7.06e-6	Kidney disease (early stage) in type 1 diabetes;
PAAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.85	0.58	2.04e-15	Menopause (age at onset);
PAAD	cis	rs1042026	0.848	rs34777421	chr4:100162348	A/G	cg09112717	chr4:100009950	ADH5	-0.53	-4.8	-0.36	3.69e-6	Esophageal cancer  (alcohol interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06855334	chr11:18610462	UEVLD	0.61	6.73	0.48	3.27e-10	Monocyte percentage of white cells;
PAAD	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	9.29	0.6	1.5e-16	Multiple sclerosis;
PAAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg20243544	chr17:37824526	PNMT	0.51	4.39	0.34	2.08e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs4343996	0.719	rs13221852	chr7:3489139	A/C	cg21248987	chr7:3385318	SDK1	0.48	5.22	0.39	5.66e-7	Motion sickness;
PAAD	cis	rs2518049	0.539	rs1892405	chr10:5159040	A/T	cg13585175	chr10:5228106	AKR1CL1	-0.47	-5.04	-0.38	1.3e-6	Metabolic traits;
PAAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-6.57	-0.47	7.63e-10	Bipolar disorder;
PAAD	cis	rs282587	0.569	rs7987086	chr13:113409889	G/A	cg04656015	chr13:113407548	ATP11A	0.55	4.4	0.34	2.05e-5	Glycated hemoglobin levels;
PAAD	cis	rs282587	0.502	rs391107	chr13:113416198	T/C	cg04656015	chr13:113407548	ATP11A	0.58	4.6	0.35	8.79e-6	Glycated hemoglobin levels;
PAAD	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	6.27	0.45	3.52e-9	Bipolar disorder or attention deficit hyperactivity disorder;
PAAD	cis	rs863345	0.584	rs6657638	chr1:158497184	C/G	cg12129480	chr1:158549410	OR10X1	-0.44	-5.06	-0.38	1.19e-6	Pneumococcal bacteremia;
PAAD	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.41	4.88	0.37	2.64e-6	Intraocular pressure;
PAAD	cis	rs10793968	0.688	rs7037209	chr9:133627692	C/G	cg01474677	chr9:133586259	NA	-0.62	-4.66	-0.35	6.85e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
PAAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.82	8.62	0.57	7.92e-15	Colonoscopy-negative controls vs population controls;
PAAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-7.49	-0.52	5.21e-12	Height;
PAAD	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg05555928	chr11:63887634	MACROD1	-0.74	-5.66	-0.42	7.16e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
PAAD	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.44	-6.07	-0.44	9.85e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
PAAD	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-6.54	-0.47	8.9e-10	Morning vs. evening chronotype;
PAAD	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg17329745	chr2:180857619	CWC22	-0.64	-6.5	-0.47	1.07e-9	Alcohol dependence;
PAAD	trans	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg01620082	chr3:125678407	NA	-1.09	-6.3	-0.46	3.05e-9	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.76	-4.46	-0.34	1.58e-5	Skin colour saturation;
PAAD	cis	rs508970	0.556	rs578734	chr11:60919229	A/G	cg24692310	chr11:60915630	VPS37C	0.33	4.61	0.35	8.58e-6	Rheumatoid arthritis;
PAAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.88	-11.15	-0.67	1.82e-21	Monocyte percentage of white cells;
PAAD	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg22827986	chr11:48284249	OR4X1	-0.42	-5.22	-0.39	5.73e-7	Migraine - clinic-based;
PAAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg19223190	chr17:80058835	NA	0.54	5.59	0.41	1.05e-7	Life satisfaction;
PAAD	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.64	-7.04	-0.5	6.31e-11	Capecitabine sensitivity;
PAAD	cis	rs943072	0.915	rs2396088	chr6:43796088	G/A	cg06892548	chr6:43243945	TTBK1	0.63	4.58	0.35	9.72e-6	Ulcerative colitis;
PAAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.55	5.22	0.39	5.75e-7	Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.61	7.21	0.51	2.4e-11	Lung cancer;
PAAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.85	8.57	0.57	1.08e-14	Glomerular filtration rate (creatinine);
PAAD	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.66	-7.28	-0.51	1.69e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
PAAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg22338127	chr1:209979572	IRF6	0.55	4.43	0.34	1.8e-5	Coronary artery disease;
PAAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.88	6.25	0.45	3.96e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg01766943	chr2:54829624	SPTBN1	0.52	4.83	0.36	3.35e-6	Schizophrenia;
PAAD	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.92	7.84	0.54	7.15e-13	Alzheimer's disease;
PAAD	cis	rs9888739	0.702	rs11574636	chr16:31368835	C/T	cg15817542	chr16:31343056	ITGAM	-0.47	-4.51	-0.34	1.28e-5	Systemic lupus erythematosus;
PAAD	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg07150166	chr2:30669952	LCLAT1	-0.69	-5.16	-0.39	7.52e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
PAAD	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.78	4.48	0.34	1.49e-5	Childhood ear infection;
PAAD	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-4.58	-0.35	9.81e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg14851346	chr12:38532713	NA	0.43	4.27	0.33	3.49e-5	Drug-induced liver injury (flucloxacillin);
PAAD	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	7.91	0.54	4.85e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.44	10.26	0.64	4.33e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
PAAD	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.55	5.55	0.41	1.22e-7	Eosinophil percentage of white cells;
PAAD	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg22532475	chr10:104410764	TRIM8	0.4	4.54	0.35	1.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
PAAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13198984	chr17:80129470	CCDC57	0.44	5.51	0.41	1.5e-7	Life satisfaction;
PAAD	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg20356878	chr3:121714668	ILDR1	0.51	4.94	0.37	2.06e-6	Cognitive performance;
PAAD	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.65	6.27	0.45	3.48e-9	Obesity-related traits;
PAAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg03989125	chr22:38214979	NA	0.61	5.92	0.43	2.09e-8	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.93	12.58	0.71	2.59e-25	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg10729496	chr3:10149963	C3orf24	0.92	7.54	0.52	3.86e-12	Alzheimer's disease;
PAAD	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	4.75	0.36	4.73e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27481594	chr15:43623282	ADAL;LCMT2	0.75	4.54	0.35	1.14e-5	Lung cancer in ever smokers;
PAAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg14926445	chr8:58193284	C8orf71	-0.61	-4.66	-0.35	6.76e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs3736485	0.966	rs12443007	chr15:51892192	G/A	cg19558802	chr15:51695713	GLDN	-0.43	-4.36	-0.33	2.37e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg24235997	chr7:105264584	ATXN7L1	0.58	6.56	0.47	7.9e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg15571903	chr15:79123663	NA	-0.5	-6.38	-0.46	2.03e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg22153463	chr1:85462885	MCOLN2	0.64	4.86	0.37	2.91e-6	Serum sulfate level;
PAAD	cis	rs11811982	0.793	rs79578285	chr1:227573505	T/C	cg24860534	chr1:227506868	CDC42BPA	0.55	5.34	0.4	3.37e-7	Optic disc area;
PAAD	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.57	-5.06	-0.38	1.19e-6	Gastric cancer;Non-cardia gastric cancer;
PAAD	cis	rs11825685	0.836	rs11822810	chr11:134581992	A/C	cg06603561	chr11:134479413	NA	-0.74	-5.15	-0.39	8.04e-7	IgG glycosylation;
PAAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.93	-11.82	-0.69	2.89e-23	Coronary artery disease;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg27536791	chr1:183010618	LAMC1	-0.7	-7.42	-0.52	7.55e-12	Obesity-related traits;
PAAD	cis	rs10781543	0.845	rs10735662	chr9:139327869	A/T	cg14019695	chr9:139328340	INPP5E	0.56	5.91	0.43	2.15e-8	Monocyte percentage of white cells;
PAAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06799790	chr17:61951754	CSH2	-0.45	-4.69	-0.36	6.13e-6	Height;
PAAD	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg15309053	chr8:964076	NA	0.61	7.08	0.5	4.9e-11	Schizophrenia;
PAAD	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg02887458	chr19:19495540	GATAD2A	-0.56	-5.35	-0.4	3.11e-7	Bipolar disorder;
PAAD	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.4	-4.25	-0.33	3.68e-5	Schizophrenia;
PAAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg00431813	chr7:1051703	C7orf50	-0.36	-4.52	-0.34	1.24e-5	Longevity;Endometriosis;
PAAD	cis	rs9880772	0.602	rs4680844	chr3:27798172	A/T	cg21473142	chr3:27762095	EOMES	0.3	5.01	0.38	1.46e-6	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
PAAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg13332499	chr17:408570	NA	-0.67	-7.23	-0.51	2.25e-11	Hip circumference adjusted for BMI;
PAAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg03264133	chr6:25882463	NA	-0.52	-4.45	-0.34	1.66e-5	Iron status biomarkers;
PAAD	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.55	5.59	0.41	1.03e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.61	4.95	0.37	1.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.65	7.02	0.49	6.82e-11	Body mass index;
PAAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.55	4.89	0.37	2.53e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs920590	0.560	rs10090638	chr8:19673750	T/G	cg03894339	chr8:19674705	INTS10	-0.46	-4.37	-0.33	2.26e-5	Acute lymphoblastic leukemia (childhood);
PAAD	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg08632701	chr21:37451849	NA	0.56	5.98	0.44	1.53e-8	Mitral valve prolapse;
PAAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21155852	chr7:2048760	MAD1L1	-0.45	-4.61	-0.35	8.56e-6	Bipolar disorder and schizophrenia;
PAAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.43	4.3	0.33	3.05e-5	Aortic root size;
PAAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-6.38	-0.46	2.03e-9	Developmental language disorder (linguistic errors);
PAAD	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.9	-0.37	2.44e-6	Schizophrenia;
PAAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	5.01	0.38	1.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.69	-0.42	6.3e-8	Life satisfaction;
PAAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.68	8.7	0.58	4.94e-15	Menopause (age at onset);
PAAD	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.71	9.16	0.6	3.27e-16	Asthma (childhood onset);
PAAD	cis	rs5756391	0.568	rs10222232	chr22:37317970	A/G	cg16356956	chr22:37317934	CSF2RB	0.4	4.83	0.36	3.27e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.68	7.51	0.52	4.63e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.48	4.9	0.37	2.48e-6	Monocyte count;
PAAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.94	0.54	4.14e-13	Prudent dietary pattern;
PAAD	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg26031613	chr14:104095156	KLC1	-0.47	-5.22	-0.39	5.83e-7	Schizophrenia;
PAAD	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg18281939	chr5:77783895	LHFPL2	0.51	6.46	0.46	1.37e-9	Triglycerides;
PAAD	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.18	19.28	0.84	1.1e-42	Platelet distribution width;
PAAD	cis	rs10821973	0.505	rs7076551	chr10:64026725	C/T	cg09941381	chr10:64027924	RTKN2	-0.42	-4.41	-0.34	1.95e-5	Hypothyroidism;
PAAD	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg03959625	chr15:84868606	LOC388152	0.5	5.42	0.4	2.31e-7	Schizophrenia;
PAAD	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	5.11	0.38	9.74e-7	Motion sickness;
PAAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg17178900	chr1:205818956	PM20D1	-0.48	-4.85	-0.37	3.08e-6	Parkinson's disease;
PAAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	1.34	10.75	0.66	2.14e-20	Schizophrenia;
PAAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.79	8.19	0.55	1.01e-13	Height;
PAAD	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	7.67	0.53	1.87e-12	Coronary artery disease;
PAAD	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.41	-4.93	-0.37	2.12e-6	Lung cancer;
PAAD	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.53	5.42	0.4	2.34e-7	Schizophrenia;
PAAD	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.94	-7.35	-0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg26942532	chr7:75678159	MDH2;STYXL1	-0.53	-4.74	-0.36	4.84e-6	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.91	7.76	0.53	1.14e-12	Alzheimer's disease;
PAAD	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg25833597	chr17:30823145	MYO1D	0.51	4.85	0.37	3.09e-6	Schizophrenia;
PAAD	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.58	-5.23	-0.39	5.52e-7	Retinal vascular caliber;
PAAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.74	7.27	0.51	1.72e-11	Renal function-related traits (BUN);
PAAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg06217245	chr20:33103252	DYNLRB1	-0.45	-5.39	-0.4	2.61e-7	Glomerular filtration rate (creatinine);
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg17315247	chr7:2754218	AMZ1	-0.7	-6.82	-0.48	1.99e-10	Obesity-related traits;
PAAD	trans	rs1075265	0.553	rs2692532	chr2:54006099	C/T	cg16115072	chr17:25938812	KSR1	0.59	6.32	0.46	2.78e-9	Morning vs. evening chronotype;Chronotype;
PAAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg02725872	chr8:58115012	NA	-0.42	-4.25	-0.33	3.66e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.96	6.65	0.47	4.86e-10	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
PAAD	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	5.72	0.42	5.6e-8	Adiposity;
PAAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.67	6.93	0.49	1.09e-10	Schizophrenia;
PAAD	cis	rs5756391	0.546	rs4820262	chr22:37317109	T/C	cg21209356	chr22:37319042	CSF2RB	0.38	4.63	0.35	7.83e-6	Itch intensity from mosquito bite adjusted by bite size;
PAAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.14	-0.39	8.17e-7	Height;
PAAD	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-1.36	-6.49	-0.47	1.15e-9	Pediatric areal bone mineral density (radius);
PAAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg04705435	chr11:17411270	KCNJ11	0.61	6.34	0.46	2.43e-9	Type 2 diabetes;
PAAD	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.76	6.48	0.47	1.19e-9	Chronic kidney disease;
PAAD	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-5.78	-0.42	4.04e-8	Blood protein levels;
PAAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.79	-9.09	-0.59	4.91e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.79	6.72	0.48	3.47e-10	Morning vs. evening chronotype;
PAAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg19337854	chr7:99768885	GPC2	0.47	4.32	0.33	2.76e-5	Platelet count;
PAAD	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg20913747	chr6:44695427	NA	-0.67	-6.69	-0.48	3.92e-10	Total body bone mineral density;
PAAD	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.82	-8.93	-0.59	1.33e-15	Mortality in heart failure;
PAAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.7	-0.42	6.13e-8	Life satisfaction;
PAAD	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.87	8.48	0.57	1.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.52	5.7	0.42	6.05e-8	Longevity;Endometriosis;
PAAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg15181151	chr6:150070149	PCMT1	0.56	6.05	0.44	1.07e-8	Lung cancer;
PAAD	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.87	7.62	0.53	2.56e-12	Recombination rate (females);
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg14986314	chr10:32345441	KIF5B	0.57	6.3	0.46	3.02e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg22143856	chr6:28129313	ZNF389	-0.5	-4.63	-0.35	7.93e-6	Parkinson's disease;
PAAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.72	5.28	0.39	4.48e-7	Tuberculosis;
PAAD	cis	rs17023223	0.537	rs61808892	chr1:119599207	C/T	cg17326555	chr1:119535693	NA	-0.43	-5.32	-0.4	3.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	8.58	0.57	1.02e-14	Alzheimer's disease;
PAAD	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	9.57	0.61	2.89e-17	Cognitive test performance;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17445987	chr19:10305305	DNMT1	-0.58	-6.89	-0.49	1.42e-10	Body fat percentage;
PAAD	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg22601191	chr20:60968625	CABLES2	0.49	4.56	0.35	1.05e-5	Colorectal cancer;
PAAD	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.08	0.59	5.31e-16	Motion sickness;
PAAD	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg17178900	chr1:205818956	PM20D1	-0.64	-4.71	-0.36	5.59e-6	Prostate-specific antigen levels;
PAAD	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.57	5.62	0.41	9.03e-8	Osteoporosis;
PAAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.61	-8.36	-0.56	3.61e-14	Longevity;Endometriosis;
PAAD	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg08999081	chr20:33150536	PIGU	0.62	6.92	0.49	1.21e-10	Height;
PAAD	trans	rs10503871	0.526	rs7000875	chr8:30522313	A/G	cg22814929	chr6:26458213	BTN2A1	0.55	6.62	0.47	5.67e-10	Metabolite levels  (X-11787);
PAAD	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.54	6.83	0.48	1.89e-10	Atrioventricular conduction;
PAAD	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg07159951	chr1:45983175	PRDX1	0.45	5.01	0.38	1.48e-6	High light scatter reticulocyte count;
PAAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.97	-13.36	-0.73	2.07e-27	Height;
PAAD	cis	rs11887277	0.868	rs6717682	chr2:27069211	A/G	cg12368169	chr2:27073192	DPYSL5	-0.43	-4.42	-0.34	1.85e-5	Obesity-related traits;
PAAD	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.78	6.56	0.47	7.9e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
PAAD	cis	rs138918	0.772	rs138937	chr22:43568060	C/G	cg00343092	chr22:43547974	TSPO	0.42	4.71	0.36	5.5e-6	Monocyte count;
PAAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-4.82	-0.36	3.38e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.49	5.1	0.38	1.01e-6	Longevity;Endometriosis;
PAAD	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg21496419	chr19:44306685	LYPD5	-0.34	-4.31	-0.33	2.98e-5	Breast cancer;
PAAD	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.41	4.99	0.38	1.64e-6	Total body bone mineral density;
PAAD	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.94	7.98	0.54	3.25e-13	Dupuytren's disease;
PAAD	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg22961457	chr20:62370310	LIME1;SLC2A4RG	0.47	4.35	0.33	2.49e-5	Prostate cancer;
PAAD	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.69	-7.57	-0.52	3.36e-12	Aortic root size;
PAAD	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg21994712	chr19:21861136	NA	0.48	4.54	0.35	1.14e-5	Pain;
PAAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.59	-6.87	-0.49	1.51e-10	Lung cancer;
PAAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.79	5.35	0.4	3.18e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2455799	1.000	rs13092817	chr3:15889398	C/G	cg13420985	chr3:16524424	RFTN1	-0.46	-4.44	-0.34	1.71e-5	Mean platelet volume;
PAAD	cis	rs7816613	0.850	rs16868134	chr8:102664174	C/T	cg20585841	chr8:102729926	NCALD	-0.7	-5.87	-0.43	2.66e-8	Age-related hearing impairment;
PAAD	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg23024343	chr7:107201750	COG5	0.6	4.96	0.37	1.88e-6	Osteoarthritis;
PAAD	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-4.98	-0.37	1.72e-6	Height;
PAAD	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-5.28	-0.39	4.41e-7	Glomerular filtration rate;
PAAD	cis	rs3736485	0.966	rs7170217	chr15:51890678	A/G	cg19558802	chr15:51695713	GLDN	-0.43	-4.4	-0.34	2e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs9810890	1.000	rs73207973	chr3:128568365	A/G	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg00543991	chr22:32367038	NA	1.19	7.29	0.51	1.55e-11	Childhood ear infection;
PAAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-7.7	-0.53	1.6e-12	Coronary artery disease;
PAAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	9.77	0.62	8.56e-18	Platelet count;
PAAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.64	8.5	0.57	1.62e-14	Type 2 diabetes and other traits;Type 2 diabetes;
PAAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg04160749	chr8:58172571	NA	-0.66	-4.68	-0.36	6.23e-6	Developmental language disorder (linguistic errors);
PAAD	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg17595323	chr11:93583763	C11orf90	-0.36	-4.52	-0.34	1.26e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
PAAD	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.6	-5.07	-0.38	1.13e-6	Schizophrenia;
PAAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg12215294	chr3:40350768	EIF1B	-0.45	-4.5	-0.34	1.35e-5	Renal cell carcinoma;
PAAD	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.98	-0.59	9.97e-16	Morning vs. evening chronotype;
PAAD	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg09127314	chr1:152161683	NA	0.74	5.33	0.4	3.53e-7	Atopic dermatitis;
PAAD	trans	rs13196614	1.000	rs35198526	chr6:148941726	G/A	cg01596495	chr11:57317706	SMTNL1	-0.71	-6.39	-0.46	1.97e-9	Migraine;
PAAD	cis	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg15676455	chr3:128564943	NA	-0.86	-5.06	-0.38	1.2e-6	Dental caries;
PAAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.67	8.34	0.56	4.1e-14	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.71	-8.73	-0.58	4.2e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
PAAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg13468214	chr4:1046988	NA	0.53	4.94	0.37	2e-6	Recombination rate (females);
PAAD	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg00105475	chr2:10696890	NA	0.64	6.76	0.48	2.79e-10	Prostate cancer;
PAAD	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	4.92	0.37	2.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
PAAD	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14159747	chr11:113255604	NA	0.4	5.63	0.42	8.64e-8	Neuroticism;
PAAD	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	6.98	0.49	8.64e-11	IgG glycosylation;
PAAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg00579200	chr11:133705235	NA	-0.43	-4.84	-0.37	3.2e-6	Childhood ear infection;
PAAD	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.62	-5.46	-0.41	1.87e-7	Type 2 diabetes;
PAAD	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	5.13	0.38	8.87e-7	Motion sickness;
PAAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg26513180	chr16:89883248	FANCA	0.62	7.26	0.51	1.87e-11	Vitiligo;
PAAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.62	0.62	2.08e-17	Menopause (age at onset);
PAAD	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.5	-4.55	-0.35	1.11e-5	Triglycerides;
PAAD	cis	rs3736485	0.966	rs12441167	chr15:51850652	T/C	cg19558802	chr15:51695713	GLDN	-0.42	-4.29	-0.33	3.14e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg25501666	chr2:127640322	NA	0.92	4.95	0.37	1.97e-6	Heart failure;
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14130374	chr5:172411105	ATP6V0E1	-0.79	-6.75	-0.48	2.89e-10	Neuroticism;
PAAD	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.55	4.47	0.34	1.55e-5	Blood protein levels;
PAAD	cis	rs7264396	0.832	rs224371	chr20:34074831	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.56	-0.41	1.19e-7	Total cholesterol levels;
PAAD	cis	rs6718203	1.000	rs1011407	chr2:60665768	A/G	cg10480506	chr2:60280451	NA	0.77	4.65	0.35	7.29e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg27005118	chr17:13972210	COX10	0.36	4.67	0.35	6.66e-6	Temperament;
PAAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg24846680	chr1:228362309	C1orf69	-0.44	-4.27	-0.33	3.42e-5	Diastolic blood pressure;
PAAD	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg00717180	chr2:96193071	NA	-0.57	-6.35	-0.46	2.4e-9	HDL cholesterol;
PAAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.78	6.3	0.45	3.08e-9	Lung disease severity in cystic fibrosis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg06786424	chr6:4021316	PRPF4B	0.67	6.6	0.47	6.53e-10	Obesity-related traits;
PAAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.57	-5.33	-0.4	3.55e-7	Neurofibrillary tangles;
PAAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.67	6.94	0.49	1.05e-10	Systemic lupus erythematosus;
PAAD	cis	rs1620921	0.524	rs12194271	chr6:161195895	A/G	cg01280913	chr6:161186852	NA	-0.48	-5.31	-0.4	3.86e-7	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs818427	0.548	rs373059	chr5:112188437	G/A	cg06941702	chr5:112196734	SRP19	-0.54	-5.2	-0.39	6.39e-7	Total body bone mineral density;
PAAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26926768	chr12:34528122	NA	0.4	4.84	0.37	3.1e-6	Morning vs. evening chronotype;
PAAD	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04717802	chr22:42394638	WBP2NL	-0.39	-4.29	-0.33	3.14e-5	Cognitive function;
PAAD	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.66	7.79	0.53	9.6e-13	Metabolite levels;
PAAD	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.85	-4.69	-0.36	6.1e-6	Cholesterol, total;
PAAD	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg25418670	chr11:30344373	C11orf46	-0.65	-6.32	-0.46	2.77e-9	Morning vs. evening chronotype;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg21166781	chr9:124262344	GGTA1	0.64	6.59	0.47	6.88e-10	Obesity-related traits;
PAAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg05562828	chr17:3906858	NA	0.56	6.73	0.48	3.32e-10	Type 2 diabetes;
PAAD	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg20913747	chr6:44695427	NA	0.67	6.6	0.47	6.5e-10	Total body bone mineral density;
PAAD	cis	rs80282103	0.867	rs11250231	chr10:1082040	T/C	cg23653240	chr10:1828900	NA	-0.6	-4.32	-0.33	2.78e-5	Glomerular filtration rate (creatinine);
PAAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg04160749	chr8:58172571	NA	-0.63	-4.42	-0.34	1.84e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg27094323	chr7:1216898	NA	-0.52	-5.99	-0.44	1.44e-8	Longevity;Endometriosis;
PAAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.73	-9.92	-0.63	3.32e-18	Glomerular filtration rate (creatinine);
PAAD	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.78	9.13	0.6	4.02e-16	Colorectal cancer;
PAAD	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg10072921	chr12:121022843	NA	-0.37	-4.92	-0.37	2.19e-6	High light scatter reticulocyte count;
PAAD	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.67	-8.77	-0.58	3.46e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
PAAD	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg18721089	chr20:30220636	NA	-0.57	-4.45	-0.34	1.64e-5	Mean corpuscular hemoglobin;
PAAD	cis	rs1912528	0.814	rs2604918	chr4:140879929	A/C	cg11128457	chr4:140864437	MAML3	0.33	4.39	0.34	2.09e-5	Educational attainment (years of education);
PAAD	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.81	9.81	0.62	6.62e-18	Blood metabolite ratios;
PAAD	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.55	-5.85	-0.43	2.86e-8	Schizophrenia;
PAAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.66	7.93	0.54	4.29e-13	Iron status biomarkers (transferrin levels);
PAAD	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.56	-5.95	-0.43	1.79e-8	Systolic blood pressure (alcohol consumption interaction);
PAAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg16205897	chr5:131564050	P4HA2	-0.43	-4.52	-0.34	1.23e-5	Blood metabolite levels;
PAAD	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.59	4.89	0.37	2.5e-6	Response to antidepressants in depression;
PAAD	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.52	4.93	0.37	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg21698718	chr17:80085957	CCDC57	-0.46	-5.13	-0.38	8.79e-7	Life satisfaction;
PAAD	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.6	4.58	0.35	9.57e-6	Exhaled nitric oxide output;
PAAD	cis	rs7674212	0.556	rs13151569	chr4:103942790	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-4.43	-0.34	1.81e-5	Type 2 diabetes;
PAAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.99	10.63	0.65	4.32e-20	Age-related macular degeneration (geographic atrophy);
PAAD	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.79	9.3	0.6	1.45e-16	Colorectal cancer;
PAAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.72	-0.53	1.42e-12	Bipolar disorder and schizophrenia;
PAAD	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.65	6.89	0.49	1.38e-10	Crohn's disease;
PAAD	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.74	0.42	4.86e-8	Subjective well-being;
PAAD	cis	rs9463078	0.546	rs7763450	chr6:45029896	G/C	cg25276700	chr6:44698697	NA	0.46	5.19	0.39	6.73e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
PAAD	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.7	-6.77	-0.48	2.64e-10	Menarche (age at onset);
PAAD	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.72	7.19	0.5	2.69e-11	Bipolar disorder;
PAAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg23188684	chr11:67383651	NA	-0.49	-4.93	-0.37	2.12e-6	Mean corpuscular volume;
PAAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg21724239	chr8:58056113	NA	0.67	5.2	0.39	6.25e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	5.27	0.39	4.57e-7	Height;
PAAD	cis	rs16975963	0.843	rs73041004	chr19:38263430	T/C	cg25793785	chr19:38281423	NA	0.55	4.54	0.35	1.14e-5	Longevity;
PAAD	cis	rs9810890	1.000	rs73196967	chr3:128437236	C/T	cg18531004	chr3:128564980	NA	-0.81	-4.48	-0.34	1.46e-5	Dental caries;
PAAD	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.45	4.45	0.34	1.68e-5	Crohn's disease;
PAAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg18944383	chr4:111397179	ENPEP	0.56	6.34	0.46	2.44e-9	Height;
PAAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-6.4	-0.46	1.85e-9	Schizophrenia;
PAAD	cis	rs28719689	1.000	rs28719689	chr8:1270670	C/T	cg22761795	chr8:1265118	NA	0.92	6.78	0.48	2.46e-10	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg05304507	chr6:116381966	FRK	0.43	8.27	0.56	6.16e-14	Cholesterol, total;LDL cholesterol;
PAAD	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13773148	chr9:136923109	BRD3	0.45	4.59	0.35	9.33e-6	Platelet distribution width;
PAAD	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg26031613	chr14:104095156	KLC1	-0.52	-5.09	-0.38	1.03e-6	Reticulocyte count;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg07810072	chr11:66610236	RCE1;C11orf80	0.62	6.5	0.47	1.08e-9	Obesity-related traits;
PAAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.11	-8.81	-0.58	2.62e-15	Diabetic kidney disease;
PAAD	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-8.62	-0.57	8.07e-15	Morning vs. evening chronotype;
PAAD	cis	rs77880822	0.562	rs17779831	chr20:1256786	G/A	cg23117778	chr20:1206693	RAD21L1	0.92	5.01	0.38	1.46e-6	Angiotensin-converting enzyme inhibitor intolerance;
PAAD	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.74	-9.6	-0.61	2.36e-17	Asthma;
PAAD	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-4.3	-0.33	3.07e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
PAAD	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg13699009	chr12:122356056	WDR66	0.46	7.07	0.5	5.2e-11	Mean corpuscular volume;
PAAD	trans	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg00717180	chr2:96193071	NA	-0.61	-6.45	-0.46	1.39e-9	Migraine - clinic-based;
PAAD	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg19567339	chr10:100142640	NA	0.43	4.69	0.36	5.94e-6	Metabolite levels;
PAAD	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.52	5.29	0.39	4.29e-7	Resting heart rate;
PAAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg20893579	chr22:38215064	NA	0.5	4.74	0.36	4.94e-6	Optic cup area;Vertical cup-disc ratio;
PAAD	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.49	5.51	0.41	1.47e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg19640517	chr22:41707109	ZC3H7B	-0.53	-4.3	-0.33	3.03e-5	Vitiligo;
PAAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.86	8.61	0.57	8.79e-15	Body mass index;
PAAD	cis	rs10450586	1.000	rs10450586	chr11:27308483	G/C	cg10370305	chr11:27303972	NA	0.37	4.48	0.34	1.44e-5	Total body bone mineral density;
PAAD	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg00540400	chr15:79124168	NA	-0.69	-8.5	-0.57	1.68e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
PAAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.2	-6.31	-0.46	2.96e-9	Body mass index;
PAAD	cis	rs57709857	0.794	rs56322953	chr8:38243227	T/A	cg16625770	chr8:38300134	FGFR1	-0.48	-4.47	-0.34	1.52e-5	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg00599163	chr2:162100495	NA	-0.43	-6.2	-0.45	5.2e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
PAAD	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg05562828	chr17:3906858	NA	0.54	5.98	0.44	1.5e-8	Type 2 diabetes;
PAAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-15.36	-0.78	9.59e-33	Height;
PAAD	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg16602846	chr15:78114278	NA	0.43	4.76	0.36	4.52e-6	Coronary artery disease or large artery stroke;
PAAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.61	-7.39	-0.51	9.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	16.93	0.81	8.25e-37	Prudent dietary pattern;
PAAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.92	7.14	0.5	3.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.93	9.82	0.62	6.2e-18	Testicular germ cell tumor;
PAAD	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg24503407	chr1:205819492	PM20D1	0.62	4.94	0.37	2.08e-6	Parkinson's disease;
PAAD	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.54	-5.14	-0.38	8.52e-7	Mortality in heart failure;
PAAD	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.46	6.06	0.44	1.05e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-5.48	-0.41	1.74e-7	Schizophrenia;
PAAD	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg24253500	chr15:84953950	NA	0.42	4.44	0.34	1.73e-5	Schizophrenia;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg23999861	chr9:140009395	DPP7	0.57	6.36	0.46	2.2e-9	Vitiligo;Type 1 diabetes;
PAAD	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg12215294	chr3:40350768	EIF1B	-0.48	-4.86	-0.37	2.84e-6	Renal cell carcinoma;
PAAD	cis	rs7072216	0.687	rs11189588	chr10:100154551	G/A	cg19567339	chr10:100142640	NA	0.42	4.41	0.34	1.93e-5	Metabolite levels;
PAAD	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.56	5.04	0.38	1.29e-6	Plateletcrit;
PAAD	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.73	8.32	0.56	4.7e-14	Metabolic syndrome;
PAAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	4.42	0.34	1.83e-5	Neuroticism;
PAAD	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg01528321	chr10:82214614	TSPAN14	-0.52	-4.83	-0.36	3.27e-6	Diabetic kidney disease;
PAAD	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.48	4.64	0.35	7.44e-6	Airway imaging phenotypes;
PAAD	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	8.41	0.56	2.84e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.81	10.32	0.64	3.04e-19	Bone mineral density;
PAAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.55	4.49	0.34	1.4e-5	Developmental language disorder (linguistic errors);
PAAD	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.63	-5.41	-0.4	2.4e-7	Alzheimer's disease in APOE e4- carriers;
PAAD	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-5.42	-0.4	2.26e-7	Schizophrenia;
PAAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg02428538	chr16:24856791	SLC5A11	-0.64	-4.76	-0.36	4.52e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg21918786	chr6:109611834	NA	-0.45	-4.88	-0.37	2.63e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
PAAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	7.17	0.5	3.06e-11	Menarche (age at onset);
PAAD	cis	rs9834373	0.553	rs9818134	chr3:78495979	A/C	cg06138941	chr3:78371609	NA	0.39	4.42	0.34	1.84e-5	Protein quantitative trait loci;
PAAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.9	-6.1	-0.44	8.29e-9	Body mass index;
PAAD	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.85	10.3	0.64	3.32e-19	Monocyte percentage of white cells;
PAAD	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg05085585	chr16:30420623	ZNF771	0.47	4.55	0.35	1.07e-5	Tonsillectomy;
PAAD	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.97	10.61	0.65	4.94e-20	Corneal astigmatism;
PAAD	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.77	8.0	0.54	2.96e-13	Body mass index;
PAAD	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.42	4.71	0.36	5.5e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.49	-5.32	-0.4	3.63e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg10556349	chr10:835070	NA	0.72	5.61	0.41	9.2e-8	Eosinophil percentage of granulocytes;
PAAD	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.89	0.37	2.54e-6	Diisocyanate-induced asthma;
PAAD	cis	rs7873102	0.654	rs10814643	chr9:38018690	T/C	cg03528946	chr9:38069800	SHB	-0.5	-5.01	-0.38	1.52e-6	Brain structure;
PAAD	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg24747557	chr10:131355152	MGMT	-0.47	-4.92	-0.37	2.18e-6	Response to temozolomide;
PAAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg05042697	chr2:10830656	NOL10	-0.43	-4.25	-0.33	3.67e-5	Prostate cancer;
PAAD	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.55	-4.26	-0.33	3.6e-5	Coronary artery disease;
PAAD	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.48	4.85	0.37	3.01e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
PAAD	cis	rs7260598	0.539	rs1347177	chr19:24079460	T/G	cg09235885	chr19:23456588	NA	-0.63	-4.36	-0.33	2.35e-5	Response to taxane treatment (placlitaxel);
PAAD	cis	rs1364705	0.826	rs13256406	chr8:120220148	G/C	cg09273054	chr8:120220131	MAL2	0.46	4.98	0.37	1.67e-6	Hippocampal atrophy;
PAAD	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg00531865	chr16:30841666	NA	-0.5	-4.58	-0.35	9.52e-6	Dementia with Lewy bodies;
PAAD	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.68	-7.24	-0.51	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
PAAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg13206674	chr6:150067644	NUP43	0.62	6.64	0.47	5.11e-10	Testicular germ cell tumor;
PAAD	cis	rs6977660	0.652	rs2072187	chr7:19747915	A/G	cg07541023	chr7:19748670	TWISTNB	0.86	5.61	0.41	9.48e-8	Thyroid stimulating hormone;
PAAD	cis	rs6545883	0.868	rs778755	chr2:61781037	A/G	cg14146966	chr2:61757674	XPO1	-0.36	-4.33	-0.33	2.64e-5	Tuberculosis;
PAAD	cis	rs17169635	0.819	rs10954472	chr7:134497314	G/A	cg02516134	chr7:134575187	CALD1	-0.44	-4.49	-0.34	1.43e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
PAAD	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg11251234	chr10:101825055	CPN1	-0.3	-4.33	-0.33	2.7e-5	Bone mineral density;
PAAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg25753631	chr6:25732923	NA	-0.46	-5.32	-0.4	3.58e-7	Iron status biomarkers;
PAAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.73	-6.21	-0.45	4.9e-9	Blood metabolite levels;Acylcarnitine levels;
PAAD	trans	rs4325129	0.871	rs4656827	chr1:159460032	A/G	cg23283234	chr8:128806859	MIR1204;PVT1	-0.66	-6.56	-0.47	7.87e-10	Obesity-related traits;
PAAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.61	-5.84	-0.43	3.08e-8	Aortic root size;
PAAD	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	1.14	8.73	0.58	4.24e-15	Inflammatory bowel disease;
PAAD	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.64	7.05	0.5	6.01e-11	Smoking initiation;
PAAD	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg23387468	chr7:139079360	LUC7L2	0.39	4.68	0.35	6.32e-6	Diisocyanate-induced asthma;
PAAD	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.69	7.5	0.52	4.99e-12	Economic and political preferences (feminism/equality);
PAAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.89	-7.29	-0.51	1.61e-11	Developmental language disorder (linguistic errors);
PAAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.24	-0.39	5.38e-7	Obesity-related traits;
PAAD	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg26816564	chr1:7831052	VAMP3	-0.61	-5.2	-0.39	6.42e-7	Inflammatory bowel disease;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg02954052	chr3:194324527	TMEM44	0.57	6.72	0.48	3.35e-10	Gray matter volume (schizophrenia interaction);
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20140398	chr17:15164292	PMP22	0.63	6.95	0.49	9.98e-11	Monocyte percentage of white cells;
PAAD	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-1.23	-12.57	-0.71	2.75e-25	Hair shape;
PAAD	cis	rs279612	0.620	rs279621	chr8:122788769	A/G	cg15153412	chr8:121823462	SNTB1	-0.6	-4.31	-0.33	2.94e-5	Metabolite levels (5-HIAA);
PAAD	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg16205897	chr5:131564050	P4HA2	-0.41	-4.46	-0.34	1.59e-5	Blood metabolite levels;
PAAD	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.83	5.76	0.42	4.48e-8	Soluble interleukin-2 receptor subunit alpha;
PAAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg21565972	chr17:80109576	CCDC57	-0.59	-6.73	-0.48	3.24e-10	Life satisfaction;
PAAD	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.7	-5.35	-0.4	3.11e-7	Diastolic blood pressure;
PAAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.5	-5.34	-0.4	3.39e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	trans	rs901683	1.000	rs35394192	chr10:46000761	C/T	cg14076390	chr17:34947837	DHRS11	0.91	6.85	0.49	1.76e-10	Red blood cell traits;Mean corpuscular volume;
PAAD	cis	rs7707921	0.881	rs73134722	chr5:81326622	G/A	cg21483461	chr5:81570383	RPS23	-0.51	-4.3	-0.33	3.03e-5	Breast cancer;
PAAD	cis	rs735539	0.521	rs2762989	chr13:21392521	C/G	cg27499820	chr13:21296301	IL17D	0.53	4.69	0.36	5.91e-6	Dental caries;
PAAD	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.89	-9.74	-0.62	1e-17	Obesity-related traits;
PAAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.17	0.45	5.96e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.25	-0.39	5.02e-7	Schizophrenia;
PAAD	cis	rs72827839	0.644	rs72833479	chr17:45960449	G/A	cg23391107	chr17:45924227	SP6	0.71	6.64	0.47	5.32e-10	Ease of getting up in the morning;
PAAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg15117754	chr3:10150083	C3orf24	0.68	5.65	0.42	7.55e-8	Alzheimer's disease;
PAAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-0.7	-5.49	-0.41	1.66e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg15211996	chr1:2936768	ACTRT2	0.46	4.52	0.34	1.21e-5	Plateletcrit;
PAAD	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg07856975	chr6:36356162	ETV7	0.57	6.44	0.46	1.49e-9	Platelet distribution width;
PAAD	cis	rs35160687	0.901	rs12620833	chr2:86472870	T/C	cg10973622	chr2:86423274	IMMT	0.46	5.27	0.39	4.5e-7	Night sleep phenotypes;
PAAD	cis	rs9926296	0.632	rs8059398	chr16:89792228	T/C	cg03388025	chr16:89894329	SPIRE2	-0.33	-4.3	-0.33	3.1e-5	Vitiligo;
PAAD	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg18551225	chr6:44695536	NA	-0.7	-7.0	-0.49	7.52e-11	Total body bone mineral density;
PAAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00933542	chr6:150070202	PCMT1	0.54	5.74	0.42	5.05e-8	Lung cancer;
PAAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.56	6.02	0.44	1.28e-8	Depressive symptoms (multi-trait analysis);
PAAD	cis	rs2936519	0.929	rs2978928	chr8:6638435	G/A	cg22103414	chr8:6638082	NA	-0.4	-4.25	-0.33	3.78e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18043598	chr6:52930078	FBXO9	-0.76	-6.33	-0.46	2.68e-9	Neuroticism;
PAAD	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.69	7.74	0.53	1.31e-12	Leprosy;
PAAD	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.48	4.73	0.36	5.16e-6	Common traits (Other);
PAAD	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07402062	chr16:89894098	SPIRE2	0.4	4.81	0.36	3.56e-6	Schizophrenia;
PAAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg15117754	chr3:10150083	C3orf24	0.71	5.96	0.44	1.7e-8	Alzheimer's disease;
PAAD	cis	rs4423214	0.550	rs4944885	chr11:71114075	C/T	cg05163923	chr11:71159392	DHCR7	0.6	5.65	0.42	7.53e-8	Vitamin D levels;
PAAD	cis	rs77109747	0.661	rs7528320	chr1:35630822	G/T	cg14420116	chr1:35392308	NA	-0.81	-4.3	-0.33	3.03e-5	Nicotine dependence;
PAAD	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.72	6.91	0.49	1.27e-10	Parkinson's disease;
PAAD	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg24375607	chr4:120327624	NA	0.53	5.58	0.41	1.07e-7	Corneal astigmatism;
PAAD	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27367093	chr11:72145746	CLPB	0.57	6.58	0.47	6.98e-10	Brain volume in infants (cerebrospinal fluid);
PAAD	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.95	5.08	0.38	1.08e-6	Childhood ear infection;
PAAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.84	-7.01	-0.49	7.21e-11	Initial pursuit acceleration;
PAAD	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.59	5.19	0.39	6.71e-7	Life satisfaction;
PAAD	cis	rs7951870	0.560	rs3136505	chr11:46759571	A/G	cg19486271	chr11:47235900	DDB2	0.56	5.6	0.41	9.55e-8	Schizophrenia;
PAAD	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg07469887	chr10:131262384	NA	-0.43	-5.04	-0.38	1.31e-6	Response to temozolomide;
PAAD	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg09127314	chr1:152161683	NA	-0.71	-5.35	-0.4	3.12e-7	Atopic dermatitis;
PAAD	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.65	-7.51	-0.52	4.56e-12	Coffee consumption;Coffee consumption (cups per day);
PAAD	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg21191810	chr6:118973309	C6orf204	-0.48	-6.09	-0.44	8.85e-9	Electrocardiographic conduction measures;
PAAD	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg21191810	chr6:118973309	C6orf204	0.5	7.05	0.5	5.86e-11	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg21033440	chr11:65409861	SIPA1	-0.47	-5.17	-0.39	7.24e-7	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
PAAD	cis	rs12431939	0.598	rs8012074	chr14:51732101	C/G	cg23942311	chr14:51606299	NA	0.54	5.02	0.38	1.4e-6	Cancer;
PAAD	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg14019146	chr3:50243930	SLC38A3	-0.48	-4.37	-0.33	2.26e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.75	-8.07	-0.55	1.95e-13	Rheumatoid arthritis;
PAAD	trans	rs9956878	0.555	rs8085188	chr18:73544676	A/G	cg26755862	chr4:57666314	NA	0.67	6.99	0.49	8.12e-11	Obesity-related traits;
PAAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.88	-8.16	-0.55	1.16e-13	Developmental language disorder (linguistic errors);
PAAD	cis	rs338389	0.516	rs17308514	chr15:68313171	C/T	cg09788352	chr15:68522666	CLN6	-0.34	-4.27	-0.33	3.46e-5	Survival in rectal cancer;
PAAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.63	7.36	0.51	1.1e-11	Aortic root size;
PAAD	cis	rs2279817	0.818	rs71644062	chr1:17980530	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-6.02	-0.44	1.26e-8	Neuroticism;
PAAD	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	4.53	0.34	1.19e-5	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.7	-6.63	-0.47	5.41e-10	Mean platelet volume;
PAAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23791690	chr10:43904038	HNRNPF	0.56	6.38	0.46	2.05e-9	Monocyte percentage of white cells;
PAAD	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.9	-9.96	-0.63	2.68e-18	Intelligence (multi-trait analysis);
PAAD	cis	rs669446	0.591	rs636547	chr1:44106516	C/A	cg12908607	chr1:44402522	ARTN	-0.41	-4.37	-0.33	2.26e-5	Amyotrophic lateral sclerosis (age of onset);
PAAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg00507354	chr4:76598817	G3BP2	0.63	6.46	0.46	1.32e-9	Myopia (pathological);
PAAD	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11808746	chr10:95256359	CEP55	-0.74	-6.53	-0.47	9.48e-10	Neuroticism;
PAAD	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.84	-7.61	-0.53	2.69e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
PAAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.7	-5.11	-0.38	9.55e-7	Initial pursuit acceleration;
PAAD	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.9	-7.3	-0.51	1.5e-11	Axial length;
PAAD	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.75	6.96	0.49	9.5e-11	Obesity-related traits;
PAAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg18833306	chr6:118973337	C6orf204	-0.57	-4.61	-0.35	8.59e-6	Diastolic blood pressure;
PAAD	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.56	-7.06	-0.5	5.64e-11	Lewy body disease;
PAAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16758764	chr3:113529180	ATP6V1A	-0.7	-6.67	-0.48	4.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
PAAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg21395723	chr22:39101663	GTPBP1	0.47	4.86	0.37	2.84e-6	Menopause (age at onset);
PAAD	cis	rs8042680	0.554	rs2285937	chr15:91527152	A/G	cg23684204	chr15:91497937	RCCD1	0.61	4.33	0.33	2.67e-5	Type 2 diabetes;
PAAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	10.51	0.65	9.45e-20	Total body bone mineral density;
PAAD	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.68	7.83	0.54	7.91e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	7.01	0.49	7.18e-11	Coronary artery disease;
PAAD	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.81	6.31	0.46	2.84e-9	Type 2 diabetes;
PAAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg24633833	chr3:10029261	TMEM111	0.59	4.34	0.33	2.57e-5	Alzheimer's disease;
PAAD	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.65	-5.93	-0.43	1.95e-8	Crohn's disease;
PAAD	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.4	4.89	0.37	2.49e-6	Sitting height ratio;
PAAD	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.95	6.0	0.44	1.36e-8	Cognitive ability (multi-trait analysis);
PAAD	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.65	-9.69	-0.62	1.36e-17	Airflow obstruction;
PAAD	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	10.62	0.65	4.78e-20	Cognitive test performance;
PAAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.61	-6.8	-0.48	2.23e-10	Systemic lupus erythematosus;
PAAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.64	-6.26	-0.45	3.77e-9	IgG glycosylation;
PAAD	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.33	0.33	2.73e-5	Height;
PAAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.57	-6.06	-0.44	1.01e-8	Blood metabolite levels;
PAAD	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.1	-15.14	-0.78	3.76e-32	Schizophrenia;
PAAD	cis	rs7711186	0.881	rs721143	chr5:178019031	T/G	cg17371294	chr5:178012716	COL23A1	-0.83	-4.43	-0.34	1.78e-5	Urate levels in obese individuals;
PAAD	cis	rs600550	0.588	rs12225299	chr11:60084465	C/T	cg05040360	chr11:60102449	MS4A6E	-0.4	-4.69	-0.36	6.08e-6	Lipoprotein-associated phospholipase A2 activity and mass;
PAAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06217245	chr20:33103252	DYNLRB1	0.38	4.68	0.35	6.34e-6	Glomerular filtration rate (creatinine);
PAAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.13	0.55	1.38e-13	Height;
PAAD	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.45	4.63	0.35	7.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.69	-7.4	-0.51	8.77e-12	Neuroticism;
PAAD	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.59	5.58	0.41	1.07e-7	Mean corpuscular volume;Mean platelet volume;
PAAD	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.73	0.36	4.99e-6	Educational attainment;
PAAD	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	cg25843174	chr11:12811716	TEAD1	0.38	5.66	0.42	7.3900000000000007e-08	Educational attainment (years of education);
PAAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.51	-5.16	-0.39	7.53e-7	Type 2 diabetes;
PAAD	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.09	-0.38	1.04e-6	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	7.89	0.54	5.56e-13	Mean platelet volume;
PAAD	cis	rs8105895	1.000	rs117638181	chr19:22163014	C/G	cg20662725	chr19:22235022	ZNF257	-0.59	-4.6	-0.35	8.82e-6	Body mass index (change over time);
PAAD	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-4.73	-0.36	5.12e-6	Daytime sleep phenotypes;
PAAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg04025307	chr7:1156635	C7orf50	0.7	4.91	0.37	2.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-6.36	-0.46	2.21e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg04398451	chr17:18023971	MYO15A	0.62	5.9	0.43	2.3e-8	Body mass index;
PAAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.91	-10.14	-0.64	8.89e-19	Bipolar disorder and schizophrenia;
PAAD	cis	rs1864585	0.520	rs7845731	chr8:10675459	A/G	cg21775007	chr8:11205619	TDH	-0.57	-4.43	-0.34	1.79e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
PAAD	cis	rs13424612	0.965	rs34789127	chr2:240952002	C/T	cg01812947	chr2:240904978	NDUFA10	0.58	5.01	0.38	1.5e-6	Odorant perception (isobutyraldehyde);
PAAD	cis	rs4740619	0.619	rs2026661	chr9:16045125	C/G	cg14451791	chr9:16040625	NA	0.45	5.24	0.39	5.3e-7	Body mass index;
PAAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.62	6.43	0.46	1.6e-9	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	3.43e-18	Cognitive function;
PAAD	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg16060761	chr17:80687452	NA	0.45	4.33	0.33	2.69e-5	Glycated hemoglobin levels;
PAAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	6.45	0.46	1.43e-9	Menarche (age at onset);
PAAD	cis	rs12612619	0.732	rs6547355	chr2:27210205	G/A	cg00617064	chr2:27272375	NA	-0.48	-5.12	-0.38	8.92e-7	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
PAAD	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.45	-0.34	1.68e-5	Joint mobility (Beighton score);
PAAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg12757816	chr2:10669957	NA	0.56	6.03	0.44	1.18e-8	Prostate cancer;
PAAD	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.44	-6.48	-0.47	1.23e-9	Cutaneous nevi;
PAAD	cis	rs7246760	0.881	rs68018725	chr19:9855919	C/T	cg16876255	chr19:9731953	ZNF561	0.92	4.5	0.34	1.32e-5	Pursuit maintenance gain;
PAAD	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg12573674	chr2:1569213	NA	-0.68	-5.35	-0.4	3.12e-7	IgG glycosylation;
PAAD	cis	rs863345	0.604	rs10797021	chr1:158490341	T/C	cg12129480	chr1:158549410	OR10X1	-0.44	-5.05	-0.38	1.26e-6	Pneumococcal bacteremia;
PAAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg09491104	chr22:46646882	C22orf40	-0.97	-8.41	-0.56	2.72e-14	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.5	-5.28	-0.39	4.36e-7	Cerebrospinal fluid biomarker levels;
PAAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.64	8.0	0.54	2.87e-13	Prudent dietary pattern;
PAAD	cis	rs793571	0.580	rs12913383	chr15:59043786	G/T	cg05156742	chr15:59063176	FAM63B	-0.61	-4.57	-0.35	1e-5	Schizophrenia;
PAAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.68	4.94	0.37	2.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs4699052	0.507	rs6533085	chr4:104281586	A/T	cg16532752	chr4:104119610	CENPE	-0.5	-4.26	-0.33	3.61e-5	Testicular germ cell tumor;
PAAD	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.4	5.05	0.38	1.23e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.98	0.54	3.3e-13	Palmitoleic acid (16:1n-7) levels;
PAAD	cis	rs818427	0.593	rs419155	chr5:112210415	A/T	cg06941702	chr5:112196734	SRP19	0.53	5.05	0.38	1.26e-6	Total body bone mineral density;
PAAD	cis	rs1497828	0.956	rs2818965	chr1:217569776	T/A	cg04411442	chr1:217543379	NA	0.5	4.99	0.38	1.63e-6	Dialysis-related mortality;
PAAD	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.54	-6.11	-0.44	8.13e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg08888203	chr3:10149979	C3orf24	0.71	6.37	0.46	2.13e-9	Alzheimer's disease;
PAAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.75	-8.07	-0.55	1.93e-13	Aortic root size;
PAAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23281280	chr6:28129359	ZNF389	0.69	5.28	0.39	4.32e-7	Depression;
PAAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg19630374	chr17:18023558	MYO15A	-0.45	-4.79	-0.36	3.96e-6	Total body bone mineral density;
PAAD	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19671926	chr4:122722719	EXOSC9	-0.58	-5.16	-0.39	7.74e-7	Type 2 diabetes;
PAAD	cis	rs6700896	0.500	rs66728245	chr1:66127710	C/T	cg04111102	chr1:66153794	NA	0.49	4.52	0.34	1.23e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
PAAD	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg25902810	chr10:99078978	FRAT1	-0.6	-5.38	-0.4	2.74e-7	Monocyte count;
PAAD	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg22029157	chr1:209979665	IRF6	0.68	6.38	0.46	2.01e-9	Coronary artery disease;
PAAD	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.64	6.24	0.45	4.05e-9	Schizophrenia;
PAAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg05658771	chr16:89884179	FANCA	-0.91	-4.32	-0.33	2.8e-5	Skin colour saturation;
PAAD	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	1.1	8.76	0.58	3.66e-15	Iron status biomarkers;
PAAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16405210	chr4:1374714	KIAA1530	-0.67	-7.02	-0.49	7.06e-11	Longevity;
PAAD	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16417436	chr16:28758564	NA	0.47	4.38	0.33	2.24e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
PAAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg21130718	chr4:1044621	NA	0.54	4.58	0.35	9.43e-6	Recombination rate (females);
PAAD	cis	rs1144333	0.655	rs1146602	chr1:76239309	A/G	cg22875332	chr1:76189707	ACADM	-0.73	-4.39	-0.34	2.13e-5	Attention function in attention deficit hyperactive disorder;
PAAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg04154034	chr17:28927549	LRRC37B2	0.73	4.29	0.33	3.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
PAAD	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.58	-5.57	-0.41	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
PAAD	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg18436246	chr17:1640651	WDR81	0.86	7.97	0.54	3.59e-13	Serum albumin level;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg01459882	chr16:22308661	POLR3E	-0.58	-6.6	-0.47	6.4e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.64	5.07	0.38	1.15e-6	Alzheimer's disease;
PAAD	trans	rs17073641	0.500	rs78533857	chr18:62457681	C/T	cg08832414	chr3:183993571	ECE2	-0.65	-6.4	-0.46	1.81e-9	Age-related macular degeneration (smoking status interaction);
PAAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.78	7.58	0.52	3.11e-12	Tuberculosis;
PAAD	trans	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg05163071	chr3:108476540	RETNLB	0.99	7.15	0.5	3.35e-11	Dental caries;
PAAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.8	8.87	0.58	1.88e-15	Schizophrenia;
PAAD	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.46	5.96	0.44	1.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
PAAD	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg00647317	chr7:50633725	DDC	-0.43	-4.76	-0.36	4.54e-6	Systemic sclerosis;
PAAD	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.57	-0.35	9.99e-6	Reticulocyte fraction of red cells;
PAAD	cis	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg27395922	chr11:50257633	LOC441601	-0.43	-4.63	-0.35	7.76e-6	Height;
PAAD	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.7	6.93	0.49	1.12e-10	Coronary artery disease;
PAAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	cis	rs5753618	0.504	rs5749295	chr22:31932895	A/T	cg01338084	chr22:32026380	PISD	0.56	5.03	0.38	1.38e-6	Colorectal cancer;
PAAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.43	1.97e-8	Lymphocyte counts;
PAAD	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg09491104	chr22:46646882	C22orf40	-0.98	-5.18	-0.39	7.1e-7	LDL cholesterol;Cholesterol, total;
PAAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg17372223	chr3:52568218	NT5DC2	0.46	4.47	0.34	1.5e-5	Electroencephalogram traits;
PAAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.52	4.86	0.37	2.85e-6	Acylcarnitine levels;
PAAD	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	9.45	0.61	5.83e-17	Chronic sinus infection;
PAAD	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	7.22	0.51	2.31e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg17480646	chr11:65405466	SIPA1	0.91	4.32	0.33	2.83e-5	Height;
PAAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.83	7.2	0.5	2.63e-11	Alzheimer's disease;
PAAD	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-4.9	-0.37	2.46e-6	Reticulocyte count;
PAAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg12568669	chr8:11666485	FDFT1	-0.3	-4.63	-0.35	7.87e-6	Retinal vascular caliber;
PAAD	trans	rs9488343	0.647	rs7751951	chr6:114490556	C/G	cg19901994	chr8:27288146	PTK2B	0.58	6.83	0.48	1.88e-10	Gray matter volume (schizophrenia interaction);
PAAD	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg15841412	chr13:111365552	ING1	0.54	4.59	0.35	9.42e-6	Coronary artery disease;
PAAD	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-1.06	-15.35	-0.78	1.06e-32	Height;
PAAD	cis	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.6	4.47	0.34	1.51e-5	Gait speed in old age;Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-4.28	-0.33	3.25e-5	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27297192	chr10:134578999	INPP5A	0.64	6.1	0.44	8.52e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7537660	0.562	rs4417105	chr1:248016487	G/T	cg03748376	chr1:248100585	OR2L13	-0.44	-4.95	-0.37	1.99e-6	Platelet distribution width;
PAAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg21698718	chr17:80085957	CCDC57	0.41	4.32	0.33	2.81e-5	Life satisfaction;
PAAD	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.63	4.62	0.35	8.26e-6	Neuroblastoma;
PAAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.5	-5.6	-0.41	9.67e-8	Bipolar disorder;
PAAD	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26761226	chr12:56617996	OBFC2B	-0.58	-6.74	-0.48	3.03e-10	Body fat percentage;
PAAD	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17376030	chr22:41985996	PMM1	-0.68	-4.69	-0.36	6.04e-6	Cannabis dependence symptom count;
PAAD	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-6.97	-0.49	8.88e-11	Body mass index (adult);
PAAD	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.82	8.41	0.56	2.74e-14	Heart rate;
PAAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg13012494	chr21:47604986	C21orf56	0.43	4.44	0.34	1.71e-5	Testicular germ cell tumor;
PAAD	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg03938978	chr2:103052716	IL18RAP	0.5	5.06	0.38	1.18e-6	Blood protein levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg13778499	chr9:35814820	HINT2	0.66	7.76	0.53	1.12e-12	Vitiligo;Type 1 diabetes;
PAAD	cis	rs59888335	0.895	rs13100370	chr3:80812218	G/A	cg21735741	chr3:80819488	NA	0.57	4.91	0.37	2.34e-6	Schizophrenia;
PAAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.2	-0.39	6.29e-7	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg13821571	chr21:34406537	NA	-0.49	-4.74	-0.36	4.92e-6	Gastritis;
PAAD	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.82	5.3	0.4	3.96e-7	Alzheimer's disease;
PAAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.68	5.68	0.42	6.72e-8	Alzheimer's disease;
PAAD	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.78	-4.97	-0.37	1.79e-6	White matter integrity;
PAAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg25204440	chr1:209979598	IRF6	0.61	4.89	0.37	2.54e-6	Coronary artery disease;
PAAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.6	5.78	0.42	4.18e-8	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.8	7.13	0.5	3.89e-11	IgE levels in asthmatics (D.p. specific);
PAAD	trans	rs12714314	0.914	rs1991773	chr2:1957476	A/G	cg17170872	chr1:91487911	ZNF644	0.74	6.49	0.47	1.17e-9	Type 2 diabetes (age of onset);
PAAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.7	8.11	0.55	1.54e-13	Intelligence (multi-trait analysis);
PAAD	cis	rs8060686	0.841	rs7185308	chr16:67767060	A/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-4.81	-0.36	3.6e-6	HDL cholesterol;Metabolic syndrome;
PAAD	cis	rs1797885	0.763	rs1797886	chr3:12521698	C/T	cg07775309	chr3:12595852	NA	0.41	4.41	0.34	1.97e-5	Immature fraction of reticulocytes;
PAAD	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.92	0.37	2.21e-6	Blood metabolite levels;
PAAD	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.55	-5.26	-0.39	4.71e-7	P wave terminal force;
PAAD	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.85	10.91	0.66	7.85e-21	Subjective well-being (multi-trait analysis);
PAAD	cis	rs7711186	0.786	rs4976798	chr5:178021280	A/G	cg17371294	chr5:178012716	COL23A1	-0.83	-4.43	-0.34	1.78e-5	Urate levels in obese individuals;
PAAD	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg21479132	chr6:26055353	NA	0.93	5.49	0.41	1.67e-7	Autism spectrum disorder or schizophrenia;
PAAD	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.87	10.81	0.66	1.43e-20	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg12143784	chr7:64541923	NA	0.34	4.34	0.33	2.56e-5	Calcium levels;
PAAD	cis	rs11615916	0.790	rs35496480	chr12:62696477	T/G	cg11441379	chr12:63026424	NA	0.65	4.41	0.34	1.93e-5	Pulmonary function decline;
PAAD	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg01657329	chr11:68192670	LRP5	-0.74	-6.82	-0.48	2.07e-10	Total body bone mineral density;
PAAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00864171	chr11:67383662	NA	0.6	6.29	0.45	3.17e-9	Mean corpuscular volume;
PAAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.66	7.2	0.5	2.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.87	0.54	6.19e-13	Schizophrenia;
PAAD	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.53	0.65	8.32e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.66	7.93	0.54	4.44e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03605463	chr16:89740564	NA	-0.5	-4.63	-0.35	7.69e-6	Vitiligo;
PAAD	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg01304814	chr3:48885189	PRKAR2A	0.9	5.19	0.39	6.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
PAAD	trans	rs3757247	0.729	rs12209546	chr6:90912594	C/T	cg15344021	chr17:2240169	TSR1;SGSM2	0.6	6.63	0.47	5.58e-10	Vitiligo;Type 1 diabetes;
PAAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.49	0.61	4.53e-17	Rheumatoid arthritis;
PAAD	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.55	5.74	0.42	5.07e-8	Crohn's disease;
PAAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.49	-4.71	-0.36	5.56e-6	Coronary artery disease;
PAAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.51	-5.24	-0.39	5.29e-7	Schizophrenia;
PAAD	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00864171	chr11:67383662	NA	-0.52	-5.29	-0.39	4.18e-7	Mean corpuscular volume;
PAAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.4	-5.7	-0.42	6e-8	Vitiligo;
PAAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.67	6.81	0.48	2.09e-10	Cystic fibrosis severity;
PAAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.93	-9.88	-0.63	4.35e-18	Cancer (pleiotropy);
PAAD	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.53	5.38	0.4	2.73e-7	Intelligence (multi-trait analysis);
PAAD	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.61	6.44	0.46	1.49e-9	Pancreatic cancer;
PAAD	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17507749	chr15:85114479	UBE2QP1	0.64	6.25	0.45	4e-9	Schizophrenia;
PAAD	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-4.39	-0.34	2.12e-5	Mosquito bite size;
PAAD	cis	rs78456975	0.766	rs13400150	chr2:1514901	G/A	cg01028140	chr2:1542097	TPO	-0.91	-5.7	-0.42	5.9e-8	Placebo response in major depressive disorder (% change in symptom score);
PAAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.59	-6.61	-0.47	6.25e-10	Systemic lupus erythematosus;
PAAD	cis	rs6594713	0.732	rs34951736	chr5:112727149	T/C	cg12552261	chr5:112820674	MCC	0.6	4.48	0.34	1.45e-5	Brain cytoarchitecture;
PAAD	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg18678067	chr19:52674854	ZNF836	0.56	6.38	0.46	2.05e-9	Hemostatic factors and hematological phenotypes;
PAAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.53	-0.35	1.17e-5	Obesity-related traits;
PAAD	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.42	4.64	0.35	7.61e-6	HDL cholesterol levels;
PAAD	cis	rs577948	0.897	rs1615327	chr11:122044291	C/G	cg10262710	chr11:122074011	LOC399959	-0.41	-4.37	-0.33	2.27e-5	Myopia (pathological);
PAAD	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-6.6	-0.47	6.52e-10	Blood pressure (smoking interaction);
PAAD	cis	rs295140	0.743	rs952530	chr2:201081745	A/G	cg23649088	chr2:200775458	C2orf69	-0.44	-4.37	-0.33	2.33e-5	QT interval;
PAAD	cis	rs35955747	0.870	rs5997986	chr22:31834939	C/T	cg02404636	chr22:31891804	SFI1	-0.56	-5.62	-0.41	8.84e-8	Neutrophil count;Sum basophil neutrophil counts;
PAAD	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.71	8.74	0.58	3.97e-15	Schizophrenia;
PAAD	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg21191810	chr6:118973309	C6orf204	0.48	6.68	0.48	4.33e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
PAAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-4.64	-0.35	7.42e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
PAAD	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-4.42	-0.34	1.86e-5	Granulocyte percentage of myeloid white cells;
PAAD	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.69	-4.67	-0.35	6.57e-6	Coronary artery disease;
PAAD	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.37	5.51	0.41	1.51e-7	Educational attainment (years of education);
PAAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.44	5.52	0.41	1.46e-7	Psoriasis;
PAAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-1.04	-14.31	-0.76	5.99e-30	Breast cancer;
PAAD	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.71	-6.79	-0.48	2.35e-10	Schizophrenia;
PAAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.56	5.85	0.43	2.91e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.41	-5.26	-0.39	4.79e-7	Ulcerative colitis;
PAAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.34	6.24	0.45	4.18e-9	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	9.75	0.62	9.67e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
PAAD	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.52	4.97	0.37	1.81e-6	Mean platelet volume;Platelet distribution width;
PAAD	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.44	4.4	0.34	2.06e-5	Red blood cell count;
PAAD	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.63	-5.67	-0.42	7.11e-8	Corneal astigmatism;
PAAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.51	5.02	0.38	1.45e-6	Visceral fat;
PAAD	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg12858261	chr2:113808755	IL1F8	0.45	4.44	0.34	1.69e-5	Inflammatory biomarkers;
PAAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg21269045	chr12:125625041	AACS	-0.5	-4.81	-0.36	3.54e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg05925327	chr15:68127851	NA	0.39	4.49	0.34	1.39e-5	Restless legs syndrome;
PAAD	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-5.49	-0.41	1.67e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	1.27	11.98	0.7	1.04e-23	Eosinophil percentage of granulocytes;
PAAD	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-5.67	-0.42	7.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
PAAD	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg05347473	chr6:146136440	FBXO30	0.71	6.29	0.45	3.26e-9	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	5.38	0.4	2.74e-7	Total body bone mineral density;
PAAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.54	-5.96	-0.44	1.7e-8	Intelligence (multi-trait analysis);Body fat percentage;
PAAD	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.45	4.41	0.34	1.95e-5	Response to statin therapy;
PAAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.74	7.84	0.54	7.49e-13	Colorectal cancer;
PAAD	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg26209169	chr5:1316264	NA	-0.38	-4.44	-0.34	1.73e-5	Lung cancer;
PAAD	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.79	9.48	0.61	4.75e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
PAAD	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.79	-7.22	-0.51	2.33e-11	Blood protein levels;
PAAD	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.27	0.45	3.48e-9	Bladder cancer;
PAAD	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg12315302	chr6:26189340	HIST1H4D	0.52	4.43	0.34	1.81e-5	Intelligence (multi-trait analysis);
PAAD	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.93	10.93	0.66	7.08e-21	Intelligence (multi-trait analysis);
PAAD	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg16586182	chr3:47516702	SCAP	-0.73	-8.63	-0.57	7.83e-15	Colorectal cancer;
PAAD	cis	rs116248771	0.739	rs12633674	chr3:158368217	G/T	cg16708174	chr3:158430962	RARRES1	0.71	5.29	0.39	4.14e-7	diarrhoeal disease at age 2;
PAAD	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.49	-4.53	-0.35	1.17e-5	Tonsillectomy;
PAAD	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	0.92	6.5	0.47	1.08e-9	Pulse pressure;
PAAD	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01789846	chr4:135865584	NA	-0.6	-6.93	-0.49	1.14e-10	Smoking initiation;
PAAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg01815783	chr4:1047043	NA	-0.46	-4.37	-0.33	2.31e-5	Recombination rate (females);
PAAD	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.68	6.67	0.48	4.52e-10	Schizophrenia;
PAAD	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg04721828	chr11:48285200	OR4X1	0.48	6.06	0.44	1.03e-8	Migraine - clinic-based;
PAAD	cis	rs7631605	0.846	rs6768108	chr3:36998755	C/T	cg17445812	chr3:36986805	TRANK1	0.34	4.33	0.33	2.72e-5	Cerebrospinal P-tau181p levels;
PAAD	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	6.28	0.45	3.43e-9	Fuchs's corneal dystrophy;
PAAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.51	4.6	0.35	8.73e-6	Lung cancer;
PAAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.78	-7.82	-0.54	8.43e-13	Menopause (age at onset);
PAAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.6	-7.35	-0.51	1.11e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
PAAD	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg04450456	chr4:17643702	FAM184B	-0.48	-4.91	-0.37	2.31e-6	Parasitemia in Tripanosoma cruzi seropositivity;
PAAD	cis	rs1018697	0.761	rs7904281	chr10:104544836	A/G	cg04362960	chr10:104952993	NT5C2	0.61	6.22	0.45	4.66e-9	Colorectal adenoma (advanced);
PAAD	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.45	-4.32	-0.33	2.83e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs1035491	0.753	rs4700643	chr5:63927403	A/C	cg01791865	chr5:63954708	NA	0.43	4.48	0.34	1.43e-5	Body mass index;
PAAD	cis	rs9810890	1.000	rs73198881	chr3:128542760	T/G	cg15676455	chr3:128564943	NA	-0.81	-4.36	-0.33	2.42e-5	Dental caries;
PAAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg00945038	chr17:61921165	SMARCD2	0.48	5.76	0.42	4.54e-8	Prudent dietary pattern;
PAAD	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-6.94	-0.49	1.03e-10	Response to antipsychotic treatment;
PAAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg01815783	chr4:1047043	NA	-0.41	-4.41	-0.34	1.98e-5	Recombination rate (males);
PAAD	cis	rs1620921	0.505	rs9458030	chr6:161209985	G/A	cg01280913	chr6:161186852	NA	-0.46	-4.95	-0.37	1.92e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg04025307	chr7:1156635	C7orf50	0.62	4.45	0.34	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
PAAD	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.58	-5.58	-0.41	1.1e-7	Lobe attachment (rater-scored or self-reported);
PAAD	cis	rs1620921	0.505	rs9458025	chr6:161203435	T/C	cg01280913	chr6:161186852	NA	-0.47	-5.03	-0.38	1.35e-6	Lipoprotein (a) - cholesterol levels;
PAAD	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.5	-0.34	1.33e-5	Colorectal cancer;
PAAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.42	-4.42	-0.34	1.87e-5	Height;
PAAD	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.28	19.35	0.84	7.66e-43	IgG glycosylation;
PAAD	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	1.01	5.65	0.42	7.67e-8	Parkinson's disease;
PAAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg20281264	chr2:25896729	DTNB	-0.7	-4.96	-0.37	1.9e-6	Gut microbiome composition (summer);
PAAD	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg21724239	chr8:58056113	NA	0.76	5.56	0.41	1.17e-7	Developmental language disorder (linguistic errors);
PAAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.83	10.03	0.63	1.7e-18	Menopause (age at onset);
PAAD	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.89	-7.39	-0.51	9.05e-12	Triglycerides;
PAAD	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg09839279	chr12:125627357	AACS	0.48	4.78	0.36	4.07e-6	Post bronchodilator FEV1/FVC ratio;
PAAD	cis	rs72925845	0.525	rs72907478	chr17:76431015	C/T	cg03830375	chr17:76426088	DNAH17	0.54	4.35	0.33	2.47e-5	Triglycerides;
PAAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.77	-8.49	-0.57	1.78e-14	Obesity-related traits;
PAAD	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg16898833	chr6:26189333	HIST1H4D	0.63	5.02	0.38	1.44e-6	Intelligence (multi-trait analysis);
PAAD	cis	rs12541635	0.966	rs2059943	chr8:107071607	G/T	cg10147462	chr8:107024639	NA	0.44	4.47	0.34	1.52e-5	Age of smoking initiation;
PAAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.59	6.92	0.49	1.18e-10	Immature fraction of reticulocytes;
PAAD	cis	rs7742824	1.000	rs57576544	chr6:44072726	T/C	cg21657043	chr6:44035552	NA	0.52	5.27	0.39	4.5e-7	Major depressive disorder;
PAAD	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.8	9.88	0.63	4.34e-18	Gut microbiome composition (winter);
PAAD	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.62	-4.26	-0.33	3.55e-5	Biliary atresia;
PAAD	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg17401720	chr7:158221031	PTPRN2	0.4	4.76	0.36	4.56e-6	Obesity-related traits;
PAAD	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.49	-5.04	-0.38	1.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
PAAD	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26926768	chr12:34528122	NA	0.39	4.8	0.36	3.77e-6	Morning vs. evening chronotype;
PAAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	0.53	4.61	0.35	8.6e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
PAAD	cis	rs10932679	0.654	rs35169442	chr2:217679427	G/C	cg05032264	chr2:217675019	NA	0.55	4.33	0.33	2.69e-5	Pulse pressure;
PAAD	cis	rs3753841	0.832	rs12404334	chr1:103325774	T/C	cg24495344	chr1:103574097	COL11A1	0.4	4.69	0.36	6.08e-6	Glaucoma (primary angle closure);
PAAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg10411590	chr13:21900810	NA	0.63	7.35	0.51	1.12e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
PAAD	cis	rs4462272	0.557	rs17729876	chr10:101999746	G/A	cg11888571	chr10:102027403	CWF19L1	-0.49	-4.37	-0.33	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
PAAD	cis	rs3733346	0.589	rs2290404	chr4:945225	A/G	cg15105011	chr4:940614	TMEM175	0.61	7.19	0.5	2.69e-11	Sjögren's syndrome;
PAAD	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.44	4.51	0.34	1.3e-5	Menopause (age at onset);
PAAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg15448220	chr1:150897856	SETDB1	-0.56	-5.83	-0.43	3.25e-8	Tonsillectomy;
PAAD	cis	rs11159840	0.609	rs8010926	chr14:88617243	T/C	cg18078958	chr14:88630771	NA	-0.4	-5.19	-0.39	6.76e-7	Left ventricular obstructive tract defect (inherited effect);
PAAD	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.79	-9.29	-0.6	1.53e-16	Extrinsic epigenetic age acceleration;
PAAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg20805835	chr1:248005719	OR11L1	0.5	4.35	0.33	2.45e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
PAAD	cis	rs9532563	0.550	rs61963699	chr13:41140482	C/T	cg21288729	chr13:41239152	FOXO1	0.63	4.92	0.37	2.19e-6	Mean corpuscular volume;
PAAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.59	4.85	0.37	2.99e-6	Schizophrenia;
PAAD	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg26205652	chr12:48591994	NA	0.46	4.4	0.34	2e-5	Plateletcrit;
PAAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.66	7.82	0.54	8.06e-13	Colonoscopy-negative controls vs population controls;
PAAD	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	8.89	0.59	1.61e-15	Motion sickness;
PAAD	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg05250797	chr16:70222502	NA	-0.56	-4.56	-0.35	1.05e-5	Sjögren's syndrome;
PAAD	cis	rs17293817	0.562	rs7070629	chr10:1424938	A/G	cg02408697	chr10:1416920	ADARB2	-0.5	-4.63	-0.35	7.87e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
PAAD	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.74	-8.42	-0.56	2.69e-14	Coronary artery disease;
PAAD	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-4.29	-0.33	3.11e-5	Red blood cell count;
PAAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.24	-10.39	-0.64	1.98e-19	Breast cancer;
PAAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.88	8.52	0.57	1.45e-14	Homoarginine levels;
PAAD	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg08886695	chr4:3369023	RGS12	-0.53	-4.95	-0.37	1.94e-6	Serum sulfate level;
PAAD	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	7.35	0.51	1.13e-11	Migraine;Coronary artery disease;
PAAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg09473613	chr1:24152604	HMGCL	0.53	5.57	0.41	1.15e-7	Immature fraction of reticulocytes;
PAAD	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.76	9.3	0.6	1.44e-16	Bladder cancer;
PAAD	cis	rs9535307	0.719	rs10492591	chr13:50385256	C/T	cg03658251	chr13:50265850	EBPL	-0.82	-5.61	-0.41	9.14e-8	Obesity-related traits;
PAAD	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17376030	chr22:41985996	PMM1	-0.63	-4.56	-0.35	1.06e-5	Vitiligo;
PAAD	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-4.85	-0.37	2.98e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
PAAD	cis	rs11614333	1.000	rs67482087	chr12:15050262	T/G	cg00431549	chr12:15039025	MGP	-0.36	-4.32	-0.33	2.82e-5	Hand grip strength;
PAAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg19257562	chr1:2043853	PRKCZ	0.48	5.87	0.43	2.67e-8	Height;
PAAD	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg00750074	chr16:89608354	SPG7	0.47	4.29	0.33	3.16e-5	Multiple myeloma (IgH translocation);
PAAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.58	-6.68	-0.48	4.34e-10	Type 2 diabetes;
PAAD	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-7.13	-0.5	3.71e-11	Neuroticism;
PAAD	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg04850286	chr10:81895943	PLAC9	-0.43	-4.97	-0.37	1.82e-6	Sarcoidosis;
PAAD	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.63	7.57	0.52	3.3e-12	Airway imaging phenotypes;
PAAD	cis	rs7264396	0.887	rs224370	chr20:34073379	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.65	-0.42	7.51e-8	Total cholesterol levels;
PAAD	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20285609	chr1:41622030	SCMH1	0.69	7.27	0.51	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
PAAD	cis	rs12530845	0.573	rs56411048	chr7:135364748	A/T	cg23117316	chr7:135346802	PL-5283	-0.5	-4.3	-0.33	3.05e-5	Red blood cell traits;
PAAD	cis	rs25422	0.938	rs114309775	chr6:118838782	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-5.0	-0.38	1.59e-6	Renal cell carcinoma;
PAAD	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	5.99	0.44	1.42e-8	Lung function (FEV1/FVC);
PAAD	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.69	8.02	0.55	2.58e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
PAAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-4.52	-0.34	1.24e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
PAAD	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg12568669	chr8:11666485	FDFT1	-0.29	-5.11	-0.38	9.34e-7	Myopia (pathological);
PAAD	cis	rs7554547	0.667	rs2336377	chr1:11949970	A/G	cg07603449	chr1:11986842	KIAA2013	0.35	5.68	0.42	6.6e-8	Nonsyndromic cleft lip with cleft palate;
PAAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg04844267	chr4:1394941	NA	0.4	4.43	0.34	1.8e-5	Obesity-related traits;
PAAD	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.93	-8.33	-0.56	4.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
PAAD	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.67	7.15	0.5	3.35e-11	Schizophrenia;